id|nct_id|intervention_type|name|description
1947375|NCT03308747|Dietary Supplement|Instantized Whey Protein Isolate|0,4 g of whey protein isolate/kg body weight will be ingested as a bolus of 250 ml immediately after the resistance exercise bout.
1947376|NCT03309722|Other|biomarker study|
1947378|NCT03309696|Device|tDCS|transcranial direct current stimulation (tDCS)
1947379|NCT03309696|Device|rTMS|repetitive transcranial magnetic stimulation (rTMS)
1947380|NCT03309683|Device|Olympus Quick Clip Pro - Single Use Repositionable Clips|A hemoclip will be placed after every 0,5-1,0 cm of the resected area to proximate wound edges.
1947381|NCT03309670|Other|Psychiatric future|Former young psychiatric patients are contacted to determine their psychiatric outcome.
1947382|NCT03309657|Drug|Ceftolozane/tazobactam|IV ceftolozane 2000mg /tazobactam 1000mg once only
1947390|NCT03309592|Drug|Ambrisentan Pill|Will be administered as stated in Arm/Group Descriptions
1947391|NCT03309592|Drug|Tadalafil Pill|Will be administered as stated in Arm/Group Descriptions
1947392|NCT03309579|Biological|Liberal Red Blood Cell Transfusion|Hemoglobin transfusion trigger ≤100g/L
1947393|NCT03309579|Biological|Restrictive Red Blood Cell Transfusion|Hemoglobin transfusion trigger ≤80g/L
1947394|NCT03309566|Drug|Efavirenz, tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of efavirenz 600 mg, emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
1947395|NCT03309553|Other|Current Primary Care Referral Process|Children who screen positive for hearing loss will receive the same method each school had been using previously. This process involves a letter home to the parents, either sent with the child or by mail, requesting that the parent/caregiver bring the child to village health clinic for an evaluation.
1947396|NCT03309553|Other|Telemedicine Referral Process|In villages randomized to the expedited telemedicine intervention, parents of children who screen positive will receive a phone call from the school or the clinic on the day of screening notifying them of the day and time of their child's telemedicine consultation appointment. Appointments will be made same-day or next-day, with community health aides (CHAs) who have dedicated time blocked off to perform telemedicine consults. Participating children screening positive will be transported to clinic for their appointment with adult chaperones. Parents are encouraged but not required to attend, except for children grades 2 and younger, for whom parental participation will be required. Nonparticipating children in communities assigned to the expedited telemedicine intervention arm will receive standard referral following the current school primary care referral process.
1947398|NCT03309527|Behavioral|e-aid Cognitive Behavior Therapy|e-aid Cognitive Behavior Therapy
1947399|NCT03309527|Behavioral|e-aid Sleep Hygiene Education|e-aid Sleep Hygiene Education
1947400|NCT03309514|Biological|Intracerebral microinjections|Stereotactic delivery of cell suspension into basal ganglia structures
1947403|NCT03309488|Diagnostic Test|Oral food challenge|Patients with suspected food allergy will undergo clinical and dietary assessments and oral food challenge. Different allergy tests will be performed, including skin prick test, specific IgE test and basophil activation test, and its diagnostic utility will be determined against the clinical gold-standard.
1947404|NCT03309475|Behavioral|MB-SCT|MB-SCT is a cognitive-behavioral intervention that incorporates mindfulness elements, such as radical acceptance, decentering or meditation-techniques. It is designed to target social cognition, defined as the ability to recognize, understand and benefit from social stimuli.
1947405|NCT03309475|Behavioral|Structured psychoeducation|Structured psychoeducation addresses and discuss several aspects of great importance for persons who suffer a first episode of psychosis, such as biased perception and thinking, delusions-related anxiety or the nature of hallucinations. Its aim is to encourage patients to reflect upon their experiences from a critic perspective.
1947406|NCT03309475|Behavioral|Psychosocial treatment|Treatment as usual delivered by patient's practitioner
1947407|NCT03309475|Drug|Psychotropic treatment|Treatment as usual delivered by patient's practitioner
1947408|NCT03309462|Device|Miseq sequencer|The sequencer will be used to detect the gene mutations of the re-biopsy tissue samples and peripheral blood samples obtained from patients.
1947409|NCT03309449|Device|Syringe and needle|Intramuscular administration of simulated naloxone
1947410|NCT03309449|Device|Intranasal mucosal atomization device|Intranasal atomizer administration of simulated naloxone
1947411|NCT03309449|Device|Nasal spray|Nasal spray administration of simulated naloxone
1947412|NCT03309436|Drug|Clomiphene Citrate protocol|Take CC 100mg/d at the same time with Gn until hCG injection.
1947413|NCT03309436|Procedure|Procedure|When a dominant follicle diameter over 14mm or serum E2 over 350pg/ml, use GnRH-ant 0.25mg/d, until hCG injection.
1947414|NCT03309423|Diagnostic Test|venous to arterial conversion (v-TAC)|Venous to arterial conversion (v-TAC) is a software (Obimedical, Denmark), which can convert venous blood gas values to arterial blood gas values. The principle of the method is a mathematical transformation of VBG values to arterialized values (aVBG) by simulating the transport of blood back through the tissue. To facilitate this simulation the following physiologically relevant assumptions were made: 1) The peripheral extremity was well perfused; 2) change in base excess across the tissue sampling site was approximately zero; 3) the respiratory quotient (rate of CO2 production and O2 utilisation over capillaries) could not vary outside the range 0.7 and 1.0, and 4) the haemoglobin concentration was constant from artery to vein.
1947415|NCT03309410|Diagnostic Test|Venous to arterial conversion (v-TAC)|This was an observational study. Paired arterial blood gas and venous blood gas was drawn from each patient and compared. Venous blood gas was converted to arterial blood gas values using v-TAC.
1947416|NCT03309358|Drug|Inhaled SNSP113|A single ascending dose of inhaled SNSP113 will be administered to healthy subjects and subjects with stable cystic fibrosis.
1947417|NCT03309358|Drug|Inhaled Placebo|A single dose of inhaled placebo control will be administered to healthy subjects and subjects with stable cystic fibrosis.
1947418|NCT03309345|Other|No intervention|No intervention as this is an observational study investigates the difference between PKU ant matched healthy control in terms of energy components and dietary intake
1947419|NCT03309332|Device|AMPLATZER™ PFO Occluder|Implantation of the AMPLATZER™ PFO Occluder in the PFO
1947420|NCT03309319|Drug|Rosiglitazone|rosiglitazone is added to the primary treatment
1947421|NCT03309306|Other|Simulated Food Waste - Lab|Participants will use the FoodImage app and food records to measure food waste during simulated food preparation, simulated eating conditions, simulated cabinet and refrigerator clean-outs and simulated food purchases from grocery stores and restaurants. Measurements will be collected by participants with both methods while lab personnel directly weigh foods to provide the criterion value.
1947422|NCT03309306|Other|Natural Environment/Reduce Stress|Participants will use the FoodImage app to measure food waste during: food preparation, eating conditions, cabinet and refrigerator clean-outs and food purchases from grocery stores and restaurants in their natural environment. Participants will capture baseline data for 7 days before meeting with research staff for follow up training about how to use the app to capture all food waste and receive information about stress reduction. After the meeting, participants will use the app to record food waste for an additional 7 days.
1947423|NCT03309306|Behavioral|Natural Environment/Reduce Food Waste|Participants will use the FoodImage app to measure food waste during: food preparation, eating conditions, cabinet and refrigerator clean-outs and food purchases from grocery stores and restaurants in their natural environment. Participants will capture baseline data for 7 days before meeting with research staff for follow up training about how to use the app to capture all food waste and receive information about how to reduce household waste adapted from current consumer campaigns. After the meeting, participants will use the app to record food waste for an additional 7 days.
1947424|NCT03309293|Biological|blood samples|blood samples
1947425|NCT03309280|Other|Duration of intubation|Time between intubation in the operating room and exhumation in the Intensive Care Unit.
1947426|NCT03309267|Procedure|Intercostal block|Intercostal block +patient controlled analgesia
1947427|NCT03309267|Procedure|Serratus anterior plane block|Serratus anterior plane block+patient controlled analgesia
1947428|NCT03309254|Other|High Glycemic Index|High Glycemic Index Food
1947429|NCT03309254|Other|Low Glycemic Index|Low Glycemic Index Food
1947430|NCT03309241|Drug|PF-06882961|Single Ascending Doses of PF-06882961 from 3mg to TBD mg.
1947431|NCT03309241|Other|Placebo|Placebo Single Dose
1947433|NCT03309215|Other|Experimental stimulation with nickel discs|"All participants will be exposed to 8 metal discs, 3 cm in diameter, 4 on each arm, placed on the volar side of the forearms (figure 1). Three of the metallic discs consists of >99 wt.% nickel one consist of >99wt.% Aluminium.The latter is used as a negative control. The discs will be applied under occlusion and with initial pressure and friction.
One metallic disc with nickel, and one with aluminium, will be randomized for the earlobes on the patients with nickel allergy"
1947434|NCT03308734|Behavioral|Reduced-Exertion High-Intensity Interval Training|The 6-week REHIT protocol will involve 3 training sessions a week. Each session will include 10 minutes of unloaded pedalling using a cycle ergometer. Volunteers will be asked to increase to their maximal pedal frequency possible for 1-2 seconds prior to applying a resistance of 5 % of pre-training body weight for the Wingate sprint. The sprints will take place at 2 minutes and at 6 minutes. Sprint duration will be increased from 10 seconds in the first week to 15 seconds in the second and third weeks and finally 20 seconds in the remaining weeks. Patients will receive strong verbal encouragement during the sprints after which the resistance will be removed.
1947435|NCT03309176|Drug|Medroxyprogesterone Acetate 10 MG|Patients in the standard arm will receive Medroxyprogesterone Acetate 10mg daily for 10 days prior to the first ovulation induction cycle and in between anovulatory cycles.
1947436|NCT03309176|Other|Stair step protocol without Medroxyprogesterone Acetate|No administration of Medroxyprogesterone Acetate prior to each cycle. Stair step method: rapidly increasing the dose of clomiphene citrate in case of no follicular response
1947437|NCT03309163|Drug|Tramadol|Patient-controlled intravenous analgesia with Tramadol
1947438|NCT03309163|Drug|Hydromorphone|Patient-controlled intravenous analgesia with Hydromorphone
1947439|NCT03309163|Drug|Ropivacaine (Epidural analgesia)|Patient-controlled epidural analgesia with Ropivacaine.
1947440|NCT03309150|Drug|M6620|Subjects will either receive M6620 as a monotherapy administered intravenously on Day 1, 8 and 15 or as a combination therapy administered intravenously on Day 2 and 9 of the study.
1947441|NCT03309150|Drug|Carboplatin|Subjects will receive carboplatin intravenous infusion as a combination therapy on Day 1 of the study.
1947442|NCT03309150|Drug|Paclitaxel|Subjects will receive paclitaxel intravenous infusion as a combination therapy on Day 1, 8 and 15 of the study.
1457112|NCT03297398|Drug|Group-2 (25 mg,OPK-88004)|25 mg,OPK-88004
1947443|NCT03309137|Device|Chlorhexidine flush|"For patients randomized to the CHG-LockTM device, attach a attach a BD Posiflush ™ 0.9% Sodium Chloride (Na Cl) 10ml syringe and a CHG-Lock™ device for each IV line that is to be locked. Follow hospital approved protocol for flush, volumes and hand hygiene.
After a Catheter has been locked, before re-accessing the catheter for further sampling or infusions, all fluid should be aspirated from the catheter to clear the device of CHG, Heparin and the like. This should also confirm patency of the device.
Discard the syringe and device in biohazard waste.
Blue Cap the IV as per routine practice."
1947444|NCT03309124|Other|White bread|50 g of available carbohydrate meal
1947445|NCT03309124|Other|Baked potato with skin|50 g of available carbohydrate meal
1947446|NCT03309124|Other|Mashed potato served hot|50 g of available carbohydrate meal
1947447|NCT03309124|Other|Mashed potato re-heated|50 g of available carbohydrate meal
1947448|NCT03309124|Other|Fried French fries|50 g of available carbohydrate meal
1947449|NCT03309111|Biological|GBR 1342|GBR 1342 will be administered by intravenous (IV) infusion on Day 1 and Day 15 of each 28-day treatment cycle at escalating dose levels
1947450|NCT03309098|Diagnostic Test|Ligmaster Arthrometer Assessment|Perform an anterior drawer, inversion stress test and eversion stress test on the participant with an ankle arthrometer (LigMaster Version 1.26, Sport Tech, Inc, Charlottesville, Virginia).
1947451|NCT03309085|Procedure|Repeated CT scan|CT scan of chest on different PEEP levels, 4 in total
1947452|NCT03309085|Device|CT scan|CT scan
1947458|NCT03309046|Other|REACH Individual Session|Individual telephone session with parent
1947459|NCT03309046|Other|Education Webinar|Videos with information on caregiving
1947460|NCT03309007|Drug|Metformin|Total daily dose titrated up to 1500 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
1947461|NCT03309007|Drug|Placebo Oral Tablet|Total daily dose titrated up to 1944 mg po q day over the course of 4 weeks and continued for a total exposure of 12 weeks.
1947462|NCT03308994|Other|Delay between MS onset and introduction of first line DMT|Delay between MS onset and introduction of first line DMT : time between date of MS onset ( the first demyelinating neurological events clinically defined) and date of the introduction of the first-line oral DMT (Interferons, Glatiramer Acetate, Dimethyl Fumarate and Teriflunomide)
1947463|NCT03308994|Other|EDI|For all cases of multiple sclerosis residence's places of each patient were geolocalized with a Geographic Information System (ARCGIS 10.2) and assigned to an IRIS, IRIS (Ilots Regroupés pour l'Information Statistique) is the smallest French geographic unit for which census data are available and EDI score was calculated for each IRIS. In order to attribute a social deprivation score to the IRIS, we used the French EDI (European Deprivation Index). EDI stands as a continuous variable but EDI will be used as a categorical variable in order to increase the comparability with others studies, so EDI is distributed into quintiles calculated at the French level.
1947464|NCT03308981|Device|REThink therapeutic online game|The REThink therapeutic online game has seven levels. Each level has various degrees of complexity, which increase as the player progresses in the game. The scenario of the game was developed based on the REBT model, such that it focuses on: a. identifying the emotional and behavioral reactions; b. identifying cognitive processes; c. identifying the relation between cognitive processes and emotions and behavioral reactions; d. changing irrational cognitions into rational cognitions; e. building problem solving skills; f. building relaxation skills and g. building happiness skills.
1947465|NCT03308981|Other|REBE group|In the Rational-Emotive-Behavioral Education (REBE) group participants will follow 7 modules, structured based on the strategies practiced in each of the REThink level.
1947466|NCT03308968|Drug|Fremanezumab|Prefilled syringes contain Dosage B total of active ingredient fremanezumab administered by subcutaneous injection. Week 0 doses of Dosage A consisted of three injections. Week 0 doses of Dosage B consisted of one injection.
1947467|NCT03308968|Drug|Placebo|Prefilled syringes contain the same vehicle as the active intervention administered by subcutaneous injection. Week 0 doses of Dosage B consisted of two injections of placebo to maintain the blind. Week 0 doses of placebo consisted of three injections of placebo to maintain the blind.
1947471|NCT03308942|Drug|Niraparib|PARP inhibitor, Capsule, 200mg dose, QD
1947472|NCT03308942|Biological|PD-1 Inhibitor|Monoclonal antibody, IV administration
1947473|NCT03308929|Device|G7 Dual Mobility hip|Total hip arthroplasty and implantation of the G7 device
1947474|NCT03308916|Diagnostic Test|transient elastography|Ultrasound elastography using shear-wave elastography to measure liver stiffness as a marker of liver fibrosis. Patients with transient elastography above 8.0 kPa selected for liver biopsy to detect advanced liver fibrosis
1947475|NCT03308916|Diagnostic Test|Enhanced liver fibrosis test|Patented, commercially available algorithm of hyaluronic acid (HA), N-terminal propeptide of collagen type 3 (P3NP) and tissue inhibitor of metalloproteinase 1 (TIMP-1)
1947476|NCT03308916|Diagnostic Test|Indirect serum markers of liver fibrosis|Diagnostic markers using combination of routine liver biochemistry: age, AST, ALT, platelet count, cholesterol, GGT
2010436|NCT02964104|Drug|placebo|Administered once daily subcutaneously for 35 days
2010437|NCT02964104|Drug|insulin degludec|Administered once daily subcutaneously for 35 days
2010438|NCT02964104|Drug|placebo|Administered once weekly subcutaneously for 35 days
2010439|NCT02963831|Biological|ONCOS-102|ONCOS-102 will be administered intraperitoneally via a peritoneal Hickmann catheter (or institutionally preferred alternative) at weekly intervals for 6 weeks.
2010440|NCT02963831|Drug|Durvalumab|Durvalumab will be administered by IV infusion once every four weeks for a total of 12 four-week cycles.
2010441|NCT02964013|Biological|MK-7684|Administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35
2010442|NCT02964013|Biological|pembrolizumab|Administered as an IV infusion on Day 1 of infusion Cycles 1-35
2010443|NCT02962024|Drug|Morphine Sulfate|
2010444|NCT02962024|Drug|Bupivacaine Hydrochloride|
1947477|NCT03308916|Diagnostic Test|Direct serum markers of liver fibrosis|Serum markers that reflect liver extracellular matrix turnover and -accumulation
1947478|NCT03308916|Diagnostic Test|LiverTRAIL|Software that contain 199 diagnostic algorithms, containing combinations of routine tests: age, AST, albumin, alkaline phosphatase, bilirubin, GGT, INR, platelet count, cholesterol and sodium, and specialist tests: transient elastography and direct serum markers of fibrosis.
1947479|NCT03308916|Diagnostic Test|Cytokeratin 18|Cytokeratin 18 from liver cell cytoskeleton; when cells undergo apoptosis, caspase-cleaved CK18 is released (M30), whereas full-length CK18 is realised during necrosis (M65)
1947480|NCT03308916|Diagnostic Test|Omics markers|Markers combining signatures of liver fibrosis and hepatic inflammation from many 'omics technologies
1947481|NCT03308903|Diagnostic Test|DEXA scan|The participant will undergo a whole-body DEXA (DEXA; GE Medical Systems, Chalfont St Giles, UK) scan, lasting approximately 5 minutes. This scan will produce body composition data, including estimates of lean body mass (LBM), appendicular lean mass (aLM) and body fat percentage (BF%).
1947484|NCT03308877|Behavioral|BMI|Four 45-minute, brief motivational sessions for substance use
1947485|NCT03308877|Behavioral|Stadard Care (SC)|Standard procedures at pretrial program + assessement
1947486|NCT03308864|Behavioral|Interpersonal Psychotherapy for Adolescents|Experimental: Interpersonal Psychotherapy for Adolescents (IPT-A) IPT-A is a manualized intervention for depression that targets adolescents' interpersonal context and social supports as mechanisms of change. It will be provided in accordance with the treatment manual by Child and Adolescent Outpatient Service clinicians over the course of 12-16 50-minute sessions.
1947487|NCT03308864|Behavioral|Treatment as usual|Treatment as usual will consist of the standard care for adolescent depressive symptoms at CAOS. TAU is not manualized; it is consistent with care typically provided in community settings. Therapists establish a working alliance, are empathetic, reflect expressed affect, and discuss options for coping with concerns as initiated by the adolescent.
1947490|NCT03308825|Biological|Fluzone Quadrivalent vaccine|0.25 mL, Intramuscular
1947491|NCT03308825|Biological|Fluzone Quadrivalent vaccine|0.5 mL, Intramuscular
1947492|NCT03308825|Biological|Fluzone High-Dose vaccine|0.5 mL, Intramuscular
1947493|NCT03308812|Behavioral|Health360x|Participants will view an orientation video which will include information on how to access the program from home and other internet access sites, how to use their activity monitor and sphygmomanometers, introduction to the curriculum, quizzes and discussion boards. Participants will be encouraged to upload their data at least once a week and to access the curriculum as often as desired. Technological and customer service support related to use of the application will be available 24 hours by phone.
1947494|NCT03308812|Behavioral|Health Coach|Participants will be contacted by the health coach in the first week of the study to review their initial self-management behavioral goals and approaches. Follow up calls will occur each week for the first month, biweekly for the second and third months, and then once per month for the remainder of the study (months 4-6).
1947498|NCT03308786|Drug|Recombinant Interleukin-2|Subcutaneous recombinant interleukin-2 (rIL2), 5 MIU twice daily for five consecutive days every 8 weeks for 8 weeks
1947499|NCT03308773|Other|Lifestyle modification in routine care of patients|Diabetes Prevention Program Lifestyle recommendations and non-investigational pharmacotherapy in routine care of patients
1947500|NCT03308760|Other|Questionnaire|Interview concerning the post-operative rehabilitation programme and a functional analysis using the American Orthopaedic Foot and Ankle Society questionnaire
1947501|NCT03308760|Other|Static stabilometry|on a force plate, in a double- then single-foot stance, with the eyes open and then closed
1947502|NCT03308760|Other|Isokinetic test|Isokinetic test of the flexors/extensors and invertors/evertors of the ankle
1947503|NCT03309202|Drug|PF-05221304|25 mg dose
1947504|NCT03307629|Drug|NOX66|NOX66 delivered as rectal suppository.
1947505|NCT03307629|Radiation|Irradiation Therapy|Radiation per selected tumour lesion.
1947506|NCT03308539|Radiation|echocardiography and cardiac magnetic resonance|transthoracic echocardiography and magnetic resonance imaging of the heart
1947507|NCT03308448|Drug|Recombinant human erythropoietin|Intravenous administration of recombinant human erythropoietin (4000 u/vial) with different dosage for each group
1947508|NCT03308383|Other|DOING TRANSTHORACIC ECHOCARDIOGRAM|TRANSTHORACIC ECHOCARDIOGRAM WILL BE DONE IN THE PARTICIPANTS WHICH IS NON-INVASIVE
1947509|NCT03308357|Diagnostic Test|Drug assays to measure infliximab|See protocol
1947510|NCT03308318|Procedure|The supratemporalis approach|The incision differs according to specific fracture sites. It can be a hockey stick-shaped incision, hemicoronal incision, and full coronal incision. The first layer of dissection was just under the superficial temporalis fascia.Then, approximately at the level of 3-5cm above the zygomatic arch, our modified incision was carried through the deep temporalis fascia.Next, the superficial fat pad was encountered and retracted anteriorly, which was in close contact of the temporal muscle. Finally, a flap that included skin, subcutaneous tissue, the superficial temporal fascia, the areolar fat tissue, the deep temporalis fascia and the superficial temporal fat was reflected as a whole anteriorly, fully exposing the temporal muscle and zygomatic arch.
1947511|NCT03308279|Diagnostic Test|Ultrasound|Ultrasound and Anthropometric meassures
1457113|NCT03297398|Other|Placebo|Placebo
1947514|NCT03307967|Behavioral|SBIRT-PM|SBIRT-PM involves an initial telephone-delivered session followed by up to three calls to Veterans in a 12-week period to support Veteran engagement in multi-modal non-pharmacological pain care and to motivate those who misuse substances to change this problematic behavior. SBIRT-PM also includes coordination between the SBIRT-PM clinicians and the PACT nurse case manager after the initial session to support these patient outcomes.
1947515|NCT03307681|Other|White bread|50 g of available carbohydrate meal
1947516|NCT03307681|Other|Baked potato with skin|50 g of available carbohydrate meal
1947517|NCT03307681|Other|Mashed potato served hot|50 g of available carbohydrate meal
1947518|NCT03307681|Other|Mashed potato re-heated|50 g of available carbohydrate meal
1947519|NCT03307681|Other|Fried French fries|50 g of available carbohydrate meal
1947524|NCT03305705|Drug|Iron Carboxymaltose|Single intravenous infusion within 20 min
1947525|NCT03305705|Drug|Sodium chloride 0.9%|Single intravenous infusion of 250 ml within 20 min
1947526|NCT03303417|Diagnostic Test|MRI Scan|Participants will undergo hourly MRI scans on day 3 to assess bowel fluid content
1947527|NCT03303417|Other|Kiwifruit|Kiwifruit
1947528|NCT03303417|Other|calorie-matched sugar drink|calorie-matched sugar drink
1947529|NCT03301857|Drug|Cohort A Denosumab|Cohort A: subjects who were receiving denosumab at the conclusion of Study 20062004 can continue receiving denosumab at the current dose and schedule at the investigator's discretion. All subjects should be adequately supplemented with calcium and vitamin D (at least 500 mg of calcium and 400 IU of vitamin D), except in the case of pre-existing hypercalcemia. Follow-up study visits will be performed in clinic every 6 months (± 30 days) while receiving denosumab. Subjects who discontinue denosumab will have an end-of-treatment (EOT) in-person clinic visit approximately 6 months (± 30 days) after the last dose of denosumab. Thereafter, they will enter the long-term safety follow-up and will be monitored as per Cohort B requirements.
1947531|NCT03299803|Behavioral|Men's Healing Pathways|Peer implemented group self management program to reduce depressive symptoms in men with physical disabilities
1947537|NCT03294018|Other|Recording heart rate changes|Recording heart rate changes during planned sugammadex administration.
1947542|NCT03288025|Behavioral|Nutrition and Exercise|5 times a week exercise training and biweekly diet counseling for 12 weeks.
1947543|NCT03285711|Drug|Filgotinib|200 mg tablet administered orally once daily
1947544|NCT03285711|Drug|GS-9876|30 mg tablet administered orally once daily
1947545|NCT03285711|Drug|Filgotinib placebo|Tablet administered orally once daily
1947546|NCT03285711|Drug|GS-9876 placebo|Tablet administered orally once daily
1947547|NCT03285763|Drug|Atezolizumab|Participants will receive 1200 milligrams (mg) of atezolizumab administered by intravenous infusion on Day 1 of every 3-week cycle until Investigator-assessed loss of clinical benefit, unacceptable toxicity, investigator or participant's decision to withdraw from therapy, or death (whichever occurs first).
1947548|NCT03284788|Behavioral|Acceptance-Based Therapy|The ABT intervention includes 12 sessions that are each 75 minutes in length. Intervention sessions will be weekly for the first 8 weeks, then bi-weekly for the next 8 weeks.
1947549|NCT03284788|Behavioral|Enhanced Care|In the enhanced care group, participants will receive 12 mailed handouts weekly for 8 weeks, then bi-weekly for an additional 8 weeks.
1947550|NCT03282578|Device|Sternalock 360 sternal plating system|The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.
1947551|NCT03282578|Device|Sternal Wires|"Stainless steel wires are applied in a figure of 8 configuration to close the sternum"
1947552|NCT03283072|Device|Hypoxicator|Repeated bouts of hypoxia/hyperoxia
1947553|NCT03281304|Drug|CP-690,500 5 mg|CP-690,550 5 mg tablet BID
1947554|NCT03281304|Drug|CP-690,550 10 mg|CP-690,550 10 mg tablet BID
1947555|NCT03278119|Diagnostic Test|PET Scan and home sleep monitoring tests|Amyloid PET scans will be used to assess amyloid burden in the brain, and sleep evaluations will assess and test for sleep apnea.
1947556|NCT03278431|Drug|Albendazole|Albendazole (400 mg) from Janssen, donated by the World Health Organization
1947557|NCT03278431|Drug|Pyrantel Pamoate|Pyrantel pamoate (20 mg/kg), will be purchased by the World Health Organization
1947558|NCT03278431|Drug|Oxantel Pamoate|Oxantel pamoate (20mg/kg) will be produced by the University of Basel
1947559|NCT03278431|Drug|Mebendazole|Mebendazole (500 mg) from GlaxoSmithKline, donated by the World Health Organization
1947560|NCT03276052|Drug|Aclidinium Bromide 200 μg|Aclidinium Bromide 200 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
1947561|NCT03276052|Drug|Aclidinium Bromide 400 μg|Aclidinium Bromide 400 μg BID inhalation powder. One oral inhalation via Genuair® dry powder inhaler (DPI)
1947562|NCT03276052|Drug|Aclidinium Bromide 800 μg|Aclidinium Bromide 400 μg BID inhalation powder. Two oral inhalations via Genuair® dry powder inhaler (DPI)
1947563|NCT03274973|Drug|Zomacton|Injection
1947564|NCT03272698|Drug|Ketamine|IV Ketamine 0.75 mg/kg
1947565|NCT03272698|Procedure|ECT|ECT with unilateral or bilateral electrode placement and monitoring of seizure threshold by the half-age method
1947566|NCT03270358|Procedure|Blood sampling in arterioveinous fistula without stenosis|"Plasmatic osteopontin level (ng/ml) collected in the patient's arteriovenous fistula.
Blood sampling in arterioveinous fistula right before a dialysis session"
1947567|NCT03270358|Procedure|Blood sampling in arterioveinous fistula with stenosis|Blood sampling in arterioveinous fistula right before the surgery for stenosis of the fistula
1947568|NCT03268057|Drug|VX15/2503 + avelumab|Dose escalation will begin at 5 mg/kg of VX15/2503 and will increase up to 15 mg/kg with a constant dose of avelumab at 10 mg/kg. A recommended phase II dose of VX15/2503 will be determined and then utilized in the expansion phase with 10 mg/kg of avelumab.
1947569|NCT03267927|Device|Rapid palatal expansion|Fixation of rapid palatal expansion from day 0 to day 60
1947570|NCT03267927|Device|MGA™ system|Use of a mandibular advancement Appliance during the night from day 60 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
1947571|NCT03267927|Device|Yoobreath™ system|Use of a device allowing sleep in a semi-seated position during the night from day 15 to day 180 (end of treatment from day 120 if Angle Class I is obtained)
1947573|NCT03264989|Drug|crizanlizumab|SEG101 (crizanlizumab) drug at a dose of 5.0 mg/kg (or 7.5 mg/kg for exploratory group) by IV infusion
1947574|NCT03264092|Procedure|Endoscopic ultrasound guided fine needle biopsy|Using the echoendoscope the pancreatic lesion is identified and the needle is inserted in it to obtain a biopsy also under sonographic guidance
1947575|NCT03262831|Other|Yoga|The yoga practice, Gentle Hatha and Restorative Yoga, will be based on protocols that have been found to decease fatigue and weight gain by helping the participant gain insight in recognizing stress responses and ways to relax
1947576|NCT03262831|Procedure|Blood draw|"Baseline and end of neoadjuvant treatment
To evaluate change in inflammatory markers (CRP, IL-6, and TNF)"
1947577|NCT03262831|Behavioral|FACT-G questionnaire|"7 statements that other people with breast cancer have said are important, the patient is to circle or mark one number per line to indicate the response as it applies in the last 7 days
Answers range from 0=not at all to 4=very much"
1947578|NCT03262831|Procedure|Weight measurement|-Weight will be taken at baseline, on day 1 of each cycle, and the end of treatment
1947579|NCT03262831|Behavioral|Recent Physical Activity Questionnaire|-To assess physical activity, the RPAQ will be completed at baseline and at the end of neoadjuvant treatment.
1947580|NCT03262831|Behavioral|NHANES Food Questionnaire|-To assess diet, the NHANES Food Questionnaire will be completed at baseline and at the end of neoadjuvant treatment.
1947581|NCT03259386|Device|Microelectrode array|Microelectrode array implanted in area of amputation of either transradial or transhumeral amputees. This device is not designed to collect data on safety and effectiveness but rather, the device is a tool to assist in the sensory and motor properties of peripheral nerve stump fibers in amputees and is considered basic physiological research. This study was determined to be IDE exempt by the FDA; the study is considered basic physiological research.
1456361|NCT03303053|Drug|Standard treatment|Carbimazole 30 mg daily and propanolol 40 mg twice daily for 4 weeks
1456362|NCT03303040|Other|Electrical stimulation of hemidiaphragm|Electrical impulses
1459927|NCT03275090|Drug|Smoflipid ®|
1947585|NCT03256929|Behavioral|Personalized Diet-driven microbiota|Based on the results of the individual microbiota profile, we will formulate a specific diet aiming to enrich the distinct microbiota with organisms correlated to better mental health. The dietitian will visit each participant twice a month.
1947586|NCT03256929|Behavioral|General information on nutrition and health|General information on nutrition and health. The dietitian will visit each participant twice a month.
1997051|NCT02261974|Device|Active Treatment Viveve|Application of Radiofrequency Energy to the vaginal introitus
1997052|NCT02261974|Device|Sham Treatment Viveve|Subject will receive less than one (1) Joule of radiofrequency energy to the vaginal introitus
1997053|NCT02259023|Other|Liquid: Sugar sweetened beverage consumption|Sugar sweetened beverage consumption
1997054|NCT02259023|Other|Solid: Grain based desserts and candy consumption|Grain based desserts and candy consumption
1997055|NCT02258542|Biological|Benralizumab|Benralizumab administered subcutaneously
1997056|NCT02258542|Biological|Benralizumab|Benralizumab administered subcutaneously
1997060|NCT02256631|Biological|VRC01|Administered by subcutaneous injection in the thigh
1997061|NCT02256631|Biological|VRC01LS|Administered by subcutaneous injection in the thigh
1997062|NCT02252328|Drug|Simvastatin|Simvastatin 80mg once daily
1997063|NCT02252328|Drug|Placebo|Placebo tablets once daily
1947593|NCT03250377|Drug|Brivaracetam|"Pharmaceutical form: Film-coated tablet
Concentration: 25 mg and 50 mg
Route of administration: Oral use"
1947594|NCT03250325|Biological|TBI-1301|Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide pre-treatment.
1947595|NCT03250325|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
1947598|NCT03249935|Drug|Azithromycin|Azithromycin 1 gm PO single dose given as directly observed
1947600|NCT03243721|Diagnostic Test|7T MRI|A high field MRI that will take approximately one hour.
1947601|NCT03243721|Diagnostic Test|Neurocognitive testing|A series of tests to assess memory, verbal skills, and visuospatial skills.
1947602|NCT03242707|Biological|Autologous adipose tissue injection|"20ml to 40ml of subcutaneous adipose tissue will be aspirated from the abdomen. Adipose tissue will be processed using the Lipogems device, a closed-loop processing device used in medical procedures involving the harvesting, concentrating and transferring of autologous adipose tissue.
The resulting fat product will be delivered locally via ultrasound-guided, intra-articular injection."
1947603|NCT03242707|Drug|Hyaluronic Acid|GenVisc 8501 is a high molecular weight sodium hyaluronate.
1947604|NCT03242889|Drug|DARA SC|Participants will receive 1800 mg daratumumab with 30,000 U (2000 U/mL) rHuPH20 SC injection once weekly for the first 8 weeks in Cycles 1 and 2 and every 2 weeks in Cycles 3 to 6 for 16 weeks and then every 4 weeks in subsequent cycles until disease progression, unacceptable toxicity, or any other reason for discontinuation.
1947610|NCT03237845|Drug|Rimegepant|active
1947611|NCT03237845|Drug|Placebo|placebo
1947612|NCT03235479|Drug|BHV-3000|75 mg tablet QD
1947613|NCT03235479|Drug|Placebo Oral Tablet|equivalent of 75 mg tablet QD
1463192|NCT03249376|Other|Placebo|Placebo
1947617|NCT03233529|Drug|Crisaborole ointment 2% BID|Crisaborole ointment 2% BID for 15 days (double blind); additional 28 days (open label)
1947618|NCT03233529|Drug|Placebo ointment (vehicle)|Placebo ointment (vehicle) BID for 15 days (double blind)
1997064|NCT02252406|Drug|Ranolazine|Ranolazine 500 mg up to 1000 mg daily for 24 weeks.
1997065|NCT02252406|Drug|Placebo|Matching placebo tablets daily for 24 weeks.
1997068|NCT02250014|Procedure|cryotherapy|Undergo cryotherapy
1997069|NCT02250014|Biological|sargramostim|Given subcutaneously
1997072|NCT02247089|Other|Massage Therapy|Intervention consists of administering a 30-minute-long upper body massage by a registered massage therapist following a massage protocol developed by Vancouver College of Massage Therapy (VCMT).
1997073|NCT02247089|Other|Journal reading (No massage therapy)|Intervention consists of journal reading in the same sitting position as the massage therapy session for approximately 30 minutes.
1997074|NCT02244424|Behavioral|Tools for Teen Moms|"The Tools for Teen Moms intervention is a novel social media intervention platform designed by the investigators which includes cell phone text message reminders, and infant feeding website, and Facebook to increase infant-centered feeding through daily behavioral challenge activities (challenges) for this population. The intervention consists of 6 weeks of daily challenges and will be delivered within the infant's first 6 months of life."
1997075|NCT02244112|Drug|Oprozomib|Subjects will receive oprozomib 270 mg per dose in Part I and oprozomib 300 mg per dose in Part II.
1997076|NCT02244112|Drug|Midazolam|Subjects will receive a single oral dose of midazolam 2 mg in Period 1 and oral midazolam 2 mg per dose in Period 2.
1997077|NCT02242942|Drug|Chlorambucil|Chlorambucil 0.5 milligrams per kilogram (mg/kg) orally at Day 1 and Day 15 at of each 28 day cycle for 12 cycles.
1997078|NCT02242942|Drug|Venetoclax|Venetoclax, oral tablet: 20 mg daily during Cycle 1, Day 22-28; 50 mg daily during Cycle 2, Day 1-7; 100 mg daily during Cycle 2, Day 8-14; 200 mg daily during Cycle 2, Day 15-21; 400 mg daily during Cycle 2, Day 22-28 and on Day 1-28 for all subsequent cycles until the end of Cycle 12.
1997079|NCT02242942|Drug|Obinutuzumab|Obinutuzumab, IV infusion: 100 mg or 1000 mg, depending on splitting rules, at Cycle 1, Day 1 (if 100 mg was received on Day 1, 900 mg will be administered on Cycle 1, Day 2); 1000 mg at Cycle 1, Day 8 and Day 15; 1000 mg at Day 1 for all subsequent cycles until the end of Cycle 6
1997080|NCT02241720|Drug|regorafenib|
1997081|NCT02242045|Drug|Idelalisib|Tablet (s) administered orally twice daily
1997082|NCT02241564|Other|Referral to a multidisciplinary expert panel at the Uppsala University Hospital after tumor detection|
1997083|NCT02241564|Drug|Switch from calcineurin inhibitor to an mTOR inhibitor|
1947633|NCT03224689|Device|PEEK-Optima Femoral Component|TKA Surgery
1947636|NCT03223194|Genetic|AT342|AT342 is an AAV8 vector containing a functional copy of the UGT1A1 gene.
1947637|NCT03220854|Radiation|Stereotactic radiotherapy|Treatment will be planned to deliver a total of 18 to 60 Gy to the planning target volume (PTV) in 3 to 5 fractions over 1 to 2 weeks.
1947638|NCT03220854|Other|Biological: humanized anti-PD-1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-1 inhibitor they were receiving prior to study registration
1947639|NCT03220854|Other|Biological: humanized anti-PD-L1 monoclonal antibody|Standard of Care - patient will continue to be given the same PD-L1 inhibitor they were receiving prior to study registration
1947642|NCT03214861|Other|Carbohydrate quality|This is an observational study examining the association between carbohydrate quality and coronary heart disease. The investigators used a variety of carbohydrate quality metrics to evaluate carbohydrate quality including carbohydrate, starch, total fiber, cereal fiber, fruit fiber, and vegetable fiber intakes, and the ratios of carbohydrate to total fiber, carbohydrate to cereal fiber, starch to total fiber, and starch to cereal fiber intakes.
1947643|NCT03215810|Procedure|Tumor-infiltrating Lymphocytes (TIL)|Tumor harvest for TIL growth in the lab: A sample of the participant's tumor will be collected and sent to the lab for TIL growth. TIL will be prepared and cryopreserved.
1947644|NCT03215810|Drug|Nivolumab|Nivolumab will be administered intravenously at a fixed dose of 240 mg for four doses beginning after tumor harvest (+/- 7 days).
1947645|NCT03215810|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 60 mg/kg/day IV in 250 mL normal saline (NS) over approximately 2 hours. Cyclophosphamide will be initiated seven days prior to the anticipated TIL transfer, and the precise timing will depend on the rate of in vitro TIL growth. The dose will be based on the patient's body weight, but to prevent undue toxicity, it will not exceed a dose greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company, Height and Weight Table.
1947646|NCT03215810|Drug|Fludarabine|After administration of Cyclophosphamide, Fludarabine will then be infused at 25 mg/m^2 intravenous piggyback (IVPB) daily over approximately 30 minutes starting 5 days prior to TIL transfer. To prevent undue toxicity with fludarabine, the dose will be based on body surface area (BSA), but will not exceed a dose calculated on surface areas based on body weights greater than 140% of the maximum ideal body weight per Metropolitan Life Insurance Company Height and Weight Tables.
1947647|NCT03215810|Other|Tumor-infiltrating Lymphocyte Therapy|On day 0, all patients will receive TIL administered according to the current Moffitt Cell Therapy TIL Standard Operating Procedure (SOP). Eight (8) to twelve (12) hours after completing the TIL infusion, all participants will begin intermediate-dose decrescendo interleukin-2 (IL-2).
1947648|NCT03215810|Drug|Interleukin-2 (IL2)|Interleukin-2 (IL-2) - a drug used to help the body's response to treatment on the immune system. A high dose regimen of IL-2 will be given after the infusion of the T-cells.
1456223|NCT03304262|Device|rTMS|Between time point M2 and M3, participant will receive 900 pulses of rTMS at 1Hz at 0.85 of M2 resting motor threshold.
1947667|NCT03206437|Behavioral|Mindfulness-Based Stress Reduction|The MBSR course teaches mindfulness meditation skills. This 8-week course meets in person once a week for 2.5 hours. Participants are expected to complete practice assignments at home.
1947668|NCT03206437|Behavioral|Waitlist|This group will wait 8-16 weeks after their first testing visit and after their second study visit is completed they will be able to participate in an 8-week MBSR course.
1947669|NCT03206372|Other|Case group|Questionnaire to be completed, blood sample and possibly echo-doppler
1947670|NCT03206372|Other|Control group|Questionnaire to be completed, blood sample and possibly echo-doppler
1456226|NCT03304236|Device|Myelopathy Hand|Patients will undergo radiological and clinical examination at the Duchess of Kent Children Hospital. Patients will be required to put on a pair of hand gloves with 18 IMUs located on specific bony landmarks (distal phalanges of fingers, proximal phalanges of index fingers and thumbs, dorsum of the hands and bilateral wrists)
1456227|NCT03304223|Diagnostic Test|[18F]FB-IL2 PET scan|[18F]FB-IL2 PET scan procedure
1456230|NCT03304197|Dietary Supplement|Hypotonic|N/A: see arm description
1456231|NCT03304197|Dietary Supplement|Isotonic|N/A: see arm description
1456232|NCT03304197|Dietary Supplement|Water|N/A: see arm description
1456233|NCT03304197|Other|Dehydrated|N/A: see arm description
1456234|NCT03304184|Device|Photac-fil|Application of a tooth colored filling in a non-cavitated dental lesion.
1456235|NCT03304184|Device|Biodentine|Application of a white colored filling in a non-cavitated dental lesion.
1456240|NCT03304106|Device|Commercially available cochlear implant and AI system|Use of AI technology to assist in audiologist's evaluation and programming of cochlear implant recipients
1456241|NCT03304093|Drug|Nivolumab Injection|Nivolumab 3mg/kg every 2 weeks
1456242|NCT03304080|Drug|Anastrozole|1 mg orally daily, day 1 to 28
1456243|NCT03304080|Drug|Palbociclib|Dose I: 100 mg orally daily, day 1 to 21, then 7 days off in a 28 day cycle (Phase 1 only) Dose II: 125 mg orally daily, day 1 to 21, then 7 days off in a 28 day cycle
1456244|NCT03304080|Drug|Trastuzumab|8 mg/kg IV initial loading dose, followed by 6 mg/kg IV every 21 days
1456245|NCT03304080|Drug|Pertuzumab|840 mg IV followed by a maintenance dose of 420 mg IV every 21 days
1947677|NCT03193957|Drug|Etanercept|Etanercept PFS and Autoinjector
1456249|NCT03304041|Dietary Supplement|low-FODMAPs diet|"The low-FODMAPs diet(LFD) aims to keep oligosaccharides, fructose in excess of glucose, and polyol content at less than 0.5 g each per serving based on previously published data.
low-FODMAPs diet therapy for 3 weeks"
1456250|NCT03304041|Dietary Supplement|standard diet|"Standard diet advice(SDA) will focus more on how and when to eat rather than on what foods to ingest . Patients will be instructed to regularly eat, never too much or too little, never to be hungry or too full; to eat in peace and to chew thoroughly; reduce intake of fatty, spicy food, fiber, coffee and alcohol during the intervention period
standard diet for 3 weeks"
1947678|NCT03193957|Device|Autoinjector|Autoinjector
1947679|NCT03193502|Drug|rivaroxaban|rivaroxaban
1456363|NCT03303027|Device|6-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 6-0
1947684|NCT03191864|Drug|APT-1011|APT-1011 is an orally disintegrating tablet formulation of fluticasone propionate
1947685|NCT03191864|Drug|Placebo|Placebo tablets are identical in composition to APT-1011 except they exclude the active ingredient.
1947686|NCT03191799|Drug|Emicizumab|Initial dosing will be 3 mg/kg/week subcutaneously for 4 weeks; Maintenance dosing will follow at 1.5 mg/kg/week subcutaneously for the remainder of the 2-year treatment period
1947689|NCT03186339|Procedure|TAVI|transfemoral transcatheter aortic valve implantation
1947690|NCT03186339|Procedure|SAVR|isolated surgical valve replacement
1947691|NCT03186339|Other|MM|management of aortic stenosis by medical treatment only
1997091|NCT02240095|Behavioral|Intervention A - Online Clinical Questions Recorder|Students allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
1997092|NCT02240095|Behavioral|Intervention B - Online Evidence Retrieval Coach|Students allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
1997093|NCT02240095|Behavioral|Intervention C - Online Audit and Feedback|Students allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
1997094|NCT02239315|Other|Tumor RNA Disruption Assay™ (RDA)|Tumor RNA Disruption Assay™ (RDA) to generate RDA score from fine needle aspiration biopsy samples of breast cancer obtained 7-14 days after the first, second and third cycles of neoadjuvant chemotherapy; and, if there is a change of chemotherapy regimen, after the first cycle of the new chemotherapy.
1456256|NCT03304015|Behavioral|Behavioral Change Communications|HERrespect is developed by Business for Social Responsibility (BSR) and Change Associates. HERproject is one of BSR's numerous initiatives for improving women's lives through enhancement of access and knowledge (BSR, 2015). The factory-based component of HERrespect will be implemented by Change Associates. The intervention group will receive training (group session), research and consultancy services to the corporate and development sectors. HERrespect proposes to use the workplace as an incubator of dialogue among men and women to tackle underlying issues which allow violence against women and girls. Workplace offers a unique platform and environment to engage women who are gaining financial independence to reduce intimate partner violence and workplace violence.
1456257|NCT03304002|Other|Breast Cancer Surgery Decision Aid|We use a standard decision aid collaboratively developed by Health Dialog and the Informed Medical Decisions Foundation
1456258|NCT03303989|Drug|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + MMF arm will start on 1) Pegloticase 8 mg IV every two weeks#, and 2) mycophenolate mofetil at 500 mg/BID and titrating up to 1000 mg/BID in 2 weeks if tolerated. Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
1456259|NCT03303989|Drug|Placebo|Participants randomized to the pegloticase + placebo will receive placebo instead of Mycophenolate mofetil therapy for 12 weeks. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
1456260|NCT03303989|Drug|Mycophenolate Mofetil|Participants randomized to the pegloticase + MMF arm will start on 1) Pegloticase 8 mg IV every two weeks#, and 2) mycophenolate mofetil at 500 mg/BID and titrating up to 1000 mg/BID in 2 weeks if tolerated. Mycophenolate mofetil therapy will continue for 12 weeks at the highest tolerated dose. After the 12-week combination mycophenolate mofetil and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
1456261|NCT03303989|Drug|Pegloticase 8 MG/ML [Krystexxa]|Participants randomized to the pegloticase + placebo will receive placebo instead of Mycophenolate mofetil therapy for 12 weeks. After the 12-week combination placebo and pegloticase study period, participants will continue open label pegloticase therapy for an additional three months.
1456262|NCT03303976|Biological|Bioconjugate pneumococcal vaccine|Bioconjuagte vaccine against bacterial pneumococcal infection
1456263|NCT03303976|Biological|Multivalent plain polysaccharide vaccine|Multivalent plain polysaccharide vaccine against bacterial pneumococcal infection
1456264|NCT03303963|Diagnostic Test|Deeplex test, InSilixa chip assay, GeneXpert 2nd line|"Improvement of the diagnosis of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to diagnose Tuberculosis resistance to 1st and 2nd line drugs through novel molecular multiplex assays (Study 1) by:
Validating the Deeplex test and establish a network for shipment of sputum samples in ethanol to regional reference laboratories (Study 1 - phase 1)
Validating the InSilixa chip-based detection of resistance as a point of care test (Study 1 - phase 2)
Validating the Cepheid GeneXpert 2nd line cartridge at the district level (Study 1 -phase2)"
1456265|NCT03303963|Diagnostic Test|Fluorescein DiAcetate (FDA) Microscopy,GeneXpert Ct value|"Improvement of the management of Multi Drug Resistant-Tuberculosis patients with culture-free approaches. We have planned to set up alternative culture-free approaches for the monitoring of patients' response to Multi Drug Resistant-Tuberculosis treatment (Study 2), with:
FDA microscopy
Measurement of bacterial load by following Cycle threshold (Ct) values in GeneXpert Mycobacterium tuberculosis/Rifampicin"
1456266|NCT03303950|Drug|Busulfan|Given IV
1456267|NCT03303950|Drug|Cyclophosphamide|Given IV
1456268|NCT03303950|Drug|Fludarabine|Given IV
1456269|NCT03303950|Procedure|Hematopoietic Cell Transplantation|Undergo HSCT
1456270|NCT03303950|Other|Laboratory Biomarker Analysis|Correlative studies
1456271|NCT03303924|Drug|ETX2514 and sulbactam|Each subject will receive three doses of of ETX2514 1.0 g and sulbactam 1.0 g via intravenous (IV) infusion administered every 6 hours with each drug infused over 3 hours
1456273|NCT03303898|Procedure|Blood sampling|sampling of 7 blood tubes
1456275|NCT03303846|Procedure|Magnetic Resonance Imaging|Undergo screening breast MRI
1456276|NCT03303846|Procedure|Biopsy of Breast|Undergo image-guided breast biopsy
1456277|NCT03303846|Procedure|Biospecimen Collection|Undergo blood sample collection
1456278|NCT03303846|Other|Laboratory Biomarker Analysis|Correlative studies
1456279|NCT03303833|Other|No intervention, observational study.|
1456280|NCT03303807|Device|Extracorporeal CO2 removal (ECCO2-R) (PrismaLung®, Prismaflex ® Baxter)|A low-flow CO2 removal device (Prismalung®, Baxter) will be used with a conventional renal replacement therapy (RRT) platform (Prismaflex®, Baxter). In patients already treated with continuous RRT because of renal failure or metabolic acidosis, the HF 1400® (Baxter) set will be used to combine RRT and decarboxylation. Gas flow through the gas exchanger will be set up to 10 L/min, with an oxygen concentration from 0.21 to 1 and a blood flow of 200-400 mL/min. Patients will be ventilated with a target tidal volume of 6 ml/kg (predicted body weight) and a target plateau pressure below 30 cmH2O.
1456281|NCT03303794|Drug|Exparel|1.3 % liposomal Bupivacaine in patients undergoing total knee arthroplasty
1456282|NCT03303794|Drug|0.25% bupivacaine|0.25% bupivacaine in patients undergoing total knee arthroplasty
1456283|NCT03303781|Other|Cardiac Rehabilitation|phase II center-based cardiac rehabilitation
1456284|NCT03303768|Diagnostic Test|Ultrasound|Investigation of relevant ultrasound signs to improve the antenatal diagnosis of coarctation of the aorta by calculating the sensitivity and specificity of these different signs
1456285|NCT03303742|Other|deep chamfer|finish line marginal design of a full coverage crown preparation
1456286|NCT03303742|Other|feather edge|finish line marginal design of a full coverage crown preparation
1479086|NCT03126916|Drug|Thiotepa|Given IV
1456290|NCT03303703|Other|RENEwS|The intervention participants will meet with a trained interventionist for five 60-minute sessions as a group (two groups of five participants each). In the sessions time will be divided between didactic presentation of material, active practicing of techniques, group work focused on case studies, and worksheets for further practice at home. Topics covered within the intervention include emotional awareness, balancing emotional and physical wellbeing, selecting and implementing emotion regulation strategies (such as situation selections, mindfulness, engagement/avoidance, reappraisal, and emotional sharing), and emotional monitoring.
1456292|NCT03303677|Drug|Saline Nasal|topical nasal saline rinses
1456293|NCT03303677|Drug|Budesonide Nasal|saline + budesonide nasal saline irrigation
1456294|NCT03303677|Drug|Topical Antibacterial (Product)|The antibiotic would be chosen based on intra operative culture sensitives as is our standard practice. The antibiotic would be selected from Levaquin, Vancomycin, Gentamicin, Ciprofloxacin, Mupirocin, and Trimethoprim/Sulfamethoxazole
1456295|NCT03303664|Other|IMPROVE Protocol|Comprehensive pain management protocol
1456297|NCT03303638|Behavioral|Multi-sensory Environment|Multi-sensory environments (MSE), also known as Snoezelen® environments, are defined as behavioral environmental intervention to help people with cognitive and physical impairments reach sensory equilibrium. Typical elements within MSE include visual, auditory, tactile and olfactory stimuli, ergonomic vibro-acoustic furniture, bubble tubes, color-changing LED lighting solutions, music, fiber optics and aromatherapy.
1947693|NCT03186131|Drug|Ibandronate|To examine the efficacy of oral Ibandronate in osteoporosis
1947694|NCT03186131|Drug|Oral Ibandronate and Vitamin D|To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis
1456301|NCT03303612|Device|Pacemaker implant|Patient will be in the electrophysiology laboratory. The doctor will freeze the groin area and a medication may be given to help the patient relax. A catheter will be inserted into the groin up to the heart and the heart's electrical system will be recorded.
1456302|NCT03303612|Device|Transcutaneous cardiac monitor|The transcutaneous cardiac monitor is applied to the skin on the thorax. It may be necessary to shave the area. The monitor is water resistant and can be used in the shower. The monitor's location needs to be changed every 7 days. Instructions will be supplied to the patient.
1456306|NCT03303560|Drug|COR388|Administered as oral capsule
1456308|NCT03303534|Dietary Supplement|ScandiShake|weight gain supplement low in protein
1456309|NCT03303521|Drug|Placebo|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .
Single dose contains from 1 to 3 sachets of Placebo depending on dose level assigned to a patient per non-dialysis days."
1456310|NCT03303521|Drug|Sodium Zirconium Cyclosilicate (ZS)|"Suspension administered orally for a treatment period of eight weeks (4 weeks of dose adjustment, 4 weeks in stable dose) .
Single dose contains from 1 to 3 sachets of ZS 5g depending on dose level assigned to a patient per non-dialysis days."
1456311|NCT03303508|Diagnostic Test|anti-ds DNA|venous blood samples
1456312|NCT03303495|Biological|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
1456313|NCT03303495|Drug|CPT-11|180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle
1456314|NCT03303495|Drug|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
1456315|NCT03303495|Drug|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
1456316|NCT03303495|Drug|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
1456317|NCT03303482|Behavioral|Enhancing Trauma Awareness (Diane Wagenhals, MEd—Lakeside Global Institute)|The trauma awareness professional development course is delivered in a small group (up to 16 participants; 2.5 hours every other week over 12 weeks). The course provides an environment for professionals to explore in depth the complex nature of trauma, while also recognizing and emphasizing the highly sensitive nature of trauma that is essential to becoming trauma-informed. The course facilitates a heightened awareness and appreciation for trauma-related behaviors and consequences that influence relationships and systems and that persist across generations.
1456318|NCT03303469|Drug|FMISO|FMISO PET/CT imaging at baseline
1456319|NCT03303469|Drug|FMISO|FMISO PET/CT post TACE
1456320|NCT03303469|Drug|FMISO|FMISO PET/CT post SBRT
1456321|NCT03303456|Other|Mobile health application - Ginger.io|the Ginger.io is a smartphone application allowing for daily surveys assessing mood and social interactions, and weekly surveys assessing symptoms and psychosocial functioning. Collects passive movement and interaction data
1456322|NCT03303430|Diagnostic Test|MRI|Diffusion weighted imaging 24 hours after revascularisation
1456326|NCT03303404|Device|Ambulatory (24-hour) Blood Pressure|Unlike casual blood pressure measurements, 24-hour ambulatory blood pressure monitoring provides an insight into blood pressure changes in everyday life and an estimate of the overall blood pressure load exerted on the cardiovascular system over 24 hours. Blood pressure recordings over a 24-hour period of normal daily activity will be made using a noninvasive ambulatory monitor (Spacelabs, Redlands, WA). The ambulatory system will be calibrated against a mercury sphygmomanometer, and the cuff will be programmed to inflate automatically every 15 min from 6 AM to 11 PM and every 20 min between 11 PM and 6 AM. For each individual subject, the nighttime period will be defined as the time when the subject goes to bed at night until rising in the morning. Daytime will be defined as the remainder of the 24-hour period. Daytime and nighttime states will be monitored by an Actiwatch (Mini-MItter, Bend, OR), a watch-like device placed on the wrist that measures gross motor activity.
1456327|NCT03303391|Other|Intradialytic Blood Pressure Slope Based Ultrafiltration|Algorithmic Determination of ultrafiltration based on intradialytic blood pressure slopes calculated at the beginning of each month from the prior two weeks of dialysis treatments
1456328|NCT03303378|Drug|melatonin (Helsinn Chemical Co, Biasca, Switzerland)|"Patients will receive a total intravenous melatonin (Helsinn Chemical Co, Biasca, Switzerland) dose of 11.61 mg (aproximately 166 μg/kg). The dose will be distributed in a volume of 500 ml of an isotonic and sterile solution of 100 μM melatonin during 150 min with a drip rate of 4.2 ml/min.
The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention)."
1456329|NCT03303378|Drug|Placebos|The temporal distribution of perfusion will be: 30 min previous to percutaneous revascularization and remainder doses in a subsequent 120 min (1 h during the angioplasty +60 min post-intervention).
1947697|NCT03183557|Drug|"Zoledronic acid, Reclast®"|To examine the efficacy of zoledronic acid in osteoporosis
1456331|NCT03303352|Procedure|EUS FNA|Patients with solid pancreatic masses fulfilling the inclusion and exclusion criteria will be randomly allocated to receive EUS FNA (endoscopic ultrasound fine needle aspiration).
1456332|NCT03303339|Drug|PCM-075|PCM-075 orally
1456333|NCT03303339|Drug|Cytarabine|subcutaneously
1456334|NCT03303339|Drug|Decitabine|intravenously
1947698|NCT03183557|Drug|"Zoledronic acid, Reclast® and active vitamin D, alfacalcidol®"|To examine the efficacy of zoledronic acid plus alfacalcidol in osteoporosis
1456336|NCT03303313|Drug|Cemdisiran|Subcutaneous (sc) injection of Cemdisiran
1947699|NCT03182075|Behavioral|Computerized Training|OCD participants will receive 14 sessions of training via computer within 3 weeks.
1456338|NCT03303274|Procedure|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
1456340|NCT03303235|Drug|Methylergonovine|IV vs IM
1456341|NCT03303222|Diagnostic Test|breath|measurement of volatile compounds, such as TMAO in exhaled breath and blood
1456342|NCT03303209|Other|Patient-centered opioid tapering protocol|All patients who entered the study agreed to partner with their pain physician on a patient-centered opioid tapering program. The research component of the study was to observe patient response (in terms of change in MEDD and pain intensity) at month 4.
1456343|NCT03303196|Device|Bihormonal Bionic Pancreas|A 4-day inpatient admission in which subjects will wear the bihormonal pancreas. The bihormonal pancreas will be placed upon admission and there will be 1 day of run-in. This will be followed by 3 days of data collection for comparison with the data obtained from the standard of care during the control admission.
1456348|NCT03303157|Other|no intervention|not relevant
1456349|NCT03303144|Drug|Triferic|ferric pyrophosphate citrate
1456350|NCT03303131|Other|Discharge from community-based management|Comparison of patient characteristics and treatment outcomes between two groups
1947702|NCT03182374|Device|nSTRIDE APS|Intra-articular injection
1456352|NCT03303105|Drug|TEV-48125|TEV-48125 will be administered subcutaneously once every 4 weeks or 12 weeks.
1456353|NCT03303092|Drug|TEV-48125|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
1456354|NCT03303092|Drug|Placebos|Placebo will be subcutaneously administered once monthly for 3 months.
1456355|NCT03303079|Drug|TEV-48125|TEV-48125 or placebo will be subcutaneously administered once monthly for 3 months.
1456356|NCT03303079|Drug|Placebo|Placebo will be subcutaneously administered once monthly for 3 months.
1456357|NCT03303066|Drug|FG-4592|Oral
1456358|NCT03303066|Drug|Placebo|Oral
1456359|NCT03303053|Drug|Cholestyramine Powder 4g|Cholestyramine powder 4g twice daily, Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
1456360|NCT03303053|Drug|Prednisolone|Tablet prednisolone 30 mg daily for week 1, 20 mg daily for week 2, 10 mg daily for week 3 and 5 mg daily for week 4, Tablet carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks
1947703|NCT03182374|Device|Synvisc-One|Intra-articular injection
1947708|NCT03181893|Drug|PF-06823859|A humanized immunoglobulin neutralizing antibody
1947709|NCT03181893|Drug|Placebo Arm|Placebo contains histidine, sucrose, PS80, ethylene diamine, and triacetic acid
1997101|NCT02233153|Other|Elder-Friendly Surgical Unit|
1997102|NCT02233608|Behavioral|Advanced Pelvic Floor Muscle Exercise (APFX)|
1456364|NCT03303027|Device|5-0 fast absorbing gut suture|Fast absorbing surgical gut suture is a strand of collagenous material, size 5-0
1456365|NCT03303014|Device|5-0 Prolene, 5-0 Fast Absorbing Gut|The interventions are two types of sutures: 5-0 Prolene, 5-0 Fast Absorbing Gut.
1456366|NCT03303001|Procedure|Subacromial high volume infiltration|This group will receive a high volume dose of a mix of methylprednisolone (40 mg in 2 mL) plus ropivacaine at 7.5% plus simple lidocaine plus saline solution for a total of 50 mL
1456367|NCT03303001|Procedure|Subacromial conventional infiltration|This group will receive a mix of solution of 2 mL of 40 mg of methylprednisolone plus 5 ml of ropivacaine at 7.5% plus 3 mL of lidocaine simple for a total of 10 ml
1456368|NCT03302988|Other|Everted closure|Suturing technique to obtain wound eversion. Type of suturing technique at surgeon's discretion
1456369|NCT03302988|Other|Planar closure|The planar side will be closed with traditional buried simple closure and running cuticular sutures
1456370|NCT03302975|Device|Real-time visual biofeedback during treadmill running|Real-time biofeedback of braking forces during running
1456371|NCT03302962|Behavioral|Intensive Asthma Education|"One half (54) of the identified cases were randomized to receive the previously established BREATHE study educational program, emphasizing patient-centered, self management of asthma. Periodic follow-up through personal contact and surveillance of IHS RPMS or other medical provider records was conducted."
1456374|NCT03302923|Behavioral|Brisk walking|Prospective randomized clinical trial with 4 intervention groups and 1 control group.
1456375|NCT03302923|Device|Transcutaneous vagus nerve stimulation (TVNS)|Prospective randomized clinical trial with 2 intervention groups, 2 active comparative groups and 1 control group.
1456376|NCT03302923|Dietary Supplement|Protein supplementation|Prospective randomized clinical trial with 1 intervention group, 3 active comparative groups and 1 control group.
1456377|NCT03302910|Other|Short Stay Unit|Subjects will be treated for acute heart failure in the SSU and observed for improvement then, if appropriate, discharged. If not appropriate for discharge they will be admitted to inpatient.
1456378|NCT03302910|Other|Standard of Care|Subjects who come to the ER with acute heart failure who are randomized to inpatient stay.
1456379|NCT03302910|Drug|Loop Diuretics|IV loop diuretics are commonly used in AHF management
1456380|NCT03302910|Drug|Nitroglycerin|Nitroglycerin or nitrovasodilators are commonly used in AHF management
1456381|NCT03302897|Biological|LEP-F1 + GLA-SE|Investigational vaccine
1456383|NCT03302871|Drug|Botulinum toxin type A|
1456384|NCT03302871|Device|transcranial direct current stimulation|
1456385|NCT03302871|Other|hybrid training model of CIMT and BIT|
1456386|NCT03302871|Other|usual care|
1456387|NCT03302858|Device|BARRX™ Anorectal Wand|"The radiofrequency ablation (RFA) or Barrx™ Ablation System used in this protocol comprises an RFA generator (Barrx™ FLEX) and the Barrx™ Anorectal Wand. The generator and wand are cleared by the FDA for human use and the wand is specifically cleared for treatment of anal neoplasia. The present FDA indication for use statement is: The Barrx™ catheters are indicated for use in the coagulation of bleeding and non-bleeding sites in the gastrointestinal tract including, but not limited to, the esophagus. Indications include esophageal ulcers, Mallory-Weiss tears, arteriovenous malformations, angiomata, Barrett's esophagus, Dieulafoy lesions, angiodysplasia, gastric antral vascular ectasia, and radiation proctitis."
1456388|NCT03302845|Drug|Omeprazole 40 MG|Omeprazole 40 mg capsule
1456389|NCT03302845|Drug|Famotidine 40 mg|Famotidine 40 mg tablet
1456390|NCT03302845|Drug|Telotristat ethyl 250 mg|Telotristat ethyl 250 mg tablet
1456393|NCT03302819|Diagnostic Test|MARIA scan|The patient will have an additional MARIA scan along with conventional imaging, pathology and surgical procedures.
1456394|NCT03302806|Other|Non interventional Study|
1456395|NCT03302793|Device|BreEStim|BreEStim will applied for 10 to 20 minutes.
1456396|NCT03302793|Device|tDCS|tDCS will be applied for 20 minutes.
1456397|NCT03302793|Device|tDCS sham|
1456398|NCT03302780|Device|BreEStim|BreEStim will applied for 10 to 20 minutes.
1456399|NCT03302780|Device|tDCS|tDCS will be applied for 20 minutes.
1456400|NCT03302780|Device|tDCS sham|
1456401|NCT03302767|Other|Psychological and Social Consultation|Psychological and Social Consultation at Baseline, during the study and at the end of follow-up
1456403|NCT03302741|Drug|Botulinum neurotoxin (BTX)|Each patient will receive BTX injections in 2 sites. 100 units at double dilution will be injected at each site.
1456404|NCT03302741|Other|Physical Therapy|Standard physical therapy will be ordered to both groups as part of standard of care for patients after BTX injections to maximize the outcomes.
1456480|NCT03302156|Drug|PSMA-based 18F-DCFPyL PET tracer|PSMA-based 18F-DCFPyL PET tracer that will be used to determine the presence or absence of cancer
1456481|NCT03302143|Procedure|Guided bone regeneration with Bovine Bone Mineral|Guided bone regeneration with Bovine Bone Mineral
1456405|NCT03302741|Device|Standard BTX injection (ultrasound guided)|For standard injection procedures, target muscles will be visualized under ultrasound imaging which is operated by an experienced and dedicated technician. Position of needle tip within the target muscle is visualized prior to injection. Ultrasound guidance can help ensure depth of needle tip location, i.e., to make sure the needle tip is within the muscle, but it is not able to tell where it is located with reference to the innervation zones (IZs) of the entire muscle.
1456406|NCT03302741|Device|3-dimensional innervation zone (3DIZ) guided injection|Simultaneous surface EMG and intramuscular EMG measurements will be acquired from the spastic biceps of the patients. Patients will be seated comfortably on a height-adjustable chair. The arm to be tested will be secured firmly on a customized apparatus with the elbow joint at approximately 90° of flexion and the shoulder at approximately 45° of abduction and 30° of flexion. The 128-channel unipolar surface EMG signals will be recorded with 2 flexible 2-dimensional 64-channel surface electrode array. A coating fine wire electrode will be inserted into the mid-axial section of the biceps to record bipolar intramuscular EMG signals. Ultrasound scan will be performed on the biceps to identify the location of the inserted wire electrode. Patients will be asked to contract their impaired biceps to perform maximum voluntary contraction of elbow flexion against the vertical plates 3 times.
1947712|NCT03173716|Drug|Definity|Real-Time Myocardial Perfusion Echocardiography (RTMPE) will be performed as opposed to the standard echocardiogram (TTE) of the control arm
1456410|NCT03302702|Other|Exercise program|Exercise program including breathing control, pursed-lip breathing, diaphragmatic and thoracic breathing, aerobic and strengthening training
1456413|NCT03302676|Dietary Supplement|Chewing gum|
1456414|NCT03302663|Diagnostic Test|MRI scan|Addition of advanced imaging sequences for fetal MRI
1456418|NCT03302637|Other|16S rRNA gene sequencing assay|extraction of genomic DNA from oral samples using the Mobio DNA Isolation Kit. 16S rRNA amplicons covering variable regions V3 to V4 will be generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3')66 incorporating adapters and a sample barcode sequence at PI's lab. Amplicons will be sequenced with the Roche 454 FLX Titanium sequencing system at the NYU genome technology center, following the manufacturer's specifications.
1456419|NCT03302611|Behavioral|Physical Activity-based Interventions|Participants will be randomized to one of two physical activity-based interventions, surf or hike therapy.
1456420|NCT03302598|Diagnostic Test|serum C-reactive protein|
1456421|NCT03302585|Drug|Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 10,000 IU/d of oral vitamin D3 x 85 days
1456422|NCT03302585|Drug|Placebo/Standard of Care Vitamin D3|50,000 IU/d of oral vitamin D3 x 5 days followed by 40,000 IU/d of oral vitamin D3 x 85 days
1456423|NCT03302572|Other|Brief information group|Patients will be given oral brief information about the existence of advance directives after resolving the reason for the visit for which they had come. This information will not last more than 3 minutes and will not be repeated on successive visits within the recruitment period. Also, an informative triptych will be given to the patient so that he can read it at home. These leaflets have been made by the regional Department of Health. They will be advised that we can extend the information or help them to do the document in the near future if they want, we will inform that we would wait for the answer 3 months. In case of interest, they can leave their information in the User Service by specifying name, telephone number and reference doctor or ask for an appointment again.
1456424|NCT03302559|Other|Retinol Complex 0.5|Retinol Complex 0.5 topically in the evening.
1456425|NCT03302559|Other|Facial cleanser|Facial cleanser in the morning and in the evening.
1456426|NCT03302559|Other|Moisturizing lotion|Fragrance free moisturizing lotion in the morning and in the evening.
1456427|NCT03302559|Other|Sunscreen|Sunscreen broad spectrum sun protection factor (SPF) 35 topically in the morning and as needed.
1456428|NCT03302559|Device|Skin Imaging|Non-invasive in vivo skin imaging will be taken with the VivoSight Dx Optical Coherence Tomography (OCT) and VivaScope 1500
1456429|NCT03302546|Procedure|Incremental hemodialysis|Patients randomized to this arm of treatment will be treated during at least 4 hours of hemodialysis twice per week
1456430|NCT03302546|Procedure|Conventional hemodialysis|Patients randomized to this arm of treatment will be treated during at least 3.5 hours of hemodialysis three times per week
1456431|NCT03302533|Procedure|Total elbow arthroplasty|Implantation of a total elbow arthroplasty after distal humerus fracture
1947715|NCT03172260|Device|E Balance Pro Therapy|Micro-current treatment
1947717|NCT03164928|Drug|Denosumab|1mg/kg BW (up to a maximum of 60 mg) SC Q6M
1456436|NCT03302494|Device|Coherex WaveCrest® Left Atrial Appendage Occlusion System|Percutaneous left atrial appendage closure
1456437|NCT03302494|Device|Watchman® LAA Closure Device|Percutaeous left atrial appendage closure
1456438|NCT03302481|Other|liver biopsy|the biopsies will be performed under laparoscopy and taken in the lower part of the right hepatic lobe
1456482|NCT03302143|Procedure|Guided bone regeneration with freeze dried bone allograft|Guided bone regeneration with freeze dried bone allograft
1947718|NCT03164928|Other|Placebo|SC Q6M placebo
1456440|NCT03302442|Other|Non interventional study|Not applicable - Non interventional Study
1456441|NCT03302429|Other|PRF/ BCP|Platelet rich fibrin combined with biphasic calcium phosphate(experimental group)
1456442|NCT03302429|Other|Autogenous bone graft|Bone obtained from the same individual who receiving the graft
1456443|NCT03302416|Drug|Hydrocortisone|
1456444|NCT03302416|Radiation|[C-11]NOP-1A|
1456445|NCT03302403|Genetic|CAR-CD19 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
1456446|NCT03302403|Genetic|CAR-BCMA T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
1456447|NCT03302403|Genetic|CAR-GPC3 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
1456448|NCT03302403|Genetic|CAR-CLD18 T cell|"Self-controlled dose escalation and classic 3+3 dose escalation will be applied."
1456449|NCT03302403|Drug|Fludarabine|Fludarabine is used for lymphodepletion.
1456450|NCT03302403|Drug|Cyclophosphamide|Cyclophosphamide is used for lymphodepletion.
1456451|NCT03302390|Procedure|Shave Biopsy of Psoriasis Lesion|The investigator will take about 0.5x0.5 inch square section of skin from the psoriasis lesion. To numb the skin, the subject will receive a small injection of 0.5% lidocaine HCl 5mg/mL with 1:200,000 mcg/mL epinephrine solution as per standard shave biopsy protocol. The shaving instrument has a blade that will shave off a superficial piece of skin that is less than <3mm in thickness. After 14 days, the subject will return to make sure that the skin biopsy site has healed properly. The piece of skin that is removed will be grafted onto the back of an immunocompromised SCID mouse. An approved IACUC protocol covering this procedure will be in place prior to engraftment.
1456452|NCT03302377|Behavioral|physical activity counseling & Fitbit|Participants will receive individual counseling & guidance in goal setting, then will receive a Fitbit wrist monitor and guidance in personalizing the Fitbit features
1456453|NCT03302364|Drug|FK506|patients who have never received risperidone or who have received re-administration of risperidone after discontinuation of risperidone treatment
1456454|NCT03302351|Drug|Dexmedetomidine|30 patients will receive intravenous dexmedetomidine 1 mcg/kg.
1456455|NCT03302351|Drug|ketamine|30 patients will receive intravenous ketamine 0.4 mg/kg.
1456456|NCT03302351|Drug|Dexmetedomidine+Ketamine|30 patients will receive combination between intravenous dexmedetomidine 0.5mcg/kg + low dose ketamine 0.25mg/kg.
1456457|NCT03302338|Drug|SAFE group|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
1456458|NCT03302338|Drug|placebo group|distilled water 20 ml/kg/day for maximum of 7 days.
1456459|NCT03302325|Procedure|research blood draws|Twenty-five mL of peripheral blood (PB) will be collected for research. Blood will be collected in EDTA tubes and used to isolate ctDNA. For each subject we will request that he/she contribute 25 mL of plasma no more frequently than every 6 weeks, and at same time of standard of care blood draws and routine clinic visit, and for no more than 5 times (including baseline and end of study).
1456460|NCT03302299|Drug|Isoniazid 300 Mg ORAL TABLET|The study intervention will include a single arm given (1) 6H: 300 mg INH daily by mouth for 6 months.
1456461|NCT03302299|Drug|Pyridoxine 25 Mg Oral Tablet|All participants will also receive 25 mg pyridoxine (vitamin B-6) daily by mouth for 6 months for the treatment duration to reduce the risk of INH-induced peripheral neuropathy.
1456462|NCT03302286|Diagnostic Test|Heart-lung machine primining solution which includes Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1000 ml, Mannitol 200 ml, Heparin 10000 units and 80 mmol sodium.
1456463|NCT03302286|Diagnostic Test|Heart-lung machine primining solution which does not include Mannitol|This study group will undergo cardiopulmonary bypass with priming solution of Ringer's acetate 1200 ml, Heparin 10000 units and 80 mmol sodium.
1456464|NCT03302273|Other|Corneal Epithelial Stem Cell Transplant|Self-administration of formulated topical eye drops containing cadaveric epithelial stem cell-derived biologic material.
1456465|NCT03302260|Behavioral|CardioPrevent® Program|This is a 1-year, evidence-based behaviour change lifestyle program that consists of 25 contacts (in person, by phone and in groups) with a trained lifestyle counsellor to facilitate desired lifestyle behaviours within the participants' own social context.
1947719|NCT03164265|Biological|Regulatory Donor-Derived Dendritic Cell infusion|Regulatory dendritic cells that were prepared from a donor leukapheresis will be infused into liver transplant recipients 7 days prior to surgery
1456468|NCT03302234|Biological|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
1456469|NCT03302234|Biological|ipilimumab|Administered as an IV infusion every 6 weeks (Q6W)
1456470|NCT03302234|Other|placebo for ipilimumab|Normal saline solution administered as an IV infusion Q6W
1456472|NCT03302208|Drug|Pregabalin|Pregabalin capsule 300mg oral
1456473|NCT03302208|Drug|Placebo|Placebo
1456474|NCT03302195|Drug|Heparin|Based on patient body weight (UI/kg)
1456475|NCT03302195|Procedure|cardiopulmonary bypass pump flow rate|Based on patient body weight (L/min/m2)
1456476|NCT03302182|Drug|Ritonavir for cycle1 and NORVIR for cycle 2|During the study session, healthy subjects will be administered a single dose of Ritonavir Tablet 100mg in cycle 1 and NORVIR tablet 100mg in cycle 2 .
1456477|NCT03302182|Drug|NORVIR for cycle 1 and Ritonavir for cycle 2|During the study session, healthy subjects will be administered a single dose of NORVIR Tablet 100mg in cycle 1 and Ritonavir tablet 100mg in cycle 2 .
1456478|NCT03302169|Procedure|Radical prostatectomy with posterior rhabdosphincter reconstruction|To suture the Denonvilliers fascia and bladder to the median dorsal raphe according to Rocco technique.
1456479|NCT03302169|Procedure|Radical prostatectomy without posterior rhabdosphincter reconstruction|Standard technique with a running suture to perform the urethrovesical anastomosis
1483657|NCT03092726|Drug|Placebo|oral
1456483|NCT03302130|Behavioral|Mood induction (using own memories)|Subjects deliver three positive, three negative and three neutral memories 30 seconds reliving a memory - answering questions about the memory - reliving memory for 2 minutes during ASL-MRI
1456484|NCT03302130|Device|Arterial spin labeling MRI|Single PLD PCASL
1456485|NCT03302130|Device|Physiological monitoring|During MRI: heart rate, end-tidal CO2, respiratory rate and skin conductance
1456486|NCT03302117|Other|Wood smoke exposure|Healthy volunteers will exposed to filtered air alternate with wood smoke generated from incomplete wood smoke combustion to assess the local and systemic effect of theses exposures
1456490|NCT03302065|Drug|Tiotropium|
1456495|NCT03302026|Behavioral|Realtime biofeedback using fMRI|Real-time fMRI (rt-fMRI) allows for rapid analysis of brain activation while an individual is actively performing a task, and can be used to provide real-time neurofeedback to individuals during fMRI scanning. Using neurofeedback, individuals can learn to modulate activity in specific regions of the brain. We propose to use rt-fMRI neurofeedback training to help smokers consciously modulate activation in areas related to cravings and self-control in order to improve control smoking urges. Participants will complete four sessions: an intake session and 3 scanning visits. The primary outcome is the ability to resist smoking during a validated smoking lapse paradigm.
1456496|NCT03302013|Procedure|Vanguard XP Bi-cruciate Retaining Knee Replacement System|Newer design of knee replacement retaining the Anterior Cruciate Ligament as well as the Posterior Cruciate Ligament.
1456497|NCT03302013|Procedure|Vanguard CR Single Cruciate Retaining Knee System|Current 'gold standard' for total knee replacement which retains Posterior Cruciate Ligament but sacrifices the Anterior Cruciate Ligament, instead providing artificial support.
1456498|NCT03302000|Other|Early Visual Stimulation|Early visual stimulation
1456500|NCT03301974|Procedure|conjunctival autograft with fibrin glue|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by fibrin glued conjunctival autograft in 20 eyes of 20 patients (group 1).
1456501|NCT03301974|Procedure|sutured conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutured conjunctival autograft in 20 eyes of 20 patients (group 2).
1456502|NCT03301974|Procedure|sutureless and glue-free conjunctival autograft|Simple pterygium excision under local anesthesia performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 20 eyes of 20 patients (group 3)
1456503|NCT03301948|Other|Overfeed|Participants consume energy intakes that are 50% higher than their estimated requirements instead of consuming energy intakes equal to their estimated requirements
1456504|NCT03301948|Other|Energy Balance|Participants consume energy intakes equal to their estimated requirements instead of consuming intakes that are 50% higher than their estimated requirements
1456505|NCT03301935|Procedure|Electrophysiology testing and exercise stress testing|Each patient will perform an exercise stress test on bicycle before an invasive electrophysiological test. Both examinations will be performed according to current Clinical practice.
1456506|NCT03301922|Behavioral|Work-focused Metacognitive therapy|Work-focused Metacognitive psychotherapy, up to maximum 12 sessions, with weekly session of 45-60 minute duration. The metacognitive treatment program is based on Wells' manual. The work-focused intervention is based on Lagerveld and Blonk. The interventions are run in parallel.
1456507|NCT03301922|Other|Waiting list|Waiting list
1456508|NCT03301909|Device|PillCam™ Endoscopy System|Subject may be assigned to any procedure involving modification of any of the PillCam™ Endoscopy System component as listed in the arm description.
1456509|NCT03301909|Drug|Bowel prep combination|Subject may be assigned to any bowel preparation combination.
1456510|NCT03301896|Drug|LHC165|LHC165 intratumoral injection
1456511|NCT03301896|Biological|PDR001|PDR001 infusion
1456512|NCT03301883|Drug|Tocilizumab|Tocilizumab will be administered as per the schedule specified in the arm description.
1456513|NCT03301883|Drug|NSAIDs|Participants may receive NSAIDs up to the maximum recommended stable daily dose. Study protocol does not enforce any particular NSAID.
1456514|NCT03301883|Drug|CSs|Participants may receive CSs at a stable dose of 30 milligrams per day (mg/day) or 0.5 milligrams per kilogram per day (mg/kg/day), whichever is less. Study protocol does not enforce any particular CS.
1456515|NCT03301883|Drug|MTX|Participants may receive MTX at a stable dose of less than or equal to (</=) 20 milligrams per square meter (mg/m^2).
1947722|NCT03159897|Drug|Doxorubicin|Comparator arm: cycle 1-2 (and eventually 3-6): 25 mg/m2 i.v. days 1,15. Experimental arm: Cycles 1 to 4: 35 mg/m2 i.v. days 1,11. Cycles 5 and 6: 25 mg/m2 i.v. days 1,11.
1947723|NCT03159897|Drug|Bleomycin|Bleomicina Comparator arm: cycle 1-2 (and eventually 3-6): 10,000 units/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 10,000 units/m2 i.v. days 1,11. Cycles 5 and 6: 10,000 units/m2 i.v. days 1,11.
1947724|NCT03159897|Drug|Vinblastine|Vinblastina Comparator arm: cycle 1-2 (and eventually 3-6): 6 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 6 mg/m2 i.v. days 1,11. Cycles 5 and 6: 6 mg/m2 i.v. days 1,11.
1947725|NCT03159897|Drug|Dacarbazine|Dacarbazina Comparator arm: cycle 1-2 (and eventually 3-6): 375 mg/m2 i.v. days 1,15. Experimental arm: cycles 1 to 4: 375 mg/m2 i.v. days 1,11. Cycles 5 and 6: 375 mg/m2 i.v. days 1,11.
1947726|NCT03159949|Other|REHIIT|REHIIT participants will come into the lab one time per training days (3 training days per week), each session lasting 10 minutes. Training sessions involve a two-minute warm-up, 3 X 20-second cycling sprints on an exercise bike with three minutes rest in between, and a one-minute cool-down.
1456522|NCT03301844|Combination Product|Blephapad Combo|"Blephapad Combo is used to cleanse, soften, sooth and decongest inflamed eyelids and cilia.
The combo also presents an applicator with a heatable tablet that is applied to the eyelid in order to clean and open occluded Meibomian glands, thereby allowing the production of lipids necessary for a healthy tear film. The heatable tablet is to be used prior to cleansing with Blephapad wipes."
1456523|NCT03301844|Other|Standard treatment|Standard treatment, twice daily for one month, consisting in eyelid hygiene using wet, warm gauze.
1456524|NCT03301831|Behavioral|Resourcefulness Training|Cognitive-behavioral intervention that includes personal and social resourcefulness skills.
1997103|NCT02233582|Drug|Ibuprofen|We are simply testing if taking ibuprofen upon ascent to altitude is associated with a delayed acclimatization response to the high altitude hypoxia.
1456526|NCT03301805|Drug|BLEX 404|"BLEX 404 Oral Liquid is administered twice daily during the Gemcitabine monotherapy period. The dose of Gemcitabine 1,000 mg/m2 IV fusion at Day 1, 8, 15 of every cycle
28 days a cycle."
1456527|NCT03301792|Behavioral|Group prenatal care|Enrolled subjects will be randomly assigned in a 2:1 ratio to group or traditional care.
1456528|NCT03301779|Device|Hemanext Red Blood Cell Processing System|Leukoreduced red blood cell product from donors in the Investigational Product arm will be processed in the Hemanext Oxygen Reduction Bag for 3 hours and then transferred to the Hemanext Storage Bag and stored for 42 days at 1-6°C.
1456529|NCT03301766|Drug|lidocaine 5% patch|transdermal patch
1456530|NCT03301766|Drug|standard therapy|Drugs prescribed at the discretion of the treating physician (acetaminophen, NSAIDs, muscle relaxants, etc)
1456531|NCT03301766|Drug|Non-medicated patch|non-medicated patch
1456532|NCT03301740|Other|UF profiling during HD|"Experimental arm: Linear UF profiling (linearly decreasing UF rate with a UF rate starting at 1.33 times the rate that would be needed at a constant UF rate to achieve the desired post-weight; pre-programmed profile 2 on a Fresenius 2008K machine, the machine used in all participating clinics). Ultrafiltration profiling will be performed using Fresenius 2008K dialysis machines in accordance with manufacturer instructions."
1456533|NCT03301740|Other|Conventional HD|Control arm: Conventional HD (routine care) is the participant's standard HD prescription without UF profiling.
1456534|NCT03301727|Other|Cognitive-Behavioural Therapy for Insomnia (CBT-I)|Cognitive-Behavioural Therapy for Insomnia (CBT-I) is an evidence-based psycho-therapeutic intervention, combining cognitive and behavioural principles to provide psycho-education concerning contributing thoughts to sleep problem maintenance, and behavioural technique instruction to reduce sleep onset latency and promote effective sleep maintenance.
1456536|NCT03301701|Procedure|Radical prostatectomy|Radical prostatectomy
1456537|NCT03301701|Radiation|HDR (19Gy) or SBRT (35-40Gy)|Patients will receive HDR unless judged to medically unfit to undergo HDR brachytherapy, in which case they will receive SBRT
1456539|NCT03301675|Other|Orange Juice (500 mL/d)|Nutritionists prescribed the same balanced diet for both groups keeping suffice energy to maintain the current weight, estimated from total energy expenditure (TEE) for each individual and based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ/ banana or other fruits and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were colected every two weeks; blood samples and dietary questionnaires, monthly.
1456540|NCT03301662|Diagnostic Test|chest and thumb- ECG|chest and thumb- ECG using the Coala Heart Monitor
1456541|NCT03301649|Drug|Ivermectin Lotion 0.5%|Ivermectin Lotion 0.5%
1456542|NCT03301649|Drug|Placebo/Vehicle Lotion|Placebo
1456543|NCT03301636|Drug|Pembrolizumab + Indoximod|"Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
Indoximod will be administered orally every 12 hours starting at Day 1"
1456544|NCT03301636|Drug|Pembrolizumab + Placebo|"Pembrolizumab will be administered intravenously every 3 weeks starting on day 1.
Placebo will be administered orally every 12 hours starting at Day 1"
1456545|NCT03301636|Drug|Nivolumab + Indoximod|Nivolumab will be administered intravenously every 2 weeks starting on day 1. Indoximod will be administered orally every 12 hours starting at Day 1
1456546|NCT03301636|Drug|Nivolumab + Placebo|Nivolumab will be administered intravenously every 2 weeks starting on day 1. Placebo will be administered orally every 12 hours starting at Day 1
1456547|NCT03301623|Other|Clinical Decision Support|The CDS intervention will test the use of existing guideline-based EHR alerts related to the prescription of opioids. CDS alerts employ computer algorithms that account for patient characteristics and diagnoses to deliver reminders of appropriate use when a provider enters an order for a medication.
1456548|NCT03301623|Other|Patient Education and Activation Tools|"The patient education materials selected for this study: Pain Management: Which Treatment is Right for You, Preparing for Your Health Care Visit, and a video from the American Chronic Pain Association (ACPA) named A Car with Four Flat Tires, which helps to give patients a better understanding of how multi-modal treatment can be more effective than relying on one source of treatment (e.g., pain medication)."
1456549|NCT03301610|Other|Mobile Education Delivery|Patients will be provided with an iPad on admission to the post-surgical unit and will remain with the patient until discharge. The patient, independently or with the nurse, may use the program at any point during the inpatient care experience. The RN will use the iPad to engage patients in their pain management.
1456550|NCT03301610|Other|Standard Verbal and Written Education|Patients will be provided with two pamphlets on pain management on admission to the post-surgical unit. Nurses will follow-up with verbal instruction based on patient need. This will continue through hospital stay. Additional printed education materials are available through the department of patient education and verbal instruction may be tailored based on nursing assessment and patient need.
1456551|NCT03301597|Biological|NLA101|"NLA101 is a universal donor off-the-shelf ex-vivo expanded hematopoietic stem and progenitor cell (HSPC) product that is cryopreserved and ready for immediate use."
1456552|NCT03301597|Drug|Standard of Care (SOC) chemotherapy|The SOC chemotherapy regimen for each patient will be determined by local PI. Regimen must be a standard AML regimen that will result in moderate to severe myelosuppression and have curative intent.
1456553|NCT03301584|Other|Enhanced collaboration to promote patient participation|"Enhanced OT and PT collaboration: to promote patient participation. Goal setting using TLS-BasicADL protocol. Patients were encouraged to consider activities important to them to be able to perform at discharge. Adaption of goals throughout the hospital stay.
Supporting patient self-efficacy: by challenging patients' fear of falling and encouraging progression of exercise.
Training kit with instructions: To increase activity and encourage patients to take more responsibility for their training.
Enhanced exercise with protocol: More intensive training of transfers, walking, balance and P-ADL was offered at least 3 times/day by OT and PT.
Collaboration meetings: twice weekly interdisciplinary meetings plus daily OT and PT logistic meeting to schedule treatment."
1456554|NCT03301584|Other|Usual Care treatment|The control group received standard rehabilitation from occupational therapists and physiotherapists (Monday to Friday), planned individually and gradually progressed for each patient. Mobilisation was initiated within 24 hours after surgery, 7 days a week. Patients were provided with a booklet with information about the fracture, operation method, exercise regime and assistive walking and ADL aid available.
1456555|NCT03301571|Other|Change in preload and afterload|Afterload: Three levels of positive end-expiratory pressure (PEEP) will be examined post-operatively: 0 cm H20, 5 cm H2O, 10 cm H2O Preload: Trendelenburg position for 5 minutes will be investigated
1456556|NCT03301571|Other|Inspired oxygen|Following fractions of inspired O2 will be investigated: 0.5 and 1.0 for 10 minutes respectively
1456557|NCT03301571|Other|Pacemaker mode|Following pacemaker settings will be investigated: Atrioventricular pacing 10 bpm over the patients' intrinsic rhythm, atrial pacing 10 bpm over the patients' intrinsic rhythm, ventricular pacing 10 bpm over the patients' intrinsic rhythm
1456558|NCT03301558|Drug|Low dose sodium bicarbonate|1500 mg sodium bicarbonate
1456559|NCT03301558|Drug|High dose sodium bicarbonate|3000 mg sodium bicarbonate
1456560|NCT03301545|Procedure|Fast-Track to Bariatric Surgery|30 participants from the urban Indigenous community who have Type 2 diabetes and are candidates for bariatric surgery at the Centre for Metabolic and Bariatric Surgery will be randomized to the fast-track to bariatric surgery group.
1456561|NCT03301532|Drug|Triheptanoin|Dietary supplementation with triheptanoin
1456562|NCT03301506|Drug|Seladelpar 2 mg Capsule|Subjects will be assigned to a treatment group based on the seladelpar dose received at End of Treatment in a previous PBC study with seladelpar.
1456563|NCT03301506|Drug|Seladelpar 5 mg Capsule|Subjects will be assigned to a treatment group based on the seladelpar dose received at End of Treatment in a previous PBC study with seladelpar.
1456564|NCT03301506|Drug|Seladelpar 10 mg Capsule|Subjects will be assigned to a treatment group based on the seladelpar dose received at End of Treatment in a previous PBC study with seladelpar.
1456565|NCT03301493|Other|Genomic testing|Genomic profiling, indicated as assessed by the medical need and as deemed appropriate by the physician according to routine practice
1456566|NCT03301467|Drug|Avacopan|Orally administered
1456567|NCT03301467|Drug|Avacopan Matching Placebo|avacopan matching placebo
1456568|NCT03301454|Drug|pursuit of chemotherapy|Treatment with LV5FU2 (5-FU, Calcium Levofolinate) - paclitaxel, regular tumor evaluation, best supportive care Other authorized treatment : usual paclitaxel pre-treatment consisting of Dexamethasone, Chlorpheniramine and ranitidine, at 15 and 1 day before the actual paclitaxel treatment
1456570|NCT03301428|Other|Retrain pain educational website|Patients in this group will be invited to consult an educational website developped for patients with chronic pain
1456571|NCT03301428|Other|Booklet|Patients in this group will be invited toread an educational booklet developped for patients with chronic pain
1456572|NCT03301415|Drug|Valganciclovir|Valganciclovir, 16 mg/kg/dose given orally twice daily for four months
1456573|NCT03301402|Device|Air purifier|Air purifier with filter at automatic mode on all time
1947727|NCT03159949|Other|PR-REHIIT|"PR-REHIIT participants will come into the lab on 3 separate occasions on the training days, which occur 3 days per week (i.e., 9 sessions per week). Each session lasts 3 minutes and 20 seconds and consists of a two-minute warm-up, a 20-second all-out sprint on a cycle ergometer, and a one-minute cool-down. There will be 1-4 hours of rest in between training sessions where participants are free to leave the lab and go about their normal day."
1456576|NCT03301350|Drug|Carboplatin|Carboplatin is a platinum compound alkylating agent which covalently binds to DNA; interferes with the function of DNA by producing interstrand DNA cross-links.
1456577|NCT03301350|Drug|Paclitaxel|Paclitaxel promotes microtubule assembly by enhancing the action of tubulin dimers, stabilizing existing microtubules, and inhibiting their disassembly, interfering with the late G2 mitotic phase, and inhibiting cell replication. In addition, the drug can distort mitotic spindles, resulting in the breakage of chromosomes. Paclitaxel may also suppress cell proliferation and modulate immune response.
1456578|NCT03301350|Drug|Doxorubicin|Inhibition of DNA and RNA synthesis by intercalation between DNA base pairs by inhibition of topoisomerase II and by steric obstruction. Doxorubicin intercalates at points of local uncoiling of the double helix. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA. Doxorubicin is also a powerful iron chelator; the iron-doxorubicin complex can bind DNA and cell membranes and produce free radicals that immediately cleave the DNA and cell membranes.
1456579|NCT03301350|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent that prevents cell division by cross-linking DNA strands and decreasing DNA synthesis. It is a cell cycle phase nonspecific agent. Cyclophosphamide also possesses potent immunosuppressive activity. Cyclophosphamide is a prodrug that must be metabolized to active metabolites in the liver.
1456581|NCT03301324|Device|Intubation Assist Dashboard|The ZOLL X Series Intubation Assist Dashboard feature guides the operator through a three-step auscultation process to verify the proper placement of an endotracheal tube.
1456582|NCT03301311|Other|Specific Carbohydrate Diet (SCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
1456583|NCT03301311|Other|Modified Specific Carbohydrate Diet (MSCD)|Patients will be randomized to start with either a strict SCD or modified SCD. Participants will alternate between each diet in 8-week intervals for a total duration of approximately 34 weeks. Participants will complete two 8-week intervention periods on each diet.
1456585|NCT03301285|Drug|Zoledronic Acid|Treatment of osteoporosis
1456586|NCT03301272|Drug|Onabotulinumtoxin A Injection|Reconstituted 10 units/0.1 mL. Administered intramuscular once
1456587|NCT03301272|Other|Placebo (normal saline)|0.9% normal saline solution, mimicking Botox injection paradigm. Administered intramuscular once.
1456588|NCT03301259|Other|One-shape rotationary system|OneShape (MICRO-MEGA) rotary nickel-titanium use roation movement and available in two sizes N°30 - .06 rotary files. , N°25 - .06
1456589|NCT03301246|Device|Artimes Pro Low Profile Dilatation Catheter|Pre-dilation catheter for the purpose of preparing the vessel to deliver the final therapy.
1456590|NCT03301233|Drug|estradiol valerate and sildenafil|(45 women will receive clomiphene citrate (clomid 50mg ®, Sanofi aventis) 2 tab. single dose orally from the 2nd day of the cycle for 5 days with oral estradiol valerate (Cyclo-Progynova ® 2mg, white tablets, BAYER Schering Pharma), one tablet every 12 hour from 2nd day of the cycle + sildenafil (silden® 25, E.I.P.I.CO.) every 8 hour from 2nd day of the cycle till the day of trigger of ovulation).
1456596|NCT03301194|Other|RAMP-HT|RAMP-HT was launched since October 2011 by the Hospital Authority with the support from the Food and Health Bureau. Standardized cardiovascular risk factor assessment, hypertensive complication screening and assessment on patient adherence to treatment are carried out on enrolled patients. Patients are stratified into low, medium or high risk groups according to the 10-year cardiovascular disease (CVD) risk calculated from their relevant risk factors by the Joint British Society 2005 Equation. A multidisciplinary team comprised of doctors, nurses, dieticians, physiotherapists and/or occupational therapists would then deliver individualized management targeted to the patient's risk factors according to standardized risk-stratified guidelines.
1456597|NCT03301181|Drug|BGB-3111 (Arm A)|320 mg BGB-3111 single oral dose
1456598|NCT03301181|Drug|Rifampin|600 mg rifampin once daily
1456599|NCT03301181|Drug|BGB-3111 (Arm B)|Up to 80 mg BGB-3111 single oral dose
1456600|NCT03301181|Drug|Itraconazole|200 mg itraconazole once daily
1456603|NCT03301155|Drug|Anaferon for children|Per os. 1 tablet once daily (preferably at the same time of the day). For children of younger age (from 1 month through 3 years) the tablet should be dissolved in a small amount (1 tablespoon) of boiled water of room temperature.
1456604|NCT03301155|Drug|Placebo|Per os. 1 tablet once daily (preferably at the same time of the day). For children of younger age (from 1 month through 3 years) the tablet should be dissolved in a small amount (1 tablespoon) of boiled water of room temperature.
1456605|NCT03301142|Procedure|Laser|The patients will be submitted to application of the Erbium Laser: YAG(yttrium aluminium garnet) 2940nm, SMOOTH mode developed by FOTONA.The vaginal canal will be accessed using a specific speculum. The 90 degree laser tip shall be used to perform 4 applications to the anterior and lateral vaginal wall at each of the 5 clock points (9,10:30,12,1:30,3 'o´-clock´), commencing at the back of the vagina, retracting in increments of 0.5cm, where 4 shots are made at each interval up to a distance 1cm short of the external opening of the urethra. After completion of this stage, the 90 degree tip shall be switched for the 360 degree tip, whereupon 4 additional applications shall be performed with 4 shots every 0.5 cm along the vaginal trajectory outlined above.
1456606|NCT03301142|Procedure|kinesiotherapy|"Patients will be guided by the physiotherapist to perform exercises to strengthen the pelvic floor muscles at home on a daily basis in the supine position with an empty bladder. It will be performed 10 repetitions of five-second contractions, the 15 three-second contractions; 20 two seconds contractions; 20 contractions of a second; 5 repetitions of strong contractions while coughing; 10 repetitions of exercise bridge associated with pelvic floor contraction and relaxation up in descending.The level of difficulty in performing the exercises will be determined in accordance with the adopted position. In .changes position should be held every four sessions."
1456607|NCT03301129|Behavioral|Smoke|See arm/group descriptions.
1490110|NCT03042689|Drug|Regorafenib|
1456608|NCT03301116|Behavioral|Healthy Moves for Aging Well (Healthy Moves)|A safe physical activity program which consists of a brief motivational enhancement and three movements to be performed in a seated position. The intervention will be delivered by home care aides for their clients.
1456609|NCT03301116|Behavioral|Active Mind for Aging Well (Active Mind)|A word puzzle program which consists of a brief motivational enhancement and word search activities. The intervention will be delivered by home care aides for their clients.
1997161|NCT02204618|Other|6 months initial abstention|Our experimental protocol relies on real life therapeutic strategy, where a cochlear implant may be proposed once CROS and bone conductions systems have failed. Thus, all subjects enrolled in our study will try CROS and bone conduction devices. If these trials are ineffective, the remaining subjects will be randomized between two arms (cochlear implantation vs 6 months abstention followed by cochlear implantation).
1456615|NCT03301077|Other|2-phase epidemiological study (screening, interviews)|first phase is the screening phase, second phase is the interview phase
1456616|NCT03301064|Behavioral|Motivational Enhancement Therapy and Strengths Based Case Management (MET/SBCM)|Key objectives of the intervention are as follows: (1) identify health and personal goals and develop discrepancies between goals and current actions, (2) provide feedback related to risks associated with the participant's drinking (e.g., driving after drinking, liver disease), (3) provide normative feedback about the participant's pattern of drinking to alcohol use in the US among Latinos in the participant's age and gender group, (4) discuss reasons for drinking (e.g., feeling isolated from family, machismo, low status employment), (5) weigh the pros and cons of drinking and reasons to reduce drinking (e.g., to better provide for the family, improving family relationships), (6) negotiate a plan for reducing drinking and/or seeking help, (7) recognize personal strengths in the process of change (e.g., religiosity, desire to provide for family), and (8) identify needed social and health services and explore potential barriers (e.g., transportation).
1456617|NCT03301064|Other|Alcohol education brochure|The alcohol education brochure will address health risks associated with alcohol use and will provide information on low-risk drinking.
1456618|NCT03301051|Biological|Quadrivalent VLP Vaccine|Single dose of a 30 µg/strain of Quadrivalent VLP Vaccine
1456619|NCT03301051|Biological|Placebo|Single dose of a Placebo
1456621|NCT03301025|Drug|Pregabalin|Pregabalin 150 mg capsule, one h preinduction of general anesthesia
1456622|NCT03301025|Drug|placebo|given a placebo identical capsule once one hour before anesthesia
1456623|NCT03301012|Other|Recovery support as usual|same as arm
1456624|NCT03301012|Other|Smartphone assisted relapse prevention|same as arm
1456625|NCT03300999|Dietary Supplement|ginger tea|"1. Ginger tea - Swanson Organic: 100% Certified Organic Ginger Root Tea
• Subjects will use one tea bag (contains two grams ginger root), mix with eight ounces of boiling water, steep for three minutes, and allow it to cool to room temperature before drinking. This will be done every day for one month before their third menstruation cycle and during their third menstruation cycle."
1456626|NCT03300973|Procedure|sling surgery|transoburator vaginal tape ,inside out procedure under spinal anathesia
1456629|NCT03300947|Drug|Psilocybin 100 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
1456630|NCT03300947|Drug|Psilocybin 300 mcg/kg|"Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms)."
1456631|NCT03300947|Drug|Lorazepam 1 mg|A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
1456632|NCT03300934|Device|automated closed loop glucose control|FreeStyle Navigator II® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), DANA Diabecare R subcutaneous insulin pump (SOOIL Development co, Seoul, Korea) and a MPC-based glucose control algorithm running on a smartphone as developed by the Cambridge team ( Pr R Hovorka)
1456634|NCT03300908|Behavioral|Project ADHERE|"This is a 3-session ART medication adherence and risk reduction intervention. Participants are educated about the importance of staying healthy and taking their medication as prescribed; to discuss importance of improved immune functioning and what their viral load means; reminded that they can still infect others with HIV, and that there currently is no cure for HIV; expected to generate strategies to overcome adherence barriers; educated about sexually transmitted infections (STI)/HIV transmission modes; assisted in devising an appropriate medication adherence and risk reduction plan. Participants will report their progress and discuss challenges experienced when implementing their medication adherence and risk reduction plans while establishing short- and long-term goals."
1456635|NCT03300908|Behavioral|MACE|This one-session medication adherence intervention covers the following content: 1) a discussion on what viral load represents and what HIV does to the body; 2) referral to a provider for participants without a provider; 3) the importance of maintaining regular contact with a health care provider; and 4) benefits of being retained in care.
1456636|NCT03300895|Other|High-intensity interval training|21.5 minutes of high-intensity interval exercise at an intensity between 90-95 of HRmax (15x30 s), with recoveries at 50-60% of HRmax (14x60 s). 24 sessions, 3x weekly of walking and running outdoors on a sports field in a supervised manner.
1456734|NCT03300284|Behavioral|Questionnaires|Quality of Life Questionnaires
1495901|NCT03000010|Other|Standard Bandage|
1456637|NCT03300895|Other|Comparator: Moderate-intensity continuous exercise|30 minutes of continuous exercise at an intensity between 65-75% of HRmax. 24 sessions, 3x weekly of walking and jogging outdoors on a sports field in a supervised manner
1456638|NCT03300882|Other|Procedure|Serial blood draws. Participants will be enrolled either pre-transplant or within 45 days post-transplant and will be followed over the course of 18 months post transplant. Protocol mandated serial measurement of cytomegalovirus (CMV)-specific immune signature will occur pre-transplant (as applicable) and at post-transplant timepoint months 2, -3, -6, -9, -12 and -18.
1456642|NCT03300804|Drug|20-herb formulation|Two daily dosages will be investigated. The lowest dosage condition will be 17gm daily, followed by an escalation to 34gm. Participants will be treated for 8 weeks
1456643|NCT03300804|Drug|Placebo|Placebo herb formulation
1456644|NCT03300791|Other|Admitted|Readmitted patients in the next months after an episode of aute heart failure will be recruited. Controls will be selected between those who were admitted in the baseline but not readmitted in this month.
1456645|NCT03300778|Behavioral|aerobic exercise|Running at the intensity of 50%-70% of maximum heart rate (220-age) for 30 mins per day, 4 days per week, last for 3 months
1456646|NCT03300778|Behavioral|Placebo controlled group|6 sections of group activities: 3 sections of general psychological education; one section of group game, one section of group poetry reading activity, group singing entertainment.
1456647|NCT03300765|Drug|Apatinib|Apatinib will be used as induction therapy in experimental arm.
1456648|NCT03300765|Radiation|Intensity modulated radiation therapy|Intensity modulated radiation therapy will be used for patients with progression disease during induction therapy or after induction therapy.
1456649|NCT03300752|Behavioral|BREATHE Intervention|PCPs randomized to BREATHE will receive the tablet which, when the screen is advanced by the PCP, will prompt the PCP through a 7-minute, 4-step brief intervention tailored to respond to the patient's specific beliefs, and shared decision-making discussion of asthma control status and treatment.
1456650|NCT03300752|Behavioral|Control Intervention|PCP will provide discussion of healthy lifestyles.
1456651|NCT03300726|Diagnostic Test|CSF analysis|CSF analysis for tau, p-tau181, Abeta42, and CSF levels of markers of synaptic injury
1456652|NCT03300726|Radiation|Functional MRI|Functional MRI during resting state and semantic memory task activation
1456653|NCT03300713|Other|MOCITRAINING program|The program is clinical and psychometric tools for screening for interactions and postpartum psychiatric disorders. The program will expose the existing care arrangements and the different possible orientations of the families according to the identified problem.
1456654|NCT03300713|Other|usual follow-up|usual follow-up
1456655|NCT03300687|Drug|FX-322|intratympanic injection
1456656|NCT03300687|Drug|Placebo|intratympanic injection
1456657|NCT03300674|Drug|Hydromorphone|Hydromorphone intravenous infusion
1456658|NCT03300674|Drug|Lidocaine|Lidocaine intravenous infusion
1456659|NCT03300661|Behavioral|Mediterranean Style|After completion of a Food Frequency Questinnaire (FFQ) and the International Physical Activity Questionnaire (IPAQ), patients enrolled in the study undergo a personalized educational intervention by a registered dietician. During the intervention the dietician advice about the main errors in diet and physical activity (by FFQ and IPAQ) and chooses three aims in diet modification and one aim in physical activity improvement. Patients adherence is assessed by the same dietician every three months, using FFQ and IPAQ, and futher supports are provided. Total intervention lenght is twelve months.
1456660|NCT03300648|Other|Mechanical ventilation|Intubation and mechanical ventilation for a maximum of 7 days
1456661|NCT03300648|Other|Hypertonic saline|Intravenous 3 percent hypertonic saline for a maximum of 7 days
1456662|NCT03300635|Other|Mental distress and relaxation test|
1456663|NCT03300635|Other|Glucose tolerance test|
1456664|NCT03300635|Other|Exercise test|
1456672|NCT03300596|Behavioral|Brief intervention to prevent suicide attempt|A patient-centered, 3-session intervention that calls for videotaping the narrative story of a patient's suicide attempt, in his/her own words (session 1); reviewing segments of the tape to arrive at a shared understanding of the attempt and the sequence of events that led to it (session 2); and using this information, along with a homework task completed by the patient in-between sessions, in order to develop a collaborative, comprehensive written safety plan that addresses the patient's unique vulnerabilities (session 3).
1456673|NCT03300596|Behavioral|Enhanced treatment as usual|Safety procedures' control intervention. For these procedures we will share summary results of the research assessments regarding suicidal thoughts, suicidal behaviors, alcohol and drug use and related problems, and depressive symptoms with appropriate hospital clinical staff. We will also arrange to send this information, with participants' permission, to their ongoing therapist or treatment program and, if none exists, to the therapist or program to which they are being referred. In this regard, the research assessment protocol serves a dual function of helping with additional monitoring of high-risk patients in addition to providing data for the study.
1456674|NCT03300583|Behavioral|Focus groups|Focus group discussion led by the PI and facilitated by another researcher.
1456675|NCT03300583|Behavioral|Semi-structured interviews|1:1 semi-structured interviews led by the PI
1947731|NCT03157674|Other|Non-Interventional|Non-Interventional
1947732|NCT03157128|Drug|LOXO-292|Oral LOXO-292
1456695|NCT03300505|Drug|ARRx|900 mg IV
1456696|NCT03300505|Drug|Pembrolizumab|200 mg IV
1456697|NCT03300492|Other|NK-DLI|"Application of three infusions of ex vivo expanded NK cells on days
+10, +15 and +20 with increasing NK cell doses (1x107/kg, 1x108/kg and the remaining cells up to 1x109/kg) following haplo-HSCT. Maximal cumulative T-cell dose is fixed at <1x105/kg."
1456698|NCT03300479|Drug|Clevidipine|Intravenous antihypertensive therapy with Clevidipine for the first 24 hours in patients with nontraumatic intracerebral hemorrhage (ICH).
1456699|NCT03300479|Drug|Urapidil|We compare the therapy with Urapidil to Clevidipine for the acute phase (24 hours) in patients with ICH. We would like to show the efficacy and safety of Clevidipine in this special situation.
1456702|NCT03300453|Drug|rAAV2/5-hNAGLU|one-time brain intraparenchymal gene therapy dose
1456703|NCT03300440|Dietary Supplement|Probiotics and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form (7,5 x 109 CFU) Bacteria strains: Bifidobacterium bifidum W23 Bifidobacterium lactis W51 Bifidobacterium lactis W52 Lactobacillus acidophilus W22 Lactobacillus casei W56 Lactobacillus paracasei W20 Lactobacillus plantarum W62 Lactobacillus salivarius W24 Lactococcus lactis W19 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
1456704|NCT03300440|Dietary Supplement|Placebo and vitamin B7|Powder; Sachet to 3 g (3 g = 1 portion) in lyophilized form 125mg D-Biotin (Vitamin B7) 30 mg of Common horsetail 30 mg of Fish collagen 30 mg of Keratin Matrix: corn starch, maltodextrin, inulin, fructooligosaccharides, plant protein, enzymes
1456705|NCT03300427|Drug|sacubitril/valsatran|sacubitril/valsatran 100 or 200 mg BID
1456706|NCT03300427|Drug|valsartan|Valsartan 80 or 160 mg BID
1456707|NCT03300427|Drug|placebo to valsartan|placebo to valsartan 80 or 160 BID
1456708|NCT03300427|Drug|placebo to sacubitril/valsartan|placebo to sacubitril/valsartan 100 or 200 mg BID
1456709|NCT03300414|Other|One time blood draw|Same as part 1
1456719|NCT03300375|Other|Home exercise program|Home-based, progressive exercise program using resistance bands
1456720|NCT03300375|Other|Post Op instructions|Participants will follow all instructions provided to them by their physician and care team, but will be asked to refrain from starting any new strengthening exercise protocols or begin any new physical therapies during this time.
1456724|NCT03300349|Other|Fulfillment of a preventive programme|Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
1456725|NCT03300349|Other|No fulfillment of a preventive programme|No fulfillment of the preventive programme: Information about risk factors for breast cancer-related lymphedema and home-based exercise programme for shoulder
1456726|NCT03300336|Behavioral|STRIDE|Implementation of STRIDE inpatient hospital mobility program
1456727|NCT03300323|Diagnostic Test|IV fluid challenge administration|Administration of an intravenous fluid challenge to assess for fluid responsiveness
1456728|NCT03300310|Other|nursing visit|nursing visit at patient home
1456729|NCT03300310|Other|no nursing visit|the patient take his treatment without nursing visit
1456730|NCT03300297|Other|Cervical Spine Thrust Joint Manipulation|High velocity, short amplitude thrust to the cervical spine
1456731|NCT03300297|Other|Cervical Spine Sham Manipulation|Manipulative hold position shy of end range without a thrust
1456732|NCT03300297|Other|Home Program|therapeutic exercise program and education
1456733|NCT03300297|Other|Suboccipital Release|suboccipital soft tissue mobilization
1456735|NCT03300271|Other|Mobile application for self monitoring|Participants in this group will be introduced to use a mobile application to self record and monitor their life style behaviors. They will be also be provided education same as the control group.
1456736|NCT03300271|Other|Education|Participants in this group is provided education. Education includes information of metabolic syndrome, methods to manage lifestyle (diet, physical activity).
1456737|NCT03300271|Other|Mobile application for personal coaching|Participants in this group will be introduced to use a mobile application. Personal coaches such as dietitian, sports manager encourage to improve their life style behaviors. They will be also be provided education same as the control group.
1456738|NCT03300258|Device|Robotic therapy|"The Robotic group will use a robotic training protocol to incentivize recovery of motor control by changing task demands throughout the training period. One or more target tasks will be chosen to mimic different sub-functions of gait, including some which are not normally excited in typical cycling behavior. Also, tasks may be designed to target non-gait motions such as hip ab/adduction. The required task may be changed periodically. This therapy protocol will occupy 30 minutes of each training session. Prior to testing, EMG electrodes will be placed on the major muscles of both legs, a procedure that takes roughly 15 minutes. Another 15 minutes is for changing clothes, briefing the subject, and other ancillary study activities. The total time per training session is 1 hour."
1456739|NCT03300258|Device|Aerobic therapy|The Control group protocol is identical to that of the Robotic group, except the robotically-incentivized exercise is replaced with an aerobic exercise. This intervention emulates a commercial motorized exercise bike to improve cardiovascular unfitness contributions to gait impairment. This therapy implements assist-as-needed and constant-velocity control. The patient's target pedaling speed (e.g. 20 rev/min (to be finalized through pilot tests) and power level (set by heart rate to require approximately 50-70% of maximal oxygen uptake) are set at the beginning of each session and a motor provides assistance or resistance to compensate for the performance of the patient. The exercise will be performed in this mode for 30 minutes per training session.
1456740|NCT03300245|Radiation|Maxillofacial CT|clinical and maxillofacial CT data will be tabulated and analysed using by computer software e.g. Statistical Package for the Social Sciences (SPSS)
1456741|NCT03300232|Behavioral|Computer-based VC-CBT|Computer-based VC-CBT: Six, one-hour computerized therapy sessions delivered on an interactive computerized platform with two-session therapy blocks dedicated to each of three primary modules/goals: 1) psycho-education, 2) skills learning, and 3) individualized practice
1456742|NCT03300219|Behavioral|Cognitive Orientation to Occupational Performance|CO-OP is a top-down, task-oriented, client-centered approach that uses an iterative process of dynamic performance analysis and guided discovery to enable individuals to identify strategies that will improve performance
1456743|NCT03300206|Device|Breast Biopsy|A breast biopsy is a test that removes tissue or sometimes fluid from the suspicious area. The removed cells are examined under a microscope and further tested to check for the presence of breast cancer. A biopsy is a diagnostic procedure that can definitely determine if the suspicious area is cancerous.
1456744|NCT03300180|Behavioral|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
1456745|NCT03300180|Other|Screening Only|The patients in this group will receive screening for AD coupled with letters sent to the dyads and the primary care PCP informing them of the results of the screening
1456746|NCT03300167|Device|The Liquid Biopsy System|The Liquid Biopsy System is a single use percutaneously-delivered coronary blood sampling device designed to collect blood samples from within a target coronary artery so that the blood can be analysed.
1456747|NCT03300154|Behavioral|Financial incentives|The study nurses will schedule an appointment with the doctor at the health center, within 4 weeks from the participant's inclusion in the study. Participants who attend the first visit at the health center will receive a direct incentive consisting of the payment of a limited amount to be determined (approximately AR $ 150-200) through a shopping voucher for the amount mentioned. Participants attending the follow-up visit at the health center within 3 months from their inclusion in the study will participate in a lottery. The lottery will offer the possibility of winning a new voucher with a probability of 1 in 3. Participants who do not attend the health center will not receive any incentive.
1456748|NCT03300154|Behavioral|Framing (SMS)|After inclusion, participants will receive weekly text messages (SMS) using a specific framing or formulation of the message, highlighting the potential benefits and positive aspects of health care. These messages will promote follow-up visits, adherence to treatment, and benefits to be gained from a follow-up visit with the physician. Messages will be sent with a frequency of two per week during the first 30 days and then 1 per week until the end of the follow-up. These messages will have no cost to participants.
1456749|NCT03300141|Other|Veridical Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of arm movements will directly reflect the participants actual arm movements.
1456750|NCT03300141|Other|Augmented Visual Feedback|Reaching while sitting at the Looking Glass system. The representation of a participant's arm movements will be augmented to encourage different movement patterns and improved movement.
1456751|NCT03300141|Other|Healthy Comparative Reaching Task|Reaching while sitting at the Looking Glass system. This will occur over the course of 1 hour.
1456752|NCT03300128|Behavioral|Incredible Years - ASD|The IY-ASD intervention is designed for parents of children with autism spectrum disorder. The programs uses a mix of videos, collaborative brainstorming sessions, and role plays to deliver content on child-directed play and positive discipline practices.
1456753|NCT03300128|Other|Circle of Parents|"Circle of Parents is an open parent support group led by a parent leader. Participants are encouraged to share resources and other support both during groups, and between meetings."
1947736|NCT03142191|Drug|CC-90001|CC-90001 is a potent, selective inhibitor of JNK.
1947737|NCT03142191|Other|Placebo|Placebo
1456755|NCT03300102|Other|Questionnaires, interviews and or tissue donation|Subjects will be asked to complete either structured questionnaires, semi-structured interviews or donate tissue. There will be some overlap, but each subject does not have to do all three interventions.
1456756|NCT03300089|Procedure|General anaesthesia|General anaesthesia
1456757|NCT03300089|Procedure|Regional anaesthesia|Regional anaesthesia
1456758|NCT03300063|Other|Low flow nocturnal oxygen|Nocturnal low-flow oxygen via nasal cannula
1456765|NCT03300037|Device|Kinesthetic stimulation|The kinesthetic actuator is placed on the skin near the ear and emits vibrations.
1456766|NCT03300024|Device|Expanded polytetrafluoroethylene Graft|Group will receive any standard ePTFE graft (control) based on the surgeons' discretion. The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
1456767|NCT03300024|Device|Bovine Carotid Artery Graft|Group will receive the BCA graft (experimental).The graft will be placed either in the arm (brachial artery to axillary vein) or forearm (brachial artery to cephalic or suitably sized vein) depending on which location works best in your particular case.
1456768|NCT03300011|Device|stent|PTCA or PCI
1456769|NCT03299998|Procedure|Maxillary and mandibular blocks|A Pajunk SonoPlex Stim needle 22G x 55 mm was used. For maxillary nerve block, needle was introduced next to the angle of the orbitae and the zygomatic ridge. The needle was sank until coming into contact of the temporal bone. It was then orientated to the controlateral nostril and sank of 1 cm. For mandibular block, needle was introduced in the pterygoid fossa under and perpendicularly to the zygomatic arch, and sank until the pterygoid process. The needle was then orientated towards controlateral orbitae and sank with neurostimulation. After a motor response at 0.6 milliampere (mA) and the disappearance of contraction at 0.3 mA, local mixture was injected. The mixing of local anesthesia was made of ropivacaine 5 mg/mL and clonidine 30 µg. Five mL were injected in every block for a total of 20 mL.
1456770|NCT03299998|Procedure|General anesthesia|Anesthesia was standardized and provided using intravenous administration of propofol and remifentanil. Patients were mechanically ventilated with a mixture of air (50/50), and desflurane or sevoflurane, or Target-controlled infusion (TCI) propofol. One to 5 mg/kg of methyl-prednisolone were administered to reduce inflammatory response.
1456771|NCT03299985|Other|Diaphragmatic myofascial release|Subjects in this arm will receive different myofascial release techniques aimed to normalize the myofascial tension of the diaphragmatic muscle
1456772|NCT03299985|Other|Sham myofascial release|Subjects in this arm will receive the same manual techniques of the diaphragmatic myofascial release group, but without the myofascial stimulus
1456776|NCT03299946|Drug|Cabozantinib|Cabozantinib (40mg) will be taken by mouth daily for 8 weeks.
1456777|NCT03299946|Drug|Nivolumab|Nivolumab 240mg intravenously every 2 weeks (days 14, 28, 42, and 56 for a total of four doses), in combination with Cabozantinib 40mg by mouth daily for 8 weeks.
1456778|NCT03299920|Other|Standardized instructions|Specific instructions related to peripheral nerve block.
1456779|NCT03299920|Other|Conventional instructions|Usual post-operative instructions.
1456780|NCT03299907|Diagnostic Test|Spirometry|
1456782|NCT03299881|Device|Transcutaneous Nerve Stimulator (TENS)|The Elira wearable patch system is a RF coupled, wearable transcutaneous electrical nerve stimulator (TENS) device controlled via Bluetooth by a smart phone unit running a custom application which directs therapy from the patch within safe limits set by a clinician and also includes a weight loss diary.
1456783|NCT03299881|Behavioral|Diet & Exercise|Subjects to be instructed on a healthy 1200 calorie diet.
1456784|NCT03299868|Device|peripherally inserted central catheter (PICC)|comparisons of the safety, efficacy, and patient-perceived satisfaction between the initially routine PICC insertion group (routine PICC group) and general IV access group (general IV group)
1456785|NCT03299855|Other|Passation of neuropsychological test|Passation of MoCA and MMS tests associated with neuropsychological test
1456786|NCT03299842|Drug|ZX008 (Fenfluramine Hydrochloride)|ZX008 is supplied as an oral solution in a concentration of 2.5 mg/mL. Subjects will be titrated to an effective dose beginning with 0.2 mg/kg/day (maximum: 30 mg/day).
1456787|NCT03299829|Drug|Trientine|Trientine is a chelating agent for removing the copper from the body
1456788|NCT03299816|Behavioral|Coaching DASH group (C-DASH)|Participants assigned to the C-DASH diet advice group will be provided $30/week worth of fruits, vegetables, nuts and beans ordered through the study coach and delivered to a community location to reach a certain goal of potassium intake (months 0-4). During phase 2 of the study (months 5-12), a study coach will continue telephonic contact with the participants to set goals for following a DASH-like diet without the weekly food allowance.
1456789|NCT03299816|Behavioral|Self-Shopping DASH group (S-DASH)|Participants will be given a brochure containing information about the DASH diet which will be reviewed with a study team member. In months 1-4, participants will receive a gift card equivalent to a weekly allowance of $30 to Klein's ShopRite stores of Maryland for purchases of food and beverages of their choice. During phase two (months 5-12), they will be asked to continue following a DASH-like diet but will not receive a gift card for purchases.
1947738|NCT03140072|Drug|AZD9898|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of AZD9898, under fasted conditions. Starting dose in part 1 (SAD in healthy subjects) is 3 mg, subsequent doses will be selected based on emerging data. In Part 3 of the study, each subject will receive one dose level of AZD9898, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
1947739|NCT03140072|Drug|Matching Placebo|In Parts 1 and 2 of the study, each subject/patient will receive a single dose (one dose level) of matching placebo, under fasted conditions. In Part 3 of the study, each subject will receive one dose level of matching placebo, once daily, under fasted or fed conditions. Subjects participating in Part 3B (food effect cohort) will receive an additional administration of the same dose, on the last day to investigate the effects of food.
1456793|NCT03299764|Device|Pursed lip breathing ventilation|A non-invasive ventilation device mimicking the pursed lip breathing in COPD patients will be used.
1456794|NCT03299764|Device|Standard non-invasive ventilation|Standard non-invasive ventilation
1947740|NCT03141138|Biological|TDENV-PIV|Dosage: 0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant Mode of administration: intramuscular (IM) into the subject's upper arm, deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible
1456796|NCT03299738|Biological|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg
1456797|NCT03299725|Drug|colloidal bismuth sub-citrate|colloidal bismuth sub-citrate administered as an adjunctive therapy in combination with esomeprazole, amoxicillin and metronidazole
1456798|NCT03299712|Device|ArteFill|soft tissue filler
1456799|NCT03299686|Drug|CJM112|Study treatment
1456800|NCT03299686|Other|Placebo to CJM112|Placebo to match CJM112
1456801|NCT03299660|Drug|Avelumab|Avelumab 10 mg/Kg every 2 weeks for 4 cycles post LCCRT
1456802|NCT03299660|Drug|5 Fluorouracil|5FU continuous infusion 225mg/m2/day during radiotherapy
1456803|NCT03299660|Drug|Capecitabine Pill|Can be administered in place of 5FU infusion. Dose = 825 mg/m2 twice a day on each day of radiotherapy
1456804|NCT03299660|Radiation|Radiotherapy|50.4 Gy in 28 fractions delivered over 5.5 weeks as 5 fractions/week
1456805|NCT03299660|Procedure|Surgical Resection|Surgical resection of tumour mass post radiotherapy and chemotherapy
1456809|NCT03299608|Diagnostic Test|Breath analysis|Spectrometric analysis of exhaled breath as screening for opportunistic respiratory infections
1456811|NCT03299582|Device|Hypothermia|Healthy subjects will undergo 3 hours of hypothermia at various temperature levels.Cancer subjects will undergo 4 hours of hypothermia during every cycle of chemotherapy.
1456812|NCT03299582|Device|Cryocompression|Healthy subjects will undergo 3 hours of cryocompression. Cancer subjects will undergo a minimum duration of 2 hours and a maximum duration of up to 4 hours of cryocompression during every cycle of chemotherapy.
1456814|NCT03299543|Device|LEVL (Medamonitor)|Subjects will provide duplicate breath samples to the LEVL device for analysis of breath acetone
1456815|NCT03299530|Other|patients with corneal astigmatism|The total corneal astigmatism, anterior chamber depth, will be measured by a Scheimpflug tomographer. Pupil size will be measured by itrace device and MONCV3 device. Residual astigmatism will be tested by subjective refraction.
1456816|NCT03299517|Drug|Antiarrythmic Drugs|Patient will be randomly randomized 1: 1 for the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
1456817|NCT03299517|Drug|Antiarrhythmic drugs|Patient will be randomly randomized 1: 1 for the the antiarrythmic drugs. If there is no reversal and there is no adverse event, a further dose of the same pre-administered medicinal product will be performed in another 30 minutes.
1456818|NCT03299504|Other|Exercise|5 days per week, 2.5 hours per day strength, balance and endurance training on an outpatient basis
1456819|NCT03299491|Other|MWA intervention|The MWA intervention will involve upgrading existing maternity waiting areas to ensure that essential supplies and services are available to create a comfortable environment for women to temporarily reside in and have easy access to skilled obstetric services.
1456820|NCT03299491|Other|IEC intervention|"Community and religious leaders will each attend one-day workshops designed using participatory, adult learning methods to help participants better understand the importance of maternal health care services, identify barriers to accessing care and to strategize how to promote utilization of services. Half-day workshops will conducted in subsequent years to build on shared experiences.
Health extension workers will attend 3-day workshops to identify enablers and barriers to implementation of the safe motherhood components of the health extension program and strategize on how to engage community and religious leaders to support access to maternal health care services in their communities.
Half-day workshops will conducted in subsequent years for each of the participant groups to build on shared experiences."
1456821|NCT03299478|Other|Will look for immune infiltration|
1456963|NCT03298451|Drug|Durvalumab (Regimen 1)|Durvalumab IV (intravenous infusion).
1456964|NCT03298451|Drug|Durvalumab (Regimen 2)|Durvalumab IV (intravenous infusion).
1456822|NCT03299465|Behavioral|Yoga|This is a single arm study and all participants will be assigned to a six-week restorative yoga intervention. Restorative yoga sessions will consist of gentle physical poses (asanas), breathing control (pranayama), and relaxation (savasana).
1456826|NCT03299439|Other|acupuncture|a stimulation of the body or auricular points
1456827|NCT03299426|Biological|Vi-Typhoid Conjugate Vaccine (Vi-TCV)|Single 0.5-ml intramuscular injection
1456828|NCT03299426|Biological|Meningococcal A Conjugate Vaccine (MCV-A)|Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.
1456829|NCT03299413|Biological|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected intravenously
1456830|NCT03299400|Device|Contact lens sensor|Patient will continue to wear the contact lens postoperatively for a total of 24 hours or until the patient cannot tolerate the contact lens. After removal of the contact lens sensor, the recorded profiles will be collected and visualized graphically on a computer interface.
1456831|NCT03299387|Drug|Nitrofurantoin|Participants will receive oral Nitrofurantoin 100 mg twice daily for 7 days
1456832|NCT03299387|Drug|Gentamicin|Participants will receive intravesical via catheter Gentamicin solution 25 mg in 50cc for 3 days
1456833|NCT03299374|Other|Pilates Intervention|Intervention based on Pilates principles
1456834|NCT03299374|Other|Fall prevention intervention|Intervention based on principles to prevent falls
1456835|NCT03299361|Other|Magnetic resonance image (MRI)|Diffusion tensor magnetic resonance imaging (DTI) of MRI reveals tissue microstructure based on random movements of water molecules. Here we monitored, by means of DTI, median nerve integrity in CTS patients before and after corticosteroid injection. This information may help to explain the hypothesis regarding the effect of corticosteroid to the median nerve, to identify which anatomic location of median nerve relevant to the symptom relief of CTS after corticosteroid injection, and be useful for the clinical follow-up of patients with nerve entrapments following conservative treatment.
1456836|NCT03299348|Behavioral|AgingPLUS|The program consists of 2-hour meetings for a total of 4 weeks (total of 8 hours) and discusses (a) how negative views on aging and negative age stereotypes undermine adults' health-promoting behaviors; (b) how adults can take control of their own aging; and (c) how personal goals can be achieved through more effective goal planning and action plans.
1456837|NCT03299335|Other|Blood collection|assay of CPK and anti-cN-1A antibodies
1947741|NCT03141138|Biological|TDENV-LAV F17|Dosage: 0.5 mL of the post-transfection LAV F17 vaccine Mode of administration: subcutaneously into the upper-outer triceps/deltoid area of the subject's arm; vaccination will be given in the non-dominant arm whenever possible.
1456840|NCT03299309|Drug|PEP-CMV|Patients receive temozolomide (TMZ) 200 mg/m2/day x 5 days. On day 20, patients will receive a Tetanus-diphtheria pre-conditioning vaccination with Td (tetanus, diphtheria toxoid, adsorbed). Immunotherapy begins the following day, on day 21 of TMZ, with injection of the first PEP-CMV vaccine as follows: 250 µg (250 µL) of PEP-CMV Component A mixed with 250 µL Montanide ISA-51 intradermally administered in the RIGHT groin and 500 µg of PEP-CMV Component B mixed in 150 µg of GM-CSF intradermally administered in the LEFT groin.
1456844|NCT03299270|Other|Questionnaires|Quality of Life and Functional recovery questionnaires
1456845|NCT03299257|Drug|donepezil treatment|30-day treatment donepezil or placebo in patients with OSA using CPAP in a double blind fashion
1456846|NCT03299244|Drug|Etelcalcetide|"Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
Drug: Oral Placebo. Administered orally once a day."
1456847|NCT03299244|Drug|Cinacalcet|"Cinacalcet was administered orally once a day. The starting dose was 25 mg daily, titrated up to 100 mg daily based on serum PTH and corrected calcium levels.
Drug: Intravenous Placebo Administered intravenously (IV) three times per week."
1456848|NCT03299231|Device|OPEP Aerobika|Previous studies of OPEP device shows preliminary benefit in subjects with COPD. No serious adverse events were recorded in previous studies. The device is FDA registered.
1456849|NCT03299231|Device|OPEP Aerobika Sham device|The same OPEP device which is devoid of the nebulizer port valve to render it inactive. Used for control sham arm.
1456850|NCT03299218|Dietary Supplement|SNF Wawamum|A monthly ration of 30 sachets of SNF (one 50 gram sachet of Wawamum per child per day) will be provided by LHWs. Each recruited child will receive SNF on a monthly basis for the duration of 18 months during his/her age of 6-24 months.
1456851|NCT03299218|Behavioral|Enhanced behaviour change communication|Enhanced BCC messages will be delivered by LHWs in their monthly routine household visits. Male and female group sessions will be arranged on quarterly basis with the help of health committees.
1456852|NCT03299218|Other|Cash|Cash totaling 1600 rupees per month will be transferred by BISP throughout the study period.
1456853|NCT03299205|Behavioral|Exercise|The exercise intervention consists of moderate intensity aerobic exercise intervention that will include the wearing of an accelerometer (i.e. Fitbit Zip) to monitor daily activity and steps. Aerobic exercise will be conducted over 10-weeks in PLWHA +/- AUD. The programs will consist of aerobic exercise 3 days per week of moderate intensity for 30-45 minutes each session with the goal of achieving 135 minutes per week. The program will begin at low-moderate intensity and progress to higher intensity exercise after week 4 of the program. All exercise will be completed on a treadmill and supervised by study staff. Each participant will be provided with a Fitbit Zip to monitor daily activity and steps with a goal of 7000 steps per day.
1456854|NCT03299192|Behavioral|Tai Chi|Yang Style Tai Chi
1456855|NCT03299192|Behavioral|Health Education|Comprehensive Health Education relevant for Healthy Aging in Patients with Chronic Back Pain
1456856|NCT03299192|Other|Usual Medical Care|Medications, PT, Complementary and Integrative Health and other miscellaneous treatments as appropriate.
1456857|NCT03299179|Device|MRI scan|Several MRI scan modalities: MPRAGE (structural scan), arterial spin labeling (cerebral perfusion), resting state functional-MRI (fMRI, cerebral activity) and diffusion MRI (white matter diffusion and white matter tracts).
1456858|NCT03299179|Device|Physiological monitoring|During MRI: heart rate, end-tidal carbon dioxide (CO2), respiratory rate and skin conductance
1456859|NCT03299179|Biological|Blood sample|Blood sample after MRI-session: measurement of hematocrit, hemoglobin, estradiol, progesterone, follicle stimulation hormone and luteinizing hormone.
1456860|NCT03299179|Device|Blood pressure measurement|Measuring blood pressure before and after MRI-scan
1456861|NCT03299179|Device|Body temperature|Measuring body temperature before and after MRI-scan
1456862|NCT03299179|Other|Questionnaires|Questionnaires at the start of the study on lifestyle. Additionally, a questionnaire before each scan session on the actual state of the volunteer (e.g. mood, caffeine consumption, alcohol, medication, etc.)
1456863|NCT03299179|Diagnostic Test|Pregnancy test|Test for pregnancy using a pregnancy dipstick test
1456866|NCT03299153|Other|barberry juice|
1456867|NCT03299140|Behavioral|Family Focused Therapy|
1456868|NCT03299127|Behavioral|imagery rescripting|"The long version of the manual contained 4,959 words, the brief version had 3,369 words. Individuals were encouraged patients to time travel to negative personal events, enter the scene and protect or comfort their younger-ego. The participant should bring the negative event to a happy end. This could also be a fictive, compassionate person and may violate the laws of physics (e.g., a person may fly). Readers were encouraged to embellish the scenes as much as possible so that it competed with the original scene. This technique was then applied to future events. For the last technique, patients were asked to seek a corresponding mood-congruent metaphor, creature or symbol; for example, a small bird that has fallen out of its nest. Using their mind's eye, these images may be transformed into something of beauty or pride."
1456869|NCT03299114|Other|Whirlpool|
1456870|NCT03299101|Other|Prehabilitation|Prehabilitation will last 4 weeks and consist of a novel, home-based regimen of (a) aerobic conditioning; (b) strength and coordination training; (c) respiratory muscle training; and (d) nutritional coaching and supplementation.
1456874|NCT03299075|Behavioral|Food photography|Participants will engage in food photography on their smart phones while eating
1456875|NCT03299075|Behavioral|Non-food photography|Participants will engage in photography of non-food items on their smart phones while eating
1456876|NCT03299075|Behavioral|No phone|Participants will not use their phones while eating
1456877|NCT03299062|Diagnostic Test|Cytology and Immunohistochemistry|Determine if nasal swabs can provide an adequate sample for evaluation using cytology and immunohistochemistry for alpha-synuclein, A-beta and p-tau staining.
1456882|NCT03299036|Device|Taiwan ACE Beads with doxorubicin|Similar with commercializing drug-eluting beads, radiologist inject Taiwan ACE Beads with doxorubicin instead of Gelfoam or polyvinyl alcohol.
1456883|NCT03299023|Other|Medibyte Portable Monitor|Patients will be provided with the portable monitor in order to measure their apnea/hypopnea index.
1456884|NCT03298997|Procedure|Ligation and Hemorrhoidopexy|"Identification through palpation and ligation of the hemorrhoidal nodules (3rd, 7th, 11th hour), using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).
Prior to operation, the patients will be submitted to pudendal nerve block."
1456885|NCT03298997|Procedure|Ultrasound Guided Ligation of Hemorrhoidal Arteries|"Ultrasound guided identification and ligation of the hemorrhoidal arteries, using an absorbable polyglycolic acid suture (2-0, 5/8 inch needle).
Prior to operation, the patients will be submitted to spinal anesthesia."
1947742|NCT03141034|Drug|Irinotecan|-Irinotecan is commercially available and will be billed to insurance.
1947743|NCT03141034|Drug|Ramucirumab|-Ramucirumab will be provided free of charge by Eli Lilly and Company.
1456965|NCT03298425|Device|Treatment NMES|Muscle stimulation to reproduce an active muscle contraction. CE marked used for intended purpose.
1456889|NCT03298971|Other|Questionnaires|Participants were asked to respond to the questionnaires including Hong Kong Chinese Version World Health Organization quality of life measure, abbreviated version (WHOQOL-BREF (HK)), the Chinese version of The Center for Epidemiological Studies - Depression Scale (CES-D), the Chinese version of Rosenberg self-esteem scale, and the Chinese version of the Herth Hope Index (HHI).
1456890|NCT03298958|Drug|Rapamycin|Subject will be randomized to one of the 2 arms
1456891|NCT03298958|Drug|Placebo Oral Tablet|Subject will be randomized to one of the 2 arms
1456892|NCT03298945|Drug|Miralax-Gatorade Prep|2-L split-dose Miralax-Gatorade bowel prep for colonoscopy
1456893|NCT03298945|Drug|Golytely|4-L split dose Golytely is the current standard prep at the VA
1456894|NCT03298932|Procedure|Aortic valve surgery|Aortic valve surgery
1456895|NCT03298919|Behavioral|Exercise Video Games|12 weeks laboratory based exercise videogames
1456896|NCT03298919|Behavioral|Aerobic Exercise|Stationary bike and/or treadmill walking for 12 weeks
1456897|NCT03298919|Behavioral|Home exercise videogames|videogame console and active videogames
1456898|NCT03298919|Behavioral|Home Standard Exercise|Personalized physical activity promotion materials
1456901|NCT03298893|Drug|Nivolumab Injection|2 possible doses : flat dose 240 mg q2 weeks or 1mg/kg q2 weeks
1456902|NCT03298893|Drug|Cisplatin|40 mg/m2, once a week during radiotherapy
1456903|NCT03298893|Radiation|radiotherapy|"Intensity-modulated radiation therapy (including volumetric-modulated arc therapy and tomography) will be used. A dose of 45 Gy will be delivered to the pelvis in 25 fractions of 1.8 Gy using a 6-MV photon energy.
An additional dose of 54 Gy in 25 fractions of 2.16 Gy may be delivered to invaded lymph nodes using SIB-IMRT.
An additional lateral pelvic dose may be delivered if coverage of the target volumes is judged insufficient. The volumes, doses and techniques will be those usually used in each center."
1947744|NCT03141034|Genetic|Blood for angiome profiling|-Before treatment on cycle 1 day 1, cycle 5 day 1, cycle 9 day 1, and end of treatment
1947745|NCT03141034|Genetic|Blood for cfDNA|-Before treatment on cycle 1 day 1, cycle 3 day 1, cycle 5 day 1, cycle 7 day 1, cycle 9 day 1, and end of treatment
1947746|NCT03135782|Other|Communication Skills Training|Undergo motivational interviewing training
1947747|NCT03135782|Other|Medical Chart Review|Undergo medical chart review
1456910|NCT03298854|Device|99mTc-MDP SPECT/CT|Delayed whole body images, using Symbia-T-Siemens dual headed gamma camera, will be obtained 2-3 hours after injection of 15-25 mCi of Tc-99m MDP (Methylene diphosphonate) followed by SPECT images of the lumbar spine and pelvis.
1456911|NCT03298841|Device|Zeiss|"This study proposal will highlight the advanced technology features of the Zeiss Lumera surgical operating microscope which include but are not limited to:
Stereo Coaxial Illumination for improved visualization High resolution video screen/co-observation tool to help OR staff anticipate next steps Integrated toric alignment tool Surgical microscope touch screen Cordless foot control for faster turnover between cases"
1456912|NCT03298828|Biological|CD19 CAR and PD-1 knock out engineered T-cells|A single dose of 1 x 10^6/kg CD19 CAR transduced and PD-1 knock out engineered T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
1456913|NCT03298828|Biological|CD19 CAR T-cells|A single dose of 1 x 10^6/kg CD19 CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
1456914|NCT03298815|Biological|Amniotic Fluid Eye Drops (AFED)|One drop (0.25 mL) in one eye twice daily for up to 3 months
1456915|NCT03298815|Other|Saline Solution|One drop (0.25 mL) in the other eye twice daily for up to 3 months
1456918|NCT03298789|Other|Activation exercise|Two series of 4 activation exercise will be included in the intervention.
1456919|NCT03298789|Other|7 series of static stretching|7 series of 4 20 seconds static stretches will be conducted.
1456920|NCT03298776|Device|I-Scan|I-Scan is a digital enhancement technique. These endoscopes already have greater definition compared to many standard endoscopes but they also utilise a 'zoom' function and digital image enhancement.
1456921|NCT03298776|Diagnostic Test|Standard endoscopy|Patients referred for standard endoscopy to receive standard of care only
1456922|NCT03298763|Genetic|MSCTRAIL|"3 doses of MSCTRAIL, administered as an intravenous 60 minutes infusion over 3 cycles, in combination with standard chemotherapy (Cisplatin/Pemetrexed).
After 3 cycles patients will have 1-3 further treatment of pemetrexed and cisplatin without MSCTRAIL."
1456923|NCT03298763|Drug|Placebo|Placebo will be made up of the same material used to cryopreserve the ATIMP (MSCTRAIL) but will not include the active product
1947748|NCT03135782|Other|Questionnaire Administration|Ancillary studies
1947749|NCT03135782|Other|Tobacco Cessation Counseling|Attend phone or in-person motivational interviewing coaching sessions
1947750|NCT03135262|Drug|Idasanutlin|Induction Treatment: Idasanutlin tablets will be administered orally once daily at escalated doses (starting dose 100 milligrams [mg], maximum 600 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
1456925|NCT03298737|Behavioral|Covert Spatial Attention|"During behavioral sessions, subjects will sit in a dark room and view a video monitor placed at the minimum of 57 cm distance away from the subject. Staff will be present throughout all the testing to assist the subject and monitor equipment that is used for tracking their eye position. Subjects will be asked to maintain their heads in a stable position of rest in order to insure accurate tracking of their eye position. To stabilize their head, subjects will either use a chin rest in which they position their chin on a soft pad mounted in front of a video screen, or they may use a bite bar."
1456926|NCT03298724|Behavioral|Teachers and Parents as Partners|A family-school partnership intervention to improve the home-school connection, parenting and teaching strategies, and child behavior outcomes.
1456927|NCT03298698|Drug|Rituximab|Rituximab: 375 mg/m2 intravenously on day 0 and day 14 B-cells will be monitored weekly, and if no complete depletion is achieved, additional dose(s) of Rituximab will be given at a weekly interval until complete B cell depletion (maximum of 2 additional doses).
1456928|NCT03298698|Drug|Prednisone|Prednisone 1 mg/kg/day (max 80 mg/day) for 8 weeks
1456929|NCT03298685|Other|semi structured interviews for all adolescents and their parent|Before and after transition, individual semi structured interviews will be recorded by one person in the same way in all CF center. And every interview will be transcribed by an other person
1456932|NCT03298659|Diagnostic Test|iFR|Treatment guided by instantaneous wave-free ratio
1456933|NCT03298659|Diagnostic Test|CMR|Treatment guided by stress perfusion CMR
1456934|NCT03298646|Drug|Lidocaine Hydrochloride|10 ml of 2% lidocaine on hysteroscopic infusion media during office hysteroscopy.
1456935|NCT03298646|Drug|Diclofenac|100 mg Diclofenac oral tablet one hour before the procedure.
1456936|NCT03298633|Other|ICSI|Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo routine ICSI procedure according to the result of randomization in each study site.
1456937|NCT03298633|Other|Conventional IVF|Ovarian stimulation will be performed by a standard protocol using gonadotrophin-releasing hormone antagonist (GnRH-ant) in association with recombinant FSH (rFSH) and human chorionic gonadotrophin (hCG).Oocyte retrieval is scheduled for 36 (±2) after hCG injection.The retrieved cumulus oocyte complexes (COC) will be allocated to undergo conventional IVF procedure according to the result of randomization in each study site.
1456938|NCT03298620|Other|Electric toothbrush|
1456939|NCT03298620|Other|Control|Manual toothbrush
1456941|NCT03298594|Diagnostic Test|specific cervicograph|
1456942|NCT03298581|Drug|Halobetasol Propionate|Experimental: Treatment with topical halobetasol spray 0.05% Patients will instructed o apply halobetasol spray twice daily for 28 days and not to rub over the affected area after application of spray.
1456943|NCT03298568|Dietary Supplement|DAOsin|DAOsin is a food supplement for special medical purpose for the treatment of food intolerance provoked by histamine intake.
1456944|NCT03298555|Behavioral|Mobile phone based intervention|Participants in the intervention group will receive a 6-month mobile phone based program via a mobile phone application specifically designed for this study. The program will include information, advice and strategies to promote healthy gestational weight gain.
1456945|NCT03298542|Drug|Golimumab|Participants will receive subcutaneous golimumab for 26 weeks, where doses will be based on weight and/or body surface area.
1456946|NCT03298542|Drug|Placebo|Matching placebo to golimumab.
1456947|NCT03298529|Other|glucose solution|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume standard food, a glucose solution at 50%
1456948|NCT03298529|Other|Traditional egg pasta|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume traditional pasta, with 8 eggs/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
1456949|NCT03298529|Other|Pasta with eight egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with eight egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
1456950|NCT03298529|Other|Pasta with four eggs/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta, with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
1456951|NCT03298529|Other|Hyperproteic pasta (with added gluten and albumin)|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with added gluten and albumin.The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
1456952|NCT03298529|Other|Pasta with only four egg whites/kg flour|12 healthy subjects, aged 18-65 years, after a 10 to 12-hour overnight fasting period will assume pasta with four egg whites/kg flour. The serving size must contain 50 g of carbohydrates, calculated according to nutritional label
1456953|NCT03298516|Drug|DCLL9718S|DCLL9718S will be administered as per the schedule specified in the respective arm.
1456954|NCT03298516|Drug|Azacitidine|Azacitidine will be administered as per the schedule specified in the respective arm.
1456955|NCT03298503|Other|task-priority strategies|"posture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on postural task (standing/walking).
supraposture-focus strategy: when performing postural-suprapostural task (dual-task), the patient mainly focus on suprapostural task (stabilize the tray)."
1456956|NCT03298477|Device|Nellix® System|Endovascular Abdominal Aortic Aneurysm Repair using the Nellix® System
1456957|NCT03298464|Biological|NGM313|Subcutaneous injection
1456958|NCT03298464|Drug|Pioglitazone|White to off-white round tablet
1456959|NCT03298451|Drug|Durvalumab|Durvalumab IV (intravenous infusion).
1456960|NCT03298451|Drug|Tremelimumab (Regimen 1)|Tremelimumab IV (intravenous infusion).
1456961|NCT03298451|Drug|Tremelimumab (Regimen 2)|Tremelimumab IV (intravenous infusion).
1456962|NCT03298451|Drug|Sorafenib|Sorafenib, as per standard of care
1456966|NCT03298425|Device|Placebo NMES|TENS machine to mimic an active muscle contraction. CE marked used for intended purpose.
1456967|NCT03298412|Drug|Blinatumomab|"Blinatumomab will be supplied as 4 mL single-use sterile glass injection vials. Blinatumomab is administered as a continuous intravenous (IV) infusion.
Cycle 1 of blinatumomab treatment is 12 weeks (84 days) in duration and includes 8 weeks (56 days) of blinatumomab IV infusion followed by a 4-week (28-day) treatment-free interval. The initial dose of blinatumomab will be 9 μg/day for the first 7 days of treatment. Blinatumomab dose will then be escalated (dose-step) to 28 μg/day starting on day 8 (week 2) followed by a dose-step to 112 μg/day starting on day 15 (week 3) and continuing until completion of therapy (day 57 of cycle 1)."
1456968|NCT03298399|Biological|Autologous MSCs|Participants at dose level 1 receive four infusions of MSCs, given once per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
1456969|NCT03298399|Biological|Autologous MSCs|Participants at dose level 2 receive four infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
1456970|NCT03298399|Biological|Autologous MSCs|Participants at dose level 3 receive six infusions of MSCs, given twice per week. The first MSC infusion will be given no sooner than 4 hours after the bone marrow transplant. The total number of cells delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 10^6 cells/kg, which will be delivered via intravenous infusion. The infusion can be administered to patients in the inpatient or outpatient setting.
1456972|NCT03298373|Drug|Placebo|Placebo capsules that look like the 11β-MNTDC capsules but with no active ingredients.
1456973|NCT03298373|Drug|11β-methyl-nortestosterone-dodecylcarbonate|11β-MNTDC doses in castor oil/benzyl benzoate capsules (100 mg each) administered in 200 mg or 400 mg doses orally.
1456974|NCT03298360|Other|Blood sample|167mL of blood in EDTA tube will be obtained on a research visit, after signature of written informed consent
1456975|NCT03298347|Drug|80mg/kg of caffeine|80mg/kg of caffeine is given to treat AOP
1456976|NCT03298347|Drug|20mg/kg of caffeine|20mg/kg of caffeine is given to treat AOP
1456977|NCT03298334|Other|Vaginal Seeding|A gauze containing the Mother's vaginal flora will be swabbed over the face and body of the neonate shortly after cesarean delivery.
1456978|NCT03298334|Other|No Vaginal Seeding|A gauze carrying sterile saline will be swabbed over the face and body of the neonate shortly after cesarean delivery.
1456979|NCT03298321|Other|Effect of Vidaza treatment|The goal of this study is to evaluate the effects of azacytidine on arrhythmia and left atrium fibrosis.
1456980|NCT03298308|Device|Cranial Electric Stimulation|Micro amperage TCDS
1456981|NCT03298295|Device|Continous Subcutaneous Insulin Infusion Catheter|Catheters will be inserted into the abdomen of each patient using aseptic technique according to the following schedule: (1) 8 days before surgery, (2) 4 days before surgery and (3) 1 day before surgery (Table 1). At each time point 2 steel (Medtronic Sure-T, 9 mm) and 2 Teflon (Medtronic Quick-set®, 9 mm) CSII catheters will be inserted into the subcutaneous abdominal tissue. In total, 12 catheters will be inserted into each patient's abdomen using only the area predefined by the plastic surgeon for removal.
1456982|NCT03298282|Other|OCT (Optical Coherence Tomography)|Coronary images by OCT and selective CTA and FFR values will be registered.
1456983|NCT03298282|Other|selective CTA|Coronary images by OCT and selective CTA and FFR values will be registered.
1456984|NCT03298282|Other|FFR|Coronary images by OCT and selective CTA and FFR values will be registered.
1456985|NCT03298269|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention led by a therapist that combines training in mindfulness, cognitive reappraisal, and savoring skills.
1456986|NCT03298269|Behavioral|Supportive Counseling|A support group led by a therapist will allow participants to express emotions, share experiences, and receive social support.
1456987|NCT03298256|Radiation|EOS X-rays|Full length, orthogonal anteroposterior and lateral X-rays will be taken simultaneously in a standardised standing position, with arms folded anteriorly in 45 degrees . All radiographs will include C7 proximally and the femoral heads distally. 3D reconstruction of the spine can be performed. X-rays will be repeated after the brace is applied, and at intervals of no fewer than 6 months until the brace is weaned off, or if surgical intervention is required. Coronal, sagittal and axial parameters will be calculated from the reconstruction. 3D vertebral wedging will be calculated in the posterofrontal, sagittal and diagonal planes at the apex, 3 superior and 3 inferior vertebrae, as described by Scherrer et al. Changes in the pre- and post-bracing and follow-up parameters can be calculated.
1456988|NCT03298243|Behavioral|Vibrotactile stimulation|Non-invasive, computer-controlled miniature tendon vibrators, similar to those used in FitBit activity monitors.
1456989|NCT03298230|Behavioral|REmotely SuPervised Exercise Training|As described in the Arms section.
1456990|NCT03298230|Behavioral|Supervised Exercise Training|As described in the Arms section.
1457035|NCT03297918|Behavioral|Respiratory muscle training|The intervention is two-parted and includes weekly singing lessons in a choir, held by a professional instructor, with additional instructions for daily breathing exercise at home.
1457036|NCT03297905|Behavioral|Complementary and Integrative Therapies|Intervention time period is 3 - 6 weeks.
1457037|NCT03297905|Behavioral|Standard Rehabilitative Care|Intervention time period is 3 - 6 weeks.
1498708|NCT02978833|Biological|PRP|
1456991|NCT03298217|Device|Measurement of the peak tidal inspiratory flow (PTIF)|"In patients with bronchiolitis sverity mWCAS / 3-5 :
Nasopharyngeal aspiration and comfortable placement of the infant upon admission; Clinical evaluation: respiratory rate, respiratory distress scores rating (Silverman and m-WCAS); If the patient is eligible: information and collection of parental consent; If signed parental consent obtained: progressive (on at least 10 min) withdrawal of HFNC support and maintenance if necessary of conventional oxygen therapy (maximum 1 L/min); Application of the spirometer for the recording of 20 consecutive spontaneous respiratory cycles for PTIF measurements; Respiratory support with HFNC; flow adapted to the need of the patients (equal to the measured PTIF)."
1456992|NCT03298191|Drug|Magnesium Sulfate|Those women will be given Magnesium Sulfate for tocolysis
1456993|NCT03298191|Drug|Ritodrine|Those women will be given Ritodrine for tocolysis
1456994|NCT03298191|Drug|Calcium Channel Blockers|Those women will be given Calcium Channel Blockers for tocolysis
1947751|NCT03135262|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg by intravenous (IV) infusion on Days 1, 8 and 15 of Cycle 1 and on Day 1 of each subsequent cycle (Cycles 2 to 6) (each cycle = 28 days) during induction treatment, and on Day 1 of every other month during maintenance treatment (eligible participants with FL only) or during consolidation treatment (eligible participants with DLBCL only).
1457000|NCT03298139|Other|3 levels of gravity (1G, 1.8G, 0G).|healthy volunteers will experience 3 levels of gravity (1G, 1.8G, 0G).
1457001|NCT03298126|Procedure|TR BAND removal protocol|To assess radial artery patency after specific protocol used as already described in previous section.
1457002|NCT03298113|Device|Cavilon Advanced Skin Protectant|Applicator contains a polymeric-cyanoacrylate solution intended to cover and protect intact or damaged skin. Upon application to skin, the liquid dries rapidly to form a primary long-lasting waterproof, highly durable film barrier.
1457003|NCT03298113|Device|IAD Hospital Standard Care|Devices such as local skin protectants will be used accoding to the hospital IAD care regime and under consideration of the respective manufacturers' instructions for use.
1457004|NCT03298100|Other|Scoring model|Determining risk factors an calculating the risk score, recurrent vaginal bleeding 3, hypertension 2, age and endometrial thickness 1 for each
1457005|NCT03298087|Procedure|radical prostatectomy|surgical removal of the prostate
1457006|NCT03298087|Radiation|stereotactic body radiotherapy|Highly targeted radiation
1457007|NCT03298087|Drug|Leuprolide|Lowers serum testosterone
1457008|NCT03298087|Drug|apalutamide|antiandrogen
1457009|NCT03298087|Drug|abiraterone|Inhibits androgen synthesis
1457010|NCT03298074|Drug|Apatinib|Apatinib, 500mg,po qd for continuous administration
1457011|NCT03298074|Drug|Etoposide|Etoposide,100mg, PO.QD，D1-D10, Q3W
1457013|NCT03298048|Biological|Low fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 50g stool for 2 consecutive days
1457014|NCT03298048|Biological|Mid fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool on the 1st day of treatment and from 50g stool on the 2nd day of the treatment
1457015|NCT03298048|Biological|High fecal microbiota dose|receiving healthy microbiota (PRIM-DJ2727) collected from 100g stool for 2 consecutive days
1457016|NCT03298035|Device|NCPAP as mode for apnea prevention|With recurrence of apneic events, infants on NCPAP will have changes made in NCPAP settings per the clinical team's discretion in attempt to prevent future apneic events. If apneic events persist despite NCPAP adjustments, clinicians may intubate based on clinical judgment.
1457017|NCT03298035|Device|NIPPV as rescue mode for apnea prevention|With recurrence of apneic events, infants will be placed on NIPPV with settings and adjustments per the clinical team's discretion. If apneic events persist despite NIPPV placement and setting adjustments, clinicians may intubate based on clinical judgment.
1457018|NCT03298022|Biological|AbGn-168H|monoclonal antibody
1457019|NCT03298009|Drug|Canagliflozin 100mg|2-week intervention
1457020|NCT03298009|Drug|Placebo oral capsule|2-week intervention
1457021|NCT03298009|Radiation|PET imaging|1 day postprandial metabolic protocol at the end of treatment: CT scan followed by dynamic and pancorporel imaging
1457022|NCT03297996|Diagnostic Test|Mobio PowerSoil DNA Isolation Kit|16S rRNA amplicons covering variable regions V3 to V4 were generated using primers (347F-5'GGAGGCAGCAGTRRGGAAT'-3' and 803R 5'-CTACCRGGGTATCTAATCC-3') incorporating Roche 454 FLX Titanium adapters (Branford, CT) and a sample barcode sequence
1457024|NCT03297957|Drug|IC-GREEN|-Injection of ICG around the tumor per standard techniques will in the operating room and 0.5-2.5 mL of 500 micromolar ICG will be injected peri-tumorly into the subcutaneous tissue of the surrounding skin.
1457025|NCT03297957|Device|Hands-free goggle system|-Manufactured at Washington University
1457026|NCT03297944|Drug|Alprazolam|0.5 to 2mg administered at night or in the morning
1457027|NCT03297944|Drug|Zolpidem|10mg administered at night or in the morning
1457028|NCT03297944|Drug|Placebo|placebo administered at night and/or in the morning
1457038|NCT03297879|Drug|Exenatide or metformin hydrochloride|Exenatide was administrated with 5 μg bid for 4 weeks and 10 μg bid for 8 weeks. Metformin hydrochloride was initiated at a dose of 500 mg bid for 2 weeks, and added to 2.0 g/day for 8 weeks.
1457039|NCT03297840|Behavioral|Dialectical Behavioural Therapy (DBT)|Inpatient Dialectical Behavioural Therapy (DBT) according to Linehan.
1457040|NCT03297827|Other|Serum and Urine measurement of cytokines.|To evaluate serum cytokine levels and identifying serum inflammatory markers (serum interleukin-33, IL-37, IL-36, IL-4, IL-6, IL-10, IL-17, IL-23, IL-1, TNF, PDGF, VEGFM TNFa, ANNULIN, MMP-9, MMP-12, NFk-B levels plus metabolic products like MPO, etc and glial factors like GMF, SI000B, GM6001) in patients with acute ischemic & hemorrhagic stroke.
1457041|NCT03297814|Biological|Platelet lysate|Intramuscular injection of platelet lysate
1457042|NCT03297814|Biological|Placebo|intramuscular injection of normal saline
1457043|NCT03297801|Dietary Supplement|Fish oil supplements|Women who chose to supplement with fish oil during gestation or lactation.
1457044|NCT03297788|Radiation|SRS|"For SRS the dose prescription to the PTV will be as follows:
20 Gy to the 70%-isodose (lesions < 2 cm max. diameter)
18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)
6 x 5 Gy to the conformally surrounding isodose (lesions > 3 cm max. diameter)"
1457045|NCT03297788|Radiation|WBRT|WBRT will be applied in 10 fractions with single doses of 3 Gy to the whole brain.
1457046|NCT03297762|Behavioral|gamification|incentives/rewards and contact between standard visits
1457047|NCT03297762|Device|Dexcom G5|Dexcom G5 continuous glucose monitor
1457049|NCT03297736|Device|3D CAD/CAM autograft prosthesis|Surgical ossicular reconstruction with the experimental autograft prosthesis created using 3D subtraction CAD/CAM.
1457050|NCT03297736|Device|Control device|Surgical ossicular reconstruction with the standard available middle ear prosthesis.
1457051|NCT03297723|Other|Therapeutic education Programm|"Intervention will include:
an identification of educational needs and expectations,
a bilateral agreement between patient and medical staff on the priority skills acquirement,
a structured educational activities tailored to the patient's need.
the making of an educational record."
1457052|NCT03297710|Other|Quality-of-Life Assessment|Ancillary studies
1457053|NCT03297710|Radiation|Radiation Therapy|Undergo radiation therapy
1457054|NCT03297710|Drug|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
1457055|NCT03297697|Procedure|Tumor biopsy|Biopsy specimen can be from bone marrow, blood, or lymph node. This specimen should have a high disease load
1457056|NCT03297697|Procedure|Peripheral blood draw|-Baseline, C1D1, C1D8, C1D15, C2D1, C3D1, C4D1, C5D1, C6D1, end of treatment, 3 month follow-up (optional), 6 month follow-up, 9 month follow-up (optional), 12 month follow-up, 15 month follow-up (optional), 18 month follow-up, 21 month follow-up (optional), 24 month follow-up, and at relapse
1457057|NCT03297697|Device|Lymphotrack TCR clonality assay|-Assay with high sensitivity that can be performed with peripheral blood
1457058|NCT03297684|Drug|Aflibercept Injection [Eylea]|Intravitreal injection aflibercept
1457059|NCT03297671|Drug|RhIg prophylaxis|Two RhIg prophylaxis injections for Rh negative women
1457060|NCT03297671|Device|ELDONCARD|ELDONCARD point-of-care test.
1457061|NCT03297671|Diagnostic Test|ELDONCARD Test|LHVs will perform ELDONCARD test.
1457064|NCT03297645|Behavioral|School|CHWs will ensure that families submit required health paperwork (e.g., asthma action plan, medication release form) and confirm with school nurses that children have the appropriate medications. School nurses will be given a standardized protocol to follow with clear guidelines for caring for students with asthma. The CHW assigned to the family will work with the school nurse to ensure that communication with the medical provider is occurring.
1457065|NCT03297645|Behavioral|Asthma education|CHWs will deliver evidence-based asthma education to parents and children. Content is drawn from existing asthma management programs, and adapted for families in Richmond. Between sessions, CHWs will call parents at least monthly to check in and assess family asthma management, including healthcare utilization since the last contact.
1457066|NCT03297645|Behavioral|Home environmental remediation|Healthy Homes will complete home-based environmental assessments using evidence-based protocols. Healthy Homes will provide real-time education and share information about their findings and recommendations for action. Families are provided with low-cost intervention materials (e.g., filters, pillow covers), as well as behavioral modifications to aid in the reduction of asthma triggers in the home.
1457067|NCT03297645|Behavioral|Informational mail|Family will be mailed publicly available asthma information every 3 months.
1457068|NCT03297632|Behavioral|Functional resistance exercise|Functional resistance program designed for older individuals with low muscle mass and muscle strength. The goal is to implement exercises that are possible for the participants to also perform in their home environment, through the use of basic equipment.
1457069|NCT03297619|Behavioral|Mindfulness and Acceptance Workbook for Social Anxiety and Shyness|Participants assigned to this condition will be asked to read this self-help book over an 8-week period.
1457070|NCT03297619|Behavioral|The Shyness and Social Anxiety Workbook|Participants assigned to this condition will be asked to read this self-help book over an 8-week period (with some chapters omitted).
1457071|NCT03297606|Drug|Olaparib|400mg taken twice daily
1457072|NCT03297606|Drug|Dasatinib|100mg administered orally once daily
1457073|NCT03297606|Drug|Nivolumab plus Ipilimumab|"Combination Phase - 1mg/kg nivolumab administered as an intravenous infusion over 60 minutes every 3 weeks for the first 4 doses in combination with ipilmumab 3mg/kg administered intravenously over 90 minutes, followed by the single-agent phase.
Single-Agent Phase - 3mg/kg nivolumab administered as an IV infusion over 60 minutes every 2 weeks."
1457074|NCT03297606|Drug|Afatinib|40mg once daily
1457075|NCT03297606|Drug|Axitinib|5mg orally twice daily
1457076|NCT03297606|Drug|Bosutinib|500mg orally once daily
1457077|NCT03297606|Drug|Crizotinib|250mg orally twice daily
1457078|NCT03297606|Drug|Palbociclib|125mg orally once daily for 21 consecutive days followed by 7 days off treatment to comprise a complete cycle of 28 days
1457079|NCT03297606|Drug|Sunitinib|50mg orally once daily on a schedule of 4 weeks on treatment followed by 2 weeks off
1457080|NCT03297606|Drug|Temsirolimus|25mg infused over a 30-60 minute period once a week
1457081|NCT03297606|Drug|Erlotinib|150mg orally, once daily
1457082|NCT03297606|Drug|Trastuzumab plus Pertuzumab|"Trastuzumab = 3-weekly dose schedule. The recommended initial loading dose is 8mg/kg administered as a 90-minute infusion followed by 3-weekly maintenance dose of 6mg/kg administered as 90-minute infusion.
Pertuzumab = 840mg administered as a 60-minute intravenous infusion, followed every 3 weeks thereafter by a dose of 420mg administered over a period of 30-60 minutes."
1457083|NCT03297606|Drug|Vemurafenib plus Cobimetinib|"Vemurafenib = 960 mg (four 240 mg tablets) orally every 12 hours.
Cobimetinib = 60 mg (three 20 mg tablets) orally once daily for 21 days, followed by 7 days of rest"
1457084|NCT03297606|Drug|Vismodegib|150mg taken orally, once daily
1457085|NCT03297593|Drug|nivolumab|240 mg every 2 weeks during the first 20 weeks, 480 mg every 4 weeks thereafter
1457086|NCT03297593|Drug|ipilimumab|After 2 weeks 1mg/kg every 6 weeks
1457087|NCT03297567|Behavioral|verbal guidance and a booklet|Patients allocated to the intervention group will receive verbal instruction from the researchers on the importance and benefits of movement during hospital stay, as well as what they should do to increase the level of physical activity. These patients will receive the same guidelines through a playable, easy-to-understand and inexpensive booklet developed by the researchers themselves in PowerPoint 2016 (Microsoft) in order to remedy any doubt or forgetfulness during the hospitalization period
1457088|NCT03297554|Behavioral|m-Health Intervention|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
1457089|NCT03297541|Behavioral|m-health approach|Parent/child dyads attend remote counseling sessions delivered over Internet-connected device (e.g. smartphone, iPad/tablet, laptop, or desktop computer). A counselor will deliver the lesson, review progress based on the objectively measured data, and provide individualized advice and problem-solving strategies for parent and child. Families will receive weekly contact via smartphone. Each lesson will include an interactive component for parent and child related to healthy eating and active play, as well as an interactive parenting training component. Lessons are based on the family treatment methods that effectively promote child and parent weight loss that is sustained for 10 years (Epstein et al., 1990; Epstein et al., 1981).
1947752|NCT03135262|Drug|Venetoclax|Induction Treatment: Venetoclax tablets will be administered orally once daily at escalated doses (starting dose 200 mg, maximum 800 mg). Post-Induction Treatment: The dose and regimen will be determined by the Sponsor after review of all relevant data. The dose for maintenance/consolidation will not exceed the dose the participant received during induction.
1457093|NCT03297502|Drug|pimecrolimus cream 1%|
1457094|NCT03297502|Drug|Elidel (pimecrolimus) cream 1%|
1457095|NCT03297502|Drug|placebo|
1947753|NCT03135262|Drug|Rituximab|Rituximab will be administered by IV infusion at a dose of 375 milligrams per square meter (mg/m^2) on Day 1 of Cycles 1−6 during induction treatment and on Day 1 of every other month during consolidation treatment.
1457100|NCT03297463|Drug|Interleukin-2 & Ipilimumab (P-Ib)|"Phase Ib:
- Ipilimumab will be administered in a 3 + 3 dose escalation design.
The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2).
If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg.
The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs.
In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT.
Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual."
1457101|NCT03297463|Drug|Interleukin-2 & Ipilimumab (P-II)|"Phase II:
- Interleukin-2 & Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D)."
1457102|NCT03297450|Device|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA
1457103|NCT03297450|Behavioral|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
1457104|NCT03297450|Device|Sham-tDCS|tDCS during the first 20 minutes of aphasia therapy at an intensity of 0mA (Sham)
1457105|NCT03297437|Other|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
1457111|NCT03297398|Drug|Group-1 (15mg, OPK-88004)|15mg, OPK-88004
1498709|NCT02978833|Biological|Whole Blood|
1457114|NCT03297385|Drug|Enzalutamide|Men with localized prostate cancer will undergo an additional set of targeted tumor biopsies and will be subsequently treated with 3 months of enzalutamide. The prostatectomy specimen will be additionally sampled, ex vivo.
1457115|NCT03297372|Device|IOL implantation|Implantation of monofocal IOL Micropure 1.2.3
1457116|NCT03297359|Biological|Dalteparin|daily subcutaneous injection of weight-adjusted dalteparin
1457117|NCT03297346|Other|Cardiac imaging and circulating biomarkers|Automated 2D-speckle-tracking echocardiography (ECHO-ST); Computed tomography coronary angiography (CT); Cardiac magnetic resonance imaging (MRI); Blood samples for circulating biomarkers measurements (BLOOD)
1947754|NCT03133572|Device|Supraglottic airway|Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.
1457120|NCT03297320|Other|In-depth conversation about Goals of Care and ACP|In-depth conversation regarding Goals of Care and ACP by an experienced practitioner
1457121|NCT03297307|Behavioral|Presurgical Counseling|Children will attend the presurgical counseling visits with their mother
1457122|NCT03297294|Drug|EMA401|capsules, oral
1457123|NCT03297294|Drug|Placebo|Placebo to EMA401 capsules, oral
1457124|NCT03297281|Other|Maintenance of OAC in surgery of BPH by PVP.|The maintenance of AVK or DOACs treatment in the perioperative setting (without interruption of oral treatment).
1457125|NCT03297281|Other|Discontinuation of OAC in surgery of BPH by PVP.|The discontinuation of AVK or DOACs treatment with perioperative heparin relay during postoperative course.
1457126|NCT03297268|Other|Intervention with Home-Based Caregivers|We will assess whether real-time notifications of potential agitation via a wearable wrist device improves caregiver self-efficacy.
1457127|NCT03297229|Behavioral|Peer mentoring|Peers will be assigned to participants according to common socio-demographic characteristics. Each peer will be assigned up to 5 participants.
1457128|NCT03297229|Behavioral|Self-monitoring|"Along with providing patients with a BP monitor, a commitment contract will be signed, in which participants commit themselves to measure their blood pressure at home at least once a week during the 3 months of the intervention. Each participant will be given a form to weekly recording their blood pressure values."
1457129|NCT03297216|Drug|17P|Synthetic progestin
1457130|NCT03297216|Other|Placebo|Non-active placebo comparator
1457131|NCT03297203|Behavioral|Blood sample|The investigators will take two kits of blood samples for the group 1, one during the early stage of the septic shock (48 first hours of care) and one during the late stage of the disease (between the fourth and the sixth day). We'll take only one kit of blood samples for the group 2. One kit includes one EDTA tube (5 mL) and five Lithium Heparin tubes (25 mL). The immune mapping will be made by Julien Carvelli, a gold medalist resident, in the framework of a Master 2. The analyses will be made in the laboratory of immunology in the Conception Hospital (Pr Vivier's team).
1457132|NCT03297190|Behavioral|SMS|Receipt of SMS messages on nutrition and health topics
1457133|NCT03297190|Behavioral|Interpersonal Counselling|Interpersonal counselling on health and nutrition topics
1457134|NCT03297177|Procedure|Microcannula Harvest Adipose|Use Closed Syringe Microcannula Harvest Adipose, Autologous Subdermal Deposits
1457135|NCT03297177|Device|Centricyte 1000|Closed System, Digestive Isolation & Concentration of AD-cSVF
1457136|NCT03297177|Procedure|Sterile Normal Saline Infusion|Sterile Normal Saline Re-Suspension of cSVF and Delivery of AD-cSVF via IV route
1457137|NCT03297151|Dietary Supplement|CONTROL|"Food grade mixture of non-essential amino acids in powdered form, flavoured and instantised to be dissolved in water.
Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10955"
1457138|NCT03297151|Dietary Supplement|Whey Protein Concentrate|"Whey protein concentrate in powdered form, flavoured and instantised to be dissolved in water.
Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Trade name of product is Carbelac80 Instant Product Reference Number 10431"
1457139|NCT03297151|Dietary Supplement|Whey Protein Hydrolysate|"Whey protein concentrate hydrolysate (degree of hydrolysate 27%) in powdered form, flavoured and instantised to be dissolved in water.
Supplied by Carbery Food Ingredients Limited, Ballineen, Ireland. Product Reference Number 10468"
1457140|NCT03297138|Procedure|FiLAC laser|The technique consists in applying in a radial way to 360 ° an energy laser in the fistulous route. This energy allows a thermal destruction by coagulation of the wall of the fistula and the fabrics of granulations in a circular and regular way as well as a shrinkage of neighbouring fabrics. The repair is made by a call of macrophages and fibroblasts of neighbouring healthy fabrics so ending in a closure of the fistulous route
1457141|NCT03297125|Device|NovoCure-TTF-200A|Adhesive bandages hold insulated ceramic discs (transducer arrays) that deliver electricity transformed into electromagnetic energy to the scalp. The battery operated-TTF device generates low intensity, intermediate frequency, alternating electrical fields to the brain. These electrical fields exert selective toxicity in proliferating cells thereby halting cell division and destroying the cancer cells.
1457142|NCT03297112|Drug|Perflutren Lipid Microspheres|Given IV
1457143|NCT03297112|Procedure|Contrast-Enhanced Subharmonic Ultrasound Imaging|Undergo contrast-enhanced subharmonic ultrasound imaging
1457144|NCT03297099|Procedure|Robot-assisted Laparoscopic operation|Thirty patients with hepatolithiasis were selected and divided into robot group as described in the detailed description. Under general anesthesia, the patient was placed in a supine 30-degree reverse Trendelengburg position with both legs separating. The surgeon work on the console, and assist surgeon stand between legs. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
1457145|NCT03297099|Procedure|open surgery|surgery group as described in the detailed description.Open surgery was performed under general anesthesia with the patient in the supine position. Routinely, a reversed L-shape incision was performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle . A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler.
1457146|NCT03297086|Procedure|cataract surgery|cataract surgery with phacoemulsification and implantation of multifocal posterior chamber intraocular lens
1457147|NCT03297073|Drug|paracetamol|"Paracetamol 1000 mg will be administered 30 minutes before the end of the procedure and then every 6 hours systematically at the following times: 6h / 12h / 18h / 00h.
The analgesic treatment after hepatectomy with paracetamol will be maintained for at least 5 days in all patients in parenteral form"
1457148|NCT03297060|Other|SSL Implementation Strategy|Science to Service Laboratory (SSL) is an approach developed by the SAMHSA-funded Addiction Technology Transfer Centers (ATTCs) that consists of didactic training + performance feedback + leadership coaching to improve SBIRT adherence within the pediatric trauma center
1457149|NCT03297047|Device|combi cast|upper arm or forearm combi cast
1457152|NCT03297008|Other|No internvetion|No intervention, this is an observational study
1457153|NCT03296995|Device|Flash glucose monitoring system|Flash glucose monitoring systems in critically ill patients may improve glycemic control and reduce glucose variability.
1457154|NCT03296982|Other|Blood drawn by direct venipuncture|Subjects will have blood sampled (12 mL/sample) a total of 8 times by direct venipuncture. Samples will be spiked with predetermined concentrations of anticoagulants, or saline sham.
1457155|NCT03296982|Drug|edoxaban|
1457156|NCT03296982|Drug|Enoxaparin|
1457157|NCT03296969|Procedure|cesarean section|All women underwent Pfnannenstiel incision under general or spinal anaesthesia, with a combination of sharp and blunt dissection to open the abdomen. The rectus muscles are dissected off the fascia, and the muscles are separated in the midline by pulling. Then the uterus is opened followed by fetal and placental extraction. The transverse lower uterine segment incision is closed in two layers of continuous Vicryl number 1 suture. The parietal peritoneum is closed using a continuous absorbable suture. In group (A): rectus muscle re-approximation is done by 3 interrupted sutures, but muscle is not closed in the other group. The rectus sheath is sutured using continuous absorbable sutures. Finally, skin is sutured with subcuticular sutures with Vicryl Rapide
1457158|NCT03296969|Procedure|Rectus muscle approximation|aprroximation of the lower parts of rectus abdomius muscles during cesarean section
1457159|NCT03296956|Dietary Supplement|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in day-5 postpartum women.
1457160|NCT03296956|Other|Placebo|Matching placebo for appearance, taste
1457161|NCT03296943|Combination Product|Essential oil|To inhale the essential oil in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
1457162|NCT03296943|Combination Product|Perfume|To inhale the perfume in an air-conditioned room, the container was flipped over to soak the roll-on cap that was then rolled-on circularly at the right mid-palm of the subject at 2 centimeter in diameter for 5 cycles.
1457163|NCT03296943|Behavioral|Cue-induced inhalants craving|Exposing individuals with a set of 12 pictures for one-minute (e.g., 5 second display per picture) every five minutes for three sets in total followed by another three sets of neutral/relaxing pictures of nature.
1457164|NCT03296930|Drug|Sofosbuvir 400 MG Oral Tablet,|Interferon free direct acting antiviral drugs used for treatment of HCV.
1457165|NCT03296930|Drug|Ombitasvir/paritaprevir/ritonavir|Interferon free direct acting antiviral drugs used for treatment of HCV.
1457166|NCT03296917|Drug|PrEP-001|A spray dried powder for intranasal administration formulated from an aqueous mixture of pre-gelatinized waxy maize starch and the drug substance delivered using a single dose nasal powder device.
1457167|NCT03296917|Drug|G-004|A spray dried pre-gelatinized waxy maize starch powder (G-001) in the single dose nasal powder device
1457168|NCT03296904|Device|CLs++|Familiarization/training with the customized combination of the CLs++ ortho-prosthesis modules
1457169|NCT03296891|Other|PoCUS Guided Resuscitation of Shock|Point-of-care ultrasound (PoCUS) will be used to guide resuscitation of the participant with undifferentiated shock. A PoCUS study will consist of limited echocardiography (LE) and thoracic ultrasound (TUS).
1457172|NCT03296865|Device|Kinesio taping|"We applied a hypoallergenic, porous and adhesive tape of cotton (Kinesio Tex Gold) placed over Rectus Femoris muscle of the affected limb. Children were taped in accordance to Kenzo Kase's Kinesio manual. We used a facilitation technique, from muscle origin to insertion, in a Y shape. For KT condition: base of the KT strip 3cm below the anterior iliac spine, over the RF muscle until the upper edge of the patella and stretchered with 100% tension. For placebo condition: same technique without tension in the entire tape.
We verified the immediate effect of KT/placebo. After the evaluation, KT/placebo was removed."
1457173|NCT03296852|Diagnostic Test|SONAS Ultrasound Device|To assess a baseline value, ultrasound will be transmitted following an automated protocol to increase subsequently the output voltage from 5 volts to 50 volts. At each voltage step the received signals will be acquired and stored. Once the maximum output voltage of 50 Volts has been reached an additional 10 ultrasound pulses will be transmitted and the received data acquired. The total duration of this first data acquisition is 20 seconds. Following the IV bolus injection of Lumason™, ultrasound will be transmitted and received signals acquired following the same protocol as before.
1457174|NCT03296852|Drug|Lumason|An IV line will be placed in a cubital or forearm vein. A bolus of 1.0ml of the ultrasound contrast agent (so called 'Microbubbles') Lumason™, internationally known as SonoVue (Bracco Pharmaceuticals, Italy), will be injected into the IV line, followed by a 5.0ml IV bolus injection of saline. Lumason™ has been FDA approved for cardiac applications to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. In the context of the present study Lumason™ would be used off-label.
1457175|NCT03296839|Radiation|SBRT|All liver metastases will be irradiated. 4 dose prescriptions are allowed (according to the center, and the technique used and the dosimetric constraints): 3 x 15 Gy, 4 x 15 Gy, 5 x 10 Gy or 5 x 8 Gy
1457176|NCT03296839|Drug|Chemotherapy|The chemotherapy is left to the choice of the investigator
1457177|NCT03296813|Drug|Torsemide|Loop diuretic
1457178|NCT03296813|Drug|Furosemide|Loop diuretic
1457685|NCT03292796|Drug|Prostaglandins|
1457184|NCT03296774|Behavioral|Healthy Beyond Pregnancy|Web-based intervention grounded in behavioral economics and designed to improve adherence with postpartum care.
1457185|NCT03296774|Behavioral|Usual Care|
1947755|NCT03133572|Device|Face-mask|In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face mask and a conventional bag.
1457190|NCT03296722|Behavioral|The Transtheoretical Model|Intervention with the Transtheoretical Model, through group and individual sessions with topics of healthy eating habits taught by a dietician, physical activity and exercise manual taught by a physical therapist, preparation of healthy food with menu taught by graduates in gastronomy, confrontation of barriers given by a psychologist. This group had a monthly monitoring during 3 months. The food plan that was prescribed to the intervention group was with the characteristics of the DASH diet, according to the most recent international guides of the ACC and AHA, for the reduction of cardiovascular risk.
1457191|NCT03296709|Device|CPP z|Installation of a preformed pediatric zircone crown
1457192|NCT03296709|Device|CPP m|Installation of a preformed pediatric metal crown
1457194|NCT03296683|Device|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
1457195|NCT03296670|Drug|Alprostadil|alprostadil,2ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
1457196|NCT03296670|Drug|Nitroglycerin|Nitroglycerin,200ug, delivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients with CSFP
1457197|NCT03296657|Drug|stannous fluoride|subjects will brush with paste twice daily for 2 weeks
1457198|NCT03296644|Device|Class II correction using Forsus|
1457199|NCT03296644|Device|Class II correction using PowerScope|
1457200|NCT03296631|Other|collection of diapers with fresh stools|collection of diapers with fresh stools
1457201|NCT03296618|Drug|NSI-566|Dosing will consist of a one-time stereotactic, intracranial injection of a hNSC line, NSI-566, ranging from 1.2×107 cells to 8×107 cells, as tolerated.
1457203|NCT03296579|Device|BiPAP|The patient's breathing is assisted by cycling between high and low pressures at a pre-set rate.
1457204|NCT03296579|Device|CPAP|The patient breathes against a constant pressure delivered by face mask.
1457205|NCT03296579|Drug|Ipratropium|Nebulized q6h
1457206|NCT03296579|Drug|Magnesium Sulfate|50mg/kg IV, 4 doses q6h
1457207|NCT03296579|Drug|Aminophylline|6mg/kg IV (if no progress)
1457208|NCT03296579|Drug|Standard steroid dose, hourly salbutamol, oxygen as needed|Standard common therapies for all three arms.
1457209|NCT03296566|Behavioral|Patient Liaison|An experienced colposcopy nurse will contact participants once the colposcopists complete the final colposcopy report. The colposcopy report will inform the referring provider that these patients will be informed of the results. The colposcopy nurse will provide an explanation of the colposcopy results and subsequent follow-up or treatment recommendations, be available to answer patient questions (within her scope), offer educational or support resources to patients. She will forward any patient questions beyond her scope to the patient's colposcopist who may then provide answers to the patient liaison or to the patient directly depending on the complexity and nature of the question.
1457210|NCT03296553|Drug|Valganciclovir|The experimental group will receive Valganciclovir 900 mg twice in a day before the initiation of cART until viral load of HHV-8 is undetectable.
1457211|NCT03296553|Drug|Antiretroviral Combinations|Patients will receive standard antiretroviral treatment as recommended
1457212|NCT03296540|Drug|Prasugrel (Crushed tablets)|loading dose of 6 crushed tablets 10mg Prasugrel
1457213|NCT03296540|Drug|Prasugrel (Integral tablets)|loading dose of 6 integral tablets of 10mg Prasugrel
1457214|NCT03296527|Drug|Follitropin alfa|Fixed starting dose per day for first stimulation days. May be adjusted later based on individual response.
1457215|NCT03296527|Drug|FE 999049|Fixed starting dose per day for first stimulation days.
1457216|NCT03296514|Behavioral|MBSR|Eight week class on MBSR in addition to an orientation class and a half day retreat
1457217|NCT03296501|Biological|Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients|3 injections of ADRC: 1 intraspinal and 2 intrathecal
1457218|NCT03296488|Drug|Nalbuphine Sebacate|intramuscular single dose of NALDEBAIN 24±12 hours before surgery.
1457219|NCT03296488|Drug|Fentanyl Citrate|Intravenous patient-controlled analgesia with fentanyl through 48 hours after surgery.
1457220|NCT03296475|Procedure|Abdominal Wall Closure Force (N).|This measurement will be recorded for both the right and left anterior rectus sheath. We will measure this force at three anatomical points 1) at the level of the umbilicus and 2) at the halfway point between the pubic symphysis and the xiphisternum and 3) at the point of maximal hernia defect width.
1457223|NCT03296449|Procedure|CPAP|A recruitment maneuver will be applied to the ventilated lung. Immediately continuous positive airway pressure, at a pressure of 2-3cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP).
1457224|NCT03296449|Procedure|HFJV|A recruitment maneuver will be applied to the ventilated lung. Immediately, high-frequency jet ventilation, with a driving pressure of 0.5 atm and a respiratory rate of 100 cycles per minute will applied to the non-ventilated lung for 20 minutes using the Monsoone III Jet Ventilator (Acutronic, Hirzel, Switzerland). Monsoone III is a recognised ventilator design for HFJV.
1458047|NCT03289910|Drug|Topotecan Hydrochloride|Given IV
1457225|NCT03296436|Biological|NEOX® CORD 1K®|NEOX CORD 1K is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. NEOX CORD 1K is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. NEOX CORD 1K is aseptically processed in compliance with current Good Tissue Practices (cGTP). NEOX CORD 1K of various sizes is stored in a medium of Dulbecco's Modified Eagle Medium/Glycerol (1:1) containing Amphotericin B (an anti-fungal agent). NEOX CORD 1K will be applied to completely cover the wound area and is maintained stationary with sutures or even negative pressure wound therapy after adequate sharp debridement.
1457226|NCT03296423|Biological|Vaccination|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of BCG vaccine
1457227|NCT03296423|Biological|Placebo|Patients discharged from hospital will be vaccinated with one intradermal injection of 0.1ml of sodium chloride 0.9%
1457228|NCT03296410|Biological|EV71 and two measles attenuated live vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with two measles attenuated live vaccine at 8 months old.
1457229|NCT03296410|Biological|EV71 and attenuated Japanese encephalitis vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month). And meanwhile, they routine vaccined with attenuated Japanese encephalitis vaccine at 8 months old.
1457230|NCT03296410|Biological|two measles attenuated live vaccine|infants vaccined with one dose two measles attenuated live vaccine at 8 months old.
1457231|NCT03296410|Biological|live attenuated Japanese encephalitis vaccine|infants vaccined with one dose attenuated Japanese encephalitis vaccine at 8 months old.
1457232|NCT03296410|Biological|EV71 vaccine|infants vaccined with two dose (3.0 EU/dose) of inactivated enterovirus 71 vaccine (KMB-17) at 8 months old and 9 months old (namely interval one month).
1457233|NCT03296397|Biological|Vaccination with Gardasil|Vaccination with Gardasil in patients apparently cured of external genital warts
1457234|NCT03296397|Biological|Injection of Normal Saline|Injection of Normal Saline in patients apparently cured of external genital warts
1457235|NCT03296384|Other|Clinical and environmental evaluation|For schizophrenic's patients, specific assessment will be perform
1457236|NCT03296371|Procedure|Biospecimen Collection|Undergo saliva or buccal mucosa collection
1457237|NCT03296371|Other|Laboratory Biomarker Analysis|Correlative studies
1457238|NCT03296371|Other|Questionnaire Administration|Ancillary studies
1457239|NCT03296358|Drug|IV Dexamethasone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 1 and Experiment 2 groups would receive IV Dexamethasone in ED.
1457240|NCT03296358|Drug|Oral prednisolone|The patients would be random into 3 groups. The randomization process would already be prepared into 3 groups with a number coding by the statistician who doesn't get involve in the rest of experiment. The drugs would be in the 3 group of sealed envelopes which have 3 kinds of drug combination After the envelopes are sealed, it will be code in an order of number. Experiment 2 groups would receive IV Dexamethasone in ED and Oral prednisolone as home medication.
1457241|NCT03296345|Drug|Ketamine|The intervention is IV low-dose bolus ketamine as an adjuvant to standard therapy (IV opiates and NSAIDs).
1457242|NCT03296319|Device|Echocardiography|Echocardiography guided fluid administration
1457243|NCT03296306|Drug|Treatment duration of cisplatin based chemotherapy|"GP regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (60 mg/m2 D1), every 3 weeks
GP-S regimen: Gemcitabine (1000 mg/m2 D1, D8), Cisplatin (35 mg/m2 D1,D 2 or D8), every 3 weeks
MVAC regimen: Methotrexate (30 mg/m2 IV bolus, D1, 15, 22), Vinblastine (3 mg/m2 IV bolus, D2, 15, 22), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), every 4 weeks
HD-MVAC with GCSF regimen: Methotrexate (30 mg/m2 IV bolus, D1), Vinblastine (3 mg/m2 IV bolus, D2), Doxorubicin (30 mg/m2 IV bolus D2), Cisplatin (70 mg/m2 D2), G-CSF (240 ug/m2 SC, D4-10), every 2 weeks"
1457244|NCT03296293|Other|PEEP at 5cmH2O|Effect of PEEP at 5cmH2O on ICP
1457245|NCT03296293|Other|PEEP at 10cmH2O|Effect of PEEP at 10cmH2O on ICP
1457246|NCT03296293|Other|PEEP at 15cmH2O|Effect of PEEP at 15cmH2O on ICP
1457247|NCT03296267|Procedure|Gastroduodenoscopy|Gastroduodenoscopy with duodenal biospies: A tube is placed via the mouth into the second part of the duodenum. Biopsy forceps is used to take duodenal biopsies.
1457248|NCT03296254|Behavioral|Sitting Mindfulness Exercises.|5 weekly sessions of 2,5 hours/session of Sitting Mindfulness Meditation
1457249|NCT03296254|Behavioral|Body Mindfulness Exercises|5 weekly sessions of 2,5 hours/session of Body Scan and Mindful Movements
1457250|NCT03296241|Device|laser|
1457251|NCT03296241|Device|sham control|
1457252|NCT03296228|Radiation|Flexibility Radiographs (supine, supine side-bend, FB)|Supine, supine side-bend, fulcrum bend
1457253|NCT03296228|Radiation|Flexibility Radiographs (awake traction)|awake traction
1457254|NCT03296228|Radiation|Flexibility Radiographs (STUGA)|supine traction under GA
1457255|NCT03296215|Other|Observational|To determine different patterns of admission and their Outcome
1457256|NCT03296189|Drug|Levobupivacaine|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls
1457257|NCT03296189|Drug|Dexamethasone Sodium Phosphate|intraluminal injection post procedure for pain relief: alkalinised high concentration 10 mls levobupivicaine and 2mls dexamethasone
1457258|NCT03296189|Drug|Placebos|10 mls normal saline
1457264|NCT03296150|Behavioral|PRESTAGE|PRESTAGE educational program targets the acquisition by the patients and their caregivers of competencies in (1) a better understanding of their disease and (2) their treatment, (3) a better drug management, including both anticancer and supportive treatments, (4) maintenance of a good nutritional status, (5) general health and psychological well being and (6) physical well being. After an individual educational diagnosis, each patient will be proposed an individualized educational program consisting in 1 to 6 of these workshops. An individualized final interview - entitled educational synthesis - will assess patient's skills and satisfaction.
1457265|NCT03296137|Biological|Autologous tumor-infiltrating lymphocytes|Tumor-infiltrating lymphocytes grown ex-vivo from resected from cancer tissue and reapplied to the patient via an intravenous infusion.
1457266|NCT03296137|Drug|Ipilimumab|One treatment with ipilimumab (3 mg/kg) prior to tumor resection.
1457267|NCT03296137|Drug|Nivolumab|4 doses of nivolumab. Starting 2 days prior to TIL infusion and every 2 weeks hereafter.
1457268|NCT03296137|Drug|proleukin|2 MIE s.c. injection, after TIL infusion and continuing for 2 weeks
1457269|NCT03296137|Drug|Cyclophosphamide|2 doses (60 mg/kg) prior to TIL infusion
1457270|NCT03296137|Drug|Fludara|5 doses (25 mg/m2) prior to TIL infusion
1457271|NCT03296111|Other|Questionnaires on pain and quality of life|"Patients will be asked to complete several questionnaires about their pain and the impact on their quality of life.
They will complete the questionnaires in the ophthalmology consultation room or at home and return it by mail (or present it at the next consultation).
Patients will be asked to complete several questionnaires :
Questionnaire about the characteristics of ocular neuropathic pain (7 items)
DEQ-5 (Dry Eye Questionnaire)
ODI (Ocular Surface Disease Index)
BPI (Brief Pain Inventory)
HADS (Hospital Anxiety and Depression Scale)"
1457272|NCT03296098|Drug|Ulipristal acetate|Ulipristal aceteate 5 mg oral tablets to take two tablets daily.
1457273|NCT03296085|Procedure|Exam for quantity of edema|There is no intervention
1457277|NCT03296059|Other|conventional treatment with RBC transfusion|Besides conventional treatment, neonates is given RBC transfusion.
1457278|NCT03296059|Other|conventional treatment|neonates is treated with conventional treatment.
1457279|NCT03296046|Biological|Blood test|30 ml
1457282|NCT03296020|Other|HONEY|100% Natural pure Honey, produced by EIN HAROD CO-OPERATIVE, ISRAEL
1457283|NCT03296007|Behavioral|Mindfulness Meditation|A meditative practice involving paying attention to present moment experiences and focusing on breathing sensations.
1457284|NCT03295994|Procedure|Operative|Arthroscopic rotator cuff surgery followed by physical therapy.
1457285|NCT03295994|Procedure|Non-Operative|Physical therapy (without surgery).
1457286|NCT03295981|Drug|Zoledronic Acid|4 mg of zoledronic acid (Zometa) will be added to each bag of bone cement
1457287|NCT03295968|Other|High Intensity Exercise/Ibuprofen|HIEX, with and without the inflammation inhibitor, ibuprofen, on plasma levels of IL-6 and other selective biomarkers of inflammation and appetite on food intake and subjective ratings of appetite in normal-weight boys.
1457288|NCT03295955|Drug|Amoxicillin Clavulanate|"Per-oral Amoxicillin Clavulanate Given or Non-given, after surgery"
1457290|NCT03295916|Radiation|Stereotactic Body Radiotherapy|Five fraction SBRT (or two fraction in case of spine) to any sites of breast cancer oligometastasis using robotic radio surgery or linear accelerator based SBRT
1457291|NCT03295903|Dietary Supplement|Cannabidiol supplement|Subjects will be administered in a double-blinded, randomized and cross-over design
1457292|NCT03295890|Procedure|Dry Needing|Dry Needling
1457294|NCT03295864|Diagnostic Test|Multifrequency tympanometry at Inclusion|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed for both group at inclusion
1457295|NCT03295864|Diagnostic Test|Multifrequency tympanometry 6 month after surgery|Multifrequency tympanometry measurement and particularly width of conductance tympanograms at 2 kHz will be performed 6 months after surgery for Chiari type I malformation patient
1457296|NCT03295851|Drug|Ferric carboxymaltose|Patients in the intervention group will receive preoperative IV ferric carboxymaltose, given as a single dose (15 mg/kg body weight, to a maximum dose of 1000 mg) over 30 minutes.
1457297|NCT03295851|Drug|Ferrous Fumarate|Patients will be given oral iron as per current clinical protocol, which is Ferrous fumarate 200mg twice daily.
1457298|NCT03295838|Behavioral|Mentalization-based treatment|See Arm description
1457300|NCT03295812|Other|standard therapy|standard therapy,non-interventional study
1457301|NCT03295799|Other|Patient Self-Management|Patient will manage their own warfarin therapy.
1457302|NCT03295786|Drug|Cerebral Dopamine Neurotrophic Factor|Repeated intracerebral infusions
1457303|NCT03295786|Device|Renishaw Drug Delivery System|Stereotactically implanted device
1457304|NCT03295773|Diagnostic Test|3DRA|
1457305|NCT03295760|Drug|Q10 Coenzyme|
1457306|NCT03295747|Drug|Peppermint oil|Three doses of peppermint oil will be investigated: 180, 360, 540 mg.
1947759|NCT03122444|Drug|Imipramine|Imipramine will be given daily for 21-30 days.
1947760|NCT03121365|Behavioral|Digital/E-books|Promotion of early reader digital e-book reading
1457321|NCT03295682|Device|Endovascular thoracoabdominal aneurysm repair|Endovascular treatment of patients with thoracoabdominal aneurysm using a multibranch stent graft tailored to the patient´s anatomy in combination with peripheral covered stents to bridge the visceral arteries
1457322|NCT03295656|Drug|Sulfur hexafluoride lipid-type A microspheres|Contrast-enhanced US imaging of the appendix
1457323|NCT03295630|Device|Accelerometer|Participants will perform a semi-structured movement protocol to investigate the ability of the Actigraph GT3X accelerometer to identify body position (lying, sitting or standing) and quantify step count
1457324|NCT03295617|Procedure|Thoracoscopy|Thoracoscopy surgery
1457325|NCT03295604|Procedure|SCTG+EMD|Miller class I-II gingival recession defects were operated with SCTG+EMD
1457326|NCT03295604|Procedure|SCTG|Miller class I-II gingival recession defects were operated with SCTG only and
1457327|NCT03295591|Diagnostic Test|Circulating tumor cell|Circulating tumor cell enumeration and sequencing
1457328|NCT03295578|Other|Personalized feedback|"The personalized feedback report will contain a general explanation about glucose, cognition and wellbeing, healthy cut-offs and/or benchmark values, and why these measures are relevant for personal health and wellbeing. Also, a general explanation will be given about how glucose levels can be influenced.
Also, the personalized feedback will contain the individual glucose response profiles, as well as graphs showing the wellbeing scores over time. The registered food intake will be mapped and linked to the glucose and wellbeing profiles. The results of the wellbeing questionnaire will also be shown and will be linked to the individual profiles and food intake."
1457329|NCT03295578|Other|Generic feedback|The generic feedback will contain a generic explanation about glucose, cognition wellbeing and food intake and their relationship. The generic feedback will not include personal results.
1457330|NCT03295578|Device|Continuous glucose monitoring device|This is not an intervention, but a measurement device used during the study. Added here as intervention to avoid errors in the system.
1457331|NCT03295565|Drug|Cabazitaxel|Cabazitaxel 25mg/m2 IV, once every 3 weeks
1457332|NCT03295565|Drug|Abiraterone|Abiraterone 1000mg oral, taken daily + Prednisone 5mg oral, 2 times a day
1457333|NCT03295565|Drug|Enzalutamide|Enzalutamide 160mg oral taken daily
1457334|NCT03295552|Drug|Decitabine|decitabine 7mg/m2, d1-d5, q3w
1457335|NCT03295552|Drug|Carboplatin|carboplatin AUC = 6, d6, q3w
1457337|NCT03295526|Procedure|Lymph nodes debulking surgery.|Radical hysterectomy and selective enlarged lymph node dissection
1457338|NCT03295513|Other|Veneered zirconia|he use of veneered zirconia is well documented in the literatures as successful restoration modality. A two Clinical performance of two different CAD/CAM-fabricated ceramic crowns revealed no chipping for veneered zirconia
1457339|NCT03295513|Other|Monolithic zirconia|Monolithic zirconia product presented a new generation of polycrystalline material by which full anatomical crowns and bridges can be produced
1947761|NCT03121365|Behavioral|Standard/Board books|Promotion of early reader board book reading
1947762|NCT03120065|Other|Electronic Dose Monitoring (MEMS)|The MEMS cap is an electronic bottle cap that records the time and date of a bottle being opened. The research personnel will extract the timing of the MEMS bottle opening events for adherence analysis.
1947763|NCT03118843|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
1947764|NCT03116737|Drug|Benzocaine Otic Solution|
1947765|NCT03116737|Drug|Placebo|
1457341|NCT03295487|Procedure|TVT-O|transobturator tape has been applied to all the patients in the study,and local estrogen vaginal cream is only applied to patients in group A
1457342|NCT03295474|Other|Rehabilitation using telehealth technology|"Consecutive patients with chronic respiratory disease referred for pulmonary rehabilitation are offered to participate in the protocol.
Patients are taught to use the system during the first session of aerobic training.
During 2 to 5 sessions of aerobic training (depending on the number of sessions needed to be autonomous), they are monitored in the pulmonary rehabilitation center with an oximeter device (Nonin 3150).
At the end of every session, patients are asked to answer to 3 questions on a Likert scale (see outcome session).
The therapist also ascertains wether the telemonitoring gateway successfully provided informations regarding the session.
The study takes off on the session during which the patients are autonomous in using the telehealthcare system.
If patients are not autonomous on the fifth session, the study also takes off."
1457343|NCT03295461|Procedure|SRP+ 10% Emblica officinalis irrigation|
1457344|NCT03295461|Procedure|SRP + 0.2% Chlorhexidine irrigation)|
1457345|NCT03295461|Procedure|SRP + 0.9% Saline irrigation|
1457346|NCT03295461|Procedure|SRP +10% E. officinalis gel application.|
1457347|NCT03295461|Procedure|SRP+ placebo gel application.|
1457351|NCT03295435|Other|Composition of functional tooth units|"Composition of functional tooth units measured by trained oral health therapists and was categorised into 3 groups:
Group A: Natural units only Group B: Natural & Prosthetic units present Group C: No natural units present"
1457352|NCT03295422|Procedure|RF ablation PVI alone|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins.
1457353|NCT03295422|Procedure|RF ablation PVI plus LPAW|A series of RF applications will be delivered around both sets of pulmonary veins with complete entry and exit block obtained around the antrums of all 4 pulmonary veins. In addition, a roof and posterior line will be placed in the left atrium to achieve entrance and exit block on the posterior wall. Entry block will be confirmed by placing a circular mapping catheter in multiple locations along the posterior wall and confirming lack of presence of any local potentials. Exit block will be confirmed on the posterior wall with pacing at 10 amps from the ablation catheter at multiple locations within the box as well as all lines.
1457354|NCT03295409|Behavioral|Self-affirmation|Participants are asked to complete a standard questionnaire and on the last page they are asked to form a self-affirming implementation intention by copying out a sentence.
1457356|NCT03295383|Drug|Rituximab 1g IV|Rituximab at a dose of 1000 mg will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab (or matching placebo) administration on Day 182 and Day 197
1457357|NCT03295383|Drug|Cyclophosphamide 50Mg Oral Tablet|"cyclophosphamide will be administered orally once daily at the following initial doses:
patients younger than 75 years: 1.5 mg/kg/day, orally.
patients older than 75 years: 1 mg/kg/day, orally."
1457358|NCT03295383|Drug|Placebo of Rituximab|Rituximab placebo will be administered by IV infusion on Day 1 and Day 15 whatever the patient's weight, with repeat maintenance rituximab administration on Day 182 and Day 197
1457359|NCT03295383|Drug|Placebo Oral Tablet|cyclophosphamide placebo will be administered orally once daily
1457360|NCT03295370|Procedure|Electrical Stimulation|A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
1457361|NCT03295344|Other|Diaphragm ultrasonography|"Spontaneously breathing patients in the ½ seated position Heart transducer at the medio axillary position, parallel to the axis of the body, last intervertebral spaces
US mode:
2D = Evaluation of the pulmonary parenchyma Time-Movement (TM) = Evaluation of diaphragm muscle shortening in the apposition zone + Evaluation of diaphragm mobility in the posterior 1/3 of the diaphragm dome Tissue Doppler Imaging (TDI) = Evaluation of diaphragm mobility in the diaphragm dome Collection of different daily clinical data"
1457362|NCT03295344|Other|Tissue Doppler|Determine the threshold value for diaphragm mobility
1457363|NCT03295318|Biological|Non-adjuvanted study formulation NmCV-5|Non-adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A&X conjugated to tetanus toxoid and C,Y&W conjugated to CRM protein. The diluent contains Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine.
1457364|NCT03295318|Biological|Adjuvanted study formulation NmCV-5|Adjuvanted formulation of polyvalent conjugate meningococcal vaccine against serogroups A,C,Y,W&X (NmCV-5) is available as lyophilised powder of polysacchride antigens A&X conjugated to tetanus toxoid and C,Y&W conjugated to CRM protein. The diluent contains Alum as adjuvant with Normal Saline. Each antigen content is 5 micrograms per 0.5 mL dose of vaccine
1457365|NCT03295318|Biological|Menactra|Menactra is available as ready to used solution containing polysacchride antigens A,C,Y&WX conjugated to diphtheria toxoid. Each antigen content is 4 micrograms per 0.5 mL dose of vaccine.
1457366|NCT03295305|Behavioral|Action-Based Cognitive Remediation|
1457367|NCT03295305|Behavioral|Unstructured support group|
1457368|NCT03295292|Biological|stem cells after standard surgical therapy|Mixture of limbus derived corneal epithelial cells and limbus derived corneal stromal cells in a ratio of 2:1, at a concentration of 50000 cells/uL diluted in fibrin sealant
1457369|NCT03295292|Other|Vehicle|50uL of commercially available fibrin sealant (Baxter, TISEEL)
1457370|NCT03295266|Drug|MK-3866|Single IV infusion of MK-3866 200 mg administered over 30 minutes at Hour 0 on Day 1 of treatment period.
1457371|NCT03295253|Procedure|Autologous adipose tissue harvesting/grafting using Lipogems|Adipose tissue harvesting and grafting in the urethra using fat micro-fragmentation and processing device Lipogems
1457372|NCT03295240|Drug|BR-I (bendamustine, rituximab, ibrutinib)|The BR-I (bendamustine, rituximab, ibrutinib) regimen will be administered for six 28-day cycles: bendamustine (90 mg/m2; day 1 and 2), rituximab (375 mg/m2; day 1), and ibrutinib (560 mg oral daily; day 1-28).
1457373|NCT03295240|Drug|VEN (Venetoclax)|The initial cycle 1 VEN (Venetoclax) dose ramp-up will be: 20 mg daily for 1 week, 50 mg daily for week 2, 100 mg daily for week 3, and 200 mg daily for week 4. Thereafter, VEN will be administered at a fixed dose level of 400 mg daily for varying durations of each 28-day cycle.
1457374|NCT03295227|Drug|Pembrolizumab|"Part 1: 200 mg by vein on Day 1 of every 21 day cycle.
Part 2: Maximum tolerated dose from Part 1."
1457375|NCT03295214|Drug|Acetaminophen|Acetaminophen given for pain relief
1457378|NCT03295188|Dietary Supplement|Plasmalogen|Treatment group takes two 0.5 mg plasmalogen capsules per day for 12 weeks.
1457379|NCT03295188|Dietary Supplement|Placebo|Placebo Group takes two placebo capsules per day for 12 weeks.
1457380|NCT03295175|Diagnostic Test|Staining tissue with hematoxylin-eosin and smooth muscle actin markers.|"The foreskin arrives oriented in a single piece in formol to the unit of pathology, and in the pathology unit, they must:
Measure the length, width and thickness of the specimen. The specimen should include skin and mucosa with the underlying areolar tissue.
Examine the surfaces of the sample searching lesions, and describe them in size, appearance (warty, papillary, ulcerated), depth of invasion, and distance from the nearest cutting edge, if they are present."
1457381|NCT03295162|Drug|Melatonin 10 mg|Melatonin will be given at a total dose of 20 mg dissolved in 4 ml of distilled water via enteral route in two doses of 10 mg each(2 ml ), with a 1-hour interval. to one group together with conventional treatment
1457382|NCT03295162|Combination Product|Conventional treatment of neonatal sepsis|Conventional treatment of neonatal sepsis including antibiotics,IV fluids, Total Parenteral Nutrition,etc...
1457383|NCT03295136|Behavioral|Health Promotion Training for Women Employees|Group intervention over a one year, acquiring health promotion tools and skills, as well as leadership and project designing and implementation skills.
1457384|NCT03295123|Other|phone interview with the mother|it's a telephone survey about children's health
1457385|NCT03295110|Other|Functionalities of the Lili Smart Solution activated|Non-medical connected device (Lili Smart solution) activated : application for caregivers (web / mobile), GSM watch worn by the patient, smart sensors placed at different locations of the patient's home and a support service 24 /24 and 7/7.
1457386|NCT03295110|Other|Functionalities of the Lili Smart Solution non activated|Non-medical connected device (Lili Smart solution) with inactive functionalities : watch worn by the participants and sensors placed at home with their functionalities inactivated. Absence of the web / mobile application.
1457387|NCT03295097|Other|Clinical Decision Support System|The system provides clinicians with patient-specific genetic information on opioid responsiveness and multi-drug interactions. This clinical decision support system should improve the clinician's ability to identify the optimal pain medication and dosage, and reduce risks associated with multi-drug treatment.
1457388|NCT03295084|Drug|Irinotecan|Dose Escalation
1457389|NCT03295084|Drug|Capecitabine|Dose Escalation
1457390|NCT03295071|Other|Patient-reported outcomes (PROs)|Patient-reported outcomes (PROs)
1457391|NCT03295058|Drug|Conditioning regimen|Fludarabine + cyclophosphamide (F-araA 120 mg/m2 total dose for 3 days (d-3,-2,-1) over 1 h infusion and cyclophosphamide 50 mg/kg/d (d-5 to d-2) for 4 days over 1-h infusion prior to hematopoietic cell transplantation
1457392|NCT03295058|Drug|GVHD Prophylaxis|Cyclosporine A +Steroid (CsA 3-5 mg/kg + methylprednisolone at 0.5-2 mg/kg/day for at least 30 days)
1457393|NCT03295058|Procedure|Allogenic Stem Cell Transplantation|using peripheral blood stem cells
1457394|NCT03295032|Behavioral|Acceptance and Commitment Therapy (ACT)|"ACT is a psychological intervention; in this study it is being delivered as a 4-week psycho-educational group to stroke survivors and carers.
Rather than attempting to control or ameliorate pain and suffering, ACT advocates that individuals remain open to internal private experiences (both positive and negative) and should focus on committing to a life which is congruent with their core values. Individuals learn to modify their relationship with these experiences, rather than change the experiences per se through processes such as mindfulness, acceptance and attention to values. This fundamental premise of ACT helps cultivate psychological flexibility."
1457395|NCT03295019|Device|Test Oral Spray|HA formulation of FDA listed ingredients
1457396|NCT03295019|Device|Placebo Oral Spray|Placebo formulation without the active ingredients
1457397|NCT03295006|Device|TheraSphere|Patients who had received TheraSphere
1457398|NCT03294993|Device|Ultrasound assess|The investigators designed a study to assess whether there were any blood flow indexes change before and after radial artery puncture with doppler ultrasonography
1457399|NCT03294967|Dietary Supplement|Caffeine|As in group descriptions
1457400|NCT03294967|Dietary Supplement|Vitamin E|As in group descriptions
1457401|NCT03294954|Genetic|GINAKIT Cells|"Four dose levels of GINAKIT cells will be studied. Dosing will be based on the actual number of transduced cells. All doses are per m2.
Dose Level 1 = 3 x 10^6
Dose Level 2 = 1 x 10^7
Dose Level 3 = 3 x 10^7
Dose Level 4 = 1 x 10^8"
1457402|NCT03294954|Drug|Cyclophosphamide|Cyclophosphamide (500 mg/m2/day) will be given for 2 days; given on day -4 and day -3 with GINAKIT cells given on day 0.
1457403|NCT03294954|Drug|Fludarabine|Fludarabine (30 mg/m2/day) will be given for 3 days; given on day -4, day -3 and day -2 with GINAKIT cells given on day 0.
1457404|NCT03294941|Combination Product|HepQuant SHUNT Liver Diagnostic Kit|Serial testing over 48 weeks
1457406|NCT03294915|Dietary Supplement|Resistant Starch|Addition of 42g per day of green banana flour (10g / day resistant starch) to the usual diet of study participants
1457407|NCT03294915|Dietary Supplement|Placebo|Addition of 42g per day of mixture of guar gum, maltodextrin and cellulose to the usual diet of study participants
1457408|NCT03294902|Device|Pedra Tissue Perfusion Monitor|This study is a prospective single-centre, device observational study designed to enroll up to 40 evaluable subjects at 1 investigational site in the United Kingdom. Eligible subjects, who meet the requirements for one of the 2 distinct subject groups: (1) Critical Limb Ischaemia group and (2) Peripheral artery disease with superficial femoral arterial (SFA) disease. Subjects who meet study eligibility criteria will be enrolled consecutively until the total number of subjects is enrolled per each group as outlined in the protocol. All subjects at the investigational site will be enrolled in the presence of a member of the Sponsor or selected designee in order to assist with the device operation and to verify that all protocol assessments are completed appropriately at baseline.
1457409|NCT03294889|Radiation|Stereotactic body radition (SBRT)|"Ultra-hypofractionated single-fraction SBRT with urethra-sparing with image-guidance and intra-fractional control motion with the Calypso® system.
19 Gy in a single fraction to the whole prostate gland ± proximal seminal vesicles
17 Gy in a single fraction to the urethra planning-risk volume (PRV)"
1457410|NCT03294863|Device|Embrace Scar Therapy Device|16x5-cm silicone elastomeric dressing that adheres to the skin using a pressure-sensitive silicone adhesive.
1457411|NCT03294863|Other|Standard of Care|Without the embrace Scar Therapy Device
1457412|NCT03294850|Diagnostic Test|FibroScan|FibroScan will determine the health of your liver by measuring the amount of fat and stiffness.
1457413|NCT03294850|Procedure|Bariatric surgery|Subjects enrolling in the study who are undergoing bariatric surgery as part of their medical care will be studied
1457414|NCT03294824|Other|blood sample|peripheral blood samples are collected
1457415|NCT03294811|Device|Telemonitoring|The telemonitoring interference in the telemonitoring arm consists of a smartphone application that helps the patient to take their medication in time and to take their blood pressure and weight on a daily basis in order to improve the medication uptitration and medication compliance.
1457418|NCT03294785|Procedure|Chuna manual therapy|Chuna is a Korean manual therapy that has absorbed and incorporated aspects of osteopathic manipulative medicine. Chuna manual therapy utilizes spinal manipulation techniques for joint mobilization including high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement, muscle energy, and fascial techniques.
1457419|NCT03294785|Drug|Conventional medication|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
1457420|NCT03294785|Procedure|Physical therapy|Physical therapy will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of cervical sprain/strain group, cervical disc disorder with radiculopathy group, or cervicalgia according to Korean Health Insurance Review and Assessment (HIRA) 2014 statistics.
1457421|NCT03294772|Other|hand sanitizer|DCCs received alcohol-based hand sanitizer and a program educational.
1457422|NCT03294772|Other|liquid soap|DCCs received liquid soap and a program educational.
1457423|NCT03294759|Other|Bio ACL|Bone marrow aspirate will be centrifuged using the Arthrex Angel system to optimally concentrate the cells for implantation. The graft for the experimental groups will be wrapped with a sterile amnion matrix wrap, supplied by Arthrex
1457424|NCT03294759|Other|Control|Normal ACL reconstruction technique with either patella or hamstring autograft
1457425|NCT03294746|Other|Clinical evaluations|At study entry , 6 weeks and 6 months, enrolled patients will undergo pulmonary physiology tests, assessment of respiratory symptoms, respiratory examination, pulse oximetry, blood draws, respiratory and quality of life assessment. Data from bronchoscopy assessments will be collected, if this has been performed as part of routine care.
1457426|NCT03294746|Other|Thoracic CT|At study entry, patients will undergo thoracic CT before treatment adaptation, unless a study-quality scan* has already been performed . Thoracic CT will be repeated at 6 weeks. All images will be centrally reviewed for radiology scoring.
1457427|NCT03294733|Procedure|Ultrasound|This ultrasound machine is owned by the department of orthopaedic surgery and is capable of up to 15 MHz image definition with its linear transducer
1457428|NCT03294720|Procedure|Bio-ACL|ACL reconstruction with either hamstring or patellar autograft, wrapped in amion collagen wrap, and stem cells from bone marrow aspirate.
1457429|NCT03294720|Device|amnion wrap and BMAC|amnion collagen wrap and bone-marrow aspirate in ACL reconstruction autograft
1457430|NCT03294707|Drug|AG10 oral tablet|Active single ascending dose
1457431|NCT03294707|Drug|Placebo Oral Tablet|Placebo single dose
1457436|NCT03294668|Behavioral|KONTAKT Australia|KONTAKT is a manualized Social skills group training program designed for children and adolescents on the Autism Spectrum aimed at improving communication, social interaction skills, the severity of ASD symptoms, and the ability to empathise and adapt in a group setting. The KONTAKT participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
1457437|NCT03294668|Other|Super Chef|The Super Chef is a cooking group designed for this study for adolescents on the Autism Spectrum, aimed at teaching basic cooking skills in a social environment. The Super Chef participants (4-8 participants) meet face to face weekly for 16 weeks for an hour and a half in a group facilitated by two trainers.
1457439|NCT03294642|Dietary Supplement|Potatoes|Pureed russet potatoes will be used as a carbohydrate supplement for participants during one of the three cycling challenges.
1457440|NCT03294642|Dietary Supplement|Carbohydrate Gel|Commercially available PowerBar PowerGel will be used for the carbohydrate gel condition during one of the three cycling challenges.
1457441|NCT03294642|Dietary Supplement|Water|Water will be used as a control during one of the three cycling challenges (participants will not receive any carbohydrate supplementation).
1457442|NCT03294629|Device|SensAwake™ modification|SensAwake™ is a new design based on the research of Doctor Ayappa 5 years ago. The SensAwake™ modification to the Fisher and Paykel automatically titrating positive airway pressure (APAP) device aims to sense whether the patient is awake via respiratory patterns that differentiate between sleep and wake. Upon sensing that the patient is awake the device is able to reduce positive airway pressure PAP aiming to improve patient comfort which should result in more consolidated sleep.
1457443|NCT03294616|Device|transcutaneous electroacupuncture|Weak electrical current will be generated by the device and delivered via skin surface electrodes to acupuncture points related to gastrointestinal functions
1457446|NCT03294590|Other|OHT Parent targeted text messages|For the Oral health text message (OHT) group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to oral health.
1457447|NCT03294590|Other|CWT Parent targeted text messages|For the CWT group, the parent targeted text messaging program will include two core topics and a menu of options to choose from, all of which pertain to child wellness.
1457448|NCT03294577|Drug|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
1457449|NCT03294577|Drug|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
1457450|NCT03294577|Other|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
1457451|NCT03294577|Other|Saline Placebo|Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration
1457452|NCT03294577|Drug|Docetaxel, doxorubicin, and cyclophosphamide (TAC)|Docetaxel is a type of chemotherapy medicine called an taxane. Doxorubicin is a type of chemotherapy medicine called an anthracycline. Cyclophosphamide is a type of chemotherapy medicine called an alkylating agent.
1457453|NCT03294564|Biological|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
1457454|NCT03294564|Biological|Placebo|The placebo injection will consist of 0.5mL of saline.
1457455|NCT03294551|Behavioral|HPV Vaccine Reminder Recall - Autodialer|Investigators will send out HPV vaccine reminder recall notices via autodialer message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
1457456|NCT03294551|Behavioral|HPV Vaccine Reminder Recall - Texting|Investigators will send out HPV vaccine reminder recall notices via text message to the parents of adolescents 11-14 years of age who are eligible to receive a dose of the HPV vaccine per the records in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of the various modalities or reminders as compared to the standard of care control (no reminders)
1457457|NCT03294538|Drug|Estrace® Cream|Brand Product
1457458|NCT03294538|Drug|Generic Estradiol Cream|Generic formulation of the brand product
1457459|NCT03294538|Drug|Vehicle Cream|Has no active ingredient
1457460|NCT03294525|Drug|Lithium Carbonate Oral Tablet|lithium carbonate 500mg~2000mg/day
1457461|NCT03294525|Drug|Escitalopram Pill|escitalopram 10~20mg/day
1457462|NCT03294512|Behavioral|MAWDS data entry on app|Utilize the smartphone app to enter their MAWDS (Medication, Activity, Weight, Diet, Symptoms) data
1457463|NCT03294499|Other|Questionnaire|Patients will be asked to complete one off questionnaire.
1457496|NCT03294304|Drug|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV on days 1, 8 every 21 days for 4 cycles.
1457497|NCT03294291|Procedure|Quadratus lumborum block|Postoperative pain procedure
1457498|NCT03294291|Procedure|Caudal block|Postoperative pain procedure
1457523|NCT03294083|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells
1457524|NCT03294083|Biological|REGN2810|REGN2810 is a monoclonal antibody to Programmed Death-1 (PD-1)
1457464|NCT03294486|Drug|Combination of TG6002 and 5-flucytosine (5-FC, Ancotil®)|"Phase 1, TG6002 administered in a total volume of 250mL of saline solution (0.9 %) as three intravenous infusions at the following doses:
Dose 1 : 5.0 log10 pfu •Dose 2 : 6.0 log10 pfu •Dose 3 : 7.0 log10 pfu •Dose 4 : 7.5 log10 pfu
Dose 5 : 8.0 log10 pfu •Dose 6 : 8.5 log10 pfu Additional dose levels •Dose 2-1 : 5.5 log10 pfu •Dose 3-2 : 6.5 log10 pfu Phase 2a, treatment IV at the recommended Phase 2 dose 5-Flucytosine (5-FC) is provided in its commercial packaging with brand name ANCOTIL 500 mg, tablet (Ancotil®) marketed by MEDA Pharma: polypropylene tube containing 100 tablets.
5-FC administered orally as 500 mg tablets taken 4 times per day (qid). Daily starting dose is 200 mg/kg. The daily dose will be adjusted at Day 19 following the measurement of 5-FC plasma concentration at steady state (Day 7), which should be kept below 100 mg/L."
1457465|NCT03294473|Behavioral|R/R - Autodialers|Investigators will send out flu vaccine reminder recall notices via autodialer message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
1457466|NCT03294473|Behavioral|R/R - Texting|Investigators will send out flu vaccine reminder recall notices via text message to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
1457467|NCT03294473|Behavioral|R/R - mailed postcard|Investigators will send out flu vaccine reminder recall notices via mailed postcards to the parents of children 6 months - 17 years of age who are due for the flu vaccine, per the records in the New York State Immunization Information System (NYSIIS).
1457471|NCT03294447|Behavioral|Fall Prevention by the Occupational Therapist|The interventions included education on adaptive equipment for household activities, adaptive equipment for activities of daily living, proper footwear in all environments, proper body mechanics, position changes, home environment set up, high fall risk activities, safety awareness, low vision and home exercises programs. In addition, discussion and education occurred to improve participation in valued occupations.
1457472|NCT03294434|Other|Diffusion tensor Imaging (DTI)|Diffusion tensor Imaging (DTI) is a technique sensitive to the ordered diffusion of water along white matter tracts and can detect subtle disruption. A diffusion tensor signature method was developed that splits the tensor information into isotropic and anisotropic diffusion components. This can differentiate regions of pure tumour from invaded white matter.
1457473|NCT03294421|Procedure|combined access tympanomastoidectomy|Trans canal surgery with the use of a surgical microscope with a rigid endoscope measuring 14cm of length with 0º and 30º angulation allowing better visualization and removal of the cholesteatoma before mastoid debridement. In this surgery, mastoid debridement is conducted only if there was no full endoscopic removal of the cholesteatoma. The other procedures of this type of surgery are similar to the standard tympanomastoidectomy technique.
1457474|NCT03294421|Procedure|standard closed tympanomastoidectomy|"Supine position and general anesthesia with orotracheal intubation
Antisepsis and placing of sterile fields
Local anesthesia of the external auditory canal with lidocaine 2% and adrenaline 1:100. 000 UI
Retroauricular incision
Removal of the temporal muscle fascia
Elevation of the surgical flap of the tympanic meatus
Visualization and exploration of the cholesteatoma
Exploration of the ossicular chain
Mastoid debridement
Conservation of the upper posterior wall of the auditory conduct
Removal of the cholesteatoma
Tympanoplasty with the temporal fascia
Retroauricular suture with vycril 3.0 and mononylon 4.0"
1457475|NCT03294408|Diagnostic Test|multimodal imaging|
1457476|NCT03294395|Drug|Ertapenem 1000 MG|single dose 1000mg intramuscular injection
1457477|NCT03294395|Drug|Fosfomycin Oral Suspension|single dose 6g oral suspension
1457478|NCT03294395|Drug|Gentamicin Sulfate, Injectable|single dose 5mg/kg (maximum 400mg) intramuscular injection
1457479|NCT03294395|Drug|Ceftriaxone|single dose 500mg intramuscular injection
1457482|NCT03294369|Other|Observational|This is an observational study. No specific diagnostic or therapeutic procedure will be performed due to the study.
1457489|NCT03294343|Procedure|salpingo-oophorectomy only by laparoscopy|Salpingo-oophorectomy are provided for carriers with mutation genes of BRCA1, BRCA2 (both belonging to mutation genes of hereditary breast and ovarian cancer syndrome, HBOCS) and ATM, BRIP1, RAD51, RAD51C, and RAD51D (all belonging to mutation genes of other hereditary ovarian cancer syndrome). Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
1457490|NCT03294343|Procedure|salpingo-oophorectomy with hysterectomy by laparoscopy|Salpingo-oophorectomy with hysterectomy are provided for carriers with mutation genes of MLH1, MSH2, MSH6, PMS2, EPCAM (all belonging to mutation genes of Lynch syndromes) and STK11. Detailed multi-disciplinary counseling, decision-making analysis before surgeries, and long-term follow-up and health management after surgeries are provided for all participants.
1457491|NCT03294343|Other|Follow-up|Detailed multi-disciplinary counseling, decision-making analysis and long-term follow-up are provided for carriers with any mutation genes but refusal to any risk-reducing gynecologic surgeries
1457492|NCT03294330|Drug|IC-Green KIT|fluorescence lymphangiography with the use of IC-Green
1457493|NCT03294317|Device|His bundle pacing|Medtronic SelectSecure SureScan MRI model 3830 lead
1457494|NCT03294304|Drug|Nivolumab|Nivolumab will be given at a fixed dose of 360 mg IV on Day 8 every 21 days for 4 cycles.
1457495|NCT03294304|Drug|Cisplatin|Cisplatin will be given at 70 mg/m2 IV on Day 1 every 21 days, and if using split-dose cisplatin (for creatinine clearance <50 ml/min), cisplatin will be given at 35 mg/m2 IV Day 1 and Day 8 every 21 days for 4 cycles.
1457500|NCT03294265|Behavioral|Peer support sessions|"Stages of mourning and motivation Patients introduce themselves, share their experience and mention a strategy on moving on to the next stage Reminder of metabolic control goals Leaders write on the board metabolic variables and ask everybody the goal values. Patients share their results and mention plans to improve them Self-care activities Leaders ask who owns a glucometer, how regularly they use it, its importance and consequences of not doing so.
Simplified meal plan Everyone brings a snack. Leaders ask if each snack is appropriate, how everyone carries out their meal plan, barriers and possible strategies Activities to increase physical activity Everyone compares who achieves 10 thousand steps/day and who doesn't, then mention benefits of exercise"
1457501|NCT03294265|Behavioral|Reminders|"Creation of a group on WhatsApp to send leaders and patients a weekly reminder on the different areas of self-care, such as foot care, self-monitoring, adherence to meal plan, medication and exercise.
This intervention will be applied to both groups."
1457502|NCT03294252|Drug|5-Fluorouracil|Presentation: Concentrated solution for concentrated infusion in vials containing 250 mg, 500 mg, 1 g and 5 g, in 5 ml, 10 ml, 20 ml and 100 ml respectively, providing a 50 mg / ml solution. Dosage: 400mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before CIPPA.
1457503|NCT03294252|Drug|L-Folinic acid|Presentation: lyophilisate for parenteral use, dosed at 25 mg, and in the form of a solution for injection by IM or IV dosed at 25 mg / 2.5 ml. Dosage: 20mg / m2. Administration: IV. Day of administration: between 1 h and 24 h before CIPPA.
1457504|NCT03294252|Drug|Oxaliplatin|Concentrated solution for infusion dosed with 50 mg and 100 mg. Dosage: depending on the dose range assigned to inclusion (from 90mg / m2 to 300mg / m2). Administration: the solution is packaged in a syringe which is subsequently used for injection and not in a conventional bag. The product is administered in a high-pressure injector, during the PIPAC. Day of administration : J1 of PIPAC
1947770|NCT03107793|Drug|Ustekinumab|Participants will receive IV induction treatment with ustekinumab on a weight-tiered basis at a dose of approximately 6 milligram per kilogram (mg/kg) IV. At Week 8, all participants will receive a 90 mg SC injection of ustekinumab. During the routine care maintenance treatment period, in case of clinical worsening reported by the participant, consistent with disease flare in the investigator's judgment, clinical assessments of disease flare will be performed at the investigator's discretion.
1457507|NCT03294226|Device|AuraGain|After anesthetic induction without neuromuscular blocking agent, AuraGain is inserted.
1457508|NCT03294226|Device|I-gel|After anesthetic induction without neuromuscular blocking agent, I-gel is inserted.
1457509|NCT03294213|Device|aScope 4 Broncho|"Investigator is asked: In your memory, compare your daily bronchoscope and the aScope 4 Broncho just evaluated on patients admitted to the OR or ICU undergoing at least one bronchoscopy procedure Patients will not be asked to consent to participate in this study, as no patient data are obtained and the CE-marked aScope™ 4 Broncho is used within its intended use"
1457510|NCT03294200|Device|TriCinch Coil System implantation|Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve, without the need for surgical intervention.
1457511|NCT03294187|Device|Wrist-worn wearables|See arm/group description.
1457513|NCT03294161|Drug|Immucillin DI4G|Immucillin DI4G was administered by topical use at 2% concentration once a day for 20 days associated with Meglumine antimoniate administered by intravenous route at a dosage of 20mg/kg/day, during 20 days.
1457514|NCT03294161|Drug|Meglumine antimoniate|Placebo for topical use once a day at the ulcer for 20 days associated with Meglumine antimoniate administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
1457515|NCT03294148|Other|Open-Label Placebo Treatment for Chronic Back Pain|Subcutaneous injection of 1ml medical grade saline into the lower back.
1457516|NCT03294148|Behavioral|Psychotherapy Treatment for Chronic Back Pain|Twice weekly 50 minute psychotherapy sessions for 4 weeks, plus an initial medical history session
1457518|NCT03294122|Radiation|External beam radiotherapy for prostate cancer|Patients will receive radiotherapy for prostate cancer and possible adjuvant hormone therapies as foreseen by international guidelines. No modification of standard regimens is considered. PCa patients are treated with 78 Gy, 2Gy/fraction, in exclusive setting and with 70 Gy, 2Gr/fraction in the post-prostatectomy setting. Lymph node irradiation is performed (50 Gy, 2Gy/fraction) when indicated by risk class.
1457519|NCT03294122|Radiation|External beam radiotherapy for head and neck cancer|Patients will receive radiotherapy for head and neck cancer and possible concomitant chemotherapies as foreseen by international guidelines. No modification of standard regimens is considered. In curative setting, HNCa patients are treated at a total dose of 70 Gy, 59.4 Gy and 56.1 Gy in 33 fractions to high risk Planning Target Volume (PTV), intermediate risk and low risk PTV, respectively. In high risk post-operative setting they are treated with 66 Gy (according to histopathological features), 60 Gy and 56.1 Gy to high, intermediate and low risk PTV, respectively; while, in intermediate risk post-operative case, intermediate and low risk PTV are irradiated with 60 Gy and 54 Gy, respectively. Chemotherapy will be platinum based (weekly or 3-weekly cisplatin).
1457520|NCT03294109|Drug|Abdominal wall block with liposomal bupivicaine|Abdominal wall block with liposomal bupivicaine
1457521|NCT03294096|Dietary Supplement|Routine care + Nutritional product|Routine post-op care + Nutritional supplement by specific product
1457522|NCT03294096|Other|Routine care|Routine post-op care
1947771|NCT03101241|Drug|CX-8998|T-type calcium channel blocker
1947772|NCT03102255|Procedure|Sniffing position|All procedure is done under sniffing position.
1947773|NCT03102255|Procedure|Nasal tip lifting|Before inserting the endotracheal tube to patient's nose, the researcher lift up the nose tip.
1947774|NCT03101839|Drug|AZD4785|KRAS Antisense Oligonucleotide
1457525|NCT03294070|Combination Product|Fimasartan plus amlodipine besylate|Fimasartan 60 mg plus amlodipine besylate 5 mg or Fimasartan plus 12.5 mg HCTZ plus one 5 mg amlodipine besylate
1457526|NCT03294057|Behavioral|Tele-coaching programs|Tele-coaching program conducted 12 times (one time for one week), and more than 20 minutes each by a trained nurse. Coaching content specifically, 1) evaluation, 2) facing and accepting the health crisis, 3) setting up new goals, 4) making decisions and plans, and 5) practice.
1457527|NCT03294057|Behavioral|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH)
1457528|NCT03294057|Behavioral|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
1457529|NCT03294044|Behavioral|ICT programs|ICT programs that include health information learning by disease and self-management based on Smart Management Strategy for Health (SMASH).
1457530|NCT03294044|Behavioral|A book about chronic disease|A Take-home book about chronic disease are provided for self-education
1457531|NCT03294031|Other|Pilates|"Warm-up exercises included Abdominal and costal breathing and Pelvic Clock. Some exercises included in the main part of the mat session were Arm arcs, Curls up, Femur arcs, Shoulder bridge, Leg circles, among others. The main part of the sitting/standing session included in standing position exercises like Standing on one leg with support, Neck rolls, Side leg lift with support and in sitting position Spine stretch 5, Elbows back with hands behind his head, Heel/knee slides, Shoulder drops, Knee folds, among others. In mat sessions, cooling exercises included in standing position Hamstring stretch and Abdominal Breathing and Rest position and in sitting/standing session Stretching and Abdominal Breathing."
1457532|NCT03294031|Other|Conventional Exercise|All sessions started with a 15-minute warm-up phase based on walking performance and joint mobility exercises. It was followed by a 35-minute second phase, which included low-impact aerobics (music tempo was set at 120 beats per minute), gross motor coordination tasks and balance activities. The final 5-minute phase focused on gentle stretching exercises.
1457534|NCT03294005|Diagnostic Test|Thyroid ultrasonography|Each subject had been transverse and longitudinal views of thyroid ultrasonography with high-resolution ultrasound (7-14 MHz) (HP Image Point-HS, Toshiba SSA250, GE ,Aloka SSD-1200 and Siemens S2000) that was performed by our partners - endocrinologist in all patients.
1457540|NCT03293979|Diagnostic Test|Test A i Flu A&B implemented in emergency service|Test A i Flu A&B implemented in emergency service
1457541|NCT03293966|Other|implementation of care coordination card|each patient receive care coordination card
1457542|NCT03293940|Procedure|Cryoablation|The cryoablation procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle(s) in place, the study doctor(s) will freeze the nerve over 5 minutes. A 3 minutes thaw will follow, then a second 5 minutes freeze and a final 3minute thaw. This portion of the procedure can last from 25 to 45 minutes. Once the nerve has been properly treated, the cryoablation needle(s) will be withdrawn.
1457543|NCT03293940|Procedure|Therapeutic Peripheral Nerve Block (tPNB) Injection|"During the nerve block procedure, a needle will be inserted and directed toward the target pain area. More than one needle may need to be used. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area and anesthetic will be injected into the targeted area.
The tPNB injection consists of 4 cc of 0.25% Bupivicaine and 1 cc of 6mg/ml betamethasone."
1457544|NCT03293927|Drug|Fentanyl|The patient will receive IV fentanyl
1457545|NCT03293927|Drug|Dexmedetomidine|The patient will receive IV dexemedetomidine
1457546|NCT03293914|Behavioral|Lifestyle Redesign|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive approximately 8 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the intervention protocol.
1457547|NCT03293901|Behavioral|Exercise|Treadmill exercise for 60 minutes with load carriage (weighted vest, 30% body weight) completed three times during the 6 day kinetic period.
1457548|NCT03293875|Behavioral|Encuentro|a behavioral intervention designed to increase HIV testing rates and reduce behaviors that place individuals who use drugs at risk of contracting HIV
1457549|NCT03293862|Device|prophylactic polypropilene mesh|Placement of onlay polypropilene prophylactic mesh after midline fascial closure.
1457550|NCT03293862|Procedure|Midline Fascial Closure|midline fascial closure using uninterrupted PDS 0 suture
1457551|NCT03293862|Device|vacuum drainage system|Placement of a subcutaneous vacuum drainage system
1457552|NCT03293849|Other|Patient Navigation|The patient navigator will discuss the results and supportive care recommended interventions of the multidisciplinary team with the patient. Those interventions which are accepted by patient are initiated when possible, and referrals are made as planned. The study patient navigator will review advance directive planning with those patients who are candidates to complete an advanced directive under Mexican law, and will facilitate the resources to complete the advance directive.
1457553|NCT03293836|Procedure|Radiofrequency ablation|Radiofrequency ablation of insufficient saphenous and perforating veins using Closure Fast and Closure Stylet catheters (medtronic)
1457554|NCT03293836|Procedure|Multilayer Compressive Bandage|Individual receive multilayer compressive bandage once a week
1457555|NCT03293823|Behavioral|VSOP training|a computerized cognitive training of attention and processing speed
1457556|NCT03293823|Behavioral|MLA control|a computerized cognitive intervention of multiple mental leisure activities
1457557|NCT03293810|Other|Observational study|Post-Authorization Safety Study
1457558|NCT03293797|Behavioral|Abbreviated-Mindfulness-based Therapy|A-MBT will be delivered in group format, 120 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
1457561|NCT03293771|Other|Focus group interviews|Focus group participants will be asked about their postoperative urogynecologic experience. Confidentiality will be enforced and participants will be made aware that they may opt out of answering any questions.
1457562|NCT03293771|Diagnostic Test|Questionnaire packet|Participants will be asked to complete a questionnaire packet comprised of three previously validated questionnaires and one newly created focused questionnaire. They will be asked to complete the new questionnaire again 2 weeks later. We estimate about 10 minutes will be required to complete the packet.
1457563|NCT03293745|Behavioral|Face to Face CBT-I (F2F)|CBT-I delivered in-person by the therapist.
1457564|NCT03293745|Behavioral|Telemedicine CBT-I (TM)|CBT-I delivered via American Academy of Sleep Medicine Telemedicine video conference System by the therapist.
1457565|NCT03293732|Biological|DCB07010|A protein based adjuvant originated from prokaryotic organism.
1457566|NCT03293732|Biological|HA antigens|HA antigens from three strains of influenza virus ( 7.5 μg of HA each strain).
1457573|NCT03293693|Other|0.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
1457574|NCT03293693|Other|3.5 g beta-glucan|Dietary cross-over study with beta-glucan fiber
1457575|NCT03293693|Other|8 g beta-glucan|Dietary cross-over study with beta-glucan fiber
1457576|NCT03293680|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg, every 3 weeks
1457577|NCT03293667|Other|Exploratory synovial fluid analysis|An additional blood sample (3 10 ml tubes) and an additional specific analysis to characterize subpopulations of regulating T lymphocytes infiltrating the synovium of RA patients and comparing them with those of peripheral blood.
1947778|NCT03096860|Other|Active alcohol consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
1947779|NCT03096860|Other|Placebo consumption|Comparison of alcohol consumption vs. placebo consumption and hookah smoking.
1947780|NCT03091192|Drug|Savolitinib|600 mg (400 mg if <50 kg) by mouth (PO) with a meal once daily (QD), continuously
1457581|NCT03293641|Dietary Supplement|Zinc Sulfate Tablets|Zinc Sulfate Tablets 3 times every 7 days for 6 months.
1457582|NCT03293641|Drug|Standard of Care|Folic Acid, Proguanil, Penicillin V, Hydroxyurea over 6 months
1457583|NCT03293628|Procedure|Vaginal Packing|This study will evaluate the role of vaginal packing after cervical conization as haemostasis technique
1457584|NCT03293615|Other|exploration|Difference of the following parameters in patients i) with DM, ii) with another inflammatory myopathy iii) without neuromuscular disease.
1457585|NCT03293602|Device|F-MISO PET imaging|F-MISO PET imaging will be added to the preoperative staging explorations of a patient with high risk prostate cancer candidate to radical prostatectomy. Patient will be selected during multidisciplinary meeting and urology consultation of Bordeaux and Toulouse university hospitals. Functional MRI imaging should be available before surgery. If patient consent to participate in the study, F-MISO PET imaging will be planed before prostatectomy. Results of this exam will not be considered for patient therapeutic management.
1457586|NCT03293589|Procedure|open revascularization|surgical revascularization (i.e. Bypass surgery)
1457587|NCT03293589|Procedure|endovascular revascularization|endovascular revascularization (stent, ballon angioplasty)
1457589|NCT03293563|Procedure|Radical nephrectomy versus partial nephrectomy (according surgeon judgement)|
1457590|NCT03293537|Diagnostic Test|Skin conductance and Heart rate measurement|while observing selected photos the Skin conductance and heart rate will be measured.
1457591|NCT03293524|Genetic|GS010|GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). GS010 will be administrated via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) as a single baseline intravitreal injection.
1457592|NCT03293524|Drug|Placebo|The placebo is a BSS, sterile, apyrogenic solution and used for ocular surgery. The placebo will be administered via intravitreal injection in a volume of 90 μL.
1457593|NCT03293511|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
1457594|NCT03293511|Drug|intranasal placebo|24 IU of of placebo nasal spray will be applied to each subject.
1947781|NCT03091192|Drug|Sunitinib|50 mg by mouth (PO) once daily (QD), with or w/o food, 4 weeks on/2weeks off
1947782|NCT03091920|Drug|IW-1973 Oral Tablet|40 mg QD doses of IW-1973
1457600|NCT03293472|Drug|Ropivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the cerebrospinal fluid (subarachnoid space) at the L3-L4 or L4-L5 level Drug: ropivacaine Other name: Ropimol 0.5% ropivacaine (isobaric) 4.5 ml for the patients < 160 cm tall, 5.0 ml for 161-170 cm tall, 5.5 ml for 171-180 cm tall, and 6.0 ml > 180 cm, supplementary ropivacaine bolus doses as required, followed by 0.2% ropivacaine, 1 ml/h for the postoperative period Device : The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
1457601|NCT03293472|Drug|Bupivacaine|"Procedure: Continuous Epidural Anesthesia Local anesthetic injection to the subarachnoid space at the L3-L4 or L4-L5 level Drug: bupivacaine Loading dose of bupivacaine followed by 0.12% bupivacaine, 1 ml/h Other name: bupivacaine
Device:
The Wiley Spinal Catheter-Over-Needle System for Continuous Spinal Anesthesia 4-6 23-gauge intrathecal cannula over a 27-gauge pencil-point spinal needle"
1457602|NCT03293459|Procedure|Balloon Retrograde Transvenous Obliteration (BRTO)|Catheterization of the gastrorenal shunt via the left renal vein will be accomplished using a catheter with a mounted occlusion balloon. Balloon occlusion venography is then performed to define the type of varix/varices and the anatomy of the venous drainage followed by infusion of sclerosant. The occluded balloon were inflated and remained in place for a maximum of 24 hours and deflated under fluoroscopy the next day. Followed by repeat CT abdomen to look for occlusion of shunts.
1457603|NCT03293459|Dietary Supplement|Standard Medical Treatment (SMT)|These will include diet rich in BCAA (branch chain amino acids, laxatives and rifaximin)
1457604|NCT03293446|Diagnostic Test|Urinary acidification test|Urinary acidification by administration of ammonium chloride (100 mg/kg body weight, given orally) during a single-day hospital admission.
1457605|NCT03293433|Other|Blood punction|1 blood punction during the normal pathway of care of the patient. This punction will be used to perform the extraction of micro RNA.
1457608|NCT03293394|Device|Anodal bilateral motor cortex and cathodal spinal tDCS|10 sessions of anodal bilateral motor cortex and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
1457609|NCT03293394|Device|Sham bilateral motor cortex and sham spinal tDCS|10 sessions of sham bilateral motor cortex and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
1457610|NCT03293381|Device|additional biopsies|additional biopsies
1457611|NCT03293368|Biological|Platelet rich plasma|Platelet rich plasma will be prepared from the patients own blood in the same visit using a double spin technique, then 0.5 ml of PRP will be injected per 1 cm2 of eroded oral mucosa.
1457612|NCT03293368|Drug|Triamcinolone Acetonide|0.5 ml of triamcinolone acetonide 40mg will be injected per 1 cm2 of eroded oral mucosa
1457613|NCT03293355|Behavioral|VPN|Two in-person sessions will take place one week apart for the VPN intervention targeting CHW. The intervention contents aim to utilize traditional communications tools and the latest technology to tackle challenges faced by service providers working in commune health centers and the impact of these challenges on their patients' treatment initiation, retention, and adherence. In addition, booster sessions will be offered once every month during the first three months and once every three months thereafter. The booster sessions will focus on participants' reports of their experiences, reinforcement of efforts, and continued skill building for problem solving.
1457614|NCT03293342|Behavioral|D CBT|"Intervention:
a 3-5 session treatment of dental fear.
Psychoeducation about anxiety
Exploration of the individual anxiety
Exposure to the frightening stimuli (no hiding, but actively showing in detail all components of dental treatment, preferably utilizing a mirror while doing treatment)."
1457615|NCT03293342|Combination Product|Control|"Intervention:
Traditional treatment of dental fear common sense/ benzodiazepine"
1457616|NCT03293329|Other|Diaphragm manual therapy techniques|3 diaphragm manual therapy techniques performed by a physical therapist are employed in this experimental group during 10 minutes. The participants are situated in a seated, supine and side bending position.
1457617|NCT03293329|Other|Diaphragm mobilization through active hipopressive gymnastic exercise|Diaphragm mobilization through active hipopressive gymnastic exercise in two different postures: standing and standing bending forward.
1457618|NCT03293329|Other|Ischemic compression techniques in shoulder myofascial trigger points|Ischemic compression techniques in infraespinatus and supraespinatus myofascial trigger points during one minute each muscle. The pressure increases gradually until the individual feels a tolerable pain.
1457619|NCT03293316|Device|Transcranial Random Noise Stimulation|The transcranial random noise stimulation was delivered using a StarStim device (Neuroelectrics®, Barcelona, Spain). The electrodes were encased in a pair of saline-soaked sponges (25 cm2 ), and were secured within a Neurolectrics EEG cap over right DLPFC (F4) and right IPL (P4), according to the 10-20 international EEG system. Other details are stated under the 'intervention arm' descriptions.
1457621|NCT03293290|Drug|PrEP|Subjects on PrEP will be followed for 1 year with quarterly assessments by trained research assistants. Study visits will take place at in New Haven and Hartford. At every scheduled visit, participants will receive a comprehensive package of preventive services, including a prescription for the next 30-day supply of TDF/FTC (with 2 refills), a symptom screen for acute HIV, risk-reduction counseling, PrEP adherence support, bleach for cleaning injection equipment, and condoms. HIV rapid testing with Orasure® will be performed quarterly; participants testing newly positive for HIV (representing seroconversions) will be followed with confirmatory testing and referred to care as needed.
1457622|NCT03293277|Drug|Intranasal Dexmedetomidine|Intranasal Dexmedetomidine
1457623|NCT03293277|Drug|Intravenous Dexmedetomidine|Intravenous Dexmedetomidine
1457624|NCT03293277|Drug|Intranasal Placebo|Intranasal Placebo
1457625|NCT03293277|Drug|Intravenous Placebo|Intravenous Placebo
1947783|NCT03091920|Drug|IW-1973 Oral Tablet|20 mg BID and 40 mg QD doses of IW-1973
1457626|NCT03293264|Behavioral|Exercise training group|"Exercise training will consist of 3 - 6 sessions per week and will cumulate in 150 min net exercise time per week. Heart rates during exercise sessions will be monitored with the aim of physical activities at moderate-intensity. Exercises will be individualized to reach the best possible improvements to the cardiovascular and musculoskeletal system. Possible disciples will include but are not limited to: cycling, rowing (ergometer), swimming, walking, nordic-walking, running, arm-cycle-ergometer or cross-trainer as well as fitness courses offered from occupational or private providers. Everyday activities which reach an effective heart rate range can account for exercise training on a home-based basis .
Advise on complementary individual strength and coordination exercises will be added to the training program. A nutrition analyses will be completed by every subject to account for special needs of the metabolic syndrome."
1457627|NCT03293251|Procedure|Trabeculectomy with MMC|glaucoma surgeries
1457628|NCT03293238|Procedure|Joint line ultrasound|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will be aided by real time visualization utilizing ultrasound guidance.
1457629|NCT03293238|Procedure|Joint line landmark|Patients will be sitting with knee bent at 90 degrees. Clinician will palpate extremity to determine if a medial or lateral approach will be made for the injection of Euflexxa into the joint space. The procedure will not be aided by ultrasound guidance, but completed based strictly on tactile feedback from the injecting physician.
1457630|NCT03293238|Procedure|Suprapatellar ultrasound guided|Patients will be lying supine on exam table. Ultrasound will be used to capture a longitudinal view of the proximal patella and the plane between the prefemoral fat pad and suprapatellar fat pad. After the desired visualization is achieved, injection of Euflexxa will be made within the suprapatellar pouch.
1457631|NCT03293238|Procedure|Suprapatellar Landmark|Patients will be lying supine on exam table. Injecting physician will insert needle lateral to the vastus lateralis toward the suprapatellar pouch, and will inject of Euflexxa once it is believed that the needle tip is in the pouch.
1457632|NCT03293199|Procedure|Chest tube drainage|In this group, in the supine position and subsequent to prepping and draping and local anesthesia administration via lidocaine 2%, F16 or F20 (based on patients physical status) sterile plastic tube will be implemented at the level 4th or 5th intercostal space through the midaxillary line. Subsequently, the external end of the tube will be connected to water sealing bottle and water bubbles coming out will be considered as proper chest tube insertion.
1457633|NCT03293199|Procedure|Repetitive needle aspiration|In this group, prior to needle aspiration, patients will take the semi-supine position. Subsequent to local anesthesia via lidocaine 2%, as well as prepping and draping, G16 intravenous angiocath will be inserted through midclavicular line at the level 2nd or 3rd intercostal space. Air bubble inside the lidocaine syringe will be considered as needled entrance to pleural cavity, thus 5-10 cm of the angiocath will be import to inside of the cavity. The catheter needle will be removed and catheter will be fixed using sterile sticks. A three-way valve will be connected to external end of the catheter and a 50 ml syringe will be connected to the valve. The air suction will be performed using 50 ml syringe till end of the air suction or up to 3.5 liters of air suctioning.
1457634|NCT03293186|Combination Product|MEDICLORE|use MEDICLORE at the end of surgery as antiadhesive product
1457635|NCT03293173|Combination Product|R-CHOEP|rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine, prednisone
1457636|NCT03293173|Combination Product|DA-EPOCH-R|dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab
1457638|NCT03293147|Other|HPLC-MS/MS-guided intervention|The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
1457639|NCT03293147|Other|Standard care|Standard care for hypertensive patients
1457640|NCT03293121|Behavioral|Strength and Coordination Training|Perform training exercises 3/week. Weeks 1-2: general strength (isolated muscle groups) Weeks 3-4: running-specific strength (multi-joint, upright) Weeks 5-6: power/coordination I (low amplitude/intensity) Weeks 7-8: power/coordination II (higher amplitude/intensity) Weeks 9-16: Run training. Each training session will start with a 10 minute strength & coordination warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
1457641|NCT03293121|Behavioral|Walking|Perform training exercises 3/week. Weeks 1-2: 30 minute walk Weeks 3-4: 35 minute walk Weeks 5-6: 40 minute walk Weeks 7-8: 45 minute walk Weeks 9-16: Run training. Each training session will start with a 10 minute walking warm up. Group will gradually progress from mixed run/walk for 20 minutes to a 40 minute run.
1457642|NCT03293108|Drug|Denosumab|Denosumab 60 mg is subcutaneously administered to osteoporotic patients at baseline, month 6 and month 12.
1457643|NCT03293108|Dietary Supplement|calcium|All women will receive daily supplements containing at least 1000 mg of elemental calcium (divided in two doses), during 18 month of the study.
1457644|NCT03293108|Dietary Supplement|vitamin D|All women will receive daily supplements containing at least 400 IU vitamin D daily during 18 month of the study.
1457645|NCT03293095|Procedure|Standard Care|The guidelines for the management according to the musculoskeletal disorder in primary care will be the treatment guidelines for the Standard Care.
1457646|NCT03293082|Device|CGM ON|The period of time when continuous glucose monitoring was used, in edition to SMBG
1457647|NCT03293082|Device|CGM OFF|The period of time when continuous glucose monitoring was not used, only SMBG
1457648|NCT03293069|Drug|Deferiprone|One 600 mg delayed-release tablets of deferiprone twice a day, for at 30 mg/kg/day
1457649|NCT03293069|Drug|Placebo Oral Tablet|the placebo twice daily morning and evening.
1457650|NCT03293056|Other|High-intensity interval Hydrogynmastics|The HIIH to PSE group during the high intensity (HI) period should remain between 16 to 18 points, while in the moderate intensity (MI) intervals around 11. The dynamic exercises will progression, in the first month will be 1 min of HI and 2 min of MI, in the second month of 1 min of HI and 1 min of MI and in the last month of 1 min of HI and 30 s of MI, until completing 30 min in total.
1457651|NCT03293056|Other|Hydrogynmastics Continuous Moderate|For the HCM group the PSE will be around 11 points during the 30 min of moderate continuous exercise. In both groups the form of intensity monitoring that will be through the PSE, in which this scale will be printed in banner form and affixed next to the physical education teacher during the classes.
1457653|NCT03293030|Drug|Dupilumab|Dupilumab treatment
1457654|NCT03293017|Drug|Diazepam 10 MG|If a patient's linical Institute Withdrawal Assessment (CIWA-ar) is more than 15 and did not decrease with 4 points compared to the previous score, they will be given oral diazepam to supress their symptoms, in a tablet of 10 mg.
1457655|NCT03293017|Drug|Baclofen 30mg|Baclofen 30 mg/day given over three gifts daily
1457656|NCT03293017|Drug|Baclofen 60mg|Baclofen 60 mg/day given over three gifts daily
1457661|NCT03292978|Dietary Supplement|probiotics intervention|The probiotics intention is provided with 4 strains of probiotics as a 2g sachet powder, dried with corn starch for 4 weeks.
1457662|NCT03292978|Dietary Supplement|non-probiotic control|The placebo is corn starch alone provided and the shape, color, flavor and taste are same with the powder of probiotics intervention.
1457663|NCT03292965|Drug|Neostigmine|Referring to the randomisation allocation program, participants allocated to group neostigmine, administrate neostigmine as reversal
1457664|NCT03292965|Drug|Sugammadex|Referring to the randomisation allocation program, participants allocated to group sugammadex, administrate sugammadex as reversal
1457665|NCT03292952|Drug|KP415 oral capsule|Daily dose
1457666|NCT03292952|Drug|Placebo oral capsule|Daily dose
1947784|NCT03091920|Drug|Placebo Oral Tablet|Placebo Oral Tablet to Match Experimental Drug
1457668|NCT03292926|Drug|Bupivacaine|Bupivacaine will help treat pain and sensation after ACL repair
1457669|NCT03292926|Device|Ultrasound|Ultrasound will guide anesthesiologist in performing the different nerve blocks
1457670|NCT03292926|Drug|Dexamethasone|Dexamethasone will be used to prolong block duration
1457671|NCT03292913|Behavioral|Positive Health Check|"PHC is an online intervention that delivers tailored evidence-based prevention messages to HIV positive patients through a series of brief interactive videos designed to simulate a conversation with an HIV primary care provider. The intervention guides a patient through tailored discussions with a video doctor on topics including adherence, retention in care, sexual risk reduction, prevention of mother-to-child transmission of HIV, and intravenous drug use. Patients answer tailoring questions about themselves and based on their answers, are given tailored messages from their chosen video doctor. PHC is designed to facilitate patient-provider communication about these topics. In the intervention, patients can select what questions they have for their doctor on the topics covered and what health promoting strategies (tips) they want to practice before their next visit. These are populated on to a handout which is given to the patient to take to their visit."
1457672|NCT03292913|Behavioral|Standard of Care|Standard of care for patients with HIV (this includes standard of care practices around ART initiation, adherence and retention)
1457673|NCT03292874|Diagnostic Test|high resolution MRI (hrMRI)|high resolution MRI (hrMRI) and standard MRI (sMRI) will be obtained at baseline and again in approximately 1 year in patients on prostate cancer active surveillance.
1457674|NCT03292861|Drug|Thymoglobulin|Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 6 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4 hours.
1457675|NCT03292861|Drug|Mycophenolate Mofetil|3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects
1457676|NCT03292861|Drug|Tacrolimus|Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-90 and 5-10 ng/mL thereafter.
1457677|NCT03292861|Drug|Sirolimus|Maintenance doses of sirolimus at 12 months post-transplantation
1457678|NCT03292861|Drug|Corticosteroids|125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
1457679|NCT03292848|Drug|Brexpiprazole|Tablet
1947785|NCT03088709|Drug|Cyclophosphamide|IV medication given for prevention of graft versus host disease.
1457681|NCT03292822|Dietary Supplement|Licochalcone A|Licochalcone A is a chalconoid, a type of natural phenols. It can be isolated from root of Glycyrrhiza glabra (liquorice) or Glycyrrhiza inflata. It shows antimalarial, anticancer, antibacterial and antiviral (specifically against influenza neuraminidase) properties in vitro.
1457682|NCT03292822|Drug|Paclitaxel|chemotherapeutic drug
1947786|NCT03088709|Drug|Tacrolimus|IV medication given for prevention of graft versus host disease.
1947787|NCT03088709|Drug|Mycophenolate mofetil|IV medication given for prevention of graft versus host disease.
1457686|NCT03292783|Drug|NOV1501 (ABL001)|VEGF/DLL4 targeting bispecific antibody
1457687|NCT03292770|Device|Flushing Catheter|A catheter will be used to performed a flushing of the cervical canal with culture media.
1457688|NCT03292757|Drug|Indocyanine Green|Fluorescent dye - indocyanine green
1457689|NCT03292744|Drug|Alfacalcidol|alfacalcidol 0,5 mcg
1457690|NCT03292731|Drug|Hydroxyprogesterone 250 Mg|Pregnant subjects randomized to this study arm will receive a weekly Intramuscular injection of 250mg hydroxyprogesterone caproate injection weekly from 16 0/7 to 37 0/7 weeks or delivery which ever is first.from 16 0/7-37 0/7weeks or delivery which ever is first.
1457691|NCT03292731|Drug|hydroxyprogesterone 500mg|Pregnant subjects randomized to this study arm will receive a weekly Intramuscular injection of 500mg hydroxyprogesterone caproate injection weekly from 16 0/7 to 37 0/7 weeks or delivery which ever is first.from 16 0/7-37 0/7weeks or delivery which ever is first.
1457692|NCT03292718|Device|MyCyFAPP|use of the MycyFAPP with all its features during 6 months
1457693|NCT03292705|Behavioral|PEP|The PEP system is built on a picture-based touch-screen interface on tablet computers. PEP allows users to explore and participate in entertainment, educational, spiritual, and other recreational activities and content personalized according to their interests and preferences. It provides easy access to the Internet and communication applications, and has hundreds of modules spanning music, travel, trivia, games, and religious and inspirational domains. For instance, if music is among a person's lifelong interests, the system provides access to multiple music genres through jukebox, karaoke and therapeutic music applications that can be tailored to a particular activity and by individual interest (for instance, a preference for classic jazz). As another example, for someone who likes travel or visiting new places, the interface offers access to Google Earth, guided tours, slide shows and regional facts and history.
1457694|NCT03292705|Behavioral|CCI|VSOP training will use five training paradigms (Eye for detail, Peripheral challenge, Visual sweep, Double decision, Target tracker) that practice processing speed and attention. All exercises share visual components and focus on accuracy and fast reaction times. Participants respond either by identifying what object they see or where they see it on the screen. The training will automatically adjust the difficulty of each task based on the participant's performance, ensuring that the participants always operate near their optimal capacity. The training programs will automatically record the percentage of completion of each game and scores.
1457696|NCT03292679|Procedure|3D template|"A 3D-printed model of relevant portions of the patient's facial skeleton, based on patient's CT scan will be created. This model will be used to bend titanium reconstruction plates that are used to stabilize the facial fracture for subjects in the treatment group.
Bending of the plates will be performed in the operating room during the patient's surgery. Titanium reconstruction plates are used to stabilize the fracture whether or not the individual is in the study. However, for patients that are in the treatment arm of the study, the plates are bent with the aid of the 3D-printed model as template, rather than by free-hand."
1457697|NCT03292666|Drug|Oral Anticoagulant|Oral anticoagulants used to treat or prevent venous thromboembolism
1457698|NCT03292653|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet
Route of administration: Oral"
1457699|NCT03292653|Drug|Placebo|"Pharmaceutical form: Tablet
Route of administration: Oral"
1457700|NCT03292653|Drug|Heavy Water|"Pharmaceutical form: Solution
Route of administration: Oral"
1457701|NCT03292653|Drug|131-Iodine-Albumin|"Pharmaceutical form: Solution
Route of administration: Intravenous"
1457702|NCT03292640|Drug|DFD-03 (0.1% tazarotene) Lotion|Subjects will apply a quarter (U.S coin) size amount of the study product all over the moistened face and rub it into the skin until foamy. Care should be taken to avoid the areas around the eyes, mouth, and nostrils. After a short time, the subject will rinse off the product by thoroughly rinsing with warm water. This procedure will be followed twice daily, in the morning and at bedtime, approximately 12 hours apart.
1457703|NCT03292640|Drug|DFD-03 (0% tazarotene) Lotion (Placebo)|Subjects will apply a quarter (U.S coin) size amount of the study product all over the moistened face and rub it into the skin until foamy. Care should be taken to avoid the areas around the eyes, mouth, and nostrils. After a short time, the subject will rinse off the product by thoroughly rinsing with warm water. This procedure will be followed twice daily, in the morning and at bedtime, approximately 12 hours apart.
1457704|NCT03292627|Device|ICON-noninvasive cardiometer|ICON-noninvasive cardiometer is a non-invasive monitor for estimating patient's heart contratility and cardiac output by the change of thoracic electrical bioimpedance.
1457705|NCT03292614|Diagnostic Test|Measurements of the postoperative refraction|"The Measurements of the postoperative refraction will be performed with the following devices:
Autorefractor Keratometers:
Mod. ARK-760A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany), Mod. ARK-560A (NIDEK CO,LTD, Gamagõri, Japan /OCULUS, Wetzlar, Germany) KR-1W (TOPCON, Willich, Germany) KR-800s (TOPCON, Willich, Germany)
Manual Refractometer:
Eye refractometer PR 60 or PR 50 (Rodenstock, Munich),
Test device:
iTrace (TraceyTechnologies, Housten, Texas, USA),
Phoropter (Block-Optic, Model 11625B) Determination of subjective refraction for distance and near (reading distance)"
1947788|NCT03088709|Other|Haploidentical Stem Cell Transplantation|A stem cell transplant that involves matching a patient's tissue type, specifically their human leukocyte antigen (HLA) tissue type, with that of a related donor.
1457710|NCT03292575|Drug|Anticoagulants|
1457957|NCT03290586|Device|Flower Cube|single use, sterile disposable fixation construct
1457711|NCT03292562|Device|Discontinue NCPAP after weaning pressures|After randomization, CPAP pressure will be weaned by 1 every 24hours as long as the subjects continue to meet stability criteria after each wean, until CPAP of 4. If after decrease in CPAP pressure, the subject meets CPAP failure criteria (described below) pressure will be increased back to the previous level and after stabilization for 24 hours weaning process will be started again. Once the subject meets stability criteria on CPAP of 4, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1L flow, 30% FiO2).
1457712|NCT03292562|Device|Discontinue NCPAP without weaning pressures|After randomization, once the subject meets stability criteria, NCPAP will be stopped and subject will be placed on nasal cannula (NC) according to unit guidelines (max 1L flow, 30% FiO2).
1457713|NCT03292549|Procedure|Robotic partial surgery|Robotic partial surgery
1457714|NCT03292536|Drug|Merestinib|"*The merestinib does escalation timing will depend on the schedule of the other anticancer regimen*
Subjects will receive merestinib 20mg PO QDay (dose level 0) for 2, 3 or 4 weeks (depending on anticancer regimen) followed by 40mg PO Qday (dose level 1) for 2, 3 or 4 weeks followed by 80mg PO daily (dose level 2) for 8, 6 or 4 weeks."
1457715|NCT03292523|Other|questionnaire|Work Productivity and Activity Impairment (WPAI) Multidimensional Dyspnea Profile (MDP) Baseline Dyspnea Index (BDI), MOS-SF36, Hospital Anxiety Depression (HAD) Cognitive Failure Questionnaire (CFQ).
1457718|NCT03292497|Procedure|Treatment Algorithm|Patients will have their procedure dictated by a treatment algorithm. They will have their mitral valve replaced if the posterior leaflet tethering angle >=25 degrees, or repaired if the posterior leaflet tethering angle <25 degrees.
1457719|NCT03292497|Procedure|No Treatment Algorithm|Patients will have their valve repaired or replaced at the discretion of their surgeon.
1457721|NCT03292471|Device|Transcranial Magnetic Stimulation|rTMS is a non-invasive brain stimulation technique in which a focal, time-varying magnetic field is applied to a specific brain area to induce neuronal depolarization. rTMS can be used to selectively target a given brain region with a resolution as focal as 0.5 cm3 .Typically, administering a slow (1 Hz) sequence of magnetic pulses via rTMS temporarily reduces cortical excitability in the targeted brain region.
1457722|NCT03292458|Drug|Sodium Oxybate|Alcohol challenge test and oral administration of a single dose of sodium oxybate and the matching placebo.
1457723|NCT03292445|Procedure|Immune tolerance after kidney transplant|Induction of immune tolerance after kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and anti-thymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no kidney rejection.
1457724|NCT03292445|Drug|Donor blood stem cells and T cells|"Immune tolerance after kidney transplantation resulting from mixed blood cells chimerism will be induced by donor blood stem cells and T cells given to the kidney recipient. Donor cells will be collected by apheresis after mobilization of blood stem cells from bone marrow 6-8 weeks before kidney transplant. Collected cells will undergo CD34 selection to recover >10 million donor blood stem cells/kg of patient weight to be combined with up to 150 million donor T cells/kg for transfusion soon after kidney transplant. The IND for this study covers the infusion of donor blood stem cells."
1457727|NCT03292419|Procedure|Topography-guided LASIK|LASIK surgery
1457728|NCT03292406|Drug|CD11301|Topical Gel
1458044|NCT03289910|Other|Laboratory Biomarker Analysis|Correlative studies
1457733|NCT03292380|Other|No intervention was included|
1457735|NCT03292354|Other|Contrast media administration|All patients will receive contrast media with a concentration of 300 mg I/mL (Iopromide 300). The flowrate and volume will be calculated with help of the different formulas belonging to the three different arms.
1457736|NCT03292341|Other|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs
1457737|NCT03292341|Other|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
1457738|NCT03292341|Other|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
1457739|NCT03292341|Other|Interviews with stakeholders|Interviews with stakeholders Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
1457740|NCT03292328|Other|Yoga|Participants in the Yoga group will meet twice weekly for 8 weeks of classes taught by MSK yoga instructors. Each class will last for sixty minutes. In addition to these group classes, participants will utilize a home-based program on the days group classes are not held. The daily home practice will continue for four weeks after the group classes are finished.
1457741|NCT03292328|Other|Wait List Control|Participants in the WLC group will continue usual care for twelve weeks before participating in Yoga classes for eight weeks. At the end of the twelve week follow-up, these subjects will receive eight weeks of group Yoga classes and the home Yoga practice recording. At week 20, they will complete a final follow-up visit.
1457742|NCT03292315|Drug|Exenatide 2 MG Injection [Bydureon]|Once weekly injection of 2mg of Exenatide
1457743|NCT03292315|Other|No Intervention|No injection will be administered
1457744|NCT03292302|Drug|Placebo|Placebo comparator
1457745|NCT03292302|Drug|ELX-02|Synthetic aminoglycoside
1457746|NCT03292289|Procedure|Pre- and post-operative consultation|Before and between the two interventions
1457747|NCT03292289|Procedure|Stomatherapy consultation|Clinical exam. At one and six months after the 2nd intervention
1457748|NCT03292289|Procedure|Questionnaires|"QLQ-C30 and QLQ-CR29 at each time defined by the study (one month before and after the first intervention, one month before the 2nd intervention and at 1, 3, 6 and 12 months after the 2nd intervention)
Stoma-QoL before and after the 2nd intervention
LARS score at 1, 3, 6 and 12 months after the 2nd intervention"
1457749|NCT03292276|Device|Amadeo Training|"To understand the cortical modifications related to movement preparation and execution after robot-assisted training we will study the EEG modifications of cortical activity using time-frequency event-related EEG and task-related coherence (TRCoh).
Friedman ANOVA with post-hoc t-test (corrected for multiple comparisons) will be used to assess the significance of training-induced changes in the two groups."
1457750|NCT03292263|Drug|Melphalan|iv infusion 70-100 mg/m2 on day -3, -2
1457751|NCT03292263|Drug|Nivolumab|iv infusion 100 mg on day -3, +17
1457752|NCT03292263|Procedure|Autologous Stem Cell Transplantation|peripheral blood stem cell transfusion at day 0
1947789|NCT03083665|Drug|Placebo|"Pharmaceutical form: Film-coated tablets
Route of administration: Oral use"
1947790|NCT03083665|Drug|Brivaracetam|"Pharmaceutical form: Film-coated tablets
Concentration: 25 mg tablets and 50 mg tablets
Route of administration: Oral use"
1947791|NCT03081247|Drug|BGF 320/14.4/9.6 µg MDI|Budesonide, Glycopyrronium, and Formoterol Fumarate metered dose inhaler (BGF MDI)
1947792|NCT03081247|Drug|BFF 320/9.6 µg|Budesonide and Formoterol Fumarate metered dose inhaler (BFF MDI)
1947793|NCT03081494|Drug|PDR001|400 mg every 4 weeks
1457758|NCT03292237|Dietary Supplement|Supplemental parenteral nutrition|Supplemental parenteral nutrition (product to be confirmed)
1457759|NCT03292224|Diagnostic Test|- Microscopic examination and culture of collected specimens|"Unstained wet mount with 10%-20% KOH.
Wet mounts stained with:
Lactophenol cotton blue.
India ink
Gram stain Culturing on Sabouraud´s dextrose agar ."
1457760|NCT03292211|Behavioral|early mobilization|early out-of-bed activities including supine to sit training, sit on the edge of bed without supporting, standing with hand supporting, stepping while standing etc.within three days after stroke while being monitored by medical equipment.
1457761|NCT03292211|Behavioral|early standard intervention|Conventional early in-bed activities within three days after stroke
1457762|NCT03292198|Other|20-30 mmHg compression sleeve and gauntlet|"Compression garments are Juzo Soft, circular knit. Most will be off-the-shelf sizing, but custom when necessary.
Garment fittings will be performed by Certified Lymphedema Therapists."
1457763|NCT03292198|Other|Manual Lymphatic Drainage|"Manual Lymphatic Drainage (MLD) is a gentle skin-stretch massage that stimulates the lymphatic system and assists in creating collateral drainage pathways out of non-intact (damaged) lymphatic territories. MLD is a critical part of Complete Decongestive Therapy (CDT), which is accepted as the international standard of care in the treatment of lymphedema.
The MLD sessions will be performed by 2 Certified Lymphedema Therapists, Megan Klote and Sarah Stolker, both trained through the Norton School of Lymphatic Therapy. The therapists have completed reliability meetings regarding MLD sequencing and techniques."
1458045|NCT03289910|Other|Pharmacological Study|Correlative studies
1947794|NCT03081494|Drug|regorafenib|either 160 or 120 or 80 mg once daily first 21 days of each 28-day cycle (=4 weeks)
1947795|NCT03081208|Drug|Nolasiban 900mg|Nolasiban dispersible tablets for single oral administration
1947796|NCT03081208|Drug|Placebo|Placebo dispersible tablets for single oral administration
1457769|NCT03292159|Device|Active RAVANS concurrent with arm motor training|Patient receives non-painful, sensory-level stimulation to the skin of left outer ear, where nerve endings of the auricular branch of the vagus nerve reside, while participating in arm motor training
1457770|NCT03292159|Device|Inactive RAVANS concurrent with arm motor training|Patient does not receive stimulation delivered to the skin of left outer ear while participating in arm motor training
1457771|NCT03292146|Drug|Denosumab 60 MG [Prolia]|One time Denosumab 60mg injection for 6 months
1457772|NCT03292146|Drug|Placebo Injection|One time Placebo Injection for 6 months
1457773|NCT03292133|Drug|EGF816|EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
1457774|NCT03292133|Drug|Gefitinib|Gefitinib is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
1947797|NCT03077451|Other|Laboratory Biomarker Analysis|Correlative studies
1457776|NCT03292081|Device|OFDI|PCI under OFDI guidance
1457777|NCT03292081|Device|IVUS|PCI under IVUS guidance
1457778|NCT03292068|Combination Product|Acupuncture, acupressure|"Intervention group will receive usual care in combination with Pyonex-needles and Kulplåster. The control group will only receive usual care."
1457779|NCT03292068|Dietary Supplement|Timbal diet|Intervention group will receive usual care in combination Timbal diet including Protein-enriched ice cream, made with egg yolks and Cream. The control group will only receive usual care.
1457780|NCT03292068|Other|Extended telephone counseling|Intervention group will receive usual care in combination with Extended telephone counseling. The control group will only receive usual care.
1457781|NCT03292042|Behavioral|Physical health promotion program|"The program has 24 sessions. Each session has two parts:
first part: half an hour of theoretical content, about the Metabolic syndrome, the effect of unhealthy lifestyle, toxic habits such as smoking or drinking alcohol, dietary habits or physical activity.
Second part: 1 hour of physical activity (walk)"
1457783|NCT03292016|Drug|APL-130277|APL-130277 sublingual thin film
1457784|NCT03292016|Drug|APO-go|Subcutaneous APO-go
1457785|NCT03292016|Drug|Apokyn|Subcutaneous APOKYN
1457786|NCT03291990|Drug|Temozolomide|5 fraction hypofractionated stereotactic radiosurgery along with standard temozolomide
1947798|NCT03077451|Drug|Nelfinavir Mesylate|Given PO
1947799|NCT03076203|Drug|Niraparib|Given orally
1457789|NCT03291964|Diagnostic Test|Rapid Brain MRI|Children undergoing head CT for evaluation of acute head injury will also undergo rapid brain MRI with GRE sequence that is specific for blood. Their clinical care will not change at all based on the MRI.
1457790|NCT03291951|Behavioral|Resistance training|The intervention goal is for study participants to exercise with progressively higher weights for resistance training to achieve a 1-kg increase in lean body mass by the end of the intervention. During an in-person visit on the same day as a chemotherapy infusion session, exercise professionals will teach participants a series of exercises to be completed at home twice weekly throughout the intervention. Participants will also receive protein powder, which they will be instructed to consume with meals twice a day. During subsequent infusion sessions, the exercise professional will meet in-person with participants to evaluate their ability to increase weights, and adjust exercises appropriately. In between visits, the exercise professional will check-in with participants by phone.
1457791|NCT03291938|Drug|IACS-010759|"Dose Escalation Starting Dose of IACS-010759 depends on when participant joins this study.
In the first cycle, IACS-010759 administered on Days 1-7 during the Escalation Phase.
It is possible that a second schedule (5 days on/2 days off intermittent dose schedule) will also be tested. If following that schedule, IACS-010759 taken by mouth one (1) time for 5 days then skipping 2 days before taking IACS-010759 again. Study doctor will tell participant if following this schedule.
Participant admitted to the hospital on Day 7 of Cycle 1 for 24 hours and on Day 15 of Cycle 2 for 24 hours.
Dose Expansion Cohorts Starting Dose of IACS-010759: Maximum tolerated dose from Dose Escalation Cohort."
1457792|NCT03291925|Procedure|Selective invasive angiography based on CT/CCTA imaging.|
1457793|NCT03291925|Procedure|Procedure/Surgery: Invasive angiography|
1457794|NCT03291912|Procedure|Chuna Manual Therapy|"Unique manual therapy in traditional Korean medicine
Mandatory techniques for neck part and selective techniques for other part (if necessary)
Selective techniques depends on a patient's condition (judged by traditional Korean medicine doctor)"
1457795|NCT03291912|Procedure|Usual care|"Physical therapy based on traditional Korean medicine theory
Electrical stimulation: either Meridian muscle interferential current electricity or Meridian transcutaneous electricity
Heat stimulation: either Hot pack or Infrared lamp
Patient education
Physical and pathological explanation of cervicogenic dizziness
Cause and risk factors of cervicogenic dizziness
Functions of muscles related to cervicogenic dizziness
Home exercising to self-manage cervicogenic dizziness"
1457797|NCT03291886|Drug|Entinostat|Given PO
1457798|NCT03291886|Drug|Entinostat(Placebo)|Given PO
1457799|NCT03291886|Drug|Exemestane|Given PO
1457800|NCT03291873|Procedure|PRK|PRK using Alcon-Wavelight Excimer Laser EX 500
1457801|NCT03291860|Procedure|Ovum retrievum|assessment of oocytes collected by ovum retrievum to evaluate the discriminatory power of the antimullerian hormone in ICSI cycles
1457802|NCT03291847|Device|fetal monitoring|Maternal fetal monitoring
1457803|NCT03291847|Drug|Buprenorphine Naloxone|Treatment for opioid use disorder
1457804|NCT03291847|Drug|Methadone|Treatment for opioid use disorder
1457805|NCT03291821|Drug|human menopausal gonadotropin|human menopausal gonadotropin subcutaneously
1457806|NCT03291821|Drug|GnRH antagonist|GnRH antagonist subcutaneously
1457807|NCT03291821|Drug|GnRH analog|GnRH analog subcutaneously
1457883|NCT03291145|Drug|Spironolactone|Brisk Standing before and after seven days treatment with Spironolactone
1947800|NCT03076203|Radiation|Radium Ra 223 Dichloride|Given intravenously
1947801|NCT03068039|Other|Oats breakfast porridge|Isoenergetic and isovolumteric oats breakfast porridge
1457808|NCT03291821|Procedure|Trophectoderm biopsy|Trophectoderm biopsy is the process of removing few cells from an in vitro fertilization embryo.
1457809|NCT03291821|Diagnostic Test|MitoScore|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be used to assess the mitochondrial DNA content as a viability indicator in the euploid embryos.
1457810|NCT03291821|Procedure|Intracytoplasmic sperm injection|ICSI is an in vitro fertilization procedure in which a single sperm is injected directly into an oocyte.
1457811|NCT03291821|Procedure|Ovarian puncture|Egg retrieval is a simple procedure. It is performed in an operating room for safety reasons. It is performed vaginally and involves aspirating the follicular fluid through a thin needle. Embryologists then retrieve from this fluid the eggs that have matured during stimulation. It lasts for 5 to 15 minutes, and a mild sedative is administered to prevent any kind of pain during the procedure.
1457812|NCT03291821|Diagnostic Test|Preimplantation genetic test|The cells removed from an in vitro fertilization embryo during the trophectoderm biopsy will be tested for chromosomal normalcy before transferring the embryo to the uterus.
1457813|NCT03291821|Procedure|Embryo transfer|Embryo transfer refers to a step in the process of assisted reproduction in which embryos are placed into the uterus
1457814|NCT03291821|Diagnostic Test|Pregnancy test|A pregnancy test is used to determine whether a woman is pregnant.
1457815|NCT03291821|Procedure|Embryo freezing|Embryo freezing is a method for cryopreserving embryos.
1457816|NCT03291821|Procedure|Embryo thawing|Embryo thawing is the procedure to recover previously frozen embryos prior to an embryo transfer.
1457817|NCT03291808|Behavioral|Weight loss intervention|"This 6-month intervention will include restricted calorie intake and increased physical activity. Key behavioral strategies to facilitate changes in dietary habits and activity patterns will be introduced, promoted and reinforced throughout the program. Weekly group meetings in a synchronous chat (i.e., in real time) led by a facilitator will be the venue for the group process. Extensive web-based resources to support behavior changes will be offered. Group chat sessions will meet online weekly for 6 months."
1457818|NCT03291795|Other|Exercise Intervention|Study patients will undergo a program of prehabilitation exercise for 6 days per week prescribed for them by an exercise physiologist, for up to 4 weeks prior to surgery.
1457820|NCT03291743|Device|Capsule endoscopy|PillCam(TM) COLON 2 capsule endoscopy system
1457821|NCT03291730|Behavioral|Breathing and journaling exercise|May help reduce anxiety of receiving chemotherapy
1457822|NCT03291730|Other|Art-therapy|May help reduce anxiety of receiving chemotherapy
1457823|NCT03291717|Behavioral|Bridging Community Gaps Photovoice (BCGP)|Participants assigned to this group will be part of the 6-month long BCGP intervention, which involves a 12- week class that meets weekly, followed by three booster sessions - one per month in the three months following the class, and up to 24 sessions of individual support as needed throughout the 6 months provided on a weekly basis either in person or by phone. The BCGP classes follow a manualized curriculum with sessions that combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing community participation goals, all refined with input from individuals with a lived experience.
1457824|NCT03291704|Device|Thermal Therapy|Daily thermal therapy for three weeks
1457825|NCT03291678|Procedure|new laparoscopic orchiopexy|closure of the internal ring of the inguinal canal after descending of the testis to scrotum using needle percutaneous
1457826|NCT03291678|Procedure|classic laparoscopic orchiopexy|delivery of abdominal testis into scrotum without closure of the internal ring of the inguinal canal
1457827|NCT03291652|Diagnostic Test|DSA/3DRA|DSA/3DRA
1457830|NCT03291587|Other|Key Informant|Each site will have a coaching team: two members of our research team including an expert in tobacco cessation and an expert in lung cancer screening. Active coaching includes six, 1-1 ½ hour video exchanges among program sites and coaching teams, once every 4-6 weeks over an 8-month implementation phase. One week prior to the call, each site will be prompted with an email to inform the coaching team of any challenges associated with implementation.
1457831|NCT03291574|Procedure|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
1457832|NCT03291574|Procedure|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
1457833|NCT03291561|Procedure|Electroacupuncture|Acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
1457834|NCT03291561|Procedure|Sham electroacupuncture|Sham acupuncture at Baihui, Nei guan, bilateral Zu sanli and bilateral Tian shu.
1457835|NCT03291548|Dietary Supplement|Quinoa biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
1457836|NCT03291548|Dietary Supplement|Control biscuit|2x15g biscuits per day for 28 consecutive days (4 weeks).
1457837|NCT03291535|Other|Connected-device|This intervention will allow patients to upload blood pressure data automatically from a blood pressure cuff into the electronic health record.
1457838|NCT03291535|Other|Usual care|This intervention will consist of usual clinical care as determined by the clinical pharmacist.
1457839|NCT03291522|Procedure|Ultrasound-guided rete testis flushing and aspiration|Ultrasound-guided rete testis flushing and aspiration is performed on both testes before the TESE procedure
1457840|NCT03291509|Behavioral|Video Conference Meetings|Individual video conferencing with a health educator using an iPad.
1457841|NCT03291509|Behavioral|In-person Meetings|Individual face-to-face (FTF) meetings with a health educator.
1457955|NCT03290612|Other|Placebo|Inactive placebo to mimic 1.5g ascorbic acid.
1457956|NCT03290599|Other|Mini Mental and Modified Mini Mental Test|Mini Mental Test was used for literate patients and Modified mini mental test was used for illiterated patients
1458046|NCT03289910|Other|Placebo|Given PO
1457842|NCT03291509|Behavioral|Enhanced Stop Light Diet|Diet composed of healthy, pre-packaged meals, balance of fruits, vegetables, and low calories snacks, and shakes. Participants and study partners will be trained to use a color coded chart which categorize foods based on the Stop Light system (green, yellow, red) to assist in meal planning, grocery shopping, decisions regarding snack foods, and compliance with the diet in special situations such as eating away from home (restaurants, parties, etc.).
1457843|NCT03291509|Behavioral|Physical Activity|Participants will be asked to complete a set amount of time of moderate-to-vigorous physical activity each week. Participants in the Computer group will be asked to attend remote exercise sessions 2 times a week.
1457846|NCT03291483|Other|whole body vibration|whole body vibration is a mechanical stimulus characterized by oscillatory movements.Whole body vibration's potential beneficial effects occurs by transmission of mechanical and sinusoidal vibrations to the whole body through the feet.
1457847|NCT03291483|Other|plyometric training|Plyometric exercises refers to performance of stretch‐shortening cycle (SSC) movements that involve a high‐intensity eccentric contraction immediately after a rapid and powerful concentric contraction.
1457848|NCT03291470|Biological|TG-C|2 mL injection of allogeneic human chondrocytes expressing transforming growth factor-beta1
1457849|NCT03291470|Biological|Placebo Control|2 mL normal saline injection
1457850|NCT03291457|Drug|Tocilizumab|For intravenous (IV) tocilizumab, the recommended dosage is 8 milligrams per kilogram (mg/kg) once every 4 weeks. For subcutaneous (SC) tocilizumab, the recommended dosage is 162 milligrams (mg) once weekly. However, because of the observational nature of the study, dosing and treatment duration is at the discretion of the physician in accordance with local clinical practice and local labeling.
1457851|NCT03291457|Drug|Glucocorticoid Agent|Because of the observational nature of the study, the choice of glucocorticoid agent, as well as dosing and treatment duration, is at the discretion of the physician in accordance with local clinical practice and local labeling.
1457852|NCT03291444|Biological|Chimeric antigen receptor T cells|After pretreatment, chimeric antigen receptor T cells will be transfused.
1457853|NCT03291444|Biological|Eps8 peptide specific dendritic cell|After transfusion of chimeric antigen receptor T cells, Eps8 peptide specific dendritic cell were intradermal injected.
1457854|NCT03291431|Device|Intermittent theta burst transcranial magnetic stimulation|Participants will be randomized to active or sham iTBS conditions, and receive 20 iTBS sessions over the course of 2 weeks
1457855|NCT03291418|Drug|ATB-346 OR Placebo|Comparison of gastrointestinal effects
1457856|NCT03291418|Drug|Naproxen sodium|Comparison of gastrointestinal effects
1457857|NCT03291392|Genetic|Gene expression or biomarkers exploration|
1457858|NCT03291379|Drug|BTG-002814 (vandetanib-eluting radiopaque beads)|BTG-002814 containing 100 mg vandetanib
1457859|NCT03291366|Drug|UCMSCC|infusion of aUCMSC and conventional therapy
1457860|NCT03291366|Drug|conventional treatment|conventional treatment
1457861|NCT03291353|Drug|pembrolizumab|200 mg IV given every three weeks
1457862|NCT03291327|Dietary Supplement|Probiotics|Lozenges for Home use
1457863|NCT03291314|Drug|Axitinib|1. Axitinib, a VEGFR-specific small molecule tyrosine kinase inhibitor (Tki) has demonstrated anti-tumor activity when evaluated as a mono-therapy and in combination with lomustine for the treatment of patients with recGB (EudraCT 2011-000900-16) [7].
1457864|NCT03291314|Drug|Avelumab|2. Avelumab (MSB00107; anti-PD-L1) is a fully human anti-PD-L1 IgG1 monoclonal antibody (mAb) that has demonstrated anti-tumor activity in several tumor types.
1457865|NCT03291301|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia including psychoeducation, sleep restriction, stimulus control, cognitive restructuring, and relaxation.
1457866|NCT03291301|Other|Acupressure|Acupressure, a non-invasive therapy, is commonly used in Traditional Chinese Medicine
1457867|NCT03291288|Drug|S-warfarin|Commercially available S-warfarin along with vitamin K supplied by the sponsor.
1457868|NCT03291288|Drug|Midazolam|Commercially available midazolam supplied by the sponsor
1457869|NCT03291288|Drug|Pexidartinib|Pexidartinib is formulated as opaque, white, 200-mg capsules supplied by the sponsor.
1457870|NCT03291275|Other|Follow-up for death and recurrence|All patients are followed up to determine definite date of diagnosis, recurrence and death.
1457871|NCT03291262|Other|Follow up for death and recurrence|Patients are followed up to determine the specific date of diagnosis, recurrence and death.
1457872|NCT03291249|Drug|Foralumab|Anti CD3 mAb
1457873|NCT03291249|Other|placebo|Placebo oral solution
1457874|NCT03291249|Drug|Omeprazole 20mg|Omeprazole is a proton pump inhibitor used to neutralize stomach PH
1457875|NCT03291236|Other|Follow-up for death and recurrence of patients|All patients are follow-up to determine specific date of diagnosis, recurrence and death.
1457878|NCT03291197|Drug|Suprascapular and median nerve blocks|Ultrasound guided injection of the median and suprascapular nerve of the affected side.
1457879|NCT03291184|Device|peripheral neuromuscular monitor|Residual paralysis can only be measured by neuromuscular transmission monitoring of a peripheral nerve, typically the ulnar nerve innervating the adductor pollicis muscle.
1457880|NCT03291171|Behavioral|MyPlan 2.0|MyPlan 2.0 consists of five sessions. During these five sessions the following behaviour change techniques are used to motivate users to be more physically active or to sit less: exploring risk perceptions and perceived benefits, exploring social support, providing feedback, action planning, coping planning and monitoring.
1457881|NCT03291158|Drug|Minocycline|Subjects will be assigned into 5 cohorts of 5 subjects each, who will receive six doses of Minocin IV every 12 hours, starting on Day 1. Each dose of Minocin IV will be administered as an IV infusion over 1 hour. Subjects will be assigned to cohort based on time of bronchoalveolar lavage.
1457882|NCT03291145|Drug|Beta Blockers|With and without Beta Blockers
1457884|NCT03291132|Other|training camp|"The Smoke-free teens will join a 2-Day-1-Night training camp in July or August. The camp will cover a wide range of indoor, outdoor, adventure-based, experiential learning activities. Besides, the teens will be equipped with the knowledge on smoking hazards, tobacco control and smoking cessation. The teens will be taught how to deliver a brief smoking cessation intervention using the AWARD Model: By the end of the training camp, the teens should be confident and competent in delivering the brief smoking cessation intervention to smokers. The teens will then break down into groups to organize smoke-free programmes in their schools or in the community.
All Smoke-free Teens will be invited to respond to the structured questionnaire at baseline (T1), immediately after the training camp (T2), and 3 (T3) and 6 months later (T4). Each group of teens will have to submit the written proposal and final report regarding the smoke-free programme to COSH at 3 (T3) and 6 (T4) months."
1457885|NCT03291106|Diagnostic Test|immunohistochemical staining|immunohistochemical staining for MLH1, MSH2, MSH6 and PMS2
1457886|NCT03291106|Diagnostic Test|tests of microsatellite instability|microsatellite instability in tissues of endometrial cancer
1457887|NCT03291106|Diagnostic Test|clinical criteria of Lynch syndromes|Amsterdam I or II criteria and Bethesda criteria
1457888|NCT03291106|Diagnostic Test|sequencing for mismatch repair genes|next-generation sequencing, Sanger method or qPCR for mismatch repair genes (MLH1, MSH2, MSH6, PMS2, and EPCAM)
1457889|NCT03291093|Drug|18F-Flutemetamol PET/MRI|All patients will undergo a PET/MRI of the carotids after 18F-Flutemetamol injection.
1457890|NCT03291080|Drug|Liquid 13-Cis Retinoic Acid|Liquid 13-Cis Retinoic Acid
1457891|NCT03291080|Drug|Extracted capsules 13-CRA|Extracted capsules 13-CRA
1457896|NCT03291054|Drug|Pembrolizumab|Subjects will receive pembrolizumab 200 mg (flat dose) IV every 3 weeks on day 1 of a 21 day cycle.
1457897|NCT03291054|Drug|Epacadostat|Epacadostat will be dosed at 100 mg PO BID daily. Doses should be taken twice daily, in the morning and evening, approximately 12 hours apart, without regard to food.Doses will be self-administered, except on Cycle 2 Day 1, when the morning dose will be given at the study site clinic. Subjects will be required to keep a pill diary that will be provided to them.
1457898|NCT03291041|Drug|Tasimelteon|capsule
1457899|NCT03291041|Drug|Placebo|capsule
1457900|NCT03291028|Biological|Immune checkpoint inhibitor targeting PD1|RCC and UC patients treated with immune checkpoint blockade
1457901|NCT03291015|Device|radiographic|using plain x ray to determind the treatment plan
1457902|NCT03291015|Device|arthroscopy|using wrist arthroscopy to determind the treatment plan
1457905|NCT03290976|Other|Acupuncture|"Acupuncture treatments will be patient-tailored, with the acupuncture points (acu-points) to be selected by the acupuncturist at each treatment session, in accordance with the dynamic of the patient's symptoms, concerns and expectations. At the same time, acupuncturists will be required to choose at least 5 of the following 11 acupoints, which are to be incorporated into their treatment regimen:
Lower limb points: Liver (LIV) 3, Spleen (SP) 4, SP6, Stomach (ST) 36, Gallbladder (GB) 34, Kidney (KID) 3, LIV8, Web (Bafeng) points Upper limb points: Large Intestine (LI) 4, LI 11, LI10, Pericardium (PC) 6, Triple Warmer (TW) 3/4/5"
1457906|NCT03290976|Other|"Multi-modality (Acupuncture plus)"|"A number of additional CIM treatment modalities will be added to the acupuncture treatment in this arm of the study, in accordance with the practitioners available at each of the participating study centers. These will include one of more of the following:
Manual-movement therapies - e.g. acupressure/reflexology, self- and caregiver-practiced acupressure
Mind-body therapies - e.g. relaxation/imagery method, Anthroposophic music therapy The multimodal CIM treatment regimen will be re-evaluated at each session, and adapted according to the concerns and expectations of the patients, as well as the recommendation of the treating CIM practitioner."
1947802|NCT03068039|Other|Pearl (bajra) breakfast porridge|Isoenergetic and isovolumteric pearl (bajra) breakfast porridge
1947803|NCT03063268|Behavioral|Trust-Enhanced Messaging on E-Consent|Messaging with trust-enhanced modification to the language that the research team has identified as beneficial additional knowledge to provide to participants. This messaging was reviewed by participants from Phase I and edited as suggested.
1947804|NCT03063268|Behavioral|Interactive features on E-Consent|Interactive hyperlinks to open up to further information for key words that participants from Phase I and prototype design and testing have identified as gaps in subject knowledge and provision of information to subjects.
1457910|NCT03290950|Drug|daratumumab|Cycle 1 ONLY: Daratumumab 16 mg/kg days 1, 8, 15, and 22, Cycle 2: Daratumumab 16mg/kg days 1, 8, 15, and 22; Cycles 3-6: Daratumumab 16mg/kg days 1 and 15, Cycles 7-8: Daratumumab 16mg/kg day 1;
1457911|NCT03290950|Drug|carfilzomib|Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 2 and 3; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16; Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
1457912|NCT03290950|Drug|lenalidomide|Cycle 1 ONLY: Lenalidomide 25 mg/day, days 2-21 every 28 days; Cycles 2-8: Lenalidomide 25 mg/day, days 1-21 every 28 days
1457913|NCT03290950|Drug|dexamethasone|Cycle 1 ONLY: Dexamethasone 20 mg/dose, days 2, 3, 8, 9, 15, 16, Cycles 2-4: Dexamethasone 20mg/dose, days 1, 2, 8, 9, 15, and 16; Cycles 5- 8: Dexamethasone 10mg/dose, days 1, 2, 8, 9, 15, and 16
1457917|NCT03290924|Behavioral|Low dose high frequency health worker training approach|"Two 4-day training sessions for skilled birth attendants
1-day peer practice coordinator training after first training session
Weekly, peer-led practice sessions using MamaNatalie® and NeoNatalie™ anatomic models
SMS reminder messages and quizzes
Routine telephone calls between master mentors and peer practice coordinators, and between project staff and master mentors
Health information officer training
Data collection and use training
Supply of simulators, newborn resuscitation equipment, and delivery sets"
1457918|NCT03290924|Behavioral|Active Comparison|Training on data collection and reporting
1947805|NCT03063268|Behavioral|Standard E-Consent|Standard consent currently used by the University of Florida (UF) IRB with no trust-enhanced messaging or interactive hyperlinks that provide further information for subjects.
1457922|NCT03290872|Device|Carpentier Edwards Physio 2 Complete flexible mitral ring|Mitral valve Annuloplasty Ring repair using a Carpentier Edwards Physio 2 Complete flexible mitral ring
1457923|NCT03290872|Device|Simplici T Partial flexible mitral annuloplasty ring|Mitral valve Annuloplasty Ring repair using a Simplici T Partial flexible mitral annuloplasty ring
1457924|NCT03290859|Procedure|Titrate propofol monotherapy infusion to effect|Train anesthesia providers in a standardized protocol for titrating propofol infusion to effect.
1457925|NCT03290846|Drug|Secretin, Pig|Randomized, single-blinded secretin hydrochloride infusion.
1457926|NCT03290846|Drug|Placebo - Concentrate|Randomized, single-blinded saline infusion
1457927|NCT03290833|Device|Robotic|Participants will be placed in the robot and practice common hand tasks involving single finger range of motion exercise, grasping, and pinching objects.
1457928|NCT03290833|Other|Conventional therapy|An occupational therapist will provide one-on-one individualized programs focused on arm and hand function. Treatment will include function-oriented specific tasks, such as reach, grasp, transport and release of various objects between different targets.
1457932|NCT03290807|Device|SPECT/CT|Combined single photon emission computerized tomography and conventional computerized tomography (SPECT/CT) is a hybrid imaging modality, which combines a 3D bone scintigraphy (SPECT) and a conventional CT into one imaging procedure. The use of SPECT/CT offers the benefit of combined anatomical, mechanical (CT) and functional imaging (SPECT)
1457934|NCT03290781|Drug|SHP647|1 milliliter (mL) of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide an intended dose of drug (25 or 75 mg).
1457935|NCT03290781|Other|Placebo|1 mL of sterile aqueous buffered solution.
1457936|NCT03290768|Device|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
1457937|NCT03290768|Device|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
1457938|NCT03290768|Behavioral|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone and text messaging.
1457939|NCT03290755|Behavioral|semi-directed interviews|semi-directed interviews in order to collect socio-behavioral data
1457940|NCT03290729|Procedure|wedge shape implants insertion|Narrow dental implants inserted in narrow ridges
1457941|NCT03290716|Other|SS|Replace regular salt with market available potassium-enriched salt substitute in kitchens of nursing homes.
1457942|NCT03290716|Other|SSSC|A stepwise approach to reduce salt used in the kitchen of nursing homes by controlling the supply of salt.
1457943|NCT03290703|Drug|GDC-0853|Participants will receive different formulations of GDC-0853 tablet.
1457944|NCT03290703|Drug|Rabeprazole|Participants will receive rabeprazole 20 mg twice daily (BID) for three days prior to GDC-0853 administration and a single dose coadministered with GDC-0853.
1457945|NCT03290677|Procedure|Cryoablation|This involves passing a special needle into the body (cryoprobe) to freeze tumor and kill a small part (not all) of the cancer. The immune system will respond to the damage caused by freezing part of the tumor.
1457946|NCT03290677|Procedure|Biopsy|Removing a small piece of the affected area to confirm cancer
1457949|NCT03290651|Dietary Supplement|Probiotic Natural Health Product - RepHresh Pro-B|Participants will take the probiotic or placebo daily for 90 days.
1457950|NCT03290651|Dietary Supplement|Placebo|Participants will take the probiotic or placebo daily for 90 days.
1457951|NCT03290638|Procedure|Guided Bone Regeneration (GBR)|Teeth Extraction With Bone Grafting and Membrane
1457952|NCT03290625|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine hydrochloride (PrecedexTM), presented in ampoule containing 2 mL of 100 mcg / mL solution for injection
1457953|NCT03290625|Drug|Ketamine Hydrochloride|Dextrocetamine hydrochloride (KetaminTM), presented in a 10 mL vial containing 50 mg / mL solution for injection
1457954|NCT03290612|Dietary Supplement|Vitamin C|1.5g Ascorbic Acid
1458048|NCT03289910|Drug|Veliparib|Given PO
1947807|NCT03054870|Drug|Xe-133|Xe-133 ventilation scintigraphy
1947808|NCT03054870|Drug|Technegas|Technegas ventilation scintigraphy
1947809|NCT03052205|Drug|IMO-2125|IMO-2125 will be administered by intratumoral injection on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle.
1947813|NCT03051386|Biological|VEE Vaccine|0.5 mL of VEE vaccine administered subcutaneously in the upper outer aspect of the triceps region.
1947814|NCT03049189|Drug|177Lu-edotreotide PRRT|PRRT using 177Lu-edotreotide will be performed 3-monthly. A maximum of four cycles will be administered.
1947815|NCT03049189|Drug|Everolimus|Everolimus will be adminstered as a standard dosis of 10 mg daily which may be reduced where required for acceptable tolerability.
1457959|NCT03290560|Drug|Recombinant human tissue kallikrein|Recombinant human tissue kallikrein
1457960|NCT03290560|Other|Placebo|Placebo Comparator: Phosphate buffered saline
1457961|NCT03290547|Device|Cutera enLighten laser|Subjects will receive up to 10 laser treatments.
1457962|NCT03290534|Device|CivaSheet|implanting CivaSheet for localized radiation dose delivery
1457963|NCT03290521|Procedure|intraperitoneal washing with saline solution|intraperitoneal washing at the end of surgery
1457964|NCT03290521|Procedure|No washing|no washing
1457965|NCT03290508|Diagnostic Test|Prolaris Testing|Recently diagnosed treatment-naïve patients with early stage localized prostate cancer who undergo Prolaris testing
1947816|NCT03049189|Other|Amino-Acid Solution|The Amino-Acid Solution (AAS) to be used in this study will contain a mixture of 25 g lysine and 25 g arginine diluted in 2000 mL of electrolyte solution, infused over 4 - 6 h, starting 30 - 60 min before PRRT
1947817|NCT03035032|Drug|Leuprolide|Subcutaneous Injection
1457968|NCT03290482|Diagnostic Test|Barium Esophagram|Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
1457969|NCT03290482|Device|EsophaCap|Subjects will swallow the EsophaCap, which has a string attached, 10 minutes later it has devolved in the stomach. The PI will pull the string to remove the EsophaCap. We will send the sponge for cytology assessing the histologic results of eosinophils per high power field (phf)
1457970|NCT03290482|Diagnostic Test|Physical Examination and Questionnaires|Complete the modified Mayo dysphagia Questionnaire (MDQ) and the Eosinophilic Esophagitis Activity Index (EEsAI) at time of physical exam visit with PI.
1457971|NCT03290469|Other|clinical whole genome sequencing (cWGS)|Clinical Whole Genome Sequencing (cWGS) consists of the sequencing, analysis and interpretation of subjects samples and a return of the result to the ordering physician.
1947818|NCT03034577|Drug|Sugammadex|Reversal of neuromuscular block Sugammadex dosage will be adjusted to body weight and PTC/TOF count at the time of reversal, and not administered until PTC at least 1. Dosage will be 4mg/kg if TOF = 0 and PTC ≥ 1; and 2 mg/kg if TOF ≥1.
1947819|NCT03034577|Drug|Neostigmine|Neostigmine 50 micrograms/kg coupled with atropine 20 micrograms/kg or glycopyrrolate 5 micrograms/kg, to a maximum dose of neostigmine of 5.0 mg. The neostigmine should not be administered until the TOF has at least 3 twitches present.
1457974|NCT03290443|Drug|Enasidenib|100 mg enasidenib (CC-90007)
1457975|NCT03290430|Behavioral|Group Counseling|8 sessions over 4 weeks. Lasting 1-2 hours each
1457976|NCT03290430|Behavioral|Individual Counseling|8 in person sessions over 4 weeks. Lasting 30-45 minutes each
1457977|NCT03290430|Behavioral|Phone Counseling|8 phone sessions over 4 weeks. Lasting 30-45 minutes each
1457978|NCT03290430|Behavioral|Video Counseling|8 video call sessions over 4 weeks. Lasting 30-45 minutes each
1457979|NCT03290430|Behavioral|Texting support|Texts with smoking cessation support throughout the program
1457980|NCT03290430|Drug|Nicotine Replacement Therapy|Participants will receive up to 8 weeks of over-the-counter nicotine replacement therapy
1457981|NCT03290417|Dietary Supplement|Vitamin D|5000 IU/cap; One cap by mouth daily
1457982|NCT03290417|Dietary Supplement|Omega-3|720 mg/cap; one capsule by mouth 3 times per day
1457983|NCT03290417|Dietary Supplement|Turmeric|250mg/cap; two capsules by mouth 4 times per day
1457984|NCT03290391|Other|LINC-II|Strengths-based case management: 10 sessions over 12 months. ART at first HIV visit. Thirteen months of naltrexone treatment for opioid use disorder (injection at baseline, followed by 4 implants).
1457987|NCT03290365|Drug|platelet rich plasma + Hyaluronic acid|Platelet rich plasma (PRP) and Hyaluronic acid (HA) are beneficial for patients with osteoarthritis of knee.
1457988|NCT03290365|Drug|platelet rich plasma + normal saline|The normal salin as the placebo intervention was injection control group.
1457989|NCT03290352|Other|Questionnaire|Patients who enrolled in the study were asked to respond to the University of Washington Quality of Life Questionnaire one week before undergoing free flap reconstruction.
1457992|NCT03290313|Drug|shu gan yi yang capsule|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
1457993|NCT03290313|Drug|shu gan yi yang capsule simulation agent|Patients who did not use any antidepressants were given normal clinical medication； Patients who have been treated with antidepressants have been treated for more than 1 month and have reached a therapeutic dose without having to adjust the drug and dose within 2 months.In the original treatment on the basis of the same type of load to the clinical trial medication
1457994|NCT03290313|Other|Supportive psychotherapy|Each patient was given cognitive behavioral adjustment and supportive psychotherapy during the clinical trial
1457995|NCT03290300|Device|Vivaer Stylus|Previous nasal obstruction treatment with the Aerin Medical Vivaer Stylus
1457998|NCT03290274|Device|Deep brain stimulation (fornix)|Deep brain stimulation at fornix
1457999|NCT03290274|Device|Deep brain stimulation (Basal nucleus of Meynert)|Deep brain stimulation AT Basal nucleus of Meynert
1458001|NCT03290248|Biological|B244 suspension|B244 suspension in 30ml/bottle
1458002|NCT03290248|Biological|Vehicle|Vehicle, 30ml/bottle
1458003|NCT03290235|Drug|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/kit
1458004|NCT03290222|Other|TRACK questionnaire|TRACK questionnaire consists of five questions, scored 0-20, to be made to caregivers of children with asthma or recurrent respiratory symptoms, regarding respiratory symptoms, nocturnal awakenings and limitation of daily activities in the last four weeks, use of bronchodilators in the last three months and systemic corticosteroids in the last year
1947820|NCT03029559|Other|Intermittent Hypoxia|"A single session of IH will last for 45 minutes and will consist of alternating phases of hypoxia(FiO2 :9%-11%) and hyperoxia (FiO2 :22%-38%).
Each hypoxic interval will last for 2 minutes whereas the hyperoxic interval lasts for 1 minute each (15, two-minute episodes of hypoxia and 15, one-minute episodes of hyperoxia)."
1947821|NCT03029559|Other|Inspiratory Threshold Loading|Subjects will undergo inspiratory threshold loading using a commercially available Threshold IMT device (Power breathe®). ITL will be administered at an intensity of 80% of the individual's maximal inspiratory pressure (MIP). The subjects will be instructed to take 10 deep, forceful breaths through the threshold device followed by at least 2 minutes of rest. The process will be repeated 4 more times for a total of 5 sets of 10 breaths each.
1458007|NCT03290196|Drug|EXPAREL 1.3 % in 20 ML Injection|EXPAREL single shot dose given as an analgesia for arthroscopic rotator cuff repair surgery.
1458008|NCT03290183|Device|Confocal laser endomicroscopy|Real-time microscopic imaging technique
1458009|NCT03290170|Procedure|Measured Resection|Bony landmarks are used to set femoral component rotation.
1458010|NCT03290170|Procedure|Gap Balancing|Relies on ligament releases prior to bone cuts.
1458011|NCT03290157|Device|ColoprAPP|Additional downloaded SPA for reminding the crucial steps of colonoscopy preparation
1458012|NCT03290131|Drug|Arbaclofen|Arbaclofen is the active R enantiomer of baclofen.
1458013|NCT03290131|Drug|Placebo|Placebo comparator
1458014|NCT03290118|Other|Nutrition Rating System - Traffic Light|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage, by indicating the levels (low=green, moderate=amber, high=red) of sodium, saturated fat and sugar in a product based on modified Food Standards Australia New Zealand (FSANZ) criteria.
1458015|NCT03290118|Other|Nutrition Rating System - Health Star|Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating the number of stars awarded to a product, from 0.5 to 5 stars, based on modified Food Standards Australia New Zealand (FSANZ) nutrient profiling criteria.
1458016|NCT03290118|Other|Nutrition Rating System - Warning Label|"Behavioural: Nutrition Rating Systems (shown on the online survey and the mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product by indicating with a warning label products that are high in sodium, saturated fat and sugar, based on a percent daily value (%DV) greater than 15% for individual products and 30% for combination dishes."
1458017|NCT03290118|Device|Smartphone application FoodFlip Device®|This is embedded within each condition to inform and educate consumers about the labelling condition/intervention to which they are randomized. All participants are assigned to an app task to view 20 products and see the 'rating' these products would get according to their condition.
1458018|NCT03290092|Drug|Taselisib (GDC0032)|The first six participants cohort receive a starting dose of 1mg once daily of taselisib during four weeks.
1458019|NCT03290092|Drug|Taselisib (GDC0032)|The starting dose of the second cohort of 24 patients is 2 mg once daily. This dose may be adjusted down according to the pharmacokinetic data or tolerability data derived from the first cohort.
1458021|NCT03290066|Device|kinesiotape|For the Kinesio taping group, a piece of Kinesio tape 5 cm in width and 7-8 cm in length will be applied right from below the navel and will reach to where the pubic hair begins, and another piece of tape 10 cm in length will be applied to make a cross shape with the first piece. A tape of 20cm in length will be placed horizontally to the lower back.
1458022|NCT03290066|Other|Usual care|Participants will note the usual self-care used to relief pain (NSAIDs, heat, massage therapy.....).
1458023|NCT03290053|Drug|SonoVue|SonoVue-infusion over 1 hour
1458024|NCT03290053|Drug|Sodium chloride|Placebo
1458025|NCT03290053|Procedure|Transcranial Ultrasound|Transcranial ultrasound aimed at the blockage
1458026|NCT03290053|Procedure|Sham Transcranial Ultrasound|Placebo - machine is attached, but not active
1458027|NCT03290027|Drug|DFD-03|DFD-03 Lotion
1458028|NCT03290014|Diagnostic Test|polysomnography|Monitoring of brain activity and respiratory variables during sleep
1458029|NCT03290014|Diagnostic Test|Actigraphy|monitoring daily physical activity for 7 days
1458030|NCT03290014|Diagnostic Test|Osler test|Evaluation of subjects´ ability to remain awake
1458031|NCT03289988|Other|blood sampling|NK activity and gene panel expression analysis based on blood test (5cc blood sampling)
1458032|NCT03289975|Other|pulmonary ultrasound|Collect the aeration profile for each lung quadrant: profile A, profile B1, profile B2, profile C. Calculate the aeration score from O to 36 (LUS (Lung ultrasound) score).
1458035|NCT03289949|Drug|Psilocybine|Oral dose of psilocybin.
1458036|NCT03289949|Drug|Ketanserin|Oral dose of ketanserin.
1458043|NCT03289910|Drug|Carboplatin|Given IV
1458049|NCT03289897|Diagnostic Test|LiverMultiScan|LiverMultiScan is an imaging technique which is able to identify early liver disease.
1458050|NCT03289884|Other|MRI scan (not involving ionising radiation)|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
1458051|NCT03289884|Other|Ultrasound scan (not involving ionising radiation)|The US scan will be conducted by a nominated researcher
1458052|NCT03289884|Other|Ex vivo MRI scan of cyst fluid sample|The MRI study will be conducted by a trained MR radiographer, supervised by the nominated researcher
1458053|NCT03289884|Other|Aspiration of cyst fluid|For patients undergoing surgery/radiologically guided aspiration the aspiration will be performed by a surgeon (at the Royal Free Hospital) or radiologist
1458054|NCT03289884|Other|Blood test for confirmation of serum IgG levels consistent with hydatid infection|The blood sample will be drawn by a member of the clinical team
1458055|NCT03289871|Device|Excilor|
1458056|NCT03289871|Drug|Loceryl 5%|
1458057|NCT03289858|Drug|Exparel|Subcutaneous injection at conclusion of surgical fixation of hip fracture
1458058|NCT03289858|Drug|Sodium Chloride|Saline Injection
1458059|NCT03289845|Device|BHX implant (Bone anchored hearing system)|Bone anchored hearing system for hearing rehabilitation
1458060|NCT03289832|Dietary Supplement|Crucera-SGS|Crucera-SGS is a commercially available dietary supplement. The active ingredient is glucoraphanin, a phytochemical from broccoli and it is prepared as a simple extract of broccoli seeds. Glucoraphanin is converted to sulforaphane by bacteria in the human intestines. Crucera-SGS is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat broccoli every day.
1458061|NCT03289832|Dietary Supplement|Meriva 500-SF|Meriva-SF is a commercially available dietary supplement. The active ingredient is curcumin, a phytochemical from the spice, turmeric, and it is prepared as a simple extract of this plant, formulated with lipids which aid in its absorption and metabolism. Meriva-SF is formulated by Thorne Research Inc. into gel-caps that make it much more convenient to deliver than having subjects eat turmeric powder every day.
1458062|NCT03289819|Drug|Pembrolizumab|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
1458063|NCT03289819|Drug|nab-paclitaxel|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
1458064|NCT03289819|Drug|Epirubicin|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
1458065|NCT03289819|Drug|Cyclophosphamide|All patients will receive 12 cycles of weekly nab-paclitaxel intravenous (i.v.) 125 mg/m² body surface area (BSA) in combination with 4 cycles of pembrolizumab i.v. 200 mg q3w; followed by 4 cycles of epirubicin i.v. 90 mg/m² BSA and cyclophosphamide i.v. 600 mg/m² BSA, q3w in combination with 4 cycles of pembrolizumab i.v. 200 mg/kg q3w.
1458066|NCT03289806|Procedure|Samples of fibroblasts from Tenon's capsule|
1458067|NCT03289793|Other|Neurofeedback training|"Children in group A will receive BCI-based training implemented through original P300-based controlled games.
They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.
Each session includes: installation of the child, the EEG system and an eye-tracking system, a 5-minutes relaxation phase, a short EEG recording at rest, a brief reminder of the instructions, 30 minutes of training by playing video games and finally a time for the child to wash her/his hair.
Moreover, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be answered."
1458068|NCT03289793|Other|Active Sham control|"Children in group B will receive a training that is not based on brain activity, but in a blind fashion. They will attend 30 1-hour long training sessions at a pace of 2 sessions per week.
Each session includes: installation of the child, setting up the EEG and eye-tracking systems, a 5-minutes relaxation phase, short EEG recording at rest, a brief reminder of the instructions, 30 minutes of video game based training and finally a time for the child to wash her/his hair.
Besides, 4 neuropsychological sessions will complement the 30 training sessions. During these sessions neuropsychological tests and quality of life questionnaires will be performed."
1458069|NCT03289793|Other|Baseline control group|The children included in this group will not receive any training. They only take part to the 4 neuropsychological sessions. Like others, they will attend 1 neuropsychological session every two months over six months.
1458070|NCT03289767|Other|Curved-tube|"Connecting both ends of the endotracheal tube (O shape) for 5-min and releasing it provides additional anterior angle temporarily."
1458071|NCT03289754|Device|iPoly XE tibial insert with ConforMIS iTotal KRS|The implants are constructed to conform to the surface of the patient's femoral condyle and proximal tibia, replacing the damaged cartilage with a smooth articulating surface. The femoral component and tibial tray are manufactured from cobalt chromium molybdenum alloy. The tibial insert and patellar component are manufactured from ultra-high molecular weight polyethylene.
1458072|NCT03289741|Drug|Octreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Octreotide LAR for 3 injections followed by lanreotide for 3 injections
1458073|NCT03289741|Drug|LAR Lanreotide|Patients will receive three monthly injections every 28 (+/- 3) days. Lanreotide for 3 injections followed by octreotide LAR for 3 injections
1458074|NCT03289741|Behavioral|Questionnaires|Baseline questionnaire, Post-treatment questionnaire (after the first 3 injections), Preference questionnaire
1458102|NCT03289494|Other|Balanced diet high in Slowly Digestible Starch|The carbohydrate present in the diet high in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
1458103|NCT03289494|Other|Balanced diet low in Slowly Digestible Starch|The carbohydrate present in the diet low in Slowly Digestible Starch were selected according to the general recommendations made for diabetics and according to their SDS content. The diet will be consumed during one week.
1458075|NCT03289728|Other|Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE)|"Stress single photon emission CT (SPECT) or Stress ultrasound with dobutamine (DSE), performed using standard protocol.
Patients with ≥ moderate ischemia observed by SPECT (≥ 10% of the myocardium or transient ischaemic dilatation or reduced post-stress ejection fraction (EF)) or abnormal movements of the myocardial walls observed during a stress echocardiogram (≥ 3/17 segments) will benefit from coronary angiography. Depending on the results of coronary angiography and on the coronary anatomy and other clinical and para-clinical considerations (territory of myocardial ischemia) revascularisation will be performed (REVASC). Patients with < moderate ischemia will receive medical treatment only (MT)."
1458076|NCT03289728|Procedure|Cornorary angioplasty|Participants randomized to the SCA group, will benefit from a coronary angiography within 24 to 72 hours after the diagnosis of NSTEMI; without any preliminary ischemia imaging.
1458077|NCT03289715|Device|On Demand Humidification system Mark 2|The on demand humidification humidifier is set up to alternate between periods of humidification and no humidification totaling 6 periods of 30 minutes duration each. Thus, the test will consist of 3 cycles of disabled humidification and enabled humidification. Each cycle will be with a different humidification setting to assess which setting is most comfortable. In the second phase, the patient will be treated with the dose they had the best experience with in the first test.
1458078|NCT03289702|Drug|CORETOX®|upper limb will be injected and evaluated in the study. Maximun injection dose is 360U.
1458079|NCT03289702|Drug|BOTOX®|upper limb will be injected and evaluated in the study. Maximun injection dose is 360U.
1458080|NCT03289689|Device|Whole-body vibration (WBV)|Whole-body vibration (WBV) is a novel neuromuscular therapeutic intervention that has recently been developed since in the mid-1960s. Hagbart and Eklund showed in human experiments that a reflex muscle contraction can result as a consequence of applying vibrations to the muscular-tendon system. The subjects stand on a platform that generates stochastic vibrations at a frequency between 1-12.5 Hz.
1458081|NCT03289676|Combination Product|Storytelling Narrative Intervention|"In the first phase, three sections of a video, each for 5-7 minutes will be produced by Star story tellers who are eloquent and have authentic personal experiences of quitting smoking. Participants who receive 8-weekly 30-minute cessation counseling sessions along with NRT are randomly assigned to watch either the smoking cessation video or attention-control video of women taking about their HIV infection."
1458082|NCT03289663|Drug|synergistic combination of insecticides|third generation insecticide -treated bednets
1458083|NCT03289663|Drug|Pyrethroids|Conventional insecticide
1458084|NCT03289650|Drug|Tacrolimus|immunosuppressive agent tacrolimus, given twice-daily
1458085|NCT03289650|Drug|Tacrolimus Extended Release Oral Tablet [Envarsus]|immunosuppressive agent extended-release tacrolimus, given once daily
1458086|NCT03289637|Dietary Supplement|Vitamin D|Vitamin D intervention tested against placebo in a population with heart failure and a 25-OH-vitamin D level<50nmol/L at screening
1458087|NCT03289624|Behavioral|SHARE-CC|"Each of the 6 SHARE-CC sessions are structured similarly, starting with the dyad reviewing goals of the session, the CG & PWCC meeting jointly or separately with the SHARE-CC Counselor around session-specific material, & ending with a review of material, addressing questions, & previewing the next session. Sessions titles are: Communication & Health Education; Care Values; Care Preferences; Family, Friends, & Community Resources; Taking care of yourself—taking care of each other; & Take Action Now.
The SHARE plan will be developed throughout the sessions and reflects the consensus achieved because of participating in SHARE-CC. It is intended to ensure that the PWCC's values & preferences are supported when decisions have to be in the future."
1458088|NCT03289611|Biological|sFlt-1 / PlGF ratio|"Ambulatory management if sFlt-1 / PlGF ratio is below 38
usual management if sFlt-1/PlGF is between 38 and 85.
If the ratio is > 85, monitoring will be intensified and patient hospitalization will be continued"
1458089|NCT03289598|Behavioral|A rehabilitation process involving collaborative goal setting with a case manager about managing own food and meals|"The intervention consists of two parts:
Education of the health care staff with one day's education focusing of aspects of food, meals and nutrition to old people.
The individual participants in the intervention group will be participating in a rehabilitation process involving collaborative goal setting with a case manager. All the case managers have a background as registered dietician and will before start of the intervention be trained in managing a rehabilitation process with focus on meals and food. The training will consist of three days of education in, respectively, areas in relation to rehabilitation and the role as a care manager. Specific topics include; assessment of functional abilities in relation to meals and food; goal setting by means of GAS (Goal Attainment Scaling), ethical considerations and communication."
1458090|NCT03289559|Drug|GnRH antagonist|
1458091|NCT03289559|Drug|Aromatase Inhibitors|
1458092|NCT03289559|Drug|Testosterone gel|
1458093|NCT03289546|Behavioral|Mindfulness training|"The mindfulness training protocol will include the following basic components of traditional mindfulness-based stress reduction training: 1) training in awareness of sensations (body scan); 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life, and in recognizing when the attention is no longer focused on a specific object of attention; and 4) training in 'open awareness'."
1458094|NCT03289546|Behavioral|Aerobic training|Exercise sessions will be led by CPR- and exercise-certified YMCA instructors and supervised by the senior research assistant. Sessions will consist of 10 minutes of warm-up, 40 minutes of aerobic exercise (walking on a treadmill), 10 minutes of cool down and stretching. Participants will receive heart monitors at the beginning of the study and will be trained by the senior research assistant to exercise targeting heart rates at 65-75% of the age predicted max heart rate or at an intensity of 12-13 in the Borg scale of the rate of perceived exertion.
1458097|NCT03289520|Drug|Clopidogrel|
1458098|NCT03289520|Drug|Placebo|
1458099|NCT03289507|Dietary Supplement|Treatment1|Longvida Capsule formulation A
1458100|NCT03289507|Dietary Supplement|Treatment2|Longvida Capsule formulation B
1458101|NCT03289507|Dietary Supplement|Treatment3|Curcuma longa extract of Rhizomes
1458104|NCT03289481|Dietary Supplement|Active lozenge|nitric oxide generating lozenge
1458105|NCT03289468|Diagnostic Test|Voluson E8 (GE Medical Systems, USA), Minimally Invasive Endometrium Sampler|The endometrial thickness, basic characteristics information and endometrial blood flow energy index, endometrial vascularization index, blood flow index are detected by color power Doppler and the energy histogram of endometrium is obtained using a Voluson E8 (GE Medical Systems, USA) ultrasound system. The specimen of uterine cytology and endometrial tissue are obtained through minimally invasive endometrium sampler, which are diagnosed by pathology.
1458106|NCT03289455|Biological|AUTO3 (CD19/22 CAR T cells|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with 1 to 2.0 x 10⁶/kg CD19/CD22 Chimeric Antigen Receptor (CAR) positive T cells as a single or split dose.
1458107|NCT03289442|Procedure|supine position|patients were positioned on their supine position to receive colonoscopy insertion
1458108|NCT03289429|Drug|Atorvastatin|Atorvastatin in a dose of 80 mgs, twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
1458109|NCT03289429|Drug|Magnesium Sulfate|Magnesium sulfate: ( 3 grams dissolved in 100 mL of isotonic saline to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
1458110|NCT03289429|Other|intravenous placebo|100 mL of isotonic saline (to be infused over 2 hours) twelve hours preoperatively, within the first hour of ICU arrival, and on the 2nd and 3rd postoperative days.
1458111|NCT03289429|Other|tablets placebo|Placebo tablets: twelve hours preoperatively, two hours preoperatively, and on the 2nd, 3rd, 4th and 5th postoperative days.
1458112|NCT03289416|Combination Product|Pure PRP II|The Pure PRP II system will be used to collect and concentrate blood into platelet rich plasma that will be injected into the knee.
1458113|NCT03289416|Combination Product|PureBMC|The PureBMC system will be used to collect and concentrate bone marrow aspirate into bone marrow concentrate that will be injected into the knee.
1458114|NCT03289403|Drug|Immunomodulatory|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.
Moreover, patients will receive a treatment course of immunomodulatory drugs for 3 -6 months before ICSI cycle:
Prednisnlone 40mg for 2 weeks to be lowered gradually till become 5mg after 6 weeks and to be continued
Hydroxychloroquine according to body weight, patients who develop hypersensitivity will be shifted to Azathioprin.
Immunoglobulins will be used in cases not responding to treatment."
1458115|NCT03289403|Drug|Thyroxine|"Patients will receive thyroxine , low dose aspirin , low dose selenium, Calcium and vitamin D before ICSI cycle.
Patients will not receive immunomodulatory drugs"
1458116|NCT03289390|Drug|Acetaminophen|Acetaminophen given at discretion of medical team for PDA treatment. Research team to evaluate pre and post laboratory values and echocardiograms.
1458117|NCT03289377|Behavioral|RDAD Training|An interactive processes of lecture, role-play, and discussion, APNs will have the opportunity to dissect all phases of RDAD to insure they understand the objectives, can enact the program, and feel confident they can problem-solve situations that arise. APNs will receive materials to insure they are knowledgeable about ADRD symptoms, behavior management techniques, and exercise safety.
1458118|NCT03289364|Device|Penguin Cold Caps|Patients will wear Penguin Cold Cap scalp cooling device prior to each chemotherapy administration, during administration, and for four hours following administration.
1458119|NCT03289351|Drug|piperacillin-tazobactam|Single drug therapy
1458120|NCT03289338|Drug|Zoledronic Acid|Zoledronic acid 5mg intravenous once a month for 3 months
1458121|NCT03289338|Drug|Methylprednisolone|Methylprednisolone 1gm intravenous once a month for 3 months
1458122|NCT03289338|Drug|Placebos|Normal saline intravenous once a month for 3 months
1458123|NCT03289325|Drug|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).
Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 ug/kg in 10 minutes), followed by continuous infusion at a rate of [0.1*kg] ml/h (i.e., dexmedetomidine at a rate of 0.4 ug/kg/h) until the end of surgery.
After surgery, the infusion rate will be decreased to [0.025*kg] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation."
1458124|NCT03289325|Drug|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.
Before anesthesia induction, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes, followed by continuous infusion at a rate of [0.1*kg] ml/h until the end of surgery.
After surgery, the infusion rate will be decreased to [0.025*kg] ml/h and continued until the end of mechanical ventilation."
1458125|NCT03289299|Drug|Carfilzomib|36 mg/m2 IV given on days 1, 2, 8, 9, 15, and 16 of each cycle during induction, consolidation, and intensification phases of the study.
1458126|NCT03289299|Drug|Lenalidomide|"25 mg po given on days 1-21 of each cycle during the induction and consolidation phases.
15 mg po given on days 1-21 of each cycle during the intensification and maintenance phases."
1458127|NCT03289299|Drug|Daratumumab|16 mg/kg IV given on days 1, 8, 15, and 22 of cycles 1-2; days 1 and 15 of cycles 3-6; day 1 of cycle 7, 9, 11, etc through cycle 23.
1458128|NCT03289299|Drug|Dexamethasone|40 mg oral given on days 1, 8, 15, and 22 of cycles 1-4 20 mg oral given on days 1, 8, 15, and 22 of cycles 5-8 10 ng oral given on days 1, 8, 15, and 22 of cycles 9-12.
1458129|NCT03289299|Procedure|ASCT|ASCT performed after 4 cycles of induction therapy. Stem cell collection and high dose therapy with Melphalan. Stem cell collection process and transplant related supportive care per local practice.
1458130|NCT03289286|Other|Dedicated and coordinated e-follow-up.|"In pre- and post-surgery:
Completion of questionnaires using an electronic tool,
Telephone follow-up if necessary between the nurse and the patient."
1458134|NCT03289247|Device|tissue adhesive (Leukosan®)|Tissue ahaesive
1458135|NCT03289234|Drug|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes
1458136|NCT03289221|Diagnostic Test|Anal Manometry|"A suppository will be used to clean the rectum 3 to 4 hours prior to the examination. And the pressures of rest and voluntary contraction of the anal sphincter will be evaluated, as well as the behavior of the pubortal muscle during the evacuation maneuver. Retinal inhibitory reflex (RIRA), sensitivity and rectal capacity will also be evaluated.
Questionnaires that evaluate the pre and post HIFU anal physiology will also be applied at the time of manometry."
1458137|NCT03289208|Drug|MCI-186|30 mg of edaravone will be administered intravenously over 60 minutes.
1458138|NCT03289195|Procedure|MRI Biopsy|Patient will undergo percutaneous MR guided biopsy by study Breast Radiologist within 0-60 days of completing NAC.
1458139|NCT03289182|Drug|MabThera|Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
1458140|NCT03289169|Drug|MEDITOXIN®|20U of meditoxin® is injected to two places on the corrugators muscle for each eye and one place on the procerus muscle, total of 5 sites.
1458141|NCT03289156|Behavioral|Arousal Reappraisal|Brief readings educating about the stress response and usefulness of arousal reappraisal.
1458142|NCT03289156|Behavioral|Exercise|Three 5-minute bouts of exercise at increasing intensities (65%, 75%, and 85%) with 5-15 minute breaks in-between for recovery.
1458148|NCT03289104|Device|Steel Wires|Control: Steel wires (device) are selected for sternal closure after surgery. Currently, most patients who have a sternotomy during cardiac surgery have their sternum closed with steel wires.
1458149|NCT03289104|Device|ZipFix Sternal Closure System|Treatment: ZipFix system (device) are selected for sternal closure after surgery. These plastic cables can also be used to close the sternum during bypass surgery.
1458150|NCT03289091|Behavioral|water-based continuous aerobic training|Participants who will be randomized for the continuous aerobic training group will carry out exercises with no interval for exercise change. Intensity will be increased every mesocycle. In the first mesocycle (weeks 1-4), participants will carry out three 4-minute series of each exercise whose intensity corresponds to the Rating of Perceived Exertion (RPE) 13. In the second mesocycle (weeks 5-8), participants will perform four 3-minute series of each exercise corresponding to RPE 14. In the third mesocycle, participants will perform six 2-minute series of each exercise at intensity corresponding to RPE 15 from weeks 9-10, whereas intensity corresponding to RPE 16 will be experienced from weeks 11-12.
1458151|NCT03289091|Behavioral|water-based interval aerobic training|Participants who will be randomized for interval aerobic training group will carry out exercises which associate effort phases, at higher intensity and recovery phases, at lower intensity, with no interval for exercise change. Intensity will be increased every mesocycle. The first mesocycle (weeks 1-4) comprises three 4-minute series of each exercise whose intensity corresponds to the RPE 16 for 2 minutes and RPE 11 for 2 minutes. The second mesocycle (weeks 5-8) includes four 3-minute series of each exercise whose intensity corresponds to the RPE 17 for 1.5 minutes and RPE 11 for 2 minutes. The third mesocycle (weeks 9-12) comprises six 2-minute series of each exercise whose intensity corresponds to the RPE 18 for 1 minute and RPE 11 for 1 minute.
1458152|NCT03289078|Other|Spa Treatment|The spa treatments will be realised daily 6 days a week and during 18 days. The care will be provided is : Swimming pool of mobilization by physical therapist (20 minutes daily, Cataplasms (10 minutes daily), Shower in the jet (10 minutes daily), Shower under affusion (10 minutes daily)
1458153|NCT03289052|Device|Restylane Volyme|Subcutis injection
1458154|NCT03289039|Drug|Neratinib|Neratinib is a recently discovered oral drug that may stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2)
1458155|NCT03289039|Drug|Fulvestrant|Fulvestrant, works in treating breast cancer that has spread to other parts of the body
1458156|NCT03289026|Drug|Aripiprazole|Doses were flexibly titrated to between 10 and 30 mg once daily based on the individual needs of the patient as determined by the investigator.
1458157|NCT03289013|Other|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
1458158|NCT03289013|Other|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy devices
1458159|NCT03289013|Other|LT-2|Newly developed adhesive
1458160|NCT03289013|Other|LT-21|Newly developed adhesive
1458161|NCT03289013|Other|LT-25|Newly developed adhesive
1458162|NCT03289013|Other|33-20|Newly developed adhesive
1458163|NCT03289000|Device|iTotal Posterior Stabilized (PS) Knee Replacement System|Patient-specific posterior stabilized total knee replacement and patient specific surgical jigs
1458164|NCT03288987|Drug|Bevacizumab + FOLFIRI-3|Bevacizumab 5 mg/kg will be administered at day 1 every 2 weeks. Initially, it will be administered as a 90-min infusion. If the first infusion is well tolerated, the second will be delivered as a 60-min infusion, and if the 60-min infusion is well tolerated, all subsequent infusions will be given over 30 minutes. FOLFIRI-3 regimen consists of irinotecan 100 mg/m2 over 1 hour at day 1, leucovorin 400 mg/m2 at day 1 followed by a 46 hour 5-FU continuous infusion (2000 mg/m2) and irinotecan 100 mg/m2 over 1 hour on day 3 will administer. Induction treatment was administrated every 2 weeks until disease progression, unacceptable toxicities, surgical intervention, or withdrawal of consent.
1458165|NCT03288974|Drug|POMALYST® (Pomalidomide)|The recommended starting dose of POMALYST is 4 mg once daily taken orally on Days 1 to 21 of repeated 28-day cycles. The recommended dose of dexamethasone is 40 mg orally once daily on Days 1, 8, 15 and 22 of each 28-day treatment cycle
1458166|NCT03288948|Other|Binocular games for treatment of amblyopia|playing binocular games on a tablet platform 1 hour per day 5 days per week with reduced contrast for the fellow eye and high contrast for the amblyopic eye
1458222|NCT03288532|Drug|Durvalumab|controlled infusion via an infusion pump into a peripheral or central vein
1458169|NCT03288922|Procedure|Limited BF OL-HDF with SHF|"The new modality Limited BF OL-HDF with SHF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 300 ml/min and the total dialysis fluid flow rate was 800 ml/min which included pre-filter substitution rate of 150 ml/min. The super high-flux dialyzer was PES-17Dα from Nipro Corporation, Japan which contains 1.7 m2 hollow fiber polyethersulfone membrane (ultrafiltration coefficient 80 ml/h/mmHg; urea clearance 267 ml/min, Qb 300 ml/min and Qd 500ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
1458170|NCT03288922|Procedure|High-efficiency OL-HDF|"The controlled modality High-efficiency OL-HDF were performed using Fresenius 5008 hemodiafiltration machine. The prescribed blood flow rate was 400 ml/min and the total dialysis fluid flow rate was 800 ml/min which included post-filter substitution rate of 100 ml/min. The standard high-flux dialyzer that was used was HF80s from Fresenius Medical Care, Germany contains 1.8 m2 hollow fiber polysulfone membrane (ultrafiltration coefficient 55 ml/h/mmHg; urea clearance 248 ml/min, Qb 300ml/min and Qd 500 ml/min). The patients were received this treatment thrice-a-week for 2 week before entering the wash-out period and crossover to another arm."
1458171|NCT03288909|Other|MRI|
1458172|NCT03288896|Behavioral|Alerta Alcohol|The intervention consists of preventive messages about the benefits of not consuming alcohol, reducing the positive attitudes and encouraging the negative attitudes towards alcohol drinking and binge drinking, as well as social influence and self-efficacy, by personalized feedback. Skills and action plans are encouraged to help the student to reject binge drinking. This information is presented through different tailored messages. Moreover, four avatars (two males and two females), which can be chosen as part of the story development. This story consists of a short story about the alcohol consumption by adolescents.The stories take place in three different scenarios (at home, at celebrations and in public places).
1458173|NCT03288883|Device|Photothermal Non-ablative Erbium:YAG-laser|Laser treatment of the vagina for GSM
1458174|NCT03288883|Device|Fractional Microablative CO2-laser|Laser treatment of the vagina for GSM
1458175|NCT03288870|Drug|BCD-100|monoclonal antibody to PD-1 receptor
1458176|NCT03288870|Drug|Docetaxel|Chemotherapy drug (taxane)
1458177|NCT03288857|Device|NeilMed Naspira|NeilMed Naspira is a nasal-oral aspirator
1458178|NCT03288844|Procedure|Ophthalmologic examinations|epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; ocular tonometry; slit lamp examination; conjunctival (both bulbar and limbal) inflammation assessment; corneal sensitivity; central cornea involvement (for opacity or central CNV); Best-Corrected Visual Acuity; evaluation of symptoms.
1458179|NCT03288844|Other|Digital pictures|Digital pictures 2D to be taken at each visit
1458180|NCT03288844|Other|QoL Questionnaires|Quality of Life (NEI VFQ 25 and EQ-5D-3L/Y) questionnaires will be submitted at each visit
1458181|NCT03288831|Dietary Supplement|Gluten|Six grams of gluten will be mixed with water and Tang flavoring. Subjects will drink the mixture one time.
1458182|NCT03288831|Dietary Supplement|Placebo|Subjects will drink a mixture of rice water and Tang flavoring one time.
1458183|NCT03288818|Drug|Mechlorethamine Hydrochloride Gel|Given topically
1458184|NCT03288818|Procedure|Total Skin Electron Beam Radiation Therapy|Undergo low dose (TSEBT) Total Skin Electron Beam Therapy
1458186|NCT03288779|Device|Theta Burst Stimulation|Transcranial magnetic stimulation with theta burst stimulation
1458187|NCT03288766|Procedure|PICC placement with SHERLOCK 3CG™ Diamond TCS with MODUS II software|The SHERLOCK 3CG™ Diamond Tip Confirmation System (TCS) is an FDA-cleared fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology, indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients without any alterations of cardiac rhythms that change the normal presentation of the P-wave. A software package, MODUS II, has been developed to accurately analyze the entire ECG complex and identify the correct placement of the PICC tip based on a patient's individual ECG, in the absence of an easily identifiable P-wave. This software system is designed to provide visual and/or audio cues to notify the PICC placer of the location of the PICC tip relative to the cavoatrial junction (CAJ) of the patient.
1458188|NCT03288753|Other|Satisfaction questionnaire|Participants have to complete a satisfaction questionnaire on the Neuro 1 or 2 processor.
1458189|NCT03288753|Behavioral|Speech intelligibility in quiet|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
1458190|NCT03288753|Behavioral|Speech intelligibility in noise|The speech material corresponds to the lists of Lafon designed for cochlear implant patients. Each lists contains 17 monosyllabic words. Speech comprehension is evaluated by the percentage of correct words and the percentage of correct phonemes. Speech signals are presented at 65 dB SPL. 2 lists of 17 words are presented. The noise corresponds to a cocktail party presented at +10 dB SNR (Speech on Noise Ratio). At visit 1, the participants wear the sound processor Neuro 1. At visits 2 and 3, the participants wear the Neuro 2.
1458223|NCT03288532|Drug|Tremelimumab|controlled infusion via an infusion pump into a peripheral or central vein
1498710|NCT02978833|Device|Ultrasound|
1458191|NCT03288753|Behavioral|VRB (Vocale Rapide dans le Bruit)|Speech intelligibility in noise measured with the test VRB (Vocale Rapide dans le Bruit, French version of the Quick Sin). This test measures the SNR (Signal to Noise Ratio) at which the listeners understand half of the words of a sentence correctly. The outcome measure is in dB. 3 lists are presented. Speech signals are presented at 60 dB SPL.
1458192|NCT03288740|Drug|Semaglutide 0.5 mg|A dose of 0.25 mg semaglutide gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
1458193|NCT03288740|Drug|Placebo (semaglutide 0.5 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 0.5 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
1458194|NCT03288740|Drug|Semaglutide 1.0 mg|A dose of 0.25 mg semaglutide gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
1458195|NCT03288740|Drug|Placebo (semaglutide 1.0 mg)|A dose of 0.25 mg semaglutide placebo gradually increased to 1.0 mg injected subcutaneously (under the skin) once weekly for 13 weeks.
1458196|NCT03288727|Other|interviews with a psychologist|an interview with a psychologist / sociologist will take place after completion of the on-site questionnaires to find out the reasons for their choice of accessing their secondary data and their experiences with the secondary data reported.
2010445|NCT02962557|Device|NM3, Phillips Medical, Wallingford CT: verbal prompts to breathe with an optional shoulder shake|The device used is the NM3 by Phillips Medical, Wallingford CT. The prompting for breaths will include a recorded voice played at 100 decibels played by a speaker placed within 4 feet of the patient's head. If successful breath response is monitored by the patient monitors but no additional subsequent breaths occur within 20 seconds, the verbal prompt will be repeated for the patient to breathe. If the verbal prompting does not result in a breath detected by the patient monitors, the verbal prompt will be repeated within 20 seconds, optionally accompanied by a shoulder shake from the shoulder massager.
1458199|NCT03288701|Device|scale (Body Cardio Scale - Withings)|Comparison of reduction of whole body water and body weight in patients with decompensated heart failure under forced diuretic treatment
1458200|NCT03288688|Other|Exercise program and education|"The exercise program comprises warm-ups, exercises and cool-downs and aims to improve recruitment, strength and endurance of postural muscle groups that are key to the work of a musician. Basic activation exercises progress to dynamic and resisted exercises as well as functional musical movements. There is a series of six exercises of increasing difficulty for each of the following bodily regions: hips, back, neck, shoulders and abdominals.
Topics to be discussed in the educational presentation and e-mails include healthy practice habits, activity dosage, the importance of physical activity, how the body adapts to workload and physical stressors, and instructions pertaining to the exercise program."
1458201|NCT03288675|Device|aiTBS|In the active aiTBS arm, the patients will receive 100 cycli of thetaburst trains of 2s, separated by an inter-train-interval of 6 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC; i.e. 3000 pulses per session). On each stimulation day, a given patient will receive 5 sessions with a between-session interval of 15 minutes. The treatment protocol of in total 20 aiTBS sessions will be spread over 4 days (i.e. 60.000 pulses in total). The sham coil has been specifically developed to mimic the real one.
1458202|NCT03288675|Behavioral|CCT|By training working memory processing, the CCT aims at modulating similar prefrontal cortex regions as being stimulated previously by aiTBS, namely the DLPFC. thereby possibly stabilizing clinical effects of aiTBS over time. In total 20 sessions of CCT vs. control training (of approximately 25 minutes per session), will be spread over a period of 4 weeks.
1458203|NCT03288675|Drug|SSRI|All patients will be prescribed antidepressant medication (SSRI) again when starting the CCT (vs. control training).
1458204|NCT03288662|Other|CT and histopathological classification|Cross-sectional descriptive study on 53 patients with diagnosed of thymoma by CT and had postoperative histopathology results as thymic epithelial tumors. Base on the characteristics in Chest CT scan in each postoperative histopathology results.
1947822|NCT03029559|Other|Sham Intermittent Hypoxia|Subjects will be exposed to a session of sham Intermittent hypoxia.This will consist of breathing room air for 45 minutes through a hypoxicator.
1947823|NCT03023423|Drug|Atezolizumab|Participants will receive atezolizumab 1200 mg intravenously.
1947824|NCT03023423|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg intravenously.
1458209|NCT03288623|Dietary Supplement|Dark Chocolate (85% cocoa)|Dark chocolate (85% cocoa) in tablet
1458210|NCT03288623|Dietary Supplement|White/Milk chocolate (<35% cocoa)|white or milk chocolate (<35% cocoa) in tablet
1458211|NCT03288610|Diagnostic Test|Preoperative copeptin level|Measure of plasmatic copeptin from preoperative samples retained in a biorepository. Physicians are blinded to the result.
1458212|NCT03288597|Radiation|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NET|At the beginning of the treatment with SSA, after 6 months, 12 months, or chemotherapy, after 3 months or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
1458213|NCT03288597|Radiation|68Ga-DOTANOC PET/CT and 18F-FDG PET/CT in NEC|At the beginning of the treatment with chemotherapy 4-6 cycles or progression receive 68Ga-DOTANOC PET/CT and 18F-FDG PET/CT
1458214|NCT03288584|Drug|Tocilizumab (Actemra®)|Inhibition of Interleukin-6 activity by tocilizumab (Actemra®) 150mg od, sc injection
1458215|NCT03288584|Drug|Other biological agent|Other biological agent (TNFa inhibitor, abatacept, rituximab, IL-1Ra)
1458216|NCT03288584|Drug|Corticosteroid and non-biological agents.|Enhanced treatment with corticosteroid and non-biological agents.
1458217|NCT03288571|Biological|Wharton Jelly Mesenchymal stem cells|Wharton Jelly Mesenchymal stem cells will be injected in the renal parenchyma
1458218|NCT03288558|Other|A comprehensive perioperative mechanical ventilation strategy|"1) Intervention group.
Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected
Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%
Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)
Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)
For the remaining aspects the mechanical ventilation settings will be the same as in the control group.
Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass"
1458224|NCT03288506|Behavioral|Google Hangout (VC) group|Feasibility and acceptability of online peer support groups for adults with depression. Groups will be delivered using video-conferencing technology (Google Hangouts).
1458225|NCT03288493|Biological|P-BCMA-101 CAR-T cells|"P-BCMA-101 is an autologous, principally Tscm, CAR-T cell product (also called called a CARTyrin T cell product) targeting the myeloma selective protein BCMA. P-BCMA-101 cells are produced using a non-viral vector carrying the gene for an anti-BCMA Centyrin-based (small, fully human binding domain, designed to increase T cell persistence and decrease exhaustion) chimeric antigen receptor (CAR). Secondary to the large carrying capacity of the non-viral vector, P-BCMA-101 cells carry two additional genes, a selection gene used to manufacture a purified product and a safety switch gene to allow the cells to be eliminated if desired."
1458226|NCT03288480|Drug|PT-112|This is a single arm study
1458227|NCT03288467|Procedure|Root canal treatment with 5% NaOCl|
1458228|NCT03288467|Procedure|Root canal treatment with 1% NaOCl|
1458229|NCT03288454|Drug|Ciraparantag|Reversal of riva apixaban-induced anticoagulation via dose of ciraparantag or placebo
1458230|NCT03288454|Drug|Placebo|Reversal of riva apixaban-induced anticoagulation via dose of ciraparantag or placebo
1458231|NCT03288441|Drug|Hold|Hold antithrombotic therapy
1458232|NCT03288441|Drug|Dose change|Modification of antithrombotic medication dose
1458233|NCT03288441|Drug|Change Drug|Change in type of antithrombotic therapy
1458234|NCT03288441|Biological|Transfuse platelets|Use platelet transfusion
1458235|NCT03288441|Drug|No change|Continue antithrombotic therapy without change and without platelet transfusion
1458236|NCT03288441|Device|Mechanical measures|Mechanical measures to reduce thrombotic risk including: IVC filter insertion, Intermittent Pneumatic Compression (IPC), Removal of Central venous catheter
1458237|NCT03288428|Drug|Nalbuphine|patient controlled analgesia with Nalbuphine
1458238|NCT03288428|Drug|Morphine|patient controlled analgesia with Morphine
1458239|NCT03288402|Other|ongoing fasted state, intake of caffeine containing beverages or 5-item English breakfast|effects of ongoing fasted state; or intake caffeine containing beverages; or 5-item English breakfast on plasma CgA measurements, in series blood tests every 30 min over 180 min
1458242|NCT03288363|Device|tDCS|"20 sessions of tDCS stimulation with the apparatus DC-Stimulator Plus (Neuroconn) → Evaluations before the cure, after the treatment (D12), then at 6, 12 and 24 weeks :
EGS, ADAS-Cog, MMSE
Motor assessment and fragility
Blood collection for biological collection
Statement of drug treatment received"
1458243|NCT03288350|Drug|mDCF + Avelumab|Patients will receive neoadjuvant therapy consisting of 4 cycles of avelumab added to the modified chemotherapy regimen of docetaxel, cisplatin, 5-fluorouracil (mDCF), followed by surgery and assessment of pathologic response. Then they will receive 4 cycles of adjuvant therapy of mDCF and avelumab.
1458244|NCT03288324|Drug|Tofacitinib|Tofacitinib 5 mg twice daily
1458245|NCT03288311|Other|Protocolized post-extubation respiratory support|Qualifying patients undergoing extubation in an ICU bed randomized to post-extubation respiratory support will receive either non-invasive ventilation or high flow nasal cannula (as determined by a prespecified protocol and applied by a respiratory therapist) from the time of extubation until 5AM the following morning
1458246|NCT03288311|Other|Usual Care|Qualifying patients undergoing extubation in an ICU bed randomized to usual care will receive standard-of-care treatment, which may include post-extubation respiratory support at the discretion of their clinical team.
1458247|NCT03288298|Drug|luteolin|flavonoid natural extract
1458248|NCT03288298|Drug|nano-luteolin|nanoparticles of luteolin
1458249|NCT03288272|Radiation|Whole Brain Radiotherapy|Radiotherapy of the whole brain
1458250|NCT03288272|Other|Best Supportive Care|Best Supportive Care including nutrition, pain medication, steroids as needed
1458251|NCT03288259|Procedure|transnasal endoscopy|Transnasal endoscopy without sedation with ultra-thin endoscopes in patients who are candidates for bariatric surgery
1458252|NCT03288259|Drug|Local Anesthetics,Topical|Will be carried out topical anesthesia of the pharynx with lidocaine spray (10%) 6 puffs and instillation of nasal vasoconstrictor 4 drops.
1458253|NCT03288246|Diagnostic Test|point-of-care viral load test|A point-of-care viral load test returns viral load test results within 90 minutes.
1458254|NCT03288233|Diagnostic Test|Breath carbon monoxide measurement|Participants will be asked to breath in designed breathing circuits or hold their breath for short period of time and then their breath samples will be collected in special bags and the carbon monoxide and carbon dioxide will be measured with electrochemical techniques.
1458255|NCT03288194|Behavioral|Problem-Solving Treatment|
1458256|NCT03288194|Behavioral|Time Management|
1458257|NCT03288181|Device|Muscle Stretch|The splint will be applied to the affected leg as per the protocol for 30 minutes per day, 5 days per week for 4 weeks.
1458258|NCT03288155|Dietary Supplement|Cocoa|Participants will receive either a high flavonoid cocoa or a low flavonoid placebo cocoa.
1458259|NCT03288142|Other|Lark HTN Pro|The intervention group will have the HPCP installed on their iOS device during their initial office visit (screening/baseline) and will successfully take a reading from their HBMD
1458260|NCT03288129|Drug|Perampanel|film-coated tablets
1458261|NCT03288116|Diagnostic Test|Scheimplug imaging and contrast and sensitivity test|examination of the patients using the schemiplug imaging with evaluation of keratometric parametres ,pachymetric parametres ,elevation parameters.
1458262|NCT03288103|Drug|Growth hormone|Single dose of daily growth hormone regimen. Dose will be 50 micrograms/kg/day.
1458263|NCT03288090|Other|FSS: Fatigue Severity Scale|Fatigue scale with 9 items rated from 1 to 7, assessing physical fatigue, fatigue in the psychosocial environment and fatigue in general (3 items in each category).
1458264|NCT03288090|Other|Neuropsychological evaluation battery|A standardized French neuropsychological battery for the cognitive evaluation of stroke patients.
1458299|NCT03287791|Drug|Azelaic acid (Finacea®) Foam|Brand Product
1458300|NCT03287791|Drug|Generic Azelaic Acid Foam|Generic formulation of the brand product
1458301|NCT03287791|Drug|Vehicle Foam|Placebo. Has no active ingredient
1509141|NCT02901561|Drug|misoprostol 400|
1458265|NCT03288090|Other|Other functional scores|Rankin Score, Instrumental Activities of Daily Living (IADL) Score, Rivermead Mobility Index (RMI) scale, Hospital Anxiety Depression scale (HAD) scale for depression / anxiety, Stroke Specific Quality of Life scale for quality of life, Quality Index of Pittsburgh Sleep (PSQI), Vertical Analog Visual Scale for Pain and Vertical Digital Visual Scale
1458270|NCT03288051|Other|Fluid management|Primary fluid admission: 1 mL/bodyweight kg/ hour crystalloid. If Pulse pressure variation is lower than 10%; 250 mL/15 min of colloid or crystalloid is administered depending on randomization.
1458271|NCT03288051|Drug|Norepinephrine|Norepinephrine is administered if Mean arterial pressure drops below 65 mmHg. Mean arterial pressure must be maintained above 65 mmHg. Norepinephrine is titrated accordingly.
1458272|NCT03288051|Drug|Dobutamine|Dobutamine is administered if Cardiac index drops below 2.5 L/min/m2. Cardiac index must be maintained above 2.5 L/min/m2. Dobutamine is titrated accordingly.
1458273|NCT03288038|Drug|Rosuvastatin|
1458274|NCT03288038|Drug|Ezetimibe|
1458276|NCT03287999|Diagnostic Test|Thrombophilia screen|Thrombophilia screen (including antithrombin activity (AT:Ac), protein S antigen (PS:free), protein C activity (PC:Ac) , genetic analysis for FV Leiden and Prothrombin 3'UTR mutations and screening for lupus anticoagulant.
1458277|NCT03287999|Diagnostic Test|Initiation pathway analysis|Evaluation of inter-individual variability in regulation of TF.VIIa.Xa.TFPI complex (tissue factor, activated Factor VII, activated factor X, tissue factor pathway inhibitor)
1458278|NCT03287986|Other|MRI|Structural and functional sequences
1458279|NCT03287973|Behavioral|Lifestyle modification|A caloric reduction of 10-20% in daily energy intake from the patient's usual diet (i.e. a deficit ≥ 200 calories per day) will be set as the general initial goal, which will be adjusted subsequently based on changes in body weight with target body mass index (BMI) towards 23 kg/m2.
1458280|NCT03287973|Device|Continuous positive airway pressure (CPAP)|Patients randomized into the continuous positive airway pressure (CPAP) group in each arm will be interviewed by the physician on duty and invited to start autoCPAP treatment for 6 months. They will be offered a CPAP education package. Patients will then commence autoCPAP treatment for 6 months at home.
1458281|NCT03287960|Drug|setmelanotide|Once daily subcutaneous injection
1458282|NCT03287960|Drug|Placebo|During the double blind placebo withdrawal period, patients will receive RM-493 or placebo at variable times over an 8 week period
1458283|NCT03287947|Drug|nintedanib|Oral nintendanib, taken twice daily
1458284|NCT03287934|Device|selective laser sintered stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with selective laser sintering technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
1458285|NCT03287934|Device|stereolithographic stent|after planning and virtual implant placement, a guide will be designed and the STL file will be send to prototyping center for printing the guide with stereolithographic technique. during the surgical procedure , the target tooth will be atraumatic extracted, the stent is adapted in its place then implant drilling and placement will be done.
1458289|NCT03287895|Behavioral|Decision Support|A two-part intervention to help patients make better decisions about CPR
1458290|NCT03287882|Dietary Supplement|Multiple micronutrients (UNIMMAP composition)|The intervention is an oral tablet containing 15 different vitamins and minerals at the UNIMMAP composition (includes 30 mg iron, 400 μg folic acid, 15 mg zinc, 2 mg copper, 65 μg selenium, 800 μg RE vitamin A, 1.4 mg vitamin B1, 1.4 mg vitamin B2, 18 mg niacin, 1.9 mg vitamin B6, 2.6 μg vitamin B12, 70 mg vitamin C, 5 μg vitamin D, 10 mg vitamin E and 150 μg iodine). Each tablet is small (approximately 10 mm diameter) and has been procured using the UNICEF supply catalogue. A single MMN supplementation dose will consist of a single tablet.
1458291|NCT03287882|Behavioral|Life skills based education|The life skills based education will be provided bi-monthly in the format of a group session throughout the preconception period. Three topic areas related to empowerment have been prioritized, including preventing early marriage; personal and menstrual hygiene practices; and the importance of nutrition to good health. Integrated within these topics will be messages related to the importance of continuing one's education, mental health, gender norms and equality, decision making, advocacy, resiliency, participation, communication skills, facing challenges, agency, conflict resolution, and the prevention of violence.
1458292|NCT03287869|Drug|Brexpiprazole|Brexpiprazole tablet
1458293|NCT03287856|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of the ALLEGRA Transcatheter Heart Valve in failing surgical bioprosthesis
1458294|NCT03287843|Procedure|Total mesorectal excision before 56 days (4-8 weeks)|Low anterior resection or abdominoperineal resection
1458295|NCT03287843|Procedure|Total mesorectal excision after 56 days (8-12 weeks)|Low anterior resection or abdominoperineal resection
1458296|NCT03287830|Behavioral|Text message influenza vaccine reminders|Text message reminders for second dose of influenza vaccination
1458297|NCT03287817|Biological|AUTO3|Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 50 x 10⁶ to 300 x 10⁶ CD19/ CD22 Chimeric Antigen Receptor (CAR) positive T cells followed by limited duration of consolidation with anti-PD1 antibody (pembrolizumab).
1458298|NCT03287804|Biological|AUTO2|"AUTO2 (APRIL CAR T Cells) Following preconditioning with chemotherapy (cyclophosphamide and fludarabine) patients will be treated with doses from 15 x 10⁶ to 350 x 10⁶ APRIL CAR T Cells.
Following Phase 2 dose determination patients will be treated with selected dose of APRIL CAR T Cells"
1458304|NCT03287765|Drug|18F-AV-1451|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
1458305|NCT03287752|Device|BASKA MASK|Patients will be anesthetized using BASKA mask after lubrication with water soluble lubricant
1458306|NCT03287752|Device|Endotracheal tube|Patients will be anesthetized using appropriate sized cuffed oral endotracheal tube.
1458308|NCT03287726|Dietary Supplement|probiotics|NYCOPRO, a multistrain probiotic (7 strains of Lactobacilli and Bifidobacteria) sold in the Norwegian pharmacies. 2x/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
1458309|NCT03287726|Dietary Supplement|placebo|Placebo 2x/day (one with lunch and one with dinner). 2 text messages daily as a reminder. Follow up meeting at ObeCe (St. Olavs hospital) every month with a research nurse, for weighing, blood pressure measurement and collection of probiotics dose for the following month.
1458310|NCT03287713|Drug|oxygen therapy|conventional nasal prongs vs nasal high flow oxygen during Pulmonary Rehabilitation in Interstitial Lung Disease.
1458311|NCT03287700|Other|No intervention|No intervention will be administered to any group in this observational study.
1947827|NCT03020992|Drug|Certolizumab Pegol|"pharmaceutical form: solution for infusion in prefilled syringe
concentration: 200 mg/mL
route of administration: subcutaneous"
1947828|NCT03019367|Procedure|Umbilical cord milking UCM|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. This procedure infuses a placental transfusion of blood into the preterm neonate and can be done in 15-20 seconds.
1947829|NCT03019367|Procedure|Delayed cord clamping DCC|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
1947830|NCT03014804|Biological|autologous dendritic cells pulsed with tumor lysate antigen Vaccine|Given ID
1947831|NCT03014804|Other|Laboratory Biomarker Analysis|Correlative studies
1458321|NCT03287648|Diagnostic Test|optical coherence tomography and blue-fundus autofluorescence|Simultaneous infra-red and optical coherence tomography (cube and radial pattern) centered on the fovea Simultaneous fundus autofluorescence and optical coherence tomography (radial pattern) centered on the fovea
1458322|NCT03287635|Drug|H.P Acthar Gel 80Unit/Ml Repository Injection|H.P. Acthar Gel (repository corticotropin injection) is an adrenocorticotropic hormone (ACTH) analogue used for: Treatment during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
1458325|NCT03287609|Drug|Evolocumab 140 mg/mL|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
1458326|NCT03287609|Drug|Placebo|Three injections with pre-filled auto-injector pen at day 1 and at week 4.
1458327|NCT03287596|Device|MRI ZTE2 sequence|feasibility of ZTE 2 sequence to quantitatively assess normal and pathological spondyloarthropathy
1458328|NCT03287583|Behavioral|SBIRT for Gambing|The SBIRT intervention uses a brief gambling screening assessment to determine whether or not a participant is at risk for problem gambling. This is followed by a structured short brief intervention to assist people in better understanding their risk for gambling and what they can do to limit that risk.
1458334|NCT03287531|Other|conventional therapy|Exercise therapeutic Ultrasound
1458335|NCT03287531|Other|low level laser therapy|LLLT with the appropriate parameters (904 nm, 8 j/cm2, 250mw) for duration of 20 min with repletion of three treatment sessions per week.
1458336|NCT03287518|Dietary Supplement|WAK2017|WAK2017 is a solution with following active ingredients: Aged Garlic Extract. One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
1458410|NCT03286959|Procedure|PCR with direct composite|
1458337|NCT03287518|Dietary Supplement|Placebo|One (1) ml IP should be taken with breakfast and one (1) ml with supper every day
1458338|NCT03287505|Drug|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 300 and 400mg once in patients with schizophrenia.
1458339|NCT03287492|Behavioral|Question Prompt Sheet (QPS)|QPS given to participant containing relevant questions in diverse aspects of palliative care.
1458340|NCT03287492|Behavioral|General Information Sheet (GIS)|GIS given to participant containing general patient information about palliative care.
1458341|NCT03287492|Behavioral|Questionnaires|"Patients: Questionnaires completed at baseline, after question and answer visit with physician, and at the follow up visit.
Caregivers: Questionnaires completed after question and answer visit with physician."
1458342|NCT03287479|Procedure|Gavi® Vitrification|A closed, semi-automated vitrification system
1458343|NCT03287479|Procedure|Cryotop® Vitrification|An open, manual vitrification system
1458345|NCT03287453|Other|Educational Intervention|View an inflatable colon interactive exhibit, PowerPoint presentation, flip books, and flipcharts
1458346|NCT03287453|Other|Survey Administration|Ancillary studies
1458347|NCT03287440|Behavioral|COPD Wellness|This is low-intensity pulmonary rehabilitation that incorporates exercise, nutrition, patient education, and a support group class.
1458348|NCT03287440|Behavioral|Health Advocate|The Zuckerberg San Francisco General (ZSFG) Hospital Health Advocates program links social needs screening with a tiered referral and linkage process to appropriate resources
1458349|NCT03287427|Drug|TetMYB Vaccine|Weekly intra-dermal injections of either 0.1mg, 0.5mg or 1.0mg on day 1 for week 1 to week 6.
1458350|NCT03287427|Drug|BGB-A317|3 weekly IV injections of 200mg commencing from Week 4.
1458351|NCT03287414|Drug|VAY736|VAY736 administered subcutaneously (s.c.) every 4 weeks
1458352|NCT03287414|Drug|Placebo|Placebo administered s.c. every 4 weeks
1458353|NCT03287401|Device|Electroencephalography|Patients electroencephalogram will be recorded
1458354|NCT03287388|Procedure|No Rocuronium|Phase 1: The patient will undergo a routine MRI-abdomen without neuromuscular blockade: TOF ratio =1.
1458355|NCT03287388|Drug|Rocuronium (moderate NMB)|Phase 2: Rocuronium will be titrated to a moderate NMB (TOF 1-3), monitored by TOF-watch. When an adequate moderate NMB is achieved, the patient will undergo a second MRI-abdomen.
1458356|NCT03287388|Drug|Rocuronium (deep NMB)|Phase 3: The patient receives a bolus of 1.2 mg/kg rocuronium (adjusted to ideal body weight), to assure a deep or intense NMB (PTC 0-1). Then the patient will undergo the final, third MRI scan of the abdomen.
1458357|NCT03287375|Drug|PIPAC|
1458358|NCT03287362|Behavioral|schema therapy|The intervention consists of a seven-week program of schema therapy, which is a further development of cognitive behavioral therapy, designed in a three-phase combined group and single session concept
1458359|NCT03287362|Behavioral|cognitive behavioral therapy|The intervention consists of a seven-week program of cognitive behavioral therapy, which is the current gold standard of treatment
1458360|NCT03287362|Behavioral|individualized supportive therapy|The intervention consists of a seven-week program of individualized supportive therapy, including different therapeutic offers from the clinic and a high frequency of physician contacts.
1458361|NCT03287349|Other|Blood draw|Two 12.5 mL blood draws
1458362|NCT03287349|Other|Photograph|Photograph of severe reaction, will be anonymized
1458363|NCT03287349|Diagnostic Test|Autoimmune testing|Autoimmune testing in patients without prior testing
1458364|NCT03287336|Drug|Tranexamic Acid|Tranexamic acid dosage (5 mg/kg, 10 mg/kg and 15 mg/kg) administered in a dose escalating fashion by cohort with the lowest dose first.
1458365|NCT03287323|Other|Proactive Palliative Care|In the intervention part of the study, enrolled patients will be offered a set of different palliative care interventions, including symptom management, advance care planning, palliative physiotherapy, social and spiritual support, communication with patients and caregivers, in addition to standard intensive care.
1947832|NCT03014804|Biological|Nivolumab|Given IV
1947833|NCT03014804|Other|Quality-of-Life Assessment|Ancillary studies
1947834|NCT03014804|Other|Questionnaire Administration|Ancillary studies
1458369|NCT03287297|Diagnostic Test|OGTT & HBA1c|oral glucose tolerance test & HBA1c: by measuring glycated hemoglobin
1458370|NCT03287284|Device|Low Level Laser Therapy|Low Level Laser Therapy and Resistance Training
1458371|NCT03287284|Behavioral|Resistance Training|Placebo and Resistance Training
1458375|NCT03287258|Other|3 program|The participants will receive 3 programs.The educational pelvic floor dysfunction prevention program, pelvic floor muscle exercise program and perineal massage program will be educated by an investigator during the participant visit 4 weeks before her due date
1458486|NCT03286439|Other|there will be offered a follow up visit|The investigators will offer the patients a follow up visit 3 and 12 months after discharge from the hospital.
1947835|NCT03003390|Drug|Enoxaparin|The clinical nurse will give enoxaparin subcutaneously every 12 hours at the currently used starting dose of 0.75 mg/kg for children ≤2 months old or 0.5 mg/kg (maximum of 40 mg) for older children. The 1st dose will be given <24 hours after insertion of the catheter. Doses will be adjusted to target an anti-Xa level of 0.2-0.5 IU/mL.
1458376|NCT03287258|Other|one program|The participants will receive one program. That is the educational pelvic floor dysfunction prevention program.The instructions of the program will be given by an investigator once during the participant visit 4 weeks before her due date.
1458378|NCT03287232|Drug|Placebo Vaginal Insert|Daily administration of a placebo vaginal insert.
1458379|NCT03287232|Drug|Prasterone 6.5 mg (0.50%) Vaginal Insert|Daily administration of a 6.5 mg (0.50%) prasterone vaginal insert.
1458380|NCT03287219|Drug|Methylene Blue MMX 25 mg modified release tablets|Methylene Blue MMX 25 mg modified release tablets administered with a full dose regimen of a 4-L PEG-based bowel cleansing preparation.
1458381|NCT03287206|Biological|blood samples from children|CGH array, Fragile-X syndrome screening, DI459 panel, WES
1458382|NCT03287206|Biological|blood samples from parents|secondary controls for children's analyses
1458383|NCT03287193|Biological|Blood sample|for patient and its parents
1458384|NCT03287193|Genetic|high-throughput sequencing|exome or whole genome sequencing
1458385|NCT03287180|Behavioral|Adolescent Community Reinforcement Approach (A-CRA)|The A-CRA is a modified version of the Community Reinforcement Approach (CRA) for adolescents and transitional age youth . The A-CRA treatment protocol consists of nineteen procedures designed to promote positive behavior change directed towards prosocial activities and engagement in the individual's community. A community can include but is not limited to: social and peer activities, family interaction, and work or school environments. Some of the highlighted procedures include relapse prevention, sobriety sampling, problem solving, and communication skills. There are also combined parent/and or couples relationship sessions with the young adult. Treatment duration can vary from 12 to 14-weeks depending on the level of family involvement and attendance in joint sessions.
1458386|NCT03287180|Other|Combination of Buprenorphine/naloxone 4/1|Buprenorphine is a partial agonist at mu-opioid receptor, an antagonist at kappa-opioid receptor, and is a Schedule III narcotic. Naloxone is an antagonist at the mu-opioid receptor. Buprenorphine/naloxone requires the use of an induction to avoid the risk of withdrawal. Participants are instructed not to use opioids for at least 10 hours prior to first dose. Once symptoms of withdrawal score a minimum of 7 on the Clinical Opiate Withdrawal Scale (COWS), the first dose is administered. If a patient has gone through withdrawal prior to arrival in clinic and further withdrawal symptoms are not expected, the clinician will do induction as with COWS score of 0. A 4/1 mg dose will be given. Participants will be monitored for an hour. An additional 4/1 mg dose can be provided to a dose that suppresses withdrawal effects. The physician then provides a prescription for 8/2-16/4 mg for Day 2. Doses can be adjusted with a maximum of total 24/6 mg/day. The target daily dose is 16/4 mg.
1458387|NCT03287167|Drug|1 month DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 1 month, after which patients will be given ASA and placebo in next 5 months and then continue on monotherapy with ASA only, unless contraindications for ASA emerge.
1458388|NCT03287167|Drug|6 months DAPT|Subjects will continue DAPT with clopidogrel and Aspirin (ASA) up to 6 months, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
1458389|NCT03287154|Device|Active tDCS stimulations|20 min, 2mA
1458390|NCT03287154|Device|Sham tDCS|20 min, Sham
1458391|NCT03287141|Diagnostic Test|Shuttle walk test|A shuttle walk test was performed without any previous intervention.
1458392|NCT03287141|Device|Noninvasive ventilation (Bi-pap)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
1458393|NCT03287141|Device|Noninvasive ventilation (CPAP)|After 30 minutes of the mentioned intervention, the subject performed a shuttle walk test.
1458394|NCT03287128|Drug|Gemtuzumab Ozogamicin (GO)|patients included in a compassionate patient named program with GO
1458395|NCT03287115|Other|Broccoli consumption|All subjects will eat broccoli on day 11
1458396|NCT03287102|Procedure|Macular hole surgery|Vitrectomy, temporal inverted or complete ILM peeling and gas tamponade
1458397|NCT03287089|Drug|Nitrofurantoin 100 MG|Patients will receive nitrofurantoin 100mg twice daily by mouth for 5 days
1458398|NCT03287089|Drug|Placebo Oral Tablet|Matching placebo
1458399|NCT03287076|Drug|Exenatide Injection|5μg subcutaneously twice daily for five days, commencing within 9 hours of symptom onset
1458400|NCT03287063|Other|Tumor Biopsy|Stereotactic biopsies will be performed prior to resection.
1458401|NCT03287050|Drug|Pembrolizumab|200 mg IV q 21 days
1458402|NCT03287050|Radiation|SBRT|Stereotactic body radiation therapy (SBRT) administered between the second and third doses of pembrolizumab. SBRT dose and fractionation will be at the discretion of the treating radiation oncologist, but will be selected to respect the normal tissue tolerance of adjacent organs at risk.
1458403|NCT03287037|Device|tDCS over DLPFC|We applied tDCS over dorsolateral prefrontal cortex (DLPFC) for these depressed patients. Direct current (DC) generated by a DC stimulator (Eldith DC stimulator: www. neuroconn.de/dc-stimulator_plus_en/) was bilaterally delivered through a pair of saline-soaked surface sponge electrodes (35 cm2). The anodal electrode was placed over the left dorsolateral prefrontal cortex (F3, International EEG System 10-20) and cathode electrode over F4. Stimulation was applied at an intensity of 2 mA for 20 min, twice-daily on 5 consecutive weekdays. The twice daily sessions were separated by at least 3 hours. All patients were maintained on their treatment throughout the study period.
1458404|NCT03287024|Device|BeGrow Stent System|All enrolled subjects will undergo primary stenting of the target lesion by placement of the BeGrow Stent System
1458405|NCT03287011|Other|Shoplaq toothpaste|"ACTIVE INGREDIENT Sodium Monofluorophosphate 1000 PPM INGREDIENTS Precipitated Calcium Carbonate, Sorbitol, Glycerin, Precipitated Silica, Sodium Carboxy Methyl Cellulose, Sodium Benzoate, DM Water, Colour CI-45410, Holy Basil Oil, Neem Oil, Citrus Oil, Thymol Oi, Clove Oil, Piper Betel Leaf Oil, Tea Tree Oil, Eucalyptus Oil, Peppermint Oil, Spearmint Oil.
Dye containing tooth paste for disclosing plaque and efficient brushing for better oral health."
1458406|NCT03287011|Other|Colgate toothpaste|fluoridated
1458407|NCT03286972|Device|PET/MRI|Participants will be placed in standard non-ferrous head and neck immobilization devices during PET/MRI (to simulate their anticipated positioning during subsequent CT simulation and treatment). A head/neck PET/MRI (standard bore size, 60 cm) will be performed
1458408|NCT03286959|Procedure|PCR with calcium hydroxide|
1458409|NCT03286959|Procedure|PCR with RMGIC|
1458411|NCT03286946|Procedure|block with Blunt-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge blunt needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
1458412|NCT03286946|Procedure|block with sharp-type block needle.|Under fluoroscopic guidance, cervical transforaminal epidural injections were performed using 22 gauge sharp needle. The needle position was confirmed using biplanar fluoroscopy and 2 ml of nonionic contrast media was injected to detect intravascular injection.
1458413|NCT03286933|Behavioral|yoga|75 minute weekly group yoga classes for 8 weeks. Home program online.
1458414|NCT03286920|Dietary Supplement|Oral nutrition supplement|As for patients in oral nutrition supplement group, in addition to oral natural die, the participants shall receive oral enteral supplement providing 750-1500kcal/d.
1458415|NCT03286920|Dietary Supplement|Tube feeding nutrition supplement|As for patients in tube feeding group, in addition to oral natural die, the participants shall receive Tube feeding nutrition supplement providing 750-1500kcal/d.
1458419|NCT03286881|Other|Brief psychotherapy|"Individual brief psychological intervention by adaptation of the Guide NICE Common Mental Health Disorders (ISBN 978-1-84936-585-7) and the unified protocol for the trasndiagnostic treatment of the emotional disorders of Barlow (Boisseau, Farchione, Fairholme, Ellard, y Barlow, 2010). This intervention is provided by clinical psychologist in secondary care."
1458420|NCT03286881|Other|Extensive psychotherapy|Usual psychological intervention in secondary care provided by a clinical psychologist.
1458421|NCT03286881|Other|Combined intervention|Extensive psychotherapy and medication provided by a clinical psychologist and a psychiatrist.
1458422|NCT03286881|Other|Minimum psychological intervention|Psychoeducation and bibliotherapy provided by a trained general practitioner in primary care.
1458423|NCT03286881|Other|Usual treatment|Medication provided by a general practitioner.
1458424|NCT03286868|Procedure|Total Knee Arthroplasty|Total Knee Arthroplasty
1458425|NCT03286868|Device|Total Knee Arthroplasty with Verasense sensor|Total Knee Arthroplasty with Verasense sensor
1458428|NCT03286842|Drug|Olaparib|Patients will be administered olaparib orally, twice daily at 300 mg. Two (2) 150 mg olaparib tablets should be taken at the same time each morning and evening of every day, approximately 12 hours apart.
1458429|NCT03286829|Drug|"Tesomet High dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
1458430|NCT03286829|Drug|"Tesomet Low dose in fasted condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
1458431|NCT03286829|Drug|Comperator 1 mg tesofensine, 25 mg commercial IR metoprolol, 75 mg commercial ER metoprolol, fasted condition.|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
1458432|NCT03286829|Drug|"Tesomet High dose in fed condition"|To evaluate the PK profile and relative bioavailability of a single dose of the Tesomet fixed-dose combination (FDC) tablet and co-administration of tesofensine plus commercial metoprolol.
1458433|NCT03286816|Drug|SodiumChloride|
1458434|NCT03286816|Drug|Sodium Lactate|
1458435|NCT03286803|Biological|Inactivated Poliovirus vaccine|we will administer either full dose (0.5ml) or fractional dose (0.1ml) of inactivated poliovirus vaccine
1458436|NCT03286790|Other|Data collection on pneumonia events|
1458437|NCT03286777|Dietary Supplement|Placebo|Mannitol and silicon dioxide capsules
1458438|NCT03286777|Dietary Supplement|Native 6-prenylnaringenin|250 mg native 6-PN plus mannitol and silicon dioxide capsules
1458439|NCT03286777|Dietary Supplement|Micellar 6-prenylnaringenin|250 mg 6-PN in a micellar formulation with Tween-80 as adjuvant capsules
1458440|NCT03286764|Drug|Peppermint Oil|
1458443|NCT03286738|Drug|FOLFIRI, target agent|"Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab
Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab"
1458444|NCT03286725|Behavioral|Physical Education (PE) Programme|"A programme of activities for PE lessons has been developed by Oxford Brookes University (in collaboration with Oxfordshire Sport and Physical Activity) to try to optimise the benefit of PE for brain function. Staff from Oxford Brookes University will train PE teachers to deliver this programme.
The Intervention involves roughly 20 minutes of prescribed activities per week, to be delivered within school PE lessons."
1458445|NCT03286712|Drug|Renogen|Administration of erythropietin alpha to see the effect on the hemoglobin level and vascular reactivity
1458485|NCT03286452|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly™ Antimicrobial Wound Matrix consists of a collagen sheet coated with 0.1% polyhexamethylenebiguanide hydrochloride (PHMB) intended for the management of wounds.
1458701|NCT03284606|Device|TAPING|Taping in conjunction with common rehabilitation for hemiplegic patients
1458446|NCT03286699|Behavioral|Dietary Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address eating behaviors. Subjects will also participate in phone calls with the interventionist (~10 minutes). Depending on the week, subjects will have between 10 and 45 minutes of total intervention contact.
1458447|NCT03286699|Behavioral|Physical Activity Intervention|The behavioral weight loss intervention strategies will not be limited to, self-monitoring, goal setting, problem solving, mastery skills, social support, and relapse prevention. Participants will receive a standard behavioral weight control program, delivered on a one-on-one basis. They will attend in-person sessions (~30-45 minutes) with time to: distribute intervention materials, interact with the participant, identify participants that need additional support, and conduct the intervention. Each in-person visit focuses on a specific behavioral topic related to weight loss to address physical activity behaviors. Subjects will also participate in phone calls with the interventionist (~10 minutes). Depending on the week, subjects will have 10 to 45 minutes of total intervention contact.
1458448|NCT03286686|Behavioral|point targets|In the experiences 1 and 2, the participant needs to point different visual targets (LED) in the dark.
1458449|NCT03286686|Behavioral|tactile stimulation|In the experience 3, a tactile stimulation is applied to the middle finger of the 2 hands. The participant needs to indicate into a microphone when he feels the stimulation.
1458450|NCT03286686|Behavioral|visual images|Target dots or visual images are presented on a computer screen. The participant is required to point to the targets or to react as soon as possible by pressing a response button when they are detected.
1458451|NCT03286673|Dietary Supplement|calcium phosphate|
1458452|NCT03286673|Dietary Supplement|Tricalcium Phosphate|
1458453|NCT03286673|Dietary Supplement|Calcium carbonate|
1458454|NCT03286673|Dietary Supplement|Placebo|
1458455|NCT03286660|Diagnostic Test|Chair Rise Tests and short questionnaire|"Exercises consist on a Chair Rise Tests and short questionnaire It is a functional test evaluating the number of chair rise over a given time and / or frequency.
This test is combined with a questionnaire to collect quantitative and qualitative information:
dyspnea and muscular fatigue at rest before the start of the test and at the end of the exercise
Saturation at rest, and at the end of the exercise
the number of total a chair rise"
1458456|NCT03286647|Procedure|Oral hygiene instruction|the participants will receive instructions to perform a satisfatory oral hygiene
1458457|NCT03286634|Drug|Daunorubicin|Given IV
1458458|NCT03286634|Drug|Prednisolone|Given PO or IV
1458459|NCT03286634|Drug|Vincristine|Given IV
1458460|NCT03286634|Drug|Epirubicin|Given IV
1458461|NCT03286634|Drug|E-coli L-asparaginase|Given IM or IV
1458462|NCT03286634|Drug|6-Mercaptopurine|Given PO
1458463|NCT03286634|Drug|Methotrexate|Given IV, PO or IT
1458464|NCT03286634|Drug|Hydrocortisone|Given IT
1458465|NCT03286634|Drug|Cytarabine|Given IV, IT or SC
1458466|NCT03286634|Drug|Cyclophosphamide|Given IV
1458467|NCT03286621|Other|Administration of five eye-tracking paradigms|All subjects will undergo the battery of five eye-tracking paradigms to determine potential markers for autism.
1458468|NCT03286608|Other|observational study (no intervention)|Statistical association between adherence to a pattern of polyphenol intake and the risk to develop dementia and Alzheimer's disease over 12 years
1458469|NCT03286595|Other|Mobi mHealth app|"Mobile application (i.e. the app) that patients interact with via their smartphone to collect daily and weekly survey information. Data is visualized on a clinician-facing Dashboard, which can be used to inform treatment."
1458470|NCT03286582|Drug|AC-203 1% Topical Ointment|AC-203 1% ointment BID (twice daily)
1458471|NCT03286582|Drug|Clobetasol 0.05% Topical Ointment|Clobetasol 0.05% Topical Ointment BID
1458472|NCT03286569|Device|Upper arch Wilson quadhelex appliance|Upper arch Wilson quadhelex appliance
1458475|NCT03286543|Device|SPRINT Beta System|"The SPRINT Beta System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT Beta System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Beta Stimulator)."
1458476|NCT03286530|Drug|Ruxolitinib|"Patients who fulfill eligibility criteria will be entered into the trial to receive Ruxolitinib.
After the screening procedures confirm participation in the research study. The participant will be given a drug diary. The participant will be asked to document information in the drug diary about the study treatment."
1458477|NCT03286517|Biological|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany)|A neurohormone
1458478|NCT03286504|Behavioral|FANMI - Cohort Care|FANMI includes receiving integrated clinical care, group counseling, and social activities in a single session by the same provider to simplify care and strengthen relationships between peers and providers. FANMI groups consist of 5-8 adolescents meeting once per month.
1458479|NCT03286491|Diagnostic Test|Further cardiac imaging|Study patients will be reviewed whether they will have coronary interventions in 30 days
1458480|NCT03286478|Behavioral|Mindfulness|Mindfulness-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
1458481|NCT03286478|Behavioral|Dissonance|Dissonance-based body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
1458482|NCT03286478|Behavioral|Dove Confident Me|Dove Confident Me body image intervention to be delivered 1 lesson per week for 5 weeks (5 x 45 minute lessons), by trained school teachers.
1458483|NCT03286465|Device|Pediatric phlebotomy tubes|Use of pediatric size tubes for diagnostic blood collection.
1458484|NCT03286465|Device|Adult phlebotomy tubes|Use of adult size tubes for diagnostic blood collection.
1458488|NCT03286413|Procedure|microwave ablation|Microwave ablation and cryoablation are both thermal ablation techniques for minimally invasive treatment of breast tumor. They are performed percutaneously by ultrasound guidance.The tumor can be completely killed without injurying adjacent tissue.
1458490|NCT03286387|Other|Functional brain imaging without any contrast agent|"During the fMRI protocol, the subject will perform the retrieval tasks while whole-brain activity will be recorded using Echo Planar Imaging (EPI) that measures the Blood Oxygen Level Dependent (BOLD) signal (2x2x2 isotropic voxels, Echo Time (TE) = 30 ms, Repetition Time (TR) = 2.5 sec). The functional session will be subdivided into several parts (Runs, duration: 10-15 min). Together with the functional data, the protocol will include a structural scan (T1 weighted, 1x1x1 mm voxels; duration 5-7 min) and a field mapping sequence (duration: 1 min)."
1458491|NCT03286374|Behavioral|Occupational rehabilitation|"The participants in the occupational rehabilitation program get both practical and theoretical intervention in groups. Four main interventions; cognitive therapy, physical activity, diets and training in work-oriented approach. The rehabilitation stay is as followed:
Four weeks with an institutional stay at Muritunet (BL)
Follow-up;
Eight weeks, telephone contact between therapist at Muritunet and the participant.
16 weeks, video conference on SKYPE between all the participants and a therapist. Lecture on diets.
28 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T1)
40 weeks, telephone contact between therapist at Muritunet and the participant.
52 weeks, Follow-up at Muritunet. Central themes that day is education, conversation, physical test, and forms. (T2)"
1458492|NCT03286361|Device|BeGraft Peripheral Plus Stent Graft System|Patients will be treated with the BeGraft Peripheral Plus Stent Graft System
1458493|NCT03286335|Radiation|Proton Radiation|Radiation treatment
1458494|NCT03286322|Other|manuel therapy cervical spine|the manuel therapy in physiotherapy is focused on the cervival spine
1458495|NCT03286322|Other|control group|the manuel therapy in physiotherapy is classic and not focused on the cervival spine
1458496|NCT03286309|Device|soft robot hand system|subjects will wear the soft robot hand system and receive 60 minutes (including preparation time) hand exercise.
1458497|NCT03286296|Biological|LZM009,recombinant humanized anti-PD-1 monoclonal antibody for injection|LZM009 doses of 1, 3, and 10 mg/kg will be administrated intravenously on day 1 and 29 and every 3 weeks thereafter until disease progression or intolerable toxicity, withdrawal of consent, or end of study
1458498|NCT03286283|Device|J-Plasma|Dermal resurfacing procedure with J-Plasma.
1458499|NCT03286257|Behavioral|Exercise Intervention|A partially supervised 16-week moderate intensity exercise intervention consisting of 3-5 sessions per week.
1458500|NCT03286244|Drug|CM082 plus paclitaxel|"CM082 treatment: A treatment cycle is defined as 28 days. Oral CM082 tablets was given once daily for 3 weeks followed by 1-week break with escalating dose (100 mg, 150 mg and 200mg).
Drug: Paclitaxel Paclitaxel 80 mg/m2 will be administrated by intravenous injection on days 1, 8, 15 of a 28-day cycle for no more than 6 cycles."
1458501|NCT03286231|Diagnostic Test|CT imaging|Contrast-enhanced CT imaging of the pelvis in prone and jackknife positions
2010446|NCT02960555|Drug|Isatuximab|Isatuximab 20 mg/kg by vein on Days 1, 8, 15, and 22 during Cycle 1. Isatuximab 20 mg/kg by vein every other week on days 1 and 15 during Cycles 2 to 6. Isatuximab 20 mg/kg by vein every month on Day 1 during Cycles 7 to 30.
2010447|NCT02960555|Behavioral|Phone Calls|After last dose of study drug, participant called by a member of the study staff. Participants receive these calls at least every 6-12 months after the end of the study.
2010448|NCT02960555|Drug|Diphenhydramine|25 or 50 mg by vein once before Isatuximab infusion.
1458505|NCT03286205|Drug|IV iron|IV iron infusion based on weekly or every 3 week dosage.
1458506|NCT03286192|Behavioral|compassion cultivation training|Eight 2-hour group sessions that provide a structured and systematic way of cultivating daily-life skills needed to strengthen qualities of compassion, empathy, and kindness for oneself and others.
1458507|NCT03286179|Other|modified HEART score and/or Emergency Department Assessment of Chest pain Risk Score (EDACS)|Provision of estimated risk for major cardiac events at 60 days based on the modified HEART and/or EDACS, using KPNC specific estimates derived from an internal validation study
1458508|NCT03286153|Other|Ideal Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on ideal body weight. For participants age 12-19, ideal weight is calculated using the McLaren method. For participants age 20 and over, ideal weight is calculated using the following equation: [50kg + (2.3kg*every inch over 5 feet)].
1458509|NCT03286153|Other|Actual Body Weight First|Randomized to receive 50 U/kg (+/- 20%) of the factor product participants routinely use based on actual body weight.
1458510|NCT03286140|Procedure|Early endovenous ablation|
1458511|NCT03286140|Procedure|Delayed endovenous intervention|
1458512|NCT03286127|Other|specialized palliative care|specialized palliative care provided in different settings
1458514|NCT03286101|Drug|0.5% Ivermectin lotion|The intervention is composed of a single application of the 0.5% ivermectin lotion.
1458515|NCT03286101|Drug|Vehicle|The intervention is composed of a single application of the vehicle control.
1458516|NCT03286088|Diagnostic Test|TransEsophageal Echocardiography and TransEsophageal Echocardiography|imaging as standard practice
1458517|NCT03286088|Diagnostic Test|Cardiac Magnetics Resonance|imaging as standard practice
1458518|NCT03286088|Diagnostic Test|MitraClip|imaging as standard practice
1458519|NCT03286075|Device|tDCS Anode session|"The aim of this unique anode tDCS session is to study the possibility of enhancing emotional processing, attentional resources and physiological responses in healthy subjects.
The arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.
Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
1458542|NCT03285893|Other|oral cell DNA adducts|oral cells will be collected, DNA isolated, and analyzed for adducts
1458543|NCT03285880|Behavioral|Napping|Children nap during the nap opportunity
1458520|NCT03286075|Device|tDCS Cathode session|"The aim of this unique cathode tDCS session is to study the possibility of inhibiting or altering emotional processing, attentional resources and physiological responses in healthy subjects.
This arm will be compared to the other 2, enabling us to compare different tDCS stimulation modes.
Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Cathode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and anode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)."
1458521|NCT03286075|Device|tDCS Placebo session|"This arm will help compare the effects of stimulation versus no stimulation on emotional processing, attentional resources and physiological responses.
Stimulation will be performed using a tDCS stimulator (Neuroconn or Neuroelectric tDCS stimulator) with two 7×5 cm (35 cm2) sponge electrodes soaked in a saline solution (0.9% NaCl) Anode will be placed over the left dorsolateral prefrontal cortex (F3 according to the international EEG system) and cathode over the right dorsolateral prefrontal cortex (F4 according to the international EEG system)"
1458522|NCT03286062|Combination Product|Agent VM110 and laproscopic infra-red probe|Patients with evidence of persistent or recurrent ovarian/ pancreatic cancer would be injected with escalating dose of VM110 24 hr prior to laproscopic surgery to collect biopsy sample in white light and by visualizing the cancerous mass using the laproscopic infra red probe
1458523|NCT03286036|Other|biomarkers|This is an observational study, there is no intervention
1458524|NCT03286023|Radiation|stereotactic radiotherapy|stereotactic radiotherapy for brain metastases
1458525|NCT03286010|Behavioral|Women@Heart Program|The Women@Heart program is taught by trained peer leaders. Session content is focused on: emotional support (sharing your story, road to recovery, exploration of feelings, coping with changes, emotional management, coping with distress, effective communication, empowerment); informational support (self care behaviours, risk factor education and management, health care system and community resource navigation); and appraisal support (goal setting, action planning, problem solving, relapse prevention). In total there are 12-biweekly sessions offered over a 24-week period.
1458526|NCT03285997|Biological|GC3110A|A single 0.5mL dose intramuscular injection
1458527|NCT03285997|Biological|GCFLU Pre-filled syringe inj.|A single 0.25mL dose intramuscular injection
1947837|NCT02990091|Drug|Omega 3 fatty acid|LOVAZA is an FDA approved drug that is lawfully marketed in the United States by GlaxoSmithKline. There is no intent to use the results of this study to support a change in the labeling or the advertising of the drug. The highest dose administered for the study is the recommended prescribed dose of LOVAZA, therefore not creating greater risk. The patient population and route of administration will not significantly increase the risk associated with the use of the product. We will be using this drug under an IND exemption.
1458532|NCT03285971|Other|Electronic CPP pager alert|Anesthesia providers will receive a pager alert when CPP decreases beow 60 mmHG (median value over 5-minute epochs)
1458536|NCT03285945|Drug|PET3|Prednisolone 60 mg daily for 3 days
1458537|NCT03285945|Drug|PET10|Prednisolone 60 mg daily for 10 days
1458540|NCT03285919|Device|Balance Assessment Robot (BAR™)|"The BAR™ has got six degrees of freedom (DOF) that interface to the pelvis of a walking subject. Five DOFs (translation of pelvis in sagittal, lateral and vertical directions; pelvic rotation and pelvic list) are actuated and admittance-controlled, providing transparent haptic interaction with negligible power transfer; the remaining DOF (pelvic tilt) is passive. The BAR™ is capable of delivering perturbations in the directions forward/backward and left/right, but for the purpose of this study only outward perturbations in the frontal plane were considered."
1458541|NCT03285906|Drug|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
1458545|NCT03285854|Diagnostic Test|Collection of blood, urine and stool samples|Collection of blood, urine and stool samples, diet diary and bone scans
1458546|NCT03285841|Device|OCT-AFI|Both groups will be imaged with the OCT-AFI device. Imaging will not influence standard of care biospies, treatment and procedures.
1458547|NCT03285828|Behavioral|motivationnal interviewing training|"The students received three four-hour sessions of basic motivationnal interviewing training :
Viewing and commenting on video clips illustrating motivational and non-motivational doctor-patient interactions.
Lectures and the distribution of memory aids.
Practical exercises: making reflections, asking open questions; exploring ambivalence; dealing with resistance; expressing empathy, summarising.
Role-playing, based on several situations, each involving two students. The investigators deliberately chose a non-medical situation (conflict between a mother and a student asking her for pocket money to go out for fun, the day before a university examination) for the first situation. All the other situations concerned changes to healthier behaviour in a medical setting, but with a goal different from that used for the first or the second simulated interview before motivationnal interviewing training."
1458548|NCT03285815|Device|Proton Therapy|
1458549|NCT03285802|Drug|Letrozole|Letrozole 2.5mg will be taken daily q 30 days
1458550|NCT03285802|Drug|Everolimus|Everolimus 10mg daily q 28 days
1458551|NCT03285789|Other|Passing tests in dyslexics with reduced eva|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it orally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial tests to judge his visuo spatial abilities.
All of these tests will be made during an unique visit of 1h30."
1458552|NCT03285789|Other|Passing tests in controls|"Visual attention span : the subject see a 5 letters strings during 200 ms and he has to report it verbally whatever the order Visual search : the subject has to find a target among distractors (24 or 48) in different conditions of stimuli (conjunction feature or separable feature) and different conditions of view (full view or reduced view with the moving window paradigm) Elementary visuo spatial perception: the subject passes 6 visuo spatial test to judge his visuo spatial abilities.
test de l'alouette : reading test during 3 minutes, we note the number of word read and the errors. We obtain lexical age.
All of these tests will be made during an unique visit of 1h30."
1947838|NCT02990091|Dietary Supplement|Safflower seed oil|Safflower seed oil is a commonly used dietary supplement. It has been chosen to be used as a comparative to the LOVAZA because of its non-omega-3 fats. There will be no increased risk due to dosage, route of administration, or patient population.
1458554|NCT03285737|Dietary Supplement|Whey|Supplement provided twice daily in 30g doses
1458555|NCT03285737|Dietary Supplement|Collagen|Supplement provided twice daily in 30g doses
1947839|NCT02989636|Other|Laboratory Biomarker Analysis|Correlative studies
1947840|NCT02989636|Biological|Nivolumab|Given IV
1947841|NCT02989636|Radiation|Stereotactic Radiosurgery|Undergo SRS
1947842|NCT02987725|Behavioral|Hypnosis|A 30-minute Hypnosis session with a trained clinician focused on relaxation and hypnotic suggestions for pain relief and reduced stress responses.
1458560|NCT03285698|Device|DermACELL®|DermACELL® is a bilayer wound matrix made out of human tissue and is applied to the wound in standard of care fashion.
1458561|NCT03285698|Device|Integra®|Integra® is a bilayer wound matrix made out of bovine tissue and is applied to the wound in standard of care fashion.
1458562|NCT03285685|Device|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left M1 and cathodal over supraorbital contralateral area
1458563|NCT03285685|Device|active tDCS|Duration: 20 minutes; Intensity: 2 mA; Placement: anodal over left DLPFC and cathodal over supraorbital contralateral area.
1458564|NCT03285685|Device|sham tDCS|The procedure is the same as for active tDCS anodal over left M1 and cathodal over supraorbital contralateral area, but the in the placebo tDCS the stimulation is non-active / sham.
1458565|NCT03285672|Drug|FP-101|Dose 1
1458566|NCT03285672|Drug|Placebo Comparator|Dose 1
1458567|NCT03285659|Other|Intervention: INDI Implementation|Implementation of a collaborative care model in the context of primary care to manage depression
1458568|NCT03285646|Drug|Fasinumab|Subcutaneous (SC) every 4 weeks (Q4W)
1458569|NCT03285646|Drug|Placebo|Subcutaneous (SC) every 4 weeks (Q4W)
1458570|NCT03285633|Behavioral|Cognitive Behavioral Mutli-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via (Cognitive Behavioral Multi-Symptom management (CBT) four one hour sessions.
1458571|NCT03285620|Drug|AL-034|Drug AL-034
1458572|NCT03285620|Drug|Placebo|Placebo
1458573|NCT03285607|Biological|MCS110|-MCS110 is an IgG1/κ humanized monoclonal antibody directed against human macrophage colony stimulating factor
1458574|NCT03285607|Drug|Doxorubicin|-Standard of care
1458575|NCT03285607|Drug|Cyclophosphamide|-Standard of care
1458576|NCT03285607|Drug|Paclitaxel|-Standard of care
1458577|NCT03285607|Procedure|Bone marrow aspirate|-Time of enrollment and at time of surgery
1458578|NCT03285607|Procedure|Peripheral blood samples|-Time of enrollment and at time of surgery
1458579|NCT03285607|Procedure|Tumor tissue|-Time of enrollment and at time of surgery
1947843|NCT02987725|Behavioral|Attention Control|A 30-minute historical story read by a research clinician.
1947844|NCT02986373|Biological|risankizumab|Risankizumab administered by subcutaneous injection.
1947845|NCT02985762|Drug|EXPAREL|
1458583|NCT03285581|Device|arm-1|Subject(s) will receive 2 RF treatments
1458585|NCT03285555|Device|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
1458586|NCT03285555|Device|VICRYL|Vicryl #1
1458587|NCT03285542|Device|DERMABOND|DERMABOND PRINEO (Ethicon, Johnson and Johnson, Somerville, New Jersey)
1458588|NCT03285542|Device|Staples|staples for skin closure
1458589|NCT03285529|Device|STRATIFIX|STRATIFIX symmetric PDS Plus; Stratifix knotless suture
1458590|NCT03285529|Device|VICRYL|Vicryl #1
1509438|NCT02899169|Drug|Hydroxyurea|
1458591|NCT03285516|Behavioral|Safety Aid Reduction Treatment|START includes many of the key elements found in empirically supported treatments for emotional disorders including a) psychoeducation regarding the nature of distress and b) exposure to internal sensations and external situations that are connected to one's distress response via identification and reduction in safety aids. Safety aids discussed in the current protocol include cognitive avoidance, situational avoidance, checking behaviors, reassurance seeking, avoidance of bodily sensations, companions, and use of alcohol and other substances.
1458592|NCT03285503|Drug|Aripiprazole IM Depot|administration of Aripiprazole IM Depot formulation at doses of 400 mg for 5 times in patients with schizophrenia.
1458593|NCT03285490|Drug|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical AK on the face or scalp.
1458594|NCT03285490|Drug|Placebo|Vehicle Ointment wil be used in subjects with Clinically typical AK on the face or scalp.
1458595|NCT03285477|Drug|KX2-391 Ointment 1%|The experimental drug, KX2-391 Ointment 1% will be used in subjects with Clinically typical AK on the face or scalp.
1458596|NCT03285477|Drug|Placebo|Vehicle Ointment wil be used in subjects with Clinically typical AK on the face or scalp.
1458597|NCT03285464|Other|Triplanar Rotary Resistance|Trunk group will strengthen the hip using the trunk as a lever to access the hip. The hip group will use femur as the lever to strengthen the hip.
1458598|NCT03285451|Diagnostic Test|submental ultrasonography|Submental ultrasound, the noninvasive and convenient tool, has been widely applied to measure the tongue base thickness in patients with obstructive sleep apnea, so as to predict the severity and relationship with upper airway collapse.
1458601|NCT03285425|Other|Natural history|Parent interview
1458602|NCT03285412|Drug|Ribociclib|Ribociclib is a drug designed to block certain proteins called cyclin-dependent protein kinases 4 and 6 (CDK4/6). These proteins are needed for cells to divide and may also control the ability of certain cancers to grow.
1458603|NCT03285412|Other|Endocrine therapy|Hormone therapy
1458604|NCT03285386|Behavioral|Priming exercise|"All participants will perform a bout of high-intensity priming exercise for 6 minutes, 10 minutes prior to undertaking an exhaustive exercise test on four separate occasions."
1458605|NCT03285386|Behavioral|Control Exercise|All participants will perform 3 minutes of baseline cycling prior to undertaking an exhaustive exercise test on four separate occasions.
1458606|NCT03285373|Drug|NOAC|New Oral Anticoagulant
1458607|NCT03285360|Combination Product|Sylc|a dry powder (calcium sodium phosphosilicate), based on NovaMin powder. Bottle of small and coarse particles will be used for the treatment
1458608|NCT03285360|Combination Product|fluoride varnish (Bifluorid 10)|It is a rapid- drying suspension of equal amounts of sodium fluoride and calcium fluoride.
1458609|NCT03285347|Device|Computer-based cognitive training|Computer-based cognitive programmes are computer programmes designed as games with the aim of training patients in certain cognitive domains.
1458610|NCT03285334|Device|XP-endo Shaper|mechanical preparation in a 3D manner using Xp-endo Shaper
1458611|NCT03285334|Device|iRace files|rotary mechanical preparation
1458612|NCT03285321|Drug|Nivolumab|480mg
1458613|NCT03285321|Drug|Nivolumab|3mg/kg
1458614|NCT03285321|Drug|Ipilimumab|1mg/kg
1458615|NCT03285308|Drug|Relamorelin|Relamorelin 10 μg injected twice daily for 12 weeks.
1458616|NCT03285308|Drug|Placebo|Placebo injected twice daily for 2 weeks or 12 weeks.
1458617|NCT03285282|Procedure|Thoracolumber interfascial plane block|Thoracolumber interfascial plane block versus placebo
1458618|NCT03285269|Diagnostic Test|Ultrasound Protocol|Ultrasound of the inferior vena cava, heart and lungs.
1458619|NCT03285269|Device|Bioreactance|Bioreactance assessment using Cheetah Bioreactance Device (FDA Approved). Bioreactance is a non-invasive measure of cardiac output.
1458620|NCT03285269|Procedure|Passive Leg Raise|A passive leg raise involves placing the patient supine and raising the legs to simulate an intravenous fluid bolus.
1458621|NCT03285256|Behavioral|Experimental memory training|The experimental memory training will be implemented as a computer program that uses state-of-the-art immersive technology to simulate prospective memory in everyday life in which one must remember to carry out tasks throughout the day, while engaging in current ongoing activity. Participants are asked to imagine they have a work-at-home job (ongoing activity), which is an independent program (CogMed QM) designed to train working memory, but that they also need to remember to carry out a number of tasks throughout the day. Using a touch screen, participants will need to touch objects in the simulated environment to appropriately interact with these stimuli according to their pre-assigned tasks.
1458622|NCT03285256|Behavioral|Comparator memory training 1|The first comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
1458623|NCT03285256|Behavioral|Comparator memory training 2|The second comparator memory training intervention will utilize the same overall structure and immersive computer environment as the experimental memory intervention, but will not challenge the same aspects of cognition.
1458624|NCT03285243|Device|Monochromatic blue light|Exposure to monochromatic light for the first 30 minutes in the recovery period after anesthesia to assess incidence of emergence delirium as noted by the PAED scale
1458625|NCT03285217|Dietary Supplement|Ensure Plus Advance|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
1458736|NCT03284346|Other|Laboratory Biomarker Analysis|Correlative studies
1458626|NCT03285217|Dietary Supplement|Ensure High Protein|Supplements, labeled only with the name of the participant and his/her identification number, will be provided to the participants in the Translational Research Unit of the Miguel Servet Hospital. Every 2 weeks, changes in body composition, in particular in fat and muscle, will be assessed by bioelectrical impedance analysis (BIA). Likewise they will be asked about compliance and their diets will be controlled by a nutritionist. Fresh stool samples, urine and blood will be collected pre- and post treatment. An extensive bloodwork will be performed at the Clinical Biochemistry Service at the Miguel Servet Hospital (plasma HMB, total cholesterol, triglycerides, LDL&HDL-cholesterol, free fatty acids, glucose, insulin, β-hydroxybutyrate, hs-CRP, and liver transaminases (AST, ALT, GGT).
1458627|NCT03285191|Other|Numerical rating scale|Following the concept elicitation interview, participants will be presented with a list of typical RA symptoms and asked to rank how bothersome each symptom is and how important it would be to improve with treatment on a 1-5 numerical rating scale (NRS).
1458628|NCT03285191|Other|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms using a study-specific application on their own smart device. Up to ten of the thirty interview participants can participate in the app sub study, which is voluntary.
1458629|NCT03285178|Drug|IW-1701|Oral Tablet
1458630|NCT03285178|Drug|Placebo|Oral Tablet
1458631|NCT03285165|Drug|0.2-0.7 mcg/kg/h dexmedetomedine infusion.|patients will receive dexmedetomidine 0.2-0.7 mcg/kg/h infusion for 24h.
1458632|NCT03285165|Drug|10-70 mcg/kg/h propofol infusion.|Patients will receive 10-70 mcg/kg/h propofol infusion for 24h.
1458633|NCT03285152|Other|Ketogenic Diet (KD)|specially-formulated very low carbohydrate meals (KD)
1458634|NCT03285152|Other|Standard Diet (SD)|counseling on maintaining adequate nutritional intake from a normal diet (SD)
1458635|NCT03285139|Behavioral|Cognitive Behavioural Therapy|Cognitive Behavioral Therapy 9 weekly 2-hour group CBT sessions delivered by trained lay peers.
1458636|NCT03285113|Device|GiMer Medical MN 1000 External Stimulator|Trial stimulator to generate pulsed ultrahigh frequency (>200KHz) electrical stimulation, delivered via lead around DRG, in treating pain. Similar with current market available Spinal Cord Stimulators but with a higher stimulation frequency (hundred KHz) range.
1458637|NCT03285100|Diagnostic Test|Venipuncture|"Approximately 6 months after discontinuation of VKAs one additional venipuncture will be performed for determination of dp-ucMGP and desmosine.
At baseline two additional blood collection tubes will be drawn for determination of dp-ucMGP, desmosine and VKORC1 polymorphisms. Since this is during one of the last regular International Normalized Ratio (INR) testing at the anticoagulation clinic, no additional venipuncture has to be performed at this moment."
1458638|NCT03285087|Drug|DEX 0.2 μg/kg/h.|DEX 0.2 μg/kg/h. The dose will be increased in 0.1 μg/kg/h increments to achieve target Richmond Agitation Sedation Scale (RASS) levels of −2 to zero and with a maximum dose of 1.4 μg/kg/h for 24 hours.
1458639|NCT03285074|Other|No intervention|No intervention
1458640|NCT03285061|Device|Deterra Drug Deactivation System|A portable bag that will neutralize and dissolve excess medication, rendering it completely unusable and safe for landfill disposal. The system meets FDA and DEA standards for at home disposal systems.
1458641|NCT03285048|Behavioral|Cognitive Remediation Therapy|Brain HQ is a computer based cognitive training that uses hierarchical adaptive technology to provide challenging and demanding training that is not too frustrating or discouraging. Training includes auditory and visual sensory training, memory and executive function exercises. The Bridging group is based on similar training programs that focus on self-regulation training, problem focused cognitive behavior therapy and compensatory cognitive strategies.
1458642|NCT03285035|Other|administration of questionaires to patients receiving an upper endoscopy with cryotherapy in addition to chemotherapy for esophageal cancer palliation.|Upper endoscopy with cryotherapy using liquid nitrogen.
1458643|NCT03285022|Procedure|Partial caries removel techniques|Removel of all superfacial dentin and leaving the inner affectted dentin
1458644|NCT03285009|Other|Training intervention|"Based on the baseline screening, which is part of the normal prevention routine within the school, all athletes are given individual advice with regard to points of attention within training. For example: those athletes with reduced balance, will get more balance training.
Intervention is individual as said and will be guided and supervised by the physical trainer and medical staff of the school."
1458645|NCT03284996|Device|Doppler ultrasonography|Examination of the whole cases & controls by doppler ultrasound to measure renal resistive index.
1458646|NCT03284983|Other|Suture spacing for wound closure|The wound was divided in half and sutures were spaced 5mm or 10mm apart depending on side. The sutures were removed at 2-week follow-up appointment and photographs were taken. The Patient and Observer Scar Assessment Scale (POSAS) was then performed by both patient and physician.
1458647|NCT03284957|Drug|SAR439859|"Pharmaceutical form: capsule
Route of administration: oral"
1458648|NCT03284957|Drug|palbociclib|"Pharmaceutical form: capsule
Route of administration: oral"
2010449|NCT02960555|Drug|Ranitidine|50 mg by mouth once 30 minutes before Isatuximab infusion.
1458654|NCT03284918|Dietary Supplement|Plant stanol ester|
1458655|NCT03284918|Dietary Supplement|Placebo|
1947846|NCT02985879|Drug|ABBV-8E12|ABBV-8E12 (20 mg/mL) solution for IV infusion
1947847|NCT02985879|Drug|Placebo|placebo solution for IV infusion
1458658|NCT03284892|Other|PED care|A once daily, 7-day PED Care intervention on reducing time to resume oral intake, rates of penetration and intervention at 10 days postextubation, and incidences of 30-day aspiration pneumonia in adult patients with prolonged intubation (≥48 hours)
1458659|NCT03284892|Diagnostic Test|FEES test|Using FEES to see if participants have any aspiration or penetration and the level of it.
1459929|NCT03275064|Biological|LNA043|LNA043 intra-articular injection
1458660|NCT03284892|Other|usual care|usual care means the original care given by the ward the participants stay.
1458661|NCT03284866|Other|Laboratory Biomarker Analysis|Correlative studies
1458662|NCT03284866|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
1458663|NCT03284866|Other|Saline|Given IM
1458664|NCT03284853|Drug|Netarsudil/Latanoprost 0.02%/0.005%|Topical sterile ophthalmic solution
1458665|NCT03284853|Drug|GANFORT®|Topical sterile ophthalmic solution
1458666|NCT03284840|Diagnostic Test|Assessement of nutritional status|Nutritional status for vitamin D, folic acid, vitamin B12 and iron.
1458667|NCT03284840|Diagnostic Test|Thyroid size|Thyroid size by ultrasound.
1458668|NCT03284827|Drug|NOAC|edoxaban (60 mg once daily [OD]) for at least 6 months
1458669|NCT03284827|Drug|DAPT|clopidogrel (75 mg OD) plus acetylsalicylic acid (ASA, 75-100 mg OD) for at least 6 months
1458670|NCT03284814|Dietary Supplement|Single dose intervention with Standard product (SP)|hard capsules, 100 mg
1458671|NCT03284814|Dietary Supplement|Single dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg
1458672|NCT03284814|Dietary Supplement|Single dose intervention with Investigational product (IP)|syrup, 100 mg
1458673|NCT03284814|Dietary Supplement|Multiple dose intervention with Standard product (SP)|hard capsules, 100 mg - 14 days
1458674|NCT03284814|Dietary Supplement|Multiple dose intervention with Comparative product (CP)|soft-gel capsules, 100 mg - 14 days
1458675|NCT03284814|Dietary Supplement|Multiple dose intervention with Investigational product (IP)|syrup, 100 mg - 14 days
1458676|NCT03284801|Other|management of acute disseminating encephalomyelitis|clinical audit on management of acute disseminating encephalomyelitis
1947848|NCT02984384|Drug|Acetylsalicylic acid|The Aspirin intervention will be 81 mg enteral (by mouth, feeding tube or rectal) twice a day with no variation in dosing allowed.
1947849|NCT02984384|Drug|Low Molecular Weight Heparin (LMWH)|The LMWH intervention will be 30 mg enoxaparin subcutaneous (under the skin) twice a day with variations in dosing allowed, per the standard of care at sites, as needed for patients who are very obese or exhibit renal dysfunction.
1947850|NCT02983617|Drug|Tirabrutinib|80 mg (1 x 80 mg or 4 x 20 mg) tablets administered orally once daily
1458681|NCT03284749|Other|Copper impregnated wound dressing|Copper impregnated wound dressing
1458682|NCT03284749|Other|Normal wound dressing|Normal wound dressing
1458683|NCT03284749|Other|Copper impregnated maternity pads|Copper impregnated maternity pads
1458684|NCT03284749|Other|Normal maternity pads|Normal maternity pads
1458685|NCT03284736|Procedure|Resorbable membrane|
1458686|NCT03284736|Procedure|periapical surgery without membrane|after removing pathology and retro-filling the tooth /teeth wit MTA the defect area is left as it is and flap is closed without resorbable membrane.
1458689|NCT03284710|Biological|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane (TM) anchor sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain); formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10^6 cell culture infectious dose (CCID)50 and < 1 × 10^8 CCID50 (nominal dose of 10^7 CCID50) and reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose
1458690|NCT03284710|Biological|Bivalent Subtype C gp120/MF59|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion); delivered as a 0.5 mL IM injection
1458691|NCT03284710|Biological|Bivalent Subtype C gp120 admixed with Al(OH)3 Suspension|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, admixed with Aluminum Hydroxide Suspension (~625 mcg aluminum content); delivered as a 0.5 mL IM injection
1458692|NCT03284710|Biological|Bivalent Subtype C gp120|Consists of 2 subtype C recombinant monomeric proteins, TV1.C gp120 Env and 1086.C gp120 Env, each at a dose of 100 mcg, mixed with sodium chloride for injection, 0.9%; delivered as a 0.5 mL IM injection
1458693|NCT03284697|Procedure|Direct Pulp Capping with Ca(OH)2|Calcium hydroxide powder was mixed with saline and placed over the exposed pulp tissue. The cavities were then restored with resin modified GIC liner followed by composite restoration.
1458694|NCT03284697|Procedure|Direct Pulp Capping With MTA|MTA was mixed using1:3 water/ powder ratio and applied to exposure site. Then cotton pellets soaked in normal saline was placed over MTA and cavity was sealed provisionally with IRM. After 24 hours, the patient was recalled and the cavity was restored with resin modified GIC liner followed by composite restoration.
1458696|NCT03284671|Other|bifocal stimulation with tDCS|Patients will receive an active Treatment with tDCS (10 sessions of 30 mn with an intensity of 2 mA)
2010450|NCT02960555|Drug|Methylprednisolone|100 mg by vein 30 minutes before Isatuximab infusion.
1458700|NCT03284619|Device|Magnetic resonance imager linear accelerator|The MR linear accelerator (MRL) integrates a radiotherapy accelerator and a diagnostic quality 1.5T MRI, enabling soft-tissue visualization during the actual radiation delivery for improved targeting. This enables on-line treatment optimization for precise radiation delivery. Better visualization of the tumour targets and the surrounding healthy tissues, at the exact moment of treatment, makes it possible to adapt the dose to the actual anatomy while optimally sparing normal tissues.
1947851|NCT02983617|Drug|Entospletinib|400 mg (2 x 200 mg) tablets administered orally once daily
1458702|NCT03284606|Procedure|Common rehabilitation|Common rehabilitation for hemiplegic patients
1458703|NCT03284593|Drug|intensive chemotherapy|
1458704|NCT03284593|Drug|Azacitidine|
1458705|NCT03284580|Other|Ergonomic intervention|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
1458706|NCT03284580|Other|Postural plus kinesiotherapy intervention program|An ergonomic intervention program focused to caregivers, including recommendation about how they should help themself and the patients activities at home.
1458707|NCT03284580|Other|Control or conservative intervention|A control or conservative intervention, including general information about stroke disease for the caregivers of these patients
1458708|NCT03284567|Behavioral|Football fitness|"The training will consist of 30 min of warm-up exercises (running, dribbling, passing, shooting, balance and muscle strength exercises), followed by 2 x 15 minutes of 4-7 a-side games.
Training will take place on a natural grass pitch. In adverse weather conditions (i.e., < 5°C or heavy rain) training will be performed indoors"
1458709|NCT03284554|Dietary Supplement|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
1458710|NCT03284554|Dietary Supplement|Non-encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria
1458711|NCT03284554|Dietary Supplement|Placebo|Nutrient not expected to stimulate release of GLP-1 and PYY
1458712|NCT03284541|Behavioral|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
1458713|NCT03284541|Behavioral|Existing Public Health Practice|HIV testing, medication adherence, HIV risk reduction
1458714|NCT03284528|Other|hypothermia therapy|newborn infants with hypoxic-ischaemic encephalopathy are cooled for 72 hours with a target temperature of 33-34°C (whole body cooling).
1458715|NCT03284515|Biological|Vaccination with a pertussis containing vaccine|Vaccination with a pertussis containing vaccine
1458716|NCT03284502|Drug|HM95573, cobimetinib|Drug: HM95573, cobimetinib Regimen: twice daily (BID), continuous dosing for HM95573, once daily (QD) 21 days, 7 days off for cobimetinib
1458717|NCT03284502|Drug|HM95573, cobimetinib|Drug: HM95573, cobimetinib based on the data for safety, tolerability, pharmacokinetics, and anti-tumor activity from the dosing schedules tested in Stage1, a potential RP2D and schedule will be selected for Stage 2.
1458718|NCT03284489|Other|Collection of medical datas from ICU patients|Collection of medical datas from ICU patients with pancreatitis on a secured electronic database
1458719|NCT03284476|Other|Collection of medical data from ICU patients|Medical data collected on a electronic secured data base
1458720|NCT03284463|Drug|Glibenclamide|Glibenclamide is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
1458721|NCT03284463|Drug|Placebo|Placebo is administered with a loading dose of 1.25 mg within 10 hours of stroke onset, orally or through gastric tube, followed by 0.625 mg every 8 hour for 5 days.
1458722|NCT03284450|Other|DPFT|The DPFT described previously (Redding et al., 2009) involves the repetition of a 'dance phrase' representative of contemporary dance, with each phrase separated by a 2 minute rest period. For the present study the originally described test was extended; the adapted protocol involved 10 x 1 minute movement phrases, each separated by 2 minutes rest.
1458723|NCT03284450|Other|SSRS|The SSRS (Howatson & Milak, 2009) involved 15 x 30 m sprints with a rapid 10 m deceleration phase, with each sprint departing every 65 seconds.
1458724|NCT03284437|Behavioral|Early Cognitive Training|Choose level of activity (e.g., coloring, holding objects) based on occupational therapist assessment.
2010451|NCT02959827|Drug|Iodinated contrast agents|Use of iodine contrast agents and doses following the decision of the treating physician.
1458727|NCT03284385|Other|Laboratory Biomarker Analysis|Correlative studies
1458728|NCT03284385|Drug|WEE1 Inhibitor AZD1775|Given PO
1947852|NCT02983617|Drug|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
1947853|NCT02982330|Behavioral|Low Carbohydrate Breakfast|A low carbohydrate breakfast containing <10% carbohydrate, ~75% fat, and 15% protein. Matched for calories to the active comparator arm.
1947854|NCT02982330|Behavioral|Guidelines Breakfast|A low fat breakfast containing ~55% carbohydrate, <30% fat, and 15% protein. Matched for calories to the experimental arm.
1458732|NCT03284359|Behavioral|Pre-Consent Nudge Bundle|The pre-consent nudge bundle survey was developed by the study team and incorporates several behavioral interventions into a bundle of 5 types of nudges: (i) injunctive norms; (ii) descriptive norms; (iii) duty of reciprocity; (iv) self-prophecy; and (v) foot-in-the-door. Injunctive norms involve the perception of what behavior is acceptable, while descriptive norms highlight what behaviors others are engaging in. The duty of reciprocity is the sense that one should repeat pro-social behavior for which they have benefited from. The foot-in-the-door nudge involves asking a participant to perform a small request which has a high consent rate followed by a larger request. The bundle consists of six questions and one statement.
1458733|NCT03284359|Behavioral|Enhanced Active Choice Consent|The enhanced active choice consent includes a nudge whereby the available options for participating in the RCT, YES or NO, highlight the costs and benefits of participating versus not participating, respectively, and participants are required to make an active decision to participate or not by having to sign and date the form next to their choice.
1458734|NCT03284346|Behavioral|Exercise Intervention|Undergo CARE
1458735|NCT03284346|Behavioral|Exercise Intervention|Undergo standard stretching program
1947855|NCT02980068|Drug|Nitrates|1,000 mg/11.8 mmol, oral, on day one, hour zero
1947856|NCT02980068|Drug|Nitrates|1,000 mg/11.18 mmol, oral, on day hour, hour zero
1947857|NCT02975258|Procedure|Blood draw|Blood will be drawn for plasma, serum, and peripheral blood mononuclear cells.
1947858|NCT02975258|Other|Questionnaires|The following questionnaires are administered to participants by study personnel: Gingo Asthma Questionnaire (GAQ) and the Asthma Quality of Life questionnaire (AQL).
1947859|NCT02975258|Procedure|Spirometry|Spirometry is a simple breathing test that measures the amount of air in one's lungs and how well one can move that air by forcefully blowing 3 or more times into a mouthpiece. A series of these maneuvers will be performed under the instruction of a respiratory technician or respiratory therapist.
1458737|NCT03284346|Device|Monitoring Device|Receive Polar heart rate monitor
1458738|NCT03284346|Other|Quality-of-Life Assessment|Ancillary studies
1458739|NCT03284346|Other|Questionnaire Administration|Ancillary studies
1458740|NCT03284333|Device|other|no arm
1458741|NCT03284307|Drug|Dexmedetomidine|20 participants will be administered Dexmedetomidine.
1458742|NCT03284307|Drug|Ketamine|20 participants will be administered Ketamine.
1458743|NCT03284307|Drug|Propofol|20 participants will be administered Propofol.
1458744|NCT03284307|Drug|Sevoflurane|20 participants will be administered Sevoflurane.
1458745|NCT03284294|Drug|Cholecalciferol|cholecalciferol 2000 IU oral daily for 8 weeks
1458746|NCT03284294|Drug|Placebo|Oral placebo daily for 8 weeks
1458747|NCT03284281|Device|Tragus stimulator|Tragus nerve stimulation for at least 8 hours per day for 1 week post discharge.
1458748|NCT03284281|Device|Sham Tragus stimulator|No stimulation will be performed
1458749|NCT03284268|Biological|VCN-01vector|VCN-01 intravitreal injection
1458752|NCT03284242|Procedure|Apheresis|Collect white blood cells to isolate Treg cells for expansion. Once the blood cells are collected the cells will be cultured in the laboratory and will be expanded. After approximately 3 weeks in culture, the cells will have increased in number and be ready for the autologous Treg cell infusion.
1458753|NCT03284229|Device|Excimer Laser Coronary Atherectomy|Excimer Laser Coronary Atherectomy (ELCA ®) uses the high energy, monochromatic light beam to alter or dissolve (vaporize) the plaque without damaging the surrounding tissue. Fiber-optic catheters are used to deliver this light beam. For endovascular applications, Xenon Chloride excimer laser is used and its fiber-optic catheter has multiple small fibers, rather than just a few large fibers, in order to be flexible enough to navigate in the arterial tree.
1458754|NCT03284216|Procedure|Steady-state hyperglycemia|"Experimental diabetic like steady-state hyperglycemia will be induced via a variable-rate intravenous glucose infusion."
1458755|NCT03284216|Procedure|Fluctuating hyperglycemia|"Experimental diabetic like fluctuating hyperglycemia will be induced via repeated intravenous glucose injections."
1458756|NCT03284216|Behavioral|Exercise|Moderate-intensity exercise bout (45-minutes of cycling at 70% of their V̇O2max) at T=5 hours
1458758|NCT03284190|Procedure|Surgery|Surgery
1458759|NCT03284177|Drug|Calcium (13C)Carbonate|Breath test of Calcium (13C)Carbonate on Visit 1 and Visit 3 under fasting conditions.
1458760|NCT03284177|Drug|Gastric acid inhibitors|Another gastric acid inhibitor will be orally administered once daily for 4 weeks after visit 1
1458761|NCT03284164|Drug|Tenofovir Exalidex (TXL)|Drug: Tenofovir Exalidex (TXL)
1458762|NCT03284151|Radiation|Cyberknife|
1458763|NCT03284138|Device|rTMS treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Repetitive Transcranial Magnetic Stimulation (rTMS)
1458764|NCT03284138|Device|placebo treatment|patient will be treated with 10 sessions in 5 days with low frequency (1Hz) of Sham-controlled
1458766|NCT03284112|Behavioral|Old SCHOOL Hip-Hop|"A school-based intervention called Old S.C.H.O.O.L. Hip-Hop (Seniors Can Have Optimal aging and Ongoing Longevity [OSHH]), to educate 4th and 5th grade students (ages 9-11y) about key dementia signs and symptoms, basic pathophysiology of Alzheimer disease, and the importance of early recognition, care-seeking behavior, and preventative measures (lifelong healthy lifestyle decisions). The intervention is delivered in a classroom or school auditorium setting, using an innovative, modular, multimedia program and home-based activities, to increase parental and family dementia literacy."
1458767|NCT03284112|Behavioral|My Pyramid in Egypt|"The program selected for the control arm, My Pyramid in Egypt, will address nutrition, physical activity, and obesity education. This program was selected because nutrition, physical activity, and wellness programs are now being incorporated into New York City public school curriculums as part of a legislative directive. Trained facilitators will conduct My Pyramid in Egypt using Egyptian history as an entry point for the USDA's MyPyramid nutrition program. Students will learn about MyPyramid and MyPlate across the 3-day one-hour-a-day program."
1458768|NCT03284099|Drug|ACEi, ARB|To take the ACEis or ARBs before bedtime instead of in the morning
1458769|NCT03284086|Diagnostic Test|upper-body double-poling|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the upper-body double-poling mode.
1458770|NCT03284086|Diagnostic Test|arm crank ergometry|An incremental peak test to exhaustion and four 5-min submaximal stages were performed in the arm crank ergometry mode.
1458771|NCT03284073|Procedure|Uterus transplantation|Transplantation of the uterus from a live donor and IVF treatment
1458772|NCT03284060|Behavioral|Cognitive remediation program|"Cognitive remediation program is a set of reeducation techniques and aims at restoring or compensating altered cognitive functions such as memory, attentional or executive functions, and social cognition. Therapists help individuals develop new information processing strategies designed to meet their needs and wishes. Specific therapeutic sessions are designed to generalize such strategies to everyday situations to reduce the impact of cognitive deficits on daily life. Thus, social cognitive training therapy helps the development of personal strategies specifically adapted to preserve skills and reduce the difficulties.
16 sessions (45 min) of cognitive remediation with the therapist are proposed, each session is composed of three parts:
pen and paper tasks focusing on specific emotion recognition component (20 min),
computerized tasks focusing on the same process (20 min),
a proposal of a home-based task (during 20 min)."
1458776|NCT03284021|Device|Fractional erbium-glass 1550 nm laser|The fractional erbium-glass 1550 nm laser will be applied to the previously 100 cm2 determined area of the scalp with the following parameters: 5-10 mm tip, 5-10 mJ, pulse energy 500-1500 MTZ/cm2 density, one to twopasses, static mode.
1458777|NCT03284008|Other|Manual manoeuver + stretching|Patients in experimental group will receive, after AWS diagnose, a manual manoeuver to snap the cord, follow by a demonstration and education of the exercise to be made at home.
1458778|NCT03284008|Other|stretching exercise|Patients in control group will receive, after AWS diagnose, just a demonstration and education of the exercise to be made at home.
1458779|NCT03283995|Other|Cardiac Volume Monitoring VolumeView|hemodynamic measure
1458780|NCT03283995|Device|echocardiography|hemodynamic measure
1458783|NCT03283969|Other|Freeze Dried Strawberry Powder|Study participants will be randomized to receive either the freeze dried strawberry powder or the control powder first. They will be instructed to consume 39g of the powder, mixed in water, every day for 4 weeks.
1458784|NCT03283969|Other|Isocaloric powder|Isocaloric powder
1458785|NCT03283956|Device|Patient records|Retrospective analysis of medical records of all patients who underwent DC Bead TACE at National Taiwan University Hospital, National Cheng Kung University Hospital, and Taichung Veterans General Hospital from 2010-2017/7
1458786|NCT03283943|Radiation|Focal radiotherapy|Focal sensitizing radiotherapy will be given at a starting dose level of 24 Gray (6 Gy X 4 fractions), and may be escalated to 32 Gy (8Gy X4 fractions).
1458787|NCT03283943|Drug|Durvalumab|Durvalumab 1500 mg IV every 28 days
1458788|NCT03283930|Behavioral|Active Attention Bias Modification Training|Computer-based attention bias modification training administered at weekly CBT session aimed at re-training attentional biases
1458789|NCT03283930|Behavioral|Placebo Attention Bias Modification Training|Placebo version of a computer-based attention bias modification training administered at weekly CBT session thought to not influence attentional biases
1458793|NCT03283904|Other|Multicomponent physical activity intervention|School-based multicomponent intervention
1458794|NCT03283891|Other|Educational intervention - humanistic nursing practice|"Four educational sessions:
Acquisition of core concepts of caring practice (I)
Acquisition of core concepts of caring practice (II)
Search for meaning: Influencing hope in persons through humanistic practice
Enacting different caring attitudes and behaviours in an intermediary simulation exercise with actor"
1458796|NCT03283865|Diagnostic Test|Ultrasound guidance for caudal block|The attending anesthesiologist will perform or instruct the placement of a caudal block according to their standard of practice. At the time of administration of local anesthetic into the caudal space, the study collaborator (SC) will ultrasound the caudal space keeping the provider placing the block blinded to the imaging. The provider placing the block will inject 0.5mL of preservative free saline. The provider will then be asked to state if they are correctly in the caudal space or not. If the provider feels they are not in the caudal space, they will re-do the procedure. If the provider fails to identify incorrect location and this is noted by ultrasound, the SC will inform the provider to re-do the procedure
1458797|NCT03283852|Genetic|blood sample|search for genetic mutations
1458798|NCT03283839|Diagnostic Test|Posturography|Evaluation of postural control and of orientation function
1458800|NCT03283813|Dietary Supplement|Zinc|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
1458801|NCT03283813|Drug|Placebos|In this placebo Group there will be a supplementation with a product placebo equal to the active product with GOS (Galacto-oligosaccharides) of Pisum sativum(1000 mg) but without Zinc and Myo-inositol.
1458802|NCT03283813|Drug|Myoinositol|In this active Group there will be a supplementation with Zinc (5 mg), Myo-inositol (2000 mg) and GOS (Galacto-oligosaccharides) of Pisum sativum (1000 mg)
1458803|NCT03283800|Other|Copper impregnated compression stocking|Copper impregnated compression stocking
1458804|NCT03283800|Other|Normal compression stocking|Normal compression stocking without copper
1458805|NCT03283787|Device|MicroMatrix® and Cytal™ Wound Matrix 2-Layer|MicroMatrix® and Cytal™ Wound Matrix 2-Layer
1458806|NCT03283787|Device|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT|MicroMatrix® and Cytal™ Wound Matrix 2-Layer plus NPWT
1458807|NCT03283787|Device|Negative Pressure Wound Therapy|Negative Pressure Wound Therapy
1458808|NCT03283774|Other|current clinical practice|quality management (data registration, drug prescription, diagnostic and clinical tests ...), in primary care of patients with diabetes mellitus
1458809|NCT03283761|Drug|Nab-paclitaxel 150 mg/m^2|Stage I (N=12), every 14 days Stage II (N= 25), every 14 days
1458850|NCT03283436|Drug|Kenalog 40|1 mL of triamcinolone (Kenalog 40; 40 mg/mL = 40 mg).
1458810|NCT03283761|Drug|Oxaliplatin 85 mg/m^2|Stage I (N= 12), every 14 days Stage II (N= 25), every 14 days
1458811|NCT03283761|Drug|5-FU 1200 mg/m^2 x 2 D|Stage I (N= 12), every 14 days Stage II (N= 25), every 14 days
1458812|NCT03283761|Drug|Leucovorin 400 mg/m^2|Stage I (N= 12), every 14 days Stage II (N= 25), every 14 days
1458813|NCT03283748|Device|Wearable sensors|Wearable sensors will be given to the participants to be worn and movement data will be collected
1458814|NCT03283735|Behavioral|Elderly Enablement|The information given in this group will result from the knowledge obtained in previous phase of the study in the shape of small leaflets and other information materials to be made according to the best practice, to be given and remembered at scheduled times to the intervention group
1458822|NCT03283670|Drug|Nitrous Oxide 25%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 25% nitrous oxide/50% oxygen/25% nitrogen.
1458823|NCT03283670|Drug|Nitrous Oxide 50%|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at a concentration of 50% nitrous oxide/50% oxygen.
1458824|NCT03283670|Drug|Placebo Gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen.
1458825|NCT03283657|Behavioral|DiRECT|DiRECT participants will meet with a medical assistant (MA) before a routinely scheduled office and formulate a preliminary treatment plan for T2D prevention. Participants will attend their scheduled physician visit, during which they may make a definitive treatment plan to initiate metformin and/or ILI.
1458826|NCT03283657|Behavioral|Usual care (UC)|Standard care with routine medical care.
1458827|NCT03283631|Biological|EGFRvIII-CARs|Gamma-retroviral MSGV1 139 scFv EGFRvIII CAR gene-modified T cells
1458828|NCT03283618|Behavioral|Video Conferencing Group|
1458829|NCT03283605|Radiation|SBRT|SBRT to 2-5 oligometastases will be administered between Cycle 2 and 3 of durvalumab and tremelimumab. All SBRT will be completed within a 3-week period.
1458830|NCT03283605|Drug|Durvalumab|Durvalumab (1500 mg IV q4weeks) for 4 cycles in combination with tremelimumab. Then, durvalumab alone until confirmed disease progression, death, unacceptable toxicity, withdrawal of consent, or other discontinuation criteria met.
1458831|NCT03283605|Drug|Tremelimumab|Tremelimumab (75mg IV q4weeks) for 4 cycles in combination with Durvalumab.
1458832|NCT03283592|Other|Rank-Heat Plot|provides a visual presentation of treatment hierarchy across multiple outcomes
1458833|NCT03283592|Other|SUCRA Plot|provides a visual presentation of treatment ranking for a single outcome.
1458834|NCT03283566|Drug|Hydroxychloroquine|Subjects will receive a pre-transplant 200 mg daily dose of HCQ 30 days before TPAIT and will continue on the drug for 3 months after surgery.
1458835|NCT03283566|Drug|Placebo|Subjects will receive a pre-transplant placebo 30 days before TPAIT and will continue on the placebo for 3 months after surgery.
1458836|NCT03283553|Other|Checklist, MyChart, OpenNotes|1) Patient-family agenda-setting checklist, 2) Facilitated proxy registration for MyChart, and 3) Education on access to doctor's electronic visit notes.
1458837|NCT03283553|Other|Usual Care|Routine medical oncology care
1458838|NCT03283540|Procedure|TaTME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This dissection can be achieved transanally starting down in the pelvis and going up in what is known as Transanal Total Mesorectal Excision
1458839|NCT03283540|Procedure|TME|Low anterior resection of the rectum entails a sharp dissection circumferentially around the mesorectum in an avascular plane between the visceral and parietal layers of the endopelvic fascia in what is known as Total Mesorectal Excision. This surgery can also be done via an up-to-down approach beginning high in the abdomen and going low in the pelvis to achieve dissection around the mesorectum.
1458840|NCT03283514|Other|Complete denture|questionnaire
1458841|NCT03283501|Procedure|PCI after TAVI|Any patient undergoing PCI after TAVI, irrespective of clinical indications and irrespective of whether planned or not at the time of TAVI
1458842|NCT03283488|Drug|Mirtazapine|Tablets of 15mg mirtazapine will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
1458843|NCT03283488|Drug|Megestrol|Tablets of 160mg megestrol will be used according to randomization. At the first visit, patients will be instructed to take one tablet at night for better tolerability. From the second week, if there is good tolerance, they will take two tablets at night until the end of the study.
1458844|NCT03283475|Procedure|thigh lift|liposuction-assisted medial avulsion thighplasty enables technically refined contouring of the thigh and the possible preservation of the local microvasculature, which results in reduced complication rates
1458845|NCT03283462|Dietary Supplement|AMAZ-02|AMAZ-02 containing softgels
1458846|NCT03283462|Dietary Supplement|Placebo|Placebo containing softgels
1458847|NCT03283449|Drug|18F-AV-1451|
1458848|NCT03283449|Device|PET|PET scanner for brain imaging
1458849|NCT03283436|Drug|Bupivacaine Hydrochloride 0.25% Injection Solution|9 mL of 0.25% bupivacaine hydrochloride (2.5 mg/mL = 22.5 mg)
1509439|NCT02899156|Drug|Flumazenil|
1458851|NCT03283423|Device|Image-guided Lymphadanectomy in AMIGO|Image guided laparoscopic lymph node biopsy
1458852|NCT03283410|Drug|Propofol|Propofol plasmatic concentration (Marsh)
1947860|NCT02975258|Procedure|Methacholine challenge test|A methacholine challenge is a common test often used to support a diagnosis of asthma. The test consists of inhaling increasing doses of methacholine through a nebulizer to assess how quickly the participant's airways narrow.
1997204|NCT02181179|Behavioral|Yoga|The yoga intervention will be an 8-week program involving two 60-minute sessions each week at a local studio with three locations in Austin. Participants will be instructed to take classes deemed within a moderate-to-vigorous intensity dose. Participants will also be encouraged both by the PI and yoga instructors to complete the entire 60 minutes of yoga, urged to do only what is comfortable and not push themselves beyond their physical limits.
1458855|NCT03283384|Drug|Letrozole|Letrozole 2.5 mg daily.
1458856|NCT03283384|Drug|Chemotherapy|AC-T chemotherapy: 4 cycles of AC (adriamycin and cyclophosphamide at a dose of 60 and 600 mg/m² as an i.v. bolus, respectively) 3-weekly, followed by cycles of T (4 cycles docetaxel 100 mg/m² 3-weekly or 12 cycles paclitaxel 80 mg/m² weekly).
1458857|NCT03283384|Drug|Ribociclib plus letrozole|Ribociclib 600 mg/day (days 1-21, q4 weeks) plus letrozole 2.5 mg daily (days 1-28, q4 weeks).
1458858|NCT03283371|Drug|Natalizumab|As specified in the treatment arm.
1458859|NCT03283371|Other|Placebo|As specified in treatment arms.
1458860|NCT03283358|Behavioral|Person-centered follow up|
1458861|NCT03283345|Procedure|modified radical mastectomy|systemic responses to trauma are compared with evaluating inflammatory cytokine levels between premenopausal and postmenopausal patient groups with different estrogen levels who underwent modified radical mastectomy.
1458862|NCT03283332|Other|No intervention|
1458868|NCT03283293|Radiation|Target Volume Delineation after NACT|The gross tumor volumes of the primary site and the neck nodes (GTVnx and GTVnd) were delineated in accordance with the head and neck magnetic resonance imaging (MRI) and endoscopy, which obtained two weeks after the last cycle of NACT. The first clinical target volume (CTV1) was defined as the GTVnx plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the high-risk sites of microscopic extension, the whole nasopharynx, and the location and extent of the primary tumor before NACT. The second clinical target volume (CTV2) was defined as the CTV1 plus a 5-10mm margin (2 to 3mm margin posteriorly) to encompass the low-risk sites of microscopic extension, the level of the lymph node located before NACT, and the elective neck area. The prescribed dose to GTVnx, GTVnd, CTV1 and CTV2 were 68Gy/30f, 62-66Gy/30f, 60Gy/30f and 54Gy/30f, respectively.
1458869|NCT03283280|Other|Ever X Posterior|Resin composite restoration can be made as a direct onlay
1458870|NCT03283267|Drug|Sodium Zirconium Cyclosilicate (ZS)|Sodium zirconium cyclosilicate (ZS) is a non-absorbed, inorganic crystalline compound that selectively captures potassium ions in exchange for sodium and hydrogen ions in the gastrointestinal tract after oral administration.
1458873|NCT03283241|Device|Zolidd One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
1458874|NCT03283241|Device|One ExHex|"Subject will be treated/implanted at visit 2, one of the implants will be chosen as the index implantand will be followed together with other implants (maximum 6 implant per subject) at week 8,12 and month 12 and 24."
1458875|NCT03283228|Diagnostic Test|Cd11b and Cd56 markers|The expression of CD11b and CD56 in newly diadnosed cases of AML
1458876|NCT03283215|Diagnostic Test|complete blood count , electrolytes|it is a labarotory test to assess hemoglobin white blood count plate let
1458877|NCT03283202|Drug|CC-122|CC-122 by mouth at the assigned dose in Ph 1 starting on Day 1 for 5 consecutive days per week, followed by 2 days without CC-122 administration (5/7) for the first two weeks of a 21-day treatment cycle. If the highest proposed dose level to be explored in Phase 1 is applied, the dosing regimen will be 5/7 days for all 3 weeks of each 21-day treatment cycle.
1458878|NCT03283202|Drug|Rituximab|Rituxan 375 mg/m2 on Day 1 by intravenous (IV) infusion of a 21-day treatment cycle for up to a total of 6 cycles
1458879|NCT03283202|Drug|Cyclophosphamide 750mg/m2 by IV infusion|Cyclophosphamide 750mg/m2 on Day 1 by IV infusion of a 21-day treatment cycle for up to a total of 6 cycles
1458880|NCT03283202|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum of 2.0 mg total) on Day 1 by IV bolus on Day 1 of a 21-day treatment cycle for up to a total of 6 cycles
1458881|NCT03283202|Drug|Prednisone|Prednisone 100 mg PO on Days 1 through 5 of each 21-day treatment or 100mg IV on Day 1 is also acceptable for up to a total of 6 cycles
1458882|NCT03283189|Other|Group discussions|The focus group discussions will be conducted in a private room in the maternity of the women. They will last approximately 2 hours and will be led by an interviewer using an interview grid. All interviews will be audio-recorded.
1458883|NCT03283176|Diagnostic Test|Vitamin B12 and Folic Acid|Vitamin B12 and Folic Acid measurement by ELISA technique
1458884|NCT03283163|Behavioral|Exercise Testing and Training|Each study group will perform a baseline maximum load exercise test which will inform the individualized exercise prescription for the participant. Based on a progressive methodology, the participant will engage in 12 weeks of exercise of their choice (walking, running, cycling or swimming) with the goal of working towards a maximum heart rate range of 80% between weeks 6 and 12 of the study.
1458885|NCT03283150|Drug|Remifentanil|Remifentanyl will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
1458886|NCT03283150|Drug|Propofol|Propofol will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
1458887|NCT03283150|Drug|Dexmedetomidine|Dexmedetomidine will be administered for 10 -15 minutes before initiating the MER phase and the patient will be allow to wake up and the BIS values to normalize to awake level for the MER.
1458921|NCT03282929|Device|Part 2 Group 1|300 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
1458888|NCT03283137|Drug|TGR-1202|TGR-1202 will be given at a dose of 600mg (dose level 1) or 800mg (dose level 2). If the dose of 600mg is tolerated in the first cohort, then the dose will be increased to 800mg which is the only and final dose escalation. If the dose of 600mg is not tolerated, then the dose will be decreased to 400mg daily.
1458889|NCT03283137|Drug|Pembrolizumab|Pembrolizumab will be given at 200 mg every 3 weeks. The dose will not be adjusted throughout the course of the study.
1458890|NCT03283124|Procedure|pelvic floor reconstructive surgery|transvaginal mesh implantation for pelvic organ prolapse
1458891|NCT03283111|Biological|autologous stem cell transplantation|autologous stem cell transplantation
1458892|NCT03283098|Device|Hemodialysis|AMG 416 will be administered at the end of each hemodialysis session. Subjects should be on maintenance hemodialysis treatment with a prescription for dialysis 3 times per week.
1458893|NCT03283098|Device|Hemodialysis|The placebo will be administered at the end of each hemodialysis session. Subjects should be on maintenance hemodialysis treatment with a prescription for dialysis 3 times per week.
1458894|NCT03283098|Procedure|Hemodialysis|AMG 416 will be administered at the end of each hemodialysis session. Subjects should be on maintenance hemodialysis treatment with a prescription for dialysis 3 times per week.
1458895|NCT03283098|Procedure|Hemodialysis|The placebo will be administered at the end of each hemodialysis session. Subjects should be on maintenance hemodialysis treatment with a prescription for dialysis 3 times per week.
1458896|NCT03283085|Drug|25 mg SHP647|SHP647 sterile aqueous buffered solution will be administered in dose of 25 mg subcutaneously.
1458897|NCT03283085|Drug|75 mg SHP647|SHP647 sterile aqueous buffered solution will be administered in dose of 75 mg subcutaneously.
1997212|NCT02179853|Drug|Anakinra|First two doses IV followed by SQ dosing
1458902|NCT03283046|Drug|Nivolumab|"Dose Escalation Phase Starting Dose: Nivolumab 1 mg/kg by vein over 60 minutes every 3 weeks for 4 doses, followed by Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle.
Dose Expansion Phase Starting Dose: Maximum tolerated dose (MTD) from Dose Escalation Phase.
Maintenance: Nivolumab 240 mg by vein every 2 weeks until disease progression or unacceptable toxicity on Days 1 and 15 each cycle."
1458903|NCT03283046|Drug|Lenalidomide|"Dose Escalation and Dose Expansion Dose: Lenalidomide 25 mg by mouth on Days 1- 14 in 21 day cycles and Days 1-21 in 28 day cycles.
Maintenance: Lenalidomide 10 mg by mouth on Days 1-21."
1458904|NCT03283046|Drug|Dexamethasone|Dose Escalation and Dose Expansion Dose: Dexamethasone 40 mg by mouth on Days 1,8,15 in 21 day cycles and 1,8,15 and 22 in 28 day cycles
1458905|NCT03283046|Drug|Ipilimumab|"Dose Escalation and Dose Expansion Dose: Ipilimumab 1 mg/kg by vein over 90 minutes every 3 weeks for 4 doses.
Maintenance: If there is evidence of disease progression, Ipilimumab reintroduced at 3 mg/kg every 3 weeks for 4 doses. (Nivolumab dose in Combination determined by the phase 1 portion)."
1458906|NCT03283033|Behavioral|New salad bar|New salad bar placed in school
1458907|NCT03283033|Behavioral|Marketing|Marketing conditions (printed material, displays, verbal announcements, prompts and taste tests)
1458908|NCT03283020|Drug|RemifentanilMNTX|Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
1458909|NCT03283020|Drug|PlaceboMNTX|Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
1458910|NCT03283007|Drug|Nintedanib|Eligible LTx recipients with BOS receive Nintedanib treatment at a dose of 150 mg twice daily (bid) for 6 months
1458911|NCT03283007|Drug|Placebo|Eligible LTx recipients with BOS receive Nintedanib 150 mg BID matching placebo treatment for 6 months
1458912|NCT03282981|Drug|Timolol|Topical application of Timolol on non-healing diabetic foot ulcers
1458913|NCT03282981|Drug|Non biologically active gel|Topical application of non biologically active gel (Hydrogel- standard of care) on non-healing diabetic foot ulcers
1458914|NCT03282968|Device|REWIRE|First, the patient will play the Fruit Catcher (weight transfer) game on the 3rd level for 3 minutes, followed by 3 minutes of rest. Next, the patient will play the Horse Runner (squats) on the 3rd level for 3 minutes, followed by 3 minutes of rest. In the end, the patient will play the Animal Hurdler (standing on one leg) on the 3rd level for 3 minutes. During the games, the patient will be standing on the Wii Balance Board, holding to a firm support if necessary. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
1458915|NCT03282968|Other|Balance exercises|The patient will first practice balance transfer for 3 minutes (standing by a ladder, holding position on each leg for 3 seconds), followed by 3 minutes of rest. Next, the patient will be performing squats for 3 minutes, followed by 3 minutes of rest. In the end, the patient will practice alternatively lifting lower limbs (like stepping on a footstool) for 3 minutes. During the rest periods, the patients will be sitting. A physiotherapist will be present throughout the exercise for safety and help if requested.
1458916|NCT03282955|Drug|Lipidem|Lipoplus i.v. lipid emulsion for parenteral nutrition
1458917|NCT03282955|Drug|Lipofundin MCT 20%|Lipofundin MCT 20% i.v. lipid emulsion for parenteral nutrition
1458918|NCT03282942|Other|Strength training group|"Individuals in the strength training group will perform exercises based on exercises with free weights and equipment, for upper and lower limbs with a weekly frequency of three times for twelve weeks. The periodization will start with 2 sets, 15 - 20 repetitions, passive rest of 120 seconds, exercises performed alternating by segments and the intensity of 50% of maximum repetition. After twelve weeks the periodization will be finished with 3 sets, 8-12 repetitions, passive rest of 120 seconds, exercises performed alternated by segments and the intensity of 70% of maximum repetition.
The following exercises will compose the strength training protocol:
Squatting
Leg press
Knee Extension
Knee Flexion
Supine Challenge
High Pull
Elbow flexion
Extension of elbows
Development
Abdominal"
1458919|NCT03282942|Other|Aerobic Training Group|Individuals in the aerobic training group will perform aerobic treadmill exercise three times a week for twelve weeks. The training prescription will be performed through the percentage of maximum oxygen consumption with intensity in 60% to 80% with an average duration of 50 minutes of continuous exercise.
1458920|NCT03282929|Device|Part 1|A single dose of 500 μg epinephrine (0.5 mL Suprarenin®) will be administered i.m. and s.c. by using a needle and a syringe in randomized order
1458922|NCT03282929|Drug|Part 2 group 2|500 μg epinephrine auto-injector (Emerade, Bausch and Lomb, 23 mm needle length)
1458923|NCT03282929|Device|Part 2 group 3|300 μg epinephrine auto-injector (Fastjekt, MEDA Pharma, 16 mm needle length)
1458924|NCT03282929|Device|Part 2 Group 4|300 μg epinephrine auto-injector (Jext, Alk-Abelló, 15 mm needle length)
1458927|NCT03282890|Other|CHRP-BB|The CHRP-BB intervention is a theory-based, manual-guided, HIV risk reduction and PrEP adherence intervention. It is an integrated evidence-based intervention that uses a coping skills training approach to primary prevention and is delivered in a small group modality by two trained intervention facilitators using a motivational enhancement therapeutic style to address high risk drug- and sex-related HIV risk behaviors and PrEP adherence. Importantly, the CHRP-BB intervention includes specific behavioral and mHealth strategies designed and tested to accommodate difficulties stemming from moderate to severe neuro-cognitive impairment (NCI).
1458928|NCT03282877|Behavioral|iCST web-application|The iCST web-application will be delivered by a carer in regular contact with the person with dementia (family carer, a close friend, or a volunteer befriender) for 1.5 hours a week. It is up to the carer to distribute the time in a matter that is convenient to them (e.g. two long sessions of 45 minutes or 3 shorter sessions of 30 minutes). Participants will be asked to use the web-application for a duration of 11 weeks at their homes. Each session will consist of structured cognitive stimulation aided by the use of multimedia. After completing each session, participants will be guided to a new screen on the web-application in which they will be asked to briefly reflect on the session and provide us with feedback.
1458929|NCT03282864|Device|Bedroom air filtered by an air filtration device to remove airborne pollutants|The air in the bedroom of study subjects in the active comparator arm was processed by an air filtration device which pulled air through a pre-filter, a high efficiency particular air (HEPA) filter and an active carbon filter continuously. The air in the bedroom of subjects in the placebo arm was processed by a placebo air filtration device that looked identical to the real air filtration device but did not possess the HEPA filter and the active carbon filter. Each subject was assigned to the active comparator arm and the placebo arm in a randomized order with a two-week washout period scheduled in-between. The subjects, their guardians and the study staff that assessed the health indicators of the subjects were blinded to this order till the end of the study.
1458933|NCT03282838|Drug|DFN-15 (fasted)|DFN-15 administered to fasted subjects
1458934|NCT03282838|Drug|DFN-15 (fed)|DFN-15 administered to fed subjects
1458935|NCT03282838|Drug|Comparator Celebrex® (fed)|Comparator (Celebrex®) administered to fed subjects
1458936|NCT03282825|Drug|Decitabine|"The subjects will be sequential administerd with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.
Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
1458937|NCT03282825|Drug|Paclitaxel|"The subjects will be sequential administerd with Decitabine and paclitaxel 80mg/m2 by IV(intravenous) infusion.
Decitabine is starting dose of 15mg/m2 on 1D, 8D, 22D, 28D of a 28day cycle. Paclitaxel 80mg/m2 will be dosed in combination therapy with Decitabine on 8D, 22D, 28D of a 28day cycle."
1458938|NCT03282799|Drug|etonogestrel implant|The etonogestrel implant is an contraceptive implant that is placed into the upper arm.
1458939|NCT03282786|Other|carbon dioxide insufflation during colonoscopy|Use of Carbon dioxide instead of air insufflation
1458940|NCT03282773|Device|Deferred stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted 4-10 days after restoration of blood flow in left main coronary artery in a secondary PCI.
1458941|NCT03282773|Device|Immediate stent implantation|Primary angiography and pretreatment including balloon dilatation and thrombus aspiration, second generation drug-eluting stents are implanted immediately after restoration of blood flow in left main coronary artery in a secondary PCI.
1458942|NCT03282760|Biological|Human Neural Stem Cells|Allogenic human Neural Stem Cells (hNSCs) in four different dosages (5, 10, 16 or 24 millions). hNSCs are produced by the Laboratorio Cellule Staminali of Terni according to GMP guidelines and are obtained from brain specimens of several fetal human donors from spontaneous miscarriages occurred after the 8th week after conception.
1458943|NCT03282747|Behavioral|no intervention|no intervention
1458944|NCT03282734|Other|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.)|Home-based exercise program with smart rehabilitation system ((Uincare®, D-gate Co.) for more than 30 minutes per a day for 4 weeks
1458945|NCT03282734|Other|Conventional home rehabilitation exercise|Conventional home rehabilitation exercise for more than 30 minutes per a day for 4 weeks
1458946|NCT03282721|Procedure|precise location of commissure|
1458947|NCT03282708|Other|Fresh stool collection|"One sample collection of spontaneously produced fresh stool (of an approximate size of 3 green beans).
Data collection with self-administered questionnaire"
1458948|NCT03282682|Procedure|Strength training|The participants perform strength training sessions two times per week for 12 weeks. Each training session include 5-minute general dynamic warm-up followed by progressive strength training with exercises for the entire body. The strength exercises are performed with free weights and on machines. The training program consist of 6 exercises for upper and lower body at an intensity of 60-80% (8 - 12RM: the load that induces technique failure in eight or twelve repetitions) of one-repetition maximum and takes approximately 60 minutes. The exercises performed are: leg press, split squats, bench press, knee extension, knee flexion, seated cable rows, seated cable pull downs, dumbbell bench press, incline dumbbell bench press.
1458949|NCT03282669|Drug|Intrathecal Morphine|Intrathecal Morphine administered in the operating room.
1458950|NCT03282669|Drug|Intravenous hydromorphone|Intravenous hydromorphone administered via IV in the post operative area.
1511007|NCT02886494|Drug|Matched placebo|
1947861|NCT02975258|Radiation|Quantitative CT scans|There will be a standard chest CT and an abdominal CT. The CT scans capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and the abdomen and will be performed during a breath-hold at end-inspiration. The investigators will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized. If the participant has had a research chest CT scan done recently, only the abdomen CT will be done.
1458952|NCT03282643|Drug|Rivaroxaban 10 MG|Rivaroxaban pill 10mg qd, day1 and day2 after femoral venepuncture
1458953|NCT03282643|Drug|Rivaroxaban 20 MG|Rivaroxaban pill 10mg bid, day1 and day2 after femoral venepuncture
1458954|NCT03282643|Drug|Low-molecular-weight heparin|0.4 ml once daily, before femoral venepuncture(day1) and the following day (day 2)
1458955|NCT03282630|Procedure|Sphenopalatine ganglion acupuncture|"active sphenopalatine ganglion acupuncture The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process
sham sphenopalatine ganglion acupuncture The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment."
1458956|NCT03282617|Biological|CD137L-DC-EBV-VAX|Patients will receive CD137L-DC-EBV-VAX at a dose of approximately 5-50 millioncells every 2 weeks, for a total of 5-7 times.
1947862|NCT02975258|Procedure|Urine pregnancy test|All female participants with childbearing potential will be asked to provide a urine sample for pregnancy testing. The result of the pregnancy test must be negative in order for her to be in this research study.
1458961|NCT03282565|Other|Functional Resistance Training|A brace/cuff/exercise band will be strapped to the leg and apply resistance across the knee while subjects walk on a treadmill.
1458962|NCT03282565|Other|Control|A brace/cuff/exercise band will be strapped to the leg and will not apply resistance across the knee while subjects walk on a treadmill.
1458964|NCT03282539|Device|LAMS|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents
1458965|NCT03282539|Device|LAMS + pigtail|EUS-guided transmural drainage of pancreatic fluid collections with lumen apposing metal stents and a coaxial double pigtail stent
1458966|NCT03282526|Diagnostic Test|Whole body plethysmography|Whole body plethysmography : measure lung volumes Spirometry : to assess severity of chronic obstructive pulmonary disease also reversibility testing
1458967|NCT03282513|Drug|AG-120 (Ivosidenib)|Single 500 mg dose of AG-120 (Ivosidenib).
1458968|NCT03282500|Behavioral|Mindfulness Based Cognitive Therapy|The Mindfulness Based Cognitive Therapy (MBCT) intervention promotes self-regulation of emotions and behaviors within an accepting and non-judgmental therapeutic environment. During this interactive, multisensory program, participants will learn strategies to help manage their emotions and thoughts and help them to develop greater insight into the influence these experiences have on their behaviors. Participants will engage in brief at home exercises to enhance their learning of these new skills.
1458969|NCT03282487|Drug|Modified release hydrocortisone|Patients will switch from their usual conventional immediate release hydrocortisone to daily dose equivalent of modified release hydrocortisone (Plenadren®)
1458970|NCT03282474|Drug|Sofosbuvir|Sofosbuvir 400 MG Oral Tablet [Sovaldi]
1458971|NCT03282461|Drug|ABY-029|A sample size of 6-12 patients in this open label, single center, clinical trial of ABY-029. Administration will occur as a single intravenous injection to subjects with operable head and neck cancer approximately 1-3 hours prior to surgery.
1458972|NCT03282448|Behavioral|family therapy|The family-based intervention is informed by Dialectical Behavior Therapy Skills Training for Adolescents (Rathus & Miller, 2014).
1458973|NCT03282435|Biological|CIK cells with PD-1 blocking|CIK cellular therapy with PD-1 blocking
1458974|NCT03282435|Other|standard lung cancer treament|standard non-small cell lung cancer treatment: surgery, chemotherapy
1458975|NCT03282435|Biological|CIK cells without PD-1 blocking|CIK cellular therapy without PD-1 blocking
1458978|NCT03282396|Drug|Ibrutinib|560 mg by mouth daily for 28 days (one cycle) until disease progression (PD) or drug intolerance or 3 years.
1458979|NCT03282396|Behavioral|Phone Calls|Participants called by study staff every 2 months for the first 6 months after the End-of-Treatment visit, then every 2-4 months for 2 years, and then 4-6 months after 2 years.
1458984|NCT03282344|Drug|NKTR-214|0.006mg/kg IV on day 1 and every 3 weeks thereafter
1458985|NCT03282344|Drug|Nivolumab|360mg (flat dose) IV
1458986|NCT03282331|Procedure|Standard oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
1459055|NCT03281798|Device|Karl Storz Semi-Rigid TTTS Fetoscopy Instrument Set|2.0 mm fetoscopy or flexible ureteroscope
1997216|NCT02171104|Biological|Stem Cell Transplantation|Infusion given on Day 0
1997217|NCT02171104|Drug|IMD Preparative Regimen|"Anti-thymocyte Globulin (ATG)
Fludarabine
Busulfan"
1458987|NCT03282331|Procedure|High flow nasal oxygenation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
1458988|NCT03282331|Procedure|noninvasive ventilation|Electrical impedance tomographic evaluation of lung morphology variations according to the preoxygenation technique : Comparison of Standard Oxygenation, High Flow Nasal Oxygen Therapy, and NonInvasive Ventilation
1458991|NCT03282292|Procedure|Internal jugular vein CVC insertion|Double lumen CVC insertion in the internal jugular vein
1458992|NCT03282279|Procedure|TVOR|Ultrasound guided transvaginal oocyte retrieval (TVOR) in deep sedation for IVF.
1458993|NCT03282266|Procedure|PADN|PADN was performed at three sites at the conjunctional area between the distal main trunk and the ostial left branch. The following ablation parameters were programmed at each point: a temperature of 45 ℃-50 ℃, energy ≤15 W, and a time of 120 seconds. The procedure would cease for 10 seconds if the patient felt intolerable chest pain during the procedure. The EKG and pressure lines (including cardiac output) were monitored and continuously recorded throughout the procedure.
1458994|NCT03282266|Procedure|Sham operation|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
1458995|NCT03282240|Biological|QIV-HD|0.7 mL-dose to be administered intramuscularly (IM) into the upper arm area
1458996|NCT03282240|Biological|Licensed TIV-HD1|0.5 mL-dose to be administered IM into the upper arm area
1458997|NCT03282240|Biological|Investigational TIV-HD2|0.5 mL-dose to be administered IM into the upper arm area
1947863|NCT02975258|Procedure|Adipose biopsy|The doctor will obtain a sample of fat cells from the participant's abdomen. Numbing medicine will be applied. A needle is placed through the skin & into the fat pad under the skin. A blunt-tip hollow cannula is then used to aspirate fat tissue through the incision.
1459000|NCT03282201|Other|Transfusion|Transfusion of red blood cells, fresh frozen plasma, platelets
1459001|NCT03282188|Biological|Reolysin|Reolysin® is a proprietary isolate of Reovirus Type 3 Dearing, a non-enveloped human reovirus with a genome that consists of 10 segments of double-stranded RNA. The human reovirus possesses an innate ability to replicate specifically in transformed cells possessing an activated Ras signalling pathway, a situation often found in malignant cells. Reovirus has been shown to reach and target melanoma cancer cells.
1459002|NCT03282188|Drug|GM-CSF|GM-CSF is a recombinant human granulocyte-macrophage colony stimulating factor (rhu GM-CSF) produced by recombinant DNA technology in a yeast (S. cerevisiae) expression system. GM-CSF is a hematopoietic growth factor which stimulates proliferation and differentiation of hematopoietic progenitor cells. GM-CSF is a key cytokine in the differentiation of dendritic cells. It has been used as an immune adjuvant in therapeutic vaccines in pre-clinical and clinical studies, administered as cytokine released from gene-transduced tumour or stromal cells or as recombinant protein. At low doses GM-CSF may enhance migration and differentiation of dendritic cells to local antigen presentation, and is a potent adjuvant to generate specific systemic anti-tumour efficacy.
1459003|NCT03282175|Other|Exercise|Exercise session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
1459004|NCT03282175|Other|Training|Each training session consisted of general warm-up of 10 min, followed by 35-40 min of resistance exercises (chair squats, band seated: biceps curl, seated row, knee extension, leg press and hip abduction; standing behind the chair: knee flexion, and calf rise), and general cool down of 10 min.
1459005|NCT03282175|Other|Control group|The control group did not receive any treatment.
1459006|NCT03282162|Drug|intranasal oxytocin|Each subject will be assigned to intranasal administration of oxytocin (24 IU).
1459007|NCT03282162|Drug|intranasal placebo|An identical amount of intranasal administration of placebo will be assigned to each subject.
1459008|NCT03282149|Biological|XT-150|IL-10 transgene DNA plasmid injected into the knee synovial capsule
1459009|NCT03282136|Drug|Incretin Effect|The patients will receive incretins therapy.
1459010|NCT03282136|Device|Cardiac Resynchronization therapy defibrillator device|The patients will receive a Cardiac Resynchronization therapy defibrillator device
1459013|NCT03282110|Device|ta-VNS|The transcutaneous vagus nerve stimulation (taVNS) at auricular concha is a typical representative of TCM modernization. The taVNS regulates the autonomic nervous system, which shows a good therapeutic effect for the treatment of depression.
1459014|NCT03282110|Other|Electro-acupuncture|one of the most common acupuncture methods, selecting acupoints based on traditional Chinese medicine theory. It exerts the function to regulate qi and blood circulation and balance Yang and Yin energy inside body.
1459015|NCT03282110|Drug|Citalopram|Citalopram is an antidepressant drug of the selective serotonin reuptake inhibitor (SSRI) class.It has U.S. Food and Drug Administration approval to treat major depression.
1459016|NCT03282097|Behavioral|DECAD decision aid|A mammography decision aid that will help caregivers of patients with Alzheimer's make decisions about stopping or continuing breast cancer screening.
1459017|NCT03282097|Other|Home safety guide|The home safety guide provides tips about important actions older adults can take to prevent falls, poisoning, and bathroom hazards and protection against abuse, fire and other related hazards.
1459056|NCT03281785|Other|Pressure controlled mandatory ventilation mode (P-CMV)|Pressure controlled mandatory ventilation mode (P-CMV)
1947864|NCT02975258|Procedure|Exhaled nitric oxide measurement|The investigators will measure concentrations of exhaled nitric oxide by asking the participant to inhale deeply, and then exhale very slowly into a mouthpiece for between 10-15 seconds.
1947865|NCT02974439|Drug|LANDI-Amlodipine Besylate Tablet 5mg|LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.
1947866|NCT02974439|Drug|Norvasc Tablets 5mg|Norvasc Tablet 5mg will be used as a comparator drug for the BE study.
1947867|NCT02971761|Drug|Enobosarm|Given PO
1459018|NCT03282084|Diagnostic Test|EGD with biopsy|Stop PPI and schedule for EGD with biopsy and Wireless pH capsule testing for 7-10 days later. Consider gastric emptying scan or high resolution esophageal manometry
1459019|NCT03282084|Diagnostic Test|EGD and impedance-pH study on PPI|Continue PPI and schedule EGD and Impedance-pH study on PPI. Consider gastric emptying scan or high resolution esophageal manometry
1459020|NCT03282071|Behavioral|Joyful Parenting Intervention|"Two-session interactive talks for parents to promote praise & appreciation, positive thinking, enjoyable parenting (mind) and knowledge of adult mental health problem (in particular the mixed anxiety and depressive disorder) and mental well-being.
One family gathering activity (e.g. outdoor / visit / family indoor gathering) to promote and practise quality family communication (enjoyment and sharing)."
1459021|NCT03282058|Device|Silastic Stent|The silastic stent is a splint made of silicone.
1459022|NCT03282045|Drug|Lysobact Complete Sprey|Inhaling spray
1459023|NCT03282045|Drug|Tantum Verde® Spray|Inhaling spray
1459024|NCT03282045|Drug|Pharyngal® Oromucosal Spray|Inhaling spray
1459025|NCT03282045|Drug|Placebo|Inhaling spray
1459026|NCT03282032|Other|One-lung ventilation|"The patient undergoing thoracic surgery is intubated with double lumen tube after induction of general anesthesia with propofol and remifentanil.
In the intervention group, 5 cycles of one-lung ventilation preconditioning (2-min of one-lung ventilation and 2-min of two-lung ventilation for 1 cycle) is performed before surgical incision. One-lung ventilation is done at dependent lung with FiO2 100% and tidal volume 6 ml kg-1. Two-lung ventilation is done with FiO2 50%, tidal volume 8 ml kg-1."
1459027|NCT03282019|Device|High-flow nasal cannula therapy|Subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current Home oxygen therapy (HOT). The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
1459028|NCT03282019|Device|Home oxygen therapy (HOT)|All subjects will continue their current Home oxygen therapy (HOT) which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
1459030|NCT03281993|Other|CPAP AT|If the investigators observe rapid desaturation defined as a decline in O2 saturation below 85%; the CPAP apnea test (CPAP-AT) test was aborted.
1459031|NCT03281980|Other|Psychosocial stimulation (PS)|"i) Unconditional Cash Transfer(UCT)/ Maternity Allowance: MoWCA, GoB provides maternity allowance of taka 500 ($6.25) for each mother up to two years in each month.
ii) Health Education Awareness Program: All mothers receive health education training by designated LNGOs/CBOs
iii) Psychosocial stimulation: The participants will receive fortnightly sessions at home."
1459032|NCT03281980|Other|Government Intervention (UCT+HE)|fgbfgjhgykghilk
1459033|NCT03281967|Device|Minimally Invasive Ponto Surgery|Minimally Invasive Ponto surgery is used for hearing rehabilitation using Ponto Wide Implant in patients indicated and counselled for Bone Anchored Hearing System.
1459034|NCT03281954|Drug|Placebo|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + placebo IV Day 1 every 3 weeks for 4 doses.
Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.
+ placebo IV Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.
Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by placebo IV Day 1 every 3 weeks after surgery until 1 year after the first dose."
1459035|NCT03281954|Drug|Atezolizumab|"Following randomization, patients will receive Paclitaxel 80 mg/m2 IV weekly x 12 doses + Carboplatin AUC of 5 IV Day 1 every 3 weeks for 4 cycles + Atezolizumab 1200 mg Day 1 every 3 weeks for 4 doses.
Followed 2-3 weeks later by Doxorubicin (A) 60 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles OR Epirubicin (E) 90 mg/m2 IV + cyclophosphamide (C) 600 mg/m2 IV Day 1 every 2 or 3 weeks for 4 cycles.
+ Atezolizumab 1200 mg Day 1 every 3 weeks for 3 to 4 doses depending on AC/EC schedule used.
Approximately 3-4 weeks later: Surgery (Lumpectomy or mastectomy and axillary staging), followed by Atezolizumab 1200 mg Day 1 every 3 weeks after surgery until 1 year after the first dose."
1459036|NCT03281941|Other|Inhaled capsaicin cough challenge|
1459039|NCT03281915|Procedure|High inguinal Varicocelectomy|Semen parameters after high inguinal varicocelectomy will be collected
1459040|NCT03281915|Procedure|Subinguinal varicocelectomy|Semen parameters after subinguinal Varicocelectomy will be collected
1459044|NCT03281889|Radiation|Proton Beam|precision radiation that reduce the negative effects radiation has on the surrounding non-cancerous growing and developing tissue
1459045|NCT03281876|Biological|NTHi Mcat investigational vaccine (GSK3277511A)|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
1459046|NCT03281876|Biological|Placebo|Two doses administered intramuscularly at Day 1 and Day 61 in the deltoid region of the non-dominant arm.
1459047|NCT03281863|Diagnostic Test|C reactive protein, anti streptolysin o antibody test ,erythrocyte sedimentation rate|Throat culture to detect the causative organism
1459048|NCT03281837|Device|HYMOVIS plus Physical Exercise Program (PEP)|1 injection of intra-articular (IA) hyaluronan (HA), Hymovis 24mg/3ml, injection per week for 2 weeks combined with at least 8 weeks of Physical Exercise Program (PEP)
1459049|NCT03281837|Other|Physical Exercise Program (PEP) alone|Physical Exercise Program (PEP) alone for at least 8 weeks
1459050|NCT03281824|Biological|ALT-P7 (HM2-MMAE)|Antibody-Drug Conjugate
1511634|NCT02881294|Drug|SUVN-G3031|
1459057|NCT03281785|Other|Pressure synchronized intermittent mandatory ventilation|Pressure synchronized intermittent mandatory ventilation
1459058|NCT03281785|Other|Pressure support mode (PS)|Pressure support mode (PS)
1459059|NCT03281772|Other|Clinical Decision Software - provider portal|As noted in Arms
1459060|NCT03281772|Other|Clinical Decision Software - patient portal|As noted in Arms
1459061|NCT03281759|Device|Transcranial LED Therapy (Active coil helmet)|The patients will undergo 18 sessions of repetitive transcranial LED stimulation.
1459062|NCT03281759|Device|Transcranial LED Therapy (Inactive coil helmet)|The patients assigned to this group will undergo 18 sessions of transcranial LED but with an inactive coil, which will not generate LED emissions, only a similar red light color.
1459063|NCT03281746|Procedure|Dental Procedure|Undergo dental examination
1459064|NCT03281746|Other|Educational Intervention (prevention education)|Receive prevention education
1459065|NCT03281746|Other|Interview|Ancillary studies
1459066|NCT03281746|Other|Survey Administration|Ancillary studies
1459067|NCT03281746|Other|Educational Intervention (one-on one education)|Receive one-on-one education
1459068|NCT03281720|Procedure|TAD|the same intervention as listed in the arm description
1459069|NCT03281707|Procedure|NIRS|NIRS devices patch will be applied on patients' head in order to measure the cerebral saturation of each cerebral emisphere
1459070|NCT03281707|Other|DO2i|Oxygen delivery standardized to the body surface area will be calculate in order to optimize tissue perfusion
1459071|NCT03281694|Drug|Placebo|placebo skin patch and placebo oral solution
1459072|NCT03281694|Drug|Nicotine|nicotine skin patch (7 mg/24 hrs) and placebo oral solution
1459073|NCT03281694|Drug|AVL-3288|placebo skin patch and AVL-3288 oral solution (3 mg)
1459074|NCT03281694|Drug|Nicotine + AVL-3288|nicotine skin patch (7 mg/24 hrs) and AVL-3288 oral solution (3 mg)
1459076|NCT03281668|Behavioral|High intensity interval training (HIIT)|Each training session for High Intensity Interval Training will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
1459077|NCT03281655|Drug|Visnadine, prenylflavonoids and bovine colostrum|15 days, 1 application per day, with a vaginal cream containing visnadine, prenylflavonoids and bovine colostrum.
1459078|NCT03281642|Other|Tobacco management|Training of healthcare teams for tobacco management by trained nurses. The intervention will consist of 3 minimum interviews, about 30 minutes each.
1947868|NCT02971761|Other|Laboratory Biomarker Analysis|Correlative studies
1947869|NCT02971761|Biological|Pembrolizumab|Given IV
1459081|NCT03281616|Behavioral|Diet|Individually tailored diets; 30% caloric reduction according to daily energy requirements measured by indirect calorimetry
1459082|NCT03281603|Device|CAD/CAM complete denture|complete denture will be designed by computer aided designing (CAD) and manufactured by computer aided manufacturing(CAM) utilizing Milling and 3D printing techniques
1459083|NCT03281577|Drug|TAK-954|TAK-954 IV infusion
1459084|NCT03281577|Drug|Placebo|TAK-954 placebo-matching IV infusion
1459085|NCT03281564|Other|Quality of life 1 month after Essure® removal|Questionnaire to assess the quality of life 1 month after laparoscopic removal of Essure® device
1459086|NCT03281551|Drug|PZ01 CAR-T cells|Chimeric antigen receptor (CAR) T cells targeting CD19 will be evaluated for safety and efficacy in patients with relapsed/ refractory B-cell Acute Lymphoblastic Leukemia/B cell Lymphoma. The CAR consists of a CD19 targeting antibody scFv with two intracellular signaling domains derived from CD3 zeta and 4-1BB. Autologous T cells will be gene-engineered with the CAR gene using a lentivirus vector. Prior to T cell infusion, the patients will be subjected to preconditioning treatment. After T cell infusion, the patients will be evaluated for 24 months for adverse reactions, persistence of CAR T cells and efficacy.
1459087|NCT03281538|Drug|CR845|IV CR845 0.5 mcg/kg administered after each dialysis session (3 times/week)
1459088|NCT03281499|Other|da Vinci Surgical System Model IS4000|tailored radiotherapy regimen following transoral robotic surgery
1459089|NCT03281486|Device|HA formulation Oral Spray|It is an HA formulation of FDA listed ingredients
1459090|NCT03281486|Device|Placebo|Placebo formulation without the active ingredients
1459091|NCT03281473|Other|Strategy 1|PEEP titration according to transpulmonary-end-expiratory pressure
1459092|NCT03281473|Other|Strategy 2|PEEP titration according to chest wall elastance measurement
1459093|NCT03281460|Device|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation|laparoscopic myomectomy or hysterectomy with More-cell-Safe AMI bag morcellation
1459094|NCT03281460|Procedure|laparoscopic myomectomy or hysterectomy without any morcellation bag|laparoscopic myomectomy or hysterectomy without any morcellation bag
1459095|NCT03281447|Other|Nurse navigation|
1459096|NCT03281447|Other|Current care coordination|
1459097|NCT03281434|Dietary Supplement|Collagen peptide|Low leucine content protein supplement to be consumed twice daily
1459098|NCT03281434|Dietary Supplement|Whey protein isolate|High quality protein (DIAAS score), high leucine supplement, to be consumed twice daily
1459099|NCT03281421|Other|Manual Therapy|The manual therapy intervention, through the technique of mobilization with movement in the ankle joint (following the specific sense direction of the group), will be performed in a protocol that consists of four sets of five repetitions, with rest time between series of one minute.
1459100|NCT03281408|Other|Pre-operative: OSA Risk Identification|Patient to receive and wear a wrist band identifying them as at risk for OSA complication. This is to be worn at all time during the hospital stay, similar to an allergy alert band.
1512791|NCT02872649|Drug|Phenprocoumon|
1459101|NCT03281408|Procedure|Intra-operative: Regional Anesthetic Techniques|Strong recommendation to have patients undergo a spinal anesthetic and receive peripheral nerve block where possible. No morphine is to be used for the spinal anesthetic. All knee replacement patients will receive the adductor canal nerve block to decrease post-operative opioid use.
1459102|NCT03281408|Drug|Intra-operative: Sedation Techniques|Strong recommendation to use Precedex (dexmedetomidine) as part of intra-operative sedation where possible, as deemed by the OR anesthetist.
1459103|NCT03281408|Other|Post-operative: Intensified Monitoring and Care|"Subjects will spend at least the first night in a monitored bed (continuous oxygen saturation and heart rate monitoring) and discharged to normal ward subsequently once cleared by the Intensivist responsible for the high acuity unit. Once in normal ward bed, the vital sign is taken (at double the frequency than previous) every 4 hours. All patients will have their bed elevated at 30 degree incline. An incentive spirometer is to be kept at the bedside. Opioid pain medication administration by nursing is to target tolerable level or 3-4/10 on the VAS pain scale, as opposed to a pain free state."
1459104|NCT03281395|Procedure|Rapid ventricular pacing (RVP)|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short period of time during dissection of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. RVP technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations and can be lifesaving in the case of an intraoperative bleeding or rupture.
1459105|NCT03281395|Procedure|No rapid ventricular pacing|
1459106|NCT03281382|Biological|Ad5-yCD/mutTKSR39rep-hIL12|Oncolytic adenovirus expressing two suicide genes and human IL-12
2010452|NCT02959463|Radiation|Hemithoracic Radiation Therapy|Participants receive hemithoracic radiation therapy with intensity modulated radiation therapy (IMRT) or proton beam therapy (PBT) to a total dose of 45 Gy in 25 fractions to the entire hemithorax.
2010453|NCT02959463|Radiation|Palliative Radiation Therapy|Participants receive palliative radiation therapy over a course of 1-3 weeks to a region that does not include the entire side of the chest, or thorax. Participants receive either 3 Gy x 10 fractions = 30 Gy, or 4 Gy x 5 fractions = 20 Gy, or 5 Gy x 5 fractions = 25 Gy, or 45-52.5 Gy in 15 fractions. Participants treated using either IMRT or 3D conformal therapy.
2010454|NCT02959463|Drug|Pembrolizumab|200 mg by vein on Day 1 of each 3-week cycle after radiation therapy, for up to 2 years.
2010455|NCT02960646|Drug|Rituximab|CD20 positive lymphoma patients may receive Rituximab 375 mg/m2 by vein on Days -13, -6, +1, and +8.
2010456|NCT02960646|Drug|Melphalan|100 mg/m2 or 140 mg/m2 by vein for one dose only on Day -6.
2010457|NCT02960646|Drug|Fludarabine|40 mg/m2 by vein daily for four doses on Days -6 to -3.
1459119|NCT03281356|Behavioral|Intervention Group|Participants will receive a total of 8 text messages during a 4 week period.
1459120|NCT03281343|Behavioral|Motivational Interviewing & Patient Navigator|The specific content, structure, and implementation approach for MI-NAV will be guided by IDIs conducted during Phase 1 and Phase 2. Our initial plan is to deliver MI-NAV in two waves. The first wave will be aimed at promoting uptake of PrEP at the prison, through the use of motivational interviewing. The second wave will be aimed at linking at-risk women to community-based PrEP care upon release from incarceration, by utilizing a patient navigator approach.
1459121|NCT03281343|Behavioral|Standard of Care (SOC)|SOC will consist of a pamphlet regarding PrEP during incarceration, an offer of PrEP while incarcerated, and referral to community-based PrEP care upon release.
1459122|NCT03281330|Behavioral|auditory cues and music during walking|the effect of different conditions of auditory cueing and music on walking quality and perceived fatigue in persons with multiple sclerosis compared to healthy controls
1997218|NCT02171104|Drug|Osteopetrosis Only Preparative Regimen|"Anti-thymocyte Globulin (ATG)
Fludarabine
Busulfan
Thiotepa"
1997219|NCT02171104|Drug|Osteopetrosis Haploidentical Only Preparative Regimen|"Rituximab
Alemtuzumab
Busulfan
Fludarabine"
1459125|NCT03281291|Biological|RTS,S/AS01E (Full dose)|Subjects will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
1459126|NCT03281291|Biological|RTS,S/AS01E (1/5th dose)|Subjects will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml)
1459127|NCT03281291|Biological|Rabies vaccine|Subjects will receive intramuscular injection of rabies vaccine (0.1 ml).
1459128|NCT03281265|Other|standard treatment|
1459130|NCT03281226|Drug|RIPE (2m) and RI (4m)|Rifampicin 150mg + isoniazid 75mg + pyrazinamide 400mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
1459131|NCT03281226|Drug|RIPE+NAC (2m) and RI (4m)|Rifampicin 150 mg + isoniazid 75 mg + pyrazinamide 400 mg + ethambutol 275mg (oral combined fixed dose tablet according to the weight) plus oral N-acetylcysteine (NAC) 1200 mg (600mg twice daily) for 2 months and a continuation with rifampicin 150mg and isoniazid 75mg (oral combined fixed dose tablet according to the weight) for 4 months
1459132|NCT03281213|Other|Thoracotomy|
1459138|NCT03281187|Drug|Nasotestt 5 mg|The 114 participants randomized to this arm must administer one packet of testosterone 5 mg nasal gel (Nasotestt) in each nostril 3 times a day for 60 days.
1997220|NCT02171104|Drug|cALD SR-A (Standard-Risk, Regimen A)|N-acetylcysteine start day +1 through day +28
1997221|NCT02171104|Drug|cALD SR-B (Standard-Risk, Regimen B)|N-acetylcysteine start day +1through day +56
1997222|NCT02171104|Drug|cALD HR-D (High-Risk, Regimen C)|N-acetylcysteine and celecoxib start day of admission (prior to conditioning regimen) and continue through day +100
1997223|NCT02171104|Drug|cALD HR-D (High-Risk, Regimen D)|N-acetylcysteine, celecoxib, vitamin E and alpha lipoic acid start day of admission (prior to conditioning regimen) and continue through day +100
1997224|NCT02169830|Drug|nortriptyline|The nortriptyline will be given in an escalating fashion, starting at 25 mg PO qhs for 2 weeks, followed by 50 mg PO qhs for 2 weeks, and finally 75 mg PO qhs. Patients will be encouraged to use the lowest effective dose and to self-titrate their medication.
1997225|NCT02169830|Drug|Topiramate|Topiramate dosing will be 25 mg PO qhs for 1 week, followed by 25 mg BID for 1 week, followed by 25 mg in the morning and 50 mg qhs for 1 week, and finally 50 mg BID
1997229|NCT02170051|Behavioral|CBSST-CCT|
1997230|NCT02170051|Behavioral|Goal focused supportive contact|
1459139|NCT03281187|Drug|Androgel 50 mg|The 114 participants randomized to this arm must administer one packet of testosterone 50 mg topic gel (Androgel) applied once daily to skin of shoulders for 60 days.
1459140|NCT03281187|Other|Nasotestt Placebo|The participants randomized to this arm must administer one packet of placebo testosterone nasal gel (Nasotestt Placebo) in each nostril 3 times a day in addition to an active drug for 60 days.
1459141|NCT03281187|Other|Androgel Placebo|The participants randomized to this arm must administer one packet of placebo testosterone topic gel (Androgel Placebo) applied once daily to skin of shoulders in addition to an active drug for 60 days.
1459144|NCT03281148|Device|Computer guided implant insertion group|Implants will be immediately inserted in fresh extraction sockets using CAD/CAM guides
1459145|NCT03281148|Device|Free hand implant insertion group|Implants will be immediately inserted in fresh extraction sockets using free hand technique
1459146|NCT03281135|Other|HPV testing|Clusters randomly allocated to this arm of the study will be sensitized to be showed up in nearby health posts for self sampling with Evalyn brush for HPV testing.
1459147|NCT03281122|Drug|Placebo|Specified dose on specified days
1459148|NCT03281122|Drug|BMS-986224|Specified dose on specified days
1459149|NCT03281109|Diagnostic Test|diagnosis|diagnosis with ELISA
1459150|NCT03281096|Drug|Berberine hydrochloride|patients take the Berberine hydrochloride 300mg tablet by mouth, 2 times a day with 3 years.
1459151|NCT03281096|Drug|Placebo|pill manufactured to mmic Berberine hydrochloride 100mg tablet
1459152|NCT03281083|Drug|Levothyroxine Sodium|
1459153|NCT03281057|Behavioral|CRAFT|CRAFT is a counseling/therapist to concern significant others to get their loved one, with an alcohol use disorder, into treatment
1459154|NCT03281044|Drug|Fecal microbiota capsules|Patients will receive FMP-402 capsules containing the fecal microbiota drug substance within a gelatin capsule shell. The drug substance is fecal microbiota from a single donor.
1459155|NCT03281044|Drug|Placebo oral capsule|The control condition is a placebo FMT capsule. The FMT placebo capsule is identical in appearance to active capsules, but does not contain human feces, the active pharmaceutical ingredient. Placebo capsules will contain an autoclaved solution of glycerol and saline, contained in an identical gelatin capsule as the active product, including the same enteric polymer coating
1459156|NCT03281031|Procedure|Additional MRI Examination|MRI will be performed using a short protocol within 6 hours from CT and with blinding from CT results
1459157|NCT03281018|Behavioral|Caregiver Accompaniment Time (CAT) + preoperative hypnosis session|The hypnosis session is performed by a nurse trained in medical hypnosis; this interview lasts approximately one hour and is carried out 5 to 15 days before the hospitalisation. During the hypnosis session, the patient is free to choose what issues she wants to address. The patient will then go from a state of ordinary consciousness to a modified state of consciousness. This state will allow her to activate her own resources to handle difficulties, especially anxiety. Using a post-hypnotic suggestion, the patient will be able to revisit her work at any time she needs
1459158|NCT03280979|Drug|rescue regimen|In the rescue regimen , we administer MTX in an eight-day treatment regimen consisting of four administrations of TX given at 1 mg/kg I.M. every other day with folinic acid 0.1 mg/kg I.M,. given on intervening days.
1459159|NCT03280979|Drug|high dose methotrxate|In the high dose MTX protocol, the patients will receive 100 mg/m2 intravenous (IV) MTX bolus followed by 200 mg/m2IV MTX infused over 12 hours followed by folinic acid
1459160|NCT03280953|Diagnostic Test|Assessing fluid responsiveness by PWTT value|PWTT value will be analysed to find the cutoff values compared by esophageal doppler and pulse pressure variation.
1459161|NCT03280927|Drug|Jublia®|Jublia® topical solution
1459162|NCT03280914|Device|Auto-CPAP|Automatic Continuous Positive Airway Pressure treatment is the first-line treatment of obstructive sleep apnea
1459163|NCT03280901|Other|HD, Magnetic Resonance Imaging (MRI) scans|HD, Magnetic Resonance Imaging (MRI) scans using a specifically designed unit able to perform MRI scanning during HD sessions
1459164|NCT03280875|Other|pedalling exercises|pedalling exercises on a bicycle ergometer
1459165|NCT03280862|Device|Implantation of a Cardiac Resynchronisation Therapy (CRT) pacing device with or without Implanted Cardioverter Defibrillator|Implantation of CRT-P/-D device
1459166|NCT03280849|Other|Implant of bilaminar chitosan scaffold|The patient underwent endoscopic endonasal transsphenoidal surgery for resection of the sellar lesion, under the direct visualization, the lesion appeared redish and soft with moderately bleeding, a sample was taken for pathology and the remaining is extracted without complications, then the scaffold is implanted in the site of the bone defect in the sphenoid sinus, due to its moldable nature, it was easily set, covering the entire extension of the defect, a fat graft was set in the sphenoid sinus covering the bilaminar chitosan membrane, then fibrin sealant was used for hemostatic control and a nasal packing was set in both nostrils for finalize the procedure.
1459930|NCT03275064|Other|Placebo|Placebo intra-articular injection
1459167|NCT03280836|Behavioral|Exercise|"All participants randomized to the intervention group will be asked to keep an exercise log with the date, time, average heart rate obtained from a heart rate monitor, duration of workout and stretching, and any comments regarding the workout. Participants will be instructed to bring workout logs to infusion sessions for review. Participants will also wear a Polar Heart Rate monitor (US model RS400, Polar Electro Inc., Lake Success, NY) during exercise to monitor exercise intensity.
The aerobic exercise intervention will work toward the target of 75 minutes physical activity per week at 60%-85% of baseline VO2max."
1459168|NCT03280810|Other|Movement group|Experimental group : patients with schizophrenia who realise psycho-corporal training once a week, during 1 hour and a half for a period of two months
1459170|NCT03280771|Combination Product|Hope Soap|HOPE SOAP© is a colourful, translucent bar of soap with a toy embedded in its centre.
1459171|NCT03280771|Combination Product|Control group soap|A colourful, translucent bar or soap with the toy alongside it
1459172|NCT03280758|Behavioral|Muscle Strengthening exercises|Participants will be required to participate in resistance training 3 hours per week.
1459173|NCT03280745|Drug|Hypertonic saline|At admission to the ICU patients will receive 5ml/kg body weight of 7.3% NaCl by infusion pump over 60 minutes.
1459174|NCT03280745|Drug|0.9% saline|At admission to the ICU patients will receive 5ml/kg body weight of 0.9% NaCl by infusion pump over 60 minutes.
1459175|NCT03280732|Device|Lung Ultrasound|A Mindray-DC-T6 ultrasound machine equipped with a linear probe with frequencies ranging from 7.5 to 12 MHz will be use. LUS examination will consist of both longitudinal and transversal sections according to the methodology described by Copetti and colleagues.
1459176|NCT03280719|Device|Prone Radiotherapy|Prone positioning for regional nodal irradiation using the crawl breast couch.
1459177|NCT03280719|Radiation|Acceleration|Accelerated irradiation in 5 fractions over 12 days with simultaneously integrated boost
1459178|NCT03280719|Device|Supine Radiotherapy|Supine positioning for regional nodal irradiation using breastboard.
1459179|NCT03280719|Radiation|Hypofractionation|Moderate hypofractionation in 15 fractions over 3 weeks with simultaneously integrated boost
1459180|NCT03280706|Dietary Supplement|Maltodextrin|Maltodextrin 50g in water 500ml
1459181|NCT03280706|Dietary Supplement|Orange Juice|Orange juice 480ml + 20ml of water
1459182|NCT03280706|Dietary Supplement|Coffee with milk|Coffee with milk (330 ml of milk + 220 of water)
1459183|NCT03280693|Diagnostic Test|Diagnostic test|Body balance was assessed using Berg Balance Scale (BBS), while BMD of the lumbar spine was measured by dual energy X-ray absorptiometry (DEXA) scan.
1459184|NCT03280680|Other|Female+male group sessions|Female and male group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
1459185|NCT03280680|Other|Female group sessions|Only female group member received separate group session on sexual and reproductive health and rights, gender, violence against women and girls, consent and choice, conflict resolution etc. Each group received 13 sessions of 2 hours over 20 months. Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
1459186|NCT03280680|Other|No group sessions|Community mobilization and service provision for sexual and reproductive and violence against women were also provided.
1459187|NCT03280667|Drug|Pembrolizumab plus denosumab|Pembrolizumab 200 mg IV every 3 weeks plus denosumab 120 mg SC on day 1, 8, 22 and then every 3 weeks with daily oral calcium and vitamin D
1459188|NCT03280654|Other|overactive bladder|Association between groups and over active bladder symptoms
1459189|NCT03280641|Drug|Dabigatran Etexilate 110mg|Dabigatran Etexilate 110mg, BID
1459190|NCT03280641|Drug|Warfarin Sodium|Target INR:1.6-3.0
1459191|NCT03280628|Procedure|Absorbable Sutures|The patient's doctor will close the patient's laceration with absorbable sutures.
1459192|NCT03280628|Procedure|Steri-Strips|The patient's doctor will close the patient's laceration with Steri-Strips.
1459193|NCT03280628|Procedure|Dermabond|The patient's doctor will close the patient's laceration with Dermabond.
1459196|NCT03280602|Procedure|Tension band wiring (TBW)|2 x K-wire fixation (1.6 mm) and wire cerclage.
1459197|NCT03280602|Procedure|Plate fixation|Olecranon fractures in this arm are fixed with Synthes´ VA-LCP Olecranon Plates 2.7/3.5.
1459198|NCT03280589|Other|Sheetali/Sheekari Pranayama|Most pranayama involves (1) sitting quietly, (2) deep breathing (completely filling and emptying the lungs, at a slow/comfortable pace, with awareness), and (3) a specific mouth, tongue, lip and/or body shape, theorized to enhance the effects of the practice. Practitioners of pranayama modulate the cycles of inspiration and expiration, in a way that is theorized to achieve influence over autonomic functions such as heart rate, heart rate variability (HRV), and baroreflex [6]. For example, the manipulation of the tongue and face during Sheetali and Sheetkari pranayama is intended to stimulate parasympathetic nervous system activity and inhibit the sympathetic nervous system.
1459199|NCT03280589|Other|Sitting Quietly|Participant breaths in their natural way with out instruction
1459200|NCT03280589|Other|Deep breathing|Participant is required to pay attention to each breath
1459438|NCT03278951|Behavioral|In Person Group|
1459208|NCT03280550|Drug|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection every 2 or 4 weeks.
1459209|NCT03280550|Drug|Placebo|Matching placebo will be administered as a SC injection every 2 or 4 weeks.
1459210|NCT03280537|Drug|Omalizumab|Omalizumab will be administered as a subcutaneous (SC) injection every 2 to 4 weeks.
1459211|NCT03280537|Drug|Placebo|Matching placebo will be administered as an SC injection every 2 or 4 weeks.
1459212|NCT03280524|Other|reflexology|
1459213|NCT03280524|Other|self-care guidelines with feet|
1947870|NCT02961192|Behavioral|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
1459215|NCT03280498|Procedure|Intubation|elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
1459216|NCT03280485|Other|no intervention|no intervention validation of guidelines via database
1459217|NCT03280472|Behavioral|Cognitive Bias Modification|"CBM training. For those in the CBM condition, participants will complete a task. In this task, they will read ambiguous, two- to four-sentence social-related scenarios on the computer. The final word in the scenario will have a missing letter. Participants will type the missing letter. Participants will also be asked to answer a Yes/No comprehension question about the scenario. The missing letter will resolve the ambiguity of the scenario in a positive way, intended to train participants to have more positively-biased interpretations of ambiguous social information"
1459218|NCT03280472|Behavioral|Symptom tracking|Participants will track their symptoms
1459219|NCT03280459|Procedure|robot-assisted cystectomy|Removal of urinary bladder in oncologic or functional setting using a assistance of a operation robotic for laparoscopy
1459220|NCT03280446|Device|Intragen fractional radiofrequency with NeuViVa|The Transcutaneous Fractional Radiofrequency Device (TFRF) is a minimal risk device that is currently cleared by the FDA K142833.The device uses a non-invasive, transepithelial treatment probe to elevate epithelial tissue temperatures to 40-45 oC for the purpose of promoting tissue contracture. Real-time tissue impedance monitoring will be carried out using the treatment probe.
1459221|NCT03280433|Other|Aortic valve replacement|
1947871|NCT02961192|Behavioral|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
1947872|NCT02961192|Behavioral|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
1459224|NCT03280407|Drug|Capecitabine|Radio-chemotherapy with 50.4 Gy in 28 fractions to tumor and regional lymph nodes concomitantly with capecitabine 825 mg/m2 b.i.d
1459225|NCT03280407|Drug|FOLFOX regimen (oxaliplatin/leucovorin/5FU)|Six cycles: Oxaliplatin 85 mg/m2 day 1, leucovorin 400 mg/m2 day 1, 5FU 400 mg/m2 bolus day 1 and 5FU 2400 mg/ m2 over 46-48 hours day 1-3, repeated every two weeks.
1459226|NCT03280407|Drug|CAPOX (oxaliplatin/capecitabine)|Four cycles: Oxaliplatin 130 mg/m2 day 1 and capecitabine 1000 mg/m2 b.i.d. days 1-14, repeated every 3 weeks.
1459227|NCT03280394|Diagnostic Test|Liquid Biopsy|Assessing whether plasma cell free DNA improves the accuracy of early prediction of cure in mature B-cell tumor patients and whether it represents an accessible source of tumor DNA for the sensitive identification of genetic biomarkers that, at disease presentation, refine the diagnostic workup in mature B-cell tumor patients and, upon treatment, early identify the emergence of resistance mutations.
1459228|NCT03280381|Other|Nifty feeding cup|The 40 mL Nifty Feeding Cup features an extended reservoir off the lip of the cup that holds a small bolus of milk, ensuring efficient delivery of milk, is made of a durable, soft, silicone material that protects the infant's mouth from injury, has embossed measurements help with tracking volume and intake of milk, is ergonomically designed for frequent use and to enhance finger and wrist control of milk flow and is made from a quick-drying, ultraviolet radiation-resistant, durable, affordable silicone that can be boiled for sterilization. Mothers can directly express into the cup, reducing possible cross-contamination from other containers.
1459229|NCT03280381|Other|Generic medicine cup|The generic cup that will be used in this study is a small medicine cup 30 ml in size.Small medicine cups are manufactured by a variety of manufacturers and are commonly used in health facilities to feed breastmilk to infants who are having breastfeeding difficulties. The cups are generally translucent, calibrated with a variety of measurements including 2.5-30 mL.
1459230|NCT03280368|Other|Bloodtest|
1459231|NCT03280368|Other|Questionnaires|
1459232|NCT03280355|Behavioral|Singing training|"Each session will contain technical instruction in order to achieve better respiratory control and primary muscular strength, and with focus on techniques for efficient expiration. Sessions will also focus on musical content and interpretation as well as interaction, the social aspects and joy of singing together.
Prior to the trial all singing teachers will participate in a 2 days' workshop, where they will be instructed in sufficient methodology and didactics, and will obtain profound knowledge about the disease pathology and related physiology."
1459233|NCT03280355|Behavioral|Physical Training|"Physical Training (golden standard training activity in pulmonary rehabilitation) - usual care - is the active comparator in the trial.
The programme is based on the national guidelines for pulmonary rehabilitation, and consists of supervised warm-ups, aerobic exercises, workout (strength), and breathing exercises.
Physical Training is conducted by the local physiotherapists in the local health centres."
1947873|NCT02959671|Device|Lower Anterior EXD-952 Self-ligating Brackets|Placement of EXD-952 Self-ligating Brackets on mandibular incisors
1995021|NCT02871219|Drug|Lenalidomide|Participants receive 6 cycles of Lenalidomide, 20 mg daily on Days 1-21 of a 28 day cycle. Participants exhibiting a CR or CRu after six cycles then receive 12 additional cycles of 10 mg of Lenalidomide daily on Days 1-21 every 28 days for a total of 18 cycles. Participants with a PR after six cycles continue 20 mg of Lenalidomide on Days 1-21 every 28 days for 3 to 6 more cycles until they achieve a CR/CRu at which time they will receive 10 mg Lenalidomide on Days 1-21 every 28 days for a total of 18 cycles. Participants with SD or PR after 12 cycles receive 10 mg of Lenalidomide on Days 1-21 every 28 days for a total of 18 cycles.
1459236|NCT03280329|Other|Generalized Music therapy|Patients will receive broadcasted music via speakers in their room from 7am to 11pm, from admission to discharge
1460056|NCT03274141|Other|Non-Interventional|Non-Interventional
1995022|NCT02870972|Drug|BCX7353|Plasma kallikrein inhibitor
1995023|NCT02870972|Drug|Placebo|
1459237|NCT03280329|Other|Personalized Music therapy|Patients will receive music via earphones after specific music therapist advice, for 2 hours per day, from admission to discharge
1459238|NCT03280316|Procedure|surgery|patients with SVMs receive surgery
1459239|NCT03280316|Procedure|sacral neuromodulation|sacral neuromodulation (SNM) with InterStimTM
1459240|NCT03280316|Procedure|botulinum toxin A injection|BOTOX
1459241|NCT03280316|Drug|M receptor antagonist|Tolterodine
1459243|NCT03280290|Biological|blood|assessment pre-donation of hematopoietic stem cells (blood sample)
1459244|NCT03280277|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
1459245|NCT03280277|Drug|Ferumoxytol|Given IV
1459246|NCT03280264|Drug|KHK7580|oral administration
1459247|NCT03280251|Drug|Methylphenidate|Methylphenidate (capsules of Ritaline LP 10) encapsulated, 0,3 mg per kg per day during 6 weeks
1459248|NCT03280251|Drug|Placebo|Placebo, identical capsules to encapsulated MPH, number of capsules per day identical to MPH during 6 weeks
1459249|NCT03280251|Other|CogniPlus software|Structured cognitive training with CogniPlus software, twice per week during 6 weeks
1459250|NCT03280251|Other|Pseudo cognitive training|Pseudo cognitive training with 45 minutes documentary videos and 15 minutes quiz, twice per week during 6 weeks
1459251|NCT03280238|Diagnostic Test|Measurement of pupil dilation and analgesia nociception index|painful electrical stimuli of various intensities were administered to the subjects after which changes in pupil diameter and analgesia nociception index were measured
1459252|NCT03280225|Other|External facilitation|"Facilitation is an evidence-based implementation strategy to support sites that have difficulty implementing innovative programs. Facilitation is a multi-faceted process of interactive problem solving and support that occurs in the context of a recognized need for improvement and a supportive interpersonal relationship (Powell et al., 2015). Facilitation has been used nationally across VA to implement a number of different clinical interventions. The current project will examine this minimally intensive version of implementation facilitation, virtual external facilitation."
1459253|NCT03280212|Drug|Tranexamic Acid 500 MG|Tranexamic Acid 500mg oral tablets.
1459254|NCT03280199|Other|simulation types|Different types of simulation interfaces and image acquisitions
1459255|NCT03280186|Procedure|surgery|The minimally invasive surgical treatment methods and new techniques will be adopted such as spinal superselective angiography, preoperative embolization, intraoperative electrophysiological monitoring, intraoperative angiography, etc.
1459257|NCT03280160|Drug|Ibrutinib 140 MG Oral Capsule [Imbruvica]|"Ibrutinib will be administered orally 420 mg (3 x 140 mg capsules) once daily on a continuous schedule on an outpatient basis until disease progression or unacceptable toxicity.
After 12 cycles of ibrutinib, patients that do not achieve a complete response (CR) will be treated with the combination of ibrutinib and ofatumumab. Patients in CR after 12 cycles of ibrutinib will continue with ibrutinib alone.
Ofatumumab will be administered by IV infusion, 300mg on Day 1 and 1,000 mg on Day 8 of cycle 13, followed by 5 monthly infusions of 1,000 mg (Day 1 of subsequent 28-day cycles for cycles C14, C15, C16, C17, and C18).
A treatment cycle will be defined as lasting 28 days"
1459258|NCT03280147|Drug|7-day course of antibiotics|"Subjects in the 7-day course of antibiotics arm of the study will receive no further antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
1459259|NCT03280147|Drug|14-day course of antibiotics|"Subjects in the 14-day course of antibiotics arm of the study will receive 7 more days of antibiotics after randomization as they would have already received 7 days of sensitive antibiotics before randomization. The choice of antibiotics would be guided by the blood culture and sensitivity report. Thus, subjects in this arm of the study could get a variety of antibiotics, depending on the sensitivity reports. Hence, names of specific antibiotics and/or their brand names have not been mentioned."
1459260|NCT03280134|Procedure|axillary lymph node dissection (ALND)|If the patients had predictive nSLN+, need further axillary lymph node dissection.
1459261|NCT03280121|Device|EsophyX ZR transoral device|TIF
1459262|NCT03280095|Drug|co-codamol 15mg/500mg capsule|
1459263|NCT03280095|Drug|co-codamol 30mg/500mg tablet|
1459264|NCT03280082|Other|MUAC Program|All children admitted to the PB program will receive standard care according to the national Protocol and that of MSF, including preventive and therapeutic care at admission as well as hospital care in case of clinical complications. There will be no change in the Protocol for the hospital care to the CRENI (Center of Intensive Nutritional Rehabilitation). RUTF (Ready-to-Use therapeutic food) will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
1459265|NCT03280082|Other|Standard Program|All children admitted to the standard program will receive standard care according to national and MSF protocols, including preventive and therapeutic care on admission as well as hospital care in case of clinical complications. RUTF will be distributed on a weekly basis according to the dosage of RUTF in the national protocol.
1459266|NCT03280069|Device|THERMIeyes® 20 RF System|The masked evaluating physician will be blinded as to which eye is treated. The evaluation on all visits will be performed on both eyes by the masked physician who will not know which eye has been treated with the THERMIeyes® 20 RF System. The treating technician will be aware of the treated eye so as to ensure all treatments are performed to the same eye.
1459267|NCT03280056|Biological|NurOwn® (MSC-NTF cells)|Autologous transplantation of bone marrow derived mesenchymal stem cells propagated ex vivo and induced to secrete neurotrophic factors
1459268|NCT03280056|Other|Placebo|Placebo
1459269|NCT03280043|Procedure|Hematoma|Hematoma requiring return to operating room.
1461009|NCT03266692|Biological|ACTR087|Autologous T cell product
1459272|NCT03280017|Drug|Ketamine|intravenous ketamine 0.2 mg/kg/hr (concentration 1 mg/ml)
1459273|NCT03280017|Drug|Normal saline|normal saline infusion
1459274|NCT03280004|Drug|Moxifloxacin Hydrochloride and Sodium Chloride Injection|Moxifloxacin group will be given Moxifloxacin Hydrochloride and Sodium Chloride Injection and β-lactams group will be given β-lactam antibiotics for injection +/- Azithromycin for Injection.
1459278|NCT03279965|Diagnostic Test|MRI|MRI of lungs, paranasal sinuses and liver in addition to established clinical examinations (lung CT, pulmonary function testing)
1459279|NCT03279952|Drug|CNS Stimulant|Participants will be stabilized by any FDA approved CNS stimulant medication during open label trial.
1459280|NCT03278847|Dietary Supplement|Received enteral (milk) feeds during therapeutic hypothermia|"In the enteral component of nutrition, the health technology to be assessed is the gradual introduction of enteral (milk) feeds during therapeutic hypothermia:
Included in this is any type of milk (e.g. expressed maternal breast milk, expressed donor breast milk and artificial formula)
This health technology includes different routes of administering enteral feeds such as nasogastric tube (gavage feeding) and bottle
This health technology also includes different rates of increasing enteral feeds (for example by 15ml/kg/day, by 30ml/kg/day or faster)"
1459281|NCT03278847|Dietary Supplement|Enteral (milk) feeds withheld during therapeutic hypothermia|Withholding enteral feeds (keeping a baby nil per os) for the duration of hypothermia.
1459282|NCT03278847|Dietary Supplement|Received parenteral nutrition during therapeutic hypothermia|"In the parenteral component, the health technology being assessed is administration of parenteral nutrition during therapeutic hypothermia:
Included in this are different compositions of parenteral nutrition (for example standard, pre-prepared bags of nutrition and individually tailored parenteral nutrition)
This health technology includes different routes of administration of parenteral nutrition such as via a peripheral intravenous cannula, percutaneous central venous catheter ('long line') or umbilical venous catheter.
This health technology also includes different volumes of parenteral nutrition (e.g. 40ml/kg/day, 60ml/kg/day or greater)."
1459283|NCT03278847|Dietary Supplement|Did not receive parenteral nutrition during therapeutic hypothermia|Received standard intravenous fluids (10% dextrose with additional electrolytes added where required) for the duration of hypothermia.
1459284|NCT03278834|Device|Neuromuscular muscle stimulation machine- Strength Setting|Muscle stimulation to strength skeletal muscle
1459285|NCT03278834|Device|Neuromuscular muscle stimulation machine - TENS Setting|Muscle stimulation to mimic the intervention but without the strength gains.
1459286|NCT03278821|Behavioral|Self Match|Video presentation of treatment option are shown to the patient whereafter the patient must choose between the five possible treatment options.
1459287|NCT03278821|Behavioral|Ekspert Match|Referral as usual to one of five possible treatment options. The referral is based on baseline data from the patient and by the means of an algorithm, used in daily clinical praxis.
1459288|NCT03278808|Drug|Chloroquine-Azithromycin (CQ/AZ)|Chloroquine-Azithromycin (CQ/AZ); Chloroquine (CQ) 300mg and 2g of azithromycin (AZ) given orally
1459289|NCT03278808|Drug|Chloroquine (CQ)|Chloroquine (CQ); 300 mg of CQ only given orally
1459290|NCT03278808|Drug|atovaquone-proguanil (Malarone®)|All subjects will participate in the Controlled Human Malaria Infection (CHMI) and will be required to stay at a hotel for evaluation for a maximum of 14 nights starting 7 days after the challenge. A standard dose of atovaquone-proguanil (Malarone®) will be administered to all symptomatic parasitemic subjects under directly observed treatment.
1459291|NCT03278795|Procedure|pressure support ventilation mode|PSV is the sole mode of mechanical ventilation and will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In PSV weaning group , PS(pressure support) will be adjusted at 8 cmH2O until 2-h successful spontaneous breathing trial parameters according to ERS(European Respiratory Society) guidelines will be achieved and then patient will ex-tubated.
1459292|NCT03278795|Procedure|volume support ventilation mode|"VSV mode could be viewed as PRVC for spontaneous breathing as it delivers a variable pressure to meet a target VT. VSV will be used as a weaning mode in mechanically ventilated chronic obstructive pulmonary disease patients,In VSV weaning group ,VT(tidal volume ) will be adjusted at 6 ml/ Kg until 2-h successful spontaneous breathing trial parameters according to ERS guidelines will be achieved and then patient will ex-tubated."
1459293|NCT03278782|Drug|Pembrolizumab|Phase I and II Dose: 200 mg by vein every 3 weeks on Day 1 for up to 36 cycles.
1459294|NCT03278782|Drug|Romidepsin|"Phase I Starting Dose: 14 mg/m2 by vein on Day 1 and 8 of each 3 week cycle.
Phase II Starting Dose: Maximum tolerated dose from Phase I."
1459295|NCT03278769|Procedure|Lung protective ventilator settings|Positive end-expiratory pressure 12, Tidal volume 6 milliliter/kilogram predicted body weight
1459296|NCT03278756|Behavioral|Cognitive control training|10 sessions of an adaptive paced auditory serial addition task, each lasting 15 minutes, over the course of two weeks.
1459297|NCT03278756|Behavioral|Active control training|10 sessions of an low cognitive load task, each lasting 15 minutes, over the course of two weeks.
1459298|NCT03278743|Other|Cognitive performance and cognitive decline|Assess the global and domain specific (memory, speed and attention) cognitive function at baseline and over 5 years in the high vs. low/moderate tea consumption groups
1459299|NCT03278730|Drug|Para-Tyrosine supplementation|Patients will recieve the study drug during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of para-Tyrosine, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
1459300|NCT03278730|Drug|Placebo solution|Patients will recieveplacebo during their stay at the ICU, but for a maximum of 7 days. The study drug is 3x2 gramms of placebo, which will be dispensed and administered in a form of oral suspension via a nasogastric tube.
1459301|NCT03278717|Drug|Olaparib|Olaparib is a PARP inhibitor, targeting DNA repair processes.
1459302|NCT03278717|Drug|Cediranib|Cediranib is an inhibitor of vascular endothelial growth factor-A (VEGF), targeting angiogenesis.
1459303|NCT03278704|Other|RE only|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise.
1459439|NCT03278938|Drug|bupropion|FDA approved drug for treating depression
1459440|NCT03278938|Drug|citalopram|FDA approved treatment for depression
1459304|NCT03278704|Other|RE + HIIT|8 weeks of supervised training. Three times weekly with no more than two non-consecutive days without exercise. Concurrent training: RE followed by HIIT within the same session.
1459305|NCT03279926|Behavioral|PLAY|Activity trackers + curriculum information
1459306|NCT03279926|Behavioral|PLAY Parents|Enhanced parental engagement
1459307|NCT03279926|Behavioral|PLAY Teachers|Enhanced teacher engagement with active living initiates for the teachers
1459309|NCT03279887|Diagnostic Test|Lung Ultrasound|
1459311|NCT03279861|Drug|Entresto|First line therapy in Entresto arm
1459312|NCT03279861|Drug|Valsartan|"First line therapy in usual meds arm"
1459313|NCT03279835|Other|Classic evaluation of neurocognitive functions|Symbol Digit Modalities Test (SDMT)
1459314|NCT03279835|Other|New evaluation of neurocognitive functions|Cognitive Speed Computerized Test (CSCT)
1459315|NCT03279822|Other|not any intervention|not any intervention
1459316|NCT03279809|Drug|Aspirin|Aspirin medication (100mg daily) after biliary stent insertion for malignant obstruction
1459317|NCT03279809|Drug|Placebo|Case with placebo medication for 6 months after stenting
1459318|NCT03279796|Biological|Autologous adipose-derived MSCs|The dose of adipose-derived mesenchymal stem cells was related to body weight, and 1 × 10 ^ 6 cells were a unit. One unit of adipose-derived mesenchymal stem cells was injected every 10 kg of body weight and injected once a week for three times.
1459319|NCT03279796|Drug|Compound betamethasone|1ml dexamethasone mixed with 0.5-2ml of saline to achieve the same injection volume with the cell suspension (which contains betamethasone dipropionate 5mg and betamethasone sodium phosphate 2mg) ), once a week for three times.
1459320|NCT03279783|Device|LCI (Linked color imaging)|Colonoscope withdrawal was performed in the right colon evaluating the mucosa using LCI (Linked color imaging)
1459321|NCT03279757|Drug|AHES 5 minutes|Topical application of AHES with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
1459322|NCT03279757|Drug|AHES 15 minutes|Topical application of AHES with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
1459323|NCT03279757|Drug|AHES 25 minutes|Topical application of AHES with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
1459324|NCT03279757|Drug|LTC 5 minutes|Topical application of LTC with 5 minutes application time After 5 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
1459325|NCT03279757|Drug|LTC 15 minutes|Topical application of LTC with 15 minutes application time After 15 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
1459326|NCT03279757|Drug|LTC 25 minutes|Topical application of LTC with 25 minutes application time After 25 minutes: pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
1459327|NCT03279757|Device|fractional CO2 laser, 50 mJ, 5% density|Pain stimulus with the fractional CO2 laser, 50 mJ, 5% density
1459328|NCT03279744|Drug|Radion™-pdt|The Radion™-pdt will be applied topically to the lesion. The Radion™-pdt applied dosage is about 0.1 mL/cm^2 and properly cover the entire lesion.
1459329|NCT03279731|Drug|Liraglutide (Saxenda) 6Mg/Ml Inj Pen 3Ml|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). Matching the recommended dosage and administration guidelines of the FDA-approved labeling for the use of liraglutide (Saxenda), the medication will be initiated at 0.6 mg daily for 1 week, and then increased by 0.6 mg/day in weekly intervals until a dose of 3.0 mg/day is achieved.
1459330|NCT03279731|Drug|Placebo|subcutaneous injection, pre-filled, multi-dose pen that delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg, or 3 mg (6 mg/mL, 3 mL). It is designed to be identical to the pen used for liraglutide (Saxenda). Placebo product inactive ingredients: disodium phosphate dihydrate, 1.42 mg; propylene glycol, 14 mg; phenol, 5.5 mg; and water for injection
1459331|NCT03279718|Procedure|Periodontal Treatment|Scaling and root planing
1459332|NCT03279705|Device|Water jet channel|The separate water jet channel was used for infusing water.
1459333|NCT03279705|Device|Accessory channel|The accessory channel was used for infusing and/or suctioning water
1459334|NCT03279692|Drug|Pembrolizumab|pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
1459335|NCT03279679|Procedure|costoclavicular infraclavicular block|Infraclavicular brachial plexus block will be performed through new costoclavicular space approach under realtime ultrasound guidance with 0.5% ropivacaine
1459336|NCT03279679|Procedure|paracoracoid infraclavicular block|Infraclavicular brachial plexus block will be performed through traditional paracoracoid approach under realtime ultrasound guidance with 0.5% ropivacaine
1459337|NCT03279679|Device|Ultrasound|All the nerve blocks will be performed under realtime ultrasound guidance
1459338|NCT03279679|Drug|Ropivacaine|0.5% ropivacaine will be used for the brachial plexus block in both groups.
1459339|NCT03279666|Other|Tenaculum replacement|Tenaculum replacement during colposcopic biopsy
1459340|NCT03279653|Procedure|SleeveGastrectomy|Preoperative enzyme test before and after sleeve gastrectomy. Sleeve Gastrectomy will be performed. Preoperative (in one month) and Postoperative (after 3 months) pancreatic enzyme sufficiency (with steatocrit or fecal elastase) will be compared.
1459341|NCT03279640|Device|rTMS on ipsilesional M1|
1459342|NCT03279640|Device|tDCS on contralesional M1|
1459343|NCT03279627|Other|Diabetes Management Questionnaire|Patients will be asked questions regarding their understanding of instructions for home diabetes management within 48 hours of hospital discharge. At 1 and 3 months, participants will be contacted to obtain information regarding ER visits or hospital readmissions.
1459344|NCT03279614|Drug|SOX|OXA：130mg/m2 ，iv drip for 180min d1, S-1 40-60mg p.o. bid d1-14, q3W
1459345|NCT03279601|Drug|Capecitabine, Dacarbazine|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W Dacarbazine: 200mg/m2 ，iv drip,d1-5 q4W
1459346|NCT03279601|Drug|Capecitabine, Temozolomide|Capecitabine: 1000mg/m2 ，p.o. bid d1-14 q4W, Temozolomide: 200mg/m2 ，p.o. bid d10-14 q4W,
1459347|NCT03279588|Diagnostic Test|Bedside Ultrasound|Patients presenting to the Emergency Department with abdominal pain suspected of acute diverticulitis are evaluated with standard care by an Emergency Physician (tutor); at the time the tutor requests an imaging test performed by Radiologist (CT scan or US scan), he notifies another physicians skilled in bedside abdominal US (ultrasonographer), who evaluates the patient and performs the US scan. Ultrasonographer after completation of US and knowing blood samples results fills in a standardized form reporting the diagnostic hypotesis, the need for additional work-up (if deemed necessary), and the disposition of the patient. The standardized form completed by the ultrasonographer will be compared with the actual management of the patient.
1459348|NCT03279575|Behavioral|Night Shift|Physicians in this arm of the trial will be asked to play Night Shift, an adventure video game, for two hours.
1459349|NCT03279575|Behavioral|Graveyard Shift|Physicians in this arm of the trial will be asked to play Graveyard Shift, a puzzle video game, for two hours.
1459350|NCT03279575|Behavioral|Educational program|Physicians in this arm of the trial will be asked to use myATLS, an app designed by the American College of Surgeons to serve as an adjunct to the ATLS course, and Trauma Life Support MCQ Review, an app designed to help students prepare for the ATLS exam. They will be asked to spend at least two hours on the combined tasks.
1459351|NCT03279575|Behavioral|Control|Physicians in this arm will serve as a no-contact control group.
1459352|NCT03279562|Drug|Nalmefene|Educational and behaviorally oriented drug counseling
1459353|NCT03279549|Procedure|Routine dressing change|Through regular dressing changes to clean the wound, reduce bacterial growth in the wound and protect the wound. In recent years, nano-silver ion gel and dressings are widely used in burns, which effectively reduced the risk of wound infection and beneficial for wound healing. This technique is widely used in clinic.
1459354|NCT03279549|Procedure|Limited debridement & Acellular dermal matrix dressing|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. The xenogeneic acellular dermal matrix dressing has a better protective effect on burn wound after debridement. After covering, the wound will remain alive for about two weeks, providing a good microenvironment for wound repair."
1459355|NCT03279549|Procedure|Limited debridement & Epidermal cell spraying|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. Epidermal cell spraying technology is a brand new method to rapidly collect epidermal cells from patients themselves and then used on their wounds. The recipient site is 40-80 times than the donor site."
1459356|NCT03279549|Procedure|Limited debridement & Basic fibroblast growth factor|"In the removal of necrotic dermis in the rather not deep principle, as far as possible not damage the normal dermal tissue and skin accessories. This could improve circulation of wounds and improve wound healing. BFGF is a kind of polypeptide capable of promoting the growth of fibroblasts, and it also promotes the proliferation, differentiation and migration of epidermal cells. Studies have shown that bFGF could significantly improve the healing of burn wounds."
1459357|NCT03279536|Combination Product|Oral lactoferrin|Oral lactoferrin 120 mg twice /day and it's based on fast dissolving through direct swallowing per oral route with fruits flavor taste.
1459358|NCT03279536|Combination Product|TDI of LMW iron dextran|Total Dose Infusion of LMW iron dextran up to 20mg/kg body weight is infused intravenously
1459359|NCT03279523|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
1459360|NCT03279510|Device|hearing aids|Subjects are fit with hearing aids.
1459363|NCT03279484|Device|NAVIGO 4LV lead implant|All patients will be attempted to implant or implanted with NAVIGO 4LV lead
1459364|NCT03279471|Drug|Sertraline|Participants start at 12.5 mg and are increased by 12.5/day every two weeks for 14-16 weeks. Dosing is capped at minimum effective dose.
1459365|NCT03279471|Behavioral|CBT/BIACA|Participants receive 16 weeks of BIACA therapy.
1459366|NCT03279471|Drug|Placebo|Participants are given a placebo capsule with an administration schedule matching that of the sertraline subjects.
1459368|NCT03279445|Genetic|Genetic testing|Two tubes of blood samples for genetic testing.
1459369|NCT03279419|Diagnostic Test|Thermal imaging|Use of thermal imaging camera to capture images of peripheral vasculature (hands).
1459370|NCT03279406|Device|Percutaneous Left Atrial Appendage Occlusion|Percutaneous left atrial appendage occlusion in routine care for patients with atrial fibrillation
1459371|NCT03279393|Drug|fluorodeoxyglucose (FDG)-PET/MRI|Innovative PET combined with magnetic resonance imaging (PET/MRI) to simultaneously study the hematopoietic system, the artery wall, and the brain's fear system, which comprises the amygdala and anterior cingulate cortex (ACC)
1459372|NCT03279380|Other|SNP|Screening 150 endurance, 150 power athletes, and 200 healthy control individuals for genetic variant associated to sport performance.
1459441|NCT03278925|Drug|Defined Green Tea Catechin Extract|Given PO
1459442|NCT03278925|Other|Laboratory Biomarker Analysis|Correlative studies
1459443|NCT03278925|Other|Pharmacological Study|Correlative studies
1459444|NCT03278886|Drug|Low dose naltrexone|4.5 mg of low dose naltrexone taken once daily (one hour prior to bedtime) for 8 weeks
1459445|NCT03278886|Drug|Nalmefene|18 mg of nalmefene taken once daily (one hour prior to bedtime) for 8 weeks
2010458|NCT02960646|Radiation|Total body irradiation (TBI)|Total body irradiation (TBI) at a dose of 200 cGy administered on Day -2.
1459373|NCT03279380|Other|High Intensity Interval Training (HIIT)|The subgroup (n = 40) of the athletes will participate in the acute exercises (HIIT Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory at least three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
1459374|NCT03279380|Other|Low Intensity Continuous Training|The subgroup (n = 40) of the athletes will participate in the acute exercises (LIT Continuous Training). In order to investigate the acute effects of the exercise the concentration of circulating myokines will be measured (before, post-exercise and 2 h post-exercise). All participants will visit the laboratory three times, scheduled 96 h apart. Exercise will be carried out on the cycling ergometer with simultaneous monitoring of physiological responses. Participants will be asked to follow the prescribed diet regime and not to perform any physical activities / trainings the day before measurements. Baseline measurements will include the V̇o 2 peak test. Then the participants will be randomly divided into two groups. The specific acute exercises will be accomplish in the next two visits.
2010459|NCT02960646|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
1459376|NCT03279354|Behavioral|Family Move app intervention|All the recruited parent-child pairs will be randomized after baseline assessment by an independent statistician using computer randomization tool to either the FAMILY MOVE app intervention group or the HK FitNuts app control group with a 1:1 allocation ratio. Although both groups receive a stand-alone app, the apps have distinct design features: use of competition and point elements (FAMILY MOVE app) or use of traditional demonstration elements (HK FitNuts app). After both groups have completed the 8-week intervention study and follow up measurements at 1 month, 6 months and 12 months after intervention, the control group will receive the same FAMILY MOVE app. Outcome assessments will be conducted by a trained interviewer blinded to the subject group allocation.
1459377|NCT03279354|Behavioral|"HK FitNuts app intervention"|"The parent-child pairs in the control group will be given a link to download the HK FitNuts app which was developed by Hong Kong Association of Sports Medicine and Sports Science, Department of Orthopaedics & Traumatology of the Chinese University of Hong Kong and Hong Kong Dietitians Association to promote healthy lifestyle in Hong Kong. The app includes short video clips demonstrating basic individual exercise moves and provides other textual information related to PA. However, it does not have push notification function. In order to ensure that the intervention and control group will receive equal attention from our research team, we shall send a text about HK FitNuts and general exercise information to participants in the control group three times per week. Same as participants in the intervention group, the control group will also be asked to provide their weekly app usage and PA pattern by completing an online log at the end of each intervention week."
1459378|NCT03279341|Drug|polyethylene glycol|osmotic laxative
1459379|NCT03279341|Drug|Bisacodyl|stimulant laxative
1459380|NCT03279341|Drug|Prucalopride|prokinetic
1459384|NCT03279315|Dietary Supplement|iodized table salt, non-iodized table salt|During the first 3 weeks, the diet was provided with non-iodized salt, while the diet with iodized salt was only offered in the last week.
1459385|NCT03279302|Drug|Glepaglutide|Solution for injection
1947874|NCT02955823|Drug|Rituximab-Dexamethasone-Lenalidomide|"st CYCLE: Rituximab 375 mg/m2 i.v. on days 1,8,15; Dexamethasone 5 mg p.o. on days 1,8,15,22; Lenalidomide 15 mg/day p.o. day 2-22
nd-4th CYCLE: Rituximab 375 mg/m2 i.v. on day 1; Lenalidomide 20 mg/day p.o. from day 2 to day 22 At the end of 4th CYCLE disease restaging: - if ≥ PR continues with the 5th and 6th cycle: Rituximab 375 mg/m2 i.v. on day 1, Lenalidomide 20 mg /day p.o. day 2-22
if <PR stops the treatment, only follow-up At the end of the 6th CYCLE disease restaging: - if ≥ PR continues with beyond the 6th cycle with Lenalidomide 10mg dd1-21q28 until cycle 12th
if <PR stops the treatment, only follow-up Then, accordingly response rate after the sixth cycle assessment(≥ PR) lenalidomide will be continued at 10 mg dd1-21q28 until 12th cycle or unacceptable toxicity."
1947875|NCT02956057|Drug|Polyethylene Glycols|
1947876|NCT02956057|Drug|Natrium picosulfate / Magnesium citrate|
2010460|NCT02960646|Drug|Cyclophosphamide|50 mg/kg/day by vein on Days +3 and +4.
1459391|NCT03279276|Procedure|Total Hip Arthroplasty|"The usual procedures of the department: Moore incision and insertion of uncemented joints (exceed with vitamin E enriched polyethylene liner and 32 or 36 mm head). Cyclokaprone is administered peroperatively (bleeding-reducing), antibiotics and thrombosis prophylaxis. Follow the usual rehabilitation regimes, fast track, incl. Use of crutches and must support within the pain limit, possibly with crutches the first 4 weeks after surgery, then full load.
By default, postoperative X-ray and RSA recordings will be performed on the 1st or 2nd postoperative day. The surgery will be performed by specialist physicians in orthopedic surgery associated with the hip arthroplasty sector."
1459392|NCT03279263|Drug|MLR-1023|MLR-1023 Tablets
1459393|NCT03279263|Other|Placebo|Matching Placebo Tablets
1459398|NCT03279237|Drug|Irinotecan|May help shrink tumor before surgery.
1459399|NCT03279237|Drug|Oxaliplatin|May help shrink tumor before surgery.
1459400|NCT03279237|Drug|Leucovorin|May help shrink tumor before surgery.
1459401|NCT03279237|Drug|5-Fluorouracil|May help shrink tumor before surgery.
1459402|NCT03279237|Drug|Paclitaxel|Paclitaxel may stop cancer cells from growing and spreading.
1459403|NCT03279237|Radiation|Radiation Therapy|May help shrink tumor.
1459404|NCT03279237|Drug|Carboplatin|Carboplatin may stop cancer cells from growing.
1461268|NCT03264547|Drug|Trastuzumab|Every 3 weeks
1459405|NCT03279224|Biological|Allogenic FMT|"Fifty (50) g of screened donor feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.
2.The volume of fecal filtrate corresponding to fifty (50) g of donor stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.
3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
1459406|NCT03279224|Biological|Autologous FMT|"1. Fifty (50) g of the participant's feces will be weighed and homogenized with 30 mL of sterile 0.9 N NaCl + 10% glycerol using a sterile 330 micron micro-filter-separated double-compartment polyethylene bag in the Stomacher® Paddle Blender.
3.The volume of fecal filtrate corresponding to fifty (50) g of participant's stools will be transferred into a 50 mL Falcon tube with screw top and frozen at -80oC.
3. For colonoscopy administration, three (3) Falcon tubes of thawed FMT concentrated will be diluted to a total volume of 300 mL with 0.9N NaCl and will be transported to the endoscopy suite. In the endoscopy suite, the FMT product will be packaged into 6 x 50 ml syringes for patient delivery by colonoscopy."
1459407|NCT03279211|Other|Whey Protein Isolate 894 Fonterra|30 g of protein powder diluted in water
1459408|NCT03279211|Other|Zein Sigma-Aldrich W555025|30 g of protein powder diluted in water
1459409|NCT03279211|Other|Protein-free test-meal|No protein included in the drink made of water and flavour/sugar
1459410|NCT03279198|Behavioral|TIWeb|Intervention: TIWeb program is interactive and tailored to the participant's individual beliefs and demographics. Individuals receiving the TIWeb will be given information that allows them to call and receive an FOBT kit in the mail or schedule an appropriate CRC test and/or mammogram.
1459411|NCT03279198|Behavioral|CSC|Intervention: CSC - a telephone counseling call during which the participant is given the opportunity to complete CRC screening (FOBT or a colonoscopy) and/or mammography screening.The CSC included tailored counseling as well as the ability to schedule BC and CRC screening tests.
1459412|NCT03279198|Behavioral|UC|Intervention: The usual care group received usual care that varies dependent upon the practice setting.
1459413|NCT03279198|Behavioral|TIWeb+CSC|Intervention: TIWeb + CSC ((Tailored web intervetion+Cancer screening) group receive a mailed TIWeb, which is followed in four weeks by a CSC with the same opportunity to receive FOBT kits or schedule a colonoscopy and/or mammogram. The nurse counselor, knowing the participant is a good candidate for screening tests, will be trained to schedule CRC or BC screening appointments or to mail FOBT kits to individuals in the intervention groups even if they have not had a recent clinic visit.
1459414|NCT03279172|Procedure|direct laryngoscope|procedure entubatıon
1459415|NCT03279172|Procedure|videolaryngoscope|
1459416|NCT03279159|Other|Jaluronius CS cream short term evaluation|Short term evaluation to investigate the hydrating activity of a single application of the study product on the forearms (volar surface) after repeated stripping procedure,measured immediately after stripping execution (T0i), 1,8 and 24 hour/s after product application (T1h, T8h and T24h).
1459417|NCT03279159|Other|Jaluronius CS cream long term evaluation|Long term evaluation to investigate the hydrating activity of the repeated application of the study product on the face (twice a day, for an uninterrupted period of 8 weeks), measured at basal visit (T0) and after 4 and 8 week-treatment (T4, T8)
1459418|NCT03279146|Drug|Tenofovir exalidex (TXL)|Oral formulations
1459419|NCT03279133|Drug|Ledipasvir 90mg/Sofosubvir 400mg|Ledipasvir 90mg/Sofosubvir 400mg (LDV/SOF) FDC is to be administered once daily with or without food for12 weeks.
1459420|NCT03279120|Drug|TFV/LNG IVR|Used for 90 days (Continuous or Interrupted)
1459421|NCT03279120|Drug|Placebo|Used for 90 days (Continuous or Interrupted)
1459422|NCT03279107|Other|Soluble corn fiber|soluble corn fiber
1459423|NCT03279107|Other|maltodextrin|maltodextrin
1459424|NCT03279094|Biological|Hematopoietic stem cell transplantation|Haploidentical stem cell transplantation with pre-transplant immunosuppressive therapy
1459425|NCT03279081|Drug|Cx601|Allogenic eASCs 5 million cells/ml - suspension for injection Cx601
1459426|NCT03279081|Other|Placebo|Solution for injection
1947877|NCT02956057|Drug|Polyethylene glycol / Ascorbic acid|
1459428|NCT03279055|Behavioral|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a publicly available insomnia intervention program. It focuses on 5 treatment components that form the core of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep behaviors, and relapse prevention.
1459429|NCT03279042|Procedure|Flapless corticotomy surgical intervention will be conducted|Piezocision will be used to perform the procedure
1459430|NCT03279042|Procedure|Traditional corticotomy|Here the surgery involves elevation of flaps and then conducting the surgical intervention using surgical burs.
2010461|NCT02960646|Drug|G-CSF|5 mcg/kg/day started on Day +7.
2010462|NCT02958865|Drug|PF-06651600 or Placebo|Delivered orally for 8 weeks.
1459433|NCT03279003|Device|LED light|An exposure to LED light will be carried out twice a week until improvement, maximum 8 weeks.
1459434|NCT03278990|Behavioral|Value Affirmation and Future Selves Combination|Following the questionnaire, participants will complete a 10- to 15-minute writing exercise. In the control condition, they will be given a list of values, select two that are least important to them, then write about why those values might be important to others. Next, they will write a short letter to themselves in 2 weeks. In the treatment condition, they will be given a list of values, select two that are important to them, then write for about why those values are important to them and how they have played a role in their life. They will then write a short letter to themselves twenty years in the future.
1459435|NCT03278977|Biological|Blood sample for specific analyzes|"Standard management of ALTE
Hospitalization in pediatric intensive care unit or pediatric emergencies
Etiologic research
Blood volume, 2.5mL in PaxGene® tube, for specific analyzes (M2R, AchE)"
1459436|NCT03278964|Procedure|Orbital decompression|
1459437|NCT03278951|Behavioral|Video Conferencing Group|
1947878|NCT02955251|Drug|ABBV-428|ABBV-428 will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and Day 15.
1947879|NCT02955251|Drug|Nivolumab|Nivolumab will be administered by intravenous infusion according to approved dose and dosing schedules.
2010463|NCT02958865|Drug|PF-06700841 or Placebo|Delivered orally for 8 weeks.
1459446|NCT03278873|Biological|AAV - CNGB3|Comparison of different dosages of AAV-CNGB3
1459447|NCT03278860|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
1459448|NCT03278860|Drug|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
1459449|NCT03278860|Drug|intranasal oxytocin|24 IU of oxytocin nasal spray will be applied to each subject.
1459450|NCT03278860|Drug|intranasal placebo|an identical amount of placebo nasal spray will be applied to each subject.
1459451|NCT03278691|Drug|Saline|1 ml saline IV Q6H
1459452|NCT03278691|Drug|Ketorolac|15 mg (15 mg/ml) IV Q6H
1459454|NCT03278652|Other|Consumption of drugs for analgesic use|"Regular assessment of pain
Drug data will be collected (name, dosage, route of administration, time of delivery)"
1459455|NCT03278639|Behavioral|Rhythmic Auditory Stimulation|Training will be directed to ameliorate gait and balance
1459456|NCT03278639|Behavioral|Kinesiology|Training will be directed to ameliorate gait and balance
1459457|NCT03278626|Drug|Nivolimumab+Carboplatin/paclitaxel+Radiation|In the phase I portion of the study, up to six patients will be treated (radiation will be 50.4 Gy (1.8 Gy/fraction × 28 fractions)) and then observed for 28 days (following last day of treatment (Day 64)).
1459458|NCT03278613|Device|ES-130|"The ES-130 device will be used for the indication of Posterior Tibial Nerve Stimulation for the treatment of fecal incontinence using the FDA-approved protocol for treatment of urge urinary incontinence (UUI) in the PFDN NOTABLe study. There is no PTNS device cleared by the FDA for the indication of FI treatment; therefore, this is considered an investigational device."
2010464|NCT02958865|Drug|PF-06700841 or Placebo|Delivered orally for 24 weeks.
1459460|NCT03278587|Other|Community-based screening program|In communities randomized to receive the screening program, all adults aged 50 and older will be eligible to receive screening for ocular disease. Screening assessments include visual acuity, refraction, intra-ocular pressure, fundus photography, and anterior segment photography. Participants meeting criteria for referral based on screening assessments will be referred to the nearest eye care center or eye hospital for further evaluation.
1459461|NCT03278587|Other|Cataract camp program|In communities randomized to receive the cataract camp program, all adults aged 50 and older will be eligible to participate in a routine cataract camp run by Bharatpur Eye Hospital. Trained ophthalmic personnel and assistants will perform case detection for cataract via visual acuity, pen light exam, and indirect ophthalmoscope exam per Bharatpur Eye Hospital's standard cataract camp program. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
1459462|NCT03278587|Other|Community health worker program|In communities randomized to receive the community health worker program, all adults aged 50 and older will be eligible to participate. Existing community health workers will be trained to perform case detection for cataract via visual acuity assessment. Participants with cataracts will be referred to the nearest eye care center or eye hospital for further evaluation.
1459463|NCT03278574|Procedure|Mitral valve repair|Mitral valve repair with standard technique: resection of prolapsed leaflet and/or artificial neochordae implantation
1459464|NCT03278574|Device|Ring annuloplasty with posterior band|Mitral valve annuloplasty using Cardiamed (Penza, Russia) flexible posterior annuloplasty band
1459465|NCT03278574|Device|Ring annuloplasty with complete ring|Mitral valve annuloplasty using Cardiamed (Penza, Russia) complete semirigid ring
1459466|NCT03278561|Procedure|Sputum induction|Sputum induction according to the ERS protocol
1459467|NCT03278561|Procedure|Blood sample|A blood sample of 100ml will be taken.
2010465|NCT02958865|Drug|PF-06651600 or Placebo|Delivered orally for 24 weeks.
2010466|NCT02957578|Device|Solo TTD|Placement of tympanostomy tube with Solo TTD
1459470|NCT03278535|Diagnostic Test|CAREN-based gait analysis|subjects only walk at CAREN at different speed
1459471|NCT03278522|Drug|Ramosetron|Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery
1459472|NCT03278509|Drug|Metoprolol Succinate|Eligible patients randomized to active treatment will receive long-term oral beta-blockade (metoprolol succinate or bisoprolol).
1459473|NCT03278509|Drug|Bisoprolol|Please see the section above.
1459474|NCT03278496|Behavioral|Recovery Housing plus Counseling|Participants receive 3 months of abstinence-contingent program-supported rent payment in community recovery housing. They also receive intensive outpatient counseling (both individual and group) focused on relapse prevention skills training, goal setting, employment seeking and recreational activities.
1459475|NCT03278496|Behavioral|Usual Care Referral|Participants are referred to an outpatient program of their choosing with an appointment made for them.
1459476|NCT03278496|Behavioral|Recovery Housing Only|Participant may receive up to 3 months of abstinence-contingent rent payment in community recovery housing but is not invited to participate in intensive counseling.
1459477|NCT03278483|Drug|Isoniazid 300 mg Oral Tablet|Isoniazid tablets 300mg daily plus pyridoxine 50mg daily
1459478|NCT03278483|Drug|Rifampin 600 mg Oral Tablet|Rifampin capsules 600mg daily
1459479|NCT03278470|Drug|HL237|Experimental
1459480|NCT03278470|Drug|Placebo Oral Tablet|placebo with same properties except for active ingredient
1459481|NCT03278457|Diagnostic Test|Positron Emission Tomography|Positron Emission Tomography
1459482|NCT03278444|Other|Basic drugs therapy of HCC|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
1459483|NCT03278444|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
1459484|NCT03278444|Drug|Trimetazidine hydrochloride|Trimetazidine hydrochloride tablets 20mg/tablet, 40mg, twice a day.
2010467|NCT02956278|Drug|Allopurinol|
1514202|NCT02862301|Biological|blood sample|
2010468|NCT02956278|Other|Placebo|lactose placebo pill
1947886|NCT02954575|Drug|Wilate|
1947887|NCT02953301|Drug|resminostat|
1947888|NCT02953301|Drug|Placebo|
1459489|NCT03278418|Procedure|Tricuspid Valve Repair|It will be performed according to the surgeon preference
1459490|NCT03278418|Procedure|Left-sided valve surgery|It will be performed according to the surgeon preference
1459491|NCT03278405|Drug|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
1459494|NCT03278379|Drug|Avelumab|Avelumab will be administered intravenously as an infusion, at a dose of 10 milligram per kilogram once every 2 weeks, until occurence of progressive disease, unacceptable toxicity, or any of the other criteria for withdrawal listed in the protocol .
1947889|NCT02953223|Other|Free amino acid infant formula|Patients who will be fed a free amino acid based infant formula
1459496|NCT03278353|Other|Exercise|"A prescription of progressive rehabilitation exercises designed to strengthen weakened muscle groups and stretch joint movements that demonstrate range of motion limitations will be provided as a home program. Treatment is based on clinical presentation and identification of impairments by the treating clinician. Participants will be seen for 3 visits over 6 weeks and a final visit 1 year post-surgery for those electing to undergo surgery.
The interventions will consist of progressive exercise (PE) in two phases with general instruction guidelines. The assigned program will be tailored per each participant's clinical presentation and progressed based on response to exercise load. The researcher will instruct, review and supervise each program initially and, at follow-up visits; as well as monitor progress, re-enforce treatment strategies and modify the respective program accordingly. Each participant will receive a home program manual as well as a program log."
1459497|NCT03278353|Other|Manual Therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
1459500|NCT03278327|Procedure|Complete endoscopic resection at Day 1 and months 2, 4, 6 8 and month 10.|Endoscopic resection treatment
1459501|NCT03278327|Device|Endoscopic resection at month 2 and month 4|"System of endoscopic resection of the mucous hurts which can take several forms according to the technical necessities.
The device the most used in this case is the system COOK Medical Duett of Laboratories.
The duration of the treatment will be the same duration as the classic endoscopic resection, that is 30 in 60 minutes.
The resection will be preceded by injection of physiological salt solution tinged with carmine indigo in the sub-mucous membrane."
1459502|NCT03278314|Drug|tezacaftor/ivacaftor|orally administered TEZ/IVA combination therapy
1459503|NCT03278301|Device|Robotic-assisted PCI|The CorPath GRX is intended for use in the remote delivery and manipulation of guidewires and rapid exchange balloon/stent catheters, and remote manipulation of guide catheters during percutaneous coronary intervention (PCI) procedures.
1459504|NCT03278288|Device|WellWe-Intervention group|Participants (families) allocated to the intervention group get to use WellWe-app before entering to health visit to assess the current situation of their wellbeing and utilizing these results during the health visit. The access to WellWe-app is permitted throughout the data collection period. Participants (PHNs) randomized to the intervention group get standardized two hour WellWe-training, WellWe-handbook and full access to the WellWe-app during the data collection period.
1459505|NCT03278275|Drug|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NORA-AE105
1459506|NCT03278275|Device|PET/CT|Following injection of 68Ga-NOTA-AE105 the participants will be subjected to whole body PET/CT
1459507|NCT03278262|Drug|VEGF Trap-Eye (BAY86-5321)|Treatment-naïve eyes with neovascularization AMD(Age-related Macular Degeneration), with the indication to be treated with Aflibercept. One and/or two eyes per patient.
1459508|NCT03278249|Other|Modified Atkins Ketogenic Diet|Less than 20 grams of carbohydrates per day
1459509|NCT03278236|Behavioral|TRF|Participants will be instructed to consume their habitual diet within a self-selected 10 hour period every day.
1459510|NCT03278223|Device|Test solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-2.
1459511|NCT03278223|Device|Control solution|A Multi-purpose soft contact lens care solution containing polyaminopropyl biguanide, polyquaternium-1.
1459512|NCT03278197|Other|Interviews|Interviews with patients, physicians and general practitioners (GPs) to define patients' decisional needs.
1947892|NCT02951819|Drug|Daratumumab|"For induction therapy cycle 1 day 1 and day 2 doses of daratumumab will be 8 milligram/kilogram (mg/kg). Starting cycle 1 week 2 until the completion of week 8 of daratumumab patients will receive 16 mg/kg Intravenously (IV) weekly.
Starting week 9 until the completion of week 24 therapy daratumumab will be administered every other week at 16 mg/kg IV.
Starting week 25 and beyond for induction therapy daratumumab will be given once every 4 weeks."
1459513|NCT03278197|Other|Treatmentchoice Decisional Tool|Patients and physicians navigate through Treatmentchoice Decisional Tool and think aloud while running the tool
1459514|NCT03278197|Other|Questionnaires|Patients and physicians fill out questionnaires on the usual care, Delphi study
1459515|NCT03278197|Other|Interviews with stakeholders|Interviews with stakeholders (patients, clinicians, nurses, GP's, patient organizations, insurance companies) to determine the barriers and facilitators to the implementation of shared decision making and the decision aid.
1459516|NCT03278184|Device|tDCS sham motor cortex|the intervention 20 participants will be subjected to spine surgery then participants will be subjected to sham stimulation targeting left motor cortex area using the transcranial direct current stimulation device for 30 seconds then stop for 20 minutes.
1459517|NCT03278184|Device|active prefrontal cortex stimulation|the intervention 20 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left dorsolateral prefrontal cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
1459518|NCT03278184|Device|active motor cortex stimulation|the intervention 20 participants will be subjected to spine surgery then participants will be subjected to an active stimulation targeting left motor cortex area using the transcranial direct current stimulation device with a current intensity of 2 mA for 20 min
1459519|NCT03278171|Behavioral|Impact Event Scale Revisited|Evaluating the ability of the Impact Event Scale -Revisited within 8 days following the intensive care unit exit to predict a post-traumatic stress disorder at 3 months (Impact Event Scale -Revisited score strictly greater than 34)
1459520|NCT03278158|Drug|Placebo|Subjects in the placebo arm will receive a single oral tablet containing no active drug.
1459521|NCT03278158|Drug|XEN-D0501, 1 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 1 mg/tablet
1459522|NCT03278158|Drug|XEN-D0501, 2 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 2 mg/tablet
1459523|NCT03278158|Drug|XEN-D0501, 4 mg/tablet|Subjects in this arm will receive a single oral tablet of XEN-D0501, 4 mg/tablet
1459524|NCT03278145|Genetic|Genetic analyses|Patients treated at the Institute of Hematology and Pediatric Oncology (IHOPe), a department of Prof. Y. Bertrand, for acute leukemia (LA) at the time of diagnosis initial, or relapse, after obtaining signed parental consent. The same patients will benefit from a new sample at the time of their remission balance. Analyses for this research will be made from bone marrow aspiration samples performed for diagnosis and treatment of these patients. The medical team will investigate whether RDs, in particular DCC, are expressed in acute leukemia cells at the time of diagnosis or relapse and then in these patients at the time of the remission balance. This research will be both qualitative and quantitative. Next, investigators will characterize the existence and then the level of expression of the ligand specific for DCC, Netrin-1, in these same leukemic cells, at the time of diagnosis / relapse and remission.
1459525|NCT03278132|Biological|EV71 vaccine|Two doses vaccination of EV71vaccine (Intramuscular injection, 0.5ml) with a schedule of 0, 28 days.
1947893|NCT02951819|Drug|Cyclophosphamide|Subjects will receive 4 to 8 cycles of oral cyclophosphamide 300 milligram per meter square (mg/m^2 ) on Days 1, 8, 15, and 22 for every 28 days.
1947894|NCT02951819|Drug|Bortezomib|Subjects will receive 4 to 8 cycles of Bortezomib 1.5 mg/m2 subcutaneous (SC) on Days 1, 8, and 15 for every 28 days.
1459533|NCT03278054|Other|Root Canal Treatment with hand instruments|Root canal treatment was performed with K files.
1459534|NCT03278054|Other|Root canal treatment with Protaper instruments|Root canals were enlarged with S1 S2 F1F2 F2 Protaper instruments
1459535|NCT03278054|Other|Root canal treatment with hybrid instrumentation|Root canal were enlarged with combination of a combination of ProTaper Universal instruments to shape the coronal and middle thirds and Hyflex CM to prepare the apical third
1459536|NCT03278041|Procedure|Submental flap for palatal reconstruction|"Under General Anesthesia the tumor in the maxilla will be resected (partial maxillectomy) with a safety margin, then the defect will be reconstructed immediately by :
Submental artery flap : from submental area with 1 cm distance from inferior mandibular border in paddle shape.
1st step will be identify the facial artery and vein,
2nd step dissection and extend toward midline in subplatsmal plane. The flap contains submental artery and vein.
3rd step creating submucous tunnel between vestibular border of post maxillectomy defect and to extraoral incision .
The flap will be through the oral cavity and will be anchored to the intact remaining hard plate with bone sutures by 2-0 vicryl® suture."
1459537|NCT03278041|Device|maxillary obturator|immediate surgical obturator
1947895|NCT02951819|Drug|Dexamethasone|Subjects will be given corticosteroids (Dexamethasone) as pre-infusion therapy prior to daratumumab and for the first 8 cycles will also receive post-infusion corticosteroids (Dexamethasone).
1947896|NCT02950831|Other|Accelerometry|Record of activity levels using a wrist worn accelerometer
1459540|NCT03278015|Drug|Nab-paclitaxel plus Gemcitabine|Nanoparticle albumin-bound paclitaxel is given at 100mg/m2 intravenously over 30 minutes in combination with Gemcitabine 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
1459541|NCT03278015|Drug|Gemcitabine monotherapy|Gemcitabine is given at 1000mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
1459542|NCT03278015|Drug|S-1 monotherapy|S-1 is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
1459543|NCT03277976|Device|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
1459544|NCT03277976|Device|PVI using ThermoCool® SmartTouch SF® Catheter|PVI using RFA, using ThermoCool® SmartTouch SF® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index
1459545|NCT03277963|Device|Pain perception tests (mechanical : VON FREY ELECTRONIQUE or electrical stimulus : PAIN MATCHER®)|From a basal level causing no particular sensation, the mechanical or electrical stimulus is applied with a constant increasing rate of progression.
1459546|NCT03277950|Other|Virtual reality with feedback|Individuals with stroke play game with correction of movement.
1459547|NCT03277950|Other|Virtual reality without feedback|Individuals with stroke play game without correction of movement.
1459548|NCT03277950|Other|Healthy|Healthy do not play game
1459549|NCT03277937|Procedure|angiography in EUS-injection of coils + CYA|Doppler imaging will be used to allow direct visualization of the varices flow. The gastric vessels will be followed from the cardia to the proximal part of the esophagus, to detect the feeding vessel (FV). Once the FV has been found, a 19-gauge EUS-FNA will be used to access the vessel. An angiography will be performed using 5-10 ml of water-soluble contrast under fluoroscopy, to ensure intravascular location and study varix flow direction. Finally, patients will be treated by EUS-deployment of coils followed by CYA injection. The coils will be delivered into the vessel through the FNA needle, using the stylet as a pusher. The 2-Octyl-CYA will be used. It will be injected always after the coils deployment and then 1 mL of saline solution will be used to flush the glue completely.
1459550|NCT03277924|Drug|Sunitinib 37.5 MG [Sutent]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
1459551|NCT03277924|Drug|Nivolumab 10 MG/ML [Opdivo]|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
1459552|NCT03277898|Behavioral|Aerobic Exercise|Three weekly moderate-vigorous intensity supervised aerobic exercise training for the duration of adjuvant chemotherapy. Home-based exercise will also be introduced in week 3 of the intervention.
1459553|NCT03277898|Behavioral|Usual Care (Wait-list Control)|Three weekly moderate-vigorous intensity supervised aerobic exercise training starting upon adjuvant chemotherapy completion. Home-based exercise will also be introduced in week 3 of the intervention.
1459555|NCT03277872|Device|Laryngoscopy with GlideScope (GVL) Blade|"st Laryngoscopy with GVL Blade
nd Laryngoscopy with MAC Blade
rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
1459556|NCT03277872|Device|Laryngoscopy with MacIntosh (MAC) Blade|"st Laryngoscopy with MAC Blade
nd Laryngoscopy with GVL Blade
rd Laryngoscopy and ETT insertion with either GVL or MAC Blade according to 2nd randomization"
1459557|NCT03277859|Behavioral|SAA-TBI|Yoga twice a week for 75 minutes for 8 weeks
1459558|NCT03277846|Device|Nexalin Based Trans-Cranial Electrical Stimulation|The Nexalin device, FDA clearance (501K=K024377, Classification: Stimulator, Cranial Electrotherapy: CFR 882. 5800: U.S. Patent #6904322B2), produces a square waveform that provides trans-cranial electrical stimulation to the brain delivered at a frequency of 77.5 Hz at 0 to 4 mA peak current.
1459559|NCT03277833|Dietary Supplement|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day)|Gynostemma Pentaphyllum(Dungkulcha) Extract(400mg/day), parallel design
1459560|NCT03277833|Dietary Supplement|Placebo|Placebo, parallel design
1459561|NCT03277820|Dietary Supplement|Probactiol Mini|6 droplets of Probactiol Mini contain 1 billion bacteria (Lactobacillus rhamnosus GG and Bifidobacterium lactis BB-12)
1459562|NCT03277794|Behavioral|HOP-C|Service provision will be provided by Loft and Covenant House for the transitional case management component, the peer component will be supported through Sketch Arts, and the mental health component will be provided by a post-doctoral fellow clinical psychologist and a mindfulness therapist from the Centre for Mindfulness Studies, supervised by Dr. Sean Kidd.
1459563|NCT03277794|Behavioral|Transitional Case Management Only|Participants in this arm will be provided with a transition-focused community support worker who will assist in areas ranging from general support and encouragement to assistance in navigating relevant systems. They will have weekly contacts with participants by phone, informal contact via text and email, and at least twice per month will visit the participant where they are residing. It is expected that all participants will engage a community support worker. The transitional case manager hired into this role will be highly experienced in case management for youth.
1459564|NCT03277781|Other|Screening|Screening for AAA
1459569|NCT03277742|Behavioral|Community intervention|Training of patients, health personnel and community health workers. Bidirectional screening. Monitoring blood glucose levels. Home visits. Medical referral. DOTS.
1459570|NCT03277742|Drug|Standard of care|DOTS plus standard DM2 care
1947902|NCT02945501|Device|NeuroConn DC Stimulator PLUS|Prior to bedtime on the sleep restriction night, 4 transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will receive a one hour period of SO stimulation, for a total of approximately two hours of sleep.
1995024|NCT02870322|Behavioral|Fruit and Vegetable CSA Prescription|Study Participants will collect and use fruit and vegetable CSA boxes given to them weekly for 10 weeks.
1995025|NCT02870322|Behavioral|Bikeshare Prescription|Study participants will use bikeshare for transportation and physical activity for 10 weeks
1459576|NCT03277716|Procedure|TACE|TACE: With the patient under local anesthesia, a 5F French catheter was introduced into the abdominal aorta via the femoral artery using the Seldinger technique. Hepatic arterial angiography was performed using fluoroscopy to guide the catheter into the celiac and superior mesenteric arteries. Then, the feeding arteries, tumor, and vascular anatomy surrounding the tumor were identified. Subsequently, a microcatheter was super-selectively inserted into the feeding arteries. Then, a mixture solution containing chemotherapeutic agents and embolic agents were infused into the artery according to the size and blood supply of the tumors.
1459577|NCT03277716|Procedure|MWA|MWA: All patients were instructed to fast from all foods for 12 hours preoperatively. During the procedure, a CT scan was used to locate the liver tumors, and to design the optimal puncture needle route. Routine disinfection and local anesthesia was applied around the puncture point, and a 16-gauge microwave antenna was gradually inserted into the tumor along the pre-determined angle. Settings of the MWA parameters depended on the manufacturer's recommendation and our experience.
1995026|NCT02870452|Behavioral|Hypnosis|4 weekly individual sessions of Hypnosis, conducted by a certified psychologist, with the approximate duration of 90 minutes.
1995027|NCT02870452|Behavioral|Cognitive-Behavioral Therapy|4 weekly individual sessions of CBT, conducted by a certified psychologist, with the approximate duration of 90 minutes.
1459578|NCT03277716|Device|MWA system|MWA system is a kind of medical treatment instrument to restrain and kill tumor based on microwave heating technique and biology heating effect theory.
1459579|NCT03277716|Drug|Chemoembolization|Chemotherapeutic drugs: adriamycin，epirubicin and pirarubicin. Embolic agent: lipiodol and embolic microspherea The mixture solution containing chemotherapeutic drugs and embolic agent were infused into the artery according to by the number and size of the lesions, liver and kidney function of the patient, and blood supply of the tumors.
1459580|NCT03277703|Biological|Influenza vaccine|"The primary aim of this study is to assess the immunogenicity of booster dose influenza vaccine strategy in patients with rheumatologic diseases and IBD who are receiving immunosuppressive therapies.
Secondary aims of this study include assessment of the safety and clinical efficacy, of booster dose influenza vaccine in the prevention of influenza-like illnesses (ILI) in this patient population"
1459581|NCT03277690|Drug|Levoketoconazole|"During the double-blind Withdrawal Phase, patients will receive up to 1200 mg levoketoconazole daily.
During the double-blind Restoration Phase, patients will receive levoketoconazole plus placebo."
1459582|NCT03277690|Drug|Placebo|"During the double-blind Withdrawal Phase, patients will receive placebo tablets.
During the double-blind Restoration Phase, patients will receive placebo plus levoketoconazole."
1459583|NCT03277677|Drug|Normal saline|for resuscitation in sepsis patients
1459584|NCT03277677|Drug|Ringer's Acetate|for resuscitation in sepsis patients
1459585|NCT03277664|Behavioral|intervention group|"Caregivers of the recruited patients in the intervention group were added to a Wechat group. All the decive-monitored adherence data from the previous week were downloaded and calculated by a qualified asthma nurse. Weekly, according to the adherence rate, the nurse offered the feedback to caregivers and reminded them to keep taking inhaled steroids on Wechat. Monthly, Caregivers were asked Have your child inhaled the medicine according to the doctor's instructions? and How about the frequency through telephone follow-up."
1459587|NCT03277638|Drug|Pembrolizumab at 7 days prior|Pembrolizumab injections 7 days before surgery
1459588|NCT03277638|Drug|Pembrolizumab at 14 days post|Pembrolizumab injections 14 days after surgery
1459589|NCT03277638|Drug|Pembrolizumab at 35 days post|Pembrolizumab injections 35 days after surgery
1459590|NCT03277638|Procedure|Laser Interstitial Thermotherapy|surgical procedure to heat hard to reach tumors with a laser beam
1459591|NCT03277625|Procedure|modified omega-shaped single-loop|A double-layer, end-to-side, duct-to-mucosa PJ using interrupted polydioxanone 5-0 suture (PDS II, Ethicon, Somerville, USA) for the outer layer and interrupted polypropylene 5-0 suture (Prolene, Ethicon, USA) for the inner layer is the standard technique during PD at our Institution. For the modified omega-shaped single-Loop reconstruction the loop between PJ and HJ is left intentionally longer at about 25-30 cm and an additional side-to-side jejunojejunal anastomosis is performed at the lowest point between the afferent and efferent loops of the HJ This intestinal anastomosis is done in a double-layer continuous PDS 5-0 suture technique. Neither sealants, nor stents are being applied at the PJ. In cases of thin walled and tiny hepatic ducts, the HJ is splinted using an externally diverted T-tube.
1459592|NCT03277599|Drug|IV patient-controlled analgesia (PCA) tramadol|Tramadol infusion (PCA): 400 mg tramadol, IV 4 mg/mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
1459593|NCT03277599|Drug|ultrasound guided superficial cervical plexus block|ultrasound guided superficial cervical plexus blockage with 10 ml % 0.25 bupivacaine
1459594|NCT03277599|Drug|ultrasound guided Great Auricular nerve block|ultrasound guided Great Auricular nerve blockage with 5 ml % 0.25 bupivacaine +IV patient-controlled analgesia (PCA) tramadol
1459595|NCT03277586|Drug|Probio'Stick|Probiotic supplement containing Lactobacillus helveticus and Bifidobacterium longum
1459596|NCT03277586|Drug|Placebo|Identically formulated and packaged inactive substance
1459597|NCT03277573|Drug|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a non-steroidal anti-inflammatory drug (NSAID). Salsalate has been commercially available in the US as a prescription drug for the relief of the signs and symptoms of rheumatoid arthritis, osteoarthritis, and related rheumatic disorder for decades.
1459598|NCT03277573|Drug|Placebo|Inactive ingredient
1459599|NCT03277560|Other|No Intervention as it is an observational study|No Intervention as it is an observational study
1459600|NCT03277534|Other|Electrical stimulation|sensory electrical stimulation was applied prior to upper limb functional training
1459601|NCT03277534|Other|Sham electrical stimulation|electrodes were placed on the same location as the Electrical stimulation condition, but no electric current was applied
1459603|NCT03277508|Device|BCI Robot Assisted Hand Therapy|"18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of BCI Robot and 30 minutes of the standard hand therapy).
Session 1-3. Peg game: Lateral movement of gears/cups Session 4-6. Moving cups onto a shelf: Elevation process for the arm, small cups to be used.
Session 7-9. Carrying of basket: Heavier load to be used, patient to hold the basket by the handles at the side, not by its base.
Session 10-12. Opening bottle + pouring into a cup: Training of ADL Session 13-15. Eating: Use of a modified spoon to train ADL Session 16-18. Box and blocks: Precise index finger and thumb control"
1459604|NCT03277508|Device|CPM Robot Assisted Hand Therapy|18 sessions (3 times per week for a total of 6 weeks) of 1.5 hours each training (60 minutes of Passive Robot and 30 minutes of the standard hand therapy).The procedure will include the following: Session 1-18: Continuous passive motion
1459605|NCT03277495|Behavioral|Brief behavioral counseling|Staff will engage in behavioral counseling to identify strategies for reducing combustible cigarette use. All participants in the trial receive this intervention
1459606|NCT03277495|Other|Nicotine present in the SREC device and refills|Nicotine is present in the liquid in the SREC device and all refills. Two-thirds of the sample will receive nicotine in their SREC; one-third will not (placebo)
1459613|NCT03277456|Biological|MVA-NP+M1|Intramuscular injection of novel vaccine
1459614|NCT03277443|Procedure|Computer guided surgery|Preoperative surgical simulation and immediate postoperative evaluation will be carried out using Multi Slice CT scan.Craniofacial images from 3D computerized tomography (3D-CT scan) can be used to create a 3D model, which can in turn be used for 3D Cephalometry measurements and surgical simulation.The process of 3D-model contains mounting of 3D virtual models in a 3D virtual articulator; and repositioning of 3D virtual models according to the STO then Fabrication of a 3D virtual intermediate surgical wafer; and materialization of the surgical wafer using a stereolithographic technique. The 3D model can produce actual movement of surgical cuts and movement of segments accordingly
1459615|NCT03277443|Procedure|Conventional model surgery|preparation for orthognathic surgery which involves diagnosis with 2D cephalometric radiograph, face-bow transfer and model surgery on plaster dental cast, and fabrication of intermediate and final occlusal splint.
1459616|NCT03277443|Device|2D cephalometric radiograph|2D cephalometric radiograph
1459617|NCT03277443|Device|3D computerized tomography|3D computerized tomography
1459618|NCT03277430|Procedure|Live donor uterus transplantation|Transplantation of uterus from a living donor.
1459619|NCT03277430|Procedure|Deceased donor uterus transplantation|Transplantation of uterus from a deceased brain-dead donor.
1459620|NCT03277430|Drug|Tacrolimus|Maintenance immunosuppression in UTx recipient will be reduced to tacrolimus monotherapy to minimalize fetal compromise.
1459621|NCT03277417|Other|Echocardiography|Imaging of fetal heart and amniotic fluid
1459622|NCT03277404|Procedure|Root canal treatment with smear layer removal|Canal were irrigated with Naocl and EDTA to remove smear layer
1459623|NCT03277404|Procedure|Root canal treatment without smear layer removal|only sodium hypochlorite was used for irrigation
1459624|NCT03277391|Procedure|Serratus anterior plane block|SPB realized under ultrasound guidance. Infiltration of local anesthetic (bolus then infusion through a multi-holed catheter) is realized under the serratus anterior muscle at a level situated around the 5th to 6th intercostal space on the anterior axillary lign, in order to anesthetize the cutaneous lateral branches of the intercostal nerves, with a first ropivacaine 0,375% bolus (0,4ml/kg), followed by an infusion of ropivacaine 0,2% at a 10ml/hr rate, through a multi-holed catheter, for a duration of 24 hours.
1459625|NCT03277391|Device|patient-controlled analgesia|Each patient controls his analgesia with an IV bolus of 2mg of morphine every 10 minutes if needed, with a maximum of 20mg every 4 hours.
1459627|NCT03277365|Other|Receive genetic risk information|Risk scores are provided by ResearchKit app.
1459628|NCT03277352|Drug|INCAGN01876|In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose and schedule according to cohort and treatment group enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
1459629|NCT03277352|Drug|Epacadostat|Epacadostat will be self-administered orally at the protocol-defined dose.
1459630|NCT03277352|Drug|Pembrolizumab|Pembrolizumab will be administered IV at the protocol-defined dose.
1459631|NCT03277339|Drug|Paroxetine|Deroxat® (20 mg/day) 3 week; can be increase on week 2 until 50 mg.
1459632|NCT03277339|Other|Thermal cure|Thermal cure is realized for 3 weeks
1459633|NCT03277326|Procedure|ISB|ISB block with 0.5% ropivicaine 15mls ( 45mg )
1459634|NCT03277326|Procedure|aSSB|aSSB block with 0.5% ropivicaine 15mls ( 45mg )
1459635|NCT03277326|Procedure|pSSB|pSSB block with 0.5% ropivicaine 15mls ( 45mg )
1459638|NCT03277300|Dietary Supplement|dietary supplement|good dietary supplement for critically ill patients
1459639|NCT03277287|Radiation|Fractional CO2 laser|Fractional CO2 laser will be applied in cleft lip scar to assess and evaluate the later appearance of the scar
1459641|NCT03277261|Biological|Ublituximab|Subjects will be randomized in a [1:1] ratio to receive either ublituximab/oral placebo on specified days or teriflunomide/IV placebo (14 mg, OD starting on Week 1 Day 1)
1459642|NCT03277261|Drug|Teriflunomide|Subjects will be randomized in a [1:1] ratio to receive either ublituximab/oral placebo on specified days or teriflunomide/IV placebo (14 mg, OD starting on Week 1 Day 1)
1459643|NCT03277248|Biological|Ublituximab|Subjects will be randomized in a [1:1] ratio to receive either ublituximab/ oral placebo on specfied days or teriflunomide/ IV placebo (14mg, once daily starting on Week1 Day1)
1459644|NCT03277248|Drug|Teriflunomide|Subjects will be randomized in a [1:1] ratio to receive either ublituximab/ oral placebo on specfied days or teriflunomide/ IV placebo (14mg, once daily starting on Week1 Day1)
1459645|NCT03277235|Behavioral|Resilience model-based total care plan|12-week care plan with 5 times face-to-face intervention and weekly phone call follow-up to increase the protective factors (positive thinking. problem-solving, finding meaning, and social connection) and decrease the risk factors (disease-related distress and defense coping) of resilience
1459648|NCT03277209|Drug|Plerixafor|Plerixafor will be administered via IV as a continuous 7 day intravenous infusion starting at a dose of 20 ug/kg/hr and subsequent dose levels of 40, 80 and 120 ug/kg/hr
1459649|NCT03277196|Drug|Ivacaftor|Ivacaftor will be administered every 12 hours (q12h) from Day 1 through the morning dose of the Week 104 Visit.
1459650|NCT03277183|Drug|Low dose erythropoietin|Subjects randomized to this arm will receive low-dose of EPO administered thrice weekly
1459651|NCT03277183|Drug|High dose erythropoietin|Subjects randomized to this arm will receive the same cumulative dose of EPO administered as a high-dose of EPO every 2 weeks
1459652|NCT03277170|Drug|Montelukast Oral Granules|Montelukast granules, 30 mg, mixed with applesauce
1459655|NCT03277144|Device|TST-TriStaple(3lines stapler)Technology|Duodenal stump closed using a Tristaple ( three-lines linear stapler) device
1459656|NCT03277144|Other|other conventional techniques|Duodenal stump closed using other conventional techniques entailing manual suture or mechanical devices with only two lines of sutures.
1459657|NCT03277131|Device|DURAFIBER Ag|DURAFIBER Ag is a commercially available absorbent, non-woven, silver-containing antimicrobial dressing
1459658|NCT03277118|Device|Wireless Wearable Device|Wireless Wearable Device will be placed on the wrist of the patient prior to extubation in the ICU to record patient activity in terms of steps and sleep quality.
1947903|NCT02945501|Device|SHAM TES|Prior to bedtime on the sleep restriction night, 4 placebo transcranial stimulation electrodes (two on each hemisphere) will be applied to the scalps of each subject. Subjects will sleep for approximately 2 hours without stimulation.
1459663|NCT03277079|Drug|statin + ezetimibe|Combination of two drugs
1459664|NCT03277079|Drug|statin + ezetimibe + Nutraceuticals|Combination of two grus plus nutraceuticals
1459668|NCT03277053|Device|Mobile application|A mobile application designed specifically for colorectal patients treated within an enhanced recovery pathway. Contains information, guidelines, questionnaires and feedback
1459669|NCT03277053|Other|Control.|Patient receive an ipad with no application.
1459671|NCT03277027|Other|observational study|The participants wear a monitoring equipment (Actigraph) for a week. And parents do Child Health Questionnaire Parent Form 50 (CHQ-PF50), and Korean Parenting Stress Index-Short Form (K-PSI-SF)
1459672|NCT03277001|Drug|Rivaroxaban|Rivaroxaban, po. 10mg/day（CrCl≥ 50 ml/min）or 5 mg /day (CrCl ≥ 30 and < 50 ml/min) po.
1459673|NCT03277001|Drug|Enoxaparin|Enoxaparin 40mg IH
1459674|NCT03276988|Drug|GX-30 0.45mg IM|GX-30 0.45mg administered in the gluteal muscle.
1459675|NCT03276988|Drug|GX-30 0.9mg IM|GX-30 0.9mg administered in the gluteal muscle.
1459676|NCT03276988|Drug|GX-30 0.9mg x 2 times IM|First injection: GX-30 0.9mg administered in the gluteal muscle Second injection : GX-30 0.9mg administered in the gluteal muscle 24 hour after the first injection
1459677|NCT03276975|Drug|TISSEEL|TISSEEL is a fibrin sealant indicated for use as an adjunct to hemostasis in adult and pediatric patients (>1 month of age) undergoing surgery when control of bleeding by conventional surgical techniques (such as suture, ligature, and cautery) is ineffective or impractical. TISSEEL is effective in heparinized patients
1459681|NCT03276949|Device|Blood glucose measurement|Device used to measure blood glucose levels
1459683|NCT03276910|Drug|EPREX|6 doses at 50 IU/kg or 20 IU/kg in subcutaneous use
1459684|NCT03276910|Drug|sodium chloride AGUETTANT 0.9%|6 injections at 1ml in subcutaneous use
1459685|NCT03276897|Other|Nutriage SPF 30 day cream and Nutriage night cream (Difa Cooper S.p.a, Italy)|A fixed quantity of both cosmetic products was applied for an uninterrupted period of 3 months, on the face included the submental area (day cream at the morning and the night cream at the evening), preferentially always at the same hour, with a mild massage
1459688|NCT03276871|Procedure|Telescopic Dissection|Creation of extraperitoneal space with blunt dissection using the laparoscopic probe
1459689|NCT03276871|Device|Balloon Dissection|Creation of extraperitoneal space with aid of the disposable Spacemaker balloon dissector
1459690|NCT03276858|Drug|CRN00808|Investigational drug
1459691|NCT03276858|Drug|Placebo Oral Solution|Placebo
1459692|NCT03276858|Drug|Midazolam oral solution|Midazolam as part of the drug-drug interaction arm of the study
1459693|NCT03276858|Drug|Placebo oral capsule|Placebo
1459770|NCT03276481|Behavioral|Surveys assessing taste disturbances|Surveys will be administered and examine taste disturbances pre and post HCT.
1459694|NCT03276845|Diagnostic Test|Ultrasound of the breast|Multiparametric ultrasound of the breast including elastography, color/power Doppler, contrast agent application and 3D sonography.
1459695|NCT03276832|Drug|Imiquimod|Applied cutaneously
1459696|NCT03276832|Other|Laboratory Biomarker Analysis|Correlative studies
1459697|NCT03276832|Biological|Pembrolizumab|Given IV
1459698|NCT03276819|Procedure|Samples collection|OPML biopsy or resection, biopsy of normal oral mucosa, surgical specimen of HNSCC, saliva samples, buccal brushes, blood samples
1459699|NCT03276819|Behavioral|Psychological and Sociological evaluation|Cohort B ....
1459700|NCT03276819|Behavioral|Intensive and sustained smoking cessation program|Evaluation of efficacy of the smoking cessation program (intensive and sustained versus minimal)
1459701|NCT03276819|Behavioral|Tobacco and alcohol status follow-up|Evaluation of the tobacco and alcohol status all along the study (questionnaires)
1947904|NCT02943941|Device|• Reveal LINQ ICM Cardiac Monitor, taped on the subject's chest rather than inserted in the body.|Cardiac Monitor with LINQ™ HF Investigational RAMware download
1947905|NCT02943213|Drug|Chlorpromazine Hydrochloride|Chlorpromazine Hydrochloride (25 mg Tablet) - Generic US Applicant holder is USL Pharma Inc.
1947906|NCT02941471|Device|Interferential Stimulation|Transabdominal interferential electrcial stimulation
1947907|NCT02941471|Device|TENS stimulation|Transabdominal standard electrical stimulation
1459706|NCT03276793|Other|MRI scan|Patients will undergo an MRI scan
1459707|NCT03276793|Behavioral|Behavioral testing|Patients will complete a series of cognitive tasks
1459710|NCT03276767|Other|Endre|"The online intervention, Endre, a digital smoking cessation counsellor that communicates with the user primarily through interactive web-sessions. Intervention content is tailored based on user input and individual usage pattern. Up to 14 unique sessions is assigned to the users during the study period, one each day. If a user does not start a session by noon on the second day a reminder will be sendt."
1459711|NCT03276741|Dietary Supplement|gastric soft/bland diet|Patients in the experimental group will have a gastric soft/bland diet available.
1947908|NCT02939183|Drug|Oprozomib formulation 1|Immediate Release (IR) Formulation
1947909|NCT02939183|Drug|Oprozomib formulation 2|Gastro-Retentive (GR) Formulation
1947910|NCT02939183|Drug|Dexamethasone|Dexamethasone
1947911|NCT02939183|Drug|Pomalidomide|Pomalidomide
1947912|NCT02935517|Biological|AGTC-402|AGTC-402 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGA3 gene.
1947913|NCT02930772|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
(Formulation Code: Z46-100)"
1947914|NCT02928510|Procedure|Biospecimen Collection|Undergo biospecimen collection
1947915|NCT02928510|Procedure|Colonoscopy|Undergo colonoscopy
1947916|NCT02928510|Procedure|Colposcopic Biopsy|Undergo colposcopic biopsy
1947917|NCT02928510|Drug|Idelalisib|Given PO
1947918|NCT02928510|Other|Laboratory Biomarker Analysis|Correlative studies
1947919|NCT02928510|Other|Pharmacological Study|Correlative studies
1947920|NCT02928510|Procedure|Physical Examination|Undergo physical examination
1947921|NCT02928510|Procedure|Sigmoidoscopy|Undergo sigmoidoscopy
1947922|NCT02927821|Behavioral|ADS Plus|Contact occurs at a minimum for about 1 hour per month over 12 months (face-to-face/ telephone). Targeted education materials concerning clients' conditions and related matters are shared via email or traditional mail. The goal of each contact is to provide ongoing emotional support, situational counseling, education about importance of taking care of self, referrals/linkages and skills (e.g., stress reduction, behavioral management, how to talk with doctors). The care planning process is collaborative and flexible, reflecting CG fluctuating needs
1947923|NCT02925351|Procedure|Computed Tomography|Undergo PET/CT scan
1947924|NCT02925351|Radiation|Fluorine F 18 Clofarabine|Given IV
1947925|NCT02925351|Procedure|Positron Emission Tomography|Undergo PET/CT scan
1947926|NCT02922582|Drug|DepoTXA|
1947927|NCT02922582|Drug|Tranexamic Acid|
1459733|NCT03276702|Procedure|Re-biopsy|For those participants who agree, a biopsy of their tumor to obtain tissue for genetic analysis will be done at the time of relapse or disease progression.
1459734|NCT03276702|Other|Questionnaire|Parents or patients will be asked to complete a questionnaire to assess the impact and perception of an optional/research only biopsy. A second questionnaire will be administered approximately 4-8 weeks after biopsy to assess decisional regret.
1459735|NCT03276689|Drug|Duloxetine|The patients will take duloxetine for 8 weeks.
1459736|NCT03276689|Drug|Pregabaline|The patients will take pregabaline for 8 weeks.
1459737|NCT03276689|Other|Placebo|The patients will take placebo for 8 weeks.
1459771|NCT03276468|Drug|Atezolizumab|1200 mg on day 2 of each 21-day cycle during 18 months (24 cycles)
1459772|NCT03276468|Drug|Obinutuzumab|1000 mg on day 1, day 8 and day 15 of cycle 1 and each day 1 from cycle 2 to cycle 8
1459773|NCT03276468|Drug|Venetoclax|800 mg/d from day 8 of cycle 1, every day during 18 months. For MZL patients wiht lymphocytes>5 g/l : 50 mg/day: week 1 100mg/day: week 2 200mg/day: week 3 400mg/day: week 4 800mg/day: from week 5
1459928|NCT03275077|Device|Thromboelastography|A viscoelsatic test of coagulation
1947935|NCT02920021|Drug|ANB020|ANB020
1947936|NCT02920021|Drug|Placebo|Placebo
1947937|NCT02919332|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
1459738|NCT03276676|Drug|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine|Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine will be acquired in each patient at up to three time points: (1) prior to any tumor-directed therapy, either prior to surgery or immediately after surgery providing a complete surgical resection was not performed and confirmed by a post-operative contrast MRI scan where residual tumor > 1.0 cm in diameter was present and prior to any tumor-directed therapy; (2) at the conclusions of the initial (~6-8 weeks) chemoradiotherapy; and (3) patients with MRI-documented possible recurrence/progression versus treatment effect (pseudoprogression) within 6 months from the time of completion of chemoradiation.
1459739|NCT03276663|Other|Formula feeding regimen|The feeding regimen consists of an existing commercial starter formula followed by a new follow-up formula
1459740|NCT03276650|Other|data collection|biological, administrative, clinical, outcome date
1459741|NCT03276637|Genetic|Whole exome sequencing|Whole exome sequencing at 125x coverage (i.e., at least 125 sequencing reads covering each position within the exome region of interest) performed at the Laboratory of Molecular Medicine's CLIA certified laboratory on 75 enrolled individuals
1459742|NCT03276624|Procedure|CABG|surgical revascularization of stenosed coranary arteries using arterial and venous grafts.
1459743|NCT03276611|Other|echocardiograghy|transthoracic echocardiograghy
1459744|NCT03276598|Drug|Amlodipine|Treatment for four weeks. Dose: 5 mg o.d.
1459745|NCT03276598|Drug|Bisoprolol|Treatment for four weeks. Dose: 5 mg o.d.
1459746|NCT03276598|Drug|Hydrochlorothiazide|Treatment for four weeks. Dose: 25 mg o.d.
1459747|NCT03276598|Drug|Losartan|Treatment for four weeks. Dose: 50 mg o.d.
1459748|NCT03276598|Drug|Placebo|Treatment for four weeks. Dose: 1 tablet per day.
1459750|NCT03276559|Behavioral|EMPOWER|"Enhancing and Mobilizing the Potential for Wellness and Resilience (EMPOWER) is a cognitive-behavioral, acceptance-based intervention designed to reduce experiential avoidance in caregivers of ICU patients. Specifically, it was created to assist informal caregivers of patients who are incommunicable and who become surrogate decision-makers on the patient's behalf. The goal is to reduce experiential avoidance of negative thoughts and distressing feelings in the short- and longer-term.
The total amount of time EMPOWER intervention is about 90 minutes, about 15 minutes each session. It will take place in the family room outside of MICU. Booster sessions will be decided by therapists and it will be performed by phone."
1459751|NCT03276559|Other|Usual Care|Regular ICU management
1459752|NCT03276546|Behavioral|shared decision-making tool (SHARE-D)|questionnaire
1459753|NCT03276533|Drug|Saline|Participants in the group CON were received normal saline infusion until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
1459754|NCT03276533|Drug|Lidocaine|Participants in the group LIDO received lidocaine infusion (1.5 mg/kg loading, 1.5 mg/kg/h infusion)until 30 min before the end of the operation.Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
1459755|NCT03276533|Drug|Dexmedetomidine|Participants in the group DEX received dexmedetomidine infusion (0.5 µg/kg loading, 0.4 µg/kg/h infusion) until 30 min before the end of the operation. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
1459756|NCT03276533|Drug|Lidocaine plus Dexmedetomidine|Participants in the group LIDO+DEX were received lidocaine (1.5 mg/kg loading, 1.5 mg/kg/h infusion) and dexmedetomidine infusion (0.5 μg/kg loading, 0.4 μg/kg/h infusion) until 30 min before the end of the operation, respectively. Interleukin-6 and tumor necrosis factor-α levels in serum were measured at different time points: before administration of drugs (T1), at the end of the operation (T2), postoperative 2 hour (T3) and postoperative 24 hour (T4)
1459757|NCT03276520|Diagnostic Test|ethyl glucuronide|alcohol urine screening with ethyl glucuronide
1459758|NCT03276520|Diagnostic Test|ethanol|alcohol urine screening with ethanol
1459759|NCT03276507|Diagnostic Test|Pulmonary function studies|
1459760|NCT03276507|Diagnostic Test|Echocardiogram|
1459761|NCT03276507|Diagnostic Test|Electrocardiogram|
1459762|NCT03276507|Diagnostic Test|Chest radiography|
1459763|NCT03276507|Diagnostic Test|Blood test|
1459764|NCT03276507|Behavioral|Quality of life questionnaire|
1459765|NCT03276494|Drug|injection of intraosseous hypertonic saline|injection of intraosseous hypertonic saline
1459766|NCT03276494|Device|injection of intraosseous hypertonic saline|injection of intraosseous hypertonic saline
1459767|NCT03276481|Diagnostic Test|Oral microbiota assessment|Whole mouth microbiota will be assessed by having participants swish in their mouth 10 ml of sterile water for 30 sec and then expectorate in a sterile container. Specimens will be immediately placed on wet ice and transferred to the laboratory for processing or for storage at -80° C until they are ready to be prepared for sequencing.
1459768|NCT03276481|Diagnostic Test|Comprehensive chemical gustometry|Chemical gustometry assessments will be performed by a trained clinician on the study team, including a Registered Dietitian, Physician's Assistant, or Research Nurse. The test solutions and gradients will be formulated in house using sterile water and the following constituents: Sweet taste; 0.05, 0.1, and 0.2 g/ml sucrose, sour taste; 0.05, 0.09, and 0.165 g/ml citric acid, salty taste; 0.016, 0.04, and 0.1 g/ml NaCl and bitter taste; 0.0004, 0.0009, and 0.0024g/ml quinine-HCl. Umami will be tested with MSG at 25, 50, and 75 mM.
1459769|NCT03276481|Diagnostic Test|Measurement of salivary flow|Both stimulated and un-stimulated salivation will be assessed by saliva collection in pre-weighed plastic containers. Participants will be seated with their back at a 90 degree angle and asked to swallow everything in their mouth. They will then be asked not to swallow and spit the accumulated saliva in the plastic container every 30 seconds for two minutes (unstimulated flow). For measurement of stimulated saliva, we will follow the same procedure except that after the initial swallow, participants will have their tongue swabbed twice with a cotton swab dipped in ascorbic acid solution or lemon juice.
1459926|NCT03275103|Drug|BFCR4350A|BFCR4350A will be administered intravenously on a 21-day cycle, up to a total of 17 cycles.
1459774|NCT03276455|Genetic|Autologous CD34+ cells genetically modified|Autologous hematopoietic stem cell transduced with lentiviral vector encoding the therapeutic beta-globin gene. The target dose in the transduced product is 3x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously following intravenous BU ±Flu ±Cy.
1947938|NCT02919332|Radiation|Fludeoxyglucose F-18|Given IV
1947939|NCT02919332|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT
1459777|NCT03276403|Device|PiCCO Catheter|The PiCCO Catheter is an investigational device intended to measure lung water content in individuals requiring advanced haemodynamic monitoring. The device system is to be used only in accordance with the approved Investigational Plan on subjects who have signed an informed consent form. Device use is limited to the approved study investigators.
1459778|NCT03276390|Behavioral|Hispanic Kidney Transplant Program (HKTP)|The HKTP entails culturally targeted education in Spanish about transplantation, outreach to dialysis patients by bicultural health care providers.
1459779|NCT03276364|Diagnostic Test|Ultrasound|Point-of-care ultrasound examination by pulmonary and critical care fellow
1459780|NCT03276351|Device|Long-Stemmed with Hybrid Fixation|Long-stemmed revision implant with hybrid fixation for total knee arthroplasty
1459781|NCT03276351|Device|Long-Stemmed with Full Cement Fixation|Long-stemmed revision implant with full cement fixation for total knee arthroplasty
1459782|NCT03276351|Device|Short-Stemmed with Augmented Fixation|Short-stemmed primary implant with augmented fixation for total knee arthroplasty
1459783|NCT03276338|Behavioral|HOLA|To increase condom use and HIV testing
1459784|NCT03276325|Drug|Placebo-nalbuphine|Epidural injection of normal saline followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
1459785|NCT03276325|Drug|Dexamethasone-nalbuphine|Epidural injection of dexamethasone followed with intrathecal injection of 0.6 mg nalbuphine in conjunction with 4 ml of hyperbaric bupivacaine 0.5%
1459786|NCT03276312|Device|Lipogems|Lipogems® is an innovative system that, starting from minimum quantities of autologous lipoaspirate, provides, with a minimal manipulation, a micro-fragmented and non-expanded adipose tissue product
1459787|NCT03276299|Other|six minute walking test|six minute walking test
1459788|NCT03276299|Other|six minute walking test|six minute walking test with encouragement
1947940|NCT02915198|Drug|Metformin XR|"For patients < 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.
For patients 80 years of age or with most recent 30 eGFR < 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo."
1459790|NCT03276273|Device|recording of Bispectral Index|recording of Bispectral Index
1459791|NCT03276260|Device|PMD-200|Patient will be connected to PMD-200 by finger-probe before induction of anesthesia or sedation. Recording will continue during surgery until extubation or awakening. Recording will be initiated again as soon as the patient arrives to the PACU until discharge to the surgical ward or home.
1459792|NCT03276247|Other|observation|observation
1459793|NCT03276221|Behavioral|Abstinence|Cannabis users randomized to this condition will be enrolled in a contingency management intervention for 30 days of cannabis abstinence.
1459794|NCT03276208|Other|Prenatal Massage|We will utilize moderate pressure Swedish massage (SM) that utilizes long slow strokes known as effleurage and kneading strokes known as petrissage. A specific routine will be performed on each participant with focus on low back, upper back, shoulders, and neck musculature. Consistent moderate pressure, which is lighter than deep tissue massage but deeper than brush strokes, will be used.
1459795|NCT03276208|Other|Mindfulness|The intervention and control group will be enrolled in the Craving to Quit® program, a 21-day mindfulness-based program delivered via a smartphone application (https://www.cravingtoquit.com/). This program uses a mindfulness-based approach to train people to recognize and be aware of their tobacco cravings. The program includes videos, online exercises to complete, and a virtual support community.
1459796|NCT03276182|Device|Lipiview 2|Tear film lipid layer thickness and meibomian gland dropout were measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
1459797|NCT03276169|Procedure|Left atrial appendage closure|Left atrial appendage closure is performed using a single endocardial plug devices guided by fluoroscopic guidance and transesophageal echocardiography
1459798|NCT03276169|Procedure|Radiofrequency ablation|Each patient with persistent AF receives circumferential pulmonary vein isolation under the 3D electro-anatomical mapping system , and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation.
1459799|NCT03276169|Procedure|LAAC combined with radiofrequency ablation group|Each patient received the same group of patients with simple radiofrequency ablation radiofrequency ablation treatment at the same time, the transcatheter occlusion of left atrial appendage opening
1459800|NCT03276156|Drug|Apatinib plus S-1|Drug:Apatinib (425 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (500 mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (675mg/d) + S-1 (80mg to 120 mg);Drug:Apatinib (750 mg/d) + S-1 (80mg to 120 mg);
1459804|NCT03276104|Procedure|IOL repositioning|Intraocular lens repositioning by scleral suturing
1459805|NCT03276104|Procedure|IOL exchange|Intraocular lens exchange with retropupillary iris-claw lens
1459807|NCT03276078|Drug|Aclidinium Bromide/Formoterol Fumarate 400/12μg BID|Aclidinium bromide/formoterol fumarate 400/12 μg FDC administered by inhalation via the Genuair® multidose dry powder inhaler, twice daily (morning and evening) for 5 days
1459845|NCT03275766|Other|SMA inhibitory|1 Hz stimulation of preSMA/SMA (15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
1459846|NCT03275766|Other|SMA facilitatory|Three pulses of stimulation at 50 Hz of preSMA/SMA, repeated every 200 ms. 2 s trains are repeated every 10 s for a total of 190 s (600 pulses, 200 seconds). intensity 80% of individual active motor threshold; in total 9000 stimuli
1459808|NCT03276065|Device|Laser depilation|Fitzpatrick skin type classification will be assessed during the initial visit. The Fitzpatrick skin type classification is based on the level of pigmentation of the skin and its response to ultraviolet light (See Appendix). It will be used to select the best laser to perform hair removal for each patient. The laser treatment group will consist of an 810 nm (for Fitzpatrick skin types I-IV) or Nd:YAG (for Fitzpatrick skin types V-VI) 28 joule application at auto pulse duration for 400 ms. A cooling platform and application of 7% lidocaine/ 7% tetracaine cream, applied 45 minutes prior to treatment, will minimize any discomfort associated with the heat of the laser treatments.
1459809|NCT03276065|Other|Standard of care hair depilation|Patients and families in the standard of care group will be taught hair removal techniques and asked to perform either chemical or mechanical depilation as needed to keep the area hair-free. Patients will be given supplies for six months of hair removal.
1947941|NCT02915198|Drug|Placebo|"For patients < 80 years of age at the time of a study visit, and with most recent eGFR 45 mL/min/1.73 m2, study medication dose may be increased in a stepwise fashion to a maximum of 4 tablets daily, corresponding to metformin XR 2000 mg or matching placebo.
For patients 80 years of age or with most recent 30 eGFR < 45 mL/min/1.73 m2, the maximum dose of study medication is 2 tablets daily, corresponding to metformin XR 1000 mg or matching placebo"
1459813|NCT03276039|Diagnostic Test|plasma pentraxin-3|Plasma pentraxin-3 was measured using ELISA
1459814|NCT03276026|Drug|Sugammadex|Sugammadex is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
1459815|NCT03276026|Drug|Neostigmine|Neostigmine is used for the reversal of neuromuscular block in surgery that requires deep blockade to facilitate surgical procedures.
1459816|NCT03276013|Drug|Pembrolizumab|pembrolizumab in combination with doxorubicin
1459818|NCT03275987|Behavioral|Mammography direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
1459819|NCT03275987|Behavioral|Usual care|Group received usual care, and direct mail 15 months after treatment group received intervention.
1459820|NCT03275987|Behavioral|Colonoscopy direct mail coupled with a financial incentive|The intervention groups received innovative and persuasive direct mail materials coupled with an incentive for using their Medicaid benefit to get screened.
1459824|NCT03275961|Behavioral|Stress Management and Resiliency Training|Subjects will undergo an 8 week behavioral program. Treatment will consist of weekly group therapy sessions in small groups with core practices to apply the principles of SMART.
1459825|NCT03275948|Other|whole grain|whole grain rye
1459826|NCT03275948|Other|reference|white wheat bread
1459827|NCT03275922|Drug|Placebo ZNS|Placebo Zolmitriptan Nasal Spray
1459828|NCT03275922|Drug|ZNS|Zolmitriptan Nasal Spray
1459829|NCT03275909|Behavioral|Integrated Psychological Therapy|The psychological treatment includes 50 sessions of integrated psychological therapy focused on attentional skills, social perception skills, verbal communication skills, social skills and interpersonal problems solving skills and 10 sessions of specific emotional management therapy , designed for this research. and based on the contents developed by Hodel, Kern and Brenner
1459830|NCT03275896|Other|Descemet Membrane Transplantation|The diseased host Descemet membrane will first be stripped, as per a standard Descemet Stripping Automated Endothelial Keratoplasty surgery. A cadaveric, acellular Descemet membrane graft will then be harvested and transplanted onto the host.
1459831|NCT03275883|Procedure|Aortohepatic Conduit|Placement of an interposition graft between hepatic artery and aorta during liver transplantation
1459832|NCT03275870|Drug|Hydroxychloroquine|Treatment of patients with hidradenitis suppurativa with hydroxychloroquine 200mg BID for 6 months
1459833|NCT03275857|Drug|Cisplatin|Weekly IV
1459834|NCT03275844|Procedure|Physical activity assessment|Assessment of Moderate-to-vigorous physical activity
1459835|NCT03275831|Device|PluroGel|Surfactant based gel
1459836|NCT03275831|Device|Intrasite gel|Hydrogel
1459837|NCT03275818|Drug|nab paclitaxel|Subjects in the DT cohort will receive a maximum of three cycles. Subjects in the DSRCT and ES cohort will receive unlimited cycles until disease progression, the subject begins a new anticancer treatment, withdrawal of parent/guardian/subject consent/assent, parent/guardian/subject refusal, physician decision, toxicity that cannot be managed by dose delay or dose reduction alone or the study ends for any reason
1459838|NCT03275805|Device|Duration of Pavlik Harness treatment|The only intervention that varies from standard of care (12 weeks of treatment) will be the duration (for the 6 week arm). Patients in both arms will have identical follow up protocols and imaging to closely monitor hip morphology.
1459839|NCT03275805|Device|Standard of Care|12 weeks Pavlik Treatment Arm
1459840|NCT03275792|Drug|D5-0.9%NS|Admission for intravascular volume expansion
1459841|NCT03275792|Drug|Routine home oral rehydration|Routine oral fluids as is given at home to all children with acute diarrheal disease
1459842|NCT03275779|Behavioral|Low Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete a single bout of unilateral resistance exercise.
1459843|NCT03275779|Behavioral|High Frequency Condition|Young, untrained participants complete 7 days of habitual physical activity followed by a 7 day period where participants complete the same total volume of resistance exercise as the low frequency condition as five smaller bouts of unilateral resistance exercise.
1459844|NCT03275766|Other|DLPFC inhibitory|15 Hz stimulation of left dorsolateral prefrontal cortex (DLPFC)(15 sessions/3weeks, 1500 stimuli per session, stimulation intensity 100% of the individual active motor threshold; in total 22500 stimuli
1459847|NCT03275766|Other|sham TMS|Determination of active motor threshold and subsequent stimulation with the placebo coil, with the same sounds but without effects. 15 sessions in three weeks, duration of 20 mins per session
2010469|NCT02955680|Procedure|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath.  At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
1459849|NCT03275740|Drug|PF-06755347|Single doses of PF-06755347 will be administered, at planned dose levels of 0.1 mg/kg, 0.3 mg/kg, 1 mg/kg, 3 mg/kg, 7.5 mg/kg, 15 mg/kg, 30 mg/kg, and 45 mg/kg.
1459850|NCT03275740|Drug|Placebo comparator|Placebo comparator
1459851|NCT03275727|Behavioral|iACT-BC|A Guided INternet-delivered Individually-tailored ACT-influenced Cognitive Behavioural INtervention to ImprOVe Psychosocial Outcomes in Breast Cancer Survivors
1459852|NCT03275714|Device|Smartphone APP|Participants use the BiP-App for 6 months. The app continuously records data on light and motion sensors, as well as Global Positioning System (GPS) and mood surveys.
1459853|NCT03275701|Drug|Triumeq|Open Label, Switch to Triumeq (ABC/DTG/3TC)
1459854|NCT03275688|Diagnostic Test|Breath Analysis|Breath will be analyzed in all three groups using gas chromatography mass spectrometry.
1459855|NCT03275675|Drug|Oral anticancer medications|All the oral medications for cancer treatment (hormonal, cytotoxic and targeted therapies)
1459856|NCT03275662|Behavioral|Dietary Fiber|
1459857|NCT03275662|Behavioral|Fermented Foods|
1459858|NCT03275649|Other|Help-seeking for non-motor symptoms|Brief, self-paced, online individually tailored intervention using LifeGuide software. Includes information, videos and exercises.
1459859|NCT03275636|Biological|Peripheral blood stem cells|Hematopoietic stem cell transplantation with PBSC
1459860|NCT03275623|Drug|Antibiotic|Those randomized for treatment will be prescribed the most commonly used antibiotic for urinary tract infections in pregnancy. This includes: Nitrofurantoin, Cephalexin, and Amoxicillin. It is unsure which antibiotic the participant will receive but a majority of the time it will be one of the above named antibiotic. The choice will be determined by the physician, but will accommodate participants' prior medication history and adverse events.
1459861|NCT03275623|Other|Standard Prenatal Care|Continued surveillance of urinary cultures
1459862|NCT03275610|Genetic|Blood sample|5 mL of blood withdrawn from patients with history of pulmonary embolism post total hip arthroplasty or total joint arthroplasty
1459866|NCT03275584|Drug|N-13 ammonia intravenous injection|"Participants will receive two injections of N-13 ammonia, once at rest and once at stress before undergoing positron emission tomography myocardial perfusion imaging"
1459867|NCT03275571|Behavioral|cCBT intervention|During each 30 minutes sessions, the participants will learn key concepts on depression, then will apply them to the program's main character who suffers from depression, and then will apply those techniques to their own personal challenges.
1459868|NCT03275558|Drug|Axitinib 1 MG|"Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
Subjects take a nasal spray BID at a single dose in each nostril (approximately at the same time of day) for 7 weeks or unacceptable toxicity or other adverse events."
1459869|NCT03275558|Drug|Sunitinib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
1459870|NCT03275558|Drug|Pazopanib 5 MG|Pharmaceutical composition of Axitinib 5MG +Sunitinib 5MG + Pazopanib 5MG in the liquid form of a nasal spray NST-4-G.
1459871|NCT03275545|Other|No intervention|No intervention is being examined in this study
1459872|NCT03275519|Other|Randomization to not receive prophylactic antibiotics after surgery.|No antibiotics were ordered after surgery.
1459873|NCT03275519|Other|Randomization to receive prophylactic antibiotics after surgery|In general, the antibiotic given is a combination sulfamethoxazole/ trimethoprim oral suspension (2-3 mg trimethoprim/kg by mouth once a day); or if indicated, nitrofurantoin (1mg/kg by mouth once daily). All subjects did not receive intraoperative antibiotics.
1459874|NCT03275506|Drug|Pembrolizumab Injectable Product - Chemotherapy - Bev|Pembrolizumab 200 mg then carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
1459875|NCT03275506|Drug|Chemotherapy - Bev|Carboplatin (AUC5 or 6) and paclitaxel (175mg/m²), +/- bevacizumab (15 mg/kg Q3W)
1947948|NCT02911311|Drug|intravitreal injection of conbercept|conbercept is an anti-VEGF agent and is approved by the Food and Drug Administration for wet age-related macular degeneration
1459878|NCT03275467|Other|Faecal microbiota transfer (FMT)|Suspended stool from a healthy donor
1459879|NCT03275454|Drug|TNT009|Participants will receive TNT009 5.5 grams as IV infusion.
1459880|NCT03275441|Diagnostic Test|Electroretinography|An additional electroretinogram performed after 10 minutes of dark adaptation.
1459881|NCT03275428|Device|transnasal humidified rapid-insufflation ventilator exchange|high flow nasal cannula with humidified oxygen
1459882|NCT03275415|Drug|budesonide|Intra-tracheal instillation of a combination of budesonide/surfactant in preterm infants with RDS to prevent BPD
1459883|NCT03275415|Drug|Saline|Intra-tracheal instillation of a combination of saline/surfactant in preterm infants with RDS to prevent BPD
1947949|NCT02911311|Device|PRP|panretinal photocoagulation (PPR) is the standard treatment for proliferative diabetic retinopathy (PDR) and is applied to the peripheral retinal tissue to ablate areas of the peripheral retina and thereby reduce retinal oxygen consumption
1947950|NCT02907268|Drug|onabotulinumtoxinA|OnabotulinumtoxinA (Botox; Allergan) was approved by the FDA in 2002. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
1947951|NCT02907268|Drug|abobotulinumtoxinA|AbobotulinumtoxinA (Dysport; Galderma) was approved by the FDA in 2009. Intervention administered by study nurse. Intradermal administered in a regular 1 cm2 grid across the cheeks and forehead. Intramuscular administered as per normal practice.
1947952|NCT02904629|Behavioral|Respecting the Circle of Life (RCL)|"Intervention activities will consist of the delivery of RCL: an holistic sexual, reproductive health and teen pregnancy prevention curriculum. RCL was adapted in 2011 from an evidence-based intervention (EBI) for the prevention of HIV/AIDS called Focus on Youth (FOY) + Informed Parents and Children Together (ImPACT)."
1947953|NCT02904629|Other|Control Program|Control activities will consist of the delivery of educational lessons on nutrition, fitness, outdoor recreation, safety, environmental protection and nature.
1947954|NCT02904577|Other|Any treatment, watch and wait policy included|"Patients registered in the study despite their planned treatment, watch and wait policy included. The planned treatment mentioned in the protocol is just the ideal approach proposed by investigators.The treatment can change depending on the evolution of the disease, without this affects the study's purposes."
1947955|NCT02901496|Behavioral|Endurance Exercise Training|Three months of supervised training. Interval training, 3 sessions weekly of 45 min. During intervals the intensity will be minimum 70 % of VO2 max
1947956|NCT02901496|Behavioral|Resistance Exercise Training|Three months of supervised resistance training. Subjects will perform 3 weekly sessions of 45 min. The intensity will be kept at minimum 60% of 1RM.
1947957|NCT02901496|Behavioral|No Exercise|Control to exercise
2010470|NCT02955680|Procedure|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. "
2010471|NCT02954874|Other|Laboratory Biomarker Analysis|Correlative studies
1459898|NCT03275363|Diagnostic Test|Neurocognitive battery|"Cognitive impairment status (SCD, MCI, dementia), HK-MoCA, Clinical Dementia Rating (CDR sum of squares), Geriatric Depression Scale (GDS-15), Neuropsychiatric Index (NPI), Barthel Index, Lawton's IADL, Life-Space Assessment, Mini-Nutrition Assessment (MNA), Quality of Life for Alzheimer's Disease (QoL-AD, patient and carer parts), frailty status (FRAIL scale), handgrip strength, walking speed, exercise status, sleep quality, Charlson comorbidity index (CCI, age-adjusted).
NACC: Story recall, Benson's complex figure copy, colour trail test (black & white), verbal fluency, digit forward and backward span."
1459899|NCT03275363|Diagnostic Test|MRI|MRI: T1, T2, FLAIR, SWI, DTI, fMRI, ASL, MRS, for selected patients
1459900|NCT03275363|Biological|Blood tests|Stored samples (unanalysed): serum, plasma, buffy coat (PBMC); also processed for microvesicles and exosome analysis
1459901|NCT03275363|Diagnostic Test|EEG with event-related potential (ERP)|128-channel EEG with ERP for Go/NoGo and Prospective Memory (PM) tasks for selected patients
1459902|NCT03275363|Diagnostic Test|Amyloid PET CT|F18 Flutametamol PET CT for selected patients
1459903|NCT03275350|Drug|Naltrexone Injectable Suspension|Six monthly injections of extended-release naltrexone
1459904|NCT03275350|Other|Treatment as usual|Standard treatment for opioid use disorder provided at each HIV clinic
1459905|NCT03275337|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive form of neuromodulation in which a fluctuating magnetic field is placed over a cortical region of interest to induce physiological changes such as inhibition or excitation over that region. rTMS can also be used to change functional connectivity between regions.
1459906|NCT03275324|Device|Capnostream20p|Observational study of patients connected to the Capnostream20p monitor.
1459910|NCT03275272|Diagnostic Test|level of IGF-1 in infants|Measurment of blood level of IGF-1 in infants
1459911|NCT03275259|Device|THORK Shock Wave® (Extracorporeal shock waves)|Treatment with extracorporeal shock waves: energy between 100 and 180mJ, frequency of 15Hz and 6000 shots in abdomen, glutes and thigh Back and flanks 3000 shots with radial applicator and 15mm tip. The treatment is performed twice a week for 1 hour and 30 minutes each session.
1459912|NCT03275246|Device|X-PSI Knee System|Patients are operated with X-PSI Knee System guides
1459913|NCT03275220|Diagnostic Test|2D Echocardiography and 3D Echocardiography|Imaging of right ventricle by 2d echocardiography and 3D echocardiography to assess right ventricular function accurately
1459914|NCT03275207|Drug|saline|an equal volum of saline
1459915|NCT03275207|Drug|dexmedetomidine|dexmedetomidine, 0.5ug/kg/h by intravenous influsion, intraoperative
1459916|NCT03275194|Procedure|HIPEC|Following complete cytoreductive surgery without any evidence of residual disease, the patient will be randomized either HIPEC (intervention) or no-HIPEC (control) in the operative Room. If the arm HIPEC is obtained, then a HIPEC procedure with cisplatin and doxorubicin will be performed. If no-HIPEC (control arm) is assigned then the surgical procedure will be finished.
1459917|NCT03275181|Diagnostic Test|Transthoracic Echocardiography|Non-invasive assessment of left ventricle structure and function
1459918|NCT03275181|Diagnostic Test|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplethysmography
1459919|NCT03275181|Diagnostic Test|Submaximal Exercise|Incremental exercise test to 85% predicted maximal heart rate on a recumbent cycle ergometer
1459920|NCT03275168|Behavioral|Dyadic Intervention|Sexual partners will receive dyadic counseling and support for condom negotiation after receipt of individual evidence based HIV/STI prevention intervention (Sister-to-Sister (female) and Focus on the Future (male).
1459921|NCT03275168|Behavioral|Individual STI Prevention Intervention Counseling|Sexual partners will receive individual evidence-based HIV/STI prevention counseling without partner debrief and/or practice negotiating condom use.
1459922|NCT03275142|Device|Icare tonometer|Icare tonometry effects of keratometry readings, topography, and corneal staining to demonstrate that the Icare tonometer does not alter subsequent evaluation or testing. This would allow IOP testing to be performed by technical staff at any time during the examination process without affecting subsequent tests. A total of fifteen patients at each of four sites will be evaluated using Icare tonometers provided by Icare USA. The investigator will be masked as to which eye will undergo Icare tonometry. Both the study eye and the control eye will undergo pre-tonometry and post-tonometry testing; Keratometry readings, IOL master, Topography via Pentacam, and corneal staining with fluorescein using the Oxford scoring scale.
1459923|NCT03275129|Diagnostic Test|Ultrasound assessment of heart and lungs|Patients will receive an ultrasound assessment of their heart and lungs.
1459924|NCT03275116|Drug|Tiotropium 'Respimat' 5 mcg|Once daily single bronchodilation
1459925|NCT03275116|Drug|Aclidinium Bromide/Formoterol Fumarate 340/12 mcg|Twice daily dual bronchodilation
1459932|NCT03275038|Behavioral|Tai-Chi exercise|Behavioral: Tai-Chi exercise
1459933|NCT03275038|Behavioral|Aerobic exercise|Behavioral: Aerobic exercise
1459934|NCT03275025|Drug|YRA-1909 dose A|During 12 weeks of this clinical study,all subjects will receive YRA-1909 dose A
1459935|NCT03275025|Drug|YRA-1909 dose B|During 12 weeks of this clinical study,all subjects will receive YRA-1909 dose B
1459936|NCT03275025|Drug|YRA-1909 dose C|During 12 weeks of this clinical study,all subjects will receive YRA-1909 dose C
1459937|NCT03275025|Drug|Placebo|During 12 weeks of this clinical study, subjects who are randomized to the comparison arm will receive the placebo tablets
1459938|NCT03275025|Drug|Methotrexate|During 12 weeks of this clinical study, all subjects of each assigned group will maintain their stabilized dose of MTX as identical as before the enrollment of this study.
1459939|NCT03275012|Drug|Gabapentin + Morphine|"Gabapentin: liquid oral formulation (syrup) - 75 mg/ml-three times daily. The starting dose during the optimization period will be defined according to 2 weight groups (5-15kg and >15kg). Dose will be scaled at Day 1,3,5,14,and 21 according to a specific schedule. Maintenance dosing will be scheduled in accordance to the body weight.
Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period."
1459940|NCT03275012|Drug|Placebo + Morphine|Placebo liquid oral formulation. Morphine: background therapy as oral, liquid and solid formulations. Patients with BW≤30kg :liquid oral formulation four times daily throughout the whole treatment period. Patients with BM>30kg : immediate release solid and/or liquid oral formulation four times daily during titration phase and an extended release solid oral formulation twice daily during the maintenance period.
1459944|NCT03274960|Combination Product|Griess,|Experimental: Griess, Culture and antibiotic Griess reagents, sulfanilamide and NED added in urine sample for 20 minutes, urine culture using blood agar for 24 hours and treatment with antibiotic every trimester for up to 7 days.
1459945|NCT03274947|Device|Cerebellar TMS|Cerebellar transcranial magnetic stimulation
1459946|NCT03274947|Device|Sham cerebellar TMS|Sham cerebellar transcranial magnetic stimulation
1459950|NCT03274921|Diagnostic Test|Biological determination|Evaluation of plasma accumulation of the 10 retention solutes with CV complications in CKD patients
1459951|NCT03274908|Other|regular medical treatment|regular medical treatment
1459952|NCT03274895|Drug|PHMB 0.08%|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
1459953|NCT03274895|Drug|Propamidine 0.1%|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
1459954|NCT03274895|Drug|placebo|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
1459955|NCT03274895|Drug|PHMB 0.02%|16 drops in a day for 5 days,8 drops in a day for 7 days,6 drops in a day for 7 days and 4 drops in a day up to clinical resolution
1459956|NCT03274882|Drug|Trifluridine/Tipiracil hydrochloride (S95005)|Film-coated tablet containing 15 mg of trifluridine and 7.065 mg of tipiracil hydrochloride, or 20 mg of trifluridine and 9.42 mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/m²/dose. The treatment is given until unacceptable toxicity according to the investigator, disease progression or patient withdrawal. If a patient discontinues study treatment for reasons other than radiologic disease progression (e.g., intolerable side effects), patients will be followed for tumour response until radiologic disease progression or initiation of new anticancer therapy (whichever occurs first).
1459957|NCT03274869|Other|No intervention|No intervention
1459960|NCT03274843|Other|Activity of everyday life|Kitchen workshop
1459961|NCT03274830|Device|aneXys|150 patients with the aneXys cup
1459962|NCT03274817|Drug|Escitalopram Pill|Subjects randomized to group A will receive Lexapro (escitalopram), in an initial, baseline dosage of 5 mg daily.
1459963|NCT03274817|Drug|Venlafaxine Pill|Subjects randomized to group B will receive Effexor XR (venlafaxine extended release capsules), in an initial baseline dosage of 37.5 mg daily.
1459964|NCT03274817|Drug|Placebo Oral Tablet|Subjects randomized to group C will receive placebo tablets, which will be matched to the Lexapro and the Effexor XR as far as possible, and will also be administered on a once daily schedule at baseline.
1460083|NCT03273972|Other|Carotid Intima Media Thickness|Measurements will be repeated three times, and the average of the median values will be recorded
1461269|NCT03264547|Drug|Docetaxel|Every 3 weeks
1459967|NCT03274791|Diagnostic Test|Analysis of induced sputum|"Induced sputum was collected and analysed in the three arms (Healthy subjects, Never smokers with COPD and smokers with COPD) The volume of the sputum sample, was treated with an equal volume of 0.1% dithiothreitol. The samples were then vortexed and placed in a shaking water bath at 37°C for 15 min to ensure complete homogeneisation. The suspensions were centrifuged at 400× g and the sputum supernatant stored at -80°C until cytokines analysis. The cell pellet was resuspended in 0.5% bovine serum albumin in phosphate buffered saline and cytospin were made by putting 100 µL of the cell suspension in the funnels.
Slides for differential cell counts were stained with May-Grünwald Giemsa."
1459968|NCT03274791|Diagnostic Test|Lung Function test|"All the subjects underwent pulmonary function tests (Healthy subjects, Never smokers with COPD and smokers with COPD).
Pulmonary function parameters were measured using a portable spirometer (Easy One ndd. Medizintechnik; Zurich, Switzerland) according to the ATS criteria (American Thoracic Society). Reversibility test was performed 15 min after inhalation of 400 µg of Salbutamol (Ventolin, GlaxoSmithKline, Middlesex, UK). All spirometry data were graded for quality and only tests that met high quality scores were used for the final analysis."
1459969|NCT03274791|Diagnostic Test|Enzyme-linked Immunosorbent Assay|"IL-8 and TNF-α were measured in the sputum supernatant of all the subjects (Healthy subjects, Never smokers with COPD and smokers with COPD).
Commercially available kits were used to detect IL-8 (Human IL-8 Immuno-Biological Laboratories ELISA Kit) and TNF-α (Human TNF-alpha Sigma-Aldrich ELISA Kit) concentrations in the sputum supernatants. The absorbance was measured at 450 nm. The lower limits detection were 2 pg/mL for IL-8 and 5 pg/mL for TNF-α. The intra assay coefficients of variability were 8.7% for IL-8 and 7.7% for TNF- α."
1459970|NCT03274778|Drug|Ruxolitinib 20 MG|tablets
1459971|NCT03274765|Diagnostic Test|Dosage of oestradiol|"The study is based on a concept using capillary blood tests using lateral flow by migration on membrane similarly to a pregnancy test, patented by a french company (NGBiotech).
This study is therefore a feasibility study of a rapid test for oestradiol dosage during monitoring of ovarian stimulation."
1947958|NCT02901496|Drug|Tocilizumab|Tocilizumab infusion will be administered monthly (8 mg/kg body weight i.v., maximun 800 mg). Each subject will receive 3 infusions during the study period.
1947959|NCT02901496|Drug|Placebo|Saline infusion will be administered monthly (same volume as Tocilizumab). Each subject will receive 3 infusions during the study period.
1459974|NCT03274713|Device|Electro-acupuncture|"Patients in this group will be treated by use of 6-7 local acupuncture points (ST34, ST35, ST36, EX-LE2, EX-LE5, GB33, GB34, SP9, SP10, LR7, LR8 and Ashi) and 2-3 distal points (GB31, GB36, GB39, GB41, ST40, ST41, LR3, BL60, SP6 and KI3). Needles will be stimulated manually for 10 seconds to achieve De Qi sensation and an electrical apparatus (HANS-200A acupoint nerve stimulator, Nanjing Jisheng Medical Co., Ltd. production, wave of 2/100Hz) will be then connected to the needles with alligator clips to stimulate the needles in pairs ST36-SP9/GB34 and ST34-SP10. The stimulus intensity will be increased until the patient reports a strong but comfortable intensity."
1459975|NCT03274713|Device|Manual acupuncture|Participants in the group have the same schedule as the electro-acupuncture group except that the electrical apparatus has working power indicator and sound without actual current output.
1459976|NCT03274700|Drug|Tamsulosin.|Patients who will receive tamsulosin as a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
1459977|NCT03274700|Drug|Placebo.|Patients who will receive as placebo a treatment for lower ureteric stones from (10-15)mm up to 8 weeks duration.
1459978|NCT03274687|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
1459979|NCT03274687|Other|Laboratory Biomarker Analysis|Correlative studies
1459980|NCT03274687|Other|Quality-of-Life Assessment|Ancillary studies
1459981|NCT03274687|Radiation|Radiation Therapy|Undergo conventional radiation therapy
1459983|NCT03274661|Drug|Pembrolizumab 200 mg Q3W|Pembrolizumab 200 mg Intravenous Infusion every 3 weeks administered on Day 1 of each 3 week cycle
1459984|NCT03274648|Dietary Supplement|Oral butyrate|Patients follow the habitual diet supplemented with 2.4g/day of oral butyrate
1459985|NCT03274648|Dietary Supplement|Vegetarian diet|Patients follow a vegetarian diet containing inulin and resistant starch-rich foods, including no meat and fish, but containing eggs and dairy products
1459986|NCT03274648|Dietary Supplement|Habitual diet|Patients follow the habitual diet
1459987|NCT03274635|Behavioral|Desk-based pedaling device and pedaling incentives provided|Varying types of incentives, equivalent in monetary value, will be randomly assigned across the 6 arms to promote regular desk-based pedaling. A free desk-based pedaling device will be provided. Effects on amount of desk-based pedaling and work productivity will be evaluated.
1459988|NCT03274622|Behavioral|Impact Parent Training|
1459989|NCT03274622|Behavioral|No Impact|
1947960|NCT02896244|Other|no intervention|
1459991|NCT03274596|Drug|Vitamin E|
1459992|NCT03274596|Drug|Placebo|
1459993|NCT03274583|Diagnostic Test|Smartphone seismographic recording|A short recording of heart rhythm using a smartphone.
1459994|NCT03274557|Procedure|RFM|
1460084|NCT03273972|Other|Forearm blood flow studies|Assess and determine vascular function, which can interrogate endothelium dependent and independent mechanisms of nitric oxide bioavailability
1517429|NCT02836743|Drug|Placebo|
1947961|NCT02893371|Drug|Lithium Carbonate|Exposure to all dosages and delivery forms.
1947962|NCT02893371|Drug|Lamotrigine|Exposure to all dosages and delivery forms.
1947963|NCT02893371|Drug|Valproic Acid|Exposure to all dosages and delivery forms.
1947964|NCT02893371|Drug|Oxcarbazepine|Exposure to all dosages and delivery forms.
1947965|NCT02893371|Drug|Carbamazepine|Exposure to all dosages and delivery forms.
1947966|NCT02893371|Drug|Ziprasidone|Exposure to all dosages and delivery forms.
1947967|NCT02893371|Drug|Risperidone|Exposure to all dosages and delivery forms.
1947968|NCT02893371|Drug|Quetiapine|Exposure to all dosages and delivery forms.
1947969|NCT02893371|Drug|Olanzapine|Exposure to all dosages and delivery forms.
2010472|NCT02954874|Other|Patient Observation|Undergo standard monitoring
1459995|NCT03274544|Other|PROLUNG|"Chinese herbal medicine formula PROLUNG with individual herbs of the formula are listed as follows (weight in granule preparation):
Huang Qi (Radix Astragali Membranaceus): 2 g
Dan Shen (Radix Salviae Miltiorrhizae): 1 g
Jiang Huang (Rhizoma Curcumae Longae): 1 g
Yin Xing (Semen Gingko Bilobae): 1 g
Mai Men Dong (Tuber Ophiopogonis Japonoci): 1 g
Bai He (Bulbus Lilii): 1g
Jin Yin Hua (Flos Lonicerae Japonicae): 1 g
Zi Su Ye (Folium Perillae Frutescentis): 1 g
Yin Yang Huo (Herba Epimedii): 1g"
1459996|NCT03274531|Behavioral|Referral of hypertensive patients to the attending physician|Immediate referral to the treating physician in case of elevated automated office blood pressure measurements
1459997|NCT03274518|Device|Expanded Hemodialysis|"Intervention: Conversion from conventional HD to expanded hemodialysis por 1 month.
High cutoff with high retention onset dialyzers allow clearance of middle molecules, without reducing significantly serum concentration of albumin. It allows higher convective clearance in comparison to conventional hemodialysis, but it is unknown if such clearance is similar to online hemodiafiltration. Therefore, the aim of the present intervention is to compare this dialyzer with online hemodiafiltration"
1459998|NCT03274518|Device|Online Hemodiafiltration|"Intervention: Conversion from conventional HD to online Hemodiafiltration por 1 month.
Online hemodiafiltration has been associated with lower incidence of intradialytic hypotension in comparison to conventional hemodialysis."
1459999|NCT03274505|Other|Questionnaires|"Questionnaires about excessive daytime sleepiness (Epworth scale), insomnia (Severity of Insomnia Scale), Restless Legs Syndrome, Chronotype (Horne and Ostberg questionnaire), Sleep apnoea syndrome (Berlin questionnaire)
Clinical evaluation
Routine neuropsychological evaluation (for stroke patients)
Routine Polysomnography for patients with high suspicion of sleep apnoea syndrome (SOS score (Epworth + Berlin) > 10)"
1947970|NCT02893371|Drug|Aripiprazole|Exposure to all dosages and delivery forms.
1947971|NCT02893371|Drug|Fluoxetine / Olanzapine|Exposure to all dosages and delivery forms.
1947972|NCT02893371|Drug|Haloperidol|Exposure to all dosages and delivery forms.
1947973|NCT02893371|Drug|Perphenazine|Exposure to all dosages and delivery forms.
1947974|NCT02893371|Drug|Clozapine|Exposure to all dosages and delivery forms.
1947975|NCT02893371|Drug|Asenapine|Exposure to all dosages and delivery forms.
1947976|NCT02893371|Drug|Lurasidone|Exposure to all dosages and delivery forms.
1947977|NCT02893371|Drug|Paliperidone|Exposure to all dosages and delivery forms.
1460008|NCT03274479|Drug|PBF-1129|PBF-1129 once a day by oral administration
1460009|NCT03274466|Device|Closed Incision Negative Pressure Therapy (ciNPT)|Closed Incision Negative Pressure Therapy applied through a foam bolster with a wicking interface fabric that includes 0.019% ionic silver at 125 mmHg of negative pressure for 5-7 days.
1460010|NCT03274466|Device|Standard of Care Dressing|A standard silver-impregnated dressing applied to a closed surgical incision for 5-7 days post-operatively.
1460013|NCT03274440|Drug|Marijuana|"THC and CBD are cannabinoids which are found naturally in the marijuana plant. Both act on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
1460014|NCT03274440|Other|Placebo|Placebo control group, not receiving THC or CBD.
1460015|NCT03274427|Device|Basic drugs therapy of HCC by TACE|Basic drugs include: 1. Molecular targeted drugs for HCC：apatinib; 2. Antiviral drugs (ETV or TDF) should be given to patients who were infected with HBV or HCV; 3. Patients with liver dysfunction should be treated with conventional hepatoprotective agents drugs (including glycyrrhizin, reduced glutathione, vitamin C，etc); 4. Patients with ascites symptoms should be treated with furosemide and spironolactone according to the urine volume, and they also should be treated with proton pump inhibitors in the prevention of gastrointestinal bleeding; 5. Other basic diseases were treated routinely.
1460016|NCT03274427|Drug|Arginine hydrochloride|Arginine hydrochloride injection 5g/dose; 40g/d; ivgtt; sustained medication for 24 days; drug withdrawal for 4 days.
1460017|NCT03274427|Drug|Trimetazidine hydrochloride|Trimetazidine hydrochloride, 20mg/tablet, 40mg, twice a day.
1460018|NCT03274414|Drug|Cisplatin|Cisplatin, a platinum-containing cytotoxic chemotherapy, will be administered at 100 mg/m2 on days 1-2, 21-22, and 42-43 of radiotherapy.
1460019|NCT03274414|Radiation|Adjuvant Proton Radiotherapy|"Proton therapy treatment will follow the National Cancer Institute's Guidelines for the Use of Proton Radiation Therapy in NCI-Sponsored Cooperative Group Trials. Proton therapy techniques may include passively scattered or scanning or pencil beam technology."
1460020|NCT03274414|Procedure|Endoscopic Resection|In brief, an endoscope is used and two surgeons perform the intervention in a binostril manner. Tumor is generally resected with an emphasis on identification of the attachments in the paranasal sinuses, nasal cavity, or skull base.
1460021|NCT03274401|Device|Zenicor intermittent ECG device|At least two weeks of screening twice daily for atrial fibrillation using intermittent ECG recordings, and prolonged use of OAC-therapy if atrial fibrillation is detected
1460022|NCT03274388|Procedure|nutritional therapy|protein-rich nutritional therapy and counseling, during study period of 12 weeks
1460023|NCT03274388|Procedure|WB-EMS combined with nutritional therapy|protein-rich nutritional therapy and counseling plus whole body electromyostimulation exercise training, twice a week for 20 min., during study period of 12 weeks
1460024|NCT03274375|Drug|IA session|10 IA sessions performed in 28 days maximum, using TherasorbTM adsorbers which contain sheep derived polyvalent antihuman-immunoglobulin coupled to SepharoseTM CL-4B.
1460025|NCT03274375|Drug|Rituximab|"Concomitantly, Rituximab will be given each week for 4 weeks (one injection by week +/- 3 days):
at least 1 day before each IA session
the last injection will occur after the last session IA (minimum one day after)"
1460085|NCT03273972|Other|Concomitant medication check|Review of medication taken by the participant
1460086|NCT03273972|Other|Medication compliance check (Pill count)|Ensure prescribed statin has been taken
1460087|NCT03273972|Other|Physical examination|Check overall health
1947978|NCT02893371|Drug|Mirtazapine|Exposure to all dosages and delivery forms.
1947979|NCT02893371|Drug|Bupropion|Exposure to all dosages and delivery forms.
1947980|NCT02893371|Drug|Desvenlafaxine|Exposure to all dosages and delivery forms.
1947981|NCT02893371|Drug|Duloxetine|Exposure to all dosages and delivery forms.
1460026|NCT03274362|Behavioral|Headspace Mindfulness App|Participants will be given instructions on how to download Headspace on an electronic device and will be provided a free 3-month access code. The app contains a series of ten step-wise 10-minute video sessions that guide the user through mindfulness training. Upon completion of these sessions, additional content will be accessible, including sessions on health (depression, self-esteem, anxiety, sleep, and pregnancy), relationships (kindness, generosity, relationships, change, appreciation, and acceptance) and performance (creativity, focus, happiness, and balance). The frequency and duration of usage will be in accordance to the instructions of the app.
1460027|NCT03274349|Procedure|whole body electromyostimulation exercise|whole body electromyostimulation exercise training twice a week for 20 min each, bipolar, 85 Hz, intermittent pulse/pause, pulse width 350 µsec
1460028|NCT03274349|Procedure|protein-rich nutrition therapy|protein-rich nutrition therapy with an objective of reaching 1,2 to 1,5 g protein/kg body weight and day
1460029|NCT03274336|Behavioral|questionnaire|questionnaire post preanesthetic interview
1460030|NCT03274336|Behavioral|face-to-face interview|Group A = face-to-face interview
1460031|NCT03274336|Behavioral|brochure|after reading a brochure a face to face interview will take place
1460032|NCT03274336|Behavioral|movie|after seeing a film about the procedure a face-to-face interview will take place
1460033|NCT03274323|Device|iStent and travoprost or latanoprost|2 iStents will be inserted and patients will be started on travoprost or latanoprost following the procedure
1460034|NCT03274323|Procedure|Trabeculectomy|Standard trabeculectomy
1460035|NCT03274310|Behavioral|Educational text messages|Educational text message about ways to decrease household transmission of influenza and other respiratory infections
1460036|NCT03274297|Drug|EVRA patch (NGMN+EE) (Treatment A) (Reference)|A single transdermal contraceptive patch of EVRA (NGMN + EE) containing 6 milligram (mg) of the progestin NGMN and 600 microgram (mcg) of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
1460037|NCT03274297|Drug|HMW PIB patch (NGMN+EE) (Treatment B) (Test)|A single transdermal contraceptive HMW PIB (NGMN + EE) patch containing 6 mg of the progestin NGMN and 600 mcg of the EE will be applied to the buttock (right or left) of participants on Day 1 of each treatment period and is removed 7 days after patch application, ie, on Day 8.
1460038|NCT03274284|Combination Product|chemoradiation|chemoradiation in case of T1G3 BC after BCG failure.
1460039|NCT03274271|Behavioral|Action planning|Action planning is the behaviour change technique used to make users specify their goal (what they are going to do, when, where, ...).
1460040|NCT03274271|Behavioral|Coping planning|Coping planning is the behaviour change technique used to make users think about possible hindrances and according solutions when trying to reach their goal.
1460041|NCT03274271|Behavioral|Self-monitoring|Self-monitoring is the behaviour change technique used to make users keep track of their goal.
1460042|NCT03274271|Behavioral|Feedback and tips|In this intervention, users receive tailored feedback on their current health behaviour and tips and tricks to reach their goals. This tips and tricks include the behaviour change technique 'eliciting social support'.
1460047|NCT03274232|Device|SUNEKOS ® 200|micro-injections of the study product were performed by a specialized dermatologist, bilaterally on the face (zygomatic protuberance, nostril's angle, inferior margin of tragus, lip marionette lines, mandibular angle) of female volunteers aged 45-65 years, with photoaging of mild/moderate grade
1460048|NCT03274219|Biological|bb21217|autologous T cells transduced ex-vivo with anti-BCMA CAR lentiviral vector encoding the chimeric antigen receptor (CAR) targeted to human BCMA, suspended in cryopreservative solution
1460049|NCT03274206|Biological|BLS-ILB-E710c|BLS-ILB-E710c 250mg/capsule
1460050|NCT03274206|Drug|Placebo|BLS-ILB-E710c-placebo
1460051|NCT03274193|Behavioral|Yoga training program|The hatha yoga program will be led by an experienced yoga instructor. Each 60 minutes session will consist of 10 minutes of breathing exercises (pranayama), 40 minutes of yoga pose practice (asana), and 10 minutes of supine meditation/relaxation (savasana). Yoga props, such as blocks and belts, will be used in accordance to each participant's particular body type and needs to help he/she achieve precise yoga postures safely and comfortably. The yoga poses are chosen for providing a restorative session and based on their purported relationship to restorative effects. Participants will be instructed to maintain their concentration and breath control at all times during the yoga session.
1460052|NCT03274180|Other|Nursing consultation|travel preventive consultation was performed by nurse
1460053|NCT03274167|Drug|Gabapentin 300mg|
1460054|NCT03274167|Drug|Placebo oral capsule|
1460055|NCT03274154|Dietary Supplement|Pre-Hyaluron 465 Innēov|Food supplement consisting og a tablet and a capsule, composed with a precursor of HA (glucosamine) and an enzymatic co-factor of HA synthesis (manganese)
1518094|NCT02831686|Drug|Ixazomib|
2010473|NCT02954874|Biological|Pembrolizumab|Given IV
2010474|NCT02954874|Other|Quality-of-Life Assessment|Ancillary studies
2010475|NCT02954874|Other|Questionnaire Administration|Ancillary studies
2010476|NCT02954874|Radiation|Radiation Therapy|Undergo radiation therapy
1460057|NCT03274128|Radiation|Radon therapeutic baths and inhalations|The natural water with low mineralized content plays a major therapeutic role with the parameters of Rn 303,1-441,5 Bq/l. In the treatment rooms (inhalation, cabins with baths and swimming pool) measurement of alpha radiation was 184,4-450,0 MeV. The measurements were analyzed every 3 months at the Institute of Occupational Medicine in the Department of Radiation Protection in Lodz, Poland. Among the types of treatments used in the therapy there was: comprehensive radon bath - with the temperature of 37 °C, duration 15 min., the treatments were performed every 2nd day, whereas radon inhalations lasted 15 min. with the temp. 37 °C- treatments were performed every 2nd day from Monday to Friday. Baths and inhalations were performed interchangeably and the total number of radon treatments during one stay was 15.
1460058|NCT03274128|Procedure|Kinesiotherapy|It is the therapeutic treatment of disease by passive and active muscular movements (as by massage) and of exercise. It is the core element of physiotherapy/physical therapy. Kinesiotherapy - duration of 30-45 min,
1460059|NCT03274115|Device|BLI (Blue Laser Imaging)|Switch from white light to BLI (Blue Laser Imaging) to predict the histology of colonic polyps
1460060|NCT03274102|Biological|Concomitant administration of EV71 vaccine with EPI vaccines|"The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.； the recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.
The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
1460061|NCT03274102|Biological|Single injection of EPI vaccine|"The recombinant hepatitis B vaccine was manufactured by Shenzhen Kangtai Biological Products Co., Ltd; the Group A meningococcal polysaccharide vaccine was manufactured by Wuhan Institute of Biological Products Co., Ltd.
The primary vaccination schedule of hepatitis B vaccine includes 3 doses with a schedule of 0,1,6 month, and subjects only receive 3rd vaccination in this study; the primary vaccination schedule of Group A meningococcal polysaccharide vaccine includes 2 doses with 3 months interval between doses, and subjects only receive 1st vaccination in this study"
1460062|NCT03274102|Biological|EV71 Vaccine only|The investigated EV17 vaccine was manufactured by Sinovac Biotech Co., Ltd.
1460063|NCT03274089|Device|Kiosk intervention group|"SEEK automates the management of patients with stable well-controlled chronic disease. SEEK has the following capabilities:
Collects patient information using patient-specific identification
Prompts the user for answers to screening questions for acute conditions
Measures relevant physiological parameters: blood pressure, height, weight; and calculates body mass index
Triages patients based on responses to screening questions, physiological parameters and blood test results
Provides recommendations to the patient on the care plan, self management and lifestyle choices"
1947982|NCT02893371|Drug|Venlafaxine|Exposure to all dosages and delivery forms.
1947983|NCT02893371|Drug|Citalopram|Exposure to all dosages and delivery forms.
1947984|NCT02893371|Drug|Escitalopram|Exposure to all dosages and delivery forms.
1947985|NCT02893371|Drug|Fluoxetine|Exposure to all dosages and delivery forms.
1460068|NCT03274037|Diagnostic Test|Device for mechanical excitation by pressure waves|"The IRM elastography technique, proven and patented in 2010 by the IR4M (Orsay, France), consists in characterizing by IRM induced waves in the human body in order to determine the mechanical properties Of the target organ.
The mechanical waves will be induced by pressure waves guided at the mouth of the subject elongated in the MRI and consisting of a function generator at a frequency between 5 Hz and 500 Hz, linear amplifier , An electromechanical transducer, a waveguide whose length is adapted to the chosen excitation frequency, an antibacterial filter and a disposable mouthpiece
The MRI imager Achieva 1.5 T MRI (Philips Healthcare, Best, the Netherlands) and the SIGNA Architect GEM 3.0T (GE medical systems, LLC, USA) system will be used to measure brain tissue displacement fields."
1460069|NCT03274024|Device|Ahmed Glaucoma Implant|Conjunctival Flap Scleral Exposure Insertion of Episcleral Plate Priming of the tube prior to AC entrance Insertion of Tube into the Anterior Chamber Suturing tube Coverage of tube
1460070|NCT03274024|Procedure|Trabeculectomy with Mitomycin C|Conjunctival Flap Mitomycin C Application Scleral Flap Paracentesis Excision of Limbal Tissue Peripheral Iridectomy Scleral Flap Closure Conjunctival Flap Closure
1460071|NCT03274011|Drug|Apatinib|Apatinib is a small-molecule tyrosine kinase inhibitor (TKI) that highly selectively binds to and strongly inhibits vascular en-dothelial growth factor receptor 2 (VEGFR-2), with a decrease in VEGF-mediated endothelial cell migration, proliferation, and tumor microvascular density. Previous data showed that apatinib treatment significantly improved OS and PFS with an acceptable safety profile in patients with advanced gastric cancer refractory to two or more lines of prior chemotherapy. Our study will observe the efficacy and safety of Apatinib for recurrent or metastatic esophageal squamous cell carcinoma: A phase II, prospective, single-arm, multicenter trial.
2010477|NCT02954848|Drug|TAK-438 10 mg|One TAK-438 10 mg tablet will be orally administered once daily
2010478|NCT02954848|Drug|Placebo|One TAK-438 placebo tablet will be orally administered once daily
1460074|NCT03273972|Other|Written Informed Consent|To be completed prior to conducting any study related procedures
1460075|NCT03273972|Other|Inclusion/Exclusion check|Eligibility check
1460076|NCT03273972|Other|Full Clinical Chemistry and Haematology Bloods|Participant required to fast for at least 6-8 hoursprior to visit. (Clear, non-caffeinated fluids are allowed)
1460077|NCT03273972|Other|Serum sample for systemic markers and lipid sub-fractions|Serum samples may be stored for later analysis.
1460078|NCT03273972|Other|Pregnancy Test|If applicable for women of child bearing potential
1460079|NCT03273972|Other|12 Lead ECG|participant resting supine
1460080|NCT03273972|Other|Blood Pressure and Heart Rate|Measured in the seated position after 5 minutes rest
1460081|NCT03273972|Other|Arterial Stiffness|Measure of functional and structural changes which accompanies cardiovascular disease
1460082|NCT03273972|Other|Central Haemodynamics|Measure of functional and structural changes which accompanies cardiovascular disease
1947986|NCT02893371|Drug|Fluvoxamine|Exposure to all dosages and delivery forms.
1947987|NCT02893371|Drug|Paroxetine|Exposure to all dosages and delivery forms.
1947988|NCT02893371|Drug|Sertraline|Exposure to all dosages and delivery forms.
1460088|NCT03273972|Other|Medical history|Review of volunteers medial history
1460089|NCT03273972|Other|AE/SAE review & reporting|Monitor safety from the point of consent
1460090|NCT03273972|Drug|Dosing|To be performed at the end of the visit following completion all other study visits
1460091|NCT03273959|Other|Exercise protocol|Protocol of exercises performed in hospital admission in children and adolescents with cystic fibrosis in the exacerbation phase.
1460092|NCT03273946|Drug|Fluticasone propionate|Fluticasone propionate is an inhaled corticosteroid to be used via a pediatric spacer device with a face mask for prophylactic treatment of asthma.
1460093|NCT03273933|Device|DragONE|The DragONE application for iOS and Android, developed in collaboration with the Institute for Educational Technologies of the National Research Council of Palermo, allow children to daily fill electronically the C-ACT questionnaire and the symptom diary card.
1460094|NCT03273933|Device|SmartOne|A little portable spirometer connected to DragONE allows daily PEF monitoring.
1460095|NCT03273920|Procedure|Robotic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, robotic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
1460096|NCT03273920|Procedure|Laparoscopic distal gastrectomy with D2 nodal dissection|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal gastrectomy with D2 lymph node dissection will be performed with curative treated intent.The type of reconstruction will be determined by the surgeon's experience and preference. The reconstruction can be carried out by extracorporeal or intracorporeal anastomosis.
1460098|NCT03273894|Diagnostic Test|Coagulation testing|"body temperature before the intervention
body temperature during the intervention including the way of measuring, each 15 minutes
body temperature at the end of surgery, signs of the patient's heat discomfort
body temperature during resting time in the postanesthesia care
standard coagulation tests + EXTEM, FIBTEM, NATEM - after anesthesia induction
blood sampling for standard coagulation tests (prior to the end of the surgical intervention) + EXTEM, FIBTEM, NATEM.
if body temperature is below 34°C, two sets of ROTEM tests are run: one at patient's body temperature, following by another one at a standard temperature (37°C)."
1460099|NCT03273881|Drug|glucose solution and Insulin|"Women in group 1, will receive intravenous saline solution boosted with 5% glucose combined with 8 units of insulin at a rate of 125mL/h. The desirable intrapartum glucose level will be 70 to 100 mg/dL. Glucose levels will be checked hourly.
Glucose level between 100-140 mg/dL will be treated with additional intravenous insulin, 1 units/hour.
Glucose level between 141-160 mg/dL will be treated with intravenous insulin, 2 units/hour. Additionally, the 5% glucose solution will be substitute with lactated Ringer's solution.
Glucose level between 161-200 mg/dL will be treated with intravenous insulin, 4 units/hour.
Glucose level above 200 mg/dL will be treated with intravenous insulin, 6 units/hour."
1460100|NCT03273881|Drug|glucose solution only|Women in group 2, will receive intravenous saline solution boosted with 5% glucose only, at a rate of 125mL/h. Women in this group will be treated similar to group 1 if glucose levels crossed over 100 mg/dL.
1460101|NCT03273868|Other|High velocity low amplitude manipulation|The researcher manually applies a preload force on the T6 level followed by a single posterior to anterior thrust.
1460102|NCT03273868|Other|Sham manipulation|The researcher manually applies a preload force on the right scapula followed by a single lateral thrust.
1460103|NCT03273855|Other|Fecal microbiota transplantation|The intervention treatment is fecal microbiota transplantation made of frozen donor feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
1460104|NCT03273855|Other|Placebo: fecal microbiota transplantation|The placebo group get fecal microbiota transplantation made of their own feces. The FMT is transferred as rectal enema where we use a rectal probe with a balloon to prevent leakage and keep the solution long enough in the colon. The patient will stay on the bench in different positions for 20 minutes. We will encourage the participant to keep the solution in the colon as long as possible and give them four pills of loperamide before the procedure in order to reduce bowel motility.
1460107|NCT03273816|Behavioral|sessions of sophrology|10 sessions of sophrology in preparation for the intervention 5 weeks before this one.
1460108|NCT03273803|Diagnostic Test|Heart sound recording using smartphone application|Heart sound recording and analysis using android smartphones (Samsung Galaxy S5, Galaxy S6, and LG G3)
1460110|NCT03273777|Procedure|Drawing of an incision line|Drawing of an incision line prior to skin incision at cesarean section
1460111|NCT03273751|Procedure|Remote Ischemic Preconditioning|After induction of anesthesia, RIPC consisted of four 5-min cycles of limb ischemia induced by a blood pressure cuff placed on the upper arm and inflated to 250 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated.
1460112|NCT03273751|Procedure|Sham control|After induction of anesthesia, sham control consisted of the placement of a blood pressure cuff on the upper arm with no inflation during the surgery.
1460113|NCT03273738|Diagnostic Test|folate level measurement|the level of folate measured in plasma with homocysteine
1460114|NCT03273738|Diagnostic Test|B12|B12 measurement in blood
1460115|NCT03273725|Other|Dental examination including taking a saliva sample.|The main focus of the dental examination is enamel defects and caries. Saliva samples (stimulated) will also be taken.
1460116|NCT03273712|Radiation|90Y-DOTA tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used as a treatment for both children and adults with neuroendrocrine and other somatostatin receptor positive tumors.
1461270|NCT03264547|Drug|Paclitaxel|Every week
1460117|NCT03273712|Diagnostic Test|68Ga-DOTATOC PET Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
1460118|NCT03273712|Drug|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing the radiation dose to the kidneys.
1460119|NCT03273699|Device|Mindfulness|Clients will use a consumer grade EEG device that provides guided mindfulness home practices
1460120|NCT03273686|Procedure|Discharge the NG tube during the surgery|Discharge the NG tube during the surgery.
1460121|NCT03273673|Other|Biofeedback Intervention|Visual and Tactile Biofeedback
1460122|NCT03273660|Device|Aliaxin (new trademark - IBSA Farmaceutici Italia S.r.l.)|"First treatment was performed during baseline visit, after the basal evaluations planned by the study procedure.
0.5-1.1 ml of Aliaxin (new trademark) for emi-face was injected by needle (25-27 G) and/or cannula (25 G, 40 mm).
A touch-up treatment (0.5-1.1 ml of Aliaxin new trademark for subject) was performed after 3-4 weeks (T1) in order to treat possible asymmetry."
1460124|NCT03273634|Drug|Lansoprazole Pill|once daily at night time
1460125|NCT03273634|Drug|Placebo|Placebo
1460126|NCT03273621|Procedure|Bariatic surgery|One of two different types of surgery: sleeve gastrectomy and Roux-en-Y gastric by-pass.
1460127|NCT03273595|Drug|Lapatinib|
1460128|NCT03273595|Biological|Trastuzumab|
1460129|NCT03273595|Drug|Paclitaxel|
1460130|NCT03273595|Drug|Epirubicin|
1460131|NCT03273595|Drug|Cyclophosphamide|
1460132|NCT03273569|Procedure|PDI-UC protocol|Preplacental delivery intervention for uterine conservation protocol starts after delivery of the fetus during Cesarean delivery and consists of delayed cord clamping, intramyometrial injection of vasopressin, subdecidual injection of saline, ligation of the uterine arteries, multiple 8 compression sutures, followed by delivery of the placenta, application of pressure and interrupted sutures if needed
1460133|NCT03273556|Device|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.) with Lidocaine 0.3%|"The injective treatment was performed, during T0 visit after the basal evaluations, mono-laterally on nasolabial fold,(right or left face side in according to a previously defined randomisation list).
A quantity of Aliaxin® Ev (up to a maximum of 0.5 ml) with Lidocaine 0.3% was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
1460134|NCT03273556|Device|Aliaxin® EV Essential Volume (IBSA Farmaceutici Italia S.r.l.)|"The injective treatment was performed on the contralateral nasolabial fold during T0 visit, after the basal evaluations .
A quantity of Aliaxin® Ev up to a maximum of 0.5 ml was injected on the nasolabial fold to achieve the aesthetic correction of the skin defect."
1460135|NCT03273543|Device|Restylane® Defyne|hyaluronic acid filler injection
1460136|NCT03273530|Other|Integrated Supported Employment|vocational assessment followed by job placement and on-going work-related social skills revision and reinforcement
1460137|NCT03273517|Procedure|Elective surgery|Elective surgery in children aged 0-15 years ASA I and II
1460138|NCT03273504|Other|Actapil Corpo Spray (SHEDIR PHARMA Srl - Italy)|The study product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the right or left leg (tibialis area) according to a randomisation list.
1460139|NCT03273504|Other|Placebo|The placebo product will be applied twice a day (at morning and at evening) for an interrupted period of 3 months, on the controlateral leg (tibialis area) right or left leg according to a randomisation list.
1460140|NCT03273491|Behavioral|daily self-weighing|Participants are provided with a wifi-enabled scale and asked to weigh themselves daily, first thing in the morning.
1460141|NCT03273491|Behavioral|daily temperature-taking|Participants are provided with a wifi-enabled thermometer and asked to take their temperature daily, first thing in the morning.
1460142|NCT03273478|Device|Endovascular treatment of bifurcation aneurysm with pCONUS2|"Patients suffering from a bifurcation aneurysm will be treated endovascularly with the pCONUS2 device.
The patients do not face any additional risks by participating in the study as the treatment does not differ from the standard of care in any way.
The patients will only be enrolled in the study if they give their written consent.
If they do not wish to participate in the observational study or if they wish to withdraw from it at a later date, they will not have any disadvantages."
1460143|NCT03273465|Other|Fecal transplantation|Fecal transplantation administered orally via frozen capsules.
1460144|NCT03273452|Drug|Chidamide|Chidamide will be given orally 30mg,biw, along with PET regimen (prednisone 100mg,po,qd,d1-5; etoposide 100mg,po,qd,d1-5; thalidomide 100mg,po,qn,d1-14;)
1460145|NCT03273439|Device|repetitive TMS|Prior to each TMS administration, motor threshold was determined by stimulating the left motor strip with the lowest possible energy to produce, within 10 stimuli, at least 5 evoked potentials Z0.05 . In active rTMS, 10 Hz stimulations over left DLPFC occurred at a power of 110% of motor threshold (MT) for 5-s intervals with 30-s intertrain interval. 30 trains were administered each day (MondayFriday) for 4 consecutive weeks (total stimuli=30,000).
1460146|NCT03273439|Device|Sham rTMS|Sham rTMS, without stimulation
1460147|NCT03273426|Device|core needle biopsy|Ultrasound-guided core needle biopsy (14G x ≥5) for complete clinical response (cCR) or near-cCR predicted by MRI.
1460148|NCT03273426|Device|vacuum-assisted biopsy|Ultrasound-guided vacuum-assisted biopsy (10G x ≥5) for complete clinical response (cCR) or near-cCR predicted by MRI.
1460149|NCT03273413|Drug|Pravastatin|Anti-inflammatory, anti-oxidative stress, and anti-proliferative therapy
1460150|NCT03273413|Drug|Placebo|Inactive tablet
2010479|NCT02954523|Drug|Dasatinib|oral every day
1460152|NCT03273387|Drug|Trimetazidine|The participant will received trimetazidine 35 mg bid for 3 months on top of their regular PAH specific therapy.
1460153|NCT03273387|Drug|Placebo oral capsule|The participant will received placebo oral capsule bid for 3 months on top of their regular PAH specific therapy.
1460154|NCT03273374|Radiation|Intraoperative radiation therapy (IORT)|IORT with 50 kV x-ray will be delivered during surgery as a single dose of 10 Gy at 5 millimeter depths of the tumor bed, followed by gemcitabine chemotherapy (1000 mg/m2) every 4 weeks for a total of 6 cycles
2010480|NCT02954523|Drug|Osimertinib|oral every day
1460155|NCT03273361|Behavioral|Compact Cycling Device|Participants pedaled a compact cycling device while simultaneously working at a desk.
1460156|NCT03273348|Procedure|Oncoplastic breast surgery|, Skin sparing mastectomy and immediate breast reconstruction will be conducted to all women included in the study, transverse rectus abdominis musculocutaneous flap recostruction and latissimus dorsi myocutaneous pedicle-flap with and without implant
1460157|NCT03273335|Device|Millipore biomarker assay plate|Millipore biomarker assay plate CSF cytokine assays as well as CSF flow cytometry
1460158|NCT03273322|Drug|Rivaroxaban 10 mg qd|10mg qd
1460159|NCT03273322|Drug|Rivaroxaban 15 mg qd|15mg qd
1460160|NCT03273322|Drug|DAPT|Aspirin 75 mg qd + Clopidogrel 75 mg qd
1947989|NCT02893371|Drug|Vilazodone|Exposure to all dosages and delivery forms.
1947990|NCT02893371|Drug|Doxepin|Exposure to all dosages and delivery forms.
1460163|NCT03273296|Drug|Amoxicillin|Amoxicillin (po) 500 mg x 3 per day for 3 days.
1460164|NCT03273296|Drug|Azithromycin|Azithromycin (po) 500 mg x 1 on day 1, 250 mg x 1 on day 2, and 250 mg x 1 on day 3.
1460165|NCT03273296|Drug|Vancomycin|Vancomycin (po) 125 mg x 4 per day for 3 days.
1460166|NCT03273283|Behavioral|Brief Intervention|Patient's received a brief intervention on alcohol use based on motivational techniques, and a referral to treatment when indicated.
1460167|NCT03273270|Radiation|transcranial magnetic stimulation|transcranial magnetic stimulation
1460168|NCT03273257|Drug|Riociguat|"Riociguat will be initiated at 1 mg. The dosage will be increased by 0.5 mg at 2 week intervals based on tolerability as assessed by systolic blood pressure up to a maximum dose of 2.5 mg tid.
Downtitration to 0.5 mg tid is foreseen for patients with low optimal tolerability."
1460169|NCT03273257|Drug|Placebo|Placebo will be given analogue to riociguat with matching tablets.
1460170|NCT03273257|Procedure|Pulmonary endarterectomy|PEA will be performed at the end of medical treatment (Day 90)
1460171|NCT03273244|Device|NeuroSense monitoring and ANI monitoring|From the start of palliative sedation, monitoring of EEG with NeuroSense device (WAVcns: Wavelet Anesthetic Value of the Central Nervous System) and ANI-monitoring (Analgesia Nociception Index) will be initiated.
1460172|NCT03273231|Drug|Ketamine|Ketamine is administered intravenously with a loading dose of 0.25 mg/kg at 5 minutes before surgery, followed by an infusion rate of 0.05 mg/kg/h to the end of surgery.
1460173|NCT03273231|Drug|Saline|0.9% saline solution
1460174|NCT03273218|Device|Tiger catheter|
1460175|NCT03273218|Device|Judkins catheter|
1460176|NCT03273205|Device|Anodal tDCS|This group gets a real stimulation
1460177|NCT03273205|Device|Sham tDCS|This group gets a sham stimulation
1460178|NCT03273192|Drug|Adalimumab|A single 40-mg dose of Adalimumab is administered subcutaneously to all the subjects.
1460182|NCT03273140|Device|Gamification Diabetes Education Program (GDEP)|"Diabetic application focuses on diabetes management and consists of two gamelets and consist of story-telling, case scenarios with the integration of problem-based decision-making and solving skills in diabetes management. These scenarios created are familiar to the patients and nurses - to make the games more interactive and realistic to the players (participants). Immediate feedback will be given after they select their decision. The visual reward will appear after attaining one score for each correct question. Participants can easily access and play the games several times till contents are reinforced and knowledge is retained or at their own comfort level. This game mechanics aim to motivate and assist patients to achieve their desired result and self-efficacy behaviors. It addresses the deficits from the current literature review, by aiming to be up-to-date, reliable with new updated scenarios and platform."
1460183|NCT03273127|Drug|Abediterol|A β2-adrenoceptor agonists, produce smooth muscle relaxation in the airways and improves lung function.
1460184|NCT03273127|Drug|Placebo|Abediterol matching placebo without any pharmacological activity.
1460185|NCT03273114|Behavioral|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):
The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.
Specific Functional training is designed to normalize maladaptive or provocative movement and posture.
Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)
Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
1460186|NCT03273114|Other|Core Training Exercise and Manual Therapy|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with active exercises will involve contractions of abdominal and back muscles in different functional positions, as well as joint mobilization or manipulation techniques applied to the lower back or pélvis, when necessary. Most patients in this group will receive exercises to perform at home, but not related to CFT.
1460187|NCT03273101|Device|Mechanical assisted sit-to-stand training group|Mechanical assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
1460188|NCT03273101|Other|Manual assisted sit-to-stand training group|Manual assisted sit-to-stand training 100 repetitions or 10 mins / session 10 sessions
1460189|NCT03273088|Drug|Etanercept|A single dose of etanercept (25mg/0.5ml prefilled syringe) was administered subcutaneously to healthy subjects.
1460272|NCT03272477|Drug|Letrozole|2,5 mg/day for a total of 40 weeks in adjuvant therapy phase
1947991|NCT02892318|Drug|Atezolizumab|Atezolizumab 840 mg administered by IV infusion on Days 8 and 22 of each 28-day cycle.
1947992|NCT02892318|Drug|Guadecitabine|Guadecitabine 60 mg/m^2 SC on Days 1-5 of every 28-day cycle.
1460190|NCT03273075|Drug|Cangrelor|The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
1460191|NCT03273075|Drug|Placebo|The intervention comprises add-on placebo infusion (0.9% NaCl) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy as placebo comparator
1460192|NCT03273075|Drug|Prasugrel|The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
1460193|NCT03273075|Drug|Ticagrelor|The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
1460194|NCT03273062|Drug|Tolcapone 200 MG|Tolcapone 200 MG TID
1460195|NCT03273062|Other|Placebo|Placebo, TID Placebo will be in capsules that are identical in appearance to intervention drug, Tolcapone.
1460196|NCT03273036|Drug|40 mg Triamcinolone acetate 1 cc|40 mg Triamcinolone acetate 1 cc
1460197|NCT03273036|Drug|Placebos|no injected agent
1460198|NCT03273023|Device|Promus PREMIERTM Everolimus-Eluting Platinum Chromium Coronary Stent System|Promus PREMIERTM Stent System
1460199|NCT03273010|Procedure|Free gingival graft|Free gingival graft was harvested from palatal donor site
1460200|NCT03273010|Procedure|Cyanoacrylate application|Periacyrl was applied on palatal wounds
1460201|NCT03272984|Procedure|ERAS group|ERAS is the name of a procedure. Patients in this group need receive the ERAS procedure instead of one drug.
1460202|NCT03272984|Procedure|SC group|Patients were managed in accordance with SC programs during the perioperative period. SC programs were used daily in our center and were still routinely used in most of the other hospitals in China.
1460203|NCT03272971|Device|Radio-frequency Ablation|The intervention consists of a bronchoscopic approach to ablate lung tumors with radiofrequency.
1460204|NCT03272945|Procedure|Linked-color imaging|Linked-color imaging colonoscopy
1460205|NCT03272932|Other|No intervention|No intervention
1460206|NCT03272919|Other|Arm 1: Investigational INF|INF utilizes three holds or positions, which widens tiny openings in arteries surrounding nerves and improves blood flow to targeted nerves. The improved blood flow in these nerves stimulates healing and reduces or even stops nerve pain.
1460207|NCT03272919|Other|Arm 2: standardized muscle stretching and strength|subjects will receive a standardized program of muscle stretching and strengthening exercise under the supervision of treating physical therapist.
1460208|NCT03272906|Device|Anodal transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 60-minute treatment session.
1460209|NCT03272906|Device|Sham transcranial direct current stimulation|2 mA of A-tDCS stimulation is induced between two 5 cm x 7 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 2 mA occurs over 30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition.
1460210|NCT03272906|Behavioral|Speech-language therapy|Therapy tasks will be determined by the clinician on an individualized basis and will not be affected by this research protocol. The only difference between the clinical therapy that is normally provided in the clinic and this research paradigm is the application of tDCS electrodes during therapy. Therapist is blinded to stimulation type.
1460211|NCT03272893|Behavioral|Acceptance and Commitment Therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
1460212|NCT03272880|Behavioral|Arts-Based Programming|This feasibility study includes educational components and an experiential components which are assessed with pre- and post-tests. The topics of these components include: Introduction to the Arts and Health; Music, Well-Being, and Resilience; Movement and Physical Activity; Art and Well-Being; Theater and Socialization; Art Appreciation and a Healthy Brain; and Summary/Integration of the Arts into Daily Lives. The impact of this program will be assessed with qualitative follow-up interviews.
1460213|NCT03272867|Dietary Supplement|ProManna|
1460214|NCT03272854|Other|No intervention performed, the study is observational|
1460216|NCT03272815|Device|Percussion Device (PD)|A laboratory prototype of the Percussion Device (PD) has been designed and built; laboratory data collection software, signal analysis and classification algorithms have been developed. It has been designed to detect a pneumothorax.
1460217|NCT03272815|Device|Ultrasound (US)|The SonoSite hand help portable ultrasound device.
1460218|NCT03272802|Drug|Edaravone|Edaravone is a free radical scavenger. this drug showed desirable effects like slowing decline of physical function by 33 percent in previous studies.
1460219|NCT03272802|Drug|Riluzole|Riluzole is a treatment option for amyotrophic lateral sclerosis. The occurrence of ventilator-dependence or tracheostomy is delayed in selected patients who treated with this drug.
1460220|NCT03272789|Other|Interviews with coach|For Interviews : done at Day 0 and at 1, 2, 3, 6 and 12 months. Questionnaires : given at Day 0, and at 3, 6 and 12 months.
1460221|NCT03272776|Device|Protector Laryngeal Mask airway|Evaluate the time of insertion, performance, security and insertion success rate of the Protector Laryngeal Mask in patients under general anasthesia.
1460222|NCT03272750|Dietary Supplement|Bioscalin® new formulation with Galeopsis Segetum|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of study product at lunch for the first 3 months of the trial.
1460223|NCT03272750|Dietary Supplement|Reference product|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of reference product at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
1460224|NCT03272750|Dietary Supplement|Placebo|Total duration of the study was 4 months; each subject, took by mouth two capsules/die of placebo at breakfast and one tablet/die of placebo at lunch for the first 3 months of the trial.
1460225|NCT03272737|Procedure|1RM Test|The dynamic force of the lower limbs will be evaluated by 1RM test of knee extension in the extensor chair, according to the protocol presented in a previous study (Radaelli, 2014). The participants will perform a previous warm up consisting of 1 series with 10 repetitions with the minimum load of the device. The weight will be progressively raised until the maximum load is reached, with a maximum limit of 5 attempts and a 3 to 5 minute interval between them. The test will be conducted by a physical education professional who will verbally encourage participants throughout these steps and perform the load adjustment at week 5 and 10.
1460226|NCT03272737|Procedure|Speed gait test|The gait velocity analysis will be performed with time marking, in milliseconds, from the displacement of the elderly in a 4.6-meter straight course, based on the measurement (speed / distance traveled). (Guralnik, 1994)
1460227|NCT03272737|Device|Plethysmography|The leg will be elevated above the level of the heart to ensure adequate venous drainage. The cuff will be placed around the ankle and another at the top of the leg. The ankle cuff will be inflated to a supra-systolic level 30 seconds before starting the measurements. At 15-second intervals, the cuff of the leg will be inflated above the venous pressure for a period of seven to eight seconds. The signal of the muscle blood flow wave will be recorded in a polygraph and analyzed every minute, averaging three records per minute (Bahia, 2006). The protocol will be performed during 3 minutes of rest and later during isometric exercise stimulus of 3 minutes and 2 minutes of occlusion after exercise.
1460228|NCT03272737|Diagnostic Test|Laboratorial blood tests|Complete blood count with platelets, creatine phosphokinase (CPK), aspartate aminotransferase (AST), lactate dehydrogenase (LDH), fibrinogen, factor VIII, von Willebrand factor, D-dimer, t-PA and PAI 1)
1460229|NCT03272737|Device|Velocity of wave pulse (VWP)|"The electrocardiographic record will be obtained simultaneously with the carotid-femoral aortic pulse wave measurements as the reference standard to calculate the wave transit time. Two distances of surfaces will be measured by the investigator: one between the recording point of the carotid artery and the sternal furcula (distance 1) and the other between the sternal furcula and the recording point in the femoral artery (distance 2). The distance traveled by the pulse wave will be calculated as distance 2 - distance 1. The carotid-femoral aortic pulse wave will be calculated as: carotid-femoral aortic pulse wave = distance traveled by the pulse wave ¼ (m) / transit time (s)."
1460230|NCT03272737|Device|Protocols of isometric exercise|In this protocol will be performed the isometric exercise maneuver to 30% of the maximum voluntary contraction and the circulatory occlusion after exercise, for activation of the central command, mechanoreceptors and metaborreceptors (Ray, 1993). Before initiating the protocol, the individual will be placed in the supine position and then their maximum voluntary contraction will be determined using a Jamar hydraulic palmar dynamometer (Asimow Engineering, CAL, USA). The patient will be asked to exercise maximum gripping force of the dominant member for 3 consecutive attempts and later 30% of the maximum voluntary contraction will be calculated.
1460231|NCT03272737|Device|Vasodilatory capacity|The vasodilatory capacity will be calculated as the percentage of increase of the diameter of the brachial artery and femoral post occlusion in relation to its basal values.
1460232|NCT03272737|Device|Basal blood flow|Measurements of basal blood flow and flow-mediated vasodilation will be obtained by ultrasound according to the most recent recommendations (Harris, 2010; Thijssen, 2011). Images of the brachial artery and femoral artery will be recorded by a two-dimensional ultrasound device with spectral Doppler and linear transducer (Ultra-0122, Philips, The Netherlands).
1460233|NCT03272737|Diagnostic Test|Quality of life (Euro Qol)|It will be carried out a questionnaire to analyse the benefits of protocol training in the participants.
1460234|NCT03272737|Device|PA e FCC|The participants will use cardiofrequencimeter of the brand Polar before, during and after the exercise session.
1460235|NCT03272711|Drug|Vortioxetine 10 mg|
1460236|NCT03272711|Behavioral|Cognitive training program|Online training program, 30 minutes a day, 5 times a week
2010481|NCT02954653|Biological|PF-06747143|PF 06747143 is a humanized IgG1 monoclonal antibody (mAb) that is an antagonist of CXCR4.
2010482|NCT02954653|Drug|Cytarabine|100-200 mg/m2 continuous infusion for 7 days)
1460239|NCT03272685|Drug|Very Low Nicotine Content Cigarettes|0.3 mg/cig nicotine yield; 9 mg tar
1460240|NCT03272685|Drug|Normal Nicotine Content Cigarettes|0.8 mg/cig nicotine yield; 9 mg tar
1460241|NCT03272672|Other|Össür Unloading Knee Brace|"During the braced walking condition, a valgus unloader brace (Össür Unloader One®, Össur Americas, Orange County, CA) will be fitted by a certified athletic trainer per manufacturer instructions to the dominant limb while the participant is seated with knee flexed to approximately 80°.
The brace will be maximally adjusted to unload the medial compartment."
1460242|NCT03272659|Drug|Cysview|250 mL enema containing 1.6 mmol of hexaminolevulinate
1460243|NCT03272646|Procedure|surgery|gastric resection or total gastrectomy
1460244|NCT03272633|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Receive IHC
1460245|NCT03272633|Biological|Irradiated Allogeneic Cells|Correlative studies
1460246|NCT03272607|Other|Deprescribing opportunities|An electronic intervention that identifies potentially inappropriate medications (PIMs) and generates instructions for safe discontinuation, which is presented to the treating physician for their consideration.
1460247|NCT03272594|Other|Breastfeeding|Infants will be placed in skin-to-skin contact with their mother at least five minutes prior to heel lance to allow time to settle and initiate breastfeeding. Breastfeeding position will be determined based on individual maternal preference in order to optimize feeding as well as to facilitate ease of access to the infant's foot for blood collection, while also attempting to minimize disruption of continuous EEG, heart rate, oxygen saturation, and video recording. Active breastfeeding will be facilitated to ensure it takes place for a minimum of two minutes prior to heel lance, and will continue until the procedure is completed.
1460248|NCT03272594|Drug|24% oral sucrose|Administration of 24 percent oral sucrose will occur two minutes prior to the heel lance. Non-nutritive sucking will be offered using a gloved finger or pacifier (based on parental preference) immediately following administration of the complete 24 percent oral sucrose dose.
1460273|NCT03272477|Drug|Exemestane|25mg/day for a total of 40 weeks in adjuvant therapy phase
1461388|NCT03263585|Device|Spinal orthosis Spinomed|
1460249|NCT03272581|Other|Functional Training|Functional training has been defined as emphasizing multiple muscle and joint activities, combining upper and lower body movements, and utilizing more of the body in each movement. The primary goal of functional training is to transfer improvement achieve in one movement to enhancing the performance of another movement by affecting the entire neuromuscular system.
1460250|NCT03272568|Drug|Recombinant FVIII Fc fusion product Eloctate|Subjects will get FVIII activity corrected from the baseline level to 100-150% with Eloctate on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 2 hours, 4 hours, 20 hours after the infusion) will be performed to assist with subsequent dosing. 2 total doses of Eloctate likely to be given on day 1 and 3 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Eloctate (with no less than 21 days interval).
1460251|NCT03272568|Drug|Recombinant FIX Fc fusion product Alprolix|Subjects will get FIX activity corrected from the baseline level to 100-150% with Alprolix on the first day of menstruation at the beginning of the study interventional phase. The first dose of the drug will be given in the clinics via slow injection into a vein (infusion). A short assessment of pharmacokinetics (PK) (4 time-points blood draw: 15 min, 4 hours, 48 hours, 72 hours after the infusion) will be performed (by home nursing or local lab) to assist with subsequent dosing. Single dose of Alprolix likely to be given on day 1 of menstrual period. The subject will then receive three additional PK-adjusted monthly doses of Alprolix (with no less than 21 days interval).
1460252|NCT03272568|Device|Patient-operated diagnostic device for anemia AnemoCheck.|Each AnemoCheck test kit enables patients to check hemoglobin levels by pricking their finger to draw 5 μL of blood into a capillary tube, inserting that tube into a larger tube with a pre-filled chemical solution, mixing, waiting one minute, and assessing the color change of the solution using a reference color scale card included with the kit. The test is able to subjectively differentiate low, medium and high levels of hemoglobin to diagnose anemia at home. Study participants are taught to perform a hemoglobin check every other day using Anemocheck during 2 consecutive menstrual cycles. In addition they will have hemoglobin level obtained locally (LabCorp) drawn within 4-6 hours for comparison and correlation.
2010483|NCT02954653|Drug|Daunorubicin|60-90 mg/m2 daily for 3 days
1460254|NCT03272542|Dietary Supplement|Prebiotic: soluble corn fiber|prebiotic
1460255|NCT03272542|Dietary Supplement|Placebo: maltodextrin|placebo
1460256|NCT03272529|Other|Patient-specific simulated rehearsals|Using 3-D printing and polymer technology, the investigators' team will construct patient-specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology, and pathology specific to each patient. These models will be constructed at the Simulation Innovation laboratory within the Department of Urology, University of Rochester. The process involves importing DICOM files of patient participants C.T. scans into 3D processing software, creating virtual models of kidney parenchyma incorporating the kidney, urinary system, stone and abdominal wall. Surgical phantoms are then created using 3D printing and polymer hydrogels, to recreate the entire procedure.
1460257|NCT03272529|Other|Idealized simulated rehearsals|Using 3D printing and polymer technology, the investigators' team will construct a validated generic simulated hydrogel model with a complex kidney stone, incorporating the necessary anatomy, physiology and pathology. These models will be constructed at the Simulation Innovation laboratory within the department of urology at the University of Rochester. Generic models incorporating the kidney, PCS, staghorn stone, abdominal wall, and other relevant anatomical elements (bowel, perinephric fat, solid organs and bony structures) will be constructed. Participants in his group will complete the simulation replicating all steps of the procedure of this ideal training case that is not specific to a particular patient.
1460258|NCT03272529|Other|Standard simulation|Participants recruited to this cohort will only have completed the standard prerequisite simulation training similar to the two other groups (didactic lecture, hands-on simulation training to proficiency and live case observation), that represents the current standard of care. No further simulation would be conducted in participants of this group in addition to the standard.
1460259|NCT03272516|Behavioral|Mindfulness based cognitive therapy (MBCT)|Mindfulness Based Cognitive Therapy (MBCT). This group receives 8 weeks of MBCT in addition to usual treatment (TAU). The MBCT consists of weekly group sessions of 2,5 hours, where participants receive cognitive therapy as well as mindfulness meditation. This group is also assigned homework, according to the MBCT protocol.
1460260|NCT03272516|Other|Treatment as usual (TAU)|Usual treatment prescribed by each physician, specifically interview therapy, cognitive therapy, antidepressants and/or anxiolytics as well as a mixture of all of the above.
1460261|NCT03272503|Drug|Pimozide 4 mg/day|Pimozide 2mg tablets will be taken once daily for the first 7 days of the study, and then increased to 2 mg twice daily for the duration of the study.
1460262|NCT03272503|Drug|Placebo Oral Tablet|Identical matching placebo lactose tablets
1460263|NCT03272490|Procedure|Medartis|Surgery using the medartis implant
1460264|NCT03272490|Procedure|Synthes|Surgery using the Synthes implant
1460265|NCT03272477|Drug|Perjeta Injectable Product|Single dose of 840mg (loading dose) day1 cycle 1, 420mg at day1 of each subsequent cycle, every 3 weeks. (The latter cycle is called cycle of treatment and is to be given 4 times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
1460266|NCT03272477|Drug|Herceptin|Single dose of 8mg/kg (loading dose) day1 cycle 1; 6mg/kg at day1 of each subsequent cycle body weight every 3 weeks. (This is called cycle of treatment and is to be given four times in the neoadjuvant phase and 14 times in the adjuvant therapy phase.)
1460267|NCT03272477|Drug|Tamoxifen|20 mg per day for a total of 40 weeks in the adjuvant therapy phase.
1460268|NCT03272477|Drug|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment and is to be given for 12 weeks in neoadjuvant therapy phase.
1460269|NCT03272477|Drug|Epirubicin|12 weeks (4cycles) of max.120mg/sqm in adjuvant therapy phase
1460270|NCT03272477|Drug|Cyclophosphamide|12 weeks (4cycles) of 600 mg/sqm i.v. on day 1+8 or 12 weeks (4cycles) of 500 mg/sqm i.v. on day 1 in adjuvant therapy phase
1460271|NCT03272477|Drug|Anastrozole|1mg per day for a total of 40 weeks in adjuvant therapy phase
1461389|NCT03263585|Other|Equipment training|
2010484|NCT02954653|Drug|Azacitidine|75 mg/m2 sub-cutaneous or intravenous for 7 days)
1460274|NCT03272477|Drug|Leuprorelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
1460275|NCT03272477|Drug|Goserelin|3,6mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane, for a total of 40 weeks in the adjuvant therapy phase.
1460276|NCT03272477|Drug|Anastrozole|1mg per day for 12 weeks in neoadjuvant therapy phase; 1mg per day for a total of 40 weeks max. in adjuvant therapy phase
1460277|NCT03272477|Drug|Letrozole|2,5 mg per day for 12 weeks in neoadjuvant therapy phase; 2,5 mg perday for a total of 40 weeks max. in adjuvant therapy phase
1460278|NCT03272477|Drug|Exemestane|25mg/day for 12 weeks in neoadjuvant therapy phase; 25mg/day for a total of 40 weeks max. in adjuvant therapy phase
1460279|NCT03272477|Drug|Paclitaxel|80mg/sqm, day one of each cycle, every week. This is called a cycle of treatment an is to be given for 12 weeks in the adjuvant phase
1460280|NCT03272477|Drug|Tamoxifen|20mg per day (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase.
1460281|NCT03272477|Drug|Leuporelin acetate|One injection of 3,75mg every month or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
1460282|NCT03272477|Drug|Goserelin|3,5mg every 28 days or 4 weeks in pre-menopausal women treated with aromatase inhibitors Anastrozole or Letrozole or Exemestane (given over 12 weeks in the neoadjuvant therapy phase and over 40 weeks max. in the adjuvant therapy phase).
1460283|NCT03272477|Diagnostic Test|Biopsy|Core biopsy at screening (outside of protocol), at week 4 after randomization, (at week 14 in addition if neoadjuvant phase is prolonged)
1460284|NCT03272477|Procedure|Surgery|Surgery at week 14 after randomization (or later, if neoadjuvant phase is prolonged)
1460285|NCT03272464|Drug|Trametinib|Trametinib may work by binding to your cancer cells to inhibit the cancer cells' signals to decrease cell growth.
1460286|NCT03272464|Drug|Dabrafenib|Dabrafenib may work by stopping your cancer cells from duplicating.
1460287|NCT03272464|Drug|INCB039110|Itacitinib may work by stopping your tumor cells from living and growing.
1460288|NCT03272451|Procedure|culprit vessel intervention|ECG guided immediate culprit vessel intervention using a single transradial guiding catheter such as MAC or JL 3.5
1460289|NCT03272451|Procedure|traditional approach|single diagnostic catheter for complete coronary angiography and guiding catheter selection for PCI
1460290|NCT03272438|Device|Accelerometer|Participants use an accelerometer to monitor their steps activity
1460291|NCT03272438|Behavioral|Step goal|Participants are given a daily step goal to aim for
1460292|NCT03272438|Behavioral|Consistent contexts|Participants plan to take steps in contexts that are similar from day to day
1460293|NCT03272438|Behavioral|Inconsistent contexts|Participants plan to take steps in contexts that vary from day to day
1460294|NCT03272425|Drug|lesinurad/allopurinol 200/300 FDC tablets|Test Drug
1460295|NCT03272425|Drug|lesinurad 200 mg|Comparator 1
1460296|NCT03272425|Drug|allopurinol 300 mg|Comparator 2
1460297|NCT03272412|Diagnostic Test|Analysis of serum Progesterone in blood sample|Levels of progesterone will be determined on the day of embryo transfer in patients undergoing artificial endometrial preparation cycles.
1460298|NCT03272399|Other|Diet/nutrition intervention|The intervention will be administered through food products rather than dietary supplements
1460299|NCT03272386|Other|Observational study|Completing a questionnaire
1460300|NCT03272373|Device|NexGen TM Monoblock Tibia|Primary cementless tibia total knee arthroplasty
1460301|NCT03272373|Device|NexGen TM Modular Tibia|Primary cementless tibia total knee arthroplasty
1460311|NCT03272321|Drug|Oxytocin|Syntocinon nasal spray
1460312|NCT03272321|Drug|Placebo|Placebo nasal spray
1460313|NCT03272295|Other|Reference cigarette|The reference product is based on a commercially-available king-size cigarette design (length 83 mm, circumference 24.6 mm) with a single segment cellulose acetate filter and tobacco blend recipe without ingredients.
1460314|NCT03272295|Other|Cigarette with carob bean extract|Based on reference cigarette with added ingredient
1460315|NCT03272295|Other|Cigarette with cocoa powder|Based on reference cigarette with added ingredient
1460316|NCT03272295|Other|Cigarette with fenugreek extract|Based on reference cigarette with added ingredient
1460317|NCT03272295|Other|Cigarette with fig juice|Based on reference cigarette with added ingredient
1460318|NCT03272295|Other|Cigarette with glycerol|Based on reference cigarette with added ingredient
1460319|NCT03272295|Other|Cigarette with guaiacol|Based on reference cigarette with added ingredient
1460320|NCT03272295|Other|Cigarette with liquorice extract powder|Based on reference cigarette with added ingredient
1460321|NCT03272295|Other|Cigarette plus I-menthol|Based on reference cigarette with added ingredient
1460322|NCT03272295|Other|Cigarette with propylene glycol|Based on reference cigarette with added ingredient
1518095|NCT02831686|Drug|Dexamethasone|
1460323|NCT03272295|Other|Cigarette with sorbitol|Based on reference cigarette with added ingredient
1460324|NCT03272295|Other|Cigarette with multiple ingredients|Based on reference cigarette plus propylene glycol, glycerol, liquorice extract powder, cocoa powder, carob bean extract, fig juice concentrate, maltol, guaiacol, geraniol, fenugreek extract.
1460325|NCT03272269|Drug|IMCY-0098|Small synthetic peptide for SC admin. Solvent: alum hydroxide
1460326|NCT03272269|Other|Placebo|Solvent: alum hydroxide
1460327|NCT03272256|Drug|IM156|Up to 6 dose levels with a sequential 3+3 design.
1460328|NCT03272243|Procedure|short segment posterior spine fixation|
1460329|NCT03272243|Procedure|long segment posterior spine fixation|
1460330|NCT03272230|Behavioral|ECOCAPTURE|45 minutes observational session for tracking goal directed behavior into a waiting room equipped with video and sensor-based data acquisition system
1460331|NCT03272230|Behavioral|Cognitive and Behavioral experimental tasks|Cognitive and Behavioral experimental tasks to explore additional frontal cognitive and behavioral dimensions and functions
1460332|NCT03272230|Diagnostic Test|Neuropsychological assessment|MMS / ABI / NART / Mini-SEA / BREF / HAD / MATTIS / HAYLING test / STARKSTEIN / DAS
1460333|NCT03272230|Behavioral|ICM_APATHY_TASKS|Apathy experimental task
1460334|NCT03272230|Other|MRI|T1 MRI / T2 MRI / Resting state fMRI / Multi-shell diffusion-weighted MRI
1460335|NCT03272230|Biological|Neurohormonal mechanisms|Hormonal dosage / Diabetic dosage / Ionogramme dosage / Inflammatory dosage / Hepatic dosage / Lipidic dosage / Thyroid dosage
1460338|NCT03272204|Behavioral|No pubic hair|Natural pubic hair to fully removed pubic hair
1460339|NCT03272204|Behavioral|Pubic Hair|Removed pubic hair to natural pubic hair
1460340|NCT03272191|Procedure|Liposuction and stem cell implantation|The adipose tissue specimen will be collected mainly from the patient's abdomen using a liposuction cannula. The adipose tissue may be collected from other areas if necessary The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred to an injection/infusion catheter for delivery into the akinetic myocardial scar in the region of a previous infarct
1460341|NCT03272178|Device|Depuy total knee implant|patients from Dr Nunley's clinic will get a Depuy implant
1460342|NCT03272178|Device|Triathlon total knee implant|patients from Dr Barrack's clinic will get a Triathlon implant
1460343|NCT03272165|Drug|MEDI1341|Intravenous infusion over 60 minutes
1460344|NCT03272165|Drug|Placebo|Intravenous infusion over 60 minutes
1460345|NCT03272152|Genetic|Genome-wide DNA methylation|Genome-wide DNA methylation was determined using the Infinium Human Methylation 850K BeadChip.
1460351|NCT03272100|Procedure|flap|after flap incision , the sinus cavity was opened and then the membrane raised up
1460352|NCT03272087|Device|Thoracoscopy|50 % of patients will have performed af medical thoracoscopy (pleuroscopy)
1460353|NCT03272087|Device|VATS (thoracoscopy)|50 % of patients will have performed a VATS (video-assisted thoracic surgery) thoracoscopy
1460354|NCT03272074|Other|Egg and egg white|Participants will consume either one large eggs or equivalent amount of egg white (3/4 cups) for 12 weeks. Participants will maintain their regular diet and physical activities.
1460355|NCT03272061|Other|Aerobic-based exercise program|Aerobic-based exercise will be carried out on a cycling ergometer three times a week for 30 minutes at 70% of the maximal workload. Every two weeks, the maximal workload will be reassessed, and training loads will be readjusted accordingly. Fully supervised training sessions will be performed with three-to-four study participants at a time. Subjects should maintain their body weight during the intervention period.
1460356|NCT03272048|Behavioral|Lethal Means Counseling|Lethal means counseling is broadly defined as clinician-initiated discussions that encourage an individual at risk for suicide to safely store his or her firearms. Examples in this domain include applying a gun lock, separating the gun from its ammunition, dismantling the firearm and keeping its components locked and/or separated, or safely transferring the firearm to a trusted loved one, friend, or police station until risk abates (Bryan, Stone, & Rudd, 2011; Jin, Khazem, & Anestis, 2016). Further, given that recent purchasers of firearms are at markedly increased risk of death by suicide (Wintemute, Parham, Beaumont, Wright, & Drake, 1999), anticipatory counseling on firearm safety should also be considered for at-risk individuals who do not report currently owning or having access to a firearm, but who report prior firearm ownership/access or intentions of obtaining a firearm in the future (Harvard T.H. Chan School of Public Health, 2017).
2010485|NCT02954653|Drug|Decitabine|20 mg/m2 continuous intravenous infusion for 5 days in a 4-week schedule
2010486|NCT02953210|Drug|dexter ketamine|multimodal anesthesia without opioids ketamine as induction drug
2010487|NCT02953210|Drug|Lidocaine Hydrochloride|continuous infusion intravenous
2010488|NCT02953210|Drug|Fentanyl Hydrochloride|intravenous
1460361|NCT03271996|Procedure|Primary closure|Asymmetric skin incision and total excision of the lesion with monopolar scalpel. Accurate hemostasis, creation of a cutaneous-subcutaneous flap, primary closure with non-absorbable sutures, optional aspiration drainage.
1460362|NCT03271996|Procedure|Fistulectomy|Evaluation of the cavity using a 0.5-1 mm metal probe which will be inserted into the skin orifice. Excision of the skin around the orifice and debridement/excision of the cavity by monopolar scalpel or Trephines
2010489|NCT02953210|Drug|Clonidine Hydrochloride|clonidine intravenous pre induction
2010490|NCT02953210|Drug|Midazolam Hydrochloride|premedication
2010491|NCT02953210|Drug|Isoflurane Volatile Liquid|maintenance of general anesthesia
1460366|NCT03271957|Procedure|Manual rotation|Rotation of the fetal head to an anterior position at time of fuel dilation that is part of routine care
2010492|NCT02953210|Drug|Rocuronium Injectable Solution|induction of general anesthesia
2010493|NCT02953210|Drug|Propofol 1 % Injectable Suspension|induction of general anesthesia
2010494|NCT02953210|Drug|Dexamethasone-21-Sulfobenzoate, Sodium Salt|at the end of the procedure 4mg IV
2010495|NCT02953210|Drug|Ranitidine Hydrochloride|at the end of the procedure
2010496|NCT02953210|Drug|Ondansetron Hydrochloride|at the end of the procedure
2010497|NCT02953210|Drug|Ketorolac Injectable Solution|at the of the procedure
2010498|NCT02953210|Drug|Bupivacaine Hydrochloride|at the end of the procedure for infiltration of trocar wounds
1460367|NCT03271944|Device|CO2 Laser Treatment|Fractional handpiece with CO2 laser: Fractional Ablative laser Treatment of Vulvovaginal Atrophy
1460368|NCT03271931|Behavioral|Active choice intervention|EHR alert prompting cardiologists to make an active choice to prescribe a statin or not.
1460369|NCT03271918|Drug|Cabergoline|
1460370|NCT03271905|Drug|salbutamol sulfate and ipratropium bromide|Nebulization with salbutamol sulfate and ipratropium bromide during mechanical ventilation.
1460371|NCT03271905|Device|Mesh nebulization|Nebulization with Mesh device.
1460372|NCT03271879|Drug|Empagliflozin at a dose of 10 mg/day|Comparing empagliflozin versus placebo on the ventricular arrhythmia burden. This study encompass 4 periods for each study subject: screening period of 8 weeks, first treatment period of 8 weeks, washout period of 4 weeks and a second treatment period of 8 weeks in a cross-over design
1460373|NCT03271866|Drug|metformin|metformin 1500mg per day
1460374|NCT03271853|Device|Sentinel Breast Scan II®|The SBSII will automate the recording of thermal data used in the Therma-Scan manual thermology protocol by utilizing a thermal camera sensitive to changes in breast temperature. The SBSII system uses a very sensitive thermography camera that detects and visually displays heat patterns that naturally emanate from the breast. SBSII captures this data digitally for subsequent analysis by Therma-Scan.
1460375|NCT03271827|Device|Apnoeic oxygenation|3 L/min of oxygen by nasal cannula during as apnoeic oxygenation during airway management.
1460376|NCT03271814|Biological|LPS|0.6 by/kg LPS single dose iv
1460377|NCT03271814|Other|Placebo|Sterile Water
1460378|NCT03271801|Behavioral|child health education|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of education about a child health topic.
1460379|NCT03271801|Behavioral|skills training|10, 60-minute sessions with a family-based obesity treatment program implemented for the first 40-minutes of each session followed by 20 minutes of experiential learning about stimulus control strategies (portion size, energy density, variety).
1460380|NCT03271788|Other|Mindfulness, MBSR|Participants (stroke patients and one of their closest relatives) will conduct an MBSR Course in Phase B
1460381|NCT03271775|Other|physical therapy program (group)|Exercises group transmitted by physical therapist (Up to four participant in each group).
1460382|NCT03271775|Other|physical therapy program (computerized exercises)|Remote exercises program accompanied by a physical therapist guidance
1460383|NCT03271762|Device|percutaneous mitral valve repair with MITRACLIP NT|percutaneous mitral valve repair Percutaneous MitraClip Device Implantation
1460384|NCT03271762|Procedure|cardiac surgery|mitral valve repair or mitral valve remplacement
1460385|NCT03271749|Other|PROSM guidelines for preoperative, anesthesia and postoperative care for lung resections|The PROSM guidelines is described previously in study description
1460388|NCT03271723|Other|Observational study|No intervention
1460389|NCT03271710|Device|peripheral balloon angioplasty|Percutaneous transluminal angioplasty (PTA) of the lower extremities
1460390|NCT03271697|Drug|Astragalus Membranaceus|This research is trying to see if AM can enhance the clinical prognosis for spontaneous aneurysm ruptured subarachnoid hemorrhage patients.
1460391|NCT03271697|Drug|Placebo|as a comparator comparing with AM group
1460392|NCT03271684|Other|self-management|one session of up to one-hour per week over a six-week period in addition to their usual rehabilitation. During each session strategies will be used to promote specific behaviors that exemplify the hallmarks of self-management. These behaviors include enabling patients to work out ways of taking control of their daily lives by setting small targets, recording their progress and problem-solving. The content of the sessions is determined by the patient and their personal goals rather than being professionally directed
1460393|NCT03271684|Other|Control|Participants will receive usual rehabilitation treatment, they will also be given a booklet with education program and exercises they can perform at home.
1460394|NCT03271671|Other|NAVA during Non invasive ventilation|NIV during respiratory failure
1460395|NCT03271671|Other|PSV during Non invasive ventilation|PSV during respiratory failure
1460396|NCT03271658|Behavioral|Web based life support patient decision aid|The web-based life support decision aid (eLSDA) was adapted from a print-based decision aid. The eLSDA includes information on the pros and cons of both life support and comfort care. The eLSDA lays out the decision about life support for an individual patient/family in a logical stepwise fashion to permit discussion, ask questions, and permit reflection on each step. At the end of the eLSDA, unmet decision-making needs are identified to seek support from the healthcare team.
1460397|NCT03271658|Behavioral|decision coaching|During the interactive process of using the eLSDA, the study nurse provides decision coaching for patient/family, specifically a facilitated values clarification exercise.
1460398|NCT03271645|Behavioral|Space from Depression|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
1460445|NCT03271411|Behavioral|EMDR-based Flash technique|Initial EMDR session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
1519627|NCT02819804|Drug|Dasatinib|Given PO
1460399|NCT03271645|Behavioral|Space from Anxiety|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014). The treatment comprises cognitive, emotional and behavioural components. The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
1460400|NCT03271645|Behavioral|Space from Stress|The structure and content of the programme modules follow evidence-based principles of CBT for the treatment of depression and anxiety (NICE, 2006, 2011, 2014).The treatment is delivered on a Web 2.0 platform using media-rich interactive content. Each module is structured in an identical way and incorporates introductory quizzes, videos, informational content, interactive activities, as well as homework suggestions and summaries. In addition, personal stories and accounts from other clients are incorporated into the presentation of the material.
1460401|NCT03271645|Behavioral|Face-to-face counselling|Face-to-face counselling
1460403|NCT03271619|Other|Surface current measurement|Measurement of surface current between electrodes placed on the chest wall during defibrillation
1460404|NCT03271606|Combination Product|ERAS|The investigators mainly used enhanced measures perioperatively in mediastinal surgery as these used in other surgery
1460405|NCT03271606|Combination Product|Traditional measures|The investigators mainly used traditional measures perioperatively in mediastinal surgery as these used in other surgery
1460406|NCT03271593|Other|No intervention|No intervention
1460407|NCT03271580|Diagnostic Test|Finger prick test for HbA1c measurement|HbA1c measurement with finger prick method
1460408|NCT03271580|Procedure|Punch Biopsy|Wound site will be anaesthetized, by punch biopsy tissue will be collected, wound site will be monitored for bleeding(if bleeding Cautery will be used to stop bleeding).
1460409|NCT03271580|Other|Vac Sponge Collection|NPWT sponge which is discarded as biological waste, will be collected for wound macrophage isolation
1460410|NCT03271580|Other|Ankle Brachial Index|Blood pressure test
1460411|NCT03271567|Diagnostic Test|Nanodisk-MS assay|Nanodisk-MS assay is a recently reported novel assay for quantitative detection of various MTB antigen peptides, using nanotechnology and mass spectrometry that showed remarkable sensitivity and specificity in diagnosing active pulmonary and extrapulmonary TB. This assay detected MTB-specific antigens, CFP-10 and ESAT-6, in patients' serum samples.
1460414|NCT03271528|Drug|Lacosamide|Lacosamide titration will be done to a target dose of 300mg. Participants will take 100 mg of lacosamide once on day 1, twice per day from day 2 until day 6, on day 7 the lacrosamide dose will increase to 150 mg twice daily, and on day 8 the participant will take one dose of 150 mg.
1460415|NCT03271528|Drug|Placebo oral capsule|Participants will take a placebo oral capsule once on day 1, twice per day from day 2 to day 7, and once on day 8.
1460416|NCT03271515|Biological|anti-CD19 anti-CD20 Bispecific CAR-T|patients accept transfusion of anti-CD19 anti-CD20 Bispecific CAR-T cells.
2010499|NCT02952989|Drug|SGN-2FF|SGN-2FF oral daily dosing.
2010500|NCT02952508|Drug|CLR 131|Radiopharmaceutical
2010501|NCT02951663|Dietary Supplement|Protein|
1460423|NCT03271476|Behavioral|EMDR psychotherapy|Visit 0 : patient inclusion (questionnaires and interview) Visit 1 : anamnesis Visit 2 : patient supporting Visit 3 : EMDR psychotherapy care Visit 4 : EMDR psychotherapy care Visit 5 : EMDR psychotherapy care and questionnaires Visit 6 : EMDR psychotherapy care Visit 7 : EMDR psychotherapy care Visit 8 : EMDR psychotherapy care ans questionnaires Visit 9 (one month after) : semi-directive interview and data recovery (questionnaires)
1460424|NCT03271463|Behavioral|Selective Control Assessment of Lower Extremity (SCALE)|Inter- and intra-rater reliability Validity: correlation analysis with Fugl-Meyer Assessment - Lower Extremity Component (FMA-LE) and 10 meter walk test (see below)
1460425|NCT03271450|Drug|Dabigatran: extended treatment (e.g at least 90 days)|90 days
1460426|NCT03271450|Drug|Dabigatran: extended treatment (e.g at least 180 days)|180 days
1460427|NCT03271450|Drug|Dabigatran: extended treatment (e.g at least 270 days)|270 days
1460428|NCT03271450|Drug|Apixaban: extended treatment (e.g at least 90 days)|90 days
1460429|NCT03271450|Drug|Apixaban: extended treatment (e.g at least 180 days)|180 days
1460430|NCT03271450|Drug|Apixaban: extended treatment (e.g at least 270 days)|270 days
1460431|NCT03271450|Drug|Rivaroxaban: extended treatment (e.g at least 90 days)|90 days
1460432|NCT03271450|Drug|Rivaroxaban: extended treatment (e.g at least 180 days)|180 days
1460433|NCT03271450|Drug|Rivaroxaban: extended treatment (e.g at least 270 days)|270 days
1460434|NCT03271450|Drug|Edoxaban: extended treatment (e.g at least 90 days)|90 days
1460435|NCT03271450|Drug|Edoxaban: extended treatment (e.g at least 180 days)|180 days
1460436|NCT03271450|Drug|Edoxaban: extended treatment (e.g at least 270 days)|270 days
1460437|NCT03271450|Drug|Warfarin: extended treatment (e.g at least 90 days)|90 days
1460438|NCT03271450|Drug|Warfarin: extended treatment (e.g at least 180 days)|180 days
1460439|NCT03271450|Drug|Warfarin: extended treatment (e.g at least 270 days)|270 days
1460440|NCT03271437|Behavioral|PC-based Flash|Progressive counting with Flash technique
1460441|NCT03271437|Behavioral|EMDR-based Flash|Eye movement desensitization and reprocessing with Flash technique
1460619|NCT03269916|Other|Follicle-Stimulating Hormone|used to assess ovarian reserve parameters
1460446|NCT03271411|Behavioral|PC-based Flash technique|Initial PC session (with Flash technique) of up to three hours; about one week later, follow-up session of up to one hour
1460447|NCT03271398|Behavioral|EMDR|Eye movement desensitization and reprocessing (intensive format)
1460448|NCT03271398|Behavioral|PC|Progressive counting (intensive format)
1460449|NCT03271385|Diagnostic Test|evaluated by the predetermined differentiating formula|After recruiting patients, collecting the baseline data, a CMR scan will be carried out and post-processed, a predetermined differentiating formula (including left ventricular morphology, ejection fraction, presence of late gadolinium enhancement, T1 value and strain data) will be used to produce a cardiac values, which is to be input into our differentiating flow.
1460450|NCT03271372|Drug|Avelumab|Given IV
1460451|NCT03271372|Other|Laboratory Biomarker Analysis|Correlative studies
1460452|NCT03271372|Other|Placebo|Given IV
1460453|NCT03271359|Behavioral|EMDR|Initial EMDR session of up to three hours; about one week later, follow-up session of up to one hour
1460454|NCT03271359|Behavioral|PC|Initial PC session of up to three hours; about one week later, follow-up session of up to one hour
1460455|NCT03271346|Behavioral|intensive trauma-focused therapy|
1460456|NCT03271333|Other|lung function tests|Patients hospitalized realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes)
1460457|NCT03271320|Other|appearance scales|appearance scales : AVS; ASWAP; DAS 59
1460460|NCT03271294|Device|Exair Transvaginal Mesh|Exair transvaginal mesh system for the treatment of pelvic organ prolapse
1460463|NCT03271255|Drug|Apatinib Mesylate Tablets|Apatinib combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
1460464|NCT03271255|Drug|Bevacizumab Injection|Bevacizumab combination with FOLFIRI regimen as the second-line chemotherapy for mCRC
1460465|NCT03271242|Other|Systematic implementation support|Implementation support is offered by implementation trainers visiting each clinical unit every two weeks for 6 months and then monthly for 12 months. Support is given only for the practice randomly assigned to support. The aim is to engage leaders and clinicians in identifying and overcoming implementation barriers, and in building systems to support and sustain implementation. Implementation trainers from all sites are trained together and meet every 2-3 month with leaders of the implementation training for supervision, mutual discussion, and exchange of experiences. At the start of the implementation, leaders and clinicians were also invited to a workshop on the practice they have been randomly assigned to receive support for. Toolkits are made available on a website.
1460466|NCT03271242|Other|No implementation support|No implementation support is offered to clinical units for the practice randomly assigned to no implementation support, of the two practices (of the four practices in the project) that unit has chosen to implement.
1460467|NCT03271229|Biological|Concentrated Bone Marrow Aspirate (BMAC)|Participants will have a knee injected with BMAC stem cells harvested from the iliac crest
1460468|NCT03271229|Biological|Platelet-Rich Plasma (PRP)|Participants will have a knee injected with Platelet-Rich Plasma (PRP) obtained from a venous whole blood draw from the antecubital vein.
1460469|NCT03271216|Device|No intervention|no intervention
1460470|NCT03271203|Other|Michigan Hand Outcomes Questionnaire|The MHQ is a self-report measure that assesses the function of the hand(s) and/or wrist(s). The MHQ contains six distinct scales including overall hand function, activities of daily living, pain, work performance, aesthetics and subject satisfaction with hand function. In the pain scale, high scores indicate greater pain, while in the other five scales, high scores denote better hand performance.
1460471|NCT03271203|Other|Real-time data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to provide responses about their experience of HOA in real-time via varying video, audio, photographic and text forms.
1460472|NCT03271190|Behavioral|ENGAGE SPANISH/MUSIC|Cognitive strategies to improve attention and memory skills (21 hours), leisure activities (music lessons or Spanish lessons) (27 hours), selected videogames to practice variable attention strategies (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by a trained therapist for formal sessions and a professional music or Spanish teacher for leisure sessions.
1460473|NCT03271190|Behavioral|ENGAGE DISCOVERY|Educational content about brain and healthy aging (21 hours), leisure activities (watching documentaries followed by group discussion and debate) (27 hours), selected non-stimulating videogames (4 hours in class + about 10 hours at home). Total of 24 2-hour in class sessions over 4 months. The training will be delivered to small groups of 5 to 8 participants by the same trained therapist as in the ENGAGE arm.
1460474|NCT03271177|Device|7F sheathless Guide Catheter|Transradial PCI will be performed with a 7F sheathless Guide Catheter
1460475|NCT03271177|Device|6F Sheath/Guide Catheter Combination|Transradial PCI will be performed with a 6F Sheath/Guide Catheter Combination
2010502|NCT02951156|Biological|Avelumab|Investigational fully human anti-PD-L1 monoclonal antibody
2010503|NCT02951156|Biological|Utomilumab|Investigational, fully human IgG2 CD 137/4-1BB agonist
1460476|NCT03271164|Device|FBPM10 System|Application of the FBPM10 membrane followed by illumination with a multi-Light Emitting Diode (LED) lamp.
1460477|NCT03271164|Other|Massages with vitamin E cream|The other breast will be treated with wound massages with vitamin E cream.
1460480|NCT03271138|Dietary Supplement|Bifidobacterium infantis NLS super strain (Natren LIFE START®2)|2 capsules, 3 times per day, for daily total of 12x10^9 CFU Bifidobacterium infantis NLS super strain
1460481|NCT03271138|Other|Placebo|2 capsules, 3 times per day, containing rice flour, hydroxypropyl and methylcellulose
1460482|NCT03271125|Behavioral|Treadmill|Participants in the experimental group received supervised treadmill training, 4-5 sessions per week. The treatment protocol was aimed at improving participants' resistance, walking velocity, balance and cognitive functions during motor and cognitive (dual) tasks. The treadmill training was carried out without body weight support but if needed the participants were attached to a safety harness.
1460483|NCT03271125|Behavioral|Resistance|Participants in the control group were treated with Resistance exercises, 4-5 sessions per week. The treatment protocol was aimed at improving strength in muscles involved in walking (hip abductors, quadriceps, plantar flexors, dorsal flexors) according to current guidelines from the American College of Sports Medicine (2009). Three sets of 10 repetitions were performed bilaterally with appropriate weights for each exercise
1460484|NCT03271112|Other|Exercise program|Measurement of physical performance before and after the 12 wks-exercice program
2010504|NCT02951156|Biological|Rituximab|CD20-directed cytolytic antibody
1460486|NCT03271086|Behavioral|The StressEraser|The StressEraser is a handheld biofeedback device that measures heart rate variability (HRV). Heart rate increases during inspiration and decreases during expiration. The HRV, depicted on a miniature screen, essentially represents respirations. The investigator's prior study demonstrated that the device is easily mastered and acceptable to children above 6 years of age.
1460487|NCT03271086|Behavioral|Breathe2Relax|Breathe2Relax is a free mobile app, developed by the Dept. of Defense's National Center for Telehealth and Technology to help veterans with PTSD and others use breathing practice for stress management. This application guides users in relaxation breathing and is available for both android and iOS phones. It is adapted for children 6 years and up. For instance, the cycles can be shortened for children, there is a selection of quiet music and the user can choose backgrounds for personalization.
1460488|NCT03271086|Behavioral|Reminder text messages|Weekly texts will be sent out to parents in the technology-enhanced relaxation breathing group to as reminders to practice the daily relaxation breathing with their child.
1460489|NCT03271073|Drug|Apatinib|Apatinib,500mg,qd,po,d1-21;S1,40mg,bid,d1-14;every 21days a cycle
1460490|NCT03271060|Procedure|Posterior lumbar interbody fusion|Lumbar fusion by screws and inter vertebral cage
1460491|NCT03271060|Procedure|Inter transverse bone grafting|Inter transverse process bone grafting by bone graft from illiac crest or other sites
1460492|NCT03271047|Drug|binimetinib|Orally, twice daily.
1460493|NCT03271047|Drug|nivolumab|Intravenously (IV) every 4 weeks (Q4W)
1460494|NCT03271047|Drug|ipilimumab|intravenously (IV) every 8 weeks (Q8W)
1460495|NCT03271034|Dietary Supplement|Mediterranean diet|Participants will lose weight by utilizing a low caloric diet and meeting with a study dietitian weekly for ~4 months.
1460496|NCT03271021|Drug|FMX101|FMX101, 4% minocycline foam
1460497|NCT03271021|Drug|Vehicle Foam|Vehicle Foam
1460498|NCT03271008|Device|Direct laryngoscopy|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a size 4 (or size 3 if necessary) Macintosh blade direct laryngoscope.
1460499|NCT03271008|Device|Vividtrac videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a Vividtrac videolaryngoscope connected to a tablet or smartphone.
1460500|NCT03271008|Device|KingVision videolaryngoscope|During the induction of general anaesthesia, the first attempt to achieve a secured airway is carried out using a KingVision videolaryngoscope.
1460501|NCT03270995|Behavioral|Cognitive Existential Therapy Group 1|Six group sessions of two hour each using a cognitive-existential group approach
1460502|NCT03270995|Behavioral|Supportive Therapy Group 2|Six group session of two hour each using a supportive group approach.
1460503|NCT03270982|Device|Comprehensive SRS Replacement|This system consist of a proximal humeral replacement, distal humeral replacement, or total humeral replacement.
1460504|NCT03270969|Drug|Tenofovir Disoproxil Fumarate/Emtricitabine|Participants will receive daily TDF/FTC for 14 days
1460505|NCT03270956|Biological|Neo-Kidney Augment™ (NKA)|Neo-Kidney Augment (NKA) Autologous selected renal cells (SRC).
1460506|NCT03270943|Behavioral|MFY|Mindful Self-Compassion course for teens
1460507|NCT03270943|Behavioral|TCY|Healthy Lifestyles course for teens
1460508|NCT03270930|Procedure|Emergency laparotomy|All patients in study underwent emergency laparotomy within 24 hours of presentation after adequate resuscitation of minimum 1 hour.
1460509|NCT03270917|Procedure|Parenchymal preserving postero-superior liver segment resection|Parenchymal preserving liver segment resection of one or two of the postero-superior liver segments (4A, 7 or 8).
1460510|NCT03270904|Device|Moleculight i:X™ fluorescence imaging|Moleculight i:X™ is a hand held device that emits violet blue light. By controlling distance from the wound and ambient light, Moleculight i:X™ identifies bacteria above a pre-determined concentration by identifying natural fluorescence in the bacteria cell wall.
1460511|NCT03270891|Diagnostic Test|PGx test|A laboratory developed genetic test that differentiates common and uncommon alleles in genes that have been previously identified as being involved in either the metabolism or response of drugs used in the treatment of depression. The results are provided as a report that contains information related to the allele status of the patient's genes, translates this into a phenotype, and relates this phenotype to recommendation classes for drugs.
1460620|NCT03269916|Other|Antral alveolar cell count|used to assess ovarian reserve parameters
1460512|NCT03270878|Drug|Glasdegib Oral Tablet|Subjects will receive a single 100 mg oral tablet of glasdegib under fasted conditions, either in study period 1 or 2, depending on randomization.
1460513|NCT03270878|Drug|Glasdegib IV infusion|Subjects will receive a 50 mg IV infusion of glasdegib over approximately 1.25 hours, in the fasted state, in either period 1 or 2 based on randomization.
1460514|NCT03270865|Device|PAF (Positioning And Fixation device)|"Up to 60 Subjects will be evaluating for positioning accuracy and comfort by comparing different methods utilizing the PAF device. Some methods of positioning will be applied and compare for each usability factor X, Y, Z location, and fixation.
The patient will be evaluated before pupil dilation. VA and ophthalmic diagnoses will be recorded.
Pupil position will be recorded using 3 commercial off the shelf cameras when the subject is performing simple ergonomic tasks while looking at a screen presenting images. Each testing session will be limited 20 min long. Subjects will be able to rest within the testing session if required. Total session time per patient will not exceed 30 minutes."
1460517|NCT03270839|Drug|Bonine 25Mg Chewable Tablet|Motion sickness drug
1460518|NCT03270839|Drug|Kwells|Motion sickness drug
1460519|NCT03270839|Drug|Placebo Oral Tablet|No active substance in the tablet
1460520|NCT03270813|Behavioral|Relaxation training plus RAGE-Control|RAGE-Control is a biofeedback videogame in which players shoot at enemies while avoiding allies. The player's baseline heart rate is taken before the game and entered into the computer. During the game, the player wears a heart rate monitor, and if the player's heart rate rises above baseline, they are unable to shoot. The player must use relaxation skills to decrease their heart rate below the baseline before they can resume play. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the RAGE-Control videogame.
1460521|NCT03270813|Behavioral|Relaxation training plus Sham Videogame|The Sham videogame is a videogame in which players shoot at enemies while avoiding allies. The player wears a heart rate monitor during the game, but the heart rate does not affect the functioning of the game in any way. Participants will undergo relaxation training during each of 6 sessions, and then practice the skills they learned while playing the Sham videogame.
1460522|NCT03270800|Biological|CTA control|Sublingual and intradernal application of a mucosal adjuvance, drug product is not yet on the market.
1460523|NCT03270800|Biological|IMX101 vaccine|Sublingual and intradermal application of a vaccine, drug product is not yet on the market.
1460524|NCT03270787|Drug|Placebo|Drug: Placebo Placebo,10pills,tid,treat 1 weeks.
1460525|NCT03270787|Drug|Compound danshen dripping pills|Drug: Compound danshen dripping pills Compound danshen dripping pills,10pills,tid,treat 1 weeks.
1460526|NCT03270748|Drug|GvHD prophylaxis|Cyclophosphamide 50 mg/kg intravenously day+3 and +4 (total dose:100 mg/kg).
1460527|NCT03270735|Drug|Snake venom thrombin (Treatment)|Snake venom thrombin
1460528|NCT03270735|Drug|Placebo|No snake venom thrombin
1460529|NCT03270722|Device|FLIP topography|During upper endoscopy, the FLIP topography balloon will be advanced into the esophagus and inflated, providing additional information about the distensibility of the esophagus. This generally takes about 5 extra minutes and no complications have been reported. Theoretical complications include bleeding, infection, risk with extra anesthesia time, and putting a hole in the esophagus.
1460530|NCT03270722|Procedure|Upper Endoscopy|A standard upper endoscopy will also be done in all patients. A small scope will be passed via the mouth to examine the esophagus, stomach, and first part of the small intestine. The risks of this procedure include the risks associated with anesthesia, a small risk of bleeding, infection, and a very small risk of putting a hole in the gastrointestinal tract.
1460531|NCT03270709|Drug|Vitamin D3 500,000 IU orally|Study subjects will receive 2 tablets of 250,000 IU of vitamin D3 for a total of 500,000 IU by mouth.
1460532|NCT03270696|Drug|administration of propofol and rocuronium|compare the tidal volume applied from starting facemask ventilation under 15cmH2O of PCV for 1 minute according to administrating propofol and rocuronium simultaneously, or ordinally
1460533|NCT03270657|Device|IPG; RC+S|We will measure the effects of varying stimulation parameters on both the neural activity and changes in motor symptoms -- bradykinesia and tremor -- in subjects with Parkinson's disease (PD)
1460534|NCT03270644|Drug|Lasmiditan|Administered orally
1460535|NCT03270644|Drug|Propranolol|Administered orally
1460536|NCT03270631|Other|FM and MCE|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting.
1460537|NCT03270631|Other|FM and sham-MCE|Treatments (FM) are given individually and as in a normal clinical physical therapy setting. Sham-MCE is general exercises.
1460538|NCT03270631|Other|MCE and sham-FM|Treatments (FM and MCE) are given individually and as in a normal clinical physical therapy setting. Sham-FM is similar to trigger point treatment with treated points randomized.
1460539|NCT03270631|Other|Sham-MCE and sham-FM|Sham-FM is similar to trigger point treatment with treated points randomized. Sham-MCE is general exercises.
1460540|NCT03270618|Device|CAD/CAM Surgical Template|The templates were designed based on virtual planning and manufactured using three-dimensional printing technique. The template is designed to assist the surgeon to perform the osteotomy and predrill the screw holes to guide the distractor position.
1460541|NCT03270605|Procedure|myomectomy|surgical removal of uterine fibroid at the time of cesarean section
1460542|NCT03270592|Other|Service dog|Use of a individualized certified service dog
1460543|NCT03270579|Drug|[18F]JNJ-64511070|An IV injection of 185 MBq [18F]JNJ-64511070 will be administered.
1460621|NCT03269903|Device|HILZO esophageal stent|A fully covered esophageal self-expandable metal stent for malignant dysphagia
1460801|NCT03268369|Radiation|MRI of the brain|to eliminate a structural intra-cerebral lesion
1460544|NCT03270566|Device|Domestic ion-exchange water softener|Ion-exchange water softeners exchange calcium and magnesium, amongst other divalent cations, for monovalent sodium cations using a polystyrene resin. The sodium ions come from sodium chloride (common salt). The salt needs to be topped up every 3-4 weeks and sufficient quantities of block salt will be supplied to participants. The water softener used in this study does not require electricity and has two cylinders of resin which are used alternately. A control valve alternates the flow between the two cylinders and ensures a constant supply of regenerated resin. Ion-exchange water softeners typically reduce downstream water hardness to close to zero.
1948003|NCT02881151|Device|Deep brain stimulation|Delivery of continuous, low-voltage electrical pulses to deep portions of the brain via an implantable pacemaker-like device.
1948004|NCT02880904|Other|Photography|Photos will be taken of the vulvar lichen sclerosus lesions.
1460549|NCT03270514|Drug|Exparel Injectable Product|Liposomal bupivacaine 20 cc (226 mg) + Bupivacaine Hydrochloride 0.25% 40 cc (100 mg) + made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
1460550|NCT03270514|Drug|Bupivacaine Hydrochloride|Bupivacaine 0.25% 2 mg/kg not to exceed 150 mg - made up to made up to calculated volume with normal saline solution based on the length of the incision and number of chest tubes (20 cc per tube + 20cc per inch of incision)
1460551|NCT03270501|Drug|Golimumab|"Axial spondyloarthritis patients who don't have a good treatment response on 2 NSAIDs, will be treated with golimumab. After remission, the therapy will be stopped.
All patients will undergo a ileocoloscopy at baseline and, if positive, at time of remission."
1460552|NCT03270488|Other|Laser|Laser (power of 3.0w).
1460553|NCT03270488|Other|Placebo|Laser (power 0,0w)
1460556|NCT03270449|Other|Multidisciplinary intervention|10 week multidisciplinary education and exercise
1460559|NCT03270423|Device|PathMate2|
1460560|NCT03270423|Device|PathMateS|
1460561|NCT03270410|Other|Data collection|"After parental information and collection of their non-opposition, the data of the daily cardio-respiratory recordings of the newborns hospitalized in the units of Neonatology are collected and analyzed.
At the same time, a video recording is set up. This video recording does not modify the care provided for the child, the organization of the day with nursing and parental care."
1460562|NCT03270397|Behavioral|"Academic course The group- theory and practice"|"Active participation in the course The group- theory and practice."
1460564|NCT03270371|Device|Medium cut off dialysis|Hemodialysis
1460565|NCT03270371|Device|Standard High Flux Dialyzer|Hemodialysis
1460570|NCT03270293|Device|Profhilo|
1460571|NCT03270280|Drug|Nigella Sativa Oil|The individuals will apply 55 drops of Nigella sativa Oil on gingivae twice daily for two weeks
1460572|NCT03270280|Drug|Normal saline|The individuals will apply 55 drops of Normal saline on gingivae twice daily for two weeks
1460573|NCT03270267|Other|Questionnaires|
1460574|NCT03270254|Device|light activated dye photodynamic therapy (PDT)|light activated dye photodynamic therapy-PDT to periodontal pockets
1460575|NCT03270241|Device|Phototherapy (NB-UVB) via the 3 Series PC & SP phototherapy cabinet|This is an investigator-initiated, single-blinded, ascending dose study of NB-UVB treatment for Vitiligo in adults of 3 treatments for one week. It is designed to measure the molecular changes and re-pigmentation in affected and normal skin of participants with Vitiligo and normal skin in healthy participants.
1460576|NCT03270228|Other|Nonspecific pleuritis after VATS thoracoscopy|Patients with a pleural effusion with unknown origin after a VATS thoracoscopy is classified as nonspecific pleuritis.
1460577|NCT03270215|Procedure|Computed tomography|The diagnostic power to discriminate malignant from nonmalignant causes of e pleural effusion
1460580|NCT03270189|Device|prism glasses|orthoptic treatment by wearing prisms when writing
1995035|NCT02870751|Biological|TW11681 or TW10722|
1995036|NCT02867644|Other|standard care|Patients coming for preoperative breast assessment will have standard care.
2010505|NCT02951156|Other|Azacitidine|Antimetabolite antineoplastic agent and demethylation agent.
1460584|NCT03270150|Device|BTL-799|BTL-799
1460585|NCT03270137|Device|repetitive transcranial magnetic stimulation- IDLPFC|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC). Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered over left dorsolateral prefrontal cortex (lDLPFC) compared to six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex [rDLPFC]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
1460586|NCT03270137|Device|repetitive transcranial magnetic stimulation - Six regions|Repetitive transcranial magnetic stimulation (rTMS) at 5Hz administered on six regions protocol, divided in two sub-conditions: day 1 (Broca area, Wernicke area and lDLPFC) alternated by day 2 (left and right parietal association cortex, and right dorsolateral prefrontal cortex [rDLPFC]). Main outcomes will be evaluated at ending of 15 rTMS sessions and 4 weeks after.
1460587|NCT03270124|Behavioral|Daily Activity Goal|Patients are given a tailored daily activity goal in terms of the number of active minutes per day for which to aim.
1460588|NCT03270124|Behavioral|Resistance Exercises|Patients will instructed to perform 3 different resistance exercises targeting muscles pertinent to activities of daily living on 6 out of 7 days a week.
1460589|NCT03270124|Behavioral|Daily Activity Recording|An accelerometer will be worn by all participants to record daily activity.
1460590|NCT03270111|Behavioral|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
1460591|NCT03270111|Behavioral|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
1460592|NCT03270111|Behavioral|Reduced Energy Diet|Diet is a nutritionally balanced, reduced energy diet recommended by the Academy of Nutrition and Dietetics.
1460593|NCT03270111|Behavioral|Group Phone Calls|Sessions are weekly months 1-3 and every other week months 4-6. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
1460594|NCT03270098|Behavioral|Aerobic Exercise|Trainer-led one hour aerobic exercise sessions, three times per week, over 12 weeks.
1460595|NCT03270098|Behavioral|Stretching and Toning Exercise|Trainer-led one hour stretching-and-toning exercise sessions, three times per week, over 12 weeks.
1995037|NCT02867644|Other|standard care + conversational hypnosis|Patients coming for preoperative breast assessment will have standard care with conversational hypnosis
1995038|NCT02868177|Dietary Supplement|Totum-63|Each randomized subject will consume 8 capsules daily of either active (5200 mg of Totum-63) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
1460598|NCT03270059|Drug|Ferumoxytol|Given IV
1460599|NCT03270059|Drug|Gadolinium|Given IV
1460600|NCT03270059|Procedure|Magnetic Resonance Imaging|Undergo MRI
1460601|NCT03270046|Procedure|Water enema|Addition of water enema in standard PEG preparation in participants scheduled for CRC screening.
1460602|NCT03270033|Drug|Dexamethasone|0.4 millilitres (mL) of 10 milligram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
1460603|NCT03270033|Drug|Dexmedetomidine|0.5 millilitres (mL) of 100 microgram per mL sterile, preservative free solution diluted in 50 or 100mL of normal saline and administered once, over approximately 15 minutes, in the immediate preoperative period.
1460604|NCT03270020|Drug|Denosumab 70 MG/ML [Xgeva]|As already described in arm description
1460605|NCT03270007|Drug|Vinorelbine|different from primary chemotherapy(containing anthracycline or paclitaxel)
1460606|NCT03269994|Drug|Cefoxitin|Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
1460607|NCT03269994|Drug|Piperacillin-tazobactam|Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.
1460608|NCT03269981|Radiation|Whole breast irradiation|Radiotherapy to the whole breast alone.
1460609|NCT03269981|Radiation|Whole breast and nodal irradiation|Radiotherapy to the whole breast and regional lymph nodes.
1460610|NCT03269968|Device|Negative pressure wound therapy (PREVENA Incision Management Therapy System)|After cesarean delivery, women in the intervention group will receive PREVENA Incision Management Therapy System.
1460611|NCT03269968|Device|Standard dressing|After cesarean delivery, women in the intervention group will receive standard dressing.
1460612|NCT03269955|Drug|Fibrinogen/thrombin-coated collagen patch|Tachosil® is cut in half and applied to the front and back of the pancreaticojejunostomy respectively, and fibrin glue is applied on it
1460613|NCT03269942|Procedure|Endovascular Flow-Diversion|Implantation of flow-diverter in treatment of complex aneurysms of anterior circulation.
1460614|NCT03269942|Procedure|Cerebral Revascularization|Cerebral revascularization with trapping of aneurysm in treatment of complex aneurysms of anterior circulation.
1460615|NCT03269929|Other|Music therapy|Subjects listened to music for 30 minutes before undergoing brachytherapy with spinal anesthesia
1460616|NCT03269929|Drug|Midazolam|Subjects received intravenous midazolam 0,02 mg/kgBW injection before undergoing brachytherapy with spinal anesthesia
1460617|NCT03269916|Other|Anti Mueller hormone|used to assess ovarian reserve parameters
1460618|NCT03269916|Other|Estrogen|used to assess ovarian reserve parameters
1520525|NCT02813135|Drug|Topotecan|
1995039|NCT02868177|Dietary Supplement|Placebo|Each randomized subject will consume 8 capsules daily of placebo (5064 mg of maltodextrine) during 24 weeks (from visit V1 to visit V3). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
1460624|NCT03269864|Procedure|perforator flaps|40 patients with post traumatic skin defect at leg and foot will be managed by perforator flaps, 20 with pedicled perforator flaps and other 20 with free perforator flaps
1948005|NCT02879708|Other|Information Only|Households will receive information regarding their rights and entitlements pertaining to healthcare, certain health outcomes specific to their village, as well as health-related activities happening in their village (such as the VHSNC meetings and Village Health and Nutrition Days). Information will be disseminated through an initial visit to all households, and from then on either through (1) broadcast messages sent to households via mobile phone, (2) central individuals in the village social network who will be asked to spread that information, or (3) public officials charged with spreading the information throughout the village.
1460626|NCT03269838|Diagnostic Test|ECG|Primary Percutaneous coronary intervention
1460627|NCT03269812|Procedure|laparoscopic assisted pull-through oeration|Under general anesthesia and insertion of ports for laparoscopic instruments, laparoscopic assisted mobilization of sigmoid colon and dissection till pelvis and removal of a ganglionic segment of colon and laparoscopic assisted pull through of colon then colo-anal anastomosis will be done,
1460628|NCT03269799|Drug|Vitamin C 500 MG Oral Capsule|non surgical periodontal treatment+vitamin C 500 mg/day for 2 months
1460629|NCT03269799|Other|placebo|non surgical periodontal treatment+placebo for 2 months
1460630|NCT03269786|Diagnostic Test|biannual ultrasonography and laboratory testes|laboratory tests changes changes and ultrasonographic changes will be assigned to all cirrhotic patients with esophagel varisces who treated with endoscopic band ligation or injection scelerotheraby
1460631|NCT03269773|Other|FURESTEM-AD Inj.|
1460632|NCT03269773|Other|Placebo|
1460633|NCT03269760|Drug|Zolpidem|Addition of both non-pharmacologic nursing directed sleeping hygiene practices with pharmacologic zolpidem to improve sleep latency
1460634|NCT03269747|Drug|Prednisone|2 tablets of Prednisone 20 Mg in the morning
1460635|NCT03269747|Drug|Placebo|2 Placebo tablets in the morning
1460636|NCT03269721|Behavioral|Neuropsychological Assessment|Assessments include: Paper and pencil computerized measures of Memory, Language, Visuospatial Function, Executive Functioning-Processing Speed, and Attention
1460637|NCT03269721|Procedure|Spirometry|Pre and post bronchodilator spirometry will be administered according to ATS guidelines.
1460638|NCT03269721|Procedure|Arterial Blood Gas|Radial artery blood sample will be collected to measure gas exchange hemoglobin; arterial oxygen and carbon dioxide will be examined as potential covariates.
1460639|NCT03269721|Procedure|Diffusion Capacity of the Lung for Carbon Monoxide|For measurement of gas exchange in the lung. DLCO adjusted for hemoglobin will be the primary variable of interest and will be examined as a potential covariate.
1460640|NCT03269721|Diagnostic Test|6 Minute Walk Test|Distance walked in 6 minutes will be the primary outcome.
1460641|NCT03269721|Procedure|Systemic Vascular Measures|Carotid artery ultrasound, pulse wave velocity, brachial artery endothelium-dependent flow mediated dilation and endothelium-independent dilation will be measured.
1460642|NCT03269721|Biological|Blood Biomarkers|High sensitivity C-reactive protein (hs-CRP), and fibrinogen will be used as indicators of systemic inflammation, complete blood count with differential (CBC with diff) will be obtained to rule out acute infection as a cause of inflammation.
1460643|NCT03269721|Behavioral|Symptom Questionnaire Measures|M.I.N.I Screen 7.0.0, Beck Depression Inventory-II (DBI-II), State Trait Anxiety Inventory (STAI), COPD Assessment Test (CAT), St. George's Respiratory Questionnaire (SGRQ), MMRC Dyspnea Scale (MMRC), Berlin Questionnaire
1460644|NCT03269721|Procedure|Brain MRI|Primary neuroimaging outcomes of interest are white matter structural integrity
1460645|NCT03269708|Behavioral|Education regarding telomere length|Teaching concepts of cellular aging and telomere length
2010506|NCT02951156|Drug|Bendamustine|Alkylating drug
1460647|NCT03269682|Device|3D PD T1 MRI sequence|After MRI has been performed (about 5 minutes of additional time compared to the usual sequences), a double reading of the MRI will be performed by two radiologists (1 experienced and 1 junior).
2010507|NCT02951156|Drug|Gemcitabine|Nucleoside analogue
1460656|NCT03269630|Other|No intervention. Biospecimen collection only|Biospecimen collection
1460657|NCT03269617|Dietary Supplement|Bacteriophage mixture|Four bacteriophage strains: LH01-Myoviridae, LL5-Siphoviridae, T4D-Myoviridae, and LL12-Myoviridae.
1460658|NCT03269617|Other|Placebo Control|Placebo control capsule consisting of rice maltodextrin
1460659|NCT03269604|Procedure|Prophylactic antibiotic during five days previous to the procedure|Prophylactic antibiotic during five days previous to the procedure.
1460660|NCT03269604|Procedure|Prophylactic antibiotic during three days previous to the procedure|Prophylactic antibiotic during three days previous to the procedure.
1460661|NCT03269604|Procedure|Only a single dose of Prophylactic antibiotic|This group will receive a single dose of antibiotic 90 ± 20 minutes prior to the start of the surgical procedure (incision)
1460662|NCT03269591|Device|Pulsed electromagnetic field|EASY Qs portable (by ASA, Italy)
1460663|NCT03269591|Drug|diclofenac tablets|drugs
1460664|NCT03269591|Diagnostic Test|Visual analogue scale|a graphic rating scale
1460665|NCT03269591|Diagnostic Test|Progesterone blood level|blood test
1460666|NCT03269591|Diagnostic Test|Menstrual symptom questionnaire|questionnaire
1460667|NCT03269565|Biological|BCD-100|Anti-PD-1 monoclonal antibody
1460668|NCT03269552|Drug|Carfilzomib|Given IV
1460669|NCT03269552|Other|Laboratory Biomarker Analysis|Correlative studies
1460670|NCT03269552|Biological|Rituximab|Given IV
1460671|NCT03269539|Other|MRI Imaging|
1460672|NCT03269526|Drug|EGFR BATs after standard of care chemo|Subject will receive one dose of standard of care chemotherapy prior to twice weekly infusions of EGFR BATs for 4 weeks.
1460673|NCT03269513|Behavioral|Physical Exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
1460802|NCT03268369|Radiation|PET scan [18F]F-A-85380|exam performed after iv injection of 200 MBq [18F]F-A-85380
1460803|NCT03268369|Radiation|PET scan [18F]FDG|exam performed after iv injection of 200 MBq [18F]FDG
1460804|NCT03268343|Drug|Cytisine|Cytisine 1.5 mg Film-Coated Tablets
1460674|NCT03269500|Other|use of nutrition education tools|"Use of different nutrition education tools :
General advice: feeding seniors
Oral supplementation: instructions for use
Information about enriched food
Food modified in texture: chopped masticatory disorders, chopped swallowing disorders, co-mingled
How should I drink? : With stimulus, texture syrup / nectar, velvety texture, texture compote / cream
Recipe booklets for people to easily eat (chewing disorders) or recipe with molded texture (swallowing disorders)"
1460675|NCT03269474|Procedure|Experimental Group|Subjects with EBS diagnosis
1460676|NCT03269461|Device|Angiography and Optical Coherence Tomography evaluations|coronary stent implantation followed by Angiography and Optical Coherence Tomography evaluations
1460677|NCT03269448|Diagnostic Test|Peripheral venous blood sampling|Blood collected from peripheral venous (extremities) and central venous (central catheter) for blood gas analyses
1460678|NCT03269435|Procedure|Greater occipital nerve block with bupivacaine|This is a type of peripheral nerve block. 3cc of 0.5% bupivacaine will be injected adjacent to the greater occipital nerve block blaterally
1460679|NCT03269435|Drug|Metoclopramide|Metoclopramide 10mg IV will be administered over 15 minutes
1460680|NCT03269422|Radiation|MR-based image-guided, intensity-modulated radiotherapy|Patients will receive a standard dose of 8 Gy/fraction for five fractions for a total dose of 40 Gy to the prostate with a simultaneously delivered boost of 9 Gy for five fractions (clinically non-standard dose of 45 Gy total) to a single dominant lesion with a maximum dimension of at least 0.5 cm as determined on pre-treatment diagnostic T2 MRI imaging.
1460681|NCT03269409|Other|Saline|5 cc's of saline will be injected after decompression into the hip that does not receive adipose derived regenerative cells.
1460682|NCT03269409|Device|The Celution System (Cytori Therapeutics)|The Celution System will be used for the preparation of adipose derived regenerative cells from lipoaspirate. The adipose derived regenerative cells will then be transplanted into the hip, post decompression.
1460683|NCT03269409|Biological|Adipose Derived Regenerative Cells (ADRC)|Adipose Derived Regenerative Cells (ADRC) will be harvested through autologous liposuction and processed outside the body autologous transplantation..
1460684|NCT03269396|Procedure|Larynx Allograft Transplantation|This study is a prospective clinical trial designed to assess the efficacy and safety of laryngeal transplantation. A total of 10 patients will be enrolled over a five-year timeframe. Study length is 5 years.
1460685|NCT03269383|Drug|Bupivacaine|Patients will receive a stellate ganglion block using 10 ml of 0.5% bupivacaine
1460686|NCT03269383|Other|Saline|Patients will receive a stellate ganglion block using 10 ml of 0.9% saline
1460687|NCT03269370|Behavioral|Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app.
1460688|NCT03269370|Behavioral|Parent Enhanced Anchors Away|Modular Cognitive Behavioral Therapy delivered through a mobile app. Extra modules will focus specifically on parenting skills relevant to having an anxious child.
1460689|NCT03269370|Behavioral|Self-Help E-Book|"Parents will read Helping Your Anxious Child: A Step-by-Step Guide (Rapee, Wignall, Spence, Lyneham, & Cobham, 2008)"
1460690|NCT03269357|Other|LARC forward structured contraceptive counselling|Training of health care providers (HCPs), use of information material and counselling tools
1460691|NCT03269344|Drug|Gabapentin|Gabapentin is an anticonvulsant and has been used to manage neuropathic pain and is FDA-approved for the treatment of post-herpetic neuralgia and partial onset seizures
1460692|NCT03269344|Drug|Placebo Oral Capsule|Placebo
1460693|NCT03269331|Behavioral|CTEP EBP Immersion|36 continuing ed credits, virtual library access, collaboration with expert mentors
1460694|NCT03269318|Drug|Montelukast or Salmeterol or Theophylline or Steroid|Medication will be patient specific according to their current medication, clinical symptoms and genotype. It will be from a choice of; leukotriene receptor antagonist (montelukast), long-acting beta2 agonist (salmeterol), theophylline or increase dose of inhaled steroid.
1460695|NCT03269279|Drug|Mifepristone|Medication used in conjunction with misoprostol for abortion
1460696|NCT03269279|Drug|Misoprostol|Medication used in conjunction with mifepristone for abortion
1460697|NCT03269266|Diagnostic Test|Scrub Typhus RDT Test|"A transfer pipette or loop will be used to transfer 10 µL of whole blood from a finger prick to the sample pad area on the scrub typhus test strip and the test will be performed on site according to the manufacturer's instructions. Tests will be read by two independent readers and results recorded as positive, negative or invalid.
In patients with a skin eschar a sterile surgical blade will be used to gently scrape the surface of the eschar. Scrapings will be stored in a cryotube containing 95% ethanol and stored at -80°C for future analysis (PCR genotyping ± whole genome sequencing) to confirm the presence of Orientia tsutsugamushi."
1460698|NCT03269240|Behavioral|Acquisition of Knowledge and clinical skills|LDHF is a novel training approach that is being compared to the traditional training approach
1460699|NCT03269240|Other|Onsite training|Participants are training at their health facilities
1460700|NCT03269240|Other|Off-site training|Participants from different health facilities are gathered together in a central location for training, away from their workplaces
1460701|NCT03269227|Radiation|Accelerated hypofractionation with Tomotherapy|"Tomotherapy TPS will be used for treatment plannings. Patient' set-up daily control through Tomo-image (CT megavoltage) immediately before each sitting of all the patients.
Prescription doses:
Prescription dose to the target: 30 Gy in 5 daily fraction (at the reference isodose 60-70%) with an internal increasing inhomogenous dose of up to 37.5 Gy-40 Gy for GTV.
Steroids (methylprednisolone 4 mg daily) should be used from day 1 of radiotherapy to day + 30 after the end of the treatment."
1460702|NCT03269214|Drug|Topical Phenytoin 5%|Patients received topical Phenytoin 5%+ Tetracycline after necrotic bone debridement .
1460703|NCT03269175|Other|Brain MRI|Brain MRI will be performed
1460704|NCT03269175|Other|Blood sampling|Blood samples will be taken
1460705|NCT03269162|Drug|Jinfukang Koufuye|30ml per time, tid, po (d6-21, q21)
1460706|NCT03269162|Drug|Docetaxel|75mg/m2,ivgtt 30mins, d1
1460707|NCT03269162|Drug|Pemetrexed|500mg/m2, ivgtt 30mins, d1
1460708|NCT03269162|Drug|Cisplatin|75mg/m2, ivgtt >2h, d1
2010508|NCT02951156|Drug|Oxaliplatin|Platinum-based drug
1460709|NCT03269149|Other|Adapted Tango Dance|20 improvisational, 90-minute adapted tango dance sessions over a 12-week period. Classes begin with a 20-minute standing warm-up followed by partnering and rhythmic exercises. Next, novel step elements are introduced and participants will be taught how to combine the new steps with previously learned steps via improvisation. Caregivers will dance with each other or undergraduate /graduate student volunteers. Music will be played throughout classes and artistic expression, i.e., attention to aesthetics, and improvisation, will be encouraged.
1460710|NCT03269149|Behavioral|Educational lectures|Participants will take part in at least 20 educational lectures offered twice per week over 12 weeks. Classes will also be 1.5 hours long and will involve lecture, partnered and group learning and extensive Q&A will be encouraged.
1460712|NCT03269123|Device|Pressop 1|A pressure device attached to the spectacles which mimics a sensory trick (geste Antagoniste)
1460713|NCT03269110|Diagnostic Test|SRS 2, CBCL, BRIEF-P|This study does not involve an intervention.
1460714|NCT03269084|Other|No intervention. DIPP is an observational study.|
1460715|NCT03269071|Drug|human fetal-derived Neural Stem Cells (hNSCs)|"The Drug Product (DP) can be classified as an ATIMP belonging to the class of Cell Therapy Medicinal Products (EU law). The ATIMP consists of human fetal-derived Neural Stem Cells (hNSCs) re-suspended in their final formulation medium as defined in the Investigational Medical Product Dossier (IMPD).
For dosage indications, see specific Treatment Cohorts (TC), from A to D.
The product will be administered intrathecally through lumbar puncture."
1460716|NCT03269058|Drug|Dapagliflozin|Dapagliflozin 10 mg daily per os
1460717|NCT03269058|Drug|Placebos|Placebo of Dapagliflozin per day per os
1460718|NCT03269045|Drug|Biotin|Oral Biotin
1460721|NCT03269019|Diagnostic Test|HIT with thrombosis|Testing thrombin-antithrombin complex, d-dimer, fibrin degradation products and Thrombelastograghy.
1460722|NCT03269006|Device|Inesfly Paint|"Inesfly 5AIGRNG TM paint contain Alphacypermethrin 0.7%; D-Allethin 1.0% and Pyriproxyphen (0.063%).
Others intervention such as IRS, ITN and IDWLcontain Delthamethrin"
1460723|NCT03269006|Device|IDWL (1m)|Install durable wall lining up to one meter from the floor of the intervention room containing deltamethrin to kill immature stage and as well as adult sand flies
1460724|NCT03269006|Device|ITN (KO-Tab 123)|Impregnation of existing bed net by the insecticide tablet, K-O Tab 1-2-3 containing deltamethrin
1460725|NCT03269006|Device|IRS (Delthamethrin)|Indoor residual spraying with Delthamethrin in the living rooms
1460726|NCT03268993|Dietary Supplement|Avmacol|Avmacol is a dietary supplement available over the counter
1460727|NCT03268980|Other|Questionnaire Hospital Staff group|One-page questionnaire with 15 questions about tobacco habits
1460728|NCT03268980|Other|Questionnaire students and patients group|One-page questionnaire with 17 questions about tobacco habits
1460729|NCT03268967|Behavioral|Structured admission procedure|A structured ICU admission was inspired by principles of Crisis Resource Management and simulation training of ICU staff members. The Principles of Crisis Resource Management consisted of a treatment manual, a learning video, clear precise communication tool based on Identification-Situation-Background-Analysis-Recommendations (ISBAR) and Closed loop, actions cards, and ABCDE-evaluation of the patient including debriefing, and training in the simulation environment.
1460732|NCT03268941|Drug|TAK-906 Maleate|TAK-906 Maleate Capsules
1460733|NCT03268941|Drug|Metaclopramide|Metaclopramide Tablets
1460734|NCT03268941|Drug|TAK-906 Maleate Placebo|TAK-906 placebo-matching Capsules
1460735|NCT03268928|Behavioral|Story Starters Intervention|Shared reading intervention
1460736|NCT03268928|Behavioral|Wait-list Control|Wait-list control
1460737|NCT03268915|Diagnostic Test|3 minutes sit-to-stand test|3 minutes sit-to-stand test, 1 minute sit-to-stand test, 6 minutes walk test will be performed 2 times for each patients 3 minutes sit-to-stand test with oxygen uptake measurement will be performed one time for each patient
1460738|NCT03268902|Drug|Azithromycin Oral Liquid Product|Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
1460739|NCT03268902|Drug|Nitazoxanide Oral Suspension|Nitazoxanide 100 mg given twice daily for 3 days at 12 and 15 months
1460740|NCT03268902|Dietary Supplement|Nicotinamide|"Mothers in the nicotinamide arm will be given nicotinamide 250 mg daily from delivery through 6 months post-partum in capsule form.
Children in the nicotinamide arm will be given 100 mg/d in powder form between 6 and 18 months of age"
1460741|NCT03268902|Drug|Placebos|"Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.
Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.
Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age"
1460742|NCT03268889|Drug|Chidamide|Chidamide is given to the patients in this study along with CHOP regimen, to access the efficacy and safety in this cohort of PTCL patients. The dosage of the above regimen is as follows: Chidamide, 30mg,po,biw; Cyclophosphamide 750mg/m2, ivgtt, d1; Epirubicin 70mg/ m2, ivgtt, d1; Vincristine 3mg/ m2, ivgtt, d1; Prednisone 100mg/ m2, po, d1-5.
1460799|NCT03268382|Drug|APR-246|Intravenous infusion
1520526|NCT02813135|Drug|Temozolomide|
1460748|NCT03268837|Device|Programmed Intermittent Bolus|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide programmed intermittent bolus for the interscalene block.
1460749|NCT03268837|Device|Continuous Infusion|The Smith CADD(R)-Solis Ambulatory Infusion Pump will be used to provide continuous infusion for the interscalene block.
1460750|NCT03268824|Device|Electroencephalogram (EEG)|Intracerebral electroencephalogram (EEG) will be analysed to quantify the intensity of epileptic discharge (the epileptogenicity index) on each electrode contact (only for children with focal epilepsy).
1460751|NCT03268824|Device|Diffusion Tensor imaging|We will perform Diffusion Tensor imaging in order to relate tractography measures to seizure recordings. Loss of connectivity (or disconnections) will be determined with diffusion tractography for each brain region. Then we will correlate the degree of epileptogenicity with the number of disconnections.
1460752|NCT03268824|Other|Language assessment|The language assessment will be adapted to the age of the child, with a predominant neuropsychological component.
1460753|NCT03268811|Drug|Teduglutide|Teduglutide 0.05 mg/kg SC injection once daily.
1460754|NCT03268798|Device|Unilateral wrist extension training|Participants will join a five-week training protocol with 3 sessions per week. During each session, 5 sets 5 maximal wrist extension training will be performed on participants less affected side.
1460755|NCT03268785|Diagnostic Test|Intraoperative identification method|After needle pucture of suspicious nodes, Diff-quik staining was used to distinct lymph nodes and parathyroid glands. PTH test assay was used for parathyroid identification. Postoperative HE staining were applied as golden standard.
1460756|NCT03268772|Drug|PLD and IFO|PLD 30 mg/m2, d1, plus IFO 1.8 g/m2, d1-5
1460757|NCT03268759|Other|fMRI|Observation of neural markers of reward processing
1460758|NCT03268733|Drug|Folic Acid|Tablet 5 mg
1460759|NCT03268720|Other|FODMAP low diet|2 week FODMAP low diet
1460760|NCT03268720|Other|gluten-free diet|2 week gluten-free diet
1460761|NCT03268707|Device|Telemetric smartphone application|Structured follow up with a telemetric smartphone application
1460762|NCT03268707|Other|Conventional follow up|Conventional follow up at physician practice
1460763|NCT03268694|Behavioral|Working Memory Task|"Sternberg Task Items, which can be visually presented alphabets, shapes or numbers or sound tones presented through speakers, will be presented to the participant. The participant will need to maintain the presented items in their memory and indicate, when a single probe item is presented, whether the probe item was present in the immediately preceding list by pressing a key on the keyboard.
N-Back Task Items are presented continuously sequentially and participants are instructed to indicate whether items are repeated n items before by pressing a key on the keyboard. The task is divided into blocks of 0,1,2,3 -back trials based on the 'n'. For example in the 2 - back task, the participant has to indicate if the item presented 2 items before matches the current item. Similar to the previous task, the items can be presented visually or auditorily."
1460764|NCT03268694|Behavioral|Reward Learning Task|Two abstract visual stimuli are presented on the screen and participant is asked to choose one. Unknown to the participant, each stimulus is associated with distinct probabilities of virtual reward such that one stimulus is associated with net gain while the other is associated with net loss. The participant's goal is to maximize the reward. Once the participant identifies the stimulus associated with net gain, the reward probabilities are reversed. This process is repeated 5 times.
1460765|NCT03268694|Behavioral|Facial Emotion Recognition Task|On a given trial, participants will be presented with images of two faces side-by-side. The faces will either match in terms of emotion category (e.g., 2 anger faces) or not (e.g., an anger face and a fear face). Faces presented together will always be of the same gender but different identities. Participants will be asked to determine whether the two faces presented depict the same emotion category.
1460766|NCT03268668|Other|Collection of thrombus that is responsible for stroke and blood sample|"A blood sample (venous or arterial) of 10 ml will be made, on ethylene Diamine Tetra-Acetic (EDTA) tube (5 ml) and citrate (5 ml).Thrombus resulting from thrombectomy will be collected at the end of the procedure. The samples will be transferred to a biobank. Treatment efficacy, etiology and prognosis of patients will be assessed using the following criteria :
A) TOAST score (etiology) B) TICI score (status of final recanalization) C) Extravasation of contrast agent on post-intervention CT (rupture of the blood-brain barrier :yes/no) D) Symptomatic haemorrhagic transformation corresponding to an increase > 4 of the NIHSS score due to a haemorrhagic transformation identified on brain imaging 24 hours after stroke E) Decreased NIHSS score by 8 points or NIHSS score = 0 24 hours after stroke (improved neurological status: yes/no) F) Modified RANKIN score (mRS) measured at 3 months evaluating neurological prognosis"
1460768|NCT03268629|Behavioral|Joyful Sleep|"The proposed Joyful Sleep program will be conducted weekly, 2 hours per session, 8 sessions, group-based program in mindfulness."
1460769|NCT03268629|Behavioral|CBT-I|The CBT-I program was delivered to groups of 6 to 10 individuals over the course of eight, weekly, 90-minute sessions, for a total of 12 contact hours.
1460800|NCT03268382|Drug|Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion
1460770|NCT03268616|Device|inspiratory threshold load device and NPPV|"before experiment ,every subject use a flanged mouthpiece attached to a manually operated occlusion valve in order to measure maximal inspiratory pressure (MIP)at functional residual capacity .
healthy subjects:increase the pressure in a water-sealed inspiratory threshold loading device in order to increase the neural respiratory drive.
COPD patients:increase the pressure in a non-invasive positive pressure ventilation in order to decrease the neural respiratory drive"
1460771|NCT03268603|Drug|Autologous Adipose-derived Mesenchymal Stromal Cells|The investigational product consists of autologous adipose-derived Mesenchymal Stromal Cells (MSCs), suspended in 5-10 mL Lactated Ringer's. The MSC are provided in a sterile syringe labelled with appropriate patient and product identifiers ready for intrathecal injection.
1460772|NCT03268590|Drug|Oxygen|Persons will undergo MRI, EEG, and complete computerized cognitive testing in baseline room air. Persons will then breathe 100% pure oxygen and undergo MRI, EEG, and complete computerized cognitive testing. Persons will serve as their own controls.
1460773|NCT03268577|Other|Internet-Based Intervention|Complete ASA24
1460774|NCT03268577|Other|Internet-Based Intervention|Complete ACT24 reporting
1460775|NCT03268577|Device|Monitoring Device|Wear accelerometer and inclinometer physical activity monitors
1460776|NCT03268577|Other|Questionnaire Administration|Ancillary studies
1460777|NCT03268564|Behavioral|HIVST-online promotion|"Health promotion for those who are not users of previous HIVST-online services (i.e. not re-testers):
Viewing a promotion video and a demonstration video
Brief motivational interviewing through telephone
Visiting the HIVST-online webpage
Receiving a free self-testing kit and follow-up reminders
Health promotion for re-testers:
Viewing a promotion video and a demonstration video
Visiting the HIVST-online webpage
Receiving a free self-testing kit and follow-up reminders"
1460778|NCT03268525|Drug|Marcaine 0.5 % Injectable Solution|Local infiltration by Marcaine 0.5% Injectable Solution prior to incision
1460779|NCT03268525|Drug|Sodium Chloride 0.9%|Local infiltration by Sodium Chloride 0.9% prior to incision
1460780|NCT03268512|Other|L-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
1460781|NCT03268512|Other|A-PRF|"Platelet concentrates are produced from a small peripheral blood sample, which is immediately centrifuged without any anticoagulant. Coagulation starts during the centrifugation, and three layers are obtained: red blood corpuscles (RBCs) at the bottom of the tube, platelet-poor plasma (PPP) on the top and an intermediate layer called buffy coat where most platelets and leucocytes are concentrated. L-PRF has potential advantages, namely: it creates a bioactive construct that stimulates the local environment for differentiation and proliferation of stem and progenitor cells and it acts as an immune regulation node with inflammation control abilities, such as slow continuous release of growth factors over a period of 7-14 days."
1460782|NCT03268499|Drug|Cisplatin|The procedure of TACE is the same irrespective of which regimen is used.
1460785|NCT03268460|Diagnostic Test|Arterial blood gases|blood PH, HCO3
1460786|NCT03268460|Diagnostic Test|Blood anion gap|(Na+) - (Cl- + HCO3-)
1460787|NCT03268460|Diagnostic Test|serum electrolytes|Na+ , K+ , Cl- and calcium
1460788|NCT03268460|Diagnostic Test|renal function test|blood urea and serum creatinine
1460789|NCT03268460|Diagnostic Test|urine analysis|urine PH, specific gravity, aminoaciduria, glycosuria, phospaturia and 24 hr urine calcium
1460790|NCT03268447|Dietary Supplement|Lactobacillus plantarum P8|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
1460791|NCT03268447|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus plantarum P8 for brain health benefits primarily to alleviate stress, among adults in Malaysia aged from 18-60 years.
1460792|NCT03268434|Behavioral|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); once a week over a period of 8 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
1460793|NCT03268434|Behavioral|Cognitive remediation|A computerized cognitive remediation program that covers several cognitive domains, such as attention, visuomotor skills, and Memory. The difficulty level adapts automatically to the performance level of each patient. At the end of each session, the patient receives individual feedback on his or her performance; 8 sessions (60min), once a week over a period of 8 weeks
1460794|NCT03268421|Behavioral|Fibromyalgia Integrative Training for Teens|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
1460795|NCT03268421|Behavioral|Cognitive Behavioral Therapy|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
1460796|NCT03268421|Behavioral|Graded Aerobic Exercise|This intervention will consist of 16 in-person group-based sessions held twice per week over 8 weeks. Sessions last 90 minutes and will be led jointly by a psychologist/therapist and exercise trainer using manualized protocols.
1460797|NCT03268408|Behavioral|Baby Newsletter|eight newsletters sent home to newborns' parents with advices and recommendations on child care and development
1460798|NCT03268395|Diagnostic Test|Arterial Blood Gas and Transcutaneous CO2 Monitor|Each patient will receive both an arterial blood gas and a transcutaneous CO2 monitor test.
1460805|NCT03268304|Other|VR-based training including AO and MI|Virtual Reality-based training intervention including Action Observation and Motor Imagery using the YouGrabber® training device
1460806|NCT03268291|Other|Standard outpatient observation|Outpatient management according to Ministry of health standards
1460807|NCT03268291|Behavioral|"Communicational program Trust"|"The developed program is based on the experience of international research studies and includes the following sections:
daily seminars with patients going to be discharged about the benefits of adherence to therapy; distribution of printed materials; service for the regular informing of the patients which is motivating to remain adherence to medications by automated contact management systems (SMS, e-mail), as well as calls from contact center operators; questioning of participants of the program for general adherence to therapy, reasons for refusal, change of therapy / drug, complaints and other. The questioning is carried out through telephone interviewing by contact center operators and automatic collection of electronic forms through aggregator services."
1460808|NCT03268278|Drug|Buprenorphine|Buprenorphine plus local anesthetic
1460809|NCT03268278|Drug|Sterile saline|Placebo 1,8 ml
1460810|NCT03268278|Drug|lidocaine, epinephrine (Local anesthetic)|2% lidocaine 1:100,000 epinephrine
1460811|NCT03268239|Device|Additional MRI sequences|"Due to the participation in the study, the following sequences are added to the imaging protocol:
3D T1 GRE after injection (Gradient-Recalled Echo)
3D T1 TSE before injection (Turbo Spin Echo)
3D fGATIR PSIR after injection (fast Gray Matter Acquisition T1 Inversion Recovery Phase-Sensitive Inversion Recovery)
Sequences will be performed in a random order to avoid the bias induced by different time intervals between injection and acquisition."
1460812|NCT03268226|Drug|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|An inhaled dose of CHF 5993 pMDI 100+6+12.5 μg twice a day (Total daily dose: BDP 400 μg / FF 24 μg / GB 50 μg)
1460813|NCT03268213|Biological|Fecal Microbial transplant|
1460814|NCT03268200|Other|segmental reexamination|segmental reexamination during colonoscopy
1460815|NCT03268187|Device|Biofeedback|The skin conductance of the patient is measured and fed back to the patient via screen.
1460816|NCT03268187|Behavioral|Self-Alert Training|Self-Alert Training
1460817|NCT03268187|Behavioral|Relaxation Training|Relaxation Training
1460818|NCT03268174|Other|AO+Mist|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.
Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:
LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.
RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
1460819|NCT03268174|Other|Placebo|"Subjects receive 2 bottles of product at the Baseline visit for left and right side application. One bottle will contain Placebo only, the other bottle will contain AO+Mist.
Label on each bottle will indicate the arm the product is to be applied to. Subjects will be instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:
LEFT arm where skin is affected: 4 pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days.
RIGHT arm where skin is affected: 4pumps of Spray which is labeled accordingly must be applied twice-a-day to the area on the arm affected by AD- once in the morning and once in the evening for 30 days."
1460820|NCT03268161|Diagnostic Test|Mutational analysis of clonal B cells|"Mutational analysis based on medullary or blood samples stored in a bio-bank during routine lymphocyte phenotyping.
Mutations affecting MYD88 (MYD88 L265P mutation), CXCR4 (Whim-like CXCR4 mutation) loci are sought."
1460821|NCT03268148|Device|LaserPen|low level laser is used before heel-lancing for newborn screening
1460822|NCT03268135|Diagnostic Test|measurement of RNAs|
1460823|NCT03268122|Other|Standard Contact Isolation|With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patent has an infection or colonization with MRSA or VRE or a recent history (within 90 days) of either
1460824|NCT03268122|Other|Targeted Contact Isolation|"With regards to MRSA and VRE, the wearing of gowns and gloves will be required for all staff entering a patient room if the patient has an active, highly-transmissible infection with MRSA and/or VRE.
A highly-transmissible infection is defined as one with uncontained secretions or excretions (diarrhea, vomiting, or open draining wounds) or pneumonia."
1460825|NCT03268109|Other|assessment of cognitive impairment|Measure of Global Deficit Score
1460826|NCT03268096|Device|Cerebral MRI and Optical Coherence Tomography|Clinical and paraclinical assessment (cerebral MRI and Optical Coherence Tomography) will be carried out on the same day. Paraclinical evaluation consists in the realization of additional MRI sequences in order to obtain more precise information on brain lesions (unconventional parameters). An optical coherence tomography will also be performed for both eyes to describe the thickness of the different layers of the retina.
1460827|NCT03268083|Biological|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
1460828|NCT03268083|Biological|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AI(OH)3] per dose)|Two vaccinations at 28 days apart
1460829|NCT03268083|Biological|EV71 vaccine ([1 μg total protein ] per dose)|Two vaccinations at 28 days apart
1460859|NCT03267901|Other|food|45 g of walnut / iso-caloric white bread
1460860|NCT03267888|Biological|Pembrolizumab|Given 200 mg/kg IV.
1948006|NCT02879708|Other|Information and Facilitation|In addition to the information interventions described above, this intervention will provide trained facilitators to help community members engage in a participatory process with VHSNCs and identify key deficiencies for improvement in health services that most concern community members. The facilitators are trained to help organize meetings and are provided a detailed checklist of activities to be undertaken prior to the the meetings. The three key health workers at the village level (ASHA, ANM, and AWW) report to the local (village level) elected representatives and block level authorities, who receive feedback from the community in the accountability interventions.
1460836|NCT03268044|Other|Hospital admission and surgery|Hospital admission and noncardiac surgery
1460837|NCT03268031|Diagnostic Test|Visual field test|Visual field test and OCT are commonly used essential tests to make accurate diagnosis of glaucoma.
1460838|NCT03268018|Device|Laser induced pressure wave calcium modification|A calcium atherectomy and modification solution in patients with balloon resistant calcified lesions in infrainguinal disease. The intent is to both debulk and modify the vessel to restore blood flow, improve vessel compliance and drive better outcomes
1460843|NCT03267992|Behavioral|COPD Co-Pilot AIR app|App. For COPD symptoms after Coil procedure
1460844|NCT03267979|Other|Video-pupillometer|Video-pupillometer will be performed. In this study data will be collected and analyzed.
1460845|NCT03267979|Other|Electrocardiogram|Electrocardiogram will be performed. In this study data will be collected and analyzed.
1460846|NCT03267966|Diagnostic Test|Standardized method of pathological evaluation|PD specimen is evaluated according a standardized method of pathological evaluation, that includes: 1) multicolor inking; 2) axial slicing; 3) clearance definition of 1 mm
1460847|NCT03267953|Behavioral|My Health CheckUp Online Stress Management Program|Self-contained, web-based, stress management program developed by team of health care professionals, designed to encourage patients to learn evidence-based cognitive and behavioural strategies to effectively manage stress. Health risk appraisals include evidence-based recommendations to address risks. Stress management modules include education about the impact of stress, self-monitoring through a stress diary, and using four key strategies: physical activity, deep breathing and relaxation, problem-solving/addressing negative thoughts, and sleep hygiene. Through the modules, patients will learn new stress management strategies and have an opportunity to practice these, track their progress, and obtain feedback via the website. To facilitate self-monitoring of stress levels and tracking of strategies such as physical activity, tracking tools can be used on mobile devices.
1460848|NCT03267953|Behavioral|Lay telephone coaching|The goal of telephone coaching will be to provide brief encouragement on how to use the modules; however, no formal therapy will be provided. Sessions will range between 10-15 minutes. Each coach session will follow the process outlined by the GROW model, which stands for Goal, Reality, Options/Obstacles, and Will/Way forward. The sessions will start with the coach and participant agreeing on the topics for discussion and desired outcomes (goal). Then, coaches will explore the use of the intervention over the previous week, guide participants through the modules, identify barriers to using these modules, offer advice to overcome these barriers, and provide positive reinforcement. The development of an action plan for the following week will conclude each session. The short Perceived Stress Scale will be used at the end of each session to monitor progress. A script will guide the lay coach through each call.
1460849|NCT03267953|Behavioral|Motivational interviewing (telephone)|Sessions will range from 30 to 45 minutes. The goal of MI is to strengthen patients' motivation and confidence for adopting the stress management strategies suggested. The MI practitioner's interventions are based on the four processes of MI: Engaging, Focusing, Evoking, and Planning.
1460850|NCT03267940|Drug|PEGylated Recombinant Human Hyaluronidase|3.0 µg/kg PEGylated Recombinant Human Hyaluronidase (PEGPH20) will be administered by IV infusion on Days 1, 8, and 15 of each 21-day cycle in both the Run-in Portion and Expansion Portion.
1460851|NCT03267940|Drug|Cisplatin|25 mg/m^2 of CIS will be administered by IV infusion on Days 2 and 9 of each 21-day cycle in the Run-in Portion, and Days 1 and 8 of each 21-day cycle in the Expansion Portion.
1460852|NCT03267940|Drug|Gemcitabine|1000 mg/m^2 GEM will be administered by IV infusion on Days 2 and 9 of each 21-day cycle in the Run-in Portion, and Days 1 and 8 of each 21-day cycle in the Expansion Portion.
1460853|NCT03267940|Drug|Atezolizumab|1200 mg atezolizumab will be administered by IV infusion 1 to 3 hours after PEGPH20 on Day 1 of each 21-day cycle in both the Run-in Portion and Expansion Portion.
1460857|NCT03267914|Other|Tray|Control intervention Patients will use the custom-made tray to apply the fluoride locally to the teeth and wear for 5 minutes each day.
1460858|NCT03267914|Other|Brush|Patients will brush with the fluoride for 2 minutes each day.
1460861|NCT03267888|Radiation|Radiation Therapy|Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.
1460862|NCT03267875|Procedure|Blood Test|draw out 2 blood tubes from a patient
1460863|NCT03267862|Other|there was no intervention|patients were observed during routine care on separate times when their eye pressure was different on one day from another.
1460864|NCT03267849|Other|drinking 2 bottles of tap water|Two images will be compared in each subject at two different eye pressures with the higher pressure having been produced by the intervention of drinking 2 bottles of water
1460865|NCT03267836|Drug|Avelumab|-10mg/kg IV
1460866|NCT03267836|Radiation|Proton Therapy|-Proton therapy will start concurrently with the first dose of avelumab (up to 3 days before or after is permissible) and will be administered once daily during weekdays (Monday through Friday).
1460867|NCT03267836|Procedure|Surgery|-Standard of care
1460868|NCT03267823|Diagnostic Test|International Normal Ratio (INR)|Blood test for INR using laboratory and point of care methods
1460869|NCT03267810|Device|TENS|TENS 7000
1460870|NCT03267810|Other|Sham TENS|Inactive electrodes
1460871|NCT03267797|Drug|lymphocytes|Lymphocytes will injected into the endometrium two days before embryo transfer (ET).
1460873|NCT03267771|Drug|Progesterone Suppositories Vaginal|progesterone vaginal suppository
1460874|NCT03267771|Drug|Dydrogesterone Oral Tablet|oral progesterone drug
1460875|NCT03267771|Device|doppler ultrasound|pulsed doppler ultrasound
1460876|NCT03267758|Dietary Supplement|Goodbelly first|Consumption of 1 serving of Goodbelly probiotic daily for 6 weeks. This will be followed by an observation period for 6 weeks during which the subjects will not consume Goodbelly.
1460877|NCT03267758|Dietary Supplement|observation first|Observation for the first 6 weeks during which time the subjects will not consume Goodbelly. During weeks 6-12 of the study, following the observation period, the subjects will consume Goodbelly for 6 weeks.
1460878|NCT03267745|Dietary Supplement|Amino Acid|5.97 g amino acid 3 times daily for 28 days
1460879|NCT03267745|Device|Breg Brace single-leg immobilization|7 days of single leg immobilization; randomized to leg; knee brace will be worn in a fixed flexion position at 140°.
1460880|NCT03267745|Other|Placebo|5.75 g of placebo (Maltodextrin) 3 times daily for 28 days
1460882|NCT03267719|Device|laser therapy|Transvaginal erbium-laser treatment
1460883|NCT03267706|Other|Palliative Care Comprehensive Tool|Clinicians assigned to the newly developed Palliative Care Comprehensive Tool will be trained during a 1 hour period on the application of the tool; Including rationale for tool development, objective of the tool and demonstration of the tool in action
1460884|NCT03267693|Diagnostic Test|Gastric and oropharyngeal PH|measurement of gastric and oropharyngeal PH and their relation to respiratory and gastrointestinal complication in mechanically ventilated patients
1460885|NCT03267680|Drug|Cyclophosphamide|Given IV
1460886|NCT03267680|Drug|Indomethacin|Given PO
1460887|NCT03267680|Biological|IRX-2|Given via submucosal injection or SC
1460888|NCT03267680|Other|Laboratory Biomarker Analysis|Correlative studies
1460889|NCT03267680|Dietary Supplement|Multivitamin|Given zinc-containing multivitamin PO
1460890|NCT03267680|Drug|Omeprazole|Given PO
1460891|NCT03267680|Other|Placebo|Given via submucosal injections or SC
1460892|NCT03267680|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
1460893|NCT03267667|Diagnostic Test|2D Echocardiography and cardiac MRI|imaging of right ventricle by both modalities to assess right ventricle function accurately
1460894|NCT03267654|Drug|gefitinib combined with chemotherapy|"Gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours until disease progression, intolerable toxicity or patient withdraw ICF.
Pemetrexed (500mg/m²day 1 intravenously) plus carboplatin (AUC=5,day 1,intravenously) every 21 days. Every 3 weeks is a chemotherapy cycle, and 4 chemotherapy cycles is maximum limit."
1460895|NCT03267654|Drug|gefitinib combined with apatinib|"gefitinib 250mg, p.o., q.d., continuous regimens on an empty stomach or after meal for 2 hours.
Apatinib 250mg, p.o., q.d. per 21 days. until disease progression, intolerable toxicity, patient withdraw ICF or death."
1460896|NCT03267654|Drug|gefitinib single agent|Patients received Gefitinib 250mg q.d. orally until disease progression, intolerable toxicity or death.
1460897|NCT03267628|Procedure|Intrathecal morphine as well as local anaesthetic in Blocks|A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle. 150mcg morphine will be added to the spinal anaesthetic.
1460898|NCT03267628|Procedure|Intrathecal morphine as well as saline in Block|150mcg morphine will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
1460899|NCT03267628|Procedure|Saline intrathecal as well as saline in Blocks|0.3 ml saline will be added to the spinal anaesthetic. 25 ml saline will be used on each side during a quadratus lumborum type 2 block.
1460900|NCT03267628|Procedure|Saline intrathecal as well as local anaesthetic in Blocks|0.3 ml saline will be added to the spinal anaesthetic. A Quadratus lumborum type 2 block will be performed under ultrasound with 25 ml 0.375% ropivacaine deposited posterior to the quadratus lumborum muscle.
1460901|NCT03267602|Device|CPAP|"If following patients are suffering from sleep apnea and agree to receive treatment,
older than 18 years, AHI> 15 and present obvious symptoms or
less than 18 years, AHI still> 5 after tonsillectomy and present obvious symptoms.
Investigators will process CPAP treatment for 3 months, and do neuropsychological assessment and sleep examination after treatment for 6 months."
1460902|NCT03267589|Drug|Durvalumab, Tremelilumab, MEDI 9447, MEDI 0562|Three different combination are being tested. Each cohort has different combination
1520527|NCT02813135|Drug|Everolimus|
1460906|NCT03267563|Behavioral|EIAU|Enhanced implementation as usual consists of initial training and problem-solving plus planning for sustainment,
1460907|NCT03267563|Behavioral|LICF|"Enhanced implementation plus low intensity will have received initial training and problem-solving plus planning for sustainment and after that every 3 months will receive one clinical and one operational telephone booster meeting."
1460908|NCT03267563|Behavioral|HICF|Enhanced implementation plus high intensity will receive will receive everything that the clinics in LICF receive, but at a higher intensity.
1460909|NCT03267550|Device|SceneRay wireless and remote DBS system|Implement therapeutic programming in patients with network coverage at home
1460910|NCT03267537|Behavioral|Telemedicine CBT-I|Will be administered in a manner similar to the conventional CBT-I arm except that the patient would not be required to make office visits
1460911|NCT03267537|Behavioral|Conventional office-based CBT-I|Conventional office-based CBT-I
1460912|NCT03267524|Behavioral|Exercise Intervention|Receive Walking for Recovery from Surgery rehabilitation intervention
1460913|NCT03267524|Other|Quality-of-Life Assessment|Ancillary studies
1460914|NCT03267524|Other|Survey Administration|Ancillary studies
1460915|NCT03267511|Other|5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 0.5% spherical silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
1460916|NCT03267511|Other|5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 1% spherical silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
1460917|NCT03267511|Other|5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2542% NaF dentifrice with 6% abrasive silica and brush twice daily (morning and evening) for one timed minute (in their usual manner).
1460918|NCT03267511|Other|5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP|Participants will be instructed to apply a full brush head of their dentifrice containing 5% KNO3 / 0.2543% NaF dentifrice with 16% abrasive silica and 5% STP and brush twice daily (morning and evening) for one timed minute (in their usual manner).
1460922|NCT03267485|Device|real time PCR|Real Time PCR is based on the detection of the fluorescence produced by a reporter molecule which increases, as the reaction proceeds. These fluorescent reporter molecules include dyes that bind to the double-stranded DNA or sequence specific probes . Moreover, there is no need for the post PCR processing which saves the resources and the time. .
1460923|NCT03267459|Device|Dynamic contrast-enhanced MRI|Dynamic contrast-enhanced perfusion sequences added to MRI examination performed at the beginning of intra arterial chemotherapy.
1460924|NCT03267446|Device|3D Doppler Ultrasound|3D volumes will be obtained in automatic sweeps using a motorized curved-array transducer while the women held their breath. In order to interpret the data consistently, the settings of power, On Voluson E10; GE Medical Systems)
1460925|NCT03267433|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo HCT
1460926|NCT03267433|Other|Laboratory Biomarker Analysis|Correlative studies
1460927|NCT03267433|Biological|Rituximab|Given IV
1460928|NCT03267420|Diagnostic Test|BpTRU First, Unattended Omron Second|"Visit 1: The participants will have the oscillometric device, BpTRU applied to their arm with the higher blood pressure. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended readings. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.
Visit 2: Upon returning the 24 hour ABPM device, the patient will have their blood pressure measured with an unattended Omron second. The Omron HEM 907XL will be applied to the same arm that the BpTRU was applied to in the first visit. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted."
1460929|NCT03267420|Diagnostic Test|Unattended Omron First, BpTRU Second|"Visit 1: The participants will have the Omron HEM 907XL will be applied to their arm with the higher blood pressure. There will be 5 minutes of quiet rest (participant alone) and three readings subsequently while the patient is still alone with the average blood pressure measurement being noted.This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.
Visit 2: Upon returning the 24 hour ABPM device, the participants will have the oscillometric device, BpTRU applied to the same arm that the Omron HEM 907 XL was applied to in the first visit. This will allow assessment with the commonest used Canadian device, which provides an average after 5 unattended blood pressure readings."
1460930|NCT03267420|Diagnostic Test|Partially Attended Omron First, Unattended Omron Second|"Visit 1: The participant will have the Omron HEM 907 XL applied to the arm with the higher blood pressure. There will be five minutes of quiet rest (patient alone) and three reading subsequently, but with the nurse entering the room (i.e., partially attended), with the average being noted. This assessment will be followed by the participant wearing a 24 hour ambulatory blood pressure monitor (ABPM) for 24 hours.
Visit 2: Upon returning 24 hour ABPM device, the participant will have the Omron HEM 907 XL applied to same arm that was used during the first visit. There will be five minutes of quiet rest (patient alone) and three readings subsequently (patient still alone) with the average blood pressure measurement being noted."
1460931|NCT03267407|Other|Preemptive high-dose Fluconazole|Patients with advanced HIV diseases are screened for Cryptococcal Antigen using LFA CrAg tests. Then patients with CrAg positivity and without meningitis are given preemptive high-dose fluconazole to prevent the development of cryptococcal meningitis, which is one of the leading cause of death among immunocompromized patients.
1460932|NCT03267381|Other|Blood draw (before surgery)|Blood will be drawn before surgery
1460933|NCT03267381|Other|Blood draw (every 3 months)|Blood will be drawn every 3 months
1460934|NCT03267381|Other|Blood draw (at diagnosis)|Blood will be drawn at time of diagnosis
1520528|NCT02813135|Drug|AZD1775|
1460935|NCT03267368|Behavioral|Comprehensive Care Program|Pulmonary rehabilitation and smoking cessation
1460936|NCT03267355|Device|Endoscopic Ultrasound|Indication of EUS
1460937|NCT03267342|Behavioral|One-on-one financial counseling|Clients will be given access to one-on-one financial counseling, provided by trained peer specialists, initially working under the guidance of the project director. The Consumer Financial Protection Bureau's Your Money, Your Goals: Financial Empowerment Toolkit for Social Services Programs (21) will be used as a reference during counseling sessions, with a view to developing a manual based on clients' existing experiences and coping strategies, such that the desired behavior change is manageable, realistic, and based on real-life possibilities rather than idealized circumstances which may be far from the reality of people's lives. Counseling will in all cases be responsive to clients' particular needs and concerns, rather than following a predetermined sequence.
1460938|NCT03267342|Behavioral|Peer support groups|Support groups, facilitated by peer specialists and guided initially by the project director, will be offered for clients interested in specific financial issues such as budgeting, managing benefits, wise spending, planning and saving. The peer support groups will focus on enabling clients to share their own experiences with finances.
1460939|NCT03267342|Behavioral|Supported access to mainstream banking services|Interested clients will be helped to open bank accounts at banks of their choice, and to manage associated tools such as ATM cards and online bill pay. Clients will also be advised regarding use of non-bank financial products such as prepaid cards and check cashers. Representatives from both bank and non-bank providers will be invited to come in and talk with clients about the services they offer, and clients will also be invited to visit the facilities to be guided around the available services.
1460940|NCT03267342|Behavioral|A savings program|Clients will have the option of joining a savings club, which will combine group meetings, facilitated by a peer specialist under the initial guidance of the project director, and regular savings deposits towards specified goals. Clients will be offered a limited savings match as an incentive to achieve their savings goal (for example, the savings club will offer a 50% match on any money saved within a specified time period towards a specific goal, up to a maximum of a $100 match).
1460941|NCT03267329|Drug|Duowell®|telmisartan 80mg/rosuvastatin 10mg for ASCVD risk=5%~7.5% or telmisartan 80mg/rosuvastatin 20mg for ASCVD risk≥7.5%
1460942|NCT03267329|Drug|Telmisartan|telmisartan 80mg
1460945|NCT03267303|Drug|TS-091 5mg|Orally taken once daily for 3 weeks
1460946|NCT03267303|Drug|TS-091 10mg|Orally taken once daily for 3 weeks
1460947|NCT03267303|Drug|Placebo|Orally taken once daily for 3 weeks
1460948|NCT03267290|Diagnostic Test|Sonazoid- CEUS, CEMRI, CECT|Sonazoid- CEUS+CEMRI in a characterization of HCC, in comparison with CECT+CEMRI.
1460950|NCT03267264|Device|BD Nano™ vs Nucleus|"Subjects will be randomized to
Nucleus pen needle for the first 15-day period, or current pen needle (BD Nano™) for the second 15-day period or
subject's current pen needle (BD Nano™) for the first 15-day period, Nucleus pen needle for the second 15-day period"
1460951|NCT03267264|Device|NovoFine® vs Nucleus|"Subjects will be randomized to
Nucleus pen needle for the first 15-day period, or current pen needle (NovoFine®) for the second 15-day period or
subject's current pen needle (NovoFine®) for the first 15-day period, Nucleus pen needle for the second 15-day period"
1460952|NCT03267264|Device|NovoTwist®/NovoFine® Plus vs Nucleus|"Subjects will be randomized to
Nucleus pen needle for the first 15-day period, or current pen needle (NovoTwist®/NovoFine Plus®) for the second 15-day period or
subject's current pen needle (NovoTwis®t/NovoFine® Plus) for the first 15-day period, Nucleus pen needle for the second 15-day period"
1460953|NCT03267264|Device|Other Commercially Available Pen Needles (Unifine® Pentips®/Mylife Clickfine®) vs Nucleus|"Subjects will be randomized to
Nucleus pen needle for the first 15-day period, or current pen needle (Other Commercially Available Pen Needles) for the second 15-day period or
subject's current pen needle (Other Commercially Available Pen Needles) for the first 15-day period, Nucleus pen needle for the second 15-day period"
1460954|NCT03267251|Other|Vacteens Web app for mobile devices|The Web app provides parents of young adolescent girls (ages 11-14) accurate information about HPV Vaccination, and a number of tools to aid informed decision making.
1460955|NCT03267251|Other|Standard Usual and Customary HPV Information - CDC pamphlet|The usual communication about HPV Vaccination in clinics is for parents to be issued the CDC pamphlet on HPV Vaccination.
1460956|NCT03267238|Biological|Fecal Microbial Transplantation|Fecal Microbial Transplantation via will be offered to eligible Crohn's patient
1460957|NCT03267212|Device|Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
1460958|NCT03267212|Device|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
1460959|NCT03267212|Other|Functional Electrical Stimulation Row Training (FESRT)|FESRT couples volitional arm and electrically controlled leg exercise to allow whole body exercise training
1460960|NCT03267199|Drug|Thrombolytic|Thrombolytic therapy
1460961|NCT03267199|Procedure|Primary PCI|Primary percutaneous coronary intervention
1460962|NCT03267199|Diagnostic Test|Complete blood count|Blood sample for complete blood count
1460963|NCT03267199|Diagnostic Test|Platelet function test|Blood sample for platelet function test
1460964|NCT03267199|Diagnostic Test|ECG|Electrocardiogram
1460967|NCT03267173|Drug|Chimeric antigen receptor T cell|Evaluate the efficacy and safety of targeted Mesothelin/PSCA/CEA/HER2/MUC1/, EGFRvIII and other chimeric antigen receptor engineered T cell immunotherapy in the treatment of pancreatic cancer.
1460968|NCT03267160|Diagnostic Test|Hemodynamic parameters|Pulse contour cardiac output monitored heart contractility, end-diastolic volume parameters, and lung water parameters.
1460969|NCT03267147|Other|no intervention is given|no intervention is given
1460970|NCT03267121|Drug|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
1460971|NCT03267121|Drug|Tegafur Gimeracil Oteracil Potassium Capsules|20mg bid p.o. every day for 14 days as a cycle
1460972|NCT03267108|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide 30 mcg/kg IBW/hr for treatment randomization period (Day 0 to Week 8). Continued open label treatment is available following completion of randomized treatment period.
1460973|NCT03267108|Drug|Placebo|Placebo
1460974|NCT03267095|Behavioral|music therapy sessions .|In this intervention songs compose by the therapist will be use for the study. The songs included the target word .The target words will be selecte from functional vocabularies that typically developing 3years old children can use effectively in everyday interactions.The general criteria for vocabulary words included: names of familiar objects and persons, functional action words such as words for social control , and emotional words . Inherent musical structures structures and organized musical patterns in the songs will be provide .The patients will reflect on the music therapy activity as singing the song together.
1460975|NCT03267082|Other|Laparoscopic management of perforated appendicitis|"Insertion of Ports
Exposure of the Appendix
peritoneal toilet and aspiration of pus after abdominal exposure
Isolation of Mesoappendicular Artery
Clipping and Dividing of the Artery
Application of 3 x Endoloops
Division of the Appendix
Retrieval of the Appendix in an Endobag"
1460976|NCT03267069|Other|survey|surveys will be administered at inclusion and follow-ups
1460980|NCT03267030|Drug|GRASPA|Administration of 1-7 doses of 150 IU/kg IV infusion. (every 2 weeks for a maximum of 4 doses and every 6 weeks for maximum 3 doses).
1460981|NCT03267017|Other|posture changes|Following induction of general anesthesia and initiation of positive pressure ventilation, patients will be tilted 15 degrees head up for 5 minutes with positive end expiratory pressure of 8 cm H2O, and then 15 degrees head down for 5 minutes with positive end expiratory pressure of 3 cm H2O
1460982|NCT03267004|Device|Dietary Assessment of Meal A using images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal A in the laboratory
Meal A:
Turkey and Provolone Cheese Sandwich [whole wheat bread 52g(female & male), Turkey 70g(female) & 133g(male), Provolone cheese 23g(female & male), tomato 50g(female & male), lettuce 45g(female & male)]; Chicken and wild rice [chicken 98g(female & male), wild rice 71g(female) & 107g(male)]; chocolate chips cookies [44g(female) & 60.5g(male)]; potato chips [39g(female) & 52g(male)]."
1460983|NCT03267004|Device|Dietary Assessment of Meal B using Images taken by Sony Smarteyeglass|"Participant will be wearing Sony Smarteyeglass to record digital images while eating meal B in the laboratory
Meal B:
Ham & Cheddar cheese wrap [Tortilla 45g(female & male), Ham deli 76g(female) & 103g(male), cheddar cheese 21g(female) & 32g(male), Spring Mix 36g(female & male), Fat Free ranch dressing 29g(female & male)]; Pasta with broccoli and Alfredo sauce [Pasta 91g(female) & 121g(male), Broccoli 66g(female & male), Alfredo sauce 38g(female) & 50g(male)]; Chocolate Ice-cream [107g(female), 138g(male)]; Red seedless grapes [365g (female), 471g(male)]."
1460984|NCT03266991|Drug|Rifapentine|Treatment with weekly rifapentine and isoniazid as Directly Observed Therapy in 12 weeks
1460985|NCT03266991|Drug|Isoniazid|Treatment with daily isoniazid in 6 months
1460986|NCT03266965|Drug|Carbidopa|All subjects will receive a fixed dose of 50mg of Lodosyn twice daily.
1460987|NCT03266965|Dietary Supplement|L-Histidine|Sequential Dose Escalation of 250mg to 500mg to 1000mg twice daily.
1460988|NCT03266939|Drug|Lorcaserin|10 mg acute administration of lorcasein
1460989|NCT03266939|Drug|Placebo Oral Tablet|Placebo
1460990|NCT03266926|Drug|Bupivacaine|0.25% Bupivacaine with epinephrine will be applied to vaginal packing that is placed post vaginal reconstruction surgery.
1460991|NCT03266926|Drug|Premarin Vaginal cream|A Premarin vaginal cream will be used to coat the vaginal pack, prior to insertion in patients post vaginal reconstruction surgery.
1460992|NCT03266913|Drug|Probiotic|Probiotics drop
1460993|NCT03266900|Procedure|re-TURBT|2nd bladder biopsy within 4-6 weeks of initial biopsy
1460994|NCT03266900|Drug|6 weeks BCG instillation|standard 6 weeks of BCG induction
1460995|NCT03266861|Diagnostic Test|Exercise oximetry|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
1460996|NCT03266848|Diagnostic Test|Quantitative Magnetic Resonance Imaging|Radiological diagnosis
1460997|NCT03266835|Device|SoundBite™ Crossing System - Peripheral|SoundBite™ Crossing System consisting of the SoundBite™ Console and SoundBite™ Active Wire 18. The Investigator may use the SoundBite™ Active Wire during the procedure to cross the proximal aspect and/or to cross multiple lesions.
1460998|NCT03266822|Other|No intervention|Observational study
1460999|NCT03266796|Behavioral|goal setting process|goal setting process during the first consultation
1461000|NCT03266783|Drug|Apixaban|Refer to Apixaban group
1461001|NCT03266783|Drug|Rivaroxaban|Refer to Rivaroxaban group
1461002|NCT03266770|Device|RELIEF Stent|The RELIEF stent will be placed under cystoscopy. The stent with pusher will be placed over the guidewire and inserted. The pusher will be positioned, the guidewire will be removed, and the pusher will be retracted. The position of the stent will be confirmed by x-ray (C-arm).
1461003|NCT03266744|Diagnostic Test|Computerised Tomography|
1461004|NCT03266744|Diagnostic Test|Whole Body Magnetic Resonance Imaging|
1461005|NCT03266744|Diagnostic Test|Bone scan|
1461006|NCT03266731|Drug|Aspirin|evaluates the safety and efficacy of clopidogrel and aspirin as an alternative treatment in patients not eligible for recombinant tissue plasminogen activator or any other acute reperfusion therapy with acute ischemic stroke (AIS) and transient ischemic attack (TIA) within 24 hours of symptoms onset
1461007|NCT03266718|Behavioral|Physical Activity Intervention|To develop and test a couple-based physical activity intervention among cancer survivors and their partners
1520529|NCT02813135|Drug|Carboplatin|
1461010|NCT03266692|Biological|SEA-BCMA|B-cell maturation antigen (BCMA)-directed antibody
1461011|NCT03266679|Other|Metacognitive Reflection and Insight Therapy - Adapted|The intervention involves the following elements: setting an agenda, developing a therapeutic relationship, therapist transparency and insertion of therapist's mind, analysis of narrative episodes, problem definition, stimulating self-reflection and understanding of others, stimulating mastery, reflecting on therapeutic relationship, and client assessment of outcomes.
1461012|NCT03266666|Behavioral|WellnessRX Lifestyle Change Classes|Lifestyle change classes on nutrition, physical activity, and stress management.
1461013|NCT03266666|Other|Thrive Market Grocery Credits (4x$25 each)|Thrive Market is an online grocery service available nationwide. Participants will be provided with up to $100 on grocery credits.
1461014|NCT03266653|Drug|cytotoxic t-lymphocytes|EBV specific CTLs will be generated from HLA related matched and mismatched donors in a GMP facility and administered to the patient with refractory CTLs.
1461015|NCT03266640|Drug|viral specific cytotoxic t-lymphocytes|CMV specific CTLs will be collected from HLA matched or mismatched donors and manufactured in a GMP facility and administered to patients with refractory CMV infection.
1461016|NCT03266627|Drug|cytotoxic t-lymphocytes|adenovirus specific cytotoxic t-lymphocytes will be collected and manufactured from HLA matched related or HLA mis-matched related donors and administered to eligible patients with refractory adenovirus or PID.
1461017|NCT03266614|Behavioral|Recovery 4 Us|R4US is a social media program aimed at the enhancement of community participation and overall recovery of individuals with psychiatric disabilities.
1461018|NCT03266601|Drug|Recombinant Human Interferon α-2b Injection|Recombinant human interferon α-2b injection (Specifications: 1 million U/support or 3 million U/support, 2-8 ℃ dark storage and transportation) aerosol inhalation of 400,000 IU/kg, 1 time/day or 200,000 IU/kg, 2 times/day, used for 3 days, observed to the 4th day (until the 96th hour).
1461019|NCT03266601|Drug|Ribavirin|Ribavirin Spray, spray once every 4-5 hours, 1-2 times a spray, used for 3 days, observed to the 4th day(until the 96th hour ).
1461021|NCT03266575|Behavioral|Pulmonary Rehabilitation Exercise|Participants will undergo Pulmonary Rehabilitation exercise. Participants will perform endurance (treadmill or cycle ergometer), strength (weight resistance) and flexibility training twice a week for a period of an hour per session
1461022|NCT03266575|Behavioral|Home Based Exercise|Participants will undergo Home based exercise program consisting of strength and conditioning. Participants will perform REST for 10 minutes daily, increasing to 20 minutes daily, after the second week, in their home environment. The total duration of the intervention will be 12 weeks. Participants will be provided with pedometers, REST video and binder, with instructions on how to perform exercises, and resistance bands.
1461023|NCT03266562|Diagnostic Test|F-18 FES|Evaluate uptake of F-18 FES in breast tissue
1461024|NCT03266549|Procedure|botulinum toxin augmented surgery|bilateral 7.0-mm medial rectus muscle recessions, with augmentation with 1.25units of botulinum toxin in 1 muscle for patients with deviations of 65 to 70 PD, and 2.5 units (either 1.25 units in both muscles or 2.5 units in 1 muscle) for patients with deviations greater than 70 PD
1461025|NCT03266549|Procedure|conventional surgery|bilateral MR muscle recessions combined with unilateral or bilateral LR muscle resections (according to the standard correction tables )
1461027|NCT03266523|Other|Natural images in imaging waiting rooms|Standard environment for hospital imaging waiting rooms
1461028|NCT03266510|Other|Inspiratory muscle strength training|Subjects will perform inspiratory muscle strength training for 6 weeks.
1461029|NCT03266510|Other|Sham training|Subjects will perform sham training for 6 weeks.
1461030|NCT03266484|Dietary Supplement|Probiotic Mixture|The probiotic supplement contains 8 different strains of bacteria and participants will be dosed in two dosages per a total of 40 billion bacteria daily.
1461031|NCT03266484|Dietary Supplement|Placebo|A placebo which is identical to the probiotic mixture. Participants will be dosed in two dosages daily.
1461037|NCT03266458|Procedure|Primary percutaneous coronary intervention|Urgent percutaneous coronary intervention for ST- elevation myocardial infarction patients.
1461038|NCT03266445|Drug|buprenorphine/naloxone|The intervention will be to either continue taking buprenorphine/naloxone or to have the medication held perioperatively.
1461039|NCT03266432|Other|blood samples|three blood samples : first one pre intervention and the other two blood samples post-intervention
1461040|NCT03266419|Drug|Deep NMB using rocuronium|"Drug: rocuronium
Bolus dose: 0.7 mg/kg
Continuous infusion : 0.8-1.2 mg/kg/h for maintaining deep NMB (post tetanic count 1-2) during operation."
1463193|NCT03249363|Procedure|Group A - Pulsed PVP-I Irrigation|
1461041|NCT03266419|Drug|Moderate NMB using rocuronium|"Drug: rocuronium
Bolus dose: none
Continuous infusion: 0.4-0.6 mg/kg/h for maintaining moderate NMB (train of four 1-2) during operation."
1461042|NCT03266406|Drug|Hyaluronidase|4ml of retrobulbar LA with addition of 15IU/ml hyaluronidase to 2% lidocaine
1461043|NCT03266393|Drug|Envarsus XR|Once daily sustained-release tacrolimus
1461044|NCT03266393|Drug|Tacrolimus|Twice daily immediate-release tacrolimus
1461045|NCT03266380|Diagnostic Test|observational|All patients do an emergency brain computed tomography scan. Intracranial hypertension is treated with mannitol with or without a craniotomy. A third generation cephalosporin (ceftriaxone) and metronidazole are administered as antibiotic prophylaxis for accompanying wound injuries (skin and soft tissue). VAP preventive strategies that are performed in the ICU include daily interruption of sedation and a readiness to extubate assessment, early facilitation of mobility, elevating the head of the bed to 30- 45 degree, change of the ventilator circuit if visibly soiled or malfunctioning, stress ulcer prophylaxis, residual gastric volume monitoring, early parenteral nutrition, and deep venous thrombosis prophylaxis. An infusion of midazolam and propofol is to be used for sedation.
1461046|NCT03266367|Diagnostic Test|Neutrophil gelatinase-associated lipocalin (NAGL)|Serum level of Neutrophil gelatinase-associated lipocalin (NAGL) using the enzyme linked immunosorbent assay kits (ELISA)
1461047|NCT03266354|Procedure|specular microscopy before and after Artisan PIOL|specular microscopy will be performed before and after implantation of the rigid Artisan iris-fixated pIOL to analyze the change in corneal endothelial cell count
1461048|NCT03266341|Diagnostic Test|Cultures|Take different samples anddetection of anaerobes on enriched blood agar and other selective anaerobic cultures
1461049|NCT03266328|Procedure|Primary Percutaneous Coronary Intervention (PPCI)|Percutaneous Coronary Intervention in patients of acute myocardial infarction diagnosed using ECG findings
1461050|NCT03266315|Biological|FloraBaby|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
1461051|NCT03266315|Other|Placebo|1 sachet will be added to a minimum of 1 mL of brest milk, sterile water or formula (in formula fed babies) once a day
1461052|NCT03266302|Device|hemoadsorber for removal of cytokines|Use of the hemoadsorber during cardiac surgery with CPB. Hemoadsorber is integrated into the CPB circuit according to manufacturer's recommendation.
1461053|NCT03266276|Other|PSOPC pathway approach|"The intervention will use a standardized PSOPC pathway approach, prompted follow up with patients and documentation.
Additionally, clinicians will be prompted to document conversations about response to emotional or physical ESAS symptom scores, symptom management plan (self/education/monitoring/medication), illness understanding; and, if necessary, an offer of PSO/PC referral."
1461054|NCT03266263|Device|automatic computer-led feedback|automated feedback software for CPR quality, including compression depth, rate, recoil, hands-off time, and ventilation volume
1461055|NCT03266263|Other|instructor-led feedback|feedback for CPR quality by instructors
1461056|NCT03266250|Procedure|spinal anesthesia|Transthoracic echocardiography of inferior vena cava before spinal anesthesia
1461057|NCT03266237|Drug|Vaxigrip®|To describe the humoral immune response to Vaxigrip (IM) vaccination at Day 0 (baseline) and Day 28 according to the age and frailty status at baseline (i.e. in each study group) for each Influenza strain.
1461058|NCT03266211|Other|Questionnaire Patients|Patient will have to answer a quiz which is about their vaccination against tetanus.
1461059|NCT03266211|Other|Questionnaire General practitioner|General practitioner will have to answer a quiz which is about their medical practice concerning vaccination against tetanus.
1461060|NCT03266198|Other|No intervention|No intervention
1461061|NCT03266185|Other|Shorter PICT|Shorter post-infusion cooling time
1461062|NCT03266172|Drug|GSK2982772 Modified Release (MR)|GSK2982772 MR will be available as prototype MR minitablet in capsules with unit dose strength of 60 mg in Part A. In Part B GSK2982772 MR with unit dose strength of 15, 30 or 60 mg will be administered by subjects. GSK2982772 MR will be administered orally with 240 mL of water.
1461063|NCT03266172|Drug|GSK2982772 Immediate Release (IR)|GSK2982772 IR tablet will be available with unit dose strength of 30 mg and the total dose administered by subjects will be 120 mg (4 tablets of dose strength 30 mg) orally with 240 mL of water.
1461064|NCT03266159|Drug|GSK525762 Besylate tablets|GSK525762 Besylate film coated tablets will be available as a 20 mg tablet strength, yellowish pink in color, round and biconvex with no markings. It will be administered with 240mL of liquid.
1461065|NCT03266159|Drug|Trametinib tablets|"Trametinib film coated tablets will be available as 0.5 mg and 2 mg dose strengths. Trametinib 0.5 mg will be yellow colored, modified oval, biconvex, tablets with 'GS' debossed on one face and 'TFC' on the opposing face.
Trametinib 2 mg will be pink colored, round, biconvex tablets with 'GS' debossed on one face and 'HMJ' on the opposing face. Doses will be taken at least 1 hour before or at least 2 hours after a meal."
1461066|NCT03266146|Drug|36 Weeks Methylprednisolone|Participants in 36 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 20 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 36 weeks. Follow-up duration is 24 weeks.
1461067|NCT03266146|Drug|48 weeks Methylprednisolone|Participants in 48 weeks of glucocorticoid treatment group will receive methylprednisolone, 48mg/d for the 1st week, 32mg/d for the 2nd week, 24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal. Participants in 36 weeks of glucocorticoid treatment group also will receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA).The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
1995040|NCT02868983|Other|Integration|"The intervention consists of training for practice leaders, BHCs, PCPs, and office staff, a Protocolized Redesign Process support for practice redesign, and a toolkit of suggested tactics for implementing Tasks A through D:
A. Identification B. Assessment C. Treatment D. Surveillance"
1461271|NCT03264547|Drug|Eribulin|Administered for 2 weeks and is then stopped to be administered for 1 week
1461272|NCT03264534|Procedure|limbal relaxing incisions|Manually performed surgical procedure
1461069|NCT03266120|Other|Art|Participants will receive a hands-on art activities intervention consisting of two art activities sessions each week lasting approximately 60 minutes each in duration for four weeks for a total of eight sessions. Art activities will include hand papermaking, image transfer, visual storytelling, linocut printmaking, paper batik, mixed media collage, and sensation drawing based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the art intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the art intervention.
1461070|NCT03266120|Other|Gardening|Participants will receive a hands-on gardening intervention consisting of two gardening sessions each week lasting approximately 60 minutes each in duration for four weeks, for a total of eight sessions. Gardening activities will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities. Participants will complete sets of self-report psychometric assessments before, during, and following the gardening intervention. Heart rate and blood pressure will be monitored before, during, and following completion of the gardening intervention.
1461071|NCT03266107|Device|Intracept System Ablation|Radiofrequency ablation using Intracept System
1461072|NCT03266094|Device|BiZact™: A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
1461073|NCT03266081|Drug|0.75% bupivacaine|topical anesthetic
1461074|NCT03266068|Genetic|DNA Analysis of Blood Sample|DNA analysis of the genes possibly involved in IBS.
1461075|NCT03266068|Procedure|Flexible sigmoidoscopy with colonic biopsies|Endoscopy of the subject's lower colon in which biopsies of the lining of the colon will be taken.
1461076|NCT03266068|Procedure|Small bowel and colonic gastrointestinal permeability|A validated scintigraphic method to measure gastric, small bowel and colonic transit will be used.
1461077|NCT03266068|Diagnostic Test|Stool sample analysis|Stool samples will be used to extract supernatants. These supernatants will be studied in using chamber set-up to determine barrier effects on T84 monolayers.
1461078|NCT03266055|Dietary Supplement|50 g of blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry powder during 8 weeks to test the possible effects of blueberries on gut microbiota composition and on metabolic syndrome parameters.
1461079|NCT03266055|Dietary Supplement|50g of placebo blueberry powder, taken daily for 8 weeks|Subjects will consume blueberry placebo powder to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatment (blueberry powder).
1461080|NCT03266029|Device|Cordio App|
1461081|NCT03266016|Other|Computerized Ventilator Protocol|Computerized Decision Support System which recommends changes to ventilator settings to promote physiologic levels of patient effort of breathing.
1461082|NCT03266016|Diagnostic Test|Esophageal Manometry|Esophageal Manometry Catheter to measure effort of breathing an transpulmonary pressure
1461083|NCT03266016|Diagnostic Test|Respiratory Inductance Plethysmography (RIP)|RIP bands to measure thoraco-abdominal synchrony during spontaneous breathing trials
1461084|NCT03266016|Diagnostic Test|Diaphragm Ultrasound|Daily measurement of diaphragm thickness and diaphragm contractile activity
1461085|NCT03266016|Diagnostic Test|Maximal Inspiratory Pressure|Prior to Spontaneous breathing trials, measurement of airway and esophageal maximal inspiratory pressure during airway occlusion
1461086|NCT03266003|Other|Electronic DOT|"Electronic DOT is the use of electronic communication methods to observe patients swallow anti-TB drugs and monitor for medication side effects. This study will use two variations of electronic communication methods, referred to as electronic directly observed therapy or eDOT. This includes: (1) eDOT conducted live in which TB program staff interact with patients via a computer or phone application as they ingest their medication (eDOT-live), and (2) eDOT conducted using time stamped, recorded videos in which TB program staff log into an electronic system and review videos recorded by patients in order to verify that patients ingested their medication doses as scheduled (eDOT-recorded)."
1461087|NCT03266003|Other|In-person DOT|A trained person is in the physical presence of patients as anti-TB drugs are ingested.
1461088|NCT03265990|Procedure|ligasure haemroidectomy|In ligasure group,After the haemorrhoids are prolapsed out from the anal canal with an artery forceps,Ligasure haemorrhoidectomy will be performed by applying the ligasure forceps close to the edge of each pile.Repeated applications of the device will be performed and excision will be continued into the anal canal,lifting the pile from the internal anal sphincter,to the level of the vascular pedicle,which will be finally divided.
1461089|NCT03265990|Procedure|Conventional haemorrhoidectomy|"According to the Ferguson technique
Manual anal sphincter stretching up to 4 fingers
Delivery of hemorrhoidal masses with artery forceps,one being applied at the base of haemorrhoid,the other at the apex.
skin incision at the base of haemorrhoids and submucosal dissection to lift the haemorrhoid mass off the internal sphincter.
After this the haemorrhoid pedicle will be transfixed and the mucosal edges of the defect will be opposed."
1461090|NCT03265977|Biological|H56:IC31|The H56 antigen is a fusion protein created from 3 Mtb antigens: antigen 85B (Ag85B), ESAT-6, and Rv2660c.
1461091|NCT03265977|Other|Placebo|Normal saline
1461092|NCT03265964|Drug|Uridine|Uridine is the active treatment in this clinical trial.
1461093|NCT03265964|Drug|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
1461094|NCT03265951|Drug|Ramelteon|8 mg once daily administered within 30 minutes of bedtime
1461095|NCT03265951|Other|Usual Care|education brochure about sleep hygiene
1461096|NCT03265938|Device|Indirect Laryngoscopy|The attending anesthesiologist will perform video laryngoscopy with the C-MAC D video laryngoscope and with the GlideScope AVL video laryngoscope and grade the view of the larynx obtained with each laryngoscope.
1461097|NCT03265899|Drug|Oxytocin|40 IU; 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
1461098|NCT03265899|Drug|Placebo|Placebo nasal spray, 5 puffs balanced across nostrils, at an inter-puff interval of 30 seconds
1995041|NCT02867137|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
1461273|NCT03264534|Procedure|astigmatic keratotomy|femtosecond laser guided surgical procedure
1461101|NCT03265873|Other|Systematic consideration of the advice of the ENT surgeon in the determination of the radiotherapy target volumes in head and neck cancers.|The contouring of the different target volumes will be first performed by the radiotherapists. During the Head and Neck Tumor Board, the volumes initially determined by the radiotherapists will be analyzed jointly by the radiotherapists and the patient's ENT surgeon to carry out, if necessary, modifications, taking into account clinical observations, intraoperative findings (if any) and endoscopy findings. Concordance parameters will be calculated in a second time with the determined volumes (in particular, index of concordance, coefficient of similarity).
1461102|NCT03265860|Device|IntraVoxel Incoherent Motion sequence|The IVIM diffusion sequence with a duration of 2 minutes is added to the imaging protocol.
1461103|NCT03265847|Behavioral|Culturally-tailored Safety Planning|The intervention will provide safety planning/referrals tailored to the DA
1461104|NCT03265834|Other|< 10 days of antibiotics|Antibiotic duration
1461105|NCT03265834|Other|28 days of antibiotics|Antibiotic duration
1461106|NCT03265821|Procedure|Healing after treatment|
1461109|NCT03265795|Device|Poly Ether Ether Ketone PSI (patient specific implant).|reconstruction of the bone and the original volume of maxillary sinus accurately (in terms of clinical and radiographic parameters).
1461110|NCT03265782|Drug|ibuprofen|drug was adminstred with a loading dose 10 mg/kg/day followed by 5 mg/kg/day in 2 doses with 24 hrs apart for 3 days
1461111|NCT03265782|Drug|paracetamol|drug was administred for 3 consequetive days in a dosev 15 mg/kg/dose every 6 hrs and follow up echo was done after 3 days
1461112|NCT03265769|Other|radial access site|radial route
1461113|NCT03265769|Other|femoral access site|femoral route
1461114|NCT03265756|Device|Multimometer|A device for measuring respiration rate, temperature, heart rate and the degree of blood oxygenation of children
1461115|NCT03265743|Other|Self-report Written Questionnaire|Informations are gathered through a self-report written questionnaire, completed by the patients or their parents.
1461116|NCT03265717|Biological|INVAC-1|Patients are treated by INVAC-1 for 6 cycles at 4-week intervals
1461117|NCT03265704|Other|AGA - Control group|Data processing from Patient Medical Files
1461118|NCT03265704|Other|SGA - Control group|Data processing from Patient Medical Files
1461119|NCT03265704|Other|AGA-PIH Study group|Monitoring PIH-related changes in the newborn
1461120|NCT03265704|Other|SGA-PIH Study group|Monitoring PIH-related changes in the newborn
1461121|NCT03265691|Other|Early detection and treatment of hyponatremia|In the experimental group, hyponatremia will be diagnosed and treated early. Therefore, the researchers will review the patients' sodium levels at admission and throughout their stay.
1461122|NCT03265691|Other|No Intervention (SOC)|Usual pattern of work will be performed in all patients who enter in Hospital.
1461123|NCT03265665|Behavioral|ACTION Intervention|The intervention is based on the Women's Lifestyle Physical Activity Program, a culturally sensitive community-based walking intervention for African American (AA) women based on the Interaction Model of Client Health Behavior and Social Cognitive Theory. There are 2 phases to the intervention: Adoptive (16 weeks) and Maintenance (12 weeks). 3 motivational/reminder texts will be made each week during the adoption phase and 1 during the maintenance phase. 5 Group sessions(adoptive): Participants will be given individualized step goals, watch a short DVD featuring AA women demonstrating skills and sharing experiences of engaging in walking. An interventionist will lead a discussion on role-modeling and encouraging problem solving. Each intervention group will have 10 women with 1 interventionist. Data will be collected at 3 time points: baseline, post-adoptive phase and post-maintenance phase.
1461124|NCT03265665|Other|Enhanced usual care|"Participants will attend 1 two hour asthma education/physical activity session at community location near them. Participants will review basic asthma topics in a didactic session and will include exercising with asthma and exercise-induced asthma. Participants will be given Fitbit and provided instructions on how to use it. Participants may receive 2 newsletters with information on asthma and reminder texts regarding data collection visits.
Data will be collected at 3 time points: baseline, post-adoptive phase and post-maintenance phase."
1461125|NCT03265652|Device|Intense Pulsed Light (IPL) therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that is FDA-approved for various conditions in dermatology. Subjects will receive a total of 4 treatments over the course of the study, at intervals of 4 weeks. Each treatment will include applications on 10-15 IPL pulses in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
1461126|NCT03265652|Device|Sham therapy|Subjects will receive a total of 4 treatments over the course of the study, at intervals of 4 weeks. Each treatment will include a sham application of IPL on 10-15 locations in the malar region and close to the lower eyelids, followed by meibomian gland expression. Meibomian gland expression will be implemented by squeezing the meibomian glands with the aid of two Q-tips positioned on either side of the meibomian glands, or with a meibomian gland expressor forceps.
1461128|NCT03265626|Behavioral|Intervention 1: Comprehensive preventive intervention|aims to implement the existing evidence and policy documents Advocacy workshop to politicians, Community mobilization, Awareness creation on women,training community representative, Husband participation
1461129|NCT03265626|Behavioral|Intervention 2: Awareness creation and community mobilization|Advocacy politicians, Community mobilization, Awareness creation to women, Training community representative
1461130|NCT03265626|Other|available standard care|The standard care will be maintained but no other additional intevvenion designed by this study
1461131|NCT03265613|Biological|adipose-derived multipotent mesenchymal stem cells|AD-MSCs(adipose-derived multipotent mesenchymal stem cells) were infused intravenously at a dose of 0.5 million cells/kg.
1461386|NCT03263611|Drug|Placebo|single intradiscal injection
1461132|NCT03265600|Behavioral|Mindfulness Training for Primary Care|MTPC is a referral-based, insurance-reimbursable 8-week program that can be delivered as group psychotherapy by Patient-Centered Medical Home-integrated behavioral clinicians or as an 8-week primary care group visit delivered by a primary care provider. MTPC groups are 2 hours long for 8 weeks with a 7-hour weekend day of silent practice. MTPC emphasizes mindfulness-oriented skills for self-regulation, self-management of chronic illness, and health behavior change. All participants complete an action planning protocol during Week 7.
1461133|NCT03265600|Behavioral|60-minute Introduction to Mindfulness|Participants in the low-dose comparator arm receive a 60-minute introduction to mindfulness. Participants are introduced to the definition(s) of mindfulness, brief mindfulness practices, discussion, and an orientation to an 8-week mindfulness group. They are also given a list of leading community, online, print, and smartphone mindfulness resources.
1461134|NCT03265587|Other|No intervention|No intervention
1461135|NCT03265574|Drug|Enalapril|Enalapril is an Angiotensin Converting Enzyme (ACE) inhibitor which supresses the reninangiotensin-aldosterone system resulting in increased plasma renin activity and decreased aldosterone secretion
1461136|NCT03265561|Device|Bone allograft|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone allograft only.
1461137|NCT03265561|Device|Bone auto and allograft group|All patients will undergo the same surgical procedure consisting of open surgery, more debridement of infected and devitalized tissue, as well as corresponding bone resection. For the identification of the microorganism, biopsies will be performed by puncture guided by CAT and / or fluoroscopy, and culture and antibiogram will be performed in case of not obtaining enough material for this, at the time of the surgery samples will be sent to perform the same procedure. We will use the appropriate antibiotics, according to infecting microorganism and result of antibiogram. We will include patients with infections with gram positive and negative microorganisms only. This patients will go stabilized with bone autograft plus bone allograft
1461138|NCT03265548|Device|Video Laryngoscope|The use of video laryngoscopy
1461139|NCT03265535|Diagnostic Test|Single-Scan Two-Injection Protocol|Single-Scan Two-Injection Protocol
1461140|NCT03265522|Behavioral|"ThinkMed resource at baseline"|"The ThinkMed resource contains an information booklet, recipe books, menu plan cards, shopping list cards and goal setting cards. Participants will receive this resource on one occasion at baseline."
1461141|NCT03265522|Behavioral|Standard Care Control|"Participants will continue with the standard care provided by their physician. Participants will receive the ThinkMed resource after their final 12 month study visit (i.e. delayed intervention)."
1461142|NCT03265522|Behavioral|"ThinkMed resource (staged)"|"This group of participants will receive the ThinkMed resource at monthly intervals for 5 months accompanied by telephone feedback from the research dietitian"
1461143|NCT03265509|Dietary Supplement|glutamine supplementation|30 g/day glutamine supplementation for three months
1461144|NCT03265509|Dietary Supplement|fantomalt supplementation|30 g/day fantomalt supplementation for three months
1461145|NCT03265496|Procedure|Clinical exam|Clinical exam is performed before treatment start
1461146|NCT03265496|Procedure|Liquid biopsy|Liquid biopsy will be performed at baseline and every 3 cycles of chemotherapy until progression disease
1461147|NCT03265496|Procedure|Diagnostic exam|Diagnostic exam (biopsy and imagery exam) will be performed at baseline if not previously done or incompletely done.
1461148|NCT03265496|Drug|1st line treatment|1st line chemotherapy (chemotherapy or EGFR targeted therapy) will be performed until progression disease.
1461149|NCT03265496|Procedure|tumor evaluation|Tumor evaluation will be performed every 3 cycles of chemotherapy
1461150|NCT03265496|Biological|Biopsy|Biopsy will be performed at the end of study, after progression disease, if a mutation of EGFR is detected in tumor DNA.
1461151|NCT03265483|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
1461152|NCT03265483|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
2010509|NCT02950428|Device|ACURATE neo™TA Delivery System|ACURATE neo™ Aortic Bioprosthesis and ACURATE neo™TA Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
2010510|NCT02951702|Drug|Vancomycin Oral|"This arm will receive oral vancomycin 125 mg daily if high risk and determined to be appropriate by an ID physician"
1461155|NCT03265457|Other|Specular microscopy|Comparison between corneal Endothelial count in patients with pseudoexfoliation syndrome and age matched group
1461156|NCT03265444|Biological|CS10BR05|The single injection of CS10BR05 Inj. in the carotid artery; Step 1 dose : 3.0x105cells/kg; Step 2 dose : 6.0x105cells/kg; Step 3 dose : 9.0x105cells/kg; The duration of follow up study following the single dose of CS10BR05 is 28 days.
1461157|NCT03265431|Drug|18F-TPP|Imaging with 18-F-TPP (18F-BFPET)
1461158|NCT03265418|Device|BioXmark liquid fiducial markers|Before the start of the treatment planning during an extra sigmoidoscopy after enema preparation, 4 liquid marker spots will be placed 1 cm from the tumor; two in the in the cranial and two in the caudal direction of the tumor (4 markers in total per patient).
1461159|NCT03265418|Other|Imaging|"As part of standard patient set-up directly before each radiotherapy treatment, kV cone-beam CTs will be acquired. Treatment positioning will be based on the regular clinical decision protocols for treatment of rectal cancer and not on the markers. During treatment potential fiducial movement will be assessed using an externally positioned ultra-sound probe, positioned against the abdominal or perineal skin of the patients depending on de position of the tumor/fiducials in the rectum. For patients in this study 2 orthogonal kV images will be made immediately after each radiation using the electronic portal imaging (EPI) device.
As part of standard clinical practice an MR of the rectum will be made for response evaluation 6-8 weeks after the end of neo-adjuvant chemo-radiotherapy."
1461387|NCT03263611|Drug|AMG0103|single intradiscal injection
1461160|NCT03265418|Procedure|surgery or wait-and-see|"As part of standard clinical practice patients whose tumor has not responded completely will be operated on 8-12 weeks after the end of neoadjuvant chemo-radiotherapy. Patients with a complete response will be follow-upped according to the wait-and-see protocol."
1461161|NCT03265405|Drug|Low dose prednisolone|An initial dose of 20 mg/day will be administered for 8 weeks, followed by 15 mg/day for 8 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
1461162|NCT03265405|Drug|Medium dose prednisolone|An initial dose of 40 mg/day will be administered for 4 weeks, followed by 30 mg/day for 4 weeks, 20 mg/day for 4 weeks, 15 mg/day for 4 weeks, 10 mg/day for 4 weeks, and 5 mg/day for 4 weeks, after which the drug will be discontinued.
1461163|NCT03265392|Other|Bread|Wheat bread serving providing 50 g of carbohydrates
1461164|NCT03265392|Other|Pasta|Wheat pasta serving providing 50 g of carbohydrates
1461165|NCT03265392|Other|Water|250 mL of water
1461166|NCT03265392|Other|Lemon juice|250 mL of lemon juice
1461167|NCT03265392|Other|Tea|250 mL of lemon juice
1461168|NCT03265392|Other|Peas|40 peas
1461169|NCT03265379|Other|FACT-B and Brief Pain Inventory|Quality of Life Questionnaires
1461170|NCT03265366|Device|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany), without injection or inhalation of contrast agent.
1461171|NCT03265366|Device|CT scan (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
1461172|NCT03265353|Other|Moderate Potassium/Low Sodium Diet|7 days of the prescribed diet
1461173|NCT03265353|Other|Moderate Potassium/High Sodium Diet|7 days of the prescribed diet
1461174|NCT03265353|Other|High Potassium/High Sodium Diet|7 days of the prescribed diet
1461175|NCT03265340|Device|dTMS|
1461176|NCT03265327|Dietary Supplement|Oral supplement containing omega-3 and omega-6|An oral supplement containing omega-3 and omega-6
1461177|NCT03265327|Dietary Supplement|Oral supplement containing coconut and olive oil|An oral supplement containing coconut oil and olive oil
1461178|NCT03265314|Behavioral|LeadHer|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
1461179|NCT03265314|Behavioral|Sassy Science|The 30-hour curriculum is delivered for five hours per week, either split over multiple after school sessions or one five-hour-long session conducted at AFG headquarters or a community-based partner site.
1461180|NCT03265301|Procedure|Hysteroscopy|Includes Video set up, mini-hysteroscope system, continuous inflow and outflow, rod lens or fiber optic lens Zero to 30 degree angle and mechanical instruments (Scissors,Graspers , Cup biopsy forceps and bipolar instruments)
1461181|NCT03265301|Procedure|Office hysteroscopy|will be done in out patient clinic without anesthesia
1461182|NCT03265301|Procedure|Conventional hysteroscopy|will be done in operative room under general anesthesia
1461183|NCT03265288|Drug|Fenretinide|Fenretinide will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
1461184|NCT03265288|Drug|Placebo oral capsule|Placebo will be administered orally once-a-day with the first meal of the day as cycles of 21 days on, 7 days off, for a total of 6 planned cycles.
1461185|NCT03265275|Other|Fast track patient pathway|Prehospital services establish a working diagnosis of hip fracture and initiate first line treatment. In the emergency department a specially trained nurse triages the patient. Patients without signs of other acute disease or trauma and who have not previously been operated in the same hip are directly transported to the x-ray suite. The x-rays are reviewed by the radiographer and in case of an obvious fracture of the hip the patient is transported directly to the orthopedic ward where the patient is received by a nurse and seen by an orthopedic surgeon. The pathway includes standard procedures for blood sampling, pain relief, including a fascia iliaca compartment block, intravenous fluids, transfusion triggers, management of anticoagulants and premedication. The pathway puts focus on prevention of pressure sores, a short preoperative fasting period and early mobilization. Screening tools are used to assess for delirium, nutritional status and fall risk.
1461186|NCT03265262|Diagnostic Test|The basophil activation test (BAT)|Single sample: 5 mL of venous blood
1461188|NCT03265236|Diagnostic Test|Anti - modified citrullinate vimentin|patients with early and late RA
2010511|NCT02947750|Drug|6R-BH4|Participants will receive 200 mg of 6R-BH4 twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
1461190|NCT03265210|Behavioral|RELIEF|A 9-week behavioral intervention for primary care designed to reduce depression and pain-related disability.
1461191|NCT03265197|Drug|Intra-tympanic injection of drugs|Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
1461192|NCT03265197|Other|Data management of intratympanic drugs|intervention by statistical analysis of Intratympanic injection of combined lidocaine and dexamethasone in treatment of tinnitus
1461193|NCT03265184|Dietary Supplement|green coffee extract|Patients in treatment group take 400 mg GCE supplements twice a day for tow month
1461194|NCT03265171|Biological|Plasminogen (Human)|
2010512|NCT02947750|Other|Placebo|Participants will receive a placebo that is identical to 200 mg of 6R-BH4. The placebo will be taken twice daily for 12 weeks. Study pills are dissolved in water or apple juice, and taken with food.
1461199|NCT03265132|Biological|anakinra|sub cutaneous injection
1461200|NCT03265132|Drug|Placebo|sub cutaneous injection
1461201|NCT03265119|Drug|AEVI-001|Oral doses of 100 mg, 200 mg or 400 mg of AEVI-001 will be administered twice daily during the treatment period.
1461202|NCT03265119|Drug|Placebo|Oral doses of 100 mg, 200 mg or 400 mg of Placebo will be administered twice daily during the treatment period.
1461203|NCT03265106|Biological|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR- ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
1461204|NCT03265093|Other|Platelet Rich Fibrin Injection|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge. I- prf will be injected on one side and corticosteroid will be injected on the other side in patients with bilateral oral lichen planus. Once a week in the first month after treatment and one time at the end of the second month, the patient will be called to the control.
1461205|NCT03265093|Drug|Corticosteroid|Corticosteroid injection
1461206|NCT03265080|Biological|ADXS-NEO|Biopsy, blood draws, CT scans, trial product administration
1461207|NCT03265067|Device|autoRIC|Application of the autoRIC device
1461208|NCT03265054|Biological|Analysis of plasma samples|Measuring microparticles (MPs) in Human Plasma Samples
1461209|NCT03265041|Diagnostic Test|multi-slice CT coronary angiography and coronary angiography|multi-slice CT coronary angiography to evaluate graft number and patency validated by coronary angiography
1461210|NCT03265028|Behavioral|TRACE e-learning|The TRACE e-learning (www.acutecough.org) is an educational web-based module including communication training for physicians, and includes patient booklets to be used interactively during the consultation.
1461211|NCT03265015|Behavioral|Habit Override Practice|"Computerized brain training to provide practice in overriding avoidance habits."
1461212|NCT03265015|Other|Transcranial Magnetic Stimulation|Non-invasive method for temporary, focal stimulation of brain areas.
1461213|NCT03265002|Dietary Supplement|Placebo|Ingestion of 500ml water with 50ml lemon juice and 20g dextrose
1461214|NCT03265002|Dietary Supplement|Inulin|Ingestion of 500ml water with 50ml lemon juice and 20g inulin
1461215|NCT03265002|Dietary Supplement|Psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g psyllium
1461216|NCT03265002|Dietary Supplement|Inulin and psyllium|Ingestion of 500ml water with 50ml lemon juice and 20g inulin and 20g psyllium
1461218|NCT03264976|Diagnostic Test|hematological examination, ophthalmic examination|Hematological examination includes biochemical examination, routine coagulation test, HbA1c, C reactive protein (CRP)；Ophthalmic examination includes the basic situation and clinical diagnosis of eyes, ETDRS visual acuity chart score, intraocular pressure, OCT examination, OCTA examination, fundus photos, Optos wide angle fundus imaging.
1461219|NCT03264963|Other|Smart phone game play|Voice controlled smart phone game play 15 minutes daily and recording sounds of sleep environment 2 night per week for 12 weeks
1461220|NCT03264963|Other|Control|Recording of sleep environment 2 nights per week for 12 weeks
1461221|NCT03264950|Diagnostic Test|Elastography|"an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.
Similarly an acoustic window will be selected for the pancreas as well"
1461222|NCT03264937|Other|Wechat-based management|Using Wechat application, a social software, to educate and remind patients during oral warfarin anticoagulation therapy.
1461223|NCT03264924|Behavioral|IPAIR|Motivational interview training
1461224|NCT03264911|Drug|Amoxicillin or Placebo|Children will be randomized to either 6 days of amoxicilline or 6 days of placebo treatment
1461225|NCT03264898|Device|Fecal immunochemical test (FIT)|FIT is a type of fecal occult blood test that uses antibodies to hemoglobin to detect blood in stool.
1461226|NCT03264885|Other|Incentive Care|ICS is a novel intervention that incorporates patient education, social support, and financial assistance to assist individuals.
1461227|NCT03264872|Behavioral|Peer-Enhanced Motivational Interviewing|Target clients in this Peer-Enhanced Motivational Interviewing arm will receive separate one-hour Motivational Interviewing (MI) sessions, in which the therapist reviews the target clients substance use behaviors in a non-confrontational manner, listens empathetically, and reinforces any client statements indicating a desire the change. In this arm, the therapist also presents the target client's peer with data about the extent of the target client's substance use, builds the peer's motivation to help their friend, and teaches the peer communication sills they can use to influence the target client's substance use behaviors.
1461228|NCT03264872|Other|Waitlist Control|After the 12 week follow up period, if subjects in the Waitlist Control group desire to receive the Peer-Enhanced Motivational Interviewing intervention, that will be made available to them.
1461229|NCT03264859|Diagnostic Test|NGAL levels early and post STEMI|NGAL levels early and post ST elevation MI (STEMI)
1461230|NCT03264846|Diagnostic Test|Collection of Serum and Saliva Samples|Whole saliva samples were obtained via expectorating into polypropylene tubes venous blood were obtained from the antecubital vein via the standard venipuncture method.
1461231|NCT03264833|Other|TempTraq|no intervention
1461232|NCT03264820|Device|Laser Doppler|- Laser measurements at the level of each finger at 47 °C and at ambient temperature
1461233|NCT03264820|Device|Laser speckle|- Laser measurements at the forearm
1461234|NCT03264820|Behavioral|pain evaluation|Visual scale assesment pain
1461235|NCT03264820|Other|Blood pressure and heart rate|Measurement of blood pressure and heart rate
1461236|NCT03264807|Procedure|D2 lymphadenectomy|Subtotal gastrectomy with D2 lymphadenectomy (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) is conventional surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
1461237|NCT03264807|Procedure|D2 and #14v lymphadenectomy|Subtotal gastrectomy with D2 (lymph node #1, #3, #4sb, #4d, #5, #6, #7, #8a, #9, #11p, #12a) and #14v lymphadenectomy is experimental surgery in patients with advanced gastric cancer such as T3N+ or T4N+ stage.
1461238|NCT03264794|Drug|Gefitinib Tab （CTTQ），First medication；Gefitinib Tab （CTTQ），From the 8th day of trial|Gefitinib Tab （CTTQ），First medication,250mg；
1461239|NCT03264794|Drug|Gefitinib tablets (Yi Ruisha），First medication|Gefitinib tablets (Yi Ruisha），First medication,250mg；
1461240|NCT03264794|Drug|Gefitinib Tab 250 MG（CTTQ），From the 8th day of trial.|From the 8th day of the experiment, two groups of subjects were treated with Gefitinib（CTTQ）
1461241|NCT03264781|Drug|Cyclofem|Intramuscularly injection 0.5 ml of Cyclofem or placebo
1461266|NCT03264560|Behavioral|Telepsychiatry|A total of 6 synchronous or asynchronous telepsychiatry interventions conducted via telecommunications done at baseline, 1 month, 2 months, 3 months, 6 months, and 12 months.
1461267|NCT03264547|Drug|Pertuzumab|Every 3 weeks
1461242|NCT03264768|Device|endobronchial valves|A ambulatory diagnostic bronchoscopy under general anesthesia will evaluate the presence or absence of collateral ventilation . The targeted lobar airway is temporarily occluded by means of a balloon catheter, which blocks inspiratory flow but allows expiratory flow, in order to assess whether the air flow gradually declines to zero, meaning absence of collateral ventilation. Only in case collateral ventilation is excluded, a therapeutic bronchoscopy will be scheduled to insert the one-directional endobronchial valves in the targeted lobar airways. We will only perform a unilateral intervention during which we will treat one or maximal two lobes at one side.
1461243|NCT03264755|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation for cortical excitability in smokers and non smokers
1461244|NCT03264742|Other|Ghrelin|The patients are assigned within the scope of the admission according to emergency to the treatment and clarification on the Stroke Unit of the KSW. There the patients are enclosed in the study and are examined according to the draught on the Stroke Unit within the scope of the complex treatment. The inclusion of the patients occurs after clarification and in the consent of the patients. In the morning after the admission day the decrease of the first blood test occurs within the scope of the blood sample as a matter of routine to be carried out for the Ghrelinbestimmung. Also 48 H occurs after the first withdrawal and 3 months after the stroke a blood sample to the regulation of Ghrelin.
1461245|NCT03264729|Other|Isometric exercise|The isometric exercise is performed standing with the forefoot on a step. The participant is instructed to stand still with the ankle joint in neutral and hold this position. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 5 sets of 45-second isometric holds. The load used is the heaviest possible load that the participant is able to withstand for 1 minute. As with the isotonic exercise, if the participant's body weight is inadequate the participant is fitted with a backpack with books and/or weights.
1461246|NCT03264729|Other|Isotonic exercise|"The isotonic exercise is performed standing with the forefoot on a step. The toes are maximally dorsi-flexed by placing a towel underneath them. The participant is instructed to perform a heel-raise to a maximal plantar flexion in the ankle joint, and afterwards to lower the heel to maximal dorsi flexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed. The participant performs 4 sets of 8 repetitions with a load of 8RM. The contraction time is 3s concentric, 2s isometric and 3s eccentric and will be guided by a metronome.
If the participant's body weight is inadequate to reach sufficient loading during the exercises the participant is fitted with a backpack with books and/or weights."
1461247|NCT03264729|Other|Walking|The walking will be performed barefoot and the participant will be instructed in walking at a pace similar to the pace they would use when walking around in their home. The duration of the walking session will be four minutes to match the duration during the exercises.
1461248|NCT03264716|Device|HepaSphere TACE (transarterial chemoembolization)|100 mg doxorubicin will be loaded onto the HepaSphere Microspheres and delivered via microcatheter.
1461249|NCT03264677|Combination Product|Group 1|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Kiwi Water Gel
1461250|NCT03264677|Combination Product|Group 2|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Water Gel
1461251|NCT03264677|Combination Product|Group 3|NTG Hydro Boost Gelee Milk Cleanser + NTG Hydro Boost Extra Dry Emulsion
1461252|NCT03264664|Drug|E7386|oral capsules
1461253|NCT03264651|Drug|enobosarm|Oral combination therapy of enobosarm and anastrozole
1461254|NCT03264638|Drug|Dingkundan|Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
1461255|NCT03264638|Drug|Dingkundan & Diane-35|Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
1461256|NCT03264638|Drug|Diane-35|Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles
1461257|NCT03264625|Drug|Cholecalciferol (2000iu qd)|Patients will receive Cholecalciferol (2000IU qd) apart from routine therapy for PD
1461258|NCT03264625|Other|Routine therapy for PD|Patients randomized to the placebo group will receive routine therapy for PD.
1461259|NCT03264612|Behavioral|Aerobic exercise|"Females in group I were instructed to engage into swimming exercise 30 minutes daily, 3 times weekly for 3 months. Exercise was ceased on the first 3 days of menstrual cycle then resumed afterwards.
The exercise included three stages: warming up, swimming and cooling down."
1461260|NCT03264599|Device|transabdominal ultrasound|2D trans abdominal ultrasound was done during the first stage of labor. If fetal position is occiput anterior and fetal presentation is vertex, two dimensional sagittal picture of the fetal head and upper spine was acquired and stored in the ultrasound machine. On this image, the offline measurement of the angle formed by a line tangential to the occipital bone and a line tangential to the first vertebral body of the cervical spine (occiput-spine angle) will be performed to quantify the degree of fetal head flexion in respect to the trunk
1461261|NCT03264586|Drug|Lidocaine-prilocaine cream|"5gm dose of cream applied to the intact surface of the perineum and area covered with an occlusive dressing to facilitate penetration
- EMLA cream was applied, 1 hour before the expected time of birth."
1461262|NCT03264586|Drug|mepivacaine infiltration group|"10 ml of 1% mepivacaine solution was injected slowly when the fetal head was crowned with frequent aspiration to avoid intravascular injection.
In the mepivacaine group, if an episiotomy was indicated, it was performed after infiltration of perineal tissue with 10 ml of 1% mepivacaine solution.
The suture procedure was delayed 10 minutes after the injection of the aneathetic"
1461263|NCT03264586|Procedure|mediolateral episiotomy|"Episiotomy repair a loose, continous, non locking suture to close the vaginal mucosa and the muscular layer of the perineum using vicryl Number zero (0).
At the end of the vaginal mucosal repair care is taken to align the edges of the episiotomy wound
At the point where perineal skin begins; the suture is then passed beneath the vaginal mucosa, and repair of perineal muscle begins. The deep layer of muscles is closed first, ensuring no dead space one left behind
The skin was closed with the same continuous suture to approximate the subcutinuous tissue."
1461264|NCT03264573|Biological|Stem cell|after scar revision PRP is injected intradermally, also adipose derived mesenchymal stem cells
1461265|NCT03264573|Device|MSCs|manual separation of platelets rich plasma and undifferentiated mesenchymal stem cells
1461274|NCT03264521|Other|Surveys|Web surveys about experiences with chronic low back pain, demographics, coding qualitative text.
2010513|NCT02947750|Dietary Supplement|Folic acid|Participants will take 1 mg of folic acid daily for 12 weeks. Folic acid is given because it enhances the binding affinity of BH4 to nitric oxide synthase (NOS), and also enhances the regeneration of BH4 from inactive BH2
1461277|NCT03264495|Other|Weight the food served minus the left-overs|
1461281|NCT03264443|Behavioral|Health education|Weekly group lectures (1h each) giving information on patient's best practices to manage hypertension.
1461282|NCT03264443|Behavioral|Combined training|Combined training (aerobic and strength exercises), in moderate intensities (perceived exertion controlled) performed 3x/week (1h) duration with a education component (10') based on the contents of the health intervention.
1461283|NCT03264430|Drug|Ketamine|an antagonist of the NMDA receptor
1461284|NCT03264430|Drug|bupivacaine|local anaesthetic
1461285|NCT03264404|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks until progression
1461286|NCT03264404|Drug|Azacitidine|50 mg/m2 subcutaneous daily for 5 days every 28 days
1461287|NCT03264378|Behavioral|Physical Exercise Intervention|The 12-week physical exercise intervention will be delivered by trained community health workers (CHW) who are supervised by nurses. The CHW will visit the patient's home—3 sessions per week for the first 2 weeks, followed by weekly visits for 6 weeks, and then weekly telephone support for 4 weeks—to instruct the family caregiver and the patient in the exercise routine. Each session includes physical activities designed to promote gentle stretching, strength, balance, flexibility, and endurance, with a progressive schedule (i.e., the total length of time increases from 10 minutes up to 30 minutes maximum) and its intensity adjusted based on the participant's level of fitness.
1461288|NCT03264365|Behavioral|Intervention|"Intervention (plus standard care)
Patients photographs during the ICU-stay,
Written information about life after ICU
First consultation face-to-face in hospital setting at three months after ICU
Visit ICU and photographs given
Consultations as needed"
1461289|NCT03264352|Drug|Allisartan Isoproxil|Allisartan Isoproxil 240mg daily will be used.
1461290|NCT03264352|Drug|Amlodipine 5mg|Amlodipine 5mg daily will be added to Allisartan Isoproxil and afterwards increased to 10mg daily, if necessary to reach the blood pressure goal,
1461291|NCT03264352|Drug|Hydrochlorothiazide 25 mg|Hydrochlorothiazide 25 mg (first 12.5 mg or then 25 mg daily) will be given subsequently if the blood pressure goal is still not reached.
1461292|NCT03264352|Drug|Allisartan Isoproxil placebo|Allisartan Isoproxil placebo is identical to Allisartan Isoproxil 240mg.
1461293|NCT03264352|Drug|Amlodipine placebo|Amlodipine 5mg placebo is identical to Amlodipine 5mg.
1461294|NCT03264352|Drug|Hydrochlorothiazide placebo|Hydrochlorothiazide 25mg placebo is identical to Hydrochlorothiazide 25mg.
1461295|NCT03264339|Behavioral|Small Step Program|The Small Step intervention program has three alternating treatment foci (Hand use, Mobility, Communication) divided into five different steps, each lasting for 6 weeks (in total 30 weeks).
1461296|NCT03264326|Other|Blood Flow Restriction Training|Delfi Personalized Tourniquet System occludes 80% venous pressure during lower extremity exercise.
1461297|NCT03264326|Other|Sham Blood Flow Restriction Training|Delfi Personalized Tourniquet System occlude 20 mmHG venous pressure during lower extremity exercise as a sham treatment.
1461298|NCT03264326|Other|Eccentric Exercise|Subjects perform eccentric calf lowering off a step for 90 repetitions twice daily.
1461299|NCT03264313|Device|Deep Transcranial Magnetic Stimulation|Patients undergoing of Deep Transcranial Magnetic Mtimulation (dTMS) for smoking cessation
1461300|NCT03264300|Other|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min; conventional structural MRI; T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Advanced MRI to include: Diffusion Weighted MRI (DW-MRI) - 7 min; Chemical Exchange Saturation Transfer (CEST) - 9 min; Dynamic Susceptibility Contrast / Dynamic Contrast Enhanced MRI - 8 min; and, other advanced imaging, as needed, to be determined. Post-contrast conventional MRI to include T1-weighted anatomic MRI scan - 7 min. Repeat within 1 month.
1461301|NCT03264300|Other|MRI|MRI scans to include: scout images, transmitter tuning, shimming, slice prescription - 5 min. Conventional structural MRI to include: T1-weighted anatomic MRI scan - 7 min; and, T2-weighted anatomic MRI scan - 5 min. Serial DSC-MRI: staged injections of Gd-based contrast and Ferumoxytol - 20 min. Post-contrast conventional MRI: T1-weighted anatomic MRI scan - 7 min.
1461302|NCT03264287|Procedure|3 times per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 3 times per week over the 6 weeks period.
1461303|NCT03264287|Procedure|1 time per week therapeutic frequency|Participants will receive acupuncture, moving cupping and ear-tapping procedure 1 time per week over the 6 weeks period.
1461304|NCT03264274|Drug|Aflibercept|Antiangiogenic
1461305|NCT03264274|Procedure|Dynamic Contrast Enhanced Ultrasound|DCE-US (a technique using differential liver blood flow assessments using microbubble) will be performed at baseline, Week 2 and 8 of treatment.
1461306|NCT03264261|Device|robotic training|robotic training, 3 times/week for 6 weeks
1461307|NCT03264261|Device|treadmill training|treadmill training only, 3 times/week for 6 weeks
1461308|NCT03264248|Device|E-Scale|Daily bodyweight system used under legs of bed
1461309|NCT03264235|Device|Keeogo|"Keeogo is a computer-controlled lower extremity motorized orthosis worn over the user's hips and legs. The controller box contains sensors that supply information about the kinematics and the kinetics of the user's lower extremities and includes software that recognizes the user's mobility intentions. The system is powered by a lithium-polymer battery. The leg brace assembly is mainly comprised of the actuator, the electronic boards, hip joint, and soft goods (cuffs, belts) for affixing the assembly to the user's legs. The waist belt comes in various sizes adapted to each wearer, and adds additional support of the device on the user.
Keeogo does not initiate any movement but waits for the user's lead. Once the user makes the first move, Keeogo assists according to the activity. The individual must be able to initiate and terminate steps."
1461310|NCT03264235|Other|Traditional Stair Training|Individuals will participate in traditional stair training physical therapy for the same duration of time as Group 1.
1461311|NCT03264222|Other|Security screening procedure|Screening procedure with security device (model QPS 100)
1461312|NCT03264209|Behavioral|Smart After-Care (Mobile health)|Patients in intervention group will be provided with Smart After-Care Service including intervention for physical activity (aerobic exercise at least 90 or 150 minutes every week for 12 weeks depending on patients' aerobic fitness by monitoring with smartband and strengthening exercise at least 2 times a week for 12 weeks), information for prostate cancer and adequate life style, and smartband that can connect to the smartphone. Case management consists confirmation of hospital visit date, checking the adverse effect and treatment compliance.
1461313|NCT03264196|Procedure|Open Reduction and Internal Fixation|Surgical treatment of fracture
1461314|NCT03264183|Diagnostic Test|Transesophageal Echocardiography|TEE measures of right ventricular function
1461315|NCT03264183|Diagnostic Test|Transthoracic Echocardiography|TTE measures of right ventricular function
1461316|NCT03264170|Diagnostic Test|Individualised risk prediction of early pregnancy outcome|This group will all receive (with prior consent) the individualised prediction of their pregnancy ending in miscarriage (as a percentage). The prediction is calculated by a validated, accurate mathematical model using specific background information and ultrasound data for each participant
1461317|NCT03264157|Drug|HRIG|HRIG
1461318|NCT03264144|Behavioral|Social norms campaign|Intervention messages will mainly highlight the prevalence of Hong Kong adolescents who do not smoke cigarettes and have no intention to smoke cigarettes. The messages will be conveyed to students through posters, table tents, flyers and an online banner. Posters will be posted at prominent places in schools, table tents will be placed in school canteens, flyers will be distributed to students, and the online banner will be placed at the school website. The intervention will last for 2 months.
2010514|NCT02947750|Other|Exercise Training|Participants will exercise 3 times a week on a stationary ergometer. Exercise intensity will begin at low levels (50% of maximal heart rate reserve) calculated utilizing the Karvonen method. Briefly, target exercise heart rate (HR) is calculated by subtracting the persons age from 220. Resting heart rate is then subtracted from this number. The answer is then multiplied by the target percent (50% for example) and the product is added back to resting heart rate to provide the target exercise session heart rate. Intensity will be increased by 5% every week (as tolerated by the participant) to a maximum of 80% of maximal heart rate. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week.
1461321|NCT03264118|Procedure|Scaling and root planing|Furcation treatment by scaling and root planing
1461322|NCT03264118|Drug|Toluidine Blue O|Antimicrobial photodynamic therapy with toluidine blue O (10mg/ml) and red laser.
1461323|NCT03264105|Other|Hydroxyapatite Nanofiber reinforced flowable composite|retention rate evaluation of Hydroxyapatite Nanofiber reinforced flowable composite
1461324|NCT03264105|Other|conventional resin-based flowable composite|retention rate evaluation of conventional resin-based flowable composite
1461326|NCT03264079|Drug|Bardoxolone methyl capsules 10 mg|One 10 mg capsule of bardoxolone methyl administered on Study Day 1 (Period 1) of the trial and one 10 mg capsule of bardoxolone methyl administered on Study Day 18 (Period 2) of the trial
1461327|NCT03264079|Drug|Itraconazole capsules 100 mg|Two 100 mg capsules of itraconazole administered once daily during Study Days 15 - 27 (Period 2) of the trial
1461328|NCT03264066|Drug|Cobimetinib|Participants will receive cobimetinib 60 mg (3 tablets of 20 mg each) orally once a day on Days 1−21 of each 28-day cycle.
1461329|NCT03264066|Drug|Atezolizumab|Atezolizumab will be given at a fixed dose of 840 mg by intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle.
1461330|NCT03264053|Device|Socket shield|Socket shield is the Removal of the lingual portion of the anterior root thus retaining the lingual portion
1461331|NCT03264053|Procedure|Conventional immediate implantation|Conventional immediate implantation
1461332|NCT03264027|Drug|Carbon dioxide|Carbon dioxide will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
1461333|NCT03264027|Drug|Ambient air|Ambient air will be used as an insufflating gas during argon fulguration of the dilatated anastomosis.
1461334|NCT03264027|Drug|Argon fulguration|The dilatated anastomosis from the gastric bypass surgery will be reduced in diameter using fulguration with argon. Patient in both groups will be placed in the left lateral decubitus position, with anesthesia being performed exclusively using propofol; adequate cardiopulmonary monitoring will be carried out during the entire procedure. After sedation, endoscopy will be performed with an Olympus CV-180 endoscope (Olympus, Tokyo, Japan) and analysis and measurement of the anastomosis will be achieved using Raptor foreign body forceps (Endoscopy Group US, Inc., Mentor - Ohio, USA). The images will be transferred to an Olympus EvisExera II processor connected to a computer with the ZScan 5 program (Goiânia, GO, Brazil).
1461335|NCT03264001|Behavioral|Negative energy balance|20% and 40% reduction of daily energy needs for weight maintenance
1461336|NCT03263988|Device|ConCardiac|All patients receive a piezocapacitative-interlayer-technology hemodynamic measurement by ConCardiac device (SectorCon GmbH, Berlin, Germany).
1461337|NCT03263975|Other|Gatorade or Enterade|Commercially available oral rehydration therapies
1461338|NCT03263962|Drug|Canrenone|Evaluation of canrenone therapy in patients with CHF
1461339|NCT03263949|Other|Diagnostic|For the analysis of myocardial function, conventional 2D echocardiography and tissue doppler will be used. For the evaluation of myocardial mechanics, 2D speckle tracking, strain, strain rate and mechanical dispersion will be obtained.
1461340|NCT03263936|Drug|Decitabine|Dose Level #0: 5 mg/m2 Dose Level #1: 7.5 mg/m2 Dose Level #2: 10 mg/m2 Dose Level #3: 15 mg/m2 Dose Level #4: 20 mg/m2 given IV over __ hour on days 1 through 5
1461341|NCT03263936|Drug|Vorinostat|Age <18: 180 mg/m2/day once daily PO. Age≥18: 200 mg twice daily PO.
1461342|NCT03263936|Drug|Filgrastim (G-CSF)|Given on days 5 until evidence of ANC recovery (>500/µL)5µg/kg/dose IV or SQ (starting at hour 0)
1461343|NCT03263936|Drug|Fludarabine|30 mg/m2/day IV over 30 minutes (starting at Hour 0 - Immediately after G-CSF)
1461344|NCT03263936|Drug|Cytarabine|2000 mg/m2/day (Starting at Hour 0.5),IV over 3 hours, days 6-10
1520530|NCT02813135|Drug|Olaparib|
1461345|NCT03263923|Behavioral|Cognitive behavioral intervention and journaling|Cognitive behavioral skills training and 4 weeks of online journaling
1461346|NCT03263923|Behavioral|Reflective journaling|"Reflective journaling training and 4 weeks of online journaling
Training in reflective journaling and 4 weeks of online journaling"
1461347|NCT03263910|Drug|NPO-11|20 ml NPO-11
1461348|NCT03263910|Drug|Placebo|20 ml NPO-11(Placebo)
1461349|NCT03263897|Device|insufflation|mobile interface driven insufflation of the ear canal
1461350|NCT03263884|Device|Repetitive trancranial magnetic stimulation (rTMS) group|Repetitive trancranial magnetic stimulation is applied on the dorsolateral prefrontal cortex. The protocol consists on 20 minutes of 10Hz stimulation, 5 seconds on, 10 seconds off, at 110% RMT, for a total of 4000 pulses.
1461351|NCT03263884|Device|Sham group|A sham coil is used to mimic the clicking sound of the trancranial magnetic coil and skin stimulation.
1461355|NCT03263832|Diagnostic Test|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
1461356|NCT03263806|Diagnostic Test|CTFFR-Guided Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results will be communicated to the provider who will use CTFFR interpretation to guide care pathway.
1461357|NCT03263806|Diagnostic Test|SOC Group Management|Patients will receive standard of care CT on enrollment which will be analyzed by CTFFR. Results are NOT communicated to the provider who will dictate patient management according to their own clinical judgment
1461358|NCT03263793|Behavioral|Choral (group) singing therapy sessions|Choral (group) singing therapy sessions will be conducted once weekly and daily home practice exercises will be assigned. All vocal exercises are based on principles that have been successful in other intensive Parkinson Disease vocal exercise programs.
1461359|NCT03263780|Drug|18F-Fluciclovine|Imaging (comparing standard and experimental high resolution diffusion-weighted imaging [DWI] MRI with 18F-Fluciclovine)
1461360|NCT03263767|Drug|Fludarabine|30 mg/m² Intraveinous 5 days from Day-6 to Day-2
1461361|NCT03263767|Drug|Clofarabine|30 mg/m² Intraveinous 5 days from Day-6 to Day-2
1461362|NCT03263767|Radiation|Full body irradiation|2 grays at Day-1
1461363|NCT03263767|Drug|Cyclophosphamide|14 mg/kg intraveinous 2 days at Day - 6 and day -5
1461364|NCT03263767|Drug|Cyclophosphamide|50 mg/kg intraveinous 2 days at day +3 and day +4
1461365|NCT03263767|Other|stem cell transplantation|at D0 intraveinous Depending on donor : the stem cells will be extracted from blood (CD34+) or from bone marrow (CD34+ and nuclear cells)
1461366|NCT03263767|Other|nuclear cells|CD3+ cells if neeeded after transplantation
1461367|NCT03263754|Behavioral|Pocket Medic|10 short digital films utilising self-determination theory aiming to increase patient self-management
1461368|NCT03263754|Behavioral|Pulmonary Rehabilitation|PR follows National Institute for Clinical Excellence guidelines delivering 14 sessions over 7 weeks utilising a multidisciplinary approach
1461369|NCT03263741|Drug|Paclitaxel + S-1 + Oxaliplatin|"Paclitaxel: 175 mg/m2, iv, 3h, at D1 S-1: 60mg twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
Oxaliplatin: 85 mg/m2, iv, 2h, at D1"
1461370|NCT03263728|Diagnostic Test|Cardiac Magnetic Resonance|Screening of asymptomatic of high risk type 2 diabetic mellitus patients with stress cardiac magnetic resonance
1461371|NCT03263715|Drug|Tocilizumab Prefilled Syringe [Actemra]|Weekly administration of Tocilizumab 162 mg subcutaneous from Baseline to Week 16.
1461372|NCT03263715|Drug|Placebos|Weekly administration of Placebo subcutaneous from Baseline to Week 16.
1461373|NCT03263715|Drug|Glucocorticoids|Rapidly tapered Glucocorticoid treatment. 20 mg/day of prednisone at randomization and a pre-specified taper regimen will be followed over 11 weeks: Week 0: 20 mg Week 1: 17,5 mg Week 2: 15 mg Week 3: 12,5 mg Week 4: 10 mg Week 5: 9 mg Week 6: 7 mg Week 7: 5 mg Week 8: 4 mg Week 9: 2 mg Week 10: 1 mg Week 11: 0 mg
1461375|NCT03263689|Drug|Intrathecal morphine|ITM group were given 100 micrograms of preservative-free morphine in addition to the local anaesthesia (plain hyperbaric bupivacaine 10mgs) intrathecally during the spinal anaesthesia
1461376|NCT03263676|Device|Icon resuable underwear|Reusable incontinence underwear
1461377|NCT03263676|Device|Disposable pad|Standard market disposable pad
1461378|NCT03263663|Drug|targeted substance according to the avatar model|individualized second line treatment
1461379|NCT03263650|Drug|Cabazitaxel|25mg/m2 administered intravenously over 60 minutes on day 1 of cycles 1-6; given before carboplatin.
1461380|NCT03263650|Drug|Carboplatin|AUC 4 administered intravenously over 60 minutes on day 1 of cycles 1-6
1461381|NCT03263650|Drug|Prednisone 5Mg|5 mg administered by mouth twice daily on days 1-21 of cycles 1-6.
1461382|NCT03263650|Drug|Olaparib|Administered by mouth twice daily at a dose of 300 mg by mouth twice daily, dispensed on Day 1 of cycle 7 to participants randomized to receive olaparib maintenance and every 21 days thereafter until the participant completes the study, withdraws from the study or the closure of the study.
1461384|NCT03263624|Device|fractional carbon dioxide laser|One hand of each patient will receive three sessions of fractional carbon dioxide laser at four- week interval.
1461385|NCT03263624|Drug|Tazarotene Cream 0.1%|tazarotene cream 0.1% once daily
1461390|NCT03263572|Drug|Methotrexate|"Methotrexate given at 12 mg (6 mg if intra-ommaya) on Days 1, 15, and 29 of Cycles 1-4.
Total number of prophylactic intrathecal treatments for previously untreated patients will be 12.
A total of 3 given with each course of Blinatumomab on day 1 (+/- 3 days), day 15 (+/- 3 days) and day 29 (+/- 3 days) until total number reached."
1461391|NCT03263572|Drug|Cytarabine|"Cytarabine 100 mg on Days 1, 15, and 29 of Cycles 1-4.
Total number of prophylactic intrathecal treatments for previously untreated patients will be 12."
1461392|NCT03263572|Drug|Blinatumomab|Blinatumomab administered as continuous intravenous infusion at a dose of 28 μg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle for up to 5 cycles (one induction and up to 4 consolidations).
1461393|NCT03263572|Drug|Dexamethasone|Dexamethasone by mouth or vein given for 3 to 7 days within 1 hour before the start of each treatment cycle and at the time of any increase in dose to prevent side effects associated with Blinatumomab treatment.
1461394|NCT03263572|Drug|Ponatinib|"Ponatinib by mouth each day during Weeks 1-4 of Cycle 1, followed by 2 weeks of no Ponatinib. Beginning with Cycle 2, Ponatinib given by mouth every day while on study.
During cycle 1, Ponatinib 30 mg given by mouth daily from Day 1 till Day 28 of Blinatumomab.
Subsequent courses Ponatinib 30 mg by mouth daily continuously without interruptions unless due to toxicity. In patients who achieved CMR, ponatinib should be further reduced to 15 mg per day unless judged necessary to stay on 30 mg and after discussion with the PI."
1461395|NCT03263559|Procedure|Haploidentical Bone Marrow Transplantation|Eligible patients with a first degree Human Leukocyte Antigen (HLA)- haploidentical donor will undergo Haploidentical bone marrow transplantation at Day 0 with non T-cell depleted bone marrow. For Graft-vs-Host Disease (GVHD) prophylaxis, patients will be given sirolimus and mycophenolate mofetil beginning on Day +5.
1461396|NCT03263559|Drug|Hydroxyurea|HU will be given daily at 30mg/kg from Day -70 through Day -10.
1461397|NCT03263559|Drug|Rabbit-ATG|Rabbit-ATG (rATG) will be given at 0.5mg/kg on Day -9, and at 2.0mg/kg on Day -8 and Day -7.
1461398|NCT03263559|Drug|Thiotepa|Thiotepa will be given at 10mg/kg on Day -7
1461399|NCT03263559|Drug|Fludarabine|Fludarabine will be given at 30mg/m2 from Day -6 to Day -2
1461400|NCT03263559|Drug|Cyclophosphamide|Cyclophosphamide will be given at 14.5mg/kg on Day -6 and Day -5, and at 50 mg/kg on Days +3 and +4.
1461401|NCT03263559|Radiation|Total Body Irradiation|Total Body Irradiation will be given at 200cGy on Day -1
1461402|NCT03263559|Drug|Mesna|Mesna will be given at 40mg/kg on Days +3 and +4
1948007|NCT02874742|Drug|Lenalidomide|Cycles 1 through 6: lenalidomide 25 (milligram) mg orally on Days 1 through 14 and each cycle is of 21-days followed by maintenance treatment with lenalidomide 10 mg on days 1-21 daily up to 32 cycles and each cycle is of 28-days. Beginning at Cycle 10, the lenalidomide dose will be increased to 15 mg unless there is a tolerability concern.
1948008|NCT02874742|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 subcutaneously on Days 1, 4, 8, and 11 during Cycles 1-6.
1461405|NCT03263533|Drug|Vorinostat Oral Capsule Group 1|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
1461406|NCT03263533|Drug|Vorinostat Oral Capsule Group 2|Following the initial washout and first 4-week period of the trial, all patients will enter a second 1-week washout. After the washout, all patients will then enter a second 4 week alternate treatment (vorinostat or placebo). During the vorinostat sequence, doses will be increased over the first 2 weeks in each phase of the crossover study, starting by 100 mg per day, and increasing to 200 mg by week 2 and 300 mg per day at the start of week 3 until the end of week 4.
1461407|NCT03263520|Drug|Nandrolone Decanoate|Drug administration
1461408|NCT03263520|Drug|Dexamethasone|Drug administration
1461409|NCT03263507|Drug|Placebo|Saline .9%
1461410|NCT03263507|Drug|IONIS PKK-LRx|Ascending single and multiple doses of IONIS PKK-LRx administered subcutaneously
1461411|NCT03263494|Device|Continuous Glucose Monitor (CGM)|Participants randomized to the CGM Group will receive a Dexcom CGM device and be instructed on how to utilize the CGM data in real time for diabetes management.
1461412|NCT03263481|Drug|Human Secretin for injection 16 mcg|Intravenous injection of human secretin for injection (16 mcg) will be administered over one minute. Pancreatic juice will be collected intraductally by continuous aspiration in 5-minute intervals for 30 minutes. Six samples will be collected at 5, 10, 15, 20, 25 and 30 minutes after secretin administration.
1461413|NCT03263468|Procedure|Same sitting PCI with complete revascularization|revascualrization of the non IRA (infarct related artery) of > 2.0 mm by coronary angioplasty/stenting at the time of primary PCI
1461414|NCT03263468|Procedure|Staged PCI with complete revsacularization >48 hours pf primary PCI|revascualrization of the non IRA (infarct related artery) of > 2.0 mm by coronary angioplasty/stenting >48 hours to 45 days post primary PCI
1461415|NCT03263455|Other|Kinesio taping group|"The tape in the KT group will be applied with paper-off tension, which means applying the tape directly to the skin as it comes off the paper backing (approximately with 15% to 25% of available tension). KinesioTape will be applied over the SCM dystonic muscle by means of 2 I-strips: the first strip will be placed on the medial (sternal) head and the second will be applied on the lateral (clavicular) head of the SCM muscle. KinesioTape was applied from the mastoid bone to the clavicle (rostrocaudal direction) with the SCM placed in a position of maximum stretching."
1461416|NCT03263455|Other|Sham Taping|"Patients in the ST group, smaller I-strips of KinesioTape will be used and they will be applied, with no tension and without stretching the muscles, perpendicularly to the muscle belly (starting from the middle and progressing to each side) over the same dystonic muscles as in the experimental group. Although the specific therapeutic elements of KinesioTaping (ie, longitudinal stretch, start and ending point tape application) will be removed"
1948009|NCT02874742|Drug|Dexamethasone|Dexamethasone 40 mg orally every week (20 mg on Days 1, 2, 8, 9, 15, and 16).
1948010|NCT02874742|Drug|Daratumumab|Daratumumab intravenously at a dose of 16 milligram per kilogram (mg/kg) weekly during induction treatment (Days 1, 8, and 15 of Cycles 1 through 4), and every 3 weeks during consolidation treatment (Day 1 of Cycles 5 and 6), followed by maintenance treatment with daratumumab every 8 weeks (Day 1 of odd cycles up to 32 cycles).
1461419|NCT03263429|Drug|Glutaminase Inhibitor CB-839|Given by mouth
1461420|NCT03263429|Biological|Panitumumab|Given by vein
1461421|NCT03263429|Drug|Irinotecan Hydrochloride|Given by vein
1461422|NCT03263429|Other|Laboratory Biomarker Analysis|Correlative studies
1461423|NCT03263429|Other|Pharmacological Study|Correlative studies
1461424|NCT03263429|Device|Imaging with 18F-FSPG PET/CT scans|During phase II at baseline and day 28 of cycle 1
1461427|NCT03263403|Biological|Ingovax ACWY|The pharmaceutical company in Bangladesh is now currently marketing meningococcal vaccine of Yuxi Walvax Biotechnology Co. Ltd which is filled finish by Incepta Vaccines Ltd. This fill finish meningococcal vaccine is already registered and licensed in Bangladesh. However, at present, no locally produced meningococcal vaccine is available in Bangladesh. Once this clinical trial is completed, it will then proceed for registration and licensure in Bangladesh. Ingovax ACWY is a freeze-dried preparation of the group-specific polysaccharide antigens from Neisseria meningitidis Group A, Group C, Group Y and Group W135. When reconstituted, the vaccine is a clear, colorless sterile solution for subcutaneous use.
1461428|NCT03263403|Biological|Menomune® - A/C/Y/W-135|Meningococcal polysaccharide vaccine MENOMUNE® - A/C/Y/W-135 vaccine manufactured by Sanofi Pasteur. MENOMUNE® - A/C/Y/W-135 [Meningococcal Polysaccharide Vaccine, Groups A, C, Y and W-135 Combined] is a freeze-dried preparation of the Group-specific polysaccharide antigens from Neisseria meningitidis, Group A, Group C, Group Y, and Group W-135. After reconstitution with diluent, the vaccine is a clear colourless liquid.
1461429|NCT03263390|Procedure|Bariatric Surgery|Sleeve gastrectomy or Roux-en-Y Gastric Bypass
1461430|NCT03263390|Drug|Anti Obesity Drugs|Response to FDA approved anti obesity medications
1461431|NCT03263377|Dietary Supplement|The school feeding intervention|The baseline study will be conducted using a cluster randomized study design in which schools represent clusters. Seven schools will be randomly selected from each of 7 Upazilas out of 10 that have been selected for intervention. The school feeding intervention consists of a daily snack in the form of a fortified biscuit that provides 300 kcal per single 75 gm packet (approximately 15% of daily calorie requirements), and a range of micronutrients contributing to about 75% of the daily requirement of vitamin A, folate, iron, iodine, zinc and magnesium.
1461432|NCT03263351|Behavioral|Cognitive-behavioral therapy group|Psychoeducation on depression; cognitive restructuring of negative thoughts; engagement in pleasant activities; healthy rewards; stress and coping.
1461433|NCT03263351|Behavioral|Health education group|Didactic health knowledge about interpersonal violence; basic nutrition guidance; sun safety; depression and signs of suicide; gang violence; substance use.
1461436|NCT03263312|Behavioral|Exercise|Exercise training all patients enrolled.
1461437|NCT03263299|Drug|cabergoline|Cabergoline was administered in a dose of 1 mg/week in two divided doses which was terminated after embryo transfer
1461438|NCT03263299|Drug|Aspirin|Aspirin was administered in daily dose of 80 mg initiated at the start of down-regulation with luteal leuprolide
1461439|NCT03263299|Drug|GnRH agonist|Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.
1461440|NCT03263286|Device|HandSOME|Participants use the HandSOME orthosis daily for 8 weeks.
1461441|NCT03263273|Drug|1% Topical Minocycline Gel|Compare the safety and efficacy of three treatment regimens: 1% topical minocycline gel, 3% topical minocycline gel & topical gel vehicle
1461442|NCT03263273|Drug|3% Topical Minocycline Gel|Compare the safety and efficacy of three treatment regimens: 1% topical minocycline gel, 3% topical minocycline gel & topical gel vehicle
1461443|NCT03263273|Other|Topical Vehicle Gel|Compare the safety and efficacy of three treatment regimens: 1% topical minocycline gel, 3% topical minocycline gel & topical gel vehicle
1461444|NCT03263260|Device|implant|coronary stent implantation
1461445|NCT03263247|Behavioral|Memory Training|
1461446|NCT03263247|Behavioral|Psychoeducation|
1461447|NCT03263247|Behavioral|Alphabet search|
1461448|NCT03263234|Other|8 weeks of circadian adjusted LED-based lighting (CALED)|The luminaires are installed before the beginning of either the control or the intervention period. During the control period (8 weeks) the luminaires have normal light. During the intervention period (8 weeks) the luminaires have CALED. Cromaviso will calibrate CALED to mimic circadian rhythm according to the latest knowledge about the light phase-response curve for elderly.
1461449|NCT03263221|Procedure|reduction and fixation|Surgical procedures, as plating, Proximal Femoral Nail , Dynemic Hip screw and others procedures according to needed for each types
1461481|NCT03262935|Drug|(vic-)trastuzumab duocarmazine|Intravenous SYD985, Q3W
1461482|NCT03262935|Drug|Physician's choice|See drug label
1461483|NCT03262909|Device|GelrinC|Patients will undergo GelrinC implantation.
1461484|NCT03262909|Other|Microfracture historical control arm|Patients undergo an arthroscopy for evaluation purposes, followed by lesion debridement, and a standard microfracture procedure.
1461453|NCT03263182|Behavioral|Introduction of the Safe Childbirth Checklist|"Adaptation of the SCC tool to Zambia: In order to produce a tool that is fully relevant to the Zambian context, a team of clinical experts from the MOH adapted the language of the SCC.
Training of trainers on the SCC by international experts: Ariadne Labs has designed a training-of-trainers (TOT) for coach training to support quality improvement initiatives, including the implementation of the WHO SCC. Members of the district mentorship team for Nchelenge District will receive this type of TOT training.
Following the TOT session, the district mentorship team will conduct facility-level training for health workers on using the SCC. Within target facilities, all public sector health workers will be invited to participate in the training.
Mentorship and support to facility-level health workers on using the SCC: The district mentorship team will carry out coaching and support visits to health facilities following the initial SCC training."
1461454|NCT03263169|Behavioral|Community-based personalized care|volunteer support, health technology, interprofessional care, social network linkage
1461455|NCT03263156|Behavioral|Sleep hygiene practices and behavioural intervention|The first session will involve the provision of sleep-related psycho-education (e.g. sleep hygiene practices) and specific strategies to tackle problematic sleep-related behaviours, as well as collaborative goal setting and development of management plan tailored to the child's sleep problem for the next two weeks. The second session will involve a review of the sleep diary and a reinforcement of learned strategies, and focus on problem-solving to tackle any issues that have emerged from implementing the behavioural strategies at home. A follow-up phone call will be made two weeks later to provide parents with an opportunity to ask any further questions and to consolidate learned strategies and further troubleshoot.
1461456|NCT03263143|Other|Palliative Care|Palliative Care Consultation within 24 to 48 hours after admission
1461457|NCT03263130|Other|As above: diagnosis: COPD, Emphysema, Asthma-COPD Overlap|
1461458|NCT03263117|Drug|Sedation|"The protocol does not specify a particular combination of drugs that must be used for sedation.
The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist."
1461459|NCT03263117|Drug|General Anesthesia (GA)|"The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.
The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)"
1461460|NCT03263117|Procedure|Intra-arterial Thrombectomy|The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.
1461461|NCT03263104|Dietary Supplement|Lactobacillus plantarum ECGC 13110402|Lactobacillus plantarum ECGC 13110402
1461462|NCT03263104|Dietary Supplement|Maltodextrin|
1461463|NCT03263091|Drug|FG-4592|Oral
1461464|NCT03263091|Drug|Placebo|Oral
1461467|NCT03263065|Dietary Supplement|Bran|220g rice pudding meal with raspberry jam with added bran flakes
1461468|NCT03263065|Dietary Supplement|Nopal|220g rice pudding meal with raspberry jam with added nopal flakes
1461469|NCT03263065|Dietary Supplement|Psyllium|220g rice pudding meal with raspberry jam with added psyllium flakes
1461470|NCT03263052|Drug|Tacrolimus XR (Envarsus)|Elderly patients (age 60 or older) on tacrolimus experiencing neurological AEs (tremor, insomnia, vertigo, photophobia, mood disturbances, or headache) presumably from tacrolimus immediate-release or tacrolimus XL will be converted to Envarsus. This conversion will be based on the Envarsus package insert which is a 20% reduction in total daily dose and is taken once a day. The conversion from Astagraf to Envarsus will be a 36% reduction.
1461471|NCT03263039|Drug|Pembrolizumab|Pembrolizumab 200 mg Q3W
1461472|NCT03263026|Drug|Enzastaurin Hydrochloride|R-CHOP + Enzastaurin (Kinenza®) 125 mg
1461473|NCT03263026|Other|R-CHOP + placebo|R-CHOP + placebo
1461474|NCT03262974|Diagnostic Test|PCR|PCR
1461475|NCT03262974|Diagnostic Test|HPLC-UV|HPLC-UV
1461476|NCT03262961|Drug|Sildenafil 20 MG|
1461477|NCT03262961|Drug|Placebo Oral Tablet|
1461478|NCT03262948|Drug|nab-paclitaxel|albumin-bound paclitaxel is 260 mg/m2 intravenously over 30 minutes on Days 1 of each 21-day cycle cycle immediately after albumin-bound paclitaxel
1461479|NCT03262948|Drug|Paclitaxel|paclitaxel is 175 mg/m2 intravenously over 3 hours on Days 1 of each 21-day cycle cycle immediately after paclitaxel
1461480|NCT03262948|Drug|Carboplatin|carboplatin is administered on Day 1 of each 21-day，followed by paclitaxel or nab-paclitaxel
1520531|NCT02813135|Drug|Irinotecan|
1461485|NCT03262857|Drug|use of magnesium sulfate with lidocaine in inferior alveolar nerve block|
1948011|NCT02874664|Drug|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC)
1948012|NCT02873546|Device|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 2 session per day during 5 consecutive days. Subjects will be monitored during tDCS sessions for any side effects or adverse events.
1948013|NCT02871778|Drug|VX-371|
1948014|NCT02871778|Drug|Hypertonic Saline|
1948015|NCT02871778|Drug|Placebo (0.17% saline)|
1948016|NCT02871778|Drug|Ivacaftor|
1461494|NCT03262818|Device|Transvaginal ultrasound|-Will be performed by US technologists at Washington University School of Medicine and read by Dr. Cary Siegel or Dr. Kathryn Robinson
1461495|NCT03262818|Device|Ultrasound/Photoacoustic imaging|-The light illumination for the photoacoustic imaging system is provided by a wavelength-tunable Ti:Sapphire laser (LOTIS TII), optically pumped by an Nd:YAG laser (LOTIS TII) at 532 nm wavelength.
1461496|NCT03262805|Dietary Supplement|Lanconone|. Lanconone® is a joint pain supplement containing natural herbs such as Shyonak, Ashwagandha, Shunthi, Guggul, Chopchini, Rasna and Shallaki in therapeutic quantities and documented in the ancient scriptures as pain relievers.
1461497|NCT03262805|Other|Placebo|Microcrystalline cellulose
1461501|NCT03262779|Biological|combination nivolumab and ipilimumab|Combination therapy with nivolumab 3 mg/kg administered intravenously (IV) every 2 weeks, with ipilimumab 1 mg/kg administered IV every 6 weeks.
1461502|NCT03262766|Other|Acute Intermittent Hypoxia (AIH)|This will consist of up to 90 seconds of 9-10% O2 (FiO2 0.09), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of hypoxia and normoxic air mixtures will be repeated up to 18 times per session each, for a total of up to 45 minutes.
1461503|NCT03262766|Behavioral|Upper extremity training|Subjects will receive 45 minutes of task-specific, high repetition upper extremity training, given using an upper-limb robotic rehabilitation device, the Armeo Spring®. Armeo Spring is a gravity support system based on an ergonomic arm exoskeleton with integrated springs. It cradles the entire arm, from shoulder to the hand, and counterbalances the weight of the user's arm. Therefore, it enhances any residual function and neuromuscular control, and assists in active movement across a large 3-D workspace. The Armeo software contains an extensive library of game-like movement exercises supported by a virtual-reality training environment that displays the functional task along with immediate performance feedback.
1461504|NCT03262766|Other|Sham Acute intermittent hypoxia|This will consist of up to 90 seconds of 21% O2 (FiO2 0.21), alternating with up to 90 seconds of 21% O2 (normoxic air FiO2 0.21). The delivery of alternating normoxic air will be repeated up to 18 times per session each, for a total of up to 45 minutes.
1461505|NCT03262753|Procedure|Surgery|Primary end-to-end surgical treatment of coarctation of the aorta
1461506|NCT03262753|Procedure|Balloon dilation|Primary balloon dilation treatment of coarctation of the aorta
1461507|NCT03262753|Procedure|Stent|Primary stent dilation treatment of coarctation of the aorta
1461512|NCT03262714|Other|Dance|Participants randomized to the dance group will take part in a dance intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. Dance classes will be performed in group in a dance studio, including a variety of rhythms such as salsa, jazz and aerobics. The dance session wil include a warm up of 15 min (posture, join mobility and dance technique), a main part of 40 min (learning of specific choreographies and practice of moves across the floor), and a cool down of 5 min (muscle stretching and relaxation).
1461513|NCT03262714|Other|Walking|Participants randomized to the walking group will take part in a walking intervention programme for 8 weeks, including 3 sessions per week, each lasting 60 min. The walking session will include a warm up of 10 min (posture and join mobility), a main part of 40 min (walking on a treadmill with a heart rate corresponding to 60% of VO2peak), and a cool down of 10 min (muscle stretching and relaxation).
1461514|NCT03262714|Other|Stretching|Participants randomized to the control group will take part in stretching classes, once a week, each lasting 60 min, also for 8 weeks. Stretching exercises for large muscle groups will be performed standing or in a match, holding the positions for a maximum of 10 s. There will be no music playing during the session.
1461751|NCT03260751|Dietary Supplement|Zingiber officinale Roscoe extract 200 mg|
1948017|NCT02869438|Drug|Benralizumab|Benralizumab administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
1948018|NCT02869438|Other|Placebo|Placebo administered subcutaneously at Visit 1 (Day 0), Visit 8 (Day28 +/- 3 days) and Visit 9 (Day 56 +/- 3 days)
1948019|NCT02868060|Drug|Romiplostim|
1948020|NCT02864901|Drug|KSL-W|Plaque reducing gum
1948021|NCT02864901|Drug|Chewing Gum Placebo|
1461517|NCT03262688|Drug|Bupivacaine HCl collagen-matrix implant|Placement of the bupivacaine collagen-matrix in the surgical site
1461518|NCT03262688|Drug|Bupivacaine HCl with epinephrine infiltration|Infiltration of the surgical site
1461519|NCT03262662|Drug|Varenicline|oral varenicline tablets
1461520|NCT03262662|Behavioral|Brief smoking cessation counseling|~10-minute individual counseling at each of 6 clinic visits
1461521|NCT03262636|Drug|Indocyanine Green|Indocyanine Green
1461522|NCT03262623|Other|Radial nerve block|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed. At this point 3-5 ml of the anesthetic mixture is injected. Each 10 ml of the anesthetic mixture contained: 3ml lidocaine 2%, 3ml lidocaine 2% with epinephrine, 1:2000,000, 3ml bupivicaine 0.5% and 1ml clonidine 150 µg/ml.
1461523|NCT03262623|Other|Placebo|A nerve stimulator will be used to localize the radial nerve. Then radial block will be performed containing normal saline
1461524|NCT03262610|Drug|Setmelanotide|daily subcutaneous injection
1461525|NCT03262597|Other|enterade|Subjects will consume enterade, which is an amino acid-based oral rehydration solution.
1461526|NCT03262597|Other|Pedialyte|Subjects will consume Pedialyte
1461527|NCT03262597|Other|Gatorade|Subjects will consume Gatorade
1461528|NCT03262597|Other|Water|Subjects will consume water as the control beverage
1461529|NCT03262571|Diagnostic Test|Lung ultrasound|Duretic therapy is then optimized according to the presence and severity of B-lines in group A.
1461530|NCT03262558|Other|No intervention|Patients will undergo standard clinical routine practice in this indication
1461531|NCT03262545|Drug|apatinib|Patients in experimental group will take 500mg apatinib daily orally，and patients in control group will take placebo
1461532|NCT03262545|Drug|Placebos|Physical properties of placebos are consistent with apatinib
1461533|NCT03262532|Other|Web-base simulator|Training manipulation of TEE using a Web-based simulator
1461534|NCT03262532|Other|No web-base simulator|Training manipulation of TEE with out a web-base simulator
1461535|NCT03262519|Diagnostic Test|Computer based neurocognitive testing|Iowa Gambling Task, The Balloon Task, Intertemporal choices task, Cognitive Reflection Test, Physiological and self-reported measures of OSA/sleep related symptoms, General health and physiological measures.
1461536|NCT03262506|Other|Computerized cognitive training|The cognitive training program consists of a set of computerized exercises designed to improve the speed and accuracy of auditory information processing while engaging neuromodulatory systems involved in attention and reward. These exercises continuously adjust the difficulty level to user performance to maintain an approximately 85% rate of correct responses. Trials with correct responses are rewarded with points and animations.
1461537|NCT03262493|Device|Interventional Group|Use of the feeding tube attachment device (FTAD).
1461538|NCT03262480|Other|goal directed fluid therapy monitoring|"Hemodynamic variables including stroke volume (SV), stroke volume variation (SVV), stroke volume index (SVI), cardiac output (COP), cardiac index (CI), systemic vascular resistance (SVR), systemic vascular resistance index (SVRI), thoracic fluid content (TFC), corrected flow time (FTC), index of contractility (ICON), systolic time ratio (STR), oxygen delivery (DO2) and oxygen delivery index (DO2I) will be measured by Cardiac output non-invasive monitor (ICONTM, OSYPKA medical cardiotronic GMBH, Elixir, Germany). Heart rate (HR), mean arterial blood pressure (MAP), central venous pressure (CVP) and arterial oxygen saturation (Sao2) will be measured using HP monitor.
If mean arterial blood pressure(MAP) drops below 65 mmHg despite achievement of SVopt and CVPmax in both groups, a bolus dose of 5 mg ephedrine will be given and repeated as needed .Norepinephrine will be given for persistent hypotension."
1461539|NCT03262467|Procedure|Aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun)|In patients with aneurysm of native vascular access indicated for surgical treatment, aneurysmorrhaphy with or without external porous prosthesis (Provena©, BBraun) wil be performed.
1461540|NCT03262454|Drug|Atezolizumab|Patients undergo hypofractionated radiation therapy with 24 Gy over 4 fractions in days 1-4 of 1st cycle of atezolimumab and receive Atezolizumab 1200 mg fixed dose via intravenous on day 1 of each 3-week cycle until disease progression or unacceptable toxicity occurs.
1461541|NCT03262441|Drug|Mycophenolate Mofetil 500Mg Tab|500 mg twice daily
1461542|NCT03262428|Other|Semi-structured interviews|Patients, caregivers and health care professionals involved in self-management support will be sought via patient organizations and professional organizations in the region. Study information materials will be provided to these organizations for dissemination to their members, providing also contact details of the study team for interested individuals to register their interest and provide basic eligibility and screening information. Selected participants will be invited to take part in a face-to-face or telephone interview about (supporting) self-management. Data collection will consist of semi-structured interviews conducted either face-to-face or by telephone.
1461543|NCT03262415|Device|LabPatch Continuous Glucose Monitoring (CGM)|"The patch device that will be applied to subjects' arms in this study is about 3 inches in length and one inch in width, with adhesive tape on the sides.
The LabPatch circuit chip lies on the underside of the bandage. The circuit is in the form of a small chip (approximately 15.7 mm [0.618] x 15.7 mm [0.618]) placed in contact with the skin. The chip has a telescopic micropipette which draws interstitial fluid to be analyzed for glucose levels. The chip is also able to measure skin temperature to ensure appropriate skin contact.
A wire that connects the chip to a laptop that continuously captures glucose data."
1461544|NCT03262402|Procedure|Basic periodontal treatment|Basic periodontal treatment consists of scaling and root planing performed with manual curettes or ultrasonic instruments.
1461545|NCT03262389|Drug|Fludeoxyglucose|Route of administration is intravenous. Dose of each injection will be the standard 5 to 10 millicurie (mCi).
1461546|NCT03262389|Drug|Sodium Acetate C11|Route of administration is intravenous. Dose of each injection will be 10 mCi (370 MBq).
1461594|NCT03262038|Drug|Ondansetron|This arm will receive (in a blinded fashion) 0.1 mg/kg of Ondansetron IV made up to 5 mLs intra-operatively and Ondansetron IV 0.1 mg/kg made up to 5 mLs every 6 hours for 24 hours postoperatively.
1461551|NCT03262363|Combination Product|Curcumin/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules per day for one week, one in the morning 15 minutes before breakfast and another at night 15 minutes before dinner, accompanied by a cup of 240 mL of pure water. It will be indicated to continue with their usual medical treatment.
1461552|NCT03262363|Combination Product|Placebo/NFE2L2 A>G|The administration will be orally and the patient will be instructed to take two capsules for 24 weeks, one in the morning 15 minutes before breakfast and another in the evening 15 minutes before dinner, accompanied by a 240 mL cup of pure water. They will be advised to continue their usual medical treatment.
1461555|NCT03262324|Other|VAS-FA Turkish version|Self-reported outcome questionnaires
1461556|NCT03262311|Other|Hypoxia marker|Single oral dose of pimonidazole 500 mg/m2
1461557|NCT03262298|Biological|Anti-CD22-CAR-transduced T cells|a single dose of Anti-CD22-CAR-transduced T cells will be infusion after preconditioning.
1461558|NCT03262285|Procedure|phacoemulsification|removal of cataract using ultrasound waves
1461559|NCT03262285|Procedure|extracapsular cataract extraction|removal of cataract using surgical corneal incision
1461560|NCT03262272|Device|Biocompatibility|Assesment of inflammatory molecules
1461561|NCT03262272|Device|Performances|Extraction of middle molecules
1461563|NCT03262246|Other|medical report consultation|investigators consult medical report concerning patient identified for cerebral amyloid angiopathy
1461564|NCT03262233|Combination Product|nicotine|
1461565|NCT03262233|Other|placebo|
1461566|NCT03262220|Radiation|Volumetric Arc Therapy (VMAT)|Total Marrow Irradiation: 12 Gy in 3 fractions of 4 Gy on 3 consecutive days with a concomitant simultaneous integrated boost (SIB) of 4.5 Gy x 3 fractions delivered to active bone marrow (ABM).
1461567|NCT03262207|Other|Extraction genomic DNA|
1461568|NCT03262207|Other|Analysis of methylation profiles of numerous GSI and TE|
1461569|NCT03262207|Other|Analysis of methylation for the whole genome (sub-population of 15 samples from group 1)|
1461570|NCT03262207|Other|Method of protein detection by immunostaining and flow cytometry|
1461571|NCT03262181|Other|Isometric Exercise|5 sets of 45-seconds quadriceps contraction, each followed by 2-minutes of rest.
1461572|NCT03262181|Device|Sham Transcutaneous Electrical Nerve Stimulation|5 sets of 45-seconds intervals without quadriceps contraction, each followed by 2-minutes of rest.
1461573|NCT03262168|Other|Exercise Programme|Complete background demographics, Sniff Nasal Inspiratory Pressure (study group one only), grip strength, muscle strength, PHQ-9 and GAD-7 questionnaires.
1461574|NCT03262155|Biological|Blood test|
1461575|NCT03262142|Drug|Piperacillin/tazobactam|Intravenous Piperacillin/tazobactam three times daily
1461576|NCT03262142|Drug|Ciprofloxacin|Oral Ciprofloxacin twice daily
1461577|NCT03262116|Drug|Humalog|Subjects will participate in one week of wearing the insulin only bionic pancreas using humalog as the rapid acting insulin.
1461578|NCT03262116|Drug|Novolog|Subjects will participate in one week of wearing the insulin only bionic pancreas using novolog as the rapid acting insulin.
1461579|NCT03262116|Drug|Apidra|Subjects will participate in one week of wearing the insulin only bionic pancreas using apidra as the rapid acting insulin.
1461580|NCT03262116|Device|Bionic Pancreas|The insulin only bionic pancreas will be used in all three arms of the study
1461581|NCT03262103|Biological|Intratumoral (IT) Poly ICLC 0.5 mg|0.5 mg IT once/week (week 1)
1461582|NCT03262103|Biological|Intratumoral (IT) Poly ICLC 1.0 mg|1.0 mg IT once/week (week 1)
1461583|NCT03262103|Biological|Intramuscular (IM) Poly ICLC|1 mg IM twice weekly (weeks 3-6)
1461584|NCT03262103|Procedure|Radical Prostatectomy|as per standard care
1461585|NCT03262090|Drug|0.2ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.2ug/kg intravenous dexmedetomidine before skin incision
1461586|NCT03262090|Drug|0.4ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.4ug/kg intravenous dexmedetomidine before skin incision
1461587|NCT03262090|Drug|0.6ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.6ug/kg intravenous dexmedetomidine before skin incision
1461588|NCT03262090|Drug|0.8ug/kg dexmedetomidine|subjects were randomly assigned to receive 0.8ug/kg intravenous dexmedetomidine before skin incision
1461589|NCT03262090|Drug|1.0ug/kg dexmedetomidine|subjects were randomly assigned to receive 1.0ug/kg intravenous dexmedetomidine before skin incision
1461590|NCT03262077|Drug|Methylene Blue|Irradiation with low-level laser for 1, 3, and 5 min
1461591|NCT03262077|Drug|Methylene Blue Oral Product|Irradiation with low-level laser for 1, 3, and 5 min
1461592|NCT03262064|Combination Product|Pulmonary function tests,Bronchiectasis severity index score|"Pulmonary function tests: including spirometry, DLCO, and lung volumes. Sputum investigations: The following investigations will be performed on fresh sputum samples; gram stains and culture, smear and culture for mycobacteria and fungi and antibiotic sensitivity tests Bronchoscopy: Bronchoscopy with bronchoalveolar lavage will be used to obtain specimens for staining and culture to identify type of colonization.
Radiology: All patients will have a chest radiograph (PA and lateral) and high-resolution computed tomography (HRCT) scan.
Bronchiectasis severity index score parameters FACED Score"
1461593|NCT03262051|Diagnostic Test|CYP phenotyping|Phenotyping using a simplified version of the Geneva cocktail
1461669|NCT03261427|Drug|YNP-1807 330Mg Tablet|330 mg oral administered (QD)
1520532|NCT02813135|Drug|AZD2014|
1461595|NCT03262038|Drug|Placebo Comparator|This arm will receive (in a blinded fashion) a volume-matched placebo intraoperatively as well as IV every 6 hrs for 24 hours postoperatively.
1948022|NCT02864797|Other|Health related quality of life collected via CHES|Health related quality of life (QoL) is collected at each follow-up visit using tablets computer and CHES software. Thus, QoL's results are directly presented to clinicians via the CHES, in order to be considered as part of the supportive care strategy at the end of the study
1948023|NCT02863120|Drug|liposomal bupivacaine|
1948024|NCT02863120|Drug|bupivacaine HCl|
1948025|NCT02863120|Drug|Ropivacaine|
1948026|NCT02863120|Drug|Saline|
1461602|NCT03261986|Radiation|Radiostereometric Analysis|RSA exams of the operative hip are received post-op day 1, and at 6 weeks, 3 months, 6 months, 1 year and 2 years following surgery
1461603|NCT03261986|Procedure|total hip arthroplasty with RSA bead implantation|Patients receive RSA beads inserted into the bone surrounding the Trident II implant.
1461604|NCT03261973|Device|DV8|DV8 esophageal deviation tool
1461607|NCT03261947|Drug|TAK-931|TAK-931 capsules.
1461609|NCT03261921|Drug|Dexamethasone|Dexamethasone is used peri -operatively mainly to prevent nausea and vomiting. Also epidural administration of dexamethasone prolong the postoperative analgesia and reduce analgesic needs
1461610|NCT03261921|Drug|Dexmedetomidine|Dexmedetomidine is an alpha 2 agonist which has sedative ,analgesic, opioid sparing effect and was proved to prolong the duration of postoperative analgesia when added to local anesthetics
1461611|NCT03261921|Drug|Bupivacaine|local anesthetic agent
1461612|NCT03261908|Genetic|detection of genotype|detection of genotype by next generation sequencing
1461613|NCT03261895|Behavioral|Nurse-led Integrative health and wellness programme|Participants in the intervention group will go through a eight-session structured education programme. The education programme was designed by incorporating the evidences of diabetes care from the western medicine and the philosophy of traditional Chinses medicine.
1461614|NCT03261882|Other|Nativity|Mexican-American children were subdivided into two groups based on their country of birth. Mexican-American children who were not born in the U.S. were considered foreign-born and those born in the U.S. were U.S.-born.
1461615|NCT03261869|Other|Cold application|
1461616|NCT03261843|Biological|autologous platelet rich plasma|adding autologous platelet rich plasma to the bone graft harvested from the patient
1461617|NCT03261843|Procedure|posterior lumbar interbody fusion without autologous platelet rich plasma|performing posterior lumbar interbody fusion without using platelet rich plasma
1461621|NCT03261817|Behavioral|Physical activity (APA)|"2 sessions a week of 1 hour during 16 weeks. APA exercises by web will be aerobic type associated with muscle toning program; Activities will combine relaxation techniques, body expression and muscle relaxation (yoga, stretching, relaxation, step etc ...).
The intensity of the activities will be individualized for each participant according to his/her physical condition"
1461622|NCT03261817|Behavioral|Health Education program (HE)|2 sessions a week of 1 hour during 16 weeks HE by web will be delivered and was composed of information on the main mental disorders, the benefits of physical activity, healthy lifestyle (dietary balance, sleep cycle, stress management), alcohol, drug, tobacco and cardiovascular risk factors
1461623|NCT03261804|Behavioral|relation between vaginal douching and vaginal infection|personal hygiene including performing external or Internal vaginal douching, how she is performing this douching (by hand, water, jet, pump), how frequent and why they perform this internal vaginal douche.
1461624|NCT03261791|Drug|Apatinib|Apatinib mesylate tablets 500 mg po qd.
1461625|NCT03261778|Device|Acromion 2.0 Brace|Acromion 2.0 Brace will be worn for 6 weeks instead of the conventional Mitella sling
1461626|NCT03261765|Other|Assessment of adhesions|Modified Nair scoring system
1461627|NCT03261752|Diagnostic Test|blood sample|Total genomic DNA will be extracted DNA extraction kit using a QIAamp DNA Blood Mini kit .Genetic analysis of both SPG20 &STK31 by RTPCR.
1461630|NCT03261726|Device|MedEl Test Electrode Placer|This study uses a sterile dummy (i.e., not working) cochlear implant electrode inserted at the time of tumor removal to keep the inner ear from scarring or filling with bone. The significance of this to you is that if you ever become eligible for a cochlear implant sometime after surgery, it may be possible to remove the dummy and insert a functioning cochlear implant.
1461631|NCT03261713|Device|Virtual reality|Virtual reality training is provided using Jintronix Rehabilitation software. A Kinect camera captures the movements of the participant using infrared technology and allows them to control an avatar, which interacts with an activity. Several games and activities are available to train standing balance (ex. slalom skiing), reaching (ex. planting seeds/harvesting tomatoes), stepping (ex. whack-a-mole), gentle strengthening (ex. knee extensions) and aerobic exercises (ex. marching on the spot). Game and activity difficulty can be increased by requiring more repetitions, or greater speed, distance and/or accuracy. Specific games and activities, and their parameters are customized for each participant. The exercise plan is performed 5 times a week for 6 weeks for 30 minutes at each session.
1461632|NCT03261713|Device|Control|Participants in the control group are provided with an iPad which contains a selection of apps suited for memory (ex. memory card game), cognition (Sudoku, cross-word), visual tracking (word search) and fine motor skills (ex. writing, whack-a-mole). Participants are instructed to perform their exercise plan 5 times a week for 6 weeks for 30 minutes at each session.
1461670|NCT03261414|Procedure|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
1461671|NCT03261414|Procedure|usual care|Standard care before induction of anesthesia
1461633|NCT03261700|Behavioral|RISE|This provider- administered brief- counseling intervention program will increase Women Veteran's self- efficacy in addressing violence in their current or past relationships. The variable length (up to six- session) modular-based intervention aims at providing resources for WVs in the relevant domains of: 1) safety planning, 2) education on health effects of IPV, 3) improving coping and self- care, 4) enhancing social support, 5) making difficult decisions, and 5) connecting with resources.
1461634|NCT03261700|Other|Information and referral condition|Participants randomized to this arm will receive information about IPV and referrals to VA and community resources.
1461635|NCT03261687|Other|water based exercise|
1461636|NCT03261687|Other|land based exercise|
1461637|NCT03261687|Behavioral|advice|general advice given to all subjects
1461638|NCT03261674|Behavioral|CBTI|Cognitive Behavioral Therapy for Insomnia (CBTI)
1461639|NCT03261674|Behavioral|DTI|Desensitization Therapy for Insomnia (DTI)
1461640|NCT03261661|Behavioral|Reading|Students are taught the processes involved in hearing, seeing, and feeling sounds as well as differences between sounds in words. New knowledge is built on previous knowledge in a step-by-step manner. Sounds build to letter-sound relationships to reading of words and syllables. Students learn the connection between reading of words (decoding) and writing/spelling words (encoding) building from simple words to multisyllabic words to text reading with fluency and understanding.
1461641|NCT03261661|Behavioral|Mindset|Blended learning program with online and teacher-directed activities related to how the brain functions, learns, and remembers, and how it changes in a physical way when we exercise it. Instruction in how students are in control of their brain and its development, and how to apply this to their schoolwork with practical strategies for tackling academic challenges.
1461642|NCT03261661|Behavioral|Reading Embedded with Mindset|Mindset training explicitly linked to the reading content through lesson openers, feedback prompts, and self-monitoring of mindset during reading work.
1461643|NCT03261661|Behavioral|Business as Usual|Reading interventions already provided to students with reading difficulties as per typical procedures at the participating school
1461644|NCT03261648|Other|State-Trait-Anxiety Inventory (Forme Y) questionnaire|after admission in the emergency department, patient and his partner will completed STAI Y questionnaire.
1461645|NCT03261648|Other|pain level scale|as usual caregiver will ask to the patient to evaluated his pain level with a scale of one to ten
1461646|NCT03261635|Drug|Ranibizumab Injection|patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata
1461647|NCT03261635|Drug|Indomethacin|patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months
1461648|NCT03261622|Device|Sacral nerve stimulation at different stimulation amplitudes|Exploring the effect of different stimulation amplitude in a randomized study
1461649|NCT03261609|Other|preterm birth|The study compares young adult subjects born premature (< 29 weeks) versus term (-> 37 weeks)
1461650|NCT03261596|Drug|Mebendazole|Participants will be randomized using a 1:1 ratio to one of the two arms. Study participants eligible for treatment will be randomly assigned to one of the two treatment arms using a computer-generated stratified block randomization code.
1461651|NCT03261583|Other|Thoracis Surgery - Common care|Observational study. It is only a matter of collecting clinical data.
1461652|NCT03261570|Drug|Pyridostigmine|60mg by mouth
1461653|NCT03261570|Drug|Digoxin|0.5 (500mcg) by mouth
1461654|NCT03261570|Drug|Placebo|Lactulose 50mg by mouth
1461655|NCT03261557|Behavioral|CBT + SST|"It will consist of 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: cognitive skills module, which includes the basic principles of CBT for psychosis; Social skills module, which includes the usual strategies in HHSS training; and problem solving module.
All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
1461656|NCT03261557|Behavioral|Psychoeducation, habits and healthy lifestyle|"Patients randomized to the control treatment will receive the same number of Individual and group sessions, with the same periodicity and format: 1 individual sessions and 15 weekly periodicity group sessions distributed in 3 modules: psychoeducation, habits and healthy lifestyle.
All patients will receive pharmacological treatment and will be followed up by their referral psychiatrist habitual."
1461657|NCT03261544|Procedure|Proximal Femur Replacement|The purpose of this study is to assess the functional outcomes in patients undergoing proximal femur resection and reconstruction with an endoprosthesis, based on the abductor muscle repair technique.
1461658|NCT03261531|Device|Transcutaneous electrical nerve stimulation (TENS)|Participants will be treated before and after two meals of the day with T6 dermatomal electrical stimulation delivered by a TENS unit.
1461659|NCT03261518|Procedure|inferior vena cava ultrasound|Place the patient in the supine position. The degree of elevation of the head of the bed has not been shown to make a significant difference in measurements. The diameter of the IVC for calculation of the caval index should be measured 2 cm from where it enters the right atrium .An alternative way to visualize respiratory variation is to use M-mode, with the beam overlying the IVC 2 cm from the right atrium.The inspiratory and expiratory diameter can then be measured on the M-mode image, at the smallest and largest locations, respectively.
1461660|NCT03261505|Device|Acupuncture|Patients will watch a video of themselves receiving acupuncture or a control video or receive real or sham acupuncture treatment.
1461661|NCT03261492|Behavioral|Physical Activity|SAGE curriculum is a garden-based PA and nutrition educational program for early care and education centers.
1461662|NCT03261492|Behavioral|Child Safety Attention Comparison|The goal of this comparison group is to provide centers with an engaging, useful, carefully sequenced, and easy-to-deliver curriculum so that randomization to this group does not influence attrition or reach and serves as a placebo (unlikely to affect outcomes of interest).
1461663|NCT03261479|Diagnostic Test|Thermal image|We will take a non-invasive thermal image with the FLIR ONE thermal imaging camera that attaches to a study-designated iPhone.
1461664|NCT03261466|Drug|Bifidobacterium breve BR03 and Bifidobacterium breve B632|
1461665|NCT03261466|Drug|Placebos|
1461666|NCT03261453|Device|Active Elipse Device|Intervention Device
1461667|NCT03261453|Device|Elipse Sham Device|Control Device
1461668|NCT03261427|Drug|Lyrica 150Mg Capsule|150 mg oral administered (BID)
1461676|NCT03261388|Behavioral|Activity-Based Locomotor Exercise Program (ABLE)|The ABLE program is an intensive locomotor based intervention that is offered at the Golden Valley Courage Kenny Rehabilitation Institute.
1461677|NCT03261375|Device|Renal Denervation System|A renal denervation system with a 6 electrodes-on-net structure catheter
1461678|NCT03261375|Drug|Antihypertensive Agents|Calcium channel blocker，Diuretic
1461679|NCT03261375|Device|Sham Procedure|Catheterization without renal denervation
1461680|NCT03261362|Dietary Supplement|Branched-chain amino acids reduced intake|
1461681|NCT03261349|Drug|Ledipasvir and sofosbuvir|To assess whether Harvoni® (ledipasvir and sofosbuvir) could eradicate HCV and lead to durable complete remission of these lymphomas.
1461682|NCT03261336|Drug|Calcitriol, Ketoconazole, Hydrocortisone|Calcitriol (0.5 mcg caplets) given in escalating doses, orally QD X3 consecutive days every week Ketoconazole, 200 mg tablets, 2 tablets orally TID Hydrocortisone 20mg AM, 10mg PM orally starting in the evening before the first dose of Calcitriol
1461683|NCT03261323|Procedure|Immediate Breast Reconstruction|Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery. Reconstruction will be attempted immediately after mastectomy.
1461684|NCT03261323|Procedure|Delayed Breast Reconstruction|Risk reduction strategies on smoking, weight, and chronic disease control will be offered. The individual risk will be recalculated every three months. Delayed breast reconstruction will be offered when core cancer therapies (mastectomy, chemotherapy and radiation) are complete. Only implant based surgeries will be considered in this study. The patient will be followed for at least 1 year after the last reconstruction surgery.
1461685|NCT03261323|Other|Breast-Q questionnaire|Developed out of Memorial Sloan-Kettering Institute for Cancer Research, this questionnaire is designed to create a patient-reported outcome measure to provide quantifiable information about the impact and effectiveness of breast surgery. In this study it will be used for quality of life assessment
1461686|NCT03261310|Drug|Acetaminophen or Placebo|"Study subject will receive either 1000mg of acetaminophen in 100ml own diluent, or 100ml of saline during their intra-operative period and an order will be placed in their chart/Essentris order for No acetaminophen for 6 hours post operatively."
1461687|NCT03261284|Drug|Dabigatran Etexilate 150 MG [Pradaxa]|Dabigatran Etexilate 150mg,bid
1461688|NCT03261284|Drug|Warfarin Pill|Add warfarin dose according to INR values.
1461689|NCT03261271|Behavioral|Weight Loss Program|Program involves one-on-one coaching, diet meal plan, and physical activity plan.
1461690|NCT03261271|Behavioral|Standardized educational flyer|"The American Institute for Cancer Research handout Nutrition and the Cancer Survivor will be provided to participants."
1461691|NCT03261271|Behavioral|Weight Maintenance Program|Post-surgery program involves group support sessions, phone check-ins, and diet and exercise monitoring.
1461692|NCT03261258|Other|Questionnaire|
1461693|NCT03261219|Device|Intrapulmonary Percussive ventilation|mode of airway clearance using mouthpiece and alternating air currents applied directly to the airway
1461694|NCT03261219|Device|Chest Physiotherapy Vest (Incourage)|mode of airway clearance using external vibratory vest
1461695|NCT03261206|Other|5-ASA Withdrawal|Withdrawal of 5-ASA therapy
1461696|NCT03261193|Drug|ITM + Sham QLB|Sham subcutaneous non-anesthetic infiltration with saline
1461697|NCT03261193|Drug|ITM + Bupivacaine QLB|QL plane block with local anesthesia
1461698|NCT03261180|Other|Best Practice|Receive regular diet
1461699|NCT03261180|Other|Laboratory Biomarker Analysis|Correlative studies
1461700|NCT03261180|Dietary Supplement|Nutritional Intervention|Receive Nestle Impact AR
1461704|NCT03261128|Other|Self-questionnaire|Filling of a self-questionnaire before each chemotherapy cure
1461706|NCT03261102|Biological|Adalimumab|
1461707|NCT03261076|Behavioral|Strategies Enhancing Reading in Older Underperf. Students|Strategies for Enhancing Reading in Older Underperf. Students (SERIOUS) combines two scientific, research based intervention programs, each meeting specific need of youth in detention: (1) Stevenson Reading Program, manualized and uniquely suited to students with phonological awareness, attention, and memory difficulties that may impact reading; and (2) Dr. Sharon Vaughn's well-documented, validated program, explicitly designed for older, severely reading-impaired students. SERIOUS also includes: (3) metacognitive strategies for self-regulated learning, and (4) A gamified extension of the intervention on a SmartPhone, designed to reinforce word-level skills (e.g., decoding, automaticity, and vocabulary), and including features efficacious for learning.
1461708|NCT03261063|Device|Evera MRI ICD System|Subjects are implanted with Evera MRI ICD System and exposed to MRI environment per study requirements
1461709|NCT03261050|Behavioral|Counter Attitudinal Therapy|8 weekly 60 minute sessions of dissonance-based treatment wherein women with any eating disorder complete verbal, written, and behavioral activities.
1461750|NCT03260764|Device|long term Bifocal Spectacles|wearing Bifocal Spectacles for one year
1995045|NCT02866695|Drug|ingenol mebutate gel 0.015%|ingenol mebutate gel 0.015% to be applied on treatment area
1461710|NCT03261037|Other|Spirometry|Daily spirometry will be conducted by the participant at home using the study kit provided. Spirometry assessments (FVC) will be conducted at approximately the same time each day with the participant in a seated position. Additionally, site spirometry will also be performed during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
1461711|NCT03261037|Other|Accelerometry|Daily physical functional capacity assessments (e.g., steps per day, calorie expenditure) will be measured on an ongoing basis using the accelerometry device provided.
1461712|NCT03261037|Other|6MWT|The 6MWT will be performed only at sites where a formalized process is available and the test can be performed under safe conditions, during pre-diagnosis assessment period, on the day of diagnosis, post-diagnosis assessment period, and at end of study.
1461713|NCT03261024|Device|Friction mechanics|Nickel Titanium will be extended from the hook between the lateral incisors and canines to the first molar bands, to allow frictional en-masse retraction of anterior segment.
1461714|NCT03261024|Device|Frictionless mechanics|T-loops retraction arch will be placed distal to the upper canines and cinched distal to the first molar bands, to allow frictionless en-masse retraction of anterior segment.
1461715|NCT03261011|Biological|AK-104|Subjects will receive AK104 by intravenous administration.
1461716|NCT03260998|Diagnostic Test|electrocardiogram|measurment of QT dispersion and corrected QT and other electrocardiogram changes
1461717|NCT03260985|Other|Feedback Report|A report of the data from the comprehensive neuroscience assessment is provided to the patient's care team.
1461718|NCT03260972|Drug|Chloroprocaine Hcl 2% Inj|20 mls of Chloroprocaine Hcl 2% Inj (1 vial containing 400mg/20 mls of chloroprocaine) will be instilled into the abdomen prior to fascia closure.
1461719|NCT03260972|Drug|Normal saline|20 mls of normal saline will be instilled into the abdomen prior to fascia closure.
1461720|NCT03260959|Behavioral|Interview by hierarchical evocation's Method|Interview to describe the experience of the man during the announcement of a pregnancy that it is expected or not.
1461721|NCT03260946|Other|Complementary medicine use|The prevalence of complementary medicine use
1461722|NCT03260933|Other|No intervention given. This is a qualitative interview study|This is a qualitative interview study
1461723|NCT03260920|Drug|Syntocinon|Intranasal Oxytocin
1461724|NCT03260907|Procedure|Electroacupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used. An electric acupuncture device (CellMac STN-110, Stratek Co, Republic of Korea) will be connected to the CV3-CV4, KI3-SP6 acupoints and deliver stimulation with a 2-Hz frequency, asymmetric bimodal pulse, continuous wave mode, maximum intensity below the threshold (7.6~13.9mA).
1461725|NCT03260907|Procedure|Acupuncture|The treatment is to be applied twice a week for acupuncture points(unilaterally at CV3, CV4, GV20 and bilaterally at KI3, SP6), used for all the patients assigned to this group. Disposable, sterilized, filiform acupuncture needles manufactured is to be used.
1461726|NCT03260894|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
1461727|NCT03260894|Drug|Epacadostat|Epacadostat administered orally twice daily.
1461728|NCT03260894|Drug|Sunitinib|Sunitinib administered orally once daily.
1461729|NCT03260894|Drug|Pazopanib|Pazopanib administered orally once daily.
1461730|NCT03260881|Drug|Liraglutide Pen Injector [Victoza]|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
1461731|NCT03260881|Drug|matching liraglutide-placebo pre-filled pens|Study subjects will be randomized in two groups of 20 patients to receive additional liraglutide, (L-group) or to remain on current treatment or placebo (D-group).
1948031|NCT02858427|Behavioral|eye tracking|"several oculomotor parameters will be recorded using vide-oculography techniques (eye tracking) trough different tasks: saccade, antisaccade, and picture scanning.
Saccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the red dot appearing on the periphery of the screen.
Prosaccade task: the patient is looking at a screen and is asked to fix his gaze as quickly and accurately as possible on the opposite side relative to the red dot appearing on the periphery of the screen.
Picture Scanning: participant is instructed to freely watch pictures with different emotional valence."
1461739|NCT03260829|Drug|vitamin C|25 IU of vitamin C injected intraepidermally for 6-8 visits till eruption achieved
1461740|NCT03260816|Behavioral|Internet-delivered Parent-Child Interaction Therapy (I-PCIT)|Families assigned to the Internet-delivered Parent-Child Interaction Therapy (I-PCIT) group will receive Internet-delivered weekly sessions of a short-term parent-training intervention emphasizing positive attention, consistency, problem-solving, and communication. Using videoconferencing, webcams, and wireless Bluetooth earpieces, I-PCIT therapists provide in-the-moment feedback to parents during live parent-child interactions.
1461741|NCT03260816|Other|Referrals as Usual (RAU)|Families assigned to RAU will participate in services referred by their Early Steps team, as per usual care.
1461742|NCT03260803|Drug|Oligopin|Oligopin ,150 mg ,once daily, 12 week
1461743|NCT03260803|Drug|Placebo|Placebo,150 mg ,once daily, 12 week
1461746|NCT03260777|Device|Trichoscopy|Trichoscopy (hair and scalp dermoscopy) is a noninvasive diagnostic tool that allows the recognition of morphologic structures not visible by the naked eye Structures which may be visualized by trichoscopy include hair shafts of different types, the number of hairs in one pilosebaceous unit, hair follicle openings (dots), the peri and interfollicular areas and the vasculature.
1461747|NCT03260764|Device|short term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one week
1461748|NCT03260764|Device|short term Bifocal Spectacles|wearing Bifocal Spectacles for one week
1461749|NCT03260764|Device|long term Multifocal Contact Lenses|wearing Multifocal Contact Lenses for one year
1520533|NCT02813135|Drug|Nivolumab|
1461752|NCT03260751|Dietary Supplement|Zingiber officinale Roscoe extract 400 mg|
1461753|NCT03260751|Dietary Supplement|Placebo|
1461754|NCT03260738|Device|Rehabilitation program with Poppy robot|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 4 weeks. Among those 3 hours, patients receive 30 minutes of kinesitherapy exercises supervised by robot Poppy.
1461755|NCT03260738|Other|Usual rehabilitation program|Patient with a chronic low back pain. Usual 3 hours rehabilitation daily program, 5 days a week, 4 weeks.
1461756|NCT03260725|Behavioral|Parent-Child Interaction Therapy (PCIT)|PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered in the clinic.
1461757|NCT03260725|Behavioral|Internet-delivered PCIT (I-PCIT)|I-PCIT is a short-term intervention that incorporates principles of play therapy into behavioral parent training, drawing on attachment and social learning theories to emphasize positive attention, consistency, problem solving, and communication. Treatment is delivered to families in their own home in real-time via videoconferencing over the Internet by a remote therapist.
1461758|NCT03260712|Drug|Pembrolizumab|The dose of pembrolizumab in this trial is 200 mg Q3W.
1461759|NCT03260712|Drug|Cisplatin|25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle
1461760|NCT03260712|Drug|Gemcitabine|1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
1995046|NCT02866630|Biological|Blood samples|Six additional blood samples will be taken from in-situ catheters during heart surgery
1461762|NCT03260686|Other|experimental|video guide for upper limb exercise
1461763|NCT03260673|Other|specular microscope|The corneal endothelial cell density, variation in endothelial cell size (CV), percentage of hexagonal cells, and central corneal thickness(CCT) were recorded at baseline and at 3 months postoperatively.
1461764|NCT03260660|Device|Magnetic Resonance Elastography|The investigators plan to prospectively assess the agreement of liver stiffness measurements obtained using standard of care MR elastography techniques vs. MR elastography with varying amounts of imaging acceleration using compressed sensing in adult volunteers
1461765|NCT03260647|Other|Management algorithm for Malignant Bowel Obstruction|a proposed management algorithm for MBO has been developed to provide a pathway that safeguards quality and continuity of care for patients under a multidisciplinary team. It will engage key-stakeholders and foster an inter-professional approach. It incorporates an in-patient management algorithm and a novel nursing-led ambulatory management algorithm to supplement patient's medical management
1461766|NCT03260634|Drug|Voriconazole|
1461767|NCT03260621|Diagnostic Test|stress CMR|additional stress CMR to the established clinical diagnostics
1461768|NCT03260608|Behavioral|Telesupport|In the intervention will be carried out eight weekly phone calls of psychoeducation and support on the disease of the relatives approaching different themes.
1461771|NCT03260582|Other|LifePod®|"The software is a web-based application designed to support persons adhering to lifestyle advice and medication. The patient can log information about lifestyle (i.e. diet, exercise, and smoking), measurements (i.e. weight, pulse and blood pressure), symptoms and medication and can review data in graphs displaying registered values in relation to recommended targets. The software provides positive feedback on healthy choices and gives general recommendations on exercise training, physical activity and healthy diet. Reminders are generated in the case of decreasing registrations. Finally, short text messages (SMS) will be sent out 2-3 times a week with tips on healthy lifestyle.
Activity trackers are accelerometers intended to monitor daily physical activity."
1461772|NCT03260569|Drug|Inhaled Nitric Oxide|Patients randomized to this arm will receive inhaled nitric oxide 20 parts per million.
1461773|NCT03260569|Drug|Placebo|Nitrogen plus oxygen
1461774|NCT03260556|Drug|Pirfenidone|Increasing doses
1461775|NCT03260556|Drug|Placebos|Increasing doses
1461776|NCT03260543|Dietary Supplement|fermented ginseng powder|tablets (2 tablets/day, 125 mg & 500 mg/day) for 12 weeks.
1461777|NCT03260543|Dietary Supplement|Placebo|Placebo for 12 weeks.
1461778|NCT03260530|Other|Locomotor evaluation|collection of parameters associated with walking and balance in patients with their usual prosthesis and then equipped with the new prosthesis
1461779|NCT03260530|Other|Questionnaires|Houghton's scale, PPA-LCI, ABC, QEP, SF-12, SAT-PRO, ESAT
1461783|NCT03260491|Drug|U3-1402|U3-1402 consists of an antibody component (patritumab, U3-1287) covalently conjugated to a drug-linker (MAAA-1162a) containing a drug component (MAAA-1181a)
1461784|NCT03260478|Procedure|Red Blood Cells Transfusion|Transfusion of packed red blood cells unit(s).
1461785|NCT03260465|Device|seleXys PC|Total hip arthroplasty using the seleXys PC cup
1461786|NCT03260465|Device|RM|Total hip arthroplasty using the RM cup
1461787|NCT03260452|Procedure|Abdominal subcutaneous biopsies and Blood test|Abdominal subcutaneous biopsies and blood test for each volunteer.
1461788|NCT03260439|Drug|Tramadol|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with tramadol 2mg / Kg (G1: GroupBT ). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
1461789|NCT03260439|Drug|Placebo|Children receive 0.1% BPV non-adrenalinated 0.5% / kg on each side with saline serum at the same volume (G2: Group B or control). Postoperativ analgesia was assessed by: the modified OPS scale at waking (H0), 1st (H1), 2nd (H2), and 24th (H24) PO hour at home, by the number of analgesic The hospital and home, and by the time of the first demand analgesic.
1461862|NCT03259789|Drug|Bexagliflozin tablets, placebo|Each subject will receive placebo (inactive tablet) once daily for the duration of the study.
1520534|NCT02813135|Drug|Cyclophosphamide|
1995047|NCT02865837|Other|brachytherapy|"The brachytherapy applicator and a urinary catheter are set up in the operating room under general anesthesia.
Then, an MRI (or a scanner if contra-indication) is performed after a bladder filling with 120cc of normal saline solution and urinary catheter clamping.
Right after, a scanner is performed with urinary catheter declamping and emptied bladder.
Delineation of CTVs and organs at risk (bladder, rectum, sigmoid, small bowel), and dosimetric optimisation are made on study with filled bladder.
Then, organs at risk are delineated on the study with emptied bladder. The prior dosimetry is reset on this study and organs at risk doses are compared."
1461790|NCT03260426|Dietary Supplement|Clear Liquids|Clear liquids on postoperative day zero immediately upon return to the floor and subsequent days' advancement of enteral diet to regular diet is as per discretion of the attending physician.
1461791|NCT03260426|Dietary Supplement|Regular Solid|Regular diet from postoperative day zero immediately upon return to floor and onwards
1461792|NCT03260426|Device|Abstats|Intestinal rate measured by Abstats™ in patients offered immediate solid versus clear liquids after colorectal surgery
1461793|NCT03260400|Device|a bipolar percutaneous intramuscular electromyography electrode|The device, a bipolar percutaneous intramuscular electromyography electrode, is intended for use in upper-limb amputation patients who have received the regenerative peripheral nerve interface surgical procedure, in order to enable the use of advanced prosthetic arms and hands.
1461794|NCT03260387|Procedure|TPIAT|The entire pancreas is removed to treat the pain of chronic pancreatitis, and the islets are infused back into the patient to reduce diabetes risk after surgery.
1461795|NCT03260374|Device|Electric compound action potential|The electrically evoked compound action potentials, which are closely related to the electrically evoked brainstem responses, would also show a similar correlation with the behavioral threshold. Determining threshold levels requires subjective responses to a series of sophisticated psychophysical percepts. This is often difficult for cochlear implant patients. However, the neural response telemetry system renders possible the measurement of the compound action potential threshold .
1461796|NCT03260374|Device|electric stapedial reflex threshold|electric stapedial reflex threshold measurements are performed using the same software platform and electrical stimulus utilized for fitting the cochlear implant . Thus, stimulus parameters, including pulse duration and repetition rate, can be identical to those used to obtain behavioral judgments for psychophysical levels
1461797|NCT03260374|Device|electric auditory brain stem response|For most implant recipients , even the first introduction of electric stimulation from a cochlear implant evokes activity in the auditory brainstem , which can be measured as clear electric auditory brain stem response waveforms . Therefore the electric auditory brain stem response test can be used in the functional evaluation of the auditory system between the time of initial implant activation and after chronic cochlear implant use
1461801|NCT03260322|Drug|ASP8374|intravenous
1461802|NCT03260309|Procedure|Semi-closed loop infusion system tactic.|"Semi -closed loop infusion system tactic.Use volume loading test twice (before surgery and 12hrs postoperatively). Computer provides advisory hypotension treatment algorithm. Computer provides advisory anemia treatment algorithm. Programmed iv fluid and blood infusions system ,,Belmont Rapid Infuser and programmable syringe pump for adrenaline infusion."
1461803|NCT03260309|Procedure|Routine infusion therapy tactic|Routine re-hydration bolus before surgery. Routine treatment of hypotension. Routine treatment of anemia.
1461804|NCT03260296|Other|self-administered structured questionnaire|"Data will be collected by self-administered structured questionnaire. The aim of the study and the way of filling the questionnaire will be explained to the students, and then he/she fills the questionnaire by him/her self.
The questionnaire will assess smartphones addiction and some of its associated factors and its health consequences"
1461805|NCT03260283|Drug|Pethidine hydrochloride|In Group I patients will be administered with low dose of pethidine hydrochloride (0.4 mgkg-1) diluted into normal saline up to 2 ml of total volume in order to perform subarachnoid anesthesia for urologic operations
1461806|NCT03260283|Drug|Ropivacaine HCl Inj 7.5 MG/ML|In Group II patients will be administered with 2 ml of ropivacaine (0.75%)
1461807|NCT03260283|Drug|Fentanyl|15 mcg of fentanyl will be added to the solution in order to perform subarachnoid anesthesia for urologic operations
1461808|NCT03260270|Diagnostic Test|color doppler ultrasound|All patients are going to be examined by color Doppler ultrasound and the high risk patients are going to be examined by direct MDCT venography .
1461809|NCT03260257|Other|Neurofeedback|Neurofeedback (NFB) will be administered to improve gamma band response. NFBs effects will be measured on gamma coherence and working memory.
1461810|NCT03260244|Procedure|cardiac mapping and radiofrequency ablation procedure|"It is a minimally invasive procedure which can be performed using either general or conscious sedation. During catheter ablation, catheters (narrow, flexible tubes) are inserted into a blood vessel, often through a site in the groin (upper thigh) or neck, and guided through the vein until they reach the heart. Small electrodes on the tip of the catheters stimulate and record the heart's activity. This test, called an electrophysiology study (EPS), allows the doctor to pinpoint the exact location of the short circuit. Another word for pinpointing the exact location of the short circuit is 'mapping', for which precision is a key requirement to maximize a successful outcome.
Once the location is confirmed, the short circuit is either destroyed (to reopen the electrical pathway) or blocked (to prevent it from sending faulty signals to the rest of the heart)."
1461811|NCT03260231|Dietary Supplement|Milled seed mix|Dietary intervention with or without seed mix
1461812|NCT03260205|Drug|Placebo|Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.
1461813|NCT03260205|Drug|SPD489 (Lisdexamfetamine dimesylate)|SPD489 capsule in a 5:5:5:5:6 ratio to 5, 10, 20, 30 mg orally once daily for 6 weeks.
1461814|NCT03260205|Drug|SPD489|SPD489
1461815|NCT03260179|Drug|AL3810|Fasting，oral ，4w on or 3w on/1w off
1461816|NCT03260179|Drug|AL3810|Fasting，oral ，4w on or 3w on/1w off
1461817|NCT03260179|Drug|AL3810|Fasting，oral ，4w on or 3w on/1w off
1461818|NCT03260166|Drug|nicotinamide|Drug: nicotinamide; Pharmaceutical form: tablet; Route of administration: oral
1461819|NCT03260153|Drug|Deproteinised Calf Blood Serum Injection|
1461820|NCT03260153|Drug|Placebo (Sodium Chloride)|
1461821|NCT03260140|Behavioral|behavioral lifestyle intervention|The investigators will provide participants with the behavioral lifestyle intervention
1461822|NCT03260127|Behavioral|Computerized executive function training plus CPT (CEFT-CPT)|Participants randomized to the CEFT-CPT arm will receive 6 weeks of computerized executive function training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
1461900|NCT03259516|Drug|Azacitidine|75 mg/m2 subcutaneously on Days 1-7 of a 28 day cycle
1461823|NCT03260127|Behavioral|Word game training plus CPT (WT-CPT)|Participants randomized to the WT-CPT arm will receive 6 weeks of computerized word game training and then 6 weeks of standard Cognitive Processing Therapy for PTSD (total of 12 sessions)
1461824|NCT03260114|Other|Personal Activity Intelligence|Participants randomized to the PAI eHealth program will be given a Mio Slice wristband (http://www.mioglobal.com/pai/), to measure the heart rate for calculating PAI. A weekly PAI of 100 can be achieved by a combination of different exercise intensities and the participants will, at any time, get information from the device (Mio Slice) (and the PAI App if they chose to use that as well) regarding how many minutes at specified heart rates is needed to achieve the weekly goal of 100 PAI. Participants will receive automatic feedback on a daily basis, and data will be automatically recorded on a secured server.
1461825|NCT03260101|Other|non intervational|Subjects who completed ApoGraft-01 study (through 180 days post-transplantation) and have signed informed consent for this follow-up study will be eligible to enroll. Subject will attend 4 in-clinic visits, once every 6 months up to 2 years post transplantation, and will undergo the following evaluations: acute and chronic graft versus host disease (GvHD) assessments, survival status (overall, relapse-free), disease status (disease relapse/recurrence)
1461826|NCT03260088|Diagnostic Test|Immunoglobulin G4|IgG4 will be purified from pleural fluids by diethylaminoethyl (DEAE)-cellulose ion exchange nephlometry
1461827|NCT03260075|Other|cat|Cat living at the ward
1461828|NCT03260062|Behavioral|Parent-Child Early Approaches to Raising Language Skills|The PEARLS intervention will teach parents evidence-based language strategies and sensitive parenting (e.g., warmth, respect for autonomy, linguistic stimulation) to promote language development in young deaf children with cochlear implants (CI).
1461829|NCT03260062|Other|Standard Care Speech therapy|Families will participate in auditory-verbal therapy, which is the standard speech therapy with children with hearing loss.
1461830|NCT03260049|Procedure|pars plana vitrectomy|pars plana vitrectomy
1461831|NCT03260023|Biological|TG4001|PhIb Dose escalation PhII established RP2D of the combination
1461832|NCT03260023|Drug|Avelumab|Anti PD-L1
1461833|NCT03260010|Drug|Fosfomycin|Infectofos 5 g
1461834|NCT03259997|Dietary Supplement|Probiotic supplement|Probiotic supplement
1461835|NCT03259997|Dietary Supplement|Placebo|Placebo
1461836|NCT03259971|Dietary Supplement|Probiotic-Lactobacillus plantarum PS128|Probiotic supplement of Lactobacillus plantarum PS128 , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
1461837|NCT03259971|Dietary Supplement|Placebo|placebo , 1 tablet , twice a day , 12 hrs apart, lasting 2 months for Tic disorders and 4 months for Rett syndrome
1461840|NCT03259945|Other|Data collection|demographic and clinical data
1461841|NCT03259945|Other|Review of ECGs|nature and frequency of proven conduction disorders
1461842|NCT03259932|Other|no physical activity|no physical activity
1461843|NCT03259932|Other|physical activity|Rehabilitation program will start 4 weeks after discharge from acute care (S4), for a duration of 8 weeks (3 sessions / week). Physical training will include aerobic exercises 30-60 minutes at 50-80% of HRmax, associated with muscle building exercises in circuit training (20 min), and balance and flexibility exercises.
1461844|NCT03259919|Drug|Metformin|Metformin 850 mg x 1 per day for the first week, and 850 mg x 2 per day for the rest of the study period.. Orally. From inclusion (before gestational week 8) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
1461845|NCT03259919|Drug|Placebo|Placebo, 2 tablets x 1 daily for the first week, and 2 tablets x 2 for the rest of the study period.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study. In addition 1 mg tablet of folate and one daily multivitamin tablet.
1461846|NCT03259906|Other|DASH score|Questionnaire asking about Disability of Arm, Shoulder and Hand
1461847|NCT03259906|Procedure|X-ray|postoperative x-rays at 6 weeks, 3, 6 and 12 months
1461848|NCT03259906|Procedure|posterior osteosynthesis|Osteosynthesis using a posterior plate
1461849|NCT03259906|Procedure|Anterior osteosynthesis|Osteosynthesis using an anterior plate
1461853|NCT03259867|Drug|Opdivo Injectable Product or Keytruda Injectable Product|a PD-1 immune check inhibitor per Investigator decision
1461854|NCT03259867|Combination Product|Trans-arterial tirapazamine embolization|Embolization with Lipiodol and Gelfoam
1461855|NCT03259854|Device|non invasive mechanical ventilation in pediatrics|use of non invasive mechanical ventilation in pediatrics after successful weaning from invasive mechanical ventilation
1461856|NCT03259854|Device|oxygen mask|use of oxygen mask after successful weaning from invasive mechanical ventilation
1461857|NCT03259841|Other|Ultrasound assessment of gastric contet|Ultrasound assessment of gastric content is performed in fasted patient undergoing cholecystectomy.
1461858|NCT03259828|Radiation|Adjuvant image-guided radiotherapy|Image-guided adjuvant radiotherapy to the sigmoid colon surgical tumor bed and pelvic regional lymph nodes: 45-50.4 Gy in 1.8 Gy/fraction
1461859|NCT03259815|Procedure|P.I.O.S.|Physiologically-Guided Incremental Optimisation Strategy
1461860|NCT03259815|Diagnostic Test|Operator-blinded post-PCI FFR|Post-PCI FFR will be measured but not disclosed to the operator
1461861|NCT03259789|Drug|Bexagliflozin tablets, 20 mg|Each subject will receive bexagliflozin, 20 mg once daily for the duration of the study.
1461863|NCT03259776|Other|Qualitative interviews and questionnaire survey|Qualitative interviews and questionnaire survey
1461864|NCT03259763|Device|Lumen-apposing metal stent|In this technique, the gastric wall and its adjacent small intestine are punctured by a needle to make a connection between the stomach and small intestine. Then a lumen-apposing metal stent is deployed at the puncture site to keep the stomach-small intestine connection open.
1461865|NCT03259763|Device|Self-expandable metal stent|In this technique, under endoscopic visualization, a guidewire will be advanced through the obstructed part of the stomach. Then an enteral self-expandable metal stent will be deployed under direct endoscopic visualization and fluoroscopic guidance.
1461866|NCT03259750|Other|Foot and Ankle Ability Measure Turkish version (FAAM-T) questionnaire|Self reported outcome instrument
1461867|NCT03259711|Drug|Hormonal therapies L02 in the ATC classification|Hormonal therapies L02 in the ATC classification
1461868|NCT03259698|Drug|nPEP|"Toronto participants will receive tenofovir alafenamide/emtricitabine/elvitegravir/cobicistat 10/200/150/150 mg (Genvoya) one tablet once daily as study drug to complete a 28 day course of PEP.
Ottawa participants will receive PEP medications outside of the trial in the form of tenofovir disoproxil fumarate/emtricitabine 300/200 mg (Truvada) once daily + raltegravir (Isentress) 400 mg twice daily to complete a 28 day course."
1461869|NCT03259698|Behavioral|Text Messaging Support|Text messaging support service ('WelTel'): community-based research staff person provides standardized weekly 'check-in' messages during their 12-week course of nPEP follow-up.
1461870|NCT03259698|Other|Nurse-Led nPEP|nPEP follow-up is provided by nurse-led care at a local sexual health clinic instead of a hospital-based ID physician.
1461871|NCT03259685|Other|710 ml of regular soft drinks, taken daily for 10 weeks|Subjects will consume regular soft drinks to test if there is a significant difference on the impact on gut microbiota composition and metabolic syndrome parameters between this treatment and the active treatments (diet and stevia beverages).
1461872|NCT03259685|Other|710 ml of diet soft drinks, taken daily for 10 weeks|Subjects will consume diet soft drinks during 10 weeks to test the possible effects of aspartame/acesulfame-K sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
1461873|NCT03259685|Other|710 ml of stevia-sweetened soft drinks, taken daily for 10 weeks|Subjects will consume soft drinks containing stevia during 10 weeks to test the possible effects of steviol glycosides sweetened beverages on gut microbiota composition and on metabolic syndrome parameters.
1461874|NCT03259672|Drug|Sevoflurane|Sevoflurane was used as a maintenance anesthetic agent.
1461875|NCT03259672|Drug|Desflurane|Desflurane was used as a maintenance anesthetic agent.
1461876|NCT03259659|Other|ECG recording, inflammatory cytokines, microbiota, ulcerative colitis disease activity index|In this study, an electrocardiogram signal will be recorded for 30 min in the fasting state, and blood samples for inflammatory cytokines analysis (7 ml) will be taken at the end of the ECG recording; fecal samples will be taken on the experimental day before the study. In addition, ulcerative colitis disease activity index will be assessed using the Mayo scoring system.
1461877|NCT03259646|Behavioral|Universal Education|Clinic provider/staff training on implementing universal education into clinical practice to: 1.) provide all women information about IPV/SA, harm reduction, and available safety resources; 2) provide trauma-informed counseling to women who disclose IPV/SA; includes access to the myPlan safety decision aid to develop a tailored safety action plan; 3) provide warm referrals in partnership with local domestic violence and sexual assault (DV/SA) advocacy agencies; 4) integrate documentation and quality improvement templates and measures into clinical settings.
1461878|NCT03259633|Drug|Selumetinib|open-label, single-arm, multicenter intermediate access protocol
1461879|NCT03259620|Drug|CLS006|Furosemide Topical Gel
1461880|NCT03259620|Drug|CLS006 Vehicle|Vehicle Topical Gel
1461881|NCT03259607|Drug|Nicorette Extra Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
1461882|NCT03259607|Drug|Nicorette Mint 2 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
1461883|NCT03259607|Drug|Nicorette Extra Mint 4mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
1461884|NCT03259607|Drug|Nicorette Mint 4 mg Gum|A single dose of one nicotine gum will be placed on the tongue to be chewed every 2 seconds for 30 minutes.
1461885|NCT03259594|Procedure|Laparoscopic deroofing|The classic treatment of patients with simple renal cysts is deroofing, which can be performed by open surgery or laparoscopy. Laparoscopic deroofing is an effective minimally invasive approach and has gained popularity.
1461886|NCT03259594|Drug|100 g of amino acids supplementation|intravenous supplementation with 100 g of amino acids 2 day before laparoscopic deroofing.
1461887|NCT03259581|Drug|Transarterial chemoembolization|Delivery of lipiodol, chemotherapy (Deoxyrubicin), and particles (embosphere particles) to the arteries feeding hepatocellular carcinoma. While both chemotherapy and particles are delivered this is a single procedure in which the chemotherapy is delivered followed immediately by particles.
1461888|NCT03259568|Device|Repetitive TMS|1-10 Hertz rTMS will be administered
1461889|NCT03259555|Drug|Brexpiprazole|Starting dose of 2 mg/day; titrated to a max of 4 mg/day. Adjustments can be made to dosing
1461890|NCT03259555|Drug|Placebo|Tablet taken daily
1461893|NCT03259529|Drug|Bendamustine hydrochloride|70 mg/kg by intravenous (IV) infusion for up to 2 cycles
1461894|NCT03259529|Drug|Gemcitabine 500 mg|500 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
1461895|NCT03259529|Drug|Gemcitabine 700 mg|700 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
1461896|NCT03259529|Drug|Gemcitabine 1000 mg|1000 mg/m2 by intravenous (IV) infusion on day 1,8,15 for up to 2 cycles
1461897|NCT03259529|Drug|Nivolumab|1 mg/kg by intravenous (IV) infusion on day 1,15 for up to 2 cycles
1461898|NCT03259529|Drug|Rituximab|375 mg/m2 by intravenous (IV) infusion on day 0 for up to 2 cycles
1461899|NCT03259516|Drug|Nivolumab|1 mg/kg by vein on Days 1 and 15 of a 28 day cycle
1461901|NCT03259516|Drug|Fludarabine|25 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle. Dose reduction to 15 mg/m2 is permitted in cases of grade 4 hematological toxicity after first cycle.
1461902|NCT03259516|Drug|Cyclophosphamide|300 mg/m2 by vein on Days 1, 2 and 3 of a 28 day cycle.
1461903|NCT03259516|Drug|Cytarabine|10 mg/m2 subcutaneously two times a day on Days 1-10 of a 28 day cycle
1461904|NCT03259516|Drug|all trans retinoic acid|45 mg/m2 per os daily during the whole course of treatment
1461905|NCT03259516|Drug|Sildenafil|20 mg per os three times a day during the whole course of treatment
1461906|NCT03259516|Drug|Melphalan|2 mg per os daily during the whole course of treatment
1461907|NCT03259503|Drug|Palifermin|Palifermin 60 mcg/kg per dose by vein on Days -13 through -11, and on Days 0, +1, and +2.
1461908|NCT03259503|Drug|Olaparib|"Phase I Starting Dose: Olaparib 25 mg by mouth on Day -10 through Day -3.
Phase II Starting Dose: Maximum tolerated dose from Phase I."
1461909|NCT03259503|Drug|Vorinostat|Vorinostat 1,000 mg by mouth on Day -10 through Day -3.
1461910|NCT03259503|Drug|Dexamethasone|Dexamethasone 8 mg by vein twice a day from day -10 PM to day -3 PM.
1461911|NCT03259503|Drug|Rituximab|Rituximab 375 mg/m2 for patients with CD20+ tumors on Day -10 in the AM as an inpatient.
1461912|NCT03259503|Drug|Caphosol|Caphosol 30 mL oral rinses four times a day used from Day -9 until end of clinical mucositis.
1461913|NCT03259503|Drug|Glutamine|Oral Glutamine 15 g four times a day, swished, gargled and swallowed, from Day -9 until end of mucositis.
1461914|NCT03259503|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion at 10 mg/m2/min on Days -9 and -4.
1461915|NCT03259503|Drug|Busulfan|Busulfan test dose can be administered either as an outpatient (preferable) before admission, or as an inpatient on Day -11. Test dose of 32 mg/m2 based on actual body weight to be administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -9. The doses of Days -7 and -6 subsequently adjusted to target an AUC of 4,000 micromolar·min.
1461916|NCT03259503|Drug|Melphalan|Melphalan 60 mg/m2 by vein on Days -4 and -3
1461917|NCT03259503|Drug|Pyridoxine|Pyridoxine 100 mg three times a day by vein or by mouth from Day -1 until engraftment.
1461918|NCT03259503|Procedure|Autologous Stem-Cell Transplant|Stem cell infusion on Day 0.
1461919|NCT03259503|Drug|G-CSF|G-CSF 1 time each day starting on Day +5 until blood cell levels return to normal.
1461920|NCT03259490|Drug|Empagliflozin/linagliptin/metformin HCl|Once daily
1461921|NCT03259490|Drug|Empagliflozin|Once daily
1461922|NCT03259490|Drug|Linagliptin|Once daily
1461923|NCT03259490|Drug|Metformin HCl|Once daily
1461924|NCT03259477|Procedure|precise segmental renal arterial clamping|Precise segmental renal artery clamping eliminates global renal ischemia by performing highly selective clamping of single or multiple segmental arteries.
1461925|NCT03259477|Procedure|laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy (LPN) has been widely adopted as a minimally invasive nephron-sparing surgery for clinical T1 renal cell carcinoma(RCC).
1461926|NCT03259464|Drug|BI 685509|3 sequential dose groups
1461927|NCT03259464|Drug|Placebo|3 sequential dose groups
1461928|NCT03259451|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
1461929|NCT03259438|Behavioral|Qigong|Qigong is a form of gentle mind-body movement that originates in China and has traditionally been used for healing purposes. It has been reported to improve energy levels, as well as strength and endurance and mental clarity and equanimity. This study will assess how a 10-week qigong intervention compares to an exercise-nutrition intervention in improving fatigue and vitality in female cancer survivors. On a secondary level, we will asses changes in underlying brain, heart, and peripheral dynamics that occur as a result of the qigong practice to develop a mechanistic understanding of qigong's efficacy.
1461930|NCT03259438|Behavioral|Healthy Living (CHIP + Pre-Train)|The Healthy Living active comparator intervention includes two components: plant based nutrition counseling via the Comprehensive Health Improvement Program (CHIP) and core strengthening exercises and light aerobic activity via the Pre-Train exercise program.
1461931|NCT03259425|Drug|Nivolumab|Nivolumab at a dose of 240 mg given as an IV infusion starting on day 0. It will be given every 14 days for a total of 7 infusions; Then patient will undergo surgery. Nivolumab will then be administered at a flat dose of 480 mg IV every 28 days for up to one year.
1461932|NCT03259425|Drug|HF10|1 x 107th TCID50/mL, intratumoral injection to a single or multiple eligible tumors for a total of 5 mL; on days 0, 7, 14, 21, 28, 42, 56, 70, 84 for a total of 9 injections. All eligible tumors except one will be treated with HF10 up to the maximum volume allowed. The untreated tumor will be used as an untreated control lesion.
1461933|NCT03259412|Dietary Supplement|Fish Oil|Fish Oil Capsule
1461934|NCT03259412|Dietary Supplement|Placebo|Olive Oil capsule manufactured to mimic fish oil capsule
1461935|NCT03259399|Genetic|detection of genotype|detection of genotype by next generation sequencing
1948032|NCT02858427|Behavioral|neuropsychological assessement|the neuropsychological assessment aims to identify any impairment of executive functioning through several tasks: Mini mental state examination (mmse), isaac set test (STI) trail making test (TMT A and B), Grober test, Stroop test, verbal fluency, Go No Go task, memory impairment screen (MIS), picture naming test (DO30), copying figure test, digit span and categorical matching test.
1461937|NCT03259373|Behavioral|Early Intervention|"Letters to patients that (1) explain to the patient that he or she appears to have AF, characterize the risk of stroke, and emphasize that although there may be a medical reason, the patient does not seem to be on an anticoagulant and (2) encourage the patient to discuss this with his or her provider to ask if he or she might benefit from OAC therapy to prevent stroke.
Early intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who have been contacted, as the provider and patient letters will be sent at approximately the same time; describe evidence and guidelines regarding oral anticoagulation."
1461938|NCT03259373|Behavioral|Delayed Intervention|Delayed intervention letters to providers explain this project, the nature of the problem, and identify a list of the provider's patients who are at risk for stroke and have not been treated with an oral anticoagulant; describe evidence and guidelines regarding oral anticoagulation
1463459|NCT03247361|Other|Sham IMT + Aerobic/resistance exercise|Aerobic and resistance exercise
1461939|NCT03259360|Behavioral|POP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use and tailored to sexual and gender minority young adults
1461940|NCT03259360|Behavioral|TSP:|90 days of Facebook messaging, weekly live sessions targeting tobacco use
1461941|NCT03259347|Behavioral|Group-based Therapy|Young women with body dissatisfaction will be randomized to one of two conditions: 1) an educational-support group condition; or 2) a counter-attitudinal therapy condition. We will test if a brief dissonance-based eating disorder prevention program produces intervention effects when delivered to participants with sub-threshold and threshold eating disorders.
1461942|NCT03259334|Drug|SHP647|1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
1461943|NCT03259334|Other|Placebo|1 mL of sterile aqueous buffered solution.
1461944|NCT03259308|Drug|SHP647|1 mL of SHP647 sterile aqueous buffered solution at an appropriate concentration to provide the intended dose of drug (25 or 75 mg).
1461945|NCT03259308|Drug|Placebo|1 mL of sterile aqueous buffered solution.
1461946|NCT03259295|Device|Digiclamp (Skin tag removal initial)|Skin tag will be assessed for size, location, and overall appearance. After assessment that the skin tag is not infected or possibly malignant, the site will be photographed, prepped with an antimicrobial solution, anesthetized, and removed using the Digiclamp. A bandaid will be applied to the site.
1461947|NCT03259295|Device|Digiclamp (Skin tag removal follow-up)|Site of skin tag removal will be photographed to document lesion recurrence and presence of scar tissue or hyperpigmentation. Subjects will be asked to complete a brief survey about their satisfaction with the use of Digiclamp.
1461948|NCT03259282|Biological|Analysis of gamma globulin|
1461949|NCT03259269|Other|This is a non-intervention observational study|No applicable intervention; this is a secondary data analysis observational study.
1461950|NCT03259256|Procedure|Allogeneic transplantation of intrahepatic islet|Allogeneic transplantation of intrahepatic islet is one of the effective methods for diabetic therapy
1461951|NCT03259243|Drug|Bupivacaine Hydrochloride|0.5 Bupivacaine hydrochloride were port site infiltration preincision and preclosure injection
1461952|NCT03259230|Other|Blood Draws|
1461953|NCT03259230|Other|Data Collection|
1461954|NCT03259217|Drug|Stem Cell Product|Adipose tissue derived mesenchymal stem cell seeded in Curcumin loaded chitosan nanoparticles into collagen-alginate
1461955|NCT03259204|Device|Adjuvant IPC|This IPC-system delivers sequential circumferential compression. The IPC device is mobile and should therefore not restrict patient mobilization, but can be taken off if the patient wants to mobilize independently.
1461956|NCT03259191|Procedure|anti-reflux mucosectomy|Anti-reflux mucosectomy (ARMS) may be a new therapy for refractory gastroesophageal reflux disease (RGERD). The aim of the present study is to explore the safety and efficacy of ARMS.
1461957|NCT03259165|Drug|Nitrates|"For patients randomized to the Nitrate intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.
Treatment protocol:
IV furosemide (unless already given) (All patients receive at minimum 20 mg IV furosemide or equivalent)
SL nitroglycerin (400 ucg) will be given every 5 minutes, a total of three times (Held if SBP decreases to < 140 mmHg)
Reassessment every 2 hours. If LUS B-lines >15, repeat step 2. If < 15, stop algorithm."
1461958|NCT03259165|Drug|Loop Diuretics|"For patients randomized to the Diuretic intense arm, the treatment protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.
Treatment protocol:
Patients receive 1 inch topical nitropaste
IV Loop diuretic dose = patients total oral dose (max dose of 200 mg IV)
Reassessment every 2 hours. If LUS B-lines >15, repeat step 2. If < 15, stop algorithm."
1461959|NCT03259152|Drug|Denosumab|Denosumab (trade names Prolia and Xgeva) is a human monoclonal antibody for the treatment of osteoporosis, treatment-induced bone loss, metastases to bone, and giant cell tumor of bone.Denosumab is a RANKL inhibitor, which works by preventing the development of osteoclasts which are cells that break down bone.
1461960|NCT03259139|Behavioral|Video games and violence|Participants will be randomly assigned to play a video game which contains either (1) no violent content, (2) violent content with swords, or (3) violent content with guns. The game, rated E, is age appropriate and modded to include guns in the appropriate condition.
1461961|NCT03259126|Device|SCUT|Two different home made curtains were attached to the angiographic table
1461962|NCT03259113|Device|Insertable cardiac monitor|Insertable cardiac monitor (SJM Confirm Rx) subcutaneously.
1461963|NCT03259100|Other|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
1461965|NCT03259074|Biological|Secukinumab|Eligible subjects are randomized to one of three treatment arms in a 1:1:1 ratio
1461966|NCT03259074|Biological|GP2017 (adalimumab biosimilar)|Eligible subjects are randomized to one of three treatment arms in a 1:1:1 ratio
1461967|NCT03259061|Device|Flexible fiberoptic nasopharyngoscopy|"Flexible fiberoptic nasopharyngoscopy (FFN) allows direct transnasal observation of the anatomy and dynamic activity of the velopharyngeal sphincter. Such observations can be recorded for permanent documentation by coupling FFN to a video camera with simultaneous audio recording. Numerous published reports discuss the advantages of FFN as a clinical method for evaluating velopharyngeal function during speech (10).
Cephalometric analysis, is the clinical application of cephalometry. It is analysis of the dental and skeletal relationships of a human skull and is frequently used by dentists, orthodontists, and oral and maxillofacial surgeons as a treatment planning tool.
Cephalometric analysis can also be applied for assessing the velopharyngeal structure and function. More specifically, velopharyngeal function in terms of its shape and mobility was analyzed quantitatively on the basis of cephalometric principle"
1461968|NCT03259048|Diagnostic Test|Abdominal ultrasound|Abdominal ultrasound will be used in the diagnosis of acute abdomen in pediatric group.
1461969|NCT03259035|Drug|Folfox Protocol|6 cycles of q2weekly FOLFOX, or
1461970|NCT03259035|Drug|Capox|4 cycles of q3weekly CAPOX
1463491|NCT03247114|Other|Glucose|Glucose, 50 grams in 300 ml water at room temperature
1948033|NCT02858427|Behavioral|psychiatric assessment|this evaluation aims to characterize the mental status of the patient. Different scales will be used: Montgomery and ASberg depression rating scale (MADRS), Columbia-suicide severity rating scale (C-SSRS), Beck depression inventory (BDI), Barratt impulsiveness scale (BIS-10), Buss and Durkee Hostility Inventory (BDHI), Balloon, analogue risk task (BART), Iowa gambling task (IGT), and Childhood trauma questionnaire (CTQ).
1948034|NCT02858427|Behavioral|sociological interview|this interview aims to characterize social interactions of the patients, their duration, their evolution and the perception of each participant on this subject.
1461973|NCT03258983|Other|Alpha-linolenic acid|Exposure to dietary intake of alpha-linolenic acid (ALA) will be assessed using a detailed food frequency questionaire filled in by participants included in the Diet, Cancer and Health cohort at baseline. Exposure to adipose tissue content of ALA will be determined by gas chromatography in all incident cases and in subcohort of 3500 participants randomly drawn from the total cohort.
1461974|NCT03258970|Other|Observational cohort study|taking vitamin supplements
1461975|NCT03258957|Other|Fresh Milk|Mothers will be asked to provide at least 1 feed of fresh milk (i.e. within 4 hours of milk expression) per day, other time, feed frozen milk
1461976|NCT03258944|Other|Breath-Stacking|Participants will be seated, with their elbows resting on the table, holding the face mask attached to a T-tube and a one-way valve. They will be instructed to inspire and force the expiration inside the mask. The training will be conducted three times a week for a period of four weeks, totaling twelve sessions. The breath-stacking application protocol will consist of three three-minute series, with a three-minute recovery interval between each series, obtaining a total time of fifteen minutes in each session.
1461977|NCT03258931|Drug|Crenolanib|Crenolanib will be administered orally
1461978|NCT03258931|Drug|Midostaurin|Midostaurin will be administered orally
1461979|NCT03258931|Drug|Cytarabine|100 mg/m² IV continuous infusion over 24 hours
1461980|NCT03258931|Drug|Duanorubicin|90 mg/m2 IV
1461981|NCT03258918|Behavioral|Low-Carbohydrate Diabetes Prevention Program|LC-DPP participants will be instructed to follow ad-libitum very low-carbohydrate, ketogenic diet, which restricts carbohydrate intake (not including fiber) to 20-35 grams per day with the goal of achieving nutritional ketosis. Participants will be encouraged to eat a normal amount of protein (roughly 80-120 grams per day) and to derive the remaining calories from fat. Allowable foods include: meats, fish, poultry, eggs, cheese, seeds, nuts, leafy greens, non-starchy vegetables, and some fruits.
1461982|NCT03258905|Behavioral|Grounding enhanced app|A mobile app that uses the Seeking Safety grounding chapter content, enhanced with features designed to create strong engagement and interactivity
1461983|NCT03258905|Behavioral|Grounding text-only app|A mobile app that uses the Seeking Safety grounding chapter content in text format only
1461984|NCT03258892|Other|Educational Intervention|Receive STG
1461985|NCT03258892|Other|Quality-of-Life Assessment|Ancillary studies
1461986|NCT03258892|Other|Survey Administration|Ancillary studies
1461987|NCT03258879|Procedure|Modified CSE|MCSE group: 1 ml of 0.25% bupivacaine will be injected intrathecally
1461988|NCT03258879|Procedure|Dural puncture epidural|DPE group: Dural puncture performed, but no medication will be injected intrathecally.
1461989|NCT03258866|Drug|Rituximab|given with a fixed dose of 100 mg administered as an intravenous infusion weekly (on day 1, 8, 15 and 22)
1461990|NCT03258866|Drug|Rituximab|given with a single dose of 375mg/m2
1461991|NCT03258853|Device|Bionic Pancreas|Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
1461992|NCT03258853|Other|Usual Care|Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
1461993|NCT03258840|Dietary Supplement|EPA Supplement|EPA supplement, 4 × 500 mg softgel daily (2 g per day), 2 times a day, for 8 weeks.
1461994|NCT03258840|Dietary Supplement|EPA Placebo|EPA- placebo softgel (Containing 2 g edible paraffin oil), 4 × 500 mg softgel daily, 2 times a day, for 8 weeks.
1461997|NCT03258788|Procedure|Biopsy and blood samples|"Archival tumour biopsies will be analysed for baseline PD-L1 expression. Some participants will have a biopsy before radiotherapy if the archive biopsy is not suitable.
Participants will be required to undergo an additional mandatory post radiotherapy course biopsy of the irradiated site ideally during the last 7 days of radiotherapy or within 7 days of completing the course. Patients must have completed more than 2/3 of the planned treatment before taking the biopsy.
Participants will also be asked for consent to donate 50ml blood pre and post biopsy as well as 10ml blood before #2 radiotherapy and weekly throughout treatment."
1461998|NCT03258775|Other|water intake|After an overnight fast participants' RMR will be measured by indirect calorimetry for 30 minutes after which either a low (250ml) or high (500ml) dose of water will be consumed followed by an additional 90 minutes of indirect calorimetry. The test day will be repeated after 7-10 days with the second dose of water. The order in which the dose of water will be consumed will be randomized
1465291|NCT03233347|Other|Laboratory Biomarker Analysis|Correlative studies
1948035|NCT02858219|Drug|Botulinum Toxin Type A|
1948036|NCT02858219|Other|Saline solution|
1948037|NCT02858219|Other|Indexes|Visual Analogic Scale (VAS), Female Sexual Function Index (FSFI), Dermatology Life Quality Index (DLQI)
1948038|NCT02857816|Device|NURO System PTNM Therapy|
1948039|NCT02853305|Biological|Pembrolizumab|IV infusion
1948040|NCT02853305|Drug|Cisplatin|IV infusion
1948041|NCT02853305|Drug|Carboplatin|IV infusion
1948042|NCT02853305|Drug|Gemcitabine|IV infusion
1948043|NCT02852291|Behavioral|Parents Make the Difference|10 parent training sessions delivered to groups of caregivers
1948044|NCT02852291|Behavioral|Parents Make the Difference Plus|10 parent training sessions delivered to groups of caregivers, with 3 home visits
1462003|NCT03258736|Procedure|inguinal hernia surgery|repair of inguinal hernia
1462004|NCT03258723|Behavioral|Lifestyle Intervention|"The lifestyle intervention consists of a series of workshops adapted from the East Harlem Partnerships for Diabetes Prevention that discuss diabetes prevention, finding and affording healthy foods, label reading, physical activity, planning a healthy plate, making traditional foods healthy and portion control.
The newly launched East Harlem Diabetes Prevention (EHDP) project's mobile app, iHEED will be used by intervention participants to help reinforce the content they learn during the workshop series."
1462005|NCT03258723|Drug|Metformin|At 6 months, intervention participants who have no change or any increase in their HbA1c based on point of care (POC) testing will have Metformin prescribed by their provider. Metformin will be prescribed at 500mg twice a day. If no change is seen at 12 months follow up, the dose will be increased to 850mg twice a day.
1948045|NCT02848222|Device|Bruder Moist Heat Compress|
1462007|NCT03258697|Drug|Levobupivacaine Hydrochloride|Different way of LevoBupivacaine injection
1462008|NCT03258684|Drug|Hydrocortisone, Vitamin C, and Thiamine|Intervention
1462009|NCT03258684|Other|Normal saline|Placebo
1462010|NCT03258671|Drug|EGFR-TK Inhibitor|·EGFR-TKI：gefitinib will be administered 250mg/d ivgtt qd; icotinib will be administered 150mg/d ivgtt tid;
1462011|NCT03258671|Radiation|Intensity Modulated Radiation Therapy|"High dose group：DTGTV=70Gy；
first course radiotherapy：40Gy/20f/4w（DTPTV：36Gy/20f/4w）,2Gy/f/d；
late course radiotherapy：1.5Gy/f、2f/d、interval≥6 hs、DTGTV=30Gy（DTPTV=27Gy）。
Low dose group：DTGTV=50Gy;
first course radiotherapy：32Gy/16f/3w（DTPTV为28.8Gy/16f/3w），2Gy/f/d；
late course radiotherapy：1.5Gy/f、2f/d、interval≥6小时、DTGTV为18Gy（DTPTV为16.2Gy）。"
1462012|NCT03258658|Biological|Autologous Engineered Urethral Construct|urethral construct
1462013|NCT03258645|Drug|Dabigatran|Oral anticoagulant (NOAC) thrombin inhibitor
1462014|NCT03258632|Behavioral|Drinking Options - Motivate, Shared Decisions, Telemonitor (DO-MoST)|Patients will attend one 50-minute individual session during their inpatient stay with a Decision Coach (a trained clinical provider, e.g., MSW). Patients in DO-MoST will also attend 6 biweekly 15-minute telephone sessions from the same Decision Coach.
1462015|NCT03258619|Biological|Aldosterone / renin dosage|Plasma levels of aldosterone and renin
1462016|NCT03258619|Biological|Natriuresis|natriuresis levels
1948046|NCT02848222|Other|Washcloth|
1948047|NCT02844608|Other|Quality of Life Questionnaires|Patients will be asked to complete standardized HRQoL questionnaires: the EORTC QLQ-C30 with its specific module by cancer site (QLQ-BR23, QLQ-CR29, QLQ-LC13) at first visit before starting treatment and then before every medical consultation during four months.
1948048|NCT02842957|Behavioral|Lifestyle Intervention|Patients randomized to the lifestyle group will be given individual counseling regarding the implementation of a plant based diet. They will also be given a home based exercise program to complete. Patients will be assisted with the optimal use of their prescription medications and they will receive specific counseling regarding strategies to help them successfully change their behavior.
1462020|NCT03258554|Biological|Cetuximab|Given IV
1462021|NCT03258554|Biological|Durvalumab|Given IV
1462022|NCT03258554|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1462023|NCT03258554|Other|Laboratory Biomarker Analysis|Correlative studies
1462024|NCT03258554|Other|Quality-of-Life Assessment|Ancillary studies
1462025|NCT03258554|Other|Questionnaire Administration|Ancillary studies
1462026|NCT03258541|Device|TraceIT®|This pilot study wishes to investigate feasibility and efficacy of the injected hydrogel spacers TraceIT® in sparing vagina/prostate in the treatment of rectal cancer patients.
1462027|NCT03258541|Radiation|Volumetric Arc Therapy (VMAT)|VMAT - fractionation Schedule : 1.8 Gy per fraction, one fraction per day, 5 fractions per week for the elective PTV and 2 Gy per fraction, one fraction per day, 5 fractions per week for the PTV-boost using a simultaneous integrated boost technique.
1462028|NCT03258541|Procedure|Surgery|Low anterior resection of the rectum: 8-10 weeks post-radiotherapy
1462029|NCT03258528|Behavioral|positioning|Positioning neonates for 6 hours either in right lateral position or supine position
1462033|NCT03258502|Drug|RV521|RV521 drug in capsules
1462034|NCT03258502|Drug|Placebo|Placebo in capsules
1462035|NCT03258489|Device|Transcutaneous nervous electric stimulation (TENS)|TENS (Frequency 10 Hz or 100Hz /duration 200μs, Endophasys nms 0501® model, KLD Biosystems, Amparo, SP, Brazil) will be applied with intensity between 1 to 60 mA and the current will be adjusted every 5 minutes at the sensory threshold level muscle contraction or according to the tolerance to the stimulus informed by the volunteers. TENS will be applied in bilateral paravertebral region of C7 to T4 or long the brachial plexus and sciatic plexus.
1462067|NCT03258242|Drug|Keluo Xin capsule|four capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
1465292|NCT03233347|Biological|Nivolumab|Given IV
1948049|NCT02839382|Other|Coaching|An external facilitator or coach is assigned 15-20 primary care clinics and will make face-to-face site visits and monthly phone calls for 15 months to support building QI capacity in each assigned practcie
1948050|NCT02839382|Other|Educational Outreach|Practices randomized to this arm of the study will receive an educational outreach phone call by an academic expert on implementation strategies for use of a cardiovascular risk calculator within their daily work flow and clinic setting
1462036|NCT03258489|Device|Interferential electrical stimulation (IES)|The IES (Endophasys nms 0501®, KLD Biosystems, Amparo, SP, Brazil) will be applied in continuous mode with biphasic pulses. Bipolar electrodes with slope of 1/5/1. The rest of the parameters will be set to 4000 Hz, AMF of 100 Hz and the AMF variation of 25 Hz. The effect of the current will be adjusted by the intensity, it should produce paresthesia stimuli, without pain and below the motor threshold. Adhesive electrodes (MultiStick®, Axelgaard Manufacturing CO, Ltd, Fallbrook, CA, USA) will be housed in the paravertebral region, between C7 (Channel 1) and T4 (Channel 2). (SANTOS et al., 2013)
1462037|NCT03258489|Device|TENS and IES Placebo|Same protocol without electrical output.
1462041|NCT03258463|Other|Change in Texas Law|The change in Texan laws occurring from July 2013-January 2014
1462042|NCT03258450|Behavioral|Psycho-behavioural intervention arm (PBI)|The first session introduces the rationale of the intervention and is designed to encourage participants to recognize the autonomous role they can play in their health and well-being. Patients will be trained on breathing as a relaxation technique. The second session focuses on building behavioural skills to manage common symptoms for colorectal cancer patients. The third session focuses on cognitive strategies to address worries and existential distress. The last session focuses on maximizing social support and applying skills learned so far in dealing with loved ones. Participants will be provided an MP3 player that contains the relaxation exercise recording and a folder with summaries of the session content.
1462043|NCT03258437|Dietary Supplement|DA-9401|
1462044|NCT03258437|Dietary Supplement|Placebo|Placebo for 12 weeks.
1462045|NCT03258424|Drug|PTI-428|PTI-428 or placebo will be given QD for 14 days.
1462046|NCT03258424|Drug|Placebo|PTI-428 or placebo will be given QD for 14 days.
1462047|NCT03258411|Device|Rapid Expansion of palatal suture|
1462048|NCT03258398|Drug|eFT508|eFT508 will be taken orally (PO) twice a day (bid).
1462049|NCT03258398|Drug|Avelumab|Avelumab 10 mg/kg will be administered intravenously (IV) on Day 1 and once every 2 weeks (q2wk) thereafter
1462050|NCT03258385|Dietary Supplement|Vitamin B12 fortified UHT milk|Daily intake of 200 mL of UHT milk fortified with 100 µg vitamin B12
1462051|NCT03258385|Dietary Supplement|Plain UHT milk|Daily intake of 200 mL of plain UHT milk
1462052|NCT03258372|Drug|Mifepristone|Period 1: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2; then Period 2: rifampin 300 MG (2 capsules) for a total of 600 MG daily for 14 days for both cohorts; then Period 3: mifepristone 300 MG (1 tablet) for a total of 300 MG on Day 1 in Cohort 1; and mifepristone 300 MG (5 tablets) for a total of 1500 MG in Cohort 2
1462053|NCT03258359|Biological|PACTN|To treat patients with MDS that have failed treatment with hypomethylating agents or have relapsed after treatment with hypomethylating agents
1462054|NCT03258346|Other|Inertial Load Cycling Training|Each session of training will require a total of 15 min with the total time actually exercising of only 60-120 sec. The first week will consist of performing 15 'sprints' on the ILE, beginning each sprint with 56 sec of rest. During week 2-5, subjects will rest 41 sec between sprints, completing 20 bouts. Finally, during weeks 6-10, subjects will take 26 s rest between sprints and complete 30 bouts).
1462055|NCT03258346|Dietary Supplement|Pomegranate Juice|Subjects will consume 8oz of pomegranate juice daily for duration of study.
1462056|NCT03258346|Dietary Supplement|Placebo|Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
1462057|NCT03258333|Procedure|aortic valve replacement|Standart AVR using stented stented bioprosthesis aortic valve reconstruction using autologus pericardium
1462058|NCT03258320|Drug|Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin|As preoperative neoadjuvant chemotherapy, drugss including Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) will be administered as a single agent performed 45 days before surgery：Cabazitaxel 25 mg/m2, Docetaxel 35 mg/m2, Mitoxantrone 4 mg/m2 or Satraplatin 80 mg/m2, through intravenous (IV) or oral (Satraplatin) administration. IV or oral administration once every 7 days, totally 4 cycles. There is a 17-day interval between the last dose and surgery.
1462059|NCT03258307|Other|Preoperative level|Blood sample
1462060|NCT03258294|Drug|Melatonin(Circadin®)|
1462061|NCT03258294|Drug|Placebo Oral Tablet|
1462062|NCT03258281|Drug|Evolocumab|Patients will receive evolocumab 420 mg administered subcutaneously
1462063|NCT03258281|Drug|Placebo|Patients will receive placebo administered subcutaneously
1462064|NCT03258268|Device|Standard of Care with EASY DSS|"The EASY DSS is a software tool designed to process and analyze data to facilitate individualized treatment suggestions for type 2 diabetes patients.
Patients will receive standard of care with a board certified physician with EASY DSS.
The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
1462065|NCT03258268|Other|Standard of Care without EASY DSS|"Patients will receive standard of care with a board certified physician without EASY DSS.
The choice of treatment will be made by the investigator. In the investigational arm this will be based on the clinical judgment of the investigator supplemented with support from the EASY DSS and in the control arm this will be based on the clinical judgment of the investigator alone."
1462066|NCT03258255|Procedure|penil or pudendal nerve block in circumcision|regional analgesia methods during the circumsion nerve stimulator guided pudendal block performed by anesthesiologist/ penil block performed by surgeon before circumcision
1462068|NCT03258242|Drug|Placebo oral capsule|four placebo capsules at a time, three times a day, taken orally and consecutively for 24 weeks or 48 weeks.
1462069|NCT03258229|Dietary Supplement|Angelica gigas N. extract|capsules(2cap/d, 1,000mg/d) for 8 weeks.
1462070|NCT03258229|Dietary Supplement|Placebo|Placebo for 8 weeks
1462071|NCT03258216|Diagnostic Test|panendoscopy|panendoscopy
1462072|NCT03258216|Diagnostic Test|tongue image|capture tongue images by Automatic Tongue Diagnosis System
1462073|NCT03258203|Other|Preventing Overweight Using Novel Dietary Strategies|The study tests the effectiveness for weight loss and weight maintenance of four diets differing in macronutrient composition: moderate in fat (40% energy) with two different protein levels (15% and 25%), and low in fat (20% energy), also with 15% and 25% protein levels.
1462074|NCT03258190|Drug|Lime Powder Regimen|LPR is limeade-derived component that contain high concentration of citrate and moderate amount of potassium, magnesium and antioxidants
1462076|NCT03258164|Biological|ASC enriched lipofilling|Fat grafts enriched with ex vivo expanded ASC
1462077|NCT03258164|Biological|Standard Lipofilling|Non-ASC enriched fat grafts
1462078|NCT03258151|Genetic|detection of genotype|detection of genotype by next generation sequencing
1462079|NCT03258138|Behavioral|Health and wellness learning sessions|The health and wellness learning sessions provide a platform for concepts from a variety of health behaviour theories and CBT to be combined with evidence- and practice-based recommendations for healthy lifestyles. They provide the basis for participants' development of an individualized action plan. The sessions will last one hour and participants will receive them in a group setting, 18 times throughout the duration of the program. Specifically, the sessions will be delivered during weeks: 1-8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48.
1462080|NCT03258138|Behavioral|Brainstorming group sessions|The brainstorming group sessions allow for facilitated discussions where individuals explore barriers and facilitators to achieving their goals and provide an interpersonal component to the program through the building of social interactions. Participants will also receive help in finding community programs to support healthy lifestyles. These sessions will last one hour and participants will receive them in a group setting, 30 times throughout the duration of the program. Specifically, these sessions will be delivered during weeks: 9-11, 13-15, 17-19, 21-23, 25-27, 29-31, 33-35, 37-39, 41-43, 45-47.
1462081|NCT03258138|Behavioral|Individual sessions with a multidisciplinary health team|Monthly individual sessions with a family physician trained in medical CBT, a dietician and a physical therapist help individuals tailor their action plans and recommendations to their particular circumstances and provide supports based on their needs. The initial session will last 3 hours and occur at baseline. The follow-up sessions will last 1 hour.
1462082|NCT03258138|Behavioral|Health goal development|Participants in both arms will develop health goals. Several components of these goals will be measured throughout the study, including the stage of change, self-efficacy and actual goal achievement. In the more intensive program arm, participants will develop health goals and learn about how to meet those goals through the group and individual sessions. In the less intensive program arm, participants will receive support in developing health goals from a research assistant trained in theories of health behaviour and in goal setting at baseline, 3 months, 6 months, 9 months and 12 months. The initial goal setting session will be provided within a time period of 2 hours, and the follow-up sessions will be provided within one hour time periods.
1462083|NCT03258138|Behavioral|Physical activity and nutrition journals|Participants in both arm will be asked to maintain a physical activity journal and a nutrition journal for a week each every three months. These journals help participants reflect on current behaviours and areas for change.
1462084|NCT03258125|Genetic|real time PCR (rPCR)|A villus tissue (2.5 cm * 2.5 cm * 2.5 cm) will be cut off immediately from the center of placenta, avoiding the area of infarction, bleeding or calcification. After being washed with normal saline, the tissue will be preserved in liquid nitro¬gen at once for subsequent detection of miR-452 and MMP-9 expression by real time PCR (r-PCR). During this procedure total RNA will be extracted including miR-452 and mRNA of MMP-9. Then by reverse transcriptase RNA will be converted into DNA which will be amplification during the PCR, i.e. in real-time, and not at its end, as in conventional PCR. Expression of miR-452 and MMP-9 will be estimated and correlated with each other.
1462085|NCT03258112|Procedure|Radiofrequency cardiac catheter ablation|procedure used for ablation of ventricular arrhythmia using catheters introduced to target sites percutaneously through venous or arterial systems using radiofrequency power
1462086|NCT03258099|Genetic|detection of genotype|detection of genotype by next generation sequencing
1462087|NCT03258086|Diagnostic Test|blood sample test|blood sample will be taken from all diabetic children for assessment of vitamin D level
1462088|NCT03258073|Other|Medical simulation using scenario execution|Each team of students will be exposed to simulation two times in a semester totaling to four times a year. In a scenario execution, participants are placed in a simulated experience of a medical emergency. Participants are required to respond and their reactions are observed by the investigators. After the experience, participants will have a debriefing session to learn from their experience of handling this emergency.
1462089|NCT03258060|Procedure|Temporary pacing study|
1462090|NCT03258060|Radiation|Body Surface Mapping|
1462091|NCT03258047|Combination Product|CAR-T|CAR-T is a novel technique for cancer treatent, it includes procedures of modifying patients' T cells outside the body and re-transfuse these cells back into the human body to fight against the cancer cells.
1462092|NCT03258034|Drug|SPA|S1/Paclitaxel chemotherapy plus Apatinib S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:425mg once daily
1462093|NCT03258021|Device|TTFields|Tumor treating fields (TTFields) help slow down or stop glioblastoma cancer cells from dividing by disrupting dividing mechanism of cancer cells leading to apoptosis. TTFields are low-intensity, intermediate frequency, alternating electric fields delivered continuously through adhesive patches, called transducer arrays, to the area of the brain where the GBM tumor is located. These transducer arrays are applied to the scalp and are connected to the wearable and portable device. TTFields are approved for the treatment of newly diagnosed and recurrent GBM.
1520535|NCT02813135|Radiation|Radiotherapy|
1462094|NCT03258008|Drug|Utomilumab|Utomilumab given by vein (100 mg Cycle 1 and 50 mg Cycle 2 and beyond) every 4 weeks for up to 12 doses beginning cycle 1 day 1.
1462095|NCT03258008|Biological|ISA101b|ISA101b 100 mcg/peptide given subcutaneously every 4 weeks x 3 doses beginning cycle 1 day 1.
1462096|NCT03257995|Drug|Indacaterol maleate|150 μg via Concept1 device
1462097|NCT03257995|Drug|Indacaterol acetate|150 μg via Concept1 device
1462098|NCT03257995|Drug|Placebo|Capsule containing no active ingredients delivered via Concept1 device
1462099|NCT03257982|Procedure|BCI-FES hand therapy|BCI-FES rehabilitation therapy of the upper limb
1462100|NCT03257969|Behavioral|The DROP program of pharmaceutical interventions|Multidisciplinary program that includes informative sessions with a hospital pharmacist about the oral anticancer drug: information is given to the patient on adverse events occurrence and there management; and optimizing drug dosage plan, including drug-drug interactions.
1462101|NCT03257969|Behavioral|Standard of care|In the group with standard of care, patients will have interviews with a clinical research associate only dedicated to the record of data for outcomes assessment.
1462102|NCT03257943|Drug|Ivermectin Lotion, 0.5%|Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
1462103|NCT03257943|Drug|SKLICE (ivermectin) Lotion, 0.5%|SKLICE (ivermectin) Lotion, 0.5% (Arbor Pharmaceuticals, LLC)
1462104|NCT03257943|Drug|Vehicle of the Test product|Vehicle for Ivermectin Lotion, 0.5% (Taro Pharmaceuticals Inc.)
1462107|NCT03257904|Procedure|intracranial pressure monitoring|measurement of intracranial pressure
1462109|NCT03257878|Other|validated Korean version of the SF36 and EQ-5D|"This is an observational prospective study. SF36 consists of 36 questions that measure patient's HRQoL in 8 domains: physical functioning (PF), role-physical (RP), bodily pain (BP), general health (GH) that represent the physical HRQoL, vitality (VT), social functioning (SF), role-emotional (RE), and mental health (MH) that represent the mental HRQoL. Each domain is scored from 0 (worst health status) to 100 (best health status). The scores of these domains are summarized into the physical component score (PCS) and mental component score (MCS).
The EQ-5D questionnaire is made up for 2 components; health state description and evaluation. In description part, health status is measured in terms of 5 dimensions (5D); mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. In evaluation part, the respondents evaluate their overall health status using the visual analogue scale (EQ-VAS)."
1462110|NCT03257865|Drug|Brexpiprazole|Starting dose of 2 mg/day; titrated to a max of 4 mg/day. Adjustments can be made to dosing
1462111|NCT03257865|Drug|Placebo|Tablet taken daily
1462115|NCT03257839|Device|Routine Full-Field Digital Mammography|Routine screening mammography exam, CC + MLO views.
1462116|NCT03257839|Device|Routine Digital Breast Tomosynthesis|Routine screening tomosynthesis exam, CC + MLO views.
1462117|NCT03257839|Device|Automated Whole Breast Ultrasound|Bilateral breast ultrasound performed as an adjunct to mammography.
1462118|NCT03257826|Device|kirschner wire|retrograde percutaneous kirschner wire was applied to stabilize the tibia.
1462119|NCT03257813|Drug|PRO-122|1 drop every 12 hours for 30 days of alternating treatment with 30 days
1462120|NCT03257813|Drug|Krytantek Ofteno®|1 drop every 12 hours for 30 days of alternating treatment with 30 days
1462121|NCT03257800|Drug|Ketamine|Ketamine 0,5mg.kg-¹was injected intravenously one minute prior propofol 3mg.kg-¹ and one minute before LMA insertion in Ketamine-propofol group
1462122|NCT03257800|Drug|placebo|The control group which received intravenously the same volume with normal saline one minute prior propofol 3mg.kg-¹ and 1 min before LMA insertion in propofol group
1462123|NCT03257787|Other|new adhesive strip|This is a strip made of a newly developed adhesive
1462124|NCT03257774|Other|Adhesive strip A|Strip consisting of a newly developed adhesive
1462125|NCT03257774|Other|Adhesive strip B|Strip consisting of a newly developed adhesive
1462126|NCT03257774|Other|Adhesive strip C|Strip consisting of a newly developed adhesive
1462127|NCT03257761|Biological|Durvalumab|Given IV
1462128|NCT03257761|Drug|Guadecitabine|Given SC
1462129|NCT03257748|Radiation|Laser Therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
1462130|NCT03257748|Radiation|LED therapy|The groups will be submitted to 12 sessions of phototherapy held twice a week for six weeks, during which only the researcher in charge of programming the phototherapy device will be aware of which treatment is being employed. However, the programmer will not participate in the execution of the treatments, evaluations or data analysis.
1462131|NCT03257735|Diagnostic Test|next-generation sequencing|"Patients' cerebrospinal fluid, blood and tumor tissue were collected within 3 days before treatment at diagnosis.
Patients' cerebrospinal fluid and blood were extracted at the time of first evaluation of efficacy after treatment (TKI began after 1 month or chemotherapy after 2 cycles).
Patients' cerebrospinal fluid and blood were extracted at first time of tumor progression，and re-biopsy of tumor tissue was done as much as possible.
All the samples were tested by next-generation sequencing."
1462132|NCT03257722|Drug|Pembrolizumab|Anti PD-1 immunotherapeutic agent, which blocks a protective mechanism on cancer cells to allow the immune system to destroy cancer cells. Administered intravenously (IV).
1462133|NCT03257722|Drug|Idelalisib|Phosphatidylinositol 3-kinase (PI3K) inhibitor which promotes anti-tumor immune response. Administered orally (PO).
1462134|NCT03257709|Procedure|Arthroscopic acetabular labral repair|Acetabular labral tear will be identified and reattached using suture anchors until a stable repair is achieved. If evidence of FAI is present ie: a cam or pincer lesion is identified then this will be treated with osteochondroplasty (cam) or acetabular rim recession (pincer).
1462135|NCT03257709|Procedure|Arthroscopic acetabular labral resection|The acetabular labral tear will be identified and its' limits defined. The torn portion of labrum will be resected to a stable edge. As with arm 1 there will be treatment of FAI if identified.
1462137|NCT03257683|Drug|Ranolazine|Study group will receive additional therapeutic dosing of drug.
1462138|NCT03257670|Drug|4% Topical Lidocaine Gel|This group will be given 4% topical lidocaine gel to take home. The patient will apply the 4% lidocaine gel to the outside and opening of the vagina for 3 minutes before vaginal penetration. The patient will continue using the numbing gel prior to vaginal penetration for the extent of the study (3 months).
1462139|NCT03257670|Device|CO2RE fractional laser therapy|This group will undergo vaginal CO2 laser therapy for a total of three (3) treatments with one month between treatments.
1462140|NCT03257657|Behavioral|Observation Group participants|Women in the observation group will receive usual WIC care, plus the opportunity to meet with a WIC RD at the 12 week visit. Written WIC materials on lifestyle recommendations will also be given to all observation group participants at the baseline visit. The Investigators will connect with the participant prior to the 12 week visit to make an appointment to meet with the WIC RD at that time.
1462141|NCT03257657|Behavioral|Lifestyle group participants|Women in this group will receive typical WIC care plus the below described activities. The intervention will last 12 weeks.
1462142|NCT03257644|Drug|INCB018424 phosphate cream|INCB018424 phosphate cream at the protocol-defined dose strength based on cohort assignment.
1462143|NCT03257631|Drug|Pomalidomide|: Subjects will be administered pomalidomide on Days 1 to 21, followed by a 7-day rest period, of each 28-day treatment cycle and will continue treatment for up to 24 cycles or until disease progression, withdrawal of consent/assent or unresolved toxicities as described in the protocol.
1462144|NCT03257618|Drug|Temozolomide|"Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.
Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression."
1462145|NCT03257618|Other|QoL, neurocognitive and psycholpathological assessment|This assessment will be performed at baseline, at 6 months, 12 months, 18 months, at the end of the treatment with TMZ, 6 months after the end of TMZ
1462146|NCT03257592|Radiation|[11C]DPA-713 PET imaging|
1462147|NCT03257579|Other|90 Day Supply|Policy Change implementing a 90 day standardized discharge prescription form with 3 repeats for all cardiac medications available on all wards where MI patients are managed at Hamilton Health Sciences sites
1462148|NCT03257579|Behavioral|Education|Education Alone provided at St. Joseph's Hospital
1462149|NCT03257579|Behavioral|Education Plus Point of Care Reminders|Education Plus Point of Care Reminders at Discharge to promote 90 day prescriptions and 3 repeats for cardiac patients at Niagara Health System
1462150|NCT03257553|Diagnostic Test|fecal calprotectin , doppler and ultrasound|faecal sample for measurement of calprotectin level ultrasound and doppler
1462151|NCT03257540|Device|Small Bone Intramedullary Nail|Patients undergoing a Lapidus Arthrodesis procedure for hallux valgus correction who are receiving a Phantom Small Bone Intramedullary nail will begin weight-bearing at 2 weeks and follow a pre-determined post-operative protocol.
1462152|NCT03257527|Behavioral|ENHANCE group|The ENHANCE program includes an initial 3-month treatment of 12 weekly sessions (including an introductory session, a final session, and 10 content sessions) followed by a 3-month maintenance phase intervention with bi-weekly sessions. Over the course of the program, participants will learn about 10 evidenced-based principles of happiness and how these principles can be applied effectively in their lives. At the final session, participants will receive feedback outlining the happiness principles and activities that fit them best, and will then be asked to work on creating a plan for integrating those principles into their daily lives.
1462153|NCT03257527|Behavioral|MBSR group|"The MBSR program is based on the self-help workbook entitled, A Mindfulness-Based Stress Reduction Workbook. This workbook is authored by Drs. Bob Stahl and Elisha Goldstein - who are both certified MBSR trainers. The workbook is written to help everyday people learn how to replace stress-promoting habits with mindfully-based ones to improve overall well-being. The workbook begins by providing a thorough introduction to the basic tenets of mindfulness, and improving well-being through the use of mindfulness-based skills. The workbook outlines, in detail, several skills-based exercises for practicing mindfulness across different aspects of a person's life. The MBSR group will be provided with a recommended weekly schedule for the initial 3-month treatment and a list of additional resources to be completed over the 3-month maintenance phase."
1462154|NCT03257514|Drug|alpha lipoic acid drug (thioctic acid acid)|Alpha lipoic acid has anti-inflammatory, antioxidant effects and plays a role in wound healing process.
1462155|NCT03257514|Drug|Placebo Oral Tablet|placebo oral drug have the same shape of thiotacid tablet
1462156|NCT03257501|Device|FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
1462157|NCT03257488|Device|type IV portable monitoring (Somnocheck micro Weinmann)|Somnocheck micro Weinmann: a screening device for sleep disorders assessment. Somnocheck 2 Weinmann: a diagnostic device for obstructive sleep apnea.
1462158|NCT03257475|Radiation|Brachytherapy|Intracavitary irradiation starts at the end of the external beam radiation using image-guided CT/SIM.CT/SIM (transverse axis) is done to complete 3/2D treatment planning. Measurement VRL, PIBS and PIBS ± 2cm, R-V were recorded; Brachytherapy plan: Point A: 24-30Gy/4-5f, or 21-28Gy/3-4f HR-CTV: ≥85Gy, IR-CTV 65Gy dose records
1462160|NCT03257449|Dietary Supplement|Viscous Fibre|Meta-analysis of Randomized Controlled Trials
1462161|NCT03257436|Device|CRT-D|Left Ventricular MultiSite Pacing
1462162|NCT03257423|Drug|Ertapenem followed by levofloxacin and metronidazole|Ertapenem 1 g i.v. daily for either 2 days (MAPPAC + APPAC II patients) or 3 days (MAPPAC + APPAC III) followed by p.o. levofloxacin 500 mg x 1 + metronidazole 500 mg x 3 for either 5 days (APPAC II + MAPPAC) or 4 days (APPAC III + MAPPAC)
1462163|NCT03257423|Drug|Moxifloxacin|Moxifloxacin 400 mg once a day for seven days (APPAC II + MAPPAC)
1462164|NCT03257423|Procedure|Appendectomy|Primarily laparoscopic appendectomy for either complicated acute appendicitis or uncomplicated acute appendicitis (refusing to participate in APPAC II or III trials or recurrent acute appendicitis).
1462165|NCT03257423|Other|Placebo|Placebo i.v. once a day for three days (APPAC III + MAPPAC) followed by placebo capsules three times a day for four days.
1462166|NCT03257397|Device|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and cTBS over right dorsolateral prefrontal cortex for a period of three weeks. iTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. cTBS: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in a single 40s train; one session will comprise left iTBS and right cTBS. There will be two sessions daily with 60 min in between sessions
1462167|NCT03257397|Device|theta-burst stimulation (TBS) using a MagPro X1000|iTBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS consists of 3-pulse 50 Hz bursts which will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. One session will comprise left and right iTBS. There will be two sessions daily with 60 min in between sessions
1462168|NCT03257384|Other|Black box recording of surgery|Time delays will be recorded from the moment the patient is draped and enters the operating room to the moment they exit the operating room.
1462170|NCT03257332|Procedure|Low Anterior Resection for Rectum Cancer|Subjects should have received curative surgery for rectal cancer (low anterior resection) with/with-out adjuvant (radiation/chemo) therapy.
1462171|NCT03257319|Drug|inhaled titration of morphine chlorhydrate|Patient in arm A will receive 1 to 3 titration
1462172|NCT03257319|Drug|IV placebo|Patient in arm A will receive 1 to 6 injection
1462173|NCT03257319|Device|Inhaled placebo|Patient in arm B will receive 1 to 3 titration
1462174|NCT03257319|Drug|IV titration of morphine chlorhydrate|Patient in arm BA will receive 1 to 6 injection
1462175|NCT03257306|Procedure|ureteral double-J stent removal using magnet|Double-J ureteric stent removed using magnet
1462176|NCT03257306|Procedure|ureteral double-J stent removal using cystoscopy|Double-J ureteric stent removed using cystoscopy
1462177|NCT03257293|Behavioral|Modified Cystoscopy|The objective of this study is to examine whether a non-pharmacologic modification in procedure of cystoscopies improves patient perception of pain and discomfort.
1462178|NCT03257293|Behavioral|Routine Cystoscopy|Routine cystoscopy as done as part of routine clinical practice
1462179|NCT03257280|Other|Early oral nutrition|An early oral nutrition with supplements and increased progressively according to an established schedule, start 48 hours after total gastrectomy.
1462180|NCT03257267|Drug|REGN2810|Intravenous (IV) administration every 3 weeks (Q3W)
1462181|NCT03257267|Drug|Investigator Choice (IC) Chemotherapy|"IC chemotherapy options include:
Antifolate: Pemetrexed
Topoisomerase 1 inhibitor: Topotecan or Irinotecan
Nucleoside analogue: Gemcitabine
Vinca alkaloid: Vinorelbine
The only chemotherapy treatments allowed in the control arm are any of the 5 drugs that are listed as IC options above."
1462182|NCT03257254|Drug|Varithena|Administration procedures and volume are per standard of care, full prescribing information, and instructions for use.
1462183|NCT03257241|Drug|A arm (DA-90)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is > 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
1462184|NCT03257241|Drug|B arm (DAC)|After confirming the diagnosis, assuming the inclusion criteria and exclusion criteria are respected, the patients are randomized to one of two standard induction treatment protocols (A arm: DA-90 vs B arm: DAC). After completing induction I, an early bone marrow assessment is performed on day 14 from the beginning of the treatment (+ day 7 after finishing chemotherapy) using the cytological method and MRD is assessed by the immunophenotyping method. Therapeutic decision is taken on the basis of the cytological assessment. Patients, in whom the percentage of blasts in the bone marrow on day 14 is > 10%, receive early induction II from day 16. An Immunophenotype test is a complementary examination.
1462185|NCT03257241|Drug|A arm (CLAG-M)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
1462186|NCT03257241|Drug|B arm (FLAG-IDA)|"Patients who do not achieve CR after two courses of induction therapy or patients with relapsed leukemia are eligible for emergency treatment (salvage) according to the CLAG- M or FLAG-IDA protocol."
1462187|NCT03257228|Genetic|comparative semiquantitative immunohistochemistry|
1462188|NCT03257215|Drug|Stoss vitamin D|A single 1.5 mL dose containing 150,000 IU cholecalciferol (100,000 IU/mL) administered on Day 1 (Solution in Olive Oil B.P. )
1462189|NCT03257215|Drug|Daily vitamin D|Daily 0.2 mL dose containing 1000 IU cholecalciferol administered from Day 1 to 90
1462190|NCT03257215|Drug|Stoss placebo|A single 1.5 mL dose administered on Day 1
1462191|NCT03257215|Drug|Daily placebo|A once daily 0.2 mL dose administered from Day 1 to 90
1462192|NCT03257202|Drug|Clindamycin 1% Gel|topical clindamycin
1462193|NCT03257202|Drug|Benzoyl peroxide 5% gel|topical benzoyl peroxide
1462194|NCT03257202|Drug|BenzaClin 5%-1% Topical Gel|Topical clindamycin and benzoyl peroxide together
1462195|NCT03257176|Behavioral|Stepping Stones and Creating Futures|21 session intervention, comprising of 10 Stepping Stones sessions focused on gender, relationships and communication. 11 Creating Futures sessions focused on livelihoods.
1525982|NCT02771704|Other|Potassium iodide|
1462200|NCT03257150|Procedure|Irreversible Electroporation|Irreversible electroporation (IRE) is a process that uses the NanoKnife system to sent electrical currents to a cancer tumor which will disrupt the tumor cell and therefore causing the cell to die.
1462201|NCT03257150|Device|NanoKnife System|A system consisting of electrode probes connected to a machine. The probes will be surgically placed around the cancer tumor.
1462202|NCT03257150|Drug|18F-Fluoroazomycin arabinoside|Positron Emission Tomography (PET) imaging agent for assessment of tumor hypoxia.
1462204|NCT03257124|Drug|AZD9291|AZD9291 160mg per oral daily (1 cycle of 28 days)
1462205|NCT03257111|Other|activity monitors|activity monitors are worn on the wrist, much like a watch. Data from the activity monitors will be downloaded once a week and at discharge. Normal hospital and therapy activities will not be altered.
1462207|NCT03257085|Other|Low-carbohydrate, high-fat|Participants following low-carbohydrate, high-fat diet for 8 weeks.
1462208|NCT03257085|Other|High-carbohydrate, moderate-fat|Participants following high-carbohydrate, moderate-fat diet (UK dietary guidelines) for 8 weeks.
1462209|NCT03257072|Biological|50 Necator americanus L3 larvae|1x50 Necator americanus L3 larvae
1462210|NCT03257072|Biological|100 Necator americanus L3 larvae|2x50 Necator americanus L3 larvae
1462211|NCT03257072|Biological|150 Necator americanus L3 larvae|3x50 Necator americanus L3 larvae
1462212|NCT03257059|Other|Breakfast|Glutinous rice (75 grams of available carbohydrate)
1462213|NCT03257059|Other|No Breakfast|No food to be served in the morning
1462214|NCT03257046|Drug|ITI-214|Oral
1462215|NCT03257046|Other|Placebo|Oral
1462216|NCT03257033|Drug|Gemcitabine|Chemotherapy
1462217|NCT03257033|Drug|nab-paclitaxel|Chemotherapy
1462218|NCT03257033|Device|RenovoCath|Intra-arterial catheter
1462219|NCT03257020|Diagnostic Test|SD-OCT|SD-OCT was performed to all subjects to measure BMO-MRW and RNFL thickness by trained glaucoma specialist. It takes about 5 to 10 minutes. The foveal location was manually detected with a live B-scan, followed by defining BMO center. A radial pattern containing 24 angular, equidistant, high-resolution 15° B-scans centered on the BMO was used to compute the neuroretinal rim parameters. The BMO points and ILM were identified and marked in each B-scan with automated software (Glaucoma Module Premium Edition, version 6.0; Heidelberg Engineering). After radial scan completed, 3 consecutive circumpapillary B-scans were followed to measure RNFL thickness at diameter of 3.5, 4.1 and 4.7mm. BMO-MRW and RNFL thickness was automatically computed globally and sectorally.
1462220|NCT03257007|Behavioral|Mindfulness|The Mindfulness intervention sessions are designed to cultivate present-moment awareness in everyday life to facilitate adaptive and non-reactive relating to thoughts, feelings, and bodily sensations. Participants will be provided with 10-20 minute audio recordings of each of 5 mindfulness practices covered in class, recorded in the facilitator's voice. Participants will be encouraged to practice mindfulness at home 10-20 minutes per day, 6 days per week. Participants will be provided with weekly diaries on which to record type and amount of home practice of mindfulness skills.
1462221|NCT03256994|Device|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
1462222|NCT03256994|Behavioral|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient
1462223|NCT03256981|Radiation|SBRT|SBRT dose and fractionation dependent on site of metastasis and proximity to critical normal tissues.
1462224|NCT03256981|Drug|TKI|Continued background TKI alone
1462225|NCT03256968|Drug|Ataluren|ataluren
1462226|NCT03256955|Device|Tof cuff|The Tof Cuff will be installed on one arm. After anesthesia induction the Tof Cuff will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
1462227|NCT03256955|Device|Tof Watch SX|The Tof Watch SX will be installed on the opposite arm to the Tof Cuff. After anesthesia induction the Tof Watch SX will be calibrated and continuos monitoring of the neuromuscular block started until complete recovery of neuromuscular block.
1948051|NCT02839382|Other|Site Visits|"Practices randomized to this arm of the study will be given an opportunity to make a site visit to an exemplar practice to learn about innovative approaches to conducting quality improvement activities."
1948052|NCT02838784|Other|Artacent Human Amniotic Membrane|Double layer dehydrated amnion product
1462231|NCT03256916|Drug|Nelfinavir|Nelfinavir (HIV protease inhibitor) targets proteasome and inhibits AKT phosphorylation and plays an important role in radiosensitization of tumour cells.Nelfinavir will be given to the patient orally with food, because the bioavailability increases under the influence of food.
1462232|NCT03256916|Drug|Cisplatin|Cisplatin will be administered on a weekly basis with a dose of 40 mg/m2 by IV infusion over a period of 1 hour 2-4 hours prior to start of EBRT. Patient will be premedicated with I.V Ondansetron to prevent emesis. Pre chemotherapy and post chemotherapy, patient will be administered IV fluids for effective renal clearance of cisplatin.
1462347|NCT03255980|Other|Standard of Care|Standard of care suggested by MASCC' Skyn Toxicity Study Group guidelines
1465293|NCT03233347|Drug|Vinblastine|Given IV
1948053|NCT02838784|Procedure|Standard of Care|Off loading with a cast walker, non-adherent dressings, debridement and moisture retentive dressings
1462233|NCT03256916|Radiation|Pelvic EBRT and Brachytherapy|Pelvic EBRT will delivered by standard 4 field technique using 6MV/15 MV photon beams. Prior to delivery of radiation, patients will be simulated by CT simulator for planning the beam arrangements. Total dose of pelvic EBRT will be 46Gy/23 #/4.5 weeks. The prescribed dose will be specified according to ICRU 50 guidelines. All patients will be treated with 3D conformal external radiation with target delineation and multileaf collimator leaf shaping.
1462234|NCT03256903|Drug|Methoxyflurane|Up to two inhalers containing 3 mL methoxyflurane. Treatment duration: 1 administration in 1 day.
1462235|NCT03256903|Drug|Standard of care|Any kind of analgesia, administered by any route for emergency relief of moderate to severe pain in conscious adult patients with trauma and associated pain
1462238|NCT03256864|Drug|Tacrolimus and Everolimus|"In the TAC and EVR BID arm, everolimus will be initiated at a dose of 1.0 mg BID within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.15 mg/kg BID and then taper to 0.10 mg/kg BID to maintain trough (C0) concentration in the range 2.5-5 ng/mL.
In the TAC and EVR QD arm, everolimus will be initiated at a dose of 2.0 mg QD within 24 h of randomization with the dose adjusted from day 5 onward to maintain trough (C0) concentration in the range 3-8 ng/mL. Tacrolimus will be initiated at a dose of 0.1-0.2 mg/kg/day QD to maintain trough (C0) concentration in the range 2.5-5 ng/mL."
1462239|NCT03256851|Behavioral|Telephone-Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.
Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.
Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.
This home exercise program will be paired with a 1x/week telephone call with an investigator."
1462240|NCT03256851|Behavioral|In-Person Delivered Exercise Therapy|"A combination of aerobic and resistance training has been shown to be most effective for reducing fatigue in persons with MS.
Aerobic training will consist of: 30 minutes of either cycling, treadmill walking or overground walking, 2x/week. Participants will be given a wrist-worn pedometer with heart-rate monitor to track their heart rate during training. Participants will be progressed to reach 60-70% of their maximal heart rate during aerobic training over the course of the study.
Strength training will consist of hip extension, hip flexion, hip abduction, knee extension and knee flexion movements with resistance bands performed 3x/week.
This home exercise program will be paired with a 1x/week visit to the laboratory to work with a physical therapist or trained team member."
1462241|NCT03256838|Drug|Ferric Citrate|Ferric citrate will be provided as a 500mg capsule. All intervention doses will be based on serum phosphorus levels.
1462242|NCT03256825|Diagnostic Test|Rapid diagnostics alone|Urine samples present at the laboratory at opening on weekdays will be screened using urine flow cytometry and microscopy of centrifuged gram stained urine. Samples found positive for significant mono microbial bacteriuria will be investigated further by using direct automated phenotypic identification and antimicrobial susceptibility determination.
1462243|NCT03256825|Other|Real-time antimicrobial stewardship decision support|"A clinical microbiologist will be give RADS by phone to a designated clinician with the aim of:
Switch to active treatment if non-working empirical treatment
De-escalate broad spectrum empiric treatment when feasible
Promote early intravenous to per oral switch
Shorten treatment duration"
1462244|NCT03256812|Device|ICT-based ECG monitoring|Continuous monitoring will begin from the time of participation in the trial in the ICT-based centralized monitoring group. 24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups in this group, as in the Holter monitoring group. If heart rate drops below 40 beats/min or increases above 120 beats/min on ECG during ICT-based ECG home monitoring, the participant will be notified first through an alarm function.
1462245|NCT03256812|Device|Holter monitoring|24-hr Holter monitoring will be implemented at the 3-, 6-, and 12-month follow-ups
1462247|NCT03256786|Behavioral|Prewarming using forced air warmer, warmed intravenous fluid|Combined modality active warming consisting of preoperative 15 min of surface warming using a forced air warmer before spinal anesthesia and coloading of warmed intravenous fluid in active warming group
1462248|NCT03256760|Biological|Endotoxin|Endotoxin
1462249|NCT03256760|Biological|Placebo|Placebo
1462250|NCT03256747|Device|NMES|NMES will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time application will be 60 minutes. Intensity will be adjusted individually, taking into account the patient's ability to promote the full knee extension and comfort during contractions.
1463492|NCT03247114|Other|Fructose|Fructose, 50 grams in 300 ml water at room temperature
1462251|NCT03256747|Device|NMES-placebo|NMES-placebo will be placed at the knee extensors. Stimulation frequency will be 20 Hz. Pulse width will be 0.5 milliseconds and the contraction time will be 10 seconds (TON: 10s) with a 5-second rest interval (TOFF: 5s). Total time of application will be 60 minutes. Intensity will be adjusted with minimal intensity, utilized to provide a sensory stimulus, but insufficient to elicit a tetanic muscular contraction.
1462253|NCT03256721|Drug|Apatinib/docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
1462254|NCT03256721|Drug|docetaxel/pemetrexed|Participants are randomly assigned to treatment group or control group
1462258|NCT03256682|Behavioral|Stress management counseling|stress management counseling based on CBT and relaxation
1462259|NCT03256669|Procedure|umbilical incision|exploration through umbilical incision
1462260|NCT03256656|Other|Electrical stimulation on renal urine production|
1462261|NCT03256643|Behavioral|Exercise|Exercise intervention will consist of 8 exercise classes and exercises at home. A booklet will be given to each person that has a description and photograph of each exercise that designed to work on core strength and balance.
1462262|NCT03256643|Behavioral|Delayed Exercise|People will be tested up to 40 weeks after beginning the intervention.
1462263|NCT03256643|Behavioral|Exercise and enrichment|Exercise and enrichment will consist of the same exercise program described for the exercise intervention. The enrichment protocol consisting of cultural educational program will take place during the exercises and breaks for this group.
1462264|NCT03256617|Other|Cognitive reassurance training|The 2-day training program includes 3 sessions that will consist of interactive didactic lectures, solving case studies and role-playing activities. The first session uses lecture and cases to present models of pain and disability, evidence based predictors of disability and delayed recovery and evidence based interventions for patients with low back pain. The second session uses role playing and case studies help the providers to 1) develop skills in identifying maladaptive beliefs about pain in patients with low back pain and 2) develop the skills to address diagnostic uncertainty and negative pain beliefs and 3) develop skills to educate patients with low back pain. The third session will use role playing and case studies to refine the provider' skills in providing cognitive reassurance to patients with low back pain.
1462265|NCT03256604|Diagnostic Test|left-over sputum|Totally 467 samples were gathered from different clinics, and the diagnostic procedures and the therapeutic approaches were completely unknown to the study group. The coded samples were stored at 4-8°C and analyzed within 72 hours of sampling using the sputum strip test. From April to June 2016, a physician and the study nurse reviewed the journals. The age, sex, length of stay on ward, the clinical symptoms, the blood and sputum cultures and PCR along with the results, the X-rays, the antibiotic therapy, CRB-65 and the ultimate diagnosis code (ICD-10) were documented in Excel-files.
1462266|NCT03256591|Other|HBB facilitators with simulation training|HBB training from facilitators with simulation skills. Standard HBB facilitators do not have simulation skills
1462267|NCT03256578|Device|New Life Box Respiratory Function Monitor|The intervention is the use of a visible New Life Box Respiratory Function Monitor display in infants born between 24 and 27 6/7 weeks gestation receiving PPV for resuscitation after birth.
1462268|NCT03256565|Diagnostic Test|Q-tip test|A Q-Tip lubricated with anesthetic gel is inserted into the urethra, woman is then asked to cough and strain, and the angle of the Q-tip rotates is recorded.
1462269|NCT03256552|Drug|COPD|Chronic Obstructive Pulmonary Disease
1462270|NCT03256539|Behavioral|Sleep intervention|Behavioral sleep intervention program
1462271|NCT03256539|Behavioral|Placebo intervention|Quasi-desensitization intervention for insomnia (which does not include any of the active components of CBT-I but implemented in the same frequency and duration)
1462275|NCT03256513|Other|model controlling|control blood pressure by statistical l model with anticipate lowest peri-procedure risk
1462276|NCT03256513|Other|conventional controlling|control blood pressure by conventional strategy
1462277|NCT03256500|Device|Transcranial Direct Current Stimulation|One half of the subjects will receive sham and the other half will receive tDCS. The Soterix Medical 1x1 line of low-intensity tDCS stimulators which we plan to use is designed to generate low levels of direct current current between one anode and one cathode placed on the body. The current enters the body through the positive electrode, the anode exits the body through the negative electrode, the cathode. The accessories provided with the device allow for simple and comfortable positioning of the electrodes on the body.
1462281|NCT03256461|Behavioral|Lactate clearance 10% target group|Participants receive the protocolized resuscitation to achieve the goal of 10-percent lactate clearance every two hours within the initial six hours of treatment.
1462282|NCT03256461|Behavioral|Lactate clearance 20% target group|Participants receive the protocolized resuscitation to achieve the goal of 20-percent lactate clearance every two hours within the initial six hours of treatment.
1462283|NCT03256461|Behavioral|Standard EGDT group|Participants receive the strategy of early goal-directed treatment of sepsis fluid resuscitation.
1462284|NCT03256435|Behavioral|RAMP PrEP initiation, adherence, and retention intervention|The intervention arm will receive facilitated strengths-based case management (SBCM)—delivered by trained interventionists—to help navigate the PrEP medical care system and support the participant and health care staff in meeting the challenges faced with obtaining PrEP medication (e.g., overcoming insurance barriers or barriers with co-pays). This also includes facilitated integration into the PrEP clinic and obtaining monthly PrEP prescription refills.
1462348|NCT03255967|Behavioral|DSM-H|Multi-modal quality improvement program for improving the quality of care provided to PWD-informal caregiver dyads through HHC
1462285|NCT03256422|Drug|Treatment discontinuation|"• Receiving tritherapy. Allowed treatment drugs are :
nucleoside analogs : tenofovir (TDF ou TAF), emtricitabine, abacavir, lamivudine
protease inhibitors : lopinavir/r, darunavir/r ou atazanavir/r
non nucleoside reverse transcriptase inhibitors : efavirenz, rilpivirine ou etravirine
integrase inhibitors : dolutegravir, elvitegravir/cobicistat ou raltegravir"
1462286|NCT03256409|Other|Adherence mold and yeast and mesophyll aerobe|Adherence mold and yeast and mesophyll aerobe to BOD and BJOD Microbial populations have been controlled in the saliva at initial time and adherence at 30 - 180 days after the overdentures in the mouth. The saliva sample was obtained from the patient in a sterile sputum collection bottle through a sterile solution. The overdenture samples were extracted and processed for analysis. Each sample was submerged in ¼ sterile Ringer and subjected to vigorous ultrasound shaking. From each of the microbial suspensions, successive dilutions were made to determine the total number of viable microorganisms present. Total count of mold and yeast and total count of mesophyll aerobe were performed.
1462287|NCT03256409|Other|Surface Roughness (Ra)|The surface roughness of BOD and BJOD was determined with the rugosimeter the Mitutoyo Surfest SJ-301® (Mitutoyo Corporation Inc., Kanagawa, Japan), through a displacement force of 4mN and of the tray to 0.5 mm/s and back to 1 mm/s (Murtra and Arcís,1999). The roughness profile Ra was evaluated and determined in microns (ųm) through five readings for each of the samples in the study respectively.
1462288|NCT03256396|Procedure|PEEP setting based on esophageal pressure measured|PEEP is set on the basis of esophageal pressure measurement with the aim to maintain transpulmonary pressure during expiration between 0 and 5 cmH2O
1462289|NCT03256383|Device|Lead testing|Fingerstick
1462291|NCT03256357|Behavioral|Constraint-induced movement therapy|In a 2-week day camp model children receive constraint- induced movement therapy for six hours a day, for 9 out of 11 consecutive days. All children wear a tailor made hand splint on the unaffected upper limb for 6 hours per day while performing unimanual exercises individually or in a group based on shaping and repetitive practice.
1462292|NCT03256357|Behavioral|Action observation training|Action observation training consists of 15 sessions of 1 hour. Children watch 3 minute video clips of unimanual goal-directed actions followed by 3 minutes of execution of the actions.
1462293|NCT03256357|Behavioral|Placebo observation training|Placebo observation training consists of 15 sessions of 1 hour. Children perform the same actions as the AOT training after watching computer games without biological movements.
1462294|NCT03256344|Biological|Talimogene Laherparepvec|Virally based anti-cancer immunotherapy given by direct injection into tumors.
1462295|NCT03256344|Biological|Atezolizumab|A monoclonal antibody given by intravenous injection.
1462296|NCT03256331|Drug|BEL-X-HG|"This study will be carried out in 2 parts:
A sequential Dose Escalation Part of four doses following a 3 + 3 design where dose escalation will be made based on DLT, for a single cycle (28 days) of BEL-X-HG treatment
A Dose Extension Part of up to 5 cycles (28 days each) at the same dose level (starting dose) of BEL-X-HG treatment
Escalating dose levels of BEL-X-HG in 4 study cohorts will be as follows:
Cohort 1: Dose level 1 - 0.5 g/day (0.25 g, bid)
Cohort 2: Dose level 2 - 1.0 g/day (0.5 g, bid)
Cohort 3: Dose level 3 - 2.0 g/day (1.0 g, bid)
Cohort 4: Dose level 4 - 4.0 g/day (2.0 g, bid)"
1462297|NCT03256318|Other|No intervention|No intervention; surveys/questionnaires only
1462298|NCT03256305|Device|"personalized rTMS+drug treatment"|High frequency（10HZ）stimulation of brain regions corresponding to lesion, low-frequency （1HZ）stimulation of the contralateral brain, intensity=90%MT（motor thresholds). Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day, 1 times a day ,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
1462299|NCT03256305|Device|Traditional rTMS +drug treatment|Traditional rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz; localization of right DLPFC: frequency=1 Hz, intensity=90%MT, Each sequence is 20 times, duration is 10 seconds, each sequence spaced 60s, 20 sequences per day,1 times a day,total times is 15. Taking paroxetine 2 weeks, Take 20 mg a day.
1462300|NCT03256292|Drug|Testosterone replacement|Testosterone replacement therapy
1462301|NCT03256292|Behavioral|lifestyle|lifestyle intervention consisting of diet and increased physical activity
1462302|NCT03256279|Device|".014 NiTi heat-activated archwire"|".014 NiTi heat-activated archwire In the lower arch during the first three months of the orthodonci treatment"
1462303|NCT03256279|Device|".014 NiTi Superelastic archwire"|".014 NiTi superelastic archwireIn the lower arch during the first three months of the orthodonci treatment"
1462304|NCT03256253|Drug|Pregabalin|pregabalin up to 600 mg/day
1462305|NCT03256240|Other|side-to-side functional end anastomosis|type of anastomosis
1462306|NCT03256240|Other|Kono-S analstomosis|antimesenteric anastomosis
1462307|NCT03256227|Behavioral|Family Supported Prolonged Exposure|The investigators propose to bring a family member into early educational sessions of PE, one of the most researched and efficacious treatments for PTSD, to increase family support for PE adherence. Strategies for how to engage with families are drawn from existing evidence-based approaches, including Motivational Interviewing and Behavioral Couples Therapy.
1462308|NCT03256227|Behavioral|Standard Prolonged Exposure|Standard Prolonged Exposure for PTSD as delivered in routine VA care.
1462309|NCT03256214|Procedure|Closed suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with closed suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with open suction system.
1462310|NCT03256214|Procedure|Open suction system|In mechanically ventilated patients, intratracheal secretions were aspirated with open suction systems to compare the pulmonary and cardiovascular parameters (Peak Pressure, Resistance, and Pressure Plateau, Heart Rate and Mean, Diastolic, and Systolic Pressures) with closed suction system.
1462453|NCT03255148|Drug|Placebo|Placebo nasal spray
1462311|NCT03256201|Behavioral|Nutritional Counseling|Patients in both arms receive a single counseling session with a licensed dietician to determine individual protein goal for body weight and current dietary intake. Goal is then met through protein supplementation (provided) if needed beyond dietary intake. For the last 5 days, all participants switch to Impact Advanced Recovery® (provided), as standard care at our facility.
1462312|NCT03256201|Behavioral|Standard Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and AROM of upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
1462313|NCT03256201|Behavioral|Enhanced Exercise|Patients receive a single instruction session with a physical therapist, for training in moderate intensity (using Rate of Perceived Exertion) exercise including cardiovascular endurance, flexibility, and resistance exercise for upper and lower body. If no other preferred mode of endurance training, a home ergometer is provided for use with arms and/or legs.
1462314|NCT03256188|Behavioral|Active classroom|30 minutes of moderate-to-vigorous physical activity
1462316|NCT03256162|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each one week apart.
1462317|NCT03256162|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each one week apart.
1462318|NCT03256149|Drug|Dexamethasone|
1462319|NCT03256149|Drug|Placebo|Normal saline (IV placebo)
1462320|NCT03256136|Drug|Carboplatin|Chemotherapy
1462321|NCT03256136|Drug|Nivolumab|will allow the body's immune system to work against tumor cells
1462322|NCT03256136|Drug|pemetrexed|Chemo therapy
1462323|NCT03256136|Drug|Ipilimumab|will allow the body's immune system to work against tumor cells
1462324|NCT03256123|Dietary Supplement|red palm shortening group|Biscuits made of red palm shortening will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The biscuits for each subject will contain ~200 kcal with 10 g of red palm shortening/day (630 µg RE/day). This biscuit would be given four days a week on schooling days for a duration of 6 months. On average in a week, subject is expected to receive 630 µg RE of vitamin A/day. This would fulfill ~70% of the RNI of vitamin A for children aged 7-11 years old.
1462325|NCT03256123|Dietary Supplement|palm shortening group|Biscuits made of palm shortening (control group) will be distributed to the subjects given four days a week on schooling days for a duration of 6 months. The palm shortening biscuits contain corresponding fatty acids as red palm shortening group.
1462326|NCT03256110|Behavioral|Improving Communication about Serious Illness-AI/AN|A one-page summary of patient-specific preferences, barriers and facilitators for engaging in patient-provider communication about advance care planning, provided to patient and provider prior to a clinical encounter with prompts for initiating and/or improving the quality of communication about advance care planning.
1462327|NCT03256097|Device|XDP sound processing strategy|XDP is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
1462328|NCT03256097|Device|Voice Guard sound processing strategy|Voice Guard is a cochlear implant sound processing strategy that coverts environmental sound into meaningful information that a cochlear implant users' brain can comprehend.
1462329|NCT03256097|Device|Voice Track|Voice Track is a cochlear implant noise cancellation system which is designed to reduce the adverse effect of background noise on speech perception through cochlear implants
1462330|NCT03256084|Procedure|Blood and tumor samples|Blood and tumor samples
1462331|NCT03256071|Drug|Decitabine plus Modified BUCY|"Decitabine:20 mg/m²/day on day -14 to -10;
Modified BUCY:
Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
1462332|NCT03256071|Drug|Modified BUCY|"Sibling:semustine 250 mg/m²/day on day -9;cytarabine 2 g/m²/day on day -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Unrelated:semustine 250 mg/m²/day on day -10;cytarabine 2 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3.
Haploidentical:semustine 250 mg/m²/day on day -10;cytarabine 4 g/m²/day on day -9 to -8；busulfan 3.2mg/kg/day on day -7 to -5;cyclophosphamide 1.8g/m²/day on day -4 to -3."
1462335|NCT03256045|Drug|Carfilzomib|Given IV
1462336|NCT03256045|Other|Chemosensitivity Assay|Undergo in vitro chemosensitivity testing
1462337|NCT03256045|Drug|Dexamethasone|Given PO
1462338|NCT03256045|Other|Laboratory Biomarker Analysis|Correlative studies
1462339|NCT03256045|Drug|Panobinostat|Given PO
1462340|NCT03256019|Procedure|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the ambu-bagging during cardiopulmonary resuscitation
1462341|NCT03256006|Other|Blood sample|Blood sample to study per and post effort evolution markers of systemic inflammation
1462346|NCT03255980|Device|Xonrid® gel|Water based gel for the management of toxicity skin symptoms induced by Radiotherapy
1462349|NCT03255967|Behavioral|Standard of Care|Subjects receive care through usual home healthcare assignment process.
1462350|NCT03255954|Other|Interpersonal Counseling for University Counseling Centers|Interpersonal Counseling (IPC) is a brief version of Interpersonal Psychotherapy (IPT). IPC synthesizes the fundamental IPT principles into 3-6 sessions. Individuals receiving IPC are initially assessed for symptoms of depression, and then encouraged to identify interpersonal problem areas which may be contributing to their presenting symptoms.
1462353|NCT03255928|Diagnostic Test|PAS assay, TGT|Evaluation of platelet function
1462354|NCT03255915|Drug|Tenofovir Disoproxil Fumarate (TDF)-Emtricitabine (FTC)|TDF-FTC pod-IVR designed to deliver TDF at a target rate of 1 mg d-1 and FTC at a target rate of 2 mg d-1.
1462355|NCT03255915|Other|Placebo|A placebo pod-IVR containing microcrystalline cellulose pods.
1462356|NCT03255902|Behavioral|Parenting classes|Parenting Classes:The Incredible Years curriculum
1462357|NCT03255889|Drug|Glyceryl Tridecanoate|Glyceryl Tridecanoate (GT) is the triglyceride form of decanoic acid (DA), a C10 fatty acid. GT belongs to the class of medium chain triglycerides (MCT), which has been accepted as a Generally Recognized As Safe food product by FDA. Decanoic acid, also known as capric acid, occurs naturally in coconut oil (8 - 10%) and palm kernel oil (4%).
1462358|NCT03255889|Other|Placebo|Sunflower oil emulsion of equal calories.
1462359|NCT03255876|Dietary Supplement|Enriched pomegranate juice|Pure pomegranate juice enriched with grape seed and apple peel extract (200 ml) to be consumed with 109 g of bread
1462360|NCT03255876|Dietary Supplement|Placebo beverage|Beverage containing the same type and amount of carbohydrates as pomegranate juice and similar flavor (200 ml) to be consumed with 109 g of bread
1462361|NCT03255863|Other|Questionnaire|Patient Self reported questionnaire filled in.
1462362|NCT03255837|Device|Transcranial direct current stimulation (tDCS)|Transcranial Direct Current Stimulation (tDCS, a form of non-invasive brain stimulation) on the left dorsolateral prefrontal cortex (DLPFC)
1462363|NCT03255824|Drug|Dexmedetomidine and Midazolam|Administration of Dexmedetomidine and Midazolam for sedation during third molar surgery.
1462364|NCT03255824|Drug|Propofol, Midazolam, and Fentanyl|Administration of Propofol, Midazolam, and Fentanyl for sedation during third molar surgery.
1462365|NCT03255811|Drug|apatinib|Apatinib mesylate tablets treatment and to maintain the actual benefit in progression free survival.
1462366|NCT03255798|Device|G2 and G3|Two iStent inject devices and one iStent supra device
1462367|NCT03255785|Device|Cataract surgery plus one iStent and one iStent Supra implanted|Cataract surgery via phacoemulsfication plus one iStent and one iStent supra
1462368|NCT03255772|Diagnostic Test|Magnetocardiography|Study subjects will be placed within a magnetic shielding apparatus. Noninvasive sensors placed over the subject's torso will acquire magnetic field fluctuations generated by cardiac activity, which will then be analyzed for evidence of myocardial ischemia.
1462369|NCT03255759|Diagnostic Test|Multiplex molecular diagnostic assay|To assess the added value and acceptability of a multiplexed molecular diagnostic assay in the identification of pathogens in patients presenting with bacteremia at hospitals in LMICs, and to assess health care providers' satisfaction with the assay.
1462370|NCT03255746|Behavioral|Sleep Enhancement|This regimen combines education and behavioral skills to enable prolonging sleep in chronically sleep deprived subjects so as to better meet participant's sleep needs. This intervention emphasizes plain language communication of cognitive behavioral therapy strategies for initiating and maintaining health behavior change, primarily through using brief action plans (time-limited, personally relevant, behavioral goal setting with confidence), and collaborative problem-solving. Coaching will be provided to modify daily routines and adhere to sleep hygiene practices to allow for extended time in bed.
1462371|NCT03255746|Behavioral|Health Education|This is a placebo/attention control condition. Participants will receive health education based on NIH information. Number, duration, and frequency of sessions will be identical to those administered to the intervention group.
1462373|NCT03255707|Device|eye patch|Occluding the better seeing eye for a given number of hours daily
1462374|NCT03255707|Device|dichoptic treatment|dichoptic treatment in the form of playing a video game (Lazy Eye Blocks ®) while wearing a red/green goggle.
1462375|NCT03255694|Drug|PEG-somatropin|After the first stage (52 weeks) of Phase II clinical trial, the initial medication dose of this extension period is 0.2 mg/kg weight/week of PEG-rhGH for high dose group, low dose group and negative control group, and it is adjusted in accordance with yearly height velocity (HV) and IGF-1 SDS of each visit. The maximum dose shall not exceed 0.4 mg/kg weight/week.
1462376|NCT03255681|Procedure|PRP injections into nasojugal folds|"A topical anesthetic consisting of 4% Lidocaine (Topicaine) will be placed in the treatment zone prior to injections for no less than 20 minutes per manufactures recommendations.
11ml of whole blood will be drawn from the patient via venous aspiration into the Eclipse collection tube. The blood then is centrifuged into three basic components: red blood cells, PRP and platelet-poor plasma. The PRP component is collected via manufactures recommendation, drawn into sterile syringes, and prepared for injection into the patient. 0.1cc of 10% CaCl2 per 1ml of PRP will be added and mixed into the PRP solution for injections on one side of the face.
Injections will be completed using Softfil micro-cannulas inserted via a small puncture through the patients' skin to dissect into the subcutaneous plane"
1462378|NCT03255642|Drug|Melatonin 2mg|Two weeks of 2mg prolonged release melatonin (Circadin)
1462379|NCT03255642|Drug|ClonazePAM 0.5 MG|Two weeks of 0.5mg clonazepam (Rivotril)
1462380|NCT03255629|Drug|glucagon|novel, stable non-aqueous glucagon formulation provided by Xeris Pharmaceuticals
1462381|NCT03255629|Device|Closed loop glucagon pump|a novel closed-loop glucagon system (CLG) incorporating a novel, stable non-aqueous glucagon formulation together with an infusion pump system (Omnipod) guided by real-time continuous glucose monitoring (Dexcom) that is triggered by a hypoglycemia alert algorithm.
1462711|NCT03253094|Drug|SCY-078|drug
1462389|NCT03255590|Device|Real tDCS|Anodal Non-invasive brain stimulation to stimulate motor-associated areas in the brain
1462390|NCT03255590|Device|Sham tDCS|Sham Non-invasive brain stimulation to stimulate motor-associated areas in the brain
1462391|NCT03255590|Behavioral|Configuration task|Training the impaired hand on a configuration task
1462393|NCT03255564|Other|feacal calprotectin concentration|"Intervention - To monitor the impact of cardiac surgery and enteral feeding on gut inflammation, biomarkers (faecal Calprotectin) will be measured 24-48hrs after surgery and 24-48hrs after enteral feed commences. Additionally, infants that are diagnosed with NEC will have calprotectin levels measured.
Faecal calprotectin - 50-100mg of faeces will be collected in plastic containers from infant's nappies. Samples will then be homogenised by shaking, and supernatants and then sent to laboratories for immediate analysis."
1462394|NCT03255551|Drug|Amosartan|amosartan is a combination of amlodipine, which is a calcium channel blocker (CCB), and rozatan, an angiotensin II receptor antagonist (ARB), and is an antihypertensive agent
1462395|NCT03255538|Other|Deep friction massage|Deep friction massage as described by Dr. James Cyriax.
1462396|NCT03255538|Other|Deep friction massage_25|Deep friction massage as described by Dr. James Cyriax, applied with 25% of the mean pressure.
1462397|NCT03255538|Other|Deep friction massage_75|Deep friction massage as described by Dr. James Cyriax, applied with 75% of the mean pressure.
1462398|NCT03255525|Other|Deep friction massage P50|Deep friction massage as described by Dr. James Cyriax, applied with the mean pressure (P50)
1462399|NCT03255525|Other|Deep friction massage P25|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 25 of the mean pressure (P25)
1462400|NCT03255525|Other|Deep friction massage P75|Deep friction massage as described by Dr. James Cyriax, applied with the percentile 75 of the mean pressure (P75)
1462403|NCT03255499|Behavioral|Exercise|Exercise
1462404|NCT03255499|Behavioral|Cognitive|Cognitive
1462405|NCT03255499|Behavioral|Active control|Active control, including a blend of computer games, board games, quizzes, trivia
1462406|NCT03255486|Biological|Blood sample|"Blood samples will be taken by venipuncture during the initial assessment (4 tubes of 5 ml at diagnosis and 3 tubes of 5 ml to the following) These blood tests will be repeated after the first course, at the end of neoadjuvant chemotherapy and after surgery and will be carried out jointly to levies motivated by the balance sheet or the treatment of CS to avoid additional puncture.
These samples will allow us to study the profiles of circulating tumor DNA, and miRNA tumor proteins (proteomics study)."
1462407|NCT03255473|Drug|Dexamethasone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
1462408|NCT03255473|Drug|Prednisone|All subject ID numbers will be randomly assigned to the dexamethasone or the prednisone arm of the trial prior to the initiation of the study.
1462409|NCT03255447|Device|Immunoadsorption|Fresenius Globaffin
1462410|NCT03255434|Drug|Oxaliplatin|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (85 mg/m² ) + simplified LV5FU2 Length of a cycle : 2 days Interval between 2 cycles : 2 weeks (D1=D15) Expected number of cycles: 12
1462411|NCT03255434|Drug|Oxaliplatin LBM|Simplified FOLFOX 4 regimen: Association of Oxaliplatin (LBM) + simplified LV5FU2
1462412|NCT03255421|Other|Pressure measurement|Observational study No intervention, only fragmenting the emptying of the bladder
1462413|NCT03255408|Drug|Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Normoxia Exposure
1462414|NCT03255408|Drug|Drug Lowering CBF and Intermittent Hypoxia Sleep|The study participants will take Cerebral Blood Flow (CBF) lowering drug and sleep under Intermittent Hypoxia (IH) Exposure
1462415|NCT03255408|Drug|Placebo and Normoxia Sleep|The study participants will take Placebo and sleep under Normoxia Exposure
1462416|NCT03255408|Drug|Placebo and Intermittent Hypoxia Sleep|The study participants will take Placebo and sleep under Intermittent Hypoxia (IH) Exposure
1462417|NCT03255395|Device|Magnetic resonance-guided focused ultrasound|Ten amputees wil recieve a magnetic resonance-guided focused ultrasound treatment aimed at ablating neuromas, which are believe to contribute to their phantom / residual limb pain
1462418|NCT03255382|Drug|risankizumab|subcutaneous injection
1462419|NCT03255382|Drug|Fumaderm|tablet
1462420|NCT03255369|Other|Child exposed Zika virus proved|There will be applied Bayley Teste 3rd edition
1462421|NCT03255356|Other|Survey|An anonymised questionnaire will be answered for each includable consecutive patient after verifying the absence of exclusion criteria.
1462422|NCT03255343|Device|IMDENDRIM|In situ and intra tumoral injection of non removal nanodevice IMDENDRIM
1462423|NCT03255330|Drug|Gabapentin|Gabapentin will be given approximately 3 months until no chronic neuropathic pain is present
1462424|NCT03255330|Drug|Metamizol|Standardized treatment
1462425|NCT03255330|Drug|Tramadol|Standardized treatment
1462428|NCT03255304|Behavioral|health mindest|groups be confronted with health aspects of food items
1462429|NCT03255304|Behavioral|palatability mindset|groups be confronted with palatability aspects of food items
1462430|NCT03255291|Behavioral|Risk Display App|-The Risk Display App provides participants with personalized risk results
1462431|NCT03255291|Behavioral|Imagery Audio Recording - Sleep|-Imagine themselves improving sleep hygiene
1462432|NCT03255291|Other|Survey|-Assesses a number of measures including comprehension, intentions, worry, perceived severity of risks, race, education, numeracy, imagery vividness, imagery practice, self-efficacy, affect, action plans, feelings about disease risk, and exercise and sleep behaviors
1462433|NCT03255291|Behavioral|Imagery Audio Recording - Exercise|-Imagine themselves improving exercise
1462434|NCT03255291|Other|Text message reminders|-Reminders to practice mental imagery
1462435|NCT03255291|Other|Text Message Based Survey|-Assesses a number of measures including exercise, action plans, self-efficacy, affect, and behaviors
1462436|NCT03255278|Biological|Single GamTBvac vaccination (0.25 dose)|Single administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the safety.
1462437|NCT03255278|Biological|Placebo administration|Single administration of the placebo (0.5 ml) to a placebo safety study group (Arm 2).
1462438|NCT03255278|Biological|Double GamTBvac vaccination (0.25 dose)|Double sequential administration of the decreased dose of vaccine (0.25 of regular dose) to evaluate the immunogenicity.
1462439|NCT03255278|Biological|Double GamTBvac vaccination (0.5 dose)|Double sequential administration of the mean dose of vaccine (0.5 of regular dose) to evaluate the immunogenicity.
1462440|NCT03255278|Biological|Double GamTBvac vaccination (1.0 dose)|Double sequential administration of the regular dose of vaccine to evaluate the immunogenicity.
1462441|NCT03255265|Other|no interventions|no interventions
1462442|NCT03255252|Drug|Cisplatin injection|Weekly cisplatin (40 mg/m²) will be administered during radiotherapy. At least 3 cycles of cisplatin should be performed according to the hematological and renal functions but not mandatory.
1462443|NCT03255252|Combination Product|radiotherapy|A total dose of 45Gy in 25 fractions to the PTV is considered standard but simultaneous integrated boost or two steps boost to specific volumes (positive lymph nodes for example) are accepted and left to the investigator's discretion).
1462444|NCT03255239|Procedure|Ventral hernia repair|Hernia repair is a surgical procedure to return an organ that protrudes through a weak area of muscle to its original position.
1462445|NCT03255226|Drug|Tolvaptan|Tolvaptan 1% granules or tolvaptan 15 mg tablet with water once daily.
1462446|NCT03255213|Other|Lingual Muscle Training|Lingual Muscle Training using the SwallowStrong device
1462448|NCT03255187|Dietary Supplement|Fish oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in fish oil group are assigned to receive 2.5 g/day in divided doses. Each capsule contains 60% n-3 PUFA [24% docosahexanoic acid (C22:6 n-3 DHA) and 36% eicosapentaenoic acid (C20:5 n-3 EPA)].
1462449|NCT03255187|Dietary Supplement|Sunflower seed oil supplementation|Participants of this randomized double-blind placebo-controlled trial include 70 healthy Chinese adults. The investigators randomly assign participants to two parallel groups at baseline using a random-number table. Compliance is determined by directly observed supplement intake. Participants in sunflower seed oil group receive 2.5 g/day in divided doses, and the capsules are identical as the fish oil capsules.
1462451|NCT03255161|Behavioral|community health worker-audiologist communication education and support group|A 5-week educational program on hearing loss, communication strategies, and peer support facilitated by community health workers supervised by an audiologist.
1462452|NCT03255148|Drug|Oxytocin|Syntocinon nasal spray
1525983|NCT02771704|Other|Chlorhexidine|
1462454|NCT03255135|Device|HIFU|High intensity focused ultrasound prostate cancer therapy guided by biopsy specimens and multiparametric prostate magnetic resonance using Focal One, Edap TMS, France device.
1462455|NCT03255122|Behavioral|I-CALM|Families receiving I-CALM will immediately receive a videoconferencing-based, Internet-delivered format of an evidence-based CBT treatment for early child social anxiety disorder (Coaching Approach behavior and Leading by Modeling, or the CALM Program; Puliafico, Comer, & Albano, 2013) in which therapists and families meet in real-time via videoconferencing and parent-child interactions are broadcast from the family's home via a webcam while therapists provide bug-in-the-ear coaching from a remote site. Parents are taught and guided in how to coach their young anxious child to engage in brave, approach behavior.
1462456|NCT03255122|Behavioral|Delayed I-CALM|Families receiving Delayed I-CALM will participate in a waitlist period, and then will complete the I-CALM treatment program.
1462460|NCT03255083|Drug|DS-1205c|DS-1205c 200 mg capsule
1462461|NCT03255083|Drug|Osimertinib|Osimertinib 80 mg tablet
1462462|NCT03255070|Drug|ARX788|An antibody drug conjugate
1462465|NCT03255044|Drug|Atorvastatin|Atorvastatin administered as well as standard heart failure therapy
1462466|NCT03255044|Drug|Rosuvastatin|Rosuvastatin administered as well as standard heart failure therapy
1462467|NCT03255044|Other|guideline directed therapy|standard heart failure therapy
1948060|NCT02829099|Drug|JNJ-64457107|JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
1948061|NCT02829827|Drug|Radiprodil|"Pharmaceutical form: Granules and solvent for oral suspension
Route of administration: Oral use"
1948062|NCT02827877|Radiation|Copper Cu 64-DOTA-Trastuzumab|Given IV
1462471|NCT03255005|Device|Endomina|Endoscopic sleeve reduction
1462472|NCT03255005|Behavioral|Diet|Multidisciplinary follow-up
1462473|NCT03254992|Device|ASD - Abstract task|Experimental group using Kinect with more virtual activity.
1462474|NCT03254992|Device|ASD - Tangible task|Experimental group using Keyboard with more real activity.
1462475|NCT03254992|Device|TD - Abstract task|Control group using Kinect with more virtual activity.
1462476|NCT03254992|Device|TD - Tangible task|Control group using Keyboard with more real activity.
1462477|NCT03254979|Behavioral|Healthy lifestyle prescription|"3 actions for the prevention of DM2 in the clinical setting are recommended:
A screening strategy for people with impaired glucose regulation or high risk of developing DM2, with the following recommendations: screening for DM2 within the strategy of opportunistic screening for CV risk factors in population ≥45 years Or ≥30 years in the presence of a previous risk factor (eg, hypertension); Screening for DM2 based on the presence of a BMI ≥25 in the population aged 40-70 years; Or, risk screening for DM2-FINDRISC in a population of 45-70 years.
With those identified at high risk, perform a structured program of intensive intervention focused on the prescription of personalized plans on lifestyle modification (low calorie and low fat diet, and at least 150 minutes of physical exercise per week).
A follow-up intervention component to maintain the motivation of those interviewed, with more frequent contacts initially, with at least annual review visits."
1462478|NCT03254966|Drug|SHR0302|Oral tablets
1462479|NCT03254966|Drug|Placebo|Oral tablets
1948063|NCT02827877|Other|Laboratory Biomarker Analysis|Correlative studies
1948064|NCT02827877|Biological|Pertuzumab|Given IV
1948065|NCT02827877|Procedure|Positron Emission Tomography|Undergo PET
1948066|NCT02827877|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1462484|NCT03254927|Drug|CDX-3379 and cetuximab|Dose: 12 mg/kg CDX-3379 once every 3 weeks in combination with 400 mg/m2 cetuximab on the first day followed by weekly doses of 250 mg/m2 cetuximab.
1462485|NCT03254914|Procedure|Home Blood Pressure|Measure Home Blood Pressure
1462486|NCT03254901|Other|Screening test by Oraquick test|The OraQuick assay uses an indirect immunoassay method to detect hepatitis C antibodies in oral fluid or blood
1462747|NCT03252847|Genetic|AAV-RPGR|Open label, non-randomised, dose-escalation intervention
1948067|NCT02827877|Biological|Trastuzumab|Given IV
1948068|NCT02825823|Dietary Supplement|Ketone Salt|
1948069|NCT02825823|Dietary Supplement|Placebo|
1948070|NCT02819050|Device|NCPAP|Nasal Continuous Positive Airway Pressure
1948071|NCT02814669|Drug|Atezolizumab|Atezolizumab will be given at a dose of 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, or disease progression.
1948072|NCT02814669|Drug|Radium-223 Dichloride|Radium-223 dichloride will be administered at a dose of 55 kilobecquerels per kilogram (kBq/kg) via slow IV bolus on Day 1 of each 28-day cycle for up to 6 cycles.
1948075|NCT02807818|Behavioral|Home visiting Program for Young Pregnant Women|
1948076|NCT02804763|Drug|Placebo|Solution for infusion, 0,9% saline
1948077|NCT02804763|Drug|Dapirolizumab pegol (DZP)|Solution for infusion
1462487|NCT03254875|Behavioral|Individually tailored nurse navigation|The intervention consists of systematic report of symptoms to the nurse and up to six individual, manual-based, face-to-face or telephone nurse navigator sessions depending on individual needs.
1462488|NCT03254862|Procedure|CSS/AsynS|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Sequential Stimulation (ASynS) on the other leg
1462489|NCT03254862|Procedure|CSS/AsynR|16 sessions of training over a 4 week period consisting of repeated intermittent electrical stimulation (300ms On and 700ms Off stimulation) for 10 - 30 minutes. Conventional synchronous stimulation (CSS) on one leg; Asynchronous Random Stimulation (ASynR) on the other leg.
1462490|NCT03254849|Drug|Empagliflozin|1 tablet
1462491|NCT03254849|Drug|Hydrochlorothiazide 25 mg|1 tablet
1462492|NCT03254836|Other|Standard of care|Elective radical surgery for adenocarcinoma.
1462493|NCT03254810|Biological|SYN060|a single subcutaneous 0.57 mg/kg dose of SYN060
1462494|NCT03254810|Biological|Adalimumab North American source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from North American source
1462495|NCT03254810|Biological|Adalimumab European source|a single subcutaneous 0.57 mg/kg dose of adalimumab (Humira®) reference product from European source
1462496|NCT03254797|Other|Stepping training with feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells, look at the displayed section which will be positioned at their eye level. Then subjects will be instructed to shift/take their body-weight onto the trained leg until the green zone of the displayed section is lightened. When the subjects can take a proper level of their body-weight onto the trained leg, the beep sound will be alarmed to trigger the subjects and therapist that the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
1462497|NCT03254797|Other|Stepping training without feedback|Subjects stand in a step standing position with placing one leg on the load cells of the device and the other leg at the posterolateral direction to the trained leg outside the load cells. Then subjects will be instructed to shift/take their body-weight onto the trained leg as most as they can. If the subjects can take a proper level of their body-weight onto the trained leg, the subjects can step the other leg forward to the marker. Then they have to do the same when steps the leg backward.
1462500|NCT03254771|Other|Decision aid|Decision aids are tools that enables to promote and facilitate patients' involvement in medical decisions concerning their health
1462501|NCT03254758|Biological|Mesenchymal stem cell|Single dose of ADR-001, mesenchymal stem cells, is administered by intravenous 1 hour infusion.
1462503|NCT03254732|Drug|ADI PEG20|ADI is a recombinant protein cloned from M. hominis and produced in E. coli, and conjugated with PEG of 20,000 mw. Thus ADI-PEG 20 is an arginine degrading enzyme, ADI, coupled to PEG.
1462504|NCT03254732|Drug|Pembrolizumab|Pembrolizumab is a PD-1 blocking antibody indicated in the USA for the treatment.
1462505|NCT03254719|Other|Study assessments|All participants will be asked to complete study assessments at baseline visit, and weeks 3, 5, 7, and 10. Study participants will receive spinal manipulation and appropriate adjunctive therapies provided by doctors of chiropractic.
1462506|NCT03254706|Other|Peak etch-and-rinse (P1)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions.
1462507|NCT03254706|Other|Peak applied for double time(P2X)|Application Mode - Peak Adhesive system applied according to the manufacturer's instructions, but for the double time.
1462508|NCT03254706|Other|Single Link etch-and-rinse (SL1)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions.
1462509|NCT03254706|Other|Single Link double time (SL2X)|Application Mode - Single Link Adhesive system applied according to the manufacturer's instructions, but for the double time.
1462510|NCT03254693|Combination Product|1-step self-etch approach (SE)|Application mode - Do not use etchan. According to the manufacturer's instructions.
1462511|NCT03254693|Combination Product|selective enamel etching (SEE)|Application mode - Etch only on enamel for 15 s. Rinse for 15s. Air dry to remove excess water.According to the manufacturer's instructions.
1462512|NCT03254693|Other|1-step self-etch for double time (SE2X)|Application mode - Do not use etchan. According to the manufacturer's instructions, but for the double time (20 s) in the each application.
1462513|NCT03254693|Other|1-step self-etch additional layer (SE1+)|Application mode - Do not use etchan. According to the manufacturer's instructions, but apply tree times.
1462514|NCT03254680|Dietary Supplement|Turmeric|Twenty patients will be enrolled and treated with a stable dose of orally administered turmeric oil daily for 3 months.
1462515|NCT03254667|Biological|Brodalumab|Brodalumab
1462516|NCT03254667|Drug|Comparator Drug (non-biologic IL-17 inhibitors)|Comparator subjects treated with non-biologic IL-17 inhibitors
1462517|NCT03254654|Drug|Vinorelbine|Experimental: 20 mg/m2, D6, D13, D20 Active Comparator: 25 mg/m2, D1, D8, D15
1462518|NCT03254654|Drug|Apatinib|250 mg/d, D1-5, D8-12, D15-19. The starting dose will be 250mg/d in the first cycle, if tolerable, 500 mg/d will be administered from the cycle 2.
1462519|NCT03254641|Drug|human chorionic gonadotropin|5000 IE times one
1462520|NCT03254628|Other|Helping Mothers Survive - Bleeding After Birth training|One-day training in postpartum hemorrhage prevention and treatment; this includes instruction to provide oxytocin within one minute of birth to prevent postpartum hemorrhage.
1462521|NCT03254628|Other|Helping Babies Breathe|One-day training in neonatal asphyxia management; this includes routine care for the newborn, such as drying and stimulation immediately after birth, and resuscitation of asphyxiated newborns using a bag & mask device.
1463493|NCT03247114|Other|Sucrose|Sucrose, 50 grams in 300 ml water at room temperature
1462522|NCT03254628|Behavioral|Mentor|A birth attendant in the facility is designated as a clinical mentor and encouraged to lead simulator-based practice sessions in the facility after training day.
1462523|NCT03254628|Behavioral|Phone|District trainers telephone clinical mentors and encourage them to lead practice sessions.
1462524|NCT03254628|Drug|oxytocin and misoprostol|This study did not provide uterotonic drugs except in the case of stock out where locally purchased oxytocin and misoprostol were provided only as back up.
1462525|NCT03254628|Device|Newborn bag and mask|All facilities were supplied with at least 1 bag and mask for newborn resuscitation. This bag and mask was used for training, practice, and clinical care
1462526|NCT03254615|Behavioral|"I Prefer Plain Water"|The students will receive four educational sessions of approximately 1 hour. These sessions will be given every 2 weeks, and some will be supervised by a nutritionist.
1948082|NCT02802514|Drug|Albiglutide 50mg|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. A 50 mg pen contains 67 mg lyophilized albiglutide and 0.65 mL diluents. It will be injected subcutaneously (SC) in the upper arm.
1462528|NCT03254589|Drug|Methotrexate|See arm descriptions
1462529|NCT03254589|Drug|Sulfasalazine|See arm description
1462530|NCT03254589|Drug|Other DMARDs|See arm
1462531|NCT03254576|Other|Functional MRI|
1462532|NCT03254563|Behavioral|Recommended Daily Water Intake|Patient will increase from average 1-1.5L water intake a day to 2.5-3L water intake.
1462533|NCT03254550|Other|PrEP Promotion Package|A PrEP promotion package will be developed to test if this will change uptake, acceptance, retention and PrEP knowledge
1462534|NCT03254537|Dietary Supplement|Mediterranean Organic|Traditional Mediterranean diet comprised of organic ingredients
1462535|NCT03254537|Dietary Supplement|Mediterranean conventional|Traditional Mediterranean diet comprised of conventional ingredients
1462536|NCT03254524|Other|Statewide Planning and Research Cooperative System Database|The Statewide Planning and Research Cooperative System (SPARCS) is a comprehensive data reporting system created to collect information on discharges from hospitals. SPARCS currently collects patient level detail on patient characteristics, diagnoses and treatments, services, and charges for every hospital discharge, ambulatory surgery patient, and emergency department admission in New York State.
1462537|NCT03254511|Drug|Enoxaparin Sodium 40 MG/0.2 ML Subcutaneous Injectable|Patients are going to receive subcutaneouse Enoxaparin (40 mg daily).
1462538|NCT03254511|Radiation|Radiotherapy|Patients will be treated with 3D conformal radiotherapy. The median treatment dose will be 50.40 Gy in 25 to 32 fractions.
1462539|NCT03254511|Drug|Chemotherapeutic Combinations|Patients are going to receive weekly chemotherapy (paclitaxel [50 mg/m2] plus carboplatin [area under the carve=2]).
1462540|NCT03254498|Device|Endocuff|It is a randomised back to back study to compare cap and Endocuff to detect adenoma in colonoscopic examination
1462541|NCT03254498|Device|cap assisted colonoscopy (CAC)|cap assisted colonoscopy (CAC)
1462542|NCT03254485|Drug|IW-1973|Oral Tablet
1462543|NCT03254485|Drug|Placebo Oral Tablet|Oral Tablet
1462544|NCT03254472|Diagnostic Test|Measured concentrations of biomarkers|
1462545|NCT03254459|Drug|Buprenorphine Sublingual Spray|Buprenorphine Sublingual Spray 0.5 mg
1462546|NCT03254459|Drug|Morphine|Morphine
1462547|NCT03254459|Drug|Oxycodone Hydrochloride|Oxycodone Hydrochloride 10 mg tablet
1462548|NCT03254446|Drug|TRC150094|TRC150094 Tablet 45 mg
1462549|NCT03254446|Drug|Placebo|Matching Placebo Tablet
1948083|NCT02802514|Drug|Albiglutide matching placebo|It is provided as a single use fixed dose disposable pen injector (0.5 mL) system for SC delivery. It will be injected subcutaneously (SC) in the upper arm
1948084|NCT02802514|Drug|Exenatide 10microgram|It is provided as a sterile solution containing 250 microgram/mL exenatide. One dose of 10 microgram is equivalent to 0.04 ml. It will be injected subcutaneously (SC) in the upper arm
1462552|NCT03254420|Device|Calypso beacon implant|Calypso beacon implant before radiotherapy
1462553|NCT03254420|Radiation|Radiotherapy IMRT|Radiotherapy IMRT
1462554|NCT03254407|Other|Screening medical record|Communicating possible IV/PO switch to prescriber by phone or e-note in medical record
1462555|NCT03254394|Drug|Lidocaine Hydrochloride|"Intravenous lidocaine will be dosed as a brief 1 mg/kg infusion (based on Ideal Body Weight (IBW)) over 10 minutes, followed by a 0.04 mg/kg/min infusion over additional 120 minutes, resulting in a total dose of 5.8 mg/kg IBW.
If this dose is tolerable in four consecutive sessions of mFOLFOX6 in six or more of the eight patients in the tolerability phase, we will initiate the randomized efficacy pilot study."
1462556|NCT03254394|Drug|Placebo|Dextrose 5% in water will be administered as active comparator.
1462557|NCT03254394|Drug|FOLFOX regimen|"Each cycle (repeated every 14 days):
Oxaliplatin 85mg/m2 IV over 2h, Leucovorin 400 mg/m2 IV over 2h, 5-FU 400mg/m2 IV bolus, followed by a 1200mg/m2/day continuous infusion for 2 days."
1462558|NCT03254381|Behavioral|Aerobic Training|Six months of thrice-weekly aerobic training. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
1462559|NCT03254381|Behavioral|Resistance Training|Six months of thrice-weekly resistance training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down). Classes will be group classes, with up to five participants in each.
1462560|NCT03254381|Behavioral|Balance and Tone Training|Six months of thrice-weekly stretching and relaxation exercises. Each session will be 60 minutes. Classes will be group classes, with up to five participants in each.
1462561|NCT03254368|Drug|ZGN-1061|ZGN-1061 is a methionine aminopeptidase 2 inhibitor
1462562|NCT03254368|Drug|Placebo|Placebo has the same excipients and appearance as ZGN-1061
1462563|NCT03254355|Procedure|Multimodal physiotherapy|12 weeks of weekly physiotherapy treatments including education segment, electrical stimulation and PFM exercises consisting of strength, endurance and coordination exercises accompanied by biofeedback
1462564|NCT03254303|Other|Difficulty of catheterization in group 60 s|
1462565|NCT03254303|Other|Difficulty of catheterization in group 90 s|
1462566|NCT03254303|Other|Difficulty of catheterization in group 120 s|
1462567|NCT03254290|Biological|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted.
1462568|NCT03254290|Biological|Formocresol|Control group
1462569|NCT03254277|Drug|3BNC117-LS|Intravenous infusion of 3BNC117-LS
1462570|NCT03254264|Behavioral|Early Start Denver Model|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).
Children receive ESDM at minimum 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
1462571|NCT03254264|Behavioral|'as-usual' intervention|a control group receiving typical heterogeneous 'as-usual' intervention proposed by professionals and public services over the same period.
1462572|NCT03254251|Behavioral|Stair climbing|Stair climbing (SC) training was 12 weeks of progressive SC program. Each training session consisted of a general warm-up (5 min: slow and fast skipping, stretching) followed by the SC training and was supervised by experienced personnel. The program began with two bouts of stair climbing four days a week in weeks 1 and 2, increasing by one climb a day every three weeks. By the last three weeks (10-12) of the study, all subjects were completing 5 climbs four days a week. During each climb participants ascended 12 flights (192 steps) divided into 3 sets of 4 flights, with a 2 min rest period between each set. There was a 5 min rest period between climbs that allowed the participants to reach the ground floor using an elevator. Subjects in the non-exercising control group did not participate in a supervised exercise program for the duration of the study.
1462573|NCT03254238|Other|Monitoring prEscriptiondruG Abuse using DOctor Shopping bEhavior|development and identification of systems and tools able to detect earlier misuse phenomenon
1462574|NCT03254225|Behavioral|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
1462575|NCT03254212|Device|Titration of nocturnal oxygen needs to prevent desaturations|Oximetry recordings will be performed using a Pulse Oximeter. Two O2 titration sessions will be conducted at home in random order one week apart. One will consist of a stepwise night-to-night increase in O2 flow for up to 4 nights with supplemental O2, each at flow rates of 1L/min, 2L/min, 3L/min and 4L/min, respectively. During the other titration session, an automatic O2 delivery system will be used for 4 consecutive nights with O2 flow allowed to vary from 0 to 4 L/min with a 95 ± 2% SpO2 target. At the end of the titration periods, oxygen concentrators will be set at the lowest flow rate (1L/min to 4L/min) that maintained oxyhemoglobin saturation to > 90% (Tsat90%) for ≥ 98% of the estimated sleep period and reduced the oxygen desaturation index 3% (ODI3) to < 5/hour according to conventional O2 titration. If these targets are not reached, the lowest flow rate will be selected that minimizes the ODI3. These procedures will be repeated at week 5 and 11.
1948085|NCT02802514|Drug|Exenatide placebo (saline)|It is provided as a sterile saline. It will be injected subcutaneously (SC) in the upper arm
1462578|NCT03254186|Drug|Propranolol Hydrochloride|Propranolol is started 10 mg tablet twice per day per oral, two week up-titration to reach a total dose of 20mg per oral four times per day over the first two weeks, then will remain on a stable dose for six weeks.
1462579|NCT03254186|Drug|Placebo Oral Tablet|Identical placebo is started one tablet twice per day per oral, increase over the first two weeks to reach one tablet four times per day, then will remain on this dose for six weeks.
1462580|NCT03254173|Drug|Mirtazapine 30 mg oral tablets|Mirtazapine 30 mg oral tablets ( Remeron 30 mg oral tablets) , half tablet before sleep for 8 weeks
1462581|NCT03254173|Drug|Placebo oral tablets|Placebo oral tablets , half tablet daily before sleep for 8 weeks
1462582|NCT03254160|Drug|DNS-3379|DNS-3379
1462583|NCT03254160|Drug|Placebo|Placebo
1462584|NCT03254147|Drug|warfarin|warfarin
1462585|NCT03254147|Drug|dabigatran|Non-vitamin K dependent oral anti-coagulatns (NOACs)
1462586|NCT03254147|Drug|Apixaban|Non-vitamin K dependent oral anti-coagulatns (NOACs)
1462587|NCT03254147|Drug|Edoxaban|Non-vitamin K dependent oral anti-coagulatns (NOACs)
1462588|NCT03254147|Drug|Rivaroxaban|Non-vitamin K dependent oral anti-coagulatns (NOACs)
1462591|NCT03254108|Drug|OPC-61815 injection 2mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 2 mg.
1462592|NCT03254108|Drug|OPC-61815 injection 4mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 4 mg.
1462593|NCT03254108|Drug|OPC-61815 injection 8mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 8 mg.
1462594|NCT03254108|Drug|OPC-61815 injection 16mg|Once daily for 5 days placebo tablet will be orally administered, followed immediately by intravenous administration of OPC-61815 at 16 mg.
1462595|NCT03254108|Drug|Tolvaptan tablet 15mg|Once daily for 5 days tolvaptan 15-mg tablet will be orally administered, followed immediately by 1-hour intravenous administration of placebo.
1462596|NCT03254082|Other|Glycemic response of F-1000|The intervention was to determine if different flours elicit similar or different (change from baseline) 2 hour glucose responses (e.g., similar to glycemic index) after eating.
1462597|NCT03254082|Other|Glycemic response to sumac sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sumac sorghum flour as a gruel.
1462598|NCT03254082|Other|Glycemic response to MMR sorghum flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming MMR sorghum flour as a gruel.
1462599|NCT03254082|Other|Glycemic response to wheat flour|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming wheat flour as a gruel.
1462600|NCT03254082|Other|Glycemic response to sucrose|The intervention was to determine the two hour change from baseline glucose responses (e.g., similar to glycemic index) after consuming sugar (dissolved in water)
1462601|NCT03254069|Device|Stainless Steel Crowns|SSCs were placed on children's primary molars, and bite force was registered prior to the study, and periodically after the study.
1465325|NCT03233191|Procedure|Digital Mammography|Undergo DM
1948086|NCT02799485|Other|Laboratory Biomarker Analysis|Correlative studies
1948087|NCT02799485|Other|Pharmacological Study|Correlative studies
1462604|NCT03254043|Behavioral|Take-home Dosing Procedures|Within-subject evaluation across 2 phases with a final choice condition
1462605|NCT03254030|Other|Colonic inspection|Participants who are randomised to undergo the intervention will have the colonic mucosa examined during inspection and withdrawal phase of examination
1462606|NCT03254017|Procedure|Bilateral surgical implantation of DBS system to Habeluna|The SceneRay DBS device utilized in the present study is a double-channel device designed and manufactured by Suzhou Scene-Ray Medical Co., Ltd. The DBS system includes a dual-channel neurostimulator kit, lead kit, extension kit, clinician-operated wireless programmer, test stimulator, and patient controller. The lead (diameter =1.27 mm) contains four stimulating contacts made of platinumiridium alloy. The length of each contact is 1.5 mm, and interval spaces are 0.5 mm. This device shares the same basic principles utilized by Medtronic products, with unique wireless programming and electrode fixing designs. The amplitude (0-10 V), pulse width (60-960 ms), and frequency (1-1,600 Hz) can be programmed, and different frequencies may be utilized in the left and right hemispheres using this type of dual-channel IPG.
1462607|NCT03254017|Other|Follow-up Period|The researchers will remotely program the DBS biweekly after opening the stimulator and face to face test the patients' cognitive function every half year. Montgomery-Asberg Depression Rating Scale will be tested biweekly until the Programmed parameter has stable therapeutic efficacy and then tested after 3 months, 6 months, 9 months and 12 months.The other neuropsychological scales will be test on 3 months, 6 months, 9 months and 12 months.
1462608|NCT03254004|Drug|Pembrolizumab|pembrolizumab 200 mg every 3 weeks till 1 year or disease recurrence or intolerable toxicity.
1462610|NCT03253978|Radiation|Stereotatic Radiotherapy|SABR to prostate / seminal nodes
1462611|NCT03253965|Other|Metronome Normal|Steps are timed with the beat of the metronome set to the subject's cadence
1462612|NCT03253965|Other|Metronome Slow|Steps are timed with the beat of the metronome set to 85% of the subject's cadence
1462613|NCT03253965|Other|Metronome Fast|Steps are timed with the beat of the metronome set to 115% of the subject's cadence
1462614|NCT03253965|Other|Music Normal|Steps are timed with the beat of the music by a rhythm consistent with the subject's cadence
1462615|NCT03253965|Other|Music Slow|Steps are timed with the beat of the music by a rhythm consistent with 85% of the subject's cadence
1462616|NCT03253965|Other|Music Fast|Steps are timed with the beat of the music by a rhythm consistent with 115% of the subject's cadence
1462617|NCT03253965|Other|No Auditory cueing|Steps are not timed with any auditory cue.
1462618|NCT03253939|Procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure|Cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy procedure
1462619|NCT03253939|Procedure|Cytoreductive surgery alone|Exclusively Cytoreductive surgery approach
1462625|NCT03253900|Device|Stable rowing simulator|a standard stable/fixed rowing simulator
1462626|NCT03253900|Device|Slides based rowing simulator|a slides based rowing simulator, i.e. horizontal plane unstable
1462627|NCT03253900|Device|Tilt board based rowing simulator|a tilt board based rowing simulator; i.e. frontal plane unstable
1462628|NCT03253887|Drug|Ethanol-lock|This group received daily alcohol 70% (ethanol-lock) with intraluminal alcoholization of both lumens of the central venous catheters within the first 24 hours of catheter implantation and continued until the catheter was withdrawn. Each lumen received ethanol-lock for two hours and during this period venous infusion of any venous fluids / medications was discontinued only in the lumen with alcohol. At the end, the ethanol was aspirated and the lumen released for use. Before and after each alcoholization a flush with 5-10 ml of 0.9% saline solution was performed. The CVC manipulations were performed according to the protocol in force in the service and recommended by the Centers for Disease Control and Prevention (CDC).
1462629|NCT03253874|Behavioral|No Pre-Op Testing for Cataract Surgeries|Supported by the American Board of Internal Medicine's Choosing Wisely™ campaign to reduce low value care , the interventions aims to reduce pre-operative visits and testing for patients undergoing cataract surgeries.
1462630|NCT03253861|Other|No intervention|No intervention
1462631|NCT03253848|Other|Best Practice|Discussion between doctors and APL expert
1462632|NCT03253848|Other|Laboratory Biomarker Analysis|Correlative studies
1462633|NCT03253848|Procedure|Supportive Care|Receive simplified guidelines and support
1462634|NCT03253835|Diagnostic Test|Single Group Assignment|
1462635|NCT03253822|Other|Decision aid|The DA is an online tool. The web-based design opens up possibilities to feature more advanced functions, e.g. questions for the participant during the process, and a summary of answers at the end. The DA is tailored to lower educational attainment citizens, and is designed to embrace different information needs in the target population, ranging from a desire to receive a clear recommendation and a minimum of information to the desire to receive full information and make a personalized choice.
1462636|NCT03253809|Device|Biotronik Vision Guidewire|The apical, mid ventricular and basal sites within the anterior,posterior and lateral coronary sinus branch veins will be paced.
1462884|NCT03251729|Procedure|Cervical cerclage|Transvaginal cervical cerclage placed between 18 0/7 - 23 6/7 weeks
1526794|NCT02765880|Other|EEG|
1948088|NCT02799485|Behavioral|Quality-of-Life Assessment|Ancillary studies
1948089|NCT02799485|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
1948090|NCT02795780|Drug|18F-AV-1451|
1462642|NCT03253783|Behavioral|Pulse|
1462643|NCT03253770|Device|SIMMAX2|Digital cognitive aid or paper cognitive aid during the management of a cardiac arrest in the recovery room or in the delivery room.
1462644|NCT03253757|Other|This study is non-interventional.|This study is non-interventional.
1948091|NCT02794155|Drug|HDV Insulin Lispro|HDV Insulin Lispro: ~1% of the Insulin Lispro is bound to HDV (Hepatocyte Directed Vesicle)
1948092|NCT02794155|Drug|Insulin LISPRO|Insulin Lispro: no bound insulin
1462648|NCT03253679|Other|Laboratory Biomarker Analysis|Correlative studies
1462649|NCT03253679|Drug|WEE1 Inhibitor AZD1775|Given PO
1462650|NCT03253666|Other|Nutrient Intake|Dietary nutrient intake (such as folate) and supplemental nutrient intake (such as folic acid)
1462652|NCT03253640|Other|Exposure|Healthcare associated infection (HAI)
1462653|NCT03253627|Behavioral|Health Enhancement Program|The HEP control, which was developed to serve as an active control to MBSR, will receive manualized health education from experts in physical activity, functional movement, music therapy, and nutrition—without mindfulness instruction—using similar modalities to MBSR training for a matched schedule.
1462654|NCT03253627|Behavioral|Mindfulness-Based Stress Reduction|The MBSR group will receive training from a certified instructor during a group-based, 2.5-hour manualized educational activity weekly for eight weeks. Activities include body scans, gentle stretching, yoga, and mindful awareness. Participants will be asked to complete daily 45-minute, audio-guided mindfulness activities and a one-day weekend retreat to reinforce learning.
1462655|NCT03253614|Diagnostic Test|Audiometry|Extended high-frequency (EHF; 9-16 kHz) audiometry
1462656|NCT03253614|Diagnostic Test|Urine biomarkers for renal tubular function|Kidney Injury Molecule-1
1462657|NCT03253614|Diagnostic Test|Blood pressure|Blood pressure right arm, measured With standard Methods 3 times
1462658|NCT03253601|Behavioral|Strategy Training|Strategy training is a form of meta-cognitive instruction that trains individuals with stroke-related cognitive impairments to identify and prioritize problematic daily activities, identify the barriers impeding performance, generate and evaluate their own strategies to address barriers, and apply these skills through iterative practice.
1462659|NCT03253588|Procedure|laparoscopic salpingotomy or salpingostomy|A 3-port technique (2 x 5-mm and 1 x 10-mm trocars) was implemented. A diluted solution of vasopressin (20IU in 100 mL saline solution) was initially injected into the mesosalpinx of the affected tube, followed by a linear incision which allowed the removal of the gestational tissue. In case of a ruptured tubal pregnancy, the ectopic mass was evacuated directly from the ruptured site using a combination of forceps and suction device. The tubal lumen was either closed with a single-layer of continuous absorbable suture (salpingotomy) or left to heal by secondary intention (salpingostomy).
1462660|NCT03253575|Diagnostic Test|CANscript|CANscript is a predictive test that supports informed selection of cancer therapeutics for each individual patient. CANscript has the potential to predict the response of the patient under evaluation to either single-agent cancer therapeutics or combination therapeutic regimens. This is accomplished by using fresh tumor tissue from the patient in plates coated with a specific set of tumor matrix proteins (TMP). Further, patient derived autologous ligands are added to the culture. Angiogenic factors are added to maintain tumor vasculature along with autologous immune cells. In essence, CANscript recapitulates the tumor microenvironment.
1462661|NCT03253562|Drug|Metformin Pill|a biguanide used as an insulin sensitizer for patients suffering from type 2 diabetes mellitus
1462662|NCT03253562|Drug|Vildagliptin 50 mg|Dpp4i antihyperglycemic drug used for treatment of type 2 diabetes mellitus
1462663|NCT03253549|Device|SMArTVIEW|Remote automated, continuous monitoring in hospital after cardiac or vascular surgery, followed by 30-day at home monitoring, daily nurse video visits and a self-management training program.
1462664|NCT03253536|Other|observational|none (observational study)
1462665|NCT03253523|Procedure|Occipital neurolysis|Surgical occipital nerve decompression
1462666|NCT03253510|Other|Poly-amide|New denture base material that exhibit high flexibility, physical strength, heat and chemical resistance and the exceedingly rare allergy response
1462667|NCT03253510|Other|Poly-methyl methacrylate|Gold standard denture base material
1462669|NCT03253484|Radiation|NAFL-treatment|non ablative fractional laser 15 40 nm promoting wound healing and reduction of scar formation
1462672|NCT03253458|Device|Confocal Laser Endomicroscopy|Transperineal confocal laser endomicroscopy or optical coherence tomography measurements. Probe will be placed guided by ultrasound, simular procedure as transperineal template guided mapping biopsies.
1948095|NCT02790034|Drug|Sarizotan|2 to 10 mg per day of Sarizotan followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
1462673|NCT03253445|Behavioral|Acceptance and commitment therapy|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face ACT individually will additionally be provided by trained therapists on a weekly basis. Each session will last about 20-30 minutes. The therapy is guided by ACT smoking cessation protocols based on relevant literature (Gifford et al 2004, 2011; Bricker, 2010).
1462674|NCT03253445|Other|Control|All participants are given a brief educational talk on encouraging quitting smoking (about 5 mins) and a self-help leaflet on smoking cessation. Ten sessions of face-to-face Social Support will additionally be provided on a weekly basis. Each session will last about 5 minutes.
1462675|NCT03253432|Other|Genetic testing|Targeted next-generation sequencing for familial hypercholesterolemia causative mutations
1462676|NCT03253419|Other|Home for Life mobile application|Utilize home application to provide the participant with an understanding and recommendations to potentially decrease home hazards that may lead to risk of falls in their home.
1462677|NCT03253406|Behavioral|Polar M400 + Facebook Group (PM400+FG)|Throughout the intervention period experimental group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page. Additionally, experimental group participants will be asked to track all physical activity with the Polar M400 smartwatch and use this information to set physical activity-related goals conducive to improved health.
1462678|NCT03253406|Behavioral|Facebook Only Group (FG)|Throughout the intervention period comparison group participants will be asked to read and try to implement the twice-weekly physical activity- and nutrition-related health tips posted to the group's Facebook page.
1462679|NCT03253393|Device|Smart Touch Technology|hioxifilcon A contact lens in Smart Touch Technology Flat Pack (hydrogel) asmofilcon A contact lens in Smart Touch Technology Flat Pack (silicone hydrogel)
1462680|NCT03253393|Device|Conventional lens packaging|hioxifilcon A contact lens in conventional lens packaging (hydrogel) asmofilcon A contact lens in conventional lens packaging (silicone hydrogel)
1462681|NCT03253380|Other|Early Rehabilitation Program In Critically Ill Chronic Obstructed Airway Disease patients|Early rehabilitation of MV patients in the respiratory ICU
1462682|NCT03253367|Other|Blood is obtained, mostly during routine venipuncture|
1462683|NCT03253354|Device|repetitive magnetic stimulation|Neurostimulation
1462684|NCT03253341|Behavioral|Smart Aging Program|Comprehensive lifestyle and fitness program designed to improve the health of older adults. The Smart Aging Program represents a package consisting of a dedicated health coach, mobile monitoring, specialized curriculum, and exercise opportunities.
1462685|NCT03253341|Behavioral|Educational Materials|Current standard of care. Includes education materials covering benefits of a healthy lifestyle.
1462686|NCT03253328|Drug|Active Arm N-acetyl cysteine (NAC)|N-acetyl cysteine (NAC) 1200mg twice a day for 6 days post-amputation
1462687|NCT03253328|Drug|Placebo Arm|Placebo 1/2 normal saline infusion twice a day for 6 days post-amputation
1462688|NCT03253289|Drug|Meclizine Oral Tablet|All subjects will receive 50 mg of meclizine taken orally, twice a day (daily dose 100 mg) for 21 days.
1462689|NCT03253276|Drug|Obeticholic acid|Placebo-controlled
1462690|NCT03253276|Drug|Placebos|
1462691|NCT03253263|Drug|SHP607|Intravenous infusion of SHP607 at doses of 250 mcg/kg/24 hours and 400 mcg/kg/24 hours from birth up to PMA 29 weeks + 6 days.
1462692|NCT03253250|Drug|ETV；TDF；ADV|NAs
1462693|NCT03253250|Drug|Peginterferon Alfa-2a|peginterferon
1462694|NCT03253237|Device|continuous glucose monitoring (CGM)|A CGM device is to be set and take of by the GP. Before the study start all GPs will have a short education on CGM device by the diabetologist who use CGM on a daily base. Study period is seven days and includes screening before study entry and two visits. On Day 1, after screening and signing the informed consent, the CGM device is applied. Patient is instructed to keep a 7 day diary with four daily standard home blood glucose monitoring (SHBGM) along with the data on eating, physical exercise, drugs. Bayer's Contour® glucometer is used for the SHBGM. On Day 7, CGM device is took of and the data from iPro2 is uploaded to PC. At the end, each patient fill a short query on satisfaction while wearing CGM.
1462695|NCT03253224|Drug|Magnesium Sulfate|Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of normal saline over 15 min during induction of anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/h) until the end of surgery.
1462696|NCT03253224|Drug|Normal saline|Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
1462697|NCT03253198|Drug|Saline|A preoperative interscalene brachial plexus single-shot block using 25 ml of 0.5% Ropivicaine plus saline injection postoperative
1462698|NCT03253198|Drug|Bupivacaine liposome|an interscalene brachial plexus single shot block preoperatively (25 ml of 0.5% ropivicaine) + Postoperative Infiltration of local anesthetic/analgesic (20 cc Bupivacaine extended-release liposome injection (Exparel) + Diluted in 20cc of Saline into the capsule, subscapularis, deltoid, pectoralis major and subcutaneous tissues)
1462699|NCT03253185|Drug|SC-007|intravenous
1462700|NCT03253172|Dietary Supplement|Potassium Chloride|Two potassium supplements with varying anions.
1462701|NCT03253172|Dietary Supplement|Potassium Citrate|Potassium Citrate
1462702|NCT03253172|Dietary Supplement|Placebo|Placebo
1462703|NCT03253159|Behavioral|Hypnosis|The conversational hypnosis (10-15 min) is standardized and performed just before intravenous general anesthesia induction in the operative room.
1462704|NCT03253146|Diagnostic Test|VIM detection|VIM expression in serum and lymphocytes detection
1462705|NCT03253133|Drug|Oxaliplatin|"Dose levels of Oxaliplatin:
4 dose levels of Oxaliplatin (85, 100, 130 and 160 mg/m²) are planned. 1 dose level is planned (-1 : 70 mg/m²) if DLT is reached at level 1
Table 1: Dose levels
Dose Level Dose (mg/m²) Number of patients DL -1 70 mg 3-6 DL 1 * 85 mg 3-6 DL 2 100 mg 3-6 DL 3 130 mg 3-6 DL 4 160 mg 3-6
* Start level"
1462706|NCT03253133|Drug|LV5FU or Folfiri|Association of chemotherapy by LV5FU or Folfiri according pratician choice
1462707|NCT03253133|Drug|Oxycodone|Oxycodone
1462708|NCT03253120|Other|Water|Patient/ Healthy volunteer will drink 5dl of Water
1462709|NCT03253107|Drug|Chemotherapy|"Institutinal standard chemotherapy as first line
: XP (xeloda + cisplantin) or Xelox (xeloda+oxaliplitan) +/- Herceptin"
1462710|NCT03253094|Drug|Fluconazole|drug
1462712|NCT03253081|Behavioral|PARENT focused intervention|The group will comprise 3 to 4 parents and will focus on psychoeducation and support/well-being for the parent. Sessions will include a 20-minute welcome and supportive discussion where parents can provide updates on their week and seek advice and support from the group, followed by a 45-minute interactive education session focused on the principles of JASPER, and close with a 20-minute Mindfulness session. The Mindfulness session will be led by a certified expert.
1462713|NCT03253081|Behavioral|CHILD focused intervention|The session will be divided into 30-minute segments and include two 30-minute individualized 1-on-1 sessions with a trained interventionist. One of these two sessions will involve the parent in hands-on training while the other will be interventionist-led while the parent observes. The remaining 30-minutes will include a snack for the child and time for the parent to discuss and ask questions of the interventionist regarding the session content.
1462714|NCT03253068|Drug|Pembrolizumab plus amurubicin|Pembrolizumab 200mg/body plus amurubicin 40mg/m2, intravenous, every 3 weeks
1462715|NCT03253055|Radiation|DEXA|Dual energy X-ray absorptiometry (DEXA): a total of two scans will be performed, one for the assessment of whole body bone mineral density and body composition, and the other scan is performed to specifically assess fracture risk by scanning the hip and femoral head. Effective exposure doses for these scans are ~8uSv and ~4uSv respectively.
1462716|NCT03253055|Radiation|pQCT|A total of one scan will be performed on the non-dominant Tibia, the effective exposure dose will be between 1.5-1.8uSV.
1462717|NCT03253055|Other|Lifestyle Questionnaire|Participants are required to record their lifestyle, diet (5-day self reported), physical activity (IPAQ questionnaire), injury and illness incidence.
1462718|NCT03253055|Other|Aerobic Fitness|Aerobic fitness will be tested using a VO2 max exercise protocol using a stationary cycle ergometer, the participants will be expected to perform this to maximal effort or exhaustion.
1462719|NCT03253055|Other|Muscular Strength|Muscular strength of the knee extensor and handgrip muscles will be determined using an Isokinetic Dynamometer and a handgrip dynamometer respectively.
1462720|NCT03253055|Biological|Blood draw and finger prick test|15ml of whole blood will be collected for the measurement of fasting serum 25(OH)D levels, parathyroid hormone, C-terminal telopeptide (CTX) and full blood count
1462721|NCT03253055|Other|Muscular Power|Muscular power will be determined using an optical measurement system consisting of a transmitting and receiving bar to determine jump height through the interpretation of jump flight of the participant (reported in cm). The equipment used is an Optojump.
1462724|NCT03253029|Dietary Supplement|Pure Encapsulations Branched Chain Amino Acid powder|
1462725|NCT03253029|Dietary Supplement|control group (no BCAAs provided)|
1462726|NCT03253016|Diagnostic Test|vaginal swab -microbiome test and blood test for cytokines|vaginal microbiome test and blood test for cytokines repeated during pregnancy in the 3 arms
1462727|NCT03253003|Device|Line extension of the Phonak Audéo B product family|The line extension of Phonak Audéo B product family will be fitted to the participants individual hearing loss.
1462728|NCT03252990|Diagnostic Test|PET-MRI|Additional 18F-choline PET-MRI examination
1462729|NCT03252990|Procedure|Optical Coherence Tomography|Additional optical coherence tomography (OCT) examination (during the already planned routine PCI procedure)
1462730|NCT03252977|Other|Tailored regimen of IV PCA according to pain sensitivity|In tailored group, fentanyl dosage in IV PCA will be determined according to preoperative pain sensitivity. In control, group, fentanyl dosage in IV PCA will be determined without consideration of patient's pain sensitivity.
1462731|NCT03252977|Other|Regimen of IV PCA without considering pain sensitivity|In control group, regimen of IV PCA will be determined without consideration about patient's pain sensitivity.
1462732|NCT03252964|Device|Continuous Glucose Monitor (CGM)|Subjects will use a CGM to develop an understanding of how their behaviors influence their glucose levels.
1462733|NCT03252964|Device|Activity Tracker|Subjects will use the activity tracker, in combination with a continuous glucose monitor (CGM), to develop an understanding of how their activity levels affect their glucose levels.
1462734|NCT03252964|Behavioral|Coaching|Coaches will help subjects understand the readings from the CGMs and how they are affected by diet choices, use of diabetes medications, etc. Coaches and subjects will have weekly conversations about CGM data and behaviors that affect CGM readings. Coaching will occur via telephone and text messaging.
1462735|NCT03252951|Behavioral|Eccentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
1462736|NCT03252951|Behavioral|Concentric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
1462737|NCT03252951|Behavioral|Isometric Training|Different Anal Sphincter Exercise Types for muscle hypertrophy
1462738|NCT03252951|Behavioral|Biofeedback|Standard of Care Biofeedback Training
1462739|NCT03252938|Drug|IMP321|LAG-3Ig fusion protein, highly potent activator of antigen presenting cells
1462740|NCT03252925|Drug|N-Acetylcysteine|50mg/Kg.d, oral
1462741|NCT03252925|Drug|Placebo Oral Tablet|50mg/Kg.d, oral
1462742|NCT03252912|Biological|blood samples|Two EDTA tubes (5 mL) and two dried tubes (5mL) will be will be taken the same day as the first lumbar .
1462743|NCT03252899|Other|Survey therapists|A survey was conducted among therapists on upper limb treatment after stroke.
1462744|NCT03252899|Other|Survey patients|A survey was conducted among stroke survivors on upper limb treatment after stroke.
1462745|NCT03252886|Procedure|Endotracheal Intubation|Insertion of endotracheal tube into the trachea and supply oxygen using the ambu-bagging during cardiopulmonary resuscitation
1462746|NCT03252860|Other|Observation of compliance with the World Health Organisation Surgical Safety Checklist|Observation of use and compliance with the surgical safety checklist and associated perioperative surgical outcomes
1526797|NCT02765854|Drug|Ixazomib|Given PO
1462748|NCT03252834|Diagnostic Test|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI|Genetic variants of TRPV1, TRPM2, TRPA1 and ORAI1 will be analyzed. Quantitative Sensory Test, QST, will be used to determined if there is abnormal thermal sensation.
1462749|NCT03252821|Behavioral|High-intensity interval training|High-intensity interval training sessions will be conducted on cycle ergometers or treadmill with heart rate measured throughout each session.
1462750|NCT03252821|Behavioral|Resistance training|Resistance exercise will be performed on eight exercises targeting major muscle groups at 60% to 85% of their estimated one-repetition maximum (1RM).
1462751|NCT03252808|Biological|TBI-1401(HF10)|1x10^6 or 1x10^7 TCID50/mL TBI-1401(HF10) administered by intratumoral injection at 2-week intervals. Patients may continue to receive the injections for up to 1 year if eligible for injection.
1462752|NCT03252808|Drug|Gemcitabine|1000 mg/m^2 Gemcitabine administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
1462753|NCT03252808|Drug|Nab-paclitaxel|125 mg/m^2 Nab-paclitaxel administered by intravenous infusion at weekly for 3 weeks followed by a week of rest.
1462754|NCT03252795|Procedure|uterus transplantation|transplantation of a uterus from a deceased donor
1462755|NCT03252782|Device|Herbst Appliance|Acrylic Splint Herbst Appliance
1462756|NCT03252782|Device|Distal Jet Appliance|Anterior Median Palate Implant Borne Distal Jet Appliance
1462757|NCT03252769|Other|Self-sampling|
1462758|NCT03252756|Other|Placebo|600mg Saline (PO) for 4 weeks, immediately followed by 1200mg Saline/ day (PO) for an additional 4 weeks (8 total weeks).
1462759|NCT03252756|Other|Phytocannabinoid cannabidiol (CBD)|600mg CBD (PO) for 4 weeks, immediately followed by 1200mg CBD/ day (PO) for an additional 4 weeks (8 total weeks).
1462760|NCT03252743|Behavioral|Exposure-based internet-delivered CBT|"The main target in treatment is exposure for abdominal symptoms by reducing avoidance and provoking symptoms. Participants are encouraged to gradually increase the difficulty by combining multiple challenges.
The parents are taught how to reduce the risk for reinforcement of children's symptom behavior, and to support their child to complete the treatment.
All treatment content is delivered over the internet, containing texts, videos, audio-files and examples. The modules are unlocked sequentially as participants worked their way through the treatment.
Therapist support consists primarily of encouragement of any progress made in the treatment and support to find individual exercises."
1462761|NCT03252730|Other|WO 4260 Cosmetic Product for Topical Use|Application on the hair scalp at least once a day over four weeks
1462762|NCT03252717|Biological|Blood sample|"Pre-treatment blood samples will be collected for downstream analyses:
Three 6 ml EDTA samples for proteomic and genomic work package
One 6 ml dry sample for auto-antibodies analysis in the immunology work package
Two 4 ml EDTA samples for DNA extraction in the immunology work package
Two 2.5 ml PAX Gene sample for RNA extraction in the immunology work package and the non-irradiated control in the genomic work package"
1462763|NCT03252704|Other|resistant starch (high fiber muffin top)|Muffin top contained 11 g of fiber per portion
1462764|NCT03252704|Other|control (low fiber muffin top)|Muffin top contained 1 g of fiber per portion
1462765|NCT03252678|Other|a book and videos about ACP|A book and three videos about advanced care planning are provided for self-education
1462766|NCT03252678|Other|a book and videos about pain control|A book and three videos about pain control for cancer patients are provided for self-education
1462767|NCT03252665|Drug|Alprostadil|alprostadil,2ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
1462768|NCT03252665|Drug|Nicorandil|Nicorandil,2mg, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
1462769|NCT03252665|Drug|Nitroglycerin|Nitroglycerin,200ug, dilivered by targeted perfusion catheter in the culprit vessel after PCI in STEMI patients
1462770|NCT03252652|Radiation|vascular duplex ultrasound imaging|Duplex ultrasound is a non-invasive evaluation of blood flow through cranial arteries and veins.
1462771|NCT03252639|Procedure|EVT for RAS & PBV acquisition protocol for target kidneys|
1462772|NCT03252626|Drug|Alprostadil|"Alprostadil injection USP for intravascular infusion contains 500 micrograms Alprostadil, more commonly known as prostaglandin E1. Vasodilation, inhibition of platelet aggregation are among the most notable of these effects.
2ml Alprostadil injection added into 10ml 0.9% saline."
1462773|NCT03252626|Drug|Normal saline|2ml normal saline injection added into 10ml 0.9% saline.
1462774|NCT03252600|Drug|Cyclophosphamide|Given IV
1462775|NCT03252600|Drug|Dexamethasone|Given IV
1462776|NCT03252600|Biological|Elotuzumab|Given IV
1462777|NCT03252600|Other|Laboratory Biomarker Analysis|Correlative studies
1462778|NCT03252600|Drug|Lenalidomide|Given PO
1462779|NCT03252600|Other|Pharmacological Study|Correlative studies
1462782|NCT03252574|Other|A|AIR+ Smart Mask Only
1462783|NCT03252574|Other|B|AIR+ Smart Mask with micro-ventilator
1462784|NCT03252561|Procedure|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
1462785|NCT03252561|Procedure|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites will be infiltrated with a total of 20 mls 0.5% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
1462786|NCT03252535|Biological|Cellavita HD lower dose|The participants will receive a total of 9 intravenous administrations of 1x10^6 cells/kg body weight divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
1462787|NCT03252535|Biological|Cellavita HD higher dose|The participants will receive a total of 9 intravenous administrations of 2x10^6 cells/kg body weight divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
1462788|NCT03252535|Other|Placebo|The participants will receive a total of 9 intravenous administrations of placebo divided into three administrations per cycle. Each administration will occur every 30 days and cycles every 120 days (total of 3 cycles).
1462789|NCT03252522|Combination Product|Broad Spectrum Micronutrients or Placebo|blend of vitamins, minerals, amino acids and antioxidants
1948096|NCT02790034|Drug|Placebo|placebo BID followed by assessment of safety, tolerability and efficacy on reducing the respiratory symptoms in patients.
1462791|NCT03252496|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
1462792|NCT03252496|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
1462793|NCT03252496|Drug|Intrathecal Fentanyl|Fentanyl 15 μg will be administered in the subarachnoid space
1462794|NCT03252496|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
1462795|NCT03252496|Radiation|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 8-2 MHz curved array ultrasound probe placed longitudinally in the subcostal region
1462796|NCT03252496|Drug|250 mL Colloid over 5 minutes|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
1462797|NCT03252496|Drug|250 mL Crystalloid over 5 minutes|Ringer acetate 250 mL will be administered over 5 minutes starting immediately after intrathecal injection
1462798|NCT03252496|Drug|500 mL Crystalloid over 55 minutes|Ringer acetate 500 mL will be administered over 55 minutes following colloid or crystalloid administration
1462799|NCT03252496|Drug|250 mL Colloid over 60 minutes|After 60 minutes of intrathecal injection, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 250 mL will be administered over 60 minutes
1462800|NCT03252496|Drug|250 mL Crystalloid over 60 minutes|After 60 minutes of intrathecal injection, Ringer acetate 250 mL will be administered over 60 minutes
1462801|NCT03252496|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 120, 110, and 90 mmHg, respectively.
1462802|NCT03252496|Drug|Intravenous Syntocinon|Immediately after delivery, syntocinon 10 IU will be added to the running crystalloid solution
1462803|NCT03252483|Other|Bundled HCV/HIV Screening|Participants were randomized to a bundled HIV/HCV test group (intervention) to evaluate whether integrating HIV and HCV rapid screening would adversely impact HIV test acceptance.
1462804|NCT03252483|Other|HIV Screening|Participants were randomized to an HIV-only screening group as a control comparator.
1462805|NCT03252470|Procedure|Laparoscopic Roux-en-y Gastric Bypass Surgery|Laparoscopic Roux-en-y Gastric Bypass Surgery
1462806|NCT03252457|Drug|Decitabine|given intravenously at a dose of 3.5mg/m2/d for 4 consecutive days as a cycle and repeated every 2 weeks for 4 cycles
1462807|NCT03252457|Drug|Dexamethasone|given 40mg/d for 4 consecutive days as a cycle and repeated every two weeks for 4 cycles
1462808|NCT03252444|Other|Conscious control|Conscious control of the scapula is important and can correct neuromuscular coordination as well as strength deficits. The strategy in learning control of scapula into normal orientation can be facilitated by manual guides and/or external cues
1462809|NCT03252444|Other|Conscious control+biofeedback|In electromyography (EMG) biofeedback training, electronic equipment is used to reveal instantaneously certain physiological events.
1462810|NCT03252431|Drug|F-627|single dose pre-filled syringe
1462811|NCT03252431|Drug|Neulasta|single dose pre-filled syringe
1462812|NCT03252418|Drug|Ascorbic Acid 500 MG|ascorbic acid is vitamin that can cause gingival depigmentation
1462813|NCT03252418|Device|diode laser|diode laser is soft tissue laser case photothermolysis of melanoctes
1462814|NCT03252405|Device|mask ventilation|before intravenous induction, mask application is made. then intravenous cannulation and induction
1462815|NCT03252405|Device|intravenous cannulation|induction is applied by using intravenous cannulation
1462816|NCT03252379|Procedure|hepaticojejunostomy|"Under general intubation anesthesia, a generous right subcostal incision is performed and could be extended on demand upward to the xiphoid process and/or to the left subcostal area. Thorough dissection and adhesiolysis is performed to reach the CBD and prepare the unaffected proximal part for anastomosis. The Roux jejunal loop is prepared and passed retrocolic to reach the porta hepatis.
Then, the hepaticojejunostomy is done via end to side anastomosis using interrupted sutures of polyglactin of 3-0 or 4-0 size. The anastomosis is done 10-15 cm away from the free distal end of the Roux jejunum loop to allow anastomosis without tension to the stomach. A biliary stent may be optionally placed according to operative circumstances and is brought out through the anterior abdominal wall."
1462817|NCT03252379|Procedure|modified hepaticojejunostomy with subcutaneous access loop|"In the subcutaneous access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.
The closed free end of roux loop is passed through the anterior abdominal wall in the right subcostal area and then fixed to the wall in a subcutaneous position using 3/0 polyglactin sutures. The limb between the hepaticojejunal anastomosis and the subcutaneous fixation should be short and straight.
Four Ligaclips are used to mark the jejunal loop by clipping the sutures holding the access loop in place."
1462818|NCT03252379|Procedure|modified hepaticojejunostomy with gastric access loop|"In the gastric access loop, the same steps are done for performing roux-en-Y hepaticojejunostomy.The end of the Roux jejunal loop taken up for hepaticojejunostomy is not closed but is anastomosed to the anterior wall of the gastric antrum near the pyloric orifice.
All the enterogastrostomies and enteroenterostomies were in the form of single-layer continuous sutures of polyglactin of 3-0 size. An intraperitoneal drain was left in the hepatorenal pouch before closing the incision."
2010515|NCT02947750|Other|Stretching|Participants randomized to 'No Exercise Training' group will instead of aerobic exercise, undergo progressive whole body stretching and toning exercises designed for individuals 65 and older. This type of low intensity activity is designed not to increase heart rate and will serve as the Control group to the Exercise Training group. The Control group will come in for stretching sessions 3 times per week for 20-45 minutes.
1465326|NCT03233191|Procedure|Digital Tomosynthesis Mammography|Undergo TM
1948097|NCT02787564|Behavioral|Intervention Group|The intervention consists of providing free fruits and vegetables of the participants' liking for a period of 4 weeks. Each week, a total of 2 portions of either fruits and/or vegetables per day will be provided.
1948100|NCT02777814|Drug|Entecavir|anti hepatitis B virus
1948101|NCT02777801|Drug|Entecavir|anti-HBV
1462819|NCT03252366|Device|GELFOAM|"Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.
A diamond bur will be used to make a rectangular osteotomy.
The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.
Implant stability will be measured by osteal device
implant will be inserted with gelfoam (absorbable gelatin) for augmentation• The flap will then be copiously irrigated with saline in preparation for closure.
The flap will then be closed using interrupted 4/0 resorbable sutures."
1462820|NCT03252366|Device|xenograft|"Three line mucoperiosteal pyramidal flap will be reflected in the posterior maxillary edentulous area to expose the lateral wall of the maxilla.
A diamond bur will be used to make a rectangular osteotomy.
The membrane will be carefully elevated from the lateral wall and floor of maxillary sinus with simultaneous implant placement.
Implant stability will be measured by osteal device
implants will be inserted with xenograft for augmentation.• The flap will then be copiously irrigated with saline in preparation for closure.
The flap will then be closed using interrupted 4/0 resorbable sutures."
1462823|NCT03252340|Drug|ADSTEM Inj.|"ADSTEM Inj. 1.0x10^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial.
ADSTEM Inj. 3.0x10^8 mesenchymal stem cells as an intravenous infusion once in Phase I clinical trial."
1462824|NCT03252327|Other|Multiple Sensory Integrations|breast milk odor, oral expressed breast milk, heartbeat sounds, nonnutritive sucking.
1462825|NCT03252314|Device|Second-generation hydrogel coils|Hydrogel coils 90% by length
1462826|NCT03252301|Device|PMD 200|finger sensor which estimate objectively the pain level
1462827|NCT03252288|Behavioral|Reminders|Text of phone-call based reminders to mobile phones
1462828|NCT03252288|Behavioral|Conditional financial transfers|Full amount paid if visit occurs within 1 week of the scheduled visit; partial amount is paid if visit occurs >1 week but within 4 weeks of the scheduled visit
1462829|NCT03252275|Other|Peer learning|Peer learning plus HBB and ECEB
1462830|NCT03252262|Other|Vitalize 360|A comprehensive geriatric assessment system and wellness coaching program.
1462831|NCT03252249|Other|3 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 3 months dual anti-platelet therapy.
1462832|NCT03252249|Other|12 months dual anti-platelet therapy|Patients with acute coronary syndrome will be randomised to 12 months dual anti-platelet therapy.
1462833|NCT03252236|Behavioral|Tai Chi|Modified 12-form Yang style Tai Chi.
1462834|NCT03252236|Behavioral|Conventional exercise|Conventional exercises included mobilization, stretching, muscle strengthening, and walking training.
1462835|NCT03252223|Drug|Recombinant Follicle Stimulating Hormone|A modified dose-response study will be done using recombinant FSH (r-FSH), injected sc for 3 days at any one dose. r-FSH will be administered at weight-adjusted doses equivalent to 37.5, 75, and 150 IU based on an average weight of 70 kg, which approximates the weight of the average woman in the United States according to the Centers for Disease Control. Therefore, the actual dose of r-FSH will be 0.53 IU/kg for the 37.5 dose group. Accordingly, r-FSH will be repeated at doses of 1.1 IU/kg and 2.2 IU/kg that are equivalent to 75 and 150 IU for a 70 kg subject. Each FSH stimulation test will be assigned randomly and be separated by an interval of 8 weeks.
1462836|NCT03252210|Procedure|Preoperative Stereoscopic Localization|1.Confirm the nodule's location and measure the distance between the nodule and anatomic landmarks from the CT scan. 2.According to the results of the first step，confirm the needle puncture site of the chest wall. 3.After general anesthesia and Patient positioning are completed, the needle is then inserted via the needle puncture site .
1462837|NCT03252197|Device|UGIJVC with needle guide device|Study subjects assigned to each group were trained in ultrasound guided internal jugular venous cannulation (UGIJVC) in separate spaces. On each session, subjects were educated about UGIJVC for 30 minutes, and the instructor who was in charge of session, consisted of experienced physicians who had 50 or more UGIJVC success experiences without a supervisor in clinical field. The instructors explained the anatomical structure and the principles of UGIJVC and then demonstrated the procedures directly to the subjects using phantom. After that, all subjects were instructed to perform hands on practice for 30 minutes. In case group, the instructor trained subjects using device. On the other hand in control group, UGIVJC was demonstrated as a conventional method of approaching the target vessel while confirming the needle tip on the ultrasound screen in real time without a device.
1462838|NCT03252197|Device|UGIJVC without needle guide device|participants who are tested performance for ultrasound guided cannulation using conventional method.
1462839|NCT03252184|Device|Low level laser therapy|The low level laser therapy will be performed with the CHATTANOOGA® equipment and the probe cluster (head) from the same manufacturer. For the interventions in groups 1, 2 and 3 (photobiostimulation) will be used, respectively, the energy doses of 2, 4 and 6J. A 670nm wavelength with an output power of 10mW will be used. Group 4 intervention (placebo photobiostimulation) will be performed with the application of the device switched off. Each intervention will be performed in one day, with an interval of two days between each intervention. Photobiostimulation will be performed on the region of the radial and ulnar arteries of the left arm of each individual. The laser diode cluster probe will be placed in direct contact with the skin.
1462840|NCT03252171|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GD2 antigen.
1462841|NCT03252158|Behavioral|Availability of healthier vs. less healthy foods|"Altering the number of slots containing (a) healthier and (b) less healthy foods or beverages in hospital vending machines.
Changes follow a 2-step process whereby decreases are implemented in a separate study period prior to increases in the contrasting group. Following a 4-week baseline period, all vending machines will be standardised to have 75% healthier drinks and/or 25% healthier snacks (study period 1). Vending machines will be randomly allocated to the order in which they: (1) decrease less healthy foods and increase healthier foods or (2) decrease healthier foods and increase less healthy foods (study periods 2&3 and 5&6). After each decrease-increase pair, machines will return to the standardised 75% healthier drinks / 25% healthier snacks (study periods 4 and 7)."
1462844|NCT03252132|Other|12-week resistance training|Training will consist of a minimum of 5 supervised training sessions every 2 weeks and each session will be approximately 60 minutes in duration. Patients will be performing resistance training consisting of at least 3 exercises affecting the largest muscle groups of the body, training the most basic movement patterns that work the entire body as a coordinated system. Patients will train according to a linear progressive model with a slow increase in weight every training session focusing on the flexors, extensors of the ankle and knee and on flexors, extensors and abductors of the hip.
1462845|NCT03252119|Device|High flow humidified oxygen therapy|application of high flow humidified oxygen therapy at 2l/kg/min
1462846|NCT03252106|Procedure|Contour augmentation with implant placement|Contour augmentation with implant placement
1462847|NCT03252093|Drug|Angiotensin-(1-7)|Subcutaneous injection of 200 mcg/kg/day
1462848|NCT03252093|Drug|Placebo for Angiotensin-(1-7)|Subcutaneous injection of Placebo
1462849|NCT03252080|Behavioral|short-term intensive education|The patients of both groups are given the education classes once a week in the first month (total 4 times), 5 hours per class. The education classes are taught by a dedicated team of diabetes specialist doctors and nurses, with the contents including a basic understanding of diabetes, diabetic diet, exercise, drug treatments and blood glucose monitoring.
1462850|NCT03252080|Behavioral|Holistic management|The specialist nurses talk individually with the patients for 10-15 min per week. The nurses ask the patients about their results of self-blood glucose monitoring, help them find the reasons of poor blood glucose control as well as answer the patient's questions.
1462851|NCT03252067|Drug|azithromycin eyedrop|Tear samples will be collected using the strips.
1462852|NCT03252054|Diagnostic Test|Screening for memory disorders, attention disorders, and malnutrition|Screening for memory disorders, attention disorders, and malnutrition, using Six-Item Screener, Months of the Year Backwards Test, and NRS-2002 and MNA-SF, respectively.
1462853|NCT03252041|Device|MRI|Magnetic Resonance imaging modalities and sequences in pelvic congestion syndrome
1462854|NCT03252015|Drug|Probe Drug Cocktail|Administered orally
1462855|NCT03252015|Drug|Lasmiditan|Administered orally
1462856|NCT03252015|Drug|Placebo|Administered orally
1462859|NCT03251976|Behavioral|video|informational video
1462860|NCT03251976|Behavioral|usual care|usual physician counseling on end of life care
1462863|NCT03251950|Behavioral|healthy eating and gardening|15 week healthy eating and gardening intervention for children aged 3-5 years; 15 week online parenting intervention to promote healthy eating; Menu change in early childhood center to promote healthy eating
1462868|NCT03251911|Drug|Ivacaftor (VX-770)|of Ivacaftor (VX-770) for the Treatment of Chronic Bronchitis with CFTR Dysfunction
1462869|NCT03251885|Other|swabs|Two swabs will be taken at each screen: one from the vagina and the other from the rectum for vaginal and rectal assessment of maternal colonization
1462870|NCT03251872|Drug|Olaparib|Olaparib tablets
1462871|NCT03251859|Drug|Ticagrelor 90 mg|Ticagrelor 90 mg twice daily
1462872|NCT03251859|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg daily
1462873|NCT03251846|Device|Pops! One personalized mobile platform|Enrolled subjects will be given a POPS! Device (meter, lancet/test strips, and software app) to use for 6 months. Primary outcomes will be measured at baseline and 6-month follow-up.
1462874|NCT03251820|Drug|corticosteroid|Each patient will be subjected to a one month course of steroids and then re-evaluated
1462875|NCT03251807|Device|Twin-block|Functional treatment will be achieved using the Twinblock appliance
1462876|NCT03251807|Other|LIPUS (Low-intensity pulsed ultrasound)|Functional treatment will be combined with LIPUS (Low-intensity pulsed ultrasound )
1462877|NCT03251794|Diagnostic Test|three dimensional ultrasound|evaluation of the suprarenal glands
1462878|NCT03251794|Diagnostic Test|color Doppler|Doppler evaluation of the suprarenal artery
1462880|NCT03251768|Drug|rHSA-GCSF 2.4mg|Human Serum Albumin GCSF 2.4mg at day 3 and day 7
1462881|NCT03251768|Drug|GCSF|GCSF 5 mcg/kg/day
1462882|NCT03251755|Behavioral|Yoga|Exercise promotion using Chinese Yoga
1465327|NCT03233191|Other|Laboratory Biomarker Analysis|Correlative studies
1462885|NCT03251729|Drug|Vaginal progesterone|Vaginal progesterone 200mg suppository or 90mg gel nightly from randomization until 36 weeks
1462886|NCT03251716|Drug|berberine|berberine 300mg TID add-on for berberine adjunctive group
1462887|NCT03251703|Procedure|Ultrasound-Guided Suprascapular Pulsed Radiofrequency .|The ultrasound-Guided Suprascapular Pulsed Radiofrequency was administered under operating room conditions while the patient was monitored in a sitting position.An ultrasound-guided 22 G 5-mm active-tip 100-mm radiofrequency needle (SC-K; Top Neuropole, Tokyo, Japan) was pushed forward towards the suprascapular notch until it passed the transverse scapular ligament using an in-plane approach.
1462888|NCT03251690|Drug|Tenofovir/Emtricitabine/Rilpivirine|Tenofovir/Emtricitabine/Rilpivirine to compare the non-inferiority of efficacy and adverse effects to Tenofovir/Emtricitabine/Efavirenz in patients with virological suppression
1462889|NCT03251690|Drug|Tenofovir/Emtricitabine/Efavirenz|as a active comparator
1462890|NCT03251677|Procedure|Surgical procedure, Hysterectomy|Surgical removal of the uterus
1462891|NCT03251664|Dietary Supplement|Food groups consumed|
1462892|NCT03251651|Drug|Propofol|Propofol is infused continuously via the target-controlled infusion device (Orchestra®, Fresenius vial, Brezins, France), and the effect-site concentration is maintained within 0.5-2.0 μg/ml.
1462893|NCT03251651|Drug|Dexmedetomidine|Dexmedetomidine is diluted with 0.9% saline to make a concentration of 4 μg/ml. As a loading dose, 1 μg/kg dexmedetomidine is administered over a 10-min period, which is then administered continuously at 0.1-0.5 μg/kg/h.
1462894|NCT03251625|Drug|Probiotic Formula Capsule|
1462895|NCT03251612|Drug|Based on sensitivity analysis|"5FU, infusional
Capecitabine
Oxaliplatin (FOLFOX)
Irinotecan (FOLFIRI)
FOLFOXIRI (triplet)
Bevacizumab
Panitumumab
Cetuximab
Regorafenib
Tas-102
Ramucirumab
Aflibercept
Pembrolizumab
Nivolumab
Vinorelbine and capecitabine
Sorafenib
Gemcitabine and capecitabine
Olaparib
Epirubicin"
1462896|NCT03251599|Drug|Glyceryl trinitrate 0.2|These patients will receive glyceryl trinitrate infusion at a rate of 0.2 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
1462897|NCT03251599|Drug|Glyceryl trinitrate 0.5|These patients will receive glyceryl trinitrate infusion at a rate of 0.5 mcg/kg/min throughout the rewarming period of cardiopulmonary bypass, which usually lasts for 30-45 minutes.
1462898|NCT03251586|Diagnostic Test|oVEMP - infra-orbital electrode montage|oVEMPs are short latency (~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The conventional electrode montage, the infra-orbital electrode montage, has the active electrode placed directly inferior to the eye and the reference electrode placed 2-3 cm below the active on the cheek. This electrode montage may result in reference contamination, which will cause an artificially reduced amplitude response, as a portion of the response can be measured by the reference electrode.
1462899|NCT03251586|Diagnostic Test|oVEMP - belly-tendon electrode montage|oVEMPs are short latency (~10 ms) stimulus-synchronized extra-ocular muscle reflexes produced in response to appropriate stimuli. The response is believed to originate from excitation of the utricular macula with the subsequent neural response relayed to the brain by the superior portion of the vestibular nerve. Changes in the electrical field of the contralateral inferior oblique muscle can be recorded by an electrode placed at the infra-ocular midline of the lower lid while having the subject gaze upward. The belly-tendon electrode montage consists of an active electrode placed laterally to the midline of the lower eyelid and a reference electrode placed on the inner canthus. This reference location is believed to be electrically neutral, and should therefore result in larger amplitude responses as the response would not be subject to reference contamination.
1462900|NCT03251560|Drug|Fuke Qianjin capsule|Fuke Qianjin capsule 0.8g pills by mouth, three times daily
1462901|NCT03251560|Drug|Placebo oral capsule|Placebo oral capsule 0.8g pill by mouth, three times daily
1462902|NCT03251547|Drug|NovoSeven|To survey retrospectively the treatment indications, clinical outcome, transfusion need and changes in coagulation profiles of non-haemophiliac patients who had received rFVIIa during massive bleeding
1462903|NCT03251534|Procedure|Centromedullary nailing|
1462904|NCT03251521|Other|pain rating during injection with botulinum toxin|The pain intensity was rated verbally on a numeric scale. The pain was rated after each phase of injection
1462905|NCT03251508|Drug|Peanut OIT|Participants will be given increasing doses of the peanut oral immunotherapy (OIT) study drug every 2 weeks for 3 months up to the 300 mg maintenance dose and will maintain this dose for 3 months. Subjects will then switch to a food equivalent that contains 300 mg of peanut protein for an additional 6 months.
1462918|NCT03251469|Drug|Tranexamic Acid 15mg/kg , iv, Single Dose|Tranexamic Acid 15mg/kg , administered intravenously, preoperatively, in a single dose
1462919|NCT03251469|Drug|Normal Saline, 100mg, iv, Singe dose|Normal Saline, 100mg, administered intravenously, preoperatively in single dose
1462920|NCT03251456|Other|Tertiary care|"Inform the parents that there are abnormalities after eye disease screening of their children, and the program of tertiary care for visual developmental disorders
The children will be receiving the appropriate therapy in tertiary care and follow-up according to the clinical guidelines
Six months after receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
1462921|NCT03251456|Other|Usual Care|"Inform the parents that there are abnormalities after eye disease screening of their children
Inform the parents that they should take their children to the hospital for further consultation
Six months after the receiving the screening report, all the parents will be interviewed by telephone, or visiting if necessary."
1462922|NCT03251443|Drug|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
1462923|NCT03251430|Procedure|gastrectomy|Distal gastrectomy, Total gastrectomy
1462924|NCT03251417|Drug|Irinotecan|Irinotecan 150mg/m2, repeated very 2 weeks for 3 to 6 cycles.
1462925|NCT03251417|Drug|Apatinib|Apatinib 500 mg oral take, daily
1462926|NCT03251404|Other|Injury prevention exercise programs|The two intervention programs contain exercises aiming to increase lower extremity strength, core stability, balance and neuromuscular function.
1462927|NCT03251391|Other|Cardiac Rehabilitation Program|"Program will involve 36 sessions. These will be scheduled as 3 sessions per week. If you cannot complete 3 sessions per week the 36 sessions could be spread out over 6 months.
Each session will last between 30-60 minutes. Sessions will involve aerobic activity, diet/nutritional counseling, and smoking cessation information."
1462928|NCT03251391|Other|Conventional Therapy|Participants will be asked to complete tests and questionnaires that would normally be done for their condition.
1462929|NCT03251378|Drug|Fruquintinib (HMPL-013)|Fruquintinib is a small molecule tyrosine kinase inhibitor (TKI) with a novel chemical structure which belongs to the quinazoline class.
1462930|NCT03251365|Drug|HIPEC-gemcitabine|• Group II.After a R0 cytoreductive surgery, HIPEC is performed with gemcitabine, 120mg / m2 for 30' + adjuvant treatment with iv gemcitabine , 1000 mg / m2 for at least 4 cycles
1462931|NCT03251339|Drug|MSB11455|Subjects will receive single subcutaneous administration of MSB11455 on Day 1 of Period 1 and Period 2.
1462932|NCT03251339|Drug|Neulasta|Subjects will receive single subcutaneous administration of Neulasta on Day 1 of Period 1 and Period 2.
1462933|NCT03251326|Drug|Nabilone|Nabilone capsules (4 mg)
1462934|NCT03251326|Drug|Cannabis|Cigarettes (0.0 and 5.6% THC)
1462935|NCT03251326|Drug|Propranolol|Propranolol capsules (40mg)
1462936|NCT03251326|Drug|Placebo|Placebo capsules
1462941|NCT03251300|Drug|daytime dosing of mirabegron|All OAB female patients will receive daytime dosing (08:00 AM) of mirabegron
1462942|NCT03251300|Drug|nighttime dosing of mirabegron|All OAB female patients will receive nighttime dosing (08:00 PM) of mirabegron
1462947|NCT03251274|Other|machine bathing|machine bathing 20-min duration at evening
1462948|NCT03251274|Other|traditional bathing|traditional bathing
1462949|NCT03251261|Device|illumigene CMV assay, illumipro-10|CMV assay for detection of CMV
1462950|NCT03251248|Drug|MSB11455|Subjects will receive MSB11455 either on Period 1 Day 1 or Period 2 Day 1.
1462951|NCT03251248|Drug|Neulasta|Subjects will receive Neulasta either on Period 1 Day 1 or Period 2 Day 1.
1462952|NCT03251235|Behavioral|Cognitive Behaviour Therapy|
1462953|NCT03251222|Drug|Dexmedetomidine|Intranasal aplication of dexmedetomidine
1462954|NCT03251222|Other|Placebo - Concentrate|Intranasal aplication of 0.9% NaCl
1462955|NCT03251209|Other|Physical practice|Physical Practice: reproduce through the motor execution (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles), the activities assisted in the video (5 minutes / task).
1462956|NCT03251209|Other|Mental practice|Mental practice: think about the tasks watched in the videotherapy (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles) for 5 minutes / task.
1462957|NCT03251209|Other|Videotherapy|Videotherapy, being 2 minutes per task (4 distinct tasks: stacking cubes, opposition of fingers with precision gripping, passing water from one glass to another, sequencing of bottles)
1462958|NCT03251196|Other|No Intervention, and Observational Study|Observational Study
1462959|NCT03251183|Diagnostic Test|Comprehensive Cardiovascular magnetic resonance (CMR)|Cardiovascular magnetic resonance (CMR) provides non-invasive, radiation-free and in-depth evaluation of myocardial structure and function. In addition to established tools for assessment of cardiac volume, mass, function and regional myocardial scar with late Gadolinium enhancement (LGE), several novel quantitative CMR parameters will be assessed including T1-mapping or fully quantitative perfusion Imaging.
1527050|NCT02764008|Device|Ultrasound|
1462960|NCT03251183|Diagnostic Test|Blood sampling|Blood samples will eventually be analysed for markers related to heart failure (BNP/NT)-pro-BNP, myocardial inflammation and fibrosis (cytokine profiling, Galectin-3, Procollagen Type I and III, hsCRP). Whole blood will be frozen for DNA isolation and genome analysis. Peripheral blood mononuclear cells will be isolated by Ficoll in a subset of patients and will be used for RNA isolation allowing RNA-seq or reverse transcription (RT) - polymerase chain reaction (PCR) analysis.
1462961|NCT03251183|Diagnostic Test|TTE (EchoErgo)|Measurements will include cavity dimensions, flow velocities, myocardial motion velocity and strain as well as for change of parameters during ergometric stress.
1462962|NCT03251183|Diagnostic Test|Invasive pressure-volume (PV) Loops|Multiple parameters (including EDPVR, ESPVR, dp/dt min, Tau, Ea) will be derived from the various PV loop assessments and additional relevant parameters will be calculated. Right ventricular and pulmonary pressures including pulmonary vascular resistance will be measured with Swan-Ganz catheters using right venous femoral approach.
1462963|NCT03251183|Diagnostic Test|Left ventricular (LV) biopsy|"A set of myocardial biopsies for each patient will be stained with Masson Trichrome for qualitative and quantitative assessment of the collagen volume fraction; fat droplets will be identified by red oil staining, Congo Red for amyloid immunohistology will be used to determine total leukocytes (CD45), T-cells (CD3) and monocytes/macrophages (CD68).
A second set of biopsies will be frozen immediately and stored at -80°. Western blot analysis will be performed to determine alterations at the myofilament level including titin isoform composition and phosphorylation status."
1462967|NCT03251157|Other|Dietary intake of various nutrients, foods and biocompounds|Participants answered a self-administered FFQ, in which they reported the usual frequency of intake of a list of 250 food items
1462968|NCT03251144|Drug|Switch to E/C/FTC/TAF daily|"If the participant is on an antiretroviral regimen other than Elvitegravir (ELV)/cobicistat CO)/emtricitabine (FTC)/tenofovir (TDF)] (E/C/FTC/TDF) then the participant will be asked to switch to E/C/FTC/TDF for up to 6 months. This will allow for future switch (after these 6 months) from E/C/FTC/TDF 1 tablet once daily to elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/FTC/TAF) 1 tablet once daily for a period of 12 months.
b) If the participant is on E/C/FTC/TDF 1 tablet once daily then the participant will be asked to switch from /C/FTC/TDF 1 tablet once daily to /C/FTC/TAF 1 tablet once daily for a period of 12 months."
1462969|NCT03251131|Other|Restrictive fluid management|Daily fluid input is restricted to drugs and nutrition. Fluid boluses and blood products can be given if clinically indicated. Matching fluid output to fluid input whenever possible using diuretics if needed, and additionally, if clinically necessary and plausible, commencing renal replacement therapy. If renal replacement therapy is not deemed clinically desirable, acceptance of a less than targeted fluid balance.
1462970|NCT03251105|Device|supraglottic airway intubation|
1462971|NCT03251092|Drug|PTI-808|Active
1462972|NCT03251092|Drug|Placebo|Placebo
1462973|NCT03251066|Other|Proponent Nasal Spray|The medical device consists of a Saline solution containing sodium propionate which is administered as single dose
1462974|NCT03251053|Device|Electronic cigarette use|Replacement of tobacco smoking with electronic cigarette vaping
1462975|NCT03251053|Other|Control regular cigarette smokers|
1462976|NCT03251040|Device|Autologous activated fibrin sealant|Application of fibrin sealant
1462977|NCT03251027|Radiation|Intensity-Modulated Radiation Therapy|Undergo IM-SRT
1462978|NCT03251014|Other|YSS|Intervention providing steamed whole YSS (~265 g/day, 3 days/week) for eight weeks
1462979|NCT03251014|Other|Salmon|Intervention providing steamed salmon fillet (~246 g/day, 3 days/week) for eight weeks
1462980|NCT03251001|Procedure|Control|Free epithelized gingival graft, harvested from palate, was grafted in a site with lack of keratinized gingiva
1462981|NCT03251001|Device|Acellular Dermal Matrix|Acellular Dermal Matrix was grafted in a site with lack of keratinized gingiva, in substitution of an autogenous graft from patient palate
1462983|NCT03250975|Diagnostic Test|Flexible laryngoscopy|"Consented and enrolled patients will undergo routine medical examination of their larynx with flexible nasolaryngoscopy after anesthetizing and decongesting the nose with 1% lidocaine mixed in oxymetazoline. During the examination, patients will be asked to sniff (which triggers opening of the vocal cords), and say Eee which (triggers closing). These maneuvers allow assessment of vocal fold movement. The evaluation will be recorded for subsequent blinded review"
1462984|NCT03250962|Drug|SHR-1210|SHR-1210 is a humanized anti-PD-1 monoclonal antibody.
1462985|NCT03250962|Drug|Decitabine|Decitabine is an investigational (experimental) drug that works by depleting DNA methyltransferase 1 (DNMT1), which can increase tumor antigens and HLA expression, enhances antigen processing, promotes T cell infiltration, and boosts effector T cell function.
1462986|NCT03250949|Procedure|implant site over drilling protocol|"Osteotomy preparations for the loose fit group will be identical to those of the tight fit group until final drill, which will be 0.2mm wider than the diameter of the implant.
osteotomy site of the implant is wider by 0.2mm than the implant diameter"
1948102|NCT02776761|Biological|Hantaan Vaccine:|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
1462988|NCT03250910|Drug|Sofosbuvir and Velpatasvir|All patients received a generic version of VEL/SOF fixed-dose combination (Sofosvel®, VEL/SOF 100/400 mg film coated tablet, Beacon Pharmaceuticals Ltd. Mymensingh, Bangladesh) 1 tablet per day for 12 weeks.
1462989|NCT03250910|Drug|Ribavirin|Patients with decompensated cirrhosis (Child-Pugh B or C), received weight-based ribavirin (RBV)(Robatrol®, 200 mg capsule, Genovate Biotechnology Co. Ltd., Hsinchu, Taiwan; 1,200 mg per day if the body weight ≥ 75 kg; 1,000 mg per day if the body weight < 75 mg) for 12 weeks.
1465328|NCT03233178|Other|Non-interventional|
1948103|NCT02776761|Biological|Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
1462991|NCT03250858|Behavioral|Personalised advice|Provision of online personalised advice on dietary intake, weight and physical activity levels. Personalised recommendations for improved food choice based on adherence to an 11-item modified US Alternative Healthy Eating Index (m-AHEI), for weight based on ideal BMI range and for physical activity based on the Baecke questionnaire/results.
1462992|NCT03250858|Behavioral|Non-personalised advice|Provision of online non-personalised advice on dietary intake, weight and physical activity levels. Non-personalized dietary advice for improved food choice based on standard population health guidelines.
1948104|NCT02776761|Biological|Hantaan/Puumala Vaccine|DNA Vaccine 2.0 mg/1 mL phosphate-buffered saline
1948105|NCT02774265|Drug|VTE prophylaxis with Enoxaparin 30mg BID|Patients will receive Enoxaparin 30mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
1462995|NCT03250819|Other|SNP analysis|The collected blood samples will be used to investigate the occurrence of SNPs (single nucleotide polymorphisms) in both study groups
1462996|NCT03250793|Device|Physiologic study measuring work of breathing which can be estimated by the esophageal and trans-diaphragmatic pressure-time product obtained by an esophageal transducer|While the patient is under respiratory assistance on the SERVO-I respirator, he will be included in the study and one esophageal transducer of 2,3 mm of diameter will be inserted through the mouth / nose in addition to NAVA's naso / Oro-Gastric tube( Edi Catheter, 6Fr, 49 cm, PHT free 5 pcs / pkg or Catheter Edi, 6Fr, 50 cm, PHT free 5 pcs / pkg). Measurements will be performed using the esophageal transducer under two conditions: 2 hours in conventional ventilation (pressure controlled), 2 hours in NAVA ventilation and then again 2 hours in conventional ventilation (PC) for a total duration of 6 hours.The parameters of conventional ventilation will be left free at the choice of the neonatologist and will be identical between the two periods of conventional ventilation. The initial NAVA level will be defined by the neonatologist using pre-visualization curves. All signals will be recorded via an amplification and acquisition system. Values will be averaged over 100 cycles.
1462997|NCT03250780|Procedure|indigo-carmine 0.2% using a spray catheter|
1462998|NCT03250780|Procedure|0.03% using a foot pump|
1462999|NCT03250767|Device|Integra Titan Modular Shoulder System 2.5|Primary Shoulder Joint Replacement
1463000|NCT03250754|Device|Electroacupuncture|Needles on the extremities were stimulated by electro-stimulation device applied by a biphasic pulse generator apparatus at a frequency of pulses alternated between 2 Hz and 100 Hz and the maximum tolerable intensity.
1463001|NCT03250741|Drug|Rotigotine transdermal patch|Rotigotine transdermal patches 4mg/24hr
1463002|NCT03250741|Other|Placebo|Placebo transdermal patches of the same size as for Rotigotine transdermal patches
1463003|NCT03250728|Biological|Peripheral blood puncture|"Endothelial progenitor cells will be isolated from peripheral blood by density gradient and cultured in 10%FBS EGM2 medium
On the EPCs we will study:
the endothelial permeability
the protein C system"
1463004|NCT03250715|Other|Low Level Laser Therapy|For application of the LLLT in the quadriceps muscle the patient will be in dorsal decubitus, with the legs extended and will be defined by the palpation of the muscle belts six points of application: two points in the distal region of the vastus medialis muscle, two points of the distal region of the vastus lateral muscle and two points of the central region of the rectus femoris muscle. For the application of LLLT in the gastrocnemius muscle the patient will remain in the supine position, but will be oriented to keep the hips and knees flexed at 90º and 45º respectively. Two application points will be defined, one in the lateral ventricle and the other in the medial ventricle, but both in the distal region of the muscle.
1463005|NCT03250689|Drug|Danirixin|Danirixin will be available as 35 mg oval shaped, white film coated HBr embossed tablets.
1463006|NCT03250689|Drug|Placebo|Placebo will be available as oval shaped, white film coated tablets.
1463007|NCT03250689|Drug|Rescue medication|Subjects may continue to use rescue medication(s) anytime during the study. The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
1463008|NCT03250689|Drug|Inhaled COPD maintenance medication|Subjects may continue to use inhaled COPD maintenance medication(s) during the study, at the discretion of the GSK Medical Monitor and/or Investigator. The following maintenance medications may be used: long acting bronchodilator medications (e.g. long-acting muscarinic antagonist [LAMA], long-acting beta-agonist [LABA]) and long-acting bronchodilator combination therapies (e.g. LAMA/LABA) and long-acting bronchodilator/inhaled corticosteroid steroid combination (ICS) therapies (e.g. LABA/ICS, LAMA/LABA/ICS)
1463009|NCT03250676|Drug|H3B-6545|Oral Capsules
1463011|NCT03250650|Device|PTNS|Transcutaneous tibial electric stimulation
1463012|NCT03250650|Device|ES+PTNS|Transvaginal electric stimulation
1463013|NCT03250637|Other|Observational|Information on diet, lifestyle, weight, height, medical treatment, environmental exposures, and other socio-economic factors were collected at enrolment using questionnaires and interviews
1463014|NCT03250624|Drug|CD 5024 0.3% cream|Up to 4g daily, once a day, 7 days a week for 6 weeks
1463015|NCT03250624|Drug|CD 5024 cream placebo|Up to 4g daily, once a day, 7 days a week for 6 weeks
1463016|NCT03250611|Procedure|Occipital Condyle Screw|Occipito-Cervical Screw-Rod Fixation Technique
1463022|NCT03250572|Diagnostic Test|serum ferritin|serum samples and ferritin ELISA test
1463023|NCT03250559|Procedure|Percutaneous nephrolithotomy|Endoscopic kidney stone extraction technique.
1463024|NCT03250546|Procedure|transplant from a haplo-identical donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
1463025|NCT03250546|Procedure|transplant from a non related donor|The transplant procedures will be similar in the 2 groups beside the origin of cells
1463026|NCT03250533|Device|Light emitting diodes (LED)|The light-emitting diode (LED) device consists of a soft 15 x 15 cm blanket, which allows the body segment curvature of the cutaneous lesion to be monitored. The LEDs are fixed equidistant to obtain uniform irradiation over the entire ulcer. The wound site will be surrounded by a PVC film (polyvinyl chloride), to avoid contamination, for posterior positioning of the LED device, applying light directly and perpendicularly, with energy density of 6 J / cm². All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density.
1463027|NCT03250533|Device|Fixed diphasic current|The electrical stimulation treatment will be performed with the fixed diphasic current of the Dualpex 071 equipment (Quark®, Piracicaba, SP, Brazil), with the monopolar technique, 100 Hz, maximum intensity of 1 mA / cm² of lesion for 10 minutes. Autoclave sterilized aluminum electrodes will be used, one on the lesion (negative pole) and the other transversal to the segment (positive pole). The size of the electrode will be proportional to the extension of the lesion, having as a means of contact between the electrode and the ulcer, sterile gauze moistened with 0.9% saline solution.
1463028|NCT03250520|Drug|Platinum acetylacetonate (1% wt) supported by sol-gel technology functionalized titania|Sol-gel process Pt(acac)2- F-TiO2 nanostructured material with antitumoral activity used as an alternative in the treatment of cancer tumors. The biocatalysts were prepared by the sol-gel route using the complex Pt(acac)2.
1463029|NCT03250507|Drug|Bupivacaine|0.25% bupivacaine for TAP block
1463030|NCT03250507|Drug|Liposomal bupivacaine|Exparel for TAP block
1463031|NCT03250507|Drug|Saline|Saline for TAP block that will be mixed with liposomal bupivacaine to bring the liposomal bupivacaine group to 60 mL total volume.
1463032|NCT03250494|Drug|Dulox capsule (60mg)|each patient received Dulox capsule (60mg) orally with sips of water 2 hours preoperatively and 100 ml 0.9% sodium chloride solution (NS) intravenous infusion (IVI) over 15 min
1463033|NCT03250494|Drug|combined Dulox capsule (60 mg) orally and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI|each patient received combined Dulox capsule (60 mg) orally with sips of water and Dex 0.1mg/kg diluted in 100 ml 0.9% NS IVI over 15 min, 2 hours preoperatively
1463034|NCT03250494|Drug|a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone|each patient received a placebo capsule identical to Dulox capsule and 100 ml 0.9% NS IVI over 15 min, as a placebo for dexamethasone 2 hours preoperatively.
1463035|NCT03250481|Drug|Propofol|Sedation targeted to RASS -3-0 or RI 20-40
1463036|NCT03250468|Behavioral|CBT-I|Each weekly session will focus on several psychological and behavioural techniques that include sleep restriction, relaxation strategies, cognitive therapy, stimulus control therapy, and education about proper sleep hygiene.
1463037|NCT03250455|Diagnostic Test|CTA CTP|CT Angiography myocardial CT Perfusion
1463038|NCT03250455|Diagnostic Test|CTA|CT Angiography
1463041|NCT03250429|Procedure|Sinus surgery|Standard Clinical Sinus Surgery
1463042|NCT03250403|Drug|PRP injection|peri-neural injection of platelet rich plasma
1463043|NCT03250403|Other|traditional medical treatment|traditional medical treatment
1463044|NCT03250390|Device|Collection of volatile organic compounds during exhalation|"The volatile organic compounds (VOCs) are collected in sorbents at rest and at the end of exhalation according to the concentration of carbon dioxide using ReCIVA breath sampler.
The identification of the VOCs will be done by chromatography (Gas Chromatography Mass Spectrometry GC-MS)"
1995048|NCT02866487|Procedure|Bronchoscopy|A diagnostic bronchoscopy will be conducted for clinical indications in children referred to the University of Virginia Children's Hospital for evaluation of respiratory symptoms
1463046|NCT03250364|Device|Multilayer bandage|See arm/group descriptions
1463047|NCT03250364|Device|Double compression bandage|See arm/group descriptions
1463048|NCT03250364|Device|Cohesive bandage|See arm/group descriptions
1463049|NCT03250364|Device|Adhesive compression bandage|See arm/group descriptions
1463050|NCT03250364|Device|Kinesiotaping bandage|See arm/group descriptions
1463051|NCT03250364|Other|Manual lymphatic drainage (MLD) + Intermittent Pneumatic Compression|"MLD using a modification of the strokes described by Leduc will be applied to lymphedema resorption. It will be included resorption maneuver in the oedematous areas of the affected limb, in cranial to caudal direction, since the physiotherapist seeing a change in the tissue qualities of the oedema. Then, the subjects will be received thirty minutes of Intermittent Pneumatic Compression (EureducTM) with a pression of 40 mmHg."
1463052|NCT03250364|Other|Upper limb exercises|After the bandage will be put, proprioceptive neuromuscular facilitation exercises without resistance in two diagonal in asymmetrical reciprocal patterns with the affected limb will be taught. The first diagonal into flexion from hitch hike to swat fly, and into extension from swat fly to hitch hike, and the second diagonal from hand in opposite pocket to carry tray, and into extension from carry tray to hand in opposite pocket. These exercises must be done at home two times per day, ten repetitions each exercise.
1463053|NCT03250364|Behavioral|Educational strategy|Instructions about lymphatic system anatomy and pato-physiology, the prevention and identification of possible lymphedema complication or infection, how to use and exercise this arm, avoidance of trauma, injury, an excess of heat and arm constriction.
1463054|NCT03250351|Other|Neurodynamic techniques|See arm/group descriptions
1463055|NCT03250351|Other|Early physical therapy plus educational strategy|See arm/group descriptions
1463056|NCT03250338|Drug|Crenolanib|Crenolanib will be administered orally
1463057|NCT03250338|Drug|Cytarabine|"HAM regimen
FLAG-Ida"
1463058|NCT03250338|Drug|Mitoxantrone|HAM regimen
1463059|NCT03250338|Drug|Placebo Oral Tablet|Placebo will be administered orally
1463060|NCT03250338|Drug|Fludarabine|FLAG-Ida regimen
1463061|NCT03250338|Drug|Idarubicin|FLAG-Ida regimen
1463062|NCT03250338|Drug|G-CSF|FLAG-Ida regimen
1995049|NCT02865239|Procedure|Position for the 3.0 Tesla in Magnetic Resonance Imaging|"Eligible patients will have a standard MRI in prone position. At the end of this examination, all patients will have an other standard MRI in supine position.
This examination is then extended by 10 minutes without additional injection of contrast medium"
1948106|NCT02774265|Drug|VTE prophylaxis with Aspirin 81mg BID|Patients will receive Aspirin 81mg BID for DVT prophylaxis and will be followed to determine the efficacy, safety and cost when used for VTE prophylaxis in high-risk orthopedic traumas administered for the length of time indicated by standard of care based on the injury.
1463065|NCT03250312|Other|The Osteopathic Manipulation|The types of OMT techniques used will include muscle energy, articular, or high velocity-low amplitude (HVLA) as indicated by the physical findings and will be at the discretion of the treating physician. Additional techniques such as still, counter strain, facilitated positional release, balanced ligamentous tension, and cranial techniques may also be used at the discretion of the treating physician. The treatment will conclude with 2 minutes of pedal lymphatic pumping
1463066|NCT03250299|Drug|Microtubule-Targeted Agent BAL101553|Given PO
1463067|NCT03250299|Radiation|Radiation Therapy|Undergo radiation therapy
1463068|NCT03250299|Other|Laboratory Biomarker Analysis|Correlative studies
1463069|NCT03250299|Other|Pharmacological Study|Correlative studies
1463070|NCT03250286|Device|EUS|"Endoscopic ultrasound (EUS) is performed with radial scanning echo endoscope (Olympus GF UE260) by four endosonographers.
EUS examination is performed first, and if there is choledocholith, ERCP is performed."
1463071|NCT03250286|Device|ERCP|"Endoscopic retrograde cholangiopancreatography (ERCP) is performed with duodenoscope (Olympus JF-260V or TJF-260V) by four endoscopists.
In the EUS-ERCP group, ERCP is used to remove bile duct stones diagnosed via EUS. Therefore, only ERCP is performed in patients with choledocholithiasis in EUS.
In the ERCP group, diagnosis and treatment of bile duct stones are performed with ERCP."
1463072|NCT03250273|Drug|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
1463073|NCT03250273|Drug|Nivolumab|After both lead-in doses of entinostat, nivolumab (360 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
1463074|NCT03250273|Drug|Entinostat|Entinostat (5mg) will be administered starting with 2 lead-in doses at 14 and 7 days before the first dose of nivolumab in combination with entinostat. After the lead-in dose, entinostat will be administered once a week (days 1, 8, 15, and 21 of each treatment cycle).
1463075|NCT03250273|Drug|Nivolumab|After both lead-in doses of entinostat, nivolumab (360 mg) will be administered every 2 weeks (day 1 and day 15 of a cycle).
1463076|NCT03250260|Other|3-dimensional photograph with simulation|The viewing of a 3-dimensional simulation is classed as an intervention as it strays from the normal pre-operative preparation.
1463077|NCT03250260|Other|Viewing of a 2-dimensional photographic library|The viewing of a 2-dimensional photograph library is classed as an intervention as it strays from the normal pre-operative preparation.
1463078|NCT03250247|Device|Stents|"US-guided puncture of vein, fluoroscopic monitoring of catheter/guidewire manipulations, baseline venogram of CFV through infrarenal IVC.
Iliac vein should be pre-dilated to at least 12 mm. Bare, self-expanding stents made of elgiloy or nitinol legally marketed in the US for any indication and that are at least 12 mm in diameter should be used to recanalize the entire diseased segment of vein.
The use of devices > 14 mm is highly recommended for the iliac vein and dilated to at least 14 mm, unless compelling patient factors dictates dilatation to a smaller diameter.
Balloon angioplasty of inflow veins.
After successful iliac vein recanalization, patients who continue to be symptomatic beyond 2 weeks follow-up and who have valvular reflux in GSV, accessory GSV, anterolateral thigh circumflex, and/or SSV should be offered endovenous ablation.
Any FDA-approved method may be used including radiofrequency or laser ablation, sclerotherapy or pharmacomechanical ablation."
1463079|NCT03250234|Other|Adequate Carbohydrate|During the 3-hr recovery period after glycogen depletion participants will consume a carbohydrate (1 g/kg/hr) beverage For the day participants will consume a diet of 6.0 g/kg/d carbohydrate following glycogen depletion
1463080|NCT03250234|Other|Low Carbohydrate|"During the 3-hr recovery period after glycogen depletion participants will consume a nutrient free beverage.
For the day participants will consume a diet of 1.2 g/kg/d carbohydrate following glycogen depletion"
1463081|NCT03250221|Device|barbed sutures|Use of the barbed sutures for robotic or laparoscopic myomectomy
1463082|NCT03250221|Device|Vicryl@ suture|Use of Vicryl@ suture for robotic or laparoscopic myomectomy
1463083|NCT03250208|Dietary Supplement|Probiotic|Participants randomized to the intervention group will receive Women's Fem Dophilus ® by Jarrow Formulas.
1463084|NCT03250208|Other|Placebo|Participants randomized to the control group will receive a placebo containing no active ingredients
1463085|NCT03250195|Diagnostic Test|PET/MRI|PET/MRI scan
1463086|NCT03250182|Drug|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations per use as instructed per the protocol.
1463087|NCT03250169|Drug|Alemtuzumab|Licensed dose
1463088|NCT03250156|Behavioral|MBAT with proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion. Participants will have proctored practice and complete the assigned, out-of-class mindfulness exercises during the duty day as party of their physical training.
1463089|NCT03250156|Behavioral|MBAT with non-proctored practice|The training program is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised four central themes: concentration, body awareness, open monitoring, and compassion.Participants will not have proctored practice and will complete the assigned, out-of-class mindfulness exercises on their own.
1463090|NCT03250143|Drug|cyclosporine vs azathioprine|Group A cyclosporine 3mg/kg/day and group B azathioprine 1mg/kg/day
1463091|NCT03250130|Behavioral|hypnosis|The patient achieve self-hypnosis sessions in these chemotherapy treatments
1463494|NCT03247114|Other|Sucralose|Sucralose, 0.33 grams in 300 ml water at room temperature
1463094|NCT03250104|Other|Infection Control|The infection control bundle will include staff training, hand hygiene programs, disinfection measures, and contact isolation. Physicians will be discouraged to prescribe proton pump inhibitors (PPIs) where not explicitly needed. The intervention bundle will be defined based on current literature. For implementation, the investigator will adapt the bundle to specific local needs, discuss with the responsible department heads and ward staff, perform training and disseminate standards of care.
1463095|NCT03250104|Other|Antibiotic Stewardship|"Antibiotic stewards will develop local standards of procedure based on the provided training and guidelines. They will then train the responsible staff and disseminate guidelines as best suited for the local work environment, e.g. as pocket cards, posters, or electronically. Point-prevalence investigations and antibiotic visits will assure adherence to guidelines."
1463096|NCT03250091|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for histopathological examination, including H.pylori detection
1463097|NCT03250091|Procedure|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination, serum biomarkers
1463098|NCT03250091|Procedure|Biopsies for gastric microbiota|During upper endoscopy biopsies for gastric microbiota analysis will be obtained
1463099|NCT03250091|Procedure|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
1463100|NCT03250078|Diagnostic Test|MRI/MRCP|An MRI/MRCP plus IV gadolinium contrast with high resolution imaging of the pancreas will be performed annually
1463101|NCT03250065|Device|Application of prototype sensor to a standard endotracheal tube|During anaesthesia the device under study, a prototype saturation sensor will be applied to a standard endotracheal tube that ventilates the patient as normal.
1463102|NCT03250052|Drug|(fimasartan or linagliptin) x 7days|Part A: fimasartan, Part B: linagliptin
1463103|NCT03250052|Drug|(fimasartan and linagliptin) x 7days|Part A & Part B: Co-administration of fimasartan and linagliptin
1995050|NCT02864992|Drug|tepotinib|Subjects receive 500 mg of tepotinib once daily in cycles of 21-day duration until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.
1463106|NCT03250026|Behavioral|Workplace convergence dialogue|Work place contact as a convergence dialogue between the employer and employee with the Rehab Coordinator as a guide
1463107|NCT03250026|Behavioral|Care Manager|Regular contact Care Manager during around 12 weeks
1463108|NCT03249987|Other|bladder diary|electronic diary to be completed for 3 days before crossover onto paper diary for 3 days
1463109|NCT03249974|Device|Enlite sensor communicating with Minimed 640G pump|Children (5 to 18 years) with type 1 diabetes mellitus treated with an insulin pump and wearing a FreeStyle Flash Libre glucosesensor will switch to the Enlite sensor communicating with Minimed 640G pump
1463113|NCT03249948|Procedure|Vector change defibrillation|Defibrillation using pad placement in anterior-posterior position.
1463114|NCT03249948|Procedure|Double-sequential defibrillation|Defibrillation using two defibrillators, one with pad placement in anterior-posterior position, and the other with pad placement in anterior-anterior position, delivering two rapid sequential shocks.
1995052|NCT02861014|Biological|Ocrelizumab|Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
1463120|NCT03249896|Behavioral|Habits-GDM mobile app|The intervention is a self-administered mobile app designed for GDM. It targets behavioural change by providing personalised GDM management program which consists of three main elements: lessons, tracking and coaching/feedback. Lessons contains 12 interactive modules which provide patient education on GDM. Each lesson will take approximately 10-20 minutes. Information on SMBG (linked to the Aina device), weight (linked to the Bluetooth weighing scale), physical activity (physical activity tracking function in the app), and food (equipped with common local food using the Singapore food database) can be tracked and displayed visually. An interactive messaging platform is used for coaching. Generic and customised automated messages are sent from a virtual lifestyle coach to encourage and motivate patients towards healthy behaviour beneficial for GDM.
1463121|NCT03249883|Device|SACH prosthetic foot, 1M10 prosthetic foot|"In the SACH first group - the amputees will wear the SACH feet for three weeks and then switch to 1M10 feet for another three weeks.
In the 1M10 first group - the amputees will wear the 1M10 feet for three weeks and then switch to SACH feet for another three weeks."
1463122|NCT03249870|Drug|Inotuzumab ozogamicin (INO)|"INO schedule of administration is as follows:
First induction course: 0.8 mg/m² on day 1, 0.5 mg/m² on day 8, and 0.5 mg/m² on day 15
Second induction course: 0.5 mg/m² on day 1, and 0.5 mg/m² on day 8"
1463190|NCT03249389|Biological|Blood sample|patients will have a blood sample of 20 ml (4 x 5ml) for inclusion, the J1 of each course and at the end of treatment
1463126|NCT03249831|Drug|Cyclophosphamide|Orally daily
1463127|NCT03249831|Drug|Pentostatin|Intravenous
1463128|NCT03249831|Drug|Rabbit anti-thymocyte globulin|Intravenous
1463129|NCT03249831|Drug|Tacrolimus|Initially IV. If patient tolerates, convert to oral.
1463130|NCT03249831|Drug|Mycophenolate mofetil|IV or oral
1463131|NCT03249831|Biological|CD4+ T-cell-depleted Haploidentical Hematopoietic Transplant|Infusion
1463132|NCT03249818|Device|HITT device|Device scans the fovea of the eye to measure fixation. Patients will then be asked to track the fixation target across an area the size of a playing card, with the device tracking the participant's fixation throughout.
1463133|NCT03249805|Device|Steenbeek Foot Abduction Brace (SFAB)|The FAB will be equipped with discretely hidden sensors; subjects and their families will not be aware of the actual function of the sensor in order to avoid increased compliance due to the sensor. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
1463134|NCT03249805|Device|MiracleFeet Foot Abduction Brace (mFAB)|Sensors in the mFAB will measure whether the shoe is on, the foot is in contact with the sole of the shoe and the shoes are clipped into the bar. Sensors work on the principle of force-sensing resistor material whose resistance changes when a force or pressure is applied. Force-sensing resistors consist of a conductive polymer, which changes resistance in a predictable manner following application of force to its surface. On the top of braces sole we have fixed force resistive sensor (FSR), which changes resistance whenever force is applied. Threshold of detection is 30-40 gram. The changes of resistance is detected by using micro-controller.
1463137|NCT03249779|Device|Scrambler|Scrambler Therapy is a specific form of electrical stimulation which has also been utilized in chronic neurogenic pain11. This modality of therapy differs from TENS in that the goal is to mediate the patient's perception of pain, rather than masking the peripheral pain signal. The results of this modality of treatment may be longer-lasting than TENS, presumably via reduction in central signal generation. Scrambler therapy works through C fibers to retrain the peripheral sensation in the area being treated. Further description of this technology is available at: International Patent PCT/IT2007/000647 and U.S. Patent No. 8,380,317. Literature search does not yield prior studies regarding efficacy of Scrambler therapy in treating RLS
1463138|NCT03249766|Other|Observational|Observational study
1463141|NCT03249740|Drug|GB-102|Intravitreal injection of GB-102
1463142|NCT03249740|Drug|Aflibercept|Intravitreal injection of Aflibercept.
1463143|NCT03249727|Diagnostic Test|IVDD for NK cell activity in whole blood|Once subject has been scheduled for a colonoscopy by the institution (2-4 weeks prior to procedure), the subject will perform a FIT at home and an NK Vue test (one sample of one mL of blood) at the institution, prior to the day of colonoscopy.
1463144|NCT03249714|Drug|Ofatumumab subcutaneous injection|Patients randomized to the ofatumumab arm will receive subcutaneous injections of ofatumumab every 4 weeks
1463145|NCT03249714|Drug|Placebo subcutaneous injection matching ofatumumab|Patients randomized to the placebo arm will receive subcutaneous injections of placebo every 4 weeks
1463146|NCT03249701|Device|Acupoint Stimulation|The intervention will be administered by transcutaneous electrical acupoint machine, the brand is Great Wall.
1463147|NCT03249701|Device|Non acupoint stimulation|The intervention will be administered by transcutaneous electrical acupoint machine, the brand is Great Wall.
1463148|NCT03249701|Device|Non stimulation|The intervention will be administered by transcutaneous electrical acupoint machine, even no truly actualized.
1463149|NCT03249688|Other|Regular health advice|Routine healthy lifestyle counseling
1463150|NCT03249688|Behavioral|Multidomain lifestyle|Nutritional guidance, exercise, cognitive training, vascular risk monitoring
1463151|NCT03249688|Dietary Supplement|Medical food|Medical food product (Fortasyn Connect)
1463152|NCT03249662|Procedure|bupivacaine 200 mg|bupivacaine 200 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
1463153|NCT03249662|Drug|bupivacaine 100 mg|bupivacaine 100 mg ketorolac 30 mg epinephrine 400 mcg add NSS to 80 ml divided to two syringes for bilateral periarticular infiltration
1463154|NCT03249649|Behavioral|Comprehensive Healthcare Needs Assessment|Questionnaire focused on existing healthcare communication, treatment and services plus community needs in those three areas.
1463155|NCT03249636|Diagnostic Test|Flow cytometric analysis|Level of expression of the markers and the correlation between the markers with each other and with the clinical presentation and impact on patients with ALL.
1463156|NCT03249623|Device|Beacon Caresystem|The core of the system is a set of physiological models including pulmonary gas exchange, acid-base chemistry, lung mechanics, and respiratory drive. The Beacon Caresystem tunes these models to the individual patient such that they describe accurately current measurements. Once tuned, the models are used by the system to simulate the effects of changing ventilator settings. The results of these simulations are then used calculate the clinical benefit of changing ventilator settings by balancing the competing goals of mechanical ventilation.
1463157|NCT03249610|Behavioral|Lifestyle intervention|Intervention Trial with Multi-Component Lifestyle Intervention for reduction of body weight and cardio-metabolic risk factors
1463158|NCT03249597|Diagnostic Test|Blood test: Glukos, SuPAR, Laktat and HBP|"Four blood tests described in the section Biospecimen Description are analyzed within the main study; Glukos, SuPAR, Laktat and HBP."
1463162|NCT03249558|Drug|Morphine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
1463163|NCT03249558|Drug|Duloxetine|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
1463164|NCT03249558|Drug|Placebo|Subjects will be randomized into one of the treatment groups and will follow the assigned medication schedule for 10 weeks. Quantitative Sensory Testing (QST) will be performed on the subjects to compare pain threshold, pain tolerance, and wind up.
1463165|NCT03249532|Device|standard hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 36.5 degrees Celsius; convection volume: not applicable
1463166|NCT03249532|Device|cool hemodialysis|hemodialysis with high-flux dialyzer; prescription of dialysate temperature: 35.5 degrees Celsius; convection volume: not applicable
1463167|NCT03249532|Device|low volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 15 L
1463168|NCT03249532|Device|high volume hemodiafiltration|hemodiafiltration; prescription of dialysate temperature: 36.5 degrees celsius prescription of convection volume: 25 L
1463169|NCT03249519|Radiation|Radiation|50.4 Gy
1463170|NCT03249519|Radiation|brachytherapy|35-40 Gy
1463171|NCT03249519|Drug|Cisplatin|weekly 40 mg/m^2 (6cycles)
1463172|NCT03249519|Other|Hyperthermia|10 times
1463173|NCT03249506|Drug|Canagliflozin|Participants who received canagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
1463174|NCT03249506|Drug|Empagliflozin|Participants who received empagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
1463175|NCT03249506|Drug|Dapagliflozin|Participants who received dapagliflozin as a part of routine clinical practice and met new user criteria, will be included in SGLT2i new user group.
1463176|NCT03249506|Drug|Dipeptidyl Peptidase-4 Inhibitor (DPP-4)|Participants who received a DPP-4 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
1463177|NCT03249506|Drug|Glucagon-Like Peptide-1 Agonist (GLP-1)|Participants who received a GLP-1 as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
1463178|NCT03249506|Drug|Thiazolidinedione (TZD)|Participants who received a TZD as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
1463179|NCT03249506|Drug|Sulfonylureas|Participants who received a sulfonylureas as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
1463180|NCT03249506|Drug|Insulin|Participants who received a insulin as a part of routine clinical practice and met new user criteria, will be included in non-SGLT2i new users group.
1463181|NCT03249493|Other|Blood sample on DBS|"We will take 5 mL of whole blood at ART initiation, 6, 12 and 24 months of follow up after ART initiation. Blood will be transferred on DBS cards.
HIV Viral Load measurements will be done and HIV Drug Resistance measurements will be performed in case of 2 consecutive VL results > 1000 cp/mL"
1463182|NCT03249480|Biological|PEG-somatropin|30IU/10 mg/3ml/kit, 0.1-0.2mg /kg/w, once per day for 26 weeks.
1463183|NCT03249454|Device|Anodal tsDCS|During Anodal tsDCS intervention the positive end of the battery will be connected to the electrode on participant's back and negative end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
1463184|NCT03249454|Device|Cathodal tsDCS|During Cathodal tsDCS intervention the negative end of the battery will be connected to the electrode on participant's back and positive end of the battery will be connected to the electrode on participant's shoulder. The battery will be turned on for 15 minutes, and the stimulation strength will be adjusted a couple of times per tolerance level.
1463185|NCT03249454|Device|Sham tsDCS|During Sham tsDCS intervention, battery will be turned off and no current will pass through the electrodes.
1463186|NCT03249441|Behavioral|Compassion-focused therapy|"Session-by-session summary of CFT:
Week 1: Understanding your relationship with food Week 2: Making sense of overeating Week 3: The Compassionate Mind/ Preparing your mind for compassion Week 4: Developing the skill of self-compassion Week 5: Why we overeat - a Compassionate approach Week 6: Understanding your current eating pattern Week 7: Motivating yourself to change Week 8: Determining what your body needs Week 9: Towards a new way of eating Week 10: Compassionate letter writing and developing a compassionate focus on eating.
__________________________________________________________________________"
1463187|NCT03249428|Device|Improved Quality of Life of low-income Canadians that smoke tobacco and other substances|Assess effectiveness, safety and tolerability of electronic-cigarettes (e-cigs) with nicotine or Nicotine Replacement Therapy (NRT) with individual counseling for tobacco cessation.
1463191|NCT03249376|Drug|Lumateperone|Lumateperone (ITI-007 60 mg)
1463194|NCT03249350|Behavioral|Standard Contingency Management (CM)|"CM utilizes behavior modification & cognitive behavioral strategies to target adolescent substance use. Protocol components are as follows: (a) The provider introduces CM to the youth and caregiver and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the youth and caregiver; (d) Concurrently, a point and level system contract is established with the family, which provides the youth with rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
1463195|NCT03249350|Behavioral|Enhanced Contingency Management (CM+)|The CM+ protocol adds the behavioral assessment and teaching system from Parent Management Training Oregon (PMTO) to standard CM to enhance parent's skill acquisition more intensely. PMTO's behavioral assessment and teaching system uses three processes to bring about changes in parenting: daily parent reports on youth behavior, anti-coercive problem-solving, and structured learning and in vivo practice of new parenting techniques.
1463196|NCT03249337|Drug|Ripasudil hydrochloride hydrate 0.4% ophthalmic solution|"the ophthalmic solution will be administered three or six per times per day in the eye designated as the Study Eye upon study enrollment"
1463197|NCT03249324|Behavioral|Positive-Gain Counseling (PGC)|Positive-gain-based health promotion interventions capitalize on the basic human desire to maintain consistency between one's words and actions for beneficial outcomes. Participants will be asked to discuss potential adverse effects of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of maintaining a physically fit body, eating a healthy diet, and regular physical activity. They will also discuss the costs and benefits as they apply to developing children. Theoretically, discussing and reviewing these perspectives will make the mothers more apt to make healthier lifestyle choices in the future. Women randomized to the positive-gains counseling (PGC) group will have PGC sessions once during each trimester and at 2 weeks, 2 months, 4 months and 6 months postpartum. PGC participants will also receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy.
1463198|NCT03249324|Other|Usual Care|Women in the usual care (UC) group will receive prenatal care in accordance with the VA/DoD Guideline for the Management of Pregnancy. This entails regular clinic visits, routine blood and urine screening tests, and anticipatory guidance. Routine well-child care appointments will take place at 2-3 days, 2 weeks, 2 months, 4 months, 6 months, 9 months and 12 months after birth. During routine well-child visits, height, weight, and vital signs are measured, developmental milestones are reviewed, and a thorough physical examination is performed. Age-appropriate immunizations are provided as is parental anticipatory guidance, including the importance of breastfeeding. Participants enrolled in the UC group will receive anticipatory guidance from their primary care provider in the usual fashion. Providers will deliver this anticipatory guidance with no external cues or counseling provided by the research team.
1463199|NCT03249311|Drug|Levomilnacipran|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
1463200|NCT03249311|Drug|Duloxetine|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
1463201|NCT03249311|Drug|Placebos|Escalating doses of 40 to 120mg/day every 7 days (+/- 1 day) throughout a 20-26 day period.
1463202|NCT03249298|Drug|Sterofundin (Bolus of crystalloids)|Bolus of 250 ml crystaloids infused regarding the measures
1463203|NCT03249298|Drug|Voluven (Bolus of colloids)|Bolus of 250 ml colloids infused regarding the measures
1463204|NCT03249285|Drug|Peri|Perindopril 4 mg /day, orally with titration to 8 mg/day after 1 month if BP (Blood pressure) is not controlled
1463205|NCT03249285|Drug|HCTZ|Hydrochlorothiazide 12, 5 mg day, orally with titration to 25 mg/day after 1 month if BP is not controlled
1463206|NCT03249272|Drug|Regadenoson|The coronary flow reserve measured by CMR that is induced by regadenoson versus adenosine will be compared.
1463207|NCT03249272|Drug|Adenosine|The coronary flow reserve measured by CMR that is induced by regadenoson versus adenosine will be compared.
1463210|NCT03249246|Other|No intervention|
1463211|NCT03249233|Device|ZenLens™|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
1463212|NCT03249233|Device|Zen™ RC|The Zen™ RC semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
1463213|NCT03249220|Device|Placement of the CBMS Probe|Patients will be treated according to standard care in place at the investigation site, when intra-ventricular drainage is needed. Patients will receive the new multifunctional device (CBMS Probe) instead of the single function device generally used. Drainage will be performed by routine standards. Temperature, intracranial pressure and cerebral blood flow will be recorded. Treatment decision will be made by the neurointensive care specialist based on standard care.
1463214|NCT03249207|Drug|IL-1Ra|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
1463215|NCT03249207|Drug|IL-1Ra Placebo|Doses to be administered subcutaneously (SC) twice daily (12 hourly) starting within 72 hours of ictus (onset of symptoms) for a maximum of 21 days from ictus (or sooner if discharged from neurosurgical centre).
1463216|NCT03249194|Drug|Direct acting Anti-Viral Therapy using Epclusa or Zepatier|All patients will receive one 'on-call' dose of SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) immediately prior to transplant and one dose on post-operative Day 1 post-transplant. Patients who develop detectable HCV viremia will be initiated on Direct Acting Anti-viral (DAA) therapy between 2-4 weeks post-transplant. Patients with GT1 will be treated with ELBASVIR/GRAZOPREVIR (Zepatier, Merck) and those with GT2 or 3 will be treated with SOFOSBUVIR/VELPATASVIR (Epclusa, Gilead) based upon donor genotyping results
1463217|NCT03249181|Drug|Dolutegravir|Patients randomized to the study drug will be commenced on an antiretroviral regimen comprising DTG 50mg once daily in combination with 2 NRTIs
1463495|NCT03247101|Drug|Miyarisan-BM (Clostridium Butyricum Miyairi)|40mg po tid x 6months
1463218|NCT03249181|Drug|Standard of Care (EFV + 2 NRTI backbone)|Patients randomized to receive standard of care will receive the currently used antiretroviral regimens in keeping with national policy.
1463219|NCT03249168|Drug|Duloxetine 60mg|tablet
1463220|NCT03249168|Drug|Placebo|Tablet
1463221|NCT03249155|Behavioral|AO - plus sonification|patients re-learn 8 motor gestures watching video-clips showing an actor performing the same gestures, and then tried to repeat the gesture. Each video-clip is composed by images and sounds of the gestures. The sound of gestures is obtained with the sonification technique, by transforming kinematic data (velocity) recorded during the execution of gesture, into pitch variations (for an example see: bit.ly/sonif_example)
1463222|NCT03249155|Behavioral|CUE - visual and auditory|patients re-learned 8 motor gestures practicing a traditional protocol combining visual and auditory cues
1463227|NCT03249103|Drug|NYX-2925|NYX-2925 is a new molecular entity that modulates the N-methyl-D-aspartate receptor (NMDAR).
1463228|NCT03249103|Drug|Placebo oral capsule|Matching placebo capsules.
1463232|NCT03249077|Behavioral|Medicare DPP|The online DPP program and all in-person programs KPNW will include in this effort will be certified by the CDC Diabetes Prevention Recognition Program (https://nccd.cdc.gov/DDT_DPRP/Registry.aspx?STATE=OR), which means the program offers the CDC-approved National DPP curriculum. Programs are 12 months with 16 core sessions delivered over 16-26 weeks and 6 maintenance sessions delivered over 6 months.
1463233|NCT03249064|Diagnostic Test|CD 91 levels|
1463234|NCT03249064|Diagnostic Test|Tregs|
1463235|NCT03249051|Other|Indirect Calorimetry|Energy need is being determined using indirect Calorimetry
1463236|NCT03249038|Other|Measurement of external blood loss|
1463237|NCT03249038|Diagnostic Test|Serum Hemoglobin concentration|
1463238|NCT03249025|Drug|Lidocaine|Initial dose of 5.0 mg/kg (based on actual weight, up to maximum dose 600 mg) over 45-60 minutes, followed by increases of 0.5 mg/kg each infusion based on tolerability of side effects, to a maximum total dose of 600 mg. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
1463239|NCT03249025|Drug|Ketamine|initial dose of 0.25 mg/kg (based on actual weight) over 45-60 minutes (rounded to nearest 5 mg), increased by 10mg each infusion based on tolerability of side effects. The initial and subsequent dose may be increased or decreased by 20% based on patient comorbidities, age and previous experience
1463240|NCT03249012|Other|Empiric use of Calcium Carbonate and Calcitriol|Empiric calcium carbonate and calcitriol repletion
1463241|NCT03249012|Other|PTH based Calcium Carbonate and Calcitriol repletion|PTH based treatment
1463243|NCT03248986|Other|Dry needling|Dry needling of the spastic muscles of the affected arm through DNHS®.
1463244|NCT03248973|Drug|Ampicillin Injection|Ampicillin injection 2 g q4h for 3 weeks
1463245|NCT03248960|Diagnostic Test|iTreat Flu A+B Test|The iTreat Flu A+B Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal swab samples. The iTreat Flu A+B Test is designed to be simple to use and generates a result within 15 minutes.
1463246|NCT03248960|Diagnostic Test|ellume.lab Flu A+B Test|The ellume.lab Flu A+B Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasal swab samples. The ellume.lab Flu A+B Test generates a result within 10 minutes.
1463275|NCT03248752|Behavioral|Fitbit use and reports|Participants in experimental conditions (Group 1,2,3) will receive a Fitbit device to be used for the duration of the study. Groups will differ based on which parties have access to weekly Fitbit progress reports. Group 4 will not receive a Fitbit device to wear.
1463597|NCT03246308|Radiation|Phototherapy|Taking blood sample.
1463247|NCT03248960|Diagnostic Test|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
1463248|NCT03248960|Diagnostic Test|Viral culture|Nasopharyngeal samples will be inoculated into appropriate culture media for influenza viral culture. In this test, the virus is actually grown and further identified in the laboratory as influenza A or B.
1463251|NCT03248934|Other|Patient Self-Administered Diagnostic Exam|Participants will complete a patient self-administered diagnostic exam. A physician will be available to monitor the patient and record findings but will not physically assist the participants.
1463252|NCT03248934|Other|Clinician-Performed Diagnostic Exam|A clinician-performed diagnostic exam will be completed on the patients.
1463253|NCT03248921|Procedure|cardiac surgery|cardiac surgery including non-emergency, elective coronary artery bypass grafting surgery with or without valve surgery, aortic or mitral valve surgery
1463256|NCT03248895|Device|Mobile Direct Observation of Therapy (MDOT)|Patients who are enrolled in the study will be randomised into two groups (I-med or D-med) to receive Mobile Direct Observation of Therapy (MDOT). Participants or parents/guardians of participants will be asked to capture a DOT video twice daily (morning and evening) on their mobile devices of ICS use by the patient. In the I-med group, participants will be asked to upload daily video recordings via the internet to a repository for a 6 week period at the start of the study. Participants in the D-med group will be free from DOT for the first 6 weeks of the study and will be asked to carry out their usual therapy management. After that, DOT as described above will be applied for the next 6 weeks.
1463259|NCT03248869|Other|Current Daily Survey|need description
1463260|NCT03248869|Other|Mobile Health App|Participants recruited, consented and enrolled via the AMHA and complete assessments using the app
1463261|NCT03248856|Drug|Triamcinolone Acetonide|Intratympanic administration
1463262|NCT03248843|Drug|KN035|Four cohorts dosed at 1.0 mg/kg, 2.5 mg/kg, 5.0 mg/kg, and 10 mg/kg weekly. All cohorts are administered by subcutaneous injection (SC).
1463263|NCT03248830|Device|radical-7 pulse co-oximeter|Radical-7 pulse co-oximter will be applied to the patient through a special probe attached the the patient digit to measure blood hemoglobin
1463264|NCT03248817|Drug|single shot phenylephrine|a single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously
1463265|NCT03248817|Drug|fixed infusion phenylephrine|fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min.
1463266|NCT03248817|Drug|variable infusion phenylephrine|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
1463267|NCT03248817|Drug|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia
1463270|NCT03248791|Drug|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
1463271|NCT03248791|Drug|Norepinephrine|Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
1463272|NCT03248791|Drug|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg
1463273|NCT03248778|Behavioral|disclosure-support counseling intervention|The intervention will include three components: (a) assessment; (b) decision-making and support; and (c) disclosure, planning, and action. The individualized assessment comprehensively will consider the family's history, experiences with disclosure, communication skills, coping resources, and factors likely to affect disclosure (e.g., familial, psychological, social, cultural, and medical issues). The second component of decision-making and support focused on developing communication skills and strategies, with role-play and practice outside of the sessions as necessary. Costs and benefits of disclosure were considered along with the range of disclosure options. Materials, including a pros and cons chart of disclosure and a disclosure continuum worksheet, were used to stimulate discussions of possible plans and consequences. In the third component, parents were encouraged to formulate and practice a disclosure plan for later use.
1463274|NCT03248765|Other|post-surgical opioid use measured at 1 day and 1 week.|"Evaluation of intra-hospital perioperative opioid administration (including intraoperative opioids and Patient Controlled Analgesia (PCA) use). This endpoint is calculated as the total amount of morphine equivalents administered intraoperatively and in the first 24 hours after the end surgery (measured on postoperative day 1).
2) Opioid utilization after discharge from hospital (prescription refills and pills count at subsequent hospital visits). This endpoint is calculated as the total amount of morphine equivalents consumed in the first week after the surgery (measured at 1 week after surgery by electronic questionnaire and verified by direct pill count performed on occasion of the patient's postsurgical visit )."
1463276|NCT03248739|Device|Clear Bactiseal 'large' catheter (EVD)|Antibiotic-impregnated 'large' catheter (inner diameter 1.9 mm, outer diameter 3.4 mm)
1463277|NCT03248739|Device|Orange Bactiseal 'small' catheter (EVD)|Antibiotic-impregnated 'small' catheter (inner diameter 1.5 mm, outer diameter 3 mm)
1463278|NCT03248726|Drug|Polyethylene glycol and bisacodyl|Intervention: Take 3 tablets (15mg) of stimulant laxatives Dulcolax® (bisacodyl) at 10pm the day before examination. Take two pack of osmotic laxative Klean-prep® powder (Polyethylene glycol) mixed with 2000ml water at 5am on the morning of examination.
1463279|NCT03248726|Drug|Split-dose polyethylene glycol|Take two pack of Klean-prep® powder mixed with 2000ml water at 6pm before the day of examination, and take another two pack of osmotic laxative Klean-prep® powder mixed with 2000ml water at 5am on the examination day.
1463280|NCT03248713|Drug|Mifepristone|Mifepristone 600mg 2 tablets will be compared to the placebo
1463281|NCT03248713|Drug|Placebo|Placebo sugar 2 tablets will be compared to mifepristone
1463282|NCT03248700|Other|Vitamin A tracer|A stable isotope tracer of vitamin A was given orally.
1463283|NCT03248687|Other|Follow up|The intervention will be method of follow up.
1463284|NCT03248674|Diagnostic Test|CT FFR (HeartFlow)|CT FFR calculated the fractional flow reserve based on the data derived for a regular coronary CT angiography. Computation is based on development of an anatomic model of the epicardial coronary arteries for each case and calculating the maximum coronary flow during maximal hyperaemia based on a mathematical model incorporating fluid dynamics. These post-processing steps require quantification of the patient-specific myocardial mass as this allows for an estimation of the baseline coronary blood flow.
1463286|NCT03248648|Drug|Neostigmine|patient receive 0.5mg/dose neostigmine +18ml 0.25%bupivacaine in a total volume of 20 ml.
1463287|NCT03248648|Drug|ketamine|patient receive 0.5 mg/kg ketamine+18ml 0.25%bupivacaine in a total volume of 20 ml.
1463288|NCT03248609|Other|Milano grapes|Milano grapes to test post-prandial glycemic response
1463289|NCT03248609|Other|Table grapes|Table grapes to test post-prandial glycemic response
1463290|NCT03248609|Other|Grape juice|Grape juice to test post-prandial glycemic response
1463291|NCT03248609|Other|Glucose beverage|Standardized glucose beverage to test post-prandial glycemic response
1463292|NCT03248583|Other|Default option|"The default option is a behavioral economics construct that refers to the option a consumer selects if no active choice is made (e.g. opt-out 401K plans, which significantly increase enrollment, compared to active sign up).
Participants in the default condition were presented with a pre-filled online shopping cart containing a combination of groceries that meet macro- and micronutrient requirements for their gender and age, and told that they are free to delete, add, and exchange any item they wish to finalize their selections."
1463293|NCT03248583|Other|Psychoeducation|"Participants in the psychoeducation condition were instructed to read a brief psychoeducational brochure adapted from materials currently utilized by the New York State Office of Temporary and Disability Assistance (Eat Smart New York)."
1463294|NCT03248583|Other|Incentive|Participants in the incentive condition were informed that they will receive a gift card to a major retailer of their choice if they select groceries that meet recommended nutritional guidelines for macro- and micronutrient requirements. Participants were given examples of macro- and micronutrients to ensure that the instructions were clear.
1463297|NCT03248557|Diagnostic Test|Spectral analysis of ventricular fibrillation tracings|Up to 5-s long ventricular fibrillation segments will be extracted after segmentation and signal codification from artifact-free tracings. Signals will be band-pass filtered between 1.5 and 40 Hz. Averaged power spectral density will be obtained at each frequency using the non-parametric Welch method for using fast Fourier transform and normalized to the peak power in the 1.5-10 Hz band for each patient. Dominant frequency, HL-PSDR (the relative power between high and low frequency bands (cut-off: 3.9 Hz)) and HL-pKR ( relative number of spectral peaks above and below the 3.9 Hz threshold with power above 40% the frequency with the highest power), along with the number of DC shocks before ROSC, will be the variables used to obtain a model-derived risk score for outcome prediction.
1948107|NCT02772731|Procedure|Partial mastectomy plus additional Shave Margin|"For the shave group, additional superior, inferior, medial and lateral margins will be removed, oriented, and sent for pathologic evaluation at the local site. Resection of additional anterior and posterior margins will be left to surgeon discretion, as this will depend on if skin or fascia was taken. All surgeons participating in the study will be educated on the expectation of what is considered a shave margin. A shave margin is defined as an additional segment of breast tissue taken from each of the superior, inferior, medial, and lateral aspects of the cavity, such that the entire circumference of the cavity is re-excised following this procedure. Orientation of each shaved margin will be done to mark the true margin."
1463306|NCT03248505|Device|Conventional TENS|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) with two electrodes in each side of the lumbar spinal.
1463307|NCT03248505|Device|Burst TENS|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude.
1463308|NCT03248505|Other|Cryotherapy|1,5 Kg of crushed ice pack on lumbar spine.
1463309|NCT03248505|Device|Burst TENS + Cryotherapy|Burst-modulated TENS with carrier frequency of 100 Hz, burst-modulated at 4Hz, pulse duration of 200 micro-seconds and motor-level amplitude plus 1,5 Kg of crushed ice pack on lumbar spine.
1463310|NCT03248505|Device|Conventional TENS + Cryotherapy|Transcutaneous Electrical Nerve Stimulation (frequency of 100 Hz, pulse duration of 100 micro-seconds and sensory-level amplitude) plus s 1,5 Kg of crushed ice pack on lumbar spine.
1463311|NCT03248505|Other|Placebo TENS|TENS device turned on, but with zero amplitude.
1948108|NCT02772731|Procedure|Partial mastectomy|Surgeons will be instructed to close after partial mastectomy with no further excision.
1463313|NCT03248479|Drug|Hu5F9-G4|Hu5F9-G4 will be administered up to twice weekly.
1463314|NCT03248479|Drug|Azacitidine|Azacitidine will be administered daily for 7 days in each 28-day cycle.
1463315|NCT03248466|Biological|PRG combined with BMMSCs transplantation|PRG combined with BMMSCs transplantation
1463316|NCT03248453|Other|CoPS|The COPS is an automated and objective computer-based program which generate a score/number after the colonoscope has reached the cecum. The participants are able to compare the score with experts.
1463317|NCT03248440|Drug|SUN-131 1.5% TDS|SUN-131 1.5% TDS will be worn for 14 days
1463318|NCT03248440|Drug|Placebo TDS|No active substance; Placebo TDS will be worn each day for 14 days
1948109|NCT02772458|Other|Dodecanoate acid and saline|Test drink
1463327|NCT03248388|Device|Argus II Eyeglasses|The Argus II Eyeglasses (retinal prosthesis) can restore rudimentary forms of vision to patients with bare light-perception vision. Using the prosthesis, patients can identify obstacles, handles, switches, eating utensils and demonstrate improved navigation when used in conjunction with other ambulation-assist tools. Current limits in the resolution of the device prevent useful reading or face recognition.
1463328|NCT03248388|Device|ORCAM|ORCAM is a commercially-available eyeglass-mounted visual pattern recognition system capable of converting photographs of text to speech. It is comprised of a camera, a small belt-worn computer, pattern recognition software and a small audio transducer. ORCAM can acquire the image of a sheet of paper and read the text to the user through a small speaker adjacent to the ear. In addition, ORCAM can be trained to recognize faces and speak the name of the individual to the user. ORCAM can also be used to recognize everyday products after being programmed.
1463329|NCT03248375|Radiation|Radiation Segmentectomy|The administration of radioactivity in a branch of an artery of the liver
1463330|NCT03248362|Device|Transcutaneous posterior tibial nerve stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of tibial nerve stimulation
1463331|NCT03248362|Device|Sham stimulation|12 session programme (a total of 6 hours) is delivered in 30 minute sessions twice weekly over a 6 week period of of the lateral sub-malleolar area
1463332|NCT03248349|Drug|Pharmacokinetics|"Blood samples are drawn for pharmacokinetic properties of antibiotics during routine care treatment
Blood samples for relevant covariates of drug disposition (kidney function, liver enzymes, C-reactive protein (CRP), albumin)
Whole blood is stored for DNA analysis
Urine is drawn from catheter for more detailed estimation of glomerular filtration rate and drug metabolite analysis"
1463333|NCT03248336|Procedure|office-based vergence/accommodative therapy|one -to-one treatment by a trained therapists. The subject is asked to perform 5-6 therapy procedures during a 60 minute therapy session. The subject is also asked to perform 15 minutes per day of home-based therapy.
1463334|NCT03248323|Radiation|dyna-pbv|
1463336|NCT03248297|Drug|Azithromycin|Azithromycin tablet
1463337|NCT03248297|Drug|Azithromycin and amoxicillin|azithromycin and amoxicillin
1463338|NCT03248297|Drug|Placebo|Placebo tablet
1463339|NCT03248284|Procedure|Tendon biopsy procedure|Two tendon biopsy specimens will be obtained from one Achilles tendon with enthesitis.
1463340|NCT03248271|Drug|Insulin Lispro|Insulin
1463341|NCT03248258|Other|Qualitative Interview and Focus group discussions|The purpose of this study is to identify factors that influence decision-making in treatment selection and the optimal approach for sharing information about prognosis and guideline-based care.
1463342|NCT03248245|Other|LOG-model|"Besides the LOG-manual, school owners and leaders receive economic compensation and the intervention team will supervise the implementation. School-owners, school leaders and teachers will participate in dialogue-seminars at the municipal level and the school level respectively. The aim is to discuss and agree on the goal and content of the work and discuss the experiences from the implementation. The main arena for discussing and practical implementation will be in local collaborating teams or resource teams in each school. The resource teams at schools will consist of various interprofessional competences in addition to the school leader. The main method in the LOG-model is the interchange and feedback process between the discussion of measures and the execution of these measures."
1463343|NCT03248245|Other|TAU|Ordinary practices related to interprofessional team collaboration
1463344|NCT03248206|Behavioral|lifestyle changes|Providing a home-based exercise program supervised by therapists can be an acceptable strategy with the characteristics of convenience and inexpensiveness to promote neuromuscular and functional component for the patients with diabetes mellitus.
1463417|NCT03247647|Behavioral|Enhanced Intervention|Participants will complete a personal values task immediately before viewing feedback from eCheckUpToGo.
1463345|NCT03248193|Device|Concomitant limb cryocompression and scalp cooling|"Part 1: Establishing optimal temperature for hypothermia therapy. Healthy subjects will undergo 3 hours of cryocompression various temperature levels.
Part 2: Establishing optimal pressure for hypothermia therapy. Each subject will undergo cryocompression (fixed at the lowest tolerated temperature established in Section 1) over 3 hours. The pressure ranges to be tested are either low, medium, or high.
Part 3: Establishing safety and tolerability of scalp hypothermia. Scalp hypothermia will be administered over 3 hours using the cooling cap attached to the cooling device.
Part 4: Establishing safety and tolerability of concomitant therapy. Subjects will undergo simultaneous scalp hypothermia and four-limb cryocompression at the temperature and pressure established in Sections 1 and 2. The concomitant therapy will be administered over 3 hours."
1463346|NCT03248193|Device|Concomitant limb cryocompression and scalp cooling|"The study population will comprise of cancer patients scheduled to receive weekly paclitaxel chemotherapy for a maximum of 12 cycles.
Paclitaxel will be administered as a one-hour infusion. Concomitant scalp cooling and limb cryocompression sessions comprised of a pre-cooling period (one hour), continued with paclitaxel infusion and a post-cooling period (on average 30 minutes after the end of paclitaxel infusion). Overall, hypothermia will be administered for no longer than four hours.
Cryocompression will be administered on patients based on the lowest tolerated temperature and optimal pressure as determined in healthy subjects."
1463347|NCT03248167|Drug|Cannabidiol|400 mg daily
1463348|NCT03248167|Drug|Placebos|This project aims to determine whether cannabidiol (CBD) is effective in treating alcohol use disorder (AUD) comorbid posttraumatic stress disorder (PTSD). To address this aim, investigators will conduct a clinical trial in which CBD will be adminstred to fifty individuals with AUD comorbid with PTSD, and assess alcohol intake and PTSD symptoms. The aim is to test the hypothesis that CBD will reduce alcohol drinking in individuals with AUD comorbid with PTSD. To test this hypothesis, 50 otherwise healthy adult participants with moderate or severe AUD and PTSD will be randomized to treatment with either CBD (400 mg daily) or placebo, for a period of 6 weeks, such that both participants and study staff are blind to treatment condition.
1463349|NCT03248154|Device|Procellera|burn dressing
1463356|NCT03248115|Dietary Supplement|Green tea and green coffee extract tablets|"Tablets: participants were required to take 6 green tea and 3 green coffee extract tablets daily for a period of 8 weeks. No tablets were taken during the last 4 weeks of the study. Randomly chosen tablets were analysed to quantify their polyphenol content.
Urine collections: Several urine collections were required during the supplementation period in order have sufficient time points to estimate the plateau of the concentration of green tea and coffee polyphenols excreted in the urine to then be able to determine their bioavailability. There was a total of five 24-hour urine collections (at week 0 -before supplementation-, 2, 4, 8, and 12 -4 weeks after finishing the supplementation period).
Completion of study documents: Participants were provided with urine collection sheets, polyphenol questionnaires, checklists to record polyphenol tablet intake, and detailed instructions."
1463357|NCT03248102|Diagnostic Test|Blowing into the mouthpiece|Blowing into the mouthpiece of diagnostic device
1463358|NCT03248089|Diagnostic Test|Guardant360|Cell-free circulating tumor DNA (cfDNA) targeted next-generation sequencing (NGS) panel.
1463359|NCT03248076|Drug|Fentanyl Citrate|1γ/Kg fentanyl
1463360|NCT03248063|Drug|Cloxacillin|"Intravenous treatment by cloxacillin, 25 to 50 mg/kg every 6 hours (without exceeding the maximum daily dose of 12 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route.
Dosing regimen will be adapted in case of glomerular filtration rate between 30-60ml/min AND hepatic dysfunction according to SPC."
1463361|NCT03248063|Drug|Cefazolin|Intravenous treatment by cefazolin, 25 to 50 mg/kg every 8 hours (without exceeding the maximum daily dose of 6 g/day), administered as a 30-minutes infusion. This treatment will be administered for 14 days by intravenous route. Dosing regimen will be adapted in case of glomerular filtration rate between 30-50ml/min according to SPC.
1463362|NCT03248050|Behavioral|Pharmacy encouraged to promote call centre use to clients|The details of the intervention will be finalised following an intervention design workshop. The main components will be: Provision of materials with the MSZ call centre number on for pharmacy workers to give women buying MA medications to call the number for free, confidential advice on how to use the pills before they take them; incentives; monthly monitoring visits.
1463363|NCT03248037|Drug|Netarsudil|netarsudil opthalmic solution 0.02%
1463364|NCT03248037|Drug|Placebo|Placebo eye drops
1463368|NCT03247998|Drug|General Anesthesia|Patients who have had a stroke and meet the inclusion criteria for the study will receive general anesthesia during endovascular treatment. Choice of anesthetic for general anesthesia is dependent upon the patient condition and decision of the treating anesthesiologist (ketamine, propofol, fentanyl, midazolam,dexmedetomidine etc.). Induction of general anesthesia will follow standard treatment methods (Davis et al, 2012, Powers et al. 2015 Talke et al. 2015). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
1463369|NCT03247998|Drug|Conscious Sedation with Remifentanil|Patients who have had a stroke and meet the inclusion criteria for the study will receive conscious during endovascular treatment. Sedation will be accomplished using Remifentanil: 0.01-0.06 micrograms/kilogram/minute, titrated to effect. (Janssen et al., 2016). Patient monitoring and care will proceed in accordance with standard of care guidelines. Refer to Detailed Description section for complete protocol information.
1463418|NCT03247647|Behavioral|Standard Intervention|Participants will write about the food they have eaten in the last 48 hours.
1463372|NCT03247972|Drug|Evolocumab|Sixty subjects will be treated with high dose statins for 8 weeks followed by 8 weeks of high dose statin + evolocumab (420mg/4 wk) therapy.
1463373|NCT03247959|Behavioral|Video game distraction and video distraction|video game distraction and video distraction will be advocated during the extraction procedure
1463374|NCT03247946|Behavioral|upright head position|Bottle feeding of infants with their head in upward and not supine head position
1463375|NCT03247933|Device|Telemedicine: Maintenance Respiratory Rehabilitation|"Telemedicine: Maintenance Respiratory Rehabilitation. Patients will receive a personal program of maintenance respiratory rehabilitation supported by telemedicine (TeleRR).
A personal program of Respiratory rehabilitation consists on: 20-30 minutes of static bicycle exercises + 3 series of ten repetitions from 4 different types of exercises with weights / cufflinks. 3 days a week, every week for a year.
They will be in their homes doing the program of treatment prescribed by the physician. They will be provided with the material that is needed: 1 static bicycle, 2-weights / cufflinks, 3-device mobile (smartphone/PDA) + Pulse Oximeter.
The patient must send the exercises every day that are scheduled training exercises once have been completed."
1463376|NCT03247920|Drug|Amoxicillin Clavulanate|Dose 75 mg/kg/day, (3dd 25 mg/kg). Concentration amoxicillin/clavulanic acid: 4:1
1463377|NCT03247920|Drug|Antibiotics|Intravenous antibiotic therapy following local protocol
1463378|NCT03247907|Device|Condition A: CPAP with No Humidification|CPAP with No Humidification with no mouth leak
1463379|NCT03247907|Device|Condition B: CPAP with No Humidification|CPAP with No Humidification with mouth leak
1463380|NCT03247907|Device|Condition C: CPAP with Cold Passover|CPAP with Cold Passover with mouth leak
1463381|NCT03247907|Device|Condition D: CPAP with Modified humidifier|CPAP with Modified humidifier with mouth leak
1463382|NCT03247907|Device|Condition E: CPAP with Ambient Tracking|CPAP with Ambient Tracking with mouth leak
1463383|NCT03247907|Device|Condition F: CPAP with Heated Humidification|CPAP with Heated Humidification at default setting with mouth leak
1463384|NCT03247907|Device|Condition G: CPAP with Heated Humidification|CPAP with Heated Humidification at max setting with mouth leak
1463385|NCT03247907|Device|Condition H: CPAP with New level humidification|CPAP with New level humidification with mouth leak
1463386|NCT03247894|Other|Data search|Patients data were searched for the patients with MS, who laboured in tertiary perinatology center in the study period
1463387|NCT03247881|Other|Nut Free Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet with 0 g/d of mixed nuts.
1463388|NCT03247881|Other|Added Mixed Nuts Diet|Participants will consume whatever they like, as much as they like, from a pre-determined buffet which will include 2 servings (2 ounces) of mixed nuts per day (1 serving just prior to breakfast and 1 serving as an afternoon snack).
1463389|NCT03247868|Combination Product|Botulinum Toxin+SPRInt|Botulinum toxin injections in association with rehabilitative approach to cervical dystonia (SPRInt)
1463390|NCT03247855|Procedure|minimal invasive coronary artery bypass graft surgery|coronary artery bypass grafting surgery by using a minimal invasive technique
1463391|NCT03247842|Procedure|suprascapular nerve block|Sixty patients with shoulder dystocia after breast surgery will receive stellate ganglion neurolysis with supra-scapular nerve radiofrequency,
1463393|NCT03247803|Device|air-Q® SP|air-Q SP placement for airway maintenance,
1463394|NCT03247803|Device|Williams Airway Intubator (WA)|WA is placed in subject's oropharynx. If the vocal cords are not in view at the end of the WA, the operator may ask an assistant to perform an airway maneuver (e.g., jaw thrust, anterior jaw lift, or lingual traction) to attempt to bring the vocal cords into view
1463396|NCT03247777|Other|Traditional strengthening|dead lifts, bench press, wrist curls, and lat pulldowns as examples
1463397|NCT03247777|Other|Functional Strengthening|diagonal chops, one leg deadlifts, lateral plyometrics as examples
1463398|NCT03247764|Drug|SSRIs or xylaria nigripes|Patients with comorbidity of epilepsy and depression will be used SSRIs or xylaria nigripes as antidepressants after discussing with them. They will still be followed up if they don't want to use any antidepressants.
1463399|NCT03247751|Device|intraocular lens|Implant NIDEK intraocular lens after cataract surgery
1463407|NCT03247699|Other|"Basel phenotyping cocktail capsule"|"Oral intake of Basel phenotyping cocktail capsule and pharmacokinetics (PK) sampling"
1463408|NCT03247699|Other|"Basel phenotyping cocktail individual components"|"Oral intake of Basel phenotyping cocktail individual components and PK sampling"
1463409|NCT03247686|Drug|RSLV-132|RNase Fc fusion protein
1463410|NCT03247686|Drug|Placebo|Placebo
1463411|NCT03247673|Drug|CT-P16|CT-P16 is a biosimilar product for Avastin
1463412|NCT03247673|Drug|EU-approved Avastin|EU-approved Avastin
1463413|NCT03247673|Drug|US-licensed Avastin|EU-approved Avastin
1463414|NCT03247660|Other|PFM training|See information included in arm/group descriptions.
1463415|NCT03247660|Other|HE|See information included in arm/group descriptions.
1463416|NCT03247660|Behavioral|Educational strategy|See information included in arm/group descriptions.
1463419|NCT03247634|Behavioral|Getting Ahead in a Just-Gettin'-By World|The Getting Ahead program is a unique welldeveloped program that allows carefully guided introspection toward the crafting of tailored solutions aimed at addressing complex social determinants of health among individuals living in vulnerable populations where the achievement of health equity often seems unattainable. The important lens of health equity is a key component of this proposal and is consistent with the American Cancer Society overarching emphasis on reduction of health disparities and achievement of health equity.
1463420|NCT03247621|Behavioral|Whatsapp|
1463421|NCT03247621|Behavioral|Article|
1463422|NCT03247621|Behavioral|No Phone|
1463423|NCT03247608|Behavioral|Ambio Health Remote Monitoring|Participants in the Connected Heart Health study will complete a 24 week CarePlan including education, biometric monitoring, and communication with the health care team members. Each day the participant will receive an email from Ambio Health with a daily task list that includes a variety of activities. These tasks include uploading biometrics (weight and blood pressure), completing assessment on self-management skills (nutrition, physical activity, and medication management), accessing educational content (videos, web links, interactive quizzes), participation in challenges, and communicating with the care team and care givers.
1463424|NCT03247595|Dietary Supplement|Magnesium Citrate Capsules|36 magnesium citrate gelatin capsules
1463425|NCT03247595|Other|Polyethylene Glycol 3350|4 liters of Polyethylene Glycol for colonoscopy preparation
1463426|NCT03247595|Other|Dulcolax Tablets|4 Dulcolox Tablets
1463429|NCT03247556|Drug|Placebo|Placebo will be administered once daily
1463430|NCT03247556|Drug|SPN-812 ER High Dose A|SPN-812 ER high dose A will be administered once daily and compared to Placebo
1463431|NCT03247556|Drug|SPN-812 ER High Dose B|SPN-812 ER high dose B will be administered once daily and compared to Placebo
1463432|NCT03247543|Drug|Placebo|Placebo will be administered once daily
1463433|NCT03247543|Drug|SPN-812 ER High Dose A|SPN-812 ER high dose A will be administered once daily and compared to placebo
1463434|NCT03247543|Drug|SPN-812 ER High Dose B|SPN-812 ER high dose B will be administered once daily and compared to placebo
1463435|NCT03247530|Drug|Placebo|Placebo will be administered once daily
1463436|NCT03247530|Drug|SPN-812 ER Low Dose A|SPN-812 ER low dose A will be administered once daily and compared to placebo
1463437|NCT03247530|Drug|SPN-812 ER Low Dose B|SPN-812 ER low dose B will be administered once daily and compared to placebo
1463438|NCT03247517|Drug|Placebo|Placebo will be administered once daily
1463439|NCT03247517|Drug|SPN-812 ER Low Dose A|SPN-812 low dose A will be administered once daily and compared to placebo
1463440|NCT03247517|Drug|SPN-812 ER Low Dose B|SPN-812 low dose B will be administered once daily and compared to placebo
1463441|NCT03247491|Behavioral|Mindfulness|TAU + mindfulness applied face to face 8 sessions of 120 minutes/session Mindfulness and Compassion based intervention applied in groups of 12-15 people in traditional format. Written material and sound recordings will be offered as support elements. The estimated duration of the face to face program is two months.
1463442|NCT03247465|Other|Image Fusion|Addition of computed tomography 3D images and calcification raising to the usual fluoroscopy images.
1463443|NCT03247452|Other|One-day Low fiber diet|One-day low fiber diet before colonoscopy
1463444|NCT03247452|Other|Three-day low fiber diet|Three days low fiber diet before colonoscopy
1463445|NCT03247452|Drug|Polyethylene Glycol plus ascorbic acid|2 liters of Polyethylene Glycol plus ascorbic acid will be administered to both groups
1463447|NCT03247426|Other|Evaluation individuals|Sleep quality of the individuals, job satisfaction, quality of life, occupational burnout level will be evaluated.
1463448|NCT03247413|Drug|Dexamethasone 4 mg/ml|dexamethasone 4 milligram given post-ablation at each lesion site
1463449|NCT03247413|Drug|Normal saline|Placebo, normal saline administered post-ablation at each lesion site
1463450|NCT03247400|Drug|1% simvastatin-acid sodium salt ointment|1% simvastatin-acid sodium salt ointment applied onto a predefined limb
1463451|NCT03247400|Drug|1% atorvastatin calcium salt ointment|1% atorvastatin calcium salt ointment applied onto a predefined limb
1463452|NCT03247387|Device|MC10 BioStampRC|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
1463453|NCT03247387|Device|APDM actigraphy device|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
1463454|NCT03247387|Device|GENEActiv watch|"Subjects will fill out electronic diaries on a provisioned iPhone to capture On versus Off time on a daily basis while at home. In addition, subjects will be asked to wear three actigraphy devices."
1463455|NCT03247374|Device|"ProComp5 Infiniti Biofeedback"|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. At the beginning of the bio-feedback session, a surface electrode will be applied to the mylohyoid muscle. The computer will produce visual feedback of the muscular activity on the screen. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy: they are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The experimental group will perform this training for 45 minutes."
1463456|NCT03247374|Other|Standard Speech and Language Therapy|"Each participant will attend 5 sessions per week for a total duration of 5 weeks. The patient will be required to swallow at a given time, with food bolus if possible, and perform maneuvers that favour swallowing strength and efficacy receiving verbal feedback from the speech and language therapist. They are requested to do classical maneuvers that favour swallowing efficacy that is effortful swallow, supraglottic swallow, and Masako maneuver. The control group will perform this training for 45 minutes."
1463457|NCT03247361|Other|High-intensity IMT + Aerobic/resistance exercise|High-intensity IMT
1463458|NCT03247361|Other|Low-intensity IMT + Aerobic/resistance exercise|Low-intensity IMT
1463460|NCT03247348|Behavioral|ReSeT-FM intervention|The ReSeT-FM intervention focuses on behavior changes strategies aimed at reducing sedentary time and includes: education, goal setting, self-monitoring of behavior and behavioral prompts to move via an activity tracker and phone app, and feedback on behavior via weekly meetings with study coaches.
1463462|NCT03247309|Biological|IMA201 T-Cells|The cell dose will be based on viable CD3+CD8+ HLA-Dextramer+ cells per body surface area (BSA) as defined by the Mosteller formula.
1463463|NCT03247309|Diagnostic Test|IMA201_Detect|IMA201_Detect is developed as a companion diagnostic to aid in selecting patients with relapsed and/or refractory solid cancers who might be eligible for enrollment in clinical trials with investigational IMA201 T-Cell therapy. IMA201_Detect is intended for investigational use only.
1463464|NCT03247309|Diagnostic Test|ACT-HLA|An assay used to determine whether a patient is positive for the allele HLA-A*02:01 or not, and thus is eligible for treatment with an ACTengine adoptive T-cell product.
1463465|NCT03247309|Drug|Fludarabine|Fludarabine infusion
1463466|NCT03247309|Drug|Cyclophosphamide|Cyclophosphamide infusion
1463467|NCT03247309|Biological|Recombinant human interleukin-2|Low dose IL-2 Infusion for two weeks
1463468|NCT03247296|Drug|Sofosbuvir 400 mg, Daclatasvir, Ribavirin|No intervention made this is an observational study to monitor the already existing protocols of the facility
1463469|NCT03247283|Drug|BMS-986205|Carbon 14 tagged BMS-986205
1463470|NCT03247270|Behavioral|Intervention I|Low intensive physical exercise
1463471|NCT03247270|Behavioral|Intervention II|High intensive physical exercise
1463472|NCT03247257|Procedure|General Anesthesia|Patients will be put under general anesthesia for cholecystectomy
1463473|NCT03247257|Procedure|Epidural Anesthesia|Patients will receive Epidural Anesthesia for cholecystectomy
1463477|NCT03247231|Procedure|ENDOSCOPIC BAND LIGATION WITHOUT RESECTION|ENDOSCOPIC TREATMENT OF SUBEPITHELIAL TUMORS: AUTOAMPUTACION BY ENDOSCOPIC BAND LIGATION WITHOUT RESECTION,
1463478|NCT03247231|Procedure|SINK|TO OBTAIN SSAMPLE TISSUE - BIOPSIES - AFTER THE ENDOSCOPIC BAND LIGATION WITHOUT RESECTION, PERFORMING A SINGLE INCISIONAL WITH A NEEDLE-KNIFE
1463479|NCT03247218|Drug|Memantine Hydrochloride|a low-moderate affinity, uncompetitive, NMDAR antagonist
1463481|NCT03247192|Dietary Supplement|Whey protein-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
1463482|NCT03247192|Dietary Supplement|Placebo-whey protein|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
1463483|NCT03247192|Dietary Supplement|Placebo-placebo|This investigation was carried out over a period of 26 weeks divided in two phases. The first phase of the study was an eight-week period (weeks 3-10), during which subjects were familiarized to RT. Phase 2, supplementation phase, the participants was randomized in three groups and started 12 weeks dedicated to supplementation plus RT (weeks 13-24). At the beginning and the end of each phase of the experiment, two weeks were allocated for evaluations (weeks 1-2, 11-12 and 25-26) consisting of anthropometric, body composition, blood samples, blood pressure, one repetition maximum tests (1RM) and dietary intake measurements
1463484|NCT03247179|Other|PTSD Coach mobile application|The PTSD Coach app is publicly available for free, and draws on cognitive behavioral therapy components to help participants learn, manage, and cope with their PTSD symptoms in real time.
1463485|NCT03247166|Device|TOPS™ System|The TOPS™ System is an alternative to spinal fusion that is designed to stabilize but not fuse the effected vertebrai level to alleviate pain stemming from degenerative joints
1463486|NCT03247153|Diagnostic Test|Echocardiography|Imaging of the heart using ultrasound
1463487|NCT03247140|Drug|JLP-1401|Administration of JLP-1401(Telmisartan/Amlodipine/Rosuvastatin)
1463488|NCT03247140|Drug|Telmisartan/Amlodipine, Rosuvastatin|Administration of Temlisartan/Amlosipine(Twinsta®) and Rosuvastatin(Crestor®)
1463489|NCT03247127|Radiation|Hippocampal avoidance whole brain radiotherapy|Planning target volume(PTV) for whole brain is Whole brain parenchyma plus2mm margin excluding metastases and HA region, 30Gy in 10 fractions will be delivered to PTVwhole brain. Bilateral Hippocampus will be contoured according to Radiation Therapy Oncology Group 0933 and hippocampal avoidance region is Hippocampi + 5mm margin. According to Radiation Therapy Oncology Group 0933 trial, dose to 100% of the hippocampus could not exceed 9 Gy, and maximal hippocampal dose could not exceed 16 Gy; dose to 100% of the hippocampus exceeding 10 Gy
1463490|NCT03247114|Other|Water|Water, 300 ml at room temperature
1463496|NCT03247101|Drug|Urso group|ursodoxycholic acid, 200mg po tid x 6 months
1463497|NCT03247101|Drug|Biotase group|Biotase 1# [Biodiastase 30mg + lipase 65mg + newlase 10mg]/tab po tid x 6 months
1463498|NCT03247088|Drug|Sorafenib|"Phase I Starting Dose: 200 mg by mouth twice daily 12 hours apart.
Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I between Day 30 to Day 120 days after transplant, and given for up to 1 year after transplant."
1463499|NCT03247088|Drug|Busulfan|Busulfan 80 mg/m2 by vein over on Days -20 and -13 as either an outpatient in the clinic, or as an inpatient in the hospital. Then Busulfan AUC 20,000 ± 12% µMol-min given by vein on Days -6 through -3.
1463500|NCT03247088|Drug|Fludarabine|Fludarabine 40 mg/m2 by vein on Days -6 to -3.
1463501|NCT03247088|Procedure|Stem Cell Transplantation|Stem cell transplant by vein on Day 0.
1463502|NCT03247088|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
1463503|NCT03247088|Drug|Tacrolimus|Tacrolimus 0.015 mg/kg/day nonstop by vein until able to take it by mouth to help lower the risk of GVHD. Then Tacrolimus by mouth 2 times a day for about 50 days.
1463504|NCT03247088|Drug|Filgrastim|Starting on Day +7, Filgrastim 5 mcg/kg/day as an injection under the skin 1 time a day, until blood cell levels are high enough.
1463505|NCT03247075|Behavioral|Cognitive Behavior Therapy|Guided Internet-delivered CBT includes exposure training, coping techniques and cognitive components, intended to reduce social anxiety symptoms
1463506|NCT03247075|Behavioral|Support and Counseling|Guided Internet-delivered support and counseling includes educative material about social anxiety and health related issues such as physical activity, nutritious diet, sleep habits etc.
1463507|NCT03247062|Other|Quality improvement - sleep bundle|implementation of a sleep bundle
1463508|NCT03247036|Drug|IV thrombolytic (t-PA) treatment vs not|Acute Stroke Protocol
1463510|NCT03247010|Other|Blood sampling|Blood samples are taken before each cycle of Radium 223
1463511|NCT03246997|Other|Autumn Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
1463512|NCT03246997|Other|Spring Group|The intervention is participating in a fruit and vegetable farm share for 6 months.
1463513|NCT03246984|Device|VasQ|VasQ device implantation in patients with a new brachio-cephalic fistula creation .
1463514|NCT03246971|Drug|Wafermine™ 50 mg|Administered as needed for 12 hours
1463515|NCT03246971|Drug|Wafermine™ 75 mg|Administered as needed for 12 hours
1463516|NCT03246971|Drug|Placebos|Administered as needed for 12 hours
1989719|NCT02409459|Drug|Injectafer|
1463519|NCT03246945|Behavioral|Instructions on taking photographs provided, see methods|Parent-patient dyads were provided with written 3-step instructions on how best to take a photograph of skin conditions using a smart phone
1463520|NCT03246932|Behavioral|Peer-led psycho-education group|A structured, researcher-designed peer-led psycho-education program (6 months), comprising of 12 bi-weekly, 2-hour group sessions.
1463521|NCT03246932|Behavioral|Profession-led psycho-education group|A psychoeducation group program (12 sessions, bi-weekly).
1463522|NCT03246932|Other|Routine psychiatric care|Routine psychiatric outpatient care, or Treatment-as-usual (TAU).
1463523|NCT03246919|Drug|Oxytocin|Oxytocin is administered after delivery of the fetal anterior shoulder, rather than being administered after delivery of the placenta
1463524|NCT03246919|Drug|Placebo|Placebo will be administered after delivery of the placenta
1463531|NCT03246893|Device|Noninvasive positive pressure ventilation|"Noninvasive positive pressure ventilation will apply via a face mask with initial setting as the following:
Inspiratory pressure 6-8 cmH2O Expiratory pressure 3-5 cmH2O FiO2 30-60% Respiratory rate 12-16 per min"
1463532|NCT03246893|Device|High flow oxygen nasal cannula|"High flow oxygen nasal cannula will apply to patient via a nasal cannula with initial setting as the following:
Temperature 37 degree celsius Flow 30 liter per min FiO2 40-60%"
1463533|NCT03246880|Drug|Tamsulosin 0.2mg|per oral for 12weeks after 2~4weeks run-in period
1463534|NCT03246880|Drug|Tadalafil 5mg|per oral for 12weeks after 2~4weeks run-in period
1463535|NCT03246867|Other|Isolytic stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Afterwards active-assistive stretching is done. Evaluations will be done before and just after stretching exercise.
1463536|NCT03246867|Other|Static stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Evaluations will be done before and just after stretching exercise.
1463537|NCT03246867|Other|Control group|Control group will receive no stretching. They will be handed a brochure about the stretching techniques and its role in injury prevention. Control group will be evaluated for the first time and then will be passively waited until the duration of the stretching exercise program (approximately 4-5 min). Afterwards, second evaluation will be performed.
1463538|NCT03246854|Drug|DBPR112|DBPR112 hard gelatin capsule solid dosage formulation; strength: 25 mg, 100 mg.
1463539|NCT03246841|Other|Genetic testing|A panel of 24 genes, chosen in advance by a steering committee, will be tested as the same time as the BRCA1/2 genes, at one of the usual BRCA1/2 analysis laboratories belonging to the same network and participating in the study.
1463540|NCT03246828|Other|Omission of gliclazide|Participants will stop taking gliclazide for 3 days. Data from the OGTT will be compared with that prior to stopping the medication.
1989720|NCT02409459|Drug|Normal Saline|
1995061|NCT02859883|Device|gastroscope FUSE™|All patients undergoing a diagnostic gastroscopy are eligible. Using the FUSE endoscope with side screen, the duodenal and accessory papilla are monitored. Data are collected by each operator. Clinical examination of patients is performed before they leave the centre.
1463541|NCT03246802|Radiation|HDR partial prostate brachytherapy|temporary radioactive implant
1463545|NCT03246763|Behavioral|Integrated community-healthcare childhood obesity treatment|"The intervention will include nutrition and fitness programming at a local community center. The program will be open at least two sessions per week, each session lasting at least 1 hour. The program coordinator will run the programming, which will consist of wellness activities. Each session will include at least 60 minutes of exercise and/or active play, and each session will have an additional special theme. For example, one session might include a cardio focused class, and one session might include a yoga class. The number and which sessions the participants attend each week is voluntary; clinic staff will recommend participation in as many sessions per week as possible. Participation is voluntary, and patients may opt-out at any time. Participants will be told that they can indicate to their provider or the program coordinator at any time either by phone or during the clinic appointment that they wish to opt-out of the study and its assessments."
1463546|NCT03246750|Drug|B-MAD chemotherapy|B-MAD chemotherapy
1463547|NCT03246737|Other|monitoring|
1463552|NCT03246711|Behavioral|Fasting|Totally or partially fasting the holy month of ramadan for muslims
1463553|NCT03246698|Other|Isolytic Stretching group|In modified cross body position, isolytic stretching exercises will perform five times each for 15 seconds. After each stretching patient will rest for 5 seconds. When the patient contracts the agonist muscle group with 20% muscle force, the agonist muscle group is stretched at the same time for 2-4 seconds. Isolytic stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
1463554|NCT03246698|Other|Static Stretching group|In modified cross body position, active-assistive static stretching exercises will be performed 5 times each for 15 seconds. This stretching exercise is performed 5 times with 5 seconds intervals. Static stretching exercises will perform four times a week for four weeks. It's obligatory to receive at least 15 sessions in total. They will also receive standard physiotherapy program four times a week for four week, 15 sessions in total.
1463555|NCT03246698|Other|Control group|They will receive only standard physiotherapy program, four times a week for four weeks, 15 sessions in total.
1463556|NCT03246685|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
1463557|NCT03246685|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
1463558|NCT03246672|Behavioral|maintenance intervention|Participants will receive calls at weeks 1, 2, 3, 4, 6, 8, 10, 12, and 14 that focus on satisfaction with outcomes of behavior change, self-monitoring, relapse planning, and social support.
1463559|NCT03246659|Drug|111In-CP04|Radiopharmaceutical preparation
1463560|NCT03246659|Drug|111In-CP04 with co-administration of gelofusine/gelaspan|Radiopharmaceutical preparation with co-administration of gelofusine/gelaspan
1463561|NCT03246646|Behavioral|Coaching|Telephone coaching along with web-based CRAFT course
1463562|NCT03246633|Other|Perceptual Training|Participants will assess skin lesions before and after completion of an online/mobile course that has the goal of learning to triage pigmented lesions as benign or malignant. Participants will also help evaluate the usability and effectiveness of the course by completing a questionnaire after completion of the course.
1463566|NCT03246607|Device|MicroEye & ContinuMon|Continuous intravascular glucose monitoring using MicroEye/ContinuMon system, peripherally inserted via a peripheral venous catheter.
1463567|NCT03246594|Device|Placement of oesophageal probe for temperature measurement|The oesophagus probe is used to measure the intraluminal temperature inside the oesophagus
1463568|NCT03246594|Device|Power limitation of RF generator|no probe utilized; Limit the RF Generator Output to 25W
1463569|NCT03246581|Drug|Tiotropium|inhalation
1463570|NCT03246568|Procedure|Renal Nerve Denervation|Bilateral renal denervation using a multi-polar radiofrequency ablation catheter (Symplicity™ Spyral Cather, Medtronic) in the right and left main, branch, and accessory renal arteries in vessels ranging in diameter between 3 and 8 mm.
1463571|NCT03246568|Procedure|Pulmonary vein isolation|PVI by cryo-balloon ablation without linear ablation
1463572|NCT03246555|Drug|Fimasartan or Fimasartan/Hydrochlorothiazide|The treatment in this clinical study starts with fimasartan 30 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
1463573|NCT03246555|Drug|Perindopril or Perindopril/Indapamide|The treatment in this clinical study starts with penrindopril 2.5 mg; if blood pressure is not controlled (siSBP ≥ 140 mmHg or siDBP ≥ 90 mmHg), the dose is escalated once gradually, and then a diuretic combination is administered. The escalation of dose and administration of diuretic combination are decided after checking blood pressure 4 weeks after the administration of each investigational product.
1463574|NCT03246542|Diagnostic Test|shistocytes percentage|
1463575|NCT03246529|Drug|BL-8040 1.25mg/kg + G-CSF|Up to 2 SC injections of BL-8040 are anticipated during the study. Injections of G-CSF per standard of care
1463576|NCT03246529|Drug|Placebo +G-CSF|Up to 2 SC injections of Placebo are anticipated during the study. Injections of G-CSF per standard of care
1463577|NCT03246516|Other|Questionnaire|"Auto and hetero questionnaires:
STAI Y B, State-Trait Anxiety Inventoriage
Brief COPE
RHHI-24, Revised Health Hardiness Inventory
IPQ-R, Illness Perception Questionnaire"
1463581|NCT03246451|Drug|Placebo Oral Tablet|2-4 tablets in 14 days
1463582|NCT03246451|Drug|Metformin|1000-2000 mg in 14 days
1463583|NCT03246451|Drug|Saline|9 mg/ml saline infusion during experimental days
1463584|NCT03246451|Drug|Exendin (9-39)|Infusion of GLP-1 receptor antagonist used as a tool during experimental days
1463585|NCT03246438|Behavioral|Colonoscopy only|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to schedule colonoscopy.
1463586|NCT03246438|Behavioral|Colonoscopy outreach + mailed FIT follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line. Subjects not scheduled after 4 weeks will receive a reminder letter to either schedule colonoscopy or to complete the enclosed mailed FIT kit.
1463587|NCT03246438|Behavioral|Colonoscopy + Mailed FIT outreach and follow-up|Subjects will receive a mailed communication describing the importance of colorectal cancer screening with the option to schedule a colonoscopy through a VIP direct scheduling phone line OR complete the enclosed mailed FIT kit. Subjects who have not completed FIT or scheduled colonoscopy within 4 weeks will be receive a reminder letter to either schedule colonoscopy or complete the mailed FIT kit previously sent.
1463588|NCT03246425|Other|Ventilator mode change|The enrolled subjects will be moved from the baseline mode to another mode of ventilation and the changes in the arterial pulse will be observed
1463589|NCT03246425|Device|Monitoring of blood pressure variation|The changes in the blood pressure will be measured in the form of Stroke Volume Variation using SVV using Vigileo (Edward Life sciences) monitor
1463590|NCT03246412|Diagnostic Test|Nevus doctor clinical decision support|The computer program analyzes dermatoscopic images. The output is an estimate of the risk of the skin lesion representing skin cancer. The decision support tool helps the doctor to assess the significance of the computer output by taking into account clinical information.
1463591|NCT03246399|Drug|SM04690|suspension formulation of SM04690, delivered via intradiscal injection (single injection)
1463592|NCT03246386|Drug|Posaconazole Injection [Noxafil] 300mg|Single dose by intravenous infusion 300mg
1463593|NCT03246386|Drug|Posaconazole Injection [Noxafil] 400mg|Single dose by intravenous infusion 400mg
1463594|NCT03246360|Drug|Modification for administration mode of cloxacillin antibiotic|"For intermittent administration, patients will benefit from cloxacillin treatment in conventional hospitalization, in accordance with national guidelines, at a dose of 150 mg / kg per day in 4 infusions, not exceeding the maximum daily dose of 12 g / day according to.
For continuous administration the same quantity of cloxacillin 150 mg / kg per day, without exceeding the maximum daily dose of 12 g / day, will be delivered by a self-propelled syringe in twice 12 hours. Patients randomly assigned to receive continuous administration will receive a dose of cloxacillin equivalent to the dose administered 4 times daily during iterative administration using a self-pulsating syringe. For the first day of the study, this loading dose will be subtracted from the 150 mg / kg dose to be administered continuously over the remaining 23 hours of the first day of the study and never exceed 12g / day.
Pharmacological dosages will be performed on the third and sixth day in both arms"
1463595|NCT03246347|Drug|ADT+Docetaxel+Enzalutamide|combination therapy as listed above
1463596|NCT03246321|Combination Product|Upfront repeated laparoscopic PIPAC with oxaliplatin (92 mg/m2) and simultaneous intravenous bolus 5-fluorouracil/leucovorin (400/20 mg/m2)|"General steps:
General anesthesia
Open introduction of two 12mm balloon trocars, insufflation of a 12 mmHg capnoperitoneum;
If PIPAC is considered feasible: intravenous bolus leucovorin (10 minutes) and 5-fluorouracil (15 minutes);
Zühlke score, ascites for cytology, PCI, and biopsies;
Insertion of nebuliser (CapnoPen);
Connection of nebuliser to high pressure injector (Nemoto Rempress);
150 ml syringe with oxaliplatin (92 mg/m2) in 5% dextrose solution is placed in the high pressure injector;
All team members leave the operating room;
Remote controlled injection of oxaliplatin at 200 psi and 60 ml/min, for 30 minutes with addition of Ultravision technology;
Single person enters the operating room;
Exsufflation of toxic aerosol over two microparticle filters and a Pleur-evac into the air waste system of the hospital;
Other team members enter operating room;
Closure of wounds and end of procedure."
1463598|NCT03246295|Other|lifestyle intervention or insulin treatment|Firstly，the gestational diabetes mellitus（GDM） women were treated with lifestyle intervention.Those women were treated with insulin if their blood glucose was not well Controled.
1463599|NCT03246282|Device|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
1463600|NCT03246282|Drug|Normal Saline 0.9% Infusion Solution Bag|250 ml of 0.9% Sodium Chloride Solution
1463601|NCT03246282|Device|Peripheral Catheterization|"20-gauge 1.0 catheter"
1463602|NCT03246269|Diagnostic Test|MoCA|
1463603|NCT03246256|Other|Group 1|
1463604|NCT03246243|Device|nfant feeding solution|The study will record the sucking activity of the hospitalized infants over time, from their first oral sucking session including non-nutritive and nutritive sucking, until discharge, using an FDA-approved device that equips a typical bottle and nipple commonly used in the NICU with a non-invasive sensor to measure sucking activity. Each infant's nutritive and non-nutritive sucking patterns will be measured, and will comprise the 'sucking session' conducted with the bottle sensor.
1463605|NCT03246243|Device|Waveguard (TM) EEG cap|EEG and EMG data will also be collected while the infant is being measured with the sensor during one of the first and one of the last sucking sessions. In addition, EEG and EMG data will be collected while the infant is at rest during one of the first and one of the last sucking sessions.EEG cap will be placed on subjects. Each electrode is located under each disc. EEG montage used for 32 channel recordings (Modified international 10/20 system).
1463606|NCT03246243|Device|BabyMEG|Following a sucking session, simultaneous resting-state MEG/EEG data will be recorded from the infant during sleep with the BabyMEG. The resting-state MEG/EEG recording will last about 10 minutes, with preparation lasting about 30 minutes.
1463609|NCT03246217|Behavioral|Therapeutic Instrumental Music Performance|Participants will play a variety of instruments (acoustic and electronic) to facilitate retraining of everyday functional movements.
1463610|NCT03246217|Behavioral|Therapeutic Performance with Sensory-Enhanced Motor Imagery|Participants will listen to a metronome set to their preferred pace for previously practised movements while engaging in motor imagery.
1463611|NCT03246217|Behavioral|Therapeutic Performance with Motor Imagery|Participants will engage in motor imagery of previously practised movements.
1463612|NCT03246191|Other|blood sample collection|blood sample collection
1463613|NCT03246178|Other|MSD-HSCT|"Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 30mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;
Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;
Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 150-250 ng/ml. The oral MMF dose was 20 mg/kg/day from day −1 and was tapered off after 1 months if no aGVHD was observed."
1463614|NCT03246178|Other|HFD-HSCT|"Conditioning regimens: (A) Patients had SAA and PNH, or heavy transfusion (RBC≥25U), or failed rabbit ATG therapy, and received 0.8 mg/kg/6h busulfan (days -7 to -6), 35mg/m2/day fludarabine (days -5 to -2), 25 mg/kg/day cyclophosphamide (days -5 to -2) and 2.5 mg/kg/day r-ATG (days -5 to -2). (B) The other patients with SAA or VSAA received same procedure but without busulfan;
Allogeneic HSC infusion: Doner BM cells were harvested to achieve a target mononuclear cell count (MNC) of 2-4 × 108 per kilogram of recipient weight. The target MNC from PB was 4-6× 108 per kilogram of recipient weight;
Prophylaxis and treatment of GVHD: GVHD prophylaxis consisted of intravenous CSP 2-3 mg/kg/day in divided doses beginning on the day before transplantation (day -5) and the target concentration was adjusted to 200-300 ng/ml. The oral MMF dose was 20 mg/kg/day from day −3 and was tapered off after 2 months if no aGVHD was observed."
1463615|NCT03246165|Procedure|Cardiac surgery|Coronary bypass, heart valve replacement
1463617|NCT03246139|Behavioral|Action observation, imagery & execution|The participants will be asked to observe movements through a video clip, practice motor imagery, and executing the movements that the participants observed.
1463618|NCT03246139|Behavioral|Action observation|The participants will be asked to observe videos and then practice what the participants observed.
1463619|NCT03246139|Behavioral|Customary upper-extremity rehabilitation|The participants will receive UE training without watching videos or imagining movements/tasks.
1948111|NCT02766023|Biological|Lactobacillus crispatus CTV-05|LACTIN-V is an intravaginal live biotherapeutic product composed of Lactobacillus crispatus CTV-05 (LACTIN-V, Osel Inc) in a vaginal applicator. Subjects receive 2x10^9 cfu/dose applied vaginally daily x 5 days then twice weekly x 10 weeks.
1463624|NCT03246100|Behavioral|Reminders|Reminders are sent either through autodial or postcards reminding patients to get flu vaccine.
1463625|NCT03246087|Device|Acupunture|"acupuncture for plantar fasciosis
Acupuncture will be performed and the standard of care prescribed home exercise program will be reviewed."
1463626|NCT03246087|Other|Standard of care|standard of care home exercise program
1463628|NCT03246061|Device|Intracept System|RF ablation
1463629|NCT03246061|Other|Non-surgical conservative therapies|Conservative therapies
1463630|NCT03246035|Behavioral|Intervention Group|For the intervention arm, a specialized heart failure nurse practitioner will contact the patient or their primary caregiver by telephone within 5 days post-discharge and send them an education packet by mail. During the telephone call, the nurse will (1) confirm the patient's scheduled follow-up appointment in cardiology, (2) provide recommendations for heart failure self-care behaviors that were found to be deficient at baseline, and (3) provide recommendations for frailty domains that were found to be deficient at baseline. The technique used to provide educational recommendations will be motivational interviewing.
1463631|NCT03246035|Other|Control Group (Standard Care)|For patients randomized to the Control Group (Standard Care), they will receive their follow-up visits, medications, diet and physical activity advice as they normally would. This is the care they would receive even if they were not enrolled in the study
1463632|NCT03246022|Other|continuous positive airway pressure|Continuous positive airway pressure (CPAP) prevents the airway collapse, avoids the occurrence of intermittent hypoxemia and arousal, is the preferred treatment for OSAS and has been widely used in clinical. The investigator would compare the effect of CPAP treatment on awake and sleep BP level at the first night and 2 weeks therapy among three groups. Moreover, whether or not the sympathetic-parasympathetic nerve balance and the renin-angiotensin-aldosterone system are different in three groups would also be evaluated.
1463633|NCT03246009|Drug|rHSA/GCSF|single injection-1.8mg
1463634|NCT03246009|Drug|rHSA/GCSF|single injection-2.1mg
1463635|NCT03246009|Drug|rHSA/GCSF|single injection-2.4mg
1463636|NCT03246009|Drug|rHSA/GCSF|multiple injection-1.8mg
1463637|NCT03246009|Drug|rHSA/GCSF|multiple injection-2.1mg
1463638|NCT03246009|Drug|rHSA/GCSF|multiple injection-2.4mg
1463639|NCT03245996|Device|AAI 40 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 40 bpm
1463640|NCT03245996|Device|AAI 60 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 60 bpm
1463641|NCT03245996|Device|AAI 90 bpm|Cardiac pacemaker of the subjects is set to AAI-mode 90 bpm
1463642|NCT03245983|Behavioral|Questionnaire and interview|Cancer patients will answer questionnaires and will be interviewed by a pshychologist to assess their spirituality and quality of life toward their disease
1463643|NCT03245970|Drug|Labetalol Hydrocholoride 200 mg orally every 12 hours|Anti-hypertensive prescribed for increased cardiac output as determined by impedance cardiography
1463644|NCT03245970|Drug|Nifedipine 60 mg orally daily|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by impedance cardiography
1463645|NCT03245970|Drug|Atenolol 25 mg daily|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
1463646|NCT03245957|Other|Ischemic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
1463647|NCT03245957|Other|Haemorrhagic stroke|Patients with acute stage of stroke clinical picture, with ischemic, haemorrhagic or mimick stroke diagnosed using MRI or CT scan
1463648|NCT03245944|Procedure|early Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Early means pt will get the procedure at 6 weeks from time of initiation of AVFs
1463649|NCT03245944|Procedure|late Angioplasty|Angioplasty is a minimally invasive, endovascular procedure to widen narrowed or obstructed arteries or veins. A deflated balloon attached to a catheter (a balloon catheter) is passed over a guide-wire into the narrowed vessel and then inflated to a fixed size. The balloon forces expansion of the blood vessel and the surrounding muscular wall, allowing an improved blood flow. This is part of standard of care for immature arteriovenous fistulas. Late means the angioplasty is done at 3 months from time of AVF creation if still immature at that time.
1463650|NCT03245931|Other|Qualitative Interview|Complete 6 open-ended qualitative questions on patients in the HOPE program to assess basic current understanding about Hepatitis C and topics of interest that patients in the HOPE program would like to learn more about.
1463651|NCT03245918|Drug|Aprepitant Capsule 125 MG|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
1463652|NCT03245918|Drug|Aprepitant oral suspension 20 mg/mL|Patients will be randomized to either the aprepitant capsule or oral suspension for the first study period, and will receive the alternate formulation during the second study period
1463653|NCT03245905|Drug|Chidamide|Chidamide 30mg orally BIW (d1, 4, 8, 11, 15, 18). Treatment cycles are repeated every 3 weeks.The maximum duration of treatment is 2 years.
1463654|NCT03245892|Drug|Carboplatin and Paclitaxel|Paclitaxel 80mg/m2 will be administered over approximately 1 hour as an IV infusion on Days 1,8, and 15 of each 21-day cycle. Carboplatin AUC6 will be administered as approximately a 30 minute IV infusion, following paclitaxel administration on Day 1 of each 21-day cycle.
1463655|NCT03245892|Drug|Nivolumab|Nivolumab 360mg will be infused IV over approximately 30 min on Day 1 of Cycles 1-6 (to 8) of each 21 day cycle. During the maintenance phase, Nivolumab 480mg will be infused IV on day 1 of each 28 day cycle, for up to 12 months. During the maintenance period, each cycle is 4 weeks
1463656|NCT03245892|Procedure|cytoreductive surgery|cytoreductive surgery
1463657|NCT03245879|Behavioral|Program 1|Program 1 hospitals received a basic curriculum and tools for implementation of basic antibiotic stewardship interventions. Hospitals required an indication for every antibiotic order. A daily email was sent to a designated email account when a patient had been on an antibiotic for >48 hours. Curriculum included implementing antibiotic time-outs, IV to PO conversion, indications, evaluating for bug-drug mismatches, and recommendations on when to call the Infectious Diseases (ID) hotline. A daily antibiotic stewardship check list was created. All materials were provided to all pharmacists and remained on-site. Clinicians had access to an ID telephone hotline to answer clinical questions. Pharmacy directors and hospital leadership were provided a monthly, hospital-specific, antibiotic use dashboard. All pharmacy directors and staff received a monthly newsletter.
1463734|NCT03245307|Drug|Apatinib|Apatinib at a dosage of 750mg will be administered daily from day 9 of phase A
1463658|NCT03245879|Behavioral|Program 2|Program 2 hospitals received all the interventions of Program 1. In addition, Program 2 hospitals received more intense antibiotic stewardship education. Educational topics included audit and feedback, antibiotic de-escalation, the need for antibiotics targeting anaerobic bacteria, antibiotic allergy verification, and antibiotic restrictions. Pharmacists in Program 2 hospitals reviewed patients on vancomycin, piperacillin/tazobactam, imipenem, meropenem, and cefepime. For patients receiving one of these antibiotics, pharmacists reviewed the patients' microbiology data to identify opportunities for antibiotic de-escalation, IV to PO conversion, bug-drug mismatches, and/or indications for calling the ID hotline. Program 2 hospitals also restricted daptomycin, linezolid, imipenem, meropenem, ceftaroline, tigecycline, and all mold active antifungals. In Program 2 hospitals, the local pharmacy staff pre-authorized restricted antibiotics based on defined criteria.
1463659|NCT03245879|Behavioral|Program 3|Program 3 hospitals received all the interventions of Program 1 and Program 2. In addition, pharmacists in program 3 hospitals reviewed an expanded list of antibiotics for audit and feedback. These antibiotics included: Vancomycin, piperacillin/tazobactam, imipenem, meropenem, cefepime, ertapenem, aminoglycosides, ceftriaxone, and fluoroquinolones. Program 3 hospitals implemented the same antibiotic restrictions as Program 2 but ID pharmacists controlled pre-authorization of restricted antibiotics. In addition, an ID physician reviewed pre-specified positive cultures (e.g. all positive blood cultures, cultures with highly resistant Enterobacteraciae) and contacted providers with recommendations as needed. ID physician review occurred Monday through Friday and alerts were batched daily at 6am.
1463660|NCT03245866|Other|Observational/ no intervention|
1463661|NCT03245853|Drug|Riboflavin 5'-Phosphate|Photrexa (riboflavin 5'-phosphate ophthalmic solution) 0.146%, is a yellow sterile buffered solution containing 1.46 mg/mL riboflavin 5'-phosphate, The pH of the solution is approximately 7.1 and the osmolarity is 157-177 mOsm/kg. Each 1 mL of the solution contains 1.53 mg of riboflavin 5'-phosphate sodium (equivilant to 1.20 mg [0.12%] riboflavin). Riboflavin 5'-phosphate sodium USP is a mixture of the sodium salts of riboflavin, riboflavin monophosphates, and riboflavin diphosphates. The inactive ingredients are dibasic sodium phosphate, monbasic sodium phosphate, sodium chloride, and water for injection.
1463665|NCT03245814|Behavioral|Service Dog|A service dog trained to perform tasks that are specific to PTSD
1463666|NCT03245788|Other|Lay Navigation|Patients who are assigned to intervention will be contacted by a navigator who will explain and offer their services to the patient. Navigators focus efforts on supporting patients in self-management and in supporting non-medical needs.
1463667|NCT03245775|Behavioral|iChoose|12 bi-weekly sessions & 24 IVR calls/12 months, 24 physical activity sessions over 6 months; delivers intervention to parents and children only
1463668|NCT03245775|Behavioral|Family Connections|2 in-person sessions spaced one week apart & 10 IVR calls/6 months, promotes physical activity but does not include structured exercise sessions; delivers intervention to parents only
1463669|NCT03245762|Drug|Oxytocin|4 IU/day of oxytocin administered via nasal spray device each morning.
1463670|NCT03245762|Drug|Placebo|4 IU/day of placebo administered via nasal spray device each morning
1463671|NCT03245736|Drug|Tisotumab Vedotin|All patients in the trial will be administered tisotumab vedotin (HuMax-TF-ADC).
1463672|NCT03245723|Procedure|Pulmonary Function Testing|Subjects will undergo Spirometry and Plethsymography
1463673|NCT03245723|Procedure|Electrocardiogram|Subjects will undergo an electrocardiogram to ensure sinus rhythm
1463674|NCT03245723|Procedure|Positron Emission Tomography|Subjects will undergo positron emission tomography to detect images of the heart
1463675|NCT03245723|Procedure|Magnetic Resonance Imaging|Subjects will undergo positron magnetic resonance imaging to detect images of the heart
1463676|NCT03245710|Drug|Placebos|starch
1463677|NCT03245710|Drug|Zhibai Dihuang powder|the Traditional Chinese Medicine Formula Powder Product
1463678|NCT03245684|Diagnostic Test|assessment of inflammatory response during PSV|assessment cytokines level in BAL and plasma
1463679|NCT03245671|Drug|Kenalog Injectable Product|80 mg of Kenalog will be used.
1463680|NCT03245671|Drug|Decadron Phosphate, Injectable|15 mg of Decadron will be used.
1463681|NCT03245671|Procedure|Epidural Steroid Injection|Patient will receive epidural steroid injections of either Kenalog or Decadron.
1463682|NCT03245658|Drug|THC and CBD Mixture|Individually titrated doses on daily basis
1463683|NCT03245645|Other|Dietary Intervention|Food may be linked to changes in motility, visceral sensation, gut microbiome, intestinal permeability, immune activation and brain-gut axis. This study will focus on fructose, which is one of the main components of FODMAP (Fermentable oligosaccharides, dissacharides, mono-saccharides and polyols) foods. Fructose is a common part of the Western diet and can be consumed as a free monosaccharide, part of sucrose, or in polymers referred to as fructans. FODMAP foods are thought to induce gastrointestinal symptoms including gas, bloating, abdominal pain or discomfort, and loose stools by increasing small bowel water content and increasing gas production by fermentation of foods by gut bacteria. Studies including a recent controlled clinical trial demonstrated that a low FODMAP diet can be an effective nutritional therapy.
1463684|NCT03245632|Other|Carbapenem-Resistant Klebsiella pneumoniae|no intervention, this is an obervational study.
1463685|NCT03245619|Drug|GSK3335065|GSK3335065 is being developed as a treatment for acute pancreatitis with the intent of reducing 3-hydroxykynurenine (3HK) levels to the normal range (or lower) and maintaining them at this level. GSK3335065 is a solution and will be administered as intravenous injection and infusion with dose strength of 5 milligram (mg)/mL that may be diluted in 0.9% weight by volume (w/v) sodium chloride.
1463686|NCT03245619|Drug|Placebo|Placebo solution to match GSK3335065 will be given as intravenous injection and infusion.
1463687|NCT03245606|Procedure|Liver biopsy|Measurement of liver fibrosis
1463688|NCT03245606|Device|Abdominal MRI|Measurement of liver fibrosis
1463689|NCT03245606|Device|Transient elastography|Measurement of liver fibrosis
1463692|NCT03245580|Procedure|Core Liver Biopsy|Diagnostic EUS examination followed by liver biopsy to obtain core sample in benign liver disease.
1948112|NCT02766023|Drug|Metronidazole|Metronidazole is a nitroimidazole. Metronidazole gel (MetroGel) is applied vaginally 7.5 mg/gm daily for 5 days
1948113|NCT02766023|Other|Placebo|Placebo formulation applied vaginally, daily x 5 days then twice weekly x 10 weeks.
1463695|NCT03245554|Drug|Propranolol|0 or 1 were generated by using Random software. The patient entered the placebo group if number was 0; if the random number generated was 1, then entered the propranolol group.
1463696|NCT03245541|Drug|Durvalumab|Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 to PD-1 and CD80 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer. (MedImmune is a wholly owned subsidiary of AstraZeneca; AstraZeneca/MedImmune will be referred to as AstraZeneca throughout this document.) As durvalumab is an engineered mAb, it does not induce antibodydependent cellular cytotoxicity or complement-dependent cytotoxicity. The proposed mechanism of action for durvalumab is interference of the interaction of PD-L1 with PD-1 and CD80.
1463697|NCT03245541|Radiation|Stereotactive Ablative Body Radiotherapy|6.6 Gy per fraction delivered every other day x 5 fractions
1463698|NCT03245528|Drug|LJPC-501|angiotensin II
1463700|NCT03245502|Biological|Blood transfusion|The transfusion of erythrocyte suspension
1463704|NCT03245476|Other|Physical therapy focus on manual therapy and home-exercises|corticoid injection + physiotherapy with a focus on manual therapy and home-exercises
1463705|NCT03245476|Other|Physical therapy focus on education and supported home exercises|corticosteroid injection + physiotherapy with focus on education and supported home exercises
1463706|NCT03245463|Other|Educational handout|The educational handout will include information on self-management strategies.
1463707|NCT03245463|Other|Verbal script|The verbal script will include details on self-management strategies that will be reviewed with the patient.
1463708|NCT03245463|Drug|Hyaluronic Acid|All study patients are undergoing injections with hyaluronic acid prior to the administration of the teaching method. The injections are standard of care and are required as part of the inclusion criteria.
1463711|NCT03245437|Drug|Oxytocin nasal spray|nasal spray
1463712|NCT03245437|Behavioral|Social Cognition Skills Training|Group based training in social cognition skills
1463713|NCT03245437|Behavioral|Health Management|Group-based training in mental health management
1463714|NCT03245437|Drug|Placebo nasal spray|placebo condition
1463715|NCT03245424|Drug|ivosidenib (AG-120)|Patients will receive ivosidenib 500 mg by mouth once daily on 28-day cycles
1463716|NCT03245411|Behavioral|Intervention|All participants in this group will receive the standard of care intervention provided by the RN. This includes:Education in the clinic setting,Printed information about the chemotherapy drug and chemotherapy side effects. The RN will be blinded to the arm of study to which each patient is allocated.
1463717|NCT03245398|Drug|Treatment with one of the two regimens of mebendazole|Once in the morning and once in the evening for 3 consecutive days
1463718|NCT03245385|Drug|Treatment with Halobetasol propionate 0.05% topical spray|Patients will be treated with topical halobetasol 0.05% spray applied twice daily for 14 days. Patients will be instructed not to rub over the affected area after application of spray. Each patient is expected to receive 28 doses. The maximum amount of test product applied per week will not exceed 50 g
1463719|NCT03245372|Procedure|Standard care|Heart rate 60-100 beats per minute, mean arterial pressure 65 mm Hg, serum lactate 2 mmol/L, oxygen saturation 95 % (90 % during one lung ventilation).
1463720|NCT03245372|Procedure|Goal directed therapy|The hemodynamic algorithm will be based on systolic volume index and fluid challenges. FloTrac sensor (this sensor connects to any existing arterial catheter and provides advanced hemodynamic parameters through pulse contour analysis) and EV1000 clinical platform (clinical platform from Edwards Lifesciences that provides advanced hemodynamic monitoring) will be used to calculate cardiac index and systolic volume index.
1463721|NCT03245359|Device|Short-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until medication in initial balls are depleted (usually 2-4 days)
1463722|NCT03245359|Device|Short-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until medication in initial balls are depleted (usually 2-4 days)
1463723|NCT03245359|Drug|Short-term ON-Q|Bupivacaine 0.125%
1463724|NCT03245359|Device|Long-term ON-Q|single port, select-a-flow pump connected to saphenous nerve block catheter until day 7 post-operative
1463725|NCT03245359|Device|Long-term ON-Q|single port, fixed flow pump connected to posterior knee catheter until day 7 post-operative
1463726|NCT03245359|Drug|Long-term ON-Q|Bupivacaine 0.125%
1463731|NCT03245333|Drug|Recombinant Human Growth Hormone Injection|Stage 1：JINTOPIN AQ 0.2IU/kg/d（0.46mg/kg /wk）for 52 weeks.
1463732|NCT03245333|Drug|Recombinant Human Growth Hormone Injection|Stage 2: After completing phase 1, patients are administrated the appropriate dose of JINTOPIN AQ, the highest dose should be no more than 0.2IU/kg/d, from the 53rd weeks to the final height.
1463733|NCT03245320|Device|Integra TITAN™ Total Shoulder Generation 1.0|Total Shoulder Arthroplasty or Hemiarthroplasty
1948118|NCT02758717|Drug|Brentuximab Vedotin|Given IV
1948119|NCT02758717|Other|Laboratory Biomarker Analysis|Correlative studies
1948120|NCT02758717|Biological|Nivolumab|Given IV
1948121|NCT02756611|Drug|Venetoclax|Tablets
1463735|NCT03245307|Drug|Nifedipine GTIS|Nifedipine at a dosage of 30mg will be administered at day 1 and day 14 of phase A
1463736|NCT03245307|Drug|Warfarin Potassium|Nifedipine at a dosage of 3mg will be administered at day 3 and day 16 of phase A
1463737|NCT03245294|Procedure|Cervical epidural injection|the pattern of pressure decrease from ligamentum flavum to epidural space
1463738|NCT03245281|Drug|Diuretic Suspension (DS)|Stop diuretic consumption in the 48h before the follow-up visit
1463739|NCT03245281|Drug|Diuretic Increase (DI)|Double diuretics dosage in the 48h before the follow-up visit
1463740|NCT03245281|Drug|Diuretic and Medication Suspension (DMS)|Stop diuretic and MRA medication consumption in the 48h before the follow-up visit
1463741|NCT03245268|Procedure|Balloon pulmonary angioplasty|BPA is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
1948122|NCT02756169|Other|Intervention|Three actions since pregnancy until the first year of life of the baby for helping the women with obesity to increase the probability of a successful breastfeeding.
1463743|NCT03245242|Other|Enhanced Recovery after Surgery|Enhanced Recovery After Surgery (ERAS) protocol is a multi-disciplinary program that aims to standardize care processes around the pre-, intra-, and post-operative care setting. This group will prospectively receive care under a pre-defined protocol.
1463744|NCT03245242|Other|Historical usual surgical care|"Recent historical controls will have received care under usual care that existed prior to implementation of an enhanced recovery protocol."
1948123|NCT02753998|Device|Additional angioplasty with paclitaxel-coated balloon|Additional angioplasty with paclitaxel-coated balloon after conventional angioplasty
1948124|NCT02753998|Device|Additional angioplasty with placebo balloon|Additional angioplasty with placebo balloon after conventional angioplasty
1463747|NCT03245216|Behavioral|aerobic exercise|Single-bout of moderate intensity aerobic exercise on a cycle ergometer before motor learning
1463748|NCT03245216|Behavioral|rest|Seated rest before motor learning
1463749|NCT03245216|Behavioral|motor learning|Motor learning task on a stability platform (Stabilometer). Participants try to keep the tiltable platform in an horizontal position.
1463750|NCT03245203|Procedure|FOLFIRI+beacizumab|Eligible patients received bevacizumab 5.0 mg/kg followed by irinotecan 125mg/m2 combined with LV 200mg/m2 followed by 5-FU bolus 400mg/m2,then 5-FU infusion 2.4~3.0g/m2 over a 46-h period.Those agents were given for a 2-week cycle.Treatment was administered for six cycles. LARC was reevaluated and operated after 4~8 weeks.
1463751|NCT03245203|Procedure|CRT|total dose of radiotherapy was 40~50Gy, a subdose of 1.8~2Gy for continuous 5 weeks, 5 times/week.Then,5-FU infusion 400mg/m2 combined with LV 200mg/m2 over 24 h for 4 days/week during the first and fifth weeks of radiotherapy.Whereas,Capecitabine was administered orally at a dose of 825mg/m2 twice a day for 5 days of a week. Second staging and operation were performed in the sixth week after chemoradiotherapy.
1463752|NCT03245190|Drug|Chiauranib|50mg, orally once daily
1463753|NCT03245177|Biological|Pembrolizumab|Anti-PD-1 antibody
1463754|NCT03245177|Radiation|Radiotherapy|60-66 Gy in 30-33 fractions, 2 Gy per fraction
1948125|NCT02753998|Procedure|Conventional angioplasty|
1948126|NCT02752633|Drug|Allopurinol|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
1463757|NCT03245151|Drug|Lenvatinib|oral hard capsules containing 1 mg, 4 mg, or 10 mg lenvatinib, or an extemporaneous suspension
1463758|NCT03245151|Drug|Everolimus|2 mg, 3 mg, or 5 mg tablets for oral suspension
1463759|NCT03245138|Procedure|Endoscopic Third Ventriculostomy|patients receive an endoscopic third ventriculotomy as surgical procedure
1463760|NCT03245138|Procedure|Ventriculo-Peritoneal Shunting|patients receive an ventriculo-peritoneal shunt as surgical procedure
1463761|NCT03245125|Behavioral|High-intensity interval training|Patients warmed up for 3 min at 30% of peak oxygen consumption (VO2peak). Five 3-minute intervals at 80% of VO2peak and each interval was separated by 3-minute exercise at 40% of VO2peak. The exercise session was terminated by 3-minute cool-down at 30% of VO2peak. All subjects used a EKG and BP monitors as indicators of the assigned exercise intensity. Borg 6-to-20 scale was used to assess the rate of perceived exertion during and after each exercise session. Patients suffering unstable hemodynamic, ischemic cardiac symptoms/signs, and uncontrolled arrhythmia were instructed to immediately terminate exercise training.
1463762|NCT03245112|Drug|Eribulin Mesylate|The patients received intravenous eribulin 1.4 mg/m2 over 2-5 minutes on days 1 and 8 of every 21 days.
1463763|NCT03245099|Other|cross sectional|Electroencephalograph will be done to all patients who fulfill the inclusion criteria to detect presence of electrical discharge with in the brain.Complete blood count ,liver function test ,kidney function test ,blood glucose level and serum electrolytes will be done to selected cases according to the clinical presentation
1463764|NCT03245086|Device|Transanal hemorrhoid dearterialization|The hemorrhoids are operated in their natural position and not distorted by eversion The proctoscope is fully introduced transanally to reach the lower rectum. Under Doppler guidance, six arterial signals are found circumferentially above the dentate line. The approach to make the 'dearterialization' involves the transfixation of the rectal mucosa and submucosa to entrap the artery using a suture. Mucopexy is performed after the artery ligation with the same suture used for the dearterialization. Finally, the suture is tied to fix the mucopexy.
1463765|NCT03245086|Procedure|Ferguson hemorrhoidectomy|The hemorrhoids are operated in their natural position and not distorted by eversion. A Ferguson-Hill retractor is used to expose the hemorrhoids. Dissection with scissors is directed up to the dentate line where the fibers of the sphincter muscles are exposed and only a mucosal pedicle remains attached. A Buie-Smith crushing clamp is applied to this pedicle and the hemorrhoidal mass is excised at the superior level of the clamp. The pedicle is then ligated and the crushing clamp is removed. After dissection of the intermuscular septum is complete, the margins of the wound are drawn upward into the anal canal with stitches and are secured to the pedicle by the same suture. The remainder of the wound is closed with a stitch tied at the outer extremity of the wound using the same suture.
1948127|NCT02752633|Drug|Febuxostat|This is a clinical trial comparing the effect of 80 mg/day of febuxostat to 400 mg/day of allopurinol on the urinary excretion of 2,8-dihydroxyadenine in patients with APRT deficiency.
1463766|NCT03245073|Other|Action observation therapy|The normal human movement will be recorded and than the patients will be watched them.
1463767|NCT03245073|Other|Exercise|Strengthening and stretching exercise programme focuses on hip and knee muscles
1463768|NCT03245060|Behavioral|Adapted Solution Focused Brief Therapy|Solution Focused Brief Therapy is an approach to building positive change in a person's life. It builds up a picture of a client's preferred future (or how a person would like their life to be); encourages a person to notice positive signs of change; and explores personal resources, skills and resilience. In the present project, the therapy has been adapted so that it works well with people who have a language disability.
1463769|NCT03245047|Dietary Supplement|Oral Nutritional Supplement with AN 777|Oral Nutritional Supplement with AN 777, 2 servings a day
1463770|NCT03245047|Other|Oral Nutritional Supplement|Oral Nutritional Supplement, 2 servings a day
1948128|NCT02751320|Drug|0.425 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
1463772|NCT03245021|Drug|Opdivo|"All patients will receive:
Nivolumab 240mg IV q2-weekly for four cycles
Patients in complete remission (CR):
Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)
Patients with partial response (PR), stable disease (SD), asymptomatic or minor progressive disease (PD) post 4cycles receive:
Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles
Patients in CR:
Nivolumab 240mg IV q2-weekly for four further cycles (8 in total)
Patients with PR, SD, asymptomatic or minor PD post 4 cycles receive:
Nivolumab 240mg IV plus rituximab 375mg/m2 IV q2-weekly for four cycles"
1463773|NCT03245008|Drug|MT-5547|Solution for injection in pre-filled syringe
1463774|NCT03245008|Drug|MT-5547-matching placebo|Solution for injection in pre-filled syringe
1463779|NCT03244982|Drug|Fluorescein Na 10% Inj 500mg|Full-dose intravenous Fluorescein Na prior to fluorescein angiography.
1463780|NCT03244982|Drug|Fluorescein Na 10% Inj 250mg|Half-dose intravenous Fluorescein Na prior to fluorescein angiography.
1463781|NCT03244956|Drug|Trametinib|2mg daily for a maximum of 6 weeks of treatment
1463782|NCT03244956|Drug|Dabrafenib|150mg twice daily
1463783|NCT03244956|Radiation|131I|5.5 GBq
1463784|NCT03244956|Drug|rhTSH|0.9mg on two consecutive days after 35 days of treatment
1463785|NCT03244943|Procedure|Non surgical periodontal Treatment|The NSPT, which consisted of subgingival debridement - scaling and root planning (SRP) under local anesthesia. On average, the treatment of the entire oral cavity was completed within four sessions (sessions of 50 minutes). The SRP was performed by one experienced periodontist (KRVV) using Gracey curettes (Hu-Friedy MFG. Co. Inc., Chicago, IL, USA), ultra-sonic devices (Bob-Cat, Dentsply/Cavitron, Long Island City, NY, USA) and, if necessary, with multilaminated drills.
1463786|NCT03244930|Drug|Plerixafor 0.12 mg/kg|Subcutaneously G-CSF 10 mg/kg for 4 days. At day four SC plerixafor 0.12 mg/kg as a single dose 11 hours prior to initiation of aphaeresis.
1463787|NCT03244917|Behavioral|TRAIN-AD|The study intervention is a multi-component training and education program targeting direct care providers and healthcare proxies for advanced dementia NH residents, intended to improve the management of urinary and lower respiratory tract infections in advanced dementia patients. There are two components to this practice intervention: 1. Provider Training, and 2. Proxy Education. Intervention components aimed at the provider include: Professionally led infection management training seminars, online infection management course, and infection management guidance algorithms. Additionally participating prescribing providers will be sent bimonthly infection management feedback reports. Proxy Education is completed by providing an infection management in Advanced Dementia booklet to proxies of patients with AD upon resident enrollment in study.
1463788|NCT03244891|Other|Increase of central volume|"Mild hypovolemia will be induced in healthy volunteers by 12 hours fasting. Three conditions will be considered for the analysis, each of them both during spontaneous breathing and positive pressure ventilation:
baseline
after fluid shift induced by passive head down position at 15 degrees
after fluid challenge with Ringer acetate 15ml*kg in head down position
A total of six steps will be considered for the analysis"
1463789|NCT03244891|Other|Ventilation mode|"Each previous step will be done in two respiratory conditions:
spontaneous breathing
noninvasive ventilation via facial mask in pressure support mode at 8 cmH2O above positive end expiratory pressure of 5 cmH2O, inspiratory fraction of oxygen of 0.25 In both conditions respiratory rate will be set at 18 breaths per min following a metronome"
1463790|NCT03244878|Behavioral|Thrive|A interactive computerized program using structured content of cognitive behavior therapy
1463791|NCT03244865|Device|LaborView Electronic Fetal Monitor|"Per LaborView directions, electrode application sites will be prepared to reduce skin impedance, electrodes will be applied to the maternal abdomen and data acquired for comparison with CTG data obtained through the traditional monitoring system. FHR, ECG, and uterine activity data from the existing fetal monitors will be collected via a laptop PC connected to the systems for comparison. The comparison will be performed off-line.
Nothing is required of the subjects. They will be non-invasively monitored for one to several hours. The information obtained will not be used for medical decision-making and there is no significant risk to the patient or her fetus."
1463792|NCT03244839|Procedure|bariatric surgery|bariatric surgery
1948129|NCT02751320|Drug|0.85 % w/w phytate,1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
1463793|NCT03244826|Other|Shared Care|Shared Care involves four specific strategies to allow patients to have a portion of their care locally after HCT, where clinic and laboratory visits are equally shared between the local oncologist and primary HCT team
1463794|NCT03244826|Other|Standard Care|The usual care provided by the transplant center at DFCI.
1463795|NCT03244813|Other|Personalized activity program|Targeted physical activity
1463798|NCT03244787|Behavioral|patient navigation|Current standard of care is for PNs to work with patients from health centers who are referred by providers. Intervention patients will appear on a PN list without any referral by providers. Control high risk patients will proceed normally and will be eligible to transfer to a PN list after the 6-month study period.
1463799|NCT03244774|Drug|Apatinib|"500mg p.o. qd in first cohort (3 subjects). 750mg p.o. bid in second cohort (3 subjects). 850mg p.o. tid in third cohort (3 subjects)
Other Name:"
1463800|NCT03244774|Drug|POF|The POF regimen consisted of a 3-hour infusion of paclitaxel (135 mg/m2) followed by oxaliplatin (85 mg/m2) and Calcium Levofolinate (200 mg/m2).Subsequently, a 46-hour infusion of fluorouracil (2400 mg/m2) was administered using an ambulatory pump, repeating the cycle every 14 days.
1463801|NCT03244761|Procedure|The modified HFT|The HFT was modified by increasing the expiratory resistance.
1463802|NCT03244748|Procedure|Ventricular tachycardia ablation|Electrophysiologic procedure aims to ablate and terminate arrhythmia percutaneously
1463803|NCT03244735|Other|Atkins diet|A nutritional regimen characterized by high fat low carbohydrate intake.
1463806|NCT03244709|Drug|Tocilizumab|Intravenous Tocilizumab followed by subcutaneousTocilizumab
1463807|NCT03244696|Behavioral|Step Tracking|The step tracking intervention is designed to increase physical activity through the use of self-monitoring and brief motivational materials. The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
1463808|NCT03244696|Behavioral|Water Tracking|The water tracking intervention is designed to increase water intake, to a healthy level, through the use of self-monitoring and brief motivational materials.The motivational materials will be delivered at various points during the intervention. Participants are not required to access and read these materials, however, the hope is these materials will aid in study and goal adherence. Engagement in the intervention will be tracked by the experimenters using the behavioral data gathered by the tracker.
1463809|NCT03244683|Dietary Supplement|Ensure Surgical|Subjects randomized to the intervention arm will consume two Ensure Surgical for 5-7 days.
1463810|NCT03244683|Other|Nutrition counseling|All study subjects will be provided with nutrition counseling at the time of study enrollment.
1463811|NCT03244683|Other|Low-intensity exercise therapy|Patients randomized to the intervention arm will also be provided with verbal and written instructions for light resistance training. The exercises will be performed at home during the preoperative study period.
1463812|NCT03244670|Other|Observation study only, no specific intervention|Observation study only, no specific intervention
1463813|NCT03244657|Drug|conbercept ophthalmic injection （0.5mg）|"The target eye receives intravitreal injection of 0.5mg conbercept ophthalmic injection once every 12 weeks; if a subject meets additional drug administration criteria within 12 weeks between treatments, the subject can receive additional injection treatment"
1463814|NCT03244657|Drug|conbercept ophthalmic injection （0.5mg）|"In principle, the first administration time of the target eye uses the time determined by the assessment at end of STAR study; later, based on treatment-extension drug administration criteria, an investigator determines next visit time/treatment interval according to assessment result at each visit.When a subject's visit/treatment interval extends to 12 weeks, an additional safety visit can be arranged if an investigator considers that there is suspicious active lesion; if assessment result at the safety visit meets additional drug administration criteria, additional injection treatment can be given."
1463815|NCT03244644|Drug|RBX2660|RBX2660 is a microbiota suspension administered as an enema
1463816|NCT03244644|Drug|Placebo|Placebo is normal saline solution administered as an enema
1463817|NCT03244631|Procedure|Lumbar Plexus BLock|Peripheral nerve block
1463818|NCT03244631|Procedure|Pericapsular injection|Injection around the area undergoing surgery
1463819|NCT03244618|Device|CSSP Toothpaste|Toothpaste containing calcium silicate, sodium phosphate and sodium monofluorophosphate
1463820|NCT03244618|Device|Fluoride Toothpaste|Toothpaste containing sodium monofluorphosphate
1463821|NCT03244605|Other|Rehabilitation Training|Patients will be trained in one month after operation. Rehabilitation training include aerobic exercise training (using cycle ergometer for 7-14 times at all, once a day, 15-20 min/time and using treadmill for 7-14 times at all, once a day, 15-20 min/time according to the patient's endurance) and Liu Zi Jue lung exercises, which strengthen the lung function of the human body in Chinese traditional health culture, five times a week, 15 min/time.
1463822|NCT03244605|Other|Rehabilitation Education|General health education
1463823|NCT03244605|Drug|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
1463824|NCT03244605|Drug|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell，taste weight and package
1463825|NCT03244592|Drug|Minocycline|200 mg/day
1463826|NCT03244592|Drug|Sugar pill|Matched placebo
1463827|NCT03244579|Behavioral|Dietary Intervention|Adjusting the quantity and quality of food intake to improve glycemic control, maternal and newborn health outcomes of women with gestational diabetes.
1464179|NCT03241784|Biological|Autologous T-regulatory lymphocytes|intravenous administration of Autologous T-regulatory lymphocytes at a dose of 1x10 to the sixth /kg.
1463828|NCT03244566|Diagnostic Test|positron emission tomography|patients who had esophagectomy with 3-field lymphadenectomy underwent examination of positron emission tomography prior to surgery within 2 weeks.
1463830|NCT03244540|Procedure|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
1463831|NCT03244540|Procedure|QLB (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain
1463832|NCT03244540|Device|Stimuplex Ultra 360 needle|ultrasound-guided needle will be used for QLB and TAP and regional blocks
1463833|NCT03244540|Drug|Ropivacaine|0.375 % ropivacaine will be administered for both QLB and TAP (0.2 mL per kg on both sides)
1463834|NCT03244540|Drug|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
1463835|NCT03244540|Procedure|subarachnoid anesthesia|subarachnoid anesthesia for each patients participating in the study with pencil point needle
1463836|NCT03244540|Procedure|PCA (patient controlled analgesia)|All patients will receive PCA pump with morphine (1 mg/mL, 5 minute interval, no loading dose) after transfer to PACU (post-anesthesia care unit)
1463837|NCT03244540|Drug|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
1463838|NCT03244540|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
1463839|NCT03244540|Drug|Bupivacaine|Subarachnoid anesthesia with spinal bupivacaine (MARCAINE SPINAL 0.5% HEAVY)
1463840|NCT03244527|Dietary Supplement|BCAA supplement|Before each exercise session (described later), the research assistant will give subjects 40g of BCAA or placebo supplement according to the treatment assignment and ask them to drink it down right away.
1463841|NCT03244527|Other|Aerobic exercise|The exercise intervention includes 24 aerobic stationary cycling sessions (30 min/session, 3 session/week, and 8 weeks). The exercise sessions proceed under the supervision and guidance of a therapist.
1463842|NCT03244514|Other|Intervention|Implementation of the cardiovascular AKI bundle (see arm description)
1463845|NCT03244488|Drug|Scopolamine Injectable Product|2.5 or 5 mcg/kg of scopolamine via IV
1463846|NCT03244488|Drug|Mecamylamine Pill|10 or 20mg of mecamylamine orally
1463847|NCT03244475|Device|IASIS Micro Current Neurofeedback|The EEG interface device is the J&J Engineering I-330 C2, provided specifically for IASIS. The EEG sampling frequency is 256 Hz on each of 2 EEG acquisition channels. The feedback LIP-tES is delivered via the 4 EEG leads (A+, A-, B+, B-), with respect to the Common Neck Reference (isolated). During each session, 2 electrodes (A- and B-) are attached to the participant's left and right mastoids, while the remaining two electrodes (A+ and B+) are moved to various locations on the scalp to record EEG signals. All four (A+, A-, B+, B-) electrodes are involved in applying weak electric current pulses back to the brain (the feedback process). The feedback signal consists two types of narrow pulse trains, both with 150 mV in amplitude: A Type 1 pulse is 25 ms in duration and contains carrier waves at ~50 KHz. The repetition rate of Type 1 pulse train is fixed at 3.6 Hz; A Type 2 pulse is 120 ns in duration and contains carrier waves at ~100 MHz.
1948130|NCT02751320|Drug|0.85 % w/w phytate,0.3%ZnCl2 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
1948131|NCT02751320|Other|0 ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
1948132|NCT02751320|Drug|1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
1463851|NCT03244449|Other|No apply|
1463852|NCT03244436|Procedure|Surgery following catheterization|Emergency surgery following pediatric cardiac catheterization
1463853|NCT03244423|Drug|Normal saline at induction|at the induction of anesthesia before start of surgery (0.5 ml/kg)
1463854|NCT03244423|Drug|Normal saline infusion|infusion of unlabeled saline 1ml/kg/hr. during surgery till six hours postoperatively
1463855|NCT03244423|Drug|Intravenous tranexamic acid|Intravenous tranexamic acid 50 mg/kg at the induction
1463856|NCT03244423|Drug|infusion tranexamic acid|tranexamic acid 1mg/kg/hr infusion intraoperative till 6 hours postoperative
1463857|NCT03244423|Drug|topical tranexamic acid|50 mg/kg added to the poured normal saline 2 ml/kg into the pericardial cavity before sternal closure
1463858|NCT03244423|Drug|topical normal saline|normal saline 2 ml/kg into the pericardial cavity before sternal closure
1463859|NCT03244410|Diagnostic Test|complete blood picture|complete blood picture
1463860|NCT03244397|Other|Physical therapy + educational strategy|See arm/group descriptions
1463861|NCT03244397|Behavioral|Educational strategy|See arm/group descriptions
1948133|NCT02751320|Drug|0.3%ZnCl2, 0.5% sodium citrate, 1150ppm F|Participants were assigned with 1.5±0.1g twice daily dentifrice for one timed minute.
1995068|NCT02858908|Drug|Tideglusib|
1463868|NCT03244371|Other|blood draw|4 blood draws of 25 mls of blood will be performed at 4 differents time points (before treatment, 4 weeks later, at the end of the treatment and 6 months after the end of the treatment)
1463869|NCT03244358|Drug|Epalrestat|Epalrestat 50mg tid added to standard chemotherapy treatment
1463870|NCT03244345|Behavioral|Self-measurement scale of sensitivity to stress/emotion|Patient will answer self-questionner on Depression
1463871|NCT03244332|Other|Collecting Clinical Data|Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)
1463872|NCT03244332|Other|Collecting laboratory data|Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.
1464180|NCT03241784|Biological|Interleukin-2|Subcutaneous Interleukin-2 at a dose of 2x10 to the fifth IU/m2, three times a week.
1463876|NCT03244306|Biological|Patient-derived CD22-specific CAR T-cells also expressing an EGFRt|Patient-derived CD22-specific chimeric antigen receptor T-cells expressing an EGFRt
1463877|NCT03244293|Other|no intervention|
1463878|NCT03244280|Drug|MOB015B|Topical formulation
1463879|NCT03244267|Behavioral|Standard Education|Participants will receive the usual verbal education and printed information provided to patients about the importance of taking aspirin to prevent thromboembolic events after orthopedic surgery, medication dosage and scheduling.
1463880|NCT03244267|Behavioral|Medication Reminder App|Participants will use a medication reminder app that is set in collaboration with the participants for times that fit into their daily lifestyle. The app will alert participants when it is time (selected by the participant) to take their medication.
1463881|NCT03244241|Drug|Insulin Degludec 100 UNT/ML [Tresiba]|Basal-bolus insulin regime
1463882|NCT03244228|Drug|HTL0016878|Oral solution
1463883|NCT03244228|Drug|Placebo - Concentrate|Matching placebo
1463884|NCT03244215|Diagnostic Test|Corneal Confocal Imaging|Retinal imaging will be ordered for all subjects in the study group. Corneal
1463885|NCT03244215|Diagnostic Test|Magnetic resonance Imaging|MRI will be ordered for all study subjects at the completion of their participation at year 1. The MRI will assess the the progression or regression of the cerebrovascular health of the study subjects.
1463886|NCT03244215|Other|Blood sample|Blood samples will be obtained to evaluate the levels of blood inflammatory biomarkers in both the subjects and control group.
1463887|NCT03244202|Other|Decision Aid Plus Counselling|The Genomics ADViSER is an decision aid designed to inform patients about genomic sequencing (GS) and aid them selecting which incidental findings they would like to receive from GS.
1463888|NCT03244202|Other|Genetic Counselling Only|Participants will learn about genomic sequencing and incidental findings by speaking directly with a genetic counsellor and select which incidental findings they would like to receive with a genetic counsellor.
1463892|NCT03244176|Drug|Avelumab|"All participants will receive the following treatment:
Induction phase Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 2 cycles Plus Rituximab at a dose of 375mg/m2 as an IV infusion over at least 1 hour once every 2 weeks for 2 treatments
Then:
RCHOP - All participants will receive RCHOP chemotherapy treatment for 6 cycles. Each cycle will last for 21 days. Rituximab, cyclophosphamide, doxorubicin, and vincristine are given on the first day of each cycle by intravenous infusion. Prednisone is given orally from Day 1 until Day 5 of each cycle.
Then:
Maintenance phase - All participants will receive Avelumab at a dose of 10 mg/kg as a 1hour intravenous (IV) infusion once every 2 weeks for 6 cycles."
1463893|NCT03244163|Device|Spyglass DS cholangioscope|The 1.8Fr holmium:YAG laser fiber (Lumenis, Yokneam, Israel) will be inserted into the cholangioscope's working channel for lithotripsy under direct visualization. An EHL probe may alternatively be used depending on availability. Lithotripsy is applied until fragments of the targeted stone are no longer lumen filling, and can be dispersed easily with fluid irrigation. Fragmented stones are then removed by a combination of conventional techniques. To confirm stone clearance, the Spyglass DS cholangioscope will be re-introduced, and the bile duct will be examined for residual stones from the confluence of the right and left intrahepatic ducts to the papillary opening
1463894|NCT03244163|Device|BML|Biliary sphincterotomy with/without EPBD to the size of the lower bile duct with a limit of 15mm will be performed. Stones are removed by a combination of conventional BML, extraction balloon and/or baskets, without laser lithotripsy. An occlusion cholangiogram is performed to confirm stone clearance. In cases where stone clearance is incomplete, a plastic biliary stent bridging the stone will be inserted for temporary drainage until definitive management, usually within one month.
1463895|NCT03244137|Other|Pulmonary rehabilitation|See group description.
1463896|NCT03244124|Other|Self-Etching Application Strategy|In Group SET, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
1463897|NCT03244124|Other|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 30 seconds, only in enamel in 50 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
1463921|NCT03243916|Radiation|TACE plus Cyber knife|Patients with histologically confirmed MHCC(Massive Hepatocellular Carcinoma) will receive TACE therapy,after 1 or 2 week's recovery from hepatic insufficiency ,the targeted and staged cyber knife will be given
1463922|NCT03243903|Device|QS-M insulin-free injector|Using QS-M insulin-free injector as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
1463923|NCT03243903|Device|needle-insulin pen|Using needle-insulin pen as insulin carrier to control blood glucose of T2DM and insulin dose is prescribed.
1535142|NCT02705612|Drug|nimotuzumab|
1463898|NCT03244124|Other|Etch&Rinse Dry Application Strategy|In Group ERDry, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin dry (but not overdry) and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
1463899|NCT03244124|Other|Etch&Rinse Wet Application Strategy|In Group ERWet, 37% phosphoric acid will be applied during 30 seconds, only in enamel, and 15 seconds, only in dentin, in 50 teeth. This acid will be removed using water, the cavity will be air-dried, keeping dentin wet and then, the adhesive system Futurabond Universal will be used in 50 teeth, according to the manufacturer's instructions. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite Admira Fusion (VOCO GmbH, Germany), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
1463900|NCT03244111|Behavioral|simple memory tool|The goals may be implemented using the simple memory tool. Simple memory tool involves using materials such as checklists or diaries to assist with memory.
1463901|NCT03244098|Behavioral|Transition Assistance Program|TAP caregivers will receive an SCI caregiving guidebook, a 1-hour intervention session by an SCI clinician before hospital discharge, and four 1-hour telehealth clinic-to-home visits at 1, 2, 4, and 6 weeks after discharge by the same clinician
1463902|NCT03244085|Drug|QL-007 tablet|Patients will be enrolled in 1 of 3 cohorts (6 patients per cohort): QL 007 200 mg/day (100 mg BID), or QL 007 400 mg/day (200 mg/BID), or QL 007 600 mg QD. QL 007 will be administered orally daily over the 28 days under fasted state. Patients fast for 2h before administration and 1h after administration.
1463903|NCT03244072|Drug|Moxifloxacin|Intracameral injection
1463904|NCT03244072|Drug|Placebo|intracameral injection
1463905|NCT03244059|Biological|Belimumab|Belimumab is an anti-BLyS (B-lymphocyte stimulating factor) agent administered by infusion.
1463906|NCT03244059|Drug|Placebo|An identically appearing placebo infusion.
1463907|NCT03244046|Behavioral|Psychotherapy|The SE intervention followed the nine-step model as outlined by Peter Levine (2010) and involved gradually eliciting awareness of body sensations associated with the traumatic event. By the process of 'titration', patients were gradually encouraged to access somatic activation, feelings and body sensations as means to restore equilibrium to the autonomic nervous system and thereby alleviate hyperarousal, re-experiencing and avoidance of trauma-related experiences and thoughts.
1463908|NCT03244046|Behavioral|Physiotherapy|This treatment consisted of supervised exercises for low back pain delivered in 12 sessions and performed by physiotherapists in the center according to the European guidelines for the management of chronic low back pain (Airaksinen, et al., 2006).
1463909|NCT03244033|Other|Contextual clinical decision support|Incorporation of contextual data into EHR clinical decision support alerts
1463910|NCT03244033|Behavioral|Contextual survey|Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
1463911|NCT03244020|Drug|Aspirin 325mg|Aspirin 325 mg by mouth once daily
1463912|NCT03244020|Drug|Enoxaparin 40Mg/0.4mL Prefilled Syringe|Enoxaparin 40 mg subcutaneous injection once daily
1463913|NCT03244007|Procedure|Vitrectomy|
1463914|NCT03243994|Diagnostic Test|Absorption test with D-xylose and zink|Absorption of D-xylose (25 g) and zinc (132 mg), administered as a single dose. The concentration of D-xylose and zinc was measured in peripheral blood one, two and three hours after ingestion and used as markers of absorption. Furthermore, urine was collected for five hours to determine the amount of excreted D-xylose.
1463915|NCT03243981|Device|Broadband Light Technology: The Sciton SkinTyte (800-1800nm)|since this device has been used in the clinical setting to reduce cheek and submental laxity (Gold, 2010). It incorporates the broadband light technology with an emphasis on 590 nm filter to achieve these clinical results.
1463916|NCT03243955|Device|Verum TEAS|TENS unit with electrodes applied to acupuncture point locations
1463917|NCT03243955|Device|Sham TEAS|TENS unit with electrodes applied to non-acupuncture point locations
1463918|NCT03243942|Drug|Definity|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Definity infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
1463919|NCT03243929|Behavioral|Translation of District Sun Safe Policies to Schools|Translation of District Sun Safe Policies to Schools intervention was guided by Diffusion of Innovation Theory. Principals and other staff in intervention schools received 1) initial coaching meeting that guided principals through an evaluation of current sun safety practices, the selection of goals for the implementation of sun safety practices, and guidance on the use of intervention materials to support implementation of sun safety practices in the school, 2) follow-up communications from coaches including email, telephone, and virtual meetings, 3) access to media and online resources to support implementation of sun safety practices, 4) mini-grants to support changes in school sun safety practices. These components promoted implementation of the 10 policy components recommended by CDC.
1463920|NCT03243929|Behavioral|Attention Control|Schools in the control condition received three emails during the 20 month intervention period including (1) NASBE's Fit Healthy and Ready to Learn; A School Health Guide Part II: Policies to Promote Sun Safety and Prevent Skin Cancer, (2) CDC's Guidelines for Sun Safety to Prevent Skin Cancer, and (3) a link to the Surgeon General's 2014 Call to Action to Prevent Skin Cancer. This attention-control treatment will equalize schools on awareness of recommendations to implement school sun safety.
1464256|NCT03241173|Drug|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
1537388|NCT02688959|Behavioral|Exercise|
1463924|NCT03243890|Dietary Supplement|Menaquinone-7 720 µg/day including the recommended daily dose of vitamin D (25 µg/day).|Half of the patients are randomized to supplementation with MK-7 (720 µg/day) including the recommended daily dose of vitamin D (25 µg/day).
1463925|NCT03243890|Dietary Supplement|Placebo|Half of the patients are randomized to placebo treatment (no active treatment).
1463926|NCT03243877|Other|MammoAlert Screening Test|Plasma obtained from blood samples will be analyzed with the MammoAlert Screening Test for the presence of known breast cancer bio-markers.
1463927|NCT03243864|Drug|Ceftazidime-avibactam|Patients will be started on 2.5 gm IV every 8 hours
1463928|NCT03243851|Drug|Temozolomide+Metformin|Low dose temozolomide+metformin for 24 weeks
1463929|NCT03243851|Drug|Temozolomide+Placebo|Low dose temozolomide+placebo for 24 weeks
1463930|NCT03243838|Drug|Apatinib|docetaxel/carboplatin combined with apatinib as Neoadjuvant Treatment for Triple-Negative Breast Cancer
1463931|NCT03243825|Radiation|combination group|chemotherapy (paclitaxel/cisplatinum) and brachytherapy
1463932|NCT03243825|Drug|chemotherapy group|chemotherapy: (paclitaxel/cisplatinum)
1463933|NCT03243812|Biological|Blood sampling|Blood sampling will be performed to assess hematological and hemorheological parameters
1463934|NCT03243812|Other|Maximum Voluntary Contraction (MVC) test force|Maximum Voluntary Contraction (MVC) test force will be performed before and after a localized muscle endurance test
1463935|NCT03243812|Other|Localized muscle endurance test|Subject will perform 4 series of 20 submaximal dynamic contractions at 50% of the MVC interspaced with 1 min recovery.
1463936|NCT03243812|Other|Self-paced six-minute walk test|Self-paced six-minute walk test will be conducted according to the guidelines of the American Thoracic Society
1463937|NCT03243799|Behavioral|Group psychoeducation|Educational group sessions for patients with depression and physical comorbidities in order to improve the degree of control of their illnesses
1463938|NCT03243786|Behavioral|Lifestyle- Supportive Care|The intervention examines dietary and activity patterns, body composition, biomarkers and quality of life in breast cancer patients undergoing radiation therapy
1463939|NCT03243773|Other|Lung ultrasound|Point-of-care ultrasound exam of both lungs in 4 predefined zones.
1463940|NCT03243760|Drug|CCI15106 7.5 mg capsule|Orange capsule containing a white to off-white powder, 21.4 mg of CCI15106: Trehalose:Trileucine 35/55/10 weight by weight (w/w)
1463941|NCT03243760|Drug|Placebo|Orange capsule containing a white to off-white powder, 21.4 mg of Trehalose:Trileucine 85/15 w/w
1463942|NCT03243760|Drug|Placebo-2|Orange capsule containing a white to off-white powder, 21.4 mg of lactose. Placebo-2 to be used if unexpected safety signals are observed with the use of matching placebo.
1995071|NCT02859168|Behavioral|Myofascial Induction|Patients received a Myofascial Induction focused on the upper limb area for 30 minutes using the Pilat approach.
1995072|NCT02859168|Device|Unplugged pulsed shortwave therapy|Patients received a placebo session consisted of 30 minutes of unplugged pulsed shortwave therapy.
1463947|NCT03243695|Other|Angled Abutment|virtual implants will be placed on a planning software allowing abutments to be placed at an angle to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The angled abutment will be placed and a temporary crown material will be fabricated.
1463948|NCT03243695|Other|straight abutment|virtual implants will be placed on a planning software allowing abutments to be placed at straight to the implant. Teeth will be extracted at the surgery using periotome and implants will be placed using computer aided surgical guide. The straight abutment will be placed and a temporary crown material will be fabricated.
1463949|NCT03243682|Procedure|Bidirectional Shock Wave Lithotripsy|the alternating bidirectional (under and over table) approach during SWL for renal and upper lumbar ureteric stones
1463950|NCT03243682|Procedure|Standard Shock Wave Lithotripsy|the standard unidirectional approach during SWL for renal and upper lumbar ureteric stones
1463951|NCT03243669|Diagnostic Test|High-definition|High-definition colonoscopy
1463952|NCT03243669|Diagnostic Test|Virtual chromoendoscopy|Virtual chromoendoscopy
1463953|NCT03243669|Diagnostic Test|Standard|Standard colonoscopy
1463954|NCT03243656|Drug|Eltrombopag|An oral thrombopoietin receptor agonist
1463955|NCT03243643|Drug|HS-10241|HS-10241 is provided as white, film-coated,immediate release tablets containing HS-10241 at dosage strengths of 20mg/50mg/100 mg. Multiple tablets of HS-10241 will be administered daily to achieve targeted doses of HS-10241: 200 mg-1200 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
1463956|NCT03243643|Drug|Apatinib|Apatinib is provided as white, film-coated,immediate release tablets containing aptinib at dosage strengths of 250mg. Apatinib will be administered daily to achieve targeted doses of 500 mg. Tablets will be orally administered with 240 ml water, once daily, 1 hour before/after a meal.
1463957|NCT03243630|Drug|IV nicotine|Subjects in each arm will receive three infusions in a random order one hour apart. The infusions will be saline, 0.25mg/70kg and 0.5mg/70kg
1463958|NCT03243630|Drug|Menthol flavor|American e-liquids' menthol flavor used in e-cigarettes will be used as the placebo comparator
1463959|NCT03243630|Drug|green apple|green apple will be added to the menthol flavor
1463960|NCT03243630|Drug|green apple and menthol|menthol and green apple will be the active intervention
1463961|NCT03243617|Other|Placebo|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:
LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.
RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.
Subjects may not wash their body with soap and water AFTER the applications"
1464330|NCT03240770|Other|Deviation from Standard Tray Wear Time (14 Days)|Patients reduced Tray Wear Time Interval (14 Days)
1464401|NCT03240185|Behavioral|deep breathing exercises|Patients receive education on deep breathing exercises for pain control as part of their pre-operative appointment
1463962|NCT03243617|Other|AO+Mist|"Subjects are instructed in the use of the spray bottle and asked to self-administer the Test Product as follows:
LEFT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: LEFT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.
RIGHT side of the body where skin is affected: Five (5) pumps of Spray (BOTTLE LABELED: RIGHT) must be applied twice-a-day to the entire area affected by KP once in the morning and once in the evening for 28 days.
Subjects may not wash their body with soap and water AFTER the applications"
1463963|NCT03243604|Drug|L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)|Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)
1463964|NCT03243591|Other|Livionex gel|Brushing area of mucositis with gel
1463965|NCT03243591|Other|Aquafresh gel|Aquafresh gel
1463966|NCT03243578|Other|None as this is an observational study|
1463967|NCT03243565|Biological|OM-85|OM-85 is an oral bacterial lysate of 21 different strains of 8 species and sub-species of the most common respiratory tract pathogens.
1463968|NCT03243565|Biological|Placebo|Pregelatinized starch (Starch 1500)+Mannitol+Magnesium stearate+Anhydrous propyl gallate+Sodium glutamate
1463969|NCT03243552|Drug|L-DOPA versus Placebo|Participants will be randomized in a blocked schedule to yield 1:1 L-DOPA: placebo assignment.
1463970|NCT03243552|Behavioral|Social Skills Training|ASD participants will be enrolled concurrently in a 16-week manualized, structured, group-based, social skills training program (PEERS).
1463971|NCT03243539|Procedure|Lung Protective Ventilation|Neuro lung protective ventilation for patients with acute brain injury is designed to target a normal partial pressure of arterial carbon dioxide and decrease initial tidal volumes toward a target 6 ml/kg predicted body weight PBW (range 6 to 8 ml/kg PBW)
1463972|NCT03243526|Other|fluid therapy|fluid resuscitation guided by CVP or PPV
1463973|NCT03243513|Other|Retrospective Chart Review|There is no intervention in this research. This research project is a retrospective chart review.
1463974|NCT03243500|Drug|Atracurium|5mg in 1 ml normal saline
1463975|NCT03243500|Drug|Lidocaine 2%|
1463976|NCT03243500|Drug|Bupivacaine 0.5%|
1463977|NCT03243500|Drug|hyaluronidase powder|1500 iu powder diluted in 2 vial lidocaine 20 ml resulting 37.5 IU/ml lidocaine and 93.7 / 2.5 ml lidocaine or 15.6 IU/ml of the 6 ml solution
1463978|NCT03243500|Procedure|per-caruncular peribulbar injection|The patient will lie in a supine position and the eyes are in the neutral position. The needle (25 Gauge (G), 25 mm) insertion point will be just medial to the caruncle, directly perpendicular to the face and parallel to the medial orbital wall to 15-20 mm depth. After negative aspiration the already chosen local anesthetic mixture will be injected slowly. During injection, the globe will be palpated with one finger and tension in the lids will be tested frequently, if the lids become tense or if the tension is felt to rise in the globe, the injection will be stopped. After injection, external compression with Honan balloon inflated to 20-30 mm Hg will be applied for 10 minutes and will be removed every 2 minutes to test akinesia and anesthesia
1463979|NCT03243487|Behavioral|structured adherence management program|Structured adherence management service (PAMS) program and a web-based information program designed for participants beginning positive airway pressure therapy
1463980|NCT03243487|Behavioral|Standard of care|Standard care provided at a VA Sleep Center for participants beginning positive airway pressure therapy
1463983|NCT03243435|Procedure|Native 1,5 Tesla breast MRI|
1463984|NCT03243422|Other|Successful aging education intervention|"The Successful Aging intervention will follow the protocol and materials developed for the 10 Keys™ to Healthy Aging program by the Center for Aging and Population Health Prevention Research Center at the University of Pittsburgh1. This interactive, dynamic program informs older adults about risk factors for diseases. Participants will meet individually with a health educator certified to administer the program every 2-3 weeks for a total of 4 visits over 8-10 weeks, and the session content will focus on a Key. Each session will also include a 5-10 minute active upper body extremity stretching program as used in the Lifestyle Interventions and Independence for Elders (LIFE) study. Participants will return for booster sessions semi-annually beginning at 6 months post-randomization."
1463985|NCT03243422|Other|Hearing intervention|The hearing intervention consists of fitting with hearing aids and other hearing assistive technologies plus four 1-hour comprehensive, individualized hearing rehabilitation sessions spaced over the 2-3 months post-randomization designed to provide all of the active components of the intervention. Hearing aids are instructed to be worn on a daily basis for study duration. Audiologic outcomes (e.g., hearing aid data logging, real ear measures, speech in noise, etc.) to verify the best-practices hearing intervention are gathered during study intervention visits and semi-annually beginning at 6 months post-randomization.
1463986|NCT03243396|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Eight small-group sessions, including eight children and one guardian for each child, will meet separately, with joint activities in the final three sessions. TF-CBT will be delivered via community health volunteers in the community setting, and via selected teachers in the school setting--with two lay counselors leading the child group, and one leading the guardian group. Most TF-CBT components (psychoeducation, parenting, relaxation, cognitive coping, grief specific skills) will be delivered in groups, but 2-3 individual sessions mid-group will be used for imaginal exposure (i.e., talking about/processing traumatic events).
1463987|NCT03243383|Other|DiaTOHC Program|"Patient-centered education 1a) Standardized diabetes discharge instructions and education 1b) Comprehensive discharge plan review
Peri-discharge coordination of care
A1c-based adjustment of diabetes therapy
Post-discharge support"
1463988|NCT03243357|Procedure|TF Adaptive (First Apical Binding File)|"Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).
Procedure: Instrumentation based on protocol of First Apical Binding File The enlargement of the root canal will be performed with three files larger than the diameter of the previously established initial apical file."
1463989|NCT03243357|Procedure|XP Endo Finisher|"Procedure: TF Adaptive System NiTi (Nickel titanium) Endo File System (SybronEndo) The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor) according to manufacturer's protocol.
Procedure: XP Endo Finisher The device is moving in continuous rotational in Elements Motor (800 rpm/Torque 1N), after the complete instrumentation ."
1463990|NCT03243357|Procedure|TF Adaptive (Control)|"Procedure: TF Adaptive System NiTi (Nickel titanium)Endo File System The root canal instrumentation will be performed by the TF Adaptive features Adaptive Motion (Elements Motor).
Procedure: Instrumentation based on manufacturer's protocol The enlargement of the root canal will be performed according to the manufacturer's directions."
1463991|NCT03243344|Device|Surgiflo|using device during the endonasal surgery.
1463992|NCT03243344|Device|Floseal|using device during the endonasal surgery.
1463993|NCT03243344|Device|Algosteril|using device during the endonasal surgery.
1463994|NCT03243331|Drug|Gedatolisib|Gedatolisb will be intravenously administered on Day 1, Day 8 and Day 15 of every 21 day cycle at a dose of 110 mg or 180mg depending on cohort assignment.
1463995|NCT03243331|Drug|PTK7-ADC|PTK7-ADC will be administered on Day 1 of every 21 day cycle at a dose of 1.4mg/kg or 2.8 mg/kg depending on cohort assignment.
1463996|NCT03243318|Diagnostic Test|MEPs induced by TMS|Using TMS induced MEPs over motor cortex of the affected side to predict motor recovery potentials
1463997|NCT03243305|Drug|AMPHORA|non-hormonal contraceptive vaginal gel
1463998|NCT03243292|Other|Bronchial Thermoplasty|patients had radio frequency ablation of the smooth muscle for asthma
1463999|NCT03243266|Diagnostic Test|CBC/Diff Reference Interval|Results will not be used to manage patients
1464000|NCT03243253|Other|all the data collection have done by CDC.|In this study there was no intervention, just simple data collection via CDC.
1464001|NCT03243240|Diagnostic Test|mutlidetector computed tomography|"Multidetector computed tomography angiography with 16- MSCT scanner, medical system bright speed. Our protocol will include non-enhanced scanning then perform a triphasic angiography that includes arterial, portal and venous phases to detect acute gastrointestinal bleeding.
Images will be acquired with the following parameters slice thickness 5mm for the unenhanced phase and 1.25mm for the arterial phase and porto-venous phases"
1464004|NCT03243214|Device|TMS|Real or Sham TMS will be given to the PD-MCI patient
1464005|NCT03243214|Device|Sham-TMS|Real or Sham TMS will be given to the PD-MCI patient
1464006|NCT03243201|Drug|Colloidal silver nanoparticles|Contains 10ppm colloidal silver nanoparticles
1464007|NCT03243201|Other|Purified Water|Purified water will be given as placebo
1464008|NCT03243188|Other|Qualitative interview|Qualitative data will be obtained through semi-structured interviews with adults with cancer and palliative care needs. Patients will be invited to bring their carer to the interview. EG will conduct and transcribe up to 30 audio-recorded semi-structured interviews, which will be carried out at the patient's preferred location (either at home, over the phone, or in a pre-booked room at St Joseph's Hospice). EG will ask questions relating to sociodemographic data (recording this on the Personal Information Sheet) prior to starting the interview.
1464009|NCT03243175|Drug|Apixaban 5 MG|Apixaban 5mg x 2 during 24 months
1464010|NCT03243175|Device|left atrial appendage closure|left atrial appendage closure
1464011|NCT03243162|Behavioral|CBPT-ACLR|The CBPT-ACLR program focuses on a patient-oriented approach to improve sports function and return to sport. CBPT-ACLR sessions cover realistic expectations, relaxation strategies, problem-solving training, cognitive restructuring, and behavioral self-management (i.e., graded activity, goal setting, managing setbacks and symptom management plans). Each session builds upon the content of the previous session using an action plan and weekly homework is personally tailored based on patient goals. The program consists of one preoperative telephone session and six postoperative telephone sessions with a physical therapist trained in CBPT. Sessions are 30 minutes and the postoperative sessions occur for the first 8 weeks after surgery. Each patient randomized into the CBPT-ACLR program will receive a manual to follow along with the study therapist.
1464012|NCT03243162|Other|Education|The education program focuses on postoperative ACLR recovery. Sessions address benefits of physical therapy, proper biomechanics during sports and other functional activity, importance of early exercise after surgery, and ways to promote healing. Education on stress reduction, sleep hygiene, energy management, communication with health providers, and preventing future injury are also provided. The Education program is matched to the CBPT-ACLR treatment in terms of session frequency, length and contact with the study therapist. Each patient randomized into the Education program will receive a manual to follow along with the study therapist.
1464013|NCT03243149|Device|fMRI - GE Medical System|"Recovery from PTSD symptoms has been modeled experimentally as fear extinction that depends on three interconnected brain regions that involve the amygdala where extinction memories are stored, the subcallosal/subgenual cortex within the medial PFC involved in consolidation of the extinction memory, and the hippocampus which mediates the context specificity of context specificity of extinction.
The two MRI systems are used for human research by many faculty and research groups at Duke and UNC, Chapel Hill. The center has two research dedicated General Electric MR 750 scanners with a field strength of 3 Tesla. These systems use a combination of General Electric production pulse sequences and custom research pulse sequences that have been developed by Brain Imaging and Analysis Center faculty and other MR physicists. The scanners are used for imaging and spectroscopy."
1464014|NCT03243136|Other|Exposure of interest is food insecurity|Households were considered food insecure if any of the following conditions were met in the past 12 months: 1) a member of the household worried that there would not be enough food to eat because of a lack of money, 2) a member's food intake was reduced as a result of there not being enough food to eat, or 3) the desired variety or quality of foods was not eaten because of a lack of money. This exposure variable was operationalized as a binary variable with levels of food secure vs. food insecure.
1464396|NCT03240224|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
1537389|NCT02688946|Other|Not provided|
1464015|NCT03243123|Device|Robotic passive mobilization|The intervention was performed using the Gloreha (Idrogenet, Italy) robotic system. The system consists of a soft exoskeleton similar to a glove. Passive hand joints mobilization is provided by a hydraulic system. Each patient underwent a session of 20 min passive mobilization of the paretic hand.
1464016|NCT03243110|Diagnostic Test|breathing test|Spirometry is a non-invasive means of measuring lung function: The subject is asked to take a deep breath and then exhale into the sensor as hard and as long as possible. Soft nose clips may be used to prevent air escaping through the nose. If the patient does not show a definitive diagnosis of asthma, a methacholine challenge test will be performed to elicit bronchoconstriction in patients. In methacholine challenge test, the patient breaths in standardized dose of nebulized methacholine again. Methacholine challenge test is widely accepted and standardized method for assisting the diagnosis of asthma and there will be no experimental altercation in the method methacholine challenge is performed.
1464017|NCT03243097|Device|Phase I - Standard Microphone Cros Input|Subject will be fit with the research processor plus CROS microphone and wear for a 4 week period
1464018|NCT03243097|Device|Phase II - Automatic directional microphone Cros Input|Automatic directional microphone technology will be activated in the research processor. Subjects will wear the CI+CROS configuration with directionality activated exclusively for 4-weeks.
1464019|NCT03243097|Device|Phase III - No Cros Input|Subjects will return the research processor and CROS device and wear their own processor for a 2-week period
1464020|NCT03243084|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session
1464021|NCT03243084|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied
1464022|NCT03243071|Behavioral|Tailored Website|Participants randomized to the intervention arm will have free access to a password protected interactive culturally and linguistically tailored website via a tablet device. No private identifiable data about you will be collected. Participants will receive a brief 10-minute tutorial by a trained research assistant on login procedures and use of the website.
1464023|NCT03243071|Behavioral|Standard Website|Participants randomized to the control condition will have free access to the NYU standard clinical trials website. Participants in the control condition will have access to the tailored website at the date of study completion (no later than 6 months' post-date of enrollment).
1464024|NCT03243058|Drug|Proleukin® (Aldesleukin; IL-2)|Administration of Low-Dose Interleukin
1464025|NCT03243058|Drug|Placebo - Concentrate|Randomized Placebo group will be administered subcutaneously
1464026|NCT03243045|Procedure|Renal sympathetic denervation|Transcutaneous renal sympathetic denervation
1464027|NCT03243032|Drug|Ibuprofen 600 mg|Ibuprofen 600mg given 30 minutes prior to beginning of surgery
1464028|NCT03243032|Drug|Local anesthetic Group 1|0.5% bupivacaine with 1:200,000 epinephrine as the local anesthetic for Group 1 Experimental.
1464029|NCT03243032|Drug|Placebo oral capsule|Placebo (Microcrystalline Cellulose NF (Avicel PH 105) - compounded at the University of Iowa College of Dentistry Pharmacy) given 30 minutes prior to beginning of surgery
1464030|NCT03243032|Drug|Local anesthetic Control|2% lidocaine with 1:100,000 epinephrine as the local anesthetic for Group 2 - Control
1464031|NCT03243019|Drug|rapamycin|oral administration
1464032|NCT03243019|Device|MRI|cervicofacial MRI
1464033|NCT03243019|Biological|Rapamycin dosage|Biological dosage of Rapamycin level
1464034|NCT03243006|Drug|paracetamol|2 tablets of 500mg of paracetaol are given to every patient
1464035|NCT03243006|Drug|Paracetamol + Tramadol|1 t ablet of 325 mg of paracetamol + 37.5 of tramadol and one tablet of placebo are given to patient
1464036|NCT03243006|Drug|Placebo Oral Tablet|2 tablets are given to patients
1464037|NCT03242993|Drug|[18F]-AzaFol|[18F]-AzaFol is a radiotracer produced at ETH Hönggerberg in a radiopharmaceutical GMP facility. The drug product is provided as sterile solution for intravenous injection in a glass vial containing 6 mL of formulated product, the maximal applicable dose being 600 MBq.
1464038|NCT03242993|Drug|folarell|"For the purpose of this study only 1 mg folic acid (corresponding to 0.2 mL Folarell®) will be injected 5 min prior to [18F]-AzaFol. Due to this low dose of a single injection of folic acid it is unlikely that adverse events would occur.
Folarell® is a folic acid preparation for intravenous or intramuscular injection"
1464039|NCT03242980|Behavioral|Structured adherence counseling|"Patients will undergo one standardized enhanced adherence counselling session. Counselling guidelines and a brochure were specifically developed to guide the adherence counselling for individuals with unsuppressed VL. All nurses at the health centres will be trained on the counselling prior to the cross-over to the intervention. The brochure was developed by culturally adapted by social scientists and contains only 3 key messages. The brochure will be given to the patient to take home.
Four weeks after the adherence counselling session, a SMS will be sent to the patient reminding them to take their ART. The content of the text message will be anonymous to protect disclosure and discussed/agreed upon with the patient during the adherence counselling."
1464040|NCT03242967|Drug|Vadadustat|Oral tablet
1464041|NCT03242967|Drug|Darbepoetin alfa|subcutaneous or intravenous
1464074|NCT03242694|Diagnostic Test|LA pressure, voltage map, strain, scar-map, blood sampling|invasive LA pressure monitoring, LA voltage map creation, LA strain evaluation by transthoracal echocardiography, LA scar-mapping by cardiac MRI, defining biomarkers from blood samples during atrial fibrillation and after pulmonary vein isolation in sinus rhythm
1464075|NCT03242694|Procedure|pulmonary vein isolation|pulmonary vein isolation without creating additional ablation lesions
1464397|NCT03240224|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
1464045|NCT03242941|Procedure|Pulmonary vein ablation|After pulmonary vein isolation, during the routine waiting time of half an hour to confirm efficacy of the ablation, the study procedure will be performed.Septal catheter, already in place in right atrium, will be positioned on the interatrial septum, via transeptal puncture.If the patient will not be in sinus rhythm, he/she will be externally cardioverted. During sinus rhythm pacing thresholds and impedances on all septal catheter electrodes will be determined. Next, atrial fibrillation will be induced by rapid atrial pacing.AF cycle length will be determined in the left atrial appendage, during 1 minute of atrial fibrillation using ablation catheter electrodes.Subsequently a pacing scheme will be applied and capture on decapolar recording catheters, already in place for the standard ablation procedure will be assessed as well as AF termination.
1464051|NCT03242902|Device|Light therapy intensity 1|Exposure to white light (10.000 lux) in the morning
1464052|NCT03242902|Device|Light therapy intensity 2|Exposure to white light (10-20 lux) in the morning
1948134|NCT02748174|Behavioral|Audio Files|Patients will be given a link to download audio files. They consist of breathing techniques, imaging, progressive relaxation, and more. Patients will be asked to perform 20 minutes of relaxation therapy at least 3 times per week. Patients will record their headache frequency and intensivy, in addition to other symptoms, and the frequency of practiving the behavioral therapy using Curelator Headache.
1464054|NCT03242876|Other|Control|Control will be 109 g white bread to be consumed together with 200 mL water
1464055|NCT03242876|Other|Test|Test will be 109 g white bread to be consumed together with 3.819 g citric acid and 119 mg malic acid dissolved in 200 mL water adjusted to pH 3.2.
1464056|NCT03242863|Other|Food proportionality|Proportions of high and low energy dense foods manipulated
1464057|NCT03242850|Behavioral|Intervention Group|This group will view a video on shared reading upon enrollment, receive standard guidance on shared reading, and receive a series of text messages for a period of 6 months.
1464058|NCT03242837|Behavioral|Army Resilience Training|The Army Resilience Training consists four training sessions of 90 minutes each. Participants learn to reflect their stress management (including thinking, emotions, behavioral consequences; coping strategies) and build resilience using specific strategies.
1464059|NCT03242837|Other|Diversity Management Training|Diversity Management Training consists four training sessions of 90 minutes each. Participants learn about diversity and social awareness reflecting different situations and settings.
1948135|NCT02741674|Procedure|Roux-en-y gastric bypass (RYGB) - historical|Participant has had RYGB, as identified using existing data
1948136|NCT02741674|Procedure|Adjustable gastric banding (AGB) - historical|Participant has had AGB, as identified using existing data
1948137|NCT02741674|Procedure|Sleeve gastrectomy (SG) - historical|Participant has had SG, as identified using existing data
1948138|NCT02738970|Drug|Trastuzumab|Participants will receive a single dose of trastuzumab 600 mg SC separately, co-mixed or co-formulated with pertuzumab.
1464064|NCT03242785|Other|Self-monitoring/Self-titration|"The intervention of the ADAMPA trial is not pharmacological but an intervention that modifies usual clinical practice. The intervention of self-monitoring and self-titration of the medication is composed of 3 elements:
Education of the patient: information and training on hypertension, its risks, management, the benefits of an adequate control and the generic measures for an optimal control.
Training for self-monitoring: Patients will be trained to perform the self-measurement of blood pressure correctly (and recording their values in the sheet enabled for this purpose)
Training for self-titration: patients will be instructed on the target BP numbers, individualized for each patient, on the mode of action against specific figures, including self-adjustment of drug treatment."
1464065|NCT03242772|Drug|Amphetamine|Study drug will be administered in the morning. Treatment will be initiated at 1 tablet = 3.1 mg or 0 mg of mixed amphetamine. Doses will be flexibly titrated upward by 1 tablet = 3.1 mg or 0 mg every 2 weeks unless there are intolerable adverse effects or great improvement in ADHD symptoms to a target dose of 4 tablets = 12.4 mg or 0 mg of Adzenys- XR-ODT. The allowable dose range will range from 1.6/0 mg (1/2 tablet) to 18.6/0 mg (6 tablets). Doses may be reduced at any point during the trial (typically in 1 tablet increments) but only may be increased every two weeks in order to fully assess potential benefits and adverse events of the current dose.
1464066|NCT03242772|Behavioral|P-ESDM|Weekly sessions of the behavioral intervention will be delivered by a certified P-ESDM therapist. All participants in the trial and their primary caregivers will receive coaching following a manualized intervention (includes individualized learning objectives, intervention coaching for behavior management, handouts).
1464067|NCT03242772|Drug|Placebo Oral Tablet|Matched placebo tablets will be administered in the morning and provided for 30 weeks (6 weeks prior to initiation of P-ESDM Intervention). Placebo appears identical to the active drug (Adzenys-XR-ODT).
1464068|NCT03242759|Drug|nintedanib|Drug
1464069|NCT03242759|Drug|pirfenidone|Drug
1464070|NCT03242733|Other|Ultrasound assessment of gastric contents|Ultrasound assessment of gastric contents is performed in fasted elderly patients for hip fracture surgery.
1464071|NCT03242720|Procedure|Cardiac Ablation for Atrial Fibrillation|Ablation of arrhythmia focus in the heart for atrial fibrillation
1948139|NCT02738970|Drug|Pertuzumab|Participants will receive pertuzumab as a single agent injection, co-mixed or formulated as FDC with trastuzumab depending upon cohort. The dose will range from 400 to 1200 mg.
1948140|NCT02738853|Device|Medtronic Transcatheter Aortic Valve 2.0 Replacement System|Treatment of severe symptomatic aortic stenosis in subjects who are considered at high through extreme risk for surgical aortic valve replacement.
1948141|NCT02735980|Drug|Prexasertib|Administered IV
1464398|NCT03240211|Drug|Pembrolizumab|Pembrolizumab 200 mg IV
1948142|NCT02736461|Procedure|Floor repair surgery|
1948143|NCT02736695|Drug|F-18 AV 1451|Tau binding agent
1948144|NCT02730663|Device|Niti-S SPAXUS Stent|Endoscopic Ultrasound-Guided Transluminal drainage
1948145|NCT02730351|Drug|Fluticasone furoate/ Vilanterol 100 mcg/25 mcg|FF/VI 100/25 mcg will be administered via ELLIPTA inhaler once daily in the evening
1464076|NCT03242681|Procedure|Endoscopy Assisted Probing procedure|The patency of the system will be tested by irrigation with 1 ml normal saline. A cannula was introduced via the upper or lower canaliculus as far as the lacrimal sac and fluid injected through the system from a 5 ml syringe. Nasal endoscopy and irrigation will be performed simultaneously and free flow of fluid from the lacrimal sac to the nose will confirm anatomical patency of the system
1948146|NCT02730351|Drug|Fluticasone propionate 250 mcg|FP 250mcg will be administered via DISKUS inhaler, twice daily, once in the morning and once in the evening
1948147|NCT02730351|Drug|Placebo via ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler once daily in the evening
1948148|NCT02730351|Drug|Placebo via DISKUS / ACCUHALER|Placebo will be administered via DISKUS / ACCUHALER, twice daily, once in the morning and once in the evening
1464080|NCT03242655|Behavioral|HCV GET-Up (Group Evaluation and Treatment Uptake)|Groups will meet for 4 weekly 1-hour sessions facilitated by the PI and focused on providing education, motivation, and behavior change skills, along with an HCV medical evaluation. Patients will then be offered HCV treatment by individual provider after 4-week group evaluation and education intervention.
1464081|NCT03242629|Drug|oral chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by oral.
1464082|NCT03242629|Drug|enema chloral hydrate|Chloral hydrate syrup was available in a concentration of 100 mg×ml-1 at our hospital.The children assigned to receive 0.8 ml×kg-1 of chloral hydrate (80 mg×kg-1) by enema.
1464083|NCT03242616|Drug|Pemetrexed + Vinorelbine|"Vinorelbine (25 mg/m2, day 1 & 8)
Pemetrexed (500 mg/m2, day 1)"
1464084|NCT03242616|Drug|Vinorelbine|Vinorelbine (25 mg/m2, day 1 & 8)
1464085|NCT03242603|Biological|Anti-GD2 in combination with NK cells|Haploidentical donor NK cells will be expanded over 10 days and infused in combination with anti-GD2. Anti-GD2 will be given as daily infusion for 5 days ; D-1, 0,+1, +2 and +3. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day -3 and day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
1464087|NCT03242564|Device|Vevazz LED|Vevazz LED red light therapy is a non-invasive dermatological aesthetic treatment for the reduction of circumference of hips, waist and thighs.
1464088|NCT03242551|Drug|Chemotherapy|"AC followed by T Chemotherapy with or without trastuzumab, i.e. Epirubicin 100mg/m2 and cyclophosphamine 600mg/m2 for four cycles followed by paclitaxol 175mg/m2 for four cycles with (for patients with positive HER-2) or without Trastuzumab (loading dose of 6 mg/kg followed by 4 mg/kg every 2 weeks for four cycles), each cycle is 14 days."
1464089|NCT03242538|Behavioral|Pelvic Exercise|Hip extension and external hip rotation exercises are completed prior to daily external beam radiation treatment.
1464091|NCT03242512|Biological|TK006|Subcutaneous injection
1464094|NCT03242486|Device|toric intraocular lens|
1464095|NCT03242473|Other|Fluid Management|The patient will remain NPO for at least the first 24 hours. The following studies will be obtained at the time of admission if not previously obtained in the ED: CMP, GGT, Amylase, Lipase, Triglycerides, CBC, and CRP, along with an abdominal ultrasound. CBC, CRP, BMP, amylase and lipase levels will be obtained at 24 and 48 hours (+/- 2 hours). SIRS status will be evaluated with vital sign checks every 4 hours and the leukocyte counts every 24 hours.
1464096|NCT03242460|Drug|Pomalidomide 4 MG|Pomalidomide 4mg Days 1-21
1464097|NCT03242460|Drug|Dexamethasone 20mg|Dexamethasone 20mg Days 1, 8, 15, 22
1464098|NCT03242460|Drug|Cyclophosphamide 400mg|Cyclophosphamide 400mg Days 1, 8, 15
1464099|NCT03242447|Behavioral|e-Practice Self-Regulation|e-PS-R utilizes 'blended learning', the combination of online and face-to-face instruction, and incorporates online videos and interactive elements that have been shown to be effective with high-risk youth. e-PS-R consists of eight 30-minute e-learning sessions for youth participants and four 30-45 minute one-on-one in-person meetings between youth and a trained facilitator.
1464100|NCT03242447|Behavioral|Video Health Group|The video for the control condition will be The Toxic Life Cycle of a Cigarette, a 17-minute video that details the negative effects that cigarettes have on the environment and on people who manufacture and use cigarettes.
1464101|NCT03242434|Other|Lactulose and Mannitol solution|Participants will receive 100 milliliter (mL) oral solution of Lactulose [5 grams (g)]/ Mannitol (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
1464102|NCT03242434|Other|Sucralose|Participants will receive 3 capsules of Sucralose (2g), a non-investigational medicinal product, by oral route to measure intestinal permeability.
1464104|NCT03242382|Drug|Palbociclib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision
1464105|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (2+2l) PEG. 2 liters will be drunk during 2 hours in the evening the day before colonoscopy, the second 2l during 2 hours in the day of colonoscopy finishing the dose 4- 6 hours before colonoscopy.
1464399|NCT03240211|Drug|Pralatrexate|Pralatrexate 20-30 mg/m2 IV
1948149|NCT02728050|Drug|Cladribine|Given IV
1948150|NCT02728050|Drug|Cytarabine|Given IV
1948151|NCT02728050|Biological|Filgrastim|Given SC
1948152|NCT02728050|Other|Laboratory Biomarker Analysis|Correlative studies
1948153|NCT02728050|Drug|Mitoxantrone Hydrochloride|Given IV
1948154|NCT02728050|Other|Quality-of-Life Assessment|Ancillary studies
1948155|NCT02728050|Drug|Sorafenib Tosylate|Given PO
1948156|NCT02725567|Drug|ivacaftor|
1948157|NCT02724111|Drug|sufficient dose of rocuronium|
1948158|NCT02724111|Drug|sugammadex 10 min after position change|
1464106|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will by prepared with split dose of SS. The first bottle of SS with water (total volume 0,5l) will be drunk in the evening the day before colonoscopy during 1 hour, than another 1liter of clear fluid will be drunk. The same procedure will be repeated with the second bottle of SS finishing at least 3 hours before colonoscop
1464107|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose of PEG (1+1L) with ascorbic acid. The first 1l of solution will be drunk in the evening the day before colonoscopy, the second 1l of solution in the day of colonoscopy finishing 4-6 hours before the examination. Another 1l of clear fluid should be drunk during the cleansing process.
1464108|NCT03242369|Procedure|colonoscopy|100 patients undergoing colonoscopy will be prepared with split dose (150ml +150ml) of solution of magnesium acid and sodium picosulfate. The first dose will be drunk in the evening the day before colonoscopy, then at least 1l of another clear fluid will be drunk within a few hours, the second dose will be drunk in the day of examination finishing 4-6hours before colonoscopy and then another at least 750ml clear fluid.
1464110|NCT03242343|Device|VasQ|An external support device for AV fistula
1464111|NCT03242330|Device|Subperiosteal implant|Subperiosteal implants are placed and fitted 'onto' the jaw bone just right below the mucoperiosteum; where the post of the metal frame is in a protruding position through the mucosa holding the prosthesis that will be later fitted.
1464112|NCT03242317|Drug|Mitomycin C|The surgical procedure includes a low dose, short duration MMC treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
1464113|NCT03242317|Device|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominant eye for the improvement of uncorrected near vision.
1464114|NCT03242304|Other|Behavioral tests|We observed relationship between plasma levels of cortisol and neurological, cognitive, functional and emotional outcomes in patients with acute ischemic stroke.
1464115|NCT03242291|Other|Conventional resin-based flowable composite|assessment of marginal integrity of Conventional resin-based flowable composite
1464116|NCT03242291|Other|Hydroxyapatite Nanofiber reinforced flowable composite|assessment of marginal integrity of Hydroxyapatite Nanofiber reinforced flowable composite
1464117|NCT03242278|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
1464118|NCT03242265|Diagnostic Test|IVDD for NK cell activity in whole blood|Two samples of one mL of blood (for baseline IFN-gamma activity and for NK cell activity) and blood samples collected for C-Reactive Protein and White Blood Cell Count, taken up to 8 weeks prior to biopsy and before treatment with antibiotics.
1948161|NCT02712801|Drug|Zidovudine|Dose will be adjusted according to the child's weight.
1464121|NCT03242239|Biological|ALT02|
1464122|NCT03242239|Biological|EU-licensed Herceptin|
1464123|NCT03242239|Biological|US-licensed Herceptin|
1464124|NCT03242226|Device|two spectacles|single-vision spectacles for distant vision, and +3.00ADD spectacle for near vision
1464125|NCT03242226|Device|single vision spectacles|Wear single vision spectacle only
1464126|NCT03242213|Behavioral|Mobile App|The intervention in this study is a mobile health app, which provides patients with a way to track emotional wellbeing and depression symptoms, set up medication reminders, track adherence to medications, record side effects experienced, and take surveys/tests to assess cognitive symptoms and depression.
1948162|NCT02712801|Drug|Nevirapine|Dose will be adjusted according to the child's weight.
1464128|NCT03242187|Procedure|Trans-anal total mesorectal excision(TaTME)|Trans-anal total mesorectal excision(TaTME) will be offered to patients in this group (assisted by minilaparoscopy to control the IMA and splenic flexure mobilisation)
1464129|NCT03242187|Procedure|Lap. TME|Laparoscopic total mesorectal excision(Lap.TME) starting by IMA ligation then splenic flexure mobilisation and pelvic dissection
1464131|NCT03242161|Diagnostic Test|LabPatch-alcohol|a wearable, non-invasive biosensor Band-Aid like patch that is designed to detect real-time changes in interstitial alcohol concentrations in human subjects after they have consumed alcohol
1464132|NCT03242122|Other|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
1464133|NCT03242122|Other|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
1464134|NCT03242122|Other|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
1464135|NCT03242122|Other|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
1464136|NCT03242122|Other|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl oz of a flavored non-caloric beverage; 1 time consumption
1464137|NCT03242096|Combination Product|Sirolimus coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a sirolimus coated balloon (SeQuent®SCB balloon with sirolimus 4.0 μg/mm²)
1464138|NCT03242096|Combination Product|Paclitaxel coated balloon|Predilatation of coronary ISR with POBA (balloon-to-stent ratio 1:1) followed by a paclitaxel coated balloon (SeQuent®Please balloon or SeQuent®Please NEO balloon with paclitaxel 3.0 μg/mm²) (paclitaxel 3.0 μg/mm²)
1464400|NCT03240211|Drug|Decitabine|Decitabine 10-20 mg/m2
1948163|NCT02712801|Drug|Lamivudine|Dose will be adjusted according to the child's weight.
1948164|NCT02712801|Drug|Lopinavir/ritonavir|Dose will be adjusted according to the child's weight.
1948165|NCT02709889|Drug|Rovalpituzumab tesirine|
1948166|NCT02708901|Dietary Supplement|Vivomixx®|Two packets (900 billions bacteria) per os (P.O.) daily x 1 month and one packet (450 billions bacteria) P.O. daily x 5 months
1464140|NCT03242070|Other|Theory-based PP eLearning Program(T-PeP)|"Theory-based PP eLearning Program (T-PeP) was developed based on self-efficacy theory42-44 to improve older adults' use of PPs for managing their care and includes learning modules, discussion boards, and other resources. Considering variations in the types and usability of PPs used by patients nationwide, T-PeP was developed as a vendor-agnostic (not tied to a specific vendor) program."
1464144|NCT03242031|Procedure|monospot panretinal photocoagulation|panretinal photocoagulation with monospot laser
1464145|NCT03242031|Procedure|multispot panretinal photocoagulation|panretinal photocoagulation with multispot laser
1948167|NCT02708901|Dietary Supplement|Placebo|Two packets (4,4 grams of maltose and silicon dioxide x 2) P.O. daily x 1 month and one packet (4,4 grams of maltose and silicon dioxide) P.O. daily x 5 months
1948168|NCT02707952|Drug|ABT-493/ABT-530|Tablet
1464148|NCT03242005|Device|MiniMed® Pro-set®|Utilization of the MiniMed® Pro-set® to administer the subject's current insulin therapy.
1464149|NCT03242005|Device|MiniMed® Quick-set®|Utilization of the MiniMed® Quick-set® to administer the subject's current insulin therapy.
1464150|NCT03241992|Behavioral|MyChart Disease Specific|Subjects receive targeted IBD information and reminders as well as mood questionnaires.
1464151|NCT03241953|Procedure|Periodontal surgery|A total of forty dental implants were debrided with either ultrasonic instruments (test, n=20) or plastic scaler (control, n=20). Gingival recession depth (RD), keratinized tissue width (KTW), probing depth (PD), Gingival Index (GI) were evaluated at baseline and after 6 months. CBCT radiographs were used to evaluate peri-implant bone loss. Supportive and nonsurgical periodontal therapies were firstly consulted to reduce the inflammation, occurring due to the surgical treatments of the defects. The formation of bacterial biofilm on implant surfaces was removed by ultrasonic scaler and air polishing
1464152|NCT03241940|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22-CAR T cells IV
1464153|NCT03241940|Drug|Cyclophosphamide|Given IV
1464154|NCT03241940|Drug|Fludarabine Phosphate|Given IV
1464155|NCT03241940|Other|Laboratory Biomarker Analysis|Correlative studies
1464156|NCT03241940|Other|Questionnaire Administration|Ancillary studies
1464157|NCT03241927|Biological|Pembrolizumab|Day 1 of each 3 week cycle
1464160|NCT03241901|Drug|Artemether-Lumefantrine Tab 20-120mg|Artemether-Lumefantrine Tablet 20-120mg
1464161|NCT03241901|Drug|Primaquine Phosphate 0.25 mg/kg|Primaquine Phosphate 0.25 mg/kg
1464162|NCT03241901|Other|Placebo|Aqueous solution prepared to mimic the taste of the intervention drug.
1464165|NCT03241875|Drug|Pregabalin 75mg|In this group, premedication is performed with 2 capsules of pregabalin 2 hours before anesthetic induction.
1464166|NCT03241875|Drug|Gabapentin 300mg|In this group, premedication is performed with 2 capsules of gabapentin 2 hours before anesthetic induction.
1464167|NCT03241875|Drug|Placebo oral capsule|In this group, no premedication is performed, but patients receive 2 capsules of placebo 2 hours before anesthetic induction.
1464168|NCT03241862|Device|Restylane® Silk|Restylane® Silk (Galderma Laboratories, L.P.) is a hyaluronic acid injectable filler, which is approved by the FDA for submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids.
1464169|NCT03241849|Procedure|Modified surgical technique for placenta accreta|suturing of the myometrium splitted by the placenta in cases presented by placenta accreta
1464170|NCT03241836|Diagnostic Test|pelvic MRI,3D transvaginal ultrasonography|accuracy of pelvic magnetic resonance imaging and three dimensional trans vaginal ultrasonography in identification of mullarian duct anomalies
1464171|NCT03241823|Diagnostic Test|Abdominal ultrasound .|Abdominal ultrasound for each patient before and after treatment.
1464172|NCT03241823|Diagnostic Test|Model for End-Stage Liver Disease|Model for End-Stage Liver Disease before and after treatment.
1464173|NCT03241823|Diagnostic Test|Fibro Scan.|Liver stiffness by Fibro scan before and after treatment.
1464174|NCT03241823|Diagnostic Test|Child-Turcotte-Pugh score.|Child-Turcotte-Pugh score before and after treatment
1948169|NCT02707952|Drug|Ombitasvir/paritaprevir/ritonavir|Tablet
1948170|NCT02704572|Biological|Zostavax|Zostavax will be administrated by subcutaneous injection.
1948171|NCT02701829|Other|CONTROL- Usual & Customary Health Fair Follow-up|participating drivers may fall into 1 of 2 categories- Regular follow-up, or Urgent Follow-up.
1464178|NCT03241797|Procedure|EUS-FNA|Once the lesion was evaluated by EUS, the echoendoscopist would select the shortest pathway, while avoiding blood vessels, to reach the lesion. Under real-time visualization, slow-pull technique and suction technique were used to punctured each lesions. The specimens were expelled onto glass slides, and then prepared for histological and cytological examinations.
1948172|NCT02701829|Other|Health Fair + TECH [Text Messaging + Home Blood Pressure Monitoring]|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors and have the mobile health text messaging intervention.
1464182|NCT03241758|Diagnostic Test|Doppler ultrasound|Basal Doppler ultrasound and Doppler ultrasound one year after radical prostatectomy
1464183|NCT03241745|Drug|Nivolumab|Nivolumab 240 mg IV once every 2 weeks
1464184|NCT03241732|Other|Anti-inflammatory Diet|Integrative diet that reduces saturated fats and carbohydrates and emphasizes proteins and omega-3 fats that help reduce inflammation and oxidative damage.
1464185|NCT03241732|Dietary Supplement|N-acetyl Cysteine|Intravenous and Oral n-acetyl cysteine
1464187|NCT03241706|Drug|Fructose|IV fructose (1.3 mg/kg/min)
1464188|NCT03241706|Drug|Saline|Saline given as a comparison to fructose.
1464189|NCT03241706|Drug|Somatostatin|IV infusion of somatostatin (60 ng/kg/min)
1464190|NCT03241706|Drug|Insulin|IV infusion of insulin between 20-60 mU/m2/min.
1464191|NCT03241706|Drug|Glucagon|IV glucagon (0.65 ng/kg/min).
1464192|NCT03241706|Drug|Dextrose solution|IV dextrose to clamp the plasma glucose at the desired level.
1464193|NCT03241693|Other|blended-learning in ethics|"Experimental group followed clinical practices in hospital centers during 8 months.
In addition, an online specific syllabus about Professional Ethics was developed. It consisted of 6 themes and included topics as moral values, ethics and moral, bioethics and professional ethics, ecc. Six online related activities were created: to solve situations related to real clinical practices. Six face to face group sessions based on cooperative learning were planned in order to discuss ethical issues detected among clinical practices during 4 months. Students were divided in small groups, 4-5 participants each, and active participation techniques were used."
1464194|NCT03241693|Other|control group|"Control group followed clinical practices in hospital centers during 8 months as usual.
In the control group, case study method was also used, thus students in control group had to create and perform a public exposition of a real clinical case about professional ethics. Cases had to be related to clinical practices in order to recognize ethical situations in the work environment. Neither online learning nor online activities were carried out."
1464195|NCT03241680|Diagnostic Test|Search of anal citology alterations|"All patients with a pathological diagnosis of CIN II and III, and in the general gynecological surgery outpatient clinic, will be selected at the outpatient clinic of Oncology Gynecology of the HCSL for a period of six months.
Patients who meet the eligibility criteria will be clarified about the study, and only those who agree to participate will be included, by signing the informed consent form (TCLE)."
1464196|NCT03241667|Device|HemoCartridge|Our goal is to apply MEMS (microelectromechanical systems) and nanotechnology to miniaturize the bioartificial kidney (BAK) into an implantable, self-monitoring, and self-regulating renal surrogate. The implantable BAK (iBAK) is a biocompatible cartridge containing stacks of hemofilter membranes (HemoCartridge) and renal tubule cell bioreactors (BioCartridge) combined to mimic nephron function. Here, we plan to test ONLY the material being used to construct the HemoCartridge, to be sure in humans when substituted for a standard hemodialysis filter, subjects don't develop any clinical problems or side effects during several hours of blood exposure to the material. The AK material will be engineered by the study team to allow the system to be substituted in place of a standard HD filter.
1464197|NCT03241654|Procedure|flow trigger|The flow trigger will be adjust during the pressure assist ventilation.
1464200|NCT03241628|Device|Dressing Glove|Viscose dressing glove
1464201|NCT03241615|Other|Dysphagia evaluation|Dysphagia evaluation is performed in a clinical setting by an eating assessment tool. Swallowing related quality of life is also assessed.
1464202|NCT03241602|Drug|Intraperitoneal lidocaine|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure.
1464203|NCT03241602|Procedure|Pulmonary Recruitment|pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
1464204|NCT03241602|Combination Product|Combined intraperitoneal lidocaine and pulmonary recruitment maneuver|the investigator prepares syringes 1.75 ml/kg of 0.2% lidocaine (3.5 mg/kg) or the same volume of normal saline, for intraperitoneal administration. The solution to be instillated will be splashed under the right diaphragmatic area by the surgeon and complete the procedure before the recovery of the patient pulmonary recruitment maneuver will be done and consist of five manual pulmonary inflations with a maximum pressure of 40 cm H2O. The anestheiologist hold the fifth positive pressure inflation for approximately 5 seconds
1464205|NCT03241589|Other|VA Telederm mobile app introduction|VA employees begin use of OCC's VA Telederm mobile app.
1464206|NCT03241589|Other|My Telederm mobile app introduction|VA employees begin use of OCC's My Telederm mobile app.
1464207|NCT03241576|Behavioral|Small portion size provision|The intervention is the small meal size participants are provided with during a lunchtime session in the laboratory.
1464208|NCT03241576|Behavioral|Large portion size provision|The intervention is the large meal size participants are provided with during a lunchtime session in the laboratory.
1464212|NCT03241537|Radiation|Intensity modulated radiotherapy|
1464213|NCT03241524|Other|Exercise program for pelvic muscle floor|Pelvic muscles of each participant was evaluated by PERFECT and Peritron methods in terms of strengthening as well as sexual function response using 3 questionnaires, before and after 4 and 8 weeks from the beggining of an exercise program prescribed according to individual ratings obtained in the previous evaluation.
1537793|NCT02685826|Drug|Lenalidomide|
1464214|NCT03241511|Other|Test|Briefly, treatment sessions will include oral hygiene behavioral modification and scaling and root planning (removing the bacterial biofilm and calculus below the gum line) in order to eliminate etiologic factors and control periodontal inflammation. Once the treatment sessions are completed, the patients will enter the maintenance phase and will be followed for 6 months. In this phase, the patients will receive systematic supportive periodontal treatment (tooth cleanings above the gum line with re-enforcement of oral hygiene).
1464215|NCT03241498|Other|Medicines optimisation|
1464218|NCT03241472|Drug|Letrozole|oral tablets 5 mg
1464219|NCT03241472|Drug|Clomiphene Citrate plus N acetyl cystine|Clomiphene Citrate 100 mg oral tablets+ N acetyl cystiene 600 mg
1464220|NCT03241459|Device|Surmodics SurVeil DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter. Study is 1:1 randomized against comparator.
1464221|NCT03241459|Device|Medtronic IN.PACT Admiral DCB|Angioplasty procedure with a paclitaxel-coated, percutaneous transluminal angioplasty (PTA) balloon catheter. Study is 1:1 randomized against SurVeil DCB.
1464222|NCT03241446|Drug|Tilmanocept|Intravenously administered Technetium Tc 99m tilmanocept
1464223|NCT03241433|Other|High intensity interval training|exercise by use of stationary cycles
1464224|NCT03241433|Other|Moderate intensity continuous training|exercise by use of stationary cycles
1464225|NCT03241433|Other|No Exercise|no exercise training will be given and no exercise will be added to subjects routine
1464226|NCT03241420|Device|lung clearance index (LCI)|Determine the utility and sensitivity of the lung clearance index (LCI) technique as a marker of lung injury/small airways disease in adults with chronic lung conditions compared to health adults, adjusting for age, sex, and smoking status.
1464227|NCT03241407|Other|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a placebo toothpaste.
1464228|NCT03241407|Other|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
1464229|NCT03241381|Diagnostic Test|vitamin D serum assay study and control groups|Serum- vitamin D assay
1464230|NCT03241381|Diagnostic Test|Photometry|Serum- Hemoglobin assay
1464231|NCT03241381|Other|Russels periodontal index|Clinical examination for periodontitis
1464232|NCT03241368|Device|Capsule Endoscopy|At follow up visits 6 and 12 months study subjects in this group will undergo PillCam patency study at the discretion of the investigator and will undergo capsule endoscopy.
1464233|NCT03241368|Device|Comparator Group: IC plus MRE or IC alone|At follow up visits 6 and 12 months study subjects in this group will undergo IC with or without MRE procedures. Subjects with small bowel disease (proximal and/or ileal) and/or colonic disease with clinical indication (per investigator discretion) will undergo IC plus MRE. For subjects with no small bowel disease, MRE at 6 and 12 months is at the discretion of the physician.
1464234|NCT03241355|Dietary Supplement|prebiotic inulin-type fructan|
1464235|NCT03241355|Dietary Supplement|Placebo maltodextrin|
1464236|NCT03241342|Drug|GTx 024|Study drug is an opaque, white to off-white, size 5, oval Softgel capsule containing the active ingredient GTx-024.
1464237|NCT03241342|Drug|Placebo|Placebo study drug is identical in appearance to the GTx-024 study drug and contains polyethylene glycol 400 but not GTx-024.
1464238|NCT03241316|Behavioral|district-level representative rural|As a general population survey, our study does not involve a control group. Please note that the investigators do not interview patients; we involve only healthy members of the general public who consider themselves fit to be interviewed.
1464239|NCT03241303|Drug|Acarbose|Glucobay tablets on experimental day.
1464240|NCT03241303|Drug|Placebo Oral Tablet|Placebo tablets on experimental day.
1464241|NCT03241303|Drug|Exendin (9-39)|Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
1464242|NCT03241303|Drug|Placebo Saline|9 mg/ml placebo saline infusion on experimental day.
1464243|NCT03241277|Procedure|Non surgical periodontal treatment|Scaling and root planning that will be performed with manual curettes or ultrasonic instruments
1464244|NCT03241264|Drug|ND-L02-s0201|Specified dose on specified day
1464245|NCT03241251|Other|questionnaire|Questionnaire of psychosocial risk factors
1464246|NCT03241238|Other|Eating|Participants will have 10 minutes to eat all of the brownie and drink 6 oz of water. They will then have 20 minutes to eat as much or as little of a meal (consisting of a sandwich, grapes and chips).
1948173|NCT02701829|Other|Heal th Fair + TECH [Text Messaging + Home Blood Pressure Monitoring] + Social Network Support (SNS)|all participating drivers receives standard Health Fair services initially falling into 1 of 2 categories-Regular Follow-up or Urgent Follow-up. Additionally all participating drivers will receive Home Blood Pressure Monitors for daily BP self-monitoring and text messaging, and they will receive the social network support intervention including an SNS guide for each SNS.
1464249|NCT03241212|Behavioral|Texting|From baseline appointment to 6 month follow up, those participants randomly assigned to the texting intervention will receive a text message every Monday, Wednesday and Friday. Some text messages will be informational only, others will ask the participant for a response to a multiple-choice question with immediate feedback on the answer chosen.
1464250|NCT03241199|Drug|Imatinib Mesylate|a first-generation tyrosine kinase inhibitors
1464254|NCT03241173|Drug|INCAGN01949|In Phase 1 subjects will receive INCAGN01949 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
1464255|NCT03241173|Drug|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
1464257|NCT03241160|Other|Chewing evaluation|Chewing evaluation will be performed. An experienced physical therapist who will take a scale training session will do the chewing evaluation according to the chewing performance scale.This scale classifies chewing function on an ordinal scale with five levels between 0 and 4 based on the sequence of functional movements during chewing.
1464258|NCT03241147|Drug|Lu AF35700|Single dose, 10 mg film coated tablet
1464264|NCT03241108|Drug|NI-0101|Humanized immunoglobulin gamma 1 (IgG1) kappa monoclonal antibody targeting TLR4
1464265|NCT03241108|Other|Placebo|Placebo
1464266|NCT03241095|Procedure|OMT (Osteopathic Manipulative Treatment)|The co-hort will receive OMT. Each participant will perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. This co-hort will then be evaluated by the physician and be given OMT.
1464267|NCT03241095|Procedure|Sham intervention|The co-hort participants will each perform 10 swings golf swings to determine a baseline measure the strength of their golf swing. Theythen be given a sham OMT procedure.
1464269|NCT03241069|Other|Reference position|patient is put in a 30 degree supine position during 5 minutes
1464270|NCT03241069|Other|sitting position|patient is put to a 90 degree sitting position during 1 to 2 minutes then the CO is measured
1464271|NCT03241069|Other|Valsalva maneuver|patients are asked to perform the Valsalva maneuver by executing a forced blow into a manometer for 30 seconds and the CO is calculated during this test.
1464272|NCT03241069|Drug|Nitroglycerin|0.6 mg of Nitroglycerin was administered by sublingual root and CO was evaluated.
1464273|NCT03241069|Other|leg rising|45 degree passive leg rising was done for 1 to 2 minutes and CO was measured during the maneuver.
1464276|NCT03241043|Drug|Treatment 2 weeks Envarsus followed by 2 weeks Advagraf|
1464277|NCT03241043|Drug|Treatment 2 weeks Advagraf followed by 2 weeks Envarsus|
1464282|NCT03241017|Drug|Durvalumab|Immunotherapy with Durvalumab after ASCT
1464283|NCT03241004|Other|Sleep Mask|sleep mask applied for two separate 60-minute periods during anesthesia
1464284|NCT03240991|Other|Quality of life|Dermatology Life Quality Index, Angioedema Quality of Life Questionnaire, Angioedema Activity Score
1464285|NCT03240978|Behavioral|exercise intervention|A period of 12-week exercise intervention under the supervision of exercise specialists will be conducted.
1464290|NCT03240939|Drug|Dutasteride 0.5 mg|single dose
1464291|NCT03240939|Drug|Tadalafil 5 mg|single dose
1464292|NCT03240939|Drug|YY-201|single dose
1464293|NCT03240926|Device|Loop Band|Application of Loop band on radial artery of the opposite wrist that the Anesthesiologist has placed the Arterial line.
1464294|NCT03240913|Behavioral|Baseline and Follow-up Surveys|(completed online)
1464295|NCT03240913|Other|Patient Reported Outcome Measure informed Decision Aid|(PROM-DA)
1464296|NCT03240913|Other|Pamphlet|(usual care)
1464299|NCT03240887|Behavioral|Peer Group Connection|Faculty advisors at each participating high school are trained to run the program and teach a daily leadership course to peer leaders. Eleventh and twelfth-grade peer leaders who participate in the daily leadership development class facilitate outreach sessions with their assigned group of ninth graders. PGC can be offered in either a half-year (semester) or full-year format. In either format, a minimum of 18, 45-minute outreach sessions are expected to be offered to PGC participants during the course of their ninth-grade year. Outreaches are created to facilitate the transition to high school and encourage students to attend school, set goals for themselves, and make healthy decisions.
1464300|NCT03240874|Behavioral|Phase 1: SweetMama Focus Groups|Focus groups will assess tool functionality, design, interpretability, and acceptability (initial reaction, attitude, and receptiveness) of SweetMama via qualitative interviewing. The group format will generate feedback on areas that may not be revealed in a one-on-one interview.
1464301|NCT03240874|Behavioral|Phase 2: SweetMama Individual Testing|"Women will be oriented to SweetMama use on their own Android-based phones. The goals of this phase are to collect data from diverse users that will (1) confirm that the mobile apps are functioning (not crashing) across a wide range of Android devices and operating systems, (2) provide basic information about app usage and user satisfaction (3) inform the development of future iterations by analyzing participant characteristics and use, and (4) collect quality assurance data that will allow the research team to refine the applications. Women will use SweetMama for 4 weeks, engage in periodic check-in's with the research assistant, and participate in a semi-structured interview upon completion of SweetMama usage."
1464302|NCT03240861|Other|18F-FHBG|Given IV
1464303|NCT03240861|Biological|Aldesleukin|Given SC
1464304|NCT03240861|Drug|Busulfan|Given IV
1464305|NCT03240861|Biological|Cellular Therapy|Given LV-NYESO TCR/sr39TK PBSC IV and RV-NYESO TCR PBMC IV
1464306|NCT03240861|Procedure|Computed Tomography|Undergo PET/CT
1464307|NCT03240861|Biological|Filgrastim|Given SC
1464308|NCT03240861|Drug|Fludarabine|Given IV
1464309|NCT03240861|Procedure|Leukapheresis|Undergo leukapheresis
1464310|NCT03240861|Drug|Plerixafor|Given SC
1464311|NCT03240861|Procedure|Positron Emission Tomography|Undergo PET/CT
1948174|NCT02701153|Procedure|Conventional Surgery|Undergo surgery
1948175|NCT02701153|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
1948176|NCT02701153|Other|Laboratory Biomarker Analysis|Correlative studies
1464315|NCT03240835|Drug|cisplatin and docetaxel|"NACt：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two cycles.
CCRT: cisplatin (100mg/m2 on day 1) every three weeks for two cycles."
1464316|NCT03240835|Radiation|IMRT|intensity modulation radiation therapy
1464317|NCT03240822|Procedure|Penile Transplant|Penile Allotransplantation
1464318|NCT03240822|Biological|Monoclonal Antibody (Humanized Anti-CD52)|
1464319|NCT03240822|Drug|Tacrolimus|
1464320|NCT03240809|Biological|Brodalumab|140 mg SC dose
1464321|NCT03240809|Biological|Brodalumab|70 mg SC dose
1464322|NCT03240796|Procedure|intraocular lens implantation|before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
1464323|NCT03240796|Procedure|intraocular lens implantation|before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
1464324|NCT03240796|Procedure|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
1464325|NCT03240783|Drug|Betamethasone OR Dexamethasone Injectable|Procedural agents. The steroid and local anaesthetic preparation will be standardized to replicate current radiology interventional practices that use either particulate or non-particulate steroids. Betamethasone Sodium Phosphate/Acetate 5.7 mg/ml Injectable is a particulate corticosteroid and is used with the local anaesthetic bupivacaine 0.5% (1ml). Dexamethasone 4mg (1ml) is a non-particulate corticosteroid and is used with the local anaesthetic lignocaine 1% (1ml).
1464326|NCT03240783|Drug|Normal Saline Flush, 0.9% Injectable Solution|Procedural agents. The local anaesthetic preparation used with the Normal Saline Flush, 0.9% Injectable Solution, will be standardized to replicate current radiology interventional practices: either local anaesthetic bupivacaine 0.5% (1ml) or local anaesthetic lignocaine 1% (1ml).
1464327|NCT03240783|Drug|Dexamethasone Oral Tablet|Dexamethasone Oral Tablet: 15 day taper dosing is: days 1-5 8mg (4mg bd) , days 6-10 4 mg (2mg bd), and days 11-15 2 mg (1mg bd). The dexamethasone is over-encapsulated in a gelatine capsule that is identical to the placebo capsule in appearance.
1464328|NCT03240783|Other|Sham Injection and/or oral placebo|The sham Injection procedure is needle placement down to muscle at the designated spinal level and no injection of any fluid. The oral placebo is a gelatine capsule packed with filler.
1464329|NCT03240770|Device|VPro5 device|Use of the VPro5 device for 5 minutes a day
1537794|NCT02685826|Drug|Dexamethasone|
1948177|NCT02701153|Other|Questionnaire Administration|Ancillary studies
1948178|NCT02699645|Drug|telmisartan 20mg, amlodipine 2.5mg, and indapamide 1.25mg|1 capsule taken orally once daily for 36 months
1948179|NCT02699645|Drug|Placebo|1 capsule taken orally once daily for 36 months
1464331|NCT03240757|Dietary Supplement|Breakfast|All subjects received a standard 75-g OGTT to assess eligibility for the study. The 19 subjects matching the inclusion criteria completed 2 experimental trials: resting and exercise. During the resting trial, all subjects underwent an OGTT (50-g: A) and 3 meal tolerance tests [one for each breakfast tested: B1 = milk (125ml) and cereals (30g); B2 = milk (220ml), apple (200g) and chocolate cream-filled sponge cake (30g); B3 = milk (125ml), apple (150g), bread (50g) and hazelnut chocolate cream (15g)]. In the exercise trial, 100 minutes after the glucose/meal ingestion, participants cycled for 20 min at 40% of maximum oxygen uptake.
1464332|NCT03240757|Other|exercise|aerobic exercise at 40% of VO2max, for 20 minutes
1464333|NCT03240744|Biological|Inactivated EV71 vaccine (human diploid cell, KMB-17)|3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
1464334|NCT03240731|Biological|bone marrow transplant|haploidentical bone marrow transplant
1464335|NCT03240718|Procedure|Laser treatment|CORE fractional CO2 laser treatment
1464336|NCT03240705|Behavioral|Gratitude journaling|Gratitude journaling 3 times a week during surgical rotation
1464337|NCT03240692|Device|Accelerated theta burst treatment|"All participants will receive 1800 stimuli of iTBS (intermittent theta burst stimulation) to the left DLPFC per session. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of resting motor threshold adjust to the skull to cortical surface distance.
Sessions will be delivered using the MagPRo stimulator, with 3-pulse 50Hz bursts given every 200ms (at 5Hz). In the intermittent TBS, a 2s train of bursts will be given every 10s for a total of 570s (1800 pulses)."
1464338|NCT03240679|Device|Extracellular Matrix|ECM are composed of collagen and natural proteins that provide a re-absorbable scaffold for tissue remodeling have been investigated in preclinical as well as clinical pilot studies and found to facilitate constructive healing following EMR
1464339|NCT03240666|Other|non applicable|non applicable
1464340|NCT03240653|Other|Stratified response to Enzyme Therapy|Observational study involving reviewing retrospective and prospective data of participants medical history, pathology, imaging and health questionnaires.
1464341|NCT03240640|Procedure|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
1464342|NCT03240640|Procedure|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
1464343|NCT03240627|Drug|LH-8|LH-8 cutaneous solution
1464344|NCT03240627|Drug|Placebos|Placebo cutaneous solution
1464345|NCT03240614|Device|Non-rebreather oxygen mask|This intervention will be preoxygenation using a Non-rebreather that will be placed upon the participant for preoxygenation. The oxygen flow will be set at 30 L/min and the participant will be preoxygenated for a total of 3 minutes. After 3 minutes, an ABG will be taken and labeled as Intervention A.
1464346|NCT03240614|Device|Bag-valve-mask with ETO2 >85%|This intervention will be preoxygenation using a BVM apparatus connected to spirometry and a gas analysis which is capable of conducting End tidal oxygen (ETO2) measurements. Oxygen flows will be set at 30 L/min and preoxygenation will occur until an ETO2 >85% is obtained. Once an ETO2 >85% is obtained, a blood gas will be taken and labeled as Intervention B. In the event the ETO2 >85% cannot be obtained, an ABG will be taken with the highest ETO2 obtained.
1464347|NCT03240614|Device|High Flow Nasal Cannulae|This intervention will be preoxygenation using High Flow Nasal Cannulaes at an FiO2 of 100%. The oxygen flow will be set at 60 L/min and the participant will be preoxygenated for a total of 3 minutes. After the 3 minutes, an ABG will be taken and labeled as Intervention C.
1464348|NCT03240601|Device|Transcutaneous spinal cord stimulation|For tcSCS, a transcutaneous electrical nerve stimulation (TENS) unit is used. A 2 inch diameter round electrode is placed on the skin over T11/T12 (cathode), and a large butterfly electrode is placed on the skin over the umbilicus (anode). Pulse width is set to 400 microseconds at 50 Hz.
1464349|NCT03240588|Device|Neurostimulation System|Spinal cord stimulation
1464354|NCT03240562|Procedure|serratus anterior plane block|After surgery :ultrasound-guided serratus anterior plane block
1464355|NCT03240562|Procedure|paravertebral block|before surgery:ultrasound-guided paravertebral block
1464356|NCT03240562|Drug|patient controlled analgesia|three groups have same patient controlled analgesia
1464357|NCT03240549|Drug|bevacizumab|The patients in conventional group continued the previous chemotherapy,and the patients in experimental group received adding bevacizumab to previous chemotherapy regimen.
1464358|NCT03240536|Other|Choosing Wisely form|"The investigators will fax a Choosing Wisely form to ordering physicians that will include information from the Canadian Rheumatology Association Canada Choosing Wisely Guidelines. Three points will be included with some additional explanation of why these are important.
The three guidelines included will be:
Don't order an ANA as a screening test in patients without specific signs or symptoms of systemic lupus erythematous (SLE) or another connective tissue disorder (CTD).
Don't routinely image patients with low back pain regardless of the duration of symptoms unless that are clinical reasons to suspect serious underlying pathology
Don' routinely order a shoulder ultrasound as it is likely to indicate a tear in many people over the age of 50 years and will not change the initial management."
1464363|NCT03240497|Behavioral|Cold Exposure|"The start of the training is scheduled 7 to 12 days before the endotoxemia experiment day. Subjects in this group will participate in a 4 day intensive cold exposure course (see section 5.1). On day 1, venous blood will be sampled directly after ice water immersion. On day 4, venous blood will be sampled before the training procedures on that day and after the last ice water immersion.
After the 4 day course, subjects will continue to practice cold exposure at home using cold showers. The timing and length of this training is analogous to the time spend on training in the cold in our previous study protocol [7]."
1464364|NCT03240497|Behavioral|Strength Ventilation|The training is scheduled 2 to 6 days before the endotoxemia experiment day. Subjects in this group will receive a detailed, written instruction about the strength ventilation technique (see section 5.1). In addition, they will receive a 2 hour instruction session during which the research team will supervise the practices and clarify the instructions of needed. Subjects are instructed not to practice the learned techniques at home.
1464365|NCT03240484|Diagnostic Test|X-Ray Imaging|X-Ray imaging in the following positions: Lateral standing, lateral seated, standard standing AP pelvis and AP pelvis lying down
1464366|NCT03240471|Procedure|One week of plaster cast|One week of plaster cast as treatment for a non-reduced distal radius fracture.
1464367|NCT03240471|Procedure|Four-Five weeks of plaster cast|Four-Five weeks of plaster cast as treatment for a non-reduced distal radius fracture.
1464368|NCT03240458|Device|Optical Coherence Tomography|an objective non-invasive method for high-resolution cross-sectional imaging of the retina
1464369|NCT03240445|Drug|ODM-203 (Period 1)|ODM-203 400mg as tablets taken 30 minutes after food
1464370|NCT03240445|Drug|ODM-203 (Period 2)|ODM-203 400mg as tablets taken 1 hour before a light breakfast
1464371|NCT03240445|Drug|ODM-203 (Periods 3-6)|ODM- 203 400mg as tablets for oral administration or 400mg as oral dispersion either before/after food
1464372|NCT03240432|Device|Dexcom CGM|CGM group will be instructed on how to utilize the CGM data for diabetes management. Participants will be encouraged to use CGM values for making diabetes management decisions and will be provided guidelines for when to confirm with a study BGM fingerstick.
1464373|NCT03240419|Dietary Supplement|Probiotics|Bifidobacterium BB12 and Lactobacillus Rhamosus LGG (50%:50%) capsules.
1464374|NCT03240419|Dietary Supplement|Placebo|capsule manufactured to mimic probiotic capsules.
1464375|NCT03240406|Other|Multicultural Healthy Diet|An anti-inflammatory dietary pattern consists of a dietary pattern that has high anti-inflammatory potential
1464376|NCT03240406|Other|Usual Diet plus Self-Care|Usual diet plus sessions that focus on self-care such as dealing with aches and pains of aging.
1464380|NCT03240367|Other|Coutery|Stapler line bleeding control with coutery
1464383|NCT03240341|Behavioral|Patient Activation Measure Questionnaire|Measure the level of patient engagement in cancer care pathway
1464384|NCT03240328|Biological|CAR-T cells|HIV-1 specific chimeric antigen receptor cells
1464385|NCT03240302|Device|ICSI petri dish|Half of the oocytes will be placed into the standard ICSI petri dish and they will be injected with sperm with normal morphology.
1464386|NCT03240302|Device|PICSI petri dish|Half of the oocytes will be placed into a PICSI petri dish (whose bottom is coated with hyaluronic acid) and the mature spermatozoa with CD44 receptors that are attached to the bottom of the dish will be injected into them.
1464387|NCT03240289|Behavioral|Texting group|Women receive text messages to aid in their diabetes self-care tasks during pregnancy; these included appointment reminders, motivational messages, and nutrition/exercise tips.
1464388|NCT03240276|Other|Standard ICSI procedure for sperm injection into oocyte|The ICSI procedure is the standard procedure of selection and injection of sperm into oocytes
1464389|NCT03240276|Device|MSOME|Selection of ultramorphologically normal spermatozoa using an inverted microscope with 6300x magnification
1464390|NCT03240276|Other|IMSI Procedure|Injection of sperm that has been selected by the MSOME method into oocytes
1464391|NCT03240263|Procedure|Inspiratory Muscle Training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device*. Resistance adjusted to the highest tolerable load.
*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
1464392|NCT03240263|Procedure|Endurance training|"Supervised daily sessions of training including 4 sets of 6-10 breaths using a tapared flow resistive load device*. Low training resistance adjusted to <10% maximal inspiratory pressure.
*Electronic Variable Flow Resistive Loading IMT Device/ POWERbreathe®KH1, HaB International Ltd., Southam, UK"
1464393|NCT03240250|Procedure|VATS uni-portal lobectomy and lymphoadenectomy|VATS uni-portal lobectomy and lymphoadenectomy
1464394|NCT03240250|Procedure|VATS three-portal lobectomy and lymphoadenectomy|VATS three-portal lobectomy and lymphoadenectomy, Copenhagen approach
1464395|NCT03240237|Device|Optimizer SMART|Cardiac Contractility Modulation
1465094|NCT03234842|Drug|Chemotherapy|Concurrent weekly chemotherapy at standard doses
1464402|NCT03240159|Drug|Degarelix|"Degarelix 24mg Degarelix 16mg Degarelix 12mg
Active Comparator:
Down regulation of LH, during exposing in three different doses of Degarelix"
1464403|NCT03240146|Device|Pulsed Shortwave Therapy|Pulsed Shortwave Therapy device
1948180|NCT02699606|Drug|Erdafitinib|Participants will receive 8 mg of erdafitinib, once daily with option to up-titrate to 9 mg.
1948181|NCT02692560|Behavioral|I-STAND|Participants receive health coaching, a workbook, an inactivity alert wristband, and feedback charts based on objective measurement of sedentary time.
1948182|NCT02692560|Other|Healthy Living|Participants receive enhanced usual care based on general healthy living topics that are available to all Group Health Cooperative enrollees.
1464410|NCT03240094|Other|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
1464411|NCT03240081|Drug|50mcg estradiol cream|Use of study drug nightly
1464412|NCT03240081|Drug|100mcg estradiol cream|Use of study drug nightly
1464413|NCT03240068|Drug|Angiotensin 1-7|This is a biologically active hormone of the renin-angiotensin system. It may play a beneficial role in regulation of blood pressure by dilating blood vessels and reducing inflammation.
1464414|NCT03240068|Drug|Saline|Normal saline will be used as the placebo comparator.
1464415|NCT03240055|Drug|spinal anesthesia|The spinal puncture was performed with a 25 G Sprotte needle at the L3-4 or L2-3 interspinous space. Hyperbaric bupivacaine 0.5% (3 ml) was administered into the spinal space. Hyperbaric bupivacaine is obtained through the addition of glucose 10% (1ml) to bupivacaine 0.75% (2ml). Cerebrospinal fluid aspiration (0.1 ml) was done to confirm correct needle placement before and after spinal drug administration. Whereafter the patient was turned rapidly to the supine position, sensory anesthesia height was evaluated bilaterally using a pinprick test with the sharp tip of a safety pin every 1 min until 15 min after the initiation of the spinal anesthesia, bed tilting (upwards, horizontal, or downwards) was performed until bilateral sensory anesthesia level was confirmed to remain at the T4-T6 level
1464416|NCT03240055|Other|etomidate|receive etomidate only
1464419|NCT03240029|Other|Questionnaires|SPP questionnaire (Self Perception Profile for Children), Systemic inventory of life quality for children (ISQV-E), Anxiety questionnaire (STAI-C), Depression questionnaire (CDI)
1464422|NCT03240003|Behavioral|GC-MRT|Group 1 will receive a 4-week (8-sessions) course of GC-MRT
1464423|NCT03240003|Behavioral|modified GC-MRT|group 3 will receive a 4-week (8-sessions) course of GC-MRT, modified
1464424|NCT03240003|Behavioral|Non-GC-MRT|Group 2 will receive a 4-week (8-sessions) course of non-GC-MRT
1464425|NCT03239990|Behavioral|Incredible Years, Parent group supported by home visiting|Parents are taught to use positive and consistent strategies in reducing child misbehavior
1464426|NCT03239977|Behavioral|Online Social Intelligence Training|The SII consists of short 5-10 minute sessions organized into 7 modules designed to raise awareness of human nature and social relationships. The approach is based on evidence that SII is best advanced through interventions that modify key social cognitions regarding social engagement and enhance efficacy expectations regarding performance in social situations.
1464427|NCT03239977|Behavioral|Attention Control (AC)|A placebo condition delivered online to both custodial grandmothers and their adolescent grandchild which presents health-related information only.
1464428|NCT03239964|Drug|Dexamethasone|the wound edges are injected once with dexamethasone. A 1 mL syringe with a 30-gauge needle is used and injection is both intradermal and subdermal. Repeated alternate punctures are used to bathe the wound edges with the drug. Approximately 0.5-1 mL of dexamethsone (4 mg/mL) in wound tissue.
1464429|NCT03239964|Other|surgical excision|total extralesional surgical excision of the keloid is performed and minimal undermining
1464430|NCT03239951|Device|iTind|temporary implant
1464431|NCT03239951|Other|SOC|re-catheterization
1464432|NCT03239938|Behavioral|Modern pain neuroscience approach|The modern pain neuroscience approach includes 3 sessions (1 group and 2 individual sessions) of therapeutic pain neuroscience education followed by 15 individual sessions of dynamic and functional cognition-targeted exercise therapy and stress management techniques. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a time-contingent way. The 18 sessions will be spread over a period of 16 weeks.
1464433|NCT03239938|Behavioral|Usual care evidence-based physiotherapy|The usual care evidence-based physiotherapy includes 3 sessions (1 group and 2 individual sessions) of neck school followed by 15 individual sessions of graded and active exercise therapy focusing on strength, flexibility, endurance, and ergonomic principles. In addition, participants will be instructed to perform a daily set of home exercises. The exercises will be performed in a symptom-contingent way. The 18 sessions will be spread over a period of 16 weeks.
1464434|NCT03239925|Radiation|Electromagnetic field of cell phone in ''on'' mode.|In experimental group, participants would hold a cell phone to their left ears in their left hands, in 'on' mode, for 15 min, and that they would thus be exposed to a 900-1800 MHz magnetic field (EMW) for 15 min.
1464435|NCT03239925|Radiation|Electromagnetic field of cell phone in 'off' mode.|In control group, participants would hold a cell phone to their left ears in their left hands for 15 min in 'off' mode.
1464436|NCT03239912|Device|Twin-block appliance|Functional treatment will be achieved using the Twin-block appliance
1464437|NCT03239912|Other|Low level laser|Functional treatment will be combined with low-level laser therapy on the TMG region
1948184|NCT02685020|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
1464439|NCT03239886|Other|imatinib discontinuation|imatinib discontinuation
1948185|NCT02685020|Biological|Clade C gp140|The Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
1948186|NCT02685020|Drug|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
1948187|NCT02684188|Other|Enhanced Transitions Planning|While in the treating hospital, patients from small towns and rural communities are engaged in package of procedures designed to improve the transitions home, including a functional needs assessment that produces a plan that matches available rural community service providers to a patient's transitions needs and the provision of enhanced recovery supports to the patient.
1464443|NCT03239860|Drug|GNbAC1 Monoclonal Antibody|Monthly IV
1464444|NCT03239847|Other|EndoPhys Sheath and Radial Arterial Line|
1464445|NCT03239847|Other|EndoPhys Sheath|
1464446|NCT03239834|Device|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for patients presenting with suspicion of OPMD and scheduled for biopsy and 2) a multi-administered test for patients presenting with suspicious lesions not scheduled for biopsy.
1464447|NCT03239821|Device|VIPUN Balloon Catheter 0.1 deflated|deflation balloon
1464448|NCT03239821|Drug|Codeine Phosphate|58.8 mg codeïne phosphate
1464449|NCT03239821|Drug|Placebo|Sirupus Simplex
1464450|NCT03239821|Device|VIPUN Balloon Catheter 0.1 inflated|VIPUN Balloon Catheter 0.1 inflated
1464451|NCT03239808|Procedure|Incremental haemodialysis|Patients in incremental HD method will start HD with just one session a week. In each visit, the clinical situation will be assessed, biochemical determinations will be performed, dialysis parameter will be registered and also suitable medical tests will be run.
1464452|NCT03239808|Procedure|Conventional haemodialysis|conventional HD (three per week)
1464453|NCT03239795|Other|Advertisement|Advertisement by means of a poster and pamphlets in FP waiting rooms, removing all the other posters and pamphlets (except mandatory information, like opening hours, fees, etc.)
1464454|NCT03239782|Behavioral|Calorie restriction|Calorie restriction with behavioral modification and provision of one catered, reduced calorie meal a day
1464456|NCT03239756|Biological|TK006|Subcutaneous injection
1464457|NCT03239743|Device|Virtual Reality|Child will wear and interact with virtual reality headset while waiting for surgery.
1464458|NCT03239743|Drug|Midazolam|Child will receive Midazolam to help with pre-operative anxiety prior to surgery
1464459|NCT03239717|Other|Whey protein powder|Subjects in the Control Arm will replace two-thirds of participants dietary protein intake with a commercially available whey protein powder (Abbott).
1464460|NCT03239717|Other|BCAD2|Subjects in the Experimental Arm will replace two-thirds of participants dietary protein intake with BCAD2 (Mead Johnson), a BCAA-free medical food.
1464461|NCT03239704|Behavioral|Telemedicine Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-urgent care clinic appointment; to monitor the health status of patients with respect to their IBD.
1464462|NCT03239704|Other|Telemedicine Monitoring|Patients will be provided access to a smartphone application entitled: 'Health Promise'. The application will generate short questionnaires every 3 days, where patients can self-report their Crohn's disease activity as measured by the PRO-2 score or Ulcerative Colitis activity as measured by the 6-Point Mayo score, and medication adherence as measured by the MMAS-8 scale. The survey responses will be monitored by an IBD advanced practice nurse, to arrange for additional telemedicine follow-up sessions or to triage patients for an expedited appointment with a gastroenterologist.
1464463|NCT03239704|Behavioral|30 Day Comprehensive Questionnaire|Patients will complete a web-based questionnaire at 30 days following the urgent care clinic visit when they were enrolled in the study. The questionnaire will query the following: Patient Demographics; Patient Satisfaction as measured by the CACHE Questionnaire; IBD related Quality of Life as measured by the IBDQ questionnaire; and Crohn's Disease activity as measured by the PRO-2 score or Ulcerative Colitis Activity as measured by the 6-Point Mayo score.
1464466|NCT03239678|Drug|100% Oxygen|Conventional preoxygenation with 100% oxygen
1464467|NCT03239678|Drug|30% Oxygen|preoxygenation with 30% oxygen
1464468|NCT03239678|Drug|21% Oxygen|preoxygenation with 21% oxygen
1464469|NCT03239665|Behavioral|Pharmacist-led Intervention (PHARM)|60 minute didactic lecture about vaccinations.
1464470|NCT03239665|Behavioral|Peer-led Intervention (PEER)|60 minute peer led small group intervention including skits and other educational material
1464471|NCT03239652|Device|Taiwan ACE Beads|Similar with conventional Transcatheter Arterial chemo-embolization, radiologist use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
1464472|NCT03239639|Behavioral|Advance care planning education session|Administration of values clarification tool, elicitation of preference for treatment options, if preference for resuscitation, shown an educational video about cardiopulmonary resuscitation, summary document of values and preferences created by a facilitator to share with doctor
1464473|NCT03239639|Other|Wait list control|No intervention
1464476|NCT03239600|Drug|GSK2618960 2 mg/kg|GSK2618960 solution for injection, 100mg/mL is clear to opalescent, colorless to yellow or pale brown liquid.
1464477|NCT03239600|Drug|Placebo|Placebo solution will be administered by IV infusion.
1464478|NCT03239600|Drug|Methotrexate|MTX dose between 7.5 to 15 mg will be administered in tablet form once in a week till last dose of GSK2618960 to all subjects in Part I and Part II.
1464479|NCT03239587|Behavioral|Musical Intervention|Participants wait for 30 minutes in waiting area with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music.
1464558|NCT03239015|Drug|Trastuzumab|Trastuzumab is an FDA/CFDA approved targeted drugs used for Her2 amplification based on NGS results.
1464480|NCT03239587|Procedure|Blood Draws|"No Musical Intervention - Control Group: Blood drawn before, and about 30 minutes after participant stands in the waiting room without music.
Musical Intervention Group: Blood drawn before, and about 30 minutes after in waiting room with a Steinway Spirio grand piano that plays 30 minutes of simulated piano music."
1464481|NCT03239587|Behavioral|Questionnaires|Participants complete 2 questionnaires about anxiety and stress levels. It should take about 20-30 minutes to complete.
1464483|NCT03239535|Biological|Mesenchymal stem cells|Intramuscular injection
1464484|NCT03239535|Biological|Normal saline|Intramuscular injection
1464485|NCT03239522|Drug|[14C]-GSK1278863 solution for IV infusion|It is a clear, colorless solution free from visible particulate matter. Participants will receive 10 mL of 5 µg/mL of [14C]-GSK1278863 IV solution (total dose: 50 µg) by IV infusion over 1 hour.
1464486|NCT03239522|Drug|[14C]-GSK1278863 oral solution|It is a clear, colorless solution. Participants will receive 125 mL of 200 µg/mL of [14C]-GSK1278863 oral solution (total dose: 25 mg).
1464487|NCT03239522|Drug|Daprodustat 6 mg oral tablet|It is a 9.0 millimeter (mm) round, white film coated tablet.
1464488|NCT03239509|Procedure|bioprosthesis implantation between 2000-2015|Implantation of a bioprosthesis in aortic position with cardiopulmonary bypass
1464489|NCT03239509|Procedure|mechanical prosthesis implantation between 2000-2015|Implantation of a mechanical prosthesis in aortic position with cardiopulmonary bypass
1464490|NCT03239496|Biological|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
1464491|NCT03239496|Biological|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
1464494|NCT03239470|Biological|Cohort 1: 2.5 x 10^8 PolyTregs|Each participant will receive a target cell dose of 2.5 x 10^8 polyclonal Tregs.
1464495|NCT03239470|Biological|Cohort 2: 10x10^8 PolyTregs|Each participant will receive a target cell dose of 10x10^8 polyclonal Tregs.
1464496|NCT03239457|Biological|Heberprot P|75 µg vials administered at the rate of a vial 3 times per week (Sunday Tuesday, Thursday) by intralesional and perilesional route.For this, the reconstitution and dilution of the vial will be carried out with 5 mL of water for injection. The administrations will be kept up to 8 weeks of treatment or until there is achieved granulation of the 100 % of the lesion.
1464497|NCT03239444|Device|Intracardiac echocardiography imaging|Wide visualization of the the heart anatomy and additional devices used during atrial fibrillation ablation procedures.
1464498|NCT03239431|Other|asthmatic exacerbation|evaluate the risk factors, frequency and nature of asthma exacerbations
1464499|NCT03239418|Device|Neuromuscular electrical stimulation|A low level electrical current is applied to the muscle that control eyelid function through small electrodes applied to the skin over the target muscles. Treatment is applied daily for 5 consecutive days and exercises for eyelid function are performed in conjunction with the stimulation.
1464500|NCT03239418|Device|Sham neuromuscular electrical stimulation|Electrodes are applied to the skin over the target muscles and patient perform the exercises for eyelid function for 5 consecutive days just as in the experimental group, However participants do not receive the electrical stimulation. Due to the low intensity of the stimulation all participants regardless of group allocation are told they may or may not feel the electrical stimulation.
1464501|NCT03239405|Device|Suction callibrated system|One-step suction callibrated SG system
1464502|NCT03239392|Drug|BNZ132-1-40|Injectable PEGylated peptide antagonist that binds to the common gamma chain (γc) signaling receptor for the cytokines interleukin (IL)-2, IL-9, and IL-15
1464503|NCT03239379|Drug|BNZ132-1-40|Injectable peptide antagonist of IL-2, IL-9 and IL-15
1464504|NCT03239379|Drug|Placebo|Normal Saline
1464505|NCT03239366|Other|BioK+ 100% probiotic|The active BioK+ product will include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
1464506|NCT03239366|Other|Placebo|The placebo product will NOT include the 3 strains of Lactobacillus: L. acidophilus CL1285®, L. casei LBC80R® and L. rhamnosus CLR2®, representing the bacteria found in Bio-K+ probiotic capsules 50B®;
1464507|NCT03239353|Drug|Entecavir|Study drug (entecavir or placebo) will be administered with 240 mL of water following an overnight fast (no food or drink, except water, for at least 10 hours). Subjects will be required to fast (no food or beverages other than water) until after collection of the 4-hour blood draw.
1948188|NCT02684279|Drug|Dasotraline|Dasotraline 4, 6, 8 mg flexibly dosed once daily
1464509|NCT03239327|Drug|Misoprostol|
1464510|NCT03239314|Drug|Saline Solution|Injected in the adductor canal
1464511|NCT03239314|Drug|Dexamethasone|Injected in the adductor canal
1464512|NCT03239301|Procedure|Conventional Rehabilitation|Conventional rehabilitation program consisted range of motion (ROM) exercises, balance and coordination training, progressive resistive exercises, posture training, gait training, and occupational therapy as much as the patients tolerated. Conventional rehabilitation was tailored to the patient considering his requires and expectancies.
1464513|NCT03239301|Procedure|Robotic REhabilitation|The Armeo Spring HocomAG Inc. (Volketswil, Switzerland) device was used in robot assisted upper limb rehabilitation program. Assistive component of the robotic arm was adjusted in accordance with motor level of each patient. Variety and difficulty of games were chosen according to the ability and functional status of the patients. Variety and difficulty level of the games were modified according to progress of patients by the same physiotherapist.
1464514|NCT03239288|Other|Control digestible carbohydrate|Single serving of control product
1464515|NCT03239288|Other|Test resistant starch type 4|Single serving of test product
1464516|NCT03239275|Procedure|Biocreative therapy|
1539205|NCT02675335|Drug|Sitagliptin|
1948189|NCT02680535|Device|AuroShell particle infusion|Infuse AuroShell particles for irradiation by AuroLase laser to ablate neoplasms of the prostate.
1464517|NCT03239262|Procedure|Concomitant Mapping and Radiofrequency Ablation|"Mapping of GP around the orifice of pulmonary veins was performed, together with their radiofrequency ablation. In the area of right-side pulmonary veins, the procedure was performed prior to initiation of extracorporeal circulation. In case of the left-side PVs; the procedure was performed after initiation of extracorporeal circulation. Part of this procedure was also a decision and ablation of the ligament of Marshall.
GP mapping was performed using high-frequency stimulation (1000 beats min-¹, potential 18V, pulse width 1.5ms). The indication for GP ablation was a doubling in the R-R interval in the sinus rhythm, or ventricular rate slowing of more that 50% associated with a decrease of blood pressure>20mmHg in patients with AF. In case of a positive response, radiofrequency ablation of the ganglia was performed following switching of the pen at the console. This procedure was repeated until the activity of the ganglia has disappeared."
1464518|NCT03239262|Procedure|No intervention|No intervention was performed in patients without ganglionated plexi.
1464519|NCT03239249|Other|IKO-model|A systematic model for drop-out prevention.
1464520|NCT03239249|Other|Treatment as usual|Schools randomized to control group (22) work as previously with school dropout
1464521|NCT03239236|Procedure|Rapid sequence induction t-RSI|Preoxygenation via face mask, no ventilation with no PEEP until intubation
1464522|NCT03239236|Procedure|Rapid sequence induction m-RSI-PEEP|Preoxygenation via facemask with PEEP of 10 mbar. PEEP will be continued until intubation.
1464523|NCT03239236|Procedure|Rapid sequence induction m-RSI-vent|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
1464524|NCT03239236|Procedure|m-RSI-vent-cric|Preoxygenation via facemask with 10 mbar PEEP and 8 mbar pressure support. Backup frequency set at 10/min. Ventilation via anesthetic machine until intubation.
1464525|NCT03239236|Procedure|Cricoid Pressure|Cricoid Pressure will be applied during RSI until laryngoscopy
1464526|NCT03239236|Drug|Anesthetics|Induction agents will be administered as quick boluses (Propofol 2,5mg/kg total body weight, max 350mg, Fentanyl 250mcg, Rocuronium 1,2mg/kg ideal body weight).
1464527|NCT03239236|Diagnostic Test|Aspiration of gastric air via nasogastric tube|A nasogastric tube will be inserted at the beginning of laparoscopy and the air from the stomach will be aspirated with a syringe. The amount of air will be measured in ml.
1464528|NCT03239236|Diagnostic Test|Impression of gastric inflation at laparoscopy.|The impression of gastric inflation at laparoscopy. At the beginning of laparoscopy, images of the stomach will be recorded.
1464529|NCT03239236|Diagnostic Test|Arterial blood gas|Arterial blood gases will we drawn at different time points to investigate oxygenation during the procedure. Blood gases will be taken before pre-oxygenation, before anesthesia induction, before laryngoscopy, immediately after intubation when the cuff of the tracheal tube is inflated.
1464531|NCT03239210|Drug|Ondansetron|5-HT3 (serotonin receptor type 3) antagonist commonly used to treat nausea and vomiting
1464532|NCT03239210|Drug|Placebo|placebo equivalent
1464533|NCT03239184|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound
1464534|NCT03239184|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
1464535|NCT03239171|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
1464536|NCT03239171|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
1464537|NCT03239158|Device|Cancer ablation|Tumors bigger than 2 cm are fit for ablation therapy, percutaneously under CT scan or ultrasound.
1464538|NCT03239158|Drug|Life information rehabilitation therapy|Each treatment: one bottle solution each day, consecutive 3 months, oral administration
1464539|NCT03239145|Drug|Pembrolizumab|Pembrolizumab is designed to augment the natural ability of the immune system to recognize and target cancer cells
1464540|NCT03239145|Drug|Trebananib|AMG386 is a drug that may kill tumor cells and blocks blood vessels that supply the tumor with nutrients and oxygen
1464541|NCT03239132|Behavioral|Breath-based meditation|The experimental group will receive 4 group sessions of breath-based meditation over 4 weeks.
1464542|NCT03239132|Behavioral|Meditation educational materials|Meditation educational materials
1464543|NCT03239119|Biological|rE-4 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 5 mcg for 26 weeks - All are subcutaneously injected twice daily
1464544|NCT03239119|Biological|rE-4 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / rE-4 5 mcg for 4 weeks / rE-4 10 mcg for 26 weeks - All are subcutaneously injected twice daily
1464545|NCT03239119|Biological|Placebo 5 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 5 mcg for 26 weeks - All are subcutaneously injected twice daily
1464546|NCT03239119|Biological|Placebo 10 mcg|Placebo Lead In (5 mcg) for 4 weeks / Placebo 5 mcg for 4 weeks / Placebo 10 mcg for 26 weeks - All are subcutaneously injected twice daily
1464547|NCT03239106|Drug|Apremilast|Apremilast 30 mg BID daily
1464548|NCT03239093|Other|No intervention|Observational study using official data from the Federal Office of Statistics
1464549|NCT03239080|Drug|Denosumab|Subcutaneous injections of denosumab 60mg will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
1464550|NCT03239080|Other|Placebo|Subcutaneous injections of placebo (0.9% Sodium Chloride solution) will be given in 4 doses at each visit (at baseline, 6, 12 and 18 months).
1464551|NCT03239054|Behavioral|Physical activity|pregnancy prescription for physical activity as part of prenatal care can increase healthy exercise behaviors during pregnancy
1464552|NCT03239054|Behavioral|Control group|Information will be given as part of standard care
1464553|NCT03239041|Behavioral|Social navigation team|Social navigation team
1464554|NCT03239028|Behavioral|Observational|
1464555|NCT03239015|Drug|Gefitinib|Gefitinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
1464556|NCT03239015|Drug|Erlotinib|Erlotinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
1464557|NCT03239015|Drug|Afatinib|Afatinib is an FDA/CFDA approved targeted drugs used for EGFR mutation based on NGS results.
1464559|NCT03239015|Drug|Oxazolidine|Oxazolidine is an FDA/CFDA approved targeted drugs used for ALK or ROS-1 or MET fusion based on NGS results.
1464560|NCT03239015|Drug|Olaparib|Olaparib is an FDA/CFDA approved targeted drugs used for BRCA1/2 mutation based on NGS results.
1464561|NCT03239015|Drug|Everolimus|Everolimus is an FDA/CFDA approved targeted drugs used for mTOR or PI3KCA mutation based on NGS results.
1464562|NCT03239015|Drug|Cabozantinib|Cabozantinib is an FDA/CFDA approved targeted drugs used for RET mutation based on NGS results.
1464563|NCT03239015|Drug|Vemurafenib|Vemurafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
1464564|NCT03239015|Drug|Dabrafenib|Dabrafenib is an FDA/CFDA approved targeted drugs used for BRAF mutation based on NGS results.
1464565|NCT03239015|Drug|Palbociclib|Palbociclib is an FDA/CFDA approved targeted drugs used for CDK4/6 mutation or amplification based on NGS results.
1464566|NCT03238989|Other|monitoring changes in clinical symptoms, pulmonary function, and chest radiography|For patients with interstitial lung disease, the investigators regularly monitor changes in clinical symptoms, pulmonary function, and chest radiography after basic questionnaire on symptoms, lifestyle, depression, and quality of life.
1464567|NCT03238976|Other|Nature sounds|Nature sounds will be played for patients in the nature sounds exposure group.
1464570|NCT03238950|Other|Porcine model|participants to conduct training on porcine model
1464571|NCT03238950|Other|Synthetic model|participants to conduct training on synthetic model
1464572|NCT03238937|Device|Phrenic nerve stimulator|Implantation of phrenic nerve stimulator
1464573|NCT03238924|Drug|Oxytocin|40 IU oxytocin nasal spray, self-administered
1464574|NCT03238924|Drug|Placebos|Saline nasal spray, self-administered
1464575|NCT03238911|Drug|Iron isomaltoside (Monofer)|administered IV
1464576|NCT03238911|Drug|Ferric carboxymaltose|administered IV
1464577|NCT03238898|Drug|Botulinum toxin type A|"botulinum toxin type A injections
Botulinum toxin type A (100 or 30 units) was injected for each side into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
1464578|NCT03238898|Other|Normal saline|"Normal saline injections
The same dosage as the active group, but with normal saline alone were injected into the gastrocnemious or the small flexor foot muscles, respectively, according to the predominance of leg or foot cramps."
1464579|NCT03238885|Diagnostic Test|pelvic MR examination|All patients will take pelvic MR examination within 1 week before CRT and within 1 week before surgery.Pre- and post-CRT MRI examinations will be performed using a 3.0 T unit (Discovery 750) using an 8-channel phased array body coil in the supine position. To reduce colonic motility, 20mg of scopolamine butylbromide will be injected intramuscularly 30 min before MRI.
1464580|NCT03238872|Behavioral|Cognitive Behavioural Therapy|
1464581|NCT03238872|Other|Treatment as usual|
1464582|NCT03238859|Device|Real cTBS|This will be delivered with the Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
1464583|NCT03238859|Device|Sham cTBS|This will be delivered with the sham Magventure Magpro system; 3600 pulses with the active sham coil (double blinded using the USB key)
1464584|NCT03238846|Other|Three month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 3 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
1464585|NCT03238846|Other|Six month dispensing of ART in CARGs|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART in CARGs from their provider for the duration of the study. Each CARG will consist of 6-12 stable patients on ART and will meet in the community and select a group member to collect their ART at the facility every 6 months. Patients can have unscheduled clinic visits when unwell. Viral loads for the group will be collected at 12 and 24 months at the facility.
1464586|NCT03238833|Other|luteal ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the luteal phase.
1464587|NCT03238833|Other|follicular ovarian stimulation|In the in vitro fertilization cycle, controlled ovarian stimulation was started since the follicular phase.
1464588|NCT03238820|Procedure|Robotic gastric gastrointestinal stromal tumors resection|Robotic gastric gastrointestinal stromal tumors resection
1464589|NCT03238807|Drug|Human Chorionic Gonadotropin|500 IU of human Chorionic Gonadotropin
1464590|NCT03238794|Procedure|Roux-En-Y Gastric Bypass|Food will be consumed as directed by their doctor as standard of care. A food log will be completed the week before visits 3 and 5.
1464591|NCT03238794|Other|Low-calorie Diet|Food will be consumed as Week one will be liquid 400 to 500 kcal/day, weeks 2,3, and 4 will consist of 500-600 kcal/day of pureed food, weeks 5-8 will consist of 600-800 kcal/day of mechanical-soft food, weeks 9-12 will consist of 800 to 1000 kcal/day of soft foods, and the remainder of the study participants will be given 1000 to 1200 kcal/day of regular food.
1948190|NCT02679690|Behavioral|Standard Dietary Sodium Education|Standard dietary education for sodium restricted diets for patients with heart failure.
1464595|NCT03238768|Other|Enhanced Intravenous Nutrition|Increased macronutrients for first 7 days
1464596|NCT03238768|Other|Standard Intravenous Nutrition|Standard macronutrients for first 7 days
1464597|NCT03238755|Other|Cardiac MRI/MRS|whole blood, plasma, and serum
1464598|NCT03238742|Drug|Xuebijing Injection|100ml Xuebijing Injection every 12 hours for 5 days
1464599|NCT03238742|Drug|0.9% normal saline|200ml 0.9% normal saline every 12 hours for 5 days
1464600|NCT03238729|Behavioral|Heart Failure Education and Management App|Patients will be provided with an app on a smartphone that provides a daily checklist with items like reminders for logging weight and food, as well as educational components about heart failure and it's management.
1464601|NCT03238729|Behavioral|Heart Failure Literature|Patients will be provided standard literature about heart failure and the management of heart failure.
1464602|NCT03238716|Other|Electric DN|Dry needling with electric stimulation to the erector spine and paraspinal muscles in the lumbar / sacral region and tibialis anterior / posterior. Dry needling with electric stimulation of peri-neural tissue associated with lumbar / sacral nerve roots, pudendal nerve and posterior tibial nerve. 8-12 treatment sessions over 6 weeks.
1464603|NCT03238716|Other|NM Re-ed|"sEMG targeting type I slow-twitch fibers and type II fast-twitch fibers. Type I fibers maintain continuous muscle activity over prolonged periods of time; therefore, training of type I fibers will be achieved through endurance and repetition training of the pelvic floor muscles. Type II fibers are recruited during sudden increases in intra-abdominal pressure, and these fibers will be recruited with The Knack training. The Knack is a term created to use rhythm or timing to the pelvic floor. Neuromuscular re-education will be performed during the first treatment, but it will be performed as needed on subsequent treatments."
1464604|NCT03238716|Other|Exercise|Impairment-specific strength training, which may include transversus abdominis (TrA), gluteus maximus/medius/minimus and/or hip abductor/adductor muscle training. Treadmill, riding the recumbent bike at > 2 METs and/or stair climbing. Exercise training will be performed 7-11 treatment sessions over 6 weeks (following treatment 1).
1464613|NCT03238690|Device|Controlled Cardiac Reloading through LVAD Speed Adjustment|LVAD speed is reduced at a fixed rate according to the particular LVAD device model implanted. LVAD speed reduction adjustments will be performed at visits occurring every 2 - 3 weeks, up to a total of 8 visits. Reduction of LVAD speed will continue until the soonest of: minimum operating setting as recommended in the LVAD Operator's manual is reached; the minimum setting tolerated by the subject is reached; the subject completes 8 visits; or until the subject receives a heart transplant.
1464614|NCT03238677|Behavioral|Speech Motor Chaining without Biofeedback|These procedures target sound sequences (consonant-vowel, consonant-consonant, or vowel-consonant). Sessions begin with Pre-practice to elicit the target sounds, with verbal cueing and shaping strategies. The Practice component then includes chaining that is response-contingent. Participants practice in blocks of 6 consecutive trials beginning at the syllable level. If 5/6 are correct, the participant advances to monosyllabic word practice, then multisyllabic word practice, phrase practice, and sentence practice (with the target syllable embedded within each level of complexity). If fewer than 5/6 trials are correct, a different syllable with the target sound pattern is practiced next. Verbal feedback is faded from 5 of 6 trials at the syllable level to only 3 of 6 trials at the sentence level. For more description, see http://speechproductionlab.syr.edu/Resources%20for%20Researchers.html
1464615|NCT03238677|Behavioral|Biofeedback|Real-time images of the tongue are made available using ultrasound placed beneath the chin. Participants practice speech movements and can be cued to modify their tongue shape or position to achieve clearer speech. Practice structure is similar to the Speech Motor Chaining procedures, but with the addition of a visual reference.
1464616|NCT03238677|Behavioral|Distributed Practice|2 sessions per week for 10 weeks
1464617|NCT03238677|Behavioral|Massed --> Distributed Practice|Week 1: 10 hours of treatment Week 2: 3 hours of treatment Week 3: 3 hours of treatment Week 4: 2 hours of treatment Week 5: 2 hours of treatment
1464623|NCT03238651|Drug|TAK-659|TAK-659 Tablets
1948191|NCT02679690|Behavioral|Color-Coded Cue Cards|The use of a color-coded cue card to designate ranges of acceptable sodium content of food for comparison to labels while grocery shopping.
1948192|NCT02675426|Drug|ABT-494|ABT-494 oral tablet
1464626|NCT03238625|Drug|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 3:1
1464627|NCT03238625|Drug|Lidocaine and sodium bicarbonate|Lidocaine and sodium bicarbonate ratio 9:1
1464628|NCT03238625|Drug|Lidocaine|Lidocaine injection
1464629|NCT03238625|Drug|Sodium cloride 0.9%|Placebo
1948193|NCT02675426|Drug|Placebo|Oral tablet
1464632|NCT03238599|Behavioral|Pedometer-based activity monitoring after ASCT|Measurement of physical daily activity using a digital step counter (Pedometer-based activity monitoring) and assessment of patient well-being using a web-based patient reported tool.
1464633|NCT03238586|Behavioral|WELL Program|
1464634|NCT03238560|Drug|Montelukast Chewable Tablet|Montelukast treatment was used at a dosage of 5mg/day once daily
1464635|NCT03238547|Diagnostic Test|semi-quantitative urine albumin-to-creatinine ratio test|measurement of urine albumin-to-creatinine ratio using URiSCAN 2ACR, a semi-quantitative urine albumin-to-creatinine ratio test
1464636|NCT03238547|Diagnostic Test|standard quantitative spot urine albumin-to-creatinine ratio|measurement of urine albumin-to-creatinine ratio using a standard turbidimetric immunoassay
1464637|NCT03238534|Device|Neobianacid®|Oral administrations of Neobianacid® (30' after meals and on demand)
1464638|NCT03238534|Drug|Omeprazole 20mg|Daily administration Omeprazole 20mg (per os, 30' before breakfast).
1464639|NCT03238534|Other|Neobianacid® placebo|Oral administrations of Neobianacid® placebo (30' after meals and on demand)
1464640|NCT03238534|Other|Omeprazole placebo|Daily administration Omeprazole placebo (per os, 30' before breakfast).
1464950|NCT03236090|Dietary Supplement|Vivomixx|Vivomixx®sachets containing 450 x 109 bacteria, 2 every 12 hours (n=25), or placebo (n=25)
1464641|NCT03238521|Procedure|Spinal osteosynthesis|Posterior thoracic and lumbar osteosynthesis with classical pedicle finder or with pedicle finder with impedancemetry
1464642|NCT03238508|Procedure|Deferred stenting|Previously described
1464643|NCT03238495|Drug|Taxotere, Carboplatin, Herceptin + Pertuzumab|TCH+P chemotherapy every 3 weeks for 6 cycles: Taxotere 75mg/m2, Carboplatin AUC 6, Herceptin 6mg/kg (first cycle loading dose of 8mg/kg), Pertuzumab 420mg (first cycle loading does of 840mg)
1464644|NCT03238495|Drug|Metformin|TCH+P chemotherapy every 3 weeks for 6 cycles. Metformin 850 mg daily during the first cycle, then 850 mg twice daily for the remaining 5 cycles.
1464645|NCT03238482|Drug|salmeterol-fluticasone|Seretide Diskus 50/250 µg/dose
1464646|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product E
1464647|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product F
1464648|NCT03238482|Drug|salmeterol-fluticasone|Salmeterol/fluticasone Easyhaler 50/250 µg/dose, product G
1464649|NCT03238469|Device|Microwave ablation|A one-sided (either right or left axillary area) single MWA treatment using a miraDry system. The miraDry device has a microwave output frequency of 5.8 GHz and microwave energy level settings ranging from 1 to 5, corresponding with a delivery time in seconds between 2.40 sec and 3.00 sec. For this study standard 5 (i.e. 3.00 sec) is set as treatment setting.
1464650|NCT03238456|Behavioral|Motivating Pacifika Against Cigarettes and Tobacco|"Participants received one encouraging text message per day prior to their quit date. During the intervention, they received daily text messages with decreasing frequency per week. Participants were also able to craft personal text messages. On-demand text messages were optional and could be requested by texting key words to the program hotline.
The online MPACT program allowed participants to access eight educational modules and a forum where they could communicate with other participants. The modules focused on different aspects of quitting smoking, such as how to deal with withdrawal symptoms, triggers of tobacco use, and stress. Participants were limited to one module per day in order to increase the duration of exposure to the program. Upon completion, participants no longer received text messages but they were still able to access the educational modules, forum, and on-demand text messages."
1464651|NCT03238430|Drug|intrathecal morphine|A single intrathecal injection of 300 micrograms of Morphine preoperatively, just before induction.
1464652|NCT03238430|Drug|Morphine PCA|a postoperative Morphine PCA
1464653|NCT03238430|Drug|Ropivacaine infiltration|Ropivacaine 2mg / ml at the rate of 8ml per hour via a multiperforated catheter with connector
1464654|NCT03238417|Other|Evidence-Based Quality Improvement|Multilevel research-clinical partnership approach to supporting local strategic planning, priority setting, skill building and engagement in addressing targeted healthcare delivery problems. Launched at participating VA facilities through advance key stakeholder interviews, in-person site visits, data review (e.g., structure and environment of care, gender disparities in quality and patient experience), QI education/training, technical support (e.g., QI project and measures development), additional formative feedback from the evaluation (e.g., provider/survey measure summaries), external and internal practice facilitation, and across-EBQI site collaboration calls. Local leadership, EBQI champions and QI teams develop and implement innovation projects aimed at improving prioritized quality targets related to women Veterans' health and healthcare needs as well as facility-level structural changes needed to improve compliance with VA guidelines.
1464655|NCT03238404|Procedure|NAC group|NAC is the name of a procedure. NAC doesn't mean different interventions are used. Patients in this group need receive this NAC procedure instead of one drug before the gastrectomy and ERAS. The program consists of an intravenous injection of 130 mg/m2 oxaliplatin on day 1, followed by oral administration of 50 mg tegafur gimerac (the name of an anticarcinogen) twice daily on days 1-14, every 3 weeks.
1464656|NCT03238404|Procedure|Surgery alone group|Patients will not receive neoadjuvant chemotherapy and they will undergo the gastrectomy and ERAS alone.
1464657|NCT03238391|Procedure|Ischemic preconditioning|It is mentioned before in arm/group descriptions
1464658|NCT03238378|Radiation|Brachytherapy|Brachytherapy d 1-5(6)
1464659|NCT03238378|Other|Hyperthermia|Hyperthermia d 2 + 5
1464663|NCT03238326|Drug|Brexpiprazole|Once daily, oral tablets
1464664|NCT03238313|Behavioral|Plan A|
1464665|NCT03238313|Behavioral|Toxic Life Cycle of a Cigarette|Video
1464668|NCT03238287|Device|Manual and mechanical chest compression|The evaluation of advanced cardiac life support interventions with measurement of brain perfusion in cases with witnessed cardiopulmonary arrest occured during emergency service evaluation.The evaluation of the impact of resuscitation methods on brain perfusion levels in randomized manuel and mechanic compression groups.
1464669|NCT03238274|Device|Sofia 2 Lyme FIA testing|IVD testing of whole blood or serum/plasma to aid in the detection of anti-B. burgdorferi IgG / IgM antibody
1464670|NCT03238261|Radiation|Chemotherapy and concomitant radiotherapy|Radiotherapy (teletherapy + high or low rate brachytherapy)
1464671|NCT03238248|Drug|Azacitidine Subcutaneous Injection or Intravenous Infusion|75 mg/m2
1464672|NCT03238248|Drug|Pevonedistat Infusion|20 mg/m2
1464673|NCT03238248|Procedure|Bone Marrow Biopsy & Aspirate|Removal of a small piece of bone and bone marrow by inserting a needle into hip bone.
1464676|NCT03238222|Behavioral|MOSAIC|MOSAIC comprises 2 x 60-minute individual face-to-face consultations (weeks 1 & 2) and 2 x 20-minute follow-up telephone calls (weeks 6 & 12) delivered at a convenient time and location of participant's choice (local NHS Trust or participant's home). All sessions are delivered by a trained Band 6/7 physiotherapist. All participants randomized to receive MOSAIC will be provided with a pedometer and a patient manual which will include information on intermittent claudication, risk factors, walking guidelines, goal setting, problem solving and action planning worksheets and a walking diary.
1465020|NCT03235466|Behavioral|Heart Rate Variability Biofeedback|See Arm 2 & 3
1464677|NCT03238209|Diagnostic Test|Exercise testing|The test consisted of a steady-state resting period of 3 min followed by 1 min of unloaded pedaling at 60 cycles/min for each individual; the exercise load was increased by 10 W each min until the test had to be stopped because symptoms prevented further exercise. After test results were recorded, EMGdi,es and each surface inspiratory EMG of maximal exercise capacity were analysed.
1464678|NCT03238196|Drug|Erdafitinib|4mg - 8mg
1464679|NCT03238196|Drug|Palbociclib|125 mg
1464680|NCT03238196|Drug|Fulvestrant|500 mg
1464681|NCT03238183|Drug|dextrose|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
1464682|NCT03238183|Device|hyaluronic acid|compare the therapeutic effects of hyaluronic acid combined dextrose injections with hyaluronic acid injections only to patients with knee osteoarthritis
1464683|NCT03238170|Device|MRI scan|MRI scan using the Siemens Aera® (Siemens AG Healthcare, Erlangen, Germany) on the same day as their treatment planning CT scan
1464684|NCT03238157|Drug|Fluocinolone Acetonide (FA) implant|Fluocinolone Acetonide (FA) implant is designed to release FA at an initial rate of approximately 0.6 g/d, decreasing over the first month to a steady rate of 0.3 to 0.4 g/d with a duration of approximately 30 months.
1464685|NCT03238144|Other|MRF scan|MRF with or without dynamic contrast-enhanced MRI scans.
1464686|NCT03238131|Drug|Ivermectin|Participants are either given Ivermectin alone or Ivermectin in combination with Albendazole
1464687|NCT03238131|Drug|Albendazole|Albendazole will be given to participants in Arm 2 and 3 in combination with Ivermectin at varying time points.
1464688|NCT03238118|Other|Attention bias modification training|"Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.
Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
1464689|NCT03238118|Other|Attention Control Training|"Attention Control Training Participants will complete the assigned attention-training task three times a week for two weeks (six sessions), yielding 960 trials. Each session consists of three parts: evaluating the individual baseline, training and testing. Participants will also be required to complete a self-report assessment before and after each session. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators.
Psychoeducation Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2 by blind investigators."
1464690|NCT03238118|Other|Psychoeducation|Participants will receive psychoeducation once a week for two weeks. Participants will also be required to complete a self-report assessment before and after each session of psychoeducation. Participants will be evaluated at baseline, the end of week 1 and at the end of week 2.
1464691|NCT03238105|Drug|Thioglycolic Acid|Monthly sessions for 3 months with progressive increase of the duration of contact time of the drug with the skin, 3, 6 and 9 minutes.
1464692|NCT03238105|Device|Intense Pulsed Light|Monthly sessions for 3 months.
1464693|NCT03238092|Drug|Testosterone|testosterone gel daily during the late luteal phase.
1464694|NCT03238092|Drug|Estradiol|oral estradiol during the late luteal phase.
1464696|NCT03238066|Radiation|Brachytherapy|HDR/PDR brachytherapy
1464697|NCT03238066|Other|Hyperthermia|Interstitial hyperthermia
1464698|NCT03238053|Procedure|Vaginal laser treatment|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
1464699|NCT03238053|Device|sham|Fractional CO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
1464700|NCT03238053|Device|laser system|FractionalCO 2 laser system (SmartXide 2 V 2 LR,DEKA, Florence, Italy), using the following setting: dot power 30 watt, dwell time 1000 μ s, dot spacing 1000 μ m and the smart stack parameter from 1 to 3. The laser beam is provided using a vaginal probe, which is gently inserted up to the top of the vaginal canal and subsequently withdrawn and rotated in order to provide a complete treatment of the vaginal wall. At the level of the vaginal introitus, the dot power is decreased to 20 watt 27 . A treatment cycle includes three laser applications (every 4 weeks). The procedure is performed in the outpatient clinic and does not require any specific preparation (e.g. analgesia/anesthesia).
1464701|NCT03238040|Other|None, observational study|Observational study, no interventions
1464702|NCT03238027|Drug|SNDX-6352|Humanized IgG4 mAb that blocks colony stimulating factor 1 receptor (CSF-1R)
1464703|NCT03238014|Device|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation used assist/control mode treat severe stable chronic obstructive pulmonary disease.
1464704|NCT03237988|Drug|CPI-444 Capsules|100mg Capsule
1464705|NCT03237988|Drug|CPI-444 Tablets|100mg Tablets
1464778|NCT03237468|Other|Neck strengthening exercise to prevent concussion|Neck strengthening exercise to prevent concussion in student athletes.
1464706|NCT03237975|Behavioral|Be the Expert for Your Own (BEYO)|"The BEYO program is structured adopting solution focused therapy (SFT). The basic principles for SFT are focusing on positive change and establishing groups driven by goals rather than problems. Solutions are generated through searching for strengths, skills, resources that working in clients' lives.
The common flow for structured sessions contains 7 steps: 1) Health education; 2) Discuss self-care experience and identify deficit; 3) Describe exceptions; 4) Identify the strengths; 5) Miracle question and scaling; 6) Establish the solution; 7) Action plan."
1464707|NCT03237975|Other|Routine health education|The control group will receive routine health education.
1464708|NCT03237962|Device|High Flow Nasal Cannula|High Flow Nasal Cannula (HFNC) is an oxygen device that increases oxygenation and washes out CO2 within the dead space, it was also clinically used to correct hypoxemia, hypercapnia and respiratory failure.By providing flow rate that is similar to or higher than the patient's inspiratory flow, HFNC is able to provide ventilatory support. To produce stable oxygen concentration, HFNC entrains less air in order to reach the preset value.
1464709|NCT03237962|Device|Nasal Cannula|Nasal cannula is an oxygen therapy device that has been commonly used as treatment for patients with hypoxemia. With the adjustable flow of 1-6Lpm, the concentration of the oxygen differs as the breathing pattern of the patient changes.
1464710|NCT03237949|Behavioral|Phone counseling|Four telephone counseling sessions using a motivational interviewing approach
1464711|NCT03237949|Behavioral|Text message|30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory. The messages follows the self efficacy theory.
1464713|NCT03237923|Device|EasySense device|Implementation of EasySense device during hospitalization and daily post-discharge for thirty days.
1464714|NCT03237910|Diagnostic Test|AMSA|A non-invasive and real time VF (Amplitude Spectrum Area) AMSA analysis is performed during chest compression pauses for delivery of 2 ventilations, from the ECG acquired from the conventional defibrillatory pads
1464715|NCT03237910|Procedure|Defibrillation|delivery of the defibrillation is attempted to terminate VF either based on AMSA value (in the AMSA-CPR arm) or every 2-min CPR cycle as recommended by current guidelines (in the Standard-CPR arm)
1464716|NCT03237910|Procedure|CPR|chest compressions and ventilations at a rate of 30:2
1464717|NCT03237897|Behavioral|Preoperative education class|The preoperative enhanced recovery after surgery education class will be offered twice a week in coordination with anesthesia preoperative appointments to minimize inconvenience for patients. Patients will need to attend only one class. All participants will be offered the class. This class will be one hour in duration and will be taught by a surgical advanced care practitioner familiar with the details of colorectal surgery. The class will include detailed information about preoperative care, intraoperative care, and postoperative care.
1464718|NCT03237897|Behavioral|Pedometer|A pedometer will be affixed to patients in the immediate postoperative period and removed at time of discharge
1464719|NCT03237871|Behavioral|Text-message survey and informational text messages|Participants will complete a text-messaged survey each week for 5 weeks assessing economic and sexual risk behaviors. Participants will also receive 3 informational text messages each week for 5 weeks on HIV prevention and economic empowerment.
1464720|NCT03237858|Device|HeartLogic ON|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned OFF
1464721|NCT03237858|Device|HeartLogic OFF|Remote management of patients with CRT-D or ICD devices and the HeartLogic diagnostic feature turned ON
1464724|NCT03237832|Drug|ARN-6039|Ascending doses per Cohort
1464725|NCT03237832|Other|Placebo|Placebo to match ARN-6039
1464726|NCT03237819|Drug|Sulfate, Magnesium|"Magnesium sulphate will be administered at a dose of 6g over 20 min intravenously followed by a continuous infusion of 6g / 24h for 3 days.
For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of 1,5g of magnesium sulfate)"
1464727|NCT03237819|Drug|Placebo - Concentrate|For each day of treatment, 4 ampoules of 10 ml will be distributed to the nurse in charge of the patient (4 ampoules of glucose 5% as placebo)
1464728|NCT03237806|Drug|Deep sedated|Midazolam intravenous continusly infusion, Deep sedated (Ramsay 5)
1464729|NCT03237806|Drug|Light sedated|Midazolam intravenous continusly infusion, Light sedated (Ramsay 3)
1464730|NCT03237793|Procedure|Fluorosed Group|A single episode of laser therapy with without potassium nitrate (RA Thermoseal*) desensitising agent application was administered to the patients, A group only with desensitising paste and A group with desensitising paste and laser treatment depending on the study group they were assigned
1464731|NCT03237793|Procedure|Non Flourosed Group|A single episode of laser† therapy with or without potassium nitrate (RA Thermoseal*) desensitising agent application was administered to the patients, depending on the study group they were assignedGROUP 2B: Patients with healthy non fluorosed teeth receiving diode laser treatment$. (n=15)GROUP 2C: Patients with healthy non fluorosed teeth receiving diode laser + desensitising agent (potassium nitrate- RA thermoseal**) treatment.
1464732|NCT03237780|Drug|Atezolizumab|Given IV
1464733|NCT03237780|Drug|Eribulin Mesylate|Given IV
1464734|NCT03237780|Other|Laboratory Biomarker Analysis|Correlative studies
1464735|NCT03237767|Other|MIE|"The moderate intensity exercise (MIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.
The MIE bout will be in coherence with the physical activity guidelines for people with CF (150 min/week of moderate to vigorous physical activity). For the MIE, participants will cycle for approximately 30 minutes at 90% of their gas exchange threshold."
1464779|NCT03237455|Diagnostic Test|Thoracic spine x-rays+whole spine MRI|PA radiographs of the thoracic spine and MRI of the whole spine and sacroiliac joints
1464780|NCT03237455|Diagnostic Test|blood tests|blood chemistry including total cholesterol, LDL HDL, CBC, HbA1C, fasting glucose, TG, and insulin levels, HLA-B27, 2 vials of frozen serum for future studies.
1464736|NCT03237767|Other|HIIE|"The high-intensity interval exercise (HIIE) condition will begin and end with an appropriate warm-up (3 minutes at 20 W) and cool-down (2 minutes at 20 W), respectively. Throughout all exercising procedures, participants will maintain a pedal cadence of 60-80 rpm, with the average being noted and kept consistent between trials. Additionally, verbal encouragement will be given depending on the participant's preference, and kept consistent between visits.
The HIIE will be matched for the projected work done during the MIE. The HIIE protocol has been extrapolated from recent reports which have shown improvements in glycaemic control and vascular endothelial function. Specifically, participants will cycle at 90% of their peak power output for 60 seconds, followed by 60 seconds of active recovery."
1464737|NCT03237754|Device|tDCS device from neuroConn|weak electrical direct current stimulation
1464738|NCT03237741|Drug|Reference capsule GDC-0134|Oral administration of a single dose of 200 milligrams (mg) GDC-0134 reference capsule administered as two 100 mg capsules.
1464739|NCT03237741|Drug|Prototype capsule GDC-0134|Oral administration of a single dose of 200 mg GDC-0134 prototype capsule administered as one 200 mg capsule.
1464740|NCT03237741|Drug|rabeprazole|Oral administration of 20 mg rabeprazole once daily on Days -3, -2 and -1 as well as on Day 1 two hours prior to each administration of GDC-0134 during Period 4.
1464741|NCT03237728|Drug|0.06mg/kg,KB|0.06mg/kg,Q8h,Day1-Day7
1464742|NCT03237728|Drug|0.12mg/kg,KB|0.12mg/kg,Q8h,Day1-Day7
1464743|NCT03237728|Drug|0.24mg/,KB|0.24mg/kg,Q8h,Day1-Day7
1464744|NCT03237728|Drug|Placebos|Placebos,Q8h,Day1-Day7
1464745|NCT03237715|Other|Assessment of unbound bilirubin levels|Collection of residual blood for measurement of unbound bilirubin
1464746|NCT03237702|Dietary Supplement|Multi-Carotenoids|All participants in the second stage will receive multi-carotenoids 30 mg qd for 8 weeks.
1464747|NCT03237689|Drug|Hydrocortisone|Low dose hydrocortisone (10mg)
1464748|NCT03237689|Drug|Placebo Oral Tablet|capsules of starch 1500 powder
1464749|NCT03237676|Other|Structured cognitive rehabilitation therapy|A computer-based cognitive rehabilitation therapy Therapy frequency is one hour session per week for three months.
1464750|NCT03237676|Other|Patient-centred cognitive therapy|"Application of existing cognitive therapy at University Malaya Medical Centre, Malaysia. It is a patient-centred therapy approach over a period of three months, which include therapy session on symptoms management and coping strategies.
Clinical and treatment review are provided as part of routine outpatient rehabilitation clinic review."
1464751|NCT03237663|Biological|The oral O1 / O139 cholera vaccine (enteric capsules)|
1464752|NCT03237637|Drug|oral propranolol|oral propranolol 1-2mg/kg/day as crushed tablets in two divided doses
1464753|NCT03237637|Drug|oral atenolol|oral atenolol 0.5-1mg/kg/day as crushed tablets in a single dose
1464754|NCT03237624|Device|Functional Chitosan Chewing Gum|Chitosan and chitosan-related preparations have been shown to have some antimicrobial properties, possibly in the disruption of bacterial colonization. It is thought that as a component of a functional chewing gum this will supplement in the removal of daily build up of dental plaque on tooth surfaces.
1464755|NCT03237624|Device|Control Chewing Gum|Control chewing gum device does not have food additive chitosan in its composition.
1464756|NCT03237624|Behavioral|Oral hygiene measures|Patients will be given instructions on how to brush and floss routinely (twice per day)
1464757|NCT03237611|Drug|Aprepitant 125 mg|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
1464758|NCT03237611|Drug|Fosaprepitant 115 MG|Patient scheduled for the first cycle of carboplatin-based chemotherapy will be offered to receive low doses of aprepitant (125mg of oral aprepitant) or 115mg of fosaprepitant intravenously for prevention of chemotherapy-induced nausea and vomiting
1464759|NCT03237611|Drug|Dexamethasone|Dexamethasone will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 20mg on day 1 of chemotherapy and 12mg on day 3 after chemotherapy
1464760|NCT03237611|Drug|Ondansetron 16 MG|Ondansetron will be given as a part of standard CINV prophylaxis for patients receiving carboplatin-based chemotherapy, dosed at 16mg on day 1 of chemotherapy
1464761|NCT03237585|Behavioral|Rural response system (RRS) intervention to reduce violence against women|The Rural Response System which uses the strategy of trained community members known as Community-based action team, COMBAT to undertake awareness-raising on gender-based violence as well as providing support to victims of violence to access justice and other relevant services.
1464762|NCT03237572|Drug|Pembrolizumab|Pembrolizumab (200 mg)
1464763|NCT03237572|Device|High-intensity focused ultrasound (HIFU)|Ablation will target 50% of the tumor, up to 3 cubic centimeters
1464764|NCT03237546|Procedure|Anesthetic regimen including SB|Group receiving general anesthesia with the serratus block
1464765|NCT03237546|Procedure|Anesthetic regimen including SB or no block|Group receiving general anesthesia alone
1464766|NCT03237533|Drug|Dexamethasone|Dexamethasone will be applied locally on the lesion
1464767|NCT03237520|Other|Virtual Reality Therapy|VRT software and device is developed in collaboration with IIT Delhi using Kinect system. Kinect- motion sensor and computer set up is required. VRT (CIMT in a virtual environment)will be provided for 2 hours at every visit(twice weekly for first 4 weeks, once a week for next 4 weeks). VRT will be provided only during scheduled visits with the same principle as mCIMT. Functional activities like repetition of the tasks and shaping will be performed with the affected hand using VRT and CIMT while the unaffected arm is restrained
1464768|NCT03237520|Other|mCIMT|Modified constraint induced movement therapy will be provided to all children according to predefined protocol.
1464769|NCT03237507|Drug|S-1|40-60mg/m^2 bid, days 1-14, oral，every 3 weeks.
1464770|NCT03237507|Drug|oxaliplatin|100mg/m^2 days 1，intravenous infusion, every 3 weeks.
1464771|NCT03237507|Device|Hyperthermic Intraperitoneal|hyperthermic intraperitoneal chemoperfusion
1464772|NCT03237507|Drug|Paclitaxel|intraperitoneal perfusion
1539206|NCT02675335|Drug|Placebo|
1464781|NCT03237455|Other|constitutional and demographic data collection|demographics, concomitant diseases (in particular type 2 DM, hypertension, hyperlipidemia) concomitant medications, height and weight (BMI), waist circumference
1464782|NCT03237442|Biological|human umbilical cord mesenchymal stem cells|human UC-MSCs: 0.2ml(about 2*10^6 cells) subconjunctival injection
1464783|NCT03237442|Biological|placebo|Saline injection
1464784|NCT03237429|Diagnostic Test|bioimpedance spectroscopy|"Bioimpedance spectroscopy-The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. These volumes are then used to determine the amount of fluid.
Carotid-femoral pulse wave velocity-will be determined by arterial applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms.. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery."
1464785|NCT03237416|Drug|Dabigatran etexilate|In Period 1, Day 1 a single dose of 75 mg will be administered after breakfast In Period 2, Day 3 a single dose of 75 mg will be administered prior to breakfast In Period 2, Day 9 a single dose of 75 mg will be administered after breakfast
1464786|NCT03237416|Drug|Midazolam|In Period 1, Day 1 a single dose of 1 mg will be administered after breakfast In Period 2, Day 9 a single dose of 1 mg will be administered after breakfast
1464787|NCT03237416|Drug|BAY1841788 (darolutamide)|In Period 2, Days 1-11 600 mg twice a day (as 2 x 300 mg tablets) will be administered after breakfast
1464788|NCT03237403|Other|observational study|observational study between clinical criteria collected at SAMU regulation centre call and hospital orientation
1464789|NCT03237390|Drug|Gemcitabine Hydrochloride|Given IV
1464790|NCT03237390|Other|Laboratory Biomarker Analysis|Correlative studies
1464791|NCT03237390|Other|Pharmacological Study|Correlative studies
1464792|NCT03237390|Drug|Ribociclib|Given PO
1464793|NCT03237377|Drug|Durvalumab|1500mg via IV infusion every 4 weeks for up to 3 doses/cycles
1464794|NCT03237377|Drug|Tremelimumab|75mg via IV infusion every 4 weeks
1464795|NCT03237377|Radiation|Thoracic Radiation|5 days per week in once daily fractionation, 1.8-2.0 Gy per fraction
1464796|NCT03237364|Diagnostic Test|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
1464797|NCT03237351|Device|Fluid therapy|Conventional therapy group: conventional arterial blood pressure monitoring. Low value of PPV group and high value of PPV group:pulse pressure variation monitoring with arterial blood pressure monitoring.
1464798|NCT03237338|Procedure|ture acupuncture|"ture acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
1464799|NCT03237338|Procedure|sham acupuncture|"Sham acupuncture at the Magical-door, Si-shen-cong, Shen-ting, Local-cave acupoints, three times per week and last for 6 weeks"
1464800|NCT03237325|Drug|SGX942|1.5 mg/mL SGX942 administered as a 4 minute IV infusion, twice per week starting within 3 days after initiating radiation therapy and continuing through 2 weeks after radiation therapy ends.
1464801|NCT03237325|Drug|Placebo|Placebo is 0.9% sodium chloride (normal saline). The treatment preparation, frequency and duration of therapy are identical to that of the active drug.
1464802|NCT03237312|Procedure|Laparoscopic ovarian drilling|The electric current used was set at 40 Watts. The power was activated just before touching the ovary, and then the needle electrode was held against the antimesenteric surface of the ovary for 4 seconds until penetration of the ovarian capsule. Four or eight puncture points were made through the ovarian capsule of each ovary according to the study protocol. The ovaries were cooled in the pool of the Ringer's lactate after each cauterization both to minimize adhesion formation and to prevent heat trauma to the adjacent viscera. Complete hemostasis was ensured. At the end of the procedure, the ovaries were copiously rinsed with Ringer's lactate (Aqua-purator, Storz, Germany). An amount about 200 ml of heparinized Ringers lactate (5000 IU/1000 ml) was left in the pelvis to avoid postoperative adhesions.
1464803|NCT03237312|Biological|Antimullerian hormone|"In patients with Antimullerian hormone between 4-8 ng/ml 4 punctures in each ovary were performed.
In patients with Antimullerian hormone above 8 ng/ml 8 punctures in each ovary were performed."
1464804|NCT03237299|Other|Collection of data|Collection of data on clinical, bacteriological and computed tomography results and measurement some exposures during the month before the index date
1464805|NCT03237286|Drug|Intravenous ketamine|Intravenous ketamine is given at a subanesthetic dose, which previous research suggests is safe and efficacious for rapid relief from depression.
1464806|NCT03237286|Behavioral|Computer-based Cognitive Training|"Computer-based Cognitive Training will be delivered following intravenous ketamine to test whether learning during a post-ketamine window of opportunity might extend relief from depression."
1464807|NCT03237273|Other|HEAD-US scoring system|HEAD-US scoring system - Ultrasound scan performed by a non-imaging specialist to assess for joint bleed or damage
1464808|NCT03237260|Drug|Vedolizumab|Initiation: 300 mg at week 0, 2 and 6. Maintenance: Every 8 weeks after the sixth week at a fixed dose of 300 mg
1464809|NCT03237234|Other|Motor Skill Training|Motor skill training will consist of activities that will be performed while standing to promote upright control (the toe-tapping activity will be performed while seated). Participants will perform each of the 6 different activities for one minute each, until 4 cycles of the circuit have been completed (approximately 25 minutes total). Motor training activities will be performed at an intensity of 40-59% of heart rate reserve (HRR). Toe tapping will provide the opportunity for scheduled rest. During MT, all participants will wear a heart rate monitor to ensure that the optimal HR range is achieved. HRR will be calculated from resting and peak heart rate measures obtained during baseline testing via administration of a graded-exercise test.
1464867|NCT03236766|Other|Citizens' panels|This study is exploratory in nature, designed to capture lay Pacific Islanders' thoughts and beliefs about existing service engagement approaches.
1464906|NCT03236376|Other|additional motor therapy for the upper limb after stroke|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of cognitive-attention based training and motor training
1539210|NCT02675309|Drug|rosuvastatin|
1464810|NCT03237234|Device|Transcranial direct current stimulation (tDCS)|The tDCS electrode placement is based on procedures shown to improve gait and balance in a single session when used in combination with gait training activities. tDCS electrodes can simultaneously activate the bilateral leg motor areas when placed at the midline of the scalp slightly anterior to the vertex (anode) and at the inion (cathode), with a current intensity of 2mA. The tDCS device is lightweight, and can be worn in a backpack during the MT activities. As reported previously, participants in the MT-only group will receive sham tDCS to maintain analogous study procedures.
1464811|NCT03237221|Drug|Treat patient according to Global Initiative for Asthma (GINA) guideline|Treat patient according to Global Initiative for Asthma (GINA) guideline
1464812|NCT03237208|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) treatment will be activated.
1464813|NCT03237208|Device|placebo group|Transcutaneous electrical nerve stimulation treatment will not be activated.
1464814|NCT03237195|Other|additional soft tissue in neck dissections|Evaluation of submission of additional soft tissue in neck dissections for head and neck squamous cell carcinomas
1464815|NCT03237182|Drug|Individualized TB treatment with multiple drugs|"Patients with drug-resistant TB will receive a combination of any of the following drugs based on whole genome sequencing:
rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
1464816|NCT03237182|Drug|Standardized TB treatment with multiple drugs|"Patients with drug-resistant TB with receive a combination of any of the following drugs based on South African Department of Health guidelines:
rifampicin, rifabutin, isoniazid, high dose isoniazid, pyrazinamide, ethambutol, levofloxacin, moxifloxacin, ofloxacin, gatifloxacin, amikacin, capreomycin, kanamycin, streptomycin, ethionamide, prothionamide, cycloserine, terizidone, pretomanid, linezolid, sutezolid, clofazimine, bedaquiline, delaminid, para-aminosalicylic acid, imipenem/cilastatin, meropenem, amoxicillin/clavulanate, clarithromycin, azithromycin and thioacetazone"
1464819|NCT03237130|Procedure|preoperative enhanced chest CT examination|Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
1464820|NCT03237117|Biological|Growth Hormone (GH)|to evaluate the effect of GH administration in the donated oocyte recipient program among women with RIF (repeated implantation failure)
1464821|NCT03237104|Other|Immediate PT|Athletes will perform phase I (neutral spine) of the program and progress to phase II (functional motion) as able without an increase in pain and without compensations noted in function. The athlete will be assessed at each session to determine if they meet the criteria to begin the next step of functional progression program. Once the athlete has met the criteria of phase II, they will progress into the final phase of the functional progression program for return to sport activity. As these athletes progress through the third phase, and are able to meet the return to sport criteria, they will be released to return to sport. Athletes will not be released to return to sport prior to their first physician follow-up visit at 4 weeks.
1464822|NCT03237091|Device|bihemispheric transcranial pulsed current stimulation (tPCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
1464823|NCT03237091|Device|unihemispheric transcranial pulsed current stimulation (tPCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply unidirectional, positive pulses of current separated by brief interpulse intervals to the scalp via the sponges for 30 minutes.
1464824|NCT03237091|Device|bihemispheric transcranial direct current stimulation (tDCS)|Two sets of sponge electrodes (one set placed on each side of the head) will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
1464825|NCT03237091|Device|unihemispheric transcranial direct current stimulation (tDCS)|One set of sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply continuous, direct current to the scalp via the sponges for 30 minutes.
1464826|NCT03237091|Device|sham-control|Sponge electrodes will be placed on the participant's head. The transcranial electrical stimulator will apply stimulation to the scalp via the sponges for 1-2 minutes. The stimulator will then be turned off.
1464827|NCT03237078|Dietary Supplement|Lactobacillus plantarum PS128|Each PS 128 capsule contains 300 mg of probiotics. PS128 will be provided 300 mg twice, in the morning and in the afternoon, daily.
1464828|NCT03237065|Drug|Iron Isomaltoside (Monofer)|administered IV
1464829|NCT03237065|Drug|Ferric carboxymaltose|administered IV
1464832|NCT03237039|Radiation|X-ray examination|Radiological examination of frontal and lateral planes, simultaneously acquired with low dose X-ray system (EOS system, France) in one single exposition. The evaluation of the radiographic images will be performed by an orthopedic physician.Image processing will be performed by a biomedical engineer through sterEOS proprietary software and will provide the anatomical parameters needed to classify the sagittal profile.
1464833|NCT03237039|Other|fall-risk assessment|This evaluation will be performed after the radiographic scan, in the same day. The fall-risk assessment test will be performed by a biomedical engineer through OAK device (OAK, Khymeia, Italy). The OAK device integrates two force plates and sensory elastic straps applied to pelvis and limbs. This test, which takes approximately twenty minutes, accounts eight consecutive postural equilibrium exercises and provide the automatic detection of subject's postural parameters. At the end of the test, the fall-risk rating is automatically assigned.
1464904|NCT03236389|Device|Q Collar|measuring changes in brain during MRI while wearing the Q collar
1464905|NCT03236376|Other|additional sensorimotor therapy for the upper limb|The intervention will consist of additional physiotherapy for the upper limb after stroke consisting of sensory discrimination training and sensorimotor training.
1465288|NCT03233347|Drug|Brentuximab Vedotin|Given IV
1464834|NCT03237039|Other|gait cycle analysis|This assessment will be performed in the same session of fall-risk evaluation. The gait cycle analysis, which takes approximately forty minutes, will be executed by a biomedical engineer. Adhesive passive reflective markers will be placed on the skin according to a protocol suitable to characterize the alignment of lower limbs and trunk. The markers trajectories during walk will be recorded by an eight cameras optoelectronic system (BTS smart-D, Italy). A force platform (Kistler, Switzerland) placed in the middle of the pathway will detect the forces exchanged with the ground. The data analysis will provide the kinematic and kinetic descriptive parameters of gait cycle.
1464835|NCT03237026|Other|No intervention required|No intervention required
1464836|NCT03237013|Behavioral|Facial Morphing Intervention|Participants assigned to this condition were exposed to facial morphing technology that displays the progression of facial-ageing up to 72years, both with and without damage from UV exposure.
1464837|NCT03237013|Behavioral|Mindfulness Intervention|Participants assigned to this condition engaged in a self-guided mindfulness intervention audio tape. This intervention instructed participants to pay attention to the present moment, with a non-judgemental stance. For example, participants were instructed to notice their breath, thoughts, feelings, physical sensations, and to internally describe them, without passing judgement
1464838|NCT03237000|Drug|MgSO4|"Magnesium sulphate was administered by continuous intravenous infusion according to our hospital protocol as follows:
Loading dose: 4-6 gm of magnesium sulphate diluted in 100 mL of IV fluid administered over 15-20 min.
Maintenance dose: 2 gm/hr in 100 mL of IV infusion to be continued for 24 hours after delivery."
1464839|NCT03236987|Drug|Clarithromycin 1000 MG|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Clarithromycin, Ethambutol and Rifampicin.
1464840|NCT03236987|Drug|Azithromycin 250 mg|The patient will be received for at least 12 months, a daily antibiotic treatment who is a combination of Azithromycin, Ethambutol and Rifampicin.
1464841|NCT03236987|Drug|Rifampicin|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
1464842|NCT03236987|Drug|Ethambutol|The patient will be received for at least 12 months, a dailty antibiotic treatment who is a combination of Azithromycin or Clarithromycin (according to the randomisation), Ethambutol and Rifampicin.
1464845|NCT03236961|Drug|Ertapenem|I.v. ertapenem 1 g for 2 days followed by p.o. levofloxacin 500 mg x1 and metronidazole 500 mg x 3 for 5 days
1464846|NCT03236961|Drug|Moxifloxacin|P.o. moxifloxacin 400 mg x1 for 7 days
1464847|NCT03236948|Behavioral|Women for Women International Intervention|
1464848|NCT03236935|Drug|L-NMMA|pan-nitric oxide synthase inhibitor
1464849|NCT03236935|Drug|Pembrolizumab|PD-1 inhibitor
1464850|NCT03236922|Procedure|Pubococcygeus sling|The pubococcygeus muscles is dissected from the vaginal side walls and approximated at the midline just below the urethra.
1464851|NCT03236922|Procedure|Rectus fascia sling|Rectus fascia is dissected out cephalad to the pubic symphysis and tunneled beneath the urethra.
1464852|NCT03236896|Behavioral|Exercise|Strength training exercises for older adults. All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
1464853|NCT03236896|Behavioral|No exercise|All subjects will complete questionnaire (MENQOL Scale),hot flash diary and wear the fitbit flex for duration of study.
1464854|NCT03236883|Drug|Gemcitabine|Chemotherapy: Gemcitabine is administered Intravenous injection once a week，at a dose of 1000 mg/m2, for 3consecutive weeks,followed by a 7-days rest,repeated every 4weeks,three times in all.
1464855|NCT03236883|Other|GPBSC|immunotherapy :GPBSC were collected from donor .Cells were infused to the patients in 4 week,at a dose of (2-3)*10^8/kg,once a month,repeated every 4weeks,three times in all.
1464856|NCT03236857|Drug|venetoclax|Tablet for oral suspension (participants who cannot swallow tablets in both Part 1 Dose Determination and Part 2 Cohort Expansion); oral tablet for participants able to swallow tablets (Part 2 Cohort Expansion only)
1464857|NCT03236857|Drug|chemotherapy|Dexamethasone and/or vincristine and/or pegasparaginase OR cytarabine and/or etoposide and/or pegasparaginase; tyrosine kinase inhibitor; low-dose cytarabine OR azacitidine OR decitabine; rituximab and/or dexamethasone and/or vincristine; cyclophosphamide and/or topotecan
1464859|NCT03236831|Other|Clinical Recommendations|"The investigators will provide clinical recommendations to the subject's primary care provider. These will be in regards to the following:
Avoidance of potentially nephrotoxic medications.
Optimizing volume status (avoidance of volume overload or depletion)
Optimizing electrolytes and acid-base status
Minimizing IV contrast exposure when appropriate
Treating severe anemia
Optimization of hemodynamics (Mean arterial BP>65mmHg)"
1464860|NCT03236818|Drug|ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)|Combination of an ERA and PDE-5I (Sildenafil, Tadalafil, Bosentan, Macitentan)
1464861|NCT03236805|Drug|Ketamine|Initial bolus of 20 mg (around 0.3 mg per kg) followed by bolus of 10 mg every 5 minutes as reported by the recommandations of experts of the french society of urgency care
1464862|NCT03236805|Drug|Morphine|Bolus of 2 mg (patient with weight under 60 kgs) or bolus of 3 mg (patient with weight above 60 kgs) every 5 minutes as reported by the recommandations of experts of the french society of urgency care
1464863|NCT03236792|Drug|Ixazomib|3 mg or 4mg of Ixazomib will be taken orally on days 1, 8, and 15 of a 28-day cycle
1464864|NCT03236792|Drug|Cyclophosphamide|300, 400, or 500 mg of oral Cyclophosphamide on days 1, 8, and 15 of a 28-day cycle
1464865|NCT03236792|Drug|Dexamethasone|20 mg of oral Dexamethasone on days 1, 8, 15, 22 in a 28-day cycle
1464866|NCT03236779|Other|dry needling|The electrotherapy equipment used (Enruf) produces a continuous galvanic current through the cathode (modified electrosurgical scalpel with the needle) while the patient holds the anode (handheld electrode) (42). Once the needle have reach the relevant treatment area, a continuous current of 3 pulses at an intensity of 3 1.5 mA for 5 seconds conveyed to the muscle will be applied.
1539211|NCT02675309|Drug|simvastatin|
1464868|NCT03236753|Procedure|Thread-embedding Acupuncture (TEA)|"The acupoints and size of TEA are as follows:
Both EX-B2 of herniated intervertebral disc level, its upper level and its lower level (6 acupoints): perpendicular insertion, 4cm
Both BL24: transverse insertion toward L1 level along the erector muscle of spine, 6cm
Both BL25: transverse insertion toward iliac crest, 4cm
Both BL26: transverse insertion toward L1 level along the erector muscle of spine, 6cm
Both BL26: oblique insertion toward iliolumbar ligament, 6cm
Both EX-B7: oblique insertion toward gluteus medius muscle, 6cm
Both BL28: oblique insertion toward sacroiliac ligament, 6cm
Both GB30: perpendicular insertion, 6cm
Symptomatic side GB34, BL57 and ST36: oblique insertion toward foot, 4cm"
1464869|NCT03236753|Procedure|Sham Thread-embedding Acupuncture (STEA)|All procedure of STEA group, including acupoints and size of TEA will be same as that of TEA group. However, thread-removed TEA will be used for STEA group instead of normal TEA, and removing procedure of thread will be performed aseptic and secretly for patient-blinding and prevention of infection.
1464870|NCT03236740|Drug|Ethinyl Estradiol-cyprosterone acetate|Ethinyl Estradiol-cyprosterone acetate in the form of OCPs will be taken cyclically by the participants.
1464871|NCT03236740|Drug|Metformin Hydrochloride|Metformin Hydrochoride in the form of 500 mg tablets will be taken twice daily by participants.
1464872|NCT03236727|Drug|Dexmedetomidine|Changes of both amplitude and latency of SSEPs during dexmedetomidine infusion.
1464873|NCT03236701|Other|Egg White replacement|Nutritional intervention: the meat or fish of two meals will be replaced twice a week with an equivalent amount (in protein content) of egg white.
1464874|NCT03236662|Drug|(-)-Epicatechin|
1464875|NCT03236649|Drug|Icaritin|600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
1464876|NCT03236649|Drug|Sorafenib Tosylate Tablets|400mg/time, 2 tablets/time(2×200mg/tablet), 2times/day(Fasting), take orally, continuous administration until reach the standard of termination.
1464877|NCT03236636|Drug|Icaritin|Icaritin：600mg/time, 6 capsules/time(6×100mg/capsule), 2 times/day(30 minutes after breakfast, lunch and dinner), take orally, continuous administration until reach the standard of termination.
1464878|NCT03236636|Drug|HUACHANSU PIAN|HUACHANSU PIAN:Take orally 4 tablets/time(0.3g/tablet), 3 times/day(30 minutes after breakfast, lunch and dinner), continuous administration until reach the standard of termination.
1464880|NCT03236610|Drug|tenofovir monotherapy|switching to tenofovir monotherapy
1464881|NCT03236610|Drug|tenofovir plus entecavir combination|continuing tenofovir plus entecavir
1464882|NCT03236597|Other|Treadmill desk|A standing height desk with a treadmill attached.
1464883|NCT03236597|Other|Sit-Stand Desk|A sit-to-stand desk that can be placed atop an existing desk surface that makes the current open surface a sit-stand workstation.
1464884|NCT03236584|Drug|lamivudine plus adefovir combination|continuing lamivudine plus adefovir
1464885|NCT03236584|Drug|Tenofovir Disoproxil Fumarate|switching to tenofovir
1464888|NCT03236545|Other|No to Low Endogenous Estrogen|Ganirelix acetate (Antagon) will be used to prevent endogenous production of ovarian hormones in young women. Ganirelix is derived from native GnRH, and acts by competitively blocking GnRH receptors on the pituitary and subsequent pathways. Thus, administration of the GnRH antagonist (GnRHant) suppresses steroidogenesis, leading to low or undetectable serum estrogen and progesterone concentrations, which occurs within two days of initiation of administration (Oberye, Mannaerts, Huisman & Timmer, 1999; Oberye, Mannaerts, Kleijn, & Timmer, 1999).
1464889|NCT03236545|Other|Estradiol|Short term estradiol administration elicits changes in vascular function in women, and 0.1mg/day patch is the upper recommended limit for hormone therapy in women (Wenner, Taylor, & Stachenfeld, 2011; Moreau, Hildreth, Meditz, Deane & Kohrt, 2012).
1464890|NCT03236532|Dietary Supplement|Glutamine and exercise|
1464891|NCT03236532|Dietary Supplement|Maltodextrin and exercise|
1464892|NCT03236506|Drug|Zepatier Pill|Drugs will be given to participants to treat hepatitis C infection
1464893|NCT03236506|Behavioral|Psychological intervention|"Participants randomised to fortnightly pick-up with psychological intervention will have an interview with the study nurse designed to aid their compliance with the drug regimen. During the intervention participants will be guided by their trial nurse in the completion of a personalised booklet, Hepatitis C and Me. The booklet uses the principles of node-link mapping to structure the intervention."
1464894|NCT03236506|Drug|Sofosbuvir Pill|Drugs will be given along with Zepatier to participants to treat genotype 3hepatitis C infection
1464897|NCT03236467|Behavioral|Progressive Exercise Training|Designed to ease primarily sedentary individuals into exercise training, increasing in intensity up to 80% of maximum Heart Rate Range over time.
1464898|NCT03236454|Device|DC-Stimulator MC, NeuroConn|20 minutes of 2 mA anodal stimulation; Electrode placement: left dorsolateral prefrontal cortex (F3, EEG 10/20 system), return electrode at the right upper arm.
1464899|NCT03236441|Device|RIPC|Remote ischemic preconditioning
1464900|NCT03236441|Device|Sham-RIPC|Control
1541220|NCT02660281|Drug|Busulfan|Busulfan
1464907|NCT03236363|Behavioral|MOVI-da10! active breaks|MOVI-da10! active breaks, is a physical activity intervention that consists on two daily physical activity breaks of 10 minutes of duration (intensity: 4-6 METs, Heart rate ≥150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
1464908|NCT03236363|Behavioral|MOVI-da10! integrated physical activity|MOVI-da10! integrated lessons, is a physical activity intervention that consists on two daily cognitive demanding physical activity breaks of 10 minutes of duration (intensity: 2-3 METs, Heart rate <150 bpm). It is aimed to enhance physical activity, motor skills and cognition among 5 years old children
1464909|NCT03236350|Device|Active autoRIC® (CRIC Treatment)|The active autoRIC® Device is programmed to go through a preset protocol of inflation and deflation cycles every session. The sessions will be repeated daily for 28 days.
1464910|NCT03236350|Device|Sham Control autoRIC® (Sham Control)|The Sham Control autoRIC® Device is visually identical to the active autoRIC® Device but the simulated protocol applied comprises of vibrations of the device but no inflation of the cuff every session. The sham device provides the same sound and vibration as that of the pump inflating and the same LED indicators on the Active Unit. The sessions will be repeated daily for 28 days.
1464911|NCT03236337|Behavioral|MOVI intervention|MOVI-da Fit! is a multidimensional intervention that consists on: a) 4h/week of a standardized recreative, non-competitive physical activity extracurricular program; and b) informative sessions to parents and teachers about how schoolchildren can became more active. It is aimed to enhance physical fitness, motor skills, physical activity time and active behaviours among 9-to-11 years old children.
1464912|NCT03236324|Device|ultrasound-guided nerve block|Transversalis fascia plane (TFP) block, ultrasound-guided
1464913|NCT03236324|Drug|Saline|20 mL 0.9% saline administered on each side as bilateral TFP blocks
1464914|NCT03236324|Drug|Bupivacaine-epinephrine|20 mL bupivacaine 0.25% with epinephrine 2.5 mcg/mL to a maximum of 2.5mg/kg administered on each side as bilateral TFP blocks
1995073|NCT02854995|Procedure|circumcision|(i) circumcision: this will be a standard surgical circumcision whereby the prepuce (foreskin of the penis) is excised and the cut edge of the outer prepuce sutured to the cut edge of the inner prepuce. The two study team members performing the surgery in this trial (HC and SK) will be free to choose the method of circumcision (e.g. guillotine vs. sleeve) as this is not thought to influence outcome. The foreskin will be sent for histological analysis.
1464919|NCT03236298|Device|CADD-Solis Ambulatory Infusion System|The CADD-Solis pump will administer programmed intermittent boluses of 0.0625% Bupivacaine plus fentanyl 2mcg/ml.
1464920|NCT03236285|Behavioral|High-intensity interval exercise training in the fed state|High-intensity interval exercise training in the fed state
1464921|NCT03236285|Behavioral|Continous exercise training in the fed state|Continous exercise training in the fed state
1464922|NCT03236285|Behavioral|High-intensity interval exercise training in the fasting state|High-intensity interval exercise training in the fasting state
1464923|NCT03236285|Behavioral|Continous exercise training in the fasting state|Continous exercise training in the fasting state
1464924|NCT03236259|Dietary Supplement|Brainport high dose|berry extract, high dose. Daily ingestion of capsule
1464925|NCT03236259|Dietary Supplement|Brainport low dose|Berry extract, low dose. Daily ingestion of capsule
1464926|NCT03236259|Dietary Supplement|Placebo|Maltodextrin. Daily ingestion of capsule
1464928|NCT03236233|Drug|PC786 - Single doses|Safety and tolerability of single doses
1464929|NCT03236233|Drug|Placebo - Single doses|Safety and tolerability of single doses
1464930|NCT03236233|Drug|PC786 - Repeat doses|Safety and tolerability of repeat doses
1464931|NCT03236233|Drug|Placebo - Repeat doses|Safety and tolerability of repeat doses
1464932|NCT03236220|Drug|N-acetyl-L-cysteine|Acute leukemia patients with complete remission, whose bone marrow endothelial cells were less than 0.1% detected before haploidentical hematopoietic stem cell transplantation, receive N-acetyl-L-cysteine (NAC) (orally at dosages of 400mg 3 times per day). NAC treatment begins from 14 days pre-allotransplant to 2 months after-allotransplant continuously in the absence of disease progression or unacceptable toxicity.
1464933|NCT03236207|Other|Test extensively hydrolyzed formula|extensively hydrolyzed formula with HMOs
1464934|NCT03236207|Other|Control extensively hydrolyzed formula|extensively hydrolyzed formula without HMOs
1464935|NCT03236181|Other|SFA|High saturated fatty acid/SFA oil source
1464936|NCT03236181|Other|MUFA|High monounsaturated fatty acid/MUFA oil source
1464937|NCT03236181|Other|PUFA|High polyunsaturated fatty acid (linoleic)/PUFA oil source
1464938|NCT03236181|Other|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
1464942|NCT03236155|Drug|opioid pain pills|patient will receive their pain pill prescription
1464943|NCT03236142|Procedure|SIPS Operation|The SIPS modification of the DS operation entails one less division of the small intestine and one less anastomosis, thereby reducing the time of the procedure.
1464944|NCT03236142|Procedure|Standard Duodenal Switch Operation|
1464945|NCT03236129|Procedure|T-reg depleted DLI|The patients in the experimental arm benefit of a DLI depleted from regulatory T lymphocytes
1464946|NCT03236129|Procedure|Standard DLI|The patients in this arm benefit of a standard DLI.
1464947|NCT03236116|Other|Almonds|Participants will consume almonds everyday for 6 months.
1464948|NCT03236116|Other|Control (no nuts)|Participants will not be permited to consume any nuts for 6 months.
1464949|NCT03236103|Other|Clinical Recommendations|"The clinical recommendations will regard the following:
Avoidance of potentially nephrotoxic medications (e.g. NSAIDs, intravascular contrast, nephrotoxic antimicrobials)
Optimizing volume status (avoidance of volume overload or depletion)
Optimizing electrolytes and acid-base status
Optimizing hemodynamics (Mean arterial BP>65mmHg)
Assessment of kidney function with serum creatinine and/or cystatin C
None of the suggestions will be experimental. All suggestions will be based on standard nephrology practice."
1543478|NCT02644460|Drug|Abemaciclib|
1464951|NCT03236077|Behavioral|Fit and Fab|participate in a targeted exercise program at the YMCA. Will include: Targeted exercise classes, Strength-training, Group support sessions
1464952|NCT03236064|Drug|Polyethylene Glycols|Demonstrate more rapid and increased return of function by PEG-fusion compared to best current nerve repair techniques
1464953|NCT03236051|Procedure|Multimodal analgesia|Multimodal analgesia is the name of a procedure or program. Multimodal analgesia doesn't mean different interventions are used. Patients in this group need receive this analgesia program (procedure) instead of one analgesic drug or technology. The program consists of incision infiltration with ropivacaine, intravenous injection of parecoxib, and oral administration of oxycodone/paracetamol mixture.
1464954|NCT03236051|Procedure|PCIA analgesia|PCIA analgesia:patient-controlled intravenous analgesia with tramadol.
1464955|NCT03236038|Diagnostic Test|Labeled triolein urea breath test|"The diagnosis of EPI will be made through the combination of two diagnostic tests.
The labeled triolein breath test will use criteria established by the manufacturer of the product (Pancreo-Kit®) Isomed pharma.
The fecal elastase test will be performed at our own center (Bioserv Diagnostics (BS-86-01 Elastase Pancreatic ELISA) distributed by Palex Medical.) In those cases where both results are negative, it will be considered that there is no EPI. In cases where both results are positive, the diagnosis of EPI will be performed. If the results are discordant, a Sobel test or feces quantification test will be performed."
1464956|NCT03236025|Combination Product|Video+telephone counselling+pamphlet|The videos presented the health effects of smoking, especially emphasizing the importance of smoking cessation on the fetal and pregnancy. The telephone counselling is based on the AWARD and content of the video.
1464957|NCT03236025|Combination Product|telephone counselling+pamphlet|The telephone counselling is based on the AWARD and content of the video.
1464958|NCT03236025|Other|pamphlet|The pamphlet showed the general information related to the smoking cessation
1464959|NCT03236012|Diagnostic Test|Minor Iodine-Starch Test|The iodine-starch test is a valid diagnostic tool of hyperhidrosis and can be useful for the identification of focal areas of sweating on a residual limb.
1464960|NCT03236012|Other|Aluminum Chloride|Aluminum Chloride 20 percent once daily for twelve weeks.
1464961|NCT03236012|Drug|Botulinum toxin type A|Maximum dose up to 500 units given one time
1464966|NCT03235973|Drug|Fludarabine-Cladribine-Busulfan conditioning regimen|"Conditioning regimen will be performed from day -6 to day -2 and contains:
Fludarabine 10 mg/m²/d during 5 days (day-6 to day-2).
Cladribine during 5 days (day-6 to day-2) at one the following define dose level:
Dose 1: 10 mg/m²/d
Dose 2: 15 mg/m²/d
Dose 3: 20 mg/m²/d
Dose 4: 25 mg/m²/d
IV busulfan will be given on day-6 using fixed dose as following:
If age ≤ 60 years: starting dose of 130 mg/m²
If age > 60 years: starting dose of 100 mg/m² No busulfan will be administered at day-5, allowing the pharmacokinetic (PK) analyses . Subsequent infusion of IV busulfan will be performed from day-4 to day-2 at the dose recommended by PK analyses"
1464967|NCT03235960|Device|glass-ionomer fissure sealant|The encapsulated glass-ionomer cement for fissure protection was applied onto the selected permanent molar according to the manufacturer's instruction
1464968|NCT03235947|Drug|Fosfomycin disodium|Fosfomycin disodium 4 g intravenously dissolved in 100 mL of normal saline 0.9% three times in the perioperative period of renal transplant surgery.
1464969|NCT03235947|Drug|Trimethoprim / Sulfamethoxazole|Trimethoprim / Sulfamethoxazole (160/800 mg) orally every 24 hours during the study follow-up (7 weeks)
1464970|NCT03235947|Drug|Intravenous placebo|Normal saline 0.9% 100 mL intravenous administered three times in the perioperative period of the renal transplant, at the same times corresponding to disodium fosfomycin
1464971|NCT03235921|Drug|Nitroglycerin patch 5mg|application of the nitroglycerin patch 5 mg to each patient in nitroglycerin group
1464972|NCT03235921|Other|placebo|no drug given to the control group
1464973|NCT03235908|Other|Observation only|Observation only
1464974|NCT03235895|Other|Educational material|Educational material given as a part of CME activity as through enhanced internet method
1464975|NCT03235882|Diagnostic Test|LS-ratio|Accurately predict RDS using Lecithin/Sphingomyelin ratio (L/S ratio determined by a rapid FTIR test on fresh gastric aspirates) using retrospective analysis
1464976|NCT03235869|Drug|Durvalumab|Durvalumab 1500mg IV over 1 hour administered within 2-7 days of initiation of radiation, then every 28 days.
1464977|NCT03235869|Radiation|Radiation Therapy|Radiation to 1-3 cutaneous tumors: 20 Gy (4 Gy x 5 fractions)
1464978|NCT03235843|Device|AAIR pacing|Rate adaptive pacing using a MV sensor.
1464979|NCT03235843|Device|DDI-pacing|Rate adaptive pacing OFF
1464980|NCT03235830|Behavioral|Enhanced Standard of Care (ESoC) + Text|See above in arm/group description
1464981|NCT03235830|Behavioral|Enhanced Standard of Care (ESoC)|See above in arm/group description
1464982|NCT03235817|Other|Spontaneous ventilation|The patient will breathe spontaneously (on their own) while under general anesthesia throughout the duration of the surgery.
1464983|NCT03235817|Device|Pressure support ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
1464984|NCT03235817|Device|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
1465021|NCT03235453|Other|Binary rhythm|The binary rhythm intervention will be performed using the dance modalities, Forró, Merengue and Bolero. It will occur twice a week for 12 weeks with 45 minutes of sitting.
1465022|NCT03235453|Other|Quaternary rhythm|The quaternary rhythm intervention will be performed using the modalities of dance, Tango, Salsa, Zouk. It will occur twice a week for 12 weeks with 45 minutes of sitting.
1465289|NCT03233347|Drug|Dacarbazine|Given IV
1464986|NCT03235778|Drug|Felbinac Trometamol Injection|Felbinac Trometamol Injection will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
1464987|NCT03235778|Drug|Placebo|Normal saline will be infused IV as a single dose in 100 mL normal saline,in a 30-minute period using a programmable pump
1464988|NCT03235765|Diagnostic Test|MACROGEN Pan Cancer Panel (Tier 2)|This study will utilize a MACROGEN Pan Cancer Panel (Tier 2), which is a hybrid capture-based NGS assay interrogating the coding regions of 170 cancer-related genes.
1464989|NCT03235752|Drug|TJ301 300mg|TJ301 300mg IV infusion
1464990|NCT03235752|Drug|TJ301 600mg|TJ301 600mg IV infusion
1464991|NCT03235752|Drug|Placebo|Placebo IV infusion
1464994|NCT03235726|Drug|CCI15106|One capsule (single dose or repeat dose) of 30 mg of CCI15106 will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
1464995|NCT03235726|Drug|Placebo|One capsule of placebo will be administered to healthy subjects and subjects with COPD via inhalation route using Monodose RS01 device. The morning dose will be taken in fasting state and for repeat dose; the evening dose will be taken at least 2 hours after food.
1464996|NCT03235700|Other|Maximal hyperemia with adenosine followed by nicorandil|IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100) - IC nicorandil 2
1464997|NCT03235700|Other|Maximal hyperemia with nicorandil followed by adenosine|IC nicorandil 2 - IV adenosine 140 - IV adenosine 180 - IC adenosine (LCA 200/RCA 100)
1464998|NCT03235687|Diagnostic Test|ExoDx Prostate (IntelliScore)|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
1464999|NCT03235674|Other|High-intensity stair climbing exercise|High intensity stair climbing exercise at a vigorous pace as measured by rating of perceived exertion.
1465000|NCT03235661|Device|BiPAP|BiPAP is used as a primary mode of ventilation in one of the preterm infants with respiratory distress syndrome
1465001|NCT03235661|Device|nCPAP|nCPAP is used as a primary mode of ventilation in another of the preterm infants with respiratory distress syndrome
1465002|NCT03235648|Procedure|cardiophrenic lymph nodes resection|surgical resection
1465003|NCT03235622|Diagnostic Test|Coronary CT angiography|Presence of coronary plaques Characteristic of coronary plaques
1465004|NCT03235609|Drug|Fentanyl|fentanyl used with propofol for sedation
1465005|NCT03235609|Drug|Ketamine|ketamine used with propofol for sedation
1465006|NCT03235596|Device|tDCS|cathodal tDCS applied over the left dorsolateral prefrontal cortex at 2mA during 15 minutes
1465007|NCT03235583|Device|MOTIONPODTM device validation|MOTIONPODTM validation in free-living conditions using gold standards, including the DLW method
1465008|NCT03235570|Drug|INCB054828|INCB054828 at the protocol-defined dose administered once daily.
1465009|NCT03235544|Drug|INCB050465|INCB050465 at the protocol-defined dose.
1465010|NCT03235531|Drug|Valproate|Valproate is an anti-epileptic medication that can influence the chemical changes in the brain that result from alcohol withdrawal syndrome (AWS) via three mechanisms of action: (1) an increase in GABA activity, (2) inhibition of glutamate binding to NMDA, and (3) restoration of the balance between dopamine and acetylcholine activity. VPA may be effective in the prevention of AWS, and could serve as efficacious adjuvant to traditional benzodiazepine (BZD) therapy for AWS, both decreasing symptoms of AWS and decreasing the use of BZDs.
1465011|NCT03235531|Drug|Lorazepam|Lorazepam is a benzodiazepine used to treat symptoms of AWS. Standard of care at CAMC is monitoring by CIWA tool and administration of lorazepam according to CIWA score.
1465012|NCT03235505|Drug|Nicotine|"A. Nicotine containing e-cigarettes + placebo-varenicline + Motivational Interview (MI) E-Voke 15mg electronic inhaler
10 inhalations is typically needed before the craving will go away
how often a smoker needs to use the inhaler depends on how many cigarettes he/she used to smoke
130 inhalations is about the amount in each cartridge
2-3 cartridges per day is the maximum a smoker should use in this study. If max 15 cartridges per week , thus 180 cartridges /12 weeks period (5 cartridges is the maximum according to the manufacturer )"
1465013|NCT03235505|Drug|Varenicline Tartrate|"B. Nicotine-free e-cigarettes + varenicline + MI Like E-Voke electronic inhaler but without any nicotine content. This product is not yet found.
Varenicline (Chantix®) Starting week: 0,5mg once daily on days 1.-3 and 0,5mg twice daily on days 4.-5.
Continuing weeks: 1mg twice daily for a total of 12 weeks"
1465014|NCT03235505|Behavioral|Motivational Interview|"C. Placebo-varenicline + nicotine -free e-cigarettes + MI
Placebo -varenicline(Chantix®) :
Starting week: 0,5mg once daily on days 1.-3 and 0,5mg twice daily on days 4.-5.
Continuing weeks: 1mg twice daily for a total of 12 weeks
Like E-Voke electronic inhaler but without any nicotine content This product is not yet found."
1465015|NCT03235492|Device|SmartAlbu|"Plan:
Consent an individual
Measure and record temperature, blood pressure, heart rate, height and weight
Obtain two samples of saliva for the SmartAlbu portable salivary sensor
Take a venous blood sample for HbA1c and
Glycated albumin
Obtain blood sample from a finger stick for point of care HbA1c device"
1465018|NCT03235466|Behavioral|Voice Therapy|See Arm 1 & 2
1465019|NCT03235466|Behavioral|Voice Therapy and Heart Rate Variability Biofeedback|See Arm 2 & 3
1465023|NCT03235440|Behavioral|Children's Hospital - Los Angeles Kids N Fitness Program|Participants will engage in a one-week weight-management summer camp consisting of different activities related to moderate-vigorous physical activity (MVPA) and healthy eating. MVPA will consist of modifiable games and activities using a variety of equipment familiar to children of this age, such as balls, hula-hoops, Frisbees, etc., in both competitive and cooperative formats that keep participants moving at all times, and emphasize a feeling of play as opposed to a feeling of exercise. Healthy eating activities are composed of varying classroom-style learning and practical application of knowledge to topics such as recommendations from the MyPlate.gov website, the different types of food groups, and caloric intake and portion sizes, among other various topics.
1465024|NCT03235414|Device|MRI|Will receive a one time research MRI (MR elastography)
1465025|NCT03235414|Diagnostic Test|Blood draw|Will receive a one time blood draw to confirm healthy liver status
1465026|NCT03235401|Other|37-items questionnaire|Patient will answer the PAH-DBoQ questionnaire
1465033|NCT03235323|Device|External Counterpulsation|ECP is a non-invasive method which consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading. This produces a retrograde flow of blood in the aorta resulting in a diastolic augmentation of blood flow and also an increase in venous return, which leads to an improved coronary perfusion pressure during diastole.
1465034|NCT03235284|Other|Kinesiotherapy and Nintendo Wii|A program of therapeutic exercises (GC) for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions). The GC treatment program consists of the following protocols: a) protocol 1 : 30 minutes diagonal exercise upper limb, 10 minutes diagonal exercise scapula and 20 minutes 20 minutes of extension exercises for the trunk; b) protocol 2: 20 minutes diagonal exercise lower limb,10 minutes diagonal exercise pelvis, and 10 minutes gait cycle training. Nintendo Wii program (GW) for a period of two months, with sessions two times a week for 50 minutes (a total of 16 sessions). Protocol 1 games (Boxing e Soccer); b) protocol 2 games (Golf and Running). In GCW program will be performed 20 minutes G0 protocol (1 or 2, used alternately between sessions a week) and 20 minutes G1 protocol (1 or 2, used alternately between sessions a week), taking the time of the performed activities halved in both protocols.
1465035|NCT03235271|Device|BrainPulse Device|"The BrainPulse is used on a patient's head to non-invasively detect, amplify and capture the skull motion caused by pulsatile cerebral blood flow from the cardiac cycle.
The BrainPulse consists of a reusable headset that contains the accelerometers used to measure motion caused by pulsatile cerebral blood flow. The system is powered by a rechargeable battery pack. The headset is placed on the subject's head and outputs data to a data collector that forwards the data to the computer. Each accelerometer has an attached tip that makes contact with the subject's head through hair. The headset also includes a photoplethysmograph (PPG) that simultaneously captures the subject's heart-rate information. There is no energy delivered to the brain or subject by these highly sensitive sensors."
1465036|NCT03235245|Drug|Nivolumab + Ipilimumab|nivolumab 3 mg/kg q3w + ipilimumab 1 mg/kg q3w for 4 injections followed by nivolumab 480 mg IV q4w until completion of 2 years total treatment or progression.
1465037|NCT03235245|Drug|Encorafenib + Binimetinib|encorafenib 450 mg QD + binimetinib 45 mg BID orally for 12 weeks
1465038|NCT03235232|Drug|BREMEN eye drops|1 drop in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
1465039|NCT03235232|Drug|Combigan® and Azopt® concomitantly|"1 drop of Combigan® in the affected eye(s), twice a day (approximately each 12 hours) for 8 weeks.
1 drop of Azopt® in the affected eye(s), three times a day (approximately each 8 hours) for 8 weeks."
1465040|NCT03235219|Drug|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
1465041|NCT03235219|Drug|Placebo|Participants will receive placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
1465042|NCT03235206|Other|Massage Therapy|This study will compare surveys taken before the participants began their massage treatments, and after 12 one hour massages. These surveys will judge sleep quality, stress levels, and mental health during varying days in the participants work cycle. It will also compare a postural assessment and range of motion testing done before the first treatment and after the last.
1465043|NCT03235193|Other|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
1465044|NCT03235193|Other|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the CHH electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
1465045|NCT03235180|Drug|Sulfur Hexafluoride|Subjects will receive ultrasound (US) imaging of the terminal ileum without and with sulfur hexafluoride contrast at baseline, 4 week and 6 months. Subjects will receive one to two milliliters of the contrast agent.
1465046|NCT03235180|Device|Ultrasound Elastography|Subjects will receive US Imaging with the GE Logiq E9 Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
1465047|NCT03235180|Device|Ultrasound Vascularity|Subjects will receive US Imaging with the Verasonics Ultrasound Scanner at baseline, 4 week and 6 months without and with contrast.
1465048|NCT03235180|Device|Magnetic Resonance Enterography (MRE)|Subjects will receive MRE imaging at baseline and 6 months as part of regular clinical care.
1465049|NCT03235167|Drug|CpG DNA|CpG DNA concentrate
1465050|NCT03235167|Procedure|transcatheter arterial chemoembolization|transcatheter arterial chemoembolization (TACE) therapy for liver cancer
1465051|NCT03235167|Drug|Placebo - Concentrate|CpG DNA vehicle
1553106|NCT02576366|Drug|Rifampin|
1465052|NCT03235154|Drug|sofosbuvir/velpatasvir|12 week treatment with once daily sofosbuvir/velpatasivir fixed dose combination therapy. Tablets are formulated with 400mg sofosbuvir and 100mg velpatasvir in pink, diamond-shaped, film coated tablets.
1465053|NCT03235141|Drug|azithromycin eye drops by essex|azithromycin eye drops,2.5ml/25mg,by ZHUHAI ESSEX BIO-PHARMACEUTICAL),
1465054|NCT03235141|Drug|azithromycin eye drops|azithromycin eye drops,2.5ml/25mg ,by Oak Pharmaceuticals, Inc subsidiary of Akorn, Inc
1465055|NCT03235128|Diagnostic Test|‗Urine analysis ‗Urine protein quantification ‗Serum albumin ‗Lipid profile.Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood.|Specific tests Quantitation of miRNA -30a by Real-time polymerase chain reaction (Q-PCR) in peripheral blood
1465059|NCT03235102|Behavioral|No treatment given|Completion of a survey
1465061|NCT03235063|Other|routinely care- no intervention|routinely care- no intervention
1465062|NCT03235050|Drug|MEDI0382 low dose|Pharmaceutical form: solution Route of administration: subcutaneous
1465063|NCT03235050|Drug|MEDI0382 mid dose|Pharmaceutical form: solution Route of administration: subcutaneous
1465064|NCT03235050|Drug|MEDI0382 high dose|Pharmaceutical form: solution Route of administration: subcutaneous
1465065|NCT03235050|Drug|Placebo|Pharmaceutical form: solution Route of administration: subcutaneous
1465066|NCT03235050|Drug|Liraglutide|Pharmaceutical form: solution Route of administration: subcutaneous
1465067|NCT03235037|Drug|Levodopa|The target dose of Sinemet is 2-10 mg per kilogram per day of levodopa. The initial dose will be determined by your weight and age and will start at a low dosage level, 1 mg per kilogram per day. The dose will be re-evaluated after the first 2 weeks and may be adjusted at each visit depending on your response to the drug.
1465068|NCT03235024|Biological|B244|B244 suspension
1465069|NCT03235024|Biological|Vehicle|Vehicle suspension
1465070|NCT03234998|Device|motor-cognitive dual-task training|Participants in the motor-cognitive dual-task training group will will receive an individually-progressed program of dual-task balance/gait training aimed at improving standing balance, sit-to-stand, and walking abilities under motor-cognitive dual-task conditions.
1465071|NCT03234998|Device|cognitive dual-task training|Participants in the cognitive dual-task training group will perform only cognitive tasks (verbal fluency tasks, calculation tasks, and visual discrimination tasks) concurrently with the balance/gait tasks.
1465072|NCT03234985|Biological|Biological analyses|Biological analyses will be realized on samples collected before induction treatment and at the end of bone marrow aplasia i.e. about day 30 to determine the nucleotide pools in peripheral blood mononuclear cells.
1465078|NCT03234946|Behavioral|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement
1465079|NCT03234933|Device|Mobility Tracker|Tracking Patient's movements and calories
1465080|NCT03234920|Dietary Supplement|BETA-HYDROXY-BETA-METHYLBUTYRATE (HMB)|1.5 g of HMB dissolved in 200 ml of fruit juice will be provided for 12 weeks twice daily
1465081|NCT03234920|Other|Placebo|The placebo will be 200 ml of fruit juice given twice daily
1465082|NCT03234907|Drug|Vedolizumab IV|Vedolizumab IV infusion
1465083|NCT03234907|Drug|Placebo|Vedolizumab placebo-matching
1465089|NCT03234868|Device|Impression procedure|Each patient will go through both type of impression during single appointment: first the digital impression and then the conventional one (to avoid residual impression materials for the optical impressions). The time necessary for each procedure will be recorded.
1465090|NCT03234868|Device|Crown manufacturing procedures|Test and control implant crowns will be screw-retained on a multi-unit abutment. The conventional crown will be made of a Zirconia framework veneered with cosmetic ceramics directly screwed on the multi-unit platform (no titanium base). The experimental crown will be made in full zirconia and designed in the TRIOS software.
1465091|NCT03234855|Device|LMD|Physician uses LMD to measure defect during procedure.
1465092|NCT03234842|Radiation|Proton Beam Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
1465093|NCT03234842|Radiation|Photon Radiation Therapy|59.4 Gy (RBE) in 1.8 Gy per fraction plus weekly chemotherapy at standard doses
1465095|NCT03234816|Drug|Norepinephrine 0.05 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
1465096|NCT03234816|Drug|Norepinephrine 0.1 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
1465097|NCT03234816|Drug|Norepinephrine 0.15 mcg /Kg/min|Norepinephrine infusion by rate of 0.05 mcg /Kg/min after spinal anesthesia
1465098|NCT03234816|Drug|Bupivacaine|10 mg Bupivacaine intra-thecal for spinal anesthesia
1465099|NCT03234803|Other|poly-amide|new denture base material
1465100|NCT03234803|Other|poly-methyl methacrylate|gold standard for denture base materials
1465101|NCT03234790|Other|Filter Air Exposure|Exposure to Filter air
1465102|NCT03234790|Other|Diesel Exhaust Exposure|Diesel exposure to different concentrations at different times: 20, 50 and 150ug/m3
1465105|NCT03234764|Other|Immunotherapy|
1465106|NCT03234751|Drug|Continous IV infusion of Nesiritide|Nesiritide (fhBNP) administered by continuous IV infusion during 48 hours.
1465107|NCT03234751|Drug|Hyperinsulinemic euglycemic clamp|48 hours IV infusion of nesiritide on insulin sensitivity (IS) measured by two-step hyperinsulinemic euglycemic clamp in obese nondiabetic insulin resistant subjects.
1465108|NCT03234751|Drug|Placebo|48 hours of placebo.
1465109|NCT03234738|Drug|TP-271|multiple oral doses of TP-271 or placebo, dosed once daily for 7 days, randomized 3:1, doses escalating as 0.5 mg/kg, 1.0 mg/kg, 2.0 mg/kg, 2.5 mg/kg, and 3.0 mg/kg
1465110|NCT03234738|Drug|Placebo|Placebo is sterile 0.45% saline randomized 3:1 to receive
1465111|NCT03234712|Drug|ABBV-321|Intravenous infusion
1465112|NCT03234699|Drug|Cenobamate|12.5 mg q.d.(Days 13-26), 25 mg q.d. (Days 27-40), 50 mg q.d. (Days 41-54), 100 mg q.d. (Days 55-70), 150 mg q.d. (Days 71-84), 200 mg q.d. (Days 85-110)
1465113|NCT03234699|Drug|midazolam|2 mg midazolam syrup (Days 7, 69, 105)
1465114|NCT03234699|Drug|Warfarin Pill|5 mg (Days 7 and 105)
1465115|NCT03234699|Drug|Omeprazole Pill|20 mg (Days 7 and 105)
1465116|NCT03234699|Drug|Bupropion Pill|150 mg (Days 1 and 99)
1465117|NCT03234686|Drug|Deferiprone 600mg delayed release tablets|The active substance, Deferiprone, is a member of the 3-hydroxypyrid-4-one class of iron chelators, which have a high affinity for ferric iron, binding it in a 3:1 (Deferiprone:iron) molar ratio.
1465118|NCT03234686|Drug|Placebo Oral Tablet|The placebo will mimic the Deferiprone arm in every way, except the placebo will not include the active ingredient
1465119|NCT03234673|Drug|Tacrolimus ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Tarolimus ointment twice daily for 3 months.
1465120|NCT03234673|Drug|calcipotriol ointment|3 sessions of fractional CO2 laser one month apart Patients will start treatment Calcipotriol ointment twice daily for 3 months.
1465121|NCT03234673|Drug|NB-UVB|3 sessions of fractional CO2 laser one month apart Patients will start treatment NB-UVB phototherapy twice weekly for 3 months
1465122|NCT03234660|Drug|Dexmedetomidine Hydrochloride|dexmedetomidine 1mcg/kg loading and 0.5mcg/kg/hr continuous infusion during surgery
1465123|NCT03234660|Other|control|0.9% normal saline continuous infusion
1465124|NCT03234647|Device|Doraya catheter|Temporary deployment of the Doraya catheter in AHF patients.
1465125|NCT03234634|Procedure|endovascular thrombectomy|"Intervention description : Group 1: patients with good collateral, Group 2: patient with poor collateral
Group 1 patients (good collateral group) will receive endovascular thrombectomy using stent retriever, aspiration catheter, or both, if femoral puncture is possible between 150 minutes and 600 minutes after last seen well.
Group 2 patients (poor collateral group) will be randomized into endovascular thrombectomy group (2a) and best medical treatment group (2b), if femoral puncture is possible between 150 minutes and 600 minutes after last seen well."
1465126|NCT03234621|Other|ventilator setting during one-lung ventilation|providing various tidal volumes according to the groups with constant PEEP
1465127|NCT03234608|Behavioral|AASPIRE Healthcare Toolkit|The AASPIRE Healthcare Toolkit includes a variety of resources (information, worksheets, checklists, links) for patients and providers. The centerpiece of the toolkit is the Autism Healthcare Accommodations Tool, which allows a patient or their supporter to create a personalized accommodations report for the patient's provider. Intervention patients will use the toolkit and create an AHAT report. Intervention clinics will receive a copy of each patient's AHAT report, place it in the medical record, and share it with the patient's PCP and other staff.
1465128|NCT03234595|Drug|Cerebraca wafer|Eligible patients will receive Cerebraca wafer implantation with adjuvant temozolomide (TMZ) for the safety and efficacy in this study. At Phase I, the MTD will be determined by DLT. At Phase IIa, up to 12 evaluable patients will be enrolled for the efficacy and safety of Cerebraca wafer implantation. At Phase IIa, the cavity surface after tumor removal will be maximally covered by Cerebraca wafer without exceeding the MTD defined at Phase I. Patients in Phase I receive treatment as designed for Phase IIa, the data will be incorporated into Phase IIa to reduce the patient number. The overall patient number in this study is therefore between 2 to 36 evaluable patients.
1465130|NCT03234556|Procedure|Biopsy of Prostate|Undergo SR-Bx
1465131|NCT03234556|Other|Laboratory Biomarker Analysis|Correlative studies
1465132|NCT03234556|Diagnostic Test|Magnetic Resonance Imaging|Undergo MRI
1465133|NCT03234556|Diagnostic Test|MRI Ultrasound Fusion Guided Biopsy|Undergo MRUS-Bx
1465134|NCT03234543|Procedure|Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity in order to induce temporary and reversible ischemia.
1465135|NCT03234543|Procedure|No Remote ischemic conditioning|Placement of blood pressure cuff to lower extremity with minimal inflation without inducing ischemia.
1465136|NCT03234517|Drug|Vaginal Clindamycin Cream|Vaginal Clindamycin Cream
1465137|NCT03234517|Drug|Vaginal Probiotic|Vaginal Probiotic
1465290|NCT03233347|Drug|Doxorubicin Hydrochloride|Given IV
1465141|NCT03234478|Other|cognitive assessments|Cognitive assessments will be performed at baseline, 1 year, and 2 years, depending on subject cohort placement
1465144|NCT03234452|Dietary Supplement|Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
1465145|NCT03234452|Dietary Supplement|Placebo Lactoflorene plus|2 vials with dosing cap (10 mL) a day per os
1465146|NCT03234439|Behavioral|myStrength|myStrength is a digital self-care behavioral and wellness platform
1465147|NCT03234426|Other|Perturbation|Manual perturbations were given at waist region,over the Shoulders. in following positions- sitting, kneeling, standing positions,10 perturbations were given in forward,backward,both right and left side, 6 days in a week all precautionary measures taken for the patient's safety
1465148|NCT03234426|Other|Conventional Physiotherapy Treatment|Conventional Physiotherapy treatment were given to participants included in this group for 30 mins daily for 4 weeks
1465149|NCT03234413|Drug|Botulinum toxin type A|Botulinum toxin type A
1465150|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 25 mg|Vaginal Ring containing 25 mg dapivirine
1465151|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 100 mg|Vaginal Ring containing 100 mg dapivirine
1465152|NCT03234400|Combination Product|Dapivirine Vaginal Ring, 200 mg|Vaginal Ring containing 200 mg dapivirine
1465153|NCT03234387|Other|No intervention - only assessments.|No intervention only a number of assessments. Participants will be assessed during a maximal cardiopulmonary exercise testing on an exercise bike during 1 visit, and before and after an oral glucose tolerance test on a following visit.
1465154|NCT03234374|Combination Product|INL-001 (bupivacaine HCl collagen implant)|3 x 100 mg INL-001 bupivacaine HCl collagen-matrix implants (total bupivacaine HCl dose 300 mg)
1465155|NCT03234374|Drug|Marcaine 0.25% infiltration|Marcaine 0.25% (bupivacaine HCl) 175 mg infiltration
1465157|NCT03234348|Device|Percutaneous coronary intervention|PCI + stent implantation
1465158|NCT03234335|Other|Data collection|Myeloma patients with severe renal impairment who are susceptible to undergo autologous transplantation will be followed in this study, and data related to the pathology, treatments and transplantation will be reported.
1465159|NCT03234322|Other|external validated risk prediction model|The risk prediction model will be integrated into a routine health check. The diabetes risk prediction model contains modifiable non-invasive risk factors and consists of eleven questions on age, height, waist circumference, hypertension, physical activity, smoking status, intake of whole-grain bread, intake of red meat, coffee consumption, and family history of diabetes (parents and siblings) to predict the five-year diabetes risk. The filled diabetes risk score will be used in the counseling interview with the PCP at the end of the health check as a practical guide to discuss individual tailored preventive strategies.
1465160|NCT03234309|Drug|Ferumoxytol|Given IV
1465161|NCT03234309|Procedure|Magnetic Resonance Imaging|Undergo MRI
1465162|NCT03234296|Drug|Ertapenem|Intravenous antibiotic followed by per oral antibiotics
1465163|NCT03234296|Other|Placebo|Intravenous placebo followed by per oral placebo
1465164|NCT03234283|Device|IRRIS InfraRed - Red Intubation System|IRRIS will be attached to the patient's neck skin just beneath the laryngeal prominence. Tracheal intubation will be performed by using a video-laryngoscope in a standardized Fashion and by guiding the tracheal tube into the Larynx by following the visual Signal on the Screen that is caused by IRRIS. The handling of IRRIS and the Performance of tracheal Intubation will be recorded. Patients will be monitored for safety parameters and possible adverse events during the study until recovered and released from the postoperative care unit.
1465165|NCT03234270|Device|Core temperature measurements|Core temperature measurements with coretemp pill
1465166|NCT03234257|Device|UF-ultrasound|the carotid plaque stability by UF in order to improve the stroke prediction in case of asymptomatic stenosis. A UF-ultrasound approach is a non-irradiating, easily accessible, and low cost technique
1465167|NCT03234244|Drug|Combinations|Bazedoxifene and Cholecalciferol Combination
1465168|NCT03234231|Behavioral|3-month supervised tooth brushing programme|One or a few dental hygienists, who are trained to teach how to brush and provide scaling, will supervise the students to brush daily in school for three months.
1465169|NCT03234231|Behavioral|oral health education talk|It is conducted by a dentist, while written materials will be delivered to the students and their carers.
1465170|NCT03234205|Device|MRI scan|"MRI standard protocol with addition of:
a second clinical respiratory belt besides belt usually installed for clinical examination
a second clinical electrocardiogram sensor besides sensor usually installed for clinical examination
12 sequences during free respiration are added lasting supplementary 15 minutes
Use of cardiac antennae usually used for cardiac MRI scans"
1465171|NCT03234192|Procedure|Therapeutic ultra sound|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to therapeutic ultra sound treatment.
1465172|NCT03234192|Procedure|Astym Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Astym Treatment.
1465173|NCT03234192|Procedure|Graston Treatment Technique|This group will receive standard treatment consisting of eccentric strengthening, stretch, proximal strengthening, and education in addition to Graston Treatment.
1465174|NCT03234166|Other|Non interventional study|Only data will be taken of patient's file.
1465175|NCT03234153|Drug|Durvalumab (Imfinzi)|Durvalumab 1500 mg i.v. every 4 weeks in combination with Tremelimumab 75 mg i.v. every 4 weeks for a total of 4 cycles before surgery.
1465176|NCT03234153|Drug|Tremelimumab|Tremelimumab 75 mg i.v. in combination with Durvalumab 1500 mg i.v. every 4 weeks every 4 weeks for a total of 4 cycles before surgery.
1465177|NCT03234140|Genetic|Genome Wide Association Studies|Using the Genome wide association studies (GWAS) approach on these 1,565 patients, the project plan to identify new prognostic markers. These markers will then be analyzed to decipher the impact of host genetics on somatic alterations and tumor biology, using public or matched patient data.
1465178|NCT03234140|Genetic|Single-nucleotide polymorphisms's genotyping|Analyze of the influence of single-nucleotide polymorphisms on circulating t(14;18) levels
1465179|NCT03234127|Genetic|Whole Genome Sequencing|Whole Genome Sequencing Biomarkers analyses
1465181|NCT03234101|Behavioral|Low-risk lifestyle behaviours|"Low-risk lifestyle behaviours defined as:
1) Healthy body weight (Minimum: BMI <30kg/m2 or WC of <88 in females or <92 in males); 2) Healthy diet (healthy diet, diet score with higher fruits & vegetables to Mediterranean dietary pattern); 3) Regular physical activity (20 minutes ≥ 1 time/week ); 4) Smoking cessation (never smoked to smoking cessation >12 months); 5) Moderate alcohol intake (up to 30g/day); 6) Adequate sleep (>6 hours)"
1465182|NCT03234088|Behavioral|Daily weight measured by digital scale and symptom reporting|All subjects will be provided the intervention.
1465183|NCT03234075|Other|Regional organization for promotion of renal transplantation|"Early identification of candidates for renal transplantation
with the help of a care coordinator Inform all patients appropriately about the techniques of renal function supplementation
delivered by expert patients and a care coordinator Assist the nephrologists in patient graft pathway
Multidisciplinary assessment of patients in dedicated web-conferencing meetings bringing together nephrologists and transplant team ( WebRCP of kidney transplant orientation)
Helping to carry out the pre-graft assessments of patients by a care coordinator"
1465184|NCT03234062|Other|Normal choline and Low choline diet|Twenty healthy volunteers will consume meals containing 100% of the recommended intake of Choline (400-550 mg Choline/day) depending on age and gender) for 2 weeks. Subjects then will be switched to a diet containing 10% of the recommended intake of Choline for 2 weeks. On the last 5 days of each diet period, subjects will consume 22% of their total Cho in the form of Cho chloride-(trimethyl-d9, 9%, Cambridge Isotope Laboratories, Tewksbury, Massachusetts, (USA).
1465185|NCT03234062|Dietary Supplement|Multivitamin pills|Subjects will also be given a dietary supplement containing the RDI of magnesium and 1.5 times the Adequate Intake of calcium (Calcium Magnesium Complex; Vitamin Shoppe, North Bergen, NJ).
1465186|NCT03234049|Other|Checklist|The Alberta Children's Hospital Trauma Checklist was developed by the ACH Resuscitation Council Trauma Committee in response to a quality assurance review of high-acuity trauma activations. It is a cognitive aid and focuses in particular on pre-arrival preparation and a pre-departure review prior to patient transfer to diagnostic imaging or the operating room.
1465187|NCT03234036|Drug|GSK2838232 100 mg tablet|It is a white to slightly colored tablet. It will be supplied as prefilled tablets in bulk for dispensing to subjects at the site according to the treatment code.
1465188|NCT03234036|Drug|GSK2838232 50 mg capsule|It is a pink unmarked capsule. It will be supplied as prefilled capsules in bulk for dispensing to subjects at the site according to the treatment code.
1465189|NCT03234036|Drug|Ritonavir 100 mg tablets|It is a white film-coated ovaloid tablets.
1465190|NCT03234036|Drug|Placebo for GSK2838232 tablets|It is a white to slightly colored tablet. The placebo tablets supplied will not be identical to GSK2838232 tablets. It will be administered by site staff via an opaque card or paper tube.
1465191|NCT03234023|Behavioral|INTERVENTION GROUP|Offer recommendations of healthy living habits and control of pharmacy administration
1465200|NCT03233984|Behavioral|"sensibilisation program Ma maison, mon environnement santé"|The aim of this program is to spread the awarness about endocrine disruptors through workshops and presentation.
1465201|NCT03233971|Other|rPATD Questionnaire|A 5-point Likert scale questionnaire consisting of 22 questions for older adults, and 19 questions of caregivers.
1465202|NCT03233958|Behavioral|Systemic / family constellation|Systemic / family constellation integrates elements from psychodrama, family sculpture, and spontaneous dramatizations of intra- and interpersonal processes, while spatially visualizing family dynamics. Family constellations stimulate change through the following ways: 1) making visible the spatial arrangement of relationships within a conflictual system; 2) providing access to the insights of unrelated third parties regarding the sensations, feelings, and thoughts they experienced while representing family members within the constellation; and 3) making observable (from the outside) and experienceable (from within) the transformation of the problem constellation into the solution constellation [Hunger, Weinhold, Bornhäuser, Link, & Schweitzer, 2015].
1465204|NCT03232801|Behavioral|mindfulness-based multicomponent intervention|A group-based, multicomponent behavioral intervention rooted in mindfulness
1465205|NCT03232801|Behavioral|general health education group|A general health and aging education group
1465206|NCT03232788|Procedure|Bone regeneration|Autogenous bone will be placed over periodontal defect after root treatment with scaling and root planing.
1465207|NCT03232788|Device|Collagen membrane|A collagen membrane will be used to cover the autogenous bone.
1465208|NCT03232788|Device|Scaffold|A hydroxyapatite and polycaprolactone scaffolds will be used to cover the autogenous bone.
1990908|NCT01693068|Drug|Pimasertib|Pimasertib will be administered as oral capsule at a dose of 60 milligram (mg) twice daily continuously. Treatment will consist of repeated 21-day cycles which will be continued until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever comes first.
1465209|NCT03232775|Other|Treatment: Physical Exam with Visual Pedagogy and Structure|Routine physical examination participants receive visual pedagogy and reinforcement (preferred food treat).
1465210|NCT03232775|Other|Control: Physical Exam without Visual Pedagogy and Structure|Participants engage in routine physical examination without visual pedagogy and reinforcement (preferred food treat).
1465213|NCT03232749|Procedure|intraarticular corticosteroid injections (IACSI)|ultrasound-guided IACSI will be administered
1465214|NCT03232749|Drug|corticosteroid injections|Corticosteroid will be administered is used to treat pain and swelling that occurs with arthritis and other joint disorder
1465215|NCT03232749|Device|Ultrasound|ultrasound-guided IACSI
1465216|NCT03232736|Other|Pacemaker adjustments|LVAD subjects with CRT device will have leads turned both on and off in blinded manner
1465217|NCT03232736|Device|CRT|CRT device
1465218|NCT03232723|Device|Whole-cortex MEG System (with optional EEG)|"Whole-Cortex MEG System non- invasively measures the magnetoencephalographic (MEG) signals (and, optionally, electroencephalographic EEG signals) produced by electrically active tissue of the brain. These signals are recorded by a computerized data acquisition system, displayed, and may then be interpreted by trained physicians to help localize these active areas. The location may then be correlated with anatomical information of the brain. MEG is routinely used to identify the locations of visual, auditory, somatosensory, and motor cortex in the brain."
1465219|NCT03232710|Drug|Bosiqing|Aripiprazole Orally disintegrating tablets 10mg
1465220|NCT03232710|Drug|abilify|Aripiprazol orodispersible tablets 10mg
1465221|NCT03232697|Diagnostic Test|Full version of the Montreal Cognitive Assessment|Patients or subjects will be submitted to the full version of the MOCA
1465222|NCT03232697|Diagnostic Test|5 minutes version of the Montreal Cognitive Assessment|The same patients and subjects will be submitted to the 5 minutes version of the MOCA through a phone call
1465223|NCT03232684|Diagnostic Test|Rapid on-site evaluation|On-site (endoscopy suite) evaluation, by a pathologist or a pulmonologist, of specimens retrieved from intrathoracic lymph nodes during EBUS-TBNA
1465224|NCT03233932|Drug|LeuplinⓡInj|Investigational drug(=LeuplinⓡInj)is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
1465225|NCT03233932|Drug|CKD-841|Investigational drug(=CDK-841) is prescribed single injection dose by subcutaneous to 6 of randomized subjects once.
1465226|NCT03233919|Device|comprehensive remote ischaemic conditioning|"comprehensive remote ischaemic conditioning will be induced using an automated RIC device: Per-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb. The first inflation began immediately following randomization after admission. In case 5 cycles of RIC were not fully completed when the first balloon inflation or thrombus aspiration was ready to be performed, PCI was not to be delayed.
Post-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb immediately after PPCI.
Delayed-RIC consists of 5 cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on a lower limb once daily on 2-28 days after MI."
1465227|NCT03233906|Dietary Supplement|Chia Seeds- Salvia Hispanica|Chia seed added-10% of kcals and a no-chia control diet. 10% will be calculated using the following formula: Harris-Benedict equation multiplied by the activity factor of 1.2, 1.375, and 1.55 depending on each participant's activity level based on the information provided on the initial screening form.
1465228|NCT03233893|Other|light activated calcium silicate|"for the first group light activated calcium silicate can be easily placed by a 20 second light cure and ability to be syringed directly on to the cavity preparation and restore the cavity by composite restoration.
for the second group using light activated calcium hydroxide is placed by placing a disposable tip securely on to the syringe then light cure for 20 seconds depending on the light cure unit and restore the cavity with composite restoration."
1465229|NCT03233880|Drug|Azithromycin 1gm|Azithromicin 1 gm oral single dose
1465230|NCT03233880|Other|PLACEBO|placebo
1465236|NCT03233828|Biological|Aldesleukin|500,000 IU in 0.1mL
1465237|NCT03233828|Other|Saline|0.1 mL of sterile saline solution (0.9% m/v)
1465238|NCT03233815|Drug|Propofol|Propofol anesthesia Dose: 4-6mg/kg/h
1465239|NCT03233815|Drug|Sevoflurane|Inhaled anesthesia with sevoflurane. Dose: 1-2.5 Minimum Alveolar Concentration(MAC)
1465240|NCT03233802|Behavioral|Individualized Assess & Treatment (IATP)|See previous description
1465241|NCT03233802|Behavioral|Packaged Cognitive-Behavioral (PCBT)|See previous description
1465242|NCT03233802|Behavioral|Case Management (CaseM)|See previous description
1465243|NCT03233789|Behavioral|neurologic rehabilitation|in-patient rehabilitation of neurologic disorders
1465245|NCT03233763|Procedure|Bone Marrow Aspirate|Diagnostic Bone Marrow aspirate
1465246|NCT03233750|Behavioral|Stress Inoculation Training|see description in arm/group descriptions
1465247|NCT03233750|Behavioral|Crisis Resource Management|During each scenario, facilitators identify performance gaps in either situation awareness, leadership, communication or resource allocations. During debriefing session, these are raised with the learner and their cognitive frames are identified and corrected as necessary.
1465248|NCT03233737|Drug|Benzocaine and Tetracaine|A single application of 1 spray of a combination of benzocaine 14% and tetracaine 2% with a total dose of benzocaine 28 mg and tetracaine 4 mg per spray.
1465249|NCT03233737|Drug|Benzocaine|The control treatment is benzocaine 14% alone with a total dose of 28 mg per spray.
1990909|NCT01693068|Drug|Dacarbazine|"Dacarbazine will be administered intravenously at dose of 1000 mg per square meter of body surface area on Day 1 of each 21-days cycle. Treatment will be continued until progression of the disease, unacceptable toxicity, withdrawal of informed consent, or death, whichever comes first.
Eligible subjects with documented tumor progression on dacarbazine will be offered to switch to pimasertib treatment at the end of the treatment."
1990910|NCT01692691|Drug|Dacarbazine|Dacarbazine IV - Day 1
1990911|NCT01692691|Drug|Carmustine|Carmustine IV- Day 2
1465253|NCT03233711|Biological|Nivolumab|Given IV
1465254|NCT03233685|Behavioral|Visual Training|The visual training will be performed 3 times a week for 40 minutes, at the end of warm up and before the technique training. The subjects will be performed a progression of exercise to improve their visual ability, their velocity of interpretation and transformation. The training will be performed with specific panels approved for visual training (S.V.T.A., Torino, Italy).
1465255|NCT03233685|Behavioral|Normal Training|Normal training routine
1465256|NCT03233672|Radiation|Adjuvant and salvage IMRT-SIB|intensity-modulated radiation treatment with simultaneous integrated boost
1465257|NCT03233646|Device|Retinal Imaging|Non-invasive OCTA scan of retina
1465258|NCT03233633|Drug|Medical Marijuana|oral capsule, high ratio CBD:THC
1465259|NCT03233620|Other|Knee arthroplasty|Effectiveness of knee arthroplasty surgery.
1465260|NCT03233607|Device|Hemoglobin Spot Check|On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation .At the same time noninvasive hemoglobin spot check will be done with Pronto hemoglobin spot check pulse co-oximeter.
1465261|NCT03233607|Procedure|Blood Draw|On postpartum day 1 and day 2, a sample of blood will be drawn in the morning for hemoglobin and hematocrit estimation .At the same time noninvasive hemoglobin spot check will be done with Pronto hemoglobin spot check pulse co-oximeter.
1465262|NCT03233594|Other|Chiropractic Group|Participants will receive approximately 8 weeks of chiropractic care.
1465263|NCT03233581|Behavioral|Fitbit + Facebook + Coaching Group|Participants will use the FitBit device to track their physical activity (PA). Participants will receive and post messages and receive badges on the Facebook group. Weekly a research staff member will call them to provide brief health coaching. Participants will select an adult family member or friend to also receive a Fitbit during the intervention period to provide support.
1465264|NCT03233581|Behavioral|Fitbit only|Participants will receive a Fitbit device only, and will not receive health coaching, join the Facebook group, or select an adult family member or friend to receive a Fitbit to provide them with support.
1465265|NCT03233568|Diagnostic Test|Indirect calorimetry|"Indirect calorimetry will be performed by using an open-circuit calorimeter (Sensor Medics, Italy). Indirect calorimetry is the reference method for energy expenditure determination. A canopy hood covered the patient's head and expired air is extracted by a pump to be analyzed by metabolic cart sensors; flow rate is directly measured with a digital turbine flowmeter. After an overnight fast, patients will asked to lay supine in complete physical rest, not sleeping or talking for approximately 20-25 minutes, at a room temperature ranged between 22 and 24°C. The mean REE for each participant considers the last 15-20 minutes of measurements corresponding to steady state.
Software of calorimeter will be set for minute-by-minute reading report of VO2 (Oxygen flow) and VCO2 (Carbon dioxide flow) measurement.
Parameters obtained by Indirect Calorimetry will be the Resting Energy Expenditure and the Respiratory Quotient (RQ)"
1465266|NCT03233555|Other|Informational Intervention|Receive brochure
1465267|NCT03233555|Other|Internet-Based Intervention|Have access to EXCELS
1465268|NCT03233555|Other|Quality-of-Life Assessment|Ancillary studies
1465269|NCT03233555|Other|Questionnaire Administration|Ancillary studies
1465270|NCT03233555|Behavioral|Telephone-Based Intervention|Receive quarterly calls
1465271|NCT03233542|Behavioral|Cognitive Behaviour Therapy|Cognitive Behaviour Therapy (CBT) for diagnosed anxiety disorder (i.e. CBT for Panic Disorder in the Panic Disorder group, or other diagnosed anxiety disorders in the Anxious Control group.
1990912|NCT01692691|Drug|Neulasta|Neulasta SC - Day 3
1465274|NCT03233503|Diagnostic Test|Basic taste, fat sensation and texture perception|"This is an observational Sensory study methodologically similar to Astringency and bitterness perception clinicalTrials.gov identifier NCT03171402 Participants are first involved in sensory training sessions that train how they recognise between different basic tastes and differentiate perceived intensity in solutions and foods. After 6 months of training, the trained participants are involved in tasting a wide array of commonly consumed foods. At this study phase, participants will rate for the foods' taste, fat sensation perception and texture"
1465275|NCT03233490|Other|web course|Web course Help Brain Heart was conducted Before CPR training.
1465276|NCT03233490|Other|CPR training|No web course was conducted
1465277|NCT03233451|Behavioral|Psycho-behavioral intervention|The psycho-behavioral intervention included 12-week weekly guided psychological intervention (8 modules of behavioral intervention) and 24-week monthly maintenance psychological support.
1465278|NCT03233438|Drug|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
1465279|NCT03233438|Drug|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
1465280|NCT03233425|Behavioral|multiprofessional group therapy|Behavioural therapy of lifestyle including activity, family and eating habits
1465281|NCT03233412|Procedure|Control|Exertion of the cervix transformation zone
1465282|NCT03233412|Drug|Imiquimod|Application by the doctor of immunomodulatory cream on the uterine cervix 1 time per week for 12 weeks
1465283|NCT03233399|Device|Sham TMS3 stimulation|half of the subjects will receive sham stimulation first
1465284|NCT03233399|Device|rTMS of left or right angular gyrus (AG) or frontal cortex (FC)|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
1465285|NCT03233399|Device|Anodal tDCS of left or right AG or FC|Half of the subjects will receive active stimulation first; A subject may receive either TMS or tDCS stimulation, but not both, over the course of the sub-study.
1465286|NCT03233386|Behavioral|Mantente REAL|substance abuse prevention curriculum for adolescents
1465287|NCT03233373|Device|Seek CompactPro thermal imager|A device with image/video recording capability, it is non-invasive and only relies on infrared emissions from heat sources (the patient).
1465294|NCT03233334|Behavioral|Purpose Project|The purpose project intervention 8-session group intervention that integrates education, support, self-reflection, and action-expectation to help people reaffirm or reconstruct self-grounded purpose after significant life events/transitions. The 8 sessions extend over 2-3 months, with 7 weekly sessions and the final session 1 month after Session 7. The intervention is structured around the 6 dimensions of flourishing (autonomy, self-acceptance, personal growth, relationships, purpose in life, external mastery), the goal of which is to help people enact behaviors that move them forward in reframing a sense of self and reaffirming or reconstructing a sense of purpose in life that helps them flourish.
1465295|NCT03233321|Other|Dry cold application|Dry cold application using ice bag (Crushed ice was filled in ice bag with ½ table spoon of salt and then covered by clean linen to prevent moisture) was placed over the injection site for about 20 minutes.
1465296|NCT03233321|Other|sub cutaneous injection (low molecular weight heparin)|sub cutaneous injection (low molecular weight heparin) has been administered on injection site
1465297|NCT03233308|Drug|Netarsudil Ophthalmic Solution|Topical sterile ophthalmic solution once daily
1465298|NCT03233308|Drug|Placebo Comparator|Topical sterile ophthalmic solution once daily
1465299|NCT03233295|Drug|Vitamin D3 B.O.N. Injection|cholecalciferol 200,000IU
1465300|NCT03233282|Other|Electroencephalography (EEG) multi-sensor|Electrophysiological measurements of cerebral activity will be performed by multi-sensor electroencephalography (EEG), which is a non-invasive method.
1465301|NCT03233282|Other|Magnetoencephalography (MEG)|Electrophysiological measurements of brain activity will be performed by magnetoencephalography (MEG) which is a non-invasive method.
1465302|NCT03233282|Other|Behavioral Measures|The evaluation of cognitive performance will be carried out by means of behavioral measures, push-button type, handling of a mouse or a joystick.
1465303|NCT03233282|Other|Reaction time measurement|The assessment of cognitive performance will be carried out using standard behavioral measures, such as reaction time measurement.
1465304|NCT03233282|Other|Assessment of physical performance|The assessment of physical performance will be based both on bioenergetic measurements and on quantitative data collected in continuous and relative to the effort (eg instantaneous pedaling speed).
1465305|NCT03233282|Other|Electrooculogram (EOG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
1465306|NCT03233282|Other|Electromyogram (EMG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
1465307|NCT03233282|Other|Electrocardiogram with 3 leads|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
1465308|NCT03233282|Other|Electrodermogram (EDG)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
1465309|NCT03233282|Other|Consumption of O2 (VO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
1465310|NCT03233282|Other|Production of CO2 (VCO2)|In order to extract artifacts and verify the physical performances of the subjects, under the conditions of physical fatigability, peripheral electrophysiological recordings will be necessary and complementary to meet the objectives set in this study.
1465311|NCT03233269|Behavioral|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment via a prerecorded video. The Music Therapist will then engage the patients in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
1465312|NCT03233256|Procedure|Feasibility of measuring 2H:1H and 18O:16O in saliva and breath.|The investigators propose to demonstrate the feasibility of measuring 2H:1H and 18O:16O in saliva and breath. The natural abundances of 2H:1H and 18O:16O of urine, saliva, and breath samples will be determined from samples obtained simultaneously from 50 relatively healthy human subjects. We will also measure 2H:1H and 18O:16O enrichments in urine, saliva, and breath of 10 relatively healthy human subjects obtained after consuming a standard DLW dose and compare the estimates of TDEE using these different matrices.
1465329|NCT03233165|Procedure|Er:YAG laser|"Ablation of the lesions Device: Er:YAG laser (LightWalker AT, Fotona, Slovenia, 2013) with a non-contact X-Runner digitally controled hand-piece.
Settings for the Er:YAG laser were as follows: pulse mode was Quantum Square Pulse (QSP), pulse energy of 120mJ, frequency of 20Hz and water sprey level was set to10ml per minute."
1465330|NCT03233165|Procedure|Er,Cr:YSGG laser|Ablation of the lesions Device: Er,Cr:YSGG laser(WaterLase iPlus, Biolase LTD, USA) using contact mode. Settings were subsequent: power 50W, frequency 50Hz and concentration ratio of air and water was 2:4.
1465331|NCT03233152|Drug|Ipilimumab (YervoyTM, 50 mg/10 mL solution)|"Ipilimumab will be administered by at the end of the neurosurgical resection procedure at a dose of injection of 10 mg (: 2 ml of YervoyTM, 50 mg/10mL vial).
Injections will be performed manually using a 100 μ-liter dispensing syringe. Twenty needle tracks will dispense the ipilimumab solution within the brain tissue lining the resection cavity. The region suspect on preoperative MRI of the brain to be invaded by glioblastoma cells but not amenable to safe resection will be targeted by adjacent needle tracks through which up to 2 cm of depth a volume of 100 μl per needle track will be injected (: in total 20 needle tracks will be performed). This methodology has been applied previously within the context of phase III clinical trials with sitimagene ceradenovec."
1465332|NCT03233152|Drug|Nivolumab (OpdivoTM, 40 mg/4mL solution)|First administration of 10 mg of nivolumab by the intravenous route should be administered within 24 hours prior to the planned neurosurgical resection. Administrations of 10 mg nivolumab (OpdivoTM, 40 mg/4mL solution) will be by a 15 minutes intravenous infusion on days 15, 29, 43, 57, and 71 (or up to ± 3 days before or after the scheduled date if necessary).
1465333|NCT03233139|Drug|REGN2810|Patients will be administered REGN2810 as per protocol
1465335|NCT03233113|Behavioral|Exposure therapy|"Exposure therapy (i.e., exposure-based cognitive behavioral therapy) for spider phobia according to condition-specific, scripted treatment manuals inspired by evidence-based exposure programs for anxiety/phobias (for both arms: Abramowitz, Deacon, & Whiteside, 20011; Antony, Craske, & Barlow, 1995) as well as the seminal account of the judicious use of safety behaviors thesis (for the experimental arm only: Rachman, Radomsky, & Shafran, 2008). Exposure and response prevention involves confronting a live spider while resisting safety-seeking behaviors; exposure with judicious safety behaviors involves strategically using safety behaviors while confronting a live spider."
1465336|NCT03233100|Other|FMT|fecal microbiota transplantation
1465337|NCT03233074|Other|Bone marrow analyses|This is a non-interventional study for the constitution of a biobank of bone marrows, in order to further investigate in vitro the cellular properties of bone marrow-isolated mesenchymal stromal cells.
1465338|NCT03233061|Diagnostic Test|cardiorespiratory fitness and daily physical activities evaluations|"The cardiopulmonary exercise testing is performed on a cycle ergometer connected to cardiovascular and respiratory software. Subjects have a facemask, which collected respiratory and metabolic variables.An incremental exercise test is performed up to exhaustion. ⩒O2 is recorded and heart rate is averaged by an electrocardiogram system.
Cardiopulmonary exercise testing during household activities Subjects have to perform 3 everyday life household activities: ironing,cleaning floor,walking and climbing stairs.A wearable ambulatory indirect metabolic system is used with Holter mode to record cardiorespiratory measures.Subjects have to breathe through the K4b2 facemask and turbine."
1465340|NCT03233035|Drug|Ketamine|0.6 mg/kg of ketamine in 3 ml of serum saline in one pulverisation intra nasal is received
1465341|NCT03233035|Drug|Placebos|3 mL of normal saline solution as a placebo intra nasal in one pulverisation
1465342|NCT03233022|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
1465343|NCT03233009|Other|Experimental Daily Defense Serum A|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
1465344|NCT03233009|Other|Experimental Daily Defense Serum C|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
1465345|NCT03233009|Other|Experimental Daily Defense Serum G|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
1465346|NCT03233009|Other|Experimental Daily Defense Serum N|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
1465347|NCT03233009|Other|Saline Solution Sodium Chloride|Participants will apply 0.02mL/cm2 of product topically via semi-occlusive patches onto dorsum (Scapular region).
1465348|NCT03232996|Other|Computer game based balance and walking rehabilitation for individuals with Parkinson's Disease|All the participants will take part in an 8 week (twice per week) computer game based exercise program for dual task balance and dual task walk training. Participants will be standing in front of LED monitor. They will be asked to wear a head band which will be instrumented with motion sense mouse. Thus, hands-free head rotations will be used to interact with the computer games selected for the DT rehabilitation program. Participants will play few interactive computer games during - Normal standing (fixed surface), Standing on a compliant sponge pad and then while walking on a treadmill.
1465352|NCT03232957|Procedure|50 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 50 ug
1465353|NCT03232957|Procedure|100 ug IT morphine|Spinal block with bupivacaine and intrathecal morphine 100 ug
1465354|NCT03232957|Procedure|No IT morphine|Spinal block with bupivacaine and intrathecal morphine 0 ug
1465355|NCT03232957|Drug|Morphine|intrathecal morphine
1465356|NCT03232957|Drug|Bupivacaine|0.5 isobaric bupivacaine
1465357|NCT03232944|Device|Cardiac Resynchronization Therapy - MPP|The multiple point pacing feature (MPP) is designed to allow pacing from 2 LV electrodes.
1465464|NCT03231839|Behavioral|no red meat|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
1465358|NCT03232931|Device|Multisensory intervention|The intervention will be carried out in addition to standard care and will include 2 components: (1) holding and light pressure containment of the infant against the hospital-gown covered chest of the therapist for tactile and non-specific auditory stimulation simultaneous with (2) playing of mother's voice contingent on infant pacifier sucking for the first 20 minutes of holding. Additionally, a gauze square scented with parent's skin will be used to provide olfactory stimulation.
1465359|NCT03232931|Behavioral|Standard of care|Standard of care: parental skin-to-skin care and exposure to parent's voice
1465360|NCT03232918|Drug|Half dose Oxytocin|Patients randomized to the half dose oxytocin group will have the oxytocin infusion reduced to 50 % prior to placement of combined spinal epidural for labor analgesia
1465361|NCT03232905|Drug|PF-06651600|PF-06651600 will be administered as tablet
1465362|NCT03232905|Drug|Placebo|Matching placebo will be administered as tablet
1465364|NCT03232879|Behavioral|Motor Imagery|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R).
1465365|NCT03232879|Behavioral|Action Observation|Two consecutive 30 seconds imagery tasks were performed, both based on two movements that are recorded in the Revised Movement Imagery Questionnaire (MIQ-R). Before the subjects performed the mental MI practice, they were presented with a 30 seconds video that displayed the task that they ought to imagine later. A video was played prior to the first practice of imagination and after the second mental practice, a second video was shown.
1465366|NCT03232866|Other|Pilates exercise|Pilates methods exercises
1465367|NCT03232853|Other|Elearning|Elearning
1465368|NCT03232671|Diagnostic Test|MIF ELISA|Blood sample
1465369|NCT03232645|Device|Ablation procedure|Cathater ablation of pulmonary veins with the Rhythmia HDx mapping system, IntellaMap Orion mapping catheter and IntellaNav Mifi OI ablation catheter
1465370|NCT03232632|Drug|PET with 18 F-Flutemetamol|PET with 18 F-Flutemetamol (Vizamyl ®)
1465372|NCT03232593|Drug|Atezolizumab|Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
1465374|NCT03232567|Biological|NasoVAX|Single ascending dose study
1465375|NCT03232554|Drug|Buxue Yimu Pills|Buxue Yimu Pills 12g pill by mouth, twice daily.
1465376|NCT03232554|Drug|Buxue Yimu Pills &Ferrous Sulfate|Buxue Yimu Pills 12g pill by mouth, twice daily and Ferrous Sulfate 0.3g tablet by mouth, three times daily
1465377|NCT03232554|Drug|Ferrous Sulfate|Ferrous Sulfate 0.3g tablet by mouth, three times daily
1465378|NCT03232541|Other|Standard care|A) Ordinary nausea treatment means receiving ordinary antiemetic medications. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expectations concerning antiemetic effects of their treatment, using a standardized communication model.
1465379|NCT03232541|Device|Sham acupuncture|B) Sham acupuncture will be administered bilaterally to a non-acupuncture point two body-inches proximal and one body-inch radial from PC6. The telescopic Park Sham Device will be used. The needle looks identical to a real needle, but is blunt and glides upward into its handle instead of penetrating. The marking tubes holds the needle in place. The therapist will give an illusion of manipulating the needle by turning it three times until it touches the skin, but no deqi will occur. Except when placing and manipulating the sham needle, it will not be pressed against the skin at all. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expectations concerning antiemetic effects of their treatment, using a standardized communication model.
1465380|NCT03232541|Device|Genuine acupuncture|C) Acupuncture will be administered bilaterally to the standard antiemetic point PC6 located two body-inches proximal of the wrist crease, between the tendons of palmaris longus and flexor carpi radialis. Sharp acupuncture needles will be inserted into a depth of a half body-inch. The needles will be manipulated three times (at the start, middle and end of the treatment session) by twirling and lifting until deqi occurres. Within the group, the patients will be randomized to two communication types: 1) neutral communication or 2) strengthened positive communication regarding expectations concerning antiemetic effects of their treatment, using a standardized communication model.
1465381|NCT03232528|Other|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
1465382|NCT03232528|Other|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
1465383|NCT03232515|Combination Product|To estimate the dry weight of patients with chronic renal failure under hemodialysis treatment using BIVA|Using the BIVA method, excess fluid will be estimated in patients with chronic renal failure undergoing hemodialysis in order to obtain a better estimate of dry weight and thus improve the quality of life of patients.
1465384|NCT03232502|Diagnostic Test|Pharmacogenetic testing|Basic pharmacogenetic panel
1465385|NCT03232476|Device|Upper extremity voluntary loading|Subjects who are prescribed teriparatide by their healthcare provider may enroll in this study. The study intervention consists of loading one upper extremity. Subjects will be trained on how to perform the upper extremity exercises at home. Subjects will be expected to perform the exercises 3 days per week using one arm, with each session consisting of 100 loading cycles lasting a total of approximately 2 minutes each day.
1465386|NCT03232450|Drug|Aspirin|Subjects will receive 81 mg enteric coated aspirin
1465387|NCT03232450|Device|Cardiovascular Implantable Device (CIED)|All subjects will receive either a pacemaker, implantable cardioverter-defibrillator (ICD), or cardiac resynchronization therapy (CRT).
1465388|NCT03232450|Device|Gore Cardioform Septal Occluder|The Gore Cardioform Septal Occluder closes the patent foramen ovale (PFO).
1465389|NCT03232437|Device|Aina HbA1c Monitoring System|Monitoring test for quantitative determination of HbA1c
1465390|NCT03232424|Device|NovoTTF-200A|"Begins the day prior to radiotherapy start and continues until the end of temozolomide maintenance cycle #2 or until evidence of disease progression or unacceptable toxicity.
Arrays are removed immediately prior to radiotherapy and replaced immediately thereafter."
1465391|NCT03232424|Drug|Temozolomide|"Concomitant phase:
75 mg/m2 per day for 42 days concomitant with radiotherapy.
Begins 1 day prior to XRT start.
Maintenance phase:
Begins 4 weeks after concomitant phase completion (+/- 1 week).
Each cycle is 28 days (5 days of drug treatment followed by 23 days without).
Cycle 1: 150 mg/m2 once daily for the first 5 days of each treatment cycle.
Subsequent cycles: daily dose increased to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤ 2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs."
1465392|NCT03232424|Radiation|3D conformal or intensity modulated radiation therapy (IMRT)|Radiotherapy will commence 4 weeks after the definitive surgical procedure (+/- 1 week), to a total dose of 54.0 - 60.0 Gy, delivered in 1.8 - 2.0 Gy fractions over 6 - 7 weeks. XRT target volumes will be determined utilizing all available imaging studies that best delineate extent of disease. Fusion image registration for treatment planning will be utilized as possible. Either 3D conformal or intensity modulated radiation therapy (IMRT) will be utilized.
1465393|NCT03232411|Other|Questionnaires|Participants will be asked to complete a baseline questionnaire that asks questions about their demographic information, medical history, and smoking habits when they first enroll in the study. They will also be asked to complete a follow-up questionnaire 2 years later. The questionnaires will each take about 25 minutes to complete.
1465394|NCT03232411|Other|Saliva Samples|Participants will be asked to provide a saliva sample using the saliva kit that will be mailed to them. Detailed instructions for collection will be included in the saliva collection packet.
1465395|NCT03232411|Other|Tumor Tissue|Participants will be asked for permission to obtain a sample of their tumor tissue. Participants will receive a medical release form. Once they complete it and mail it back, investigators will request a small amount of tissue collected during the participant's prostate biopsy (or during their surgery, if they had surgery) from their health care provider.
1465396|NCT03232398|Drug|Apixaban Oral Tablet [Eliquis]|Apixaban 5 mg BID for 3 months. Apixaban 2.5-mg BID doses will be used in a subset of patients with two or more of the following criteria: an age of at least 80 years, a body weight of no more than 60 kg, or a serum creatinine level of 1.5 mg per deciliter (133 μmol per liter) or more. Patients with advanced renal failure (CrCl between 15 ml/min and 29 mi/min) will also receive 2.5 mg BID.
1465397|NCT03232398|Drug|Warfarin|Dose-adjusted warfarin to achieve a target international normalized ratio (INR) of 2.0 to 3.0 for 3 months
1465398|NCT03232385|Device|MR-US Fusion Arm|Use of Clear Guide SCENERGY for MR-US fusion guidance
1465399|NCT03232385|Procedure|Renal Biopsy or Ablation|Standard of Care
1465400|NCT03232372|Device|External-Connection non-submerged Imp|Through a surgical procedure, we will implant implant whit external connection and non submerged to patients.
1465401|NCT03232372|Device|Internal Connection Submerged implants|Through a surgical procedure, we will implant implant whit internal connection and submerged to patients.
1465402|NCT03232372|Device|Internal Connection non-Submerged Impl|Through a surgical procedure, we will implant implant whit internal connection and non-submerged to patients.
1465403|NCT03232359|Diagnostic Test|immature platelets fraction|IPF-% and A-IPC using a reticulocyte detection channel CBC auto analyzer
1465404|NCT03232346|Drug|Vivitrol|Oral naltrexone induction procedure followed by Vivitrol
1465405|NCT03232346|Drug|Buprenorphine|5-week buprenorphine taper
1465406|NCT03232333|Device|Biologic wound graft|Diabetic foot ulcer will be treated by grafting with MIRODERM Biologic Wound Matrix
1465407|NCT03232320|Drug|Meditoxin|Meditoxin (Botulinum toxin type A)
1465408|NCT03232320|Drug|Placebo|Placebo (Normal saline)
1465409|NCT03232307|Drug|Ibrutinib|Orally at 560 mg daily for 28 days (one cycle) up to Cycle 11. Starting at Cycle 12, a 2 month supply of ibrutinib dispensed every other cycle. After 3 years, patients treated with ibrutinib in continuous cycles until progression of disease or unacceptable toxicity.
1465410|NCT03232307|Drug|Rituximab|375 mg/m^2 intravenous infusion (IV) given on Days 1, 8, 15 and 22 for Cycles 1 and 2. Then, Day 1 of every cycle, for Cycles 3 - 8. Following Cycle 8 Rituximab given on Day 1 of every other cycle for up to 2 years.
1465411|NCT03232307|Drug|Lenalidomide|Orally at 20 mg daily on Days 1 - 21 of each 28 day cycle for up to one year.
1465412|NCT03232307|Drug|Dexamethasone Sodium Sulfate|Orally 40 mg weekly administered only for the first 2 cycles.
1465413|NCT03232281|Drug|Triptorelin Pamoate PR 3-month|15mg/injection, administered as an intramuscular injection once every 12 weeks (a total of 2 injections).
1465414|NCT03232281|Drug|Triptorelin Acetate PR 1-month|3.75mg/injection, administered as an intramuscular injection once every 4 weeks (a total of 6 injections)
1465415|NCT03232268|Biological|HLA-mismatched microtransplantation|3 administrations of hematopoietic stem cells without immunosupression
1465416|NCT03232255|Other|Mouthrinse (IQP-OLP-101)|Rinse/gargle 10mL of Mouthrinse for 60 seconds after tooth brushing, twice a day.
1465417|NCT03232242|Diagnostic Test|Next-generation sequencing|To provide rapid etiological diagnosis of patients by means of next-generation sequencing.
1465418|NCT03232216|Dietary Supplement|Vitamin D3.|Vitamin D3 50.000 UI in each packet of powder for oral solution.
1465419|NCT03232216|Dietary Supplement|Placebo|Placebo of Vitamin D3 50.000 UI in each packet of powder for oral solution.
1465420|NCT03232203|Drug|STRIMVELIS|It is the Autologous cluster of differentiation (CD) 34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA complementary Deoxyribonucleic acid (cDNA) sequence. HCP who have previously referred a patient for STRIMVELIS treatment or a parent's/carer's child who previously received treatment with STRIMVELIS will be recruited to the study
1465421|NCT03232190|Other|Web Application|Parents receive a web application that offers information and support until the age of 2.
1465422|NCT03232177|Drug|Anagre Cap.|from 0.5mg twice a day to maximally increase total10mg in 8 weeks and maintain maximal tolerable dose to 104 weeks
1465423|NCT03232164|Drug|18F-DCFPyL PET|18F-DCFPyL PET demonstrates very high tumor-to-background and tumor specific uptake which may allow for a more sensitive and accurate method for detection of early tumor recurrence and metastatic disease as compared to current PET radiotracers and current standard-of-care imaging including 99mTc-methylene diphosphonate bone scintigraphy (bone scan), contrast-enhanced computed tomography (CT) and magnetic resonance imaging (MRI).
1465424|NCT03232151|Diagnostic Test|C-Arm Cone Beam Computed Tomography|C-ARM CBCT angiogram and CBCT perfusion imaging using prototype software (SMART-RECON) can rapidly and accurately assess the cerebral blood flow maps in the setting of decreased blood flow to the brain (ischemic cerebrovascular events). This rapid assessment would eliminate the need for the patient to be imaged in another scanner and be subsequently transported again to another room; all anatomic and physiologic imaging would occur in the angiography suite.
1465431|NCT03232099|Dietary Supplement|Red Wine consumption|After a two weeks washout period,in the intervening period with red wine, patients will receive 250 mL / day of red wine per Day, 5 days a week, for 3 weeks.
1465432|NCT03232099|Other|Period without alcohol consumption|After a two weeks washout period,in the Abstemious period, patients should not consume any kind of alcohol beverages, for 3 weeks
1465433|NCT03232086|Other|Clean Air|Each subject will be exposed to clean air for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
1465434|NCT03232086|Other|PM2.5|Each subject will be exposed up to 35-50 μg/m3 PM2.5 for 4 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
1465435|NCT03232073|Drug|Ponesimod|Ponesimod; Film-coated tablet; Oral use. From Day 1 to Day 14, ponesimod is gradually up-titrated until a maintenance dose of 20 mg is reached from Day 15
1465436|NCT03232047|Device|Working Memory Training|Computerized Working Memory Training
1465437|NCT03232034|Dietary Supplement|Calcium Citrate|1000 mg calcium as calcium citrate
1465438|NCT03232034|Dietary Supplement|Milk Mineral Supplement|Milk Minerals containing 1000 mg calcium
1465439|NCT03232034|Dietary Supplement|Whey Protein Hydrolysate|50 g whey protein hydrolysate
1465440|NCT03232021|Drug|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
1465441|NCT03232021|Drug|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule [Lyrica] 75 mg administered 1 hour prior to the surgical operation
1465442|NCT03232021|Drug|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule [Lyrica] 150 mg administered 1 hour prior to the surgical operation
1465443|NCT03232008|Dietary Supplement|Canderel drink|1.4% aspartame and 0.95% acesulfame-k and 95% maltodextrin; 3g dissolved in 250ml of water
1465444|NCT03231995|Biological|Collection of nasopharyngeal specimen collected at D0, D1, D2 and D5.|"Analyses will be performed on nasopharyngeal specimen collected at D0, D1, D2 and D5.
Definition and validation of nasopharyngeal microbiome biomarkers (bacterial, viral, transcriptomic signature)"
1465445|NCT03231982|Drug|Group I|Machkhan Tab. 8/5 mg + Atacan Tab. 8 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks or Machkhan Tab. 16/5 mg + Atacan Tab. 16 mg placebo + Norvasc Tab. 5 mg placebo for 8 weeks
1465446|NCT03231982|Drug|Group II|Atacan Tab. 8 mg + Norvasc Tab. 5 mg + Machkhan Tab.8/5 mg placebo for 8 weeks or Atacan Tab. 16 mg + Norvasc Tab. 5 mg + Machkhan Tab.16/5 mg placebo for 8 weeks
1465447|NCT03231969|Drug|Bilastine 0.2%|1 drop in each eye at 3 separate times during a 25 day period.
1465448|NCT03231969|Drug|Bilastine 0.4%|1 drop in each eye at 3 separate times during a 25 day period.
1465449|NCT03231969|Drug|Bilastine 0.6%|1 drop in each eye at 3 separate times during a 25 day period.
1465450|NCT03231969|Drug|Bilastine 0%|1 drop in each eye at 3 separate times during a 25 day period.
1465451|NCT03231956|Device|ClearSight™ / EV1000NI Clinical Platform|Noninvasive Hemodynamic Monitoring utilizing ClearSight TM System
1465452|NCT03231943|Drug|GSK3640254|GSK3640254 is a capsule available in 1 milligram (mg), 10 mg and 100 mg dosing strength. GSK3640254 capsule will be given via oral route during each dosing day with approximately 240 mL of water.
1465453|NCT03231943|Drug|Placebo|Placebo capsule matching to the study treatment will be given via oral route during each dosing day with approximately 240 mL of water.
1465454|NCT03231930|Device|OraQuick HCV Ab test|The OraQuick HCV point of care test involves the collection of oral fluid and provides an accurate result in approximately 20 minutes. The test involves a clinic nurse or community health worker providing pre-test counselling, then providing an oral swab to study participants, then reading the result and counselling the participant about their HCV antibody test result.
1465455|NCT03231930|Device|Xpert HCV viral load test|"The Cepheid Xpert HCV RNA test (Xpert® HCV Viral Load test) is a reverse transcriptase polymerase-based chain reaction amplification technology (RT-PCR) and provides an accurate HCV RNA load within 2 hours (105 minutes), using a serum sample.
This test will be performed for participants who have a positive OraQuick HCV antibody result."
1465458|NCT03231904|Diagnostic Test|Blood test|blood samples will be taken for maternal and fetal levels of ACTH and LIF
1465459|NCT03231878|Drug|MIN-102|MIN-102 treatment
1465460|NCT03231878|Drug|Placebos|Placebo
1465461|NCT03231865|Diagnostic Test|Non-invasive measurement of ZincProtoporphyrin IX|Within 30 seconds, a measurement is performed on the lip of a patient to determine a ZincProtoporphyrin value
1465462|NCT03231852|Other|Survey|Attitudes and Randomized Trial Questionnaire (ARTQ), Hospital Anxiety and Depression Scale, Perception Survey
1465463|NCT03231839|Behavioral|Caloric restriction|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
1465465|NCT03231839|Behavioral|Increased fiber intake|After the baseline measurements individuals underwent dietary counseling and had 6 sessions with a dietician (after, 1,4,8,12 16 and 20 weeks).
1465466|NCT03231813|Procedure|Sodium lauryl sulphate induced irritation|Sodium lauryl sulphate will be applied to specified skin sites according to randomization protocol to induce irritation. 60 uL of 2% w/v SLS will be applied to skin under occlusion by large Finn chamber for 24 hours as described in the guidelines by Standardization group of European Society of Contact Dermatitis.
1465467|NCT03231813|Other|Emollient, moisturizing cream|Commercially available topical emollient cream will be applied by each participant to treatment sites according to randomization protocol.
1465471|NCT03231761|Other|Service user testimonial videos|Service users describe their personal experiences receiving care for depression or psychosis and the impact of the treatment on their quality of life
1465472|NCT03231761|Other|mhGAP didactic video|Video with a narrated slide presentation describing diagnosis and treatment of depression and psychosis
1465473|NCT03231735|Device|Mid frequency ventilation|Mechanical ventilator used at rates > 60 per minute and ≤ 150 per minute, with patient triggered ventilation and pressure support.
1465474|NCT03231735|Device|Standard frequency ventilation|Mechanical ventilator used at rates < 60 per minute and ≥ 20 per minute, with patient triggered ventilation and pressure support.
1465475|NCT03231722|Drug|Panitumumab|6 mg/kg iv over 60 minutes, day 1
1465476|NCT03231722|Drug|Irinotecan|150 mg/sqm iv over 60 minutes day 1
1465477|NCT03231722|Drug|Oxaliplatin|85 mg/sqm iv over 2 hours day 1
1465478|NCT03231722|Drug|l-leucovorin|200 mg/sqm iv over 2 hours
1465479|NCT03231722|Drug|5-fluorouracil|400 mg/sqm iv bolus, day 1 followed by 2400 mg/sqm 48 h-continuous infusion, starting on day 1;
1465482|NCT03231683|Drug|Esketamine|intravenous S+ketamine 0.25 mg/kg (i.v. bolus) at the beginning and 0.25 mg/kg (i.v. bolus) 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Marsh model
1465483|NCT03231683|Drug|Saline|intravenous normal saline (as placebo, with similar volume) at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
1465484|NCT03231683|Drug|Remifentanil|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
1465485|NCT03231683|Drug|Propofol|Either S+ketamine or saline at the beginning and 20 minutes before extubation along with remifentanil according to Minto model and propofol according to Schnider model
1465486|NCT03231670|Procedure|Blood sampling|5ml blood will be taken in addition to standard sampling
1465488|NCT03231631|Behavioral|Education plan and adherence to exercise|"Send text messages with motivational sense at any time of the day, every 3 or 4 days.
They will be given the option of performing directed exercise at the cardiac rehabilitation center.
It will be recorded in an Excel table every time that text is sent to the patient.
At the beginning and monthly, a brochure will be sent out explaining how physical activity is performed at home in case you can not walk.
A monthly survey will be applied where the adherence to the exercise during the previous month is measured.
These activities will be carried out for 12 weeks. At the end of week 12, patients will be referred to the cardiac rehabilitation unit in order to perform the aerobic capacity test again."
1465489|NCT03231618|Dietary Supplement|1. Low-fat and high-carbohydrate diet; 2. High-fat and low-carbohydrate diet; 3. High-protein and low-fat diet|Every participate was provided with 3 types of diets in random order
1465490|NCT03231605|Biological|Hepatitis A Vaccine|Vaccinating two Hepatitis A Vaccines separately in 18-24 months Children based on the grouping result .
1465491|NCT03231592|Other|CSA Group|Already included in the arm descriptions.
1465492|NCT03231592|Other|Enhanced Usual Care Group|Already included in the arm descriptions.
1465493|NCT03231579|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS, enabling providers to deliver evidence-based and personalized treatment care plans to their CLL patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
1465494|NCT03231566|Behavioral|Pain Neuroscience Education|See arm/group description
1465495|NCT03231553|Other|MiQuit text message support programme|MiQuit is an automated, responsive text message support programme lasting 12 weeks which sends texts containing self-help smoking cessation support and advice to participants mobile phones.
1465496|NCT03231540|Dietary Supplement|Whey protein supplement|Whey protein supplement to target protein intake of 1.5 g/kg/day
1465497|NCT03231527|Procedure|coronary artery bypass grafting (CABG)|myocardial revascularization
1465498|NCT03231514|Dietary Supplement|Carbohydrate Supplement (Carb10)|2 of 4 arms will be supplemented with carbohydrate pre-workout (Carb10, Compound Solutions, Carlsbad, CA)
1465499|NCT03231514|Other|Diet|2 groups will be on a carbohydrate-based diet (% energy from carbohydrate:fat:protein, 53:24:23) and 2 groups will be on a ketogenic diet (72:5:23)
1465500|NCT03231514|Other|Exercise|All groups will participate in a standardized exercise intervention.
1465501|NCT03231501|Drug|epitinib succinate|This is a single-arm open label study. A subject would take 160 mg of the study medication (epitinib succinate) every day on a 28-day cycle, until he or she reaches disease progression or intolerability.
1465502|NCT03231488|Other|Mindfulness intervention|A 10 minute mindfulness of breath exercise
1465503|NCT03231488|Other|Control intervention (unfocused attention)|A 10 minute unfocused attention intervention - participants are asked to let their mind wander on anything that comes to mind.
1465504|NCT03231475|Drug|SPH1188-11|qd.po
1465505|NCT03231449|Other|observation of current care|The study FEVRIER (survey of hospitalizations in cardiology units in sub-Saharan Africa) aims to establish a description of sub-Saharan standard of care, in order to get a cross sectional analysis (globally and per country) and a longitudinal analysis (evolution during 5 years).
1465506|NCT03231436|Drug|Fixed dose of 12.5mg bupivacaine|Spinal anesthesia performed with 12,5mg of bupivacaine with 25mcg fentanyl for cesarean section
1465507|NCT03231436|Drug|Height-adjusted dose of bupivacaine|Spinal anesthesia performed with height-adjusted dose of bupivacaine with 25mcg fentanyl for cesarean section
1465508|NCT03231423|Other|Drainage|Using drain after operation
1465509|NCT03231397|Device|Assess AAA rupture risk by PET-CTA scans|Assess AAA rupture risk by PET-CTA scans
1465510|NCT03231397|Diagnostic Test|18F-fludeoxyglucose (FDG)|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
1465511|NCT03231397|Diagnostic Test|11C-PBR28|Assess AAA rupture risk by PET-CTA scans using 18F-fludeoxyglucose (FDG)and 11C-PBR28 PET-CT and contrast-enhanced CTA imaging
1465512|NCT03231384|Device|Remote ischemic conditioning|"In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
Doctormate, IPC-906"
1465513|NCT03231371|Drug|Adenosine|Administration of intravenous adenosine infusion over 3 minutes (0.14 ml/kg, 3mg/ml concentration, total dose).
1465514|NCT03231358|Behavioral|Our Family Our Future|Our Family Our Future is a 'selective' behavioral prevention program, designed to address HIV/STI acquisition, sexual risk behavior, and depression among adolescents (ages 14-16) in communities with high HIV prevalence and from families where adolescents and parents already exhibit mild, potentially troublesome, depressive symptoms but do not reach the threshold for further screening for a significant clinical depressive disorder. This intervention involves parent-child dyads who receive the intervention in a community setting, in a facilitated group format. The intervention is comprised of 3-hour sessions, held weekly for 3 consecutive weeks with an individual family meeting in the third or fourth week depending on family desires.
1465517|NCT03231332|Other|Microbiome Diversity detection|detection of microbiome composition and detection of specific mutations in genes conferring resistance to antibiotics
1465518|NCT03231319|Procedure|Fascia iliaca compartment block with IV-PCA|1. Fascia iliaca compartment block: The injection was performed under ultrasound guidance. Surface landmark is identified on the line between anterior superior iliac spine and pubic tubercle. The injection site is at the medial one-third of the line. The needle is threaded medial to lateral and standardization of local anesthetic deposit is in the fascia plane between fascia iliaca and iliacus muscle. Anesthetic regimen: 2% xylocaine 15mL + 0.5% bupivacaine 15mL.
1465519|NCT03231319|Procedure|Femoral nerve block and lateral femoral cutaneous nerve with IV-PCA|"Femoral nerve block: The injection was performed under ultrasound guidance. Femoral nerve was identified in the femoral neurovascular bundle below or around inguinal ligament. The needle is threaded with lateral to medial approach. Local anesthetics will be deposited around the femoral nerve, the standardization of protocol is that femoral nerve should be lifted off from iliacus muscle. Anesthetic regimen: 2% xylocaine 10mL + 0.5% bupivacaine 10mL.
Lateral femoral cutaneous nerve block: The injection was performed under ultrasound guidance. Lateral femoral cutaneous nerve was identified in the fascia plane between sartorius muscle and tensor fascia lata muscle. Anesthetic regimen: 2% xylocaine 5mL + 0.5% bupivacaine 5mL"
1465520|NCT03231319|Procedure|IV-PCA|IV-PCA was programmed and provided to the patient for optimize pain control
1465524|NCT03231254|Device|Remotely Controlled Mandibular Positioner (RCMP)|RCMP device can accurately identify patients who are likely to be successful OA candidates. With a temporary dental appliance connected to a RCMP, the mandible could be progressively, mildly and precisely protruded in only anterior-posterior dimension, under the monitor of PSG, without disturbing sleep, until obstructive apneas and hypopneas were eliminated, particularly in REM sleep while supine. Besides, RCMP device can also determine the optimal therapeutic level of mandibular protrusion during sleep.
1465527|NCT03231215|Drug|Dexamethasone|dexamethasone + plain Bupivacaine injected epidurally.
1465528|NCT03231202|Procedure|Embolization|"The intervention arm will perform SAE as a central embolization of the splenic artery.
Additional peripheral embolization is left to the discretion of the interventional radiologist."
1465529|NCT03231176|Drug|Varlitinib|Varlitinib:300mg, oral tablets, twice daily for 2 weeks, followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
1465530|NCT03231176|Drug|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
1465531|NCT03231163|Other|No Music|Participants lie supine on a table while no music is played.
1465532|NCT03231163|Other|Relaxing Classical Music|Participants lie supine on a table while classical music is played.
1465533|NCT03231163|Other|Self-Selected Relaxing Music|Participants lie supine on a table while self-selected relaxing music is played.
1465534|NCT03231150|Procedure|Local Steroid Injection into the plantar heel|Injections consisting of 0.5 ml 0.25% bupivacaine plain, 0.5 ml dexamethasone phosphate, and 0.5 ml triamcinolone acetonide 40 mg/ml.
1465535|NCT03231150|Procedure|Ultrasound Guided Injection|Execution of the USGI will employ an actual diagnostic US machine (Voluson E8 Expert, General Electric Company, Boston, MA) and a plantarmedial approach
1465536|NCT03231150|Procedure|Anatomical Guided injection|Execution of the ATGI will employ a sham diagnostic US machine and a plantarmedial approach.
1465537|NCT03231137|Combination Product|PRGF/ATV|Atorvastatin (ATV) loaded on plasma rich in growth factor (PRGF) Derived Fibrin Scaffold
1465538|NCT03231137|Drug|ATV gel|Atorvastatin gel
1465539|NCT03231137|Biological|PRF|Platelet rich fibrin
1465540|NCT03231137|Biological|PRGF|plasma rich in growth factor
1465541|NCT03231124|Drug|LEO 32731|LEO 32731 is being developed by LEO Pharma.
1465542|NCT03231124|Drug|Placebo|Placebo contains the same excipients in the same concentration, only lacking LEO 32731
1465543|NCT03231111|Other|Preventive Multimedia Teaching Program|Preventive Multimedia Teaching Program
1465544|NCT03231085|Drug|Ferrous fumarate|Young children operated with craniosynostosis and treated with EPO and ferrous fumarate per os or intravenous ferric carboxymaltose.
1465545|NCT03231072|Device|Electrical Impedance Tomography record|Monitoring of pleural effusion evacuation by means of EIT
1465546|NCT03231046|Device|CBCT-US Fusion Arm|Use of Clear Guide SCENERGY for CBCT-US fusion guidance
1465547|NCT03231046|Procedure|Hepatic Biopsy or Ablation|Standard of Care
1465549|NCT03231020|Other|Interview|"The proposed research study uses a comparative case study methodology, utilizing multiple sources of data to deeply examine 8-10 cases, each of which is defined as parent(s) of a child (< 5 years of age) with single ventricle disease who used the mHealth application. One group of cases (4-5) will have used the mHealth application less than recommended (non-adherent to the home monitoring recommendations) or declined to use the application and returned it before the end of the interstage period. The other group of comparison cases (4-5 cases) will have used the application as recommended by the clinical team (adherent) and continued doing so through the interstage period."
1465551|NCT03230981|Device|Optical imaging of the cornea in healthy subjects|OCT vibrography and Brillouin microscopy
1465552|NCT03230968|Behavioral|Integral Action Program for Respiration|
1465553|NCT03230955|Behavioral|Psychological and psycho-educational support by phone|The intervention is based on cognitive-behavioural therapy (CBT). The intervention, in order to achieve behavioural changes, will include components based in Bandura's social learning theory and social cognitive theory (Bandura, 1986) and the transtheorical model of change (Prochaska, 1992). It has been shown that expectations and self-efficacy are behavioural predictors and that they are an effective framework for the assistance to quit smoking. This theory allows evaluating patient motivation phase and adapting the interventions according to each phase (Fiore, 2011)
1465554|NCT03230955|Other|Brief counselling session|Brief counselling session
1465557|NCT03230929|Device|BIS-PLE|Anesthesiologist attaches the sensors of BIS and PLEM 100 on the forehead of the patient, and adheres the neuromuscular monitoring device on the medial side of the wrist and the ipsilateral thumb to continuously monitor the state of consciousness and muscle relaxation before, during and after surgery. Reversal of muscle relaxant could be performed by intravenous injection of sugammadex 4 mg/ kg in the case of deep neuromuscular relaxation, and 2 mg / kg in the case of shallow muscle relaxation degree under neuromuscular monitoring. After then, they monitor and record the values of BIS, PLEM 100, and neuromuscular monitoring in 1 minute increments for 5 minutes.
1465559|NCT03230903|Other|Home telerehabilitation|Patients will receive an individualized exercise plan sent to a computer at their home. Patients will have daily access to a physical therapist and exercise physiologist.
1465560|NCT03230903|Other|Usual Care|Patients will receive a written individualized exercise plan during their baseline visit on top of their usual disease care.
1465562|NCT03230864|Drug|Lu AF35700|10 mg/day, encapsulated tablets, orally
1465563|NCT03230864|Drug|Risperidone|4-6 mg/day, encapsulated tablets, orally
1465564|NCT03230864|Drug|Olanzapine|15-20 mg/day, encapsulated tablets, orally
1465565|NCT03230851|Drug|aspirin 100mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/d
1465566|NCT03230851|Drug|aspirin 100mg/2d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/2d
1465567|NCT03230851|Drug|aspirin 100mg/3d therapy|100mg aspirin for at least 5 days followed by aspirin 100mg/3d
1465568|NCT03230851|Drug|aspirin 50mg bid therapy|100mg aspirin for at least 5 days followed by aspirin 50mg bid
1465569|NCT03230851|Drug|aspirin 75mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 75mg/d
1465570|NCT03230851|Drug|aspirin 50mg/d therapy|100mg aspirin for at least 5 days followed by aspirin 50mg/d
1465571|NCT03230851|Drug|indobufen 100mg bid therapy|100mg aspirin for at least 5 days followed by indobufen 100mg bid
1556539|NCT02551926|Behavioral|brochures|
1465575|NCT03230825|Drug|Oral contraceptive|Daily oral contraceptive agent for 3 weeks (FLAME, containing 0.02 mg Ethinylestradiol and 0.075 mg Gestodene)
1465576|NCT03230825|Other|Expectant management|No intervention and a follow up visit a wewk later
1465577|NCT03230812|Drug|Carnitene (L-Carnitine or Levocarnitine)|All subjects will undergo oral Carnitene (L-Carnitine or levocarnitine) supplementation for 96 days.The total dosage of L-carnitine per day will be 2970mg. Consumption of the chewing tablets will be divided over the day. Intake of these chewing tablets will be during breakfast (990mg), lunch (990mg) and during diner (990mg). Since the chewing tablets are only available in concentrations of 330mg, participants have to consume 3 chewing tablets per meal, a total of 9 chewing tablets each day.
1465578|NCT03230799|Procedure|secondary intraocular lens implantation|before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
1465579|NCT03230799|Procedure|minimal invasive lens surgery|before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
1465580|NCT03230799|Procedure|traditional cataract surgery|ACCC+ I/A + PCCC + Anti-vit: anterior continuous capsulorhexis + irrigation/aspiration + posterior capsulorhexis + anterior vitrectomy
1465582|NCT03230773|Device|Defibrillator model|Comparison of the performance of different public access defibrillators
1465583|NCT03230760|Device|acupuncture|Device: acupuncture Acupuncture is the treatment which balances qi and blood by inserting needles into the acupoints of the meridians in human body.
1465584|NCT03230734|Drug|Radium-223|Radium-223: administered at the dose of 55 kBq per kg body weight, given at 4 week intervals for 6 injections, by slow intravenous injection
1465585|NCT03230734|Drug|Docetaxel|Docetaxel: administered at the dose of 75 mg/m2 by intravenous infusion over a period of 1 hour every 3 weeks for 10 cycles. It is associated with prednisone 5 mg orally twice daily administered continuously.
1465586|NCT03230721|Procedure|Thulium-fiber laser enucleation of the prostate|A high-power (120 W) thulium fiber laser (Urolase, IPG IRE-POLUS, Russia) with wavelength of 1940 nm was used for thulium laser enucleation. In our study, we used a 600-μm laser fiber. The operations were performed at power of 60 W energy of 1.5 J and repetition rate of 40 Hz. Laser power in the verumontanum zone was decreased to 30 W and repetition rate to 20 Hz.
1465587|NCT03230721|Procedure|Monopolar enucleation of the prostate|Monopolar enucleation was performed with a high-frequency generator (50-60 Hz), a pusher-electrode, and a hook-electrode.
1465588|NCT03230721|Procedure|Ho:YAG laser enucleation of the prostate|Holmium laser enucleation of prostatic hyperplasia was performed with a 100 W laser (VersaPulse Powersuite 100, Lumenis, USA/Israel) with wavelength of 2100 nm and 550-μm fiber at the tip. The operation was performed at power of 70 W; it was decreased to 40 W when incisions were made at the verumontanum.
1465589|NCT03230708|Other|Erythrocytes derived MPs containing MTX|General conventional treatment and peritoneal drainage, additional peritoneal perfusion with erythrocytes derived MPs containing MTX
1465590|NCT03230708|Drug|convention drugs|according to usage method of drugs
1465591|NCT03230695|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
1465592|NCT03230695|Device|Active stimulation|Active transcranial direct current stimulation will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
1465593|NCT03230695|Device|Sham stimulation|In sham transcranial direct current stimulation, no current will be delivered through the transcranial direct current stimulation device after the first 30 seconds.
1465594|NCT03230682|Drug|antidepressant|regular one-drups treatment of selective serotonin reuptake inhibitor(SSRIs)
1465595|NCT03230669|Other|cbt4cbt|This arm receives treatment as usual and in addition are given access to an online therapy, cbt4cbt. If placed in this group, individuals are asked to use the online therapy for a minimum of 30 minutes each week for the trial duration of 8 weeks.
1465596|NCT03230656|Other|Early cognitive-communication therapy|
1465597|NCT03230643|Device|Barostim neo implantation|"The Barostim neo Implantation is a new promising treatment option for patients with advanced heart failure (HEFrEF) as it might improve cardiac and vascular function by restoring sympathovagal-balance through its effects on the autonomic nervous system.
In this observational study, data from patients who have received the Barostim neo System as part of clinical routine will be collected and analyzed. The implantation of this new device is not part of the study."
1465598|NCT03230630|Diagnostic Test|plasma melatonin levels|
1465599|NCT03230617|Device|Mechanical ventilator|Mechanical ventilation, in the healthcare setting or home, helps patients breathe by assisting the inhalation of oxygen into the lungs and the exhalation of carbon dioxide. Depending on the patient's condition, mechanical ventilation can help support or completely control breathing.
1465600|NCT03230604|Device|Filtek Bulk Fill Composite and Tetric N Ceram Bulk Fill Composite|Restorative cavities one, two and five with material Filtek Bulk Fill Composite
1465601|NCT03230604|Device|Z 350 Xt Composite|Restorative cavities one, two and five with material Z 350 XT Composite
1465602|NCT03230591|Other|Echocardiography|LV vortex flow in Echocardiography
1465603|NCT03230578|Other|Pharmacists and women's perspectives on pharmacist prescribed hormonal contraception|The goal of this study is to identify the thoughts and perceptions of pharmacy access to hormonal contraception among rural women and pharmacists. This will be key in order to address concerns or perceived barriers in order to inform the implementation of this program.
1465604|NCT03230565|Drug|Ropivacaine|Patient will be given a continuous infusion of local anesthetic.
1465605|NCT03230565|Drug|Ropivacaine|Patient will be given a scheduled intermittent bolus of local anesthetic.
1465606|NCT03230552|Other|Instructional surgical video|An instructional surgical video shown to residents before they perform LSO surgery.
1465607|NCT03230539|Drug|Ulipristal Acetate IUS delivering Cu and 5μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
1465608|NCT03230539|Drug|Ulipristal Acetate IUS delivering Cu and 20μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
1465609|NCT03230539|Drug|Ulipristal Acetate IUS delivering Cu and 40μg|This is a proof-of-concept study utilizing a randomized dose-finding, parallel design to assess the effects of an IUS delivering Cu and 5, 20, or 40 μg of UPA over 12 weeks.
1465610|NCT03230526|Drug|[18F]DPA-714 PET scan|"One PET scan using [18F]DPA-714 is done at M2 between two [123I]FP-CIT scan (DaTscan) done at M1 and M35.
Neuropsychological assessment is done at M0, M18 and M36"
1465611|NCT03230513|Other|Self Epley Manoeuvre|The patient has to position himself long sitting on the bed, then turn his head 45 degrees to the problematic side. When in this head position, he will rapidly lie himself supine with a pillow under his shoulders. He then turns his head 90 degrees to the opposite direction followed by turning of his body to the same side before returning to a sitting position at the edge of the bed. Each position should be kept for 30 seconds each, and the patient is required to perform 3 cycles of this manoeuvre just prior to going to bed daily for 2 weeks.
1465612|NCT03230513|Other|Brandt-Daroff Exercise|The patient has to sit at the edge of the bed, turn his head laterally 45 degrees to one side and move rapidly into the side lying position, keeping his head in the same position. He then returns upright and turns his head to the opposite direction and the same movement is repeated on the other side. Each position is held for at least 30 seconds and the patient is required to perform it for 5 repetitions, three times a day, daily for 2 weeks duration.
1465613|NCT03230500|Procedure|computer guided implant placement|implant will be placed immediately using computer aided surgical guide
1465614|NCT03230487|Drug|BI 1015550|Part 1 - single rising dose. Part 2 multiple rising dose
1465615|NCT03230487|Drug|Placebo|Part 1 - single rising dose. Part 2 multiple rising dose
1465616|NCT03230474|Drug|Morphine|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 0.5 ml as placebo (total volume 2 mL)
1465617|NCT03230474|Drug|Morphine-Naloxone|50 patients of this group will receive 5 mg of 0.5% hyperbaric bupivacaine with 0.2 mg morphine in 0.5 ml volume plus 5ng\ kg naloxone in 0.5 ml volume (total volume 2mL).
1465618|NCT03230461|Behavioral|Compression depth|
1465619|NCT03230448|Other|questionnaire|after the inclusion patient will answer to a questionnaire about the suicidal intentionality and a second about the alcool consumption
1465620|NCT03230435|Other|Treatment settings as usual.|Treatment according to guidelines and the local instructions (psychotherapy and dietary guidance).
1465621|NCT03230422|Device|normal airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
1465622|NCT03230422|Device|difficult airway|The Time interval between the laryngoscope blade passing the teeth/gums to the announcing of the first ventilation was recorded as the time to ventilation with the Video laryngoscopy (VL) or conventional direct laryngoscopy (DL)
1465623|NCT03230409|Behavioral|Leaflet written in the patient's/family mother tongue|At baseline visit, the parents or carers of the children and/or the young patients themselves (in the case of adolescents >12 years of age), were given a leaflet including questions and answers about the most common doubts that people have about anti-TB treatment (what to do if you forget a dose, if you vomit, if you have stomach ache, etc.). The study nurse read and reviewed the leaflet with the family. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.
1465624|NCT03230409|Behavioral|A follow-up telephone call|A follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits. The parents and/or patient were informed about this. This call was made to reinforce the information, answer any questions that may have arisen and insist on the importance of proper follow-up.
1465625|NCT03230409|Biological|Eidus-Hamilton Test|E-H test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test. This test is a rapid, simple point-of-care method to detect urinary acetyl-isoniazid, the main metabolite of isoniazid, up to 12-24 hours following isoniazid administration and is used as a surrogate marker of treatment adherence. The test consists of placing 4 drops of a 10%potassium cyanide solution and 9 drops of a 10%chloramine solution in a test tube containing 4 drops of patient urine. The result is considered positive if a deep red color develops after 1 minute. If a pink color slowly appears,this indicates that there are only traces of the metabolite. If there is no change in color, the result is considered negative and suggests no recent isoniazid intake. The sensitivity and specificity of this test have been reported to be over 99%
1465626|NCT03230409|Behavioral|A written questionnaire|The parents or carers of the children and/or the young patients themselves were asked to complete a written questionnaire about adherence to anti-TB treatment on all the follow-up visits, which was partially adapted from two validated questionnaires on adherence to chronic therapies (SMAQ compliance test, Svarstad et al., 1999; and Hermes test, Rodríguez-Chamorro et al., 2008).
1465627|NCT03230396|Dietary Supplement|Vitamingum Sport|Vitamin -supplemented chewing gum
1465628|NCT03230396|Dietary Supplement|Vitamingum Immunity|Vitamin -supplemented chewing gum
1465629|NCT03230396|Dietary Supplement|Placebo|Control chewing gum. No vitamin content.
1948194|NCT02675777|Other|Quality Improvement Intervention|"Group Health clinical leaders and clinicians implement all aspects of behavioral health integration (screening, assessment, and shared decision-making followed by treatment). The implementation strategy, which was refined during the pilot phase, will include:
Identification of a clinical champion and Local Implementation Team.
Participatory Design.
Training primary care providers and Medical Assistants.
EHR clinical decision support tools
Weekly facilitated Local Implementation Team meetings.
Performance monitoring with feedback, including monthly PDCA meetings with the Local Implementation Team and clinic leaders.
Learning sessions for primary care providers during implementation.
Social worker use of an EHR registry with weekly supervision.
Video and handout explicitly designed to shift attitudes about unhealthy alcohol use (overcoming misconceptions and stigma)"
1948195|NCT02669849|Drug|VX-210|
1948196|NCT02669849|Drug|Placebo|
1948197|NCT02670369|Behavioral|Sitting time prompt|Participants will receive a device that prompts them to take breaks from sitting approximately every 15-20 minutes.
1948198|NCT02665065|Drug|Iomab-B|
1465638|NCT03230370|Other|UFT|The EUEP group receives additional daily 50 mins program focusing on training of the hemiplegic upper extremity,
1465639|NCT03230370|Other|LFT|The ELEP group receives additional daily 50 mins program focusing on training of the hemiplegic lower extremity.
1465640|NCT03230357|Device|PICC guided by EDUG|ECG Doppler ultrasound guidance technology (EDUG) is the combination of MST puncture and ECG technology through the use of ECG Doppler ultrasound machine and valve conduction PICC to conform the localization of EDUG technology by the study of real-world
1465641|NCT03230344|Procedure|open flap debridement|open flap debridement simultaneously with root canal treatment
1465642|NCT03230344|Procedure|open flap debridement|open flap debridement and delayed root canal treatment
1948199|NCT02665065|Drug|Conventional Care|
1465644|NCT03230305|Other|Ethnographic interview|"If a patient is invited to participate in the a clinical trial, inclusion's status (included or/not) will be sought.
If included: an ethnographic interview will be held with patient (or his representant) who agreed to participate in the clinical trial, his family caregivers, his physician(s) in charge of him and the trial and, and clinical studies technician responsible for management.
If not included, an ethnographic interview has offered to him, his caregivers, his physician(s) in charge of him and the trial and clinical studies technician responsible for management. In parallel, the reasons for non-inclusion are collected from a pre-established epidemiological questionnaire.
If a patient is not invited to participate,an ethnographic interview will be held with his physician(s) in charge of him and the clinical trial and with clinical studies technician responsible for management.The reasons for non-invitation will be collected from an epidemiological survey multiple choices."
1465645|NCT03230292|Drug|Bimekizumab|Bimekizumab will be administered subcutaneously in 2 different doses.
1465646|NCT03230279|Procedure|Sacroiliac joint fusion|Minimally invasive SIJ fusion will be performed under general anesthesia with fluoroscopy. Using SI-LOK®, Sacroiliac Joint Fixation System, Globus Medical Inc. (Audubon, PA), this procedure involve placement of 2 to 3 implants across the SIJ to achieve stabilization and arthrodesis.
1465647|NCT03230279|Procedure|Sacroiliac joint radiofrequency ablation|Sacroiliac joint radio frequency ablation will be performed using either conventional or cooled radiofrequency ablation techniques aimed at the S1-S3 lateral branches and the L5 dorsal ramus. The choice between conventional or cooled RFN will be determined by the provider expertise.
1465648|NCT03230266|Procedure|Collection of intra-peritoneal catheters for insulin infusion|Collection of intra-peritoneal catheters for insulin infusion
1465649|NCT03230253|Behavioral|Sequential training|The participant will cycle on a stationary bike for 30 minutes, which includes a 3-min warm-up phase followed by the aerobic training components (25 minutes), then a 2-min cool-down phase. The target heart rate during the aerobic training phase will be 40 to 70% of maximal heart rate (HRmax). After cycling, the participant will engage in a 30-minute of computer-based cognitive training program using BrainHQ (Posit Science Inc., San Francisco, CA, USA). The following are the areas of training: visuospatial processing, attention, memory, language, and logical thinking.
1465650|NCT03230253|Behavioral|Dual training|The dual-task training group will cycling concurrently with the computer-based cognitive training. The training principle of cycling and cognitive training is similar to the SEQ group; however, the training intensity will be adjusted according to each participant's ability.
1465651|NCT03230253|Behavioral|Control training|The control participants will receive 60 minutes of health-related rehabilitation programs which involves non-aerobic physical exercise (e.g., muscle stretching, range of motion exercises, relaxation techniques) and unstructured cognitive related rehabilitation programs (e.g., watch health-related videos or read newspapers or magazines and then answer the content-related questions raised by the therapist).
1465652|NCT03230240|Drug|HIPEC|heated intraIP chemotherapy
1465653|NCT03230227|Drug|Bupivacaine magnesium|bupivacain 0.125% magnesium sulfate 5%) infusion in the presternum , for 48 hours
1465654|NCT03230227|Drug|Bupivacaine only|bupivacaine 0.125% infusion in the presternum , for 48 hours
1465655|NCT03230214|Diagnostic Test|PCR for bacterial translocation|samples taken from the blood and ascites of patients to search for bacterial DNA
1465656|NCT03230201|Procedure|Lymph node dissection|Lymph node dissection during radical nephroureterectomy
1465657|NCT03230188|Other|functional Magnetic Resonance Imaging (research grade)|Subjects will undergo a simulated and actual functional Magnetic Resonance Imaging scan.
1465658|NCT03230188|Other|Cognitive Function Testing (non-diagnostic)|Subjects will take non-diagnostic cognitive function tests
1465659|NCT03230188|Other|Asthma and Psychological Questionnaires (non-diagnostic)|Subjects will fill out asthma and psychological questionnaires (non-diagnostic)
1948200|NCT02665065|Drug|Fludarabine|30 mg/m2/day on days -4, -3, and -2 prior to transplant
1465661|NCT03230162|Drug|Sildenafil|sildenafil citrate 25 mg every 8 hours (Silden EIPICO co.) orally, starting at the diagnosis of FGR till delivery
1465662|NCT03230162|Drug|low molecular weight heparin|a single daily dose of LMWH (tinzaparin) (Innohep LEO pharmaceutical products.) subcutaneously starting at diagnosis of FGR till delivery
1465699|NCT03229863|Other|Pears|Earth's Best, First Pears
1468749|NCT03205800|Other|Mini-screw|Placement of a mini-screw
1948201|NCT02665065|Radiation|Total Body Irradiation|2 Gy on day of transplant
1948202|NCT02665065|Procedure|HCT|
1465663|NCT03230149|Diagnostic Test|Measurements of the alpha-GAL enzyme activity|Blotting paper blood tests in order to highlight an enzyme deficiency for hemizygous males with DBS kits in order to detect Fabry disease, with genetic confirmation if an abnormality is detected. For women genotyping is mandatory.
1465664|NCT03230136|Other|multimodal cardioprotection strategy|Multimodal cardioprotection therapeutic strategy will include (1) remote ischemic preconditioning, (2) volatile anesthetic sevoflurane-induced preconditioning, (3) blood glucose control every 30 minutes during cardiac surgery, (4) temporary respiratory acidosis prior to the aortic cross-unclamping and (5) gradual restoration of blood flow after aortic cross-unclamping (gentle reperfusion).
1465665|NCT03230136|Other|standard anesthetic procedure|standard anesthetic procedure will include: anesthesia under propofol throughout the cardiac surgery, blood glucose control every 60 minutes, arterial pH maintained at 7.40, theoric blood flow restored at the earliest after aortic cross-unclamping.
1465666|NCT03230123|Dietary Supplement|Green banana biomass|Green banana biomass will be suplemented to diet as 4.5 g per day.
1465667|NCT03230110|Diagnostic Test|WP200U home sleep study device|WP200U, is a Type III, wrist-worn, FDA-approved home sleep testing device that utilizes finger plethysmography (peripheral arterial tone, oxyhemoglobin saturation and heart rate), actigraphy (movement), acoustic decibel detection (snoring volume), and accelerometry (body position) to help diagnose sleep-related breathing disorders (including snoring), and to give information about sleep stages and position during actual sleep time.
1465670|NCT03230084|Device|Urine PDG test|Urine dipstick test that detects the presence of the urinary metabolite of progesterone, PDG.
1465671|NCT03230071|Drug|TMBCZG|0.1g per pill which contains 14mg TMBCZG
1465672|NCT03230071|Other|placebo|0.1g per pill which contains 0mg TMBCZG
1465673|NCT03230058|Drug|Group 1 Natamycin 5% Suspension + voriconazole 1% eye drops; Group 2 Natamycin 5% Suspension + Vehicle eye drops|instillation of drops
1465674|NCT03230045|Device|acupoint stimulation|Acupoint Zhongfu and Zusanli are stimulated through electrodes attached on the skin
1465675|NCT03230045|Device|no treatment|electrodes are attached, but no stimulation is given
1465676|NCT03230032|Device|pacifier-activated device|The utilization of the pacifier-activated-music player combines the sound of the mother's voice with a pacifier routinely used with each patient during their inpatient NICU stay
1465677|NCT03230019|Procedure|chest tube|VATS with chest tube placement
1465678|NCT03230019|Procedure|two-lumen catheterization|VATS with two-lumen catheterization long the midclavicular line, second intercostal space
1465679|NCT03230019|Device|two-lumen catheter|central venous catheter(two-lumen 7-Fr-20cm)
1465680|NCT03230006|Behavioral|Unified Protocol for Transdiagnostic Treatment of Emotional Disorders|The UP will be conducted in a standardized fashion, over 16 sessions, following the published therapist guide with minor refinements for application in the proposed comorbid population.
1465681|NCT03230006|Behavioral|Take Control|TC is a computerized psychotherapy platform derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA) self-help approach, Rethinking Drinking. In this study, TC will be administered in a computerized format, but will involve direct therapist contact to control for effects that may be related to patient-therapist interaction (as opposed to elements of the treatment itself). Specifically, on a weekly basis, therapists will review material from TC and offer general advice on implementation of the alcohol reduction skills in daily life.
1465686|NCT03229967|Diagnostic Test|16S rRNA stool microbiome sequencing.|This is an observational cohort that will undergo gut microbiome sequencing.
1465687|NCT03229954|Drug|iron isomaltoside (Monofer) intravenous infusion|"The investigational drug is a newest formulation of intravenous iron. The drug, iron isomaltoside (Monofer), will be infused one single high dose with infusion time more than 30 minutes (< 1,000 mg) or 60 minutes (≥ 1,000 mg). The dosage is determined using the Ganzoni formula and divided when the calculated dose exceeds 20 mg/kg.
If the calculated dose exceeds 1,500 mg, the patient will be excluded from trial for patient safety."
1465688|NCT03229954|Drug|Ferrous sulfate(Feroba-YOU) per oral|160 mg/day of ferrous sulfate (Feroba-YOU) will be taken per oral for 12 weeks.
1465689|NCT03229941|Procedure|Blood Transfusion|Blood Transfusion
1465690|NCT03229928|Device|MOCHA|"MOCHA phone-based application
Event tracker button that marks the beginning and end of a behavioral event. Similar to a FOB that connects to MOCHA application via bluetooth
Wrist based sensor (applicable only to sensor wearing participants)."
1465692|NCT03229902|Behavioral|mantra meditation|see study description
1465693|NCT03229889|Drug|Cialis 5Mg Tablet|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Patients will be asked to 1 pill for 7 days prior to surgery.
1465694|NCT03229889|Drug|Flomax 0.4Mg Capsule|Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. Patients will be asked to 1 pill for 7 days prior to surgery.
1465695|NCT03229889|Combination Product|Cialis + Flomax|Cialis is a PDE-5 inhibitor that has been shown to relax smooth muscle. Tamsulosin is an alpha-blocker that has been shown to relax smooth muscle in the genitourinary system. A combination of these two drugs may increase the relaxation effects in the ureter. Patients will be asked to 1 of each pill for 7 days prior to surgery.
1465696|NCT03229889|Drug|Placebo|This is plant cell based pill that contains no active ingredient. Patients will be asked to 1 pill for 7 days prior to surgery.
1465698|NCT03229863|Other|Sweet Potatos|Plum Organics, Just Sweet Potato
1465700|NCT03229850|Drug|Insulin lispro|Insulin lispro will be injected into the abdomen into an area of subclinical lipohypertrophy or an area with no subclinical lipohypertrophy
1465701|NCT03229824|Device|Antiseptic occlusive dressing group|A chlorhexidine gluconate occlusive adhesive dressing (Tegaderm CHG) will be applied to the intervention drain sites and changed every seven days.
1465702|NCT03229811|Other|ESRD education + ACP|Targeted advance care planning education delivered in person by trained healthcare providers
1465703|NCT03229798|Drug|Sumatriptan Succinate Oral Tablet|Sumatriptan succinate commercial Imitrex 100 mg tablet
1465704|NCT03229798|Combination Product|Transdermal delivery of sumatriptan succinate|Sumatriptan succinate transdermal drug delivery system
1465705|NCT03229785|Biological|Human Umbilical Cord Blood Plasma|Plasma collected from human umbilical cord blood
1465706|NCT03229772|Device|Discovery NM/CT 670 CZT Imaging Scan|At a single visit, subjects will undergo nuclear medicine scintigraphy imaging scanning on the investigational GE Discovery 670 NM/CT CZT (with CZT) device and the commercial GE Discovery 670c (without CZT).
1465707|NCT03229759|Drug|Octenidine Dihydrocloride in aqueous solution|application of investigational product
1465708|NCT03229759|Other|Vehicle Control|application of vehicle control
1465709|NCT03229759|Other|Saline Control|application of placebo
1465710|NCT03229746|Drug|Hydroxychloroquine|200mg twice daily orally for at least 12 weeks
1465711|NCT03229746|Drug|vincristine|1mg intravenous weekly for 4 weeks
1465712|NCT03229746|Drug|azathioprine|dose 100mg daily for at least 3 weeks
1465713|NCT03229733|Device|Kinect|Receive Kinect games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks
1465714|NCT03229733|Behavioral|Traditional occupational therapy|Patients will receive individually tailored conventional training consisting of the similar movement and dose by using the traditional equipment, such as climbing bar.
1465715|NCT03229720|Device|Nibiru 3D Virtual Reality Headset|This device is a kind of head glass that obstructs the vision with a wide screen showing movies or photos. Earphones are extended from it and inserted in ears. so it obstructs the vision and audio of the surroundings.
1465716|NCT03229707|Device|Digital photography using software Photoshop|"When taking the image, a gray card is used for subsequent exposure calibration in Adobe Camera Raw (which is packaged with Photoshop).
Images are then opened into Photoshop.
The INFO panel must be open.
Click on the small eyedropper in the Info panel window and click on ''Lab Color.
Place the mouse over the center of the tooth to be measured for L value.
Click on the HSB Color option, which stands for hue, saturation, and brightness."
1465717|NCT03229707|Device|Vita 3D master shade guide|Alpha (A)Perfectly matched Beta (B)Not perfectly matched Charlie (C)unacceptable Determent by 10 observers
1465718|NCT03229694|Drug|Tracleer 125Mg Tablet|Tracleer was administered orally at two hours before surgery and six hours after surgery.
1465719|NCT03229694|Drug|Placebo|Placebo was administered orally at two hour before surgery and six hours after surgery.
1465720|NCT03229681|Behavioral|Baduanjin exercise|"Participants in this groups received routine rehabilitation training and Baduanjin exercise. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. Baduanjin exercise protocol according to the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003. Due to the low-activity tolerance of CHF patients, we performed with a refined version of Baduanjin. Each Baduanjin exercise session lasts 45 minutes and continues twice per week for 12 weeks."
1465721|NCT03229681|Behavioral|Routine rehabilitation group|Participants in this qroup only received the routine rehabilitation training. During the period of rehabilitation, physicians provides a wide range of medical, nutrition and mental health counseling, as well as rational drug-treatment. They should also come to rehabilitation center for physical exercise,45 minutes per day，twice per week, lasts 12 weeks.
1465722|NCT03229668|Drug|Placebo oral capsule|Placebo oral capsule administered 1 hour prior to the surgical operation
1465723|NCT03229668|Drug|Pregabalin Oral Capsule [Lyrica] 75mg|Pregabalin Oral Capsule [Lyrica] 75 mg administered 1 hour prior to the surgical operation
1465724|NCT03229668|Drug|Pregabalin Oral Capsule [Lyrica] 150 mg|Pregabalin Oral Capsule [Lyrica] 150 mg administered 1 hour prior to the surgical operation
1465725|NCT03229655|Procedure|Protocol for increasing number of stents across the anastomosis|Sequential placement of straight plastic biliary stents across the duct-to-duct anastomosis without dilation or stent exchange. Multiple ERCPs will be performed with addition of a single stent at each ERCP until the final ERCP when all stents will be removed.
1465726|NCT03229642|Device|Active rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
1465727|NCT03229642|Device|Sham rTMS|The stimulator device was a Magstim super rapid magnetic stimulator (Magstim Company, Ltd., Wales, United Kingdom) with 4 booster modules equipped with a 70-mm air-cooled figure-eight-shaped coil. We performed rTMS on the left dorsolateral prefrontal cortex (DLPFC).The TMS parameters were as follows: 15Hz frequency, pulse intensity 100% of the rMT, 60 pulses per train, inter train pause of 26 sec, 40 stimulation trains, and 2400 total pulses for a total duration of 20 min. The patients received one rTMS session per day during the first five days of treatment, and then twice a week for the following three weeks, for a total of 11 rTMS sessions. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
1465728|NCT03229629|Behavioral|Behavior change communication|Weekly behavior change communication (BCC) to mothers for the duration of 16 weeks Weekly behavior change communication (BCC) to fathers for the duration of 12 weeks
1465729|NCT03229629|Other|Food Voucher (Monetary)|Monthly voucher worth 200 birr(~$10) every month for the duration of 6 month
1469069|NCT03203499|Drug|Placebo Oral Tablet|Placebo administered orally.
1948203|NCT02665065|Drug|Mycofenolate mofetil (MMF)|On day 0 through day 28 (15mg/kg every 12 hours) for related donor and day 40 (15mg/kg every 8 hours) for unrelated donor (taper to day 96 in absence of GVHD)
1465733|NCT03229603|Other|Cluster of 3000 women|An evaluation of the feasibility, reach, adoption and implementation of a cervical cancer screening program where we diagnose HPV using the GeneXpert point of care testing kit prior to VIA and cryotherapy.
1465734|NCT03229590|Procedure|Surgical dislocation|Reduction of slipped epiphysis by surgical dislocation
1465738|NCT03229564|Biological|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
1465739|NCT03229564|Biological|STSG|Transplantation of autologous split-thickness skin graft to the control area
1465740|NCT03229551|Drug|Xylitol|Topical 5% Xylitol (wt/vol) diluted in saline nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
1465741|NCT03229551|Drug|Saline|Saline as a standard-of-care nasal irrigant. Topical corticosteroid and antibiotic as directed by bacterial DNA sequencing results will be diluted in this irrigant and administered concurrently.
1465744|NCT03229525|Behavioral|Trauma Related Expressive Writing|Participants will write about the traumatic event over the course of six sessions.
1465745|NCT03229525|Behavioral|Trauma Related Expressive Speaking|Participants will speak about the traumatic event over the course of six sessions.
1465746|NCT03229525|Behavioral|Neutral Expressive Writing|Participants will write about a neutral event over the course of six sessions.
1465747|NCT03229512|Drug|Sildenafil|Topical 1% Sildenafil Cream
1465748|NCT03229499|Drug|Anastrozole|"Anastrozole is an aromatase inhibitor indicated for:
adjuvant treatment of postmenopausal women with hormone receptor-positive breast cancer
first-line treatment of postmenopausal women with hormone receptor-positive or hormone receptor unknown locally advanced or metastatic breast cancer
treatment of advanced breast cancer in postmenopausal women with disease progression following tamoxifen therapy."
1465749|NCT03229499|Drug|Placebo Oral Tablet|matching placebo tablet
1465750|NCT03229486|Drug|Sugammadex Injection [Bridion]|Return to T2 point (two contractions) on TOF device is replied by iv 2 mg/kg sugammadex administration, contained in a blinded syringe.
1465751|NCT03229486|Drug|Neostigmine+Glycopyrronium|Return to T2 point (two contractions) on TOF device is replied by iv 0.06 mg/kg neostigmine and 0.005 mg/kg glycopyrrolate administration, contained in a blinded syringe.
1465752|NCT03229460|Other|standard low flow therapy|In the standard low flow therapy oxygen group, oxygen at a flow rate of 10 liters per minute or more.
1465753|NCT03229460|Device|high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 60 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 >92%.
1465754|NCT03229460|Device|association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 >92% with the minimal FiO2.
1465755|NCT03229447|Behavioral|eLearning Modules|All participating courts will view two eLearning modules. Module one discusses opioid addiction and treatment; module two discusses specific concerns of criminal justice with regard to MAT and ways in which those concerns may be addressed.
1465756|NCT03229447|Behavioral|Change Team Intervention|Courts selected for the experimental condition will participate in a hands-on change team intervention to provide instrumental assistance and to reinforce the information contained in the eLearning modules.
1465757|NCT03229434|Behavioral|Mountain hiking|Compare arm description
1465758|NCT03229421|Other|Survey|18 question symptom assessment tool including non-identifying demographic information questions.
1465761|NCT03229382|Drug|Obinutuzumab|Patients, in whom all inclusion criteria have been confirmed and all exclusion criteria have been ruled out, will receive 4 intravenous infusions of obinutuzumab (GA101, Gazyvaro) at a dose of 1000 mg on Days 1, 8, 15 and 22.
1465762|NCT03229369|Procedure|Isolated anatomic ACL reconstruction|Hamstrings free grafts using a two-incision intra-articular Anterior Cruciate ligament (ACL) reconstruction technique. Both ST and gracilis will be prepared with doubled strands, a standard quadrupled graft. The femoral tunnel will be performed in outside-in manner. The tibial tunnel will be drilled in the center of the ACL tibial footprint, sparing the ACL tibial stump, when possible. ACL graft will be first fixed in the femur and then in the tibia, both with an interference screw at 30 degrees of knee flexion.
1465763|NCT03229369|Procedure|Combined Anterior Cruciate Ligament and Anterolateral Ligament reconstruction|Hamstrings free grafts using a two-incision ACL reconstruction with the addition of a gracilis prolongation for ALL reconstruction. ACL graft will exhibit a quadruple strand (tripled ST + single gracilis) and the ALL graft, a single strand with the gracilis prolongation. ALL tibial tunnels will be performed 1cm distal to the articular level, 2cm way from one another, midway from the fibular head and Gerdy Tubercle. Femoral ACL and ALL tunnels are coincident and located posterior and proximal to the lateral epicondyle. Intra-articular surgery will be performed in the same manner as comparative group. Gracilis prolongation is routed through the tibial ALL tunnels and then retrieved proximal towards the femoral tunnel. ALL is fixed in full extension and neutral rotation. This is a modification of a previously described technique (Sonnery-Cottet 2015).
1467307|NCT03217409|Drug|Rosuvastatin+Ezetimibe|Rosuvastatin 5mg+Ezetimibe 10mg
1465764|NCT03229356|Other|Best Practices Advisory (BPA)|"BPA: The BPA is an Epic prompt that fires when a provider opens an encounter with a patient who is actively smoking. Providers will be asked to assess smoking cessation readiness and to refer patients to the free Maryland Quit Line if the patient is receptive. The Quit Line will receive an electronic referral with the patient's details. A Quit Line certified smoking cessation counselor will then call the patient at a later date and provide counseling. Receptive patient will receive up to four calls. They will receive counseling from a trained quit coach and be offered free access to NRT.
Quit Line: This free telephone-based counseling service is offered to smoker in Maryland. Services offered include on-the-phone smoking cessation counseling and free nicotine replacement."
1465765|NCT03229356|Other|BPA + Enhanced Education|BPA with Quitline Referral plus 1)Consolidated educational hand out: The hand out will include a information about counseling, pharmacotherapy, and cessation referrals 2)Online modules: Providers will be directed to optional, self-paced educational modules through the Maryland HABITS program 3)Academic detailing: This will include a single session during a clinic day in which counseling experts from the MD Quit Line will visit providers in their practice setting.
1465766|NCT03229343|Other|Supportive care|supportive care, systematic and joint to pneumological consultation, monthly, starting at M0 and continuing up to M6.
1465767|NCT03229330|Procedure|Low-level Light Therapy|Low-level Light Therapy 660nm (red laser), 1 to 3 Joules, irradiation time and number of points varied.
1465768|NCT03229330|Combination Product|Conventional treatment|Topical treatment: essential fatty oil, hydrogel, papain gel, petrolatum gauze, calcium or silver alginate, zinc oxide and barrier cream; and high compression bandage SurePress
1465769|NCT03229317|Other|Plethysmography|Lung plethysmography
1465770|NCT03229291|Drug|SM04755|SM04755 is a small molecule inhibitor of the Wnt pathway.
1465771|NCT03229291|Drug|Vehicle|Same formulation as topical SM04755 solution, without SM04755 included.
1465776|NCT03229265|Drug|Patiromer|Patiromer (8.4 grams) will be taken daily at 3 hours after oral tacrolimus and MMF dosing by subjects commencing 3 days (± 1 day) prior to visit 1.
1465777|NCT03229252|Drug|Placebo Inhalation Solution|Normal Saline Inhalation Solution
1465778|NCT03229252|Drug|SPX-101|SPX-101 Inhalation Solution
1465779|NCT03229239|Procedure|corneal stroma implantation|During the operation,implant the corneal stroma to the diseased cornea of keratoconus.
1465780|NCT03229226|Other|Verbal versus procedural assessment|Faculty were assessed on both verbal and simulated performance of procedures.
1465781|NCT03229200|Drug|Ibrutinib|Subjects will continue with the current ibrutinib dosing regimen established in the parent ibrutinib study.
1465782|NCT03229174|Drug|Droxidopa|Droxidopa initial dose 100mg TID, titrated in increments of 100mg every 24-48 hours to symptomatic response.
1465783|NCT03229174|Drug|Placebo|Placebo (sugar pill)
1465784|NCT03229161|Behavioral|IWT-group|
1465785|NCT03229148|Procedure|General anaesthesia|Procedure in which patients are induced into an unconscious state through use of various medications so that they do not feel pain during surgery
1465786|NCT03229148|Procedure|Conscious Sedation|A drug-induced depression of consciousness during which patients respond purposefully to verbal commands, either alone or accompanied by light tactile stimulation. No interventions are required to maintain a patent airway. (From: American Society of Anesthesiologists Practice Guidelines)
1465787|NCT03229135|Device|other antibacterial agents，breathing machine|If treatment failure for patients in group A，group B，group C and group D，change dose of teicoplanin or other antibacterial agents. Mechanical ventilation was adopte.Treatment failure was defined as no improvement or worse of clinical symptoms, laboratory data, requiring change of teicoplanin therapy.
1465788|NCT03229109|Diagnostic Test|Analysis of sweat secretions|Spectrophon DBM located on Samsung Gear S2
1465789|NCT03229096|Drug|Apatinib plus XELOX|"three weeks is one cycle, 4 cycles followed by radical gastrectomy. Apatinib: 250 mg, p.o., qd, every 3 weeks for the first two cycles. if no level 3 or severer AEs happened, change apatinib to 500mg, p.o.,qd, otherwise keep 250mg in the third cycle. no apatinib in the fourth cycle.
Capecitabine: 1000mg/m2, p.o., bid, D1-14, every 3 weeks (treatment for 2 weeks and rest 1 week).
Oxaliplatin: 130mg/m2, i.v. over 2h, D1, every 3 weeks."
1948204|NCT02665065|Drug|Cyclosporine or Tacrolimus|Immunosuppression with either CSP or TAC starting 3 days prior to transplant and continuing with taper through 180 days post-transplant
1465791|NCT03229070|Other|Interval effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Active phase (high load) lasting 60 seconds, followed by an active recovery phase with light / moderate load (60% of the maximum load) lasting 4 minutes. The pedaling speed should be maintained between 30-60rpm. There will be 5 cycles that will total 20 minutes of physical effort, and assessments at discharge.
1465792|NCT03229070|Other|Continuous effort group|Pre-surgical evaluations (Six-minute walk test, sit and lift test 30 in seconds, and Piper fatigue scale) Intensity used will be mild / moderate, ie 60% of the maximum load reached in the incremental test. The pedaling speed should be maintained between 30-60rpm. The execution time, from this exercise regime will be 20 minutes, and assessments at discharge.
1465793|NCT03229057|Drug|OCP + Metformin|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
1556540|NCT02551926|Other|Usual care|
1465794|NCT03229057|Drug|OCP + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
1465795|NCT03229057|Drug|Metformin + Placebo|This will be a three-arm, double-blind, double-dummy, multicenter, prospective, randomized clinical trial comparing OCP vs. Metformin vs. OCP + Metformin on the prevalence of MetS in women with PCOS. This 6-month study will consist of a screening visit, followed by 6 study visits (Subjects will undergo 6 in person study visits and life style modification counseling regarding diet and exercise. Phone contact will be made 2 weeks after randomization and at the end of each month when there is no in person visit to ensure study compliance with medications, keeping study logs and to review side effects). No longer term follow-up is planned.
1465796|NCT03229044|Genetic|Tetranectin|Adipose tissues were obtained from the breast of breast cancer patients with 0 to 1 progression stage. The subjects were 33-51 y of age (mean = 43.6, SD = 6.2) with a BMI of 16-33 kg/m2 (mean = 21.5, SD = 4.5). Blood samples were collected after an overnight fasting. Serum was separated by centrifugation and stored at -80 ℃ until analysis. Plasma Tetranectin,triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), cholesterol, glucose and insulin were measured. And the tetranectin mRNA and protein level was measure in adipose tissue
1465797|NCT03229031|Drug|ES135|ES135 will be administered via intrathecal
1465798|NCT03229018|Diagnostic Test|Voxel size|200 μm and 300 μm Voxel Sizes
1465799|NCT03229005|Procedure|implant insertion|during surgery soft tissues will be measured
1465800|NCT03229005|Procedure|operculectomy|during second surgery soft tissues will be measured again
1465801|NCT03229005|Procedure|prosthetic rehabilitation|after three months implants will be loaded with screw retained crown
1465802|NCT03228992|Drug|Ibuprofen 400 mg|Subjects will receive 4 doses of oral ibuprofen over a 24 hour period.
1465803|NCT03228992|Other|Placebo|Subjects will receive 4 doses of placebo over a 24 hour period.
1465804|NCT03228979|Other|Structured Semi-Interactive Stroke Prevention Package|the intervention arm will receive a Structured Semi-Interactive Stroke Prevention Package including patient workbook, short messaging services and health education videos for a period of one-year in addition to standard of care as per current guidelines.
1465805|NCT03228966|Diagnostic Test|Echocardiogram|Screening echocardiogram
1465806|NCT03228953|Other|Pharmacogenomic testing|Pharmacogenomic testing is delivered to treating providers of patients with major depressive disorder
1465808|NCT03228927|Other|comparison of twin A to twin B|Comparison of Twin A to Twin B
1465809|NCT03228914|Drug|Oxymetazoline|Pledgets will be soaked in 0.05% oxymetazoline solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
1465810|NCT03228914|Drug|Epinephrine|Pledgets will be soaked in 1:1000 epinephrine solution Two pledgets with the associated medication will be placed into the nasal cavity; one along the floor of the nose and another directed towards the middle meatus.
1465811|NCT03228901|Drug|Oxytocin|Administration of the hormone oxytocin
1465812|NCT03228901|Drug|Placebos|
1465813|NCT03228888|Other|Administration of rhytmic acoustic stimuli for gait training|The intervention consist in 5 weeks, 20 min/day gait training assisted by rhythmic acoustic stimuli administered using a portable MP3 player
1465814|NCT03228862|Drug|Ergocalciferol|Ergocalciferol 40000, 60000 and 80000 once weekly
1465815|NCT03228849|Procedure|Suture anchor technique|Suture anchors were used to attach bony fragment. On week 6, patients were then started on physical therapy for 2 weeks.
1465816|NCT03228849|Procedure|Conservative Treatment|The injured finger was immobilized in an aluminium splint for 6 weeks. Patients were then started on physical therapy for 2 weeks.
1465817|NCT03228836|Drug|PD-1 Antibody|IBI308 200mg/3 weeks
1465818|NCT03228823|Procedure|Radiofrequency ablation|RFA to achieve PVC suppression will be performed using standard techniques and protocols similar to those patients that do not participate in this clinical study.
1465819|NCT03228823|Drug|Amiodarone (Antiarrhythmic drug)|AAD therapy of choice is amiodarone. Amiodarone loading dose of 10 grams is recommended, followed by maintenance dose of 200-400mg daily to achieve successful PVC suppression. Alternatively, sotalol and/or propafenone could be considered at discretion of electrophysiologists (sotalol dose of at least 120mg twice daily, propafenone 150-300mg tid) if there is a significant concern of safety profile of amiodarone.
1465820|NCT03228810|Other|Blood draw|(2) 10 mL tubes will be collected
1465821|NCT03228810|Procedure|Tissue biopsy|Tissue biopsy of metastatic tissue if undergoing clinical care-directed biopsy
1465822|NCT03228797|Procedure|an ultrasound guided rectus sheath block|
1465823|NCT03228797|Procedure|multiholed catheter|gauge multiholed catheter will be inserted at the end of surgery and after the closure of the peritoneal layer at 3 to 5 cm away from the lower end of the surgical incision
1465824|NCT03228797|Procedure|an ultrasound guided rectus sheath block &multiholed catheter|a multiholed catheter will be inserted as in Group II and will receive also an ultrasound guided rectus sheath block as described for Group I.
1465825|NCT03228784|Procedure|LASIK|
1465826|NCT03228771|Drug|PRGF/ATV|Atorvastatin loaded in PRGF fibrin scaffold
1465827|NCT03228771|Drug|ATV gel|Atorvastatin loaded in methyl cellulose gel
1465828|NCT03228758|Procedure|Per Oral Endoscopic Myotomy|The Per Oral Endoscopic Myotomy procedure is the cutting of the lower esophageal sphincter. This procedure is a natural orifice transluminal endoscopic surgery (NOTES)
1465829|NCT03228745|Behavioral|Pre-operative MBSR|A MBSR program typically consists of 8 weekly 2.5 hour sessions, home practice (typically 45 minutes per day, 6 days per week), and one day retreat. During the program, participants engage in a number of mindfulness practices (e.g., body scan, mindful movement, meditation) and discussions of their experiences, with the aim enhancing awareness to moment-to-moment experiences in a non-judging and accepting manner.
1556541|NCT02551926|Device|mobile phone|
1465835|NCT03228719|Behavioral|Standardize PT after TKR with a Physical Activity Intervention|Standardized PT and a physical activity intervention. Participants will be provided a FitbitTM Zip within one week after enrolling in the study. Participants will self-track their steps/day using their FitbitTM Zip. Participants ≤ 3 weeks' post-operative TKR are expected to maintain and not increase steps/day. Beyond 3 weeks after surgery, step goals will be initiated and evaluated on a weekly basis. Progression of weekly steps/day goal will be a joint decision between the participant and physical therapist. As a guide, a 10-20% increase in steps/day until at least 6,000 steps/day is achieved. Each week the physical therapist will review the participant's steps/day goal and if at least 4 of the 7 previous days per week were at or above the prior week's steps/day goal, then next week's steps/day goal will increase. The physical therapist will discuss current steps/day with the participant using the Fitbit TM Zip and set a personalized steps/day goal each week during PT.
1465836|NCT03228719|Other|Standardized PT after TKR|Participants in the control group will receive standardized PT provided by a licensed physical therapist at UDPT using the University of Delaware's Rehabilitation Guidelines for Unilateral Total Knee Replacement. Standardized PT also includes a printed home exercise program with an exercise log that is updated weekly by a physical therapist. PT appointment times range from 45-60 minutes with appointment occurring 1-3 times a week for 6-8 weeks.
1465838|NCT03228693|Procedure|Biopsy and/or triamcinolone injection|Subjects will have their blood drawn during the first study visit. Subsequently, a punch biopsy and/or triamcinolone injection will be given based on group timeline.
1465839|NCT03228693|Procedure|Excisional Biopsy|Complete excision of an earlobe keloid will be taken.
1465840|NCT03228680|Drug|FE 999049|Subcutaneous administration through pre-filled injection
1465841|NCT03228680|Drug|Follistim|Single daily subcutaneous injection in the abdomen.
1465844|NCT03228654|Procedure|Unipolar Electrocautery sealing of vessels|"Vaginal walls are incised by monoplar current (40 W)
A curved Bulldog Clamp is applied just 0.5 cm lateral to the uterine border along its attachements all through the pedicles. Then unipolar electrocautery (40 W) is applied to the pedicles along the lateral border of the uterus medial to the artery with maximum thickness 1 cm.
uterine vessels are individually secured.
Conventional volume reduction maneuvers are used as associated procedures in cases of large uteri to create the parauterine space to approach the lateral attachements."
1465845|NCT03228654|Procedure|Purohit technique for vaginal hysterectomy|using Bipolar electrosurgical sealing of vessels during vaginal hysterctomy
1465846|NCT03228641|Device|micro-excisional skin removal with coring needle|
1465847|NCT03228628|Drug|Fixed 50:50 mixture of nitrous oxide and oxygen|Gaz inhalation will start 5 minutes before the puncture and will be continued until the end of the procedure.
1465848|NCT03228628|Other|Placebo|inhale medical air (22% O2 - 78% N2)
1465849|NCT03228615|Other|SDM Intervention|Intervention Component A: letter to activate families; Intervention Component B: in-clinic decision support; Intervention Component C: follow-up phone call
1465850|NCT03228602|Other|Recording of GEP (Gustatory Evoked Potentials)|record cerebral activity thanks to electrodes placed on the head and fixed with a painless, harmless adhesive paste and linked to a computer equipped with specific software to interpret the signals obtained. The collection of data for the electric signal takes 20 minutes.
1465851|NCT03228589|Dietary Supplement|Bif195|8 weeks of treatment with Bif195
1465852|NCT03228589|Dietary Supplement|Placebo|8 weeks of treatment
1465853|NCT03228576|Combination Product|Extended release Tacrolimus-Everolimus association|Envarsus® will be used as Tacrolimus Certican® will be used as Everolimus
1465854|NCT03228563|Other|Probioics|taking 1 probiotic capsule qd and H.S for three months
1465855|NCT03228550|Dietary Supplement|Efamol Active 50+|1000 mg docosahexaenoic acid, 160 mg eicosapentaenoic acid, 20 µg B12, 1 mg folic acid, 124 mg phosphatidylserine, 240 mg ginkgo biloba standardized leaf extract and 20 mg vitamin E
1465856|NCT03228550|Behavioral|Aerobic exercise|Static exercise cycle
1465857|NCT03228550|Dietary Supplement|Placebo multinutrient|Placebo multinutrient supplement
1465858|NCT03228537|Drug|Atezolizumab|Given IV
1465859|NCT03228537|Drug|Cisplatin|Given IV
1465860|NCT03228537|Procedure|Extrapleural Pneumonectomy|Undergo EPP
1465861|NCT03228537|Other|Laboratory Biomarker Analysis|Correlative studies
1465862|NCT03228537|Drug|Pemetrexed Disodium|Given IV
1465863|NCT03228537|Procedure|Pleurectomy|Undergo PD
1465864|NCT03228537|Radiation|Radiation Therapy|Undergo RT
1556776|NCT02550275|Radiation|MRI|
1465865|NCT03228524|Drug|D-Aspartate|Patients will be randomized to receive oral D-aspartatoe (2660 mg, once daily) or placebo,as an addition to conventional therapy as indicated by physicians, for a 6 weeks period.
1465866|NCT03228524|Behavioral|Therapeutic exercise|Standard physiotherapy
1465867|NCT03228524|Drug|Placebo Oral Tablet|Placebo
1465868|NCT03228511|Device|endoscope|It is a Prospective descriptive hospital based clinical study to determine the value of introduction of endoscope after microscopic excision of cerebello-pontine angle lesions
1465869|NCT03228498|Drug|Choline alphoscerate|Choline alphoscerate 600 mg b.i.d plus Nimodipine 30 mg t.i.d
1465870|NCT03228498|Drug|Placebo|Placebo b.i.d plus Nimodipine 30 mg t.i.d
1465871|NCT03228485|Device|My BPH Tracker|The application that will give daily medication reminders and via which the questionnaires can be filled out.
1465874|NCT03228459|Other|Clinical data collection|Sociodemographic variables (age, sex and race), medical history of comorbidities and medical treatments will be collected from the electronic Primary Care medical history (e-CAP). The following variables will be recorded in the MU: weight, height, waist circumference and neck circumference, body mass index in kg/m2, hours of fasting, systolic blood pressure, diastolic blood pressure and pulse pressure (mmHg). Blood pressure will be measured 3 times (Omron 6) at 2-min intervals and the mean of the last 2 will be collected. In addition, variables related to physical exercise (International Physical Activity Questionnaire (IPAQ)), diet (adapted from the PREDIMED study), and variables daytime somnolence (the Berlin Questionnaire and the Epworth somnolence scale).
1465875|NCT03228459|Diagnostic Test|Dried blood spot|Dried capillary blood testing creatinine, uric acid and total cholesterol (Reflotrons® Plus system, Roche). Determination of the complete lipid profile in cases in which total cholesterol is greater than 200 mg/dl: HDL cholesterol (mg/dl), LDL cholesterol (mg/dl) and triglycerides (mg/dl) (Cobas B 101® system, Roche). Calculation of non-HDL cholesterol levels. Glycated haemoglobin will be analysed with the Cobas B 101 system,Roche. The CKD-EPI glomerular filtration rate will be determined.
1465876|NCT03228459|Diagnostic Test|Urine spot tests|A urine sample from spontaneous micturition will be collected and analyzed using Clinitek Microalbumin 2 Reagent Strips and a Siemens Clinitek Status® analyzer. It will be determined albuminuria (mg/l) and albumin/creatinine ratio (mg/g).
1465877|NCT03228459|Diagnostic Test|Artery ultrasound|Carotid and femoral artery ultrasound for atheroma plaque diagnosis. Abdominal aorta ultrasound for early diagnosis of aortic aneurism. Transcranial ultrasound for cerebral arterial blood flow alterations.
1465878|NCT03228459|Diagnostic Test|Ankle-brachial index|Systolic blood pressure measurement in the brachial artery, posterior tibial artery and dorsalis pedis artery in both limbs. The ratios between tibial and pedal systolic blood pressure in each leg and the higher brachial blood pressure will be calculated.
1465879|NCT03228459|Diagnostic Test|Spirometry|Spirometry will be used to assess lung capacity. It will be performed by the same nurse who will measure forced vital capacity (FVC); forced expiratory volume in one second (FEV1); the ratio between FEV1 and FVC and the lower limit of normality, as a percentage.
1465880|NCT03228459|Diagnostic Test|Determination of advanced glycation end products|These will be measured using skin autofluorescence (SAF) in the forearm with the AGE Reader® system (Diagnoptics, the Netherlands). SAF is measured using spectrophotometry which is calculated as the relationship of the intensity of reflected light compared to refracted light.
1465881|NCT03228459|Diagnostic Test|Atrial fibrillation screening|The presence of atrial fibrillation is assessed with a device (SRA, EVINA Health Solutions) during one hour in the mobile unit.
1465882|NCT03228459|Other|Biobank|Blood samples from a peripheral vein of the hand or forearm to obtain serum, plasma, DNA and RNA will be collected. These samples will be prepared in aliquots following a standardized protocol, and sent frozen (dry ice) to a centralized biobank (IRBLleida Biobank, Spain) for processing and storage for subsequent studies of CV, inflammatory and mineral-metabolism biomarkers and genetic polymorphisms. Urine samples will be frozen and stored in a biobank for subsequent study of biomarkers.
1465883|NCT03228459|Other|Exploration results and recommendations|A report with exploration results and recommendations based on the current guidelines will be uploaded to the e-CAP history for the Primary care evaluation.
1465884|NCT03228446|Behavioral|filter training|one-week filter training on the computer: computerized visual change detection experiment (selective attention )
1465885|NCT03228446|Behavioral|memory training|one-week storage training on the computer: computerized visual change detection experiment (memory storage)
1465886|NCT03228446|Other|no training (control)|no training applied
1465887|NCT03228433|Drug|TAK-418|TAK-418 Capsule
1465888|NCT03228433|Drug|TAK-418 Placebo|TAK-418 placebo-matching capsules
1465889|NCT03228420|Device|Senza HF10 Therapy|Senza 10kHz Spinal Cord Stimulation
1465890|NCT03228420|Other|CMM|Conventional Medical Management
1465891|NCT03228407|Procedure|Confocal endomicroscopy|Confocal laser endomicroscopy (CLE) permits real-time in-vivo histologic analysis of esophageal mucosa at the time of upper endoscopy. The technology is based on the principle of illuminating a tissue with a low-power laser and then detecting fluorescent light reflected from the tissue. Because CLE relies upon tissue fluorescence, intravenous fluorescein is generally used to highlight the vasculature and intercellular spaces of the tissue being examined.
1465892|NCT03228407|Diagnostic Test|Endoscopic biopsies|Additional biopsies will be obtained of the esophageal mucosa in the addition to the biopsies required as a standard of ace. These will be obtained with a standard biopsy forceps inserted through the channel in
1465926|NCT03228121|Procedure|Treatment Then Placebo|Cohort A will receive stem cells/PRP infusion during round one then placebo of normal saline infusion during round two.
1465927|NCT03228121|Procedure|Placebo Then Treatment|Cohort B will receive placebo of normal saline infusion during round one then stem cells/PRP infusion during round two.
1465928|NCT03228108|Drug|Ciprofloxacin|see study arms.
1465929|NCT03228108|Drug|Trimethoprim/Sulfamethoxazole|see study arms.
1465895|NCT03228381|Device|BOSS Device|The BOSS will be comprised of a flexible, medical grade silicone handle and interchangeable inflatable medical grade silicone chambers. The inflatable chambers will vary in geometry and will have silicone tubing attached to them to allow inflation and deflation of the chamber while in the pericardial space. During open chest cardiac surgery, a small incision will be made in the pericardium to allow for insertion of the BOSS device into the pericardial space. Once inserted, the BOSS device will be positioned in different locations around the outside of the heart and anatomical and geometric changes will be observed echocardiographically. Use of the BOSS device is expected to lengthen the procedure by an average of 15 minutes, and in rare instances may be extended beyond 15 minutes as deemed appropriate by the investigator. The BOSS will be removed prior to continuing with the planned surgery.
1465896|NCT03228368|Drug|Atezolizumab (MPDL3280A)|anti-programmed death-ligand 1 (PD-L1) antibody
1465897|NCT03228355|Drug|Levcromakalim|To investigate the role of Levcromakalim on cerebral hemodynamic in migraine patients
1465898|NCT03228355|Drug|Saline|To investigate the role of levcromakalim compared with saline cerebral hemodynamic in migraine patients.
1465899|NCT03228342|Diagnostic Test|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will be informed to his/her attending Rheumatologist.
The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
1465900|NCT03228342|Diagnostic Test|MusculoSkeletal Ultrasound|"Patient will be assess with ultrasound (GUS-7 score) and the results will not be informed to his/her attending Rheumatologist.
The Patient Reported Outcomes will be evaluated a 0,6 and 12 months after randomization."
1465901|NCT03228329|Other|fluid boluses|fluid boluses will be given when there will be hypovolemia assessed by presence of pulse pressure variations
1465902|NCT03228316|Procedure|superior hypogastric plexus block|nerve plexus block
1465903|NCT03228316|Radiation|pulsed radiofrequency|pulsed radiofrequency on sacral nerve roots 2,3 and 4
1948207|NCT02657954|Behavioral|CCT|10-week Compensatory Cognitive Training
1948208|NCT02657954|Behavioral|HCE|10-week Holistic Cognitive Education
1465906|NCT03228277|Drug|Olmutinib|Patients to be provided with Olmutinib 800mg (2 x 400 mg tablets) once daily (QD)
1465907|NCT03228264|Behavioral|ucSLT|The psychological intervention consists of usual care SLT (ucSLT). During four weeks the patients in both arms will receive a 45 minutes ucSLT once a week
1465908|NCT03228264|Device|teleSLT|The teleSLT intervention consists of a daily training session with a tablet computer at the patients' home. The teleSLT application that will be used for this study was developed within a multidisciplinary team of speech and language therapists, neurologists and computer engineers that have transferred well-established SLT exercises to a tablet computer. The investigators call this application Bern Aphasia App (BAA). During the four weeks the training time with the BAA differs between the two arms. The experimental group trains for 48 minutes per day (80% of an hour) and the control group for 12 minutes per day (20% of an hour).
1465909|NCT03228264|Device|teleCT|For the cognitive training the investigators will use two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC, Bejeweled, PopCap Games). The video games are also delivered on tablet-computers. Again, during the four weeks the training time differs between the two arms. The experimental group trains for 12 minutes and the control group for 48 minutes per day.
1465911|NCT03228238|Drug|Vitamin C and Vitamin E|Ascorbic acid Tablet 1g and Tocopherol Capsule 400IU
1465912|NCT03228238|Drug|Statin|Atorvastatin calcium 10mg
1465913|NCT03228238|Drug|Standard medication for variant angina|Calcium Channel blocker or NG
1465914|NCT03228225|Behavioral|Tele Cardiac Rehabilitation|Comprehensive intervention according to the secondary prevention goals
1948209|NCT02658201|Device|MRI|Ultrafast MRI to assess constipation
1948210|NCT02655198|Drug|Fenfluramine|study of efficacy and safety of add-on fenfluramine at different dosages in refractory Lennox Gastaut patients : 0.2 - 0.4 and 0.8 mg/kg/day (max 30 mg).
1465917|NCT03228186|Drug|Pevonedistat|25mg/m2 days 1, 3, 5
1465918|NCT03228186|Drug|Docetaxel|75mg/m2 day 1
1465919|NCT03228160|Other|Linearly Polarized Near-Infrared light Irradiation|The SGI was carried out with the use of a linear-polarized near-infrared irradiation device, Minato Alphabeam Infrared Ray Therapy Unit (Minato Medical Science Co., Ltd., Hyogo, Japan), by a senior physical therapist. The maximum output was 3000 mW/cm² at wavelengths of 0.7 to 1.6 m⁻⁶, including a combination of red and near-infrared radiation. All patients in the experimental group received SGI under the conditions as follows: output, 90%; irradiation circle 1:2 (irradiation 3 seconds followed by 7-seconds pause); duration of irradiation, 10 min; and total irradiation energy density, 194.8 J/cm². The instrument in the control group with shame irradiation was the same as that in the experimental group with the exception that emitted radiation from device was inactive.
1465920|NCT03228147|Dietary Supplement|Nutritional Supplementation|Given PO
1465921|NCT03228147|Other|Questionnaire Administration|Ancillary studies
1948211|NCT02654509|Biological|Eastern Equine Encephalitis Vaccine, Inactivated, Dried, TSI-GSD 104|Eastern Equine Encephalitis Vaccine, Inactivated, Dried
1948212|NCT02642809|Drug|Pembrolizumab|
1948213|NCT02642809|Radiation|Brachytherapy|
1948214|NCT02642809|Procedure|Endoscopic biopsy|
1465930|NCT03228108|Drug|Fosfomycin|see study arms.
1465931|NCT03228108|Drug|Pivmecillinam/augmentin|see study arms.
1948215|NCT02642809|Procedure|Computed tomography-guided biopsy|
1948216|NCT02642809|Procedure|Peripheral blood collection|
1948217|NCT02640053|Procedure|Cryotherapy|Applied topically
1465932|NCT03228095|Diagnostic Test|VOC detection in breath and in skin headspace|VOC will be detected in breath with off-line and on-line testing and in skin headspace with off-line testing
1465933|NCT03228095|Diagnostic Test|Breath sampling|Breath sampling for VOCs detections will be carried out using nano-sensor based devices (electronic nose)
1465934|NCT03228095|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
1465935|NCT03228095|Procedure|Colonoscopy with biopsies|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
1465936|NCT03228095|Procedure|Whole blood/ Plasma / serum sampling|Whole blood/Plasma/serum sampling will be used to obtain information for group stratification
1465937|NCT03228095|Diagnostic Test|Faecal sampling|Facal samples will be obtained for faecal occult blood testing as well as microbiota analysis
1465938|NCT03228095|Procedure|Histological examination of surgical specimen|Routine histological exam for patients undergoing curative or palliative surgery. Indication for surgery are set based on underlying condition. Study does not interfere with decision making for surgical treatment
1465939|NCT03228095|Diagnostic Test|Headspace analysis for biological material|VOC analysis from headspace of surgical specimen, biopsy materials, blood/plasma, microbiota etc.
1465940|NCT03228082|Device|Home Blood Pressure Monitoring (HBPM)|Home blood pressure monitoring using the Withings Wireless BP monitor. Patients will be asked to measure their blood pressure twice daily for 7 consecutive days. This will be repeated for every month for 1 year.
1465941|NCT03228069|Procedure|Blood drawn after rabies booster vaccination|Blood would be drawn for testing of rabies neutralizing antibody titers, rabies specific T lymphocytes and regulatory T cells after receipt of rabies booster vaccination at least a year before.
1465942|NCT03228056|Procedure|pain intensity measured in VAS scale|Pain intensity in 0-100 mm VAS scale is measured every 4 hours on standard ruler beginning from the end of the surgery.
1465943|NCT03228043|Drug|Apatinib|Apatinib combine with XELOX adjuvant chemotherapy for resectable colorectal
1465944|NCT03228043|Drug|XELOX|XELOX adjuvant chemotherapy for resectable colorectal
1465945|NCT03228030|Dietary Supplement|Thiamine|Capsules
1465946|NCT03228030|Dietary Supplement|Placebo|Identical capsules
1465947|NCT03228017|Drug|Aspirin and/or Atorvastatin|This follow-up will allow us to assess how aspirin and/or atorvastatin affect platelet and endothelial function and inflammation.
1465948|NCT03228004|Behavioral|Glooko MeterSync|The participant and caregiver will receive a reminder via text or email to upload glucose data via Glooko on a biweekly basis.
1465951|NCT03227978|Combination Product|PCL mesh pleurodesis|Coverage of the lung surface by PCL mesh
1465952|NCT03227965|Biological|Immune cells population assesment|T lymphocytes population description through blood, urine and faeces samples
1465953|NCT03227952|Device|Vibrotactile stimulation|Vibrotactile sensory stimulation will consist on whole-body stimulation with mechanical stimuli of pallesthetic type at high rate (20-90 Hz), low intensity and long daily duration (3h).
1465954|NCT03227939|Procedure|Laparoscopic sleeve gastrectomy（LSG）|LSG：All these operations were performed by the same surgeon team. Dissect the greater omentum alongside the greater gastric curvature, make sure that the greater gastric curvature and fundus of stomach were completely made free from pancreas and spleen.Fully Exposed left and right diaphragm angle and taking care not to injure the esophagus. Resection was started 2 to 4 cm from pylorus and alongside a 40Fr tube up to the esophagogastric junction and created a 60 to 80ml gastric lumen, removed the fundus of stomach thoroughly and take care of the esophagus and preventriculus. Repaired the hiatal hernia if it was exsit.
1465955|NCT03227939|Procedure|Uvulopalatopharyngoplasty(UPPP) and Adenoidectomy/Tonsillectomy|UPPP：PPP is typically administered to patients with obstructive sleep apnea in isolation. It is administered as a stand-alone procedure in the hope that the tissue which obstructs the patient's airway is localized in the back of the throat. The rationale is that, by removing the tissue, the patient's airway will be wider and breathing will become easier.
1465956|NCT03227926|Drug|Panitumumab 20 MG/ML Intravenous Solution [VECTIBIX]|Panitumumab 6 mg/kg in 100 cc 0.9% NaCl solution on Day 1 every two weeks by IV administration over 1 hour.
1465957|NCT03227913|Other|Two samples of saliva|"Without stimulation: the first will be used to measure the flow of naturally secreted saliva
With stimulation: the second will will be used to measure the flow and viscosity of the saliva secreted after stimulation"
1465958|NCT03227913|Other|Chewing behaviour|Measure the time taken by subjects to chew the food and the number of bites they use before swallowing
1465959|NCT03227913|Other|Study of the food bolus|"Analysis by a compression and viscosity test
Evaluation of the quantity of saliva incorporated by drying"
1465960|NCT03227900|Drug|Lidocaine|Intragastric infusion of lidocain
1465961|NCT03227900|Drug|Placebos|Intragastric infusion of water for injections
1465962|NCT03227887|Other|Two samples of saliva|"Without stimulation : the 1st will be used to measure the flow of naturally secreted saliva
With stimulation: The 2nd will be used to measure the flow and viscosity of the saliva secreted after stimulation"
1465963|NCT03227887|Other|Chewing behaviour|Measure the time taken by the subjects to chew the food and the number of bites they use before swallowing The test will be done twice.
1465964|NCT03227887|Other|Study of the food bolus|"2 tests:
Evaluate using a compression test the structure of each bolus to determine their degree of destructuration over time Measure the quantity of the saliva incorporated
The bolus will be analysed visually"
1465965|NCT03227887|Other|Mouthfeel|Describe the mouthfeel by answering a paper questionnaire after consumption of the cereal products
1465966|NCT03227874|Dietary Supplement|Dried apple|diced dried apple with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
1465967|NCT03227874|Dietary Supplement|Muffin|two muffins with 55 g carbohydrate, was consumed by the participants with 220 ml of water.
1948218|NCT02640053|Drug|Paclitaxel|Given IV
1465969|NCT03227848|Device|Computer Aided Auscultation|Automated digital heart sound analysis for heart murmur detection and murmur classification
1465970|NCT03227835|Other|intravascular iodinated contrast material administration|Evaluation of the consequences of the protocol change to not giving prophylaxis to patients with an eGFR >29mL/min/1.73m2
1465971|NCT03227822|Procedure|Short spot stenting|
1465972|NCT03227822|Procedure|Long lesion stenting|
1465973|NCT03227809|Behavioral|Handbook condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students.
1465974|NCT03227809|Behavioral|Handbook plus condition|Parents of first-year university students receive parent handbook summer before start of university. Handbook contains suggestions for activities and conversations parents can conduct with students. Parent also receive text messages throughout the year.
1465975|NCT03227796|Drug|LEVI-04|LEVI-04 intravenous infusion
1465976|NCT03227796|Drug|Placebo|Placebo intravenous infusion
1465977|NCT03227783|Device|transcranial direct current stimulation (tDCS)|tDCS is one of non-invasive brain stimulation. Constant, low current is delivered to the specific brain areas to change brain plasticity.
1465980|NCT03227757|Device|Tricuspid Valve Repair System|Subjects who received TVRS will be included in this arm. The TVRS is intended for reconstruction of the insufficient tricuspid valve through tissue approximation.
1465981|NCT03227744|Behavioral|Group therapy|Twelve 1-hour group therapy sessions with a licensed psychologist for prostate-cancer related anxiety.
1465982|NCT03227744|Other|Surveys|MAX-PC, GAD and FACT-P
1465985|NCT03227705|Drug|Prometrium|Intravaginal use, off label, of Prometrium
1465986|NCT03227705|Device|Dr. Arabin, cerclage pessary perforated|A Dr. Arabin, cerclage pessary perforated will be inserted participants diagnosed with a short cervix
1465987|NCT03227692|Device|Persona Knee System|Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
1465988|NCT03227692|Procedure|Total Knee Arthroplasty|Damaged cartilage due to degerative arthritis is replaced by knee joint prosthesis.
1465989|NCT03227692|Device|iAssist Knee|Osteotomy of TKA is navigated by iAssist system, iAssist requires pin inserted in bone.
1465990|NCT03227679|Other|Nicotine Metabolite Ratio|This intervention used information from a genetically-informed biomarker (Nicotine Metabolite Ratio, NMR) to assign one of 3 FDA-approved smoking cessation pharmacotherapies (varenicline, bupropion, or NRT) to participants.
1465991|NCT03227679|Drug|Varenicline|FDA-approved smoking cessation pharmacotherapy
1465992|NCT03227679|Drug|Bupropion|FDA-approved smoking cessation pharmacotherapy
1465993|NCT03227679|Drug|Nicotine patch|FDA-approved smoking cessation pharmacotherapy
1465994|NCT03227666|Behavioral|Exercise|The intervention group will perform three supervised group training sessions a week, consisting of 30 minutes of balance training for 4 weeks.
1465997|NCT03227640|Procedure|stripping technique|The cyst is stripped from the healthy ovary by traction and countertraction; after the removal of the cyst, hemostasis is achieved by selective bipolar coagulation.
1465998|NCT03227640|Device|CO2 laser (AcuPulse Duo, Lumenis)|The cyst content is drained and the internal wall is vaporized with CO2 laser beam (AcuPulse Duo, Lumenis, Israel)
1465999|NCT03227627|Device|VitalStim|One group of children (Group A) will receive 24 sessions of NMES for combined with traditional therapy including oral motor exercises and laryngeal exercises will be performed to the participants. The equipment to be used for NMES is VitalStim®. VitalStim is a product of Empi®.
1466000|NCT03227627|Other|Traditional Therapy|The other group (Group B) will be receiving 24 sessions of traditional dysphagia therapy.
1466001|NCT03227614|Behavioral|Support Person Intervention|The patient participant will have a support person of her choice accompany her during her abortion procedure.
1466002|NCT03227601|Device|posture adapter|continued use of the device at home for 2 months after instructions of how to do it
1466003|NCT03227588|Diagnostic Test|Fractional Flow Reserve|This is a prospective data collection study for patients that have undergone FFR.
1466004|NCT03227575|Behavioral|Exercise Intervention|The use of exercise to improve glycemic responses in young adults who are at risk for Metabolic Syndrome.
1466005|NCT03227562|Drug|RisperiDONE 0.5 MG|To be prescribed a 0.5mg risperidone treatment for anxiety is required to be enrolled.
1466006|NCT03227549|Procedure|Direct Superior Approach|Total hip arthroplasty using direct superior approach
1466007|NCT03227549|Device|Total Hip Arthroplasty|Total Hip Arthroplasty using direct superior or posterior approach
1466008|NCT03227549|Procedure|Posterior Approach|Total Hip Arthroplasty using posterior approach
1467308|NCT03217409|Drug|Rosuvastatin|Rosuvastatin 5Mg Tablet
1948219|NCT02640053|Other|Quality-of-Life Assessment|Ancillary studies
1948220|NCT02640053|Other|Questionnaire Administration|Ancillary studies
1466009|NCT03227497|Dietary Supplement|Whole Walnuts|Intervention arm includes whole walnuts taken as dietary replacement meal during the day, and between breakfast and lunch, and/or lunch and dinner. Importantly, none of the main meals, including breakfast, lunch and dinner are to be replaced by study intervention, and the study subjects are instructed to do so. Walnuts are provided with the same producer at the Belgrade market.
1466010|NCT03227484|Drug|Empagliflozin 25mg|Once daily over 8 weeks
1466011|NCT03227484|Drug|Placebo Oral Tablet|Once daily over 8 weeks
1466018|NCT03227458|Other|DHEA|Participants will take 1 study pill (50 mg DHEA) daily for 36 weeks.
1466019|NCT03227458|Other|Placebo|Participants will take placebo daily for 36 weeks.
1466020|NCT03227458|Behavioral|Exercise|bone-loading exercise on 3 days per week for 38 weeks
1466025|NCT03227432|Drug|Dexamethasone|Dexamethasone, a corticosteroid, is similar to a natural hormone produced by adrenal glands. It relieves inflammation.
1466026|NCT03227432|Drug|Pomalidomide|Pomalidomide which is an immunomodulatory drug. This means that pomalidomide modulates the immune system to help fight diseases.
1466027|NCT03227432|Drug|Elotuzumab|Elotuzumab is an antibody, that stimulates the immune system to fight diseases
1466028|NCT03227432|Drug|Nivolumab|Nivolumab works by blocking an inhibitory signal within immune cells, potentially allowing the immune system to fight the cancer
1466029|NCT03227419|Drug|Tocilizumab Prefilled Syringe|"Treatment arm: tocilizumab (RoActemra®):
162 mg weekly a schema for therapeutic adaptation with injection intervals determined according to transaminase levels or blood cell counts (neutropenia, thrombopenia) as recommended by Roche-Chugaï (see table below)."
1466030|NCT03227419|Drug|Abatacept Prefilled Syringe|"Treatment arm: abatacept (Orencia®)
125 mg weekly after an initial dose of 500 mg (body weight <60kg), 750 mg (body weight between 60 and 100 kg), or 1000 mg (body weight >100 mg) 24 hours before the first subcutaneous injection."
1466031|NCT03227406|Behavioral|Sleep deprivation|Subjects are kept awake all night.
1466032|NCT03227406|Behavioral|Nap|Participants are given a 90-minute nap opportunity in the early afternoon.
1466033|NCT03227406|Behavioral|Overnight sleep|Participants are allowed to sleep normally overnight.
1466034|NCT03227393|Behavioral|Yoga training|Subjects will complete in class yoga training weekly for 8 weeks with additional practice at home
1466035|NCT03227380|Other|thoracic densitometry with contrast|injected CT scan at 3 or 6 months after segmentectomy VATS
1466036|NCT03227367|Other|other : PRF|mononuclear cells from the peripheral blood of chronic periodontitis patients were intervened with PRF, BCP and PRF/BCP combination
1466037|NCT03227354|Device|Vittamed 205|non-invasive Intracranial Pressure measurement
1466038|NCT03227341|Other|Exercise|8 week exercise program including breathing exercises consisted of pursed-lip breathing, diaphragmatic breathing and thoracic expansion exercises, relaxation and stretching exercises, upper and lower extremity muscle strength training, and aerobic exercises. In addition, bronchial hygiene techniques and dyspnea-reducing positions
1466039|NCT03227328|Drug|concomitant chemotherapy plus an aromatase inhibitor (AI)|"Allowed chemotherapy regimens are all those registered for metastatic breast cancer including: anthracycline plus taxane, taxane-based (without anthracycline), anthracycline-based (without taxane), capecitabine- (or other fluoropyrimidines)-based, and others.
Possible endocrine treatments are:
non-steroidal AIs:
anastrozole 1 mg daily continuously
letrozole 2.5 mg daily continuously
steroidal AI: o exemestane 25 mg daily continuously"
1466040|NCT03227328|Drug|chemotherapy followed by an aromatase inhibitor (AI)|"Allowed chemotherapy regimens are all those registered for metastatic breast cancer including: anthracycline plus taxane, taxane-based (without anthracycline), anthracycline-based (without taxane), capecitabine- (or other fluoropyrimidines)-based, and others.
Possible endocrine treatments are:
non-steroidal AIs:
anastrozole 1 mg daily continuously
letrozole 2.5 mg daily continuously
steroidal AI: o exemestane 25 mg daily continuously"
1466041|NCT03227302|Procedure|attending obstetrician|Attending obstetrician can do the caesarean operation without pregnant complications.
1466042|NCT03227302|Procedure|associate obstetrician|Associate chief Obstetrician can do the caesarean operation without or mild or middle pregnant complications.
1466043|NCT03227302|Procedure|chief obstetrician|Chief obstetrician can do all caesarean operation without limitations.
1466044|NCT03227289|Other|Stayed in NRDS|The neonates with NRDS are stayed in NRDS.
1466045|NCT03227289|Other|Converted to ARDS|The neonates with NRDS are converted to ARDS.
1466046|NCT03227276|Dietary Supplement|Litramine|2 tablets to be taken 3 times a day after meals
1466047|NCT03227276|Dietary Supplement|Placebo tablet|2 tablets to be taken 3 times a day after meals
1466052|NCT03227198|Biological|Intramyocardial injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intramyocardial injection of the cells is performed in patients with Heart failure in open heart surgery (CABG)
1466053|NCT03227198|Biological|Placebo|Injection of Placebo in patients with Heart failure in open heart surgery (CABG)
1948225|NCT02629159|Drug|ABT-494|ABT-494 Oral Tablet
1466056|NCT03227172|Procedure|apicoectomy|After flap elevation and osteotomy , peri-apical lesion and the root tip were located: after root-end resection using a fissure bur, the resected root tip and the pathological tissue were removed and immediately preserved in 1% formaldehyde solution.
1466057|NCT03227146|Biological|EHSG-KF|Transplantation of autologous dermo-epidermal skin substitute EHSG-KF to the experimental area
1466058|NCT03227146|Biological|STSG|Transplantation of autologous split-thickness skin graft to the control area
1466059|NCT03227133|Other|Neuropsychological evaluations|Neuropsychological evaluations including oral fluency, performed specifically for the study
1466060|NCT03227133|Other|Psychiatric interview|
1466061|NCT03227133|Other|Cardiovascular risk assessment|
1466062|NCT03227120|Other|Prehabilitation exercise|"Three times weekly exercise program of strengthening, balance and functional activities.
Weekly evaluation and progression with daily use of the Borg Rating of Perceived Exertion (RPE) supplemented with Heart Rate (HR) and Blood Pressure as needed to target the moderate intensity training level (40-60% HR Max) or above as appropriate to each individual."
1466063|NCT03227094|Diagnostic Test|Standard OGTT|Standard-OGTT Plasma glucose : 0, 30, 60, 90, 120 minutes Complete biochemical profile, weight and size (body mass index), drugs list, pulmonary function by spirometry (FEV, etc.) Questionnaires CGMS training & delivery of Jelly-Bean/75g glucose beverage
1466064|NCT03227094|Diagnostic Test|Home-based OGTT (Beverage)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
1466065|NCT03227094|Diagnostic Test|Home-based OGTT (Candy)|In a random order Candy-OGTT (Jelly-Bean) or 75 g glucose beverage Glycemia every 15 minutes from CGMS collection; standardized condition (fasting + rest) Questionnaires
1466066|NCT03227081|Behavioral|Sleep Deprivation|Sleep Deprivation
1466067|NCT03227068|Other|PEDSS - symptom management|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - symptom management will be delivered prior to the initial hospital discharge. The nurse will review the symptom management worksheet verbally with the parent, then distribute the written worksheet to the parent.
1466068|NCT03227068|Other|PEDSS - support for the caregiver|All subjects will receive education regarding their specific disease and treatment in accordance with current practices. Cancer care providers describe detailed side effects of treatment to parents during the treatment consent process. In addition, all parents will receive standard discharge education before hospital discharge, which includes a list of home medications and information regarding whom to call for emergencies. The PEDSS - support for the caregiver will be delivered prior to the initial hospital discharge. The nurse will review the worksheet verbally with the parent, then distribute the written worksheet to the parent.
1466072|NCT03227016|Drug|veliparib|Topotecan at increasing doses (1x or 2x per day) will be administered in each cycle.
1466073|NCT03227016|Drug|Topotecan|Topotecan at dose 1.25 mg/m2 will be administered in each cycle.
1466074|NCT03226990|Other|impression technique|impression technique with and without wax spacer
1466075|NCT03226977|Device|NIPPV|NIPPV is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
1466076|NCT03226977|Device|NCPAP|NCPAP is used as a primary mode of ventilation in premature infants with respiratory distress syndrome
1466077|NCT03226964|Device|high flow nasal oxygen|humidified high flow nasal oxygen
1466078|NCT03226951|Device|SDM laser|Subthersh hold diode micropluse laser
1466079|NCT03226925|Diagnostic Test|Non-invasive mechanically-assisted ventilation|Mechanically ventilation will be done through facial masks connected to a respirator. Volunteers/patients are fully conscious during the ventilation.
1466080|NCT03226925|Diagnostic Test|Dynamic MRI acquisition|Dynamic MRI acquisition are specific dynamic sequences intended to visualise the motion of internal structures (anatomical structures or tumour) under non-invasive mechanically-assisted ventilation
1466081|NCT03226925|Diagnostic Test|Planning 4D-CT|In order to perform in-silico planning, 4D-CT will be acquired on patients under non-invasive mechanically-assisted ventilation
1466082|NCT03226899|Drug|Lesinurad|200 MG Oral Tablet
1466083|NCT03226899|Drug|XOI|All participants must be on a stable, medically appropriate dose of XOI as their sole urate-lowering therapy (ULT) indicated for the treatment of gout for at least 4 weeks prior to Screening and throughout the Screening Period. This stable dose of XOI will be maintained throughout the study period.
1466084|NCT03226899|Drug|Placebo|matching placebo oral tablet
1466085|NCT03226873|Behavioral|Peer Navigation|Peer education, counseling, and facilitation of PrEP care
1466086|NCT03226860|Device|Gait Myoelectric Stimulator|Electrical stimulation during gait for children with CP
1466087|NCT03226860|Other|5210|Children will eat 5 fruits/vegetables each day, watch 2 hours or less of screen time, perform 1 hour or more of physical activity, and drink 0 sugar-sweetened beverages.
1466088|NCT03226847|Procedure|Pulmonary Vein Isolation|Standard antral pulmonary vein isolation using radiofrequency ablation catheters
1467707|NCT03214354|Drug|Alemtuzumab|Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
1466089|NCT03226834|Device|MUSIC CARE|Musicotherapy session using one of the U musical sequences of MUSIC CARE among the preselected music styles
1466090|NCT03226834|Other|PERSONAL PLAY-LIST|Musicotherapy session using the patient's play-list composed by the patient with her favourite songs
1466091|NCT03226821|Drug|Tesamorelin|Patients will be treated with tesamorelin 2 mg by subcutaneous injection daily
1948226|NCT02629159|Drug|Placebo for ABT-494|Placebo Oral Tablet
1466093|NCT03226795|Other|" Information-Motivation-Behavioral skills  intervention."|"information -> Reminders of medication: mobile application
Motivation -> Coaching by patients: intervention or coaching by an expert patient, animation of a social network of patients
Behavioral skills -> Accompaniment by professionals: therapeutic education, assessment of membership during medical visits, prioritization of treatments"
1466094|NCT03226782|Other|Short intervention protocol|Will be offered an instructional material that will consist of a routine of 12 exercises to be performed autonomously for range of motion and muscular fitness, using the environmental resources of the home. It will be suggested a daily frequency in the execution of this exercise routine. Also, stimuli and guidelines will be given for the practice of active movement (walking) so that they accumulate at least 10 to 20 minutes of this activity daily. All control and training guidelines for using the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises.
1466095|NCT03226782|Other|Long intervention protocol|This Manual guides its implementation in a progressive way and at the end it totals about 30 to 45 min of physical exercises per day. All control and training guidelines for use of the manual will be offered through an introductory lecture and subsequent weekly telephone contacts (twice a week). Participants should complete their respective program for a total period of 12 weeks and mark in the manual how often they performed the exercises. Therefore, it guides the implementation of daily walks with cumulative effect.
1466098|NCT03226756|Drug|Nivolumab Injection|Nivolumab 3 mg/kg, every 2 weeks
1466099|NCT03226743|Other|collaborative and stepped care model|"Including elements:
collaborative and stepped care of patients with mental disorders
treatment in a multiprofessional network consisting of primary care physicians, psychologists, psychiatrists and inpatient facilities
initial training of participating health care providers
formalized and standardized screening procedure for early recognition of depressive, anxiety, somatoform and alcohol abuse disorders
formalized ICD-diagnostics
guideline-oriented treatment recommendations
bibliotherapy or internet-based self-help for patient with mild to moderate disorders
online referral platform
case management for patients with severe disorders
systematic and regular monitoring
regular quality circles for participating health care providers"
1466100|NCT03226730|Behavioral|Household Visits|Household visits will be conducted to build trust in the health system, educate regarding different forms of modern contraception, (how administered, how they work, availability), dispel related myths (i.e., those regarding infertility), promote the health advantages of birth spacing, and create related dialogue among adolescent wives and other household members present during these visits. The relais will provide and resupply oral contraceptive pills and condoms to interested participants and will accompany the married adolescent to the nearest health facility for other forms of contraception, if requested to do so. To complement the household visits to married female adolescents, male relais will conduct home visits to discuss healthy timing and spacing of pregnancy with husbands of adolescent females, provide education on different forms of contraception, and discuss concerns husbands may have regarding use of contraception.
1466101|NCT03226730|Behavioral|Small Groups|In the wife-only groups, adolescent wives will be convened by trained adult female community members to learn and discuss a broad range of gender and health-related topics, with a focus on modern contraception, and cultivate self-efficacy, social support and life skills. The small groups will be led by trained female small group mentors who are trained peers and will follow a designated curriculum consisting of different topics each week developed by Pathfinder International and derived from Population Council/UNFPA's Safe Spaces curriculum. The husband groups will follow a curriculum adapted from Promundo's Program P6 and supplemented by the tools and activities developed by Pathfinder International. These groups of husbands will focus on fostering reflection and dialogue to contribute to more equitable gender norms, support for contraception use for HTSP, positive health seeking behavior for them and their families, and increased couples communication and joint SRH decision-making.
1466102|NCT03226717|Drug|Antiviral agents|combination therapy consists of Sofosbuvir,daclatasvir and ribavirin
1466103|NCT03226691|Drug|Plerixafor|This is a single cohort phase 1 study to determine the safety of plerixafor mobilization and apheresis in SCD patients
1466104|NCT03226678|Drug|APL-2|Complement Inhibitor
1466106|NCT03226626|Drug|Tumescent Anesthesia and antibiotic delivery (TAAD) plus IVAD|Concomitant tumescent anesthesia antibiotic delivery (TAAD) & Intravenous antibiotic delivery (IVAD).
1466107|NCT03226626|Device|SubQKath|The device intervention consists of using the SubQKath device to provide subcutaneous delivery of antibiotics.
1466108|NCT03226613|Procedure|Transcervical Oropharyngeal Ultrasound|One time approximately 15 minute ultrasound will be conducted at the time of clinic visit, focusing on the base of tongue and palatine tonsil via transcervical approach.
1466109|NCT03226613|Procedure|Oral Rinse Collection|Patients will provide a one time oral rinse specimen using a non-alcoholic mouthwash at the time of clinic visit. The participant will be instructed to swish vigorously for 5 seconds and then gargle 5 seconds. The participant will be asked to repeated the swish and gargle (5 seconds each) three times for a total of 30 seconds and then expel the wash in a 10mL conical tube.
1466110|NCT03226613|Procedure|Blood Draw|A certified phlebotomist will perform a one time blood draw of 10mL at the time of clinic visit from each participant for purposes of HPV serologic testing.
1466111|NCT03226600|Device|OrACELL|OrACELL is human dermis that undergoes the MATRACELL process. MATRACELL is a patented and validated process that renders allograft tissue acellular, without compromising the biomechanical or desired biochemical properties of an allograft bio-implant for its intended surgical application.
1466112|NCT03226600|Device|Connective Tissue Graft|A measured layer of dermis is surgically removed from the palate for use as a graft to cover gingival recession
1466113|NCT03226587|Procedure|Blue light|Subjects will be exposed to blue light (453 nm wavelength) for 30 minutes
1466114|NCT03226587|Procedure|control exposure|Subjects will get control exposure to 30 minutes of whole body, which causes only comparable warming of skin as with blue light exposure.
1466116|NCT03226561|Procedure|Phaco / Panoptix|Phacoemulsification with bilateral diffractive trifocal lens implantation
1466117|NCT03226548|Other|Paycheck Plus|A four-fold increase in the Earned Income Tax Credit
1466118|NCT03226535|Device|Ultrasound-CT Fusion|The Clear Guide SCENERGY is an Ultrasound-CT fusion device which supplements existing ultrasound and CT capabilities. The participants randomly selected (out of 20 patients) for use of the Clear Guide SCENERGY (test group) will receive ultrasound-CT fusion guidance from the MDs performing the procedure.
1466119|NCT03226522|Drug|AXS-05|AXS-05
1466120|NCT03226522|Drug|Bupropion|Bupropion
1466121|NCT03226522|Drug|Placebo|Placebo
1466122|NCT03226496|Behavioral|motivational interviewing|
1466123|NCT03226483|Radiation|Intraoperative Radiotherapy|Intraoperative Radiotherapy is performed with a mobile radiation device emitting soft energy x-rays in a spherical way. Different size applicators are available to cover the resection cavity after the tightest fit rule.
1466124|NCT03226470|Biological|T27|T27 suppository contain 500 µg of T27 and suppocire.
1466125|NCT03226470|Biological|T512|T512 suppository contain 500 µg of T512 and suppocire.
1466126|NCT03226457|Drug|Empagliflozin 25mg|Empagliflozin (SGLT2 inhibitor) 25 mg once daily for 6 weeks
1466127|NCT03226457|Drug|Placebo oral capsule|Capsules containing microcrystalline cellulose Ph Eur over encapsulated in a hard gelatine capsule shell to match the active comparator once daily for 6 weeks
1466128|NCT03226444|Drug|0.005% Lacripep|One drop (approximately 50 microliters) of 0.005% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
1466129|NCT03226444|Drug|0.01% Lacripep|One drop (approximately 50 microliters) of 0.01% ophthalmic solution will be administered three times a day (TID) to both eyes for four weeks.
1466130|NCT03226444|Drug|Placebo|One drop (approximately 50 microliters) of placebo solution will be administered three times a day (TID) to both eyes for four weeks.
1466132|NCT03226418|Drug|Cytarabine|Given IV
1466133|NCT03226418|Drug|Decitabine|Given IV
1466134|NCT03226418|Drug|Idarubicin|Given IV
1466135|NCT03226418|Other|Laboratory Biomarker Analysis|Correlative studies
1466136|NCT03226418|Other|Quality-of-Life Assessment|Ancillary studies
1466137|NCT03226418|Other|Questionnaire Administration|Ancillary studies
1466138|NCT03226405|Other|Patient Navigation Program|PN program improve access, timeliness and adherence with cancer treatment
1466139|NCT03226405|Other|Usual Care|the standard of care provided by the institution
1466140|NCT03226392|Drug|QAW039|QAW039 once daily
1466141|NCT03226392|Drug|Placebo|Placebo once daily
1466142|NCT03226366|Other|Immediate evaluation by multidisciplinary team|Simultaneous initial evaluation by the ED physician, nurse, and patient care associate
1466145|NCT03226340|Drug|S-amlodipine 2.5mg + Chlorthalidone 25mg|patients will receive S-amlodipine 2.5mg + Chlorthalidone 25mg p.o. once a day for 12 weeks.
1466146|NCT03226340|Drug|S-amlodipine 2.5mg + Telmisartan 40mg|patients will receive S-amlodipine 2.5mg + Telmisartan 40mg p.o. once a day for 12 weeks.
1466147|NCT03226327|Dietary Supplement|formula salt with limited sodium named ManLiKang|hypertension patients will use the formula salt with limited sodium ManLiKang in six weeks, and will be followed up at 1, 2, 4 and 6 weeks to assess the safety, the effect of reducing blood pressure and the change of 24-hour urine sodium.
1466148|NCT03226314|Procedure|stool sample|study will be proposed to all patients entering emergency ward or intensive care unit in Reunion Island university hospital. Upon consent, a stool sample will be taken (either directly on emitted stools or by rectal sampling) and analysed for enterobacteriaceae.
1466149|NCT03226301|Drug|Ibrutinib + Venetoclax 15 cycles|"Cycle 1 + 2: 420 mg ibrutinib, day 1-28 | Cycle 3: 420 mg ibrutinib, day 1-28 | 20 mg venetoclax, day 1-7 | 50 mg venetoclax, day 8-14 | 100 mg venetoclax, day 15-21 | 200 mg venetoclax, day 22-28 | Cycle 4-15: 420 mg ibrutinib, day 1-28 + 400mg venetoclax, day 1-28"
1466150|NCT03226301|Drug|Ibrutinib until progression/relapse|420mg ibrutinib daily until progression/relapse
1466151|NCT03226301|Drug|Possible reinitiation treatment: Ibrutinib + Venetoclax 12 cycles|"Cycle 1: 420 mg ibrutinib | 20 mg venetoclax, day 1-7 | 50 mg venetoclax, day 8-14 | 100 mg venetoclax, day 15-21 | 200 mg venetoclax, day 22-28 | cycles 2-12: 420 mg ibrutinib, day 1-28 + 400 mg venetoclax, day 1-28"
1466152|NCT03226275|Drug|Bisoprolol-Amlodipine FDC|Subjects will receive 5 mg/5 mg bisoprolol-amlodipine FDC tablet as a single oral dose on either Day 1 or Day 15 of the study.
1466153|NCT03226275|Drug|Bisoprolol|Subjects will receive 5 mg bisoprolol tablet as a single dose either on Day 1 or Day 15 of the study.
1466154|NCT03226275|Drug|Amlodipine|Subjects will receive 5 mg amlodipine tablet as a single oral dose on either Day 1 or Day 15 of the study.
1466221|NCT03225755|Drug|Growth hormone|Patients will receive growth hormone replacement therapy as per standard clinical care during this study.
1466222|NCT03225742|Diagnostic Test|to measure the residual volume after catheterization|after first micturition to measure the residual volume in bladder
1467708|NCT03214354|Radiation|Total Body Irradiation|TBI 300 cGy on Day -2
1466155|NCT03226262|Device|FFRangio|"FFRangio is a non-invasive image-based software device that provides physicians with a quantitative analysis of functional significance of the coronary lesion, similar to invasive FFR (Fractional Flow Reserve), and a qualitative three-dimensional model of the demonstrated coronary arteries, during routine PCI procedure. The CathWorks FFRangio software device is able to perform all required processing and calculations, based only on angiography images and hemodynamics information that are acquired during the coronary catheterization procedure.
The CathWorks FFRangioTM technology does not require any additional use of invasive devices, or any additional vasodilation treatment, as required by other known FFR techniques."
1466164|NCT03226236|Radiation|boost radiotherapy (XRT)|Three daily doses boost radiotherapy (XRT) at 6-12 Gy to at least 1, and up to a maximum of 5, metastatic fields, will be administrated on days -4 -3 -2 or -3 -2 -1 before the first and the third cycle of vaccine+IL-2
1466165|NCT03226236|Biological|Autologous DC vaccine|The first dose (7 to 14 x 10_6 total dendritic cells) will be performed with freshly prepared vaccine, 9 days after leukapheresis; on day +1 starting from cycle 2 (3 weeks after the first cycle, on completion of QA assessments on the cryopreserved products), 5 additional doses will be administered every 3 weeks until maximum six vaccines.
1466166|NCT03226236|Drug|High-Dose IL-2|high dose IL-2: 18 MIU/m2/day in 500cc administered by continuous IV infusion for 72 hours starting day +2.
1466167|NCT03226223|Drug|Intranasal Methamphetamine|Intranasal Methamphetamine HCL administered at a dose of 30mg per 70 kg of the participants' body weight)
1466168|NCT03226210|Drug|aspart insulin or lipro insulin|After completing OGTTS, enrolled subjects (new diagnosed T2DM) were randomly assigned into two groups: NovoRapid group (group Asp, Novo Nordisk, Bagsvaerd, Denmark) and Prandilin group (group Lis, Gan & Lee pharmaceuticals, Beijing, China) in CSII, combined with metformin (Bristol-Myers Squibb, USA) therapy. During insulin intensive therapy, every patient general use 1.5g metformin per day. If the patient is unable to tolerate the side effects of metformin, such as diarrhea, nausea, vomiting, allergies, etc., the daily dose of metformin is reduced to 1.0g. If the patients are still unable to tolerate the daily 1.0g of metformin, exit from this study.
1466169|NCT03226197|Dietary Supplement|Ketone ester drink|Ketone ester drink
1948227|NCT02629159|Drug|Adalimumab|Adalimumab subcutaneous injection
1466171|NCT03226145|Procedure|MRI Motility|MRI sequence to assess colonic motility
1466172|NCT03226145|Procedure|High Resolution Manometry|HRM of colon to assess motility
1466173|NCT03226145|Drug|Bisacodyl|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
1466174|NCT03226145|Drug|Hyoscine butylbromide|Given as agent to monitor effect on symptoms and then to compare with motility data. Drug itself not being tested.
1466175|NCT03226132|Behavioral|Brief Behavioral Therapy for Insomnia|Brief Behavioral Therapy for Insomnia
1466176|NCT03226132|Behavioral|Repeated Contact|Repeated Contact
1466177|NCT03226119|Diagnostic Test|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
1466178|NCT03226106|Behavioral|Physical Activity Behavior Intervention|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and researcher. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
1466179|NCT03226106|Other|Attention Control|Conventional rehabilitation with supplemental 10 telerehabilitation sessions that match the frequency and duration of the experimental arm. Attention control intervention provided as 10 telerehabilitation sessions of non-physical activity related education-only sessions.
1466180|NCT03226093|Procedure|Stromal Vascular Fraction|The fat was separated via centrifuge to isolate the SVF and the cells were delivered intraarticularly, intravenously, intrathecally, or intradiscally directly into the same patient
1466181|NCT03226080|Drug|Rocuronium|The neuromuscular blockade group will receive intravenous rocuronium
1466182|NCT03226080|Drug|Sugammadex|The neuromuscular blockade group will receive intravenous sugammadex for reversal of residual rocuronium
1466183|NCT03226080|Drug|Normal saline|Normal saline will be administered as a placebo in equal volume for the placebo group
1466186|NCT03226054|Behavioral|Lifestyle Modifications|Lifestyle Modifications to wean off of a Proton Pump Inhibitor, i.e. avoiding dietary triggers, waiting 3 hours to lie flat, and elevating the head of the bed
1466188|NCT03226028|Procedure|Music listening|Patient is given an ipod with earphone and with saved playlists of different music genres. Music listening session will be given for 30 minutes before and after surgery. Questionnaires will be asked to fill in. All the earphones will be disinfected following the hospital's infection control guideline.
1466189|NCT03226002|Device|Airtraq NT|channeled video laryngoscope for nasotracheal intubation
1466190|NCT03225989|Drug|LOAd703|Oncolytic adenovirus serotype 5/35 encoding TMZ-CD40L and 4-1BBL
1559468|NCT02530710|Drug|Placebo|
1948228|NCT02629159|Drug|Placebo for Adalimumab|Placebo subcutaneous Injection
1466191|NCT03225976|Device|Light-Emitting Diode Device|"The therapy will be applied on the second day of collection using a 15x30 cm2 LED blanket, with an equidistant distribution, with total energy per area of 30 J bilaterally on the quadriceps femoris muscle.
All LEDs will be calibrated prior to the start of applications in the Laboratory of Photobiophysics of the Faculty of Sciences and Letters of Ribeirão Preto, University of São Paulo, in which the wavelengths will be checked, the angle of radiation, power and power density."
1466192|NCT03225976|Device|Sham Light-Emitting Diode Device|The Sham Light-Emitting Diode Device will be applied on the second day of collection using a 15x30 cm2 LED blanket, with an equidistant distribution, with total energy per area of 30 J bilaterally on the quadriceps femoris muscle. At the time of application the device will not be activated
1466193|NCT03225963|Radiation|Chemoradiation with temozolomide|
1466194|NCT03225950|Other|In vitro stimulation of blood with periodontitis-associated- and control bacteria|Peripheral mononuclear blood cells are stimulated with periodontitis-associated- and control bacteria to measure the amount of positive cytokine-producing cells.
1466195|NCT03225950|Diagnostic Test|Anti-CCP- and anti-P.g.-antibodies titers|Anitbody titers will be measured in saliva and serum samples.
1466196|NCT03225950|Genetic|Analysis of selected single nucleotide polymorphisms (SNPs)|DNA obtained from saliva samples will be used to determine the genotype of the participants for selected SNPs.
1466197|NCT03225950|Diagnostic Test|periodontitis-associated bacteria presence|Determination of the presence of periodontitis-associated bacteria e.i. Porphyromonas gingivalis in saliva and blood samples.
1466198|NCT03225937|Drug|Trastuzumab, Lapatinib|Patients enrolled in Cohort A will receive lapatinib 1000 mg daily per os + trastuzumab 4 mg/kg iv load, followed by 2 mg/kg iv weekly. Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first.
1466199|NCT03225937|Drug|Pertuzumab, trastuzumab-emtansine|"Patients enrolled in Cohort B will receive pertuzumab 840 mg iv load, followed by 420 mg iv Q3weeks + trastuzumab-emtansine 3.6 mg/kg iv on day 1 of each subsequent 3 week cycle.
Patients will receive study medication until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever come first."
1466200|NCT03225924|Drug|Entospletinib|200mg or 400mg twice a day for 7 days every 21 cycles - total of 8 cycles
1466201|NCT03225924|Drug|Rituximab|cycles of 21 days - 375mg/m²
1466202|NCT03225924|Drug|Cyclophosphamide|cycles of 21 days - 750 mg/m²
1466203|NCT03225924|Drug|Doxorubicin|cycles of 21 days - 50mg/m²
1466204|NCT03225924|Drug|Vincristine|cycles of 21 days - 1.4mg/m²
1466205|NCT03225924|Drug|Prednisone|cycles of 21 days - 40mg/m²
1466206|NCT03225911|Device|Lateral wedge insole (insole)|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation.
1466207|NCT03225911|Device|simple knee sleeve (sleeve)|The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
1466208|NCT03225911|Device|simple knee sleeve + lateral wedge insole|The lateral wedge insole is an orthotic device that is placed inside the shoe. It has different thicknesses, with the lateral side being thicker than the medial side. This difference in thickness leads to the lateral side being higher than the medial side, with a different angulation. The simple knee sleeve is support which is worn around the knee with no hinge or provide external valgus moment.
1466209|NCT03225898|Other|Resistance Exercise with Blood Flow Restriction|A cuff will be used to restrict blood flow to the extremities.
1466210|NCT03225898|Other|High-intensity Resistance Exercise|Participants will follow a conventional resistance exercise regime.
1466211|NCT03225885|Other|Multimedia Information|Is a multi-media mobile application that addresses information about prematurity, resuscitation, and NICU hospitalization.
1466212|NCT03225885|Other|Printed Handout|Printed Handout is a gestational age specific handout that addresses resuscitation and prematurity information.
1466213|NCT03225859|Behavioral|Self-Management Program|This therapist-assisted self-management program will increase Veterans' self-efficacy for managing their PTSD, enable the maintenance or building upon gains made in trauma-focused therapy, and encourage engagement in meaningful activities. Patients will have four contacts with their providers over the ten weeks following trauma-focused therapy completion. The intervention will help patients: 1)self-monitor symptoms, 2) continue to practice skills learned in trauma-focused therapy, 3) acquire and apply additional coping skills, 4) engage in meaningful activities, and 5) set goals
1466218|NCT03225794|Diagnostic Test|Simian foamy virus Infection|Plasma samples are tested for the presence of antibodies directed against foamy viruses by western blotting (WB). The BHK-21 cell line infected with a chimpanzee foamy virus is used as a source of viral antigen. Samples are considered to be positive if there is net reactivity against the GAG doublet (70 to 74 kD). High molecular weight DNA will be extracted, from either buffy coats, cell cultures, or both, for molecular biology studies. The presence and quality of the DNA will be verified by amplification of a fragment of the beta-globin gene. Two regions of foamy virus genomic DNA will be amplified by nested PCR, using generic amplimers, giving rise to fragments of the integrase gene (425 bp) and LTR (109 bp).
1466219|NCT03225781|Device|Electrochemotherapy with Bleomycin|Application of Reversible Electroporation (Electrochemotherapy) with Bleomycin
1466220|NCT03225768|Behavioral|Guided Training|Guided training is an intervention strategy designed to help individuals identify barriers in their daily life and guide them to generate their own strategies to address these barriers. This intervention strategy is different from traditional direct skill training, in which rehabilitation practitioners are responsible for identifying their patients' challenges to perform activities and teaching them task-specific problem-solving strategies. Guided training has been applied in a variety of clinical populations, including individuals with stroke and TBI, and has demonstrated significant effect on improving independence with daily activities among persons with acute stroke-related cognitive impairments enrolled in inpatient rehabilitation.
1467709|NCT03214354|Drug|Sirolimus|Sirolimus is used for GVHD prophylaxis
1466227|NCT03225703|Behavioral|Hopping|A unilateral, hopping based exercise programme lasting six months.
1466228|NCT03225690|Drug|Morphine|Prevention of remifentanil induced hyperalgesia
1466229|NCT03225690|Drug|Serum physiologic|For placebo, serum physiologic will use
1466230|NCT03225677|Procedure|blood draw and muscle biopsy|One venous catheter will be used for bolus injection of multiple labeled AA at the beginning .The second venous catheter will inserted in the other arm for 5 ml of arterialized venous blood draw.Following the infusions, a single muscle biopsy will be performed from the vastus lateralis of the thigh using the Bergstromm needle.
1948229|NCT02629562|Biological|B12019 and Neulasta|GCSF, Growth Colony Stimulating Factor
1948230|NCT02624986|Drug|Idasanutlin|Participants will receive idasanutlin film-coated tablets at a starting dose of 100 mg daily on Days 1 to 5 of each 28-day cycle. Escalation will occur in at least 50-mg increments, and daily dosages greater than or equal to (>/=) 400 mg will be split into twice daily dosing.
1466233|NCT03225651|Biological|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear cells
1466234|NCT03225651|Behavioral|Psychological therapy and Rehabilitation|Psychological Therapy and Rehabilitation for autism children around 3 months
1466235|NCT03225638|Combination Product|Intramuscular ZENEO® injection of nominal strength|Sodium Chloride (0.9%)
1466236|NCT03225638|Combination Product|Intramuscular ZENEO® injection of low strength (upper limit)|Sodium Chloride (0.9%)
1466237|NCT03225638|Combination Product|Intramuscular ZENEO® injection of low strength (lower limit)|Sodium Chloride (0.9%)
1466238|NCT03225625|Procedure|Paraspinal|BMSC provided by paraspinal injection, intravenous and intranasal
1466239|NCT03225625|Procedure|Paraspinal EX|BMSC provided by paraspinal injections, intravenous and intranasal followed by exoskeleton or equivalent stimulation
1466240|NCT03225625|Procedure|Paraspinal VR|BMSC provided by paraspinal injections, intravenous and intranasal followed by virtual reality or equivalent visualization
1466241|NCT03225612|Device|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) is delivered by a percutaneous transcatheter procedure. The Trialign PTVAS procedure utilizes catheters and wires to deliver up to two sets of pledgeted sutures across the tricuspid annulus near the septal/posterior and the posterior/anterior commissures. Each set of implants is pulled together to plicate the posterior tricuspid annulus.
1948231|NCT02624986|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 (1 Cycle=28 days). For eligible participants with FL, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month for a maximum of up to 24 months.
1466243|NCT03225560|Other|Bowel Preparation|Bowel Preparation is completed prior to colonoscopy to ensure adequate visualization of the bowel lumen. This requires diet modifications and taking of medications at specified time intervals.
1948232|NCT02624986|Drug|Rituximab|Participants will receive a fixed dose of rituximab, 375 mg/m^2 IV infusion on Day 1 of Cycles 1-6. Post-induction treatment for eligible participants may be given at a dose of 375 mg/m^2 IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
1948233|NCT02617901|Radiation|Left hand DXA|"All recruited children will have a left hand DXA scan which will be anonymised and from which 3 observers will independently assess bone age according to Greulich and Pyle and TW3 methods on 2 separate occasions at least 4 weeks apart.
Radiographs and DXA will be read in random and varied order."
1466246|NCT03225521|Behavioral|HeartSteps: A just-in-time adaptive intervention for increasing physical activity amongst sedentary adults.|HeartSteps is an Android-based mHealth intervention that contains two main intervention components: contextually-tailored suggestions for activity and planning of the next day's activity. Activity suggestions provide individuals with actionable suggestions for how they can be active in their current context. Delivered suggestions are tailored based on time of day, user's location, day of the week (weekend/weekday), and weather. HeartSteps can deliver a user activity suggestions up to five times a day. Evening planning asks users to create or choose a plan of how they will be active on the following day. Planning can be delivered once a day, in the evening.
1466247|NCT03225508|Diagnostic Test|Linear Ultrasound to Measure Diaphragmatic Movement|A linear 10-12 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the zone of apposition. Diaphragmatic excursion will be measured from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken. The distance between the two external skin markings, one at the end of full expiration and one at the end of full inspiration will indicate the excursion of the diaphragm.
1466248|NCT03225508|Diagnostic Test|Curvilinear Ultrasound to Measure Diaphragmatic Movement|A curvilinear 2-5 MHz ultrasound probe will be used to determine diaphragmatic excursion, by examining the dome of the diaphragm. M-mode will be used to image the motion of the diaphragm from end inspiration to end expiration. The measurement will be repeated twice, and an average of the two will be taken.
1466249|NCT03225508|Diagnostic Test|Pulmonary function tests|Bedside pulmonary function tests to measure forced vital capacity (FVC). The FVC measures the maximal volume of gas that can be expired as forcefully and rapidly as possible after a maximal inspiration to total lung capacity. This measurement will help determine if the patient has any obstructive or restrictive diseases of the airways. Three measurements will be taken.
1466250|NCT03225495|Procedure|Standard implant|Arm - Standard Implant: implant placement in combination with guided bone regeneration;
1466251|NCT03225495|Procedure|Ultra-narrow implant|Arm - Ultra-narrow implant: implant placement without guided bone regeneration
1466252|NCT03225482|Behavioral|Motivationally Enhanced Compensatory Cognitive Training|ME-CCT is a manualized group-based behavioral intervention (10 weeks, 2 hours per week, 20 hours total) designed to improve cognitive and everyday functioning in patients with MCI.
1948234|NCT02611466|Drug|ASP7962|oral
1466253|NCT03225482|Behavioral|Goal-focused Supportive Contact|SC is a group therapy intervention that provides the same frequency and amount of therapist and other group member contact as ME-CCT, but does not provide training in cognitive strategies, lifestyle strategies, or motivational enhancement. The SC intervention focuses on setting and achieving short or long-term goals.
1466254|NCT03225469|Behavioral|reinforced family member education|Based on regular instructions for patent education, at least one family member who lives with the patient together will be given special instruction.
1466255|NCT03225456|Drug|Syntocinon|Intra-nasal oxytocin
1466256|NCT03225456|Drug|Placebos|Intra-nasal placebo
1466257|NCT03225430|Behavioral|Cognitive behavioural treatment for tics|Mainly based on the habit reversal treatment (HRT) and in addition to HRT components, they learn awareness training, relaxation, competing response, contingency management, and generalization training.
1466258|NCT03225430|Behavioral|Cognitive psychophysiological|Focus on the processes influencing thoughts and behaviors underlying tics.
1466259|NCT03225417|Drug|Ixazomib|Ixazomib capsules. Phase I: Starting dose of Ixazomib: 3.0 or 4.0 mg by day +1, +8 and +15. Phase II: Starting Dose of Ixazomib: Maximum tolerated dose from Phase I.
1466260|NCT03225417|Drug|Tacrolimus|Tacrolimus at a dose of 0.02 mg/kg/day and then 0.06 mg/kg/day.
1466261|NCT03225417|Drug|Sirolimus|Sirolimus oral solution. Starting 6 mg orally on day -5 and continued 4 mg per day. This drugs should be slowly tapered starting 3 months posttransplant in order to stop them at 9 to 12 months posttransplant according to physician criteria.
1466262|NCT03225404|Other|Epte group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
1466263|NCT03225404|Other|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
1466264|NCT03225391|Behavioral|nap from 0:00 to 3:00 hours|A nap from 0:00 to 3:00 hours during a night shift.
1466265|NCT03225391|Behavioral|nap from 3:00 to 6:00 hours|A nap from 3:00 to 6:00 hours during a night shift.
1466266|NCT03225378|Other|Fluid loading of 500 mL of crystalloid solution|Infusion of 500 mL of crystalloid solution in less than 15 minutes
1466267|NCT03225378|Other|Passive Leg Raising test|This intervention is done before the fluid loading in order to predict fluid responsiveness.
1466268|NCT03225365|Biological|Blood and biopsy sampling|"Blood samples (52mL) will be taken at week 1, week 3, week 7, week 13, week 53 or at the progression.
Skin biopsies will be taken at week 1, week 7, week 53 or at the progression."
1466273|NCT03225339|Dietary Supplement|Low Energy Diet|Low Energy Diet
1466274|NCT03225326|Drug|Computer controlled 4% articaine delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject)
1466275|NCT03225326|Drug|Conventional 4% articaine delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
1466276|NCT03225313|Drug|Bupivacaine Hydrochloride|ultra sound guided injection into the rectus sheath
1466277|NCT03225313|Drug|Normal saline|injected into rectus sheath & locally
1466278|NCT03225313|Drug|Bupivacaine Hydrochloride|injected locally
1466279|NCT03225300|Radiation|Simultaneous integrated boost|Simultaneous integrated boost (SIB), a field-in-field escalation technique, has been introduced to deliver higher radiation dose to the certain part of target with the same fractionation scheme.
1466281|NCT03225274|Other|Breathing Exercises as Therapeutic Play|"On day 1, pre- intervention assessment of respiratory status was done before administration of breathing exercises as therapeutic play and after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and then after 5 minutes 1st post-intervention assessment was done on same day.
On 2nd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day.
On 3rd day again after 5 minutes of administration of Nebulization therapy, breathing exercises was administered among children for 15 minutes once in a day and after 5 minutes again post-intervention assessment was done on same day."
1466282|NCT03225261|Dietary Supplement|Citrus extract|Citrus extract
1466283|NCT03225261|Dietary Supplement|Placebo|Maltodextrin
1466284|NCT03225248|Drug|UI05MSP015CT|UI05MSP015CT and Placebo of Gasmotin
1466285|NCT03225248|Drug|Gasmotin|Placebo of UI05MSP015CT and Gasmotin
1466286|NCT03225235|Radiation|SBRT|hypofractionated stereotactic radiotherapy (SBRT) using CyberKnife for Patients With Low and Intermediate Risk of Progression Prostate Cancer
1466287|NCT03225222|Diagnostic Test|biopsy|prostate biopsy
1466288|NCT03225209|Other|OPTIFAST|OPTIFAST meal replacement includes shakes, bars and soups. These meal replacements will completely replace the subject's diet for the first 12 weeks of the study (baseline-week 12) followed by a gradual transition back to prepared meals over 6 weeks (week 13-18). Attempt will be made to reduce or eliminate Lantus and Metformin as long as glycemic control is maintained.
1948235|NCT02611466|Drug|Naproxen|oral
1559565|NCT02530112|Other|Survey|
1948236|NCT02611466|Drug|Placebo|oral
1948237|NCT02609867|Device|Flowise Cerebral Flow Diverter|Flowise Cerebral Flow Diverter Placement
1466292|NCT03225092|Biological|Ultrasound-guided platelet rich plasma injection|Each participant will receive a single injection into the pes anserine bursa (using the Arthrex Angel system with a setting of 180cc of peripheral blood and 1% hematocrit concentration) under sterile technique
1466293|NCT03225066|Device|Poly-L-lactic acid - Sculptra|Participants using Sculptra - Poly-L-lactic acid 3 sessions in the first side and 3 sessions on the second side
1466294|NCT03225053|Device|MEP® technique|G1 (n = 15), referred to as LMF, will be submitted to the myofascial release technique consisting of: classic massage (superficial sliding, deep sliding, pumping-kneading, pulse and four-finger smear and sliding) Minutes. G2 (n = 15) will be applied to the MEP® technique, in which the needles will be introduced in three occasions during each session, in different points of the musculature of the most painful region, for a total of 3 minutes. The G3 (n = 15) will execute the two techniques above, being applied the first version Myofascial and later to the MEP®. G4 (n = 15) will be the control group, not performing any of the interventions. The reevaluations will occur immediately and after 48 hours of the intervention.
1466295|NCT03225040|Drug|Pegvisomant|Subjects receiving pegvisomant as part of their clinical care for acromegaly will be studied.
1466296|NCT03225027|Behavioral|Emotional judgment task|Participants had to indicate on a computer the emotional intensity of audio recordings.
1466297|NCT03225027|Behavioral|Post-experimental questionnaire|Participants will be invited to give us the cognitive strategy used to resolve the emotional judgment task.
1466298|NCT03225027|Behavioral|Recognition task|Participants will be invited to indicate which recordings they had heard during the emotional judgment task to verify that they have paid attention to the emotional task.
1466299|NCT03225027|Behavioral|Detection task|Participants indicate every time they heard a given sound in order to verify their audition level.
1466300|NCT03225027|Other|CAPE-42|This questionnaire allows evaluating the nature of psychotic experiences.
1466301|NCT03225027|Diagnostic Test|Trait Emotional Intelligence Questionnaire|To evaluate their emotional intelligence.
1466302|NCT03225027|Diagnostic Test|Positive And Negative Syndrome Scale|Evaluating the clinical status of patients with schizophrenia.
1466303|NCT03225027|Other|Mini International Neuropsychiatric Interview|Evaluating the exclusion criteria in healthy participants.
1466304|NCT03225014|Device|Accelerated Recovery Performance Wave Therapy|ARP Wave therapy utilizes direct current compounded with a high frequency double exponential background waveform that creates an electromyostimulation with characteristics that contrast with more conventional therapeutic neuromuscular electrical stimulation, including: interferential, microcurrent, galvanic, Russian stimulation, and iontophoresis. ARPWave therapy is a class II FDA medical device that has been approved for muscle re-education, relaxation of muscle spasms, increased neovascularization, prevention of disuse atrophy, and maintaining/increasing joint range of motion. The ARPWave Rx100 uses a main electrostimulation pulse of 40 to 500 cycles per second that is coupled with a background high-frequency carrier signal at 10,000 cycles per second. The polarity direction of electron flow is reversible within the unit and this is utilized as part of the therapy.
1466305|NCT03225014|Diagnostic Test|Physical therapy|PT protocol for traumatic knee pain focuses on flexibility and development of hip core strength over a 6 week period, visiting the therapist twice per week and encouraged to maintain a home exercise program (HEP). They will all receive a handout with basic exercises to use at home to ensure that progress with their HEP is maximized (Appendix I). Basic stretches for the hamstring and quadriceps muscles will also be provided with line drawings. During this treatment period the patients will complete a daily diary of time spent on the HEP with attestation from their parents or guardians, in order to improve compliance.
1466306|NCT03225001|Device|Edwards SAPIEN XT transcatheter valve, Model 9300TFX|Edwards SAPIEN XT THV system Model 9300TFX with the associated delivery systems.
1466307|NCT03224988|Device|TMS|A multimodal approach consisting of single pulse TMS, dual-coil TMS, and EEG will be used to examine whether synchronous hemispheric interactions associated with TMS will be present in weighted phase-lag coherence (WPLI), if these measures will be enhanced by in-phase TMS and reduced by counter-phase TMS, and if WPLI will be greater for normal controls than MCI-ADs.
1466309|NCT03224962|Device|fluorescence camera|drug - diagnostic test
1466310|NCT03224949|Other|Blood draw|Patients will have a one time blood draw
1466311|NCT03224936|Device|PSI|The PSI delivered by Masimo Root (Sedline) will be measured in all patients.
1466312|NCT03224923|Drug|Ticagrelor 60mg|twice daily
1466313|NCT03224923|Drug|Clopidogrel 75mg|once daily
1466314|NCT03224923|Drug|Aspirin 81 mg|once daily
1466315|NCT03224910|Other|Cytologic techniques used for rapid on site interpretation|Diagnostic efficiency of touch imprints of needle core biopsies vs smears of fine needle aspirations during rapid on-site interpretation
1466316|NCT03224897|Device|Cathodal tDCS|"Volunteers will be submitted to 1,0 mA cathodal stimulation during experiment. The stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
1466317|NCT03224897|Device|Anodal tDCS|"1,0mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 20 minutes, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system."
1466318|NCT03224897|Device|Sham tDCS|"1,0 mA anodal stimulation will be applied through a pair of saline-soaked surface sponge electrodes for 30 seconds, with a 10s ramp up and down. The 4,5 x 5,0 cm active electrode will be placed over the crossing point between Fz-T3 and F7-Cz and the 12 x 5 cm return electrode will be placed over Fp2 according to the 10-20 EEG system. The participant will not know when the stimulator is turned off and will continue to perform the experimental task as in the other groups."
1466319|NCT03224884|Procedure|Interscalene block|Ultrasound guided brachial plexus block injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL in the interscalene groove, under the prevertebral fascia.
1466320|NCT03224884|Procedure|Supraclavicular block|"Ultrasound guided brachial plexus injecting 20 mL of 0.5% levobupivacaine with 5 micrograms of epinephrine per mL (3 mL in the corner pocket followed by 17 mL posterolateral to the brachial plexus)."
1466321|NCT03224871|Drug|Intralesional IL-2|High dose IL-2 (HD-IL-2) is a cytokine produced endogenously by activated T cells and is effective in the treatment of a variety of malignancies because it has both immune-modulating and antitumor properties. In an attempt to take advantage of the robust immune activating effects of IL-2 but avoid the toxicity of high dose systemic IL-2 we and others have investigated the use of intralesional IL-2 injections.
1466322|NCT03224871|Drug|Nivolumab|Nivolumab is a fully humanized IgG4 PD-1 blocking antibody which has shown promising efficacy as an immune checkpoint inhibitor in lung cancer. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 2 weeks for patients on Nivolumab.
1466323|NCT03224871|Drug|Pembrolizumab|PD-1 inhibitor. Immune checkpoint blockade will be started on week 1 day 1, concurrent with radiotherapy and continue with cycles every 3 weeks for patients on Pembrolizumab.
1466324|NCT03224871|Radiation|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of therapy using an 8 Gy x 3 fractions palliative regimen. Fractions may be delivered on consecutive or every other day but must be completed during week 1 and will not be repeated in future cycles.
1466325|NCT03224858|Other|SUMMIT intervention|See description in experimental arm.
1466326|NCT03224858|Other|Enhanced usual care|See description in active comparator arm.
1466327|NCT03224845|Behavioral|Cognitive behavioural skills training|The intervention will be delivered in two stages: First, the parent with an anxiety disorder will attend between six and sixteen weekly sessions of cognitive behavioural skills training focusing on their own anxiety. They will work on developing behaviours that will help them become less anxious in the long-run and on learning to evaluate danger in a realistic way. Next, the parent will take part in four to eight weekly sessions of anti-anxiety parenting skills training aiming to help them transfer the skills that they learned into parenting their children. In the parenting intervention, the parents will be guided to gradually expose their children to new situations, build communication skills and confidence, in addition to general parenting skills and principles.
1466328|NCT03224832|Procedure|Artery-first Approach|"Dissection at the origin of the superior mesenteric artery and the celiac trunk all along their right side of the vessels. -En bloc resection of the primary tumor and regional lymph nodes through complete excision of the mesopancreatic plane, utilizing the artery-first approach.
The mesopancreatic plane consists of the pancreas head, the uncinate process of the pancreas, and the meso-pancreatoduodenum.
All the tissues that lay in this triangular space (SMA down, CT up, and SMV-PV anterior) is cleared.
Then the investigators continue the dissection along the right then anterior surface of the SMV and PV until reaching the dissected posterior surface the neck of the pancreas .
Last step is the division of the neck of the pancreas. After the specimen is removed and before it is sent to the pathology we put mark on each boundary of the specimen one towards SMA, another towards PV/SMV area and the last towards the posterior surface of the mesopancreas."
1466329|NCT03224832|Procedure|Standard Approach|In standard approach after kocharization of the duodenum the investigators start to asses the tunnel under the neck of the pancreas whether tumor infilterating PV/SMV axis and if not we cut the neck of pancreas early in the procedure then we continue to dissect the uncinate process and control pancreatoduodenal vessels and draining lymph nodes and LNS around portal vein and up to hepatic artery and we will add to the standard procedure the previously defined mesopancreatic triangle dissection which lies between SMA caudal, Coeliac artery cranial and PV/SMV axis anterior and the specimen will be marked and sent as previous to pathology.
1466331|NCT03224806|Other|Wholegrain bread|156.8g wholegrain bread
1466332|NCT03224806|Other|White bread|122.6g white bread
1466333|NCT03224806|Other|15% fiber-rich bread|139.2g bread made with 15% added wheat bran
1466334|NCT03224806|Other|30% fiber-rich bread|166.5g bread made with 30% added wheat bran
1466335|NCT03224793|Drug|BIIB059|Administered as specified in the treatment arm
1466336|NCT03224793|Drug|Placebo|Administered as specified in the treatment arm
1466337|NCT03224780|Diagnostic Test|maternal serum creatine kinase|Biochemical marker
1466338|NCT03224780|Diagnostic Test|3D Doppler ultrasound|Doppler for placental vessels
1466339|NCT03224767|Drug|Vemurafenib|Given PO
1466340|NCT03224767|Drug|Cobimetinib|Given PO
1466341|NCT03224767|Other|Laboratory Biomarker Analysis|Correlative studies
1466342|NCT03224767|Other|Quality-of-Life Assessment|Ancillary studies
1466343|NCT03224754|Behavioral|Determination of risk of malignancy of these thyroid lesions|This is a retrospective study that will help us to find out the rate of AUS/ FLUS in our population of Mississippi and the percentage of malignancies in these cases.The specimens will be searched through the University of Mississippi Medical Center's Pathology Laboratory Information system (Copath), from April 2010 to December 2016. The retrospective cases will be retrieved using natural language search. The total number of thyroid FNA will be retrieved and the percentage of cases with AUS/ FLUS will be calculated. Followup of these cases will be done looking for additional fine needle aspirations of the thyroid or thyroidectomy specimens. Cases with diagnosis of AUS/ FLUS will have correlation with the diagnosis on the thyroidectomy specimens if available in our system.
1466344|NCT03224741|Behavioral|Monetary Incentive|Subjects in this condition will be read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information.Iin addition, they will be told that if they will get tested for HIV/AIDS within the next two weeks, they will receive $10 (the US dollar became Ecuador's official currency in 2001).
1466345|NCT03224741|Behavioral|Information|Subjects assigned to this condition are read a script informing them of the benefits and importance of routine HIV/AIDS testing for themselves, the benefits for one's partner and loved ones, and for the broader community; they are also given a flyer including the same information. Then, they are invited to get tested in the next two weeks.
1466954|NCT03219996|Other|prognosis|The participants were divided into two groups based on survival at their hospital discharge.
1466346|NCT03224741|Behavioral|Active Choice|"Subjects in this condition will receive the same information and flyer as in T1; in addition, they are told that they have the opportunity to express their intention to get tested for HIV/AIDS. To this aim, they will be given a sheet of paper and asked to tick one of two boxes. The first box will say I intend to get tested within the next two weeks, and the second will say I will consider getting tested within the next two weeks but I am not ready to commit at this time. They will also be asked to write their initials at the bottom of the sheet, and will be told to keep it. This is a form of soft commitment which has proven effective in other contexts (Bryan et al. 2010)."
1466347|NCT03224728|Device|intraocular lens|
1466348|NCT03224715|Other|DNA Repair Enzyme Cream|ver-the-counter cosmeceutical. We were going to be using it adjunctively before standard treatment of the actinic cheilitis was done
1466352|NCT03224663|Other|Module based learning|self-reading method using learner's guide module on FBNC provided by Department of Pediatrics.administered 45 minutes
1466353|NCT03224663|Other|Mobile application based learning|"learning method using android based mobile application on Facility Based Newborn Care provided by Division of Department of Pediatrics WHO-CC AIIMS FBNC deals with posters , videos , Modules.administered 45 minutes"
1466354|NCT03224650|Procedure|Surgery|Surgery
1466355|NCT03224637|Procedure|radiofrequency|radiofrequency done in the three genicular nerves upper medial and upper lateral and lower medial
1466356|NCT03224637|Drug|Paracetamol (conventional)|
1466357|NCT03224637|Drug|Ketorolac Tromethamine (conventional)|
1466358|NCT03224624|Other|self-management protocol for hypertension care|participants in this arm will be taught to monitor and record their blood pressure. On a regular basis they will evaluate their blood pressure record and follow an algorithm to decide whether to adjust their medication.
1466359|NCT03224611|Device|light wand|"The light wand is used as a stylet of the flexible LMA. When the investigator inserts the flexible LMA in light wand group, the correct position of the LMA is confirmed by the light."
1466360|NCT03224598|Drug|A-101 Topical Solution 40%|A-101 Topical Solution 40%
1466361|NCT03224585|Drug|Anakinra|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.
Period 2 (Time 72 hours to 7 days) - anakinra 100 mg subcutaneous injections daily for 4 days"
1466362|NCT03224585|Drug|Placebo|"Period 1 (Time 0-72 hours) - this will be an open-label phase during which all subjects meeting enrollment criteria will receive anakinra 100 mg subcutaneously injections daily for 3 days.
Period 2 (Time 72 hours to 7 days) - placebo 100 mg saline subcutaneous injections daily for 4 days"
1466363|NCT03224572|Drug|high-dose vitamin C 20gm|High-dose vitamin C 20 gm, two times per week, and total 4-week treatment.
1466364|NCT03224572|Other|normal saline|250ml, two times per week, and total 4-week treatment
1466365|NCT03224572|Drug|oral vitamin C 500mg|500mg qd for 4 weeks
1466367|NCT03224546|Behavioral|Contingency Management|Subjects will receive payments for providing cocaine negative urine samples.
1466368|NCT03224533|Diagnostic Test|Diabetes Outcome|based on self report definition, fasting plasma glucose, and hemoglobin A1c
1466369|NCT03224520|Behavioral|Recommender CTHC|Enhanced Messaging
1466370|NCT03224520|Behavioral|Standard CTHC|Standard Messaging
1466371|NCT03224520|Other|Peer Recruitment|Tools to facilitate smokers' recruiting their peers
1466372|NCT03224520|Other|Standard Online Recruitment|Search Engine and Social Media Advertisements
1466373|NCT03224507|Drug|KRdD followed by auto-HCT|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will be followed by autologous hematopoietic cell transplantation and KRdD consolidation.
1466374|NCT03224507|Drug|KRdD only|Dosages of each drug will vary depending on therapy type and cycle number. KRdD therapy will not be followed by autologous hematopoietic cell transplantation but will proceed with KRdD consolidation.
1466375|NCT03224494|Device|Rapid Barostat Bag|Both healthy controls (n= 100) and IBS patients (n=100) will undergo anorectal studies using a Rapid barostat bag catheter.
1466376|NCT03224494|Other|IBS severity scoring system questionnaire (IBS-SSS)|We will correlate the changes to IBS symptoms using the IBS severity scoring system questionnaire (IBS-SSS). The questionnaire will be administered twice for IBS patients who have consented to return for a second study visit, at each of the two RBB studies.
1466377|NCT03224494|Other|HAD scale questionnaire|It is a validated anxiety and depression questionnaire
1466378|NCT03224481|Other|Electronic reminder|The frequency and content of the reminders will be informed by the qualitative findings of an ongoing trial, but are likely to include an intra-oral photograph taken pre-treatment and following removal of the active appliances, instructions on the necessary duration of retention, advice on maintenance of retainers, departmental details, advice on appropriate management for appliance breakages, and delineation of the implication of suboptimal retainer wear.
1466379|NCT03224468|Drug|Medical Marijuana|Patients in this group can choose when, where, and how much medical marijuana to use.
1466380|NCT03224442|Procedure|PRF|soft tissue augmentation by prf
1466381|NCT03224442|Procedure|Palatal Pedicle|soft tissue augmentation by palatal pedicle
1466382|NCT03224429|Other|Qualitative Interviews Decisional Needs Assessment|Subjects will participate in an open-ended interview regarding type of sickle cell disease, complications, current treatment, and experiences with decision making and sickle cell treatment. Participants will be asked to describe what is important when making health care decisions. Treatment options (hydroxyurea, chronic or monthly blood transfusions, and bone marrow transplantation) will be discussed as well as how a web-based decision aid tool should be developed. The interview will be audio recorded and will take 45 to 60 minutes to complete.
1466457|NCT03223922|Radiation|whole brain radiation therapy|Corpus Callosum Genu-Sparing Whole Brain Radiation Therapy Genu-sparing whole brain radiation therapy (GS-WBRT) 30 Gy in 3 Gy per fraction
1466458|NCT03223909|Drug|PRO-087|0.1% sodium hyaluronate, free-preservative 0.18% chondroitin sulphate
1466383|NCT03224429|Other|Sickle Cell Decision Aid|Participants will be asked to navigate the Sickle Cell Decision Aid site that provides information about risks and benefits of therapies. As the participant navigates the site, the interviewer will ask the participants to describe thoughts about the site, including but not limited to ease of navigation, content and construction. Testing may be performed in-person or via telephone. Interviews will be audio recorded and take up to 60 to 90 minutes to complete.
1466384|NCT03224416|Other|Alcohol Administration|In the alcohol condition (target BrAC = 0.080g%), the participant will be told he is receiving alcohol and will receive beverages of 1:4 parts vodka and tonic water with dashes of lime juice and mint, all mixed in his presence.
1466385|NCT03224416|Other|Placebo Alcohol Administration|"In the placebo condition (target BrAC = 0.000g%), the participant will be told he is receiving alcohol but will receive beverages of 1:4 parts flat tonic water (served from a vodka bottle) and tonic water, with a minimal amount of vodka floated on the surface (using a lime juice bottle) to provide the smell and taste of vodka, with lime juice and mint, all mixed in his presence and served in glasses with vodka-soaked rims."
1466386|NCT03224416|Other|No Alcohol Administration|In the true control (or nonalcohol) condition, the participant will be told he is receiving no alcohol and will be given water (poured in his presence) in a volume comparable to the other conditions.
1466387|NCT03224403|Drug|Test acetaminophen|single dose of 2 Test acetaminophen 500 mg tablets
1466388|NCT03224403|Drug|Commercial acetaminophen|single dose of 2 acetaminophen 500 mg caplets
1466389|NCT03224403|Drug|Commercial ibuprofen|Single dose of 2 ibuprofen 200 mg Liquid-filled Capsules
1466390|NCT03224403|Drug|Placebo|2 placebo caplets
1948238|NCT02609776|Drug|JNJ-61186372|The first cohort of participants will receive intravenous infusions of JNJ-61186372 at a dose of 140 milligram (mg). Each subsequent cohort will receive intravenous infusions of JNJ-61186372 at an increased dose level. Dose escalation will continue until the maximum tolerated dose is reached or all planned doses are administered. Participants will receive intravenous infusion of JNJ-61186372 once weekly during cycle 1 and once every 2 weeks during subsequent cycles. The duration of each treatment cycle is 28 days.
1466392|NCT03224377|Diagnostic Test|anti mutated citrullinated vimentin antibodies|Blood sampling using ELisa technique
1466393|NCT03224364|Procedure|nonsolo LA|This patient is scheduled to undergo nonsolo laparoscpic appendectomy.
1466394|NCT03224364|Procedure|solo LA|This patient is scheduled to undergo solo laparoscpic appendectomy.
1466401|NCT03224338|Drug|Dolutegravir 50 mg|Dolutegravir will be used in combination with 2 nucleoside reverse transcriptase inhibitors (NRTIs). The NRTIs used in combination with DTG will be abacavir (ABC) plus lamivudine (3TC) or tenofovir (TDF) plus emtricitabine (FTC), which is in line with the current standard of care. The combination ABC/3TC/DTG will be preferential except in case of hepatitis B co-infection or in case the subject has a positive HLA-B*5701 allele screening assessment.
1466402|NCT03224325|Drug|TAK-831|Tak-831 tablets or suspension.
1466403|NCT03224325|Drug|Placebo|TAK-831 placebo-matching
1466404|NCT03224312|Other|no intervention|no intervention
1466405|NCT03224299|Drug|Octenidine Dihydrochloride [OCT] in Isopropyl Alcohol (1)|Application of investigational product #1
1466406|NCT03224299|Drug|Octenidine Dihydrochloride [OCT] in Isopropyl Alcohol (2)|Application of investigational product #2
1466407|NCT03224299|Other|ChloraPrep|Application of active control
1466408|NCT03224286|Device|Pressure sensitive mat|Infant placed on pressure sensitive mat and has physiological parameters recorded.
1466409|NCT03224273|Other|proximal box inlay retained bridge|inlay retained bridge is the less invasive type to restore single missing teeth in the posterior area
1466410|NCT03224260|Drug|BMS-986177|Oral Suspension
1466411|NCT03224260|Other|Matched Placebo|Oral Suspension
1466412|NCT03224247|Procedure|Transverse cutting|Transverse cutting and/or pulling.of lower uterine segment during lower cesarean section extending the uterine incision laterally.
1466413|NCT03224247|Procedure|vertical splitting|vertical splitting of lower uterine segment during lower cesarean section making the direction of traction up and downward instead of being laterally and we suppose that this will allow the tissues to split along their natural arrangement, decreasing the probability of extension of the wound into the uterine vessels, thus; decreasing blood loss; operative time and maternal recovery.
1948239|NCT02609776|Drug|JNJ-61186372|Participants will receive intravenous infusions of JNJ-61186372 at a recommended Phase 2 dose (RP2D) regimen. The duration of each treatment cycle is 28 days.
1948240|NCT02608034|Drug|Itraconazole|Itraconazole will be administered as a 200 mg oral solution QD during Part 1 only for 20 consecutive days.
1466416|NCT03224221|Drug|Apatinib|Patients will receive Apatinib at 500mg/times,oral one times daily for 28 days
1466417|NCT03224221|Drug|fluorouracil and platinum|the dosage of the fluorouracil and platinum need to be determined by the doctors according to the actual condition of the patients
1466418|NCT03224208|Drug|Vemurafenib|Vemurafenib will be orally adminitered at 960 mg b.i.d. on Days 1-28
1466419|NCT03224208|Drug|Cobimetinib|Cobimetinib will be given orally at 60 mg qd on Days 1−21 of each 28-day treatment cycle
1466420|NCT03224182|Drug|Qapzola|One dose of 8 mg Qapzola on Day 1
1466421|NCT03224182|Drug|Placebo|One dose of Placebo on Day 1
1466422|NCT03224169|Behavioral|Directly observed hand hygiene|Directly observed hand hygiene to the residents and staff
1466423|NCT03224156|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Patients undergo baseline characterisation including CMR, ECG, blood samples prior to ICD implantation.
1467309|NCT03217396|Procedure|lumbar puncture|lumbar puncture performed to detect OCB for diagnostic purposes
1948241|NCT02608034|Drug|Rifampin|Rifampin will be administered as a 600 mg oral solution QD during Part 2 only for 20 consecutive days.
1466424|NCT03224143|Behavioral|Doll Therapy Intervention|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the doll in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the doll in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the doll after the second request, the N will not insist and she will leave. If the doll will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
1466425|NCT03224143|Behavioral|active control group (SI)|"Daily sessions, lasting an hour, will take place in a room known to patients (P). The only people in the room will be a nurse (N) and the researcher with video-tape, never interacting with P. The procedure is: the N will accompany the P in the room and the P will take a seat. The N will put the cube in front of the P and will say Good morning Mr./Mrs....look, with a quiet voice. If the P will not take it at the first attempt, the N will sit down in front of her holding the cube in the arms and will wait for 2 minutes. The N will invite the PWD again. If the P will not take the cube after the second request, the N will not insist and she will leave. If the cube will be taken, the N will leave the P and say I have to go, goodbye Mr./Mrs. . . ... The gaze will always be upon the P."
1466426|NCT03224130|Other|Nurse Phone Call|One time nurse phone call within 96 hours of discharge.
1466427|NCT03224130|Other|Standard of Care|Standard of Care
1466430|NCT03224104|Drug|TG02|"The initial cohorts of Groups A and B will receive TG02 at 200 mg on intermittent schedules in combination with either RT or TMZ. TG02 will be escalated to 250 mg if the dose decision criteria are met in the first cohort.
The initial cohort in Group C will receive TG02 alone at 250 mg on intermittent schedules. It will be continued at this dose if feasible or decreased to 200 or 150 mg if not tolerated."
1466431|NCT03224104|Radiation|Radiation Therapy|For group A standard involved-field hypofractionated RT will be administered at 39.9 Gy in 15 fractions of 2.66 Gy for 3 weeks
1466432|NCT03224104|Drug|Temozolomide|For group B TMZ will be given in the standard 28-day cycle regimen (150-200 mg/m2) for 5 days.
1466433|NCT03224078|Other|data extraction|No Special interventions except from data extraction form the respective routine data sources are planned .
1466434|NCT03224065|Diagnostic Test|Genotype detected through GenSeizer high-throughput gene capture technology|The sputum and/or alveolar lavage fluid of the optimal treatment group was first identified by GenSeizer, which was used to remove the resistant agents and choose the sensitive agents, so as to optimize the initial antimicrobial program. All agents are within the recommended range of 2007 ATS / IDSA Guidelines. All treatment regimens need to be corrected in time according to the final results of culture and in vitro susceptibility testing.
1466435|NCT03224039|Drug|Sufentanil|Intranasal for one dose (experimental)
1466436|NCT03224039|Drug|Normal saline|Intravenous for one dose as placebo (to be administered with sufentanil or morphine arm as part of double-blinding). If patients are randomized to receive IN sufentanil, they will also receive IV normal saline. If patients are randomized to receive IV morphine, they will also receive IN normal saline.
1466437|NCT03224039|Drug|Morphine|intravenous push for one dose (active comparator)
1466438|NCT03224013|Procedure|LASIK|LASIK with concurrent prophylactic high fluence crosslinking in right eye ( After the excimer laser ablation, and with the flap folded onto itself and protected with a dry sponge, one drop of Vibex Rapid™ , consisting of 0.10% saline-diluted riboflavin (a very slightly hypotonic solution, mixed with hydroxypropyl methylcellulose, a dextran substitute), was placed on the exposed stromal bed afforded by the open LASIK flap and carefully spread over the bed area with an irrigating cannula for 60 seconds and LASIK only in left eye
1466439|NCT03224000|Procedure|Modified Barium Swallow (MBS)|Modified barium swallow (MBS) performed at baseline and at 6 months, 2 years, and 5 years after finishing radiation therapy.
1466440|NCT03224000|Behavioral|Swallowing Questionnaire|Swallowing questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
1466441|NCT03224000|Behavioral|Symptom Questionnaire|Symptom questionnaire completed at baseline, every week while receiving radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
1466442|NCT03224000|Procedure|Video-Strobe Procedure|Video-strobe procedure to check vocal cords performed at baseline, at week 3 during radiation therapy, and at 6 months, 2 years, and 5 years after finishing radiation therapy.
1466443|NCT03224000|Procedure|MRI Guided Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned with MRI guidance.
1466444|NCT03224000|Procedure|Standard-of-Care Intensity Modulated Radiotherapy (IMRT) Planning|IMRT planned by standard-of-care.
1466445|NCT03224000|Radiation|Intensity Modulated Radiotherapy (IMRT)|Participants receive an individualized prescription of up to 70 Gy in 33 fractions with radiation therapy (RT) given once daily, 5 days a week, over 6 weeks and 3 days.
1466446|NCT03223987|Dietary Supplement|Strath® Kräuterhefe Original (liquid)|"The food supplement is taken 3 x 1 coffee spoon à 5ml = 15ml per day for three weeks.
Stool analysis at 2nd visit and last visit. Before-after study."
1466447|NCT03223974|Device|Paclitaxel DCB|Balloon/vessel diameter ratio 0.8-1.0, 8-10 ATM, lasting for >30 seconds. If quantitative coronary angiography determines residual stenosis ≤ 30% , it is considered to be a successful operation.
1466448|NCT03223974|Device|DES|MB should be sufficiently predilated to facilitate the positioning of the stent and the stent residual stenosis should be ≤10% to be a successful operation.
1466449|NCT03223961|Drug|EPREX|60 000 U/week for at least 12 weeks
1466450|NCT03223948|Device|'Optiflow'|High flow nasal oxygen delivery device 'Optiflow'
1466451|NCT03223935|Other|Corn nuts|Roasted corn nut snack
1466452|NCT03223935|Other|Chickpeas|Roasted chickpea snack
1466453|NCT03223935|Other|Yellow peas|Roasted yellow pea snack
1466454|NCT03223935|Other|Pinto beans|Roasted pinto bean snack
1466455|NCT03223935|Other|Soybeans|Roasted soybean snack
1466456|NCT03223935|Other|Almonds|Roasted almond snack
1467344|NCT03217149|Drug|MV|MV is given to infant with ARDS
1560252|NCT02525172|Drug|Methotrexate|
1466459|NCT03223909|Drug|Systane Ultra|Is a sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, sorbitol, aminomethylpropanol, boric acid, potassium chloride, sodium chloride and POLYQUAD® (poly-hydronium chloride) 0.001% as preservative.
1466460|NCT03223909|Drug|Systane Ultra Preservative Free|Polyethylene Glycol 400 0.4%Lubricant, Propylene Glycol 0.3% Lubricant,
1466461|NCT03223896|Drug|Naloxone hydrochloride 20mg/ml|Nasal spray
1466462|NCT03223883|Drug|Curcumin|Oral supplement for 12 months
1466463|NCT03223883|Other|Placebo|Oral placebo for 12 months
1466464|NCT03223870|Diagnostic Test|Diagnostic|Diagnostic
1466465|NCT03223857|Procedure|Femtosecond-laser-assisted lens exchange|Bilateral implantation of multifocal intraocular lens (MIOL) following femtosecond-laser-assisted lens exchange
1466466|NCT03223844|Drug|Dextroamphetamine Sulfate|Repeated oral administration of dexamphetamine 0.4mg/KG bodyweight four times.
1466467|NCT03223831|Other|Partially covered pyloro-duodenal stent|The PCDS (Niti-S COMVITM - Flare, Taewoong, Gyeonggi-do, South Korea) used in the current study is a partially covered metallic pyloro-duodenal stent. It consists of two portions (Figure 1). The stent is 2cm in diameter and the proximal 2cm of the stent is uncovered and flared. This is designed to provide anchorage of the stent to surrounding tissue and reduce the risk of migration. The remaining of the stent is covered, where a polytetrafluoroethylene (PTFE) membrane is held between two nitinol mesh to prevent the risk of tumour ingrowth into the stent. The stents come in lengths of 6, 8, 10 & 12cm.
1466468|NCT03223831|Other|Uncovered pyloro-duodenal stents|The UCDS (Niti-S pyloric-duodenal D stent, Taewoong, Gyeonggi-do, South Korea) used in the current study is an uncovered stent made of nitinol wire, with a diameter of 20mm and length of 6,8,10,12cm. This stent is an unfixed-cell braided stent with low axial force, high flexibility and good conformability.
1466469|NCT03223818|Other|Fast-track peri-operative program|"Patients who are scheduled for elective liver resection will be screened in clinic or in wards for the eligibility for ERAS program. Patient will then visit a nurse-led clinic for pre-operative assessment of risk adjustment and education. A guided tour on surgical ward and an information booklet about preoperative management will be given.
All patients will receive local infiltration of local anaesthesia (0.25% levobupivacaine) followed by continuous wound instillation using the On-Q PainBuster System balloon pump. Pain control will be supplemented by using opioid-sparing multimodal analgesia."
1466470|NCT03223805|Other|Respiratory Distress Symptom Intervention|"The RDSI comprises of four components
Controlled breathing techniques - consists of diaphragmatic breathing exercises and calming techniques practised twice a day and used as needed for episodes of intense breathlessness and/or anxiety
Cough suppression techniques - includes education (capacity for voluntary cough easing, identifying warning signs for cough and replace with modified swallow technique or relaxed throat breath
Acupressure: a small number of acupressure points are taught: L7, L9, LI4 (located on the hand and wrist areas), CV21 and 22 (sternum), and ST36 (knee). Patients can select any of these points in any combination to apply pressure for one-minute at least twice a day for symptom relief
Exercise: Individually-tailored exercise plan, for example, walking incrementally increasing distances in their local environment, incorporating breathing techniques as required"
1466471|NCT03223792|Other|Control|Routine cow's milk-based infant formula
1466472|NCT03223792|Other|Investigational|Partially-hydrolyzed cow's milk protein infant formula
1466473|NCT03223779|Drug|TAS-102|Trifluridine stops DNA replication which may prevent the cancer cells from growing
1466474|NCT03223779|Radiation|Photon SBRT|SBRT stands for Stereotactic Body Radiation Therapy. Radiation may help to kill the cancer cells while protecting your normal tissue cells
1466475|NCT03223753|Other|Educational Intervention|Receive educational handouts about to physical activity
1466476|NCT03223753|Other|Internet-Based Intervention|Access limited version of Sqord website
1466477|NCT03223753|Other|Internet-Based Intervention|Access full version of interactive reward-based Sqord website
1466478|NCT03223753|Other|Laboratory Biomarker Analysis|Correlative studies
1466479|NCT03223753|Device|Monitoring Device|Wear Sqord activity monitor
1466480|NCT03223753|Other|Quality-of-Life Assessment|Ancillary studies
1466481|NCT03223753|Other|Questionnaire Administration|Ancillary studies
1466482|NCT03223740|Other|Arm 1 pre-operative chemoradiation|"Chemotherapy 1:
First 2 courses of chemotherapy with the Capacitabine /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a one-hour bolus on day1-5.
Chemoradiotherapy:
At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.
Chemotherapy2:
Four to five weeks after chemoradiotherapy, Restaged and surgical resection, a D2 resection is encouraged. Peritoneal cytology will be obtained. The J-tube will be left in for at least 8 weeks after surgery to supplement patient's nutrition.
2nd courses of chemotherapy with the Capacitabine. Capacitabine1 g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29."
1466483|NCT03223740|Other|Arm 2 post operative chemoradiation|"Surgical resection, a D2 resection is encouraged.
Chemotherapy 1:
All patients will first receive two courses of chemotherapy with the Capacitabin /cisplatin/ combination.Capacitabine1 g/me2 day 1 to 14. Cisplatin will be given at 20 mg/m2 as a bolus on day1-5. Chemotherapywill be repeated beginning on Day 22.
Chemoradiotherapy:
At the end of the second 21 days of chemotherapy and one week of rest (day 57), a total of 45 Gy(1.8 Gyfx/d) of radiotherapy will be given with concurrent capacitabine 625 mg/m2 and weekly Taxol 45mg/m2 over 3 hours for 5 weeks.
Chemotherapy2:
2nd courses of chemotherapy with the Capacitabin. Capacitabine 1g/me2 day 1 to 14. Chemotherapy will be repeated beginning on Day 29"
1466484|NCT03223727|Diagnostic Test|Blood tests|Blood tests for several bone markers (see summary)
1466485|NCT03223714|Drug|Conbercept Ophthalmic Injection|
1466486|NCT03223714|Drug|sham injection|
1466518|NCT03223454|Biological|biological amnion|Biological amnion is purchased from JiangXi RuiJi BioTechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
1466519|NCT03223428|Drug|Xermelo|This study will include patients with carcinoid syndrome who are initiating treatment with XERMELO.
1466487|NCT03223701|Combination Product|Solum IV, Bone Marrow Concentrate with general fluid concentrate (GFC) in Transforaminal Lumbar Interbody Fusion|The bone marrow aspirate (BMA) will be taken from the iliac crest of the enrolled subjects. The BMA will be transferred to a processor that will use ART BMC Plus (Celling Biosciences, Austin, TX) platform technology to obtain the BMC preparation. The plasma component that remains as a by-product of generating the BMC will then be concentrated by the ART BMC Plus device to create a concentrated plasma/general fluid concentrate (GFC). The enrolled subjects' BMC and GFC will be provided to the principle investigator who will combine the two together with Solum IV using the Graft Delivery Kit (Celling Biosciences) and perform a TLIF procedure. (See Appendix B for Graft Delivery Kit). All subjects will be assigned to receive lumbar interbody fusion via a TLIF approach with Solum IV bone graft and BMC with GFC in the interbody space of a TLIF using cynch bullet cage (@SpineSmith) and Stryker based pedicle screw system (Xia 3 system).
1466488|NCT03223688|Behavioral|Day-Care early intervention program|The daily treatment session had eight children along with their major caregivers. The treatment was conducted by two experienced occupational therapists (OT), and each session lasted for four hours in the week-day morning with a 10-minute break. The goal of the sessions was to enhance children's development through cognitive training, behavioral modification plan and parenting skill training.
1466489|NCT03223688|Behavioral|OPD+SI intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training. Adjunctive SI therapy was also performed by said OT for improving children's sensory motor development in an additional hour.
1466490|NCT03223688|Behavioral|OPD intervention program|The treatment program had eight children along with their major caregivers. The treatment was also performed by two experienced OT, and each session lasted for one hours, once a week. The sessions consisted of cognitive training, behavioral modification plan and parenting skill training.
1466491|NCT03223675|Radiation|hippocampal-sparing WBRT|
1948242|NCT02608034|Drug|Vemurafenib|Vemurafenib will be administered in both Part 1 and Part 2 at a dose of 980 mg BID for at least 40 conseutive days.
1948243|NCT02605785|Drug|F-18 AV 1451|Tau PET scan
1466494|NCT03223649|Behavioral|Walking Bouts|Six daily 3 hour sessions with prompted 3-minute moderate-intensity walking bouts performed on a treadmill every 30 minutes throughout the 3 hour duration. There will be a total of 6 walking bouts (18 minutes total) each day. Moderate-intensity walking speed and grade will be selected to achieve 80% of the heart rate achieved at the ventilatory threshold as determined during a V02max test.
1466495|NCT03223649|Behavioral|Sedentary|(Control 'intervention') Six daily 3 hour sessions with no physical activity (i.e. subject remains sedentary in seated or recumbent position) throughout the 3 hour duration.
1466501|NCT03223597|Drug|Radium-223 dichloride|Registry of patients who receive Radium-223.
1466502|NCT03223571|Other|Motor rehabilitation training|Post-stroke participants receive 6 week of rehabilitation training of the paretic upper-limb.
1466503|NCT03223558|Behavioral|timing of initiation of cardiac rehabilitation|earlier timing of cardiac rehabilitation
1466504|NCT03223545|Behavioral|MBCT-T|This 8-week program combines mindfulness training with cognitive therapy and is delivered to small groups of patients by telephone using a conference line. Each weekly session is 1 hour long and is comprised of a check-in period, teaching on the week's topic, group discussion, a skill-building exercise, and a home-based practice assignment.
1466505|NCT03223545|Behavioral|Usual Care|"Treatment guidelines recommend counseling patients with prehypertension on the importance of lifestyle modification to reduce BP. Because of variability in counseling across primary care practices, the study team will provide all participants with NHLBI print educational materials to ensure exposure to lifestyle recommendations: Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan."
1466506|NCT03223532|Device|PrePex Day 7 FRP|Standard PrePex procedure, foreskin and device are removed 1 week after device application.
1466507|NCT03223532|Device|PrePex Day 0 FRP|Removal of the foreskin shortly after device application, the device is removed 1 week later
1466508|NCT03223519|Drug|Comboprofen|Triple combination of Ibuprofen, Magnesium and Vitamin C Powder for oral solution administered TID for 3 days
1466509|NCT03223519|Drug|Placebo|Powder for oral solution administered TID for 3 days
1466510|NCT03223519|Drug|Ibuprofen|Powder for oral solution administered TID for 3 days
1466511|NCT03223519|Drug|Magnesium|Powder for oral solution administered TID for 3 days
1466512|NCT03223519|Drug|Vitamin C|Powder for oral solution administered TID for 3 days
1466514|NCT03223493|Behavioral|No treatment given|Completion of a questionnaire
1466515|NCT03223480|Device|EUS-guided gastrojejunstomy|As listed in the arms description
1466516|NCT03223467|Procedure|Bariatric surgery|Bariatric surgery includes several different types of surgical procedures used to achieve weight loss.
1466517|NCT03223454|Biological|hAECs|hAECs are provided by Chongqing iCELL Biotechnology Co.,Ltd., which is a subsidiary of Shanghai iCELL Biotechnology Co.,Ltd. The participants are blind to their arms because the surgery is done under anesthesia. After hysteroscopic adhesiolysis, subsequently oral antibiotics will be given for 3 days to prevent infection. Estrogen will be administrated for 3 cycles to stimulate the repair of endometrium after the surgery.
1560459|NCT02523612|Procedure|Biopsy|
1466520|NCT03223415|Other|Detection and isolation of C. difficile carriers|"Screening for C. difficile carriage will be conducted by performing a polymerase chain reaction (PCR) assay detecting the toxin B gene (tcdB) on a rectal swab. Screening will occur within 24 h of admission to the ward. To ensure compliance with the policy, automatic orders will be developed. The patient care nurse will perform the screenings. The results will be reported according to the standard institutional policy.
Isolation precautions for C. difficile carriers: healthcare workers will also follow a set of isolation precaution rules during the care of C. difficile carriers. C. difficile carriers will remain under isolation precaution as long as they remain carriers and on the intervention ward. Precautions would be discontinued upon discharge from the ward."
1466521|NCT03223402|Other|Nevirapine plus lamivudine|In this Pilot study, the efficacy of a bi-therapy consisting of NVP+3TC instead of NVP+2NRTI should be evaluated before a large multicenter study evaluating this combination is started.
1466522|NCT03223389|Dietary Supplement|C-8 dietary oil|Ingestion of 13.15 g C-8 dietary oil providing 0.0216 mol of triglycerides.
1466523|NCT03223389|Dietary Supplement|Tricaprylin|Ingestion of 10.17 g tricaprylin providing 0.0216 mol of triglycerides.
1466524|NCT03223389|Dietary Supplement|Olive oil|Ingestion of 19 g olive oil providing 0.0216 mol of triglycerides.
1466525|NCT03223376|Combination Product|fruquintinib +paclitaxel|treatment arm- subjects will receive Fruquintinib 4mg orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/m2 at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
1466526|NCT03223376|Combination Product|fruquintinib placebo + paclitaxel|control arm- subjects will receive Fruquintinib placebo 4mg orally, once daily for 3 wks on/ 1 wk off combined with paclitaxel 80mg/m2 at day 1,8,15 of 4-week cycle. Patients will receive a cycles of 4 weeks of study treatment or until the occurrence of progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or other conditions that meet the end of treatment cretieria
1466527|NCT03223363|Diagnostic Test|2D and 3D ultrasonography|All of the examinations are performed with the same transabdominal ultrasonic transducer (RAB 2-5-D) on the same E8 (GE Medical Systems, Milwaukee, WI, USA) ultrasonic machine experienced operators. 2D ultrasonic measurements includes 5 standard fetal biometry parameters, and after routine 2D ultrasonography, the acquisition of 3D measurements are performed.
1466528|NCT03223350|Drug|Capsaicin 0.075% Cream|Topical application
1466529|NCT03223350|Drug|Placebos|placebo cream
1466530|NCT03223337|Drug|Daprodustat (GSK1278863)|Daprodustat (GSK1278863) 6 mg tablet will be given to all subjects as a single dose via oral route. Daprodustat (GSK1278863) is a 9.0 millimeter (mm) round, compound radius, white film coated tablet.
1466531|NCT03223324|Device|abdominal fetal/maternal monitor|A single passive patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
1466532|NCT03223298|Drug|Botulinum toxin type A|37.5 units injected into each masseter muscle and 12.5 units into each temporalis muscle
1466533|NCT03223298|Drug|0.9% Sodium Chloride Injection|1cc syringe
1466534|NCT03223285|Behavioral|Real Treatment Group|"Real Diaphragm manoeuvres The experimental manoeuvres include the Doming The Diaphragm Technique as described by Digiovanna (2004), Chila (2011) and Yao (2014) and the Manual Diaphragm Release Technique as described by Ricard (2009), De Coster (2005) and Roha (2015). Both manoeuvres are performed in two sets of 10 repetitions, within a 1-minute interval.
Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
1466535|NCT03223285|Behavioral|Sham Treatment Group|"Sham Diaphragm manoeuvre: the physiotherapist will simply lie hands on the rib cage, and rest along the anterolateral costal margin below rib 7, during normal breathing of the patient for 40 breathes.
Multifaced physiotherapy/osteopathic treatment includes: vertebral mobilisations (C0-D1), high-velocity low-amplitude (HVLA) thrusts of the cervical spine, soft tissue techniques"
1466536|NCT03223272|Drug|Reserpine|Open label reserpine 0.1-0.25 mg pill orally
1466537|NCT03223259|Behavioral|Injury Prevention Workshops|Each workshop will last 90 minutes and consist of approximately 20-30 minutes of lecture, 30 minutes of movement, no more than 20 minutes for a pre-test (workshop 1) or post-test (workshop 2), and remaining time for Q&A.
1466538|NCT03223246|Other|Additional teaching|A brief safety intervention, combining a pictorial handout, dosing demonstration with dispensed syringe, and teach-back for confirmation of understanding.
1466540|NCT03223220|Drug|Ketamine|IV infusion
1466541|NCT03223220|Other|Normal Saline|IV infusion
1466542|NCT03223220|Drug|Midazolam injection|Injection
1466544|NCT03223168|Device|Hayek RTX ventilator|Participants will receive Noninvasive negative pressure from the Hayek RTX ventilator for 30 minutes during diagnostic catheterization procedure.
1466545|NCT03223155|Drug|Nivolumab|"Patients in Sequential Arm will begin treatment with nivolumab (given with ipilimumab) between 1-7 days after completion of SBRT.
Patients in Concurrent arm will begin treatment with nivolumab (given with ipilimumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.
In both arms, patients will receive treatment with nivolumab 3 mg/kg as a 30-minute infusion +/- 10 minutes every 2 weeks for a maximum of 24 months. Patients will receive treatment on days 1, 15, and 29 of each 6 week cycle."
1466546|NCT03223155|Drug|Ipilimumab|"Patients in Sequential Arm will begin treatment with ipilimumab (given with nivolumab) between 1-7 days after completion of SBRT.
Patients in Concurrent arm will begin treatment with ipilimumab (given with nivolumab) first and will continue treatment within 2 weeks, after completion of SBRT to 2-4 sites.
In both arms, patients will receive treatment with ipilimumab 1 mg/kg as a 30-minute +/- 10 minutes infusion every 6 weeks for a maximum of 24 months. Patients will receive treatment on day 1 of each 6 week cycle."
1466547|NCT03223155|Radiation|Stereotactic body radiation therapy|All patients will receive 3 or 5 fractions of radiation as determined by the location of the lesions to be irradiated. There should be a minimum of 40 hours between treatments for an individual lesion. However, a patient may receive radiation for different lesions on consecutive days. Starting dose depends on metastasis locations.
1466626|NCT03222427|Drug|[13C415N3] LY3314814|Administered as an IV infusion
1466548|NCT03223142|Device|Multi-modal Precision Ablation|In Multi-modal Precision Ablation group, patients received Image-guided cryoablation immediately followed by radiofrequency ablation
1466549|NCT03223129|Other|Oral glucose tolerance test|Oral glucose tolerance tests were glucose is administrated orally with an increasing load (25g, 75g, 100 g)
1466550|NCT03223129|Other|Graded intravenous glucose infusion|Graded intravenous glucose infusion where glucose is infused in order to receive an plasma glucose pattern comparable to those received during the oral glucose tolerance tests.
1466551|NCT03223116|Procedure|Radiofrequency delivery|Radiofrequency to the gastroesophageal junction
1466552|NCT03223103|Drug|Poly-ICLC|Poly-ICLC 100mcg per peptide per dose
1466553|NCT03223103|Device|Tumor Treating Fields|an FDA approved treatment for patients with recurrent GBM and newly diagnosed GBM
1466554|NCT03223103|Biological|Peptides|synthetic long peptides (SLP) as vaccine substrate
1466555|NCT03223090|Behavioral|Tool-use|Motor training with a tool during max 5 weeks (3 days per week, around 30 minutes per day)
1466556|NCT03223090|Behavioral|Hand|Motor training with the right hand during max 5 weeks (3 days per week, around 30 minutes per day)
1466557|NCT03223064|Diagnostic Test|Ferumoxtran-10 enhanced MRI; MRI contrast agent|Patient undergo MRI with an USPIO contrast agent
1466558|NCT03223064|Diagnostic Test|68Ga PSMA PET-CT|Patient undergo an 68Ga PSMA PET-CT scan
1466559|NCT03223051|Other|Motor assessment|An occupational therapist install the patient sitting in front of the test board and tell him the instructions
1466560|NCT03223038|Other|No intervention|No intervention - exposure is mechanical ventilation in PICU
1466561|NCT03223025|Drug|CinnaTropin®|0.03 mg/kg daily subcutaneous injections
1466562|NCT03223025|Drug|Nordilet®|0.03 mg/kg daily subcutaneous injections
1466563|NCT03222999|Other|No intervention planned|No intervention planned
1466566|NCT03222960|Drug|propolis-containing toothpaste|participants will use propolis-containing toothpaste for 6 months
1466567|NCT03222960|Drug|Fluoride-containing toothpaste|participants will use Fluoride-containing toothpaste for 6 months
1466568|NCT03222947|Genetic|Deoxyribonucleic acid analysis|This study consists in the high throughput exome sequencing and subsequent genetic bio-analysis of 19 deoxyribonucleic acid samples from 6 families, already collected and consented, including patients diagnosed with a Taybi-Linder syndrome and their relatives (parents and/or siblings).
1466569|NCT03222934|Device|multislice computed tomography|radiological diagnosis of the status and variations in the sphenoid sinus
1466570|NCT03222921|Procedure|High tibial osteotomy|Patients undergoing high tibial osteotomy are investigated by a pressure insole for post-operative weight bearing behavior
1466571|NCT03222908|Behavioral|Intervention1: Contract Agreement|Smoking Cessation Contract
1466572|NCT03222908|Behavioral|Intervention2: Implementation Intentions|Smoking Cessation Contract with worksheet for implementation intentions
1466573|NCT03222882|Procedure|personal embryo transfer|According to the histological dating and transcriptomic profile of endometrium of hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer . The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on day P＋7 in an HRT cycle. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy outcome of the FET cycle .
1466574|NCT03222869|Diagnostic Test|Measure Airway Resistance Across Stenosis|Measure pressure and air flow Across Stenosis
1466575|NCT03222856|Drug|Pembrolizumab|MK3475 (pembrolizumab) will be supplied directly as a solution for infusion in a single-use vial. Each vial contains 100 mg of MK3475 (pembrolizumab) in 4 ml of solution.
1466576|NCT03222856|Drug|Eribulin|Eribulin will be supplied as a clear and colourless aqueous solution for injection provided in glass vials containing 2 ml. Each 2 ml vial contains eribulin mesylate equivalent to 0.88 mg eribulin.
1466577|NCT03222843|Drug|Hetrombopag Olamine|once daily
1466578|NCT03222843|Drug|matching placebo|once daily
1466579|NCT03222830|Procedure|personal embryo transfer|"According to the histological dating and transcriptomic profile of endometrium of natural cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .
The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating and transcriptomic profile by endometrial biopsy on 7 days after ovulation. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating and transcriptomic profile were determined according to the pregnancy. outcome of the FET cycle ."
1466580|NCT03222817|Behavioral|HPV self-sampling|Participants will be provided with education regarding cervical cancer screening, as well as instructions regarding how to use the HPV self-sampler. Participants will also receive referrals to trans-competent healthcare providers for follow-up screening and care.
1466581|NCT03222804|Dietary Supplement|Bifidobacterium|Each B. infantis (strain: BIEVC001) dose will be provided in one 625 mg sachet delivering 156 mg of live bacteria at a dose of 9x10^9 CFU plus 469 mg of pharmaceutical-grade lactose as the excipient and dispensed to participants by the study personnel.
1466582|NCT03222791|Other|Algorithm-based diet|Personalized nutrition plan based on an algorithm for predicting the personalized glucose response to food. The algorithm's predictions are based on many personal measurements, including blood tests, personal lifestyle and gut bacteria.
1466583|NCT03222791|Other|Mediterranean-style low-fat diet|The Israeli standard of care dietary guidelines for prediabetes.
1466584|NCT03222765|Drug|Placebo, metformin, linagliptin, linagliptin + metformin|
1466585|NCT03222752|Device|Cranial Electrotherapy Stimulation|Alpha-Stim® AID microcurrent and cranial electrotherapy stimulator will be used. Daily one hour cranial electrotherapy stimulation (CES) treatment using ear clip electrodes with current set at fixed level of 100 uA (a subsensory current level), 0.5 Hertz will be used for active CES treatment group for 6 weeks. For the sham group the Alpha-Stim® AID ear clips will not emit electricity.
1466586|NCT03222752|Device|Sham Cranial Electrotherapy Stimulation|The sham treatment will be using a sham Alpha-Stim AID which will look and sound exactly like the active treatment but will deliver no current.
1466587|NCT03222739|Device|Ultrasound|An industry standard ultrasound will be fitted with a self-tracking probe to track along the spine. The ultrasound will be performed three (3) times along the spine at initial consultation for scoliosis.
1466588|NCT03222726|Other|exercise group|less than 6000 steps/day or 40,000 steps/week
1466589|NCT03222713|Other|Program Self-regulation in health|The intervention program with children will be run by teachers and health professionals (Condition Group II) in 50-minute biweekly sessions which will take place in class in school year. During these sessions, the children will complete the following tasks: the reading of the chapters of Yellow Trials and Tribulations (one chapter per week) and the discussions and activities related to the topics of healthy eating and oral health.
1466590|NCT03222700|Procedure|surgical procedure|In robotic thyroidectomy group, patients are received surgery using robotic system. In open thyroidectomy group, patients are received conventional open surgery.
1466591|NCT03222687|Drug|tacrolimus|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
1466592|NCT03222687|Drug|prednisone|Immunosuppressive therapy included tacrolimus and prednisone. Tacrolimus treatment was initiated at a dosage of 0.05-0.1 mg/kg/day twice daily and used for at least 6 month. Prednisone was started at 2 mg/kg/day and tapered off gradually after initiation of treatment.
1466593|NCT03222674|Biological|Muc1/CD33/CD38/CD56/CD117/CD123-specific gene-engineered T cells|Infusion of Muc1/CD33/CD38/CD56/CD117/CD123-specific gene-engineered T cells
1466594|NCT03222661|Diagnostic Test|Refraction|Refractive error measurement
1466595|NCT03222648|Other|Structured Responsive Exercise Training|Twice weekly, 8 week structured responsive exercise training programme. Protocol used the same as that used in previous EMPOWER Trial (Loughney et al. 2016)
1466596|NCT03222635|Procedure|Endoscopic follow-up|Endoscopic follow-up by means of regular upper endoscopies and endoscopic ultrasounds
1466597|NCT03222622|Drug|Icotinib hydrochloride cream|Apply topically twice daily for 12 consecutive weeks
1466598|NCT03222622|Drug|Placebo cream|Apply topically twice daily for 12 consecutive weeks
1466599|NCT03222609|Drug|Navitoclax|Tablet; navitoclax QD various doses added to ruxolitinib BID at participants current stable dose (greater than or equal to 10 mg) until end of clinical benefit or occurrence of unacceptable toxicity or discontinuation criteria have been met.
1466600|NCT03222596|Behavioral|Exercise training|Exercise programme includes breathing and upper limbs exercises.
1466606|NCT03222557|Procedure|Electroacupuncture|Refer to arm description
1466607|NCT03222557|Procedure|Sham Acupuncture|Refer to arm description
1466608|NCT03222557|Device|Electroacupuncture|Refer to arm description
1466609|NCT03222557|Device|Sham Acupuncture|Refer to arm description
1466610|NCT03222544|Combination Product|Indocyanine Green|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
1466611|NCT03222544|Combination Product|Photon therapy instrument|Continue treatment after 5mins suspension if the patient feels that the local temperature is too high to stand
1466612|NCT03222531|Procedure|Heart Transplant|Hepatitis C positive heart transplant into hepatitis C negative patients
1466613|NCT03222531|Drug|Epclusa|Patients testing positive for HCV viremia will receive 12 weeks of Epclusa.
1466614|NCT03222518|Drug|Paracetamol|21 pills of Paracetamol 1000mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
1466615|NCT03222518|Drug|NSAID|21 pills of Ketaprofen 50mg are provided with a preconised dose of 1 pill 3 times per day over 7 days period
1466616|NCT03222518|Drug|Placebo Oral Tablet|21 identical pills of Placebo are provided with a preconised dose of 1 pill 3 times per day over 7 days period
1466617|NCT03222505|Device|Honda Stride Assist Device ON|Subjects performed assessments of walking and motor performance while wearing the Honda Stride Assist Device.
1466618|NCT03222505|Other|No Device Worn|Subjects performed assessments of walking and motor performance without wearing the Honda Assist Device.
1466619|NCT03222492|Biological|Brentuximab Vedotin|Ascending dose cohorts. All cohorts will receive intravenous administration of study medication every 3 weeks for 21 weeks, for a total of eight doses.
1466620|NCT03222492|Biological|Placebo|Placebo control for blinding (masking), 0.95% normal saline.
1466621|NCT03222479|Behavioral|Stress guide|smartphone-based application that can evaluate stress level and teach how to manage their stress
1466623|NCT03222453|Biological|Hematopoetic stem cells|Patient will inject with hematopoetic stem cells differentiated from beta-thalassemia induced pluripotent stem cells
1466624|NCT03222440|Drug|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
1466625|NCT03222427|Drug|LY3314814|Administered orally
1466627|NCT03222414|Device|Non-invasive BP recording with conical Ultracheck Curve BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using conical Ultracheck Curve BP cuff
1466628|NCT03222414|Device|Non-invasive BP recording with traditional cylindrical BP cuff|Non-invasive SBP, DAP and MAP will be measured in both arms using traditional cylindrical BP cuff
1466629|NCT03222414|Other|Direct invasive arterial pressure|Direct invasive arterial pressure readings will be recorded simultaneously with non-invasive measurements
1466630|NCT03222401|Drug|1 mg/kg single infusion of F598|1 mg/kg single infusion of F598
1466631|NCT03222401|Drug|3 mg/kg single infusion of F598|3 mg/kg single infusion of F598
1466632|NCT03222401|Drug|10 mg/kg single infusion of F598|10 mg/kg single infusion of F598
1466633|NCT03222388|Other|Questionnaire - IIEF 5/15|International Index of Erectile Function
1466634|NCT03222375|Device|SQUED™ series 28.1 home-use|"Semiconducting QUantum Excitonic Device - artifificial active medium, where the processes of self-organization lead to creation and converter of Autowaves energy.
Some autowaves have the properties of quasi-particles!"
1466635|NCT03222362|Other|Surgery|
1466637|NCT03222336|Behavioral|Family pedigree and data collection|"Enroll first generation (newborn), at least one member from second (parent) and third generation (grandparent) for a complete IVS4 family tree mapping.
Collect and analyze medical history, genetic and biochemical assessment data"
1466638|NCT03222323|Drug|Dexmedetomidine perineurally|Dexmedetomidine is added perineurally on one side and will influence the nerve block perineurally on this side. Dexmedetomidine is also absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
1466639|NCT03222323|Drug|Ropivacaine 5mg/ml|Ropivacaine is used in 5mg/ml in the perineural, systemic and placebo nerve blocks.
1466640|NCT03222323|Drug|Ropivacaine 7.5mg/ml|In the high dose ropivacaine group a ropivacaine concentration of 7.5mg/ml is used.
1466641|NCT03222323|Drug|Dexmedetomidine systemically|Dexmedetomidine administered perineurally on one side is absorbed and redistributed systemically and will influence the opposite ulnar nerve block systemically.
1466642|NCT03222323|Drug|Isotonic saline|placebo (saline) is administered perineurally in all but the perineural group.
1466643|NCT03222310|Drug|Ipatasertib|Ipatasertib 100 mg tablet orally once daily.
1466644|NCT03222310|Drug|Itraconazole|Itraconazole 100 mg capsules orally once daily.
1466645|NCT03222297|Device|early skull repair|Patients with craniocerebral injury were randomized into test group (n = 40) with early skull repair using titanium mesh within 1-3 months after decompression.
1466646|NCT03222297|Device|late-stage skull repair|Patients with craniocerebral injury were randomized into control group (n = 46) with late-stage skull repair using titanium mesh within 6-12 months after decompression.
1466647|NCT03222284|Device|Cornerstones4Care Powered by Glooko App|Cornerstones4Care Powered by Glooko App is an iOS or Android smartphone application designed to support diabetes management by offering people with diabetes easily accessible, personalized tools for self-monitoring and education. C4C allows people with diabetes to monitor personal health metrics and blood glucose levels, with the aim to achieve participant behavior changes that may contribute to lower hospitalizations, diabetes-related complications and overall healthcare costs.
1466648|NCT03222271|Device|Extubation to NIV|Weaning using NIV immediately after extubation with the mentioned parameters
1466649|NCT03222258|Behavioral|Early palliative care|Palliative Care Team provide a self-learning booklet, medical treatment and consultation about Advance Care Planning with chemotherapy by oncologist.
1466650|NCT03222258|Behavioral|Routine hospice care|Palliative Care Team provide a routine hospice care the same as other patients who doesn't participate this study after the chemotherapy is totally terminated
1466651|NCT03222232|Behavioral|catheter salvage|In each case of catheter-related bloodstream infection the management of the central venous catheter was registred to evaluate the future risk of new infections
1466652|NCT03222219|Procedure|dental implant insertion|the registration of the torque values is discriminant for the group assignment after dental implant insertion
1466653|NCT03222206|Drug|Salsalate|"Medicate salsalate 2g/day after run-in period
Check side effect after 1 month and Control dosage (2g/day or 3g/day)
Check side effect after 2 month"
1466654|NCT03222206|Other|Placebo|"Medicate placebo 2g/day after run-in period
Check side effect after 1 month and Control dosage (2g/day or 3g/day)
Check side effect after 2 month"
1466655|NCT03222193|Device|TRP|3 months of TRP tongue retraining
1466656|NCT03222180|Behavioral|Website|Participants in the Website condition will be provided with password-protected access to the online resource created for this trial that provides a variety of information, support and guidance that could permit them to adapt more effectively to the demands of parenting a very young child with type 1 diabetes.
1466657|NCT03222167|Drug|Elbasvir/ Grazoprevir 50/100 mg fixed dose combination|Enrolled patients will be treated by Elbasvir/ Grazoprevir 50/100 mg fixed dose combination during 12 week. Followed-up on week 24. SVR12 will be evaluated.
1466658|NCT03222154|Device|Experimental - Shock wave therapy|Shock wave therapy was performed with the Master Plus 200® Storz Medical equipment, radial emission 2000 pulses, frequency 15 Hz and pressure 1 Bar.
1466659|NCT03222154|Device|Placebo - Shock wave therapy|Simulation of shock wave therapy
1466660|NCT03222141|Device|TAVR Implantation of the THV Prosthesis|Patients with TAVR implantation
1466661|NCT03222128|Device|TAVR|Implantation of the SAPIEN 3
1466662|NCT03222102|Device|Phasix mesh|After the closure of the Abdomen, Phasix mesh will be placed and affixed on the exposed fascia.
1466663|NCT03222089|Drug|Irinotecan|Irinotecan 165 mg/m² 1-hour IV day 1
1466664|NCT03222089|Drug|Oxaliplatin|oxaliplatin 85 mg/m² 2-hours IV day 1
1466665|NCT03222089|Drug|Levoleucovorin|Levoleucovorin 200 mg/m² 2-hours IV day 1
1466666|NCT03222089|Drug|5-FU|5-FU 2800 mg/m² 46-hours flat continuous infusion IV
1466667|NCT03222089|Drug|GM-CSF|GM-CSF 150ug s.c. d3-7 , Repeated every 4 weeks.
1466668|NCT03222089|Drug|IL-2|Interleukin-2 100MIU s.c. d8-14 and d17-d28, Repeated every 4 weeks.
1560460|NCT02523612|Procedure|Blood sample|
1466669|NCT03222076|Drug|Nivolumab|"Arms A + B: Nivolumab: Nivolumab at 240 mg by vein every 2 weeks for 3 doses. Then 4 weeks after surgery, Nivolumab 240 mg by vein every 2 weeks in the adjuvant setting until disease progression or for 2 years, whichever is sooner.
Arm C: Nivolumab 240 mg by vein every 2 weeks for 3 doses. After post-treatment biopsy and liver imaging, Nivolumab 240 mg by vein every 2 weeks until deemed surgically resectable or up to 2 years, whichever is sooner."
1466670|NCT03222076|Drug|Ipilimumab|"Arm B: Ipilimumab 1 mg/kg by vein on day 1 of therapy. Then 4 weeks after surgery, Ipilimumab 1 mg/kg by vein every 6 weeks in the adjuvant setting until disease progression or for 2 years, whichever is sooner.
Arm C: Ipilimumab 1 mg/kg by vein on day 1 of therapy. After post-treatment biopsy and liver imaging on Day 1 of week 7, Ipilimumab 1 mg /kg by vein every 6 weeks with re-staging every 12 weeks until deemed surgically resectable or up to 2 years, whichever is sooner."
1466671|NCT03222063|Other|Play interventions|The following play were included in play interventions i.e building blocks, paint, puzzles, crayons, doctor set, ludo, snake and ladder. All hospitalized children in experimental group received play interventions at bed side. Taking into consideration the busy clinical setting, each participant received continuously 1 hour of hospital play interventions each day for continuous 5 days. Although the hospitalized children were free to choose according to their choice but still the younger children would be engaged in play such as doctor set, Drawing etc. to obtain more sensory experience and older children were offered play interventions such as puzzle, building blocks, ludo etc.with high cognitive demand.
1466672|NCT03222050|Other|Distraction technique|
1466673|NCT03222037|Device|senofilcon A|Acuvue Oasys 1-Day
1466674|NCT03222037|Device|Control|Trial Frame with best spherocylindrical refraction (SCR)
1466675|NCT03222024|Other|routine medical care|This is an observational study for clinical course and outcomes of severe ischaemic stroke; therefore, interventions are prescribed by responsible doctors based on patients' clinical conditions, which is not interfered by current study
1466676|NCT03222011|Procedure|Standard (single) endoscopic stricture dilatation|single endoscopic stricture dilatation
1466677|NCT03222011|Procedure|Intensive endoscopic stricture dilatation|3 endoscopic dilatations 3 weeks apart and possible needle knife strictureplasty
1466678|NCT03221998|Drug|IV paracetamol|100 gram paracetamol infusion for moderate pain management
1466679|NCT03221998|Drug|IV saline (NaCl 0.9 %)|100 ml of Normal Saline (IV NaCl 0.9 %) as placebo
1466680|NCT03221985|Other|questionnaires|questionnaire with application on smartphone
1466681|NCT03221959|Device|Medical Device Vittamed 205|Intracranial pressure measurement
1466682|NCT03221946|Drug|Diclofenac Sodium|tablet of 50mg,
1466683|NCT03221946|Drug|Diclofenac sodium|Transdermal patch 100 mg
1466684|NCT03221946|Drug|Diclofenac|intra muscular injection 100mg
1466685|NCT03221933|Biological|Somatropin Injection low dose group|0.23mg/kg /wk，inject for seven divided doses
1466686|NCT03221933|Biological|Somatropin Injection high dose group|0.46mg/kg /wk，inject for seven divided dose
1466687|NCT03221920|Other|Very Low Carbohydrate Diet|1 : 4 ratio of carbohydrate to fat of the total daily calories intake
1466688|NCT03221907|Drug|GLA5PR GLARS-NF1|Pregabalin tablet
1466689|NCT03221907|Drug|GLA5PR GLARS-NF1 placebo|tablet manufactured to mimic GLA5PR GLARS-NF1
1466690|NCT03221907|Drug|Pregabalin|Pregabalin capsule
1466691|NCT03221907|Drug|Pregabalin placebo|tablet manufactured to mimic pregabalin capsule
1466692|NCT03221894|Dietary Supplement|GRAPE granules|GRAPE granules was mainly consisted of herbal medicines: Ren Shen (Ginseng, 10g/d), Di Huang (Rehmannia glutinosa, 30g/d), Shi Cangpu (Acorus tatarinowii, 10g/d), Yuan Zhi (Polygala tenuifolia, 10g/d), Yin Yanghuo (Epimedium brevicornu, 10g/d), Shan Zhuyu (Cornus officinalis, 10g/d), Rou Congrong (Cistanche deserticola, 10g/d), Yu Jin (Curcuma aromatica, 10g/d), Dan Shen (Salvia miltiorrhiza, 10g/d), Tian Ma (Angelica sinensis, 10g/d), Tian ma (Gastrodia elata, 10g/d), and Huang Lian (Berberine, 10g/d), which were supplied by Beijing Tcmages Pharmaceutical Co., LTD, Each bag of granules with 150ml warm water melt was taken orally twice a day.
1466693|NCT03221881|Drug|Pegylated Liposomal Doxorubicin and docetaxel|
1466694|NCT03221868|Behavioral|Exercise group|An exercise-based program following a 12-week periodization using mostly circuit-like activities.
1466695|NCT03221868|Behavioral|Control group|Counseling to practice physical activity and meetings every 15 days with women to conduct group walks. Booklet with walking schedule and for registering sessions.
1466696|NCT03221855|Drug|Domperidone|Capsules 10mg orally each 8 hours for 7 days.
1466697|NCT03221855|Drug|Placebo|Capsules 10mg orally each 8 hours for 7 days.
1466698|NCT03221842|Drug|C1-esterase inhibitor|C1-esterase inhibitor is a human plasma-derived lyophilised powder for reconstitution
1466699|NCT03221842|Drug|Placebo|Excipients of C1-INH plus albumin
1466700|NCT03221816|Drug|Tenavit®|The experimental group received one tablet of Tenavit® daily for a period of 4 months.
1466701|NCT03221816|Drug|Placebo Oral Tablet|Placebo group received the same tablet with the organoleptic characteristics of Tenavit® for a period of 4 months.
1466702|NCT03221803|Other|OT Vertical attachment|new extra coronal castable attachment
1466703|NCT03221803|Other|OT cap attachment|standard extra coronal attachment
1466704|NCT03221790|Other|Low FODMAP Diet followed by a High FODMAP Diet|3 weeks on a low FODMAP diet followed by 3 weeks on a high FODMAP Diet
1466705|NCT03221777|Diagnostic Test|14 Day ECG Patch (Zio XT Patch, iRhythm Technologies)|The ZIO XT Patch (http://www.irhythmtech.com/zio-solution/zio-patch/) is an ultra-portable wearable adhesive patch monitor that provides continuous single-lead ECG recording for up to 14 days. It has been cleared by the FDA for arrhythmia detection and is in current clinical use in the U.S.[87]. It will be used in this study under an investigational testing authorization by Health Canada. The ZIO XT Patch is a single-use device worn over the left pectoral region with a skin adhesive (Figure 4). Its small, lightweight, water-resistant, patch-based design has advantages for patients compared with traditional ECG screening methods (e.g. Holter, event loop recorders, mobile outpatient telemetry systems), which are all more cumbersome and require detachable wired leads, two or more removable skin contact electrodes, plus separate recording units (+/- smartphone attachment).
1466734|NCT03221530|Behavioral|Early Intervention for Suicide Risk Among Immigrant Youth|The EISR-I intervention includes family treatment engagement, shared problem definition, and sessions designed to address family cohesion, communication, and conflict resolution.
1466708|NCT03221751|Drug|prazosin hydrochloride|Prazosin is an oral capsule identical in appearance to prazosin capsules titrated in the same manner as prazosin.
1466709|NCT03221751|Drug|placebo|Prazosin is an oral capsule identical in appearance to prazosin capsules titrated in the same manner as prazosin.
1466711|NCT03221725|Procedure|sacrospinous ligament fixation|sacrospinous ligament fixation will be applied to prevent vaginal vault prolapse
1466712|NCT03221712|Behavioral|cardiac rehabilitation|cardiac rehabilitation in patients with chronic total occlusion of the coronary arteries.
1466713|NCT03221699|Other|Formula with ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on with ZnO
1466714|NCT03221699|Other|Formula without ZnO|Forearms and axillae are treated by the volunteers once daily with a standardized amount of the roll-on without ZnO
1466715|NCT03221686|Dietary Supplement|Intervention|The patients in the intervention group are given 55 mg zinc, 1251 mg vitamin C, and 15 g arginine once daily 14 days pre-operatively and post-operatively together with a high quality protein supplement.
1466716|NCT03221686|Dietary Supplement|Control|High quality protein supplement 14 days pre-operatively and post-operatively.
1466717|NCT03221660|Device|F-Composite 2 system|Procedures will be done using local anesthesia (if the patients wants that). The cavity is prepared according to the principles of the adhesive technique. First the adhesive will be applied and polymerized, afterwards the flowable resin-based restorative material will be applied and polymerized and then the sculptable resin-based restorative material will be applied and polymerized; all materials will be light-cured within short time with an experimental curing light.
1466718|NCT03221647|Other|Intestinal biopsies|Intestinal biopsies obtained from Patients and Controls by EGDS. The patients and controls had the intestinal biopsies as a diagnostic step or routine check independently from the present study. For this study 3 additional biopsies samples were done in patients and controls that signed the informed consent.
1466719|NCT03221634|Biological|Pembrolizumab|IV infusion
1466720|NCT03221634|Biological|Daratumumab|IV infusion
1466721|NCT03221621|Procedure|Wide Excision|Wide excision is performed under general anaesthesia or procedural sedation and analgesia (PSA). All lesional tissue, including fibrosis, is electrosurgically removed until the area is clear. The subcutaneous fat and epithelised sinus floors are left intact where possible. The wounds are left open to heal by secondary intention.
1466722|NCT03221621|Drug|Adalimumab Injection|Adalimumab will be administered through subcutaneous injections in weekly dose of 40mg from week 4 up to 24 months (V8), after an initial dose of 160mg at week 0 and a 80mg dose at week 2 until end of study or last surgery.
1466723|NCT03221608|Procedure|Surgery and HIPEC with Lobaplatin|The combination of surgery and HIPEC with Lobaplatin are performed in patients with colorectal cancer (T4N0-2M0).
1466724|NCT03221608|Procedure|Surgery without HIPEC|The patients with colorectal cancer (T4N0-2M0) are undergone a curative resection by laparoscopy or open approach.
1466725|NCT03221595|Device|Operative|This operation involves reducing and providing rigid fixation of displaced rib fractures with permanent plates or splints
1466726|NCT03221582|Drug|EBR/GZR|Elbasvir and Grazoprevir (EBR/GZR) tablet by mouth, once daily.
1466727|NCT03221569|Drug|Intranasal ketamine|ketamine to be administered via intranasal atomizer.
1466728|NCT03221569|Drug|Diphenhydramine|as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
1466729|NCT03221569|Drug|metoclopramide|as active comparator, will be administered together with metoclopramide in one normal saline 50ml bag
1466730|NCT03221569|Drug|Normal saline|"Will be given as 50ml intravenous bag as placebo for double-blinding purposes in patients who will also receive intranasal ketamine.
Will be prepared in intranasal syringe for double blinding purposes for patients who are randomized to receive intranasal ketamine."
1466733|NCT03221543|Device|ReeVue Indirect Calorimeter|The ReeVue Indirect Calorimeter will be used in this study to measure the resting metabolic rate. The test takes approximately ten minutes to complete. The subject should prepare for the test by avoiding stimulants and exercise on the day of the test, as well as eating meals four hours before the test. The subject will be seated during the test. They will be given a nose clip that looks like a clothes pin to be placed on their nose. A plastic mouth piece that allows all of the air they breathe to come in through the top of the mouth piece and the air they breathe out to go into the ReeVue Calorimeter will also be provided. The subject will remain in this position for ten minutes until the testing is complete.
1466735|NCT03221530|Behavioral|Enhanced usual care|This intervention includes a session with the family to engage in safety planning and provide feedback on their baseline assessment data.
1466736|NCT03221517|Other|Standardized meal with a glucose challenge test|Postprandial glucose and insulin response
1466737|NCT03221504|Other|Longer therapy duration|Patients will receive cefuroxime axetil orally. Treatment will involve the supply of cefuroxime axetil 30 mg/kg/d in two divided doses (in blinded bottles).
1466738|NCT03221504|Other|Shorter therapy duration|Patients will receive placebo orally (in blinded bottles). The volume of the placebo will be like cefuroxime syrup.
1466739|NCT03221491|Device|Patient-Controlled Analgesia(PCA)|Patients receive analgesic regimens using Patient-Controlled Analgesia(PCA) with different background infusion.
1466740|NCT03221478|Other|Kinesio Taping placebo and exercises|Kinesio Taping placebo and exercises
1466741|NCT03221478|Other|Kinesio Taping with tension and exercises|Kinesio Taping with tension and exercises
1466742|NCT03221478|Other|Kinesio Taping with tension|Kinesio Taping with tension
1466743|NCT03221465|Behavioral|Self-monitoring of physical activity with incentives|Participants are given a pedometer (e.g. Misfit brand wrist pedometer) to allow self-monitoring of physical activity and receive financial incentives. Participants also answer two health questions a week for 12 weeks.
1466744|NCT03221465|Behavioral|Usual care and self-monitoring of physical activity|Participants simply given a pedometer (e.g. Misfit brand wrist pedometer) with no other intervention to allow self-monitoring of physical activity.
1466745|NCT03221452|Behavioral|Memory, Attention, and Problem Solving Skills for Diabetes|Classes will include: (1) information on diabetes self-management including glucose self-monitoring and medication management; (2) assessment of cognitive problems; (3) resources and barriers to self-management; and (4) lifestyle changes to maximize cognitive health. Participants will also practice those skills with online computer games.
1466746|NCT03221439|Behavioral|Cognitive Functional Therapy|"There will be four main components in the intervention, following the protocol used by O'Keefe et al. (2015):
The cognitive component will focus on on the multidimensional nature of persistent pain about individual beliefs, and how emotions and behaviors (movement and lifestyle) can reinforce a vicious cycle of pain and disability.
Specific Functional training is designed to normalize maladaptive or provocative movement and posture.
Functional integration directed to activities of daily life that are avoided by the patient (rolling in bed, sitting, sitting to standing, walking, bending and lifting)
Patients will be advised to gradually increase physical activity based on their preference, also focusing on sleep hygiene, stress, and management strategies"
1466747|NCT03221439|Other|Manual Therapy and Motor Control Exercise|According to the pragmatic clinical decision of the physiotherapist responsible for this intervention arm, participants allocated to the comparison group will be treated with joint mobilization or manipulation techniques applied to the lower back or pelvis. The active exercises will involve isolated contractions of the deep abdominal and multifidus muscles in different functional positions. Most patients in this group will receive exercises to perform at home. This will include general exercise or motor control exercise, but not related to CFT.
1466748|NCT03221426|Biological|Pembrolizumab|IV infusion
1466749|NCT03221426|Drug|Placebo|Normal saline solution IV infusion
1466750|NCT03221426|Drug|Cisplatin|IV infusion
1466751|NCT03221426|Drug|Capecitabine|Oral tablets
1466752|NCT03221426|Drug|5-fluorouracil|IV infusion
1466753|NCT03221413|Device|transcranial alternating current stimulation (tACS)|
1466754|NCT03221400|Drug|PEN-866|PEN-866 is a miniaturized conjugate that comprises an HSP90 targeting ligand linked to SN-38, the active metabolite of irinotecan. PEN-866 is available as a sterile lyophilized powder for solution for infusion.
1466755|NCT03221387|Device|Humidified nasal high flow with oxygen|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases.
1466756|NCT03221374|Behavioral|Mindfulness Based Stress Reduction|8-week mindfulness based stress reduction course intended to develop mind-body awareness through mindfulness practices.
1466757|NCT03221361|Device|thermoplastic complete denture|a device used ti substitute teeth for edentlous patient made of thermoplastic resin
1466758|NCT03221361|Device|conventional acrylic resin complete denture|A device used to substitute the teeth for edentlous patient made of acrylic resin
1466759|NCT03221348|Biological|CHO-H01|Glyco-engineered anti-CD20 antibody
1466760|NCT03221335|Device|EUS-guided RFA|All patients would undergo EUS with a linear array echoendoscope. The location and size of the lesion would be assessed for suitability of treatment. After locating the lesion, the RFA needle would be inserted to the centre of the lesion. RFA would then be initiated and hyperechoic interferences would be observed around the electrode signifying heating of the tissue. The duration of ablation would be according to the size of the lesion.
1466761|NCT03221322|Behavioral|Superlean|Behavioural data will be collected on all subjects in either control group or superlean group. Blood or saliva samples will be collected for DNA extraction and genotyping.
1466762|NCT03221309|Other|Evaluate model of care for HCV-infected adults with on-going injection drug use|Participants will be treated with direct-acting antivirals per standard of care and will be concomittantly be offered PreP for HIV prevention and buprenorphine for treatment of opioid-use disorder when clinically indicated
1466763|NCT03221296|Behavioral|Vestibular Training (Intervention Group)|Exercises three times daily, for up to approximately 20 minutes. Changes in functional status and physical status shall be measured at study onset and follow up.
1466767|NCT03221257|Drug|Pirfenidone (PFD)|Participants will receive PFD titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
1466768|NCT03221257|Drug|Placebo (Plac)|Participants will receive a Plac, matched to resemble PFD, titrated up to a target dose of 801 mg taken three times daily as tolerated (3-step titration occurring at 2 week intervals).
1466855|NCT03220607|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
1466769|NCT03221257|Drug|Mycophenolate Mofetil (MMF)|Participants will receive MMF titrated up to a target dose of 1500 mg taken twice daily as tolerated (4-step titration occurring at monthly intervals).
1466770|NCT03221244|Device|VR Treatment|Distractors
1466771|NCT03221244|Device|VR Active Control|No distractors
1466772|NCT03221231|Drug|N-acetylcysteine|1200 mg/day, twice daily, N-acetylcysteine
1466773|NCT03221231|Drug|Placebo Oral Tablet|twice daily, placebo
1466774|NCT03221231|Other|Magnetic Resonance Imaging|
1466775|NCT03221231|Other|Neurocognitive measures|
1466776|NCT03221231|Other|Neuro-inflammatory measures|
1466777|NCT03221218|Other|Enhanced screening-informed follow up letter|Family Physicians will be sent a letter that includes their screening test results and associated symptom-specific recommendations from the Ontario Neurotrauma Foundation clinical practice guidelines.
1466778|NCT03221205|Device|Sham CPAP|CPAP (ResMed AutoSet S9 with humidifier) to be used by the participant via nasal mask and tube, programmed to apply 0.5 cmH2O (messured at the nasal mask) via a resistance to assure the lack of distal pressure.
1466779|NCT03221205|Device|Therapeutic CPAP|Use of CPAP (ResMed AutoSet S9 with humidifier) through nasal mask and tube with automatized pressure from 4 to 20 cmH2O.
1466780|NCT03221192|Other|VAS questionnaire|VAS questionnaire is a PRO tool in which subjects will be asked to evaluate overall symptom severity, or the severity of individual symptoms of nasal polyps along a continuum, typically of 10 centimeter (cm) or 100 millimeter (mm) whereby 0 represents 'no symptom' and '10 or 100 represents 'as bad as you can imagine', Scores of 0-3 (or 0-30) are defined as mild disease, >3-7 (or >30-70) as moderate disease and >7-10 (or >70-100) as severe disease.
1466781|NCT03221192|Other|SNOT-22 questionnaire|SNOT-22 is a PRO tool to measure HRQoL associated with rhinosinusitis with or without nasal polyps. It contains 22 nose, sinus, and general HRQoL items and subjects will be required to score the experience on a 6-point scale ranging from 0 (no problem) to 5 (Problem as bad as it can be) and identify the five most important items affecting their health.
1466782|NCT03221192|Other|Data capture app|Real time data capture app is a smart-phone or web-based application which will allow the subjects to communicate about their experience of nasal polyps in real-time as they go about their daily lives via varying video, audio, photographic and text responses.
1466783|NCT03221179|Biological|RO7049665|A single ascending dose (starting dose 1.5 micrograms [mcg])of RO7049665 will be administered SC.
1466784|NCT03221179|Biological|Placebo|Matching placebo will be administered SC once.
1466787|NCT03221153|Procedure|Simulation techique|The intervention group will be in a simulated case with mock scenarios and interaction by 'acting out' the clinical situation where knowledge and attitudes about safety in hospitalized patients will be assessed.
1466788|NCT03221140|Drug|Outpatient parenteral antimicrobial therapy|Administration of intravenous antimicrobials on an outpatient basis
1466789|NCT03221114|Behavioral|Positive Psychological Intervention|Our culturally-tailored Positive Psychology Intervention is a non-pharmacotherapy approach aimed at increasing positive emotional experiences by teaching individuals to engage in intentional activities known to increase psychological and emotional well-being through targeting of constructs such as optimism, gratitude, mindfulness/relaxation, and resilience.
1466790|NCT03221101|Device|Home ventilator|
1466791|NCT03221088|Drug|Jintrolong® low dose group|PEG-somatropin 0.1mg/kg/wk by weekly subcutaneous injection for 52 weeks.
1466792|NCT03221088|Drug|Jintrolong® high dose group|PEG-somatropin 0.2 mg/kg/wk by weekly subcutaneous injection for 52 weeks.
1466793|NCT03221075|Other|Registry|There is no intervention.
1466794|NCT03221062|Device|Laser en Bloc Resection|Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection
1466795|NCT03221049|Diagnostic Test|radiomics|
1466796|NCT03221036|Drug|Vedolizumab IV|Vedolizumab IV infusion
1466797|NCT03221036|Drug|Placebo|Matching-placebo IV infusion
1466798|NCT03221023|Drug|Vancomycin Hydrochloride|Individuals in the experimental arm will receive intrawound Vancomycin-saline + IV antibiotics
1466799|NCT03221023|Drug|Saline Solution|Individuals in the control arm will receive intrawound saline solution
1466800|NCT03221010|Behavioral|Motivational Interviewing|Motivational Interview (MI) is a person-centered, communicative method whose purpose is to work and increase the user's motivation for behavior change.
1466801|NCT03221010|Behavioral|Traditional cognitive-behavioral approach|This approach aims to combine cognitive interventions in the training of behavioral skills in patients, developing strategies to cope with the problem and detecting situations of risk, mobilizing the subject for his own process of change. Helps correct cognitive dysfunctions and behavioral changes in specific situations.
1466802|NCT03220997|Dietary Supplement|Vitaflow Preload|Carbohydrate loading drink
1466803|NCT03220984|Biological|Immuncell-LC intravenous infusion using a CIK cell agent|Patients with metastatic colorectal cancer, which is refractory to the 3rd-line chemotherapy are enrolled in this study. Enrolled patients receive a total of 12 times of Immuncell-LC therapy: 8 times in every 1 week and the next 4 times in every 2 weeks. The treatment responses of immuncell-LC are evaluated by radiologic findings (Abdomin-pelvic CT and Chest CT), immune-markers and a selorogic tumor marker (Carcinoembryologic antigen (CEA)) at the 8th week and 17th week. The safety of Immuncell-LC is evaluated by the results of serologic tests, vital signs, ECOG-PS and adverse events. The follow-up period is the 1 year after the enrolled date.
1466804|NCT03220971|Other|lipoprotein and apolipoproteins|To find out the role of lipoprotein and apolipoproteins (apos) in pathogenic hepatic diseases
1466805|NCT03220958|Drug|Metoclopramide|Metoclopramide 20mg
1466806|NCT03220958|Drug|Diphenhydramine|Diphenhydramine 25mg
1466807|NCT03220958|Drug|Normal saline|100ml normal saline
1466808|NCT03220945|Other|Yoga|Receive yoga instruction
1466809|NCT03220932|Procedure|Cytoreductive surgery combined with HIPEC|Cytoreductive surgery combined with HIPEC (Cisplatin 70 mg/m2).
1466810|NCT03220932|Drug|Chemotherapy and bevacizumab (CT-BEV)|Chemotherapy and bevacizumab (CT-BEV) 15 mg/kg once every 3 weeks from enrollment until disease progression (RECIST 1.1)
1466811|NCT03220919|Other|Weight-based|Glargine titration: 0.1U/kg per day when FBG is over 8.0 mmol/L. Aspart titration: total dose 0.1U/kg per day when next pre-meal BG is over 8.0 mmol/L, which is divided into three equal parts adding to three pre-meal boluses
1466812|NCT03220919|Other|Glucose level-based|"Glargine titration: 4, 6, or 8 U when FBG is, respectively, within the following ranges: 8.0-8.9, 9.0-9.9, >10.0 mmol/L.
Aspart titration: 1, 3, 5, 7 or 8 U when next pre-meal BG is, respectively, within the following ranges: 8.0-10.9, 11.0-13.9, 14.0-16.9, 17.0-19.9, > 20 mmol/L."
1466813|NCT03220906|Other|Blood pressure measurement|Blood pressure will be measured in both upper and lower extremities.
1466814|NCT03220893|Diagnostic Test|Molecular Breast Imaging|Molecular breast imaging (MBI) is a new nuclear medicine technique that utilizes small semiconductor-based γ-cameras in a mammographic configuration to provide high-resolution functional images of the breast.
1466815|NCT03220893|Diagnostic Test|Digital Breast Tomosynthesis|Digital Breast Tomosynthesis (DBT) creates a three dimensional picture of the breast using X-rays.
1466816|NCT03220880|Drug|Intranasal dexmedetomidine|Intranasal dexemedetomidine (100 mcg/mL), 0.5 to 4 mcg/kg
1466817|NCT03220867|Drug|Risperidone: Xian Risperdal (test)|Participants will receive 1*1 mg tablet of Xian Risperdal under fasting or fed condition.
1466818|NCT03220867|Drug|Risperidone: Gurabo Risperdal (reference)|Participants will receive 1*1 mg tablet of Gurabo Risperdal under fasting or fed condition.
1948252|NCT02601573|Drug|Grazoprevir|GZR 100 mg provided in a FDC tablet also containing EBR 50 mg (MK-5172A) taken q.d. by mouth in the morning.
1948253|NCT02601573|Drug|Elbasvir|EBR 50 mg provided in a FDC tablet also containing GZR 100 mg (MK-5172A) taken q.d. by mouth in the morning.
1948254|NCT02601573|Drug|Ribavirin|RBV 200 mg capsules taken b.i.d. (morning and evening) by mouth at a total daily dose of 800 mg to 1400 mg based on participant body weight.
1466822|NCT03220841|Drug|Adalimumab Injection|Standard dose adalimumab induction and maintenance
1466823|NCT03220841|Drug|Thiopurine|Dose optimized thiopurine
1466824|NCT03220828|Behavioral|Technology Based Distractions|Technology based distractions (VR headsets, AR headset, tablets, or BERT projector)
1466825|NCT03220815|Procedure|Drilling at low speed|
1466826|NCT03220815|Procedure|Conventional drilling at high speed|
1466828|NCT03220789|Procedure|Drilling at low speed|
1466829|NCT03220789|Procedure|Drilling at conventional or high speed|
1466830|NCT03220776|Drug|N-Acetylcysteine|5 day trial of N-acetylcysteine with titration to 2,400mg
1466831|NCT03220776|Drug|Gabapentin|5 day trial of gabapentin with titration to 1,200mg
1466832|NCT03220776|Drug|Placebo Oral Tablet|5 day trial of matched placebo
1466833|NCT03220763|Other|This is an observational study--there is no intervention.|This is an observational study, there is no intervention.
1948255|NCT02601573|Drug|Sofosbuvir|SOF 400 mg tablet taken q.d. by mouth in the morning with food.
1948256|NCT02599922|Biological|rAAV2tYF-PR1.7-hCNGB3|rAAV2tYF-PR1.7-hCNGB3 is a non-replicating, rep/cap-deleted, recombinant adeno-associated virus vector that expresses the CNGB3 gene.
1466836|NCT03220724|Biological|CH505TF|Administered by intramuscular (IM) injection in the thigh
1466837|NCT03220724|Biological|CH505w53|Administered by IM injection in the thigh
1466838|NCT03220724|Biological|CH505w78|Administered by IM injection in the thigh
1466839|NCT03220724|Biological|CH505w100|Administered by IM injection in the thigh
1466840|NCT03220724|Biological|DNA Mosaic-Tre|Administered by IM injection in the thigh
1466841|NCT03220724|Biological|GLA-SE adjuvant|Admixed with all CH505 gp120 proteins
1466842|NCT03220724|Biological|Placebo|Administered by IM injection in the thigh
1466843|NCT03220711|Device|confocal endomicroscope|"This instrument provides real-time endoscopic histology to guide endoscopic biopsy or endoscopic mucosal resection (EMR) in the patient study group during colonoscopies."
1466844|NCT03220711|Drug|Fluorescein|Fluorescent dye used for imaging contrast only.
1466845|NCT03220698|Device|Tracheal ultrasonography|Tracheal ultrasonography
1466846|NCT03220685|Biological|Stool analysis|Bacterial extraction in faeces by repeated fractional centrifugation to obtain bacterial mass and DNA sequencing.
1466847|NCT03220672|Behavioral|Tailored assessment and educational|Intervention will consist of 45 minutes of anatomy education, pelvic floor assessment and neuromuscular re-education. Women will be given an explanation of how the pelvis is composed, including the viscera and pelvic floor function and anatomy, through a simple explanatory sheet. They will be also informed of the causes of pelvic floor deterioration as well as its consequences.. Neuromuscular re-education will continued by teaching them how to perform slow contractions, fast contractions and lifting contraction. They will be also shown vaginal cones and advised on possible treatment methods if they were needed. After that, women will be given a tip sheet to improve pelvic floor function. Those recommendations will included: Tips to take into account during habits like urination, doing sport, gymnastics or any efforts, pelvic floor muscles exercises and how to use vaginal cones adequately.
1466850|NCT03220646|Drug|abemaciclib|abemaciclib 200mg PO q12 hours (+/- 2 hours) on days 1-28 of each 28 day cycle.
1466851|NCT03220646|Drug|abemaciclib|200mg PO q12 hours (+/- 2 hours) for 4-7 days prior to surgery upon recovery from surgery, patients will resume abemaciclib at the same dose and schedule as cohorts A and C.
1466852|NCT03220633|Drug|ATB-346|
1466853|NCT03220633|Drug|Placebo|
1466854|NCT03220620|Other|GDT|individualized fluid therapy
1466898|NCT03220321|Other|Lithium disilicate (IPS e.max) hybrid abutment crown|Glass ceramic
1466856|NCT03220594|Procedure|hypogastric artery ligation|hypogastric artery ligation is the ligation of the internal iliac artery to stop bleeding related to obstetrics obstetric hemorrhage Hysterectomy is the removal of the uterus if bleeding can't stop by hypogastric artery ligation
1466859|NCT03220568|Other|Fatty acids present in adipose tissue samples|
1466860|NCT03220555|Device|Buzzy® device|Just before the vaccination or venipuncture the device will be applied on the selected site during 30 seconds and then it will be moved 5 cm above the selected site to make the injection or the puncture. The child will choose if he wants to use the cooling system.
1466861|NCT03220555|Drug|EMLAPATCH (lidocaine, prilocaine)|The patch will be applied during 1 hour to 1 hour and half before the vaccination or venipuncture, on the selected site. After 1 hour to 1 hour and half, it will be removed and the injection or the puncture will be made on the selected site.
1466862|NCT03220542|Drug|Probiotics|Saccharomyces boulardii
1466863|NCT03220542|Dietary Supplement|Broccoli|Broccoli sprouts extract
1466864|NCT03220542|Drug|Esomeprazole|Esomeprazole
1466865|NCT03220542|Drug|Amoxicillin|Amoxicillin
1466866|NCT03220542|Drug|Clarithromycin|Clarithromycin
1466867|NCT03220529|Device|Brillouin Ocular Scanner|
1466868|NCT03220516|Procedure|single use digital ureteroscope|All participants in this arm will undergo RIRS using a single use digital ureteroscope.
1466869|NCT03220516|Procedure|reusable fiberoptic ureteroscope|All participants under this arm will undergo RIRS using a reusable fiberoptic ureteroscope
1466870|NCT03220516|Procedure|reusable digital flexible ureteroscope|All participants under this arm will undergo RIRS using reusable digital flexible ureteroscope
1466871|NCT03220503|Procedure|endometrial injury|single induced injury will be done on the posterior endometrium on day 7 of the transfer cycle by using modified Cook catheter.
1466872|NCT03220490|Behavioral|5 minute interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs while keeping a five minute time interval between instillation of the first and second drug for a duration of one month.
1466873|NCT03220490|Behavioral|no interval between regular glaucoma drops - Long term|In the selected eye, the patient will be asked to take his two regular IOP reduction drugs one after the other with no waiting period for a duration of one month.
1466874|NCT03220490|Drug|IOP reduction of Brimonidine and Timolol with time interval|"In the selected eye the subject will be given two types of IOP reduction drops: first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given with a time interval of five minutes between the first and second drop."
1466875|NCT03220490|Drug|IOP reduction of Brimonidine and Timolol no time interval|"In the selected eye the subject will be given two types of IOP reduction drops:first Brimonidine, Alphagan® (an alpha-agonist) followed by Timolol, Tiloptic® (a beta-blocker). The drops will be given one after the other with no waiting period."
1466876|NCT03220477|Drug|Pembrolizumab|Pembrolizumab will be administered at 200mg IV on day 1 of each 21 day cycle.
1466877|NCT03220477|Drug|Guadecitabine|Guadecitabine will be administered subcutaneously given daily on days 1-5 of each cycle with escalating doses by cohort.
1466878|NCT03220477|Drug|Mocetinostat|Mocetinostat will be administered orally with escalating doses on days 8, 10, 13, 15, 17 and 20 of each cycle with escalating doses by cohort.
1466879|NCT03220464|Radiation|Ultra low dose chest computed tomography (ULDCT)|Participants in the study will receive ULDCT at enrollment, after 3-month visit, and after 12-month visit.
1466880|NCT03220464|Radiation|Chest X-ray|Participants in the study will receive chest x-ray at enrollment, after 3-month visit, and after 12-month visit.
1466881|NCT03220464|Diagnostic Test|Interferon-gamma Release Assay (IGRA)|Participants in the study will receive IGRA test at enrollment, after 3-month visit, and after 12-month visit. About 11mL of blood will be drawn from the participants for test of T-SPOT®.TB test and QuantiFERON test.
1466882|NCT03220451|Procedure|Adhesive elastic taping|Adhesive elastic taping placed around a pressure ulcer, according to a planned placement technique
1466884|NCT03220425|Drug|Insulin detemir|
1466885|NCT03220425|Drug|NPH insulin|
1466886|NCT03220412|Behavioral|Movies without Guns|Participants in this arm viewed movies (National Treasure, The Rocketeer) without guns. The movies, rated PG, were edited to remove guns from the scenes
1466887|NCT03220399|Drug|NVP-1603-1 (P)|1capsule, single oral dosing
1466888|NCT03220399|Drug|NVP-1603-2 (T)|1tablet, single oral dosing
1466889|NCT03220399|Drug|NVP-1603-1 and NVP-1603-2 (P+T)|1capsule and 1tablet co-administration, oral single dosing
1466890|NCT03220386|Other|Decolonization by nasal Octinidin treatment and skin washings|Patients receive nasal Octinidin treatment and skin washings for five consecutive days
1466891|NCT03220360|Procedure|indirect pulp capping|Sixty children with deep caries of deciduous teeth underwent indirect pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
1466892|NCT03220360|Procedure|direct pulp capping|Sixty children with deep caries of deciduous teeth underwent direct pulp capping and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
1466893|NCT03220360|Procedure|vital pulpotomy|Forty-five children with deep caries of deciduous teeth underwent vital pulpotomy and they were selected and randomized into four groups according to pulp capping agents: MTA group, calcium hydroxide group, Biodentine group and TheraCal group.
1466894|NCT03220347|Drug|CC-90010|CC-90010 is an oral, potent and reversible inhibitor of the epigenetic target bromodomain and extra-terminal (BET) proteins.
1466895|NCT03220334|Drug|Platelet rich plasma|The experimental group was treated with PRP for artificial gastric ulcer after ESD.
1466896|NCT03220334|Drug|Normal saline|The control group was treated with normal saline for artificial gastric ulcer after ESD.
1466897|NCT03220321|Other|PICN (VITA Enamic) hybrid abutment crown|Hybrid ceramic
1561108|NCT02518945|Drug|Insulin|
1466899|NCT03220308|Other|MYmind mindfulness training|The MYmind mindfulness training uses a standardised protocol based on mindfulness-based cognitive therapy. It consists of 8 weekly group sessions of 90 minutes for youth with ADHD, and parallel mindful parenting training for the parents. Eight weeks after the last session there is a single 90 minutes booster session.
1466900|NCT03220308|Other|Care-as-usual for children (8-16 years old) with ADHD|According to the Dutch Multidisciplinary guidelines for the diagnosis and treatment of ADHD, care-as-usual for children aged 8-16 years with ADHD consists of psycho-education and the prescription of medication approved for ADHD and/or evidence-based parent and/or teacher-administered behaviour therapy, preferably both medication and behaviour therapy. First-line option for medication is a psychostimulant, second-line option is atomoxetine, and third-line options are alpha-2 presynaptic agonists or tricyclic antidepressants (imipramine).
1466901|NCT03220295|Drug|Single Dose of VU319|Single dose of VU319
1466902|NCT03220295|Drug|Single Dose Placebo|Single dose of placebo
1466903|NCT03220295|Other|Fed State|drug is given 30 minutes after a high fat breakfast
1466904|NCT03220295|Other|Fasted State|drug is given after an overnight fast
1466905|NCT03220295|Drug|Dose Escalation of VU319|dose levels of the cohorts will be increased step wise
1466906|NCT03220295|Drug|Placebo Dose Escalation|dose levels of the cohorts will be increased step wise
1466909|NCT03220269|Other|Out-of-hospital cardiac arrest (OHCA)|Data collection
1466910|NCT03220269|Other|In-hospital cardiac arrest (IHCA)|Data collection
1466911|NCT03220256|Drug|Lamotrigine|The dose of lamotrigine (0.1mg) started to increase and gradually increased according to the drug tolerance induction protocol, and the efficacy was evaluated by dosing to the commercial capacity (100mg bid) within 2 weeks. In addition, the ratio of regulatory T cells was measured before lamotrigine administration, and the proportion of regulatory T cells was measured by two-week administration of lamotrigine after tolerance induction protocol. Add 6 ml of EDTA tube to each cryovial, and dispense 1 ml each in cryovial. After the appropriate number of patients of the same phenotype were collected, the analysis was performed.
1466913|NCT03220217|Drug|68Ga-OPS202|Positron emission tomography (PET) imaging agent
1466914|NCT03220204|Behavioral|PP-based health behavior intervention|The positive psychology exercises include 3 modules: gratitude-based activities, strength-based activities, and meaning-based activities. The goal-setting portion of the program focuses primarily on physical activity (8 weeks) but also includes 4 weeks focusing on diet and medication adherence.
1466915|NCT03220204|Behavioral|MI-based educational control condition|The MI-based educational program includes information on five topics: (1) information about heart disease and risk factors for worsening heart disease, (2) physical activity, (3) a heart-healthy diet, (4) medication adherence, and (5) stress management.
1466918|NCT03220178|Drug|Palbociclib|Palbociclib 125mg/day orally dosed for 3 weeks followed by 1 week off; repeated for each treatment cycle
1466919|NCT03220178|Drug|Fulvestrant|500mg per use-after first application, again at wk2, then once per month
1466920|NCT03220178|Drug|Anastrozole|1mg per day
1466921|NCT03220178|Drug|Letrozole|2,5mg/day
1466922|NCT03220178|Drug|Exemestane|25mg/day
1466923|NCT03220165|Drug|MGL-3196|oral, 100 mg
1466924|NCT03220152|Drug|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
1466925|NCT03220139|Other|fat intake|Observational study on fat intake and mortality
1466926|NCT03220126|Biological|LY3074828|Administered IV
1466927|NCT03220126|Biological|LY900021|Administered SC
1466928|NCT03220113|Combination Product|Dexamethasone, Lidocaine, Thiamine cohort|Bilateral and simultaneous administration of composition of De-Novo Treatment Cohort medication (Dexamethasone, Lidocaine, Thiamine) into the trigeminal and greater/lesser occipital nerves in one session.In children and hypersensitive individuals with needle phobia pre-treatment of skin with Lidocaine 2.5% Prilocaine 2.5% cream, and oral Alprazolam 0.25 mg (an Anxiolytic) 2 hours prior to initiation of procedure will be used.
1466929|NCT03220100|Other|Stepped Palliative Care|Palliative care clinicians will develop a therapeutic relationship with participants and address their symptoms, coping, prognostic awareness and illness understanding, treatment decision-making, and end of life care needs and preferences.
1466930|NCT03220087|Other|Data collection|The study consists of a single visit in which socio-demographic and clinical variables will be collected from the medical record or directly from the patient. In addition, the physician will provide information on the clinical status of the disease and the patient will fill in the questionnaire.
1466931|NCT03220074|Drug|Oral Tablet|study drug given and monitored for efficacy and tolerability
1466932|NCT03220061|Behavioral|music therapy|
1466933|NCT03220048|Drug|PrEP-001|
1466934|NCT03220048|Other|Placebo Comparator|
1948263|NCT02592967|Biological|JNJ-64041757 (Cohort 1A and 1B)|JNJ-64041757 will be administered IV at a lower dose in Cohort 1A (1x10^8 colony forming units [CFU] ) and at a higher dose in Cohort 1B (1x10^9 CFU)
1466937|NCT03220022|Drug|Cyclophosphamide|Given IV
1466938|NCT03220022|Drug|Doxorubicin Hydrochloride|Given IV
1466939|NCT03220022|Drug|Etoposide|Given IV
1466940|NCT03220022|Biological|Filgrastim|Given SC
1466941|NCT03220022|Drug|Ibrutinib|Given PO
1466942|NCT03220022|Other|Laboratory Biomarker Analysis|Correlative studies
1466943|NCT03220022|Biological|Pegfilgrastim|Given SC
1466944|NCT03220022|Other|Pharmacological Study|Correlative studies
1466945|NCT03220022|Drug|Prednisone|Given PO
1466946|NCT03220022|Biological|Rituximab|Given IV
1466947|NCT03220022|Drug|Vincristine Sulfate|Given IV
1466955|NCT03219983|Drug|Ropivacaine|Patients will have an interscalene block under ultrasound guidance and receive .5% ropivacaine pre-operatively. Upon arrival to the Post-Operative Care Unit a continuous infusion of .5% ropivacaine will be started at 8ml/hr and increased by 2ml/hr every 15 minutes for pain score > 4 with a maximum rate of 14ml/hr. Infusion will be delivered by ON-Q Select-a-Flow pump (volume 750ml)
1466956|NCT03219983|Drug|liposomal bupivacaine|A total injection volume of 100ml will be comprised of 60ml 0.9% normal saline+ 20ml .5% bupivacaine + 20ml liposomal bupivacaine will be administered into the deep tissue of the operative are with an 18 or 20 gauge needle.
1466957|NCT03219970|Drug|Osimertinib|80mg oral daily
1466958|NCT03219957|Drug|AT-527|Ascending doses of AT-527 administered orally.
1466959|NCT03219957|Other|Placebo Comparator|Matching placebo
1466960|NCT03219944|Procedure|Platelet Rich Fibrin|: Platelet Rich Fibrin for soft tissue augmentation around implant in the aesthetic zone
1466961|NCT03219944|Procedure|sub epithelial connective tissue graft|sub epithelial connective tissue graft for soft tissue augmentation around implant in the aesthetic zone
1466962|NCT03219931|Drug|Bifidobacterium breve BR03 and Bifidobacterium breve B632|This is the active product containing 108 viable cells/strain
1466963|NCT03219931|Drug|Placebos|This is the placebo product containing a similar product without bifidobacterium inside.
1466964|NCT03219918|Device|EndoRings II Distal Attachment|Colonoscopy cap
1466965|NCT03219905|Device|Therapeutic Kinesio-taping|"The experimental group received a therapeutic Kinesio Tape application. Three I strips were applied to the both ankle joints for joint stability with subject's ankle at 90 degrees."
1466966|NCT03219905|Device|Sham Kinesio-taping|"The control group received a sham Kinesio Tape application. Ankle position was hold at minimally plantar flexion during taping. AI strip was placed from the anterior midfoot, not stretched and attached to the midline of anterior leg."
1466967|NCT03219892|Device|High-frequency rTMS|It is delivered at a 5-second burst of 10Hz stimuli, repeated 20 times at every minute. Each treatment contains a total of 1000 pulses. Stimulus intensity is 90% of resting motor threshold. The SMA stimulation will be given using a coil centered at points 3-cm anterior to the leg motor area in the sagittal midline.
1466968|NCT03219892|Device|Sham rTMS|The procedure will be same as the high-frequency rTMS except that the coil is 90° angled away.
1466978|NCT03219853|Dietary Supplement|selenium enriched parsnips|Parsnips which have been grown in a selenium enriched enviroment
1466979|NCT03219853|Dietary Supplement|Conventional parsnips|Parsnips which have been grown in a conventional enviroment
1466982|NCT03219827|Other|Human biological samples|Blood samples collection
1466983|NCT03219814|Other|The Body Project|The Body Project is a dissonance-based body-acceptance program designed to help high school girls and college-age women resist cultural pressures to conform to the appearance ideal standard of female beauty and reduce their pursuit of unrealistic bodies. The Body Project is supported by more research than any other body image program and has been found to reduce onset of eating disorders.
1466984|NCT03219814|Other|Mediapsychoeducation|Mediapsychoeducation is used to educate individuals on psychological issues through the use of various medias, in this study mediapsychoeducation is being used to educate individuals on eating disorders and the thin ideal.
1466985|NCT03219801|Biological|mesenchymal stem cells|SLE patients in the treated group were given human umbilical cord derived mesenchymal stem cells by intravenous infusion and conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1, 3 and 6months were evaluated respectively the curative effect.
1466986|NCT03219788|Drug|Normal Saline|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline will be given
1466987|NCT03219788|Drug|Remifentanil 0.1 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.1 ug/kg Remifentanil will be given
1466988|NCT03219788|Drug|Remifentanil 0.2 ug/kg|All the patient will be anesthetized using a standard anesthetic technique. One ml normal saline contains 0.2 ug/kg Remifentanil will be given
1466989|NCT03219775|Biological|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 4)
If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)
If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)
If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)
If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 1 mg/kg i.V. and Ipi 3 mg/kg i.V. / Q3W x 2)
If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)"
1467022|NCT03219515|Drug|Gongjin-Dan|Gongjin-dan (Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea) is composed of Cervi Parvum, Angelica Gigas Root, Cornus Fruit, Ginseng, Steamed Rehmannia Root, and Musk.
1466990|NCT03219762|Drug|Nabpaclitaxel|Chemotherapy will be continued until a maximum of 6 courses or progressive disease or intolerable toxicity or patient refusal. In patients with confirmed and prolonged disease response, clinical benefit and good tolerance to study drug treatment, the investigators can evaluate to continue therapy beyond 6th cycle, after discussion with Principal Investigator (PI) of the study
1466991|NCT03219749|Behavioral|exercise training|Eligible participants will undergo 6 weeks of a combined aerobic and resistance exercise intervention. Training will take place 3 times per week for 1 hour. Forty minutes will be dedicated to aerobic training while 15 to 20 minutes will be devoted to resistance training.
1466992|NCT03219736|Procedure|Standard of Care therapies|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from the control arm (Group 1) requires an escalation of therapy, they may be moved from the group to the NIPPV/BiPAP group (Group 2) or be removed from the study (i.e. if intubated).
1466993|NCT03219736|Device|NiPPV Therapy|If at any point during the treatment it is deemed medically necessary by the treating PED attending that a subject from a NIPPV/BiPAP group (Group 2) is not tolerating NIPPV they may be removed from the study. Patients may not tolerate NIPPV due to agitation, vomiting or need for escalation of care.
1466994|NCT03219736|Procedure|Routine Respiratory Care|It may be up to the treating physicians discretion to treat patient with other medications that are currently used to treat severe asthma exacerbations, such as Epinephrine and Terbutaline
1466995|NCT03219723|Drug|Vonoprazan|Vonoprazan tablets
1466996|NCT03219723|Drug|Amoxicillin hydrate|Amoxicillin hydrate (potency)
1466997|NCT03219723|Drug|Clarithromycin|Clarithromycin (potency)
1466998|NCT03219723|Drug|Metronidazole|Metronidazole
1466999|NCT03219710|Drug|Ondansetron|Ondansetron will be given at a dosage of 0.15mg/kg IV/PO q8h.
1467000|NCT03219710|Drug|Dexamethasone|Dexamethasone will be given as 3mg/m2 IV/PO q8h.
1467001|NCT03219710|Drug|Aprepitant|Aprepitant will be given as per the weight. weight (15-40kg) - Day1 to Day 3 - 80 mg PO weight (>40 kg) - Day 1 -125mg , Day 2 & Day 3 - 80 mg PO
1467002|NCT03219710|Drug|Olanzapine|olanzapine will be given as 0.14mg/kg PO (rounded off to nearest 2.5 mg )
1467003|NCT03219697|Behavioral|Parenting education program|If you are in the parenting education program group, you will be enrolled in our 10-week parenting education program, followed by three monthly 1-hr sessions. You and/or your partner will attend weekly parenting sessions which will take place at the office of your child's primary care provider for 10 weeks, followed by 3 booster sessions. Our Toronto Public Health Nurse, will arrange 2-4 home visits with you and your family during the 6 months. This first home visit will include learning more about your routines at home, and what is available in your neighbourhood. The home visits will focus on helping to apply the messages and skills from the group sessions in your home, and making connections in your neighbourhood that you find helpful such as recreational or nutrition programs or other supports for your family.
1467004|NCT03219684|Diagnostic Test|serum protein ,kidney function ,liver function.,serum cholesterol|monthly review of serum protein kidney function ,liver function and serum cholesterol in all patients
1467005|NCT03219671|Drug|Nivolumab|nivolumab 240mg every 2 weeks
1467006|NCT03219671|Drug|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks
1467007|NCT03219658|Behavioral|Parenting education sessions|If assigned to the parenting education session group, families will start with the 10-week group parenting education sessions and 2-4 home visits immediately after being enrolled. During this time, they will also come in for four one-on-one check-ins with the STOMP team. Each check-in will be approximately 1 hour. At least one parent/caregiver will attend weekly parenting sessions which will take place at SickKids. The Toronto Public Health Nurse will arrange 2-4 home visits with the family during the 6 month period of the study. The home visits will focus on helping to apply the messages and skills from the group sessions in their homes, and making connections in the neighbourhood to recreational or nutrition programs or other supports for the family.
1467008|NCT03219645|Drug|Ginkgo Diterpene Lactone Meglumine Injection|The injection must be added slowly into 0.9% sodium chloride injection and diluted to 250 ml , intravenous drip for about 2 hours.
1467009|NCT03219645|Drug|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) given in a total dose of 300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 14.
1467010|NCT03219632|Drug|Fimasartan|Fimasartan is a non-peptide angiotensin II receptor antagonist (ARB) used for the treatment of hypertension and heart failure.
1467011|NCT03219619|Device|Cap-EGD|Undergoing cap-assisted endoscopy
1467012|NCT03219619|Device|Duo|Undergoing side-viewing duodenoscope
1467013|NCT03219606|Other|Organized education course of Modified Rodnan Skin Scoring|"Lecture: An expert rheumatologist (master instructor) give a lecture to explain the technique of Modified Rodnan Skin Scoring (MRSS).
Demonstration: Master instructor demonstrate the patient assessment without revealing his score.
Practical training: Participants assess the MRSS of 8 patients with systemic sclerosis. Two other expert rheumatologists assist the course."
1467014|NCT03219593|Drug|Apatinib mesylate tablets|Apatinib is taken 500 mg every day orally, half hour after breakfast with warm water. The drug is taken 4 weeks one cycle until disease progression or intolerable toxicity or death. The dose of the study drug may be decreased to 250 mg/d following the occurrence of a clinically significant adverse event (AE). Treatment will be discontinued if the subject is unable to tolerate a daily dose of 250 mg.
1467015|NCT03219580|Drug|5-Fluorouracil|50mg/ml concentration of 5-Fluorouracil to be injected intra-dermally in direct brow skin incisions
1467016|NCT03219580|Drug|Normal Saline Flush, 0.9% Injectable Solution|0.9% concentration of Normal Saline Injectable Solution to be injected intra-dermally in direct brow skin incisions
1467017|NCT03219554|Drug|Palbociclib|oral palbociclib 125mg daily for 21days followed by a 7-day break. Cycle will be repeated every 28 days.
1467018|NCT03219541|Behavioral|Interventional Automated mobile phone text|Participants will receive 2 messages per day in the pre-quit phase, 3 messages per day on the quit date and the first week in the post-quit phase, and 2 messages per day in the last 3 weeks of the intervention.
1467019|NCT03219541|Behavioral|Control Automated mobile phone text|Participants will receive 2 text questions each week asking the number of smoking days in the past week and the average number of cigarette smoked per day.
1467023|NCT03219515|Drug|Placebo|Placebo drugs (similar in appearance, taste, and odor to the Gongjin-dan) contains excipients, coloring agents, binders, flavoring agents, and preservative, and gilt-paper covering. Placebo pills of Gongjin-dan will be also made by Iksu Pharmaceutical Co. Ltd, Gwangju, Republic of Korea.
1948264|NCT02592967|Biological|JNJ-64041757 (Cohort 2A and 2B)|JNJ-64041757 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
1948265|NCT02589119|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
1948266|NCT02588612|Genetic|Autologous Genetically modified T cells, NY-ESO-1ᶜ²⁵⁹T|
1948267|NCT02585713|Drug|Apixaban|Given PO
1948268|NCT02585713|Drug|Dalteparin|Given SC
1467029|NCT03219489|Other|Electronic medical record alert|"An electronic medical record alert will be inserted into the clinic's electronic medical records. The alert reads: The odds of PTB are decreased with natural progesterone by 50% <34 weeks and 40% <37 weeks. The odds of neonatal death from PTB are also halved. Most trials used 200 mg per vagina nightly, >/=16 weeks. Contraindications: allergy to progesterone.
This alert will appear on the Ministry of Health-mandated Antenatal Records."
1467030|NCT03219476|Drug|Anastrozole|1 mg once daily.
1467031|NCT03219476|Drug|Letrozole|2.5mg once daily.
1467032|NCT03219476|Drug|Exemestane|25 mg once daily.
1467033|NCT03219476|Drug|Tamoxifen|20 mg once daily.
1467034|NCT03219463|Dietary Supplement|Ginger|3g ginger powder supplement once a day with meals (preferably in the morning) for a duration of 8 weeks. Powder can be mixed with juice or water.
1467035|NCT03219450|Drug|NeoVax|It stimulates the immune system to attack cancer cells.
1467036|NCT03219450|Drug|Cyclophosphamide|It is a chemotherapy drug used to treat many cancers. At low doses, it is an investigational drug to help the immune cells to be better at attacking cancer cells while avoiding chemotherapy toxicity.
1467039|NCT03219411|Dietary Supplement|Cinnamon|Cinnamon burmannii administered orally as 500-mg capsules three times a day over 12 weeks
1467040|NCT03219411|Other|placebo|Placebo administered orally as capsules three times a day over 12 weeks
1467041|NCT03219398|Procedure|Pneumoperitoneum pressure|Subjects were set to 8- 10 mmHg pressure during laparoscopic surgery; Subjects were set to 12-14 mmHg pressure during laparoscopic surgery
1467042|NCT03219385|Device|Mirabilis System|The intervention is a transabdominal treatment performed with the Mirabilis System, during which high-intensity focused ultrasound (HIFU) is applied noninvasively through the skin using an applicator placed against the abdomen. One or more appropriately selected uterine fibroids will be treated with HIFU using integrated ultrasound imaging to guide the treatment. HIFU causes localized heating and mechanical effects to develop in the targeted fibroid(s) that result in therapeutic destruction of the fibroid tissue, leading to improvement in related symptoms.
1467043|NCT03219372|Drug|Pravastatin Pill|statin
1467044|NCT03219372|Drug|Placebo Oral Tablet|placebo
1467045|NCT03219359|Procedure|Autologous stem cell transplant|Hematopoietic stem cell transplantation
1467046|NCT03219359|Drug|Vedolizumab|Starting first day after discharge from transplant admission, then 2 weeks after 1st infusion, 4 weeks after 2nd infusion, followed by every 8 weeks for 52 weeks (8 doses)
1467047|NCT03219359|Drug|Cyclophosphamide|Days 1 and 2: Cyclophosphamide 2gm/m2/day x 2 days (total dose 4gm/m2) Day 3 until leukapheresis: G-CSF 10μg/kg/day to CD34+ >20x104/ml then leukapheresis daily to collection goal
1467048|NCT03219359|Drug|Cyclophosphamide|Day -5 to -2: Cyclophosphamide 50 mg/kg/day (200 mg/kg total dose)
1467049|NCT03219359|Drug|Thymoglobulin|Day -3 to -1: 2.5 mg/kg/day (7.5 mg/kg total dose)
1467050|NCT03219359|Drug|Methylprednisolone|Day -3 to -1: 500mg prior to each dose
1467051|NCT03219346|Other|oral care program|Oral care (sputum and special needs of people cleaning teeth) time for three days a week (with swallowing treatment time before), once a day, each about 10 minutes of oral care program.
1467053|NCT03219320|Drug|NYX-2925|NYX-2925 is a new molecular entity that modulates the N-methyl-D-aspartate receptor (NMDAR).
1467054|NCT03219320|Drug|Placebo|Matching Placebo capsules.
1467055|NCT03219307|Combination Product|NOVOCART 3D|Matrix associated autologous chondrocyte implant
1467056|NCT03219294|Drug|Vecuronium 0.1 mg/kg|Vecuronium will be administered to achieve and maintain 1 to 2 TOF contractions.
1467057|NCT03219294|Drug|Vecuronium 0.2mg/kg|Vecuronium will be administered to achieve and 0 TOF/PTC 1-2.
1467060|NCT03219242|Device|Caiman® device|Using CAIMAN device in primary surgery for ovarian cancer. Analyze potential time-sparing and the incidence of post-surgical complications.
1467061|NCT03219216|Drug|Glecaprevir/Pibrentasvir|Film-coated tablet
1467062|NCT03219203|Biological|Hepatitis B vaccine|Hepatitis B vaccine (20 µg/ml) 1 ml intramuscular injection in single (at 0 month) or 3-dose series (at 0, 1, 6 months)
1948269|NCT02585713|Other|Questionnaire Administration|Ancillary studies
1948270|NCT02578225|Other|Non interventional study|
1948271|NCT02576470|Behavioral|Biofeedback|Motor learning is improvement in movement overtime, followed by retaining what was learned. To determine whether movements are improving, kinematics must be assessed over time, beginning with defining specific kinematic goals, then continually re-evaluating goals throughout rehabilitation while providing the participants with biofeedback. Biofeedback is fundamental in motor learning, because it increases guidance and motivation, supplements losses in intrinsic feedback (proprioception), and facilitates generalization and retention. Biofeedback enhances the training of novel movements and could be essential for training swallowing maneuvers. Biofeedback training will occur 3 times.
1467063|NCT03219190|Behavioral|LST High School Online|The proposed preventive intervention for high school PDA will (1) utilize both online e-learning modules and interactive classroom sessions to address PDA and concurrent alcohol/drug abuse; (2) positively change social norms surrounding PDA and alcohol/drug abuse; (3) challenge positive expectancies about the benefits of PDA; (4) discourage diversion of prescription medication; (5) enhance protective factors by building social, self-regulation, and relationship skills through interactive learning and behavioral rehearsal scenarios; and (6) include online booster sessions.
1467064|NCT03219177|Behavioral|Patient education regarding indications for opioid use and side effects of opioid use after hand surgery|Patients in the active education group will be given information pre-operatively on the current opioid epidemic, alternative pain management strategies that should be tried before proceeding to prescription opioid use, appropriate indications for opioid use, and side effects of opioids.This information will be reinforced by the research coordinator and nursing staff in the post-anesthesia care unit.
1467065|NCT03219177|Other|Standard of care post-operative counseling|Patients will receive standard of care post-operative counseling. They will not be given pre or post-operative opioid education.
1948272|NCT02576470|Device|Transcranial Direct Current Stimulation|Weak direct currents can be applied non-invasively, transcranially and painlessly. Such application leads to transient changes in corticomotor excitability that are fully reversible. There are no known risks of tDCS of the brain, other than mild local discomfort at the electrode sites.The tDCS sessions will be separated by at least 24hrs, the electrode pads will not be used more than 4 times and they will be clean with a sterile saline solution.
1948273|NCT02576470|Behavioral|Financial Reward|Motor learning training can be enhanced by adjuvant techniques such as non-invasive neural stimulation and explicit reward. Both influence the primary motor cortex (M1), a key neural substrate of motor skill learning. Non-invasive neural stimulation reduces dysphagia after stroke as measured with subjective swallowing severity scales, however it is unknown whether it could also enhance swallowing maneuver training. Explicit reward (i.e. financial) incentivizes successful gains during motor training. Explicit reward has never been investigated in swallowing rehabilitation. However, it has been shown that increasing stress and financial penalty can reduce swallowing frequency in healthy adults.
1467068|NCT03219151|Device|eMAR game|The eMAR simulator videogame affords students a virtual and immersive opportunity to practice medication administration using an eMAR system, in a structured fashion that provides real-time feedback related to best-practices and safety compliance of the medication process
1467069|NCT03219151|Other|Normal pre-work|Participants complete normal education pre-work related to eMAR administration, in advance of simulated return-demonstration
1467070|NCT03219138|Device|Acceleromyography|Use of an uncalibrated acceleromyography
1467071|NCT03219125|Device|Dixon Magnetic Resonance Imaging|MRI of the lumbar spine (L1 to L4) and hip (non-dominant) for the measurement of Ad Med. (In%) by the DIXON sequence.
1467072|NCT03219125|Device|dual-energy X-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
1467073|NCT03219112|Other|Balance rehabilitation using X-box One & Kinect|the virtual reality games (Kinect sports rivals) can be controlled with movements of the body that are registered through the kinect camera.
1467074|NCT03219086|Procedure|combined spinal epidural anaesthesia|To give surgical anesthesia for performance of the caesarian section a combined spinal epidural anesthesia will be performed with different spinal solutions according to the appointed study group
1467075|NCT03219086|Drug|Prilocaine|A combined spinal epidural anesthesia with spinal administration of 50 mg hyperbaric prilocaine 2% (Tachipri, Nordic Pharma) + 2,5mcg sufentanyl (5 mcg/ml) (Janssens-cilag)
1467076|NCT03219086|Drug|Bupivacaine|combined spinal epidural anesthesia with spinal administration of 7,5 mg hyperbaric bupivacaine 0,5% (Marcaine H) + 2,5mcg sufentanyl ( 5 mcg/ml)( Janssens -cilag) +1 ml nacl0,9%
1467077|NCT03219073|Device|Active tDCS using tDCS device|Active tDCS using tDCS device is a noninvasive brain stimulation technique that utilizes low amplitude direct currents applied via scalp electrodes to apply currents to the brain and modulate the level of cortical excitability. tDCS applied over the dorsolateral prefrontal and motor cortex has been reported to be able to decrease pain sensation and to increase pain threshold in healthy subjects and is effective in reducing central chronic pain in PwMS.
1467078|NCT03219073|Device|SHAM tDCS using tDCS device|SHAM tDCS emulates active tDCS in all but the actual stimulation. Electrodes of the tDCS device are placed in the same place as with active tDCS however no current is activated.
1467079|NCT03219060|Behavioral|Motivational interviewing for smoking cessation in nurses|Intervention, four one-to-one sessions on an approximately weekly basis, with 3 components: MI context, toolkit, and relapse prevention. The sessions were embedded in a MI context and followed two phases: exploratory and resolutive. The former explored the potential ambivalence that nurses experienced and constructed motivation for change; the latter reinforced the decision to quit and developed a change plan. Participants could choose over a range of tools: some more helpful in the exploratory phase (i.e. decisional balance sheet) and others in the resolutive phase (i.e. problem solving skills). The third component was directed at maintenance strategies. The therapy stayed with the nurses in terms of where they were in relation to they readiness for change.
1467080|NCT03219060|Behavioral|Brief advice|Brief advice based on 5As
1948274|NCT02576470|Behavioral|targeted dysphagia training maneuver|training swallowing maneuvers or compensatory techniques (referred to as targeted dysphagia training throughout this document) that might reduce their swallowing pathophysiology
1948275|NCT02576470|Radiation|Videofluoroscopy (VF) and Barium|The videofluoroscopy (VF) and barium will be used to record swallowing in all participant groups. This will capture full resolution VF images of all subjects in real time in the lateral view. From the digital recording, image sequencing will be exported to an image processing computer system and archived. The image intensifier will be focused on the lips, posterior pharyngeal wall, hard palate, and just below the upper esophageal sphincter (UES), providing a full view of the oral cavity and neck. A simultaneously recorded time-code will facilitate frame-by-frame data analysis. VF is the only option for visualizing swallowing kinematics during the pharyngeal swallow.
1948276|NCT02576470|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation (TMS) will be used to provide a single-pulse to the brain.
1948277|NCT02576470|Device|Submental Electromyography|Submental Electromyography (sEMG) is used to train participants swallowing maneuvers.
1948278|NCT02565147|Procedure|primary PCI|Primary PCI for treatment of patients presenting with STEMI
1948279|NCT02565147|Drug|Bivalirudin|prolonged infusion of bivalirudin with a dose already included in the SmPC to assess it's impact on infarct size compared to standard dose of heparin
1948280|NCT02564653|Behavioral|Technical Assistance, training and clinical reminders|Technical Assistance, training and clinical reminders (TTC)
1467101|NCT03218982|Behavioral|Enhanced psycho-education about dementia and caregiving|Enhanced psycho-education re dementia and caregiving helping family members come to shared understanding of the nature and cause of dementia. Discussion of cultural values in Vietnamese and American cultures and how this can influence perceptions of dementia and caregiving strategies will help family members who disagree on the etiology of dementia and strategies for care to empathize with each other's perspective. Other sessions will teach skills to develop self-efficacy in dealing with patient symptoms, to access resources (e.g., in-home support), and to gain family support in culturally-congruent ways. Mindful Tai Chi is rooted in East Asian traditions and philosophies that promote balance and healing of the mind and body, thus addressing holistic beliefs Vietnamese have about wellness.
1467102|NCT03218969|Drug|Ecopipam|oral drug in subjection currently experiencing dopamine agonist induced augmentation
1467103|NCT03218969|Drug|Placebo|matching placebo
1467105|NCT03218943|Device|APRV ventilation mode|They will start on APRV mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 4:1 for 3 hours
1467106|NCT03218943|Device|BIPAP ventilation moood|start on BiPAP mode with high pressure (Phi) 20 cmH2O , low pressure(Plo) 5 cmH2O with I:E ratio ( Phi phase: Plo phase ratio ) 1:1 for 3 hours
1467107|NCT03218930|Behavioral|Delayed antibiotic prescription|Delayed antibiotic prescription pads will be disseminated to all participating general practitioners in both hard and soft copies.
1467108|NCT03218930|Behavioral|Antibiotic prescribing guidelines|Antibiotic prescribing guidelines will be disseminated to all participating general practitioners in both hard and soft copies.
1467109|NCT03218930|Behavioral|Education|General practitioners will receive a package of educational sessions tailored towards their specific needs.
1467110|NCT03218930|Behavioral|Educational materials|Educational materials for patients, namely posters and leaflets, will be disseminated to all participating general practitioners.
1467111|NCT03218917|Drug|INS1007 10 mg oral tablet|Administered once per day for 24 weeks
1467112|NCT03218917|Drug|INS1007 25 mg oral tablet|Administered once per day for 24 weeks
1467113|NCT03218917|Drug|Placebo Oral Tablet|Administered once per day for 24 weeks
1467114|NCT03218904|Dietary Supplement|Glucose intake|Experiment 1: study day1- single oral dose of glucose study day 2-single oral dose of glucose with U-13C-glucose
1467115|NCT03218904|Dietary Supplement|Carbohydrates intake|Experiment 2:study day1- single oral dose of uncooked cornstarch study day 2-single oral dose of uncooked cornstarch with U-13C-glucose study day 3- single oral dose of Glycosade® study day 4-single oral dose of Glycosade® with U-13C-glucose
1467116|NCT03218891|Behavioral|Cardiac Rehabilitation|"The physical training program will start shortly after the initial exams have been completed. The physical training protocol will consist of a 12-week duration, with a frequency of 3 weekly sessions of 60 minutes duration each. The intensity will be prescribed from the echocardiogram with effort and cardiopulmonary test. All sessions will be monitored by telemetry and will be distributed as follows:
5 minutes warm up
30 to 40 minutes of aerobic exercise (treadmill). The training intensity will be prescribed individually, based on the results of the test results;
10 minutes of localized exercises;
5 minutes of relaxation."
1467117|NCT03218865|Device|VIE high flux dialyzer|Asssesment of the therapeutic effect of the vitamin E coating
1467118|NCT03218865|Device|Leoceed H high flux dialyzer|Use of the Leoceed H dialyzer during one year per patient enrolled in the control group
1467119|NCT03218852|Drug|prednisone and cyclophosphamide|Prednisone and cyclophosphamide are both administered to participants in this group.
1467120|NCT03218852|Drug|prednisone alone|Prednisone is administered to participants in this group.
1467121|NCT03218839|Device|PrePex male circumcision device|PrePex non-surgical male circumcision device applied to eligible, consenting HIV-infected men in Zimbabwe to determine the rate of adverse events as compared to non HIV-infected men.
1467122|NCT03218826|Drug|Docetaxel|Given IV
1467123|NCT03218826|Other|Laboratory Biomarker Analysis|Correlative studies
1467124|NCT03218826|Other|Pharmacological Study|Correlative studies
1467125|NCT03218826|Drug|PI3Kbeta Inhibitor AZD8186|Given PO
1467157|NCT03218605|Other|physical activity|Subjects performed five activities: running, static stretch, dynamic stretch, cycling and rope skipping
1467158|NCT03218592|Drug|Maraviroc Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
1467126|NCT03218813|Behavioral|Intervention cohort ('after' group)|"The intervention will take place during hospitalisation. Patients will complete the BMQ-S and their responses will form the basis of what will be discussed in Session 1. Pharmacists will elicit patients' thoughts and opinions about their medicines and highlight the need to take them. Any erroneous treatment beliefs will be discussed and any concerns will be addressed.
After Session 1, patients will be given a planning sheet and will be asked to think about their usual daily routine and how taking medicines may fit into it. Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose')."
1467127|NCT03218800|Combination Product|Ertapenem|"Dose: 1g per day if creatinine clearance > 30mL/min or 500 mg per day if creatinine clearance < 30mL/min.
Dilution: 50 ml saline solution. Duration 30 minutes."
1467128|NCT03218787|Device|XIENCE|Subjects who received XIENCE family stent systems will be included.
1467129|NCT03218787|Drug|DAPT|3-month clear subjects who receive 3 months of DAPT and 12 months of aspirin after index procedure
1467130|NCT03218774|Behavioral|Home Exercise Group|The Home group will meet with an exercise professional once and be given a home exercise program to complete 3 to 5 times per weeks at home.
1467131|NCT03218774|Behavioral|Fitness Center Group|The Center group will be given an exercise program, a membership to a community fitness gym where they will be asked to exercise 3-5 times per week, and will be provided with 6 individual personal training sessions.
1467132|NCT03218761|Diagnostic Test|NET mRNA level|quantification of mRNA to the Norepinephrine Transporter (NET)
1467133|NCT03218761|Diagnostic Test|Plasma catechols|plasma for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
1467134|NCT03218761|Diagnostic Test|Urine Catechols|urine for assay of norepinephrine (NE), DHPG (intraneuronal metabolite of NE), and other catechols
1467136|NCT03218735|Procedure|Labor induction at 37.0 weeks to 37.6 weeks of gestation|Diagnosis of LGA with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
1467137|NCT03218735|Procedure|Expectant monitoring and delivery|Diagnosis of LGA with expectant monitoring and delivery as indicated by standard obstetric practices
1467138|NCT03218722|Drug|Pro-Thrombin Concentrate Complex|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg PCC.
1467139|NCT03218722|Drug|NaCl 0.9%|Patient at risk of massive hemorrhage will be managed with standard care with 1ml/kg Saline solution.
1467140|NCT03218709|Combination Product|High-dose multi-vitamins with minerals|The high-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.37mg,vitamin C 0.27mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
1467141|NCT03218709|Combination Product|Low-dose multi-vitamins with minerals|The low-dose multi-vitamins with minerals contained vitaminB1 0.72mg,vitamin B20.72mg,vitamin B12 1.35μg,folic acid 0.20mg,vitamin C 0.50mg,vitamin D 5.04μg,selenium 30.5μg per pill, respectively.
1467142|NCT03218709|Combination Product|Hypouricemic tablets|The hypouricemic tablets contained skipjack,salvia and rosemary extract.
1467143|NCT03218709|Combination Product|Placebo|The placebo tablets contained maltodextrin and tartrazine.
1467144|NCT03218696|Device|Cough Syrup for adults and children|The intervention product is a medical device in Europe due to its non-pharmacological mode of action, which makes the product compliant to the medical device definition. It is made of specific extracts of plants (plantago and thymus) which provide the product with protective characteristics of the oropharynx. These protective features enable the syrup to reduce the irritative cough promoting stimuli on the throat, which decrease urge to cough threshhold. In addition to these extract, honey completes the formula. The product does not contain any artificial component and no preservatives.
1467145|NCT03218696|Device|Placebo|The placebo intervention is a syrup of same taste and colour without the natural protective components but with the necessary synthetic preservatives and other co-sweeteners to guarantee quality and safety. The placebo has, in fact, all the features of a cough syrup since true placebo syrup is not possible in cough. The lack of specific natural protective components is weighed against the presence of other necessary substances which may still have an effect on cough, but this effect is not envisaged to be a specific protective effect.
1467151|NCT03218657|Drug|levamisole hydrochloride|levamisole hydrochloride take orally 150mg qod
1467152|NCT03218657|Drug|Androgens|Androgens take orally 80mg qd
1467153|NCT03218657|Drug|Cyclosporins|Cyclosporines take orally 3-5mg/kg*d qd
1467154|NCT03218644|Other|Mobility exercises|Usual treatment and exercises of cervical mobility before a mirror.
1467155|NCT03218644|Other|Proprioception exercises|proprioceptive exercises for craniocervical sensorimotor control.
1467156|NCT03218631|Drug|Oxandrin|"The primary outcome for this study will be measurements of the pharmacokinetics of a single dose of oxandrolone 0.1 mg/kg both in tablet form and in the MCT oil preparation. Blood samples for pharmacokinetics will be drawn at 9 timepoints.
Safety will be assessed by recording adverse events and assessment of hepatic function at baseline and one week following oxandrolone dosing."
1467159|NCT03218592|Drug|Dolutegravir Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
1467160|NCT03218592|Drug|Truvada Pill|Subjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weeklySubjects will take a single dose in Phase 1, Daily Doses in Phase 2 for 28 days, and then be randomized in Phase 3 to zero doses, one dose a week or three doses weekly
1467161|NCT03218579|Dietary Supplement|Probiotic treatment|4 weeks of probiotic treatment after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
1467162|NCT03218579|Biological|Bacteriotherapy|Bacteriotherapy (autologous fecal microbiota transplantation) after 7 days of antibiotics (Metronidazole+Ciprofloxacin)
1467163|NCT03218566|Device|Indigo Aspiration System|use of mechanical thrombectomy to treat pulmonary embolism
1467166|NCT03218540|Procedure|Fluid management protocol|SVV protocol: keep SVV 10-13% and give fluid when SVV > 13% CVP protocol: keep CVP 8-12 mmHG and give fluid when CVP < 8 mmHg
1467167|NCT03218514|Drug|Dalteparin|
1467168|NCT03218501|Drug|SK-1405 high dose|SK-1405 high dose is to be administered orally once daily for 2 weeks
1467169|NCT03218501|Drug|SK-1405 low dose|SK-1405 low dose is to be administered orally once daily for 2 weeks
1467170|NCT03218501|Drug|Placebo|Placebo is to be administered orally once daily for 2 weeks
1467171|NCT03218488|Drug|Ustekinumab|Participants will not receive any intervention as a part of this study. Participants with moderate to severe plaque psoriasis who are initiating treatment with ustekinumab within clinical practice (patients should either start therapy with ustekinumab within 30 days of baseline or have started therapy with ustekinumab in the 12-week period before enrollment for the treatment of psoriasis) will be observed for the long-term safety of ustekinumab and the long-term effects of ustekinumab on growth and development of pediatric participants.
1467172|NCT03218475|Other|MR Guided HIFU|Single treatment of high intensity focused ultrasound under MRI guidance
1467173|NCT03218462|Behavioral|Sensory Adapted Dental Environment (SADE)|No fluorescent room lights, solar projector on ceiling, regular dental x-ray apron laying on patient, quiet music playing in background
1467174|NCT03218436|Procedure|CAP treatment|Treatment with low-temperature argon plasma during colposcopic examination. No general anesthesia required.
1467175|NCT03218423|Device|Epi proColon|Plasma cell free DNA SEPT9 promoter methylation test for colorectal cancer screening.
1467176|NCT03218410|Procedure|surgical pulmonary embolectomy|
1467177|NCT03218410|Combination Product|catheter-directed thrombolysis|
1467178|NCT03218397|Device|Accelerate PhenoTest™ BC Kit|Rapid identification and AST using the Accelerate PhenoTest™ BC Kit, performed on the Accelerate Pheno™ System (AXDX)
1467179|NCT03218397|Device|Standard Culture and AST|Standard culture and antimicrobial susceptibility testing (AST)
1467180|NCT03218384|Drug|Ferric Carboxymaltose|750 MG Iron Per 15 ML Injectable Solution
1467181|NCT03218384|Drug|Placebo|normal saline
1467182|NCT03218371|Procedure|chandelier-assisted peripheral vitrectomy under air|chandelier-assisted peripheral vitrectomy under air for management of peripheral vitreous during RD vitrectomy; whether using indentation or non-indentation
1467183|NCT03218345|Procedure|EUS-guided RFA|EUS-guided RFA would be performed using a 19-gauge RFA electrode and a generator
1467184|NCT03218332|Diagnostic Test|Biomarkers for detecting possible CTE invivo|Detection biomarkers for possible CTE: Imaging/blood/CSF/PET-tau/MRI/europsychological assessment
1467185|NCT03218319|Biological|Renin measurement|patients will have a blood sample for measuring renin activity
1467188|NCT03218293|Device|RIPC device (IPC-906X)|Patients in the RIPC group had five cycles of 5‑min cuff inflation followed by 3‑min deflation to the bilateral upper arm after thrombolysis.
1467189|NCT03218280|Drug|Vitamin C|
1467190|NCT03218267|Other|Static Posturography|The balance platform (Good Balance by Metitur) and one leg standing test (OLS) were used to assess the static balance. OLS test was performed on left and right foot separately. The static posturography was performed with several various positions of feet. Position : normal standing with eyes open and eyes closed - an upright standing with feet placed parallel 20 cm apart for 30 s. Position: tandem - a stance with one foot placed ahead of the other for 10 s. Position: second form of tandem - a stance with one foot placed ahead of the other with feet placed on both sides of the line dividing platform to two parts for 20s. Position: one leg standing: stance on the one leg for 5 s.
1467191|NCT03218267|Other|One-leg standing test (OLS)|During the one-leg standing test (OLS) the time of maintain this position by the patients was measured. The placement of the limbs was the same as in the case of the balance platform test. Subjects performed 3 trials on each lower limb. Time ended when subject either: loosed balance and touched raised foot the floor, moved supporting leg on the ground, a significant loss of balance or a maximum of 60 s had elapsed. Results achieved by the subjects after THR on both operated (OLS-O) and non operated limbs (OLS-N) were compared with the index of the control group (OLS-C: mean result of the tests performed on the left and right legs).
1467192|NCT03218254|Drug|Methylphenidate|Titration of MTP for treatment of fatigue
1467193|NCT03218254|Drug|Placebo|Placebo
1467194|NCT03218241|Biological|PRT064445|Intravenous
1467195|NCT03218241|Drug|Placebo|Intravenous to mimic PRT064445
1467196|NCT03218228|Procedure|implants in periodontitis|it targets immediate implant placement in patients suffering from aggressive periodontitis
1467197|NCT03218189|Other|Country characteristics|Observational study of country characteristics
1561161|NCT02518685|Device|Sham procedure|
1467206|NCT03218163|Drug|MEDI-551 Maintenance|Cycle 1 - Days 1, 8, 15, and 22: 4mg/kg IV Cycles 2-12 - Day 1: 4mg/kg IV
1467207|NCT03218150|Procedure|cranioplasty|". The margins of the craniectomy defects exposed, and the bone flaps fixed in their original positions using wires or titanium plates with screws. As prophylaxis, all patients intravenously administered with pre- and postoperative antibiotics.
In cases of artificial substitutes , The polymethyemethacrylate implant fixed to the defective region with titanium plates and self-tapping screws."
1467208|NCT03218137|Drug|Adenosine|Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes)
1467209|NCT03218124|Other|Remifentanil Effect site concentration|"After skin suture, a predetermined Effect site remifentanil concentration will be achieved. Starting from 1.5 ng/ml in the first patient and increased or decreased by 0.2 ng/ml intervals based on the previous patient response: up if cough present, down otherwise (Dixon's up and down method)."
1467210|NCT03218111|Other|MR Imaging|All subjects will undergo six sessions of MR imaging over a 10-12 hour period
1467211|NCT03218111|Other|CT-guidance|All subjects will be injected, intrathecally using CT-guidance, with an MRI contrast.
1467212|NCT03218098|Procedure|Lobectomy via UVATS|lobectomy with small skin access 4 cm
1467213|NCT03218085|Drug|Tenofovir|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
1467214|NCT03218085|Drug|Emtricitabine|Two cervical biopsies, blood plasma, PBMC, and two cervicovaginal swabs will be collected at a single study visit
1467215|NCT03218072|Drug|HLX01|a potential rituximab biosimilar
1467216|NCT03218059|Procedure|Methotrexate Combined With Transvaginal Surgery|The methods of treatment of CSP
1467217|NCT03218046|Behavioral|EMDR|Eye Movement Desensitisation and Reprocessing
1467218|NCT03218033|Behavioral|Social Media|
1467219|NCT03218020|Other|No intervention assigned, this is an observational study.|No intervention assigned, this is an observational study.
1467220|NCT03218007|Biological|blood samples|to evaluate expression and functionnaly activity of A2AR
1467221|NCT03217994|Drug|gel HP|gel of hygrogen peroxide for teeth bleaching
1467222|NCT03217981|Other|Sepsis protocol|Adherence to the sepsis protocol
1467223|NCT03217968|Device|Cefaly® Abortive Program device|The Cefaly® Abortive Program device is an external cranial neurostimulator designed for supraorbital neurostimulation, also known as external Trigeminal Nerve Stimulation (e-TNS).
1467224|NCT03217955|Behavioral|CBT-SA|Info has been included in arm description
1467225|NCT03217955|Behavioral|Standard Treatment|Info has been included in arm description
1467226|NCT03217942|Drug|NGF|Intramuscular injection
1467227|NCT03217929|Device|Active-taVNS|Stimulation will be performed using the Neurodyn II (Ibramed) equipment approved by the national regulatory agency (ANVISA). The following parameters will be used: 120 Hz (hertz) of frequency, 250 μs of pulse duration and 12 milliamperes of intensity for a continuous stimulation for 30 minutes. This intensity corresponds to a non-painful mild paresthesia without muscle contraction previously described and evaluated. The 25 cm² (centimeters) electrodes will be positioned over the retroauricular area. A total of 10 sessions (one session per day during 10 week-days) will be performed. Every session will be followed by an interview with a trained psychiatrist to evaluate possible adverse effects and guarantee safety issues regarding the study itself.
1467228|NCT03217929|Device|Sham-taVNS|Regarding sham protocol, the device will be turned off after 60 seconds of stimulation without the knowledge of the patient. After this initial period, the referred paresthesia seems to diminish due to nerve accommodation.
1467229|NCT03217916|Diagnostic Test|Elisa assay of podocyte glycoprotein in urine|"Biomarkers evaluated in urine specimens including podocyte glycoproteins nephrin and podocalyxin, All biomarkers were measured by ELISA. Assay information for sources of ELISA kits, standard cure range, sample dilution factors, etc.
All assays will be performed following the manufacture's instructions. All specimens will be measured in duplicate.
Personnel who performed the assays of analyteswere blinded to the clinical information."
1467230|NCT03217903|Diagnostic Test|Myelogram|Bone marrow aspiration after 3 cycles of Azacytidine treatment
1467231|NCT03217877|Diagnostic Test|routine stress testing|In the group of routine stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed at 9~15 months after the procedure according to the practice pattern of each participating center.
1467232|NCT03217877|Diagnostic Test|symptom oriented stress testing|In the group of symptom oriented stress testing group, the preselected functional test (exercise ECG, nuclear stress testing, or stress echocardiography) will be performed when chest pain or angina symptom is occured after the procedure according to the practice pattern of each participating center.
1467233|NCT03217851|Diagnostic Test|Blood Collection|blood smear and/or rapid diagnostic
1467234|NCT03217851|Diagnostic Test|Dried Blood Spot|Dried Blood Spot on filter paper
1948281|NCT02564653|Behavioral|TTC+Referral to Community Health Worker|TTC+ referral to a VHW for additional counseling and follow-up
1467236|NCT03217825|Drug|Rostafuroxin|This is a potent, selective and safe inhibitor of this altered mechanism and has been proved to be effective in reducing blood pressure levels in Adducin mutated rat strains and in chronic Ouabain infused rat model.
1467237|NCT03217825|Drug|Losartan|COZAAR (losartan potassium) is an angiotensin II receptor (type AT1) antagonist. Losartan potassium, a nonpeptide molecule, is chemically described as 2-butyl-4-chloro-1-[p-(o-1H-tetrazol-5-ylphenyl)benzyl]imidazole- 5-methanol monopotassium salt.
1467242|NCT03217799|Device|Measurement of coagulability of blood|A small pneumatic cuff is attached to the root of the index finger. The sensor cuff is attached several centimeters distal to the pneumatic cuff. Measurement is taken for a 60-second control period, and then the pneumatic cuff is inflated to above-systolic blood pressure (200 mm Hg) for 180 seconds, and measurement is taken during this period of time. The cuff is then deflated, and another 60-second measurement is taken. Data is collected by the measuring device for later analysis.
1467243|NCT03217773|Procedure|ESD|Refer to arm description
1467244|NCT03217773|Procedure|TAMIS|Refer to arm description
1467245|NCT03217760|Procedure|Endodontic treatment|Endodontic treatment or root canal therapy is a sequence of treatment for the infected pulp of a tooth which results in the elimination of infection and the protection of the decontaminated tooth from future microbial invasion.
1467246|NCT03217760|Other|VAS of stress|The VAS is a 10-cm scale without graduation on which subjects are asked to score the specific level of stress experienced from 0 (not stressed at all) to 10 (worst stress imaginable)
1467247|NCT03217760|Other|CORAH scale|At the beginning of the treatment (T1), the patient is asked to complete a French version of the Corah Dental Anxiety scale (DAS).
1467248|NCT03217760|Other|HAD Scale|At the beginning of the treatment (T1), patients and students are asked to complete the Hospital Anxiety and Depression Scale (HAD Scale) which is presented as a reliable instrument for assessing clinically significant anxiety and depression.
1467249|NCT03217760|Other|Cardiovascular Parameters|For each subject, the physiological indicators of stress (ie, heart rate [HR], systolic blood pressure [SBP], and diastolic blood pressure [DBP]) are monitored during each of the 6 steps.
1467250|NCT03217760|Other|Cortisol Measurements|Salivary samples are collected during each of the 6 steps of endodontic treatment which are then stored at -20° before being sent to the laboratory to test cortisol levels .
1467251|NCT03217760|Other|Discomfort and Pain Experienced During Treatment|Patients were asked to report the levels of discomfort and pain experienced during the 6 steps using the VAS and at the next visit for the final restoration.
1467252|NCT03217760|Other|Patient's preferences.|After the completion of each treatment patients will have to report whether they thought that they would have experienced as much pain, stress, or discomfort if they had received premedication before treatment.
1467253|NCT03217760|Other|student preferences.|"When the treatment is complete the students are asked to report:
his/her level of satisfaction with the course of treatment,
whether he/she felt awkward faced with the patient's manifestations of stress, discomfort, or pain during the session
whether he/she would have preferred that the patient had received sedative medication before the endodontic treatment."
1467259|NCT03217734|Biological|Adalimumab|Subcutaneous Injection
1467260|NCT03217734|Drug|Methotrexate|Oral Tablet
1467261|NCT03217734|Drug|Placebo|Oral Tablet
1467262|NCT03217708|Device|Jawbone UP4|Wrist worn wearable technology will be utilized to study HR, temperature, sleep, activity changes before and after surgery.
1467263|NCT03217695|Behavioral|Mindfulness-based Yoga Arm|
1467266|NCT03217669|Drug|Epacadostat|Epacadostat tablet: 100mg or 300mg
1467267|NCT03217669|Drug|sirolimus|Sirolimus tablet: 1mg, 2mg, 3mg, or 6mg
1467268|NCT03217656|Other|No intervention|
1467306|NCT03217422|Other|Placebo|Placebo control with conversion to active VAY736
1467270|NCT03217630|Other|Fasting 2 h after clear liquid or 6h after a light meal|The fasting time for all patients is 2 h after clear liquid or 6h after a light meal, then gastric ultrasound examination is performed.
1467271|NCT03217617|Biological|Gene-modified autologous stem cells|Infusion of transduced autologous stem cells
1467274|NCT03217591|Drug|IW-1973|Oral Tablet
1467275|NCT03217591|Drug|IW-1973|Oral Tablet
1467276|NCT03217591|Drug|Placebo|Oral Tablet
1467277|NCT03217578|Other|SMA Newborn Screening|
1467280|NCT03217552|Diagnostic Test|Mologic Biomarker Panel|In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
1467281|NCT03217539|Diagnostic Test|Imaging|
1467282|NCT03217526|Other|Gait Training|Gait Training: Training will be applied by a physiotherapist on a treadmill or on an overgorund.
1467283|NCT03217500|Procedure|Corneal epithelial autograft|After removal of the recipient's pterygium tissue, a donor epithelial tissue equal in length to the bared limbus, will be obtained from the peripheral epithelial of the same eye (corneal epithelial autograft) using femtosecond laser technology. The epithelial graft will be sutured to the recipient limbal bed, with the goal of reconstruction of palisades of Vogt. The graft will act as a barrier to regrowth of pterygium. The area of the graft will be left with the Tenon capsule exposed.
1467284|NCT03217500|Procedure|Limbal conjunctival autograft|After removal of the recipient's pterygium tissue, an adjustable diamond knife will be used to create a superficial circumferential incision at the corneal end of the limbal vascular arcade, equal in length to the bared limbus. This will be followed by harvesting the limbal-conjunctival flap. The limbal-conjunctival autograft will be sutured to the recipient bed, with the Tenon capsule exposed. The graft will serve as a barrier to regrowth of pterygium.
1467285|NCT03217500|Procedure|Simple removal|Simple removal of the recipient's pterygium tissue, with the Tenon capsule exposed.
1467286|NCT03217500|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
1467287|NCT03217500|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
1467288|NCT03217487|Procedure|Corneal epithelial autograft|Epithelial tissue, equal in area to the diseased eye's cornea bed, will be obtained from the fellow eye using femtosecond laser technology. This corneal epithelial autograft is then ready for transplantation on the disease eye, following removal of scarred and diseased epithelium.
1467289|NCT03217487|Procedure|Limbal conjunctival autograft|A 3- to 5- clock hour limbal-conjunctival autograft will be obtained from the fellow eye. This is then ready for transplantation on the disease eye following removal of scarred and diseased epithelium.
1467290|NCT03217487|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
1467291|NCT03217487|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
1467292|NCT03217474|Procedure|FLDEB|The eye will be anesthetized, and femtosecond laser technology will be used to remove epithelial tissue (diameter: 8mm; depth: 100micron) that includes the loosened diseased corneal epithelial cells. Antibiotic ointments and drops will be instilled postoperatively.
1467293|NCT03217474|Drug|Ganciclovir (GCV)|Patient will be treated with GCV orally (200mg, 3 times a day, for 14 days).
1467294|NCT03217474|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation.
1467295|NCT03217461|Procedure|CorneaL epithelial autograft|After removal of the recipient's diseased dermoid, a size-match donor epithelial tissue will be obtained from the healthy area of the same eye (corneal epithelial autograft) using femtosecond laser technology, with the goal of closure of bare stromal area by sutured corneal epithelial tissue to ensure the integrity of ocular surface. This closure may also create a microenvironment that stimulates stromal cells' regenerative capacity and regulates their epithelial-mesenchymal transition process.
1467296|NCT03217461|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
1467297|NCT03217461|Procedure|Limbal autograft|Simple dermoid excision will be performed, followed by closure of the bare sclera by sutured femtosecond laser-assisted limbal autograft.
1467298|NCT03217461|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
1467299|NCT03217448|Drug|Dabigatran etexilate|Subjects should take Dabigatran etexilate 150mg twice a day for 6 months after randomization.
1467300|NCT03217448|Drug|Warfarin|Subjects should take Warfarin for 6 months after randomization and the dose will be changed according to investigator's judgment.
1467301|NCT03217435|Procedure|Corneal epithelial allograft|A living-related donor's epithelial flap, equal in area to the recipient's diseased cornea bed, will be created using femtosecond laser technology. This corneal epithelial allograft is then ready for transplantation on the recipient's disease eye, following removal of the recipient's scarred and diseased epithelium.
1467302|NCT03217435|Procedure|Limbal conjunctival allograft|A 3- to 5- clock hour limbal-conjunctival allograft will be obtained from the living-related eye. This is then ready for transplantation on the recipient's disease eye following removal of the recipient's scarred and diseased epithelium.
1467303|NCT03217435|Device|Femtosecond laser|A commercial femtosecond laser to create a particular shaped graft for transplantation
1467304|NCT03217435|Device|Diamond knife|A diamond knife to create a particular shaped limbal graft for transplantation
1467305|NCT03217422|Biological|VAY736|VAY736
1561768|NCT02514681|Drug|Eribulin|
1467310|NCT03217383|Device|MATRx plus|The MATRx plus test is a 2- or 3-night home sleep test that uses temporary titration trays to move the lower jaw in response to respiratory events. The purpose of the test is to predict oral appliance therapy outcome, and to provide a protrusive position for individuals predicted to experience therapeutic success.
1467311|NCT03217370|Other|education of guidelines|"Guidelines will be updated and education will be given to haematologists in several ways.
ICT implementations: a) last result of haemoglobin and platelet count will be shown on the electronic blood order; b) an electronical clinical decision support system will be implemented to order blood components"
1467312|NCT03217357|Device|Transcranial stimulation in direct current|tDCS (2mA, 30 minutes with the anode at the left DLPFC and the cathode at the right DLPFC) active or placebo
1467313|NCT03217344|Procedure|conservative treatment|immobilization on sling of the injured arm
1467314|NCT03217331|Drug|CRD-102|14 mg CRD-102 capsules administered twice daily orally for 14 days.
1467315|NCT03217318|Device|ureteral stenting with standard or modified ureteral stent|Ureteral stenting because of kidney and or ureteral stones at the iliacal vessel crossing of the ureter or proximally
1467316|NCT03217305|Device|NAVA|Neurally Adjusted Ventilatory Assist is a fairly new ventilation mode
1467317|NCT03217292|Procedure|Serratus Anterior Plane Block|
1467318|NCT03217292|Drug|IV patient-controlled analgesia (PCA) tramadol|
1467319|NCT03217266|Other|Laboratory Biomarker Analysis|Correlative studies
1467320|NCT03217266|Drug|MDM2 Inhibitor AMG-232|Given PO
1467321|NCT03217266|Other|Pharmacological Study|Correlative studies
1467322|NCT03217266|Radiation|Radiation Therapy|Undergo radiation therapy
1467323|NCT03217253|Other|Laboratory Biomarker Analysis|Correlative studies
1467324|NCT03217253|Other|Pharmacological Study|Correlative studies
1467325|NCT03217253|Drug|Tazemetostat|Given PO
1467326|NCT03217240|Procedure|Cardiac Magnetic Resonance - MRI|All participants will have to undergo CMR which uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images. Participants will be asked to lie on a narrow bed placed inside of a large magnet for about 1 hour. Several sets of images are needed. Participants are required to stay very still and follow the instruction of the MRI technologist who operates the machine from a room next door.
1467327|NCT03217240|Other|Cardiopulmonary Exercise Test|Participants will be asked to undergo a cardiopulmonary exercise test (CPET). Participants will need to wear a mask. Several electrodes will be placed on the chest to record heart activity during exercise. Participants will need to pedal for at least 8-12 minutes. Pedalling will be instructed to report any symptoms such as chest discomfort, shortness of breath, leg fatigue or dizziness. A small probe will be placed on participant's finger during the test to measure the oxygen content in the blood. Immediately after exercising, participants will rest for 5-10 minutes while the blood pressure and electrocardiogram are monitored. The results will be read by a cardiologist.
1467328|NCT03217240|Other|Blood Sampling for all participants|Serum samples will be obtained before CMR. The sample will be stored at -80 degree until assay. Investigators will perform various tests related to participants heart function
1467329|NCT03217227|Other|Cardiovascular Magnetic Resonance Imaging with Exercise Bike|A rest scan is performed and a gadolinium contrast may be administered during the scan (depending on the kidney function). After the rest scan is completed, images of the subject's heart during exercise via cycling in the supine position, will be scanned.
1467330|NCT03217227|Procedure|Cardiac Catherization|"It is a procedure to diagnose and treat cardiovascular diseases by inserting a long and thin tube known as a catheter into the artery or vein in the neck, groin or arm and threaded through the blood vessels to the heart.
A coronary angiogram is also performed during the procedure where an invisible contrast dye (only visible in the X-rays) is injected through the catheter and X-ray images scanned will show the flow of the dye through the heart arteries to determine any blockages in the arteries.
In the case where there is severe narrowings, fractional flow reserve (FFR) may be performed to measure the pressure in the coronary arteries."
1467331|NCT03217227|Other|Retinal Photography (Optional)|The test studies the structure and function of the eye vessels. It involves using eye drops to dilate the pupils, allowing the retinal photographer to have a better view of the back of the eye.
1467332|NCT03217214|Diagnostic Test|Thermography|Passive thermography for Phase I subjects and Active Thermography for Phase II subjects
1467333|NCT03217201|Device|Litebook Edge (Experimental)|"The Litebook Edge is a small (5 x 5 x 1) and lightweight (4.6 oz.) box designed to be placed on a table about 18 from the participant's head and within 45º visual field. The Litebook uses 60 premium light emitting diode (LED) lights which mimic the visible spectrum of sunlight for minimum glare and maximum eye comfort. For purposes of safety, the Litebook emits no ultraviolet (UV) light."
1467334|NCT03217201|Device|Litebook Edge (Comparison)|"The Litebook Edge is a small (5 x 5 x 1) and lightweight (4.6 oz.) box designed to be placed on a table about 18 from the participant's head and within 45º visual field. The Litebook uses 60 premium light emitting diode (LED) lights which mimic the visible spectrum of sunlight for minimum glare and maximum eye comfort. For purposes of safety, the Litebook emits no ultraviolet (UV) light."
1467337|NCT03217175|Device|Bihormonal Bionic Pancreas|The glucagon pump will be filled with glucagon during the exercise visit
1467338|NCT03217175|Device|Insulin Only Bionic Pancreas|The glucagon pump will be filled with placebo during the exercise visit, and the bionic pancreas will operate in an insulin only mode.
1467339|NCT03217175|Drug|Glucagon|Glucagon will be given according to the algorithm in the bihormonal bionic pancreas
1467340|NCT03217175|Drug|Placebo|Placebo will be given instead of glucagon according to the algorithm in the insulin-only bionic pancreas
1467341|NCT03217162|Drug|surfactant combined with mechanical ventilation (MV)|surfactant combined with mechanical ventilation (MV) is given to the infant with ARDS
1467342|NCT03217162|Drug|mechanical ventilation (MV)|mechanical ventilation (MV) is given to the infant with ARDS
1467343|NCT03217149|Drug|heliox combined with MV|heliox combined with MV is given to infant with ARDS
1561769|NCT02514681|Drug|Capecitabine|
1467350|NCT03217123|Device|Deep Brain stimulation|Electrical stimulation at subcortical level
1467351|NCT03217110|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive theta frequency stimulation of the cerebellum. We will target the cerebellar vermis.
1467352|NCT03217110|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects with neuropsychiatric diagnoses and matched-controls will be receive sham stimulation of the cerebellum. We will target the cerebellar vermis.
1467353|NCT03217097|Drug|Oxaliplatin-based chemotherapy|"The oxaliplatin-based group will receive gemox (gemcitabine-oxaliplatin, 1x/2 week); alternatively folfox (5 fluorouracil-leucovorin-oxaliplatin, 1x/2 week) or capox (capecitabine-oxaliplatin, 1x/3 week)."
1467354|NCT03217097|Drug|Alkylating-based chemotherapy|"The alkylating-based group will receive CapTem regimen (capecitabine and temozolomide, /4 week), alternatively LV5FU2 (folinic acid-5 fluorouracil)-dacarbazine (1x/2 week) or LV5FU2 (folinic acid-5-fluorouracil)-streptozotocine (1x/2 week)."
1467355|NCT03217084|Drug|MI varnish GC|MI Varnish GC is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. MI Varnish also contains RECALDENT. Open the unit-dose package of Varnish. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
1467356|NCT03217084|Drug|White varnish 3M|White varnish 3M is a 5% sodium fluoride varnish that has a desensitizing action when applied to tooth surfaces. Clinpro White Varnish contains an innovative tri-calcium phosphate.Open the unit-dose package of Varnish and dispense the entire content onto the round application guide provided with the packet. Use the applicator brush to thoroughly mix Varnish. Apply Varnish evenly in a thin layer over treatment area(s). For larger surface areas, apply Varnish in sweeping horizontal brush. After application, instruct the patient to close his or her mouth to set the Varnish. No need to use suction. The patient may feel the thin coating when rubbing the treated area with his or her tongue. The treatment period for Varnish is minimally 4 hour.
1467357|NCT03217071|Drug|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
1467358|NCT03217071|Radiation|stereotactic radiation therapy (SRT)|Patients in Cohort 2 of the Safety run-in and patients in the expansion cohort who are randomized to the 'pembrolizumab +radiation arm' will receive one dose of SRT within 1 week (+/- 3 days) following the second administration of pembrolizumab.
1467359|NCT03217058|Behavioral|Clinic-based screening and behavioral interventions|As part of routine HIV primary care visits, patients will complete self-administered computerized substance use and depression screening measures. Results will be integrated into the electronic health record. A behavioral health specialist on the clinic staff will contact patients who screen positive for high-risk substance use or depression, and offer behavioral interventions including motivational interviewing and cognitive behavioral therapy.
1467360|NCT03217045|Other|nutrition protocol introduction|Growth comparison of 2 cohorts of infants evaluated in a before-after design
1467361|NCT03217032|Biological|YUVA-GT-F801|factor VIII gene modified autoHST
1467362|NCT03217032|Biological|YUVA-GT-F901|factor IX gene modified autoHST
1467363|NCT03217019|Procedure|Guidewire-assist|catheter insertion with guidewire-assist(catheter over guidewire)
1467364|NCT03217019|Procedure|Direct|catheter insertion without guidewire assist(catheter over needle)
1467365|NCT03217006|Procedure|Single arterial graft|This interventions consists of patients receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. In addition to the left internal thoracic artery patients will receive venous grafts for all additional grafting.
1467366|NCT03217006|Procedure|Multiple arterial grafting|This intervention consists of the patient receiving the left internal thoracic artery to the left anterior descending coronary artery of the heart. The second arterial graft (right internal thoracic artery or radial artery) will be directed to the major branch of the circumflex. Additional grafts will include saphenous veins or arterial conduits.
1467367|NCT03216993|Other|Standard care|Standard care: patients receive enteral nutrition in accordance with the usual practice in the participating units
1467368|NCT03216993|Other|Protocol care|Protocol care： patient receive enteral nutrition in accordance with enteral nutrition protocol studied
1467369|NCT03216980|Dietary Supplement|PTSD Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
1467370|NCT03216980|Dietary Supplement|PTSD Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
1467371|NCT03216980|Dietary Supplement|Healthy Control Antioxidant|Subjects will ingest an antioxidant cocktail containing 800 milligrams of alpha lipoic acid, 1 gram of vitamin C (ascorbic acid), and 400 milligrams of vitamin E (alpha tocopherol).
1467372|NCT03216980|Dietary Supplement|Healthy Control Placebo|Subjects will ingest placebo (microcrystalline cellulose) pills.
1467373|NCT03216967|Drug|everolimus|Patients with viremia above 3 log of copies/ml will be randomized (ratio 1:1) into either of 2 groups Group 1 : control group : immunosuppression lowering or Group 2 : experimental group : immunosuppression lowering and replacement of mycophenolate acid by everolimus Evolution of BKV viremia and allograft function will be assessed during 2 years after randomization
1467374|NCT03216954|Drug|Alcohol|During each arm, subjects will receive doses of alcohol, designed to raise BALs to 0.015 and 0.03 g/dl.
1467375|NCT03216954|Drug|Placebos|Subjects will receive placebo capsules
1467376|NCT03216954|Drug|N-acetyl cysteine|Subjects will receive n-acetyl cysteine capsules
1467697|NCT03214393|Diagnostic Test|Doppler|Doppler will be done to pregnant women with Pre-Eclampsia
1561770|NCT02514681|Drug|Gemcitabine|
1467377|NCT03216941|Drug|Ketamine|"study medications were packaged in identical color-coded boxes. first dosage included either 10 mg of olanzapine, or 10 mg of ketamine Dosages were chosen based on previous studies After the initial dose, no additional dosis were allowed if supplemental medication eas needed according to clinician judgment the subject will be immediately removed from the study.
All subjects will be assessed 1 hour, 2 hours, 4 hours, 6 hours and 12 hours after t he first administration of the medication."
1467378|NCT03216928|Diagnostic Test|Blood test|
1467379|NCT03216915|Drug|Gilenya®; Novartis Pharmaceuticals Corporation|This is a prospective cohort-based study. Eligible are all patients planned for a treatment with fingolimod at the Hamburg University Hospital who are willing and able to participate in an observational study.
1467380|NCT03216902|Drug|Vehicle of DE-126 Ophthalmic Solution, high dose of DE-126 Ophthalmic Solution|Vehicle of DE-126 Ophthalmic Solution dosed once daily for 6weeks, followed by high dose of DE-126 dosed once daily for 6 additional weeks
1467381|NCT03216902|Drug|Topical ultra-low dose of DE-126 Ophthalmic Solution|Topical ultra-low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
1467382|NCT03216902|Drug|Topical low dose of DE-126 Ophthalmic Solution|Topical low dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
1467383|NCT03216902|Drug|Topical medium dose of DE-126 Ophthalmic Solution|Topical medium dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
1467384|NCT03216902|Drug|Topical high dose of DE-126 Ophthalmic Solution|Topical high dose of DE-126 Ophthalmic Solution dosed once daily for 12 weeks
1467385|NCT03216902|Drug|0.005% Latanoprost Ophthalmic Solution|0.005% Latanoprost Ophthalmic Solution dosed once daily for 12 weeks
1467386|NCT03216889|Behavioral|Cognitive Behavioral Therapy for Insomnia|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will be one-on-one or in a group.
1467387|NCT03216889|Behavioral|Control|Involves attending 1 hour long sessions weekly for 6 weeks. Sessions will involve stretching and thinking games.
1467388|NCT03216876|Drug|Ursolic acid|Ursolic acid (UA) is a natural triterpenoid carboxylic acid, which has been studied for its anti-proliferative and anti-inflammatory activities.
1467389|NCT03216863|Other|Respiratory rehabilitation|It consists of a global care of the patient: therapeutic education, nutritional maintenance, psychological support and re-training to the effort at home after discharge or after follow up visit of targeted therapy
1467391|NCT03216837|Device|Cathodal transcranial direct current stimulation|The primary intervention will be cathodal (inhibitory) tDCS over the contralesional M1. Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle. The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp. tDCS will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
1467392|NCT03216837|Device|Sham transcranial direct current stimulation|Soft, replaceable 25cm2 electrodes (Soterix, NYC) will be placed on clean, dry areas of the scalp. The cathode will be placed over the contralesional M1, precisely mapped for each patient using neuronavigated (Brainsight2, Rogue Research, Montreal QU) MRI-TMS co-registration over the hotspot for the contralateral first dorsal interosseous muscle.The current-controlled model stimulator (Soterix, NYC) will automatically ramp up slowly over 30 seconds to the treatment current of 1.0 milliamp and then ramp down over 30 seconds to 0 milliamps. Sham will be administered each day during the first 30 minutes of the daily 1:1 therapy sessions.
1467393|NCT03216824|Other|Dressing|A dressing is maintained on the CVAD exit site.
1467394|NCT03216824|Other|No-Dressing|The CVAD exit site is not covered with a dressing.
1467395|NCT03216811|Drug|nutraceutical|8-week administration of nutraceutical compound
1467396|NCT03216798|Other|questionnaires survey|The questionnaires will be self-administered and anonymous. Information obtained from the questionnaire will not contain identifiable information of patients, CBO staff or health care workers.
1467397|NCT03216772|Device|Olympus PK Morcellator in PneumoLiner|Laparoscopic Supracervical Hysterectomy (LSH) or Total Laparoscopic Hysterectomy (TLH) using Olympus PK Morcellator in PneumoLiner containment device
1467398|NCT03216759|Procedure|Ischemic preconditioning|After the anesthesia induction and before surgery,the patient's left upper limb was subjected to ischemic preconditioning then patients received ischemic preconditioning.
1467399|NCT03216759|Drug|Dexmedetomidine|At the beginning of anesthesia induction, 3 ug/kg/h of dexmedetomidine was infused and adjusted to 0.3 ug/kg/h after 10 min of infusion until 30 minutes before the end of the procedure.
1467400|NCT03216759|Procedure|Patient-controlled epidural analgesia|Before the induction of anesthesia, the steel wire epidural catheter was placed in the T8-9 or T10-11 gap.The first volume of morphine 2mg + 0.2% ropivacaine + 0.9% saline 6ml, maintenance dose of morphine 18mg + 0.1% ropivacaine + 0.9% saline total 150ml. PCEA work with a continuous background dose of 2 ml/h with a single dose of 2ml/time, load 2ml, locking time 15min.
1467402|NCT03216733|Device|COMBO|PCI with COMBO stent
1467403|NCT03216733|Device|ORSIRO|PCI with ORSIRO stent
1467404|NCT03216720|Procedure|CABG|"Cannulation: 24-F arterial cannula, 29/29 F dual-stage venous cannula, and aortic root vent-/cardioplegia cannula
Grafting: pedicled left internal mammary artery, and no-touch
saphenous vein graft Heparin and protamine doses assessed by HMS Plus® Hemostasis Management System
Target activated coagulation time of >400 seconds"
1467405|NCT03216720|Procedure|Miniaturized extracorporeal circulation|"Centrifugal pump to reduce mechanical stress
Circuit coated with biosurface to increase haemocompatibilty.
Ante- and retrograde autologous priming and low-volume cardioplegia solution (intermittend cold modified Calafiore) to minimize haemodilution
Collapsible soft-shell reservoir for blood volume management
Cell-saving device
Venous air removing device and electric clamp system to air embolism"
1467406|NCT03216720|Procedure|Conventional extracorporeal circulation|"Roller pump
Circuit uncoated
Hard-shell venous reservoir
Intermittend cold blood Harefield cardioplegia"
1563125|NCT02504580|Drug|HTX-011B|
1467407|NCT03216707|Device|HD tDCS active motor cortex|the intervention will be 10 participants will be subjected to 1.5-gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting motor cortex area with the high-definition transcranial direct current stimulation device with current intensity 2 milliampere for 20 min
1467408|NCT03216707|Device|HD tDCS active insula cortex|the intervention will be 10 participants will be subjected to 1.5 gram of Capsaicin cream 0.075 concentration for 30 min then participants will be subjected to active stimulation targeting Insular cortex area with the high-definition transcranial direct current stimulation device, with current intensity 2milliampere for 20 min
1467409|NCT03216707|Device|HD tDCS sham motor cortex|the intervention 10 participants will be subjected to1.5 gram of Capsaicin cream 0.075% concentration for 30 min then participants will be subjected to sham stimulation targeting motor cortex area using the high-definition transcranial direct current stimulation device by starting stimulation for 30 seconds then stop stimulation for 20 min
1467410|NCT03216707|Other|Capsaicin cream|Capsaicin cream
1467411|NCT03216694|Diagnostic Test|Cardiopulmonary exercise testing|Aerobic fitness measured using a cycle ergometer and metabolic cart
1467412|NCT03216681|Drug|Hoat Huyet Nhat Nhat|Administered orally twice a day, 2 tablets each time, for 45 days.
1467413|NCT03216681|Drug|Tanakan 40mg|Administered orally three times a day, 1 tablet each time, for 45 days.
1467414|NCT03216668|Drug|TONKA|Administered orally twice a day, 2 tablets each time, for 6 weeks.
1467415|NCT03216668|Drug|LEGALON|Administered orally three times a day, two tablets each time, for 6 weeks
1467416|NCT03216655|Other|phone call|Investigators give a regular follow-up to participants: phone call monthly
1467417|NCT03216655|Other|wechat group|Investigators give a regular follow-up to participants: wechat follow up. Investigators send useful information and answer their questions monthly.
1467418|NCT03216642|Diagnostic Test|bacterial culture and analysis|Specimens were collected with soft-tipped applicators of sterile cotton swabs after syphilis of lacrimal passages.
1467419|NCT03216629|Behavioral|"Saying sorry"|"The objective of this study is to investigate how empathy expressed in form of saying sorry affect the perception of pain during dressing change?"
1467420|NCT03216616|Behavioral|Cognitive Behavioural Therapy|
1467421|NCT03216603|Behavioral|Health literacy intervention group|In the health literacy intervention group all patients will receive self-management help using a motivating interviewing (MI) technique delivered by two MI and COPD trained nurses once a week for eight weeks after hospitalization. Subsequently, the contact between the patients and the nurses will be by follow up motivational telephone calls once a month or more if needed for four months (i.a a total of six months intervention period).
1467422|NCT03216590|Device|Compressive draping using adhesive incise drape|In the intervention group the shoulder will be drape with compressive draping using adhesive incise drape (Ioban™2 Antimicrobial Incise Drape, 3M Inc.,USA).
1467423|NCT03216577|Other|Phone interview measuring health-related quality of life variables|A phone interview will be conducted by a dedicated nurse who will be blinded to the exposed/non-exposed status of the patient.
1467424|NCT03216564|Drug|Calcitriol|Active vitamin D (Calcitriol) 0.25 micrograms
1467425|NCT03216551|Diagnostic Test|Intra-operative frozen section|Tumor histologic subtypes will be determined by the intra-operative frozen section.
1467426|NCT03216538|Drug|AS101 1% oral solution|0.4 ml daily p.o.
1467427|NCT03216538|Drug|Placebo|0.4 ml daily p.o.
1467428|NCT03216525|Drug|Alvimopan|To determine if Alvimopan during radical cystectomy with urinary diversion results in faster return of bowel function.
1467429|NCT03216525|Drug|Placebo|To determine if placebo during radical cystectomy with urinary diversion results in faster return of bowel function.
1467431|NCT03216499|Drug|HIF-2alpha Inhibitor PT2385|Given PO
1467432|NCT03216499|Other|Pharmacological Study|Correlative studies
1467433|NCT03216499|Other|Laboratory Biomarker Analysis|Correlative studies
1467434|NCT03216499|Other|Pharmacogenomic Study|Correlative studies
1948282|NCT02557776|Genetic|Germline genetic testing of BRCA1 and BRCA2|
1467436|NCT03216473|Drug|Neuronox|Clostridium Botulinum Toxin A 100 U
1467437|NCT03216473|Drug|Botox|Clostridium Botulinum Toxin A 100 U
1467438|NCT03216460|Device|Insulet automated glucose control system|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4Share® AP System and personalized model predictive control algorithm.
1467439|NCT03216447|Drug|Advagraf|Tacrolimus prolonged-release hard capsules (QD)
1467440|NCT03216447|Drug|Prograf|Tacolimus capsules (q12h)
1467441|NCT03216434|Diagnostic Test|MRI using DaTscan|"A standard, non-contrast-enhanced structural/anatomic brain MRI will be performed. It will be used to exclude potential subjects and controls with significant and potentially confounding structural/anatomic findings. It will also be used as an anatomic overlay with the functional DaTscan image to aid in anatomic/physiologic correlation. At the same imaging session, a brief functional MRI (not requiring the subject to perform any tasks) will also be performed."
1467442|NCT03216421|Other|Quality of Life Questionnaires|Quality of Life questionnaires will be completed by each subject.
1467443|NCT03216408|Drug|Neuronox|
1467444|NCT03216408|Drug|Botox|
1467445|NCT03216395|Device|Over-the-scope Clips|Over-the-scope Clips is mounted onto a transparent cap, which is attached to the tip of the endoscope. To deploy the claw device, a cogwheel at the scope head is turned pulling a trip string. This in turn retracts the cap releasing the OTSC onto tissue.
1467446|NCT03216395|Device|Hemo-clipping|Hemo-clipping <=20 clips
1467447|NCT03216395|Device|thermo-coagulation|contact thermo-coagulation < = 8 pulses
1467448|NCT03216395|Drug|Epinephrine|epinephrine injection (diluted 1:1000) beneath peptic ulcer <20 mls
1467449|NCT03216382|Behavioral|Attention Training Technique|The ATT is a 12-minute audio recording that includes sounds and a voice guiding attention to the sounds. The sounds play continuously during the training task.
1467450|NCT03216382|Behavioral|Control Condition|In the control condition, participants listen to an audio recording with the same sounds as the ATT recording, and a voice that delivers placebo instructions.
1467451|NCT03216369|Other|MRI|MRI perfusion imaging
1467452|NCT03216356|Behavioral|CBT + ImRs|Cognitive Behavioral Therapy with Imagery Rescripting
1467453|NCT03216356|Behavioral|CBT + I.E.|Cognitive Behavioral Therapy with Imagery Exposure
1467454|NCT03216356|Drug|D-Cycloserine|250 mg DCS (derived from Seromycin 250 mg capsules)
1467455|NCT03216356|Drug|Placebo|polyethylene glycol 3350 powder
1467456|NCT03216343|Drug|Chiauranib|CS2164
1467457|NCT03216330|Other|No Intervention|There is no treatment intervention. We are assigning measurement tools such as the Electronic Thimble Algometer for QST and questionnaires to both groups.
1467458|NCT03216317|Behavioral|Intervention Group|Isometric handgrip training consisting of four series
1467459|NCT03216304|Drug|100 mg safinamide|"Safinamide will be administered as follows:
Days 5-11: 100 mg safinamide (one Xadago® tablet), once a day
Day 12: a single dose of 100 mg safinamide (one Xadago® tablet), immediately followed by a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)
Days 13-15: 100 mg safinamide (one Xadago® tablet) once a day The medication will be orally administered in the morning, at 8:00±1h, under fasting conditions, with 240 mL (total volume) of still mineral water."
1467460|NCT03216304|Drug|20 mg rosuvastatin calcium period 1|"Rosuvastatin will be administered as follows:
- Day 1: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet)"
1467461|NCT03216304|Drug|20 mg rosuvastatin calcium period 2|- Day 12: a single dose of 20 mg rosuvastatin calcium (one Crestor® tablet) immediately after the safinamide administration
1467462|NCT03216291|Behavioral|biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems. Complete training sessions once a week for 6 weeks in the office.
1467463|NCT03216291|Device|Home Biofeedback therapy|Biofeedback therapy is a labor-intensive, multi-disciplinary, team approach for the management of patients with anorectal problems, but instead of an office therapy, the subject will use a biofeedback device to gain strength in their anorectal muscles. This device will be taught how to use in the first session and then the subject will take it home to complete at least 1 session a day for 6 weeks.
1467472|NCT03216265|Other|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
1467473|NCT03216265|Other|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned sites twice daily (in the morning and evening).
1467474|NCT03216265|Other|No treatment|No treatment.
1467475|NCT03216252|Biological|samples|Blood samples, oral smear and urine
1467476|NCT03216226|Drug|dasiglucagon|Glucagon Analog
1467477|NCT03216226|Drug|GlucaGen|Native Glucagon
1467478|NCT03216213|Other|Frame|
1467479|NCT03216213|Other|Prime|
1467480|NCT03216213|Other|Norms|
1467482|NCT03216187|Drug|Pregabalin|pregabalin 150 mg capsules
1467483|NCT03216187|Drug|Placebos|capsules identical to pregabalin but without active drug
1467484|NCT03216174|Procedure|NESS-EFTR|NESS-EFTR includes steps of laparoscopic seromuscular suturing, EFTR of the inverted stomach wall, and endoscopic mucosal suturing with endoloops and clips.
1467485|NCT03216148|Diagnostic Test|FET-PET|All participating patients will receive a FET PET-scan parallel to the routine MRI at the end of the first line therapy (restaging) according to the HIT-protocol Second FET PET: In case of suspected tumour recurrence or progression within the follow-up period of 24 (12) months, the participating patient will receive a second FET PET-scan (parallel to an MRI)
1467486|NCT03216122|Procedure|Conventional/Delayed Loading|
1467487|NCT03216122|Procedure|Immediate Loading|
1467489|NCT03216096|Drug|Placebo ophthalmic solution and 3% DE-089 ophthalmic solution|Placebo ophthalmic solution; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 2-week run-in period 3% DE-089 ophthalmic solution; ; 1 drop, 6 times daily (every 2-3 hours) instilled into both eyes for 4-week treatment period
1467490|NCT03216083|Drug|Tranexamic Acid Injectable Solution|1g IV tranexamic acid mixed in normal saline (67mL)
1467491|NCT03216083|Other|Placebo|67mL IV normal saline
1467492|NCT03216070|Drug|Dasatinib 50 MG|50mg of dasatinib orally daily
1948283|NCT02554630|Other|Adjuvant|Blood will be incubated, ex-vivo, with one of the adjuvant therapies or no adjuvant and then, using microfluidic techniques the immune genomic profile and the functional capacity of immune cells will be assessed.
1563126|NCT02504580|Drug|HTX-009|
1948284|NCT02554630|Other|Blood Collection|Blood collection will be performed on all groups.
1948285|NCT02554279|Drug|menotropin|
1948286|NCT02554279|Drug|recombinant FSH|
1948287|NCT02553473|Drug|Doxycycline|
1467496|NCT03216018|Behavioral|"Prevention program: In Favor of Resilient Self"|"Prevention program: In Favor of Resilient Self"
1467497|NCT03216005|Device|BlueLeaf System|The BlueLeaf System will be used to create an autogenous leaflet to mimic valve function.
1467498|NCT03215992|Device|Diffuse Optical Tomography (DOT) System|Diffuse optical tomography (DOT) is a novel imaging modality that uses low-intensity, near-infrared light to characterize tissue. As light of a specific wavelength travels through tissue, it is absorbed and scattered by different chromophores and cellular structures. Using four wavelengths of light allows the detection of four chromophores: oxyhemoglobin, deoxyhemoglobin, water and fat.
1467501|NCT03215966|Combination Product|Macitentan / tadalafil FDC|Tablets for oral administration containing 10 mg of macitentan and 40 mg of tadalafil
1467502|NCT03215966|Drug|Macitentan (Opsumit®)|Film-coated tablets for oral administration formulated at a strength of 10 mg
1467503|NCT03215966|Drug|Tadalafil (Adcirca®)|Film-coated tablets for oral administration formulated at a strength of 20 mg
1467504|NCT03215953|Device|cast shoe|ankle-high, custom-made, well-moulded cast shoe
1467505|NCT03215953|Device|forefoot offloading shoe|Prefabricated shoe especially designed for relieving forefoot locations on the foot
1948288|NCT02553473|Drug|Placebo|
1948289|NCT02549092|Drug|ABT-SLV187|Dose levels will be individually optimized.
1467511|NCT03215914|Device|MiniMed 670G system|Eligible subjects with type 1 diabetes will initiate hybrid closed-loop insulin delivery based on interstitial glucose monitoring via the MiniMed 670G system according to Medtronic's labeling. This system combines subject-delivered pre-meal boluses with automatic interprandial insulin delivery that includes automated functions for both predictive and threshold suspension of insulin delivery intended to minimize exposure to glucose levels < 70 mg/dl.
1467512|NCT03215901|Behavioral|A Beautiful Future Video|Video delivering information on the longevity gains due to HIV treatment in the area.
1467513|NCT03215901|Behavioral|Control video|Video from South African television show.
1467514|NCT03215888|Procedure|bariatric surgery|Obese patients will undergo brain imaging, neurocognitive function testing and measurement of insulin resistance and inflammatory markers pre- and post bariatric surgery
1467515|NCT03215875|Drug|Fed- 60mg ER Torsemide|60mg ER Torsemide will be given after high fat, high-calorie meal
1467516|NCT03215875|Drug|Fasting- 60mg ER Torsemide|60mg ER Torsemide will be given after overnight fasting
1467517|NCT03215862|Drug|Lactated Ringer|This is a Lactated Ringer's solution infusion before, during, and after the ERCP procedure.
1467518|NCT03215862|Drug|Normal Saline 0.9% Infusion Solution Bag|This is a Normal Saline solution infusion before, during, and after the ERCP procedure.
1467519|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy
1467520|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy + LVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + LVP
1467521|NCT03215849|Device|CRT-pacemaker device set to Routine Medical Therapy + BiVP|Medtronic Serena™ QUAD CRT-P MRI™ SureScan™ W4TR05 set to Routine Medical Therapy + BiVP
1467522|NCT03215836|Procedure|Bronchoscopy and Nasal Epithelium Brush Sampling|After meeting screening criteria, participants will undergo further evaluation to determine whether or not inclusion and exclusion criteria are met. Participants will undergo a baseline evaluation, lung function testing and a subsequent bronchoscopy and nasal epithelial brush sampling in those that meet study enrollment.
1948290|NCT02548091|Other|Blood samples for assays of plasma inflammatory markers (cytokines InterLeukin-6, InterLeukin-8, InterLeukin-10)|"The same amount of blood sample is collected from both arms of study at the same time of the procedure.
In each patient, in the per procedure period, a total of 50 milliliters of blood sample is drawn from the pulmonary circulation downstream and upstream of obstructive lesion, the trunk of pulmonary artery, the superior vena cava and the femoral arterial line prior to angioplasty and at the end of procedure; in the post interventional care unit 10 milliliters of blood sample will be draw daily from the superior vena cava catheter line and femoral arterial line."
1948291|NCT02548091|Procedure|Non invasive ventilation|
1948292|NCT02548091|Procedure|monitoring system Pulse-Induced Contour Cardiac Output (Picco)|
1948293|NCT02548091|Procedure|Computed tomography (CT)|
1467698|NCT03214393|Diagnostic Test|serum antibodies|serum antibodies will be measured for pregnant women with Pre-Eclampsia
1948294|NCT02545283|Drug|Cytarabine|Participants will receive cytarabine 1 gram per square meter (g/m^2) intravenous (IV) infusion for 5 days of every treatment cycle.
1948295|NCT02545283|Drug|Idasanutlin|Participants will receive idasanutlin 300 mg per oral (PO) twice daily (BID) (in Cycle 1) or once daily (QD) (in Cycles 2 and 3) for 5 days of every treatment cycle.
1948296|NCT02545283|Other|Placebo|Participants will receive idasanutlin matching placebo PO BID or QD for 5 days of every treatment cycle.
1948297|NCT02537509|Drug|Cholecalciferol|
1948298|NCT02537509|Drug|Placebo of cholecalciferol|
1948299|NCT02531685|Other|Placebo|Placebo: 0.9% Sodium Chloride injection. 3 subjects in each cohort receive placebo injection intradermally on days 1, 22 and 43.
1467529|NCT03215797|Drug|phenylephrine|phenylephrine 100ug/ml IV infusion at a rate of 5ml/h in case of hypotension.
1467530|NCT03215797|Drug|Norepinephrine|Norepinephrine 5ug/ml IV infusion at a rate of 5 ml/h in case of hypotension
1467531|NCT03215784|Dietary Supplement|Fish Oil|
1467532|NCT03215784|Dietary Supplement|Probiotic|
1467533|NCT03215784|Dietary Supplement|Placebo|
1467534|NCT03215771|Device|MyoPro Motion-G|The MyoPro Motion-G is an elbow-wrist-hand myoelectric orthosis.
1467535|NCT03215758|Drug|QAW039|QAW039 once daily
1467536|NCT03215758|Drug|Placebo|Placebo once daily
1467538|NCT03215732|Diagnostic Test|HBV testing with dried blood spots (DBS) technique|Survey participants will be tested at home for chronic HBV infection using the DBS technique (collection of drops of whole blood dried onto filter paper).
1467539|NCT03215719|Radiation|Standard Radiation Treatment|An interval scan at 4 weeks to assess for a good response defined as >40% nodal shrinkage will stratify patients into receiving standard treatment (≤40% nodal shrinkage) or a dose-deescalated treatment regimen (>40% nodal shrinkage).
1467540|NCT03215719|Radiation|Dose-Deescalated Treatment|Intensity-modulated radiation therapy (IMRT) is an advanced type of radiation therapy used to treat cancer and noncancerous tumors. IMRT uses advanced technology to manipulate photon and proton beams of radiation to conform to the shape of a tumor. Patients will be treated with intensity-modulated radiation therapy (IMRT) with megavoltage photons
1467541|NCT03215719|Drug|Cisplatinum|Standard of care chemotherapy
1467542|NCT03215706|Biological|Ipilimumab|Specified dose on specified day
1467543|NCT03215706|Biological|Nivolumab|Specified dose on specified day
1467544|NCT03215706|Drug|Carboplatin|Specified dose on specified day
1467545|NCT03215706|Drug|Paclitaxel|Specified dose on specified day
1467546|NCT03215706|Drug|Pemetrexed|Specified dose on specified day
1467547|NCT03215706|Drug|Cisplatin|Specified dose on specified day
1467548|NCT03215693|Drug|X-396 capsule|225mg once daily
1467549|NCT03215680|Other|Climate|Hot and temperate climate
1467550|NCT03215667|Device|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to a single extraction socket and covered by polylactide membrane to facilitate regeneration of new bone in order to preserve alveolar ridge dimensions.
1467551|NCT03215654|Other|"EspaiJove.net mental health literacy program"|"The EspaiJove.net: a space for mental health (EspaiJove.net) project is a MHL program which aims the promotion of mental health, the prevention of mental disorders, the facilitation of help-seeking behaviors and the eradication of stigma among secoundary students into the Spanish context."
1467552|NCT03215641|Device|Fitbit|The Fitbit is a consumer-grade personal activity tracker. It is used to track physical activity. Patients will be given devices at the beginning of the study, and they will continue to use it for 7 weeks. Their data will be collected on a weekly basis, and patients will receive feedback on their level of activity based on the Fitbit data.
1467553|NCT03215628|Diagnostic Test|TCEUS|Intravenous sulphur hexafluoride microbubbles
1467554|NCT03215615|Procedure|Periodontal surgery|Coronally advanced flap for root coverage
1467555|NCT03215615|Procedure|Total Etch adhesive|Total-etch adhesive system (two step)
1467556|NCT03215615|Procedure|Universal Adhesive|One-step self-etching adhesive system
1467557|NCT03215615|Procedure|Nanofilled Composite|Partial nanofilled-resin composite restoration
1467558|NCT03215615|Procedure|Micro-Hybrid Composite|Partial micro-hybrid composite restoration
1467559|NCT03215602|Other|NEMEX and education + strength training|Optimizing sensorimotor control and achieving functional stability. Increasing knee extensor muscle strength. Teaching everyday disease management.
1467560|NCT03215602|Other|NEMEX and education|Optimizing sensorimotor control and achieving functional stability. Teaching everyday disease management.
1467561|NCT03215563|Radiation|18F PET-MRI|18F-fluoride Hybrid PET-MRI
1467562|NCT03215563|Diagnostic Test|Transcranial Doppler|Microembolic Signals detection
1467563|NCT03215550|Procedure|CEA|Carotid Endarterectomy
1467564|NCT03215550|Radiation|18F PET-MRI|18F-fluoride Hybrid PET-MRI
1467565|NCT03215550|Diagnostic Test|Transcranial Doppler|Microembolic Signals detection
1467566|NCT03215537|Behavioral|comprehensive intervention|preoperative and postoperative exercise program
1467567|NCT03215524|Biological|Daratumumab, Cyclo, Dex and Pomalidomide|DCDP vs DCD+P for treatment of RRMM
1467568|NCT03215511|Drug|LOXO-195|Oral LOXO-195
1467571|NCT03215485|Behavioral|Nutrition lessons|Face-to-face interactive group lessons delivered in the classroom.
1467572|NCT03215485|Behavioral|Virtual world learning environment|Every participant has their own unique avatar in the virtual world learning environment named Rippleville. They can choose to complete quests, watch archived nutrition video lessons, explore, and socialize with other avatars. They receive rewards (Rippleville dollar and badges) for their efforts.
1467573|NCT03215485|Other|Newsletter|All participants in the intervention and comparison groups receive up to 10 professional newsletters on topics related to sports nutrition and performance, healthy eating and active living tips.
1467574|NCT03215472|Other|DASH Cloud|With DASH Cloud, the investigators will ask participants to track their diet daily using a commercial diet tracking app. The investigators will retrieve the diet data on our DASH Cloud platform and provide tailored feedback about a participant's DASH adherence via fully automated daily or weekly text messages. These feedback messages will describe both an individual's absolute performance and change over time. The investigators also include theory-driven tailored content that reinforces successes, offers motivational strategies, and offers short behavior change tips.
1467575|NCT03215472|Other|Nutritionix Track app|DASH Light Control participants will be asked to use the Nutritionix app daily and receive publicly available written materials on the DASH diet.
1467576|NCT03215459|Device|Cardiopulmonary Exercise Test|Cardiopulmonary Exercise Test
1467577|NCT03215446|Drug|maintenance of anaesthesia with propofol|
1467578|NCT03215446|Drug|maintenance of anaesthesia with sevoflurane|
1467580|NCT03215407|Drug|Intra-articular Tocilizumab|Patients will be randomly chosen to be intra-articular injected of tocilizumab injection
1467581|NCT03215407|Drug|Intra-articular Compound Betamethasone|Patients will be randomly chosen to be intra-articular injected of compound betamethasone injection
1467582|NCT03215394|Behavioral|Attention Training Program|The attention training involves 8 visits over 4 weeks with pre/post data collection before and after the training, and a follow-up 6 months later. Pre/post data collection involves the ESCS and a Laboratory Temperament Assessment Battery (LabTAB), and a series of on-screen assessment tasks that measure cognitive control, distraction tolerance, sustained attention, habituation, gap-overlap, disengagement, and attention to static images. Training runs from Wk 2-5 with 2 visits per week and is completed in home with the child sitting on the parents lap in front of a monitor. The parent and child are inside a tent to reduce environmental stimuli. The research trainer is outside the tent running the program from a laptop. The program consists of a battery of 9 gaze-contingent training tasks using custom MATLAB scripts. The animated tasks are designed to engage the child and present as developmentally appropriate games. At each visit 6 of the 9 tasks will run for a total of 4min each(24min).
1467583|NCT03215394|Behavioral|Social ABCs|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
1467584|NCT03215394|Other|Treatment As Usual|The Treatment as Usual group acts as a pre-existing convenience sample, consisting of families currently enrolled in a different approved research study run by the same group of investigators. Children in this group have comparable clinical concerns for ASD, and complete the same standardized measures (ADOS, MSEL, ESCS, AOSI) as the Baseline assessment in this RCT, but will not receive Social ABCs or the Attention Training Program. They are able to access any programs or interventions available to them in the general community. This is tracked on a Services Log form, included as part of that study's protocol. Families in this group will have consented to their child's data being shared across studies in this research group.
1467585|NCT03215394|Behavioral|Sham Attention Training|The sham attention condition will use identical hardware, administered by the same research staff for the same frequency and duration as the attention training program (8 visits over 4 weeks including pre/post data collection). In this condition, infants will be exposed to non-gaze contingent visual stimuli that offer no adaptive difficulty levels (ie. clips of age appropriate television shows). Placebo stimuli will be presented until toddlers become fidgety or distressed.
1467587|NCT03215355|Drug|Primovist|"Primovist is currently a drug marketed for MRI. In this study it will be administered intravenously at 4 times what it is quoted for MRI to enhance the different imaging modality (CBCT) to improve the accuracy of liver SBRT. Although liver SBRT usually consists of 5 treatments, contrast will only be administered during the first treatment.
Consulting Health Canada and Bayer HealthCare Canada (the drug manufacturer) deemed this use off label dosing which in Canada is at the discretion of the physician. Based on preliminary imaging testing, and a review of toxicity literature for this drug, the administration for this specific use was deemed appropriate to give adequate image quality, while simultaneously maintaining patient safety."
1467588|NCT03215342|Behavioral|Pediatric Goal Management Training|7 GMT modules will be administered in 7x2 hours sessions (ten groups). Manualized intervention; metacognitive strategies for improving attention and problem solving. Homework assignments between sessions.
1467589|NCT03215342|Behavioral|Pediatric Brain Health Workshop|7 pBHW modules will be administered in 7x2 hours sessions (ten groups). Psychoeducation; brain (dys)function, plasticity, memory, executive function, and attention. Stress, physical exercise, sleep, nutrition, and energy management. Homework assignments between sessions
1467590|NCT03215329|Procedure|abdominal or vascular surgery|Intermediate or high risk abdominal or vascular surgery
1467591|NCT03215303|Device|Continuous Positive Airway Pressure (CPAP)|In the first moment, CPAP will be installed, and the researcher will hold a mask in the position in which it is coherent, explaining the method to the patient and allowing their gradual adaptation. Patients will adapt for a few minutes to make sure the mask is consistent with the specifications, so that the patient is comfortable. Participants in the intervention group will start with a PEEP of 1cmH2O that will increase by 2 cmH2O until a PEEP of 10 cmH2O is reached. Therefore, participants in the intervention group will remain with CPAP, PEEP of 10cmH2O, FiO2 0.21, for a period of 40 minutes.
1467592|NCT03215290|Procedure|TCS|"The cutting surface recognized as not good cutting surface was further trans-parenchymal compressing sutured, if possible, using a hepatic needle."
1467596|NCT03215264|Drug|hydroxychloroquine|160mg daily
1467597|NCT03215264|Drug|entinostat|2-5mg weekly
1467598|NCT03215264|Drug|regorafenib|400-1200mg daily
1467599|NCT03215251|Other|Intervention bundle|Assessment of the patient's mouth and lips determined, to check any stickiness or dryness in the mouth or around lips or split skin at the corners of the mouth or cracked lips. Intervention bundle consisted of sterile cold wet oral swab wipes and sterile ice cold water sprays administered for in two sessions of 15 minutes each. First session was given in 15 minutes, patients received cold wet oral swab wipes in oral cavity 2 to 3 times and mouth spray with 5 to 6 sprays. A maximum of 9 wipes and 18 sprays of sterile water. After administration of intervention bundle, Posttest 1 was taken after 15 minutes observation with the same tools. Then researcher waited for 15 minutes after post test1 and session two was administered in 15 minutes with a maximum of 9 wipes and 18 sprays of sterile water. Post test 2 was taken after 15 minutes of session two.
1467600|NCT03215225|Procedure|Root canal orthograde treatment|
1467601|NCT03215212|Other|eye mask|eye mask administered from 10 pm to 7 am
1467602|NCT03215212|Other|ocean sound|Ocean sound administered via ear phone for 30 minutes from 9:15 pm to 9:45 pm
1467603|NCT03215212|Other|ear plug|ear plug administered from 10 pm to 7 am
1467604|NCT03215199|Other|NAPT|Web-based depression and distress monitoring application
1467605|NCT03215186|Other|observational study|
1467606|NCT03215173|Behavioral|Fit After Baby|Mobile application
1467607|NCT03215173|Behavioral|Text4Baby Control Group|Receive free text messages
1467608|NCT03215160|Behavioral|Exercises|mobilization exercises (Patellofemoral joint, Tibiofemoral joint, Soft tissue) and classical exercises performed in the early post-op period
1467609|NCT03215147|Diagnostic Test|Confirmation of Airway Disease combined with IPF|To confirm the airway disease combined with IPF, PFT+BDR+DLCO, MBPT, Induced sputum exam, MAST, Total IgE, serum Eosinophil count, FENO will be done at the time of registration and 6~8 weeks later.
1467611|NCT03215121|Procedure|One handed mask airway + chin lift|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.
Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, one hand for Group one patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. The initial mask management will be performed for 20 seconds.
After another 20 seconds (50 seconds from the start of induction), in Group one, the mask holding will switch to two hands for 20 seconds."
1467612|NCT03215121|Procedure|Two handed mask airway + jaw thrust|"Prior to the induction of anesthesia, a shoulder role will be used to have the child's head in sniffing position for induction. Horizontal alignment of the external auditory meatus with the sternum, will be used as a marker for, proper positioning.
Oxygen and nitrous oxide for 10-15 seconds will be administered and sevoflurane will then be commenced.The provider will hold the mask as randomized, one hand for Group one patients and two hands for Group two patients. Any changes in airway patency when mask is held by one hand versus two hands will be observed and documented by various parameters. In Group 2 patient's mask will be held with two hands first for 40 seconds."
1467613|NCT03215108|Device|Endoscopic Retrograde CholangioPancreatography(ERCP)|This study is prospective randomized multicenter study by using Endoscopic Retrograde CholangioPancreatography(ERCP). Comparison between Novel flower-type covered stent and Conventional covered stent in malignant extrahepatic biliary obstruction will be conducted after stent insertion by using Endoscopic Retrograde CholangioPancreatography(ERCP).
1467614|NCT03215095|Drug|Durvalumab (Medi4736)|durvalumab 1500 mg IV every 4 weeks
1467615|NCT03215095|Radiation|Radioiodine (RAI)|100 mCi (+/- 10 mCi) of 131I will be administered a day after Thyrogen injections have been administered for two consecutive calendar days.
1467616|NCT03215082|Other|Vestibular-Visual Intervention|vestibular-visual exercises
1467617|NCT03215082|Behavioral|standard care|standard care
1467618|NCT03215069|Drug|Empagliflozin 10 MG|Empagliflozin 10 mg PO daily
1467619|NCT03215069|Drug|Placebo oral capsule|Placebo PO daily
1467620|NCT03215056|Drug|Methoxyflurane|PENTHROX 3mL inhalation vapour, liquid
1467621|NCT03215056|Drug|Normal saline|Placebo
1467622|NCT03215043|Dietary Supplement|Eriocitrin|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
1467623|NCT03215043|Other|Placebo|The selected individuals will be randomly distributed in 4 groups through random number generator program. Group A (n = 20) will receive a dose of 140 mg / d eriocitrin; Group B (n = 20) eriocitrin 280 mg / d; The C group (n = 20) 560 mg / d eriocitrin; And group D (n = 20) will receive the placebo with corn starch excipient. All doses will be packaged in Manipulation Pharmacy, and should be of the same type, color and size. Individuals will be instructed to regularly ingest a pre-dinner capsule for 12 weeks.
1467625|NCT03215017|Device|Transanal irrigation|Effect of Transanal irrigation (TAI) using Peristeen® anal irrigation system - Coloplast
1467626|NCT03215017|Drug|Medication|Medication to help control of the bowel movement (One or a combination of Loperamide, Sorbitol, Sterculia gum)
1467627|NCT03214965|Behavioral|Facebook group|A closed facebook group used to deliver multimedia content specifically produced to inform the participants about chronic kidney disease, kidney transplantation and related topics. This group is also used to share doubts and life experiences among participants and the interdisciplinary team.
1467628|NCT03214952|Drug|Vonoprazan|Vonoprazan tablets
1467629|NCT03214939|Biological|Immunotherapy based on dendritic cells|Intravenous injection of cells
1467630|NCT03214926|Device|Moving Through Glass intervention|
1467631|NCT03214913|Other|Early Goal Directed Therapy|EGDT therapy ：30ml/kg in the first bolus to have a CVP 8-12 mmHg and MAP 65-85 mm Hg,and urine output ≥0.5 ml/kg/h, ScvO2 ≤70%；If not, use noradrenine，red blood cell transfusion if necessary.
1467632|NCT03214913|Other|Ruijin Strategy|"Ruijin Strategy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation;using noradrenaline at the same time;red blood cell transfusion if necessary.
target： fulfillment of two or more of four criteria:1. HR <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT 25%~35%."
1467633|NCT03214887|Biological|RV-P1501|Gel-like product with BMMNCs in each ml of hyaluronan (HA) solution
1467634|NCT03214874|Drug|Demadex 20mg Tablet|Immediate Release (IR) Torsemide
1467635|NCT03214874|Drug|ER Torsemide 20mg Tablet|Extended Release Torsemide 20 mg tablet given once daily
1948300|NCT02531685|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral entertoxigenic Escherichia coli (ETEC) Vaccine|LT(R192G/L211A), or dmLT is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700mcg of vaccine protein in a 3 ml, multi-dose. Cohorts 1-4 receive doses of 0.1, 0.3, 1.0 and 2.0 mcg respectively, intradermally on days 1, 22 and 43. Cohort 5 receives a TBD dose on days 1, 22, and 43
1467637|NCT03214848|Behavioral|Contraceptive education prior to abortion|Contraceptive education script will be delivered over the phone prior to abortion visit.
1467638|NCT03214835|Device|Endo CDx Brush biopsy|In patients with laryngeal lesion the brush biopsy will be taken with the standard cup biopsy - either in the clinic or in the OR. In LPR patients brush biopsy will be taken in the clinic.
1467640|NCT03214809|Diagnostic Test|ultrasound protocol|after first assessment and treatment by the MET team, an Multi-organ ultrasound protocol will be run by the MET doctor
1467641|NCT03214796|Drug|Human albumin|Infusion of human albumin
1467642|NCT03214783|Other|Facial characteristics|The exposures are facial characteristics which differ significantly in exposure rates between triple-vessel (3VD)/ left main (LM) diseases group and no coronary artery disease (CAD) group.
1467643|NCT03214770|Drug|TheraCal|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
1467644|NCT03214770|Drug|light-cured calcium hydroxide|Biomaterial used for carious lesions reaching to dentin. Material is applied and after 6 month dentin sample collection and the bacterial count by digital colony counter, Agar diffusion test.
1467645|NCT03214731|Drug|Artesunate|Artesunate was produced by pharmaceutical factory for research specifically
1467646|NCT03214731|Other|placebo|placebo was produced by pharmaceutical factory for research specifically
1467647|NCT03214718|Diagnostic Test|Measurement level of myeloid derived suppressor cells in CML patients treated with imatinibe 400 mg/day|"For each patient these investigation will be done:
- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .
Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
1467648|NCT03214718|Diagnostic Test|Measurement level of myeloid derived suppressor cells in CML patients treated with nilotinib 600 mg/day|"For each patient these investigation will be done:
- Complete blood count,bone marrow aspirate and bone marrow biopsy Measure BCR-ABL GENE Level by FISH at diagnosis and every 3 months till one year .
Measurement Level of myeloid derived suppressor cells both granulocytic and monocytic cells by flowcytometry ."
1467649|NCT03214692|Dietary Supplement|Gum Arabic|Oral intake of GA in powder from30 grams per day
1467650|NCT03214679|Other|Accessible Care|Accessible Care will be provided by co-locating a hepatitis treatment provider, together with a Hepatitis C Care Coordinator, on-site at our collaborating needle exchange program.
1467651|NCT03214679|Other|Usual Care|Usual care entails referral to an on site HCV care coordinator (not provided by study)
1467654|NCT03214653|Drug|Propofol|Subjects were given target-controlled infusion of propofol using Schinder technique effect mode with the administration of maintenance agent was adjusted by the depth of sedation using bispectral index monitor with target of 45-50
1467655|NCT03214653|Drug|Sevoflurane|Subjects were given sevoflurane 1,5-2% as maintenance agent of anesthesia.
1467656|NCT03214640|Device|Rivanna Accuro Ultrasound Device|For subjects randomized to use of the handheld ultrasound, the device will be utilized in the location of landmarks to see if it decreases the amount of time it takes to place the neuraxial block
1467657|NCT03214640|Other|Palpation|Standard of care methods will be utilized in the placement of the neuraxial analgesia block; no ultrasound will be used.
1467658|NCT03214627|Device|Anemia Control Model (ACM)|The ACM is mainly composed of 2 sub-Systems - predictor model which, depending on the input data, forecasts the response to anaemia drug therapy for a specific patient. The predictor model is implemented as a feed-forward artificial neural network. The ACM is an algorithm that extracts the optimal policy to achieve the established clinical outcome for anaemia management using the predictor model.
1467659|NCT03214627|Drug|IV iron|IV iron given monthly as required - dose determined by the ACM and as agreed by the investigator
1467660|NCT03214627|Drug|Erythropoiesis-Stimulating Agent (ESA)|ESA given monthly as required over 6 months - dose determined by the ACM and as agreed by the investigator
1467661|NCT03214614|Drug|GLPG2451 multiple dose|GLPG2451 oral suspension, multiple ascending doses, daily for 14 days
1467662|NCT03214614|Drug|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
1467663|NCT03214614|Drug|GLPG2451/GLPG2222 multiple dose|GLPG2451 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
1467664|NCT03214614|Drug|Combined Placebo multiple dose|Combined Placebo, oral suspension, daily for 14 days
1467665|NCT03214601|Device|penetrating atherosclerotic ulcer, aorta branch cardiovascular implant|The Relay Branch System is intended to provide an option for patients with arch and proximal descending chronic thoracic aortic pathologies.
1467666|NCT03214588|Drug|TAK-831|TAK-831 tablets
1467667|NCT03214588|Drug|TAK-831 Placebo|TAK-831 placebo matching tablets
1467668|NCT03214575|Device|Conventional method|
1467669|NCT03214575|Procedure|GPS Method|
1467670|NCT03214562|Drug|Fludarabine|30 mg/m2 by vein over approximately 30 minutes daily on days 2, 3, 4, 5, 6.
1467671|NCT03214562|Drug|Cytarabine|2 g/m2 by vein over approximately 4 hours daily starting 4 hours (+/- 1 hour) after the completion of Fludarabine on days 2, 3, 4, 5, 6.
1467672|NCT03214562|Drug|Idarubicin|6 mg/m2 by vein over approximately 15 to 30 minutes given following Fludarabine administration on days 4 and 5.
1467673|NCT03214562|Drug|Filgrastim|5 mcg/kg subcutaneously daily on days 1, 2, 3, 4, 5, 6, 7.
1467674|NCT03214562|Drug|Pegylated Filgrastim|6 mg can be administered subcutaneously after day 5 as a single injection to replace remaining injections of Filgrastim.
1467675|NCT03214562|Drug|Venetoclax|"Venetoclax starting dose of 100 mg by mouth on day 1, 200 mg on day 2, and 400 mg on day 3-21 of the first 28 day cycle.
Expansion Phase: Venetoclax starting dose is MTD from Induction Phase taken by mouth Days 1-14 of each cycle during the consolidation phase.
Maintenance Phase: Arm: Venetoclax monotherapy maintenance at MTD continues for a period of one year after completion of induction/consolidation therapy, for those patients who do not proceed to stem cell transplantation."
1467676|NCT03214549|Procedure|gull wing preparation of laminates veneers|preparation involving mesial and distal extension further lingualy.
1467677|NCT03214549|Procedure|conventional preparation of laminates veneers|preparation not involving mesial and distal extension further lingualy.
1467678|NCT03214536|Procedure|erector spinae block|bilateral injection of local anaesthetic between the erector spinae muscle and the transverse process
1467679|NCT03214536|Drug|Ropivacaine|injection of 20 ml ropivacaine 0.375 % bilateral by erector spinae block
1467680|NCT03214536|Procedure|Spine surgery|Surgery of lumbar spine
1467681|NCT03214536|Procedure|anesthesia|general anesthesia
1467682|NCT03214523|Behavioral|Sleep Education|The subject will undergo a 30-minute session on sleep education from one of the study coordinators.
1467683|NCT03214510|Drug|Bupivacaine|"Transversus Abdominus Plane Block: The volume, concentration and mixture of plain Bupivacaine follows FDA and manufacturers guidelines.
Epidural Pain Management: Bupivacaine (0.075%) at 10 ml/hr continuous infusion and a 3 ml every 10 minutes demand dosing, and a 5 ml every 3 hours clinician bolus as needed for additional pain control."
1467684|NCT03214510|Drug|Liposomal Bupivacaine|The volume, concentration and mixture of Liposomal Bupivacaine follows FDA and manufacturers guidelines.
1467685|NCT03214510|Drug|Hydromorphone|Hydromorphone (10 mcg/kg for patients 65 yrs or younger and 5 mcg/kg for patients > 65yrs).
1467686|NCT03214510|Behavioral|Questionnaires|"Participants complete questionnaires about pain and quality of life before surgery.
Every other day after surgery (Day 1 through Day 6), participants also complete questionnaires about recovery and any side effects and symptoms participants may be having from the pain medication.
Participants complete questionnaires about recovery and quality of life every other week for 6 weeks, monthly for 4 months, and at Month 6."
1467687|NCT03214497|Device|Protector|All patients which are assigned to the Protector are studied with this laryngeal mask
1467688|NCT03214497|Device|Supreme|All patients which are assigned to the Supreme are studied with this laryngeal mask
1467689|NCT03214484|Other|By comparing the evolution of the visual acuity curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
1467690|NCT03214484|Other|By comparing the evolution of the curves.|By comparing the evolution of the curves, the investigator can confirm that the AV measured on ET / Computer can be an interesting and useful element to help us follow up our patients and improve the quality of life's patients by decreasing the number of visits control.
1467691|NCT03214471|Behavioral|Lifestyle intervention|Nutritional and behavioural tele-counselling , self-monitoring and a 12-week supervised tailored exercise programme. Participants will receive a regular tele-counselling throughout the 12-month. Each session will take approximately 15 minutes, underpinned by behavioural psychological techniques. After their 3-month post-surgery assessment visit, participants in the BARI-LIFESTYLE Intervention Study will be enrolled in a supervised exercise programme at health facility gyms for 12 weeks.
1467692|NCT03214458|Device|Nasal high flow|The AIRVO 2 is for the treatment of spontaneously breathing patients who would benefit from receiving high flow warmed and humidified respiratory gases/
1467693|NCT03214445|Procedure|Sealing margins with flow composite|Seal the margin of restoration with Composite flow with nanofiller
1467694|NCT03214445|Procedure|Sealing margins with seal|Seal the margin of restoration with sealant without filler
1563127|NCT02504580|Drug|Marcaine|
1467710|NCT03214341|Radiation|MRI diffusion|using MRI diffusion to differentiate between benign and malignant mediastinal masses
1467711|NCT03214328|Diagnostic Test|Determination of causes of fetal death|Determination of causes of fetal death using systematic protocol testing
1467712|NCT03214315|Procedure|Visceral adipose tissue specimen|specimen
1467713|NCT03214302|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
1467714|NCT03214289|Biological|Fecal Microbiota Transplantation|Twenty fecal microbiota capsules produced from a single healthy donor, unrelated to the participant.
1467715|NCT03214276|Dietary Supplement|Vinitrox polyphenols|Vinitrox™ (Nexira - France) is a combination of specific profile polyphenols from grape and apple. The main polyphenol classes are proanthocyanidins (as catechins, B2 dimer), phenolic acids (as chlorogenic acids, gallic acids) and anthocyanins (as malvidin-3-glucoside). It was administrated the night and the morning before the endurance test (oral administration)
1467716|NCT03214276|Dietary Supplement|Placebo|Made with maltodextrin. It was administrated the night and the morning before the endurance test (oral administration).
1467721|NCT03214237|Other|no intervention - cross-sectional observational only|no intervention - cross-sectional observational only
1467722|NCT03214224|Device|remote pulmonary function testing|Telemedicine delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
1467723|NCT03214224|Device|standard pulmonary function testing|Standard clinical delivery of pulmonary function testing in ALS, including Forced Vital Capacity (FVC) and Maximal Inspiratory Pressure (MIP)
1467724|NCT03214198|Drug|Vonoprazan|Vonoprazan tablets
1467725|NCT03214185|Procedure|IVF/ICSI|in vitro fertilization or intracytoplasmatic sperm injection
1467726|NCT03214185|Genetic|PGS 2.0|Blastocysts are selected by PGS 2.0(SNP-microarray or NGS based) and only euploid embryos will be transferred.
1467727|NCT03214185|Other|Morphology standard|Blastocysts are selected by morphology criteria and only good-scored embryo will be transferred.
1467728|NCT03214172|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15/20 mg
1467729|NCT03214159|Drug|Ritonavir Tablet 100mg|Ritonavir Tablet 100mg is a generic product manufactured by Ascletis Pharmaceutical Co., Ltd.
1467730|NCT03214159|Drug|NORVIR tablet 100mg|NORVIR Tablet is a generic product manufactured by AbbVie. NORVIR Tablet 100mg will be used as a comparator drug for the BE study.
1467731|NCT03214146|Biological|HYNRCS-Allo inj|The patients enrolled in the trial will be successively allocated into single cohort for HYNRCS-Allo inj., 1.0 X 10^6 cells/kg according to the protocol design.
1467732|NCT03214133|Other|Epicatechin-rich cocoa dose response|Subjects consume randomized doses of 0, 1, 2, 3 mg epicatechin/kg from epicatechin-rich cocoa. The optimal dose of epicatechin-rich chocolate will be the dose which have the greatest increase PNIP levels.
1467733|NCT03214133|Other|Epicatechin-rich cocoa vs placebo on performance|An optimized dose of epictechin-rich cocoa or placebo will be given for 3 weeks alongside a prescribed power-based training program. In a randomized parallel design the effect of the optimal dose of epicatechin-rich chocolate, compared to placebo, on maximal isometric squat force, RFD, and jump testing will be quantified.
1467734|NCT03214107|Other|Exercise|Participants will be admitted at IRCM at 14:00. At 15:30, participants will performed a 60-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). During exercise, capillary glucose levels will be measured every 10 minutes. At 16:30, the exercise will be completed and capillary glucose levels will be monitored every 20 minutes for 1 hour. At 17:30, the participant will be discharged.
1467735|NCT03214107|Other|Snack|Full snack or Distributed snack
1467736|NCT03214094|Drug|Vonoprazan|Vonoprazan tablets
1467738|NCT03214055|Drug|Mannitol|The mannitol has been administered routinely to prevent renal dysfunction in patients undergoing robot-assisted laparoscopic radical prostatectomy. Participants will receive the mannitol as part of routine medical care, and we will evaluate the change in optic nerve sheath diameters before and after mannitol administration.
1467739|NCT03214042|Device|K-rod dynamic stabilization system|Sixty-seven patients with lumbar degenerative diseases were treated with K-rod dynamic stabilization system. All patients were followed for 2 years. K-rod dynamic stabilization system was purchased from Biotech, USA, consisting of titanium alloy pedicle screw, titanium alloy line and polyether ether ketone (PEEK) shell between pedicle screw heads.
1467740|NCT03214029|Diagnostic Test|Cardiac troponin testing|Fresh EDTA plasma samples will be measured with both the hs-cTnI (Abbott) and hs-cTnT (Roche) assays.
1467741|NCT03214016|Other|Aerobic Exercise|1 hour of aerobic training on a treadmill, 3 times a week, during 8 weeks.
1467742|NCT03214016|Other|Pilates|1 hour of Mat Pilates, 2 times a week, during 8 weeks.
1467743|NCT03214003|Radiation|SIB|patients will recieve twice-daily radiotherapy by simultaneous integrated boosting technique concurrent with chemotherapy
1467744|NCT03214003|Radiation|Standard|patients will recieve standard twice-daily radiotherapy concurrent with chemotherapy
1467745|NCT03213990|Other|Continuous infusion|Clinician prescribed beta-lactam antibiotic will be administered via continuous infusion for as long as prescribed whilst in the ICU
1467746|NCT03213990|Other|Intermittent infusion|Clinician prescribed beta-lactam antibiotic will be administered via intermittent infusion for as long as prescribed whilst in the ICU
1467747|NCT03213977|Drug|R-DA-EPOCH|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
1467748|NCT03213977|Drug|R-DA-EPOCH + auto-HSCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
1467749|NCT03213977|Drug|R-CEOP90|R-CEOP90 treatment without auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
1467750|NCT03213977|Drug|R-CEOP90 + auto-HSCT|R-CEOP90 treatment with auto-SCT for DLBCL patients age between 16 to 60 years with intermediate and high risk for IPI.
1467753|NCT03213951|Other|Experimental beta probe|3mCi (or similar) dose of 68Ga-PSMA-11 will be given prior to resection of cancer. Experimental beta probe designed to detect 68Ga-PSMA-11 will be used on prostate tissue after it has been surgically removed.
1948301|NCT02524054|Drug|Furosemide|80 mg of Furosemide in 8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
1948302|NCT02524054|Drug|Aerosolized saline|8ml saline will be aerosolized using ultrasonic screen nebulizers. Aerosol will be delivered using a clinical volume-control ventilator to regulate inspiratory flow and volume.
1467756|NCT03213925|Radiation|Radiation therapy|"Radiation therapy to the breast with or without regional nodal area is performed within 12 weeks after completion of chemotherapy with conventional dose (25x200cGy). Additional boost of 16 Gy in the primary involved tumor region.
Techniques: 3D conformal radiation therapy or intensity modulated radiation therapy (IMRT).
Standard systemic treatment for patients with hormonal positive receptor (hormone therapy for at least 5 years) and HER2 positive (trastuzumab for 1 year)"
1467757|NCT03213886|Drug|Calcifediol (Vitamin D)|"After surgical treatment, participants with vitamin D deficiency (25OHD < 30 ng/mL) will be randomly allocated to an intervention group or control group.
For the intervention group, participants will receive 16. 000 U oral Calcifediol daily for 5 days.
For the control group, participants will receive 16.000 U oral Calcifediol weekly for 5 weeks.
Both groups:
Will follow the usual hip fracture rehabilitation pathway.
25OHD serum levels will be measured after 4 weeks. Depending on the serum 25OHD level, the patients will receive different vitamin D strategies (according to the protocol) Patients will be monitored for up to 12 months after the discharge from the hospital, with 3 clinic visits at 3, 6 and 12 months (to determine serum vitamin D levels and to evaluate functional status)"
1467758|NCT03213873|Behavioral|HiBalance|Intervention of highly challenging balance training for 10 weeks.
1467759|NCT03213873|Behavioral|Speech and communication therapy|Intervention conducted by speech and language therapist for 10 weeks.
1467760|NCT03213860|Other|Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China|The experimental group will receive protective devices Single use eye masks during nocturnal sleep (Flight Eye-masks; Dreaming, Zhuji City, Zhejiang, China). The researcher will explain to them that they should wear eye masks during their stay in ICU to ensure rest and instructed patients to use them properly. During the ICU stay, ICU nurses will assist patients with wearing eye masks from 9:00 pm to 7:00 am the next morning.
1948303|NCT02522650|Drug|Amiloride|5mg twice a day for 8 weeks
1467762|NCT03213834|Procedure|Chest thoracoscopy|Thoracoscopy will be performed as per standard protocols, with patient lateral decubitus position. Ten mLs of fluid will be collected to check for biomarkers. Adhesiolysis will be attempted and pleural irrigation will be done. At the end of the procedure, a drain will be inserted and connected to an underwater seal with a negative pressure suction
1467763|NCT03213834|Procedure|Chest fibrinolytic therapy|A chest tube will be inserted under ultrasonography into the most dependent area of the pleural effusion or into the largest loculation in patients with multi-loculated effusions. A of DNase and tPA will be given. Concurrent tPA and DNase will be administered intrapleurally through the chest tube followed by saline flush. The tube will then be clamped for 120 minutes and after which it will be connected back to wall suction. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
1467764|NCT03213834|Drug|tPA|tPA administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
1467765|NCT03213834|Drug|DNase|DNase administered intrapleurally through the chest tube followed by saline flush. The intrapleural therapy will be given twice daily for a maximum of 6 doses.
1467766|NCT03213821|Other|protein intake|For each participant, weighed food records of 3 consecutive days will be analyzed for estimation of calorie and macronutrient intake and dietary preferences. To make sure good compliance, diets will be developed regarding patient's dietary habits and preferences individually. High calorie (30-35 kcal/kg Ideal body weight) diets including 6-8 small meals will be formulated. Intervention group will receive high protein diet as recommended to preserve muscle mass (1.2-1.5 g/kg IBW). Comparison group will receive protein based on GFR to preserve renal function. For older adults (>65 years) protein content of diet will be as recommended by the international study group to review dietary protein needs with aging (PROT-AGE). In subjects with lower intake of protein, carbohydrate will be substituted. Both group will receive low fat diet.
1467767|NCT03213808|Other|No intervention: analysis of health data from patients with|No intervention: analysis of health data from patients with respiratory allergies (asthma, rhinitis), skin allergies (dermatitis, urticarial, angioedema), anaphylaxis, gastrointestinal allergic conditions and ocular allergies (conjunctivitis) for the validation of the chapter allergies and hypersensitivity in the future version of the WHO CIM
1467768|NCT03213782|Other|Nature based sounds|Nature based sound was administered to the experimental group with head phones for continuously 20minutes. Posttest was done by continuously 30 minute observation after administration of nature based sound with the same tools.
1467769|NCT03213769|Drug|topical coenzyme Q10 gel|Q10 gel will give 2 times /day after breakfast and evening meal for 7 days.
1948304|NCT02522650|Drug|Triamterene|50mg twice a day for 8 weeks
1948305|NCT02519452|Drug|Daratumumab Subcutaneous (SC) Administration|Participants will receive Daratumumab mixed with rHuPH20 in part 1 and co-formulated with rHuPH20 in part 2 administered via SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
1467770|NCT03213769|Drug|Carpabol gel|placebo carbapol gel will give 2 times /day after breakfast and evening meal for 7 days.
1467771|NCT03213756|Device|Isometric exercises using Hand grip and elastic bands|"Isometric exercises using hand-grip. This exercise consists of two sets of 30 hand-grip contractions with the hand of the upper arm candidate for AVF (in case of doubts about the most appropriate arm for AVF the exercise will be performed with both arms). The patient will rest one minute every 10 contractions and 5 minutes between both sets. The patient will repeat this protocol twice a day, morning and night (Approximately 15 minutes each session). The contraction intensity will start with half of the maximum force obtained by dynamometry and will be increased or decreased to be placed on an effort intensity 2-3 in the Borg scale.
Isometric exercise using elastic bands. At noon the patient will perform a slow contraction session using elastic band with 20 slow repetitions with the arm in flexion and 20 repetitions with the arm in extension. (Total duration: less than 10 minutes)"
1467772|NCT03213743|Drug|Dexmedetomidine Injection|Investigators gave the patients loading dose of dexmedetomidine for 10 minutes and maintaining dose of dexmedetomidine for 20 minutes. Investigators took blood samples before and after the administration of dexmedetomidine.
1467773|NCT03213730|Other|3D-MOT Neurotracker|"A predetermined number of spheres (eight) are presented in the 3D-MOT task. The spheres are all identical in shape and color. Before each trial, four spheres are highlighted, and then returned to their original color. Participants will be asked to track those four spheres for the duration of the trial (8 seconds). Spheres will be moving, bouncing, colliding, until they finally stop moving and the participant has to identify the spheres that were initially highlighted. Previous work with healthy individuals has shown that the minimum optimal number of sessions (3 blocks) necessary to induce brain plasticity and enhance other, non-trained brain functions is between 5-6. The training protocol will therefore include 6 sessions (3 blocks each), at intervals of 48 to 72 hours, over a maximum of 3 weeks."
1467774|NCT03213730|Other|Visual Attention Intervention|The visual attention intervention will consist of the 2048 game, a single-player sliding block puzzle game of which the objective is to slide numbered tiles on a grid to combine them to create number 2048. 2048 is played on a gray 4×4 grid, with numbered tiles that slide smoothly when a player moves them using the four arrow keys. Every turn, a new tile will randomly appear in an empty spot on the board with a value of either 2 or 4.Tiles slide as far as possible in the chosen direction until they are stopped by either another tile or the edge of the grid. If two tiles of the same number collide while moving, they will merge into a tile with the total value of the two tiles that collided. Higher-scoring tiles emit a soft glow. Children will play for a time equivalent to that of the 3D-MOT.
1467775|NCT03213717|Other|Heavy Casall HIT weight vest|A weight west with a weight of 10 % compared to the study subject
1467776|NCT03213717|Behavioral|Standing|Study subjects will be standing for at least 50 minutes every hour
1467777|NCT03213717|Dietary Supplement|Water load|Study subjects will drink 5 ml per kg body weight at the start of experiment and continue drinking the same volume as excreted by the kidneys during the experiment
1467778|NCT03213717|Behavioral|Sitting|Study subjects will be sitting for at least 50 minutes of every hour
1467779|NCT03213717|Other|Light Casall HIT weight vest|A weight west with a weight of 1 % compared to the study subject
1948306|NCT02519452|Drug|Recombinant Human Hyaluronidase [rHuPH20]) SC infusion|Participants will receive Recombinant Human Hyaluronidase [rHuPH20]) mixed with Daratumumab in part 1 and co-formulated with Daratumumab in part 2 administered as SC administration once weekly in Cycles 1 (each cycle is 28 days) and 2, every 2 weeks in Cycles 3-6, and every 4 weeks in subsequent cycles.
1948309|NCT02512172|Drug|Oral CC - 486|
1948310|NCT02512172|Drug|Romidepsin|
1948311|NCT02512172|Drug|MK - 3475|
1467793|NCT03213639|Drug|Esomeprazole 40 mg Oral Tablet|once daily oral tablets
1467794|NCT03213639|Drug|Placebo Oral Tablet|once daily oral tablets
1467797|NCT03213613|Behavioral|Adaptive Attention Training|The training is comprised of a time-based titration of rich audiovisual and sparse audio interactive environments. Training progressively transitions the participants from an immersive and rapid reward setting to a less immersive, sensory impoverished, and slower reward setting. Further, the participants' actions require delayed gratification decisions to accomplish play in the sparse setting, building fronto-parietal control through sustained attention and suppression of ventral-striatal reward impulses.
1467798|NCT03213613|Behavioral|Active Control|Participants in the expectancy-matched active control group will play a visuo-spatial iPad game, in which players use their finger to move a ball to different successive square platforms. Expectancy matching to the adaptive attention training was pre-confirmed in 121 participants (18-20 years of age), using targeted surveys on MTurk about their expectations of either training exposure on our specific outcome measures.
1467799|NCT03213600|Device|transcranial Direct Current Stimulation tDCS|75 participants will receive 20 minutes of active tDCS (1,5mA, 20 minutes stimulation over frontal (F3/F4) electrodes ); A group of 75 participants will receive 1,5mA 20 minutes of stimulation over parietal (CP3 CP4) electrodes. During this stimulation session and we will also measure your ability to perceive visual and auditory objects presented by a computer, while recording your brain activity using electroencephalography or EEG (a technique using electrodes that measures the electrical activity of your brain)
1467800|NCT03213587|Drug|Apatinib|500 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
1467801|NCT03213574|Other|Control Group|Intraoperative fluids will be administer per the discretion of anesthesia provider and not per SVV data or study protocol.
1467802|NCT03213574|Other|Treatment Group|FloTrac arterial line data will be used to administer fluid bolus, based on study algorithm.
1467930|NCT03212625|Drug|Urea Cream 20%|Sorafenib 400mg (twice daily), Spread urea cream (urea 20%)
1471099|NCT03188393|Procedure|Biopsy of Breast|Undergo stereotactic biopsy
1467803|NCT03213561|Device|Stable and Independent Brain-computer Interfaces for Communication|"The participants will perform an MRI head scan, which the investigators will use to construct 3D head models of participants. The investigators will use these modele to reconstruct the activity of brain sources from EEG signals. The participants will then take part in a series of EEG recording sessions. During the initial calibration sessions, the participants will react with real or attempted movements to visual cues. The investigators will use the EEG signals from these sessions to calibrate the text-entry interface used in the validation sessions that follow. During the validation sessions, the participants will control the text-entry interface to write messages using their EEG signals."
1467804|NCT03213548|Procedure|Alar facial groove incision|All procedures related to alterations in the alar base will be based on an algorithm proposed by 2010 Adamnson et al lar Soft-Tissue Techniques in Rhinoplasty Algorithmic Approach, Quantifiable Guidelines, and Scar Outcomes From a Single Surgeon Experience ,published at Archives Facial Plastic Surgery in which a sequential approach is used, evaluating step-by-step surgical needs. Initially, the alar base can be reduced by removing tissue from the nasal sill. At this step, modifications at the shape or the width of the nostrils can be done. After that, a rotation-advancement flap is made, and the sill defect is closed. The nasal flair is then assessed and tissue from the alar border can be removed if needed. The incisions not spare the alar facial groove.
1467805|NCT03213548|Procedure|Alar facial groove spared|The technique is the same of the Alar facial groove incision intervention group, but the incisions spare the groove. The incisions will be at 1 mm above the groove.
1467806|NCT03213522|Procedure|Pelvic Floor Physical Therapy|Educating the PFPT group on therapeutic exercise, which includes, but not limited to, the pelvic brace, pelvic floor muscle exercise, and diaphragmatic breathing. If the patient is presenting with hypertonia of lower extremity muscles and/or muscles connecting to or part of the pelvic floor, the patient may be instructed on gentle static stretching and/or treated with passive stretching and diaphragmatic breathing.
1467807|NCT03213522|Procedure|Craniosacral Therapy|Modified Upledger Institute 10-step protocol.
1467808|NCT03213509|Other|Interview (Social and Verbal Autopsy)|Verbal autopsy is a technique used to determine the cause of death by asking caregivers, friends or family members about signs and symptoms exhibited by the deceased in the period before death. This is usually done using a standardized questionnaire that collects details on signs, symptoms, complaints and any medical history or events. The cause of death, or the sequence of causes that led to death, are assigned based on the data collected by this questionnaire and on any other available information. The social autopsy tool is used in conjunction with the verbal autopsy tool to explore the non-biological factors contributing to a death, including the social, behavioural and health systems determinants of maternal and child deaths.
1467809|NCT03213496|Behavioral|Walk prescription|30-40 minutes daily, for five days at the week, all weeks up to surgery.
1467810|NCT03213496|Other|Conventional care|Patient do not walk before surgery
1467811|NCT03213483|Procedure|Coronally advanced flap and subepithelial connective tissue graft|The connective tissue graft is obtained by a single line incision from the palate.
1467812|NCT03213483|Procedure|Coronally advanced flap and deepithelialized free gingival graft|The connective tissue graft is obtained by deepithelialization of a free gingival graft.
1467813|NCT03213470|Other|magnetic resonance imaging|
1467814|NCT03213457|Drug|Elagolix|Tablet
1467815|NCT03213457|Other|Placebo for Elagolix|Tablet
1467816|NCT03213457|Drug|Estradiol/Norethindrone Acetate|Capsules
1467817|NCT03213457|Other|Placebo for E2/NETA|Capsules
1467818|NCT03213444|Drug|adjuvant chemotherapy with 5-FU isolated|Patients submitted to adjuvant chemotherapy with 5-FU isolated
1467819|NCT03213444|Drug|adjuvant chemotherapy with 5-FU associated with oxaliplatin|Patients submitted to adjuvant chemotherapy with 5-FU associated with oxaliplatin
1467820|NCT03213418|Behavioral|Contingency management|Contingency management is an evidence-based psychotherapy program that promotes behavioral change with financial incentives.
1467821|NCT03213405|Biological|rBCG-N-hRSV 1/100|5x10^3 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
1467822|NCT03213405|Biological|rBCG-N-hRSV 1/10|5x10^4 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
1467823|NCT03213405|Biological|rBCG-N-hRSV full dose|5x10^5 colony forming units (CFU) of rBCG-N-hRSV will be administered as an intradermal injection.
1467824|NCT03213405|Biological|Conventional BCG full dose|5x10^5 colony forming units (CFU) of conventional BCG will be administered as an intradermal injection.
1467825|NCT03213392|Drug|Anesthetic Agents|four different anesthetic agents will be used during the surgical clipping or coiling of the aneurysm for the maintenance of anesthesia.
1467826|NCT03213379|Device|Actimetry measures|The patient will wear actigraphy bracelet during a week that will enable to record patients' movements. The report based on the recording will provide an assessment of daytime somnolence and an indication of propensity for impulsive behaviours.The intervention consisted in 2 supplementary actimetry measures and sending of the actimetry reports to the investigator.
1467827|NCT03213366|Behavioral|E-PrEP- Peer-Led Intervention about PrEP|Intervention contents and targets were informed by a systematic review of PrEP barriers and facilitators, a locally conducted qualitative study, and key informant and peer leader inputs. The contents were developed or adapted by study staff and peer leaders. Components and associated text have been designed to engage participants in online discussions about PrEP and related health and social topics. Posts will also include information about linkage-to-care, and insurance access. New contents will be posted almost daily.
1467828|NCT03213366|Behavioral|BxNow - General Health Campaign|BxNow will focus on general health topics unrelated to HIV or sexual health (i.e. fitness, nutrition, smoking), as chosen by PLs. Contents will be developed or adapted by PLs and posted almost daily. Posts will also include information about linkage-to-care and insurance access. At the end of the intervention, BxNow participants will be exposed to E-PrEP components at the end of the trial.
1467829|NCT03213353|Drug|Combination tablet with paracetamol, guaifenesin and phenylephrine hydrochloride|Each subject will receive two tablets, each containing 250 mg paracetamol, 100 mg guaifenesin, and 5 mg phenylephrine hydrochloride
1467830|NCT03213353|Drug|Vicks Active SymptoMax Plus powder for oral solution|Each subject will receive one sachet, containing 500 mg paracetamol, 200 mg guaifenesin, and 10 mg phenylephrine hydrochloride
1467834|NCT03213327|Device|StayOk web application|Patients fill in the questionnaires of the web application and receive an analyzed profile of their psychosocial condition and health-promoting advices
1467835|NCT03213314|Diagnostic Test|Multiparameter magnetic resonance imaging|LiverMultiScan before and after surgery to assess liver health prior to liver resection and in the regenerative phase.
1467836|NCT03213301|Drug|Lurbinectedin|3.2 mg/m2 i.v. every 3 weeks
1467837|NCT03213288|Dietary Supplement|Delphinidin type anthocyanins|Bilberry extract containing Delphinidin type anthocyanins
1467838|NCT03213288|Dietary Supplement|Cyanidin type anthocyanins|Black rice extract containing Cyanidin type anthocyanins
1467839|NCT03213288|Dietary Supplement|Placebo|No anthocyanins
1467841|NCT03213249|Other|Normal saline|Intraoperative pocket irrigation with normal saline
1467842|NCT03213249|Drug|Cefazolin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
1467843|NCT03213249|Procedure|Skin biopsy|Biopsies will be taken from the skin at the time of mastectomy and at the time of implant exchange.
1467844|NCT03213249|Procedure|Bilateral skin- or nipple-sparing mastectomies|Standard of care
1467845|NCT03213249|Device|Tissue expander|Standard of care
1467846|NCT03213249|Device|Breast implant|"Standard of care
Either breast implant or autologous flap"
1467847|NCT03213249|Procedure|Autologous flap|"Standard of care
Either breast implant or autologous flap"
1467848|NCT03213249|Other|Acellular dermal matrix sling|Standard of care
1467849|NCT03213249|Drug|Gentamicin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
1467850|NCT03213249|Drug|Bacitracin|Cefazolin, gentamicin, and bacitracin will be mixed together in 1 L of normal saline and placed in the pocket created by the breast once it is removed
1467851|NCT03213236|Diagnostic Test|Homemonitoring diagnostic system|"In addition to the standard full-night diagnostic polysomnography, patients will be evaluated during the same night with a homemonitoring diagnostic system that consists out of a pulse oximeter, accelerometer, smartphone for audio recording and a mattress that measures the ballistocardiogram."
1467852|NCT03213210|Device|easy-graft CLASSIC (beta-Tricalcium Phosphate)|easy-graft will be grafted to the bone defect supporting a dental implant and covered by polylactide membrane to facilitate regeneration of new bone and healthy attachment to stabilize the dental implant.
1467853|NCT03213197|Other|CPR video|Patient watches a short CPR video
1467854|NCT03213171|Behavioral|Reception staff providing handout.|Reception staff will provide an educational pamphlet to patients that have not yet registered for organ donation
1467855|NCT03213171|Behavioral|Mobile Tablet (e.g. iPad)|Patients will have the opportunity to immediately register for organ donation using an a mobile tablet (e.g. IPad)
1467857|NCT03213145|Drug|intraconazole|Subjects will receive itraconazole once daily from Day 5 through Day18
1467858|NCT03213145|Drug|Rifampin|Subjects will receive rifampin once daily from Day 5 through Day 16
1467859|NCT03213145|Drug|EDP 305|Subjects will receive EDP 305 once daily on Day 1 and Day 14
1467860|NCT03213132|Behavioral|SHUTi (Sleep Health Using the Internet)|Cognitive Behavioral Therapy for insomnia delivered online and metered out over 6 weeks in a fully automated, interactive, tailored web-based program
1467861|NCT03213132|Behavioral|Patient Education|Educational website containing information on insomnia
1467862|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
1467863|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function.
1467864|NCT03213119|Procedure|Non-invasive brain stimulation of the vestibular system through caloric vestibular stimulation.|Caloric vestibular stimulation (CVS) involves the irrigation of cold or warm water into the external ear canal, and induces a temperature gradient across the semicircular canals stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function. The SHAM condition uses body-temperature water, and thus does not result into vestibular unbalance.
1467865|NCT03213106|Device|Transcranial Magnetic Stimulation (TMS)|Low frequency (1Hz) transcranial magnetic stimulation aimed to the dentate nucleus contralateral to the most symptomatic side.
1467866|NCT03213106|Device|Sham Stimulation|The stimulation coil will be placed in the same spot as the TMS stimulation, but coil will not be attached to the TMS machine.
1467867|NCT03213093|Other|Measure of cutaneous microcirculation|Measure of cutaneous microcirculation in response to a local application of pressure, to local heating and to the iontophoretic administration of acetylcholine
1467868|NCT03213080|Device|Targeted Lung Denervation (TLD)|Targeted Lung Denervation (TLD) procedure.
1467869|NCT03213054|Biological|OBP-301|OBP-301 administration on the Day 1, Day 18 and Day 32
1467870|NCT03213054|Radiation|Radiation|Standard radiation therapy for esophageal cancer patient. total 60 Gy for 6 weeks
1467871|NCT03213041|Drug|Carboplatin|Given IV
1467872|NCT03213041|Other|Laboratory Biomarker Analysis|Correlative studies
1467873|NCT03213041|Biological|Pembrolizumab|Given IV
1467874|NCT03213028|Other|WHO Decision-Making Tool for Family Planning Clients and Providers|Contraception decision-making tool
1467931|NCT03212625|Drug|Placebos|Sorafenib 400mg (twice daily), Spread placebo cream (urea 0%)
1472257|NCT03180268|Radiation|Radiation Therapy|Undergo radiation therapy
1467875|NCT03213015|Diagnostic Test|Ankle dorsiflexion measurement|It was used the test with WB, called Lunge Test, in which each evaluator marked a point 15 cm distal to the anterior tuberosity of the tibia (TAT) with a felt tip pen. After that the smartphone (app iHand) will be placed at this point. Between each measurement, the mark was removed with alcohol 70% The demarcated point served as a guide for positioning the smartphone. In order to standardize the smartphone positioning, BHome (home button on the iPhone), was aligned with the TAT pen mark. To ensure the same distance from the foot to the test, the distance of the hallux to the wall was measured (tape measure), recorded and reused for each test.
1467876|NCT03213002|Drug|Capecitabine|Capecitabine at 1500 mg/m2
1467877|NCT03213002|Drug|Temozolomide|Temozolomide at 150 mg/m2 - 200 mg/m2
1467878|NCT03212989|Drug|Vorinostat|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
1467879|NCT03212989|Biological|HXTC|Participants meeting criteria for Step 1 (exhibit ex-vivo response to VOR) will progress to Step 2 where they will receive a single dose of VOR 400 mg followed by a leukapheresis. If an increase in cell-associated HIV RNA (ca-RNA) is observed in-vivo following the single VOR dose, they will be eligible to donate cells for the manufacture of HXTC (Step 3). Successful manufacturing of the HIV-1 antigen expanded specific T cells will progress participants to combination treatment in Steps 4 and 5. In Steps 4 and Step 5, participants will receive two series of VOR dosing and HXTC infusions, for a total 20 doses of VOR 400 mg and 5 HXTC infusions.
1467880|NCT03212976|Procedure|Phase contrast magnetic resonance imaging|Phase-contrast magnetic resonance imaging will be done to assess intracranial pressure
1467881|NCT03212963|Drug|Halobetasol Topical Lotion|Halobetasol Lotion 0.05%, applied twice daily in subjects aged 12 to 16 years 11 months with stable plaque psoriasis.
1467882|NCT03212950|Drug|Fast-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
1467883|NCT03212950|Drug|Regular-CL|After the admission we will insert new insulin (blinded) into the insulin pump. At 13:00 they will have lunch (with manual bolus). At 15:00 we will start CL control, participants/investigators will not be allowed to deliver manual bolus till the end of the study period. All meals and afternoon exercise (in the time between 16:30 and 19:30) will be unannounced and managed with CL.
1467884|NCT03212937|Drug|Selinexor|Oral KPT-330 is administered on Day 3, 5, and 7 of each 21-day cycle. Starting dose is 40mg will be adjusted according to toxicity
1467885|NCT03212937|Drug|ICE Chemotherapy|"IV Ifosfamide 5g/m^2 on Day 2 (inpatient) or D1 (outpatient) of each 21-day cycle
IV Carboplatin AUC 5 on Day 2 (inpatient) or D1-3 (outpatient) of each 21-day cycle
IV Etoposide 100 mg/m^2 on Days 1-3 of each 21-day cycle"
1467886|NCT03212924|Behavioral|Pupillometry|Measure of pupil dilatation simultaneously to the evaluation of speech intelligibility. The variation of the pupil size is monitored during the presentation of speech stimuli in quiet and in the presence of a background noise.
1467887|NCT03212924|Behavioral|Evaluation of speech comprehension in quiet|Three lists of 17 monosyllabic words (Lafon) are presented in quiet at 65 dB SPL. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
1467888|NCT03212924|Behavioral|Evaluation of speech comprehension in noise|Three lists of 17 monosyllabic words (Lafon) are presented in a wide band noise at 65 dB SPL with a SNR (signal to noise ratio) of +10 dB. Listeners have to repeat what they understood. The results correspond to the percent of phonemes correctly identified.
1467889|NCT03212924|Behavioral|MOCA|The Montreal Cognitive Assessment (MoCA) is a screening instrument to detect cognitive dysfunction. It assesses different cognitive domains: attention and concentration, executive functions, memory, language, visuoconstructional skills, conceptual thinking, calculations, and orientation. The time to administer the MoCA is approximately 10 minutes. The total possible score is 30 points. The test suggests the existence of a cognitive impairment if the participant scores less than 26 points. The test is presented on a single sheet of paper.
1467890|NCT03212924|Behavioral|auto evaluation of listening effort in quiet|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in quiet. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
1467891|NCT03212924|Behavioral|auto evaluation of listening effort in noise|The participant has to represent, on a continuous line, the amount of listening effort he used when listening to the monosyllabic words presented in the background noise. A score from 0 (no listening effort) to 10 (effort maximum) is extracted from his response.
1467892|NCT03212911|Biological|Hepatitis B vaccine|Hepatitis B vaccine (20 mcg/ml) 1 ml intramuscular injection in 3 (at 0, 1, 6 months) or 4 doses (0, 1, 2, 6 months)
1467893|NCT03212898|Other|anticoagulation care|Patients in the intervention group will: 1) have a repeated pharmacist-led education on all aspects of warfarin treatment; 2) receive enhanced medication instructions and a care and follow up plan; 3) receive a pill box 4) be refered to the GP with proposal for dose change when outside the therapeutic range or therapy modification to avoid drug interactions with warfarin
1467894|NCT03212885|Device|Deep Brain Stimulation|Electrode that provides electrical stimulation to deep brain structures for relief of Parkinson's Disease symptoms.
1467895|NCT03212872|Diagnostic Test|Endoscopy|
1467924|NCT03212677|Dietary Supplement|Aspiron|Aspiron is a product of the natural fermentation of Koji (Aspergillus oryzae) in the presence of ferrous sulfate. The iron-rich koji biomass is heated, harvested and dried which results in the inactivation of Koji powder that contains 8-10% iron. Koji (A. oryzae) is widely used for making such foods as soy sauce, tempeh, miso, and for producing food-grade α-amylase, and is considered safe by Joint Food and Agriculture Organization of the United Nations (FAO)/WHO Committee on Food Additives and has been accepted as a GRAS constituent of food.
1467925|NCT03212677|Other|Placebo|Cornstarch
1467898|NCT03212846|Other|Hippotherapy|Children will receive the hippotherapy treatment, based on horse walking in a regular way led by an experienced leader. Sessions will be performed for 45 minutes once weekly for 12 consecutive weeks in an indoor riding area.
1467899|NCT03212833|Diagnostic Test|fasting serum insulin|fasting serum insulin in chronic hepatitis C patients
1467900|NCT03212820|Procedure|Drilling at low speed|
1467901|NCT03212820|Procedure|Drilling at conventional or high speed|
1467902|NCT03212807|Drug|Durvalumab|Investigational Medicinal Product
1467903|NCT03212807|Drug|Lenalidomide|Investigational Medicinal Product
1467904|NCT03212794|Behavioral|Recovery coach|The recovery coach will support the subjects in the following areas: 1) monitor and manage symptoms, 2) patient education and self-management, and 3) enlisting community and social supports. Encouragement to continue buprenorphine treatment will be a primary focus of the recovery coach. In addition, the coach will conduct weekly sessions on various topics and offer personal insights and facilitate a discussion.
1467905|NCT03212781|Drug|Iron dextran|total dose infusion
1467906|NCT03212781|Drug|Ferrous Fumarate|oral tablets
1467907|NCT03212768|Procedure|Trans-syndesmotic fixation|antromedial approach for medial malleolus fractures, posterolateral or direct lateral approach for fibula fractures, direct fixation of third malleolus by posterior approach, Trans-syndesmotic fixation ,cement augmentation and Tibiotalocalcaneal fusion
1467908|NCT03212755|Diagnostic Test|serum immunoglobulin G level|measurement of the serum level as a marker of diabetic complications
1467912|NCT03212729|Radiation|ANTIMICROBIAL PHOTODYNAMIC THERAPY|The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.
1467913|NCT03212729|Procedure|Conventional endodontic treatment|After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
1467914|NCT03212716|Drug|Oseltamivir|150 mg twice a day during 10 days (ANSM guidelines for severe flu).
1467915|NCT03212716|Drug|Etilefrine|10 mg x3 per day during 10 days.
1467916|NCT03212716|Drug|Diltiazem|60 mgx3 per day during 10 days.
1467917|NCT03212716|Drug|Placebos|Placebo of diltiazem or placebo of etilefrine
1467918|NCT03212703|Behavioral|Mindfulness-Based Skills Training (MBST)|8-week mindfulness skills training sessions based on Mindfulness-Based Cognitive Therapy (MBCT) program by Zindel Segal, Mark Williams and John Teasdale
1467919|NCT03212703|Other|Waitlist control (WLC)|Observation surveys at baseline, mid-point and end-point of an 8-week period
1467920|NCT03212690|Drug|Local standard of care|Local standard of care will include fluid resuscitation, use of vasopressor drugs and renal support.
1467921|NCT03212690|Procedure|Mechanical ventilation|Mechanical ventilation will be based on volume-assist control mode, with a target tidal volume of 6-8 milliliter per kg (mL/kg) and a target plateau pressure of 30 centimeter of water (cmH2O).
1467922|NCT03212677|Dietary Supplement|Ferrous sulfate|Standard-of-care therapy for iron deficiency anaemia
1467923|NCT03212677|Dietary Supplement|IHAT|IHAT is a nanoparticle composed of three General Regarded As Safe (GRAS) substances, iron hydroxide, tartaric acid and adipic acid. The particle itself resembles the normal metabolite ferritin, which is a larger polyatomic particle. Like ferritin, IHAT can be absorbed by endocytosis, but dissociates within the enterocyte and is subsequently metabolized as ferrous iron.
1467926|NCT03212664|Other|exercise|physical therapy exercises
1467927|NCT03212651|Drug|Pembrolizumab|Pembrolizumab 200mg IV infusion
1467928|NCT03212638|Drug|Baricitinib suspension|Administered orally
1467929|NCT03212638|Drug|Baricitinib tablet|Administered orally
1467932|NCT03212612|Diagnostic Test|samples obtained by laparoscopy or punch biopsy for analysis by ELISA|Endometrial samples(1-2 gram) will be separated from each women during proliferative phase(days 5-15) by laparoscopy or punch biopsy and washed several times with 0.9% sterile saline solution to remove any blood from the tissues. The tissue samples will homogenized by tissue homogenizer at 40,000rpm. The supernatant extracts will be collected in Ependorf tubes and frozen at -80°C till analysis by ELISA
1467933|NCT03212599|Drug|Disulfiram|alcohol addicted patients receive an oral Disulfiram application as recrudescence prevention after successful detoxication
1467936|NCT03212573|Combination Product|ERAS protocol|ERAS protocol includes early oral intake and deambulation and multimodal analgesia
1467937|NCT03212573|Combination Product|Standard care|Oral intake and deambulation 24h after surgery and only intravenous analgesia.
1467938|NCT03212547|Behavioral|Verbal Intervention|"Promotion of verbal interventions:
Detecting whether the infant has social withdrawal.
The physician will verbally intervene.
Positive response (+) from the infant, the evaluator will point out this to the parents.
Negative response (-) from the infant, the evaluator will include the parents in the interaction.
If he infant establishes positive contact (+) with the parents, he/she will point out this response to them.
If the infant does not establish positive contact (-)with the parents, repeat step 2.
If the infant offers a positive response (+) to the second attempt of verbal intervention, the evaluator will point out this response to the parents.
At the end of each medical check-up, give and explain the ADBB Intervention Sheet."
1467939|NCT03212534|Other|Patient mortality prediction|Healthcare provider is notified of patient mortality prediction.
1467940|NCT03212521|Drug|glecaprevir/pibrentasvir|Tablet; ABT-493 coformulated with ABT-530
1467941|NCT03212508|Device|RAM cannula and Hudson prongs|Measuring intraoral pressure using two different nasal interface for applying nasal continuous positive airway pressure
1467942|NCT03212495|Drug|dexamedetomidine|intraarticular injection of 1µg/kg dexametomidine +18ml 0.25%bubivacaine in a total volume of 20 ml.
1467943|NCT03212495|Drug|neostigmine|intraarticular injection of 0.5mg/dose neostigmine +18ml 0.25%bubivacaine in a total volume of 20 ml.
1467944|NCT03212469|Drug|Durvalumab|"Preliminary steps : Safety Runs Safety run of the dual combination Durvalumab as single agent at the selected dose of 1500mg, every 4 weeks (Q4W) from C1D1 up to 13 doses
Safety run of the triple combination:
Durvalumab at 1500mg every 4 weeks (Q4W) from C1D1 up to 13 doses,
Efficacy step
Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with
SBRT at C1D15, then
Durvalumab Q4W alone for up to 9 additional doses"
1467945|NCT03212469|Drug|Tremelimumab|"Preliminary steps : Safety Runs
Safety run of the triple combination:
Tremelimumab at 75mg/Q4W for up to 4 doses
Efficacy step
Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with
SBRT at C1D15, then
Durvalumab Q4W alone for up to 9 additional doses"
1467946|NCT03212469|Radiation|SBRT|"Preliminary steps : Safety Runs
Safety run of the dual combination:
SBRT at C1D15.
Safety run of the triple combination:
SBRT at C1D15.
Efficacy step
Durvalumab Q4W + Tremelimumab Q4W for up to 4 doses at the DL defined in safety runs, in conjunction with
SBRT at C1D15, then
Durvalumab Q4W alone for up to 9 additional doses"
1467947|NCT03212456|Drug|opioid-free group|We'll study if the opioid-free anesthesia can reduce the biochemical recurrence of prostate cancer.
1467948|NCT03212456|Drug|Opioid Group|This group will receive fentanyl in the induction of anesthesia.
1467949|NCT03212456|Procedure|transversus abdominal plane block with ropivacaine|The opioid-free group will receive transversus abdominal plane block with ropivacaine 0,375% 20 ml each side
1467950|NCT03212456|Procedure|transversus abdominal plane block with placebo|the non-opioid free group will receive transversus abdominal plane block with physiological solution 0,9% 20 ml each side
1467951|NCT03212443|Procedure|Suprascapular nerve- axillary nerve block combination|In Group B, suprascapular (10 ml of 0.250% bupivacaine ) and axillary block (10 ml of 0.250% bupivacaine) will be performed with ultrasound and nerve stimulator guidance before induction of anesthesia
1467952|NCT03212443|Procedure|Subacromial infiltration|In group A, the surgeon will apply 20 ml of 0.250% bupivacaine to the subacromial region at the end of the procedure
1467953|NCT03212430|Drug|L-kynurenine|intravenous infusion of L-kynurenine to healthy individuals.
1467954|NCT03212417|Other|Educational intervention|Presentation of risk factors, signs and symptoms, and interventions on compassion fatigue
1467955|NCT03212404|Drug|CK-301|CK-301 will be administered in periods of 28-day cycles.
1467956|NCT03212391|Behavioral|Diet|52 weeks of Diet supervised by a dietician
1467957|NCT03212391|Behavioral|Walking|26 weeks supervised Walking 3 times per week, followed by 26 weeks of unsupervised Walking
1467958|NCT03212391|Behavioral|Nordic Walking|26 weeks supervised Nordic Walking 3 times per week, followed by 26 weeks of unsupervised Nordic Walking
1467959|NCT03212378|Other|percutaneous coronary interventions|Percutaneous coronary intervention.
1467960|NCT03212365|Drug|Enoxaparin|Participants will receive 40 mg enoxaparin twice daily
1467961|NCT03212365|Drug|Enoxaparin|Participants will receive 0.5mg/kg enoxaparin twice daily
1467962|NCT03212352|Drug|Mifepristone|Adding 600 mg of Mifepristone to the regular treatment with Misoprostol 800 mcg.
1467963|NCT03212352|Drug|Misoprostol|Regular treatment with Misoprostol 800 mcg.
1467964|NCT03212339|Other|Therapeutic intervention|Therapeutic interventions will be delivered in ten 2-hour sessions over 12-15 weeks, which includes 2 research data collection sessions at the beginning of the study (pre-intervention) and at the end of the study (post-intervention). During the pre-intervention data collection session, participants will be asked to provide demographic information and complete interviews about their past experiences and current experiences as a parent, and their child's current functioning. Parents will also be video recorded interacting with their child for 10 minutes. During the post-intervention data collection session, participants will be asked to complete a similar set of interviews and will also be video recorded interacting with their child for 10 minutes.
1467967|NCT03212300|Behavioral|High Intensity Interval Training|patients will engage in 4 training sessions/week over a 4-week period, with 24-hour rest-periods after each training day. Each session begins with a 3 min, low intensity warm-up on a stationary cycle, then patients cycle as rapidly as they can for 20 sec, aiming to reach 85% of their maximum heart rate (HR) as established during cardiorespiratory fitness testing. This 20 sec period is followed by 40 sec of low intensity cycling. Patients complete 8 such intervals for sessions 1 and 2, 10 intervals for sessions 3 and 4, and 12 intervals thereafter.
1467968|NCT03212274|Other|Laboratory Biomarker Analysis|Correlative studies
1467969|NCT03212274|Drug|Olaparib|Given PO
1467970|NCT03212261|Behavioral|3RP-Lymphoma|An adapted version of the Relaxation Response Resiliency Program (3RP) for individuals who have recently completed treatment for lymphoma.
1467971|NCT03212248|Diagnostic Test|Thoracic Ultrasound (TUS)|
1467972|NCT03212235|Radiation|Hypofractionated radiation therapy|Hypofractionated radiation therapy Total dose: 60 Gy (20 fractions / 3 Gy per fraction)
1467973|NCT03212222|Other|Peek Acuity|Cell phone application for visual acuity screening
1467974|NCT03212222|Other|Standard Visual Screening|Visual screening exam conducted in Duke University Eye Center
1467975|NCT03212209|Device|CPAP Fixed Pressure|Continuous positive airway pressure (CPAP) is the gold standard treatment for moderate and severe OSA, and it has been known to apply positive pressure in the upper airways, acting as a pneumatic splint preventing the upper airway collapse during sleep. CPAP C- Flex Plus by Philips - Respironics works just as CPAP Fixed Pressure, but increases the pressure delivered in the begining of inhalation to softens the breathing rhythm of the CPAP user. CPAP with SensAwake by Fisher and Paykel works just as CPAP fixed pressure but when the breathing pattern suggests that patient is awake, a prompt relief in pressure to the lowest most comfortable level is activated, like ramp feature.
1467976|NCT03212196|Procedure|Pancreaticogastrostomy with external drain|"Pancreatico-enteric anastomosis is provided according to the Bassi technique, pancreatic remnant is pushed into the gastric cavity through a posterior gastrotomy. An externalized drain is placed into the main pancreatic duct."
1467977|NCT03212196|Procedure|Pancreaticojejunostomy with transanastomotic drain|Pancreatico-enteric anastomosis is provided through a double-layer, duct-to-mucosa anastomosis with a transanastomotic externalized drain.
1467978|NCT03212183|Behavioral|EPI-TAVIE|ÉPI-TAVIE is a web-based intervention focusing on epilepsy self-management. This interactive session (25 minutes) is facilitated by a virtual nurse.
1467979|NCT03212183|Other|Websites|The conventional websites offers reliable information about epilepsy. Their content were validated by experts.
1467980|NCT03212170|Drug|[18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging|18F-Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging tracer
1467981|NCT03212157|Other|Glucose infusion|Infusion of 20% dextrose (drug) and using this as an imaging tracer in detecting and staging tumours.
1467982|NCT03212157|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI scanners (device) use strong magnetic fields, radio waves, and field gradients to generate images of the organs in the body. Specifically using the MRI scanner with the infusion of dextrose in detecting and staging tumours.
1467983|NCT03212157|Diagnostic Test|FDG PET|FDG is a sugar (glucose) labelled with a small amount of radioactivity which goes to parts of the body that use glucose for energy. PET/CT images are acquired on a single scanner. An FDG PET scan can be used to assess the presence, location and severity of cancers.
1467984|NCT03212144|Other|High Intensity Interval Training|Subjects will exercise according the the high intensity aerobic interval training regiment four times a week for four weeks
1467985|NCT03212144|Other|Peanut Consumption|Subjects will consume peanuts twice a day to replace 20% of their daily caloric intake for four weeks.
1467986|NCT03212131|Drug|Somapacitan|3 once-weekly subcutaneous administrations (s.c., under the skin) of somapacitan with a dose of 0.08 mg/kg
1467987|NCT03212118|Behavioral|Treatment as usual (TAU-0)|"The standard NAV procedure, which consists of a telephone call within 8 weeks to an employer who have employees on 100% sick leave, in addition to regular NAV conversations on-demand (not fixed intervals) between the NAV caseworkers and the employees."
1467988|NCT03212118|Behavioral|Structured talks (TAU-2)|Two structured talks (not including elements from motivational interviewing)
1467989|NCT03212118|Behavioral|motivational interviewing (MI)|Two structured talks (must have a valid motivational interviewing content).
1467990|NCT03212105|Behavioral|60 Second Video|The mindfulness intervention will be a video-flash found at http://www.pixelthoughts.co. In this exercise patients are asked to write down a concern or worry, and watch it get put into perspective within a 60 seconds time frame.
1467991|NCT03212105|Behavioral|Educational Brochure|The educational pamphlet will contain information about pain and stress, which patients will be able to read within 60 seconds.
1467992|NCT03212092|Dietary Supplement|Multivitamin, mineral & n-3 FA|The 2 multi vitamin capsules with the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
1467993|NCT03212092|Dietary Supplement|Placebo|The placebo of the multi vitamin capsules and the two multi vitamin softgel capsules will be handed out once a day during a meal by the staff of the care organization. The compliance will be registered
1467994|NCT03212079|Behavioral|Mycoach Smart Text|Personalized text messages to you cellphone to help you become more active
1467995|NCT03212079|Behavioral|MyCoach on Amazon Alexa|This is an intelligent voice that you can communicate with via Amazon echo speaker
1467996|NCT03212066|Behavioral|Master Mind|Master Mind is a 25-lesson elementary school mindfulness education substance abuse prevention program. Each lesson takes approximately 15 minutes and is designed to be taught by trained teachers every day for 5 weeks.
1467997|NCT03212053|Biological|biological tests of haemostasis at each consultation (Multiplate, ROTEM, VASP)|Patients will have blood samples at each consultation (2 or 3 sampling tubes) in order to carry out systematically three biological tests
1565523|NCT02487381|Drug|Placebo|
1467998|NCT03212040|Diagnostic Test|needle biopsy|breast biopsy using different needle gauges
1467999|NCT03212014|Other|LSVT-BIG|LSVT BIG can be delivered by a physical or occupational therapist. Treatment is administered in 16 sessions over a single month (four individual 60 minute sessions per week). This protocol was developed specifically to address the unique movement impairments for people with Parkinson disease. The protocol is both intensive and complex, with many repetitions of core movements that are used in daily living. This type of practice is necessary to optimize learning and carryover of your better movement into everyday life!
1468000|NCT03212014|Other|POWER|Power Rehabilitation(PR), a new resistance training regime, can improve in power and independence level of the elderly people. The first word of PR was in brief of Produce Outcome Worthwhile for the Elderly Rehabilitation (POWER)
1468001|NCT03212014|Other|Traditional rehabilitation|traditional exercise models in currently clinical use
1468002|NCT03211988|Drug|Entinostat|Dose is 5 mg orally every week (days 1, 8, 15, and 22) of a 28 day treatment cycle. Study drug should be taken in the morning and on an empty stomach, at least 2 hours after a meal and at least 1 hour before the next meal. Tablets should be taken whole and not crushed.
1468003|NCT03211975|Other|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses|To study the evolution of the prognosis of infectious endocarditis on native valves and on prostheses
1468004|NCT03211962|Other|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest|Analysis of urinary levels of TIMP2 and IGFBP7 within 6 hours after cardiac circulatory arrest
1468005|NCT03211949|Procedure|axillary block|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
1468006|NCT03211949|Drug|Scandicaine|2 ml of scandicaine 1.5 % is deposited in an inplane technique around the medial antebrachial cutaneous nerve with a 22 G sonoplex needle as a surplus to an axillary block
1468007|NCT03211936|Procedure|PEEP TITRATED|After titrated peep levels, we choice this level of peep for de group (peep titrated)
1468008|NCT03211936|Device|Use ultrasound|We make a lung ultrasound after we setup a different level of PEEP
1468009|NCT03211936|Device|Impedance tomography|We use the impedance tomography to titrate peep levels, and acquire dates of collapse, hyperdistension and compliance.
1468010|NCT03211936|Other|Best PEEP for less collapse|After titrated PEEP levels we setup the best PEEP the according of tomography impedance
1468011|NCT03211936|Other|PEEP 4|We set the peep level after titrated peep = 4 cmH20.
1468012|NCT03211923|Diagnostic Test|Transcranial magnetic stimulation (TMS)|Single pulse, monophasic transcranial magnetic stimulation
1468013|NCT03211910|Device|SacralSaver|Sacral Savers is a combination of a strong bubble wrap sheet with a fold at the head end and a nylon sham with a pocket into which the bubble wrap sheet is inserted. This combination is then placed under the fitted sheet on the patient's mid back and the pressure exerted by the lower back of the patient is markedly reduced or nearly eliminated (tested and proven using computer models), thereby preventing the onset of pressure ulcers in the sacro-coccygeal area.
1468014|NCT03211910|Other|Standard Care of Treatment|Standard Care of Treatment
1468015|NCT03211897|Drug|Haloperidol Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive haloperidol as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
1468016|NCT03211897|Drug|Ziprasidone Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive ziprasidone as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
1468017|NCT03211897|Drug|OLANZapine Injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive olanzapine as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
1468018|NCT03211897|Drug|Midazolam injection|As part of the quality initiative protocol, patients who are treated for acute agitation in the ED will receive midazolam as their initial sedative agent during the 21 day block. All subsequent agitation medications are at the discretion of the provider.
1468019|NCT03211884|Other|Problem-solving therapy|"PST consists of nine, 60-90 minute educational sessions conducted face-to-face via the Internet (through video conferencing software) approximately 2 weeks apart. After attending a preliminary 15 minute meet & greet session, participants will receive written and verbal education about solving everyday problems. Together, the participant and interventionist complete the 7 steps to solve at least one problem together before ending the training. Participants will keep a record of their problem-solving efforts between sessions and questions they have related to the application of PST. These records will be used as a basis for discussion during the intervention."
1468020|NCT03211871|Drug|Dexmedetomidine|Intraoperative intravenous dexmedetomidine infusion 0,5 mcg/kg/h
1468021|NCT03211871|Drug|Normal Saline Flush, 0.9% Injectable Solution_#1|Intraoperative intravenous normal saline infusion
1948312|NCT02509598|Drug|Tc99m tilmanocept|A single dose of 0.5 mCi and 50 ug of Tc99m tilmanocept administered intradermally, peritumorally approximately 1-2 hours before surgery
1948313|NCT02509598|Drug|Vital Blue Dye|A single dose 1-3 ml of vital blue dye (1%) administered intradermally at the start of or during surgery
1468025|NCT03211845|Other|Nutritional telemonitoring|Participants receive a weighing scale, pedometer and television channel in order to perform self-measurements and receive guidance on nutrition and physical activity. Nurses use a website in order to receive telemonitoring measurements and decide about proper follow-up. In case of risk of undernutrition, nurses provide personal advice to optimize nutritional status of the participant.
1468026|NCT03211832|Other|Dissemination of public health knowledge|Participating local health departments will help develop and choose dissemination strategies they prefer for their staff working in and supporting diabetes and chronic disease prevention and control to receive. Dissemination strategies may include multi-day in-person training workshops, electronic information exchange modalities, remote technical assistance, and information on ways to enhance organizational climates favorable to evidence-based diabetes prevention and control.
1468110|NCT03211052|Drug|TAK-700 and LHRH agonist|TAK-700 for 6 months 300mg BD with Leuprorelin Acetate Injections prior to planned prostatectomy
1472745|NCT03176303|Device|SpinalStim|PEMF osteogenesis stimulator
1468027|NCT03211819|Procedure|immediate implant placement|"A prophylactic antibiotic(Flumox 500mg, Egyptian Int. Pharmaceutical Industries Co.,A.R.E.) would be given to the patient 3 days prior to the surgery. Then on the day of surgery, (AK) will extract the remaining root or tooth in an atraumatic procedure using lancet, periotome (Nordent Manufacturing Inc. U.S.A), minimal force and rotational movement.
After extraction the socket will be examined for intact labial and palatal bone using depth probe. If all walls are intact the socket would be eligible for immediate implant placement."
1468028|NCT03211806|Behavioral|Sedentary Behavior|Messages delivered via smartphone prompting patients to walk after prolonged sedentary behavior bouts are detected via Bluetooth-enabled activity monitor
1468029|NCT03211806|Device|Bluetooth-enabled activity monitor|Monitoring activity using a Bluetooth-enabled activity monitor
1468032|NCT03211780|Device|General Electric LOGIQ E9 ultrasound system|Patients will be brought to the operating room in line with standard clinical practice and after esophageal exposure, but before surgical mobilization of the esophagus, shear wave vibrometry and B-mode imaging will be performed after esophageal distension with a fluid filled balloon intra-operatively.
1468035|NCT03211754|Dietary Supplement|walnuts and almonds|The subjects consumed 15g of walnuts and 15g of almonds/day for 8 weeks
1468036|NCT03211741|Drug|Bevacizumab Injection [Avastin]|Bevacizumab 1.25mg/0.05 mL will be injected intravitreally using one 30-gauge x 1/2-inch injection needle vials are for single eye use only.
1468039|NCT03211715|Other|questionnaire|Rectal cancer patients who received sphincter saving surgery will be asked to fill up questionnaire related to bowel dysfunction
1468040|NCT03211689|Other|Exercise Program|Participants will utilize the Physitrack exercise program to engage in up to 150 minutes of exercise at a rating of 11-14 on the Borg Rate of Perceived Exertion scale, per week.
1468041|NCT03211676|Device|Theranova-500 dialyzer|hemodialysis with Theranova-500 dialyzer.
1468042|NCT03211676|Device|Elisio-21H|hemodialysis with Elisio-21H dialyzer
1468044|NCT03211650|Drug|hyaluronic Acid + platelet-rich plasma|Intra-articular injections of hyaluronic acid combined with platelet-rich plasma
1468045|NCT03211650|Drug|hyaluronic acid|Intra-articular injections of hyaluronic acid
1468046|NCT03211650|Drug|platelet-rich plasma|Intra-articular injections of platelet-rich plasma
1468047|NCT03211637|Combination Product|Wounds Protocol|Nurses who have been trained to use wound dressing supplies and also on the use of the protocol.
1468048|NCT03211611|Behavioral|Questionnaire given to the two groups|"Questionnaire given to the two groups :
Patients with BRCA ½ mutation GP"
1468049|NCT03211598|Procedure|TACE with Surefire|Subjects that consent to the study will receive their TACE procedure through the Surefire Infusion System
1468050|NCT03211585|Device|Perfecta V-Beam laser|This s a single study and a prototype of the FDA-cleared, flashlamp-pumped pulsed-dye laser, that is currently on the market, that has evolved over almost 25 years of continuous development. The broad-spectrum flashlamp pumps energy into a cavity containing liquid dye. The dye is excited resulting in the emission of 595 nm orange light.
1468051|NCT03211572|Drug|Tamoxifen|Participants will take endocrine therapy for 2 weeks prior to surgery.
1468052|NCT03211559|Other|Exercise|
1468053|NCT03211546|Procedure|Conservative (non-surgical) treatment|Spica cast Traction Traction and spica cast
1468054|NCT03211546|Procedure|Surgical treatment|Elastic Stable Intramedullary Nailing (ESIN) Conventional locking intramedullary nail Plating External fixation
1468055|NCT03211507|Other|Computer-assisted telephone interview|Occupational history
1468056|NCT03211507|Genetic|Genetic analysis|To include analysis of known susceptibility markers
1468057|NCT03211494|Device|INTELLiVENT-ASV|INTELLiVENT-ASV, with software 2.60
1468058|NCT03211494|Other|Conventional lung protective ventilation|Lung protective ventilation according to the ARDSnet guidelines
1468059|NCT03211468|Behavioral|Clinical intervention program to prevent eating disorders|See previous
1468060|NCT03211455|Drug|Lidocaine|intravenous lidocaine versus placebo
1468061|NCT03211455|Drug|isotonic saline|intravenous isotonic saline
1468062|NCT03211442|Radiation|Radiotherapy|Breast cancer patients treated with radiotherapy
1468063|NCT03211429|Behavioral|Cognitive behavioural therapy|The program aims to teach participants how to deal with their concerns about falls and related avoidance of activity
1468064|NCT03211429|Other|Tai chi|Tai Chi training in the Yang style of 24 movement
1468065|NCT03211429|Other|Postural control exercise|Individually adjusted progressive and specific postural control training,
1468066|NCT03211416|Other|Laboratory Biomarker Analysis|Correlative studies
1468067|NCT03211416|Biological|Pembrolizumab|Given IV
1468068|NCT03211416|Drug|Sorafenib Tosylate|Given PO
1468111|NCT03211052|Procedure|prostatectomy|SURGICAL REMOVAL OF THE PROSTATE
1468072|NCT03211364|Other|Glenohumeral mobilization|Comparing the effect of angular mobilization in frontal or scapular plane and of providing soft tissue techniques on hemiplegic shoulder range of motion and pain.
1468073|NCT03211364|Other|Scapular mobilization|
1468076|NCT03211338|Biological|Culture with progesterone|Progesterone, a steroid hormone will be cultured with placental IMC cells or peripheral blood CD14+ monocyte cells
1468077|NCT03211338|Biological|Culture without progesterone|Culture of placental IMC cells or peripheral blood CD14+ monocyte cells without progesterone
1468078|NCT03211338|Biological|Culture with growth factors|Culture of placental IMC cells with growth hormones only and analysis
1468079|NCT03211325|Procedure|Biopsy|
1468080|NCT03211286|Drug|Tranexamic Acid|1 g of intravenous tranexamic acid in 100 mL of saline solution
1468081|NCT03211286|Drug|Saline Solution|saline solution 100 mL intravenous
1468082|NCT03211260|Device|EQUISTASI|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive four patches to be placed on both legs for 4 weeks.
1468083|NCT03211247|Biological|Viaskin Peanut 250 mcg|Viaskin Peanut 250 mcg, once daily
1468084|NCT03211247|Biological|Viaskin Peanut 100 mcg|Viaskin Peanut 100 mcg, once daily
1468085|NCT03211247|Biological|Placebo|Placebo patch, once daily
1468086|NCT03211234|Drug|DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of low dose DE-122 in the study eye, in combination with Lucentis.
1468087|NCT03211234|Drug|DE-122 Injectable Solution + Lucentis|Subjects will receive 6 monthly intravitreal injections of high dose DE-122 in the study eye, in combination with Lucentis.
1468088|NCT03211234|Drug|Lucentis|Subjects will receive 6 monthly intravitreal injections of Sham in the study eye, in combination with Lucentis.
1468089|NCT03211221|Device|rTMS (repetitive transcranial magnetic stimulation)|rTMS is a non-invasive neuromodulation technique that is able to modulate cortical and subcortical function with the use of rapidly changing electromagnetic fields generated by a coil placed over the scalp (George and Post, 2011). Depending on the parameters of stimulation, rTMS can either decrease or increase cortical excitability in relatively focal areas, with frequencies < or = 1 Hz (low frequency rTMS or LF-rTMS) being usually inhibitory and higher frequencies (> or = 5 Hz; high frequency rTMS or HF-rTMS) being usually excitatory (Rosa and Lisanby, 2012). Moreover, rTMS has proven to have long-lasting effects on brain neuroplasticity through different mechanisms (e.g. by inducing long-term potentiation, increasing several neurotrophic factors etc.) (Chervyakov et al., 2015).
1468090|NCT03211195|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet
Route of administration: oral"
1468091|NCT03211182|Behavioral|lifestyle modification intervention|healthy lifestyle education and individualized counseling by well-trained case manager. The main goals of the lifestyle intervention included regular moderate intensity physical activity 150 min per week or more, and dietary strategies which reduce the risk of developing diabetes. The dietary suggestion was modified by Dietary Approaches to Stop Hypertension (DASH) Diet. Participants with BMI>= 24 kg/m2 were encouraged to gradually lose weight at a rate of 0.5-1.0 kg per week until they achieved a BMI of 24 kg/m2.
1468092|NCT03211169|Procedure|Biopsies of bile duct stricture with pediatric biopsy forceps|Biopsies of the stricture will be taken to evaluate diagnostic yield of Pediatric Biopsy Forceps
1468093|NCT03211169|Procedure|Biopsies of bile duct stricture with cholangioscopy-directed biopsies|Biopsies of the stricture will be taken to evaluate diagnostic yield of cholangioscopy-directed biopsies
1468096|NCT03211143|Drug|CKD-381|Test drug: CKD-381
1468097|NCT03211143|Drug|Nexium|Reference drug: Nexium
1468098|NCT03211130|Behavioral|SystemCHANGE™|During the intervention phase, the PI will visit both groups of participants at home at baseline and telephone them three times (day 3 ±2 days and months 1 and 2). Refer to tables 1 and 2 for intervention details. Treatment participants will implement SystemCHANGE™ activities related to medication taking with the assistance of the PI while attention-control participants will receive patient education materials on stroke. Perceived health data will be collected during the intervention phase. A 1-month maintenance phase follows the intervention phase. Electronic medication monitoring continues, but no intervention is delivered to either group.
1468099|NCT03211130|Behavioral|Attention-Control|An experienced stroke nurse will deliver the attention control intervention. Table 3.2 shows the 2-month attention-control intervention. The stroke materials were developed by the Saint Luke's Marion Bloch Neuroscience Institute and are given to every stroke patient prior to dismissal. The PI will call participants at day 3 ±2 days, and months 1 and 2 to review chapter(s) from the book and answer questions about it. Interval, frequency, and setting are all exactly the same for the intervention and control groups. If the control participant raises questions about medications or medication-taking, PI will refer them to their Neurologist.
1468100|NCT03211117|Drug|Docetaxel|Given IV
1468101|NCT03211117|Drug|Doxorubicin Hydrochloride|Given IV
1468102|NCT03211117|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1468103|NCT03211117|Other|Laboratory Biomarker Analysis|Correlative studies
1468104|NCT03211117|Biological|Pembrolizumab|Given IV
1468105|NCT03211117|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1468106|NCT03211104|Dietary Supplement|curcumin|
1468107|NCT03211104|Dietary Supplement|Placebo|
1468108|NCT03211078|Procedure|super-D ENB guided-PDT|PDT with super-D EBN localization will be given for treating the target lung lesion. Intrvenous photofrin (2mg/kg) will be given 48 hours before intervention. After localization of the tumor by ENB, a 630nm of light will be give for the lesion with the dosage of 2oo J/cm. Intravenous general anesthesia and endobronchial intubation will be performed under the whole procedure.
1468109|NCT03211065|Drug|20% subcutaneous immunoglobulin|Subcutaneous Immunoglobulin
1468112|NCT03211039|Genetic|Genomic sequencing and molecular diagnostic results, if any.|Patients and their families will be randomized to either receive whole genome sequencing or whole exome sequencing.
1468113|NCT03211026|Other|No intervention|No intervention
1468114|NCT03211013|Drug|Oxytocin|single-dose administration of OT nasal spray, complete computer-based tasks post-dose for approximately 1 hour
1468115|NCT03211013|Drug|Placebos|single-dose administration of placebo nasal spray, complete computer-based tasks post-dose for approximately 1 hour
1468116|NCT03210987|Procedure|patient case presentation bedside|Patient case presentation in absence or presence of Patient at bedside.
1468117|NCT03210987|Procedure|patient case presentation Outside-the-room|Patient case presentation Outside-the-room.
1468118|NCT03210961|Drug|PF-06826647 tablet|PF-06826647 tablet for oral administration
1468119|NCT03210961|Drug|PF-06826647 oral suspension|PF-06826647 suspension for oral administration (oral suspension to be administered to the 3mg starting dose cohort only)
1468120|NCT03210961|Other|Placebo oral solution/suspension|placebo oral solution for the single ascending dose, first cohort only
1468121|NCT03210961|Other|Placebo tablet|Matching placebo tablet
1468122|NCT03210948|Device|RTE-guided EUS-FNA|Fine needle aspiration with 25 gauge needle under RTE-guidance
1468123|NCT03210948|Device|Conventional EUS-FNA|Fine needle aspiration with no RTE guidance
1468124|NCT03210922|Device|Miami cervical collar|Collar group is put on the Miami cervical collar.
1468125|NCT03210909|Drug|BMS-986231|BMS-986231
1468126|NCT03210896|Dietary Supplement|Orange juice|Sub group I will drink Orange juice and have repeat measures.
1468127|NCT03210870|Behavioral|nutritional education classes|The objective to be accomplished through the completion of a nutritional education program for pregnant women that incorporates the biopsychosocial principles of the Satter Eating Competence Model. Emphasizing healthy food choices and improve eating competency.
1468128|NCT03210857|Other|apnea performing|"The included subjects will make an apnea of two minutes or more, sitting on a chair with cold strips on the face, initially with the head in neutral position. Then, when they feel the end of their apnea, they will have to raise their left hand to signal it to the Doppler manipulator, who will then realize the apnea reference measurement.
As soon as this is done, the subjects will be asked to perform an extension of the neck, so as to look at the ceiling. A final measurement will then be made in apnea, the head always in extension. Subjects then resume their breathing in this same position. A final measurement will then be made."
1468129|NCT03210844|Procedure|Surgical approaches of total hip arthroplasty|Surgical approaches of total hip arthroplasty
1468130|NCT03210818|Device|Extra-corporeal membrane oxygenation life support|Adjustment of blood flow of extra-corporeal membrane oxygenation life support
1468131|NCT03210805|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acids Supplementation|28 days of a commercially available supplement. 4 capsules per day.
1468132|NCT03210792|Device|Application of Rib Splint|Investigators randomly apply handmade Rib Splint or manufactured Rib Splint to subjects.
1468133|NCT03210779|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 16 days and topical application of active oil once daily for 8 days
1468134|NCT03210779|Dietary Supplement|Placebo|Ingestion of inactive lozenge twice daily for 16 days application of inactive oil once daily for 8 days
1468135|NCT03210766|Drug|Nabilone|
1468136|NCT03210766|Drug|THC/CBD|
1468137|NCT03210740|Drug|AM001 Cream, 7.5%|Active Cream
1468138|NCT03210740|Drug|Vehicle Cream|Placeo
1468139|NCT03210727|Behavioral|Ready to CARE program|"The intervention is built upon a model of caregiver well-being that identifies four domains of quality of life: physical, psychological, social, and spiritual well-being. For each domain, there are stressors (i.e., factors that make it hard to be a caregiver) and buffers (i.e., factors that help people be effective caregivers). Our Ready to CARE intervention begins by presenting caregivers with the model in order to generate a profile of personal stressors and buffers. From there, caregivers select from a menu of strategies that can be used to minimize stressors and create buffers in their daily life. The investigators will have six 45-minute sessions with the caregivers that will primarily occur while the patient is admitted for stem cell reinfusion."
1468140|NCT03210714|Drug|Erdafitinib|Given erdafitinib PO
1468141|NCT03210714|Other|Laboratory Biomarker Analysis|Correlative studies
1468142|NCT03210714|Other|Pharmacological Study|Correlative studies
1468143|NCT03210701|Other|A HIV POCT program adapted for & provided by community pharmacists|Using a Type II hybrid Implementation-Effectiveness study design investigators will assess the implementation and effectiveness of a multi-faceted, integrated, contextualized model of HIV POCT in pharmacies in urban and rural settings in NL and AB, Canada. This design will be flexible, responsive and capable of capturing changing elements at multiple points in time. A mixed methods approach will be used to assess Implementation and Effectiveness aims.
1468144|NCT03210688|Drug|Prednisolone|Tablet prednisolone
1468145|NCT03210688|Drug|Alfacalcidol|Capsule alfacalcidol 0,5 microgram/day
1468146|NCT03210675|Diagnostic Test|Polysomnography (PSG)|PSG will be perfomed every 6 months in the Study group from the age of 6 months to 3 years
1468149|NCT03210649|Drug|CKD-519|Part 1 : CKD-519(100mg x 4 Tablets) for D1 Part 2 : CKD-519(100mg x 4 Tablets) for D1~D14
1468150|NCT03210649|Drug|Placebo|Part 1 : CKD-519 placebo(100mg x 4 Tablets) for D1 Part 2 : CKD-519 placebo(100mg x 4 Tablets) for D1~D14
1468151|NCT03210636|Device|LapSpace|use of atraumatic laparoscopic retractor for patients undergoing laparoscopic surgery
1468327|NCT03209102|Biological|salivary collections of amylase and cortisol|Collection of saliva samples of cortisol and amylase repeated three times
1569006|NCT02462837|Drug|Placebo|
1468152|NCT03210623|Device|stent retriever(TonbridgeMT)|mechanical thrombectomy with stent retriever(TonbridgeMT), digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging (MRI), diffusion weighted imaging (DWI)
1468153|NCT03210623|Device|Solitaire™|mechanical thrombectomy with Solitaire™ , digital subtraction angiography(DSA), computed tomography(CT), magnetic resonance imaging(MRI), diffusion weighted imaging(DWI)
1468154|NCT03210610|Diagnostic Test|colchicine level measurement|levels of colchicine will be measured in FMF patients taking colchicine
1468155|NCT03210597|Other|Exercise|The subjects performed training in aquatic environment
1468156|NCT03210571|Device|eyeWatch system|The eyeWatch device is composed of an AGDD, a control unit and a draining plate
1468157|NCT03210558|Drug|Testosterone cream 1% (Andro-Feme® )|Testosterone cream 10 mg (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
1468158|NCT03210558|Drug|Placebo cream|Placebo cream (1 ml) daily, supplied every evening via a dose applicator to the upper outer thigh for 10 weeks.
1468159|NCT03210545|Drug|Dexamethasone|A cross-over study where patients with Addison´s disease will undergo two treatment periods where their usual hydrocortisone replacement therapy will be replaced by the glucocorticoid dexamethasone in physiological and supra physiological doses. A wash-out period of 2-5 weeks in-between the treatment periods will be carried out where participants intake their usual hydrocortisone replacement therapy.
1468160|NCT03210532|Drug|Telmisartan + Amlodipine + Rosuvastatin|Telmisartan + Amlodipine + Rosuvastatin + Telmisartan placebo
1468161|NCT03210532|Drug|Telmisartan + Amlodipine|Telmisartan + Amlodipine + Rosuvastatin placebo + Telmisartan placebo
1468162|NCT03210532|Drug|Telmisartan + Rosuvastatin|Telmisartan + Amlodipine placebo + Rosuvastatin + Telmisartan placebo
1468163|NCT03210519|Dietary Supplement|Eleutherococcus senticosus|taken orally once/day for 90 days
1468164|NCT03210519|Other|Placebo|taken orally once/day for 90 days
1468165|NCT03210506|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
1468166|NCT03210493|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group
1468167|NCT03210480|Drug|Lithium sulphate prolonged-release 660 mg|Oral administration of one tablet once or twice daily (one tablet in the morning and one tablet in the evening) or two tablets in a single dose (two tablets in the evening) of Lithium sulphate 660 mg (Lithium sulphate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
1468168|NCT03210480|Drug|Lithium carbonate immediate-release 150 mg and 300 mg|Oral administration of 300-1800 mg daily divided into 2-6 doses of Lithium carbonate capsules (Lithium carbonate dose will be individualised for each patient according to the relevant SmPC). Treatment duration: 3 months.
1468169|NCT03210454|Other|Smallholder Marketing|The smallholder marketing intervention involves product purchasing (e.g., bananas, beans, goats, eggs) from smallholder farmers' associations through WFP's large procurement procedures. WFP is will also provide technical training on topics such as sustainable farming practices, quality control, and business practices.
1468170|NCT03210454|Other|Intimate Partner Violence (IPV) Prevention Training|IPV prevention training involves 24 hours of gender training (gender equality and rights, economic empowerment, gender-based violence prevention), and 8 hours of nutrition and food security training (with a focus on gender).
1468171|NCT03210415|Other|Observational Study Model|There is no intervention for the study.
1468172|NCT03210402|Device|Elevated night pacing on|Device will be programmed to 100 beats per minute (bpm) for five hours during normal sleep times
1468173|NCT03210402|Device|Elevated night pacing off|Device will be programmed to normal lower rates
1468174|NCT03210389|Drug|Lobaplatin|Patients enrolled will receive lobaplatin 30mg/m2 d1+ 5-FU 0.5g/m2/d d2-5 in every 21days. 4-6 cycles of chemotherapy are recommended.
1468175|NCT03210376|Drug|Deep Neuromuscular Blockade (NMB)|Deep Neuromuscular Blockade (NMB) given during surgery.
1468176|NCT03210376|Drug|Moderate Neuromuscular Blockade (NMB)|Moderate Neuromuscular Blockade (NMB) given during surgery.
1468177|NCT03210376|Drug|Sugammadex|4 mg/Kg, intravenously as a single bolus injection after surgery.
1468178|NCT03210376|Drug|Neostigmine|70 mcg/Kg up to a total of 5 mg, intravenously slowly over a period of at least 1 minute after surgery.
1468179|NCT03210376|Behavioral|Pain Assessment|Pain assessment done at about 15, 45, and 90 minutes after surgery.
1468180|NCT03210363|Other|Human Biological samples|Blood sample
1468181|NCT03210350|Diagnostic Test|Optic nerve sheath diameter|Optic nerve sheath diameter measurement using ultrasound
1948314|NCT02508870|Drug|Atezolizumab|Participants will receive atezolizumab as per the schedule described in individual cohort.
1468183|NCT03210324|Drug|Mifepristone tablets|Daily 10mg, Po, Qd, each 10mg/tablets。Start from 1 to 3 days of the menstruation, take 1 tablet after 2 hours of fasting, and no eating for 2 hours after taking the pill. Group A and group B: treatment for 12 weeks, Group C: treatment for 24 weeks.
1948315|NCT02508870|Drug|Azacitidine|Participants will receive azacitidine as per the schedule described in individual cohort.
1468185|NCT03210298|Combination Product|PIPAC|A chemotherapeutic solution is aerosolized into the expanded abdominal cavity during laparoscopy, under pressure. This allows a relatively homogeneous repartition of the drug and an effective tissue penetration.
1468186|NCT03210285|Diagnostic Test|Whole exome sequencing|Whole exome sequencing
1468187|NCT03210272|Drug|Placebo|Tablet and solution formulation
1468188|NCT03210272|Drug|BI 1358894|Tablet and solution formulation
1468189|NCT03210272|Drug|BI 1358894 (Test)|Fasting state
1468190|NCT03210272|Drug|BI 1358894 (Reference)|Fed state
1468191|NCT03210259|Drug|Humira®|Duration - 58 weeks
1468192|NCT03210259|Drug|BI 695501|Duration - 58 weeks
1468328|NCT03209076|Procedure|Robotic|Robotic low anterior resection
1948320|NCT02495025|Behavioral|Telephone-based developmental screening and care coordination|
1468197|NCT03210233|Procedure|Blood test, skin testing and challenge testing.|Skin Prick Testing (SPT) and Intradermal Testing (IDT). We will follow the STARD framework for reporting studies of diagnostic accuracy
1468198|NCT03210207|Procedure|GASTROPLICATURE|All procedures were performed by a single surgeon. All patients underwent 2-row gastric plication. Dissection was started at the greater curvature of the stomach in contact to the gastric wall from prepyloric area to 2-cm proximal to the Hiss angle preserving the anatomy of Hiss angle. All vessels along the greater curvature were separated using LigaSure (Covidien, Mansfield, MA, USA). The greater curvature (from the perimeter) was invaginated using 2 rows of 00 prolene or 00 nylon sutures. Two layers of plication were performed with continuous sutures with 1 surgical sting in all patients to prevent any displacement of inverted folds such as eversion outside or intussusception into esophagus or pylorus. All sutures were extramucusal to avoid their absorption by gastric acid. Finally, a tube shaped stomach was achieved in which the greater curvature was inverted in to the stomach.
1468199|NCT03210194|Behavioral|Standard Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Standard Training
1468200|NCT03210194|Behavioral|MP-ICT Neonatal Resuscitation Training|Theoretical and practical training on basic and advanced neonatal resuscitation skills, directed to personnel from remote health centers using Information and Communication Technologies
1468201|NCT03210181|Other|Superficial cervical plexus block|A nerve stimulator is used to guide the superficial cervical block. The nerve stimulator needle is first passed over the skin after aseptic preparation from the distal to proximal part of the posterior border of the sternocleidomastoid. Upon contraction of the levator scapulae, a mark is placed and the skin is infiltrated with 1 ml lidocaine 1%. A 22-G, 2.5 cm nerve stimulator needle is subsequently advanced through the skin by 0.5-1 cm depending on patient's weight while passing 5-8.5 mA current at 1 Hz. Then, the stimulating current is reduced to 0.5-0.6 mA while maintaining muscle contraction. At this point, 3-5 ml of the anesthetic mixture is injected.
1468202|NCT03210181|Other|Placebo|Patients will receive an equivalent volume of normal saline
1468203|NCT03210168|Other|BioFe Medical Food|BioFe is comprised of cultured nutritional/Baker's yeast (Saccharomyces cerevisiae) with high levels of Ferritin/Iron complex, pasteurized, and dried
1468204|NCT03210155|Device|Alpha-Stim AID CES (Active Comparator)|The Alpha-Stim® AID CES device delivers a mild electrical current (100-500 µA) to the brain via ear clips electrodes. The treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks at 0.5 Hz. 50% duty cycle with a fixed current of 100 µA (subsensory level).
1468205|NCT03210155|Device|Alpha-Stim AID CES (Sham Comparator)|The Alpha-Stim® AID CES sham device is inactive and does not emit electrical current to the brain via ear clip electrodes. The sham treatment regimen is one daily 60 minutes Alpha-Stim® CES treatment using ear clip electrodes for 6 weeks.
1468206|NCT03210142|Procedure|Transvenous hypoglossal nerve stimulation|Transvenous hypoglossal nerve stimulation to open upper airway.
1468207|NCT03210129|Behavioral|Motivational interviewing|"the patients of the motivational interviewing group will receive 12 motivational interviewing sessions within 12 weeks: 2 face-to-face sessions and 10 phone call sessions. The first and the seventh motivational interviewing sessions will be face-to-face sessions. An intervention is considered valid if a minimum of 10 sessions has been completed. The face-to-face motivational interviewing sessions will be administered at the Luxembourg Institute of Health (Strassen, Luxembourg). They generally last up to 30 minutes, while the motivational interviewing phone calls generally last up to 15 minutes. Thereby, patients in the motivational interviewing group will receive a total of approximately 3.5 hours of contact time over a period of 12 weeks.
Motivational interviewing techniques will explore self-assessed confidence, ambivalence, and personal values concerning changes in active lifestyle."
1468208|NCT03210116|Other|Palliative Care|Palliative Care Consultation
1468209|NCT03210103|Radiation|Radiation|Standard of Care: Radiation +/- Chemotherapy
1468210|NCT03210103|Procedure|Transoral Surgery (TOS) + Neck Dissection|Transoral Surgery (TOS) + Neck Dissection
1468211|NCT03210077|Device|Monitoring|Monitoring
1468212|NCT03210064|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd po
1468213|NCT03210064|Drug|5-fluorouracil|5-Fluorouracil 400mg/m2 iv d1，2400mg-3000mg/m2 civ 46h,q2w.5-Fluorouracil derivatives(Capecitabine 1000mg/m2 bid po d1-d14 q3w.S1 40mg/m2 bid po d1-d14 q3w).
1468214|NCT03210051|Device|Remote ischemic conditioning|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeatedly for 5 times.
1468215|NCT03210051|Procedure|Endovascular treatment|Endovascular treatment include strategies that used to recanalize the occluded artery. Strategies often used include thrombectomy, intra-arterial thrombolysis, stenting and balloon angiography.
1468216|NCT03210038|Drug|Lidocaine|Pad soaked with lidocaine gel (Esracaine) left on the introitus for 5 minutes
1468217|NCT03210038|Drug|Water|Water based non-anesthetic lubricant gel left on the introitus for 5 minutes.
1468218|NCT03210025|Drug|BF-Methyldopa 250mg Tablet|BF-Methyldopa 250mg Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
1468219|NCT03210025|Drug|Metopa Tab 250mg|Metopa Tab 250mg is manufactured by APT
1468220|NCT03210012|Diagnostic Test|Transthoracic echocardiography|Diagnostic test done prior and after the dive
1468221|NCT03210012|Diagnostic Test|Blood samples|Diagnostic test done prior and after the dive
1468222|NCT03209986|Procedure|mesenchymal stem cell transplantation via peripheral vein|1x10E6 MSCs/kg body weight will be administered via peripheral vein for 3 times at week 0, 4 and 8
1468223|NCT03209986|Other|mesenchymal stem cell|mesenchymal stem cell infusion produced by Cell products of National Engineering Research Center(short for CPNERC), Tianjin, China
1468224|NCT03209973|Drug|BGB-A317|BGB-A317 200 mg intravenously (IV) every-3-weeks
1468329|NCT03209076|Procedure|Laparoscopic|Laparoscopic low anterior resection
1468330|NCT03209063|Diagnostic Test|polymerase chain reaction|diagnostic test as Polymerase chain reaction for detection of Prothrombin gene mutation
1573920|NCT02427243|Drug|Crenezumab|
1468228|NCT03209908|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate was used for the experimental group of pregnancy women in the 32 weeks during pregnancy
1468229|NCT03209895|Dietary Supplement|Joint Health Product|Krill oil, Astaxanthin, Hyaluronic Acid Formulation, 353 mg per day; Softgel capsule
1468230|NCT03209895|Dietary Supplement|Placebo|Palm oil Softgel capsule
1468231|NCT03209895|Dietary Supplement|Glucosamine / Chondroitin|Glucosamine 1500 mg, Chondroitin 1200 mg per day
1468232|NCT03209882|Device|TILS|Continuous-wave laser of a specific wavelength (1064 nm) that will be directed to the right forehead. The laser diode is supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
1468233|NCT03209882|Device|sham|Same aperture of CG-5000 laser (HD Laser Center, Dallas, TX, USA), but the laser power will be turned to be 0 Watts.
1468236|NCT03209856|Drug|Vitamin D|Vitamin D supplement will be given. Then, it will be maintained if pregnancy occurred
1468237|NCT03209843|Procedure|Percutaneous recanalization of chronic total occlusion|Percutaneous recanalization of chronic total occlusion followed by immediate systematic coronary optical frequency domain imaging (OFDI) at inclusion. Intra-individual post stenting assessment of reendothelialization with a second coronary angiography with OFDI analysis at 3 months.
1468238|NCT03209830|Drug|OSU 6162|All patients will receive a dose of OSU6162 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
1468239|NCT03209830|Drug|Placebo Oral Tablet|All patients will receive a dose of placebo 15 mg BID x 2 per day. The expected duration of therapy is 12 weeks. After 1 week of treatment, patients who do not respond to treatment will have their dose increased to maximum 30 mg BID x 2 per day.
1468240|NCT03209817|Dietary Supplement|Red cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
1468241|NCT03209817|Dietary Supplement|Yellow cherry tomato|300 grams of cherry tomatoes per day for four weeks (each)
1468242|NCT03209804|Procedure|hybrid operating techniques|A one-stage cooperation of existing endovascular interventional techniques and microsurgical techniques, including microsurgical resection, endovascular embolization, balloon occlusion.
1468243|NCT03209791|Other|Biopsies|Biopsy will be done on the Vastus Lateralis muscle in all groups
1468244|NCT03209778|Other|Patients with Schizophrenia|Patients with schizophrenia or schizoaffective disorder according to DSM-V criteria
1468245|NCT03209765|Other|WhatsApp reminder|An interactive WhatsApp reminder to return to the centre for taking faecal tubes for screening
1468246|NCT03209739|Other|WhatsApp reminder|An additional WhatsApp reminder with same content of the written instruction and a video of explanation of bowel preparation by a nurse 4 days prior colonoscopy
1468249|NCT03209700|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
1468250|NCT03209687|Drug|human menopausal gonadotropin|Merional injections will be given to participants after ovum pickup in in-vitro fertilization cycles
1468251|NCT03209674|Procedure|Cardiothoracic surgery|Cardiac or thoracic procedure
1468252|NCT03209661|Drug|E-cigarette|E-Cigarette containing 5.4% nicotine will be administered to determine the effects on vascular function.
1468253|NCT03209661|Drug|Nicotine 0%|E-Cigarette containing 0% nicotine will be administered to determine the effects on vascular function.
1468254|NCT03209661|Drug|Menthol Inhalant Product|Menthol inhaler will be administered to determine the effects on vascular function.
1468257|NCT03209635|Dietary Supplement|Placebo|4 capsules (300 mg/capsule) containing 52% crystalline cellulose and 46% lactose in identical-looking with test product
1468258|NCT03209635|Dietary Supplement|Probiotic|4 capsules (300 mg/capsule) containing each capsule 1.0 x 10^10 colony-forming units (cfu) of Weissella cibaria JW15, twice a day
1468259|NCT03209622|Procedure|Nicotine replacement therapy delivred in cardiology intensive care unit versus Nicotine replacement therapy delivered after hospital discharge|when patient is admitted in intensive care of cardiology for acute coronary syndrome he is randomized to Arm A or Arm B
1468260|NCT03209622|Drug|Nicotine patch|Arm A
1468261|NCT03209622|Other|the external consultation|without patch
1468262|NCT03209609|Device|VEST|External support for vein grafts, cobalt chrome braid
1468263|NCT03209609|Procedure|Coronary artery bypass vein grafts|Bypass coronary arteries with autologous saphenous vein grafts
1948326|NCT02483260|Drug|Ribavirin|"Loading dose, 33 mg/kg (maximum dose: 2.64 g)
Followed in 6 hours by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses)
Followed by a dose of 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 6 days (18 doses)."
1468264|NCT03209596|Dietary Supplement|Orange juice (1L/d)|The players (n=17) drank 1 liter per day of orange juice. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
1468265|NCT03209596|Dietary Supplement|Control drink (1L/d)|The players (n=13) drank 1 liter per day of the control drink during a 60-day period. We do not interfere on the volunteers' usual diet during the study, and they did not ingest any commercial nutritional supplements in this period. During the intervention, the volunteers were engaged in a common training routine specified by the coach's team.
1468266|NCT03209583|Device|Medtronic|Pacing is done by the implanted device after seeing how the electrical system is functioning giving energy when needed to maintain a stable state or rhythm
1468267|NCT03209570|Other|Care planning using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear and will have data available for care planning.
1468268|NCT03209570|Other|Care planning without using TENA Identifi sensor wear data|All individuals in this arm will receive TENA Identifi sensor wear but the sensor wear data will not be used for care planning.
1468269|NCT03209557|Other|SmartWatch SmokeBeat Application|The SmokeBeat app is a digital health app that allows for the user to monitor their smoking behavior in real time, set smoking cessation goals, and allows investigators, doctors and others using the app with participants to send messages directly related to smoking behavior. The SmokeBeat app, developed by Somatix Inc., will collects time-stamped on hand movements associated with smoking behavior. Participants will receive notifications on their phone and smartwatch when a smoking bout has been detected. In addition this app will deliver daily text messages aimed at improving quit rates among participants. We will be able to create the types of messaging we want to send and to modify when these messages will be sent to all participants. http://somatixinc.com/smokebeat/
1468270|NCT03209544|Behavioral|Online self-help intervention|The intervention was originally developed by van Spijker, van Straten, and Kerkhof (2010). For this study, it was adapted to the Flemish context and called Think Life. Think Life is mainly based Cognitive Behaviour Therapy (CBT). Additionally, it encompasses elements from Dialectical Behaviour Therapy (DBT), Problem Solving Therapy (PST), and Mindfulness Based Cognitive Therapy (MBCT). It encompasses six modules and every module starts with a psycho-educational section followed by a weekly assignment, core exercises and optional exercises. The participant weekly receives access to a new module. A more detailed description of the intervention is described elsewhere (Kerkhof, van Spijker, & Mokkenstorm, 2013; van Spijker et al., 2010; van Spijker, van Straten, et al., 2014).
1468271|NCT03209531|Behavioral|Operant Conditioning|Active encouragement and feedback to increase motor evoked response when stimulated.
1468272|NCT03209531|Behavioral|Control|Absence of active encouragement and feedback to increase motor evoked response when stimulated.
1468273|NCT03209531|Device|Single Pulse Transcranial Magnetic Stimulation|Transcranial magnetic stimulation to elicit a motor evoked response from the quadriceps muscles.
1468274|NCT03209518|Drug|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
1468275|NCT03209505|Device|Acuvue Oasys|FDA approved contact lens, fit for daily wear
1468276|NCT03209505|Device|Air Optix Night & Day Aqua|FDA approved contact lens, fit for daily wear
1468277|NCT03209492|Drug|Leuprorelin acetate|Leuplin PRO for Injection Kit 22.5 mg
1468278|NCT03209479|Drug|Glatiramer acetate|Copaxone subcutaneous injection syringe
1468279|NCT03209466|Drug|Chlorhexidine gluconate at 0.125%|Application every 24 hours, six weeks Intervention: Procedure: chlorhexidine gluconate
1468280|NCT03209466|Drug|Placebo Comparator with physiological saline sterile solution|Standard management and physiological saline sterile solution with application every 24 hours, six weeks Intervention.
1468281|NCT03209453|Other|family work shop|Children with developmental delays, under regular rehabilitation programs, participate 6 sessions of family work shop The family work shop had 6 families in one course, 2 hours per week, for a total of 6 weeks.
1468282|NCT03209440|Behavioral|Dignity Therapy - Nurse Led|The nurse-led intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
1468283|NCT03209440|Behavioral|Usual care|Palliative care nurses usually see patients each clinic visit to assess vital signs, function, symptoms, and to provide patient and family education. They document findings and interventions in the electronic health record (EHR). Whereas usual care for palliative care chaplaincy in the outpatient setting varies by site, chaplaincy care for usual care patients in this study will follow the usual practice for inpatient palliative care chaplaincy, which is to visit all new referrals to the clinic and assess their spiritual and religious needs. This assessment is then memorialized in a spiritual treatment plan documented in the EHR.
1468284|NCT03209440|Behavioral|Dignity Therapy - Chaplain Led|The chaplain-led DT intervention involves three sessions, each of which follows a set process. The standardize approach to the delivery of the intervention facilitates a personal process of reflection and recognition that allows the patient to make meaning of their experience.
1468285|NCT03209427|Drug|Morphine 100 μg|Intrathecal injection of morphine100 μg
1468286|NCT03209427|Drug|Morphine 200 μg|Intrathecal injection of morphine 200 μg
1468291|NCT03209349|Procedure|Water Exchange Sigmoidoscopy|See arm description.
1468292|NCT03209349|Procedure|Air Insufflation Sigmoidoscopy|See arm description.
1468293|NCT03209336|Radiation|Intraoperative radiotherapy by Intrabeam（Zeiss Meditech，Jena，Germany）|We confirmed that if the patients had the distant metastasis before IORT. The median radiation dose was 5.00 Gy (range: 5.00-10.00Gy), the average dose was 6.00 Gy. The median radiation time was 0:33:24 (range: 0:21:45-1:06:23), which was the same with the patients'. All patients' surface dose ranged from 15.00 to 28.50 Gy.
1468331|NCT03209050|Device|Central Venous Access Placement|Device inserted into the femoral vein to insert a central venous access catheter
1468521|NCT03207581|Behavioral|Professional Coaching|Professional, individualized coaching
1468294|NCT03209323|Device|electroencephalography (EEG)|Four EEG channels were recorded using electrode positions as defined in the International 10-20 System with Ag/AgCl2 cup electrodes (Spes Medica) attached to the scalp with EC2 Electrode Cream (Grass Technologies). The impedance was set below 1 k, and the electrodes were attached to module S/5 E-EEG of the anaesthetic monitor S/5 (GE Healthcare).
1468295|NCT03209323|Device|bispectral index (BIS)|The BIS score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
1468296|NCT03209323|Device|response and state entropy (RE and SE)|The respone and state entropy (RE and SE) score was derived from a sensor (Aspect Medical Systems) positioned diagonally on the patients' foreheads according to producer's instructions.
1468297|NCT03209323|Device|middle latency auditory evoked potentials (MLAEP)|value of A-line Auto Regressive Index (AAI) derived from middle latency auditory evoked potentials (MLAEP) (A-line Monitor, Danmeter A/S, Odense, Denmark) was observed which measures the central nervous system responsiveness to a specific auditory stimulus
1468298|NCT03209297|Other|TMD treatment: physiotherapy and/or occlusal splints|The patient will receive the most appropriate TMD treatment, based on current literature.
1468299|NCT03209284|Procedure|transcrestal sinus floor elevation|augmentation procedure with xenograft
1468300|NCT03209271|Drug|Ringer's Acetate (warm)|Body temperature fluid
1468301|NCT03209271|Drug|Ringer's Acetate (cold)|Room temperature fluid
1468302|NCT03209258|Other|Care bundle of active management|"Intensive BP lowering to systolic target of <140mmHg;
Glucose control target 6.1-7.8 mmol/l for non-diabetic; 7.8-10.0 mmol/l for diabetic patients;
Treatment of pyrexia to a target body temperature ≤37.5 ℃;
Reversal of anticoagulation to target INR <1.5 involving use of vitamin K and prothrombin complex concentrate (PCC) or alternatively, fresh frozen plasma (FFP).
As the trial is an assessment of care bundle of physiological management, there is some flexibility in the use of particular BP lowering agents and antipyretic agents to achieve targets."
1468303|NCT03209258|Other|Usual care|Usual care decisions about the location of care delivery, investigations, monitoring, and all treatments will be made by the treating clinical team.
1468304|NCT03209245|Biological|Purethal Mites|perennial allergren specific immunotherapy during 24 months
1468305|NCT03209245|Other|placebo injection|perrenial injection wich were administered in same protocol as Purethal
1468306|NCT03209245|Diagnostic Test|monitoring of allergen specific IgE|measurement the serum specific IgE at the start and at the end of trial
1468307|NCT03209245|Diagnostic Test|monitoring of allergen specific IgG4|measurement the serum specific IgG4 at the start and at the end of trial
1468308|NCT03209232|Drug|Infliximab|Accelerated induction of infliximab in moderate to severe ambulatory prdiatric UC patients
1468309|NCT03209219|Drug|Interferon Alfa-2A|3×10^6 IU， subcutaneous or intramuscular injection, qd for × 4 weeks, and qod thereafter
1468310|NCT03209219|Drug|Cyclosporine Pill|100mg， oral, bid
1468311|NCT03209206|Drug|Docetaxel|Intravesical Instillation of Docetaxel (Docetaxel 75 mg diluted in 100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
1468312|NCT03209206|Drug|Placebo Normal saline|Intravesical Instillation of Normal saline (100 cc of normal saline) after operation of Upper urinary tract urothelial carcinoma (With in 48 hrs)
1468313|NCT03209193|Drug|Sevoflurane|Sevoflurane use as main anesthetic drug during the surgery
1468314|NCT03209193|Drug|Desflurane|Desflurane use as main anesthetic drug during the surgery
1468315|NCT03209180|Drug|CarVeDilol-SR (Slow Release)|patients will receive slow-release carvedilol (SR) once daily
1468316|NCT03209180|Drug|Carvedilol IR (Immediate Release)|patients will receive immediate release carvedilol (IR) twice daily
1468317|NCT03209167|Behavioral|Questionnaire|Two study-specific questionnaires
1468320|NCT03209141|Diagnostic Test|Diastolic function evaluation|Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)
1468321|NCT03209128|Radiation|Irradiation prophyllactique cérébrale|Irradiation prophyllactique cérébrale
1468322|NCT03209115|Drug|combination of calcium hydroxide and chlorhexidine|placement of calcium hydroxide and chlorhexidine as intracanal medicament after removal of old filling and mechanical preparation of root canal
1468323|NCT03209115|Drug|Calcium Hydroxide|placement of calcium hydroxide as intracanal medicament after removal of old filling and mechanical preparation of root canal
1468324|NCT03209102|Other|Clinical assessment|"Self-assessments based on questionnaires : Strengths and Difficulties Questionnaire - Development and Well-Being Assessment (SDQ-DAWBA) ; Pubertal Development Scale ; Life Events Questionnaire ; Childhood Trauma Questionnaire ; Abbreviated - Diagnostic Instrument for Borderline (Ab-DIB) ; Beck Depression Inventory ; Socio-demographic questionnaire)
and clinical evaluation by a psychiatrist : Mini-International Neuropsychiatric Interview (MINI); Global Assessment of Functioning"
1468325|NCT03209102|Behavioral|Stress elicitation experiment|"The stress elicitation experiment is based on a time-constrained mental arithmetic test in the presence of an observer. The task usually lasts about 30 minutes.
During the task, the investigators will monitor: neuro-vegetative parameters (skin conductance, temperature, respiratory and cardiac frequencies, and VNA) ; biological parameters : salivary Cortisol and Amylase before test (baseline), 15 min and 30 min after testing (respectively corresponding to Reactivity and Recovery) ; micro-behavioral cues extracted from 2D video and 3D sensors (Microsoft Kinect)."
1468326|NCT03209102|Other|Structural and Functional MRI|"Structural and Functional Magnetic Resonance Imaging (MRI). The functional acquisition will last 20 minutes and the structural acquisition 18 minutes. All MR image acquisition methodologies are already functioning on the 3 Tesla Prisma machine within the ICM(Brain and Spine Institute), Salpetriere. The fMRI session will provide three types of data: (1) task-related activity to probe the striato-limbic and prefrontal regions, (2) resting state connectivity to examine the integrity of canonical networks, and (3) MR structural images to measure regional volumes of key functional nodes.
For the task-related fMRI study, the investigators will use the monetary incentive delay task that reliably elicit an activation in known functional networks underlying reward anticipation/outcome."
1468332|NCT03209037|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
1468333|NCT03209024|Other|Handwritten logbook recording of home blood pressure readings|Participants use a handwritten logbook to record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
1468334|NCT03209024|Device|Smartphone assisted wireless recording of home blood pressure readings|Participants use a smartphone app and Bluetooth® technology to wirelessly record the details of their home blood pressure measurements, including systolic blood pressure, diastolic blood pressure, date, and time.
1468335|NCT03209011|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
1468336|NCT03208998|Drug|Peginterferon Alfa-2a|patients untreated in immune-active phase were given subcutaneous injection of Peginterferon Alfa-2a with starting dose of 180 mg/weekly in experiment group.
1468337|NCT03208985|Drug|Use Phase (Ulipristal Acetate, 30 mg)|"All subjects enrolled in the use phase of this open-label study will be given the opportunity to purchase and take 30 mg of ulipristal acetate.
Subjects are to use the investigational product based on their understanding of the directions on the outer packaging including Drug Facts Label and inside the product packaging (in the Consumer Information Leaflet)."
1468338|NCT03208972|Drug|low dose hCG|
1468339|NCT03208972|Drug|hp-FSH|
1468340|NCT03208972|Drug|Corifollitropin Alfa|"Corifollitropin Alfa (Elonva) dosage depending on weight, once administered first day of ovarian stimulation for all subjects, and on day 7 they proceed with the treatment of the allocated group.
<60 kg: Elonva 100 MCG > 60 kg: Elonva 150 MCG"
1468341|NCT03208959|Drug|HTI-1090|IDO
1468342|NCT03208946|Other|High-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
1468343|NCT03208946|Other|Low-CML diet|Participants will be randomly assigned to either a high-CML or to a low-CML diet for 5 days, and they will receive the 5 corresponding meals (breakfast, lunch, snacks and dinner) during the 5 days of the intervention. These preparations will be elaborated by a catering company with indications and supervision by the research group. The intervention will be based on an isocaloric diet with a distribution of 55 to 63% carbohydrates, 12 to 15% protein, 25 to 30% lipids and less than 10% saturated fat and it macro and micronutrients will be similar in both diets. The only difference will be the CML content.
1468344|NCT03208933|Drug|Pirfenidone|Pirfenidone 2403 mg/d capsules orally will be given in divided doses (TID) after titration period of 14 days.
1468345|NCT03208920|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each Pro-Omega capsule is 550 mg. Must take 4400 mg/day x 6 months.
1468346|NCT03208920|Other|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA). Each soybean capsule is 550 mg. Must take 4400 mg/day x 6 months.
1468347|NCT03208907|Drug|CQ coadministered with PQ|115 subjects will be given 3-day regimen treatment with the schizonticidal drug Chloroquine concomitantly to 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day.
1468348|NCT03208907|Drug|DHA-PQP coadministered with PQ|In this treatment group, others 115 subjects will take DHA-PQP for three days and Primaquine for 14 days in the following dose: 0.50 mg/kg/day.
1468349|NCT03208907|Drug|CQ and PQ starting on Day 42|115 subjects will be given 3-day regimen treatment with Chloroquine with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
1468350|NCT03208907|Drug|DHA-PQP and PQ starting on Day 42|115 subjects will be given 3-day regimen treatment with DHA-PQP with a 14-day regimen treatment with Primaquine in a dose of 0.50 mg/kg/day starting on Day 42 after first dose of the schizonticidal drug.
1468351|NCT03208894|Drug|Furosemide Injection|efficacy of salbutamol and furosemide in TTN
1468352|NCT03208881|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
1468353|NCT03208868|Dietary Supplement|Leucine enriched essential amino acid (EEA/LEU)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
1468354|NCT03208868|Dietary Supplement|Balanced amino acid supplement (BAA)|Patient with cirrhosis will be randomized to either take a Leucine enriched essential amino acid or a balanced amino acid supplement.
1468355|NCT03208855|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|8 week 1-hour sessions of group CBT-I with each group including 3-4 men.
1468356|NCT03208842|Radiation|trans vaginal ultrasound|"trans vaginal ultrasound with partially filled bladder to nullify effect of anteversion of the uterus for assessment of
---the site of the intrauterine gestational sac in relation to the endometrial cavity"
1468357|NCT03208829|Other|Rehabilitation exercises|Patients in group 1 will participate in a physical exercise protocol supervised by a physiotherapist. The sessions will focus on the rehabilitation of muscle strength and the exercises will be performed with increased external load.
1468358|NCT03208829|Other|Postoperative guidance|Group 2 will receive only guidelines regarding postoperative care.
1468359|NCT03208816|Behavioral|symptom management program for chemotherapy patients|Nurses will call study participants two times a week, to proactively assess and manage symptoms they might be experiencing during chemotherapy.
1468360|NCT03208790|Drug|Thymoquinone 100mg|thymoquinone will be extracted from Nigella Sativa and packed in capsules of 100mg
1468361|NCT03208790|Drug|thymoquinone 200mg|thymoquinone will be extracted from Nigella Sativa and packed in capsules of 200mg
1468362|NCT03208790|Drug|Placebo oral capsule|capsules with the same color and form as the active ones but without active ingredient will be given to the patients
1468363|NCT03208777|Genetic|taking blood samples|taking blood samples and measure telomeric abnormalities
1468364|NCT03208764|Drug|Nitric Oxide|Subjects will be treated with 91 thirty minute sessions of 160 ppm Nitric Oxide with at least 3 hours between each session.
1468365|NCT03208751|Behavioral|Exercise training|"Exercise intervention was divided into 3 phases:
Phase 1: 6 weeks of moderate continuous training (MCT) 20 to 40 minutes at intensity of 60% of VO2peak, 3 times/week Phase 2: 6 weeks of moderate intensity interval training (MIIT) 30-40 min, intensity 60 to 80% of VO2peak, twice weekly plus at least once weekly MCT home based training Phase 3 (after performing new exercise testing to adapt training intensities): 12 weeks of MIIT 40 min once/week, intensity 60-80/85% of VO2peak, plus at least twice weekly home based MCT. From phase 2, supervised sessions included resistance training of at least 3 muscle groups, 3x15 repetitions at moderate intensity (Borg 12-14).
Nutritional counseling is offered up to 4 times in 6 months on an individual basis."
1468366|NCT03208738|Behavioral|VetChange|VetChange is a self-management mobile application designed to to concurrently reduce both alcohol misuse and PTSD symptoms.
1468367|NCT03208738|Behavioral|web-based drinking assessment and feedback tool (AFT)|Program will administer a comprehensive assessment of drinking and consequences of drinking, and will provide normative feedback and highlight negative consequences of drinking.
1468368|NCT03208712|Drug|Atezolizumab|Atezolizumab 1200 mg IV once every 3 weeks
1468369|NCT03208712|Drug|Radium-223|Radium- 223 IV (55 kBq/kg) every 3 weeks for up to 6 doses
1468370|NCT03208686|Behavioral|Intervention Group|A single-arm intervention comprised of (a) 10 weekly discussion groups; (b) motivational text messages; (c) a remote sensing persuasive health technology − a cloud-based cellular glucometer connected to a dedicated web site to reduce A1c by 0.5% by improving diabetes self-management behaviors.
1468371|NCT03208673|Device|Optive® Fusion + Optive® Gel Drop|Optive® Fusion eyedrop will be used as needed up to four times a day but at least twice a day. The eyedrop will be used once in the evening; the gel drop being instilled any time during the last hour prior to sleep.
1468373|NCT03208647|Other|AA or not|to study their risk factors
1468374|NCT03208634|Device|Robotic intervention|One-month robotic intervention. Twelve sessions, three sessions a week, 40 minutes each. Twenty minutes of fully assisted reaching + 20 minutes of assisted Hand-to-Mouth
1468375|NCT03208608|Diagnostic Test|RBANS-H|The RBANS-H is a diagnostic cognitive test battery
1468376|NCT03208595|Diagnostic Test|Endometrial sampling of a Typical Embryo transfer catheter|no intervention no additional change from unit protocol
1468377|NCT03208582|Drug|Risedronate Sodium|Participants will be initially tested on the response to mechanical stimulation as a baseline and then tested again after 6 weeks treatment with Risedronate
1468378|NCT03208582|Dietary Supplement|Calcichew tablets|Participants will take calcichew tablets during the 6 week period of risedronate treatment
1468379|NCT03208556|Biological|iPD1 CD19 eCAR T cells|"iPD1 CD19 eCAR T cells are administrated in a 3-day split-dose regimen （d0, 30%; d1, 30%; d2, 40%）.
CAR T cell dose escalation: 1×10^5 /kg，1×10^6 /kg，3×10^6 /kg，and 6×10^6 CAR T cells/kg"
1468380|NCT03208556|Drug|Fludarabine and cyclophosphamide|Fludarabine 25 mg/m2 d1-3; cyclophosphamide 250 mg/m2 d1-3. Lymphodepletion chemotherapy is completed 1 to 4 days before CAR T cell infusion
1468381|NCT03208543|Device|HECT-CL|To evaluate the effectiveness, safety and feasibility of thermotherapy with the low cost Hand-held Exothermic Crystallization Thermotherapy pad in the treatment of cutaneous leishmaniasis in Quetta, Balochistan, Pakistan.
1468382|NCT03208530|Behavioral|Brief motivational interview intervention|A brief (<7minutes) interview by an emergency department clinician to empower patients to formulate and communicate their goals for medical care with patients' outpatient clinicians.
1468383|NCT03208517|Other|Improving Wellbeing and Health for People with Dementia (WHELD) e-learning training programme|The e-learning WHELD intervention The optimised e-learning programme will consist of five 25-minute interactive online modules based on a recently completed RCT of an in person training programme (WHELD), combining the most effective elements of existing approaches to create a comprehensive but practical staff training intervention. Based on a factorial study and qualitative evaluation, WHELD combines: person-centred care, person-centred activities and interactions, and updated knowledge regarding optimal use of psychotropic medications.
1468384|NCT03208504|Device|Nexus™ Aortic Arch Stent graft|surgical implantation of Nexus™ Aortic Arch Stent graft
1468385|NCT03208491|Other|serious games use|This program has enabled several SGs to be developed that allow physical and cognitive workouts to be carried out with a therapist
1468386|NCT03208491|Other|usual care|usual care of patient
1468387|NCT03208478|Procedure|Adductor Canal perineural catheter placement|Patients will receive an Adductor Canal Block intervention for pain control following ACL reconstructive surgeries.
1468388|NCT03208478|Procedure|Femoral Nerve perineural catheter placement|Patients will have a Femoral perineural catheter placed for pain control following ACL reconstructive surgery.
1468389|NCT03208478|Device|Nimbus pump (Infutronix)|This is a FDA approved infusion device that is used in standard of care to store pain medication and to provide patients with continuous pain control medication at a set rate. This pump will be used for both the Adductor Canal and Femoral Nerve block participants.
1468390|NCT03208465|Drug|Empagliflozin|In empagliflozin group, patients will be prescribed empagliflozin 10mg/day.
1468391|NCT03208465|Drug|Sitagliptin|In sitagliptin group, patients will be prescribed sitagliptin 100mg/day.
1468392|NCT03208452|Drug|Magnesium Sulfate|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
1468393|NCT03208452|Drug|Normal saline|Comparing the effect of continuous infusion magnesium sulfate and normal saline in the occurrence of emergence agitation
1468394|NCT03208439|Device|lower-limb cycling system|patients will receive 30-minute cycling exercise
1468395|NCT03208426|Drug|Esomeprazole (S14)|Nexium, esomeprazole 40mg bid, 14 days
1468396|NCT03208426|Drug|Esomeprazole (BQ10)|Nexium, esomeprazole, 40mg bid for 10 days
1468397|NCT03208426|Drug|Amoxicillin (ST14)|Day 1-7 amoxicillin (Brand name: Amoxicillin Capsule) 1000mg bid for 7 days
1468699|NCT03206177|Drug|Paclitaxel|Paclitaxel 175 mg/m2 over 3 hours
1468398|NCT03208426|Drug|Clarithromycin (ST14)|Klaricid-XL, clarithromycin, 500mg, bid, for 7 days, (day 8-14)
1468399|NCT03208426|Drug|Metronidazole (ST14)|Flagyl, metronidazole, 500mg bid, for 7 days (day 8-14)
1468400|NCT03208426|Drug|dibismuth trioxide 120mg (BQ10)|KCB F.C. TABLETS, dibismuth trioxide 120mg qid for 10 days
1468401|NCT03208426|Drug|Metronidazole (BQ10)|Flagyl, metronidazole 500mg tid for 10 days
1468402|NCT03208426|Drug|tetracycline (BQ10)|Tetracycline (Brand name: Tetracycline Capsule ) 500mg qid for 10 days
1468403|NCT03208413|Drug|Thalidomide|Thalidomide with a dosage of 25 microgram at bedtime daily one week (days 1-7), then 50 microgram at bedtime daily for one week (days 8-14), then 75 microgram at bedtime daily for one week (days 15-21), then 100 microgram at bedtime daily for 12 weeks (days 22-106), in the absence of unacceptable toxicity or severe deterioration.
1468404|NCT03208400|Behavioral|virtual reality exposure|one-session exposure conveyed via virtual reality technology
1468405|NCT03208387|Diagnostic Test|Diffusion tensor imaging (DTI)|DTI quantifies the degree to which water diffuses in different directions through a given brain region. The use of DTI as an in vivo index of the integrity of white matter has been applied to many disease states using several proprietary and open-source software programs (e.g. FSL 5.0). DTI tractography, employed via toolboxes such as Probtrackx within the FSL 5.0, allows the identification of white matter tracts connecting cortical and subcortical regions of interest. Furthermore, structural connectivity as measured with DTI does not duplicate functional connectivity as measure with rs-fcMRI, but rather provides complimentary perspectives.
1468406|NCT03208387|Diagnostic Test|Resting state functional connectivity MRI (rs-fcMRI)|rs-fcMRI is a relatively new neuroimaging technique that has been applied to studying multiple clinical populations including ADHD, schizophrenia, major depressive disorder, and other neurological disorders. The approach exploits measurement of changes in brain blood oxygenation (BOLD) as is employed in task based functional MRI (measuring changes in focal cortical vascular oxygenation when engaged in a defined task, e.g. motor movement).
1468407|NCT03208387|Behavioral|Wechsler Intelligence Scale for Children - 5th edition (WISC-V)|Will gather IQ data and is the gold standard for IQ assessment for those between the ages of 6:0 and 16:11 years.
1468408|NCT03208387|Behavioral|California Verbal Learning Test (CVLT-C)|Validated measure of verbal learning and memory for those between the ages of 5:0 and 16:11.
1468409|NCT03208387|Behavioral|Beery Test of Visual Motor Integration 6th edition|Measure designed to assess visual-motor functioning of subjects between the ages of 2-99 years old by copying designs using paper and pencil.
1468410|NCT03208387|Behavioral|Grooved Pegboard|This is a standard assessment of fine motor functioning and dexterity by asking the subject to place metal pegs into holes on a board.
1468411|NCT03208387|Behavioral|PedsQL Multidimensional Fatigue Scale|Designed to measure fatigue in pediatric patients (ages 5-17 years) and is comprised of the General Fatigue Scale (6 items), Sleep/Rest Fatigue Scale (6 items) and Cognitive Fatigue Scale (6 items).
1468412|NCT03208387|Diagnostic Test|MRI|Images will be acquired on a 3.0 Tesla MRI scanner at each of the four study sites. At MSK, resting state fMRI data will be obtained using a 3T GE scanner with an 8-channel head coil (Discovery 750w DV25)
1468413|NCT03208374|Behavioral|Prior Exercise Behavior Questions - Harvard Health Professionals Exercise Questionnaire|Participants will be asked how often on average over the past year they participated in walking or hiking; jogging; running; calisthenics, aerobics, rowing, Nordic track; bicycling; tennis, squash, racquetball; lap swimming; weightlifting; and other aerobic exercise (e.g. heavy outdoor work), as well as their usual walking pace and flights of stairs climbed daily over the past 12 months prior to diagnosis.
1468414|NCT03208374|Behavioral|Current Exercise Behavior Questions: International Physical Activity Questionnaire Short Form (IPAQ SF)|The purpose of this questionnaire is to provide common instruments that can be used to obtain internationally comparable data on exercise exposure in adults aged 15 to 80 years old.
1468415|NCT03208361|Drug|Penicillin V|
1468416|NCT03208361|Drug|Amoxicillin|
1468417|NCT03208348|Other|Pilot Virtual Reality|Exposure to a virtual reality vignette with anxiety rating to support exposure therapy
1468418|NCT03208335|Drug|recombinant human endostatin|The cycles of rh-endostatin's treatment depends on the effect of reaction and tolerance.
1468420|NCT03208309|Drug|Diacerein|
1468421|NCT03208309|Drug|Placebo|
1468422|NCT03208296|Biological|ASN-002|ASN-002 has been designed for clinical applications, especially for intratumoral administration in the treatment of various cancers. This rAd vector delivers the gene of interest, in the case of ASN-002 the human IFNγ gene, into target cells. The rAd vector in ASN-002 is replication deficient and although it infects cells, it is not able to replicate in the tumor or in normal human cells. The infected cells are able to transcribe and translate the IFNγ DNA leading to a sustained local concentration of IFNγ in the tumor mass that is designed to avoid high levels of systemic IFNγ that may be lead to unacceptable toxicity.
1468423|NCT03208283|Diagnostic Test|Water method group|During the insertion phase of the initial 30 FS procedures, sterile water will be infused by a standard endoscopy water pump into the distal colon to allow passage of endoscope to ≥ 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Air insufflation will not be used during the insertion phase. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
1468424|NCT03208283|Diagnostic Test|Air insufflation group|During the insertion phase of the initial 30 FS procedures, air insufflation will be used to allow passage of endoscope to at least 50cm above anal verge (including rectum, sigmoid colon and part of descending colon), or to the limit of patient tolerance of an unsedated procedure. Trainees will be allowed 10 minutes for the insertion phase. The unassisted portion of the examination would be terminated if reasonable progress is not being attained, excessive patient discomfort observed, or the supervising endoscopist believes that patient safety may be compromised. During the withdrawal phase, air insufflation will be used in standard fashion for examination of the colonic mucosa.
1468425|NCT03208270|Drug|Antithrombin supplementation|antithrombin concentrate will be supplemented to maintain a functional antithrombin level between 80%-120%
1468426|NCT03208270|Drug|No antithrombin supplementation|"supplementation of antithrombin will not be provided unless heparin resistance occurs"
1468427|NCT03208257|Drug|Esmolol|Esmolol hydrochloride infusion
1468431|NCT03208218|Drug|SYP-1512|Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
1468432|NCT03208218|Drug|Revlimid cap|Lenalidomide 25mg/capsule, po, 1 capsule once daily for period I&II D1(crossover)
1468433|NCT03208205|Procedure|vitrectomy|Complete 23G PPV with scleral indentation was performed using Constellation system. Posterior vitreous detachment was induced very carefully by the cutter probe using aspiration. The peripheral vitreous was removed in all eyes with 360° of the vitreous base shaved under scleral indentation. After complete retinal attachment was achieved, endolaser photocoagulation was applied around the retinal break(s) as three to four rows of burns or/and cryopexy under HPFCL. Then a HPFCL/air/5000cst silicone oil exchange was performed. In one eye only HPFCL/air exchange was performed. Sclerotomies were sutured when needed with Vicryl 8.0 sutures.
1468434|NCT03208192|Procedure|liver transection during laparoscopic liver resection|liver transection during laparoscopic liver resection
1468435|NCT03208179|Drug|dihydroartemisinin-piperaquine|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin placebo
1468436|NCT03208179|Drug|sulphadoxine-pyrimethamine|Women randomised to this intervention will receive stat dose of 3 tablets of 500 mg sulphadoxine and 25 mg of pyrimethamine each (total dose of 1,500mg sulphadoxine and 75mg pyrimethamine) on a single day of clinic visit
1468437|NCT03208179|Drug|dihydroartemisinin-piperaquine plus azithromycin|Women randomised to this intervention will receive 3 day treatment dose of dihydroartemisinin-piperaquine by body weight plus azithromycin (500mg)
1468438|NCT03208166|Device|Doctormate|Ischemic conditioning device
1468439|NCT03208166|Other|Usual Care|Standard medical care
1468440|NCT03208153|Procedure|Invasive|Coronary angiogram and revascularization if anatomically feasible
1468441|NCT03208153|Procedure|Conservative|Conservative
1468442|NCT03208127|Drug|Combination treatment with Sofosbuvir and Velpatisvir fixed dose tablet|HCV Treatment for 12 Weeks
1468443|NCT03208114|Other|Receiving written information on breast milk substitute|Receiving written information on breast milk substitute
1468444|NCT03208101|Biological|DTP-HepB-IPV-Hib vaccine|Hexavalent vaccine (DTP-HepB-IPV-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Inactivated Poliovirus-Haemophilus influenzae type b vaccine)
1468445|NCT03208101|Biological|DTP-HepB-Hib vaccine & IPV|Pentavalent vaccine (DTP-HepB-Hib vaccine: Diphtheria-Tetanus-Pertussis-Hepatitis B-Haemophilus influenzae type b vaccine)+ IPV(Inactivated poliovirus vaccine)
1468449|NCT03206983|Device|Cana's Ring|The device is used during cataract surgery to help dilate small pupils (under 5mm)
1468450|NCT03206970|Drug|BGB-3111|BGB-3111 160 mg will be administered orally BID. Daily treatment with BGB-3111 may be continued for up to 3 years until disease progression, unacceptable toxicity or death, withdrawal of consent, lost to follow up, or study termination by sponsor.
1468451|NCT03208075|Other|normal diet|Diet containing 1500mg of phosphorus
1468452|NCT03208075|Other|low-phosphorus diet|Diet containing 500mg of phosphorus
1468453|NCT03208075|Other|high-phosphorus diet|Diet containing 2300mg of phosphorus
1468454|NCT03208062|Other|collection of waste materials|osteoarthritis of the hip or knee and rehabilitated in the institute; primary and secondary tumors of the skeleton; prosthetic examination as a result of plant infection
1468514|NCT03207607|Other|Oat snack|Isovolumetric (238.4g) gel snack with oats and maltodextrin (275.8kcal)
1468515|NCT03207607|Other|Coconut oil snack|Isovolumetric (238.4g) gel snack with coconut oil (276.4kcal)
1468516|NCT03207607|Other|Snack skipping|no snack
1468517|NCT03207594|Other|Survey|Subjects will be asked to complete a survey asking questions about his/her current health, well-being and quality of life.
1468455|NCT03208049|Behavioral|Sleep Restriction Therapy|Sleep Restriction Therapy will regulate the time you spend in bed on the basis of information collected about your sleep from sleep diaries during the evaluation and during treatment. Sleep restriction therapy is designed to improve your sleep quality by matching the opportunity you give yourself for sleep to the amount of average sleep ability you exhibit on your sleep diaries. Once the quality of your sleep has improved then then sleep quantity is gradually increased by slowly increasing your sleep opportunity. Sleep restriction therapy will also attempt to strengthen your bed sleep connection by focusing on what activities you engage in when you are awake in the middle of the night.
1468456|NCT03208049|Behavioral|Cognitive Therapy|Cognitive Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep. The treatment part of the study lasts six weeks. During the treatment, you will meet with the therapist for a total of six sessions: once per week for six consecutive weeks. Each session lasts approximately 60 minutes.
1468457|NCT03208036|Device|TDCS|1 mA of anodal stimulation will be applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training for 20 minutes
1468458|NCT03208036|Device|Sham Stimulation|Participants will receive 20 seconds of 1 mA anodal stimulation applied to the left dorsal lateral cortex (F3) concurrent with working memory focused cognitive training to mimic the effect of the active condition
1468459|NCT03208023|Procedure|RESIPI Management Strategy|a structured hemodynamic monitoring and treatment plan: RESIPI includes normalization of vascular resistance, correction of fluid responsiveness, and inotropy, and hemodynamic monitoring with the Starling SV (Cheetah Medical, Inc).
1468460|NCT03208023|Other|No intervention|No intervention
1468461|NCT03208010|Behavioral|Diabetes Prevention Intervention|"Educational sessions with emphasis on physical activity, healthy diets, and strategies to promote behavioral change.
Specific goals set for weight loss and physical activities
Fitbits provided for monitoring physical activity goals
Weekly review of and feedback on effects of physical activity (Fitbits) & dietary changes (checklists) will be held.
12 bi-weekly + 3 monthly support group sessions + 3 booster sessions every 6 months thereafter."
1468462|NCT03208010|Other|Enhanced Usual Care|"Monitoring by existing personal physicians
Feedback on lab results
Referrals to physicians, if needed
Diabetes prevention educational materials"
1468463|NCT03207997|Other|unenhanced MR sequences|2 additional unenhanced MR sequences
1468464|NCT03207984|Procedure|Root coverage surgery|Periodontal plastic surgery aiming the treatment of multiple gingival recessions in aesthetics areas with SCTG and MG
1468465|NCT03207971|Procedure|Root coverage treatment with subepithelial connective tissue graft|Periodontal plastic surgery aiming root coverage by palatal tissue graft removed from an area with predominance of lamina propria and predominance of submucosa.
1468467|NCT03207945|Drug|Alirocumab|Alirocumab (Sar236553/REG 727) is a fully humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), and is developed by Regeneron Pharmaceuticals/Sanofi.
1468468|NCT03207945|Other|Placebo|Placebo
1468470|NCT03207919|Behavioral|Lullaby Project|Pregnant women will participate in 3 group sessions. They will write and record a lullaby, and then listen to each recorded lullaby and reflect on their experience.
1468472|NCT03207893|Behavioral|GEM lifestyle modification & continuous glucose monitoring|Four treatment sessions of GEM lifestyle modification in 3 months and continuous glucose monitoring during the first 14 days of each of the 3 months.
1468473|NCT03207893|Other|Routine Care|Subject's current t2d treatment
1468474|NCT03207880|Device|Multi-level pregnancy test|Study participants will be instructed to perform a baseline MLPT immediately prior to administering the first dose of abortion medication and a second MLPT one week later to ascertain the follow-up hCG range. Any woman who obtains a stable or increasing hCG result, when comparing the baseline test result with the follow-up test result, will be instructed to contact safe2choose. Any woman who obtains a decrease in her hCG range, when comparing the baseline test result with the follow-up test result, will be informed that her abortion was a success and she is no longer pregnant.
1468475|NCT03207867|Drug|NIR178|NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.
1468476|NCT03207867|Drug|PDR001|PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
1468477|NCT03207854|Procedure|Biospecimen Collection|Undergo collection of peripheral blood, bone marrow, and tissue
1468478|NCT03207854|Other|Laboratory Biomarker Analysis|Correlative studies
1468479|NCT03207854|Other|Questionnaire Administration|Ancillary studies
1468480|NCT03207841|Other|LC/HP|Intervention group will receive 8 weeks of LC/HP diet. The daily LC-HP dietary intervention will include ~30% total energy as protein (1.6 g/kg per day) with a carbohydrate-to-protein ratio <1.5 and fat intake set at ~30% of the total energy intake.
1468481|NCT03207828|Behavioral|Behavioral activation|The Brief Behavioral Activation Treatment for Depression (Lejuez, Hopko, Acierno, Daughters, & Pagoto, 2011; Lejuez, Hopko, LePage, Hopko, and McNeil; 2001) will be used. It aims are (1) to increase engagement with activities associated with pleasure or mastery experiences; (2) decrease engagement with activities that maintain or increase the risk of depression; (3) and remove the barriers that limit the access to gratification. The sessions of therapy are well structured and described in its manual. The protocol was originally designed to be applied individually. However, for the present research, it will be adjusted to be applied in group sessions (5-8 participants). Materials will be also adjusted to be use with Chilean population. Treatment core aspects will not be altered. The treatment will last 10 sessions over two months. Two psychologist trained in behavioral activation will lead the sessions.
1468518|NCT03207594|Other|Saliva sample|Subjects will have saliva collected by a member of the study team using a cotton swab.
1468519|NCT03207594|Other|Smoking Status questions|Subjects will be asked to complete an assessment asking questions about his/her current smoking status
1468520|NCT03207594|Other|Health Services|Subjects will receive additional health services.
1468482|NCT03207828|Other|Usual care|Participants will be attended by a Medical Doctor that has a high level of expertise in fibromyalgia (rheumatologist or chronic pain specialist) at the Red Salud Christus, the most important private medical care network in Chile. In this clinic the protocol for the treatment of fibromyalgia includes administering pregabalin or gabapentin and pain killer (avoiding opioids). I addition, muscle relaxant such as cyclobenzaprine can be also administered to improve sleep quality. In a high proportion of cases (around 42%), antidepressant with analgesic properties, namely duloxetine, is prescribed. In addition, usual care includes derivation to psychiatrist if needed.
1468486|NCT03207802|Device|Discontinuation of using device|Subject will be instructed to discontinuation of use of device
1468487|NCT03207776|Other|Usual Care|Treatment of patients in the usual manner based on their diagnosis and resources available at that site.
1468488|NCT03207776|Other|COPD Clinical Pathway|A group of 4 Usual Care components that are applied consistently and completely amongst all patients who present with COPD acute exacerbation symptoms, plus access to navigator services.
1468489|NCT03207763|Device|Microneedle Formulation 1|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The total mass of excipients delivered by placebo microneedle patch will be <1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).
Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
1468490|NCT03207763|Device|Microneedle Formulation 2|"Microneedle patches will be made of solid conical structures made of water-soluble excipients that from the Food and Drug Administration's Generally Recognized as Safe (GRAS) list and/or on the FDA list of inactive ingredients in approved products. The ratio of the excipients and excipients used will vary slightly from Formulation 1. The total mass of excipients delivered by placebo microneedle patch will be <1.5 mg. The adhesive backing component is made from hypoallergenic material (commercial medical tapes designed to adhere to skin).
Microneedle patches will be administered topically by manual application to the skin. The sites of microneedle patch application will be cleaned with an alcohol swab and allowed to dry before the microneedle patch is applied. The microneedle patches will be packaged and provided as single patches."
1468491|NCT03207750|Biological|Rotarix®|Two doses administered orally according to a 0, 2 month schedule as per the immunization schedule for HRV vaccine administration in the US.
1468492|NCT03207750|Biological|Pediarix®|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
1468493|NCT03207750|Biological|Hiberix®|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
1468494|NCT03207750|Biological|Prevenar 13®|Three doses administered intramuscularly according to a 0, 2, 4 month schedule.
1468495|NCT03207737|Behavioral|MENTOR + Telehealth|Participants will live on campus for one week and complete the MENTOR program, which is a course about resilience and how nutrition, exercise and mindfulness help with resilience for individuals with a spinal cord injury. Different experts will cover the three main topics with lectures and application of knowledge through related activities. Participants will then begin a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
1468496|NCT03207737|Behavioral|Telehealth Only|Participants will complete a one-year telehealth program at home. The telehealth program will consist of readily available information focusing on nutrition, exercise and mindfulness for individuals with a spinal cord injury and a telehealth coach who will interact on the phone with the participants once every two weeks. This will continue for a total of 26 phone calls until the participant returns for 1-year follow-up testing.
1468497|NCT03207724|Drug|Xilonix plus Onivyde and 5FU|Xilonix by IV
1468498|NCT03207711|Behavioral|Carbohydrate-restricted diet|Education for carbohydrate-restricted diet
1468499|NCT03207711|Behavioral|Mindfulness|Mindful eating app-use and instruction
1468500|NCT03207698|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
1468501|NCT03207698|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
1468502|NCT03207698|Procedure|OFD with Platelet rich fibrin (PRF)+1% Metformin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
1468503|NCT03207685|Device|Additional Seizure Monitoring|Embrace could offer an additional layer of seizure monitoring
1468504|NCT03207672|Drug|E7389-LF|intravenous infusion
1468505|NCT03207659|Procedure|Retrograde Intrarenal Surgery|Treament of urinary stones by fragmentation of stone under direct vision through a scope and then actively extracting them in basketing or leaving them to pass spontaneously in dusting.
1468506|NCT03207646|Other|BrightHeart®|BrightHeart® has two components: smartphone mobile based application and a human coach. It is a combined approach of medication adherence, exercise, diet, sleep and stress reduction.
1468507|NCT03207633|Procedure|Repetitive trans-magnetic stimulation (rTMS) on DLPFC|Repetitive trans-magnetic stimulation (rTMS) on DLPFC
1468508|NCT03207633|Procedure|Repetitive trans-magnetic stimulation (rTMS) on OFC|Repetitive trans-magnetic stimulation (rTMS) on OFC
1468509|NCT03207633|Procedure|Sham repetitive trans-magnetic stimulation (rTMS)|Sham repetitive trans-magnetic stimulation (rTMS)
1468510|NCT03207620|Drug|Corticosteroid|Airway corticosteroid sensitivity will be assessed by change in pre-brochodilator FEV1 to two week trial of drug.
1468511|NCT03207607|Other|Control snack|Isovolumetric (238.4g) gel snack prepared by real fruits (186.2kcal)
1468512|NCT03207607|Other|Maltodextrin snack|Isovolumetric (238.4g) gel snack with maltodextrin (271.8kcal)
1468513|NCT03207607|Other|Whey protein snack|Isovolumetric (238.4g) gel snack with whey protein (201.8kcal)
1468522|NCT03207568|Device|Thoracic Endovascular Aortic Repair (TEVAR)|thoracic endovascular repair (TEVAR) with a thoracic stent-graft
1468523|NCT03207555|Drug|Ibrutinib|420 mg by mouth once daily.
1468524|NCT03207542|Drug|Daratumumab|16 mg/kg by vein weekly for the first 2 cycles (8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year of treatment whichever comes earlier.
1468525|NCT03207529|Drug|Alpelisib|"Dose Escalation Phase: Participants take Alpelisib at starting dose of 250 mg by mouth daily.
Dose Expansion Phase: If any specific molecular subtype or other signals such as PIK3CA status among responder patients are observed, 10 additional patients enrolled with that specific characteristic (e.g., TNBC patients only, or patients with PIK3CA H1047R mutation only) as an expansion cohort at RP2D. Participants take the maximum tolerated dose (MTD) of Alpelisib that was tolerated during Dose Escalation Phase. All 10 patients enrolled in the dose-expansion cohort receive one-week single agent treatment with Alpelisib."
1468526|NCT03207529|Drug|Enzalutamide|Dose Escalation and Expansion Phase: Enzalutamide taken at 160 mg fixed dose daily.
1468527|NCT03207516|Dietary Supplement|Sourdough --> Brewer's Yeast|Impact of bakery products with sourdough or brewer's yeast on digestive function
1468528|NCT03207516|Dietary Supplement|Brewer's Yeast --> Sourdough|Impact of bakery products with sourdough or brewer's yeast on digestive function
1468530|NCT03207490|Device|AMADEO|"Robot therapy: 1-Degrees-Of-Freedom (1DOFs) robot training for flexion and extention movements of the hand.
Standard rehabilitation therapy includes speech, physical, occupational therapies and group activities"
1468531|NCT03207477|Diagnostic Test|Visual acuity measurement|visual acuity measurement by Baby Vision cards at 18 months corrected age, by Rossano Weiss test at 4 years of age and optometric tests of Parinaud and Snellen at 7 years of age
1468532|NCT03207464|Drug|[C-11]Methylreboxetine|4 individuals with Multiple Sclerosis will undergo a [C-11]MRB PET scan and a MRI scan.
1468533|NCT03207451|Drug|Vorapaxar|Vorapaxar is the principle study drug and will be given to all subjects.
1468534|NCT03207451|Drug|Vorapaxar and Aspirin|Subjects in groups 3 will be on Aspirin when they begin Vorapaxar therapy.
1468535|NCT03207451|Drug|Vorapaxar and Clopidogrel|Subjects in groups 2 will be on Clopidogrel when they begin Vorapaxar therapy.
1468536|NCT03207451|Drug|Vorapaxar, Aspirin, and Clopidogrel|Subjects in groups 4 will be on both Aspirin and Clopidogrel when they begin Vorapaxar therapy.
1468537|NCT03207438|Drug|Quetiapine 50 MG Extended Release Oral Tablet|OD
1468538|NCT03207438|Drug|Quetiapine Fumarate XR 150-300 mg|Dose ranged from 150 to 300mg, XR preparation, OD
1468539|NCT03207438|Drug|Placebos|Placebo
1468540|NCT03207425|Drug|EDP 305|Each subject will receive a single dose of EDP 305 on Day 1.
1468541|NCT03207412|Biological|hAECs|human amniotic epithelial cells
1468542|NCT03207412|Procedure|Minimally invasive implantation|Minimally invasive implantation with ultrasound guidance
1468544|NCT03207386|Behavioral|Youth VIP|Youth VIP involves youth in partnerships with adults to adapt evidence based sexual violence prevention strategies for the local community environment. Youth VIP includes a three day intensive youth summit for prevention training and ongoing youth-adult prevention working groups.
1468545|NCT03207373|Diagnostic Test|Stress test (ECG)|Every study participant undergoes a standard diagnostic stress ECG
1468547|NCT03207347|Drug|Niraparib|Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.
1468548|NCT03207334|Drug|Midostaurin|"Induction Phase: 50 mg orally twice daily beginning on day 7 and ending 48 hours prior to beginning the consolidation phase
Consolidation Phase: 50 mg orally twice daily beginning on Day 6 and ending 48 hours prior to either the start of the next cycle or beginning conditioning therapy for allogenic stem cell transplant.
Maintenance Phase: 50 mg orally twice daily everyday"
1468549|NCT03207334|Drug|Cytarabine|"Induction Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients > 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1-6.
Consolidation Phase: 3 g/m2 (patients 18-65 years old) or 1 g/m2 (patients > 65 years old or those with co-morbidities precluding a higher dose) by vein over 3 hours every 12 hours on Days 1, 3, and 5 of each cycle."
1468550|NCT03207321|Dietary Supplement|Upma|A balanced protein-calorie supplement - made from locally available corn-soya ingredients and called 'upma'.
1468551|NCT03207308|Dietary Supplement|Vitamin A supplementation|200,000 IU of preformed vitamin A
1468552|NCT03207295|Drug|Nesiritide|A standard dose of study drug was administered by a continuous infusion for ≥24 hours and ≤7 days after cardiac intensive care unit admission
1468553|NCT03207295|Drug|Normal saline|Normal saline(2ml/h) is administered by a continuous infusion for ≥24 hours and ≤7 admission days after cardiac intensive care unit in postoperative children
1468554|NCT03207269|Other|Dietary|Diet will be manipulated by providing different bedtime snacks within an otherwise isocaloric diet.
1468555|NCT03207256|Drug|TGR-1202|Oral Daily TGR-1202
1468556|NCT03207256|Drug|TGR-1202 + Ublituximab|Oral Daily TGR-1202 + Ublituximab IV Administration
1468557|NCT03207243|Drug|GSK3772847|GSK3772847 10 mg/kg will be administered as IV infusion once every 4 weeks to randomized subjects.
1468558|NCT03207243|Drug|Placebo|Placebo sterile normal saline will be administered as IV infusion once every 4 weeks to randomized subjects.
1468559|NCT03207243|Drug|Fluticasone propionate/salmeterol|FP/Sal 500/50 mcg will be administered via inhalation route twice daily to all subjects.
1468560|NCT03207243|Drug|Fluticasone propionate|FP 500, 250, 100 or 50 mcg will be administered via inhalation route twice daily to all subjects.
1468561|NCT03207230|Device|Cardea SOLO|Participants will be asked to wear everyday for 7 days after the Baseline visit. the monitor attaches to the skin with adhesive and records heart rate and heart rhythm.
1468786|NCT03205475|Behavioral|Video Feedback Only Phase 2|Receive video feedback and calls only
1468562|NCT03207230|Device|ActiGraph wGT3X-BT|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable tracks activity and the step count during the day.
1468563|NCT03207230|Device|Wavelet Wristband|Participants will be asked to wear everyday for 2 weeks after the Baseline visit. The wearable measures the activity and the heart rate as measured by PPG sensor.
1468564|NCT03207217|Other|Web-based training Product|A series of 4 modules to train providers to more effectively manage patients who screen positive for risk of suicide. The modules are: Risk Assessment, Safety Planning, Access to Lethal Means, and Willingness to accept referral.
1468565|NCT03207204|Procedure|35% Hydrogen peroxide bleaching|Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
1468566|NCT03207204|Procedure|30% Carbamide peroxide bleaching|Protocol: Application of 35% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions.
1468567|NCT03207204|Procedure|Violet LED bleaching 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
1468568|NCT03207204|Procedure|Violet LED bleaching 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 2 times a week.
1468569|NCT03207204|Procedure|Photochemical protocol 1|Protocol: Application of 35% hydrogen peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
1468570|NCT03207204|Procedure|Photochemical protocol 2|Protocol: Application of 30% Carbamide peroxide on buccal face of anterior teeth (15-25). The application will be performed according to the manufacturer's instructions and associated with the application of Violet LED with a distance of 8mm between the light source and teeth surface. The application of Violet LED will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. The procedure will be performed 1 time a week.
1468571|NCT03207204|Procedure|Hybrid technique 1|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 35% Hydrogen peroxide to act concomitantly with the light.
1468572|NCT03207204|Procedure|Hybrid technique 2|Protocol: Application of the Violet LED on buccal face of anterior teeth (15-25) with a distance of 8mm between the light source and teeth surface. The application will be performed for 60s, and then turned off for 30s. It will be repeated for 20x. In the last 10 illuminations of Violet LED it will be applied the 30% Carbamide peroxide to act concomitantly with the light.
1468573|NCT03207191|Drug|F16IL2|F16IL2 dose escalation with provisional doses of 10, 20 and 30 Mio IU on Day 1, 8, 15 and 22 of each cycle through a rate-controlled intravenous infusion of 3 hours
1468574|NCT03207191|Drug|BI 836858|BI 836858 dose escalation with provisional doses of 10, 20, 40, 80 and 160 mg on days 3, 10, 17 and 24 of each cycle through a rate-controlled intravenous infusion up to 5 hours
1468575|NCT03207178|Biological|Mixed CD19/CD20 CAR-T Transfer|Autologous CD19 CAR-T cells and CD20 CAR-T cells with average 1-5*10^6 cells/kg body weight,separately.
1468576|NCT03207165|Drug|Milrinone|Patients will be initiated on Milrinone at 0.125 mcg/kg/min [stage 1] and will be titrated according to a blinded protocol from stages 2 to 5 [0.250, 0.375, 0.5 and >0.5 ug/kg/min]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be [increased/decreased/maintained] at stage [1-5]' so as to ensure that treating physicians remain blinded to the allocated drug.
1468577|NCT03207165|Drug|Dobutamine|Patients will be initiated on Dobutamine at 2.5 mcg/kg/min [stage 1] and will be titrated according to a blinded protocol from stages 2 to 5 [5.0, 7.5, 10 and >10 ug/kg/min]. All orders to initiate and titrate the dose of the allocated inotrope will be written in the chart as follows: 'Study inotrope dose to be [increased/decreased/maintained] at stage [1-5]' so as to ensure that treating physicians remain blinded to the allocated drug.
1468578|NCT03207152|Biological|Influenza A/California/04/09|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
1468579|NCT03207139|Drug|Ga-68 PSMA ligand|"For PET/CT PSMA ligand scan, the subject will have catheter(s) placed for intravenous administration of [68Ga]PSMA ligand . Subjects will receive a single intravenous bolus of 2-5 mCi [68Ga]PSMA ligand and received PET/CT scan 60 minutes later. The data acquisition begin with non-contrast CT at 120kVp, automated mAs, and a pitch of 1.5, followed by PET acquisition from the mid-thigh to skull-base, 3 minutes each bed. After image acquisition, the subject will be observed for half an hour, and will be discharged if no adverse event happens.
The estimated organ doses show that the kidneys and the urinary bladder wall were the organs with the highest dose. As presented, the effective doses for patients were 0.023 mSv/MBq ± 15% (maximum deviation), leading to an effective dose of 3.4 mSv for an injected activity of 150 MBq."
1468580|NCT03207126|Diagnostic Test|Ultrasound guided biopsy|For women needed a hysteroscopy guided biopsy as part of routine standard of care, women will now receive an ultrasound guided biopsy first
1468582|NCT03207100|Behavioral|Analgosedation|Patinets will receive analgesia-based sedation，in which remifentanil is administrated（bolus does 0.2μg/kg，administration time＞60s；infusions 0.05μg/kg/min）firstly and titrated to the target level （Nonverbal Pain Assessment Tool：0-1；Richmond Agitation-Sedation Scale：-2-+1）. If the patient still seemed uncomfortable after the treatment，the patient will be seated with dexmedetomidine（0.1-0.6μg/kg/h）.
1468583|NCT03207100|Behavioral|Procedural pain relief|Patients will receive an intravenous bolus of remifentanil（bolus 20μg every 3min until the painful procedure is finished） ordered by the attending physician for procedural pain relief during routine clinical practice.
1468787|NCT03205462|Drug|Fluorothyazinone 300 mg|Fluorothyazinone in a dosage of 300 mg (1 tablet)
1468584|NCT03207087|Device|WEB Aneurysm Embolization|Subjects will be screened for study eligibility after giving informed consent. The WEB embolization procedure will be performed in the catheterization room using standard angiographic techniques.
1468585|NCT03207074|Diagnostic Test|iKnife i.e. Rapid Evaporative Ionisation Mass Spectrometry|The endometrial tissue will be analysed by this new technology and compared to gold standard (histopathology)
1468586|NCT03207061|Diagnostic Test|3D Ultrasound|A 3D ultrasound will be performed for all patients presenting to the clinic for suspected endometrial cancer (in addition to routine standard of care)
1468587|NCT03207048|Device|Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 3-second trains with a 15-second inter-train interval, for 50 trains per session
1468588|NCT03207048|Device|Sham repetitive transcranial magnetic stimulation|Sham Transcranial Magnetic Stimulation
1468589|NCT03207035|Procedure|Axillary brachial plexus block|Ultrasound guided axillary brachial plexus block with local anaesthetic lidocaine with epinephrine
1468590|NCT03207022|Procedure|axillary brachial plexus block|ultrasound guided axillary brachial plexus block with 20 ml local anaesthetic lidocaine with epinephrine and clonidine
1468591|NCT03207009|Genetic|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
1468597|NCT03206944|Drug|acetylsalicylic acid|Group 1(ASA) included 33 patients who received acetylsalicylic acid at a dose of 75 mg in the morning
1468598|NCT03206944|Drug|Tomato Fruit Extract|Group 2 (STE) included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a dose of 213 mg orally in the morning
1468599|NCT03206931|Drug|LOXO-195|Open-label expanded access
1468600|NCT03206918|Drug|BGB-3111|BGB-3111 160 mg (two - 80 mg white opaque capsules) PO BID
1468601|NCT03206905|Procedure|Endoscopic Sleeve Gastroplasty|endoscopic, rather than surgical approach, to perform sleeve gastroplasty
1468602|NCT03206905|Behavioral|Diet and Exercise|nutritional/exercise counseling
1468603|NCT03206892|Device|laparoscopic ovarian drilling|laparoscopic ovarian drilling for polycystic ovary syndrome in infertile women comparing LESS surgery to conventional multiport laparoscopy
1468604|NCT03206866|Diagnostic Test|serum regucalcin antibody|serum regucalcin antibody
1468605|NCT03206853|Procedure|Hybrid Operating Techniques|It is a cooperation of existing endovascular interventional techniques and microsurgical techniques. Different from traditional management, hybrid operating techniques make it possible for 2 existing techniques conducting simultaneously in a hybrid operating theater. It optimizes the traditional microsurgical techniques for complex intracranial aneurysms and avoids the transportation of patients and the risks of intervals between stages in traditional ones. It includes balloon-assisted parental arterial occlusion, one-stage aneurysm clipping/wrapping/isolation and embolization/diverter implantation, etc.
1468607|NCT03206827|Other|70% animal, 30% plant proteins in diet|Diet contains 70% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 30% from plant sources (bread and cereals).
1468608|NCT03206827|Other|50% animal, 50% plant proteins in diet|Diet contains 50% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 50% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
1468609|NCT03206827|Other|30% animal, 70% plant proteins in diet|Diet contains 30% of proteins from animal sources (beef, pork, chicken, dairy products, fish) and 70% from plant sources (bread and cereals, legumes, nuts, seeds, soy products).
1468610|NCT03206814|Other|Usual care|Antihypertensive therapy is adjusted every 3 months on the basis of office blood pressure values.
1468611|NCT03206814|Other|POST-strategy|Antihypertensive therapy is adjusted every 15 days on the basis of home blood pressure values.
1468612|NCT03206801|Procedure|Kidney transplant biopsy|Elevated urine CXCL10 will trigger a study biopsy in patients randomized to the intervention arm. Subclinical rejection will be treated per protocol.
1468613|NCT03206788|Drug|Losartan|50 or 100 mg of losartan twice daily for 12 weeks, based on participant's weight.
1468614|NCT03206788|Drug|placebo|matching placebo twice daily for 12 weeks
1468615|NCT03206775|Behavioral|Cognitive Assessments|Participants will participate in up to 6 assessments in 4 domains of cognition: Processing Speed; Executive Attention; Learning and Memory; and Social Cognition.
1468616|NCT03206762|Device|Jetstream Atherectomy with randomization to the Ranger DCB Arm or the POBA+DCB Arm|Jetstream Atherectomy with randomization to the Ranger DCB Arm or the POBA+DCB Arm
1468617|NCT03206749|Drug|VX-150|Administered orally every 12 hours (q12h) for 2 days.
1468618|NCT03206749|Drug|hydrocodone bitartrate/acetaminophen (HB/APAP)|Administered orally every 6 hours (q6h) for 2 days
1468619|NCT03206749|Drug|Placebo|"Placebo matched to VX-150 orally q12h for 2 days.
Placebo matched to HB/APAP orally q6h for 2 days."
1468620|NCT03206736|Other|Loop DS surgery|these patients will receive a loop DS bariatric procedure
1468700|NCT03206177|Drug|Carboplatin|IV day 1 Carboplatin AUC 6* over 1 hour (or 5* if no prior radiation therapy)
1573921|NCT02427243|Drug|Crenezumab|
1468621|NCT03206723|Device|Bandage contact lens|"Bandage contact lenses (BCL) have the advantage of pain reduction, facilitating epithelial healing, and improved surface healing. They have been used in the ophthalmology community to treat post-operative eye pain due to the large corneal abrasion created during Excimer photorefractive keratectomy (PRK), laser in situ keratomileusis (LASIK), and radial keratotomy (RK) with good success.
Bandage contact lenses have also been used in studies in Europe through ophthalmology clinics to treat traumatic corneal abrasions with excellent results. A British study from 1987, found that large diameter contact lenses can be fitted satisfactorily without the use of special equipment such as keratometry. Studies in rabbits have also been performed showing improved rates of healing when using bandage contact lenses. BCLs have been used to treat epithelial defects from various causes for up to 7 months at a time."
1468622|NCT03206723|Drug|Eyedrop|Fluoroquinolone eyedrops 4x/day
1468623|NCT03206723|Drug|Hydrocodone|Hydrocone 1-2 tabs 4x/day if needed
1468624|NCT03206710|Other|No current intervention|This is a follow-up of two randomized trials. No active intervention is being given in the follow-up
1468625|NCT03206697|Other|Mitochondrial DNA content and metabolic parameters|Analyze the correlation between the mitochondrial DNA content and metabolic parameters.
1468626|NCT03206684|Drug|PEG-rhG-CSF|PEG-rhG-CSF single-dose was administered subcutaneously 48h after chemotherapy，weight ≥ 45kg were given 6mg once per chemotherapy cycle, weight <45kg were given 3mg once per chemotherapy cycle.
1468627|NCT03206684|Drug|rhG-CSF|rhG-CSF was administered subcutaneously 48h after chemotherapy，weight≥45kg were given 300μg/d, weight<45kg were given 150μg/d,continuous injection for 3-5 days until the absolute neutrophils count≥2×10^9/L.
1468628|NCT03206671|Drug|Rituximab window|Rituximab window (375 mg/m²)
1468629|NCT03206671|Drug|Additional doses of Rituximab|2 doses of Rituximab (375 mg/m²) before the start of the first chemotherapy cycle, 2 doses of Rituximab before the start of the second chemotherapy cycle, 1 dose of rituximab before the start of the third chemotherapy cycle, 1 dose of Rituximab before the start of the forth chemotherapy cycle
1468630|NCT03206671|Drug|Cyclophosphamide|see detailed protocol description
1468631|NCT03206671|Drug|Cytarabine|see detailed protocol description
1468632|NCT03206671|Drug|Dexamethasone|see detailed protocol description
1468633|NCT03206671|Drug|Doxorubicin hydrochloride|see detailed protocol description
1468634|NCT03206671|Drug|Vindesine Sulfate|see detailed protocol description
1468635|NCT03206671|Drug|Etoposide|see detailed protocol description
1468636|NCT03206671|Drug|Ifosfamide|see detailed protocol description
1468637|NCT03206671|Drug|Methotrexate|see detailed protocol description
1468638|NCT03206671|Drug|Prednisolone|see detailed protocol description
1468639|NCT03206671|Drug|Vincristine|see detailed protocol description
1468640|NCT03206658|Drug|Spironolactone 25 mg|A dose of 25 mg of spironolactone will be administered orally or through the nasogastric /nasoenteral tube to the patients every 24 hours, at 8-9 am.
1468641|NCT03206658|Drug|Placebo oral capsule|The contents of a placebo capsule will be administered orally or through the nasogastric / nasoenteral tube to the patients every 24 hours, at 8-9 am.
1468642|NCT03206645|Drug|PTC596|PTC596 will be given in combination with carboplatin and paclitaxel for up to 5 cycles depending on which cohort the patient is in.
1468645|NCT03206619|Other|Social, Local and Mobile|Patients in a smoking cessation program will use a mobile application to receive messages and rate them from their smartphones. The messages patient will receive belong to one of the following five topics: general motivation, diet tips, physical exercise tips, personal performance, and the benefits of being a non-smoker. For each one of these topics, there will be a pool of 150 different messages with tailored information for the patient. Topics and messages were approved by a smoking cessation psychologist and a pulmonologist. The selection of the time the messages have to be sent, and the message topic is selected by an health recommender system algorithm based on the patients' user profile (demographic information, message rating information, and app interaction information).
1468646|NCT03206606|Device|SPIRO|Participants in the Experimental Group will be asked to use SPIRO mobile application during a period of 4 months.
1468647|NCT03206580|Other|Concentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
1468648|NCT03206580|Other|Concentric-Eccentric training|Subjects will be submitted to 8 weeks (16 sessions) of a concentric-eccentric training for knee flexors and knee extensors. This training will be performed in an isokinetic dynamometer at 70% of the subject's maximal voluntary isometric contraction.
1468649|NCT03206567|Dietary Supplement|Nutrafol Supplement capsules|NUTRAFOL's Synergen Complex® is a patent-pending formulation of botanicals with potent anti-inflammatory, anti-stress adaptogenic, antioxidant and DHT-inhibiting properties - combined to synergistically combat the multiple underlying factors that compromise hair growth and health. Some patented ingredients include Sensoril Ashwagandha, BCM-95 BioCurcumin, USPlus Saw Palmetto, EVNolMax 20% Tocotrienol/Tocopherol complex, Bioperine (piperine), Cynatine HNS (solubilized keratin), and Capsimax (capsaicin), all of which are standardized and clinically tested. the Nutrafol supplement capsules are compared to the placebo capsules which contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
1468650|NCT03206567|Other|Placebo capsules|The placebo capsules contain no active ingredients. Four (4) capsules are taken by mouth once daily with a substantial meal.
1468651|NCT03206554|Drug|Ropivacaine|Large volume local anaesthetic intraarticularly
1468652|NCT03206554|Other|Saline|sham injection
1468653|NCT03206528|Device|Vital Signs Monitoring System|The VSMS will be adhered to each enrolled patient for the entire hospitalization period.
1468654|NCT03206515|Device|18F Peel-Way Sheath|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F peel-way sheath
1468655|NCT03206515|Device|18F access sheath with a suction-evacuation function|Patients undergoing Mini Percutaneous Nephrolithotomy with The 18F access sheath with a suction-evacuation function
1468656|NCT03206489|Device|noninvasive high-frequency ventilation (nHFOV)|noninvasive high-frequency ventilation (nHFOV) as a primary mode of ventilation in one of the preterm twins infants with respiratory distress syndrome
1468657|NCT03206489|Device|nasal continuous positive airway pressure (nCPAP)|nasal continuous positive airway pressure (nCPAP) as a primary mode of ventilation in another of the preterm twins infants with respiratory distress syndrome
1468658|NCT03206476|Behavioral|Nutritional intervention based on the SCT and the TM|Nutritional workshop based on the Cognitive Social Theory and the Transtheorical Model: twelve group sessions (one per week) lasting 40 minutes each, aimed at adolescents; With delivery of printed material to work at home (workbook); And two sessions (every month and a half) addressed to parents.
1468659|NCT03206476|Behavioral|Nutritional information|Three informative sessions of 25 minutes (one each month) on healthy eating habits and delivery of educational material to adolescents.
1468660|NCT03206463|Drug|4 mg Delta-9-THC|Subject will have 1/3 chance of receiving 4 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
1468661|NCT03206463|Drug|Placebo|Subject will have 1/3 chance of receiving the inhaled placebo condition administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing. The placebo condition will include no active cannabinoids.
1468662|NCT03206463|Drug|2 mg Delta-9-THC|Subject will have 1/3 chance of receiving 2 mg THC administered through a vaporizer, over approximately 20 minutes, followed by approximately 45 minutes of neuropsychological and physiological testing.
1948327|NCT02481674|Drug|VX15/2503|VX15/2503 is a humanized IgG4 monoclonal antibody and will be administered intravenously at a dose of 20 mg/kg. The antibody is formulated at 20 mg/mL in 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
1948328|NCT02481674|Drug|Placebo|Placebo consists of formulation buffer only which is 20 mM Sodium Acetate buffer, pH 5.4, containing 130 mM Sodium Chloride and 0.02% Polysorbate 80.
1468668|NCT03206411|Diagnostic Test|Renal and liver function tests , ECG , Sex Hormones Profile|Renal Function tests as creatinine , Uric Acid , Blood urea. Liver Function tests as AST , ALT, ALP ECG (Electrocardiogram recording) SEX hormones as LH , FSH , and Testosterone
1468669|NCT03206398|Device|anti-gravity treadmill|anti-gravity treadmill for a total of 40 days in addition to physiotherapy
1468670|NCT03206385|Radiation|Radiation treatment|50 Gy will be delivered in the PTV 1 and 60 Gy in the PTV 2 simultaneously in 28 fractions (5 fractions a week) in no more than 40 days. Anytime, 95% of the prescribed dose will have to cover at least 90% of the PTV 1 and PTV 2.
1468671|NCT03206385|Radiation|CK Boost Pelvis|Two high CyberKnife dose sessions will deliver a pelvic boost of 6.5 Gy each to the initial GTV or eventually to the residual GTV in case of too close vicinity of the OAR
1468674|NCT03206346|Drug|Ingavirin|Ingavirin ( Imidazolyl ethanamide pentandioic acid) capsules, 60 mg once daily, regardless of meal, for 5 days.
1468675|NCT03206346|Drug|Placebo oral capsule|Placebo, capsules daily for 5 days.
1468676|NCT03206320|Drug|Lidocaine Topical|Comparison of lidocaine topical gel with lidocaine infiltration and with no local anesthesia in reducing needle insertion and injection pain
1468677|NCT03206294|Other|pharmacist assessment|St Joseph Hospital pharmacist assess every diabetic patient hospitalized in cardiology service in term of antidiabetic treatment during the hospitalization
1468678|NCT03206281|Diagnostic Test|Fetal wight estimation|We will estimate the fetal weight by sonographic and clinical estimation
1468679|NCT03206268|Device|SD-OCT and SLP using GDx variable corneal compensation|RNFL thickness measurements obtained using SD-OCT and SLP using GDx variable corneal compensation
1468680|NCT03206255|Procedure|3 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
1468681|NCT03206255|Procedure|2 doses of HPV 16/18 bivalent vaccine|Participants have received 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
1468682|NCT03206242|Other|Physiotherapy|Interventions of physical therapy will be implemented after reconstructive surgery including edema control, scar management, pain management, respiration training, oral function training, neck and shoulder function training, donor site mobility training.
1468683|NCT03206229|Drug|PEG-rhG-CSF|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
1468684|NCT03206229|Drug|Neulasta (PEG-rhG-CSF)|PEG-rhG-CSF is going to be administered 2 mg/0.2 ml subcutaneously single dose in each study period as per the randomization schedule
1468685|NCT03206216|Diagnostic Test|Peripheral Nerve Stimulation|Undergo DLss test
1468686|NCT03206216|Other|Questionnaire Administration|Ancillary studies
1468687|NCT03206203|Drug|Atezolizumab|Given by vein
1468688|NCT03206203|Drug|Carboplatin|Given by vein
1468689|NCT03206203|Other|Laboratory Biomarker|Correlative study
1468690|NCT03206203|Other|Quality-of-Life Assessment|Ancillary studies
1468691|NCT03206190|Other|SPRS Score and clinical signs|Patients will clinically characterized by using the SPRS Score and the inventory V3
1468692|NCT03206190|Behavioral|Cognition Testing using CANTAB|Patients will be tested using the CANTAB
1468693|NCT03206190|Diagnostic Test|Lumbar Puncture and blood draw|Biomaterial will be collected (not obligate) to compare e.g. Nfl levels in serum and CSF
1468694|NCT03206190|Diagnostic Test|MRI|MRI will be used to reveal presymptomatic brain morphology changes (not obligate)
1468695|NCT03206190|Diagnostic Test|Electrophysiology|Electrophysiological tests will be used to characterize patients better.
1468696|NCT03206190|Diagnostic Test|Testing functional performance|By using the 3 minute walk, 5 stair-climb test, and 10m walking test we will try to identify and measure subclinical progression prior to disease onset
1468697|NCT03206190|Diagnostic Test|Non motor symptoms|By using a number of different tests we try to identify other non-motor symptoms which might manifest prior to disease onset.
1468698|NCT03206177|Drug|Galunisertib|Galunisertib 150mg po BID day 4-17.)
1468701|NCT03206164|Other|Asynchronous, eLearning Intervention|20 CBOs with 3-member team (n= 30) will be recruited and placed into either the experimental or the comparison group.
1468706|NCT03206138|Biological|GX-188E, GX-I7|Experimental: 1mg of GX-188E administered IM using EP device 3 times and 3mg of GX-I7 administered in cervix 4 times.
1468707|NCT03206138|Biological|GX-188E, Imiquimod|1mg of GX-188E administered IM using EP device 3 times and 12.5mg of Imiquimod application at cervix 8 times.
1468708|NCT03206112|Other|PAS25-cTBS150|PAS pairs TMS with peripheral nerve stimulation. PAS has the same risk as single-pulse TMS and is a safe procedure that has been used on thousands of participants worldwide. TBS is a special form of patterned TMS. TBS has more than minimal risk.
1948336|NCT02476838|Procedure|Hand Transplantation|microvascular VCA transplant
1948337|NCT02472964|Biological|Trastuzumab|Trastuzumab 8mg/kg Iv over 90 minutes x 1 then Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
1948338|NCT02472964|Biological|HERMyl 1401O Trastuzumab|HERMyl 1401O Trastuzumab 8mg/kg Iv over 90 minutes x 1 then HERMyl 1401O Trastuzumab 6 mg/kg IV over 30 minutes every 3 weeks
1948339|NCT02472964|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV over 60 minutes weekly.
1948340|NCT02472964|Drug|Docetaxel|Docetaxel 75mg/m2 IV over 60 minutes on day 1 of a 3 week cycle
1948341|NCT02472067|Behavioral|Psychologically - Based Physical Therapy|Psychologically - Based Physical Therapy targeting risk factors for disability.
1468722|NCT03206034|Behavioral|Stylistic Memory Enhancement|
1468723|NCT03206021|Drug|5 Azacytidine|Dose escalation of carboplatin combined with 5'azacytidine
1468724|NCT03206008|Drug|Magnesium Sulfate|
1468725|NCT03206008|Drug|Normal saline|Placebo
1468726|NCT03205995|Biological|OMS721|Intravenous loading dose followed by daily subcutaneous injections
1468727|NCT03205982|Device|Wise app with medication adherence reminders|The Intervention group will receive the Wise app that delivers medication adherence reminders.
1468728|NCT03205982|Device|Wise app with fitness reminders|The control group will receive the Wise app with fitness reminders
1468729|NCT03205969|Device|Functional mobile game|Functional mobile game for chemotherapy side effect education
1468730|NCT03205956|Drug|Levodopa|"At least 1 hour after 200mg carbidopa p.o., each subject will receive an intravenous solution of levodopa in saline at a rate based on age and body mass according to the final dose described in Black et al 2003.The total dose for a 70-year-old, 70kg subject will be approximately 60mg.
Subjects with untreated PD will then take 6 ± 1 weeks of clinically dosed oral carbidopa-levodopa tablets for clinical purposes and then repeat the carbidopa plus intravenous levodopa dose as above."
1468731|NCT03205930|Biological|Neo-MASCT|The end product of Neo - MASCT technology is DC and CTL cells.DC injection,in each treatment cycle day 8, axillary, inguinal lymph node with subcutaneous injection. CTL cells， in every treatment cycle 21-28 days.
1468732|NCT03205917|Biological|PGDM1400/Placebo - 3mg/mL IV|3/1 (6/2 if DLT); 3mg/mL IV
1468733|NCT03205917|Biological|PGDM1400/Placebo - 310mg/mL IV|3/1 (6/2 if DLT); 10mg/mL IV
1468734|NCT03205917|Biological|PGDM1400/Placebo -30mg/mL IV|3/1 (6/2 if DLT); 30mg/mL IV
1468735|NCT03205917|Biological|PGDM1400 + PGT121/Placebo - 3mg/mL + 3mg/mL IV|3/1 (6/2 if DLT); 3mg/mL + 3mg/mL IV
1468736|NCT03205917|Biological|PGDM1400 + PGT121/Placebo - 10mg/mL + 10mg/mL IV|3/1 (6/2 if DLT); 10mg/mL + 10mg/mL IV
1468737|NCT03205917|Biological|PGDM1400 + PGT121/Placebo - 30mg/mL + 30mg/mL IV|3/1 (6/2 if DLT); 30mg/mL + 30mg/mL IV
1468738|NCT03205917|Biological|PGDM1400|6 (max 18); MTD IV
1468739|NCT03205917|Biological|PGDM1400+PGT121|6 (max 18); MTD IV
1468740|NCT03205904|Dietary Supplement|Diet|Nutrition booklet with guidelines on types of fats and glycemic index
1468741|NCT03205891|Drug|Brentuximab Vedotin|1.8 mg/kg by vein on Day 1 per cycle by vein over about 30 minutes on Day 1 of each cycle.
1468742|NCT03205891|Drug|TAK228|Starting Dose and Schedule of TAK228: 2 mg by mouth, 5 days on and 2 days off per week with repeated weekly cycles. The study doctor will tell participant how often to take the study drug.
1468743|NCT03205891|Device|Glucose Monitor|Participant monitors glucose (sugar) levels at home with a glucose monitor during the first 2 months participant is taking the study drug.
1468744|NCT03205878|Other|Telecoaching|"Patients in the intervention arm will receive a step counter and a cell phone with an app on which the amount of steps are daily sent to.
Initial targets on steps per day will be discussed with the patient after an activity monitoring before the telecoaching procedure. Dependent whether the patient reaches his/her proposed goal each week, new goals are set."
1468745|NCT03205878|Device|CPAP|Patients will receive CPAP according to standard care
1468746|NCT03205852|Other|questionnaire|fulfillment of questionnaire
1468747|NCT03205839|Behavioral|Acceptance-based self-help intervention|"Surviving to Thriving: ACT self-help for living well with a visible difference in appearance.
A self-help booklet, based upon Acceptance and Commitment Therapy (ACT). The booklet includes some ACT techniques and encourages participants to set themselves behavioural tasks, based upon their values. There is a suggested timetable for participants to navigate through the self-help during the four-week intervention period.
In addition to the pdf booklet, there are accompanying audio exercises and a lived experience video."
1468748|NCT03205826|Other|Type of sedation used|All patients will undergo two subsequent Chartis measurements. The first measurement will be performed with the patient undergoing conscious sedation and the second measurement with the patient under general anesthesia.
1468750|NCT03205787|Dietary Supplement|Trifolium pratense|Red Clover extract standardized to isoflavone content.
1468751|NCT03205774|Behavioral|6 hours fasting and free oral intake of water|Ultrasound examination of the gastric antrum are performed in volunteers after prolonged fasting and 10 min after oral intake of water. Volunteer should be lying on his/her back, right lateral decubitus position and left lateral decubitus position with randomization of the order.
1468752|NCT03205761|Drug|Olaparib|see information in arm description
1468753|NCT03205735|Diagnostic Test|lymphocyte DPD dosage|lymphocyte DPD dosage in peripheral blood
1468754|NCT03205722|Other|Non-Interventional|Non-Interventional
1468758|NCT03205683|Other|Intraneural facilitation (INF)|INF is a novel non-invasive therapy based on the principle of restoring vascular function at the capillary level in peripheral nerve.
1468759|NCT03205683|Other|Sham INF|Will be performed by a different therapist than actual INF. The patient will be asked to do the following combination of passive range of motion (PROM) and active ROM activities to promote blood flow in the affected arm.
1468760|NCT03205670|Procedure|Urethroplasty with a tissue-engineered construct|The investigators will perform urethroplasty with the tissue-engineered construct - epithelial cells isolated from patient's buccal mucosa and seeded on a collagen-polylactoglycolide matrix.
1468761|NCT03205657|Procedure|auto transplant followed by allo transplant|patients who got MAC conditioning with auto SCT followed by RIC followed by alloSCT for mature B-NHL
1468762|NCT03205631|Other|Natural Frequency Patch|Participants will receive in randomized order the differing patches to wear during three nights separated by a washout period of 3-4 nights
1948342|NCT02471664|Device|Mitral Loop Cerclage Annuloplasty|
1468766|NCT03205592|Diagnostic Test|Ultrasound examination of the antrum|Ultrasound assessment of gastric content will be performed : prior to suction of gastric content through a gastric tube (method to assess the residual gastric content volume), after this suctioning of gastric content, then after reinjection of the content suctioned into the stomach (max 250 ml) and 1h30 later
1468767|NCT03205579|Other|Video group|Using video for educate cancer pain patients
1468768|NCT03205579|Other|conventional group|Face to face cancer pain education by trained nurse
1468769|NCT03205566|Drug|Raltegravir 400Mg Tab|bd for 7 days
1468770|NCT03205566|Drug|Lamivudine 150Mg Tablet|+ Raltegravir 400Mg tablet bd for 7 days
1468773|NCT03205540|Procedure|Continuous epidural block|Continuous epidural block at level L2-3 or L3-4 with 0.0625% bupivacaine + fentanyl 2 mcg/ml infusion epidurally 5 ml/hr for 48 hours postoperatively.
1468774|NCT03205540|Procedure|Bilateral single-shot bilateral adductor canal blocks|Bilateral single-shot adductor canal blocks, ultrasound guidance, with 0.33% bupivacaine 15 ml on each side.
1468775|NCT03205527|Other|Overground slip perturbation training|Slips will be induced by a low-friction platform (65×30×0.6 cm, μ<0.05) embedded side-by-side in the walking path, set nearly flush with the floor surround. The moveable platform, mounted on top of a pair of force platforms (AMTI, Newton, MA) for measuring ground reaction forces is firmly locked in a stationary position. An unannounced release occurs at heel strike of the perturbed, without the knowledge of subject, after which the platform is free to slide up to 150 cm. The mechanical release is controlled by the loading on the force platforms and the computer.
1468776|NCT03205514|Diagnostic Test|NSTE-ACS with intermediate stenosis and negative FFR|Patients will undergo intracoronary imaging evaluation with IVUS-NIRS and OCT, endothelial function and inflammatory state evaluation.
1468777|NCT03205501|Drug|IV-administation of EMI-137|Intravenous administration of 0.13 mg/kg of the fluorescent tracer EMI-137 approximately 2.5 hours prior to the endoscopy procedure.
1468778|NCT03205501|Device|Molecular Fluorescence Endoscopy platform|A flexible fluorescence fiber-bundle is attached to a fluorescence camera platform to enable the detection of fluorescence signals. The fluorescence fiber-probe is inserted through the standard working-channel of the standard clinical endoscope. Fluorescence imaging will be performed prior to and post the endoscopic resection, during the same endoscopy procedure.
1468782|NCT03205475|Behavioral|Alternate Coaching and Video Feedback Phase 1|Alternates each week between live/tele-health coaching (coaching) or Video review and call (feedback)
1468783|NCT03205475|Behavioral|Weekly Coaching in Phase 1|Weekly coaching (live or telehealth)
1468784|NCT03205475|Behavioral|Weekly Coaching plus Intensive Refresher Course Phase 2|Continue weekly coaching with senior trainer and add one week intensive refresher course
1468785|NCT03205475|Behavioral|Weekly Coaching plus Peer Coaching Phase 2|Continue weekly coaching with senior trainer and add weekly peer coaching from another interventionist in the region who is at high fidelity
1468788|NCT03205462|Drug|Fluorothyazinone 600 mg|Fluorothyazinone in a dosage of 600 mg (2 tablets) is received per os (oral administration) as a single dose
1468789|NCT03205462|Drug|Fluorothyazinone 3900 mg|The total dose of Fluorothyazinone per treatment course is 3900 mg.
1468790|NCT03205449|Behavioral|Masayang Pamilya Para Sa Batang Pilipino Parenting Programme (MaPa)|The MaPa programme includes the following content: 1) spending one-on-one time with children; 2) describing actions and feelings for cognitive development and socio-emotional awareness; 3) using praise and rewards to encourage positive behaviour; 4) establishing limits through effective instruction giving and consistent household rules; 5) nonviolent discipline such as ignoring negative attention seeking behaviour, and consequences for noncompliance, rule-breaking, and aggressive behaviour; 6) problem solving with children; and 7) mindfulness based stress reduction for caregivers.
1468791|NCT03205449|Other|Parenting Effectiveness Service|Content uses a thematic manual that includes sessions on Filipino family dynamics, early childhood development, child behaviour management, marital relationships, prevention of child maltreatment, health care, nutrition, and government anti-poverty initiatives, as well as disaster preparedness. [12].
1468792|NCT03205436|Other|Affinity human amniotic membrane|fresh hypothermically stored human amniotic membrane
1468793|NCT03205423|Drug|Gabapentin|Maintenance medication under investigation for its ability to alter the subjective and reinforcing effects of experimenter-administered doses of oxycodone and alcohol.
1468794|NCT03205410|Procedure|remote ischemic preconditioning|The remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
1468795|NCT03205410|Procedure|no - remote ischemic preconditioning|The sham - remote ischemic preconditioning protocol described before began after anesthesia induction, and was completed prior to the start of surgery.
1468796|NCT03205397|Other|Experimental Group|Preparation for anesthesia (explanations, film, booklet), the presence of a parent in the operating room and the awakening of the child
1468797|NCT03205397|Other|usual care|Usual care
1468798|NCT03205384|Procedure|surgery|
1468799|NCT03205371|Biological|MenACYW conjugate vaccine|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine
1468800|NCT03205371|Biological|MMR|Measles, Mumps, and Rubella Virus Vaccine Live
1468801|NCT03205371|Biological|Varicella|Varicella Virus Vaccine Live
1468802|NCT03205371|Biological|DTaP-IPV-HB-Hib|Diphtheria, Tetanus, Pertussis (acellular component), Hepatitis B, Poliomyelitis (inactivated), and Haemophilus influenzae type b conjugate vaccine (adsorbed)
1468803|NCT03205371|Biological|PCV13|Pneumococcal 13-valent Conjugate Vaccine
1468804|NCT03205358|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
1468805|NCT03205358|Biological|Meningococcal polysaccharide groups A, C, W 135 and Y conjugate vaccine|0.5 mL, Intramuscular
1468806|NCT03205345|Drug|Emricasan (25 mg)|25 mg emricasan
1468807|NCT03205345|Drug|Emricasan (5 mg)|5 mg emricasan
1468808|NCT03205345|Drug|Placebo|Matching Placebo
1468809|NCT03205332|Behavioral|Concreteness Training|
1468810|NCT03205319|Device|e-learning|The e-learning for patients is a user friendly, audiovisual based, online-accessible program, designed especially for this study. The e-learning will contain information on dyspepsia and advice on lifestyle interventions
1468811|NCT03205293|Behavioral|Intervention Program to Promote Healthy Eating and Physical Activity among Palestinian Female Schoolchildren|
1468812|NCT03205267|Drug|Bosulif|Patients will start with dose-level 1 (300 mg once daily) Bosutinib. If patients do not experience any toxicity or only G1 toxicity, they will be dose-increased first to dose-level 2 (400 mg once daily ) and then to dose-level 3 (500 mg once daily). Dose will not be escalated above 500 mg which is the dose recommended by the summary of product information. If patients experience G2 toxicity, the study drug will be further continued at the same dose-level. In patients with G3 or G4 toxicities, therapy will be withheld until toxicity resolved to <G2.
1468813|NCT03205254|Other|Mediterranean Diet|four days of participant-scaled isocaloric Mediterranean meals
1468814|NCT03205254|Other|Fast food diet|four days of participant-scaled isocaloric fast food meals
1468815|NCT03205241|Dietary Supplement|n-3 PUFA|n-3 PUFA capsules containing EPA and DHA
1468816|NCT03205241|Dietary Supplement|Placebo|Olive oil capsules
1468817|NCT03205228|Drug|Omeprazole|A capsule of Omeprazole 20 mg & 1 capsule of placebo will be given in individual subject, once daily for 4 weeks. Both drugs will be presented in the same appearance (white capsule).
1468818|NCT03205228|Behavioral|psychoeducation|Psychoeducation will be given by psychologists at the Day 1 and Day 15 of the study period.One white capsule of placebo will be given once daily for 4 weeks of the study period.
1468819|NCT03205228|Drug|Flupentixol +Melitracen|A capsule containing of a tablet of melitracen 10 mg + flupentixol 0.5 mg & a capsule of placebo will be given once daily, for 4 weeks. Both would be presented in the same appearance (white capsule)
1468820|NCT03205215|Other|Hyperbaric Oxygen Therapy|100% oxygen delivered by hood at 2 ATA for 90 minutes with 5 minute air breaks
1468821|NCT03205215|Other|Sham Hyperbaric Oxygen Therapy|Air delivered by hood at slightly above normal atmospheric pressure for 90 minutes with 5 minute simulated air breaks
1468822|NCT03205202|Dietary Supplement|Cocoa extract|
1468823|NCT03205202|Dietary Supplement|Multivitamin|
1468824|NCT03205202|Dietary Supplement|Cocoa extract placebo|
1468825|NCT03205202|Dietary Supplement|Multivitamin placebo|
1468826|NCT03205189|Other|Comparison between pre-operative prescription and post-operative prescription|The first group will have a pre-operative prescription delivered during the preoperative anesthesia clinic and the second group will receive the postoperative prescription.
1473200|NCT03172936|Drug|MIW815|MIW 815 (ADU-S100) is a STING agonist
1468841|NCT03205098|Biological|Blood analysis|Blood test of biological markers of mesenteric ischemia
1948343|NCT02466737|Procedure|no axillary surgery versus SLNB|in cases with newly diagnosed breast cancer and clinically negative axillary status
1948344|NCT02466737|Procedure|SLNB versus completion ALND|in cases with 1-3 macrometastases in sentinel lymph nodes
1468845|NCT03205072|Device|Spy Glass DS|The SpyScope™ DS Access and Delivery Catheter (SpyScope™ DS Catheter) is a sterile, single-use endoscope that enables access and delivery of accessories to targeted pancreaticobiliary anatomy and displays live video when connected to a Spy Glass DS Digital Controller.
1468846|NCT03205059|Behavioral|LST MS curriculum+ Bullying/Cyberbulling serious game|The prevention materials for middle school bullying and cyberbullying will (1) utilize both interactive classroom sessions and serious/educational games (digital games used to educate in an entertaining format); (2) positively change social norms surrounding bullying and cyberbulling; (3) challenge positive expectancies about bullying and cyberbullying; (4) enhance protective factors by building social, self-regulation, and relationship skills throughout the interactive learning and behavioral rehearsal; and (5) include booster sessions.
1468847|NCT03205059|Behavioral|LST MS curriculum|The evidence-based LifeSkills Training program has been successfully used as a universal, school-based substance abuse and violence prevention program for middle school youth. The goals of the LST program are to teach youth the personal self-management skills, social skills, and other life skills needed to successfully resist drug and alcohol use, navigate developmental tasks, increase resilience, and facilitate healthy psychosocial development.
1468848|NCT03205046|Drug|acalabrutinib|Acalabrutinib is a selective, irreversible small molecule Bruton's tyrosine kinase (BTK) inhibitor.
1468849|NCT03205046|Drug|vistusertib|Vistusertib is an inhibitor of mechanistic target of rapamycin (mTOR) kinase
1468850|NCT03205033|Drug|Melatonin 20 MG Oral Capsule|1 capsule/day 1 hour before go to bed
1468851|NCT03205033|Drug|Placebo oral capsule|1 capsule/day 1 hour before go to bed
1468852|NCT03205020|Diagnostic Test|serum amyloid a test|"Women who are diagnosed with preterm labor (28-36 weeks) will be enrolled in this study. Serum samples will be collected from all women before any intervention. All women will be sampled once at the time of admission.
Venous blood sample (5 c.c) will be taken from each participant for examination of serum amyloid A.
The collected blood will be centrifuging and serum will be stored to measure the level of amyloid A by (ELISA) technique in clinical pathology department- Ain shams University"
1468853|NCT03205007|Behavioral|Health promotion nutrition program|Health promotion nutrition program
1468854|NCT03204994|Drug|Indocyanine Green|Fluorescence guided lymphatic mapping using indocyanine green.
1468857|NCT03204968|Device|Vagus nerve stimulation|transcutaneous Intermittent stimulation of the vagus nerve using neurostimulator V (Ducest®, Germany)
1468858|NCT03204955|Drug|Sodium chloride /sodium acetate (16.4%)|"Sodium Acetate is a sterile, nonpyrogenic solution of Sodium Acetate intended as an alternative to sodium chloride to provide sodium ion in parenteral (IV) fluid therapy.
Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy."
1468859|NCT03204955|Drug|Sodium chloride (23.4%)|Sodium Chloride is sterile, nonpyrogenic hypertonic saline (concentrated sodium-chloride) solution for parenteral (IV) fluid therapy.
1468860|NCT03204955|Drug|PlasmaLyte|PlasmaLyte is an isotonic IV solution that mimics human physiological plasma electrolyte concentrations, osmolality and pH.
1468899|NCT03204695|Device|Percutaneous LAA Closure|LAA Closure with the WaveCrest LAA Occlusion System (study device)
1468928|NCT03204474|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
1468861|NCT03204942|Device|PRF on DRG|After sterile skin preparation, RF will be performed with the patient in the prone position with mild flexion of the spine and the fluoroscopy beam positioned in an antero-posterior (AP) direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is then inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen .So the location of the needle tip will confirmed not only by image but also by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.
1468862|NCT03204942|Device|TRF on DRG|"Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described"
1468863|NCT03204942|Drug|Control group|Similar to the previous groups, but without applying any type of Radiofrequency but just injecting steroids and local anaesthestics as previously described
1468864|NCT03204929|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
1468865|NCT03204916|Other|Medical Chart Review|Data abstraction and central review
1468866|NCT03204916|Other|Questionnaire Administration|Ancillary studies
1468867|NCT03204903|Procedure|Laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen (GaAlAs laser diode, 810 nm, 150 mW, pulsed waves), which delivered 0.375 J of energy (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
1468868|NCT03204903|Procedure|Sham laser acupuncture|Subjects were treated 3 times per week for 12 weeks with the LaserPen without laser output (5 s) to BL2, TE23, ST2, LI4, ST36, and GB37.
1468869|NCT03204890|Other|Transcutaneous Posterior Tibial Nerve Stimulation|Three (3) sessions per week for twelve (12) consecutive weeks, with a duration of 30 minutes each, with the application of 20 Hertz with a pulse amplitude of 200 MI sec. in each session. The intensity will be applied individually for each patient depending on the tolerance of the individual. In each session, it is normal to have plantar flexion of the foot and flexion of the first toe, and after the session and particularly during the first sessions there is the possibility of muscle pain, which should be tolerable.
1468870|NCT03204877|Drug|Melatonin|Oral capsules
1468871|NCT03204877|Other|Placebo|Oral capsules
1468872|NCT03204864|Device|RLD Group|patients CS placement will be guided by RLD measurement. Physician will place the CS lead in the site of longest RLD with a stable and acceptable pacing threshold.
1468873|NCT03204864|Device|Conventional CS lead placement|Clinical Practice
1468874|NCT03204851|Device|Wound Healing|Microlyte Ag is a class-II medical device cleared by the FDA for prescription and over the counter use in humans with skin wounds.
1468875|NCT03204838|Genetic|IDH mutation test performed at diagnosis|Observation of the test result
1468876|NCT03204825|Device|Active TENS|TENS is a form of electrical stimulation that provides symptomatic pain relief that is used extensively within the health-care setting. It is a non-invasive modality; packaged in a small, portable unit that is easy to apply via small electrodes placed on the skin.
1468877|NCT03204825|Behavioral|Patient-Centred Education|Group education for patients with peripheral arterial disease and intermittent claudication about their condition, improving patient ownership, and promoting self-managed walking
1468878|NCT03204825|Device|Placebo TENS|TENS device use with setting so that the stimulation delivered is ineffective
1468881|NCT03204799|Other|Metformin|newly diagnosed type 2 diabetes patients who start to metformin monotherapy
1468882|NCT03204799|Drug|SGLT2 inhibitor|newly diagnosed type 2 diabetes patients who start to SGLT2 inhibitor monotherapy
1468883|NCT03204799|Drug|ezetimibe|newly diagnosed dyslipidemia patients who start to ezetimibe therapy
1468884|NCT03204786|Drug|Vasopressin (USP) Injectable Solution [Vasostrict]|Nasal Spray
1468885|NCT03204786|Drug|Placebo|Placebo Nasal Spray
1468891|NCT03204760|Drug|Dexamethasone 8Mg Solution for Injection|Effect single dose of intramuscular dexamethasone (0.6 mg/kg to a maximum of 18 mg) in the treatment of mild to moderate acute asthma exacerbations in children
1468892|NCT03204760|Drug|Prednisolone Oral, Per 5 Mg|Effect of prednisolone for 3 days (1 mg/kg to a maximum of 40 mg), given orally in two devided doses in the treatment of mild to moderate acute asthma exacerbations in children.
1468893|NCT03204747|Other|Observational study : gait speed|No intervention, only propose water and wait for need to void
1468894|NCT03204734|Drug|Capecitabine|Capecitabine will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.
1468895|NCT03204734|Drug|endocrine therapy|endocrine therapy will been given as a sequential treatment who are got benefit in capecitabine-base chemotherapy.Endocrine therapy is determined by the doctor, including any kind of letrozole, anastrozole, exemestane, fulvestrant, tamoxifen, toremifene, combined with or without drugs or surgery in the inhibition of ovarian function.
1468896|NCT03204721|Other|Extracorporeal photophoresis (ECP)|The treatment procedure of ECP consists of three steps. First, the leukocytes are removed by apheresis; second, the mononuclear cells are primed with the photosensitizing agent 8-methoxypsoralen; then third, these cells are exposed to radiation with ultraviolet A light before they are re-infused into the patient
1468897|NCT03204708|Device|catheter|catheter was placed under clavipectoral fascia by open technique by surgeon at the 1/3 lateral part of clavicula neighbourhood of nervus thoracicus longus, nervus thoracodorsalis, nervus pectoralis lateralis, nervus pectoralis medialis
1468898|NCT03204708|Drug|iv analgesia|patients were given 100 ml of tramadol 30 minutes before extubation
1468900|NCT03204682|Device|Repetitive transcranial magnetic stimulation|Realization of a brain and medullary MRI to allow neuronavigation. Realization of 5 sessions of rTMS in 5 days during the first week then evaluation (physical examination, questionnaires) in consultation on post-stimulation. Then followed for 28 days in total through self-assessment of pain that will be filled daily on REDCap and last consultation on D28 for further evaluation
1468901|NCT03204669|Other|Trace elements replacement|
1468902|NCT03204643|Behavioral|BH-VPN|A bundle of usual care components, applied consistently and completely, along with access to behavioral health specific patient navigators and navigation services.
1468903|NCT03204630|Dietary Supplement|Lfer|Probiotic bacteria originally isolated from breast milk: the strain Lactobacillus fermentum CECT5716
1468904|NCT03204630|Dietary Supplement|Bifido|Probiotic bacteria originally isolated from breast milk: the strain Bifidobacterium breve CECT7263
1468905|NCT03204630|Other|Control|Standard infant formula
1468906|NCT03204617|Biological|DNA.HTI 4 mg and MVA.HTI 2x10^8pfu vaccines|Vaccine DNA.HTI 4 mg at weeks 0, 4 and 8 + Vaccine MVA.HTI 2x10^8pfu at weeks 12 and 20.
1468907|NCT03204617|Drug|Placebo|0.9% sterile normal saline solution at weeks 0, 4, 8, 12 and 20.
1468908|NCT03204604|Dietary Supplement|Challenge A - low calorie Ensure®|Challenge A will include a low calorie Ensure shake for the participant to drink with no ketone esters (KE).
1468909|NCT03204604|Dietary Supplement|Challenge B - Ensure® plus ketone esters (KE)|Challenge B will include an Ensure shake for the participant to drink with deltaG ketone ester, which has generally recognized as safe (GRAS) supplement status .
1468910|NCT03204604|Procedure|PET Scan|Subject will drink the shake. Immediate recall memory testing. Subject will be placed in the scanner. Prior to PET acquisition, a low dose CT scan of the head will be obtained for attenuation correction. Patients will be injected with an intravenous bolus of up to 5-10mCi (370 MBq) (+/- 10%) of [11C]AcAc (over 2 minutes). This is the standard dose used in published clinical studies using [11C]AcAc. The PET acquisition will begin immediately after the tracer injection and last for a total of 30 minutes. 2 ml of blood will be sampled from the forearm vein at 3, 6, 8, 12, 20, and 28 minutes post [11C]AcAc tracer injection. This will be used for quantification of radiation estimates throughout the scan-period
1468911|NCT03204604|Behavioral|Cognitive Testing - FCSRT|The Free and Cued Selective Reminding Test (FCSRT) measures verbal memory through multiple trials of a list learning task. A list of 16 items is visually presented to the participants, who then recall as many items as possible. On subsequent trials, participants are told only those items they omitted on the previous trial. The procedure continues until the participant recalls all items on two subsequent trials. After approximately 30-minute delay, participants are asked to recall as many items as possible. The number of items recalled after the delay is then summed.
1468912|NCT03204604|Behavioral|Story Recall|Story Recall: This test is a modification of the episodic memory measure from the Wechsler Memory Scale-Revised (WMS-R). In this modified version, free recall of one short story that consists of 44 bits of information will be elicited immediately after it is read aloud to the participant and again after a thirty-minute delay. The total bits of information from the story that are recalled immediately (maximum score = 44) and after the delay interval (maximum score = 44) are recorded. Six comparable versions of this task have been validated in prior studies with older adults.
1468913|NCT03204604|Behavioral|BVRT|Benton Visual Retention Test (BVRT): The BVRT is a multiple-choice visual recognition task. Participants view a visual pattern and are then asked to select the target from an array of four patterns, three of which are distractors. It assesses visuospatial working memory. This recognition format has the advantage assessing visual memory while eliminating the influence of visuomotor and manual dexterity difficulties.
1468914|NCT03204604|Behavioral|CogState One Card Learning|The One Card Learning Test involves a visual learning task sensitive to early-stage cognitive impairment. It is one of several computerized assessments developed by CogState that assess executive function and working memory.
1468915|NCT03204591|Other|No intervention|No intervention
1468916|NCT03204578|Drug|AB (Midazolam OD formulation/Dormicum)|Oral disintegrating formulation (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
1468917|NCT03204578|Drug|BA (Dormicum/Midazolam OD formulation)|Oral disintegrating film (Midazolam OD Formulation). The Midazolam OD Formulation was developed by Kyukyu Pharmaceutical Co., Ltd
1468918|NCT03204565|Procedure|coronally advanced flap|coronally advanced flap alone (CAF- control)
1468919|NCT03204565|Device|hyaluronic acid|hyaluronic acid associated to coronally advanced flap (CAF + HA- test)
1468920|NCT03204552|Other|No intervention (observational study)|No intervention (observational study)
1468921|NCT03204539|Drug|Wilate|Wilate® is a high-purity (i.e. 100 IU FVIII/mg total protein) pdVWF/FVIII complex concentrate.Wilate® possesses all the important features asked for in ITI, namely high purity, a very high pathogen safety profile, and an excellent protection of its FVIII by VWF - all achieved through unique, novel, and innovative techniques.
1468922|NCT03204526|Device|deep brain stimulation|
1468923|NCT03204513|Device|Vanderbilt Powered Knee-Ankle Prosthesis|The Vanderbilt powered prosthesis is a transfemoral prosthesis with powered and coordinated knee and ankle joints. The Generation 3 prosthesis is actuated by two brushless direct current (DC) motors, providing up to 100 Nm of torque at the knee joint, and with the assistance of a parallel stiffness, up to 200 Nm in plantar flexion at the ankle. Sensors measure knee and ankle joint angles, axial load in the shank, and position and orientation of the prosthesis in space (via a 6-axis inertial measurement unit). An onboard lithium-ion battery provides sufficient energy for approximately 10,000 steps between battery charges. The prosthesis prototype weighs approximately 4.3 kg (9.5 lb), the mass of which is approximately equivalent to the intact limb of a 48 kg (105 lb) person.
1468924|NCT03204513|Device|Microprocessor (MP) Knee Prosthesis|Participants enrolled will already have their own microprocessor controlled (MP) non-powered knee prostheses as per inclusion criteria. Examples: OttoBock's C-Leg, Ossur's Rheo, Freedom Plie, Endolite Orion,etc.
1468925|NCT03204500|Combination Product|Active treatment with dual therapy|Blue pills ( 200 mg of magnesium valproate ) and white pills ( 300 mg of lithium carbonate) are administered orally with meals.
1468926|NCT03204500|Drug|Placebos|Administered orally under the same conditions
1468927|NCT03204487|Drug|Tafluprost 15µg/ml|Tafluprost 15µg/ml (Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis, Merck Sharp & Dohme, Wien)
1473201|NCT03172936|Biological|PDR001|PDR001 is an anti-PD-1 antibody
1468929|NCT03204474|Drug|Lacosamide (LCM) solution for infusion|Treatment B: Single dose of Lacosamide (LCM) 200 mg administered as intravenous infusion
1468930|NCT03204461|Diagnostic Test|Oral glucose tolerance test (OGTT)|For the assessment of glucose metabolism, including beta-cell function and insulin sensitivity an 75g-OGTT was conducted.
1468931|NCT03204461|Other|1H-magnetic resonance spectroscopy|The amount of ectopic lipids in the liver, heart and the skeletal muscle was measured using 1H-magnetic resonance spectroscopy.
1468932|NCT03204448|Device|BioCLIA Ro60|BioCLIA Ro60 is a Chemiluminescent Immuno Assay (CLIA) as a fully automated testing process, reporting with arbitrary units, RU/mL
1468933|NCT03204435|Procedure|Microsurgical aneurysmal operating techniques|The microsurgical techniques used to evacuate the aneurysm out of circulation or reduce its risk of rupture by aneurysmal clipping, wrapping,or isolation.
1468934|NCT03204435|Procedure|endovascular techniques for cerebrovascular stenosis|The endovascular techniques that recanalize the narrowed or occluded cerebrovascular, including stent implantation, balloon dilatation.
1468935|NCT03204435|Procedure|endovascular techniques for intracranial aneurysms|The endovascular techniques that embolize the cavity of aneurysms to reduce the risk of rupture, including coiling embolization, balloon-assisted occlusion.
1468936|NCT03204435|Procedure|carotid endarterectomy|A microsurgical technique to recanalize the stenosis or occluded proximal segment of carotid artery.
1468937|NCT03204422|Other|No intervention|no any other intervention
1468938|NCT03204396|Drug|Dulaglutide|Application of Dulaglutide (Trulicity®) 1.5 mg s.c. once weekly for 12 weeks.
1468939|NCT03204396|Drug|0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl])|Application of 0.5 ml normal saline (0.9% sodium chloride [0.9% NaCl]) once weekly for 12 weeks
1468940|NCT03204370|Drug|Elosulfase Alfa 1 MG/ML Intravenous Solution [VIMIZIM]|A subgroup of MPS4A patients will be treated by VIMIZIM drug, prescribed in usual care
1468941|NCT03204357|Other|Fresh Autologous whole Blood|Subjects randomized this arm will receive fresh autologous whole blood
1468942|NCT03204357|Other|Standard of Care Expectant management of bleeding|the control group that will receive the standard of care expectant management of bleeding and transfusion of allogenic banked blood products
1468943|NCT03204344|Dietary Supplement|Oral carbohydrate (Outfast)|"For all patients, 2 bottles of oral carbohydrate (Outfast, 710 ml) is provided between 22:00-24:00 on the day before surgery. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated by an endocrinologist according to patients' daily glucose controlling plan.
For patients who entered operating room before 12:00, 1 bottle of oral carbohydrate (Outfast) is provided at 6:00 on the day of surgery. For patients who enter the operating room after 12:00, another bottle of oral carbohydrate (Outfast) is provided at least 2 hours before entering the operating room. Subcutaneous insulin is administered before drinking. The dose of insulin is calculated is the same way as described above."
1468944|NCT03204344|Other|Routine fasting|"For all patients, routine fasting (water drinking allowed) begin from 22:00 on the day before surgery until entering the operating room on the day of surgery.
For patients who enter the operating room before 12:00, no oral or intravenoous fluid is provided. For patients who enter the operating room after 12:00, 5% glucose (500-1000 ml) is provided by intravenous infusion from 6:00 on the day of surgery. Intravenous insulin is added in the 5% glucose (glucose:insulin=4-6:1). Electrolytes (such as sodium chloride, potasium chloride, and magnesium sulfate) are added when considered necessary."
1468953|NCT03204305|Drug|11C-OMAR|11C-OMAR is a PET radiotracer that binds to cannabinoid type 1 receptors (CB1R). It is an analog of the CB1R antagonist/inverse agonist rimonabant. 11C-OMAR was developed, synthesized and validated for inhuman use at the Johns Hopkins University PET center.
1468954|NCT03204305|Drug|Cannabis|Cannabis will be administered to cannabis users. Doses include 0 and 25 mg THC.
1468955|NCT03204279|Drug|Netupitant|Netupitant 1.33 mg/kg oral suspension up to a maximum of 100 mg
1468956|NCT03204279|Drug|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
1468957|NCT03204279|Drug|Netupitant|Netupitant 4 mg/kg oral suspension up to a maximum of 300 mg
1468958|NCT03204279|Drug|Palonosetron|Palonosetron 20 μg/kg solution for oral use up to a maximum of 1.5 mg
1468959|NCT03204266|Drug|Arginine recovery supplement|Participants take 1 ounce (30mls) of Arginine recovery supplement four times daily 7 days preoperatively and 14 days postoperatively.
1468960|NCT03204266|Dietary Supplement|Omega-3 Fatty Acids|Participants given omega-3 fatty acids, 1 gram four times a day, 4 grams total per day. This will be started 7 days preoperatively and continued 14 days postoperatively.
1468961|NCT03204253|Drug|rFSH + r-LH in combination|29 women stimulated with rFSH supplemented by rLH in the late follicular phase started at the same time of starting the antagonist administration.
1468962|NCT03204253|Drug|rFSH alone|32 women who were stimulated with recombinant FSH alone
1469002|NCT03203967|Drug|Intravenous morphine analgesia|Intravenous morphine analgesia is provided with a patient-controlled analgesia pump which is established with 100 ml of 0.5 mg/ml morphine, programmed to deliver a 2 ml bolus with a lockout interval of 8-10 min and a background infusion of 0.5 ml/h.
1469003|NCT03203954|Behavioral|Standard Learning|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
1469004|NCT03203954|Behavioral|Guided Learning: Instructed statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
1468963|NCT03204240|Other|Neuromuscular electrical stimulation|NMES-RE will involve concentric/eccentric contractions of the quadriceps from a seated position. Briefly, each session will include four sets of 10 actions evoked using 50 Hz trains of 450 µs biphasic pulses. The protocol will be implemented using surface NMES. Upon completion of the NMES-RE session, participants will be given a short break (10-15 minutes) for recovery before starting aerobic training. NMES aerobic exercise will involve twitch electrical stimulation (pulse duration/interval=200/50 µs) applied to the quadriceps muscle via surface NMES. The current amplitude will set to 175 mA. The training will start with 10 minutes of twitch stimulation at 2 Hz. After the first weeks, the duration of the session will progressively increase up to 60 minutes at 10 Hz.
1468964|NCT03204227|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
1468965|NCT03204227|Biological|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
1468966|NCT03204201|Drug|Indocyanine Green Solution|Urethral instillation of ICG (Indocyanine Green) mixed with urethral lubricant
1468967|NCT03204188|Drug|Ibrutinib|ibrutinib
1468968|NCT03204188|Drug|Fludarabine|fludarabine
1468969|NCT03204188|Drug|Pembrolizumab|pembrolizumab
1468970|NCT03204175|Other|FIT Plus|"Group handwashing facilities
Daily group handwashing and toothbrushing activities
Sanitation operation and maintenance manuals for school officials
Toilet cleaning consumable
Toilet and handwashing station maintenance kits
Soap, toothbrushes, and toothpaste"
1468971|NCT03204175|Other|Comparator arm|This is the same intervention as FIT Plus, but will be delivered to schools following endline data collection
1468972|NCT03204162|Other|CPR Coaching|Teams in the experimental arm will have a member of their team assigned to be the CPR Coach. This person will provide CPR Coaching in the form of feedback in CPR quality (depth, rate) to the CPR providers as well as provide guidance on time for defibrillation, etc.
1468973|NCT03204149|Device|MC-8XL low level laser device and Standard wound care|"The MC-8XL, a handheld Low Level Laser Therapy (LLLT) device, comprised of an infrared laser diode that generates wavelength of 808 nm and a green laser diode with a wavelength of 525 nm will be used to treat the experimental group.
Along with the active LLLT, generally accepted standard wound care procedures will be used during the clinical trial by a qualified study nurse or doctor. These procedures will include wound cleaning and drying before irradiation with the laser device (sham or active). Each ulcer will be also assessed and debrided if needed.
After irradiation, each ulcer will be dressed with saline gauze dressing and offloaded."
1468974|NCT03204149|Device|Sham laser device and Standard wound care|"The Sham device is of similar appearance, emitting only green light for indication with a wavelength of 525 nm of a low power, with inactive IR laser which will be used in the Control group.
Along with the sham device, the same generally accepted standard wound care procedures will be used."
1468975|NCT03204123|Drug|Ga-HBED-iPSMA PET|Patients will be injected with 100-300 MBq of 68Ga-HBED-iPSMA and after a waiting of 60-90 minutes patients will be scanned from mid-skull to mid-thigh.
1468976|NCT03204123|Diagnostic Test|CT|CT will be acquired using a GE 710 time-of-flight PET/CT scanner. Following a waiting period of 60 minutes, patients will be scanned from mid-skull to mid-thigh. Imaging will start with low-dose CT scan for attenuation correction.
1468977|NCT03204123|Diagnostic Test|MRI|MRI will be acquired on a GE 750 3T scanner. Whole body MRI will include an axial field of view ranging from mid-skull to mid-thigh, using multichannel spine and body coils. The protocol will consist of a combination of multiplanar T1-weights and fat/water sequences and axial diffusion-weighted MRI using two b values (b=50 and b=900s/mm^2).
1468978|NCT03204097|Drug|placebo|Oral prophylaxis followed by placement of placebo gel
1468979|NCT03204097|Drug|Alendronate|Oral prophylaxis followed by placement of Alendronate gel
1468980|NCT03204097|Drug|Aloe Vera|Oral prophylaxis followed by placement of Aloe Vera gel
1468981|NCT03204084|Device|Low-temperature Plasma Surgery System|In pterygium surgery with fibrin glue(FG) and conjunctival autograft we use Low-temperature Plasma Surgery System(LTP)do the ablation of tissue and hemostasis.
1468982|NCT03204071|Drug|placebo gel|Oral prophylaxis followed by Placebo gel to be delivered in intrabody sites of chronic periodontitis subjects.
1468983|NCT03204071|Drug|Aloevera|Oral prophylaxis followed by placement of aloevera gel
1468984|NCT03204071|Drug|Metformin|Oral prophylaxis followed by placement of metformin gel
1468985|NCT03204058|Drug|Placebos|Oral prophylaxis followed by placement of placebo gel
1468986|NCT03204058|Drug|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
1468987|NCT03204058|Drug|Metformin|Oral prophylaxis followed by placement of metformin gel
1468988|NCT03204045|Drug|fentanyl|2 mL mixture of fentanyl with isotonic saline
1468989|NCT03204045|Drug|Oxycodone|2 mL mixture of oxycodone with isotonic saline
1468990|NCT03204045|Drug|control|isotonic saline 2 mL
1468991|NCT03204032|Drug|Tegafur|Tegafur 40-60mg po bid(d1-d14);
1468992|NCT03204032|Drug|Temozolomide|200mg po qd(d10-d14)
1468993|NCT03204032|Drug|Thalidomide|Thalidomide 100mg po qd(d1-d7) Thalidomide 200mg po qd(d8-d14) Thalidomide 300mg po qd(d15-d21)
1468994|NCT03204019|Drug|Tegafur and Temozolomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qd(d10-d14)
1468995|NCT03204019|Drug|Tegafur and Temozolomide combined with Thalidomide|Tegafur 40-60mg po bid(d1-d14); Temozolomide 200mg po qe(d10-d14) Thalidomide 100mg po qd(d1-d7) /Thalidomide 200mg po qd(d8-d14)/Thalidomide 300mg po qd(d15-d21)
1468996|NCT03204006|Drug|Dexmedetomidine|Dexmedetomidine preinduction
1468997|NCT03204006|Drug|sterile saline|normal saline preinduction
1468998|NCT03203980|Other|Triple antithrombotic therapy|patients who are prescribed double antiplatelets agents and oral anticoagulation (except VKA)
1468999|NCT03203967|Procedure|Epidural morphine|2 mg of morphine (0.4 mg/ml morphine in 5 ml normal saline) is administered through the epidural catheter at the end of surgery.
1469000|NCT03203967|Procedure|Epidural placebo|5 ml normal saline is administered through the epidural catheter at the end of surgery.
1469001|NCT03203967|Procedure|Single femoral nerve block|Single femoral nerve block is performed with 20 ml 0.5% ropivacaine under the guidance of ultrasonography and nerve stimulator after surgery.
1469067|NCT03203512|Dietary Supplement|Olive oil capsules|Olive oil for 12 weeks
1469005|NCT03203954|Behavioral|Guided Learning: Changing statistics|Participants will complete repeat sessions of a computer-based learning task, and task performance and symptoms will be assessed.
1469006|NCT03203941|Biological|Autologous Cord Blood Stem Cells|This is an individual patient expanded access protocol.
1469007|NCT03203928|Behavioral|Occupational Therapy Intervention for Women with ADHD|"The intervention will run for 7 weeks and consist of the following 1-hour sessions. Each intervention session will be facilitated by two CUMC occupational therapy students in each participant's home environment (or another environment of the participant's choosing such as the work or school environment).
Implementation of organizational, time management, stress management, and sensory regulation strategies for the home, school/work, and community environments."
1469008|NCT03203915|Dietary Supplement|Chardonnay grape pomace powder high polyphenol dose (120mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 120mg of total polyphenols
1469009|NCT03203915|Dietary Supplement|Chardonnay grape pomace powder low polyphenol dose (75mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 75mg of total polyphenols
1469010|NCT03203915|Dietary Supplement|Placebo (0mg)|3 prepackaged capsules taken once in the morning with meal for 3 weeks. The total dose will be 0mg of polyphenols
1469011|NCT03203902|Other|Psychoeducation and Therapeutic Touch|6-week, 1-hour psychoeducation group followed by 30-minute therapeutic touch
1469012|NCT03203889|Behavioral|CRAFT-AI|Community Reinforcement Approach and Family Training (CRAFT) uses principles of operant conditioning to help a concerned significant other improve their own psychological functioning and influence the identified person with addiction to seek help
1469013|NCT03203889|Behavioral|TSF-CSO|In individual sessions, the counselor facilitates the CSO's affiliation and involvement in Nar-Anon or Al-Anon groups to work the steps.
1469017|NCT03203863|Diagnostic Test|anthropometric measures of fatness|The aim of this study was to determine the discrimination capacity for cardiovascular risk factors of BMI, fat mass (FM), waist circumference (WC), and waist to height ratio (WHtR) in a population of Chilean children from Puente Alto County. Additionally, new cutoff points were established and compared with those described by other authors
1469018|NCT03203850|Drug|Deferasirox FCT|Taken orally once per day (QD)
1469019|NCT03203850|Procedure|No Drug|surgical opening or puncture of a vein in order to withdraw blood
1469020|NCT03203837|Other|Plasma collection|We will be collecting plasma at 7 different timepoints in hepatocellular carcinoma patients that are treated with radioembolization.
1469021|NCT03203824|Dietary Supplement|dark chocolate|Participants will be provided Parliament dark chocolate (70% cocoa) from Redlands, CA. The Parliament chocolate is made with cacao and cane sugar. Each participant will be given half a piece (1.4 g) of dark chocolate to consume for this experiment over three minutes.
1469022|NCT03203824|Other|non dark chocolate|No dark chocolate will be given to this group during the procedures.
1469023|NCT03203811|Drug|HTI-2088|3 dose levels
1469024|NCT03203811|Drug|Placebo|placebo oral tablet
1469025|NCT03203798|Procedure|Training of pelvic floor muscles|The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.
1469026|NCT03203798|Procedure|Hipopressive abdominal gymnastics|The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
1469027|NCT03203785|Dietary Supplement|Carbohydrate (maltodextrin)|maltodextrin flavored
1469028|NCT03203785|Other|Placebo|non-caloric drink
1469029|NCT03203772|Other|Immersive Virtual Reality|Participants will engage in virtual visualization therapy in an immersive virtual reality environment
1469030|NCT03203759|Other|Home hospitalization|See above
1469031|NCT03203759|Other|Traditional inpatient hospitalization|See above
1469032|NCT03203746|Drug|Lycopene + SRP|
1469033|NCT03203746|Procedure|SRP only|
1469036|NCT03203720|Behavioral|Brief Motivational Intervention|A brief motivational intervention centered around Motivational Interviewing (MI) techniques. Sessions are adjunct to standard clinical care, and focus on psychoeducation regarding treatment for bipolar disorder, and resolving ambivalence regarding taking medications for mood disorder.
1469064|NCT03203525|Drug|Liposomal Doxorubicin|"Dose Escalation Group Starting Dose of Liposomal Doxorubicin: 20 mg/m2 by vein on Days 1 and 15 of a 28 day cycle.
Dose Expansion Group Starting Dose of Liposomal Doxorubicin: Maximum tolerated dose from Dose Escalation Group."
1469065|NCT03203525|Drug|Temsirolimus|"Dose Escalation Group Starting Dose of Temsirolimus: 25 mg by vein on Days 1, 8, 15, and 22 of a 28 day cycle.
Dose Expansion Group Starting Dose of Temsirolimus: Maximum tolerated dose from Dose Escalation Group."
1469068|NCT03203499|Drug|ANS-6637 Oral Tablet|Ascending single doses administered orally.
1469037|NCT03203707|Behavioral|Interpersonal and Social Rhythm Therapy|The Brief IPSRT intervention for at-risk youth includes : 1) Psychoeducation about risk for BP ; 2) Social rhythm therapy (SRT) aiming to establish and maintain stable routines to protect against onset of mood symptoms in vulnerable individuals ; and 3) Interpersonal Psychotherapy (IPT) centering on the adolescent's feelings about having a parent with BP, and linking stressful family events to mood. The intervention is delivered in 8 in-person sessions over 6 months of treatment. Parents are involved in the psychoeducation sessions, and further involvement is determined as clinically appropriate based on age and developmental status.
1469038|NCT03203694|Behavioral|Walking|The walking program will consist of 45 minutes of walking (at a moderate pace) 5 days per week for 8 weeks.
1469039|NCT03203681|Drug|NATESTO® (4.5% nasal testosterone) Nasal Gel|To determine the effects of 125 uL/nostril, 11.0mg testosterone/dose of Natesto on serum testosterone, LH, FSH and Semen parameters.The study will identify men with confirmed hypogonadism (testosterone (T) <350 on 2 consecutive T samples collected greater than 1.5 hours apart between 6am and 10am with demonstrated symptoms of hypogonadism). Subjects will undergo a total of six study visits. At the first visit they will undergo screening procedures which will include signing of the consent form, physical exam, assessment for inclusion and exclusion criteria, SHIM and quality of life questionnaire, blood samples ( FSH, LH, Estradiol, and Testosterone) and a semen analysis. At visit 2, second semen analysis and blood analysis for Testosterone. After 12 weeks, a third visit for blood sample and semen analysis. The subjects will also be given SHIM and quality of life questionnaires, and repeated after 25 weeks.This is a prospective case study.
1469040|NCT03203668|Radiation|18F-choline PET/CT|18F-choline PET/CT imaging (neck, mediastinum)
1469041|NCT03203655|Behavioral|CareMessage™|Adult Obesity texting program, which sends a text message 3 to 5 times a week, encouraging lifestyle modifications (diet and exercise education, and behavioral strategies) that can lead to healthy weight loss.
1469042|NCT03203655|Behavioral|Control Condition|Control condition will receive an initial talk about weight loss but will not be enrolled in any program or intervention.
1469045|NCT03203629|Device|Wearable Cardioverter Defibrillator (WCD)|Observe and compare the heart sound measurements recorded by the WCD
1469046|NCT03203616|Drug|Kadcyla 160Mg Powder for Injection|Kadcyla 160Mg Powder for Injection: 3.6 mg/kg iv every 3 weeks
1469047|NCT03203603|Other|No active intervention|This is a follow-up of a randomized trial. No active intervention is being given in the follow-up.
1469048|NCT03203590|Drug|Oral Navelbine + Carboplatin|The patient will be given Navelbine 60 mg/m2, p.o. day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v. day 1 of every cycle.After 2 cycle we will evaluate their clinical response.Then operable patients will have surgery.
1469049|NCT03203590|Drug|Gefitinib|The patient will be given Gefitinib 250mg,p.o.,q.d. for 8 weeks.After 8 weeks we evaluate their clinical response.Then operable patients will have surgery.
1469050|NCT03203577|Procedure|Initiation of mechanical ventilation|In patient with chronic respiratory insufficient chronic mechanical ventilation will be initiated in the patient his/her setting.
1469052|NCT03203551|Other|Disinfection Protocol|The participants assigned to this group carried out the disinfection protocol that recommended brushing the palate (3 times a day), brushing the total prosthesis with neutral liquid soap (3 times a day) and immersing in different desinfection solutions (once a day/ 20 minutes)
1469053|NCT03203538|Device|LED-light, 1000 lux|Full-spectrum light, 1000 lux, 4000 K. Represent a light intensity within acceptable range (light that is not too glary); 4000 K is among the most commonly used indoor light colour temperatures.
1469054|NCT03203538|Device|LED-light, 100 lux|Full-spectrum light, 100 lux, 4000 K. Represent a light intensity within acceptable range (light that provides sufficient eye sight); 4000 K is among the most commonly used indoor light colour temperatures.
1469055|NCT03203538|Device|LED-light, 7000 K|Full-spectrum light, 7000 K, 200 lux. Represent the upper border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
1469056|NCT03203538|Device|LED-light, 2500 K|Full-spectrum light, 2500 K, 200 lux. Represent the lower border of common colour indoor light temperature, 200 lux is a common indoor light intensity.
1469057|NCT03203538|Device|Blue LED-light|Blue light with peak wavelength 455 nm. Known to delay the circadian rhythm, suppress melatonin, and increase alertness.
1469058|NCT03203538|Device|Red LED-light|Red light with peak wavelength 615 nm. Known not to affect the circadian rhythm, melatonin, and alertness.
1469059|NCT03203525|Drug|Oxaliplatin|"Dose Escalation Group Starting Dose of Oxaliplatin: 85 mg/m2 by vein on Days 1 and 15 of a 28 day cycle.
Dose Expansion Group Starting Dose of Oxaliplatin: Maximum tolerated dose from Dose Escalation Group."
1469060|NCT03203525|Drug|Leucovorin|"Dose Escalation Group Starting Dose of Leucovorin: 400 mg/m2 by vein on Days 1 and 15 of a 28 day cycle.
Dose Expansion Group Starting Dose of Leucovorin: Maximum tolerated dose from Dose Escalation Group."
1469061|NCT03203525|Drug|5-fluorouracil|"Dose Escalation Group Starting Dose of 5-fluorouracil: 400 mg/m2 by vein on Days 1 and 15 of a 28 day cycle.
Dose Expansion Group Starting Dose of 5-fluorouracil: Maximum tolerated dose from Dose Escalation Group."
1469062|NCT03203525|Drug|Bevacizumab|"mFOLFOX6 + Bevacizumab + NovoTTF-100L System Dose Escalation Group Starting Dose of Bevacizumab: 5 mg/kg by vein on Days 1 and 15 of a 28 day cycle.
mFOLFOX6 + Bevacizumab + NovoTTF-100L System Dose Expansion Group Starting Dose of Bevacizumab: Maximum tolerated dose from Dose Escalation Group.
DAT + NovoTTF-100L System Dose Escalation Group Starting Dose of Bevacizumab: 10 mg/kg by vein on Days 1 and 15 of a 28 day cycle.
DAT + NovoTTF-100L System Dose Expansion Group Starting Dose of Bevacizumab: Maximum tolerated dose from Dose Escalation Group."
1469063|NCT03203525|Device|NovoTTF-100L|"NovoTTF-100L system applied to torso where the tumor is located for at least 18 hours a day.
NovoTTF-100L system delivers 100 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 1414mA RMS."
1469066|NCT03203512|Dietary Supplement|Fish oil capsules|Each serving contains 360mg eicosapentaenoic acid (EPA), 270mg docosahexaenoic acid (DHA) and total supplement is 1.8 g per day n-3 PUFA for 12 weeks
1469070|NCT03203486|Other|Mediterranean Diet|Participants were instructed to include vegetables, whole grains and fruits in their diet and increase fish, legumes and raw nut intake. Emphasis was given to extra virgin olive oil as the main added fat in meals. Particular attention was drained to decrease fermented dairy and poultry, with small amounts of red meat and homemade sweets. All participants were given meal plans in which the distribution of nutrients in relation to total caloric value was as follows: 40% of total energy as fat (50% as MUFAs), 20% as protein, 40% as carbohydrate, 300mg/d as dietary cholesterol and 20-30g fiber/d.
1469076|NCT03203434|Diagnostic Test|Urinary volatile organic compound analysis|
1469077|NCT03203421|Biological|ChAdOx1 LS2|A viral vectored vaccine, using a chimpanzee adenovirus as a vector encoding malaria liver-stage dual antigen LS2 (LSA1 and LSAP2) fused with the transmembrane domain from shark invariant chain.
1469078|NCT03203421|Biological|MVA LS2|Modified vaccinia Ankara vector encoding liver-stage dual antigen LS2 (LSA1 ad LSAP2) fused to the C-terminal end of the leader sequence of tPA.
1469081|NCT03203395|Behavioral|Screening and counselling|Screening for symptoms of depression and anxiety in heart patients, giving advice for prevention and managing of such symptoms and stimulating collaborative care between the hospital and the general practitioner.
1469082|NCT03203369|Biological|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen.
1469083|NCT03203356|Drug|growth hormone|Children with a diagnosis of GHD will practice GH replacement therapy in line with normal clinical practice and international guidelines. Controls will be evaluated just at baseline.
1469084|NCT03203343|Procedure|Operation - PIRS|Operation by its known design for PIRS group
1469085|NCT03203343|Procedure|Operation - MARCY|Operation by its known design for MARCY group
1469086|NCT03203330|Biological|TG-C|2 mL injection of allogeneic human chondrocytes expressing transforming growth factor-beta1
1469087|NCT03203330|Biological|Placebo Control|2 mL normal saline injection
1469088|NCT03203317|Drug|Insulin|2 h insulin clamp
1469089|NCT03203317|Other|Exercise|Cycling exercise
1469090|NCT03203304|Drug|Nivolumab|240mg every two weeks by IV infusion
1469091|NCT03203304|Drug|Ipilimumab|1mg/kg every six weeks by IV infusion
1469092|NCT03203291|Device|TPAD (Tethered Pelvic Assist Device)|Each day of intervention will include a 1-hour treadmill based intervention to promote increased loading onto the affected limb. Visual feedback will be provided and faded over the course of the 5-day training. Immediately on completion of the treadmill intervention, participants will receive an additional 5-10 minutes of overground intervention reinforcing weight shifting onto the affected limb.
1469093|NCT03203278|Behavioral|Web-based exercise programme|Aerobic, resistance and balance exercises
1469094|NCT03203265|Other|Group A: Offline HTC|Offline or online referral to HIV treatment facility HIV-positive participants can choose to receive either an offline or online referral to HIV treatment facilities. An offline referral method usually includes a referral letter and/or a telephone call, followed by a series of calls to participants to ensure successful referral. Those who choose an online referral will be able to register online with an HIV treatment facility which provides ART without cost under the national programs. Participants will receive a registration code which will allow them to access HIV treatment clinics directly without the need to go through the regular registration and appointment system at that facility.
1469095|NCT03203265|Other|Group B1: Offline HIV testing and post-test counseling|participants will be guided to access services at the 'Adam's Love Offline Clinic,' a clinic set up specifically to provide private and fast HIV testing and post-test counseling only referred from the Adam's Love Online Clinic.
1469096|NCT03203265|Other|Group B2: Online HIV testing and post-test counseling|A trained online counselor will guide the participant through an online HIV testing process which includes quality checking of the test kit,obtaining blood through finger prick,performing the testing steps,reading the test result. A positive result from the first test will trigger the need for referral to confirmatory tests. The provisional nature of the positive result from the single rapid HIV test will be emphasized but the urgency to get immediate confirmatory tests and linkage to HIV treatment facilities will encouraged and supported. HIV positive test result will be confirmed only with three positive tests. Any online testing session with uncertain qualities at any step will be repeated at a later time or the participant will be offered offline HIV testing.
1469097|NCT03203252|Other|Reconstruction BREAST-Q|Validated Patient reported outcome measure specifically designed to assess Quality of life domains and satisfaction following breast reconstruction.
1469098|NCT03203252|Other|3-dimensional Surface Image|Non-invasive 3-dimensional photograph using VECTRA® XT 3D imaging system.
1469099|NCT03203252|Other|Treatment Questionnaire|Online questionnaire pertaining to treatment received pertaining to breast cancer or risk reduction for breast cancer.
1469100|NCT03203239|Device|Red Light (670 nm energy)|Light Emitting Diode light source (670 nm wavelength with output up to 75mW/cm2) will be placed over the gastrocnemius muscle. The light will be on for 5 minutes.
1469101|NCT03203239|Drug|Octafluoropropane|All subjects will undergo infusion of octafluoropropane to measure peripheral blood flow.
1469162|NCT03202745|Other|Patient Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for patients. It also includes a peer comparison.
1473711|NCT03169582|Drug|Avanafil|Drug administration (Avanafil)
1469102|NCT03203226|Other|FELDENKRAIS METHOD (FM)|They EG will receive the intervention of FM consisting of 30 lessons (1h-lesson per week; 30 weeks) verbal instructions provided by the therapist to participants. These instructions provide different options on how to perform a specific task with the purpose of leaving the decision on how to do the movement up to the performer, who has to focus on thinking, feeling, sensing and doing the movement as easily as possible.The lessons can be conducted sitting, standing or moving within a room.
1469103|NCT03203213|Procedure|Sampling of a few drops of blood, lock of hair and urine|Sampling of a few additional drops of blood to deposit them on blotting paper (DBS: Dried Blood Spot) ad hoc and to send this sample for analysis and identification of a possible toxic cause by psychoactive substance in relation to the clinical picture presented by the patient. An oriented capillary sampling is also performed if possible. Similarly a urine sample is taken if possible.
1469104|NCT03203200|Behavioral|ZETRA cognitive behavioral structural|ZETRA cognitive behavioral structural
1469105|NCT03203187|Other|Mango|330 grams (2 cups) of daily mango intake for two weeks, one cup in the morning, the other in the evening
1469106|NCT03203187|Other|No intervention|No mango intake for two weeks.
1469107|NCT03203174|Device|Microneedle|Microneedles are small needles used to create holes in the stratum corneum (top layer of skin) with relatively low amount of pain.
1469108|NCT03203174|Device|Sham Microneedle|Flat roller with no needles on the roller
1469109|NCT03203174|Drug|Botulinum Toxin Type A|Botulinum toxin type A will be applied to the palm
1469110|NCT03203174|Other|Saline|Saline applied to the palm
1469112|NCT03203148|Diagnostic Test|Point-of-Care ACT|Comparison between two point-of-care devices for measurement of the activated clotting time
1469113|NCT03203135|Behavioral|Nutritional prevention programme|The nutritional prevention programme will offer a wide range of food and physical activity activities adapted to the life of the company (example: culinary demonstration, physical activity, provision of fruit baskets, etc.) .
1469114|NCT03203122|Other|IPL laser|IPL laser monthly. Vertical and horizontal treatment, one pass over. Settings according to fitzpatrick skin type
1469115|NCT03203122|Other|No sham treatment|The treatment is slightly painful, and noisy. Sham treatment impossible
1469116|NCT03203109|Behavioral|Postural Assessment Scale for Stroke (PASS)|Postural Assessment Scale for Stroke (PASS)
1469117|NCT03203096|Dietary Supplement|Magnesium|Magnesium citrate / Magnesium oxide
1469118|NCT03203096|Dietary Supplement|Placebo|
1469119|NCT03203083|Other|performance of the single leg squat task|The single-leg squat (SLS) is a clinical functional test commonly used to evaluate clinical abnormal movement patterns of the lower limbs in terms of kinetic chain or co-ordinating muscle activity. This scale accounts for the assessment of five dimensions: overall impression, trunk posture, pelvis in space, hip joint motion and knee join motion. The SLS is potentially promising as a functional test since it involves both daily activity and athletic task.
1469120|NCT03203070|Drug|Metamizol iv|Postoperative analgesia iv with Metamizol 2g/8h will be administered.
1469121|NCT03203070|Procedure|TAP block|Intraoperative laparoscopic-guided TAP block will be performed with 30ml Bupivacaine 0.5%
1469122|NCT03203057|Other|coronary occlusion|percutaneous coronary intervention
1469123|NCT03203044|Other|Soylent and water diet|A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
1469124|NCT03203031|Procedure|General anesthesia|Standard general anesthesia
1469125|NCT03203031|Procedure|Quadratus lumborum block|Guided by ultrasonography, injection of 0.5 ml/kg of ropivacaine (2 mg/ml) between the quadratus lumborum muscle and the internal oblique muscle, before skin incision
1469126|NCT03203018|Behavioral|Interactive workshop based on community specific needs|"Intervention components will include lecture on women's CVD, workshop on how to prepare for a doctor's visit, patient's rights and patient-doctor communication skills, and a know your numbers workshop, including understanding blood test results."
1469129|NCT03202979|Drug|Trazodone 20 mg|"Oral administration of trazodone 20 mg (corresponding to 10 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 60 mg.
After the 8-week treatment period, patients will receive trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution) three times a day for 1-week tapering period in double blind conditions."
1469130|NCT03202979|Drug|Trazodone 10 mg|"Oral administration of trazodone 10 mg (corresponding to 5 drops of trazodone hydrochloride 6% oral solution), three times a day, for 8 weeks. Trazodone total daily dose: 30 mg.
In order to maintain the study double-blind conditions,patients randomized in this group will be co-administered with placebo oral solution (5 drops).
After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
1469131|NCT03202979|Drug|Placebo|"Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.
After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions."
1469132|NCT03202966|Other|Rehabilitation therapy|Rehabilitation therapy will be provided by a trained community rehabilitation worker (CRW) and specialist (i.e., physical therapist, occupational therapist, special educator and/or speech therapist) with a focus on the one or more domains where delays are identified (i.e. speech, motor, cognition). Therapy will be tailored based on the needs of the individual child and will follow current evidence-based practice.
1469163|NCT03202745|Other|Prescriber Consequences Letter|This letter focuses on the consequences of inappropriate prescribing for prescribers. It also includes a peer comparison.
1469133|NCT03202953|Procedure|ventilation strategy 1|"In Group I, after trendelenburg position, patients will be applied 1:1 ratio VCV.
Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:1, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
1469134|NCT03202953|Procedure|ventilation strategy 2|"In group A, after trendelenburg position, patients will be applied autoflow VCV.
- Tidal volume : 8ml/kg, inspiration:expiration ratio = 1:2, FiO2 = 0.5, maintain end tidal CO2 around 40±5 mmHg. Positive end expiratory pressure will not used."
1469135|NCT03202940|Drug|Alectinib|Alectinib is an oral ALK inhibitor. The term ALK inhibitor means that alectinib targets the abnormal ALK protein that is causing lung cancer cells to grow
1469136|NCT03202940|Drug|Cobimetinib|Cobimetinib is an oral inhibitor of MEK, a signaling protein that can cause some types of lung cancer to grow
1469137|NCT03202927|Drug|PEGFILGRASTIM|Pegfilgrastim is a covalent conjugate of recombinant methionyl human granulocyte colony-stimulating factor and monomethoxy polyethylene glycol.
1469138|NCT03202914|Behavioral|Usual protein and phosphorus diet|Diet intervention
1469139|NCT03202914|Behavioral|Low protein and phosphorus diet|Diet intervention
1469140|NCT03202914|Behavioral|Very low protein and phosphorus|Diet intervention
1469141|NCT03202901|Dietary Supplement|B-turmactive|"The treatment consists of daily administration of B-TURMACTIVE®.
Treatment with B-TURMACTIVE® will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:
V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).
V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
1469142|NCT03202901|Dietary Supplement|Placebo|"The treatment consists of daily administration of placebo capsule with identical format and harmless thant B-turmactive product.
Treatment with placebo will last 7 days to determine the effects of the product in the short term, during which the volunteers will be visited 4 times:
V0 screening: to evaluate the inclusion and exclusion criteria. V1 inclusion and randomisation (Day 1): 1st day treatment and intervention. Measure primary and secondary variables V2 (Day 3): the primary endpoint will be monitored by telephone (perception of pain).
V3 (Day 7): Day 7 of treatment and final intervention. Measure primary and secondary variable"
1469144|NCT03202875|Drug|SAR341402|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1469145|NCT03202875|Drug|Insulin Aspart|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1469146|NCT03202875|Drug|Insulin Aspart|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1469147|NCT03202862|Drug|Fulvestrant|Fulvestrant 500 mg given as two 5 ml intramuscular inections, one in each buttoc, on days 1, 15, 2 and every 2 ( ) days thereafter.
1469148|NCT03202849|Dietary Supplement|Vitamin D and A|"Single dose of each prior to HSCT.
Vitamin D:
Dose: To be determined by the results of the high dose vitamin D phase 1 study with an estimated dosing range to lie between 7000-14,000 units/kg with a maximum dose of 600,000 units.
Formulation: Cholecalciferol 5000 and 50,000 oral capsules
Vitamin A:
Dose: To be determined by the results of the high dose vitamin A phase 1 study and estimated to range between 500- 5000 IU /kg with maximum dose of 250,000 IU orally.
Formulation: 10,000 IU liquid filled oral capsules."
1469149|NCT03202849|Dietary Supplement|Vitamin D and Placebo|"Single dose prior to HSCT + placebo.
Vitamin D:
To be determined by the results of the high dose vitamin D phase 1 study with an estimated dosing range to lie between 7000-14,000 units/kg with a maximum dose of 600,000 units.
Formulation: Cholecalciferol 5000 and 50,000 oral capsules
Placebo:
Placebo pills will be dispensed in patients who are randomized to this arm."
1469150|NCT03202836|Drug|progesterone|vaginal utrogestan
1469151|NCT03202836|Drug|Tocolytics|tocolysis for 48 hours
1469152|NCT03202836|Drug|Steroids|antenatal corticosteroids for 48 hours
1469153|NCT03202823|Procedure|blood samples|3 tubes (5 ml volume) collected during surgery
1469154|NCT03202823|Procedure|recover samples of atheromatous plaque|a carotid sample collected during surgery
1469155|NCT03202797|Other|audiometric tests|tone and speech audiometry
1469156|NCT03202797|Other|Questionnaires|APHAB (Abbreviate Profile of Hearing Aid Benefit), HISQUI (Hearing Implant Sound Quality Index), Munich music questionnaire
1469157|NCT03202797|Other|Settings of cochlear implants|pitch matching, evolutionary algorithm setting
1469159|NCT03202771|Device|Home Biofeedback Therapy|Patients will be taught how to use the home-trainer in a single lab session. Then we will place a reusable, dual sensor, probe into their rectum. The probe is connected to a hand- held pressure monitor displaying the patient's response. Next, the clothed patient will be asked to sit on a commode, and attempt 15 bearing down maneuvers. When the anal sphincter pressure decreases more lights go on. If the patient cannot relax then fewer lights go on. Thus, the number of lighted lights gives instant feedback about their performance. Patients will get a 20-minute tape recording for home use. Patients will be asked to insert the probe at least twice daily and each time practice at least 15 bearing down maneuvers; a daily log will be kept. At 4 and 8 weeks, they will return for follow up. Based on their progress, new targets will be set by adjusting the device's sensitivity.
1469160|NCT03202771|Other|Office Biofeedback Therapy|A monitor screen will provide visual feedback by showing changes in pressure activity. First patients will be taught abdominal muscle coordination exercise to improve the pushing effort during defecation. Here, patients are taught how to distend the abdomen by inhaling slowly and then holding their breath for at least 15 seconds and to practice this for 20 minutes, twice a day. Thereafter, patients will be asked to attend the motility laboratory, biweekly for up to 6 training sessions. BT will be performed by a 3-sensor manometry probe. The clothed patient will be seated on a commode in front of a monitor. The physician/nurse therapist will give verbal feedback by either complimenting the patient for performing a correct maneuver or rectifying any errors. Each 60 minute treatment session will comprise of the following maneuvers:
1469161|NCT03202758|Drug|Durvalumab, Tremelimumab and ,FOLFOX|"Study will be performed in 2 step:
STEP 1 (phase Ib) will assess the safety of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX during the 2 first cycles of treatment (1 month)
STEP 2 (phase II) will assess the efficacy of the combination of Durvalumab 750mg q2w + tremelimumab 75mg q4w + FOLFOX"
1469164|NCT03202732|Other|DiabetesFlex|"DiabetesFlex consist of one mandatory and two optional consultations. Before the consultations patients receive the AmbuFlex Diabetes questionnaire.
The AmbuFlex Diabetes questionnaire is based on both validated questionnaires and clinical consensus. The AmbuFlex Diabetes questionnaire consists of: SF36 well-being question, WHO-5 Well-being Index. Questions concerning: HgA1c, home-based blood pressure monitoring, incidents of hypoglycemia, diabetes complications, regular eye check, regular food check, erectile dysfunction and peripheral neuropathy, The PAID scale, Topics patients may want to talk with the health care professional about, the patient's evaluation of the need for diabetes care. View the AmbuFlex Diabetes questionnaire at the homepage: www.diabetesflex.auh.dk."
1469165|NCT03202719|Biological|Bivalent oral poliovirus vaccine (bOPV) at 6,10 and 14 weeks of age|bOPV at 6, 10 and 14 weeks of age
1469166|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 14 weeks and 18 months of age|IPV at 14 weeks and 18 months of age
1469167|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 14 weeks, 18 weeks and 18 months of age|IPV at 14 weeks, 18 weeks and 18 months of age
1469168|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 14 weeks and 9 months of age|IPV at 14 weeks and 9 months of age
1469169|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 6 weeks and 9 months of age|IPV at 6 weeks and 9 months of age
1469170|NCT03202719|Biological|Inactivated poliovirus vaccine (IPV) at 6 and 14 weeks of age|IPV at 6 and 14 weeks of age
1469171|NCT03202706|Procedure|Samples of adipose tissue|Samples of visceral and subcutaneous adipose tissue collected during hernia surgery
1469172|NCT03202693|Drug|PA-824|
1469173|NCT03202680|Other|USDA Style Diet|USDA style healthy diet, low in saturated fats.
1469174|NCT03202680|Other|Lean Beef Diet|A lean beef containing healthy diet, low in saturated fats.
1469177|NCT03202654|Other|Corn Oil|4 tablespoons/day of corn oil for 4-week treatment period.
1469178|NCT03202654|Other|Coconut Oil|4 tablespoons/day of coconut oil for 4-week treatment period.
1469179|NCT03202641|Procedure|PEEPinc|PEEP systematically increased, in small increments, until the best respiratory system mechanics is identified.
1469180|NCT03202641|Procedure|LRM plus PEEPdec|LRM is a transitory and controlled increase in airway pressure to open collapsed alveoli. After lung recruitment, PEEP is systematically decreased, in small decrements, until the best respiratory system mechanics is identified
1469181|NCT03202628|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
1469182|NCT03202628|Drug|Dexamethasone|Given PO
1469183|NCT03202628|Drug|Ixazomib Citrate|Given PO
1469184|NCT03202628|Other|Laboratory Biomarker Analysis|Correlative studies
1469185|NCT03202628|Drug|Pomalidomide|Given PO
1469186|NCT03202615|Dietary Supplement|L (lactoferrin)|Dietary Supplement: Pravotin sachets (Hygint, Egypt) containing bLf One sachet of Pravotin contains 100 mg of bLf. Dosage: one sachet twice a day before meals with placebo tablets
1469187|NCT03202615|Drug|F (ferrous sulphate)|Drug: FerroGrad by Abbott Dosage: one capsule three times /day containing150 mg of dried ferrous sulfate capsules (Ferrofol capsules, Eipico, Egypt), with placebo sachets.
1469188|NCT03202602|Other|Telemonitoring of CPAP treatment|Telemedicine technology allows for monitoring of CPAP pressure, air leaks, apnea-hypopnea index (AHI) and compliance on a daily basis.
1469189|NCT03202602|Other|Standard care|Office visits and monitoring of CPAP treatment at each visit.
1469190|NCT03202589|Other|FOCUS Echocardiography|FOCUS Echocardiography
1469191|NCT03202576|Device|Nasal Bridle|Nasal bridle placement and securement of the tube. Instead of taping the tube to the patient's face, nose or upper lip the bridle is a device whereby a magnetic retrieval system is attached to 1/8 inch umbilical tape which is inserted via the nares, looping around the nasal septum and vomer bone and ending with both ends of the bridle (umbilical tape) secured together and to the feeding tube just outside the nose.
1469192|NCT03202563|Drug|Gemigliptin 50mg|For patients who have been randomized to Gemigliptin(Experimental arm), the patients continue to take a gemigliptin 50mg 1 tablet by once daily during study treatment period(Visit 3(day 1)~Visit 6(day 91))
1469193|NCT03202563|Drug|Dapagliflozin 10mg|For patients who have been randomized to Dapagliflozin(Active Comparator arm), the patients continue to take a dapagliflozin 10mg 1 tablet by once daily during study treatment period(Visit 3(day 1)~Visit 6(day 91))
1469194|NCT03202563|Procedure|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regular diet without greater changes in life style as much as possible during the whole study period.
the questionnaire regarding diet/exercise will be collected at -day 6, day 1, day29, day85, day 91"
1469195|NCT03202563|Device|Continuous Glucose Monitoring System(CGMS)|For patients who have been screening completely, the subjects will be attached CGMS(ipro-2) twice from Visit 2(-day 6) to Visit 3(day 1) and Visit 5(day 85) to Visit 6(day 91)
1469196|NCT03202563|Drug|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
1469197|NCT03202550|Drug|Oxycodone and Lorazepam (Active Comparator)|Oxycodone and Lorazepam
1469198|NCT03202550|Drug|Placebo Comparator|Placebo oral pills
1469199|NCT03202537|Drug|dexlansoprazole|dexlansoprazole treatment for Gastroesophageal Reflux symptoms
1469200|NCT03202524|Biological|Fresh Frozen Plasma (FFP)|FFP will be used as a substitute for albumin for the prevention of post-paracentesis circulatory dysfunction.
1469201|NCT03202524|Biological|Albumin|Albumin will be used for the prevention of post-paracentesis circulatory dysfunction, as is the standard of care
1469202|NCT03202511|Drug|Probenecid Oral Tablet|Included in arm/group descriptions.
1469203|NCT03202511|Drug|Tenofovir disoproxil fumarate/Emtricitabine|Included in arm/group descriptions.
1469204|NCT03202498|Device|4g Yaq-001|Study patients will be dosed daily with 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 15 weeks, including the screening (up to 2 weeks), treatment (12 weeks) and 7-day follow up period.
1469205|NCT03202498|Other|4g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 4g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 15 weeks, including the screening (up to 2 weeks), treatment (12 weeks) and 7-day follow up period.
1469206|NCT03202498|Device|8g Yaq-001|Study patients will be dosed daily with 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 15 weeks, including the screening (up to 2 weeks), treatment (12 weeks) and 7-day follow up period.
1469207|NCT03202498|Other|8g Placebo|Study patients will be dosed daily with a quantity of placebo equivalent to 8g of product Yaq-001 for a period of 12 weeks. The product will be provided as beads packed in individual sachets intended each for one oral administration. For each patient, the study duration will be up to 15 weeks, including the screening (up to 2 weeks), treatment (12 weeks) and 7-day follow up period.
1469208|NCT03202485|Device|Toric Implantable Collamer Lens|uses Toric Implantable Collamer Lens implantation to correct the high myopic astigmatism.
1469209|NCT03202485|Device|ICL + Astigmatic keratotomy|uses Implantable Collamer Lens implantation combined with Astigmatic keratotomy to correct the high myopic astigmatism
1469210|NCT03202472|Device|Implanted Medical Device|Radiofrequency tag
1469211|NCT03202472|Procedure|Mammography|Undergo mammogram for image-guided placement of radiofrequency tag
1469212|NCT03202472|Other|Questionnaire Administration|Ancillary studies
1469213|NCT03202472|Procedure|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
1469214|NCT03202472|Procedure|Ultrasonography|Undergo ultrasound for image-guided placement of radiofrequency tag
1469215|NCT03202459|Drug|Group A - gabapentin 600 mg|The patient will receive oral 600 mg gabapentin 2 h before surgery
1469216|NCT03202459|Drug|Group B - pregabalin|The patient will receive oral pregabalin 150 mg 2 h before surgery
1469217|NCT03202459|Drug|Group C - placebo|The patient will receive oral placebo 2 h before surgery and ondansetron 8mg intravenous at the end of the surgery
1469218|NCT03202446|Drug|1% Glycated Chitosan|
1469219|NCT03202446|Device|Photothermal Laser|
1469220|NCT03202446|Drug|Placebo|
1469221|NCT03202446|Drug|Cyclophosphamide|
1469222|NCT03202446|Drug|Standard of Care|
1469223|NCT03202433|Device|Use of virtual reality lenses, with relaxing audio-visual contents|Use of virtual reality lenses (and audio) as a distraction for the blood donor patients.
1469225|NCT03202407|Drug|Calcium acetate and sevelamer hydrochloride|receive the conventional renal replacement therapy including calcium-based phosphate (calcium acetate) and active form of vitamin D for 3 months with regular follow up of serum phosphate ,calcium, parathyroid hormone and alkaline phosphate every month
1469226|NCT03202394|Drug|BIO-11006|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
1469227|NCT03202394|Drug|Placebo|"Intervention involves aerosolized delivery of either the active drug or placebo by the Aeroneb Pro nebulizer."
1469228|NCT03202381|Drug|Degarelix|"Degarelix (Firmagon®) will be administered as a subcutaneous injection in the abdominal region every 28 days, in according to the following schedule:
Starting dose: 240 mg administered as two consecutive subcutaneous injections of 120 mg each (2 x 3 mL injections).
Maintenance dose: 80 mg administered as one subcutaneous injection of 80 mg (1 x 4 mL injection).
Treatment will be continued till clinically indicated or till disease progression."
1469229|NCT03202368|Drug|Tocilizumab|162 milligrams (mg) of tocilizumab every week for a maximum of 156 weeks or until the commercial availability of tocilizumab, whichever comes first
1469230|NCT03202355|Device|Fixed Appliance Orthodontic Treatment|Patients receive fixed appliance orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
1469231|NCT03202355|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
1469232|NCT03202342|Other|Water|Water, 300 ml, at room temperature
1469233|NCT03202342|Other|Glucose|Water containing 50 g glucose, 300 ml, at room temperature
1469234|NCT03202342|Other|Ethyl butyrate|Water containing ethyl butyrate (pineapple flavour) 300 ml, at room temperature
1469235|NCT03202342|Other|Glucose + ethyl butyrate|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at room temperature
1469236|NCT03202342|Other|Glucose + ethyl butyrate 0 C|Water containing 50 g glucose and ethyl butyrate (pineapple flavour) 300 ml, at 0 degrees centigrade
1469237|NCT03202329|Other|standard care|cardiologists assist in treatment and provide heart failure guidance post-operatively if required by the treating surgeon
1469238|NCT03202329|Other|Nurse-based care|board-certified heart failure nurses provide heart failure guidance post-operatively on every working day
1469239|NCT03202316|Drug|Cobimetinib|"Safety Lead-In Starting Dose of Cobimetinib: 60 mg by mouth daily. Participants take Cobimetinib by mouth at the same time every day with or without food on a 3 weeks on, 1 week off schedule.
Phase II Starting Dose of Cobimetinib: Maximum tolerated dose from Safety Lead-In."
1469240|NCT03202316|Drug|Atezolizumab|840 mg by vein over about 30 minutes every 2 weeks while on study.
1469241|NCT03202316|Drug|Eribulin|1.4 mg/m2 by vein over about 5 minutes on Days 1 and 8 of Cycles 1-4.
1469244|NCT03202290|Behavioral|Cognitive and clinical assessment|The content of the assessment will be the same for all subjects and will consist of a cognitive assessment (neurocognition, social cognition, metacognition, emotional reactivity) and a clinical assessment (impulsivity, personality, psychriatric and addictive comorbidities)
1469245|NCT03202277|Behavioral|BeWell24 smartphone app|This app delivers an evidence-based suite of lifestyle interventions targeting behavior change in sleep, sedentary behavior, physical activity, and dietary intake. The app connects with a commercially available activity monitor to provide real-time feedback on behaviors over time.
1469246|NCT03202277|Behavioral|Health education app|This app delivers basic health education and hygiene content related to sleep, sedentary behavior, physical activity, and dietary intake.
1469247|NCT03202264|Other|TAPER|"The intervention is medication reduction. This arm is comprised of:
Medication reconciliation
Identification of patient priorities for care
Identification of medications that are potentially appropriate for discontinuation/dose reduction
Linked pharmacist/family physician consultations with patient to discuss medication with intention to reduce
Identification of medications for trial of discontinuation/dose reduction (shared decision making)
Pause of medication and clinical monitoring"
1469248|NCT03202251|Other|It's is a cohort|It is a prospective, observational, cohort study
1469249|NCT03202238|Device|Veinlite|Commercial transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
1469250|NCT03202238|Device|FireFly Prototype 1|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
1469251|NCT03202238|Device|FireFly Prototype 2|Transilluminator device that allows veins to show up as a silhouette among surrounding soft tissue
1469252|NCT03202225|Device|constrained polyethylene|constrained polyethylene insert
1469253|NCT03202212|Procedure|mixed on-line hemodiafiltration|This is a mixed hemodepurative technique exploiting diffusion and convection through a semi-permeable membrane. Dialysis solution is not only interfacing with blood through the membrane (as in bicarbonate hemodialysis) but it is also mixed with it with a pre- and a post- filter dilution. The same amount of fluid added to the bloodstream is then removed within the filter through an appropriate negative pressure in the dialysis solution compartment and thanks a high permeability membrane. Patients will be treated three sessions per week, four hours per session
1469254|NCT03202212|Procedure|High flux bicarbonate dialysis|Standard high flux bicarbonate dialysis with polysulfone membrane, three sessions per week, four hours per session
1469255|NCT03202199|Device|PET/MRI|2 PET/MRI examinations
1469256|NCT03202186|Drug|Progesterone oral capsule|Oral capsule treatment
1469257|NCT03202186|Drug|Placebo oral capsule|Oral capsule treatment
1469258|NCT03202173|Diagnostic Test|10% fluorescein|The nasopharyngeal lesions were first identified endoscopically by nasal endoscope. Then, an initial dose of 0.5 mL prior to the examination with a maximum dose of 2.5 mL of 10% fluorescein (IV; Akorn Inc, Lake Forest, Illinois, USA) during the measurement procedure was defined according to the experiences of workgroup in the gastrointestinal tract.
1469259|NCT03202147|Drug|Cromolyn|Active capsules for inhalation.
1469260|NCT03202147|Other|Placebo|Non-active capsules for inhalation.
1469261|NCT03202134|Other|general anesthesia|
1469262|NCT03202121|Other|insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to insomnia group that contained 25 cases.
1469263|NCT03202121|Other|non-insomnia group|After screening according to inclusion and exclusion criteria, patients were assigned to non-insomnia group that contained 25 cases.
1469264|NCT03202121|Other|normal control|Persons without stroke or insomnia served as normal controls that contained 25 cases.
1469265|NCT03202108|Dietary Supplement|Krio|"Krio is a ready to eat, chocolate-flavoured, solid bar containing 20g fat per 28g bar. It contains protein and carbohydrate with added sweetener and flavourings. It does not contain any added micronutrients. Krio is not for use as a sole source of nutrition.
It has a fat to protein and carbohydrate ratio of 3 to 1, making it suitable for use in all versions of the ketogenic diet.
This product is to be consumed daily under the direction of a dietitian."
1469266|NCT03202095|Drug|Creatine Monohydrate|5 grams daily of oral creatine monohydrate powder.
1469267|NCT03202082|Behavioral|Neuropsychological testing|Neuropsychological testing evaluates various aspects of a participants cognitive ability as well as mood.
1469268|NCT03202069|Other|Even protein|Intake of even protein 5 day rotating menu
1469269|NCT03202069|Other|Skewed protein|Intake of skewed protein 5 day rotating menu
1469270|NCT03202056|Other|Dry needling|Dry needling is a skilled intervention that uses a thin filiform needle to penetrate the skin and stimulate underlying myofascial trigger points, muscular, and connective tissues for the management of neuromusculoskeletal pain and movement impairments.
1469271|NCT03202056|Other|Sham Dry needling|Sham Dry needling use a non-penetrating acupuncture needle
1469272|NCT03202043|Other|High dose vegetable juice|High dose (13 fl oz) vegetable juice
1469273|NCT03202043|Other|Medium dose vegetable juice|Medium dose (10 fl oz) vegetable juice
1469274|NCT03202043|Other|Low dose vegetable juice|Low dose (5.5 fl oz) vegetable juice
1469275|NCT03202043|Other|Control bottled water|Control (12 fl oz) bottled water
1469276|NCT03202030|Procedure|Immediate dentoalveolar restoration|Block of bone removed from the tuber and placed in the buccal resorption of the socket together with an immediate implant
1469277|NCT03202030|Procedure|Demineralized bovine bone|Block of demineralised bovine bone placed in the buccal resorption of the socket together with an immediate implant
1469278|NCT03202017|Procedure|Expiratory Muscle Strength Training (EMST)|EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
1469279|NCT03202017|Procedure|EMST + Lung Volume Recruitment (LVR)|"EMST uses a training device that has a valve set to 50% of a patient's maximum expiratory pressure (MEP). The patient exhales forcefully until the valve releases. Patients perform 5 sets of 5 repetitions a day, 5 days a week.
LVR is a technique to increase cough function that is performed with a resuscitation bag fitted with a mouthpiece and a one-way valve. The bag is used to expand the lungs, after which the patient makes a voluntary cough. Half of the participants will perform the LVR technique in addition to the ESMT technique."
1469280|NCT03202004|Drug|GSK2894512 1% cream|1 % (10 mg/g) GSK2894512 cream will be provided in tubes labeled in compliance with country requirements.
1469281|NCT03202004|Drug|Vehicle cream|Vehicle cream will be provided in tubes labeled in compliance with country requirements.
1469282|NCT03201991|Other|Resistance Exercise Program|The resistance exercise program will involve three sets of 10 repetitions of each exercise in levels 1 and 2 every day. Participants will be given instructions to follow.
1469522|NCT03200392|Procedure|blade DGG harvesting|De-epithelialized palatal graft harvested using scalpel blade (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession defect coverage
1469283|NCT03201978|Drug|GSK2894512 1% CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
1469284|NCT03201978|Drug|GSK2894512 MATCHING VEHICLE CREAM|It will be prepared as close as possible to the time of administration to avoid a prolonged exposure to light. Each single cream application will be made by weight, dispensed on hand (fingertips) covered with clean disposable glove and evenly spread using fingertips.
1469291|NCT03201939|Drug|Lisinopril|ACE-inhibitor (lisinopril)(intervention arm
1469292|NCT03201939|Other|Placebo Oral Tablet|Comparator placebo (control arm)
1469293|NCT03201926|Dietary Supplement|mealworms|10g , 3 times a day , po, 2 months
1469294|NCT03201926|Dietary Supplement|grain powder|grain powder, 10g ,3times one day,2months
1469296|NCT03201900|Drug|E2007|Oral tablet
1469297|NCT03201887|Behavioral|Sub-optimal effort|Participants will be asked to play a patient who wishes to present himself as having cognitive deficits or exaggerate existing cognitive deficits
1469298|NCT03201887|Behavioral|optimal effort|Participants will be asked to perform tasks to the best of their abilities.
1469301|NCT03201861|Drug|Paclitaxel, Cisplatin|weekly paclitaxel and cisplatin
1469302|NCT03201861|Drug|EC to docetaxel or paclitaxel|Standard adjuvant chemotherapy recommended by guideline
1469303|NCT03201848|Drug|Placebo|Placebo given to subject will be adjusted by body weight (<10kg, Placebo given to subject will be adjusted by body weight(<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day;) .
1469304|NCT03201848|Drug|Huaiqihuang Granule|Huaiqihuang Granule given to subject will be adjusted by body weight (<10kg, half a bag, 2 times a day; 10-20kg; 1 bag, 2 times a day; 20-30kg, 1.5 bag, 2 times a day; 30-50kg, 2 bags, 2 times a day; ≥50kg, 3 bags, 2 times a day)
1469305|NCT03201835|Drug|PNL-THC:CBD soft gelatin capsule|3 soft capsules, containing a total of 10.8 mg THC and 10 mg CBD (Each capsule contains 3.6 mg THC and 3.3 mg CBD)
1469306|NCT03201835|Drug|Sativex|spray X 4 actuations
1469307|NCT03201835|Drug|CBD hard capsule dose 1|1 hard capsule containing 10 mg CBD
1469308|NCT03201835|Drug|P-PNL-THC:CBD soft gelatin capsule|2 soft capsules containing a total of 7.2 mg THC, 6.7 mg CBD and 20 mg piperine (Each capsule contains 3.6 mg THC, 3.3 mg CBD and 10 mg piperine)
1469309|NCT03201835|Drug|CBD hard capsule dose 2|1 hard capsule containing 100 mg CBD
1469310|NCT03201822|Other|100 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 100 cocoa flavanols/70kg BW.
1469311|NCT03201822|Other|200 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 200 cocoa flavanols/70kg BW.
1469312|NCT03201822|Other|400 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 400 cocoa flavanols/70kg BW.
1469313|NCT03201822|Other|1000 mg of Cocoa Flavanols/70 kg BW|Fruit-flavored non-dairy drink containing 1000 cocoa flavanols/70kg BW.
1469314|NCT03201809|Device|On-Q|0.2% Ropivicaine at 4 mL/h via On-Q catheter placed sub-pectoral
1469315|NCT03201809|Drug|Ultrasound guided pectoral nerve block|Single Shot Pre-operative injections of 10 mL of 0.25% Ropivicaine for the Pecs 1 injection, and 20 mL of 0.25% Ropivacaine for the Pecs 2 injection
1469316|NCT03201796|Drug|Prulifloxacin 600 mg|Oral administration of one tablet once daily for 28 days of prulifloxacin 600 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
1469317|NCT03201796|Drug|Levofloxacin 500mg|Oral administration of one tablet once daily for 28 days of levofloxacin 500 mg. The investigational drug will be taken with a glass of water, preferably in the evening and at about the same time each day, 2 hours before or at least 4 hours after the eventual administration of cimetidine, antacids containing aluminum and magnesium or preparations containing iron and calcium.
1469318|NCT03201783|Other|immediate frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed in the first cycle following the stimulated IVF cycle
1469319|NCT03201783|Other|delayed frozen-thawed embryo transfer|Frozen-thawed embryo transfer will be performed at least in the second cycle following the stimulated IVF cycle
1469320|NCT03201770|Drug|pyronaridine artesunate|Antimalarial treatment
1469366|NCT03201341|Other|Electrooculogram (EOG)|The acquisition of the surface EOG activity will be carried out by means of 3 surface electrodes, one of which, referred to as a reference, is placed on a bone zone (the glabella, above the nasion) and two others placed on The temples, coupled to an EOG amplifier.
1469551|NCT03200093|Drug|Placebo|Ora-Sweet 5mL taken by mouth once daily.
1469322|NCT03201744|Procedure|Patients will be randomized to moderate (TOF 1-2) or deep (post tetanic count 1-2) relaxation. Low pressure insufflation (start pressure set at 8 mm Hg)|All procedures will start with low insufflation pressure (8 mmHg). Surgical field assessment (scale 1-5) will be performed every 5 minutes (Martini Br J Anaesth 2014). If conditions are poor (rating 1-2), intraperitoneal insufflation will be incrementally increased (10 mmHg, 12 mmHg, 15 mmHg) every 5 minutes as needed.Reversal of muscle relaxation will be performed at the end of the procedure using established medications used in clinical practice. In theory, deep relaxation may require a more prolonged reversal process, but using contemporary medical agents (sugammadex), reversal from deep relaxation is prompt (2-3 minutes) without any additional delays.
1469323|NCT03201705|Device|Burst + Tonic|Patients fulfilling the inclusion criteria will be enrolled in the study and receive electrocatheter implant (Precision Spectra system, Boston Scientific). Then, they will be observed for a two-weeks trial period in which the efficacy of the stimulation and the compliance of the patient is evaluated. During this trial a Tonic wave stimulation is administered by the external generator. After the trial, the definitive generator will be implanted. Tonic stimulation will be selected as wave form for four weeks. After this period, the stimulation will be switched into the combined waveform for 30 days. At the end of the study period, the final waveform setting of the SCS will be in accord with the patient's stimulation preference.
1469324|NCT03201692|Device|Virtual Reality Treadmill Training|Subjects in the experimental group will receive 40 minutes comprising exercises focused on improving dynamic balance following auditory and visual cues.
1469325|NCT03201692|Device|Treadmill training|Subjects in the active comparator group will receive 40 minutes walking training aimed to improve velocity and endurance.
1469326|NCT03201679|Procedure|Repair of hip fracture|Patients undergoing hip fracture surgery
1469327|NCT03201653|Procedure|Stump closure using NU-KNIT SURGICEL|We would use the Oxidized Regenerated Cellulose as NU-KNIT SURGICEL.
1469328|NCT03201640|Behavioral|slideshow|Participants will be shown a slideshow showing a child being prepared for surgery
1469329|NCT03201640|Behavioral|virtual|Participants will be shown an immersive virtual reality preparation for surgery
1469330|NCT03201627|Drug|Lithium Carbonate|To observe whether lithium carbonate has protective role on the brain of Niemann-Pick disease C1
1469331|NCT03201601|Drug|D-chiro-inositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
1469332|NCT03201601|Drug|Myoinositol|Each participant will consume 2 capsules daily of each treatment, in the morning and at night without any restriction in the diet nor in their habits of life. The treatment will last 12 weeks.
1469333|NCT03201588|Dietary Supplement|Formulaid|Arachidonic acids (AA) Docosahexaenoic Acids(DHA) 2:1
1469334|NCT03201575|Device|Remote Ischemic conditioning|A brachial cuff is positioned around the arm of the patient. Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible after randomization. The intervention is repeated at 12 and 24 hours after inclusion.
1469335|NCT03201575|Device|Patients with no remote ischemic conditioning|A brachial cuff is positioned around the arm of the patient and no inflation or deflation is made.
1469339|NCT03201549|Dietary Supplement|oral fructose challenge|Participants will consume fructose for two weeks and fast for 8 hours before study visits where they will drink a fructose beverage.
1469340|NCT03201536|Device|conventional Suture|Sutures
1469341|NCT03201536|Device|Zip3|wound closure device
1469342|NCT03201523|Other|Socio-ecologial, community-based intervention|Intervention components will include a health newsletter, health workshops, community evening/health project registration, lay leader training, neighborhood exercise groups, community walking programs with pedometers, healthy cooking contest, and school health promotion activities.
1469343|NCT03201510|Other|Observational|HPTN 075 is an observational study in sub-Saharan MSM
1469344|NCT03201484|Other|FACE-Q questionnaire, 3D photography|FACE-Q questionnaire, 3D photography
1469345|NCT03201471|Drug|Chidamide + R-CHOP regimen|Patients will receive 2 courses of Chidamide+ R-CHOP regimen, the way of administration and dosage of the medicine used in the trial is as follows: Rituximab 375mg//m2, ivgtt,d1;CTX 750mg/m2, ivgtt,d2;EPI 70mg/m2, ivgtt,d2;VCR 1.4 mg/m2, ivgtt, d2; Pred 60 mg/m2,PO, d2-6; Chidamide 20mg/d,d1、4、8、11、14、18;one cycle every 21 days;
1469346|NCT03201458|Drug|Atezolizumab|Given IV
1469347|NCT03201458|Drug|Cobimetinib|Given PO
1469348|NCT03201458|Other|Laboratory Biomarker Analysis|Correlative studies
1469352|NCT03201432|Device|Drug eluting stent (DES)|Polymer-free paclitaxel eluting stents
1469353|NCT03201432|Device|Bare metal stent (BES)|Bare metal stent
1948369|NCT02453347|Device|CES Therapy|Cranial Electrotherapy Stimulation (CES) may serve as an effective complimentary, noninvasive/non-pharmacological treatment for this Veteran population. CES is administered through a therapeutic device (such as Alpha-Stim®) marketed and approved by the FDA to treat insomnia, depression, anxiety, and pain.
1469360|NCT03201380|Other|TEP scanner with choline|
1469361|NCT03201367|Drug|Rivaroxaban|Rivaroxaban 10 mg/12 hour
1469362|NCT03201367|Other|symptomatic therapy for ascites, abdominal pain|
1469363|NCT03201354|Procedure|Filtration surgery with Ex-PRESS|Filtration surgery with Ex-PRESS
1469364|NCT03201354|Procedure|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy
1469365|NCT03201354|Procedure|Cataract extraction|Cataract surgery and IOL implantation
1469367|NCT03201341|Other|Surface Electromyography (EMG)|In behavioral or transcranial stimulation protocols, surface EMG activity may be recorded for further analysis. No protocol included in this project will involve the recording of intramuscular electromyographic activity, which is invasive and involves the implantation of needle electrodes into the muscles.
1469368|NCT03201341|Other|Electrodermal response|The electrodermal response is a useful, simple and reproducible method for recording sweat gland activity that reflects autonomic nervous activity. Recordings will be made using traditional devices, including an amplifier (Delsys or BrainAMP or equivalent) as well as disposable electrodes.
1469369|NCT03201341|Other|Changes in skin temperature|The skin temperature will therefore be recorded during behavioral protocols using techniques for manipulating the representation of the body (perceptual illusion, prismatic deviation, etc.) using a specific measuring device.
1469370|NCT03201341|Other|MRI|Whatever the protocol, a diffusion tensor MRI (DTI) acquisition sequence as well as an image of the entire brain and high spatial resolution (T1 weight, 1x1x1 mm, nasion markers and pre-atrial points) will be acquired (Total duration: 20 minutes).
1469371|NCT03201341|Other|MEG|During the examination, the subject will have to perform tasks comparable to those described for the fMRI procedure, but with the additional possibility, offered by the MEG environment, of performing pointing or seizing of objects, provided that the Trunk and the subject's head be held in place by a suitable restraint system.
1469372|NCT03201341|Other|Transcranial magnetic stimulation (TMS)|TMS is a non-invasive technique that uses very short (~ 100μs) magnetic pulses applied to the scalp to transiently and focally disrupt or improve the functioning of neuronal populations in the underlying superficial cortical regions.
1469373|NCT03201341|Other|Transcranial electrical stimulation in direct current (tDCS)|The tDCS consists in passing a current of low intensity (generally ≤ 1mA to stimulate the cerebral cortex) between an anode and a cathode placed on the scalp, a part of this current crossing the tissues, and in particular the cortical regions situated between these two Electrodes. Generally, if the cathode is placed on the region of interest, it will be inhibited, while it will be energized if the anode is positioned thereon.
1469374|NCT03201328|Other|Audio-vestibular examination|Vestibular tests (videonystagmoscopy and head video impulse test), the tonal and vocal audiogram and the localigramme to the cochlear implanted subjects. Tonal audiometry and localigramme to the healthy subjects.
1469375|NCT03201328|Other|Videonystagmoscopic study|Rotating sound stimulation on a rotatory armchair and a laborer of Fukuda with sound stimulation and questionary before and after examination.
1469376|NCT03201328|Other|Posturographies study|(stabilometry, sensory preferences, indications of energy consumption) with stereophonic stimulation and questionnaire before and after the examination.
1469377|NCT03201302|Other|School physical education class|Children participated only in school physical education classes only.
1469378|NCT03201302|Other|Taekwondo|Children participated only in taekwondo training only.
1469379|NCT03201302|Other|Martial arts|Children participated only in martial arts training only.
1469380|NCT03201302|Other|Climbing|Children participated only in climbing training only.
1469381|NCT03201302|Other|Volleyball|Children participated only in volleyball training only.
1469382|NCT03201302|Other|Artistic gymnastics|Children participated only in artistic gymnastics training only.
1469383|NCT03201302|Other|Swimming|Children participated only in swimming training only.
1469384|NCT03201302|Other|Dance|Children participated only in dance training only.
1469385|NCT03201302|Other|Basketball|Children participated only in basketball training only.
1469386|NCT03201302|Other|Wrestling|Children participated only in wrestling training only.
1469387|NCT03201302|Other|Football (soccer)|Children participated only in football (soccer) training only.
1469388|NCT03201302|Other|Rhythmic gymnastics|Children participated only in rhythmic gymnastics training only.
1469389|NCT03201302|Other|Track and field|Children participated only in track and field training only.
1469390|NCT03201302|Other|Tennis|Children participated only in tennis training only.
1469391|NCT03201302|Other|Combination of activities 1|Children participated in two weight-bearing activities.
1469392|NCT03201302|Other|Combination of activities 2|Children participated in one weight-bearing activity and in one non weight-bearing activity.
1469393|NCT03201276|Drug|Glucosamine Sulfate|Patients taking glucosamine sulfate 1500mg every day for at least four days.
1469394|NCT03201263|Procedure|Sigh|Application of cyclic pressure control breath delivered at 30 cmH2O for 3 seconds once per minute in patients undergoing pressure support ventilation
1469395|NCT03201263|Procedure|Standard of care|Standard of care
1469396|NCT03201250|Drug|Cabozantinib|"Cabozantinib:
Phase I: Level -1 = 20 mg or Level 0 = 40 mg or Level +1 = 60 mg, PO daily on days 1-28 Phase II: One of phase I dosing levels identified as MTD, PO daily on days 1-28
Carfilzomib: 27 mg/m2 IV over 10 min on days 1, 2, 8, 9, 15, 16
Dexamethasone: 40 mg PO/IV on days 1, 8,15 and 22 (for patient age ≥ 75, acceptable to be given as 20 mg PO/IV on days 1, 2, 8, 9, 15, 16, 22, 23)"
1469397|NCT03201237|Other|Action observation training|Each child observed a task video and then performed a task
1469398|NCT03201224|Device|"After Group"|
1948374|NCT02449239|Biological|Vicinium|Intravesical administration
1948384|NCT02445963|Biological|Shigella flexneri 2a InvaplexAR|The investigational product is S. flexneri 2a InvaplexAR. The product is composed of three individual components IpaB, IpaC, and LPS. The components were assembled into the high molecular weight S. flexneri 2a InvaplexAR complex and subsequently purified by ion-exchange chromatography yielding a bulk lot.
1469403|NCT03201198|Behavioral|Active Life|The Active Life intervention focuses on increasing light physical activity (LPA) with 18 sessions over 10 weeks. Each session starts with 20 minutes of walking followed by functional circuit training. The intensity of the exercises and the speed of execution are adjusted to attain a rating of perceived exertion equal to somewhat hard to hard at the end of each circuit. Sessions end with stretching the major muscle groups. Sessions include a behavioral component (self-efficacy enhancing or confidence building) and health education. Subjects are encouraged to increase their total PA by at least 60 minutes a day, focusing on LPA. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
1469404|NCT03201198|Behavioral|Chair exercises|Chair exercises focus on toning and stretching from a seated position with 18 sessions over 10 weeks. Each session includes 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery. Guided imagery is used to promote relaxation. Health education includes topics of interest to people with COPD such as basic lung physiology, pathophysiology of COPD, commonly used medications, breathing techniques, healthy eating and physical activity, relaxation, travel considerations, and energy conservation. After completion of the structured intervention subjects will receive 11 5-minute phone coaching sessions and two booster sessions over the next 12 months.
1469405|NCT03201185|Drug|Ramipril|Initial dose: 2,5 mg. Up-titrated at one month to 5 mg and 10 mg at three months (following clinical practice recommendations for up-titration). Target dose: 10 mg (or maximum tolerated dose).
1469407|NCT03201159|Drug|VLX103|150mg tablets
1469408|NCT03201146|Drug|Apatinib|Doses to be determined following the completion of Phase I of the study.
1469409|NCT03201146|Drug|AP or AC|Pemetrexed(A) 500mg/m2, IV, Day 1; Cisplatin(P) 25mg/m2,IV,Day 1-3 or Carboplatin(C) area under curve(AUC)=5, IV, Day 1; AP or AC will be administered every 21 days starting on Day 1.
1469410|NCT03201146|Drug|Apatinib 250mg|250mg/d,q.d.,p.o.every 21 days.
1469411|NCT03201146|Drug|Apatinib 500mg|500mg/d,q.d.,p.o.every 21 days.
1469412|NCT03201146|Drug|Apatinib 750mg|750mg/d,q.d.,p.o.every 21 days.
1469416|NCT03201107|Other|Pilates|"Training based on a basic level Pilates exercise program will be as follows:
A duration of weeks with a frequency of 2 sessions a week and with a duration of 55 minutes each. The exercises to be performed will be divided into three distinct phases: warm-up, lasting 15 minutes; Main part with a duration of 30 minutes and the return to calm, based mostly on stretching and with a duration of 10 minutes. The repetitions of the exercises will be between 5 and 10 according to the difficulty."
1469417|NCT03201094|Device|Neuromuscular Electrical Stimulation (NMES)|Neuromuscular electrical stimulation twice daily during study period.
1469418|NCT03201094|Dietary Supplement|High Protein Supplementation|High protein supplementation with whey protein shakes taken three times a day during study period.
1469419|NCT03201081|Other|Motivational resistance-training programme|The experimental group exercised at a moderate intensity (8 to 12 repetitions). The load was increased during the 12 weeks from 65% 1-RM to 80% 1-RM. This training load was increased when the individual could perform more than the prescribed number of repetitions (12 repetitions), following the OMNI-RES scale and a hard effort perception level.74 A 1-2 minutes resting period was allowed between sets. During the sessions, the participants were verbally encouraged to perform the complete range of motion for each exercise and received motivational strategies.
1469420|NCT03201068|Dietary Supplement|Probiotic supplement|Probiotic supplement capsule
1469421|NCT03201068|Dietary Supplement|Placebo|Placebo capsule
1469422|NCT03201055|Device|Snore PAP System|The Snore PAP system delivers a set Continuous Positive Airway Pressure (CPAP) and consists of a CPAP flow generator and an approved pillows mask.The system will deliver a fixed positive airflow to the participant via approved tubing and pillows mask.
1469452|NCT03200821|Drug|Gemcitabine|1000 µg/m^2 intravenously administered once weekly for seven weeks starting at Week 0 followed by one week of rest. After, treatments will occur in cycles of 3 weeks of treatment followed by one week of rest.
1469453|NCT03200808|Drug|mixed methylene blue compound injection|Every patient received intradermal mixed methylene blue compound injection twice.
1469423|NCT03201042|Diagnostic Test|PCR based assay|"Whole blood specimens will be tested for the presence of Borrelia DNA by PCR in a two-step test (Imugen). In Cohort 1a and 1b. The first step tests for the presence of any Borrelia DNA. The second step is employed on positive samples and tests for the presence of either B. burgdorferi DNA or B. miyamotoi DNA. Positivity by PCR has a short but early window in the infection cycle for Borrelia burgdorferi and results may enable this window period and diagnosis rates to be better defined.
In addition co-infection PCR analysis will be performed for the presence of Babesia, Anaplasma or Ehrlichia DNA (Imugen)."
1469424|NCT03201042|Diagnostic Test|Serology based assay|"The Imugen Lyme Antibody Analysis which includes immunoglobulin M (IgM),immunoglobulin G (IgG), and immunoglobulin A (IgA) antibody capture immunoassay and IgG and IgM based Western blots. In Cohort 1a and 1b.
The Immunetics C6 Lyme ELISA assay.
A 2-tier Lyme test performed and interpreted according to Centers for Disease Control (CDC) Guidelines
A Rickettsia antibody test will be used to identify Spotted Fever and Typhus fever groups infections.
Lyme test methodologies generally indicate a need to run a combination of tests in order to overcome limitations in either sensitivity or specificity of the various individual tests. Performance of all these tests on the same set of samples should enable both individual and combinatorial performance values to be calculated and compared."
1469425|NCT03201042|Diagnostic Test|Tcell based assay|A research based ELISpot assay will be performed on peripheral blood mononuclear cells (PBMC) extracted from whole blood samples to test for presence of T cells activated against Borrelia antigens. Unlike serology based methods, this signal may not persist over extended periods of time in the absence of Borrelia antigens. The diagnostic window may be different for a test measuring adaptive immune response (i.e. T cells) and thus such test may identify patients with undetectable antibody response and may aid sensitivity of diagnosis.
1469426|NCT03201016|Diagnostic Test|Bone densitometry|Procollagen Type I Propeptides, alkaline phosphatase, Crosslinked Telopeptides of Type I Collagen
1469427|NCT03201003|Biological|AR101|AR101 powder
1469428|NCT03201003|Other|Placebo|Placebo powder
1469429|NCT03200990|Device|iVAC2L pVAD|To determine the effects of the new PFLVAD PulseCath® iVAC2L and the CFLVAD Impella CP on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.
1469430|NCT03200990|Device|Impella CP pVAD|To determine the effects of the new PFLVAD PulseCath® iVAC2L and the CFLVAD Impella CP on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.
1469432|NCT03200964|Other|anesthesia given as required for surgical procedure|
1469433|NCT03200951|Drug|Bolus group for epidural block|Randomly selected patients of the bolus group are given 0.3 ml/kg bolus of 0.15% ripivacaine for epidural block.
1469434|NCT03200951|Drug|Infusion group for epidural block|Randomly selected patients of the infusion group are given 0.3 ml/kg/hr 0.15% ripivacaine for epidural block.
1469435|NCT03200938|Device|formocresol and zinc oxide.|Removal of the coronary pulp from primary molar teeth, use of formocresol and zinc oxide
1469436|NCT03200938|Device|PBS CIMMO cement.|Removal of the coronary pulp from primary molar teeth, use of PBS cement
1469437|NCT03200925|Other|"Jumping into Kangaroo Care - a video created by the Ohio Department of Health"|The video is 8 minutes and 52 seconds in length. The video discusses the benefits and logistics of Kangaroo Care from professional's perspectives and from new mother's perspectives.
1469438|NCT03200912|Drug|Ingenol Mebutate (Picato®)|Brand product
1469439|NCT03200912|Drug|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
1469440|NCT03200912|Drug|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
1469441|NCT03200899|Behavioral|MAPSS-MS|MAPSS-MS is a computer-assisted cognitive rehabilitation intervention. It is a combination of home computer training and 8-weeks of group sessions on lifestyle change and compensatory cognitive strategies.
1469442|NCT03200899|Other|Usual Care plus computer games|"Participants assigned to this arm receive their usual medical care and referral to the My Brain Games website."
1469443|NCT03200886|Device|Sinovial H-L|Patients were treated with an hybrid form of hyaluronic acid (Sinovial H-L) obtained through thermo-chemical processes from the combination of high (1100-1400 kDa) and low (80-100 kDa) MW fractions.
1469444|NCT03200886|Drug|Triamcinolone Acetonide|The patients have received two i.a. injections (at baseline and 15 days apart) of 0.5 ml of triamcinolone acetonide (Kenacort® 20 mg, Bristol-Myers Squibb Srl)
1469449|NCT03200834|Procedure|Right Hemicolectomy with D2 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, №211, №212 (if present), №221,№222 (Japanese classification).
1469450|NCT03200834|Procedure|Right Hemicolectomy with D3 lymph node dissection|Remove right part of colon with lymph node dissection №201, №202, № 203, №211, №212 (if present), №213 (if present) №221,№222, №223 (for hepatic flexure and proximal part of transverse colon cancer)(Japanese classification).
1469451|NCT03200821|Biological|G17DT|250 µg/0.2 mL administered by intramuscular injection at Weeks 0, 2 and 6. 125 µg booster administered at Week 24.
1948385|NCT02438293|Other|rhinovirus diagnostics|rhinovirus PCR on a nasopharyngeal swab
1469454|NCT03200795|Other|Rebound exercise|"Each participant will undergo 3 sessions a week for 8 weeks with each session lasting 20 minutes. Bouncing frequency will be determined by signals from an metronom and will be set at between 90 and 120 bounces per minute. Heart rate training zone will be maintained, during the exercise, at moderate intensity of 40-60% and will be calculated using the Karvonen formula ([Heart rate reserve x training percentage] + resting heart rate)(Nuhu & Maharaj, 2017).
The exercise will involve bouncing on the center portion of the mini trampoline (Portable 2013 Model Half-Fold Cellerciser with feet slightly apart and knees in full extension. Each foot strike equaled one step or bounce with step height, this will be defined as the distance between the foot at maximum height of jump and the bed of the center of the trampoline ranging between 10 and 15 cm (Nuhu & Maharaj, 2017)."
1469455|NCT03200795|Other|Circuit training exercise|"Participants will be instructed to exhale while lifting a weight and inhale while lowering it, to minimize blood pressure excursions, and to rest for 2 to 3 minutes between sets. Participants will perform 1 set per resistance exercise three time weekly for the first 2 weeks and 4 sets of each resistance exercise three time weekly during weeks 3 and 4. Resistance will be increase by 5 to 10 kg when the participant could perform more than 15 repetitions while maintaining proper form.
All aerobic activities of the circuit training will be performed on a cycle ergometer or treadmill. Participants are free to vary the machine used from one visit to the next. Exercise intensity will be standardized by using heart rate monitors (Polar Electro Oy) that will display the participant's heart rate and emitted a warning signal when the heart rate was outside the prescribed training zone, thus guiding the participant in adjusting the workload up or down to achieve the desired intensity."
1469456|NCT03200782|Drug|Empagliflozin|Glucose lowering effect of empagliflozin for reducing the counter-regulatory glucose-lowering response
1469457|NCT03200782|Drug|Anakinra|IL-1Beta blockage effect on insulin secretion and thereby influencing postprandial glucose level
1469458|NCT03200782|Other|oral placebo (winthrop tablet)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) 3 hours before the test meal and an oral placebo (winthrop tablet) 2 hours before the test meal will be administered by an Independent nurse to the blinded patient
1469459|NCT03200782|Other|subcutaneous placebo (0.67 ml of 0.9% sodium chloride)|subcutaneous placebo (0.67 ml of 0.9% sodium chloride) will be administered in arm 'Placebo-Placebo' and arm 'drug: Empagliflozin'
1469460|NCT03200769|Device|CPAP active|CPAP PR1 Philips Respironics with a pression between 4 and 14 mm Hg
1469461|NCT03200769|Device|CPAP placebo|CPAP PR1 Philips Respironics with a constant pression of 4 mm Hg.
1469462|NCT03200756|Behavioral|Sedentary Group|The sedentary group undergoes a behavioral intervention to reduce sedentary behavior which includes a patient centered approach with monitoring and goal setting.
1469463|NCT03200756|Behavioral|Exercise Group|The Active Comparative group undergoes a standard clinical approach to increase exercise which is patient centered with monitoring and goal setting.
1469464|NCT03200730|Behavioral|Family Dignity Intervention group|A brief psychotherapeutic intervention offered to a family dyad (i.e., patient and one identified family caregiver) using narrative approach with life review elements. The purpose is to facilitate an open dialogue between the family dyad that strengthens family connectedness and emotional connection.
1469465|NCT03200717|Drug|pazopanib|Pazopanib will be administered as a flat-fixed dose and not by body weight or body surface area.
1469466|NCT03200704|Combination Product|IC2000 and SPY-PHI|This is a randomized prospective, open label, multicenter, non-inferiority within-patient study to determine the effectiveness of IC2000 and SPY as an intraoperative fluorescence visualization tool in the identification of lymph nodes during lymphatic mapping as compared to Isosulfan Blue.
1469467|NCT03200691|Radiation|3-DCRT or IMRT radiation|Radiation of primary tumor and local lymph nodes with 95% planning target volume (PTV) of 40 Gy/20f.
1469468|NCT03200691|Drug|anti-PD-1 antibody SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 2 cycles) will be administered as an intravenous infusion over 60 minutes.
1469469|NCT03200678|Other|isokinetic assessment|muscle torque assessement
1469470|NCT03200665|Diagnostic Test|Ultrasound 35-36 (6 / 7 days weeks)|An obstetric ultrasound will be performed at 35-36 (6 / 7 days weeks) including biometric parameters and functional parameters of the fetus
1469471|NCT03200652|Dietary Supplement|Metabolic availability of lysine in wheat|Four levels of lysine intakes will be provided by the reference protein drinks, 3 levels of lysine from wheat and 1 level from wheat with lentils.
1469472|NCT03200639|Other|Combined training|The CT and CTc protocol (total length time ~60 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by 30-min walk at 70% of maximum heart rate or Borg Scale at 5-6 following resistance exercises (RE: 45-degree half squat, bench press, leg curl, rowing machine and unilateral leg extension) at 70% of one repetition maximum (1RM) with three sets of 8-12 repetitions and 1.5 min rest interval between sets and exercises. If the volunteer exceeded or did not reach the walk intensity, the volunteer was stimulated by to decrease or increase the walk speed, respectively. Regarding the resistance exercises, the load was adjusted in the 6th week with the 1RM test to ensure the 70% of 1RM between 8-12 repetitions.
1469473|NCT03200639|Other|High intensity interval training with body weight|The HIITBW and HIITBWc protocol (total length time ~28 min) were performed three times a week for 12 weeks, in nonconsecutive days, and were composed by ten sets of 60 s of high (vigorous) intensity exercises at 80-95% of HRmax or Borg Scale at 8-9 (i.e. 30s of stepping up and down on a step and 30s of squatting up and down as fast as possible) interspersed with a recovery of 60 s of light walk (<60% of HRmax or Borg Scale at <5). To ensure vigorous zone of all sets, if the volunteer exceeded or did not reach the vigorous zone the volunteer was stimulated by the fitness professionals to decrease or increase the number of steps and squats, respectively.
1469474|NCT03200626|Procedure|Autologous hematopoietic cell transplant|Autologous hematopoietic cell transplant
1469475|NCT03200613|Drug|Apixaban|2.5 mg orally twice daily
1469476|NCT03200613|Drug|Low molecular weight heparin|Dalteparin 5000 units daily or Enoxaparin 40 mg subcutaneous daily
1469477|NCT03200600|Drug|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
1469478|NCT03200600|Drug|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
1469521|NCT03200392|Device|laser root surface conditioning & blade DGG harvesting|laser root surface biomodification (single application) and scalpel blade harvesting of de-epithelialized palatal graft (Zucchelli et al. 2010) and coronal repositioned flap for gingival recession Miller's I, II defect coverage
1469479|NCT03200600|Drug|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the end of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
1469480|NCT03200600|Drug|Lipid microsphere|Lipid microsphere 5 ml is administered before the end of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
1469481|NCT03200587|Drug|Avelumab|Avelumab 10 mg/kg infusion every 2 weeks (Days 1 and 15) of every 28 day cycle for up to 12 cycles
1469482|NCT03200587|Drug|Cabozantinib|Cabozantinib oral daily at 20 (starting dose 1), 40 (Dose Level 2) or 60 mg (Dose Level 3)
1469483|NCT03200574|Diagnostic Test|4D Cardiac CT Scan|4D CT scan obtained at minimum of 1 month after the discontinuation of the anticoagulation or dual antiplatelet therapy
1469484|NCT03200574|Device|LivaNova Bioprothetic Aortic Valve Implant|Study includes patients that have received a commercially approved LivaNova bioprosthetic aortic heart valve (Perceval, Crown PRT, Solo Smart) as standard of care.
1469485|NCT03200561|Drug|Prednisolone|Prednisolone 2mg/Kg/day for 5 days
1469486|NCT03200561|Biological|immunoglobulin|immunoglobulin 2g/Kg for 12 hours
1469487|NCT03200548|Behavioral|Relaxing acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
1469488|NCT03200548|Behavioral|Usual care|Negative control group. Participants are asked to carry on with their usual management practices and habits.
1469489|NCT03200548|Behavioral|Stimulating acupressure plus usual care|Experimental group. Self-administered acupressure is one possible safe, self-management technique for which may be effective for improving fatigue as well as physical and psychosocial functioning in several chronic disease populations. Acupressure, a technique derived from acupuncture, is a component of Traditional Chinese Medicine (TCM) in which pressure is applied to specific acupoints on the body using a finger or small device, to treat disease.
1469490|NCT03200548|Behavioral|Sham acupressure plus usual care|Positive control group. Chosen pressure points are not known to be effective.
1469491|NCT03200535|Other|EHR gaps|Gaps will appear in the electronic health record and patient portal in order to prompt referral by provider or patient
1469492|NCT03200535|Other|Bulk outreach|A bulk letter or email will be sent
1469493|NCT03200535|Other|Dietician call|Patients will receive a personalized call by a registered dietitian
1469494|NCT03200522|Other|Prudent diet|Six days of meals provided with high amounts of fruits and vegetables, whole grains, fiber, omega-3 fatty acids, low-fat dairy products, and overall high levels of antioxidants.
1469495|NCT03200522|Other|Western diet|Six days of meals provided with high amounts of processed foods, fast foods, sweets, omega-6 fatty acids, and a low intake of fiber.
1469498|NCT03200496|Drug|DA-5206(Fasting)|Test drug l : DA-5206(Fasting)
1469499|NCT03200496|Drug|DA-5206(Fed)|Test drug ll : DA-5206(Fed)
1469500|NCT03200496|Drug|TALION®|Reference drug : Talion®
1469501|NCT03200483|Other|Control Protocol|In this period the volunteers were at rest, in the supine position for 15 minutes, followed by 30 minutes of aerobic exercise on a treadmill (five minutes at a speed of 6.0 km / h followed by 25 minutes with 60% of Vmax + 1% grade) and then a recovery period lasting 60 minutes (three minutes standing on the treadmill followed by 57 minutes in the supine position). The volunteers were instructed to remain awake during all the protocol and this was verified and monitored by one of the researchers.
1469502|NCT03200483|Other|Classical Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to classical music during exercise and recovery.
1469503|NCT03200483|Other|Rock Music Protocol|Volunteers accomplished the same activities of the control protocol, but with exposure to rocky musical style during exercise and recovery.
1948387|NCT02431481|Drug|LEE011|400 mg
1469505|NCT03200457|Device|1,5 Tesla abdominal MRI|Measurement of the fat and iron
1469506|NCT03200457|Device|3 Tesla abdominal MRI|Measurement of the fat and iron
1469507|NCT03200444|Other|Standard adhesive 1|This strip consists of a standard hydrocolloid adhesive found in ostomy products
1469508|NCT03200444|Other|Standard adhesive 2|This strip consists of a standard hydrocolloid adhesive found in ostomy products
1469509|NCT03200444|Other|Standard adhesive 3|This strip consists of a standard hydrocolloid adhesive found in ostomy products
1469510|NCT03200444|Other|P-4|Newly developed adhesive P-4
1469511|NCT03200444|Other|P-15|Newly developed adhesive P-14
1469512|NCT03200444|Other|P-16|Newly developed adhesive P-8
1469513|NCT03200431|Other|New adhesive strip|This is a newly developed strip.
1469514|NCT03200418|Other|Standard hydrocolloid adhesive|This patch is made of standard hydrocolloid adhesive
1469515|NCT03200418|Other|P-4|This patch is made of new adhesive
1469516|NCT03200418|Other|P-15|This patch is made of new adhesive
1469517|NCT03200418|Other|P-16|This patch is made of new adhesive
1469518|NCT03200405|Device|DynaMeshVisible|The umbilical hernias will be fixed with a mesh. In this group a MRI-visible mesh will be used.
1469519|NCT03200405|Device|DynaMeshCICAT|The umbilical hernias will be fixed with a mesh. In this group a non-visible mesh will be used.
1469520|NCT03200392|Device|laser root surface conditioning & laser DGG harvesting|laser root surface biomodification (single application) and placement of harvested de-epithelialized gingival graft (DGG) followed by coronal repositioned flap for gingival recession Miller's I, II defect coverage
1469523|NCT03200379|Other|directly acting antivirals (DAAs)|Eligible subjects would be those CHC patients who receive approved DAA in the daily practice in Taiwan. No clinical developing medications will be allocated patients.
1469524|NCT03200366|Behavioral|DVD|"A 20 minute tailored DVD titled Approaches to Colon Testing is viewed by participants. It is designed to encourage CRC screening uptake by colonoscopy or FIT by increasing the participant's CRC knowledge and beliefs about the benefits of screening, reducing barriers to screening, and increasing self-efficacy for screening by demonstrating how these tests are performed."
1469525|NCT03200366|Behavioral|Patient Navigation|Participants talk by telephone with a Patient Navigator who is a population health nurse in the healthcare system. The Patient Navigator determines if participants viewed the tailored DVD and answers any questions about the content. The Patient Navigator then provides telephone counseling on CRC and screening tests to: (1) increase knowledge, perceived benefits, and self-efficacy; (2) reduce barriers; (3) enhance access; and (4) provide social support.
1469526|NCT03200353|Device|system NATROX (device name)|system NATROX (device name) application on the wounds of lower limbs
1469527|NCT03200340|Drug|EC-18|Oral administration of EC-18 twice daily
1469528|NCT03200340|Drug|Placebo|Placebo to match EC-18 capsule administration
1469531|NCT03200314|Other|Measurment of blood recirculation|Ultrasound based measurments of blood recirculating through the vvECMO circuit.
1469532|NCT03200301|Procedure|Intact Umbilical Cord Milking|Immediately after delivery, the infant will be placed at or ∼20 cm below the level of the placenta and about 20 cm of the intact umbilical cord will be milked towards the umbilicus three times. The technique consists of pinching the cord close to the placenta and milking about 20 cm segment of the cord proximal to the umbilicus, towards the infant over a 2-second duration. The cord will then be released and allowed to refill with blood for a brief 2-second pause between each milking motion. After completion of milking three times, the cord will be clamped close to the umbilicus and the neonate handed over to the neonatal team. The procedure of cord milking will be completed within 20 seconds.
1469533|NCT03200288|Device|HL-01: high and low molecular weight hyaluronic acid|2 ml intra-articular single injection
1469534|NCT03200288|Device|Placebo|2 ml intra-articular single injection
1469535|NCT03200275|Diagnostic Test|Immunocatch™ Legionella Urine Antigen Test|A total number of 503 urine specimens from study participants will be tested with LUAT - Immunocatch™. This test utilises the immunochromatographic (ICT) membrane assay to detect antigenuria which has revolutionized the usage of UAT to diagnose Legionella infections. The results can be obtained within minutes and the test does not require any sophisticated laboratory support. A comparison of the ICT with the Enzyme Immuno Assay (EIA) test showed comparable performance characteristics.
1469536|NCT03200249|Radiation|Preoperative chemo-radiation with IG-IMRT dose escalation|
1469537|NCT03200236|Behavioral|Intensive Telephone Counseling (8 sessions) with nicotine replacement|Participants are provided up to 8 counseling sessions lasting approximately 20 minutes each and access to 8-weeks of free nicotine replacement patches. A counselor-initiated discussion of screening results will also be included throughout the counseling sessions.
1469538|NCT03200236|Behavioral|Usual Care: Telephone counseling (3 sessions) with nicotine replacement|Participants are provided up to 3 counseling sessions lasting approximately 20 minutes each and access to 2-weeks of free nicotine replacement patches.
1469539|NCT03200223|Behavioral|Personalized healthcare service|Personalized healthcare service, such as exercise recommendation, lifestyle activity coaching, health data monitoring
1469540|NCT03200210|Drug|Febuxostat|Febuxostat tablets would be given to patients at dose of 20mg/d, once a day, and dose would be adjusted according to serum uric acid at specific visits.
1469541|NCT03200210|Drug|Placebo|Pills manufactured to mimic Febuxostat tablets
1469542|NCT03200197|Other|Menthol chewing gum|The experimental group received one unit of mentholated chewing gum, chewing and swallowing the saliva in a natural rhythm for 10 minutes. The menthol chewing gum used is called TRÍDENT®and is composed as follows: base gum, hydrogenated vegetable oil, vegetable oil, sweeteners: sorbitol, xylitol, mannitol, maltitol, aspartame, acesulfame potassium, and sucralose, humectants: glycerin and triacetin, flavorings (contains wheat derivatives), anti-humectant talc, emulsifiers: esters of mono- and diglycerides of fatty acids with acetic acid, soy lectin and mono and diglycerides of fatty acids and colorings: tartrazine and brilliant blue FCF, presenting a weight of 1.8g per unit.
1469543|NCT03200197|Other|Usual care (fasting)|The control group received the usual care given at the hospitalization units, that is, when the patient reported thirst, the need to maintain fasting for 10 minutes was reaffirmed.
1469544|NCT03200184|Drug|sofosbuvir and daclatasvir|A fixed dose combination pill containing 400mg sofosbuvir and 60 mg daclatasvir given daily for 12 weeks. If a patient is cirrhotic, treatment duration would be 24 weeks.
1469545|NCT03200158|Other|Endoscopy biopsy and blood|Medical operation
1469546|NCT03200145|Other|ACP intervention|"The intervention group made by persons living in nursing homes using a person centered attention model relying on two dimensions:
- Attention to the person based on:
Knowledge of the person in several dimensions (biological, psychological, social, etc), interests and preferences.
Respect and acknowledge of the person.
Promotion of the autonomy.
Personalized treatment, with tailored attention and integrative cures
Protection of physical well-being, preventing damages and risks and promoting healthy habits.
Promotion of independence on daily activities.
Protection of privacy and personal matters
- Positive environment based on:
Physical space, including accessibility, comfort, homely environment, with stimulating spaces for physical activity, social relationships and significant activities for the persons.
Social relationships, with proximity and collaboration with families.
Friendly organization, with empathetic professionals empowering users."
1469547|NCT03200132|Diagnostic Test|Cardiac PET/MRI|For patients undergoing 18-Fluor- fluorodeoxyglucose (18F-FDG) PET/MRI or PET/Computed Tomography (CT), additional cardiac PET/MRI scans are acquired.
1469548|NCT03200119|Behavioral|Daily health-related lifestyle modification prescription|Daily health-related lifestyle modification prescription
1469549|NCT03200106|Device|Alfapump|Alfapump implant
1469550|NCT03200093|Drug|Oral Vancomycin|Oral vancomycin solution 125 mg in 2.5 mL combined with 2.5 mL Ora-Sweet. A total of 5 mL combined solution taken by mouth once daily.
1469556|NCT03200067|Behavioral|Personalized health care service|Personalized health care service, such as rehabilitation exercise recommendation, lifestyle activity coaching, health data monitoring
1469557|NCT03200054|Other|Adherence Clubs|Women will be referred to the ACs at their postpartum ART clinic visit at the midwife obstetric unit (MOU) at the Gugulethu community health centre (CHC). AC visits occur 2-4 monthly at a community hall near the CHC. At routine visits, which last ~1 hour, community health workers provide health education, weigh participants, ask about symptoms, and dispense pre-packed ART. Symptomatic participants are referred back to the main ART facility at the CHC for assessment by a nurse. A nurse performs routine phlebotomy at an annual club visit, and does a clinical assessment and reviews blood results at the subsequent visit. Participants requiring more regular follow-up and those with raised viral loads are referred back to the ART clinic at the CHC by the nurse.
1469558|NCT03200041|Procedure|Blood sample|20 ml blood sample taken from vein in arm
1469559|NCT03200028|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-five minutes of training on computerized exercises that targets executive function, memory and attention.
1469560|NCT03200015|Drug|Metformin|Potentially increasing the efficacy and safety of standard chemotherapy through several mechanisms
1469561|NCT03200002|Drug|Cyclophosphamide|Cyclophosphamide injection was administered in the dose of 0.5 to 1 gram per m2 of body surface area. The medicine, which is available in the strength of 1 gram in powder form, was first dissolved in 20 ml of normal saline. Only15 ml of this preparation was mixed in 100 ml of normal saline and was infused over a period of one hour. CYC was not given to those patients who had total leukocyte counts (TLC) less than 2500/mm3. Those patients were re-evaluated after one week and intravenous pulse CYC was reinstituted if the TLC exceeds 2500/mm3. Pulse CYC was administered every month for a total of six infusions.
1469562|NCT03200002|Drug|Mycophenolate Mofetil|Participants in the MMF group were administered tablet mycophenolate mofetil at a starting dose of 500 mg twice daily if the weight of the patient was less than 50 kilograms and 750 mg twice daily if the weight was more than 50 kilograms. After one month, the dose of MMF was increased to 750 mg twice daily. The clinical response was monitored in terms of reduction in serum creatinine and proteinuria. MMF dose was decreased or interrupted in patients experiencing an absolute neutrophil count <1300/mm3 at any study visit; MMF treatment was discontinued if a patient experienced an absolute neutrophil count <1000/mm3.
1469563|NCT03199989|Drug|CapeOX（Capecitabine+Oxaliplatin）|Patients enrolled in the chemotherapy group would receive postoperative chemotherapy CapeOX（Capecitabine+Oxaliplatin）for 6 months
1469564|NCT03199989|Other|Observation|Patients enrolled in the observation group would not receive any chemotherapy drugs just for observation
1469565|NCT03199976|Drug|Tiotropium Bromide|Tiotropium Bromide 2.5 µg/dose inhaled aerosol
1469566|NCT03199976|Drug|Fluticasone Propionate|Fluticasone Propionate 125 µg/dose inhaled aerosol
1469567|NCT03199976|Drug|Salbutamol|Salbutamol 0.1 mg/dose inhaled aerosol
1469568|NCT03199963|Drug|4-OH tamoxifen|4-Hydroxytamoxifen (afimoxifene) gel
1469569|NCT03199963|Drug|Placebo gel|An absorptive hydroalcoholic gel preparation of the same ingredients as BHR-700, but without 4-OHT.
1469570|NCT03199950|Drug|Haloperidol|Haloperidol 2dd1mg (08.00am - 10.00pm)
1469571|NCT03199950|Drug|Placebo Oral Tablet|Placebo oral 2dd (08.00am - 10.00pm)
1469572|NCT03199937|Behavioral|Flexible Futures|Flexible Futures is a novel and innovative cognitive-behavioral treatment that directly addresses executive function and self-regulation deficits in ASD. Flexible futures targets flexibility and planning through self-regulatory scripts that are consistently modeled and reinforced. Scripts compensate for the inner speech and organization/integration deficits in ASD, and are practiced repeatedly to achieve automaticity. Content focuses on key functions needed for college success, such as: intrinsic motivation, how to implement skills socially, self-advocacy skills application of flexibility and organization scripts and strategies in the service of a long-term goal, and management of time and priorities.
1469573|NCT03199937|Other|Current standard of care|Flexible Futures will be compared to a social skills treatment as usual that capitalizes on current standard of care provided by local school districts.
1469574|NCT03199924|Drug|Diclofenac|Intramuscular injection of 75mg / 3ml of Diclofenac solution
1469575|NCT03199924|Drug|Magnesium Sulfate|intravenous injection of 1 g magnesium solution diluted in 10ml of saline solution administered over 2 minutes
1469576|NCT03199924|Drug|Lidocaine|intravenous injection of 10ml lidocaine 1% solution administered over 2 minutes
1469579|NCT03199898|Diagnostic Test|Silverman-Andersen Retraction Score|The Silverman-Andersen Retraction Score (SAs) is used to assess severity of respiratory distress in newborn and preterm infants without respiratory support.The score comprises 4 inspiratory categories of movements (thoraco-abdominal, intercostal, xiphoid, and chin movements) and one expiratory category (grunting).
1469585|NCT03199872|Biological|RV001V|Sc injection
1469628|NCT03199560|Drug|Tc 99m filtered sulfur colloid|lymphatic mapping agent
1469629|NCT03199547|Drug|Azithromycin|The women will be randomized to receive a single dose of Azithromycin or Placebo
1469630|NCT03199547|Drug|Placebo Oral Tablet|The women will be randomized to receive a single dose of Azithromycin or Placebo
1469631|NCT03199534|Drug|Botulinum toxin A 50u|Subject will receive injection of 50u Botulinum toxin A with local sedation as an office procedure.
1469632|NCT03199534|Drug|Botulinum toxin A 150u|Subject will receive injection of 150u Botulinum toxin A while anesthetized.
1576876|NCT02406508|Device|Melphalan/HDS|
1469587|NCT03199833|Device|RETRAINER-S2|"It consists of the execution of different exercises with the affected forearm-hand supported by the RETRAINER-S2 device. The subject is actively involved in the exercises and the system provides two types of support: wrist-fingers motion constraining and FES. The following exercises can be performed: controlled wrist flexion and wrist extension; controlled fingers flexion and extension; repeated grasping of an object; anterior reaching and grasping of an object; moving of objects on a plane or in space.
A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
1469588|NCT03199833|Other|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the patient's specific needs:
Upper limb passive motion
Arm Cycle ergometer with or without FES
Neuro Muscular Electrical Stimulation
Upper limb exercises using augmented or virtual reality environment
Occupational therapy exercises
Constraint induced movement therapy
Upper limb active movement (reaching, grasping, elevation, spatial orientation)
Repetitive task training
Mirror therapy
Writing training
Chemodenervation Therapy"
1469591|NCT03199807|Biological|NRT|Peripheral blood lymphocytes will be collected and neoantigen reactive T cells(NRTs) will be generated in the laboratory. NRTs 0.5~1 x 10^10, will be i.v.Q3 weeks for total 4-6 doses.
1469592|NCT03199807|Radiation|Radiotherapy|Radiotherapy of the major mass by dose of 5Gy/F * 10F
1469594|NCT03199781|Device|Motorized mechanical massage with the Dermothonus Slim® Ibramed with cosmetics|Patients will be treated with motorized mechanical massage with the Dermothonus Slim® electromedical equipment (Ibramed- Brazilian Industry of Electrical Equipment) associated with cosmetics with lipolytic active principle, being performed twice a week totaling 10 sessions by a dermato-functional physiotherapist.
1469595|NCT03199755|Drug|ACT|Current approved drug for treating malaria
1469596|NCT03199755|Drug|DLA1|Experimental drug treatment, single dose.
1469597|NCT03199755|Drug|DLA2|Experimental drug treatment, doubled the dose of DLA1.
1469598|NCT03199742|Behavioral|Personalized App Coaching|All coaching messages will be based on how each participant responds to baseline survey questionnaires and how they interact with the experimental mobile phone application during the course of the study. Participants will be provided with feedback about recent progress & use of the app, information about coping strategies provided by the app, and a recommendation for making the best use of the app over the subsequent few days.
1469599|NCT03199742|Behavioral|Active Comparator|Mobile phone application providing extensive information about PTSD and treatment, tools for managing PTSD symptoms, self-monitoring using the PTSD Checklist, and resources for obtaining support.
1469600|NCT03199729|Other|Slip-only training|Subjects in this arm will receive overground, slip specific perturbation training only. The total perturbation training trials received by this group will be 24 but the protocol will consist of a total of 70-75 trials (to match the training length and time of Combined slip and trip training group).
1469601|NCT03199729|Other|Trip-only training|Subjects in this arm consisting of a total of 24 trials of trip specific training delivered in an identical sequence (mixed with non-trip trials) as the Group with slip only training.
1469602|NCT03199729|Other|Combined slip+trip training|Subjects in this arm will receive training consisting of repeated exposure to both slips and trips with a total of 24 slips plus 24 trips to keep the number of trials of each perturbation same as the perturbation specific training groups (slip only and trip only), however, the total dose will be doubled. The total trials walked (perturbed + unperturbed) will be 75.
1469603|NCT03199716|Other|Parent mentors|Parent mentors are to meet up with their assigned intervention group 4 times in 1 year and call the families monthly to document any diabetic complications
1469604|NCT03199703|Device|Baylis transseptal system group|
1469605|NCT03199703|Device|Standard conventional transseptal group|
1469608|NCT03199677|Drug|Apatinib|Apatinib is an oral tyrosine kinase inhibitor.
1469609|NCT03199664|Radiation|NB-UVB|NB-UVB given twice weekly for 6 months
1469610|NCT03199664|Combination Product|NB-UVB & Tacrolimus 0.03%|NB-UVB given twice weekly for 6 months and tacrolimus 0.03 % ointment given for twice daily for the first month of treatment and once daily for the rest 5 months of treatment
1469611|NCT03199651|Other|Best Practice|Receive usual care
1469612|NCT03199651|Procedure|Biospecimen Collection|Undergo collection of tumor tissue and blood sample for repository
1469613|NCT03199651|Procedure|Biospecimen Collection|Undergo tumor tissue and blood sample for AGIT/DS
1469614|NCT03199651|Other|Laboratory Biomarker Analysis|Correlative studies
1469615|NCT03199651|Other|Medical Chart Review|Undergo medical record abstraction
1469616|NCT03199651|Other|Quality-of-Life Assessment|Ancillary studies
1469617|NCT03199651|Other|Questionnaire Administration|Ancillary studies
1469618|NCT03199651|Behavioral|Smoking Cessation Intervention|Undergo usual care or NCCN-driven CTC/DS
1469619|NCT03199638|Drug|Glutamine vs. Placebo|oral supplementation with either glutamine or placebo twice daily for 3 months
1469620|NCT03199638|Other|Exercise|short bouts of exercise ('exercise snacks') 3 times daily for 3 months
1469621|NCT03199625|Behavioral|Cognitive therapy|
1469622|NCT03199625|Behavioral|Behavior therapy|
1469623|NCT03199625|Drug|SSRI antidepressants|
1469624|NCT03199612|Drug|Sildenafil|To conduct a randomized placebo controlled study to test the hypothesis that platelet activation and aggregation during ongoing low level hemolysis in outpatients on chronic CF pump support can be reduced by sildenafil.
1469625|NCT03199612|Drug|Placebo Oral Tablet|Negative control to understand the potential changes in platelet activation adn aggregation in comparison to sildenafil.
1469627|NCT03199560|Drug|Tc 99m tilmanocept|lymphatic mapping agent
1576877|NCT02406508|Drug|Sorafenib|
1469634|NCT03199508|Diagnostic Test|the 3-day voiding diary|The 3-day voiding diary is a medical record which need participants to fill in a table about urine volume for 2 days and 3 nights.
1469635|NCT03199508|Diagnostic Test|the 7-day voiding diary|The 7-day voiding diary is a medical record which need participants to fill in a table about urine volume and drinking water volume for 4 days and 7 nights.
1469636|NCT03199495|Other|electroacupuncture|acupuncture needle with TENS device
1469637|NCT03199482|Drug|Dexamethasone Oral Tablet|single dose of tablet 0.5 mg dexamethasone given to patients before starting of root canal treatment by 30 minutes or placebo
1469638|NCT03199482|Drug|Placebo|Placebo will be administrated 30 minutes before start of root canal treatment
1469640|NCT03199456|Device|Zip 4 surgical skin closure device|Zip surgical skin closure device manufactured by ZipLine Medical, Inc. is a CE-marked, non-invasive, single use device that is designated to provide closure of the skin layer for lacerations or surgical incisions.
1469641|NCT03199456|Device|Standard of Care sutures|Standard of Care sutures according to the hospitals current clinical praxis.
1469642|NCT03199443|Diagnostic Test|EMG pelvic floor|EMG activity during tined lead test procedures will be monitored and the response on needle stimulation will be evaluated
1469643|NCT03199430|Dietary Supplement|Epigallocatechin gallate|
1469644|NCT03199430|Dietary Supplement|Placebo|1450mg Corn Flour
1469645|NCT03199417|Drug|Multiprofen|A multimodal topical cream treatment with Ketoprofen, Baclofen, Amitryptiline, and lidocaine in a carrier gel.
1469646|NCT03199417|Other|Placebo|An identically packaged placebo cream
1469647|NCT03199404|Device|TRAP|Mechanical thrombectomy performed with the combination of a stent retriever that is partially re-sheathed and withdrawn under constant aspiration along with the use of a balloon guide catheter for distal flow control during thrombectomy.
1469648|NCT03199391|Device|BioWick SureLock Implant|The BioWick™ SureLock™ implant is a device for shoulder and extremity surgery, constructed of Ultra High Molecular Weight Polyethylene Suture. BioWick™ SureLock™ is uniquely designed to minimize these risks by avoiding manual tensioning with an inserter mechanism that ensures that the implant is consistently deployed below the cortex.
1469649|NCT03199378|Other|Neuropsychological Testing|Each group will be administered a battery of neuropsychological tests
1469655|NCT03199352|Other|RYGB hand-sewn|Patients will have the RYGB anastomosis hand-sewn
1469656|NCT03199352|Other|RYGB linear-staple|Patients will have the RYGB anastomosis performed using a linear staple.
1469657|NCT03199339|Drug|TBA-7371|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
1469658|NCT03199339|Drug|Matching Placebo for TBA-7371|The test product is TBA-7371 25 mg/ml oral suspension formulation and TBA-7371 matching placebo oral suspension.
1469662|NCT03199300|Drug|Anthracyclines|Chemotherapy regimen containing anthracyclines.
1469663|NCT03199300|Drug|Trastuzumab|Systemic treatment including trastuzumab.
1469664|NCT03199300|Drug|Cisplatin|Chemotherapy including cisplatin.
1469665|NCT03199300|Drug|Bleomycin|Chemotherapy including bleomycin.
1469666|NCT03199274|Procedure|Yttrium-90 Microsphere Radioembolization|Undergo standard of care Y-90 radioembolization
1469667|NCT03199274|Drug|Perflutren Protein-Type A Microspheres|Given IV
1469668|NCT03199274|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
1469669|NCT03199261|Drug|rE-4 Injection|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Injection 10µg administered 30 minutes prior to the start time of a standard breakfast.
1469670|NCT03199261|Drug|rE-4 Freeze-dried Powder|During the study session, healthy subjects will be receive a subcutaneous single dose of rE-4 Freeze-dried Powder 10µg administered 30 minutes prior to the start time of a standard breakfast.
1473712|NCT03169582|Drug|Sildenafil|Drug administration (Sildenafil)
1469671|NCT03199248|Procedure|Aspiration with percutaneous capsulotomy For digital mucous cysts|The surgical procedure for DMCs was using a 18G needle performing aspiration first and then cutting the stalk tract by the needle tip for capsulotomy. All procedure were done with anesthesia. After operation, we asking patient using dressing to pressure the wound about 10 mins to stop bleeding. Later on, the wound was covering with antimicrobial oint(Neomycin) and simple dressing. Educating patient from water for 24 hr.
1469672|NCT03199235|Device|Lucky Iron Fish|200g iron ingot that is placed in boiling water for 10+ minutes, and then removed. The water is then used to eating and drinking.
1469673|NCT03199235|Other|enhanced standard of care|parents of subjects are provided oral iron supplementation per usual clinical care at clinic and followed for their anemia in addition to study visits
1469674|NCT03199222|Device|Prosthetic smart socket technology with patient prompting|The smart socket technology will send feedback to the user's smartphone with suggestions including the removal or application of prosthetic socks over the residual limb or other volume management strategies to improve fit and comfort.
1469675|NCT03199209|Behavioral|Questionnaires|"Questionnaires about participant's feelings, moods, motivation for physical activity and eating healthy, any social support participant may receive from others, the neighborhood participant lives in, and other physical activity-related topics. The questionnaires should take about 45 minutes to complete.
Questionnaires completed 1 time at the beginning of the study, 1 time about 6 months after beginning the study, and 1 time about 12 months after beginning the study."
1469676|NCT03199209|Behavioral|Community Health Worker (CHW) for Tu Salud, ¡Si Cuenta! Familiar (TSSC-Family) Group|Six monthly home visits by a CHW who talk about how to be more physically active and eat healthier. The modules are delivered on a laptop/tablet device, are available in Spanish and English, and include culturally appropriate videos to emphasize key messages and spark discussion.
1469677|NCT03199209|Behavioral|Community Health Worker (CHW) for Contact Control Group|Six monthly visits by a CHW based on the National Center for Healthy Housing's Healthy Homes program.
1469678|NCT03199209|Device|Accelerometer|Participant given an accelerometer at each visit to wear for 7 days.
1469679|NCT03199196|Device|Activity Tracker|"Group 1 - Intervention: Participants given an accelerometer at each visit. Participant wears the accelerometer for 7 days.
Group 2 - Newsletters: After completing the 16 week visit, participant given an activity tracker."
1469680|NCT03199196|Device|Smartphone Application|"Group 1 - Intervention: Participant given smartphone application baseline visit to track physical activity, connect with participant's partner to share information about participant's physical activity, and provide support to partner to be more physically active.
Group 2 - Newsletters: After completing the 16 week visit, participant given instruction in the use of a smartphone application."
1469681|NCT03199196|Behavioral|Questionnaires|Participants complete questionnaires about feelings, moods, motivation for physical activity, any social support received from others, the neighborhood participant lives in, and other physical activity-related topics. Questionnaires completed 1 time at the beginning of the study, 8 weeks after joining the study, and 16 weeks after beginning the study.The questionnaires should take about 45 minutes to complete.
1469682|NCT03199196|Behavioral|Focus Group|Participants invited to take part in a final focus group. Focus group takes place sometime after the 16-week visit. Focus groups/interviews are audio recorded.
1469683|NCT03199196|Behavioral|Electronic Newsletters|Participant emailed electronic newsletters to read that may help participant be more physically active.
1469684|NCT03199196|Behavioral|Telephone Counseling|Research staff provides telephone counseling to participant and partner biweekly during weeks 1-8 (weeks 1, 3, 5, and 7), and monthly during weeks 9-16 (weeks 11 and 15).
1469685|NCT03199183|Radiation|PET-CT|PET-CT will be proceed on the basis of clinical status and aspiration of individual patient. The imaging results will be analysed by professional radiologists.
1469686|NCT03199183|Other|laboratory biomarker analysis|Screening of potential biomarkers related to Takayasu arteritis and verification tests will be operated.
1469687|NCT03199183|Genetic|genetic sequencing|Genetic sequencing results will be analysed to identify susceptible alleles or single nucleotide polymorphisms of Takayasu arteritis.
1469688|NCT03199170|Drug|Intrathecal morphine|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia
1469689|NCT03199170|Drug|Bilateral Quadratus Lumborum Block|0.25% Bupivacaine 25 ml each side for quadratus lumborum block without spinal morphine
1469690|NCT03199170|Drug|Intrathecal morphine with bilateral Quadratus Lumborum Block|0.5% Hyperbaric bupivacaine 2 ml add morphine 0.2 mg for spinal anesthesia and 0.25% Bupivacaine 25 ml each side for quadratus lumborum block
1469691|NCT03199157|Drug|Fentanyl transdermal patch|Patients received fentanyl 12 mcg transdermal patch group 8 hours preoperatively and until 24 hours after the surgery
1469692|NCT03199144|Drug|Chemotherapy|3 cycles of Gemzar-Abraxane
1469693|NCT03199144|Radiation|Stereotactic radiotherapy|Stereotactic radiation treatment delivering 30 Gy in 5 fractions over 9 days
1469694|NCT03199144|Procedure|Surgery|Whipple procedure will be the recommended procedure but will be modified according to the initial tumor location
1469695|NCT03199131|Procedure|Right ventricular biopsies|a right ventricular biopsy will be taken intraoperatively during either pulmonary endarterectomy (experimental group) or open cardiac surgery (control group).
1469696|NCT03199118|Procedure|CAF +SCTG|the use of coronally advanced flap (CAF) with sub-epithelial connective tissue graft (SCTG) from the palate to cover gingival recession
1469697|NCT03199118|Other|platelet rich fibrin|in addition to coronally advanced flap and sub-epithelial connective tissue graft, PRF is also used in the surgical procedure to cover gingival recession
1469698|NCT03199105|Other|Preoperative education with cartoon illustrations and/or local tetracaine mucilage|The patients were given preoperative education with cartoon illustrations and/or local tetracaine mucilage to alleviate CRBD during the post-operative period.
1469701|NCT03199079|Device|Cervix Monitor|Cervix elasticity and length measurements by Cervix Monitor
1469709|NCT03199027|Other|Adherence Club|Participants will be referred to an Adherence Club at 4 months post-ART initiation. Adherence club visits occur 2-4 monthly at a community hall near the Community Health Centre (CHC). At routine visits, which last 1-2 hours, community health workers provide health education, weigh patients, ask about symptoms and dispense pre-packed ART. Symptomatic patients are sent back to the ART clinic for clinician assessment. An assigned nurse takes blood tests annually at each club, and then returns on the subsequent visit to perform a clinical assessment and check the results. Patients requiring more follow-up or with high viral loads are referred back to the ART clinic at the CHC by the nurse.
1469710|NCT03199014|Device|deploying the Drug-eluting Stents with a prolonged time|the inflation time was more than 30 seconds when the Drug-eluting Stents deploying.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
1469711|NCT03199014|Device|deploying the Drug-eluting Stents with a conventional time|the actual inflation time was within 10s determined by interventional cardiologist.The PROMUS Element Plus Stent or Co-Cr sirolimus-eluting coronary stent system（GuReater）was used in this study
1469712|NCT03198975|Diagnostic Test|Magnetic resonance image|Histologically-diagnosed primary HCC after curative hepatectomy. The magnetic resonance image will be imported into the software ,and the radiomic textural features will be automatically extracted by the Analysis-Kit software.The high-throughput extracted features will be then selected and a prediction model will be developed in the training set in which patients were collected from a retrospective study. In this project, an independent validation set will be collected and used to validate the prediction accuracy of the model.
1469713|NCT03198949|Drug|Afinitor (everolimus)|"Everolimus doses will be 4.5mg/m2 po daily given at first time and then during the 4-week titration period everolimus dose may get adjusted to reach trough concentration of 5 - 15 ng/mL.
(In order to keep the blind, placebo doses will be also adjusted during core phase based on a random scheme of dose changes.)"
1469714|NCT03198936|Dietary Supplement|Brain Pill|2 capsules to be taken twice a day with meals with a glassful of water
1469715|NCT03198936|Dietary Supplement|Placebo|2 capsules to be taken twice a day with meals with glassful of water
1469716|NCT03198923|Biological|natural killer and natural killer T cell|The eligible patients are infused with 10 doses of (2-2.5)x10^9 NK and NKT cells in one course of treatment.
1469720|NCT03198858|Procedure|CartoUnivu™|Ablation with Carto® 3 System and image integration module = IIM, CartoUnivu™
1469721|NCT03198858|Procedure|Ablation with Carto® 3 System|usual Pulmonary vein isolation Ablation with Carto® 3 System only
1469722|NCT03198845|Other|video game|20-min per session for 3 times per week for a 4-week duration
1469723|NCT03198845|Other|exercise|20-min per session for 3 times per week for a 4-week duration
1469724|NCT03198832|Procedure|Non-surgical periodontal treatment|Debridement in a single session in which patients will be anesthetized and receive scaling and root planing with ultrasound equipment .
1469725|NCT03198819|Drug|Local Rifampisin and İnrtravenous cefotaxime|
1469726|NCT03198806|Other|Treadmill aerobic exercise with recovery of 60 minutes|First session: The volunteers will be submitted to a cardiovascular rehabilitation session consisting of 10 minutes of rest in the supine position, 15 minutes of warm-up, with activities involving stretching and global exercises, 40 minutes of physical exercise on a treadmill (equivalent intensity between 60% and 80% of the VO2peak or anaerobic threshold), 5 minutes os exercise with half the intensity performed on maximum test, followed by 60 minutes of recovery in supine position
1469727|NCT03198806|Other|Water intake with recovery of 60 minutes|Second session: The volunteers will perform activities similar to the control group (Treadmill aerobic exercise with recovery of 60 minutes), but with the administration of mineral water that will be distributed in 8 equal portions offered at regular intervals of 10 minutes from the 10th minute of treadmill exercise to the last 25 minutes of the recovery period
1469728|NCT03198806|Other|Treadmill aerobic exercise with recovery of 10 minutes|Third session: The volunteers will be submitted to a cardiovascular rehabilitation session consisting of 10 minutes of rest in the orthostatic position, 15 minutes of warm-up, with activities involving stretching and global exercises, 40 minutes of physical exercise on a treadmill (equivalent intensity between 60% and 80% of the VO2peak or anaerobic threshold), followed by 10 minutes of recovery in orthostatic position
1469729|NCT03198806|Other|Water intake with recovery of 10 minutes|Fourthy session: The volunteers will perform activities similar to the control group (Treadmill aerobic exercise with recovery of 10 minutes), but with the administration of mineral water that will be distributed in 4 equal portions offered at regular intervals of 10 minutes from the 10th minute of treadmill exercise.
1469730|NCT03198793|Drug|QGC001|Twice daily (BID) administration of oral (PO) QGC001 (250 mg BID, 500 mg BID, and 500 mg BID + hydrochlorothiazide (HCTZ) 25 mg once daily [QD]) over 8 weeks.
1578610|NCT02393833|Drug|Fluorouracil|
1469731|NCT03198780|Other|Breathing Awareness|Participants will use a pulse-oximeter and biofeedback app to guide them through pursed-lip breathing training.
1469733|NCT03198754|Device|Bright White Light (BWL)|
1469734|NCT03198754|Device|Dim White Light (DWL)|
1469735|NCT03198741|Drug|Aspirin + clopidogrel|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + clopidogrel 75mg/d for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
1469736|NCT03198741|Drug|Clopidogrel monotherapy|After randomization(6 months±2 weeks after enrollment),receive clopidogrel 75mg/d + placebo (clopidogrel monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
1469737|NCT03198741|Drug|Aspirin monotherapy|After randomization(6 months±2 weeks after enrollment),receive aspirin 100mg/d + placebo (aspirin monotherapy group) for an additional 6 months. The above treatments between 6 and 12 months are double-blinded.
1469738|NCT03198728|Drug|SOV2012-F1|oral preparation of testosterone undecanoate (TU)
1469739|NCT03198728|Drug|AndroGel|topical testosterone gel
1948388|NCT02432066|Drug|GTS-21|GTS-21 is a partial alpha7 nicotinic agonist. GTS-21 will be compounded by the UF investigational pharmacy, and administered orally.
1948389|NCT02432066|Drug|Placebo|Oral placebo pills, compounded by the UF investigational pharmacy
1469742|NCT03198702|Drug|Botulinum toxin type A injection|A total of 8UI/kg will be injected in the internal shoulder rotator muscles: 2UI/kg in the sub scapular muscle, 3UI/kg in the pectoralis major muscle and 3UI/kg in the teres major/latissimus dorsi muscle.
1469743|NCT03198702|Other|Sham|The injection is mimed, the procedure is the same as the botulinum toxin injection.
1469744|NCT03198689|Drug|Brentuximab Vedotin|Initial dose 0.6 mg/kg (may increase up to 1.8 mg/kg) i.v. will be given every 3 weeks for 16 cycles (48 weeks) in addition to standard of care medications for SSc that may include cyclophosphamide, methotrexate, azathioprine, mycophenylate mofetil (MMF, cellcept) and mycophenolic acid (myfortic).
1469745|NCT03198676|Drug|PrEP-001 6.4 mg|6.4 mg as 4 sprays per nostril (ie total of 8 sprays for a single dose) using Aptar unit dose strength powder (UDSP) device
1469746|NCT03198676|Drug|PrEP-001 6.4 mg|6.4 mg as 2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
1469747|NCT03198676|Drug|PrEP-001 3.2 mg|3.2 mg as 1 spray per nostril (ie total of 2 sprays for a single dose) using Aptar UDSP device
1469748|NCT03198676|Drug|Placebo|2 sprays per nostril (ie total of 4 sprays for a single dose) using Aptar UDSP device
1469749|NCT03198663|Behavioral|POSSE|Popular-opinion leader
1469751|NCT03198637|Drug|Cisatracurium's monitoring by TOF (train-of-four) WATCH device.|Neuromuscular blockade's monitoring by Cisatracurium thanks to TOF (train-of-four) WATCH device.
1469752|NCT03198637|Drug|clinical assessment|
1469753|NCT03198624|Drug|HTL0018318|Part A single dose Part B five doses
1469754|NCT03198624|Drug|Placebo oral capsule|Part B only
1469755|NCT03198611|Diagnostic Test|Echocardiography|Usual echocardiographic studies in patients suffering septic shock
1469756|NCT03198598|Behavioral|Iyengar Yoga|The patients are going to practice Yoga two times per week during 60 minutes each composed by: 40 minutes of postures, 10 minutes of breathing exercises and 10 minutes of meditation. The proposed Yoga postures will depend on disease severity and will be adapted according to each patient.
1469757|NCT03198598|Behavioral|Yoga app|The patients showing EDSS scores above 6.0 will be divided in two groups of 20. Due to their movements limitations it is not possible to perform a regular Yoga class. In this case they will receive a smartphone application that has an eight-week program including meditation practices, Yoga exercises that can be done in a seated or laid position and daily care tips.
1469758|NCT03198585|Drug|Empagliflozin 10 MG|Capsule, once a day for 90 days
1469759|NCT03198585|Other|Placebo|Capsule, once a day for 90 days
1469760|NCT03198572|Behavioral|Lifestyle intervention|Lifestyle intervention is consisted of diet control and aerobic exercise. calorie restriction: to subtract 500 kcal from daily calorie intake aerobic exercise: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50-70% of the maximal heart rate.
1469761|NCT03198572|Drug|Placebo|placebo tablets 0.5 tid, 30 minutes before each meal, for 48weeks
1469762|NCT03198572|Drug|Berberine|Berberine tablets 0.5 tid, 30 minutes before each meal, for 48weeks
1948390|NCT02431806|Drug|Placebo|
1948391|NCT02431806|Drug|Levomilnacipran ER|
1469765|NCT03198546|Biological|GPC3 targeting CAR-T cells|Engineering GPC3 targeting CAR into T cells isolated from patients with advanced HCC, and then transfusing them back the patients.
1469766|NCT03198533|Device|Triathlon PA|Implantation of Knee Prosthesis
1469767|NCT03198533|Device|Triathlon Pressfit|Implantation of Knee Prosthesis
1469768|NCT03198520|Device|Solvay Dental 360™|polymer Removable Partial Denture (RPD)
1469769|NCT03198507|Drug|RHB-105|"The intended dose of RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, is equivalent to a total daily dose of:
Rifabutin 150 mg
Amoxicillin 3000 mg
Omeprazole 120 mg
One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
1469770|NCT03198507|Drug|Active Comparator|"The intended dose of the Active Comparator (250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:
Amoxicillin 3000 mg
Omeprazole 120 mg
One 50mg Riboflavin tablet to be taken once daily to maintain the blind."
1948392|NCT02431806|Drug|Fluoxetine|
1948393|NCT02425098|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
1469773|NCT03198481|Behavioral|Patient-Centered Counseling Video|Patients will watch a patient-centered education video regarding MUS prior to standard pre-operative counseling.
1469774|NCT03198481|Behavioral|Physician Counseling Video|Patients will watch a physician-centered video regarding MUS prior to standard pre-operative counseling.
1471666|NCT03184272|Procedure|baseline in narcosis 1|measurement in supine position in narcosis
1948394|NCT02425098|Biological|Takeda's High-Dose Tetravalent Dengue Vaccine Candidate (HD-TDV)|High-dose TDV subcutaneous injection
1469775|NCT03198468|Device|Bronchoscopic Thermal Vapor Ablation|Vapor (steam) is infused into the targeted region for 8 seconds at a precisely controlled flow rate and power
1469776|NCT03198455|Dietary Supplement|Agaricus blazei Murill-based mushroom extract, Andosan™|Dietary Supplement: Agaricus blazei Murill-based mushroom extract, Andosan™
1469777|NCT03198455|Other|Placebo|Drinking water with food coloring and salt
1469778|NCT03198442|Procedure|F-18 FDG breast PET scan|
1469779|NCT03198429|Behavioral|Caring Dads|Caring Dads is a 15-week group intervention program for fathers, with an intensive intake and two additional individual sessions to set and monitor specific, individualized change goals. Major aspects of innovation in the Caring Dads program include: the use of a motivational approach to engage and retain men in intervention; consistent emphasis on the need to end violence against children's mothers alongside of improving fathering; program content addressing accountability for past abuse and a model of collaborative practice with child protection. The Caring Dads program was developed with a specific commitment to remain focused on the safety and well-being needs of children as a primary goal of intervention and with the recognition that children's safety and well-being is integrally connected to that of their mothers.
1469780|NCT03198429|Behavioral|Mothers in Mind|Mothers in Mind uses an attachment and trauma-informed psycho-educational process approach in 12 weekly sessions (10 of which are in group) with mothers. These sessions focus on raising awareness and validation about the experience of violence and the impact it has on mothering. Specifically, MIM increases mothers' awareness of the impact that exposure to family violence/trauma may have had on their infants and themselves as mothers, helps identify and promote positive parenting skills such as sensitivity and responsiveness to infant needs by increasing parental competence, helps promote emotional closeness and decreasing mothers' social isolation, increases mother and infant physical safety, and encourages positive attachment processes.
1469781|NCT03198416|Device|High-resolution pharyngeal manometry catheter|The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
1469782|NCT03198403|Drug|Bupivacaine-epinephrine|Popliteal plexus block with 10 mL of bupivacaine-epinephrine 5 mg/mL + 5 microgram/mL.
1469783|NCT03198377|Device|TENS: Randomized frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:
Frequency modulation: randomized pattern (from 80 to 120 Hz) Pulse width 200 microseconds"
1469784|NCT03198377|Device|TENS: Scan 6/6 of frequency modulation|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:
Frequency modulation: Scan of frequency from 80 to 120 Hz in 6/6 mode (frequency sweep from 80 Hz to 120 Hz in 6 seconds and from 120 to 80 Hz in 6 secons) Pulse width 200 microseconds"
1469785|NCT03198377|Device|TENS: Fixed frequency|"Transcutaneous application of Conventional TENS current over the course of the superficial radial nerve in the right forearm for a 20 minutes session. The intensity of the current will increase until participants report a strong but comfortable sensation, just below motor threshold. Currents parameters are:
Fixed frequency at 100 Hz Pulse width 200 microseconds"
1469786|NCT03198377|Device|Sham Stimulation|Electrodes are placed over the course of the superficial radial nerve in the right forearm for a 20 minutes in the same manner as experimental groups, but will be applied a sham electrical stimulation increasing the current intensity of an unconnected channel.
1469787|NCT03198364|Behavioral|Safety and Recovery Therapy|4 session individualized psychoeducation tailored to people with bipolar disorder or schizophrenia targeting coping skills for suicidal thoughts and their determinants.
1469788|NCT03198364|Behavioral|Mobile Augmentation|Though a smartphone device, participants receive 12 weeks of personalized prompts derived from content produced in individual START sessions to increase transfer of skills to day to day life
1469789|NCT03198351|Drug|Teriflunomide (HMR1726)|"Pharmaceutical form: tablet
Route of administration: oral"
1469790|NCT03198338|Drug|0.25% Bupivacaine, 0.5mL/kg|Ultrasound guided TAP block using 0.25% Bupivacaine, 0.5ml/kg
1469791|NCT03198338|Drug|Normal Saline|0.9% Normal Saline
1469792|NCT03198338|Device|Ultrasound|Ultrasound guided TAP block
1469793|NCT03198325|Other|Stop of ART|Patients willing to stop antiretroviral therapy will stop ART.The occurrence of two consecutive HIV-1 RNA values >50 copies/mL or the occurrence of stage B or C AIDS-defining events will be criteria for ART resumption or any serious non-AIDS clinical event at least potentially related to treatment interruption.
1469794|NCT03198312|Device|CathiportTM|fully implanted
1469795|NCT03198312|Device|Implant Port|fully implanted
1469796|NCT03198299|Device|MEI BIN insoles|wearing insoles for 12 weeks
1469797|NCT03198286|Other|Informational Intervention|Receive treatment summary and survivor care plan
1469798|NCT03198273|Other|Clinical pilates exercises|servical, lumbal, pelvic muscles
1469799|NCT03198273|Other|physiotherapy program|hot-pack will apply for 20 minutes. Convansionel TENS will apply on the lumbar regions of the cases of the control group paravertebrally with
1469800|NCT03198260|Other|Fascial manipulation|Deep frictional massage
1469801|NCT03198247|Other|Usual care|"The biomedical education session will be imparted 2 weeks before surgery by the preoperative nurse and a physiotherapist. It will have a duration of 2 hours and it is designed for a group of 5 subjects.
The hospital rehabilitation starts 6 hours after surgery, and it is based in early wandering stimulation, articular mobility exercises and isometric exercises."
1469802|NCT03198247|Other|PNE + CST|The PNE and CST program will be divided in 3 individual sessions.
1469882|NCT03197636|Drug|Pembrolizumab|Pembrolizumab is already approved for treatment of malignant melanoma in advanced stages. We will investigate if sPD-1 or vitamin D status is changed in patients receiving pembrolizumab.
1474438|NCT03164109|Drug|Placebo|Infused IV over 15 minutes
1469803|NCT03198234|Biological|T-allo10|The T-allo10 drug product consists of donor derived, host (patient) alloantigen hyporesponsive (anergic) CD4+ (cluster of differentiation 4) cells containing Type 1 regulatory T (Tr1) cells induced in vitro in the presence of IL-10 (interleukin-10), which are also defined as IL-10 anergized T cells. T-allo10 cell infusion is being developed to prevent acute Graft-versus-Host Disease (GvHD) and induce graft tolerance in patients with hematologic malignancies receiving mismatched related and unrelated unmanipulated hematopoietic stem cell transplant (HSCT).
1469806|NCT03198208|Drug|Fentanyl dose administration|
1469807|NCT03198195|Procedure|cyclophosphamide|on days +3，+4,using cyclophosphamide 50mg/kg
1469808|NCT03198182|Drug|Placebo|Specified dose on specified days
1469809|NCT03198182|Drug|BMS-986036|Specified dose on specified days
1469810|NCT03198169|Device|Atteris Antimicrobial Skin and Wound Cleanser|Wounds will be cleansed with either the experimental wound cleanser or a placebo and will then be covered with standard of care wound dressings.
1469811|NCT03198169|Device|Atteris Antimicrobial Barrier Film Dressing|Wounds will be covered with either the experimental barrier film dressing or a placebo and will then be covered with standard of care wound dressings.
1469812|NCT03198156|Device|Transcranial Direct Current Stimulation|tDCS is a form of noninvasive, painless, brain stimulation that uses a mild direct electrical current passed between electrodes on the scalp to modify neuronal membrane resting potential in a polarity dependent manner, elevating or lowering neuron excitability in a region.
1469813|NCT03198156|Device|Sham stimulation|Sham stimulation
1469814|NCT03198143|Drug|Ghrelin|Subjects will receive a subcutaneous injection of synthetic acyl ghrelin (12 µg/kg) at the start of the study.
1469815|NCT03198143|Drug|Saline|Subjects will receive a subcutaneous injection of saline (0.9%) at the start of the study.
1469816|NCT03198130|Drug|REGN2810|Intravenous (IV) use
1469817|NCT03198117|Drug|Huaier Granule|a Chinese traditional medicine
1469818|NCT03198117|Other|placebo|placebo
1469819|NCT03198104|Device|MRI|
1469820|NCT03198091|Drug|Dun Ye Guan Xin Ning|Dun Ye Guan Xin Ning tablet 320 mg orally every time and 3 times per day for 6 months.
1469824|NCT03198065|Procedure|Hand-made glove setting|The patients receive Hand-made glove setting for single-incision laparoscopic appendectomy
1469825|NCT03198065|Procedure|Commercialized single-incision multiport setting|The patients receive commercialized single-incision multiport setting for single-incision laparoscopic appendectomy
1469826|NCT03198052|Genetic|PSCA,MUC1,PD-L1,or CD80/86 targeting CAR-T cells|Genetically engineered PSCA, MUC1, PD-L1, or CD80/86 targeting CAR transfected T cells isolated from patients with advanced cancer with high expression of PSCA,MUC1,PD-L1,or CD80/86 will be transferred back the patients for treatment of the cancer.
1469828|NCT03198026|Drug|Ibrutinib|Given PO
1469829|NCT03198026|Drug|Obinutuzumab|Given IV
1469830|NCT03198013|Drug|Prednisolone|Specified dose on specified days
1469831|NCT03198013|Drug|BMS-791826|Specified dose on specified days
1469832|NCT03198013|Drug|Placebo|Specified dose on specified days
1469833|NCT03198000|Drug|F# 13418-148 Eye Drops|ocular clear liquid. Tetrahydrozoline 0.05%; Glycerin 0.40% 1-2 drops will be instilled as instructed over one day
1469834|NCT03198000|Drug|F#13418-158 Eye Drops|ocular clear liquid Tetrahydrozoline 0.05%; Glycerin 0.20%, Hypromellose 0.2%, Polyethylene glycol 400 1.0% 1-2 drops will be instilled as instructed over one day
1469835|NCT03198000|Drug|F# PF-004390 Eye Drops|Ocular clear liquid Tetrahydrozoline 0.05%; 1-2 drops will be instilled as instructed over one day
1469836|NCT03197987|Device|Endocuff|Endocuff-assisted colonoscopy
1469837|NCT03197987|Device|cap|Cap-assisted colonoscopy
1469838|NCT03197974|Behavioral|Mindfulness for Bipolar|Brief online self-management program with email coaching support
1469839|NCT03197974|Behavioral|Psychoeducation for Bipolar|Brief online self-management program with email coaching support
1469840|NCT03197961|Combination Product|tenofovir/emtricitabine|At the enrollment visit, participants will be given a 14-day supply of tenofovir/emtricitabine 200mg/300mg to take once daily for 14 days. Drug concentrations will be measured as outlined in the outcomes section at the end of the two week period. The tenofovir/emtricitabine 200mg/300mg course will be repeated approximately 2 to 6 weeks later to allow washout of tenofovir/emtricitabine.
1469841|NCT03197961|Drug|DMPA|After completion of the first 14 day course of tenofovir/emtricitabine depot medroxyprogesterone acetate 150 mg will be administered as intramuscular injection.
1469842|NCT03197948|Other|Internet-Based Intervention|Complete questionnaire via a smartphone application
1469843|NCT03197935|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered as per schedule described in respective arm.
1469844|NCT03197935|Drug|Placebo|Placebo matched to atezolizumab will be administered as per schedule described in respective arm.
1469845|NCT03197935|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as per schedule described in the arms.
1469846|NCT03197935|Drug|Doxorubicin|Doxorubicin will be administered as per schedule described in the arms.
1469847|NCT03197935|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per schedule described in the arms.
1469848|NCT03197935|Drug|Filgrastim|Filgrastim will be administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
1469849|NCT03197935|Drug|Pegfilgrastim|Pegfilgrastim will be administered according to local prescribing information as determined by the Investigator for 4 doses after completion of initial 12 weeks.
1469883|NCT03197623|Drug|LLP2A-ALENDRONATE|A small molecule, LLP2A-Ale that directs endogenous mesenchymal stem cells (MSCs), the cells that have the potential to grow bone tissue, to the bone surface to form new bone. Single administration of LLP2A-Ale given intravenously over 120 minutes.
1469884|NCT03197623|Drug|Placebo|Placebo, one time single administration given intravenously over 120 minutes.
1948395|NCT02424838|Procedure|EUS-FNA of pancreatic masses|EUS-FNA of pancreatic masses will be performed using a 22 or a 25 gauge needle with or without applying suction.
1469851|NCT03197909|Other|Determination of pro-inflammatory plasma factors|Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old
1469852|NCT03197896|Other|Educational Intervention|Review prostate cancer information
1948396|NCT02424838|Device|22 gauge needle|
1948397|NCT02424838|Device|25 gauge needle|
1948398|NCT02421367|Biological|TDENV-PIV with AS03B adjuvant. Placebo: 0.9% Sodium Chloride Solution.|Tetravalent dengue virus purified inactivated vaccine (1 µg/virus type)
1469856|NCT03197870|Drug|AKB-9778|Subcutaneous AKB-9778 15mg
1469857|NCT03197870|Drug|Placebo|Subcutaneous Placebo
1469858|NCT03197857|Behavioral|Physical activity program : aquabike|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
1469859|NCT03197857|Behavioral|Physical activity program : bicycle|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation.
1469860|NCT03197857|Behavioral|Physical activity program : with protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
1469861|NCT03197857|Behavioral|Physical activity program : without protein supplementation|The aim of this project is to investigate in obese patients the changes induced by bariatric surgery on the various components of the physical condition and their postoperative evolution following an intervention combining a physical activity program (aquabike vs bicycle) with or without protein supplementation
1469862|NCT03197818|Drug|CHF 5993 100/6/12.5 µg|Fixed combination of extrafine beclometasone dipropionate 100 µg plus formoterol fumarate 6 µg plus glycopyrronium bromide 12.5 µg / metered dose
1469863|NCT03197818|Drug|160 µg budesonide + 4.5 µg formoterol fumarate|Fixed combination of budesonide 160 µg plus formoterol fumarate 4.5 µg
1469865|NCT03197792|Other|All patients|"TEE is performed before cardiopulmonary bypass (before the opening of the pericardium, if possible) and immediately after weaning from cardiopulmonary bypass and optimization of the hemodynamic status by the attending anesthesiologist. A detailed ultrasound examination including portal vein pulsatility, splenic vein pulsatility, right and left ventricular global longitudinal strain and right and left systolic and diastolic function is recorded. A measure of portal vein pulsatility using TTE is also recorded before the onset of general anesthesia and on the morning of the 7th postoperative day.
On the 7th postoperative day, the investigators will evaluate for the presence of the primary outcome, POD + death."
1469866|NCT03197779|Drug|BMS-962212|Intravenous Infusion administration over 2 hours or 5 days
1469867|NCT03197779|Drug|Aspirin|Oral administration
1469868|NCT03197779|Other|Placebo|Oral administration
1469869|NCT03197766|Drug|BMN 111|Subcutaneous injection of 15 μg/kg of BMN 111 daily
1469870|NCT03197766|Drug|Placebo|Subcutaneous injection of 15 μg/kg of placebo daily
1469871|NCT03197753|Device|Laryngeal mask airway|Laryngeal mask airway
1469872|NCT03197753|Device|Nasotracheal intubation|Nasotracheal intubation
1469873|NCT03197740|Drug|Donepezil patch|Treatment
1469874|NCT03197740|Drug|aricept Tab|Comparator
1469875|NCT03197727|Diagnostic Test|GC Saliva-Check BUFFER|Evaluating the saliva flow rate, saliva pH and saliva buffering capacity
1948399|NCT02416622|Biological|rAAV2tYF-CB-hRS1|adeno-associated virus vector expressing retinoschisin
1469877|NCT03197688|Other|Notapplicable|Not applicable as non-interventional study
1469878|NCT03197675|Other|Acupuncture|Participants within the acupuncture treatment group will receive traditional body acupuncture with electrical stimulation for 30 minutes three times a week, additionally participants will also receive auricular acupuncture once a week with the needles retained in both ears for seven days and replaced the following week, for a total of eight weeks (24 treatments of conventional acupuncture and 8 treatments of auricular acupuncture). Relative pain levels will be measured via the NRS by a member of the research staff before and after each treatment. All participants will then be reevaluated with the described assessment tools at three months and again at six months. Acupuncturists will not participate in the three and six month evaluations of subjects.
1469879|NCT03197662|Drug|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
1469880|NCT03197662|Drug|Matched Placebo|Each subject will receive a dose of 16 IU QD, and will be instructed to inhale 2 puffs per nostril every day (4 IU each). If needed, treatment will be titrated due to side effects or non-response.
1469881|NCT03197649|Procedure|Laser phototherapy treatment|Laser phototherapy treatment administered in OR
1469885|NCT03197610|Procedure|enamel matrix derivatives|enamel matrix derivatives and subepithelial connective tissue grafts
1578611|NCT02393833|Drug|Methotrexate|
1948400|NCT02416609|Radiation|LDR|LDR will be delivered on days 1 and 2, 8 and 9 of each of four GemOx cycles
1948401|NCT02416609|Drug|Gem|Gemcitabine (1.000 mg/sqm in a 30-minute infusion) will be administered on day 1-8 of each 21-day cycle, concurrent with LDR (for four cycles). Further two cycles of additional GemOx without LDR can be administered after SBRT
1948402|NCT02416609|Drug|Ox|Oxaliplatin (130 mg/sqm in a 2-hour infusion) will be administered on day 1 of each 21-day cycle, concurrent with LDR (for four cycles). Further two cycles of additional GemOx without LDR can be administered after SBRT
1948403|NCT02416609|Radiation|SBRT|SBRT will be administered after the fourth GemOx cycle, if no progression; three fractions will be administered
1469927|NCT03197506|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
1469928|NCT03197506|Other|Laboratory Biomarker Analysis|Correlative studies
1469929|NCT03197506|Biological|Pembrolizumab|Given IV
1469930|NCT03197506|Radiation|Radiation Therapy|Undergo radiation therapy
1469931|NCT03197506|Drug|Temozolomide|Given PO
1469932|NCT03197506|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1469934|NCT03197480|Drug|Dexamethasone intravitreal implant|In non-responder group, patients will undergo ozurdex injection at month 4, followed by a monthly PRN protocol of aflibercept for month 5. Retreatment criteria is any fluid/cyst on OCT.
1469935|NCT03197480|Drug|Aflibercept|In responder group, patients will undergo month 4 aflibercept followed by a PRN protocol for month 5. Retreatment criteria is any fluid/cyst on OCT.
1469936|NCT03197467|Drug|Pembrolizumab|Pembrolizumab at fixed dose: 200 mg q3w i.v. for 2 cycles
1469937|NCT03197454|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Forty-two minutes of training on computerized exercises that targets processing speed, memory and attention.
1469938|NCT03197454|Other|Commercially available computerized training|Forty-two minutes of training on computerized, casual video games.
1469939|NCT03197441|Other|Platelet-rich plasma|Intraoperative platelet-rich plasma injection during arthroscopic knee surgery
1474547|NCT03163329|Procedure|SAVR|Surgical Aortic Valve Replacement
1469940|NCT03197428|Other|Platelet-rich plasma|Platelet-rich plasma gel applied during the modified Broström-Gould procedure for reconstructing lateral ligament
1469941|NCT03197428|Other|Control|Whole blood applied during the modified Broström-Gould procedure for reconstructing lateral ligament
1469942|NCT03197415|Other|Platelet-rich plasma|intradiscal injection of plasma-rich platelet
1469943|NCT03197402|Dietary Supplement|Leucine-enriched protein gel delivery system|Leucine enriched
1469944|NCT03197402|Dietary Supplement|Milk protein gel delivery system|Non-leucine enriched
1469946|NCT03197376|Biological|Pneumosil|10-Valent Pneumococcal Conjugate Vaccine
1469947|NCT03197376|Biological|Synflorix|Pneumococcal conjugate vaccine (Non-Typeable Haemophilus influenzae (NTHi) protein D, diphtheria or tetanus toxoid conjugates) adsorbed
1469948|NCT03197363|Other|Discovering novel risk factors.|The study protocol includes multiple imaging and functional investigations (including heart, carotid, thyroid, kidney, liver, gallbladder ultrasound, fundoscopy, plethysmography, pulse wave velocity, ankle-brachial index, ECG, body composition measured by bioimpedance and dual energy x-ray absorptiometry, anthropometric assessment, rhinometry, hand grip test, oral glucose tolerance test, advance glycation end-products measurement, the effect of standardized meal. There will be a detailed and verified questionnaires concerning various activities of the subject: physical activity, depression, sino-nasal symptoms, prostate hypertrophy, female urinary tract symptoms, quality of life, smoking and drinking addiction, hirsutism.
1469949|NCT03197350|Diagnostic Test|cMR|cardiac MRI done to complete the diagnosis
1469950|NCT03197350|Biological|biomarker|Biomarker correlation with cMR parameters Prognostic information
1469951|NCT03197337|Procedure|Pressure-test|Pressure will be applied to the posterior fornix using a speculum.
1469952|NCT03197324|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
1469953|NCT03197324|Drug|Digoxin|2 0.25 mg Digoxin tablets (total dose 0.5 mg digoxin)
1469954|NCT03197311|Other|Mobile app|A customized mobile application will be developed and downloaded to subjects; smartphones to monitor postoperative analgesic consumption, and disposal; pain control and patient satisfaction. The mobile app will provide notifications for medications and select education links on the prescribed analgesics. Subjects will receive reminders to take medications as directed. Subjects will be able to monitor and report their pain during the first week after surgery.
1469955|NCT03197298|Drug|Clopidogrel|
1469956|NCT03197298|Drug|Ticagrelor|
1469957|NCT03197285|Other|EYE-CERVICAL RE-EDUCATION PROGRAM|"Subjects received a total of ten sessions on alternate days.
This includes a total of 10 exercises that has proprioceptive reprogramming in the cervical area with the following phases:
To stimulate ocular mobility without including the cervical movement. The patient was placed in the supine position and the physiotherapist seated, at the height of the head.
To exercise cervical mobility with restricted eye movement. The patient is placed on a rotating stool. The ocular mobility is excluded with opaque glasses that allowed exclusively the foveal vision
Finally we stimulate eye and neck movement coordination. The patient continued to sit on the stool, this time without the glasses."
1469958|NCT03197285|Other|Combined Physiotherapy Protocol|Thermotherapy (70 w continuous microwave for 10 minutes), therapeutic massage (surface rubbing for 5 minutes, 10 minutes of compression and kneading massage and 2 minutes of final surface friction), application of analgesic currents (TENS, by self-adhesive silicone electrodes 4x4 cm, symmetrical biphasic rectangular current, 200 µs width pulse, a frequency of 1 Hz for 10 minutes. The patient should notice a slight vibration, without it being painful).
1469959|NCT03197272|Procedure|PiXL|Phototherapeutic intrastromal corneal collagen cross-linking (PiXL) performed in a high-oxygen environment without corneal epithelial debridement, for treatment of mild myopia.
1469960|NCT03197246|Device|IVECG|Monitoring IVECG signals for verification for exact tip placement during the actual insertion of the PICC. When the p-wave amplitude increases the PICC-tip is in the superior vena cava. When max positive amplitude, the PICC-tip is by definition at the cavo atriale junction, and thereby in correct position.
1469961|NCT03197246|Device|Chest X-ray|Standard method; PICC confirmed by chest X-ray after the insertion (postoperatively)
1469962|NCT03197233|Other|Maternal vitamin A and D intake during pregnancy|Dietary exposures during pregnancy and infant supplement use were assessed from maternal questionnaire report
1469963|NCT03197220|Other|fish|300 gr/week fish
1469964|NCT03197220|Other|walnut|6 walnut per week
1469965|NCT03197220|Other|fish-walnut|150 gr fish and 3 walnut per week
1469966|NCT03197207|Procedure|"Dragon and Tiger warring in lifting and thrusting"|"Tight press slow insert in each acupoint through the superficial,intermediate, deep layer, then tight lifting slow withdraw needle through the deep, intermediate, superficial layer . Two acupoints (GB34, GB39) are manipulation in the process three times each during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later."
1469967|NCT03197207|Procedure|"Dragon and Tiger warring in twisting-rotating"|When needle insert in each acupoint through the superficial,intermediate, deep layer, within each layer twisting thumb forward nine times, then twisting backward six times. Two acupoints (GB34, GB39) are manipulation in the process during one minute, then let patients lift shoulder up and down for three times, then draw out the needle 20 minutes later.
1469968|NCT03197194|Drug|Alteplase|alteplase administered as an intravenous infusion (0.9 mg/kg; maximum dose 90 mg): 10% given as an IV bolus, followed immediately by the remaining given as an IV infusion over 1 hour.
1469969|NCT03197194|Drug|acetylsalicylic acid|one tablet of aspirin 300 mg
1469970|NCT03197194|Drug|Placebo Oral Tablet|One placebo oral tablet which doesn't contain the active ingredient acetyl salicylic acid
1469971|NCT03197194|Drug|placebo IV|IV saline solution (0.9 %):10 mL in a syringe administered over 1 minute, followed by 50 mL as an infusion over 1 hour
1469972|NCT03197181|Device|transcranial direct current stimulation|Participants receive anodal or sham transcranial direct current stimulation while performing effort-based decision tasks.
1470004|NCT03196934|Drug|Cannabidiol oral solution|Cannabidiol; Pharmacological class of drug
1470005|NCT03196921|Drug|Encochleated Amphotericin B|lipid-crystal nanoparticle formulation of amphotericin B; oral
1469973|NCT03197168|Behavioral|Intervention to reduce self-stigma among people with mental illness|"This is a 10-session group intervention (held once a week), each lasting approximately 90 minutes, taking place where the participants receive mental health treatment.
The intervention is informed by the following key areas: (1) recovery perspective of mental health and severe mental disorders; (2) constructivist epistemology approach to learning, using cases and users' experiences; and (3) psychotherapeutic and collective narrative practices, to address internalized problems and challenges shared among the group members, respectively."
1469974|NCT03197168|Behavioral|Control|Generally, each community mental health center in Chile includes two full-time psychologists, a full-time social worker and half-time occupational therapist, nurse, and psychiatrist. This team mainly offers psychiatric medication, psychotherapy, and psycho-education for users and relatives. They do not offer any specific intervention to tackle stigma among providers.
1469975|NCT03197155|Drug|Direct Acting Antivirals against hepatitis C virus infection|The cohort includes cirrhotic patients infected with HCV and successfully treated for their first history of hepatocellular carcinoma. Some of these patients were treated with direct-acting antivirals for their HCV infection while the others did not receive any direct-acting antivirals treatment during the follow-up period.
1469976|NCT03197129|Other|sensory adapted waiting room|The SADE waiting room: a small waiting room (2.5mx2.5m) inside the clinic with 6 seats. All ceiling fluorescent lighting is removed. The adapted lighting consisted of slow-moving, repetitive visual color effects created by a projector, and a lighting column that children can touch and climb on. Auditory stimuli include rhythmic music, which is heard via loudspeakers.
1469977|NCT03197129|Other|traditional waiting room|The traditional waiting room: a waiting area outside the clinic with ten seats in one row faces the reception desk in an area of 15 square meters. The area is air-conditioned, moderately well-lit, without posters or paintings on the walls, and no reading material.
1469978|NCT03197116|Other|Telephone reminder|Interactive telephone reminder by a trained layperson with a standard script to remind return to the center for taking fecal tubes for CRC screening
1469979|NCT03197116|Other|No other|No additional reminder will be offered
1469980|NCT03197103|Drug|N-Acetylcysteine (NAC)|For more information read Experimental Arm description
1469981|NCT03197090|Device|Zenicor ECG|Participants will place their thumbs on the device twice daily and whenever they notice palpitations.
1469988|NCT03197064|Drug|Fosaprepitant 150 mg|Antiemetic used to prevent nausea and vomiting after general anesthesia.
1948404|NCT02415270|Drug|Reduced Nicotine Content Cigarettes|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
1469993|NCT03197012|Drug|90Y-DOTA-TOC|Starting 30 minutes prior to the administration of 90Y-DOTA-TOC, amino acid solution will be administered via IV, and will continue through the PRRT procedure. An angiographic catheter will be inserted under fluoroscopic guidance to the appropriate location in the hepatic artery. 90Y-DOTA-TOC will be administered via the hepatic arterial catheter.
1469994|NCT03197012|Drug|68Ga-DOTA-TOC|In the sub-study, 10 patients will receive 68Ga-DOTA-TOC concurrent with the 90Y-DOTA-TOC dose and 90 minutes after treatment, these patients will be imaged using a PET/CT. The following day, patients enrolled in the sub-study will undergo a PET/MRI.
1469995|NCT03196999|Device|Personalized Attention Bias Training|"This mobile app will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing novel treatments for PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be personalized for each user."
1469996|NCT03196999|Device|Neutral Attention Training Condition|This app will a placebo attention bias modification that will be used on an iOS compatible phone. The placebo will contain only neutral words.
1469997|NCT03196999|Device|Non-Personalized Attention Bias Training|"This mobile app will aim to reduce neurobiological threat sensitivity with the ultimate goal of developing novel treatments for PTSD. The app can be used on an iOS compatible phone and involves a training program that aims to directly reduce threat sensitivity by modifying attention. The contents of the app will be the same of each user."
1469998|NCT03196986|Drug|MIL60|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
1469999|NCT03196986|Drug|Bevacizumab|15mg/kg in combination with paclitaxel/carboplatin for 6 cycles, then maintains at 7.5mg/kg
1470000|NCT03196973|Drug|DF289 plus DF277|1 vial into the affected ear twice daily for 7 days
1470001|NCT03196973|Drug|DF289|1 vial into the affected ear twice daily for 7 days
1470002|NCT03196973|Drug|DF277|1 vial into the affected ear twice daily for 7 days
1470003|NCT03196947|Drug|APO010|APO010 is given iv on D1, D8 and D15 followed by a one-week drug rest (cycle duration 4 weeks).
1470006|NCT03196908|Dietary Supplement|Energy Drink Brand 1|Two 16-oz containers of Energy Drink Brand 1 consumed in 60 minutes
1470007|NCT03196908|Dietary Supplement|Energy Drink Brand 2|Two 16-oz containers of Energy Drink Brand 2 consumed in 60 minutes
1470008|NCT03196908|Other|Placebo|Lime juice, water, and cherry flavoring
1470013|NCT03196882|Drug|40mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution. The doses of 40 mg per day of elemental iron correspond to 300 mg ferrimanitol ovoalbumin
1470014|NCT03196882|Drug|20mg/day of iron|Ferrimanitol ovalbumin granulated Powder for oral solution. The doses of 20 mg per day of elemental iron correspond to 150 mg ferrimanitol ovoalbumin
1470015|NCT03196882|Drug|80mg/day of iron|Ferrimanitol ovalbumin granulated. Powder for oral solution The doses of 80 mg per day of elemental iron correspond to 600 mg ferrimanitol ovoalbumin.
1470016|NCT03196869|Device|Chrono-chemotherapy|Chrono-chemotherapy+concurrent radiochemotherapy
1470017|NCT03196869|Device|Routine intravenous drip|Routine intravenous drip-chemotherap
1470018|NCT03196869|Drug|induction Chrono-chemotherapy|Experimental group:docetaxel,cisplatin,5-FU
1470019|NCT03196869|Drug|induction Routine-chemotherapy|control group:docetaxel,cisplatin,5-FU
1470020|NCT03196869|Drug|cisplatin chrono-chemotherapy|Experimental group: cisplatin chrono-chemotherapy
1470021|NCT03196869|Drug|cisplatin routine-chemotherapy|control group:cisplatin routine-chemotherapy
1470022|NCT03196869|Radiation|intensity-modulated radiation therapy|control group is similar to Experimental group
1470023|NCT03196856|Behavioral|Resistance and Plyometric Exercise|8 weeks of Resistance (twice weekly) and Plyometric (once weekly) training
1470024|NCT03196856|Dietary Supplement|Greek Yogurt (0% Plain)|200g 3x/day for 8 weeks.
1470025|NCT03196856|Dietary Supplement|Placebo - Study Designed Supplement|Iso-energetic to yogurt. 3x/day for 8 weeks.
1470026|NCT03196843|Drug|Raltitrexed|Raltitrexed 2.5mg/m2 on day 1,22,43 during radiotherapy
1470027|NCT03196843|Radiation|Intensity Modulated Radiotherapy|Radical radiotherapy:70Gy/2Gy/7 weeks Preoperative and postoperative adjuvant radiotherapy:50-60Gy/2Gy/5-6 week
1470028|NCT03196830|Biological|CAR-T|For eligible patients, CAR-T cells targeted to patients' tumor cell antigen will be infused after 48 hours later of chemotherapy
1470029|NCT03196817|Drug|betamethasone dipropionate, betamethasone disodium phosphate and lidocaine 2%|6.43 mg of betamethasone dipropionate, 2.63 mg of betamethasone disodium phosphate and 0.5 ml plus lidocaine 2%
1470030|NCT03196817|Device|Wrist splinting|Splinting only at night to maintain the wrist positioned in 15 degrees of extensionin.
1470031|NCT03196804|Drug|LC28-0126|LC28-0126
1470032|NCT03196804|Drug|Placebo|Placebo
1470033|NCT03196791|Drug|Sugammadex Sodium|"INDICATIONS AND USAGE BRIDION® is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide in adults undergoing surgery. BRIDION (sugammadex) injection is a sterile, clear, colorless to slightly yellow-brown, non-pyrogenic aqueous solution intended for intravenous infusion.
DOSAGE AND ADMINISTRATION BRIDION (sugammadex) injection, for intravenous use, should be administered by trained healthcare providers familiar with the use, actions, characteristics, and complications of neuromuscular blocking agents (NMBA) and neuromuscular block reversal agents."
1470034|NCT03196778|Radiation|Low Dose Radiotherapy|Patients will receive 10 fractions of very low dose hemi-body radiation, delivered, twice per week, over five weeks
1470036|NCT03196752|Procedure|laryngeal handshake|palpate for the cricothyroid membrane using the laryngeal handshake technique
1470037|NCT03196752|Other|conventional method|conventional
1470038|NCT03196739|Device|Virtual rehabilitation|A total of 10 sessions were held for 30 minutes, 2 to 3 times a week for upper limb rehabilitation using immersive virtual reality under the assistance of an occupational therapist.
1470039|NCT03196726|Behavioral|Brief Cognitive Behavioral Therapy|Week 1: Understanding postnatal depression Week 2: Relaxation techniques and tips to reduce stress Week 3: Positive thinking style and Self-Esteem Week 4: Relationship with partner Week 5: Relationship with infant Week 6: Relapse prevention
1470040|NCT03196726|Behavioral|standard management based on Clinical Practice Guideline|Mild depression: behavioral therapy; moderate depression: behavioral therapy and consider anti-depressant if required
1470041|NCT03196713|Behavioral|Early Intensive Behavioral Intervention|
1470042|NCT03196700|Radiation|Short course radiotherapy|An accelerated hypo-fractionation radiotherapy is delivered for palliation in patients with metastatic or locally advanced head and neck cancer.
1470043|NCT03196674|Other|Biofeedback via motion capture|The motion capture system will provide visual and auditory feedback of success, via a large screen, located on the wall. This could be manipulated so that the feedback is provided for a slightly higher range than instructed by the therapist.
1470044|NCT03196661|Biological|Influenza A (H7N9) virus vaccine|To prevent the infection of H7N9 virus.
1470045|NCT03196648|Other|Gingival health formulation in an accelerating device|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used with the GLO Science Device
1470046|NCT03196648|Other|Gingival health formulation on a toothbrush|The intervention is a gingival health formulation for soft tissue maintenance, oral malodor and gentle teeth whitening to be used on a toothbrush together with toothpaste.
1470047|NCT03196648|Other|OTC fluoride toothpaste|OTC anti-cavity toothpaste containing fluoride and sodium monofluorophosphate.
1470048|NCT03196622|Device|Handgrip test|Handgrip strenght can be used in daily clinical practice to screen patients having sarcopenia to improve treatment and quality of life.
1470203|NCT03195361|Device|SRS - Self Retaining Support system|
1470049|NCT03196609|Biological|Collection of stool and serum samples|"During the inclusion visit (for the 5 cancer sites): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) +Blood sample (1 tube SST + 1 tube EDTA)
1 month after treatment (only for non-small cell lung cancer): Stool collection (1 tube RNA later + 1 tube DMQO-EDTA) + Blood sample (1 tube SST + 1 tube EDTA)"
1470050|NCT03196596|Other|Computer simulation|In these patients, a computer simulation model will be obtained based on pre procedural CT
1470051|NCT03196583|Device|Velo-Lingual Bite (BVL)|The administration of the device will proceed according to both the essential requirements of the European directives concerning medical devices (Annex I and X of directive 93/42/EEC) and the clinical practice standards and guidelines provided by the AASM and AASDM. These include the obtainment of alginate impression of both jaws and an interocclusal record, with the mandible at 50% of its maximal protrusive position. Since no single standard titration protocol is available, progressive mandibular advancement will be conducted according to the best available medical standard.
1470052|NCT03196570|Behavioral|Physical Activity Intervention|After randomization into the intervention arm, participants will be instructed on how to use the Spanish language study website. During the six month intervention, they will complete online questionnaires to determine their stage of change towards increasing physical activity. A manual of information will be automatically generated based on their responses. Participants can read this information online, along with tip sheets related to increasing physical activity. On the website they can also set weekly goals and log their weekly PA. It will also include short videos with demonstrations for PA they can do at home and around their neighborhood. Information will also include community resources (community centers, public events, parks) where they can be physically active. Participants will also receive prompts and encouragement via text-message to encourage them to log into the website and continue to track their progress.
1470053|NCT03196570|Behavioral|Wellness Contact Control|Participants in the control arm will attend the same baseline orientation sessions and measurements as the intervention arm. After randomization into the control group, participants will complete an introductory in-person session to introduce them to a website, similar in design, with information on health topics other than physical activity, including diet and other factors associated with CVD risk. It will include information from NHLBI heart health materials for Latinos. Topics include healthy eating, increasing fruit and vegetable consumption, reducing fat and salt intake, learning about cholesterol, stress management. Participants will log onto a separate website unique to the control group and complete monthly surveys on the wellness topics and their progress. Participants will also receive prompts and encouragement text-messages to encourage them to log onto the website.
1470054|NCT03196557|Drug|Prenisolone|Specified dose on specified days
1470055|NCT03196557|Drug|Placebo|Specified dose on dose on specified days
1470056|NCT03196544|Behavioral|Social Approach Training (5 sessions)|5 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
1470057|NCT03196544|Behavioral|Social Approach Training (10 sessions)|10 one-hour, clinician-administered treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) designed to increase positive emotions, cognitions, and behaviors.
1948405|NCT02415270|Drug|Reduced ROS/RNC|Human topography data will show if smokers smoke their cigarettes differently from baseline following randomization. Select biosamples of participants will be used to analyze how biomarkers differ among groups
1948406|NCT02415270|Other|Control|Control Group
1470060|NCT03196518|Procedure|PET Imaging|PET/CT study immediately after injection
1470061|NCT03196518|Other|18F-tetrafluoroborate (18F-TFB)|administration of a single dose of approximately 5-10 mCi 18F-TFB (mass <= 50 μg) for imaging purposes
1470064|NCT03196492|Other|No intervention|No intervention
1470065|NCT03196479|Drug|ketamine and propofol mixture with 1:6 ratio|K16: K16 group was received ketamine:propofol with ratio of 1:6, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 30 ml of 1% propofol (10 mg/ml), and 19 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 6 mg of propofol
1470066|NCT03196479|Drug|ketamine and propofol mixture with 1:4 ratio|K14 group was received ketamine:propofol with ratio of 1:4, filled in 50 cc syringe, which consisted of 1 ml of ketamine (50 mg/ml), 20 ml of 1% propofol (10 mg/ml), and 29 ml of normal saline so that every ml of mixture consisted of 1 mg of ketamine and 4 mg of propofol
1470067|NCT03196466|Biological|Valproic acid|titration
1470068|NCT03196466|Biological|carbamazepine|titration
1470069|NCT03196466|Biological|phenobarbital|titration
1470070|NCT03196466|Biological|phenytoin|titration
1470071|NCT03196466|Biological|levetiracetam|titration
1470072|NCT03196466|Biological|lamotrigine|titration
1470073|NCT03196466|Biological|topiramate|titration
1470074|NCT03196466|Biological|oxcarbazepine|titration
1470075|NCT03196466|Biological|stiripentol|titration
1470076|NCT03196466|Biological|clobazam|titration
1470077|NCT03196453|Dietary Supplement|Probiotic|probiotic and/or placebo intervention in toddlers
1470078|NCT03196427|Drug|Vedolizumab|Vedolizumab intravenous infusion
1470079|NCT03196414|Biological|Cyclophosphamide，Fludarabine，CART-138/BCMA cells|Cyclophosphamide :300 mg/m2 IV over 30 minutes on days -5,-4 and -3; Fludarabine:30 mg/m2 IV over 30 minutes on day -5, -4, and -3; Biological: Anti-CD138/BCMA CART cells 5x106- 50x106 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
1470080|NCT03196401|Drug|Durvalumab|durvalumab 1500mg administered intravenously every 28 days, for a total of six doses
1470081|NCT03196401|Radiation|Radiation therapy|concurrent definitive radiation therapy to the bone plasmacytoma initiated within two weeks of starting
1948407|NCT02411708|Drug|SANGUINATE|Single two-hour infusion of SANGUINATE
1470082|NCT03196388|Drug|Enzalutamide|"Radiation: External Beam Radiation Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is >95% of the prescribed dose to a volume that is at least 0.03 cc.
EBRT shall receive prescription doses to the PTV 70 Gy delivered in 2.5 Gy"
1948408|NCT02411708|Drug|Placebo|Single two-hour infusion of placebo
1470085|NCT03196362|Drug|Pioglitazone + Metformin|One tablet of fixed dose of Pioglitazone/ Metformin (15mg/30mg) will be given twice daily
1470086|NCT03196362|Drug|Placebo Oral Tablet|One tablet of placebo will be given twice daily
1470087|NCT03196349|Drug|Warfarin|Will be randomized to receive open label warfarin daily to achieve a target INR of 2-3
1470088|NCT03196349|Drug|Apixaban 2.5 MG|Will be randomized to receive open label apixaban of 2.5 mg twice daily
1470089|NCT03196349|Drug|Rivaroxaban 20 MG|Will be randomized to receive open label rivaroxaban of 20mg daily
1470090|NCT03196336|Other|Pharmacotherapy follow-up care|The pharmacotherapy follow-up care consists of five pharmaceutical consultations (every up to 2-3 months) aimed to identify, prevent and solve the drug related problems regarding the indication, effectiveness and safety of the use of medicines.
1470091|NCT03196310|Drug|Platelet Concentrate|Platelet Rich plasma
1470092|NCT03196310|Drug|Corticosteroid injection|Kenalog
1470093|NCT03196310|Other|Normal Saline|Placebo
1470098|NCT03196271|Dietary Supplement|Ketocal 2.5:1|A ketogenic feed for the dietary management of intractable epilepsy is given over a period of four weeks, after a control period of 4 weeks. The amount of the feed given is determined by the Dietitian and/or Doctor responsible for the patient's care (at least one carton per day).
1470099|NCT03196258|Behavioral|Cognitive behavioural therapy|Participants who are randomized to the CBT intervention are required to start CBT within 8 weeks of their fracture surgery. The CBT intervention will consist of 6 weekly one-on-one, 1-hour sessions that will focus on addressing maladaptive beliefs related to pain and recovery as well as teaching skills to enhance coping and management of pain symptoms. The specific focus of CBT sessions will be informed by each individual patient's responses on the SPOC questionnaire. All other aspects of post-operative care will be at the discretion of participant's surgeon
1470100|NCT03196245|Other|There is no intervention.|There is no intervention. This is a purely observational study. We enrolled pregnant women as they received a vaccine as part of their regular medical care; we did not administer the vaccine. We also enrolled pregnant women acutely infected with influenza.
1470101|NCT03196232|Drug|Epacadostat|Given PO
1470102|NCT03196232|Other|Laboratory Biomarker Analysis|Correlative studies
1470103|NCT03196232|Biological|Pembrolizumab|Given IV
1470104|NCT03196219|Drug|C16G2|C16G2
1470105|NCT03196219|Other|Placebo|Varnish Placebo
1470106|NCT03196206|Drug|BMS-986177|Oral Suspension
1470107|NCT03196193|Procedure|Open Reduction and Internal Fixation|Fractured bone fragments are reduced and stabilized by intramedullary nail.
1470108|NCT03196193|Device|ZNN CM Asia|Reduced bone fragments are to be stabilized by Zimmer Natural Nail CM Asia System.
1470109|NCT03196193|Device|Anterior Support Screw|Experimental group will receive insertion of ACE 4.5/5.0mm cannulated lag-screw anteriorly to Zimmer Natural Nail CM Asia Lag-screw.
1470110|NCT03196180|Drug|Imiquimod|Given intravaginally
1470111|NCT03196180|Other|Laboratory Biomarker Analysis|Correlative studies
1470112|NCT03196180|Drug|Topical Fluorouracil|Given intravaginally
1470113|NCT03196167|Drug|Sugammadex|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
1470114|NCT03196167|Other|Placebo|The administration of the study and placebo compounds will be performed by CTICU nurses who will receive the drugs in a blinded fashion from the departmental research pharmacy.
1470115|NCT03196154|Diagnostic Test|Fasting insulin level|Fasting insulin and C-peptide level measured using LCMS which is then used to calculate the insulin resistance and beta cell function using homeostasis model assessment
1470116|NCT03196154|Diagnostic Test|Plasma drug level|Plasma trough level of metformin and gliclazide will be measured using LCMS to ensure true compliance.
1470117|NCT03196141|Diagnostic Test|StO2 and EndoPAT|"StO2 probe is a lightweight plastic probe that will be applied over the brachioradilalis muscle (anterolatereal aspect of the forearm) where there is less subcutaneous fat and taped in place.
The EndoPAT probe will be place on a finger on the same arm.
Pulse oximeter probes will be connected to a finger on each hand."
1470120|NCT03196102|Behavioral|BTI|Brief Tobacco Intervention (BTI). The group intervention was designed to include the components of effective tobacco control programs for military personnel, and specifically tailored to the Technical Training environment. The intervention is approximately 40 minutes and delivered in a group format (e.g., groups of 50 Airmen). The format of the BTI is meant to be interactive, utilizing the Socratic teaching style and eliciting participation through the principles of motivational interviewing. A series of open-ended questions, reflections, and decisional balance, were used to increases motivation to remain tobacco free.
1470121|NCT03196102|Behavioral|Cigarette smoking military tailored pamphlet|The Airmen's Guide is 5×7 inches, 46 pages, with text and color illustration. The text covers the advantages of remaining tobacco-free after Basic Military Training, and the opportunity the ban provides to begin a lifetime without tobacco, focusing on cigarettes and smokeless tobacco. Information is included about challenges and coping suggestions for the times that Airmen are at particular risk of smoking. The text is supplemented by images created specifically for Airmen and designed to reinforce the messages that smoking: 1) is responsible for more fatalities than combat; 2) conveys a negative image to civilians; and 3) impedes military readiness and promotion through the ranks.
1470122|NCT03196102|Behavioral|Standard smoking cessation intervention|This booklet is a 36-page, comprehensive guide for quitting smoking with 7 pages dedicated to relapse-prevention.
1470123|NCT03196089|Procedure|Oxygen application|Supplemental oxygen via mask
1470124|NCT03196076|Drug|Perflutren Lipid microsphere|Perflutren will be administered in a bolus or continuous infusion using the dosing range and administration type within the perflutren prescribing information.Once perflutren lipid has been administered, the transducer is maintained in a constant position over the area of interest to show the target lesion in order to assess the enhancement pattern during the early, mid and late vascular phases. Images will also be taken of kidney parenchyma in a suitable longitudinal plane.If there are multiple lesions in one subject requiring a second dose, the subject will have the option to undergo a 2nd contrast-enhanced study 30-minutes after the initial contrast dose, per dosing instructions in the package insert.
1470125|NCT03196063|Other|Eccentric|Exercises based on eccentric contractions of the quadriceps femoris muscle, using a 15º inclined plane. A serie of 15 repetitions of the squat will be performed, with the frequency of three times a week for eight weeks. The load of the exercises will be increased weekly.
1470126|NCT03196063|Other|Modified Protocol|Protocol based on the Heavy Slow resistance program, with the addition of an isometric phase at the beginning of the protocol, and with exercises using body weight without the use of mechanotherapy.
1470127|NCT03196050|Device|Handheld Device (Smart Phone)|"Handheld device will be used for 3 tasks:
1x per day: status update (how are you today?)
1x per week: 10 questions on general health status
1x per month: EORTC QLQ-C30 questionnaire"
1470128|NCT03196037|Behavioral|Tai Chi|An 8-week Tai Chi intervention consisting of 75-minute group sessions held twice a week, over 8 weeks (i.e., total of 16 sessions).
1470129|NCT03196024|Behavioral|Family-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and a co-participating family member will be enrolled in the study. After completing baseline data they will be randomly selected to participate in one of the two study arms. For the family-focused arm, the family pair will attend 8 2-hour weekly educational sessions about type 2 diabetes and CVD risk reducing lifestyle behaviors. The sessions will be presented by community health workers (CHWs) in Spanish to groups of 5 to 6 family pairs. Following completion of the sessions, data will be collected from the family pairs. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the family pairs.
1470130|NCT03196024|Behavioral|Individual-focused intervention arm|Family pairs including an individual family member at-risk for type 2 diabetes or CVD and co-participating family member will be enrolled in the study. After completing baseline data pairs will be randomly selected to participate in one of two interventions. For the individual-focused intervention, the at-risk individual will attend 8 weekly 2-hour education sessions on type 2 diabetes and CVD risk reducing lifestyle behaviors. Sessions will be presented by CHWs in Spanish to groups of 10 to 12 individuals. Following completion of sessions, data will be collected from the individuals. CHWs will call monthly to provide information and support through the end of the 12-month period at which time data will be collected from the at-risk individuals and their co-participating family members.
1470131|NCT03196011|Other|TKR with mechanical alignment method|TKR implanted using manual instruments and traditional mechanical alignment methods
1470132|NCT03196011|Other|TKR with alternative alignment method|TKR implanted using manual instruments and alternative alignment methods
1470133|NCT03195998|Diagnostic Test|TcB Measurement|TcB measurements will be obtained within approximately 30 minutes of the TSB being drawn before initiation of phototherapy, approximately 24 hours after the initiation of phototherapy and approximately 24 hours after completion of phototherapy. The TcB measurement will involve lightly pushing three times at each site which will yield an average transcutaneous bilirubin value. This will be calculated for the interscapular, buttock and sternal automatically by the bilirubinometer. While on phototherapy a measurement of the diapered, non-exposed buttock area will be obtained at approximately 24 hours to coincide with the standard of care serum bilirubin measurement.
1470134|NCT03195985|Other|Mindfulness-based intervention|A shortened, 4 week mindfulness intervention course based on the original 8 week mindfulness-based stress reduction course by Jon Kabat-Zinn
1470135|NCT03195985|Other|Age Well psycho-education|4-week active control condition aimed at psycho-education regarding healthy ageing
1470136|NCT03195972|Other|Drug diary filling|patient will fill every day a drug diary
1470137|NCT03195959|Other|Hypoxia and Hyperoxia|10 minutes of breathing a gas mixture with FiO2 0.16 via a tight fitting mask. After 10 minutes of breathing ambient air (normoxia), patients were exposed to hyperoxia (FiO2 1.0) for 10 minutes.
1470138|NCT03195946|Drug|Lu AF35700|tablets for oral use, 10 mg/day
1470139|NCT03195946|Drug|Midazolam|syrup for oral use, 4mg/day
1470140|NCT03195946|Drug|Cocktail of CYP450 substrates|Caffeine tablets for oral use, 200 mg/day. Omeprazole tablets for oral use, 40 mg/day. Dextromethorphan tablets for oral use, 30 mg/day. Midazolam IV solution for Intravenous use, 0.025 mg/kg/day
1470141|NCT03195933|Other|Cortisol|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
1470142|NCT03195933|Other|Placebo|We compared placebo vs. 20 mg oral dose of cortisol, which pharmacologically elevated cortisol levels.
1470144|NCT03195907|Other|Pulmonary physiotherapy|
1470145|NCT03195894|Device|TripleA|
1470205|NCT03195335|Other|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
1470146|NCT03195881|Other|Ocular ultrasound|Post-cardiopulmonary arrest patients meeting inclusion/exclusion criteria for targeted temperature management will undergo ocular ultrasound at three time points: within 6 hours (h) of initiation of hypothermic protocol, between 10-24 h after hypothermic protocol initiation, and between 24-36 h after hypothermic protocol initiation.
1470147|NCT03195868|Device|Realief Therapy|Patients will be treated using class IV laser using a proprietary algorithm developed by REALief neuropathy centers
1470148|NCT03195855|Other|Manual therapy / joint mobilisations|Manual therapy is a common form of treatment employed usually by physiotherapists, in order to help increase range of motion of a specific joint region by restoring the arthrokinematic accessory gliding and rolling movement that is associated with normal joint movement. The hypothesised mechanism of action for this is that improvements of gliding and rolling will normalise osteokinematic rotation and consequently enable the normalisation of active movements. Another possible mechanism of action of mobilisations includes increasing the extensibility of the noncontractile capsular and ligamentous tissues. The effectiveness of passive accessory gliding techniques to increase joint ROM has been widely explored in the literature; with some studies revealing an increase in ankle dorsiflexion and others no change in ankle dorsiflexion. However, the subjects taking part in these studies were people without diabetes and mostly people with ankle sprains or ankle instability.
1470149|NCT03195842|Other|Recordable card|
1470150|NCT03195829|Behavioral|Computerized Cognitive Stimulation|The intervention group performed 12-week, 90-minutes per week of cognitive stimulation in group using a tablet with a commercial software with specific exercises to train the cognitive functioning and promote the relation ties in group-session.The program's difficulty level was adjusted to the MMSE score, and was gradually increased.
1470151|NCT03195829|Behavioral|Multimedia-based internet|The active control group had access to different Multimedia contents (travel, photos, music, TV program, cooking recipes) using a tablet, 90-minutes per week each week during 3-months. Each group session was centered in a particular topic, participants were able to select different media free available in Internet.
1470152|NCT03195816|Behavioral|Computerized Cognitive training|Experimental group will receive 1 year of a computer-based cognitive stimulation program, first 6 months, 60-minutes twice a week and next 6 months once a week training in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
1470153|NCT03195803|Behavioral|Computerized Cognitive Stimulation|All participants performed 12-week, 60-minutes twice a week of a computer-based cognitive stimulation program in group-setting, using a tablet with a software with specific training focused on attention, executive and speed processing functions.
1470154|NCT03195790|Behavioral|Family-based pediatric obesity treatment|Families with at least one overweight/obese child between ages 6 and 11 years will receive 12-months of family-based pediatric obesity treatment that emphasizes healthy changes to the home environment and family routines. The intervention targets dietary intake, physical activity, and consistent sleep.
1470155|NCT03195777|Device|PET/CT|PET/CT imaging will be performed (with fluorodeoxyglucose, [FDG] as a tracer). Thereafter, subjects will be monitored for development of PTS. We will then assess the ability of PET/CT top predict the subsequent development of PTS.
1470156|NCT03195764|Drug|T-1101 (Tosylate)|T-1101 (Tosylate) powder in bottle
1470157|NCT03195751|Device|Software development kit measurements|This proprietary SDK (FocusMotion) processes user motions recorded by the hardware (accelerometer, gyroscope, magnometer). As data is collected, the software development kit (SDK) classifies the motion as repetitive or non-repetitive, and repetitive motions are further analyzed. As the user completes a movement, the SDK tracks the number of repetitions performed, technique, and rest time. The SDK can provide real-time feedback to the user regarding their form by comparing the movement to a template of an ideal motion for that particular action. The SDK is compatible with any operating system, phone, or wearable device, providing seamless integration with pre-existing technologies.
1470158|NCT03195751|Device|Manual Goniometer Measurements|A manual goniometer was used to measure the range of motion of the shoulder.
1470159|NCT03195738|Other|Cognitive Orientation to Occupational Performance (CO-OP)|"In the CO-OP intervention participants are first assisted to identify 3-5 occupation based goals which then become the focus of the intervention sessions. Over the course of the 10 intervention sessions, participants are guided to learn and practice problem solving using a metacognitive strategy, Goal-Plan-Do-Check applied to their self-identified goals. Study therapists use 'guided discovery' an iterative technique to facilitate problem solving by the participant to develop plans to work toward their goals and to evaluate their progress. Intervention takes place in the location that is most meaningful for the participant's selected goal (e.g. home, school, playground etc.). Participants are provided with a work book to track progress."
1470160|NCT03195725|Other|Review of notes|No intervention will occur
1948409|NCT02406157|Device|577-MPL|Device for 577nm micropulse treatment of the diabetic macular edema with the following parameters:100 microns spot size,5% duty cycle of 0.2 seconds,power is tested on micropulse mode and then reduce power to 50% of visible
1470162|NCT03195686|Device|PLE100(Inbody®)|PLE100(Inbody®) monitoring in children to be operated under the total intravenous anesthesia (Propofol)
1470163|NCT03195673|Drug|Terazosin|TZ 0.5mg once a day for 3-7 days before carotid artery stenting to 12 months later.
1470164|NCT03195673|Procedure|Carotid artery stenting|Carotid artery stenting is an alternative treatment of carotid artery stenosis, which would be performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.
1470165|NCT03195660|Device|ASV Therapy|AirCurve 10 ASV device set up in AutoSet mode
1470166|NCT03195647|Drug|Potassium|"The trial treatment will start when patients are admitted to the intensive care unit after their surgery. The patient will undergo regular blood investigations, as per current practice. The frequency of K+ monitoring while on ICU will be according to clinician / nursing staff preference.
Potassium supplementation will be according to local hospital protocols. This can be either via an intravenous infusion or as a tablet. Patients will otherwise be treated as per current hospital protocol."
1470167|NCT03195634|Drug|Carvedilol|an initial dose of 6.25 mg once-daily that was adjusted over 5-7 days to the maximum tolerated dose, keeping heart rate >55 beats per minute, or up to 12.5 mg/day
1470168|NCT03195621|Device|Stent implantation|Stent placement after risk factors assessment plus FFR or ultrasound or OCT detection for critical lesions.
1470169|NCT03195608|Device|Lane change assistance system|This study will investigate the feasibility and preliminary efficacy of a 6-session lane change ADAS-intervention on the simulated driving performance of individuals with mild to moderate PD. We anticipate that the use of lane change assist technology will decrease the number of driving errors in individuals with PD. As this is a feasibility study, we will evaluate: -recruitment capability and sample characteristics - data collection methods, procedures, and outcome measures - acceptability and suitability of the lane change assist technology intervention - preliminary efficacy The outcomes of this study will inform the design of a larger study, should such large-scale study be warranted.
1470170|NCT03195595|Device|mitral valve replacement|early postoperative outcome regarding pain in minimal invasive technique
1470171|NCT03195595|Device|conventional mitral valve replacement|early postoperative outcome regarding pain in conventional median sternotomy
1470172|NCT03195582|Drug|Corsodyl|following local anesthesia buccal and lingual flaps will be raised minimally, the cover screw will be removed from the implant. In the test group, Corsodyl gel 1% CLOROHEXIDINE will be applied on the implant and the healing abutment.
1470173|NCT03195569|Drug|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
1470174|NCT03195569|Drug|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
1470175|NCT03195569|Drug|Paclitaxel|175 mg/m2, IV following investigational product on day 1 of each 21 day cycle.
1470176|NCT03195569|Drug|Carboplatin|AUC 5 IV, following paclitaxel on day 1 of each 21 day cycle.
1470177|NCT03195556|Device|Ultrasound|Ultrasound exposure of Definity microbubbles infused over 10 min. Ultrasound administered at 1.3 MHz, mechanical index of 1.3, and pulsing interval of 10 s.
1470178|NCT03195543|Diagnostic Test|Platelet function analyzer-100|The PFA-100 system evaluates primary hemostasis in whole blood samples.
1470179|NCT03195543|Diagnostic Test|Light transmission aggregometry|Light transmission aggregometry is the gold standard method for assessing platelet function.
1470180|NCT03195543|Diagnostic Test|Rotational thromboelastometry|ROTEM is a viscoelastic method for hemostasis testing in whole blood.This assay investigates the interaction of blood cells, coagulation factors and their inhibitors during clotting and subsequent fibrinolysis.
1470181|NCT03195543|Diagnostic Test|Endogenous thrombin potential|The endogenous thrombin potential assesses the amount of thrombin which can be generated after the in vitro activation of coagulation and represents the balance between pro- and anti-coagulant forces in plasma.
1470182|NCT03195530|Drug|Propofol|Induction of anesthesia using propofol, and recording the BIS values and EEG patterns during the induction
1470184|NCT03195504|Device|HFNC|High flow nasal oxygen (60 l) under GA
1470185|NCT03195504|Device|CON (control)|Standard oxygen (10-15 l) under GA
1470186|NCT03195491|Biological|Nivolumab|Intravenous infusion administered over 30 minutes at 240 mg
1470189|NCT03195465|Dietary Supplement|Dark Chocolate|Dark Chocolate bars with 70% cacao and 30% organic cane sugar will be administered at 3 squares (6 grams) every four hours during waking hours between 8:00 a.m. and 8:00 p.m. daily for four weeks.
1470190|NCT03195452|Drug|Raltegravir and 2 Nucleoside/Nucleotide reverse transcriptase inhibitor (NRTI)|All virologically suppressed
1470191|NCT03195439|Device|TTP|TTP™ allows to continuously measure body temperature using a new non-invasive method, and was cleared for marketing by US FDA (K150160) for as a temperature monitoring system intended to measure and monitor core body temperature of patients of all ages, by applying a sensor unit on the forehead.
1470192|NCT03195426|Procedure|distal nerves blocks group|"ICB: US probe will be placed just below clavicle inferior to site of needle entry. Following identification of axillary artery and cords, the needle will be advanced posterior to axillary artery. 20 cc of Ropivacaine 0.375% will then be deposited in a U-shaped distribution posterior and to each side of the axillary artery.
SSNB will be performed by locating the brachial plexus and the departure of the suprascapular nerve from the superior trunk under the inferior belly of the omohyoid muscle by sliding the transducer distally and then injecting 5 mL of ropivacaine 0.375%.
SCNB will be performed injecting 5 mL of ropivacaine 0.375% in the intermuscular plane between the sternocleidomastoid and scalene muscles using a lateral to medial in-plane technique."
1470193|NCT03195426|Procedure|Diaphragmatic function assessment|"Diaphragmatic excursion will be assessed under ultrasound immediately before and after regional anesthesia.
This a pain free and safe procedure, that we usually perform in patients at risk of respiratory failure."
1470194|NCT03195413|Procedure|Ultrasound-guided forearm nerve block|An ultrasound machine will be used to identify the median, radial, and ulnar nerves in the forearm, so that a needle may be used to apply lidocaine into the soft tissue space around those nerves.
1470195|NCT03195413|Drug|1:1 volume measured solution of: 1% lidocaine without epinephrine and 0.5% bupivacaine without epinephrine|This is the anesthetic solution that will be administered during the ultrasound-guided nerve block
1470196|NCT03195413|Device|Bedside ultrasound machine|This is the device that will be used to visualize tissues during the ultrasound-guided nerve block.
1470197|NCT03195400|Diagnostic Test|Oral Glucose Tolerance Test|The oral glucose tolerance test (OGTT) measures the body's ability to use a type of sugar, called glucose, that is the body's main source of energy. An OGTT can be used to diagnose prediabetes and diabetes.
1470198|NCT03195400|Diagnostic Test|Hyperglycemic Clamp|Test of beta-cell function and insulin secretion. Involves increasing and maintaining blood glucose concentration with IV variable infusion of dextrose.
1470199|NCT03195400|Diagnostic Test|Isoglycemic Intravenous Glucose Test|Test which exposes pancreas to blood glucose levels matched to the ones obtained at the OGTT.
1470200|NCT03195400|Diagnostic Test|Hyperinsulinemic Euglycemic Clamp and 2H20|Test is used to assess insulin effects on hepatic glucose production.
1470201|NCT03195387|Drug|MMV390048|Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
1470202|NCT03195374|Other|Prescription Opioid Misus Index|Opioid misuse will be assessed by the Prescription Opioid Misuse Index (POMI) scale. A score ≥ 2 is considered positive and will define a misuse behavior.
1470206|NCT03195322|Procedure|Pre-pectoral Tissue Expander|All participants in the study will undergo bilateral mastectomy followed by Immediate, bilateral pre-pectoral tissue expander breast reconstruction with complete AlloDerm® coverage.
1470207|NCT03195309|Drug|Ropivacaine|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
1470208|NCT03195309|Drug|Fentanyl|Compare different concentration of ropivacaine and fentanyl for elective Cesarean delivery post operative pain control.
1470209|NCT03195296|Other|No intervention|No intervention related to the study is foreseen
1470210|NCT03195283|Other|Meal service|The type of meal service in the hospital (usual care)
1470211|NCT03195270|Drug|[18F]FDG|10 mCi± 1 mCi of [18F]FDG via the antecubital vein in a bolus injection
1470212|NCT03195270|Device|PET/MRI|PET/MRI hybrid scanner used as diagnostic device
1470213|NCT03195257|Other|GIP|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
1470214|NCT03195257|Other|GLP-1|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
1470215|NCT03195257|Other|Saline|On 3 matched days with 'hypoglycemia' (i.e. plasma glucose clamped between 3-7 mol/L for 120 minutes) either GIP (4 pmol/kg/min), glucagon-like-peptide-1 (GLP-1) (1 pmol/kg/min) or placebo (saline) was administered; and on 2 separately matched days with 'hyperglycemia' (i.e. clamped at 12 mmol/L for 90 minutes) either GIP (4 pmol/kg/min) or saline was administered.
1470216|NCT03195244|Other|Aquatic Physical Therapy|Swim Whisperer's Aquatic Therapy Sessions
1470217|NCT03195231|Drug|Wuling Powder|Patients of Wuling Group are instructed to take Wuling Powder 3 times a day and 3 pills each time for 12 weeks.
1470218|NCT03195231|Drug|Placebo|Patients of Placebo Group are instructed to take placebo drug 3 times a day and 3 pills each time for 12 weeks.
1470219|NCT03195218|Device|HRME examination|HRME will capture images from all areas considered abnormal by VIA and/or colposcopy. In addition, all four quadrants will be probed with HRME to ensure that any non-acetowhite lesions are also observed
1470220|NCT03195205|Diagnostic Test|OraQuick HCV Rapid Antibody Test|HCV Screening
1470221|NCT03195192|Other|biomarker study|This is a biomarker study
1470223|NCT03195153|Drug|Atorvastatin 80mg|30 DAYS OF atorvastatin 80 mg
1470224|NCT03195153|Drug|ALLOPURINOL 300 MG|30 DAYS OF ALLOPURINOL 300 MG
1470225|NCT03195153|Drug|Atorvastatin 80mg AND allopurinol 300 mg|30 days of atorvastatin and allopurinol 300 mg
1470227|NCT03195127|Other|multimodal physical therapy|Consist of limb strengthening exercises, endurance training, and balance/coordination drills. These exercises and training maneuvers may involve the use of handheld weights, nautilus weight equipment, elastic exercise bands, stationary exercise machines (recumbent exercise cycles, hand ergometer cycles), or treadmills. If the subject is fit enough, Tai Chi may be added to as a training method to help improve your balance and strength. In addition, the subject will be asked to wear an accelerometer on their wrist
1470228|NCT03195114|Diagnostic Test|Multimodality Imaging and Biomarkers|Cardiac MRI, Cardiac MDCT, Echocardiography and Biomarkers Testing
1470229|NCT03195101|Procedure|transconjunctival orbitotomy approach|approach the orbital tumor through an incision in the conjunctiva, This is followed by blunt dissection of the tenons capsule. A traction suture is applied over the corresponding rectus muscle to guide the globe toward the desired direction. The orbital fat is retracted by malleable retractor and blunt dissection through the orbital connective tissue continues until reaching the edge of the tumor. After the mass is exposed, a biopsy or complete resection of the mass is taken place
1470230|NCT03195088|Drug|BI 473494|Solution for injection
1470231|NCT03195088|Drug|Placebo|Solution for injection
1470232|NCT03195075|Procedure|Endoscopic ultrasonography guided biliary drainage|Endoscopic ultrasonography guided biliary drainage includes rendezvous techniques, endoscopic ultrasonography guided choledochoduodenostomy, and endoscopic ultrasonography-guided hepatogastrostomy using self-expandable metal stent will be done for group 1
1470233|NCT03195075|Procedure|Percutaneous trans-hepatic biliary drainage|Percutaneous trans-hepatic biliary drainage in interventional radiology department using self-expandable metal stent will be done for group 2
1470234|NCT03195062|Other|Test meal|Liquid test meal (fructose+glucose)
1470235|NCT03195049|Diagnostic Test|blood group,complete blood count|measure levels of total and direct bilirubin before, during and after the procedure of exchange transfusion
1470236|NCT03195036|Behavioral|Home-based ECD services|Health facilities will be randomized to intervention and control groups. The clients at clinics assigned to the intervention group will receive Home-based Early Childhood Development (ECD+) program in addition to facility- and community-based messages on ECD. The clients at clinics assigned to the control group will not receive the Early Childhood Development (ECD) program; however, they will only exposed to facility- and community-based ECD programming.
1470237|NCT03195023|Drug|Lisinopril|
1470238|NCT03195023|Drug|Amlodipine|Patients in this arm will receive antihypertensive treatment different from RAS blockers. If they previously received RAS blockers, they will be substitute for either Amlodipine or Lercanidipine +/- diuretics
1470239|NCT03195010|Biological|Platelet Transfusion|Undergo lower dose platelet transfusion
1470240|NCT03195010|Biological|Platelet Transfusion|Undergo higher dose platelet transfusion
1470241|NCT03194997|Other|Dance|The Dance intervention will be performed with belly dance methods. It will occur 3 times per week, during 24 weeks, with 60 minutes the session.
1470242|NCT03194997|Other|Pilates|The Pilates intervention will be performed using specific exercises of Pilates Methods. During the classes it will be used thera band, toning ball and pilates ball. It will occur 3 times per week, during 24 weeks, with 60 minutes the session.
1470243|NCT03194984|Drug|Hydrogen peroxide 35%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
1470244|NCT03194984|Drug|Hydrogen peroxide 38%|The office bleaching products will be applied on one of dental hemi-arch of young patients (18-25 years) or adult patients (40-65 years), after randomization. The product will apllied according manufacture instrutions.
1470245|NCT03194971|Other|Tumor samples from patients treated with TTFields at initial diagnosis.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
1470246|NCT03194971|Other|Tumor samples from patients treated with TTFields at tumor recurrence.|Pathological assessment of tumor cellularity, apoptosis, and quantitative histo-morphometry of residual tumor cells will be performed. Each metric will be statistically compared between groups.
1470247|NCT03194958|Behavioral|Specialized Quitline|Very low-income smokers are different from other smokers in important ways not always addressed by standard quitline services. The research team and Alere staff has created custom protocols, scripts, prompts and other content to maximize intervention relevance and acceptability to very low-income smokers. Research Implementation Unit (RIU) coaches who will be delivering the Specialized Quitline services have received training from clinical quitline staff, the research team and 2-1-1 staff who have extensive experience with the target population. Focus areas for training and distinctive content and protocol for the Specialized Quitline include: health literacy, abstract vs. concrete language, lived experience, resource constraints, future orientation, getting cigarettes, living situation, phone/internet access.
1470248|NCT03194958|Behavioral|Basic Needs Navigator|Navigators will: (1) identify and assess smokers' needs, including the reasons they called 2-1-1; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help smokers access available resources by scheduling appointments and provide appointment reminders; (8) prepare smokers to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly.
1470249|NCT03194945|Drug|CSII followed by Lina+MET|short-term intensive CSII followed by Linagliptin 5mg qd and Metformin 0.5g bid for 48 weeks
1470250|NCT03194945|Drug|CSII followed by Lina|short-term intensive CSII followed by Linagliptin 5mg qd for 48 weeks
1470251|NCT03194945|Drug|CSII followed by MET|short-term intensive CSII followed by Metformin 0.5g bid for 48 weeks
1470252|NCT03194945|Drug|CSII alone|No OHA is given after short-term intensive CSII
1470253|NCT03194932|Drug|Venetoclax|Given orally (PO).
1470254|NCT03194932|Drug|Cytarabine|Given intravenously (IV) or intrathecally (IT).
1470255|NCT03194932|Drug|Idarubicin|Given IV.
1470256|NCT03194932|Drug|Intrathecal Triple Therapy|Given IT.
1470257|NCT03194919|Other|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen & Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
1470258|NCT03194906|Drug|Memantine|Medication dosing will be overseen by one of the study neurologists, with step-wise dose reductions (5 mg intervals) allowable in the case of side effects.
1470259|NCT03194906|Other|Placebo|A placebo that appears exactly like the study drug, memantine, will be given in a manner identical to the study drug.
1470260|NCT03194906|Other|Cognitive Assessment|Cognitive and neurologic examinations will be conducted to assess cognitive, social, quality of life, and neurological outcomes associated with memantine will be completed at baseline prior to medication start, and at 6 weeks (end of radiation therapy), 12 weeks (discontinuation of study medication or placebo), and one year post radiation therapy.
1470263|NCT03194880|Device|AlereCOMBO and Alere q Detect|"The feasibility assessment will comprise of two components:
User's perspective: A questionnaire will be developed and used to assess the level of satisfaction among community health workers performing the two new tests, using a 5 point Likert scale. We will assess the training and manual, the use of the test, the user's confidence, troubleshooting and technical support components and resolving problems.
The laboratory component: For each test we will evaluate:
The percentage of assays completed
The percentage of assays incomplete (i.e. invalid result on two attempts)
Reasons for incomplete assays, e.g.
The sample could not be delivered to the strip or cartridge correctly
Invalid control
Results could not be interpreted
Others"
1470266|NCT03194854|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
1579680|NCT02386306|Drug|GC021109|
1470267|NCT03194841|Other|Heart failure application|A mobile phone application that allowed for input of physiologic data, qualitative question input and education retrieval along with SMS use.
1470268|NCT03194828|Behavioral|Medication reminder|Using the real-time data capture of the electronic device, an automated voice call or text message will be sent to active arm participants only when a missed dose is determined
1470269|NCT03194828|Behavioral|Medication monitoring only|Patients will use an electronic medication monitoring device to record their actual medication use
1470270|NCT03194815|Drug|Intravenous immunoglobulin|This is a blood product containing antibodies from thousands of healthy donors.
1470271|NCT03194815|Drug|Placebo|This is the control, or sham, treatment
1470272|NCT03194815|Drug|Rituximab|Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation
1470273|NCT03194802|Behavioral|Sleeping Without Pills Program|Participants receive this program online and are asked to log in daily for 6 weeks.
1470274|NCT03194802|Behavioral|Self-monitoring|Participants enter sleep diary data online daily for 6 weeks
1470275|NCT03194789|Device|Footwear Generated Bio-Mechanical Manipulation (using shoes with pertupods) along with Traditional Pelvic Floor Therapy|Participants will have FGBMM using shoes with pertupods along with traditional pelvic floor therapy over the course of six months. This will include five sessions of gait assessment and re-calibration with daily at home exercise with the device (shoes) over the course of six months. Along with that, participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
1470276|NCT03194789|Other|Traditional Pelvic Floor Therapy|Participant will receive traditional pelvic floor therapy of six sessions, up-to one sessions every alternate week. This will involve exercise and modalities as decided by medical providers and therapists. Participants will also have a home exercise program prescribed along with each session and for the remainder of six months.
1470277|NCT03194776|Drug|LLG783|LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
1470278|NCT03194776|Drug|Placebo|Placebo to LLG783 concentrate solution for infusion/injection suitable for i.v. administration as well as s.c. administration.
1470280|NCT03194750|Other|Share ultrasound measurement of IVC collapsibility to Nephrology Attending|Nephrology attending will be provided with the respiratory variability of IVC diameter as a percent, in addition to a predefined cutoff for responsiveness to volume resuscitation of < 12%. The information will be provided before rounds and before the attending sets the fluid removal goals on dialysis for that day.
1470281|NCT03194750|Other|Do not share ultrasound measurement of IVC collapsibility to Nephrology Attending|Respiratory variability of IVC diameter will be measured, but the measurement result will not be shared with the treating team.
1470283|NCT03194724|Other|Vitamin A supplementation|Bi annual vitamin A supplementation programme
1470284|NCT03194711|Device|BVS implantation|BVS implantation using conventional semicompliant or non-compliant balloon
1470285|NCT03194698|Device|IPL|Intense Pulsed Light with Meibomian Gland Expression
1470286|NCT03194698|Procedure|MGX|Meibomian Gland Expression
1470287|NCT03194685|Drug|FF-10101-01|FF-10101-01 will be administered orally once a day on Days 1-28 of a 28-day cycle. In Phase 1, the dose escalation will proceed until MTD is reached. In Phase 2a, subjects will be randomly assigned to 1 of 3 dose levels in a balanced fashion. The treatment will continue until, intolerable toxicity, or investigation/subject decision.
1470288|NCT03194672|Behavioral|Healthy Adolescent Transitions (HAT) program|"The components of the intervention are described in the arm description.
The intervention is based upon the theoretical framework of behavioral economics, which suggests that low intensity nudges can help recipients accomplish their own goals. All components of the intervention are voluntary; some participants may wish to discuss all components, while other participants may wish to discuss selected components consistent with their priorities."
1948410|NCT02406157|Device|532-SLP|Device for 532nm subthreshold treatment of the diabetic macular edema, by decomposing a subthreshold short pulse, with 10 milliseconds, 100 microns, and power(100-1000mW) adjusted according to patient's diopter transparency and pigmentation
1948411|NCT02404246|Behavioral|Peer support program|
1470298|NCT03194620|Other|Thearubigins|Single oral intake of 94.9 mg of therubigins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink
1470299|NCT03194620|Other|Theaflavins|Single oral intake of 120 µmol of an equimolar mixture of theaflavins (isolated from black tea) in a flavanol-free, fruit flavored, non-dairy drink. The theaflavin mix includes theaflavin, theaflavin-3-gallate and theaflavin-3,3'-gallate
1470300|NCT03194620|Other|Procyanidin Dimer B2 (DB2)|Single oral intake of 120 µmol of Procyanidin Dimer B2 (DB2) (isolated from Theobroma cacao) in a flavanol-free, fruit flavored, non-dairy drink.
1579681|NCT02386306|Other|Placebo|
1470301|NCT03194620|Other|(−)-Epigallocatechin-3-O-gallate (EGCG)|Single oral intake of 120 µmol of (−)-Epigallocatechin-3-O-gallate (EGCG)(isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
1470302|NCT03194620|Other|(−)-Epicatechin-3-O-gallate (ECG)|Single oral intake of 120 µmol of (−)-Epicatechin-3-O-gallate (ECG) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
1470303|NCT03194620|Other|(−)-Epicatechin (EC)|Single oral intake of 120 µmol of (−)-Epicatechin (EC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
1470304|NCT03194620|Other|(−)-Epigallocatechin (EGC)|Single oral intake of 120 µmol of (−)-Epigallocatechin (EGC) (isolated from green tea) in a flavanol-free, fruit flavored, non-dairy drink.
1470305|NCT03194620|Other|Control|Single oral intake of a flavanol-free, fruit flavored, non-dairy drink.
1470306|NCT03194607|Other|Functional walk tests|
1470307|NCT03194607|Other|3D analysis of locomotion and posture|
1470308|NCT03194607|Other|questionnaires|
1470309|NCT03194594|Drug|Ketamine Hydrochloride, dexamethasone, and combination of two drugs|After receiving by IRB approval and obtaining informed consent from patients, 93 patients who were aged between 18 and 70 years old and classified as American Society of Anesthesiologists (ASA) classes I and II. Afterward, the patients are randomly (sealed envelopes) allocated into one of three treatment; Group K (n = 31) receives a single dose of ketamine 0.5 mg/kg i.v. plus 2 ml normal saline, Group D (n = 31) receives dexamethasone 0.5 mg/kg i.v. and a maximum dose of 8 mg plus 2 ml saline, and Group KD (n = 31) receiveds ketamine 0.5 mg/kg i.v. and dexamethasone 0.5 mg/kg i.v. at 5 minutes after the induction of anesthesia in a double-blinded method.
1470310|NCT03194581|Device|Cerebral oxygenation|Evaluate cerebral oxygenation using normoxic challenges
1470311|NCT03194568|Device|Anterior Vertebral Tether|Vertebral Body Tethering through anterior thoracoscopic approach under general anesthesia and fluoroscopic guidance.
1470314|NCT03194542|Drug|Luspatercept|Luspatercept is a recombinant fusion protein consisting of a modified form of the extracellular domain of the human active in receptor type IIB linked to the IgG1 Fc domain. Luspatercept, through a mechanism of action different from erythropoietin, works to correct ineffective erythropoiesis by promoting late-stage maturation of erythroblasts.
1470315|NCT03194529|Biological|FMT|Fecal Microbiota Transplantation, single dose, 50g of stool, delivered via standard of care upper endoscopy into jejunum.
1470316|NCT03194516|Other|Surveillance|The investigators propose an 8-week ketogenic diet intervention with pre-/post-intervention assessment of serum and tissue metabolic and inflammatory biomarkers, including metabolomics analysis, among a sample of 12 overweight or obese prostate cancer patients on active surveillance. There will be no randomization; all patients will receive the diet intervention.
1470317|NCT03194503|Device|VL Coaching training using C-MAC video laryngoscope|"Each neonatology attending providers will receive a video laryngoscopy coaching training using a C-MAC video laryngoscope and an intubation training manikin available at each site by a site leader. During the training, site leader will act as a trainee confederate, and each neonatology attending provider will be trained to coach a trainee utilizing video images from C-MAC video laryngoscope and a cognitive aid with standardized language in a laminated card. This training part typically takes approximately 15-30 minutes including consenting process.
Each site leader will be trained by PI or PI's designee using remote simulation. In this remote simulation, each site leader will coach an actor at the Children's Hospital of Philadelphia (CHOP) using a profile video image and C-MAC video laryngoscopy image through CHOP approved video conferencing software. A standardized language will be taught to each site leader with a cognitive aid (laminated card)."
1470318|NCT03194490|Other|Stretching, cervical passive mobilisation, and range of motion|"The manual therapy will be conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs) that are selected to increase the intervertebral foramen space. The nature of PAIVMs technique will be selected by the physical therapist based on the participant's condition.
Stretching exercise will be given to the participants by the main investigator. The anterior and middle scalene muscles stretch will be occurred by applying a gentle pressure for 30 seconds for 3 times. Upper trapeze muscle stretch will be occurred by applying a gentle pressure for 30 seconds for 3 times. Moreover,stretch sternocleidomastoid muscle will be occurred by applying a gentle pressure for 30 seconds for 3 times.. In addition, a home exercise will be given to the participant."
1470319|NCT03194490|Other|Cervical mobilisation and range of motion|The manual therapy will be conducted by a physical therapist who has experience in manual therapy and is licensed from the California Board of Physical Therapy. The manual therapy intervention will consist of Passive Accessory Intervertebral Movements (PAIVMs) that are selected to increase the intervertebral foramen space. The nature of PAIVMs technique will be selected by the physical therapist based on the participant's condition.
1470320|NCT03194477|Behavioral|Mobile-enhanced Engagement Intervention|Mobile phone based enhanced case management intervention for HIV positive & HIV negative young Black men who have sex with men.
1470321|NCT03194464|Other|submaximal exercise (grip)|participants perform repeated gripping with visual feedback to task failure
1470322|NCT03194451|Other|non-interventional study|teeth collection
1470323|NCT03194438|Behavioral|Urban Zen Integrative Therapy (UZIT)|Multi-modal components integrative therapy program (UZIT) that includes essential oil, gentle body movement, body-awareness meditation, and Reiki.
1470324|NCT03194425|Diagnostic Test|Pelvic floor EMG|Define pelvic floor EMG template measured by probe
1476357|NCT03148509|Drug|aripiprazole|DA receptor-mediated drugs
1470329|NCT03194399|Behavioral|Personalized health care service|Physical activity coaching, other functional outcome observation
1470330|NCT03194386|Other|Reassurance|At the end of cares, before ED discharge, a trained psychologist will conduct a session in order to reassure patients about their future after ED visit.
1470331|NCT03194386|Other|Eye-Movement Desensitization and Reprocessing (EMDR)|At the end of cares, before ED discharge, a trained psychologist will conduct a single EMDR session. Each session may last about 60 minutes
1470332|NCT03194373|Drug|Palbociclib|"Palbociclib (Ibrance) (PO), dose= 125 mg PO daily, days=1-14, cycle length: 21 days
Maintenance Palbociclib:
Palbociclib (Ibrance) 125 mg PO daily, days 1-21, cycle length: 28 days"
1470333|NCT03194373|Drug|Carboplatin|Carboplatin (IV), dose= AUC 6, day= 1, cycle length: 21 days
1470334|NCT03194347|Diagnostic Test|molecular genetic analyses|molecular genetic analyses
1948419|NCT02369432|Drug|Biodegradable and biocompatible polymeric microparticles containing a fluorochrome applied to the skin followed by a skin biopsy|
1470338|NCT03194321|Drug|Tacrolimus Extended Release Oral Capsule|Maintenance immunosuppression will consist of tacrolimus extended-release, mycophenolate mofetil 500mg twice daily or mycophenolate sodium 360mg twice daily, and prednisone.
1470339|NCT03194308|Behavioral|PrEP for Safer Conception|Evaluation of uptake of and adherence to PrEP and safer conception strategies including: CHCT, ART for the infected partner, and uptake of contraception for those who decide not to conceive by enrolled women, during periconception and pregnancy follow up.
1470340|NCT03194295|Behavioral|Community Support Intervention Group|This 12-week community support intervention is designed to activate and harness the powerful influences of drug-free family and friends to enhance recovery support and participation in community activities. Addiction Treatment Services (ATS) participants and their CSPs will be directed to participate in recovery-oriented community activities together 2 times per week and work together toward developing regular drug-free social support for the ATS participant. The group provides an opportunity for both the participant and CSP to discuss their experiences participating in the scheduled activities. For those electing not to engage in community activities, problem-solving strategies will be used to remove obstacles to participation, with other group members providing support and encouragement.
1470341|NCT03194295|Behavioral|Substance Use Disorder Educational Group|This 12-week educational group is designed as an attention-control group. Group topics include: 1) definition of substance dependence, 2) the disease model, 3) medical aspects, 4) mood, 5) personality, 6) self-esteem, 7) relapse prevention, 8) HIV/AIDS, 9) anger, 10) negative thinking, 11) nutrition, and 12) assertiveness. Participants will be assigned 2 homework assignments each week based on the topic.
1470342|NCT03194282|Other|insole|The subjects are randomly assigned to assess balance capacity either with or without insole.
1470343|NCT03194269|Device|EARFOLD®|EARFOLD® implant is inserted subcutaneously using the sterile disposable EARFOLD® introducer under local anaesthetic
1470344|NCT03194256|Behavioral|Spectrum Research Cigarettes|Participants will be assigned to either normal nicotine content cigarettes or very low nicotine content cigarettes.
1470345|NCT03194230|Other|With cervical dilatator|Induction of labour by cervical placement of hygroscopic dilators (Dilapan-S Hygroscopic cervical dilator )
1470346|NCT03194217|Drug|BEN-2001|Bavisant dihydrochloride monohydrate for oral use
1470347|NCT03194217|Drug|Placebo|Placebo
1470348|NCT03194204|Diagnostic Test|matrix metalloproteinase -3(MMP-3) and Matrix metalloproteinase-9 (MMP-9)|MMP-3 and MMP-9 will be done with blood samples using ELISA technique CIMT will be done using colored doppler ultrasound
1470349|NCT03194191|Device|Acupuncture needles|The patient will be in a semi recumbent position during needle penetration. Duration of needle insertion: 30 minutes
1470350|NCT03194178|Other|Pierre Robin sequence patients|"4 questionnaires will be completed by the patient :
Kidscreen 52 (generic quality of life questionnaire)
Voice Handicap Index : VHI-9i (specific quality of life questionnaire)
Child Oral Health Impact Profile : COHIP (specific quality of life questionnaire)
MDI-C (composite depression scale for minors)"
1470351|NCT03194165|Biological|Dolutegravir|Dosage
1470352|NCT03194165|Biological|Raltegravir|Dosage
1470353|NCT03194165|Biological|Rilpivirine|Dosage
1470354|NCT03194165|Biological|Nevirapine|Dosage
1470355|NCT03194165|Biological|Atazanavir|Dosage
1470356|NCT03194165|Biological|Darunavir|Dosage
1470357|NCT03194165|Biological|Ritonavir|Dosage
1470358|NCT03194152|Dietary Supplement|Peanut|Dietary Supplement: Peanut
1470359|NCT03194152|Dietary Supplement|Control|Dietary Supplement: High carbohydrate snacks
1470365|NCT03194113|Behavioral|Trauma-focused treatment|Weekly sessions
1470366|NCT03194113|Behavioral|Emotion regulation training|Managing and tolerating negative emotions, e.g. anger, sadness. Weekly sessions; preparatory to Prolonged exposure treatment
1470367|NCT03194113|Behavioral|Intensive Trauma-focused treatment|Intensive version (3 sessions per week) of Trauma-focused treatment
1470368|NCT03194074|Drug|Propofol|In propofol/remifentanil group, propofol at a rate 75~150 µg/kg/min and remifentanil at 0.1-0.3 µg/kg/min are maintained throughout surgery.
1470369|NCT03194074|Drug|Desflurane|In desflurane/remifentanil group, desflurane at end tidal concentration at 0.7~1.0 minimum alveolar concentration (MAC) and remifentanil 0.1-0.3 ug/kg/min are used.
1470370|NCT03194061|Radiation|Hypofractionated Radiotherapy|20 fractions of 275cGy 5 days/week
1470371|NCT03194061|Drug|Weekly cisplatin|Concomitant weekly cisplatin 35mg/m2 x 4 weeks
1470372|NCT03194048|Other|Functional Chewing Training|"FuCT;
Family training
Providing optimal sitting posture for children to support oral sensorimotor functions
Positioning the food to the molar area during every meal to stimulate lateral and rotational tongue movements
Massage of the upper and lower gums through the front teeth to molar area
Chewing training to stimulate lateral and rotational tongue movements
Gradually increasing the food consistency, for 12 weeks in 5 sets (1 set = 20 min) each day"
1470373|NCT03194048|Other|Classical Oral Motor Exercises|"Classical Oral Motor Exercises;
Family training
passive and active lip and tongue exercises, for 12 weeks in 5 sets (1 set = 20 min) each day"
1470374|NCT03194035|Biological|blood sample|Study per and post-exertional changes in proinflammatory biological (IL1, IL6, TNF alpha, HMG beta1 and CRP) and anti inflammatory parameters (IL4, IL10 and IL13, TGF beta, LPS, lipoproteins, lipids) during an ultra endurance race.
1470375|NCT03194022|Other|Blood sample|measurement of electrolytes and blood count
1470376|NCT03194009|Drug|Metformin|The patient will received metformin 1 tablet of 850mg every 12 hrs besides lifestyle modification recommendations
1470377|NCT03194009|Behavioral|Lifestyle intervention|The patient will received recommendations to modify their diet and increase their physical activity every three months towards prevention of diabetes
1470378|NCT03193996|Device|4DCT|4DCT will be used to assess the location of the torn scapholunate interosseus ligament.
1470379|NCT03193983|Procedure|Flaps Coverage|"Surgical group will undergo surgical coverage of the fingertip defect by one of two methods
V-Y flap using the skin on the volar aspect of the same finger designed as V shaped then mobilized dorsally to cover the defect and stitches to be Y shaped. Stitches are removed after 2 weeks.
Cross finger flap using the skin on the dorsum of the middle phalanx of the adjacent finger. Both fingers will remain attached for 2 weeks; the period enough for the transplanted skin to acquire an independent blood supply and then separated under local anesthesia."
1470380|NCT03193983|Procedure|Occlusive Dressing|Conservative group will undergo minimal trimming of the bone end and an occlusive dressing that is changed on a weekly basis till complete healing of the defect that occurs after 6 weeks.
1470381|NCT03193970|Behavioral|Post‐Operative Recovery Registry|Multi‐institutional prospective database of patients with bladder cancer undergoing radical cystectomy.
1948420|NCT02369445|Behavioral|Moisture Pager Intervention for Toilet Training|
1948421|NCT02369445|Behavioral|Standard of Care|
1470384|NCT03193944|Drug|D-vitin, soft gelatin capsule (vitamin D3,50000 IU)|Intervention group: The respondents in intervention group will receive 50000 vitamin D for 8 weeks. Plus, brochures and pamphlets related to nutrition and health.
1470385|NCT03193944|Drug|Placebo vitamin D3|vitamin D as a placebo
1470386|NCT03193931|Drug|Pembrolizumab Injection|Pembrolizumab 200 mg q3w i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
1470387|NCT03193931|Drug|Methotrexate Injectable Solution|Methotrexate 40 mg/m2 weekly i.v. until disease progression or non-tolerable toxicity (maximum 2 years)
1470388|NCT03193918|Drug|Crenolanib|Crenolanib continuously on Days 1-28 at 1 of 3 BID doses - 60 mg, 80 mg or 100 mg
1470389|NCT03193918|Drug|Ramucirumab|Ramucirumab IV 8 mg/kg on Days 1 and 15 q28 days
1470390|NCT03193918|Drug|Paclitaxel|Paclitaxel IV 80 mg/m2 on Days 1, 8 and 15 q28 days
1470391|NCT03193905|Procedure|Bairhugger Full Access Underbody Blanket|30 patients undergo new procedure with a Bairhugger Full Access Underbody Blanket
1470392|NCT03193905|Procedure|Cotton blanket - control group|30 patients undergo standard procedure with a cotton blanket
1470393|NCT03193866|Drug|Rituximab|Comparisons of efficacy and safety between rituximab and all other frequently used immunomodulating drugs against multiple sclerosis
1470394|NCT03193853|Drug|Tak-228 & Tak-117|Patients will receive oral TAK-228 and TAK-117 tablets until disease progression.
1470395|NCT03193853|Drug|Cisplatin & Nab Paclitaxel|following Tak-228 & Tak-117 standard nab paclitaxel plus cisplatin infusion for six cycles. Patients who did not progress may continue nab paclitaxel under treating physicians discretion
1470396|NCT03193840|Procedure|posterior wall osteotomy|posterior wall osteotomy is conducted through Kocher-Langenbeck approach.
1470397|NCT03193827|Device|In-line filtration|In-line filtration is used during anesthesia and postoperative 96 hrs in study group to purify endovascular fluids administrations reducing postoperative phlebitis
1470398|NCT03193827|Device|Standard treatment|Patients are treated with standard intravenous solutions and vascular access management
1470399|NCT03193814|Drug|Chemotherapy + Apatinib|chemotherapy regimens could be folfox or folfiri; apatinib 500mg po qd
1470400|NCT03193801|Device|Edwards SAPIEN 3 transcatheter valve, Model 9600TFX|Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.
1470401|NCT03193788|Drug|pemetrexed|Pemetrexed 500 mg/m2mixed in normal saline 100 mL as a 10 minute IV infusion on day 1 of each 21 day cycle
1470402|NCT03193788|Drug|Folic Acid|folic acid 1000 μg daily orally from 7 days prior to treatment initiation until the end of treatment
1470403|NCT03193788|Drug|Vitamin B12 Injection|vitamin B12 1000 μg IM 7 days prior to treatment initiation and the end of treatment
1470404|NCT03193788|Drug|Dexamethasone|Dexamethasone 4 mg twice orally for 3 days beginning the day before treatment until the end of treatment to minimize cutaneous reactions
1471667|NCT03184272|Procedure|passive leg raising|measurement under passive leg raising
1470405|NCT03193775|Biological|HBV vaccine|HBV vaccine which contains Purified HBsAg produced by recombinant DNA technology (Euvax-B, LG Life sciences, Korea) intramuscularly in deltoid region at three different time intervals (0, 1, 6 months).
1470406|NCT03193762|Other|Anxiety VAS|Anxiety will be measure with a 10-points visual analogic scale (VAS)
1470407|NCT03193749|Drug|Amiodarone Hydrochloride|Starting (loading) dose 400 mg PO once a day for 10 days. Maintainance dose 200 mg PO once a day for at least 6 months, up to 24 months
1470408|NCT03193749|Drug|Placebo Oral Tablet|Matching placebo for tablets of 200 mg of Amiodarone
1470409|NCT03193736|Device|MINIject implant|"MINIject implant is used to reduce intra-ocular pressure in the eye through a minimally-invasive Glaucoma surgical intervention.
The intervention is to be performed as stand-alone surgery."
1470410|NCT03193723|Procedure|US guided five step field block|"Ultrasound will guide needle insertion in the following layers (except intradermic injection):
Subdermic infiltration. Approximately 8 milliliters
Intradermic injection (making of the skin wheal). of approximately 6 milliliters.
Deep subcutaneous injection. 8 milliliters of the mixture will be injected deep into the subcutaneous adipose
Subfascial infiltration. Approximately eight milliliters of the anesthetic mixture will be injected immediately underneath the aponeurosis of the external oblique.
Pubic tubercle and hernia sac injection. Occasionally, infiltration of ten milliliters of the mixture at the level of the pubic tubercle, around the neck and inside the indirect hernia sac"
1470411|NCT03193723|Procedure|Spinal anesthesia|Spinal anesthesia will be administered in sitting position, with 25 gauge Quincke spinal needle in L3-L4 intervertebral space, under all aseptic precautions and local infiltration, with 3.0 ml of 0.5% bupivacaine (heavy) after ensuring free, clear and adequate flow of cerebrospinal fluid. After giving spinal anesthesia, patient will be made to lie supine.
1470412|NCT03193710|Drug|Propofol|Propofol will be used for anesthesia maintenance in the total intravenous anesthesia group.
1470413|NCT03193710|Drug|Sevoflurane|Sevoflurane will be used for anesthesia maintenance in the inhalation anesthesia group.
1470414|NCT03193710|Drug|Remifentanil|Remifentanil will be used for analgesia in both groups.
1470415|NCT03193697|Device|cemented SPII prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-four patients in the control group received a cemented SPII prosthesis (Link, Germany).
1470416|NCT03193697|Device|cementless Wagner prosthesis|Old patients with unstable intertrochanteric fractures underwent total hip arthroplasty. Forty-two patients in the trial group received cementless Wagner prosthesis (Zimmer, USA).
1470417|NCT03193684|Drug|Dapagliflozin 10mg|subjects will receive daily dose of 10 mg dapagliflozin for 3 months
1470418|NCT03193684|Drug|Control|Placebo
1470419|NCT03193671|Diagnostic Test|Diagnosis|Improving diagnosis
1470420|NCT03193658|Procedure|Thoracolumbar Interfascial Plane (TLIP) block|"A 10 cm 21G Stimuplex needle (Braun Medical Inc, Bethlehem, PA, USA) will be inserted in a lateral-to-medial orientation with an approximate angle of 30 degrees to the skin. The needle will then be advanced under real-time in-plane ultrasound guidance through the belly of the LG towards the MF. The needle tip will be directed towards the LG/MF interface deep to the midpoint then a total volume of 20 ml of Bupivacaine 0.25% will be incrementally injected with intermittently repeated negative aspiration. Anterior spread of local anesthetic will be viewed as favourable.
The same procedure will be repeated on the left side. The patient will then be disinfected and draped and surgery will be allowed to proceed normally."
1470421|NCT03193658|Drug|I.V drug based multimodal approach|A base low dose opioid of 5mg morphine I.V every 8 hours. Rescue analgesia will be given to the patient if reported a VAS equal or more than 4 in the form of I.V morphine in 2.5mg increments till VAS returns to 4 or less in addition to 1 gm of oral acetaminophen every 6 hours
1470423|NCT03193632|Diagnostic Test|US Muscle layer thickness (MLT) estimation|"Three measurements will be made at each of three sites; mid-upper arm, forearm and thigh anteriorly and the mean value will be calculated. Measurement sites will be marked with indelible ink to ensure day-to-day consistency.
Thigh: MLT of the quadriceps femoris muscle (M. Vastus intermedius and M. rectus femoris) will be assessed bilaterally
Mid-upper arm: Muscle layer thickness will be measured over the biceps,midway between the tip of the acromion and the tip of the olecranon
Forearm: A point midway between the antecubital skin crease and the ulnar styloid was marked and muscle thickness down to the interosseus membrane"
1470424|NCT03193632|Diagnostic Test|REE estimation by indirect calorimetry|REE will be calculated using indirect calorimetry via metabolic module on General Electric ventilator (Engstrom Carestation and Carescape R860, GE Health care, USA) All indirect calorimetric measurements will be done using standardized technique. Gas calibration will be performed before each measurement, and the measurements will last for at least 30 minutes. Measurements will be taken with the patient lying supine and ventilator settings left unchanged for at least 60 minutes ahead of indirect calorimetry. The REE will be calculated during the first 24 hours of admission to ICU.
1470425|NCT03193619|Device|PTA (UltraScore Focused Force PTA Balloon)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.
The UltraScore Focused Force PTA balloon through the blood vessel to the narrowed area to be treated."
1470426|NCT03193606|Other|nano silver fluoride solution|prepared Nano-silver fluoride could have the capability to arrest caries. As its Nano silver particles have an antimicrobial activity against Mutans Streptococci and Lactobacilli; the main pathogens involved in the development of carious lesions. In addition, its fluoride component is well known to enhance remineralization and inhibit bacterial activity. So, Nano silver fluoride could be a promising solution to combat residual bacteria in tooth cavity with effective remineralization potential on remaining carious dentin
1470427|NCT03193593|Drug|EB-001|EB-001
1470428|NCT03193593|Drug|Placebo|Placebo
1476358|NCT03148509|Drug|bupropion|DA receptor-mediated drugs
1470434|NCT03193489|Other|Follow-up|
1470435|NCT03193489|Other|Post-treatment control|After 3 weeks of intensive treatment, no special exercises are performed as a control.
1470436|NCT03193489|Other|Control Parkinson group|No treatment.
1470437|NCT03193463|Drug|Topotecan (<=8cc)|In predominantly enhancing mass with a volume of 8 cc or less of topotecan administered
1470438|NCT03193463|Drug|Topotecan (>8cc)|In predominantly enhancing mass with a volume of > 8 cc of topotecan administered. Initial rate is 0.834ml/hour with an increase to 1.668 ml/hour at the second infusion
1470439|NCT03193463|Device|Cleveland Multiport Catheter|an investigational device, will be used to deliver the topotecan
1470440|NCT03193463|Diagnostic Test|Magnetic Resonance Imaging (MRI)|to monitor the infusion of topotecan into the tumor
1470441|NCT03193463|Drug|Lower Does Topotecan|Rate for non-enhancing tumors has an initial dose of 0.29ml/hour
1470445|NCT03193424|Drug|Apatinib|Subjects were randomly divided into two groups,A group:apatinib 500mg/d,po,qd, Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) . B group:Docetaxel 75 mg / m2 was administered on day 1 repeated every 21 days until progressive Disease(PD) .
1470446|NCT03193411|Device|Visumax femtosecond laser|
1470447|NCT03193411|Device|Moria M2 microkeratome (MK)|
1470450|NCT03193385|Procedure|closed reduction|Closed reduction is where the thigh bone is placed into the socket without any surgical incision being made. This is more likely to be performed in a child under the age of four year. The femoral head is gently manipulated into the socket, whilst the child is under anaesthetic. Once the femoral head is in place, a hip Spica is applied and can remain in place for up to three months to maintain the hip in the correct position. This allows time for healing and for the socket and the thigh bone to mould together as a joint.
1470451|NCT03193372|Drug|Finacea Foam, (Azelaic Acid, BAY39-6251)|Finacea Foam, Active substance Azelaic acid
1470452|NCT03193359|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) IM 155U to 195U injections in head/neck areas.
1470453|NCT03193346|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) 155U to 195U IM injections in head/neck areas.
1470454|NCT03193346|Drug|placebo (sodium chloride 0.9 mg)|Placebo matching BOTOX® [Sodium chloride 0.9 mg] IM injections in head/neck areas.
1470455|NCT03193333|Drug|PRO-122|Posology: 1 drop every 12 hours for 90 days
1470456|NCT03193333|Drug|Timolol eye drops|1 drop every 12 hours for 90 days
1470457|NCT03193333|Drug|Dorzolamide-Timolol Ophthalmic|1 drop every 12 hours for 90 days
1470458|NCT03193333|Drug|Brimonidine Ophthalmic Solution|1 drop every 12 hours for 90 days
1470459|NCT03193333|Other|Placebo1|1 drop of each dropper bottle every 12 hours for 90 days
1470460|NCT03193333|Other|Placebo 2|1 drop of each dropper bottle every 12 hours for 90 days
1470461|NCT03193333|Drug|Krytantek|Posology: 1 drop every 12 hours for 90 days
1470462|NCT03193320|Other|Fluid therapy protocol|Only ringer lactate (RL solution will be used). 1. Fluid loading at induction with 500 ml of ringer lactate solution will be given to some groups. 2. Base infusion rate varies according to group. 3. Fluid challenges - infusion of 250 ml over 5 min, a hemodynamic parameter specific to each group will be monitored for 10 min after the end of infusion to look for changes. Patients who do not respond to four (4) fluid challenges (volume infused 1000 ml) will be excluded.
1470465|NCT03193294|Diagnostic Test|Stratified medicine involving a diagnostic intervention|Adjunctive tests of coronary artery function at the time of invasive coronary angiography. Diagnostic groups: stable coronary syndromes in patients with no-obstructive coronary artery disease including the following sub-groups (coronary artery vasospasm, microvascular spasm, impaired vasorelaxation due to (1) endothelial dysfunction and/or (2) non-endothelial dysfunction, or unaffected (normal test results). Medical management is linked to contemporary clinical guidelines for the management of patients with stable coronary artery disease (European Society of Cardiology (2013)).
1470466|NCT03193281|Drug|Dasatinib|"In order to test the study hypothesis patients need to stay on dasatinib (Sprycel) treatment for the first 12 months of the study (Stage 1).
Patients who do not reach MR3.0 at 12 months will remain on dasatinib treatment."
1470467|NCT03193281|Drug|Imatinib|Patients who reach MR3.0 at 12 months (and the result is confirmed at 13 months) will switch to imatinib (Imatinib-AFT) treatment.
1470468|NCT03193268|Other|Single-blind RTC of PD patients|The groups participate in observation for 5 weeks. Two groups take part in a motion therapy over the 5-week period.
1470469|NCT03193268|Other|cycling|Patients must undergo a daily exercise cycle of 1 hour during the intervention
1470470|NCT03193255|Device|OPHTECS cleadew GP|Povidone-iodine based disinfecting solutions for rigid contact lenses
1470514|NCT03192930|Other|Hyperbaric exposure|Hyperbaric exposure 4 ATA for 36 hours followed by 70 hours decompression
1476361|NCT03148496|Procedure|Large Bytes|1.0 x 1.0 sutures used
1470471|NCT03193242|Other|Electronic Asthma Management System: eAMS|"Electronic Asthma Management System: eAMS Intervention
eAMS consists of simple questionnaire completed either through an app on a patient's smartphone or tablet computer, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and a printable asthma action plan that is given to patients. eAMS will also provide access to a patient-oriented asthma management tool called Breathe."
1470472|NCT03193229|Behavioral|MapTrek|The objective of the study is to provide an inexpensive and scalable m-health tool to increase both volume and intensity of physical activity and reduce sedentary behavior in patients at risk for or already diagnosed with pre-diabetes.
1470473|NCT03193229|Device|Fitbit|Fitbit
1470474|NCT03193216|Drug|Alginates|Liquid Alginate therapy will be added to twice daily PPI regimen. Patients will be asked to take the alginate solution four times daily (following meals and at bedtime) at 10ml/dose.
1470475|NCT03193203|Drug|Etanercept|50 mg/mL PFS and AI
1470476|NCT03193190|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle.
1470477|NCT03193190|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 IV infusion on Days 1, 8, and 15 of each 28-day cycle.
1470478|NCT03193190|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 IV infusion on Days 1 and 15 of each 28-day cycle.
1470479|NCT03193190|Drug|Leucovorin|Leucovorin 400 mg/m^2 IV infusion on Days 1 and 15 of each 28-day cycle.
1470480|NCT03193190|Drug|Fluorouracil|Fluorouracil 400 mg/m^2 IV push on Days 1 and 15; and fluorouracil 2400 mg/m^2 IV continuous infusion over 46 hours on Days 1 and 2 and on Days 15 and 16 of each 28-day cycle.
1470481|NCT03193190|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
1470482|NCT03193190|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
1470483|NCT03193190|Drug|PEGPH20|PEGPH20 will be administered as per the schedule specified in the respective arm.
1470484|NCT03193190|Drug|BL-8040|BL-8040 will be administered as per the schedule specified in the respective arm.
1470485|NCT03193177|Other|the 21-day fasting-like diet|a fasting-like diet with 400 KJ energy intake per day for 21 days
1948422|NCT02365597|Drug|JNJ-42756493|8 mg orally once daily for 28 days on a 28 day cycle.
1948423|NCT02363439|Drug|IMO-8400|IMO-8400 at 0.6, 1.2 or 2.4 mg/kg/wk as defined per Protocol 8400-401
1470489|NCT03193138|Drug|Hormonal therapies: G03, H01C and L02 in the ATC classification|Hormonal therapies including all therapies classified G03, H01C and L02 in the ATC classification
1470490|NCT03193125|Dietary Supplement|L-Carnitine|500 mg tablets of L-Carnitine taken 3 times daily before meals.
1470491|NCT03193125|Dietary Supplement|Placebo|500 mg tablets of L-Carnitine taken 3 times daily before meals.
1470492|NCT03193112|Drug|Agomelatine 25 MG Oral Tablet|We will treat our patients with Agomelatine tablet of 25 mg.
1470493|NCT03193099|Other|Brain imaging|Volume, DWS and DTI
1470494|NCT03193099|Other|Neurological assessments|UHDRS
1470495|NCT03193099|Behavioral|Psychological assessments|STAI (Spielberger state and Trait Anxiety Inventory) A and B, BDI-II (Beck Depression Inventory), MINI (Mini-International Neuropsychiatric Interview) and MINI-SEA (mini Social cognitive and Emotional Assessment)
1470496|NCT03193099|Behavioral|Behavioural assessments|Computerized game
1470497|NCT03193086|Drug|Alemtuzumab|Alemtuzumab is administered to eligible patients in accordance with established treatment regimes. Initially 60 mg of alemtuzumab is injected intravenously over the course of 5 days. The first treatment series is followed by the injection of 36 mg of alemtuzumab over the course of 3 days 12 months later. During both drug interventions, the transient exacerbation in disease severity is alleviated by concomitant steroid therapy.
1470498|NCT03193073|Diagnostic Test|detailed echocardiography|Detailed Echocardiography including ejection fraction, interventricular septum thickness, posterior wall thickness, left ventricular end -diastolic and end- systolic diameter and left ventricular mass index will be correlated with body surface area for both groups serum FGF-23
1470499|NCT03193073|Diagnostic Test|serum fibroblast growth factor-23|serum levels of FGF-23
1470500|NCT03193073|Diagnostic Test|flow mediated dilatation of forearm|superficial sonar assess the diameter of brachial vessel on exposure to stress
1470501|NCT03193047|Drug|bempedoic acid 180mg|Daily bempedoic acid 180mg tablet in addition to monthly PCSK9i background therapy
1470502|NCT03193047|Other|placebo|Daily matching placebo tablet in addition to monthly PCSK9i background therapy
1470503|NCT03193034|Device|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using the configuration of the ATTUNE Cementless knee (CR RP)
1470504|NCT03192995|Drug|lorcaserin|lorcaserin 10 mg tablets taken orally twice daily
1470505|NCT03192995|Drug|Placebo Oral Tablet|placebo tablets taken orally twice daily
1470506|NCT03192982|Device|A-V impulse 6000 Series|foot pad and pump
1470507|NCT03192982|Device|Standard treatment (compression)|Compression stocking (TED Stocking 18 mm Hg at the ankle) or short-stretch bandage from toes and up yo the upper thigh 40 mm Hg
1470508|NCT03192969|Drug|Abatacept|Abatacept subcutaneous injection, 125 mg/prefilled syringe (125 mg/mL)
1470509|NCT03192969|Other|Placebo|Placebo for abatacept for subcutaneous injection in 1 mL pre-filled syringes
1470510|NCT03192969|Drug|Glucocorticoid Treatment|Glucocorticoid taper (up to 52-week or 28-week of oral prednisone/prednisolone)
1470511|NCT03192956|Other|No active intervention|No active intervention is performed
1580089|NCT02383108|Drug|EVG +DRV/r|
1948424|NCT02352753|Drug|Denosumab|All subjects will receive denosumab 1 mg/kg (up to a maximum of 60 mg) given subcutaneously every 6 months for 36 months.
1948425|NCT02352480|Device|Aurix|Aurix is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
1948426|NCT02352467|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
1470515|NCT03192917|Procedure|Low intensity extracorporeal shock wave treatment (LI-ESWT)|Shock wave treatment with 3000 Hz for 10 min on the penile shaft. This will be done one time a week for five weeks.
1470516|NCT03192917|Procedure|Low intensity extracorporeal shock wave treatment (LI-ESWT) sham|A specialized cap can be applied to the chock wave device, which disallow shock waves to transmit through the unit.
1470517|NCT03192904|Device|Energy Instruments|Energy Instruments, including electrocautery, harmonic scalpel and LigaSure.
1470518|NCT03192904|Device|Stapling Device|Stapling Device, including linear stapler and curved stapler.
1470519|NCT03192891|Diagnostic Test|Stress cardiac magnetic resonance (CMR) perfusion imaging|Gadolinium-enhanced stress CMR perfusion imaging is a tool increasingly used for the risk assessment and diagnosis of coronary artery disease.
1470520|NCT03192878|Drug|Infliximab|infliximab biosimilar
1470521|NCT03192865|Procedure|diaphragmatic assessment using ultrasounds.|A diaphragmatic assessment will be performed using ultrasound. This is a pain free assessment. This assessment is commun in our unit after arthroscopic shoulder surgery.
1470522|NCT03192852|Other|dental bleaching|dental bleaching can be achieved with light, light+ peroxide carbamide gel, or only with peroxide carbamide gel
1470523|NCT03192852|Procedure|Gingivoplasty|gengivoplasty will be realized to in illuminated tissue an no illuminated tissue to morphometrically evaluate the tissue
1470524|NCT03192839|Other|Low dose PUFA|Low dose PUFA
1470525|NCT03192839|Other|High dose PUFA|High dose PUFA
1470526|NCT03192839|Other|Placebo|Placebo
1470527|NCT03192826|Drug|Brinzolamide/Brimonidine FC|1 drop of Brinzolamide/Brimonidine FC 1 hour before capsulotomy
1470528|NCT03192826|Drug|Brimonidine 0.2%|1 drop of Brimonidine 0.2% 1 hour before Nd-YAG capsulotomy
1470529|NCT03192826|Drug|Artificial tears|1 drop of artificial tears 1 hour before Nd-YAG capsulotomy
1470530|NCT03192813|Device|Symetis ACURATE neo™ transfemoral TAVI system|Symetis ACURATE neo™ transfemoral TAVI system: Support frame made of nitinol, supra-annular processed tri-leaflet porcine pericardial valve and an outer skirt to mitigate paravalvular regurgitation (manufactured by Symetis SA, Ecublens, Switzerland).
1470531|NCT03192813|Device|Medtronic CoreValve Evolut R TAVI System|Medtronic CoreValve Evolut R Transcatheter Aortic Valve Implantation (TAVI) System (or any future CE-marked Corevalve versions): The support frame is manufactured from nitinol, which has multilevel, self-expanding properties and is radiopaque. The bioprosthesis is manufactured by suturing valve leaflets and a skirt from porcine pericardium into a tri-leaflet configuration (manufactured by Medtronic CoreValve LLC, Santa Ana, USA).
1470532|NCT03192774|Device|Transcatheter Aortic Valve Implantation|Interventional replacement of the aortic valve
1470533|NCT03192761|Procedure|ACL reconstruction hamstrings|"HG reconstruction is performed according to the standard procedure of the department:
A double semi-Tendinosus and gracillis graft is used. Placement of the bony tunnels is anatomical, and the femoral tunnel is positioned through the antero-medial portal. Fixation proximally is by CL-endobutton and at the tibia by Intrafix sheet and screw"
1470534|NCT03192761|Procedure|ACL reconstruction patella tendon|"PTBG reconstruction is performed according to the standard procedure of the department:
A bone patella tendon bone graft of 1 cm width from the midportion of the tendon is used. Placement of the bony tunnels is anatomical, the femoral being positioned through the antero-medial portal. Fixation proximally and distally is by interference screws."
1470535|NCT03192761|Procedure|ACL reconstruction iliotibial tract|"TIFLG reconstruction is performed as follows:
The TIFL graft is harvested using two lateral incisions. The graft is left attached to the distal iliotibial tract. Placement of the bony tunnels is anatomical, the femoral being drilled outside-in. The tibial drill tunnel is made by retrograde drilling 20 mm, leaving cortical bone at the distal end of the tunnel. Fixation distally is by CL-endobutton or interference screw and on femur by an interference screw outside-in."
1470536|NCT03192735|Drug|ApatinibMesylateTablets|Subject will be given ApatinibMesylateTablets 500mg/per day, from day1-day 21,per os; Oxaliplatin for Injection 130mg/m2 /per day，ivgtt，in day1; Gimeracil and Oteracil Porassium Capsules twice times a day,from day1-day 14,per os,and the dosage according body surface area:<1.25m2, 40mg every time;1.25-1.5m2,50mg every time; >1.5m2, 60mg every time.A course of treatment need 21days. Every subject need 2-5 courses accrding to tumor assessment by clinician. The last course stop ApatinibMesylateTablets.
1470537|NCT03192722|Device|Colored near reading glasses|Participants are provided with colored near vision glasses.
1470538|NCT03192709|Drug|Sildenafil vaginal suppositories|Sildenafil vaginal suppositories (100 mg/day) from the start of HMG administration day until the day of oocyte retrieval.
1470539|NCT03192709|Other|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until 2 days before the hCG injection day, then will be switched to vaginal sildenafil suppositories (100 mg/day) until the day of oocyte retrieval.
1470540|NCT03192709|Other|vaginal placebo|Daily vaginal placebo from the start of HMG administration day until the day of oocyte retrieval.
1470541|NCT03192683|Device|Providence Pedi Cast-Sling|Custom made sling with readily available casting materials
1470542|NCT03192683|Device|Regular sling|
1470543|NCT03192670|Device|Low-level light therapy device|Peak wavelength:610nm, Power intensity: 1.7mW/cm2, Energy density: 2.0J/cm2, Skin-adhesive light-emitting probes: spot size, 1cm diameter
1470544|NCT03192657|Drug|Basiliximab|The first administration should be within 8 weeks after disease onset.
1470545|NCT03192657|Drug|Calcineurin Inhibitors|Researchers can choose cyclosporin A or tacrolimus according to patient tolerance. Either agent should be applied promptly once infection is ruled out for a patient.
1470546|NCT03192657|Drug|Steroids|Dosage of steroid can be adjusted according to personal experience of the researcher.
1470547|NCT03192644|Procedure|TAI|transarterial chemoinfusion with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
1470548|NCT03192644|Procedure|TACE|transarterial chemoembolization with epidoxorubicin and cisplatin and lipiodol
1470549|NCT03192644|Drug|epidoxorubicin and cisplatin and lipiodol|epidoxorubicin and cisplatin and lipiodol
1470550|NCT03192644|Drug|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
1470551|NCT03192631|Other|Financial incentive|Incentive of $15 Canadian
1470552|NCT03192618|Procedure|adjuvant transarterial chemoinfusion (TAI)|transarterial chemoinfusion (TAI) with mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)
1580090|NCT02383108|Drug|SOC|
1470553|NCT03192618|Drug|mFOLFOX6 (oxaliplatin, calcium folinate, and 5-FU)|oxaliplatin, calcium folinate, and 5-FU
1470554|NCT03192605|Other|Blueberry|Blueberry - 150 grams wild blueberries (whole fruit)
1470555|NCT03192605|Other|Placebo|Placebo - matched for calories and fiber
1470556|NCT03192592|Other|Body moisturizer|Daily body moisturizer application for skin protection and barrier.
1470557|NCT03192579|Drug|EPA and high dose rosuvastatin|After randomization, patients with intensive lipid lowering therapy start EPA (1800mg/day) and high dose rosuvastatin (10mg/day) for 12 months.
1470558|NCT03192579|Drug|Standard dose rosuvastatin|After randomization, patients with standard lipid lowering therapy start only rosuvastatin (2.5mg/day) for 12 months.
1470559|NCT03192566|Drug|Tylenol|Dosing of Tylenol for post operative pain control
1470565|NCT03192527|Drug|KN015|experimental drug
1470566|NCT03192527|Drug|Placebo|Comparator.
1470567|NCT03192527|Drug|Triptorelin|The drug is used for down-regulation of endogenous FSH.
1470568|NCT03192514|Other|Electronic Deprescribing tool|"Each GP of the intervention group will have exclusive access to an electronic tool that will guide them on deprescribing. The innovative electronic tool created by the researchers provide the rationale on indications for prescribing or deprescribing Benzodiazepines or/and Non-benzodiazepine hypnotics and also provides an interactive tapering suggestion integrated on a calendar.
The tool emphasizes that any decision to continue or discontinue a drug remains a shared decision between GP and the patient.
The electronic Deprescribing tool is designed to support clinical decisions"
1470569|NCT03192488|Drug|Cetirizine|Cetirizine tablet 10 mg
1470570|NCT03192488|Drug|Placebo oral capsule|Gelatin placebo
1470571|NCT03192475|Behavioral|GLB plus phone contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The active treatment group also receives 8 additional group phone conference calls for social support and problem solving.
1470572|NCT03192475|Behavioral|GLB plus newsletter contacts|GLB is a comprehensive evidence-based lifestyle intervention derived from the Diabetes Prevention Program intensive lifestyle intervention; combines behavior modification strategies and making health changes to diet, physical activity and weight. The placebo comparator includes 4 additional newsletters only.
1470573|NCT03192462|Biological|multiTAA specific T cells|Each patient will receive 6 infusions of multiTAA T cells at a fixed cell dose (1 x 10^7 cells/m2) at the times specified in the group description. The expected volume of infusion will be 1 to 10 cc.
1470574|NCT03192449|Drug|Albendazole.|Single dose 400mg orally
1948427|NCT02352454|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
1470576|NCT03192410|Behavioral|Dietary intake|Intake of nutrients, foods, food groups, beverages; dietary patterns.
1470577|NCT03192410|Behavioral|Lifestyle factors|Physical activity; smoking; alcohol use; educational level.
1470578|NCT03192410|Biological|Blood biomarkers|Biomarkers of dietary intake (e.g. fatty acids); biomarkers of disease.
1470579|NCT03192410|Biological|Health|Current health status; medical history; medication use; self-rated health; risk factors for disease (e.g. body mass index, blood pressure, blood lipids, glucose)
1470580|NCT03192410|Genetic|DNA|SNPs (GWAS)
1470581|NCT03192410|Biological|Mental well-being|Cognitive function; dispositional optimism; depression.
1470582|NCT03192397|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
1470583|NCT03192397|Drug|Cyclophosphamide|Given IV
1470584|NCT03192397|Drug|Fludarabine Phosphate|Given IV
1470585|NCT03192397|Other|Laboratory Biomarker Analysis|Correlative studies
1470586|NCT03192397|Drug|Melphalan Hydrochloride|Given IV
1470587|NCT03192397|Drug|Mycophenolate Mofetil|Given IV
1470588|NCT03192397|Drug|Tacrolimus|Given IV and PO
1470589|NCT03192397|Radiation|Total-Body Irradiation|Undergo TBI
1470590|NCT03192384|Behavioral|Educational programme|Educational programme for ward staff
1470591|NCT03192371|Biological|Rabipur|Rabies vaccine administered as an intramuscular injection according to Zagreb or Essen regimen to subjects aged ≥6 to ≤17 years.
1948428|NCT02350634|Drug|18F-AV-1451|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451.
1477770|NCT03136939|Other|No intervention|No intervention
1948429|NCT02345408|Drug|CCX872-B|Tablets (oral administration)
1948430|NCT02342379|Drug|Bevacizumab|10mg/kg
1470598|NCT03192319|Biological|Zostavax|Zostavax will be administrated by subcutaneous injection
1470599|NCT03192306|Drug|Merlin|glycolic acid/ethanol solution
1470600|NCT03192306|Drug|Ethanol|Ethanol solution
1470601|NCT03192293|Drug|Metformin/Simvastatin/Fulvestrant|"7 days Lead-in period: Metformin: 850mg (one tablet) twice a day Simvastatin: 20mg (one tablet) once every night
Once the doctor has deemed that patients have tolerated Simvastatin and Metformin well, patients will receive Fulvestrant at standard doses:
Cycle 1: 500mg (in the form of two injections, 1 in each buttock) at Day 1 and Day 15. Each cycle comprises of 28 consecutive days starting from Day 1.
Cycle 2 and beyond: 500mg at Day 1 of each 28-day cycle.
Tumour biopsy at 8 weeks. Every 8 weeks for the first 6 months, every 12 weeks thereafter:
Performance status evaluation Medical history and physical examination Clinical tumor measurement Review of treatment-related side-effects Blood taking for research purpose and routine blood tests Routine scans"
1470602|NCT03192280|Drug|Leukotriene B4|Leukotriene B4 (LTB4)
1470603|NCT03192280|Device|FLIR One|Thermal imaging attachment to iPhone
1470604|NCT03192280|Device|SCIO|Handheld near-IR molecular spectroscopy device
1470605|NCT03192280|Device|MS Band 2|"Wearable watch-like device with multiple sensors"
1470606|NCT03192280|Device|AGE reader|Portable bench top device for in-clinic near UV assessment
1470607|NCT03192280|Device|HSI prototype (PARC) hyper-spectral camera|Portable bench top device for in-clinic multispectral imaging
1470608|NCT03192280|Device|iPhone 7|Smart phone
1470609|NCT03192254|Behavioral|self-monitoring|reporting counts and photos of fruit and vegetable consumption
1470610|NCT03192254|Behavioral|monetary incentives|payments for consuming fruits and vegetables
1470611|NCT03192241|Other|Pump|Intervention is providing mothers with a manual breast pump and instructions for when it could be used.
1470612|NCT03192241|Other|Book|Active control intervention is providing mother's with a children's book and information about reading to baby.
1470613|NCT03192228|Other|Treatment adequacy score|Evaluation of the program rate of success rate by a score evaluating the different criteria that the patient was supposed to modify following the therapeutic education program: practice of a physical activity, reduction of the amount of fat in Diet, practice of self-monitoring blood sugar as a motivational tool and decreased distress related to diabetes
1470614|NCT03192215|Drug|Apixaban|5 mg by mouth twice daily (2.5 mg for subjects meeting standard criteria for an adjusted dose).
1470615|NCT03192215|Drug|Aspirin|Aspirin 81 mg by mouth once daily.
1470616|NCT03192202|Drug|AFM13|AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
1470617|NCT03192189|Other|monitoring for progression to chronic kidney disease|Collect clinical information and assess risk factors
1470618|NCT03192176|Drug|ESN364|The dose of ESN364 varies across 7 treatment groups, with groups receiving once a day or twice a day blinded study drug. Doses range from 30 mg to 180 mg total daily dosing for 12 weeks.
1470619|NCT03192176|Drug|Placebo|Placebo administered BID for 12 weeks
1470620|NCT03192176|Drug|Placebo|Placebo administered QD for 12 weeks
1470626|NCT03192124|Device|Bactisure|"Level 1 Panel is a quantitative real-time PCR test to detect 12 microbial organisms that may be present in patient specimen (bacteria and fungi) and includes test for resistance factors to vancomycin and methicillin.
Microbial DNA in each sample will be sequenced using the Ion Torrent PGM sequencer in order to establish what type of bacterial and fungal species are present."
1470627|NCT03192111|Drug|Entinostat|HDAC (histone deacetylase) inhibitor
1470628|NCT03192098|Device|Savary bougie dilation|Patients will be dilated with the use of the Savary bougienage device
1470629|NCT03192085|Diagnostic Test|SITA FAST VISUAL FIELD TEST|Diagnostic test for glaucoma
1470630|NCT03192085|Diagnostic Test|SITA STANDARD VISUAL FIELD TEST|Diagnostic test for glaucoma
1470631|NCT03192059|Drug|Pembrolizumab|Efficacy of the combined treatment
1470632|NCT03192059|Radiation|Radiation|Efficacy of the combined treatment
1470633|NCT03192059|Drug|Vitamin D|Efficacy of the combined treatment
1470634|NCT03192059|Drug|Aspirin|Efficacy of the combined treatment
1470635|NCT03192059|Drug|Lansoprazole|Efficacy of the combined treatment
1470636|NCT03192059|Drug|Cyclophosphamide|Efficacy of the combined treatment
1470637|NCT03192059|Dietary Supplement|Curcumin|Efficacy of the combined treatment
1470638|NCT03192046|Device|Carbon Fiber Ankle Foot Orthosis (AFO)|Custom AFOs in conjunction with a walking program, working up to walking 30 minutes 6 days a week.
1470639|NCT03192033|Other|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure devices used: Proglide® (Abbott)
1470640|NCT03192033|Device|Proglide® (Abbott)|Arterial closure device used: Proglide® (Abbott)
1470641|NCT03192033|Device|Femoseal® (Terumo)|Arterial closure device used: Femoseal® (Terumo)
1470642|NCT03192033|Other|Arterial closure to ensure hemostasis at femoral artery puncture points|Arterial closure device used: Femoseal® (Terumo)
1470751|NCT03191123|Procedure|hepatic resection|The aim of this intervention is to reach curative resection.
1470752|NCT03191123|Procedure|TACE|The aim of this intervention is one of the palliative treatment.
1470753|NCT03191110|Other|No intervention: observational study|
1948431|NCT02342379|Drug|TH-302|670mg/m2
1470646|NCT03192007|Device|Magnetic Resonance Imaging|Investigate anatomic and functional characteristics of transplant kidneys using MRI
1470647|NCT03191994|Behavioral|Exercise|a structured, supervised eight week moderate intensity exercise intervention
1470648|NCT03191981|Drug|Cyclophosphamide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
1470649|NCT03191981|Drug|Lenalidomide|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
1470650|NCT03191981|Drug|Pembrolizumab|Treatment for all patients will be with cyclophosphamide, lenalidomide and pembrolizumab at fixed doses.
1470651|NCT03191968|Behavioral|Supervised Physical Activity Plus Behavioral Counseling|In addition to supervised physical activity, behavioral counseling sessions will be delivered with a PA specialist based on the Multi-process Action Control (M-PAC) framework and include behavior change techniques addressing information regarding the consequences, social support, goal setting, self-monitoring, cues and prompts, barrier identification, intention formation, planning, and habit and identity formation
1470652|NCT03191968|Behavioral|Supervised Physical Activity Plus Exercise Counseling|In addition to the supervised exercise sessions, standard exercise counseling will be delivered by a PA specialist to teach proper PA and resistance training techniques, how to monitor intensity, and to progress PA safely and effectively to achieve the public health PA guideline.
1470653|NCT03191942|Device|Modified ortho-k lenses|KETT MC lens
1470654|NCT03191942|Device|Ortho-k lenses|KATT BeFree lens
1470655|NCT03191929|Other|HIT Intervention|"Patients in the HIT intervention completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider. Patients' scores were transmitted to the provider prior to their clinic visit.
Providers in the HIT intervention received a web-based training developed by the Harvard Program in Refugee Trauma to train providers in delivering culturally competent, trauma-informed care to address mental health problems and other trauma-related medical issues in patients who experienced extreme war trauma. Providers also received ongoing clinical decision support through a mobile application to support the diagnosis and initiation of treatment for depression and/or PTSD."
1470656|NCT03191929|Other|Minimal Intervention Control Arm|"Patients in the Minimal Intervention Control Arm completed a multi-media, culturally adapted, mental health risk assessment tool in their preferred language prior to their baseline health care visit with their primary care provider; however, patients' scores in the Minimal Intervention Control Arm were only transmitted to the provider prior to their clinic visit if they showed evidence of being at risk to harm either themselves or others.
Providers in the Minimal Intervention Control Arm completed the online tutorial, A physician's practical guide to culturally competent care, which was provided by The Office of Minority Health, US Department of Health and Human Services Website."
1470657|NCT03191916|Device|transcranial direct current stimulation|2milliamps will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
1470658|NCT03191916|Device|Sham (for transcranial direct current stimulation)|For 30 seconds the patient will experience a ramp up of the stimulation, after which point no stimulation will be transmitted for the remainder of the session. This will be administered for 5 consecutive days for a duration of 20 minutes with electrode placement at the left dorsolateral prefrontal cortex.
1470662|NCT03191877|Dietary Supplement|coffee|"Nescafe brand of coffee made by Nestlé, red mug 100 % pure coffee 12083811"
1470669|NCT03191825|Other|Endre: a digital smoking cessation counsellor|A comprehensive 25-session intervention delivered by web, e-mail and SMS-text messages. Sessions are released one each day for 18 days, and then every second day for 14 days. Intervention content is tailored based on user input and individual usage pattern. The intervention is described in detail in Holter, Johansen & Brendryen (2016). How a fully automated eHealth program simulates three therapeutic processes: A case study. Journal of Medical Internet Research 18 (6).
1470670|NCT03191825|Other|Lapse management system triggered from web-page|"The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status every time they log on to Endre (the digital smoking cessation counsellor). Participants that report a lapse is routed to a fully automated counselling session delivered by web."
1948437|NCT02339090|Drug|somavaratan|long acting growth hormone therapy
1470671|NCT03191825|Other|Lapse management system triggered by SMS-textmessage|The lapse management system is based on a day-to-day logging of the target behavior (smoking). This logging goes on for four weeks after an initial quit attempt. The current version of the system logs by asking the participant about their smoking status in a textmessage (SMS) sent each evening. Participants that report a lapse, receives a new SMS with a link to a fully automated counselling session delivered by web.
1470672|NCT03191812|Other|transcranial Direct Current Stimulation (tDCS)|There will be three different tDCS targets as well as a sham stimulation condition. The stimulation for each of these conditions will be delivered via 6 already-placed gel electrodes on the participant's scalp with different combinations of current intensities among all the electrodes.
1948438|NCT02339090|Drug|Daily rhGH|daily growth hormone therapy
1470674|NCT03191786|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered as per the schedule specified in the respective arm.
1470675|NCT03191786|Drug|Vinorelbine|Vinorelbine will be administered according to the label.
1470676|NCT03191786|Drug|Gemcitabine|Gemcitabine will be administered according to the label.
1470677|NCT03191773|Combination Product|Drugs and anti-CD19 CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 (IV) will be infused over 30 minutes.
Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300-500mg/m2 IV will be infused over 60 minutes followed by fludarabine.
Biological: Anti-CD19-CAR T cells On day 0, cells will be infused intravenously IV over 20 - 30 minutes."
1470678|NCT03191760|Behavioral|Behavioral Activation|Participants will be asked to attend 6 in-person therapy sessions lasting approximately 45 minutes per session, to be held in Primary Care settings. Content of therapy sessions includes education about PTSD symptoms, discussion of the role of avoidance in maintaining PTSD symptoms, self-monitoring homework to identify links between activity level and emotions, and homework designed to increase engagement in valued activities, with a focus on increasing social contact and support. If relevant, participants will be instructed in basic communication skills, social skills, and relaxation skills.
1470679|NCT03191734|Device|AQUABEAM System|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-pressure saline stream to resect and remove prostate tissue.
1470680|NCT03191721|Procedure|Surgical anti-infective therapy|Two months before randomization, implants with peri-implantitis received surgical anti-infective therapy. After local anesthesia (2% lidocaine with 1:100,000 epinephrine), intrasulcular incisions were done and buccal and lingual full-thickness flaps were dissected. Granulation tissue was removed to expose the implant threads and bone defect. To remove biofilm and calculus, the implant surface was scaled with teflon curettes and decontaminated with bicarbonate jet (Jet Sonic System). The flap was repositioned in the original position and stabilized with interrupted sutures, which were removed after 10 days
1470681|NCT03191721|Procedure|Periodontal treatment|Two months before randomization, all subjects received full-mouth supragingival plaque removal and scaling and root planing (SRP), as needed. The SRP was performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites were scaled throughout the first week and treatment of the entire oral cavity was completed in 14 days.
1470682|NCT03191721|Procedure|Oral Hygiene Instruction|Delivery of a soft bristle adult toothbrush (Colgate Palmolive, Brazil), dental floss (Colgate Palmolive, Brazil), and interdental toothbrushes (Colgate Palmolive, Brazil) , according to their individual needs at pre-baseline, baseline, 3, 6, 12, 18 and 24 months. Information was given about the importance of keeping an excellent oral hygiene over the course of the study. The subjects were instructed to brush their teeth for one minute twice a day (morning and evening) using only the toothbrush and toothpaste provided.
1470683|NCT03191721|Drug|Triclosan toothpaste|Dental brushing with a toothpaste containing 0.3% triclosan and 1450 ppm sodium fluoride in a regular maintenance program for 24 months.
1470684|NCT03191721|Drug|Fluoride toothpaste|Dental brushing with a toothpaste containing 1450 ppm sodium monofluorphosphate in a regular maintenance program for 24 months.
1470685|NCT03191721|Procedure|Regular maintenance program|OHI, supragingival and subgingival biofilm removal from teeth and implants, and oral prophylaxis. If the examiner suspected of peri-implant disease progression, periapical radiographs were taken. If the implant showed ≥ 2 mm of bone loss, it was withdrawn from the study to receive additional treatment (e.g. another surgery procedure). Implants showing severe disease progression associated with mobility were removed. Maintenance visits were performed every 3 months.
1470686|NCT03191708|Diagnostic Test|Fractional Flow Reserve (FFR)|FFR measured by pressure wire, QFR computed by coronary angiographic images
1470687|NCT03191695|Other|Assessment via questionnaire|All the children will be assessed via assessment questionnaires.
1470688|NCT03191682|Drug|PRL3-ZUMAB|The starting dose will be 0.3 mg/kg, administered Q2 weekly, with the subsequent dose levels being 0.9 mg/kg, 3.0 mg/kg, and 6.0 mg/kg, all administered on a Q2 weekly basis until disease progression. The investigator will monitor each subject for the occurrence of AEs. In event of infusion-related adverse events, the Investigator, in consultation with the PI, may increase the duration of the infusion over a period of up to 24 hours at their discretion. Dosing will continue in a standard 3+3 design for dose escalation.
1470690|NCT03191656|Device|IASD Implant|Implantation of the IASD device using trans-septal puncture and the IASD system
1470754|NCT03191097|Drug|Ingavirin|Ingavirin capsules 60 mg once daily, regardless of meal, for 5 days.
1470755|NCT03191097|Drug|Placebo oral capsule|Placebo, capsules daily for 5 days.
1580091|NCT02383095|Behavioral|Art therapy|
1470693|NCT03191617|Dietary Supplement|Human milk fortifier|Fortification of breastmilk with liquid human milk fortifier in premature infants
1470694|NCT03191604|Other|Video intervention|Video clips of endoscopy footage with just HD-WLE and clips with NBI will be shown to endoscopists.
1470695|NCT03191591|Behavioral|First 1,000 Days Program Site|Program components will include 1) Enhancements to and improved use of electronic health records to improve the quality of preventive services and screening for social determinants of health; 2) Staff and provider training; 3) Consistent behavior change messaging; 4) Patient education via print materials, text messaging and short videos; and 5) Strengthening the integration of clinical and public health services to support behavior change and address social determinants of health.
1470696|NCT03191578|Drug|RUTI®|Administration of RUTI®
1470697|NCT03191578|Drug|Placebo|Administration of placebo
1470698|NCT03191565|Other|Paper diary sheet|Writing skill-use and symptoms on a week matrix type sheet
1470699|NCT03191565|Device|Monsenso DBT-app and IT monitoring program|Entering skill-use and symptoms on a smartphone with Monsenso DBT-app and IT monitoring program
1948439|NCT02337803|Behavioral|Strength Training Program|The strength training program consists of 6 exercises using resistance bands three times a week
1948440|NCT02337803|Behavioral|Usual Care|Will continue daily physical activity and complete surveys online
1470703|NCT03191526|Drug|KW-0761 0.3 mg/kg IV|Intravenous injection every 12 weeks.
1470704|NCT03191526|Drug|Placebo (saline)|Intravenous injection every 12 weeks.
1470705|NCT03191513|Dietary Supplement|Interesterified blend of palm kernal and plam stearin|50 g fat provided as interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
1470706|NCT03191513|Dietary Supplement|Un-interesterified blend of palm kernal and plam stearin|50 g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
1470707|NCT03191513|Dietary Supplement|Rapeseed oil|50 g fat provided as rapeseed oil in a single meal (sub-group, n=12, also have 75 mg 13C labelled tripalmatin and 1.2 g / kg body water deuterated water)
1470708|NCT03191500|Device|steerable catheter|peripheral vascular disease
1470709|NCT03191487|Other|ChimioPal|"Systematic collection of clinical and laboratory toxicities (TXs) during the 2-4 days preceding a chemotherapy (CT) session (48H before a session (D-2 towards the end of the afternoon) and a maximum of 96h before sessions occurring on Mondays (D-4 towards the end of the afternoon). Clinical TX data will be collected via ChimioPal (a self-questionnaire administered by smartphone) and laboratory TX data will be collected via Apicrpyt (secure messaging service) or a fax-to-email service. Data flow management by a nurse dedicated to this activity in each centre will be implemented. If the results of the assessment do not authorize CT, additional assessments may be prescribed. If the experimental data transmission does not occur, the usual pathways will be implemented.
Patient training on how to use a smart phone and the questionnaire will be performed by a nurse before the start of the first chemotherapy session, with reminders at the following sessions if required."
1470710|NCT03191487|Other|Usual pathways|In the standard arm, the usual management and logistic pathways will be respected. Only extra data collection is required by this study.
1470711|NCT03191474|Behavioral|T-POWr Intervention|"All participants will be asked to complete a secure confidential online survey focusing on needs assessment.
Participants in the T-POWr Intervention Arm will receive a client-centered case management consultation based on how the participant responds to the online survey. The T-POWr will refer participants to assistance services based on the needs assessment, including accessing general health care, health insurance, hormone replacement therapy, housing, mental health care, domestic violence care, substance use treatment, etc. Each resource is extensively vetted to assure a trans-friendly experience and will be tailored to each geographic area across the project enrollment sites. The study facilitates referrals for services but will not provide extensive and ongoing case management."
1470713|NCT03191448|Procedure|Ridge preservation|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously.
1470714|NCT03191448|Device|FDBA|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
1477771|NCT03136913|Device|Cytoplast® TXT-200|Non-resorbable membrane
1948441|NCT02336594|Drug|RDEA3170 10 mg|
1948442|NCT02336594|Drug|RDEA3170 2.5 mg|
1470715|NCT03191448|Device|Collagen wound dressing|Ridge preservation consists of grafting an extraction socket with a bone substitute and /or cover it with a membrane or a dressing. This intervention is aiming at limiting the osseous dimensional changes that would have taken place if the extraction would have been left to heal spontaneously. In this study a freezed dried bone allograft (FDBA) will be used and the site will be covered with a collagen wound dressing (Collaplug)
1470716|NCT03191435|Device|Inspiratory muscle training.|Patients will perform the inspiratory muscle training using a moderate load of 30% of maximal inspiratory pressure (MIP 30%). The training will be conducted at home in a period of 30 minutes, 7 times a week, during 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed. Furthermore, load in the device (powerbreathe) will be adjusted for the individual to use next week.
1470717|NCT03191435|Device|Placebo inspiratory muscle|Patients will perform the inspiratory muscle training using a very low load of 2% of maximal inspiratory pressure (MIP 2%). The training will be conducted at home in a period of 30 minutes, 7 times a week, in the course of 12 weeks. During inspiratory muscle training, individuals will attend Hospital de Clinicas de Porto Alegre once a week to the supervision of the way the exercise is being performed.
1470718|NCT03191422|Behavioral|LSVT BIG|LSVT BIG is a motor learning based intervention 4 hour long sessions per week for 4 weeks following a specific protocol. Each session is composed of exercises and participant specific activities, as well as a homework program.
1948444|NCT02331173|Drug|Dorzolamide 2% TID or brinzolamide 1% TID|"Dosing of all medications will be based upon standard of care. Standard dosing for the treatment of pediatric and adult patients with XLRS is as follows:
Topical dorzolamide 2% three times per day
Topical brinzolamide 1% three times per day"
1948445|NCT02329847|Drug|Ibrutinib|Participants will receive oral capsule of ibrutinib once daily as either 420 mg or 560 mg or at recommended Phase 2 dose in any of the cohort.
1948446|NCT02329847|Drug|Nivolumab|Participants will receive nivolumab intravenously as 3 mg/kg on Day 1 every cycle of 14 days.
1470725|NCT03191370|Other|Simple distraction technique|Asking the patient to count backwards from 30 to1 in even numbers whilst the procedure is being performed.
1470726|NCT03191370|Drug|Local Anesthetics,Topical|Anesthetic spray
1470727|NCT03191357|Other|n/a observational|Observational study
1470728|NCT03191344|Behavioral|with IPSS|all patient in one group use IPSS to record the parathyroid status. the other group operation as ordinary. record the parathyroid status in verbal description
1470729|NCT03191331|Behavioral|Dietary intervention|Written material on healthy diet during pregnancy, dietary counseling at each maternity clinic visit given by public health nurse, group meeting with a dietician x2.
1470730|NCT03191318|Other|ERAS pathway|ERAS pathway after laparoscopic sleeve gastrectomy
1470731|NCT03191318|Other|Standard pathway|Standard pathway after laparoscopic sleeve gastrectomy
1470732|NCT03191305|Drug|Coumadin|Patients in Coumadin Group would be administered Coumadin with overlap of heparin for first two days followed by Coumadin given orally ,dose being adjusted according to INR .The INR range would be between 2-3.it would be given once a day. The total duration Of coumadin would be six months.
1470733|NCT03191305|Drug|Rivoroxaban|The dose protocol would be similar to the one used in Deep Venous Thrombosis. 15 mg PO q12hr for 21 days with food, Then 20 mg PO qDay for 6 months.
1470734|NCT03191279|Procedure|First aid|Open airway (head tilt, chin lift), recovery position, staunch of bleeding, prevention of hypothermia, cooling of burn, CPR
1470735|NCT03191266|Device|Active rTMS|Active rTMS will receive FDA-approved rTMS stimulation protocol.
1470736|NCT03191266|Device|Sham rTMS|Sham rTMS group will receive all conditions except actual FDA-approved rTMS stimulation protocol.
1470737|NCT03191253|Other|Medically-appropriate meals and groceries|Full nutrition Intervention Components: (1) 7 pre-packaged frozen meals; (2) Groceries or another 7-pack of meals; (3) Nutritional supplement bag to round out the nutrition in terms of nutrients, or dietary reference intakes (DRIs), and number of servings from fruits/vegetables, whole grains, legumes, nuts/seeds and dairy. The nutritional supplemental bag will also contain bulk ingredients to aid in cooking e.g., cooking oil, spices, and herbs as well as bulk items e.g., jar of peanut butter, quart of milk; (4) Individual nutritional counseling (x2 sessions); and (5) Group nutrition education classes (X3 classes) by POH registered dietitian (RD) team.
1470738|NCT03191240|Drug|Vasopressins|Administer additional vasopressin 40 IU IV for 2 times during cardiopulmonary resuscitation
1470739|NCT03191240|Drug|Normal saline|Placebo
1470740|NCT03191214|Device|Intraoperative Forced Air Warming|As part of their standard care, patients undergoing surgery >30 min in duration will receive forced air warming in the form of a Bair Hugger. This is a blanket covering their upper torso and arms into which warm air is blown.
1470743|NCT03191188|Drug|Levothyroxine Sodium|Thyroid hormone supplement
1470744|NCT03191188|Drug|Placebo Oral Tablet|Placebo
1470745|NCT03191175|Other|blood sample|47ml blood (40 ml EDTA whole blood for Peripheral blood mononuclear cell (PBMC) and monocytes isolation and 7 ml for serum).
1470746|NCT03191162|Drug|Benznidazole|To evaluate different regimens of Benznidazole for the treatment of chronic Chagas disease
1470747|NCT03191149|Other|Laboratory Biomarker Analysis|Correlative studies
1470748|NCT03191149|Drug|Osimertinib|Given PO
1470749|NCT03191136|Drug|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fasting condition Period 2:a single dose of YHD1119 300mg is administered in fed condition
1470750|NCT03191136|Drug|YHD1119 300mg|Period 1:a single dose of YHD1119 300mg is administered in fed condition Period 2:a single dose of YHD1119 300mg is administered in fasting condition
1470756|NCT03191084|Drug|Low Dose THC Marijuana|Dosing via vaporized marijuana using a lower concentration of THC, participants receive this dose on two of the five study visits.
1470757|NCT03191084|Drug|High Dose THC Marijuana|Dosing via vaporized marijuana using a higher concentration of THC, participants receive this dose on two of the five study visits.
1470758|NCT03191084|Drug|Placebo Marijuana|Dosing via vaporized marijuana with no THC, participants receive this dose on one of the five study visits.
1470759|NCT03191071|Diagnostic Test|UltraPro|"First, procalcitonin will be measured using a rapid point-of-care test. In case of elevated procalcitonin result (≥0.25 µg/L), a lung ultrasound will be performed to look for the presence of a lung infiltrate or consolidation suggesting the presence of community acquired pneumonia. A portable ultrasound machine with a convex probe, that will be provided to the general practitioner by the study, will be used.
The lung ultrasound will be done following international evidence-based recommendations for point-of-care lung ultrasound using the basic eight-region sonographic technique and the criteria for positive scan and positive examination for the diagnosis of pneumonia ."
1470760|NCT03191071|Diagnostic Test|Procalcitonin|Procalcitonin will be measured using a rapid point-of-care test
1470761|NCT03191071|Diagnostic Test|Blood sampling|A venous blood sample (5 mL) will be collected and plasma will be stored at - 80°C. Further analysis will be performed in order to identify novel biomarkers that could predict the necessity of antibiotic prescription.
1470762|NCT03191071|Diagnostic Test|Nasal swab|A pooled nasal swab will be performed. Samples will be stored at 4°C. Further analysis of the naso-pharyngeal swab will be performed to identify by molecular techniques pathogens implicated in the clinical presentation.
1470763|NCT03191058|Device|Magnetic Seizure Therapy|MST treatment will be administered using the MagPro MST with a twin coil over the frontal cortex in the midline position. 25 HZ stimulation will be provided to achieve seizure activity to a maximum of 20 second train of magnetic impulse. Duration of stimulation train are titrated with adding 4 seconds to the duration of seizure threshold and if the seizure threshold is 12 seconds or longer, treatment will be provided at the 20 second maximum train. This will be performed under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes.
1470764|NCT03191058|Device|Electroconvulsive Therapy|In the ECT arm treatment, the MECTA spectrum 5000Q machine will be used, which is an FDA approved device used for providing standard-of-care clinical ECT treatments. Right unilateral, ultra-brief pulse ECT will be administered at 6 times the seizure threshold under the effect of anesthesia. The treatment procedure is approximately 10 minutes, followed by a recovery period of approximately 30 minutes
1470765|NCT03191045|Diagnostic Test|MRI and concomitant perfused manometry of bowel motility|We will carry out serial cine MRI of the bowel. At the same time we will record perfused manometry readings of the bowel in healthy adult participants.
1470766|NCT03191032|Other|Early sensory re-education of the hand with a sensor glove model|Training Group patients were submitted to application of a three-month protocol for early sensory re-education of the hand using the sensor glove model developed by Mendes et al. (2011). Patients also received conventional physical therapy for this type of injury in a specialized hand therapy center in a university hospital. Control Group patients received only conventional physical therapy treatment. No home sensory re-education program was established for any group and the CG patients were not submitted to any protocol for early sensory re-education of the hand.
1470767|NCT03191019|Behavioral|Mobile-phone app for smoking cessation|Android App for smoking cessation
1470768|NCT03191006|Device|MEI BIN insoles|insoles
1470769|NCT03190993|Other|Sugar Sweetened Solid Treatment|Consume Sugar Sweetened Solid Treatment (product) daily.
1470770|NCT03190993|Other|Sugar Sweetened Beverage Treatment|Consume Sugar Sweetened Beverage Treatment (product) daily.
1470771|NCT03190980|Other|5% glucose|Neonates will receive 5% glucose, then heel prick wil be performed during which pain will be assessed
1470772|NCT03190980|Other|30% glucose|Neonates will receive 30% glucose, then heel prick wil be performed during which pain will be assessed
1470773|NCT03190980|Other|Placebo|Neonates will receive sterile water, then heel prick wil be performed during which pain will be assessed
1948447|NCT02330380|Drug|Methotrexate|"Subjects will receive Methotrexate as detailed in the Group description."
1948448|NCT02330380|Drug|Ustekinumab|"Subjects will receive Ustekinumab as detailed in the Group description."
1470776|NCT03190954|Other|Placebo|Placebo (po) will be given 60 minutes prior to [11C]raclopride scan. MRI scan to follow end of PET scan.
1470777|NCT03190954|Drug|Methylphenidate|Methylphenidate 60 mg. po will be given 60 minutes prior to [11C]raclopride scan. MRI scan to follow end of PET scan.
1948449|NCT02330380|Drug|Etanercept|"Subjects will receive Etanercept as detailed in the Group description."
1948450|NCT02330380|Drug|Adalimumab|"Subjects will receive Adalimumab as detailed in the Group description."
1948451|NCT02330380|Drug|Acitretin|"Subjects will receive Acitretin as detailed in the Group description."
1948452|NCT02330380|Other|UVB Excimer Laser|"Subjects will receive UVB Excimer Laser therapy as detailed in the Group description."
1948453|NCT02330380|Other|Narrowband UVB|"Subjects will receive Narrowband UVB as detailed in the Group description."
1948454|NCT02329093|Procedure|To MRI-detecting bone signal changes in radiographic hip OA|To examine whether or not non-weight bearing reduced OA progression
1948455|NCT02326883|Behavioral|Care Management|The Care Management intervention includes routine outreach to assess ongoing risk of suicide attempt and care management to monitor and facilitate ongoing engagement in outpatient follow-up. The Care Manager will coordinate care with treating mental health and primary care providers (ongoing usual care) using Epic Staff Messaging (or telephone contacts if necessary).
1470785|NCT03190902|Behavioral|Attention Processing Training program (APT)|
1470786|NCT03190902|Behavioral|nonspecific computer training (n-ST)|
1470789|NCT03190876|Procedure|Variable drain usage|Influence of drain usage on seroma formation rate
1470819|NCT03190603|Drug|Celecoxib|Continue celecoxib 400mg/day for 3months in axial spondyloarthritis patients.
1470820|NCT03190590|Device|tDCS-NeuroConn.|tDCS is delivered noninvasively via electrodes applied to the surface of the head, and a mild electrical current is given during motor training.
1470918|NCT03189784|Other|mobilization with movement techniques|patient will receive an anteroposterior stimuli in the talus in order to restore the range of motion
1470790|NCT03190863|Behavioral|Motor imagery combined with neurofeedback (MINF)|"7 individuals with C6-C7 tetraplegia randomize in the experimental group consisting in motor imagery practice combined with visual neurofeedback (NF - i.e. performance of the imagined movement).
Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions. After each imagined movement, the NF based on brain activity measured by electroencephalography is display on a screen."
1470791|NCT03190863|Behavioral|Motor imagery (MI)|"7 individuals with C6-C7 tetraplegia randomized in the active comparator group consisting in motor imagery practice alone without visual NF. This means that the performance of the imagined movement is not displayed to the participants.
Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
1470792|NCT03190863|Behavioral|Control (C)|"7 individuals with C6-C7 tetraplegia randomized in the sham comparator group consisting in imagining geometric shapes by visualization. Shapes are successively displayed on a screen.
Intervention consists in a total of 15 sessions repeated 3 times a week and lasting 5 weeks. Each session will last 45 minutes. An experienced physical therapist supervised all sessions."
1470793|NCT03190850|Other|Intervention|The device in which the breathing exercises will be performed will be adjusted with progressive loading aiming to improve muscular strength
1470794|NCT03190850|Other|Control|The device in which the breathing exercises will be performed will not be adjusted with progressive loading.
1470795|NCT03190824|Drug|OBP-301|A novel, replication-competent Ad5 based adenoviral construct that incorporates a human telomerase reverse transcriptase gene (hTERT) promoter.
1470796|NCT03190811|Biological|Anti-PD-1 plus DC-CIK|"Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
DC-CIK Immunotherapy: Mononuclear cells were collected aseptically with blood cell separator composition apheresis, and cultured DC-CIK cells for 10-14 days. Cells were infused back to the patients in 3 times via intravenous infusion .Patients will received at least 2 cycles of DC-CIK Immunotherapy along with 4 dosage of anti-PD-1 antibody treatment. If the evaluation of the treatment is partial response or stable disease, additional cycles were eligible."
1470797|NCT03190811|Biological|Anti-PD-1 alone|Anti-PD-1 antibody treatment: Patients will receive pembrolizumab 100mg every three weeks until disease progression, unacceptable toxicity or patient refusal.
1470800|NCT03190785|Other|Benzoic acid washout and exposure|see above
1470801|NCT03190772|Other|Placebo nasal spray|The placebo nasal spray consists of sesame oil and does not contain any active drug.
1470802|NCT03190772|Other|Film sequence|All groups watch the film sequence that is supposed to induce sadness.
1470803|NCT03190746|Diagnostic Test|TaqMan SNP analysis|TaqMan SNP analysis of the YWHAH gene
1470804|NCT03190733|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 4 or 5 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include fludarabine (Flu), busulfan (Bu),cyclophosphamide (Cy). All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF) for aGVHD prevention.
1470805|NCT03190720|Device|Mobile community|A mobile community based on smartphone application (WalkOn) which gives participants to information about their own steps and others'.
1470806|NCT03190707|Behavioral|Intervention|"Detection of ill-being: An extended consultation with the midwife. The midwife will screen the women for symptoms of anxiety, depression and personality disorders.
Knowledge sharing: An additional midwife consultation accompanied by the health visitor. The aim of is sharing knowledge and transmission of information between the two sectors responsible for making a shared plan for the course of the process for the pregnant woman.
Strengthen parenting skills through:
Two visits by the health visitor before birth and eight after. The visits are based on the parent training program The Circle of Security, aiming at promoting a secure attachment between child and carer.
Teaching the woman/couple on the importance of breast-feeding and how to succeed."
1470807|NCT03190694|Drug|Dapagliflozin 10mg|Tablet
1470808|NCT03190681|Drug|Ritalin 10Mg Tablet|ingestion of an oral single-dose
1470813|NCT03190655|Device|Aluminaid|Aluminaid wound dressings is a hydrogel based wound dressing that is integrated with aluminium
1470814|NCT03190655|Device|Hydrogel|Hydrogel based wound dressing
1470815|NCT03190642|Drug|Methylprednisolone|Administration of 1000mg vs 125mg methylprednisolone preoperatively in orthognathic surgery.
1470816|NCT03190629|Device|High-flux hemodialysis|Hemodialysis treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Hemodialysis treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care).
1470817|NCT03190629|Device|On line-hemodiafiltration|Post-dilution on line-hemodiafiltration treatment thrice weekly with the high-flux FX-100 dialyzer (Fresenius Medical Care, Bad Homburg, Germany; membrane: Helixone®; surface: 2.2 m2; UF coefficient: 73 ml/h mm Hg; ß2-microglobulin-sieving coefficient: 0.8; albumin-sieving coefficient: 0.001), including a minimum target dialysis dose (Kt/Vurea) ≥1.2 and a session length of 3.0 to 6.0 h. Post-dilution on line-hemodiafiltration treatments were performed with the 5008 hemodialysis system (Fresenius Medical Care), with automatic adjustment of the substitution fluid flow rate for maximising substitution volume while simultaneously avoiding haemoconcentration and filter clotting.
1470818|NCT03190616|Drug|apatinib|apatinib 500mg/qd, 28d/cycle
1580161|NCT02382510|Other|Placebo|
1470821|NCT03190590|Device|TMS - Magstim.|TMS is delivered noninvasively via a hand-held coil applied to the surface of the head, and a magnetic pulse probes cortical circuitry [this is not repetitive TMS and so does NOT modulate brain excitability
1470822|NCT03190590|Device|Sham tDCS|delivered by briefly turning on and off the stimulator at the beginning of training, which mimics the sensation of true stimulation.
1470823|NCT03190577|Genetic|blood sample|two 5 ML EDTA tubes of blood will be collected once by patient
1470824|NCT03190551|Other|retroclavicular approach|Retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
1470825|NCT03190551|Other|costoclavicular approach|costoclavicular approach for ultrasound guided infraclavicular brachial plexus block
1470826|NCT03190538|Other|No intervention|There will be no specific intervention to these paediatric NASH patient
1470827|NCT03190525|Other|Quality of life questionnaires|QLQ-C30
1470828|NCT03190512|Other|Psychological measurements|Four questionnaire tests for depression, body image, self-esteem, and anxiety was performed baseline and after 6 weeks.
1470829|NCT03190499|Other|Family based assessment|Family of the children will be assessed with questionnaires about their child health condition.
1470830|NCT03190486|Other|functional Magnetic Resonance Imaging (fMRI)|During fMRI, healthy volunteers will listen 80 baby's cry.
1470831|NCT03190473|Device|DES|PCI with implantation of a DES
1470832|NCT03190460|Other|Cognitive Training|Web-based cognitive training intervention targeting specific cognitive tasks. Subjects complete 3 training sessions per week with at least 24 hours in between sessions.
1470833|NCT03190460|Other|Technology-based Education|Subjects complete 16 web-based educational modules on healthy aging content. Following each module, subjects complete a learning reflection.
1470834|NCT03190447|Device|Aquacel Surgical®|Measuring the skin integrity with each dressing and the patient satisfaction
1470835|NCT03190447|Device|Mepilex Border post-op®|Measuring the skin integrity with each dressing and the patient satisfaction
1470836|NCT03190447|Device|Opsite post-op visible®|Measuring the skin integrity with each dressing and the patient satisfaction
1470837|NCT03190447|Device|Urgotul ABSORB border silicona®|Measuring the skin integrity with each dressing and the patient satisfaction
1470838|NCT03190447|Device|Conventional dressing|Measuring the skin integrity with each dressing and the patient satisfaction
1470839|NCT03190434|Device|AL-SENSE|The AL-SENSE reacts differently when in contact with amniotic fluid than it does with urine. The indicator changes color to blue-green and fades back to yellow in case of urine and changes to stable blue-green in case of amniotic fluid.
1470840|NCT03190421|Diagnostic Test|Expanded Urinary Culture|involves the inoculation of 100X (0.1mL) more urine onto diverse types of media (BAP, chocolate agar, colistin and nalidixic acid (CNA) agar, CDC anaerobe 5% BAP) with incubation in more environments and temperatures (5% CO2 at 35°C for 48 h, aerobic conditions at 35°C and 30°C for 48 h, Campy gas mixture (5% O2, 10% CO2, 85% N) or anaerobic conditions at 35°C for 48 h). The level of detection for EQUC is 10 CFU/mL, represented by 1 colony of growth on any of the plates. EQUC is designed to isolate a broad array of Gram-negative and Gram-positive bacteria, including anaerobes and fastidious bacteria that grow slowly.
1470841|NCT03190421|Diagnostic Test|Standard Urine Culture (SUC)|involves inoculation of 0.001 mL of urine onto 5% sheep blood agar plate (BAP) and MacConkey agar plate with the plates being incubated aerobically at 35°C for 24 h. Thus, the level of detection for standard culture is 103 CFU/mL, represented by 1 colony of growth on either plate. Standard culture is designed specifically to grow Gram-negative rods, especially UPEC.
1470842|NCT03190408|Other|Fluids|Fluids Administered in Shock
1470845|NCT03190382|Other|Decision Support Tool|Patients enrolled in the study will receive the decision tool prior to the first PAD clinic visit and the medical decision making conversation with the provider.
1470848|NCT03190356|Device|Soberlink Cellular Device|Soberlink Cellular Device delivers real-time blood alcohol results to people who support individuals in recovery. MAP platform helps monitor and support compliance with discharge plans while providing tools to improve outcomes for behavioral health diagnoses.
1470849|NCT03190343|Procedure|cholangio-pancreatoscopy|
1470850|NCT03190330|Drug|Ibrutinib 420 mg|Ibrutinib capsule administered orally at a dose of 420 mg for CLL participants.
1470851|NCT03190330|Drug|Ibrutinib 560 mg|Ibrutinib capsule administered orally at a dose of 560 mg for MCL participants.
1470852|NCT03190317|Other|HIV-infected Veterans who use MHV|We will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, will interview Veterans to understand why they use MHV. Finally we will create an intervention based on the information we learn that will encourage use of MHV and ask Veterans to test it out.
1470853|NCT03190317|Other|HIV-infected Veterans who do not use MHV|We will use information from Veteran medical records to assess the relationship between Veteran HIV health care outcomes and the use of MHV. Next, will interview Veterans to understand why they do not use MHV. Finally we will create an intervention based on the information we learn that will encourage use of MHV and ask Veterans to test it out.
1470854|NCT03190304|Drug|Neprilysin|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
1470855|NCT03190304|Drug|Enalapril|To compare the effect of Enalapril and Neprilysin on exercise tolerance in patients with heart failure
1470856|NCT03190291|Behavioral|Stepped Care: Low Intensity|Self-guided CBT workbook teaches people to monitor depressive and anxiety-producing thoughts, modify these thoughts, and modify behaviors that reinforce depression and anxiety.
1470893|NCT03190031|Other|Resistance inspiratory muscle training|Training program of the inspiratory muscles in resistance by using repeated inspiratory maneuvers against a resistance
1470857|NCT03190291|Other|Enhanced Usual Care|"Will receive information about referrals/resources in their local area, including support groups and mental health providers. They will also be provided Facing Forward: Life after Cancer Treatment, a book developed by the National Cancer Institute to assist with the transition from active treatment to survivorship."
1470858|NCT03190291|Behavioral|Stepped Care: High Intensity|Will consist of the CBT workbook, plus psychotherapy delivered by telephone with a licensed therapist.
1470859|NCT03190278|Biological|UCART123|Allogeneic engineered T-cells expressing anti-CD123 Chimeric Antigen Receptor given as a single dose following a lymphodepleting regimen
1470860|NCT03190265|Drug|Cyclophosphamide|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Cyclophosphamide (200 mg/m2) will be administered IV on day 1 of Cycles 1 and 2.
1470861|NCT03190265|Drug|Nivolumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Nivolumab (360 mg) will be administered IV on day 1 of Cycles 1-6.
1470862|NCT03190265|Drug|Ipilimumab|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Ipilimumab (1 mg/kg) will be administered IV on Day 1 of Cycles 1, 3, and 5.
1470863|NCT03190265|Drug|GVAX Pancreas Vaccine|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). Vaccine will be administered on Day 2 of Cycles 1 and 2.
1470864|NCT03190265|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 3-6.
1470865|NCT03190265|Drug|CRS-207|Patients will receive treatment every 3 weeks for 6 cycles of treatment within a course (total of 18 weeks). CRS-207 (1 × 109 CFU) will be administered IV on Day 2 of Cycles 1-6.
1470866|NCT03190252|Other|Exposure to oxygen partial pressure of 130 kPa|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
1470867|NCT03190252|Other|Exposure to ambient pressure of maximum 11 ATA|Open sea diving to a maximum depth of 100 msw while breathing Trimix.
1470868|NCT03190239|Drug|Apatinib|Apatinib 250mg qd
1470869|NCT03190239|Drug|Pemetrexed|Pemetrexed 500mg/m2 qm
1470870|NCT03190226|Procedure|L-PRF membranes|split-mouth design, randomized L-PRF membranes vs. free gingival graft
1470871|NCT03190226|Procedure|Free Gingival Graft|split-mouth design, randomized L-PRF membranes vs. free gingival graft
1470874|NCT03190187|Other|Spinal Manipulation|Spinal manipulation based on orthopaedic manual therapy approach
1470875|NCT03190187|Other|Sham manipulation|Patients will receive simulated spinal manipulation without force application
1470876|NCT03190174|Drug|Nab-Rapamycin|Escalating doses of ABI-009 will be given IV over 30 min for 2 of every 3 weeks beginning Day 8 Cycle 2. Only nivolumab will be given in Cycle 1. At Dose Level 1, 3-6 patients will receive 56 mg/m2; at Dose Level 2, 3-6 six patients will receive 75 mg/m2; and at Dose Level 3, 3-6 patients will receive 100 mg/m2.
1470877|NCT03190174|Biological|Nivolumab|A defined dose of nivolumab, 3 mg/kg, will be given IV over 30 minutes q 3 weeks
1470878|NCT03190161|Behavioral|Music session|Participants will be asked to refrain from smoking from 24 hours before the music listening session as confirmed by breath carbon monoxide level <6 ppm on the day of the session. They will be contacted by phone or in person at the clinic as a reminder prior.
1470879|NCT03190148|Other|OGTT|A standardized 75g oral Glucose tolerance test was accomplished.
1470880|NCT03190148|Other|IVGTT|For the exact assessment of Glucose metabolism in the study participants an intravenous Glucose tolerance test (IVGTT) was accomplished
1470881|NCT03190148|Other|1H-magnetic resonance spectroscopy|For the assessment of the ectopic lipid content in the liver, heart and the muscle a 1H-magnetic resonance spectroscopy was accomplished three to six months after delivery
1470882|NCT03190135|Behavioral|BOKS: 2 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 2 times per week.
1470883|NCT03190135|Behavioral|BOKS: 3 day a week before-school physical activity program|Students participate in BOKS, a before-school physical activity program for 12 weeks, 3 times per week.
1470884|NCT03190122|Procedure|surgical excision of the tumor|Neurocognitive Outcome Assesment in Patients With Peri-optic Meningiomas After Excision With Or Without Pealing Of The Outer Layer Of The Cavernous Sinus: A Randomized Controlled Single Blinded Trial. [NCT ID not yet assigned]
1470885|NCT03190096|Procedure|SVC isolation|After PVI ablation SVC will be performed. The CB will be retrieved to the right atrium and the achieve catheter will be advanced in the SVC. The CB will be inflated in the right atrium and advanced towards the ostium of the SVC to occlude the vessel
1470888|NCT03190070|Dietary Supplement|Ingestion of protein|Oral protein load as a physiological stimulus to temporarily increase glomerular filtration rate
1470889|NCT03190057|Device|BioFreedom stent|Percutaneous coronary intervention with BioFreedom stent
1470890|NCT03190044|Dietary Supplement|PACR|Daily assumption of PACR for a 3-month period
1470891|NCT03190044|Dietary Supplement|Placebo|Daily assumption of placebo
1470892|NCT03190031|Other|Endurance respiratory muscle training|Training program of the respiratory muscles in endurance by using sustained isocapnic hyperpnea
1470919|NCT03189771|Procedure|occlusal surface reduction|occlusal surface reduction after single visit root canal treatment
1470894|NCT03190018|Device|lCarry Life System Peritoneal Dialysis (CLS PD)|The assigned intervention is with the CLS PD device in patients currently receiving peritoneal dialysis for the duration of one study session. A temporary Pigtail catheter is inserted on the same morning as the study session and removed after the session on the same day.
1948456|NCT02326883|Behavioral|Skills Training|The Skills Training intervention uses an online skills training program to support patients in developing and using self-management skills for emotion regulation and crisis management. A Coach will monitor each participant's use of the program and send periodic messages (using Epic secure messaging) to encourage and support use of the program and practice of program skills.
1948457|NCT02326883|Behavioral|Usual Care|Those assigned to usual care will not be contacted at all by study staff and will continue to receive usual care from treating primary care and mental health providers.
1470897|NCT03189992|Drug|Bushen-Jianpi Dedoction|A traditional chinese medicine prescription
1470898|NCT03189992|Drug|cinobufotalin injection|an effective Chinese preparation to treat malignant tumor.
1470899|NCT03189979|Behavioral|Physical activity and healthy eating intervention|Using a community-based participatory approach, BGC staff and academic researchers developed intervention components informed by formative studies and based on a social ecological theory framework. Components included healthy eating and physical activity policy implementation, staff training, a challenge/self-monitoring program for healthy behaviors, a peer-coaching program for healthy behaviors, and a social marketing campaign.
1470900|NCT03189966|Procedure|transversalis fascia plane block|With the patient in a supine position, the needle is advanced from the anterior using an in-plane technique. A linear ultrasound probe is orientated transversely over the lateral abdomen between the iliac crest and the costal margin. Local anesthetic is injected to separate the transversalis fascia from the transversus muscle. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the anterior border of QLM and its fascia, in addition to a minimal anterior spread in TAP plane. After negative aspiration, 1 ml/Kg of ropivacaine 0.3%was injected.
1470901|NCT03189966|Procedure|quadratus lumborum block|The needle is directed in the posterior to anterior orientation with the practitioner standing behind the patient. The triangular quadratus lumborum (QL) muscle is adherent to the apex of the transverse process of L3 vertebra. Using the Shamrock method, the needle penetrates the QL muscle with an in-plane approach from the posterior side of the ultrasound probe. The target point is the inter fascial plane between the QL and the psoas major muscle just deep to the transversalis fascia, in order to lessen the risk of unintentional penetration of the peritoneal cavity contrary to the technique. The correct needle position was confirmed by injection of 2 ml of normal saline solution that was spreading anterio-posteriorly between the QL and the psoas major muscle. After negative aspiration, 1 ml/Kg of ropivacaine 0.3%was injected.
1470902|NCT03189953|Radiation|68Ga-NODAGA-exendin 4 PET/CT|68Ga-NODAGA-exendin 4 PET/CT
1470903|NCT03189940|Behavioral|Life style modification by using and app with a wrist-worn activity tracker|The mobile app was designed to collect daily lifestyle data by wearing a wrist activity tracker and reporting dietary intake. At the visit after 2 weeks of use, a summary of the lifestyle was displayed on the hospital EMR and reviewed by both physicians and app users. Further lifestyle modification was encouraged on the basis of the electronically collected data.
1470904|NCT03189940|Behavioral|Conventional Life style modification|Physician's usual consultation for life style modification at 0 week, and 2 weeks of enrollment
1470905|NCT03189927|Device|BD-Covered esophageal stent|a biodegradable covered stent is implanted to achieve a long-term relieve of dysphagia in refractory benign esophageal strictures
1470908|NCT03189888|Device|apheresis|
1470911|NCT03189836|Biological|ACTR707|autologous T cell product
1470912|NCT03189836|Biological|rituximab|CD20-directed cytolytic antibody
1470913|NCT03189823|Device|Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA|In MCS, an electrode is placed perpendicular to the central sulcus in the epidural space (Specify, model 3998, Medtronic Inc., Minneapolis, MN, USA) in order to obtain pain relief.
1470914|NCT03189810|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods [Cardenas-Morales et al. 2013] and the rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz (25 trains, 30 pulses per train, 30 second intertrain interval).
1470915|NCT03189810|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|On Day 1, the resting motor threshold (RMT) will be determined according to previous published methods [Cardenas-Morales et al. 2013] and the Sham rTMS will be delivered at an intensity of 90% of the participant's RMT. rTMS will be administered at 20 Hz with the B65 placebo coil (25 trains, 30 pulses per train, 30 second intertrain interval).
1470916|NCT03189810|Behavioral|Weekly Counselling Session|In order to support participants in their abstinence plan, individual weekly sessions of supportive counselling will be administered over the course of the study on 1 time per week over 4 weeks (28 days of abstinence).
1470917|NCT03189797|Other|tailored preventive program|"After defining the individual patient's likelihood risk status and the diagnosis for each lesion, ICCMS presents a management element to build a comprehensive patient care plan as follow:
Homecare program:
Tooth brushing 2/day with a higher efficacy fluoride toothpaste (≥ 1,450 ppm F-), or High F- prescription toothpaste following the dental team instructions
Prescribed F- mouth rinse
Clinical approaches :
Motivational engagement (discuss with patients how to improve oral health behaviours - including amount of sugar), maintain dental visits at risk-based intervals
Sealants
F- varnish 2 times /6months .
F- gels or solution
Recalls up to every 3 months: professional cleaning & topical F- application on active lesions
Dietary intake interventions
Altering medication-induced hyposalivation if exists."
1470920|NCT03189758|Other|Observational Control Diet|Participants will follow their usual or normal diet for 30 days.
1470921|NCT03189758|Other|Controlled Dietary Sodium Restriction|Participants will be provided with all meals and snacks daily, for 30 days. These meals should meet nutrition and medical needs, while limiting salt intake.
1948458|NCT02325388|Device|ForeSite PT™ system|"XSENSOR Technology Corporation's ForeSite PT™ Patient Turn System (referred to as the ForeSite PT™ system) continuously monitors interface pressure and provides CPI that quantifies real-time interface pressure information. It also provides patient turn tracking to assist with management of the patient turn schedule by alerting healthcare providers and/or caregivers to the location of body areas that have experienced the greatest exposure, and when the next turn/repositioning is due as per pre-set alerts."
1470923|NCT03189732|Drug|Metformin Oral|
1470924|NCT03189732|Drug|Metformin local in AT|
1470925|NCT03189732|Other|Exercise|
1470930|NCT03189706|Drug|Irinotecan|50mg/m^2/day IV will be administered from day 1-5
1470931|NCT03189706|Drug|temozolomide|(given concurrently with Irinotecan) 150mg/m^2/day orally
1470932|NCT03189706|Biological|Hu3F8|2.25mg/kg IV will be administered on days 2, 4, 8 and 10
1470933|NCT03189706|Drug|GM-CSF|250mg/m2/day SC will be administered on days 6-10
1470934|NCT03189693|Other|PVB|nerve stimulator-guided PVB will be performed at two levels
1470935|NCT03189693|Other|Placebo|nerve stimulator-guided PVB containing placebo will be performed at two levels
1470936|NCT03189693|Other|GA|All patients will receive general anesthesia.
1470937|NCT03189693|Other|Anesthetic injections|4 mL of the local anesthetic mixture is injected at each injection site. Each 20 mL of the local anaesthetic mixture contains: 8mL lidocaine 2%, 8 mL lidocaine 2% with epinephrine 5µg/mL and 4 mL bupivacaine 0.5%.
1470938|NCT03189680|Other|Exercise therapy|3-week-long intervention, administered daily, targeted postural instability and mobility using at-limit intensity sensorimotor and visuomotor agility training
1470939|NCT03189667|Device|Vessel preparation with angioplasty|"Vessel preparation with Pre dilatation:
All lesions to be predilated with high pressure balloons until waist is obliterated.
At least two minutes dilatation.
Balloon sizing: not to exceed the average diameter of adjacent normal appearing non-aneurysmal segments by more than 25%.
Multiple lesions:
To be treated with single balloon if possible.
To be treated with multiple inflation if cannot be covered with single balloon."
1470940|NCT03189667|Device|Plain balloon angioplasty|"Plain balloon angioplasty
Vessel treatment with additional Plain balloon angioplasty:
Inflation to nominal pressure for at least 1 minute.
Balloon size: similar to predilation balloon."
1470941|NCT03189667|Device|Drug coated balloon angioplasty|"Lutonix® Drug Coated Balloon: The balloon is coated with a specialized formulation that includes the drug, paclitaxel. The paclitaxel coating is evenly distributed across the working length of the balloon at a surface concentration of 2 μg/mm2. The key functional characteristic of the formulation is to allow for release of paclitaxel to the tissue of the vascular wall during inflation.
Inflation to nominal pressure for at least 1 minute.
Balloon size: similar to the predilation balloon.
New drug coated balloon will be required for each lesion."
1470942|NCT03189654|Device|Non-invasive ventilation|Non-invasive Ventilation for a Minimum of 8 h per day after pleurocentesis
1470943|NCT03189641|Device|Cilostazol eluting stent system (CES-1)|Implantation of drug eluting stent
1470944|NCT03189628|Biological|stromal vascular fraction|The adipose tissue(no less than 40ml) in abdomen will be harvested and digested at 37 °C for (45-60) min with (0.125-1.5)mg/ml collagenase . After filtration and centrifugation at the speed of (700-1500)g, mature adipocytes are separated from the cell pellet. The pellet then is treated with saline twice to remove cell fragment and rudimental collagenase . The harvested pellet is stromal vascular fraction (SVF) The SVF was resuspended in 1 ml saline and transplanted for 3 area including the forehead、palpebra inferior and crow's-feet.
1470945|NCT03189628|Drug|Saline|1 ml saline was injected for 3 area including the forehead、palpebra inferior and crow's-feet.
1470946|NCT03189615|Drug|Lu AF35700|Single oral dose of 10 mg Lu AF35700
1470947|NCT03189589|Drug|GSK2269557 500 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 500 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
1470948|NCT03189589|Drug|GSK2269557 750 µg|GSK2269557 is a potent and highly selective inhaled Phosphoinositide 3 Kinase delta inhibitor. Single dose of GSK2269557 750 µg will be administered to randomized subjects via inhalation route using ELLIPTA DPI.
1470949|NCT03189576|Diagnostic Test|blood draw|
1470950|NCT03189563|Drug|DA-9805 45mg|DA-9805 15mg tid
1470951|NCT03189563|Drug|DA-9805 90mg|DA-9805 30mg tid
1470952|NCT03189563|Other|Placebo|Placebo, tid
1470953|NCT03189550|Procedure|ERAS perioperative care|Standard of care implementation of multi-modal evidence-based care pathway, including standardized preoperative preparation (medical and diet), perioperative goal-directed fluid therapy, multi-modal perioperative pain management, postoperative nausea and vomiting prevention, surgical care and bowel isolation, and surgical site infection prevention
1470954|NCT03189550|Procedure|Standard perioperative care|Standard perioperative care prior to implementation of ERAS care pathway
1470955|NCT03189550|Procedure|Noninvasive hemodynamic monitoring|Standard of care perioperative noninvasive hemodynamic monitoring with the ClearSight System (Edwards LifeSciences)
1470956|NCT03189537|Drug|Ingavirin (Imidazolyl Ethanamide Pentandioic Acid)|Broad-spectrum antiviral agent
1470957|NCT03189537|Drug|Placebo oral capsule|Placebo capsule to match Ingavirin capsule
1470958|NCT03189524|Drug|BGB-3111|
1470959|NCT03189511|Drug|Fluvastatin|Fluvastatin 40 mg twice daily per mouth for 14 days.
1470960|NCT03189498|Drug|JNJ-64041575|All participants will receive a single oral dose of 1,000 mg JNJ-64041575 (4*250 mg tablets) on Day 1.
1470986|NCT03189290|Procedure|posterior Quadratus Lumborum Block (QLB)|Procedure (experimental): ultrasound guided posterior Quadratus Lumborum Block (QLB) Procedure (experimental): Sham Block
1470962|NCT03189472|Device|Active tDCS|low amplitude direct currents to induce changes in cortical excitability. tDCS produces current intensities in the brain orders of magnitude below other stimulation techniques such as transcranial magnetic stimulation (TMS) or electroconvulsive therapy (ECT)
1470963|NCT03189472|Device|Sham tDCS|The device will be programmed to deliver either active or sham tDCS (all study personnel and participants will be blinded), and operated with unlock codes provided by the study technician daily to release one session
1470964|NCT03189459|Behavioral|Home Visit Intervention:|RN: Informed consent discussion, documentation RN: UPDRS I-II, vitals, medication reconciliation RN: Home safety assessment SW: Psychosocial assessment of dyad
1470965|NCT03189459|Behavioral|Aim 3 (caregiver peer mentoring):|Mentor Training - One 5-hour session at NYU (time, presenter)
1470969|NCT03189433|Drug|Ryanodex (dantrolene sodium) for injectable suspension|Ryanodex (dantrolene sodium) for injectable suspension, 250 mg/vial to be reconstituted in 5 mL of sterile water for injection to yield a 50 mg/mL suspension that will be administered as a rapid IV push of 2.5 mg/mL.
1470970|NCT03189420|Procedure|Tumor resection|The tumors will be resected in routine therapeutic surgeries
1470971|NCT03189407|Dietary Supplement|Moringa oleifera tea|
1948459|NCT02324257|Drug|RO6958688|RO6958688 is given as an intravenous (IV) infusion as a single administration in Part I and as QW or Q3W administration (cycle = 7 days in the QW regimen and cycle = 21 days in the Q3W regimen) in Part II of the study.
1470973|NCT03189381|Radiation|Cohort A|Cohort A - WBRT dose = 30 Gy, SIB dose = 42 Gy, # of daily fractions = 10, SIB dose in EQD2 = 49.7 Gy
1470974|NCT03189381|Radiation|Cohort B|Cohort B - WBRT dose = 25 Gy, SIB dose = 40 Gy, # of daily fractions = 8, SIB dose in EQD2 = 50.0 Gy
1470975|NCT03189368|Device|Activation of multi-site pacing capability on CRT devices|"Instead of administering a single LV pulse at the most (electrically) delayed segment of the ventricle, multi-site pacing allows for a more detailed sculpting of the LV activation sequence. Based on the MPP-IDE study results, activation of the antero-lateral wall, or at least its most delayed segments, closely followed by a pulse to the apex and then by a right ventricular one will yield favorable results in terms of hemodynamics and clinical parameters.
Programming features:
Interpolar distance for the first left ventricular pulse >30mm (i.e. non-sequential poles used)
Nearly simultaneous (Δt=5msec) second left ventricular pulse and
Threshold of ≤3.5V@0.5msec"
1470976|NCT03189355|Procedure|Blood sampling|"D1 PTP1B + zonulin +PAXGENE tube +aprotinin tube
D4 zonulin"
1470977|NCT03189355|Procedure|Bioelectrical impedance vector analysis|"D1
D4"
1470978|NCT03189355|Procedure|Muscular echography|"D1
D4"
1470979|NCT03189342|Behavioral|Single task training|The participants in single task training received 30 minutes single task balance and gait exercises, 3 times a week for 4 weeks. The program included static and dynamic balance exercises. Static balance exercises involved body stability (e.g., standing legs open and closed, standing with eyes closed, tandem standing, standing on foam surface and one leg standing, standing while throwing and catching a ball ), forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction (backward, side to side), transfer activities (from 1 chair to another) and sit to stand 5 times
1470980|NCT03189342|Behavioral|dual task training|The participants practiced 30 minutes balance and gait exercises while simultaneously performing cognitive tasks. The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The participants practiced cognitive tasks while simultaneously performing balance and gait exercises. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems
1470981|NCT03189342|Behavioral|exercise-cognitive activity combined training|The participants first practiced 30 min of cognitive activities then performed 30 min of balance and gait exercises after 5 min of resting.The program included static and dynamic balance exercises. Static balance exercises involved body stability, forward and backward weight shifting and keeping standing position while being disturbed by external perturbation. Dynamic balance exercises included tandem walking, walking to different direction, transfer activities and sit to stand 5 times. The cognitive tasks included visual attention, auditory attention, planning, verbal fluency, simple mental math and maze activities. At each week, participants performed different type of activities which were designed to foster the executive functions: (1) Visual and auditory attention, (2) Planning and verbal fluency, (3) Simple math problems (4) Visual and auditory attention, planning, verbal fluency, math problems.
1470982|NCT03189329|Drug|2% lidocaine hydrochloride|Retrobulbar block was performed with 5 ml of 2% lidocaine hydrochloride (AritmalR, Osel, Istanbul, Turkey) in Group L patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
1470983|NCT03189329|Drug|0.5% levobupivacaine|and 5ml of 0.5% levobupivacaine (ChirocaineR, Abbvie, Chicago, USA) in Group LB patients. The block was performed by the same practitioner (fourth year assistant of Ophthalmology Department) using inferotemporal approach as described by Sanderson using 27 gage disposable needles (Atkinson Retrobulbar NeedleR, Asico, USA)
1470984|NCT03189316|Other|peritoneal fluid and blood sample|Peritoneal fluid sample obtained from peritoneal dialysis fluid of patients with chronic renal insufficiency and blood sample or Peritoneal fluid obtained from coelioscopy for exploration of ovarian cysts and blood cell
1580162|NCT02382510|Drug|Tiotropium|
1470987|NCT03189264|Procedure|percutaneous nephrolithotomy for kidney stones|Use of various methods of access to the renal collecting system (pneumatic balloon dilatation vs. traditional technique with coaxial dilators) during percutaneous nephrolithotomy for treatment of kidney stones greater than 2 cm.
1470988|NCT03189251|Other|Dietary intakes|Analysis of association between consumption of high excess free fructose (EFF) beverages (high fructose corn syrup sweetened soft drinks, fruit drinks, apple juice)
1470989|NCT03189238|Biological|Peri-urethral and clitoral injections|Peri-urethral and clitoral injections
1470990|NCT03189225|Other|Capillary And Venous Accuracy|Capillary And Venous Accuracy: LifeScan Products vs Hospital Reference instrument and LifeScan reference instrument (YSI 2300)
1470991|NCT03189212|Behavioral|Usual Care Visit|Routine 6-month follow up appointment at the NYULMC transplant center
1470992|NCT03189212|Behavioral|Telemedicine Visit|TM visit conducted at the patient's dialysis unit as a replacement to usual 6 month routine f/u visit
1470993|NCT03189199|Other|a cohort using Dazhuhongjingtian injection|All patients will be measured and assessed at the time Dazhuhongjingtian Injection is administered to them until they discharge. Patients using Dazhuhongjingtian Injection will be registered on a registration form including disease background, Dazhuhongjingtian Injection's administration, and extraction information from hospital information system. An adverse event or drug adverse reaction form also will be used to describe any doubted symptoms or signs from patients. A judgment will be made by doctors directly and a further analysis will be conducted by researchers to decide those potential side effects of Dazhuhongjingtian Injection.
1470994|NCT03189186|Drug|Pembrolizumab Injection [Keytruda]|Same as arm description
1470995|NCT03189186|Procedure|Cryoablation|Cryoablation uses liquid argon in metal needles to freeze tumors. Tumor cells are ruptured due to the forming ice crystals and die. Cryoablation is standardly used in tumors less then 4cm in diameter.
1470996|NCT03189186|Procedure|Nephrectomy|Nephrectomy is the surgical excision of either the entire kidney or a small portion of the kidney. Nephrectomy is standardly used to treat renal cell cancer.
1470997|NCT03189173|Device|Oral appliance|"An oral appliance (dental mouthpiece) will be used to improve upper airway patency. Patients who do not have their own custom dental oral appliance (various brands, commonly Herbst) will be provided with a device (BluePro, BlueSom) for the duration of the study.
Patients will also be administered sham (room air) at 4 L/min via nasal cannula."
1470998|NCT03189173|Drug|Oxygen|Supplemental oxygen will be delivered at 4 L/min via nasal cannula to improve ventilatory control stability.
1470999|NCT03189173|Other|Oral appliance plus oxygen|Both treatments will be administered simultaneously.
1471000|NCT03189173|Other|No treatment|Subjects will not wear an oral appliance, and will be administered sham (room air) at 4 L/min via nasal cannula.
1471001|NCT03189160|Biological|PEG-rhGH low dose|PEG-rhGH Injection 0.1 mg/kg/w by subcutaneous injection for 52 weeks.
1471002|NCT03189160|Biological|PEG-rhGH high dose|PEG-rhGH Injection 0.2 mg/kg/w by subcutaneous injection for 52 weeks.
1471003|NCT03189160|Other|Non-treatment control group|
1471004|NCT03189147|Procedure|Biceps Tenodesis|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
1471005|NCT03189147|Procedure|Debridement|Surgical procedure that is usually performed for the treatment of labral lesions in patients undergoing arthroscopic rotator cuff repair
1471006|NCT03189134|Drug|Fluorescite|Dilute fluorescite will be applied to cardiac tissue prior to imaging
1471007|NCT03189134|Device|Cellvizio 100 Series System with Confocal Miniprobes|Microscopy system will image cardiac tissue.
1471008|NCT03189095|Behavioral|WOWii (Workout on Wheels Internet Intervention)|"Participants will self-monitor their exercise on the WOWii website, which has a page to record the type, duration, and intensity of daily exercise bouts.
Two devices will track participants' exercise, a Polar heart rate monitor (RS300X, Polar®), which will provide data on the day, duration, and intensity (average and maximum) of aerobic activity and an ActiGraph accelerometer (model GT3X), which detects movement in three planes to indicate frequency and intensity of movement throughout the day. Experimental participants will be provided a Polar heart rate monitor to wear during each exercise bout for the entire length of the 6-month study, and exercise data will be collected weekly.
Physiological outcomes on fitness will be assessed by measuring weight and aerobic capacity in a Cardiopulmonary Lab by a doctoral-trained physical therapist.
Participants will complete surveys to report on their exercise self-efficacy and perceived barriers."
1471009|NCT03189082|Procedure|Microbotox|Microbotox is the injection of multiple microdroplets of diluted botulinum toxin into the dermis of the lower face
1471010|NCT03189069|Drug|Apixaban|Treatment for NVAF patients
1471011|NCT03189069|Drug|Dabigatran|Treatment for NVAF patients
1471012|NCT03189069|Drug|Rivaroxaban|Treatment for NVAF patients
1471013|NCT03189069|Drug|Warfarin|Treatment for NVAF patients
1471014|NCT03189056|Diagnostic Test|Chagas serology|IFI + ELISA method if no biological confirmation of chagas disease is in our possession
1471015|NCT03189056|Biological|Creatinina|Plasmatic single mesure after consultation 1, to evaluate renal function
1471016|NCT03189056|Procedure|Urodynamic exploration|With a new equipement SmartDyn Albynmedical imported from Spain for the study Single use sterile equipment shipped Control of urine sterility before procedure Informed consent signed If acquired urinary infection after procedure, patient treated free of charge and clinical evolution controlled
1471017|NCT03189043|Device|Antimicrobial Surface|Antimicrobial Surface
1471018|NCT03189030|Biological|pLADD|via IV infusion
1471019|NCT03189017|Drug|ICP-022|The drug product is a white, round, uncoated tablet.
1471020|NCT03189017|Drug|Placebos|The placebo is a white, round, uncoated tablet.
1471021|NCT03189004|Behavioral|Impact of Mobile Phone Technology to Improve Health Nutrition and Population (HNP) Service Utilization in Rural Bangladesh|"Identification and registration of pregnant women and services for them
Birth notification
Childhood vaccination services under EPI
Newly married couple identification
e-Referral.
e-monitoring"
1948460|NCT02324257|Drug|Obinutuzumab|Obinutuzumab is given as an IV infusion at a dose level of 2000 mg on Day -13 or 1000 mg on Days -13 and -12 prior to the treatment start with RO6958688 on Cycle 1 Day 1.
1471026|NCT03188952|Diagnostic Test|International Caries Classification and Management System|Caries assessment and management system
1471027|NCT03188939|Procedure|single injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine , In single-injection technique using in plane method and lateral to medial direction, local anesthetic is injected at the point where the subclavian artery meets the first rib.
1471028|NCT03188939|Procedure|intracluster injection supraclavicular brachial pieuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , the local anesthetic(30 ml bupivacaine) is injected inside main and satellite neural cluster.( Circumferential administration of local anesthetic rather than creating a single point injection )
1471029|NCT03188939|Procedure|double injection supraclavicular brachial pleuxus block|the investigator will prepare 20 gauge 10cm block needle and portable ultrasound machine (Siemens ACUSON X300 Ultrasound System with linear probe 8-14 MHZ).using in plane method and lateral to medial direction , half the volume of local anesthetic(15 ml bupivacaine) is injected at intersection of first rib and subclavian artery and another half(15 ml bupivacaine) is injected supero- lateral to subclavian artery to assure spread of the local anesthetic solution in all planes containing brachial plexus
1471030|NCT03188926|Procedure|intramedullary fixation or endoprosthetic reconstruction|Surgical treatment of impending or pathologic fracture in the extremities
1471031|NCT03188913|Diagnostic Test|Coagulation tests|The following plasma values will be measured: prothrombin time, activated partial thromboplastin time, thrombin time, functional fibrinogen, lactate, base excess, fibrin monomers, Factor XIII, Factor XII, Factor VIII, Fact von Willebrand, Plasmin, Plasminogen, Alpha-2-antiplasmin, antithrombin, protein C, Heparan sulfate, synecan 1. Surveys on the state of healing and moisture titration will be performed using Tewamether
1471032|NCT03188900|Biological|A collection of maternal plasma and serum|A collection of maternal plasma and serum from patients with preeclampsia (PE) and normal pregnancy (NP)
1471033|NCT03188887|Drug|corticotherapy|3 IV pulses steroids followed by oral steroids for 4 months
1471034|NCT03188887|Drug|Renin Angiotensin system (RAS) blockade|treatment with Renin angiotensin system (RAS) blockade
1471035|NCT03188848|Drug|BPI-3016|Single-dose subcutaneous injection of BPI-3016
1471036|NCT03188848|Drug|Placebo|Single-dose subcutaneous injection of placebo to match BPI-3016
1471037|NCT03188835|Dietary Supplement|Diet|A 2 weeks of hypercaloric diet supplemented with fructose or glucose
1471038|NCT03188835|Other|cold exposure|Acute cold exposure using a water-conditioned cooling suit will be applied from time 0 to 180 min. At the same time mean skin temperature will be measured by 11 thermocouples.
1471039|NCT03188835|Radiation|18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed, followed by 30 min dynamic and 50 min wholebody PET/CT scanning.
1471040|NCT03188835|Radiation|11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
1471041|NCT03188835|Radiation|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of [3-3H]-glucose
1471042|NCT03188835|Other|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate
1471043|NCT03188835|Other|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
1471044|NCT03188835|Device|MRI/MRS|Visceral and cervico-thoracic MRI and MRS acquisition.
1471045|NCT03188835|Device|Electromyogram (EMG)|Skeletal muscle activity and shivering intensity will be measured by electromyography using surface electrodes
1471046|NCT03188835|Device|DXA|Lean mass will be determined by dual-energy X-ray absorptiometry
1471047|NCT03188835|Device|Indirect calorimetry|VCO2 will be measured by indirect calorimetry between 15 and 20 min every hour until time 180.
1471050|NCT03188809|Procedure|Adductor Canal Block|Adductor channel is roughly triangular in cross section and is bounded by three muscles: quadriceps anterolaterally (specifically vastusmedialis), sartorius medially and adductor magnus posteriorly. Within this canal is the femoral artery, femoral vein, the posterior branch of the obturator nerve, and branches of the femoral nerve; specifically the saphenous nerve and nerve to vastus medialis. When the femoral artery is shown by ultrasonography 21 gauge, 50 mm needle in-plane technique and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.and the catheter will be inserted with the peripheral nerve stimulator lateral to the femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
1471051|NCT03188809|Procedure|femoral nerve block|The probe is placed just below the inguinal crease , when the femoral artery is shown by ultrasonography, the femoral nerve stays in the lateral direction and 21 gauge, 50 mm needle will be advanced from the anterior to the posteriomedial with an in-plane technique and the catheter will be inserted by the peripheral nerve stimulator in the lateral femoral artery. Bupivacaine 0.25% will be applied to the catheter at 6 hours, when the first dose of catheter is inserted.
1471054|NCT03188783|Drug|GDC-0853|GDC-0853 tablets orally, either a single dose or twice-daily.
1471055|NCT03188783|Drug|Placebo|GDC-0853 matching placebo tablets orally, either a single dose or twice-daily.
1471056|NCT03188757|Other|hyperglycaemic clamp|2h hyperglyceamic clamp
1471057|NCT03188744|Other|Pelvic floor muscle training|"PFMT protocol will have sessions held once a week lasting 45 minutes each over the 10-week period and supervised by a single physiotherapist. In addition to the supervised sessions, the women will be guided on the practice of home exercises, receiving an exercise guidance booklet. The exercises will be performed on a daily basis and the dates in which the exercises were performed in the worksheet will be recorded for evaluation of the program's adherence.
PFMT includes 10 sustained contractions for 6 seconds followed by 6 quick contractions in the dorsal decubitus, lateral decubitus, sitting, and standing positions."
1471058|NCT03188718|Device|WatchPAT Intervention|Wearing the device during their clinically indicated sleep study. This is a validation study to the gold-standard polysomnogram.
1471061|NCT03188692|Biological|DPT-IPV-Hib (Combined Vaccine)|0.5mL, intramuscular injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
1471062|NCT03188679|Device|amniocentesis|mRNA sequencing on amniotic fluid samples of fetuses after maternal seroconversion for CMV
1471063|NCT03188666|Drug|REGN2477|Pharmaceutical form: Powder for solution for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment periods 1 and 2.
1471064|NCT03188666|Drug|Matching placebo|Pharmaceutical form: Powder for solution for injection/infusion; Route of administration: Intravenous (IV); Administered during treatment period 1 only.
1471072|NCT03188640|Procedure|Laparoscopic gastric-bypass surgery|Female participants with BMI >30, between age 18-50, will be operated with laparoscopic gastric bypass surgery by an experienced gastric bypass surgeon.
1471073|NCT03188627|Biological|Bronchial basal cells|Transplantation of autologous bronchial basal cells
1471074|NCT03188614|Drug|Fluid resuscitation|The placebo group is resuscitated with normal saline, the experimental group is resuscitated with balanced fluid.
1471075|NCT03188575|Behavioral|SilverCloud Internet-delivered Cognitive Behavioural Therapy|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
1471076|NCT03188575|Other|Waiting List|8 week waiting list period.
1471077|NCT03188562|Other|PET/CT|Positron Emission Tomography (PET/CT)
1471078|NCT03188562|Procedure|EBUS-TBNA, EUS-NA|Transbronchial and Transesophageal endoscopic ultrasound-guided needle aspiration ( EBUS-TBNA, EUS-NA) Transbronchial ultrasound examination allow to access upper and lower right paratracheal nodes (2R, 4R), subcarinal (7), hilar and interlobar (10, 11), transesophageal ultrasound examination allow to visualize upper and lower left paratracheal nodes (2L, 4L), subaortic (5), para-aortic (6), subcarinal (7), paraesophageal (8), pulmonary ligament (9) nodes. Furthermore EUS allow to localize mediastinal structures including heart, big vessels, main bronchi, vertebral column and diaphragm and can be used in for visualization of tumor infiltration of surrounding structures especially aorta, pulmonary artery or left atrium.
1471079|NCT03188562|Procedure|TEMLA|Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) Transcervical Extended Mediastinal Lymphadenectomy (TEMLA) is minimally invasive surgical technique enabling extensive bilateral lymphadenectomy. The procedure starts from 5-8 cm collar incision in the neck, sternum is elevated with a hook connected to a Rochard frame, both laryngeal recurrent nerves and vagus nerves are visualized. During TEMLA all mediastinal nodal stations except for the pulmonary ligament nodes (9) are removed.
1471083|NCT03188536|Other|No Intervention|No Intervention
1471086|NCT03188510|Biological|LY3074828|Administered SC
1471087|NCT03188497|Drug|Lobaplatin|Lobaplatin for Injection
1471088|NCT03188497|Device|linear accelerator|Medical linear accelerator
1471089|NCT03188471|Drug|GnRH antagonist|GnRH antagonist 0.25mg daily from the day of oocyte retrieval for seven days for high risk of ovarian hyper stimulation syndrome patients
1471090|NCT03188471|Drug|aspirin|aspirin (100 mg daily, plus saline as placebo of GnRH antagonist ) for seven days
1471092|NCT03188445|Drug|Iron Isomaltoside 1000|Administered iv
1471093|NCT03188445|Drug|ferrous fumarate with ascorbic acid|Oral administration
1471100|NCT03188380|Diagnostic Test|Plain abdominal radiography|After meeting enrolment criteria each patient will have an AR performed. One image will be obtained with a vertical beam and a horizontal beam, with the patient supine.
1471101|NCT03188380|Diagnostic Test|Abdominal ultrasound|If the AR is inconclusive or no abnormalities typical for NEC are recorded, an AUS will be ordered.
1471102|NCT03188367|Diagnostic Test|Gluten or placebo capsules|Administration of gluten or placebo capsules
1471103|NCT03188354|Diagnostic Test|18F-FDG|PET scan with 18F-FDG as a tracer, taken both for primary staging and therapy assessment.
1471104|NCT03188354|Diagnostic Test|18F-fluciclovine|PET scan with 18F-fluciclovine as a tracer, taken both for primary staging and response to therapy assessment.
1471105|NCT03188354|Diagnostic Test|standard MRI|clinical routine MRI examination, both for primary staging and response to therapy assessment.
1471106|NCT03188341|Other|vascular surgery procedure|"an elective open vascular surgery procedure
ECG Holter recording during the procedure and 24 hours after operation (continuous electrocardiographic tracing (digital Holter ECG monitor)"
1471107|NCT03188328|Drug|AvidinOX|"AvidinOX vial containing 22.5 mg AvidinOX
+ vials containing 10 ml of water for injection (WFI) for the reconstitution in a clear solution with an AvidinOX concentration of 3 mg/ml. One Intralesion administration of a volume of reconstituted AvidinOX equal to about 15 % of the estimated lesion volume"
1471108|NCT03188328|Drug|177Lu-ST2210|177Lu-ST2210 dose starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
1471109|NCT03188328|Drug|177Lu-ST2210|Second dose of 177Lu-ST2210 dose (14 days after the first dose) starting at 7.5 Gigabequerel (GBq) ±10%with escalation steps of 2.5 GBq up to 15 GBq ±10%, approximately 1 mg ST2210
1471110|NCT03188315|Genetic|HPV oncogenes|PCR and oncogenes detection
1471111|NCT03188302|Other|Collection of stool samples|The subjects collect stool samples to be used for validation of a new direct measurement of stool consistency. Every stool sample produced during 2 collection periods of approximately 60 hours each have to be collected using the Commode Specimen Collection System (Medline Industries, Inc.). Each collection period starts preferably in the evening (20h00) and ends 3 days later in the morning (08h00). The collected samples must be stored at subject's home in a refrigerator provided by the sponsor until handover to the site staff.
1471112|NCT03188289|Drug|Placebo gel|Placebo is the control group treated with a placebo gel.
1471113|NCT03188289|Drug|Clorhexidine gel|Clorhexidine will be compare with placebo, clorhexidine-chitosán and hyaluronic acid bioadhesive gels
1471114|NCT03188289|Drug|Clorhexidine-Chitosan gel|Clorhexidine-chitosan will be compare with placebo, clorhexidine and hyaluronic acid bioadhesive gels.
1471115|NCT03188289|Drug|Hyaluronic Acid gel|Hyaluronic acid will be compare with placebo, clorhexidine, clorhexidine-chitosan bioadhesive gels
1471116|NCT03188276|Drug|Ledipasvir-Sofosbuvir|15 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
1471117|NCT03188276|Drug|Daclatasvir-Sofosbuvir|17 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
1471118|NCT03188263|Other|Bright Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance is 230 μW/m2 and lux is 500 lux.
1471119|NCT03188263|Other|Dim Light|1 hour daily morning light treatment provided through a head-worn device for 4 weeks with the following settings: irradiance in this dimmed is reduced from 230 μW/m2 to 3 μW/m2, and lux reduced from 500 lux to 7 lux
1471120|NCT03188250|Behavioral|Chama cha Mamtoto|Chama cha Mamatoto is a community-based model of peer support group in pregnancy and infancy that combines health education, relationship building and a savings and loans program, led by community health workers
1471121|NCT03188237|Behavioral|AfyaJamii|AfyaJamii is a group antenatal and well-child care program developed in Kenya for use in Kenyan health centers
1471122|NCT03188224|Other|MyTransition app|MyTransition app is designed to support youth moving from pediatric to adult healthcare.
1471123|NCT03188211|Other|E-learning educational program|A number of 10 cases of patients 65 years of age or older with AF, acutely admitted to Internal Medicine or Geriatric wards for any medical condition, will be edited into the Dr. Sim system. Diagnostic and therapeutic choices for ordinary and/or complex medical situations will be taken through the development of the simulated scenario.
1471124|NCT03188211|Other|Control|Any educational program will be delivered to clinicians assigned to control arm
1471125|NCT03188198|Drug|rituximab, etoposide, cyclophosphamide, doxorubicin, vincristine,prednisone, filgrastim|
1471126|NCT03188185|Drug|ALKS 5461|Samidorphan + buprenorphine, administered sublingually
1471127|NCT03188185|Drug|ALKS 5461 Placebo|Placebo tablet, administered sublingually
1471128|NCT03188172|Drug|Cyclophosphamide|Chemotherapy
1471129|NCT03188172|Drug|Bortezomib|Chemotherapy
1471130|NCT03188172|Drug|Lenalidomide|Chemotherapy
1471131|NCT03188172|Drug|Daratumumab|Chemotherapy
1471132|NCT03188172|Drug|Dexamethasone|Chemotherapy
1471133|NCT03188172|Drug|Melphalan|Chemotherapy
1471134|NCT03188172|Drug|Filgrastim|Haematopoietic agent for the stem cell harvest
1471135|NCT03188159|Drug|Vinorelbine|Vinorelbine 25 mg/m2 intravenously on day-1 and day-8 of a 3 week cycle to commence following confirmation of eligibility into the study for a maximum of 12 months, until disease progression, intolerable toxicity or withdrawal of patient consent (whichever event occurs first).
1471136|NCT03188146|Drug|Ursodeoxycholic Acid|Standard care of PBC patients
1948461|NCT02320435|Drug|Pertuzumab|Pertuzumab single agent or in combination with other anti-cancer therapies, at the same dose and schedule at which it was given at the end of the Parent study
1471139|NCT03188107|Other|Video based assessment|All the infants included in this study will be assessed with Infant Motor Profile based on video recording.
1948462|NCT02316509|Drug|GDC-0927|GDC-0927 will be administered as per schedule specified in the respective arm.
1471142|NCT03188068|Drug|Sirolimus|Oral administration
1471143|NCT03188068|Drug|Prednisolone|Oral administered with sirolimus
1471301|NCT03186820|Other|Susceptibility Weighted Imaging as 3D SWAN sequence|Susceptibility Weighted Imaging as 3D SWAN sequence
1471148|NCT03188016|Behavioral|Intensive Interaction with Music|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist. The music in the intervention is live music improvised by a (UK) registered music therapist present in the room with treatment subject and support worker, who watches but does not participate socially in their interactions, and who develops musical input to encourage and enhance those interactions.
1471149|NCT03188016|Behavioral|Standard Intensive Interaction|Intensive Interaction is a form of non-verbal communicative behaviour performed by a support worker to encourage and develop spontaneous communicative behaviour by the treatment subject, for which support workers are prepared by a speech and language therapist.
1471152|NCT03187990|Drug|[68Ga]PSMA-11|PET/MRI with [68Ga]PSMA will be compared to mpMRI for biopsy guidance.
1471153|NCT03187977|Behavioral|Cognitive training|Cogmed is a computer-based cognitive training program that consists of rotating exercises that train attention and working memory. The exercises are presented in a child-friendly, game-like format. The program is completed at home for 15-30 minutes each weekday for 5-9 weeks.
1471154|NCT03187964|Diagnostic Test|PLHIV Point of Care Xpert Ultra|Sputum-based TB diagnostic test that takes 80 min to run. Test performed on the same day as the patient visit.
1471155|NCT03187964|Diagnostic Test|PLHIV Point of Care Xpert VL|Blood-based HIV-1 VL diagnostic and monitoring test that takes 60 min to run. Test performed on the same day as the patient visit.
1471156|NCT03187951|Behavioral|Questionnaires|Participants complete 4 questionnaires about physical abilities, motivation, and quality of life They should take about 25 minutes total to complete.
1471157|NCT03187951|Behavioral|Nutritional Questionnaire and Nutritional Counseling|Participants complete a nutritional questionnaire and receive nutritional counseling. It should take about 5 minutes to complete. Participants receive educational materials and personalized counseling based on participant's answers.
1471158|NCT03187951|Other|Booklet|Participants receive a booklet that contains a stretching guide with full-body stretches and safety.
1471159|NCT03187951|Behavioral|Aerobic Exercise and Strength Training Exercises|Participants complete up to 30 minutes of moderate-intensity aerobic exercise (such as brisk walking, stationary cycling, and/or elliptical or stair stepping machines) for at least 5 days each week. Participants complete strength training exercises at least 2 times per week.
1471160|NCT03187951|Behavioral|Phone Calls|Participants contacted by phone by member of study staff one (1) time each week for the first 4 weeks, and then every 2 weeks after that for behavioral skills training and to see how participant is doing. These calls should last about 15 minutes.
1471161|NCT03187951|Behavioral|Physical Assessments|After completion of chemotherapy and/or radiation, 3-6 weeks after surgery, and then 3-7 months after surgery: Participant's hand grip strength measured using a hand-held machine. Participants arm strength measured using an arm curl test. Participants asked to rise from a chair without using their arms to push off. Participants complete a 6-minute walk test to see how far participant can walk in 6 minutes.
1471162|NCT03187938|Diagnostic Test|Testing of Alkaline Phosphatase Levels|Testing of alkaline phosphatase levels at the time of the 24w0d to 28w6d week labs.
1471164|NCT03187912|Drug|Riboflavin|Riboflavin with 20% Dextran or HPMC will be admininstered every 2 minutes for overall 30 minuts (Dextran) or 10 minutes (HPMC), respectively
1471165|NCT03187899|Drug|Ropivacaine|0.5% of Ropivacaine will be used patients in both groups. Ropivacaine is very common in the investigator's practice of regional anesthesia. The investigator has experienced minimal adverse effects with 0.5% Ropivacaine used in volume suggested in our study.
1471166|NCT03187899|Drug|Normal saline|5-10cc of Normal Saline will be given to patients receiving a traditional interscalene block and a sham superficial plexus block.
1471368|NCT03186326|Drug|FOLFIRI Protocol|"A course of treatment every 14 days
Irinotecan: 180 mg/m² IV over 1H30 Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
1471669|NCT03184272|Procedure|baseline in narcosis 2|measurement in supine position
1948474|NCT02306746|Dietary Supplement|TARGET protocol EN 1.5 kcal/mL|Enteral feed 1.5 kcal/mL
1471167|NCT03187873|Behavioral|Chama cha MamaToto|Chamas are a community-led model of peer support for women in pregnancy and infancy. Chamas are highly gendered institutions that women have relied on for survival to pool resources. Using this existing cultural script, chamas have been tailored to the needs of pregnant women. Central to the approach is the integration of health, social and financial literacy education with a savings/loans program. Chamas are designed to improve MNCH by generating positive peer support for women to advocate for themselves and account for the care they receive.
1471168|NCT03187860|Procedure|Bronchial Biopsy|Bronchial biopsies will be performed on all subjects.
1471169|NCT03187860|Other|ALI culture|Air-liquid-interface cell cultures will be derived from bronchial biopsy specimens. We are expecting several replicate cell lines from each biopsy specimen.
1471170|NCT03187847|Device|Actigraph|"The primary outcomes are measured by the Actigraph GT3X (physical activity) and FSMC (fatigue scale for motor and cognitive functions questionnaire) at three different points in time (Actigraph is worn for three weeks in total).
The secondary outcomes are quality of life, measured by the Hamburg Quality of Life Questionnaire (HAQUAMS), emotional status, measured by the hospital anxiety and depression scale (HADS) and heart rate variability (HRV). Increasing exhaustion reduces HRV in standing or lying. If the heart rate does not adjust to the change of ones position anymore, which is a sign of insufficient regeneration, this indicates at a higher level of exhaustion."
1471171|NCT03187834|Drug|Azithromycin|Children in this arm will receive Azithromycin once a day.
1471172|NCT03187834|Drug|Amoxicillin|Children in this arm will receive Amoxicillin twice a day.
1471173|NCT03187834|Drug|Cotrimoxazole|Children in this arm will receive co-trimoxazole once a day.
1471174|NCT03187834|Drug|Placebo|Children in this arm will receive Placebo once a day.
1471175|NCT03187821|Procedure|Laser peripheral iridotomy|location of laser peripheral iridotomy
1471176|NCT03187808|Other|Single thoracic manipulation|The subjects, who were randomly allocated to single thoracic manipulation group, will receive the single thoracic manipulation interventions directly to both sides of zygapophyseal joints of T6-T7. Each subject will be asked to lie on prone position on an experimental table. After that, the researcher will mark on both sides of zygapophyseal joints of T6-T7. Then, the subject will be instructed to take a deep inhalation and exhalation. During the exhalation, the therapist will perform the single thoracic manipulation (screw thrust technique) at zygapophyseal joints of T6-T7. If the audio pop is not heard during the first attempt, the therapist will ask the subject to reposition and repeat the technique. The procedure will be performed for maximum of 2 attempts and within 2 minutes.
1471177|NCT03187808|Other|Special massage technique (RT technique)|The special massage technique or RT technique is a treatment that was developed by Puntumetakul and colleagues in 2013 (copyright registration number 314783). The subjects in this group will be asked to lie on side lying position with 90 degrees of hip flexion and 90 degrees of knee flexion. The researcher will perform the RT technique by press their thumb on the treatment lines beside the posterior vertebral line from level of inferior angle of scapula to the lowest rib for 5 seconds per point and 3 sets per treatment line (Figure 8). Total time of this procedure is approximately 2 minutes.
1471178|NCT03187795|Drug|Oxybutynin Chloride IR|Oxybutynin chloride immediate release (IR) 5 mg three times daily for 6 weeks
1471179|NCT03187795|Drug|Mirabegron|Mirabegron 25 mg tablet once daily for 2 weeks, followed by mirabegron 50 mg once daily for 4 weeks (Note: Placebo twice daily will be included with mirabegron once daily to match the three-time daily dosing of oxybutynin IR in the other intervention).
1471180|NCT03187782|Diagnostic Test|ANSWatch|
1471183|NCT03187756|Drug|Cyclophosphamide|Shortened duration immunosuppression following nonmyeloablative peripheral blood stem cell transplant with high dose post transplantation cyclophosphamide in malignancies to engraft.
1471184|NCT03187743|Other|Blood samples|"Blood samples at 3 visits :
V0 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis only if previous treatment with low-dose prednisone
V1 : - 5 mL in heparin tube / sample (2 to 5 samples) Pharmacokinetics + Pharmacogenetics + Gene Expression Analysis
V2 : - 5 mL in heparin tube / Pharmacokinetics + Gene Expression Analysis and - 5 mL in EDTA tube / DNA bank"
1471185|NCT03187730|Behavioral|Integrated Smoking Cessation and Financial Counseling|Participants in the intervention group will receive up to nine counseling sessions that integrate two evidence-based counseling approaches: financial management counseling and smoking cessation counseling. Participants will also be eligible to receive a free four-week supply of NRT. Participants will be surveyed at baseline, 2- months, 6-months and 12-months to assess outcomes and treatment satisfaction.
1471186|NCT03187730|Behavioral|Waitlist Integrated Smoking Cessation and Financial Counseling|Control participants in the waitlist control group will receive usual care for the first 6 months of the study, while the Intervention Arm receives integrated counseling. The waitlist control group will receive the same counseling program as the Intervention group 6 months after enrollment (up to nine counseling sessions and four weeks of NRT). Participants will be surveyed at baseline, 2-months, 6-months and 12-months to assess outcomes and treatment satisfaction.
1471187|NCT03187730|Drug|Nicotine Replacement Therapy (NRT)|Participants in both arms will be eligible to receive a free four-week supply of NRT.
1471188|NCT03187704|Other|HEPA air filtration|Air filters were placed in participant homes
1471189|NCT03187691|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
1471190|NCT03187678|Drug|i.v. selexipag|Selexipag for intravenous administration, twice daily as an infusion over 87 min. The dose is individualized for each subject to correspond to his/her current oral dose of Uptravi®.
1471191|NCT03187678|Drug|oral selexipag|Selexipag tablets for oral administration administered twice daily, according to the local prescribing information
1471192|NCT03187665|Device|Radical 7|The Radical 7 is the traditional wall-connected pulse oximeter currently used at Children's Hospital of Wisconsin (CHW) which requires a 12 foot cable connecting the patient to a wall unit. While being continuously monitored with the Radical 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
1471377|NCT03186313|Drug|Sofosbuvir + Daclatasvir|Daily dose Sofosbuvir 400 mg & Daclatasvir 60 mg for 12 weeks
1471193|NCT03187665|Device|Radius 7|The Radius 7 is a newer, partially wireless pulse oximeter which eliminates the cable connecting the patient to a wall unit by instead connecting to a small device worn on the patient's arm or leg. The small device then sends the continuous pulse oximeter data wirelessly to the central monitoring station. While being continuously monitored with the Radius 7 pulse oximeter, subjects will be asked to complete age appropriate activities. The pulse oximetry data will be analyzed for instances of alarm state corresponding to loss of signal integrity as defined by complete inability to pick up the subject signal or a change in the pulse oximetry saturation value by 4%.
1471194|NCT03187652|Diagnostic Test|CT Perfusion Study|Brain and cardiac CT perfusion scan
1471195|NCT03187652|Diagnostic Test|Echocardiogram|STI Echocardiography
1471198|NCT03187626|Drug|botulinum toxin A|Ultrasound-guided injection of 50 Allergan Unities of botulinum toxin A (Botox®, Allergan) resuspended in 1 ml of saline in the trapeziometacarpal joint and custom-made neoprene splint to be worn for 48 hours after intra-articular injection then nightly
1471199|NCT03187626|Drug|saline|Ultrasound-guided injection of 1 ml of saline in the trapeziometacarpal joint and custom-made neoprene splint to be worn for 48 hours after intra-articular injection then nightly
1471200|NCT03187600|Procedure|Mucosa/submucosa Pharyngeal Flap|Included in study arm description
1471201|NCT03187600|Procedure|Standard of Care Pharyngeal Flap|Included in study arm description
1471202|NCT03187587|Device|imILT|The imILT treatment arm recieves imILT treatment and no simultaneous chemotherapy.
1471203|NCT03187587|Drug|Standard chemotherapy treatment|The standard chemotherapy treamtment arm recieves only chemotherapy.
1471204|NCT03187574|Device|Elevate Ant™|Surgery with Elevate Ant™
1471205|NCT03187574|Device|Perigee™|Surgery with Perigee™
1471206|NCT03187561|Behavioral|Infant sleep-adapted coparenting intervention|The Family Foundations intervention, as originally formulated, and a sleep-adapted Family Foundations intervention, will be implemented to participants in arm 1 and arm 2, respectively.
1471207|NCT03187548|Drug|Casein Phosphopeptide-Amorphous Calcium Phosphate Dental Paste|Application of CPP-ACP on one premolar once every 2 weeks for 3 months.
1471208|NCT03187535|Device|TEAS via ES-130|Transcutaneous Electrical Acupoint Stimulation will be administered delivered by the ES-130 device for 20 minutes at the time ondansetron is given (typically 30 minutes before the end of surgery). Subjects randomized to this intervention will have the TEAS device connected to the previously placed ECG patches to deliver the stimulus.
1471209|NCT03187535|Other|No TEAS|No Transcutaneous Electrical Acupoint Stimulation will be delivered to the subjects randomized to this group; ECG patches will be placed at the identified acupoints, however, no electrical stimulus will be delivered.
1471210|NCT03187522|Device|TREO Stent-Graft System|The TREO® Stent-Graft is designed for use in the management of patients with AAAs and is composed of self-expanding nitinol stents sutured to polyester vascular graft fabric.
1471211|NCT03187509|Drug|Torsemide|These subjects who are randomized to a weight-based torsemide regimen will be instructed via phone encounters three times per week to take an individualized dose of torsemide based on their current weight and symptoms. These subjects will have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
1471212|NCT03187509|Other|Standard Outpatient Heart Failure Management|Those subjects randomized to standard outpatient management group will be prescribed a daily fixed dose of a loop diuretic upon discharge from the hospital. These subjects will have a follow-up appointment within one week of discharge where all medications including loop diuretic type, dose and frequency will be managed at the discretion of the subject's physician. These subjects will also have a follow-up study appointment at week 5 for a final weight and blood work to assess kidney function, electrolytes and brain-natriuretic peptide levels.
1471213|NCT03187496|Drug|Midazolam|Each subject will receive midazolam on Days 1 and 12.
1471214|NCT03187496|Drug|Caffeine|Each subject will receive caffeine on Days 1 and 12.
1471215|NCT03187496|Drug|Rosuvastatin|Each subject will receive rosuvastatin on Days 2 and 13.
1471216|NCT03187496|Drug|EDP-305|Each subject will receive EDP-305 on Days 5 through 15.
1471217|NCT03187483|Procedure|orthodontic treatment|orthodontic treatment in maxillary crowding
1471218|NCT03187470|Device|Different programming of a CRT defibrillator|Different programming of a CRT defibrillator using pacing modalities of a quadripolar left ventricular lead
1471219|NCT03187457|Other|Metronidazole|Women with Bacterial Vaginosis treated with Metronidazole for 5 days
1471220|NCT03187457|Other|Control: no treatment|Healthy women without Bacterial Vaginosis
1471221|NCT03187444|Procedure|Examinations|Several examinations are realized on each patients, in addition to the usual visit and after verification of the criteria of inclusion and signature of consent.
1471222|NCT03187431|Biological|autologous bone marrow mesenchymal stem cells|intravenous infusion
1471369|NCT03186326|Drug|Avelumab|"A course of treatment every 14 days. Premedication obligatory with antihistamines and paracetamol (example: 25-50 mg diphenhydramine and 500-650 mg paracetamol) IV, approximately 30 to 60 minutes before each dose of avelumab.
Then:
Avelumab: 10 mg/kg IV in 1 hour diluted with 0.9% saline solution; alternatively a 0.45% saline solution can be used if needed"
1471223|NCT03187418|Device|MicroPulse® P3 Glaucoma Device (MP3)|"Laser settings will be programmed as follows: power—2000mW-2500mW (average 2000mW) of 810nm infrared diode laser set on micropulse delivery mode; micropulse on time—0.5ms; micropulse off time—1.1ms; and duty cycle (proportion of each cycle during which the laser is on)—31.33 %.
The laser probe will be applied in a continuous sliding or painting motion from 9:30 to 2:30 and from 3:30 to 8:30. The probe will be applied perpendicular to the limbus with the edge directly on the limbus at all times (fiberoptic tip at 3 mm posterior to the limbus).
The laser will be delivered over 360° for 160-320s. Treatment duration will be adjusted based on iris color and glaucoma severity (mild glaucoma: 160s, moderate glaucoma: 240s, advanced glaucoma: 240-320s)."
1471224|NCT03187405|Drug|EVD + IVF with Alteplase|Intraventricular fibrinolysis: Injection through the EVD of 1mg in 1 mL of Alteplase every eight hours during 3 days (9 doses).
1471225|NCT03187392|Drug|Lidocaine Injectable Product|3 cm of Lidocaine- will be injected subcutaneous for 5 minutes before insertion of subcutaneous birth control implant
1471226|NCT03187392|Drug|Lidocaine Topical Cream [LMX]|3 mg of Lidocaine- will be applied to skin for 5 minutes before insertion of subcutaneous birth control implant
1471227|NCT03187379|Drug|Exparel|Exparel liposomal bupivacaine - 20cc Exparel® + 60cc Bupivicaine
1471228|NCT03187379|Drug|Bupivacaine|60cc Bupivacaine
1471229|NCT03187366|Other|Bottom-up intervention|Some interventions are bottom-up, where we manipulate the resources of snails and some are top-down, where we manipulate the predators of snails.
1471230|NCT03187353|Drug|Lisdexamfetamine|Stimulant medications are used to reduce interruptive behavior, fidgeting, and other hyperactive symptoms, as well as help a person finish tasks and improve his or her relationships for adults who have ADHD. Please note that the FDA has not approved the use of Vyvanse® for the treatment of memory and concentration difficulties related to medically induced menopause.
1471231|NCT03187353|Drug|Placebo oral capsule|The placebo capsule will be filled with microcellulose.
1948475|NCT02306746|Dietary Supplement|TARGET protocol EN 1.0 kcal/mL|Enteral feed 1.0 kcal/mL
1471234|NCT03187314|Drug|Radiation|RT to 60 Gy, 5 x per week，for 6 weeks. Radiation begun the day after the first dose of SHR-1210
1471235|NCT03187314|Drug|SHR-1210|SHR-1210 (200mg fixed dose every 2 weeks for 5 cycles) will be administered as an intravenous infusion over 60 minutes.
1948478|NCT02300090|Device|Test Group|Patients receive a mobile phone with the Me & My COPD app installed. Patients also receive a bluetooth inhaler device that is fitted to their usual reliever inhaler.
1948479|NCT02300090|Other|Control Group|Patients in the control group receive only standard care; there are no interventions within this group of patients
1471240|NCT03187275|Other|Swedish Massage Therapy|"The therapist uses non-aromatic massage oil to facilitate making long, smooth strokes over the body. Swedish massage is done with the subject covered by a sheet, a technique called draping. One part of the body is uncovered, massaged, and then covered up before moving onto another part of the body. Primary techniques used in the research protocol therapy are: effleurage, petrissage, tapotement. These will be administered according to a very specific, standardized protocol. The total session time will be 45 minutes."
1471241|NCT03187275|Other|Light Touch Intervention|The light-touch research intervention is based on the concept that there will be a noticeable effect with regard to massage when compared to light-touch alone without the massage. The protocol followed will be the same as the massage protocol other than that the therapist will use light-touch only. The total session time will be 45 minutes.
1471242|NCT03187262|Drug|Daratumumab|Daratumumab is a monoclonal human antibody. Daratumumab has shown the ability to slow or stop the growth of cells that have CD38 on the cell surface when tested in laboratories
1471243|NCT03187249|Behavioral|Cognitive Behavioral Therapy|12 weeks cognitive-behavioral lessons, once a week
1471244|NCT03187249|Behavioral|Pulmonary Rehabilitation Therapy|12 weeks pulmonary rehabilitation exercise
1471245|NCT03187249|Behavioral|Combined Therapy|cognitive-behavioral lessons and pulmonary rehabilitation exercise for 12 weeks
1948480|NCT02294903|Procedure|Coiled Bipolar Radiofrequency Ablation|Radiofrequency ablation by use of bipolar electrodes
1471370|NCT03186326|Drug|Panitumumab|Administered at 6 mg/Kg
1471371|NCT03186326|Drug|Cetuximab|Administered at 500 mg/m²
1471372|NCT03186326|Drug|Bevacizumab|Administered at 5 mg/Kg
1471373|NCT03186326|Drug|Aflibercept|Administered at 4 mg/Kg
1471376|NCT03186313|Drug|Dactavira|Single daily dose (1 Tablet) of Dactavira each tablet contains (EPGCG 400 mg , Sofosbuvir 400mg, Daclatasvir 60 mg) for 12 weeks
1948481|NCT02292758|Biological|Bevacizumab|Given IV
1948482|NCT02292758|Biological|Cetuximab|Given IV
1948483|NCT02292758|Drug|Irinotecan|Given IV
1948484|NCT02292758|Other|Laboratory Biomarker Analysis|Correlative studies
1471252|NCT03187171|Other|Allograft Fusion|ACDF is a surgical technique used to treat a variety of cervical spine disorders, such as nerve root or spinal cord compression, cervical spondylosis, and cervical spinal stenosis. The anterior approach to the cervical spine for discectomy and fusion by the insertion of an autologous iliac crest tricortical bone graft was first described by Robinson and Smith in 1955. In 1958, Cloward described a wide anterior cylindrical discectomy performed with a special reamer combined with anterior fusion by the insertion of autologous iliac bone graft of the same shape. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
1471253|NCT03187171|Device|Cohere PEEK Fusion Group|Bagby et al. developed the first interbody fusion cage. Cages of different shapes and materials are used to perform ACDF which, in some cases, could be associated with plate fixation. At Duke University Health Systems, both allografts and Cohere porous PEEK fusion device are used for ACDF.
1471254|NCT03187158|Diagnostic Test|Forced Oscillation Technique|F.O.T. method can be used to assess obstruction in the large and small peripheral airways , Changes in lung volumes will be measured using a digital spirometer . Every participant will be asked to sit straight, seal the mouthpiece completely with their lips, breathe in fully, blow as hard as possible into the mouthpiece, emptying the lungs completely., Whole blood collected on site (20 mL from every participant, for about 23 metabolites) will be separated into cells and serum. A detailed questionnaire assessing respiratory health, demographic data, habits, and environmental exposure has been developed and validated by Chest Research Foundation.
1471255|NCT03187132|Device|Digital Pain Reduction Kit|A three component intervention consisting of: (1) virtual reality, experiences lasting 3-30 minutes used to distract individuals from pain; (2) TENS unit, used to reduce acute localized pain, and (3) remote monitoring and clinical support as necessary.
1471256|NCT03187132|Device|Passive Monitor|An active control biometric wrist-worn sensor (Samsung Gear Fit 2) used for monitoring participants on standard of care.
1471257|NCT03187119|Behavioral|Pictorial Asthma Action Plan|Participants will receive a PAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their PAAP.
1471258|NCT03187119|Behavioral|Written Asthma Action Plan|Participants will receive a WAAP plan, personalized to their asthma treatment. Each participant will take part in a brief education session during which their asthma provider will outline the treatment plan summarized in their WAAP.
1471262|NCT03187093|Drug|Vortioxetine|10-20 mg once daily for 8 weeks
1471263|NCT03187093|Drug|Escitalopram|10-20 mg once daily for 8 weeks
1471264|NCT03187080|Procedure|Paravertebral block procedure using either local anesthetic (0.25% bupivacaine) or sterile saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of 0.25% bupivacaine with 2.5 mcg/mL of epinephrine will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
1471265|NCT03187080|Other|Enhanced recovery after breast surgery (ERABS) strategies|"For comparing ERABS strategies to our current standard of care, we will utilize the following perioperative strategies [Arsalani]:
Standardized written information given preoperatively.
Allow clear liquids for up to 2 hours prior to arrival at the surgery center.
Use paravertebral block to augment postoperative pain control.
Standardized multimodal analgesic regimen
Antiemetics
Easily accessible call-in or walk-in postop care/support
The proposed strategies differ from standard of care in the following ways:
PVB is less commonly used in elective surgery.
Patients do not eat or drink after midnight.
There is no standardized preoperative information packet.
Anesthetic/intraoperative analgesic and antiemetic regimen varies between providers."
1471266|NCT03187080|Procedure|Sham paravertebral block using saline|Paravertebral block (PVB) will be performed in the standard fashion using an out-of-plane ultrasound approach by an anesthesiologist with appropriate training in regional anesthesia. Landmarks on the patient will be identified. The skin will be sterilized. The intended target (paravertebral space) will be located using an ultrasound. A Pajunk UniPlex NanoLine needle will be inserted. A syringe filled with sterile saline (used for hydrodissection) connected to a syringe of sterile saline will be connected to the Pajunk needle and used for injection. The needle will be advanced toward and through the superior costotransverse ligament or internal intercostal membrane. Once through the ligament, the pleura will be seen deflecting anteriorly with the hydrodissection. Negative aspiration will be confirmed, and the local anesthetic will be injected into the paravertebral space.
1471267|NCT03187080|Drug|Paravertebral block using local anesthetic|Use of local anesthetic (0.25% bupivacaine) that is *NOT* an experimental drug but will be used as part of the paravertebral block to provide local anesthetic. This will not be given to those in the sham block groups.
1471268|NCT03187067|Device|Lung ultrasound|Lung ultrasound will be performed on all children to investigate imaging patterns characteristic of pneumonia.
1471269|NCT03187054|Procedure|anterior or posterior colporrhaphy|will be performed in a traditional manner with midline plication of the fibromuscular layer using 2-0 delayed absorbable sutures.
1471298|NCT03186846|Device|multimodal monitoring|LiDCO Rapid, unilateral INVOS and unilateral BIS monitors will be applied. Should there be pre-existing carotid stenosis, INVOS sensor will be applied on the same side. In case of pre-existing cerebral pathology, the INVOS sensor will be applied to the contralateral side. Baseline values of nominal stroke index (SI), cardiac index (CI), BIS, mean arterial pressure (MAP) and regional oxygen saturation (rSO2) will be recorded. Basal rSO2 will be recorded prior to preoxygenation which raises the value. • Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
1471271|NCT03187028|Behavioral|Diet Only|Diet counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet counseling.
1471272|NCT03187028|Behavioral|Diet + Exercise|Diet and exercise counseling will be delivered using visual communication (e.g., Skype). Participants will be provided a computer tablet for the intervention with participants randomized to receive diet and exercise counseling.
1471273|NCT03187015|Drug|Entinostat|HDAC (histone deacetylase inhibitor)
1471274|NCT03187015|Drug|Midazolam|benzodiazepine central nervous system (CNS) depressant
1471279|NCT03186989|Drug|IONIS MAPTRx|IONIS MAPTRx is administered intrathecally at 4 week intervals over the course of a 13 week treatment period for dose levels A, B, C, and D
1471280|NCT03186989|Other|Placebo|A placebo is administered intrathecally at 4 week intervals over the course of 13 weeks
1471281|NCT03186976|Behavioral|Aggressive Risk Factor Control|"1.) Sleep apnea screening, therapy is recommended if apopnea-hypopnea (AHI) index is greater than 15, with a target index of less than 5.
2) Counseling regarding alcohol reduction to 2 drinks/day for men, 1 drink/day for women, no binge drinking (>5 drinks at one setting).
3) Participation in a 12 week structured, home-based exercise program and nutritional counseling. Weight reduction will be emphasized through modification of diet and exercise.
4) An OMRON BP monitor will be supplied to each patient. A target SBP of <140/80 mm/Hg will be targeted.
5) Smoking cessation - through local resources already established at each site 6) Management of diabetes to achieve HgA1c<6.5%"
1471282|NCT03186976|Other|Standard of Care|Recommendations based on current guidelines
1471283|NCT03186963|Procedure|No immobilization|Conventional wrist dressing
1471284|NCT03186963|Procedure|Volar splint|Volar plaster splint
1471285|NCT03186950|Procedure|Restoration with Stainless Steel Crowns|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using Stainless Steel Crowns.
1471286|NCT03186950|Procedure|Restoration using BulkFill CR|After finishing the endodontic treatment with Guedes-Pinto Paste, the restoration of the teeth will be made using BulkFill composite resin
1471287|NCT03186937|Dietary Supplement|hominex-2|Hominex-2 is a methionine-free amino acid modified medical supplement
1471288|NCT03186924|Behavioral|Take a STAND for health|The Take a STAND for health is a newly developed 4-month goal-setting intervention aimed at reducing sedentary behavior
1948485|NCT02292758|Other|Placebo|Given IV
1471290|NCT03186898|Radiation|Proton Therapy (Radiation Therapy)|Undergo proton therapy
1471291|NCT03186898|Radiation|Photon Therapy (Radiation Therapy)|Undergo photon therapy
1471292|NCT03186885|Behavioral|Healthy Frio In-Person Family-focused Intervention|Participants learn about energy balance behaviors, skills to support health behavior change, managing personal wellness, and parenting strategies. Sessions use interactive learning strategies to elicit knowledge and experience of participating families to encourage families to learn from each other. YMCA staff members lead a 50-minute group exercise session after each health education session to help participants meet their commitment of engaging in PA at least 3 times/week.
1471293|NCT03186885|Behavioral|Healthy Frio Remote Technology Family-focused Intervention|Tablet computers will be used as the platform to deliver the health education content for the FI-RT. Each session will present the class content and guide the participants to complete class activities. Videos of health education and class activities (e.g., cooking demonstrations, exercise demonstrations) will be embedded in the lesson. Interactive assessment questions with feedback will be presented throughout the session to check for understanding of the content. Viewing time and responses to the assessment questions will be recorded to evaluate progress and comprehension. Participants will view the health education sessions at home as a family and discuss the content as prompted by lesson instructions.
1471294|NCT03186885|Behavioral|Control|Participants receive standard of care
1471295|NCT03186872|Behavioral|Digital behavioral program app|mobile app utilizing cognitive behavioral techniques to help alleviate anxiety
1471296|NCT03186859|Procedure|Roux-en-Y Gastric Bypass (RYGB) surgery|RYGB operation using surgeons' standard technique
1471297|NCT03186859|Procedure|Sleeve Gastrectomy (SG) surgery|SG surgery using surgeons' standard technique
1471299|NCT03186846|Device|placebo|Before the induction, up to 250ml of balanced crystalloid solution will be administered. These will include antibiotics solvents and other pre-induction i.v. therapy.
1471300|NCT03186833|Other|no intervention|no intervention
1948486|NCT02288247|Drug|Enzalutamide|Oral
1948487|NCT02288247|Drug|Docetaxel|intravenous infusion
1948488|NCT02288247|Drug|Prednisolone|Oral
1471302|NCT03186807|Diagnostic Test|ultrasonographic scan of fetal brain|"Routine measurement of BPD, HC, OFD, cisterna magna, cerebellum, lateral ventricle(1).
specific measurements as follow:
Parietoccipital fissures will be measured from the most external border of cortex to the luminar line.
Lateral fissure depths will be measured from the most external border of the insular cortex to the interface confirmed between the subarachnoid space and the skull.
Cingulate fissures will be measured in the mid-coronal plane tracing a perpendicular line from the median longitudinal fissure to the apex of the cingulate fissures.
6. Calcarine fissures will be measured in the coronal transcerebellar plane as tracing a perpendicular line from the median longitudinal fissure to the apex of the calcarine fissures."
1948489|NCT02288247|Drug|Placebo|Oral
1948490|NCT02278991|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
1471306|NCT03186768|Behavioral|Soap on a rope hall pass intervention|School health and nutrition coordinators will be trained on how to make and utilize the soap on a rope hall pass to improve hand washing behavior in schools.
1471307|NCT03186755|Drug|Hyaluronic acid 0.05% & Ectoine 2.0%|Treatment of 1 drop three times a day in both eyes for 8 weeks
1471308|NCT03186755|Drug|Olopatadine hydrochloride ophthalmic solution 0.1%|Treatment of 1 drop two times a day in both eyes for 8 weeks
1471309|NCT03186742|Drug|Eplerenone 50 mg Tab|Eplerenone 50 mg Tab once a day
1471310|NCT03186729|Drug|Antithrombotic Agent|Anticoagulant or antiplatelet drugs
1471311|NCT03186716|Dietary Supplement|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
1471312|NCT03186716|Dietary Supplement|Maltodextrin|Control patients will be received enteral formula and maltodextrin mixed in with water and given via nasogastric tube as boluses q 4hrs.
1471313|NCT03186703|Behavioral|Tailored knowledge translation|Tailored knowledge translation strategies specific to evidence-based cancer prevention recommendations
1471314|NCT03186690|Other|Biodentine|
1471315|NCT03186690|Other|Mineral Trioxide Aggregate|
1471316|NCT03186677|Biological|ISU304/CB2679d|ISU304/CB2679d 75~300IU/kg by intravenous or subcutaneous
1471317|NCT03186677|Biological|BeneFix|BeneFIX 75 IU/kg, intravenous administration
1471318|NCT03186664|Device|Lokomat training|The neurorobotic treatment will be performed by using the Lokomat (Lokomat, Hocoma, Volketswil, Switzerland) device. The work load will be progressively adjusted based on the improvement of motor performances. Training parameters (weight support, etc) will be individually adapted. During the first Lokomat session, support will be set at 50% of the body weight and will be adapted on observation of the gait. The Lokomat motor guidance system will be first set at 100%, corresponding to a passive walk.
1471319|NCT03186664|Drug|Sativex|"Patients in treatment with Sativex will receive cannabis-based medicine extract presented in a pump action sublingual spray. Sativex is composed of whole cannabis plant extract, containing THC (27 mg/mL) and CBD (25 mg/mL), in ethanol/propylene glycol (50:50) excipient.
Each actuation delivers 100 KL of spray, containing THC 2.7 mg and CBD 2.5 mg. The number and frequency of dosing (sprays) with Sativex will vary from individual to individual and it may take a number of weeks to find the correct dose of Sativex for the individual patient."
1471320|NCT03186651|Device|TVS|Efficacy of a novel intra-vaginal device for temporary reduction of urine leakage in women suffering from stress urinary incontinence and to evaluate the safety and ease of use.
1471321|NCT03186638|Behavioral|Exercise Intervention|Participate in home-based walking and progressive resistance exercise
1471322|NCT03186638|Drug|Ibuprofen|Given PO
1471323|NCT03186638|Other|Informational Intervention|"Discuss Chemotherapy and You? pamphlet"
1471324|NCT03186638|Other|Laboratory Biomarker Analysis|Correlative studies
1471325|NCT03186638|Other|Placebo|Given PO
1471326|NCT03186638|Other|Questionnaire Administration|Ancillary studies
1471327|NCT03186625|Drug|Compound Panax Notoginseng Granule|"Dosage form:granule. Composition: Panax notoginseng,Codonopsis pilosula,Salvia miltiorrhiza,Pinellia ternata,Medicated Leaven,Coptis chinensis,Citrus reticulata Blanco,etc.
Frequency:two times a day, one package per time. Duration:three months."
1471328|NCT03186625|Drug|Placebo Granule|Placebo granule has the same as Compound Panax Notoginseng Granule in the appearance, shape,colour,taste,frequency and duration.
1471329|NCT03186612|Behavioral|OT+VR intervention with videogames for the upper limb (dexterity)|Patients will performe exercises with video capture of the upper limb movements via the performance of functional and manual dexterity activities based on the following games: Flip Out, Air Hockey, Particlesículas, Dunkit, Cuenta PecesCounting fishes and Robo Maro.
1471330|NCT03186599|Behavioral|low adherence intervention group|Monthly, the study coordinator will give calls to encourage physical activities and medication adherence using MEMS and WALKON activity data.
1471331|NCT03186586|Drug|Ulipristal acetate|5mg/day/five days
1471332|NCT03186586|Drug|Placebo|Placebo one pill a day for 5 days at the bleeding episode
1471333|NCT03186573|Dietary Supplement|Grape juice|400ml diary of grape juice
1471334|NCT03186573|Dietary Supplement|Maltodextrin|400ml diary of maltodextrin
1471374|NCT03186313|Drug|Dactavira Plus|1 Single daily dose (2 Tablets) of Dactavira Plus each tablet contains (EPGCG 200 mg , Sofosbuvir 200mg, Daclatasvir 30 mg, Ribavirin 400 mg) for 12 weeks.
1471375|NCT03186313|Drug|Sofosbuvir + Daclatasvir + Ribavirin|Daily dose including Sofosbuvir 400 mg , Daclatasvir 60 mg & Ribavirin 800 mg for 12 weeks.
1477844|NCT03136354|Procedure|Endoscopic Submucosal Dissection|
1948493|NCT02276482|Drug|Tedizolid Phophate 200 mg, IV and/or oral for 6 days|
1948494|NCT02276482|Drug|Antibiotic comparator|
1948495|NCT02274519|Other|Tai Chi|Arm 1
1948496|NCT02274519|Other|Education|Arm 2
1948497|NCT02272218|Procedure|bariatric lap band surgery|The intervention in this study is laparoscopic gastric banding (LAGB) surgery as a treatment option for obese patients with pain from knee osteoarthritis (KOA) refractory to medical treatment
1948498|NCT02267226|Drug|Octafibrin|
1948499|NCT02266173|Drug|Pertuzumab|Study protocol does not specify/enforce any particular dosage regimen. Pertuzumab will be administered according to standard of care and in line with current SmPC/local labelling.
1471335|NCT03186560|Device|gekoTM|The geko™ W-2 devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg. The W-2 device has a fixed 27mA current. The devices are self-adhesive and are applied to the outer/posterior aspect of the knee. This positioning enables integral electrodes to apply a stimulus to the lateral popliteal nerve (often additionally termed the common peroneal) which branches from the sciatic nerve. This nerve controls the contraction of several muscles in the lower leg.
1471336|NCT03186547|Drug|Botulinum Toxin A Injection|adult patients with gummy smile due to hypermobile upper lip will receive Botulinum Toxin A Injection with a single injection1 cm lateral to the ala horizontally and 3 cm above the lip line vertically.
1471337|NCT03186547|Procedure|Modified Lip Repositioning Surgery|the surgical procedure will be done by removal of strip of epithelium by careful dissection and stabilizing the new mucosal margin to the gingiva to improve the gingival display in adult patients with gummy smile.
1471338|NCT03186534|Behavioral|2GETHER|Communication skills, coping skills, problem-solving, acceptance, HIV prevention
1471339|NCT03186534|Behavioral|Positive Affect Enhancement|coping skills for enhancing positive emotions, mindfulness
1471346|NCT03186469|Behavioral|Safety Baby shower|"A Safety Baby Shower using didactic and experiential teaching methods to educate participants on safety topics focused on reducing infant mortality. Participants receive safety products as their shower gifts with education on appropriate use of the products. The relaxed setting also encourages participants to seek answers and clarify myths from credible sources not otherwise available among family and friends. For intervention provides information on the infant's sleep position, bedding, co-sleeping, and tobacco exposure, all of which, alone or in combination, are risk factors for sleep-related deaths in infants. Breastfeeding, a protective factor for SIDS, will be encouraged."
1471347|NCT03186469|Behavioral|Standard of Care|Participants will received standard of care in regards to infant injury prevention. Written material on car seat safety, prevention of abusive head trauma, and safe sleep environments will be provide to participants.
1471348|NCT03186456|Biological|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion into by forearm intravenous transplantation, 0.5 - 1 *10^6/kg. once a month, total 3 times.
1471349|NCT03186456|Drug|Aspirin Tablet|Drug: Aspirin Tablet, 100 mg/d
1471350|NCT03186443|Drug|Pregabalin|Pregabalin was taken 300mg,q 12h for 6 month.
1471351|NCT03186443|Drug|Gabapentin|Gabapentin was taken 0.4, tid for 6 month.
1471352|NCT03186430|Behavioral|Comprehensive Vaccine Promotion Package|"Practice-level components: Periodic feedback on adolescent immunization coverage. Assistance with implementing and utilizing standing orders for adolescent vaccine administration in the practice, utilizing standardized materials as provided by the Centers for Disease Control and Prevention and the Immunization Action Coalition. Identification of an immunization champion to facilitate immunization activities in the practice. Linkage to peer-to-peer training on adolescent vaccination through the Georgia Educating Providers In their Communities (EPIC) program.
Provider-level components: Providers will receive standardized talking points, vaccine promotion scripts and answers to frequently asked questions, with training on how best to discuss, recommend and answer questions about vaccines.
Patient/Parent-level components: An iPad tablet-based educational presentation will be provided for parents while they are waiting with their adolescent child in the examination room."
1471353|NCT03186417|Biological|2 million hMSC/kg|2 million hMSCs/kg infusion
1471354|NCT03186417|Biological|4 million hMSC/kg|4 million hMSC/kg infusion
1471355|NCT03186417|Biological|6 million hMSC/kg|6 million hMSC/kg infusion
1471356|NCT03186417|Biological|placebo|placebo infusion
1471357|NCT03186404|Drug|Atorvastatin|Atorvastatin 40mg od
1471358|NCT03186404|Drug|Placebos|Placebo
1471359|NCT03186391|Other|Data collected|Use the data collected during a usual consultation to study the relationship between different parameters (rest pressure ...) and imaging
1471360|NCT03186378|Drug|VP-102|Subjects will receive treatment to their molluscum contagiosum with VP-102.
1471361|NCT03186378|Device|VP-102 Applicator|The product is being considered by FDA as a combination therapy which includes the drug VP-102 and the applicator which is the device.
1471362|NCT03186365|Drug|Zepatier Oral Product|Grazoprevir, an HCV nonstructural protein 3/4A (NS3/4A) inhibitor 100 mg, plus elbasvir, an HCV NS5A inhibitor 50 mg fixed dose combination,Zepatier Oral Product, will be prescribed for 8-12 weeks
1471363|NCT03186352|Procedure|photoactivated disinfection|"After manual preparation of the cavity with an excavator and taking a sample for a microbial analysis with a rose bur on micro motor (size 014) the cavity undergoes the procedure of photodynamic disinfection:
application of photosensitizer 'Fotosan' Agent (CMS Dental, Denmark) for 5 minutes, radiation with low power laser, wavelength 635 nm power 200mW 120 s. ('Lasotronix', DiodeLX model SMART) rinsing with water and drying"
1471367|NCT03186326|Drug|FOLFOX regimen|"A course of treatment every 14 days
Oxaliplatin: 85 mg/m² IV over 2 hours Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine) IV over 2 hours 5FU bolus: 400 mg/m² IV bolus over 10 minutes in 100 ml 0.9% NaCl 5FU continuous: 2,400 mg/m² in NaCl 0.9% in IV over 46 hours"
1471378|NCT03186300|Device|PEPPER system|In the phase 1 participants will use PEPPER safety system (with the CBR algorithm enabled) and in the phase 2 participants will use whole PEPPER system (with the CBR algorithm integrated).
1471382|NCT03186274|Behavioral|Facilitated Group Session|Participants will review the SPIKES model with a facilitator and then participate in a guided and supported simulated patient encounter utilizing aspects of the SPIKES model, with feedback at the end of the session.
1471383|NCT03186274|Behavioral|CELA Session|Participants will review the SPIKES model on their own and then participate in a simulated patient encounter utilizing the SPIKES model. They will receive feedback following the encounter.
1471384|NCT03186261|Drug|Nano silver fluoride solution|Nano silver fluoride that composed of silver nanoparticles, chitosan and fluoride that combines preventive and antimicrobial properties.
1471385|NCT03186261|Drug|Cavity Cleanser|Moistens dentin surface after cavity preparation using a micro brush.
1471386|NCT03186248|Procedure|Per oral endoscopic myotomy|General anesthesia will be administered and an esophagogastroduodenoscopy will be performed. Mucosal incision proximal to the gastroesophageal junction (GEJ) will be identified depending on short or long myotomy. A 1.5- to 2-cm mucosal incision will be performed after raising a submucosal wheal. The endoscope will be inserted to create a submucosal tunnel with a combination of blunt dissection, carbon dioxide insufflation, hydro dissection and careful electrocautery. The tunnel will be extended past the GEJ, 3 cm onto the gastric cardia. after myotomy, the mucosal incision will then be closed using standard endoscopic clips.
1471387|NCT03186235|Other|Flow cytometry|Isolation of T regulatory cells from blood
1471388|NCT03186222|Diagnostic Test|blood sample|"Serum PRL levels are measured using ELISA assay kit in both groups and correlated with severity of acne in acne group.
The genomic DNA from peripheral leukocytes is extracted. Genotyping of 1149G/T single nucleotide polymorphism (SNP) PRL extrapituitary promoter is done in acne patients and healthy individuals (control group) using PCR-RFLP method."
1471391|NCT03186196|Dietary Supplement|Diet containing Folate|
1471392|NCT03186183|Behavioral|GPS program|GPS is a sexual health promotion and HIV prevention program. It has 4 components: provision of information on HIV and sexually transmitted infections, motivational interviewing counselling, sexual health behavioural skills building, and linkage to care in the local community (e.g., referrals to medical, social service, social, mental health, and substance use programs). Among HIV-positive men who have sex with men (MSM) GPS is associated with positive health outcomes including decreased likelihood of condomless anal sex (CAS), particularly CAS with serodiscordant partners. GPS is also associated with decreased fear of being rejected for insisting on condom use and increased condom use self-efficacy.
1471393|NCT03186170|Other|SSA sperm selection|The investigators propose to assess one method of sperm selection based on the characteristics of spermatozoa recently introduced: Sperm Selection Assay, which used a gradient of concentration of progesterone to act as chemoatractant of spermatozoa of better quality. We will assess in vitro fertilization with two techniques (SSSA versus traditional technique of swin up) as well as embryo development.
1471394|NCT03186157|Procedure|Decompressive craniectomy|Decompressive craniectomy is a surgical procedure used to treat patients with acute intractable intracranial hypertension. It includes removing a large portion of lateral skull wall in order to alleviate the effects of increased intracranial pressure and allow the brain to expand.
1471395|NCT03186157|Procedure|Cranioplasty|Cranioplasty is a routine neurosurgical procedure to repair the continuity of the bone tissue of the skull with autologous bone or synthetic bone flap from heterologous material.
1471396|NCT03186144|Genetic|Blodd punction for genetic analysis|
1471399|NCT03186118|Biological|T-cell Antigen Presenting Cells expressing truncated CD19 (T-APC)|Autologous CD4 and CD8 T cells transduced to express a truncated CD19 (CD19t) Transgene
1471400|NCT03186105|Other|Ambulatory appendicectomy|The intervention consist of an ambulatory care by appendicectomy of the acute appendicitis. The normal care is an appendicectomy and an hospitalisation during 2 or 3 days .
1471401|NCT03186092|Other|respiratory muscle training|The TMI protocol will be performed with POWERbreathe Line Plus (POWERbreathe International Ltd. Warwickshire, England) linear loader with resistance load of 30% of maximal inspiratory pressure (PImax) value for a period of 12 weeks, 7 times at Week, 30 min / day, one of the times in the week with the supervision of the researcher and, on the other six days of the week, patients will perform IMT at their homes, having as a control a records record of the protocol that will be delivered to each patient To record the time and duration of the exercise. At the end of each week, patients will be reevaluated for MIP, so that the load values are regulated according to the possible increase in inspiratory muscle strength. The data collection will be performed by a single evaluator and the patients will be properly oriented on the procedures to be performed.
1471402|NCT03186079|Drug|Xiaojidaozhi Decoction oral capsules|Capsules with mixture of twelve Chinese herbal medicines granule inside
1471403|NCT03186079|Drug|Placebo oral capsules|Capsules with flour granule inside
1471404|NCT03186079|Drug|Fiberform|Fiberform is a low-phytate wheat fibre which can increase the gastrointestinal motility.
1471405|NCT03186079|Behavioral|Toilet training|Toilet training has been considered a routine method in treatment of constipation
1471406|NCT03186066|Device|Flamingo Device|Endoscopic Treatment of Buried Bumper Syndrome with the Flamingo Device
1471407|NCT03186066|Procedure|Standard Therapy|Endoscopic Treatment of Buried Bumper Syndrome with an endoscopic submucosal dissection knife
1471408|NCT03186053|Drug|sodium creatine phosphate|sodium creatine phosphate .Loading dose followed by continuous infusion in operation
1471409|NCT03186053|Drug|saline|.Loading dose followed by continuous infusion in operation
1471410|NCT03186040|Drug|Lacosamide|Sodium channel blocker
1471411|NCT03186027|Dietary Supplement|Coenzyme Q10 plus NADH|"Active arm: Coenzyme Q10 plus NADH CFS/ME patients who will be randomized to measure the effect of oral ReConnect supplementation (CoQ10: 200 mg/day plus NADH 20 mg/day; 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.
Intervention: Reconnect"
1471412|NCT03186027|Dietary Supplement|phosphoserine plus vitamin C|"Placebo arm: phosphoserine plus vitamin C CFS/ME patients who will be randomized to measure the effect of oral Placebo supplementation (phosphoserine and vit C, 4 tablets/day) on changes in the fatigue, sleep problems, autonomic function and HRQoL during 8-weeks in term.
Intervention: placebo"
1471413|NCT03186014|Device|Fully covered irradiation stent|A esophageal fully covered segmented irradiation stent loaded with 125I seeds is placed in Patients with malignant dysphagia
1471414|NCT03186001|Drug|Abobotulinum toxin A|The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
1471415|NCT03185988|Drug|chemotherapy in combination with trastuzumab|Arm1: GI tumor beyond CRC, ESCC, BTC and GC&GEJA Trastuzumab (Herceptin ®): 6 mg/kg every 3 weeks (8 mg/kg as loading dose at 1st administration), iv, d1.The first infusion is to be given over 90 minutes, and subsequent infusions are to be given over 30 minutes if the first infusion is well tolerated.Combined chemotherapy (by investigator's choice)
1471416|NCT03185988|Drug|chemotherapy in combination with trastuzumab|Arm2: esophageal squamous cell carcinoma (ESCC) Trastuzumab (Herceptin ®): the same as above Combined with Irinotecan: 120 mg/m2 IV, day 1 and day 8, every 3 weeks.
1471417|NCT03185988|Drug|chemotherapy in combination with trastuzumab|"Arm 3: biliary tract cancer (BTC) Trastuzumab (Herceptin®): the same as above Combined chemotherapy (by investigator's choice) The combined chemotherapy of cohort 1 and 3 is Irinotecan: 120 mg/m2 IV, day 1and day 8, every 3 weeks.
OR 5-Fu: 720 mg/m2/day, continuous IV. Infusion over 5 days, every 3 weeks. OR Capecitabine(Xeloda®):1000 mg/m2 bid, d1-d14, every 3 weeks. The chemotherapy regimen is chosen at the Investigator's discretion and can be determined on an individual patient basis. Special cases should be discussed with the principal investigator."
1471418|NCT03185975|Behavioral|at-home test kit|Transgender youth in the control arm will receive test kits, but will not receive any testing intervention. Once individual results are reported, participants will be contacted via phone or email by study staff with options for referrals to services. Participants will complete follow-up surveys at 3, 6, 9, and 12 months post-testing.
1471419|NCT03185975|Behavioral|Motivational Interviewing and Certified Testing and Referral|Transgender individuals randomized to the experimental group (MI/CTR) will receive HIV counseling and testing via an online, HIPPA-compliant videoconferencing service. The session will last less than one hour and focus on HIV testing, prevention strategies, and/or linkage to HIV care, depending on the individual's test results. Participants will complete follow up surveys at 3, 6, 9 and 12 months.
1471420|NCT03185936|Procedure|pars plana vitrectomy with internal limiting membrane (ILM) peeling|pars plana vitrectomy (PPV) combined with internal limiting membrane (ILM) peeling, endolaser photocoagulation and gas tamponade in management of optic disc pit (ODP) maculopathy.
1471421|NCT03185923|Drug|TCM plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The Experimental group will receive TCM according to the TCM syndrome.
qingfeijieduhuatan granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome in 28 treatment days.
zaoshihuatanxiefei granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome in 28 treatment days.
qingxinkaiqiao granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome in 28 treatment days.
shenmai injection（Sichuan chuanda west China Pharmaceutical Co., Ltd.）,15ml/ ampulla, 10～60ml each time (when needed), for yin exhausted syndrome in 28 treatment days.
shenfu injection（Sanjiu Medical & Pharmaceutical Co., Ltd.）,10ml/ ampulla, 50～100ml each time (when needed), for yang exhausted syndrome in 28 treatment days."
1471422|NCT03185923|Drug|TCM placebo plus conventional drug|"All patients were treated with antibiotics according to international guidelines. The control group will receive TCM placebo according to the TCM syndrome.
placebo qingfeijieduhuatan granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for phlegm-heat obstructing in the lung syndrome every day in 28 treatment days.
placebo zaoshihuatanxiefei granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for pulmonary stagnation of phlegm syndrome every day in 28 treatment days.
placebo qingxinkaiqiao granule (Sanjiu Medical & Pharmaceutical Co., Ltd.), 10g/packet, twice daily, for Pathogenic heat trapping the pericardium syndrome every day in 28 treatment days."
1471423|NCT03185910|Behavioral|MBCP education|MBCP education involves mindfulness breathing and other skills with mindfulness meditations.
1471424|NCT03185910|Behavioral|Hospital-based antenatal education|Hospital-based antenatal education involves all aspects of pregnancy, childbirth and postpartum.
1471426|NCT03185884|Other|Control|control carbohydrate blend
1471427|NCT03185884|Other|Experimental|experimental carbohydrate blend
1471428|NCT03185871|Drug|Celecoxib|Celecoxib is the only COX-2 inhibitor currently approved by the FDA to be used in the United States. Recently, it has been shown that celecoxib prevents sporadic colorectal adenomas and there are more clinical trials evaluating the use of celecoxib in combination with chemotherapy regimens in breast cancer settings. Celebrex® oral capsules that will be used in this study contain 200 mg of celecoxib, in combination with inactive ingredients that include the following components: croscarmellose sodium, edible inks, gelatin, lactose monohydrate, magnesium stearate, povidone and sodium lauryl sulfate.
1471429|NCT03185858|Behavioral|SINEMA intervention|The two components of the SINEMA intervention are: 1) regular evidence-based primary care by VDs including a) primary healthcare system strengthening by providing systematic training to VDs and establishing support system to integrate health human resources around tertiary, secondary and primary levels; b) monthly follow-up visits delivered by VDs with the support of SINEMA application (SINEMA App); and c) performance feedback and payment; and 2) health education on medication adherence and lifestyle modification delivered by voice messages to both patients and their family caregivers.
1471430|NCT03185845|Drug|Warfarin|tailored dose according to international normalized ratio (INR) for 3 months
1471431|NCT03185832|Device|CRT-D|This subject cohort is made by all patients enrolled and implanted with defibrillator with CRT capabilities
1471432|NCT03185832|Device|ICD|This subject cohort is made by all patients enrolled and implanted with defibrillator capabilities
1471433|NCT03185832|Device|PM / CRT-P|This subject cohort is made by all patients enrolled and implanted with pacemakers with or without CRT capabilities
1471434|NCT03185832|Other|Non-device|Patient enrolled but not implanted with a Defibrillator or Pacemaker
1471442|NCT03185793|Drug|Placebo|Placebo once daily for 5 weeks
1471443|NCT03185793|Drug|SHR4640|1mg SHR4640 once daily for a week, 2.5mg, 5mg or 10mg SHR4640 once daily for 4 weeks
1471444|NCT03185793|Drug|benzbromarone|25mg benzbromarone once daily for a week, 50mg benzbromarone once daily for 4 weeks
1471445|NCT03185780|Other|Acupuncture|"Acupuncture: the insertion of use of ultra-fine needles (diameter 0.18 - 0.30mm) into designated acupoints in the skin, along the limbs and trunk areas.
Reflexology: The massage + application of localized pressure on designated points along the plantar aspect of the feet.
Shiatsu: The application of localized pressure along designated points (similar to acupoints) along the limbs and trunk areas."
1471446|NCT03185767|Other|blood sampling|blood sampling
1471447|NCT03185754|Procedure|Sublobar resection|Sublobar resection
1471448|NCT03185754|Procedure|lobectomy|lobectomy
1471449|NCT03185741|Behavioral|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
1471450|NCT03185741|Behavioral|SMS Text Messaging|Patients will receive daily text message reminders about when to take medicines based on UMS intervals.
1471451|NCT03185728|Other|iLook Out for Child Abuse|"Online, interactive educational intervention that uses a video-based story-line and gamification to teach childcare providers about child abuse and mandated reporting."
1471452|NCT03185715|Behavioral|Oral and written counselling|Recipients were informed about success rates of SET and DET and also about the possible risks of DET. All the information was given orally and written.
1471453|NCT03185702|Genetic|Research genetic tests|DNA and tissue-based tests: karyotype, copy number variants and genome-wide association studies
1471455|NCT03185676|Other|Bilberry|A bilberry based probiotic beverage
1471456|NCT03185676|Other|beverage without bilberries or probiotics|A control beverage without bilberries or probiotics
1471457|NCT03185663|Other|traction-stuck|continuous pulling method: tensile force is exerted directly on the skin by means of adhesive strips, connected to weight
1471458|NCT03185663|Other|a pillow between the legs|setting up a pillow between the legs before the care
1471459|NCT03185650|Device|tPAD Device|A novel, transnasal aerosol generator
1471460|NCT03185650|Device|PARI LC Star Nebulizer|Standard oral nebulizer
1471461|NCT03185637|Procedure|Various interventions for each of the conditions.|"This is an observational study. Patients were not allocated to different interventions.
Common interventions for each of the conditions, which will be compared during analysis include the following:
Gastroschisis - primary operative closure, surgical silo, preformed silo. Anorectal malformation - various types of stoma, anoplasty, PSARP, other. Appendicitis - antibiotics, open appendicectomy, laparoscopic appendicectomy. Intussusception - air enema reduction, hydro-enema reduction, laparotomy. Inguinal hernia - open repair, laparoscopic repair."
1471462|NCT03185624|Drug|Rifaximin|Antibiotics
1471463|NCT03185611|Drug|Rifaximin|Antibiotics
1471464|NCT03185611|Drug|Azathioprine|immunomodulator
1471465|NCT03185585|Other|Mini Nutrition Assessment (MNA® )|MNA® is a validated nutrition screening and assessment tool that can identify geriatric patients age 65 and above who are malnourished or at risk of malnutrition.
1471466|NCT03185585|Other|Comprehensive Older Adult Screening Tool (COAST)|Develop a comprehensive older adults screening tool for community dwelling older adults who attend congregate meal sites to assist in the evaluation of undernourishment or those at risk that is simple, faster, and less expensive
1471467|NCT03185559|Device|Relievion Device- Treatment Stimulation|1 Hour self-administered treatment specific occipital and supraorbital transcutaneous nerve stimulation
1471468|NCT03185559|Device|Relievion Device- Sham stimulation|1 Hour self-administered sham occipital and supraorbital transcutaneous nerve stimulation
1471670|NCT03184272|Procedure|start capnoperitoneum|measurement in supine position
1471475|NCT03185533|Behavioral|Quality improvement (QI) interventions|"1. The ED admissions exhibited prolonged length of stay.
2. The Interventions for Reducing Medical Decision Time:
The ED director created QI education sessions and reported monthly QI outcomes.
The ED nurses reported the current number of ED admission patients twice a day to the director. The director summarized the bed requests to the administrative personnel.
The nurses reported the in-scene complicated cases to the ED director. The director would give an assistance in managing these cases.
3. The Interventions for Reducing Boarding Time
The ED patients could be admitted before 8 a.m. if the bed was vacant.
The ED director initiated an on-line meeting at 8 a.m. and 4 p.m.
Monthly QI outcomes were reported in the hospital affairs meeting."
1471476|NCT03185507|Device|CryoHelmet|Cryotherapy was administered using the Catalyst CryoHelmet™ (All-Star Sporting Goods®, Shirley, Massachusetts, USA). The CyroHelmet is a flexible helmet equipped with gel ice packs meant to cool the head and neck.
1471477|NCT03185494|Biological|anti-CD19/22-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
1471486|NCT03185468|Genetic|4SCAR-PSMA|PSMA-specific 4th Generation CART
1471487|NCT03185468|Genetic|4SCAR-FRa|FRa-specific 4th Generation CART
1471488|NCT03185455|Other|Remote (text based) surveillance|Women with hypertensive disorders of pregnancy with access to a cell phone with unlimited text message capabilities will be randomized to either office visit blood pressure checks after discharge or receive a blood pressure cuff and text in blood pressures for two weeks postpartum using a standardized, HIPAA compliant, physician derived automated platform.
1471490|NCT03185429|Biological|Tumor Specific Antigen-loaded Dendritic Cells|Subjects will be given subcutaneous injection of 5.0x10^6-1.0x10^7 TSA-DC on week 1,3,5,11,17,23,35,47.
1471491|NCT03185429|Drug|Cyclophosphamide|300 mg/m2 by vein before the first cell infusion.
1471492|NCT03185416|Other|Palliative Care Training|The intervention group- will include 30 patients receiving treatment by the Interventional Radiology team along with their primary caregiver. Patients and caregivers will receive a brief palliative care training intervention during their first follow-up visit. Patients and their caregivers will receive questionnaires to assess their health status (physical and psychosocial) and health services utilization outcomes at 1, 2, and 3 months post-procedure during their follow-up visits.
1471493|NCT03185403|Other|paravertebral block|in the paravertebral block , the catheter was placed under ultrasound echography , at the right thoracic T4/T5 level
1471494|NCT03185403|Other|thoracic epidural block|in the epidural block the catheter was inserted without echography , at T4/T5 level
1471495|NCT03185403|Drug|ropivacaine|
1471496|NCT03185403|Drug|Sufentanil|
1471497|NCT03185390|Procedure|ERCP guided biopsy or brush cytology|ERCP guided biopsy or brush cytology
1471498|NCT03185364|Drug|Sildenafil Citrate|sildenafil treatment for 12 weeks, monitoring blood pressure and other adverse events
1471499|NCT03185364|Drug|Placebo Oral Tablet|placebos treatment for 12 weeks
1471500|NCT03185351|Drug|Bupivacaine|20 ml of 0.5% bupivacaine using supraclavicular BPB.
1471501|NCT03185351|Drug|Midazolam|midazolam 0.03 mg/kg dissolved in 5 ml normal saline (0.9%) using supraclavicular BPB
1471502|NCT03185351|Drug|Midazolam|0.03 mg/kg of midazolam by I.V. route
1471503|NCT03185338|Behavioral|Active commuting to/from school|Active transport to/from school on foot or by bike will be promoted
1471504|NCT03185338|Behavioral|Active Physical Education lessons|Specific lessons designed for increasing moderate to vigorous physical activity in Physical Education will be applied
1471505|NCT03185338|Behavioral|Active school recess|Teachers will design games and activities and will encourage children for being active
1471506|NCT03185338|Behavioral|Sleep health promotion|This intervention will aim to raise the awareness of the importance of having a good quality sleep at night and to teach healthy sleep behaviours that will contribute to improving sleep hygiene
1471507|NCT03185338|Behavioral|School global intervention|A simultaneous implementation of all four interventions (see the others arms) will be examined in one of the intervention schools.
1471508|NCT03185325|Other|bone marrow puncture and venous blood samples|bone marrow and peripheral blood samples are collected in non hodgkin lymphoma patients
1471509|NCT03185325|Other|venous blood samples|venous blood samples are collected in healthy voulnteers
1471510|NCT03185312|Diagnostic Test|skin biopsy|"Clinical evaluation including full history taking and dermatological examination will be done for all patients. Assessment of disease severity will be performed using VASI score for vitiligo and Global acne severity grading for acne vulgaris Skin biopsies will be taken from lesional and non-lesional skin of patients as well as controls. immunohistochemical staining using specific antibodies for detection of expression of JAK1, JAK2 and JAK3.
Additionally, biopsies will be preserved in RNA later solution at -20°C. RNA isolation and real-time qPCR analysis will be performed for measurement of cutaneous JAK1, JAK2 and JAK3 gene expression."
1471511|NCT03185299|Other|Video|Patients randomized to the intervention arm will be contacted 48-72h before their procedure via telephone using a standardized script and will be provided a link to a website allowing posting of videos for public viewing
1471512|NCT03185299|Other|Standard preparation instructions|The control arm will receive written instruction on preparing for a colonoscopy per standard of care
1471513|NCT03185286|Device|3d-printed personalized metal implant|3d-printed personalized metal implant will be used in subtalar arthrodesis.
1471514|NCT03185247|Behavioral|Transdiagnostic Group-Based Treatment|10 week 90-minute weekly therapy sessions including both the adolescent and caregiver. Treatment will consist of psychoeducation about dysautonomia, motivational interviewing techniques to promote readiness for change, support around lifestyle and behavioral changes, core CBT components (e.g., relaxation training, linking thoughts, feelings, and behaviors, minimizing catastrophizing thoughts, cognitive coping, and exposure), and components of ACT aiming to increase cognitive flexibility (e.g., mindfulness, experiential avoidance, values, cognitive defusion, committed action), and relapse prevention and maintenance. Most sessions will involve homework assigned to the adolescent and their parent/legal guardian(s) to encourage practice at home.
1471515|NCT03185234|Device|anodal tDCS|2 mA, 10 min, 5 sessions
1471516|NCT03185234|Device|sham tDCS|sham stimulation, 10 min, 5 sessions
1471517|NCT03185221|Device|Cordimax|One rapamycin eluting stent for treating the adapted coronary patients
1471518|NCT03185221|Device|XIENCE V|One everolimus eluting stent for treating the adapted coronary patients
1471519|NCT03185208|Drug|Lithium Carbonate|See lithium carbonate arm
1471520|NCT03185208|Drug|Placebo oral capsule|See placebo arm
1471521|NCT03185195|Drug|AQX-1125 Oral Tablet|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
1471522|NCT03185195|Drug|[14C]-AQX-1125 IV|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
1471523|NCT03185195|Drug|[14C]-AQX-1125 Oral Solution|Part 1: Subjects will receive a single oral dose of AQX-1125 followed by [14C]-AQX-1125 IV Microtracer dose. In Part 2 subjects receive [14C]-AQX-1125 oral solution.
1471524|NCT03185182|Drug|Ioflupane I123|185 MBq ioflupane I133 will be administered at one single occasion to the study subjects
1471525|NCT03185169|Combination Product|Replens and coconut oil|
1471526|NCT03185156|Drug|Propofol|first dose 0.3mg/Kg propofol, then 1mg/Kg/hr micro-pump
1471527|NCT03185156|Drug|Normal saline|first dose 0.03ml/Kg placebo saline, then 0.1ml/Kg/hr micro-pump
1471531|NCT03185130|Drug|Normal Saline 5mL|Control arm subjects will receive Normal Saline 5 mL IV over 1 hour
1471532|NCT03185130|Drug|Normal Saline 20mL/kg|Study arm subjects will receive Normal Saline 20 mL/kg IV (up to 1000 mL) given IV over 1 hour,
1471533|NCT03185130|Drug|Prochlorperazine 0.15 mg/kg up to 10 mg IV|Standard Treatment Arm and Study Arm will recieve prochlorperazine 0.15 mg/kg up to 10mg IV slow push
1471534|NCT03185130|Drug|Diphenhydramine 1 mg/kg up to 50 mg IV|Diphenhydramine dose 1 mg/kg up to 50 mg IV slow push
1471535|NCT03185104|Drug|Silver Diamine Fluoride|Silver diamine fluoride solution is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
1471536|NCT03185104|Drug|Distilled Water|Distilled water is applied to the dried and exposed coronal and root surfaces of all teeth by means of a disposable microbrush.
1471537|NCT03185091|Other|rapid ventricular pacing|
1471538|NCT03185091|Procedure|Surgery|
1471539|NCT03185078|Device|Extracorporeal Shock Wave Therapy|Extracorporeal shock wave therapy (ESWT) is a treatment method for the application of single-pulse acoustic pressure waves generated by sudden changes in pressure by creating shock waves with piezoelectric, electrohydraulic and electromagnetic systems. The main purpose of the treatment is to stimulate tissue repair and regeneration. It has been reported that ESWT treatment is effective in the treatment of pain with hyperstimulation analgesia by inhibiting afferent pain receptors, and also improve angiogenesis and restore and reorganize the musculoskeletal system
1471540|NCT03185078|Other|Physiotherapy|Hotpack will be done for 20 minutes Transcutaneal Nerve Stimulation-will be done for 20 minutes Soft tissue mobilization and Joint mobilization techniques, Stretching exercises, Active joint movements, Strengthening exercises, Proprioceptive exercises.
1471541|NCT03185065|Drug|Amantadine|100 mg of amantadine increased to 200 mg of amantadine, if tolerated
1471542|NCT03185065|Drug|Modafinil|100 mg of modafinil increased to 200 mg of modafinil, if tolerated
1471543|NCT03185065|Drug|Methylphenidate|5 mg of methylphenidate uptitrated to max of 20 mg of methylphenidate, if tolerated
1471544|NCT03185065|Drug|Placebos|1 placebo capsule increased to max of 2 capsules twice daily
1471545|NCT03185052|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
1471546|NCT03185039|Procedure|Blood and tumor samples|Blood and tumor samples
1471581|NCT03184805|Drug|Stopping aspirin|Subject assigned to comparison arm will stop antiplatelet therapy before scheduled surgery or procedure. If subject is taking aspirin, clopidogrel, ticagrelor, or prasugrel, it should be discontinued for 7 days, 5 days, 3-5 days, and 7 days before surgery. Antiplatelet therapy may be restarted as previous regimen at fourth postoperative day or sooner unless significant bleeding risk or bleeding event occurs.
1471582|NCT03184792|Device|Transcutaneous spinal stimulation|Non-invasive electrical stimulation of cervical spinal cord over the skin
1471583|NCT03184792|Other|Physical therapy|Physical therapy to improve arm and hand functions
1471668|NCT03184272|Procedure|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
1471547|NCT03185026|Behavioral|Interventional group : PEPSUI psychoeducational program|"The program includes 10 weekly, 2-hours sessions led by two trained animators (nurse, medical doctor/psychologist), each focusing on a specific theme or skill :
Education on suicidal behavior (clinic and epidemiology), and conceptualization of the phenomenon on a matrix
Education on the suicidal crisis, identification of important life areas and values for the patient, experimentation on the way to use the matrix as a decision-making tool.
and 4) Self-assessment of suicidal ideations, coping strategies based on suicide ideation intensity and emotional tension (acceptation, distress tolerance, personal aid kit, and emergency care)
5) Stress-diathesis model of suicidal behavior, innovating cognitive skills (defusion), and valued actions 6) Stress factors (psychiatric diseases and negative life events), resilience, and contact with present moment 7) Suicidal vulnerability, personal strengths 8) Social support, skills to create quality relationships"
1471548|NCT03185026|Other|Relaxation group|Participants will be included in a standardized relaxation program, consisting of 10 weekly sessions lasting 2 hours. There will be 2 therapists for each patients group. Abdominal and muscular relaxation skills will be experimented.
1471552|NCT03185000|Drug|TR004 (Treg immunotherapy)|Administered Intravenously (IV)
1471553|NCT03185000|Other|Placebo|Administered Intravenously (IV)
1471554|NCT03184987|Drug|FF/UMEC/VI 100/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
1471555|NCT03184987|Drug|FF/UMEC/VI 200/62.5/25 mcg|Subjects will self-administer the study treatment via the ELLIPTA device. The ELLIPTA holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister. ELLIPTA is a registered trademark of GSK groups of companies.
1471556|NCT03184987|Drug|Salbutamol|Salbutamol is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
1471557|NCT03184987|Other|ACQ-7|ACQ-7 will be used for the assessment of control status of asthma.
1471558|NCT03184961|Diagnostic Test|lung recruitment maneuver|Lung recruitment maneuver (application of continuous positive airway pressure of 25 cm H2O for 20 s)
1471559|NCT03184948|Device|Brilliance|The intervention is the provision of the Brilliance phototherapy machines to hospitals. This device is to be provided to facilities regardless of the study -- the study's involvement has been to collaborate with the Ministry of Health so that Brilliance is distributed in a randomized staggered method. In that sense, the study may be considered observational, as the study is not driving whether or not a hospital receives Brilliance, only when it receives Brilliance in a short time frame.
1471560|NCT03184935|Biological|Allogeneic umbilical cord mesenchymal stem cells|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
1471561|NCT03184935|Drug|Decitabine|Decitabine，20mg/m^2/d
1471562|NCT03184922|Procedure|Adjustable versus fixed suspensory loop femoral side graft fixation|A comparison of 2 different types of surgical technique for attaching the femoral side graft in ACL reconstruction: with a fixed suspensory loop or an adjustable one
1471563|NCT03184909|Drug|Ocimum Sanctum|Active capsules containing leaves of organically prepared ocimum sanctum
1471564|NCT03184909|Drug|Placebo|Placebo capsules of look alike inert substance for control
1471565|NCT03184896|Procedure|Hip Fracture Surgery|Hip Fracture Surgery
1471566|NCT03184883|Procedure|single conventional denture|mandibular conventional denture with soft liner
1471567|NCT03184883|Procedure|single flexible denture|mandibular flexible compete denture
1471575|NCT03184857|Procedure|open maxillary sinus lifting|biopsy of the region 6 months later
1471576|NCT03184844|Drug|Thalidomide|thalidomide:50mg/d p.o at bedtime
1471577|NCT03184831|Procedure|sinus lift, implant placement, sole bovine bone|sinus lift augmentation with a sole deproteinized bovine bone with simultaneous implant placement
1471578|NCT03184831|Procedure|sinus lift, implant placement, injectable PRF + bovine bone|sinus lift augmentation with a mixture of injectable platelet rich fibrin plus a deproteinized bovine bone with simultaneous implant placement
1471579|NCT03184818|Other|Advanced care|The pharmacist will assess for symptoms of urinary tract infection and, for patients in Arm 1, prescribe antibacterials when appropriate. For patients in Arm 2, pharmacists will ensure optimal therapy and adapt or perform therapeutic substitution when appropriate (or work with the patient to discontinue therapy or just put the prescription on file in instances where the patient is assessed to have asymptomatic bacteriuria for which treatment is inappropriate).
1471580|NCT03184805|Drug|Continuing aspirin|Subject assigned to control arm will maintain antiplatelet therapy using aspirin only at least 7 days before surgery. If subject is taking one or more antiplatelet drugs, it should be changed (for subjects taking antiplatelet drug except aspirin at enrollment) or continued (for subject taking aspirin at enrollment) with low-dose, aspirin monotherapy before surgery. Cessation of clopidogrel, ticagrelor, and prasugrel should be started at least 5 days, 3 days and 7 days before surgery, respectively. Administration of aspirin will be started at the day of cessation of previous antiplatelet regimen and maintained until third postoperative day with 100 mg once a day.
1471584|NCT03184779|Other|Ski and Snowboard Safety Video|The ski and snowboard safety video (~10 minutes) includes information on preparation, correct protective equipment use (e.g. helmets), and strategies for speed control and collision avoidance. Focus groups were conducted among parents, students, ski patrol, and ski instructors to inform the content and format of the video. Feedback and suggestions from focus groups were utilized to ensure that the video optimized information uptake from children and adolescents who watch the video. The Health Action Process Approach (HAPA) model was embedded throughout the video to ensure evidence-informed pathways towards positive behaviour change.
1471585|NCT03184766|Drug|Test Nurofen Cold and Flu®, Ibuprofen and pseudoephedrine liquid capsules|2 x 200 mg ibuprofen & 30 mg pseudoephedrine
1471586|NCT03184766|Drug|Comparator 1 Nurofen Cold and Flu®, ibuprofen and pseudoephedrine tablets|2 x 200 mg ibuprofen & 30 mg pseudoephedrine
1471587|NCT03184766|Drug|Comparator 2 Nurofen Immedia 200 mg Weichkapseln, ibuprofen liquid capsules|2 x 200 mg solubilised ibuprofen
1471588|NCT03184753|Biological|OC-IgT cells|Autologous human OC-IgT cells.
1471589|NCT03184740|Device|Active Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over Primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
1471590|NCT03184740|Device|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned over primary motor cortex, C3 area for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator will be turned off after 30 seconds of stimulation.
1471591|NCT03184714|Device|NIPPV|BiPAP treatment for 3 years
1471592|NCT03184701|Other|Telehealth|Patients will be given an ipad with preloaded app (secured questions assessing their symptoms and cognitive function in a systematic timely way). The responses will be delivered to the care providers instantly, which will trigger an algorithmic clinical approach.
1471593|NCT03184688|Procedure|platelet rich plasma|Ultrasound-guided PRP injection between proximal carpal tunnel and median nerve.
1471594|NCT03184688|Drug|Normal saline|Ultrasound-guided normal saline injection between proximal carpal tunnel and median nerve.
1471595|NCT03184675|Other|Functional action observation training|the Four Square Step Test (FSST) performance video for enhancing the dynamic balance and the video including participants' daily activities to increase the gait ability such as walking in a corridor, walking around the hospital, walking to the therapy room, coming out of the ward after opening and closing the door of it, coming in and out of toilet, shifting their blue plate. and bringing something from a refrigerator were produced and watched.
1471596|NCT03184675|Other|General action observation training|step 1, looking at the front, while walking comfortably; step 2, looking left and right, while walking; step 3, looking up and down, while walking; step 4, looking at the front, left and right, up and down while walking. After 15 minutes of watching the video, the exercise program with a therapist was conducted to increase the gait ability, for 15 minutes.
1948503|NCT02261714|Biological|TG01|"TG01 and GM-CSF will be administered on days 1, 8, 15, 22 and 36. TG01 alone will also be given on days 36 and 50 for DTH assessment. Gemcitabine will start at least 3 weeks after TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.
Once chemotherapy is completed, GM-CSF and TG01 injections will resume and will be given every 4 weeks from the end of the chemotherapy period up to week 52 (plus once at week 5 post-chemotherapy) and then every 12 weeks from week 52 to week 104. TG01 alone will be given 8 weeks after the end of chemotherapy for DTH assessment.
TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.
Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
1471599|NCT03184649|Drug|Ibuprofen|It is a pre-analgesic will be taken before painful procedures.
1471600|NCT03184649|Drug|paracetamol|it is a pre-analgesic drug will be taken before painful procedure.
1471601|NCT03184649|Dietary Supplement|A fruit-flavored orange color placebo solution|orange juice as a comparative group.
1471602|NCT03184623|Other|muscle mass measurement|measurement of muscle mass by echocardiography
1471603|NCT03184610|Device|OCT-scanning|All participants will be scanned with a OCT-device
1471604|NCT03184597|Diagnostic Test|HLA screening before commencing aromatic AEDs|When the risk HLA alleles are tested positive for the patients, aromatic AEDs were avoided or administrated with caution according to the risk level.
1471605|NCT03184584|Drug|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily
1471608|NCT03184545|Device|EMS|The EMS device Flex MT Plus (Electrostim Medical Services Inc. Tampa, FL) is a neuromuscular stimulator. It is approved by the FDA. The Electrical muscle stimulation (EMS) applied to vastus medialis obliquus (VMO) muscle for 20 minutes, 3 times daily and it would be 5 times a week for 12 weeks at 40 Hz. The pulse duration will be 0.26ms, at 5 seconds on and 10 seconds off.
1471609|NCT03184545|Other|Physical therapy|Standard physical therapy exercises
1471610|NCT03184532|Diagnostic Test|ultrasound|ultrasound examination of pyloric antrum
1471611|NCT03184519|Diagnostic Test|Pregnancy test|Instead of one blood sample, patients will have three blood analyses to predict pregnancy earlier after the embryo transfer.
1471612|NCT03184506|Other|pre-warming|On arrival at the preoperative care unit, assignments were determined using an opaque sealed envelope opened by investigator with no clinical involvement in the study. In the pre-warming group, the forced-air blanket (COVIDIEN™ WarmTouch™ Full Body/Multi Access Blanket, Covidien Ilc, Mansfield, MA, USA) was positioned over the whole body except head and neck, covered by cotton blanket. Forced air warmer (COVIDIEN™ WarmTouch™ WT6000 Warming Unit, Covidien Ilc, Mansfield, MA, USA) was set to 'high level' (45℃) during 20 min. During the warming procedure, patients were asked every 5 min about their thermal comfort; if they felt overheated, the warmer was lowered to 41℃
1471613|NCT03184506|Other|no warming|patients were covered only with two layers of cotton blanket
1471614|NCT03184493|Drug|Celebrex plus Metformin|This group patients will receive metformin and celebrex.
1471615|NCT03184493|Drug|Celebrex|This group patients will receive celebrex.
1471616|NCT03184493|Drug|Metformin|This group patients will receive metformin.
1471665|NCT03184272|Procedure|ATB in narcosis|measurement under ATB in narcosis
1471618|NCT03184467|Drug|Normal Saline 0.9%|Normal saline 0.9% is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
1471619|NCT03184467|Drug|GV1001 0.56 mg|GV1001 0.56 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
1471620|NCT03184467|Drug|GV1001 1.12 mg|GV1001 1.12 mg is subcutaneously administered once weekly schedule for 4 weeks (4 times) followed by every two weeks until week 24 (10 times). A total number of administration is 14 times.
1471621|NCT03184454|Device|Medtronic PC+S Deep Brain Stimulation|"Deep Brain stimulation involves bilateral stereotactic placement of stimulating leads into specific brain structures. Leads are attached to permanent subcutaneous wires and battery-powered implantable neurostimulators (INSs). Noninvasive INS programming can achieve a balance between maximal benefit (reduction in disabling OCD symptoms), while minimizing adverse effects (eg sensorimotor effects such as dysarthria or paresthesias; as well as behavioral side effects, e.g., hypomania, insomnia, or increased anxiety)."
1471622|NCT03184441|Device|Premie Pouch|The Premie Pouch is an experimental device meant to manage the development of Deformational Plagiocephaly (DP) starting immediately following birth. The Premie Pouch has a concave-shaped foam insert that will provide a resting surface for the infant's head and body that will eliminate uneven pressure on the infant's occiput while maintaining correct body alignment. Also, the posterior neck area of the infant will be supported by a fixed bridge section of the foam insert. The Premie Pouch is designed specifically for the very low birth weight (VLBW) infant.
1471623|NCT03184428|Other|Postoperative observation and survey|For postoperative Observation with a survey we ask the patients (or in case of no information the ophthalmologist) whether they had undergone a YAG-Laser-Capsulotomy after Cataract-Surgery or not.
1471624|NCT03184415|Drug|DWC20155|tablet
1471625|NCT03184415|Drug|DWC20156|tablet
1471626|NCT03184415|Drug|placebo of DWC20155|tablet
1471627|NCT03184415|Drug|placebo of DWC20156|tablet
1471628|NCT03184402|Drug|DWJ1252|tablet
1471629|NCT03184402|Drug|Gasmotin|tablet
1471630|NCT03184402|Drug|Placebo of Gasmotin|tablet
1471631|NCT03184402|Drug|Placebo of DWJ1252|tablet
1471632|NCT03184389|Behavioral|Prompt to use smartphone apps for stress management|Study smartphone and software will be used to deliver intervention prompts to use stress management applications on the study smartphone at various times throughout the day, during at least 10 days of study participation. The delivery of prompts will be micro randomized to occur when participants are classified as stressed, and when participants are not classified as stressed. Headspace, a commercial stress management application, will be installed on the study smartphones. Thought Shakeup and Mood Surfing, stress management applications that are not commercially available, also will be installed on the study smartphones. These smartphone applications guide participants through stress management exercises that draw upon techniques from mindfulness, cognitive behavioral therapy, and acceptance and commitment therapy.
1471633|NCT03184376|Dietary Supplement|Prebiotic oligofructose|Powder format
1471634|NCT03184376|Dietary Supplement|Placebo maltodextrin|Powder format
1471635|NCT03184363|Drug|Clostridium Botulinum A Toxin|Clostridium Botulinum A Toxin
1471636|NCT03184350|Radiation|Adjuvant pelvic proton radiation|Patients will receive a dose of 45-50.4 Gray in 1.8 Gray fractions 5-6 times per week using active raster-scanning pencil beam proton radiation
1471637|NCT03184337|Behavioral|CDC's PreventT2 Program|The PreventT2 program will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving nutritional intake and increasing physical activity. It will also include individual biweekly phone calls for 6 months.
1471638|NCT03184337|Behavioral|CDC's PreventT2 Program with Added Sleep Content|The CDC's PreventT2 program with added sleep content will involve 8 group sessions administered over 3 months. It is a behavioral intervention focused on achieving weight loss by improving sleep quality and nutritional intake and increasing sleep duration and physical activity. It will also include individual biweekly phone calls for 6 months.
1471639|NCT03184324|Drug|DWP14012|tablet
1471640|NCT03184324|Drug|Esomeprazole|tablet
1471641|NCT03184324|Drug|DWP14012 placebo|tablet
1471642|NCT03184324|Drug|Esomeprazole placebo|tablet
1471643|NCT03184311|Other|High-intensity interval training (HIT)|Supervised 12-week HIT 3 times per week on a bicycle ergometer.
1471644|NCT03184311|Other|Usual care|Usual care, no supervised training sessions.
1471645|NCT03184298|Other|Social Norms Questionnaire|
1471646|NCT03184298|Other|Standardized Interview|
1471647|NCT03184298|Other|Group Discussion|
1471648|NCT03184285|Procedure|baseline alert 1|measurement in supine position
1471649|NCT03184285|Procedure|Anti-Trendelenburg-position (ATB)|measurement under ATB
1471650|NCT03184285|Procedure|ATB in narcosis|measurement under ATB in narcosis
1471651|NCT03184285|Procedure|baseline in narcosis 1|measurement in supine position in narcosis
1471652|NCT03184285|Procedure|passive leg raising|measurement under passive leg raising
1471653|NCT03184285|Procedure|volume bolus substitution|measurement in supine position after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
1471654|NCT03184285|Procedure|baseline in narcosis 2|measurement in supine position
1471655|NCT03184285|Procedure|start capnoperitoneum|measurement in supine position
1471656|NCT03184285|Procedure|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
1471657|NCT03184285|Procedure|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
1471658|NCT03184285|Procedure|ATB loss of capnoperitoneum|measurement under ATB
1471659|NCT03184285|Procedure|baseline|measurement in supine position
1471660|NCT03184285|Procedure|baseline alert 2|measurement in supine position
1471661|NCT03184285|Procedure|torso position rising 30° at the beginning|measurement in the recovery unit
1471662|NCT03184285|Procedure|torso position rising 30° at the end|measurement in the recovery unit
1471663|NCT03184272|Procedure|baseline alert 1|measurement in supine position
1471664|NCT03184272|Procedure|Anti-Trendelenburg-position (ATB)|measurement under ATB
1471671|NCT03184272|Procedure|ATB plus capnoperitoneum|measurement under ATB plus capnoperitoneum
1471672|NCT03184272|Procedure|ATB plus capnoperitoneum plus volume bolus substitution|measurement in ATB plus capnoperitoneum after volume bolus (15 ml/kgKG Sterofundin balanced solution intravenous)
1471673|NCT03184272|Procedure|ATB loss of capnoperitoneum|measurement under ATB
1471674|NCT03184272|Procedure|baseline|measurement in supine position
1471675|NCT03184272|Procedure|baseline alert 2|measurement in supine position
1471676|NCT03184272|Procedure|torso position rising 30° at the beginning|measurement in the recovery unit
1471677|NCT03184272|Procedure|torso position rising 30° at the end|measurement in the recovery unit
1471678|NCT03184259|Device|robotic lower limb system|patients will wear the robotic lower limb system and undergo 20-minute over-ground walking and 10-minute stair walking
1471681|NCT03184233|Procedure|Rapid ventricular pacing|Rapid ventricular pacing (RVP) is a technique to obtain flow arrest for short periods of time during dissection or rupture of the aneurysm. RVP results in an adequate fall in blood pressure which presents as an on-off phenomenon. The technique facilitates the dissection and manipulation of cerebral aneurysms and arteriovenous malformations (AVMs) and can be lifesaving in the case of an intraoperative bleeding or rupture
1471682|NCT03184233|Procedure|No rapid ventricular pacing|No rapid ventricular pacing is applied perioperatively.
1471683|NCT03184220|Procedure|Physiotherapy treatment|"The MRT group was treated five times with several maneuvers. Each maneuver was performed once per session by slow and progressive application of a light force. The whole procedure lasted no more than 45 minutes. The treatment included four basic maneuvers.
Suboccipital induction
Posterior elongation of the cervical fascia in Supine position
Assisted cervical fascia
Myofascial induction of sternocleidomastoid"
1471684|NCT03184220|Procedure|Physiotherapy treatment|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
1471685|NCT03184194|Drug|nivolumab-daratumumab|nivolumab-daratumumab will be given without len-dex until progression
1471686|NCT03184194|Drug|nivolumab-daratumumab with lenalidomide-dexamethasone|nivolumab-daratumumab with lenalidomide-dexamethasone will be given until progression
1471687|NCT03184181|Other|EPTE® group|Therapeutic Percutaneous Electrolysis once week for four weeks associated with eccentric exercises devices at home.
1471688|NCT03184181|Other|Dry needling group|The intervention for this group consisted of dry needling in trigger points associated with eccentric exercises devices at home.
1471689|NCT03184168|Drug|[14C]lorlatinib|Extemporaneously compounded oral solution of [14C]lorlatinib (approximately 100 mg/100 µCi)
1471690|NCT03184155|Drug|Nicardipine|200 mcg intracoronary nicardipine injection prior to PCI followed by an additional 2-4 doses of 100 mcg intracoronary nicardipine depending on complexity of PCI
1471691|NCT03184155|Drug|Sterile Saline|Bolus of intracoronary sterile saline injection prior to PCI followed by an additional 2-4 doses of sterile saline depending on complexity of PCI
1471692|NCT03184142|Behavioral|Simulation|Students witness the intimidation of one of their peers (who is an actor) by a professor (also an actor). (see arm description)
1471693|NCT03184142|Behavioral|Video|Student watch a 15-minute intimidation video (see arm description).
1471694|NCT03184142|Behavioral|Control group|No intervention. The students suture for 70 minutes
1471695|NCT03184129|Device|trial group|Patients with knee disease who will undergo knee arthroplasty will be randomized into trial group. The patients from the trial group will receive newly developed knee arthroplasty with knee prostheses purchased from Wuhan Yijiabao Biomaterial Co., Ltd..
1471696|NCT03184129|Device|control group|Patients with knee disease who will undergo knee arthroplasty will be randomized into control group. The patients from the control group will receive knee arthroplasty with knee prostheses purchased from Beijing AKEC Medical Co., Ltd., Beijing, China (approved by China Food and Drug Administration).
1471697|NCT03184116|Behavioral|Individual intervention|Individual intervention based on a cognitive-behavioral program Reasoning & Rehabilitation
1471698|NCT03184103|Diagnostic Test|anti streptolysin o titre and serum complement test|diagnostic lab test
1471701|NCT03184077|Procedure|Laceration Repair with Polyglactic 910|Polyglactic 910 suture for laceration repair
1471702|NCT03184077|Procedure|Laceration Repair with Monocryl|Monocryl suture for laceration repair
1471703|NCT03184064|Dietary Supplement|Blackcurrant extract (low dose)|Participants will consume a small beverage that contains blackcurrant extract (low dose) immediately before a high-carbohydrate meal.
1471704|NCT03184064|Dietary Supplement|Placebo|Participants will consume a small beverage that contains no fruit extracts immediately before a high-carbohydrate meal.
1471705|NCT03184064|Dietary Supplement|Citrus extract (low dose)|Participants will consume a small beverage that contains citrus extract (low dose) immediately before a high-carbohydrate meal.
1471706|NCT03184064|Dietary Supplement|Blackcurrant extract (high dose)|Participants will consume a small beverage that contains blackcurrant extract (high dose) immediately before a high-carbohydrate meal.
1471707|NCT03184064|Dietary Supplement|Blackcurrant and citrus extracts (low dose / low dose)|Participants will consume a small beverage that contains blackcurrant and citrus extracts (low dose / low dose)immediately before a high-carbohydrate meal.
1477845|NCT03136354|Procedure|Laparoscopic assisted Gastrectomy|
1471711|NCT03184025|Other|dentin adhesive|HEMA-containing and HEMA-free Self-Etch dentin adhesives clinical performance with or without surface sealant
1471712|NCT03184012|Device|NuSmile Zirconia crowns by NuSmile company|anterior carious teeth restored with Zirconia crowns
1471713|NCT03184012|Device|Composite resin strip crowns by 3M company|anterior carious teeth restored with Strip crowns
1471714|NCT03183999|Dietary Supplement|fermented ginseng (GINST)|Intervention group should take fermented ginseng (GINST) capsule 3 times a day, 2 capsules at one time for 12 weeks
1471715|NCT03183999|Dietary Supplement|Placebo|Control group should take placebo capsule 3 times a day, 2 capsules at one time for 12 weeks
1471716|NCT03183986|Device|Phototherapy|Phototherapy for 24 hours.
1948504|NCT02261714|Biological|TG01|"For patients not able to start TG01 quickly after surgery, the vaccination can start at the same time as the chemotherapy as long as they start within 12 weeks from surgery. Gemcitabine will start at the same time as TG01/GM-CSF and will be given on days 1, 8 and 15 of a four-weeks cycle up to 6 cycles in total.
TG01 will be given at a dose of 0.70 mg/injection and GM-CSF will be given at a dose of 30 micrograms both as intradermal injections.
Gemcitabine will be given at a dose of 1000 mg/m2 iv over 30 minutes"
1471719|NCT03183960|Behavioral|Mentor|Traditional rehabilitation.
1471720|NCT03183947|Procedure|fMRI|collection of functional brain data for 1 hour per day
1471721|NCT03183947|Behavioral|Neurofeedback|Task of the participants is to increase the activity in the selected brain region (left or right prefrontal cortex). After regulation they will get a feedback about the regulation success. (Patients: days 3 & 4; controls: Days 2 & 3)
1471722|NCT03183947|Other|PANAS|to assess the mood before and after the fMRI and after 4 weeks during a telephone interview
1471723|NCT03183947|Other|BDI-II|to assess depressive symptomatology before neurofeedback and 4 weeks after the intervention during telephone interview
1471724|NCT03183947|Other|ERQ|To assess emotion regulation strategies before and after neurofeedback training (patients: day 3&4; controls: day 2&3) and after 4 weeks during a telephone interview
1471725|NCT03183934|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a Dystrophic Epidermolysis Bullosa.
This study is a follow-up study without intervention.
Other Names:
Allogenic adipose-derived mesenchymal stem cells"
1471726|NCT03183921|Other|No intervention|No Interventions
1471727|NCT03183908|Biological|FLUAD|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
1471728|NCT03183908|Biological|Fluzone High-Dose|Advisory Committee on Immunization Practices (ACIP) Recommended Vaccine
1471729|NCT03183882|Behavioral|Personal Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months
1471730|NCT03183882|Behavioral|Peer Normative Comparison Feedback|One-time summary report of their individual history of opioid prescribing over the past 14 months WITH comparisons to (a) other providers at their site and (2) other providers at all 15 ED sites with similar prescribing
1471731|NCT03183869|Drug|Fecal microbiota|fecal microbial transplantation
1471732|NCT03183856|Device|Morning walk|a end-effector typed gait robot with a saddle
1471733|NCT03183856|Other|no Morning walk|ambulation voluntary or with a help of walker
1471734|NCT03183843|Drug|Dabigatran Etexilate|Dabigatran Etexilate 150 mg capsules for oral administration twice a day
1471735|NCT03183843|Drug|Warfarin|Warfarin 2.5 mg tablets for oral administration once a day
1471736|NCT03183830|Dietary Supplement|Nitrate-rich Beetroot Juice|The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day.
1471737|NCT03183830|Dietary Supplement|Nitrate-deplete Beetroot Juice|"See description of placebo juice in Arms for comparative information. The beetroot juice contains approximately 100kcal per 100mL of juice, equivalent to a glass of orange juice; the volume of juice per day for the study is 70mL. Volunteers will be informed that an average woman weighing 65kg should not consume more than 2000kcal per day, and an average man of 75kg not more than 2500kcal per day."
1471738|NCT03183817|Behavioral|Person-centred care at distance|Person-centred care at distance through an eHealth platform
1471739|NCT03183804|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer. This study is a follow-up study without intervention.
1471740|NCT03183804|Other|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer. This study is a follow-up study without intervention.
1948507|NCT02257294|Drug|Alteplase|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
1948508|NCT02257294|Other|Placebo|Single treatment consisting of a single slow infusion administration after reperfusion with aspiration thrombectomy ± angioplasty but before stenting during primary PCI.
1948509|NCT02241967|Device|Transcranial Direct Current Stimulation|Stimulation of brain areas associated with pain perception using low amplitude direct current delivered by electrodes attached to the scalp.
1471812|NCT03183206|Procedure|Cryosurgery , IRE surgery ,surgery|surgery will be used in local tumor
1471813|NCT03183206|Biological|γδ T cells|γδ T cells will be used against
1471814|NCT03183206|Other|γδ T cells/ Surgery|Combination γδ T cell and Cryosurgery, IRE surgery or surgery will be used in Breast Cancer
1948510|NCT02239614|Biological|TDENV-LAV|0.5 mL of the post-transfection LAV F17 vaccine
1948511|NCT02239614|Biological|TDENV-PIV 4 µg + alum adjuvant|0.5 mL of DENV serotypes 1-4 (4 µg / serotype) in alum adjuvant
1471745|NCT03183765|Drug|Measles-Mumps-Rubella Vaccine|"MMR vaccine will be injected 0.5 ml into the largest wart at 2-week intervals until complete clearance was achieved or for a maximum of 3 treatments.
Response to treatment will be evaluated by photographing the patients before treatment and 2 weeks after each session. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size or a decrease in the total number of warts), and no response (no change in size and number of warts)."
1471746|NCT03183765|Procedure|cryotherapy|"patients received cryotherapy with liquid nitrogen once every 2 weeks until complete clearance or for a maximum of 3 sessions.
Response to treatment will be evaluated by photographing the patients before treatment and 2 weeks after each session. The clinical response was graded into complete (complete cure), partial (if there was a decrease in the size or a decrease in the total number of warts), and no response (no change in size and number of warts)."
1471747|NCT03183752|Drug|Metformin|500 mg metformin three times daily
1471748|NCT03183752|Drug|Placebo|500 mg placebo three times daily
1948512|NCT02239094|Drug|Lurasidone (Latuda)|Antipsychotic medication approved for use with Bipolar disorder
1948513|NCT02233517|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy provides patients with the skills to 1) identify and challenge maladaptive cognitions that are contributing to self-destructive behaviors; and 2) implement techniques such as relaxation training, communication skills, and relaxation training to address physiological and environmental barriers to effective functioning.
1471751|NCT03183726|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor (VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide an new option in treating a diabetic foot ulcer.
This study is a follow-up study without intervention."
1471752|NCT03183713|Behavioral|Cognitive Behavioral Therapy|Psychologically symptomatic patients will then be randomized to 4-8 weeks of placebo phone calls (Group PS-PL-Sx) or 4-8 weeks of cognitive behavior therapy treatment (PS-CBT-Sx) based on a 1:1 randomization ratio. Subjects randomized to receive CBT before surgery will proceed to 6 sessions given within 4-8 weeks by a licensed psychologist specializing in pain. CBT sessions will be 30 minutes in length, and focus on empirically supported behavior management, problem solving, cognitive restructuring, and relaxation training. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone.
1471753|NCT03183713|Behavioral|Sham Therapy|Study nurse will conduct six sessions (30 minutes/ session) over a 4-8 week time period. The first session will be performed in person, and the subsequent 5 sessions will be performed over the phone. Sham sessions will entail how to prepare for surgery and expectations for recovery, and will go over content that the treatment and control groups will receive in handout form.
1471754|NCT03183700|Device|Self sampling device|The investigators will allocate randomly the women to two different self sampling devices differing in having or not a preservative buffer
1471755|NCT03183700|Other|Cervical ThinPrep sampling|Women are inviated with a standard invitation letter to perform cervical ThinPrep sampling at the clinic on a pre-fixed date
1471756|NCT03183674|Drug|Oxytocin|Single dose oxytocin 45 minutes before the test
1471757|NCT03183674|Other|placebo|saline solution 0,9% spray nasal
1471758|NCT03183661|Biological|ALLO-ASC-CD|ALLO-ASC-CD is intravenous infusion containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells are directed to injured tissue, and reduce inflammation. Furthermore their immunomodulatory effects are significant for treating immune-related disease. Finally, ALLO-ASC-CD may provide a new option in treating a crohn's disease. This study is a follow-up study without intervention.
1471759|NCT03183648|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.
This tudy is a follow-up study without intervention.
Other Names:
Allogenic adipose-derived mesenchymal stem cells"
1471760|NCT03183635|Procedure|Balance training|Improvement of balance ability in stroke patients
1471761|NCT03183622|Biological|ALLO-ASC-DFU|"ALLO-ASC-DFU is a hydrogel sheet containing allogenic adipose-derived mesenchymal stem cells. Adipose-derived stem cells have anti-inflammatory effect and release growth factors such as vascular endothelial growth factor(VEGF) and hepatocyte growth factor (HGF), which can enhance wound healing and regeneration of new tissue, finally may provide a new option in treating a burn.
This tudy is a follow-up study without intervention.
Other Names:
Allogenic adipose-derived mesenchymal stem cells"
1471762|NCT03183609|Other|Gluten Flour in Protein Shake|15 Grams Gluten Flour BID
1471763|NCT03183609|Other|Rice Flour in Protein Shake|15 Grams Rice Flour BID
1471764|NCT03183596|Drug|Bupivacaine|20-60cc of 0.25% Bupivacaine
1471765|NCT03183596|Drug|Dexamethasone|2-4mg of Dexamethasone
1471766|NCT03183583|Procedure|Tissue adhesive in primary Total Hip and Total Knee arthroplasty|Use of tissue adhesive in primary Total Hip and Total Knee arthroplasty
1471767|NCT03183570|Drug|[18F]FP-R01-MG-F2|7mCi (range 6-9mCi) [18F]FP-R01-MG-F2 will be administered to patients with IPF
1471770|NCT03183544|Combination Product|Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit|The patients will receive a single injection of Gallium-68 PSMA-11 to diagnose biochemical relapse of prostate cancer after treatment.
1471771|NCT03183531|Diagnostic Test|C reactive protein|Addition of C-reactive protein test for management strategies to follow-up febrile neonates in outpatient.
1471772|NCT03183518|Other|Facial micellar cleanser|Each participant will have the test product applied topically via semi occlusive patch, on-site by a technician.
1471773|NCT03183518|Other|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Each participant will have the reference product applied topically via semi occlusive patch, on-site by a technician.
1471774|NCT03183505|Drug|Anyu Peibo|Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
1471775|NCT03183505|Drug|Placebo|Placebo Capsule, twice per day, oral after breakfast and supper
1471882|NCT03182738|Device|VIP app without HIV-related symptom strategies.|The control group will receive the VIP app without HIV-related symptom strategies
1471777|NCT03183479|Drug|Fibrinogen Concentrate Human|When the estimated blood loss reaches 15% of estimated blood volume, the patients in treatment group will receive fibrinogen concentrate 30mg kg-1. For safety concern, functional fibrinogen will be measured and the maximum fibrinogen concentrate administration for each individual shall not exceed either the results calculated based on functional fibrinogen measurements: fibrinogen concentrate dose (g) = (FLEVintraop [mg/dL] - FLEVpreop [mg/dL])×bodyweight (kg)×0.0007 or 2g. Fibrinogen concentrate will be diluted in 100mL of sterile water and then be administered to patients.
1471778|NCT03183479|Drug|Normal saline|100mL normal saline will be administered to patients in control group as placebo
1471779|NCT03183466|Procedure|arthroscopic repair|
1471780|NCT03183466|Procedure|arthroscopic debridement|
1471781|NCT03183453|Behavioral|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
1471782|NCT03183440|Dietary Supplement|PREBIOTICS|women will daily take a mixture of Galacto-Oligo-Saccharide/inuline (ratio 9:1) from inclusion to delivery
1471783|NCT03183440|Other|PLACEBO|women will daily take placebo (maltodextrine) from inclusion to delivery
1471784|NCT03183427|Diagnostic Test|MR of the brain|MR of the brain without gadolinium, incl. T2-weighted image
1471785|NCT03183414|Other|echocardiographic measurements|echocardiographic parameters of the RV, measured with TEE and the right ventricular ejection fraction (thermodilution)
1471786|NCT03183388|Behavioral|BE-SMART|Subjects will participate in 12 therapy sessions, at a rate of about 1 session every one to two weeks. Sessions are anticipated to last about 1 hour each. Sessions may be focused on teaching skills to regulate emotions or regularize sleep and activity. These therapy sessions may be videotaped and audiotaped (only with the expressed written consent of the subject, and when appropriate, the subject's parent or guardian). Subjects will be asked to complete worksheets and practice the skills learned from these sessions and they will be asked questions about how they are feeling. There will interview assessments and scanning performed prior to treatment and at the midpoint and end to assess progress. The intervening 9 sessions may be by video telecommunication.
1471787|NCT03183375|Drug|Hydroxyurea|Hydroxyurea (starting from 10mg/kg/day with increasing dose by 2mg/kg/day until the desired response is achieved. The maximum dose given will be 20mg/kg/day)
1471788|NCT03183362|Device|Barbed suture ( STRATAFIX™ )|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures.
1471789|NCT03183362|Device|Conventional suture (VICRYL™)|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Patients who will return for a repeat caesarean (elective or emergency) will be evaluated intraoperatively for the presence of adhesions between various pelvic structures .
1471790|NCT03183349|Procedure|deprotienized bovine bone (tutogen)|
1471791|NCT03183349|Procedure|platelet rich fibrin|
1471792|NCT03183336|Procedure|ridge split interpositional block graft|
1471793|NCT03183336|Procedure|decortication Onlay block graft|
1471794|NCT03183323|Behavioral|Telerehabilitation|Activity trackers. Mio Slice is worn through the whole study. Actigraph is worn for one week, at 4 different timepoints through the study.
1471795|NCT03183310|Drug|Chlorpromazine|an intravenous bolus injection of Chlorpromazine will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of dopamine antagonism on esophageal sensitivity
1471796|NCT03183310|Device|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
1471797|NCT03183310|Drug|Placebo - Concentrate|an intravenous bolus injection of saline (NaCl 0.9%) will be administered . After an incubation period of 15 minutes esophageal sensitivity will be assessed by multimodal stimulation.
1471798|NCT03183297|Drug|JMI-001|JMI-001, a combination product of naproxen and fexofenadine
1471799|NCT03183297|Drug|Naproxen|Naproxen sodium 220mg
1471800|NCT03183297|Drug|Fexofenadine|Fexofenadine 60mg
1471801|NCT03183297|Drug|placebo|placebo comparator
1471802|NCT03183271|Radiation|external beam proton radiation therapy.|Treatment of irradiation with protons beam The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, or at referral Hospitals enrolling head and neck patients for treatment with photon IMRT.
1471803|NCT03183258|Other|Sentinel skin flap|Donor-derived vascularised composite allograft (sentinel skin flap)
1471804|NCT03183245|Biological|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
1471805|NCT03183245|Procedure|Arteriovenous fistula (AVF)|Surgical creation of an autologous arteriovenous fistula and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
1471806|NCT03183232|Procedure|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
1471807|NCT03183232|Biological|γδ T cell|γδ T cells will be used against Lung Cancer
1471808|NCT03183232|Other|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Lung Cancer
1471809|NCT03183219|Procedure|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
1471810|NCT03183219|Biological|γδ T cell|γδ T cells will be used against Liver Cancer
1471811|NCT03183219|Other|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Liver Cancer
1471815|NCT03183193|Other|Control diet|The participants follow a conventional and balanced distribution of macronutrients (30% fat, 15% protein, 55% carbohydrates), adequate fiber (25-30 g/day) and dietary cholesterol (<250 mg/day) intake according to AHA guidelines. This strategy was included within a personalized energy-restricted diet (-30% individual needs) under healthy lifestyle advice in order to achieve the objectives of AASLD (loss of at least 3-5% of the initial body weight and up to 10% needed to improve necroinflammation).
1471816|NCT03183193|Other|FLiO diet|The participants follow a strategy based on a distribution of macronutrients 30-35% lipid (extra virgin olive oil and fatty acids Ω3 in detriment of saturated, trans and cholesterol)/ protein 25% (vegetable against animal)/carbohydrates 40-45% (low glycaemic index, fiber 30-35 g/day); high adherence to the Mediterranean diet and natural antioxidants; meal frequency of 7 meals/day; size/composition of the ration suitable for each moment; including traditional foods with no additional economic cost that will allow diet adherence without abandonment; avoid inappropriate mealtimes and the eating manners as the eating rate. The participants are instructed to follow this strategy within a personalized energy-restricted diet (-30%) and under healthy lifestyle advice to achieve AASLD objectives.
1471817|NCT03183180|Diagnostic Test|Echocardiogram|Current cardiac state will be assessed by an experienced cardiologist, including a full new Echocardiogram examination
1471818|NCT03183167|Other|No intervention|
1471819|NCT03183154|Other|no intervention|no intervention
1471821|NCT03183128|Drug|SER-109|"SER -109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
Other Names:
Eubacterial Spores, Purified Suspension, Encapsulated"
1471822|NCT03183128|Drug|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
1471823|NCT03183115|Procedure|Radiofrequency ablation|HALO360 System (Covidien GI Solutions, Sunnyvale, California, USA), which has been approved by the US Food and Drug Administration (FDA) and is approved for use in Europe (CE mark) and Taiwan (Ministry of Health and Welfare).
1471824|NCT03183115|Device|Endoscopy|The participants will receive meticulous endoscopic examination with Lugol chromoendoscopy and Narrow-band imaging
1471825|NCT03183115|Drug|Lugol's Solution (1.5%)|Before the RFA intervention, the participants will received Lugol staining over the esophagus
1471826|NCT03183102|Dietary Supplement|Flaxseed|2 months of dietary flaxseed supplementation
1471827|NCT03183102|Drug|Estrogen suppression|30 days GnRH agonist treatment
1471828|NCT03183089|Drug|Rohto Dry-Aid®|
1471829|NCT03183089|Drug|Systane® Ultra|
1471830|NCT03183076|Other|modified adkins diet|Patients were assigned to two groups, one of them received modified adkins diet for treatment of drug-resistant epilepsy. It consists in the free intake of proteins and fats, and the restriction of carbohydrates that are gradually being installed. Its mechanism of action that induces a state of ketosis
1471831|NCT03183076|Drug|Pharmacotherapy without diet|Patients were assigned to two groups, one of them received conventional treatment with antiepileptic drugs without a special diet
1471832|NCT03183063|Device|4DCT and SPECT/CT|Each patient will receive 2x4DCT followed by SPECT/CT.
1471833|NCT03183050|Behavioral|Question Prompt List|Patients receive a booklet that contains questions regarding their diagnosis, testing and treatment.
1471834|NCT03183037|Procedure|Acupuncture|The acupuncture group will undergo 8 weeks of outpatient acupuncture or sham acupuncture treatments (twice weekly for 2 weeks, then weekly for 6 weeks, 10 treatments in total). The investigators have designed this approach to standardize acupuncture treatment for future broad use; it is based on the understanding that CIPN is a global symptom complex rather than individual isolated or local symptoms.
1471835|NCT03183037|Procedure|Sham Acupuncture|Subjects in this group will receive the sham acupuncture procedure on the same schedule as subjects in the real acupuncture group. In both groups, patients' eyes will be covered with patches so they cannot observe the treatment procedure. To improve incentive to join and stay in the study, we will unblind all patients at Week 12, and offer those randomized to the Sham group 8 weeks of Acu (real) treatment. All points used will be documented.
1471836|NCT03183037|Other|Usual Care Group|Patients go to clinic three times during the study, at Baseline, Week 8, and Week 12 to undergo QST and CPM tests. Patients will complete all questionnaires (CIPN severity by 0-10 11-point numeric rating scale, FACT/GOG-Ntx-11, NPS) and their pain medication use at these time points. Week 4 questionnaires can be completed over the phone. As an incentive for patients to join the study - and for those randomized to control to stay in the study - controls will be offered 8 weeks of Acu (real) treatment once they have completed Week 12 assessments.
1471837|NCT03183037|Behavioral|questionnaires|FACT/GOG-Ntx, Neuropathic Pain Scale (NPS),Treatment Expectancy Scale (TES), Quantitative Sensory Testing (QST), Insomnia Severity Index (ISI), Hospital Anxiety and Depression Scale (HADS), Brief Fatigue Inventory (BFI)
1471838|NCT03183024|Biological|benralizumab|open-label treatment
1471839|NCT03183024|Biological|placebo|sterile water to mimic benralizumab
1471840|NCT03183011|Other|MRI|Cardiac MRI
1471841|NCT03182998|Other|Internet-Based Intervention|"Receive Knowing your Options decision aid"
1471842|NCT03182998|Other|Internet-Based Intervention|"Receive Prostate Choice decision aid"
1471843|NCT03182998|Other|Best Practice|Undergo usual care
1471844|NCT03182998|Other|Quality-of-Life Assessment|Ancillary studies
1471845|NCT03182998|Other|Questionnaire Administration|Ancillary studies
1471846|NCT03182998|Other|Survey Administration|Ancillary studies
1471847|NCT03182998|Other|Laboratory Biomarker Analysis|Correlative studies
1471848|NCT03182985|Behavioral|Time Restricted Feeding|Participants will reduce the amount of time they eat to 10 hours per day and will log their dietary intake using a smartphone application.
1471849|NCT03182972|Other|Medication reconciliation intervention|
1471850|NCT03182959|Drug|Avmacol®|Avmacol® tablets
1471851|NCT03182946|Diagnostic Test|Platelet mapping Thromboelastography|These diagnostic tests will be acquired in patients with brain injury, to determine prediction of clinical, functional and psychological outcome.
1471949|NCT03182257|Drug|ONO-7579|ONO-7579 Tablets
1471852|NCT03182933|Drug|Peripheral Nerve Blockade|Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization
1471853|NCT03182933|Behavioral|10 meter walk test on post-operative day 1|Patient asked to walk 10 meters at comfortable pace on post-operative day one when deemed safe to do so by the physical therapist
1471854|NCT03182933|Other|In person and over the phone questionnaire|Presuming the patient has left the hospital each patient will be called on post-operative day 2, 3 to assess nausea, opioid consumption, satisfaction with anesthesia technique, nausea and vomiting as well as pain scores
1471855|NCT03182933|Device|Force transduction of quadriceps strength|Patient will be asked to flex quadriceps at maximal ability and a transducer (Kiio device) will record a force value pre operatively and on post operative day 1
1471856|NCT03182920|Drug|Lasmiditan|Oral administration
1471857|NCT03182920|Drug|Placebo|Oral administration
1948514|NCT02233517|Behavioral|Present Centered Therapy|"Present Centered Therapy utilizes interpersonal process, supportive techniques, identification of response options, encouragement of adaptive reactions, and focus on the here-and-now to support patients in their efforts to improve functioning."
1471861|NCT03182881|Other|Lymphatic Drainage|It was applied with the patient in a supine position with 30º elevation of the arm and very superficial and smooth maneuvers were performed in the axillary lymph nodes, the chest region and the arm.
1471862|NCT03182881|Other|Myofascial Release|For the use of the treatment the bases of Pilat, A. 2016 were followed. The global and specific techniques for the periganglionar and upper thoracic region were chosen. The application of each smooth maneuver three-dimensional fascial movement has been carried out has an approximate duration of about 10 minutes and a total of 50 minutes.
1471863|NCT03182855|Drug|Ticagrelor|ADP-receptor blocker. Oral formulation. Standard Therapy in Acute Myocardial Infarction. Administered in the ambulance in arm 1 and in the hospital (catheterization laboratory) in arm 2.
1471864|NCT03182855|Drug|Cangrelor Tetrasodium|Intravenous ADP-receptor blocker. Administered after hospital arrival in the catheterization laboratory.
1471865|NCT03182842|Device|FreeStyle Libre FGM|Insulin dosing based on FreeStyle Libre FGM system that is indicated for measuring interstitial fluid glucose levels in people (age 4 and older) with diabetes mellitus.
1471866|NCT03182842|Device|SMBG - Blinded Sensor|Insulin dosing based on SMBG
1471867|NCT03182829|Diagnostic Test|DOAC Dipstick|Patients collect a sample of urine for analysis.
1471868|NCT03182816|Biological|anti-CTLA-4/PD-1 expressing EGFR-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
1471869|NCT03182803|Biological|CTLA-4/PD-1 antibodies expressing mesoCAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing mesothelin-targeted CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
1471870|NCT03182790|Behavioral|Instant Messaging IM|Smokers can communicate with counsellors in real-time through instant messaging (social media). Our counsellors will trigger the conversation and invite the smokers to response after initial contact. Counsellors will keep contact with the smokers to offer help, positive encouragement, reflections and reminders about SC according to smokers' personal needs and to encourage them to seek SC services. Details of successfully booked SC appointment (e.g. SC services address, contact information, date, appointment number etc.) will be delivered to the smokers using IM. All smokers will receive a reminder-to-attend IM messages 1-3 days before the appointment date.
1471871|NCT03182790|Behavioral|Regular messages|Regular messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent to smokers after initial contact via social media.
1471872|NCT03182790|Behavioral|AWARD advice|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again (if the smokers refused to set quit date).
1471873|NCT03182790|Behavioral|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans"
1471874|NCT03182790|Behavioral|Brief advice|Very brief, minimal and general smoking cessation advice
1471875|NCT03182790|Behavioral|COSH booklet|A general smoking cessation self-help booklet
1471876|NCT03182790|Behavioral|Placebo Messages|Placebo messages will be sent via smart phones (e.g. social media) to remind subjects to take follow-up calls before each follow-up time points.
1471877|NCT03182790|Behavioral|Warning Leaflet|The leaflet will include the information about the health risks of smoking.
1471878|NCT03182777|Procedure|Dental restorative procedure|Infiltration of two cartridges (3.6 mL) of local anesthetics with 2% lidocaine with or without epinephrine 1:100,000, in two sessions with an interval of seven days between them, in oral mucosa in patients with cardiac channelopathies.
1471879|NCT03182764|Other|No intervention|No intervention
1471880|NCT03182751|Drug|Tranexamic Acid (TXA)|The cohort of patients treated with early administration of TXA in the Emergency Department will be compared to a control group who were not treated with TXA at any point.
1471881|NCT03182751|Drug|Placebo|The cohort of patients treated with a placebo in the Emergency Department will be compared to the active comparator group that will receive early administration of Tranexamic Acid.
1948515|NCT02232672|Device|Choline PET/CT and MeAIB PET/CT|Choline PET/CT and MeAIB PET/CT
1948516|NCT02232724|Device|Choline PET/CT and Dual time point FDG PET/CT|Choline PET/CT and dual time point FDG PET/CT
1471883|NCT03182738|Device|VIP app that delivers HIV-related symptom strategies.|The Intervention group will receive the VIP app that delivers HIV-related symptom strategies
1471884|NCT03182725|Drug|Ivabradine|Ivabradine is prescribed for treatment of chronic heart failure through inhibition of the f-channels (If) within the sinoatrial node.
1471885|NCT03182725|Drug|Placebo|A substance that has no therapeutic effect and will act as a control.
1471886|NCT03182712|Dietary Supplement|n-3 PUFA Group|Participants received n-3 PUFA capsules (capsules containing 180 mg of eicosapentaenoic acid, 120 mg of docosahexaenoic acid and 2 mg of vitamin E). Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
1471887|NCT03182712|Dietary Supplement|Placebo Group|Participants received capsules containing 500 mg of gelatin.Three capsules were ingested daily for eight weeks, distributed between breakfast, lunch and dinner.
1471888|NCT03182699|Diagnostic Test|cardiac MRI|non contrast heart MRI at baseline and after 1 year of therapy
1471889|NCT03182699|Diagnostic Test|echocardiography with strain|echocardiography at baseline and after 1 year of therapy
1471890|NCT03182699|Diagnostic Test|Laboratory tests|drawing blood from dialysis machine
1471891|NCT03182699|Diagnostic Test|Body composition monitoring|Measurement with BCM (Fresenius) machine
1471892|NCT03182699|Diagnostic Test|lung ultrasound|ultrasound
1471895|NCT03182673|Drug|SHR7390|Drug: SHR7390 SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
1471896|NCT03182673|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 immunoglobulin G4 (IgG4) monoclonal antibody. SHR-1210 is provided as the lyophilized powder,200 mg/vial.SHR-1210 was given with 200mg fixed dose intravenously per 2 weeks at the D1 and D15.Intravenous infusion over 30 min
1471897|NCT03182647|Procedure|Surgically treatment of the ACL|Surgical initial ACL treatment
1471898|NCT03182647|Other|Non surgical initial ACL treatment|Non surgical initial ACL treatment
1471899|NCT03182634|Drug|Fulvestrant|
1471900|NCT03182634|Drug|Neratinib|
1471901|NCT03182634|Drug|AZD5363|
1471902|NCT03182621|Behavioral|THINK|The THINK curriculum was based on the principles of exercise physiology and health behaviors. Sessions included educational components, concentrating on physiology, nutrition, laboratory experiences, and structured physical fitness activities.
1471903|NCT03182621|Behavioral|SPARK|traditional YMCA program
1471904|NCT03182608|Diagnostic Test|Noninvasive ultrasound assessment|An investigator evaluate the L4-5 interspinous level using anatomic landmarks in turn, then another independent investigator assess the consistency of the landmarks-guided interspinous level with the actual one by noninvasive ultrasound assessment.
1471905|NCT03182595|Drug|Paracetamol|Volunteers will be screened at visit 1, and if they meet the inclusion/exclusion criteria they will receive the intervention at visit 2. At visit 2, complying subjects will receive a tablet containing 1 gram of paracetamol and have a blood sample collected 2 hours after administration; these procedures will be repeated on 2 more occasions (visits 3 and 4). The subjects will come for 5 visits during the study. Visit 1 and 2 must occur within 7 days of each other, visits 2, 3 and 4 will be four weeks (± 3 days) apart and visit 5 scheduled four weeks (± 3 days) after visit 4.
1471906|NCT03182582|Device|Erbium:Yttrium-Aluminum-Garnet (Er:YAG) Laser Debridement|Laser debridement entailed usage of an Er:YAG laser, employing the JOULE® machine (Sciton, Inc., Palo Alto, California). Full-field ablation was performed using the 2940 nm Er:YAG Contour TRL Resurfacing® application with the following settings: fluence - 50 J/cm2, spot overlap - 50%, pattern repeat - 0.5 seconds, spot size - 3-mm (Figure 1). Debridement was carried out until all fibrinous and/or necrotic tissues were removed, and healthy, bleeding tissue was visualized.
1471907|NCT03182582|Procedure|Scalpel/Curette Debridement|Using a scalpel/curette, each patient's chronic wound is debrided until healthy, viable tissue is noted.
1471908|NCT03182569|Device|FLEXIBLE CATHETER|
1471909|NCT03182569|Device|hourly rigid needle puncture|
1471910|NCT03182556|Behavioral|Electromyography-Biofeedback (EMG-BFB) training|The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.
1471911|NCT03182556|Behavioral|Aquatic exercise|Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
1471912|NCT03182543|Dietary Supplement|Mango pulp beverage|"The subject consumes mango pulp beverage (200 g mango pulp + 600 mL water). 2 hours later subject performs the exercise test.
Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
1471913|NCT03182543|Dietary Supplement|Mango pulp and peel beverage|"The subject consumes mango pulp and peel beverage (160 g mango pulp + 40 g mango peel + 600 mL water). 2 hours later subject performs the exercise test.
Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
1471914|NCT03182543|Dietary Supplement|Control beverage|"The subject consumes control beverage (600 mL water). 2 hours later subject performs the exercise test.
Washout: 1 week washout period prior to the administration of this intervention to avoid possible carryover effect."
1471954|NCT03182231|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
1471915|NCT03182530|Device|ulnar artery compression device|a radial compression device will be applied at the access site. another closure device will be used for ipsilateral ulnar artery compression for 1-hour duration in order to increase peak velocity blood flow into the radi¬al artery. neither pulse oxymetry nor duplex ultrasonography will be performed in case of ulnar artery compression. after ulnar artery compression, the initial compression of the radial artery will be reduced by letting up the pressure until bleeding will be seen and then adding minimal pressure whenever needed in order to maintain radial artery patency.
1471916|NCT03182530|Device|radial artery compression device guided with plysthmography|a radial compression device will be applied at the access site. A pulse oximeter sensor was placed over the index finger. Transient ipsilateral ulnar artery will be occluded manually to evaluate the status of radial artery patency by plethysmography (digital pulse analysis), and if there's lack of signal, the process of deflation and reinflation of the radial artery device's bladder will be repeated over the next 15 min to attempt re-establishment of antegrade radial artery flow without affecting hemostasis
1471917|NCT03182530|Device|radial artery compression device|patients undergo the conventional hemostasis compression by using a radial compression device applied at the access site.
1471920|NCT03182491|Diagnostic Test|Biomarkers (platelet activating factor [PAF], anaphylatoxins) and basophil activation test (BAT)|Analysis of biomarkers and basophil activation test
1471921|NCT03182478|Behavioral|Rothbaum protocol in individual format|8-week 45 minute session Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
1471922|NCT03182478|Behavioral|Rothbaum protocol in group format|8-week 90 minute session of Rothbaum CBT protocol adapted to Skin Picking, changing the focus on pulling hair to picking skin. Session 1: psychoeducation of the skin picking habit and how CBT works, patients initiate the self-monitoring of the habit. Session 2: techniques of habit reverse, adapted by having the skin as a target instead of the hair. The session 3: anxiety management using diaphragmatic breathing and muscle relaxation. Sessions 4 to 6: management of dysfunctional thoughts, using cognitive tools as the evidence analysis, reattribution of roles and gravity scale. Session 7: change of roles and role-playing, with patient playing the role of therapist, applying the Rothbaum Protocol to treat Skin Picking, so reviewing all the protocol techniques. Session 8: relapse prevention.
1471923|NCT03182465|Diagnostic Test|Value of ProCalcitonin|The predictive value of ProCalcitonin in patients with solid tumors presenting a febrile neutropenia due to chemotherapy at emergency unit will be a factor to detect the level of bacteria.
1471924|NCT03182452|Other|Alarm Advisor Software|Software provides advice on tailoring alarm limits to patients
1471929|NCT03182426|Drug|Plerixafor|Systemic CD34+ stem cell mobilization for beta-cell repair
1471930|NCT03182426|Drug|Alemtuzumab|T-cell depletion
1471931|NCT03182426|Drug|Anakinra|Anti-inflammatory
1471932|NCT03182426|Drug|Etanercept|Anti-inflammatory
1471933|NCT03182426|Drug|Liraglutide|Beta-cell regeneration
1471934|NCT03182413|Drug|Placebo|
1471935|NCT03182413|Drug|Modafinil|
1471936|NCT03182413|Drug|THN102|
1471937|NCT03182400|Behavioral|Neurophysiological assessment|Assessment of cerebral electrical activity Assessment of ocular exploration Neurovegetative assessments
1471938|NCT03182400|Behavioral|Neuropsychological assessment|sub-tests, scales, surveys, reaction time measurement
1948523|NCT02206529|Behavioral|Social Network Engagement+Std Treatment|
1471941|NCT03182361|Device|Implantation of BioComp Industries cranio-maxillo-facial (CMF) screw implants|Placement of BioComp Industries extraoral screw implants with diameters 3.4mm or 4mm and lengths 3.4mm or 4mm in temporal, nasal or orbital bone
1471942|NCT03182348|Procedure|Optical coherence tomography|As part of the clinical angioplasty procedure the patient will have a coronary guidewire passed down the artery usually from the groin to the heart which is used to position balloons and stents. OCT passes over the wire in the same way. From the patients perspective the procedure may take a small amount of additional time - maximum 10-15 minutes. We would like to be able to pass a second wire down the same coronary artery called a 'buddy wire' which is sometimes required in coronary procedures. This would be used to inflate a balloon at low pressure near the area of interest in the heart in order either to exclude blood or to oppose the OCT catheter to the vessel wall if required.
1471943|NCT03182335|Other|sedation awakening trial|vital signs and delirium assessment (CAM-ICU) at baseline then following routine sedation awakening trial. Patient will thus serve as their own control for these interventions
1471944|NCT03182322|Drug|intranasal insulin|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter (formulation containing rH-insulin, benzalkonium chloride, glycerol and water)
1471945|NCT03182322|Other|Placebo|Total of 6 months treatment; daily for the first 7 intervention days and one day per week thereafter placebo (formulation containing benzalkonium chloride, glycerol and water)
1471946|NCT03182296|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT
1471947|NCT03182283|Behavioral|Person-centered psychosis care|Person-centered care educational intervention for staff with following implementation of person-centered care in the clinic
1471948|NCT03182270|Diagnostic Test|nCLE|Procedure: EUS-FNA Device: nCLE
1471955|NCT03182218|Drug|Direct oral anticoagulant|Time of direct oral anticoagulant withdrawal Use or not of bridging with low molecular weight heparin
1471956|NCT03182205|Other|IME|The IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets. Inspiratory load will be set at 40% of maximum static inspiratory pressure. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a clip nasal.
1471957|NCT03182205|Other|Sham IME|The Sham IME session protocol will consist of 8 sets of 2 minutes with 1 minute rest between sets, but without a load generating resistance. In addition, the volunteer will be instructed to perform diaphragmatic breathing, maintaining a respiratory rate in the range of 12 to 15 ipm (feedback from the evaluator) and the entire exercise protocol will be performed with the patient sitting with their feet flat on the floor and using a nasal clip.
1471958|NCT03182192|Radiation|68Ga-NODAGA-exendin-4 PET/CT|68Ga-NODAGA-exendin-4 PET/CT scan
1471959|NCT03182179|Drug|Ondansetron 4 MG|Ondansetron is taken orally BD
1471960|NCT03182179|Drug|Placebo|Placebo is taken orally BD
1471964|NCT03182153|Device|Extended Cardiac Monitoring|Extended External Cardiac Monitoring
1948524|NCT02206529|Behavioral|Standard Treatment|Standard Treatment = family-based behavioral pediatric obesity treatment, as per protocol outlined in FOCUS trial (Family Overweight: Comparing Use of Strategies; NCT00746629)
1471966|NCT03182127|Radiation|Magnetic resonance imaging|MRI of the elbow is performed in either the supine or prone position A high-resolution surface coil is essential in order to obtain high-quality images . Elbow MRI scanning protocols consist of a combination of T1-weighted and fat-suppressed T2- or proton density-weighted images obtained in the axial, coronal oblique, and sagittal oblique imaging planes. Axial images should extend from the distal humeral diaphysis to the level of the bicipital tuberosity of the radius. From the axial images, coronal oblique images should be prescribed parallel to a line drawn through the centre of the humeral epicondyles, with sagittal oblique images prescribed perpendicular to this. Additional sequences may be helpful in certain circumstances; .
1471967|NCT03182127|Device|Ultrasound|ultrasound is performed by patient in supine or setting position,applied superficial probe , 2D image and color doppler if indicated.
1471968|NCT03182114|Other|supine position|the patient will be placed in regular supine position after spinal anesthesia
1471969|NCT03182114|Other|left lateral tilted position|the patient will be placed in left lateral tilted position after spinal anesthesia
1471970|NCT03182114|Drug|Bupivacaine|The patient will receive 10 mg Bupivacaine for spinal anesthesia
1471971|NCT03182101|Behavioral|Exposure Therapy|Exposure Therapy is a form of Cognitive Behavioral Therapy. There is strong evidence for exposure as a necessary and primary ingredient for treating anxiety and OCD, and exposure is the most common practice element in treatment protocols for anxiety.
1471972|NCT03182088|Drug|norepinephrine infusion (0.05 mcg/Kg/min)|The patients will receive a bolus of 10 mcg norepinephrine followed by norepinephrine infusion of (0.05 mcg/Kg/min)
1471973|NCT03182088|Drug|norepinephrine infusion (0.1 mcg/Kg/min)|The patients will receive a bolus of 10 mcg norepinephrine followed by norepinephrine infusion of (0.1 mcg/Kg/min)
1471974|NCT03182088|Drug|norepinephrine infusion (0.15 mcg/Kg/min)|The patients will receive a bolus of 10 mcg norepinephrine followed by norepinephrine infusion of (0.15 mcg/Kg/min)
1471975|NCT03182088|Drug|Bupivacaine|The patient will receive spinal anesthesia using Bupivacaine (10 mg).
1471977|NCT03182062|Procedure|Alveolar recruitment maneuver|To start the Alveolar Recruitment Maneuver (ARM) the ventilatory mode will be changed to pressure-controlled mode (PCV) with 20 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 5 cmH2O. The PEEP level will be increased in 5 cmH2O steps every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (20 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
1471978|NCT03182062|Procedure|PEEP Titration Trial|The ventilation mode will then switch back to volume controlled ventilation with the same baseline settings but with 20 cmH2O PEEP level. Then PEEP will be reduced in 2 cmH2O steps each maintained for 5 breaths the level of PEEP with the best (higher) dynamic compliance.
1471979|NCT03182062|Procedure|Lung protective ventilation|Ventilatory strategy with a PEEP level of 5 cmH2O but without recruitment maneuvers and PEEP titration trial.
1471980|NCT03182049|Procedure|Airway assessment|Airway Specialist (Otolaryngology, Pulmonology, Thoracic Surgery), assess clinical location and degree of airway compromise, glottic mobility, and sinonasal disease.
1471981|NCT03182049|Procedure|Rheumatology assessment|Clinically assess systemic function (renal/pulmonary ect), biochemical profile (routine labs), neurocognitive function, and completing entry BVAS tool.
1471982|NCT03182036|Device|Portable pulsed oxygen|Hypoxemic patients will use portable pulsed oxygen at rest, and while performing a six-minute walk test.
1471983|NCT03182010|Device|Cesarean section incision closure using barbed sutures|Cesarean section incision will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
1471984|NCT03182010|Device|Cesarean section incision closure using conventional sutures|Cesarean section incision will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .Ultrasound examination will be performed 6 months after the operation to measure the residual myometrial thickness and the scar depth.
1471985|NCT03181997|Device|Native aortic valve|Native valve, with any transcatheter heart valve type
1472086|NCT03181256|Procedure|Biospecimen collection|Undergo collection of urine
1471986|NCT03181997|Procedure|Transcatheter aortic valve implantation (TAVI)|Percutaneous aortic valve implantation preformed in one of these methods: transfemoral, transapical,subclavian or other.
1471987|NCT03181984|Drug|Hemoporfin|Hemoporfin mediated photodynamic therapy
1471988|NCT03181971|Behavioral|Water First|The Water First intervention consists of increased access to safe and appealing drinking water in schools, school-wide promotion to increase students' intake of water, and education directed to 4th grade students and their families to increase intake of water.
1948525|NCT02194699|Biological|Experimental: Tralokinumab|Tralokinumab subcutaneous injection
1948526|NCT02194699|Other|Placebo|Placebo subcutaneous injection
1948527|NCT02192749|Biological|Umbilical cord mesenchymal stem cells|
1471992|NCT03181945|Other|Group 4 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 4 weeks followed by taper in 10-14days
1471993|NCT03181945|Other|Group 12 weeks|Anti-epileptic drug (as used by treating physician for management of acute symptomatic seizure) for 12 weeks followed by taper in 10-14days
1471994|NCT03181932|Drug|Vancomycin inhalation powder|There will be 200 patients treated with Vancomycin inhalation powder or placebo (1:1 active to placebo).
1471995|NCT03181932|Drug|Placebo inhalation powder|There will be 200 patients treated with Vancomycin inhalation powder or placebo (1:1 active to placebo).
1471996|NCT03181919|Drug|Letrozole|Letrozole is a third generation inhibitor that is emerging as a new oral agent for induction of ovulation.
1471997|NCT03181906|Other|Pre-Consultation Medication Reconciliation|Medication reconciliation service to be done for participants randomised to the intervention group
1472000|NCT03181880|Drug|Aclidinium bromide/formoterol fumarate combination|"Patients will be randomized to receive either Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®), or Standard Of Care (SOC) Bronchodilators.
The product in study is Aclidinium bromide/formoterol fumarate fixed-dose combination (Duaklir™ Genuair®).
Each inhaler will contain at least 60 doses (and a maximum of 68 doses) of aclidinium bromide/formoterol fixed-dose combination 400μg /12μg. Patients will be instructed to take 1 puff in the morning (09:00 ± 1 h) and 1 puff in the evening (21:00 ± 1 h) during the 12 weeks of treatment."
1472001|NCT03181880|Drug|Standard of Care|Brochodilators
1472002|NCT03181867|Drug|18F-DCFPyL|Subjects will receive 18F-DCFPyL under the direct supervision of study personnel. Each subject will receive a single IV dose of 18F-DCFPyL by bolus injection at a rate of approximately 1ml/3-5sec. The maximum amount of injected active drug will be less than 4.02mcg. The injection will be followed by a 10 ml saline flush (sodium chloride IV infusion 0.9% w/v) over approx 10sec. The target administered activity will be 8 mCi.
1472003|NCT03181854|Behavioral|Coaching on the phone|Coaching about overcoming the crisis during the cancer journey on the phone provided once a week for 3 months and once in 2 weeks for another 3 months.
1472004|NCT03181854|Behavioral|Consultation with PCT physician|Consultation with PCT physician every 3 weeks.
1472005|NCT03181841|Drug|PF-06412562|double-blind oral intake of single doses of the aforementioned drug or placebo
1472006|NCT03181841|Drug|Placebo|double-blind oral intake of single doses of the aforementioned drug or placebo
1472007|NCT03181828|Drug|Acetohydroxamic Acid Oral Tablet [Lithostat]|"AHA:
Acetohydroxamic acid has been an FDA approved medication for the treatment of struvite nephrolithiasis for over 25 years. According to the prescribing information, about 150 patients, including children, have been treated, most for periods of more than 1 year."
1472008|NCT03181815|Drug|Cladribine|5mg/㎡ d1-5
1472009|NCT03181815|Drug|G-CSF|300ug d0-9
1472010|NCT03181815|Drug|Aclarubicin|10mg d3-6
1472011|NCT03181815|Drug|Cytarabine|10mg/㎡ q12h SC d3-9
1472012|NCT03181802|Drug|Botox|single injection of 200 International Unit of BoNT-A in 10 bilateral paravertebral intramuscular points for treating chronic LBP
1472013|NCT03181802|Drug|Placebos|4 ml of physiological serum injected intramuscularly into the lumbar paravertebral muscles.
1472025|NCT03181750|Behavioral|Patient Navigator Intervention Group|Bicultural, bilingual navigators conducting home visits with patients and caregivers.
1472026|NCT03181737|Behavioral|Covivio/Relaxio|Informations already included in arm/group descriptions.
1472087|NCT03181256|Procedure|Pulmonary Function Test|Undergo pulmonary function test
1472088|NCT03181256|Procedure|Computed Tomography (CT)|Undergo chest CT
1472089|NCT03181256|Other|Laboratory Biomarker|Correlative studies
1472159|NCT03180814|Other|Whole Body Vibration|A whole body vibration session will be performed through a vibrating platform with three axes and vibration frequency set at 35 Hz. The amplitude used will be 04 mm.
1472258|NCT03180255|Combination Product|Dexamethasone phosphate|Ocular iontophoretic delivery of a steroid
1472027|NCT03181724|Behavioral|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
1472028|NCT03181698|Diagnostic Test|Magnetic resonance imaging|"A full Magnetic Resonance Imaging examination of the brain will be done for each of the subjects included in the study. The protocol of the study will include a high-resolution thin-cuts three Dimensions-T1 weighted gradient echo sequence to be used for the morphometric study.
The obtained images will be analyzed for any gross structural abnormalities. by using fully-automated computational voxel-based volumetric software that calculates the volume of different structures of the brain. The obtained data will be analyzed statistically using linear regression tests to determine the differences between Bipolar Disorder type I mania patients and the healthy controls"
1472029|NCT03181685|Drug|Progesterone 25 MG subcutaneous|A single subcutaneous administration per day from the day of oocyte retrieval
1472030|NCT03181685|Drug|Micronized progesterone 200 MG|3 vaginal administrations per day from the day of oocyte retrieval
1472031|NCT03181685|Drug|recombinant FSH|Controlled ovarian stimulation (COS)
1472032|NCT03181685|Drug|Cetrorelix Acetate|Inhibition of Luteinizing Hormone (LH) premature surge during COS
1472033|NCT03181672|Procedure|Stellate ganglion block|Stellate ganglion block with 1% lidocaine 10ml
1472034|NCT03181672|Procedure|control group|Deltoid muscle injection with 1% lidocaine 10ml
1472037|NCT03181646|Drug|citicoline|intravenous citicoline 15 mg per kg per dose BD will be given to babies until oral feeds are established
1472038|NCT03181633|Drug|ACH-0144471|ACH-0144471 will be administered to all patients enrolled in the study.
1472039|NCT03181620|Other|Intermittent Dosing of Medication|Typical sedative/narcotic medication administered for sedation while mechanically ventilated is given in an intravenous intermittent bolus fashion rather than a continuous intravenous drip.
1472040|NCT03181594|Device|ClariFix Device|Cryoablation in the nasal passageway using the ClariFix Device
1472041|NCT03181581|Biological|acoustic coupling fluid|ultrasound images obtained with both ACF and Ringer's acetate
1472042|NCT03181581|Biological|Ringer's acetate|ultrasound images obtained with Ringer's acetate only
1472043|NCT03181568|Device|MolecuLight i:X™ Imaging Device|Offers real-time detection of important biological and molecular information of a wound. The MolecuLight i:X Imaging Device is intended to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device can capture and document either an image or video of the wound where the presence of fluorescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
1472044|NCT03181568|Procedure|Wound care|Standard wound care of chronic wounds e.g. sampling, debridement, infection control
1472045|NCT03181555|Other|Exploratory|
1472046|NCT03181542|Device|Infrared illumination|Infrared illumination of veins using the FDA approved AccuVein (AccuVein, Inc., Huntington, NY) device.
1472047|NCT03181529|Drug|Psilocybin|Participants will receive a moderately high psilocybin dose in the first session and will receive either a moderately high or high psilocybin dose in the second session.
1472050|NCT03181503|Drug|CD14152 Dose A|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
1472051|NCT03181503|Drug|CD14152 placebo|3 subcutaneous injections (every 4 weeks during the 12-week treatment period)
1472052|NCT03181490|Diagnostic Test|Circulating Tumor DNA Methylation Test|Methylation profiling by high-throughput bisulfite DNA sequencing in blood sample to differentiate benign and malignant pulmonary nodules
1472053|NCT03181477|Device|Radiotherapy|Radiotherapy of 80 GY + Chemotherapy (Temozolomide)
1472054|NCT03181464|Drug|Lidocaine 4%|lidocaine solution
1472055|NCT03181464|Drug|Placebo|saline .9% injection
1472057|NCT03181438|Procedure|TAP Block|It will be performed a ultrasound-guided transverse abdominal plane block with 20 ml of 0.375% of ropivacaine for patients submitted to renal transplantation
1472058|NCT03181438|Procedure|Saline Group|t will be performed a ultrasound-guided transverse abdominal plane block with 2o mL of saline for patients submitted to renal transplantation
1948532|NCT02191579|Biological|onabotulinumtoxinA|155U onabotulinumtoxinA (BOTOX®) total dose per treatment by intramuscular injection every 12 weeks.
1472160|NCT03180801|Biological|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500mcg of FLU-v as 0.5ml emulsion in 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
1948533|NCT02191579|Drug|Topiramate|Topiramate up to a maximum oral dose of 100 mg/day.
1472059|NCT03181412|Diagnostic Test|Questionnaire|"Tests from Cincinnati prehospital stroke severity scale (CPSSS) will be carried out by the physician at emergency medical services on telephone call with firemen, paramedics or the emergency medical services team for any stroke suspicion that meets the criteria for inclusion. Emergency department physician will have to follow a standardized questionnaire to complete the different items of the score. The score will not be calculated by emergency department physician and will not influence the orientation and management of patients.
The final diagnosis will be the presence or absence of a large vessel occlusion. This diagnosis will be done on cerebral imaging by a neurologist."
1472061|NCT03181386|Drug|Rivaroxaban|Rivaroxaban 15 or 20mg tablet by mouth, every 24 hours, continuous use.
1472062|NCT03181386|Drug|Dabigatran and Apixaban|Dabigatrana 110 or 150 mg tablet and Apixaban 2,5 or 5mg tablet by mouth, every 12 hours, continuous use.
1472063|NCT03181386|Drug|Warfarin|The dosage of Warfarin is individualized for each patient, according to the patient's TP/INR value. The value of TP/INR should be in the therapeutic dosage of 2.0 to 3.0
1472064|NCT03181373|Other|Cognitive rehabilitation program|Rehabilitation
1472065|NCT03181360|Drug|Tenecteplase|Single dose intravenous injection of recombinant fibrin-specific tissue plasminogen activator (tenecteplase) 0.25 mg (200 IU) per kg body weight up to a maximum of 25 mg (5000 IU), given as a bolus over approx. 10 seconds.
1472066|NCT03181360|Other|Control|Best standard treatment
1472070|NCT03181334|Behavioral|Condition 1: Pure Control|FIT kits and a Standard (control) invitation to complete CRC screening is mailed to the homes of eligible patients.
1472071|NCT03181334|Behavioral|Condition 2: Brief Time|"FIT kits and a Brief Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.
Participants are assigned to the following invitation:
Letter 2: Invitation to participate in free CRC screening, requesting they return the kit within 1-week."
1472072|NCT03181334|Behavioral|Condition 2: Extended Time|"FIT kits and an Extended Time invitation to complete CRC screening is mailed to the homes of eligible patients. Time letters are used to evaluate the effect of procrastination on CRC screening compliance.
Participants are assigned to the following invitation:
Letter 3: Invitation to participate in free CRC screening, requesting they return the kit within 3-weeks."
1472073|NCT03181334|Behavioral|Condition 3: Time + High Incentive|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.
Participants are assigned to the following invitation:
Letter 4: Invitation to participate in free CRC screening, requesting they return the kit within 1-week for a higher monetary incentive or within 3-weeks for a lower (half of the higher) monetary incentive."
1472074|NCT03181334|Behavioral|Condition 3: Time + Low Incentive|"FIT kits and a Time + Incentive invitation to complete CRC screening is mailed to the homes of eligible patients. Time + Incentive letters are used to evaluate the effect of incentive on procrastination in CRC screening compliance.
Participants are assigned to the following invitation:
Letter 5: Invitation to participate in free CRC screening, requesting they return the kit within 1-week for a higher (same as the lower in Letter 4) or within 3-weeks for a lower (half of the higher in Letter 5) monetary incentive."
1472075|NCT03181321|Behavioral|The First Twenty|The TF20 incorporates individual goal setting and health coaching, leveraging cultural aspects of the fire service and group cohesion to motivate behavior change. The TF20 focuses on the unique needs of FF with culturally relevant nutrition and fitness strategies. TF20 was primarily designed as a cost-effective, stand-alone program for departments which have no health promotion initiative. Program components include practical approaches to nutrition, fitness and mental health.
1472078|NCT03181295|Behavioral|Personalized exercise Rx and resources|Patients will receive the IPAQ to collect baseline PA levels as well as questions evaluating precursors to behaviour change and identifying medical conditions that may affect PA capability. In the Electronic Medical Record chart, a 'stamp' will be automatically created, accompanied by a link which will open a printable 'toolkit' with individualized PA recommendations, a personalized exercise Rx, as well as educational and community resources, all based on the patient's survey responses. The exercise Rx and resources can be edited by the PCP based on the resulting discussion between patient and PCP, and printed during the PHR for the patient to take home. The exercise Rx and resources will also be emailed to the patient following their appointment.
1472079|NCT03181282|Behavioral|Physical Therapy|Postural stability exercises will follow a framework targeting quiet stance, anticipatory and reactive postural adjustments, and dynamic postural control. Gait exercises will include treadmill walking and practice with dual-task gait. A home exercise program (HEP), to be completed twice weekly, will be provided on each participant's initial visit with the physical therapist following STN-DBS surgery. The HEP will include the following exercises: trunk rotation, standing hip flexion, standing hip abduction, standing plantarflexion, and standing squat.
1472080|NCT03181269|Other|Intervention education|An education package that includes an enhanced emphasis on maternal-infant skin-to-skin contact and a detailed activity log for recording early post-partum care practices that includes specific skin-to-skin contact time and frequency goals.
1472081|NCT03181269|Other|Placebo Education|An education package that includes a basic emphasis on maternal-infant skin-to-skin contact, as well as other general post-partum care practices and a general early post-partum care practices log without specific skin-to-skin contact goals.
1472082|NCT03181256|Procedure|Biospecimen Collection|Undergo collection of sputum
1472083|NCT03181256|Procedure|Biospecimen collection|Undergo collection of nasal epithelium
1472084|NCT03181256|Procedure|Biospecimen collection|Undergo collection of buccal epithelium
1472085|NCT03181256|Procedure|Biospecimen collection|Undergo collection of blood
1472337|NCT03179618|Drug|Coronary Vasodilator|Mainly including nitrates
1992458|NCT03321084|Other|MatPliates|The MatPilates program was specialized developed for this trial, in which all exercises belong to contemporaneous Pilates style. Each session has 60 minutes of duration, divided in three blocs (stretching, exercise and relaxation), with mean of 10, 40 and 10 minutes respectively (VIEIRA et al., 2016). Each exercise will be performed in one series of 10 to 15 repetitions and will be modified accordingly the patient need.
1472092|NCT03181230|Other|No intervention|No intervention
1472093|NCT03181217|Other|water 0|300 ml tap water at 0 ºC
1472094|NCT03181217|Other|water 22|300 ml tap water at 22 ºC
1472095|NCT03181217|Other|Glucose 0|300 ml tap water at 0 ºC with 75 grams of glucose added
1472096|NCT03181217|Other|Glucose 22|300 ml tap water at 22 ºC with 75 grams of glucose added
1472097|NCT03181204|Procedure|Bronchial biopsy|The bronchial biopsy is part of this study's inclusion criteria and is required during routine care for the patient. Bronchial fibroscopy is performed under general or local anesthesia. Biopsies are performed using forceps and according to current recommendations. One biopsy will be fixed immediately in RCL2 medium while the others (between 3 and 6) will be kept in isotonic saline and rapidly prepared for air-liquid-interface (ALI) cell culture.
1472098|NCT03181204|Procedure|Skin biopsy|The skin biopsy will be performed after local anesthesia by hypodermic injection of a 1% Xylocaine solution. A single sample of a skin fragment about 3 mm in diameter will be necessary.
1472099|NCT03181204|Procedure|Blood sample|The blood sample will be taken at the end of the cutaneous biospy, approximately 20 ml of blood will be collected.
1472100|NCT03181191|Other|Oral glucose tolerance test|Oral glucose tolerance test and biopsies
1472101|NCT03181178|Dietary Supplement|Macro-micronutrient complementary food supplement|This intervention provided a 15 g complementary food supplement called KokoPlus with nutrition education
1472102|NCT03181178|Dietary Supplement|A micronutrient powder|This intervention provided a 1 g micronutrient powder with nutrition education
1472103|NCT03181178|Behavioral|Nutrition education|This intervention provided nutrition education sessions
1472104|NCT03181165|Behavioral|Low-carbohydrate Therapeutic Nutrition|The pharmacist or pharmacy lifestyle coach will work with the participant to develop a diet plan that is low in carbohydrate and energy-restricted based on personal preferences and characteristics. A combination of pre-packaged low-carbohydrate foods and whole foods from pre-specified lists will be used.
1472105|NCT03181152|Diagnostic Test|Impulse Oscillometry|"1，Before the experiment, the patient is arranged to rest 10min. 2, IOS: The patient take seats, body relax, make sure the mouthpiece is fully covered by mouth, then clip nose with both hands to cover both sides of the cheek, and then calm breathing 1 minutes, the computer is automatically collected data calculation and print out the measurement results.
3, Bronchial Dilation Test: The patient is asked to take IOS again after gaven aerosol inhalation of 200g salbutamol for 15min, the computer is automatically collects the data computation and prints the measurement result."
1472106|NCT03181139|Other|ERAS pathway for Total Mastectomy|Enhanced Recovery after Surgery (ERAS) pathway for Total Mastectomy
1472110|NCT03181113|Drug|Peginterferon Alfa-2B|pre-received standard peginterferon alfa-2b therapy
1472111|NCT03181113|Drug|Peginterferon Alfa-2A|pre-received standard peginterferon alfa-2a therapy
1472112|NCT03181100|Drug|Nab-paclitaxel - INDUCTION COHORT|INDUCTION COHORT: Nab-paclitaxel 100 mg/m2 by vein weekly for up to 3 doses.
1472113|NCT03181100|Drug|Paclitaxel - INDUCTION COHORT|INDUCTION COHORT: Paclitaxel 80 mg/m2 by vein weekly for up to 3 doses.
1472114|NCT03181100|Drug|Vemurafenib - COHORT 1|COHORT 1: Vemurafenib 960 mg by mouth twice a day (Day 1-21). Vemurafenib dose reduced to 720 mg twice a day (at cycle 1 day 21).
1472115|NCT03181100|Drug|Cobimetinib - COHORT 1|COHORT 1: Cobimetinib 60 mg by mouth every day (Day 1-21) run-in before starting Atezolizumab.
1472116|NCT03181100|Drug|Atezolizumab - COHORT 1|COHORT 1: Atezolizumab 840 mg by vein on Day 1 and Day 15 in a 28 day cycle, started on Cycle 1, Day 1. Patients who have > grade 3 LFTs (AST, ALT or total bilirubin) will not receive Atezolizumab but may continue on Vemurafenib + Cobimetinib with dose reduction. If after dose reductions, the LFTs are below grade 3, patient may start Atezolizumab.
1472117|NCT03181100|Drug|Bevacizumab - COHORT 3|COHORT 3: Bevacizumab 15 mg/kg by vein every 21 days in a 21-day cycle.
1472118|NCT03181100|Drug|Nab-paclitaxel - COHORT 4|COHORT 4: Nab-paclitaxel 100 mg/m2 by vein on Days 1, 8, and 15.
1472119|NCT03181100|Drug|Paclitaxel - COHORT 4|COHORT 4: Paclitaxel may be substituted for nab-paclitaxel but nab-paclitaxel is preferred. Dose of Paclitaxel is 175 mg/m2 by vein every 21 days.
1472120|NCT03181100|Drug|Cobimetinib - COHORT 2|COHORT 2: Cobimetinib 60 mg by mouth on Days 1−21.
1472121|NCT03181100|Drug|Atezolizumab - COHORT 2|COHORT 2: Atezolizumab 840 mg by vein on Day 1 and Day 15 in a 28 day cycle.
1472122|NCT03181100|Drug|Atezolizumab - COHORT 3|COHORT 3: Atezolizumab 1200 mg by vein every 21 days.
1472123|NCT03181100|Drug|Atezolizumab - COHORT 4|COHORT 4: Atezolizumab 1200 mg by vein every 21 days.
1472124|NCT03181087|Other|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
1472125|NCT03181074|Other|Non-Interventional|Non-Interventional
1472126|NCT03181061|Other|Semi-structured interviews|Providers will participate in a semi-structured interview using an interview guide that addresses 4 domains of interest including: (1) initiation of abortion services, (2) barriers to abortion provision, (3) facilitators of abortion provision and (4) acquired expertise and coaching for success.
1472127|NCT03181048|Procedure|Periacetabular osteotomy|The Bernese periacetabular osteotomy has become the osteotomy of choice in North America for correction of the dysplastic hip. The ability to position the acetabular component in a specifically desired position for each individual patient improves joint biomechanics, restores joint balance and stability, and offloads the structures at risk for damage such as the labrum and the adjacent articular cartilage.
1472161|NCT03180801|Biological|adjuvanted placebo|Subcutaneous injection in the upper arm with 0.5ml emulsion made of 0.25ml of WFI and 0.25ml of adjuvant Montanide ISA-51
1992459|NCT03321084|Other|Control|Will not be submitted to any physical intervention. It continues in your daily life with only phone monitoring.
1472128|NCT03181048|Procedure|Periacetabular osteotomy with hip arthroscopy|An intraarticular assessment with hip arthroscopy (HA) at the time of periacetabular osteotomy allows the surgeon to assess and treat the associated labral and chondral pathology and allows the surgeon to treat abnormalities of the femoral head junction.
1472129|NCT03181035|Radiation|(18)F-Fluoroazomycin arabinoside|FAZA PET diagnostic testing
1472130|NCT03181035|Drug|Pimonidazole|oral pimonidazole hypoxia labeling
1472131|NCT03181022|Behavioral|Motivational Interviewing|HIV care providers will be asked to attend an MI training workshop lasting a total of 12 hours. The workshop will be conducted by members of the MI Network of Trainers. MI training relies on experiential activities and cooperative learning methods. After the training, study staff will monitor MI fidelity, or how providers are using the MI skills, using the MI Coach Rating Scale. This will occur 3 times prior to the training, 3 times during the practice period, and then quarterly. They will be asked to complete an audiotaped standardized patient interaction (approximately 30 minutes) with one of the study staff. These will be coded and providers will be informed of their competency level for all but the pre-training role plays. Coaching will be provided for all participants during the practice period. For the quarterly role plays, no coaching occurs unless their score indicates they need additional coaching (an additional 45 minute session with an MI trainer).
1472132|NCT03181009|Drug|Omalizumab|All subjects will receive omalizumab, stored and prepared according to the investigator brochure. Subjects greater or equal to 4 yrs receive 150 mg. Subjects less than 4 yrs receive 75 mg.
1472133|NCT03181009|Drug|Food Flour Allergens|The subject's allergens will be introduced after receiving the third omalizumab dose.. Subjects will return to clinic to escalate the dose of their allergens until 300 mg (group A) vs. 1200 mg (group B) total protein daily dose is reached. There will be equivalent allergen protein portions depending on test allergen per each subject's history. Subjects will be randomized 1:1 to either group A or group B after meeting eligibility criteria. All subjects and study personnel will be blinded to group A vs B. Research staff will administer food flour to the subject orally in an age-appropriate food vehicle.
1472135|NCT03180983|Behavioral|multimodal intervention|Investigators will propose an online training. In addition, investigators will make phone calls to nursing home interlocutor between two nursing home visits. The tools of this intervention will consist on posters , quiz about bacteriuria and urinary tract infection (UTI) and algorithm to help nurse's reasoning when UTI is suspected.
1472136|NCT03180970|Drug|1.2% Lugol's solution|1.2% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
1472137|NCT03180970|Drug|1.0% Lugol's solution|1.0% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
1472138|NCT03180970|Drug|0.8% Lugol's solution|0.8% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
1472139|NCT03180970|Drug|0.6% Lugol's solution|0.6% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
1472140|NCT03180970|Drug|0.4% Lugol's solution|0.4% Lugol's solution will be sprayed on the lesion suspected early esophageal squamous neoplasia .Then the lesions will be treated with endoscopic submucosal dissection(ESD).
1472141|NCT03180957|Drug|Adalimumab|
1472142|NCT03180957|Drug|Saline|
1472143|NCT03180944|Drug|1.2% Lugol's solution|This group patients were given dosages of 1.2% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained lesions.
1472144|NCT03180944|Drug|1.0% Lugol's solution|This group patients were given dosages of 1.0% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained lesions.
1472145|NCT03180944|Drug|0.8% Lugol's solution|This group patients were given dosages of 0.8% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained lesions.
1472146|NCT03180944|Drug|0.6% Lugol's solution|This group patients were given dosages of 0.6% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained lesions.
1472147|NCT03180944|Drug|0.4% Lugol's solution|This group patients were given dosages of 0.4% Lugol's solution for chromoendoscopy.Then biopsy specimens will be taken at the well-demarcated unstained lesions.
1472149|NCT03180918|Procedure|testicular tissue biopsy|testicular tissue biopsy during general anesthesia
1472150|NCT03180905|Device|ImPACT Online/Paper Pencil Tests|Compare ImPACT Online versus Paper and Pencil Neurocognitive Tests
1472151|NCT03180905|Device|ImPACT Online|ImPACT Online will be administered at 2 time points.
1472152|NCT03180892|Other|The investigators did not apply any intervention for the participants.|The investigators did not apply any intervention for the participants.
1472153|NCT03180879|Drug|Test - RB ibuprofen acid orodispersible tablets|RB ibuprofen acid orodispersible tablets, 2 x 200 mg, single dose, oral.
1472154|NCT03180879|Drug|Reference - RB Nurofen ibuprofen acid tablets|RB Nurofen ibuprofen acid tablets, 2 x 200 mg, single dose, oral.
1472155|NCT03180879|Drug|Comparator - Dolormin ibuprofen lysine tablets|Dolormin ibuprofen lysine tablets 2 x 342 mg (each 342 mg tablet contains 200 mg ibuprofen), single dose, oral.
1472156|NCT03180866|Device|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
1472157|NCT03180840|Biological|Pegunigalsidase alfa|Pegunigalsidase alfa 2 mg/kg every 4 weeks
1472158|NCT03180827|Procedure|ovarian tissue biopsy|ovarian tissue biopsy during general anesthesia
1472217|NCT03180528|Other|Laboratory Biomarker Analysis|Correlative studies
1472162|NCT03180801|Other|Influenza challenge|On day 0, administration with an intranasal sprayer of 1ml of PBS containing 10(7) TCID50 of Influenza A 2009 H1N1 human virus manufactured under GMP in certified Vero cells.
1472163|NCT03180788|Procedure|Traction assisted ESD|A clip attached to a thread is mounted on the lesion. Traction is achieved by pulling the thread during ESD
1472164|NCT03180788|Procedure|Traditional ESD|Endoscopic submucosa dissection
1472165|NCT03180775|Other|Cellulose (control)|Cellulose (a vegetal product, in powder form, used as dietary fiber, that is not digested or absorbed in the intestines), will be supplemented in the form of water soluble powder.
1472166|NCT03180775|Dietary Supplement|Glycine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glycine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
1472167|NCT03180775|Dietary Supplement|Alanine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Alanine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
1472168|NCT03180775|Dietary Supplement|Leucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Leucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
1472169|NCT03180775|Dietary Supplement|Isoleucine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Isoleucine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
1472170|NCT03180775|Dietary Supplement|Valine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Valine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
1472171|NCT03180775|Dietary Supplement|Cysteine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Cysteine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
1472172|NCT03180775|Dietary Supplement|Arginine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Arginine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
1472173|NCT03180775|Dietary Supplement|Methionine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Methionine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
1472174|NCT03180775|Dietary Supplement|Glutamate|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamate will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
1472175|NCT03180775|Dietary Supplement|Glutamine|Amino acids are the building blocks of proteins, they are essential organic compounds in the normal diet, and are also individually administered as nutritional supplements. Glutamine will be supplied in the form of water soluble powder (the commercial form), for one daily dose. The corresponding amino acid doses were established based on the highest intakes at the 99th percentile in adult men (Institute of Medicine. 2005. Dietary Reference Intakes for Energy, Carbohydrate, Fiber, Fat, Fatty Acids, Cholesterol, Protein, and Amino Acids. Washington, D.C.: The National Academies Press. doi.org/10.17226/10490).
1472256|NCT03180268|Other|Clinical Observation|Undergo observation
1472184|NCT03180749|Other|Follow up per standard of care|Patients will come in 2 years post implantation and receive standard examinations
1472185|NCT03180736|Drug|Daratumumab|Daratumumab at a dose of 16 mg/kg administered as an IV infusion at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter
1472186|NCT03180736|Drug|Pomalidomide|Pomalidomide will be administered at full dose of 4 mg orally (PO) on Days 1 through 21 of each 28-day cycle.
1472187|NCT03180736|Drug|Dexamethasone|Dexamethasone will be administered at a dose of 40 mg (20 mg for patients ≥75 years of age) orally, once daily on Days 1, 8, 15, and 22 of each 28-day treatment cycle.
1472188|NCT03180723|Drug|Rituximab|Intravenous injection
1472189|NCT03180723|Drug|Cyclosporin|Oral tablets
1472190|NCT03180710|Drug|BioChaperone® Combo 75/25 at 0.6 U/kg|Injection of BioChaperone® Combo 75/25 at 0.6 U/kg
1472191|NCT03180710|Drug|BioChaperone® Combo 75/25 at 0.8 U/kg|Injection of BioChaperone® Combo 75/25 at 0.8 U/kg
1472192|NCT03180710|Drug|BioChaperone® Combo 75/25 at 1.0 U/kg|Injection of BioChaperone® Combo 75/25 at 1.0 U/kg
1472193|NCT03180710|Drug|Humalog® Mix25 at 0.8 U/kg|Injection of Humalog® Mix25 at 0.8 U/kg
1472194|NCT03180697|Diagnostic Test|APT MR Imaging|Patients who will receive target therapy( Bevacizumab) for recurrent malignant gliomas will obtain routine sequences, Gd- enhanced MR imaging and APT MR imaging will be performed before and after target therapy. We will observe the change of tumor after target therapy using APT imaging. We will compare the change of tumor between Gd-enhanced and APT Imaging before and after therapy.
1472195|NCT03180684|Biological|VGX-3100|One milliliter (1 mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA® 2000 on Day 0, Week 4, Week 12 and Week 24. A fifth dose and sixth dose of six mg VGX-3100 may be administered IM with EP per the judgment of the Investigator.
1472196|NCT03180684|Drug|Imiquimod 5% cream|Participants will apply imiquimod 5% cream to the vulvar lesion three times per week for 20 weeks.
1472197|NCT03180684|Device|CELLECTRA® 2000|IM injection of VGX-3100 is followed by EP with the CELLECTRA® 2000 device.
1472198|NCT03180671|Device|Deprogramer Sliding Guide|Use of the intraoral device.
1472199|NCT03180671|Device|Deprogrammer Dawson B-Splint|Use of the intraoral device.
1472200|NCT03180671|Device|Deprogrammer Kois|Use of the intraoral device.
1472201|NCT03180658|Procedure|GTR + CGF + bone graft|Guided tissue regeneration (GTR) combined with CGF and bone graft to treat mandibular furcation involvements
1472202|NCT03180658|Procedure|CGF + bone graft|CGF combined with bone graft to treat mandibular furcation involvements
1472203|NCT03180645|Other|Test product (Moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
1472204|NCT03180645|Other|Positive control (Commercial market place moisturising cream)|Participants will be instructed to apply their assigned product to the randomly assigned side of the face, to include, the crow's feet area, cheek, forehead and chin twice daily (in the morning and evening).
1472205|NCT03180645|Other|No treatment|No treatment
1472209|NCT03180606|Other|Multi-disciplinary and personalized primary care|Team-based primary care where nurse, GP, social-worker, physiotherapist, occupational therapist evaluate and give treatment
1472210|NCT03180593|Drug|Valsartan 80 mg|Compare office and 24-hour Blood Pressure Control and regression of Left Ventricular Hypertrophy
1472211|NCT03180580|Behavioral|HEAL guideline and healthy tiffin box intervention|"Healthy Eating and Active Living (HEAL) guideline and healthy tiffin box intervention is a combination of intervention to promote healthy eating behavior and improve physical activity level of school going children. The guideline was developed to deliver healthy lifestyle message encouraging healthy dietary habit and physical activity pattern in order to control childhood overweight and obesity. Investigators was designed a Healthy Tiffin Box for children that contained five different compartments of various sizes for stuffing with five different food types in order to ensure healthy balanced diet including low carbohydrate, moderate protein, low fat and high vitamin. We also provided with a recommended physical activity list for children."
1472212|NCT03180567|Diagnostic Test|Genetic Mutations|By next generation sequencing
1472213|NCT03180554|Device|Transcutaneous Vagal Nerve Stimulation (tVNS)|The tVNS system consists of a non-invasive, handheld stimulator and ear electrode that patients wear like an earphone. Intensity, pulse duration, and frequency of the tVNS stimulation is optimized in order to induce signals in thick-myelinated Aβ fibres of the auricular branch of the vagus nerve (ABVN).
1472214|NCT03180554|Other|Deep Breathing (DB)|Deep Breathing (DB) is a breathing technique that comprises of the contraction of the diaphragm and the expansion of the abdomen, which can lower the breath rate to 5-6 breaths per minute. Both inhalation and exhalation can be done through the nose or the mouth.
1472215|NCT03180541|Behavioral|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
1472216|NCT03180528|Drug|Enzyme Inhibitor Therapy|Applied (remetinostat) topically
1472218|NCT03180515|Device|Activa PC+S Neurostimulator|Activa PC+S Neurostimulator is approved for both aDBS and cDBS paradigms.
1472219|NCT03180502|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|Undergo IMRT
1472220|NCT03180502|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
1472221|NCT03180502|Drug|Temozolomide|Chemotherapy drug
1472222|NCT03180489|Drug|Dapagliflozin Tablet|Daily oral administration of dapagliflozin with dietary counseling to promote weight loss. Dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
1472223|NCT03180489|Drug|Placebo Tablet|Daily administration of placebo tablet with dietary counseling to promote weight loss. Matching placebo for dapagliflozin 5 mg tablet will begin as one tablet per day for the first 14-days. In the absence of complications, side effects, or unfavorable reactions, the dose will then increase to two tablets for the remainder of the study.
1472224|NCT03180476|Drug|Apatinib|Apatinib, also known as YN968D1, is a tyrosine kinase inhibitor that selectively inhibits the vascular endothelial growth factor receptor-2 (VEGFR2, also known as KDR). It is an orally bioavailable, small molecule agent which is thought to inhibit angiogenesis in cancer cells; specifically apatinib inhibits VEGF-mediated endothelial cell migration and proliferation thus blocking new blood vessel formation in tumor tissue. This agent also mildly inhibits c-Kit and c-SRC tyrosine kinases.
1472225|NCT03180463|Drug|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#) will be injected through surgery tunnel, 2*10^7 cells,
1472226|NCT03180463|Procedure|core decompression|The surgery will drill into the femoral neck (hip bone) and through the necrotic area of the bone that died from the lack of blood flow, take out partial osseous tissue.
1472227|NCT03180450|Biological|Allogeneic umbilical cord mesenchymal stem cells (SCLnow 19#)|Allogeneic umbilical cord mesenchymal stem cells will transfusion by intravenous transplantation.
1472228|NCT03180450|Drug|conventional treatment|The drug and usage will be determined based on patient's condition, including milrinone, furosemide, beta-blocker blues, Angiotensin-Converting Enzyme Inhibitors (ACEI), angiotension receptor blocker (ARB), or antiplatelet aggregation etc.
1472229|NCT03180437|Procedure|Cryosurgery or IRE surgery|Cryosurgery or IRE surgery will be used in local tumor
1472230|NCT03180437|Biological|γδ T cell|γδ T cells will be used against Pancreatic Cancer
1472231|NCT03180437|Other|γδ T cells/ A Cryosurgery or IRE|Combination γδ T cell and Cryosurgery or IRE surgery will be used in Pancreatic Cancer
1472232|NCT03180424|Drug|L Carnitine|L Carnitine liquid, single daily dose of 2g orally.
1472233|NCT03180424|Behavioral|Supervised exercise|Modified Otago exercise programme, 2 times a week with a duration of 45 minutes, to be supervised by a previously qualified and trained instructor. Follow up of the established plan includes an adequate monitoring, evaluating the evolution and the possible adverse effects that may appear.
1472234|NCT03180424|Drug|Placebos|Liquid substance, similar to the one containing L carnitine, in the same presentation
1472235|NCT03180424|Behavioral|Exercise at home|A schedule of exercises will be given in the consultation, which the patient will perform at home, without supervision
1472236|NCT03180411|Behavioral|Interview|"Cognitive Testing Phase Group: Participants take part in one-on-one interview with research staff and asked questions about participant's health and the disease. The interview may take from 45-60 minutes to complete.
Pilot Testing Phase Group: After Cognitive Testing Phase interview, participants have a second one-on-one interview. The interview will last from 45-60 minutes."
1472237|NCT03180411|Behavioral|Questionnaire|Participant completes a questionnaire about the disease, what participant understands about it, and the treatment plan recommended. Participant asked to give participant's opinion about colorectal cancer follow-up materials. The questionnaire will take 35-45 minutes.
1472238|NCT03180398|Device|Multiparametric MRI|MRI will be acquired before, during and after radiation treatment to evaluate treatment response
1472239|NCT03180385|Device|Neurally-Adusted Ventilatory Assist (NAVA)|Delivery of positive pressure is based on the electrical activity of the diaphragm (Edi) via a nasogastric (NG) catheter that is placed on the phrenic nerve, which runs along the esophagus. This results in synchronous ventilation for the patient.
1472240|NCT03180385|Device|Biphasic Positive Airway Pressure Support (BiPAP)|Conventional form of non-invasive respiratory support that does not deliver positive airway pressure in a synchronous fashion.
1472241|NCT03180372|Device|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
1472242|NCT03180359|Biological|Recommended vaccine scheme according to French Vaccine Schedule 2015|"BCG
Measles mumps rubella (MMR)
Varicella (chicken pox)
Rotavirus
Seasonal flu (live vaccine delivered nasally and inactivated vaccine injectable)
Yellow Fever
Diphteria tetanus poliomyelitis whopping cough (DTwP)
Haemophilus influenzae type b
Hepatitis B
Meningococcus conjugate
Pneumococcus
Human papillomavirus
Hepatitis A
Vaccine administration would be done according to French Vaccine Schedule 2015 for mainstream population and for grafted children or transplant candidate children"
1472243|NCT03180346|Device|PICO|Single Use Negative Pressure Dressing
1472244|NCT03180346|Device|Aquacel|Occlusive surgical dressing infused with ionized silver
1472245|NCT03180333|Drug|PNA|
1472246|NCT03180333|Drug|PNA placebo|
1472247|NCT03180320|Behavioral|BESMILE-HF program|"The following activities will be conducted as part of the BESMILE-HF program:
Baduanjin exercise;
evaluations of exercise capacity and clinical conditions;
consultations on exercise prescription and management of symptoms/signs during exercise;
education covering topics related to the CHF and exercise; and
a series of adherence strategies."
1472248|NCT03180320|Drug|Usual medications|Throughout the study period, all participants will receive typical Western medications for chronic heart failure, according to national guidelines.
1472249|NCT03180307|Drug|OTL38|0.025 mg/kg of OTL38 in 250ml D5W infused intravenously over 60 minutes
1472250|NCT03180307|Device|near infrared imaging|Infrared imaging used to excite OTL38 for fluorecence
1472251|NCT03180294|Drug|Bupropion Hydrochloride|Given PO
1472252|NCT03180294|Other|Placebo|Given PO
1472253|NCT03180281|Drug|DPP4|sitagliptin phosphate 100mg qd
1472254|NCT03180281|Drug|Insulin|Insulin Glargine or detemir 0.2U/kg qd
1472255|NCT03180281|Drug|SU|Glimepiride 1-2mg qd
1472259|NCT03180255|Other|Placebo|Ocular iontophoretic delivery of a placebo
1472260|NCT03180242|Biological|EG12014|EG12014, single-dose IV infusion over 90 min at 6 mg/kg
1472261|NCT03180242|Biological|EU-sourced Herceptin|EU-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
1472262|NCT03180242|Biological|US-sourced Herceptin|US-sourced Herceptin, single-dose IV infusion over 90 min at 6 mg/kg
1472263|NCT03180229|Drug|Granisetron 1 Mg/mL Intravenous Solution|1 milligram (mg) will use on group Granisetron before 5 min induction
1472265|NCT03180203|Device|INTELLiVENT-ASV|"After ICU admission:
The first three hours: only ventilation with INTELLiVENT-ASV with Quickwean.
After three hours: Automatic spontaneous breathing trials (SBT) is activated and SBT starts if >10minutes PEEP:<9cmH2O,FiO2:<41%,VT/IBW<5ml/kg and RSB:<106l/l*min.
Settings SBT are MV% 25%,PEEP 5cmH2O.SBT automatically stops if respiratory rate >35b/min or increases >100% since start of SBT, FiO2 >50%, PeTCO2 increases >8mmHg.
Extubation criteria: Leakage <50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT >10min.
If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
1472266|NCT03180203|Device|Conventional modes|"After ICU admission:
The first three hours: only ventilation with CMV or PS. If required care providers may change the mode to adaptive support ventilation.
After three hours: manual SBT is required if >10min PS<11cmH2O,PEEP<9cmH2O,FiO2<41%.
Settings SBT are PS 5cmH2O, PEEP 5cmH2O, FiO2 30%. SBT must be stopped if respiratory rate >35b/min or increases >100% since the start of SBT, saturation <92% or the PeTCO2 increases >8mmHg.
Extubation criteria: Leakage <50ml/hr,hemodynamically stable, awake with enough muscle strength and successful SBT >10min.
If during mechanical ventilation the ICU care providers decide that it is necessary for the treatment, they may switch to another ventilation mode or extubate without a SBT."
1472267|NCT03180190|Drug|Hydroxychloroquine Oral Tablet|"slit lamp and fundus examination using both direct and indirect ophthalmoscope Screening for HCQ ocular toxicity by
Perimetry using Octopus perimeter and utilizing 24-2 test strategy,
Electroretinography (ERG) under scotopic and photopic conditions and Spectral domain optical coherence tomography (SD-OCT)"
1472272|NCT03180164|Other|hospital anxiety and depression scale|self-assessment scale has been developed and found to be a reliable instrument for detecting states of depression and anxiety in the setting of an hospital medical outpatient clinic
1472273|NCT03180151|Procedure|piezotome assisted orthodontic tooth movement|"Surgical procedure
After local anesthesia, vertical interproximal incisions will be done under the interdental papilla, on the labial aspect of upper arch using a blade No. 15.
The incisions will be kept minimal.
The incisions go though the periosteum, which permit the blade to reach to the alveolar bone.
A Piezo surgical knife will be used to make the cortical alveolar incision through the gingival incisions to a depth of approximately 3mm.
As we will not use bone graft so we don't need use suturing after cortication.
We give patient antibiotic and analgesic cover."
1472274|NCT03180138|Behavioral|Reminders alone|Automated reminders (text and /or voice in local language) for upcoming vaccination visit(s) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
1472275|NCT03180138|Behavioral|Compliance-linked incentives|Automated compliance-linked incentives (as cell-phone minutes) will be provided via cell-phone to the subject (mother / caregiver) or pregnant woman.
1472276|NCT03180125|Drug|Sodium Hyaluronate|median nerve in CTS hydro-dissection using 1% lidocain followed by injection of Sodium hyaluronate guided by ultrasound
1472277|NCT03180125|Device|ultrasound|ultrasound guided injection
1472278|NCT03180125|Drug|Sodium Hyaluronate and 1% lidocain|injection in the carpal tunnel
1472279|NCT03180125|Drug|Corticosteroid and 1%lidocain|injection in the carpal tunnel
1472280|NCT03180112|Genetic|enzyme linked immunosorbent assay and polymerase chain reaction|Blood samples will be collected and analyzed for herpes simplex viruses (type one and two) antibody by sensitive enzyme-linked immunosorbent assay and quantitative polymerase chain reaction.
1472281|NCT03180099|Drug|Bupivacaine|Ultrasonically assisted, 0.5-1 mL 0.9% NaCl test is given between m.longissimus and m.iliocostalis to confirm the position of the needle and local anesthetic drugs will be given here
1472282|NCT03180099|Drug|Bupivacaine|20 ml %0.1 Bupivacaine administered to Epidural Space
1472338|NCT03179618|Drug|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
1472339|NCT03179605|Drug|DFD06|Apply twice per day for 15 days
1472340|NCT03179592|Drug|Ultravist 370Mg I/Ml Solution for Injection|Reduced contrast-volume injection protocols based on patient specific tube voltage.
1472283|NCT03180086|Other|Breast cancer risk report|An individualized report will inform women of their 5-year breast cancer risk using BCRAT or Tice (when breast density is available from a past mammogram), whichever is higher, and the average 5-year risk for women their age. The report will present 5-year risk as a frequency and in a pictograph and it will describe what experts recommend in terms of mammography screening, breast cancer prevention medications, breast MRIs, and BRCA testing, for women in their 40s based on their risk.
1472284|NCT03180073|Diagnostic Test|Ziopatch Pre discharge|Ziopatch applied 2 weeks prior to procedure
1472285|NCT03180073|Diagnostic Test|Ziopatch at Discharge|Ziopatch applied at discharge from hospital to be worn for 2 weeks
1472286|NCT03180073|Diagnostic Test|Ziopatch at 2 months|Ziopatch applied 2 months from procedure to be worn for 2 weeks
1948534|NCT02191137|Drug|Riociguat (Adempas, BAY63-2521)|Participants received therapy with riociguat during a 10-week titration phase. The starting dose for riociguat for all patients was 0.5 milligram (mg) three times a day (TID). The dose of riociguat was increased every 2 weeks in 0.5 mg increments to 1.0, 1.5, 2.0, and 2.5 mg until patients reached their individual optimal dose based on their systolic blood pressure and well-being. After reaching their optimal dose, patients then entered a maintenance phase and remained on this dose for an additional 14 weeks. End of treatment was reached at Visit 10 after 24 weeks of treatment with riociguat.
1948535|NCT02187861|Drug|Venetoclax|Venetoclax will be administered as per the schedule specified under arm description.
1472289|NCT03180021|Procedure|MRI|"This is a multicenter, non-interventional, pilot study. Eligible subjects will have a baseline MRI of the kidney, including anatomical, DWI, BOLD, T1rho, and DCE-MRI, utilizing a macrocyclic gadolinium-based contrast agent (GBCA), followed by planned standard of care (SOC) renal biopsy and clinical laboratory assessments. Additional serum and urine will be collected from subjects at baseline for analysis of research biomarkers. Following the results of the biopsy and clinical laboratory assessments, subjects will be treated for their underlying disease at the discretion of the investigator.
At 6 months, subjects will return to the clinic for a second MRI, SOC clinical and laboratory evaluation and collection of serum and urine for analysis of research biomarkers."
1472290|NCT03180008|Behavioral|Fit and Strong!|Fit and Strong! is a group exercise and self-management program that meets for 90 minutes, 3 days per week, for 8 weeks. Each 90 minute session consists of 60 minutes of multi-component physical activity (stretching/flexibility exercises, low-impact aerobics, and strength/resistance exercise) and 30 minutes of health education delivered from a structured curriculum. The health education topics build self-efficacy for managing arthritis through physical activity.
1472291|NCT03180008|Behavioral|Fit and Strong! Plus|The intervention consists of the traditional Fit and Strong! intervention (see previous description), but the health education component has been revised to focus on diet and weight management in addition to physical activity and arthritis.
1472292|NCT03179995|Drug|Octreotide|Octreotide will be administered 50 µg intravenously per hour for up to five days postoperatively, starting at the time of vascular inflow disruption.
1472293|NCT03179995|Other|Placebo|Normal saline will be administered in the same fashion as Octreotide
1472294|NCT03179982|Behavioral|Safe South Africa|"Core components of the Safe South Africa intervention include the following:
Theory driven, best-evidence intervention approaches to adolescent HIV prevention
Linkages between HIV and IPV
Victim Empathy
Healthy Norms Regarding Masculinity
Bystander Intervention Skills"
1472295|NCT03179969|Other|paravalvular leak|Observational study on patients with paravalvular leak
1472299|NCT03179930|Drug|Entinostat|Entinostat 5 mg PO on D1, 8, and 15 of a 21 day cycle. If treatment is well tolerated the dose of entinostat will be increased to 7 mg PO on D1, 8, and 15 from cycle 2 onward.
1472300|NCT03179930|Drug|Pembrolizumab|pembrolizumab 200 mg IV on D1
1472301|NCT03179917|Drug|Pembrolizumab|pembrolizumab 200mg IV will be given over 30 minutes on day 1 of each 21 day cycle for a total of 4 cycles
1472302|NCT03179917|Radiation|Involved Site Radiation Therapy|30 Gy of ISRT
1472308|NCT03179878|Drug|Placebo|Placebo
1472309|NCT03179878|Drug|SYNB1020|Investigational Product
1472310|NCT03179852|Behavioral|nutrition education|nutrition education
1472311|NCT03179839|Behavioral|Mindfulness-based Cognitive Therapy|"The intervention will be carried out according to the handbook of the Dr. Didonna. There is a Session Agenda from Dr. Didonna for the use of the Instructor and session handouts for the participants. Some records of mindfulness practices will be given to participants for facilitating practice between sessions. Before each session, the instructor needs to review the session agenda and prepare copies of handouts for participants.
MBCT instructors were experienced psychotherapists and psychiatrists with several years' expertise in OCD treatment. They had been trained by one of the founders of MBCT, Mark Williams and the founder of MBCT for OCD, Fabrizio Didonna. Supervision will be provided by Dr.Didonna."
1472341|NCT03179579|Procedure|HIPEC with neoadjuvant chemotherapy|HIPEC 3 times +NACT 2 cycles +CRS +HIPEC 3 times+ ACT 4-6 cycles
1948536|NCT02187861|Drug|Bendamustine|Bendamustine will be administered as per the schedule specified under arm description.
1948537|NCT02187861|Drug|Rituximab|Rituximab will be administered as per the schedule specified under arm description.
1948538|NCT02185599|Device|DySIS|Colposcopy performed with the DySIS digital colposcope
1472312|NCT03179839|Behavioral|Psycho-education Program|As a widely used placebo control condition, the Psycho-Education Program can play an active role through the psychological suggestion and forward thinking mostly. It is designed to be similar with MBCT in level of structure, setting and other non-specific effects of psychological intervention. All instructors will be qualified graduate students who major in clinical psychology with training in cognitive behavioral therapy and psychodynamic therapy.
1472313|NCT03179839|Drug|sertraline, fluvoxamine|The participants can be adjustable once a week dose and the maximum dose does not exceed the maximum amount of instructions. And benzodiazepine drugs also can be used by the OCD patients with sleep disorders, but not be used continuously for more than two weeks. Besides this, other psychotropic drugs are not allowed to use. The use of drugs in this study are commonly used drugs with good safety, and its common adverse reactions include dry mouth, constipation, nausea, indigestion, dizziness, fatigue, sweating and so on.
1472316|NCT03179800|Device|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
1472317|NCT03179800|Other|Sham Implantation|Sham Implantation
1472318|NCT03179787|Drug|Aripiprazole oral product|oral administration of aripiprazole
1472319|NCT03179774|Device|Endovascular revascularization|All interventions will be performed via 8F femoral sheath. Target common carotid artery will be engaged with 8F JR 4 guiding catheter. Intra-luminal wiring using coronary guidewires and microcatheters or alternative subintimal tracking with antegrade re-entry technique. Wiring would be abandoned after 30 minutes of futile effort, consumption of more than 300 ml of contrast, or when the wire tip is confirmed to be extravascular. Once wire enters distal true lumen, the microcatheter was exchanged to a 1.5 mm diameter coronary balloon for pre-dilatation. Distal embolic protection device would be deployed if an adequate landing zone can be identified. Properly sized balloon expandable stents and self-expanding stents were then deployed to scaffold the occlusion. Balloon post-dilatation may be done if stent expansion was inadequate.
1472323|NCT03179748|Drug|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa according to local clinical practice at the discretion of the physician
1472324|NCT03179735|Drug|Essential oils|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.
First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
1472325|NCT03179735|Drug|Cetylpyridinium Chloride 0.7 mg/ml|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.
First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
1472326|NCT03179735|Drug|Placebos|"Patients will be submitted to one-stage ultrasonic debridement to remove plaque, stain(s), and any possible supragingival dental calculus. Further, oral instructions and an oral hygiene kit with fluoride dentifrice, toothbrush and plastic cups marked to indicate the rinse volume will be provided. According to study group, the first rinse will be performed under supervision at the study center and the remaining rinses will be performed unsupervised at home.
First rinse will be performed 15 days before orthodontic appliances bonding while the last rinse will be performed 6 months after bonding."
1472327|NCT03179722|Behavioral|Medication review|The intervention consists of a medicines use review provided by community pharmacists in Belgium. A medicines use review is a medication review type 2a in which both a patient interview and dispensing data are used as information sources to identify drug-related problems with a specific focus on the medicines use of the patient.
1472328|NCT03179722|Behavioral|Additional data collection: questionnaires|"Pre-post study design.
At three timepoints, data is collected:
before the medication review (T-1week)
during the review (Tweek 2)
after the review (Tweek12) The questionnaire provide data for the outcomes: medication related quality of life, adherence questionnaire, service satisfaction, use of emergency health services, self-management"
1472329|NCT03179709|Behavioral|Interview|The investigators will perform and analyze semi-structured interviews with enrolled participants.
1472330|NCT03179696|Behavioral|Mobile-assisted CBT|mCBTn combines the CBT components that target defeatist attitudes from Cognitive Behavioral Social Skills Training (CBSST) group therapy and mobile smartphone interventions from our prior clinical trials research.
1472331|NCT03179683|Device|Diode laser application|an 630-660 nm aluminum gallium indium phosphide (AlGalnP) laser device (Scorpion Dental Optima Model 405-7A; Optica Laser, Sofia, Bulgaria) was used immediately after surgery, third day, fifth day and seventh day only for one operation side. Treatment side were randomly selected by another surgeon who applied LLLT. Tissue was irradiated at 25mW power for total six minutes, two minutes for each point (buccal, palatal, crestal). 72J /cm2 energy density was deposited in one session.
1472332|NCT03179644|Other|Measurement of oesophageal pressure and pleural pressure|Measurement of oesophageal pressure by a nasogastric tube with an esophageal balloon (also enabling the patient to be fed) and pleural pressure measurement by means of several pleurocath-type catheters (Prodimed Inc, France) which the thoracic surgeon will have previously Positioned at the end of the surgery without any additional skin intrusion
1472333|NCT03179631|Drug|Ataluren|10, 10, 20 mg/kg
1472334|NCT03179631|Drug|PLACEBO|10, 10, 20 mg/kg
1472335|NCT03179618|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
1472336|NCT03179618|Drug|Lipid Regulating Drugs|Mainly including statins
1472342|NCT03179579|Procedure|Systemic chemotherapy|NACT 3 cycles +CRS +ACT 4-6 cycles
1472343|NCT03179566|Behavioral|Information Sheet|Patients will receive an informational sheet about how to dispose of leftover opioid medication during discharge. Nurses will provide this information sheet and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
1472344|NCT03179566|Behavioral|Deterra Drug Deactivation System|This system is a pouch that deactivates prescription drugs, rendering them ineffective for misuse and safe for regular garbage disposal. It uses a patented activated carbon technology to deactivate drugs, including pills, liquids, and patches, and has been found to be 99% percent effective in studies funded by the National Institute of Drug Abuse (NIDA). Additionally, the pouches are made from environmentally friendly materials and contain active ingredients that are considered non-toxic and pose minimal risk, according to their MSDS. Nurses will provide the Deterra bag and a brief, scripted description of its use and importance of safe disposal at the time of discharge following surgery.
1472345|NCT03179540|Procedure|Non-operative management|Patients who are eligible and provide informed consent to participate in the trial will undergo non-operative management (i.e., active surveillance for 24 months) according to the schedule outlined in the study protocol.
1472346|NCT03179527|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc
1472347|NCT03179527|Drug|Lipid Regulating Drugs|Mainly including statins
1472348|NCT03179527|Drug|Coronary Vasodilator|Mainly including nitrates
1472349|NCT03179527|Drug|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
1472350|NCT03179514|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
1472351|NCT03179514|Drug|Lipid Regulating Drugs|Mainly including statins
1472352|NCT03179514|Drug|Coronary Vasodilator|Mainly including nitrates
1472353|NCT03179514|Drug|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
1472354|NCT03179501|Drug|NP001|NP001
1472355|NCT03179501|Drug|Placebo|Normal saline
1472356|NCT03179488|Device|Spinal TENS|Spinal TENS stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1472357|NCT03179488|Device|Sham stimulation|Sham stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1472358|NCT03179475|Drug|Oxycodone Naloxone Combination|"A flexible dosing schedule will be used in this study. The dose and schedule will be based on the minimal amount of medication required to manage pain related to spinal cord injury. The dose and/or frequency will be titrated to the individual's pain level at the discretion of their regular attending physician and/or investigator.
Oxycodone-Naloxone is available in the following oral dosages:
5 mg oxycodone hydrocholoride / 2.5 mg naloxone hydrochloride
10 mg oxycodone hydrocholoride / 5 mg naloxone hydrochloride
20 mg oxycodone hydrocholoride / 10 mg naloxone hydrochloride
40 mg oxycodone hydrocholoride / 20 mg naloxone hydrochloride"
1472359|NCT03179462|Dietary Supplement|Pork intake|Each participant will consume 2 ounces of cooked lean pork.
1472360|NCT03179462|Dietary Supplement|Mixed nuts intake|Each participant will consume 1 ounce of mixed nuts.
1472361|NCT03179462|Dietary Supplement|Tofu intake|Each participant will consume 2 ounces of tofu.
1472362|NCT03179449|Diagnostic Test|Diagnostic (ferumoxytol-enhanced MRI)|Undergo ferumoxytol-enhanced MRI
1472363|NCT03179449|Procedure|Surgery|Undergo surgical resection
1472364|NCT03179449|Drug|Ferumoxytol|Given IV
1472365|NCT03179449|Other|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
1472368|NCT03179423|Drug|GNbAC1|Monthly IV repeated dose
1472369|NCT03179423|Drug|Placebo|Monthly IV repeated dose
1472370|NCT03179410|Drug|Avelumab|10 mg/kg intravenously every 2 weeks
1472371|NCT03179397|Device|Model SC9|Experimental
1472372|NCT03179397|Device|Model LI61SE|Active Comparator
1472373|NCT03179384|Drug|Ceftriaxone|ceftriaxone (1g intravenous or 1g/35mL intramuscular) will be given to patients during 7 days
1472374|NCT03179358|Device|C-REX Ring-locking Procedure|"The C-REX Ring-locking Procedure is a method based on adaptive anastomosis, in which intestinal ends adapt to each other after resection due to tumor, injury, or other disease.
The investigational devices comprised of two components, i.e. C-REX LapAid and C-REX DMH/DMHC"
1472375|NCT03179345|Drug|Gabapentin|
1472376|NCT03179345|Drug|Pregabalin|
1472377|NCT03179345|Other|Placebo|
1472378|NCT03179332|Drug|BioChaperone® insulin lispro|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
1472379|NCT03179332|Drug|Fiasp®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
1472380|NCT03179332|Drug|Novorapid®|Single subcutaneous administration of a bolus of 0.15 U/kg body with a pump
1472381|NCT03179319|Behavioral|MyChoices|Access to the MyChoices mobile app which includes the HIV test plan with reminders, STI information, PrEP resources, links to testing and PrEP sites, and geo-location features.
1472382|NCT03179293|Drug|Propofol|propofol 1 mg/kg IV bolus will be given to the patient with a further 2 mg/kg administered manually over the next 3 min prior to the patient leaving the OR
1472383|NCT03179293|Drug|Normal saline|Normal saline will be administered manually over the next 3 min prior to the patient leaving the OR
1472384|NCT03179280|Drug|insulin|All participants used the rapid-acting insulin analogue aspart (NovoRapid®, Novonordisk A/S, Bagsvaerd, Denmark) and total insulin dose administered to each one for each test meal was known in advance, according to the insulin to carbohydrate ratio that had been calculated during the 2-week pre-study period.
1472386|NCT03179254|Drug|Metformin continue|Oral hypoglycemic agent continue on the day of ambulatory surgery
1472415|NCT03178929|Drug|S-Adenosyl Methionine|2000mg, po
1472387|NCT03179254|Drug|Metformin discontinue|Oral hypoglycemic agent discontinue on the day of ambulatory surgery
1472389|NCT03179215|Diagnostic Test|fluid challange|A set of hemodynamic measurements will be obtained at baseline and after infusing a fluid challenge (FC) of 150-250 ml normal saline over 5-10 minutes.Fluid-responders are patients with a SV increase ≥10% after fluid challenge
1472391|NCT03179176|Other|High Frequence Ultrasound Doppler (HFUD) utilisation|Utilisation of HFUD will be done during on patients during an operation in waking condition. This procedure extends the usual procedure from 15 to 20 minutes.
1472392|NCT03179163|Drug|Captopril Pill|ACEi+SH
1472393|NCT03179163|Drug|Enalapril Pill|ACEi
1472394|NCT03179163|Drug|Hydrochlorothiazide|diuretic
1472395|NCT03179150|Diagnostic Test|Computed Tomography|CT scans were performed on a 128 detector rows CT scanner (Somatom Definition Flash Siemens Medical Systems, Erlangen, Germany) as in routine clinical practice in the centre
1472396|NCT03179137|Other|Standard therapy|Patients with therapy prescribed independent of the study
1472398|NCT03179098|Other|Modified Weeks protocol|The modified Weeks group (GWM) will apply the protocol suggested by Flowers (2002), the positioning will be maintained and at rest will be done electromyographic registers, active goniometry and EVA. Soon afterwards the patients will be submitted to the whirlwind for 20 minutes at a temperature of 41 ° C performing active flexion and elbow extension movements. After the swirl the patients will be submitted to a stretching maintained for 10 minutes with load proportional to the force captured during MVIC according to the pain of the patient. The load will be positioned through a leather device 20 cm from the lateral epicondyle of the elbow.
1472399|NCT03179098|Other|CIVM|Patients underwent electromyographic analysis for the determination of maximal voluntary isometric contraction. The force will be collected for 5 seconds during a CIVM, in which a load cell model MM50 (Kratos, Cotia, SP, Brazil) will be positioned between the floor and the forearm of the volunteer, being coupled to a leather device at 20 cm Make the lateral epicondyle of the elbow. The angle between the forearm and the cable containing a load cell with a 90 degree service.
1472400|NCT03179098|Other|GC- Sustained Stretching|The control group will be applied to sustained stretching, patients will be placed in the supine position with abduction of the shoulder of 30 ° in the plane of the scapula and the forearm in neutral throughout the entire test and the elbow will be supported in a towel to avoid discomfort And compression in the region of the olecranon.
1472404|NCT03179046|Diagnostic Test|Laboratory tests and cardiac imaging|Laboratory tests (blood count, liver and kidney functions, antibodies, acute phase reactants), Echocardiography and gadolinium enhanced cardiac MRI
1472405|NCT03179020|Other|Checklist use|Management of the potential donor guided by the use of an evidence-based checklist. This checklist is based on main recommendations of the Brazilian guideline for the management of potential multiple organ donors.
1472406|NCT03179020|Other|Usual care|Management of the potential donor according usual care.
1472407|NCT03179007|Biological|Anti-CTLA-4/PD-1 expressing MUC1-CAR-T|Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop. Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion. Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing MUC1 targeted CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
1472408|NCT03178994|Drug|2% ketoconazole cream|2% ketoconazole cream applies twice daily
1472409|NCT03178994|Drug|Hydrophilic Cream|Hydrophilic cream (in-house preparation) applies twice daily
1472410|NCT03178981|Other|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
1472411|NCT03178968|Other|Orange juice|3 immersion times in orange juice were investigated
1472412|NCT03178955|Drug|Etanercept|Circadian activity rhythm parameters will be evaluated for 7 days prior to Enbrel treatment through 7 days after initiation of Enbrel treatment and again 28-35 days after the second Enbrel treatment.
1948546|NCT02180243|Behavioral|Yoga/Acupuncture|Individuals randomized to this group will participate in iRest Yoga Nidra and auricular acupuncture.
1948547|NCT02180243|Other|Gulf War Health Education|Participants randomized to this group will take part in a health education group.
1948548|NCT02175251|Procedure|high frequency (20Hz)|10 session in 5 days with high frequency (20 Hz)
1948549|NCT02175251|Procedure|low frequency (1Hz)|10 session in 5 days with low frequency (1Hz)
1948550|NCT02175251|Procedure|Sham Comparator|10 session in 5 days with sham-controlled
1948551|NCT02174978|Biological|FMP012 with AS01B adjuvant system|Candidate malaria vaccine based on the recombinant protein FMP012, which is Escherichia coli-expressed Plasmodium falciparum cell-traversal protein for ookinetes and sporozoites (PfCelTOS)
1948552|NCT02174978|Other|P falciparum Controlled Human Malaria Infection (CHMI)|
1472416|NCT03178903|Other|tDCS|Participants in transcranial direct current stimulation (tDCS) will receive tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
1472417|NCT03178903|Other|Sham tDCS|Participants in sham transcranial direct current stimulation (tDCS) will receive shame tDCS over the dorsal-lateral prefrontal cortex for 20 minutes, 3 times per week for 8 weeks.
1472418|NCT03178903|Behavioral|Aerobic Exercise (AE)|Participants will engage in supervised, 30-minute bouts of moderate-intensity exercise 3x/week for 8 weeks.
1472419|NCT03178890|Device|OHMG|Device will be implanted in all enrolled patients.
1472420|NCT03178877|Other|No intervention|
1472423|NCT03178851|Biological|Atezolizumab|Atezolizumab, 840 mg intravenously every two weeks (Q2W) on Days 1 and 15 of each 28-day cycle, until loss of clinical benefit
1472424|NCT03178851|Drug|Cobimetinib|Cobimetinib, 60 mg orally once daily (QD) on Days 1−21 of each 28-day cycle, until loss of clinical benefit
1472425|NCT03178851|Biological|Atezolizumab|Atezolizumab, 840 mg intravenously on Day 15 of Cycle 1; thereafter Q2W on Days 1 and 15 of Cycle 2 and all subsequent 28-day cycles, until loss of clinical benefit
1472426|NCT03178851|Biological|Atezolizumab|Atezolizumab, 1200 mg intravenously every three weeks (Q3W) on Day 1 of each 21-day cycle, until loss of clinical benefit
1472427|NCT03178825|Device|Hybrid Fractional Laser|Consecutive and coincident fractional 2940 nm and 1470 nm lasers
1472428|NCT03178812|Procedure|EUS with fine-needle aspiration of pancreatic cyst|EUS with fine-needle aspiration
1472429|NCT03178812|Diagnostic Test|Laboratory Blood test|Laboratory Blood Test
1472430|NCT03178799|Other|FLS|FLS subjects received osteoporosis-related assessments, treatments, consultations on diet, medications, exercise, fall preventions given mainly by care managers with followed up telephone call at 4, 8, 12, 18, 24 months then annually for up to 10 years.
1472431|NCT03178786|Behavioral|PAT sessions|PD subjects will be tested twice, that is, within four weeks before (Baseline) and after the completion of 9 PAT projects (Follow up).
1472432|NCT03178773|Behavioral|TExT-MED|messages designed to inspire motivation and behavior change
1472433|NCT03178773|Behavioral|FANS|SMS delivered messages to family members to improve social support
1472434|NCT03178760|Diagnostic Test|Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified.|"Ultrasonic Measurement will be taken from optic nerve sheat diameter and compared-classified. Classifications will be done for;
Age
Gender
Weight
Length
Waist Circumference
Body mass index"
1472435|NCT03178747|Diagnostic Test|Methylene blue|working solution methylene blue
1472436|NCT03178747|Diagnostic Test|Giemsa stain|working solution Giemsa stain (Wolbach's modification)
1472437|NCT03178734|Device|Foley Catheter vs Self-Contained Valved Catheter|This study aims to compare UTI rates and patient satisfaction between an indwelling Foley catheter group (established SOC); and a relatively (FDA-approved) new valved addition to the Foley catheter which requires no drainage bag.
1472438|NCT03178721|Diagnostic Test|blood sample|study B regulatory in blood and its correlation with atherosclerosis
1472439|NCT03178708|Drug|Group A amantadine sulfate|infusion solution for slowly intravenous application 3 hours preoperative
1472440|NCT03178708|Other|Group B ringer lactate|infusion solution for intravenous application 3 hours preoperative
1472441|NCT03178695|Biological|Autologous Platelet-Rich Plasma Infusion Into Ovaries|Using FDA-approved equipment, blood plasma is received from the participant, enriched into Platelet-Rich Plasma, and infused into the ovaries.
1472442|NCT03178682|Diagnostic Test|ultrasound parameters|ultrasonographic parameters (mean gestational sac diameter, yolk sac diameter, crown rump length, embryonic heart rate and uterine artery Doppler) in predicting early pregnancy failure in patients with recurrent pregnancy loss.
1472443|NCT03178669|Drug|cobitolimod|Rectal administration
1472444|NCT03178669|Drug|Placebo|Solution manufactured to mimic cobitolimod
1472445|NCT03178656|Drug|Sorafenib|continuous application of the drugs
1472446|NCT03178656|Procedure|surgery|curative resection
1472447|NCT03178643|Drug|Proguanil Oral Tablet|Dosing of daily proguanil will be approximately 3mg/kg/day,
1472448|NCT03178643|Drug|Sulfadoxine/Pyrimethanine-Amodiaquine (SP-AQ)|Age 1-5 on Day 1: One tablet 500/25mg SP and one tablet 153mg AQ Day 2 and Day 3: one tablet 153 mg AQ only each day For ages 6-10: Day 1 - 1.5 tablets 500/25mg SP and 1.5 tablets 153mg AQ Days 2 and 3: 1.5 tablets 153mg AQ only each day
1472449|NCT03178643|Drug|Dihydroartemisinin-Piperaquine (DP)|"3) The weight-based dosing of tablets of 40/320mg of DP is described below:
Weight (kg) No. of 40/320mg tabs DP daily for 3 days
≤ 5 ¼ 6-10 ½ 11-14 ¾ 15-19 1 20-23 1 ¼ 24-25 1 ½"
1472450|NCT03178617|Other|Educational Intervention|Attend standard of care LIP
1472451|NCT03178617|Other|Educational Intervention|Attend HIP
1472452|NCT03178617|Other|Quality-of-Life Assessment|Ancillary studies
1472453|NCT03178617|Other|Questionnaire Administration|Ancillary studies
1472454|NCT03178604|Other|Massage|It includes 5 minutes of gentle friction, 10 minutes of kneading and slow and deep friction to finish with 5 minutes of gentle friction. It is done bilaterally and in the leg and calf, both anterior and posterior. In total the duration of the massage in both legs lasts 40 minutes.
1472455|NCT03178604|Other|Muscle chains|The Denys-Struyf G method guidelines are followed on both legs with strokes made in the right direction. It was performed on both legs in the calf as well as in the quadriceps and hamstrings with a duration of 40 minutes.
1472456|NCT03178604|Other|Placebo treatment|The placebo treatment consisted of the application of lotion in the calf, quadriceps and hamstrings, with no intention of treatment.
1472457|NCT03178591|Drug|vildagliptin|
1472458|NCT03178591|Drug|Dapagliflozin|
1472498|NCT03178240|Behavioral|photoaging mirroring intervention|selfies of the students are photoaged showing them the consequences of their UV protection behavior on their own face
1472459|NCT03178565|Other|Mechanical insufflation-exsufflation|The mechanical insufflation-exsufflation device will be connected in the orotracheal tube. Four series of insufflation-exsufflation will be conducted. Each serie will be composed by 10 cycles of alternated insufflation (40 cmH2O) and exsufflation (- 40 cmH2O).
1472460|NCT03178565|Other|Standard Respiratory Physiotherapy|Standard chest physiotherapy will be conducted through bilateral thoracic maneuvers (percussion and vibration) followed by manual hyperinflation using a manual resuscitator bag.
1948553|NCT02174562|Behavioral|Primary Care-Occupational Therapy|PC-OT consists of: 1) primary care physician (PCP) - occupational therapist (OT) collaboration; 2) DM education tailored to cognitive impairment; 3) in-home OT cognitive-functional assessment; and 4) OT-delivered Behavior Activation to increase adherence to medications and other diabetes self-management (DSM) practices (e.g., diet).
1948554|NCT02174562|Behavioral|Enhanced Usual Care|Usual care enhanced with education and attention
1472467|NCT03178539|Drug|diclofenac|non steroidal anti-inflammatory drug
1472468|NCT03178539|Drug|ketorolac|non steroidal anti-inflammatory drug
1472469|NCT03178526|Drug|Lovastatin gel|Lovastatin gel1.2% topical gel was put into the periodontal pocket using an insulin syringe
1472470|NCT03178526|Drug|Placebo|placebo gel
1472471|NCT03178513|Other|Home visit|"The visit will be entirely patient tailored, last approximately one hour, and at a minimum will entail:
Medical assessment
Psychosocial assessment
Medication reconciliation
Follow-up of inpatient primary team's specific recommendations
Follow-up, as needed, with primary care team or inpatient team"
1472472|NCT03178500|Drug|Clomiphene Citrate 50mg|stair-step clomiphene adminstration
1472473|NCT03178487|Drug|Upadacitinib|Tablet
1472474|NCT03178487|Drug|Upadacitinib Placebo|Tablet
1472475|NCT03178474|Other|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®|JINLINGGUAN Infant formula,PRO-KIDO™ I-PROTECH®: a type of Phase I infant formula for 0-6 month infants, with a trademark of PRO-KIDO™ I-PROTECH®. The formula contains both OPO structured lipid and α+β patented protein (patent number: ZL200810241156.3).It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
1472476|NCT03178474|Other|TOFER Infant formula,TOFER®|TOFER Infant formula,TOFER®: a type of Phase I infant formula for 0-6 month infants, with a trademark of TOFER®. The formula was characterized by (1) Moderate digestible small-molecule protein; and (2) BID® complex probiotics. It was produced by Inner Mongolia Yili Industrial Group Co.Ltd.,China
1472477|NCT03178474|Other|Breast milk|Breast milk: Human breast milk, provided and fed by the corresponding infant's mother
1472478|NCT03178461|Other|Body temperature parenteral fluids|2 study groups shall receive the same parenteral fluids but at different temperatures.
1472480|NCT03178422|Drug|CQSS2|Nicotine Replacement Therapy
1472481|NCT03178422|Drug|NicoDerm CQ Patch|Nicotine Replacement Therapy
1472482|NCT03178409|Procedure|Hepatectomy|Removal of a part of the liver
1472483|NCT03178396|Dietary Supplement|melatonin|controlled release, 9 mg taken 30 minutes before bedtime x 6 weeks
1472484|NCT03178383|Behavioral|Project HEAL|Standard group churches will not be asked to, or provided special encouragement to technical assistance with, institutionalizing health promotion activities in their churches.
1472485|NCT03178383|Behavioral|Project HEAL 2.0|In this approach, rather than developing a separate health ministry, cancer activities could be integrated throughout existing church ministries (e.g. men's, women's, seniors).
1472486|NCT03178370|Device|Gastric Electrical Stimulation|Temporary and permanent gastric electrical stimulation
1472487|NCT03178357|Other|Cardiac rehabilitation + standard therapy|Patients with HCM subjected to cardiological rehabilitation
1472488|NCT03178357|Other|Standard therapy|Standard treatment according to current guidelines and outpatient visits with psychological and / or psychoeducational counseling
1472489|NCT03178344|Device|XCSITE100 Stimulator tACS|Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
1472490|NCT03178344|Device|XCSITE100 Stimulator Sham|The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.
1472491|NCT03178331|Other|Screening questionnaires|filled by parents, school nurse and teacher
1472492|NCT03178318|Procedure|ultrasound|ultrasound of the neck to identify the position of upper and lower border of the cricothyroid membrane.
1472493|NCT03178305|Behavioral|Do CHANGE|"Besides the behavior change programme (Do Something Different)
All patients will receive: Fitbit, Beddit, Care-portal, Do CHANGE app (including dietary habits picture taking), CookiT (smart spatula that monitors cooking behavior)
patients with heart failure will, in addition to the above mentioned, be offered a weight scale, blood pressure monitor, and FluiT (smart cup to measure fluid intake).
Patients with hypertension will also be offered a bloodpressure monitor.
Data from these devices will be gathered and visible for patients (in patient portal) and for their health care provider (health care provider portal). In case of negative results the patient will be contacted by their health care provider (usually the cardiologist).
Once every week the patients will be contacted to discuss their progress and will be given feedback about their dietary intake."
1472494|NCT03178292|Drug|Levofloxacin|Levofloxacin 500Mg daily for 5 days
1472495|NCT03178292|Drug|Placebo|Placebo Oral Tablet daily for 5 days
1472496|NCT03178279|Other|Physical Health Plan|Use of a Physical Health Plan by service users
1472497|NCT03178266|Device|Knee Arthroplasty|Standard Knee Arthroplasty will be performed on study subjects. The closure method will be studied at 3 weeks and 6 weeks and patients will be asked about satisfaction with the closure method assigned.
1472499|NCT03178227|Behavioral|Photoaging Mirroring Intervention|"Medical students perform mirroring with the pupils in the schools where they shoot selfies with tablets and photoage them to future non-smokers vs. future smokers."
1472500|NCT03178214|Drug|Infacort|Immediate-release multiparticulate formulation of hydrocortisone.
1472501|NCT03178201|Drug|TGR-1202|Treatment will be self-administered on an outpatient basis. Patients will take TGR-1202 800 mg, oral, one tablet daily on a continuous basis. Each cycle lasts 28 days.
1472502|NCT03178188|Device|Pulsed-dye Laser|595 nm Pulsed-dye Laser; 7mm spot sizes, 6msec pulse durations, 8j/cm2 fluences, dynamic cooling device 30/20, 4 sessions with 4 weeks interval
1472503|NCT03178188|Device|Sham|Cryogen spray with the setting of dynamic cooling device 30/20
1472504|NCT03178175|Procedure|Acupuncture|"In the acupuncture with De Qi group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) until the De Qi phenomenon occurs. The duration is about 30 minutes, and all patients will receive the procedure 16 times within 2 months."
1472505|NCT03178175|Procedure|Needle Insertion|"In the Sham acupuncture group, using stainless tiny needles is inserted to the specific acupoints over the scalp (Si Shen Cong and Baihui) but the needle doesn't reach the exact depth and De Qi phenomena doesn't occur. The duration is about 30 minutes, and all patients will receive this procedure 16 times within 2 months."
1472506|NCT03178149|Drug|ASP7317|subretinal injection
1472507|NCT03178149|Other|Placebo|no treatment
1472508|NCT03178149|Drug|tacrolimus|oral
1472509|NCT03178149|Drug|mycophenolate mofetil (MMF)|oral
1472512|NCT03178110|Behavioral|Physical therapy and dynasplint|Participants will receive a session of 30-45 minutes of manual therapy three/two times per week, for twenty four weeks. All participants will be instructed how to use the Dynasplint® Trismus System at home. Participants will start the use of the DTS for 10-30 minutes three times per day, every day. If the exercises are well tolerated, time will be progressively increased to 30 minutes and then intensity (force) will be increased every 2 weeks until maximum tolerance is reached.
1472513|NCT03178084|Drug|Maraviroc (UK-427,857) QD + Zidovudine/Lamivudine BID|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
1472514|NCT03178084|Drug|Efavirenz QD + Zidovudine/Lamivudine BID|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
1472515|NCT03178084|Drug|Maraviroc (UK-427,857) BID + Zidovudine/Lamivudine QD|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily
1472517|NCT03178058|Other|Questionaire|"Prior to surgery women will be given a questionnaire detailing previous motion sickness, previous history of PONV, emesis during pregnancy, smoking history , itching history, skin atopy and allergies. After surgery details about surgery will be added: intraoperative hypotension, use of phenylepherine, intraoperative nausea and vomiting, exteriorization of uterus, extent of adhesions, need for uterotonic medications, and estimated bleeding.
Parturients will be assessed 1 hour and 24 postoperatively by attending anesthesiologist, PONV incidence will be reported using a three point ordinal scale (0 = none, 1 = nausea, 2 = retching, 3 =vomiting)."
1472518|NCT03178045|Other|Team Monitoring|In this cohort, the electronic system will provide advanced informatics support for push notifications to the care team based on the severity of the symptoms reported. This platform promotes early detection and intervention. The care team is alerted when patients experience symptoms out of the expected range or if symptoms are worsening. Nurses receive secure message notifications and will contact the patient by phone depending on symptom severity. If a patient responds with a moderate-severe answer, the office team gets an alert and calls the patient during business hours.
1472519|NCT03178045|Other|Enhanced Feedback|In this cohort, the electronic system will provide tailored normative data visualizations that offer context and education to patients regarding expected symptom severity. The information provided to patients in the Enhanced Feedback group will be procedure specific and based on continuously updated PRO-CTCAE data from previous patients. Patients are thus able to see their own recovery trajectory relative to that of patients who have undergone the same procedure. Care is patient activated in that patients will use the information about expected symptoms to decide whether they should call the care team (e.g., if they are experiencing symptoms that are more severe or more prolonged than expected). If a patient reports severe symptoms, they are instructed to immediately contact their physician's office or seek medical attention.
1472520|NCT03178032|Biological|DNX-2401|Brain infusion of the virus through the cerebellar peduncle
1472521|NCT03178019|Other|Laser-Doppler methods|This was a cross-sectional study in which participants were subjected to a screening phase before being eligible to participate in the study. All subjects were submitted to Laser-Doppler methods (assessment of microcirculatory blood flow), bioimpedance analysis (assessment of body composition), venous blood collections (laboratory analysis), and Finometer Pro (assessment of heart rate variability and blood pressure variability).
1472522|NCT03177993|Drug|3 drug dose - IDA|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Participants excluded from ivermectin will receive a topical dose of permethrin cream.
Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:
severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);
allergy to ivermectin, diethylcarbamazine or albendazole;
pregnant;
breastfeeding within 7 days of delivery;
less than 2 years old; OR
less than 15 kg
In addition if less than 5 years old excluded from ivermectin.
Exclusion criteria for permethrin:
allergy to permethrin
crusted scabies"
1472523|NCT03177993|Drug|3 drug dose - IDA with second dose of ivermectin|"Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA). Eight days after treatment participants will be given a second dose of ivermectin alone.
Participants excluded from ivermectin will receive a topical dose of permethrin cream both on day 0 and day 8.
Exclusion criteria for ivermectin, diethylcarbamazine and albendazole:
severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);
allergy to ivermectin, diethylcarbamazine or albendazole;
pregnant;
breastfeeding within 7 days of delivery;
less than 2 years old; OR
less than 15 kg
In addition if less than 5 years old excluded from ivermectin.
Exclusion criteria for permethrin:
allergy to permethrin
crusted scabies"
1472524|NCT03177993|Drug|2 drug dose - DA|"Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA).
If scabies is present in the participant or a household member permethrin cream will be provided 8 days after dose of DA.
Exclusion criteria for diethylcarbamazine and albendazole:
severe illness (chronic renal insufficiency, severe chronic liver disease, or any illness that is severe enough to interfere with activities of daily living);
allergy to diethylcarbamazine or albendazole;
pregnant;
breastfeeding within 7 days of delivery;
less than 2 years old; OR
less than 15 kg
Exclusion criteria for permethrin:
allergy to permethrin
crusted scabies"
1472525|NCT03177980|Drug|Fentanyl|The dosing and administration of fentanyl will serve as the first drug intervention in infants in need of analgesia according to an algorithm based on pain scoring results.
1472526|NCT03177980|Drug|Fentanyl and clonidine|In infants in need of further analgesia clonidine will be administered as an add on drug according to an algorithm based on pain scoring results.
1472527|NCT03177967|Behavioral|Sleep Restriction Therapy/Stimulus Control|Sleep Restriction Therapy focuses on forcing your available sleep time into a fixed window. The sleeper sets a bedtime and wake-up time and sticks to those times closely. The time allocated for being allowed in bed is determined from an estimate of how long the patient in average has been sleeping during the night, in the week before treatment. The goal is to have the patient sleeping the entire time he or she is in bed by making this period so restricted that the patient has no chance of sleeping enough. Once this goal is achieved, the time allocated for bed can be slowly increased, for example by 15 minutes at a time. After enough iterations, an equilibrium is achieved that the patient can keep maintaining after treatment has completed.
1472528|NCT03177967|Other|Discussions about adverse cognitions about sleep|Group discussions about insomnia, CBT-i treatment and it's effects
1472529|NCT03177967|Other|Psychoeducative advice about how to improve sleep|Learning about sleep and sleep hygiene tips. It also includes learning about stimulus control and sleep restriction.
1472530|NCT03177954|Behavioral|Patient Oriented Discharge Summary|Participants will undergo a Patient Oriented Discharge Summary (PODS). The PODS is a personalized summary of the discharge plan presented in an easy to understand worksheet that covers (1) medication instructions; (2) follow-up appointments with phone numbers; (3) normal expected symptoms, warning signs, and what to do if they experience a problem; (4) lifestyle changes and when to resume activities; and (5) information and resources to have handy. The meeting will take place one week prior to discharge.
1472532|NCT03177928|Device|Transthorathic echocardiogram|In echocardiography lab and using transthoracic echocardiogram to reveal any cardiac changes in patients.
1472533|NCT03177915|Drug|Sodium Hyaluronate|median nerve hydro-dissection using 1% lidocain followed by injection of low molecular weight sodium hyaluronate ,
1472534|NCT03177915|Drug|triamcinolone acetonide|1% lidocain followed by injection of 40 mg of triamcinolone acetonide
1472535|NCT03177902|Drug|Chemotherapy|Newly diagnosed breast cancer patients undergoing at least four cycles of chemotherapy.
1472536|NCT03177889|Combination Product|Traditional Chinese Medicine (TCM)|"Traditional Chinese Medicine plus oral mucolytics [ambroxol 30mg tid, or N-acetylcysteine 0.2g tid, serrapeptase 10mg tid, or carbocisteine 500mg tid];
Agastache rugosus 5g, Scutellaria baicalensis 10g, Radix Puerariae 10g, Acorus tatarinowii schott 10g, Fructus Liquidambaris 5g, gypsum 15 g, Rheum officinale 5 g, Folium sennae 5 g, Codonopsis pilosula 10g, Radix Salviae Miltiorrhizae 10g, Lignum millettiae 10 g, Liquiritia glycyrrhiza 10 g
Optional formulae: bile arisaema 15g, polygala tenuifolia 15g, Mangnolia officinalis 10g, Fructus aurantii immaturus 10g; Magnetite 15-30g and reddle15-30g"
1472537|NCT03177876|Procedure|sinus lift implant placement Hydroxyapatite Nano particles|shneiderian membrane elevation and augmentation with Hydroxyapatite Nano particles with simultaneous implant placement
1472538|NCT03177876|Procedure|sinus lift implant placement tenting|shneiderian membrane elevation and augmentation with graft less tenting technique with simultaneous implant placement
1472539|NCT03177863|Procedure|Expectancy|Clinical monitoring. See arm description
1472544|NCT03177824|Drug|Sildenafil Citrate 25Mg Tab|Group 1, consists of 30 patients who will receive Sildenafil citrate (25mg) tab (Silden, Epico, Egypt) 3times daily till the time of delivery, followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score.
1472545|NCT03177824|Drug|Placebo Oral Tablet|Group 2, consists of 30 patients receiving placebo Oral Tablet 3times daily , followed by repeating the Doppler US scan serially to detect changes in the measured indices and then assess the neonatal outcome after delivery as regard birth weight and APGAR score
1472548|NCT03177798|Drug|Icatibant|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, The investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
1472549|NCT03177798|Drug|Placebo|Subjects will receive either Icatibant or placebo in the first study day. After a washout period of 3 weeks, participant will receive the other treatment. Icatibant (50µg/kg/h) or placebo will be infused for 1 hour prior to the initiation of dialysis and continue through hemodialysis. Hemodialysis session will last approximately 4 hours. Two hours after the end of hemodialysis, the investigators will evaluate mitochondrial function by 31 phosphorus magnetic resonance spectroscopy.
1472550|NCT03177785|Behavioral|EverydayMatters|
1472552|NCT03177746|Drug|Dapoxetine/Tadalafil 30/20 mg film coated tablet|"During 4-weeks treatment period, patients will take one Dapoxetine/Tadalafil 30/20 mg film coated tablet 1-3 hours before sexual intercourse.
Study drug should not be used more than 1 tablet every 24 hours during the treatment."
1472553|NCT03177733|Procedure|Evaluation of a breast double block|"we made an association of the serratus block and the PIF block, which allows for a complete block of both the laterals branches of intercostal nerves (with the serratus block) and of anterior branches of intercostal nerves (with the PIF block). Therefore, this association of blocks may lead to a complete analgesia of the breast, while the serratus block alone only allows for an analgesia of the lateral part of the breast.
The objective is to analyze this technique through a collection form that evaluates the satisfaction and post-operative morphine consumption of women receiving this association before a general anesthesia for a unilateral mastectomy with homolateral total lymphadenectomy.
This is a purely observational study that assesses our current practice in this type of surgery."
1472554|NCT03177720|Drug|Ciprofloxacin|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
1472555|NCT03177720|Drug|Imipenem|Ciprofloxacin 400mg will be administered as single dose infusion over 60 minutes, imipenem/cilastatin 1000mg as single intravenous dose applicated over 60 minutes.
1472556|NCT03177707|Other|Mindfulness-based Therapy Group for Couples|"Eligible couples will take part in a 4-session mindfulness-based therapy group for couples. The groups will last 2 hours in length, for a total of 8 hours of treatment time, and sessions will be scheduled once per week in successive weeks.
The groups will have one highly experienced female facilitator, who is the Study Coordinator. The facilitator led the design of the treatment manual, and has experience in facilitating similar groups. The facilitator will follow a detailed, empirically-informed mindfulness-based treatment manual that was designed for the purpose of this study. All groups will take place in a private group treatment room at Vancouver General Hospital."
1472557|NCT03177694|Device|Wireless bed sensor|Remote data collection
1472558|NCT03177681|Other|Tongue Assessment|The coating on the top of the tongue assessed and categorized into three categories: no coating, thin coating and thick coating. The coating of the tongue may be related to the microorganisms in the intestine.
1472559|NCT03177681|Other|Stool Sample|Stool sample collected at baseline and once during Days 3-7 and once during Days 8-12.
1472560|NCT03177681|Behavioral|Questionnaires|Participants complete 4 questionnaires about symptoms in the past 24 hours, irritable bowel syndrome (IBS), most recent stool, and quality-of-life. Questionnaires completed at baseline and once during Days 3-7 and once during Days 8-12. Questionnaires should take about 30 minutes total to complete.
1472561|NCT03177681|Device|Holter Monitor|Participants wear a Holter monitor for 20-24 hours to check nervous system and heart function at baseline and once during Days 3-7 and once during Days 8-12.
1472562|NCT03177681|Other|Yogurt|Participants given 2 tablespoons (33 cc) of DannonÒ OikosÒ yogurt each day for 12 days.
1472563|NCT03177668|Drug|YS110|Intravenous administration
1472564|NCT03177655|Other|Guided Imagery|Guided Imagery meditation
1472565|NCT03177655|Other|Journaling|Keeping a journal
1472566|NCT03177629|Drug|treatment : H. pylori eradication|"treatment: H. pylori eradication (pantoprazole, amoxicillin, clarithromycin, metronidazole) to treatment group at visit 1 and to control group 2nd stage at visit 4.
Day 1-5: pantoprazole 40mg bid, amoxicillin 1000mg bid, PO Day 6 - 10: pantoprazole 40mg bid, clarithromycin 500mg bid, metronidazole 500mg tid, PO"
1472567|NCT03177616|Other|Chiropractic Treatment|"The treatment plan will be customized to the patient's needs. The chiropractic interventions are summarized as follows:
posture correction/spinal stabilization exercises
soft tissue relaxation techniques
spinal manipulation (i.e. chiropractic adjustment)/mobilization
breathing and relaxing techniques
stretches, self-care
ergonomic modifications
bracing and supports"
1472569|NCT03177590|Other|Recordings of facial and vocal emotional productions|"Children are asked to perform three tasks:
an emotional production on imitation (the child with autism or TED will imitate the emotion expressed by an animated avatar)
an emotional production by mime of the emotion on command (oral and written) without visualizing the model of imitation
Emotional production in context: the child with autism or EFD will describe images forming the story of Frog and as it is read, will produce the appropriate facial and vocal emotions in the context."
1472570|NCT03177577|Device|Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis.
1472571|NCT03177577|Device|Splint with strengthening exercises|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists as part of standard care for treatment of carpometacarpal (CMC) osteoarthritis and will also be taught two first dorsal interosseous (FDI) strengthening exercises.
1472572|NCT03177564|Procedure|Protective ventilation 1|Low tidal volume, high inspired oygen fraction (FiO2) and recruitment maneuver.
1472573|NCT03177564|Procedure|Protective ventilation 2|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
1472574|NCT03177564|Procedure|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 3 to 10 cmH2O during one-lung ventilation and a FiO2 of 60%
1472575|NCT03177538|Drug|Corifollitropin alfa and menotropin|"Procedure: Ovarian stimulation is performed by the combination of a single Corifollitropin alfa 150 mcg injection on menstrual cycle day 2-3 and daily menotropin administration at the dose of 150 IU from stimulation day 1-7 and at the dose of 300 IU from day 8 to the end of stimulation (maximal dose adjustment to 450 IU).
Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle"
1472576|NCT03177538|Drug|Follitropin alfa and lutropin alfa|"Procedure: Ovarian stimulation is performed with daily 300 IU of Follitropin alfa and lutropin alfa starting on menstrual cycle day 2-3. Maximal allowed dose adjustment is 450 IU daily.
Other interventions: conventional GnRH antagonist protocol and in vitro fertilization (IVF/ICSI) cycle."
1472577|NCT03177525|Behavioral|Social SUCCESS|"Social SUCCESS will run for 12 weeks, with up to 5 children with ASD per group. Parents will attend didactic group sessions focused on motivating children with ASD to initiate to peers (90 min weekly) and will attend a portion of the existing 90 min social group to practice applying these strategies with their children and peer volunteers. Parent training will utilize the manual Improving Socialization in Individuals with Autism."
1472578|NCT03177525|Behavioral|Wait List|Participants assigned to the Wait List will continue stable community treatments for 12 weeks and will be provided an intervention similar to Social SUCCESS upon completion of all post measures.
1472579|NCT03177512|Behavioral|LYNX Mobile App|Access to the LYNX mobile app which includes the Sex Pro score tool, PrEP videos, HIV/STI testing reminders and geo-location features.
1472580|NCT03177499|Procedure|Invasive PPG|Invasive PPG obtained by means of catheterization.
1472581|NCT03177473|Device|CervicalStim bone growth stimulator|Orthofix CervicalStim bone growth stimulator
1472584|NCT03177447|Behavioral|ENABLE CHF-PC|An Advanced Practice Palliative Care Nurse Coach implements Charting Your Course (CYC), a phone-based, 6-session patient curriculum and a 3-session caregiver curriculum, followed by monthly phone supportive care follow-up. Sessions 1-3 incorporate Hegel's problem-solving approach that was modified to counsel seriously ill patients using MacMillan's COPE model reactivity, which includes 4 components: Creativity, Optimism, Planning and Expert information. These sessions address adjusting to chronic illness, symptom management, communication, and decision-making. Patient sessions 4-6 comprise OUTLOOK, a life review intervention to improve QOL in serious illness developed at Duke.
1472585|NCT03177434|Drug|polyethylene glycols (PEG) 3350|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
1472586|NCT03177434|Drug|Lactulose Oral Product|Evaluating the efficacy of Dicopeg Junior in comparison with lactulose for the treatment of functional constipation in children aged 6 months to 6 years.
1472587|NCT03177421|Other|Problematic bedtime media use counseling|Participants will be screened for bedtime media use and sleep problems, and the clinical decision support system will recommend counseling on the respective problems identified on screening.
1472588|NCT03177421|Other|Sleep problem counseling|Participants will be screened for sleep problems, and the clinical decision support system will recommend counseling if problems are identified.
1472589|NCT03177395|Drug|PP100-01 (calmangafodipir)|PP100-01
1472590|NCT03177382|Radiation|Total neoadjuvant treatment|The interventions of experimental group include 1 cycle of CAPOX before radiotherapy; and then start concurrent chemoradiotherapy with CAPOX regimen (capecitabine: 825mg/m2, bid, 5d/w; oxaliplatin, 130mg/m2, D1, q3w) for 2 cycles followed by 3 cycles of CAPOX 2-3 weeks after the completion of radiotherapy. Intensity modulated radiotherapy (IMRT/VMAT) was used for radiotherapy, and the dose was 50-50.4Gy/25-28f, 1.8-2.0Gy/d, 5f/w.
1472591|NCT03177382|Radiation|concurrent chemoradiotherapy|The interventions of control group is standard preoperative concurrent chemoradiotherapy. The radiotherapy target areas and dosage are the same as group TNT. During radiotherapy, only oral capecitabine will be delivered and capecitabine dose was 825mg/m2, bid, 5d/w. The TME surgery will be performed 6-8 weeks after the end of concurrent chemoradiotherapy. Then, patients will receive another 6 cycles of CAPOX.
1472592|NCT03177382|Procedure|TME|The TME operation will be given after the end of the neoadjuvant treatment.
1472593|NCT03177382|Drug|Adjuvant chemotherapy|Patients will receive another 6 cycles of CAPOX after TME.
1472594|NCT03177356|Procedure|extraction,implant placement,PRF|Surgical extraction of mandibular molar using periotome and forceps followed by implant placement in inter-septal bone. Then a blood sample is withdrawn from patient and placed in the centrifuge. Then Platelet-Rich fibrin is placed in the extraction socket as space filling material
1472595|NCT03177356|Procedure|Exctraction,Implant placement,Bone graft|Surgical extraction of mandibular molar using extraction forceps and periotome followed by implant placement in interseptal bone. De-proteinized bovine bone graft material is placed as space filling material
1472596|NCT03177317|Drug|Dexamethasone|"Dexamethasone 8mg IV before chemotherapy on cycle 1 day 1
Once the complete response is achieved, the dose of dexamethasone will be reduced by 2 mg in the next cycle."
1472597|NCT03177304|Other|Web based IPT Training|
1472598|NCT03177291|Drug|Pirfenidone|"Pirfenidone: 267 mg Capsules by mouth (PO) 3 times per day (TID). Dose Escalation: Level 1:One capsule (total daily dose 801 mg); Level 2: Two capsules (total daily dose 1602 mg); Level 3: Three capsules (total daily dose 2403 mg).
Dose Expansion: Treatment at dose determined by the Phase 1 Dose Escalation."
1472599|NCT03177291|Drug|Carboplatin|Area under the curve (AUC) 6 on Day 1 of a 21-day cycle for 4 - 6 cycles.
1472600|NCT03177291|Drug|Paclitaxel|200 mg/m^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
1472601|NCT03177291|Drug|Pemetrexed|500 mg/m^2 on Day 1 of a 21-day cycle for 4 - 6 cycles.
1472602|NCT03177278|Drug|[14C]-plazomicin|single intravenous dose
1479080|NCT03126916|Drug|Isotretinoin|Given PO
1472603|NCT03177265|Behavioral|Text messaging prior to first counseling call|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive up to 8 text messages prior to the first counseling phone call to provide education regarding cessation treatment.
1472604|NCT03177265|Behavioral|Text-to-Enhance|Two weeks following receipt of the letter (PrO condition) or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
1472605|NCT03177265|Behavioral|Mail Notice|This is the first randomization (text to engage vs. mailed notice). Patients randomized to this condition will receive a notice in the mail that they will receive a phone call in about 2 weeks to offer telephone cessation treatment.
1472606|NCT03177265|Behavioral|Telephone Counseling|Two weeks following receipt of the mailed notice or upon completion of the engagement text messages (Text-to-Engage condition) a counselor trained in motivational interviewing and smoking cessation treatment will phone participants. The Text-to-Enhance condition will receive SMS appointment reminders for telephone counseling appointments and 5 texts per week with tips and suggestions for quitting for a duration of 8 weeks. The telephone counseling condition will receive standard 8 weeks of telephone counseling only.
1472612|NCT03177226|Device|Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
1472613|NCT03177226|Device|Non-Functional TENS stimulation|A short continuous electrical stimulation, beginning at 0 mAmp and gradually increased by +0.5 mAmp every 2-10 sec to identifying Sensory Threshold (Is) and Motor Threshold (Imc), followed by continuous non-functional electrical stimulation, throughout the entire self-stimulation phase, equal to his Icm'
1472614|NCT03177187|Drug|AZD5069|10mg and 40mg plain, beige, film-coated tablets packaged in bottles
1472615|NCT03177187|Drug|Enzalutamide 40 MG|Enzalutamide is presented in 40mg white to off white capsules. The capsules are provided in a cardboard wallet incorporating a PVC/PCTFE/aluminium blister which holds 28 soft capsules. Each carton contains 4 wallets (112 soft capsules).
1472616|NCT03177174|Drug|Cisplatin|radiotherapy combined with Chemotherapy Drugs, Cancer
1472617|NCT03177174|Drug|Docetaxel|Docetaxel
1472618|NCT03177161|Other|15 Patient Reported Health Status Questions|The PROMIS-10 Global Health, three single item questions (ambulation, toileting, and dressing) that have been borrowed from the RiksStroke (The National Quality Register for Stroke - Sweden) and two further questions on feeding and communication have been included from the ICHOM Standard Set for Stroke.
1472619|NCT03177148|Behavioral|Intervention by Clinicians|PCPs deliver 4 sessions of MI in person, and RDs deliver 6 sessions of MI via telephone. PCPs and RDs will receive 2 days of MI training.
1472620|NCT03177148|Behavioral|Usual Care|PCPs provide care as normal
1472621|NCT03177135|Device|AmnioSense|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis.
1472622|NCT03177122|Drug|Myo-inositol|Patients belonging to this group will receive 1 gram of Myo-Inositol, in combination with alpha- lipoic acid and cysteine, (Celine Tablets; Surveal Pharmaceuticals; Belgium) starting 6 weeks prior to stimulation and extending until final oocyte maturation, combined with 400 µg of folic acid supplemented daily.
1472623|NCT03177109|Drug|5% fluoride varnish|Applied topically as a coating at single point in time
1472624|NCT03177109|Drug|8% arginine containing paste|Applied topically as a coating at single point in time
1472625|NCT03177109|Drug|Self-adhesive resin|Applied topically as a coating at single point in time and light cured for 20 seconds
1472626|NCT03177096|Behavioral|Peds QL questionnaire and diabetes modulate|Peds QL questionnaire and diabetes modulate is a pediatric questionnaire about quality of life - children's version and parents version : assessed in the 1st visit (enrollment visit) and after ten months ( V6 End of study)
1472627|NCT03177096|Behavioral|WHO-5 questionnaire|WHO-5 questionnaire is a questionnaire about quality of life : assessed in the 1st visit (enrollment visit) and after ten months (V6 End of Study) by the children
1472628|NCT03177096|Behavioral|Felt questionnaire|Felt questionnaire completed by parents with regard to the welcome of their child in community and by the staffs in preschool, school or in out-of school center : assessed 2 months (V2) and ten months (V6 End of study) after enrollment visit
1472629|NCT03177083|Drug|peginterferon beta-1a|SC every 2 weeks
1472630|NCT03177083|Drug|interferon beta-1a|Per Summary of Product Characteristics (SMPC)
1472631|NCT03177083|Drug|interferon beta-1b|Per SMPC
1472632|NCT03177070|Drug|Methylene Blue|As described above. Intravenous injection with visualisation via fluorescence enabled laparoscope.
1472633|NCT03177057|Behavioral|Compliance Monitoring|Record behavior
1472634|NCT03177057|Other|Health Telemonitoring|Receive health monitoring text messages
1472635|NCT03177057|Other|Questionnaire Administration|Ancillary studies
1472636|NCT03177044|Behavioral|Behavioural treatment|2 to 6 sessions of behavioural training with a pelvic floor physiotherapist
1472637|NCT03177031|Device|Stay Safe Link (SSL)|CAPD system produced in Malaysia by Fresenius Medical Care
1472638|NCT03177031|Device|Stay Safe (STS)|CAPD system produce in Germany by Fresenius Medical Care
1472712|NCT03176537|Drug|Testosterone gel|Androgel (50mg testosterone), gel, daily
1472639|NCT03177018|Diagnostic Test|Cardiomyocytes collection|collect intact cardiomyocytes from which high quality DNA extraction will be achieved
1472640|NCT03177005|Biological|CSL830|
1472641|NCT03176992|Drug|SURGICEL®|insertion of 4 pieces of Surgicel inside the uterine cavity after formal curettage
1472642|NCT03176979|Other|Contrast Agent|Given IV
1472643|NCT03176979|Procedure|Digital Tomosynthesis Mammography|Undergo CESM with DBT
1472644|NCT03176979|Procedure|Dual-Energy Contrast-Enhanced Digital Spectral Mammography|Undergo CESM with DBT
1472645|NCT03176966|Drug|Vitamin E|Patients will take 400 IU vitamin E nightly for 3 months.
1472646|NCT03176966|Drug|Ropinirole|Patients will take 0.5mg ropinirole nightly for 3 months.
1472647|NCT03176966|Other|Muscle cramp survey|Patients will complete a survey of muscle cramp frequency and severity at baseline, 3 months, and 6 months.
1472648|NCT03176953|Drug|topiramate|active medication
1472649|NCT03176953|Behavioral|prolonged exposure|psychotherapy
1472650|NCT03176953|Drug|placebo|non-active medication
1472651|NCT03176940|Dietary Supplement|2-HOBA|2-HOBA is a compound found in buckwheat and is given as 2-HOBA acetate
1472652|NCT03176927|Diagnostic Test|magnetogastrogram|
1472653|NCT03176914|Behavioral|prevention and management of childhood illnesses at community level|provision of critical health education and targeted promotion services to the participants in their locality
1472654|NCT03176914|Behavioral|conventional community interventions|community health programs as the sole source of health education
1472655|NCT03176901|Behavioral|Mindfulness-Based Stress Reduction|This experimental arm presents the actual Mindfulness-Based Stress Reduction program as developed in the late seventies and early eighties in its original eight week format
1472656|NCT03176901|Behavioral|Health Enhancement Program|This active comparison arm presents the official Health Enhancement Program in its eight week format as developed by MacCoon in 2009.
1472659|NCT03176875|Other|ALICALM (75% of daily caloric requirements)|PEN group will receive 75% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) and 25% of daily dietary needs (1 meal per day) from an antiinflammatory diet for CD (AID-CD) for 6 weeks.
1472660|NCT03176875|Other|ALICALM (100% of daily caloric requirements)|EEN group will receive 100% of their daily dietary needs from a polymeric formula (Alicalm, Nutricia) for 6 weeks.
1472661|NCT03176862|Diagnostic Test|cardiac magnetic resonance scan|An MRI scan of the heart
1472662|NCT03176862|Diagnostic Test|Cardiopulmonary exercise test with stress echocardiogram|An exercise bicycle test with echocardiogram done during the exercise.
1472663|NCT03176862|Diagnostic Test|24-hour ECG holter monitor|3 stickers attached to a small monitor are worn for 24 hours.
1472664|NCT03176862|Diagnostic Test|12-lead ECG|Can be done immediately by the bedside.
1472665|NCT03176862|Diagnostic Test|Cardiopulmonary exercise test|An exercise bicycle test. No stress echocardiogram.
1472666|NCT03176862|Biological|Blood test|20 mls of blood will be taken to measure routine laboratory tests and biomarkers of fibrosis.
1472667|NCT03176849|Dietary Supplement|Vitamin D3|The single, oral dose of vitamin D3 is based on patient's age and baseline 25-hydroxy-vitamin D level. Dosing is as follows: (1) For children under 3 years of age. 200000IU for those deficient, 150000IU for those insufficient, and 100000IU for those sufficient; (2) For children 3-12 years of age, 400000IU for those deficient, 350000IU for those insufficient, and 200000IU for those sufficient; (3) For children greater than 12 years of age, 600000IU for those deficient, 500000IU for those insufficient, and 300000IU for those sufficient. This is a single, one time oral dose given prior to the start of transplant.
1472668|NCT03176849|Dietary Supplement|Standard Vitamin D3 Supplementation|"Those who have sufficient vitamin D will be supplemented with 400-600IU/day of Vitamin D3 orally.
Those who have insufficient or are deficient in vitamin D will be supplemented with 50,000IU/week of Vitamin D3 orally."
1472669|NCT03176836|Diagnostic Test|Whole body STIR MRI|Standard technique that detects abnormalities related to excess of water in tissues (edema).
1472670|NCT03176836|Diagnostic Test|DW-MRI|MRI technique that analyzes areas of dead cells within tissues, present in some types of tumor.
1472671|NCT03176836|Diagnostic Test|PET-MRI|MRI technique that detect's the cells' use of glucose, more intensely in harmful cells.
1472672|NCT03176823|Device|CellAegis Technologies autoRIC device|The autoRIC device from CellAegis technologies will be applied as per the manufacturer's instructions on an upper extremity. The device will automatically inflate and deflate a blood pressure cuff to supra-systolic blood pressures, maintaining an occlusive pressure for a period of five minutes, followed by five minutes of re-perfusion with cuff deflation, completing a ten minute cycle. This cycle will repeat four times for a cumulative total of twenty minutes of occlusive conditioning over forty minutes of intervention time.
1472673|NCT03176823|Other|Best Practice Management of Traumatic Brain Injury|Standard treatment of TBI in a dedicated trauma-neuro intensive care unit will include a tiered management strategy corresponding to many published treatment algorithms, including the American College of Surgeons Trauma Quality Improvement Program (ACS TQIP) guidelines for the management of intra-cranial hypertension. Standard practice without limitations will be applied to both cohorts of patients in this study.
1472674|NCT03176810|Device|OCT|OCT is used to guide PCI.
1472675|NCT03176810|Device|Angiography|Angiography is used to guide PCI.
1472676|NCT03176797|Diagnostic Test|Liver MRI|Liver MRI including DWI, IVIM, DKI, T1ρ, T1 mapping of pre-contrast and hepatocyte phase and SWI.
1472680|NCT03176771|Drug|MT-5199|MT-5199 40 mg capsules
1472681|NCT03176771|Drug|Placebo|MT-5199 placebo capsules
1472713|NCT03176537|Drug|Placebos|Placebo, gel, daily
1479081|NCT03126916|Other|Laboratory Biomarker Analysis|Correlative studies
1472682|NCT03176758|Drug|Spinal Block|Intrathecal 10 mg Heavy Marcaine, 200 mcg Morphine + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
1472683|NCT03176758|Drug|General anesthetic|1-3 mg IV propofol 0.5 mg/kg IV Rocuronium + Fentanyl 2-3 mcg/kg + Morphine 0.1mg/kg IV Maintenance: Volatile anesthetic + High volume local anesthesia infiltration Bupivacaine 5mg/ml + adrenaline 5 mcg/ml 3mg/kg IBW diluted with 100cc Normal Saline
1472684|NCT03176758|Device|Total knee replacement|A total knee arthroplasty surgery, which is not the intervention of interest
1472685|NCT03176745|Diagnostic Test|multiple breath washout|determination of lung clearance index using SF6 multiple breath washout
1472686|NCT03176732|Device|Positive Airway Pressure|Participants will use Positive Airway Pressure (PAP) treatment
1472688|NCT03176706|Other|no intervention|this is a completely observational study, NO INTERVENTION
1472689|NCT03176693|Drug|Phenoxybenzamine|Non-selective alpha blocker
1472690|NCT03176693|Drug|Doxazosin|Selective alpha blocker
1472691|NCT03176680|Procedure|Fluid therapy optimization|colloid 250 mL bolus to increase stroke volume index (SVI). If the increase of SVI is more than 10% of baseline, repeat the bolus. If the increase of SVI is less than 10% of baseline, stop the bolus.
1472692|NCT03176667|Procedure|Ultrasound guided erector spinae plane block|A high-frequency linear ultrasound transducer will be placed in a longitudinal parasagittal orientation 3 cm lateral to the T5 spinous process. The trapezius, rhomboid major, and erector spinae muscles will then be identified superficial to the tip of the T5 transverse process. The patient's skin will be anesthetized with 2% lidocaine. A 17-gauge 8-cm needle will be inserted using an in-plane superior-to-inferior approach to place the tip into the fascial plane on the deep (anterior) aspect of erector spinae muscle. The location of the needle tip will be confirmed by visible fluid spread lifting erector spinae muscle off the bony shadow of the transverse process. A total of 30 mL of 0.5% ropivacaine with 5mcg/mL of epinephrine will be injected in 5-mL aliquots through the needle (maximum of 3mg/kg), followed by insertion of a 19-gauge catheter under direct vision 5 cm beyond the needle tip. The catheter will then be secured in place.
1472693|NCT03176667|Procedure|Intercostal block|The surgeons will identify the desired rib, and advance the needle at an approximately 20-degree angle until contact with rib is made, the needle is then walked of the inferior border of the rib and advanced slightly to plaice the tip of the needle in the neurovascular bundle. The intercostal nerve blocks will be performed at T4-T11 using 0.25% Marcaine with epinephrine and a volume of 5 ml per block (maximum of 2.5mg/kg) after negative aspiration has been confirmed.
1472694|NCT03176654|Procedure|HVLAT manipulation|HVLAT will be performed 10 minutes after the first blood draw.
1472695|NCT03176654|Procedure|Sham HVLAT manipulation|Sham HVLAT will be performed 10 minutes after the first blood draw.
1472696|NCT03176641|Other|platelet-rich plasma|Autologous platelet-rich plasma gel applied during meniscus repair surgery
1472697|NCT03176641|Other|control|Meniscus repair surgery only
1472698|NCT03176628|Dietary Supplement|Basis|NR is a form of vitamin B3; Pterostilbene is a natural dietary compound and the primary antioxidant component of blueberries
1472699|NCT03176628|Dietary Supplement|Placebo|Placebo capsule(s)
1472700|NCT03176615|Dietary Supplement|Experimental diet|The intervention will run concurrently with the gastric bypass treatment at the hospital. The first intervention is carried out before weight loss, and the intervention is repeated two times concurrently with two periods of weight loss (lifestyle and gastric bypass)
1472701|NCT03176589|Device|positive expiratory pressure (PEP)|Patients take a deep inspiration followed by PEP expiration with an expiratory pressure of 10-15 cm H2O
1472702|NCT03176589|Other|Placebo comparator, Deep inspiration and expression in a placebo tube without resistance|Deep inspirations 3 times 10 and expiration in a placebo tube without expiratory resistance
1472703|NCT03176576|Behavioral|Patient Navigator (PN)|Patient navigation (PN) is an intervention model designed to assist vulnerable patients in overcoming health system, personal and/or logistical barriers to care throughout the cancer care continuum. The strategic aims of PN are to reduce barriers and improve disease outcomes while also reducing distress and enhancing quality of life for the patient and family. Participants in the PN group will meet with a patient navigator.
1472704|NCT03176576|Other|Baseline Questionnaire|Complete a baseline questionnaire online or by meeting with a member of the study team. This questionnaire has items asking about the participant's health, distress levels, satisfaction with their care at Moffitt Cancer Center, and what support services they have used since their diagnosis. This questionnaire will take about 15 to 20 minutes of their time.
1472705|NCT03176576|Other|Follow-up Questionnaire|After participants complete the baseline questionnaire, they will be asked to complete a follow-up questionnaire approximately 6 weeks from when they completed the baseline questionnaire. The follow-up questionnaire will take about 15 to 20 minutes to complete.
1472706|NCT03176576|Other|Patient Navigator Satisfaction Survey|Evaluation of Patient Navigator intervention process.
1472707|NCT03176563|Drug|Arctuvan|application of a herbal drug in the clinical trial REGATTA (NCT03151603)
1472708|NCT03176563|Drug|Placebo to Fosfomycin|application of Placebo to Fosfomycin in the clinical trial REGATTA (NCT03151603)
1472709|NCT03176563|Drug|Fosfomycin|application of an antibiotic drug in the clinical trial REGATTA (NCT03151603)
1472710|NCT03176563|Drug|Placebo to Arctuvan|application of Placebo to Arctuvan in the clinical trial REGATTA (NCT03151603)
1472711|NCT03176550|Device|Transcutaneous electrical nerve stimulation|TENS is performed using a commercially available device (ProStim, Alimed Inc, Dedham, Massachusetts, USA). One pair of 2 x 3.5 inches rectangular electrodes (Vermed ChroniCare TENS Electrodes, Vermed, Buffalo, NY, USA) are placed to simultaneously stimulate both median and ulnar nerves at the wrist, while a second pair of round 2 inch diameter electrodes are used to stimulate the radial nerve on the forearm. Bursts of electrical stimulation at 10 Hz (100 microsecond pulse width duration) are delivered to all nerves simultaneously for 2 hours.
1472714|NCT03176524|Drug|BioChaperone® glucagon formulation 1|Injection of BioChaperone® glucagon formulation 1 at Day 1: 50 µg and at Day 2: 1 mg
1472715|NCT03176524|Drug|BioChaperone® glucagon formulation 2|Injection of BioChaperone® glucagon formulation 2 at Day 1: 50 µg and at Day 2: 1 mg
1472716|NCT03176524|Drug|GlucaGen® HypoKit®|Injection of GlucaGen® HypoKit® at Day 1: 50 µg and at Day 2: 1 mg
1472719|NCT03176498|Biological|Allogeneic umbilical cord mesenchymal stem cell|Experimental group receive Allogeneic umbilical cord mesenchymal stem cell，i.v (SCLnow 19#)
1472720|NCT03176498|Drug|Aspirin Enteric-coated Tablets & Atorvastatin Calcium|Aspirin Enteric-coated Tablets, 0.1g/d by mouth; Atorvastatin Calcium, 20mg/d by mouth.
1472721|NCT03176485|Other|Solar Simulator|A Multiport UV Solar Simulator Model 600 (Solar Light Co., Inc., Philadelphia, PA) will be used to administer Solar Simulated Light (SSL) exposures to formerly unexposed buttock skin.The device is equipped with six 8mm liquid light guides (LLG), allowing for 6 simultaneously conducted exposures.A large 3x2 endplate places the LLGs several centimeters apart and is specifically designed for Sun Protection Factor (SPF) and photo patch testing. The dose of emission from each LLG can be precisely regulated and the spectrum of emission can be limited to UVA (320-390 nm) or UVB+UVA (290-390 nm). The operator can select between UVA only and a combined Ultraviolet-A (UVA)/ Ultraviolet-B (UVB) spectrum by placement of an optical filter. The spectral output (indicated below) follows the distribution of sunlight from 290 to 390 nm.
1472722|NCT03176472|Drug|ricolinostat|120 mg per dose in 12 mL liquid formulation
1472723|NCT03176472|Drug|Placebo|12 mL liquid formulation placebo
1472724|NCT03176459|Drug|Exparel + Bupivacaine|EXPAREL is a local analgesic that utilizes bupivacaine in combination with the proven product delivery platform, DepoFoam®.
1472725|NCT03176459|Drug|Bupivacaine|Bupivacaine Hydrochloride is indicated for the production of local or regional anesthesia or analgesia for surgery, dental and oral surgery procedures, diagnostic and therapeutic procedures, and for obstetrical procedures.
1472726|NCT03176446|Procedure|Local anesthesia with traditional technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized Injection of local anesthetic, with speed 1ml / min
1472727|NCT03176446|Procedure|Local anesthesia with computerized technique|Puncture with short needle in the region of the apical third of the tooth to be anesthetized according to the recommendations of the manufacturer Injection of local anesthetic with computerized anesthesia equipment, with speed 0.5 ml / min
1472728|NCT03176446|Procedure|Local anesthesia with DentalVibe technique|Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with traditional carpule, with speed 1 ml / min
1472729|NCT03176446|Procedure|Local anesthesia with Computerized more DentalVibe technique|Use of DentalVibe in the apical region of the tooth to be anesthetized according to the manufacturer's guidelines Puncture with short needle enters the tips of the DentalVibe Injection of local anesthetic with computerized anesthesia according to the manufacturer's instructions, with speed 1 ml / min
1472730|NCT03176446|Drug|Topic anesthesia|Application of topical anesthetic for 60 seconds with benzocaine
1472731|NCT03176446|Drug|Local anesthetic|2% lidocaine with epinephrine 1: 100000 1.8 mL
1472732|NCT03176433|Device|Normothermic Machine Liver Perfusion|Liver Preservation Method
1472733|NCT03176420|Procedure|angioplasty and stenting of occluded cervical ICA|The procedure is performed under monitored anesthetic care. We will perform a thorough and complete six-vessel diagnostic angiogram to completely characterize the occlusion and presence of collaterals. A distal protection device is used unless technically can't be delivered beyond the occlusion or when the occlusion extends beyond the petrous segment of the internal carotid artery. Balloon angioplasty is performed followed by deployment of covered stents to jail the clot/organized thrombus. The carotid reconstruction is performed from the distal to the proximal segment with coronary stents that are telescoped until normal flow is encounter. The Blood pressure is managed rigorously during and after the procedure to minimize the chances of reperfusion hemorrhage.
1472734|NCT03176407|Diagnostic Test|HemoPill acute|Capsule is swallowed by the patient and an external study receiver records the capsule sensor data for 4 consecutive hours. Patients undergo endoscopy within 12 hours after capsule ingestion. Afterwards, the endoscopic findings (endoscopy pictures and patient's endoscopy report) are compared to the sensor capsule data results. Capsule excretion is monitored for up to 4 days. If excretion is not recorded during that time, a follow-up examination of the patient is conducted after 10 days.
1472735|NCT03176394|Device|BLASTX Gel|Foley Catheter lubricated with BLASTX Gel
1472736|NCT03176394|Device|McKesson Jelly|Foley Catheter lubricated with McKesson Jelly
1472737|NCT03176368|Other|Coconut Oil|Coconut Oil
1472738|NCT03176355|Procedure|Canaliculo- Dacryocystorhinostomy|Bypass lacrimal passage obstruction by opening a shunt between the lacrimal sac and the nasal mucosa
1472739|NCT03176342|Other|patch test|Patch test allergen from chemotechnique diagnostics, pure drug and drug as is combine with petrolatum or aqueous.
1472740|NCT03176329|Other|Nursing 1 : INTELLIVENT-ASV|
1472741|NCT03176329|Other|Nursing 2 : INTELLIVENT-ASV|
1472742|NCT03176329|Other|Nursing 1 : Conventional mode|
1472743|NCT03176329|Other|Nursing 2 : Conventional mode|
1472744|NCT03176316|Drug|Naloxone|"Blinding/labeling/preparation of agents: No blinding is required in this study. The study drug will be prepared, unit dose labelled, and patient labelled according to institutional protocols.
Storage: Secured at room temperature in the central pharmacy then dispensed as a patient specific supply and stored at room temperature the automated dispensing cabinet. No more than a 24 hour supply will be dispensed at any given time.
Administration: 1 mg/ml oral solution administered enterally (oral, nasogastric, orogastric, gastrostomy, or jejunostomy ) every 8 hours for 48 hours"
1479082|NCT03126916|Drug|Melphalan|Given IV
1472746|NCT03176290|Diagnostic Test|Fibro-α score = (1.35 (numeric constant) +AFP (IU ml−1) × 0.009584 + aspartate aminotransferase (AST)/alanine aminotransferase(ALT) × 0.243 − platelet count (×109 l−1) × 0.001624).|Radiological investigations included Abdominal Doppler ultrasound, Magnetic Resonance Elastography(within 3 months of liver biopsy) and fibroscan.
1472751|NCT03176251|Other|Gamified-Integrated Curriculum|The experimental group will receive identical training compared to the control group, with the additional incorporation of several elements of gamification, as outlined in the Arm/Group descriptions.
1472752|NCT03176238|Drug|everolimus|10 mg tablet will be administered orally once daily on a continuous dosing schedule starting on Day 1
1472753|NCT03176238|Drug|exemestane|25 mg tablet will be administered orally once daily on a continuous dosing schedule starting on Day 1
1472754|NCT03176225|Procedure|Open heart surgery to address the heart disease|The patient will first have open heart surgery to achieve access to the diseased site in the heart
1472755|NCT03176225|Device|Close the defects with XenoSure Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with LeMaitre XenoSure Patch.
1472756|NCT03176225|Device|Close the defects with Chest Polyester Patch|The heart defects, such as ASD (Atrial Septal Defect) or VSD (Ventricular Septal Defect ), are closed with a Polyester Patch made by Shanghai Chest Medical Technology Co.
1472757|NCT03176212|Dietary Supplement|Milk fat globule membrane|
1472758|NCT03176199|Drug|Oxycodone|Every 12 hours for control-released oxycodone (OxyContin®)
1472759|NCT03176199|Drug|Oxycodone|Every 6 hours for immediate-released oxycodone (OxyNorm®)
1472760|NCT03176186|Combination Product|Xenon|50% xenon by inhalation, delivered by customized xenon delivery system, that includes a ventilator, for the 24h period of TH/TTM. The inhalation therapy is provided in combination with protocol-directed Post-Cardiac Arrest Care dictated by the 2015 guidelines from the American Heart Association and the European Resuscitation Council.
1472761|NCT03176173|Biological|Immunotherapy (standard of care)|Receive standard of care immunotherapy (nivolumab, pembrolizumab, atezolizumab)
1472762|NCT03176173|Radiation|Image Guided Radiation Therapy|Undergo image guided radiation therapy
1472763|NCT03176173|Other|Laboratory Biomarker Analysis|Correlative studies
1472764|NCT03176160|Procedure|Laser Interstitial Thermal Therapy (LITT)|LITT is a minimally invasive technique to necrotize intracranial lesions using the NeuroBlate® System (NBS)
1472765|NCT03176160|Radiation|Short-Course Radiation Therapy (SCRT)|5 Gray (Gy) daily fractions administered over 5 consecutive days
1472766|NCT03176160|Device|NeuroBlate® System (NBS)|NBS is a minimally invasive robotic laser thermo-therapy tool that is manufactured by Monteris Medical, Inc.
1472767|NCT03176147|Other|Iron deficiency anemia|The prevalence of iron deficiency anemia is determined at T3 (after 34 SA). The predictive factors for this anemia will be sought according to the data collected in T1.
1472770|NCT03176121|Drug|Oxycodone|Patients will take either CR oxycodone or IR oxycodone or both for initial dose and used it to titrate his/her background dose.
1472771|NCT03176108|Behavioral|Cognitive Behavorial Therapy (CBT)|Cognitive Behaviorial Therapy (CBT)
1472772|NCT03176108|Behavioral|Body mediation|Body mediation (theatre)
1472773|NCT03176095|Dietary Supplement|Probiotic|
1472774|NCT03176095|Dietary Supplement|Placebo|
1472775|NCT03176082|Other|Mailed Reminders with Fecal Immunochemical Testing kits|
1472776|NCT03176082|Other|Reminder letter only|
1472777|NCT03176069|Other|Evaluation and Comparison of women pelvic floor with and without sexual dysfunction|Pelvic floor muscles will also be evaluated by electromyographic biofeedback.
1472778|NCT03176069|Other|The physiotherapeutic treatment|"The available treatment tools are educational, behavioral and rehabilitating. The physiotherapeutic treatment will consist of the following features:
Kinesiotherapy
Manual therapy
Electrotherapy (electric electrostimulation, ultrasound)
Behavioral therapy"
1472779|NCT03176056|Dietary Supplement|Low carbohydrate diet|For the LCD group, the daily carbohydrate intake was limited to less than 90g, without any restriction to total energy. The concept of a LCD was introduced and an educational 15 g equivalent carbohydrate food list was provided. The easy conversion method is that 15 g equivalent carbohydrate =1/4 bowel of rice= 1/2 bowel of noodle = 1 slice of toast = 3 soup-spoon of oats = one bowl of fruit =1/2 regular size banana= one glass of milk = 3 dumplings. Less than two equivalent 15g-carbohydrate intakes per meal were advised.
1472780|NCT03176056|Dietary Supplement|Calori restricted diet|For the calori restricted diet group, the target total calorie intake was calculated by multiplying the ideal body weight by 25 kcal/kg for those with a BMI in the range 18.5 to 24, 20 kcal/kg for obese subjects with a BMI > 24 and 30 kcal/day for underweight subjects with a BMI <18.5. The macronutrient percentage was 50-60% for carbohydrate, 1.0-1.2 g/kg for protein and fat ≦30%.
1472781|NCT03176043|Procedure|IV Fluid Administration|Administration of 4% Dextrose in 0.18% Sodium Chloride, through an IV cannula via a volumetric infusion pump.
1472782|NCT03176030|Dietary Supplement|Fortified Foods|The intervention under study is the provision of between-meal fortified foods (enhanced with protein, energy, and micronutrients) and meal supplementation where meals are poorly consumed. Foods will include both savory and sweet foods with different flavors. Foods will be matched as closely as possible in protein and energy and are calculated to provide typically 210 kcal and 5g protein per item. The volume / weight of the foods are standardized to be of relatively small portion size, such as 100 ml for ice-creams, 40 g for cakes and biscuits, and 100 ml for soup. Some of the products will be supplemented with micronutrients particularly needed by older adults, such as Vitamins (C, D, folic acid, B2, B6) and calcium at one third of the Dietary Reference Values (DRV) per portion. The aim is to achieve a daily consumption of two additional fortified food items.
1472783|NCT03176017|Procedure|Holmium Laser ejaculatory sparing TUIP|Holmium (Hol): YAG laser at a power ranging from 35 to 60 W. The bladder neck will be incised and vaporized at the 5 or 7-o'clock position. The incision will start near the ureteral orifice and carry downward to about 0.5-1.0 cm proximal to the verumontanum
1472784|NCT03176017|Procedure|Conventional TUIP|the bladder neck will be incised by Collins knife at the 5 or 7-o'clock position till the verumontanum.
1472785|NCT03176004|Other|Attention Bias Modification|A computer game is used to facilitate attention away from threatening words.
1472786|NCT03175991|Diagnostic Test|ultrasonography|"A morphologic evaluation will be performed according to International Ovarian Tumor Analysis Group recommendations for the following parameters:
Bilaterality , wall thickness, septations , papillary projections, solid areas, and echogenicity. The presence of ascites also will be recorded. Pattern recognition analysis will be used for ovarian masses highly suggestive of some diseases , then color Doppler will be activated to identify vascular color signals within the lesion."
1472787|NCT03175978|Drug|IGF/MTX|765IGF-MTX is supplied as a 5 ml sterile solution at 4.0 µeq per ml 765IGF-MTX concentration in aqueous 10 mM HCl in a 10 ml glass vial
1472789|NCT03175952|Diagnostic Test|virtual histology intravascular ultrasound|Patients with saphenous vein graft disease will be examined using virtual histology intravascular ultrasound, and treated with percutaneous coronary intervention. Then they will be followed up at 1, 6 and 12 months.
1472790|NCT03175939|Radiation|Radiotherapy|External beam radiotherapy with curative intent, at least 66 Gy
1472791|NCT03175939|Drug|Cisplatin|cisplatin IV injection over 3 hours
1472792|NCT03175939|Drug|5-FU|5-FU IV 24 hours continuous infusion
1472793|NCT03175926|Device|placebo Diskus®|device will be given daily for one week, two puffs per day
1472794|NCT03175926|Device|placebo Ellipta®|device will be given daily for one week, one puff per day
1472795|NCT03175926|Device|Pulmicort® Turbuhaler®|device will be given daily for one week, two puffs per day
1472796|NCT03175913|Device|vapocoolant spray|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was sprayed using an vapocoolant spray for 10-sec from a distance of 30 cm
1472797|NCT03175913|Drug|local infiltration|As a topical pre caudal epidural block anesthesia, spinal needle insertion site was injected subcutaneously using 3ml of 2% lidocaine
1472800|NCT03175887|Device|TMS|Transcranial magnetic stimulation (TMS) is a noninvasive procedure that uses magnetic fields to stimulate nerve cells in the brain to improve symptoms of depression.
1472801|NCT03175874|Procedure|Hip bone sampling|Quantification of autophagy (LC3II and SQSTM1 / p62) by Western blotting of purified OST proteins from a bone sample
1472802|NCT03175861|Other|Stereotactic radiotherapy|"The patient will have an initial pre-therapeutic assessment in the 8 weeks before the start of radiotherapy Then, radiation therapy planning with 3 free breathing 4D (4 dimensions) scanners performed over 8 days without injection of iodinated contrast agent.
Then the patient will receive his treatment by conventional stereotactic radiotherapy"
1472803|NCT03175848|Radiation|Chemotherapy,radiotherapy|Pelvic,pelvic-inguinal,or extended field radiotherapy：Therapy 45 - 50 Gy in 1.7 - 2.0 Gy daily fractions over 4.5 - 5.5 weeks for PTV Brachytherapy: Therapy 5-6 fractions of 4-6Gy prescribed to the high-risk CTV or A piont.
1472804|NCT03175835|Drug|Rosuvastatin 20 mg|Treatment A: Rosuvastatin 20 mg(20 mg X 1 tablet) for Day1~Day5
1472805|NCT03175835|Drug|CKD-519 200 mg|Treatment B: CKD-519 200 mg(100 mg X 2 tablets) for Day9~Day21
1472806|NCT03175835|Drug|Rosuvastatin 20 mg & CKD-519 200 mg|Treatment C: Rosuvastatin 20 mg(20 mg X 1 tablet), CKD-519 200 mg(100 mg X 2 tablets) for Day22~Day26
1472807|NCT03175822|Behavioral|Visual Arts Training|The art training program has been designed as a drawing program and focuses on basic visual art concepts (the elements [e.g., colour and line] and principles [e.g., proportion and balance] of design). Each week has a different activity and a different focus (one activity per week focusing on one element and principle of design). Each art training program will occur one hour per day, two days per week, for eight weeks. The art training program will take place at the participants' respective dementia care location in an area separate from waitlist control participants and uninvolved clients. All art programs are free for participants.
1472808|NCT03175809|Other|PFM training|The PFM training will be delivered with an electromyographic biofeedback (bEMG). In order to perform the muscular training, the Biotrainer software was used, the training protocol will follow a rationale of evolutionary complexity throughout each session. The training protocols will focus on both muscle relaxation and contraction training and coordination.The parameters for the biofeedback will be tailored to the participant's presentation and will be determined and adjusted between each session as needed by the treating therapist. The treatment parameters will be determined by the treating therapist based on the participant's assessment that will be conducted at each treatment session. The Maximum voluntary contraction will be assessed at the beginning of each training day.
1472809|NCT03175809|Other|Dry needling|The dry needling technique will be applied to the abdominal muscles (external oblique, rectus abdominis), lumbar spine (lumbar multifidus and erector spinae) and hip muscles (piriformis, gluteus medius, psoas major and adductors). Both active of latent myofascial trigger points will be treated with sterile stainless steel needles (0.25x0.4 mm or 0.2x0,7mm, DongBang, Korea). After diagnosis of the area of muscle pain, the tight band of the muscle will be palpated and the needle will be introduced subcutaneously. The second insertion will be toward the muscle point until a local twitch response (LTR) is elicited. Then the needle will be removed and the area will be compressed for 30 seconds.
1472903|NCT03175133|Other|Strength exercise|Strengthening exercises performed with physical therapist.
1472811|NCT03175783|Device|Fitbit Zip Activity Tracker|Subjects from both treatment and control group will be put on wristband starting from one week before the scheduled operation until 7 post-operative days. Patients will be instructed to wear the wristband continuously 24 hours per day except during water based activity. The treatment group will receive normal wristband with indicator showing steps count, distance, and calories. Meanwhile, the control group will receive Fitbit Zip with a display covered with adhesive tape and will not receive automatic feedback on the mobility from the device.
1472812|NCT03175770|Procedure|transoral radiofrequency Resection in Oropharyngeal Tumor Surgery|Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
1472813|NCT03175757|Dietary Supplement|Turmeric and Black Cumin Seed|Turmeric and Black Cumin Seed formulation
1472814|NCT03175757|Dietary Supplement|Placebo|Placebo
1472815|NCT03175731|Drug|PPI|Pantoprazole(PPI) 40-80mg intravenously everyday during bleeding.
1472816|NCT03175731|Drug|PPI|Pantorazole(PPI) tablet 40mg by mouth everyday for 4 weeks after endoscopic treatment.
1472817|NCT03175731|Drug|Placebo|Placebo 40-80mg intravenously everyday during bleeding.
1472818|NCT03175731|Drug|Placebo|Placebo tablet 40mg by mouth everyday for 4 weeks after endoscopic treatment.
1472819|NCT03175718|Other|VAC Wound Dressing|A total of 291 patients will be randomized to receive 2 weeks of Incisional Negative pressure wound dressing (Acetily®). The sterile dressing will be applied under a continuous pressure of 125mmHg. The dressing will be changed every 2-3 days. For a total duration of 2 weeks.
1472820|NCT03175718|Other|Wound Dressing|A total of 291 patients will be randomized for standard gauze dressing. This dressing requires no pressure and is applied according to the current standard dressing procedures of the institution. The dressing will be changed every 2-3 days. For a total duration of 2 weeks.
1472821|NCT03175705|Biological|HCC antigens-specific CD8+ T lymphocytes|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.
The following dose levels will be evaluated:
Loading Dose 1: 3x10^7/m2 Loading Dose 2: 6x10^7/m2 Loading Dose 3: 9x10^7/m2 The doses are calculated according to the actual number of GPC3/NY-ESO-1/AFP specific cytotoxic lymphocytes (CTLs)"
1472822|NCT03175705|Drug|IL-2|IL-2 will be given at a dose of 25000 IU/kg/day for 5-14 days.
1472823|NCT03175705|Drug|Tegafur|Tegafur will be given at a dose of 40~60 mg bis in die (BID) 2 weeks.
1472824|NCT03175692|Diagnostic Test|Whole Exome Sequencing|Using next generation sequencing to analysis patient's whole exome. To explore the pathogenic gene variation.
1472825|NCT03175679|Biological|iNKT cells|"Three different dosing schedules will be evaluated. Three patients will be evaluated on each dosing schedule.
The following dose levels will be evaluated:
Loading Dose 1: 3x10^7/m2 Loading Dose 2: 6x10^7/m2 Loading Dose 3: 9x10^7/m2 The doses are calculated according to the actual number of iNKT cells."
1472826|NCT03175679|Drug|IL-2|IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.
1472827|NCT03175679|Drug|Tegafur|Tegafur will be given at a dose of 40~60 mg bis in die (BID) 2 weeks.
1472846|NCT03175653|Other|Oxycodone Pill A|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
1472847|NCT03175653|Other|Oxycodone Pill B|Prescription for oxycodone pills for post-Cesarean delivery pain control after hospital discharge. Oxycodone is an opioid.
1472848|NCT03175640|Behavioral|Implementation intervention|The implementation intervention includes peer-to-peer training, post-training outreach, proactive expert support, and assistance with addressing environmental barriers.
1472849|NCT03175627|Device|Filtek One|Restoring a posterior permanent tooth in need of a filling applying Filtek One using bulk fill technique.
1472850|NCT03175627|Device|Filtek Z250|Restoring a posterior permanent tooth in need of a filling applying Filtek Z250 using incremental filling technique.
1472851|NCT03175614|Other|Intervention group|Smartphone with APP (EVIDENT III) and a Smartband for 3 months. Counseling on physical activity and nutrition
1472852|NCT03175614|Other|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
1472853|NCT03175588|Other|Virtual Rehabilitation|Nintendo Wii program with balance board, which is the most frequently preferred game consoles in rehabilitation will be used
1472854|NCT03175575|Behavioral|Access to a community garden in deprived neighborhoods|
1472855|NCT03175562|Other|Facial micellar cleanser|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
1473043|NCT03174041|Drug|Simvastatin and GDC-0853|Multiple doses GDC-0853 and single dose simvastatin
1472856|NCT03175562|Other|Saline Solution: Sodium Chloride (NaCl; 0.9%)|Participant will have each product applied topically via semi occlusive patch, on site by the technician. Each patch will remain in place for 48 (± 2) hours on weekdays and 72 (± 2) hours on weekends.
1472857|NCT03175549|Drug|Apremilast|50 mg/bid, oral pill, 5 days following 9 day titration
1472858|NCT03175549|Drug|Placebo|Oral pill, 14 days
1472859|NCT03175536|Other|HDHP with PDL|Enrollment in a Health Savings Account-eligible high-deductible health plan with an annual individual deductible of >$1000 that includes a preventive drug list (a list of certain chronic medications that are exempt from the deductible)
1472860|NCT03175523|Device|quantitative coronary angiography guided Bioresorbable scaffold implantation|In the QCA-guided group, BRS size and length were chosen by both visual estimation and on-line QCA, and adjunct high-pressure dilation is routinely performed to achieve angiographic residual diameter stenosis less than 30% by QCA and absence of angiographically visible dissections.
1472861|NCT03175523|Device|imaging guided Bioresorbable scaffold implantation|In the imaging-guided group, imaging is used at any step of percutaneous coronary intervention(PCI) before, during, or after PCI. Final image examination after PCI is mandatory.
1472862|NCT03175497|Drug|Telatinib Mesylate|Telatinib mesylate tablets will be administrated twice a day orally
1472863|NCT03175458|Procedure|sinus lift,implant placement,tenting|elevation of the sinus membrane then insertion of the implants without any bone graft material( graft-less) for augmentation
1472864|NCT03175458|Procedure|sinus lift,implant placement,bovine bone|sinus membrane elevation then placement of the implants together with deproteinized bovine bone substitute as a graft material for augmentation
1472865|NCT03175445|Other|CBCT scan by planmeca promax|software measurement tool of CBCT
1472870|NCT03175406|Diagnostic Test|Manipal cervical scoring system|
1472871|NCT03175393|Device|coronary angiography|per cutaneous coronary intervention to identify severity of coronary artery disease by syntx score
1472873|NCT03175367|Drug|Evinacumab|SC or IV administration
1472874|NCT03175367|Drug|Matching placebo|SC or IV administration
1472875|NCT03175367|Other|Background Lipid Modifying Therapy (LMT)|All participants should be on a stable, maximally tolerated statin throughout the duration of the study. The dose of statin and of PCSK9 inhibitor, such as alirocumab or evolocumab, as well as other LMT (if applicable), should remain stable throughout the study duration, from screening through the end of study (EOS) visit.
1472876|NCT03175354|Drug|ALX-101 Gel 1.5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 1.5% and ALX-101 Gel Vehicle
1472877|NCT03175354|Drug|ALX-101 Gel 5% and ALX-101 Gel Vehicle|Bilateral application of ALX-101 Gel 5% and ALX-101 Gel Vehicle
1472878|NCT03175341|Drug|Ascorbic Acid|1,5 g ascorbic acid dissolved in 100 ml sterile water, and 0,75 g ascorbic acid dissolved in 100 ml sterile water.
1472879|NCT03175341|Drug|Placebos|100 ml normal saline 0.9%
1472880|NCT03175328|Procedure|continuous renal replacement therapies|The choice of the method of continuous renal replacement therapy (device setting and anticoagulation method) is left to the discretion of each study site and was prescribed and monitored according to national guidelines.
1472881|NCT03175315|Behavioral|Treatment and education program for patients with diabetes who use flash glucose monitoring (FLASH)|Treatment and education program based on the self-management theory of behavioral medicine. The program is delivered by certified and specially trained diabetes educators.
1472882|NCT03175302|Behavioral|digital cognitive testing|The digital testing is hypothesized to identify latent features for differentiating cognitively impaired presurgical patient subgroups
1472883|NCT03175289|Other|Best Practice|Undergo therapy session conducted by a speech pathologist
1472884|NCT03175289|Other|Educational Intervention|Receive standard of care patient education materials focusing on oral care, signs/symptoms of dysphagia/aspiration, and trismus
1472885|NCT03175289|Other|Exercise Intervention|Perform prescribed home exercises
1472886|NCT03175289|Other|Expiratory Muscle Strength Training|Participate in EMST
1472887|NCT03175289|Other|Quality-of-Life Assessment|Ancillary studies
1472888|NCT03175289|Other|Questionnaire Administration|Ancillary studies
1472889|NCT03175250|Behavioral|Health Education|Videos (AIDSvideos.org) were presented on individually-assigned laptops and covered HIV risk, condom use, safe sex, and infection testing
1472890|NCT03175250|Behavioral|Action Plan|Participants selected situations for condom use and screening for HIV and hepatitis on individually-assigned laptops. They linked these situations to preventive behaviors regarding screening and condom use.
1472891|NCT03175250|Behavioral|Memory Practice|Participants engaged in several different types of memory practice procedures on assigned laptops. The procedures focused on memory for action plans for screening and condom use.
1472892|NCT03175237|Other|Mirror Therapy|
1472893|NCT03175224|Drug|CBT-101 Oral Capsules|Subjects will be assigned to a dose level of CBT-101 in the order of study entry. Treatment includes 28-day cycles at five planned dose levels (100 mg, 200 mg, 300 mg, 400 mg, 550 mg). Each treatment cycle is administered by oral capsules consecutively every 12 hours.
1472899|NCT03175159|Behavioral|Time & Intensity Matched Control|Ten counseling sessions
1472900|NCT03175159|Behavioral|IMPACT|Ten counseling sessions
1472901|NCT03175159|Behavioral|Standard of Care|Two counseling sessions
1472902|NCT03175146|Radiation|Stereotactic Body Radiation Therapy|5 treatments given over 2 weeks
1473044|NCT03174041|Drug|GDC-0853|Single dose GDC-0853
1472906|NCT03175107|Device|Exergaming|
1472907|NCT03175094|Behavioral|Holistic Health Recovery Program for HIV+|Holistic Health Recovery Program for HIV+ (HHRP+) is a CDC-recommended, evidence based behavioral (psychoeducational) group intervention focused on harm reduction principles. The investigators systematically adapted HHRP+ using findings from qualitative interviews with the target population of adult women living with and at-risk for HIV who are justice-involved (on probation, parole, or recently released from prison or jail).
1472908|NCT03175081|Drug|Ropivacaine|Patient undergo elective bariatric surgery will receive 20mL of 150mg ropivacaine (0.75%) diluted in 180mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
1472909|NCT03175081|Drug|Normal saline|Patient undergo elective bariatric surgery will receive 200mL normal saline to be injected through a catheter along the greater curvature and left subdiaphragmatic region of the stomach at the end of the surgical procedure. After the surgery, the medical doctors or nurses in the ward that is not otherwise involved in this research will assess and record the pain score using visual analog scale (VAS) (0-10). The abdomen and shoulder tip pain intensity will be rated at two, four, six, eight, 24 and 48 hours postoperatively.
1472914|NCT03175029|Drug|TAC-302|TAC-302 200 mg administered orally twice per day after meals, for 12 weeks.
1472915|NCT03175029|Drug|Placebo|Placebo administered orally twice per day after meals, for 12 weeks.
1472916|NCT03175016|Procedure|TACE|Transcatheter arterial chemoembolization（TACE）is a minimally invasive procedure performed to restrict a tumor's blood supply.
1472917|NCT03175016|Drug|Irinotecan|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in eluting-beads and injected in the tumor.
1472918|NCT03175016|Device|eluting-bead|The eluting-bead,loaded with irinotecan (DEBIRI) to treat patients with hepatic metastases from colorectal cancer.
1472919|NCT03175003|Other|Food Product|Each food product will provide similar calories, but a different micro- and macro-nutrient composition
1472920|NCT03174977|Drug|18F-Raltegravir|A single microdose of 18F-Raltegravir will be given to individuals currently being treated for HIV-1 with antiretroviral therapy.
1472923|NCT03174938|Diagnostic Test|Flutemetamol F18 Injection|PET imaging of Abeta amyloid
1472924|NCT03174938|Diagnostic Test|[18F]-RO6958948|PET imaging of Tau aggregates
1472925|NCT03174938|Diagnostic Test|Elecsys (Roche) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
1472926|NCT03174938|Diagnostic Test|Lumipulse (Fujirebio) Abeta42, Ttau and Ptau|Measurement of Abeta42, Ttau and Ptau in the cerebrospinal fluid
1472928|NCT03174912|Procedure|Intravesical BCG instillation|ıntravesical BCG instillations were done two weeks after transurethral resection of bladder cancer
1472929|NCT03174899|Radiation|Diffusion weighted magnetic resonance imaging|All MRI examinations will be performed with a 1.5-T scanner (Acheiva, Philips, and Netherland). All MRI scans will be obtained with the following parameters: Repetition time (TR); 1580 MS, echo time (TE); 60 MS, slice thickness; 1-5 mm, receiver bandwidth; 1158 kHz/pixel, field of view (FOV); 40 cm, matrix size; 164 × 159. ADC value of the kidneys will be calculated with Diffusion weighted magnetic resonance imaging gradient b-values of 0 and 1000s/mm2. In the axial ADC map, a region of interest (ROI) will be placed for measurement of ADC values on the renal parenchyma of both kidneys, without any preference for cortex or medulla. Three circular ROIs of size 1 cm2 will be placed-one each at the upper pole, inter-polar region, and lower pole of both kidneys—and 6 total ROIs from bilateral kidneys will be averaged for each patient.
1472930|NCT03174886|Drug|AADvac1 40 µg|Active immunotherapy against neurofibrillary pathology.
1472931|NCT03174886|Drug|AADvac1 160 µg|Active immunotherapy against neurofibrillary pathology.
1472932|NCT03174873|Procedure|laparoscopy|Laparoscopy will be done for unexplained infertile couples before starting IVF because not all pathologic lesions that discovered by laparoscope need IVF and so, protect patients from unneeded IVF program
1472933|NCT03174860|Drug|Diclofenac Potassium 50mg Tab|A 50 mg tablet of the medication to be taken one hour before initiation of endodontic treatment.
1472934|NCT03174860|Drug|Placebo|A placebo will be taken one hour before initiation of endodontic treatment.
1472935|NCT03174847|Procedure|Adrenalectomy|Adrenalectomy for unilateral adrenal hyperplasia / adenoma
1472936|NCT03174847|Drug|Mineralocorticoid Receptor Antagonists|Medical treatment with MRA / amiloride
1997467|NCT02050308|Other|Internet-All Nations Breath of Life (I-ANBL)|"Participants will be asked to log into the website prior to the first session to allow for any problems with the site to be fixed prior to sessions starting. Topics we anticipate covering include, but are not limited to: preparing to quit, dealing with cravings, support systems, traditional tobacco, stress reduction, weight management, and staying quit, along with other topics determined during program development. For each session, the tribal college student will begin the session by answering a series of questions to produce an individually-tailored report that will be provided on the screen at the end of each week's session so that the smoker can work on strategies during the week before the next internet session
Weekly procedures will follow the same format as for the first session"
1948557|NCT02162563|Drug|FOLFOX/ FOLFIRI with bevacizumab|"FOLFIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
FOLFOX6 + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
1472938|NCT03174821|Device|Insulin pump|Blood glucose management device
1472939|NCT03174808|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants will attend weekly 2.5-hour group sessions (of 10-14 persons) based on the standard MBSR protocol.
1472942|NCT03174782|Drug|Bupivacaine|Patients randomized to the treatment group will receive regional nerve blocks (sciatic and femoral) with bupivacaine at the dose of 1 mg/kg.
1472943|NCT03174782|Drug|Saline Solution|Patients randomized to the control group will receive two needle sticks (in the sciatic and femoral distributions) with normal saline to maintain the double-blinded investigation.
1472944|NCT03174769|Other|Normal protein|Following a two week baseline assessment period, subjects will consume a diet with normal protein diet while undergoing weight loss for 12 wk.
1472945|NCT03174769|Other|High protien|Following a two week baseline assessment period, subjects will consume a diet with high protein diet while undergoing weight loss for 12 wk.
1472949|NCT03174743|Procedure|Convential Ventilation 1|High tidal volume, moderate inspired oygen fraction (FiO2).
1472950|NCT03174743|Procedure|Convential Ventilation 2|High tidal volume, high inspired oygen fraction (FiO2).
1472951|NCT03174743|Procedure|Protective Ventilation 1|Low tidal volume, PEEP, moderate inspired oygen fraction (FiO2) and recruitment maneuver.
1472952|NCT03174743|Procedure|Protective Ventilation 2|Low tidal volume, PEEP, High inspired oygen fraction (FiO2) and recruitment maneuver.
1948558|NCT02162563|Drug|FOLFOXIRI with bevacizumab|FOLFOXIRI + bevacizumab Bevacizumab 5 mg/kg in 15-30 minutes i.v., followed by irinotecan 165 mg/m2 i.v. in 60 minutes, followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by continuous infusion of 5-fluorouracil 3200 mg/m2 in 46 hours, every 2 weeks
1472955|NCT03174717|Behavioral|Music performance|residents of LTC will learn and perform songs with musicians from the community
1472956|NCT03174691|Diagnostic Test|Blood collection|"A total of ten (10) blood samples (2ml/each) will be collected during the study.
Blood samples will be collected on the following days for subsequent analysis of LH, Estradiol, hCG, progesterone and 17-Hydroxyprogesterone."
1472957|NCT03174678|Drug|Dexmedetomidine|1µg/kg dexmedetomidine oral
1472958|NCT03174678|Other|apple juice|apple juice
1472960|NCT03174639|Procedure|Inverted and free ILM insertion|ILM was peeled and the ILM flap was inverted and inserted into the macular hole, followed by insertion of free ILM flap.
1472961|NCT03174626|Behavioral|WLSCC|"Briefly, WLSCC contents are as follows: Psychosocial skill 1: Increase objectivity and awareness of thoughts and feelings in a distressing situation and learning the technique of a log entry; Psychosocial skill 2: Evaluate the situation to decide whether to change one's reactions or to take actions; Psychosocial skill 3: Increase the positive and the sense of meaning in your life; Psychosocial skill 4: Deflection strategies; Psychosocial skill 5: Take action when action is called for; Psychosocial skill 6: Assertion; Psychosocial skill 7: Saying No; Psychosocial skill 8 : Communication; Psychosocial skill 9: Become a better listener; Psychosocial skill 10: Empathy."
1472962|NCT03174626|Other|Usual Care|No training provided. After data collection period is over, participants have the option to receive the WLSCC training
1472965|NCT03174600|Other|Questionnaire|The patients were questioned using the Danish Prostatic Symptom Score (DAN-PSS), and evaluated using modified Barthel index, incontinence quality of life questionnaire (I-QOL), and the Mini-Mental Test (MMT) on the 1st, 3rd and 6th months.
1472966|NCT03174587|Biological|allogenic bone marrow derived mesenchymal stem cells|Step -1 dose : 1.0x10^6cells/kg Step 1 dose : 2.0x10^6cells/kg Step 2 dose : 3.0x10^6cells/kg The single injection of CS20AT04 Inj. in the peripheral veins.(IV) The duration of follow up study following the single dose of CS20AT04 is 28 days
1472967|NCT03174561|Dietary Supplement|Inuline, Choline and Silymarin|Combination of one sachet: Inuline (5000 mg), Silybum marianum seed extract (50 mg), Choline (37 mg) The dose: 1 sachet first 7 days and 1 sachet x 2 times daily for the next 21 days. Diet restriction is consider together with dietary supplement intake.
1472968|NCT03174561|Other|diet restriction|diet restriction for 28 days
1472969|NCT03174548|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet
Route of administration: oral"
1472970|NCT03174548|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: solution
Route of administration: oral"
1472971|NCT03174522|Drug|Rexmyelocel-T|Rexmyelocel-T is administered through an intra-arterial catheter.
1472972|NCT03174522|Drug|Placebo|Placebo is administered through an intra-arterial catheter.
1472973|NCT03174509|Procedure|Positive pressure extubation|Positive pressure ventilation without endotracheal aspiration/suction during extubation procedure.
1472974|NCT03174509|Procedure|Traditional during extubation|Spontaneous ventilation with endotracheal aspiration/suction during extubation procedure.
1472975|NCT03174483|Drug|Hypertonic saline|nasal spray
1472976|NCT03174483|Drug|Fluticasone Nasal|nasal spray
1473000|NCT03174275|Radiation|IMRT|"involved field radiation will refer to areas demonstrated to harbor disease on pathology, and not elective areas"
1472977|NCT03174470|Device|TENS Stimulator|Initial stimulation of arm (conditioning) followed by Increasing Intensities of Electrical Stimulation Delivered to The Bulbospongiosus Muscle
1472979|NCT03174444|Behavioral|Small Media|Bilingual brochures and access to bilingual website
1472980|NCT03174431|Device|Continence Pessary|Continence pessaries are inexpensive, reusable intravaginal devices made of flexible silicon that provide support to the urethra to prevent urinary leakage. Continence pessaries are fitted by trained clinicians in the office and managed by patients or their provider.
1472981|NCT03174431|Device|Poise Impressa (Disposable Intravaginal Device)|In 2014, the FDA approved an over-the-counter disposable intravaginal device as another nonsurgical treatment for SUI. This device is comprised of 4 support poles covered in a non-absorbable nylon mesh that is deployed using an intravaginal applicator.
1472982|NCT03174418|Procedure|Coronary angiography and optical coherence tomography|Coronary angiography and OCT images will be combined to obtain a three-dimensional model of the diseased coronary vessels that will be used to calculate the local blood flow patterns and the arterial time-averaged wall shear stress at the bifurcated lesion level
1948559|NCT02162563|Drug|FOLFOX/ FOLFIRI with panitumumab|"FOLFIRI + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by irinotecan 180 mg/m2 i.v. in 60 minutes together with leucovorin 400 mg/m2 i.v. in 120 minutes, followed by bolus 5-fluorouracil 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks
FOLFOX6 + panitumumab Panitumumab 6 mg/kg i.v. (1st dose in 60 minutes, if well tolerated subsequent doses in 30 minutes), followed by oxaliplatin 85 mg/m2 i.v. together with leucovorin 400 mg/m2 i.v. in 120 minutes, and bolus 5FU 400 mg/m2 within 4 minutes, all on day 1, followed by continuous infusion of 5-fluorouracil 2400 mg/m2 in 46 hours, every 2 weeks"
1472984|NCT03174392|Other|Resistance Based Training|Resistance based training study: Each training session will begin by determining the treadmill walking speed that an individual will train. The speed of the treadmill will be incrementally increased stepwise and individuals will affirm which speed feels the most comfortable to walk. Thus, the training speed of individuals will not necessarily be fixed over the 8-week study. Heart rate will be monitored and resistive force will be applied stepwise until the heart rate reaches at least 60% heart rate reserve. Individuals will be encouraged to walk at least five minutes and then allowed to rest. Achieved heart rate reserve and time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
1472985|NCT03174392|Other|Speed Based Training|Speed based training study: Individuals will train at the fastest walking speed that an individual asserts that they can maintain for five minutes. The training time will then begin. Individuals will be encouraged to walk at least five minutes and then be allowed to rest. Speed will be progressed for each individual every 1-2 weeks at increments between 0.02 m/s and 0.08 m/s. Treadmill inclination will remain at 0°. Participants will be allowed to use the handrail or forearm support while being encouraged to walk without support if possible. Achieved heart rate reserve and the time the spent training at 60-80% heart rate reserve will be quantified for each session. Subjective measures of effort will also be sampled using the Borg Scale.
1472986|NCT03174379|Procedure|Standard of Care with no acupuncture|The control group will lie on a treatment table in the acupuncturist's office for the same amount of time that the treatment group did, but receive no acupuncture
1472987|NCT03174379|Procedure|Acupuncture|The first set consists of core point selection, used in an MS Standard of Care (SOC). The second set of points will be individualized to the patient's needs as determined by the acupuncturist. SOC treatment will be based upon Traditional Chinese Medicine (TCM) interpretation of 4 phases of MS.
1472988|NCT03174366|Drug|Denosumab|Subjects will receive medication once following enrollment, and will be monitored for 1 year thereafter.
1472989|NCT03174353|Drug|Lanreotide Prefilled Syringe|All patients enrolled in this study will receive SOMATULINE DEPOT 120 mg immediately prior to planned pancreatic resection. The pharmacist will dispense loaded syringes of the study drug. The single preoperative dose will be given in the pre-surgical center at the University of Washington by a trained health care professional. The study drug will be injected via the deep subcutaneous route in the superior external quadrant of the buttock.
1472990|NCT03174340|Behavioral|Exercise|Once per week, participants will be enrolled in supervised group exercise intervention. They will be encouraged in walking 45 minutes per day
1472991|NCT03174327|Diagnostic Test|Hepatic Transplantation|Systematic long-term monitoring of liver transplant patients includes an annual consultation and more comprehensive follow-up at one year, 5 years and 10 years of transplantation during which patients are hospitalized in day hospital hepatology and have a clinical examination Complete, biological assessment, Fibroscan® graft elastography measurement, hepatic Doppler ultrasound and liver biopsy. Measurement of liver stiffness by SuperSonic® will be added during ultrasound.
1948560|NCT02162277|Device|diagnostic osteoporotic kit ( including 7 genes and 4 life styles)|Most osteoporotic patients want to know what kinds of life styles they should take care of. The device will help it.
1472993|NCT03174288|Other|Exercise|24 weeks of exercise treatment
1472994|NCT03174288|Drug|Spironolactone|24 weeks of spironolactone
1472995|NCT03174275|Drug|Durvalumab|Subjects will receive durvalumab, 750 mg every 2 weeks by IV infusion over approximately 1 hour (± 5 minutes).
1472996|NCT03174275|Drug|Carboplatin|Carboplatin is commercially available and approved by the US FDA for use in patients with ovarian cancer.
1472997|NCT03174275|Drug|Nab-paclitaxel|Nab-paclitaxel is commercially available and approved by the US Food and Drug Administration (FDA) for use in patients with metastatic breast cancer, metastatic pancreatic cancer, and for the treatment of locally advanced or metastatic NSCLC.
1472998|NCT03174275|Drug|Cisplatin|Cisplatin is commercially available and approved by the US Food and Drug Administration (FDA) for the treatment of advanced bladder, ovarian and testicular cancer. It has been widely studied in a variety of solid tumor types.
1472999|NCT03174275|Procedure|Surgical resection|Surgical therapy will be at the discretion of the treating surgeon per standard of care.
1948561|NCT02158520|Biological|Bevacizumab|Given IV
1948562|NCT02158520|Biological|Ipilimumab|Given IV
1948563|NCT02158520|Other|Laboratory Biomarker Analysis|Correlative studies
1948564|NCT02158520|Drug|Nab-paclitaxel|Given IV
1948565|NCT02158520|Other|Pharmacological Study|Correlative studies
1473001|NCT03174262|Behavioral|Ergonomic Computer Workstation Training|Training in proper body alignment and use of computer at computer workstations for people who spend 30% or more of a typical day at a computer. Training consists of learning proper positioning for head, neck, shoulders, arms, hands, and legs; proper arrangement of computer monitor, keyboard, mouse, and accessories.
1473002|NCT03174249|Behavioral|Exposure therapy|Daily training at an in-patient ward during four plus four weeks, separated by a home training period of 6-8 weeks.
1473003|NCT03174236|Drug|Ceftriaxone|Ceftriaxone a third-generation cephalosporin. Ceftriaxone is active against a broad spectrum of Gram positive and Gram negative bacteria.
1473004|NCT03174236|Drug|Benzyl penicillin plus gentamicin|The currently recommended first-line antibiotics for the treatment of severe acute malnutrition are gentamicin plus ampicillin or penicillin.
1473005|NCT03174236|Drug|Metronidazole|"The WHO guidelines recommend that Metronidazole may be given in addition to broad-spectrum antibiotics, however, the efficacy of this treatment has not been established in clinical trials."
1473006|NCT03174236|Other|Placebo|Suspension manufactured to match metronidazole
1473007|NCT03174223|Drug|deep neuromuscular block|a continuous dosing of rocuronium is used to achieve neuromuscular block of 1-2 twitches post tetanic count
1473008|NCT03174210|Device|liquid oxygen device (LOD)|This oxygen Supplementation is used in special order
1473009|NCT03174210|Device|portable oxygen concentrator (POC)|This oxygen Supplementation is used in special order
1948566|NCT02156960|Drug|Denosumab treatment in osteoporotic patients|To examine the effectiveness of denosumab in osteoporotic patients
1948567|NCT02156960|Drug|Teriparatide treatment in osteoporotic patients|To examine the effectiveness of teriparatide in osteoporotic patients
1948568|NCT02156960|Drug|Denosumab and teriparatide treatment in osteoporotic patients|To examine the effectiveness of denosumab and teriparatide in osteoporotic patients
1473013|NCT03174184|Drug|Rifampin|Oral administration of rifampin at a dosage of 20 mg/kg daily
1473014|NCT03174184|Drug|MEROPENEM 2 grams TID|Intravenous administration at a dosage of 2 grams thrice daily
1473015|NCT03174184|Drug|MEROPENEM 1 gram TID|Intravenous administration at a dosage of 1 gram thrice daily
1473016|NCT03174184|Drug|MEROPENEM 3 grams QD|Intravenous administration at a dosage of 3 grams once daily
1473017|NCT03174184|Drug|Amoxicillin/Clavulanate Potassium 500 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 500 mg/125 mg thrice daily
1473018|NCT03174184|Drug|Amoxicillin/Clavulanate Potassium 875 MG-125 MG Oral Tablet|Amx/Clv will be administered orally at a dose of 875 mg/125 mg once daily
1473019|NCT03174171|Drug|Everolimus 0.75 mg|Everolimus 0.75 mg b.i.d. orally for 14 days.
1473020|NCT03174158|Drug|Mailed nicotine replacement therapy|Daily smokers will be offered patches and lozenges dosed according to package instructions (patches dosed according to cigarettes smoked per day and lozenges dosed according to time to first cigarette). Non-daily smokers will be offered a 2 week supply of 2 mg lozenges. Smokers not ready to quit will be offered one box of lozenges dosed according to time to first cigarette to use in a practice quit attempt.
1473021|NCT03174158|Behavioral|Text messaging|12 week text messaging program tailored to readiness to quit and quit date. Program includes content encouraging NRT use. Content is personalized with user's name and Massachusetts General Hospital resources.
1473022|NCT03174158|Behavioral|Brief advice|Brief advice delivered by telephone by a clinical research coordinator who underwent Tobacco Treatment Specialist core training
1473023|NCT03174145|Behavioral|Positive behaviour|Information about T4P1010 treatment
1473024|NCT03174145|Drug|T4P1010 administration|Provide treatment to be taken twice a day between Visit 2 and Visit 5 as add-on therapy to patient's regular analgesic treatment
1473025|NCT03174145|Genetic|Pharmacogenetic|Blood sample of 10 millilitres maximum
1473026|NCT03174145|Other|Questionnaires and diary completion|Personnality, pain and disease questionnaires completion during the study Diary completion between Visit 1 and Visit 5
1473031|NCT03174106|Device|Smartphone-Application|Longterm follow-up after Cardiac rehabilitation With an Smartphone-Application
1473032|NCT03174093|Behavioral|MATCh AFib application|The application comprehends five steps: (1) An educational video about how AF can cause stroke; (2) A calculator of risk scores (CHA2DS2-VASc, HAS-BLED and SAMe-TT2R2); (3) A screen with pictograms to allow better understanding of the scores by patients and to demonstrate how much each anticoagulant can decrease stroke risk or increase bleeding risk; (4) A summary about types of medications available, and (5) An output formulary in which the physician can register patient's contact to continue receiving information about atrial fibrillation and anticoagulation through SMS. Physicians can save patient's history of INR tests and previous doses of anticoagulation prescribed and also use a calculator to adjust the dose.
1473033|NCT03174080|Radiation|FDG (glucose labeled isotope of fluorine)|Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI
1948569|NCT02157012|Drug|The effectiveness of Xeljanz in rheumatoid arthritis patients|
1948570|NCT02156999|Device|Ibandronic acid, vitamin D|
1473036|NCT03174054|Procedure|Biopsy|Biopsies are part of standard procedures in the patients recruited and will not be done due to this study.
1473037|NCT03174041|Drug|Midazolam|Single dose midazolam
1473038|NCT03174041|Drug|GDC-0853|Multiple doses GDC-0853 for 6 days
1473039|NCT03174041|Drug|Midazolam and GDC-0853|Multiple doses GDC-0853 and single dose midazolam
1473040|NCT03174041|Drug|Rosuvastatin|Single dose rosuvastatin
1473041|NCT03174041|Drug|Rosuvastatin and GDC-0853|Multiple doses GDC-0853 and single dose rosuvastatin
1473042|NCT03174041|Drug|Simvastatin|Single dose simvastatin
1479083|NCT03126916|Other|Pharmacological Study|Correlative studies
1473045|NCT03174041|Drug|Itraconazole|Multiple doses itraconazole for 6 days
1473046|NCT03174041|Drug|GDC-0853 and itraconazole|Multiple doses itraconazole and single dose GDC-0853
1473047|NCT03174028|Device|laparoscopic pull-through|laparoscopic pull-through
1473048|NCT03174015|Behavioral|Bauleni Secret|The intervention will invite enrolled landlords to a series of meetings in which various mechanisms will be used, each designed to increase their likelihood of improving the toilet(s) on their plot. These meetings will be the main vehicle for a status-building campaign associated with increasing wealth by improving plot sanitation, understanding tenants' implicit demand, understanding the processes by which toilets can be improved, and a competition rewarding landlords that make the greatest improvements to the improvement of their toilet(s).
1473049|NCT03174002|Drug|Oxygen|Oxygen administration to achieve a PaO2 of 8 kPa (60 mmHg) from ICU admission to ICU discharge
1473050|NCT03174002|Drug|Oxygen|Oxygen administration to achieve a PaO2 of 12 kPa (90 mmHg) from ICU admission to ICU discharge
1473051|NCT03173989|Device|Orthosis Exercises Orientation|Use of orthosis, exercises and orientation for home.
1473052|NCT03173989|Behavioral|Orientation|Orientation for home.
1473056|NCT03173950|Drug|Nivolumab|"Patients will be treated with the immune checkpoint inhibitor, nivolumab, at a standard dose of 240 mg intravenously every 2 weeks.
A maximum of 32 treatments will be given (64 weeks). A cycle will be defined as 2 treatments (4 weeks) and patients will undergo efficacy assessments using MR imaging every 2 cycles."
1473057|NCT03173937|Biological|CordIn(TM)|Stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic umbilical/unrelated cord blood (UCB) cells. CordIn(TM) comprises: 1) cord blood-derived ex vivo expanded CD133+ cells (CordIn(TM) cultured fraction (CF)); and 2) the non-cultured cell fraction (CD133-) of the same CBU (CordIn(TM) Noncultured Fraction (NF)). Both fractions, i.e. CordIn(TM) CF and CordIn(TM) NF are kept frozen until they are infused on the day of transplantation.
1473058|NCT03173924|Drug|18F-NaF|IV x 1 followed by PET/CT IMAGING
1473059|NCT03173924|Drug|18F-DCFPyL|IV x 1 (or x2) followed by PET/CT IMAGING
1473060|NCT03173911|Device|Bandage|Application of Elastic Bandage Therapy by the Therapy Taping method
1473061|NCT03173898|Procedure|PDL anesthesia versus local infiltration|Every patient received the recommended volumes of 2% lidocaine with 1:100.000 epinephrine for PDL injection on the experimental side, and for local infiltration on the control side. A Visual Analogue Scale (VAS) was used to describe the pain felt during injection.
1473062|NCT03173885|Diagnostic Test|Preimplantation Genetic Screening|"laser assisted hatching
trophectoderm biopsy
next generation sequencing"
1473063|NCT03173872|Procedure|Reiki Protocol Hand Placement Procedures|Ten Reiki hand placement procedures will last 3 minutes each for a total Reiki session lasting 30 minutes long.
1473064|NCT03173859|Drug|Abiraterone|Abiraterone acetate 1000mg qD and prednisone 5mg bid administered orally
1473065|NCT03173859|Drug|Apalutamide|apalutamide 240mg qD orally
1473066|NCT03173833|Other|CAGO questionnaire outcome|Every time when cancer patients fulfill the following questionnaires, SDS, PTGI, CNS, PedsQL, the outcome of the questionnaires will be provided to the experimental group of the participants by using a computer assessment with graphic outcome.
1473067|NCT03173820|Genetic|Genotype guided|Tacrolimus will be prescribed depend on CYP3A5 genotype. CYP3A5*1/*1 patients will receive tacrolimus 0.125 mg/kg/day. CYP3A5*1/*3 patients will receive tacrolimus 0.1 mg/kg/day. CYP3A5*3/*3 patients will received tacrolimus 0.08 mg/kg/day. Tacrolimus target level for this phase will be 5-8 ng/ml.
1473068|NCT03173820|Genetic|Conventional|Tacrolimus will be prescribed 0.1 mg/kg /day for all patients to achieve tacrolimus level 5-8 ng/ml.
1473069|NCT03173807|Behavioral|diet and exercise guidance and modifications|Review of diet, food diary, and guidance from the dietician; review of activity journal, assessment of body composition, tests for gait, balance and muscle strength, and new assignment from the exercise trainer
1473070|NCT03173794|Other|CommunityRx-H|"CommunityRx-H has two components: (1) health-information technology (HIT) e-prescribing, and (2) a Community Resource Specialist (CRS). CommunityRx functions like an e-prescribing system: a HealtheRx prescription is automatically generated at the point of care. The HealtheRx provides referrals to food resources and federal nutrition assistance information tailored to the caregiver's address and proactive social support in the form of SMS-text message nudges from the CRS. Caregivers in the intervention arm are able to request information on resources not limited to food, including employment support, help paying rent or mortgage, etc. Nudges will promote caregiver self- and family management by increasing knowledge of and encouraging activation of community resources."
1473071|NCT03173781|Drug|droxidopa|medication
1473072|NCT03173781|Drug|Placebo|medication
1473073|NCT03173768|Procedure|ID specialist approval|Appropriateness of intravenous antibiotics ordered by the primary team was assessed by ID specialist. ID fellow modified the intravenous antibiotics ordered by the primary team if those intravenous antibiotics were judged as inappropriate by ID fellow as follows: 1) discontinue intravenous antibiotics (treatment was complete), 2) switch to oral antibiotics, 3) change intravenous antibiotics to cover isolated pathogens, 4) adjust the dose of intravenous antibiotics, and 5) change the duration of intravenous antibiotics. Finally, ID specialist retrospectively assessed the appropriateness of intravenous antibiotics at hospital discharge managed by ID fellow in post-intervention period.
1473074|NCT03173742|Drug|T1, T2, T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
1473075|NCT03173742|Drug|T1,T3,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
1473076|NCT03173742|Drug|T2,T1,T3|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
1473121|NCT03173469|Other|magnetic resonance imaging of breast|all patients will undergo preoperative MRI
1473077|NCT03173742|Drug|T2,T3,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
1473078|NCT03173742|Drug|T3,T1,T2|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
1473079|NCT03173742|Drug|T3,T2,T1|"T1: Ivermectin 6 mg (Revectina®) administered according to the SmPC by body weight.
T2: Ivermectin 18 mg (IVM 18 mg Tablet Liconsa x 1 tablet) T3: Ivermectin 36 mg (IVM 18 mg Tablet Liconsa x 2 tablets)"
1473080|NCT03173729|Diagnostic Test|Biosensor Point of Care Device|This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.
1473082|NCT03173703|Device|Implant the XenoSure patch|The LeMaitre XenoSure patch will be used when close the repaired vessel
1473083|NCT03173703|Procedure|Repair/reconstruction of the diseased vessel|The diseased vessel is surgically repaired such as removing the clots.
1473084|NCT03173703|Device|Implant the Vascular-Patch|The B. Braun Vascular-Patch will be used when close the repaired vessel
1473085|NCT03173690|Other|Medication reconciliation at the ICU|Medication reconciliation performed according to Integrated Medicines Management model
1473086|NCT03173690|Other|Medication Reconciliation at the Ward|Medication reconciliation performed according to Integrated Medicines Management model
1473087|NCT03173677|Dietary Supplement|Lipid Intake|90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate
1473088|NCT03173677|Dietary Supplement|Glucose intake|300 calories of glucose
1473089|NCT03173677|Dietary Supplement|Protein intake|Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
1473090|NCT03173664|Device|KAMRA Inlay|Unilateral implantation of the KAMRA inlay in the corneal stroma.
1473091|NCT03173651|Device|Modified Williams airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group W
1473092|NCT03173651|Device|Modified Guedle's airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group G
1473093|NCT03173651|Device|LMA MADgic airway|This airway used as a conduit for fiberoptic bronchoscopic tracheal intubation in Group M
1473094|NCT03173638|Procedure|intravitreal injection of MSV|A unique intravitreal injection of MSV in acute fase of NAION
1473095|NCT03173625|Drug|AC-076 for s.c. administration|Lyophilized AC-076A to be reconstituted with 1 mL of water for injection
1473096|NCT03173625|Drug|Placebo|Sterile 0.9% w/v sodium chloride solution
1473097|NCT03173612|Drug|Dasatinib|Primary AML includes CBF-AML and non-CBF-AML. Children with a WBC (white blood cell) lower than 4,000/μL and low proliferative bone marrow at diagnosis are treated with CAG. Other children are treated with MAE. The rescue regimen for children who showed M3 marrow after MAE or CAG is IAE. Consolidation therapy consisted of four (for CBF-AML) or five (for non-CBF-AML) courses, and triplein trathecal therapy is given as a part of each course. After the second course of therapy, CBF-AML are stratified into two risk groups, while non-CBF-AML patients in remission are stratified into three risk groups.Consolidation regimen for CBF-AML includes IA, MA, IA, MA. Dasatinib is used in CBF-AML as a part of consolidation therapy. Consolidation regimen for non-CBF-AML includes IAE, MAE, EA, IAE, EA or MAE.
1473098|NCT03173599|Drug|PNA 40mg|The beginning dose is 40mg.
1473099|NCT03173599|Drug|PNA 80mg|The single dose is 80mg.
1473100|NCT03173599|Drug|PNA 160mg|The single dose is 160mg.
1473101|NCT03173599|Drug|PNA 240mg|The single dose is 240mg.
1473102|NCT03173599|Drug|PNA 360mg|The single dose is 360mg.
1473103|NCT03173599|Drug|PNA 480mg|The single dose is 480mg.
1473104|NCT03173599|Drug|PNA Placebo|The beginning dose is 40mg/d, the dose escalation method is 40mg/80mg/160mg/240mg/360mg/480mg.
1473105|NCT03173586|Other|Sugar sweetened beverage (SSB)|This is an observational study examining sugar sweetened beverage intake in relation to biomarkers in the NHS.
1473110|NCT03173547|Drug|146-9251 cream|146-9251 cream contains an active drug and is applied topically.
1473111|NCT03173547|Drug|Vehicle cream|Vehicle cream does not contain an active drug and is applied topically.
1473112|NCT03173534|Device|WATCHMAN|WATCHMAN Device is composed of a self-expanding nitinol structure with a porous membrane on the proximal face. The implant device is delivered to the Left Atrial Appendage by femoral venous access and transseptal puncture to enter the left atrium.
1473113|NCT03173534|Device|TAVR|Transcatheter Aortic Valve Replacement
1473114|NCT03173521|Biological|AAV2/8.TBG.hARSB|"Adeno-associated viral vector serotype 8 with liver-specific thyroxinebinding globulin (TBG) promoter driving the expression of the human ARSB gene. Three dose levels are available:
Starting dose is 6x1011 gc of vector per kg of body weight.
High dose is 2x1012 gc of vector per kg of body weight and will be administered after at least two subjects at the starting dose have experienced no DLT
Low dose is 2x1011 gc of vector per kg of body weight. Intermediate doses are also possible. The administration of the IMP will be performed into a peripheral vein. The IMP final volume to be injected is calculated based on the patient's weight (determined on the day of hospital admission), as 3 mL/kg."
1473115|NCT03173508|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
1473116|NCT03173508|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
1473117|NCT03173495|Dietary Supplement|FRUCTOSE|Fructose-rich beverage with a high fat meal, without exercise.
1473118|NCT03173495|Dietary Supplement|DEXTROSE|Dextrose-rich beverage with a high fat meal (control), without exercise.
1473119|NCT03173495|Dietary Supplement|EXERCISE|45 minutes of 60% VO2peak aerobic exercise
1473120|NCT03173482|Other|questionnaire|asking about details of indication of cesarean section
1473122|NCT03173456|Drug|oxycodone/APAP|Oxycodone/acetaminophen 5 mg-325 mg oral tablet
1473123|NCT03173456|Drug|hydrocodone/APAP|Hydrocodone/Acetaminophen 5 Mg-300 Mg oral tablet
1473124|NCT03173456|Drug|codeine/APAP|Codeine/acetaminophen 30 mg-300mg oral tablet
1473125|NCT03173456|Drug|400 ibuprofen/APAP|ibuprofen/acetaminophen 400 mg-1000mg oral tablet
1473126|NCT03173456|Drug|800 ibuprofen/APAP|ibuprofen/acetaminophen 800 mg-1000 mg oral tablet
1473127|NCT03173443|Device|single lumen tube and bronchial blocker|fiberoptic intubation with single lumen tube and bronchial blocker
1473128|NCT03173443|Device|double lumen tube|fiberoptic intubation with double umen tube
1473129|NCT03173430|Drug|Blinatumomab|Blinatumomab (Blincyto), an anti-CD19/anti-CD3 bi-specific T cell engager
1473130|NCT03173417|Biological|IM19 CAR-T|T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
1473131|NCT03173417|Drug|fludarabine and cyclophosphamide|Two days before cell infusion,all patients will be treated with fludarabine and cyclophosphamide for 3 days
1473132|NCT03173404|Procedure|Hysteroscopy|The hysteroscopy is the visualization of the cervical canal and uterine cavity with a camera. Patients randomized to group I underwent hysteroscopy prior to the IVF cycle.
1473133|NCT03173391|Drug|HMS5552|BID Oral administration
1473134|NCT03173391|Drug|Placebos|BID Oral administration
1473135|NCT03173378|Other|Questionnaires|Participants will have to complete questionnaires to compare the distribution of occupational situations in narcoleptic patients and matched non-narcoleptic subjects (controls)
1473136|NCT03173365|Drug|Brimonidine Tartrate|1 gram of Brimonidine 3 mg/g gel (Mirvaso®) in 24 hours on the randomized palm equal to a finger tip unit (FTU) of 0.5 gram , topical application under occlusion twice per day, every 12 hours.
1473137|NCT03173339|Procedure|Endotracheal intubation using laryngoscope|Endotracheal intubation was done using laryngoscope for general anesthesia.
1473138|NCT03173339|Drug|High remifentanil|Remifentanil was started as 0.25 mcg/kg/min. Remifentanil dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.05 mcg/kg/min.
1473139|NCT03173339|Drug|Low remifentanil|Remifentanil was administered as 0.1 mcg/kg/min.
1473140|NCT03173339|Drug|High sevoflurane|Sevoflurane was started as 0.5 MAC. Sevoflurane dose was adjusted to maintain blood pressure (20% of preoperative blood pressure) and bispectral index (40-60) by 0.2 %.
1473141|NCT03173339|Drug|Low sevoflurane|Sevoflurane was administered as 0.5 MAC.
1473142|NCT03173326|Procedure|General anesthesia|General anesthesia will be delivered per standard procedure. General anesthesia will include induction with propofol 1-3mg/kg followed by placement of a laryngeal mask airway with maintenance anesthesia of sevoflurane 0.5-1 minimum alveolar concentration (MAC).
1473143|NCT03173326|Procedure|Subarachnoid block|Neuraxial anesthesia will be performed at the L2-3 or L3-4 interspace with a 25-gauge Whitacre needle in the sitting position. After free flow of cerebrospinal fluid (CSF), 40-45mg of 2-chloroprocaine will be injected based on patient's height and discretion of attending anesthesiologist, needle withdrawn and the patient placed supine.
1473144|NCT03173313|Device|Intravascular permissive hypothermia as an adjunct to PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI) -or- Standard of Care for PCI
1473145|NCT03173287|Procedure|Quantification of liver fibrosis|Procedure MRI and liver biopsy
1473146|NCT03173274|Behavioral|Brief Motivational Intervention|Participants in both groups will be given an BMI intervention in which they will be counseled to quit smoking.
1473147|NCT03173274|Behavioral|Contingency Management|Contingent Reinforcement for negative breath CO samples
1473148|NCT03173274|Behavioral|Non-Contingent Reinforcement|Participants will receive reinforcement for submitting samples ona yoked schedule unrelated to CO sample value [CM control]
1473149|NCT03173261|Diagnostic Test|Genexpert|diagnosis of tuberculous pleural effusion and genitourinary tuberculosis by Genexpert by urine and pus and pleural fluid aspirate
1473150|NCT03173248|Drug|AG-120 (ivosidenib) with Azacitidine|Continuous 28-day cycles of AG-120 (ivosidenib) 500 mg orally (PO) once daily (QD) in combination with azacitidine 75 mg/m2/day SC or IV for the first week of each cycle
1473151|NCT03173248|Drug|Placebo with Azacitidine|Continuous 28-day cycles of Placebo orally (PO) once daily (QD) in combination with azacitidine 75 mg/m2/day SC or IV for the first week of each cycle
1473152|NCT03173235|Diagnostic Test|Plasma level of vitamin D|messurement of plasma level of vitamin D
1473153|NCT03173222|Procedure|Electroacupuncture|A combined procedure with acupuncture and electric current stimulation. Local electroacupuncture will be given in group EA 1, while local with distal electroacupuncture will be given in group EA 2.
1473154|NCT03173209|Behavioral|professional development in Calm Moments Cards program|Professional development (lecture and coaching)was used in combination with informal coaching by occupational therapy practitioners to educate school personnel on signs of stress and how to embed evidence based strategies (cognitive behavioral, mindfulness, and sensory) throughout the school day to reduce stress and enhance emotional well-being in students using the Calm Moments Cards program.
1473155|NCT03173196|Device|Non-invasive Multispectral Sonography|We measure both groups wirh the non-invasive multispectral sonography for 3 and for 30 minutes.
1473156|NCT03173183|Drug|genuine regional Rhizoma Atractylodis (Maozhu granule)|"Maozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.
Luozhu granule, 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Co., Ltd.
Simulants (granule), 9g per bag, manufactured by Guangdong Yifang Pharmaceutical Group Co., Ltd."
1473157|NCT03173170|Drug|TAK-954|TAK-954 Infusion
1473158|NCT03173170|Drug|Itraconazole|Itraconazole Capsule
1473159|NCT03173157|Other|Value Feedback Email|a biweekly email to three house staff-run cardiology services at VUMC presenting the in-hospital charges and appropriate use of echocardiography. A weekly email will also be sent to the intervention services detailing their team's in-hospital charges for echocardiograms during the preceeding week.
1473197|NCT03172975|Other|Necator americanus Larval Inoculum|50 infectious Necator americanus larvae applied via dermal application (challenge infection).
1473198|NCT03172962|Behavioral|Strength training|Specific strength training exercises for the lumbar and abdominal muscles for 12 weeks
1473199|NCT03172962|Behavioral|Usual care (control)|Will receive the usual care at the hospital
1473160|NCT03173144|Other|Primary exposure variable|"Upper tertile (33.3% of the total sample) based on the ratio: fibre/meat intake is associated with better treatment outcome
Low intake of red and processed meat (defined as below the lower tertile [33.3% of the total sample]) and high intake of dietary fibres (defined as those above the upper tertile [33.3% of the total sample]) are independently associated with better treatment outcome, and their synergy (interaction between the factors meat and fibres) gives the best treatment outcome"
1473161|NCT03173144|Other|Other (exploratory) exposure variables|"Lifestyle factors independently or combined (red and processed meat, vegetable, dietary fibre, cereals, gluten, legumes, red wine, dairy products, physical activity, smoking, total protein/ fat, protein/ fat from red and processed meat, glucemic index)
Pretreatment lifestyle-associated biomarkers
Combinations of lifestyle factors and lifestyle-associated biomarkers
Gene-environment interaction analyses
Pretreatment levels of inflammatory molecules"
1473162|NCT03173131|Behavioral|Pre-operative opioid counseling|Patients will be randomized to receive counseling regarding opioid medication and post operative pain control.
1473163|NCT03173118|Procedure|Endoscopic ultrasound elastography|Endoscopic ultrasound elastography performed on both groups of patients as per routine
1948571|NCT02153619|Behavioral|Meaning-Centered Grief Therapy (MCGT)|MCGT is a manualized, one-on-one intervention that uses psychoeducation, experiential exercises, and homework focusing on themes related to meaning, identity, purpose, and legacy. Post-intervention qualitative exit interviews will assess acceptability of the MCGT intervention (see Appendix I). Participants randomized to MCGT will provide their feedback about MCGT and the measures (n = 33).
1948572|NCT02153619|Behavioral|Supportive Psychotherapy (SP)|"SP is the comparison condition in this study and is a standardized, manualized intervention developed by the MSKCC Psychiatry Service and utilized in our completed and ongoing RCTs of Meaning-Centered Psychotherapy."
1948573|NCT02153619|Behavioral|questionnaires assessments|
1948574|NCT02134158|Device|anodal tDCS and sham tDCS stimulations|"Two conditions will be tested in randomized order: 2 arms in the first one anodal tDCS and then sham tDCS. In the other arm sham tDCS and then anodal tDCS.
All the investigations will associate with clinical, functional and 3D motion analysis assessments."
1473171|NCT03173079|Other|pre- and postinterventional geriatric assessment in patients undergoing TAVI|geriatric assessment
1473172|NCT03173066|Drug|Ferumoxytol|ferumoxytol-enhanced magnetic resonance angiography for the diagnosis of pulmonary embolus
1473173|NCT03173053|Drug|Doxycycline|tablet
1473174|NCT03173053|Drug|Trimethoprim|tablet
1473175|NCT03173053|Drug|Sulfamethoxazole/trimethoprim|tablet
1473176|NCT03173053|Drug|Clindamycin|tablet
1473177|NCT03173053|Drug|Clarithromycin|tablet
1473178|NCT03173053|Drug|Ciprofloxacin|tablet
1473179|NCT03173053|Drug|Fusidic Acid|tablet or ointment
1473180|NCT03173053|Drug|Rifampin|tablet
1473181|NCT03173053|Drug|Chlorhexidine|Mouthwash or bodywash
1473182|NCT03173053|Drug|Mupirocin|Nasal ointment
1473183|NCT03173053|Drug|Betadine|Shampoo
1473184|NCT03173040|Drug|NiuBangZi pill or NiuBangZi pill placebo|For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
1473185|NCT03173027|Drug|Fangji Huangqi pill or Fangji Huangqi pill placebo|For the treatment group (Fangji Huangqi pill group), patients will administrate Fangji Huangqi pill (4 g) in 200 milliliter hot water as the instruction and take the solution orally twice a day for 1 month. While patients in the placebo group will take Fangji Huangqi pill placebo as the same way as the Fangji Huangqi pill group. Besides that, both groups will administrate Mobic (7.5 mg once a day) in addition.
1473186|NCT03173014|Device|EEG|EEG monitoring
1473187|NCT03173001|Diagnostic Test|Parasitological examination|Three stool samples for parasitological examination will be taken from control subjects and CRC patients at 1-2 days interval.
1473188|NCT03172988|Drug|Dexamethasone|Dexamethasone 10 mg is administered before anesthesia induction.
1473189|NCT03172988|Drug|Normal saline|Normal saline 2 ml is administered before anesthesia induction.
1473190|NCT03172988|Drug|Flurbiprofen axetil|Flurbiprofen axetil 50 mg is administered before the end of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 2 mg/ml flurbiprofen axetil, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
1473191|NCT03172988|Drug|Lipid microsphere|Lipid microsphere 5 ml is administered before the end of surgery. Postoperative analgesia is provided with a patient-controlled analgesia pump, which is established with 100 ml of 1.25 μg/ml sufentanil and 20 ml lipid microsphere, programmed to deliver a 2 ml bolus with a lockout interval of 6-8 min and a background infusion of 1 ml/h.
1473192|NCT03172975|Biological|Na-GST-1/Alhydrogel|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel
1473193|NCT03172975|Biological|Na-GST-1/Alhydrogel + CPG 10104|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with CPG 10104, a synthetic oligodeoxynucleotide
1473194|NCT03172975|Biological|Na-GST-1/Alhydrogel + GLA-AF|Recombinant ˆNecator americanusˆ Glutathione-S Transferase adjuvanted with Alhydrogel and co-administered with an aqueous formulation of Glucopyranosyl-Lipid A (GLA-AF)
1473195|NCT03172975|Biological|Placebo|Physiological sterile saline solution
1473196|NCT03172975|Drug|Albendazole|Treatment with 3 daily oral doses of 400 mg albendazole at end of study.
1948575|NCT02134015|Drug|Patritumab|Infusion of Patritumab (loading dose of 18 mg/kg, followed by 9 mg/kg every 3 weeks)
1948576|NCT02134015|Drug|erlotinib:|Oral erlotinib 150 mg/day.
1948577|NCT02134015|Drug|Placebo|Placebo infusion every 3 weeks
1473202|NCT03172923|Device|sliding hip screw|fixation of the fracture with a sliding hip screw
1473203|NCT03172923|Device|intramedullary nial|fixation of the fracture with an intramedullary nail
1473204|NCT03172910|Drug|Ciraparantag|Reversal of rivaroxaban-induced anticoagulation via dose of ciraparantag or placebo
1473205|NCT03172910|Drug|Placebo|Reversal of rivaroxaban-induced anticoagulation via dose of ciraparantag or placebo
1473206|NCT03172897|Drug|Dexmedetomidine|Dexmedetomidine is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h (0.1 μg/kg per h) from study recruitment in the ICU for no more than 72 hours.
1473207|NCT03172897|Drug|Placebo (normal saline)|Placebo (normal saline) is administered as a continuous intravenous infusion at a rate of 0.025 mL/kg per h from study recruitment in the ICU for no more than 72 hours.
1473209|NCT03172871|Drug|Aripiprazole IM Depot|Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
1473210|NCT03172871|Drug|Aripiprazole tablet|Oral aripiprazole tablets 10 to 20 mg daily
1473211|NCT03172858|Device|Intracervical balloon catheter|cervical ripening balloon
1473212|NCT03172858|Drug|Oxytocin|medication used to induce contractions
1473213|NCT03172845|Procedure|percutaneous coronary intervention|percutaneous coronary intervention with drug-eluting stent implantation.
1473214|NCT03172832|Procedure|PTBD|Percutaneous access and tube placement into the bile duct
1473215|NCT03172832|Procedure|ERC|Endoscopic access and stent placement in the bile duct
1473218|NCT03172806|Diagnostic Test|Polysomnography|To compare the ability of the clinical scores, all patients included in this study underwent a polysomnography.
1473219|NCT03172793|Drug|Telavancin Injection|Receive 3 doses of telavancin as described in arm/groups, followed by collection of blood for pharmacokinetic analyses.
1473220|NCT03172780|Drug|Diclofenac sodium gel 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
1473221|NCT03172780|Drug|Voltaren® Gel (Diclofenac Sodium Topical Gel) 1%|Diclofenac Sodium Topical Gel, 1%. 4 gm, 4 times a day for 4 weeks
1473222|NCT03172780|Drug|Placebo gel|Vehicle Gel 4 gm, 4 times a day for 4 weeks
1473223|NCT03172754|Drug|Nivolumab|PD-1 inhibitor
1473224|NCT03172754|Drug|Axitinib|Tyrosine kinase inhibitor
1473225|NCT03172741|Drug|Medical Marijuana|1-gram marijuana cigarette smoked once per day for 3 months
1473226|NCT03172741|Drug|Placebo|Matching 1 gram placebo cigarette smoked once per day for 3 months
1473227|NCT03172728|Behavioral|psycho-education pamphlet|psycho-education intervention, based on Cognitive Behavioral Therapy, that is easy to provide and feasible in standard perinatal care. It is intended to increase awareness of obsessive thoughts and to decrease anxiety and encourage treatment seeking.
1473231|NCT03172689|Device|CardioQ|comparison of cardiac output measurements between gold standard transpulmonary thermodilution (by PiCCO) versus an oesophageal doppler monitor (CardioQ) They will be used simultaneously
1473232|NCT03172676|Drug|Amoxicillin 50 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Amoxicillin for 14 days.
1473233|NCT03172676|Drug|Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
1473234|NCT03172676|Drug|Proton pump inhibitor 1 mg/kg/day in 2 divided doses 1 month|chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive proton pump inhibitor for 1 month.
1473235|NCT03172663|Device|pure tone audiometry|for estimate the type and degree of hearing loss
1473236|NCT03172650|Diagnostic Test|glomerular filtration rate|collection of blood sample 5 milliliter for calculation of glomerular filtration rate
1473237|NCT03172624|Drug|Nivolumab|nivolumab 3 mg/kg every 2 weeks
1473238|NCT03172624|Drug|Ipilimumab|ipilimumab 1 mg/kg every 6 weeks (1 cycle= 6 weeks)
1473239|NCT03172611|Other|Dietary Intervention|Subjects consumed a defined, plant-based diet for 4-weeks. Emphasized were raw fruits and vegetables.
1473240|NCT03172598|Drug|MT-8554 low dose|Capsule
1473241|NCT03172598|Drug|MT-8554 middle dose|Capsule
1473242|NCT03172598|Drug|MT-8554 high dose|Capsule
1473243|NCT03172598|Drug|Placebo|Capsule
1473244|NCT03172585|Other|High resolution computed tomography|High resolution computed tomography of the chest is the gold standard imaging modality for most pulmonary diseases
1473245|NCT03172585|Other|trans thoracic ultrasonography|Trans thoracic ultrasonograghy is used progressively for evaluation of pulmonary diseases . Its non invasive nature , relatively low price ,portability for bedside use, and high reproducible of results allows for incorporation of imaging findings with clinical data
1473246|NCT03172572|Procedure|Minimally invasive pancreatoduodenectomy|Laparoscopic, robot-assisted, or hybrid resection
1473247|NCT03172572|Procedure|Open pancreatoduodenectomy|Open resection
1473248|NCT03172559|Radiation|Stereotactic body radiotherapy|The recommended dose will be 30 Gy in 5 fractions. The treatment will be administered in 5 alternative days and will be individualized with the dose based on baseline liver function, effective liver volume irradiated and proximity to other normal tissues.
1473249|NCT03172546|Genetic|PK-PD genetic polymorphisms|PK-PD genetic polymorphisms analysis in patients receiving either anti-IIa or anti-Xa treatment
1473440|NCT03171116|Other|none intervention|it is not an interventional study; it is an observational study
1473250|NCT03172533|Drug|ethinyl estradiol 0.03mg and dienogest 2 mg (combination)|approved oral contraceptive (Germany): Maxim
1473251|NCT03172533|Drug|Placebo oral capsule|placebo
1473257|NCT03172481|Drug|PRC-063 oral capsules|Daily dose
1473258|NCT03172481|Drug|Placebo oral capsules|Daily dose
1473259|NCT03172455|Drug|Glassia|Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 to day 15), once weekly 120 mg/kg from day 15 to day 50
1473260|NCT03172442|Device|Vacuum plate|Vacuum plate with two hooks between lateral incisor and canine in each side will be applied on the lower arch.
1473261|NCT03172442|Device|Rapid maxillary expander|Rapid maxillary expander will be applied in the maxilla to disarticulate maxillary sutures to allow more efficient forward protraction of the maxilla.
1473262|NCT03172442|Device|Class III elastics|Class III elastic traction from upper first molar to the hook in both side will be applied.
1473263|NCT03172416|Drug|Oxaliplatin|"This is a prospective, single arm phase I trial in a 3 + 3 dose escalation and cohort expansion design evaluating the safety and tolerability of PIPAC using oxaliplatin in patients with peritoneal carcinomatosis.
The pre-planned dose levels of oxaliplatin are 45mg/m2 (Cohort 1), 60mg/m2 (Cohort 2), 90mg/m2 (Cohort 3), 120mg/m2 (Cohort 4) and 150mg/m2 (Cohort 5) administered as PIPAC. Successive cohorts of patients (3 participants/cohort) will be enrolled and started on a fixed dose of oxaliplatin. The protocol specifies oxaliplatin 45mg/m2 once every 6 weeks for Cohort 1. Dose escalation continues until dose-limiting toxicities (DLT) are observed in one-third of participants. If no DLT occurs, the next cohort will be enrolled at the next planned dose level. If 1 DLT occurs in a cohort, another 3 patients will be treated with the same dose level."
1473269|NCT03172390|Device|4D Cardiac Magnetic Resonance|4D Cardiac Magnetic Resonance for patients with a ascending aorta dilatation without current indication for surgery for measured parameters of ascending aorta
1473270|NCT03172377|Other|Lengthening adalimumab dosing interval|Lengthening adalimumab dosing interval from 2 weeks to 3 weeks and -later- to 4 weeks.
1473271|NCT03172364|Other|Micellar cleanser|Participants will apply the micellar cleanser topically twice a day (morning and evening). Micellar cleanser will be applied on cotton pad and wiped over the entire face and closed eye to gently cleanse. No need to rub or rinse the micellar cleanser.
1473272|NCT03172364|Other|Micellar foaming cleanser|Participants will use the micellar foaming cleanser topically twice a day (morning and evening). Micellar foaming cleanser will be massaged gently onto wet skin on the face using fingertips. After which participants will rinse thoroughly and pat the skin dry.
1473273|NCT03172351|Device|EDoF1|extended depth of focus IOL - EDoF1
1473274|NCT03172351|Device|Monofocal|Monofocal IOL
1473275|NCT03172351|Device|EDoF2|Comparison EDoF2 IOL
1473276|NCT03172325|Drug|Adalimumab|40 mg Adalimumab every other week is administered subcutaneously to all the patients.
1473277|NCT03172325|Drug|Methotrexate|15 mg Methotrexate is weekly administered to all the patients.
1473278|NCT03172325|Drug|Folic Acid|At least 1 mg Folic acid is daily administered to all the patients.
1473279|NCT03172325|Drug|Prednisolone|7.5 mg Prednisolone is daily administered to all the patients.
1473280|NCT03172312|Procedure|Different range of thyroid surgery|Observe and record parathyroid status during thyroid surgery
1473281|NCT03172299|Drug|Aflibercept Injection|Intravitreal injection of aflibercept 40mg/mL will be done on patients. The injections will be performed on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, injections will be performed every 3 months for a period of 21 months.
1473282|NCT03172299|Drug|False injection|A false injection will be done on patients on the last day of the proton therapy, then 1 and 2 months later for the induction phase. During the maintenance phase, falses injections will be performed every 3 months for a period of 21 months.
1473283|NCT03172286|Device|Radiofrequencer|Patients will be treated with a radiofrenquencer switched on or off depending on the attributed group after randomization
1473284|NCT03172273|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
1473285|NCT03172273|Procedure|paracentesis|paracentasis plus albumine invision
1473287|NCT03172234|Drug|oral amantadine sulfate|In amantadine group:the patients will receive100 mg oral amantadine sulfate 90 minute prior to the surgery
1473288|NCT03172234|Drug|oral gabapentin|In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
1473330|NCT03171961|Behavioral|self-directed group|self-directed group receives nutritional information via web and their energy needs for weight loss
1473289|NCT03172221|Diagnostic Test|HS-RDT|A single finger-prick blood sample will be collected and used to test participants with the HS-RDT. The results of the results of the test will not be used for treatment purposes nor used to inform patient care.
1473290|NCT03172208|Biological|Caplacizumab Dose 1 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 1
1473291|NCT03172208|Biological|Caplacizumab Dose 2 iv (single-dose)|Single intravenous (iv) administration of Caplacizumab Dose 2
1473292|NCT03172208|Biological|Caplacizumab Dose 2 sc (single-dose)|Single subcutaneous (sc) administration of Caplacizumab Dose 2
1473293|NCT03172208|Biological|Caplacizumab Dose 2 sc (multiple-dose)|Once daily subcutaneous (sc) administration of Caplacizumab Dose 2 during 7 consecutive days
1473294|NCT03172208|Other|Placebo iv (single-dose)|Single intravenous (iv) administration of Placebo
1473295|NCT03172208|Other|Placebo sc (single-dose)|Single subcutaneous (sc) administration of Placebo
1473296|NCT03172208|Other|Placebo sc (multiple-dose)|Once daily subcutaneous (sc) administration of Placebo during 7 consecutive days
1473297|NCT03172195|Procedure|rectosigmoidoscopy|A rectosigmoidoscopy will be realized and two fragments will be collected.
1473298|NCT03172195|Biological|biopsies|For this study, two biopsies in healthy area and two biopsies in ulcer will be collected.
1473299|NCT03172195|Biological|blood sample|Blood sample will be collected in more.
1473300|NCT03172182|Behavioral|a 360-degree VR video tour|At operation day, pediatric patients of the VR group and their parents are educated using virtual tour program explaining preoperative procedures and showing environment of the operating room. A 360-degree virtual reality (VR) video for the tour program was filmed in advance and is provided using a head mount device into which a smartphone is installed, at 30 minutes before the induction of anesthesia.
1473301|NCT03172169|Other|no Intervention|no Intervention
1473305|NCT03172130|Device|Straight CPAP|
1473306|NCT03172130|Device|Sham CPAP|
1473307|NCT03172117|Biological|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
1473308|NCT03172117|Other|Normal saline 2mL|Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
1473309|NCT03172091|Device|eNose (electronic nose)|Collection of exhaled breath for an immediate analysis by electronic nose
1473310|NCT03172091|Device|Spectrometry|Collection of exhaled breath for an immediate analysis by mass spectrometry
1473311|NCT03172078|Procedure|advanced endoscopic procedure|The advanced endoscopic procedure include endoscopic Ultrasound (EUS), endoscopic retrograde cholangiopancreatogram (ERCP).
1473312|NCT03172065|Drug|Hyperbaric Bupivacaine|anaesthetic drug
1473313|NCT03172065|Drug|ketorolac|pain killer, anaesthesia adjuvants
1473314|NCT03172065|Drug|Dexmedetomidine|anaesthetic adjuvants and pain killer medication.
1473315|NCT03172052|Drug|streptokinase|• Chemical adhesiolysis by instillation of streptokinase at a dose of 250,000 I.U dissolved in 40 ml of normal saline will be instil in the pleural cavity through the chest tube. we planning to continue the daily instillation as long as the drained fluid volume is >100 cc with a maximum of 14 doses and to stop further instillation if severe complication occurred.
1473316|NCT03172052|Drug|MESNA (2-mercaptoethane sulfonate Na)|• Chemical adhesiolysis by instillation of MESNA at a dose of 1800 mg of MESNA i.e. 3 ampoules ( each ampoule contains 3ml and each ml contains 200 mg of MESNA) will be diluted with 20ml of Normal Saline and will be injected into the pleural cavity through the chest tube for three consecutive days.
1473317|NCT03172052|Device|Medical thoracoscopy|Medical thoracoscopy procedure will be carried at endoscopy unit at chest department via, semi rigid thoracoscope (LTF; Olympus; Tokyo, Japan).
1473318|NCT03172052|Device|Video assisted thoracoscopy (VATS)|Video assisted thoracoscopy (VATS) at cardiothoracic surgery department.
1473319|NCT03172026|Drug|Maraviroc 300 mg|FDA approved chemokine receptor (CCR5) inhibitor. Maraviroc will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
1473320|NCT03172026|Behavioral|Rehabilitation therapy|"All participants will have routine outpatient or home health physical and occupational therapy after inpatient discharge as prescribed by their physicians.
Each group will be contacted weekly by phone to help maintain interest in the trial, count the number of usual care physical and occupational therapy completed, assure use of the assigned medication, ask about possible adverse reactions, and to encourage them to be active. The coordinator will obtain this information and provide the feedback using a standard script and checklist. A unique aspect of this trial is a telerehabilitation component that aims to give feedback to all participants to practice with the affected arm and walk daily."
1473321|NCT03172026|Drug|Placebo 300 mg|Matched placebo will be started within two weeks of discharge from inpatient rehabilitation, which most often will occur from 4-6 weeks after stroke onset.
1473322|NCT03172013|Diagnostic Test|Platelet indices|MPV, PDW
1473323|NCT03172000|Diagnostic Test|Colonoscopy and biopsy|Colonoscopic biopsy were taken from the rectum, the sigmoid, descending, transverse, ascending colon, and the cecum of each patient.
1473324|NCT03171987|Drug|Lidocaine patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
1473325|NCT03171987|Drug|Flurbiprofen patch local application|Attach the patch to back pain area 1 piece per day with no more than 6 hours.
1473326|NCT03171974|Drug|Dexamethasone|dexamethasone will be injected intracapsular under US
1473327|NCT03171974|Device|US|dexamethasone will be injected intracapsular under US
1473328|NCT03171961|Behavioral|online visit group|subjects has online visit with dietitian every 2 weeks+diet
1473329|NCT03171961|Behavioral|Clinic visit group|Clinic visit group ,subjects has every 2 weeks in person visit at clinic+diet
1473331|NCT03171948|Behavioral|Almond Group|Almond Group (AG) are asked to have a 30 gr. almond every day in their afternoon snack plus following the hypoenergetic diet
1473332|NCT03171948|Behavioral|Nut Free group|continue their diet without any nut consumption.
1473333|NCT03171935|Device|High-Flow Nasal Cannula Oxygenation|High-flow nasal cannula oxygenation will be applied immediately after early extubation, with a gas flow rate of 50 liters per minute and a fraction of inspired oxygen of 1.0 at initiation. The fraction of inspired oxygen will be subsequently adjusted to maintain a peripheral oxygen saturation of 92% or more.
1473334|NCT03171935|Device|Noninvasive Positive Pressure Ventilation|Noninvasive positive pressure ventilation will be applied immediately after early extubation, with a noninvasive ventilator (Respironics V60, Philips) using the NIPSV mode at initiation. The fraction of inspired oxygen will be adjusted to achieve SpO2 >92% with an initial expiratory positive airway pressure (EPAP) of 4 cmH2O. EPAP will be increased gradually in increments of 1-2 cmH2O, up to a maximum of 12 cmH2O, to achieve SpO2 >96%. Inspiratory positive airway pressure (IPAP) will be initially set at 8 cmH2O and be increased gradually in increments of 1-2 cmH2O according to patients' tolerance to obtain a tidal volume (VT) of 6-8 mL/kg.
1473335|NCT03171935|Device|Conventional weaning|The patients will undergo conventional weaning protocol. Extubation and subsequent oxygen therapy with venturi mask will be performed after successful spontaneous trial.
1473336|NCT03171922|Behavioral|Internet Diet|ID group have online dietary coach every 2 weeks
1473337|NCT03171922|Behavioral|Clinic Diet|CD group have every 2 weeks visit at clinic
1473338|NCT03171896|Other|clown|A medical clown will be offerred to the parturient and will spend time with her during labor as long as she will want it
1473339|NCT03171896|Other|Sham|No clown will be present in the room during labor
1473340|NCT03171870|Diagnostic Test|high resolution computed tomography|high resolution computed tomography is an essential component of the diagnostic pathway in idiopathic pulmonary fibrosis. Unusual interstitial pneumonia is characterized on high resolution computed tomography by the presence of reticular opacities, often associated with traction bronchiectasis
1473341|NCT03171844|Other|Skin to skin|3 sessions of skin to skin will be made on newborn wearing an umbilical venous catheter
1473342|NCT03171831|Drug|Busulfan|Busulfan（4 mg/kg/day,4 days）
1473343|NCT03171831|Drug|Cyclophosphamide|Cyclophosphamide（50 mg/kg/day,4 days）
1473344|NCT03171831|Drug|Fludarabine|Fludarabine（50 mg/m2/day,3 days）
1473345|NCT03171831|Drug|Mycophenolate mofetil|Mycophenolate mofetil（0.25g/day）
1473346|NCT03171831|Drug|Tacrolimus|Tacrolimus（0.03mg/kg/day）
1473347|NCT03171831|Drug|Methotrexate|Methotrexate（15mg/m2 on day +1,10mg/m2 on day +3,+6,+11）
1473348|NCT03171831|Drug|Thymoglobulin|Thymoglobulin（2.5 mg/kg/day,4 days）
1473349|NCT03171831|Drug|Basiliximab|Basiliximab（10mg on day 0 and +4）
1473350|NCT03171818|Drug|Darbepoetin Alfa|Darbepoetin alfa (Aranesp, Amgen) 2 doses of 10 microgram/kg i.v.
1473351|NCT03171818|Drug|Saline|The placebo will consist of saline, containing 9.0 g of salt per liter (0.90%) i.v.
1473352|NCT03171805|Drug|Propranolol|Propranolol was given after patients with cirrhosis and isolated gastric varices underwent balloon occluded retrograde transvenous obliteration successfully.
1473353|NCT03171792|Other|semi-structured interviews|Semi-structured face to face or telephone interviews with an open-ended approach. Duration: about 45 minutes. Audio-recorded. Exploration of the experience of taking care of the suffering adolescents.
1473354|NCT03171779|Other|Patients approaching the end of their lives|To determine whether the use of simple tools by a primary care team for the early identification of end-of-life patients can improve access to specialized palliative care resources
1473355|NCT03171766|Diagnostic Test|Mini-Mental State Examination (MMSE)|It is simple scored form of the cognitive mental status examination which includes eleven questions and requires only 5 to 10 minutes.
1473356|NCT03171766|Diagnostic Test|Visual Analog Scale (VAS)|Visual Analog Scale (VAS) for pain score (including aphasia, motor disability, major neurocognitive disorder, etc)
1473357|NCT03171766|Diagnostic Test|Mini Cog test|The Mini-Cog© test is another validated and simple tool to screen for dementia and cognitive dysfunction. It measures the cognitive reserve at the time of acute stress with a low degree of interobserver variability.
1473358|NCT03171753|Diagnostic Test|questionnaire|questionnarie will be performed before the application of headphone and after their removal.
1473359|NCT03171753|Diagnostic Test|laboratory test|laboratory test will be collected before the application of headphone and after their removal. the cardiac monitoring will be performed during the all study period
1473360|NCT03171753|Diagnostic Test|cardiac monitoring|the cardiac monitoring will be performed through study period
1473361|NCT03171753|Diagnostic Test|skin resistance|the skin resistance monitoring will be performed through study period
1473362|NCT03171753|Device|Music listening|Listening prerecorded music through an individual headset for 30 min
1473363|NCT03171753|Device|No sound|No sound through an individual headset for 30 min
1473364|NCT03171740|Drug|Dexmedetomidine|Intranasal dexmedetomidine, 1mcg/kg (it is a 100mcg/ml solution)
1473365|NCT03171740|Drug|Midazolam oral solution|Oral midazolam, 0.5mg/kg (its a 2mg/ml solution)
1473366|NCT03171740|Drug|Oral saline|Oral saline, 0.25ml/kg
1473367|NCT03171740|Drug|Nasal saline|Nasal saline 0.01ml/kg
1473368|NCT03171727|Drug|low molecular weight heparin|After TIPS procedure was performed, low molecular weight heparin was given for three days.
1473369|NCT03171714|Device|Derma-Stent|The novel device will facilitate self removal by patients, as it has a narrower profile, and, as a nonabsorbent material, will not become saturated with bodily fluids. Although it will not absorb body fluids
1473370|NCT03171714|Device|Usual care, cotton gauze packing|Standard gauze packing used to pack a drained abscess.
1473371|NCT03171662|Other|Evaluation of Pediatric Appendicitis Score|Imaging and Histopathological examination for Evaluation of Pediatric Appendicitis Score
1473406|NCT03171389|Drug|Ponatinib 30 MG|Ponatinib: once-daily oral dose of 30mg. A cycle of treatment is defined as 28 days. Doses may be reduced to manage drug-related adverse events and may be re-escalated once events resolve.
1473438|NCT03171129|Device|Adaptive Dynamic Inspiratory Nasal Apparatus|Oxygen will be administered via ADINA
1473439|NCT03171129|Device|High flow Nasal Canula|Oxygen will be administered via nasal canula
1473372|NCT03171649|Device|RETRAINER-S1|"It consists of the execution of different exercises with the affected arm supported by the RETRAINER-S1 device. The subject is actively involved in the exercises and the system provides two types of support: weight relief and FES. The following exercises can be performed:
anterior reaching (in a plane or in the space)
lateral elevation of the arm
hand to mouth movements with or without an object in the hand
moving objects on a plane or in the space. A subset of exercises is defined based on the patient's capability and the training time is equally shared between the selected exercises. The different training sessions can include different exercises and a different number of repetition for each exercise."
1473373|NCT03171649|Other|Conventional therapy|"It consists of a combination of different treatment modalities among the following, based on the petient's specific needs:
Upper limb passive motion
Arm Cycle ergometer with or without FES
Neuro Muscular Electrical Stimulation
Upper limb exercises using augmented or virtual reality environment
Occupational therapy exercises
Constraint induced movement therapy
Upper limb active movement (reaching, grasping, elevation, spatial orientation)
Repetitive task training
Mirror therapy
Writing training
Chemodenervation Therapy"
1473374|NCT03171623|Drug|globalagliatin hydrochloride|orally administration, single dose
1473375|NCT03171623|Drug|placebo|orally administration, single dose
1473376|NCT03171610|Drug|Sufentanil group|PCA device containing sufentanil (3 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
1473377|NCT03171610|Drug|Fentanyl group|PCA device containing fentanyl (20 mcg/kg), ramosetron (NaseaTM) 0.3 mg and ketorolac 120 mg in a normal saline with a total volume of 100ml was connected.
1473378|NCT03171597|Drug|Anti-Platelet Drugs|Including aspirin and clopidogrel, etc.
1473379|NCT03171597|Drug|Lipid Regulating Drugs|Mainly including statins
1473380|NCT03171597|Drug|Coronary Vasodilator|Mainly including nitrates
1473381|NCT03171597|Drug|Xuefu Zhuyu Decoction|Mainly including Peach Kernel, Safflower, Angelica, Bupleurum etc.
1473382|NCT03171597|Drug|Gualou Xiebai Banxia Decoction & Danshen Decoction|Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
1473383|NCT03171597|Drug|Shuanghe Decoction|Mainly including Ginseng, Poria, Calamus, Cyperus, Salvia miltiorrhiza, Radix Polygalae etc.
1473384|NCT03171584|Drug|Terbinafine|oral antifungal drugs
1473385|NCT03171571|Other|Coaching procedure|"In this study, the volunteers will be followed during one year. The wellbeing will be followed with :
survey like FFQ, SF36, dietary habits.
actimetry measurement
one year follow-up of weight, waist measurement
nutritional biomarkers"
1473386|NCT03171558|Procedure|Gastric Pull Up|Using gastric tissue to reconstruct the esophagus and pharynx after pharyngo-esophagectomy.
1473387|NCT03171558|Procedure|Free Flap Surgery|Using radial forearm free flap or anterolateral thigh free flap to reconstruct the cervical esophagus and pharynx after pharyngectomy and cervical esophagectomy.
1473388|NCT03171545|Behavioral|Patient Activation|Patients in clinics assigned to this group will be offered peer mentoring and digital resources.
1473389|NCT03171545|Behavioral|Provider Education|Staff in clinics assigned to this group will receive team training and workflow checklists
1473390|NCT03171532|Procedure|Strands of Hamstring Autograft in ACL reconstruction|The femoral and tibial ends will be tubularised and the final graft diameter will be recorded after passing through sizing cylinders graduated in 0.5mm increments. The femoral and tibial tunnels will be drilled as per standard technique for single bundle ACL reconstruction via trans-portal or trans-tibial route and both ends fixed by interference screw with additional post on the tibial end.
1473393|NCT03171506|Other|Ketogenic diet|Participants in the usual care plus ketogenic diet group will receive usual care plus dietary counseling in accordance with a ketogenic diet such that ~5% energy comes from carbohydrate, 25% energy from protein, and 70% energy from fat for the duration of the 12 week study.
1473394|NCT03171506|Other|AND diet|Participants in the usual care plus AND diet group will receive usual care plus dietary counseling in accordance with the Academy of Nutrition and Dietetics guidelines in 2013 for the duration of the 12 week study.
1473395|NCT03171493|Biological|MV-NIS|Attenuated measles virus encoding NIS (MV-NIS)
1473396|NCT03171480|Drug|Monoket Pill|Intra-vaginal application of Monoket as a cervical ripening agent for pregnant women undergoing induction of labor
1473397|NCT03171467|Procedure|Salpingectomy|
1473398|NCT03171454|Procedure|Delayed Intrauterine Balloon therapy|D-IUB dilatation therapy group will be performed using a (size 12-14fr) Foley catheter and according to the methodology published in the literature. This will be prepared by cutting the catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 5mls of saline will be slowly instilled into the balloon under ultrasound guidance.
1473399|NCT03171454|Procedure|immediate Intrauterine Balloon therapy|At the conclusion of the surgery, in the immediate balloon group: a Foley-catheter will be immediately inserted into the uterine cavity and the balloon will be distended with 4-5mls of saline under ultrasound guidance and the balloon will stay in situ for 7 days.
1473400|NCT03171441|Diagnostic Test|nailfold videocapillaroscopy|non-invasive nailfold videocapillaroscopy
1473401|NCT03171441|Diagnostic Test|inflammatory biomarkers|blood sample collection to asses leptin and C-reactive protein
1473402|NCT03171428|Procedure|Hepatectomy|Surgery for liver tumors is the removal of a part of the liver affected by a tumor.
1473403|NCT03171415|Drug|RZL-012|Subject receive a single-time injection. Multiple injections of RZL-012 are administered at 8-48 sites (0.1mL per site) into the abdominal subcutaneous fat.
1473404|NCT03171415|Drug|Placebo|Subject receive a single-time injection. Multiple injections of the Placebo are administered at 8-48 sites (0.1mL per site) into the abdominal subcutaneous fat.
1473405|NCT03171402|Diagnostic Test|Astringency and bitterness perception|Participants will be involved in 1-4 experiments that test how they rate and differentiate between bitter and astringent flavored beverage samples
1473436|NCT03171142|Drug|Heliox|Heliox (21:79) via nasal cannula 2 litter per minutes
1473437|NCT03171142|Drug|Air|Air 21% via nasal cannula 2 litter per minutes
1473407|NCT03171376|Procedure|Root canal treatment and coronal restoration|After primary root canal treatment, Glass Ionomer Cement (Ketac™ Molar, 3M ESPE) applied as intraorifice barrier 3mm inside canal from root canal orifice in first group, as 2mm base on floor of pulp chamber in second group and direct composite restoration in 3rd group without Intraorifice barrier or base.
1473408|NCT03171363|Behavioral|Gaze-contingent feedback|Participants will receive gaze-contingent feedback according to their viewing patterns
1473409|NCT03171350|Diagnostic Test|ellume.lab Group A Streptococcus Test|ellume.lab Group A Streptococcus Test is a rapid diagnostic test intended to be used as an aid in the diagnosis of Group A Streptococcus in symptomatic patients. The sample type used is a throat swab.
1473410|NCT03171337|Device|Acupuncture|Acupuncture at acupoints for CTTH according to TCM theory using stainless filiform needle.
1473411|NCT03171337|Device|Fu's Subcutaneous Needling (FSN)|Fu's subcutaneous needling at specific points for CTTH using soft casing needle.
1473412|NCT03171337|Device|Sham acupuncture|Sham acupuncture at non-acupoints using Steinberger placebo needles
1473413|NCT03171324|Drug|Iron Supplement|2 mg/kg/day elemental iron
1473416|NCT03171298|Procedure|Laparoscopic Assisted Transanal Total Mesorectal Excision|"Abdominal approach with laparoscopic mobilization of the left colon
Laparoscopic isolation and transection of inferior mesenteric vessels .
Transabdominal dissection of the upper rectum and mesorectam.
Insertion of transanal platform and the creation of pneumorectum.
Occlusion of rectum 2 cm distal to the rectal lesion via purse string.
Transanal dissection of lower and mid mesorectam
The specimen will be extracted transanally"
1473417|NCT03171285|Other|Less than 35 years old|Clinical and laboratory evaluations
1473418|NCT03171285|Other|Greater than or equal to 35 years|Clinical and laboratory evaluations
1473419|NCT03171272|Other|Inspiratory Muscle Training|"Experimental: IMT will include training of the inspiratory muscles five times per week over six weeks, divided into two fiftten-minute sessions of inspiratory training totaling 30 minutes of training. Thresholds regulated at 50% of the subjects' maximal inspiratory pressure values, the load being increased weekly. Associated with the IMT, subjects will participate in the rehabilitation program, when they will perform 7 sessions of physiotherapy per week, totaling 42 sessions, as well as 180 minutes per week of aerobic exercise, for six weeks.
Sham Group: This group will underwent exactly the same protocol but the participants will receive the threshold devices with the minimum resistance of the spring, which will be also concealed. The control group will also participate in the rehabilitation program and undergo the same procedures, except for the load adjustments."
1473420|NCT03171259|Other|care as usual|The investigators will be following patients with critical limb ischemia and documenting the usual care that the participants receive.
1473421|NCT03171246|Dietary Supplement|Solid food-based intervention|Individually tailored energy content according to age/activity
1473422|NCT03171233|Other|Mobilization with movement|Participants Mobilization Group with Movement are positioned knee facing the physiotherapist, are not elastic passages above the participant's malleolus and are from the physiotherapist's pelvis. The therapist applies a posterolateral slip sustained to a tibia through the belt, leaning backward, while the talus and forefoot are secured with the space between the thumb and the second finger of the hand of both hands. The participant will be instructed to perform a slow dorsiflexion movement for their maximum amplitude.
1473423|NCT03171233|Other|Self mobilization with movement|In the Auto Mobilization with Movement group, participants will self-mobilize the ankle on top of a box (15 centimeters with a 10 ° incline), a non-elastic band will pass below the malleoli and the back of the band will be placed in the middle of the other Lower limb, thus mobilizing the talus in the posteroinferior direction, the participant should maintain the force in that direction while making the dorsiflexion movement in closed kinetic chain until returning to the initial position again. Using the same group protocol as the therapist will help.
1473424|NCT03171220|Biological|Neoantigen Reactive T Cells(NRTs)|Neoantigen Reactive T Cells in an expected volume of 100 milliliter（mL） will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
1473425|NCT03171220|Biological|SHR-1210|SHR-1210 200mg will be administered as an intravenous infusion over 60 minutes.
1473426|NCT03171220|Drug|Fludarabine|Fludarabine(FLU) 30mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
1473427|NCT03171220|Drug|Cyclophosphamide|Cyclophosphamide(CTX) 300mg/m2/d×3d，3 days prior to each NRTs infusion as preconditional chemotherapy.
1473428|NCT03171220|Biological|Interleukin-2|Interleukin-2(IL-2)will be continuous intravenous infused since the first day of the cell infusion for 5 consecutive days, 4000,000 international unit per day.
1473429|NCT03171207|Device|Lite Run Gait Trainer|The Lite Run Gait Trainer is a novel device with pneumatic pants that can be used to assist with body support assisted gait therapy.
1473430|NCT03171207|Device|Current Harness System|There are a variety of harness systems (e.g., ceiling lift, Lite Gait) that are currently used to assist with body support assisted gait therapy.
1473431|NCT03171194|Drug|Low Dose Mesenchymal Stem Cells (MSCs)|Mesenchymal stromal/stem cells (MSCs) are cells that can be derived from umbilical cords, bone marrow, adipose tissue, and dental pulp, among other sites. MSCs have the ability to mediate a range of immuno-modulatory actions for both the innate and adaptive immune systems.
1473432|NCT03171181|Other|Vestibular reeducation|Balance quality was registered with static and dynamic posturography. For spatial orientation is was registered Visual vertical and visual orientation perception. Vestibular disability was also assessed. Variables were registered at the beginning and at the end of a vestibular rehabilitation in UPVD participants. Vestibular rehabilitation consisted of 10 sessions of vestibular rehabilitation using dynamic posturography and visual reeducation. Duration of each session: 40 minutes. Twice a week.
1473433|NCT03171168|Device|AposTherapy|AposTherapy is a home-based exercise program utilizing footwear that causes exercise with normal daily activity that may significantly improve function in patients with knee pain in general, and specifically knee osteoarthritis (OA).
1473434|NCT03171168|Other|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
1473435|NCT03171155|Device|XPro System|Implantation of the XPro System
1473441|NCT03171090|Other|sphenopalatine block with local anesthetic|bilateral ultrasonic guided sphenopalatine ganglion block using local anesthetic after induction of general anesthesia in maxilofacial cancer surgeries
1473442|NCT03171090|Other|sphenopalatine block with saline|bilateral ultrasonic guided sphenopalatine ganglion block using saline after induction of general anesthesia in maxilofacial cancer surgeries
1473443|NCT03171077|Other|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance in post-stroke patients.
1473444|NCT03171077|Other|PNF Method|It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
1473445|NCT03171077|Other|Virtual Rehabilitation and PNF Method|It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
1473447|NCT03171051|Device|950 nm LED Device|Device to be used in aesthetic and cosmetic procedures which consists of a console and an applicator belt that delivers the treatment LED to the subject's skin.
1473448|NCT03171051|Device|1050nm Diode Laser Device|FDA approved laser device that has been shown to reduce fat in the flanks by heating the fat cells and causing them to burst. The contents of the cells are then cleared naturally by the body.
1473449|NCT03171038|Other|Telemonitoring|
1473450|NCT03171025|Drug|Nivolumab|Nivolumab at a dose of 480 mg will be administered as an IV infusion over 60 minutes every 4 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 12 treatments over an expected duration of 1 year.
1473451|NCT03171012|Other|Lower limbs CRT|cycle ergometer for lower limbs
1473452|NCT03171012|Other|Upper limbs CRT|cycle ergometer for upper limbs
1473453|NCT03171012|Other|Proprioceptive Neuromuscular Facilitation|Proprioceptive Neuromuscular Facilitation patterns will be performed in seated, dorsal, ventral and side.
1473454|NCT03171012|Other|respiration|respiration
1473455|NCT03170999|Other|Focus group interview|Focus group interviews will take place to discuss the key domains of COPD exacerbation which then will be used in the formation of the draft item set.
1473456|NCT03170999|Other|Draft item set|Items that form the draft item set will be subject to cognitive debriefing. Questions in the draft item set will collect information on whether the subjects with COPD have experienced that item during an exacerbation. Changes in this draft set will result in the formation of candidate item set.
1473457|NCT03170999|Other|Candidate item set|Item reduction will be done using candidate item set and the subjects will be asked to respond to the candidate items on a 4-point scale in terms of how that item changed with the onset of the last episode. Item reduction will take into account frequency and magnitude of items, floor and ceiling items and consistency between regions. The candidate item set will then be used for generation of CERT.
1473458|NCT03170986|Behavioral|Multisectoral agriculture and Microfinance Intervention|
1473459|NCT03170973|Other|Exercise|After a 12-hour fast, volunteers will collect blood in the antecubital vein to measure basal serum values. 12 after the first blood collection they will perform a physical exercise session on a treadmill. The same will be divided in 3 times: heating, conditioning and cooling. The heating will be of 7 minutes, the cooling of 5 minutes and the time of conditioning will correspond to the energy expenditure of 250Kcal with light intensity based on Borg's perception of effort, that is, in the original scale a value between 9 and 11. After 24 hours after the first blood collection the volunteers will return to the laboratory after a 12-hour fast and blood samples will be collected again.
1473460|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at dose levels of 20 mg, 40 mg, or 60 mg.
1473461|NCT03170960|Drug|atezolizumab|Supplied as 1200-mg vials; administered as an IV infusion once every 3 weeks (q3w).
1473462|NCT03170960|Drug|cabozantinib|Supplied as 60-mg and 20-mg tablets; administered orally daily at the CRC-determined recommended dose from the Dose Escalation Stage
1473465|NCT03170934|Behavioral|Psychotherapy skills class|Rapid access, large-scale, psychotherapy classes that are open format and delivered in lecture style. One class - Managing Difficult Emotions (MDE) - is an 8-session, DBT-informed program. The other class - Mindfulness-Based Cognitive Behavioral Therapy (CBTm) - is a 4-session program.
1473466|NCT03170921|Other|Angola|The rhythm performance (Angola) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
1473467|NCT03170921|Other|Benguela|The rhythm performance (Benguela) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
1473468|NCT03170921|Other|São Bento|The rhythm performance (São Bento) had duration of 90 seconds. During recovery period (post- intervention) in the moments 1, 3, 5, 7, and 9 minutes was measured the physiological and the perceptual variables of the study.
1473469|NCT03170908|Behavioral|Interpersonal Psychotherapy|Interpersonal Psychotherapy (IPT) is an empirically-validated time-limited treatment for depression
1473470|NCT03170895|Drug|Sorafenib|Sorafenib a kinase inhibitor indicated for the treatment of Unresectable hepatocellular carcinoma; Advanced renal cell carcinoma
1473471|NCT03170895|Drug|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
1479084|NCT03126916|Biological|Sargramostim|Given SC
1473475|NCT03170869|Device|Surefire Precision Infusion System|All patients enrolled in this protocol will receive DEB-TACE, which is the standard of care prescribed by their physician. Standard 5 Fr and 3 Fr catheters will be used to perform diagnostic angiography to map the hepatic vasculature to the tumor. Using standard technique, the target vessel feeding the tumor will be catheterized and DEB-TACE administered using the Surefire Precision catheter. The Doxorubicin dosing used in the DEB-TACE will be based upon tumor volume. DEB-TACE will be administered until the first of the following endpoints are reached: Achievement of target dose with stasis, leeching of contrast through the expandable tip and development of distal intrahepatic collaterals.
1473476|NCT03170856|Other|Sub-maximal exercise|Subjects will participate in aerobic exercise 3 days a week. This includes walking, biking, jogging and running. While participating in these activities, they will be wearing their Polar Wrist Unit and Heart Rate Monitor to help subjects track their exercise intensity. They will exercise for 60 minutes three times a week at 60% of their maximum heart rate or 80% of their symptom limited heart rate.
1473477|NCT03170843|Device|use of plastic ring wound retractor|the experimental arm will use the plastic ring wound retractor for wound protection.
1473478|NCT03170830|Diagnostic Test|the diagnosis value of cUck2 in acute myocardial infarction.|Collect blood at different time points and compare cUck2 in three groups.
1473480|NCT03170791|Device|vagal nerve stimulation intervention|During exercise sessions the therapist will the therapist will press a switch to trigger a run of vagal nerve stimulation in time with the patient's activity. No further activity involved.
1473481|NCT03170765|Biological|Measles vaccine|Live attenuated measles vaccine of brands currently being used in National Immunization Schedule of India.
1473483|NCT03170739|Drug|Dexmedetomidine|Dexmedetomidine given during surgery.
1473484|NCT03170739|Drug|Dopamine|Dopamine given during surgery.
1473485|NCT03170726|Drug|arveles|Intraoperative and postoperative pain values between these three groups will be compared.
1473486|NCT03170726|Drug|intrafen 800 mg|ibuprofen 800 mg in normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
1473487|NCT03170726|Other|plasebos|normal saline 150 cc before operation will be given in 30 minutes. Intraoperative and postoperative pain values between these three groups will be compared.
1473488|NCT03170713|Drug|arveles|800 mg ibuprofen and 50 mg dexketoprofen in 150 cc normal saline before operation will be given in 30 minutes. The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
1473489|NCT03170713|Drug|intrafen|800 mg ibuprofen in 150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
1473490|NCT03170713|Other|placebos|150 cc normal saline before operation will be given in 30 minutes.The edema size, mouth opening (trismus) will be recorded in all patients in the preoperative period, postoperative period, postoperative 48th hour and 1 st week.
1473491|NCT03170700|Behavioral|Nutrition program with in-person parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active) and be provided with in-person parental feeding content.
1473492|NCT03170700|Behavioral|Nutrition program with online parental feeding content|Participants will attend the nutrition program (Eating Smart • Being Active). They will access parental feeding content online.
1473493|NCT03170687|Device|short foot cast|metatarsal foot cast
1473494|NCT03170687|Device|short leg cast|full short leg cast
1473495|NCT03170674|Other|FT21039|an electronic cigarette product
1473496|NCT03170674|Other|FT21092|an electronic cigarette product
1473497|NCT03170674|Other|FT21018|an electronic cigarette product
1473498|NCT03170661|Drug|Deep neuromuscular block|Deep neuromuscular block will be achieved with high dose rocuronium to achieve a depth of 1-2 twitches post tetanic count
1473499|NCT03170648|Device|Acupuncture|Acupuncture has been studied in clinical trials in cancer patients and has been shown to be helpful for management of pain, nerve damage from chemotherapy, and nausea
1473500|NCT03170635|Behavioral|Refreshing Recess program|6-week program integrated into recess in order to build capacity of recess supervisors to foster active play and socialization so that all students enjoy recess and socialization with peers.
1473504|NCT03170596|Drug|tazarotene gel 0.1%|Patients will be instructed to apply 0.1% tazarotene gel as a thin film over the affected area once daily in the evening.
1473505|NCT03170596|Device|Microneedling|Microneedling is a method of percutaneous collagen induction
1473506|NCT03170583|Device|St. Jude Medical Tendril MRI™ lead|pacemaker, leads
1473507|NCT03170570|Device|intensity-modulated radiotherapy|IMRT: intensity modulated radiotherapy, Treatment schedule: 4-7 weeks, 20-35 fractions, unless the stop indications were met, treatment will continue.
1473508|NCT03170557|Other|Traditional chinese acupuncture|Traditional chinese acupuncture (somatopuncture points, auriculotherapy points, craniopuncture and wrist-ankle acupuncture). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
1473509|NCT03170557|Other|Aspecific needle skin stimulation|Superficial needling of needles in skin areas outside the pain affected dermatome(s). Simultaneously, the usual pharmacological treatment for pain is maintained, based on clinical needs.
1948578|NCT02130557|Drug|Bosutinib|Bosutinib (Bosulif®) is an orally bioavailable, potent, multi-targeted, dual Src-Abl tyrosine kinase inhibitor (TKI) that has been approved for the treatment of adult patients with Philadelphia positive (Ph+) chronic phase (CP), accelerated phase (AP) and blast phase (BP) chronic myelogenous leukemia (CML) previously treated with other TKI inhibitor therapy.[1] This study will investigate the use of bosutinib as first-line treatment for patients with Ph+ CP CML.
1948579|NCT02130557|Drug|Imatinib|"Imatinib mesylate (referred to in this protocol as imatinib) is an inhibitor of the BCR-ABL kinase and been the standard first-line therapy for patients with chronic-phase CML. Imatinib was granted approval by the European Commission in November 2001 and by the FDA in December 2002 for the treatment of newly diagnosed patients with CP Ph+ CML based on results from the IRIS trial.
Imatinib is considered the standard of care for both first-line and later line settings, and consequently is an appropriate active comparator."
1948580|NCT02129205|Drug|PF-06650808|Dose Escalation Phase [Part 1] - PF-06650808 will be administered at doses starting at 0.2 mg/kg. Increases in dose will continue until MTD is determined.
1948581|NCT02129205|Drug|PF-06650808|Dose Expansion Phase [Part 2] - Patients will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
1948582|NCT02128997|Device|Closed incision wound vacuum (Prevena)|wound vacuum to be placed on a closed incision
1948583|NCT02127281|Device|Prevena|Device will be applied at end of procedure over closed incision.
1473521|NCT03170531|Diagnostic Test|Custom Designed Spine Coil|During the participant's MR scan, the custom spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.
1473522|NCT03170531|Diagnostic Test|FDA approved spine coil|During the participant's MR scan, the FDA spine coil will be placed between the participant and the immobilization mold. image parameters will be optimized for spine anatomy for the pulse sequences which are standard for MR imaging.
1473526|NCT03170505|Procedure|repairing fistula|A tailored piece of Acellular Dermal Matrix or Conchal Cartilage will be placed between the oral and nasal layers for repair of a Cleft Palate.
1473527|NCT03170492|Other|RehaCom Computerized Cognitive Training for 480 minutes|Student OT doctoral researchers will guide the subject when participating in the RehaCom program. RehaCom is computer hardware and software designed for assisted cognitive rehabilitation. The program is designed to target specific aspects of attention, concentration, memory, perception, and problem-solving. As the training goes on, the tasks will become easier or harder depending on the subject's performance. The first session will begin with a screening module with an example and a practice session to make sure the client understands the task. After screening, the results page shows the subject's performance compared with age-matched norms. This gives a helpful indication as to the severity of the deficit and advises the researcher on the particular training module to be used. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
1473528|NCT03170492|Other|Pencil-and-Paper Cognitive Training for 480 minutes|Student OT doctoral researchers will engage the subject in various pen-and-paper exercises designed to improve cognitive functions: attention and concentration, memory, language, calculation, and orientation. These could include, but are not limited to: word puzzles, calculation or number puzzles, and map reading. The subject will continue the training modules for a total of 480 minutes of training over 12 weeks.
1473529|NCT03170479|Dietary Supplement|Vitamin D|Two doses of Vitamin D supplementation in ampoules form (ED3) were procured. Ampoule contains Cholecalciferol in 200,000 IU both for oral and intra muscular use.
1473530|NCT03170479|Dietary Supplement|Ready to Use Therapeutic Food (RUTF)|RUTF is recommended by WHO for sever malnourished children in community settings as a therapeutic diet. The quantity depends upon the child body weight.
1473532|NCT03170453|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
1473533|NCT03170453|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
1473540|NCT03170401|Dietary Supplement|Protein supplementation|half the subjects will receive protein supplementation via enteral feedings and half will not receive the protein supplementation
1473541|NCT03170388|Drug|IDP-126 Gel|Gel
1473542|NCT03170388|Drug|IDP-126 Component A|Component A
1473543|NCT03170388|Drug|IDP-126 Component B|Component B
1473544|NCT03170388|Drug|IDP-126 Component C|Component C
1473545|NCT03170388|Drug|IDP-126 Vehicle Gel|Vehicle Gel
1473548|NCT03170362|Other|Pharmacogenetic Test|The intervention is a battery of pharmacogenetic test results that mostly affect the metabolism of antidepressants and other medications.
1473549|NCT03170349|Device|Mitral Valve Repair|Minimal Invasive Transcatheter Mitral Valve Repair
1473550|NCT03170336|Drug|Amiloride|Amiloride first for 8 weeks, then for a washout for 4 weeks, and cross over to receive hydrochlorothiazide for another 8 weeks.
1473551|NCT03170336|Drug|Hydrochlorothiazide|hydrochlorothiazide first for 8 weeks, then for a washout for 4 weeks, and cross over to receive amiloride for another 8 weeks.
1473552|NCT03170323|Drug|Mycophenolate Mofetil|steroid 1mg/kg/d and Mycophenolate mofetil 500mg bid
1473553|NCT03170323|Drug|Cyclosporins|steroid 0.15mg/kg/d and Cyclosporin 3-5mg/kg/d
1473554|NCT03170310|Drug|Apatinib|Apatinib500 mg,po,qd,continuous dosing until PD, death or not tolerated toxicity.
1473555|NCT03170297|Other|Research interventions of blood sampling and data collection|Patient-Specific Functional Scale (PSFS) survey will be administered to patients to record symptoms at both the time of evaluation in the emergency department and in follow up by phone at 3, 7, 14, 21 and 28 days after discharge from the emergency department or hospital. The rest of the patients' care will be as usual care, and patients will have had research interventions of blood sampling and data collection as noted in the previously approved SC2i Tissue Data Acquisition Protocol (TDAP) Pro00054947 (ClinicalTrial.gov ID: NCT02182180).
1473556|NCT03170284|Drug|Bevacizumab|Bevacizumab is prescribed by physicians as per SPC.
1473559|NCT03170258|Device|Real-time functional magnetic resonance imaging neurofeedback|During part of the task, a thermometer stimulus will be used to display the average VTA activity for each participant. This signal will be acquired every 1 second during the MRI session and will dynamically update to reflect ongoing changes in brain activity. This continuously updated thermometer is the primary feedback mechanism provided to the participant.
1473560|NCT03170245|Diagnostic Test|Interleukin-6|serum samples used for doing the test by ELISA
1473561|NCT03170245|Diagnostic Test|HsC-RP|serum samples used for doing the test by ELISA
1473562|NCT03170245|Diagnostic Test|Adiponectin level|serum samples used for doing the test by ELISA
1473563|NCT03170245|Diagnostic Test|Carotid intima media thickness|Done by carotid doppler
1473568|NCT03170219|Combination Product|subcutaneous furosemide and sc2wear device|subcutaneous furosemide administered via sc2wear device vs. standard of care
1473569|NCT03170206|Drug|Binimetinib|Binimetinib is also an oral drug which stops a signal that a cell receives, instructing it to grow.
1473570|NCT03170206|Drug|Palbociclib|It is a selective inhibitor of the cyclin-dependent kinases CDK4 and CDK6
1473571|NCT03170193|Drug|AMG 529|Ascending single doses of AMG 529
1473572|NCT03170193|Drug|Placebo|Calculated volume to match experimental drug
1473573|NCT03170180|Drug|Sunitinib|sunitinib 37.5mg daily
1473574|NCT03170180|Drug|Gefitinib|Gefitinib 250mg daily
1473575|NCT03170180|Drug|Imatinib|Imatinib 400mg daily
1473576|NCT03170141|Biological|GBM-specific CAR-IgT cells|"CAR IgT cells are infused intravenously or directly to the tumor location of the patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose .
Drug: cyclophosphamide 250 mg/m^2 d1-3 Drug: Fludarabine 25mg/m^2 d1-3"
1473577|NCT03170128|Procedure|Outpatient physical therapy in addition to standard follow-up visits|Patients in Group 1 will be given a prescription for outpatient physical therapy.
1473578|NCT03170128|Behavioral|Home exercises in addition to standard follow-up visits|Patients in Group 2 will be carefully instructed on home exercises for range of motion and strengthening of their affected elbow. All therapy regimens will be prescribed at initial presentation, as is the current practice. All other care will be identical for patients in both groups. This
1473579|NCT03170115|Drug|Aspirin|chemoradiotherapy with capecitabine and aspirin Aspirin daily during chemoradiotherapy
1473580|NCT03170115|Drug|Placebo Oral Tablet|chemoradiotherapy with capecitabine and placebo Placebo daily during chemoradiotherapy
1473581|NCT03170102|Other|Building capacity through education|Participants engaged in 2 webinars and 3 online discussions following reading selected material.
1473582|NCT03170089|Behavioral|Oral Health Educational Program|Oral Hygiene methods learned
1473583|NCT03170063|Procedure|Procedure/Surgery: Biofluid samplings|Biofluid samplings (blood and cerebrospinal fluid (CSF))
1473584|NCT03170050|Device|YYD701-2|HA Filler
1473585|NCT03170050|Device|Restylane Perlane Lidocaine|HA Filler
1473610|NCT03169842|Device|pancreatic cyst fluid glucose analysis using a bedside glucometer|Small amount of pancreatic cyst fluid will be analyzed for glucose level using a bedside glucometer from EUS-FNA procedures.
1473586|NCT03170037|Procedure|Standard V-E ventilation technique|For the two-handed standard V-E technique, the facemask is first placed over the bridge of the nose and mouth and then held in place by performing at two-handed jaw thrust maneuver with the index and second finger of each hand and maintaining mask contact with the patient's face by using both thumbs with mouth open. A head-tilt is performed by applying a caudal force on the mandible and mask.
1473587|NCT03170037|Procedure|Reversal V-E ventilation technique|While using reversal V-E technique, the anesthesia provider stands 180 degrees opposite from the head of the bed. Thenar eminence and thumbs secure the mask around the nose while the remaining fingers pull the mandible anteriorly while keeping the mouth open.
1473588|NCT03170011|Behavioral|Exercise using the Biodex Sit2Stand Trainer|Week 1-2 - Focused on lower intensity, higher volume, comfortable/self-selected velocity Week 3-4 - Focus on higher intensity, lower volume, comfortable/self-selected velocity Week 5 - Focus on moderate intensity, moderate volume, transitioning to higher velocity Week 6 - Focus on moderate intensity, moderate volume, high velocity
1473589|NCT03169998|Device|EV1000 platform|a continuous arterial pressure monitoring was performed via EV1000/ FloTrac (Edwards Lifesciences, Irvine, CA, USA) (Fig 1) with the continuous monitoring of cardiac index (CI), stroke volume index (SVI) and stroke volume (SV).
1948584|NCT02124642|Dietary Supplement|Folic acid, 400 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements).
1473593|NCT03169959|Drug|2.5 mg Saxagliptin tablet|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with Type 2 diabetes mellitus (T2DM).
1473594|NCT03169959|Drug|5 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of sodium-glucose co-transporter 2 (SGLT-2), reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
1473595|NCT03169959|Drug|Triple FCDP - 2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.
Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
1473596|NCT03169959|Drug|5 mg saxagliptin|A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.
1473597|NCT03169959|Drug|10 mg dapagliflozin / 1000 mg metformin XR tablet|"Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
1473598|NCT03169959|Drug|Triple FCDP - 5 mg saxagliptin / 10 mg dapagliflozin / 1000 mg metformin XR|"Saxagliptin - A competitive dipeptidyl peptidase-4 (DPP-4) inhibitor, slows the inactivation of the incretin hormones, thereby increases their bloodstream concentrations and reduces fasting and post-prandial glucose concentrations in a glucose-dependent manner in subjects with T2DM.
Dapagliflozin - An inhibitor of SGLT-2, reduces re-absorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion.
Metformin - Lowers both basal and post-prandial plasma glucose by decreasing hepatic glucose production and intestinal absorption of glucose; improves insulin sensitivity by increasing peripheral glucose uptake and utilization."
1473599|NCT03169946|Procedure|RCT with CHX-MTZ,OFD|Endodontic treatment using chlorhexidine metronidazole combination as an intracanal medicament along with open flap debridement .
1473600|NCT03169946|Procedure|RCT with CHX,OFD|Endodontic treatment using chlorhexidine as an intracanal medicament along with surgical periodontal therapy in form of open flap debridement.
1473601|NCT03169933|Radiation|Combined, intensified and modulated adjuvant radiotherapy|
1473602|NCT03169920|Procedure|Modified-Minimally Invasive Surgical Technique + PRF|
1473603|NCT03169920|Procedure|Modified-Minimally Invasive Surgical Technique|
1473604|NCT03169907|Radiation|Mid trimesteric fetal ultrasonography|"Venous and arterial Doppler indices:
Middle cerebral artery (MCA) peak systolic velocity (PSV):
Umbilical Artery Pulsitility Index (PI) and Resistant Index (RI):
Ductus venosus (DV) Doppler:
Cardiac functions:
Global cardiac function evaluated by Modified Myocardial Performance Index (Mod-MPI):
Systolic cardiac function using the four-dimensional (4D) spatiotemporal imaging correlation (STIC) ultrasound technique:
Diastolic cardiac function evaluated by relationship between the maximal velocities of the E and A waveforms of ventricular filling (E/A ratio)"
1473605|NCT03169894|Drug|MDGN-002|MDGN-002 is a fully human IgG4 monoclonal antibody specific to human LIGHT.
1473606|NCT03169881|Drug|Darbepoetin|Darbepoetin 10 micrograms/kg/once every week (IV or SC). Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
1473607|NCT03169881|Drug|Placebo|normal saline for IV administration, or sham dosing. Infants will be treated until 35 completed weeks gestation, discharge, or transfer to another hospital.
1473608|NCT03169868|Diagnostic Test|Sano Patient Medication Profile|The Sano Patient Medication Profile (PMP) is a graphical report comparing prescribed medications to LC/MS/MS-detected drugs from patient blood samples
1473609|NCT03169855|Diagnostic Test|Slit lamp (LOCS III Score)|Diagnostic procedure only
1473614|NCT03169816|Drug|Lorcaserin|Lorcaserin 10mg, twice daily
1473615|NCT03169816|Drug|Placebo|Matched placebo for lorcaserin condition dosed twice daily
1473616|NCT03169803|Device|NeuroTronik CANS Therapy™ System|The NeuroTronik CANS Therapy™ System is a percutaneous, catheter-based, bedside electrical stimulation system. The System consists of the single-use, disposable NeuroCatheter™ and NeuroCatheter™ Placement Kit, along with the reusable, bedside NeuroModulator™ Development System, and the NeuroTronik CANS Therapy™ Cable.
1948585|NCT02124642|Dietary Supplement|Folic acid 800 mcg/day|The supplement regime for this arm will consist of (1) a women's multivitamin/ multimineral (MVM) supplement containing 400 mcg folic acid, (2) a capsule containing 200 mg DHA and (3) a capsule formulated to contain 10 mg iron (which represents the difference in the amount of iron in the women's MVM formulation and that in prenatal MVM supplements) and 400 mcg folic acid.
1473698|NCT03169725|Biological|Inactivated Poliomyelitis Vaccine (Sabin strain)|Investigational IPV based on Sabin strain (LBVC). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
1473699|NCT03169725|Biological|Inactivated Poliomyelitis Vaccine (Salk strain)|Commercialized IPV based on Salk strain (Imovax Polio). Should be injected by intramuscular three injections in the anterolateral aspect of thigh at 6, 10 and 14 weeks of age.
1473700|NCT03169712|Behavioral|Cognitive Behavioral Therapy for PTSD|Trauma-focused CBT protocol elaborated by Marchand and Guay from the Trauma Studies Centre at Louis-H. Lafontaine Hospital in Montreal and adapted from Foa, Hembree and Rothbaum (2007)
1473701|NCT03169712|Behavioral|Imagery Rehearsal Therapy|IRT protocol published by Nappi and collaborators (2010)
1473702|NCT03169686|Behavioral|Cognitive and Behavioral Intervention|Participants who allocate to the intervention group will receive regular messages providing smoking cessation related information, such as advice, support, and distraction by professional team.
1473703|NCT03169673|Diagnostic Test|Hyperpolarized Helium 3 Magnetic Resonance Imaging|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 3He gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
1473704|NCT03169660|Drug|Vascular endothelial growth factor trap-eye|Intravitreal injection of vascular endothelial growth factor trap-eye During the first 3 months, 3 monthly injections are performed After 3 serial injections, additional injections are performed once per 2 months
1473705|NCT03169647|Behavioral|Listening-based intervention|Participants will listen to pre-specified material on a CD
1473706|NCT03169634|Procedure|short or long stemmed rTKR cemented|An evaluation of the outcomes of different ways of performing revision total knee replacement surgery
1473707|NCT03169634|Procedure|Cone with short stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with short stems is cemented in to it
1473708|NCT03169634|Procedure|Cone with long stem|Revision knee replacement using a metaphyseal cone and then a knee replacement with long stems is cemented in to it
1473709|NCT03169621|Procedure|Endometrial Biopsy and endometrial fluid collection|"On day 20 of the cycle, the doctor will perform endometrial fluid aspiration (EF) followed by an endometrial biopsy (EB) the same day of hysteroscopy that is performed as usual clinical practice. EF sample will be analyzed by molecular techniques (Next Generation Sequencing) for the detection of infectious agents and the EB sample will be divided into three parts, one of them will be used for molecular analysis (as control of the bacterial content present in the EF) and the others will be used for microbiological analysis and histological techniques respectively.
The Assisted Reproductive Treatment (ART) will be performed once the specialist considers it appropriated according to the clinical standard practice and the reproductive rates will be correlated with the diagnosis of CE comparing the results of ART before and after its diagnosis of CE."
1473710|NCT03169595|Procedure|Surgery|Patients affected by epithelioid hemangioma treated with surgery
1473713|NCT03169569|Procedure|Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) group|For patients in the study group, after hemostasis on the post-resection ulcer using conventional method and removal of specimen, Endo-clot™ (EndoClot Plus, Unc., Santa Clara, CA, USA) was applied immediately onto the post-resection surface.
1473714|NCT03169569|Procedure|Hemostatic forceps Only (Coagrasper®, Olympus, Japan) group|All ESDs were performed according to the standard procedure sequence in the hemostatic group and control group except hemostatic powder application.
1473717|NCT03169543|Behavioral|Sleep deprivation|36-hours total sleep deprivation
1473718|NCT03169530|Other|Alcohol|~15 gm daily of beer, wine, or spirits for ~6 years
1473719|NCT03169504|Other|Acupuncture|Feishu (BL13), Dazhui (DU14) and Fengmen (BL12) will be selected as main acupoints. There are four groups of acupoints: Taiyuan (LU9) and Zusanli (ST36) for Qi deficiency of the lung ZHEGN, Taiyuan (LU9), Pishu (BL20) and Zusanli (ST36) for Qi deficiency of the lung and spleen ZHEGN, Taiyuan (LU9), Shenshu (BL23) and Zusanli (ST36) for Qi deficiency of the lung and kidney ZHEGN, and Gaohuang (BL43), Shenshu (BL23), Taixi (KI3) and Guanyuan (RN4) for Qi and Yin deficiency of the lung and kidney ZHEGN. Besides, acupoints for specific symptoms will also be considered. Hwato Sterile Acupuncture Needles For Single Use (Hwato®, Suzhou Hua Tuo Medical Instruments Co., Ltd.) size in 0.30*25 mm, 0.30*40 mm or 0.30*50 mm will be used 3 times weekly for 12 weeks.
1473720|NCT03169504|Drug|Conventional drug|"Salbutamol Sulphate Inhalation Aerosol (Ventolin®, GlaxoSmithKline Australia Pty Ltd.), 100 μg/press, 200 press, 100 μg each time (when needed), no more than 8 press daily for 12 weeks.
Tiotropium Bromide Powder for Inhalation (Spiriva®, Boehringer Ingelheim International GmbH), 18 μg/capsule, 10 capsule, 18 μg each time, once daily for 12 weeks.
Fluticasone Propionate Powder for Inhalation (Seretide®, Laboratoire GlaxoSmithKline), 50ug/250μg/inhalation, 60 inhalations, 50ug/250μg each time, twice daily for 12 weeks."
1473721|NCT03169504|Other|Acupuncture plus conventional drug|Both acupuncture and conventional drug will be used for 12 weeks treatment.
1473722|NCT03169491|Device|Continuous positive airway pressure (CPAP)|CPAP dispositives will be used by the children in the study every night for two weeks. Devices AutoSet Spirit from ResMed.
1473723|NCT03169478|Procedure|multiple myoma IUB dilatation group|A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and stretching and blunt dissection of any intrauterine adhesions, if present.
1473724|NCT03169465|Procedure|open approach|open excision of the bursa and deformity then debridement of Achilles tendon
1473725|NCT03169465|Procedure|endoscopic approach|excision of the bursa and deformity then debridement of Achilles tendon through endoscopy
1473726|NCT03169452|Device|Non-invasive mechanical ventilator|mechanical assisted breaths without the placement of an artificial way
1473727|NCT03169439|Procedure|Irreversible electroporation|minimal invasive ablative technique for tumors
1473728|NCT03169426|Drug|Beta Blockers Carvedilol Phosphate|Subjects are going to take Beta Blockers Carvedilol Phosphate (12.5mg once) before undergoing remote ischemic conditioning.
1473729|NCT03169413|Genetic|Human Leucocytic antigen typing and mutation of adenosine triphosphate sensitive K channel gene in diabetic patients diagnosed under the age of one year.|Gene study
1473730|NCT03169400|Device|Theranova dialyzer|Hemoadialysis
1473731|NCT03169387|Behavioral|Virtual Reality|For the VRG training, Microsoft's Xbox 360® will be used with Kinect™, which features an infrared camera sensor that recognizes user movements without a controller. The games used will be YourShape™(Fitness Evolved) and Dance Central 3™, which will be played for 25 minutes each; the former will be associated with the use of Velcro weights on the ankles and dumbbells in the hands to provide resistance.
1473732|NCT03169387|Behavioral|Conventional Training|treadmills (embreex) will be used to perform the aerobic training for a period of 30 minutes and free weights and weight training equipment for the resistance training, which will be carried out in 3 sets of 10 repetitions, with a recovery interval of 1 minute between sets.
1473734|NCT03169361|Drug|Ixazomib|Ixazomib capsules
1473735|NCT03169348|Drug|sofosbuvir daclatasvir|oral tablets
1473736|NCT03169348|Drug|Ledipasvir/sofosbuvir|oral tablets
1473737|NCT03169335|Drug|QL1101|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
1473738|NCT03169335|Drug|Avastin®|targeted vascular endothelial growth factor (VEGF) monoclonal antibodies
1473739|NCT03169335|Drug|Paclitaxel|175 mg/m2, IV (in the vein) following investigational product on day 1 of each 21 day cycle. Number of cycles 4-6.
1473740|NCT03169335|Drug|Carboplatin|AUC 5 IV, (in the vein) following paclitaxel on day 1 of each 21 day cycle. Number of cycles: 4-6.
1473741|NCT03169322|Procedure|SRP|patients having chronic periodontitis with mouth breathing habit will receive scaling and root planing
1473742|NCT03169309|Device|Brain Entrainment Technology|Brain Entrainment Technology (BET), also known as Binaural Beat Technology (BBT), is a sound technology where two slightly different tones are present to each ear and the brain produces a third tone. This third tone impacts the reticular activating system which alters the action potentials of the thalamus and cerebral cortex in turn changing the brain wave frequency to alter the state of consciousness of the listener.
1473743|NCT03169283|Other|Cereal with B glucan|A cereal high in viscous dietary fiber B glucan
1473744|NCT03169283|Other|Cereal without B glucan|Cereal without B glucan
1473811|NCT03168763|Behavioral|Video|Participants shown Video 1A or 1B, then shown Video 2A or 2B.
1473745|NCT03169270|Other|Exercise training|All subjects performed a supervised 8-week, 5 days-week of endurance exercise training program in cycle-ergometer Each session included 5 minutes of warm-up and cool-down pedalling at 30% of peak work-rate (WR) and 50 minutes of interval training. The interval training combined 2 minutes of high-intensity pedalling and 3 minutes of active rest. Work-rate progress during the 8-week period was tailored on individual basis, according to subjects' symptoms, to maximize the training effect. During the first 2 weeks, high intensity pedalling interval was at least 70% of peak WR and active rest interval was at least 40% of peak WR. Thereafter, work-rate was increased by approximately 5% every week up to a maximum of 100% of peak WR during the last 2 weeks for the high intensity period and 50% of peak WR for the active rest. The cycling rate during the sessions was maintained at 60-70 rpm.
1473746|NCT03169257|Behavioral|diet plus physical activity|OB subjects will undergo an isocaloric Mediterranen balanced diet plus a daily aerobic training for at least 60 minutes. All the evaluations will be performed at baseline and after 6 and 12 months of this behavioral therapy. To assess food consumption, foods will be divided according to the classic basic food groups by the Italian Institute of Research on Food and Nutrition. Food frequencies questionnaires, validated for a wide range of ages, will be also completed by parents. Physical activity will be recorded by parents daily on a specific questionnaire.
1473747|NCT03169244|Drug|Bupropion|Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
1473748|NCT03169244|Drug|Placebo Oral Tablet|Placebo will be initiated on Day 1 and continue throughout the course of the study.
1473749|NCT03169231|Biological|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
1473750|NCT03169231|Other|Placebo|Intravenously delivered
1473751|NCT03169218|Other|Mirror therapy|The treatment proposed for the mirror group consisted of 8 weeks of treatment, performing a series of exercises 2 times a day / 4 times a week. The first 4 weeks the treatment was done in the hospital next to the physiotherapist for 2-3 days a week, and the next 4 weeks the patient performed the exercises following the same guidelines at home.
1473752|NCT03169218|Other|Placebo group|The treatment was the same than proposed in inference group but with a mirror covered to avoid the reflexion on the hand and looking at the hand that did not remain hidden.
1473753|NCT03169205|Other|observation registry|observation registry
1473754|NCT03169192|Drug|Zoledronic Acid|intravenous injections once every 3 months
1473756|NCT03169166|Drug|Triptorelin|Triptorelin pre-filled syringes (Gonapeptyl 0.1mg; Ferring GmbH, Germany) will be administered subcutaneously in three repeated doses 12 hours apart
1473757|NCT03169153|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
1473758|NCT03169153|Device|Senofilcon C contact lenses|Silicone hydrogel contact lenses used as per their Conformité Européenne (CE) marking
1473759|NCT03169140|Device|TheraBand Kinesiology Tape|A 20 cm strip of tape will be applied to each side of the low back directly over the erector spinae muscles at the site of pain. This tape will remain there, and be reapplied when necessary, for one week.
1473760|NCT03169140|Device|Biofreeze|The topical analgesic will be sprayed directly on top of the erector spinae and site of pain low back directly, from inferior to superior to inferior 4 times a day for one week.
1473761|NCT03169140|Behavioral|Advice|An at-home pain management care sheet, outlining standard care advice will be followed for at home pain management for one week.
1473762|NCT03169127|Drug|Ibuprofen 600 mg|After lower third molars surgeries, pharmacogenetic and clinical efficacy of Ibuprofen 600mg was study.
1473763|NCT03169114|Drug|Amikacin Injection|Participants allocated to Antibiotic Non-operative Management Strategy will be given intravenous Amikacin 15mg/kg/day divided over 3 doses for first 48 hours and followed by oral ciprofloxacin 500mg bd for 7 days
1473764|NCT03169114|Procedure|Appendicectomy|Patients allocated to Surgery Management Strategy will undergo appendicectomy
1473765|NCT03169101|Drug|Nicotine patch|"All participants will receive nicotine patches to aid in quitting smoking. TN is available over the counter and is very well tolerated. Participants will use the patch in a tapering fashion as recommended by the manufacturer. Participants who smoke 10 or more cigarettes per day will adhere to the following dosing guidelines: 21 mg for 4 weeks; 14 mg for 2 weeks and 7 mg for 2 weeks. Individuals who smoke between 5 and 9 cigarettes per day will follow a modified dosing regimen: 14 mg for 6 weeks and 7 mg for 2 weeks."
1473766|NCT03169101|Behavioral|Behavioral counseling|Participants will attend 6 counseling sessions and receive standard smoking cessation counseling (SC).
1473767|NCT03169088|Other|Coaching procedure|"In this study, the volunteers will be followed during one year.
The wellbeing will be followed with :
survey like FFQ, IPAQ, SF36, dietary habits.
actimetry measurement
one year follow-up of weight, waist measurement
nutritional biomarkers"
1473768|NCT03169075|Behavioral|SSPA|"A weekly supervised SPA session of 60 min at the patient's home is planned for 3 months.
These sessions will be supervised by an educator or physiotherapist trained, with respect to the pathology and the clinical study, specifically for this activity (Fédération Française Sport et Cancer) . The proposed exercises will be normalised and adapted to each patient's profile.
Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT modul AC/S, FACT-Gog, HADS, IPAQ, Evaluation by a coach VAE"
1473769|NCT03169075|Behavioral|PA|"Program based on the recommendations for performing a physical activity A booklet containing physical activity recommendations will be given to the patients after randomisation.
The weekly sessions at the patients home for the experimental group (Program A) must begin as soon as possible within the 15 days after starting oral targeted therapy.
Self reported questionnaires: FACT-F, FACT-G, EQ-5D, FAACT modul AC/S, FACT-Gog, HADS, IPAQ"
1473770|NCT03169062|Device|Gated Stationary Chest Tomosynthesis|The technologist will comfortably position the patient laying face up on the imaging table. EKG leads will be placed in appropriate positions to derive an EKG signal. The EKG will be used to trigger the image collection. The subject will be asked to hold his or her breath for 25-30 seconds during the scan. Total patient preparation and imaging time should not exceed 20 minutes.
1473812|NCT03168763|Behavioral|Questionnaires|Questionnaires completed at baseline, after each video viewing, and at completion.
1473771|NCT03169049|Device|High-Frequency Stimulation|high-Frequency electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1473772|NCT03169049|Device|sham Stimulation|Sham transcutaneous electrical stimulation over superficial ulnar and median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1473773|NCT03169023|Behavioral|ScaleDown|-Participants receives behavioral prompts and daily feedback by text messaging with motivational instructions for specific dietary and behavior modifications
1473774|NCT03169023|Behavioral|Enhanced Usual Care Packets|-From the American Cancer Society Website
1473775|NCT03169023|Other|12-Item Short Form Health Survey|-Measures functional health and well-being from the patient's perspective
1473776|NCT03169023|Other|International Physical Activity Questionnaire short form|-7 item scale that measures a range of physical activity from vigorous to sedentary over the last 7 days
1473777|NCT03169023|Other|Multidimensional Body Self Relations Questionnaire - Appearance Subscales|-Gold-standard for the assessment of body image attitudes and contains 34 items
1473778|NCT03169023|Other|Cancer-Related Body Image Scale|-13 item scale adapted from The Breast - impact of Treatment Scale, which assesses survivors' intrusive thoughts and avoidant behaviors with respect to their bodies since cancer treatment
1473779|NCT03169023|Other|Patient Health Questionnaire 9-Item Version|-Widely used measure that assesses mood, including an item that screens for suicidality
1473780|NCT03169010|Other|laboratory biomarker analysis|Laboratory results will be analysed to identify disease related biomarkers.
1473781|NCT03169010|Genetic|Genetic analysis|Gene sequencing results will be analysed to identify disease related mutations.
1473782|NCT03168997|Drug|Memantine Hydrochloride|Memantine Hydrochloride treatment according to clinical routine treatment
1473783|NCT03168984|Drug|UCB0942|"Pharmaceutical form: Film-coated tablet
Route of administration: Oral use"
1473784|NCT03168984|Other|Placebo|"Pharmaceutical form: Film-coated tablet
Route of administration: Oral use"
1473785|NCT03168971|Behavioral|Managing Anxiety from Cancer (MAC)|The intervention consists of seven telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques, problem-solving strategies, and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
1473786|NCT03168958|Drug|Methadone|Methadone will be provided at induction of anesthesia
1473787|NCT03168958|Drug|Saline|Saline will be administered at induction of anesthesia
1473788|NCT03168945|Other|GeneXpert MTB/RIF|Screening intervention: novel diagnostic for active case finding (GeneXpert MTB/RIF) for TB collected and performed at point-of-contact in a mobile van
1473789|NCT03168945|Other|Smear microscopy|Screening intervention: routine diagnostic test (smear microscopy) for active case finding for TB on sputum collected at point-of-contact in a mobile van but sent to laboratory
1473790|NCT03168919|Radiation|Fractionated Radiation|Standard of care fractionated radiation therapy will be given to the tumor.
1473791|NCT03168919|Drug|Temozolomide|Standard of care temozolomide will be given along with radiation therapy
1473792|NCT03168919|Device|MRI|Four MRI scan will be performed according to the protocol. The first one will be obtained before start of radiation therapy, the second MRI will be obtained after completion of 20 +/- 4 Gy, the third MRI will be obtained after completion of 40 +/- 4 Gy, and the final MRI will be obtained after completion of the radiation therapy.
1473793|NCT03168906|Drug|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
1473794|NCT03168906|Drug|Placebo|Saline bag
1473795|NCT03168893|Device|Deep brain stimulation ON|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is activated
1473796|NCT03168893|Device|Deep brain stimulation OFF|Infinity model of deep brain stimulation is placed ( 2 brain elecrodes and subcutaneus generator ) under general anhestesia. The system is not activated
1473797|NCT03168880|Drug|Paclitaxel + Carboplatin|Platinum based chemotherapy against the standard taxane based chemotherapy in the neo- adjuvant setting
1473798|NCT03168880|Drug|Paclitaxel only|
1473799|NCT03168867|Behavioral|The 3Ms Intervention|The 3 Ms is a brief e-health intervention delivered via an internet-based software application (CIAS) that incorporates principles of Motivational Interviewing. The goal of the 3 Ms intervention is to increase caregiver motivation to supervise children's daily diabetes care. The intervention consists of 3 brief sessions that are delivered at routine diabetes clinic appointments.
1473800|NCT03168854|Biological|Genetically-attenuated p52-/p36-/sap1- Plasmodium falciparum parasite (GAP3KO) strain|Genetically attenuated parasite created by triple deletion (GAP3KO) by deleting the P52, P36, and SAP1 genes in the NF54 wild-type (WT) strain of Plasmodium falciparum (Pf p52(-)/p36(-)/sap1(-) GAP).
1473801|NCT03168854|Other|Malaria challenge|Exposure to mosquitoes infected with P. falciparum.
1473802|NCT03168841|Drug|Efinaconazole Topical|Enrolled subjects will be dispensed medical for topical application, and followed for a period of 50 weeks.
1473803|NCT03168828|Drug|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
1473804|NCT03168815|Device|High Flow Nasal Cannula|High Flow Nasal Cannula or Low Flow Nasal Cannula
1473805|NCT03168802|Procedure|MRgFUS ablation|Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.
1473806|NCT03168802|Procedure|Radiofrequency ablation|Radiofreuqency ablation therapy under C-arm navigation for facet joint syndrome.
1473807|NCT03168789|Behavioral|Tension Tamer (TT)|Tension Tamer is an app that provides training and motivation for breathing awareness meditation (BAM). The app also tracks heart rate values during each session by placing a finger tip over the rear camera.
1473808|NCT03168789|Behavioral|Lifestyle education program (SPCTL)|SPCTL group will use Runkeeper app to log physical activity. They will also receive text messages with short healthy lifestyle tips, and links to media with pamphlets or videos with more in-depth information.
1473816|NCT03168724|Behavioral|GMT intervention|
1473819|NCT03168698|Drug|Carbetocin|Patient is given carbetocin (20 or 100 mcg) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
1473820|NCT03168698|Drug|Oxytocin|Patient is given oxytocin (0.5 or 5 IU) intravenously over 1 minute, immediately upon delivery of the anterior shoulder of the baby.
1473821|NCT03168685|Device|SureSource Engage application|"Eligible patients who choose to participate in the study will be asked to wear an actigraphy device [ActiGraph GRT9X Link Actigraph Link] on their wrist continuously during both 4-week study phases.
The ActiGraph Link is a small (3.5 X 3.5 X 1 cm) wristwatch like device weighing approximately 14 grams that measures indicators of the wearer's activity and sleep patterns, including: acceleration, energy expenditure, steps, basal metabolic rate, activity intensity, sleep time, sleep efficiency, sleep latency, and body position.
The application being utilized is SureSource Engage application from Clinical Ink. The application is compatible to most Android and iOS devices.
Participants will also use a basic Bluetooth-enabled weight scale that syncs with the application."
1473822|NCT03168672|Device|Global ICON|The study device is the GLOBAL ICON stemless humeral component, consisting of the Anchor Plate and Humeral Head.
1473823|NCT03168659|Device|HeartLight|HeartLight Endoscopic Ablation System
1473824|NCT03168659|Procedure|Ablation|Pulmonary vein isolation ablation
1473825|NCT03168646|Procedure|wafer procedure|wrist arthroscopy and debridement of Triangular fibrocartilage and shortening of the head ulna by burr
1473826|NCT03168646|Procedure|arthroscopy and ulnar shortening osteotomy|wrist arthroscopy,debride debridement of Triangular fibrocartilage and shortening of the ulna by osteotomy and plate
1473827|NCT03168633|Behavioral|web-based DM2 information pages|"Each email will include information on one of the following topics:
The importance of physical activity
Correct nutrition
The importance of adhering to medication regimens.
Emails will be either positive (e.g., the importance of good nutrition, and what constitutes good nutrition) or negative (e.g., the risks of not adhering to medications).
The information will be provided by different approaches: medical research results, practical tips, patient testimonies.…"
1473828|NCT03168620|Procedure|Restoration|
1473829|NCT03168607|Drug|FOLFIRI Protocol|Irinotecan：180mg/m2 ，iv drip for 90min d1, 5-FU 2400mg/m2, iv drip for 46h, 5-FU 400mg/m2 iv d1, CF 200mg/m2 iv drip for 2h d1, q2W
1473830|NCT03168594|Drug|irinotecan cisplatin|Irinotecan：60mg/m2 ，iv drip for 90min，d1,8 q3W cisplatin: 60mg/m2 ，iv drip for 120min，d1 q3W
1473831|NCT03168594|Drug|Etoposide cisplatin|Etoposide：100mg/m2 ，iv drip for 60min，d1-3 q3W cisplatin: 75mg/m2 ，iv drip for 120min，d1 q3W
1473832|NCT03168581|Drug|CN-105|Patients with supratentorial intracerebral hemorrhage (ICH) will be evaluated for eligibility within 12 hours of symptom onset. Eligible participants will receive CN-105 administered intravenously (IV) for a 30 -minute infusion every 6 hours for up to a maximum of 3 days (13 doses) or until discharge (if earlier than 3 days)
1473833|NCT03168568|Drug|Valsartan/Sacubitril or placebo|tablet (double dummy)
1473834|NCT03168568|Drug|Valsartan or placebo|tablet (double dummy)
1473835|NCT03168555|Drug|chenodeoxycholic acid|1250 mg CDCA is given with a study meal
1473836|NCT03168529|Drug|Ivabradine|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
1473837|NCT03168529|Drug|Placebo|At discharge from the observation unit, subjects will receive a pill bottle containing oral capsules not containing active drug to take at home. This arm will require the subject to take the study medication BID for the duration of the study period. Neither study team nor subject will know if the pill bottle contains active drug or placebo.
1473838|NCT03168516|Device|closed-loop automatic control of the inspiratory fraction of oxygen (FiO2-C)|Application of FiO2-C (provided by standard infant ventilators) in addition to manual adjustments of the inspired oxygen fraction (FiO2) during mechanical ventilation and continuous positive airway pressure (CPAP) in ELGANs at least up to 32weeks PMA according to a standardized protocol
1473839|NCT03168503|Dietary Supplement|LGG+Promitor™|synbiotic
1473840|NCT03168503|Dietary Supplement|Promitor™|Soluble Corn Fiber
1473841|NCT03168503|Dietary Supplement|LGG-PB12+Promitor™|synbiotic
1473842|NCT03168503|Dietary Supplement|Maltodextrin|Control
1473843|NCT03168490|Dietary Supplement|Gluten Friendly bread|parallel study
1473844|NCT03168477|Other|dry needling|Dry needling to the supraspinatus (proximal/distal teno-osseus junction and musculotendinous junction under acromion process), deltoid muscle, upper trapezius muscle and levator scapulae muscle on the painful side. Clinicians may also needle the terres major, infraspinatous, rhomboids and thoracic paraspinals, as needed. Up to 12 treatment sessions over 6 weeks.
1479087|NCT03126916|Drug|Topotecan Hydrochloride|Given IV
1473845|NCT03168477|Other|spinal manipulation|HVLA thrust manipulation to cervical, thoracic and/or upper rib articulation (R1-R3).
1473846|NCT03168477|Other|manual therapy|Impairment-based manual therapy targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 8 treatment sessions over 4 weeks.
1473847|NCT03168477|Other|exercise|Impairment-based exercise targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 8 treatment sessions over 4 weeks.
1473848|NCT03168477|Other|modalities|Impairment-based electrothermal modalities targeting the muscles, scapulae and joint capsule of the painful shoulder. Up to 8 treatment sessions over 4 weeks.
1473849|NCT03168464|Drug|Ipilimumab and Radiation therapy|Ipilimumab (3mg/kg) is given concurrently (+/- 24hrs from first RT dose) with radiation therapy on Day 1 of the study. On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
1473850|NCT03168464|Drug|Nivolumab|On day 22 the combined treatment of ipilimumab plus nivolumab will start (nivolumab 240mg q 2 weeks, ipilimumab 1mg/kg q 6 weeks), and administered until evidence of progression.
1473851|NCT03168451|Behavioral|Culturally Tailored Text Messages|Members of the intervention group receive culturally tailored messages on the following schedule: 4 messages per day for 1 week prior to target quit date, 4 messages per day for 4 weeks following target quit date, 3 messages per week for 20 weeks following weeks.
1473856|NCT03168412|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 7, 21 days.
1473857|NCT03168412|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
1473858|NCT03168399|Dietary Supplement|PKU Explore|PKU Explore is an unflavoured, powdered, phenylalanine-free, protein substitute, containing essential and non-essential amino acids, carbohydrate, sugar, vitamins, minerals, trace elements and the long chain polyunsaturated fatty acids (LCPs); arachidonic acid (AA) and docosahexaenoic acid (DHA).
1473859|NCT03168386|Procedure|Intensive motor rehabilitation|Intensive motor rehabilitation during subacute stroke phase
1473860|NCT03168373|Procedure|language rehabilitation therapy|language therapy is language rehabilitation by language therapist during subacute phase in stroke patients
1473861|NCT03168360|Procedure|Cognitive rehabilitation|Intensive cognitive rehabilitation by cognitive therapist for 1 hours on every working day during subacute stroke phase
1473862|NCT03168347|Behavioral|Anecdotal Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal evidence.
1473863|NCT03168347|Behavioral|Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only research study evidence.
1473864|NCT03168347|Behavioral|Anecdotal + Research Study Evidence|Communicate basic information on the therapeutic effect of a drug using only anecdotal and research study evidence.
1473865|NCT03168347|Behavioral|No Evidence|Communicate basic information on the therapeutic effect of a drug using neither anecdotal evidence nor research study evidence.
1473866|NCT03168334|Drug|IDP-123 Lotion|lotion
1473867|NCT03168334|Drug|IDP-123 Vehicle Lotion|Vehicle
1473868|NCT03168321|Drug|IDP-123 Lotion|lotion
1473869|NCT03168321|Drug|IDP-123 Vehicle Lotion|lotion
1473872|NCT03168295|Drug|Dapagliflozin 10mg|SGLT2 inhibitor - Dapagliflozin
1473873|NCT03168295|Drug|Placebo Oral Tablet|Placebo for Dapagliflozin
1473874|NCT03168269|Diagnostic Test|Coronary Computed Tomographic Angiography (CCTA)|CCTA of coronary arteries
1473875|NCT03168256|Drug|CF101 2mg|CF101 tablets, 2mg BID for 16 weeks
1473876|NCT03168256|Drug|CF101 3mg|CF101 tablets, 3mg BID for 16 weeks
1473877|NCT03168256|Drug|Apremilast 30mg|Apremilast tablets, 30mg BID for 16 weeks
1473878|NCT03168256|Drug|Placebo Oral Tablet|Placebo tablets, BID for 16 weeks
1473880|NCT03168230|Procedure|Portal vein embolization (PVE)|"Portal vein embolization (PVE) is a procedure that induces regrowth on one side of the liver in advance of a planned hepatic resection on the other side. The procedure is frequently used in primary liver cancer (hepatocellular carcinoma) and colorectal liver metastases.
An interventional radiologist will place a needle percutaneously (through the skin) into the liver and identify the blood vessel on the side where the largest part of the tumor is being supplied. Tiny microspheres are then infused into the portal vein which supplies blood to the area, embolizing it by cutting off its blood supply.
This blockade of the blood supply induces the other side of the liver to regrow. After several weeks, the non-embolized side has grown enough so that surgery is now a viable option.
Source of this information : http://general.surgery.ucsf.edu/conditions--procedures/portal-vein-embolization-(pve).aspx"
1473882|NCT03168191|Drug|Nicotine|Participants will receive low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
1473883|NCT03168191|Other|Experimental Flavor|Experimental fruit flavored e-cigarette for lab session
1473884|NCT03168191|Other|Menthol Flavor|Menthol flavored e-cigarette for lab session
1473885|NCT03168178|Drug|Standard Antibiotic Treatment|"Participants randomized to this intervention will receive standard antibiotic treatment.
The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes"
1473886|NCT03168178|Other|No Antibiotic Treatment|Participant randomized to this arm of the study will not receive antibiotics. The placenta will be submitted for pathologic exam after delivery and investigators will collect maternal and neonatal outcomes
1473888|NCT03168152|Radiation|Microwave Ablation (MWA)|MWA will typically be administered in one ablation session during which time up to 2 tumors are treated.
1473889|NCT03168152|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered in five fractions of up to 10 Gy per fraction. SBRT will be administered 5-15 days per tumor.
1473890|NCT03168139|Drug|Olaptesed pegol - Monotherapy|"Monotherapy (MT) period:
Treatment with 300 mg olaptesed pegol only, weekly on MT D1 and MT D4 for up to 2 weeks"
1473891|NCT03168139|Drug|Olaptesed pegol + Pembrolizumab - Combination Therapy|"Combination therapy (CT) period:
Treatment with 300 mg olaptesed pegol in combination with 200 mg pembrolizumab every three weeks (Q3W) until progressive disease or limiting toxicity, for a maximum of 24 months in total"
1473892|NCT03168126|Device|Pro-AQT|Use of the device for advanced hemodynamic monitoring
1473893|NCT03168100|Drug|Elotuzumab|administered via IV infusion
1473894|NCT03168100|Drug|Lenalidomide|taken by mouth
1473895|NCT03168100|Drug|Dexamethasone|taken by mouth
1473896|NCT03168100|Drug|Bortezomib|administered as a subcutaneous injection
1473897|NCT03168087|Other|Plasmalyte-148|Venous blood is taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 20%, 40%, and 60%) using a plasmalyte-148 solution.
1473898|NCT03168074|Drug|lenvatinib|Eligible patients will be treated with approximately 2 weeks of single agent lenvatinib (range 10-28 days, depending on the date of breast cancer surgery; last dose of lenvatinib to be administered no later than 48 hours before surgery in patients who are planned to receive ≤14 days lenvatinib, and no later than 120 hours before surgery in patients who are planned to receive 15-28 days lenvatinib).Tissue sections from the pre-treatment and post-treatment tumor will be collected for biomarker analysis. Pre- and post-treatment ultrasound will be used to document the size of the target lesions.
1473900|NCT03168048|Other|mobile application|Oncologic therapy support by means of a mobile application
1473901|NCT03168035|Drug|NC-4016|"Dose Escalation Group Starting Dose: 15 mg/m2 by vein on Day 1 of a 21 Day cycle.
Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
1473902|NCT03168022|Drug|Treatment A|1 x TNX-102 SL 2.8 mg yellow tablet (commercial manufacturer) to be held under the tongue until dissolved.
1473903|NCT03168022|Drug|Treatment B|1 x TNX-102 SL 2.8 mg white tablet (original manufacturer) to be held under the tongue until dissolved.
1473904|NCT03168009|Procedure|Bariatric Surgery|Patients will undergo bariatric surgery as routinely scheduled. The type of bariatric procedure will be suggested by the surgeon based on clinical considerations.
1473905|NCT03167996|Device|HealthPals smartphone application (digital health technology)|"HealthPals is a smartphone-based chronic disease management mobile application. It uses the mobile health capabilities of smartphones to provide a secure communication portal for patients with their Care Teams to help achieve cardiovascular risk reduction through a digital health coach-based coaching for lifestyle and medication compliance.
The HealthPals app was developed by HealthPals, Inc."
1473906|NCT03167970|Device|Pill cam|Patient is asked to swallow the esophageal capsule.
1473907|NCT03167970|Other|EGD|Patient will undergo standard EGD
1473908|NCT03167957|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
1473909|NCT03167957|Drug|Oral Encochleated Amphotericin B (CAMB)|Lipid-crystal nano-particle formulation amphotericin B
1473910|NCT03167944|Device|Low thermal electrosurgery system|PEAK Plasmablade
1473911|NCT03167944|Device|Conventional Electrocautery|Conventional Electrocautery
1473912|NCT03167931|Other|MRI + transcranial Magnetic Stimulation|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
1473913|NCT03167931|Other|transcranial electric stimulation + electroencephalogram|Healthy subjects undergo 2 sessions of MRI + transcranial Magnetic Stimulation + transcranial electric stimulation + electroencephalogram. The 2 sessions are performed with an interval of 3 to 7 days.
1473914|NCT03167918|Drug|Calcium Dobesilate|gave each patient 0.5 g bid，
1473915|NCT03167918|Drug|Xuefuzhuyu Decoction|gave each patient100 ml bid，po
1473916|NCT03167918|Drug|Xuefuzhuyu Decoction & Calcium dobesilate|gave each patient Calcium dobesilate 0.5 g bid，po and Xuefuzhuyu Decoction 100 ml bid，po
1473917|NCT03167918|Drug|metformin|gave each patient 1000 mg, bid, PO
1473918|NCT03167918|Drug|Mecobalamin Tablets|gave each patient 0.5 mg bid, PO
1473919|NCT03167905|Device|Epidural delivery system|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
1473920|NCT03167905|Drug|Entonox|Entonox will be given upon request in non-epidural group.
1473921|NCT03167905|Drug|Meperidine|Intramuscular pethidine (75mg/1.5ml) will be given upon request in non-epidural group.
1473922|NCT03167905|Drug|Ultiva|Intravenous patient controlled remifentanil (20-40mcg/ml) is only given when the patient rejects or cannot receive pethidine and entonox in non-epidural group..
1473923|NCT03167905|Drug|Fentanyl|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
1473924|NCT03167905|Drug|Ropivacaine|Epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution.
1473925|NCT03167892|Device|Oral screen|Oral screen training three times per day with an effective training time of 1.5 minutes, for 3 mo
1473926|NCT03167879|Behavioral|safer conception counseling|Multi-component counseling to help HIV-affected couples to make an informed decision about childbearing, and to provide counseling to use contraception or safer conception methods, depending on whether the couples chooses to seek or prevent pregnancy after initial consultation.
1473927|NCT03167866|Behavioral|motivational SMS|the participant receives a weekly text message that is aimed to increase motivation
1473928|NCT03167866|Behavioral|informational SMS|the participant a weekly text message that is provides information on improving lifestyle
1473929|NCT03167853|Biological|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
1473930|NCT03167840|Behavioral|Physical and Cognitive Training|Physical Exercise and Cognitive Training
1473931|NCT03167840|Behavioral|Physical Training|Physical training alone
1473932|NCT03167840|Behavioral|Cognitive training|Cognitive training alone
1473933|NCT03167827|Other|Exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
1473934|NCT03167827|Other|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
1473935|NCT03167827|Other|placebo|Daily supplementation in 1 capsule per day containing starch of corn.
1473936|NCT03167814|Dietary Supplement|Diet group|In the diet, there is no long-chain triglycerides. Fat and protein needs are met with adding medium-chain-fat acid as oil and protein supplements to the diet. Diet has been constructed together with clinical nutrition specialist.
1473937|NCT03167788|Device|rejuvesol Solution|The rejuvenation process involves incubation of stored red cells with a rejuvenating solution, rejuvesol Red Blood Cell Processing Solution (rejuvesol® Solution), Citra labs, MA, a Zimmer Biomet Company, IN, USA) which restores red cell adenosine triphosphate (ATP), 2,3-DPG (diphosphoglycerate), oxygen transfer characteristics and rheology. Post rejuvenation red cells are washed to remove the rejuvesol Solution, and cells are re-suspended in additive solution for transfusion.
1473938|NCT03167788|Other|Standard Care|Allogeneic red cells, harvested in citrate-phosphate-dextrose (CPD), leucocyte depleted, saline-adenine-glucose-mannitol (SAGM) stored red cell units, issued by National Health Service Blood & Transplant (NHSBT) will be administered to cardiac surgery patients as per standard practice, and according to established unit protocols.
1473939|NCT03167775|Drug|Elemene Injection/Elemene Oral Emulusion|
1473940|NCT03167762|Device|Fluorescence and thermal imaging|Two cameras used to take images of the skin. One, to measure the fluorescence from the photosensitiser, and the second to measure the surface temperature of the skin
1473941|NCT03167749|Diagnostic Test|Laboratory test|Semen analysis and reproductive hormonal assay (free and total testosterone, luteinizing hormone, follicle-stimulating hormone , estradiol and prolactin hormone) for both patients and control group
1473942|NCT03167736|Other|electric dry needling, manipulation|HVLA thrust manipulation to lumbar spine. Dry needling to lumbar/sacral paraspinal muscles and gluteus medium/minimus muscles. Treatment may include dry needling of the piriformis muscle, quadrates lumborum muscle and perineurial needling of sciatic/tibial nerve. Up to 8 treatment sessions over 4 weeks.
1473943|NCT03167736|Other|conventional physical therapy|Impairment-based manual therapy, stretching, strengthening and electrothermal modalities targeting the lumbar/sacral spine and hips. Up to 12 treatment sessions over 6 weeks.
1473945|NCT03167710|Other|Dry Needling, manipulation, stretching|HVLA thrust manipulation to elbow, wrist and spine (C5-C6). Dry needling to wrist extensor muscles on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
1473946|NCT03167710|Other|manual therapy, exercise, ultrasound|Impairment-based manual therapy, exercise and ultrasound targeting the wrist extensors on the dorsal forearm, proximal and distal of the lateral epicondyle. Up to 8 treatment sessions over 4 weeks.
1473949|NCT03167684|Device|Oral appliance therapy|Fitted oral appliance
1473950|NCT03167671|Device|AposTherapy|AposTherapy® is a home-based exercise program utilizing footwear that causes exercise with normal daily activity
1473951|NCT03167671|Other|Traditional Physical Therapy|Up to 20 sessions of traditional physical therapy
1473952|NCT03167658|Behavioral|Workplace wellness program|Multi-prong workplace wellness program, with components such as nutrition counseling, fitness challenges, and stress management workshops, including supports and incentives.
1473953|NCT03167645|Drug|Human albumin|Substitution according to pre-specified dosage
1473954|NCT03167619|Drug|Olaparib Oral Product|olaparib 300mg twice daily
1473955|NCT03167619|Drug|Olaparib Oral Product in combination with Durvalumab|olaparib 300mg twice daily plus intravenous durvalumab every 28 days
1473956|NCT03167606|Behavioral|MyPEEPS Mobile|Mobile technology to deliver HIV prevention information specifically developed for at-risk YMSM.
1473957|NCT03167593|Dietary Supplement|Lactobacillus coryniformis K8 CECT5711|Lactobacillus coryniformis CECT5711
1473958|NCT03167593|Other|Control placebo|Maltodextrin
1473959|NCT03167580|Procedure|restricted PEEP|Patients are randomized and ventilated with restricted PEEP (the lowest possible PEEP level, 0 - 5 cm H2O)
1473960|NCT03167580|Procedure|liberal PEEP|Patients are randomized and ventilated with liberal PEEP (the median PEEP level used in the Netherlands, 8 cm H2O)
1473961|NCT03167567|Behavioral|Presence of a medical clown during labor|Presence of a medical clown during labor
1473962|NCT03167554|Other|Sham comparator|The electrolysis technique was simulated to be delivered. The guide tube of the needle contacted with the skin, located on the painful area, and the device remained switched on to simulate its functioning.
1479088|NCT03126916|Drug|Vincristine Sulfate|Given IV
1473963|NCT03167554|Other|Experimental group 1|Percutaneous Therapeutic Electrolysis (EPTE®) with monopolar needle, 330 microamps, 1 min 20 sec.
1473964|NCT03167554|Other|Experimental group 2|Percutaneous Therapeutic Electrolysis (EPTE®) with bipolar needle, 120 microamps, 1 min 20 sec.
2010516|NCT02946164|Behavioral|Stick To It|The intervention is a prize system linked to points earned through online and real-world activities designed to incentivize young MSM to test for HIV and STIs every three months. Participants receive points for pre-determined activities, such as: answering online quizzes, inviting friends to participate, and getting tested for HIV/STIs. Points are redeemable in person at two AIDS Healthcare Foundation Men's Wellness Centers, where participants will be able to exchange their points for gumballs from a gumball machine; different color combinations of gumballs correspond to prizes of different values. Participants are reminded to get tested regularly via SMS messages; in addition, they can check when their next test is due by checking their testing timer on the stick2it.org website.
1473967|NCT03167528|Behavioral|Relaxation|Relaxation
1473968|NCT03167528|Behavioral|Hypnosis|Hypnosis
1473969|NCT03167528|Behavioral|Holistic gymnastics|holistic gymnastics
1473970|NCT03167528|Device|Transcutaneous electrical nerve stimulation (TENS)|TENS
1473971|NCT03167528|Behavioral|Mindfullness|Mindfullness
1473972|NCT03167515|Device|074-6751 Lotion|Apply lotion once in the morning and once in the evening daily at approximately the same time every day with 12 hours between doses. Apply the lotion only to the active psoriatic lesions, as instructed by your study doctor.
1473973|NCT03167502|Other|eccentric work|patient will follow 2 eccentric trainings per week during 6 weeks
1473974|NCT03167502|Other|concentric work|patient will follow 2 concentric trainings per week during 6 weeks
1473975|NCT03167489|Behavioral|Lifestyle Plus Emotional Regulation|Group intervention over 5 months, integrating the Mediterranean Diet into a lifestyle intervention and emotional regulation skills.
1473976|NCT03167463|Procedure|flap|Repair choanal atresia with using flap during surgery
1473978|NCT03167424|Device|Treatment of restenosis|Treatment of in-stent restenosis
1473979|NCT03167411|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
1473980|NCT03167411|Drug|Exenatide Injection|Byetta® (Exenatide), 10 ug, bid, subcutaneous injection
1473981|NCT03167398|Other|Fecal Microbiota Transplantation|Patients able to swallow will be given capsulized FMT using 15 capsules a day for two consecutive days. Patients will be treated concomitantly with omeprazole 20mg once in the evening before FMT and daily for the next 2 days.
1473982|NCT03167385|Drug|Apatinib Mesylate|oral intake of Apatinib Mesylate 500mg once a day until progression of diesase or severe adverse effect
1473983|NCT03167372|Device|Bright White Light|Bright white light therapy is to be administered to participants
1473984|NCT03167372|Device|Dim White Light|Dim white light is used within the sham group
1473985|NCT03167372|Device|Dim Red Light|Dim red light is to be used in sequence against the experiment group (bright white light) and the sham group (dim white light)
1473986|NCT03167359|Radiation|Hypofractionated Simultaneous Integrated Boost Radiotherapy|Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.
1473987|NCT03167333|Drug|platelet rich plasma|The amount of PPR was about 4-5 cc
1473988|NCT03167333|Drug|Hyaluronic acid|HA was 2.5cc
1473989|NCT03167307|Drug|Omega 3 fatty acid|Omega-3 fatty acids in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
1473990|NCT03167307|Drug|Placebo oil|medium chain triglycerides in addition to standard treatment for depression in children and adolescents according to the German S3 Guidelines
1473991|NCT03167294|Device|AquaBeam System|Aquablation
1473992|NCT03167281|Combination Product|early tPA and DNase|Early addition of tPA and DNase (immediately at chest tube placement) versus later (24-48 hours) after chest tube placement.
1473993|NCT03167268|Drug|Lycopene|
1473994|NCT03167268|Other|Placebo|
1473995|NCT03167255|Drug|NS-065/NCNP-01|Received during weekly intravenous infusions
1473998|NCT03167229|Drug|Tenofovir Disoproxil Fumarate|Daily tenofovir 300 mg will be self-administered by the woman and continued until one month post-partum. Discussions about the study drug are ongoing and the investigators aim to have Gilead, the manufacturer of Tenofovir (VireadTM) provides the drug free of charge, however in the event that this is not possible the investigators will then purchase generic TDF. The drug will be delivered directly to the study site at Mae Sot.
1473999|NCT03167216|Drug|Cromolyn Sodium|Mast cell stabilizer
1474000|NCT03167216|Drug|Cetirizine Hydrochloride|Histamine receptor antagonist
1474002|NCT03167190|Procedure|Point-of-care ultrasound|A point-of-care ultrasound machine will be utilized to identify and mark midline and the interspinous space based on visualization of spinous processes.
1474003|NCT03167190|Procedure|Traditional Landmark-based Lumbar Puncture|Palpation of anatomical landmarks to identify midline and interspinous space
1474037|NCT03167151|Drug|Pembrolizumab|Solution for Infusion (Intravesical and Intravenous) 100mg/ 4mL vial
1474038|NCT03167138|Biological|Autologous micro-fragmented adipose tissue|Micro-fragmented adipose tissue is obtained from abdominal region or thighs using the Lipogems® system and injected into the injury site under ultrasound guidance.
1474039|NCT03167138|Device|Lipogems system|The Lipogems® system is a non-enzymatic method to obtain micro-fragmented adipose tissue from the abdominal region or thighs for injection into the injury site.
1474040|NCT03167125|Other|Automated Prompts|This intervention is an automated data-driven program, using automated phone calls, text messages, and/or emails, for delivering FIT kit prompts to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
1474041|NCT03167125|Other|Automated Plus Live Prompts|This intervention is a higher-intensity program, using automated data-driven prompts plus linguistically and culturally tailored live prompts, for delivering FIT kit messages to patients due for colorectal cancer screening. The specific components of the intervention are forthcoming and will be determined using a community-based participatory research approach known as boot camp translation which seeks input from patients and providers.
1474042|NCT03167112|Drug|Oxaliplatin|Patients receive Oxaliplatin 85 mg/m2 over 2 hours.
1474043|NCT03167112|Drug|Irinotecan|Oxaliplatin is followed by Irinotecan (CPT-11) 180 mg/m2 over 90 min.
1474044|NCT03167112|Drug|Leucovorin|Oxaliplatin and Irinotecan is followed by Leucovorin (LV) 400 mg/m2 over 2 hours day1
1474045|NCT03167112|Drug|Fluorouracil|Oxaliplatin and Irinotecan and Leucovorin is followed by Fluorouracil (5-FU) 400 mg/m2 bolus day1 and 2,400 mg/m2 46h continuous infusion.
1474046|NCT03167099|Procedure|Full Weight Bearing|Participants will be randomized to one of two groups; full weight bearing, which is the intervention, or partial weight bearing, which is standard of care, after fixation of a distal femur fracture.
1474047|NCT03167086|Behavioral|"From Catastrophizing to Recovery (FCR)"|"From Catastrophizing to Recovery (FCR): A single-session approximately 2-hr group intervention to treat PC.
Format of intervention: Therapist-delivered PowerPoint presentation with experiential exercises. Experienced senior level psychologist and two (2) additional doctoral level psychologists will conduct the FCR sessions.
Content of intervention: FCR Participants have the 'FCR Relaxation Resource' app (guided relaxation audiofile) loaded on their apple or android electronic device."
1474048|NCT03167086|Behavioral|Cognitive Behavioral Therapy (CBT)|"Format of intervention: 8-week Manualized Pain-CBT Group Intervention will be delivered by PhD-level psychotherapists (3 in total). The group is run weekly for 8 consecutive classes. Each class is 2 hours with a midpoint break (16 hours total intervention time).
Content of intervention: The protocol and materials were developed with funding from NIH/NCCAM R01 AT006226 (Dan Cherkin, PI) [1& 2], and include content from a pain-CBT program developed by Drs. Ehde, Dillworth, and Turner [3].
Participants receive a workbook with homework and a copy of The Pain Survival Guide: How to reclaim your life © 2005 by Turk & Winter [4] for optional reading."
1474049|NCT03167086|Behavioral|Health Education (HE)|"Format of intervention: The HE class will be instructor taught and will involve a PowerPoint presentation and handouts. Two additional providers will be identified and trained to conduct the sessions. Selected instructors will have substantial health education experience.
Content of intervention: HE content will include basic information such as nutrition and interacting with the healthcare system; these relatively 'inert' topics are unlikely to impart any specific effects typically found with a true psychobehavioral intervention."
1474050|NCT03167073|Other|BreastFeeding Friend (BFF)|A novel android app designed to improve breastfeeding rates among low-income women
1474051|NCT03167073|Other|dummy app|A novel android app that looks identical to the intervention app (BFF) but contains limited content.
1474052|NCT03167060|Device|Active RhinoChill|"Participants will be provided with a RhinoChill® device (Active) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.
The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
1474053|NCT03167060|Device|Control Rhinochill|"Participants will be provided with a RhinoChill® device (Sham) and an Intranasal Migraine catheter. Once they have the RhinoChill® device, they are asked to treat the next two of your migraines with the device. This requires a maximum of 10 minute intra-nasal treatment as soon as possible after the start of your migraine.
The participation in the trial will last until 3 migraine headaches have been treated with the RhinoChill® device."
1474054|NCT03167047|Procedure|Caudal block|Caudal epidural
1474055|NCT03167047|Procedure|Nerve Block|Peripheral nerve block
1474056|NCT03167047|Drug|Standarising intraoperative pain relief|All patients will receive a standarised dose of paracetamol 15mg/kg and fentanyl 2mcg/kg.
1474057|NCT03167034|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
1474058|NCT03167034|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
1474059|NCT03167021|Other|Survey|This observational and transversal study will be conducted as a survey using the REDCap software and the response to this survey will be done online, in real time, with an automatic, secure and centralized data collection (CHU Clermont-Ferrand).
1474060|NCT03167008|Diagnostic Test|semen sample|-Semen samples will be collected from all patients Semen analysis will be examined after 2-5 days of sexual abstinence based on World Health Organization (WHO) (2010)
1474061|NCT03167008|Diagnostic Test|blood sample|blood samples will be taken &the following will be done Serum vitamin D level ,Serum calcium level ,Serum testosterone level ,luteinizing hormone (LH), and follicle-stimulating hormone (FSH), will be measured
1474064|NCT03166982|Procedure|transvaginal approach|
1474065|NCT03166982|Procedure|laparoscopic approach|
1474066|NCT03166969|Procedure|Holter 21 days|
1474067|NCT03166956|Dietary Supplement|Glutamine and vitamin C enteral supplement|Subjects in the GA group received enteral supplement of 10 g L-glutamine and 90 mg vitamin C per serving provided by Nutritec-Enjoy Nutrition Inc. (Taipei, Taiwan). Subjects in the C group received isocaloric maltodextrin as placebo.
1474068|NCT03166943|Procedure|Systolic function by echocardiography|"Echocardiography for evaluation of systolic function:
by biplane Simpson's method.
by speckle tracking:"
1474069|NCT03166943|Procedure|Diastolic function by echocardiography|"Echocardiography for evaluation of diastolic function:
Left atrial Volume
Mitral Inflow Patterns
Pulsed wave Doppler
Mitral inflow patterns include normal, impaired left ventricular relaxation, pseudonormal, and restrictive left ventricular filling patterns.
Tissue Doppler Annular Early and Late Diastolic Velocities
Pulsed wave tissue doppler imaging
Primary measurements include the systolic , early diastolic, and late diastolic velocities."
1474072|NCT03166917|Procedure|3D printing implant|3D printing implants in bone defect
1474073|NCT03166917|Procedure|autogenous bone grafting|3D printing implants in bone defect
1474074|NCT03166904|Drug|Vistusertib(AZD2014)|Vistusertib(AZD2014) is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
1474075|NCT03166891|Drug|Chiauranib|Take 50mg orally once daily
1474076|NCT03166878|Biological|UCART019|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose. D2: 60% of total dose if patient is stable (no significant toxicity) from prior dose
1474077|NCT03166865|Biological|Umbilical-cord mesenchymal stromal cells (UC-MSCs)|Allogeneic UC-MSCs 1 x 10~7 diluted on 5 mL of Platelet Rich Plasma
1474078|NCT03166865|Other|Hyaluronic acid|intra-articular injection of Hyaluronic Acid
1474079|NCT03166852|Other|Home-training|5 weeks of interval training at home. The training consisted of 3 minutes of warm-up. 10 intervals of 1 minute at 90% of maxHR interspersed with one minute of low intensity pedalling. Cool-down period of 2 minutes.
1474080|NCT03166839|Other|Experiencing PPH|No intervention given
1474081|NCT03166826|Other|Modified Apgar Scoring System|Modified APGAR scoring system
1474084|NCT03166800|Drug|Mitoquinone|MitoQ will administered in either 20mg or 40mg capsules. The dose will administered for a 12-weeks treatment.
1948586|NCT02103582|Other|Intervention|Participants who are randomized to the 'intervention arm' will be asked to come to the study site to exercise 3 days per week for 12 weeks. The exercise duration will increase over time from 75 minutes per week to 150 minutes per week. Intervention participants will have anthropometric measurements of weight, height, hip size and waist size taken at the beginning of the study, 6 weeks, and at 12 weeks. Intervention participants will also have a fitness test on a treadmill, full body scan, blood pressure, heart rate and questionnaires given at the beginning of the study, 6 weeks and at 12 weeks.
1474156|NCT03166254|Procedure|Leukapheresis|-At baseline and beginning of Cycle 6
1474092|NCT03166774|Other|Program of support of the sexual health in oncology by questionnaire|Patients included in the study have to answer to a questionnaire
1474093|NCT03166761|Drug|Dexamethasone|Dexamethasone injection into the sacroiliac joint
1474094|NCT03166761|Drug|Triamcinolone Acetonide|Triamcinolone injection into the sacroiliac joint
1474095|NCT03166748|Combination Product|Potassium Nitrate in Polycarboxylate cement|"The application of polycarboxylate cement containing 5% KNO3 for direct capping of traumatically exposed pulp in animal models did not result in any degenerative changes in dental pulp, thought creating optimal conditions for preservation of pulp vitality and root completion.
Polycarboxylate cement has very thin film thickness and bonds firmly to the tooth structure, is capable of withstanding the overlying pressure during restoration procedures. The good adhesive properties of polycarboxylate cement containing 5% KNO3 guaranteed the closure of cavity, good and lasting protection of traumatically exposed dental pulp and the formation of alkaline environment possessing a strong antiacidic, anti-inflammatory and antibacterial effect of this pulp capping material, creating optimal conditions for expression of its natural reparative potential. The increased release of potassium nitrate from polycarboxylate cement by time, might be the cause of decreasing the inflammatory intensity"
1474098|NCT03166722|Other|Control group|SpO2 and HR monitoring and routine treatment during immediate transition
1474099|NCT03166722|Device|Study group|Cerebral NIRS measurement with INVOS 5100 during immediate transition in addition to SpO2 and HR monitoring
1474100|NCT03166709|Behavioral|Preventing Addiction Related Suicide (PARS)|PARS is a module designed for a single session of an Intensive Outpatient Program (IOP) including a specified combination of didactic presentations and group discussions. PARS topics include: Goals and Objectives; Suicide Overview; Addiction and Suicide: A Strong Relationship; Suicide Myths and Facts; Suicide Risk Factors; Suicide Protective Factors; Common Triggers of Suicidal Thoughts and Behaviors; Warning Signs and Guidelines for Preventing Addiction Related Suicide.
1474101|NCT03166709|Behavioral|Treatment as Usual (TAU)|Intensive Outpatient Program substance abuse group session focused on depression, grief, or managing emotions. Specific topic is what that Intensive Outpatient Program usually provides.
1474102|NCT03166683|Other|Hemopatch|Liver resection surgery with collagen and polyethylene glycol haemostatic/sealant patch placement
1474103|NCT03166683|Other|Standard of care|Standard of care include other sealant / hemostatic devices as patches or liquid/gels
1474106|NCT03166657|Procedure|office hysteroscopy|A speculum is first inserted into the vagina. The hysteroscope is then inserted and gently moved through the cervix into uterus. Carbon dioxide gas or a fluid, such as saline will be put through the hysteroscope into uterus to expand it. The gas or fluid helps see the lining more clearly. The amount of fluid used is carefully checked throughout the procedure
1474107|NCT03166644|Device|Analgesia Nociception Index (ANI)-guided sufentanil administration|One recent observational study showed that ANI-guided remifentanil administration during vascular surgery resulted in low opioid consumption and low postoperative pain rates.
1474110|NCT03166618|Device|Juvéderm® VOLUMA XC|Juvéderm® VOLUMA XC hyaluronic acid injectable gel
1474111|NCT03166605|Drug|Simethicone|Giving simethicone before and after capsule ingestion.
1474112|NCT03166592|Device|Magnetic resonance imaging with contrast|injection of gadolinium contrast then acquisition of images with magnetic resonance imaging then spectroscopy
1474113|NCT03166579|Behavioral|Dialectical Behaviour Therapy|Dialectical Behaviour Therapy (DBT) is a psychological intervention which was originally developed for women with Borderline Personality Disorder. DBT is delivered by a team of multidisciplinary mental health professionals, and comprises of individual therapy sessions for each patient, group skills training sessions, phone coaching and consultation meetings for the clinicians on the DBT team. Group skills are delivered in blocks of three modules which teach mindfulness, distress tolerance, emotion regulation and interpersonal effectiveness. The three modules are delivered over a 24-week period and are then repeated.
1474114|NCT03166566|Device|Laminar drainage implant surgery.|A clear corneal traction suture was placed to achieve superior-temporal quadrant exposure, where a 90° conjunctival fornix-based flap was made, associated with two radial relaxing incisions. A half-thickness scleral tunnel (4.5 mm from the limbus and 4.0 mm wide) was made using a crescent blade and a superior-temporal iridectomy was performed through . Then, the tunnel end was shunted to the AC using a 1.5-mm-wide blade with a sharp tip. The LDI was inserted into the scleral tunnel so that its tip was positioned in the AC periphery and the implant was anchored to the sclera using 7-0 polypropylene thread with two separate sutures. Next, fistula function was assessed by the aqueous humor leakage test at the scleral tunnel entry site. Then, the conjunctiva was repositioned and running sutures were performed with 7-0 polyglactin for the relaxing incisions and mattress sutures were performed in the limbus using 10-0 nylon.
1474115|NCT03166553|Drug|Elemene|
1474435|NCT03164122|Drug|injection of microfat and plasma rich platelet PRP|intra-articular injections
1948596|NCT02092285|Drug|Golimumab|50mg or 100mg solution for injection; subcutaneous injection
1948597|NCT02091141|Drug|Trastuzumab|Trastuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
1948598|NCT02091141|Drug|Pertuzumab|Pertuzumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
1948599|NCT02091141|Drug|Erlotinib|Erlotinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
2010517|NCT02945813|Drug|Metformin|850mg PO BID; 48 weeks
2010518|NCT02945813|Radiation|Salvage Radiotherapy SRT|SRT 35 x 2Gy; 7 weeks
1474118|NCT03166527|Drug|Immune Globulin 10% Intravenous Solution|standard Immune lobulin 10% intravenous solution infusion at standard and high infusion rates.
1474119|NCT03166514|Dietary Supplement|Commercially Available Food Bar|
1474120|NCT03166514|Dietary Supplement|Placebo|
1474121|NCT03166501|Drug|Lanicemine|Three 60 min parenteral infusions over a 5 day period
1474122|NCT03166501|Drug|Placebo|Three 60 min parenteral infusions over a 5 day period
1474123|NCT03166488|Device|MRI|Subjects will receive an MRI sequence called Magnetic Resonance Elastography (MRE).
1474124|NCT03166475|Procedure|Surgical procedures|All the extractions were performed under local anaesthesia, minimally traumatic as possible. After the extraction, each patient was treated according to the group of their allocations.
1474125|NCT03166462|Other|Evaluation by Sleep Medicine Specialists|Patients randomized to the intervention arm will be referred to the sleep medicine specialists for evaluation. All of their recommendations will be followed if indicated.
1474126|NCT03166449|Dietary Supplement|Neomune|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
1474127|NCT03166449|Dietary Supplement|Fresubin® HP energy|Enteral feeding with Neomune was delivered within 24 to 48 h after admission or surgery according to Brain Trauma Foundation (BTF) Guidelines
1474128|NCT03166436|Procedure|Radiofrequency ablation|radiofrequency ablation
1474129|NCT03166436|Procedure|Biliary stenting|biliary stenting
1474130|NCT03166423|Drug|MU001 patches (Investigational)|Patches containing snail slime, calendula extract and propolis extract
1474131|NCT03166423|Device|Conventional patches (Control)|Patches containing conventional formulations in medical devices for ulcers (hydrocolloids, activated charcoal silver, alginate, carboxymethylcellulose or hydrogel).
1474132|NCT03166410|Procedure|Cell injection|
1474133|NCT03166397|Drug|Fludarabine|Reduced intensity, myeloablative, lymphodepleting regimen
1474134|NCT03166397|Radiation|Radiation|Total Body Radiation (TBR) (2 Gray as a single treatment) for 1 day
1474135|NCT03166397|Biological|TIL|TIL administration
1474136|NCT03166397|Drug|IL-2|Bolus high-dose (720,000 IU/kg) IL-2 will be administered to each patient every 8 hours, to tolerance. A maximum of 10 doses will be administered per patient.
1474137|NCT03166384|Device|electrosurgical bipolar sealing devices|Electrosurgical bipolar sealing devices use the body's own collagen and elastin to create a permanent fusion zone through a combination of pressure and energy. Previous studies suggested that surgery using these devices lead to significant decrease of seroma formation, however their advantages are not well established in case of mastectomy for breast cancer.
1474138|NCT03166384|Procedure|conventional suture and tie|the surgeon uses electrosurgical bipolar sealing device during tissue dissection and vessel ligation as much as possible.
1474139|NCT03166371|Dietary Supplement|Liposomal Glutathione (GSH)|Two teaspoons (containing 840 mg GSH, 420 mg/tsp) liposomal GSH (ReadiSorb®) will be taken orally twice daily for a total daily dose of 1680 mg GSH/day. Liposomal GSH will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The study product will be consumed daily for 90 consecutive days after hospital discharge.
1474140|NCT03166371|Other|Placebo|Two teaspoons of placebo product will be taken orally twice daily. The placebo will be refrigerated until use and mixed in ≈ 250 mL water or juice for oral intake. The placebo will be consumed daily for 90 consecutive days after hospital discharge.
1474141|NCT03166358|Behavioral|Hatha yoga|8 Hatha yoga classes lasting approximately one hour each and delivered in small group format (i.e., classes no larger than 8 participants). Classes are tailored to address pediatric tension-type headache.
1474142|NCT03166345|Other|Treatment of Thin Endometrium|This is a trial to improve endometrial thickness by autologous injection of PRP into the Uterine Cavity compared with CSF or no treatment.
1474143|NCT03166332|Behavioral|Mediterranean diet|Mediterranean diet supplemented with extra-virgin olive oil and nuts
1474144|NCT03166332|Behavioral|Mindfulness|Mindfulness-Based Stress Reduction program (MBSR)
1474145|NCT03166319|Device|MRI, including intracranial vessel wall imaging|MRI/MRA/intracranial high-resolution vessel wall imaging (HR-VWI)
1474146|NCT03166306|Diagnostic Test|PET-CT Imaging with [89Zr]-bevacizumab|Subjects will receive 1 millicurie of 89Zr and less than 5 mg of bevacizumab, followed by PET-CT imaging.
1474147|NCT03166293|Behavioral|Intensive leg training with a physical therapist|Intensive, self initiated activities of the lower extremities including walking over ground or on a treadmill (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise. A physical therapist will supervise sessions.
1474148|NCT03166293|Behavioral|Intensive leg training with a parent|A parent will be coached by a physical therapist to provide intensive, self initiated activities of the lower extremities including walking over ground (with or without support), kicking, jumping, standing balance, climbing stairs and slopes and other leg activities. Small weights will be added to the ankle and foot to increase the intensity of the exercise.
1474149|NCT03166280|Drug|Sofosbuvir 400 mg|treatment for hepatitis c by sofosbuvir (Sovaldi) 400 mg/day
1474150|NCT03166280|Drug|Daclatasvir 60 mg/day|treatment for hepatitis c by Daclatasvir 60 mg/day
1474151|NCT03166267|Device|External fixator|Tibia fracture (AO 41-43) treated with external fracture fixation (large external fixator)
1474152|NCT03166254|Drug|Pembrolizumab|Pembrolizumab will be given intravenously over the course of 30 minutes (-5 min/+10 min) at 200 mg every 21 days.
1474153|NCT03166254|Biological|Personalized synthetic long peptide vaccine|Each vaccination consists of up to 4 separate injections, with each syringe containing peptides from one of the up to four peptide pools combined with adjuvant (poly-ICLC).
1474154|NCT03166254|Procedure|Biopsy|Surgical or core needle biopsy of an accessible site
1474155|NCT03166254|Drug|Poly ICLC|-This is the adjuvant for the vaccine
2010519|NCT02945696|Procedure|laparoscopic guided nerve blocks|It is common to use ultrasound to define the correct plane for abdominal wall nerve blocks, however, the utilization of laparoscopy to identify this plane is a new intervention that is previously undescribed in children.
1474157|NCT03166254|Procedure|Peripheral blood draw|-Baseline, Cycle 2 Day 1, Cycle 4 Day 1, Cycle 8 Day 1, Cycle 10 Day 1, Time of response (if applicable), and time of progression (if applicable)
1474158|NCT03166241|Diagnostic Test|serum interleukin 21|it is cytokine used as a marker to detect it's level in patients with adverse drug reactions
1474159|NCT03166241|Diagnostic Test|Complete Blood Picture|It is a blood sample will taken from patients to detect any abnormalities in blood component at the start of the study
1474160|NCT03166241|Diagnostic Test|Liver function test|It is a blood sample will taken from patients to detect any associated liver disease at the start of the study
1474161|NCT03166241|Diagnostic Test|Random Blood Sugar|measure blood sugar in patients included in the study at the start of the study
1474162|NCT03166241|Diagnostic Test|Erythrocyte Sedimentation Rate|blood sample will be taken from patients to detect any abnormalities in erythrocyte sedimentation rate at the start of the study
1474163|NCT03166241|Diagnostic Test|Kidney function tests|blood sample will be taken from patients to detect any kidney disease before the start of the study
1474164|NCT03166228|Drug|Normal Saline 0.9% Infusion Solution Bag|0.9% saline as distension medium as long as diathermy is not in use
1474165|NCT03166228|Drug|1.5% Glycine only|1.5% Glycine alone during hysteroscopy as long as diathermy is in use
1474166|NCT03166215|Drug|TAK-935|TAK-935 tablets
1474167|NCT03166215|Drug|Placebo|TAK-935 placebo-matching tablets
1474168|NCT03166189|Biological|bone marrow-derived MSC and HRT|"Transplantation procedure to endometrial cavity is performed with ultrasound guidance on menstrual cycle day 5-6 through uterine cervix using cater for embryo transfer with 1 ml of suspension containing 5 millions of autologous bone marrow-derived mesenchymal stem cells
Three cycles of HRT following MSC transplantation;
Pipelle-biopsy of endometrium on day 20 of hormonal replacement therapy of the last (third) cycle;
Frozen/thawed embryo transfer 3-6 months after transplantation."
1474169|NCT03166189|Other|hormonal replacement therapy|"standard treatment of hypoplastic endometrium or Asherman's syndrome:
Three cycles of HRT preceding frozen/thawed embryo transfer;
Frozen/thawed embryo transfer."
1474170|NCT03166176|Drug|Vistusertib(AZD2014)|vistusertib(AZD2014) is selective inhibitor of mTOR kinases and inhibits signalling of both mTOR complexes, mTORC1 and mTORC2.
1474171|NCT03166163|Drug|Azadirachta indica|Its a herbal mouthwash that will be given to group of Egyptian Children twice daily for 3 weeks
1474172|NCT03166163|Drug|Chlorhexidine mouthwash|its an antimocrobial, antiplaque mouthwash that will be given to a group of Egyptian children twice daily (10 ml each) for 3 weeks
1474173|NCT03166150|Other|Multi-modal rehabilitation program|Patients will receive 12 weeks of exercises.
1474174|NCT03166150|Other|Pelvic Floor Physical therapy|Pelvic Floor Physical therapy
1474175|NCT03166137|Device|Carbon dioxide laser|Radiation by carbon dioxide laser
1474176|NCT03166137|Device|Cryotherapy|Device using cooling effect
1474179|NCT03166111|Drug|lidocaine gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
1474180|NCT03166111|Drug|placebo gel|syringe filled with 5 ml gel to be self-administered vaginal 10 minutes prior to insertion
1474181|NCT03166098|Diagnostic Test|Cognitive Function Assessments|The NIMH-Measurement and Treatment Research to Improve Cognition in Schizophrenia (MATRICS) is a consensus battery that is considered state-of-the art in the evaluation of cognitive skills for schizophrenia research.(Burton et al., 2013, Harvey, 2014) The complete cognitive battery takes about one hour to administer, and is comprised of 10 subtests measuring seven essential domains of function, with very good reliability and validity.(Nuechterlein 2008, August et al., 2012) The MATRICS subtests have been incorporated into the cognitive battery described below, with supplementary subtests included where indicated within each domain.
1474182|NCT03166085|Drug|PU-H71|PU-H71 will be given as an intravenous infusion on Day 1 of a 21 day cycle
1474183|NCT03166085|Drug|Nab-paclitaxel|nab-paclitaxel will be administered at a dose of 260mg/m2 intravenously on Day 1
1474184|NCT03166072|Other|Low-vision rehabilitation program|Low Vision Rehabilitation Program includes functional vision assessments (low-vision refraction), prescription of a variety of visual aids including microscopes, magnifiers, telescopes, absorptive filters and electronic spectacle eyewear, large print books, and automatic self-transcending meditation plus essential skills for daily living and mobility training offered by CNIB including demonstration of visual aids as well as training on proper use of visual aids.
1474185|NCT03166072|Other|No Intervention|Participants will continue to receive treatment as usual
1474186|NCT03166059|Device|CaveoVasc® Thrombolysis Protection System|CaveoVasc® Thrombolysis Protection System for Femoral Artery Access and Protection in Patients Treated with Thrombolysis for Limb Ischemia
1474187|NCT03166046|Device|Pulsed Shortwave Therapy|Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
1474188|NCT03166046|Device|Placebo Pulsed Shortwave therapy|Placebo Stimulation of the supratrochlear and supraorbital branches of the ophthalmic nerve.
1474189|NCT03166033|Other|the disease|Observation the patients and non-patients
1474190|NCT03166020|Other|Rehabilitation|An occupational therapist will be required only for patient installation in front of the table.
1474191|NCT03166007|Behavioral|Abdominal massage|The participant should be supine and in a relaxed atmosphere, though this may depend on level of disability. The massage comprises 4 basic strokes (10minutes); Stroking from the small of the back over the iliac crest and down both sides of the pelvis towards the groin; Effleurage follows the direction of the ascending colon across the transverse colon and down the descending colon. This is repeated several times with increasing pressure; Palmar kneading tracks down the descending colon up the ascending colon and down the descending colon once again. Effleurage is repeated and continued with a relaxing transverse stroke over the abdomen; Vibration over the abdominal wall to relieve flatus concludes the massage session. The participants in this group will receive one telephone call per week for 6 weeks and again at 24 weeks to further discuss their bowel management.
1948600|NCT02091141|Drug|Vemurafenib|Vemurafenib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
1948601|NCT02091141|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
1474192|NCT03166007|Behavioral|Optimised bowel care|During a 1 hour outpatient appointment, the participants' existing bowel care routine will be reviewed and optimised. For example, explaining the necessity of adequate fluid intake. No change in medication will be advocated. The participants in this group will also receive one telephone call per week during the following 6 week period to further discuss their bowel management and again at 24 week time point.
1474201|NCT03165968|Device|Neuro Kinetics, Inc, i-PAS|This is a test of i-PAS device reliability only.
1474202|NCT03165955|Drug|Oraxol|HM30181 methanesulfonate monohydrate - supplied as 15-mg HM30181AK-US tablets, Paclitaxel - supplied as 30-mg capsules
1474203|NCT03165942|Other|Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
1474204|NCT03165942|Other|Non-Alcoholic Beverage|In addition to the oral delivery, an IV line will be placed for the purpose of drawing blood during the MRI session.
1474205|NCT03165942|Drug|Ethanol|
1474206|NCT03165929|Drug|Flurbiprofen|oral flurbiprofen spray
1474207|NCT03165929|Drug|placebo|oral placebo spray
1474208|NCT03165916|Device|Bard 5 Fr diameter feeding tube|A pediatric feeding tube is used as a stent over which biliary anastomosis is performed. This is not a permanent stent and generally migrates out on its own.
1474209|NCT03165903|Behavioral|Cue and Implementation Intention-Based Intervention|Families from a school assigned to Cue and Implementation Intention-Based Intervention received an intervention targeting increased levels of healthy snacking and reduced levels of sugar sweetened beverage consumption. The intervention consisted of a 90-minute meeting with a trained Health Coach, two 20-minute phone calls, 4 tailored newsletters, and a series of emails and text messages. Cues for snacking and sweetened beverage consumption were removed or relocated and implementation-intentions were created to trigger alternative behaviors to snacking and sweetened beverage consumption in the presence of cues. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
1474210|NCT03165903|Behavioral|Control arm|Families that were from a school assigned to Control received an intervention on sun safety that consisted of a 10-minute meeting with a trained Health Coach, 2 generic newsletters, an email, and a text message. Both interventions were delivered over 3-10 weeks depending on the self-directed pace of the participants. All participants completed a follow-up assessment 3 months after consent.
1474211|NCT03165890|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
1474212|NCT03165890|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
1474213|NCT03165877|Other|Low-glycemic index|Subjects ate low-glycemic index lunches and dinners (<55%),consisting of salad, main course and dessert, respectively.
1474214|NCT03165877|Other|Control|Subjects ate standard lunches and dinners (>60%),consisting of salad, main course and dessert, respectively.
1474215|NCT03165864|Drug|IONIS TMPRSS6-Lrx|Ascending single and multiple doses of IONIS TMPRSS6-Lrx administered subcutaneously
1474216|NCT03165864|Other|Placebo|Saline .9%
1474217|NCT03165851|Other|Risk-stratified therapy|Dose-dense intensive chemotherapy and high dose of Ara-C in the consolidation therapy.
1474218|NCT03165838|Behavioral|Postpartum Visit 3-4 Weeks|This visit will be the same as the standard of care postpartum visit, but it will be scheduled earlier.
1474219|NCT03165838|Behavioral|Postpartum Visit 6-8 Weeks|This standard of care postpartum visit will be scheduled for the standard time interval.
1474220|NCT03165825|Drug|Transforaminal Epidural Steroid Injection with Dexamethasone|Transforaminal Epidural Steroid Injection with Dexamethasone
1474221|NCT03165825|Drug|Interlaminar Epidural Steroid Injection with Betamethasone|Interlaminar Epidural Steroid Injection with Betamethasone
1474222|NCT03165812|Procedure|SADJB-SG group|Patients will undergo bariatric surgery. A clear liquid high protein diet will be started in the first two postoperative days. If no complications were detected by physical examination, patients will be stimulated to walk and will be dismissed from the hospital on postoperative day 3. Patients will be subjected to a strict adherence to diet and close monitoring of their blood glucose and HbA1c levels during the study period. Standard follow-up includes a visit to the outpatient clinic at 1, 2, 3, 4 weeks after surgery, then 3, 6, 9, 12, 18, 24 months and after that, a life-long annual visit. Glycaemic control at home will be maintained as in the preoperative period and patients will need to inform the results of their blood glucose levels to the doctor during each follow-up visits.
1474223|NCT03165812|Procedure|IMT group|Patients will be subjected to strict adherence to their diet, optimisation of their diabetic medications and close monitoring of their blood glucose and HbA1c levels at 0, 6, 12, 24 months. The endocrinologist will be monitoring the patients in this group. Detailed individualized lifestyle and dietary counseling will be given by a dietitian emphasizing on nutrition knowledge, the timing of meal with medication, portion control, and increasing daily physical activity level.
1474224|NCT03165799|Behavioral|Mindfulness Education|Mindfulness Education
1474225|NCT03165786|Behavioral|FREE|Cognitive behavioral therapy with real-time continuous glucose monitoring.
1474226|NCT03165773|Other|Oatmeal|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
1474227|NCT03165773|Other|Corn grits|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
1474228|NCT03165760|Procedure|protective ventilation|the aim of the intervention is to ovoid Ventilator induced lung injury and inflammatory stress
1474263|NCT03165448|Diagnostic Test|Post-operative doctor's reported USOS|Operating doctor has to fill the USOS doctor's part o questionnaire just after the procedure.
1474436|NCT03164122|Device|MRI|MRI 3T
1948602|NCT02091141|Drug|Vismodegib|Vismodegib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
1474232|NCT03165721|Drug|SGI-110 (guadecitabine)|SGI-110 will be administered subcutaneously at 45mg/m2/day x 5 days on a 28-day cycle. Cycles may be repeated until there is evidence of tumor progression clinically or by RECIST v1.1 or there is intolerable toxicity that is not alleviated by dose reduction.
1474233|NCT03165695|Drug|Ramelteon|Ramelteon 8 mg tablet orally at 21:00 for 7 days or until discharge whichever comes first
1474234|NCT03165695|Drug|Placebo|Placebo, 1 tablet orally at 21:00 or until discharge whichever comes first
1474235|NCT03165669|Device|"Viscospring PostuRite - medium model"|Cervical pillow use, 30-minutes instruction session supported by a brochure
1474236|NCT03165669|Other|Education|30-minutes educational session delivered by a physical therapist and supported by an informative brochure.
1474237|NCT03165643|Diagnostic Test|OGTT|75 g glucose tolerance test was provided to all pregnant women during 24-28 weeks.
1474238|NCT03165630|Behavioral|Transportation incentives|Free transportation only for the first 3 months post-discharge.
1474239|NCT03165630|Behavioral|Transportation and rehabilitation services incentives|Free transportation and rehabilitation services 3 months post-discharge.
1474240|NCT03165617|Biological|QIVc|Cell-derived Quadrivalent Influenza Vaccine for intramuscular use containing each of the 2 influenza type A strains and each of the 2 influenza type B strains
1474241|NCT03165617|Biological|Non-influenza Comparator Vaccine|Non-influenza comparator vaccine for intramuscular use
1474242|NCT03165604|Other|standard information|The participates will be given a standard information regarding the water drink before physical activity
1474243|NCT03165604|Other|positive information|"The participates will be given positive information (the drink will be presented as an energy drink) regarding the drink before physical activity"
1474244|NCT03165591|Biological|V3-P|one tablet of V3-P given once daily for 2 months
1474245|NCT03165578|Other|Neurofeedback training|In a neurofeedback setting, brain activity is measured non-invasively, the brain imaging data is analyzed in real-time, and then feedback regarding the current level of brain activity is provided to the subject.
1474246|NCT03165578|Other|Sham Feedback|Sham controlled neurofeedback training. Subjects in the sham control group will undergo the same procedure as subjects in the experimental group, but instead of being shown feedback derived from their own brain activity, they will be shown replayed feedback values from a randomly chosen subject of the experimental group.
1474249|NCT03165552|Other|Acute kidney injury education|A face to face, a constructivist learning approach to encourage users to explore and learn about the topic of AKI in a way that maximises educational value. The programme is supported by a web based resource that presents a series of realistic case studies highlighting common causes of AKI in primary care designed to be easy to access and navigate, whilst being visual and interactive to enhance user engagement. The educayion is delivered to healthcare staff not to patients.
1474251|NCT03165526|Device|AMPLATZER™ Post-infarct Muscular VSD Occluder|The AMPLATZER™ PIVSD Occluder is intended for percutaneous transcatheter closure of post-myocardial infarct muscular VSDs in patients who are not satisfactory surgical candidates.
1474252|NCT03165513|Behavioral|mhGAP-IG|psychosocial interventions
1474253|NCT03165500|Drug|Diazepam|"Patients' vital signs (blood pressure, heart rate and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with diazepam 5mg, during the extraction procedure and 15 minutes after the extraction.
After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
1474254|NCT03165500|Drug|Midazolam|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of oral sedation with midazolam 7.5mg during the extraction procedure and 15 minutes after the extraction.
After the surgical procedure of extraction, the patients remained in recovery in the same room, being the criteria of discharge realized, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid."
1474255|NCT03165500|Drug|Nitrous Oxide + Oxygen Gas|"Patients' vital signs (blood pressure, heart rate, and oxygen saturation) were measured and recorded after 30 minutes of sedation Inhalation with the mixture of 40% of nitrou oxide and 60% of oxygen, during the exodontia procedure and 15 minutes later.
After the surgical procedure of extraction, the patients remained in recovery in the same room, being the discharge criteria performed, from the normality of the vital signs and the response to the verbal commands, with the patient responsive and lucid, and after the accomplishment of the test developed by Trieger et al.,(1971)."
1474256|NCT03165500|Procedure|Third molar extraction|Anxious patients in need of third molar extraction
1474257|NCT03165487|Other|Breast tissue collection|During Breast Conservation Surgery, one sample will be collected before and after IORT.
1474258|NCT03165487|Other|Blood sample collection|Blood will be collected before and after IORT, and at the two week follow-up.
1474259|NCT03165474|Other|Web-based comic and newsletters|Web-based comic and health messages (child component) and health newsletters (parent component)
1474260|NCT03165474|Other|Didactic health information|Didactic health information and resources by email and/or text
1474261|NCT03165448|Diagnostic Test|Pre-operative USOS scale testing|Patient has to self-report USOS questionnaire just before the procedure as main scale.
1474262|NCT03165448|Diagnostic Test|Pre-operative SDPQ, MDAS and VAS testing|Patient has to sel-report SDPQ, MDAS and VAS questions as control scales.
1948603|NCT02091141|Drug|Alectinib|Alectinib will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
1474264|NCT03165448|Diagnostic Test|Re-testing 4-6 weeks later|All the participants has to refill USOS questionnaire 4-6 weeks later.
1474265|NCT03165435|Biological|CV-MG01|3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
1474266|NCT03165435|Biological|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
1474267|NCT03165422|Other|Non-Interventional|Non-Interventional
1474268|NCT03165409|Biological|Nivolumab|Melanoma intervention
1474269|NCT03165409|Biological|Ipilimumab|Melanoma intervention
1474270|NCT03165396|Drug|Propofol|Propofol is the most common clinical anesthetics.
1474271|NCT03165396|Drug|Sevoflurane|Sevoflurane is the most common clinical anesthetics.
1474272|NCT03165383|Drug|Bupivacaine (Transversus Abdominis Plane Block)|Intervention - At the end of surgery Ultrasound guided Transversus Abdominis Plane block was given with 20 ml 0.25 % bupivacaine bolus and repeated every 8 hourly up to 24 hours.
1474273|NCT03165383|Drug|Intravenous Patient Controlled Analgesia (PCA) Morphine|PCA Intravenous Morphine 1 milligram bolus on demand was given as rescue analgesia up to 24 hours.
1474274|NCT03165357|Dietary Supplement|Sodium bicarbonate supplementation|
1474275|NCT03165357|Dietary Supplement|Placebo treatment|
1474276|NCT03165344|Other|Hydrocortisone sodium succinate mixed with Aluminium Phosphate gel (route of administration)|the test group begin to take hydrocortisone sodium succinate mixed with Aluminium Phosphate gel after 24 hours and gradually reduse the dose.
1474277|NCT03165344|Other|Triamcinolone Acetonide (route of administration)|The control group will get local injection of triamcinolone acetonide in wound during the operation.
1474278|NCT03165344|Other|Prednisone (route of administration)|The control group begin to take oral prednisone after 24 hours and gradually reduse the dose.
1474279|NCT03165331|Other|UNG Face IT|UNG Face IT is an online intervention tool (programme) that provides easy access to specialist advice and support via a home computer/tablet, using illustrations, information, videos, and interactive activities, and a discussion forum for participants only (supervised by the research team). Through these tools, it provides advice and teaches coping skills based on cognitive behavioural therapy and social interaction skills training.
1474280|NCT03165318|Device|Pulsed Electromagnetic Field Therapy|"Participants of this arm will be exposed to 10 minutes of Pulsed Electromagnetic Field (PEMF) once a week for a total of 16 weeks.
The PEMF device produces pulsed magnetic fields at flux densities up to 1 mT peak."
1474281|NCT03165318|Device|Sham Therapy|"Participants of this arm will be exposed to 10 minutes of sham therapy once a week for a total of 16 weeks.
The Sham device is identical to the PEMF device in physical appearance."
1474282|NCT03165305|Other|Sustained Inflation|Administering a pressure of 30 cm H20 by a T-piece resuscitator for 5 seconds immediately after birth.
1474283|NCT03165292|Radiation|131I- mIBG|Day 1 131I-mIBG course 1: about 444MBq/kg with in vivo whole-body dosimetry Day 15 131I-mIBG course 2: the target is to deliver a combined whole-body radiation dose of 4 Gy
1474284|NCT03165292|Drug|Topotecan|Day 1-5 Topotecan 0.7 mg/m2 daily Day 15-19 Topotecan 0.7 mg/m2 daily
1474285|NCT03165292|Drug|Thiotepa|Day 1-3 Thiotepa 300 mg/m²/day
1474286|NCT03165292|Procedure|Autologous stem cell transplant|ASCT as soon as radiation level allows it in ARM A
1474287|NCT03165279|Procedure|Zenith Alpha Abdominal stentgraft|
1474288|NCT03165266|Diagnostic Test|Two dimensional Echocardiography|"I- Routine transthoracic assessment for Left Atrium and Left Ventricle dimensions :
II- transthoracic assessment of the Right ventricular systolic function by:
. Right Ventricle fractional area change.
. Tricuspid annular plane systolic excursion .
. Tissue Doppler derived tricuspid annular systolic velocity.
. Right ventricle myocardial performance index . III- Assessment of Right ventricular diastolic function: is carried out by pulsed Doppler of the tricuspid inflow, or tissue Doppler of the lateral tricuspid annulus.
IV Assessment of Right Ventricle chamber quantification:
Right ventricular basal, mid ,and longitudinal dimensions.
Right ventricular Outflow Tract, and wall thickness V- Assessment of right atrial major ,and minor dimensions ,and right atrial End- systolic area IV- Assessment of longitudinal Right ventricular strain and strain rate by speckle tracking"
1474289|NCT03165253|Drug|Bifidobacterium Animalis Oral Product|The synbiotic group will receive this product.
1474290|NCT03165253|Drug|Amoxicillin Oral Tablet|50mg/kg/day B.I.D.
1474291|NCT03165253|Drug|Clarithromycin Oral Tablet|15 mg/kg/day B.I.D.
1474292|NCT03165253|Drug|Omeprazole|1 mg/kg/day
1474298|NCT03165214|Device|coil|microcoils
1474299|NCT03165214|Device|hystoacryl glue|hystoacryl mixed with lipidol
1474300|NCT03165201|Device|LiverMultiScan|We will study participants who are due to be evaluated for possible liver transplant rejection. There will be no change to usual care as part of the study, but patients will get an additional MRI scan, so that the results can be compared to the biopsy results. Each centre has a consultant radiologist specialising in liver imaging with experience in post-transplant review; the radiologist will review the MRI scans and inform the patient's doctor if any structural liver abnormalities are found (e.g. abnormal vessels, haemangiomas, tumours or cysts) as this may have implications for the patient's planned biopsy.
1474301|NCT03165175|Behavioral|MedAware|As a patient-centered prevention effort, MedAware is a brief intervention in a mobile phone app that focuses on helping military members reduce their risk for prescription drug misuse. It contains modules to: (1) assess risk for misuse and related behavioral health concerns; (2) provide individualized feedback on risk level; (3) store information on current medications and look up drug interaction and related information; (4) enhance communication and decision-making skills within healthcare and other interpersonal contexts by providing interactive scenarios; (5) teach about the risks of prescription drug misuse; and (6) provide available resources for help with prescription drug misuse.
1474302|NCT03165162|Behavioral|Food Order|randomly assigned orders of 7 bowls of granola, each with a different food label.
1474303|NCT03165149|Drug|group (A)|patients will receive 1mg / kg of Ketamine diluted by 20 ml saline (0.9 % ) and irrigated onto surgical field after hemostats and before skin closure.
1474304|NCT03165149|Drug|group (B)|patients will receive 2 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
1474305|NCT03165149|Drug|group (c)|patients will receive 3 mg /kg of Ketamine diluted by 20 ml saline (0.9 %) and irrigated onto surgical field after hemostasis and before skin closure.
1474308|NCT03165123|Drug|Oral Erythromycin A tablet|Oral erythromycin A tablet will be given one hour before induction of anaesthesia.
1474309|NCT03165123|Drug|Intravenous dexamethasone|5 mg of intravenous dexamethasone is given within one to two minutes after the umbilical cord is clamped.
1474310|NCT03165110|Device|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed the features of the App.
1474311|NCT03165097|Drug|ACT-709478|Hard gelatine capsules for oral administration
1474312|NCT03165097|Drug|Placebo|Placebo capsules matching ACT-709478 capsules
1474313|NCT03165084|Behavioral|Intervention arm: Person-centred interactive self-management support|"Person-centred tailored digital self-management support hypothesised to decrease HbA1c, improve other metabolic measurements, improve lifestyle habits, and increase diabetes empowerment, increase diabetes-dependent quality of life, improve illness perception, and improve eHealth literacy.
Access to the diabetes mobile application and the homepage during 16 weeks. Each individual will set personal goals for use of the digital resources."
1474314|NCT03165084|Other|Control arm|Participants will receive usual care and take part in a minimal intervention in the form of a brochure on the importance of self-management in diabetes.
1474315|NCT03165084|Other|External comparison group|External comparison groups in order to analyse possible Hawthorne effects.
1474317|NCT03165058|Diagnostic Test|mucosal impedance (MI) testing|During routine colonoscopy, consented study participants will have a MI catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The physician will take measurements in each segment of the colon, including segments that appear inflamed and normal adjacent areas (up to 10 locations). To obtain a stable reading, the sensor must remain in contact with the mucosa for five seconds. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant. Basic demographic information, prior IBD treatments, and prior colonoscopic data will be collected from the medical record following the procedure for those patients who consent to research.
1474319|NCT03165006|Procedure|Mode of detection: Cancer detected at screening|Cancers detected as a result of screening mammograms.
1474320|NCT03165006|Procedure|Mode of detection: Interval cancer|Cancers diagnosed after a negative screening mammogram and before the next screening invitation (2 years in Spain)
1474321|NCT03164993|Drug|Atezolizumab|Atezolizumab is a monoclonal antibody designed to target and bind to a protein called PD-L1 (programmed death ligand-1), which is expressed on tumour cells and tumour-infiltrating immune cells. PD-L1 interacts with PD-1 and B7.1, both found on the surface of T cells, causing inhibition of T cells. By blocking this interaction, Atezolizumab may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells.
1474322|NCT03164993|Drug|Pegylated liposomal doxorubicin|Chemotherapy
1474323|NCT03164993|Drug|Cyclophosphamide|Chemotherapy
1474324|NCT03164993|Other|Placebo|Placebo
1474325|NCT03164980|Other|no intervention - observational study|To compare QoL in patients treated with trabectedin/PLD vs. other standard combination therapy of carboplatin/ PLD, carboplatin/ gemcitabine, or carboplatin/ paclitaxel
1474326|NCT03164967|Biological|Bivigam|
1474327|NCT03164954|Diagnostic Test|automatic risk detection|automatic alert of the risk for CPSP, triggered by one of the following entries in the hospital information system: psychological risk factors (depression, anxiety, PTSD, catastrophizing, high pain anticipation), chronic use of benzodiazepines or opioids, intense postoperative pain or need of large opioid doses in the recovery room
1474328|NCT03164941|Procedure|Selective Laser Trabeculoplasty|Laser treatment for glaucoma.
1474331|NCT03164915|Biological|LIV-GAMMA SN Inj.|
1474332|NCT03164902|Device|Digital Medicine|The subjects in the study will be monitored using the Proteus Discover offering. Subjects will use Proteus Discover plus a digital version of HCV therapy (IS co-encapsulated with fixed-dose ledipasvir and sofosbuvir, fixed-dose velpatasvir and sofosbuvir, or fixed-dose combination of elbasvir and grazoprevir). The subject's prescribed HCV medication (e.g., fixed-dose combination of ledipasvir and sofosbuvir, fixed-dose combination of velpatasvir and sofosbuvir, or fixed-dose combination of elbasvir and grazoprevir) will be co-encapsulated with the Proteus Ingestible Sensor pill by an appropriately licensed and qualified pharmacy as per a licensed health care provider's order (prescription).
1474333|NCT03164889|Drug|Granulocyte Macrophage-colony Stimulating Factor|The intervention drug was used as an immunomodulator in order to improve rates of HBsAg loss and HBeAg loss.
1474334|NCT03164889|Drug|Entecavir|Antiviral drug for hepatitis b virus (HBV)
1474335|NCT03164876|Drug|AUT00206|4 capsules of 200mg AUT00206, twice daily, to take orally with food for 4 weeks
1474336|NCT03164876|Drug|Placebo|4 capsules of placebo, twice daily, to take orally with food for 4 weeks
1474337|NCT03164863|Diagnostic Test|Onco4D Biodynamic Chemotherapy Selection Assay|The Onco4D Biodynamic Chemotherapy Selection Assay uses Motility Contrast Tomography (MCT) to measure ex-vivo fresh tumor biopsy response when challenged by an array of chemotherapeutic agents. A machine learning algorithm uses the MCT datastream to predict in vivo tumor response or non response to chemotherapy.
1474338|NCT03164850|Device|Laparoscopic Tactile Imaging|Provides Tactile feedback during laparoscopic surgery
1474339|NCT03164837|Drug|68Ga-NOTA-RM26|Single-dose 68Ga-NOTA-RM26 were injected into the patients before the PET/CT scans.
1474437|NCT03164109|Drug|GC4419 IV|50mg infused IV over 15 minutes
1474340|NCT03164824|Other|questionnaire|"Cross-cultural adaptation stage:
The FRI was cross-culturally adapted to Thai (called the Thai FRI) and the pre-final version of the Thai FRI was administered to patients.
Psychometric properties testing stage:
The questionnaires were administered 3 times: the first visit, the second visit and at 2 weeks.
At the first visit: the patients with back pain completed the Thai FRI , Thai Roland-Morris Disability (Thai RM), Thai modified Oswestry Low Back Pain Disability (Thai modified ODQ), Thai multi-level Roland-Morris Disability (Thai multi-level RM). The patients with neck pain completed the Thai FRI and Thai Neck Disability Index.
At the second visit: all patients completed the Thai FRI and Global Perceived Effect Scale (GPES).
At 2 weeks: the patients completed the same questionnaires as the first visit. All patients and their treating physical therapists completed the GPES."
1474341|NCT03164811|Procedure|goal directed fluid therapy|give fluid bolus if PPV >13
1474342|NCT03164811|Other|Controlled|standard fluid treatment
1474343|NCT03164798|Procedure|Conventional inpatient rehabilitation|comprehensive inpatient rehabilitation for 2 weeks
1474345|NCT03164772|Drug|Durvalumab|anti-PD-L1
1474346|NCT03164772|Drug|Tremelimumab|anti-CTLA-4
1474347|NCT03164772|Biological|BI 1361849|mRNA Vaccine
1474348|NCT03164746|Other|Dry sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in Dry damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
1474349|NCT03164746|Other|WET sheet Therapeutic body wraps|At the beginning of the session, the patient's consent to proceed was orally obtained, as no session was compulsory. The therapists checked behavioral manifestations of refusal. Then, the patient was first wrapped in wet damp sheets (cold phase) and covered up with a rescue and a dry blanket. Afterward the body spontaneously warmed up (warm phase). The patient was then invited to freely express his feelings.
1474350|NCT03164733|Other|incubation|standardized wear particles are co-incubated with isolated patient cells (monocytes)
1474351|NCT03164707|Diagnostic Test|Blood Glucose Level|ON Admission Blood Glucose Level Fasting Blood Glucose Level
1474352|NCT03164694|Drug|Apatinib|Apatinib was given 850 mg per day orally.
1474353|NCT03164694|Drug|Pemetrexed|pemetrexed (500 mg/m2)
1474354|NCT03164694|Drug|Carboplatin|carboplatin (AUC =5)
1474355|NCT03164668|Other|menthol flavored e-cigarette|menthol flavored e-cigarette
1474356|NCT03164668|Other|tobacco flavored e-cigarette|tobacco flavored e-cigarette
1474357|NCT03164655|Drug|Oxaliplatin, Cetuximab, Bevacizumab, Panitumumab, Irinotecan, Leucovorin, 5Fluorouracil|Oxaliplatin 100mg/m² infusion in 2 hours, Cetuximab 500mg/m² infusion in 2 hours, Bevacizumab 5mg/kg infusion in 30 minutes, Panitumumab 6mg/kg, Irinotecan 180mg/m² over 90 minutes to begin 30 minutes after folinic acid infusion is started, Leucovorin 400mg/m² infusion in 2 hours, 5Fluorouracil 2400mg/m² infusion continuous in 46h
1474358|NCT03164642|Behavioral|LENA with Feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations. During their regular EI providers will use a standardized feedback protocol that includes emphasizing the mother's strengths, reviewing the LENA visual output from the previous recording, and asking questions to elicit how the mother can increase her child-centered and reciprocal communications during daily routines. The conversation will include concrete examples of how the mother can increase the language exchanges, encouragement, and practical ways to individually tailor the strategies to the family.
1474359|NCT03164642|Behavioral|LENA no feedback|The LENA with Feedback intervention will involve mothers running the Language ENhancement Assessment/intervention system, an audiorecorder language pedometer that records adult speech centered on the child, child vocalizations, and parent-child reciprocal turn-taking conversations
1474360|NCT03164629|Device|cone-beam CT 3D Emboguide|cone-beam CT with Embolization Guidance software (Emboguide) to identify prostatic arteries and assist endovascular navigation, by projecting a 3D road map of prostatic arteries on live fluoroscopy, in order to differentiate them from non-target vessels.
2010520|NCT02945696|Drug|Ropivacaine|Ropivacaine is a local anesthetic used to prevent pain during and after procedures. In this study, ropivacaine will be injected either directly at the port sites, or for a regional abdominal wall nerve block, either under ultrasound or laparoscopic guidance.
1474368|NCT03164603|Drug|NLG802|Indoleamine 2,3-Dioxygenase (IDO) Inhibitor
1474369|NCT03164590|Drug|Ketamine|patients receive local anesthetic wound infiltration with 1 mg /kg ketamine
1474370|NCT03164590|Drug|dexmedetomidine|patients receive local anesthetic wound infiltration with 1µg/kg dexmedetomidine
1474371|NCT03164590|Drug|bupivacaine|patients receive local anesthetic wound infiltration with bupivacaine 0.5 % diluted in 20 ml saline
1474372|NCT03164577|Behavioral|Drum-Assisted Recovery Therapy for Native Americans (DARTNA)|An intervention that utilizes AI/AN drumming as its core component of treatment.
1474373|NCT03164577|Other|Usual Care Plus|Participants randomized to usual care plus will participate in activities for approximately the same amount of time as DARTNA participants. They will engage in health and wellness education session once weekly for 6 weeks. They will also receive care for their alcohol and other drug use, This typically consists individual counseling, group therapy, and AI/AN traditional activities in their community.
1474380|NCT03164551|Device|GERI+ incubator|The embryo culture of consented subjects will be carried out in GERI+ incubator for both bright-field and dark-field time lapse monitoring until Day 3 of embryo culture. On Day 3, all embryos will be reviewed firstly by GERI Assess software, using bright-field imaging. A GERI Assess score will be calculated for each embryo. The three embryos with the highest GERI Assess scores of a subject are then further assessed by Early Embryo Viability Assessment (EEVA). Finally the embryo(s) with the highest EEVA grade among the three are transferred and will be followed up until the achievement of implantation and confirmation of pregnancy.
1474381|NCT03164551|Device|Conventional incubator|The embryo culture of consented subjects will be carried outin conventional incubator for culture until Day 3 of embryo culture. On Day 3 of embryo culture, all embryos are assessed using a bench-top microscope. The embryo(s) with optimal cell stage and grade will be transferred and will be followed up until the achievement of implantation and confirmation of pregnancy.
1474382|NCT03164538|Behavioral|PP-MI health behavior intervention|Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the study sessions.
1474383|NCT03164538|Behavioral|Diabetes education intervention|Educational topics include diabetes self-care, medication adherence, physical activity, and having a healthy diet.
1474384|NCT03164525|Diagnostic Test|Critical care pain observation tool (CPOT)|test validity and reliability of Thai-version CPOT and BPS
1474385|NCT03164512|Drug|Oral or vaporized cannabidiol|Acute drug exposure
1474386|NCT03164512|Drug|Placebo|Placebo capsule/vapor
1474387|NCT03164499|Behavioral|Individual counselling on lifestyles|Individual standardized counselling on healthy diet, daily physical activity, stress management, smoking cessation, and moderation in alcohol consumption.
1474388|NCT03164499|Behavioral|Additional group counselling on lifestyles|"Group sessions focusing on cardiovascular risk, diet and moderation in alcohol consumption, physical activity and stress management, and smoking cessation will be held in health centres for four consecutive weeks. Each session will last 60-90 minutes, and will be led by two trained nurse practitioners. Ten participants will assist each group. During each session, attendance will be recorded and printed educational materials related to the topic addressed will be distributed.
Follow-up calls to reinforce lifestyle modification and record the barriers to behaviour change found will be performed 6 and 9 months after enrolment."
1474389|NCT03164486|Drug|18F-αvβ6-BP|Subjects will be injected once with up to 10 mCi of 18F-αvβ6-BP as a rapid intravenous bolus (within 30 seconds).
1474390|NCT03164473|Drug|Rituximab|pre-emptive 500-mg fixed-dose of IV rituximab every 6 months (total duration of 18 months = 4 infusions)
1474391|NCT03164473|Drug|Azathioprine|oral tablets : 2 mg/kg/day for 24 months
1474392|NCT03164473|Drug|Placebo-rituximab|4 infusions for 18 months
1474393|NCT03164473|Drug|Placebo-azathioprine|oral tablets for 24 months
1474394|NCT03164460|Radiation|SBRT|Participants receive 45 Gy in 5 fractions prescribed to PTV delivered every other day for an overall treatment time of two weeks.
1474395|NCT03164460|Radiation|IMRT/IMPT|Participants receive 66 - 70 Gy delivered in 33 - 35 fractions 1 time each weekday (Monday-Friday) for a total of up to 30-35 treatments.
1474396|NCT03164460|Behavioral|Questionnaires|Symptom and quality of life questionnaires completed at baseline, before and after radiation treatment, at each visit during radiation therapy, and 2 months after last radiation treatment and then every 3 months after that for up to 2 years.
1474399|NCT03164421|Drug|N-Acetylcysteine|N-Acetylcysteine in clomiphene resistant pcos women
1474400|NCT03164421|Drug|L-carnitine|L-carnitine in clomiphene resistant pcos women
1474401|NCT03164408|Procedure|Orthopaedic Implant Removal|
1474402|NCT03164395|Procedure|Internal Cardioversion|Internal Cardioversion with device maximum output shock from RV coil to Can versus external cardioversion per institutional protocol
1474403|NCT03164395|Procedure|External Cardioversion|External Cardioversion per institutional protocol
1474404|NCT03164382|Drug|FOLFOX regimen|
1474405|NCT03164382|Drug|Sorafenib 200Mg Tab|
1474406|NCT03164356|Other|Socket Modification Regime|Data obtained from the arm 1 cohort will be used to inform socket modifications made for arm 2 cohort.
1474407|NCT03164343|Device|Pain Neuroscience Education for children|Children and their parent will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
1474408|NCT03164330|Behavioral|Workplace Wellness Program|Treatment group members will then be offered the opportunity to participate in a biometric screening and health risk assessment (biometric screening + HRA), and -- conditional on completing an biometric screening + HRA -- up to two, semester-long wellness programs. Treatment group members will be offered varying levels of cash reward for completing the biometric screening + HRA (none, moderate, high), and an additional cash reward for completing each wellness activity (low, high), for a total of 6 treatment cells. Follow-up surveys and biometric screenings will be administered one year later, among a subset of control and treatment group members.
1474409|NCT03164330|Behavioral|Biometric Screening/HRA - No Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. No compensation for completion.
1474410|NCT03164330|Behavioral|Biometric Screening/HRA - Moderate Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, & waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); & (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. Moderate compensation for completion.
1474411|NCT03164330|Behavioral|Biometric Screening/HRA - High Compensation|The biometric test will measure: (1) anthropometrics such as height, weight, and waist circumference (to assess obesity and overweight status); (2) resting blood pressure (to assess hypertension); (3) blood glucose (to assess diabetes risk); and (4) total, LDL, and HDL cholesterol levels, total cholesterol ratio, and triglycerides (to assess risk of cardiovascular disease). The HRA is a survey designed to identify areas of health improvement, by asking a series of questions related to wellness, health status, nutrition, healthy activities, desire to improve health, preventative health measures. The HRA is also pre-populated with biometric information from the screening. Upon completion, participants are given customized feedback on areas of improvement. High compensation for completion.
1474412|NCT03164330|Behavioral|Wellness Activities - Low Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. Low compensation for each class.
1474413|NCT03164330|Behavioral|Wellness Activities - High Compensation|Courses are designed by the UI Wellness Center and include an Active Living class; self-paced online health challenges in physical activity, weight management, and healthy eating; a weight management class; a tobacco cessation hotline; a stress management class; a Tai Chi class; and a chronic disease management class. High compensation for each class.
1474414|NCT03164317|Other|Intervention|A trained nurse care coordinator enabled with a electronic decision support system placed at the CHCs to share the task of management of hypertension.
1474415|NCT03164317|Other|Control|No NCC or EDSS will be placed in the CHCs. Doctors working in the CHCs will be given training (one day) on evidence based management of hypertension
1474416|NCT03164304|Drug|Magnesium Sulfate|intravenous
1474417|NCT03164291|Drug|Rifabutin|Rifabutin dosage dependent on clinical factors such as age, weight, and patient-specific health status
1474418|NCT03164278|Behavioral|Independent Transfer Training|Independent Transfer Training Program: ITTP training starts with an overview and self-evaluation using the transfer assessment instrument questionnaire (TAI-Q) followed by three core modules: wheelchair setup, body setup, and flight/landing. Wheelchair setup includes factors such as the angle and distance of the wheelchair to the transfer surface, removing barriers, applying the brakes, and height of the transfer. Body setup involves positioning one's body for an optimal transfer and covers foot, hip, arm and hand positions. Flight/landing discusses how to achieve a smooth and controlled transfer, the head-hips relationship, use of transfer device, and safe landing.
1948604|NCT02091141|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm, until tumor progression or occurrence of unacceptable toxicity.
1474420|NCT03164252|Radiation|Grupo I- Lower laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
1474421|NCT03164252|Radiation|Grupo II- Greater laser fluency|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
1474422|NCT03164252|Radiation|Grupo III- Laser sham|The region determined for the application of the laser will be 4 points of the gingival mucosa: 1 - center of the alveolus; 2- center of the cervical third of the lingual face; 3 - lingual face; And 4 - apical third of the lingual face. The application time of the laser will be divided equally between the four points of application.
1474423|NCT03164239|Behavioral|Intervention group - telephone and print exercise intervention|Intervention has previously been described.
1474424|NCT03164226|Device|Digital plethysmography in the diagnosis of Acute Coronary Syndrome|To verify the contribution of digital plethysmography in the early diagnosis of acute coronary syndrome in emergency departments.
1474425|NCT03164213|Device|experimental: tDCS|The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of anodal-tDCS (1mA) will be administered at the beginning of the daily treatment session. Following the stimulation will be 45 minutes of naming therapy.
1474426|NCT03164213|Device|sham tDCS|"The anode will be placed over the left M1 representation of the hand (C3 of the 10-20 EEG system). Twenty minutes of sham-tDCS will be administered at the beginning of the daily treatment session.
During sham-tDCS, the current will be ramped up and remained at 1mA only for 30 s before ramping down, which does not affect neural functions, but assures effective blinding of participants due to the initial tingling sensation on the scalp. Following the sham stimulation will be 45 minutes of naming therapy."
1474427|NCT03164200|Other|High fat breakfast|High fat breakfast
1474428|NCT03164200|Other|Higher carbohydrate breakfast|Higher carbohydrate breakfast
1474429|NCT03164187|Drug|Diabeton 60 MR|Administer Diabeton MR 60 mg 1/2 tablet. Increasing dosage of Diabeton MR 60 mg by ½ tablet is recommended if fasting glucose level exceeds 6 mmol/L.
1474430|NCT03164161|Device|Cold pressor test|Described before.
1474431|NCT03164161|Other|β-endorphins evaluation in saliva|Described before.
1474432|NCT03164161|Other|β-endorphins evaluation in blood plasma|Described before.
1474433|NCT03164148|Device|T-REX TRI00A|Case management consists of confirmation of hospital visit date, checking the adverse effect
1474434|NCT03164135|Genetic|CCR5 gene modification|CD34+ hematopoietic stem/progenitor cells from donor are treated with CRISPR/Cas9 targeting CCR5 gene.
1474439|NCT03164109|Drug|Oral moxifloxacin|400 mg tablet orally with 250 mL room temperature water
1474440|NCT03164096|Drug|Bupivacaine Hydrochloride|intrathecal bupivacaine will be used for spinal anesthesia in obstetric patients undergoing C-section
1474441|NCT03164083|Biological|Mesenchymal stem cell|intra articular injection of mesenchymal stem cell Other Name: stem cell transplantation
1474442|NCT03164083|Biological|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
1474457|NCT03164031|Device|Orthotic shorts|The orthotic shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. They will provide both the orthotic shorts and a pair of placebo shorts for each participant, both constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the compression and fit of the shorts, such as whether support for the lower trunk is required. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
1474458|NCT03164031|Device|Placebo shorts|Placebo shorts will be custom-made by DM Orthotics, a UK based company that specialises in dynamic, elastomeric orthoses for healthcare and sport. Shorts will be constructed from a 275 g/m2 fabric, which is 51% Polyamide, 32% Dorlastan and 17% cotton. A company representative will assess each participant to decide the fit of the shorts. The shorts can be manufactured with a toileting hole, if preferred, allowing participants to toilet without removing the shorts. Shorts with a toileting hole are worn beneath usual underwear.
1474459|NCT03164018|Drug|Fampridine|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments and management of the disease will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behavior.
1474460|NCT03163992|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200 mg every 3 weeks (Q3W)
1474461|NCT03163979|Biological|18F-FDG PET/CT and Comet assay guide RapidArc|1.A Rapid-Arc plan for cancer of the cervix uteri improved the sparing of organs at risk (OARs) with uncompromised target coverage. 2.Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
1474462|NCT03163979|Biological|18F-FDG PET/CT and Comet assay guide IMRT|Based on FDG-PET/CT and comet analysis, higher doses of irradiation can be delivered to low sensitivity tumor region, so as to achieve individualized treatment.
1474463|NCT03163979|Biological|RapidArc|"RapidArc:
A maximum DR of 600 MU/min was set for comparing the 7f-IMRT treatment time. Two 360° coplanar arcs (one clockwise arc rotated from 181° to 179° and the other counter-clockwise arc rotated from 179° to 181°) sharing the same isocentre were used."
1474464|NCT03163979|Biological|7f-IMRT|seventy-five patients received IMRT. The 7f-IMRT gantry angles were 0°, 51°, 102°, 153°, 204°, 255° and 306°, with 20 intensity levels and a dose rate of 400 monitor units (MU)/min. Doses were delivered using the step-and-shoot method.Conventional fractionation was used in all patients for a total dose 45-50.4 Gy with 6 MV high-energy photons.
1474465|NCT03163966|Drug|CR6086|oral CR6086 capsules
1474466|NCT03163966|Drug|Methotrexate|oral Methotrexate tablets
1474467|NCT03163966|Drug|Placebo|oral CR6086 Placebo capsules
1474468|NCT03163953|Behavioral|TPAG with long break|PA coaching based on Thai Physical Activity Guideline (TPAG) and long break or break 15 minutes for every 2 hours (TPAG with LB)
1474469|NCT03163953|Behavioral|TPAG with short break|PA coaching based on TPAG and short break or break 1-2 minutes for every 1 hours (TPAG with SB)
1474470|NCT03163953|Other|Control|No intervention
1474471|NCT03163940|Behavioral|Laughter Yoga|A LY group will be composed of 8-12 participants. Each sessions will include 4 essential elements steps of laughter yoga, laughter meditation and grounding exercises. The 4 steps of laughter yoga are 1) warm up exercise, 2) deep breathing exercises, 3) childlike playfulness and 4) laughter exercises. The laughter meditation is a deeper experience of unconditional laughter in which laughter often comes in natural waves and it becomes infectious and set off a chain reaction to infect other people. The grounding exercises allow individuals to ground the energy of laughter and relax. The LY intervention will be facilitated by a certified lead LY trainer.
1474472|NCT03163927|Other|Simulation-based training|See arm description
1474473|NCT03163914|Drug|Epinephrine|Epinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
1474474|NCT03163914|Drug|Norepinephrine|Norepinephrine infusion rate will adjust 30 ml/h (5µg/ ml )
1474475|NCT03163914|Drug|Phenylephrine|Phenylephrine infusion rate will adjust 30 ml/h (100µg/ ml )
1474476|NCT03163901|Other|Osteopathic Manipulative Treatment|OMT techniques applied in the thoracic spine soft tissue, cervical spine soft tissue, suboccipital release, occipital condyle condylar decompression, and cranial venous sinus release.
1474477|NCT03163888|Procedure|Navigation TKR|Traditional over Conventional TKR
1474478|NCT03163875|Other|Hospital Anxiety and Depression Scale|To assess the levels of depression and anxiety, quality of sleep and quality of life (QoL) in chronic urticaria patients, using an interdisciplinary approach combining interview/questionnaire-based psychiatric and dermatological evaluations
1474479|NCT03163862|Procedure|Endometrial scratch|the intervention group, endometrial biopsy will be performed with a pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France). The pipelle was introduced gently through the cervix up to the uterine fundus. the examiner applied regular back-and-forth movements (2-4 cm) during a period of 30 s. The obtained specimens will be sent for histology evaluation.
1474480|NCT03163862|Drug|G-CSF administration|1- 300 µg trans cervical intrauterine of G-CSF was administered at the oocyte retrieval day, subcutaneous 300 micrograms G-CSF on the day of embryo transfer
1474481|NCT03163862|Drug|Saline Solution|saline infusion every day from the day of embryo transfer through the day of beta HCG test
1474482|NCT03163849|Drug|Sofosbuvir , daclatasvir|Tablets
1474483|NCT03163849|Drug|Placebos|oral tablets
1474484|NCT03163836|Procedure|double valve replacement|After median sternotomy, cardiopulmonary bypass was established via bicaval and aortic cannulation. After cross-clamping of the aorta and cardioplegia, mitral and aortic replacement were performed. Supplementary procedures such tricuspid annuloplasty, ascending aorta replacement and coronary artery bypass grafting were performed as required. The left atrial appendage was excised to avoid thrombus formation.
1474485|NCT03163836|Procedure|surgical ablation|Both left and right atrial ablation were performed using a bi-polar radiofrequency ablation clamp.
1474486|NCT03163823|Other|Proloquo2Go|Use of communication application Proloquo2Go modified for the ICU setting on an iPad device
1474487|NCT03163823|Other|Standard of Care|Standard of Care communication methods
1474488|NCT03163810|Device|Erchonia Verju Laser|The Erchonia Verju Laser is applied 2 times a week to the front and back of the waist, hips and upper abdomen for 30 minutes each time over 8 to 12 weeks.
1474489|NCT03163810|Device|Erchonia EVRL Laser|The Erchonia EVRL Laser is applied under the right ribcage angled towards the liver for 10 minutes, one time per week over the same 8 to 12 weeks as the Verju Laser is administered.
1474490|NCT03163797|Diagnostic Test|PET/MRI for evaluation|Before pretreatment, each enrolled patients will undergo PET/MRI and detail clinical examination, including human papillomavirus test. They will also undergo low dose chest CT on the same day before PET/MRI. In the posttreatment period, baseline whole body MRI will be obtained 3 months after chemoradiation. Thereafter, the patients will then be followed up also with alternative extend-field CT and whole body MRI by every 6 months. If tumor recurrence is confirmed or highly suspected, PET/MRI will also be performed for tumor re-staging.
1474491|NCT03163784|Biological|Fecal Inoculum Capsule|Sieved fecal matter prepared in glycerol/saline solution
1474492|NCT03163784|Biological|Placebo (for Fecal Inoculum Capsule)|Placebo capsule manufactured to mimic Fecal Inoculum Capsules
1474493|NCT03163784|Drug|Antibiotic|Antibiotic pre-treatment
1474494|NCT03163784|Drug|Antibiotic Placebo|Placebo tablets manufactured to mimic antibiotics
1474495|NCT03163758|Device|real Repetitive Transcranial Magnetic Stimulation|The rTMS treatments were performed using a Medtronic MagPro type magnetic stimulation device (Medtronic, Minneapolis, MN, USA) and a figure-of-eight coil (MC-B70, Medtronic). Coils were placed tangent to the scalp. The stimulation protocol involved 50 trains of 20 pulses applied over the ipsilesional M1 at a frequency of 5 HZ, with the stimulus intensity set at 120% of the resting motor threshold of the unaffected extremity.
1474496|NCT03163758|Device|sham Repetitive Transcranial Magnetic Stimulation|The sham rTMS was performed on the same site as the rTMS treatment group but without any true stimulations. Coils were placed perpendicular to the scalp.
1474497|NCT03163745|Procedure|paracentesis|paracentesis will be done for all patient for ascitic fluid study and ascitic fluid culture
1474498|NCT03163732|Genetic|Blood and tumor samples|Evaluation of the added value of a large molecular profiling panel versus a limited molecular profiling panel
1474499|NCT03163719|Diagnostic Test|CK and Lactate dosages|"A patient consulting the emergency department for suspected seizure will have an usual blood test at the admission in this context with notably ionogram, fasting glucose, venous gasometry. As the CHU purchased a venous and arterial gasometry reader for the emergency department, blood ionogram, Hb, lactates, HCO3-, pH are collected without delay. The Creatine kinase dosage will be collected in the usual way as a tube bottom. As recommended by the French Society of Neurology, a new sample will be collected at 4 hours of seizure for a dosage of Creatine kinase. The determination of the lactates will be based on a tube bottom."
1474500|NCT03163706|Behavioral|Modified Stroop effect|to assess whether attention deficits and executive functions in patients with schizophrenia are general (semantic and response conflict) or specific (semantic or response conflict).
1474501|NCT03163693|Drug|dexmedetomidine|receive dexmedetomidine 0.5 μg/kg
1474502|NCT03163693|Other|normal saline|receive equal volume of normal saline
1474503|NCT03163680|Drug|Omeprazole 40 MG|Omperazole 40 mg twice daily
1474504|NCT03163667|Drug|CB-839 plus everolimus|CB-839 is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.
1474505|NCT03163667|Drug|Placebo plus everolimus|Placebo is administered as oral tablets twice daily (BID) in combination with standard daily (QD) everolimus in 28 day cycles.
1474506|NCT03163654|Procedure|Surgery 1|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Porcine-derived acellular dermal collagen matrix (PADM) was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
1474548|NCT03163316|Other|Unenhanced magnetic resonance imaging.|"The axillary lymph nodes will be evaluated on axial Time 1-weighted images obtained without fat saturation. We will measure the largest dimension and cortical thickness of each lymph node and ratio of the two measurements will be calculated.
The lymph nodes seen in Time 1-weighted images will be subsequently identified on the diffusion-weighted images to calculate the apparent diffusion coefficient value of each lymph node.
Axillary lymph nodes scanned by magnetic resonance imaging will be compared by results of histopathological examination."
1474549|NCT03163303|Behavioral|Tobacco Status Project Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use
1474507|NCT03163654|Procedure|Surgery 2|Following local anaesthesia (Articaine hydrochloride 4% with 1:200,000 epinephrine injection) administration, sulcular incisions were made in the recession's areas of teeth without damaging interdental papilla. Mucoperiosteal (MP) dissections were made using the periostal elevator creating the deep pouch beyond the mucogingival junction so that the (MP) flap could be moved coronally without tension. Connective tissue graft was positioned at the level of a cemento-enamel junction (CEJ) and skin tight for teeth to avoid forming a blood clot. Separate single sutures per tooth with 5-0 resorbable suture were used to stabilise graft. The tunnel flap was positioned coronally above the CEJ to completely cover the graft and sutured with non-resorbable polypropylene suture.
1474508|NCT03163641|Device|Acuvue Oasys|Bandage Contact Lens
1474509|NCT03163641|Device|Ocular Bandage Gel|0.75% crosslinked HA
1474510|NCT03163628|Biological|Diagnostic performances of a combination of biomarkers|"3 ml of blood will be drawn at inclusion at the same time of the venipuncture prescribed for standard care. The dosage of the 7 biomarkers will be performed in a central laboratory. The adjudication committee will classify patients in 6 groups, based on their clinical data. The committee will not be aware of the biological results. The analysis of Train Set data will aim to identify the most effective combination of markers in response to the primary objective of identifying biomarkers for the diagnosis of severe bacterial infections. The best combination selected will then be applied to the Test Set data (approximately the other half of patients), in order to obtain its real and unbiased performance.
The calculation of positive and negative likelihood ratios will be performed.
The targeted performances are:
A positive likelihood ratio (LR +) of 5.67 minimum, ideally greater than 8.5.
A negative likelihood ratio (LR-) of 0.5 maximum, ideally less than 0.3."
1474511|NCT03163615|Drug|Tibet Rhodiola Capsule|4 capsules, po, from admission up to 84 days
1474512|NCT03163615|Drug|Placebo oral capsule|4 capsules, po, from admission up to 84 days
1474513|NCT03163602|Drug|Control group|Access flap and debridement
1474514|NCT03163602|Device|Test group|Regenerative treatment
1474515|NCT03163589|Drug|Erythropoietin|injection
1474516|NCT03163589|Drug|normal saline|injection
1474517|NCT03163576|Drug|Niacin|tablets
1474518|NCT03163576|Drug|Phosphate Binder|tablets
1474519|NCT03163563|Device|Easywarm|Warming blanket
1474520|NCT03163563|Device|BairHugger|Patient warming mattress with continuous warm air.
1474521|NCT03163550|Drug|ACHN-383|Oral dose
1474522|NCT03163550|Drug|ACHN-789|Oral dose
1474523|NCT03163550|Drug|Placebo|Oral dose
1474524|NCT03163537|Device|HealthPatch|Smart patch that is able to measure stress real time using an algorithm between HR and HRV
1474525|NCT03163524|Other|e-Coupon Text Modification and Reminders|The treatment group will receive a modified text of the current e-coupon. They will also receive notification that they have been enrolled in the study via a second text. They will also receive a series of text message reminders to redeem their e-coupons at intervals of 6, 13 and 18 days after coupon origination.
1474526|NCT03163524|Other|e-Coupon standard text|Participants receive control text (SMS) message, which contains a numeric coupon code and no additional text to the standard coupon.
1474527|NCT03163511|Combination Product|VC-02 Combination Product|PEC-01 cells loaded into a Delivery Device
1474528|NCT03163498|Other|No intervantion. It´s a Cross-Sectional Study|No intervential
1474531|NCT03163472|Procedure|Axillary brachial plexus block|patients will receive axillary brachial plexus block with 10 ml of lidocaine 2% with epinephrine.
1474532|NCT03163472|Procedure|Axillary brachial plexus block|patients will receive axillary brachial plexus block with 30 ml of lidocaine 2% with epinephrine.
1474533|NCT03163459|Drug|selective brain cooling by cold saline perfusion|During the procedure, a microcatheter which was used to deploy the stent retriever was threaded into the femoral artery in the groin through a guiding catheter and up through the neck, until it reached beyond the clot causing the stroke under the assistance of micro-guide wire, 50 mL cold 0.9% saline (4°C) was infused into the ischemic territory at 10 mL/min through the microcatheter, thus allowing the cold solution to infuse into the ischemic territory prior to reperfusion. After that, mechanical thrombectomy with a stent retriever was performed to recanalize the occluded vessel as soon as possible. After the recanalization, cold 0.9% saline (4°C) was infused into the ischemic brain tissue through the guide catheter at 30 mL/min for 10 minutes.
1474534|NCT03163459|Device|mechanical thrombectomy|conventional mechanical thrombectomy using Solitaire
1948606|NCT02077140|Drug|MDT-10013|
1474538|NCT03163420|Drug|Diclofenac potassium|Diclofenac potassium 50 mg granules for oral solution
1474539|NCT03163420|Other|Placebo|Fructose
1474540|NCT03163407|Drug|Norepinephrine|Treatment of the postspinal anesthesia hypotension by administrating 5 mcg of Norepinephrine intravenously every 3 min until normal systolic blood pressure
1474541|NCT03163407|Drug|Ephedrine|Management of the post spinal hypotension by administrating 6 mg of Ephedrine intravenously every 3 min
1474542|NCT03163381|Drug|Apatinib|Apatinib 500mg,po,qd,medicine to disease progression.
1474543|NCT03163368|Radiation|Neoadjuvant stereotactic radiosurgery|Dose escalation of neoadjuvant SRS followed by surgical resection of newly diagnosed brain metastases.
1474544|NCT03163355|Other|a gelling agent|Pureed rice containing a gelling agent (Softia U, Nutri Co., Ltd., Yokkaichi, Japan) is compared with the standard purred rice in the condition of swallowing.
1474545|NCT03163342|Biological|Licensed seasonal influenza vaccine|20 healthy subjects will be enrolled and receive a single dose of licensed seasonal influenza vaccine
1474546|NCT03163329|Procedure|TAVR|Transcatheter Aortic Valve Replacement
1948607|NCT02077140|Drug|Standard of care for pain|
1948608|NCT02073682|Drug|Edoxaban|
1474550|NCT03163303|Behavioral|Tobacco Status Project + Alcohol Intervention|90 days of Facebook messaging, weekly live sessions targeting tobacco use and alcohol use
1474551|NCT03163303|Drug|nicotine patch|14-day supply of nicotine patch
1474552|NCT03163290|Other|Posterolateral Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: abduction exercise, Clam exercise and external rotation exercise
1474553|NCT03163290|Other|Anteromedial Hip Complex Exercises|The treatment protocol was composed of: Heating, lower limb stretching, strengthening the quadriceps e hip muscles. The following exercises were included: hip adduction exercise, adduction with a ring between the thighs and internal rotation exercise.
1474554|NCT03163277|Drug|emtricitabine, darunavir/cobicistat, maraviroc|Treatment change
1474555|NCT03163264|Behavioral|Move Toward Your Goals|Patients will use MTG online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals.
1474556|NCT03163264|Behavioral|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
1474557|NCT03163251|Behavioral|READ-SG Sessions|In the Internal Medicine residency program at Columbia University Medical Center, PGY-1 trainees receive an hour of protected time to attend a monthly peer-facilitated small group session, outlined above. PGY-2 and 3 trainees have a similar combined session separate from the PGY-1s. Facilitators are chosen by the READ-SG Committee, which is comprised of Mark P. Abrams (Director, Co-Investigator), Evelyn Granieri (Faculty Advisor, PI), a Chief Resident from the program (Program Liaison), and the facilitators.
1474558|NCT03163238|Drug|Dexmedetomidine|Dexmedetomidine 0.5 mcg/kg diluted with normal saline in Dexmedetomidine group. Second syringe (50 ml) will contain normal saline (0.9%) in addition to Dexmedetomidine in addition to normal saline in Dexmedetomidine group. Concentration of Dexmedetomidine will be diluted according to the body weight so that we will fix the rate of infusion (1 ml/kg) to achieve a concentration of 0.5 mcg/kg/h in Dexmedetomidine group.
1474559|NCT03163238|Drug|Normal saline|One syringe contain normal saline in 5 ml in Saline group. Second syringe (50 ml) will contain normal saline (0.9%) alone in rate of infusion (1 ml/kg) in Saline group
1474560|NCT03163212|Dietary Supplement|Lactoferrin/FOS|Bovine Lactoferrin/FOS 100mg/ml dissolved in sterile water
1474561|NCT03163199|Device|Translesional Hemodynamic Measurement|Measurement of hemodynamics using the NAVVUS catheter during endovascular therapy
1474562|NCT03163186|Procedure|Transarterial embolization|Transarterial hepatic embolization of liver cancer
1474563|NCT03163173|Drug|GC4419|30 mg (~100 μCi) dose of [14C]GC4419
1474564|NCT03163160|Procedure|Pelvic floor manual therapy group|Soft-tissue (myofascial) stretching techniques on pelvic floor muscles through external and internal (intra-vaginal) mobilizations. One weekly session for four weeks.
1474565|NCT03163160|Procedure|Pelvic floor electrolysis group|"An ultrasound-guided application of a galvanic electrolytic current with an acupuncture needle in the soft tissue of pelvic floor. EPI technique was applied using a specifically device (EPI-X Omega Advanced Medicine, Barcelona, Spain) which produces modulated galvanic electricity. This is applied using a modified electrosurgical scalpel that incorporates acupuncture needles (0.3 mm in diameter) of different lengths. The intensity can be adjusted by changing either the duration of stimulation or the output current (mA) of the device.
One weekly session for four weeks."
1474566|NCT03163134|Device|Lumbar Drain|
1474567|NCT03163121|Biological|PfSPZ-GA1 Vaccine|Aseptic, purified, cryopreserved, genetically attenuated P. falciparum sporozoites (Pf∆b9∆slarp), strain NF54
1474568|NCT03163121|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation attenuated P. falciparum sporozoites (PfSPZ Vaccine), strain NF54
1474569|NCT03163121|Other|Normal Saline|0.9% sodium chloride
1474570|NCT03163121|Biological|Mosquito-bite CHMI|Bites of 5 infected mosquitoes of NF54 strain
1474571|NCT03163108|Device|Closed-loop automatic oxygen control (CLAC) fast in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 30s).
1474572|NCT03163108|Device|Closed-loop automatic oxygen control (CLAC) slow in addition to RMC|Closed-loop automatic oxygen control is an automated, algorithm based adjustment of the fraction of inspired oxygen in relation to arterial saturation (WAIT-interval 180s).
1474575|NCT03163082|Other|Cognitive Intervention|The cognitive intervention has partners come up with reasons why their partners do things they don't like, until they come up with benign attributions for those behaviors.
1474576|NCT03163082|Behavioral|Behavioral Intervention|The behavioral intervention has partners develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
1948609|NCT02073682|Drug|Dalteparin|
1474638|NCT03162562|Drug|Poly ICLC|Immune adjuvant
1948610|NCT02067520|Drug|intrathecal hydromorphone (IT hydromorphone)|
1948611|NCT02065700|Drug|Filgotinib|Tablets administered orally
1948612|NCT02064439|Drug|BAY 59-7939|10 mg tablet once daily for 12 months
1948613|NCT02064439|Drug|BAY 59-7939|20 mg tablet once daily for 12 months
1948614|NCT02064439|Drug|ASA|100 mg tablet once daily for 12 months
1948615|NCT02059499|Drug|imiquimod|Given intra-anally
1474580|NCT03163056|Behavioral|Cognitive-behavioral treatment (CBT)|The CBT was implemented in group-based sessions of four patients. Sessions were carried out once a week over a 8-week period, with quite date occurring at fifth session. The main component was nicotine fading. From the first to the fourth week, patients were asked to gradually reduce their nicotine intake based on a weekly reduction of 30%. A maximum number of cigarettes per day and also specific cigarette brands with lower nicotine levels were recommended. Other components of the CBT program included information about tobacco, a behavioral contract, self monitoring and graphical representation of cigarette smoking, stimulus control, strategies for controlling nicotine withdrawal symptoms, physiological feedback, training in alternative behaviors, and relapse prevention strategies.
1474581|NCT03163056|Behavioral|CBT+Behavioral Activation (BA)|This intervention was provided as in the above CBT condition, that is, eight group-based sessions of four patients. Nevertheless, this treatment included a BA component for addressing both smoking cessation and depression management. The BA module included: treatment rationale, information on the relationship between smoking and depression, identification of life areas, values and activities, generation of meaningful and reinforcing activities, social support (i.e., behavioral contracts).
1474582|NCT03163056|Behavioral|CBT+BA+ Contingency Management (CM)|This intervention was provided in the same manner as the above mentioned treatment protocols but with the addition of a contingency management procedure reinforcing abstinence since fifth session and onwards. The number of sessions was the same as in the aforementioned treatment conditions and CO and cotinine samples were also collected. Participants providing negative specimens of both CO (≤4 ppm) and cotinine (≤80 ng/ml) earned points exchangeable for rewards (e.g., cinema tickets) on a schedule of escalating magnitude of reinforcement (from 10€ voucher value with maximum possible earnings of 175€ in vouchers).
1474584|NCT03163030|Device|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
1474585|NCT03163017|Device|2D Fluoroscopy|Patients with syndesmotic instability will undergo reduction of the syndesmosis followed by provisional fixation with a clamp or Kirshner wire. The reduction quality will be initially compared to the contralateral ankle mortise and talar-dome lateral radiographs using the technique of Summers et al i.e. 2D Fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system.
1474586|NCT03163017|Device|3D Fluoroscopy|After the attending surgeon is satisfied with the reduction quality from 2D Fluoroscopy, 3D fluoroscopy using device Ziehm Vision RFD 3D image-intensified fluoroscopic x-ray system will be used to generate additional images to assess syndesmotic and fibular reductions.
1474588|NCT03162991|Other|Aerobic Exercise Intervention|Aerobic Exercise Intervention- 12-weeks, exercise 3 non-consecutive days/week for ~30-55 minutes per exercise session.
1474589|NCT03162978|Other|HIIT + POE|Subjects will participate in high-intensity interval training (HIIT) with an additional treatment component to increase positive outcome expectations (POE) of exercise.
1474590|NCT03162978|Other|HIIT only|Subjects will participate in high-intensity interval training (HIIT) only.
1474591|NCT03162965|Diagnostic Test|Oraquick HIV Self Test|This is an oral swab in home HIV test.
1474592|NCT03162965|Diagnostic Test|Clinic Based HIV Counseling and Testing (HCT)|Receiving Counseling and Testing for HIV at the clinic.
1474593|NCT03162926|Combination Product|VC-02 Combination Product (aka PEC-Direct)|PEC-01 cells loaded into a Delivery Device
1474594|NCT03162913|Dietary Supplement|Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
1474595|NCT03162913|Other|Placebo|12g red, strawberry-flavored powder, twice daily with water, for 90 days
1474600|NCT03162887|Other|Educational Intervention|Receive a research team member-led breast cancer and mammogram educational module
1474601|NCT03162887|Other|Counseling|Undergo a web-based decision counseling session
1474602|NCT03162887|Other|Informational Intervention|"Receive a next steps document"
1474606|NCT03162861|Drug|sevoflurane inhalation for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the observation group. In the observation group, tracheal intubation will be conducted for general anesthesia after lumbar plexus-sciatic nerve block, accompanying sevoflurane inhalation for anesthesia maintenance.
1474607|NCT03162861|Drug|propofol for anesthesia|The elderly patients undergoing unilateral total hip arthroplasty will be randomized to assigned to the control group. In the control group, tracheal intubation will be conducted for general anesthesia, accompanying intravenous administration of propofol for anesthesia maintenance.
1948616|NCT02059499|Drug|fluorouracil|Given intra-anally
1474640|NCT03162523|Radiation|High-Dose Rate Brachytherapy|
1948617|NCT02059499|Other|questionnaire administration|Ancillary studies
1948618|NCT02059499|Other|laboratory biomarker analysis|Correlative studies
1948619|NCT02049385|Drug|Diazoxide|A nondiuretic vasodilator thiazide-related agent
1948620|NCT02049385|Drug|Placebo|Placebo
1474609|NCT03162835|Other|Pain Neuroscience Education|Children as well as their parents will receive a +/- 1h one-on-one educational session about the neurophysiology of pain, adjusted to the child's comprehension status. Parents will be present in the PNE session too. The PNE program for children contains two sections: (1) The healthy pain system and its function, divided in subsections each consisting of a specific neurophysiological pain concept (i.e. central nervous system anatomy, nociception and nociceptive pathways, up- and down-regulation of the nervous system) and (2) adaptations of the pain system following persistent pain. To ensure interaction between therapist and child, an interactive board game was developed and used throughout the full educational session.
1474610|NCT03162822|Behavioral|Behavioral Intervention|The behavioral intervention has the parents develop an if-then plan for dealing with conflict and negativity, using strategies to downregulate their own negative emotions.
1474611|NCT03162822|Other|Cognitive Intervention|The cognitive intervention has parents come up with reasons why their children do things they don't like, until they come up with benign attributions for those behaviors.
1474612|NCT03162796|Drug|Guselkumab|Participants will receive 100mg of guselkumab as a sterile liquid for SC injection.
1474613|NCT03162796|Drug|Placebo|Participants will receive matching placebo as SC injection.
2010521|NCT02944578|Drug|Curcumin|"Curcumin (Curcumin C3 Complex®, prepared by Sabinsa Corporation), a constituent of the spice turmeric, is considered to be a low-toxicity, dietary-derived agent with chemopreventive and therapeutic benefits.
Study participants will be instructed to insert four 500 mg (2000 mg total) curcumin capsules at bedtime every day (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.
Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
1474617|NCT03162770|Behavioral|Mindfulness meditation practice|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychological principles. The program has been conducted during hemodialysis session. It will last for 12 weeks, with duration of 15 to 25 minutes, three times a week.
1474618|NCT03162757|Procedure|Central venous catheterization|Central venous catheterization via either internal jugular vein or subclavian vein up to a maximum of two attempts.
1474620|NCT03162731|Biological|Nivolumab|Given IV
1474621|NCT03162731|Biological|Ipilimumab|Given IV
1474622|NCT03162731|Radiation|Simultaneous-Integrated Boost Intensity-Modulated Radiation Therapy|Undergo simultaneous integrated boost integrated modulated radiation therapy
1474623|NCT03162731|Radiation|Volume Modulated Arc Therapy|Undergo volumetric modulated arc therapy
1474624|NCT03162718|Behavioral|Exercise|single arm feasibility study of an unsupervised, pre-operative exercise prescription (uPEP) augmented by a wearable fitness device.
1474625|NCT03162679|Behavioral|Skills training of Affect-Regulation - A culture-sensitive approach: STARK|Emotion Regulation Group Therapy, 14 sessions, 1.5 hour sessions, group therapy, meeting weekly.
1474626|NCT03162666|Device|ALTERA|degenerative disc disease (DDD) at one or two contiguous levels from L2 to S1. with up to grade 1 spondylolisthesis
1474627|NCT03162653|Drug|Allopurinol|Allopurinol, powder for injection (PFI), administered in two doses. First dose (20 mg/kg in 2ml/kg sterile water for injection) given as soon as intravenous access is established and no later than 30min postnatally and second dose (10mg/kg in 1ml/kg sterile water for injection) 12 hours thereafter. The second dose will only be administered to in infants on therapeutic hypothermia. Infants who recover quickly and do not qualify for and hence do not undergo hypothermia will not receive a second dose. Administration will be by continuous infusion using a syringe pump over 10min through secure venous access.
1474628|NCT03162653|Drug|Mannitol|Placebo (Mannitol, PFI, 20mg/kg in the same volume and at the same time intervals as the intervention group - (2nd dose 10mg/kg only if infant undergoes therapeutic hypothermia)).
1474629|NCT03162627|Drug|Selumetinib|"Dose Escalation Phase Starting Dose: 50 mg by mouth twice a day on Days 1-28.
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
1474630|NCT03162627|Drug|Olaparib|"Dose Escalation Phase Starting Dose: 150 mg by mouth twice a day on Days 1-28.
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
1474631|NCT03162614|Biological|RTS,S/AS01E|Subjects will receive intramuscular injection of RTS,S/AS01E.
1474632|NCT03162614|Biological|RTS,S/AS01B|Subjects will receive intramuscular injection of RTS,S/AS01B.
1474633|NCT03162614|Procedure|Sporozoite-infected mosquitoes challenge.|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the subjects. For each subject, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored. If required additional mosquitoes will be allowed to feed until a total of five infected mosquitoes with a minimum of 2+ salivary gland scores have fed.
The challenge occurs approximately 90 days (three months) after the last vaccination.
Subjects will be monitored during 28 days after having bitten by mosquitoes and when parasites are found in their blood, they will be treated with appropriate anti-malarial drugs."
1474634|NCT03162601|Procedure|Neurovascular percutaneous intervention|Patient will receive one extra CACT scan while they are receiving percutaneous neurovascular intervention.
1474635|NCT03162588|Drug|erythropoietin|Epokine®, CJ healthcare, South Korea is used preprocedurally to promote revascularization. Total 120,000 units of EPO is injected for three consecutive days, 40,000 units mixed in IV saline 100 ml over 1 hour. The multiple burrhole procedure is performed in area of hemodynamic insufficiency by D-SPECT. It is performed under local anesthesia.
1474636|NCT03162575|Behavioral|Mindfulness-Based Cognitive Therapy|Structured MBCT intervention based on the protocol of Williams, Teasdale, and Segal
1474637|NCT03162562|Biological|Oregovomab|Monoclonal antibody against CA 125
1474641|NCT03162510|Drug|Oxaliplatin|Oxaliplatin 60 - 85 mg/m2 IVD 2hr at D1, every 14 days as a cycle till disease progression
1474642|NCT03162510|Drug|Albumin-Bound Paclitaxel /nab-Paclitaxel|150 mg/m2 IVD 30 min bi-weekly.
1474643|NCT03162510|Drug|S-1|Tegafur,oral S-1 35mg/m2 twice daily from D1 to D7, every 14 days as a cycle till disease progression.
1474644|NCT03162510|Drug|LV|LV 30mg twice daily from D1 to D7, every 14 days as a cycle till disease progression
1474645|NCT03162497|Drug|Azithromycin|Azithromycin 15mg/g eyedrops
1474646|NCT03162497|Drug|Doxycycline|Doxycycline 100 mg per os
1474647|NCT03162484|Behavioral|Experimental group|The program includes different activities: swimming, paddle tennis, football and aerobic exercises into the swimming-pool.
1474648|NCT03162471|Diagnostic Test|non-contact measurement of intraocular pressure|Non-contact measurement of corneal biomechanical properties and intraocular pressure with an Ocular Response Analyzer. Parameters measured: corneal hysteresis (CH), corneal resistance factor (CRF), Goldman-correlated IOP (IOPg), corneal compensated IOP (IOPcc) and waveform score (WS).
1948628|NCT02046369|Drug|Lurasidone|Lurasidone flexibly dosed 20-80 mg once daily
1948629|NCT02046369|Drug|Placebo|Placebo Comparator once daily
1474651|NCT03162432|Drug|Vitamin D3|Oral Vitamin D3 therapy.
1474652|NCT03162419|Drug|Standard Medical Therapy|The patients in group A will be given standard medical therapy only as per requirement. Lactulose, bowel wash, albumin, terlipressin, antibiotics and anti-virals in hepatitis B reactivation will be continued and recorded.
1474653|NCT03162419|Biological|Plasma Exchange|High volume plasma exchange sessions till a maximum of ten sessions.
1474654|NCT03162419|Biological|GCSF|The GCSF in a dose of 5 ug/kg/day on day 1,2,3,4,5 followed by every 3rd day till day 28
1474655|NCT03162406|Dietary Supplement|Vitamin D3|Oral supplementation 25000 IU once per week for 6 months
1474656|NCT03162406|Dietary Supplement|Placebo|Oral supplementation once per week for 6 months
1474657|NCT03162393|Procedure|nerve transfer|
1474658|NCT03162380|Other|Date collection|Date collection
1474659|NCT03162367|Biological|Autologous epidermal cell suspension|First skin samples taken from normal skin by 4mm punch will be send to laboratory for preparation of epidermal cell suspension and this suspension transfer to one area of second degree burn
1474660|NCT03162367|Drug|Silver sulfadiazine ointment|the area with second degree burn dresses by silver sulfadiazine ointment and dressing change each 12 hour till 10 day
1474661|NCT03162354|Other|Application of a validated Clinical Decision Rule (CDR) as an AHT screening tool|"The Clinical Decision Rule (CDR) for AHT reads as follows:
Every acutely head-injured infant or young child hospitalized for intensive care presenting with any one or more of these four variables should be considered high risk and thoroughly evaluated for abuse: (1) any clinically significant respiratory compromise at the scene of injury, during transport, in the Emergency Department, or prior to admission; (2) Any bruising involving the child's ear(s), neck, or torso; (3) Any subdural hemorrhage(s) or fluid collection(s) that are bilateral OR involve the interhemispheric space; (4) Any skull fracture(s) other than an isolated, nondiastatic, linear, parietal, skull fracture."
1474662|NCT03162341|Procedure|ultrasonography|The tophus volume will be assess using ultrasonography.
1474663|NCT03162341|Procedure|DECT|The tophus volume will be assess using dual-energy computed tomography (DECT).
1474664|NCT03162315|Procedure|Freeze all|
1474665|NCT03162302|Diagnostic Test|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) is a non-invasive imaging technique that uses a magnetic field and radio waves to create detailed images of the organs and tissues within the body.
1474666|NCT03162289|Other|Fasting|Patients follow a modified fasting regime of 60-72 h (36-48 h before and 24 h after CT) with a dietary energy supply of 350-400kcal per day with vegetable juices during the first four cycles of CT. During the rest of the CT cycles they will observe two days of caloric restriction (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed and the patients are encouraged to follow a pattern of time restricted feeding with 14 h fasting over night at least for six days a week. The patients will receive an individual nutrition training by trained nutritionists.
1474667|NCT03162289|Other|Vegan|Patients follow a 60-72 h vegan diet with sugar restriction (36-48 h before and 24 h after CT) during the first four cycles of CT. During the rest of the CT cycles they will observe two days of vegan and sugar-restricted diet (24 h before and after CT). Between CTs a mainly vegetarian diet will be performed. The patients will receive an individual nutrition training by trained nutritionists.
1474668|NCT03162289|Other|Diet as usual|Participants of this group will have usual care (CT as usual with no changes to dietary habits)
1474669|NCT03162276|Behavioral|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
1474670|NCT03162276|Behavioral|Control|At end of intervention, the control group will receive a brief intervention consisting of a home kit for practicing IBSR techniques.
1474671|NCT03162263|Device|EKso training|Patients affected by chronic stroke underwent gait training by using the Ekso device; they performed a total of 20 sessions (5 day/week for 4 weeks) of at leat 40min duration.
1475054|NCT03159156|Behavioral|Applied Tension/Respiration Control|Described above.
1948630|NCT02035696|Biological|Trivalent influenza vaccine (TIVc)|
1948631|NCT02035696|Biological|Trivalent influenza vaccine-licensed|Licensed influenza vaccine
1948632|NCT02032784|Drug|octreotide|Octreotide 100mg subcutaneous every 8 hours for 5 days
1948633|NCT02032784|Other|No Octreotide|No drug
1474675|NCT03162237|Other|Porcine islets|"Porcine islets: 10000IEQ/Kg;
Tacrolimus: 0.087mg/kg, Bid;
mycophemo—latemofetil (MMF): 1g x 2/d;
NULOJIX(belatacept): Day 1 (prior to transplantation), Day 5, Week 2, Week 4, Week 8, Week 12 10mg/kg"
1474676|NCT03162237|Other|Autologous Treg|Autologous Treg: 2x10^6/Kg
1948634|NCT02026908|Device|Prostate Artery Embolization|Procedure completed in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Embosphere microspheres to slow/block blood flow to the prostate.
1474680|NCT03162211|Other|Feedback Report|There are two types of feedback forms: 1. Patient feedback forms and 2. Clinician feedback forms. Feedback form content has been developed in consultation with a board of clinicians, service providers, and patients living with depression. Feedback forms will be comprehensive and condensed to a one page report including graphical presentations of symptom course and text. Clinician feedback forms will include content on depression severity over time and recommendations for individualized treatment. Patient feedback forms will also incorporate depression severity over time as well as summary information on achievement towards personalized treatment goals.
1474681|NCT03162198|Other|Cirrhosis with HCC|Cirrhosis with Hepatocellular Carcinoma
1474682|NCT03162198|Other|Cirrhosis without HCC|Cirrhosis without Hepatocellular Carcinoma
1474683|NCT03162185|Drug|Escitalopram|Experimental group participants (n = 30) will receive 20 mg of Escitalopram for 7 days.
1474684|NCT03162185|Drug|Placebo|Control group participants (n = 30) will receive a placebo for 7 days.
1474685|NCT03162159|Other|Collection of growth and bone maturation data|
1474686|NCT03162146|Other|Deaths in intensive care unit|Assessment of the influence of team familiarity among the members of medical and nursing staffs on risk of patient death
1474687|NCT03162133|Other|Baduanjin exercise|
1474688|NCT03162120|Drug|Ranolazine plus Metoprolol Combination|Ranolazine plus Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
1474689|NCT03162120|Drug|FlecainidE pluS Metoprolol Combination|FlecainidE pluS Metoprolol Combination in ATrial Fibrillation Recurrences FOllowing PhaRmacological or Electrical CardioverSion of AtRial Fibrillation
1474693|NCT03162081|Diagnostic Test|Substance misuse screening|Diagnostic and Statistical manual of mental disorders, version 4 (DSM-IV)/MINI-international Neuropsychiatric interview (MINI interview) for Diagnostics of dependence, additional questions for DSM-V classification, severity of dependence scale (SDS)
1474694|NCT03162081|Diagnostic Test|EQ-5D|Health related Quality of life
1474695|NCT03162081|Diagnostic Test|Impulsivity screening|Barratts impulsivity test v. 11, Behavioural inhibition/behavioural activation test
1474696|NCT03162081|Diagnostic Test|Cognitive screening|Minimental state examination (MMSE), Hospital anxiety and depression scale (HADS), Trail-making test, clock drawing test
1474697|NCT03162081|Diagnostic Test|Functional tests|Timed up and go (TUG), Single leg balancing test (SLB)
1474698|NCT03162081|Diagnostic Test|Cognistat|Assessment of cognitive domains
1474699|NCT03162081|Diagnostic Test|Neuropsychological profiling|Controlled Oral Word Association Test, Categorical fluency tests, Wechsler Adult Intelligence Scale, Color-Word Interference Test (CWIT) from the Delis-Kaplan Executive Function test
1474700|NCT03162081|Other|Clinical interview|Interview for sociodemographics, utilisation of health care, economic varables, The De Jong Gierveld Loneliness Scale
1474701|NCT03162081|Other|Medication use|Detailed screen of used medications, interactions, side effects in electronic patient registry
1474702|NCT03162081|Other|Comorbidity|Charlson comorbidity index and Cumulated illness rating scale (CIRS) based on electronic patient registry
1474703|NCT03162068|Other|Osteodensitometry and pQCT|The peripheral Quantitative Computed analyses the bone architecture with distinction between cortical and trabecular compartment. We aim to determine the specificity of osteoporosis induced by glucocorticoids excess in comparison to post menopausal osteoporosis thanks to pQCT analysis.
1474706|NCT03162042|Procedure|Tumor removal|Surgery
1474707|NCT03162029|Other|CBCT imaging|CBCT imaging of participants, then take measurement by radiomorphometric indices
1474708|NCT03162016|Procedure|transplants|Transplant of palatine tissue and transplant of connective tissue Mucoderm
1474709|NCT03161990|Procedure|Transgluteal approach to the hip joint|Operative approach to the hip joint where the abductors are partly detached from the greater trochanter and the hip joint is approached through the anterior part of the capsule.
1474710|NCT03161990|Procedure|Posterior approach to the hip joint|Operative approach to the hip joint where the short external rotators are detached from the greater trochanter and the hip joint is approached through the posterior part of the capsule.
1474711|NCT03161977|Other|Mannitol|Mannitol was intravenous infused within 15-20 mins when drilling skull
1474714|NCT03161938|Drug|Dexamethasone|intravenous
1474716|NCT03161886|Device|Colon Capsule Endoscopy|Second generation of colon capsule endoscopy (Medtronic)
1474717|NCT03161873|Device|Ava|Ava is a fertility monitoring bracelet that collects various physiological parameters
1475099|NCT03158805|Drug|LIRAGLUTIDE|3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML)
1474718|NCT03161860|Behavioral|Personalised citizen assistance for social participation(APIC)|The APIC involves a non-professional attendant who, after 2 to 5 days of training, provides a two to three-hour stimulation session each week over a six to eighteen-month period targeting significant social and leisure activities that are otherwise difficult for older adults to accomplish.
1474719|NCT03161847|Other|Non-interventional study|Non-interventional study
1474720|NCT03161834|Other|Observational|
1474721|NCT03161821|Other|Observational|
1474722|NCT03161782|Other|PNF stretching|For hold-relax stretching, each subject in PNF Stretching group will be comfortably positioned in a supine lying position, and patient will move the joint to the end of the passive or pain-free ROM. The therapist will ask for an isometric contraction of the restricting muscle or pattern (antagonists) with emphasis on rotation. The patients will be asked to perform submaximal isometric contractions of the target muscle for 10 seconds. After the contraction, the patients will be instructed to relax for 5 seconds. The joint will be repositioned actively to the new limit of range, and then therapist will passively control the new ROM. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
1474723|NCT03161782|Other|Static Stretching|For static stretching, each subject in Static Stretching group will be comfortably positioned in a supine lying position, and the stretching of target muscle will be maintained for 20 seconds followed by 10 seconds of rest. The procedure will be repeated 10 times with 10 seconds of rest between two successive trials. Patients will be treated 2 times per week for 6 weeks.
1474724|NCT03161782|Other|Exercise|Shoulder, elbow and wrist AROM exercises. Elbow flexion and extansion self-stretching exercises Elbow and wrist strengthening exercises Proprioception exercises for elbow. Grip strengthening exercises.
1474725|NCT03161782|Other|Cold Therapy|Cold therapy will be applied over the elbow for 15 minutes in the form of cold pack after stretching and exercise protocol.
1474726|NCT03161769|Procedure|Neurovascular treatment of intracranial aneurysms|Endovascular treatment of intracranial aneurysms using flow diverting stents
1474727|NCT03161769|Device|AneurysmFlow image processing software|Software to process and display images of intracranial aneurysm treatment using flow diverting stents.
1474728|NCT03161756|Drug|Denosumab|Denosumab is a fully human monoclonal immunoglobulin type 2 (IgG2) antibody that binds with high affinity and specificity to RANK ligand (RANKL) and neutralises the activity of human RANKL, similar to the action of endogenous osteoprotegerin (OPG). Denosumab binding prevents the activation of RANK and inhibits the formation, activation, and survival of osteoclasts. As a consequence, bone resorption and cancer-induced bone destruction are reduced.
1474729|NCT03161756|Drug|Nivolumab|Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab inhibits the interaction of PD-1 with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation and interferon-gamma (IFN-γ) release in vitro.
1474730|NCT03161756|Drug|Ipilimumab|Ipilimumab is a fully human monoclonal immunoglobulin specific for human cytotoxic T-lymphocyte antigen 4 (CTLA-4), which is expressed on a subset of activated T cells. Ipilimumab is a monoclonal antibody(mAb) that binds to CTLA-4 and blocks the interaction of CTLA-4 with its ligands, cluster of differentiation antigen 80 / cluster of differentiation antigen 86 (CD80 / CD86). Blockade of CTLA-4 has been shown to augment T-cell activation and proliferation, including the activation and proliferation of tumor-infiltrating T-effector cells.
1474731|NCT03161743|Procedure|venipuncture|blood draw for the purpose of determining the platelet concentration in PRP
1474732|NCT03161730|Other|McGrath videolaryngoscopy|Participants perform three intubation attempts using McGrath videolaryngoscope in the normal and cervical immobilized manikin by novice
1474733|NCT03161730|Other|Pentax videolaryngoscopy|Participants perform three intubation attempts using Pentax Airway Scope in the normal and cervical immobilized manikin by novice
1474734|NCT03161730|Other|Macintosh laryngoscopy|Participants perform three intubation attempts using Macintosh laryngoscope in the normal and cervical immobilized manikin by novice
1474735|NCT03161717|Device|Epidural electrical stimulation (EES)|Using loss of resistance technique and electrical stimulation
1474736|NCT03161717|Device|Loss of resistance (LOR)|Using loss of resistance technique only
1474737|NCT03161691|Procedure|Percutaneous treatment of ischemic stroke|An additional C-arm CT imaging scan will be done during neurovascular treatment to evaluate perfusion and collateral vessels in ischemic stroke patients.
1474738|NCT03161678|Drug|Clopidogrel|Clopidogrel (75 mg/d for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
1474739|NCT03161678|Drug|Ticagrelor|Ticagrelor (90 mg twice daily for 8 days) will be administered. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
1474741|NCT03161652|Drug|DME lactose pill|Patients with DME will take placebo orally 3 times a day (TID) for 8 weeks.The placebo is taken on top of standard therapy for diabetes and blood pressure control.
1474742|NCT03161652|Drug|DME levosulpiride|Patients with DME will take levosulpiride (75 mg/day) orally TID for 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
1474743|NCT03161652|Drug|DR lactose pill|Patients with non-proliferative DR will take a lactose pill (placebo) orally TID for 8 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
1474744|NCT03161652|Drug|DR levosulpiride|Patients with non-proliferative DR will take levosulpiride (75 mg/day) orally TIDfor 8 weeks. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
1474745|NCT03161652|Drug|DR vitrectomy lactose pill|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will have to take a lactose pill (placebo) orally TID for one week. The last placebo pill will be taken on the morning of the day vitrectomy is performed. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
1474775|NCT03161457|Biological|MabThera|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
1475100|NCT03158805|Other|Placebo|Placebo injection
1474746|NCT03161652|Drug|DR vitrectomy levosulpiride|Patients with proliferative DR (undergoing medically prescribed vitrectomy 7 days after starting the study medication) will take levosulpiride (75 mg/day) orally TID for one week. The last pill will be taken on the morning of the day vitrectomy is performed. Levosulpiride is taken on top of standard therapy for diabetes and blood pressure control.
1474747|NCT03161652|Drug|DME plus ranibizumab lactose pill|Patients with DME with conventional intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks) will take a lactose pill (placebo) orally TID for 12 weeks. The placebo is taken on top of standard therapy for diabetes and blood pressure control.
1474748|NCT03161652|Drug|DME plus ranibizumab levosulpiride|Patients with DME with receive intravitreal antiangiogenic therapy with ranibizumab (0.5 mg every 4 weeks) will take a levosulpiride (75 mg/day) orally TID for 12 weeks. The study medication is taken on top of standard therapy for diabetes and blood pressure control.
1474750|NCT03161626|Drug|Coagadex|Plasma-driven blood coagulation factor X concentration
1474752|NCT03161600|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at a surgical visit, enabling providers to deliver evidence-based and personalized treatment care plans to their breast cancer patients. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
1474753|NCT03161574|Drug|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
1474754|NCT03161561|Other|capacity of primary phagocytes|measurement of capacity of primary phagocytes (neutrophils, monocytes and macrophages) isolated from COPD patients' blood or alveolar macrophages isolated from patients' lungs to carry out key host defence functions and compare these to similar cells isolated from age and sex-matched non-smokers or smokers without COPD as controls.
1474755|NCT03161548|Drug|Induction chemotherapy|"All eligible subjects will receive ICT with DCU regimen every 21 days as follows:
Docetaxel 36 mg/m2 intravenous infusion over 1 hr, followed by Cisplatin 30 mg/m2 intravenous infusion over 1 hr, on day 1 and day 8, Oral tegafur/uracil 300 mg/m2/day plus leucovorin 90 mg/day on days 1 - 14"
1474756|NCT03161548|Procedure|Tongue conservation surgery|Surgical excision of residual oral tongue tumor will be performed in 3-4 weeks after the start of the last cycle of ICT. Neck dissection will also be done as indicated.
1474757|NCT03161548|Radiation|postoperative CCRT|"Post-op CCRT will be started 4-6 weeks after surgery, with regimen as follows:
Radiotherapy in 2 Gy once-daily fraction size, Monday to Friday, with dose up to 60 Gy (total of 30 fractions); Cisplatin 25 mg/m2 intravenously for 4 hours every week a cycle to total 6 cycles; Tegafur/uracil (UFUR) 200 mg po bid for whole course of radiotherapy"
1474758|NCT03161535|Other|exercise|A 12-week regimen of home-based walking exercises, comprising walking at a moderate intensity for 40 min, three times a week, was administered along with weekly exercise counseling. After collecting pretrial measurements, we explained the participants how to perform the exercises, according to an instruction manual for the exercise regimen. The detailed instructions, provided at the hospital clinics, included the determination of activity intensity, demonstration of pulse measurement, criteria for scores of 6-20 on the Borg's rating of perceived exertion (RPE), prevention of exercise-related injuries, and conditions necessitating termination of an exercise session. Participants were instructed that the exercises would be effective only if they reached 60%-80% of the target heart rate, as determined by the Karvonen method, and 13-15 on the RPE.
1474759|NCT03161535|Other|weekly exercise counseling|For each participant, we discussed exercise regimen-related issues weekly through the telephone. For instance, we discussed whether participants' exercise fulfilled the prescribed intensity, duration, or frequency and whether the participants experienced any adverse effects.
1474760|NCT03161522|Drug|Chemotherapy|Chemotherapy may include the following alone or in combination with each other: Cisplatin, 5-fluorouracil (5-FU), Mitomycin C, Vindesine, or Paclitaxel at discretion of physician.
1474761|NCT03161522|Radiation|Radiation|Dose of radiation therapy at discretion of treating radiation oncologist.
1474762|NCT03161522|Procedure|Surgery|If eligible, surgery performed to all involved sites.
1474763|NCT03161522|Behavioral|Symptom Questionnaires|Symptom questionnaire completed at baseline consultation and subsequently for every follow up after treatment.
1474764|NCT03161509|Drug|Paracetamol|single dose of 1 gr paracetamol
1474765|NCT03161509|Drug|Antiepileptic (either carbamazepine, lamotrigine, phenytoin or valproic acid)|Single dose of antiepileptic drug (either carbamazepine, lamotrigine, phenytoin or valproic acid) for which the participant is taking chronically in stable dose
1474766|NCT03161496|Genetic|detection of genotype|detection of genotype by next generation sequencing
1474767|NCT03161483|Drug|CC-220|0.45 mg QD PO
1474768|NCT03161483|Drug|CC-220|0.3 mg QD PO
1474769|NCT03161483|Drug|CC-220|0.15 mg QD PO
1474770|NCT03161483|Other|Placebo|Placebo QD PO
1474771|NCT03161470|Other|Standard Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
1474772|NCT03161470|Other|Mechanical Chair Repositioning|It is standard clinical practice for patients with BPPV to undergo treatment by moving the patient through specific head/body positions which moves the displaced otoconial debris out of the involved area of the inner ear.
1474773|NCT03161470|Other|Sham Treatment|Participants will be placed into the mechanical chair and moved into various positions that do not treat BPPV.
1474774|NCT03161457|Biological|JHL1101|1000 mg containing 10 mg/mL rituximab to be diluted to a concentration of 1 to 4 mg/mL in 0.9% normal saline or 5% D-glucose for administration
1474869|NCT03160716|Device|Restylane Lyft with Lidocaine|a sterile gel of hyaluronic acid (HA)
1474776|NCT03161444|Other|Biological sample collection|A blood sample collection for the study will be taken to each participant Each subject enrolled must have previously participated to the study CHIKVIH.
1474777|NCT03161431|Drug|SX-682|SX-682 is an oral small molecule selective inhibitor of C-X-C Motif Chemokine Receptor 1 (CXCR1) and C-X-C Motif Chemokine Receptor 2 (CXCR2)
1474778|NCT03161431|Biological|Pembrolizumab|Pembrolizumab is a humanized antibody that targets the programmed cell death 1 receptor (PD-1).
1474779|NCT03161418|Drug|KSP-910638G, 0.4 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (0.4 mg dose)
1474780|NCT03161418|Drug|KSP-910638G, 1.2 mg|The investigational agent to be used in this study is KSP heptapeptide, which is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached via a 5 amino acid linker to a near-infrared fluorophore, IRDye800CW. (1.2 mg dose)
1474781|NCT03161405|Drug|TAK-906 Maleate|TAK-906 capsule
1474782|NCT03161405|Drug|Itraconazole|Itraconazole solution
1474783|NCT03161392|Diagnostic Test|Follow-up|"Group No ductal lesion will be submitted to follow-up with periodic breast ultrasonography/mammography every 6 months for 2 years."
1474784|NCT03161392|Diagnostic Test|Ultrasound-guided percutaneous biopsy|"Group Ductal lesion will be submitted to ultrasound-guided percutaneous biopsy and the specimen will be histologically analysed."
1474789|NCT03161366|Biological|rVSVΔG-ZEBOV-GP|Ring vaccination with vaccination of contacts and contacts of contacts after laboratory confirmation of one Ebola Zaire case
1474790|NCT03161353|Drug|Perjeta|All patients will receive Perjeta® as an IV infusion on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg on Day 1 of each subsequent 3-week cycle. Perjeta® IV should be administered 60 minutes after the end of Herceptin® SC (subcutaneous) administration. An observation period of 30-60 minutes is recommended after each Perjeta® infusion.
1474791|NCT03161353|Drug|Herceptin|All patients will receive a fixed dose of 600 mg, irrespective of the patient's weight, will be administered throughout the treatment phase. All doses of Herceptin® SC will be administered as an SC injection into the thigh by a trained health care professional over a period of 2-5 minutes. No loading dose is required with Herceptin® SC.
1474792|NCT03161353|Drug|Docetaxel|Docetaxel will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC, Perjeta® IV, and carboplatin
1474793|NCT03161353|Drug|Carboplatin|Carboplatin will be administered in line with the respective product information and/or recognized clinical practice guidelines. It will be administered after Herceptin® SC and Perjeta® IV.
1474794|NCT03161353|Drug|Letrozole|Postmenopausal women will receive letrozole 2.5 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
1474795|NCT03161353|Drug|Tamoxifen|"Premenopausal women will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy.
Male patients will receive tamoxifen 20 mg tablet orally once daily beginning on Day 1 and continuing through Day 21 of a 21-day cycle as neoadjuvant therapy."
1474798|NCT03161288|Drug|KY1005|A human anti-OX40 ligand monoclonal antibody
1474799|NCT03161288|Drug|Placebo|Matched placebo
1474800|NCT03161262|Behavioral|SMS-based reminders|The SMS-based reminders consist of sending messages to participants assigned to this study arm reminding them to take their medication and prompting participants to complete surveys. Medication reminders are sent as per the participant's prescribed frequency and weekly surveys allow participants to report their pain level as well as send an image of their surgical site. Beyond pre-determined reminders and surveys sent to patients, the Memora Health platform is interactive and allows patients to text in questions they may have regarding their medications, care, or condition. Participants will receive the messages for 3 months.
1474801|NCT03161249|Behavioral|Experimental group|The experimental group receiving mobile treatment: treatment as usual plus a psychotherapy intervention by the telephone app (a total of 5 modules of psychotherapy: psychoeducation plus mindfulness plus alerts plus social wall plus problems solving)
1474802|NCT03161249|Other|Control group|Group that does not receive any treatment added to its usual treatment
1474803|NCT03161236|Other|home exercise program|Subjects in the exercise group will be instructed to follow the intervention protocol for eight weeks. The intervention consists of five exercises: standing on one foot, walking heel to toe, heel walking, side kicks, and wall squats. Each exercise will be repeated three times per week for eight weeks.
1474804|NCT03161236|Other|non exercise program|continue usual lifestyle
1474805|NCT03161223|Drug|Durvalumab|"Durvalumab is an investigational human monoclonal antibody that works to inhibit (block) a protein called programmed cell death-1 ligand 1 (PD-L1). Durvalumab has not been approved by the FDA for the treatment of PTCL but has been given to patients other types of cancers. Given intravenously (through the vein).
Starting dose: 1500 mg"
1474806|NCT03161223|Drug|Pralatrexate|"Pralatrexate is an antimetabolite drug. Pralatrexate alone is FDA-approved for the treatment of PTCL. Given intravenously (through the vein).
Starting dose: 25 mg/m2"
1474807|NCT03161223|Drug|Romidepsin|"Romidepsin is another type of chemotherapy known as histone deacetylase (HDAC) inhibitors. Romidepsin has not been approved for use in lymphoma other than Cutaneous T cell lymphoma (CTCL) by the FDA. Given intravenously (through the vein).
Starting dose: 12 mg/m2"
1474808|NCT03161223|Drug|5-Azacitidine|"Oral 5-azacitidine is used for the treatment of myelodysplastic syndrome and acute myeloid leukemia. Azacitidine prevents the body from making DNA and RNA that cells need to grow. This stops the growth of cancer cells and causes them to die. Given by mouth (orally).
Starting dose: 300 mg daily"
1474809|NCT03161210|Other|Dextrose Prolotherapy|Dextrose is a solution, mixture of dextrose and water.
1474810|NCT03161210|Other|Local Anaesthesia|A local anaesthetic is a medication that causes reversible absence of pain sensation
1474811|NCT03161210|Other|Saline|Saline is a control group
1474812|NCT03161197|Behavioral|Mindfulness-Based Stress Reduction|The intervention consists of mindfulness-based stress reduction. Key components of what the intervention consists relate to stress management, breathing, and meditation, as well as, techniques aimed at improving relations with others, sense of mastery and purpose in life. Additionally, the intervention subjects, during every point of contact, will be asked how often they utilized the strategies they were taught. This information will be helpful in understanding each subject's individual level of mastery and proficiency in Mindfulness-Based Stress Reduction (MBSR).
1474813|NCT03161184|Behavioral|SUSTAIN Smartphone training of CHW (SP+)|"Intervention (Smart phone assisted): During prenatal household visits, the smart phone based application guides CHW through electronic decision tree protocols, directing them to specific health/nutrition counseling topics and messages based on each woman's gestational age, and her answers to a specific series of diagnostic questions. Based on the client's gestational age, the tool directs CHW to lessons in an accompanying photo book, and reminds them to counsel on the importance of accessing timed and targeted maternal health services at health facilities. The application also assists CHW to identify danger signs during pregnancy, flags clients who require immediate referral to health facilities, and reminds CHW to follow-up with clients who were previously referred to clinics."
1474814|NCT03161184|Behavioral|SUSTAIN Paperbased training of CHW (SOC)|SUSTAIN Paperbased training of CHW (SOC): During prenatal household visits, the CHW asks a specific series of diagnostic questions based on the client's gestational age, offers counsel on the importance of accessing appropriate maternal health services at health facilities and uses lessons in an accompanying photo book to deliver messages on a variety of maternal and newborn health and nutrition topics. CHW are trained to identify danger signs during pregnancy, flag clients who require immediate referral to health facilities, and follow-up with clients who were previously referred to clinics.
1474815|NCT03161171|Other|This is an observational study|This is an observational study
1474816|NCT03161158|Device|CHIARA-System|Treatment with veno-venous ultrafiltration (CHIARA-System) complementary to low-dose diuretic therapy according to treatment algorithm. 1-7 Ultrafiltration sessions (6-10h/session, number of sessions depending on clinical assessment) for at least 1-2 consecutive days and a maximum of 7 days.
1474817|NCT03161158|Other|Usual care IV diuretics|Guideline-directed therapy including IV loop diuretics (according to treatment algorithm)
1474818|NCT03161132|Drug|Olaparib|Combination of continous olaparib 300mg for oral administration plus Pegylated Liposomal Doxorubicin (PLD), followed by maintenance treatment further described.
1474819|NCT03161132|Drug|Pegylated Liposomal Doxorubicin|PLD 40mg/m2 every 28 days intravenous
1474820|NCT03161119|Device|Catheter Cook K-Jets-551910-S (Ultrasound guided embryotransfer)|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.
The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
1474821|NCT03161119|Device|Catheter Cook k-soft-5000 (Ultrasound guided embryotransfer)|"On the day of ET, patient will be asked to come with full bladder. ET will be done with patient in lithotomy position. No anesthesia will be used for the procedure. Under sterile condition, vaginal parts will be cleaned with saline and draped and speculum inserted to expose cervix. Cervical mucus and cervix will be cleaned with sterile media.
The Et procedure itself is standardized as far as possible amongst the participating physicians to eliminate bias."
1474822|NCT03161106|Dietary Supplement|Nutrition|Nutrional group-30 kcal/kg with 1.5 grm protein with protein supplements
1474823|NCT03161106|Drug|Lactulose|Lactulose plus diet consumed by patient
1474824|NCT03161106|Dietary Supplement|Diet|Protein Powder 15 to 20 gm/meal/day
1474825|NCT03161093|Drug|Fasinumab|Solution for injection in pre-filled syringe
1474826|NCT03161093|Drug|Naproxen|Pharmaceutical form: Capsule
1474827|NCT03161093|Drug|Fasinumab-matching placebo|Solution for injection in pre-filled syringe
1474828|NCT03161093|Drug|Naproxen-matching placebo|Capsule
1474829|NCT03161080|Device|Neovis Total Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), lipoic acid, hydroxypropyl methylcellulose
1474830|NCT03161080|Device|Vismed Multi® Eye Drops|Eye Drops containing Sodium hyaluronate (0.18%), potassium chloride, disodium phosphate
1474831|NCT03161080|Device|Hydrabak® Eye Drops|Eye Drops containing sodium chloride (0,9%), sodium dihydrogen phosphate dehydrate
1474832|NCT03161067|Device|BiCNS|Surgical implantation
1474833|NCT03161054|Drug|Prednisone|"Induction Phase: Prednisone (Deltacortene) 25 mg /day will be orally administered from day 1 to day 28 only in cycle 1 From cycle 2 to 6 reduce to three times a week (after breakfast).
Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast).
Post Maintenance Phase: Prednisone 25 mg/day will be orally administered twice a week continuously (after breakfast)."
1475101|NCT03158792|Drug|Enoxaparin 20Mg/0.2mL Prefilled Syringe|Enoxaparin 20mg subcutaneously once daily
1474834|NCT03161054|Drug|Vinorelbine|"Induction Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Maintenance Phase: Vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast).
Post Maintenance Phase: vinorelbine 30 mg/day will be orally administered three times a week, 3 weeks on and 1 week off (after breakfast)."
1474835|NCT03161054|Drug|Etoposide|Induction Phase Etoposide: 50 mg/day will be orally administered from day 1 to day 14 (before lunch);
1474836|NCT03161054|Drug|Cyclophosphamide|"Induction Phase: Cyclophosphamide 50 mg/day will be orally administered from day 1 to day 21 (after dinner).
Maintenance Phase: 50 mg/day will be orally administered from day 1 to day 14 (after dinner)."
1474837|NCT03161054|Drug|Rituximab|Induction Phase: Rituximab: 375 mg/m2 will be administered by IV infusion up to four infusions on days 8, 15, 22, 29, only in patients suitable for infusion treatment and relapsed after >6 months from last R-chemotherapy. Refractory patients who received at least 5 doses of Rituximab will not repeat it during the metronomic therapy.
1474838|NCT03161041|Procedure|Cytoreductive surgery combined with HIPEC|Procedure/Surgery: Cytoreductive surgery combined with HIPEC (Oxaliplatin 360 mg/m2).
1474839|NCT03161041|Drug|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).|bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
1474840|NCT03161028|Drug|Lipoic acid|1200 mg taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation.
1474841|NCT03161028|Drug|Placebo|The placebo comparator will be taken by mouth daily for two years starting on day one of the study and ending on the last day of study participation
1474842|NCT03161015|Drug|GBT440|Oral
1474843|NCT03161002|Genetic|detection of genotype|detection of genotype by next generation sequencing
1474844|NCT03160989|Other|physical exercises|The intervention will consist of a single session and after ten weeks of combined physical exercises (aerobic and resisted). All volunteers will participate in the same procedure.
1474845|NCT03160976|Other|Cryolipolysis|First, the demarcation of the lower abdomen area at the same landmarks of the ultrasonography will be done. Secondly, the patient will be positioned on the stretcher in the supine position with a 45 ° elevation of the trunk. In this position, to protect the region to be treated, a glycerine antifreeze membrane will be placed. The treatment parameters will be: temperature of -10 ° C, treatment time of 50 minutes (first 3 minutes of heating at 42°C) and moderate vacuum pressure (60 - 40 Kpas). The applicator will be chosen according to the size of the area of each subject and positioned in the target region. At the end the skinfold will be released automatically, the antifreeze membrane removed and a manual massage will be carried out for five minutes to stimulate local blood reperfusion.
1474846|NCT03160963|Other|Power Testing|Chair stand, vertical jump, computerized squat
1474847|NCT03160950|Device|LuxaCrown|"Teeth that would be requiring RCT, would be initially treated by a endodontist using the standardized principles of rotary endodontics.
Restoration using the LuxaCrown as a direct composite crown: In short, the impression material will be loaded with the LuxaCrown material (DMG, Germany). The impression will be then reloaded in the patient's mouth and will stay there for approx. 1.5- 2.3 minutes, that is, till the material is partially set. The impression will then be taken out and the material will be allowed to set outside patient's mouth up to approximately 5 minutes after the start of mixing. The Crown will then be finished using a fine buff and pumice, followed by application of Glaze and Bond (DMG, Germany). The preparation will then be cleaned and slightly roughened with a bur or sand blaster at the adhesion sites. The crown fabricated will then be cemented using TempoCem luting cement (DMG, Germany)."
1474848|NCT03160937|Other|Manual therapy|The subjects repeated this motion for 1 min, rested for 30 s, and then repeated it again for 5 sets.
1474849|NCT03160924|Other|Enhanced Recovery After Surgery (ERAS)|"same as above as described in the arms."
1474850|NCT03160911|Device|Over-the-scope clip (OTSC)|The device provides a robust and strong tissue apposition. The system was developed to close perforations and treat bleeding in the gastrointestinal tract. In chronic ulcers, an anchor device can be used to pull the ulcer base toward the aspiration cap to facilitate accurate clip application. Endoscopic haemostasis would be achieved with the use of this device and/or injection of adrenaline
1474851|NCT03160911|Device|Conventional Endoscopic Haemostasis|This includes the use of heater probe, endoscopic clipping and injection of adrenaline for endoscopic haemostasis
1474854|NCT03160885|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
1474855|NCT03160885|Drug|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
1474856|NCT03160872|Diagnostic Test|Anti Mullerian Hormone Measurement|Anti Mullerian Hormone was measured in all patients within two months before the first insemination cycle
1474857|NCT03160859|Other|Control|Unsedated colonoscopy with water exchange (WE) where the residual air in the colon will be removed and water will be infused to guide insertion through an airless lumen. Infused water is removed predominantly during insertion.
1474858|NCT03160859|Device|Study method|Unsedated colonoscopy with water exchange (WE + cap) and the addition of a cap fitted to the colonoscope.
1474859|NCT03160846|Drug|Inotrope|Home intravenous infusion of Dobutamine, Dopamine, or Milrinone
1474860|NCT03160833|Drug|HMPL-453|oral administrative
1474861|NCT03160820|Biological|Measles, mumps and rubella Combined Vaccine, Live|Subjects will be inoculated one dose of MMR vaccine and collected blood samples before and after vaccination.
1474862|NCT03160807|Drug|Levofloxacin|Levolet 500 mg OD for 5 days
1474863|NCT03160807|Drug|Levofloxacin|Levolet 500 OD for 10 days
1474864|NCT03160794|Diagnostic Test|[18F]DCFPyL PET/MRI scan|PET/MRI imaging using the radiotracer, [18F]DCFPyL
1474865|NCT03160794|Radiation|Stereotactic Ablative Radiotherapy|SABR as treatment for lesions identified using [18F]DCFPyL PET/MRI
1474866|NCT03160781|Biological|Platelet Rich Plasma|Combination of Intraosseous and Intraarticular Infiltration of Platelet Rich Plasma
1474868|NCT03160729|Drug|Dexamethasone|pre-operative, single-shot injection
1475131|NCT03158506|Drug|HMS5552|[14C]-labelled HMS5552
1474870|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), 2.0% abrasive silica|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 2.0% abrasive silica (RDA~58) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
1474871|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), Sodium tripolyphosphate (STP, 5%), abrasive silica (3.5%)|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 / 5% STP; 3.5% abrasive silica (RDA~77) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
1474872|NCT03160703|Other|Sodium Monofluorophosphate (1000 ppm fluoride ), RDA~80|Participants will apply a full brush head of their dentifrice containing 1000 ppm fluoride as SMFP with moderate abrasivity (RDA~80) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
1474873|NCT03160703|Other|Stannous fluoride (SnF2, 0.454%), RDA~120|Participants will apply a full brush head of their dentifrice containing 0.454% SnF2 with higher abrasivity (RDA~120) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
1474874|NCT03160690|Procedure|Non penetrating deep sclerectomy|Non penetrating deep sclerectomy for open angle glaucoma
1474875|NCT03160677|Other|Systolic blood pressure target < 130 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target < 130 mm Hg
1474876|NCT03160677|Other|Systolic blood pressure target < 185 mm Hg|Adaptation of antihypertensive treatments to reach the Systolic blood pressure target < 185 mm Hg
1474877|NCT03160664|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
1474878|NCT03160664|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
1474879|NCT03160664|Other|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
1474880|NCT03160651|Drug|Methylprednisolone or placebo|Patients will receive 28 days of methylprednisolone 32 mg/day
1474881|NCT03160638|Drug|Azithromycin 250 mg|Patients will be treated with azithromycin 250 mg once daily for 28 days. An azithromycin loading dose of 500 mg (two tablets of 250 mg) will be administered on day 1
1474882|NCT03160625|Device|Rate Adaptive Pacing|Rate Adaptive Pacing varies the pacing rate in response to the patient's physical motion as detected by an activity sensor.
1474883|NCT03160612|Behavioral|Transfer Training|Transfer training interventions will take approximately 1 hour to complete and consist of an interactive web based module that participants interact with which includes text, pictures, videos and time to practice new skills. Additionally, participants will receive an educational handout summarizing the online module.
1474884|NCT03160599|Other|ketogenic diet|The treatment is mainly restricted calorie ketogenic diet. KD will consist of 4:1-1:1[fat]:[protein+carbohydrate].Carbohydrate is limited to 10-30 g / day.
1474885|NCT03160586|Diagnostic Test|Stuttering severity instrument-3|To measure of degree of stuttering in child
1474886|NCT03160586|Diagnostic Test|Child Behavior Checklist for age 4-18|To measure of percent of anxiety in child by ask parents about his or her behaviour
1474887|NCT03160573|Drug|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse
1474888|NCT03160573|Drug|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse
1474889|NCT03160573|Other|Placebo|Subjects in Placebo group will receive Placebo Rinse
1474890|NCT03160560|Drug|ClōSYS® Unflavored Rinse|Subjects in Test group will receive ClōSYS® Unflavored Rinse.
1474891|NCT03160560|Drug|ClōSYS® Flavored Rinse|Subjects in Test group will receive ClōSYS® Flavored Rinse.
1474892|NCT03160560|Other|Placebo|Subjects in Placebo group will receive Placebo Rinse.
1948635|NCT02025634|Drug|Intravenous Acetaminophen|Participants randomized to intravenous acetaminophen (Ofirmev) will receive an infusion of Ofirmev in 100 ml of 0.9 NS according to manufacturer's recommendations related to subject's weight.
1948636|NCT02025634|Drug|Placebo (0.9% Normal Saline infusion)|Infusion of 100 ml of 0.9% NS
1474896|NCT03160521|Drug|Risperidone ISM|Risperidone ISM and placebo requires a reconstitution procedure to be performed each dose to be administered. The study drug or placebo will be administered immediately after reconstitution in a single IM injection in the gluteal or deltoid muscle.
1474897|NCT03160508|Procedure|Fracture fixation with the TFNA|Fracture fixation with the TFNA
1474898|NCT03160495|Other|All patients|All patients are scanned with PET/MR prior to surgery.
1474899|NCT03160482|Diagnostic Test|Immunohistochemistry|Immunohistochemistry procedure on the formalin-fixed, paraffin-embedded tissue.
1474900|NCT03160469|Device|intragastric Elipse Device|"Obesity prevalence is increasing worldwide, and Kuwait is currently considered to be the country with the most obese population1. Accordingly, standardization of the weight loss procedures has been made according to the Body Mass Index (BMI), keeping the more advanced surgeries for class II obesity (BMI 35- 39.9) and above, with consideration of other factors like, for example, obesity-related comorbidities. For those patients whom considered in the category of overweight (BMI = 25- 29.9) & class I obesity (BMI 30- 34.9), after failure of diet attempts, the weight loss options are limited. Of the highly requested options are the various types of intra-gastric balloons. Conventional endoscopic gastric balloons have proven to be safe and effective, with Excess Weight Loss (%EWL) of 25-50%2. A new swallowable gastric balloon, named Elipse, has been launched recently in Kuwait and became highly popular due to its unique concept of being procedure-less."
1475047|NCT03159221|Behavioral|BFST for Teens with Type 2 Diabetes|BFST for Teens with Type 2 Diabetes: 12 (90 minute sessions) over 6 months of Behavioral Family Systems Therapy (BFST), delivered by a Licensed clinical social worker. BFST consists of 4 components: problem-solving, communication skills training, cognitive restructuring, and functional and structural family therapy.
1948637|NCT02024204|Drug|Fluticasone propionate 230mcg for 3 Months|
1474901|NCT03160456|Device|Transcutaneous electrical stimulation|The device needs to be started by pressing the '+' and the '-' button together for 3s. Once the device is turned on the current intensity can be increased by pushing the '+' button (7 levels) and lowered by pushing the '-' button. When a comfortable skin sensation is felt the patients should press the '-' button once more. At that time the device stimulates with a low current which is not felt but provides a neuromuscular tone to the muscles whilst asleep. The device is kept on all night and in the morning taken off with the hydrogel and disconnected. Once disconnected it should be turned off by pressing the '+' and the '-' button for 3s. The device should then be placed on the provided wireless charger so that it is fully charged again for the next night.
1474902|NCT03160456|Device|Continuous positive airway pressure|CPAP will be applied according to usual clinical care, the follow up will be organised in the same way as the active intervention group.
1474903|NCT03160443|Behavioral|Ambulatory cares in a day-hospital (University Hospital of Montpellier) specialized in the evaluation of eating disorders|"All patients assessed in the day-hospital will performed the same evaluation :
Blood sampling
Calorimetry
Osteodensitometry
Psychiatric assessment
Endocrinologic assessment
Dietetic assessment
Neuropsychological assessment
Self-questionnaires
With the patient agreement, a biological collection will be constituted. The objective is the subsequent study of biological factors involved in eating disorders (in particular genetic factors)"
1474904|NCT03160430|Drug|apabetalone|RVX000222 oral (apabetalone), 100 mg capsule
1474905|NCT03160430|Drug|Placebos|matching placebo capsule
1474906|NCT03160404|Drug|Zolpidem|The ZOLPIDEM group will be treated with zolpidem 10mg / night and the
1474907|NCT03160404|Behavioral|Exercise|The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
1474908|NCT03160404|Combination Product|Zolpidem and Exercise|The COMBINED will be treated with zolpidem 10mg / night and will participate in the aerobic exercise program.
1474909|NCT03160391|Behavioral|Music Training|Training curriculums were developed using guidelines set by the Ontario Ministry of Education (The Ontario Curriculum, 2009) for teaching music to grades 1 to 3. Music was delineated into duration, pitch, dynamics and other expressive controls, timbre, texture/harmony, and form. training included direct instruction and group activities. All training programs had the same structure: a warm-up period, following by instruction from a teacher, and then group activities to practically demonstrate the concepts learned. Both programs involved working towards a variety of ensembles.
1474910|NCT03160391|Behavioral|Dance Training|As with music training, dance was operationally defined by fundamental concepts for the art form, namely elements for body, space, time, energy, and relationship. The intervention involved both individual and group activities, with a combination of instruction and practical activities, and preparation for a final performance.
1474911|NCT03160378|Behavioral|Organizational skills training|10 sessions of parent and child training in a group format.
1474912|NCT03160378|Other|Treatment as usual|Treatment as usual in the outpatient clinic
1474913|NCT03160365|Procedure|ACQUISITION OF IMAGES|In addition to the conventional clinical protocol, 4 MRIs qere performed at Day 0, day 1,day 15 and day 30 and a preoperative CT scan without injection of a contrast agent.
1474914|NCT03160352|Other|Exergame|In total, 10 sessions were accomplished including baseline and post intervention measurements. The remaining eight exercise sessions lasted 40 minutes, with an actual training duration of 20 minutes. This resulted in a cumulative total intervention exercise time of 160 minutes.
1474915|NCT03160339|Biological|PXVX0047 Vaccine|PXVX0047 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in PXVX 0047 are unattenuated strains propagated in A549 human adenocarcinomic alveolar basal epithelial cells.
1474916|NCT03160339|Biological|Teva Ad4/Ad7 Vaccine|Teva Ad4/Ad7 is a live Adenovirus Type 4 (Ad4) / Adenovirus Type 7 (Ad7) vaccine for single-dose oral administration. The Ad4 and Ad7 strains in Teva Ad4/Ad7 are unattenuated strains propagated in WI-38 human diploid fibroblast cells.
1474917|NCT03160313|Behavioral|InFuSE|Each session includes a 45-minute education and group discussion. A 60-minute exercise component then completes the session. Each topic was specifically picked and tailored to benefit Veterans with TBI. The education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities. The activities are included to help improve understanding and promote group discussion. The exercise piece consists of a warm-up, endurance training (20-30 minutes), strengthening (15 minutes), balance/cognitive training (15 minutes), and a cool-down.
1474918|NCT03160313|Behavioral|Patient Education/Group Discussion|Each week you will participate in a 1 hour health education class with other Veterans. Each topic was specifically picked and tailored for Veterans with TBI. These education sessions will be led and moderated by different professionals including physical therapists, recreation therapists, and physicians. Participants will be asked to participate in several learning activities which are included to help improve understanding and promote group discussion.
1474919|NCT03160300|Device|Music with Binaural Beats|Relaxing music with embedded binaural beats at a frequency of 5 Hz
1474920|NCT03160300|Device|Music|Relaxing music without a binaural beat component
1474922|NCT03160274|Genetic|Genetic screening|Germline and/or tumor samples will be screened for mutations
1474923|NCT03160261|Drug|Exenatide Injection|Single injection of Exenatide 10μg subcutaneously
1474924|NCT03160248|Drug|Apremilast|This study aims on investigating the efficacy of Apremilast in nummular eczema patients.
1474925|NCT03160248|Drug|Placebo Oral Tablet|This study aims on investigating the efficacy of Apremilast in nummular eczema patients - placebo controlled
1474926|NCT03160235|Radiation|Magnetic resonance imaging|
1474927|NCT03160235|Device|EEG|
1474928|NCT03160235|Device|NIRS|
1475325|NCT03156829|Drug|Betamethasone|Corticosteroid Injection Brand name of the drug: Celestone Soluspan Dosage: 6 mg/ml
1474929|NCT03160222|Other|Body Composition Measurements|Body composition measurements comprise the ultrasound measurement of fat and muscle thickness of both upper arms and thighs, the bioelectrical impedance analysis (BIA), measurement of weight, handgrip strength, overall muscle strength (Medical Research Council scale) and questionnaires about physical activity, nutrition and fluid status.
1474930|NCT03160196|Other|Clinical Decision Support System|It is about a Clinical Decision Support System based on a diabetes mellitus clinical practice guideline.
1474931|NCT03160196|Other|Usual care based on clinical practice guideline|It is about usual care aligned with the diabetes guideline.
1474932|NCT03160170|Device|SISTER device|Use of the Suction-Integrated Surgical Tissue Elevator & Retractor (SISTER) device during surgery
1474933|NCT03160144|Procedure|open lung approach|
1474934|NCT03160131|Device|Neuro Vision Technology|"The Neuro Vision Technology method uses a special device in the form of light panels and neurological vision tests that give an overview of cognitive difficulties. This light panel is connected to a computer.
Static scanning is investigated using the special light panel with 24 light bulbs divided into two rows, the panel length corresponding to the 180 degrees that normal and well-functioning human eyes can see. Where it is considered relevant, the study participants are referred to the ophthalmologist, specialist optician, or a reading / visual clinic to ensure participants the optimal starting point for using his or her vision."
1474935|NCT03160118|Drug|Seasonal,quadrivalent,influenza vaccine|1 dose to be administered on Day 0, the first visit
1474938|NCT03160092|Other|Intervention|"The intervention aims to:
Support the participant to explore their unusual experiences
Reduce the distress or anxiety participants feel in response to their unusual experiences, through:
Helping them to recognise how common these unusual experience
Supporting them to make sense of their unusual experiences
Supporting them to understand why they may be experiencing these symptoms
Challenging any unhelpful beliefs they hold about their symptoms
Help the participant to recognise the triggers to their unusual experiences
Support the participant to increase their activities and socialisation
The intervention is not aiming to 'get rid' of the participant's symptoms, but to reduce their distress in response to them, which may result in improved wellbeing and reduced symptoms."
1474939|NCT03160079|Drug|blinatumomab|"Cycle 1 Blinatumomab Day 1-7 Continuous IV infusion for 28 days (9 mcg/day) Blinatumomab Day 8-28 Continuous IV infusion for 28 days (28 mcg/day)
Cycle 2-5 Blinatumomab Day 1-28 Continuous IV infusion for 28 days (28 mcg/day)
Cycle length 42 days"
1474940|NCT03160079|Drug|pembrolizumab|"Cycle 1 Pembroluzumab Day 15 and 36 IV infusion over 30 minutes (200mg)
Cycle 2-5 Pembroluzumab Day 15 and 36 IV infusion over 30 minutes (200mg)"
1474941|NCT03160066|Dietary Supplement|Lactobacillus Rhamnosus (JB-1)|Lactobacillus Rhamnosus (JB-1) capsule
1474942|NCT03160066|Dietary Supplement|Placebo|Placebo
1474943|NCT03160053|Device|NB-UVB|NB-UVB has an emission spectrum in the ultraviolet B range of 290-320 nm. The system consists of a light source, a spot handpiece, and a light guide that connects the handpiece to the light source. The light source has a Start/Stop switch for light beam activation. Activation can also be controlled remotely with a foot switch. The light source has a timer and an output level control to adjust the intensity of the ultraviolet light. This will be calibrated using a manufacturer-provided UV meter prior to every treatment to ensure accurate doses of ultraviolet light.
1474944|NCT03160040|Drug|Minocycline IV|This study is an observational study. All participants were administered minocycline IV prior to enrollment in this study.
1474945|NCT03160027|Device|Vielight Neuro Gamma|The Vielight Neuro Gamma is headset that delivers transcranial (through the scalp and skull) and intranasal (through the nose) near infrared (NIR) light. The device is engineered for increased efficacy and easy domestic use for comprehensive brain photobiomodulation (PBM). The NIR lights are pulsed at a 40 Hz rate, which correlates with electroencephalogram (EEG) gamma brain wave entrainment.
1474946|NCT03160014|Drug|SHR3824|Drug: SHR3824 20mg/day, oral tablet, single dose
1474947|NCT03160001|Drug|Placebo|Patients with active RA and receive Etanercept for 8 weeks.: Placebo lactose 500mg cap twice daily
1474948|NCT03160001|Drug|Niclosamide|Patients with active RA and receive etanercept with niclosamide cap 500mg twice daily orally as adjuvant therapy for 8 weeks
1474949|NCT03160001|Drug|Etanercept|Etanercept 50mg weekly
1474950|NCT03159988|Drug|Angiotensin-(1-7)|Angiotensin-(1-7) 100mcg/kg/day for 12 weeks
1474951|NCT03159988|Behavioral|Memory Training|50% of the treatment arm will receive 2 session per week for 2 weeks of memory training
1474952|NCT03159975|Drug|GX-70 by electroporation|Gx-70 0.26mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
1474953|NCT03159975|Drug|GX-70 by electroporation|Gx-70 1mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
1474954|NCT03159975|Drug|GX-70 by electroporation|Gx-70 4mg will be administered by electroporation in the deltoid muscles every 4 weeks 5 times
1474955|NCT03159962|Device|Bonded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.
The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
1474956|NCT03159962|Device|Banded RME (Rapid Maxillary Expander) appliance|"The expansion screw was activated 1 quarter of a turn per day (0.25 mm per turn) until the palatal cusps of the maxillary posterior teeth approximated the lingual cusps of the mandibular posterior teeth.
The expander was kept in place as a passive retainer for 8 months. After expander removal, patients were followed without performing any additional treatment for 4 months."
1948638|NCT02024204|Drug|Current Treatment or no treatment|Patients who had symptoms at monitoring visit but are now controlled at V1 will be asked to continue their current treatment (or no treatment) and will continue with the study. They will not be provided with any medications.
1475049|NCT03159182|Device|Pressure garment and silicone insert|Custom made fabric pressure garment with textile bonded silicone insert on either proximal or distal portion of pressure garment.
1948639|NCT02024204|Drug|Salmeterol 21mcg for 3 Months|
1474959|NCT03159936|Biological|Tofacitinib citrate|10 mg daily by mouth
1474960|NCT03159923|Other|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.|Moderate to severe tricuspid regurgitation (≥ 2/4) diagnosed with echocardiography in patients stabilized.
1474961|NCT03159910|Behavioral|Shoulder-Café|Education and individual counselling, clinical examination, supervised shoulder exercise. Some participants can be offered a workplace visit.
1474962|NCT03159910|Behavioral|Shoulder-Guidance|Home-based shoulder exercise and written counselling.
1948640|NCT02023697|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
1948641|NCT02018250|Drug|MMB4 DMS|Subjects will be administered the drug product formulation at the assigned dosage of MMB4 DMS or placebo i.m. to the anterior thigh using a 5 mL syringe.
1948642|NCT02018250|Drug|Placebo|Subjects will be administered the drug product formulation at the assigned dosage of placebo i.m. to the anterior thigh using a 5 mL syringe. The placebo group in each cohort will receive the same injection volume and number of injections as the dose group in that cohort.
1948643|NCT02013414|Procedure|PET/Ultrasound Fusion Targeted Biopsy of the Prostate|Patients will have a PET/CT prior to the biopsy. The CT images will be combined with the PET images for improved localization of suspicious tumors. During the biopsy, the 3-D ultrasound images will be acquired immediately before the biopsy while the patient is on the table. The ultrasound images together with the PET images will be used to guide the targeted biopsy of the prostate.
1474967|NCT03159884|Drug|Conbercept|
1474968|NCT03159871|Device|Stratafix suture|Stratafix barbed sutures during C-Sections.
1474969|NCT03159871|Device|Vicryl suture|Standart Vicryl suture during C- Sections.
1474970|NCT03159858|Device|Fenerated AAA Endovascular Graft with H&L-B One Shot Introduction System|The Compassionate Use Request is for the use of the Cook Zenith Fenestrated Endovascular Graft (4 branches) for the treatment of a 70‐year‐old male patient considered unfit for open surgical repair of his 6cm paravisceral abdominal aortic aneurism (AAA).
1474971|NCT03159845|Drug|Zinc Sulfate Oral Product|
1474972|NCT03159845|Drug|Levofloxacin 500Mg Oral Tablet|once daily from day +10 until day +30 after stem cell transplantation
1474973|NCT03159845|Drug|Fluconazole 200mg tab|twice daily from day +10 until day +30 after stem cell transplantation
1474974|NCT03159845|Drug|Acyclovir 400 MG|twice daily from day +10 until day +30 after stem cell transplantation
1474975|NCT03159832|Drug|SHR3824|All subjects were given SHR3824 20mg only one time.
1474976|NCT03159819|Genetic|CAR-CLD18 T Cells|Dose escalation will be applied in this study.
1474977|NCT03159806|Device|Microdialysis sampling|Insertion of CE-marked intravenous microdialysis catheter, use of CE-marked microdialysis pump to collect intravenous microdialysis samples
1474978|NCT03159793|Behavioral|Live Modelling Technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
1474979|NCT03159793|Behavioral|Filmed Modelling technique|Direct observation is the term used to describe both the filmed and live modelling technique. These techniques depend on familiarizing the patient with the dental environment and allowing the patient to ask the questions he/she wants to ask. The patients are shown a film or are permitted to directly observe a cooperative patient undergoing dental treatment. These techniques have no contra indications they simply may be used with any patient.
1474980|NCT03159767|Device|ViMove Spinal Sensor|Sensors will be used to measure spinal movement
1474981|NCT03159754|Procedure|Early Appendectomy|Removal of the appendix within 24 hours of admission
1474982|NCT03159754|Procedure|Interval Appendectomy|Removal of the appendix after initial antibiotic treatment and at least 6 weeks of recovery.
1474983|NCT03159754|Drug|Antibiotics|Zosyn will be administered unless the patient has a penicillin allergy, in which case patients will receive both ciprofloxacin and metronidazole.
1474984|NCT03159741|Other|Inhibitor + GLP-2|Inhibitor and GLP-2 are used as study tools.
1474985|NCT03159741|Other|Placebo + GLP-2|Placebo and GLP-2 are used as study tools.
1474986|NCT03159741|Other|Placebo + GIP|Placebo and GIP are used as study tools.
1474987|NCT03159741|Other|Placebo + Saline|Placebo
1474988|NCT03159728|Behavioral|Educative intervention:|"In the induction of the new group members are present, including caregivers who start the program and those who coordinated.
In Module I: to strengthen the knowledge of the situation and the people involved in care.
In Module II: to strengthen the value in the caregiver through decision making, skill and social support to back it up.
In Module III: or end, after analyzing that uneasy caregiver, patience is reviewed through the meaning of family care and self."
1474989|NCT03159715|Behavioral|Internet-based Global Protocol|Internet-based Global Protocol is an Internet-based treatment which includes therapeutic components of evidence-based treatments for depression: Motivation, Psychoeducation, Cognitive Therapy, and Relapse Prevention. Furthermore, it incorporates a Behavioural Activation component (BA). The whole protocol stresses the importance and benefits of being active and remaining involved in life, values and goals. The program also includes a component of Positive Psychology (PP). It allows the individual to learn and practice adaptive ways to cope with depressive and anxiety symptoms and confront daily problems. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
1474990|NCT03159715|Behavioral|Internet-based Behavioral Activation Protocol|Internet-based Behavioral Activation Protocol is an Internet-based treatment based on Behavioral Activation. It stresses the importance and benefits of being active and remaining involved in life, values and goals . It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
1475050|NCT03159182|Device|Pressure garment|Custom made fabric pressure garment
1475777|NCT03152955|Drug|ondansetron|Ondansetron(13ug/kg/h) is applied in patient-controlled analgesia.
1948644|NCT02013271|Device|Lutonix Paclitaxel Drug Coated Balloon|
1474991|NCT03159715|Behavioral|Internet-based Positive Psychology Protocol|Internet-based Positive Psychology Protocol is an Internet-based treatment based on Positive Psychology, offering strategies to promote and enhance positive mood. It is an Internet-based treatment based on Positive Psychology. It is a multimedia (video, image, etc.) interactive program designed for optimal use on the computer, but it can also be used on a tablet.
1474995|NCT03159689|Other|Mixed Tree Nuts|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz mixed tree nuts
1474996|NCT03159689|Other|Pretzels|Individuals on a hypo caloric weight loss dietary plan supplemented with 1.5oz pretzels
1474997|NCT03159676|Radiation|Proton beam|Proton beam
1474998|NCT03159650|Device|intravascular ultrasonography|intravascular ultrasonography will be used during the study for the resolving proximal cap ambiguity of chronic total occlusion, facilitating re-entry into the true lumen after subintimal crossing and confirming distal true lumen guidewire position
1474999|NCT03159637|Procedure|Laparoscopic Surgery|Insufflation of a gas (carbon dioxide) into the peritoneal cavity producing a pneumoperitoneum will be done. The positioning of the patients in Trendelenburg position will be done. intraoperative and postoperative outcomes will be assesed
1475000|NCT03159624|Other|Biodesign™ SIS graft|2x3 cm Biodesign™ SIS perforated mesentery graft
1475001|NCT03159624|Other|Doyle silastic sheet|Doyle silastic sheet
1475002|NCT03159611|Drug|Tenoten for children|"Oral. A dose of 10 drops daily, at the same time in the morning, 15 minutes before feeding the child.
The drops can be diluted in a small amount of room temperature drinking water (1/2 tsp.) before use."
1475003|NCT03159611|Drug|Placebo|"Oral. A dose of 10 drops daily, at the same time in the morning, 15 minutes before feeding the child.
The drops can be diluted in a small amount of room temperature drinking water (1/2 tsp.) before use."
1475004|NCT03159598|Device|Tissue Glu|Once adequate hemostasis has been achieved during surgery and the abdominal fascia and flaps have been irrigated, Tissue Glu will be applied. Tissue Glu is applied at approximately one centimeter intervals while remaining one centimeter away from the umbilicus and inferior incisions.
1475005|NCT03159598|Device|Drain|Drains will be placed during surgery to allow for the drainage of seroma which may develop after surgery
1475006|NCT03159598|Other|Questionnaires|Questionnaires given to patients pre-and post surgery to determine pain, impact of breast reconstruction on activity, and impact of breast reconstruction on caregivers
1475007|NCT03159585|Drug|Cyclophosphamide|Three days prior to infusion of TCR-T cell, patients receive cyclophosphamide treatment at dose 1 g/day for 2 days and take a rest for one day before infusion.
1475008|NCT03159585|Biological|TAEST16001|A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×10^9) will be intravenously administered. Then, interleukin-2 subcutaneous injections (250,000 IU/day) will be administered for 14 days concomitantly to each patient.
1475009|NCT03159559|Drug|Lipo-PGE1|Patients received conventional therapy plus Lipo-PGE1 10μg once daily intravenous injection for 7 days
1475010|NCT03159546|Device|Device: FreeStyle Libre Flash Glucose Monitoring System|Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System and will receive no treatment except for safety purposes.
1475011|NCT03159533|Behavioral|CHW Intervention|Patients randomized to Group A will be invited to attend 4 more group educational sessions on self-management immediately.CHWs will follow up with participants by phone or in person through a home or clinic visit. At these follow-up meetings, CHWs will engage in goal-setting activities regarding changes to health behaviors, medication adherence, or other issues related to hypertension control as identified jointly by the patient and CHW. CHWs will also collect height, weight, and blood pressure measurements at initial and in-person follow-up visits. The CHW will make necessary referrals to other services available in the community (i.e. exercise classes, social services, mental health, tobacco cessation, etc.).
1475012|NCT03159533|Behavioral|Wait List Control Group|4 education sessions beginning 6-12 months later.
1475013|NCT03159520|Behavioral|Advice sheet|Advice on management of post orthodontic pain
1475014|NCT03159507|Dietary Supplement|MAG-EPA|Based on the result of the participant's Omega-3 index obtained from the blood sampling of visit 1, the daily dose of MAG-EPA will be adjusted to obtain an Omega-3 Index of 8.
1475015|NCT03159494|Other|High-Intensity Training|8 times of Hit consisting of 3 minutes of Warm-up on an indoor bike followed by 10 intervals of 1 minute at 90% og HRmax interspersed of 1 minute of recovery.
1475016|NCT03159481|Behavioral|Usual Care + Health Promotion Intervention|Telephone sessions for approximately 5-6 weeks to enhance empowerment and skills for managing medication adherence.
1475017|NCT03159468|Behavioral|Cognitive Restructuring|Participants receive didactic instruction regarding cognitive restructuring skills and then practice using these skills in hypothetical situations.
1475018|NCT03159468|Behavioral|Mindfulness|Participants receive didactic instruction regarding mindfulness skills and then practice using these skills in hypothetical situations.
1475023|NCT03159429|Behavioral|Standard rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing usual procedures, which include: maintaining a diary, breathing coordination excercises, voluntary control of breathing rate, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
1475051|NCT03159169|Device|Spinal Cord Stimulation (SCS)|Implantation of SCS electrodes and stimulator according to clinical standards
1475024|NCT03159429|Behavioral|Nasal breathing rehabilitation|The patient will participate in a therapeutic education programme consisting of 4 visits (days 1 +- 14, 21 +- 14, 61 +- 14 and 90 +-14) representing the experimental procedures, which include: maintaining a diary, evaluating nasal breathing by the nostril-alternating technique according to Anuloma Viloma Pranayama Yoga, releasing contracted muscles, posture harmonization, a six minute walking test, and walking up four flights of stairs.
1948645|NCT02010281|Device|rTMS of prefrontal or motor cortex|description:rTMS of the motor or prefrontal cortex (repetitive magnetic stimulation targeting the motor or prefrontal cortex) assisted with neuronavigation
1475026|NCT03159403|Drug|Oritavancin|This study is an observational study. All participants were administered oritavancin prior to enrollment in this study.
1475027|NCT03159390|Other|phenylacetate salt of ornithine|
1475028|NCT03159377|Device|Ultra low dose chest CT|Performing an ultra low dose chest CT (ULDCT) in addition to a clinically indicated chest CT and assessing nodule detection with a recently developed denoising algorithm
1475029|NCT03159364|Biological|CMV/EBV/ADV/BKV specific CTLs|Patients will receive approximately 1x10^5~4x10^6 CTLs/kg as a single infusion via IV injection and may receive 1 to 4 additional infusions at intervals of one week.
1475030|NCT03159351|Device|active rTMS treatment|active rTMS treatment protocol parameters: localization of left DLPFC: frequency=10 Hz, intensity=110%MT, times per train=200 seconds, trains=10, duration= 40 seconds, total times=20;localization of right DLPFC: frequency=1 Hz, intensity=100%MT, times per train=30 seconds, trains=10, duration= 10 seconds, total times=20.
1475031|NCT03159351|Device|sham rTMS treatment|sham rTMS treatment protocol parameters: sham rTMS treatment in the localization of left DLPFC and right DLPFC for 30 minutes,total times=20.
1475032|NCT03159338|Biological|Platelet rich fibrin|Platelet rich fibrin will be prepared by taking 20 cc blood and centrifugation with 28000 rpm.
1475033|NCT03159338|Biological|Placebo|In control group , after spliting the osteotomy site before fixation a placebo gel will be placed
1475034|NCT03159325|Behavioral|Healing Circles|See description in the arm description.
1475035|NCT03159312|Behavioral|Physical activity based on a moderate exercise program|A controlled clinical trial study, there will be an experimental group that will undergo a moderate physical exercise program and another group that will not be operated and used as a control. The sample will be selected following a non-probabilistic sampling and for convenience. The sample will consist of 20 subjects in each group. In the experimental group, anthropometry, 6-minute walk test (T6M), strength assessment and follow-up during the stipulated time period for the development of the research will be performed, total four months, three times a week for the Intervention group, as opposed to the control group that will continue to be cited only to the assessments established for the study.
1475036|NCT03159299|Behavioral|Yo Puedo + mHealth|This intervention is an adapted diabetes self-management education program. Study participants will attend group classes weekly for 6 weeks, and receive daily text messages over 6 months.
1475037|NCT03159286|Behavioral|Abstainer|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use.
1475038|NCT03159286|Behavioral|Abstainer + User|Participants view social networking site profiles with alcohol content referencing abstaining from alcohol use and using alcohol.
1475039|NCT03159286|Behavioral|Control|Participants view social networking site profiles with no alcohol content.
1475040|NCT03159273|Dietary Supplement|Beetroot Juice Group|Beetroot juice drink- 7 daily doses (70 ml, containing 0.4-0.5 mg nitrate) taken over a week
1475041|NCT03159260|Device|Theraworx|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
1475042|NCT03159260|Other|Placebo|Subjects will be instructed to apply the topical foam they have been assigned to their entire upper and lower legs and feet using 8 pumps from the product dispenser per leg (upper thigh to foot) before retiring each evening for the next 14 days. If subjects experience leg cramps or spasms after retiring they will be instructed to reapply to 2 pumps of the foam to the affected area in response to each event. Each morning during the 14 days in which subjects apply the foam they will be asked to complete the Compliance and Symptom Log that documents the incidence and severity of night-time cramps and spasms their use of the foam and any other therapies they used to treat their night-time cramps and spasm.
1475043|NCT03159247|Behavioral|eyeGuide|The eyeGuide, a web-based tool to facilitate a personalized behavior change program for non-adherent glaucoma patients.
1475044|NCT03159234|Radiation|fetal lung volume|the best method for measurement of fetal lung volume is by the rotational technique in which each lung is obtained by serial contouring of the pulmonary area after rotating the volumetric image.this is more recent method seems to have advantages allowing finer contouring of the lung and subsequent modification of the contour as well as being better able to estimate the volumes of irregular and small lung as in congenital diaphragmatic hernia
1475045|NCT03159234|Radiation|pulmonary artery resistance index|Women placed in semirecumbent position and an axial plane through the fetal thorax to achieve 4 chamber view of the heart. The main pulmonary artery was followed to the point where it divides into right and left branches by rotating the transducer from the 4 chamber view to the short axis view of the heart. Pulsed and colour Doppler was used. The fetal pulmonary artery flow waveform measurements was taken within the proximal portion of the main pulmonary artery
1475046|NCT03159234|Radiation|Fetal adrenal gland volume:|the adrenal gland has a characteristic sonographic appearance; each limb is seen as a long anechoic structure with a thin, echogenic line within its center . Both limbs can sometimes be seen in the coronal plane, and if so there is a strong echogenic line between limbs (probably fat). On the basis of pathologic and histologic studies , we believe the anechoic bulk of the gland represents the fetal zone of the cortex, while the central echogenic core is the medulla.
1475052|NCT03159156|Behavioral|Applied Tension|Described above.
1475053|NCT03159156|Behavioral|Respiration Control|Described above.
1475055|NCT03159143|Drug|Docetaxel|Docetaxel (28) is a semi-synthetic taxane which blocks mitosis by preventing microtubule depolymerization. It mediates its actions by binding to a different set of microtubule-associated proteins than paclitaxel. It is administered every 3 weeks as a 30 minute infusion at doses between 60 to 75 mg/m^2.
1475056|NCT03159143|Drug|Oxaliplatin|Alkylating antineoplastic agent. It is administered on day 1 of each cycle at a dose of 110 mg/m^2
1475057|NCT03159117|Drug|PF-06688992|Part 1 will be a dose-finding phase in which patients will be treated with various doses of Pfizer PF-06688992. (PF 06688992) will be administered by the intravenous route over approximately 60 minutes every 21 days. The dose expansion phase will include a single cohort of up to 20 evaluable patients treated at the recommend dose.
1475058|NCT03159104|Drug|Tenoten for children|Safety and Efficiency
1475059|NCT03159104|Drug|Placebo|Safety and Efficiency
1475060|NCT03159091|Drug|Rengalin|"Oral. Single dose: 2 tablets (to be held in the mouth until dissolution is complete).
Dosage regimen: 2 tablets three times daily, not concomitantly with food (i.e., 15-30 minute before or 15-30 minutes after eating)"
1475061|NCT03159091|Drug|Placebo|"Oral. Single dose: 2 tablets (to be held in the mouth until dissolution is complete).
Dosage regimen: 2 tablets three times daily, not concomitantly with food (i.e., 15-30 minute before or 15-30 minutes after eating)"
1475062|NCT03159078|Drug|Polymyxin B|Comparison of Poly B monotherapy vs Polymyxin B plus carbapenem in MDR infections
1475063|NCT03159065|Other|Bilberry|Fruit beverage with bilberry and fermented oatmeal
1475064|NCT03159065|Other|Blackcurrant|Fruit beverage with blackcurrant and fermented oatmeal
1475065|NCT03159065|Other|Mango|Fruit beverage with mango and fermented oatmeal
1475066|NCT03159065|Other|Beetroot|Fruit beverage with beetroot and fermented oatmeal
1475067|NCT03159065|Other|Rose hip|Fruit beverage with rose hip and fermented oatmeal
1475068|NCT03159065|Other|Glucose drink|A reference glucose drink
1475069|NCT03159052|Drug|SHR3824|Once daily, 52 weeks
1475070|NCT03159052|Drug|Placebo|Once daily, 24 weeks
1475071|NCT03159039|Other|Conventional Physiotherapy|
1475072|NCT03159039|Other|Prolonged slow exhalation technique|Postural drainage associated with manual vibration and a mild pressure in the end of expiratory phase
1475073|NCT03159013|Other|Exposure|"Oral exposure: 0,025 mg/kg bw dissolved in oil, on day 1, with blood withdrawn on days 2,3,4.
Dermal exposure: 145 µl of commercial formulation (0,25 mg/kg bw) on 40 cm2 of forearm skin for 6 hours, on day 28, with blood withdrawn on days 29,30,31."
1475074|NCT03159000|Drug|Saline|1ml of 1/3 saline
1475075|NCT03159000|Combination Product|lidocaine/bupivacaine|1ml of a 50% 2% lidocaine and 50% 0.5% bupivacaine
1475076|NCT03158987|Other|Medical record review|Review of medical records of patients diagnosed for the first time as HIV seropositivity
1475078|NCT03158961|Procedure|Transoral endoscopic thyroidectomy vestibular approach|TOVETA is a new approach in surgery of thyroidectomy no longer open on the neck
1475079|NCT03158948|Drug|MOTREM|Formulated LR12 peptide
1475080|NCT03158948|Drug|Placebo|placebo
1475081|NCT03158935|Drug|Cyclophosphamide|Cohort 1: i.v., 60mg/kg per day for 2 days Cohort 2: i.v., 30mg/kg per day for 2 days
1475082|NCT03158935|Drug|Fludarabine|Cohort 1: i.v., 25mg/m2 per day for 5 days
1475083|NCT03158935|Procedure|Pembrolizumab|Cohort 1 and 2: i.v., 200mg every 3 weeks
1475084|NCT03158935|Biological|Tumor-Infiltrating Lymphocytes (TILs)|Cohort 1 and 2: i.v., 1x10^10 - 1.6x10^11 cells
1475085|NCT03158935|Biological|Interleukin-2 (IL-2)|Cohort 1 and 2: i.v., 125,000 IU/kg subcutaneous per day
1475086|NCT03158922|Genetic|Genetic SNP profiling|Genetic SNP profiling of known prostate cancer predisposition SNPs will be performed on DNA extracted from saliva samples.
1475087|NCT03158922|Other|Prostate cancer screening|Prostate cancer screening in the form of PSA testing will be offered to all men who have a benign biopsy result for five years in order to track development of cancer in the future.
1475088|NCT03158922|Procedure|Prostate biopsy|Prostate biopsy will be offered to men identified within the top 10% genetic risk score profile.
1475089|NCT03158909|Device|Eyemask and earplugs|Eyemask and earplugs for use during the night, to improve sleep.
1475090|NCT03158909|Other|Orientation about space and time|Information and orientation about space and time, given every night.
1475091|NCT03158896|Biological|MSCTC-0010 Dose Escalation|"Cohort 1: 2.0 × 106 cells per kilogram (cells/kg) body weight, given on day 0 and on day 7 in Participants having de novo High Risk Acute or Steroid Refractory Acute Graft Versus Host Disease (HR/SR aGvHD)
Cohort 2: 10 × 106 cells/kg of body weight, given on day 0 and on day 7 in Participants having de novo HR/SR aGvHD"
1475092|NCT03158883|Drug|Avelumab|Avelumab: 10 mg/kg administered by IV infusion q2w (1 cycle = 14 [±2] days).
1475093|NCT03158883|Radiation|Stereotactic ablative radiotherapy (SAR)|SAR: the prescription dose will be 50 Gy over 5 fractions of 10 Gy each on an every 2 day basis (i.e., 2-3 treatments per week, with a minimum of 40 hours and a maximum of 96 hours between treatments) and completed within 1.5-2 weeks. SAR treatment will not be repeated.
1475094|NCT03158870|Procedure|Surgery complications|Assessment of the influence of surgeon-anesthesiologist collaboration on surgery complications during and up to 30 days after pheochromocytoma surgery.
1475095|NCT03158857|Drug|Sofosbuvir 400 mg|These drugs are being offered as part of routine care
1475096|NCT03158844|Other|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
1475097|NCT03158831|Diagnostic Test|Placebo-Controlled Graded Drug Challenge|All patients receive a placebo followed by 30 minutes of observation. Patients then receive 1/10 of the treatment dose of the challenge drug followed by 30 minutes of observation. If no reaction, they will then receive a full dose of their challenge drug followed by 1 hour of observation. If they do not experience any reactions, they are deemed not to be allergic. All patients are asked to monitor for delayed reactions after the challenge. Patients are also called within 1 month of the challenge to determine if any delayed reactions occurred. Patients are called again within 1 year of the challenge to determine if they have subsequently taken the challenge drug and experienced any reactions.
1475098|NCT03158818|Other|Standard of care|Routine standard of care per Ministry of Health protocol, including blood draws and examinations.
1475102|NCT03158792|Drug|Enoxaparin 60Mg/0.6Ml Inj Syringe 0.6Ml|Enoxaparin 30mg subcutaneously once daily. Half of the graduated 60Mg/0.6Ml Inj Syringe is administered
1475103|NCT03158779|Combination Product|SBRT and chemotherapy|Patients affected by locally unresectable pancreatic cancer receive integrated treatment of FOLFIRINOX or Gemcitabine-Abraxane and a Stereotactic Body Radiation Therapy with a total dose of 54 Gy in 6 fractions of 9 Gy /fractions.
1475104|NCT03158766|Other|Microdiscectomy|It will be an observational study without interventions. Subjects with diagnose of lumbar disc herniation undergoing open decompression surgery (microdiscectomy) will be included and analyzed. There will be no direct intervention to the patient proposed by the study.
1475105|NCT03158740|Behavioral|DII-Based Counseling System|DII-Based Counseling System, including 12 weekly classes in reducing inflammation by adopting dietary patterns low in inflammation and also through physical activity and stress reduction. Participants will also have access to our Imagine Healthy Online Portal. Group-based behavior change programs provide a way for members to share successes and obtain and provide support to one another.
1475106|NCT03158740|Behavioral|general health education control|The standard of care arm will receive general health information (e.g., general guidelines of healthy eating and physical activity, stress management, cancer screening, etc.). This information will be provided through email, which will include a weekly newsletter, healthy recipes that are not focused on reducing the DII scores, links to online content, and health-related event announcements in and around Columbia, SC. Any participants in the standard of care arm who does not use email regularly may request for items to be mailed to their mailing address.
1475107|NCT03158727|Drug|Cx611 or Placebo|Two intravenous infusions, one on day 1 and another one on day 3
1475108|NCT03158714|Behavioral|Couples Connecting Mindfully|
1475109|NCT03158714|Behavioral|ELEVATE|
1948646|NCT02007915|Drug|Pamidronate Disodium|Pamidronate will be given intravenously over one hour, one day per month for three out of every four months. The initial dose is 0.5mg/kg and subsequent doses are 1mg/kg. Infusions will continue for at least one year with a second year possibly recommended by the surgeon from data on the x-ray and bone scan.
1948647|NCT02008357|Drug|Solanezumab|Administered IV
1948648|NCT02008357|Drug|Placebo|Administered IV
1475113|NCT03158675|Procedure|fractional carbon dioxide(CO2) laser|-Fractional CO2 laser: Laser sessions will be performed at half month interval and it will be used with a wave length of 10,600nm.
1475114|NCT03158675|Drug|Topical corticosteroid|Topical corticosteroid will be applyed twice weekly on both sides for 4 months.
1475115|NCT03158675|Radiation|Ultraviolet B narrow band|Ultraviolet B narrow band will be performed (wave length ranged from 300 to 320nm).The sessions will be performed twice weekly for 4 months.
1475116|NCT03158662|Other|Survey|Survey Study
1475117|NCT03158649|Other|"Embarazo y Bienestar"|"The intervention programme is called Embarazo y Bienestar (Pregnancy and Well-being). Embarazo y Bienestar is a modular, self-placed program mainly designed to foster women's prenatal well-being by practicing some positive psychology-based exercises. The intervention programme consist of four modules of intervention, one welcome module, and a final resume page."
1475118|NCT03158623|Biological|Platelet Rich Plasma|
1475119|NCT03158623|Biological|Cellerate|
1475121|NCT03158584|Drug|Intrathecal Morphine|Intrathecal administration of Morphine in children undergoing major abdominal surgeries
1475122|NCT03158558|Behavioral|Accelerated, Multi-Couple Group CBCT for PTSD|Intensive weekend retreat version of cognitive-behavioral conjoint therapy for PTSD (Monson & Fredman, 2012)
1475123|NCT03158545|Dietary Supplement|Olive oil Placebo|olive oil
1475124|NCT03158545|Dietary Supplement|EPA-rich|EPA-rich omega-3 oil
1475125|NCT03158545|Dietary Supplement|DHA-rich|DHA-rich omega-3 oil
1475126|NCT03158532|Drug|Nitroglycerin I|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
1475127|NCT03158532|Drug|Placebo I|Saline 0,9% intra-arterially administered through the radial sheath, right after sheath placement and before catheterization.
1475128|NCT03158532|Drug|Nitroglycerin II|500 microgram of Nitroglycerin intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
1475129|NCT03158532|Drug|Placebo II|Saline 0,9% intra-arterially administered through the radial sheath, just before sheath removal and before hemostasis.
1475130|NCT03158519|Behavioral|iMETX intervention|"Pre-intervention the participants will wear the running watch for 3 weeks so that researchers can collect data about their daily routines regarding where and how much energy they expend.
During the intervention participants will wear the running watch for 12 weeks. Every 1-3 days the participants will be given an individualized recommendation for how to increase their activity via the iMETX application. Participants will be able to provide feedback to the researchers throughout intervention period regarding what works and does not in terms of the recommendations for increasing activity.
Post-intervention the participants will wear the running watch for 12 weeks so that researchers can collect data in order to determine whether physical activity changes made during the intervention are sustained."
1948660|NCT01995097|Behavioral|Scheduled Gradual Reduction Text Messages|
1948661|NCT01995097|Behavioral|Support Text Messages|
1948662|NCT01994525|Biological|PfRAS|Radiation-attenuated Plasmodium falciparum sporozoites (PfRAS) administered by the bite of infected Anopheles stephensi mosquitoes
1948663|NCT01994525|Biological|Placebo|Administered by the bite of noninfected Anopheles stephensi mosquitoes
1475132|NCT03158480|Biological|DC-CIK immunotherapy|Cytokine-induced killer (CIK) cells are co-cultured with HPV induced dendritic cells (DCs); HPV specific DC-CIK will be induced to condylomata acuminata patients
1475133|NCT03158467|Other|Surveys|Instruments will be administered via the online RedCAP platform. The survey instruments will include a Decision Conflict Scale (DCS), the McGill Quality of Life (MQoL), the Human Connection (THC), and a general demographics questionnaire. Patients will have the opportunity to complete the instruments via a research iPad while in clinic or via a survey link emailed to their private email account.
1475134|NCT03158454|Procedure|Capsula Closure|The capsular closure is performed with a minimum of two vicryl # 2 resorbable sutures
1475135|NCT03158454|Procedure|Non-Capsula Closure|No capsular closure procedure is performed.
1475136|NCT03158441|Diagnostic Test|Breast MRI|comparison of DTI to dynamic MRI
1475137|NCT03158428|Other|CSD170202AA|A moist snuff product
1475138|NCT03158428|Other|CSD170202AB|A moist snuff product
1475139|NCT03158415|Behavioral|T1DToolkit.org mobile diabetes education|"Participants will receive a reminder via text and/or email twice per week to invite them to view diabetes education materials on the study's mobile website, T1DToolkit.org. Topics on this website include, among others, Caregiver Burnout; Your Child is Now an Adult; Sharing Responsibility; Sources of Support; Common Fears for Parents of Young Adults; and Your Child, Your Child's Doctor, and You.
Six weeks after enrollment, participants will complete the Modified Diabetes Distress Scale: Parents of Young Adults."
1475140|NCT03158402|Other|Prehabilitation with inspiratory muscle training|3 to 6 weeks of two times a day inspiratory muscle training at 80% of the Maximum Inspiratory Pressure.
1475148|NCT03158376|Drug|Gabapentin|
1475149|NCT03158376|Drug|Placebo|
1475151|NCT03158350|Other|Instructed Brushing Method|Stationary Bristle Technique
1475152|NCT03158337|Behavioral|Aerobic exercise|
1475153|NCT03158324|Drug|OPB-111077|Receive 600 mg of OPB-111077 on a 4 days-on, 3 days-off per week in 28-day cycles till disease progression or intolerable toxicity
1475154|NCT03158311|Drug|QVM149|Indacaterol acetate / Glycopyrronium bromide / Mometasone furoate
1475155|NCT03158311|Drug|Salmeterol/fluticasone plus tiotropium|free triple arm of Salmeterol/fluticasone plus tiotropium
1475156|NCT03158298|Other|Specimen collection|Maternal blood sample of 10 ml collected by venepuncture upon delivery
1475157|NCT03158285|Drug|Guselkumab|Participants will receive 100 mg of guselkumab as a sterile liquid for SC injection.
1475158|NCT03158285|Drug|Placebo|Participants will receive matching placebo as SC injection.
1475159|NCT03158272|Biological|Cabiralizumab|Specified dose on specified days
1475160|NCT03158272|Biological|Nivolumab|Specified dose on specified days
1475161|NCT03158259|Other|Prehospital diagnosis and treatment|The patient will be diagnosed and treated by anesthesiologist in the mobile stroke unit (MSU). The diagnosis will be NIHSS, CT scans by a CT-scanner fitted in the MSU, and blood-analysis in a mobile lab inside the MSU. All performed by a three-person crew consisting of an anesthesiologist, paramedic and nurse-paramedic. The CT images will be sent to the lokal hospital and contact with neurologist in ward established. A decision to treat will be given in collaboration between the neurologist and anesthesiologist.
1475162|NCT03158246|Drug|Generic Zoledronic Acid|Generic Zoledronic Acid (Yigu®) 5mg/100ml injection
1475163|NCT03158246|Drug|Original Zoledronic Acid|Original Zoledronic Acid (Aclasta®) 5mg/100ml injection
1475164|NCT03158246|Dietary Supplement|calcium|600mg/d calcium for oral daily
1475165|NCT03158246|Dietary Supplement|vitamin D|925IU/d vitamin D for oral daily
1475167|NCT03158207|Device|Waters Mask|All anesthesiologists and CRNAs will view an instructional video on the use of the Warters Mask. Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales).
1475168|NCT03158207|Other|Standard Mask|Following induction of general anesthesia with the standard of care sequence of medications, each patient will then have mask ventilation performed and graded (Han and Warters Scales). Mask ventilation will be scored with both masks before and after the standard administration of paralytic medication.
1475169|NCT03158194|Behavioral|CBT for anxiety-related asthma|The specific assignments in the intervention will be based on individual behavior analysis for each participant.
1475170|NCT03158181|Other|Non interventional study|None intervention will be conduct on patient. Only the operating room will be randomized to have an intervention or not (Bundle of measure for optimizing the discipline of personnel in the operating room)
1475171|NCT03158168|Drug|Candida Antigen|Candida Albicans Antigen injection
1475172|NCT03158168|Drug|Zinc Sulfate|Zinc Sulfate injection
1475173|NCT03158142|Drug|Atropine Sulfate 1% Oph Soln|Atropine sulphate 1% ophthalmic solution is both a mydriatic and cycloplegic
1475174|NCT03158129|Drug|Nivolumab|3 mg/kg by vein on Days 1, 15, and 29.
1475175|NCT03158129|Drug|Ipilimumab|1 mg/kg by vein on Day 1.
1475176|NCT03158129|Procedure|Thoracic Surgery|Surgery performed after completion of induction therapy. Operative approach and extent of surgical resection based on the treating surgeon's judgment.
1475177|NCT03158116|Drug|Inhaled Aztreonam|Inhaled antibiotic with anti-pseudomonal properties
1475180|NCT03158090|Procedure|Transnasal butterfly surgery|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient.
1475181|NCT03158090|Drug|sandostatin|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
1475182|NCT03158090|Radiation|radiotherapy|The patient will be treated in accordance with the advice of the local doctor in charge, and this study does not interfere with any treatment of the patient
1475183|NCT03158064|Drug|Durvalumab|1500 mg by IV
1475184|NCT03158064|Drug|Tremelimumab|75 mg by IV
1475187|NCT03158038|Biological|Monovalent Influenza Vaccine|A single dose of 10^(7.0 +/- 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
1475188|NCT03158038|Other|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
1475189|NCT03158025|Drug|Zolpidem tablets|Zolpidem 3 x 10 mg tablets will be administered orally.
1475190|NCT03158025|Drug|Suvorexant tablets, over-encapsulated|Suvorexant 2 x 20 mg tablets, over-encapsulated, will be administered orally.
1475191|NCT03158025|Drug|Lemborexant tablets|Lemborexant 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg tablets will be administered orally.
1475192|NCT03158025|Drug|Placebo lemborexant|Placebo 1 x 10 mg, 2 x 10 mg, or 3 x 10 mg lemborexant tablets will be administered orally.
1475193|NCT03158025|Drug|Placebo zolpidem|Placebo 3 x 10 mg zolpidem tablets will be administered orally.
1475194|NCT03158025|Drug|Placebo suvorexant|Placebo 2 x 20 mg suvorexant tablets, over-encapsulated, will be administered orally.
1475195|NCT03158012|Biological|Autologous Microbial Transplant|Twice-daily application of Active or Placebo comparators to the right and left ventral arms of patients
1475196|NCT03157999|Behavioral|Intervention group (CAST)|"Intervention duration is expected to be 6 months. A full-time registered nurse (RN) will function as a Care Transitions Coordinator (CTC) who works collaboratively with one local hospital and other health and non-health representatives to deliver the intervention, which includes:
care coordination and system navigation (including facilitating timely primary care follow-up);
medication management;
assessing the needs and risk of the participants (including in-depth assessment of depressive symptoms);
evidence-based management of depressive symptoms and other chronic conditions to prevent the onset and worsening of other chronic conditions;
patient and caregiver education; and goal setting and problem-solving therapy."
1475197|NCT03157986|Other|Balance Training on a vibration platform|n=24 patients with severe chronic obstructive pulmonary disease. Exercises will be performed on a side-alternating Vibration platform (Galileo) at frequencies between 15 to 26 Hertz.
1475198|NCT03157986|Other|Conventional Balance training|n=24 patients with COPD, Exercises will be performed on a Balance pad
1475199|NCT03157973|Other|Education intervention|eHealth tool and standardized nurse-led follow-up.
1475200|NCT03157960|Other|Blueberry drink|Participant receive blueberry drink
1475201|NCT03157960|Other|Blueberry and pizza|Participant receive blueberry drink and a slice of pizza
1475202|NCT03157960|Other|Soft beverage|Participant receive a soft beverage drink
1475203|NCT03157960|Other|Soft beverage and pizza|Participant receive a soft beverage drink and a slice of pizza
1475204|NCT03157960|Other|Fructose|Participant receive a drink containing fructose
1475205|NCT03157960|Other|Fructose and pizza|Participant receive a fructose drink and a slice of pizza
1475206|NCT03157947|Behavioral|Decision Aid Tool|Subjects will be given an I-pad with the decision aid program on it. A member of the study team will enter some preliminary information, then the subject will be able to review the tool with his doctor.
1475207|NCT03157947|Behavioral|baseline survey|patients will be given baseline surveys to gather demographic information and readiness to make a decision regarding prostate cancer care
1475208|NCT03157947|Behavioral|follow-up surveys|at 3, 6, 9, and 12 months patients will be given follow-up surveys regarding prostate cancer care
1475209|NCT03157934|Other|not applicable (observational study)|Observational study without study related intervention
1475210|NCT03157921|Radiation|transvaginal ultrasound|assessment of ovarian volume and antral follicle count
1475211|NCT03157921|Diagnostic Test|Hormonal levels|follicle stimulating hormone level, luteinizing hormone level and anti-mullerian hormone level
1475212|NCT03157908|Device|CareConekta|CareConekta is a smartphone app developed in parallel with a series of focus group discussions that uses global positioning system (GPS) data to identify the user's location to meet two primary functions: (1) to allow the participant to locate ART facilities in South Africa that are near her current location, and (2) to trace mobility prospectively.
1475213|NCT03157895|Behavioral|Connecting|Connecting was adapted for use within the child welfare system from the Staying Connected With Your Teen program that has been demonstrated to prevent substance abuse, risky sexual behavior, and violence during adolescence.
1475214|NCT03157869|Device|Transcranial Direct Current Stimulation|Anodic tDCS during 20 minutes ON, intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
1475215|NCT03157869|Other|Simulated|Simulated anodic tDCS (only 30 seconds ON), intensity 2milliamps, on the contralateral motor cortex of the trained hand simultaneously with the motor training. The cathode (negative electrode) will be positioned over the contralateral supraorbital region. It wil be used rubber electrodes covered by a vegetal electrode embedded in saline solution, physiological saline, measuring 5 x 5 cm (25 cm2).
1475326|NCT03156829|Combination Product|Splint + Cortico-steroid injection|Splint + Cortico-steroid injection given in combination
1475216|NCT03157856|Other|Fluorescence assessment|All subjects of the study are going to have a radical prostatectomy. The FEMTO-ST medical device is used on 3 fresh biopsies (2 healthy and 1 malignant) which will be prelevated from the resected prostate in order to determine the prostatic or non-prostatic nature of tissue.
1475217|NCT03157843|Drug|low-molecular-weight heparin|
1475218|NCT03157804|Procedure|IV administration of Genetically Engineered Hematopoietic Stem/Progenitors Cells (HSPCs)|
1475219|NCT03157804|Biological|Genetically Engineered Hematopoietic Stem/Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
1475220|NCT03157804|Other|Laboratory Biomarker Analysis|Correlative studies
1475221|NCT03157804|Biological|Filgrastim|Given subcutaneously (SC)
1475222|NCT03157804|Drug|Plerixafor|Given SC
1475223|NCT03157804|Procedure|Bone Marrow Aspiration|
1475225|NCT03157778|Other|Obese men|Biological measures before, just before, and after lunch, in obese men
1475226|NCT03157778|Other|Normal-weight men|Biological measures before, just before, and after lunch, in normal-weight men.
1475227|NCT03157765|Procedure|endometrial biopsy|endometrial biopsy
1475228|NCT03157752|Behavioral|Quality of life questionnaire|Quality of life questionnaire
1475229|NCT03157739|Behavioral|MigraineManager: Individualized Self-Management Tool|Answers provided during the online assessment will result in certain intervention recommendations. Once assessments are completed, a treatment plan will be automatically generated for patient and parent guidance.
1475230|NCT03157726|Procedure|Transurethral plasmakinetic enucleation of prostate|Transurethral plasmakinetic enucleation of prostate(PAKEP),an operation mode devised by Liu Chunxiao Team in southern medical university urology department. The theory of the operation is using transurethral resectoscope instead of the finger in the open operation, to find the surgical capsule of prostate and to peel the hyperplastic prostate gland visually in a antidromic way.
1475231|NCT03157726|Procedure|transurethral resection of prostate|"Transurethral resection of prostate(TURP), a kind of mature minimally invasive surgery of prostate , taking the place of the traditional open surgery in 1930s , still is the gold standard operation for surgical treatment of BPH."
1475235|NCT03157700|Behavioral|REAL media curriculum|REAL media is a 5-level, interactive, self-paced, e-learning media literacy curriculum to prevent youth substance use.
1948664|NCT01994525|Other|Challenge|5 infectious Anopheles stephensi mosquito bites carrying infectious Plasmodium falciparum sporozoites within a controlled clinical environment.
1475237|NCT03157648|Other|observing for shivering symptom|In the PACU investigators measure body temperature of all patients at tympanic membrane, forehead, and dorsal of hand. Investigators calculate the difference between body temperature measure at tympanic membrane and forehead/dorsal of hand. Investigators observe the shivering symptom and grading for severity.
1475240|NCT03157622|Behavioral|Exposure in vivo|10 sessions based on an individualized fear hierarchy
1475241|NCT03157622|Behavioral|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
1475243|NCT03157596|Other|Oral Health Educational Program for Caregivers of Children with developmental disabilities|Oral Health Education Program for Caregivers of Children with developmental disabilities included information about health issues and obstacles encountered in children with DD & methods of prevention and management. It also emphasized on proper oral hygiene measures for this group. (University of Washington 2010)
1475244|NCT03157583|Other|NGBUV000A, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 (milligram per centimeter square of test site area) NGBUV000A (test product 1) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 1 will be applied to the test plates.
1475245|NCT03157583|Other|NGBUV000B, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000B (test product 2) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 2 will be applied to the test plates.
1475471|NCT03155607|Behavioral|Virtual Reality Distraction|Patient will utilize a virtual reality device during wound care.
1475246|NCT03157583|Other|NGBUV000C, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000C (test product 3) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 3 will be applied to the test plates.
1475247|NCT03157583|Other|NGBUV000D, (Expected SPF 30)|A total of 2.0 ± 0.05 mg/cm2 NGBUV000D (test product 4) will be spread at the topical test sites on the back of each participant. And a total of 1.3 mg/cm2 of test product 4 will be applied to the test plates.
1475248|NCT03157583|Other|P3 Standard, (Expected SPF 16)|A total of 2.0 ± 0.05 mg/cm2 reference P3 standard will be spread at the topical test sites on the back of each participant.
1475249|NCT03157583|Other|Sunscreen formulation S2|A total of 1.3 mg/cm2 of sunscreen formulation S2 will be applied to the test plates.
1475250|NCT03157583|Other|Glycerin|A total of 1.3 mg/cm2 of glycerin will be applied to the test plates.
1475251|NCT03157570|Behavioral|Exercise|7-min High Intensity Interval Training with 12 different exercises (each exercise 30 seconds continuously with 10 seconds rest interval)
1475252|NCT03157557|Behavioral|Lifestyle treatment|Lifestyle treatment
1475253|NCT03157544|Behavioral|multimodal non-pharmacological Pain Relief Kit|"Participants will be told: No two people have the same kind of pain and that pain management must be individualized to your pain. Thus, we want you to try the four modes of the non-pharmacological interventions included in the kit individually and in combination in order to determine what works best to relieve your pain
The Pain Relief kit will also include written instructions and materials for three behavioral techniques directed at maintaining compliance with the non-pharmacological interventions. During the review of the Pain Relief Kit with a member of the research staff participants will be informed about the recommended use of the three behavioral techniques including setting goals, working with a buddy and keeping a graph of your progress. This information will also be included in written form in the Pain Relief Kit."
1475254|NCT03157518|Dietary Supplement|Seeking Health Probiota Bifido|• This is a proof of concept study to demonstrate that oral probiotic use can modulate the airway microbiome. After informed consent has been obtained, this study will consist of 2 visits over a four week time period. Each visit will include a blood draw (30ml) and a research bronchoscopy/ bronchoalveolar lavage (BAL) (200ml) visit . A urine pregnancy test will be done on all females of childbearing potential prior to the first BAL as well as a CBC, BMP, and blood clotting tests in all participants. Following the first BAL, subjects will be asked to take an over the counter probiotic supplement (Seeking Health Probiota Bifido) nightly which will be provided to the participant by the study coordinator until the 2nd BAL is performed 4 weeks after the first BAL.
1475255|NCT03157505|Drug|Purethal Birch immunotherapy|Purethal birch was administered as perennial therapy: 24 months
1475256|NCT03157505|Other|Placebo and symptomatic treatment|symptomatic treatment including: antihitamine drug, nasal dropps and placebo injection
1475257|NCT03157492|Behavioral|Aural Rehabilitation Group|Participants will complete sessions in their home or office via the internet. Sessions will include listening activities, informational counseling and communication strategies training. Three assessment appointments are required. The goal is to evaluate the benefit of training on performance with a cochlear implant.
1475258|NCT03157492|Behavioral|Cognitive Training Group|The Cognitive Training Group will receive six 90-minute sessions including training exercises (Ken-Ken, Sudoku, Crosswords, Word Search, Spot the Difference) to improve speed and accuracy. Three assessment sessions are also required.
1475259|NCT03157479|Drug|Intravenous anesthetic|Anaesthesia induction will be obtained with i.v. 2-3 mg/kg propofol, 0,6-0,8 mcg/kg fentanyl, and 0.9-1,2 mg/kg rocuronium. Anaesthesia will be maintained with i.v. propofol continuous infusion, with a dose titrated to achieve a bi-spectral index value between 40 and 50
1475260|NCT03157479|Drug|Crystalloid Solutions|Balanced crystalloids will be administered to patients in both groups as a standard rate of 3-5 ml/kg/h. Treatment of eventual hemodynamic instability will be left to the attending physician
1475261|NCT03157479|Diagnostic Test|Esophageal pressure measurement|A nasogastric polyfunctional tube (Nutrivent, Sidam, Italy) will be placed after anaesthesia induction in all enrolled patients to measure esophageal pressure, estimate pleural pressure and compute transpulmonary pressure
1475262|NCT03157479|Diagnostic Test|Lung volume measurement with the nitrogen washin-washout technique|Lung volume will be measured through nitrogen wash-in wash-out technique and low-flow Pressure-volume curve will be recorded to estimate differences in alveolar recruitment between the two study groups.
1475263|NCT03157440|Diagnostic Test|Ring oxymetry|a new type oxymetry wear on index finger like a ring
1475264|NCT03157427|Device|CRYOBEAUTY MAINS|CYOBEAUTY MAINS diffuses Difluoroethane gas to the skin. The administration of the cryogenic gas is temperature controlled, accurate and contactless (by means of a spray nozzle), in small quantity (<1g) and during a predetermined short duration (3 seconds)
1475265|NCT03157414|Drug|Empagliflozin|Empagliflozin tablets enclosed with red capsules (Capsugel AAEL) by Kragerø Tablettproduksjon AS for blinding purpose
1475266|NCT03157414|Other|Placebo|Placebo tablets made by Kragerø Tablettproduksjon AS and enclosed with red capsules (Capsugel AAEL) for blinding purpose
1475267|NCT03157401|Drug|intravenous infusion group|In the tranexamic acid intravenous infusion group (n = 30), 15 mg/kg tranexamic acid diluted in 100 mL physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
1475268|NCT03157401|Drug|intra-articular injection group|In the tranexamic acid intra-articular injection group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, the mixture of 1.5 g tranexamic acid and 20 mL physiological saline was intra-articularly injected.
1475269|NCT03157401|Drug|control group|In the control group (n = 30), 100 mL of physiological saline was intravenously infused at the beginning of the surgery. After suturing deep fascia, 20 mL of physiological saline was intra-articularly injected.
1475270|NCT03157388|Drug|Combined Vancomycin and Gentamycin and Meropenem|"The following combined antibiotic regime will be administered for eradication of gut bacteria.
7 days combined antibiotic treatment, per oral route, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate and gentamycin 40 mg (Hexamycin®), solution and meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined in approximately 100 ml of apple juice."
1475271|NCT03157375|Device|Intraocular Lens Implantation|
1475472|NCT03155594|Device|Freestyle Libre|Continuous glucose monitoring patch
1475272|NCT03157362|Other|Near Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated.
1475273|NCT03157362|Other|Near Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces the room in which they are seated, and converse with a confederate represented by an avatar.
1475274|NCT03157362|Other|Far Non-Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces a different room.
1475275|NCT03157362|Other|Far Social|Participants will be stably seated, and observed by a research assistant, as they complete an induced pain threshold task while they experience a virtual environment that reproduces another room, and converse with a confederate represented by an avatar.
1475276|NCT03157349|Other|Biofreeze|Biofreeze is a topical analgesic that uses the cooling effect of menthol, a natural pain reliever, to soothe minor muscle and joint pain. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
1475277|NCT03157349|Other|Placebo|The placebo is the Biofreeze product with all active ingredients removed. The product will be applied 10 minutes prior to manipulation and at home for 4 times a day for 1 week
1475278|NCT03157336|Other|Non Inferiority WTM Interventional Trial|The intervention will implement the WTM cassava processing technique in participating households. Twenty women (in leading roles) will be our principal candidates to serve as peer trainers. Together with a 20 community health worker specialists, these women will be trained in the WTM technique by the Kinshasa team of community health workers who are experts in the WTM method. Those who master the technique will then be certified as trainers to train and support other small groups of other mothers throughout a two-year period in the implementation of the WTM for the safer processing of food for their families. Both the community health worker specialists and trained women (prospective trainers) would have to be able to bring the cassava cyanogenic content to the lowest achievable level, which must be < 10 ppm as per the recommendations of the World Health Organization.
1475279|NCT03157323|Behavioral|Low Glycemic Index Diet|The nutritional intervention is theory-based and will provide nutritional education and counseling to children and their families. Nutritional counseling will be provided by the institutional designate and will focus on increasing patients' understanding of the benefits of a low GI diet, increase knowledge of low GI diet, overcoming barriers, and establishing expectations of the diet.
1475280|NCT03157310|Drug|Gefitinib|Daily oral administration of 250 mg Gefitinib
1475281|NCT03157297|Device|MARVEL algorithm|Software download into implanted Micra device
1475282|NCT03157284|Dietary Supplement|Rice Flour|For 12 weeks, a group of children will receive 7gr fermented rice flour according to a randomised, double-blind design.
1475283|NCT03157284|Dietary Supplement|Placebo|For 12 weeks a group of children will receive a 7gr of a placebo (maltodextrin), according to a randomised, double-blind design.
1475284|NCT03157271|Other|Intramuscular Dry Needling|Dry Needling is a procedure in which a solid filament needle is inserted into the skin and muscle directly at a myofascial trigger point. A myofascial trigger point consists of multiple contraction knots, which are related to the production and maintenance of the pain cycle and interfere with movement patterns.
1475285|NCT03157258|Behavioral|Social Network Training|Members of HIV+ social networks randomized to this arm will be trained to endorse compliance with medical guidelines and adherence to medical treatment regimens to their friends.
1475286|NCT03157258|Behavioral|Single Care-Related Counseling Session and Referral to Care|Members of HIV+ social networks randomized to this arm will attend a single, brief care-related counseling session and referral to care at baseline.
1475287|NCT03157245|Diagnostic Test|DOPPLER ULTRASOUND|MESURE OF THE PRESENCE OR NOT OF A CATHETER RELATED VEIN THROMBOSIS
1475288|NCT03157232|Device|Rainbow DCI and R1-25 sensor|Noninvasive Measurement of SpHb
1475289|NCT03157193|Drug|Hyaluronic Acid|Hyaluronic acid gel application as coadjuvant in the treatment of perimplantitis.
1475290|NCT03157193|Drug|Hydroxypropyl Guar|Hydroxypropyl Guar gel application as sham comparator
1475291|NCT03157167|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
1475292|NCT03157154|Other|Non interventional study|A query form to all concerned patients by each investigating centre will be send
1475293|NCT03157141|Procedure|Ankle arthrodesis|Ankle arthrodesis consists of fusioning the joint surfaces of the ankle. The procedure will consist of removing the diseased cartilage and subchondral bone until bleeding of the cancellous bone surfaces is revealed. The bone ends will be opposed in the most appropriate and stable position and stabilized with screws or plates.
1475294|NCT03157141|Procedure|Total ankle replacement|A two-component ankle prosthesis will be inserted using the surgeon's standard technique, which essentially involves an anterior approach to the ankle joint. Once the joint is exposed, talar and tibial surfaces will be prepared and the prosthesis will be implanted according to the prosthesis surgical technique and its instrumentation.
1475296|NCT03157115|Device|Kinocardiography|"This device records the electric and mechanic function of the heart. With electrodes and adequate electronics, ECG is recorded. 6 degrees of freedom accelerometers are also included in the device to measure the micro accelerations of the body at the body surface when the device is placed on the skin. Using physics principles and adequate calibration, those accelerations allow us to calculate parameters such as kinetics energies related to heart contractility.
During a standard appointment for a patient suffering from a cardiac condition with/without heart failure, the cardiologist will monitor the heart of the patient with the Kino device (examination lasting a few minutes with the patient lying down on a bed). Data will be matched between the control group and the experimental group."
1475321|NCT03156842|Drug|Fimasartan/Amlodipine, Rosuvastatin|"A fixed dose combination tablet of Fimasartan and Amlodipine and Rosuvastatin will be administrated once daily on treatment period."
1475322|NCT03156842|Drug|Fimasartan/Amlodipine|"A fixed dose combination tablet of Fimasartan and Amlodipine will be administrated once daily on treatment period."
1475323|NCT03156842|Drug|Fimasartan, Rosuvastatin|"Fimasartan and Rosuvastatin will be administrated once daily on treatment period."
1475324|NCT03156829|Other|Splint|Custom made splint
1475297|NCT03157102|Device|HFNC|"Oxygen therapy will be delivered through high flow nasal cannulas. Aerosol treatments will be administered through a vibrating mesh nebulizer directly connected to the circuit (aerogen®). The airvo® system (Fisher & Peykel Healthcare, Auckland, New Zealand) will be used as the high flow cannula system in the study. Cannula size will be tailored to the child according to the manufacturer's recommendations. The gas flow will be adjusted according to the child's weight in a predefined chart. FiO2 will be adjusted to allow for a SpO2 >92%.
All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM (Pediatric Respiratory Assessment Measure) score, pain assessment by the FLACC (Face Legs Activity Cry Consolability) score). ."
1475298|NCT03157102|Device|Standard Oxygen Treatment|"Children will receive supplemental oxygen as commonly delivered through a non-rebreather face mask or low flow nasal cannula (standard oxygen treatment) and beta2 agonist aerosol via vibrating mesh nebulizer (aerogen®) according to the procedures usually used in the unit and according to the GINA (Global Initiative for Asthma) protocol. This group is the standard treatment group and is therefore the control group.
All the patients, regardless of their treatment failure status, will be evaluated at H2, H6, H12 and H24 to monitor their evolution (evaluation of the standard parameters, consciousness, PRAM score, pain assessment by the FLACC score). The use of adjuvant therapies (magnesium sulfate, salbutamol IVSE, and ipratropium bromide) will remain at the discretion of the physician in charge of the child and will be evaluated as a secondary criterion."
1475301|NCT03157076|Device|Cardiac Resynchronization therapy device with Closed Loop Stimulation (CLS)|The feature CLS will be programmed ON or Off according to a randomization list after one month after baseline visit. One month later the alternate will be programmed.
1475302|NCT03157063|Diagnostic Test|Data Collection Procedures|"Orientation (Consent, Screening Questionnaires) Clinic Measurements Body composition, via dual energy X-ray absorptiometry (DXA) Resting metabolic rate (RMR), via indirect calorimetry; Metabolic responses to a meal, via thermic effect of feeding (TEF) Subjective aspects of eating behavior using the Three Factor Eating Questionnaire (TFEQ) and Control of Eating Questionnaire (CEQ) Appetite, via visual analogue scales (VAS) pre- and post a prepared fixed meal and hormones related to satiety and hunger (insulin, leptin, ghrelin, peptide YY, glucagon-like peptide-1) obtained during blood samples (BLOOD) from an indwelling catheter.
Home assessments - Data collected at home during a 14 day window Fitness Test (VO2submax and VO2max) and DXA functional magnetic resonance imaging (fMRI)"
1475303|NCT03157050|Other|Intravenous iron therapy|each patient with iron def anemia received an IV syringe of iron sucrose 100 mg every dialysis session for 10 doses
1475304|NCT03157037|Biological|HMed-IdeS|One dose of 0.25 mg/kg BW HMed-IdeS on study day 1
1475305|NCT03157024|Device|Ring Sham (RS)|
1475306|NCT03157024|Device|Real Needle (RN)|
1475307|NCT03157024|Device|Kim Sham (KS)|
1475308|NCT03157011|Other|Global symptom score (GSS) questionary|systematic research of digestive symptoms in patients with SGSp with Global symptom score (GSS) questionary, which allowed to grades severity of 10 digestive symptoms (absent, mild, moderate, or severe), asthenia and fever.
1475309|NCT03156972|Procedure|Replacment of mitral valve|Mitral valve replacment by prothsis
1475310|NCT03156959|Behavioral|EMDR|The Eye Movement Desensitization and Reprocessing (EMDR) is a psychotherapy developed by Francine Shapiro (2001) that emphasizes disturbing memories as the cause of psychopathology. These memories and associated stimuli are inadequately processed and stored in an isolated memory network (Shapiro and Laliotis, 2010). The goal of EMDR is to reduce the long-lasting effects of distressing memories by developing more adaptive coping mechanisms.
1475311|NCT03156959|Behavioral|CBT-Eb|"The broad form of Enhanced Cognitive Behavioural Therapy (CBT-Eb; Fairburn and colleagues, 2009) addresses psychopathological processes external to the eating disorder, such as clinical perfectionism, low self-esteem or interpersonal difficulties, which interact with the disorder itself."
1475312|NCT03156946|Behavioral|breastfeeding mother-to-mother support|The mother-infant dyads in the intervention arm will receive breastfeeding mother-to-mother support from the hospitalization in the maternity and NICU up to 1 month after discharge. The intervention will be in addition to the usual or routine care. Breastfeeding counselors will be voluntary mothers who breastfed their own preterm infant (aged between 6 months and 5 years at the time of the study) for a minimum of 2 months, and who have had a positive personal breastfeeding experience, and who have undertaken a training course.
1475313|NCT03156946|Behavioral|Control|The mother-infant dyads in the control arm will continue to receive the usual/routine care provided by participating centers during the hospitalization and Mother and Infant Protection service after discharge.
1475314|NCT03156933|Other|Assessment of splicing variants|This is a biological study with primary samples without any intervention on patients.
1475317|NCT03156907|Drug|Buprenorphine/naloxone|HDB is started (J0) at the dosage of 4 mg/ day (with a possible adjustment ± 2 mg at 24h, depending on the patient withdrawal symptoms intensity or tolerance).
1475318|NCT03156881|Other|Global Osteopathic Treatment|"The study objectives is to observe a difference and improvement of liver function based on liver enzyme count from blood work after osteopathic treatments. Also to observe an improvement in the patients quality of life after receiving treatment and in their readiness to change.
Osteopathy is a type of manual therapy that uses gentle manipulations taking into consideration of the whole person when treating. For example if the liver is being treated, osteopaths look for mobility, to carry out its proper function. However one will also assess its interrelationships that can influence the liver such as its neighbours, articulating structures, example the diaphragm as well as its neurological input from T5-T9 for instance."
1475319|NCT03156855|Drug|14-day sequential therapy|D1-D7: (esomeprazole 40mg qid + amoxicillin 500mg qid) for 7 days D8-D14: (esomeprazole 40mg qid + clarithromycin 500mg bid + metronidazole 500mg bid) for another 7 days
1475320|NCT03156855|Drug|Bismuth quadruple therapy|D1-D10: (esomeprazole 40mg bid + dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
1475327|NCT03156816|Drug|Colchicine group (experimental arm)|In the experimental group, patients will receive colchicine, starting with a loading dose of 2 mg (1.5 mg initially followed by 0.5 mg 1 hour later) at the time of revascularization and continuing with 0.5 mg twice daily (b.i.d) for 5 days.
1475328|NCT03156816|Drug|Placebo group (control arm)|In the placebo group, patients will receive placebo, starting with a loading dose of 2 mg (1.5 mg initially followed by 0.5 mg 1 hour later) at the time of revascularization and continuing with 0.5 mg twice daily for 5 days.
1475329|NCT03156803|Behavioral|Healthy eating blog|For a 6-month period, mothers randomised to the HEB group will receive a weekly blog post discussing various positive aspects of healthy eating and presenting recipes and strategies to increase dairy product intakes and vegetable and fruit intakes. The posts will be developed with an emphasis of food skills acquisition.
1475330|NCT03156790|Drug|Spectrila®|3 intravenous doses of 10 000 U/m² BSA each during induction phase I of the underlying BRALL 2014 treatment protocol on Days 21, 23 and 25. Additionally, the subjects (standard risk subjects only) will receive doses of 10 000 U/m² BSA each on Days 2, 4, 6, 9, 11 and 13 of the consolidation phase II, III and VI of BRALL 2014 treatment protocol.
1475331|NCT03156764|Other|Qp/Qs ratio monitoring|Op/Qs -monitor will be calculated using SpO2 and cerebral oximetry Op/Qs -blood will be calculated using ABGA and VBGA
1475332|NCT03156751|Diagnostic Test|Feasibility of introducing onsite test for syphilis in the package of antenatal care at rural primary health care in Burkina Faso|This study used a pre post intervention mixed methods quasi-experimental design with a group of health facilities offering ANC services. It was conducted in three phases, which consisted of a situational analysis using qualitative methods (Phase 1), selecting an appropriate test through evaluating 4 candidate tests and the participatory design and implementation of an intervention(Phase 2), and an evaluation combining review of record tools, interviews, time motion study and estimating incremental costs (Phase 3). The conceptual framework draws on multilevel assessment (MLA), policy triangle framework, MRC framework for designing complex interventions and the Normalization Process Model (NPM). The findings suggested that an intervention that introduces point of care test for syphilis at antenatal care services is feasible, acceptable, and of comparable costs to HIV screening in pregnancy. Nonetheless, barriers identified by health workers need to be overcome.
1475335|NCT03156725|Drug|Ferrous Sulfate|
1475336|NCT03156725|Dietary Supplement|Aspiron|
1475337|NCT03156712|Dietary Supplement|Ferrous sulfate|The intervention is the ASP, a natural form of iron supplement and compared to a widely used dietary iron supplement ferrous sulfate in terms of serum iron response over a 4h period.
1475338|NCT03156686|Procedure|HOME-based hospitalization|patients in Home care treatment (HC) group will be treated at home
1475339|NCT03156673|Biological|bronchial basal cells|Patients will receive of clinical grade bronchial basal cells (BBCs) with a dosage of 10^6 (1 million) cells/Kg/person via fiberoptic bronchoscopy after fully lavage of the localized lesions.
1475340|NCT03156660|Behavioral|Weight gain prevention (Group 1)|"Participants will be asked to keep their weight stable during the initial 8 weeks of the study.
Intervention Components:
Lesson materials adapted from the Small Changes intervention, which will provide guidance for meeting the goals of this intervention (i.e., increasing steps by 2000 steps per day, making one Small dietary Change each day).
Daily self-monitoring of steps and number of Small Changes
Daily weight self-monitoring on the BodyTraceTM e-scale
Fit Bit Alta activity trackers to self-monitor steps"
1475341|NCT03156660|Behavioral|Weight loss intervention (Group 2)|"Participants will be asked to achieve a weight loss goal of at least 5% of their baseline weight by week 8.
Intervention Components:
Tailored calorie and fat goals based on their baseline weight.
Daily dietary intake and physical activity self-monitoring using a website or app.
Daily weight self-monitoring on the BodyTraceTM e-scale
Lesson materials for each session, drawn from the Look AHEAD intensive lifestyle intervention
Meal replacements for two meals and one snack for 8 weeks as a method to achieve the study's calorie and fat goals and as a strategy to control portions
Graded physical activity goals of 175 minutes of moderate intensity exercise (e.g., brisk walking) per week, or 10,000 steps per day
Fit Bit Alta activity trackers to self-monitor steps"
1475342|NCT03156660|Behavioral|Self-guided intervention (Group 3)|"Participants randomized to Group 3 will wait for 8 weeks before initiating the same smoking cessation intervention as the other two conditions, while they review the provided weight management focused book.
Intervention Components:
EatingWell Diet book.
Daily weight self-monitoring on the BodyTraceTM e-scale"
1475343|NCT03156647|Diagnostic Test|Level of alpha-synuclein|Test of levels of total and ratio total:oligomeric in saliva
1475344|NCT03156634|Other|PALS|PALS is a web based patient education system that uses text and audiovisual formats to deliver patient education materials.
1475345|NCT03156634|Other|WebMD|WebMD is an internet based health information source.
1475346|NCT03156621|Drug|Alirocumab|Alirocumab SC Q2W
1475347|NCT03156621|Drug|Placebo|Matching placebo SC Q2W
1475350|NCT03156595|Behavioral|Nurse interview|Personal interview with nurses to evaluate the relief of neuropathic pains with the reference treatment. (If necessary send to the medical team ) It's a listening time around neuropathic pain which altered the quality of life.
1475351|NCT03156595|Behavioral|Hypnosis sessions|Hypnosis sessions with a nurse or psychologist, with deepening sessions to facilitate self-hypnosis learning.
1475352|NCT03156582|Other|Data collecting|
1475353|NCT03156569|Diagnostic Test|Analysis of the saliva|IFN-, IL-10, IL-1b, IL-4 and IL-6
1475354|NCT03156556|Behavioral|Mood Mechanic Course|French-Canadian version of the Mood Mechanic Course. Performed by a professional translator (Bourret Translation Inc.) and reviewed by the research supervisor, Professor France Talbot, clinical psychologist as well with expertise in CBT.
1475390|NCT03156205|Behavioral|passive music listening|For the passive music listening group, each patient participated in music listening during night time without involving in interactive music therapy sessions during daytime.
1475391|NCT03156205|Behavioral|passive earphone-use|For the passive earphone use group (control group), each participant used headphone and eye mask without music listening at night time.
1475355|NCT03156543|Device|Jumpstart Dressing|"JumpStart™ is a wireless, advanced microcurrent generating, dressing used for the management of surgical incision sites. Microcell batteries made of silver and zinc, generate an electrical current when activated by conductive fluids, such as saline, hydrogel or wound exudate. These microcells create low voltage electrical fields to stimulate the surrounding area and to provide antimicrobial protection to assist with wound healing. JumpStart has demonstrated superior broad spectrum bactericidal activity of a wound dressing against antibiotic-resistant strains of wound isolates within 24 hours.
It will be applied pre-op in all patients and post operatively in group B"
1475356|NCT03156543|Other|Standard Dressing|This is a standard of care bandage that will be placed on participants in group A post operatively
1475357|NCT03156530|Device|Auricular acupunture|Evaluation of balance before, during and after applying of auricular acupuncture.
1475358|NCT03156530|Other|Control|Not receive stimulation.
1475359|NCT03156517|Device|Deep Brain Stimulation|
1475361|NCT03156478|Behavioral|Digital lifestyle intervention group|Intervention with digital application for lifestyle changes
1475362|NCT03156478|Behavioral|Combined digital and face-to-face lifestyle intervention group|Intervention with digital application and group meetings for lifestyle changes
1475363|NCT03156465|Device|Hybrid L24|Fifteen infants will receive one Nucleus L24 array and a FDA approved standard-length array on contralateral ears.
1475364|NCT03156452|Drug|Mycophenolate Mofetil|500 mg and 250mg tablets for oral administration
1475365|NCT03156452|Drug|Prednisolone|5mg tablets for oral administration
1475366|NCT03156439|Drug|BIS-001 ER|BIS-001 ER is an extended release formulation of the nutritional supplement Huperzine A.
1475368|NCT03156413|Device|F&P nasal mask|Investigative Nasal Mask to be used for OSA therapy
1475369|NCT03156400|Other|Exercise Stress Test|Gradual increase in treadmill grade while collecting respiratory gases.
1475370|NCT03156387|Procedure|Diode laser|2.8 W diode laser surgery were applied on high frenulum attachment and follow-up VAS scores were evaluated
1475371|NCT03156387|Procedure|Scalpel|Scalpel surgery were performed after local anesthetic administration and VAS scores were recorded.
1475372|NCT03156374|Device|Test use|Use of home ovulation test to predict ovulation
1475373|NCT03156361|Drug|HDV insulin lispro 100 UNIT/mL|Hepatic Directed Vesicle (HDV) added to commercial insulin lispro
1475374|NCT03156361|Drug|Insulin Lispro 100 Units/mL|Sterile Water for Injection added to commercial insulin lispro
1475375|NCT03156348|Other|Clinical Pharmacist Care|"During hospitalization and at discharge a clinical pharmacist (CP) will monitor daily pharmacological safety and efficacy of the medication to asses and make appropriate recommendations. CP will explain the use reasons of each of the drugs.
At 30 days post-discharge, the CP will review the updated clinical record of patient and conduct a home visit to enhance and ask about adherence, self-medication, medication use at that time and possible results of laboratory tests performed and clarify doubts regarding the use of current medications. The same activities will be made at 60 days by telephonic way, to reinforce the recommendations."
1475376|NCT03156335|Device|Focused Ultrasound|MR-guided Focused Ultrasound (MRgFUS) offers the possibility of lesioning deep brain targets, while obviating the need for open surgical approaches. There is no radiation, incision, or burr hole, and lesions are generated in real-time under MR image guidance. Intracranial FUS for other applications, essential tremor most notably, has been shown to be safe and effective, recently receiving Health Canada approval for this indication. The technology, methods and procedures used in this study are identical to those in essential tremor.
1475377|NCT03156322|Drug|5 mL epidural initiation volume (bupivacaine + fentanyl)|5 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
1475378|NCT03156322|Drug|10 mL epidural initiation volume (bupivacaine + fentanyl)|10 mL 0.625% bupivacaine + 2 μg/mL fentanyl solution is administered from epidural catheter
1475379|NCT03156322|Drug|20 mL epidural initiation volume (bupivacaine + fentanyl)|20 mL 0.625% bupivacaine + + 2 μg/mL fentanyl solution is administered from epidural catheter
1475380|NCT03156296|Drug|Dexmedetomidine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 0.25 mg/kg dexmedetomidine dissolved in 2 ml normal saline (0.9%)
1475381|NCT03156296|Drug|Bupivacaine|patients will receive ultrasound guided TAP block using 0.3 ml/kg bupivacaine (0.125%) with a maximum volume of 20 ml + 2 ml normal saline (0.9%)
1475382|NCT03156283|Behavioral|SleepWell24 Application|An evidence-based behavioral change smartphone application designed to promote adherence to positive airway pressure (PAP) therapy
1475383|NCT03156283|Other|Usual Care Plus Activity Monitor|Participants will receive usual care at the Mayo Clinic Center for Sleep Medicine when first diagnosed with sleep apnea and prescribed positive airway pressure therapy. In addition, they will receive a commercial activity monitor with an associated smartphone application to isolate the effect of SleepWell24 on PAP adherence from potential novelty effects due to receiving a generic health behavior change app.
1475384|NCT03156270|Device|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
1475385|NCT03156257|Biological|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
1475386|NCT03156231|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
1475387|NCT03156231|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
1475388|NCT03156218|Drug|Modulation of FiO2|Modulation of FiO2: FiO2 will be reduced to 21% or until peripheral oxygen saturation of 92%, whatever occurs first. Subsequently FiO2 will be increased up to 100%.
1475389|NCT03156205|Behavioral|interactive music therapy|For the interactive music therapy intervention group, each patient received individual interactive music therapy sessions administered by professional music therapists during daytime; the patient participated in listening to music predetermined based on his/her preference during night time.
1475392|NCT03156192|Behavioral|Survey|Survey on the level of depression, quality of life, current and past music experiences, and perceived benefits of music in relation to psycho-social needs
1475393|NCT03156179|Diagnostic Test|calcium isotope analysis|A dual stable calcium isotope method will be used to determine fractional calcium absorption. Two stable calcium isotopes will be administered to participants in order to determine fractional calcium absorption. 7 mg of 44Ca will be administered orally in 60 mL of liquid at the start of the study. 2 mg of 42Ca will then be administered intravenously. 24 hour urine collection will begin immediately following oral tracer administration for the assessment of urinary calcium excretion. The enrichment of 44Ca and 42Ca in urine will be determined by magnetic sector thermal ionization mass spectrometry. The isotopic ratios of 44Ca and 42Ca to 48Ca (another naturally occurring calcium isotope present in the human body) will be calculated (42Ca/48Ca and 44Ca/48Ca). The relative fraction of the oral to intravenously administered isotope in the 24 hour urine sample [(42Ca/48Ca) / (44Ca/48Ca)] is the fractional calcium absorption.
1475394|NCT03156166|Procedure|fiberoptic bronchoscope|Distance from grille (the end of shaft in supraglottic airway) to glottis is measured using FOB
1475395|NCT03156153|Drug|Bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
1475396|NCT03156153|Drug|Placebo|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
1475397|NCT03156140|Other|Motion|Volunteer has motion on right hand while with continuous pulse oximetry during three oxygenation plateaus
1475398|NCT03156127|Drug|BR-UPS 5 mg tablet, Inisia 5 mg tablet|Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
1475401|NCT03156101|Biological|BinD19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
1475402|NCT03156088|Device|"Sacral Neuromodulator InterStim"|
1475403|NCT03156075|Behavioral|Nutrition and exercise program|"Nutrition education will be about increasing the intake calcium and vitamin D rich foods and exposure to sun will provided for the intervention group.
Education of the patients about exercises that increases the strength of lower limb and hip muscles to increase the mobility of the patients earlier and decrease the mortality in turn."
1475404|NCT03156062|Drug|Topical corticosteroids with salicylic acid|comparison between climatotherapy and topical combination of corticosteroids and salicylic acid in treatment of psoriasis
1475405|NCT03156049|Procedure|Sphenopalatine block|patients will receive bilateral sphenopalatine ganglion block using 3ml mixture of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each nostril).
1475406|NCT03156049|Procedure|Greater occipital nerve block|patients will receive bilateral greater occipital nerve block using a mixture of 3ml of 2ml 2% lidocaine plus 1ml dexamethasone 4mg (on each side of the occipital region).
1475407|NCT03156036|Drug|Capecitabine plus temozolomide VS Capecitabine|"For each cohort of MGMT hypermethylated versus MGMT unmethylated, patients will be randomised (ratio 1:1 for each arm) into preoperative CRT with capecitabine or preoperative CRT with temozolomide plus capecitabine arms.
Chemotherapy during preoperative chemoradiotherapy:
Capecitabine and temozolomide will be administered during radiotherapy with drug holidays (weekend break).
dosage: Capecitabine 825 mg/m2 twice daily, Temozolomide 75 mg/m2/day"
1475408|NCT03156023|Drug|AMG 570|Investigational product solution in vial
1475409|NCT03156023|Drug|Placebo|Placebo investigational product in vial
1475410|NCT03156010|Device|Neuro Kinetics IPAS|Testing with PAS device
1475411|NCT03156010|Device|Oculogica EyeBox|Testing with Oculogica EyeBox device
1475412|NCT03156010|Device|SyncThink EyeSync Device|Testing with SyncThink EyeSync device
1475415|NCT03155984|Drug|Anti-CD20 antibody|All patients receiving anti-CD20 therapy (rituximab, ofanumumab, obinutuzumab) for hematological malignancies
1475416|NCT03155971|Device|Paclitaxel-Coated Balloon|SeQuent ® Please; B.Braun, Melsungen, Germany
1475417|NCT03155945|Drug|APD371|APD371 active treatment for 8 weeks.
1475418|NCT03155932|Drug|APD334|APD334 active treatment for 24 weeks.
1475419|NCT03155919|Dietary Supplement|TAUchoc|The supplements were offered during eight weeks in capsules containing three grams of taurine powder and 400 ml of chocolate milk ready to drink.
1475420|NCT03155919|Dietary Supplement|PLAchoc|The supplements were offered during eight weeks in capsules containing three grams of placebo (starch powder) and 400 ml of chocolate milk ready to drink.
1475421|NCT03155906|Other|Health care delivery|Integrated HCV treatment within the OST clinics will compared to standard treatment. Those who are eligible to receiving treatment in line with national guidelines, have no exclusion criteria and consent to study participation, will be randomised to either standard or integrated treatment. For the integrated treatment, treatment initiation, follow-up and delivery of medication will be given at a MAR outpatient clinic where they already receive care including OST. Those randomised to standard treatment will be referred to a medical ward clinic for assessment of treatment initiation and follow-up. Assessment of outcomes will be done 12 weeks after completed treatment and adherence will be assessed at 4, 8 and 12 weeks after initiation of treatment.
1948665|NCT01985360|Procedure|Cardiac Catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
1948666|NCT01985360|Procedure|Coronary Artery Bypass Graft Surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
1948667|NCT01985360|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
1948668|NCT01985360|Behavioral|Lifestyle|Diet, physical activity, smoking cessation
1948669|NCT01985360|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
1948670|NCT01984346|Device|Convergent Procedure EPi-Sense-AF Guided Coagulation System|Convergent Epicardial Endocardial Ablation Procedure
1948671|NCT01984346|Device|Endocardial Catheter Ablation|Endocardial Catheter Ablation only
1948672|NCT01977027|Other|Alternate Hand Training or Affected Hand Training|Participants will receive a training intervention with either the Alternate Hand Training Strategy, or Affected Hand Training alone.
1948674|NCT01972464|Drug|Progesterone|
1948675|NCT01972464|Drug|Placebo|
1475435|NCT03155867|Other|Meal replacement|The study interventions contain protein, carbohydrate and fat and are intended for use as complete meal replacements for weight loss.
1475436|NCT03155854|Procedure|Pretendinous cord excision|The cord/palmar fascia will be excised during surgery.
1475437|NCT03155854|Procedure|Division/manipulation of the cord|The pretendinous cord will be divided and incised during surgery.
1475438|NCT03155841|Behavioral|Life Skills Coaching|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics and geographic location.
1475439|NCT03155841|Behavioral|Community Resources|The investigators will provide a resource locator as the attention-control condition. The resource locator provides a list of health (e.g., HIV testing) and social (e.g., support groups) resources across study regions.
1475441|NCT03155789|Procedure|Lumbar Fusion|"Standard Transforaminal Lumbar Interbody Fusion (S TLIF)
Minimally Invasive Transforaminal Lumbar Interbody Fusion (MI TLIF)
AxiaLIF Fusion"
1475442|NCT03155776|Diagnostic Test|GUS|gastric volume estimation using gastric ultrasound was performed immediately after anesthetic induction, and after aspirating the residual gastric contents using nasogastric tube
1475443|NCT03155763|Procedure|Intraoperative kidney allograft preimplantation biopsy; Intraoperative kidney allograft postreperfusion biopsy|
1475446|NCT03155737|Other|Self-acupressure|A training course will be offered to subjects in this group to train them to perform self-acupressure.
1475447|NCT03155737|Other|Knee health education|A course regarding knee health will be offered to the subjects in this group.
1475448|NCT03155724|Device|MultiPole Pacing|CRT non-responders are programmed with MultiPole pacing ON.
1475449|NCT03155711|Procedure|HFNC group|Positive pressure plus supplemental oxygen through a high flow nasal oxygen device
1475450|NCT03155711|Procedure|Standard group|Supplemental oxygen through venturi mask
1475451|NCT03155698|Combination Product|microneedling and Platelet rich plasma|"Patient's skin is first cleaned with ethyl alcohol. Topical anaesthetic cream is then applied to skin for 30 min. Once anaesthesias is fully developed, Dermapen will be applied on the lesional skin in four direction, vertical, horizontal and the two diagonal until pin point bleeding occur which will be gently massaged.
After ten minutes the prepared platelet rich plasma will be applied topically and after about 2 minutes. Occlusive dressing will be done and kept for 1 day then the patient will use topical antibiotic. The procedure will be repeated every 15 days."
1475452|NCT03155698|Radiation|NB-UVB phototherapy|All patients will receive NB-UVB twice weekly for maximum 6 months, starting with a dose of 0.21 J/cm² independent of skin type and increased by 20% every session until we reach the minimal erythema dose
1475453|NCT03155672|Behavioral|Art therapy|Art Therapy
1475454|NCT03155646|Drug|Dexmedetomidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml each side + 0.5 ug/kg dexmedetomidine Hydrochloride dissolved in 2 ml normal saline (NaCl 0.9%)
1475455|NCT03155646|Drug|Clonidine|patients will receive ultrasound-guided TAP block using 0.3 ml/kg levobupivacaine (0.125%) with a maximum volume of 20 ml + 0.5 ug/kg clonidine dissolved in 2 ml normal saline (NaCl 0.9%)
1475456|NCT03155633|Other|Athletics track|Running at 95-105% aerobic Threshold on athletics track 48h, 96h, 144h after the race. Control heart devices
1475457|NCT03155633|Other|Elliptical machine|Running at 95-105% aerobic Threshold on elliptical machine 48h, 96h, 144h after the race. Control heart devices
1948676|NCT01955382|Drug|Actidose Aqua|Actidose Aqua (oAC)(Paddock Laboratories is sold over the counter in the United States in bottles containing 25 g/120 mL (NDC # 0574-0121-04) or 50 g/240 mL (NDC # 0574-0121-08). oAC is stable at room temperature.
1948677|NCT01955382|Drug|Artesunate|Artesunate (AS) obtained from Guilin Pharma (Shanghai), the only pharmaceutical company GMP pre-qualified by the WHO. The product artesunate for injection + 5% sodium carbonate inj + 0.9% sodium chloride inj will be delivered in vials of 30 mg and 60- mg vials, respectively, and will be dosed at 2.4 mg/kg as recommended for SM treatment by the WHO
1475473|NCT03155581|Behavioral|User intervention|To make participants aware of the lack of participation in screening programs and its consequences, and help to manage obstacles to participation
1475474|NCT03155581|Behavioral|Health professional intervention|To provide information on the low attendance of migrants to cervical cancer screening and tools to improve the situation
1475475|NCT03155568|Procedure|sciatic nerve block|sciatic nerve block at popliteal fossa
1475476|NCT03155568|Procedure|ankle block|block of major nerves supplying the foot at the level of the ankle
1475477|NCT03155568|Drug|Bupivacaine|blocking the lower limb nerve supply at the level of the popliteal fossa and ankle using the local anesthetic bupivacaine
1475478|NCT03155555|Other|Measurement of aortic and carotid Doppler peak systolic velocity variation|Aortic peak systolic velocity variation to be measured by echocardiography from apical five chamber and suprasternal windows alongwith carotid peak systolic velocity variation by Doppler ultrasound simultaneously at intermittent time points intermittently.
1475479|NCT03155529|Procedure|radical hysterectomy|A standard radical hysterectomy with lymphadenectomy was performed. Static and dynamic MRI were performed. A suggested urodynamic examination was done according to the ICS. A 3D reconstruction technique was used to construct the 3D model of the pelvis, pelvic floor muscle, pelvic organ such as bladder and urethral.
1475480|NCT03155516|Other|Good pain management (GPM) procedure|"In the GPM ward, a close pain assessment will be carried within 1 hour after admission. After the assessment, patient will be given analgesic treatment as needed, by acceptable route, frequency and dosage. A good titration is required in GPM ward. Patient will be close monitor his/her pain level regarding pain score. In opioid use, when patient complains patient level ≥ 4, low dose strong opioids will be introduced in patient suffering with moderate pain.
Compare with current practice, GPM ward will perform pain assessment with higher frequency for adjusting of analgesic medications if required."
1475481|NCT03155516|Other|Current practice procedure|Current practice clinical procedure for pain management
1475482|NCT03155503|Drug|SUVN-911|Oral Tablet
1475483|NCT03155503|Drug|Placebo|Oral Tablet
1475484|NCT03155490|Behavioral|Leadership training|Subjects randomized to the experimental arm of the study will receive an additional 4 hours of simulation-based trauma team leadership training. This training is in addition to the baseline 2 hours of trauma leader training and orientation all subjects receive.
1475485|NCT03155477|Dietary Supplement|"Cholecalciferol and C. Xanthorrhiza"|Cholecalciferol are given 400 IU 3 times daily for 3 months C. Xanthorrhiza are given 200 mg 3 times daily for 3 months
1475486|NCT03155477|Dietary Supplement|"Cholecalciferol and placebo"|Cholecalciferol are given 400 IU 3 times daily for 3 months Placebo are given 3 times daily for 3 months
1475487|NCT03155464|Procedure|Order of two elements of surgical procedure|Please see the arm/group descriptions for the order of elements of the surgical procedure in group 1 and group 2.
1475488|NCT03155464|Drug|Indocyanine Green|Intraoperative ICG has been validated to correlate to postoperative outcomes. ICG is administered by means of peripheral or central intravenous access, is excreted exclusively by the liver into the bile, and is not associated with risk for nephrotoxicity. We will be using a concentration of 2.5mg/cc. 12.5mg will be administered at each injection of ICG. Complete washout of the ICG occurs after 15 minutes, plenty of time considering the interval surgery that must occur. As per the protocol, ICG will be administered 3 times during the surgery. The patients will receive a total of 37.5mg of ICG, well below the recommended threshold of 2mg/kg. No significant toxic effects have been observed in humans with the high dose of 5 mg/kg of body weight.
1475490|NCT03155438|Diagnostic Test|Oxidative stress-related gene expression (RNA expression)|Oxidative stress-related gene expression (RNA expression),Superoxide dismutase 1 (SOD1) , SOD2 , Glutathione peroxidase (GPX) and Inducible nitric oxide synthase (iNOS) , measured by Real time PCR technique.
1475491|NCT03155438|Diagnostic Test|oocyte competence biomarkers|Oocyte competence biomarkers ,GDF9, BMP15, Amphiregulin and CoQ10 measured by ELISA
1475492|NCT03155425|Drug|SHR-1210|A humanized monoclonal immunoglobulin
1475493|NCT03155399|Other|Proprioceptive based training (PBT)|During the PBT patient will stay in supine position with the upper limbs positioned in symmetric posture. He/She will be asked to move both limbs with the same frequency performing bilateral flexion-extension of one of the upper limb districts according to the available free ROM of the target joint. The movement execution of the affected arm will be supported by the physiotherapist performing passive movement at the same rhythm, as the one executed with the unaffected side. Patient will be asked to focus the attention on the movement performed against gravity, which will be reinforced by a verbal command. Afterwards, the physiotherapist will fully support movement execution coherently with the patient's movement initialization. The active movement performed voluntarily by the patient with unaffected limb will be considered as the reference movement, that the physiotherapist has to emulate passively, by synchronization of passive movement executed in phase with the affected side.
1475494|NCT03155399|Other|Conventional neuromotor treatment (CNT).|The patients randomized to the CNT group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity.
1475495|NCT03155386|Other|Angiommamography|"A blinded central re-reading of the acquisition technique will be carried out by 3 radiologists (2 seniors and 1 junior) who will evaluate:
The intensity of lesion enhancement
The presence and type of artefacts on the recombined images.
The quality of low-energy images according to recognized criteria for mammography.
The gold standard will be histology (biopsies or surgery) or follow-up to 1 year for non-biopsied benign lesions"
1475496|NCT03155373|Diagnostic Test|Cardiac catheterisation|Pre-operative left heart catheterisation +/- right heart catheterisation
1475497|NCT03155373|Diagnostic Test|Cardiopulmonary exercise testing|Pre and post-operative cardiopulmonary exercise testing
1475498|NCT03155373|Diagnostic Test|Pulmonary function tests|Pre and post-operative pulmonary function tests
1475499|NCT03155373|Diagnostic Test|Cardiac MRI|Pre and post-operative cardiac MRI
1475500|NCT03155373|Other|Quality of life survey|Pre and post-operative quality of life survey (SF36)
1475501|NCT03155373|Procedure|Mitral valve operation|Clinically indicated mitral valve repair/replacement +/- coronary artery surgery +/- tricuspid valve surgery +/- atrial fibrillation surgery
1475502|NCT03155373|Procedure|Myocardial biopsies|Right and left epicardial ventricular biopsies taken at time of clinically indicated surgery
1475503|NCT03155360|Other|Non interventional study|Non interventional study
1475504|NCT03155347|Drug|Tocilizumab|Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.
1475505|NCT03155347|Drug|MTX|Participants will receive MTX stable doses at 10 to 25 mg orally.
1475506|NCT03155347|Drug|Placebo Matched to MTX|Placebo matched to MTX.
1475507|NCT03155347|Drug|Placebo Matched to Tocilizumab|Placebo matched to tocilizumab.
1475508|NCT03155334|Other|PIS User Testing|"PIS User Testing based on an iterative 4-step process in a cohort of participants (the target group):
individual reading of the text;
individual questionnaire for a quantitative and qualitative evaluation;
a brief semi-structured interview to each participant;
a text revision to address any problems identified from participant feedback."
1475509|NCT03155321|Other|It's an observational study - no intervention is planned|No intervention is planned
1475510|NCT03155308|Device|Pentax chromoendoscopy (i-scan and Optical Enhancement)|All lesions will be evaluated using the 3 i-scan modes and the 2 OE modes without magnification. The lesion size data, location and macroscopic shape of the lesions based on the Paris classification will be recorded. Finally all lesions will be classified in real-time into 3 types based on NICE classification (NICE 1, hyperplastic polyps; NICE 2, adenoma and superficial submucosal carcinoma; NICE 3, SM-d invasive carcinoma). A level of confidence (high or low) will be assign in each stage. Polyp's images will be photographically and videotape recorded. All polyps will be resected or biopsied for histopathological examination used as the criterion standard for the analysis.
1475513|NCT03155282|Procedure|EUS-E to measure liver and spleen stiffness.|The EUS-E quantitative evaluation will be performed on the left hepatic lobe transgastrically. For the SR calculation, the area A will be manually selected including as much of hepatic tissue as possible and the area B will be selected on the red gastric mucosa. For the strain histogram measurement, the ROI selected will have a surface of 60 mm2. The same procedure will be repeated 10 times at different points on the left hepatic lobe and finally the mean SR and SH values will be calculated. The same sequence will be repeated to measure the spleen stiffness. Finally the azygos vein (AV) will be evaluated using EUS Doppler. The mean velocity and the AV diameter will be measure and the AV blood flow volume index (BFVI) will be calculated.
1475514|NCT03155269|Dietary Supplement|Fortified Beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
1475515|NCT03155269|Dietary Supplement|Non fortified beverage Powder|The tumbler will be filled with water up to the 200 mL mark. The entire contents of one sachet (Non fortified beverage powder) will be gradually emptied in the tumbler with intermittent stirring to avoid formation of lumps. The reconstituted product will be consumed by the participants immediately orally.
1475516|NCT03155256|Procedure|EUS-guided injection of coils with cyanoacrylate|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with Coils plus CYA (Group A)
1475517|NCT03155256|Procedure|EUS-guided injection of coils|First a standard diagnostic upper endoscopy will be performed in order to classify the varices according to the classification of Sarin and Kumar. Only GOV II and IGV I varices will be included. Once the patient is conceder a candidate will be treated with only coils (Group B).
1475519|NCT03155204|Drug|tiotropium pMDI|inhalation
1475520|NCT03155191|Biological|TBI-1501|"Phase-I portion:
Cyclophosphamide is administered for conditioning medication of CD19-CAR-T (cohort -1: 3×10^5 cells/kg, cohort 1: 1×10^6 cells/kg, cohort 2: 3×10^6 cells/kg).
Phase-II portion:
Recommended dose of Phase-II part will be administered. Cyclophosphamide will be administered as conditioning. The end of study will be Week 52 after administration of TBI-1501."
1475521|NCT03155178|Drug|3M CHG/IPA Prep|Apply topically applied to intact skin.
1475522|NCT03155178|Drug|ChloraPrep|Apply topically applied to intact skin.
1475523|NCT03155165|Device|Retroview™ colonoscope|The colonoscopy will be performed twice, with 2 different scopes, in tandem, by 2 endoscopists trained on retroflex withdrawal. First a conventional HD colonoscope with I-Scan will be used following the standard withdrawal technique and then the second endoscopist blinded to the first colonoscopy results, will perform the second colonoscopy using the Retroview™ scope with a combining withdrawal (retroflexed + standard withdrawal). The endoscopist that will perform each colonoscopy will be chosen randomly. After the examination, the endoscopist will fill a questionnaire detailing each polyp / adenoma found including the size and location.
1475524|NCT03155152|Other|DECT|The DECT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is imposed in a decremental fashion.
1475525|NCT03155152|Other|HIIT|The HIIT program consists of a 4-week training intervention with three weekly sessions of high-intensity interval training, in which during each exercise bout the workload is kept constant.
1475778|NCT03152955|Drug|Sufentanil|Sufentanil(0.02ug/kg/h) is applied in patient-controlled analgesia.
1475526|NCT03155139|Diagnostic Test|Aldosterone/renin ratio (ARR) testing|Plasma aldosterone concentration tests, Direct renin concentration tests
1475527|NCT03155139|Diagnostic Test|Confirmatory tests|Captopril challenge test, Saline infusion test
1475528|NCT03155126|Other|Fluid resuscitation|Patients in the saline group were resuscitated with saline, patients in the other group were resuscitated with acetated Ringer's sodium
1475529|NCT03155113|Other|blood drawing|Before starting therapy a blood sample will be collected from any subject.
1475530|NCT03155100|Drug|Carfilzomib for Inj 60 milligram (MG)|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
1475531|NCT03155100|Drug|Elotuzumab 400 MG|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
1475532|NCT03155100|Drug|Dexamethasone|All patients will have similar effective study drug combination; karfilzomib plus elotuzumab plus dexamethasone
1475533|NCT03155087|Drug|Metformin|
1475534|NCT03155074|Behavioral|High-intensity training|The exercise program will include a cardiovascular warm-up, high intensity interval training and progressive resistance training (PRT). The intervention will focus on high-intensity training, mainly by uphill walking on a treadmill at 80-95 % of the maximal heart rate and PRT in three series at 6-12 RM by leg press, chest press, back extension, seat row, and front raises. During the first four weeks, the patients will be introduced to the program while focusing on safety, techniques and familiarization. The endurance intensity and strength load will then continuously increase based on the patients' improvement, tolerance of dyspnea, and feelings of well-being or fatigue on each exercise day.
1475535|NCT03155061|Drug|ONO-4578|ONO-4578 specified dose on specified days
1475536|NCT03155061|Drug|ONO-4538|ONO-4538 specified dose on specified days
1475537|NCT03155035|Drug|Albendazole|Albendazole 400 mg chewable tablets (200 mg each) Two tablets as a single dose recommended as ovicidal, larvicidal and vermicidal against all soil transmitted helminths
1475538|NCT03155035|Dietary Supplement|Calcium 400 mg + Vitamin D 2.5 mcg|2 chewable tablets provide recommended daily allowance for calcium and vitamin D
1475539|NCT03155022|Device|Remote ischemic conditioning and intracoronary ischemic conditioning|"RIC: Four cycles of [5 min brachial cuff inflation at 200 mmHg followed by 5 min of cuff deflation] started as soon as possible prior to PCI reperfusion. At least one full cycle (inflation + deflation) has to be completed before PCI reperfusion.
ICIC: Four cycles of [1 min balloon inflation followed by 1 min balloon deflation] started as soon as possible after reopening of the culprit coronary artery (maximum within 3 minutes after reflow). The balloon will be placed carefully above the culprit lesion so as to minimize potential micro-embolization."
1475540|NCT03155022|Device|Patients with no remote ischemic conditioning and no intracoronary ischemic conditioning|Brachial cuff is positioned during 40 minutes but not inflated. No intracoronary balloon inflation.
1475542|NCT03154996|Drug|Topotecan|"Topotecan is a chemotherapeutic agent that is a topoisomerase inhibitor. TPT is administered through an externalized catheter and external microinfusion pump.
Dose: 146 uM"
1475543|NCT03154996|Drug|Gadolinium|Gadolinium is a widely available MRI contrast agent that is used routinely in clinical practice via IV administration, especially for imaging of intracranial tumors.
1475544|NCT03154996|Device|Synchromed II infusion pumps|FDA-approved for the treatment of spasticity and chronic pain, will be implanted subcutaneously to facilitate chronic infusion.
1475546|NCT03154970|Device|Craniocervical flexion training|The cervical stabilization will be performed with craniocervical flexion training with two weekly sessions for 6 weeks
1475547|NCT03154944|Device|Ostomy device 1|This device consists of a known adhesive and a new top film
1475548|NCT03154944|Device|Ostomy device 2|This device consists of a new adhesive and a known top film
1475549|NCT03154944|Device|Ostomy device 3|This device consists of a known adhesive and a new top film
1475550|NCT03154931|Other|CBT-SG|To support the group.
1475551|NCT03154931|Other|CFT-G|Teach compassionate skills.
1475552|NCT03154918|Drug|GLIDE|The dose and schedule of GLIDE chemotherapy was as follows: gemcitabine 800 mg/m 2 days 1, 8; Peg-ASP 2500 U/m 2 days 4; ifosfamide 1000 mg/m 2 days 1 - 3; dexamethasone 20 mg days 1 - 4; etoposide 100 mg/m 2 days 1 - 3.
1475553|NCT03154892|Procedure|Intracameral injection|Intracameral Conbercept injection for the treatment of NVG
1475554|NCT03154892|Procedure|Intravitreal injection|Intravitreal Conbercept injection for the treatment of NVG
1475555|NCT03154879|Device|Amplitude integrated electroencephalography|Frontal Amplitude-integrated Electroencephalogram in Early Prognostication After Cardiac Arrest
1475556|NCT03154866|Dietary Supplement|Lactobacillus kefiri LKF01 DSM32079|Lactobacillus kefiri LKF01 DSM32079 in drop formulation. 5 drop/daily for 21 days
1475557|NCT03154866|Dietary Supplement|Placebo|Placebo in drop formulation. 5 drop/daily for 21 days
1475558|NCT03154853|Other|Behavioral: short foot exercise|Behavioral: short foot exercise 30 repetitions per section (10 seconds for each contraction, 1 minute between sections), 3 times/ week, 3 weeks
1475559|NCT03154840|Drug|Eutropin 4IU, Eutropin AQ 12IU, Eutropin Pen 36IU|Investigate the Relative Bioavailability among Different Eutropin Formulations
1475560|NCT03154827|Drug|BL-8040|Subjects will receive once daily SC injections of 1.25 mg/kg of BL-8040 on the first 3 days of each cycle.
1475561|NCT03154827|Drug|Atezolizumab|Subjects will receive Atezolizumab 1200 mg by IV infusion on Day 2 of every cycle.
1475562|NCT03154814|Drug|ulinastatin|ulinastatin (10000 U/kg and 5000 U/kg/h) was administered during CPB
1475563|NCT03154814|Drug|control|conventional CPB was applied without ulinastatin treatment
1475564|NCT03154801|Other|Paramedical care|Paramedical early detection of sexual dysfunction and sexual health counseling
1475565|NCT03154775|Biological|C-CAR011|Autologous 2nd generation CD19-directed CAR-T cells, single infusion intravenously at a target dose of 0.5-5.0 x 10^6 anti-CD19 CAR+ T cells/kg
1475566|NCT03154762|Device|NIPPV|Application of chronic distension of the airway through NIPPV to produce a reduction in bronchial hyperreactivity.
1475567|NCT03154762|Device|CPAP|4 cmH2O CPAP as the minimum pressure necessary to mobilize the air flow and avoid the space death with no effect on the ventilation.
1475568|NCT03154749|Drug|TC (docetaxel/carboplatin) versus EC followed by T (epirubicin/cyclophosphamide followed by docetaxe)|TC (docetaxel/carboplatin) versus EC followed by T (epirubicin/cyclophosphamide followed by docetaxe) regimens as Neoadjuvant Treatment for Triple-Negative Breast Cancer
1475570|NCT03154723|Drug|Vitamin A|Vitamin A daily dose 1500IU/day will be added to infant's enteral feeds in drop form as soon as minimal feeding is introduced. The vitamin A supplementation was last for 28 days.
1475571|NCT03154710|Device|SENTINEL|web-mediated follow up
1475572|NCT03154697|Other|Data collection of sleep disturbances in individuals with SMS|Data related to Smith-Magenis syndrome and sleep disturbances are collected through a web or phone survey
1475573|NCT03154684|Other|STARK intervention|"The STARK Intervention is a new care concept for hip fracture patients that enable hip fracture patient to return to their home directly after discharge from acute care. The STARK comprehensive autonomy health care package includes following services;
Multidisciplinary collaboration of geriatricians, nurses and Spitex (ambulant nursing service at home) starting already during acute care
Inspection of the environment at the patient's home
Care and autonomy support
Social life support
Secondary prevention strategies:
Home exercise program (3x/weeks)
Protein enriched food preparation (20g whey protein/day)
Support to take vitamin D supplementation (2000 IU/day)
Recommendation and support to eat calcium rich foods
Motivation to be physically active"
1475574|NCT03154684|Other|Standard of Care|Standard of Care involves inpatient rehabilitation or home-based or inpatient transitional nursing care
1475576|NCT03154658|Drug|Ropivacaine 0.35%|The serratus plane block is used to supplement the pain management of a patient receiving a surgical procedure of the chest wall or breast.
1475577|NCT03154645|Drug|Ibuprofen|non-steroidal anti-inflammatory drug
1475578|NCT03154645|Drug|Acetazolamide|a diuretic
1475579|NCT03154632|Device|Ultrasound Therapy|Ultrasound equipment will be used, choosing a continuous mode, with a frequency of 1MHz and an intensity of 1.0 W/cm2. The technique will be applied during 6 minutes with circular movements and a speed of approximately between 2.5 and 4 centimeters per second.
1475580|NCT03154632|Device|Digital Capacitive Diathermy Therapy|"The DCD equipment will be used choosing the musculotendinous injury FAST program which lasts 6 minutes. The applicator will move with a velocity approximately between 2.5 and 4 centimeters per second."
1475581|NCT03154619|Drug|0.1% TR 987|TR 987 0.1%
1475582|NCT03154619|Drug|Placebo gel|Placebo gel twice weekly for 4 weeks, then once weekly for 8 weeks. Gel will be applied to cover the wound cavity and wound surface to a thickness of 5 mm.
1475583|NCT03154606|Other|Micellar Casein (#1)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
1475584|NCT03154606|Other|Micellar Casein (#2)|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from micellar casein. All ingredients are GRAS listed and approved.
1475585|NCT03154606|Other|Calcium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from calcium casein. All ingredients are GRAS listed and approved.
1475586|NCT03154606|Other|Sodium Caseinate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from sodium caseinate. All ingredients are GRAS listed and approved.
1475587|NCT03154606|Other|Milk Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from milk protein caseinate. All ingredients are GRAS listed and approved.
1475588|NCT03154606|Other|Pure Protein Blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pure protein blend. All ingredients are GRAS listed and approved.
1475589|NCT03154606|Other|Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from whey protein blend. All ingredients are GRAS listed and approved.
1475590|NCT03154606|Other|Native Whey Protein Isolate|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from Native Whey Protein Isolate. All ingredients are GRAS listed and approved.
1475591|NCT03154606|Other|Soy Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from soy protein. All ingredients are GRAS listed and approved.
1475592|NCT03154606|Other|Pea Protein|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from pea protein. All ingredients are GRAS listed and approved.
1475746|NCT03153176|Behavioral|Training|Training program 30 hours accumulated before, during and after intervention
1475914|NCT03151863|Drug|Dexmedetomidine|Dexmedetomidine is provided intranasally
1475593|NCT03154606|Other|Native Whey: Micellar Casein (50:50) blend|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain protein sourced predominantly from native whey: micellar casein (50:50) blend. All ingredients are GRAS listed and approved.
1475594|NCT03154606|Other|Carbohydrate Control|The study participants will be provided with breakfast meals to consume. The energy content of the breakfast meals will be standardized to ~250 kcal. The meals will include the same fat content but will contain predominantly carbohydrates as a control. All ingredients are GRAS listed and approved.
1475595|NCT03154593|Other|Stage 2 - Bariatric Surgery|This observational study follows patients after routine bariatric surgery.
2010522|NCT02944578|Drug|Placebo|"Study participants randomized to the placebo arm will insert four 500 mg (2000 mg total) of the placebo (gelatin) capsules at bedtime every day (excluding days when they are on their menses). Participants will insert the capsules using the vaginal applicator while lying on their back with their knees bent. Participants will be instructed to gently insert the capsules into the vagina as far as they will go comfortably, similar to a tampon insertion or other common intravaginal drugs.
Cervical cytology, colposcopies and biopsies will be performed at the Baseline, Week 4, 8, 12 and 16 visits to collect samples to analyze for the study outcomes."
1475599|NCT03154528|Diagnostic Test|serum vitamin D level by ELISA|The study will include 60 patients with androgenetic alopecia (30 males & 30 females) and 30 age and sex-matched healthy volunteers. Study subjects will be recruited from the Dermatology Outpatients' Clinic, Assiut University Hospitals, Assiut, Egypt. Informed consent will be obtained from all subjects
1475600|NCT03154515|Drug|Ingavirin|
1475601|NCT03154515|Drug|Placebo|
1475602|NCT03154502|Diagnostic Test|Urinary sodium excretion|Urinary sodium and potassium were measured using the Ion-Selective Electrode (ISE) indirect Na-K-Cl for Gen.2 (Roche Diagnostic, Switzerland).
1475603|NCT03154489|Other|acenocoumarol|medication review with follow-up in acenocoumarol treatment
1475604|NCT03154489|Other|control|group
1475605|NCT03154476|Drug|Sildenafil|Sildenafil will be initiated at 5 mg 3 times per day for the first week, and titrated to 10 mg 3 times per day for the second week and 20 mg 3 times per day from the third week to the end of the study period, 12 months.
1475606|NCT03154476|Drug|Placebo|Placebo capsules matching study drug
1475607|NCT03154463|Procedure|TAP Blocks|TAP blocks were performed using ultrasound as a guide and injected on three points on trans abdominal plane using 100 mm stimuplex needle and 0.25% bupivacaine with total volume of 20 ml in each point (with total of 60 ml in three points)
1475608|NCT03154463|Procedure|continuous epidural infusion|Continuous epidural infusion was given with epidural regimen of 0.25% bupivacaine without any adjuvant
1475609|NCT03154450|Device|EncoreAnywhere with data available to review|Encore Anywhere will be installed and available for review by the clinical team
1475610|NCT03154450|Device|EncoreAnywhere with no data available to review|Encore Anywhere will be installed but not available for review by the clinical team
2010523|NCT02944136|Behavioral|enhanced usual care|usual care from health providers
1475612|NCT03154424|Procedure|External fixation in treatment the distal radius fracture|Compare two techniques
1475613|NCT03154411|Drug|ABY-029|A minimum of 12 and a maximum of 18 adult patients with a diagnosis of primary soft-tissue sarcoma will be enrolled. Initial diagnostic biopsy specimens will be analyzed for EGFR positivity by immunohistochemistry following routine diagnostic processing by Pathologist. Patients will be administered a single intravenous dose of ABY-029 1-3 hours before surgery. Two cohorts will be enrolled with a minimum of 6 and a maximum of 12 subjects in Cohort 1 and 6 patients in Cohort 2. Cohort 1 will include patients with an EGFR pathology score ≥ 1; Cohort 2 will include patients with an EGFR pathology score of < 1 (control).
1475614|NCT03154385|Drug|Rituximab (Mabthera ®) Belimumab (Benlysta ®)|Rituximab (Mabthera ®): 1g IV at W0 and W2 Belimumab (Benlysta ®) : 10mg/kg IV, W0 + 2days, W2 + 2 days, W4, W8, W12
1475615|NCT03154372|Other|Expert supervised practice with validated metrics|
1475616|NCT03154372|Other|self guided practice with validated metrics|
1475617|NCT03154359|Drug|Atomoxetine Hydrochloride|Atomoxetine dose adjusted to achieve pre-defined concentration
1475618|NCT03154333|Drug|Diacerein 1% Ointment Topical Formulation|Diacerein 1% Ointment administered topically
1475619|NCT03154333|Drug|Vehicle|Place ointment administered topically
1475620|NCT03154320|Other|Same-Day Treatment|Treatment with ART or TB medication on day of HIV diagnosis
1475621|NCT03154320|Other|Standard treatment|Standard treatment
1475622|NCT03154307|Device|Low frequency repeated TMS (LF-rTMS)|Each patient will then begin treatment with 14 minute sessions of 1 Hz rTMS or sham rTMS, 120% minimum threshold (MT), and 800 stimuli on the position of the calculated 3D source using EEG, MRI, and digitized electrode locations. Two different timelines of delivering the rTMS will be compared against a sham/delayed treatment group.
2010524|NCT02944136|Behavioral|stepped collaborative care|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
2010525|NCT02942888|Dietary Supplement|Nicotinamide riboside|Oral administration of Niagen ramp up 250mg to 1g/day as tolerated
2010526|NCT02942888|Dietary Supplement|Sugar Pill|This is a placebo compounded by ChromaDex, Inc.
2010527|NCT02941172|Other|Cold exposure|Controlled cold exposure is performed before and during PET scan
2010528|NCT02941172|Other|[18F]FMPEP-d2|PET radiotracer used in imaging
2010529|NCT02941172|Other|[18F]FDG|PET radiotracer used in imaging
2010530|NCT02941328|Drug|Pyridostigmine|Pyridostigmine, administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
2010531|NCT02941328|Drug|Placebo|Placebo administered orally starting with 2mg/kg/day (in 4 daily doses, i.e. 0,5mg/kg/dose) and slowly increasing to a maximum dosage of 6mg/kg/day (4 daily doses of 1,5mg/kg/day)
2010532|NCT02942095|Drug|Ixazomib|"Dose Escalation Phase Starting Dose: Ixazomib 3.0 mg on Days 1, 8, and 15 of a 28-day cycle.
Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase"
2010533|NCT02942095|Drug|Erlotinib|Dose Escalation and Dose Expansion Phase: Erlotinib 150 mg by mouth on Days 1 - 28 of a 29 day cycle.
1475623|NCT03154294|Drug|paclitaxel|Paclitaxel will be diluted prior to infusion in 0.9% Sodium Chloride for Injection, USP; 5% Dextrose Injection, USP; 5% Dextrose and 0.9% Sodium Chloride Injection, USP; or 5% Dextrose in Ringer's Injection to a final concentration of 0.3 to 1.2mg/mL. At ambient temperature (approximately 25°C) and room lighting conditions the solution is physically and chemically stable for up to 27 hours. The diluted product will be prepared and stored in glass, polypropylene, or polyolefin containers; DEHP-containing (polyvinyl chloride (PCV)) containers should not be used. Paclitaxel will be administered using a vented Paclitaxel set with in-line 0.22-micron filter and run over 1 hour.
1475624|NCT03154294|Drug|TAK-228|TAK-228 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-228 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
1475625|NCT03154294|Drug|TAK-117|TAK-117 will be provided in 30-ct, 60-cc high density polyethylene (HDPE) bottles with polypropylene, child-resistant caps and induction seal. TAK-117 will be administered on an empty stomach. It is recommended that each dose of TAK-228 + TAK-117 be given PO with 8 ounces (240 mL) of water. Patients should be instructed to refrain from eating and drinking (except for water and prescribed medications) for 2 hours before and 1 hour after each dose.
1475626|NCT03154281|Drug|niraparib|Niraparib 100 mg will be administered orally once daily continuously. Niraparib will be administered as a flat-fixed dose (100mg, 200 mg, or 300 mg daily) depending on the cohort the patient is enrolled to, and not by body weight or body surface area. Each dose should be swallowed whole without chewing. The consumption of water is permissible. Patients should take doses at approximately the same times each day, and record this information in the patient diary. Patients will be provided with a diary in which to record their intake of study drug. However, the actual number of doses taken by the patient must be calculated from the number of tablets dispensed and returned.
1475627|NCT03154281|Drug|everolimus|Everolimus 5 mg tablets will be used. Everolimus will be self-administered orally on a daily basis and doses will either be 5 mg (1 tablet) thrice weekly or 5 mg daily depending on the cohort the patient is enrolled to. Each cycle will be 28 days; everolimus will be taken continuously with no rest between cycles.
1475632|NCT03154216|Behavioral|Exercise|90 minutes of moderate-intensity walking exercise on a treadmill
1475633|NCT03154216|Other|Drink|Beverage to be consumed after exercise
1475634|NCT03154203|Other|No intervention in this study|No intervention in this study
1475635|NCT03154190|Other|Best Practice|Receive usual care
1475636|NCT03154190|Other|Laboratory Biomarker Analysis|Correlative studies
1475637|NCT03154190|Procedure|Supportive Care|Undergo health care coach support
1475638|NCT03154190|Other|Survey Administration|Ancillary studies
1475641|NCT03154164|Device|Ultrasonic tissue coagulation dissection|ultrasonic coagulation for dissection during laparoscopic cholecystectomy
1475642|NCT03154151|Behavioral|Online Cognitive-Behavioral Therapy|Each participant will complete writing assignments focusing on how their experiences during the WTC recovery effort continue to affect their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
1475643|NCT03154151|Behavioral|Online Supportive Therapy|Each participant will complete writing assignments focusing on problems and stressors that are currently affecting their life, and the therapist will provide written responses and guidance within two work days, through the secure Web platform. Participants will be asked to complete one to two 45-minute writing assignments per week, over a six-week period (11 in total). Participants are asked not to begin new psychotherapy or medication with an outside therapist or doctor during the study.
1475644|NCT03154138|Device|The prismatic adaptation (PA)|Prismatic adaptation (PA) is based on the wearing of a pair of glasses producing a visual field deviation of 10° to rightward. While wearing theses glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements with a shift toward the right side (initial errors consecutive to the prism deviation). Taking into account theses errors, the patient then compensates the optical deviation. After removing the prismatic glasses, the asked pointing movement to the targets is once again shifted but to the left side this time (after-effects attesting the prismatic adaptation)
1475698|NCT03153579|Drug|LSD|"Lysergic Acid Diethylamide
200ug per os, single dose"
1475699|NCT03153579|Drug|Placebo|Capsules containing mannitol looking identical to LSD
1475700|NCT03153566|Biological|tuberculin|inject the mother wart with .3 ml tuberculin vaccine every 2 weeks
1475645|NCT03154138|Device|The sham prismatic adaptation (S-PA)|"The sham prismatic adaptation (S-PA) is based on the wearing of a pair of glasses producing no visual field deviation. Theses sham glasses is identical with theses used in PA group without the optical deviation. The conditions are similar with theses in the PA group.
The procedure with the sham glasses are similar with these one used in the PA group: While wearing the sham glasses, the patient is asked to perform fast pointing movements towards targets by the right hand. Targets are symmetrical located at 10° in the right and left side in front of the patient. The support with targets are the same as these one used in the PA group. The order of pointing between these two targets is pseudo-randomly by the therapist. At the beginning of the exposure, the patient performs pointing movements without shift. No compensation of movement is observed. After removing the prismatic glasses, the asked pointing movement to the targets is not shifted (No after-effects observed)"
1475646|NCT03154125|Drug|Sayana® Press|The active ingredient in Sayana® Press is Medroxyprogesterone acetate (MPA). Sayana® Press (MPA injectable suspension, 104 mg/0.65 mL, pre-filled in the UnijectTM delivery injection system) for subcutaneous injection.
1475647|NCT03154112|Device|Measurement of oxygen consumption and caloric expenditure|This study will involve an ~1 hour, single point in time measurement of oxygen consumption, carbon dioxide production, resting energy expenditure, and respiratory quotient using two methods while patients are breathing an FiO2 of 40%. These measurements will be measured using the novel, responsive device and compared with gas collected simultaneously collected from a Douglas bag.
1475648|NCT03154086|Drug|GSK3352589|It will be available in the dose of 1, 5, 25 and 100 mg tablet for oral administration.
1475649|NCT03154086|Drug|Matching Placebo|It will be available across all strengths to match active drug in the form of tablet for oral administration.
1475650|NCT03154073|Behavioral|Moderate Intensity Exercise Training (MOD)|For the first 4 weeks, participant will be asked to complete 3 days of exercise/week at 50-65% heart rate maximum. Sessions will last between 30-40 minutes excluding the warm-up and cool down (5-10 minutes). After 4 weeks, the MOD group will be expected to match the exercise prescription. The exercise prescription for the MOD group for weeks 5-12 will be 4 days/week, 45 min/session completed at 60-65% heart rate maximum.
1475651|NCT03154073|Behavioral|Vigorous Intensity Exercise Training (VIG)|The exercise lead in period will be the same as the moderate intensity exercise training program. After 6 weeks, the VIG group will be expected to match the exercise prescription. The exercise prescription for the VIG for weeks 7-12 will be 4 days/week, 45 min/session completed at 80-85% heart rate maximum.
1475652|NCT03154060|Device|Abbott FreeStyle Libre Flash Glucose Monitoring sensors|Three FGM sensors will be inserted simultaneously (one on the back of the upper arm, abdomen and thigh) and will be worn for a consecutive 14 days. Throughout the study, patients should measure capillary blood glucose (BG) with the built-in BG meter of the Freestyle Libre at least 7 times per day (before and 1-2 hours after every meal and before bedtime). Additionally, patients should scan each sensor at least every 8 hours to obtain every measured interstitial glucose value. At the end visit (after 14 days), patients will come back to the hospital to download FGM and SMBG data.
1475653|NCT03154047|Drug|NEOD001|humanized monoclonal antibody
1475654|NCT03154021|Combination Product|Next Science OTC Oral Rinse with Essential Oils|This group will receive Next Science Oral Rinse with Essential Oils and the other half will be give OTC Oral Rinse Control
1475655|NCT03154021|Combination Product|OTC Oral Rinse Control|This group will receive OTC Oral Rinse Control
1475656|NCT03154008|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will follow the Adolescent Coping with Depression Course (CWD; Clarke et al., 1999), an established 16-session group treatment protocol, and consist of behavioral activation, relaxation skills, cognitive therapy, social skills, problem solving, and relapse prevention.
1475657|NCT03153995|Procedure|soft tissue expansion|"Three surgeries will be carried out for each patient:
Soft tissue expansion (1st surgery); at baseline
Alveolar ridge augmentation (2nd surgery); after five weeks
Implant surgery (3rd surgery); after six months"
1475661|NCT03153956|Device|Calibrated AposTherapy®|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology.
1475662|NCT03153956|Device|Non-Calibrated Sham Apos Therapy Device|The comparator group will receive a non-calibrated sham device.
1475663|NCT03153943|Device|HIP Mobile e-Monitoring support|4-month community-based extended-rehabilitation e-Monitoring and Coaching support program
1475664|NCT03153943|Other|Workbook support|Printed material support
1475665|NCT03153930|Behavioral|Walking breaks|In-Lab (full sample): participants will be asked to walk on a treadmill for 3 minutes every 30 minutes at a moderate pace during a 3-hour OGTT Free-living (sub-sample; N=12): participants will be prompted via an ActivPAL vtap monitor to walk for 3 minutes every time sedentary behavior lasts longer than 30 continuous minutes
1475666|NCT03153930|Behavioral|Sitting only|In-Lab (full sample): participants will remain seated for 3 hours during an OGTT Free-living (sub-sample; N=12): participants will perform their habitual sedentary behaviors
1475667|NCT03153917|Other|melatonin and cortisol sampling|The study will take place over 15 days during which the nurses will wear an actigraphic wristband and will fulfill a sleep log. During 3 periods of 24 hours selected during these 15 days, including a 12h day shift (Day 2), a 12h night shift (Day 8) and a rest (Day 13), the participants will collect their urine by 4 to 8 hour periods, note the corresponding urine volumes and for each period, sample a 5 mL tube which will be analyzed later (6-sulfatoxymelatonin and urinary cortisol assays). The subjects will complete questionnaires at the beginning of the study (Horne and Ostberg, Insomnia Severity Index, Epworth, Pichot, Hospital Anxiety and Depression) and the days corresponding to the urine sampling (Karolinska and St Mary Hospital).
1475701|NCT03153566|Device|cryotherapy|10 sec 1 cycle into all genital warts
1475702|NCT03153553|Other|Ischemic Preconditioning|Ischemic preconditioning (IPC) is an experimental technique for producing resistance to the loss of blood supply, and thus oxygen, to tissues of many types. In the heart, IPC is an intrinsic process whereby repeated short episodes of ischaemia protect the myocardium against a subsequent ischaemic insult
1475668|NCT03153904|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita & Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules—i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
1475669|NCT03153904|Other|Monitoring and Feedback System|For each child, the web-based MFS provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Brief Problem Monitor (BPM) and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all weeks of treatment.
1475670|NCT03153891|Other|Natural Environment|the natural environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
1475671|NCT03153891|Other|Built Environment|the built environment will be delivered via Samsung VR gear goggles with Samsung smartphone.
1475672|NCT03153852|Drug|Modified Jessner's solution|Modified Jessner's solution will be applied on the right side until frosting
1475673|NCT03153852|Drug|Glycolic acid|Glycolic acid 70% on the other side of the face, then it will be neutralized with water after 5 minutes
1475674|NCT03153852|Drug|Trichloroacetic acid|Trichloroacetic acid 20% will be applied in one uniform coat to both sides of the face until frosting
1475675|NCT03153839|Behavioral|Aquatic physical activity in babies|"A programme based on four different types exercises realized in a swimming pool for twelve months.
Before the beginning of the aquatic physical activity, the infants will be evaluated. Afther that, the study group will practise the exercises with their parents in 20 minutes sessions twice a week and when they finish the programme they will be evaluated again."
1475676|NCT03153826|Other|Comparison of clinical and biological characteristics of patients|Comparison of clinical and biological characteristics of patients with less variation in muscle mass (evaluated by CSARF) compared to patients with greater variation during an hospitalization for COPD exacerbation
1475677|NCT03153813|Drug|capsaicin 8% patches (Qutenza)|
1475678|NCT03153813|Other|Placebo patches|
1475679|NCT03153800|Biological|bronchial basal cells|Transplantation of autologous bronchial basal cells by fiberoptic bronchoscopy.
1475680|NCT03153787|Other|Probiotic|Vaginal probiotic administration according to the standard regimen: 1 tablet (via vaginal) for 5 days after menstruation during the same cycle of the next embryo transfer.
1475681|NCT03153774|Diagnostic Test|Assessment of sarcopenia prevalence|Handgrip test, Bioimpedance analysis (Bodystat), 6-min walking test, Short physical performance battery (balance test, 4-min walking test, 5 times getting-up test), Biological markers test, Trans-thoracic echography, Electrocardiogram 12 leads, Palm gripping test
1475684|NCT03153735|Device|CMDHA0101|Maximum injection dose : 22 ml
1475685|NCT03153735|Device|PowerFill®|Maximum injection dose : 22 ml
1475686|NCT03153722|Procedure|Pediatric discharge process interventions|"As this is an iterative quality improvement process, interventions will be evidence-based and chosen to test effectiveness for addressing areas of discharge bottlenecks or inefficiency within our specific hospital's context. Examples of possible interventions may include implementation of a discharge risk assessment (as in Statile et al, Pediatrics 2016), institution of a medications-in-hand policy on hospital discharge (as in Sauers-Ford et al, Pediatrics 2016), or initiation of a ward discharge coordinator who will help coordinate outpatient follow-up for patients. Interventions will be implemented in a stepwise fashion, utilizing successive plan-do-study-act cycles, with a minimum 2 month period between interventions to monitor outcomes."
1475687|NCT03153696|Behavioral|Cellie Coping Kit Intervention|The Cellie Coping Kit intervention is grounded in empirical evidence regarding injury recovery. By utilizing parents as coaches, the Cellie Coping intervention can be initiated in the hospital and continued as the child recovers at home. The intervention's portable, engaging design and active partnership with parents as consistently available coaches, allows families to use the intervention anywhere (i.e., home, hospital, during procedures) ensuring the child is supported at the time the injury-related stressor arises. The Cellie Coping Intervention consists of 1) a stuffed toy to promote engagement, 2) caregiver book, and 3) coping cards. Skills are presented in a way usable by most parents and children without medical team support.
1475688|NCT03153683|Other|Registry|Collect standard of care clot and arterial blood during standard of care thrombectomy from Acute Ischemic Stroke Patients for lab analysis.
1475689|NCT03153670|Other|functional magnetic resonance imaging|Performing functional magnetic resonance imaging with the deep brain stimulation activated.
1475690|NCT03153657|Drug|Piroxicam-Beta-Cyclodextrin|The patients will receive a single-dose of Piroxicam-Beta-Cyclodextrin (20 mg) thirty minutes before the bleaching procedure.
1475691|NCT03153657|Drug|Placebo|The patients will receive a single-dose of placebo with the same presentation of the experimental drug thirty minutes before the bleaching procedure.
1475692|NCT03153644|Behavioral|Interview|1 hour semi-structured
1475693|NCT03153644|Behavioral|Observation|Field Observation
1475694|NCT03153618|Other|VALIDATE system|Will be invited to interact with VALIDATE to answer questions about Family Cancer history and some personal medical and lifestyle history. Based on responses, VALIDATE will determine if they meet referral indications for cancer predisposition assessment.
1475695|NCT03153605|Other|Common toothpaste|different toothpaste
1475745|NCT03153202|Drug|Pembrolizumab|200mg IV pembrolizumab on Day 1 of each cycle
1475703|NCT03153553|Other|Sham Intervention|Sham intervention will be administered to the right upper limb using a manual BP cuff which will be inflated at a pressure 30mmg Hg below the diastolic blood pressure. The sham cycles comprised of three cycles of cuff inflation each lasting 5 minutes in duration followed by 5-min period of cuff deflation
1475704|NCT03153540|Device|Active iTBS|Intermittent theta burst transcranial magnetic stimulation
1475705|NCT03153540|Device|Sham iTBS|Sham intervention
1475706|NCT03153527|Drug|Prednisone|The control intervention (standard treatment) consists of prednisone treatment in decreasing doses, starting with 7.5 mg q.d. and reducing the dose every 7 days, such that prednisone treatment is stopped after a total of 4 weeks.
1475707|NCT03153527|Other|Placebo Arm|The experimental intervention consists of stopping glucocorticoid treatment abruptly and administering matching placebo over 4 weeks.
1475708|NCT03153514|Biological|Obinutuzumab|"Obinutuzumab i.v.
[Day 0 = day of stem cell transplant]
Cycle 1: 100 mg (d -8), 900 mg (d -7), 1000 mg (d -1, +7, +14)
Cycle 2: 1000 mg (d +1, +8, +15, +22)"
1475709|NCT03153501|Diagnostic Test|CT-guided Abrams needle biopsy, US-guided cutting needle, medical thoracoscopy|
1475710|NCT03153488|Drug|Methylphenidate LA (Ritalin)|Subjects will be prescribed a titrated dose of Methylphenidate LA for 6 months.
1475711|NCT03153488|Drug|Mixed Amphetamine Salts XR (Adderall)|Subjects will be prescribed a titrated dose of Mixed Amphetamine Salts XR for 6 months.
1475712|NCT03153475|Device|ATTUNE Revision Knee System in Revision Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their existing implants need to be removed and replaced.
1475713|NCT03153462|Biological|Axicabtagene Ciloleucel|Axicabtagene Ciloleucel and A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
1948678|NCT01955382|Drug|Amodiaquine|Amodiaquine obtained from Pfizer (Dakar), is provided as 200-mg tablets or syrup (50 10 mg/mL), and will be provided as age-based doses per the manufacturer s directions.
1475715|NCT03153436|Biological|Myoinositol|
1475716|NCT03153423|Procedure|Strabismus surgery|Recession and resection of horizontal extra ocular muscles
1475717|NCT03153410|Drug|Cyclophosphamide|"200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX for a total of 8 doses.
Other Names:
Cytoxan CY"
1475718|NCT03153410|Drug|GVAX|"5E8 cells is to be administered one day after CY, pembrolizumab, and IMC-CS4/ LY3022855 for a total of eight doses.
Other Names:
Pancreatic cancer vaccine Panc 10.05 pcDNA1/GM-Neo, Panc 6.03 pcDNA1/GM-Neo"
1475719|NCT03153410|Drug|Pembrolizumab|"200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine for a total of 18 doses.
Other Names:
MK-3475 KEYTRUDA"
1475720|NCT03153410|Drug|IMC-CS4|75 mg for dose level 1 and 100 mg at dose level 2 will be administered (Day 1, Day 8 and Day 15) as a 30 minute(s) IV infusion one day prior to GVAX pancreas vaccine for a total 18 doses.
1475721|NCT03153397|Other|Nutraflora scFOS|prebiotic fiber (Nutraflora scFOS via Vital AF)
1475722|NCT03153397|Other|Osmolite|non-prebiotic fiber containing formula (Osmolite)
1475723|NCT03153384|Procedure|Blood Culture|For each patient, one single high volume blood culture (3 aerobic and 3 anaerobic of 8 to 10 mL each, numbered), and then 2 samples of 16 to 20 mL (one aerobic bottle and one anaerobic for each sample).
1475724|NCT03153358|Drug|Icotinib|icotinib 125 milligram three times a day
1475725|NCT03153358|Radiation|SBRT|given radiation for the primary lesion
1475726|NCT03153345|Device|bedside respiratory muscle training|The program consisted of three sessions: (1) 10 minutes of breath stacking exercise, followed by (2) 10 minutes of inspiratory muscle training using a flow-oriented incentive spirometer and (3) 10 minutes of expiratory muscle training using Acapella vibratory PEP device.
1475727|NCT03153345|Behavioral|conventional stroke rehabilitation program|The program consisted of joint range of motion exercises, muscle strengthening, gait training, fine motor exercises, and activity of daily living training.
1948679|NCT01954576|Device|NovoTTF-100A|
1475729|NCT03153319|Drug|Adalimumab Injection [Humira]|Investigational Drug
1475730|NCT03153319|Drug|Saline Solution for Injection|Placebo Comparator
1475731|NCT03153306|Drug|albumin|"Two groups were formed at random for each fluid. In one group, 10ml/kg of 5% albumin was given over 1 hour (the bolus group), and in the other group, the same volume was given over 6 hrs (thecontinuous group)"
1475734|NCT03153280|Drug|Lithium|Dose escalation of Lithium to determine the maximum tolerated dose (MTD)
1475735|NCT03153280|Drug|Oxaliplatin|Dose as used in standard of care - 130 mg/m2.
1475736|NCT03153280|Drug|Capecitabine|Dose as used in standard of care - 800 - 1000 mg/m2
1475740|NCT03153254|Device|Test upper limb robot assisted therapy device|During 1 session of 1/2 hour.
1475741|NCT03153254|Device|Training with new upper limb robot assisted therapy device|During 2 to 5 sessions of 1/2 hour.
1475742|NCT03153241|Other|No intervention|No intervention
1475743|NCT03153215|Other|treatment|We will offer Sildenafil citrate (20 mg per os three times daily until delivery) as innovative therapy to 23 women with severe IUGR ('Sildenafil-treated') in addition to low dose aspirin, fish oil, antioxidants, beta agonist and zinc supplementation.
1475744|NCT03153202|Drug|Ibrutinib|once daily oral intake ibrutinib
1948680|NCT01954576|Procedure|Quality-of-life assessment|
1948681|NCT01954576|Genetic|Laboratory biomarker analysis|
1948682|NCT01940354|Device|AccuCath IV device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
1948683|NCT01940354|Device|Conventional IV catheters|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples
1948684|NCT01933685|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600 ug/dose administered)
1948685|NCT01933685|Biological|AIDSVAX B/E Placebo|1 mL per injection
1475747|NCT03153176|Behavioral|Individual level|7 to 10 minutes in Physical Education in class time, 3 sections for week during lunch break
1475748|NCT03153176|Behavioral|Organizational level|Inclusion of actions in the school curriculum: counseling sections with health for parents and adolescent, active lesson breaks during theoretical class, gardening experience in school, nutrition guidance for school lunch professionals.
1475757|NCT03153137|Drug|Macitentan 10 mg|film-coated tablet; oral use
1475758|NCT03153137|Drug|Placebo|film-coated tablet; oral use
1475759|NCT03153124|Other|Respiratory muscle training|The intervention group will perform three months of intradialytic training of a physical therapy protocol with PowerBreath
1948686|NCT01930786|Drug|onabotulinumtoxinA|onabotulinumtoxinA administered according to physician standard of care. All treatment decisions lie with the physician.
1475762|NCT03153098|Behavioral|Active Herts|Active Herts is a community physical activity intervention aimed at inactive adults aged 16 and over who have one or more risk factors for CVD and/or a mild to moderate mental health condition. The programme uses the latest evidence-based behaviour change techniques to target physical activity, wellbeing, and key drivers of behaviour from the COM-B model of behaviour change.
1475763|NCT03153085|Biological|TBI-1401(HF10)|"1x10^7 TCID50/mL TBI-1401(HF10) (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals).
Following combination therapy, patients may continue to receive the 1x10^7 TCID50/mL TBI-1401(HF10) alone for up to an additional 13 injections (total of 19 injections = 1 year) if eligible for administration."
1475764|NCT03153085|Drug|Ipilimumab|3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
1475765|NCT03153072|Biological|Assess the absorption of oral amiodarone|Evaluate the pharmacokinetics of oral amiodarone solution at 15 mg / mL after oral administration
1475767|NCT03153046|Dietary Supplement|prebiotics|Bimuno (BGOS): The active supplement of the food supplement (Bimuno) used in this study is called galacto‐oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; <01g Fat; <0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless. Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
1475768|NCT03153046|Dietary Supplement|Maltodextrin|Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria. The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink. This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention.
1475769|NCT03153033|Behavioral|Fatigue protocol|The figure 8 protocol (fatigue intervention) requires the participants to propel three times as many laps as possible for four minutes each with their wheelchair. The protocol has been developed and used previously. Every bout of four minutes is separated by 90 seconds of rest. Each lap consists of a right and left turn and two complete stops after half a lap. Measurements during the protocol include the Rate of Perceived Exertion (RPE) scale, heart rate, and propulsion kinetics.
1475770|NCT03153020|Other|Patients with stroke or transient ischemic attack|Determination of factors associated to the conformity to secondary prevention treatment 1, 2 and 3 years post a stroke or transient ischemic attack.
1475771|NCT03152994|Other|Checking fasting blood glucose(FBG)|This is an observational study,fasting blood glucose(FBG) of each patient will be checked every six months.
1475772|NCT03152981|Drug|Desflurane|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
1475773|NCT03152981|Drug|propofol|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
1475774|NCT03152981|Drug|remifentanil|In desflurane group, desflurane 6-8 vol% and remifentanil (target controlled infusion 2-3 ng / ml) are used for maintenance of anesthesia during surgical procedure. In propofol group, propofol 3-4 ug/ml and remifentanil 2-3 n /ml using target Controlled Infusion are used for maintenance of anesthesia during surgical procedure
1475775|NCT03152955|Drug|Ketamine|Ketamine will be applied in patient-controlled analgesia.
1475776|NCT03152955|Other|scalp nerve block|Scalp nerve block is performed for the blockade of the greater occipital, superficial cervical and lesser occipital nerves with 0.5% ropivacaine.
1481541|NCT03108365|Device|Cotton Gauze|Size: 1 x 1 cm
1475779|NCT03152942|Drug|Progesterone|Progesterone 400mg to be administered once daily for 34 weeks in the patients randomised to receive progesterone alone
1475780|NCT03152942|Drug|Aminophylline|Patients randomised to the combination arm to be administered aminophylline 225 mg to be taken once at night for 1 week and then if tolerated increased to 225 mg twice daily Progesterone 400mg to be administered once daily for 34 weeks.
1475781|NCT03152929|Drug|Paravertebral Block|20-30 mL 0.5% Ropivacaine
1475782|NCT03152929|Drug|Pectoral Nerve Block|20-30 mL 0.5% Ropivacaine
1475783|NCT03152916|Device|3d printing personalized plate|3d printing personalized plate will be used in the subtalar arthrodensis
1475784|NCT03152903|Biological|VPM1002 (Recombinant BCG Vaccine)|"VPM1002 is a formulated, lyophilized cake of live recombinant Mycobacterium bovis rBCGÄureC::Hly+; VPM1002.
VPM1002 is the active pharmaceutical ingredient. It is a genetically modified BCG vaccine derived from the Mycobacterium bovis BCG subtype Prague characterized as rBCGÄureC::Hly+. Single dose of VPM1002 is administered intradermally."
1475785|NCT03152903|Other|Placebo|Single dose of Placebo is administered intradermally.
1475786|NCT03152890|Drug|Insulin|If blood glucose level after reperfusion of liver graft exceeds 180 mg/dL, the insulin dose proposed by the linear mixed effects analysis is given as a bolus.
1475787|NCT03152877|Drug|Bupivacaine Liposome Injectable Product|20cc of liposomal bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
1475788|NCT03152877|Drug|0.25% plain bupivacaine|20cc of 0.25% plain bupivacaine will be injected into the vaginal/perineal laceration site, once, following completion of the surgical repair.
1475789|NCT03152864|Behavioral|Full Package|Individuals will be randomly allocated to receive the full HealthRhythms package (Rhythm Sensing, Rhythm Trending, and Rhythm Stabilization) program on their smartphones
1475790|NCT03152851|Procedure|Pressure stimulus group|
1475791|NCT03152838|Genetic|DNA methylation and Real-time Polymerase Chain Reaction Analysis|"Fasting blood samples will be collected from both autism and controls for DNA extraction. Peripheral blood (2ml) will be drawn from the cubital vein intoplastic syringes. Lymphocytes will be isolated from blood samples. We will examine the gene methylation in the peripheral blood lymphocytes of drug-naı¨ve autism patients and control subjects.
DNA will be isolated from lymphocytes, purified and processed for bisulfate modification. Bisulfate treatment of genomic DNA will be performed using DNA methylation kit according to the manufacturer´ instructions. Bisulfite treatment of genomic DNA converts cytosine to uracil, but leaves methylated 5'Cytosines unchanged. Quantitative real time Polymerase chain reaction will be used to determine the DNA methylation status of the Brian derived neurotrophic factor and glia fibrillary acidic protein genes using primers specific to the human genes."
1475792|NCT03152838|Diagnostic Test|Gilliam Autism Rating Scale Arabic version|"An assessment of the severity of autism using the Gilliam autism rating scale Arabic version: This test was used for diagnosis and assessment of the severity of autistic features for ages 3-22 years. It consists of 56 items, subdivided into 4 subscales: communication, social interaction, stereotyped behaviors, development and total score. The Arabic version has been validated with good reliability and validity and used in many studies before. The lower the scores are, the worse the condition is.
The scale will be done by trained and certified psychologist. The protocol and informed consent for this study will be reviewed and approved by the ethics committee at the Faculty of Medicine, Assiut University, Egypt."
1475793|NCT03152825|Procedure|PCI|percutaneous coronary intervention attempt
1475794|NCT03152812|Procedure|plantar surface reconstruction by free flaps|use of free skin or free muscle flaps for reconstruction of plantar surface
1475795|NCT03152799|Procedure|RIPC Remote Ischaemic Pre-Conditioning|intermittent limb ischaemia via a peripheral blood pressure cuff inflation and deflation
1475796|NCT03152799|Other|Sham Control|intermittent peripheral blood pressure cuff inflation and deflation which does not induce a protective cellular response
1475797|NCT03152786|Other|Laboratory Biomarker Analysis|Correlative studies
1475798|NCT03152786|Drug|Propranolol Hydrochloride|Given PO
1475799|NCT03152786|Other|Questionnaire Administration|Ancillary studies
1475800|NCT03152786|Other|Survey Administration|Ancillary studies
1475802|NCT03152747|Device|ultrasound, b-scan|Some selected centres will participate in a substudy. In the substudy population, if the vitreous cortex is not visible on OCT both in the study eye and the fellow eye, or if the OCT is of poor quality and most likely will not allow definite diagnosis, a B-scan ophthalmic ultrasound will be performed by an experienced examiner. The presence or absence of a PVD in the ultrasound measurement will be recorded in the case report form (CRF). If ultrasonography was not performed, allocation to the groups is based on the staging of the reading centre. Otherwise ultrasonography will be used for final diagnosis and group allocation if the reading centre classifies the OCT as not decisive.
1475803|NCT03152734|Procedure|Surgical or non-surgical intervention|Each kind of surgical or non-surgical intervention with anesthesia applied by an anesthetist
1475804|NCT03152721|Device|Parkinson KinetiGraph|The Parkinson Kinetigraph (PKG) is a wrist-worn accelerometer shaped as a watch. It records spontaneous movements and for every two minutes provides a bradykinesia score and a dyskinesia score. Furthermore it analysis movement for tremor-like episodes and registers the time with tremulous movements as well as time with extreme immobility suggesting sleep. The device can be programmed with drug intake times and provide a reminder signal. Intake of drug can be indicated on the device.
1475805|NCT03152721|Other|Self assessment|Administration of self assessment questionnaires are made within 2 weeks from starting a PKG recording. The assessments are Parkinson Disease Quality of life 8 question short version and the Non Motor Symptom in Parkinson Disease Questionnaire.
1475806|NCT03152695|Device|High-intensity focused ultrasound|Local tumor ablation by ArcBlate (EpiSonica, Taiwan) will be performed, and the entire procedure will be monitored by MRI
1475807|NCT03152682|Dietary Supplement|GoodIdea|Active product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
1475808|NCT03152682|Other|Placebo|Non-active placebo product. Amount: 355mL. Consumed at a clinic visit over 14 minutes.
1475809|NCT03152643|Procedure|blastocyst-stage embryo transfer|To transfer embryos on blastocyst-stage Day 5
1475810|NCT03152643|Procedure|cleavage-stage embryo transfer|To transfer embryos on cleavage-stage Day 3
1475811|NCT03152591|Drug|LIK066|LIK066 tablets for oral administration
1475812|NCT03152591|Drug|Placebo|Placebo tablets matching LIK066 tablets, for oral administration
1475813|NCT03152578|Other|BetaC + Capsaicin Topical Cream|BetaC + Capsacin Topical Cream applied to painful knee area 3 times per day.
1475814|NCT03152578|Other|BetaC Topical Cream|BetaC Topical Cream Cream applied to painful knee area 3 times per day.
1475815|NCT03152578|Other|Placebo Topical Cream|Placebo Cream applied to painful knee area 3 times per day.
1475820|NCT03152539|Radiation|MRI|
1475821|NCT03152539|Device|EEG|
1475822|NCT03152539|Device|NIRS|
1475823|NCT03152526|Device|Interventions|CliniMACS® CD3 and CD19 Reagent System
1475824|NCT03152500|Device|FEMTIS 313G IOL|Haptic design that enclaves the capsulorrhexis
1475825|NCT03152500|Device|Acrysof SN60WF IOL|IOL in the bag
1475826|NCT03152487|Other|Celiac Plexus Neurolysis|This intervention involves accessing the Celiac Plexus Nerve via endoscopic guided ultrasound and then injecting the nerve bundle with bupivacaine.
1475827|NCT03152487|Other|Radiofrequency Ablation|Radiofrequency ablation is performed via the probe for 90 seconds, followed by a 90 second rest. This is repeated until the entire ganglion becomes hyperechoic on EUS.
1475828|NCT03152474|Drug|Solumedrol 20mg|Dosed Intravenous every 8 hrs.
1475829|NCT03152474|Drug|Vitamin A 100,000 IU|Dosed Intramuscular once daily
1475830|NCT03152474|Other|Placebo|Placebo dosed intravenous every 8 hrs. or Intramuscular once daily.
1475831|NCT03152461|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
1475832|NCT03152448|Behavioral|Prolaris|Series of three questionnaires to capture treatment decisions based upon standard clinical-pathological information with the addition of Prolaris genomic testing result
1475833|NCT03152435|Biological|EGFR CART|EGFR CART cells will be administered using a split dose on day0 (10%),1(30%), and 2(60%).
1475834|NCT03152422|Diagnostic Test|Urinary proteomics|Urinary proteomics for risk stratification and graft monitoring in recipients of a heart transplant
1475835|NCT03152409|Drug|Aspirin 325mg|Participants will take intervention drug dose once a day in combination with their existing antidepressant treatment regimen.
1475836|NCT03152409|Drug|Placebo Oral Tablet|Participants will take a placebo tablet of the same size, shape, and color as the aspirin tablet.
1475837|NCT03152396|Other|CV risk assessment and modification of global risk|Individualized CV risk assessment using the validated RxEACH CV risk calculator for baseline and subsequent risk assessment. Pharmacists will assist patient's to decrease CV risk over 6 months thru education, medication modification, and monthly follow-up.
1475838|NCT03152383|Behavioral|Training trials|"A highly preferred edible item will be selected to teach the contingencies for the assessment. Materials to engage in the work response (i.e., button press) will be placed within arm's reach of the child, and the edible item will be in sight. The therapist will deliver a vocal prompt for the child to engage in the work response (e.g., press the button and you can have some candy). If the child engages in the response, the therapist immediately delivers the edible item. The therapist will guide the child to engage in the instrumental response, and will then gradually begin to fade the prompt level. If the child makes an error at any level of prompting, the therapist will guide the participant to emit a correct response. The edible item will be delivered to the child each time that the child responds correctly at any prompt level."
1475839|NCT03152383|Behavioral|Progressive Ratio Session|The child will be guided to engage in the instrumental response then the stimulus will be immediately delivered for 30 seconds. The leisure item or the individual who will provide attention will be directly outside of the session room. If the child emits the work response, they will be allowed access to either a leisure item or to attention (depending on the condition) for 30 seconds. The child is initially required to respond one time, then they will be required to respond two times to gain access to the item or attention (then 4, then 8, and so on) such that the response requirement progressively increases according to a pre-determined schedule. A minimum of 3 sessions will be conducted for each condition. The amount of time required for participation depends on the child's responding, and caregiver availability. Participation may take as little as a couple hours, or as long as 3-4 hours per day for approximately one week.
1475840|NCT03152383|Behavioral|Re-test|10 children with ASD will return to repeat the progressive ratio (PR) assessment one week after completing it the first time to examine the reliability of the measure.
1475841|NCT03152383|Behavioral|Pairing Protocol|15 children with ASD will receive an intervention designed to increase social approach after completing the PR assessment. Participants will attend 2 hour appointments 3-5 days per week in which a therapist will deliver highly preferred items, play with the child, work on teaching communication skills, and teach the child to comply with demands. After completing the intervention (once the child is willingly staying near and interacting with the therapist and complying with instructions), the PR assessment will be repeated to measure change due to the intervention.
1475842|NCT03152370|Drug|E7046|oral administration
1475843|NCT03152370|Radiation|Long Course Chemoradiotherapy (LCRT)|pelvic radiotherapy
1475844|NCT03152370|Radiation|Short Course Radiotherapy (SCRT)|pelvic radiotherapy
1475845|NCT03152370|Drug|capecitabine|chemotherapy
1475846|NCT03152370|Drug|folinic acid/5-FU/oxaliplatin (mFOLFOX-6)|chemotherapy
1475847|NCT03152357|Device|ConforMIS iUni, iDuo, or iTotal (CR)|ConforMIS iUni, iDuo, or iTotal (CR)
1475915|NCT03151863|Drug|Placebo|Normal saline is either given subcutaneously or intranasally
1475848|NCT03152344|Procedure|Timed Up and Go|It's a functional test evaluating the time to rise from a chair, walk 3 meters, turn around, walk back to the chair and sit down (abnormal cut-off value >12 seconds).
1475849|NCT03152331|Behavioral|Receptive Awareness Training|Two 12-minute learning sessions will be conducted for each learning day. Separate instructions will be provided before session 1 and before session 2 to facilitate receptive awareness. The participant is seated in front of a BIS monitor and learns that the BIS number will decrease when in a state of receptive awareness. The trainee will learn to use attentional flexibility in daily activities and adopt willful attention (focal concentration) alternatively with receptive awareness (relaxed attention), as a situation dictates.
1475850|NCT03152318|Drug|rQNestin34.5v.2|Intratumor administration over 5 minutes, Indicated dose as per cohort, Single dose on day of surgery (day 0).
1475851|NCT03152318|Drug|Cyclophosphamide|Single dose 2 days (+/- 6 hrs) before administration of rQNestin34.5v.2
1475852|NCT03152318|Procedure|Stereotactic biopsy|In both arms, subjects will go to the intraoperative MRI operating room. The stereotactic needle will be placed stereotactically into the tumor bed using intraoperative MRI guidance
1475853|NCT03152305|Other|Intracranial pressure variations|Self-measure of ICP will be performed outside and during menstrual migraine attacks.
1475854|NCT03152292|Other|Real-world, non-interventional|N/A - non-interventional
1475855|NCT03152279|Diagnostic Test|Mucosal Impedance Catheter|During routine endoscopy, consented study participants will have a mucosal impedance catheter sensor positioned along the mucosal wall to measure resistance across the mucosa. The study procedure will add approximately 1-2 minutes of anesthesia time for each participant.
1475856|NCT03152279|Diagnostic Test|Blood sample|At time of endoscopy, subjects with initial positive CeD serology will have a blood sample taken for any missing CeD serologies and intestinal fatty acid-binding protein (IFABP). This will be done at time of IV initiation as to avoid any additional venipuncture.
1475857|NCT03152266|Other|No intervention. Observational study|Follow up of the function of the hip in after reduction of the impacted fragment which associated with acetabular fractures
1475858|NCT03152253|Behavioral|Text My Quit (TMQ)|Text messages designed to aid smoking cessation
1475859|NCT03152253|Behavioral|Peer Support|A group chat room for peer support
1475860|NCT03152253|Other|Motivational Messages|Generic motivational messages not related to smoking cessation
1475861|NCT03152240|Other|Non intervention|Non intervention
1475862|NCT03152227|Other|ACGG|50 high-producing chicks to households along with provision of technical input on production
1475863|NCT03152227|Behavioral|BCC|Nutrition sensitive BCC on poultry-specific aspects of nutrition, WASH, women's empowerment, and use of income combined with home gardening.
1475864|NCT03152214|Other|Vigorous Intensity Aerobic Exercise and Community Engagement|"Each veteran will be provided with an Apple watch for the duration of the study. Research staff will use the resultant data to monitor the veteran's activity level. Veterans will be asked to complete three 25-minute sessions of vigorous intensity aerobic exercise per week (either running, cycling, rowing, or elliptical workouts). Data collected will include the number of minutes exercised and the heartrate level (77-85% maximum heart rate). Any exercise session of 25 minutes at > 76% of maximum heart rate will be characterized as 1 completed session of vigorous-intensity exercise. Veterans will enter the activity, minutes exercised, average heartrate, and perceived exertion into REDCap.
Community engagement will involve attending at least one Team RWB event per week through the Austin or Killeen chapters. This could be a weekly running group, hike, or community service project-among other activities. Veterans will enter whether or not they attended a Team RWB event on REDCap."
1475865|NCT03152214|Other|Community Engagement|Veterans in the study will receive a monthly calendar of Team RWB events upon assignment. Veterans will be able to participate in any Team RWB event located in Austin or Killeen. Veterans will be asked to attend at least one Team RWB event. This could be a weekly running group, hike, or community service project- among other activities. Veterans will enter whether or not they attended a Team RWB event on the REDCap exercise adherence surveys.
1475866|NCT03152201|Diagnostic Test|electrophysiological signal|trasmit the electrophysiological signals to the neurosurgeon through the hardware
1475869|NCT03152175|Drug|Propranolol Hydrochloride|1mg / kg of propranolol hydrochloride, oral capsule
1475870|NCT03152175|Drug|Placebo|1mg / kg of matched placebo, oral capsule
1475871|NCT03152162|Device|iTotal PS KRS|Total knee arthroplasty for treatment of osteoarthritis
1475874|NCT03151044|Drug|High-dose Epirubicin Combined with CVP ± Rituximab|Experimental group shall be given high-dose Epirubicin (90mg/m2) combined with standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
1475875|NCT03151044|Drug|Standard-dose Epirubicin Combined with CVP ± Rituximab|Active comparator group shall be given standard-dose Epirubicin and standard-dose Cyclophosphamide (750mg/m2), Vincristine (1.4mg/m2) and Prednisolone (100mg/m2) ± Rituximab
1475876|NCT03151031|Procedure|Cryotherapy|The cooling procedure for the knee joint will be initiated by using a cryopack or cold-pack. On completion of the initial SEBT, the participant will lie supine and the investigator will apply the cryotherapy for 10 minutes. After the 10 minute period of cryotherapy, the cryopack will be removed, and the participants will perform SEBT for the second time.
1475877|NCT03151018|Device|Resolute Onyx|
1475878|NCT03151005|Drug|Metformin-GLP-1 Receptor Agonist|metformin oral with exenatide/liraglutide subcutaneous injection.
1475879|NCT03151005|Drug|Metformin-Oral Contraceptive(OC)|metformin with Diane 35 oral intake.
1475880|NCT03150992|Dietary Supplement|Elemental 028 Extra Liquid|A nutritionally complete, liquid elemental diet consisting of a mixture of essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and flavourings with sugars & sweeteners.
1475916|NCT03151850|Other|ulcerative colitis|We take 2 pieces of biopsies in the sigmoid colon mucosa inflammation area during the colonoscopy and then perform gene sequencing.
1475883|NCT03152123|Drug|Pitolisant|Pitolisant 40 mg or 240 mg (tablets over-capsuled)
1475884|NCT03152123|Drug|Placebos|tablets over-capsuled
1475885|NCT03152123|Drug|Phentermine|Phentermine 60 mg (capsule over-capsuled)
1475886|NCT03152110|Other|HIIT|"A handcycle or tabletop ergometer will be used for HIIT. Exercise sessions will be scheduled 3x/week for 6 weeks (2 sessions supervised, 1 session unsupervised). The HIIT goal is to achieve 10 sets of 60 second bouts of arm cycling at 90% of their PPO with 60 seconds of active recovery.
Supervised exercise sessions: Measures include HR, BP, RPEs, Feeling Scale, and PPO. After warming up, individualized work/rest phases will be prescribed based on their PPO from their maximal aerobic test. Participants will be held at 90% PPO as a constant target intensity to start, shortening the work phase, and if necessary, lengthening the recovery phase. These parameters will be progressed each session. The trainer will determine when to change their work/rest parameters based off of HR and RPEs.
Unsupervised exercise sessions: Participants will repeat the same HIIT protocol they performed during the previous supervised session. The bike computer automatically stores HR and PPO."
1475887|NCT03152097|Dietary Supplement|Commercially available Diindolylmethane|Commercially available Diindolylmethane is a compound derived from cruciferous vegetables (e.g. broccoli)
1475888|NCT03152097|Other|Placebo|A matching placebo capsule will be compounded by the UPMC Investigational Drug Service
1475892|NCT03152058|Drug|Certolizumab Pegol|"Certolizumab [400 mg (given as two subcutaneous injections of 200mg) initially and 2 and 4 weeks later, followed by 200 mg every other week thereafter] The 1st dose of certolizumab will be administered by 8 weeks and 6 days gestation and discontinued at 27 weeks 6 days.
The regimen of heparin and low dose aspirin is a standard of care treatment for this patient population and is not considered part of the research intervention."
1475898|NCT03151993|Drug|Recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
1475899|NCT03151993|Drug|Alteplase|Intravenous alteplase 0.9 mg/kg (10% bolus and 90% as IV infusion over 1 hour, maximum 90 mg)
1475900|NCT03151980|Procedure|Hamam treated skin and sun exposure|Hamam is a skin treatment (soaping and scrubbing).
1475901|NCT03151980|Other|Untreated skin and sun exposure|Skin that will not receive Hamam.
1475902|NCT03151967|Drug|Lactobacillus crispatus CTV-05|vaginal applicator with medium containing drug
1475903|NCT03151967|Drug|Placebo|vaginal applicator with medium containing no drug
1475904|NCT03151954|Procedure|functional endonasal sinus surgery|collect nasal polyps from patients
1475905|NCT03151954|Procedure|nasal septal construction|collect inferior turbinates from patients as control arm
1475906|NCT03151928|Diagnostic Test|BDMax Vaginal Panel|The tests will be used to compare results between clinician diagnosis/routine care testing and the above interventions
1475907|NCT03151889|Device|TENS|TENS Group: Pre-test evaluations (Clinic Conditions; Live Quality; Salivary Flux); TENS treatments (50Hz / pulse duration of 250 ms / high intensities tolerated / continuously for 20 minutes / 2 sessions a week / 4 weeks / total of the 8 TENS sessions) and Post-test evaluations.
1475908|NCT03151876|Drug|Chidamide|30 mg oral twice weekly for 2 weeks
1475909|NCT03151876|Drug|Cladribine|6 mg/m2 intravenously daily for 5 days
1475910|NCT03151876|Drug|gemcitabine|2500 mg/m2 intravenously twice weekly for 1 week
1475911|NCT03151876|Drug|Busulfan|3.2 mg/kg intravenously daily for 4 days
1475912|NCT03151876|Procedure|Autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cells infusion after ChiCGB chemotherapy
1475913|NCT03151863|Drug|Opioids|The usual opioid treatment used for nursing care
1997626|NCT01992718|Procedure|Evaluation of MRI, US for pelvic and uterine conditions|"Pelvic ultrasound with transabdominal and transvaginal imaging. The transvaginal ultrasound will include elastography (TVUS-E). Also, a pelvic MRI will be performed if not done in the last 6 months. The MRI is performed with IV gadolinium-based contrast (MultiHance ®).
A patient survey will be included."
1475917|NCT03151850|Other|Control|We take 2 pieces of biopsies in the sigmoid colon mucosa during the colonoscopy and then perform gene sequencing.
1475918|NCT03151837|Dietary Supplement|Greenyn Momordica charantia extracts|Extracts from Momordica charantia containing Momordica charantia insulin receptor binding protein (mcIRBP)
1475919|NCT03151837|Dietary Supplement|Placebo control|Starch
1475920|NCT03151824|Other|quality of life|Quality of life which was measured by the Korean version of the 36-item short-form health survey (SF-36)
1475924|NCT03151798|Behavioral|Phase II: Lifestyle treatment|Subjects will undergo energy restriction and exercise training over a 9 month period.
1475925|NCT03151798|Behavioral|Phase II: Control treatment|Subjects will receive dietary advice and receive information on a stretching program.
1475926|NCT03151798|Other|Phase I: Observational studies|The liver samples from patients undergoing bariatric surgery or a diagnostic liver biopsy will undergo in vitro assays to determine the capacity of the tissue to burn fat
1475927|NCT03151785|Other|Face-to-face BLS training|Pupils will receive CPR training by standardised face-to-face BLS training only
1475928|NCT03151785|Other|Lifesaver training|Pupils will receive CPR training by Lifesaver programme only
1475929|NCT03151785|Other|Lifesaver and Face-to-Face BLS training|Pupils will receive CPR training by Lifesaver and standardised face-to-face BLS training
1475930|NCT03151772|Drug|Disulfiram|200 mg disulfiram two times daily and 2,5 mg copper once daily taken preoperatively
1475931|NCT03151772|Drug|Metformin|Metformin 850 mg x 3 taken preoperatively
1475932|NCT03151759|Radiation|Neoadjuvant radiotherapy|Neoadjuvant radiotherapy prior to rectal cancer surgery
1475933|NCT03151746|Drug|Placebo|Placebo pill administered orally 1 hour before planned surgical procedure
1475934|NCT03151746|Drug|Gabapentin|Gabapentin pill (1200mg) administered orally 1 hour before planned surgical procedure
1475935|NCT03151733|Procedure|single incision laparoscopic surgery|Patients undergo single incision laparoscopic surgery
1475936|NCT03151733|Procedure|conventional laparoscopic surgery|Patients undergo conventional laparoscopic surgery
1475937|NCT03151720|Drug|loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
1475938|NCT03151720|Drug|loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
1475939|NCT03151707|Drug|Nicotinamide Riboside|Nicotinamide riboside 1000 mg/day
1475940|NCT03151681|Drug|Propranolol Pill|1mg/kg of propranolol 60 minutes prior to memory reactivation
1475941|NCT03151668|Drug|Dexmedetomidine|
1475942|NCT03151655|Behavioral|MATTeRS Video|Narrative-based video intervention and accompanying workbook
1475943|NCT03151655|Behavioral|Didactic Video|Education only video
1475944|NCT03151642|Radiation|Chemotherapy|Patients will have their chemotherapy coordinated through the Medical Oncology department at the University of Pennsylvania, and will be followed by Medical Oncology at Penn during chemoradiation. As part of the standard of care for locally advanced esophageal cancer, neoadjuvant concurrent chemotherapy will likely consist of weekly carboplatin and paclitaxel, beginning within 1 day of starting radiation therapy and continuing until the completion of radiation treatment. Alternative chemotherapy regimens, dose adjustments or delays in administration will be determined at the discretion of the treating medical oncologist and recorded in the patient's chart.
1475945|NCT03151642|Radiation|Radiation Therapy|Patients will have their radiation therapy coordinated and performed through the Radiation Oncology Department at the University of Pennsylvania. The development and delivery of the patient's radiation treatment plan will be at the discretion of the treating radiation oncologist, and details will be recorded in the patient's chart.
1475946|NCT03151642|Procedure|Surgery|Patients will have their surgery coordinated and performed through Thoracic Surgery department at the University of Pennsylvania. Patients will undergo esophagectomy 4-8 weeks after the completion of neoadjuvant chemoradiation as part of the standard of care.
1475947|NCT03151642|Device|MRI Imaging|A total of 40 paired MRI examinations from eligible participants will be collected in the Department of Radiology at the Hospital of the University of Pennsylvania. Participants will undergo two 1.5T MRI studies performed at two time points: (1) within 28 days prior to starting neoadjuvant chemoradiation, and (2) between radiation fraction 8-13 during treatment. The quantitative imaging studies for the trial (DWI) will be performed with and without respiratory gating using a navigator, with B values of 0, 100, 600 and 800 s/mm2.
1475948|NCT03151642|Other|Blood Draws|The procedure of blood collection for each patient will be as follows: the total amount being drawn each time will be approximately 30 cc. Approximately 25 ml of blood will be collected into heparinized tubes, and immediately placed on ice in a prepared plastic bag and transported to the laboratory for processing within 1 hour. If necessary, we may need up to 2 hours in order to begin processing the blood; in the event that longer than this time period has transpired, the sample will be deemed inadequate for processing purposes. The first blood draw will be obtained prior to the first fraction of radiation treatment and will be coordinated to occur at the time of pre-treatment MRI. Thereafter, the second sample will be obtained during chemoradiation therapy, between fraction 8-13 and the blood draw will be coordinated with the on-treatment MRI scan.
1475949|NCT03151629|Other|Standard of Care|Drugs routinely administered for metastatic prostate cancer per local standard.
1475950|NCT03151616|Other|anticholinergic risk scale|Risk summation scale for grading and studying anticholinergic medication exposure
1475951|NCT03151603|Drug|Arctuvan|application of a herbal drug
1475952|NCT03151603|Drug|Fosfomycin|application of an antibiotic drug
1475953|NCT03151603|Drug|Placebo to Arctuvan|application of Placebo to Arctuvan
1475954|NCT03151603|Drug|Placebo to Fosfomycin|application of Placebo to Fosfomycin
1475955|NCT03151590|Behavioral|exercise training|
1475956|NCT03151577|Procedure|XEN® Gel Stent implantation|Minimally invasive glaucoma surgery (MIGS) which consists of implanting a XEN® Gel Stent in the irido-corneal angle of the eye to drain the aqueous humour in the sub-conjunctival space to lower the IOP.
1476030|NCT03150940|Diagnostic Test|bedside cardiac ultrasound|bedside cardiac ultrasound to see 2D images of each participants heart. Without the use of radiation.
1475957|NCT03151564|Diagnostic Test|Computed Tomography Scan - 50% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 50% dose reduction.
1475958|NCT03151564|Diagnostic Test|Computed Tomography Scan - 70% Dose Reduction|Participants undergo routine standard of care CT examination for colon carcinoma restaging, then have an additional scan of the liver at 70% dose reduction.
1475961|NCT03151538|Behavioral|Exercise Training Mixed With Play|To assess effects of training program which includes mixed exercises with playing.Study included 90 pre-school children who suffer from pes planus and increased femoral anteversion angle. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak Index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used. CSI measurements were positive correlation with severity of pes planus.
1475962|NCT03151538|Other|Controlled|First and last measurements will be done. There will be no intervention. Study will include 30 healthy pre-school children. Demographic data, navicular height, weight-bearing and non-weight bearing of subtalar joint motion, metatarsal width(weight and non-weight), range of hallux valgus,height of foot, tension of Achilles tendon, habits of W standing(hour/day), angle of Quadriceps(Q degree), angle of hip rotation were recorded . Craig Test, foot posture index, Chippaux-Smirak index(CSI),Beighton hypermobility score, valgus index, thigh foot angle examination were used.
1475963|NCT03151525|Drug|Azathioprine|AZA treatment after IFX withdrawal for maintenance of remission
1475964|NCT03151525|Drug|Infliximab|IFX treatment for maintenance of remission
1475965|NCT03151499|Drug|BI 409306|Reference and Test Treatment
1475966|NCT03151499|Drug|Rifampicin|Test Treatment
1475967|NCT03151486|Drug|JNJ-55308942 0.5 mg|Participants will receive JNJ-55308942 0.5 mg as an oral solution after an overnight fast on Day 1.
1475968|NCT03151486|Drug|JNJ-55308942 1.5 mg|Participants will receive JNJ-55308942 1.5 mg as an oral solution after an overnight fast on Day 1.
1475969|NCT03151486|Drug|JNJ-55308942 4 mg|Participants will receive JNJ-55308942 4 mg as an oral solution after an overnight fast on Day 1.
1475970|NCT03151486|Drug|JNJ-55308942 12 mg|Participants will receive JNJ-55308942 12 mg as an oral solution after an overnight fast on Day 1.
1475971|NCT03151486|Drug|JNJ-55308942 36 mg|Participants will receive JNJ-55308942 36 mg as an oral solution after an overnight fast on Day 1.
1475972|NCT03151486|Drug|JNJ-55308942 100 mg|Participants will receive a single oral dose of JNJ-55308942 100 mg as an oral solution after an overnight fast on Day 1.
1475973|NCT03151486|Drug|JNJ-55308942: Fed State|Participants will receive JNJ-55308942 as an oral solution in fed state on Day 1. The dose selected for this cohort will be based on the data obtained from the single ascending dose cohorts.
1475974|NCT03151486|Drug|JNJ-55308942: MAD Part|Participants will receive JNJ-55308942 once daily as an oral solution for 10 consecutive days (Day 1 to 10). The doses for the MAD will be determined based on the data from the SAD part.
1475975|NCT03151486|Drug|Placebo|Participants will receive matching placebo in all cohorts.
1475976|NCT03151460|Drug|Dopamine Agent|"Patients were assessed in two experimental conditions that were performed on different days, with an intersession interval of about one month. In the off condition PD subjects performed the experimental tasks in the morning after 12/18 hours of Dopamine Agent withdrawal. In the on condition they were examined 90-120 minutes after they had taken their first morning dose of levodopa and/or dopamine agonists."
1475977|NCT03151447|Radiation|stereotactic body radiation therapy|"In patients with metastatic triple negative breast cancer, stereotactic body radiation therapy will be combined with anti-PD-1 antibody.
Stereotactic body radiation therapy: SBRT is delivered to 1~5 measurable metastatic lesions of liver, lung, bone, brain or lymph nodes in limited fractions .
Anti-PD-1 treatment: anti-PD-1 antibody (JS001) is injected intravenously 120mg or 240mg or 360mg every two weeks."
1475978|NCT03151434|Procedure|US Guided Single Shot Paravertebral Block|Single shot paravertebral block will be placed under ultrasound guidance at the thoracic region prior to surgery.
1475979|NCT03151434|Procedure|US Guided Paravertebral Catheter|Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.
1475980|NCT03151434|Procedure|Thoracic Epidural|Epidural catheter will be placed in the thoracic region prior to surgery.
1475981|NCT03151421|Behavioral|Home air quality monitoring and feedback|Two-hundred smokers (50 in each country) will be recruited and offered low-cost, simple to operate particle counting instruments to measure and log SHS levels in their home for a period of 30 days. During this time near real-time, personalised feedback will be provided to, and discussed with, the smoker along with target-setting and exploration of suitable methods of behaviour-change. Feedback will be given via text message to mobile phones, emails and personal voicecalls. A final visit will gather data on changes made while a proportion of participants (10-20%) in each country will take part in a further qualitative interview by phone to gather data on their experience of the intervention.
1475986|NCT03151382|Drug|Tandospirone Citrate|Tandospirone, 30-60 mg/d
1475987|NCT03151382|Drug|Donepezil Hydrochloride|Donepezil, 10 mg/d
1475988|NCT03151369|Drug|Morphine|patients with the visual analog scale over 3 will receive morphine
1475989|NCT03151356|Device|Measurement of Prostate Health Index (PHI)|Use of a diagnostic tool to predict prostate biopsy outcome: measurement of total and free PSA as well as the [-2]proPSA and calculation of The Prostate Health Index according to the following formula: Prostate Health Index (PHI) = [p2PSA /fPSA] x √tPSA
1475990|NCT03151343|Drug|Empagliflozin|Empagliflozin tablet
1475991|NCT03151343|Drug|Placebo Oral Tablet|Sugar pill, visually identical to active comparator
1476113|NCT03150511|Drug|Tesamorelin 2 Milligrams (MG)|Daily self-administered study drug
1476114|NCT03150511|Drug|Placebo|Daily self-administered placebo
1475992|NCT03151330|Other|Screened Arm|Woman who are identified as high risk will be advised of potential interventions which will include support through care link(nurse education), cervical surveillance, consider vaginal progesterone, low dose aspirin if not already taking.
1997627|NCT01992718|Procedure|Patient preference between MRI and Ultrasound|"Subjects may take part in this arm because they have recently had a MRI performed and scheduled for, or have recently undergone a pelvic ultrasound.
Subjects will also be asked to complete a survey that will state their preference with regards to examination/imaging. This will be done over the phone and will take no longer than 30 minutes to complete."
1997628|NCT01992042|Drug|Fluvastatin|HMG-CoA reductase inhibitors that lowers cholesterol levels. 40mg twice daily
1475996|NCT03151291|Dietary Supplement|β-hydroxy-β-methylbutyrate (HMB)|daily intake of 3 g HMB
1475997|NCT03151291|Dietary Supplement|L-carnitine (LC)|daily intake of 4 g LC
1475998|NCT03151291|Dietary Supplement|Eicosapentaenoic acid (EPA)|daily intake of 2.2 g EPA
1475999|NCT03151291|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
1476000|NCT03151278|Procedure|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of one kind of three-dimensional navigation system and without fluoroscopic guidance.
1476001|NCT03151278|Procedure|Conventional fluoroscopy ablation|Catheter ablation will be performed using fluoroscopy plus one kind of three-dimensional navigation system.
1476002|NCT03151265|Device|ThermaCare Low Back Heat Wrap|The ThermaCare Low Back Heat Wrap, is a continuous, low-level, direct heat therapy. It comes in the form of a heat-pack that is strapped to the low back. Heat is provided for approximately 8-hours.
1476003|NCT03151252|Diagnostic Test|Cytobrush|During the endoscopic Investigation the mucosa cells were collected by brushing the colon via cytobrush.
1476004|NCT03151239|Dietary Supplement|NMN supplement|Intervention will last 8 weeks in the form of two capsules (250 mg total).
1476005|NCT03151239|Other|Placebo|Intervention will last 8 weeks in the form of two capsules.
1476006|NCT03151226|Device|Capnography monitoring|capnography and pulse oximetry will be initiated in the recovery room and worn for 12-24 hours post delivery
1476007|NCT03151213|Drug|Pregabalin 150mg|Pregabalin 150mg before RFA of liver cancer
1476008|NCT03151213|Other|Placebo|Placebo before RFA of liver cancer
1476009|NCT03151200|Device|Computer based binocular treatment|Binocular amblyopia treatment involves presenting stimuli over a computer screen to the amblyopic eye those are at higher contrast compared to the stimuli that are presented to the good eye, which balances the performances of the two eyes and over time improves the amblyopic eye vision.
1476010|NCT03151200|Device|Transcranial magnetic stimulation|TMS is a non-invasive research method that generates electrical current at the cortex that can excite neuronal activities and neuronal plasticity.
1476011|NCT03151187|Other|Teaching intervention|Two two hour teaching modules on the diagnosis and treatment of disruptive behaviour disorders in children and youth
1476012|NCT03151174|Drug|Vitamin D 10000 UNT|10000 IU Vitamin D per day
1476013|NCT03151174|Drug|Vitamin D 5000 UNT|5000 IU Vitamin D per day
1476016|NCT03151148|Biological|TMT Lotion|TMT product and Vegetable glycerin-Cetaphil®
1476017|NCT03151148|Drug|Placebo Lotion|Cetaphil® moisturizing lotion and vegetable glycerin
1476018|NCT03151122|Behavioral|Nurse-led Continuous Support|"The Nurse-Led Continuous Support was provided by a integrative care team. In-hospital support included(1) Promoting early parental-infant interaction;(2) Instruct the mother and/or father to use sensory stimulation activities to promote infant neuro-development in the NICU;(3) Parental educational support. The integrative care team will teach infant care skills, prepare them for successful transition from hospital to home setting.
After infant discharge support will consist of regular home visits by the nurses. Home visits will be offered every other week until children reaching 3 Months of corrected age."
1476019|NCT03151122|Procedure|routine follow-up care|after infant discharge, parents were usually called upon to remind the date and time of follow-up care with physicians in outpatient department. A contact number was also given to parents in case they have questions about follow-up care.
1476020|NCT03151109|Diagnostic Test|CT Scan|CT scan at minimum 1 year post op
1476021|NCT03151096|Dietary Supplement|Riboflavin|one pill of Riboflavin will be taken orally with water
1476022|NCT03151096|Dietary Supplement|Placebo|one pill of placebo will be taken orally with water
1476023|NCT03151083|Behavioral|Internet-based Self-help Insomnia Intervention|The investigators will use the program, SHUTiTM for the treatment of insomnia. The intervention is a CBT-based 6-week, self-administered course accessed via the Internet on mobile, desk-top, and other devices. The program is split into six modules, completed weekly, which include instruction on psycho-education, stimulus control, relaxation training, sleep restriction, medication tapering, and addressing cognitive distortions. The content is delivered via text, video vignettes, case histories, interactive learning tools, interactive skills assessments, symptom assessments, and a sleep log. Homework is assigned after each module. Providers and support staff can follow treatment progress via access to a dashboard of patient information collected by the program. Such information includes progress through the modules, date of last engagement, symptom assessment outcomes, and sleep log data abstracted into commonly used sleep indices such as sleep onset latency and sleep efficiency.
1476024|NCT03151070|Other|QVLM Intervention package|"QVLM intervention package consists of 3 simultaneous interventions:
Social marketing to promote insitutional deliveries.
PRONTO training to public health personnel
Improve interaction with traditional birth attendants"
1476025|NCT03151057|Drug|Idelalisib 100 MG|100mg BID beginning on day 30 and continuing until day 180 post transplant.
1476028|NCT03150953|Device|MRI-safe bore covering|
1476029|NCT03150940|Diagnostic Test|ECG|12 lead electrocardiogram used to demonstrate cardiac function
1476031|NCT03150927|Dietary Supplement|Probiotic Microbial Composite|125mg (or 250 mg) of BiOWiSH Probiotic Microbial Composite™ is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
1476032|NCT03150927|Dietary Supplement|Placebo|125mg (or 250 mg) of Placebo is to be dosed once daily. Product will be supplied in capsule form to be administered orally. Each subject will be given a 15-day supply (30 capsules) to take with them after their initial visit. Capsules will be administered every 15 days by primary investigators at follow up visits.
1476033|NCT03150914|Drug|Sirolimus|mTOR inhibitor or placebo
1476034|NCT03150901|Diagnostic Test|no drug|laboratory tests
1476035|NCT03150888|Drug|Antihypertensive Agents|Single or combination therapy with five type of antihypertensive agents, such as Ca channel blockers, ACE inhibitors, ARBs, diuretics, or beta-blockers.
1476036|NCT03150888|Other|Cardiovascular risk factors|Different level of cardiovascular risk factors associated with genetics, environments and lifestyles.
1476037|NCT03150875|Biological|IBI308|Anti-PD-1 therapy in Chinese non-squamous NSCLC patients will be investigated in this clinical trial.
1476038|NCT03150875|Drug|Docetaxel|As 2nd line treatment to subjects with non-squamous NSCLC
2010534|NCT02941770|Behavioral|Physical activity behavior change|Physical activity consultation will consist in a patient-centered, one-to-one session based on the transtheoretical model and will use motivational interview in order to strengthen individual's intrinsic motivation to achieve a positive PA behavior change. In these sessions the following topics will be explored: (i) explore and resolve ambivalence; (ii) identify difficulties/barriers, and benefits of behavior change; (iii) find their own means and their own solutions for step over the identified barriers; (iv) enhancement of autonomy and self-efficacy.
1476042|NCT03150849|Diagnostic Test|C-X-C Chemokine Receptor 4|marker assessed by flowcytometry in a blood sample
1476046|NCT03150823|Procedure|Upward Direct Current (Ascending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the ascending stream direct current (Ascending effect) the proximal cathode and distal anode are placed, a excitatory effect on the nervous system being described in theory.
1476047|NCT03150823|Procedure|Downward Direct Current (Descending Effect)|Application of direct current (Galvanic) in milliamperes current which varies according to the positioning of the electrodes. In the descending stream direct current (Descending effect) the proximal anode and distal cathode are placed, a sedative and analgesic effect on the nervous system being described in theory.
1476048|NCT03150823|Procedure|Sham Direct Current|Installation of electrotherapy equipment off (Sham tratment).
1476053|NCT03150797|Drug|Melatonin|Melatonin
1476054|NCT03150797|Drug|Placebo oral capsule|Placebo
1476055|NCT03150784|Other|EPIC Club|Weekly exercise gym sessions. Participants will start with a warm-up of 20-25 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. In addition to the above, a novel rhythmical stepping task will be performed over 10 mins.
1476056|NCT03150771|Drug|Aripiprazole|Injection
1476057|NCT03150758|Device|10Hz + 100 micro-seconds|10Hz Electrical Stimulation with a pulse width of 100 micro-seconds
1476058|NCT03150758|Device|10Hz + 200 micro-seconds|10Hz Electrical Stimulation with a pulse width of 200 micro-seconds
1476059|NCT03150758|Device|7Hz + 100 micro-seconds|7Hz Electrical Stimulation with a pulse width of 100 micro-seconds
1476060|NCT03150758|Device|7Hz + 200 micro-seconds|7Hz Electrical Stimulation with a pulse width of 200 micro-seconds
1476061|NCT03150745|Procedure|3- Cervical Pap smears|Cervical Pap smears will be obtained using the long tip of an Ayre's spatula that will be placed in the endocervical canal with the proximal bulge resting on the ectocervix. The spatula will be carefully rotated around the cervix so that a representative sample of the whole cervix will be obtained. An additional endocervical sample will be obtained by placing a cytobrush or by the other end of the Ayer's spatula in the endocervical canal and gently rotated through 360 degrees as previously described. The samples will be then immediately plated on a slide, fixed by immersing the slide in 95% ethyl alcohol fixative for 15 to 20 minutes and stained by modified Papanicolaou stain using a hand staining procedure
1476062|NCT03150745|Procedure|Colposcopic examination|"0.9% saline technique to assess the cervical lesion and vasculature of the cervix, 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment using (Bossman forceps or endocervical speculum or counter pressure with Q stick).
e- Biopsy using the punch biopsy forceps. Biopsy will be obtained from every abnormal colposcopic examination"
1476063|NCT03150745|Procedure|Office hysteroscopy|0.9% saline technique to assess the cervical lesion and vasculature of the cervix. 5% acetic acid technique to determine acetowhite-positive areas. Schiller's iodine technique to visualize high glycogen containing cells. Endocervical canal assessment. Endometrial cavity evaluation whenever possible. Biopsy. Biopsy will be obtained from every abnormal hysteroscopic examination.
1476064|NCT03150732|Drug|Systemic nalbuphine|Patients will receive systemic nalbuphine 10 mg
1476065|NCT03150732|Drug|Local nalbuphine|Patients will receive local nalbuphine 10 mg
1476251|NCT03149432|Procedure|Rehabilitation|Daily care with physiotherapist ; orthoprosthetists , and specialized sports educators ; if necessary : occupational therapy.
1476070|NCT03150706|Drug|Avelumab|"Patients will receive 10 mg/kg of avelumab via intravenous infusion every 2 weeks.
Response evaluation will be performed every 6 weeks (± 1-week window period). Treatment will be continued until disease progression, unacceptable adverse events or the patient's refusal.
Treatment through progression is at the investigator's discretion, and the investigator should ensure that patients do not have any significant, unacceptable, or irreversible toxicity that indicate that continuing treatment will not further benefit the patient. The Investigator should ensure that patients still meet all of the inclusion criteria and none of the exclusion criteria for this study."
1476071|NCT03150693|Drug|Allopurinol|Given PO
1476072|NCT03150693|Drug|Cytarabine|Given IT, IV, SC
1476073|NCT03150693|Drug|Daunorubicin Hydrochloride|Given IV
1476074|NCT03150693|Drug|Vincristine Sulfate|Given IV
1476075|NCT03150693|Drug|Dexamethasone|Given PO or IV
1476076|NCT03150693|Drug|Pegylated Recombinant L-Asparaginase Erwinia Chrysanthemi|Given IV
1476077|NCT03150693|Drug|Methotrexate|Given IT, IV, PO
1476078|NCT03150693|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
1476079|NCT03150693|Drug|Cyclophosphamide|Given IV
1476080|NCT03150693|Drug|Mercaptopurine|Given PO
1476081|NCT03150693|Biological|Rituximab|Given IV
1476082|NCT03150693|Drug|Doxorubicin|Given IV
1476083|NCT03150693|Drug|Thioguanine|Given PO
1476084|NCT03150693|Biological|Inotuzumab Ozogamicin|Given IV
1476085|NCT03150693|Other|Laboratory Biomarker Analysis|Correlative studies
1476086|NCT03150680|Genetic|SNPs associated with CAD, SNPs associated with pharmacological response to clopidogrel and statins|Genotyping will be carried out by Next-Generation Sequencing (NGS)
1476087|NCT03150667|Drug|Ticagrelor|Ticagrelor in patients with CKD presenting with ACS.
1476088|NCT03150667|Drug|Clopidogrel|Clopidogrel in patients with CKD presenting with ACS.
1476089|NCT03150654|Device|Laser pan-retinal photocoagulation|Green laser photocoagulator
1476090|NCT03150641|Procedure|Umbilical cord clamping|The umbilical cord will be clamped and cut after delivery, with timing as specified in each arm
1476094|NCT03150615|Other|Early enteral nutrition|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament. Standard enteral diet, administered through a nasojejunal tube, is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
After PD, enteral nutrition liquid regimen will be used step by step from postoperative day 1 to postoperative day 7.Patients are targeted to receive calories for 25 kcal/kg/day. Meanwhile, oral food intake was not restricted."
1476095|NCT03150615|Other|Saline|"Naso-jejunal tube will be placed intraoperatively. The distal end of the feeding tube would be placed at 30 cm distal to Treitz ligament.
After PPPD,Only Normal Saline were given through nasojejunal tube. Entral nutrition was not administrated. Patients intake food orally at will."
1476096|NCT03150615|Device|nasojejunal tube insertion|
1476097|NCT03150615|Other|Oral intake|Patients was encouraged to drink water on postoperative day 1, to eat liquid diet on postoperative day 2, to eat semi-solid on postoperative day 3, to eat solid food on postoperative day 4.
1476098|NCT03150602|Drug|Pralatrexate|This is a single arm study. Pralatrexate will be administered via IV over 3-5 minutes into a IV line containing normal saline (0.9% sodium chloride, NaCl) with the initial dose of 30 mg/m2/week on days 1, 8, 15, 22, 29, and 36 for 6 weeks in a 7-week cycle. The scheduled date can be done within a window time of plus or minus 1 day. The pralatrexate dose may be reduced to 20 mg/m2/week or omit if a patient experiences adverse events. Pralatrexate administration can be up to 5 cycles or until subject meets withdrawal criteria.
1997629|NCT01992042|Drug|Pimonidazole|
1997630|NCT01990404|Drug|Premixed 50% nitrous oxide and oxygen|Premixed 50% nitrous oxide and oxygen is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B.
1476101|NCT03150576|Drug|Olaparib|Patients will self-administer Olaparib by mouth. Olaparib tablets should be taken twice daily at the same time each day approximately 12 hours apart.
1476102|NCT03150576|Drug|Paclitaxel and Carboplatin|Paclitaxel I.V. 80mg/m2 in 0.9% sodium chloride 500ml or according to local practice, will be given over 60 minutes on days 1, 8 & 15, every 3 weeks for 4 cycles. Carboplatin I.V. AUC5 in 5% dextrose 500ml or according to local practice, over 30-60minutes on day 1 every 3 weeks for 4 cycles.
1476103|NCT03150563|Other|Passive static stretch|Each experimental group will be submitted to 10 (ten) sessions, with three (3) weekly sessions of static passive stretching, with a 48 h interval between them. Each session will be performed 3 (three) maneuvers containing a duration of 30 seconds, this being the same rest time, performed in all experimental groups.
1476104|NCT03150550|Behavioral|Mindfulness practice|Mindfulness interventions are behavioral cognitive psychotherapies which allow patient to identify, pay attention and accept external (sensory stimuli) and internal (cognition and emotions) phenomena.
1476105|NCT03150550|Behavioral|Relapse prevention|It's a conventional relapse prevention program which allow to measure the alcoholic relapse in the first glass consumed.
1476106|NCT03150537|Biological|Fluviral influenza vaccine|Influenza vaccine (Fluviral) given via Med-Jet or IM injection
1476107|NCT03150524|Diagnostic Test|TCD- cerebral blood flow velocities|Participants will undergo daily TCD for monitoring of cerebral blood flow.
1476108|NCT03150524|Behavioral|Headache pain score|Participants will be evaluated by nurses for headache frequency and severity every shift.
1476109|NCT03150524|Other|Neurological examination|Patients will be examined routinely for evidence of neurological improvement/decline and/or evidence of a complication such as stroke or hemorrhage.
1476110|NCT03150524|Diagnostic Test|Repeat Neuroimaging|All patients will also be seen at 90 days (+/- 30 days) and administered a headache diary, repeat neuroimaging, and neurological examination.
1476111|NCT03150524|Drug|Nimodipine|Participants will be administered nimodipine every 4 hours.
1476112|NCT03150524|Drug|Verapamil ER|Participants will be administered long acting verapamil every 12 hours.
1997631|NCT01990404|Drug|Medical Air|Medical air is a gas in cylinder of 5 litres delivered by a face mask. The gases of the study are contained in anonymous bottles of the same capacity. Bottles will only be differentiated by a letter: A or B
1476116|NCT03150472|Device|Graft Matrix|Both Graft matrix products are supplied sterile, for single use only and packed in vials or a syringe-like applicator. All products consist of the same bone graft particles with the only variants being due to different amounts per package or different containers.
1476117|NCT03150459|Drug|Simvastatin 20 mg|Simvastatin 20 mg/day for 12 weeks (Group 1)
1476118|NCT03150459|Drug|Simvastatin 40mg|Simvastatin 40 mg/day for 12 weeks (Group 2)
1476119|NCT03150459|Drug|Rifaximin 400 mg|Rifaximin 400 mg/8 hours for 12 weeks (Group 1 and 2)
1476120|NCT03150459|Other|Placebo of Simvastatin|Placebo of Simvastatin for 12 weeks (Group 3)
1476121|NCT03150459|Other|Placebo of Rifaximin|Placebo of Rifaximin for 12 weeks (Group 3)
1476122|NCT03150446|Device|flexible cystoscopy|After intracorporeal insertion of the double-J catheter, additional endoscopic monitoring with flexible cystoscopy was performed. The surgeon manipulating the double-J catheter used monitor A, while an assistant inserted a flexible cystoscope into the bladder through the urethral route and determined whether the double-J stent was correctly placed in the bladder using monitor B before suturing the site of ureterotomy. If the stent was well-placed, the flexible cystoscope was withdrawn. If the double-J stent was not visualized in the bladder, the surgeon pushed the stent inferiorly using a laparoscopic instrument and monitor A until the stent came out through the ureteral orifice on monitor B.
1476123|NCT03150433|Behavioral|Behavioral symptom management|Individual sessions focused on behavioral and cognitive strategies for managing sleep disturbance, pain, and other symptoms of sickle cell disease
1476124|NCT03150433|Other|Sickle cell disease management|Individual sessions focused on understanding and managing sickle cell disease
1476125|NCT03150420|Drug|Sodium Thiosulfate|Intravenous Sodium Thiosulfate Injection (25 grams sodium thiosulfate) to be administered each hemodialysis session (3 times weekly) for 3 weeks
1476126|NCT03150420|Drug|Placebo-Normal Saline|Placebo: to be administered each hemodialysis session (3 times weekly) for 3 weeks
1476127|NCT03150394|Dietary Supplement|GASTRUS|Gastrus will be given from the first day of eradication treatment to completion after 30 days of treatment
1476128|NCT03150394|Other|PLACEBO|Placebo will be given from the first day of eradication treatment to completion after 30 days of treatment
1476129|NCT03150381|Behavioral|Weight Loss Only|24- month weight loss program (year 1: weekly in person meetings for 6 months, followed by 2 meetings per month for 3 months, then monthly for 3 months; year 2: monthly phone calls)
1476130|NCT03150381|Behavioral|Weight Loss Plus|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
1476131|NCT03150381|Behavioral|Control|Participants receive quarterly newsletters containing generic cancer prevention messages and participate in community-wide cancer awareness educational sessions.
1476132|NCT03150368|Drug|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
1476133|NCT03150355|Procedure|Arthroplasty or open reduction and internal fixation|fixation of proximal femoral fractures or replacement with prosthesis
1476134|NCT03150342|Diagnostic Test|myocardial perfusion imaging|dipyridamole-stressed MPI scan using thallium-201
1476135|NCT03150329|Other|Laboratory Biomarker Analysis|Correlative studies
1476136|NCT03150329|Biological|Pembrolizumab|Given IV
1476137|NCT03150329|Drug|Vorinostat|Given PO
1476138|NCT03150316|Drug|Treat Regimen|CKD-581(investigational Drug): on days 1, 8, 15 of repeated 28day cycles Lenalidomide: on days 1~21 of repeated 28 day cycles Dexamethasone: administrated once weekly every 28day cycles
1476139|NCT03150290|Other|Indirect Calorimetry.|REE measurement
1476140|NCT03150290|Device|18-FDG-PET|18-FDG-PET
1476141|NCT03150277|Behavioral|Plyometric exercise|2 sets of 10 ankle hops, 3 sets of 5 hurdle hops, 5 drop-jumps from a height of 50 cm
1476142|NCT03150277|Behavioral|Heavy resistance exercise|10 single repetitions of back half squats at 90% of 1 repetition maximum
1476143|NCT03150264|Device|PCV-VG, PEEP5cmH₂O|This is an innovative ventilation mode developed in recent years. The preset tidal volume help the machine modify inspiratory pressures and compensate the decrease of lung compliance.
1476144|NCT03150264|Device|PCV, PEEP5cmH₂O|This is a traditional ventilation mode used in obese patients in the past.
1476145|NCT03150251|Other|Cereal - oats|Consumption of one cereal in the beginning of each visit
1476146|NCT03150251|Other|Cereal - cream of rice|Consumption of one cereal in the beginning of each visit
1476147|NCT03150238|Other|observation of prognostic factors for relapse|The identification of the most relevant prognostic factors and the definition of their weight in predict the risk of re-intervention will be the basis for the definition of a combined score
1476148|NCT03150225|Other|Concurrent training|"In this protocol the participants will perform aerobic and resistance training according to published evidence for middle-aged men; Characterized as concurrent training.
The protocol will last six months and will be divided into two quarters. In the first trimester, initial 30 minutes will be assigned to resistance training, followed by 30 minutes of aerobic training; Already in the second trimester will be 20 initial minutes for the aerobic training and later 40 minutes for the resistance training; Aiming to obtain benefits in the levels of muscular strength, aerobic capacity, body composition, besides positive results in relation to the hormonal adaptations of testosterone, as well as in the psychological well being of the participants. Classes will occur at a frequency of three times weekly, lasting 60 minutes a session."
1476149|NCT03150212|Dietary Supplement|Saccharomyces cerevisiae CNCM I-3856|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
1476150|NCT03150212|Dietary Supplement|Placebo|2 capsules daily, just before the breakfast with a glass of water, during 8 weeks.
1476151|NCT03150199|Behavioral|PP-MI health behavior intervention|Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the 8 study sessions.
1476152|NCT03150199|Behavioral|MI-based health behavior education intervention|Educational topics include diabetes self-care, medication adherence, physical activity, and having a healthy diet.
1476252|NCT03149432|Other|Local care|local care for directed healing of the stump.
1476153|NCT03150186|Other|SHS exposure in homes|The investigators will recruit 20 non-smoking volunteers living in different homes with at least one smoker: 10 participants living in more deprived neighborhoods and 10 participants living in wealthier neighborhoods. Nicotine vapor phase will be measured using passive SHS samplers. The investigators will contact with participants and make an arrangement for measuring levels of nicotine at homes. First, the investigators will hang up a passive sampler in the main room of the house in accordance with the written protocol of sample collection. One week later, the investigators will come back to the house in a second visit to remove the sample. During the second visit the investigators will administer a specific questionnaire about environmental tobacco exposure to the participant.
1476154|NCT03150186|Other|SHS exposure in private cars|The investigators will measure levels of nicotine in 30 cars (two samples per car) in 2 European countries with different smoke-free legislation (Spain and UK). A convenience sampling will be performed considering feasibility. The investigators will recruit 30 drivers: 10 daily-smoking volunteers that usually smoke within their car; 10 daily-smoking volunteers that do not smoke within their car; and 10 non-smoking volunteers. To be eligible, participants have to spend a minimum of 30 minutes per day within the car. Nicotine vapor phase will be measured using passive SHS samplers. Two samplers will be hung up in each car during a period of 24 hours. One sampler will be open during the 24-hour sampling period. The other sampler will be only open during travelling time.
1476155|NCT03150186|Other|SHS exposure in outdoor settings|In three types of outdoor settings (children playgrounds, terraces of hospitality venues, and entrances of primary school buildings), nicotine vapor phase will be measured using active SHS samplers. For each country, a convenience sampling of 60 outdoor settings (20 of each of the above mentioned settings) will be performed. Data collection will be conducted from March to October. The measurements will be able to be taken at any time of day providing that there are at least five adults. The investigators will collect nicotine samples using samplers attached to an air pump. Measurements will last 30 minutes. While measurements are being taken, data collectors will also conduct observations in accordance with the protocol of active sampling collection.
1476156|NCT03150173|Behavioral|Onsite treatment|Participants will see a buprenorphine treatment provider who will assess for clinical criteria for opioid use disorder and write a prescription for buprenorphine treatment, which will be filled in a community pharmacy.
1476157|NCT03150173|Behavioral|Enhanced referral|Participants will receive an expedited appointment at a community health center for evaluation for buprenorphine treatment
1476158|NCT03150160|Drug|brinzolamide 1% / brimonidine 0.2%|twice-daily brinzolamide 1% / brimonidine 0.2% fixed dose combination as an adjunctive therapy to travoprost 0.004%
1476159|NCT03150160|Drug|Placebo|placebo + travoprost 0.004% as an adjunctive therapy to travoprost 0.004%
1476160|NCT03150147|Device|Non-ischemic hypothermic perfusion (NIHP)|The device is a portable heart-lung machine; an automatic pressure and flow-controlled perfusion system. The heart is submerged in a solution and the medium is circulated in the heart, at a temperature of 8°C.
1476161|NCT03150147|Other|Ischemic cold static storage|Standard ischemic cold static storage; a crystalloid solution (cardioplegia) is used to stop and preserve the heart. Cardioplegia is given. The heart is storage i a transport box containing ice to keep the temperature around 8°C.
1476162|NCT03150134|Drug|Cyclosporine|Patients with advanced AML received early tapering of immunosuppressive drugs(Cyclosporine)
1476163|NCT03150134|Drug|routine reduction of immunosuppressive drugs(cyclosporine)|patients with AML in CR were given the routine reduction of immunosuppressive drugs(cyclosporine)
1476164|NCT03150121|Procedure|Uterine lavage|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
1476165|NCT03150121|Procedure|Blood sample|5-10mL of blood will be drawn from participants.
1476166|NCT03150121|Device|Uterine lavage catheter|Uterine lavage is performed using an intrauterine insemination catheter or rigid pipelle uterine sampler. The catheter is inserted into the cervical canal. 10mL of saline are infused into the uterine cavity and fallopian tubes and immediately retrieved.
1476167|NCT03150108|Drug|rhPTH(1-84)|25 mcg rhPTH(1-84) SC injection
1476168|NCT03150108|Drug|rhPTH(1-84)|50 mcg rhPTH(1-84) SC injection
1476169|NCT03150108|Drug|rhPTH(1-84)|100 mcg rhPTH(1-84) SC injection
1476170|NCT03150095|Behavioral|Health coaching|Patients will work with a health coach by telephone
1476171|NCT03150082|Drug|GR37547 tablet|"A single tablet of GR37547 should be taken orally with 240 mL of water. GR37547 500 mg tablet will be a white to off white capsule shape with break line on upper side and embossed GSK500on lower side."
1476172|NCT03150082|Drug|Ciprofloxacin reference tablet|"A single tablet of ciprofloxacin reference should be taken orally with 240 mL of water. Ciprofloxacin 500 mg reference will be nearly white to slightly yellowish film coated oblong tablets with break line and ''CIP 500 marked on upper side and BAYER on lower side."
1476173|NCT03150069|Other|Interview|In-person or telephone in-depth interview
1476174|NCT03150056|Drug|GSK525762|GSK525762 will be available as 5 milligram (mg) and 25 mg white to slightly colored, round, biconvex with no markings, film-coated tablet and will be administered with 240 milliliter (mL) water. The 20 mg tablet formulation is in development and will be used when available.
1476175|NCT03150056|Drug|Abiraterone|Abiraterone will be available as 250 mg white to off-white, oval tablets debossed with AA250 on one side. It will be administered with 240 mL water.
1476176|NCT03150056|Drug|Enzalutamide|Enzalutamide will be available as 40 mg white to off-white oblong soft gelatin capsules imprinted in black ink with ENZ. It will be administered with 240 mL water.
1476177|NCT03150056|Drug|Prednisone|5 mg prednisone will be administered as a concomitant medication in combination with abiraterone
2000704|NCT03323307|Device|OCT imaging|imaging of retina using OCT device
1476214|NCT03149731|Device|NIRS|The recent technological advancement of tissue NIRS enables continuous, real time and bedside monitoring of hemoglobin oxygen saturation in mixed arterial, venous, and primarily capillary blood in the tissue bed being probed.
1476253|NCT03149419|Drug|Paroxetine|
1476254|NCT03149419|Drug|Placebo oral capsule|
1476359|NCT03148496|Device|Biologic Mesh|Biologic mesh placed during surgery
1476179|NCT03150030|Other|Combined hyper- and hypoglycaemic clamp|During the entire clamp, participants will be monitored by ECG, pulse oximetry, and blood pressure and plasma glucose will be measured bedside every fifth minute. Additionally, patients with type 2 diabetes will be monitored by a loop recorder (LR) and a continuous glucose monitor (CGM). Comparison of LR and CGM recordings with the recordings obtained by ECG Holter monitor and blood sampling will be used for validation of the method used in Part 2 of the study. Blood samples will be drawn and analysed for changes in electrolytes, insulin, glucagon, catecholamines and cortisone. A cardiac haemodynamic evaluation will be performed by echocardiography at baseline, hyperglycaemia, and hypoglycaemia.
1476180|NCT03150030|Device|Loop recorder (Reveal LINQ, Medtronic, Minneapolis, MN, USA)|Implantation of a loop-recorder
1476181|NCT03150030|Device|Continuous glucose monitoring (iPro2, Medtronic, Minneapolis, MN, USA)|Monitoring with a continuous glucose monitor
1476182|NCT03150017|Other|SPIRE|Online pain management programme.
1476183|NCT03150004|Drug|CLAG-M regimen|"Patients will be started on CLAG-M regimen, which consists of the following:
Cladribine 5mg/m2 IV over two hours on days 1-5;
Cytarabine 2 gm/m2 IV over four hours on days 1-5, starting two hours after the Cladribine infusion is complete;
Mitoxantrone 10mg/m2 IV on days 1-3;
G-CSF at a dose of 300 μg on days 0-5."
1476184|NCT03149991|Drug|Brexpiprazole|Administration of up to 3mg brexpiprazole
1476185|NCT03149991|Drug|Ketamine|administration 6 times over two weeks of inhaled ketamine
1476186|NCT03149991|Drug|Placebo|Administration of placebo which matches brexpiprazole in size and number of tablets per dose
1476187|NCT03149965|Other|transperineal ultrasound|transperineal ultrasound was used by placing a vaginal ultrasound probe towards the vaginal distal wall pointing to the anus, measuring the anovaginal distance.
1476188|NCT03149952|Other|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells|Evaluation of the feasibility of the establishment of a logbook in patients hospitalized for allogeneic haematopoietic stem cells.
1476189|NCT03149939|Drug|Febuxostat 40 milligramsTablet|Febuxostat 40 milligramsTablet every other day for 3 months
1476190|NCT03149926|Other|Stimuli presentation|Different stimuli associated with self-injury are presented. Participants have to rate the emotional effect elected by the stimuli.
1476191|NCT03149913|Device|SequentPlease OTW paclitaxel coated balloon catheter|PTA with SequentPlease OTW paclitaxel coated balloon catheter
1476192|NCT03149913|Device|conventional uncoated balloon for BTK endovascular therapy|PTA with uncoated balloon for BTK endovascular therapy
1476193|NCT03149900|Drug|Secukinumab|See Arm Description
1476194|NCT03149887|Drug|Liposomal bupivacaine|Liposomal bupivacaine solution (Exparel) for injection
1476195|NCT03149887|Drug|Placebo|Inert solution created to appear as liposomal bupivacaine (Exparel) for injection
1476196|NCT03149874|Drug|Hepatitis B Vaccines|either Hepatitis B recombinant DNA vaccine or Combined hepatitis A and B vaccine given to the patients
1476197|NCT03149861|Procedure|PET/MR-ultrasound guided Fusion biopsy|All focal lesion with PI-RADS >=3 on MR or with DCFPyL uptake on PET will undergo a focal fusion biopsy
1476198|NCT03149861|Procedure|Systemic TRUS guided biopsy|Transrectal ultrasound guided systemic prostate biopsy
1476199|NCT03149848|Drug|Cabotegravir|It will be available as a white aquarius film coated tablet for oral administration. CAB Tablet is composed of GSK1265744B (micronized) lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate
1476200|NCT03149848|Drug|Rifabutin|It will be available as an opaque red-brown hard gelatin capsules containing 150 mg of rifabutin for oral administration. These capsules are composed of rifabutin, microcrystalline cellulose, sodium lauryl sulphate, magnesium stearate, and silica gel
1476201|NCT03149835|Other|Non-invasive ventilation|NIV was provided by BiPAP-Vision™ ventilator (Philips Respironics Inc, Murrysville, PA, USA) set at the BIPAP mode and applied by a nasal mask, with room air, for 60 minutes. Volunteers were studied during the application of NIV (inspiratory pressure of 14cmH2O and expiratory pressure of 4cmH2O), with a pressure support of 10cmH2O and without oxygen support (FIO2 0.21). These pressure levels were chosen based on the current practice of NIV in the intensive care setting.
2000705|NCT03324620|Other|Specific program functional and respiratory rehabilitation|It is a question of introducing a small program of physical activation pre-transplantation of hematopoietic progenitors, to continue developing it during the hospitalization and to use the functional measurements as a measure of its impact, as well as the different quality of life questionnaires.
1476206|NCT03149796|Other|laboratory blood tests|Serum concentrations of leptin, adiponectin, resistin, interleukin-6 and high sensitivity C reactive protein were measured by ELISA in both study groups
1476207|NCT03149783|Drug|Ropivacaine HCL|Ropivacaine injected after placement of catheters, then infused during the operation
1476208|NCT03149783|Drug|sodium chloride|Placebo
1476209|NCT03149770|Drug|Naloxone|naloxone vs placebo
1476210|NCT03149770|Drug|Placebo|placebo vs naloxone
1476211|NCT03149757|Behavioral|YouTHrive|"The YT website is a mobile-enhanced private social networking website. Participants on the site are anonymous and choose alternate usernames and personalized profile features for a new online identity within YT. The investigators designed YouTHrive to encourage social support, reduce isolation, improve HIV medication adherence, and promote general well being. The study involves rolling recruitment so that new members are continuously entering the intervention. Participants use YT for five months before graduating from the program. The core components of YT are: 1) peer-to-peer interaction in a shared feed; 2) daily monitoring of HIV medication adherence and real-time mood; and 3) daily mixed-media content with strategies to improve medication adherence."
1476212|NCT03149757|Behavioral|Thrive Tips|Participants will receive 21 emails, once per week, for five months. The emails will include static informational content relatable to YLWH, but informational content will not be focused on ART medication adherence.
1476213|NCT03149744|Device|RespiraSense Sleep Screener|RespiraSense will be worn at the same time as the standard of care SomnoScreen and it's results will be masked to the site team
1476348|NCT03148574|Drug|Oxytocin|intravenous
1948687|NCT01929265|Drug|Bendamustine|"INDUCTION PHASE
Rituximab - Bendamustine (RB): cycles 1 to 4 (0, 4, 8, 12 week):
Rituximab: 375 mg/sqm iv, day 1*
Bendamustine: 90 mg/sqm iv, days 1-2 or days 2-3 according to istitutional/patient/physician choice
Repeat cycles every 28 days for a total of 4 cycles
*In cycle 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8.
CONSOLIDATION PHASE
Rituximab - Bendamustine (RB): cycles 5 to 6 (16, 20 week):
Rituximab: 375 mg/sqm iv day 1
Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to istitutional/patient/physician choice
Rituximab two monthly doses
Rituximab: 375 mg/sqm iv week 24 and 28"
1948688|NCT01928082|Drug|Transdermal estradiol|4 weeks of Vivelle-Dot 0.05 mg/day followed by 4 weeks of Vivelle-Dot 0.10 mg/day
1476217|NCT03149692|Other|Penile allograft transplantation|Proof of concept of surgical procedure
1476218|NCT03149679|Drug|Cyclophosphamide|Chemotherapy
1476219|NCT03149653|Drug|ClinOleic (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
1476220|NCT03149653|Drug|ClinOleic + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
1476221|NCT03149653|Drug|Lipoplus (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
1476222|NCT03149653|Drug|Lipoplus + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
1476223|NCT03149653|Drug|SMOFlipid (baseline)|Lipid emulsion in pharmacy compounded all-in-one admixture
1476224|NCT03149653|Drug|SMOFlipid + Omegaven|Lipid emulsion in pharmacy compounded all-in-one admixture
1476225|NCT03149640|Drug|Inhaled amikacin|Once a day, inhaled amikacin at day 4, day 5 and day 6 of invasive mechanical ventilation: 20 mg/kg of ideal body weight, maximum 2 g per day.
1476226|NCT03149640|Drug|Inhaled placebo|Once a day, inhaled placebo at day 4, day 5 and day 6 of invasive mechanical ventilation.
1476227|NCT03149627|Other|Estimates - prevalence of lifetime/chronic HBV infection|Estimation of the prevalence and correlates of lifetime HBV infection defined as hepatitis B core antibody (HBcAb) positivity and chronic HBV infection defined as HBsAg positivity.
1476228|NCT03149614|Other|Spine Mobilizations|Patients receive spinal mobilizations in grades II to III of central posterior-anterior from cervical and thoracic spine as described Maitland in 2000
1476229|NCT03149614|Other|Vertebral Resonant Oscillation|"The vertebral resonant oscillation using the POLD method is similar to spine mobilizations, but there are some differens ; the oscillatory movement has a sinusoidal waveform, the frequency used between 1.2 and 2 Hz and the amplitude is similar to neutral zone to described by Panjabi 1992."
1476230|NCT03149588|Drug|propofol|Using propofol and remifentanil as maintenance of general anesthesia during caesarean section.
1476231|NCT03149588|Drug|sevoflurane|Using sevoflurane and remifentanil as maintenance of general anesthesia during caesarean section.
2000706|NCT03324607|Drug|hyperpolarized 129Xe gas MRI|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi. Images obtained using 129Xe MRI will be compared with standard lung function tests that are used routinely in the clinic, 6 minute walk test that assesses walking ability and several questionnaires that assess shortness of breath and life quality.
2000707|NCT03324607|Drug|Bevespi Aerosphere|There will be MRI imaging before the treatment with Bevespi and another one 2 weeks after use Bevespi.
2000709|NCT03324581|Drug|OPC-64005|Tablet
1476236|NCT03149562|Drug|plasma transfusions|These critical ill neonates with plasma transfusions
1476237|NCT03149562|Drug|non-plasma transfusions|These critical ill neonates without plasma transfusions
1476238|NCT03149549|Drug|CX-2009|CX-2009 Monotherapy
1476239|NCT03149536|Diagnostic Test|Pharmacogenetic test|To develop a pharmacogenetic prediction test
1476240|NCT03149510|Behavioral|Mobile Application|Participants will use the mobile application daily to assess heart failure symptoms.
1476241|NCT03149497|Procedure|anterior approach only in cervical spine trauma|evaluation of efficacy of single approach
1476242|NCT03149484|Device|Personal remote microphone (RM) system|Speech perception in noise performance will be evaluated in the unaided, bone conduction device (BAHA) aided, and bone conduction device (BAHA) + RM conditions. All test measures are non-experimental and commercially available.
1476243|NCT03149484|Other|Subjective Questionnaire|These subjective questionnaires will be given pre- and post-evaluation to both the subject and their guardian in order to determine the impact of RM on subject and guardian perceptions of listening in noise.
1476244|NCT03149471|Diagnostic Test|Endothelial dysfunction test|The endothelial function test will be assessed after 48 hours post admission and 1 year post discharge using the non-invasive Endo-PAT2000 device. The device is intended for use as a diagnostic aid in the detection of coronary artery endothelial dysfunction (positive or negative) using a reactive hyperemia procedure. It is based on the use of Peripheral Arterial Tone (PAT) signal technology, during a clinically established procedure, which measure post-ischemic vascular responsiveness following upper arm blood flow occlusion.
1476245|NCT03149458|Other|dance|dance program
1476246|NCT03149458|Other|control|upper limb rehabilitation
1476247|NCT03149445|Drug|Tesofensine/Metoprolol|Study medication will be administered for 91 days.
1476248|NCT03149445|Drug|Placebos|Study medication will be administered for 91 days.
1476249|NCT03149432|Procedure|Mirror Therapy|by a mirror effect the patient sees his remaining arm at the place of the amputated arm that cause an illusion of presence of this arm to the brain and would have an effect of reducing phantom pain
1476250|NCT03149432|Drug|Gabapentin|titration of Gabapentin up to 3600 mg or maximum tolerated dose for 8 weeks
1476360|NCT03148496|Procedure|Small Bytes|0.5 cm x 0.5 cm sutures used
1476255|NCT03149406|Other|Comparing the expression of miRNAs in symptomatic and asymptomatic carotid plaques|Comparing the expression of miRNAs in symptomatic and asymptomatic carotid plaques
1476256|NCT03149393|Drug|Qizhi Weitong Granules|Patients in this group will take Qizhi Weitong Granules 2.5g,3 times/day,30 minutes before dinner for 8 weeks.
1476257|NCT03149393|Drug|Mosapride Citrate Tablets|Patients in this group will take mosapride citrate tablets 5mg,3 times/day,30 minutes before dinner for 8 weeks.
1476258|NCT03149380|Behavioral|Web-based educational recommendations|The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
1476259|NCT03149367|Procedure|levator muscle resection with fixed sutures technique|The levator muscle is approached through skin incision and the muscle shortened and sutured directly to the tarsus then the skin crease reformed with interrupted sutures which pick up the underlying levator muscle
1476260|NCT03149367|Procedure|Levator muscle resection with adjustable sutures technique|The adjustable sutures technique in which the sutures passes through the levator muscle into the tarsal plate and out through the skin edge .the skin crease is formed separately so that adjusting the suture doesn't open the wound, the suture can be adjusted according to the result up to 4 days post operative.
1476261|NCT03149354|Other|Assay of TSH, FT3 and FT4 by immuno-radiometric method|Assay of TSH, FT3 and FT4 by immuno-radiometric method Determine the current prevalence of hypothyroidism in HIV-infected patients
1476262|NCT03149341|Other|Magnetic Resonance Imaging|All subjects will undergo or have already undergone Magnetic Resonance Imaging. Normal volunteers will be used for comparison with subjects. To minimize risk, normal volunteers will NOT undergo anesthesia, sedation or receive intravenous contrast during procedure.
2000710|NCT03324581|Drug|Atomoxetine|Capsule
1476264|NCT03149315|Drug|Ibrutinib|Ibrutinib 420mg, PO once daily for 2-7 days
1476265|NCT03149302|Other|Local neck treatment (LNT)|The local neck treatment consists of cervical mobilization and specific therapeutic exercises (30 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
1476266|NCT03149302|Other|LNT plus sensorimotor exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes). The sensorimotor exercises include cervical joint position sense and oculomotor training. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
1476267|NCT03149302|Other|LNT plus balance exercises|The local neck treatment (30 minutes) plus the balance exercise program (15 minutes).The balance program includes with static balance and progress to dynamic balance and gait. The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
1476268|NCT03149302|Other|LNT plus sensorimotor/balance exercises|The local neck treatment (30 minutes) plus the sensorimotor exercise program (15 minutes) and the balance exercises (15 minutes). The participants will attend 12 individual treatment sessions (2 visits per week for 6 weeks).
1476269|NCT03149289|Drug|Antiviral drugs|sofosbuvir, ribavirin, daclatasvir, ledipasvir, simeprevir, paritaprevir, dasabuvir, ombitasvir
1476270|NCT03149276|Other|Interpreter services|
1476271|NCT03149263|Behavioral|distraction|Children will all benefit toxin injections with the same protocol. Only the distraction will be different during the session: either the children will have a distraction realized by the team of clowns / or children will benefit a classic distraction (TV, music, ...)
1476272|NCT03149250|Diagnostic Test|Aggregometry, Monitoring of plasmatic hemostasis|Multiple Electrode Aggregometry using the Multiplate system Coagulation factor analyses (FXIII, FVIII, vWF) Parameters of conventional coagulation testing (aPTT, INR, Platelet count)
1476273|NCT03149237|Behavioral|Couples-based services|Couples-based services, including treatment, counseling and peer mentoring in the community.
2000711|NCT03324581|Drug|Placebo|Tablet/Capsule
2000712|NCT03324568|Behavioral|Parent Education Videos|Participants will receive educational videos describing behavioral techniques to improve parent and child eating behavior.
1476276|NCT03149198|Other|Mat Pilates exercises|The exercise program based on the pilates method will be performed on the ground in the group room of the FACISA / UFRN Physiotherapy School Clinic in Santa Cruz. The room has ample space and air conditioning for better patient accommodation. The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by a physical therapy student along with the research coordinator. A total of 10 exercises will be performed.
1476277|NCT03149198|Other|Aquatic aerobic exercises|"The aerobic exercise program will be held in the therapeutic pool of the Physiotherapy School Clinic of FACISA / UFRN in Santa Cruz. The pool is heated and provides better effects to the proposed treatment.
The exercises will be performed twice a week for 12 weeks. Each session will last about 50 minutes and will be supervised by another physical therapy student along with the research coordinator."
1476278|NCT03149185|Behavioral|Technology based cognitive behavioral stress management|Intervention is delivered through Telecare (web based technology) in a group for 60-90 minutes/session. During each session, participants are taught/discuss a new anxiety/arousal reduction technique and focus on stress management. Efficacy of available treatments, disease course, symptom burden, communication with intimate partner and/or family members and health care provider, impact of stress on physical and mental health and symptoms, and management of APC and HT symptoms are used for educational purposes and as catalysts for discussing TCBSM techniques. We allow participants to describe psychosocial stressors with an emphasis on symptoms and disruption, HRQOL and their coping responses for in-session role-plays. Participants are able to access the system at any time to retrieve relaxation and stress management didactics, and contact community resources and other participants in their group.
1476349|NCT03148561|Drug|misoprostol|It will receive misopristol 800 µg (Misotac 200 µg tablets, SIGMA pharmaceutical) once dose vaginally
1476350|NCT03148548|Genetic|thrombophilia screening|genetic Evaluation of Factor-V-Leiden, Factor-II_G20210A Mutation;
1476351|NCT03148535|Drug|Lithium Carbonate|bipolar depression recieve lithium Carbonate treatment
1476352|NCT03148535|Drug|lithium carbonate combined with SSRI antidepressant treatment|lithium carbonate combined with SSRI antidepressant treatment
2000713|NCT03324568|Behavioral|Educational Handout|Participants will receive educational handouts describing behavioral techniques to improve parent and child eating behavior.
2000714|NCT03324555|Drug|ORIC-101|Oral suspension
1476279|NCT03149185|Behavioral|Technology based health promotion group-based attention matched control condition|Sessions include content from relevant NCI, ACS and other resources developed to address the needs of advanced cancer populations into each topic session. All sessions address APC-specific issues. While men receiving treatment for APC remain interested in general health issues and as they become increasingly aware of the end-of-life issues raised by facing advanced disease, they seem to be interested in making life changes in areas in which they do exercise control (e.g., nutrition), and as such have been integrated into the T-HP modules in addition to general recommendations from sources such as American Heart Association, the NIA and the ACS. T-HP participants are scheduled for weekly group-based health information and promotion sessions (60-90 mins.), which are delivered via our videophones by our T-HP facilitators.
1476280|NCT03149172|Device|Equimatrix®|Ridge preservation bone grafting after tooth extraction
1476281|NCT03149172|Device|Bio-Oss®|Ridge preservation bone grafting after tooth extraction
1476282|NCT03149172|Device|Endobon®|Ridge preservation bone grafting after tooth extraction
1476283|NCT03149159|Drug|Nivolumab|Nivolumab will be given every 21 days for the first 12 weeks at a dose of 3mg/kg. After 12 weeks, the dose will be 240mg and will be given every 14 days.
1476284|NCT03149159|Drug|Ipilimumab|Ipilimumab will be given at a dose of 1mg/kg every 21 days for up to 12 weeks.
1476285|NCT03149159|Radiation|Steriotactic radiation therapy|The dose of radiation will be 6 Gy daily x 5 days. Radiation will be given between the first and second doses of ipilimumab plus nivolumab.
2000715|NCT03324542|Drug|Aflibercept [Eylea]|Anti-vascular endothelial growth factor (VEGF)
2000716|NCT03324529|Device|Tako Breath|Device guided breathing. A medical device with a computerized control unit, a breathing sensor and a set of earphones with audio-prompts to guide breathing at a slow rate (<10 breaths/min) with prolonged exhalation.
1476288|NCT03149133|Other|Heavy hypertrophy training|Training with 75-80 % of 1-RM
1476289|NCT03149133|Other|Light hypertrophy training|Training with 35-50 % of 1-RM
1476290|NCT03149120|Biological|Nivolumab|Nivolumab will be given as an intravenous infusion at a dose of 240 mg every 2 weeks for at least 6 months.
1476291|NCT03149120|Drug|Pazopanib|Pazopanib given at a dose of 800 mg by mouth daily.
1476292|NCT03149107|Drug|N-Acetylcysteine|N-Acetylcysteine (2000 mg/d, 1000 mg in the morning/evening, oral intake). Will be applied continously over 26 weeks parallel to the psychological intervention (IPPI or PSM).
1476293|NCT03149107|Drug|Placebo|Will be applied continously over 26 weeks (oral intake of capsules) parallel to the psychological intervention (IPPI or PSM).
1476294|NCT03149094|Behavioral|CBSM-SMI|The group will receive Cognitive Behavioral Stress Management (CBSM) for Individuals Living with HIV via mHealth through smartphones and tablets.
1476295|NCT03149081|Drug|Boswellia|Boswellia is an extract from frankinscense
1476296|NCT03149055|Drug|Isavuconazole|Intravenous or oral: Isavuconazonium sulfate 372 mg Q 8hour for 6 doses as loading dose, followed by 372 mg Q day as maintenance dose.
1476297|NCT03149042|Diagnostic Test|CTAC Coronary|Diagnostic Test
1476298|NCT03149029|Drug|Pembrolizumab|Pembrolizumab is a type of antibody that inhibits the cancer cell growth
1476299|NCT03149029|Drug|Dabrafenib|Dabrafenib is also a cell inhibitor and works by stopping the cancer cell from duplicating
1476300|NCT03149029|Drug|Trametinib|Trametinib is a cell inhibitor that binds to the cancer cells to inhibit the cancer cells' signals to decrease cell growth
1476301|NCT03149016|Procedure|Corticotomy-assisted Retraction|Using a tunneling technique, the researcher will perform the intervention in the alveolar bone surrounding the upper incisors before retraction.
2000718|NCT03324503|Drug|Glucocorticoid (prednisone or prednisolone)|≥ 30 mg/day prednisone or prednisolone taken orally as per local clinical practice of sarcoidosis initial induction therapy
1476304|NCT03148990|Biological|Measles and Rubella vaccine|Administration of the experimental vaccine (MR).
1476305|NCT03148990|Biological|Measles, Mumps and Rubella vaccine|Administration of the comparator vaccine (MMR).
1476306|NCT03148977|Procedure|Graft|Autogenous skin grafting is the only definitive treatment for the full thickness burn injuries, and thus represents the centerpiece of modern burn care.
1476307|NCT03148964|Biological|blood sampling|Blood Sampling at J0, M1, M3, M6, M12, M18, M24 and every 6 months until the end of the study
1476308|NCT03148938|Other|Digital Assessment on mobile|"The digital assessment is composed on 4 tests:
walking test
coordination test
attention test
vision test"
1476309|NCT03148925|Biological|SELA-070|Sub-cutaneous injection, multiple dose
1476310|NCT03148925|Biological|Saline|Sub-cutaneous injection, multiple dose
1476311|NCT03148912|Diagnostic Test|Diagnostic algorithm|The treating physician will complete an enrollment assessment including the 4T score pretest probability assessment14. All patients will have laboratory testing for HIT anti-PF4 as well as SRA testing. Results of the anti-PF4 assay (OD value) will be available to the treating physician who will be instructed to follow the study diagnostic algorithm
1476312|NCT03148899|Drug|Oxytocin Intranasal Spray|In human volunteers intranasal administration of oxytocin significantly increases parasympathetic and decreases sympathetic cardiac control. In addition to the classic effects of oxytocin on uterine contraction and milk ejection, recent work indicates oxytocin is present in both males and females and has an important role in both behavior and cardiovascular homeostasis, particularly during anxiety and stress.
1476313|NCT03148899|Drug|Placebo Intranasal Spray|The placebo has been compounded to be an inactive, blinded comparative to the oxytocin nasal spray.
1476353|NCT03148522|Drug|Escitalopram|receive escitalopram
1476354|NCT03148522|Drug|Duloxetine|receive duloxetine
1476355|NCT03148522|Drug|Mirtazapine|receive mirtazapine
1476356|NCT03148509|Drug|risperidone|DA receptor-mediated drugs
2000719|NCT03324490|Procedure|Thoracic Spinal Anesthesia|"Spinal anesthesia will be performed for patients of the TSA group at the T7-T8 intervertebral space, using a 27 G pencil point needle with an introducer (Braun Melsungen, Melsungen, Germany).
When correct placement is confirmed by the free flow of clear CSF, 1.5 ml of hyperbaric Bupivacaine 0.5% (7.5 mg) in addition to 0.5 ml Fentanyl (25 μg) & 5 μg dexmedetomidine will be injected."
1476314|NCT03148886|Other|PA intervention|"The program is individualized according to age, fitness level, place of residence, access to adapted specific training group or associations, PA preferences and wishes of each participant. Patients are informed of the recommendations in terms of PA, and the target of 150min per week in order to maintain health benefits. Patients are asked to walk at least 30 minutes per day and increase their activities into daily routine. Several individual strategies are established with the patients to attain their objectives and increase their daily life PA.
Withings® PA trackers have been used to provide an incentive effect to increase PA, to measure the number of steps per day and make people think about their PA. Patients wore a Withings Go® wristband PA tracker throughout the whole study and had in real time a feedback on their number of steps per day.
A 7 mL blood sample is collected at baseline (D1) and at the end of the 6-month study (M6) for the biological study."
1476315|NCT03148873|Device|RespiraSense patient respiratory monitor system|Subjects will have their respiratory rate monitored for two hours using three different methods for capturing it
1476316|NCT03148860|Drug|Methotrexate|subjects will receive once weekly 15 mg (3 capsules) MTX
1476317|NCT03148860|Drug|Ustekinumab|subject will receive Ustekinumab open-label over a treatment period of 52 weeks
1476318|NCT03148860|Other|Placebo|subjects will receive once weekly 3 capsules PLC to MTX
1476319|NCT03148847|Other|Baseline care|
1476320|NCT03148847|Other|Referential's dissemination|
1476321|NCT03148834|Procedure|Controlled Reperfusion|"Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.
Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.
Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.
The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio."
1476322|NCT03148808|Combination Product|NVS Therapy|Combination Product: NVS Therapy which includes NVS Injection (investigational product) and the following investigational devices: NVS Delivery Catheter, NVS Light Fiber, and NVS Light Source.
1476324|NCT03148782|Behavioral|OST Intervention for participants with Organizational skill difficulties|Will undergo two magnetic resonance imaging (MRI) sessions: one within 2 weeks prior to OST treatment and one within 2 weeks of completion of the OST treatment.
1476327|NCT03148743|Biological|Fecal microbiota|fecal microbiota transplantation
1476328|NCT03148730|Device|closed-loop group|Use of 3 indenpendent closed-loop systems to deliver the propofol, remifentanil, fluid and to adjust ventilation
1476329|NCT03148717|Drug|Misoprostol|Cytotec
1476330|NCT03148717|Other|Placebo|Placebo tablet similar in shape, odour and consistency to misoprostol tablet.
1476331|NCT03148704|Drug|palonosetron hydrochloride capsules|Collect all the patients' safty and efficacy data as long as they use palonosetron hydrochloride capsules(Ruo Shan®) .Specific methods of using the drugs are not limited .
1476332|NCT03148691|Drug|A-101|Topical Solution
1476333|NCT03148678|Behavioral|Mindfulness|Subjects are provided with smartphone-based mindfulness intervention.
1476334|NCT03148678|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of their own brain activity.
1476335|NCT03148678|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
1476336|NCT03148678|Behavioral|Mind Wandering|Subjects are provided with smartphone-based mind wandering intervention.
1476337|NCT03148665|Device|OncAlert|A noninvasive point of care salivary rinse test performed as 1) a one-time test for control subjects, 2) at pretreatment and post treatment 3,6, 12, and 18 month time points in oral cavity/oropharynx cancer patients
1476338|NCT03148652|Other|Enhanced Intervention Condition|The intervention incorporates 1) a standard, evidence-based cognitive behavioral therapy-based smoking cessation program, 2) working memory training, and 3) a motivational enhancement component. Working memory training will be administered via the computerized program Cogmed QM. Investigators will be able to monitor participants' progress throughout the study, using the data that the program gathers.
1476339|NCT03148639|Behavioral|Avatar therapy|Patients will receive 6 sessions of avatar therapy consisting of 45 minute (1 session per week). The therapy will consist in prompting patients to enter in a dialogue with their persecutor to better regulate their emotional responses. Over the course of the therapy, the character of the avatar will progressively become under patients' control. More precisely, the avatar's speech and tone will gradually be changed by the therapist to echo patients' improved ability to regulate their emotions. That is, the avatar will progressively change from being abusive to becoming helpful and supportive. By doing so, the therapy will seek to reinforce patients' feeling of empowerment over their voices.
1476340|NCT03148639|Other|Treatment-as-usual|Treatment as usual will consist of typical or atypical antipsychotic medication and regulars appointments with psychiatrists and others care team members for a period of 6 weeks.
1476341|NCT03148626|Other|MINDI mindfulness curriculum|A seven-session mindfulness curriculum implemented over six-months during pediatric internship.
1476342|NCT03148626|Other|Control|Usual Education
1476343|NCT03148600|Behavioral|Pelvic floor and bowel behavioural training|Physiotherapist-led pelvic floor muscle and bowel behavioural training
1476344|NCT03148600|Other|Standard arm|Standard medical and nursing care
1476345|NCT03148587|Behavioral|Self-assessment: MLPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the multi-level pregnancy test.
1476346|NCT03148587|Behavioral|Self-assessment: LSPT|Patients enrolled in the study will self-assess the outcomes of their medical abortion using the low sensitivity pregnancy test.
1476347|NCT03148574|Drug|Misoprostol|intrauterine tablets
1476362|NCT03148483|Other|Early PT|Women will receive conventional non-surgical periodontal therapy (PT), consisting of prophylactic dental polishing to remove the sticky bacterial film that forms on the teeth over time, scaling and root planing, as necessary throughout pregnancy, up to delivery
1476363|NCT03148483|Other|Delayed PT|Women will receive conventional non-surgical PT delayed until after delivery.
1476364|NCT03148483|Dietary Supplement|Fortified Milk|participants will be advised to take two servings of a powdered milk-based drink enriched with calcium and vitamin D daily during breakfast and afternoon snack or supper to avoid concomitant intake of the prenatal iron supplements routinely prescribed for consumption with hot main meals (e.g. lunch or dinner). Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with 500 IU of vitamin D3 and 1,2 g of a calcium supplement from milk extract (300 mg of calcium) twice a day.
1476365|NCT03148483|Dietary Supplement|Plain Milk|Women will be advised to consume 20 g of commercially available semi-skimmed milk powder (provided by the study) and one sachet with flour (placebo).
2000720|NCT03324490|Procedure|Thoracic Epidural Anesthesia|"Epidural anesthesia will be performed for patients of the TEA group at the T7-T8 intervertebral space, using the Prefix Custom Epidural Anesthesia Tray with an 18 G Tuohy epidural needle & a 20 G epidural catheter.
Patients will initially receive 5-10 ml of a mixed preparation of 0.5% isobaric Bupivacaine with 2 μg Fentanyl per ml volume as a bolus dose via the epidural catheter, this will be followed by a continuous infusion of 5-10 ml/hr started 1 hour after the bolus dose & continued throughout the procedure."
2000721|NCT03324490|Drug|Bupivacaine 0.5% (hyperbaric)|Neuro-axially injected
2000722|NCT03324490|Drug|Bupivacaine 0.5% (isobaric)|Neuro-axially injected
2000723|NCT03324490|Drug|Fentanyl|Neuro-axially injected
2000724|NCT03324490|Drug|Dexmedetomidine|Neuro-axially injected
2000725|NCT03324477|Drug|hypertonic saline 3%|hypertonic saline 3% is a type of crystalloid solutions with osmolarity higher than that of plasma
1476372|NCT03148444|Drug|cefalexin 500 mg qid or roxithromycin 150 mg bid|antibiotics treatment for five days following implantation of cardiac device
1476373|NCT03148431|Drug|LY3002815|Administered IV
1476374|NCT03148431|Drug|Placebo|Administered IV
1476375|NCT03148418|Drug|Atezolizumab|Atezolizumab will be administered as monotherapy or combined with other agent(s) or comparator agent(s) in a Genentech or Roche-sponsored study (the parent study). Dosing regimen will be in accordance with the parent study and local prescribing information.
1476378|NCT03148366|Drug|Levofloxacin based sequential therapy|D1-D7: (esomeprazole 40mg bid + amoxicillin 1gm bid) for 7 days D8-D14: (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid) for another 7 days
1476379|NCT03148366|Drug|bismuth quadruple therapy for 10 days (BQ)|D1-D10: (esomeprazole 40mg bid + Dibismuth trioxide 120mg qid + metronidazole 500mg tid + tetracycline 500mg qid) for 10 days
1476380|NCT03148353|Procedure|Subacromial injection|"Modified ultrasound guided corticosteroid subacromial injection
Standardized ultrasound guided corticosteroid subacromial injection"
1476381|NCT03148340|Diagnostic Test|VIPS Monitoring|Bioimpedance asymmetry
1476384|NCT03148314|Drug|vaginal misoprostol|(800µgm.x 2 doses 3 hours).
1476385|NCT03148314|Drug|buccal/sublingual misoprostol|200 µgm.x4 hrs.x 6 doses
1476386|NCT03148301|Other|Survey|Survey
1476387|NCT03148288|Dietary Supplement|Vitamin D|VItamin D
1476388|NCT03148288|Dietary Supplement|placebo|placebo
1476389|NCT03148275|Other|Laboratory Biomarker Analysis|Correlative studies
1476390|NCT03148275|Other|Questionnaire Administration|Ancillary studies
1476391|NCT03148275|Drug|Trametinib|Given PO
1476392|NCT03148262|Device|The Comfort Flo system|The Comfort Flo system will be used for the high flow nasal cannula during procedural sedation
1476393|NCT03148262|Device|The Salter nasal cannula|A Salter nasal cannula will be used at 4L/ minute during the procedural sedation.
1476394|NCT03148249|Other|interview|control group: interview, study group: explanation and exploration
1476395|NCT03148236|Drug|Vitamin C|200mg/kg/day split into 4 doses infused every six hours over 30 minutes in 50ml D5W
1476396|NCT03148236|Other|Placebo|50mL infused over 30 minutes
1476397|NCT03148223|Device|auriculotherapy|The participants will be submitted to a session per week with duration of 20 minutes, for three consecutive months, to fix the adhesives. The points selected for stimulation, according to Chinese atrial mapping, are: uterus, endocrine, ovary, pituitary, shen men, sympathetic, and liver. Participants will be advised to remain with the stickers fixed to the auricle for six days.
1476398|NCT03148210|Drug|Treatment strategy using evidence-based guidelines for asthma or COPD|The respirologist will determine the clinical extent of the patient's symptoms, activity limitation, and degree of airflow obstruction and will commence the subject on asthma or COPD medications if indicated
1476399|NCT03148210|Behavioral|Smoking Cessation|Smoking cessation counselling by a qualified educator if currently smoking
1476400|NCT03148210|Behavioral|Participant Education|Standardized education for asthma or COPD disease
1476401|NCT03148184|Diagnostic Test|shoulder x-ray|post operative shoulder x-ray at minimum 2 year post op
1476402|NCT03148171|Other|PrEP-R Supportive Contact|Provide emotional support and practical support. Support friend/family by helping him to stay engaged in PrEP Care.
1476403|NCT03148158|Device|Cystoscopy|Outpatient flexible cystoscopy and inpatient rigid cystoscopy
1476404|NCT03148145|Behavioral|Step Goal Delivery by Smartphone|Step Goal Delivery by Smartphone
1476405|NCT03148145|Behavioral|Message Delivery by Smartphone|Message Delivery by Smartphone
1476406|NCT03148132|Drug|Bevacizumab Injection|0.5mg/0.02 mL
1476407|NCT03148132|Drug|Ranibizumab Ophthalmic|0.25mg/0.025 mL
1481542|NCT03108352|Drug|Conbercept ophthalmic injection|
1997635|NCT01984333|Behavioral|Online cognitive training|Online cognitive training is a web-based video game that offers systematic training of response inhibition capabilities. Participants will be guided to make progress in an individually-tailored fashion to master increasingly difficult game levels.
1997636|NCT01983904|Device|deep brain stimulation with short & long pulse width|surgical implantation for bilateral electrodes and stimulation using short and long pulse width
1476408|NCT03148119|Drug|QRH-882260 Heptapeptide|topical spray; fluorescently-labeled peptide composed of a 7-amino acid sequence [Gln-Arg-His-Lys-Pro-Arg-Glu] attached via a 5 amino acid linker [Gly-Gly-Gly-Ser-Lys] to a near-infrared fluorophore, Cy5. The complete peptide sequence is written as: Gln-Arg-His-Lys-Pro-Arg-Glu-Gly-Gly-Gly-Ser-Lys(Cy5)-NH2, and is abbreviated as: QRHKPRE-GGGSK-(Cy5)-NH2.
1476409|NCT03148119|Device|Scanning Fiber Endoscope|Endoscope used for providing the light via laser to image the area of interest in the colon after the QRH has been sprayed and rinsed.
1476410|NCT03148106|Device|Somatosensory Electrical Stimulation|We will put adhesive electrodes on the affected arm and connect it to a device that will deliver a gentle electrical stimulation to the hand and arm. The stimulation will last for different amounts of time, depending on the stimulation condition. This can be 30 minutes twice a day (1 hour apart), 1 hour continuously, 2 hours continuously, or 3 hours continuously. The stimulation conditions will also vary in stimulation strength. It is normal that some people may feel a tingling sensation, while others may feel nothing.
1476411|NCT03148080|Other|Data Collection Only:|Brief cognitive testing; questionnaire assessing occupation, education status, variety of work measures, self-reported physical, psychosocial and cognitive function; medical history, cancer treatment information and medication use.
1476412|NCT03148067|Procedure|Intramedullary nailing for fracture fixation|
1476413|NCT03148054|Device|Computer Tomography and Endoscopy|"Pelvic CT scan with i.v. and rectal contrast (Siemens Healtheneers, Erlangen, Germany) with the following scan parameters: collimation 0.6 mm, pitch 1.2 mm, CareKV with reference 120 mAs and reference 120 kV, rotation time 0.5 sec. Portal venous phase (individually tailored contrast media injection of Xenetix 300, Guerbet GmbH) and rectal contrast (500cc: 470cc water + 30cc Telebrix® gastro, a water soluble iodinated contrast agent, Guerbet GmbH).
Endoscopy takes 5 minutes: A gastroscope with a diameter of 10mm is used for inspection of anus, rectum, anastomosis incl. measurements (distance to dentate line, diameter of anastomosis) and distal part of colon (to rule out ischemia) during short term insufflation of the rectum with CO2. No biopsies are taken. Digital photo documentation will be provided. In case of anastomotic insufficiency: optional sedation of patient and clip closure with endoscopic OTSC (over the scope clip) system."
2000726|NCT03324464|Behavioral|Central Executive Training: Working Memory|Computerized working memory training
1476415|NCT03148015|Other|Biomarkers|Evaluate the intracellular and intraluminal distribution of autophagy and calcium efflux markers in each breast lesion in comparison to the HER2, proliferation (Ki-67, PCNA), p53, inflammatory, and apoptotic (Annexin-1) markers in the same patient. Determine the qualitative amount and localization of PMCA2 and Vitamin D Receptor in each breast lesion with intraductal calcium spicules compared to lesions without microcalcifications.
1476416|NCT03148002|Drug|Current Bowel Protocol (senna/lactulose)|Stimulant and Osmotic Laxatives.
1476417|NCT03148002|Drug|PEG Bowel Protocol (PEG/lactulose)|Osmotic Laxatives.
1476418|NCT03147989|Drug|MultiHance|gadolinium contrast agent
1476419|NCT03147976|Drug|AMG 337|6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4- yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2- methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
1476420|NCT03147963|Drug|Docetaxel|Docetaxel will be given until progression or patient intolerance
1476421|NCT03147950|Procedure|Prone-Flexed PCNL|Prone-Flexed Position For Percutaneous Nephrolithotomy (PCNL)
1476422|NCT03147950|Procedure|Prone PCNL|Prone Position For Percutaneous Nephrolithotomy (PCNL)
1476423|NCT03147937|Other|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online
1476424|NCT03147924|Other|Improvisation Group|The aim of this pilot study is to investigate the effects of improvisational comedy in a group of help-seeking youth at risk of developing a range of mental health disorders, including social anxiety.
2000727|NCT03324464|Behavioral|Central Executive Training: Inhibitory Control|Computerized inhibitory control training
1476426|NCT03147885|Drug|Selinexor|Given PO
1476427|NCT03147872|Other|2% Oxygen|2% oxygen concentration in the incubator in which embryos are being cultured after day 3 of development
1476428|NCT03147859|Biological|Vedolizumab (brand name Entyvio)|IV infusion
1476429|NCT03147846|Procedure|delayed cord clamping|delay of cord clamping for 60 seconds
1476430|NCT03147846|Procedure|cord milking|active cord milking 5 times
1476431|NCT03147833|Dietary Supplement|Sport beverage Protein|Beverage ingested before each night sleep during the intervention
1476432|NCT03147833|Behavioral|Training|Training program for 8 days
1476433|NCT03147833|Dietary Supplement|Sports beverage Carbohydrate|Beverage ingested before each night sleep during the intervention
1476434|NCT03147040|Drug|Carboplatin|Chemotherapy treatment with carboplatin and atezolizumab
1476435|NCT03147040|Drug|Atezolizumab|Chemotherapy treatment with carboplatin and atezolizumab
1476436|NCT03147027|Procedure|VT ablation|Substrate mapping for VT will be performed with the CARTO electroanatomical system.
1476437|NCT03147027|Other|medication|medication to prevent sustained VT and ICD therapies
1476438|NCT03147014|Biological|Maternal hyperoxygenation|approximately 10-15 minutes of maternal hyperoxygenation
1476439|NCT03147001|Other|Protein ingestion|A protein drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
1476440|NCT03147001|Other|Non-caloric placebo ingestion|A placebo drink was ingested prior to the 90min bike ride in one of the completed trails (order randomised).
1476441|NCT03146988|Drug|RGB-02 or Neulasta® (pegfilgrastim)|Pre-filled syringe containing 6 mg RGB-02 or Neulasta® in 0.6 mL, administered as subcutaneous injection into the abdominal area
2000728|NCT03324451|Behavioral|TTM Intervention for Insulin Initiation|The intervention contains three parts: (1) individual intervention; (2) insulin injection follow-up management; (3) motivational group activities. Different intervention strategies are applied to patients according to their stages of change.
2000729|NCT03324451|Behavioral|Usual care|Regular patient education on insulin injection at the control arm hospital.
1476442|NCT03146975|Procedure|Non-surgical periodontal treatment|Quadrant-wise ultrasonic debridement followed by manual scaling and root planing under local anesthesia provided in weekly sections. Oral hygiene instructions.
1476443|NCT03146962|Drug|Vitamin C|Vitamin C infusion will be administered intravenously at 1.25 g/kg for 4 days per week for 2-4 consecutive weeks (cohort A) or up to 6 months (cohort B).
1476444|NCT03146949|Device|Sorin Inspire Oxygenator|This is an oxygenator manufactured by the Sorin group. It is a hollow fibre polypropylene oxygenator.
1476445|NCT03146949|Device|Medtronic Affinity Fusion|This is an oxygenator manufactured by the Medtronic group. It is a hollow fibre polypropylene oxygenator.
1476446|NCT03146923|Other|Current Low Phosphorus Diet Prescription|"Routine / Standard Care: Routine dietary intervention is currently provided by one-to-one counselling to the subject and his/her relevant family members or carers, by a state registered dietitian regarding a diet which provides <15mg Phosphorus /g Protein (over the day). This is equivalent to approximately 1000mg P / day. This is based on the 'Eating Well with Kidney Disease' dietsheet produced by the Renal Interest Group (RIG) of the Irish Nutrition & Dietetic Institute (INDI) in 2010 and includes following main components:
Restricting protein intake to requirements (1-1.2g/kg Ideal Body Weight)
Restricting dairy intake (1-1.5 portions per day)
Avoiding foods high in phosphate
Avoiding foods with phosphate additives"
1476447|NCT03146923|Other|Modified Low Phosphorus Diet Prescription|"Modified Low Phosphorus Diet Prescription: The new prescription recommends five changes to current management
Introduction of some plant protein in the form of pulses and nuts where the phosphorus is largely bound by phytate
Increased focus on avoiding additives
Introduction of more whole grains e.g. wholemeal sliced pan/ pasta/rice .
Avoiding over-prescription of protein which carries an obligatory phosphorus load.
Focus on high protein foods with a low phosphorus to protein ratio"
1476448|NCT03146897|Dietary Supplement|Supplementary Food|Supplementary food for treating MAM
1476449|NCT03147807|Device|betaLACTA® rapid diagnostic test|Since ≥1 bacteriological sample(s) from ICU patients empirically treated with carbapenems (i.e. respiratory sample such as quantitative tracheobronchial aspirate with available volume ≥1 mL; urinary sample such as single catheter urine specimen; or blood culture) is positive for ≥2 GNB/field on direct examination, empirical carbapenem will be adapted: 1) early, since the second dose, according to the results of the betaLACTA® rapid diagnostic test (BLT) in the intervention arm (i.e. de-escalation to cefepim or to ceftazidim+amikacin in case of negativity, and carbapenem continuation in case of positivity); or 2) after 48-72h according to the results of the antibiotic susceptibility test in the control arm.
1476450|NCT03147794|Device|MyndMove|A new technology system called MyndMove has been developed by MyndTec Inc. (Missisauga Canada) to administer FES. The purpose of this technology is to improve voluntary upper limb (hand and arm) function (i.e. reaching and grasping) for patients with hemiparesis as a results of stroke or spinal cord injury (7). It is a non-invasive application that delivers electrical stimulation to the affected limb transcutaneously. MyndMove has been licensed by Health Canada and is indicated as a functional electrical stimulator for improvement of arm and hand function and active range of motion in patients with hemiplegia due to stroke or upper limb paralysis due to C3-C7 spinal cord injury.
1476451|NCT03147781|Device|True AT with magnetic pellets|Affixing magnetic pellets onto pre-selected auricular acupoints with tape.The treatment will be initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
1476452|NCT03147781|Device|Sham AT with Medulla Junci|Medulla Junci segments are crumbled into ball-shape and then attached to the pre-selected auricular acupoints with tape. The treatment will be initiated within 4 to 8 hours post cesarean for 96 hours during the hospital stay.
1476453|NCT03147768|Device|Distal Pancreatectomy Sealing Using LTW|The device's intended use is to seal the pancreatic surface using a laser to weld human albumin based biomaterials after surgical removal of pancreatic tumors during a partial pancreatectomy.
1476454|NCT03147755|Other|No intervention|No intervention
1476455|NCT03147742|Drug|Ruxolitinib|Ruxolitinib starting dose level 5 mg orally, twice daily (BID). For patients with acute GVHD, the dose may be escalated to 10 mg BID.
1476456|NCT03147729|Radiation|Radiofrequency non ablation|Use of radiofrequency
1476457|NCT03147716|Other|Enrollment Flyer|Enrollment flyer that provided information about the Triple P Positive Parenting Program and an enrollment form.
1476458|NCT03147716|Other|Testimonial Booklet|Booklet that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare, as well as an enrollment form.
1476459|NCT03147716|Other|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended that the parent attend. The teacher also gave the parent a brochure that gave information about the Triple P program and an enrollment form.
1476460|NCT03147716|Other|Provider Engagement Call|This was a manualized, 15-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent anticipate and problem solve possible barriers to attendance.
1476461|NCT03147703|Behavioral|Food Timing|the timing of the main meal of the day (lunch in Spain) is changed from early (14:00) to late (17:30) and viceversa in a randomized and crossover way
1476462|NCT03147690|Drug|Lumason|Lumason will be administered at a dose of 0.03 mL/kg up to a maximum dose of 2.4mL injected into a peripheral intravenous catheter. An abdominal contrast enhanced ultrasound will be performed to look for solid organ injury. The dose may be repeated once during the intervention, for a total maximum dose per subject of 4.8mL.
1476465|NCT03147638|Drug|Warfarin, NOAC|duration of treatment
1476527|NCT03147274|Behavioral|Intervention|Patients randomized to the intervention group will attend 3 SMART T1D group curriculum sessions over the study period, in addition to usual diabetes clinic care. Each interactive group session will last 2 hours and will be facilitated by a diabetes nurse educator.
1476528|NCT03147261|Other|Lifestyle intervention|Intensive changes in lifestyle with a reduced calorie mediterranean diet, physical activity and behavioral therapy
1476529|NCT03147248|Biological|Infliximab|
1476852|NCT03144297|Other|BOD POD (air-displacement plethysmography)|Assessment of body fat
1481543|NCT03108352|Other|sham injection|
1476466|NCT03147625|Behavioral|SHAPE Intervention|SHAPE seeks to identify, equip and strengthen resources in elderly residing in elderly-only households. The content will be further developed according to the findings of an existing descriptive qualitative study, literature review and a multi-disciplinary expert panel review. The home visit will involve assessment, observation and evaluation of elderly' health status, lifestyle and home environment, followed by guidance on health-promoting behaviour and emphasis on strengthening inner health resources. This provides an individualized approach to enhance personal health skills. Group-based activity sessions are directed to facilitate group interaction among peers as well as equipping and enhancing external resources.
2000730|NCT03324438|Behavioral|Home Telehealth T1D C2oYoT1-HR|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
2000731|NCT03324438|Behavioral|Personalized Behavioral Health|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
2000732|NCT03324438|Behavioral|Personalized Adherence Feedback|1) assessment of physical and behavioral health characteristics associated with high-risk status; 2) delivery of home telehealth that incorporates: 2a) medical and behavioral health care delivered with the endocrinologist and behavioral health specialist working together with high-risk youth; 2b) personalized intervention to improve T1D adherence and T1D clinical health outcomes; 2c) personalized intervention to improve mental health comorbidities and T1D clinical health outcomes; and 3) an underused methodological approach for optimizing intervention components to be delivered at point of care.
2000733|NCT03324425|Drug|Simvastatin 40mg|Participants will receive simvastatin 40 mg by mouth daily at bedtime
1476478|NCT03147599|Drug|Coloverin|Mebeverine hydrochloride 135 mg
1476479|NCT03147599|Drug|Placebo|Placebo
1476480|NCT03147586|Drug|Bio-tech and omega-3 plus|immune nutrition : Bio-tech ( multivitamins and essential amino acids), and omega-3 plus (omega-3 fatty acids)
1476481|NCT03147586|Drug|placebo|placebo
1476482|NCT03147573|Diagnostic Test|1-hour blood pressure monitoring (1BPM)|This method consists of performing blood pressure measurements programmed at 5-min intervals over 1 hour. Two extra recordings taken at the start and end of this period are discarded. Blood pressure is measured in a quiet room at the same health centre.
1476483|NCT03147573|Diagnostic Test|24-hour ambulatory blood pressure monitoring (ABPM)|The device is programmed to record the participant's BP every 20 min and 30 min during the day and night, respectively. Participants are advised to carry on with their normal daily activities, avoiding any intense physical exertion, and to remain at rest when their BP is being measured.
1476484|NCT03147573|Diagnostic Test|Office blood pressure measurement (OBPM)|Two readings were made one minute apart with a validated automatic sphygmomanometer in a sitting position after five minutes of rest. The average of two readings is calculated. The procedure is repeated during 3 office visits at least a week apart.
1476485|NCT03147573|Diagnostic Test|Home blood pressure monitoring (HBPM)|For each blood pressure recording, at least two consecutive measurements should be taken, at least one minute apart. Blood pressure should be recorded twice daily, ideally in the morning and evening. Blood pressure recording should continue for at least four consecutive days, ideally seven. The average of the above readings should be calculated, ignoring the first day.
1476486|NCT03147560|Biological|Sabin IPV+ bOPV+ bOPV|Give 3 doses of polio vaccine, get 2 blood samples before the first dose and 35-42 days after the last dose.
1476487|NCT03147560|Biological|Sabin IPV + Sabin IPV + bOPV|Give 3 doses of polio vaccine, get 2 blood samples before the first dose and 35-42 days after the last dose.
1476488|NCT03147560|Biological|Sabin IPV + Sabin IPV + Sabin IPV|Give 3 doses of polio vaccine, get 2 blood samples before the first dose and 35-42 days after the last dose.
1476489|NCT03147547|Other|Promotional Brochure|Promotional brochure with information about the Triple P Positive Parenting Program and an enrollment form.
1476490|NCT03147547|Other|Family Testimonial Flyer|Flyer that included quotes and photos from parents who had previously participated in the Triple P Positive Parenting Program and/or their children who participated in the free childcare.
1476491|NCT03147547|Other|Teacher Endorsement|Brief conversation between the parent and their child's teacher in which the teacher told the parent about the benefits of participating in the Triple P Positive Parenting Program and recommended the parent attend.
1476492|NCT03147547|Other|Provider Engagement Call|This was a manualized, 20-minute call from the Triple P Positive Parenting Program provider to a parent in which the provider elicited the parent's child-focused goals and showed how the parent's goals could be addressed by Triple P. The provider also helped the parent problem solve barriers to attendance and develop an action plan to handle common barriers (e.g., scheduling conflicts) as well as set session reminders.
1476493|NCT03147534|Device|InstaTemp MD|The InstaTemp MD is a hand held electronic infrared thermometer that is intended to accurately measure human body temperature without contact with the human body.
1476494|NCT03147534|Device|"Welch Allyn, rectal"|"The Welch Allyn rectal thermometer is intended to measure human body temperature."
1476495|NCT03147534|Device|"Welch Allyn, oral"|"The Welch Allyn oral thermometer is intended to measure human body temperature."
1476496|NCT03147534|Device|Covidien, tympanic|The Covidien tympanic thermometer is intended to measure human body temperature.
1476530|NCT03147235|Behavioral|vitrectomy with music listening|Those randomized to music listening will be exposed to a standardized playlist of previously validated relaxation music.
1477005|NCT03142958|Device|Integra Cadence Total Ankle Sysyem|Primary or revision on total ankle replacement
1476497|NCT03147521|Other|Care bundle|Risk fall assessment at hospital admission with Conley scale or with findings of specific risk characteristics (previous falls, cognitive impairment, neuropsychological damage, increased need to go to the bathroom for increased evacuative needs, neuroleptic or cardiovascular drugs assumption); if risk is found shear the information with the team, writing it in patient chart, and positioning a specific symbol on patient bed. Inform patient and family about fall risk and ask, if possible, a continuous caregiver presence. Universal strategy application for the environmental safety and patient safety. Periodic assessment of drugs therapy, with the aim of reduce those that acts on central nervous system and cardiovascular system. If patient is at risk and alone, verify each 2 hours the need to go to the bathroom, change position or drink.
1476498|NCT03147495|Other|no intervention|The proximal tibiofibular joint radiographs will be taken for the participants in both groups.
1476499|NCT03147469|Procedure|Neutral|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, ventilation score, and fiberoptic bronchoscopic view will be assessed at this position.
1476500|NCT03147469|Procedure|Extension|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, ventilation score, and fiberoptic bronchoscopic view will be assessed at this position.
1476501|NCT03147469|Procedure|Flexion|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, ventilation score, and fiberoptic bronchoscopic view will be assessed at this position.
1476502|NCT03147469|Procedure|Rotation|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, ventilation score, and fiberoptic bronchoscopic view will be assessed at this position.
1476503|NCT03147469|Device|Ambu AuraGain™|The AuraGain is Ambu's 3rd generation laryngeal mask, satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway.
1476504|NCT03147456|Dietary Supplement|(Cubitan Protein, Nutricia, Netherlands).|Supplement contains (per 200 ml can) 20 g of protein, 250Kacl plus different micronutrient and macronutrient.
1476505|NCT03147456|Dietary Supplement|(preOp, Nutricia, Netherlands).|contains per can (200 ml), 0g protein, fat free, 100 kcal and enriched with electrolytes
1476506|NCT03147443|Drug|Individualized Decoction|Applied in the Tested Drug Observation Period. It is the highly individualized treatment of traditional Chinese medicine,the modification of Bronchiectasis Stabilization Decoction(Radix Lithospermi 15 g, Rhizoma Fagopyri Cymosi 30 g, Radix Ophiopogonis 15 g, Poria cocos 15 g, Radix Astragali 20 g, Rhizoma Bletillae 10 g, Platycodon grandiflorum 10 g, and Semen Coicis 30 g) based on syndrome differentiation. For example,for patients with qi and yin deficiency syndrome, we added Radix Adenophorae, and Radix Rehmanniae Recens. Besides, the herbs in a prescription could be changed according to different symptoms of individual patients.
1476507|NCT03147443|Drug|placebo|Applied in the placebo Observation Period. Placebo is made by dextrin, bitter agent, edible pigment etc and added 5% test drug. The test drug and control drug have no differences in dosage form, appearance, color, specification, label, and so forth.
1476508|NCT03147443|Drug|Tested drug minus heat-clearing herbs|It is the decoction of the Syndrome Differentiation Decoction(tested drug) minus heat-clearing herbs. For example, heat-clearing herbs such as Scutellaria baicalensis or Herba Violae will be removed from the Syndrome Differentiation Decoction.
1476509|NCT03147430|Other|Biomarkers|Experimentally discover putative plasma markers for detecting early, stage I breast cancer in the setting of a suspicious mammogram and distinguish those cancers from benign lesions b) verify the putative markers through molecular profiling; and c) validate the markers by mass spectrometry.
1476510|NCT03147404|Drug|Avelumab|Avelumab 10 mg/kg i.v. every 2 weeks (Q2W)
1476511|NCT03147391|Device|LAA closure with LAmbre|Percutaneous Left Atrial Appendage Closure Using the LAmbre Device in Patients With Atrial Fibrillation
1476512|NCT03147378|Drug|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets in fed or fasting condition
1476513|NCT03147365|Behavioral|Aerobic exercises|Aerobic exercises will do by using treadmill for children of study group A. it will consist of (max.incline15% - max. speed - heart rate grips and wireless chest strap - smooth virtual fitness trainer - smooth drop folding frame - impression shock absorption cushioning system).
1476514|NCT03147365|Behavioral|Modified strength training|Dumbbells will be used to conduct the modified strength training program for children of group B. This exercises included five exercises for the main muscle groups: bench press, leg press, seat row, leg extension and lat pull down.
1476515|NCT03147352|Device|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy with 100 % oxygen at 1.8 ATA for 2 hours.
1476516|NCT03147339|Other|AGEs restricted diet|Diet modification to reduce advanced glycation end products in diet. for example to change ways of cooking, time of cooking and also omit some foods.
1476517|NCT03147326|Diagnostic Test|FDG-PET-CT|scanning method
1476518|NCT03147326|Diagnostic Test|NaF-PET-CT|scanning method
1476519|NCT03147326|Diagnostic Test|Whole-body MRI|scanning method
1476520|NCT03147313|Device|MTS Medical UG Orthogold 100|300 or 500 pulses, frequency 3Hz, energy 1 (0,1mJ/mm2)
1476521|NCT03147313|Device|Sham|Extracorporeal shock wave treatment will be faked.
1476522|NCT03147300|Behavioral|Current routine practice|Current routine practice for the primary care management of LBP
1476523|NCT03147300|Behavioral|Multifaceted implementation of the BetterBack|"The multifaceted intervention is composed of the following:
Forming an implementation forum including head of departments/managers of the rehabilitation units and the clinical researchers.
Forming a support team comprised of experience clinicians as local supervisors and faculty researchers as knowledge facilitators.
Developing the Betterback model of care through a collaboration of the implementation forum, support team and international experts.
Forming and delivering a 2-day package of education and training that the support team can utilize to assist the use of the BetterBack model of care by clinicians."
1476524|NCT03147287|Drug|Palbociclib|Palbociclib is a drug that may stop cancer cells from growing
1476525|NCT03147287|Drug|Fulvestrant|Fulvestrant prevents growth of hormone receptor positive breast cancer by blocking stimulation of cancer cells by estrogen
1476526|NCT03147287|Drug|Avelumab|Avelumab is an antibody designed to block the PD-1 pathway and helps the immune system in detecting and fighting cancer cells
1477006|NCT03142945|Other|Traditional Physical Therapy|Physical therapy-based interventions
2000734|NCT03324412|Drug|Treatment of MTX|Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）placebo：20mg， 3 times a day, oral, for 24 weeks.
1476532|NCT03147209|Behavioral|Health Coaching|This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
1476533|NCT03147196|Drug|Bicalutamide|Given PO
1476534|NCT03147196|Other|Laboratory Biomarker Analysis|Correlative studies
1476535|NCT03147196|Other|Questionnaire Administration|Ancillary studies
1476536|NCT03147196|Drug|Raloxifene Hydrochloride|Given PO
1476537|NCT03147183|Drug|Thymoglobulin|This study will use non-probability, convenience sampling from patients kidney transplants who receive induction immunosuppressive therapy with thymoglobulin
1476538|NCT03147170|Diagnostic Test|High and low salt diets|Effects of high and low salt diets on blood pressure in individuals with normal and elevated levels of NT-proBNP
1476539|NCT03147157|Other|tacrolimus regimen guided by HLA matching rate|required low,middle and high tacrolimus concentration in high,middle and low MR group respectively
1476540|NCT03147144|Other|Ultrasonographic imaging|Ultrasound pelvic scan
1476541|NCT03147131|Procedure|Total Hip Arthroplasty|Total hip arthroplasty was randomly performed wither either a Fitmore short or a CLS straight stem.
1476542|NCT03147118|Diagnostic Test|Arthrogram|Contrast dye will be included in the standard injection of lidocaine and corticosteroid. After injection, the participant will have 2 radiograph views of the thumb.
1476543|NCT03147105|Behavioral|arm ergometry|home based arm ergometry, at least 4-5 sessions/week for 12 weeks
1476544|NCT03147092|Drug|Captopril 25Mg, Hydrochlorothiazide 25Mg Oral Tablet,|Treatment of hypertensive subjects
1476545|NCT03147092|Drug|Atenolol|Treatment of hypertensive subjects
1476546|NCT03147092|Drug|Losartan potassium 50mg|Treatment of hypertensive subjects
1476547|NCT03147092|Drug|Clonidine|Treatment of hypertensive subjects
1476548|NCT03147079|Behavioral|Lifestyle intervention|
1476551|NCT03147053|Drug|Jiedu Tongluo granules|Patients in this group were administered the Jiedu Tongluo granules, 3.9mg/bag, 2 times/day for 8 weeks.
1476552|NCT03147053|Drug|Placebo|Patients in this group were administered the placebo, 3.9mg/bag, 2 times/day for 8 weeks.
1476553|NCT03146871|Drug|Azacitidine|Given IV or SC
1476554|NCT03146871|Drug|Decitabine|Given IV
1476555|NCT03146871|Other|Laboratory Biomarker Analysis|Correlative studies
1476556|NCT03146871|Other|Pharmacological Study|Correlative studies
1476557|NCT03146871|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
1476558|NCT03146858|Drug|Enoxaparin|Enoxaparin is an anticlotting treatment that targets the other aspect of clot formation known as the coagulation cascade. Enoxaparin or an alternative is recommended as a single does to support PPCI procedure.
1476559|NCT03146845|Device|Allevyn Life Non-Bordered|Foam Dressing
1476560|NCT03146845|Device|Standard Care|Foam Dressing
1476561|NCT03146832|Behavioral|Exposure therapy (according to habituation approach)|Exposure instruction focuses on fear reduction during exposure sessions
1476562|NCT03146832|Behavioral|Exposure therapy (according to inhibitory learning approach)|Exposure instruction focuses on expectation violation during exposure sessions
1476563|NCT03146819|Device|iTotal PS Knee Replacement System|Total Knee Replacement systems (Patient Specific)
1476564|NCT03146819|Device|Off-the-Shelf Knee Replacement System|Total Knee Replacement systems (Off-the-shelf)
1476565|NCT03146806|Drug|Intranasal ketamine|"10mg of intranasal ketamine will be given to make sure that the study patients are able to tolerate a small dose of NAS ketamine.
On the second visit, 10 mg of IV ketamine will be given to help establish bioavailability of NAS ketamine, with patients serving as their own controls.
On the third and fourth visit, higher doses of ketamine, 30 mg and 50 mg respectively, will be given.
All doses of ketamine will be administered by an anesthesia research nurse."
1476566|NCT03146793|Drug|Sodium Thiosulfate|25g intravenously 3 times per week
2000735|NCT03324412|Drug|Treatment of MTX and TwHF|Methotrexate : 10-15mg per week according to patient's weight, oral, for 24 weeks.Tripterygium wilfordii Hook F（TwHF）：20mg， 3 times a day, oral, for 24 weeks.
1476571|NCT03146767|Device|Tetanus stabilization of baseline|Administering a Tetanic stimulus before baseline stabilization shortens the stabilization period of baseline of a neuromuscular block monitor. This acts on the baseline value
1476572|NCT03146754|Other|Methodology|No intervention will be performed. Study is designed to test methodology of lung ultrasound in accessing b lines
1476573|NCT03146741|Drug|Zepatier|Zepatier (grazoprevir 100mg and elbasvir 50 mg once daily) is taken by mouth for 12 weeks unless a genetic variation is detected. In this case treatment with Zepatier will be extended to 16 weeks. Study subjects with treatment failure will be provided open-label Zepatier + sofosbuvir (sovaldi) 400mg + Ribavirin (generic), renally dosed based on creatinine clearance per the manufacturer guidelines.
1476665|NCT03145857|Drug|[68]Ga-HA-DOTATATE|All participants will be injected with [68]Ga-HA-DOTATATE approximately 60 minutes before PET/CT scan.
1481743|NCT03106753|Drug|Bupivacaine|intrathecal bupivacaine 7.5 mg
1476574|NCT03146728|Other|exercise|energy expenditure will be measured for each of the participants during different conditions, rest, during exercise with the arm crank height high or low. Energy expenditure will also be measured during exercise using different modes (arm ergometer, wheelchair and arm-bike). Results will be compared between rest and exercise and between individuals with SCI and able-bodied.
1476575|NCT03146715|Other|Feeding trial|Children were asked to eat the designated portion of the assigned food once a day for six weeks.
1476576|NCT03146702|Other|Quality of Life|Patients self administor quality of life questionnaires such as Minnesota Living with Heart Failure Questionnaire and EmPHasis-10 questionnaire
1476579|NCT03146663|Drug|NUC-1031 500 mg|NUC-1031 500 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
1476580|NCT03146663|Drug|NUC-1031 750mg|NUC-1031 750 mg/m2 on Days 1, 8, and 15 of a 28-day cycle
1476581|NCT03146650|Biological|Ipilimumab|Given IV
1476582|NCT03146650|Other|Laboratory Biomarker Analysis|Correlative studies
1476583|NCT03146650|Biological|Nivolumab|Given IV
1476584|NCT03146637|Biological|Activated CIK and bispecific antibody|CIK cells was activated by PD-1 inhibitor and bispecific antibody of anti-CD3/MUC1
1476585|NCT03146637|Biological|Activated CIK|CIK cells was activated by PD-1 inhibitor
1476586|NCT03146624|Other|attachment retained obturator|obturator which retained by attachment
1476587|NCT03146624|Other|clasp retained obturator|obturator which retained by clasp
1476588|NCT03146611|Diagnostic Test|nCD64|neutrophil CD64
1476589|NCT03146611|Diagnostic Test|Neutrophil/Lymphocyte Ratio|Neutrophil/ lymphocyte ratio
1476590|NCT03146598|Other|No intervention as it is a observational study|No intervention as it is a observational study
1476591|NCT03146585|Device|PBR assessment|Sublingual microcirculation will be investigated by specialized handheld videomicroscopy device for PBR index.
1476592|NCT03146572|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room
1476593|NCT03146572|Other|Handout|Handout providing written descriptions of strategies to encourage positive parenting behaviors
1476594|NCT03146559|Device|EMG and TENS|Healthy hand EMG signal measured while making voluntarily wrist dorsi flexion will activate TENS, which will be placed on the paretic forearm and will produce wrist dorsi flexion.
1476595|NCT03146559|Device|TENS only|Automatic TENS stimuli to the paretic dorsi flexors (i.e., producing wrist dorsi flexion).
1476596|NCT03146533|Drug|Fludarabine|Fludarabine 30 mg/m2/day IV for 3 days.
1476597|NCT03146533|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8g/m2/day IV for 2 days.
1476598|NCT03146533|Biological|CD19 CART|CD19 CART cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
1476599|NCT03146520|Device|EarlyTect Colon Cancer|SDC2 methylation assay by qPCR using EarlyTect Colon Cancer kit
1476602|NCT03146468|Drug|Nivolumab Injection|Human monoclonal antibody targeting programmed death-1 (PD-1) cell surface receptor
1476603|NCT03146455|Other|no intervention|no intervention
1476604|NCT03146442|Behavioral|Breakfast|For 6 months, the participants will either skip breakfast or will habitually consume a NP or HP breakfast every day.
1476605|NCT03146429|Diagnostic Test|I-123 FP-CIT Single photon emission tomography|Brain scan for dopamine transporter
1476606|NCT03146416|Drug|Evinacumab|SC or IV administration of Evinacumab
1476607|NCT03146416|Drug|Placebo|Matching placebo
1476608|NCT03146403|Biological|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP4 and glycoprotein D
1476609|NCT03146403|Biological|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
1476610|NCT03146403|Other|0.9% normal saline|Placebo
1476611|NCT03146390|Drug|Essential oils|all subjects will perform all interventions of all arms
1476612|NCT03146390|Drug|Alcohol free essential oils|all subjects will perform all interventions of all arms
1476613|NCT03146390|Other|Water|all subjects will perform all interventions of all arms
1476614|NCT03146377|Drug|Capecitabine|1250 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
1476615|NCT03146377|Drug|Oxaliplatin|85 mg/m2 IV on day 1 of a 2-week cycle
1476616|NCT03146377|Drug|Irinotecan|165 mg/m2 IV on day 1 of a 2-week cycle
1476617|NCT03146364|Device|Virtual Reality - Virtual Interactive Supermarket|"SeeMe is a PC based, innovative, comprehensive, clinician-controlled exercise and diagnostic system. SeeMe is designed to aid the rehabilitation process, and track patients' progress.
Virtual Interactive Supermarket- one of the SeeMe Tasks, the user need to buy products by according to specific instruction"
1476618|NCT03146351|Other|Family based early intervention program (NDT-Bobath based)|Family based early intervention program is NDT - Bobath based home program. Physiotherapist teaches principles of the treatment to infants' family. Family applies the program at home.
1476619|NCT03146338|Other|Magnesium-rich mineral water (Rozana)|intakes of 1.5 L by day
1476620|NCT03146325|Drug|BISMUTH TETRACYCLINE METRONIDAZOLE OMEPRAZOLE|A 14-day quadruple Hp eradication therapy consisting of: omeprazole (20 mg twice daily) plus 3 capsules q.i.d., each containing 420 mg of bismuth subcitrate potassium, 375 mg of metronidazole and 375 mg of tetracycline hydrochloride, for 14 days
1476621|NCT03146325|Drug|MATCHING PLACEBO|TO BE PREPARED BY LICENSED COMPOUNDING PHARMACY
1476622|NCT03146312|Dietary Supplement|MVM/phytochemical supplement|Consumption of an MVM/phytochemical supplement for 4 weeks
1476623|NCT03146312|Dietary Supplement|Placebo|Consumption of a placebo tablet identical in size, shape and color to the treatment tablet
1476624|NCT03146299|Procedure|TLH vs LAVH|"TLH: The subjects undergoing laparoscopic hysterectomy with a giant uterus of 500 g or more
LAVH: The subjects undergoing Laparoscopic Assisted Vaginal Hysterectomy with a giant uterus of 500 g or more"
1476625|NCT03146286|Dietary Supplement|Saturated fat|Palm stearin
1476626|NCT03146286|Dietary Supplement|Placebo|Water
1476627|NCT03146273|Dietary Supplement|Multivitamins|"After the study product administration blood tests will be performed in order to calculate the AUC for each mineral and vitamin - Vit A Vit E Folic Acid Vit C Calcium Magnesium
After the washout period, the same procedure will be done for the additional formulation of the multivitamins."
1476628|NCT03146260|Procedure|Conventional TESE|usual procedure for sperm extraction
1476629|NCT03146260|Procedure|Microdissection TESE|Procedure of extraction is performed under the operating microscope
1476631|NCT03146234|Genetic|CAR-GPC3 T cells|"Self-controlled dose escalation will be applied to the first 3 - 6 subjects enrolled.
Classical 3+3 dose escalation will be applied to subsequent subjects based on the self-controlled dose escalation study."
1476632|NCT03146221|Other|To look for serum microRNA profiles associated with restenosis|To look for serum microRNA profiles associated with restenosis
1476633|NCT03146195|Other|Dynamic Magnetic resonance imaging|
1476634|NCT03146182|Behavioral|CRP-algorithm|a strategy based on CRP guided antibiotic stewardship
1476635|NCT03146182|Behavioral|PCT-algorithm|a strategy based on PCT guided antibiotic stewardship
1476636|NCT03146169|Behavioral|Training group|"The training workshop includes four two-hour sessions:
Session one - a knowledge enhancement session at baseline; Session two - a leadership and interpersonal communication skills session at one week; Session three - a motivation enhancement session at one month Session four - an experience sharing and case discussion session at three months"
1476637|NCT03146156|Behavioral|Lifestyle Intervention|
1476639|NCT03146130|Biological|Variation of hyper dopaminergic behaviors of Parkinson's disease|Variation of hyper dopaminergic behaviors of Parkinson's disease
1476640|NCT03146104|Drug|Propofol|Intraoperative anesthesia will be maintained using propofol 100-150 mcg/kg/min, oxygen and air and FiO2 of 40% in propofol group (GROUP P)
1476641|NCT03146104|Drug|Isoflurane|in(GROUP I) maintenance will be done with 1 MAC of isoflurane, oxygen and air and FiO2 of 40%.
1476642|NCT03146091|Other|Nonantibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated without antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
1476643|NCT03146091|Other|Antibiotic treatment of uncomplicated diverticulitis|Patients randomized to this arm will be treated with antibiotics in the outpatient setting. Pain will be managed with appropriate analgesia as per protocol.
1476646|NCT03146052|Drug|PEG-4000 added with citrates and simethicone (PEG-CS) plus Bisacodyl|PEG-4000 added with citrates and simethicone (PEG-CS) (Kit contains 4 pouches, each containing 64.5gr of PEG) and bisacodyl 5 mg tablets
1476647|NCT03146039|Radiation|Radiation Therapy|"Whole pelvis radiation therapy will be delivered according to institutional standard of care.
SBRT is delivered with 5 fractions of 5.5-8 Gy prescribed to the high-risk CTV, with dose constraints identical to those for high dose rate, volume-directed brachytherapy. The patient will undergo arc therapy with a minimum of two arcs. On-line kV CBCT will be used to verify the isocenter prior to each arc delivery. Patients will be resimulated for SBRT boost planning."
1476648|NCT03146026|Behavioral|Combined Exercise Training|The CET program was performed for 60 minutes with 5 minutes of warm-up and cool-down per day, 3 times a week for 12 weeks. Combined exercise consisted of 20 minutes of various resistant band exercises (Upper body: seated rows, biceps curl, shoulder flexion, elbow flexion, chest press; Lower body: hip flexion, hip extension, calf raise, leg press, squat) and 30 minutes of treadmill walking. The warm-up and cool down consisted of static stretching. Intensity of exercise was gradually increased from 40-50% heart rate reserve (HRR) in weeks 1-4, and to 60-70% HRR in weeks 9-12. Each training session was fully supervised by the researchers. Every subject wore a heart rate monitor during the whole training session so as to maintain the correct training intensity.
1476649|NCT03146013|Diagnostic Test|MP Diagnostics HTLV Blot 2.4|HTLV I/II Confirmation and Differentiation
1476650|NCT03146000|Drug|lidocaine-prilocaine cream|topical cream
1476651|NCT03146000|Drug|meloxicam rectal suppository|suppository
1476652|NCT03145987|Dietary Supplement|Vitis vinifera extract|
1476653|NCT03145987|Other|Placebo|
1476654|NCT03145974|Device|mechanical ventilation|ventilatory support
1476655|NCT03145961|Drug|Pembrolizumab|200mg intravenous infusion
1476656|NCT03145948|Drug|ABBV-553|It is administered orally.
1476657|NCT03145948|Drug|Placebo|It is administered orally.
1476658|NCT03145935|Diagnostic Test|Abdominal compression (AC)|An echocardiography with stroke volume measurement coupled with an abdominal compression will be performed before and after ta diuretics induced diuresis of 10ml/kg in pediatric patients hospitalized in a pediatric intensive care unit (PICU) diagnosed with fluid overload
1476659|NCT03145935|Diagnostic Test|blood sample|proteinemia and hematocrit will be measured before and after a diuretics induced diuresis of 10ml/kg
1476660|NCT03145922|Other|Observational Study|Observational study utilizing bronchoscopy, and imaging
1476661|NCT03145909|Drug|ABBV-176|Intravenous infusion
1476662|NCT03145896|Dietary Supplement|vitamin D|After the gastroscopy all patients will be taught to take 4000 unit of vitamin D (25(OH)D) daily (not a specific brand) , for the next 2 week. All patients will be invited for follow-up in 2 weeks to get the histopathology result. In this encounter we will take again blood sample for 25(OH)D, calcium, phosphate, CRP and complete blood count including hemoglobin. a control group will not take the Vitamin D supplements.
1476664|NCT03145870|Other|Echoing of the lower limbs and measuring the systolic pressure index|Echoing of the lower limbs and measuring the systolic pressure index
1476666|NCT03145831|Drug|Somavaratan|All subjects will receive somavaratan 3.5 mg/kg twice monthly (every 15 days ± 2 days). Administered as a subcutaneous bolus injection.
2000741|NCT03324373|Drug|Lenvatinib|Lenvatinib is a receptor tyrosine kinase (RTK) inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). Lenvatinib also inhibits other RTKs that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1, 2, 3, and 4; the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET.
1476668|NCT03145792|Behavioral|Seeking Safety|Seeking Safety (SS) is a present-focused, evidence-based cognitive-behavioral therapy for trauma and/or addiction. It offers safe coping skills and education relevant to both problem areas.
1476669|NCT03145792|Behavioral|CBT for Pathological Gambling|Cognitive Behavior Therapy for Pathological Gambling (CBT-PG) is an evidence-based therapy for gambling problems. It focuses on cognitive correction, problem solving, social skills and relapse prevention.
1476670|NCT03145766|Biological|VRVg 2|Modified formulation 1 of Purified Vero Rabies Vaccine Serum Free
1476671|NCT03145766|Biological|VRVg 1|Initial formulation of Purified Vero Rabies Vaccine Serum Free
1476672|NCT03145766|Biological|Imovax Rabies|Purified inactivated rabies vaccine prepared on human diploid cell cultures
1476673|NCT03145766|Biological|VRVg 2|Modified formulation 2 of Purified Vero Rabies Vaccine Serum Free
1476674|NCT03145766|Biological|VRVg 2|Modified formulation 3 of Purified Vero Rabies Vaccine Serum Free
1476675|NCT03145753|Other|HIV/HCV Education plus Testing|Education included a half day educational program and the provision of supporting materials to enhance HIV testing, such as a clinical decision algorithm to perform HIV test and clinical remainders to help meet with the current Spanish Early Diagnosis HIV Testing Recommendations. Half day educational program, to promote early diagnosis of HIV, HCV, in a Primary Care Health Area.To Improve knowledge and current trends in the prevention, diagnosis and management of HIV infection among non health professionals specialists in infectious diseases.DRIVE 03 program will offer rapid HIV tests, and testing staff to conduct all study procedures.The study activities will be carried out by the trained testing staff.
1476676|NCT03145753|Other|HIV/HCV Education|Only education and support will be provided in this arm
1476677|NCT03145740|Other|Intensive F.O.T.T.®|Therapeutic F.O.T.T.® intervention provided by Occupational Therapists (OTs). The intervention consists of positioning the patient, and giving sensory input to the hands and face in order to stimulate and facilitate swallowing of saliva or small amounts of food and drink, if considered safe.
1476678|NCT03145740|Other|Unspecific Stimulation of face and mouth|The intervention consists of positioning the patient and either washing his face, the hands, or brushing teeth, apply lipbalm, with no specific stimulation or facilitation of swallowing
1476679|NCT03145727|Device|Placebo Group|In this group, the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the opposite arm of the chemotherapy infusion, but in this group the electrical stimulation will be performed just by 10 seconds and turn off for all reminiscent time of the protocol.
1476680|NCT03145727|Device|Low Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
1476681|NCT03145727|Device|High Frequency Group|In this group the TENS will be administered by 30 minutes prior to chemotherapy administration with the stander electrodes positions, in the arm opposite the chemotherapy infusion. The electrical stimulation will be continued for all time secession. The electrical pulse parameters will be setting according describe early.
1476682|NCT03145714|Drug|Maintainance of anesthesia with Intravenous Propofol infusion|The dosage of Intravenous Propofol will be titrated to maintain BIS Values between 40 -60.
1476683|NCT03145714|Drug|Maintainance of anesthesia with Intravenous Dexmedetomidine|The dosage of Intravenous Dexmedetomidine will be titrated to maintain BIS Values between 40 -60.
1476684|NCT03145688|Behavioral|Family Physical Activity Planning|
1476685|NCT03145688|Behavioral|Family Physical Activity Habit Formation|
1476686|NCT03145675|Drug|Enoxaparin (Staged-dose PCI Group)|Enoxaparin 0.5+0.25 mg/kg administered intravenously.
1476687|NCT03145675|Drug|Enoxaparin (Single-dose PCI Group)|Enoxaparin 0.75 mg/kg administered intravenously.
1476688|NCT03145675|Drug|Enoxaparin (High-dose Group)|Enoxaparin 0.75 mg/kg administered intravenously.
1476689|NCT03145675|Drug|Enoxaparin (Standard-dose Group)|Enoxaparin 0.5 mg/kg administered intravenously.
1476690|NCT03145662|Device|high pressure balloon|high pressure balloon will be used to treat stenosis
1476691|NCT03145662|Device|cutting balloon|cutting balloon will be used to treat stenosis
1476692|NCT03145649|Other|Dietary therapy or insulin injection|
1476694|NCT03145623|Drug|Elbasvir and Grazoprevir|Elbasvir 50 mg and grazoprevir 100 mg during the French temporary authorization for use (ATU) program
1476695|NCT03145610|Other|Placebo toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to Placebo group will be submitted to a chemical plaque control (three times per day) using a Triclosan toothpaste.
1476696|NCT03145610|Other|triclosan/copolymer/fluoride toothpaste|During an experimental 3-week period of undisturbed mechanical plaque accumulation in the implants, implants randomly assigned to triclosan/copolymer/fluoride group will be submitted to a chemical plaque control (three times per day) using a triclosan/copolymer/fluoride toothpaste.
1476697|NCT03145597|Device|Laminate veneer of composite|Composite laminate veneers, 2-4-6 veneers per patient
1476698|NCT03145597|Device|Laminate veneer of ceramic|laminate of ceramic (Empress Esthetic, Ivoclar Vivadent), ceramic laminate veneer, 2-4-6 veneers per patient will be made.
1476699|NCT03145584|Drug|Continuous Bupivacaine via Adductor Canal Saphenous Catheter|12.5 mg/hr of bupivacaine was administered continuously via a paraneural catheter for 48 hours following surgery to determine whether superior analgesia was obtained when compared to single shot block with a sham catheter.
1476700|NCT03145584|Other|Single Shot Adductor Canal Saphenous Block with Bupivacaine|A sham catheter was placed on the skin and covered in a dressing to blind the patient, data collector and investigator as to group allocation
1476701|NCT03145571|Procedure|Continuity of midwifery care|Pre-natal care in rural villages performed by the midwives from the local hospital
1476702|NCT03145558|Drug|Tirapazamine|Replacing the standard chemotherapy agent doxorubicin used in TACE with tirapazamine
1476703|NCT03145558|Drug|Doxorubicin|Standard of care for TACE
1476704|NCT03145545|Device|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique.
1476705|NCT03145532|Other|tDCS plus robotic training|Children will first receive 20 min of tDCS (real or sham, see Arms), then will receive 1 hr of upper limb robotic therapy in which the child will use their impaired arm and hand to move a joystick controlling a cursor to a set of targets on a video screen in front of the child.
1476706|NCT03145519|Device|Vasofix Certo Catheter|Placement of IV-catheter
1476707|NCT03145519|Device|OptiVein Catheter|Placement of IV-catheter
1476708|NCT03145506|Device|Multimodal Spectroscopy|optical measurement of excised tissue
1476709|NCT03145493|Device|drainage|Administration of IV tranexamic acid at the moment of anesthetic induction (1g) and at tourniquet release (1g), installing a suction drain
1476710|NCT03145480|Drug|Obinutuzumab|100 mg on day 1 and 900 mg on day 2 Cycle 1, 1000 mg on day 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6
1476711|NCT03145480|Drug|Ibrutinib|560mg po daily
1476712|NCT03145480|Other|CHOP|cyclophosphamide, doxorubicin, vincristine, and prednisone
1476713|NCT03145467|Drug|Paracetamol|1000 mg of paracetamol (Parol Tablet - Atabay İlaç Fabrikası A.Ş.) Oral (PO) was given 100 patients
1476714|NCT03145467|Drug|Zolmitriptan|Zolmitirptan 2,5 mg (Zomig Tablet - Astra Zeneca) oral (PO) was given 100 patients
1476715|NCT03145454|Device|electroencephalography helmet|electroencephalography helmet with twelve electrodes will be performed during surgical gesture to determine the pain of child.
1476716|NCT03145454|Device|dermal electrode|dermal electrode on the back of the hand will be performed during surgical gesture to determine the pain of child.
1476717|NCT03145454|Device|blood pressure sensors|blood pressure sensors on the finger will be performed during surgical gesture to determine the pain of child.
1476718|NCT03145454|Device|Pupillometry glasses|Pupillometry glasses will be performed during surgical gesture to determine the pain of child.
1476719|NCT03145454|Device|Holter|Three electrodes electrocardiography on the chest will be performed during surgical gesture to determine the heart rate variability.
1476720|NCT03145441|Device|CytoSorb®|CytoSorb® is a biocompatible, high adsorptive polymer indicated in conditions where cytokine levels are extremely elevated.
1476721|NCT03145428|Diagnostic Test|CBC-Diff Monocyte volume width distribution (MDW)|MDW measurement used to detect sepsis. Results will not be used to manage patients
1476722|NCT03145415|Procedure|Caudal block|1 cc per kg of 0.2% ropivicaine in the caudal space given before the start of surgery.
1476723|NCT03145415|Procedure|Bilateral Pudendal block|0.5 cc per kg of 0.2% ropivicaine. Half of the volume given as a right pudendal block and the remaining volume given on the left pudendal nerve block given prior to the start of surgery
1476724|NCT03145402|Biological|Intracoronary injection of stem cell|Autologous bone marrow-derived mononuclear cells are obtained from 100-150ml of bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed in patients with Heart failure via conventional percutaneous intracoronary intervention techniques.
1476725|NCT03145402|Biological|Placebo|Injection of Placebo in patients with Heart failure via coronary arteries
1476726|NCT03145389|Procedure|Epidural catheter placement|After explaining about the procedure an 18 Gauge epidural catheter was inserted into thoracic 11-12 inter vertebral space under strict asepsis. Before inserting the epidural needle same space was infiltrated with adequate amount of 2% Lignocaine with Adrenaline (1: 200,000) to make the procedure pain free. Epidural space was confirmed by loss of resistance technique.
1476728|NCT03145363|Behavioral|Intervention|The intervention group will receive 2-5 interactive text message sequences per week. These messages will invite students to reply using keywords and short free text replies. Messages come from a library of strength-based peer quotations (reviewed for safety), psychoeducational interactions, and games designed to promote emotional skills and use of resources.
1476729|NCT03145363|Behavioral|Control|"The control group will receive 1-2 (non-interactive) text messages per week containing general SoS concepts (e.g., Remember: more strengths are better when times get tough)."
1476730|NCT03145350|Other|High-fat, low-carbohydrate|Dietary intervention: 4 week
1476731|NCT03145350|Other|Low-fat, high-carbohydrate|Dietary intervention: 4 week
1476732|NCT03145337|Biological|FlexHD ADM (Cohort A)|Tissue assisted breast reconstruction with FlexHD pliable perforated ADM
1476733|NCT03145337|Biological|AlloDerm RTU ADM (Cohort B)|Tissue assisted breast reconstruction with AlloDerm RTU perforated ADM
1476734|NCT03145324|Other|Collection of vaccine histories|
1476735|NCT03145311|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|
1476736|NCT03145298|Biological|Allogeneic Human Cardiosphere-Derived Stem Cells|Human Allogeneic Cardiosphere-Derived Cells is a biologic product consisting largely of cells grown from donated human heart muscle tissue
1476737|NCT03145298|Biological|Placebo|For use in Phase 1b - Double-blind randomized control portion of the study
1476803|NCT03144765|Procedure|Transanal Total Mesorectal Excision (taTME)|Study procedures consist in 1-team (sequential) or 2-team (combined) low anterior resection with transanal TME using laparoscopic or robotic abdominal assistance.
1476849|NCT03144323|Behavioral|Reminders|"Four reminders will be set on the patient's mobile phone's Calendar-type app, saying Don't forget to wear your elastics, at 08:00, 13:00, 17:00 and 22:00."
1476738|NCT03145285|Drug|Abiraterone Acetate|"Cohort 1:
Patients locally advanced/metastatic ACC patients with uncontrolled Cushing's syndrome despite Mitotane +/- chemotherapy will be treated with single agent AA.Mitotane and chemotherapy will be interrupted and AA will be continued till progression and/or until progression of Cushing's syndrome.
Cohort 2:
Mitotane-naïve patients with newly diagnosis of ACC associated with Cushing's syndrome not amenable to surgical resection will be treated with AA for 4 weeks followed by AA + Mitotane +/- first-line chemotherapy. AA in association with Mitotane will be administered for 3 months. If the primary endpoint is obtained before 1 month (i.e. 2 or 3 weeks from Abiraterone start), then Mitotane +/- chemotherapy can be started upon the clinician's decision."
1476739|NCT03145272|Drug|Oxycodone|A single weight-adjusted oxycodone dose of 0.1 mg/kg is administered as per standard clinical dosing guidelines
2000742|NCT03324373|Drug|Everolimus|Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular protein, FKBP-12, resulting in an inhibitory complex formation (mTORC1) and thus inhibition of mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic elongation factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.
2000743|NCT03324373|Procedure|Partial or Radical Cytoreductive Nephrectomy|"Surgical removal of a kidney.
After completion of 8 weeks of therapy and restaging, investigators will require 2 weeks wash out period. The patients will be evaluated by urology oncology team and appropriate surgery will be planned. This includes partial nephrectomy and radical nephrectomy."
1476742|NCT03145246|Procedure|regeneration treated teeth loss|number of regeneration treated teeth loss
1476743|NCT03145246|Procedure|regenerated treated teeth with clinical attachment loss|regenerated treated teeth with clinical attachment loss ≥ 2 mm
1476744|NCT03145233|Other|Isometric exercise programme|Exercise programme where the muscle length and joint angle do not change due to the limb being held in a static position
1476745|NCT03145233|Other|Isotonic exercise programme|Exercise programme where both the muscle length and joint angle do change, consisting of concentric muscle actions (where the muscle shortens) and eccentric muscle actions (where the muscle lengthens)
1476746|NCT03145220|Drug|EA-230|Active intervention
1476747|NCT03145220|Other|Placebo (NaCl)|Placebo intervention
2000744|NCT03324360|Drug|Hyperpolarized 13C-Pyruvate|MRI with Hyperpolarized 13C-Pyruvate Injection
1476749|NCT03145194|Drug|Ticagrelor|2 x 90mg Ticagrelor tablets
1476750|NCT03145194|Other|Placebo|2 x matching placebo tablets
1476752|NCT03145168|Other|High Target Mean Arterial Pressure|High target group (80-85 mm of Hg).
1476753|NCT03145168|Other|Low Target Mean Arterial Pressure|Low target MAP group (60-65mm Hg).
1997638|NCT01982045|Device|AttraX® Putty|Synthetic bone graft comprised of calcium phosphate granules and hydroxyapatite with an advanced biodissolvable polymer carrier that allows for better handling of the granules in putty form.
1476758|NCT03145129|Device|Continuous Positive Airway Pressure|Continuous Positive Airway Pressure
1476759|NCT03145116|Device|CT ASPHINA 509|Intraocular lens
1476760|NCT03145103|Device|CT ASPHINA 409|intraocular lens
1476761|NCT03145077|Procedure|Magnetic Resonance Imaging (MRI)|Multi-parametric MRI performed at Baseline and at each study visit.
1476762|NCT03145077|Behavioral|Questionnaires|Patient-related outcomes (PROs) questionnaires completed at Baseline, and at each study visit. These will also include questionnaires regarding daily life, diet, and ability to swallow and speak.
1476763|NCT03145064|Drug|BGB-3111|BGB-3111 at a dose of 160 mg orally (PO) twice daily (BID)
1476764|NCT03145051|Other|Saline solution|a nasal irrigation care
1476765|NCT03145051|Other|Respimer Netiflow|a nasal irrigation care
1476772|NCT03145025|Device|Retisert|Intravitreal Implant
1476773|NCT03145025|Drug|Fluocinolone Acetonide Intravitreal Implant|Intravitreal Implant
1476774|NCT03145012|Drug|Ranitidine|Thirty subjects will receive Ranitidine to a maximum of 900 mg/day in 2 daily oral doses for 6 weeks. The dosage target is 8 mg/kg/day, but the range of ranitidine intake will be between 7.5- 9 mg/kg/day. This is due to the formulation of the tablets, sold as 75, 150, and 300mg tablets.
1476775|NCT03144999|Biological|AAVCAGsCD59|AAVCAGsCD59 is administered as a single intravitreal injection in an office setting
1476804|NCT03144739|Other|Training in management of children's mental health problems|"General practitioners will be trained using internationally-developed materials, including the World Health Organization's mental health need/service gap (mhGAP) materials and others, adapted for the trial setting (based on formative work that is part of the project). They will be assisted and monitored as part of the ongoing collaborative care program in which they are participating."
1476850|NCT03144310|Other|lung ultrasound|lung ultrasound and blood gas
1997639|NCT01982045|Other|Autologous bone graft|Corticocancellous bone harvested from the iliac crest, with our without local bone obtained from decompression and/or preparation for fusion (facetectomy and denudement).
1997640|NCT01981057|Other|Numeta|parenteral receipt prescribed with Numeta
1997641|NCT01981057|Other|Individual|parenteral receipt prescribed individually
1476776|NCT03144986|Device|Deep Insula-coil rTMS|Before administering TMS participants will undergo cue stimuli provocation, consisting of 32 professional color images of high calorie, sweet and savory food. This will follow with TMS. All subjects will receive prefrontal deep TMS (18 Hz, 2 sec on, 20 sec off, over approximately 30 min) 5 times per week, for 6 weeks, for a total of 30 sessions as a part of an active treatment phase. Maintenance treatment phase will include two sessions of rTMS (18 Hz, 2 sec on, 20 sec off, over approximately half an hour) weekly for the period of 6 weeks.
1476777|NCT03144973|Diagnostic Test|periosafe|mouth rinsing quick-test
1476778|NCT03144960|Procedure|Mechanical Thrombectomy|mechanical thrombectomy with retrievable stents, thrombus aspiration, retraction, wire disruption
1476779|NCT03144947|Biological|Trastuzumab IV|"Pre-randomization phase:
FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2; cyclophosphamide 500 mg/m2) x 3 cycles
Post-randomization phase:
Group A: Trastuzumab IV (8 mg/kg loading dose, followed by 6 mg/kg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.
by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.
*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
1476780|NCT03144947|Biological|Trastuzumab SC|"Pre-randomization phase:
FEC (fluorouracil 500 mg/m2; epirubicin 75 mg/m2;
Group B: Trastuzumab SC (fixed dose of 600 mg) plus pertuzumab IV (840 mg loading dose, followed by 420 mg) plus docetaxel (75 mg/m2)*, every 3 weeks for 4 cycles.
*The dose of docetaxel may be escalated to 100 mg/m 2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated. After surgery, study patients will receive trastuzumab x 14 cycles using the same formulation (SC or IV) of the preoperative phase."
1476781|NCT03144947|Biological|Pertuzumab|pertuzumab IV (840 mg loading dose, followed by 420 mg) weeks for 4 cycles (both arms)
1476782|NCT03144947|Drug|Docetaxel|docetaxel (75 mg/m2), every 3 weeks for 4 cycles (both arms). The dose of docetaxel may be escalated to 100 mg/m2 at the investigator's discretion on subsequent cycles if the initial dose is well tolerated.
2000745|NCT03324347|Procedure|Therapydog|Presence of a therapydog during a clinical examination in a dental clinic
1476785|NCT03144921|Behavioral|psychoeducational skills training intervention|This protocol is a minimal risk care values clarification /care planning and psychoeducational skills training intervention, delivered as a workshop series plus one in-home session for people in the early stages of memory loss and their care partner together.
1476786|NCT03144908|Other|Standard Operating Procedures|Observational on Standard Operating Procedures
1476787|NCT03144895|Procedure|Laying a radial or femoral arterial catheter|Laying a radial or femoral arterial catheter
1476788|NCT03144882|Drug|Curcumin Pill|Turmeric rhizome at first was washed and dried out in a warm and dry place for a week , then powdered rhizomes were encapsulated by Clinical Pharmacy Research Center of Shahid Beheshti University of Medical Sciences, using hard gelatin capsules. Also placebo capsules were made by the same center using Sorbitol. Curcumin level of turmeric was measured by HPTLC analysis for quantification of variability in content of curcumin
1476789|NCT03144882|Drug|Placebo|placebo
1476790|NCT03144869|Behavioral|physical activity monitor and feedback|Children will wear a Runscribe accelerometer for two weeks (children in Arm 2 will also wear a CGM). Runscribe will measure activity levels. Activity data will be downloaded by a researcher, analysed and graphs of daily activity levels prepared. At the child's next routine clinic appointment, child and parent will have 1:1 session with researcher acting as 'physical activity champion'. Session content will be informed by Phase 1, but will involve educational support around PA (including barriers and facilitators to participation) and individualised feedback on PA level). Individualised feedback will involve review of daily PA graphs - addressing times of high and low activity levels. For participants in Arm 2, there will also be review of daily line graphs showing BG trends. As part of standard clinical care, CGM data gets downloaded at routine clinic appointments and is visible on the patient's clinic notes in daily graph form.
1476791|NCT03144856|Drug|Apatinib|Apatinib 500mg, po, qd, every 4 weeks.
1476792|NCT03144843|Drug|Apatinib|Apatinib 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
1476793|NCT03144843|Drug|Placebos|Placebo: 500mg, po, qd, every 4 weeks Paclitaxol: 80mg/m2, d1, d8, d15, every 4 weeks
1476794|NCT03144830|Device|Exoskeleton|This is an open study and so all participants involved with be using the exoskeleton to determine the safety and feasibility of its use during the acute rehabilitation phase.
1476795|NCT03144817|Other|Dialysate Sodium Lowering|Dialysate sodium is lowered until nadir sodium level is reached. Participant dialyzes at this sodium level until end of follow-up.
1476796|NCT03144804|Drug|Lamivudine|This drug may help prevent the growth and spread of the cancer cells to other parts of the body.
1476797|NCT03144778|Drug|Durvalumab|1500 mg (equivalent to 20 mg/Kg) in patients > 30 Kg by vein for a total of 2 doses on Day 1 and Day 29.
1476798|NCT03144778|Drug|Tremelimumab|75 mg (equivalent to 1 mg/kg Q4W) for 2 doses in patients >30 kg by vein for a total of 2 doses on Day 1 and Day 29.
1476799|NCT03144778|Behavioral|Questionnaire|Symptom questionnaire completed on Day 1, Day 29, Day 5, 42 days after surgery or, if receiving standard-of-care chemotherapy/radiation therapy, within 7 days before starting the regimen, 6 months after surgery, 24 months, and 5 years after surgery.
1476800|NCT03144778|Procedure|Surgery|Standard of care surgery performed preferably no earlier than 8 weeks and no later than 10 weeks after the first administration of the investigational agents.
1476801|NCT03144778|Drug|Chemotherapy|Post-operative chemotherapy delivered at the best judgment of the treating physicians, preferably within 6 weeks of surgical resection.
1476802|NCT03144778|Radiation|Radiation Therapy|Post-operative radiation therapy delivered at the best judgment of the treating physicians, preferably within 6 weeks of surgical resection.
1476851|NCT03144297|Other|Lumbar puncture|diagnostic lumbar puncture
1476805|NCT03144739|Other|Current collaborative care protocol|General practitioners have been trained to recognize children's mental health problems and to refer them to a partner community mental health center. They receive feedback about the referral but are not encouraged to take on care for the child themselves.
1476806|NCT03144726|Device|Negative pressure wound therapy|Negative pressure wound therapy is a commonly utilized tool in the hospital setting and will be applied to amputations in our study to determine the effect on surgical site infections
1476807|NCT03144726|Other|Standard dressing|A standard dressing will be applied to the amputations in this arm of the study
1476808|NCT03144713|Drug|Terlipressin|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
1476809|NCT03144713|Drug|Midodrine|Terlipressin 1mg intravenous bolus at the onset of paracentesis and the remaining as 1 mg doses intravenous at 8 and 16 h after the first dose. ( total -3mg)
1476810|NCT03144713|Drug|Albumin|Albumin-8g/L of tap- one half of dose at beginning of tap and rest half after 6 hours of tapping.
1476811|NCT03144687|Drug|Itacitinib|Itacitinib self-administered orally once daily at the protocol-defined dose.
1476812|NCT03144687|Drug|Ruxolitinib|Ruxolitinib self-administered orally at the stable dose of < 20 mg daily established before entering the study.
1476813|NCT03144674|Drug|INCB050465|INCB050465 at the protocol-defined dose.
1476814|NCT03144661|Drug|INCB062079|In Part 1, initial cohort dose of INCB062079 at the protocol-defined starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended dose(s) from Part 1 will be taken forward into Part 2 cohorts.
1476815|NCT03144648|Other|lifestyle|Observational study
1476816|NCT03144635|Drug|Grazoprevir plus Elbasvir|An oral dose of 100 mg/day of grazoprevir as well as an oral dose of 50 mg/day of elbasvir for 12 weeks.
1476817|NCT03144609|Procedure|low PEEP|The control group consisted of obese patients mechanically ventilated by a standardized volume-controlled breathing mode with low respiratory volume without alveolar recruitment maneuver and using low values of PEEP up to 4 cm H2O.
1476818|NCT03144609|Procedure|ARM|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with alveolar recruitment maneuver performed immediately after induction, followed every 30 minutes during the hemodynamic stable condition under operation.
1476819|NCT03144609|Procedure|high PEEP|The experimental groups also consisted of obese patients mechanically ventilated by a volume-controlled breathing mode with low respiratory volume 7 ml/kg ideal body mass, but with higher PEEP, provided that the upper limit of 40 cm H20 was not exceeded.
1476820|NCT03144596|Drug|Alfuzosin Hydrochloride 10 MG|Alfuzosin hydrochloride Tablet
1476821|NCT03144596|Drug|Tamsulosin Hydrochloride 0.4 MG|Tamsulosin Hydrochloride Tablet
1476822|NCT03144583|Biological|Adult differentiated autologous T-cells|After pretreatment, adult differentiated autologous T-cells with a chimeric antigen receptor with anti-CD19 specificity will be transfused.
1476823|NCT03144570|Other|None, non-interventional study|Not applicable, non-interventional study
1476824|NCT03144557|Other|Education|Education protocol included 4 individual sessions of verbal and graphic instructions to correct inhalation technique in patients with COPD
1476825|NCT03144544|Procedure|Pediatric surgical procedures|Eligible surgical procedures were identified using Canadian Classification of Health Interventions (CCI) therapeutic intervention codes.
1476826|NCT03144531|Behavioral|Sleep Intervention for Kids and Parents (SKIP)|Dyadic approach using self-efficacy theory to set goals, anticipate barriers, problem solve
1476827|NCT03144518|Other|Positive Affect Intervention|See Previous Description
1476828|NCT03144518|Other|Neutral Control Intervention|See Previous Description
1476829|NCT03144518|Biological|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)|Northern Hemisphere Influenza Vaccine 2017/18 (Delivered as part of Standard Care)
1476830|NCT03144505|Behavioral|MCT combined with RT Group|
1476831|NCT03144505|Behavioral|HIIT combined with RT Group|
1476832|NCT03144492|Biological|Blood volume collected specifically for this study|The subject will be sitting in a chair, and a needle will be inserted into a vein in their arm. Study Team will draw about 45ml or 3 tablespoons of whole blood for research.
1476833|NCT03144479|Procedure|right-sided double lumen tube|Verification of a new technique to assess the correct positioning of a right-sided double-lumen tube for left thoracic surgeries, using a central venous catheter wire guide and a radioscopy
1476834|NCT03144466|Combination Product|Pembrolizumab|antiPD1 monoclonal antibody
1476835|NCT03144453|Drug|Sugammadex Injectable Product|Patients receive sugammadex at the end of the surgery
1476836|NCT03144453|Drug|Neostigmine, Atropine|Patients receive neostigmine+atropine at the end of the surgery
1476837|NCT03144414|Procedure|Laparoscopic hysterectomy|Laparoscopic hysterectomy
1476838|NCT03144401|Drug|Misoprostol|mesotac
1476839|NCT03144401|Other|Placebo|Placebo tablet identical to the misoprostol tablet but without the active ingredient
1476840|NCT03144388|Procedure|Variable Stepping Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
1476841|NCT03144388|Procedure|Variable Non-specific Training|Six weeks (20 sessions) of high intensity stepping training in multiple variable environments
1476842|NCT03144375|Other|Medical optimization and education|Medical treatment and education about the sinusitis disease process prior to surgery as compared to baseline surgical and treatment counseling
1476843|NCT03144375|Procedure|Standard of Care sinus surgery|
1476844|NCT03144362|Procedure|Bilateral Sliding Techniques|Bilateral Sliding Techniques
1476845|NCT03144362|Procedure|Unilateral Sliding Techniques|Unilateral Sliding Techniques
1476846|NCT03144336|Behavioral|Information provision|All study participants will receive weekly messages with HIV prevention information.
1476847|NCT03144336|Behavioral|Weekly quizzes|Those in the intervention group receive a weekly quiz by text message that gains them points increasing their chances of winning a prize if answered correctly
1476848|NCT03144336|Behavioral|Rewards for testing HIV-negative|Those in the intervention group are entered into a prize drawing if they test HIV-negative at least once in a three-month period.
1476853|NCT03144284|Other|Knowledge, attitude, and practice survey|A knowledge, attitude, and practice questionnaire is going to be distributed to dental interns.
1476854|NCT03144271|Drug|semaglutide|A single dose of 0.625, 1.25, 2.5, 5, 10, 20, 40 or 80 μg/kg semaglutide will be administered subcutaneously (s.c. under the skin).
1476855|NCT03144271|Drug|Placebo|A single dose of placebo will be administered subcutaneously (s.c. under the skin)
1476856|NCT03144245|Biological|AMV564|AMV564 for administration via continuous intravenous daily infusion.
1476857|NCT03144232|Device|Active rTMS|rTMS will be delivered via a MagPro double blinded rTMS Research System (MagVenture, Denmark) with a Cool-B65 Butterfly Coil (a combined active and sham coil). We will use a standard resting motor threshold (rMT) determination to determine the TMS dose (49). Treatment will be delivered at 120% rMT. Each active TMS treatment will consist of a total of 4000 pulses of 10Hz stimulation (5s-on,10s-off). Treatments will be delivered at the EEG coordinate for F3 (which approximates the left DLPFC), and will be found using the Beam-F3 method.
1476858|NCT03144232|Device|Sham rTMS|Sham sessions will be delivered using an electronic sham system consisting of a coil that mimics the appearance and sound of TMS, combined with a TENS device which produces a small electric shock mimicking the feeling of real TMS. This type of sham has been demonstrated to be indistinguishable from real TMS.
1476859|NCT03144219|Diagnostic Test|Transcranial Doppler (TCD) ultrasound monitoring|TCD monitoring comatose patients in ICU looking for signs of impaired cerebral compliance
1476860|NCT03144206|Drug|Hyperbaric oxygen|Patients with soft tissue sarcomas will receive HBOT treatment in the immediate postoperative period
1476861|NCT03144193|Other|Topical anti-aging cosmetic cream|Topical anti-aging cosmetic cream
1476862|NCT03144180|Device|Q-cup|This technology is a different way of collecting umbilical cord blood.
1476863|NCT03144167|Other|Analysis of spectroscopic biomarkers of proliferation for six-month survival|Analysis of spectroscopic biomarkers of proliferation, glial reaction, infiltration and glutaminergic metabolism or glycolytic metabolism for six-month survival
1476864|NCT03144154|Behavioral|Self-hypnosis + Self-care|Our groupal intervention is divided into 8 weekly 2-hour sessions in which one self-hypnosis exercise is proposed to participants. Self-care techniques are also discussed (knowing our own needs, self-respect, assertiveness, coping with ruminations...) and homework assignments are proposed to participants, in order to foster positive change.
1476865|NCT03144141|Other|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization|Electrical recording of uterine activity by EHG either directly at the emergency or at the hospitalization
1476868|NCT03144115|Drug|Oxytocin|
1476869|NCT03144115|Drug|Placebos|
1476870|NCT03144102|Behavioral|Virtual Reality-based therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 VR-based exercises that involve reaching, grasping, and intercepting virtual objects. The training will last a total of 30 min per session.
1476871|NCT03144102|Device|Anodal transcranial direct-current stimulation (tDCS)|Concurrent anodal tDCS on sensorimotor cortex on the ipsilesional hemisphere.
1476872|NCT03144102|Behavioral|Occupational Therapy for upper-limbs motor rehabilitation|During each session, the subject will perform 4 occupational therapy exercises that involve reaching, grasping, and intercepting objects. The training will last a total of 30 min per session.
1476873|NCT03144102|Device|Sham transcranial direct-current stimulation (tDCS)|Concurrent sham tDCS on sensorimotor cortex on the ipsilesional hemisphere.
1476874|NCT03144089|Device|Articulated Oral Airway|The AOA is a novel device which actively displaces the tongue, allowing for a greater cross-sectional area for mask ventilation. When randomized to be placed first, the AOA will be inserted and evaluated first, followed by the Guedel oral airway.
1476875|NCT03144089|Device|Guedel oral airway (active comparator)|The Guedel oral airway is a standard oral airway commonly used to facilitate mask ventilation. When randomized to be placed first, the Guedel oral airway will be inserted and evaluated first, followed by the Articulating Oral Airway (AOA).
1476876|NCT03144076|Other|RSBY Health Insurance|RSBY is a national inpatient public insurance plan in India, made available through this study to participants in Groups A, B, and C.
1476877|NCT03144050|Device|SFDI Imaging|Imaging with SFDI device
1476878|NCT03144024|Device|band implantation|
1476879|NCT03144024|Device|rigid ring implantation|
1476880|NCT03143998|Drug|MK-5172A|A single FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
1476881|NCT03143985|Drug|TEW-7197|TEW-7197 is an inhibitor of protein serine/threonine kinase activity of TGF-β receptor type 1 (TGFBR1; ALK5). TEW-7197 inhibits the phosphorylation of the ALK5 substrates, Smad2 and Smad3, and the intracellular signaling of TGF-β. Dosing begins at 60mg by mouth, daily and may increase to 240mg by mouth daily in the absence of dose limiting toxicities
1476882|NCT03143985|Drug|Pomalidomide|POM, an analog of thalidomide, is an immunomodulatory agent with antineoplastic activity. Myeloma tumor cells exposed to POM, undergo growth arrest and increased apoptotic cell death. POM enhances T cell- and natural killer cell-mediated immunity and inhibit production of pro-inflammatory cytokines by monocytes. POM may be taken orally with water. Capsules should not be broken, chewed or opened. POM should be taken without food (at least 2 hours before or 2 hours after a meal). POM will be commercially available. POM will be taken by mouth at a dose of 4mg per day
1476883|NCT03143972|Drug|Dexmedetomidine|Single drug administration
1476884|NCT03143972|Drug|Remifentanil|Single drug administration
1476885|NCT03143946|Dietary Supplement|Vitamin supplement;|Vitamin K, vitamin A, vitamin D, vitamin E, nicotinamide, vitamin B12
1476886|NCT03143946|Other|Diet advice|
1476887|NCT03143933|Drug|Propofol|I.V propofol
1476888|NCT03143933|Drug|Fentanyl|
1477007|NCT03142945|Other|MDT based physical therapy|MDT based physical therapy
1477008|NCT03142932|Device|Individualized carbon monoxide (iCO) monitor|a personal monitor for a breath test for carbon monoxide (CO)
1476890|NCT03143907|Behavioral|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, and in the pilot study conducted at the Early Psychosis Program at London Health Sciences Centre in London, Ontario. Its youth-focus and emphasis on building social and emotional competencies through mindfulness make it a promising intervention for youth recovering from their first episode of psychosis.
1476891|NCT03143894|Device|TDCS|Transcranial direct current stimulation (tDCS) is a safe, portable, non-invasive form TDCS is a form of non-invasive electrical brain stimulation using low amplitude direct current to facilitate neuronal transmission beneath scalp electrodes.
1476892|NCT03143881|Behavioral|Education|Standardized information on the etiology of HF, mechanisms and side effects of medications prescribed, strategies for minimizing exacerbations, and warning signs of worsening clinical status will be discussed with the patient.
2000749|NCT03324308|Diagnostic Test|Computed Tomography Angiography|This will be a prospective study comparing the low-dose dynamic vs. static CTP combined with the CTA for detecting hemodynamically significant coronary artery stenosis. Patients will have two 18-20 gauge intravenous lines placed for contrast administration. The following image sequences will be completed: coronary calcium scan (non-contrast), rest coronary arterial imaging (with 4-5 mL/sec intravenous ISOVUE-370 infusion), stress myocardial perfusion imaging 20 minutes after rest acquisition imaging (blood pressure will be checked then an infusion of adenosine will be started for a total of 5 minutes; after 5 minutes of adenosine infusion, CT perfusion imaging will be performed during a 4-5 mL/sec ISOVUE-370 infusion). Total estimated radiation dose: 10.551 mSv.
1476894|NCT03143855|Drug|Lorcaserin|Lorcaserin will be administered at a dose of 10 mg twice daily for 5 days
1476895|NCT03143855|Drug|Placebo|Placebo will be administered twice daily for for 5 days
1476896|NCT03143842|Device|Vagus Nerve Stimulation|Delivering electrical pulses to the Vagus Nerve
1476897|NCT03143829|Other|eSSET-CINV|This intervention is an educational intervention, a serious game, which allows older adults under treatment for cancer to practice making self-care decisions for an avatar who is being sent home after their first chemotherapy treatment. This serious game is coupled with a discussion with a nurse about choices related to managing nausea and vomiting at home.
1476898|NCT03143816|Drug|Technosphere insulin|This multi-center study will enroll 60 patients with T1D, A1c values between 6.5 to 10%. The patients will be randomized in 1:1 fashion to either TI or NL. Patients who are randomized into the NL arm will continue using their usual prandial insulin dose before meals. Patients who are randomized into the TI arm will be instructed to dose before the meals and take necessary corrections at 1- and 2-hours after meals to optimize PPBG (Table 1B). There will be a total of 7 study visits (screening visit, randomization visit, 2 clinic, and 3 phone visits). There will be a 4-week treatment comparison between TI and NL and 1-week of post-study follow up. (Phone visit; Figure-1). Standard lab tests (A1c, complete metabolic panel {CMP}, complete blood count {CBC}) will be performed at the screening visit.
1476899|NCT03143803|Drug|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
1476900|NCT03143803|Drug|Placebo|Similar looking inactive powder
1476901|NCT03143790|Procedure|Extracorporeal Shockwave Terapy|Intervention is treatment with ESWT. Placebo treatment is using the same device as the active treatment, but the shock waves stopped in a non pressure-conductive filter
1476902|NCT03143777|Device|Sara Combilizer|Combined tilt table and stretcher chair
1476903|NCT03143764|Behavioral|Commuting with electrically assisted bicycles|25 participants were provided with electrically assisted bicycles fitted with GPS bike computers to record usage
2000750|NCT03324295|Diagnostic Test|cortical cataract|Blood urea
1476905|NCT03143738|Procedure|continuous anesthesia of adductor canal|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented to the adductor canal and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
1476906|NCT03143738|Procedure|continuous anesthesia of femoral nerve|After subarachnoid anesthesia, but before the beginning of surgery, a catheter will be implemented next to the femoral nerve (below inguinal ligament) and infusion of 5 mL/h of 0.2 % ropivacaine will be started.
1476907|NCT03143738|Procedure|Spinal anesthesia|Before the beginning of surgery all patients will be anesthetised with 0.5 % hyperbaric bupivacaine (Marcaine Heavy), 2.0 - 2.5 mL solution. Pencil point spinal needle will be used.
1476908|NCT03143725|Drug|GLPG1972|Oral administration of GLPG1972 in four different treatment conditions (Treatments A throug D)
1476909|NCT03143712|Drug|GLPG1690|Oral administration of GLPG1690 in three different treatment conditions (treatment A through C)
1476910|NCT03143699|Other|Immediate Feedback|Students will be trained to measure blood pressure in the same way, with a brief 4-hour theoretical-practical intervention. After the training, students will measure the blood pressure of a standardized patient and observers will evaluate them using a checklist. After that, students from the intervention group will receive an immediate feedback based on the previous literature. Briefly, feedback will be based on what was directly observed and will be phrased in non-judgmental language, following the Pendleton model.
1476911|NCT03143686|Device|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
1476912|NCT03143673|Device|ACURATE TA™|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement Surgery.
2000751|NCT03324282|Drug|Avelumab|Combination of Gemcitabin-Cisplatin and avelumab given for 6 cycles (each cycle is 21 days)
1477009|NCT03142932|Other|COach2Quit smartphone application|This smartphone application works in conjunction with the iCO monitor
2000752|NCT03324282|Drug|GC|Combination of Gemcitabin-Cisplatin given for 6 cycles (each cycle is 21 days)
1476915|NCT03143647|Other|Collect a study-specific blood sample of healthy subjects|One heparin tube (4ml) and one hirudin tube (4ml) blood sample will be collected through standard venipuncture. After applying a tourniquet with moderate pressure around the arm of the patient's choice, skin will be disinfected over a suitable vein in the elbow or fore-arm. A hirudin and a heparin tube will be filled with venous blood through a single puncture with a 22 Ga needle (manufacturer, location). After release of the tourniquet, bleeding will be stopped by applying local pressure for 5 minutes with a sterile gauze.
1476916|NCT03143634|Behavioral|The Modular Protocol for Mental Health|This intervention is based on evidence-based cognitive-behavioural approaches to psychological disorders and offers a flexible approach to treatment delivery that targets the maladaptive processes common to mood and anxiety disorders.
1476917|NCT03143634|Behavioral|Treatment-as-usual|This intervention will consist of psychological therapies delivered by high-intensity therapists or clinical psychologists.
1476918|NCT03143621|Dietary Supplement|Coffee|Brewed, caffeinated coffee, 100 cc's each dose
1476919|NCT03143621|Other|Water|Tap water heated to same temperature as coffee
1476920|NCT03143608|Device|Esophyx|Laparoscopic hiatal hernia repair followed immediately by transoral incisionless fundoplication under general anesthesia using the Esophyx device
1476921|NCT03143582|Other|Running|A 13-week running program where youth run for 30 minutes twice weekly.
1476922|NCT03143569|Device|aPTT guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device.
1476923|NCT03143569|Device|Anti-factor Xa guided heparin management|post-surgical implantation anti-coagulation therapy to prevent clotting in ventricular assist device
1476925|NCT03143543|Drug|Group A Lorcaserin (10mg)|10 mg lorcaserin orally for 7 days
1476926|NCT03143543|Drug|Group A2 Lorcaserin (20 mg)|20 mg lorcaserin orally for 7 days
1476927|NCT03143543|Other|Group B Parallel Placebo|Oral placebo vs 10 mg lorcaserin
1476928|NCT03143543|Other|Group B2 Parallel Placebo|Oral placebo vs 20 mg lorcaserin
1476929|NCT03143530|Procedure|Pectoralis block|Pectoralis block involving injection near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior muscles (pecs II).
1476930|NCT03143530|Drug|Normal saline injection|Pectoralis block involving injection of normal saline 30ml near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
1476931|NCT03143530|Drug|Ropivacaine Injection|Pectoralis block involving injection of ropivacaine injection 30ml of 0,25% (75 mg) near the coracoid process in the fascial planes between both the pectoralis major and minor muscles (pecs I), and the fascial plane between the pectoralis minor and serratus anterior
1476932|NCT03143517|Diagnostic Test|Stool collection|Stool sample collected by a subject who have been diagnosed with IBD, IBS or other GI disorder. The stool sample is tested in a laboratory where fecal calprotectin levels are quantified.
1476933|NCT03143504|Diagnostic Test|Skin Testing for Atopic eczema|"FTIR Spectroscopy. This will involve placing the assessment tool briefly in contact with the baby's skin on the arm and thigh.
Transepidermal Water Loss. This will involve placing a probe on the baby's skin for approximately 60 seconds on the arm and thigh. The probe measures the rate of water loss from the baby's skin, which indicates how well it acts as a barrier.
Collection of skin samples. This will involve collecting surface skin samples using small sticky-tape discs to collect only the very top skin cells that are already dead and about to be shed naturally by the body.
Microbial swab. The researchers will rub the baby's skin gently with a wet sterile swab to collect a sample of the microbes on the baby's skin surface.
Buccal swab / saliva sample. The researchers will collect a sample of the baby's saliva using a buccal swab. This sample will be used to analyse the baby's genes (DNA) to assess their inherited risk of eczema."
1476935|NCT03143478|Device|M-MARK|"M-MARK will be used by therapists for assessment of the upper limb, and stroke participants will be asked to use M-MARK whilst performing individually tailored and prescribed exercises for a minimum of 5 days/week.
A set of tailored arm exercises using M-MARK (including targets for repetitive and functional activities) will be prescribed which the participant will be asked to practice independently at home for four weeks.
During the four weeks, the patient (with support from their carer as required) will be encouraged to don the M-Mark garment and log-on to the M-Mark computer tablet each day to carry out their programme of exercises. They will be asked to use M-Mark to repeat as many exercise sessions per day as prescribed to them by their research therapist."
1476936|NCT03143465|Drug|Calcitonin Gene-Related Peptide|
1476937|NCT03143465|Drug|Sildenafil|
1476938|NCT03143465|Drug|Placebo|
1476941|NCT03143439|Behavioral|Fathers Advancing Communities Together (FACT) program|The FACT program offers fathers and their families responsible parenting, healthy relationship, and economic stability services and activities.
1476942|NCT03143426|Procedure|3D laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed under 3D visualization as opposed to 2D visualization (conventional method). 3D supposedly provide sharper view with better depth perception and therefore might lead to reduce complication rates.
1476943|NCT03143413|Other|Ultrasonography|"Patient will be enrolled in the rheumatology department of University hospital of Clermont-Ferrand (France).
Salivary glands ultrasonography will be performed on all patients enrolled by the same expert and blinded to the diagnosis of the patient. Echostructure of the two salivary glands will be graded 0 to 4 and the size calculated."
1997653|NCT01976065|Drug|Triple Antibiotic Paste|USP antibiotic drugs mixed at a 1:1:1 ratio into a powder that is mixed with sterile saline to a paste-like consistency
1997654|NCT01976065|Other|Standard Treatment|Standard Treatment no use of study drug
1476944|NCT03143400|Drug|Lactobacillus salivarius BL 3123|Two classic forms will be tested (powder and pill). An innovative galenic form (pill with retarded release), developed to enhance intestinal viability and probiotic efficacy, will also be tested.
1476945|NCT03143387|Other|Caries removal using only manual instruments|Caries removal using only manual instruments according to Atraumatic Restorative Treatment
1476946|NCT03143387|Other|Caries removal using Papacarie gel|Caries removal using a chemical-mechanical method - Papacarie gel and manual instruments.
1476947|NCT03143374|Device|[18F]T807 (also known as 18F-AV- 1451)|"experimental PET/CT scan of the brain. In this scan, imaging is done with specialized cameras that can pick up radiation signals given off by a radioactive tracer and determine where the signals come from.
The tracer used for this study is called [18]FT807 (also known as 18F-AV-1451). [18]FT807 is a specialized radioactive PET tracer used to detect the presence of tau proteins in the brain. [18]FT807 is an experimental tracer that has been studied in patients with known or suspected Alzheimer's disease, Progressive Supranuclear Palsy (PSP) and Corticobasal Degeneration (CBS/CBD). In this study, patients will have one (1) [18F]T807 PET/CT scan performed at the University of Pennsylvania. The [18F]T807 PET/CT scan will require up to 3 hours of time, including preparation. The scan will take place using PET/CT scanners in the Perelman Center for Advanced Medicine or the Hospital of the University of Pennsylvania."
1476948|NCT03143361|Procedure|Aortic valve replacement|All surgical procedures used for both traditional and mini-invasive aortic valve replacement, as well as transcatheter valve implantation.
1476949|NCT03143348|Procedure|Single blood draw|One blood draw of 0.5 ml volume prior to discharge
1476950|NCT03143348|Procedure|Multiple blood draws|Blood draw at 6 peri-operative time points.
1476951|NCT03143348|Procedure|Multiple blood draws|Blood draw at 7 peri-operative time points
1476952|NCT03143335|Procedure|Retropectoral immediate breast reconstruction|Immediate reconstruction with the implant placed in a standard fashion, i.e. retropectoral in combination with an acellular dermal matrix.
1476953|NCT03143335|Procedure|Prepectoral immediate breast reconstruction|Immediate breast reconstruction with the implant placed prepectoral supported by acellular dermal matrix alone.
1476954|NCT03143322|Radiation|SBRT|SBRT will be added to systemic (standard) treatment of bone metastases.
1476955|NCT03143309|Behavioral|Intervention|Brief introductory session, pedometer instruction, daily pedometer use, and health messages delivered via WhatsApp 2-3 times per week.
1476956|NCT03143309|Other|Control|Non-health related messages delivered via WhatsApp 2-3 times per week.
1476957|NCT03143283|Behavioral|Safety Study Lethal Means Counseling|Clinicians provide applicable families with locking devices and handouts on safe storage of firearms and medications.
1476958|NCT03143270|Drug|Drug Eluting Bead Transarterial Chemoembolization|Hepatic embolization will occur on Day 0 of the study for all cohorts. On the day of the procedure, baseline angiography including celiac and superior mesenteric angiography will be performed to delineate arterial anatomy and blood supply to the tumor. After the entire dose has been used, the embolized vessels will be re-catheterized and embolized to stasis with Bead Block beginning with 100-300 micron spheres and using a maximum of 10 cc of any given size per vessel before moving to the next size microsphere.
1476959|NCT03143270|Drug|Nivolumab|All participants will receive at a flat dose of 240 mg IV q 12 weeks for up to one year. In cohort 1, participants will begin nivolumab two weeks (+/- 5 days) after deb-TACE every two weeks. In cohort 2, participants will begin nivolumab every 2 weeks for 1 year and undergo deb-TACE 4 weeks after the initiation of nivolumab (+/- 5 day). Nivolumab will not be dosed on the day of embolization in this cohort. In cohort 3, nivolumab will be dosed every two weeks starting 4 weeks (+/- 5 days) prior to deb-TACE and continue every 2 weeks for up to one year. Nivolumab will be dosed on the day of embolization in this cohort. It will be administered before the deb-TACE procedure.
1476960|NCT03143257|Device|Sophono Bone Conduction Hearing Systems|"The Sophono Bone Conduction Hearing Systems are a family of sound processors and accessories that operate on the principle of BC of sound vibrations. The Sophono Bone Conduction Hearing Systems transmits audio vibrations through the skin into the bone where sound is sensed by the inner ear/cochlea.
The Sophono Sound Processor is magnetically attracted to the Magnetic Implant and Magnetic Spacer. The Magnetic Implant, which is secured to the skull bone, affixes the Magnetic Spacer to the head transcutaneously through magnetic attraction forces, and the Sound Processor is magnetically affixed to the Magnetic Spacer. Vibration from the Sound Processor is transduced through the Magnetic Spacer to the Magnetic Implant and through the bone to the inner ear."
1476961|NCT03143244|Drug|Dexmedetomidine group (D)|Patients received 1ug/kg dexmedetomidine in 50 ml saline over 10 min i.v 30 min before induction then 0.4 ug/kg/h dexmedetomidine (4ug/ml) and normal saline 0.1 ml/kg till end of surgery, using two syringe pumps one for dexmedetomidine and the other for saline
1476962|NCT03143244|Drug|Ketorolac-Midazolam group (KM)|Patients received 0.5mg/kg ketolac in 50 ml saline over 10 min before induction and 25ug/kg midazolam in 50 ml saline over 10 min i.v 30 min before induction then 50ug/kg/h of ketolac and 40ug/kg/h midazolam till end of surgery in two separate syringe pumps.
1476963|NCT03143244|Drug|Control group (Normal Saline) (C)|Patients received normal saline in two sets
1476964|NCT03143231|Other|Normal saline|The normal saline will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60[0]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
1476965|NCT03143231|Other|Hypertonic saline|The mixture (500 ml Sodium Chloride 0.9% with 60 ml Sodium chloride 20%) will be divided in 3ml aliquots that will be preserved in the pharmacy refrigerator between 2 and 60[0]C. Once a patient had been randomized, 6 aliquots would be prepared daily until the end of the trial.
1476966|NCT03143218|Biological|RABIPUR®|Year 1 (2017) Three doses of rabies vaccine (April, May, June) Year 2 and 3 (2018/19) One dose of Hepatitis A vaccine (June)
1476967|NCT03143218|Biological|RTS,S/AS01|Year 1 (2017) Three doses of RTSS/AS01 (April, May, June) Year 2 and 3 (2018/19) One booster dose of RTSS/AS01 (June)
1476968|NCT03143218|Drug|SMC with SP+AQ|Year 1, 2 and 3(2017/18/19) Four rounds of SMC (SP+AQ) (August, September, October, November) One round of SMC for children above one year of age consisting of sulphadoxine - pyrimethamin (SP) 500mg/25 mg, and amodiaquine (AQ) 150mg on day 1, and AQ 150mg on days 2 and 3. Infants will receive half of these doses.
1476969|NCT03143218|Drug|SMC placebo|Year 1, 2 and 3(2017/18/19) Four rounds of SMC placebo (August, September, October, November)
1477054|NCT03142672|Procedure|tooth filling|tooth filling
1476970|NCT03143205|Behavioral|AWARENESS for Sexual Minorities|9 session, individually delivered, cognitive behavioral intervention focused on modifying sexual minority stress responses to reduce the impact of sexual minority stress experiences.
1476971|NCT03143205|Behavioral|Writing tasks|Writing sessions to explore daily activities.
1476972|NCT03143192|Combination Product|Micropulse Laser|Aflibercept injection with Micropulse laser.
1476973|NCT03143192|Device|Sham Laser|Aflibercept injection with Sham Laser
1476974|NCT03143166|Drug|Dabigatran Etexilate|Tablet, film coated
1476975|NCT03143166|Drug|Rabeprazol sodium|Tablet
2000754|NCT03324256|Other|energy drink|16 oz cold commercially-available energy drink
2000755|NCT03324256|Other|caffeinated drink|16oz cold commercially-available caffeinated drink
2000756|NCT03324256|Other|Energy gum|2 pieces of commercially-available energy gum
1476980|NCT03143140|Other|PAFA|percutaneous ablation of tumor feeding artery
1476981|NCT03143140|Other|tumor ablation|ablation of tumor area directly
1476982|NCT03142360|Drug|Beraprost sodium (Berasil)|Within two days after successful arteriovenous graft surgery, the treatment group is randomly assigned to start taking 120 mcg of Berasil.
1476983|NCT03142347|Procedure|Remote endarterectomy|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
1476984|NCT03142347|Procedure|Remote endarterectomy + DCB balloon|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of xenopericardium. And balloon angioplasty of superficial femoral artery with DCB balloon is perform. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
1476985|NCT03143114|Procedure|Myomectomy|Laparotomy then incision in the uterine wall to remove the myoma followed by closure of the uterine incision
1476989|NCT03143088|Behavioral|Medical clown|Blood pressure will be taken to children admitted to the pediatric emergency department with and without the presence of a medical clown.
1476990|NCT03143075|Dietary Supplement|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day|Eicosapentaenoic acid enriched omega-3 fatty acids, 2 g/day, added to pre-stabilized antidepressant medication
1476991|NCT03143062|Diagnostic Test|NEWS|NEWS
1476992|NCT03143049|Drug|PCD|"For PCD, patients will be treated as follows: PO pomalidomide 4mg from D1-21, PO cyclophosphamide 400mg on D1, 8 and 15, and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.
Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
1476993|NCT03143049|Drug|PD|"For PD, Patients will be treated as follows: PO pomalidomide 4mg from D1-21 and PO or IV dexamethasone 40mg D1, 8, 15 and 22 in a 28-day cycle.
Patients will be assessed every 28 days (+/- 10 days). Patients shall receive the treatment until disease progression, unacceptable toxicity as determined by treating physician, withdrawal of consent or mortality (whichever occurs first)."
1476994|NCT03143036|Drug|Daratumumab, thalidomide and dexamethasone|"Patients will be treated with with the following schedule. IV daratumumab 16mg/kg body weight weekly for weeks 1-8 followed by daratumumab 16mg/kg body weight once every 2 weeks from weeks 9 to 24 and then daratumumab 16mg/kg once every 4 weeks from weeks 25 onwards until disease progression; PO thalidomide 100mg daily for 1 year and PO Dexamethasone 40mg (starting dose of dexamethasone is 20mg once weekly for patients >75 years old) once weekly for 1 year (13 cycles, each cycle is 4 weeks). After 1 year, patient only continue on daratumumab until progression
Patients will be assessed every 28 days (+/-10 days)."
1476995|NCT03143023|Drug|arginine toothpaste|acid neutralizer toothpaste
1476996|NCT03143023|Drug|fluoride toothpaste|bactericidal toothpaste
1476997|NCT03143010|Drug|intrathecal Dexmedetomidine|injection of different doses of Dexmedetomidine intrathecally received 3mL (15mg) of 0.5% levobupivacaine +0.5mL normal saline.
1476998|NCT03143010|Drug|Dexmedetomidine 1.5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 1.5 micrograms of Dexmedetomidine.
1476999|NCT03143010|Drug|Dexmedetomidine 3 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 3 micrograms of Dexmedetomidine.
1477000|NCT03143010|Drug|Dexmedetomidine 5 micrograms|injection of different doses of Dexmedetomidine intrathecally in the form of 3mL (15mg) of 0.5% levobupivacaine +0.5mLof 5 micrograms of Dexmedetomidine.
1477001|NCT03142997|Diagnostic Test|Lung ultrasound|we will perform lung ultrasound for both groups to calculate lung score.
1477002|NCT03142984|Other|Cosmetic Products|"Phase 1:
Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071)
Phase 2:
Baby Wash & Shampoo (F# 13217-070) Baby Lotion (F# 13217-071) Alternative Baby Wash & Shampoo (GTIN/UPC # 5011451106260)"
1477003|NCT03142971|Procedure|focused shock wave therapy|
1477004|NCT03142971|Procedure|ultrasound therapy|
1477010|NCT03142932|Behavioral|Cessation counseling|The advice to quit smoking message will follow NCI's 5 A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
1477011|NCT03142919|Biological|Lipopolysaccharide|Lipopolysaccharide (LPS) derived from E. Coli group O 113:H10:K negative
1477012|NCT03142919|Biological|Placebo|Saline solution
1477013|NCT03142906|Diagnostic Test|Scan|The preoperative point of care ultrasound includes a protocolized focused cardiac ultrasound, lung and pleural ultrasound and a gastric volume and content ultrasound assessment, all of which will be performed as an adjunct to the anesthesiologist's assessment. The result of this ultrasound examination will be disclosed to the anesthesiologist and patient care teams. Repeat ultrasounds may be done as the patient's clinical condition changes, or as requested by the anesthesiologist or patient care team.
1477014|NCT03142893|Drug|Ketoconazole Pill|Ketoconazole pill is taken 4 times per Inpatient Stay
1477015|NCT03142893|Drug|Ganirelix|Ganirelix subcutaneous injection is administered twice per Inpatient Stay
1477016|NCT03142893|Drug|Dexamethasone|Dexamethasone Pills is taken twice per Inpatient Stay
1477017|NCT03142893|Drug|Dexamethasone Injection|Dexamethasone IV injection is given twice per Inpatient Stay
1477018|NCT03142893|Drug|Cosyntropin Injectable Product|cosyntropin injection is given twice per Inpatient Stay
1477019|NCT03142893|Drug|Recombinant Human Luteinizing Hormone|Leutinizing-Releasing Hormone is given 6 IV infusion pulses per Inpatient Visit
1477020|NCT03142893|Drug|Hydrocortisone Injection|Hydrocortisone IV push is given twice per Inpatient Visit
1477021|NCT03142893|Drug|Gonadorelin|Gonadorelin IV injection is given twice per Inpatient Stay
1477022|NCT03142893|Drug|Corticorelin|Corticorelin IV injection is given twice per Inpatient Stay
1477023|NCT03142893|Drug|Placebo oral capsule|Placebo for ketoconazole are given 4 times per Inpatient Stay
1477024|NCT03142893|Drug|Saline Solution|Saline Solution (Placebo) for Dexamethasone IV injection or hydrocortisone IV injection given up to four times per Inpatient Stay
1477025|NCT03142893|Drug|Saline Solution for Injection|Saline Solution (placebo) for ganirelix subcutaneous injection
1477026|NCT03142880|Combination Product|hyperbaric ropivacaine|We change the density of ropivacaine solution to make it into an marginally hyperbaric state or into an commonly hyperbaric state.and we hypothesized that the marginally hyperbaric ropivacaine will get a similar efficacy to commonly hyperbaric solutions but a more steadily hemodynamic status.
1477027|NCT03142867|Other|non-applicable|non-applicable
1477028|NCT03142854|Drug|Polyethylene Glycol (PEG)|participants in Group A and Low risk patients in group B are given standard regimen: 2 L Polyethylene Glycol (PEG) regimen.
1477029|NCT03142854|Drug|Polyethylene Glycol (PEG)|High risk patients in Group B will receive 4 L Polyethylene Glycol (PEG) regimen.
1477031|NCT03142828|Drug|Chlorhexidine|Healing abutment with Clorhexidine
1477032|NCT03142828|Other|Placebo|Healing abutment without any antiseptic
1477033|NCT03142802|Diagnostic Test|Low-dose computed tomography (LDCT)|"In phase A of the study, patients will undergo conventional CT along with low dose CT. If patients have a normal conventional CT and a satisfactory low dose CT, they will move onto Phase B of the study in which they will undergo surveillance using low-dose CT. Three outcomes are possible with low-dose CT surveillance:
Normal LDCT:
- Patient continues on the study (i.e. continued surveillance)
Suspicious LDCT:
- Will undergo conventional CT and if results are normal, patient will continue on study. If conventional CT is abnormal, they will be taken off study
Elevated serum tumour markers or other evidence of metastatic disease:
Patient goes off study"
1477034|NCT03142789|Drug|Initial bolus (Certa and standard catheter groups)|10 ml of ropivacaine 0,75% will be used to ensure correct position of the needle and to expand the adductor canal, followed by injection of another 10 ml of ropivacaine 0.75% via the catheter during real time US imaging to ensure correct placement of the catheter.
1477035|NCT03142789|Drug|Initial bolus (Single bolus group)|20 ml of ropivacaine 0.75%
1477036|NCT03142789|Drug|Intermittent boluses (Certa and standard catheter groups)|20 ml of ropivacaine 0.2% every 8 hour in the catheter
1477037|NCT03142789|Drug|Intermittent boluses (Single bolus group)|0.1ml of ropivacaine 0.2% every 8 hour in the sham catheter
1477038|NCT03142776|Procedure|periodontal debridement|
1477039|NCT03142776|Procedure|photodynamic therapy|
1477040|NCT03142776|Drug|systemic clarithromycin|
1477041|NCT03142763|Other|Eggs|Consumption of 3 eggs per day for breakfast, 4 weeks
1477042|NCT03142763|Dietary Supplement|Choline Supplement|Consumption of choline supplement, 1 1/2 tablet (395mg choline), with breakfast for 4 weeks
1477043|NCT03142750|Other|Gastrostomy tube dressing|Two types of dressings to secure gastrostomy tube in children
1477044|NCT03142737|Other|Red kidney bean intake|Each participant will consume 1/2 cup of cooked red kidney bean
1477045|NCT03142737|Other|Eggs intake|Each participant will consume 2 cooked large eggs.
1477046|NCT03142737|Other|Peanut butter intake|Each participant will consume 2 tablespoons of peanut butter.
1477047|NCT03142737|Other|Ground beef intake|Each participant will consume 2 ounces of 90% lean ground beef.
1477048|NCT03142737|Other|Intact beef intake|Each participant will consume 2 ounces of intact beef.
1477050|NCT03142711|Other|No Medical Intervention|Validation of phone ePRO
1477051|NCT03142698|Procedure|Quantification of hepatic steatosis|Quantification of hepatic steatosis (histology, and in MRI)
1477052|NCT03142685|Device|Bowel Ultrasound|Subjects randomized to Arm B will undergo a bowel ultrasound q24 for 48 hours after time of clinical suspicion of NEC. This is in addition to the standard of care KUBs which patients in both arms will get.
1477053|NCT03142672|Procedure|pulpotomy|vital endodontic procedure
1477055|NCT03142659|Other|registry-no intervention|registry-no intervention After filling the informed consent the patients will be evaluated for clinical history and physical examination by the nurse and a cardiologist. Then, the patients may perform the following test: ECG, Chest X-RAY, Blood test including: complete blood count, renal and liver function, electrolytes, thyroid function, cholesterol, glucose, Troponin and Brain Natriuretic Peptide
1477057|NCT03142620|Drug|Esomeprazole|40mg twice daily
1477058|NCT03142620|Drug|Amoxicillin-Potassium Clavulanate Combination|1000mg twice daily
1477059|NCT03142620|Drug|Clarithromycin|500mg twice daily
1477060|NCT03142620|Drug|Vitamin D3|5000IU
1477061|NCT03142607|Drug|Metronidazole gel|1% Metronidazole gel
1477062|NCT03142607|Drug|Chlorhexidine Gluconate|0.2% Chlorhexidene gluconate gel
1477063|NCT03142568|Drug|Sildenafil|Infants will be randomized using a 3:1 scheme to receive sildenafil or placebo.
1477064|NCT03142568|Other|Placebo|Infants randomized to the placebo group will receive the equivalent volume of dextrose 5% for IV use or enteral use (if receiving enteral study drug).
1477065|NCT03142555|Behavioral|Intensive Health Talk|Subjects in this group will receive treatments including a health education talk which focuses on smoking harms and provides information of active referral to other smoking cessation services.Intervention also includes quitting reminders, active referral information via social media. Subjects will also get involved in the personalized what's app interaction (up to 2 months duration) to receive social support to quit smoking. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
1477066|NCT03142555|Behavioral|General Health Talk|Subjects in this group will receive treatments including a general health education talk about smoking cessation but without the information of active referral to other smoking cessation services. Subjects will receive less intensive reminders via social media. The intervention outcomes and subjects' smoking status will be followed up regularly via telephone interviews (15 - 30 minutes).
1477067|NCT03142542|Drug|ZYDENA TAB.75mg(Udenafil 75mg)|ZYDENA TAB.75mg(Udenafil 75mg): by mouth, Once daily, for 32 weeks
1477068|NCT03142542|Drug|Placebo Oral Tablet|Placebo Oral Tablet: by mouth, Once daily, for 32 weeks
1477069|NCT03142529|Drug|colon lotion|The colon lotion used in this clinic trial is a kind of hospital preparation. It is brown liquid,which consists of Rhubarb, Concha ostreae and some other traditional Chinese medicine.The colon lotion is diluted from 30ml to 150ml each time and will be used once a day for 10 days.
1477070|NCT03142516|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous (IV) infusion over 60 min on days 1 and 14 of every cycle just before administration of chemotherapy
1477071|NCT03142516|Drug|Irinotecan|Irinotecan 180 mg/m2 will be administered as IV infusion over 90 min on day 1
1477072|NCT03142516|Drug|Folinic acid|Folinic acid 200-400 mg/m2 will be administered as IV infusion over 2 hours on day 1
1477073|NCT03142516|Drug|5-FU|5-FU will be administered IV 400 mg/m2 bolus followed by 2400 mg/m2 IV continuous infusion over 46-48 hours on days 1 and 2
1477074|NCT03142503|Dietary Supplement|Diet + supplementation|Supplementation of 1g of fish oil, 3 time a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
1477075|NCT03142503|Dietary Supplement|Diet + placebo|Supplementation of 1g of soybean oil, 3 times a day, and hypocaloric diet (-500 calories) for 12 weeks, to evaluate weight loss, antioxidant markers and disease activity.
1477076|NCT03142503|Dietary Supplement|Placebo|Supplementation of 1g soybean oil, 3 times a day.
1477077|NCT03142490|Other|Acupuncture|Acupuncture as a complementary therapy will be done in In vitro fertilization patients of the treatment group.
1477078|NCT03142490|Other|Questionnaires|Patients in both groups will be evaluated by 4 different questionnaires (before and after 8 to 12 weeks)
1477079|NCT03142477|Other|Questionnaires|Two different quality of life questionnaires (WHOQOL-Bref and EORTC QLQ-C30) will be applied before and after treatment. No true or placebo therapeutic touch intervention will be performed.
1477080|NCT03142477|Other|Placebo therapeutic touch|Placebo therapeutic touch will be done by graduate students without any specific training. The students are instructed to perform the placebo therapeutic touch with no objective intention of improving the patient's health.
1477081|NCT03142477|Other|Therapeutic touch|Therapeutic touch will be done by therapeutic touch trained professionals graduate students without any specific training with the intention of improving the patient's health.
1477082|NCT03142464|Other|Suspension of the IV fluids|No IV fluids prescription, IV catheter filled with saline solution
1477083|NCT03142451|Drug|FMX-103|FMX-103 1.5% Topical Minocycline Foam
1477084|NCT03142451|Other|Vehicle Foam|Vehicle Foam
1477085|NCT03142438|Device|Trial full face or nasal mask|Participants will be placed on this arm for a total 14 ± 4 days from Visit 1. Participants will be using the trial full face or nasal mask during this treatment arm.
1477086|NCT03142399|Dietary Supplement|whey protein|Supplementation with whey protein isolate or maltodextrin (30 grams per day) for 12 weeks associated with supervised exercise and nutritional counseling in patients with heart failure.
1477087|NCT03142386|Other|Osteopathic manipulative treatment|
1477088|NCT03142386|Other|Physiotherapy|
1477089|NCT03142373|Other|CV4 technique|
1477090|NCT03142373|Other|RR technique|
1477091|NCT03142373|Other|Placebo treatment|
2000757|NCT03324256|Other|placebo gum|2 pieces of commercially-available placebo gum
1477094|NCT03142321|Drug|Vedolizumab 300 MG Injection [Entyvio]|Vedolizumab Injection
1477095|NCT03142295|Procedure|urine transfusion|Two transfusions of 100 ml of urine within 5 days by transurethral catheterization after an antibiotic free interval of 3 days.
1477096|NCT03142282|Drug|maintenance chemotherapy|National Comprehensive Cancer Network (NCCN) or European Society for Medical Oncology (ESMO) suggested maintenance chemotherapy regimens: xeloda, bevacizumab
1477097|NCT03142282|Radiation|Consolidative Radiotherapy|Stereotacticbodyradiationtherapy (SBRT) or intensity modulated radiation therapy (IMRT) for metastatic sites (less than 5)
1481744|NCT03106753|Drug|Terbutaline|0.25 mg Terbutaline subcutaneously
1477098|NCT03142269|Procedure|360°anterior capsule polishing|360°anterior capsule polishing was performed with double-ended capsule polisher
1477099|NCT03142256|Behavioral|Incentivised - Conditional Cash Transfer|Participant will be randomized to receive a cash transfer conditional on drug levels at months 1, 2, and 3 versus no cash transfer
1477100|NCT03142256|Drug|Truvada 200Mg-300Mg Tablet|Both study arms will be offered Truvada as PrEP. Only one arm will be randomized to the conditional cash transfer.
1477101|NCT03142230|Other|the laying of the gastric tube and a group using the holed baby bottle nipple, the feeding tube ideally positioned at the center of the intersection pharyngeal|The newborn then receives the care with the introduction of the gastric tube after randomization with holed baby bottle nipple
1477102|NCT03142230|Other|the laying of the gastric tube and a group with simple non-nutritive suction, the feeding tube passing next to the newborn's personal pacifier|The newborn then receives the care with the introduction of the gastric tube after randomization with the newborn's personal pacifier
1477103|NCT03142217|Other|Study of dysarthria in patients with Huntington's disease|Study of dysarthria in patients with Huntington's disease
1477104|NCT03142204|Drug|[18F]F-AraG|Single dose IV injection of [18F]F-AraG for each imaging day.
2000758|NCT03324256|Other|Control drink|16oz cold control drink
2000759|NCT03324256|Other|Total sleep deprivation|24-hour total sleep deprivation prior to consumption of energy drink and placebo gum
1477107|NCT03142178|Drug|Experimental: 3VM1001 Cream|3VM1001 Cream with active ingredient.
1477108|NCT03142178|Other|Placebo: 3VM1001 vehicle|3VM1001 Cream vehicle placebo
2000760|NCT03324243|Drug|Crenolanib|66.7 mg/m2 three times a day (TID)
2000761|NCT03324243|Drug|Fludarabine|30 mg/m2/day, intravenous infusions over 30 mins.
1477113|NCT03142152|Device|Carillon Mitral Contour System|The CARILLON implant (mXE2) is designed to be deployed, tensioned, and locked in the coronary vein in order to reshape the mitral annulus and thus reduce mitral annular dilation and mitral regurgitation.
1477114|NCT03142152|Other|Guideline Directed Heart Failure Medication|Heart failure medication per ACC/AHA guidelines
1477115|NCT03142139|Biological|RQ1a: Delayed vs. timely vaccination with the 1st dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 1st dose within the month of scheduled vaccination:
timely vaccinated: received 1st dose of DTaP-IPV-Hib before 4 months of age
delayed vaccinated: did not receive the first dose of DTaP-IPV-Hib before 4 months of age."
1477116|NCT03142139|Biological|RQ1b: Delayed vs. timely vaccination with the 2nd dose of DTaP-IPV-Hib|"Children will be categorized as timely vaccinated if they receive the 2nd dose within the month of scheduled vaccination:
timely vaccinated: received 2nd dose of DTaP-IPV-Hib before 6 months of age
delayed vaccinated: did not receive the 2nd dose of DTaP-IPV-Hib before 6 months of age."
1477117|NCT03142139|Biological|RQ2: Vaccination with DTaP-IPV-Hib compared to being unvaccinated|"• Vaccination status will be assessed as a time dependent exposure, whereby children will be categorized as unvaccinated until date of vaccination where they will shift exposure group to vaccinated."
1477118|NCT03142126|Device|Early ambulation with Angioseal closure device|To reaffirm safety and efficacy of using Angioseal for early ambulation by patients after femoral artery arteriotomy
1477119|NCT03142100|Device|cochlear implants and hearing aids|speech perception tests and bimodal fitting
1477120|NCT03142087|Other|exercises|exercise
1477121|NCT03142074|Other|Biomechanical and microstructural analysis of ATAA|Tissue collection; microstructural testing of tissue; mechanical testing of tissue; image analysis of 4D CT.
1477122|NCT03142061|Procedure|Electrochemotherapy|Bleomycin plus local electroporation of cutan accessible tumor tissue in patients with advanced inoperable vulva carcinoma
1477123|NCT03142048|Other|Schools of Health for the Elderly|"The intervention School of Health for the Elderly  consists of 22 weekly group sessions of 1.5 hours each. In addition to helping participants learn about different health issues, the intervention encourages interaction among participants and works on personal skills. Furthermore, most sessions are led by professionals who are experts on the topic covered and work in the neighborhood (professionals from the health services, social services, markets or neighborhood associations), making it easier to inform participants of the neighborhood's available resources. The aim of the intervention is to decrease social isolation and loneliness and, therefore, to improve mental health, self-perceived health and wellbeing"
1477124|NCT03142035|Drug|Dienogest 2 MG|Dienogest is a fourth-generation progestin of 19-nortestosterone derivative, that has been shown to improve endometriosis associated pelvic pain. It is well tolerated with no androgenic, glucocorticoid or mineralocorticoid activity. Dienogest creates a hyperprogestogenic and hypoestrogenic environment that initially induces a secretory state and then a decidualization of the ectopic endometrium and finally its atrophy. It also inhibits aromatase and COX-2 expression as well as prostaglandin E2 production in endometriotic stromal cells. It also normalizes the activity of natural killer cells and decreases the release of interleukin-1b by macrophages. These anti-inflammatory properties further help in reducing the size of endometriotic lesions
1477125|NCT03142035|Drug|gonapeptyl|gonadotropic releasing hormone agonist
1477126|NCT03142035|Procedure|IVF/IVF+ART|In-vitro fertilization +/- assisted reproductive technology
1477127|NCT03142022|Other|No intervention - Diagnostic polysomnography at 1 year after lung transplantation|
1477128|NCT03142009|Other|Intergenerational culturally adapted curriculum|"Each session starts with a collective dinner with families eating together. Then practice their Indian and clan names. The sessions are led by facilitators in their own language or bilingually. The facilitators then divide the families into children and adult groups to address the theme of the session, and they then return together at the end of the session to share their learnings. The sessions always end with the children and adults writing in their journals which are individual pages that they then put in their curriculum binders. Families are then given their home practice, which is a task that the families do together during the intervening week. The facilitators collect the curriculum binders after each session to bring back to the families the next week."
1477129|NCT03141996|Other|Vibration to upper posterior neck muscles|Vibration to upper posterior neck muscles using a vibrational tool.
1477130|NCT03141996|Other|Standard of Care|Standard of care treatment
1477252|NCT03141151|Behavioral|COACH: Strong Minds|School Readiness Intervention focusing on literacy and parent skills
1477131|NCT03141983|Drug|Anakinra|Anakinra (Kineret®) is a therapeutic agent that blocks the effects of IL-1α and IL-1β by competitively binding to the interleukin-1 type I receptor (IL-1RI). Anakinra is a recombinant, non-glycosylated form of the naturally occurring human interleukin-1 receptor antagonist (IL-1Ra). It differs from native human IL-1Ra in that it has the addition of a single methionine residue at the amino terminus. Anakinra is produced using recombinant technology in an E. coli bacterial expression system. Anakinra is supplied commercially in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution. Each 1 ml prefilled glass syringe contains: 0.67 ml (100 mg) of anakinra in a solution (pH 6.5) containing sodium citrate (1.29 mg), sodium chloride (5.48 mg), disodium EDTA (0.12 mg) and polysorbate 80 (0.70 mg) in Water for Injection, USP.
1477132|NCT03141983|Drug|Placebo|Saline (0.9%) will be used as the placebo, in single use 1 ml prefilled glass syringes as a sterile, clear, colorless-to-white, preservative free solution.
1477133|NCT03141970|Drug|Prednisolone|Prednisolone for 12 weeks as follows 30 mg/m2 on alternate days for 4 weeks 20 mg/m2 on alternate days for 4 weeks 10 mg/m2 on alternate days for 4 weeks
1477134|NCT03141944|Other|Starkstein scale of Apathy|"The degree of apathy will be evaluated with the Starkstein scale of Apathy"
1477135|NCT03141931|Dietary Supplement|Lacritec|Concentrated Omega-3 Triglycerides-fish 332 mg Equiv. Eicosapentaenoic Acid (EPA) 134 mg Equiv. Docosahexaenoic Acid (DHA) 66.8 mg Flax Seed Oil (Linseed Oil) 334 mg Equiv. Oleic acid 58.5 mg Equiv. Linoleic acid 58.5 mg Equiv. Linolenic acid 192 mg Borago officinalis seed oil fixed (Borage) 434 mg Equiv. gamma-Linolenic acid 95.5 mg
1477136|NCT03141931|Dietary Supplement|Placebo|polyethylene glycol (500mg), oleic acid (659mg) and propylene glycol (115mg)
1477137|NCT03141918|Dietary Supplement|Curcumin|The intervention will consist of the supplementation of curcumin for 30 days. Curcumin supplementation will be done by administration of 2 doses of 500mg of the product BioMor Curcumin® which is composed of 95% standardized extract of the root extract of Curcuma longa.
1477138|NCT03141918|Dietary Supplement|Epigalocatequina 3 galate|"The intervention will consist of the supplementation of Epigallocatechin-3-gallate for 30 days.
Epigallocatechin-3-gallate supplementation will be done by administration of 2 capsules of 150 mg of decaffeinated green tea extract, Teavigo from Health Originals® brand, standardized at 90% EGGC. Doses will be administered daily, totaling 300 mg / day."
1477139|NCT03141918|Other|Placebo of Curcumin|"The intervention will consist of the placebo administration curcumin for 30 days.
The Curcumin placebo will be given in 2 doses of 500mg per day."
1477140|NCT03141918|Other|Placebo of Epigalocatequina 3 galate|The intervention will consist of the placebo administration Epigalocatequina 3 galate for 30 days. The Epigallocatechin-3-gallate placebo will be given in 2 doses of 150mg per day.
2000762|NCT03324243|Drug|Cytarabine|2000 mg/m2/day, intravenous infusions over 1-3 hours.
1477143|NCT03141892|Device|FreeStyle Libre Flash Glucose Monitoring System|Blood Glucose Monitoring
1477144|NCT03141879|Other|HUR equipment resistance training intervention|Resistance training intervention
1477145|NCT03141866|Other|Physical Activity Intervention 1: Move It Or Lose It (MIOLI)|An established chair-based physical activity programme for older adults.
1477146|NCT03141866|Other|Physical Activity Intervention 2: HUR Resistance training intervention|Specialised, chair-based, pneumatic resistance training equipment for older adults.
1477147|NCT03141853|Other|Equine-assisted Therapy|Participants will groom and ride horses. Horses will be kept at a walk with tasks such as serpentine, circles, and zig zags to complete. Stretching, and tasks like throwing a ball into a net from horseback will be completed
1477148|NCT03141853|Other|Arthritis Exercise Education|Standard of Care from the Arthritis Foundation - How-to Exercise With Arthritis. (n.d.). Retrieved April 18, 2016, from http://www.arthritis.org/living-with-arthritis/exercise/how-to). This intervention will consist of 6 -1 hour education sessions once a week on exercise to improve symptoms of arthritis
1477149|NCT03141840|Device|ABL01|Experimental medical device
1477150|NCT03141840|Device|Placebo|ABL01 lacking active component
1477151|NCT03141827|Drug|Insulin|Insulin 40 IU, nasal spray, single dose
1477152|NCT03141827|Drug|Placebo|Placebo, nasal spray, single dose
1477153|NCT03141801|Device|DELFI PTS Personalized Tourniquet System for Blood Flow Restriction Training|cuff is inflated to 80% of an individuals limb occlusion pressure
1477154|NCT03141801|Other|Eccentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an eccentric leg press exercise performed at 70% of the 1 repetition maximum
1477155|NCT03141801|Other|Concentric Exercise with BLAST Leg Press System|4 sets of 10 repetitions of an concentric leg press exercise performed at 70% of the 1 repetition maximum
1477156|NCT03141788|Device|Clear Aligner|Clear Aligner used to straighten teeth to desired outcome
1477157|NCT03141775|Other|Treatment of CDI|Treatment (e.g. antibiotics, fecal microbiota transfer (FMT), probiotics) for patients with Clostridium difficile associated diarrhea
1477158|NCT03141736|Other|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
1477159|NCT03141736|Other|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost [3 cents per bag]
1477160|NCT03141736|Other|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling
1477161|NCT03141736|Other|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene non-medical low-cost [3 cents per bag]
1477162|NCT03141723|Other|KMC & WHO protocol (0-1 hour)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive breastfeeding, postponement of bathing and weighing, and appropriate bundling.
1477163|NCT03141723|Other|KMC, WHO protocol & bag (0-1 hour)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost [3 cents per bag] linear low-density bag measuring 10 × 8 × 24 in. and 1.2 mil thick) that will cover the infant's torso and lower extremities.
1477164|NCT03141723|Other|KMC & WHO protocol (1-24 hours)|WHO thermoregulation care - warm delivery rooms, immediate drying after birth, early and exclusive
1477165|NCT03141723|Other|KMC, WHO protocol & bag (1-24 hours)|In addition infants will be placed in a plastic bag (clear polyethylene nonmedical low-cost [3 cents per bag]
1477167|NCT03141697|Device|Carbon Dioxide|Insufflation of Carbon Dioxide
1477168|NCT03141697|Device|Room air|Insufflation of room air
1477169|NCT03141684|Drug|Atezolizumab|Given IV
1477170|NCT03141684|Other|Laboratory Biomarker Analysis|Correlative studies
1477171|NCT03141684|Other|Pharmacological Study|Correlative studies
1477172|NCT03141671|Drug|GnRH|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
1477173|NCT03141671|Drug|Bicalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
1477174|NCT03141671|Radiation|Salvage radiation|Radiation
1477175|NCT03141671|Drug|Abiraterone|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
1477176|NCT03141671|Drug|Prednisone|Prednisone is a corticosteroid. It prevents the release of substances in the body that cause inflammation. It also suppresses the immune system.
1477177|NCT03141671|Drug|Apalutamide|-blocks the function of hormones including testosterone which prostate cancer uses to grow and spread
1477182|NCT03141645|Other|Fluid loading|Patients in the preoperative intravenous fluid loading group (group F) will receive ringer lactate solution 10ml/kg in 15 minutes before starting operation.
1477183|NCT03141645|Drug|Ondansetron|Patients in the ondansetron group (group O) will receive an 8 mg of intravenous ondansetron in 15 minutes before finishing operation
1477190|NCT03141580|Diagnostic Test|Near-infrared spectroscopy and intravascular ultrasound (NIRS-IVUS)|Examination of the extracranial portion of the internal and common carotid artery with pre-existing stent with NIRS-IVUS.
1477191|NCT03141554|Drug|1% Betadine® PVP-I based mouth wash and gargle,|1% Betadine® PVP-I based mouth wash and gargle
1477192|NCT03141554|Drug|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash|0.2% Chlor-Rinse™ Chlorhexidine based mouth wash
1477193|NCT03141554|Drug|Normal saline gargle|Normal saline gargle
1477194|NCT03141541|Behavioral|Group based pain management intervention|The intervention is delivered as six separate sessions of each two hours duration over a four month period. The sessions are managed by a multidisciplinary team from the Spine Center, led by a psychologist. Before the first session, each patient in the intervention group participates in an individual consultation with the psychologist or nurse, with the aim of matching expectations for the group intervention, and hereby ensure the patients compliance throughout the intervention.
1477195|NCT03141528|Other|Self-learning|Training without supervision
1477196|NCT03141528|Other|Instructor-led learning|Supervision by a tutor (either general practitioner or medical student, all trained in CPR teaching)
1477197|NCT03141515|Device|Lung ultrasound|Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
1477198|NCT03141502|Device|Skin stretching device (SSD)|By making use of skin viscoelasticity, the special metal crochet of SSD would be embedded in both sides skin of the wound. Multiple cycles of stretching and relaxing wound lead to extended skin, changing the high tension incision into a low tension incision and facilitating the direct suture.
1477199|NCT03141502|Procedure|Skin grafting|the standard technique of skin grafting after wound preparation.
1477200|NCT03141489|Dietary Supplement|Tubefeeding|NICE guidelines regarding refeeding syndrome, based on a very cautious refeeding regime reaching estimated calorie and protein needs within 7 days, compared to a protocol at Diakonhjemmet Hospital using a higher starting rate, reaching estimated needs within 3 days.
1477201|NCT03141476|Drug|Cefuroxime 1,5g|Patients with BMI of <30kg/m*m: 1,5 g Cefuroxime
1477202|NCT03141476|Drug|Cefuroxime 3g|Patients with BMI of 30-50kg/m*m: 3g Cefuroxime
1477203|NCT03141476|Drug|Cefuroxime 4,5g|Patients with BMI of >50kg/m*m: 4,5 g Cefuroxime
1477204|NCT03141463|Biological|Vvax001 therapeutic cancer vaccine|Vvax001 is a vaccine consisting of a replication-incompetent Semliki Forest Virus (SFV) vector encoding HPV-derived tumor antigens. Patients will receive three consecutive doses, with an interval of 3 weeks.
1477205|NCT03141437|Behavioral|Questionnaires|"MDACC Group: Participants complete questionnaire before viewing the website about healthcare decision making and fertility. Questionnaire completed 1 week after viewing the website about opinions on the decision aid website.
Questionnaire completed 2 months after consultation visit about which methods of fertility preservation that were chose (if any).
HALs Group: Participant completes 3 questionnaires before viewing the website about healthcare decision making and fertility, and then at 1 week and then 2 months after viewing the website.
Standard Care HALs Group: Participants complete 3 sets of questionnaires at enrollment in the study, and then at 1 week and 2 months after enrollment."
1477206|NCT03141437|Other|Decision Aid Website|"MDACC Group: Participant views the decision aid website about fertility preservation at home or at routine fertility consultation visit.
HALs Group: Participant views the decision aid website about fertility preservation at home."
1477207|NCT03141437|Other|Educational Materials|Standard Care HALs Group: Participants receive education materials about fertility preservation from the Livestrong organization.
1477208|NCT03141424|Other|Tapering of ICS treatment|Tapering of ICS treatment over 8 weeks. Follow-up over 52 weeks in total. Dosis reduction of 50% in ICS treatment for 8 weeks, followed by total ICS removal. Other inhaled asthma medication remains unchanged during the entire study period.
1477209|NCT03141398|Diagnostic Test|Continuous Glucose Monitoring (CGM)|Where a pager-sized device fixed to the patient's forearm by a diabetic educator and it will connect to his/her body with the sensor, which measures blood glucose for three days. Patients' may experience little pain from needle prick when a sensor is introduced.
1477210|NCT03141398|Diagnostic Test|Oral Glucose Tolerance Test (OGTT)|Oral glucose tolerance test requires the patient to be fasting and checking of blood sugar after 8 to 10 hours overnight fasting the blood sugar will be checked three times When you arrive to the lab then twice one hour, apart you can have pain due to needle prick or little bleeding at the puncture site.
1477211|NCT03141398|Diagnostic Test|T2* MRI of the Pancreas|MRI [Magnetic resonance imaging] of the pancreas which is safe and takes around 30 minutes.
1477212|NCT03141385|Other|remote ischemic preconditioning|Remote ischemic preconditioning (RIPC) will be induced after the general anesthesia prior to the cardiopulmonary bypass by four cycles of right limber ischemia (5-min blood pressure cuff inflation to a pressure of 200mmHg or a pressure that is 50 mmHg higher than SAP and 5-min cuff deflation)
1477213|NCT03141385|Other|Control|A deflated cuff placed on the right upper arm
1477214|NCT03141372|Device|Void Trial using Foley catheter|A void trial is a test to ensure that a subject does not have urinary retention after a surgical procedure. In an autofill void trial, the subject is allowed to void after surgery and the amount of resulting urine and the amount of urine still remaining in the bladder are measured. In a backfill void trial, water is instilled into the bladder, the foley is removed, and the subject is then allowed to urinate. Again, the amount of urine resulting and the amount of urine still in the bladder are measured.
2000764|NCT03324204|Other|Neuromuscular Training|Each session lasted 30 minutes and consisted of three sets of exercises with 20-30 repetitions. Emphasis was placed on proper knee alignment during exercise. Most of the women exhibited excessive medial rotation and adduction of the femur, resulting in knee valgus, although knee varus was also observed. The women were instructed how to correct their abnormalities using mirrors as visual feedback. All exercises were completed without pain. If the exercises were too easy, the level of difficulty was increased individually in accordance with the rehabilitation protocol
1477221|NCT03141346|Behavioral|Sugar Reduction Program|A home visitation program incorporating sugar reduction education and monitoring and home water delivery administered over 24 months.
1477222|NCT03141346|Behavioral|standard home visitation program|standard home visitation program
1477223|NCT03141346|Other|home water delivery|home water delivery administered over 24 months
1477224|NCT03141333|Behavioral|Teleintervention|Participants of this group will have access to the following sections in the web plate-form: information, forum, chat and live online consultation. The teleintervention consists of having access to the forum, chat and live online consultation sections of the web plate-form.
1477225|NCT03141320|Other|Interview/observation of social media comments|Interview with pregnant or postnatal women and observation of relevant social media comments
1477226|NCT03141307|Behavioral|EICI Movie|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by watching a brief video.
1477227|NCT03141307|Behavioral|EICI App|The purpose of this intervention is to improve comprehension about broad consent for future biobank-dependent research by exploring an educational app.
1477228|NCT03141307|Behavioral|Control|Standard of care, paper-based brochure
1477229|NCT03141294|Procedure|reformative dilation technique|reformative dilation technique was used when operating tracheostomy
1477230|NCT03141281|Behavioral|BrainHQ|BrainHQ
1477231|NCT03141281|Behavioral|Rise of Nations|Rise of Nations
1477232|NCT03141281|Behavioral|IADL Training|IADL Training
1477233|NCT03141281|Behavioral|Active Control|Puzzle solving
1477234|NCT03141268|Diagnostic Test|Lactulose breath test|Lactulose 0.67 mg/mL, dose 15 mL (10 grams). No contaminants of lactose. Pharmacy quality.
1477235|NCT03141255|Device|IVTM™ System|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
1477236|NCT03141255|Device|Quattro® Catheter|TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
1477237|NCT03141242|Behavioral|ENACT group visit|Participation in two 2 hour group visits about advance care planning.
1477238|NCT03141242|Behavioral|Mailed Resources|Participants will receive advance care planning resources in the mail with instructions to follow up with their primary care provider.
1477239|NCT03141229|Behavioral|Mindfulness based stress reduction|
1477240|NCT03141216|Device|VCV+PSV|invasive mechanical mechanical modes by volume cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
1477241|NCT03141216|Device|PCV+PSV|invasive mechanical mechanical modes by pressure cycling and by pressure support which the patients will be submitted to before weaning. Post-operative mechanical ventilation average time: 6 hours after ICU admission.
1477242|NCT03141203|Drug|Romidepsin|10mg vial for Injection
1477243|NCT03141203|Drug|Carfilzomib|60mg vial for injection
1477244|NCT03141190|Behavioral|Mindfulness Based Stress Reduction - modified|already described
1477245|NCT03141190|Behavioral|Active listening and reading|group reading, listening and discussion of articles pertaining to the development and experience of the surgical personality
1477250|NCT03141164|Other|computerized training|Computerized training
1477251|NCT03141151|Behavioral|COACH: Healthy Bodies|Staged intensity behavioral intervention focusing on healthy lifestyles in the context of family.
1948693|NCT01906385|Radiation|Rhenium Liposome Treatment|At the time of stereotactic biopsy a catheter will be placed within the tumor using stereotactic guidance. Once the patient has adequately recovered from the procedure as determined by the neurosurgeon, 186RNL will be infused through the catheter at the predetermined dose. Spectroscopic imaging will then be obtained at predefined time points to visualize the distribution of the 186RNL as well as calculated the actual dose retained within the tumor. Patients will be monitored longitudinally for evidence of toxicity and response by MRI.
2000765|NCT03324204|Other|Extracorporeal Shock Wave Therapy (ESWT)|ESWT will be applied to the iliotibial band and tensor fascia latae muscle with the following parameters: pressure - 4.5 bar, emission frequency -8 Hz, number of pulses per dose -2,500 per session
1477255|NCT03141125|Other|Physalis angulata ethanol extract|Ethanol extract of physalis angulate Linn with dosage of 3x250 mg/day given orally for 3 months
1477256|NCT03141125|Other|Placebo|No active component at the same dosage of 3x250 mg/day given orally for 3 months
1477257|NCT03141112|Procedure|renal replacement therapy|
1477258|NCT03141099|Other|Low normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by +10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 63 mmHg.
1477259|NCT03141099|Other|High normal MAP|The patients are randomized to recieve a Phillips M1006B blood pressure measuring module, offset by -10 %. All patients will target a MAP of 70, but due to the offset module, the patients will target an actual blood pressure of 77mmHg.
1477260|NCT03141099|Other|Low normal PaO2.|The patients are randomized to a PaO2 target of 9-10 kPa (open-label).
1477261|NCT03141099|Other|High normal PaO2|The patients are randomized to a PaO2 target of 13-14 kPa (open-label).
1477262|NCT03141086|Drug|LML134|LML134
1477263|NCT03141086|Drug|Placebo|placebo
1477264|NCT03141073|Drug|HMS5552|BID oral administration
1477265|NCT03141073|Drug|Placebos|BID oral administration
1477266|NCT03141060|Drug|Delamanid|Administered orally; dosing will be based on participants' age and weight.
1477267|NCT03141060|Drug|Optimized multidrug background regimen (OBR) for children with MDR-TB|Non-study prescribed OBR will vary according to local, national, and/or international guidelines for treatment of children with MDR-TB. Administered in addition to DLM for 24 weeks.
1477268|NCT03141047|Other|Lifespan Integration|A protocol based psychological treatment method
2000766|NCT03324191|Dietary Supplement|Placebo|Placebo will be matched for flavour, odour, and colour, to a tea beverage, without any active ingredient (tea extract).
2000767|NCT03324191|Dietary Supplement|Tea beverage|Tea beverage
2000768|NCT03324191|Dietary Supplement|Tea extract (medium concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a medium concentration of tea extract.
2000769|NCT03324191|Dietary Supplement|Tea extract (high concentration)|Tea extract (medium concentration) will be matched for flavour, odour, and colour, to a tea beverage, with a high concentration of tea extract.
1477273|NCT03141008|Other|Fibroscan changes with different diets|Observational study of liver fat and stiffness and cardiometabolic parameters comparing two different standard of care dietary regimens
1477275|NCT03140982|Diagnostic Test|FOUR coma scale and frontal espectrograpy evaluation|systematic evaluation using the validated FOUR coma scale during propofol administration
1477276|NCT03140969|Drug|QR-110|RNA antisense oligonucleotide for intravitreal injection
1477277|NCT03140956|Drug|Levodopa, carbidopa, ODM-104|Crossover design. Study treatments will be administered in randomized order 4 times a day.
1477278|NCT03140943|Drug|Carfilzomib, Thalidomide and Dexamethasone|"Carfilzomib will be given on days 1,2,8,9,15,16 in a 4-week (28 day) cycle during induction cycles 1-12, followed by days 1,2,15,16 in a 4-week cycle during maintenance cycles 13-18 (section 4.0) Dexamethasone, 40mg po will be given on days 1,8,15, 22 in a 4-week cycle during induction cycles 1-12, followed by days 1,15, in a 4-week cycle during maintenance cycles 13-18.
Thalidomide, 100mg po will be given daily during induction cycles 1-12 only."
1477279|NCT03140930|Dietary Supplement|Tastants duodenal|Duodenal infusion of combination of tastants (sweet, bitter and umami)
1477280|NCT03140930|Dietary Supplement|Tastants ileal|Ileal infusion of combination of tastants (sweet, bitter and umami)
1477281|NCT03140930|Dietary Supplement|Placebo duodenal|Duodenal infusion of placebo (tap water)
1477282|NCT03140930|Dietary Supplement|Placebo ileal|Ileal infusion of placebo (tap water)
1477283|NCT03140917|Diagnostic Test|Multimodal liver function assessment|HBS, MRI, CE-CT and ICG
1477284|NCT03140904|Other|Standard weekly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a weekly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
1477285|NCT03140904|Other|Monthly visits|Distribution of the therapeutic feeding rations, as well as medical and anthropometric surveillance, will take place on a monthly basis at the outpatient therapeutic feeding center according to the random assignment of the site, until discharge
1477288|NCT03140878|Dietary Supplement|LGG|LGG is dissolved in water and consumed at one occasion (either at visit 2 or 3)
1477289|NCT03140878|Dietary Supplement|Placebo|Placebo is dissolved in water and consumed at one occasion (either at visit 2 or 3)
1477290|NCT03140852|Behavioral|Mind Over Matter; Healthy Bowels, Healthy Bladder|This three-session workshop is based on proven principles of behavior change addressing urinary and bowel continence self-management and health education and has been developed specifically for administration to women age 50 and older in senior centers.
1477291|NCT03140839|Behavioral|Imaginal Rescripting|A stand-alone single session intervention for social anxiety disorder
1477292|NCT03140839|Behavioral|Imaginal Exposure|A stand-alone single session intervention for social anxiety disorder
1477293|NCT03140839|Other|Supportive Counselling|Non-specific talk therapy focused on non-directive and empathic listening and on supporting patients' existing coping skills and strategies.
1477295|NCT03140813|Drug|AZD7325 (High-Dose)|15mg PO BID
1477296|NCT03140813|Drug|AZD7325 (Low-Dose)|5mg PO BID
1477393|NCT03139929|Diagnostic Test|MSFP|MSFPhold and MSFParm
1948699|NCT01881971|Drug|Placebo|suger pill manufactured to mimic crestor pills
1948700|NCT01881971|Drug|Rouvastatin calcium|
1477297|NCT03140813|Drug|Placebo oral capsule|Placebo will be dosed similar to AZD7325, in terms of dosage form, frequency and duration.
1477298|NCT03140800|Device|intrauterine device|a method of contraception inserted in the uterus
1477299|NCT03140787|Drug|Nasal Spray of Lidocaine HCL|This spray consists of lidocaine hydrochloride-epinephrine hydrochloride
1477300|NCT03140787|Drug|Infiltration injection of Lidocaine HCL|This is the ordinary method of establishing anesthesia for patients undergoing dental treatment for caries.
1477301|NCT03140748|Other|To evaluate the initial levels and kinetics of serum β-D-glucan|To evaluate the initial levels and kinetics of serum β-D-glucan during fungal peritonitis compared to a control group of yeast-free peritonitis
1477302|NCT03140735|Other|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction|Study the relationship between the arterial rigidity of large vessels and the presence and severity of degenerative aortic constriction
1477303|NCT03140735|Other|Control group without heart disease|Control group without heart disease
1477304|NCT03140722|Drug|vadadustat|vadadustat
1477305|NCT03140722|Drug|epoetin alfa|epoetin alfa
1477306|NCT03140709|Drug|Oxytocin|"Induction-Vaginal Delivery: Begin at 1mU/min IV infusion and increase by 2mU/30min q30min to a max of 30mU/min. Postpartum infusion adjusted to 2U/hr.
Cesarian Delivery: 1U bolus via IV at delivery, followed by 7.5U/hr up to 30U/hour max depending on uterine tone. Postpartum infusion adjusted to 2U/hr"
1477307|NCT03140696|Dietary Supplement|Egg Alone|A chicken egg will be offered for 2 days
1477308|NCT03140696|Dietary Supplement|Egg and ready to use supplementary food (RUSF)|A chicken egg and ready to use supplementary food (RUSF) will be offered for 2 days
1477309|NCT03140696|Dietary Supplement|Egg and breast milk|A chicken egg and breast milk will be offered for 2 days
1477310|NCT03140683|Device|non-stress test|antepartum fetal monitoring
1948701|NCT01881113|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
1948702|NCT01881113|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
1477314|NCT03140644|Other|Patients with thoracic sarcoidosis|Ultra-low dose CT scan and MRI with UTE
1477315|NCT03140631|Drug|Protamine Sulfate|Protamine sulfate is a highly basic protein that forms stable compounds with acidic heparin to rapidly neutralize the anticoagulation effects.
2000770|NCT03324191|Dietary Supplement|High fat liquid meal challenge|"A dairy based standard study meal challenge providing 40 g dietary fat and less than 2 g carbohydrate or 1.2 g protein.
For the tracer test subpopulation (n=15) the test meal will also contain 300 mg [1,1,1-13C3] tripalmitin to trace the incorporation of dietary lipid into plasma fatty acids."
1477317|NCT03140592|Procedure|Biopsy|Two extra EUS guided pancreatic biopsies collected for only research purposes.
1477318|NCT03140579|Other|APRV|Airway pressure release ventilation is a method of inverse ventilation, where high levels of positive end expiratory pressure are maintained to optimise oxygenation with brief releases of pressure to allow ventilation and release carbon dioxide. It is an approved and frequently used method of ventilation.
1477319|NCT03140566|Diagnostic Test|Ultrasound evaluation of the inferior vena cava diameter|Treatment will be guided by clinical assessment and ultrasound evaluation of the inferior vena cava (IVC) diameter. Decongestion should lead to maximal IVC diameter ≤2.1 cm and IVC collapsibility index >50% in addition to relief of symptoms and signs of congestion before discharge.
1477320|NCT03140566|Diagnostic Test|Sham ultrasound evaluation of the inferior vena cava diameter|Teatment guided by clinical assessment alone. Decongestion should lead to relief of symptoms and signs of congestion before discharge. IVC ultrasound evaluation is performed, but results are not reported to treating physicians.
1477321|NCT03140553|Drug|TCH (docetaxel/carboplatin/trastuzumab) versus EC-TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab)|TCH (docetaxel/carboplatin/trastuzumab) versus EC followed by TH(epirubicin/cyclophosphamide followed by docetaxe plus trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer
1477322|NCT03140540|Other|TEE guided fluid therapy will be administered|Transesophageal echocardiography will be used to guide the fluid therapy. Velocity time integral of aorta <20 ,200ml colloid bolus to be administered.
1477323|NCT03140540|Other|Stroke volume variation guided intravenous fluid.|Active Comparator: Group A control group (SVV guided fluid ) Stroke volume variation guided intraoperative intravenous fluid will be administered. SVV >10, 200 ml of colloid bolus to be given
1477324|NCT03140527|Drug|PTI-801|Active
1477325|NCT03140527|Drug|Talc|Placebo
1477326|NCT03140514|Drug|Rejection treatment according to clinical standard-of-care|Standard-of-care treatment is based on the severity and phenotype of biopsy-proven rejection
1477327|NCT03140501|Device|"Mobile application (app)"|"The self-management app has 3 main features: 1) SCI-specific education modules; 2) a circle-of-care in which the users select health allies (formal and informal caregivers); and 3) a variety of tools to assist with goal identification, symptom/behaviour tracking, etc. The intervention will involve 5-6 contacts that occur over a 3-month period and ongoing use of the app. There will be 1 to 2 in-person sessions, where the principles of self-management are reviewed, self-management goals are identified, and features of the app are explained. Over the next month, there will be 2 follow-up contacts to review any questions/issues participants have. Participants can set additional goals during this time. Over the last 2 months, there will be monthly contacts to address the same issues."
1477328|NCT03140488|Drug|Oxytocin|Patients will be randomized to low dose or high dose oxytocin for induction of labor.
1477329|NCT03140449|Drug|Rapamycin|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.
In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
1948703|NCT01870401|Device|Lutonix DCB|
1948704|NCT01870401|Device|Uncoated PTA Catheter|
1477330|NCT03140449|Drug|Calcitriol|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.
In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
1477331|NCT03140449|Drug|Rapamycin-calcitriol combination|"topical rapamycin (0.1%) or calcitriol (3 mcg/g) single-agent therapy versus their combination were applied twice a day by a left-right randomized, split-face comparison for 12 weeks.
In period 2, the patients entered an open-label study and were reassigned to use the more effective ointment on both cheeks for another 12 weeks (week 13-24)."
1477332|NCT03140436|Drug|sodium bicarbonate powders with grain size 65 µm|sodium bicarbonate powders with grain size 65 µm
1477333|NCT03140436|Drug|sodium bicarbonate powders with grain size 40 µm|sodium bicarbonate powders with grain size 40 µm
1477334|NCT03140423|Drug|Arm 1. Routine Care (Mupirocin/CHG)|The intervention / decolonization regimen will consist of 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
1477335|NCT03140423|Drug|Arm 2. Iodophor/CHG Decolonization|The intervention / decolonization regimen will consist of 5 days of topical intranasal iodophor (10% povidone-iodine nasal swabs) (bilateral nares, twice daily) on ICU admission, in the context of continued daily baths with 2% chlorhexidine cloths.
1477336|NCT03140410|Other|Antibiotic resistance|"Test for susceptibility to linezolid using phenotypic tests, according to guidance from EUCAST group.
Screening for the presence of crf gene, and mutations associated"
1477337|NCT03140397|Dietary Supplement|Placebo|
1477338|NCT03140397|Dietary Supplement|6-prenylnaringenin|
1477339|NCT03140397|Dietary Supplement|8-prenylnaringenin|
1477340|NCT03140384|Biological|Assess the efficacy and side effects of Misoprostol according to the route of administration|Assess the efficacy and side effects of Misoprostol according to the route of administration
1477341|NCT03140371|Dietary Supplement|High energy high protein peptide feed study|"Each patient will receive the high energy, high protein peptide-based feed for a period of up to 4 weeks (28 days). The feed will be available as an enteral tube feed in a 500ml bottle, and as a Vanilla flavoured oral nutritional supplement in a 200ml plastic bottle. The appropriate feed presentation (tube feed or oral nutritional supplement) and prescription will be determined on an individual basis by the Dietitian responsible for the patient's nutritional management, based on the patient's clinical requirement and preference, and the Dietitian's clinical judgement.
The study feed is classed as a 'Dietary Food for Special Medical Purposes' (EC Directive 1999/21/EC, 1999) ."
2000771|NCT03324178|Behavioral|Neurofeedback training|Sixteen 30-minute sessions of neurofeedback training over four weeks: 7 x 3-minute blocks of training flanked by a 3-minute resting state block with eyes-open.
2000772|NCT03324178|Behavioral|Video game|Sixteen 30-minute sessions of video game playing over four weeks: 7 x 3-minute blocks flanked by a 3-minute seated relaxation.
1477344|NCT03140332|Other|Scannographic evaluation of the tumor response performed with mRECIST criteria after 3 months of treatment with sorafenib|To evaluate the association between tumor perfusion criteria (blood flow, blood volume, mean transit time, capillary permeability) at the initial perfusion scan and tumor control according to the mRECIST criteria after 3 months of treatment with sorafenib.
1477345|NCT03140319|Biological|Fibroblast|Transplantation of 20 million cell by three injection
1477346|NCT03140319|Biological|Placebo|Injection of Placebo
1477347|NCT03140306|Diagnostic Test|Patients who have had split dose CT|Computed tomography
2000773|NCT03324165|Other|Proposed Algorithm|Proposed algorithm that uses Alvarado Score to guide CT utilization
1477350|NCT03140280|Drug|Freeze-Dried Black Raspberry Powder|25 gm (2x/day) of freeze-dried black raspberry powder taken orally in 8 ounces of water for 12 weeks. If the patient is tolerating BRBs well and is benefiting from therapy, he or she will continue treatment for a total maximum of 48 weeks.
1477351|NCT03140267|Diagnostic Test|Difficult to wean patients|Subjects will be following during 18 hours in an invasive mechanical ventilation in a controlled mode. After failure of first single breath trial during 2 hours and presence of sevrability criterias defined by the European consensus conference in 2007, Maximal Inspiratory Pressure and Peak Pressure will be measure.
1477352|NCT03140254|Drug|Chlorhexidine gluconate|
1477353|NCT03140254|Drug|N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride|
1477354|NCT03140254|Drug|Placebo|
1477355|NCT03140241|Procedure|PDR measurement|"PDR measurement at two standardized times perioperatively:
: anesthetized subject by propofol sedation until sedation depth monitor NeuroSense® (NeuroWave Systems Inc, Cleveland, OH) between 40-50
: administration of remifentanil via effect site target concentration (Minto-model) at 5 ng/ml, in the absence of adjustments in sedation depth"
1477356|NCT03140228|Device|I-Gel|I-gel is the single use supraglottic airway from intersurgical, UK (Intersurgical Ltd, Wokingham, Berkshire, UK) with an anatomically designed mask made of a gel like thermoplastic elastomer to fit over perilaryngeal and hypopharyngeal structures. It is designed to separate the gastrointestinal and respiratory tracts and also allow a gastric tube to be passed into the stomach.
1477357|NCT03140228|Device|LMA|The AmbuAuraOnce (Ambu A/S, Ballerup, Denmark) is a supraglottic airway device with an inflatable cuff. It is a disposable device as well, but unlike I-gel, it does not feature a gastric channel.
1948705|NCT01870076|Behavioral|Healing Touch|
1948706|NCT01870076|Behavioral|Healing Touch, Sham|
1477360|NCT03140202|Device|CPRmeter (feedback device) with feedback|Participants have a real time feedback and record.
1477361|NCT03140202|Device|CPRmeter (feedback device) without feedback|Participants have a real time record without feedback.
1948707|NCT01870076|Behavioral|Control, Presence|
1477363|NCT03140163|Radiation|ULD-CT|Siemens Healthcare SOMATOM FORCE Ultra Low Dose chest CT
1477364|NCT03140163|Radiation|CXR|Conventional chest radiograph
1477365|NCT03140150|Device|Follow-up by Carelink express|Followed by the cardiologist exclusively using Carelink Express during the study period: a single visit 1 to 3 months after implantation, then followed by the cardiologist and interrogation of the stimulator by Carelink Express
1948708|NCT01867593|Device|C-11 methionine PET|
1948709|NCT01862952|Other|starting of anti-epileptic drug treatment|
1477366|NCT03140150|Other|Follow-up according to the usual recommendations|According to follow-up recommendations for pacemakers, a visit is planned every 6 months if the patient is dependent on the stimulator (either visits to M6, M12, M18 and M24) or annually if the patient is not dependent on the stimulator (visits to M12 and M24).
1477367|NCT03140137|Drug|Checkpoint inhibitor therapy|Treatment by ipilimumab, nivolumab or pembrolizumab for advanced cancer in clinical practice
1477368|NCT03140124|Behavioral|Exercise|Each participant will be provided with an ActiveLife Trainer to use during visit 2 or 3. The ActiveLife Trainer is a stationary pedaling machine that one can use while seated. It was designed to be used while working and makes very little noise. It is a safe, low-impact physical activity machine with adjustable resistance. The machine communicates via Bluetooth with the Wahoo Fitness app which records activity metrics such as distance cycled. Participants will be provided with a tablet on which the Wahoo Fitness app will track their exercise during the session. The ActiveLife Trainer has been used in numerous research studies (Carr et al., 2014; Botter et al., 2013; Burford et al., 2013; Carr et al., 2013).
1477369|NCT03140124|Behavioral|Worry Stone|For the worry stone condition, both the participants will rub a stone for the duration of the session. Each participant will be provided with a worry stone to rub during visit 2 or 3. These are small sooth stones that fit in the palm of one's hand.
1477370|NCT03140111|Device|LAMELLEYE|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
1477371|NCT03140111|Device|OPTIVE FUSION|Multi-dose sterile solution which contains sodium hyaluronate 0.1%, sodium carboxymethylcellulose 0.5%, glycerine 0.9%, erythritol, boric acid, sodium citrate dihydrate, potassium chloride, calcium chloride dihydrate, magnesium chloride hexahydrate, and is preserved with PURITE® 0.01% which breaks down into natural tear components on the eye.
1477372|NCT03140098|Device|cardiac surgery requiring a collagen membrane COVA™+|At the end of the cardiac surgery, the collagen membrane is implanted on the dissection area in order to prevent the formation of postoperative adhesions.
1477373|NCT03140085|Biological|PYO Phage|Intravescial instillation
1477374|NCT03140085|Drug|Antibiotics|Oral application
1477375|NCT03140085|Other|Sterile bacteriology media|Sterile bacteriology media, with identical color as bacteriophage preparation
2000774|NCT03324152|Other|High-intensity interval training (HIIT) - myositis|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
2000775|NCT03324152|Other|Standard low-intensity home exercise|12 weeks of 5 days/week low-intensity resistance home exercise in combination with outdoor walks of 20 minutes.
2000776|NCT03324152|Other|High-intensity interval training (HIIT) - healthy|12-weeks of 3 days/week HIIT. 6 sets of 30-60 seconds on 85-100% of maximal heart rate performed on a stationary bike followed by resistance training on 10 voluntary repetition maximum.
2000777|NCT03324139|Drug|Low molecular weight heparin|Patients included in this study group will receive 3,500 IU / 0.2 ml / day of Bemiparina sc, from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
1477380|NCT03140046|Procedure|photorefractive keratectomy (PRK)|"The cornea will be ablated while the patient fixating on target light under constant eye-tracking control. The ablations will be made using the ALLEGRETTO X 500WAVE excimer laser (WaveLight Laser Technologie AG)."
1477381|NCT03140033|Drug|Misoprostol Oral Tablet|at cord clamping the patient will recieve 400 micrograms of misoprostol sublingually
1477382|NCT03140033|Drug|Ranitidine Oral Tablet|at cord clamping the patient will recieve ranitidine sublingually
1477383|NCT03140020|Procedure|Clipping|During the microsurgical operation a titan clip will be placed round the aneurysm neck to exclude the aneurysm from the bloodflow and prevent fatal subarachnoidal hemorrhage.
1477384|NCT03140020|Procedure|Coiling|Using a catheter technique the aneurysm dome will be filled up with coils to prevent subarachnoidal hemorrhage.
1477385|NCT03140007|Device|single operator cholangioscopy|If patient is randomized to the Study arm, then the procedure will consist of the following in order: Cannulation and sphincterotomy per standard of practice. POCS with recording of POCS-based impression of malignancy (yes/no/indeterminate). POCS will be performed using the Spy DS system. POCS-guided biopsies will be collected, consisting of 6 macroscopically visible biopsies. The POCS-guided biopsy forceps will be the SpyBite forceps.
1477386|NCT03140007|Device|ERCP guided brushing and biopsy|• If patients are randomized to the Control arm, then they will undergo an ERCP. ERCP-based impression of malignancy (yes/no/indeterminate) will be recorded. ERCP-guided brushing and ERCP-guided biopsy will be performed.
1477387|NCT03139994|Other|Diagnostic|OBSERVATIONAL, DIAGNOSTIC PROCEDURES. Young adults with no signs or symptoms of TMD will be assessed. The chewing function, condylar path angles and lateral guidance angles will be recorded. Maximum comfortable and unassisted jaw opening, hemispheric dominance and hemimandibular retrognathia will be considered as secondary pre-specified outcomes. Three-Four years later, both TMJs of each participant presenting signs and/or symptoms will be evaluated according to DC/TMD. Same recordings as baseline will be carried out.
1477388|NCT03139981|Drug|ASN002|Daily dose of ASN002 for 28 days
1477389|NCT03139981|Drug|Placebo Oral Tablet|Placebo for ASN002 for 28 days
1477390|NCT03139968|Device|(sham) radiation absorbing drape (RADPAD®)|
1477391|NCT03139955|Device|Bodytrak|Bodytrak is a wireless earpiece which can monitor the user's vital signs such as tympanic (ear) temperature and heart rate. The earpiece is non-invasive and should fit comfortably within the right ear, similar to an earphone with an over-the-ear hook. Bodytrak is currently in a prototype stage. For further information please visit http://www.bodytrak.co
1477392|NCT03139942|Device|Optical spectral reflectance and autofluorescence imaging|When a suitable area of tissue is identified by the clinician during a patient's colonoscopy (e.g., a polyp), the imaging probe is inserted into the colonoscope so that it can view the tissue. Optical spectral reflectance and autofluorescence imaging is then performed to collect white light reflected by, and fluorescent light emitted from, the tissue. This is then analysed by hardware and software components in the external analysis unit.
2000778|NCT03324139|Drug|Placebos|Patients included in this study group will placebo (same presentation as the active drug), from inclusion to delivery (estimated median of 5-6 weeks, with a maximum of 13 weeks).
2000779|NCT03324113|Biological|SAR408701|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1477397|NCT03139890|Other|High-fat (HF-LC-LP) milkshake|During this experimental day, men will receive a high-fat milkshake
1477398|NCT03139890|Other|High-carbohydrate (LF-HC-LP) milkshake|During this experimental day, men will receive a high-carbohydrate milkshake
1477399|NCT03139890|Other|High-protein (LF-LC-HP) milkshake|During this experimental day, men will receive a high-protein milkshake
1477400|NCT03139864|Procedure|controlled physical activity|Comparison between infants with type 1 diabetes and infants without type 1 diabetes during exercise :
1477401|NCT03139851|Drug|Cyclophosphamide 50mg|One tablet per day. Cyclophosphamid will continue to be administered as long as patient experience clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
1477402|NCT03139851|Drug|Pembrolizumab 100 MG in 4 ML Injection|IV infusion every 3 weeks. Pembrolizumab will continue to be administered as long as patient experience clinical benefit in the opinion of the investigator or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
2000780|NCT03324113|Drug|trifluridine and tipiracil TAS-102|"Pharmaceutical form: tablet
Route of administration: oral"
2000781|NCT03324113|Drug|naphazoline|"Pharmaceutical form: solution for eye drop
Route of administration: eye drop"
1477405|NCT03139825|Other|Exploring the feasibility of learning during cognitive tasks (EEG-NIRS)|Exploring the feasibility of the study in its aspects of recruitment and tolerability of tasks and acquisition of electrical and hemodynamic data that can be used during cognitive tasks
1477406|NCT03139812|Drug|Daily irrigation|Daily morning irrigation of the eye with sterile, borate-buffered, saline solution (Unisol 4) and gentle nudging of the lens to promote solution flow beneath the lens
1477407|NCT03139812|Device|30-day SiH CW|30-day continuous wear of silicone hydrogel contact lenses
1477408|NCT03139799|Behavioral|Experimental - Puzzle Video Game Intervention|The psychological intervention consists of two custom-made versions of popular commercial casual puzzle video games (Flow Free, Big Duck Games LCC; Bejeweled, PopCap Games). The puzzle games are delivered on tablet-computers computer (12.9-inch tablet computer iPad Pro, Apple Inc., Cupertino, CA, USA).
1477409|NCT03139799|Behavioral|Control - Tablet Newspaper Reading Intervention|The control intervention uses a newspaper/ magazine reading task that will be delivered to participants using the same device (iPad Pro) as in the experimental intervention. The newspaper/ magazine reading task will be running on the built-in Apple Newsstand application. Participants will be offered subscriptions for two newspapers and/or magazines that they are instructed to read following the same regime as in the experimental condition.
1477410|NCT03139786|Other|Study the natural history of bicuspid|Study the natural history of bicuspid
1477411|NCT03139773|Dietary Supplement|Control Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
1477412|NCT03139773|Dietary Supplement|Omega-3 Breakfast Beverage|Each participant consumes the breakfast beverage every morning before 10:00 am for 14 days.
1477413|NCT03139760|Behavioral|POWERSforID|Feasibility and outcomes associated with use of the POWERSforID system and coaching phone calls over the course of 24 weeks
1477414|NCT03139747|Drug|Lenvatinib|Lenvatinib is an anti-cancer drug for the treatment of certain kinds of thyroid cancer, and potentially for other cancers as well. It was developed by Eisai Co. and acts as a multiple kinase inhibitor against the VEGFR1, VEGFR2 and VEGFR3 kinases.
1477415|NCT03139747|Drug|Everolimus|It is currently used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
1477416|NCT03139734|Device|Sacral Neuromodulation|S3 nerve root (sometimes S4) is stimulated with low electrical current via an electrode placed through a sacral foramen. This electrode is connected to a stimulator resembling a cardiac pacemaker.
2000782|NCT03324113|Drug|dexamethasone|"Pharmaceutical form: solution for eye drop
Route of administration: eye drop"
1477418|NCT03139708|Drug|Alphagan|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one."
1477419|NCT03139708|Drug|Phenylephrine|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
1477420|NCT03139708|Drug|Tropicamide|"Arm: Experimental: Alphagan plus Alphagan plus group is one drop Brimonidine then, Tropicamide and Phenylephrine ophthalmic one drop,times one.
Arm: Experimental: Tropicamide and Phenylephrine plus Tropicamide and Phenylephrine plus intervention is one drop of each then Brimonidine one drop, times one.
Arm: Active Comparator: Tropicamide and Phenylephrine only Tropicamide and Phenylephrine only arm is given one drop of each times one."
1477421|NCT03139695|Diagnostic Test|Ultrasound|High resolution Ultrasound of the Diaphragm and Intercostal muscles
1477422|NCT03139669|Device|Viba collection brush|HPV home collection kit using the viba collection brush to collect cervical cells for HPV DNA testing.
1948718|NCT01842308|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous stem cell transplant
1948719|NCT01842308|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
1948720|NCT01842308|Drug|Carfilzomib|Given IV
1948721|NCT01842308|Other|Laboratory Biomarker Analysis|Correlative studies
1948722|NCT01842308|Drug|Melphalan|Given IV
2000783|NCT03324113|Drug|diphenhydramine|"Pharmaceutical form: tablet
Route of administration: oral"
2000784|NCT03324087|Diagnostic Test|HRQoL|use SF-36 and ITP-PAQ questionnaires to assess the HRQoL in patients with ITP in the real world, and analyze the influencing factors of HRQoL so as to provide a sufficient basis for clinical decision making.
1477423|NCT03139656|Behavioral|Values Clarification|This intervention will incorporate elements from several widely established self-regulatory strategies aimed at enhancing the motivational aspects of goal pursuit, including mental contrasting (Oettingen, 2000), self-reflection (Koestner et al., 2002), self-affirmation (Schmeichel and Vohs, 2009), and the values clarification components of Acceptance and Commitment Therapy (ACT; Hayes, Strosahl, & Wilson, 1999). Participants will be prompted to enter their selected health goal and will then be instructed to identify personal values that might be practiced in pursuit of this goal. Participants will write about these values for several minutes, after which they will be instructed to select a short phrase or image that conjures up for them the reasons they choose to engage in their goal. Participants will be asked to type the phrase into a textbox and will have the option of receiving a confidential print-out of their chosen phrase at the end of the study visit.
1477424|NCT03139656|Behavioral|Planning|"Participants in this condition will be guided to create detailed implementation intentions, or if-then planning statements (Gollwitzer & Sheeran, 2006), specifying when, how, and where they will engage in their selected health goal. Participants will be provided with a detailed rationale adapted from earlier research on implementation intentions (e.g., Webb et al., 2010). Participants will be guided to generate a plan indicating when, where, and how they will enact their goal-based behavior over the next week. They will also be prompted to identify 3 obstacles they are likely to encounter during the pursuit of each goal, and to specify in an if-then format what specific actions they will take to overcome each obstacle (following the procedures and sample if-then responses of Koestner et al., 2002). They will be asked to rehearse each if-then statement to themselves before the end of the visit."
1477425|NCT03139656|Behavioral|Combined|"Participants in this condition will complete abbreviated versions of both the values clarification and planning procedures, as detailed above. Participants will be prompted to identify 2 obstacles (as opposed to 3) they might encounter during the pursuit of each goal. For each of the obstacles they identify with respect to each of their target goals, they will be prompted to form an additional implementation intention in the form: When [I encounter the specified obstacle], I will do [X] and remember [values-based statement or image identified during values clarification exercise]. They will be asked to rehearse these if-then statements to themselves before the end of the visit."
1477426|NCT03139643|Other|Cognitive Dissonance|After reading the materials about their chosen behavior, participants will be asked write an essay about their behavior of choice (studying/exercising). For this essay they will be asked to imagine that they have reached their ideal level of academic achievement/fitness, describe what this would look and feel like, and reflect on how this would impact how they view themselves, their relationships, and their day to day life.
1477427|NCT03139643|Other|Action Planning|After reading the materials about their chosen behavior, participants will be asked to make a detailed plan for the following two weeks based on the following items taken from a study by Sniehotta and colleagues (2004): 1) when to complete studying/exercise, 2) where to complete studying/exercise, 3) how to complete studying/exercise (e.g., what types of exercise- cardio, class, etc. or what types of studying activities- reading, taking notes, creating outlines, etc.), and 4) how often to complete studying/exercise. Participants will be given a calendar as an aid to planning their behavior.
1477428|NCT03139643|Other|Reflection (Control Condition)|After reading the materials about their chosen behavior, participants will be asked to summarize and reflect on what they read.
1477429|NCT03139617|Procedure|Fascia Iliaca Compartment Block (FICB)|"The FICB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block. Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel. Lignocaine 2% for local anaesthetic infiltration at punctured site.A blunted needle (Plexufix® 24G x 2, B Braun Melsungen AG 34209 Germany).A line was drawn from pubic tubercle to anterior superior iliac spine, the punctured point is 2-3cm distal to the point where medial 2/3rd and lateral 1/3rd of the line meet. Loss of resistance 2 times indicated the punctured of fascia lata and iliaca.A total volume of Ropivacaine 0.375% per body weight was given with repeated aspiration."
1477430|NCT03139617|Procedure|3 in 1 femoral block (FNB)|"The FNB was done in the OT with standard monitoring with emergency airway intervention and resuscitation drug prepared before performing intended block.Patient was put in supine position, using aseptic technique, chlorhexidine solution and draped with sterile medical towel.Lignocaine 2% for local anaesthetic infiltration at punctured site.An insulated stimulating needle (Stimuplex® D Plus 22g x 2, B Braun Melsungen AG 34209 Melsungen Germany). Ultrasound was used to locate the femoral vessel and nerve and by using 'in plane' technique, the skin was punctured with the insulated needle and advance in transverse plane at around 30 angle to the skin. Local anaesthetic solution as per ideal body weight given after negative aspiration of blood ."
1477431|NCT03139604|Drug|Itacitinib|Itacitinib at the protocol-defined dose administered orally once daily (QD) plus corticosteroids.
1477432|NCT03139604|Drug|Placebo|Matching placebo tablets administered orally once daily (QD) plus corticosteroids.
1477433|NCT03139604|Drug|Prednisone|Oral prednisone may be used to begin standard corticosteroid background treatment at the investigator's discretion, at a dose equivalent to methylprednisolone 2 mg/kg per day.
1477434|NCT03139604|Drug|Methylprednisolone|Methylprednisolone 2 mg/kg IV daily (or prednisone equivalent) or at a dose appropriate for the severity of disease as background treatment.
1477435|NCT03139591|Drug|lidocaine inhalation; intravenous dexamethasone|1.5 mg/kg body weight (BW) of 2% lidocaine inhalation, diluted with 2-3 ml of normal saline until the total volume was 6 ml, and intravenous normal saline injection; Intravenous dexamethasone group: normal saline inhalation and 10 mg of intravenous dexamethasone.
1477436|NCT03139578|Device|Investigational Contact Lens|ACUVUE OASYS® 1·Day with HydraLuxe™
1477437|NCT03139578|Device|Marketed Contact Lens|1·Day ACUVUE® TruEye®
1477438|NCT03139565|Biological|Fluzone High-dose Influenza Vaccine|This treatment consists of 60 microgram of each influenza antigen provided as a single injection, which will be injected in the deltoid muscle of the non-dominant arm.
1477439|NCT03139565|Biological|Standard 2016-2017 Flu vaccine|The intramuscular preparation of the vaccine used for the control group will be the Standard influenza vaccine made available by public health. The intramuscular dose (standard 0.5 mL) will contain 15 microgram antigen from each strain and delivered in the deltoid muscle by trained personnel.
1477477|NCT03139305|Drug|Glucagon|High dose intravenous infusion for 72 hours at 25 ng/kg/min
1477478|NCT03139305|Drug|Placebo|Intravenous infusion of saline for 72 hours
1948723|NCT01836783|Other|Amnion Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
1948724|NCT01836783|Other|Allograft|Atraumatic extraction and grafting procedures will be followed by insertion of a dental implant into to the grafted area at week-8. The implant will be restored and be monitored for 24 months post-insertion. Two special dental cone-beam CT images (pre-baseline and week-7) and a minimum of 6 intraoral radiographs will be taken during the study
1477443|NCT03139539|Device|Ioban|
1477444|NCT03139526|Other|observational study so no intervention|observational study, so no intervention
1477445|NCT03139513|Drug|Cobimetinib|Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
1477446|NCT03139513|Drug|Vemurafenib|Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
1477447|NCT03139500|Drug|JNJ-61803534|Participants will receive JNJ-61803534 tablets orally.
1477448|NCT03139500|Drug|Placebo|Participants will receive matching placebo.
1477449|NCT03139500|Drug|Midazolam|Participants will receive single oral dose of midazolam.
1477450|NCT03139487|Drug|Rivaroxaban|15 mg q12 hours for 3 weeks followed by 20mg q24 hours for 21 weeks
1477451|NCT03139487|Drug|Dalteparin|200 IU/kg q24 hours for 4 weeks followed by 150 IU/kg q24 hours for 20 weeks
1477452|NCT03139474|Drug|Gonadotropin-Releasing Hormone Analogue|Triptorelin at a dose 1 mg per day from the midluteal phase of the cycle preceding the treatment cycle to day 2 of the cycle then 0.5 milligram of triptorelin will be used during the period of stimulation.
1477453|NCT03139474|Drug|Gonadotropin releasing hormone antagonist|antagonist group :Multiple dose gonadotrophin-releasing hormone antagonist regimen will be used for ovarian stimulation 0.25 microgram per day cetrorelix will be administered from the 6th day of ovarian stimulation or from the presence of follicle 14 millimeter diameter .We will give them gonadotrophin for 5 days , Triggering by Human Chorionic Gonadotrophin will be administered for each group when size of follicle reach > 17 millimeter .Oocytes will retrieved by transvaginal ultrasound , 34-36 hours after Human Chorionic Gonadotrophin administration .
1477454|NCT03139461|Other|PT-REFER Capacity-building Toolkit|"Written guidelines for building partnerships with physical therapists. Information includes information on who to contact, how to contact them, and how to present information about the program (e.g., evidence base, program structure)
Support from Change Agent
Technical Assistance Calls"
1477455|NCT03139448|Device|Oxygen via nasal cannula|Oxygen will be supplied to the patient via nasal cannula according to the routine standard of care practice at Vanderbilt University Medical Center.
1477456|NCT03139448|Device|Oxygen via SuperNO2VA nasal mask|The anesthesia provider will attach the SuperNO2VA's (Revolutionary Medical, Inc) circuit port to the anesthesia machine, turn the oxygen flow rate to 10L/min, and set the APL valve to 10 cm H2O.
1477457|NCT03139435|Procedure|Biopsy|Undergo skin biopsy
1477458|NCT03139435|Other|Questionnaire Administration|Ancillary studies
1477459|NCT03139435|Other|Ultrasound Tomography|Undergo peripheral nerve ultrasound
1477460|NCT03139422|Drug|Tranexamic Acid 500 MG|oral tablets
1477461|NCT03139422|Drug|Calcium Dobesilate|oral tablets
1477462|NCT03139409|Procedure|adhesive bond with chlorhexidine|Peak® Universal Bond (ultradent, 505 West 10200 South, South Jordan, UT 84095،USA ) light-Cured Adhesive with Chlorhexidine (0.2%), 7.5% filler, phosphate and containing hydroxyethyl methacrylate with ethyl alcohol as the carrier. its viscosity has been optimized for minimal film thickness (2μm) and superior strength. using self etch adhesive with chlorexidine as one step in the bonding component may give chance to proper penetration of resin tags, decrease the micro-organisms due to the antibacterial effect of chlorexidine (Bin-Shuwaish, 2016) and also the addition of chlorexidine in bonding system may be an excellent tool to increase the stability of collagen fibrils within the hybrid layer against host-derived metaloproteinases (MMP) without the need for additional steps for the bonding protocol (Stanislawczuk, et al., 2009), which results in better durability and good restorations with decreasing the incidence of recurrent caries
1477463|NCT03139409|Other|Time variable|Diagnosis and follow up will be immediate , 6 months later and 1 year
1477464|NCT03139396|Procedure|tub shaped inlay bridge design|inlay retained bridge with tub shaped retainer on both abutments
1477465|NCT03139383|Other|dextrose solution|The patients received 5%D/N/2 during surgery
1477466|NCT03139383|Other|saline solution|The patients received NSS during surgery
1477467|NCT03139370|Genetic|Autologous genetically modified MAGE-A3/A6 TCR transduced T cells (KITE-718)|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of TCR transduced autologous T cells (KITE-718).
1477468|NCT03139370|Diagnostic Test|MAGE-A3/A6 test|MAGE-A3/A6 test
1477469|NCT03139357|Other|GAD7, SF12, medical utilization, helpfulness questionnaire|The questionnaires are administered to track stress level and medical utilization over a 2 year period.
1477470|NCT03139344|Other|Low-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of 1 Hz electrical stimulation.
1477471|NCT03139344|Other|High-frequency Exercise|The quadriceps/hamstrings will perform exercise via the application of 3 Hz electrical stimulation.
1477472|NCT03139331|Drug|Pazopanib|Pazopanib will be administered orally as a tablet according to an assigned dose level per protocol. A cycle will be defined as 21 days. Drug dosing for the tablet formulation will be determined using a study-specific nomogram.
1477473|NCT03139331|Drug|Irinotecan|All patients will be given irinotecan at a dose of 50 mg/m2/dose IV on days 1-5 of a 21-day cycle during Cycle 1. In subsequent cycles, irinotecan may be given intravenously at a dose of 50 mg/m2/dose or orally at a dose of 90 mg/m2/dose on days 1-5 of a 21-day cycle.
1477474|NCT03139331|Drug|Temozolomide|Temozolomide will be given at a dose of 100 mg/m2/dose orally on days 1-5 of each 21-day cycle.
1477475|NCT03139318|Radiation|GRID radiotherapy|Patients will be treated with GRID radiotherapy
1477476|NCT03139305|Drug|Glucagon|Low dose intravenous infusion for 72 hours at 12.5 ng/kg/min
2000785|NCT03324061|Drug|Fulvestrant for Injectable Suspension|Test drug is administered as a single 5mL intramuscular injection in the right or left dorsogluteal muscle area
1477479|NCT03139292|Device|ProSeal Laryngeal Mask Airway|ProSeal Laryngeal Mask Airway was used as the supraglottic device
1477480|NCT03139292|Device|AmbuAuraGain Laryngeal Mask Airway|AmbuAuraGain Laryngeal Mask Airway was used as the supraglottic device
1477481|NCT03139279|Drug|Dexmedetomidine|Dexmedetomidine 0.3 ug/kg intravenous bolus
1477482|NCT03139279|Other|Saline placebo|Intravenous saline/placebo
1477483|NCT03139279|Drug|Propofol|Propofol titrated intravenous boluses
1477484|NCT03139266|Behavioral|UPLIFT|Participation in the sessions involves skills practice, discussions, and group exercises based on the sessions' main topics. CBT-related topics include thought monitoring, identifying cognitive distortions, self-esteem, problem identification, goal setting, and identifying supports. Relaxation exercises, including a body scan (i.e., a mindfulness exercise) and progressive muscle relaxation, are also used for coping and to facilitate awareness of the body. Mindfulness activities include attention to skin, sights, and sounds and other meditations. Participants will practice their skills between sessions through homework assignments including monitoring and changing thoughts, and practicing relaxation exercises, meditation exercises, and mindfulness.
1477485|NCT03139266|Behavioral|Treatment as usual|The control group will receive the recommendation to consider maintaining mental health services
1477486|NCT03139253|Drug|amoxicillin|amoxicillin 1000 mg bid. for 14 days
1477487|NCT03139253|Drug|clarithromycin|clarithromycin 500 mg bid. for 14 days.
1477488|NCT03139253|Drug|tinidazole|tinidazole 500 mg bid. for 14 days.
1477489|NCT03139253|Drug|levofloxacin|levofloxacin 500 mg qd. for 14 days.
1477490|NCT03139253|Drug|furazolidone|furazolidone 100 mg bid. for 14 days.
1477491|NCT03139253|Drug|tetracycline|tetracycline 750 mg bid. for 14 days.
1477492|NCT03139253|Drug|Ilaprazole|Ilaprazole 5 mg bid. for 14 days.
1477493|NCT03139240|Drug|Oxycodone 10mg oral|Oxycodone 10mg oral given for pain control in addition to standard of care medications in women undergoing medical abortion
1477494|NCT03139240|Other|Placebo|Placebo given in addition to standard of care medications in women undergoing medical abortion
1477495|NCT03139227|Procedure|Bio specimen Collection|Patients undergo collection of blood and urine
1477496|NCT03139227|Dietary Supplement|Dietary Intervention|Consume celery-banana bread
1477497|NCT03139227|Other|Laboratory Biomarker Analysis|Correlative studies
1477498|NCT03139214|Behavioral|Parenting Intervention|
1477499|NCT03139201|Device|OxyAqua|OxyAqua (olifilcon D) silicone hydrogel soft contact lens
1477500|NCT03139201|Device|Si-Hy|Si-Hy (oliflcon B) silicone hydrogel soft contact lens
1477501|NCT03139175|Device|balance assessment with Biodex balance system|All subjects of three groups will be assessed with the evaluation device( balance system).
1477502|NCT03139162|Other|Swiss RAI-HC assessment|RAI-HC assessments done by trained nurses in clinical routine
1477503|NCT03139149|Procedure|Adhesiolysis|"Method of video laparoscopic operation:
Open access in the left upper quadrant of the anterior abdominal wall,
Installation of trocars, depending on the prevalence of the adhesion process
Assessment of the peritoneal adhesion index
Detection of the asleep gut
Detection of obstacle area
Removing the obstacle without trying to completely eliminate the adhesion process in the abdominal cavity
If there is no possibility to eliminate the cause of intestinal obstruction laparoscopically laparotomy is performed."
1477504|NCT03139149|Radiation|X-ray diagnostics|X-ray of the thoracic (1) and abdomen (2-5 times) with water soluble contrast.
1477505|NCT03139149|Radiation|Computer tomography|Computer tomography of abdomen with iv contrast
1477506|NCT03139149|Procedure|Ultrasound|Ultrasound of the abdomen (2 times)
1477507|NCT03139149|Other|General and biochemical blood test|General blood test and biochemical blood test 2 times a day
1477508|NCT03139136|Drug|MBS2320|As described in the arm descriptions
1477509|NCT03139136|Drug|Placebo|As described in the arm descriptions
1477510|NCT03139123|Other|Hemodynamic monitoring during passive leg raising|Measurement of hypotensive episodes related to preload dependance.
1477511|NCT03139110|Behavioral|Presence of a mediator in the emergency departments|"The mediator tasks are :
Be available to patients who can solicit him and respond to their requests for information, in particular on the organization of the emergency departments and on waiting times
Have a proactive attitude towards patients showing nervousness signs
Report patients expressing the will to leave the emergency departments before medical care
Manage conflicts between patients / accompanying persons and emergency staff and also between patients."
1477512|NCT03139097|Diagnostic Test|Quantra System|Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
1477513|NCT03139058|Other|Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)|Evaluation of the hepatic fibrosis stage by a hepatological assessment (Clinical, biological and imaging)
1477514|NCT03139045|Biological|Venous puncture in elderly patients|Venous puncture in elderly patients
1477515|NCT03139032|Drug|APD334|APD334 active treatment for 12 weeks.
1477516|NCT03139019|Behavioral|Process incentives|Participants will receive cash based incentives for achieving process based measures (class attendance).
1477517|NCT03139019|Behavioral|Outcome incentives|Participants will receive cash based incentives for outcome based measures (weight loss).
1477518|NCT03139019|Behavioral|Process and Outcome incentives|Participants will receive cash based incentives for both achieving process based measures (class attendance) and outcome based measures (weight loss).
1477519|NCT03139006|Device|Dual-layer spectral detector CT|A dual energy CT approach
2000786|NCT03324061|Drug|Faslodex (Reference)|Reference drug is administered as two 5mL intramuscular injections, one in each of the right and left dorsogluteal muscle areas
1477522|NCT03138980|Behavioral|BodiMojo Buddy for IBS|"Mobile application focusing on emotional coping skills for teens and young adults with IBS. Components of the module include: mood recorder and mood cloud, with supportive feedback given based on mood choice; health behavior change support messages informed by mindfulness and self-compassion; quizzes with tailored feedback; library of meditations; an interactive coping skills advice section; and a link to an optional social support feature."
1477523|NCT03138967|Drug|Rocuronium|Rocuronium used to induce the neuromuscular blockade and given in a rapid sequence for endotracheal intubation at a dose of 0.6 mg/kg.
1477524|NCT03138967|Drug|Sugammadex|4 mg/kg by vein to reverse the muscle relaxation.
1477525|NCT03138967|Drug|Neostigmine|70 mcg/kg by vein to reverse the muscle relaxation.
1477526|NCT03138967|Drug|Glycopyrrolate|14 mcg/kg by vein to reverse the muscle relaxation.
1477527|NCT03138928|Device|XEN45 gel stent implantation in glaucoma surgery|The XEN gel stent (Allergan, Dublin, Ireland) is a recently developed, permanent, ab interno collagen implant that reduces IOP by draining aqueous fluid from the anterior chamber into the subconjunctival space
2000787|NCT03324048|Other|relaxation session|"During relaxation session, patients anxious will have three electrodes for save heart rate variability and a sensor for save value of the partial pressure of carbon dioxide.
Before and after relaxation session, patient evaluates his anxiety by visual analogue scale (VAS) and State-Trait Anxiety Inventory (STAI-Y)."
1477530|NCT03138902|Dietary Supplement|TRUTOL Glucose Tolerance Beverage|A caffeine-free, non-carbonated, glucose tolerance beverage
1477531|NCT03138889|Drug|Combination of NKTR-214 + atezolizumab|"NKTR-214: The starting dose will be a 0.006 mg/kg intravenous (IV) infusion administered over 15 (± 5) minutes q3w.
Atezolizumab (anti-PD-L1) will be dosed as per label."
1477532|NCT03138876|Device|EEG Cap|Patient will be fitted with an EEG cap by the on-call neurology resident to assess for NCSE.
1477533|NCT03138876|Drug|Anti-seizure medication|Patients may be treated for NCSE or seizures based on EEG cap findings, if the findings are clear to an attending EEG reviewer. If the subject is treated with anti-seizure medication, the primary care provider will choose which medication will be given.
1477534|NCT03138876|Procedure|Standard EEG|An electroencephalogram (EEG) is a test used to find problems related to electrical activity of the brain. An EEG tracks and records brain wave patterns. Small metal discs with thin wires (electrodes) are placed on the scalp, and then send signals to a computer to record the results.
1477535|NCT03138863|Device|BALT GoldbBAL2 Detachable Balloon|Latex balloon, with radio‐opaque inclusion
1477536|NCT03138863|Device|Catheter System|100 cm tapered micro‐catheter
1477537|NCT03138850|Device|Olympus standard bite block|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and nasal cannula with oxygen 5L/min
1477538|NCT03138850|Device|YX mandibular advancement bite block|Intravenous sedative upper gastrointestinal endoscopy performed under mandibular advancement bite block for endoscopy (Yong Xu breathing mouth piece, Yong Xu) and oxygen connected to mouth piece 5L/min
1477539|NCT03138850|Device|Optiflow High flow nasal cannula|Intravenous sedative upper gastrointestinal endoscopy performed under standard bite block (MB142 reusable bite block, Olympus) and high flow nasal cannula
1477540|NCT03138837|Diagnostic Test|Magnetic resonance imaging|Diffusion Weighted Magnetic resonance imaging
1477541|NCT03138824|Procedure|SPIES assisted TURBT|SPIES assisted TURBT of NMIBC
1477542|NCT03138824|Procedure|WLI assisted TURBT|White Light Imaging (WLI) assisted TURBT for treatment of NMIBC
1477543|NCT03138811|Drug|CSJ117|inhaled once daily dose
1477544|NCT03138811|Drug|Placebo Comparator|inhaled once daily dose
1477545|NCT03138798|Device|Laboraide TM dental support device|Patients will give consent in the first stage of labor. Subsequently a randomization will be performed using sealed envelopes opened at the time of pushing in the second stage of labor. Women assigned to Group A will received a sealed Laboraide TM package. Duration of the second stage and time spent pushing will be recorded. Obstetric management will not be altered by group assignment. Following delivery, patients assigned to Group A will complete a patient satisfaction survey.
1477546|NCT03138785|Drug|topical voriconazole / levofloxacin systemic itraconazole|starting topical voriconazole every hour tapering after 4 days , levofloxacin every 6 hours, Itraconazole 100mg /BD for 2 weeks
1477547|NCT03138785|Radiation|CXL|30 min Riboflavin prescription to the cornea followed by 30 min UV-A radiation at 3mW/cm2 associated with Riboflavin administration
1477548|NCT03138772|Other|This is an observational study, no intervention used.|No intervention is being used in this study.
1477549|NCT03138759|Drug|Pexidartinib|Orally, on Day 2
1477550|NCT03138759|Drug|Probenecid|Orally, on Day 2
1477551|NCT03138746|Procedure|HBO|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow oxygen for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
1477552|NCT03138746|Procedure|Hyperbaric air|"Compression in a hyperbaric chamber in air to 2 atmospheres absolute, then donning a hood supplying high flow air for 90-minutes followed by a linear decompression back to 1 atmosphere over 30 minutes"
1477553|NCT03138733|Drug|Ceftobiprole medocaril|Ceftobiprole medocaril 500 mg as 2 h infusion
1477554|NCT03138733|Drug|Daptomycin|Daptomycin 6 mg/kg as 0.5 h infusion, with or without Aztreonam
1477555|NCT03138720|Drug|Paclitaxel Protein Bound (Abraxane)|Participants will be treated with the regimen prior to having surgery. Participants will complete 3 cycles (cycle is 21 days) and then will be evaluated for CA19-9 normalization. If CA19-9 is normalized, then participant will be scheduled for surgery and moved to standard of care. If CA19-9 is not normalized then participants will complete another 3 cycles.
1477556|NCT03138707|Other|patients who die|
1477557|NCT03138694|Other|BHCG monitoring|Participants in the study will be invited to our outpatient clinic for BHCG monitoring including blood count and BHCG levels test and serial Transvaginal Ultrasound examination
1477558|NCT03138681|Drug|Placebo|placebo is given intravenously twice a day for 14 days
1477559|NCT03138681|Drug|ATP|ATP (100mg) is given intravenously twice a day for 14 days
1477560|NCT03138681|Drug|Phosphocreatine|Phosphocreatine (1g) is given intravenously twice a day for 14 days
1477561|NCT03138668|Drug|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
1477629|NCT03138070|Drug|BYL719|BYL719 400 mg daily by mouth continue for 14 days
1478036|NCT03135054|Drug|Quizartinib|Quizartinib is an oral FLT3 receptor tyrosine kinase inhibitor
1477562|NCT03138668|Drug|Ropivacaine Injection|"All 20 study participants will receive both treatment Low dose Ropivacaine and High dose Ropivacaine in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment Low dose Ropivacaine and High dose Ropivacaine will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment Low dose Ropivacaine in the right lower extremity, treatment High dose Ropivacaine will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control."
1477563|NCT03138655|Drug|Vedolizumab|Vedolizumab intravenous infusion
1477564|NCT03138629|Drug|VAL-083|VAL-083 will be administered intravenously
1477565|NCT03138616|Drug|vitamin D|take 1600 units of vitamin D daily for nine months
1477566|NCT03138603|Drug|Metoprolol Tartrate|Patients will receive up to 3 IV doses of study drug IV metoprolol tartrate 5mg) prior to extubation, and subsequently an oral dose 25mg metoprolol tartrate in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
1477567|NCT03138603|Drug|Placebo|Patients will receive up to 3 IV doses of study drug placebo prior to extubation, and subsequently an oral dose placebo in the PACU, and then oral dosing at approx. every 8 hours thereafter through postop day 3 (72 hrs).
1477568|NCT03138590|Device|Transcranial Direct Current Stimulation- Neuroconn DC Stimulator PLUS|Transcranial Direct Current Stimulation targeting the trigeminal nerve
1477569|NCT03138577|Diagnostic Test|Ultrasound Imaging|M-mode measurement of diaphragmatic excursion
1477570|NCT03138577|Other|Bedside Spirometry|Assessment of pulmonary function [Forced Vital Capacity (FVC), Forced Expiratory Volume in 1 second (FEV1), Peak Expiratory Flow (PEF)]
1477571|NCT03138577|Other|Supraclavicular Block|The patient will be positioned supine with the head turned to the contralateral side. The ultrasound will be placed in the supraclavicular fossa, and the skin and subcutaneous tissues will be infiltrated lateral to the probe with 2% lidocaine. The anesthesiologist can redirect the needle and perform additional injections for complete coverage of the brachial plexus. The local anesthetic will be a 2:1 mix of 1.5% mepivacaine and 0.5% bupivacaine.
1477572|NCT03138564|Behavioral|SPIRIT|"SPIRIT is a two-session, structured psychoeducational intervention assisting patients clarify their end-of-life preferences and helping surrogates understand the patient's wishes and prepare for the surrogate role.
During the first session (about 45 minutes) individualized information is provided about the effectiveness of life-sustaining treatment for people with end-organ failure, and the care provider will assist the patient to examine his/her values about life-sustaining treatment. The surrogate will receive help preparing for end-of-life decision-making and the emotional burden of decision-making. A Goals-of-Care document will be completed to indicate the patient's preferences.
Two weeks later, the second session (about 15 minutes) addresses remaining or new concerns. The patient's Goals-of-Care document will be reviewed. The patient's end-of-life preferences and surrogate's name and relationship to the patient will be documented in the medical record."
1477573|NCT03138564|Behavioral|Comparison Condition|As required by Centers for Medicare and Medicaid Services (CMS), written information on advance directives (ADs) is provided to a patient on the first day of dialysis, and a social worker reviews this information with patients and encourages them to complete an AD. This typically takes about 10 minutes.
1477574|NCT03138551|Behavioral|Mealtime PREP (Promoting Routines of Exploration and Play)|
1477576|NCT03138525|Other|Blood sampling (MS)|Blood samples will be collected before initiation of Ocrelizumab treatment and after 6 and 12 months of treatment.
1477577|NCT03138525|Other|Blood sampling (controls)|Blood samples will be collected once at enrollment.
1477578|NCT03138512|Biological|Nivolumab|Specified dose on specified days for 24 weeks
1477579|NCT03138512|Biological|Ipilimumab|Specified dose on specified days for 24 weeks
1477580|NCT03138512|Drug|Placebo|Specified dose on specified days for 24 weeks
1477581|NCT03138499|Biological|Nivolumab|Specified dose on specified days
1477582|NCT03138499|Biological|Brentuximab vedotin|Specified dose on specified days
1477583|NCT03138473|Diagnostic Test|Residual SYNTAX Score|"The baseline SYNTAX score and the residual SYNTAX score (rSS) are calculated by summing up the individual scores for each lesion with a diameter stenosis ≥50% in vessels with a diameter ≥ 1.5 mm in the angiography obtained before and after the procedure. The SYNTAX algorithm of scoring is fully described elsewhere.
The modified Age, Creatinine, and Ejection Fraction (ACEF) score is calculated based on the age, glomerular filtration rate (GFR) and left ventricular ejection fraction (LVEF), using the formula age/LVEF +1 point for every 10 ml/min/1.73 m2 reduction of GFR below 60 ml/min/1.73 m2 (1 point for GFR between 59 and 50, 2 points for GFR between 49 and 40 and 3 points for GFR between 39 and 30 ml/min/1.73 m2). The GFR is calculated via the Cockroft-Gault equation using age, gender weight and serum creatinine before PCI. The baseline SYNTAX score was then multiplied by the modified ACEF score to obtain the baseline clinical SYNTAX score."
1477584|NCT03138473|Diagnostic Test|SYNTAX Revascularization Index|The SYNTAX Revascularization Index (SRI), representing the proportion of CAD burden treated by PCI, was calculated using the following formula: SRI= (1-[rSS/bSS]) ×100.
1477585|NCT03138460|Other|standard medications crossed over to cannabis|
1477586|NCT03138447|Device|Basal Insulin Titration Application|"Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose."
1477587|NCT03138421|Drug|ABX-1431 HCl|ABX-1431 HCl, capsules, 20 mg
1477588|NCT03138421|Drug|Placebo|Matching placebo
1477589|NCT03138408|Drug|SC-004|Intravenous
1477701|NCT03137485|Device|Easy Go system Endoscopy|This system will be used to remove herniated disc in endoscopic group
1477702|NCT03137472|Device|Transcranial Magnetic Stimulation (TMS)|The Magventure TMS stimulator will be used to perform intermittent theta burst followed by high frequency Transcranial Magnetic Stimulation (TMS).
1477590|NCT03138395|Diagnostic Test|droplet digital PCR|This study will use our droplet digital PCR (ddPCR) method to quantify and track peripheral blood plasma MAF in MDS and AML patients before, during and after chemotherapy treatment. Quantification of MAF from fingersticks and saliva samples will also be performed to determine feasibility of obtaining adequate circulating tumor DNA (ctDNA) for ddPCR. Results from this project will generate a non-invasive means to monitor cancer response and progression months before current clinical methods, and provide an opportunity to intervene before the patient relapses.
1477591|NCT03138382|Device|Vestibular Nerve Stimulator|Electrical stimulation of the vestibular nerve for for 45 minutes using binaural mastoid placement.
1477592|NCT03138382|Device|Sham stimulator|Looks identical to vestibular nerve stimulator but discharges current into an internal resistor rather than activating the vestibular nerves.
2000788|NCT03324035|Drug|Amitriptyline|Administer amitriptyline on flexible doses variating from 25mg to 75mg, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
2000789|NCT03324035|Drug|Placebo oral capsule|Administer amitriptyline on flexible doses variating from 1 to 3 capsules, with backup of tramadol, and evaluate the reduction of the pain based on the Brief Pain Inventory Questionnaire.
2000790|NCT03324035|Drug|Tramadol|"Administer to both arms on as needed scheme, to a maximum of 150mg/day."
2000791|NCT03324009|Diagnostic Test|2-stage screen|Pap smear is currently the standard of care for cervical cancer screening in Botswana. In this study, participants will undergo HPV DNA testing at the time of Pap smear collection. If HPV DNA test is positive, they will be referred for colposcopy. Patients who have an HPV negative test but positive Pap smear will be referred for colposcopy per Botswana cervical cancer screening guidelines.
2000792|NCT03323996|Other|Semi-Structured interviews|individual semi-structured interviews
2000793|NCT03323983|Other|data collection|data collection
1477602|NCT03138330|Other|this study is observational, it is not an intervention|
1477603|NCT03138317|Biological|PRP|This group will receive a knee injection with 6 ml of platelet rich plasma (PRP)
1477604|NCT03138317|Biological|Plasma|This group will receive a knee injection with 6 ml of plasma.
1477605|NCT03138317|Biological|Placebo|This group will receive a knee injection with 6 ml saline solution.
1477606|NCT03138304|Behavioral|Video game|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center.
1477607|NCT03138304|Behavioral|Educational program|Two commercially available applications designed to teach physicians the trauma triage guidelines disseminated by the American College of Surgeons.
1477608|NCT03138291|Device|Somnodent|Each pregnant women will be treat with a Somnodent
1477609|NCT03138278|Other|Telephone support on demand|Dedicated phone number for help and advice for caregivers
1477610|NCT03138265|Behavioral|HIIT Device: ergometer|Supervised exercise training.
1477611|NCT03138252|Drug|Oxytocin|
1477612|NCT03138239|Radiation|Ga-68-PSMA scan, and PET -CT F-18-FDG|"The patient will do tow mappings on two different days. It should be noted that there is no importance to the order between the two tests on the condition that they be performed within 7-10 days of each other.
Both tests will be performed with the Discovery 690 camera, which is located at the Nuclear Medicine Institute.
First test PET-CT with F-18-FDG PET-CT second test with Ga-68-PSMA"
1477613|NCT03138226|Procedure|uterus transplantation|
1477614|NCT03138213|Procedure|Three dimensional laparoscopic pancreaticoduodenectomy|Three dimensional laparoscopic pancreaticoduodenectomy
1477615|NCT03138213|Procedure|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
1477616|NCT03138200|Biological|Blood transfusion|Blood transfusion is a safe, routine procedure in which blood is given to a patient through an intravenous cannula inserted into one of the patient's veins.
1477617|NCT03138187|Behavioral|Moderate exercise|The training phase of the moderate exercise group (MEG) will consist of 4 sets of 10 minutes walking/running at moderate intensity, with 5 minutes walking at low intensity for recovery between sets
1477618|NCT03138187|Behavioral|Vigorous exercise|The training phase of the vigorous exercise group (VEG) will consist of 4 sets of 10 minutes running at vigorous intensity, with 5 minutes walking at low intensity for recovery between sets
1477619|NCT03138174|Device|OneTouch Verio Flex Blood Glucose Monitoring System|Blood Glucose Monitoring System
1477620|NCT03138161|Drug|Trabectedin|Trabectedinis an alkylating drug indicated for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
1477621|NCT03138161|Drug|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4)-blocking antibody indicated for (1) treatment of unresectable or metastatic melanoma, and (2) adjuvant treatment of patients with cutaneous melanoma with pathologic involvement of regional lymph nodes of more than 1 mm who have undergone complete resection, including total lymphadenectomy.
1477622|NCT03138161|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1, PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-medicated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and plays a key role in tumor evasion from host immunity.
1477623|NCT03138148|Other|Routine mechanical ventilation|Routine mechanical ventilation in PICU amid children with acute respiratory failure
1477624|NCT03138135|Behavioral|HOME Study intervention|Access to home HIV test kits, home STI self-collection kits, the HOME Study website, and the SexPro HIV risk assessment tool.
1477625|NCT03138135|Behavioral|Control|Counseling about the importance of quarterly HIV/STI testing and a PrEP information pamphlet.
1477626|NCT03138096|Biological|Pb(PfCS@UIS4)-infected mosquitoes|Pb(PfCS@UIS4)-infected mosquitoes
1477627|NCT03138096|Other|Challenge infection P. falciparum|Challenge infection with bites of five infected Pf mosquitoes
1477630|NCT03138044|Procedure|Combined Treatment|This modality of palliative treatment includes initial surgical operation where arterial vascular supply of the tumor carrying liver lobe of the corresponding hepatic artery as well as the extrahepatic collateral arteries (EHCAs) feeding the large HCC (> 5 cms size) under general anesthesia. Four weeks after the operation the tumor is injeted (intralesionally and intravascularly) with absolute ethanol alcohol injections on regular weekly percutaneous sessions until the tumor become saturated and its vascularity rendered inactive.
1477631|NCT03138031|Procedure|Percutaneous ethanol alcohol injection|"Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of 8 limits the procedure. Post-procedure analgesia may be required."
1477632|NCT03138018|Diagnostic Test|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuropsychological tests
1477633|NCT03138018|Diagnostic Test|Diagnosis of MCI versus No MCI (SCI or healthy patient)|Neuroimaging biomarkers of neurodegeneration
1477634|NCT03138005|Other|target SpO2 98-100%|Prehospital, post-ROSC oxygen maintained at ≥10L/minute of oxygen (equivalent to ~100% oxygen) into SGA/ETT if hand ventilated or 100% (i.e. FiO2 of 1.0) oxygen settings if mechanically ventilated. Patients will continue on treatment to handover in the ED. Between arrival at ED and first ABG in ICU, the oxygen setting may then be decreased provided SpO2 is maintained between 98-100%.
1477635|NCT03138005|Other|target SpO2 90-94%|Prehospital, post-ROSC oxygen reduced initially to 4L/minute (i.e. approximately 70% oxygen) into SGA/ETT if hand ventilated or an air mix setting if mechanically ventilated. If oxygen saturation remains ≥94% for 5 minutes, the oxygen flow rate will be further reduced to 2L/minute (i.e. approximately 46% oxygen) and hand ventilated to target an oxygen saturation between 90-94%. This treatment will continue to patient handover in the emergency department. Between arrival at ED and first ABG in ICU, oxygen will be titrated to target a oxygen saturation of 90-94%.
1477636|NCT03137992|Drug|Placebo|Single dose of placebo inhalation powder administered by test and reference dry powder inhalers.
1477637|NCT03137992|Drug|Test Product|"Double -Blind: Single dose of test product 18 mcg administered by test dry powder inhaler with placebo inhalation powder administered by reference dry powder inhaler.
Open-Label: once daily administration of test product 18 mcg administered by test dry powder inhaler."
1477638|NCT03137992|Drug|Reference Product|Reference product 18 mcg.
1477639|NCT03137979|Biological|GMSCs and collagen scaffolds|Patients in this group were given GMSCs and collagen scaffolds.
1477640|NCT03137979|Biological|Collagen scaffolds|Patients in this group were given collagen scaffolds.
1477641|NCT03137979|Procedure|Open flap debridement|The patients in this group will only receive the treatment of open flap debridement.
1477642|NCT03137966|Drug|Deferoxamine|Deferoxamine (0.66mg/ml) will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
1477643|NCT03137966|Drug|Placebo|Placebo will be applied locally as a gel (3 times a week) for a period of maximum three months or until intact skin.
1477644|NCT03137953|Procedure|Clinical Evaluation|The skin pinch test would be done by three independent oncologists to assess ability for skin conservation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
1477645|NCT03137953|Diagnostic Test|Radiological Imaging|Computed Tomography or Magnetic Resonance Imaging would be done by a radiologist and used to measure the distance between tumor and skin which would guide the decision for skin presevation. The decision for skin conservation would be taken by the surgeon intra-operatively based on clinical and radiological assessments.
1477646|NCT03137940|Device|real tDCS|one-shot of real tDCS session (1.5mA; 0.06 mA/cm2 for 20 minutes) with BrainStim Stimulator.
1477647|NCT03137940|Device|sham tDCS|one-shot of sham tDCS session (20 minutes) with BrainStim Stimulator.
1477648|NCT03137927|Biological|Vaccine GamLPV|live intranasal vaccine for whooping cough prevention
1477649|NCT03137927|Other|Placebo|Placebo
1477650|NCT03137914|Biological|Autologous chondrocyte transplantation|intraarticular injection into the TMJ (arthrocentesis) of autologous chondrocytes diluted in hyaluronic acid
1477651|NCT03137914|Procedure|orthognathic surgery|Orthognathic surgery for correction of dentofacial deformity, performed before the cellular transplantation
1477652|NCT03137901|Device|Capstesia|Picture of the arterial waveform taken with a smartphone
1477653|NCT03137888|Radiation|Dose-Escalated Radiation Therapy|Undergo sMRI-guided radiation therapy, dose painted to maximum of 75 Gy over six weeks
1477654|NCT03137888|Procedure|Spectroscopic Magnetic Resonance Imaging|Patients will undergo sMRI scans within a 14 day window prior to starting treatment
1477655|NCT03137888|Drug|Temozolomide|Given PO
1477656|NCT03137862|Other|Gluten free bread|patients will receive bread containing 3 g of cornstarch daily for 12 weeks; these patients will serve as controls
1477657|NCT03137862|Dietary Supplement|Gluten friendly bread 3g/day|"patients will have to continue the GFD supplemented with 3 gr of gluten friendly bread daily for 12 weeks"
1477658|NCT03137862|Dietary Supplement|Gluten friendly bread 6g/day|"patients will have to continue the GFD supplemented with 6 gr of gluten friendly bread daily for 12 weeks"
1477659|NCT03137849|Other|Yoga Poses|Yoga poses routine including specific muscles contractions known as bandhas (pelvic floor, core and throat/neck contraction) within each pose, which are advised to be done with steadiness and comfort.
1477660|NCT03137849|Other|Breath Control|"Ujjayi pranayama (Victorious breath) Inhalation and exhalation are both done through the nose. The ocean sound is created by moving the glottis as air passes in and out. As the throat passage is narrowed so, too, is the airway, the passage of air through which creates a rushing sound. The length and speed of the breath is controlled by the diaphragm, the Strengthening of which is, in part, the purpose of ujjayi. The inhalations and exhalations are equal in duration."
1477661|NCT03137849|Other|Stretching exercises|Stretching exercises routine based on dynamic and static exercises excluding those similar to yoga poses. This routine works on great range of motion of all body joints and main muscles groups/ chains.
1477662|NCT03137836|Behavioral|Intervention|"Multi-level intervention focused on school environment (furniture) will be conducted.
Device: Sit-to-stand desks (Ergotron LearnFit®); Device: (Actigraph, Pensacola, FL, USA); Device: ActivPALTM ."
1477663|NCT03137823|Diagnostic Test|throat culture|throat culture - from the tonsills and from the bucal surface
1477664|NCT03137810|Procedure|placental cord drainage|"In the study group a of total number of 90 women placental end of the cut umbilical cord 1st will be clamped for few seconds and then unclamped and left open to drain blood in a vessel until flow stoped. This will prevent the drained blood from getting mixed with blood lost in the 3rd stage.
Blood loss in the third stage will be measured using a Kelly's pad which will be used during delivery and the blood lost will be collected in a clean metal bowl which will be kept at the tail end of Kelley's pad."
1477665|NCT03137810|Procedure|non placemtal cord drainage|In 90 women after vaginal delivery of the baby placental end of the cut umbilical cord will be kept clamped.
1477666|NCT03137784|Drug|NVA237 (glycopyrronium bromide)|In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
1477667|NCT03137784|Drug|Placebo|In each treatment arm, patient will receive placebo
1477668|NCT03137771|Radiation|3-Dimensional Conformal Radiation Therapy (3D-CRT)|Undergo 3DCRT
1477669|NCT03137771|Drug|Docetaxel|Given IV
1477670|NCT03137771|Drug|Gemcitabine|Given IV
1477671|NCT03137771|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Undergo IMRT
1477672|NCT03137771|Drug|Pemetrexed Disodium|Given IV
1477673|NCT03137771|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Undergo SBRT
1477674|NCT03137758|Drug|PCUR - 101|PCUR-101 Capsules 25 mg are solid dosage forms for oral administration
1477675|NCT03137745|Other|thromboelastography|thromboelastography was done pre HIPEC ,post HIPEC and first and second postoperative days
1477676|NCT03137732|Device|Rectus Sheath Catheter|Insertion of rectus sheath catheter via either method
1477677|NCT03137706|Procedure|Biospecimen Collection|Undergo fresh tumor tissue collection
1477678|NCT03137706|Other|Laboratory Biomarker Analysis|Correlative studies
1477679|NCT03137706|Other|Laboratory Procedure|Tissue stiffness and cell viability analysis
1477680|NCT03137693|Other|Standard of Care Schedule Variation: SABR|SABR will be delivered over 3 days, prior to surgery.
1477681|NCT03137693|Procedure|Breast-conserving Surgery|Breast-conserving surgery will be scheduled for 6-8 weeks after SABR and will be conducted by a Moffitt breast surgeon.
1477682|NCT03137680|Behavioral|Hand Exercise|Exercise protocol for the intervention group will be to squeeze a soft ball 10 times for set and perform 3 sets of 10 squeezes each at an 1 minute interval. Three sets of exercises to be performed twice in the morning and twice in the evening, for a total of six weeks.
1477683|NCT03137667|Other|School-located Influenza Vaccination|Children in the intervention arm are enrolled in schools in Monroe County, New York that are offering school-located influenza vaccination clinics during school hours
1477684|NCT03137654|Other|Affective Training|Intervention includes up to 12 training sessions (~45 minutes each). Training sessions includes practice on cognitive tasks embedded with emotionally salient stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
1477685|NCT03137654|Other|Neutral Training|Intervention includes up to 12 training sessions (~45 minutes each). Training sessions includes practice on cognitive tasks embedded with neutral stimuli. Tasks include a dual modality n-back and a directed attend/ignore memory task.
1477686|NCT03137641|Other|Nurses urine samples|Collected urine samples from nurses in contact with antineoplastic drugs.
1997729|NCT01947452|Behavioral|Employment|Community organizations will place youth in summer jobs based on youth interests and the availability of positions. Jobs will be part-time in non-profit and government organizations. Youth will be paid the IL minimum wage of $8.25 per hour. The community organizations will provide job mentors to assist youth with barriers to work like transportation or clothing, and to provide supervision at the job site.
1477688|NCT03137615|Procedure|Pituitary surgery|Trans-sphenoidal resection of a pituitary gland lesion.
1477689|NCT03137615|Drug|local anaesthetic injection|The surgeon infiltrates the nasal septum with local anaesthesia as per usual practice. This consists of Moffet's solution and lidocaine with adrenaline (1:200,000).
1477690|NCT03137602|Device|ATOMIC mobile app|(a) PA Coach, One-on-one Chats. Coaches will conduct three one-on-one phone or video conferencing sessions and will also conduct a text messaging session once per week to reinforce and follow-up on the one-on-one phone sessions during the course of the intervention. (b) PA-Self Monitoring. An activity tracker (Fitbit Charge 2) will be used to allow participants to monitor their activity behaviors (e.g. step counts). (c) PA Information. In addition the coach will send weekly tailored PA informational posts/messages aligned with Social Cognitive Theory (SCT) to all participants. (d) Educational Modules. MS specific web-based interactive PA modules will be provided to patients.
1477691|NCT03137576|Procedure|Serratus Plane Block|SPB consists in the injection of a Large Volume, low concentration of Ropivacaine (30 ml, 0.3%), in the plane between the Ribs, the External Intercostal Muscle and the Serratus Anterior Muscle [10]. The injection is performed after induction of general Anesthesia, after the patient has been placed in lateral decubitus for the procedure. Briefly, an Anesthesiologist, proficient in the procedure, under US guidance will localize the plain, at the Anterior Axillary Line, and inject the anesthetic under direct vision.
1477692|NCT03137563|Other|questionnaire|The questionnaire will be distributed and collected by the same investigator in one of the eight centers involved in the study. The investigator will verify the inclusion criteria and the absence of exclusion criteria.
1477693|NCT03137537|Drug|Ivabradine|lower heart rate in heart failure patients.
1477694|NCT03137537|Drug|Placebo Oral Tablet|Procedure prescribed to compare the active effect of a medicine.
1477695|NCT03137524|Device|Hand Held Fan Therapy|Hand-Held fan therapy used to generate airflow directed to face during specific exercise test
1477696|NCT03137511|Other|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist|Taking photographs of suspicious lesions with his smartphone and sending them to the dermatologist
1477697|NCT03137498|Drug|Lidocaine|Lidocaine 1.5mg/kg IVPB in 50ml normal saline over 10 minutes x 1dose
1477698|NCT03137498|Drug|Ketorolac|Ketorolac 30mg (1ml) intravenous push injection x 1dose
1477699|NCT03137485|Procedure|Conventional lumbar discectomy|Removal of single level lumbar disc herniation through conventional discectomy.
1477700|NCT03137485|Procedure|Endoscopic lumbar discectomy.|Removal of single level Lumbar disc herniation using endoscope.
2000794|NCT03323970|Other|semi-structured interviews|individual semi-structured interviews
1477703|NCT03137459|Combination Product|Transtheoretical Model (TTM) of health behavior change|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report. For individuals in early stages of change for a given behavior, the feedback focuses on changing attitudes, a necessary prerequisite for changing behavior, by addressing common barriers and by reminding individuals they can engage in small steps.
1477704|NCT03137459|Other|Usual Care|Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. Participants in this group will not receive any components of the TTM intervention.
1477705|NCT03137446|Other|Intravenous Fluid Cap|Normal Saline or Ringers Lactate limited to 60ml/kg for first 72 hours
1477707|NCT03137420|Diagnostic Test|Numeric Scale of Family Distress|Questionnaires at 1, 3, 6 and 12 months
1477708|NCT03137407|Biological|Botulinum Toxins, Type A|Intramuscular injection
1477709|NCT03137407|Biological|Placebo|Intramuscular injection
1477710|NCT03137394|Other|Observation|Data for each participant in the SCI group will be collected at baseline, 6 months, and 1 year post injury; control group data will be collected at baseline and at the 1-year follow-up.
1477713|NCT03137368|Drug|Exemestane Tablets|drug therapy
1477714|NCT03137368|Other|ovarian function suppression/ablation|Gonadotropin-releasing hormone analogue Goserelin Injection 3.6mg or Leuprorelin Injection 3.75 mg, a subcutaneous injection should be done every 28±2 days; or Bilateral ovariectomy.
1477715|NCT03137368|Genetic|CYP2D6*10 gene test|CYP2D6*10 gene test
1477716|NCT03137368|Drug|Tamoxifen|drug therapy
1477717|NCT03137342|Behavioral|Pepped on PrEP Package|A counseling and problem-solving adherence intervention with a Behavioral Activation approach to re-engage participants in safe but pleasurable activities in life and addresses stimulant abuse as well as associated factors, including depression, as barriers to optimal PrEP adherence.
1477718|NCT03137329|Behavioral|Exercise program|Physical therapy for aerobic and resistance training exercises
1477719|NCT03137329|Dietary Supplement|Nutrition|Nutrition supplementation via HMR for lifestyle arm only
1477720|NCT03137329|Procedure|WLS|Weight loss surgery as planned
1477721|NCT03137316|Diagnostic Test|intact parathyroid hormone level|obtain intact parathyroid hormone level from patients records.
1477722|NCT03137303|Device|Spirometry|"Initial visit for the intervention group, an initial demographics form and health questionnaires. To evaluate the breathing, a pre and post broncho dilator will be performed as well as a spirometry test.
At the end of the 1 year followup, the patient will be scheduled for a pre and post BD spirometry test and undergo the same spirometry protocol as the intervention group."
1477723|NCT03137303|Drug|Albuterol|The post broncho dilator spirometry test will be preformed after a breathing medication called Albuterol. Albuterol is used in standard practice for COPD and is commonly used during spirometry.
1477724|NCT03137290|Drug|Neostigmine|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF Watch Sx was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it was between 2-3. Then a reversal dose for TOF count of 2 to 3 was 0.05 mg/kg of Neostigmine with 0.02 mg/kg of Atropine. Therefore the volume would be 0.2 mls per kg is to be administered.
1477725|NCT03137290|Drug|Sugammadex Sodium|The TOF Watch Sx, and Paediatric Bispectral Index (BIS) monitoring were put on patient. Gaseous induction, with oxygen and Sevoflurane was given until BIS was 40-50, then a intravenous line was obtained. 2 mcg/kg of fentanyl was given for analgesia. then,the TOF was calibrated.The patient was paralyzed with 0.6mg/kg of rocuronium, and intubation of the trachea was done once TOF count was less than 1. A maintenance of 0.2 mg/kg of Rocuronium was given boluses every 30 minutes to maintain TOF count between 2-3. At the end of surgery, TOF count was checked to ensure it between 2-3. Then the dose for reversal of sugammadex with a TOF count of 2 or 3 would be 2 mg/kg. This will also be equivalent to a volume of 0.2 mls per kg and given at the end of surgery.
1477726|NCT03137277|Procedure|screening colonoscopy|"Introduction and forwarding of the device up to caecum/terminal ileum. Then withdrawal and inspection of colonic wall. Biopsies and polypectomies if necessary. overall and diagnostic (only withdrawal) times being recorded separately.
Polyps are documented with regards to location (caecum, ascending, transverse and descending colon, sigmoid and rectum), size (open forceps or snare for comparison) and morphology using the Paris classification (polypoid pedunculated or sessile, non-polypoid slightly elevated/flat/depressed, ulcerous) Polyps were then resected using biopsy forceps or cold snare (for polyps < 5 mm), or conventional polypectomy according to local standards."
1477727|NCT03137264|Drug|Other|Patients who are T790M positive via cobas plasma and/or cobas tissue testing during Part 1 will be treated per standard of care during Part 2, which may include osimertinib.
1477728|NCT03137251|Device|TENS 1|A portable TENS unit will be used by the principal investigator to apply the experimental intervention. Two pairs of electrodes measuring 5 x 9 cm will be fixed on the paravertebral regions of the participants of the experimental group using hypoallergenic surgical tape. Two paired electrodes will be placed 1 cm laterally on either side of the spine at the T10 to L1 and S2 to S4 levels.
1477729|NCT03137251|Device|TENS 2|An intervention similar to arm 1 will be performed but with different doses.
1477730|NCT03137251|Device|Placebo TENS|An intervention similar to arm 1and 2 will be performed but,in this case, it is a sham device.
1477731|NCT03137238|Other|Investigation of self-perception in Parkinson's disease|There is no therapeutic intervention.
1477732|NCT03137225|Device|Neurally Adjusted Ventilatory Assist|Neurally Adjusted Ventilatory Assist delivered via RAM cannula .
1477733|NCT03137225|Device|Nasal Intermittent Positive Pressure Ventilation|Nasal Intermittent Positive Pressure Ventilation delivered via RAM cannula
1477734|NCT03137212|Combination Product|thrombolysis and PCI of A type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 3-6 hours after thrombolysis.
1477735|NCT03137212|Combination Product|thrombolysis and PCI of B type|STEMI patients first are given thrombolysis and then transfer to PCI centers to be treated by PCI 6-24 hours after thrombolysis.
1477736|NCT03137199|Biological|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
1477737|NCT03137186|Drug|Metformin|Metformin will be added as a daily treatment to the standard treatment in both neoadjuvant and adjuvant settings of locally advanced cases and lifelong to metastatic cases. The starting daily dose of metformin is 850mg Once daily, to be increased to 850 mg if tolerated
1477738|NCT03137173|Drug|Ceftobiprole medocaril|Ceftobiporole medocaril as 2 h infusion
1477739|NCT03137173|Drug|Vancomycin plus Aztreonam|Vancomycin as 2 h infusion; Aztreonam as 0.5 h infusion
1477740|NCT03137160|Biological|Ixekizumab|Injection
1477741|NCT03137147|Behavioral|Intervention for Sleep and Pain in Youth|See arm description.
1477744|NCT03137121|Drug|Olanzapine|Olanzapine is used as an anti-emetic.
1477745|NCT03137121|Other|Placebo|The placebo is a non-anti-emetic.
1477746|NCT03137108|Device|Transcutaneous electrical spinal cord stimulation|Study intervention consists of the application of tSCS at three different frequencies (15 Hz, 30 Hz, 50 Hz) using the CE certified electrostimulator RehaMove 3. Stimulation will only be applied by an investigator during the two testing sessions. During the overground walking, the participants will be secured and assisted with the cable-driven body-weight support system FLOAT.
1477747|NCT03137095|Other|Cognitive testing|computerized and paper-based cognitive tests that assess memory, executive function, processing speed and concentration performed at Assessments 1, 3 & 5.
1477748|NCT03137082|Drug|Guanfacine XR 3mgs/daily|Guanfacine 3mg tablet
1477749|NCT03137082|Drug|Placebo (for guanfacine)|Sugar pill manufactured to mimic guanfacine tablets
1477750|NCT03137069|Drug|GDC-0853|GDC-0853 orally, twice daily, from Day 1 to 56.
1477751|NCT03137069|Drug|Placebo|Matching placebo, orally, twice daily, from Day 1 to 56.
1477752|NCT03137056|Device|Hemodialysis with Theranova|"Theranova is a polyarylethersulfone-based hemodialysis membrane manufactured by Baxter International Corp All the dialysis sessions in this arm will be performed with the theranova membrane. This membrane will exclusively be used in hemodialysis.
Modalities of hemodialysis : Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min"
1477753|NCT03137056|Device|Hemodialysis with FX1000|"FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodialysis.
Modalities of hemodialysis: Blood flow: 300-400 mL/min ; Dialysate flow: 500-800 mL/min"
1477754|NCT03137056|Device|Hemodiafiltration with FX1000|FX1000 is a helixone-based membrane manufactured by Fresenius All the dialysis sessions in this arm will be performed with the FX1000 membrane. This membrane will be used in hemodiafiltration Modalities of hemodialysis: Blood flow: 300-400 mL/min; Dialysate flow: 500-800 mL/min ; post reinjection convection volume of at least 25L.
2000795|NCT03323957|Diagnostic Test|nutritional screening tool|screening of disease associated malnutrition in sick infants
1477757|NCT03137030|Drug|GRT7014 - Abuse Deterrend Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
1477758|NCT03137030|Drug|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods and in the standard cross-over trial periods.
1477759|NCT03137017|Drug|Norco 5Mg-325Mg Tablet|Single oral dose in one of the four cross-over trial periods.
1477760|NCT03137017|Drug|GRT7014 - Abuse Deterrent Tablet|Single oral dose in one of the four cross-over trial periods.
1477761|NCT03137004|Drug|Docetaxel|Docetaxel 50mg/m2 in 60 min on day 1 and repeated every 14 days.
1477762|NCT03137004|Drug|S-1|S-1 was administered orally at 40 mg/m2 twice daily on days 1-7 of each cycle. Patients with a body surface area of less than 1.25 m2 received 80 mg S-1 daily, those with a body surface area of 1.25 m2 or more but less than 1.5 m2 received 100 mg S-1 daily, and those with a body surface area of 1.5 m2 or more received 120 mg S-1 daily.
2000797|NCT03323931|Behavioral|(2) robot--enhanced intervention|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by the robotic agent (Softbank Robotics Nao robot). All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
1477766|NCT03136965|Biological|PRP|Injection of autologous platelet rich plasma (PRP)
1477767|NCT03136965|Procedure|Dry Needling|This is a therapeutic procedure that involves the same injection procedures under ultrasound guidance as in the PRP group but no PRP will be injected inside the patellar tendon.
1477768|NCT03136965|Procedure|Dry Needling - Sham|This is a sham procedure that involves similar injection procedures under ultrasound guidance as in the PRP and DN groups with no injection of PRP or needle placement inside the patellar tendon.
1477769|NCT03136952|Device|NIRS frontal and occipital|NIRS frontal and occipital on pediatric population during general anesthesia
1477772|NCT03136913|Device|MinerOss® Cortical and Cancellous Chips (FDBA)|Mixture of allograft mineralized cortical and cancellous chips
1477773|NCT03136913|Procedure|Open Flap Technique|After extraction, the socket wound is left open to heal by secondary intention
1477774|NCT03136913|Procedure|Closed Flap Technique|After extraction, the socket wound is closed by primary closure
1477775|NCT03136900|Dietary Supplement|Nutrilon without lactose® fortified by concentration|enteral diet with cow milk protein-based infant formula without lactose 20% in place of 14%
1477776|NCT03136900|Dietary Supplement|Nutrilon without lactose® fortified by Maltodextrin and oil supplementation|enteral diet with cow milk protein-based infant formula without lactose 14%
1477777|NCT03136887|Device|JOURNEY II XR Total Knee System|JOURNEY II XR Total Knee System
1477778|NCT03136874|Other|Interview and questionaires|"Quantitative method : Two questionnaires will be used to define sociodemographic data, motivations and personality traits of donors.
Qualitative method : Clinical interviewing allows data collection adapted to study the motivations of sperm/egg donors, their representations, the experience and the inscription of the donation in their personal stories."
1477779|NCT03136861|Biological|AIN457|anti IL-17a monoclonal antibody
1477780|NCT03136861|Drug|AIN457 Placebo|Placebo matching AIN457
1477781|NCT03136848|Drug|Normothermic ex-vivo kidney perfusion Solution -Toronto|"The perfusion device will circulate warmed, oxygenated blood-based perfusate (Normothermic ex-vivo kidney perfusion solution-Toronto) through the kidney."
1477782|NCT03136835|Drug|Maternal Hyperoxygenation|Oxygen via nasal prongs at 4L/min continuously during 2nd and 3rd trimester of pregnancy until birth
1477783|NCT03136822|Other|Standard Dressing|Standard dressing is applied for treatment of diabetic foot ulcers
1477784|NCT03136822|Device|DERMALIX|DERMALIX, a class III Medical Device will be applied in addition to standard dressing
1477785|NCT03136809|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
1477786|NCT03136796|Drug|Meropenem|Patients will receive intravenous antibiotics eighter empirically or based on a culture.
1477787|NCT03136783|Other|Development of the most specific physiologically relevant experimental patient models|Development of the most specific physiologically relevant experimental patient models: organotypic culture of biopsies, reconstituted skin (equivalents of dermis with melanoma, dermis equivalents and epidermis with melanoma), and in vitro evaluation The response of tumor cells to different combinations of targeted therapy molecules
1477788|NCT03136770|Dietary Supplement|CK-30|Compound K 600 mg
1477789|NCT03136770|Dietary Supplement|Red ginseng extracts|Red ginseng extracts 2.94 g
1477790|NCT03136757|Other|Transcriptomic analysis of GVHD biopsies|"The transcriptomic analysis of GVHD biopsies aims at:
to demonstrate an evocative or even specific molecular profile, making the diagnosis of GVHD easier
to identify new intracellular signaling pathways that could lead to new therapeutic"
2000798|NCT03323931|Behavioral|(1) discrete trial training / cognitive-behavior therapy|The tasks included in the treatment follow a structured behavioral approach, called the discrete trial training (DTT). The learning process is guided by an interaction partner (human), under the supervision of the therapist. All activities follow a gameplay scenario and they take place at a table, which in the case of joint attention and turn taking tasks incorporates a large touchscreen. Each behavior presented to the child is preceded by instructions and followed by a contingent reinforcement. The contingent reinforcement and prompting are used to train each targeted behavior/action. The behaviors are presented over multiple and successive trials and explicit prompting is giving when the child doesn't succeed to accomplish the targeted behavior. Each action is repeated three times. For every child, the intervention for each ability starts from the level determined in the first two sessions, but as the child's performance improves, the task moves to a more complex level.
1477792|NCT03136731|Diagnostic Test|Celiac disease antibody screening|Observational parameters
1477793|NCT03136718|Other|Mobile-enabled RLOs (mRLOs)|A theoretically-driven, personalised educational intervention delivered through mobile technologies based on the C2Hear (https://www.youtube.com/C2HearOnline) RLOs. The mRLO intervention will include shorter 'bite-sized' RLOs suitable for mobile technologies. This will allow a unique dynamic tailoring approach, whereby relevant mRLOs will be provided based on the user's responses to a self-evaluation filter aid, which will enable individualised, tailored learning.
1477794|NCT03136705|Drug|Nicotinamide|Nicotinamide tablet
1477795|NCT03136705|Drug|Lanthanum Carbonate|Lanthanum Carbonate tablet
1477796|NCT03136705|Drug|Lanthanum Carbonate Placebo|Sugar pill manufactured to look like Lanthanum Carbonate tablet
1477797|NCT03136705|Drug|Nicotinamide Placebo|Sugar pill manufactured to look like Nicotinamide tablet
1477798|NCT03136692|Behavioral|Lose It! commercial weight loss app|Lose It! is a commercial weight loss smart phone app designed for easy caloric tracking. It provides a free mobile and web interface for users to construct an individualized weight loss plan by entering their goal weight and desired weekly weight loss. Using the user's height, current weight, gender and age, the app generates a daily caloric budget designed for the user to reach their goal. Users can then log their caloric intake, exercise, and weight to track progress toward their goal.
1477799|NCT03136666|Drug|Nifedipine gastrointestinal therapeutic system (GITS) (Adalat LA, BAY a1040) + Candesartan cilexetil|Candesartan and nifedipine were administered together as loose combination with 240 mL non-sparkling water in the morning after a fasting period of at least 10 hours.
1477800|NCT03136653|Biological|MP0250 plus BOR+DEX|"6 mg/kg or 8 mg/kg or 12 mg/kg of MP0250, IV (in the vein,) on day 1 of each 21 day cycle. Bortezomib and Dexamethasone according to label.
Number of Cycles: until progression or unacceptable toxicity develops."
1477801|NCT03136640|Drug|ModraDoc006/r|Treatment with weekly ModraDoc006 (oral docetaxel) 10mg tablets in combination with ritonavir 100mg tablets
1477802|NCT03136627|Drug|Tivozanib|Tivozanib (AV-951): Phase 1b study and Phase 2a study: Subjects will receive 1 dose of tivozanib daily for 21 days followed by a 7 day rest period (1 cycle = 4 weeks).
1477803|NCT03136627|Drug|Nivolumab|Nivolumab: Phase 1b study and Phase 2a study: All subjects will receive IV nivolumab 240 mg every 2 weeks administered over 1 hour.
1477804|NCT03136614|Device|Arteriograph|
1477805|NCT03136601|Other|PTNS maintenance|The intervention is the timing of PTNS for maintenance (monthly treatment versus as patient needs)
2000799|NCT03323918|Other|ImPACT|Teaching parents to train social communicative skills as outlined in arm description.
1477806|NCT03136588|Device|Feedback using ICT based monitoring system|In case of a missed immunosuppressant dose, the first violation does not generate a feedback while the second one does within one hour at the break of the ±3 hour range from the fixed dosing time. Up to two additional alarms/texts are sent at an interval of 30 minutes if the dose is still not taken after the feedback. For any discrepancy between the dosage taken and the dosage prescribed, a feedback is sent within 1 hour from the moment of recognition. Again, the first violation goes without response, while any violation after that generates feedbacks. Similarly, if a dose is taken outside of the allowed ±3 hour dosing time range, a feedback is sent within 1 hour of recognition, starting with the second violation.
1477807|NCT03136575|Behavioral|Qigong|a 30 minutes exercise program, 3 times a week and lasts for 6 weeks during radiotherapy course
1477808|NCT03136575|Behavioral|Wait-list control|patients enrolled in this group are informed orally to have exercise only and are arranged in a waiting list
1477809|NCT03136562|Diagnostic Test|Synacthen test|250 microg synacthen test performed fasting, in the morning. P-cortisol measured before and 30 minutes after Synacthen injection.
1477810|NCT03136549|Procedure|Thermo-softening|The thermosoftening treatment of the tubes was performed by using a warm cabinet set to 45°C (approximately 117°F). One bottle of normal saline (1 L) containing a thermometer and three tubes (6.0 -7.0 mm ID) was put into a chamber of the cabinet 30 min before intubation.
1477811|NCT03136549|Procedure|Room temperature|nasotracheal tube, sized 6.0 -7.0 mm inner diameter (ID), were put into a bottle of sterilized normal saline (1 L, 25 °C) at room temperature.
1477812|NCT03136510|Drug|Apixaban 5 mg|"Bood collection for biological analyses at:
inclusion visit
follow-up visit at 1 month
end of research at 3 month"
1477813|NCT03136497|Drug|ABT-199|Oral dose daily until disease progression
1477814|NCT03136497|Drug|Ibrutinib|Oral dose daily until disease progression
1477815|NCT03136497|Drug|Rituximab|Rituximab will be administered IV per institutional standards. weekly X 4 (Cycle 1); once on Day 1 of cycles 2-6 only, then every other cycle until Cycle 24 (total 18 doses of Rituxan from C1D1
2000800|NCT03323918|Other|TAU|TAU can include targeting eating and sleeping problems, adaptive skills, or other goals.
2000801|NCT03323905|Device|Symphony MRI guided High Intensity Focused Ultrasound (HIFU)|The use of the MRI-HIFU for the ablation of leiomyomas
2000802|NCT03323892|Other|second masturbation|Husbands will be asked to produce a second sperm sample in the masturbatorium
2000803|NCT03323879|Radiation|LDR/HDR|Focal LDR to dominant lesion with whole gland 19 Gy HDR
1477820|NCT03136458|Procedure|Ischemic preconditioning|Repeated remote ischemic preconditioning by arterial cuff insufflation.
1477821|NCT03136458|Drug|Endovenous normal saline|endovenous normal saline 1 mL per Kg per hour before and after contrast media injection.
1477822|NCT03136445|Drug|Tranexamic acid (TXA).|IV or oral preparation. Oral treatment capsules contain a tablet of tranexamic acid and inert filler .
1477823|NCT03136445|Drug|Placebo|IV (saline) or oral preparation. Oral treatment capsules contain inert filler.
1477824|NCT03136419|Dietary Supplement|Lactobacillus casei DG|Lactobacillus casei DG probiotic supplementation for 8 weeks
1477825|NCT03136419|Dietary Supplement|Placebo|Placebo supplementation for 8 weeks
1477838|NCT03136393|Behavioral|Community based dietary counselling|The dietary counseling will be delivered to mothers through group sessions (will include cooking demonstration) and home visits by lay health workers. The counseling will promote foods that are nutritious and locally available and general better food preparation practices. The choices of the foods to be promoted will be based on linear programming results from a preceding survey on dietary intake of pregnant women in the area as well as results of analysis of foods associated with infant birth size (same data). The goal in the linear programming was to find a model of food combinations among the most frequently consumed foods which better meets required intakes during pregnancy. Additionally, adherence to pregnancy iron supplements will also be promoted.
1477839|NCT03136393|Behavioral|Community based antenatal counselling|The antenatal counselling will focus on preparations for neonatal care and encouragement for facility based delivery.
1477840|NCT03136380|Drug|GSK1325756H|Danirixin will be available as 10 and 50 milligram (mg) white film coated, round and oval tablets intended for oral administration. It will be administered with 240 mL of water.
1477841|NCT03136380|Drug|Placebo|Subjects will receive visually matching danirixin placebo tablets. It will be administered with 240 mL of water.
2000804|NCT03323866|Drug|Budesonide 0.5 MG/ML|2 cc nebule of budesonide in 240 cc of saline water (Sinus Rinse) once daily
2000805|NCT03323866|Drug|Mometasone nasal spray|Mometasone 50 mcg/spray 2 sprays twice daily
2000806|NCT03323853|Other|CARS Report|Patients will be evaluated by emergency providers using the CARS report
1477846|NCT03136341|Drug|Abobotulinum toxin A|Dosing will be determined at each study visit based upon muscles involved
1477847|NCT03136341|Other|Placebo|Dosing will be determined at each study visit based upon muscles involved
1477848|NCT03136328|Drug|68Ga-DOTATOC|The intervention is to administer 68Ga-DOTATOC PETCT for detecting NET.
1477849|NCT03136315|Other|INFERNAL Intervention|The intervention consists in serum and urinary dosage (creatinine and Cystatin C) at the beginning and the end of the 110 km race.
1477850|NCT03136302|Procedure|Deep Brain Stimulation|Deep Brain Stimulation
1477851|NCT03136289|Behavioral|Family Consumer Behaviors|The relationship between family consumer behaviours (healthy food availability and supermarket spending) and adolescent prediabetes and diabetes.
1477852|NCT03136276|Other|IPS Empress CAD|standard etchable glass ceramics
1477853|NCT03136276|Other|polished Celtra Duo|new glass ceramic material
2000809|NCT03323801|Drug|13-cis retinoic acid|Accutane is used for the treatment of severe acne
1477856|NCT03136250|Other|Group A (Control Group - Static Stretching + Standard Treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Conventional Static Stretching 15-30 seconds hold 3-5 repetitions (Page P, 2012) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles.
1477857|NCT03136250|Other|Group B (Autogenic Inhibition - PIR + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Post Isometric Relaxation MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid, Levator Scapulae and Upper Trapezius Muscles. (Chaitow L, 2006)
1477858|NCT03136250|Other|Group C (Reciprocal Inhibition - RI + Standard treatment)|o Conventional Gold Standard treatment (Manual Therapy + Modalities) Reciprocal Inhibition MET (3-5 reps) for Ant/Middle/Posterior Scaleni, Sternocleidomastoid,Levator Scapulae and Upper Trapezius Muscles (Chaitow L, 2006)
1477865|NCT03136224|Device|Thermocautery|
1477866|NCT03136224|Device|Plastic Clamping|
1477867|NCT03136224|Device|Surgical Circumcision|
1477868|NCT03136211|Behavioral|EIRA intervention|Individual intervention has an average intensity between 2 and 3 visits; if necessary, professionals have the freedom to make a greater number of visits. Group intervention is carried out through health education workshops. These workshops take place 15-20 days after initiating the individual intervention and they are conducted by primary care providers in the health center. A group of 12-15 people attend in each workshop. Community intervention focuses mainly on the social prescription of resources and activities that are carried out in the community where the participant person resides. In addition the intervention has the support of information and communication technologies, such as a web addressed to the participant, a mobile app or the sending personalized text messages.
1477869|NCT03136198|Other|LUS-guided strategy-of-care|"For patients randomized to the strategy-of-care arm, the LUS guided protocol will be initiated and continued until there is a decrease in B-lines to ≤ 15 or 6 hours of care has been delivered, whichever comes first.
Treatment protocol:
IV furosemide (unless already given): 2x single oral dose if on chronic therapy or 20-40 mg if diuretic naive.
Optional therapies: non-invasive ventilation, vasodilators (SL, topical, or IV)
Reassessment every 2 hours"
1477870|NCT03136198|Other|Usual Care|Patients will receive usual AHF care
1477871|NCT03136198|Drug|Intravenous Loop Diuretic|IV loop diuretic
1477872|NCT03136198|Drug|Vasodilator|IV, topical, or SL Vasodilator
1477873|NCT03136198|Device|Non invasive Ventilation (NIV)|Face, mouth, or nasal mask applied to provide positive pressure ventilation
1477874|NCT03136185|Drug|IMG-7289|Differentiation therapy
1477875|NCT03136172|Device|NIRS (near Infra-red spectroscopy)|"NIRS, INVOS 5100 cerebral/somatic oximeter monitor (Somanetics Corp, Troy, Michigan, USA)
Radical-7 pulse oximeter (Masimo Corp, Irvine, CA, USA)
Echocardiography (Phillips HD 15 Ultrasound system, CA, USA)"
1477876|NCT03136159|Device|Silver-impregnated antimicrobial dressing|All participants will receive an adherent soft silicone silver impregnated anti-microbial occlusive foam dressing after cesarean section. The dressing will stay on for up to seven days.
1477877|NCT03136146|Drug|Clofarabine|"Induction/Reinduction Phase Cycles 1-2: 30 mg/m2 by vein over 1-2 hours daily Days 1 - 5.
Consolidation Phase: 30 mg/m2 by vein over 1-2 hours daily Days 1 - 4.
Starting Dose Confirmatory/Expansion Phases: 30 mg/m2 by vein over 1-2 hours daily Days 1 - 4."
1477878|NCT03136146|Drug|Etoposide|"Induction/Reinduction Phase Cycles 1-2: 100 mg/m2 by vein 2 hours daily Days 1 - 5 (following Clofarabine infusion).
Consolidation Phase: 100 mg/m2 by vein over 2 hours daily days 1 - 4 (following Clofarabine infusion).
Starting Dose Confirmatory/Expansion Phases: 100 mg/m2 by vein over 2 hours daily days 1 - 4 (following Clofarabine infusion)."
1477879|NCT03136146|Drug|Cyclophosphamide|"Induction/Reinduction Phase Cycles 1-2: 440 mg/m2 by vein over 1 hour daily Days 1 - 5 (approximately 4 hours +/- 2 hours after the clofarabine).
Consolidation Phase: 440 mg/m2 by vein over 1 hour daily days 1 - 4 (approximately 4 hours +/- 2 hours after the clofarabine).
Starting Dose Confirmatory/Expansion Phases: 440 mg/m2 by vein over 1 hour daily days 1 - 4 (approximately 4 hours +/- 2 hours after the clofarabine)."
1477880|NCT03136146|Drug|Liposomal Vincristine|"Induction/Reinduction Phase Cycles 1-2: 2.0 mg/m2 (capped at 4 mg) over 1 hour on Days 2 & 11 (no dose administered less than 7 days apart).
Consolidation Phase: 2.0 mg/m2 (capped at 4 mg) over 1 hour on days 2 & 11 (no dose administered less than 7 days apart)
Starting Dose Confirmatory/Expansion Phases: 2.0 mg/m2 over 1 hour on days 2 & 11 (no dose administered less than 7 days apart)."
1477881|NCT03136146|Drug|Bortezomib|"Induction/Reinduction Phase Cycles 1-2: 1.3 mg/m2 subcutaneously Days 1, 4, 8 & 11 (no dose administered less than approximately 72 hours apart).
Consolidation Phase: 1.3 mg/m2 subcutaneously Days 1, 4, 8 & 11 (no dose administered less than approximately 72 hours apart).
Starting Dose Confirmatory/Expansion Phases: 1.3 mg/m2 subcutaneously Days 1, 4, 8 & 11 (no dose administered less than approximately 72 hours apart)."
1477882|NCT03136146|Drug|Ofatumumab|"If CD20 expression at least 10% or any CD20 positivity by immunostain for LL
Prescribed at discretion of treating physician
Induction/Reinduction Phase Cycles 1-2: 300 mg by vein Day 2 of cycle 1, then 2 gm by vein Day 11 of cycle 1. For cycles 2 - 4, 2 gm by vein Days 2 & 11.
Consolidation Phase: 300 mg by vein Day 2 of cycle 1, then 2 gm by vein Day 11 of cycle 1. For cycles 2 - 4, 2 gm by vein Days 2 & 11.
Starting Dose Confirmatory/Expansion Phases: 300 mg by vein Day 2 of cycle 1, then 2 gm by vein Day 11 of cycle 1. For cycles 2 - 4, 2 gm by vein Days 2 & 11."
1477883|NCT03136146|Drug|Rituximab|"If CD20 expression at least 10% or any CD20 positivity by immunostain for LL
Prescribed at discretion of treating physician
Induction/Reinduction Phase Cycles 1-2: 375 mg/m2 by vein on Days 2 & 11 of cycles 1 - 4.
Consolidation Phase: 375 mg/m2 by vein on Days 2 & 11 of cycles 1 - 4.
Starting Dose Confirmatory/Expansion Phases: 375 mg/m2 by vein on Days 2 & 11 of cycles 1 - 4."
1477884|NCT03136146|Drug|Pegfilgrastim|"Induction/Reinduction Phase Cycles 1-2: 6 mg subcutaneously Day 6 (may delay up to 72 hours after completion of the chemotherapy).
Consolidation Phase: 6 mg subcutaneously Day 6 (may delay up to 72 hours after completion of the chemotherapy).
Starting Dose Confirmatory/Expansion Phases: 6 mg subcutaneously Day 6 (may delay up to 72 hours after completion of the chemotherapy)."
1477885|NCT03136146|Drug|Dexamethasone|"Induction/Reinduction Phase Cycles 1-2: 20 mg by mouth or vein on Days 1 - 5.
Consolidation Phase: 20 mg by mouth or vein on Days 1 - 5.
Confirmatory/Expansion Phases: 20 mg by mouth or vein on Days 1 - 5."
1477886|NCT03136133|Dietary Supplement|Active protein drink|Fish protein from cod to be used for man after Heavy excercise to restitute
1477889|NCT03136107|Other|Physiogel Daily Defence Protective Day Cream Light|Investigator controlled, topical application to the epidermis at a dose of 2 milligrams per square centimeter (mg/cm2). Single application.
1477890|NCT03136107|Other|ISO 24444:2010 P3 Standard Sunscreen|Investigator controlled, topical application to the epidermis at a dose of 2 mg/cm2. Single application.
1477891|NCT03136094|Behavioral|SBIRT Usual Care|Participants in this arm will receive the usual standard of care: Screening, Brief Intervention, and Referral to Treatment (SBIRT)
1477892|NCT03136094|Behavioral|SBIRT+6|In addition to SBIRT, participants in this experimental arm will receive text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native youth and young adults for 6-months following identification of suicide risk.
1477893|NCT03136094|Behavioral|SBIRT+12|In addition to SBIRT, participants in this experimental arm will receive text messages adapted from empirically-based, effective interventions for suicide prevention among American Indian and Alaska Native youth and young adults for 12-months following identification of suicide risk.
1477894|NCT03136081|Diagnostic Test|Candidiasis infection occurence|Candidiasis infection occurence
1477895|NCT03136068|Drug|Digoxin|Trans-abdominal injection
1477896|NCT03136068|Drug|Placebo|Trans-abdominal injection
1477897|NCT03136055|Drug|Pembrolizumab|200 mg every 3 weeks via IV infusion.
1477898|NCT03136055|Drug|Irinotecan|"For patients in part B receiving pembrolizumab and chemotherapy with irinotecan. The starting dose for the safety lead-in is 125 mg/m2 irinotecan via IV infusion in a 2 weeks on, 1 week off format over 3 week cycles.
If the initial dose is not tolerated, the dose level will be decreased to 100 mg/m2."
1477899|NCT03136055|Drug|Paclitaxel|For patients in part B receiving pembrolizumab and chemotherapy with paclitaxel. Patients will receive 80 mg/m2 of paclitaxel via IV infusion every week, with treatment breaks as needed.
1477900|NCT03136042|Other|physiotherapy techniques|oscillating positive expiratory pressure during nonstop 5 minutes. After that more five minutes to a forced expiratory technique
1477901|NCT03136042|Other|hypertonic saline 3%|four nebulizations with 3% hypertonic saline, the aerosol was generated by an ultrasonic nebulizer
1477902|NCT03136042|Other|saline + physiotherapy maneuvers|sputum induction by hypertonic saline at 3% for seven minutes. And more five minutes under physiotherapists maneuvers
1997867|NCT01857414|Procedure|Remote Ischaemic Conditioning|The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflate to 200 mmHg for 5 minutes followed by 5 minutes of deflations. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes).In recruiting centres where randomisation occurs at the hospital or in cases with short transportation time, the RIC protocol will continue during PCI until successful or until immediately before reperfusion.
1477906|NCT03136016|Behavioral|educational activities|Group 2 will receive classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans
1477907|NCT03136016|Behavioral|nudging|In group 3, changes in the environment will be included that will facilitate both physical activity and healthy food choices
1477908|NCT03136016|Behavioral|nudging + educational activities|Group 4 will receive both interventions
1477909|NCT03136003|Drug|DDAVP intervention|For the DDAVP intervention the participant will take either 1 or 2 nasal sprays of IN DDAVP (known as Octostim® in Canada). After receiving IN DDAVP, the participant will rest for 30 minutes.
1477910|NCT03136003|Behavioral|Exercise Intervention|For the exercise intervention the participant will exercise on a stationary cycle-ergometer using the previously-validated, progressively-incremental Godfrey protocol. Per the Godfrey protocol, the participant starts cycling on the calibrated cycle-ergometer with an initial exercise load that is dependent on their height. The workload is increased every minute in standard increments also based on the participant's height. All participants will exercise till they complete 3-minutes of cycling at 85% of their maximum predicted heart rate or till exhaustion (whichever comes first). Upon completion of planned exercise, work load will be decreased to zero watts and participants will be instructed to continue cycling at this cool-down rate for additional 3-minutes, before getting of the ergometer.
1477911|NCT03135990|Behavioral|Cognitive Behavioral Therapy with Virtual Reality Technology|Cognitive Behavioral Therapy Intervention: This manualized intervention is a modified version of the Unified Protocol for Emotional Disorders in Youth, a modular Cognitive Behavioral Therapy protocol for anxiety disorders and depression with demonstrated efficacy in youth. The 10-session intervention includes psychoeducation about anxiety disorders and their treatment (1 session), emotion awareness and regulation (2 sessions), exposure therapy using virtual reality environments (6 sessions), and review and relapse prevention (1 session). All treatment sessions will be videotaped to ensure fidelity to treatment manual and modules.
1477912|NCT03135977|Drug|Apatinib, Etoposide|Patients receive etoposide 50mg from day 1 to day 14 and apatinib 250mg/d from day 1 to day 21, repeated every 21 days until progressive Disease(PD) .
1477913|NCT03135964|Device|filler dressing of NPWT|a dressing or filler material is used to fit to the contours of a wound (which is covered with a non-adherent dressing film) .
1477914|NCT03135951|Drug|SPI-2012|Supplied in prefilled, single-use syringes for subcutaneous injection and administered on Day 2 of each cycle.
1477915|NCT03135938|Procedure|Grading Inferior Oblique Anterior Transposition surgery|in the grading group, IO muscle of the eye with more severe DVD will be sutured at the level of IR insertion and IO muscle of the eye with lower magnitude of DVD will be sutured 2mm posterior to the sclera to consider the preoperative DVD difference between the two eyes.
1477916|NCT03135938|Procedure|Classic Inferior Oblique Anterior Transposition surgery|in the classic group, IO muscle will be sutured to the sclera at the level of inferior rectus (IR) insertion at its temporal border, without considering the asymmetric DVD between the two eyes
1477917|NCT03135925|Other|Supervised Exercise Program|Participants will be invited to attend a weekly supervised exercise program over six weeks, in the time before their bone marrow transplantation
1477918|NCT03135912|Drug|Experimental Drug SESC 01|Topical experimental treatment comprising a combination of approved topical therapies and a new dosage method.
1477919|NCT03135912|Drug|Placebo|Dosage method of SESC 01, without active ingredients.
1477920|NCT03135912|Drug|Terbinafine Hydrochloride|Topical terbinafine hydrochloride cream.
1477923|NCT03135886|Other|Information Control|The OTPs assigned to this group will be provided access to the NIDA/SAMHSA Blending Initiative product for HIV rapid testing. Resources generated from the HIV rapid testing Blending Initiative product include a fact sheet, resource guide, marketing materials, and an Excel-based budgeting tool. In addition to the HIV-specific materials, the website provides opportunities for training, self-study progress, workshop, and distance learning. OTPs also will receive a link to the Anti-Retroviral Treatment and Access to Services (ARTAS) intervention training website which provides information and training courses. Sites also will receive a hard copy of the ARTAS implementation manual and information about the provision of HIV testing, linkage to care and PrEP.
1477924|NCT03135886|Other|HIV and HCV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the program team a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV and HCV testing and evidence--based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV and HCV testing. Also, due to the expense of HCV treatment, and potentially more complicated mechanisms for linking HCV-positive patients to further evaluation and care which may take more time than anticipated, PCs will provide OTPs with basic education and motivation about the importance of HCV testing for reasons other than immediate curative treatment. Information on PrEP also will be provided. The intervention will occur over approximately 26 weeks.
1477925|NCT03135886|Other|HIV Testing Practice Coaching Intervention|The practice coaches (PCs) will work with the programs a) to establish capabilities, reimbursement systems and/or partnerships necessary to support HIV testing and evidence-based linkage to care and b) to reduce barriers (e.g., staffing, training) to the implementation and sustained provision of HIV testing. Information on Pre-Exposure Prophylaxis (PrEP) also will be provided. The intervention will occur over approximately 26 weeks consisting of four distinct evidence-based phases designed to establish competency in the implementation of organizational change towards establishing HIV testing outcomes among OTP clientele.
1477928|NCT03135860|Drug|Inhaled Nitric Oxide 30mcg/kg IBW/hr|Inhaled Nitric Oxide 30 mcg/kg IBW/hr will be administered through the INOPulse Device open label for 4 weeks
1477929|NCT03135847|Device|Tactor|The tactor is a small robot providing touch and vibration.
1995160|NCT02836496|Drug|Placebo matching OCS capsules|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed.A subject who does not reach the pre-specified blood eosinophil threshold with a similar blood draw date will be selected to initiate a placebo OCS treatment in a blinded manner, unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
1997876|NCT01852045|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1.
1477934|NCT03135821|Diagnostic Test|TCM|
1477935|NCT03135795|Drug|Sufentanil|Patients received intravenous sufentanil 0.5μg/kg for induction,and received PCA after surgery with sufentanil 1ug/ml using a controlled infusion pump, which was programmed to use a loading dose of 2ml, background infusion at 2m/h, PCA dose of 1ml, lockout time of 10min, and maximal dose of 12ml within 1 hour period.
1477936|NCT03135795|Drug|dexmedetomidine|Patients received intravenous dexmedetomidine 1μg/Kg for induction.
1477937|NCT03135795|Drug|propofol|Patients received intravenous propofol 2mg/Kg for induction, and received intavenous pump of propofol (0.3-0.6mg/kg/h) for maintenance.
1477938|NCT03135795|Drug|Rocuronium|Patients received intravenous rocuronium 0.6mg/Kg for induction.
1477939|NCT03135795|Drug|sevoflurane|Patients received inhalation of sevoflurane (1-2%) for maintenance.
1477940|NCT03135795|Drug|remifentanil|Patients received intavenous pump of remifentanil (0.1-0.2ug/kg/min) for maintenance.
1477941|NCT03135795|Drug|Parecoxib|Parecoxib 40mg was given single intravenously before incision.
1477946|NCT03135769|Drug|Avelumab administration at 10mg/kg|Avelumab administration at 10 mg/kg as a 1 hour IV infusion once every 14 days during 6 months (maximum).
1477947|NCT03135743|Other|Show an increase in incidence of cancers in patients with synchronous lymphoma|Show an increase in incidence of cancers in patients with synchronous lymphoma
1477948|NCT03135730|Genetic|ROHHAD|Suspected and Confirmed ROHHAD cases
1477949|NCT03135717|Dietary Supplement|Nutritional care|"Diagnosis of protein energy wasting : anthropometry, calculation of the nutrient intakes, evaluation of appetite, evaluation of gastrointestinal syndromes, hand grip test and bioimpedancemetry
Treatment of protein energy wasting : estimation of nutritional requirements, prescription of oral nutritional supplement or artificial nutrition, physical rehabilitation
Multidisciplinary approach (nephrologists, dieticians, physiotherapists, nurses)
Evaluation of the nutritional treatment (plasma albumin and prealbumin, weight evolution, muscle strength and body composition)"
1477950|NCT03135704|Device|"Re Spine"|A new mattress design made of special materials and built in a specially shaped structure that allows the brain to relax the body and dissipate tension accumulated on the lumbar spine.
1477951|NCT03135704|Other|Physiotherapy|Usual protocol for treatment of low back pain
1477952|NCT03135665|Device|Ultrasound|"Scolioscan, the ultrasound system reported to be reliable and valid for spinal deformity assessment, will be used. The system composes of an ultrasound scanner with a linear probe of 100 mm in width and frequency range of 4-10MHz, a frame structure and a spatial sensor which is attached to the ultrasound probe for spatial data capture. Daily calibration will be performed using a phantom to assure accuracy of spine image formation and subsequent angle measurement.
Subjects will stand on the Scolioscan platform with a standardized posture kept stable with pegs throughout the scanning process.. After adjusting the ultrasound scanner setting, the probe will be steered from L5 to T1 spinous process for scanning.
SPA will be used to determine the ultrasound-based Referral Status through predicting whether the Cobb angle is beyond the referral threshold of ≥20° or not. There are two values for the Referral Status: either for specialist referral or not for specialist referral."
1477953|NCT03135652|Radiation|adjuvant SBRT|adjuvant SBRT of liver lesions
1477954|NCT03135652|Drug|Chemotherapy|mFolfox6/ CAPEOX/ Folfiri±cetuximab or bevacizumab, 2 months for neoadjuvant treatment and 4 months for adjuvant treatment
1477955|NCT03135639|Device|NeuroConn Plus Stimulator tACS|Transcranial alternating current stimulation (tACS) is a novel, noninvasive brain stimulation approach in which weak electric currents are applied to the scalp. The electric currents that are applied to the scalp are in a sine-wave pattern.
1477956|NCT03135639|Device|NeuroConn Plus Stimulator Sham|For sham stimulation, the participant receives up to 1 minute of tACS stimulation until the stimulation fades. This mimics the same skin sensations that a participant would experience during a tACS session.
1477957|NCT03135626|Drug|Biodentine|
1477958|NCT03135626|Drug|ProRoot (Aggregate)|
1477959|NCT03135626|Drug|MTA Plus|
1477960|NCT03135626|Drug|Ferric Sulfate 20 % Dental Gel|
1477961|NCT03135613|Procedure|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot at self-selected gait speed.
1477962|NCT03135600|Procedure|Procedure|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk/run on the treadmill in barefoot at 4/6km/h.
1477963|NCT03135587|Procedure|Loading level|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The gait analysis system will collect the data while they walk on the treadmill in barefoot with selected weight loading suit at 3.0km/h.
1477964|NCT03135574|Diagnostic Test|MRI T2 sequence of the oculomotor tract|Patients with ophthalmoplegia will benefit from an MRI T2 sequence of the oculomotor tract (additional time of 4 minutes).
1477965|NCT03135561|Behavioral|pedometer-plus-email|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. During the intervention period, patients will receive 8 counselling emails based on behavioural techniques.
1477966|NCT03135561|Behavioral|pedometer-only|After randomisation, participants will receive a pedometer and will be instructed to wear the pedometer daily for the next four months, check the step count every evening and gradually increase their daily number of steps to at least 10,000. They will also be required to upload data to a website at least once a week. There will be no further interaction during the intervention period unless they fail to upload data, in which case they will be offered technical support.
1477970|NCT03135535|Device|Avex Footbeat|Subjects will receive diabetic shoes equipped with Boa Technology shoelace system and Footbeat compression insoles, which for simplicity will be named intervention shoes. All participants will be asked to wear the intervention shoes for duration of 4-weeks on daily basis (minimum 4 hours per day). Daily use of the intervention shoes will be assumed to improve balance, mobility, plantar sensation, lower extremity edema, and lower extremity skin perfusion.
1477971|NCT03135522|Drug|Zinc Acetate 50Mg Oral Capsule|"Day 0 (randomization) to day 3 Zinc acetate 50 mg per day (one capsule)
Day 4 to day 7 If well tolerated: Zinc acetate 100 mg per day (two capsules)
Day 8 to V5 (6 weeks) If well tolerated: Zinc acetate 150 mg per day (three capsules)"
1477972|NCT03135522|Drug|Placebo oral capsule|"Day 0 (randomization) to day 3 Placebo (one capsule per day)
Day 4 to day 7 If well tolerated: placebo (two capsules per day)
Day 8 to V5 (6 weeks) If well tolerated: placebo (three capsules per day)"
1477973|NCT03135509|Drug|CC-220|CC-220 gelatin capsules
1477974|NCT03135496|Other|Study of endothelial function biological markers|Study of endothelial function biological markers
1477975|NCT03135457|Procedure|Autologous RBC transfusion|Autologous RBC transfusion 300ml 10 ml/min
1477976|NCT03135457|Procedure|Saline transfusion|Saline transfusion 300ml 10ml/min
1477977|NCT03135444|Behavioral|PSA TOOL|Providers will be given the initial PSA TOOL and will be asked to give their feedback to revise the tool.
1477978|NCT03135444|Behavioral|Revised PSA TOOL|Patients will be given the revised PSA TOOL, after providers have given their initial feedback.
1477979|NCT03135444|Behavioral|Informal Interview|Both patients and providers will have informal interviews with the study team to get feedback on the survey taking process.
1477980|NCT03135431|Procedure|Bilateral Salpingectomy|Surgical removal of entire fallopian tubes
1477981|NCT03135431|Procedure|Bilateral Tubal Ligation|Surgical tying, cutting, or removal of a portion of the fallopian tubes
1948725|NCT01827826|Behavioral|Telephonic intervention to prevent Diabetes Mellitus, Type 2|Participants assigned to the intervention group received a total of 16 phone calls from the study interventionist over 24 weeks. The first 12 weeks was the intervention phase and calls were made weekly. The second 12 weeks was the maintenance phase and calls were made every 3 weeks. After 24 weeks, the investigators continued to follow this group for 52 weeks post-randomization, allowing half of the group to continue to receive monthly maintenance calls while the other half received no further calls. The study interventionist used behavior modification techniques to encourage intervention group participants to adopt healthy eating and exercise habits so that improvement might be seen in fasting glucose, glycated hemoglobin (HbA1c), weight, and waist/hip measurements.
1948726|NCT01821573|Drug|botulinum toxin type A|"Experimental arm group:
150 Units in rectus femoris ( 3 ml and 3 points)
70 units in medial gastrocnemius (1.4 ml and 1 point)
70 units in lateral gastrocnemius ( 1.4 ml and 1 point)
60 units in soleus ( 1.2 ml and 3 points)"
1477984|NCT03135405|Behavioral|Automated messages|Automated motivational messages and visit and medication reminders will be provided via interactive voice response calls or text messages.
1477985|NCT03135405|Behavioral|Home BP monitors|Participants will have the option of receiving home blood pressure monitors.
1477986|NCT03135405|Behavioral|Care partner reminders|Participants will have the option of designating a care partner who will also receive automated reminder calls or text messages.
1477987|NCT03135392|Procedure|Breast Reconstruction with Artificial Implant|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with artificial implants
1477988|NCT03135392|Procedure|Autologous Breast Reconstruction|Patients undergo unilateral or bilateral reconstruction of breasts after nipple sparing mastectomy. Breasts are reconstructed with the patient's own tissue
1477989|NCT03135392|Procedure|Neurotization|Nerve will be reconstructed during autologous breast tissue reconstruction
1948727|NCT01821573|Drug|injection of NaCl 0.9%|"Placebo comparator group: injection of NaCl 0.9%:
3 ml of NaCl 0.9% in rectus femoris in 3 points
1.4 ml of NaCl 0.9% in medial gastrocnemius in 1 point
1.4 ml of Nacl 0.9% in lateral gastrocnemius in 1 point
1.2 ml of NaCl 0.9% in soleus in 3 points"
1948728|NCT01807871|Drug|nicotine patch, experimental use|nicotine patch-transdermal, continue during lapses Nicotine patches are used according to normal package label, except if the participant lapses and smokes, they will continue to use the patch.
1477992|NCT03135366|Behavioral|Keheala|
1477993|NCT03135366|Other|Standard of Care|Patients receive medication for a week or two weeks at a time. They are assigned a friend or family member 'supporter' to verify the patient's at-home treatment and instructed to return to the clinic with the patient during medication refills.
1477994|NCT03135353|Device|3D saline infusion sonohysterography|instillation of saline in the uterine cavity using pediatric foley's catheter, then performing 3D ultrasound scan of the uterus and adenexae
1477995|NCT03135353|Device|Office Hysteroscopy|an outpatient procedure done to assess the uterine cavity using the office hysteroscopy
1477996|NCT03135340|Procedure|WALANT|These patients will receive local anesthetic for flexor tendon repair injected directly into the operative site on the hand. The local anesthetic used 1% lidocaine with 1:100,000 epinephrine.
1477997|NCT03135340|Procedure|General/regional anesthesia|These patients will receive general/regional anesthesia for flexor tendon repair. This is ropivacaine 0.5% injected by an anesthetist under image-guidance in the axillary region of the arm. If the regional anesthesia is not functioning at the time of OR, this is converted to a general anesthetic as per standard protocol.
1477998|NCT03135340|Drug|WALANT Injection|1% lidocaine with 1:100,000 epinephrine injected directly into operative site. The typical quantity is 5-10cc aliquots.
1477999|NCT03135340|Drug|Regional Anesthetic Injection|0.5% ropivacaine injected under ultrasound guidance into the axilla. The typical quantity is 30-40cc aliquots.
1478000|NCT03135327|Other|No intervention|No intervention
1478001|NCT03135314|Dietary Supplement|cocoa flavanol|7 days intake of cocoa flavanol supplement (naturex)
1478002|NCT03135314|Dietary Supplement|placebo|7 days of placebo intake
1478003|NCT03135301|Drug|letrozole plus metformin|letrozole 5 milligram tablets plus metformin 850 milligram tablets
1478004|NCT03135301|Drug|letrozole|letrozole 5 milligram tablets
1478005|NCT03135288|Device|Cell-phone|a reminder of their postpartum family planning visit 5 weeks after the delivery (one week before the scheduled visit) and a phone call 48 hours before the scheduled visit. They will also receive two follow-up phone calls to answer any questions and to remind them with the follow-up visits after insertion. Woman will be given a referral card to the outpatients' family planning clinic denoting her study group and serial number and with a specific date for postpartum family planning visits.
1478006|NCT03135275|Procedure|Staged complete PCI|During the index procedure patients will have treated with primary PCI the culprit lesion only. Patients will be hospitalized again after 19-45 days to undergo PCI of ther other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent implantation.
1478007|NCT03135275|Procedure|Immediate complete PCI|During the index procedure patients will have treated with primary PCI the culprit lesion, as well as all the other significant coronary lesions. All the revascularizations will be performed with Synergy™ stent.
1478008|NCT03135275|Device|Synergy™ stent|Bioabsorbable Polymer Drug-Eluting Stent
1948729|NCT01807871|Drug|nicotine patch, labeled use|nicotine patch-transdermal, discontinue during lapses Participants will use the nicotine patch while abstinent, but will remove the patch if there is a lapse and smoking resumes. This is the use indicated on current FDA approved labeling.
1478014|NCT03135236|Behavioral|Parent training|Participants will attend 3 trainings. There will be a pre-test before training 1 and an initial post-test after training 3. There will be a final post-test 1 month after the final training.
1478015|NCT03135223|Behavioral|Co-created intervention to promote physical activity|A working group of girls and researcher co-created a school-specific intervention to promote physical activity
1478018|NCT03135184|Device|HDL Therapeutics PDS-2 System|Delipidation of plasma HDL to reduce coronary atheroma
1478019|NCT03135171|Drug|Trastuzumab|All dose levels will receive 8 mg/kg loading dose for cycle 1, followed by 6 mg/kg in subsequent cycles, every 3 weeks.
1478020|NCT03135171|Drug|Pertuzumab|Dose Levels two and three will receive 840 mg loading dose for cycle 1, followed by 420 mg in subsequent cycles, every 3 weeks.
1478021|NCT03135171|Drug|Tocilizumab|Tocilizumab 4-8 mg/kg, administered intravenously every three weeks
1478022|NCT03135158|Other|Exposure to vaginal delivery|Women who have vaginal births are observed for a minimum of 1 hour postpartum
1478023|NCT03135145|Device|Lite Run Gait Trainer|"Lite Run is a new system for the treatment of patients with gait and balance difficulties that uses differential air pressure inside a lower body suit to reduce up to 50 percent of a patient's body weight. The suit is similar to a pair of pants in appearance and is as easy to don and doff as a pair of pants. The suit uses technology like astronaut spacesuits to achieve comfort and flexibility while providing a unique unweighting effect that facilitates patient ambulation from sitting through taking steps. The suit is used in conjunction with the Lite Run Gait Trainer, which provides air pressure to the suit and support for the patient."
1478024|NCT03135145|Other|Usual Treatments|The usual clinical treatments (standard of care treatments) will be used to assist patients in weightbearing and walking.
1478025|NCT03135132|Behavioral|Control group|Recommend to consume usual diet during 12-week study period
1478026|NCT03135132|Behavioral|LCD group|Recommended to reduce calorie intake (a 300 kcal/day); educated to take out 1/3 of a bowl of rice from per meal a day for an easier application of 100kcal deficits, thereby reducing a 300kcal/3 meal/day
1478027|NCT03135119|Behavioral|TF-CBT|TF-CBT is typically described as including 3 phases, each focusing on a common goal and encompassing a third of treatment (4 sessions). The first phase focuses on skills-building and includes psychoeducation, parenting skills training, relaxation skills training, affect modulation skills training, and cognitive coping skills training. The second phase involves focused gradual exposure activities, including construction of a narrative account of the child's maltreatment experiences and cognitive processing of maladaptive thoughts. The third phase emphasizes the child's mastery over environmental reminders of the maltreatment and includes sharing the trauma narrative with the caregiver, in vivo exposure to physical stimuli, and enhancing future development.
1478028|NCT03135119|Behavioral|TF-CBT+AAT|TF-CBT, as described in the other arm, with animal-assisted therapy as an adjunct intervention. During the administration of TF-CBT, a certified service dog will be in the room and the participant may elect to interact with the dog as various points throughout the sessions.
1478029|NCT03135106|Drug|Erdafitinib|A single 4-mg of erdafitinib tablet will be administered on Day 1 in Treatment A and on Day 5 in Treatment B and C.
1478030|NCT03135106|Drug|Fluconazole|A 400-mg fluconazole orally (4*100 mg capsules) will be administered from Day 1 to Day 11.
1478031|NCT03135106|Drug|Itraconazole|A 200-mg itraconazole orally (2*100 mg capsules) will be administered from Day 1 to Day 11.
1478032|NCT03135093|Other|No intervention|No Intervention
1478033|NCT03135080|Other|Long-Term HEAD START Training|The Human Eyelid Analogue Device for Surgical Training And skill Reinforcement in Trachoma (HEAD START) is a surgical simulation device used to bridge the gap between classroom and live-surgery training specifically for trichiasis surgery. Long-term HEAD START practice will involve the following components, after completion of standard training (as described in the standard of care arm). Each week the participant will complete 2 surgeries on the HEAD START device. Monthly, the participant will send the accumulated cartridges to Addis Ababa for review by a senior trichiasis surgery trainer. The trainer will evaluate the cartridges and then will discuss his impression of the surgeries with the participant during a regular monthly call and note the findings. Practice will continue for 4-6 months, depending on the length of the rainy season and time of enrollment. At the end of the rainy season, an external examiner will evaluate the first 2 surgeries that the participant completes.
1478034|NCT03135080|Other|Standard of Care|All participants will receive trichiasis surgery training following Orbis' standard training approach, with the inclusion of HEAD START training between classroom and live surgery training. At the end of the surgical training session, an independent examiner will evaluate all trainees using the World Health Organization's Final Assessment of Surgeons form, as part of standard practice. The examiner also will complete a standard questionnaire focusing on the specific skill level achieved for each of the critical aspects of TT surgery. This form will be completed for all trainees undergoing training this spring, regardless of whether they are part of the long-term HEAD START assessment program.
1478035|NCT03135067|Behavioral|Provision of multiple self-tests|Participants will be given multiple Oraquick Advance HIV-1/2 test kits for testing themselves more frequently and for offering to selected sexual partners. The self-test kits will be given to participants on a monthly basis as needed. The intervention is designed to facilitate partner and couples testing, with resulting reduction in risky sexual behavior and HIV incidence among participants.
1948736|NCT01801917|Drug|Placebo|
1948737|NCT01801917|Drug|BAF312|
1997878|NCT01852305|Other|Lab Sleep Study Group|Patients in this group will under go lab sleep study overnight at the sleep clinic.If the patient has severe sleep apnea (AHI>30) or moderate sleep apnea (AHI>15 to <30) with significant co-morbidities (e.g. cardiovascular disease, diabetes), CPAP treatment will be recommended. For mild sleep apnea (AHI>5 to <15) or moderate sleep apnea without significant co-morbidities, CPAP will not be required. If patient is not able to tolerate or refuses CPAP, dental device and positional therapy will be recommended.
1997879|NCT01852305|Device|Oximetry|The patients in the Oximetry group will undergo overnight pulse oximetry. The patients with ODI>10 events/hour will be referred to the sleep medicine specialist.A split- night PSG will be employed to confirm OSA diagnosis. The 1st part of the night will be a sleep study and depending on AHI, CPAP titration will be done for the 2nd part of the night
1478037|NCT03135054|Drug|Omacetaxine Mepesuccinate Injection|Omacetaxine Mepesuccinate is a pharmaceutical drug substance that is indicated for treatment of chronic myeloid leukemia (CML)
1478043|NCT03135015|Other|Placebo capsules|16 x 250mg placebo capsules with 250ml water
1478044|NCT03135015|Other|2g Axulin capsules|8 x Axulin capsules plus 8 x 250mg placebo capsules with 250ml water
1478045|NCT03135015|Other|4g Axulin capsules|16 x Axulin capsules with 250ml water
1478046|NCT03135015|Other|0g Axulin tablets|250ml water
1478047|NCT03135015|Other|2g Axulin tablets|2 x 1g Axulin tablets with 250ml water
1478048|NCT03135015|Other|4g Axulin tablets|4 x 1g Axulin tablets with 250ml water
1478049|NCT03135002|Other|Other|
1478050|NCT03133897|Drug|Dexamethasone|experimental group will receive 2 day treatment
1478051|NCT03133897|Drug|Prednisone|control group will receive 5 day treatment
1478052|NCT03133884|Other|acupuncture|The needles will be inserted into the acupoints and the depths will be adjusted to the standard permissible layers, then even reinforcing-reducing technique will be performed on the needles until achieving deqi sensation.The needles will be retained for 30 minutes in each session and manipulated twice every 10 minutes with intermittent stimulation. Each manipulation will last for 30 seconds.
1478053|NCT03133884|Other|superficial acupuncture|The selected acupoints will be punctured superficially by the depth of 1-3 mm, and the needles will be retained for 30 minutes without any manipulation.
1478054|NCT03133845|Procedure|Light sedation with propofol|Patients having lumbar spinal surgery and receiving spinal anesthesia will receive propofol for light sedation.
1478055|NCT03133845|Procedure|Induction with propofol|Patients having lumbar spinal surgery and receiving general anesthesia will receive propofol and their induction agent.
1478056|NCT03133845|Procedure|Maintenance anesthetic using a volatile anesthetic|Patients having lumbar spinal surgery and receiving general anesthesia will receive a volatile anesthetic for their maintenance anesthesia.
1478057|NCT03133845|Procedure|Muscle relaxant during maintenance anesthesia|Patients having lumbar spinal surgery and receiving general anesthesia with receive a muscle relaxant for muscle paralysis.
1478058|NCT03133845|Procedure|Pain control with fentanyl|Patients having lumbar spinal surgery and receiving general anesthesia will receive fentanyl for their pain during surgery.
1478059|NCT03133845|Procedure|Bispectral Index (BIS) monitoring for depth of anesthesia|All patients will be monitored with Bispectral Index (BIS) to monitor the patient's depth of anesthesia.
1478060|NCT03133845|Procedure|Spinal Anesthesia|Patients receiving spinal anesthesia will receive hyperbaric bupivacaine into the subarachnoid space.
1478061|NCT03133845|Procedure|Midazolam administered during spinal anesthesia|Midazolam may be administered during spinal needle insertion for patients receiving spinal anesthesia.
1478062|NCT03133845|Procedure|Cerebrospinal fluid collection|8 ml of cerebrospinal fluid will be collected prior to the administration of intrathecal administration of morphine for pain control.
1478063|NCT03133845|Procedure|Administration of intrathecal morphine|All patients will receive intrathecal morphine for post-operative pain control.
1478064|NCT03134976|Drug|Levothyroxine|Immediately post-operatively, all patients undergoing laryngectomy will be started on established weight-based dosing of levothyroxine administered intravenously due to the variable enteral absorption in post-operative patients including those on continuous tube feed regimens. Standard enteral dose is 1.6 mcg/kg/day. Eighty percent of this dose (1.3 mcg/kg/day) will be given IV to account for the increased bioavailability of IV levothyroxine compared to enteral levothyroxine. The maximum dose will be 200 mcg/day. Patients previously on levothyroxine at doses lower than the above dose will changed to the aforementioned standard dose. Patients on higher doses of levothyroxine pre-operatively will be maintained on on their current dosing.
1478065|NCT03134963|Other|Transcranial doppler ultrasonography|Measurement of cerebral blood flow whilst undertaking cognitive tasks with TCD monitoring.
1478066|NCT03134963|Other|Blood pressure monitoring|Continuous blood pressure recording
1478067|NCT03134963|Other|Heart rate monitoring|Continuous heart rate monitoring
1478068|NCT03134963|Other|End tidal CO2 monitoring|Continuous ETCO2 monitoring
1478069|NCT03134963|Other|Addenbrooke's cognitive examination|Performance of a memory test
1478070|NCT03134950|Behavioral|ADAPT|Aim to Decrease Anxiety and Pain Treatment is a tailored CBT ranging from 4 sessions (pain-focused) to 6 sessions (blend of pain and anxiety coping strategies depending on the needs of the individual patients. The first 2 sessions will be in person with a trained psychologist and the following 2-4 sessions will be web-based. Each web-based session will be followed by phone support.
1478071|NCT03134937|Device|High-Flow Heated and Humidified Oxygen Therapy (HFNO)|Participants will undergo two session of high-flow heated and humidified oxygen therapy (HFNO) (one at 30 litres/min and the other at 70 litres/min). They will undergo a gastric ultrasound scan after each session of HFNO therapy.
1478072|NCT03134924|Behavioral|Women's and Sexual Health [WASH]|The WASH was a group-based, 45-minute group session on vaginal health and healthy vaginal practices led by two trained facilitators. The sessions covered topics related to vaginal practices and the potential harm of vaginal practices.
1478073|NCT03134924|Behavioral|Enhanced Standard of Care|"The enhanced standard of care (SOC+) condition received a genital tract examination, collection of a vaginal swab with gram stain of vaginal secretions, diagnosis of BV, and medication as needed. At baseline participants received an individual education session on the risk of engaging in IVP and tips on discontinuing IVP."
1997882|NCT01850004|Drug|Dasatinib|
1478076|NCT03134872|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
1478077|NCT03134872|Drug|Carboplatin|Carboplatin
1478078|NCT03134872|Drug|Pemetrexed|Pemetrexed
1478079|NCT03134859|Behavioral|Tummy Time|deliberate, supervised play time with the baby on his or her front (tummy) when he or she is awake
1478080|NCT03134846|Drug|Cetuximab-IRDye800CW|Pre-operatively administration of Cetuximab-IRDye800CW for intra operative margin assessment using a fluorescent antibody-based optical tracer
1478081|NCT03134833|Behavioral|Automated Messaging & Monitoring|"Youth will receive messages 1-5 messages per day for 24 months. Message banks of about 750 text messages (70-120/domain) will focus on the HIV Prevention Continuum, with messages dedicated to healthcare, wellness, sexual health, drug use and medication reminders (e.g., for PrEP) for MSM and non-MSM. Youth will be able to choose the time that they receive daily texts. Text timing and the frequency of texts (e.g., if the youth comes out) will be updated at 4-month intervals.
Youth will complete weekly monitoring surveys by text message. The survey will cover seven domains related to the HIV Prevention Continuum. In case of non-response, reminder messages will be sent to the youth. After three days of non-response, a follow-telephone call will occur."
1478082|NCT03134833|Behavioral|Peer Support|"Youth will be enrolled in online, private discussion groups.
Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.
Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
1478083|NCT03134833|Behavioral|Coaching|Youth will have access to a dedicated Coach to assist with crisis support and problem-solving, linkage to HIV and related services (e.g., for substance use, mental health), and care coordination. Coaches will be accessible electronically (using social media, e-mail, text messaging) and by phone. In cases where virtual support has failed, Coaches will be available in-person (e.g., to accompany a participant to a doctor's appointment). We anticipate that Coaches will provide each youth with 10 hours of support, on average, per year.
1478084|NCT03134807|Other|Observation prospective|No intervention
1478085|NCT03134794|Behavioral|Educational intervention applying the traffic light system (TLS)|The TLS emerged to facilitate consumers' decisions. It has been applyied in medical decision making.
1478086|NCT03134781|Behavioral|FFIT workout|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training and performed according to a periodized model of exercise prescription as an alternative approach for weight management. FFIT was performed 3 times/week with 48 hours recovery between sessions for 40 weeks.
1478087|NCT03134781|Behavioral|FFIT workout - Detraining|A hybrid small-group (5-10 women/session) training modality, that combines interval training, resistance exercise and functional training, performed according to a periodized model of exercise prescription for a 20-week period (3 times/week). Immediately after a 20-week detraining period (no training was performed) was followed.
1478088|NCT03134781|Behavioral|Control - No training|No training was performed during a 40-week period. Participation only in measurements.
1478089|NCT03134768|Other|This is not an interventional study|This is an observational study
1478090|NCT03134755|Drug|Inhaled corticosteroid (mometasone)|The investigators are not measuring the effect of the intervention (ICS), but rather the effect of stress (which is not being intervened on), and this is thus an observational study. The ICS is given to children with asthma in whom an ICS is clinically indicated
1478091|NCT03134742|Other|Control Group|No interventions this is the control group-no additional scans
1478092|NCT03134742|Diagnostic Test|CT Scan|CT Scan of affected and contralateral limb
1478093|NCT03134742|Diagnostic Test|DEXA Scans|DEXA Scan of affected and contralateral limb
1478094|NCT03134742|Diagnostic Test|CT and DEXA Scans|CT Scan and DEXA Scan of affected and contralateral limb
1478095|NCT03134729|Drug|Ropivacaine for Serratus Plane Block (SPB)|Serratus Plane Block (SPB) injection of low concentration Ropivacaine (30 ml, 0.3%), in the plane between the External Intercostal Muscle and the Serratus Anterior Muscle.
1478096|NCT03134703|Drug|Methadone|Infants in the Methadone Treatment Group will receive the study drug, methadone, instead of morphine to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
1478097|NCT03134703|Drug|Morphine|Infants in the Comparison Group will receive standard of care narcotic (morphine) to treat withdrawal symptoms from Neonatal Abstinence Syndrome (NAS)
1478098|NCT03134690|Procedure|delayed start|In this protocol, ovarian stimulation will be started from ninth day of menstrual cycle .
1478099|NCT03134690|Procedure|Conventional|In this protocol, ovarian stimulation will be started from the 2th or 3th day of the menstrual cycle.
1478100|NCT03134677|Drug|Bupivacaine|2 ml of hyperbaric bupivacaine (0.5%) was given intrathecally to patients in a sitting position by midline attempt between the L3 and L4 intervertebral space.ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
1478101|NCT03134677|Drug|Sevoflurane|General anesthesia was maintained with 2-3% sevoflurane. ECG recordings were performed at preoperative, 5, 15, and 30 minutes after initial anesthesia and 30 minutes post-operatively.
1478102|NCT03134664|Procedure|Experimental group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the SuperPATH approach in the experimental group.
1478103|NCT03134664|Procedure|Control group|Patients with femoral neck fractures are randomly assigned to undergo femoral head replacement via the conventional posterior approach in the control group.
1478104|NCT03134651|Device|Monitoring brain function|
1478105|NCT03134651|Drug|propofol|
1478106|NCT03134638|Drug|SY-1365|SY-1365 will be administered by intravenous infusion over 1 hour twice a week for three weeks in each 28 day cycle
1478107|NCT03134612|Drug|Ondansetron 8 mg|
1478108|NCT03134612|Drug|Lidocain 40 mg|
1478112|NCT03134586|Other|Diagnostic imaging|
1997883|NCT01849783|Drug|dexamethasone|Given PO
1997884|NCT01849783|Drug|cisplatin|Given IV
1478117|NCT03134547|Drug|low dose sevoflurane group|low volume volatile anesthetics (1.0%)
1478118|NCT03134547|Drug|high dose sevoflurane group|high volume volatile anesthetics (2.5%)
1478119|NCT03134534|Procedure|VATS lobectomy|a minimal invasive surgical types for NSCLC: VATS lobectomy
1478120|NCT03134534|Procedure|RATS lobectomy|a minimal invasive surgical types for NSCLC: RATS lobectomy
1478121|NCT03134508|Other|treated by antiTNFα|pregnant IBD women treated by antiTNFα
1478122|NCT03134508|Other|not treated by antiTNFα|pregnant IBD women not treated by antiTNFα
1478123|NCT03134495|Other|all children with at least one prescription of PPI|all children with at least one prescription of PPI
1478124|NCT03134495|Other|all children with no prescription of PPI|all children with no prescription of PPI
1478125|NCT03134482|Procedure|IVM|No gonadotropin is used, but hCG priming is utilized 36 hour before oocyte maturation.
1478126|NCT03134482|Procedure|Minimal stimulation IVF|IVF with minimal use of gonadotropin, i.e. 150 or less IU of recombinant FSH, followed by hCG triggering in GnRH antagonist protocol.
1478127|NCT03134469|Dietary Supplement|Probiotic supplement|Probiotic supplement
1478128|NCT03134469|Dietary Supplement|Placebo supplement|Placebo supplement
1478129|NCT03134456|Drug|Pembrolizumab Injection|Pembrolizumab according to the dosage and administration in Product Information of Keytruda in Korea (2mg/kg) until it is changed to 200mg flat dose.
1478130|NCT03134443|Drug|Andrographolide sulfonate|Routine treatment for acute tonsillitis + Xiyanping injection
1478131|NCT03134443|Drug|Andrographolide sulfonate simulation|Routine treatment for acute tonsillitis + Xiyanping injection simulation
1478132|NCT03134430|Other|Normal saline|Injection of Normal saline around peripheral nerve
1478133|NCT03134430|Other|peripheral Nerve block|Injection of local anesthetics around peripheral nerve
1478134|NCT03134417|Dietary Supplement|Vitamin D and magnesium|Daily vitamin D and magnesium supplements are given to participants daily for 12 weeks.
1478135|NCT03134417|Dietary Supplement|Vitamin D|Daily vitamin D supplements are given to participants daily for 12 weeks.
1478136|NCT03134417|Dietary Supplement|Placebo|Daily placebo are given to participants daily for 12 weeks.
1478137|NCT03134404|Other|No Intervention|No Intervention is required for this study
1478138|NCT03134391|Drug|Vapocoolant spray, EMLA|Subjects were given vapocoolant spray to reduce pain from spinal injection; subjects were given EMLA to reduce pain from spinal injection
1478139|NCT03134378|Drug|Rabeprazole Sodium 20mg|Twice daily
1478140|NCT03134378|Drug|Clarithromycin 500mg|Twice daily
1478141|NCT03134378|Drug|Amoxicillin 500 Mg|Twice daily
1478142|NCT03134365|Other|Mixed meal|Mixed meal with identical composition and physical characteristics (colour, texture, consistency, temperature) but distinctively different palatability.
1478143|NCT03134365|Other|Combined meal|Combined meal.
1478144|NCT03134352|Drug|ZL-3101|A brown ointment, 10g/tube, 0.4g herb/g ointment, Topical
1478145|NCT03134352|Drug|Placebo|A brown ointment, 10g/tube, 0.02 g herb/g ointment (5% of Fugan active ointment), Topical
1478146|NCT03134339|Drug|Nicotine saline 0.00mcg/kg/s|saline 0.00mcg/kg/s
1478147|NCT03134339|Drug|Nicotine 0.24 mcg/kg/s|nicotine 0.24 mcg/kg/s
1478148|NCT03134339|Drug|Nicotine 0.048 mcg/kg/s|nicotine 0.048 mcg/kg/s
1478149|NCT03134339|Drug|Nicotine 0.024 mcg/kg/s|nicotine 0.024 mcg/kg/s
1478150|NCT03134326|Device|R1-25 and R2-25 Pulse Oximeter Sensor|
1478151|NCT03134313|Device|Rainbow Adhesive Noninvasive R1 Pulse Oximeter Sensor|
1478152|NCT03134300|Diagnostic Test|Cytokine from blood|Blood draw- one intraoperative, one 3 weeks postoperative
1478153|NCT03134287|Procedure|two-finger method, reverse sellick's method|Subjects received nasogastric tube placement by two-finger method; Subjects received nasogastric tube placement by reverse sellick's method
1478154|NCT03134274|Device|Dip HBDA|Participant receive Dip HBDA semiquantitative urinalyiss kit to be used at home one day after routine prenatal consultation. Dip HBDA consists of a testing kit containing calibration color board, 10 parameter urine dipstick and a urine cup as well as a smartphone application. Application guides participant through the test flow. Dipstick is immersed in urine cup, placed on color board and scanned with smartphone.
1478155|NCT03134261|Diagnostic Test|WB-MRI|scanning methods
1478156|NCT03134261|Diagnostic Test|SPECT-CT|scanning methods
1478157|NCT03134261|Diagnostic Test|Cholin-PET-CT|scanning methods
1478158|NCT03134261|Diagnostic Test|PSMA-PET-CT|
1997885|NCT01849783|Drug|doxorubicin|Given IV
1478167|NCT03134209|Device|Zipper surgical skin closure|The device acts like a scaffold to stabilize the adjacent sides of a wound in order to minimize forces that can disrupt normal healing of the skin.
1478168|NCT03134209|Other|Monocryl + Dermabond|conventional sutures and skin adhesive glue
1478169|NCT03134209|Other|Polyester mesh + Dermabond|conventional sutures and skin adhesive glue
1478170|NCT03134196|Drug|Masked Placebo|Oral Placebo
1997886|NCT01849783|Drug|cyclophosphamide|Given IV or PO
1997887|NCT01849783|Drug|etoposide|Given IV
1997888|NCT01849783|Drug|bortezomib|Given IV
1478171|NCT03134196|Drug|Masked Oral Valacyclovir|Oral Valacyclovir 1000 mg/day
1478172|NCT03134183|Drug|Vaginal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) vaginally 1-2 hours prior and placebo (buccal mint powder) buccally 1-2 hours prior to D&E
1478173|NCT03134183|Drug|Buccal Misoprostol|Mifepristone 200mg orally 20-24 hours prior and misoprostol 400mcg (two 200mcg tablets) ground with mint into buccal powder and placebo (two lactose tablets designed to appear similar to misoprostol) vaginally 1-2 hours prior to D&E
1478174|NCT03134170|Other|Pharmacist review of therapy|Patients who are randomized to the pharmacist group will have their treatment reviewed by a pharmacist
1478175|NCT03134157|Drug|oral drug and vaginal placebo|prescription of simvastatin 40 mg orally+ vaginal placebo every day for 3 months.
1478176|NCT03134157|Drug|oral drug and oral placebo|prescription of simvastatin 40 mg orally+ oral placebo every day for 3 months.
1478177|NCT03134157|Drug|Vaginal placebo+ oral placebo|prescription of Vaginal placebo + oral placebo every day for 3 months.
1478179|NCT03134131|Drug|ONC201|
1478180|NCT03134118|Drug|Nivolumab|Patients will be centrally registered and will receive nivolumab 240 mg IV every 2 weeks
1478181|NCT03134105|Other|Monthly Feedback on activity and patient-reported angina|Providers will receive monthly updates on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
1478182|NCT03134105|Other|End-of-Study Feedback|Providers will receive an end-of-study update on step count and patient reported angina for each of their patients, with data derived from a wearable fitness tracker and every other week emailed surveys
1948738|NCT01796509|Other|Medical, psychological, social|After having given his consent, the patient filled auto questionnaire, and then randomized either in follow up arm (i.e. intervention group) or in no follow up arm (i.e. control group). In the follow up arm, medical, psychological and social consultation will be planned within the first seven days after inclusion, and then 3, 6, 12 months. During medical consultation a general examination will be performed, muscle strength, cognitive function, functional disabilities will be assessed with help of MRC, MMS. During psychological consultation, anxiety and depression will be assessed with the help of HAD, IES. The psychologist will also have a free interview. During social consultation personal and professional reinsertion will be assessed.
1948739|NCT01789216|Drug|NSAID|
1948740|NCT01789216|Drug|Gabapentinoids|
1478188|NCT03134053|Device|extracorporeal shock-wave|to treat painful and retracting scars
1478189|NCT03134053|Other|massage|to treat painful and retracting scars
1478190|NCT03134040|Behavioral|Incentives (Rebate)|
1478191|NCT03134040|Behavioral|Incentives (Donation)|
1478192|NCT03134040|Behavioral|Feedback|
1478193|NCT03134027|Procedure|Bone marrow biopsy|Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.
1478194|NCT03134014|Dietary Supplement|Breakfast|If randomized to a breakfast consuming group, participants will be given breakfasts to consume between 6:00-8:00 am.
1478195|NCT03134001|Device|patients receiving oral analgesics via the PCoA™ Acute|PCoA™ Acute is an oral PCA device, designed to provide safe and easy-to-use pain medication at the bedside. It identifies patients by Radio Frequency Identification (RFID) technology and provides pill dispensing upon patient's request.
1478196|NCT03133975|Drug|Vitamin D3 (Treatment)|Single high dose vitamin D3 in treatment of dyslipedemia
1478197|NCT03133975|Other|Mixed diet of carbohydrate and protein (Control)|Mixed diet of carbohydrate and protein
1478198|NCT03133962|Other|Adult patients who are candidates for a CAP or long-term central catheter placement|Evaluate the feasibility of finding the correct positioning of the distal end of the PAC or of the long-term catheter by cardiac ultrasound in comparison with the brightness scopy, reference method.
1478199|NCT03133949|Other|Establish the clinical, biological and radiological characteristics of patients|Establish the clinical, biological and radiological characteristics of patients
2000812|NCT03323749|Combination Product|elamipretide|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
1948741|NCT01789216|Drug|placebo|
1948742|NCT01789047|Drug|Topiramate|Topiramate as adjunct to amantadine
1948743|NCT01789047|Drug|Placebo|Placebo control
1948744|NCT01767909|Drug|Insulin (Humulin® R U-100)|20 IU bid taken twice daily (approximately 30 minutes after breakfast and dinner) for a total of 40 IU daily, which will be administered intranasally. The device used to administer insulin releases a metered dose into a chamber covering the participant's nose. The insulin is then inhaled by breathing evenly over a specified period.
1478200|NCT03133936|Biological|Fluarix|Fluarix (GSK). Quadrivalent (IIV-4) subvirion vaccine produced in embryonated hen's eggs and administered intramuscularly at a dose of not less than 15 ug of HA (as determined by SRID) per component.
1478201|NCT03133923|Biological|≥3.0 lgCCID50/mlbut ＜3.5lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥3.0 lgCCID50/ml but ＜3.5lgCCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
1478202|NCT03133923|Biological|≥4.5 lgCCID50/ml Live Attenuated Mumps Vaccine (Human Diploid Cell) in infants(8-24 months old)|≥4.5CCID50/ml;Live Attenuated Mumps (F-genotype) Vaccine (Human Diploid Cell, KMB-17) in 360 infants(aged 8-24 months ) on 0 day
1478203|NCT03133923|Biological|Measles and Mumps Combined Vaccine，Live(SIBP)( positive control)|Measles and Mumps Combined Vaccine，Live(SIBP) in 360 infants(aged 8-24 months ) on 0 day
1478204|NCT03133832|Drug|Companion Tablet|Chinese-made drug for schistosomiasis treatment
1478205|NCT03133819|Device|Q-Sense_QST (TSA II)|QST will perform using the Medoc device (TSA2001/VSA3001) following previous published procedures. The measurement will perform on the thenar eminence of the dominant hand and the lateral distal aspect of the foot dorsum of the same side.
1478206|NCT03133806|Device|Ultrasept LAA Closure System|The Ultrasept Left Atrial Appendage Closure System Device is a percutaneous transcatheter device intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients with non-valvular atrial fibrillation.
1478207|NCT03133793|Drug|CoQ10|Participants will take 300mg capsules two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
1478208|NCT03133793|Drug|D-Ribose Oral Powder|Participants will mix 15 grams D-Ribose powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
1478209|NCT03133793|Other|Placebo pills|Participants will take matched placebo pills that are 300mg capsules, two times daily, 1 taken in the morning and 1 taken in the evening, for up to 12 weeks.
1478210|NCT03133793|Other|Placebo powder|Participants will mix 15 grams placebo powder, mixed with non-carbonated liquid, one time per day for up to 12 weeks.
1478211|NCT03133780|Drug|Dexmedetomidine|Patient will receive IV dexmedetomidine1 μg/kg for 10 min
1478212|NCT03133780|Drug|Midazolam|Patient will receive IV midazolam 0.03mg/kg for 10 min
1478213|NCT03133767|Drug|Lactated Ringer Solution|2 liters of intravenous lactated ringers solution will be administered by peripheral IV
1478214|NCT03133767|Drug|Normal Saline 0.9% Infusion Solution Bag|2 liters of intravenous normal saline solution will be administered by peripheral IV
1478215|NCT03133754|Procedure|DP-PEEP|PEEP titration trial for the lowest DP after the alveolar recruitment maneuver
1478216|NCT03133754|Procedure|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
1478221|NCT03133728|Diagnostic Test|Standard of Care Testing Clinic Participants|HIV-exposed Infants/young children (IYC) (from 6 weeks of age) of randomized standard of care clinics will have heelprick-obtained blood tested for HIV with standard of care assay, DBS DNA PCR testing. Samples will be sent to centralized offsite lab for testing with Roche COBAS® Ampliprep/TaqMan HIV Quantitative Test v2.0 testing platform. DBS sample packaging and shipping will be arranged by health-facility based Ministry of Health staff. Parent/guardian will be asked to return to the clinic with infant in 4 wks for test results. IYC found to be HIV-infected will have second, confirmatory DBS DNA PCR sample drawn, initiate ART immediately and attend routine follow-up visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study-specific data will be obtained on first 8 routine visits after ART initiation. HIV-uninfected IYC on first PCR testing will attend routine care per national guidelines, however, they no longer be followed in study.
1478222|NCT03133728|Diagnostic Test|Alere Q Testing Clinic Participants|Infants of intervention clinics will have heelprick-obtained blood tested by standard of care method (SOC) and Alere™ q HIV-1/2 Detect Test Point of Care testing onsite. Point-of-care (POC) testing results will be available in 52 minutes. HIV-infected infants, based on the Alere Q test result, will start ART as soon as possible and start routine SOC visits at weeks 2, 4, 8, 12, 16, 20, 24, 36, and 48 post ART-initiation. Study data will be obtained on first 8 routine visits after ART initiation. Infants will return for results of DBS-based DNA PCR testing. Positive SOC infants remain on ART/study follow-up. Negative POC test/negative SOC infants will attend only routine care visits and continue on HIV prophylaxis per national guidelines. Discordant results require DNA PCR test, with positive results continuing ART, negative results being repeated for confirmation before discontinuation. Study specific data will be collected at first 8 routine visits.
1478223|NCT03133715|Procedure|laparoscopic repair|surgical repair of ventral hernia using laparoscopic repair
1478224|NCT03133715|Procedure|robot-assisted repair|surgical repair of ventral hernia using robot-assisted repair
1478225|NCT03133702|Other|Forensic cases|Forensic cases which were admitted to the Emergency Department
1478226|NCT03133676|Drug|KA34|50 µg - 400 µg intra-articular injection (single or multiple doses)
1478227|NCT03133676|Drug|Placebo|50 µg - 400 µg intra-articular injection (single or multiple doses)
1478228|NCT03133663|Other|Electrocardiogram group|Experimental
1478229|NCT03133663|Other|Pulse oximeter and auscultation group|Control
2000813|NCT03323749|Combination Product|placebo comparator|40 mg of placebo administered as once daily 0.5 mL subcutaneous injections for 24 weeks using the elamipretide delivery system
1478231|NCT03133637|Drug|ceftriaxone|Eligible infants will receive ceftriaxone
1478232|NCT03133611|Other|Speech assessment|Each subject will undergo short non-invasive speech assessment lasting approximately 15 minutes that will be recorded using microphone.
1478233|NCT03133611|Other|Routine clinical assessment|Volunteers who enroll in the study will undergo various assessments lasting about 2 hours, including neurological examination of both motor and non-motor skills, autonomic testing and cognitive testing.
1478234|NCT03133585|Device|2 piece appliance for stomy|Use of the Flexima®/Softima® 3S during 6 months following the patient's usually frequency of appliance change
1948745|NCT01767909|Drug|Placebo|Placebo taken twice daily (approximately 30 minutes after breakfast and dinner), which will be administered intranasally. The device used to administer placebo releases a metered dose into a chamber covering the participant's nose. The placebo is then inhaled by breathing evenly over a specified period.
1948746|NCT01759121|Radiation|T-PRP|532nm-short pulse panretinal photocoagulation with PASCAL function
1478237|NCT03133559|Other|Observational|We will use a deep phenotyping approach to collect multidimensional datasets from individuals infected with HIV compared to healthy controls to define circadian rhythm disruptions associated with HIV infection.
1478238|NCT03133546|Drug|Osimertinib|"Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.
AstraZeneca will supply osimertinib as tablets for oral administration."
1478239|NCT03133546|Drug|Bevacizumab|Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.
1478240|NCT03133533|Procedure|laparoscopic repair|Surgical inguinal hernia repair using laparoscopic approach.
1478241|NCT03133533|Procedure|robot-assisted repair|Surgical inguinal hernia repair using robot-assisted approach.
1478242|NCT03133520|Device|High flow oxygen therapy|High-flow nasal oxygen [HFNO] therapy is a focus of growing attention as an alternative to standard oxygen therapy. By providing warmed and humidified gas, HFNO allows the delivery of higher flow rates [of up to 60 L/min] via nasal cannula devices, with fraction of inspired oxygen(FiO2) values of nearly 100%.
1478243|NCT03133507|Behavioral|Reapprasial Condition|Children in this condition will be instructed to think about how the procedure will help them become adjusted to cold weather.
1478244|NCT03133507|Behavioral|Reassurance Condition|Children will be reassured by the experimenter .
1478245|NCT03133507|Behavioral|Distraction Condition|Children in this condition will be instructed to focus their attention on a picture on a computer screen rather than on the pain.
1478246|NCT03133494|Other|ABG analysis|ABG analysis was performed and compared between two groups
1478247|NCT03133481|Procedure|Adductor Canal Nerve Block|Adductor Canal never technique
1478248|NCT03133481|Drug|Femoral Nerve Block|Traditional technique
1478249|NCT03133468|Drug|AJM347|Oral administration
1478250|NCT03133468|Drug|Placebo|Oral administration
1478251|NCT03133455|Other|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.|Evaluate the link between an abstract / analytical thinking style and depressive manifestations in FM.
1478252|NCT03133442|Device|Somnomat V4|Vestibular stimulation is provided using an innervated bed platform. This robotic device consists of a standard single bed, mounted on a moving mechanism. It was developed and produced by the ETH Zürich and approved for use in this study by Swissmedic.
1478253|NCT03133429|Device|MER|carotid artery stenting
1478254|NCT03133416|Other|PRP preparation|
1478255|NCT03133416|Device|Physiotherapy|
1478256|NCT03133416|Other|PRP and physiotherapy|
1478257|NCT03133403|Drug|Tecfidera (BG12)|Tecfidera (dimethyl fumarate) is the methyl ester of fumaric acid. It is an oral compound which has potent anti-inflammatory properties thought to be related to the induction of stress protein HO-1. There is also some evidence to suggest that Tecfidera include direct cytoprotective effects through upregulation of nuclear factor (erythroid-derived 2)-like 2 (Nrf2) and subsequent induction of an antioxidant response
1478258|NCT03133403|Drug|Gilenya|Gilenya is an oral sphingosine 1-phosphate receptor modulator, which sequesters lymphocytes in lymph nodes, preventing them from contributing to an autoimmune reaction
1478259|NCT03133403|Drug|Tysabri®|Tysabri® is a recombinant humanized IgG4K monoclonal antibody produced in murine myeloma cells. Natalizumab contains human framework regions and the complementary -determining regions of a murine antibody that binds to α4-integrin. The molecular weight of natalizumab is 149 kilodaltons
1478260|NCT03133403|Drug|Avonex/Betaseron/Copaxone/Rebif|"Avonex®, Betaseron®, Copaxone®, Rebif® is standard of care for RRMS. Except for flu-like symptoms from interferons, these drugs are generally well tolerated. The usual doses are:
Copaxone: 20 mg subcutaneous once daily
Avonex: 30ucg (6 million units) intramuscularly (IM) once a week
Betaseron: 250 ucg subcutaneous every other day. To decrease flu-like side effects may gradually escalate from 62.5 ucg for 2 weeks then increased 62.5 ucg every two weeks until reaching 250 ucg every other day.
Rebif®: 44ucg subcutaneous three times a week. To decrease flu-like side effects may gradually escalate from 8.8 ucg for 2 weeks then increased 22 ucg every for week 3 and 4 then 44 ucg starting week five"
1478261|NCT03133403|Procedure|Hematopoietic stem cell transplantation (HSCT)|Selection of the Conditioning Immunosuppressive Therapy, Harvesting Stem Cells , Rabbit-Derived Anti-Thymocyte Globulin
1948747|NCT01759121|Radiation|S-PRP|532nm-partially subthreshold short pulse panretinal photocoagulation with PASCAL endpoint management function
1948748|NCT01742117|Drug|Clopidogrel|Subjects will receive Clopidogrel, one 75 mg tablet per day by mouth for one year.
1478264|NCT03133377|Behavioral|Early activity and mobilisation|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
1478265|NCT03133364|Other|Sensory optimized meals|19 main meals and 12 between-meals are optimized and composed to a menu for 12 weeks.
1478266|NCT03133351|Device|PCM|A fresh whole blood sample will be tested by PCM to determine the reference range.
1478267|NCT03133338|Device|pelvic binder|The requirement of angioembolization can be predicted by the presence of intravenous contrast extravasation (ICE) on computed tomography (CT)
1478268|NCT03133325|Device|GP0045|Hyaluronic acid gel
1478269|NCT03133325|Device|Restylane Lyft Lidocaine|Hyaluronic acid gel
1478270|NCT03133312|Drug|Chlorhexidine Gluconate|Pre-operative vaginal preparation with 4% Chlorhexidine Gluconate Intervention
1478271|NCT03133312|Drug|Povidone-Iodine Scrub and Paint|Pre-operative vaginal preparation with 10% Povidone-Iodine Scrub and Paint Intervention
1478272|NCT03133299|Drug|Glucocorticoids|Oral prednisolone for four months
1478273|NCT03133299|Drug|Vitamin D|Oral vitamin D for two months
1478275|NCT03133260|Diagnostic Test|Troponin|Troponin will be measured before surgery and postoperative at days 1,2 and 3.
1478276|NCT03133260|Drug|Acetylsalicylic acid|100mg acetylsalicylic acid will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
1478277|NCT03133260|Drug|Statin|40mg atorvastatin will be started in case of MINS if no contraindication, it will be continued after hospital discharge. We will evaluate cardiovascular complications till 1 year after surgery
1478278|NCT03133247|Drug|SHR-1316|PD-L1
2000814|NCT03323749|Combination Product|elamipretide open label treatment|40 mg of elamipretide administered as once daily 0.5 mL subcutaneous injections for up to 144 weeks using the elamipretide delivery system
1478280|NCT03133221|Drug|Zydelig|Zydelig given at 150mg continuously in 28-day cycles
2000815|NCT03323723|Device|SUI Device|Pessary SUI device
1478282|NCT03133195|Drug|Teriparatide|Teriparatide 20 μg subcutaneous once daily for 12 weeks (Patient self administration at home by pen injector)
1478283|NCT03133195|Drug|Placebo|Placebo subcutaneous once daily for 12 weeks. (Patient self administration at home by pen injector)
1478284|NCT03133195|Dietary Supplement|Calcium supplement|1000 mg/day of elemental calcium
1478285|NCT03133195|Dietary Supplement|Vitamin D|20,000 IU/week of vitamin D2
1478286|NCT03133182|Drug|Polypharmacy|Patients who are taking >=5 unique prescription drugs in the 3 months prior to surgery
1478287|NCT03133169|Diagnostic Test|Erythrocyte glutamine/glutamate ratio|Erythrocyte glutamine/glutamate ratio is a biomarker of oxidative stress. Will be obtained through examination of a blood sample
1478288|NCT03133169|Diagnostic Test|Tricuspid regurge velocity|Tricuspid regurge velocity will be measured by doppler echocardiography denoting the pulmonary hypertension risk in children
1478289|NCT03133156|Other|Exercise Intervention|10-Week Aerobic Exercise Training
1478290|NCT03133143|Behavioral|Overwatch (Blizzard Entertainment)|The intervention last 12 weeks. Effective gaming time in each training session is 60 min at least 5 days/week. A minimum of 50 gaming hours are acquired to ensure observable neuroplasticity. Patients have scheduled gaming sessions at out-patient clinics where researchers/nursing staff can motivate and support gaming. A manual gaming diary is completed daily by the participants together with the help of the researchers/nursing staff at the study setting. Beside automatic gaming logs, the information is used to record and analyse intervention fidelity. The involvement of researchers/ nursing staff is crucial to ensure that the diaries are accurately and fully completed to measure the participants' gaming motivation and thoughts related to gaming.
1478291|NCT03133143|Behavioral|Project:Neural|The intervention last 12 weeks. Effective gaming time in each training session is 60 min at least 5 days/week. A minimum of 50 gaming hours are acquired to ensure observable neuroplasticity. Patients have scheduled gaming sessions at out-patient clinics where researchers/nursing staff can motivate and support gaming. A manual gaming diary is completed daily by the participants together with the help of the researchers/nursing staff at the study setting. Beside automatic gaming logs, the information is used to record and analyse intervention fidelity. The involvement of researchers/ nursing staff is crucial to ensure that the diaries are accurately and fully completed to measure the participants' gaming motivation and thoughts related to gaming.
1478292|NCT03133143|Behavioral|SimCity|The intervention last 12 weeks. Effective gaming time in each training session is 60 min at least 5 days/week. A minimum of 50 gaming hours are acquired to ensure observable neuroplasticity. Patients have scheduled gaming sessions at out-patient clinics where researchers/nursing staff can motivate and support gaming. A manual gaming diary is completed daily by the participants together with the help of the researchers/nursing staff at the study setting. Beside automatic gaming logs, the information is used to record and analyse intervention fidelity. The involvement of researchers/ nursing staff is crucial to ensure that the diaries are accurately and fully completed to measure the participants' gaming motivation and thoughts related to gaming.
1478293|NCT03133130|Drug|BMT101|BMT101 is administered to 6 subjects in each of 4 groups.
1478294|NCT03133130|Drug|Placebo|Placebo is administered to 2 subjects in each of 4 groups.
1478295|NCT03133117|Radiation|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)
1478296|NCT03133104|Other|Antenatal corticosteroids|Women and neonates with PPROM who received a repeat dose of antenatal corticosteroids, compared to women with PPROM who did not received a repeat course of antenatal corticosteriods
1478297|NCT03133091|Drug|PCEA versus PIEB|Comparison between both arms looking for primary and secondary outcomes already described.
1478298|NCT03133078|Other|Step-Down Test (2 min)|The 2-minute single limb lateral-step down test will be used to induce lower extremity muscle fatigue. Participants will be instructed to perform a single limb lateral step-down test on a 31 cm box (12-inches), touching their heel to the floor each time as many times as possible in 2 minutes. The number of lateral step-downs will be recorded.
1478299|NCT03133078|Other|Side hop test (30 s)|The 30 second side hop test will be used to induce lower extremity muscle fatigue. Participants will be instructed to jump as many times as possible over two parallel strips of tape placed 40 cm apart, but must initiate approximately 30 degrees of knee flexion each jump. The number of successful jumps performed within 30 seconds will be recorded and used for data analysis. An unsuccessful jump will be defined as touching the tape or the area inside the tape. We will record the number of successful trials.
1478300|NCT03133065|Drug|treatment of HCV with oral direct acting antiviral therapy|A total number of 89 patients transplanted for HCV genotype 4 related end stage liver disease Were included in this study 53 PATIENTS were treated after 6 months of transplantation with sofosbuvir 400mg and weight based ribavirin for 24 weeks. 7 patients were treated with sofosbuvir 400mg + simeprevir 150 mg + weight based ribavirin for 12 weeks after 6 months post transplant. In September 2015, we started to adopt early treatment strategy for all recipients after the first 3months post- transplant. 26 recipients were treated with sofosbuvir 400mg+Daclatasvir 60mg ± weight based ribavirin for 12 weeks or 24 weeks. 2 recipient are treated with sofosbuvir 400mg + ledipasvir 90mg for 24 weeks and one recipient is treated with fixed-dose combination of ombitasvir (12.5 mg), paritaprevir (75 mg) and ritonavir (50 mg) + weight based ribavirin due to having persistent renal impairment post transplantation.
2000816|NCT03323710|Drug|Propranolol|Propranolol will be administered orally at a starting dose of 40 mg (one tablet) two times a day (total daily dose of 80 mg). In case of acceptable safety profile, the dose may be increased to 80 mg (two tablets) two times a day (total daily dose of 160 mg) or farther to 80 mg (two tablets) three times a day (total daily dose of 240 mg).
1478301|NCT03133052|Behavioral|internet-based adaptive cognitive control training program|The cognitive training will be an adaptive cognitive control training program, Specific training paradigms include delayed match to sample task, paired-associate recall task, go-no go task, Stroop task, task switching, and n-back working memory task. To maintain task difficulty, the tasks will be grouped based on the task difficulty. Furthermore, each task will have various difficulty levels.
1478302|NCT03133052|Behavioral|placebo program|For the control group, a fixed, primary difficulty level program for all participants is set.
1478303|NCT03133039|Procedure|surgery, bioabsorbable screw|In this study we compare bioabsorbable and titanium screw in the hallux valgus and hallux rigidus surgery
1478304|NCT03133026|Device|Single operator cholangioscopy, Endoscopic biliary RFA|Single operator cholangioscopy will be done to acess the cause of occluded SEMS, if tumour ingrowth or overgrowth seen then endoscopic biliary RFA will be done
1478305|NCT03133013|Device|SLEEPSCOPE|Brainwave measurement device which is connected to the participant by an electrode attached to the forehead and another electrode behind one ear
1478306|NCT03132987|Other|Progressive strengthening program|The progressive strengthening program will be performed for 3 weeks and emphasize development of strength and power. Feasibility will be established if we can recruit up to 8 participants and retain at least 80% over the 3 week intervention program. We will determine effect sizes for changes outcome measures.
1478307|NCT03132974|Drug|Sogyeonghwalhyeol-tang granule|Sogyeonghwalhyeol-tang herbal extract granule
1478308|NCT03132974|Other|Sogyeonghwalhyeol-tang granule with manipulation procedure|Sogyeonghwalhyeol-tang herbal extract granule with manipulation procedure
1478309|NCT03132974|Other|Placebo with manipulation procedure|Placebo granule with manipulation procedure
1478310|NCT03132961|Other|Infrasound exposure|All cohorts will receive an identical infrasound exposure of equal time duration, varying only the order in which the testing is performed. To simulate the frequencies generated by a common source of environmental infrasound (wind turbines), recordings measured at a full-scale research wind turbine at the University of Minnesota will be utilized to create an infrasound stimulus. The resultant sound file consists of the fundamental frequency at approximately 0.7 Hz, equal to the blade passage rate, plus the harmonic overtones of the fundamental frequency. The presentation level is 85 dB SPL. The stimulus will be presented in a sound field.
1478311|NCT03132948|Behavioral|Physical Activity|Nintendo WII fit console, Xbox console, sport activities (soccer, basketball, yoga, walking and other physical games)
1478312|NCT03132935|Procedure|Telemedical support|Telemedical support by a physician in a telemedicine centre
1478313|NCT03132922|Genetic|Autologous genetically modified MAGE-A4ᶜ¹º³²T cells|Infusion of autologous genetically modified MAGE-A4ᶜ¹º³²T on Day 1
1478314|NCT03132909|Other|Determine the feelings of doctors caring for their colleagues|Determine the feelings of doctors caring for their colleagues
1478315|NCT03132870|Other|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions|Define predictive criteria for the diagnostic performance of echo-guide samples by mini-probe in peripheral lung lesions
1478316|NCT03132857|Other|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.|Assess the state of knowledge of the subjects falling or at risk, their risk of recurrence or first episode, compared to medical knowledge.
1478317|NCT03132844|Other|Analysis records of patients over 75 years of age|Demonstrate the percentage of patients over 75 years of age attending general medicine in the Somme, with an up-to-date vaccination schedule, in view of the HAS 2016 recommendations, for the following vaccines: DTp, influenza, pneumococcus, shingles.
1478318|NCT03132831|Other|Determine the DMS of the Total Hip Prosthesis of the University Hospital of Amiens (PTH) and the Total Knee Prosthesis (PTG)|To determine the DMS of the orthopedic department of the Amiens University Hospital after Total Hip Prosthesis (PTH) and First-line Total Knee Prosthesis (PTG) with its confidence interval and to compare it according to the patient's day of operation
1478319|NCT03132818|Other|To evaluate the prevalence of sexual disorders in patients receiving AMP|To evaluate the prevalence of sexual disorders in patients receiving AMP
1478320|NCT03132805|Behavioral|PATHS to PAX|A universal classroom-based preventive intervention designed to prevent aggression.
1478321|NCT03132805|Behavioral|PATHS to PAX and the Incredible Years|A universal classroom-based preventive intervention in combination with an indicated preventive intervention, both of which are designed to prevent aggression.
1478323|NCT03132779|Drug|Intralipid|Adose of intralipid given and rechecking NKcells activity
1478324|NCT03132766|Behavioral|Case Management|Community Mental Health Workers (CMHW), who are trained surveillance system staff, will conduct the monitoring and case management visits in participants' homes or other private settings at baseline, 1, 2, 3 and 6 months post-enrollment. The CM visit includes rapport-building, use of the SIQ to assess imminent risk, and referral to a local mental health center. Case managers will also facilitate connections to other care providers (traditional healers, church, Indian Health Service (IHS) social services/mental health, and private providers).
1478325|NCT03132766|Behavioral|New Hope Curriculum|New Hope (NH) is psychoeducation to supplement and promote mental health services, while encouraging connections to traditional healers and caring adults. The intervention is designed to be implemented over 1 visit (2-4 hours) in a youth-preferred setting. NH emphasizes the seriousness of a suicide attempt; teaches coping skills to reduce risk, including emotion regulation, cognitive restructuring, social support, and safety planning; and helps participants overcome barriers to treatment motivation, initiation, and adherence. A center-piece of the intervention is a 20-minute video produced by WMAT-CAIH with Native actors, vignettes specific to this community, and Elders speaking in their tribal language (with sub-titles) about the seriousness of suicide, its impact on the community, their concern for the adolescent, and beliefs about the communal importance of each individual's life. Youth are encouraged to choose a support person from his/her family to take part in the intervention.
1478402|NCT03132168|Behavioral|Assessments|These cognitive assessments will be utilized during the study to evaluate cognitive levels comparing prior to surgery and post-operatively in order to determine if the subject is delirious. BIS monitoring will be utilized for all subjects.
1478922|NCT03127995|Radiation|HYPOFRACTIONATED|40 Gy/ 15 fractions / 3 weeks
1478326|NCT03132766|Behavioral|Elders' Resilience Curriculum|Elders' Resiliency (ER) intervention. Apache traditions confer behavioral repertoires and values taught through storytelling, observation, and parenting at the family and community level that have carried the Apache people through generations of adversity and historical trauma. ER is a brief (2-4 hours) distillation of these concepts intended to bolster Apache youths' resilience to suicide ideation, attempts and substance abuse by promoting Apache cultural identity and values, youth's self-worth and role in the community, and fostering connectedness to society and community, with an emphasis on extended family as a nexus of strength.
2000817|NCT03323710|Drug|Sunitinib|Sunitinib will be administered orally at a starting dose of 50 mg once daily, for 4 consecutive weeks, followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks.The schedule may be changed to 2 weeks on / 1 week off (schedule 2/1) and a daily dose may be reduced to 37.5 mg or 25 mg to decrease the level of toxic side effects.
1478328|NCT03132727|Other|Pharyngo laryngeal MRI|"Patients will be outgoing a pharyngolaryngeal MRI, with injection of gadolinium, in addition to the CT imaging. They will have this MRI in case of doubt about cartilage invasion. It will be realised during the time between the CT imaging and the day of surgery.
Device : gadolinium-based MRI contrast agent This will be realized according to the standard procedure."
1478329|NCT03132714|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
1478330|NCT03132714|Drug|Amoxicillin 500mg|Administration of Amoxicillin 500mg tid for 7 days
1478331|NCT03132714|Drug|Metronidazole 400mg|Administration of Metronidazole 400mg tid for 7 days.
1478332|NCT03132714|Drug|Clarithromycin 500mg|Administration of Clarithromycin 500mg bid for 7 days
1478333|NCT03132714|Procedure|Single application of PDT|Single application of photodynamic therapy (PDT) at day 0.
1478334|NCT03132714|Procedure|Repeated application of PDT|Repeated application of photodynamic therapy (PDT) at 0, 1, 2, 7 and 14 days post-operatively.
1478335|NCT03132701|Drug|Magnesium|Mg is administered during anesthesia until 5 minutes before surgery ends
1478336|NCT03132701|Drug|Saline|Same volume of saline is infused until 5 minutes before surgery ends
1478337|NCT03132688|Drug|Propofol|Intravenous administration with dose of 100-200mcg/kg/min
1478341|NCT03132662|Dietary Supplement|Omega-3|3 gr/day of Omega-3
1478342|NCT03132662|Dietary Supplement|Very Low Calorie Diet|4 servings/day Optifast
1478343|NCT03132636|Drug|REGN2810|Regimen as per protocol
1478344|NCT03132623|Drug|andrographolide sulfonate|Xiyanping injection 10-20ml/d, With 0.9% Sodium Chloride Injection 100ml-250ml diluted intravenous drip (not with other drugs in the same container mixed use), control drip speed per minute of 30-40 drops.
1478345|NCT03132623|Drug|andrographolide sulfonate simulation|Xiyanping injection simulation(0.9% normal saline) 10-20ml/d, The treatment method is the same as the experimental group.
1478346|NCT03132610|Drug|andrographolide sulfonate|Conventional Therapy+Xiyanping injection
1478347|NCT03132610|Drug|andrographolide sulfonate simulation|Conventional Therapy+Xiyanping injection simulation
1478348|NCT03132597|Behavioral|Mindfulness training|six weeks of 2 hours class of mindfulness training and orientations for home training
1478349|NCT03132584|Drug|Cyclophosphamide|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days
- Via IV Day 3"
1478350|NCT03132584|Drug|Alemtuzumab|"The chemotherapy drugs will be given in the hospital. During the first cycle of treatment, participants will stay in the hospital until their blood counts have recovered after treatment. During cycles 2 and 3, participants may go home after chemotherapy if they are doing well. The length of each cycle is 28 days
Alemtuzumab will be administered as follows:
IV Day 1
IV Day 2
Target dose IV on Day 3 and 4"
1478351|NCT03132571|Drug|Naltrexone|37.mg oral capsule taken once daily for over the course of the study (16 weeks)
1478352|NCT03132571|Drug|Bupropion|Extended release bupropion taken once daily for the course of the study (16 weeks) flexible dosing up to 450mg target.
1478353|NCT03132571|Other|Placebo|Oral placebo taken once daily for the course of the study (16 week)
1478354|NCT03132558|Drug|Radiopaque Media|
1478355|NCT03132545|Diagnostic Test|SenseWear Armband (SWA) monitoring|Participants wore the SWA on their right arm
1478356|NCT03132545|Diagnostic Test|total body dual-energy X-ray absorptiometry|DEXA was used to estimate abdominal visceral adipose tissue and subcutaneous adipose tissue
1478357|NCT03132532|Device|Proton Beam Therapy|Proton Beam Therapy (radiation) at either 60 Gy, 66 Gy, or 72 Gy.
1478358|NCT03132532|Drug|Carboplatin|IV infusion at standard dose, route, and schedule. Concurrent chemotherapy, Carboplatin, weekly during radiotherapy followed 3-6 weeks later by 2 cycles of consolidative chemotherapy
1478359|NCT03132532|Drug|Paclitaxel|IV infusion at standard dose, route, and schedule. Concurrent chemotherapy, Paclitaxel, weekly during radiotherapy followed 3-6 weeks later by 2 cycles of consolidative chemotherapy
1478360|NCT03132519|Drug|Remifentanil|To maintain remifentanil Ce at 1.0 (control) vs. 2.0 vs. 2.5 ng/ml by a TCI system during anesthesia emergence until tracheal extubation
1478361|NCT03132506|Other|patient-reported-outcomes|Explorative pilot study combining collected data from the PRAEGNANT study on paper-based patient-reported-outcomes with additional collected data on web-based patient-reported-outcomes
1478362|NCT03132493|Drug|Nivolumab 10 MG/ML|nivolumab 3 mg/kg as an intravenous infusion every 2 weeks until progression
1478363|NCT03132480|Other|fluid resuscitation|when the patients showed the clinical signs of hypovolemia, the fluid resuscitation with 10ml/kg crystalloid solution was performed.
2000818|NCT03323697|Other|SZ-05|2.5g a day (3 capsules twice a day)
2000819|NCT03323697|Drug|Escitalopram Pill|10 mg capsule plus 5 placebo capsules
2000820|NCT03323684|Other|Quadratus lumborum block Group (QL)|20 mL of 0.375% isobaric bupivacaine for each side deposited at the posterior aspect of the quadratus lumborum muscle (QLB type 2) using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
1478367|NCT03132454|Drug|Palbociclib|"Arm A, B, C: Participants take Palbociclib 125 mg alone by mouth 1 time each day on Days 1-21 of Cycle 1 only.
Arm A: In Cycle 2, participants continue to take Palbociclib 125 mg by mouth on Days 1-21 of each 28 day cycle.
Arm B: In Cycle 2, participants continue to take Palbociclib 125 mg by mouth on Days 1-7 of each 28 day cycle.
Arm C: In Cycle 2, participants continue to take Palbociclib 125 mg by mouth on Days 1-21 of each 28 day cycle."
1478368|NCT03132454|Drug|Sorafenib|"Phase I Starting Escalation Dose: 200 mg by mouth twice a day on Days 1-28 of each 28 day cycle.
Phase II Starting Expansion Dose: Maximum tolerated dose from Escalation Dose."
1478369|NCT03132454|Drug|Decitabine|"Phase I Starting Escalation Dose: 15 mg/m2 by vein on Days 8 - 17 of first combination cycle, and Days 8 - 12 of combination cycle 2 and beyond.
Phase II Starting Expansion Dose: Maximum tolerated dose from Escalation Dose."
1478370|NCT03132454|Drug|Dexamethasone|"Phase I Starting Escalation Dose: 20 mg by mouth or by vein Daily on Days 1-4 & Days 15-18 of a 28 day cycle.
Phase II Starting Expansion Dose: Maximum tolerated dose from Escalation Dose."
1478371|NCT03132441|Other|Strength Training for Frailty|Cardiac Rehabilitation, abbreviated course
1478372|NCT03132428|Drug|Nitric Oxide Gas, for inhalation: Observational Study|nitric oxide gas, for inhalation INOMAX provided either via mechanical ventilation or non invasive ventilation
1478373|NCT03132415|Behavioral|Get Connected|The investigators designed the intervention to help participants increase their HIV risk awareness, promote self-appraisal and increase motivation for engaging in prevention services, problem solving barriers to accessing care, and locating culturally-sensitive providers. Intervention content is customized based on participants' socio-demographic characteristics, HIV/STI testing history and testing motivations, and recent sexual behaviors.
1478374|NCT03132415|Behavioral|AIDSVu|The investigators will use AIDSVu's available HIV/STI testing locator as the attention-control condition. The AIDSVu test locator provides a list of HIV testing sites in a city or zipcode.
1478375|NCT03132402|Diagnostic Test|ELISA validation|ELISA validation of hypersensitive rapid diagnostic test results for detection of P. falciparum
1478376|NCT03132389|Other|No intervention|All patients included in the study will be offered the same examination and treatment procedure as the patients who are not included. Identical procedures and examinations will be performed in participants and non-participants.
1478377|NCT03132376|Dietary Supplement|Water Preload Drink|Participants were given 275 ml (0 kcal) water to consume in the morning following an overnight fast. This served as the control drink.
1478378|NCT03132376|Dietary Supplement|Whey Protein Isolate Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g whey protein to consume in the morning following an overnight fast.
1478379|NCT03132376|Dietary Supplement|Micellar Casein Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g micellar casein to consume in the morning following an overnight fast.
1478380|NCT03132376|Dietary Supplement|Egg White Isolate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white isolate protein to consume in the morning following an overnight fast.
1478381|NCT03132376|Dietary Supplement|Egg White Concentrate Protein Drink|Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white concentrate protein to consume in the morning following an overnight fast.
1478382|NCT03132337|Other|Serial Blood Draws|Day 0 and Day 3 blood draw for SOS biomarkers. If subject develops SOS blood draw prior to dose of Defibrotide, Day 14 after Defibrotide and Day 21 after Defibrotide.
1478383|NCT03132324|Drug|INCB059872|INCB059872 at the protocol-defined dose administered QOD or QD based on cohort assignment.
1478384|NCT03132311|Biological|Yellow Fever vaccination (17 DD Biomanguinhos)|One intramuscular injection
1478385|NCT03132298|Other|Implicit Theories of Personality Program|This 30-minute, self-administered computer program teaches youths that personality is malleable, as opposed to fixed, due to the human brain's constant potential for change and growth (i.e., neuroplasticity).
1478386|NCT03132298|Other|Control Program|This 30-minute, self-administered computer program was designed to control for nonspecific aspects of completing a series of computer-based activities in the context of the present study. It was also designed to mimic 'supportive therapy' that youths might receive in usual care settings, stressing the importance of sharing one's feelings with close others.
1478387|NCT03132285|Device|PrePex|Prepex is a non surgical male circumcision device
1478388|NCT03132272|Device|Immunoadsorption with Globaffin|Immunoadsorption for treatment of persons with Alzheimer Dementia
1478389|NCT03132259|Drug|high dose dexmedethomidine|Dexmedethomidine continuous drip 0.5 mcg/kg/hr a
1478390|NCT03132259|Drug|low dose dexmedethomidine|Dexmedethomidine continuous drip 0.2 mcg/kg/hr
1478391|NCT03132246|Diagnostic Test|Blood draw|The only intervention patients experience is a non-standard of care blood draw. The blood is then tested in a basic science laboratory.
1478392|NCT03132233|Dietary Supplement|Beta-hydroxybutyrate calcium and magnesium salt|Exogenous ketone body in mineral salt form.
1478393|NCT03132233|Other|placebo powder|matched placebo powder to the IMP.
1478394|NCT03132220|Behavioral|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive therapy is an 8 week-2 hours per week intervention. The intervention in this population is designed to reduce symptoms of PTSD and BOS and increase resiliency scores.
1478395|NCT03132220|Behavioral|Book Club Active Control Intervention|Participants randomized to the book club active control intervention will meet for 8 weeks for two hour sessions. Books will be assigned to read during homework time and discussions regarding the books will occur during the 8 weekly two hour sessions. The time involved will be similar to the MBCT intervention.
1478396|NCT03132207|Other|Non interventionel study|Only one questionnaire will be done for women and professional
1478397|NCT03132194|Drug|DPSG 7.5%|topical gel
1478398|NCT03132194|Drug|Aczone|topical gel
1478399|NCT03132194|Drug|Placebo|topical gel
1478400|NCT03132181|Drug|Empagliflozin|Patient will be treaded according to standard care but additionally take one tablet Empagliflozin per day
1478401|NCT03132181|Other|Placebo|Patient will be treaded according to standard care but additionally take one tablet placebo per day
1478403|NCT03132168|Procedure|Blood Draw|Subjects will have blood draws at surgical preadmission visit, Day 1, Day 2, and Day 3 post surgery only; one tube containing approximately one teaspoon (5 mL) of blood will be drawn at each visit.
1478404|NCT03132168|Other|Standardized Anesthetic Care|Standardized anesthetic care will be provided as described by the protocol for each subject consented for this trial.
1478405|NCT03132155|Drug|AMG 337|6-{(1R)-1-[8-fluoro-6-(1-methyl-1H-pyrazol-4-yl)[1,2,4]triazolo[4,3-a]pyridin-3-yl]ethyl}-3-(2-methoxyethoxy)-1,6-naphthyridin-5(6H)-one•hydrate (1:1)
1478406|NCT03132142|Drug|Capsaicin|4x4 cm patch of 8% topical capsaicin applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
1478407|NCT03132142|Drug|Trans-cinnamaldehyde|1mL of 10% trans-cinnamaldehyde applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
1478408|NCT03132142|Drug|L-Menthol|1mL of 40% L-menthol applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
1478409|NCT03132142|Drug|Vehicle patch|Inert vehicle patch applied to the skin of the volar forearm for 1 hour 4 times on 4 consecutive days
2000821|NCT03323684|Other|Transversus abdominis plane Group (TAP)|20 mL of 0.375% isobaric bupivacaine for each side using ultrasound after induction of general anesthesia and 15 minutes before start of surgery
2000822|NCT03323684|Other|Control group (C)|No intervention will be done
2000823|NCT03323684|Drug|Paracetamol infusion|Paracetamol infusion (15 mg.kg) will be given by intravenous infusion after induction of general anesthesia.
2000824|NCT03323684|Drug|Ketorolac analgesia|In PACU Ketorolac 30 mg ampoule will be given by intravenous infusion to all cases and then every 8 hours.
1478414|NCT03132116|Drug|gentamicin|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of gentamicin .
As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
1478415|NCT03132116|Drug|placebo|"After inclusion in the study, patient will be randomized. According to randomization, patient will receive an intra-nodal injection of placebo.
As well, azithromycin will be prescribed for all patients for 5 days. Patients will be followed-up each week until week 4 (Day 28)."
1478416|NCT03132103|Dietary Supplement|Oral Vitamin D3|
1478417|NCT03132103|Dietary Supplement|Placebo Oral Vitamin D3|
1478418|NCT03132103|Radiation|Solar simulated radiation (SSR)|
1478419|NCT03132103|Radiation|Placebo SSR|
1478420|NCT03132090|Diagnostic Test|PET/MR (Biograph mMR)|The combination of PET and MRI allows for evaluation of metabolic, functional and morphological parameters such as glucose metabolism, perfusion, diffusion restriction or size in one examination. Due to the combination of MRI and PET in one scanner it is possible to align the acquired PET and MR datasets with high precision
1478421|NCT03132077|Procedure|total knee arthroplasty|surgical intervention for end stage of knee osteoarthritis
1478422|NCT03132064|Procedure|total knee arthroplasty|surgical repair for end stage of knee osteoarthritis.
1478423|NCT03132051|Drug|steroid injection|ultrasound-guided steroid injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide
1478424|NCT03132038|Drug|Nivolumab|3mg/kg, every two weeks, during a maximum of one year
1478425|NCT03132025|Drug|"Apatinib and Capecitabine"|"Combine Apatinib and Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
1478426|NCT03132025|Drug|"Capecitabine"|"Single Drug Capecitabine to Maintain Treating Metastatic Colorectal Cancer"
1478427|NCT03132012|Behavioral|Indoor tanning intervention|6 Web-based modules that focus on preventing skin cancer through sun protection and indoor tanning reduction using the Theory of Planned Behavior and Prospect Theory
1478428|NCT03132012|Behavioral|Standard of care control|One website with content similar to those available in dermatology offices on skin cancer prevention
1478429|NCT03131999|Drug|Imatinib Mesylate 400Mg Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
1478430|NCT03131999|Drug|Placebo - Capsule|Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
1478431|NCT03131973|Drug|BMS-986195|Specified dose on specified days
1478432|NCT03131973|Drug|Methotrexate|Specified dose on specified days
1478433|NCT03131973|Drug|Leucovorin|Specified dose on specified days
1478434|NCT03131960|Device|Paired Vagus Nerve Stimulation|Stimulation of the vagus nerve that is paired with upper limb rehabilitation movements.
1478435|NCT03131960|Other|Rehabilitation|Rehabilitation movements to improve upper limb function after stroke
1478436|NCT03131947|Other|HIV positive patients|As above
2000825|NCT03323684|Drug|fentanyl|With induction of general anaesthesia, fentanyl (1 microgram.kg) will be given. Intraoperatively, Fentanyl boluses (0.5 microgram.kg) will be given in case of increase in intraoperative mean arterial blood pressure or heart rate of more than 20% of baseline for longer than 5 minutes. Postoperatively, Fentanyl boluses (20 micrograms) will be given if VAS is more than 3 and it might be repeated after 30 minutes until VAS is ≤ 3.
2000826|NCT03323671|Drug|preemptive mefenamic acid|preemptive analgesia before menstrual pain
2000827|NCT03323671|Drug|mefenamic acid|mefenamic acid given only during menstruation
1478442|NCT03131895|Drug|30 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
1478443|NCT03131895|Drug|30 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
1478444|NCT03131895|Drug|60 mg dexlansoprazole capsules manufactured at TOB|Dexlansoprazole delayed-release.
1482848|NCT03098433|Drug|Levothyroxine|Active comparator
2000831|NCT03323619|Procedure|anesthesia type|No intervention. General anesthesia or local anesthesia with sedation are decided by the physicien according to his usual practice
2000832|NCT03323606|Behavioral|Gambling Internet Intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
2000833|NCT03323606|Behavioral|Check Your Drinking|A brief online intervention designed to provide personalized normative feedback aimed at motivating reductions in drinking
1478445|NCT03131895|Drug|60 mg dexlansoprazole capsules manufactured at TPC|Dexlansoprazole delayed-release.
1478446|NCT03131882|Drug|Hyaluronic Acid|1 ml of Low molecular weight hyaluronic acid injection under ultrasound guidance after subcutaneous 0.5ml of 1%lidocaine injection
1478447|NCT03131882|Drug|Triamcinolone Acetonide|1ml of 10 mg of triamcinolone injection under ultrasound guidance after subcutaneous 0.5 ml 1%lidocaine injection
1478448|NCT03131869|Other|Thickened Beverages Nectar|Thickened beverages in nectar consistency
1478449|NCT03131869|Other|Thickened Beverage Honey|Thickened beverages in honey consistency
1478450|NCT03131856|Behavioral|Nutritional intervention programme|The intervention consisted of an individual dietary plan conducted by a clinical dietician before discharge in combination with three follow-up visits after discharge (1, 4 and 8 weeks) conducted by a district nurse.
1478451|NCT03131843|Drug|Alcohol|Alcohol cleansing swab/wipe
1478452|NCT03131843|Drug|No alcohol|No alcohol will be used; alcohol cleansing swab/wipe will be used at a different injection site
1478453|NCT03131830|Other|Online-based questionnaire|Participants receive a web-link to a questionnaire, which is active for 3 months
1478454|NCT03131817|Device|Activa PC+S Prefrontal|
1478455|NCT03131804|Other|Intradialytic aerobic low intensity exercise|Intradialytic aerobic low intensity exercise program of 45 minutes per each hemodialysis session throughout the 6-month study duration
1478456|NCT03131791|Device|Shock Wave|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
1478457|NCT03131791|Drug|Botulinum toxin A|42 chronic stroke patients with upper limb spasticity were randomly assigned to receive either 1 session of ESWT per week for 3 consecutive weeks or BoNT-A injection. The biceps, flexor carpi radialis, and flexor carpi ulnaris muscles were treated. Assessments were performed at baseline and at 1, 4, and 8 weeks after the intervention. The primary outcome measure was the change in the Modified Ashworth Scale (MAS) score for the elbow from the baseline to after 4 weeks of treatment.
1478458|NCT03131778|Procedure|Liver resection|liver resections for colorectal liver metastases
1478459|NCT03131765|Biological|YS-0N-001|Cancer vaccine
1478460|NCT03131752|Behavioral|Elastic Resistance Intervention in Exacerbated Patients|The intervention protocol will performed during 7 days for all patients and this will begin 24 -48 hours after the start of medication for exacerbation. Those who are hospitalized and discharged before this period will continue their treatment at the Laboratory of Spirometry and Respiratory Physiotherapy (LEFIR) of the Federal University of São Carlos. The intervention will also perform for at least 5 continuous days. The ideal elastic band for the training will be chosen through the test of 10 maximum repetitions. The test and the training will be performed in an ergonomic chair allowing the lower limbs to remain pending. After 24 hours of the test, patients will perform knee extension exercise with the appropriate elastic band. Three sets of 10 repetitions will be done in each exercise, with a minimum rest interval of 1 minute between sets or until heart rate values return to baseline. Patients will be re-evaluated 1 and 3 months after the first contact.
1478461|NCT03131726|Drug|Simvastatin 40mg|see arm description
1478462|NCT03131726|Drug|Diclofenac Potassium 50 MG|see arm description
1478463|NCT03131713|Drug|Acetaminophen|Acetaminophen 1000mg
1478464|NCT03131700|Biological|RPH001|Avastin® has been approved for treatment of various cancers in many countries of the world including the USA, EU countries, and Turkey. In Turkey, Avastin® is approved with a different trade name, Altuzan®, for treatment of metastatic colorectal cancer.
1478465|NCT03131700|Biological|Avastin®|R-Pharm created a biological analog of Avastin®, RPH-001. RPH-001 and Avastin® have similar physicochemical properties, pharmacokinetic profile and affinity to human vascular endothelial growth factor, similar toxicity and efficacy confirmed by preclinical study results.
2000834|NCT03323593|Drug|Dexmedetomidine|blood is sampled for quantification of plasma concentration after intravenous, intranasal by atomisation and intranasal by drops.
2000835|NCT03323580|Other|SVV-based GDFT|Target SVV will be titrated with fluid bolus, and thus individual amount varied depending on the SVV value at that time. Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as minimal cardiac indices, mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
1478469|NCT03131674|Other|Cervical physical therapy|Patients receive a multimodal cervical physical therapy treatment
1478472|NCT03131635|Behavioral|Developmental Reciprocity Treatment Program (DRT-P)|Developmental Reciprocity Treatment is an early intervention that applies developmentally-informed teaching methods in naturalistic settings in order to target social and communication deficits.
1478473|NCT03131622|Behavioral|Digital Therapeutics|
1478474|NCT03131609|Other|Container|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
1478475|NCT03131609|Other|Silver Impregnated Wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
1478476|NCT03131609|Other|Funnel|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
1478477|NCT03131609|Other|Castile-soap wipe|Ambulatory patients in the Emergency Department who have a urine culture ordered by the physician receive one of four urine collection/hygiene options.
1478478|NCT03131596|Procedure|IUB dilatation therapy|A Foley catheter (size 8-12fr) will be prepared by cutting the excess catheter tip protruding beyond the balloon prior to insertion into the uterine cavity. Once the catheter has reached the fundus, 3-5mls of saline will be slowly introduced into the balloon under ultrasound guidance, in order to directly visualize the distention of the cavity and division of any intrauterine adhesions, if present.
1478479|NCT03131583|Drug|Colchicine|Day-14~Day16 qd
1478480|NCT03131583|Drug|Febuxostat|Day1 and Day8 qd
1478481|NCT03131583|Drug|SHR4640|Day3~Day8 qd
1482849|NCT03098433|Drug|Placebos|Placebo
1478482|NCT03131570|Drug|Secukinumab|Arms: Group 1 - Group 1 will receive Secukinumab at a dose of 300 mg with injections administered once weekly at baseline and at weeks 1, 2, 3, and 4 and then every 4 weeks for 6 months of period. In order to maintain the blind for the Group 2, Group 1 will receive placebo injections at weeks 13, 14, and 15. Group 1 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
1478483|NCT03131570|Drug|Placebo followed by Secukinumab|Arms: Group 2 - Group 2 will receive placebo injections corresponding to the Group 1 regimen until week 8 in order to maintain a double-dummy design until week 12. From week 12, Group 2 will receive Secukinumab with injections administered once weekly at week 12 and at weeks 13, 14, 15, and 16 and then every 4 weeks for 3 months of period. Group 2 will discontinue Secukinumab after 6 months of period being observed from week 25 to week 72 (48 weeks).
1478484|NCT03131557|Device|Line extension of the Phonak Audéo B product family|The line extension of the Phonak Audéo B product family will be fitted to the participants individual hearing loss.
1478485|NCT03131557|Device|Phonak Audéo B|Phonak Audéo B will be fitted to the participants individual hearing loss.
1478486|NCT03131544|Device|MRI Guided Transrectal Periuretheral Transitional Zone Ablation|Patients will undergo an MRI guided transrectal ablation of tissue within the periuretheral transitional zone.
1478487|NCT03131531|Other|Patient registry|Clinical data, specific procedures and treatments will follow the Institutional standard operative procedures
1478488|NCT03131518|Behavioral|Access to an e-bicycle with trailer|Participants will be provided with an e-bike with trailer for 3 months.
1478489|NCT03131518|Behavioral|Access to a longtail bicycle|Participants will be provided with a longtail bike for 3 months.
1478490|NCT03131518|Behavioral|Access to a traditional bike with trailer|Participants will be provided with a traditional bicycle with trailer for 3 months.
1478491|NCT03131492|Diagnostic Test|Blood test|C-reactive protein and PCT measured preoperatively, and on the second, fourth and sixth postoperative days.
1478493|NCT03131466|Device|High-voltage pulsed radiofrequency|The manual PRF mode of the pain treatment generator will be turned on, the upper temperature limit will be set at 42°C, the PRF output voltage will be gradually increased to the highest voltage the patient can tolerate, and the patient will be treated for 360 s. After the treatment, 1.4 ml of a mixture of 0.4 mL of normal saline and 1 mL of 1% plain lidocaine will be injected through the needle of the cannula, and before the needle being removed, 0.5 mL of normal saline will be injected.
1478494|NCT03131466|Drug|Nerve block|The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
1478495|NCT03131453|Drug|CNP520 50mg|Arm#1
1478496|NCT03131453|Drug|CNP520 15mg|Arm#2
1478497|NCT03131453|Other|Placebo to CNP520|Arm#3
1478498|NCT03131440|Behavioral|Core|The core intervention will include educational materials, access to a basic smartphone app and a Fitbit.
1478499|NCT03131440|Behavioral|Support Calls|Participants will receive 6 bi-weekly phone calls from study staff.
1478500|NCT03131440|Behavioral|App+|"Participants will receive deluxe version of smartphone app with additional features."
1478501|NCT03131440|Behavioral|Online gym|Participants will receive access to online exercise videos.
1478502|NCT03131440|Behavioral|App notifications|Participants will receive motivational app notifications
1478503|NCT03131440|Behavioral|Buddy|Participants will choose a buddy to receive a Fitbit and support them during the intervention.
1478504|NCT03131427|Drug|Standard of care|Standard of care according to the updated national and/or international guidelines
1478505|NCT03131414|Other|Diet|Dietary intake
1478506|NCT03131414|Other|Gastrointestinal microbiome|Genomic sequencing of stool for gut bacteria
1478507|NCT03131401|Diagnostic Test|Diagnosis of lymphatic filariasis|Field validation of the diagnostic performance of diagnostic tests for infection with W. bancrofti.
1478508|NCT03131401|Diagnostic Test|Diagnosis of lymphatic Filariasis and onchocerciasis|Field validation of the diagnostic performance of diagnostic tests for infection with both W. bancrofti and O. volvulus.
1478509|NCT03131401|Diagnostic Test|DEC Patch|Field validation of the diagnostic performance of diagnostic tests for infection with O. volvulus.
1478510|NCT03131388|Diagnostic Test|Access AMH Assay|
1478511|NCT03131375|Drug|Dexmedetomidine|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group A receives a 50 ml NS infusion containing 1 mcg kg-1 Dexmedetomidine drug Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B, and 0.16 mg kg-1 in Group A. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index , Train of four ratio.
1478512|NCT03131375|Drug|Normal saline|Group A and B: Anesthesia induction drugs:propofol, fentanyl, rocuronium . After induction of anesthesia: Group B receives a volume matched Normal saline infusion. Group A and B: Atropine as an antisialagogue, dexamethasone, ondasetrone for the prevention of postoperative nausea and vomiting. Anesthesia maintainance: propofol, remifentanil and oxygen in air. End of surgery, the infusion of propofol and remifentanil stop and sugammadex for reversal of neuromuscular block is given. Postoperative analgesia by nalbuphine 0.2 mg kg-1 given before the end of surgery in Group B. Monitoring: ECG, NIBP, ETCO2, SpO2, Bispectral index, Train of four ratio.
1478513|NCT03131375|Device|Bispectral index|Group A and B: Monitoring depth of anesthesia by BIS device and adjusting propofol infusion according to measurements, aiming to BIS values: 40-60
1478514|NCT03131375|Device|Train of four ratio|Group A and B: Monitoring recovery of neuromuscular function with TOF-Watch device, to ensure TOFR equals or greater than 90% at the end of the procedure
1478515|NCT03131349|Diagnostic Test|serum zinc and iron|history ,examination,investigations
1478516|NCT03131336|Drug|PeproStat|solution for local application
1478517|NCT03131336|Drug|Saline|solution for local application
1478518|NCT03131323|Procedure|• Flexible fiberopticnasopharyngoscope|"II- Equipments:
Flexible fiberopticnasopharyngoscope, 2.7 mm in diameter and fiberoptic light cable.
The camera: fitted with Three-CCD (Charged Couple Device) sensors.
A high resolution monitor.
A recording unit. III- Positioning:Infants and small children have to be held by a parent or an adult. Older children and adolescents usually tolerate office flexible nasopharyngoscopy once the procedure is explained. If office flexible nasopharyngoscopy failed because the child is not cooperative or if there is excessive secretions, general anesthesia may be required [8].
IV- Technique: Lubricant gel will be applied to the tip of the endoscope which will be now will be passed along the floor of the nose, between the inferior turbinate and the nasal septum, till it reaches the nasopharynx. Now the entire nose and the nasopharynx could be thoroughly examined and any abnormal findings could be detected and documented."
1478519|NCT03131310|Other|clinical audit|is to assess the quality of care and management of children with cardiorespiratory arrest admitted to assuit university children hospital according to the American Heart Association (AHA) Guidelines for Cardiopulmonary Resuscitation
1478520|NCT03131297|Procedure|treatment by radiofrequency|Radiofrequency might destroy fistula tract without lesion of anal sphincter.
1478521|NCT03131284|Behavioral|Intensive education|"For each well visit within the first two years of their child's life, parents are provided with oral and written information on behaviors to adopt for their child to be protected from obesity: breast feeding, feeding on demand, responsive feeding, correct time of introduction of complementary feeding, portions shaped on the child's appetite, avoiding pressing the child to eat more and rewarding or punishing the child with food, avoiding added sugar and beverages other than milk and water, practicing active game with the child, alternating protein sources correctly and avoiding protein excess. Written menus examples and coloured photos of average portions are given for complementary feeding. Parents are also provided with information about health consequences of childhood obesity."
1478522|NCT03131271|Other|cold application|In the experimental group, the researcher provided a cold application for 20 minutes by placing an ice bag to the site of the femoral catheter.
1478523|NCT03131258|Procedure|Donor Nephrectomy|48 Donor Nephrectomy Patients
2000836|NCT03323580|Other|traditional fluid therapy|Fluid therapy will be done without goal-directed SVV . Maintenance of oxygenation, hemoglobin, blood glucose, core temperature and hemodynamics, such as minimal cardiac indices, mean arterial pressure and heart rate, will be applied according to the same standard for each patient.
1478525|NCT03131206|Drug|Alectinib|"Oral, BID
Phase I: A 7-day lead-in dosing period will be administered at the start of each dose level. Each treatment cycle will be defined as 28 consecutive days.
Phase II: Participants will be treated at the RP2D identified during Phase I. Each treatment cycle will be defined as 28 consecutive days."
1478526|NCT03131193|Other|Physician|Study primary health centers will be staffed with an additional physician
1478527|NCT03131193|Other|Mid-level provider|Study primary health centers will be staffed with an additional mid-level provider
1478528|NCT03131193|Behavioral|Conditional Cash Transfer|Study participants (who are pregnant women) will receive a cash transfer conditional upon: registering for and attending antenatal care in the study clinic, giving birth in the study clinic and completing a postnatal visit with the new infant
1478529|NCT03131180|Other|Rapid Learning Healthcare System|The investigators created a Rapid Learning Healthcare System that integrates pre-specified data elements and validated surveys within the clinical workflow in order to operationalize automated research data collection and integrate predictive analytics into the electronic health record (EHR). Patients, caregivers, and physicians access data in order to make informed, shared decisions about care and align expectations about outcomes.
1478530|NCT03131167|Drug|SHP639 (n=60)|Participants are divided into groups called cohorts. There will be approximately 12 cohorts, each consisting of 7 subjects. In each cohort 5 out of 7 subjects will be assigned a specified concentration of SHP639 (0.1%, 0.3%, or 0.6%) ophthalmic solution and a specific dosing schedule (the study subjects will be instructed to insill the study drug one, two, three, or four times a day) in both eyes during the study.
1478531|NCT03131167|Drug|Placebo Comparator (n=24)|In each cohort 2 out of 7 subjects will be assigned a placebo ophthalmic solution matched to 0.1%, 0.3%, and 0.6% SHP639 ophthalmic solution and specific dosing schedule (the study subjects will be instructed to instill the study drug one, two, three, or four times a day) in both eyes during the study.
1478534|NCT03131141|Drug|BC-3781|Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
1478535|NCT03131128|Behavioral|Mindfulness-based Intervention|"Keeping mindful when selecting food.
Be aware of hunger and satiety by the body clues.
Understanding how stress affect diet and life, and learn how to cope with stress in life.
Learning to identify overeating caused by mood, social stress and specific food."
1478536|NCT03131128|Behavioral|Health Education Intervention|"Identifying improper diet patterns and attitudes
Understanding the impact of irrational cognition and attitudes on dietary behavior
Training coping skills for stresses in real life and preventing the recurrence of bulimia."
1478537|NCT03131115|Procedure|Lateral Crural Strut Graft|surgical technique as described
1478538|NCT03131115|Procedure|Bone Anchored Suspension|Surgical technique as described
1478539|NCT03131076|Diagnostic Test|IPMN follow up|Follow up with MRI and laboratory blood tests
1478540|NCT03131063|Other|Antibiotic plasma dosage|Measurement of the concentration of antibiotics administered as part of the routine care of intensive care patients
1478541|NCT03131050|Drug|Scopolamine|Intramuscular injection with scopolamine (0.3 mg/1ml,QD or Bid) during the first three days;
1478542|NCT03131050|Drug|Escitalopram|Oral escitalopram 10 mg/d throughout the total of 4 weeks treatment
1478543|NCT03131050|Drug|Saline|Intramuscular injection with saline (1ml, QD or Bid) during the first three days;
1478544|NCT03131037|Biological|AdV-tk (aglatimagene besadenovec) + valacyclovir|AdV-tk will be administered intratumorally followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
1478545|NCT03131024|Dietary Supplement|50% caloric restriction|Meals mimicking participant dietary preferences and matching North American macronutrient guidelines will be provided consisting of 50% of total caloric intake for 48 hours
1478923|NCT03127995|Radiation|NORMOFRACTIONATED|50 Gy/ 25 fractions / 5 weeks
1478546|NCT03131024|Other|Aerobic exercise|The supervised exercise session will consist of a 10-minute warm-up, 30 minutes performed at 70-75% of heart rate reserve, which corresponds to a vigorous intensity, followed by a 5-minute cool-down
1478547|NCT03131011|Other|UV fluorescent ink|"The use of UV tattoo ink results in a tattoo that is visible only under an ultraviolet light. Conventional black tattoo ink is replaced with UV ink for the application of radiotherapy dot tattoos. Handheld UV flashlights are used to make the tattoos visible for use during radiotherapy treatment set-up."
1478548|NCT03130998|Behavioral|eKnowledge Broker|The intervention is the tailored support received by a knowledge broker via technology in Group B. The eKB will: ensure relevant research evidence related to depression and smoking is transferred to the FHTs in ways that are most useful to them; develop capacity for evidence-informed decision-making at each site; and assist sites in translating evidence into local practice. These tasks will be accomplished by an initial 2-hour, virtual visit with each site and regular phone- and email-based check-ins. The specific tasks will be dictated by the needs of each site, and will create opportunity for practitioners to share their experiences with the eKB, learn new evidence, and work with the eKB on how to best implement the evidence.
2000838|NCT03323554|Device|Ustrap®|Patients will receive Ustrap® under general or loco-regional anaesthesia, by perineal approach.
1478551|NCT03130946|Device|Cryo-assisted core needle biopsy|Rotational core needle biopsy would be done under local anesthesia. A small incision would be made in the axilla and core needle biopsy be performed using a special cryo-assisted stick freeze device (Cassi II, Scion Medical Technologies, USA). The cytological and histological specimens would be sent for diagnosis.
1478552|NCT03130946|Device|FNA|FNA would be performed using a 10ml syringe with a 24 gauge needle without anesthesia.
1478553|NCT03130933|Procedure|Lower third molar surgery|"All surgical procedures were performed under local anaesthesia (alveolar nerve block) with 2% lidocaine chloride. The full-thickness mucoperiosteal flap was raised using buccal approach, adequate osteotomy was done using micromotor handpiece and bur, and third molar removal was finished using elevating instruments in the appropriate direction. Removal of bone dust, granulation tissue and broken tooth fragments were done in order to wound toileting. Gentle, sterile saline irrigation was done on the end.
Primary closure of the surgical area was done using 3-0 silk sutures."
1478554|NCT03130933|Drug|Amoxicillin 500 Mg|The tested subgroups received a prophylactic single dose of 4 x 500 Mg Amoxicillin one hour prior the lower third molar surgery.
1478555|NCT03130933|Other|Placebo|The control subgroups received a prophylactic single dose of placebo one hour prior the lower third molar surgery.
1478556|NCT03130920|Procedure|Preconditioning|"Local ischemic preconditioning (LIPC) is process during which a short period of ischemia is followed by a period of reperfusion prior to the prolonged ischemia which seems to render organs more tolerant to the IR(ischemic-reperfusion) injury.
Remote ischemic preconditioning (RIPC) involves the protection of an organ from prolonged ischemia by brief periods of ischemia and reperfusion to a remote organ."
1478557|NCT03130907|Device|Placement of ureteral stent|will randomize groups to either receive a postoperative ureteral stent or not.
1478558|NCT03130894|Other|Plasma TMAO concentration|Plasma TMAO concentration
1478559|NCT03130881|Drug|PLB1003|PLB1003 is a capsule and is administered orally.
1478560|NCT03130868|Other|Characterizing changes in the microbiome|Analyzing the microbial content from stool samples
1478561|NCT03130855|Drug|inferior alveolar nerve block with 4% articaine|an anesthetic technique using 4% articaine anesthetic solution
1478562|NCT03130855|Drug|buccal infiltration with 4% articaine|anesthetic technique using 4% articaine anesthetic solution
1478563|NCT03130842|Drug|Sublingual alprazolam|Patients receive one dose of oral formulation of alprazolam 0.5 mg for sublingual-administered at least 30 minutes before the procedure.
1478564|NCT03130842|Drug|Oral midazolam|Patients receive one dose of intravenous formulation of alprazolam 7.5 mg for oral-administered (in syrup with apple juice) at least 30 minutes before the procedure.
1478565|NCT03130829|Dietary Supplement|Oligo Fucoidan|Oral, twice daily
1478566|NCT03130829|Dietary Supplement|Placebo|Oral, twice daily
1478567|NCT03130816|Biological|allogeneic cord blood transplantation|UCB with total nucleated cell count ≤ 7x108/kg will be used for this clinical trial. Suitable UCB (i.e., containing total nucleated cell count ≥2x107/kg with three or less mismatch among HLA-A, -B, and -DR) will be selected. This criterion was selected upon the rationale that even though minimal HLA mismatch is preferred, prior studies indicate significant effects of UCB therapy for patients with 3 HLA mismatches.
1478568|NCT03130803|Behavioral|Insufficient Sleep|2 days with 5 hour sleep opportunity per day
1478569|NCT03130790|Drug|Varlitinib|300mg, oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
1478570|NCT03130790|Drug|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
1478571|NCT03130790|Drug|Placebo|oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
1478572|NCT03130790|Drug|mFOLFOX6|concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
1478573|NCT03130777|Device|Edwards Alterra Adaptive Prestent with SAPIEN 3 THV|The Edwards Alterra Adaptive Prestent is designed to provide a simple and safe way to reduce the diameter of these large irregular RVOTs and provide a circular, semi-rigid landing zone to place an Edwards SAPIEN 3 THV.
1478574|NCT03130764|Drug|Durvalumab|1500 mg, IV over 1 hour Every 4 weeks for 1 year
1478575|NCT03130764|Drug|Tremelimumab|75 mg, IV over 1 hour Every 4 weeks for 4 doses
1948749|NCT01742117|Drug|Ticagrelor|Subjects will receive Ticagrelor, one 90 mg tablet twice per day by mouth.
1948750|NCT01742117|Genetic|Retrospective Genotype testing|Mayo Clinic will use ABI TaqMan assay of three variants in the CYP2C10 gene: *2, *3 and *17
1997889|NCT01849783|Drug|thalidomide|Given PO
1478577|NCT03130738|Drug|7-Day Miconazole Oil|7 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
1478578|NCT03130738|Drug|14-Day Miconazole Oil|14 days of 2x per day treatment with Miconazole Oil (Active Drug Product 2% Miconazole)
1478579|NCT03130738|Drug|14-Day Placebo - Oil Vehicle|14 days of 2x per day treatment with Placebo - Oil Vehicle, Study Drug base without active ingredient
1478580|NCT03130725|Procedure|Amalgam sealant|Amalgam sealant placed on incipient enamel caries and deep enamel fissures.
1478581|NCT03130725|Procedure|Resin based sealant|Resin based sealant placed on incipient enamel caries and deep enamel fissures.
1478582|NCT03130712|Drug|GPC3-CART cells|Intratumol injection as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
1478583|NCT03130699|Behavioral|Dulce Digital|One-size-fits-all educational text messages, with patient monitoring and transmission of blood glucose values.
1478584|NCT03130699|Behavioral|Dulce Digital-Me (Automated Delivery)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered via automated algorithm-driven messaging, incorporated into existing primary care team processes.
1478585|NCT03130699|Behavioral|Dulce Digital-Me (Medical Assistant)|Educational text messages, with patient monitoring and transmission of blood glucose values, plus personalized goal-setting and tailored feedback delivered by Medical Assistants, incorporated into existing primary care team processes.
1478586|NCT03130686|Device|OMRON blood pressure monitor HEM-9210T|To measure systolic blood pressure, diastolic blood pressure and pulse rate in patients.
1478587|NCT03130660|Device|Ultrasonography|Ultrasound guidance for central line
1478588|NCT03130647|Device|Focused ultrasound|Focused ultrasound
1478589|NCT03130634|Drug|Silymarin|During six cycles of FOLFIRI chemotherapy, the patients will take silymarin (150mg) three times daily from day 1 to day 7 during one cycle of treatment.
1478590|NCT03130621|Diagnostic Test|Gene detection|Next-generation sequencing
1478591|NCT03130608|Other|Inspiratory Muscle Training|Subjects will breath through a hand held valve that has adjustable resistance to strengthen the muscles used for breathing. Subjects will perform the exercise approximately 20-30 minutes, twice a day for 8 weeks.
1478592|NCT03130582|Drug|high-dose etoposide|an epipodophyllotoxin, is one of the most common chemotherapy agents for lymphoma without reciprocal resistance with other kinds of agents.
1478593|NCT03130569|Behavioral|Web-based Module Group|
1478594|NCT03130556|Drug|Glasdegib|Subjects receive 100 mg single dose of ICH glasdegib under fasted condition with washout and then 100 mg single dose of Phase 2 tablet under fasted condition with washout in a randomized fashion. Finally subjects either receive a 100 mg single dose ICH tablet after a high fat, high calorie meal or receive a 100 mg single dose of ICH tablet after repeated daily dosing with rabeprazole.
1478595|NCT03130556|Other|High Fat, High Calorie Meal|A subset of subjects in the study will receive a high fat, high calorie meal prior to being administered a single 100 mg tablet ICH tablet of glasdegib.
1478596|NCT03130556|Drug|Rabeprazole|A subset of subjects will receive repeated daily dosing of 40 mg rabeprazole for 7 days with 100 mg single dose of ICH glasdegib being administered on Day 7.
1478597|NCT03130543|Dietary Supplement|Rice cereal|Standard formula thickened with rice cereal
1478598|NCT03130543|Dietary Supplement|Enfamil AR|Enfamil AR formula
1478599|NCT03130517|Drug|intravenous immunoglobulin|giving intravenous immunoglobulin to neonates included in inclusion criteria in a dose of 0.5-1 gm
1478600|NCT03130504|Drug|17α hydroxy progesterone caproate|where patients will have a 17α hydroxy progesterone caproate intramuscular injection every week starting from 24 weeks of gestation till completed 37 weeks
1478601|NCT03130491|Procedure|Transcatheter Aortic Valve Replacement (TAVR)|placement of a filter to capture and remove embolic material from entering the cerebral vascular circulation during aortic valve replacement
1478602|NCT03130491|Device|EMBLOK filter|Embolic Protection System During TAVR
1478603|NCT03130452|Drug|Lansoprazole 30mg|lansoprazole 30 mg tablet
1478604|NCT03130452|Drug|Amoxicillin 1.0g Tab|Amoxicillin 1.0g tablet
1478605|NCT03130452|Drug|Clarithromycin 500mg|Clarithromycin 500mg tablet
1478606|NCT03130452|Drug|Metronidazole 500 mg|Metronidazole 500 mg tablet
2000839|NCT03323554|Device|AMS 800®|Patients will receive AMS 800® under general or loco-regional anaesthesia. Small openings are made near the scrotum and below the abdomen to insert an inflatable cuff, a pump and a small balloon (pressure regulating balloon).
1478608|NCT03130426|Drug|iGlarLixi|Dose is titrated to achieve fasting normoglycemia
1478609|NCT03130426|Drug|Insulin Glargine|In those who need additional insulin or who cannot tolerate iGlarLixi, insulin glargine will be used. Dose is titrated to achieve fasting normoglycemia.
1478610|NCT03130426|Drug|Metformin|Dose is titrated to 2000 mg daily or maximal tolerated dose
1478611|NCT03130426|Behavioral|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
1478612|NCT03130413|Device|Ambu Aura Gain supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Ambu Aura Gain is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
1478649|NCT03130127|Drug|Terlipressin|According to the current practice guidelines and consensus, terlipressin is the standard treatment option for acute variceal bleeding in liver cirrhosis.
1478650|NCT03130114|Drug|Azithromycin|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 10 mg (0.35 ml) / kg of azithromycin syrup per day, for three days
1478613|NCT03130413|Device|Air-Q supraglottic airway|Anesthesia is induced with sevoflurane in oxygen. The anesthesia plane is gradually deepened by increasing the inspired concentration of sevoflurane (2-8%) till the loss of eyelash reflex. After intravenous (IV) cannula is inserted and intravenous fentanyl 1mcg/kg and rocuronium 0.6mg/kg are administered. Use of neuromuscular blocking agent is to minimize the risk of reflex activation of the airway. After 3 minutes, the appropriate size (depending upon body weight) of Air-Q supraglottic airway is lubricated with water soluble lubricant (KY jelly) is inserted by investigator based on manufacturer recommendation with the patient's head in neutral position. The cuff then is inflated to an intra-cuff pressure of 40 cm H20, measured using a digital cuff pressure monitor.
1478614|NCT03130400|Procedure|Observational gait analysis procedure|All the participants underwent a standard observational procedure: i) diagnosed with knee injuries/arthritis; ii) For KOA, take radiographic examination (x-ray) and take gait analysis on a treadmill in barefoot; iii) For knee injuries, take gait analysis before surgery, the disease of patients was confirmed by surgery (knee arthroscopy); iv)Normal people take an physical examination to avoid other disease;
1478615|NCT03130387|Device|Office Hysteroscope|Diagnosis of C.S niche in patients wit AUB by office hysteroscope
1478616|NCT03130374|Biological|Olfactory mucosa-derived mesenchymal stem cells|Olfactory mucosa-derived mesenchymal stem cells
1478617|NCT03130361|Device|Non-Invasive Ventilation|
2000841|NCT03323528|Drug|Benzalkonium Chloride-Benzocaine Topical|Dorithricin = tyrothricin, benzalkonium chloride, benzocaine
1478624|NCT03130322|Other|Imagery and Sleep questionnaires|Participants complete a motor imagery questionnaire to assess their ability to form vivid mental images, as well as sleep questionnaires to control the quality of their sleep
1478625|NCT03130322|Other|MEG recordings (pre-test)|"Participants of the Day group perform two motor tasks (a finger sequential motor task and an adaptation motor task using a trackball) in the MEG, during a pre-test (Day 1 - 9h).
Task 1: Participants perform an 8-digit motor sequential task where each finger (except the thumb) is used twice. Performance is assessed by using a 4-keys keyboard. Participants are required to keep their fingers on the keys to minimize amplitude are instructed to tap the sequence as few errors as possible Task 2: Participants perform a motor adaptation task requiring scrolling a trackball to superimpose a geometric shape on another one, strictly similar but presented from another angle, as fast as possible."
1478626|NCT03130322|Other|Practice session|Participants of the Day group perform a block of motor imagery practice of the two motor tasks.
1478627|NCT03130322|Other|MEG recordings (Post-test)|Participants perform the two motor tasks in the MEG (post-test, strictly similar to the pre-test)
1478628|NCT03130322|Other|MRI|The registration of the brain anatomy of each participant will be done by MRI 3D / T the week before the first experimental session.
1478629|NCT03130283|Other|Home Hospitalization|Visit every 24 hours
1478630|NCT03130283|Other|Conventional Hospitalization|No intervention
1478631|NCT03130270|Drug|Apatinib mesylate tablet|"Patients with locally recurrent or metastatic nasopharyngeal carcinoma (NPC) after second-line treatment are assigned to receive apatinib mesylate tablet. A treatment cycle was defined as 28 days (4 weeks). The starting dose was 500 mg, orally, qd; tolerance assessment for a cycle, patients with poorly tolerance were treated with low dose (500 mg, qd), and patients with well tolerance were treated with high dose (750 mg, qd). All patients continuous treatment until progression disease or non-tolerated toxicity.
Note: good tolerance was defined that no grade 3/4 hematology or/and non hematologic side effects occurred within 4 weeks after initiation treatment; poor tolerance was defined that grade 3/4 hematology or/and non hematologic side effects appeared within 4 weeks after initiation treatment."
1948751|NCT01742117|Genetic|Prospective Genotype testing|Rapid turnaround Spartan^TM Bioscience in vitro diagnostic assay for analysis of three variants in the CYP2C19 gene: *2, *3 and *17
1478633|NCT03130244|Device|Incisionless Magnet Anastomosis System|The IMAS will be placed using an endoscope in the jejunum and ileum. A compression anastomosis will be created in each of the patients and the diversion of enteral flow from the jejunum to ileum treats Type 2 diabetes.
1478634|NCT03130244|Drug|Best Medical Management|The best medical management for the patients in this arm will be decided by the endocrinologist based on protocol parameters.
1478635|NCT03130218|Other|Peppermint oil aromatherapy|Aroma therapy with peppermint oil administered with presoaked diffuser and bag.
1478636|NCT03130205|Procedure|Core Needle Biopsy|Core Needle Biopsy is performed from liver metastasis.
1478637|NCT03130205|Radiation|Computed Tomography|Computed Tomography
1478638|NCT03130205|Radiation|18F-FDG-PET|18F Fluorodeoxyglucose Positron emission tomography
1478639|NCT03130205|Procedure|Phlebotomy|3 EDTA tubes drawn from peripheral vein
1478640|NCT03130205|Genetic|Molecular genetic analysis|Performed on biomaterial from peripheral vein and core needle biopsy
1478641|NCT03130179|Drug|Nicorette Strongmint lozenge 4 mg|A single dose of one Nicorette lozenge 4mg lozenge administrated orally to slowly dissolve in the mouth.
1478642|NCT03130179|Drug|Niquitin MiniMint lozenge 4 mg|A single dose of one Niquitin Minimint lozenge 4mg administrated orally to slowly dissolve in the mouth.
1478643|NCT03130166|Procedure|Intracorporeal anastomosis|Use of intracorporeal anastomosis technique
1478644|NCT03130166|Procedure|Extracorporeal anastomosis|Use of the conventional extracorporeal anastomosis technique
1478645|NCT03130153|Drug|Aspirin Pwdr|Aspirin powder to be dissolved in water and to be used as mouthwash twice daily for 7 days after tooth extraction.
1478646|NCT03130153|Drug|Normal saline|Normal saline to be used as mouthwash twice daily for 7 days after tooth extraction among non-hypertensive subjects.
1478647|NCT03130140|Procedure|Macroscopic on-site evaluation|Macroscopic on-site evaluation: any aspirated material on a glass slide for inspection of the presence of a macroscopic visible core (MVC). Length of MVC will be measured to determine the adequacy of that puncture.
1478648|NCT03130140|Other|Control|Conventional EUS-FNA
1478753|NCT03129113|Drug|Metformin|1:1:1:1 randomisation to one of four arms for 48 weeks
1948752|NCT01740037|Other|Specialized AF Clinic|
1478651|NCT03130114|Other|Placebo|Participants will receive rehydration, dietary counseling, one 20 mg tablet of zinc per day and 0.25 ml / kg of placebo drug syrup per day, for three days
1478652|NCT03130101|Other|Change in their basal insulin rate|Individual with type 1 diabetes on insulin pump therapy typically lower their basal insulin delivery for exercise. This study will compare 3 common strategies of basal insulin reductions for 75 minutes of aerobic exercise.
1478653|NCT03130088|Other|no intervention planed|no intervention planed
1478654|NCT03130062|Other|Exercise|The following muscular clusters were exerted: latissimus dorsi, deltoid, pectoralis major , triceps brachialis, biceps brachialis, quadriceps, hamstring, thigh adductor muscles, thigh abductor muscles and gastrocnemius.
2000842|NCT03323528|Drug|Placebo Oral Tablet|"Placebo Oral Tablet = a lozenge with matched appearance and the same excipients as Active Comparator Dorithricin lozenge.
Intervention: Patients are instructed to administer at home 1 lozenge at intervals of 2 hours (±15 minutes) up to a maximum of 8 lozenges per day."
2000843|NCT03323502|Behavioral|ACP Specialist Program|New structured role with responsibility for ACP
2000844|NCT03323489|Radiation|Celiac Plexus Radiosurgery|patients will receive a single radiation treatment of 25 Gy directed towards the celiac surgery, and at the physician's discretion also abutting tumor
1478658|NCT03130023|Device|Pulse Oximeter with ORI|Pulse oximeter that measure Oxygen Reserve Index
1478659|NCT03130010|Drug|Nefopam or saline|One hour before the end of the operation, the Nefopam group was received 20 mg of nefopam and the saline and the control group was received 20 ml of saline.
1478660|NCT03129997|Dietary Supplement|Gluten test food|Dietary supplement: corn muffins with 7.5g of gluten/muffin Two muffin were blindly administered for 21 days
1478661|NCT03129984|Device|Mandibular movement tracking|Patients wore the Brizzy device while sleeping. Mandibular movements (A mid-sagittal mandibular movement magnetic sensor measured the distance in mm between two parallel, coupled, resonant circuits placed on the forehead and chin.) were tracked during sleep.
1478662|NCT03129971|Procedure|conventional surgery|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to control group, which received conventional surgery.
1478663|NCT03129971|Procedure|autologous platelet-rich plasma|Patients with atrophic nonunion of femoral shaft fractures are equally and randomly assigned to experimental group, which are injected with autologous platelet-rich plasma on the basis of conventional surgery.
1478664|NCT03129945|Drug|Nifedipine|Subjects will be given nifedipine 10mg orally and repeated every 20 minutes for a maximum dose of 30mg in the first hour followed by 20mg every 6 hours for the first 48 hours.
1478665|NCT03129945|Drug|Indomethacin|Those randomized to indomethacin will be given 100mg orally as a loading dose followed by 50mg every 6 hours for the first 48 hours of treatment.
1478666|NCT03129932|Dietary Supplement|gluten phase|2 cakes containing 9g of vital gluten/each will be consume during the 4 weeks of intervention
1478667|NCT03129932|Dietary Supplement|placebo phase|2 cakes without gluten will be consume during the 4 weeks of intervention
1478668|NCT03129919|Device|Carriere SLX® (Passive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
1478669|NCT03129919|Device|Empower® (Interactive self-ligating braces)|Changes in the inclination of the incisors, expansion of the arches at the end of the alignment and leveling phase of the orthodontic treatment
1478670|NCT03129906|Dietary Supplement|Gluten|
1478671|NCT03129906|Dietary Supplement|Rice protein|
1478672|NCT03129893|Device|Cuffed tracheal tubes|Cuffed tracheal tube with an anatomically designed high volume - low pressure tube cuff, with a recommendation chart for tube size selection available for pediatric anesthesia
1478673|NCT03129880|Behavioral|Weekly Voice Therapy|Participants will be randomized to receive weekly voice therapy
1478674|NCT03129880|Behavioral|Intensive Voice Therapy|Participants will be randomized to receive multiple sessions of voice therapy in one day.
1478675|NCT03129867|Drug|Ticagrelor|Ticagrelor 60mg or 90 mg as routine use of each Center
1478676|NCT03129854|Device|prostate cryotherapy|prostate cryotherapy added to experimental group within 6 months of ADT
1478677|NCT03129841|Behavioral|Early dinner+Diet|Subjects are asked to eat dinner meal between 7:00- 7:30 PM in ED group, while they are on a multidisciplinary weight loss plan for 12 weeks.
1478678|NCT03129841|Behavioral|Late dinner+Diet|Subjects are asked to eat their dinner meal between 10:30-11:00PM, while they are on a multidisciplinary weight loss plan for 12 weeks.
1478679|NCT03129828|Drug|Ibrutinib and Bortezomib + R-CHOP|A pre-phase therapy with Prednisone 100 mg p.o. is mandatory from d-4 until d0. Patients receive 6 cycles of a combined immunochemotherapy with the anti-CD20 antibody Rituximab (375 mg/m2 d0 or d1) together with 6 cycles of a chemotherapy consisting of Cyclophosphamide (750 mg/m2 d1), Doxorubicin (50 mg/m2 d1), Vincristine 1 mg absolute d1), Prednisone (100 mg absolute p.o. d1-5) and Bortezomib s.c. (1.3 mg/m2 C1 on d3 and 8, other cycles d1 and d8), in 21-day intervals and Ibrutinib 560 mg p.o. (from d6 of C1 until d21 of C6), followed by two additional 3-week cycles of Rituximab (375 mg/m2).
1478680|NCT03129789|Other|Volumetric Bladder Ultrasound Training|teaching residents to perform bladder volumetric ultrasound
2000845|NCT03323476|Other|Discontinuation (or not initiation) of Immunosuppressive Therapy|Discontinuation (or not initiation) of Immunosuppressive Therapy
2000846|NCT03323476|Drug|Maintenance (or initiation) of immunosuppressive treatment: Imurel®, Mabthera®,Cellcept®, Cortancyl®|Maintenance (or initiation) of Immunosuppressive Therapy: Imurel®, Mabthera®,Cellcept®, Cortancyl®
1478683|NCT03129763|Behavioral|60mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 60mmHg.
1478684|NCT03129763|Behavioral|70mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 70mmHg.
1478685|NCT03129763|Behavioral|80mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 80mmHg.
1478686|NCT03129763|Behavioral|90mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 90mmHg.
1478687|NCT03129763|Behavioral|100mmHg capsule pressure expansion|With a self-made apparatus composed of a spring-loaded sphygmomanometer and a disposable three-way pipe, the capsule pressure is measured. Increasing capsule pressure till 100mmHg.
1478688|NCT03129750|Device|Drug Coated Balloon|Peripheral PTA with a drug coated balloon
1478689|NCT03129737|Procedure|Mitral valve surgery|Mitral valve repair is preferred whenever technically feasible over valve replacement. Annuloplasty may be used as sole therapy or in conjunction with other repair maneuvers to support the reconstruction and reinforce the annulus as well as prevent future annular dilatation. The mitral regurgitation secondary to myxomatous degeneration is prolapse of the middle scallop of the posterior leaflet result from chordal rupture or chordal elongation. Quadrangular resection of the involved middle scallop of the posterior leaflet combined with a posterior mitral annuloplasty is the best way to handle this situation. Chordae replacement could be used also to treat flail/prolapse of the anterior leaflet. Annuloplasty is always doing in mitral valve repair to stabilize and reshape the annulus.
1478690|NCT03129737|Procedure|Tricuspid valve annuloplasty|Depending on the extent of the valve disease, there is the possibility to perform valve repair. In mitral valve reference center the rate of repair will reach 100%. In many patients with mitral valve regurgitation, tricuspid valve will be insufficient or the annulus dilated. Tricuspid annuloplasty ring will be helpful to treat dilation by reshaping, or to treat the regurgitant diseases. The ring will be secured and sutured to the native annulus by U-stitches.
1478691|NCT03129711|Other|glazed Celtra Duo|zirconia reinforced lithium silicate
1478692|NCT03129711|Other|IPS Empress CAD|Standard etchable glass ceramic for laminate veneers
1478693|NCT03129698|Drug|Apatinib|Apatinib 250mg daily
1478694|NCT03129685|Procedure|ILAD|This is attained via a laparotomy involves isolation of the arterial blood supply of the tumor-containing liver lobe (the ipsilateral hepatic artery as well as the extrahepatic arterial collaterals) while preserving the feeding veins.
1478695|NCT03129672|Procedure|allograft arthrodesis of ankle|patients that underwent trought a block resection of a malignant tumor of the distal tibia and reconstruction with allograft arthrodesis
1478696|NCT03129659|Diagnostic Test|Coronary CT Angiography|Coronary CT angiography
1478697|NCT03129646|Drug|Miltefosine|Miltefosine 10mg and 50mg capsules
1478698|NCT03129646|Drug|Paromomycin|Paromomycin sulfate equiv to 750mg paromomycin / 2ml amp
1478699|NCT03129646|Drug|Sodium stibogluconate|Sodium stibogluconate 33% 30 ml inj.
1478700|NCT03129633|Other|Intervention group|One-on-one contact with a promotor(a) over the 6 month intervention.
1478701|NCT03129594|Diagnostic Test|plasma glucagon-like peptide-1 levels|The plasma GLP-1 levels was determined by enzymatic assays.
1948753|NCT01740037|Other|Usual Care|
1478703|NCT03129568|Biological|CDC infusion|Injection of CDCs (0.3 million per kg of body weight).
1478704|NCT03129555|Drug|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
1478705|NCT03129555|Drug|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
1478706|NCT03129555|Drug|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
1478707|NCT03129555|Drug|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with venous thromboembolism when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
1478710|NCT03129529|Device|Focused shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
1478711|NCT03129529|Device|Radial shock wave|The outcome evaluation include ankle range of motion (ROM), modified Ashworth scale (MAS),modified Tardieu scale (MTS), baropodometric measurement, and gait speed.
1478712|NCT03129516|Behavioral|Determining Imaginary levels|Determining the motor imaginary: internal visual, external visual and kinesthetic imagery
1478713|NCT03129490|Drug|Dabigatran Etexilate Oral Capsule|After cluster randomization, the cluster will use dabigatran to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
1478714|NCT03129490|Drug|Rivaroxaban Oral Tablet|After cluster randomization, the cluster will use rivaroxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
1478715|NCT03129490|Drug|Edoxaban Oral Tablet|After cluster randomization, the cluster will use edoxaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
1478716|NCT03129490|Drug|Apixaban Oral Tablet|After cluster randomization, the cluster will use apixaban to all their patients with non-valvular atrial fibrillation when possible for six months. Hereafter the cluster will use the other three NOACs for six months one at the time. It is the clusters and not the patient that are randomized.
1997890|NCT01849783|Drug|melphalan|Given IV
1997891|NCT01849783|Procedure|autologous stem cell transplant|
1478717|NCT03129477|Procedure|Telemonitoring in noninvasive ventilation|Compare telemonitoring to conventional monitoring to optimize Ventilation
1478718|NCT03129464|Device|Cold therapy via reusable cold gel pack|Patients in the experimental group will be asked to apply cold therapy to their abdominal incisions every 6 hours for the first 72 hours following their surgery (total laparoscopic hysterectomy). Cold therapy will be applied via a reusable cold gel pack.
1478719|NCT03129451|Diagnostic Test|Microbiome specimens in stool|Analyzing Microbiome specimens in stool
1478720|NCT03129438|Diagnostic Test|continuous EEG (cEEG)|differential use of continuous versus routine EEG
1478721|NCT03129438|Diagnostic Test|routine EEG (rEEG)|differential use of continuous versus routine EEG
1478722|NCT03129425|Behavioral|ReNACE Psychoeducational Intervention|9 sessions in groups of 15-20 people at most so as to promote reflection and facilitate the interchange of opinions between participants about issues of interest from their day to day experience of coping with Parkinson's disease.
1478723|NCT03129425|Other|General Educational Program|5 sessions in groups of 15-20 people
1478724|NCT03129412|Radiation|radical radiotherapy|radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.
1478725|NCT03129399|Device|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
1478726|NCT03129399|Device|McGrath MAC video laryngoscope|nasal intubation with McGrath MAC video laryngoscope Device after general anesthesia induction
1478727|NCT03129373|Device|Cryogenic treatment of warts|Treatment of common and plantar wart by cryotherapy treatment.
1478728|NCT03129360|Drug|Levetiracetam|Levetiracetam is an atypical anticonvulsant that is frequently used in children and adults due to its superior tolerability, ease of use and excellent safety profile.
1478729|NCT03129347|Drug|Nalmefene|Comparing pharmacokinetics of intranasal nalmefene to intramuscular nalmefene
1478730|NCT03129334|Behavioral|LST Middle School Online|The adapted intervention will (1) utilize both online e-learning module (self-guided) and classroom-based sessions (facilitator led) to address PDA and concurrent ATOD abuse; (2) positively change social norms and challenge positive expectancies regarding PDA and ATOD abuse; (3) discourage diversion of prescription medications; (4) enhance protective factors by building social and self-regulation skills through interactive learning and behavioral rehearsal scenarios; and (5) incorporate booster sessions.
1478731|NCT03129321|Drug|Econazole Nitrate Cream, 1%|
1478732|NCT03129321|Drug|Placebo|
1478733|NCT03129308|Diagnostic Test|Blood Sampling|4.5ml of blood will be collected and analyzed for the presence of cutaneous autoantibodies (indirect immunofluorescence, desmoglein1/3, BPAG1/2, collagenVII, and envoplakin ELISA)
1478734|NCT03129295|Drug|MPC-SHRC|Oral tablet four times a day for 3 days
1478735|NCT03129295|Drug|Placebo Oral Tablet|Oral tablet four times a day for 3 days
1478736|NCT03129282|Other|Home-based Metacognitive Therapy (Home-MCT)|Home-based metacognitive therapy (Home-MCT) is a facilitated self-help manual comprising six modules which participants will complete at their own pace over approximately 6 weeks. Participants will have an initial appointment with a Home-MCT trained cardiac rehabilitation staff members (face to face or by telephone). In addition, they will receive two telephone calls from trained cardiac rehabilitation staff members over the course of the intervention to offer support with completing the modules of the self-help manual.
1478737|NCT03129269|Procedure|MRI and PET scan|Neuroimaging with MRI and PET scan Amyloid tracer : For PET-scans, 4 MBq/kg of [18F]AV-45 will be injected into each subject in an intravenous bolus.
1478738|NCT03129256|Drug|Apatinib Mesylate tablet combined with S-1 capsules|Oral use with low-dose Apatinib combined with S-1 until disease progression
1478739|NCT03129243|Diagnostic Test|Sperm DNA integrity by flow cytometry|flowcytometric test where sperm DNA breaks are evaluated indirectly through the DNA denaturability. The assay measures the susceptibility of sperm DNA to acid-induced DNA denaturation in situ, followed by staining with the fluorescence dye acridine orange. By using a flow cytometer 5.000-10.000 sperm can be analyzed within few seconds and thus provide a less subjective result compared to the World health organization analysis where only 1-300 cells are analyzed.
1478740|NCT03129230|Procedure|free nonvascularized fibula autograft|Sixteen pediatric patients before epiphyseal closure were treated with free nonvascularized fibula autograft after resections of tumor-like lesions in the femoral neck between Aug. 2012 and Sep. 2016. All the patients were given supplementary skeletal traction through supracondyle of femur for 4 weeks to 6 weeks after the resections.
1478742|NCT03129191|Device|Non-invasive bone conduction hearing aid A|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an elastic headband.
1478743|NCT03129191|Device|Non-invasive bone conduction hearing aid B|The intervention is a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.
1478745|NCT03129165|Other|Screening and prevention of CVD|"Drug: Pharmacological control of risk factors in agreement with primary physicians.
Behavioral: Smoking cessation / Control of depression and anxiety / Nutritional counseling / Motivation for physical activity.
Social: Social worker care."
1478746|NCT03127891|Behavioral|pranayama yoga|providing short term pranayama yoga for 5 sessions before surgery patients under going cardiac surgery.
1478747|NCT03127891|Other|control group|no intervention should be given to patients allocated to this group
1478748|NCT03127878|Other|Exercise|
1478750|NCT03129126|Drug|Placebo|Placebo, normal saline
1478751|NCT03129126|Drug|LP-10|Intravesical tacrolimus
1478752|NCT03129113|Drug|Maraviroc|1:1:1:1 randomisation to one of four arms for 48 weeks
1478756|NCT03129087|Behavioral|Vocal rest versus vocalization|A comparison of one hour of vocal rest versus continuous vocalization after botulinum toxin injection
1478757|NCT03129074|Drug|Varlitinib|everyday
1478758|NCT03129074|Drug|Capecitabine|from Day 1 to Day 14 followed by 7-day of rest period, every 21 days.
1478759|NCT03129061|Drug|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"Baseline: Blood sampling, tumor biopsy, [18F]F-AraG PET/CT scan within two weeks prior to standard of care anti-PD-1 therapeutic dose.
Anti PD-1 per standard of care
Blood sampling and tumor biopsy within 2-3 weeks after first anti-PD-1 SOC dose.
[18F]F-AraG PET/CT scan 6 - 12 weeks post first anti-PD-1 dose."
1478760|NCT03129061|Drug|[18F]F-AraG PET Scan, baseline + post anti-PD-1 therapy.|"Baseline: Blood sampling, tumor biopsy, [18F]F-AraG PET/CT scan within two weeks prior to treatment.
Anti PD-1, single dose
Blood sampling, tumor biopsy and [18F}F-AraG PET/CT scan within 2-3 weeks after single dose of anti-PD-1 treatment. For patients having surgical resection, biopsy will be immediately prior to resection or from sample of resection."
1478761|NCT03129048|Behavioral|MedDiet|"Research subjects will be randomly assigned to one of three intervention groups.
The MedDiet-A group will learn about and how to adhere to the Mediterranean Diet. Over the course of 8 months, they will receive twenty-two classes 60-minute in length.
The MedDiet-WL group will learn about the Mediterranean Diet, how to adhere to is and engage in lifestyle choices like exercising and eating fewer calories so that they will loose weight. Over the course of 8 months they will receive 22 classes, each 90 minutes in length.
The Typical Diet Control group will be asked to maintain current eating and activity patterns over the course of the 14 month study."
1478762|NCT03129035|Procedure|Cesarean hystrectomy|Upper segment cesarean section followed by fetal extraction and cesarean hystrectomy started without any attempts of placental removal
1478763|NCT03129035|Procedure|Internal iliac artery ligation|The retroperitoneal space was entered at the level of common iliac bifurcation and followed to the point of division into the external and internal iliac arteries. The ureter was retracted medially by gentle finger dissection, revealing the retroperitoneal anatomy. The fat and loose connective tissue around the IIA and vein were removed and a right-angle clamp was passed beneath the IIA from the lateral to the medial side approximately 4 cm distal to its origin. Using an absorbable suture, the IIA was ligated doubly in all cases . Pulsations of the external iliac and femoral arteries were identified after internal iliac ligation. The procedure was then repeated on the other side
1478764|NCT03129022|Procedure|epidural anaesthesia|Women requesting epidural analgesia received a bolus of intravenous infusion of lactated Ringer's solution before initiation of the procedure. An 18-gauge Tuohy needle and closed-tip clear catheter with three lateral orifices were used in the sitting or lateral position, with a loss-of-resistance to air technique. Epidural catheters were routinely inserted 5-6 cm inside the epidural space. A test dose of 2 ml of lidocaine 2% was initiated followed by a loading dose of 10 ml of bupivacaine 0.25%. Analgesia is maintained throughout labor using 0.125% bupivacaine with fentanyl 2 μg/ml with patient-controlled epidural analgesia by means of a continuous epidural infusion (8 ml/h basal rate) and patient-controlled boluses (3 ml each) with 20-minlock-out intervals
1478765|NCT03129009|Drug|Total intravenous anesthesia group|Total intravenous anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with propofol,cisatracurium and remifentanil target controlled infusion
1478766|NCT03129009|Drug|Balanced anesthesia group|Balanced anesthesia induced with sufentanil,etomidate,cisatracurium and midazolam and maintained with cisatracurium and remifentanil target controlled infusion and sevoflurane inhalation
1478767|NCT03128996|Drug|RIC regimen|Days -60 to -21: hydroxyurea (30mg/kg/day po) >6hrs prior to 1st dose: alemtuzumab (3mg IV) Day -21: alemtuzumab (10mg IV or S/C) Day -20: alemtuzumab (15mg IV or S/C) (10mg if < 10kg) Day -19: alemtuzumab (20mg IV or S/C) (10mg if < 10kg) Days -8 to -4: fludarabine (30mg/m2/day IV) Day -4: thiotepa (8mg/kg IV) Day -3: melphalan (140mg/m2) Days -2 to -1: rest days/no therapy Day 0: bone marrow transplant
1478768|NCT03128996|Drug|GVHD prophylaxis regimen|Day +3 to +4: cyclophosphamide (50mg/kg/day IV) Day +5: Start of tacrolimus & Start of mycophenolate mofetil (MMF) Days +30, +60, and +90: abatacept (IND) (10mg/kg/day IV)
1478769|NCT03128983|Device|Participants wear a sensor bracelet for collecting physiological data and conducted urine tests to estimate the day of ovulation|
1478770|NCT03128970|Other|synchronizing blastocysts|transferring frozen/thawed a synchronized blastocysts at hatching or hatched stage into female uterus.
1478771|NCT03128957|Device|IVOS cerebral oximeter|Measuring percutaneous cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
1478772|NCT03128957|Device|Licox cerebral oxygenation monitor|Measuring tissue cerebral oxygenation secondary to changing end tidal carbon dioxide and inspired oxygen fraction.
1478773|NCT03128957|Other|Cerebral oxygenation|Measuring cerebral oxygenation with varying ventilation strategy
1948754|NCT01736722|Device|Visualase®|The target tumor/lesion will undergo laser therapy using the MRI scan to plan the treatment and ensure proper placement of the laser within the tumor. An MRI (Magnetic Resonance Imaging) is a exam that creates pictures using magnetic rays instead of x-rays. The tumor(s) will then be heated by the laser in an attempt to eliminate their presence. The physician will be able to see and control the temperature of the laser.
1478776|NCT03128879|Drug|Venetoclax|"Participants take Venetoclax by mouth on Day 1 of Cycle 1 and dose-escalate according to the following schedule:
i) Day 1 - Venetoclax 20mg daily. ii) Day 8 - Venetoclax 50mg daily. iii) Day 15 - Venetoclax 100mg daily. iv) Day 22 - Venetoclax 200mg daily. v) Day 29 - Venetoclax 400mg daily and continuously thereafter."
1478777|NCT03128879|Drug|Ibrutinib|Participants receive Ibrutinib by mouth up to 420 mg per day.
1478778|NCT03128879|Drug|Allopurinol|Allopurinol 300 mg/day by mouth beginning at least 72 hours prior to Venetoclax dose.
1478779|NCT03128866|Drug|Tranexamic Acid|"Adult patients and pediatric patients > 40 kg given a loading dose of 15 mg/kg 30 min prior to skin incision over 15 minutes followed by a 10 mg/kg/hour maintenance infusion during the surgical procedure. TXA infusion discontinued after wound closure.
Pediatric patients (age < 12 and weight 5 - 40 kg) given a loading dose of 6.4 mg/kg (maximum 1 gram) dose 30 minutes prior to skin incision over 15 minutes, followed by 2 - 3.1 mg/kg/hr maintenance infusion until skin closure."
1478780|NCT03127852|Device|Medly|
1948757|NCT01722045|Drug|Intravitreal Aflibercept Injection (IAI)|
1478781|NCT03127839|Procedure|Eccentric Strengthening|Use of eccentric strengthening exercises in treatment plan during visits and at home.
1478782|NCT03127839|Procedure|Traditional Strengthening|Use of traditional strengthening exercises in treatment plan during visits and at home.
1478783|NCT03127839|Behavioral|Pain education|Addition of pain neuroscience-focused education in addition to strengthening exercise program
1478784|NCT03127826|Procedure|Risk Stratified Care|"Physical therapists providing care will all have attended live training in PIPT principles and be involved in monthly continuing education on these principles. The use of specific principles is guided by the patient's risk stratification (as determined by the STarT Back Tool).
Medium Risk:
- Reassurance will be provided to address specific concerns related to their LBP and implications on work
High Risk:
- Physical therapy will be psychologically augmented with the assessment of biopsychosocial risk factors and the adoption of cognitive behavioral principles that explore patient concerns and address unhelpful beliefs and behaviors, including tailored education (e.g., stress management and pain neuroscience), graded exercise, & graded exposure"
1478785|NCT03127826|Procedure|Usual Care|Usual care at the general practitioner's discretion
1478786|NCT03127813|Other|Application of continuous positive airway pressure (CPAP)|CPAP will be delivered at 4 different pressure levels (6, 10, 13 and 16cmH2O) in a randomly allocated order
1478787|NCT03127800|Drug|Morphine sulphate|5mg of intravenous morphine sulphate diluted to 5ml with normal saline (0.9% sodium chloride) will be administered 30 minutes before participant's bed time. The same dose will be administered four hours later. In both instances 4 mg of intravenous ondansetron will be administered after the morphine sulphate dose to prevent sickness.
1478788|NCT03127787|Diagnostic Test|CMV Assay|Molecular diagnostic test to detect CMV
1478789|NCT03127774|Drug|Cisplatin|"Route of administration: Intraperitoneal for tumor treatment. Dose of 250 mg/m2
Drug 1 of the hyperthermic intraperitoneal chemotherapy (HIPEC)"
1478790|NCT03127774|Drug|Sodium thiosulfate|"Route of administration: Intravenous Loading dose of 7.5 gm/m2 over 20 minutes followed by 2.13 gm/m2/hr for 12 hours
Drug 2 given intravenously during hyperthermic intraperitoneal chemotherapy (HIPEC)"
1478791|NCT03127774|Procedure|Cytoreductive surgery|Standard of care: Surgical procedure used to remove tumors from patients with peritoneal tumors.
1478792|NCT03127761|Other|Allogeneic Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of matched autoHCT controls.
1478793|NCT03128801|Procedure|Global Stretching Program|Participants will be submitted to a GSP in self-management postures weekly for 40 minutes session conducted by one one physical therapist, certified to use the technique (Stretching Global Active). The GSP will last for a period of 8 weeks. The protocol is based on the study of Lawand et al (2015) who used all postures global therapeutic stretching. The investigators will use six self-management postures in a standardized manner, each of which will last for 10 to 20 minutes.
1478794|NCT03128801|Procedure|Stabilization Exercises|The exercise protocol and criteria to increase exercise progression was previously described by Hicks et al (2005). It will be directed by a single therapist one to one session based on specific criteria (being able to maintain muscle contraction eight seconds during 30 repetitions in bilateral exercises or during 20 repetitions for unilateral exercises). Each session will be conducted weekly for 40 minutes.
1478795|NCT03128788|Procedure|thoracic epidural catheterization|thoracic epidural catheterization thoracic epidural catheterization for the management of postoperative pain
1478796|NCT03128775|Behavioral|Nudge|"School lunchrooms are the central place of modifications regarding food consumption, where the following strategies will be conducted:
arrange the fruits served in the school lunch in a prominent position, in containers of bright and contrasting colors to serve them;
Create creative names for food served at meals will be created by the students used on displays at canteen tables, posters on the way of the cafeteria and at a menu outside the cafeteria.
To encourage water consumption, footprints that lead to them to water fountains will be painted on the floor. To stimulate physical activity, several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the school sports court. The courts will be renovated and footsteps painted in order to nudging students to the sports equipment."
1478797|NCT03128775|Behavioral|Primary prevention|Classroom-based educational activities based on an earlier study, called PAPPAS, which was developed in the same city and constituted a school-based intervention with the objective of reducing the consumption of sweetened beverages and biscuits and increase the consumption of fruits, vegetables and beans. Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
1478798|NCT03128775|Behavioral|Primary prevention + nudge|This group will receive both primary prevention and nudge activities. At school lunchrooms, the fruits served in the school lunch will be put in a prominent position, in containers of bright and contrasting colors to serve them; create creative names for food served at meals will be created by the studentes, footprints that lead to them to water fountains will be painted on the floor. Several sports equipment (basketball hoops, volleyball nets, balls, ropes, shuttlecock and a lot of toys) will be available for use in the schools sport court. Also, classroom-based educational activities based on an earlier study, called PAPPAS, will be held. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
1478799|NCT03128762|Biological|ILC2 levels in blood|The levels of circulating ILC2 cells relative to other lymphocytes will be determined via flow cytometry
1478800|NCT03128749|Behavioral|Mindfulness Based Intervention|"The mindfulness based intervention protocol used in this project is adapted from the original and validated MBCT program for depression (Segal, Williams & Teasdale, 2002). Two more sessions, focused on obsessive symptoms specfic to each participant, will be included. Those two sessions will be adapted from the manual The Mindfulness Workbook for OCD (Hershfield and Corboy, 2013)."
1478801|NCT03128749|Drug|Treatment as Usual|The psychiatric referee will follow OCD guidelines modifying or potentiating drug treatments if needed.
1478802|NCT03128736|Drug|Esomeprazole group|Esomeprazole 40mg qd
1478803|NCT03128736|Drug|Dexlansoprazole group|Dexlansoprazole 60mg qd
1483268|NCT03095326|Drug|Sucrose|Placebo of sucrose syrup
1478804|NCT03128723|Device|Acne Mask|The light therapy acne mask contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes.
1478805|NCT03128697|Behavioral|Satiating diet|
1478806|NCT03128697|Behavioral|Control diet|
1478807|NCT03128684|Other|Small Green Lentil Muffin|Consumption of small green lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
1478808|NCT03128684|Other|Split Red Lentil Muffin|Consumption of split red lentil muffin; consumption of ad libitum pizza test meal after 180 minutes
1478809|NCT03128684|Other|Wheat Muffin|Consumption of wheat muffin; consumption of ad libitum pizza test meal after 180 minutes
1478810|NCT03128684|Other|Small Green Lentil Chili|Consumption of small green lentil chili; consumption of ad libitum pizza test meal after 180 minutes
1478811|NCT03128684|Other|Split Red Lentil Chili|Consumption of split red lentil chili; consumption of ad libitum pizza test meal after 180 minutes
1478812|NCT03128684|Other|Rice Chili|Consumption of rice chili; consumption of ad libitum pizza test meal after 180 minutes
1478813|NCT03128684|Other|Small Green Lentil Soup|Consumption of small green lentil soup; consumption of ad libitum pizza test meal after 180 minutes
1478814|NCT03128684|Other|Split Red Lentil Soup|Consumption of split red lentil soup; consumption of ad libitum pizza test meal after 180 minutes
1478815|NCT03128684|Other|Potato Soup|Consumption of potato soup; consumption of ad libitum pizza test meal after 180 minutes
1478816|NCT03128671|Behavioral|FAVoR Intervention|The FAVoR intervention includes a set of 8 scripted recorded messages, no longer than 2 minutes long, includes subject's name, uses simple terms, and is written at a 5th grade reading level. Messages include information about the critical care environment, the visual and auditory stimuli to be expected, and the availability of providers and family.
1478817|NCT03128658|Diagnostic Test|Thromboelastography|Thromboelastography (TEG) tests for parameters related to efficiency of blood coagulation. The parameters are: reaction time (R value), the K value, the angle and the maximum amplitude (MA)
1478818|NCT03128658|Diagnostic Test|Computational model|The computational whole-patient systems model is a multiscale, multi-compartment model whose state-space is defined by a very large and heterogeneous set of variables as well as a large number of input parameters. The model will be integrated in time for various initial trauma conditions in an attempt to determine whether the model can be predictive, and help us discover new variables that are more predictive of clinical outcomes than those employed in current clinical protocols.
1478819|NCT03128645|Device|Abdominal Corset|The patient's colonoscopy procedure in group 2 after randomization will be performed with the abdominal corset.
1478820|NCT03128619|Procedure|Biopsy of Breast|Undergo biopsy
1478821|NCT03128619|Drug|Copanlisib|Given IV
1478822|NCT03128619|Other|Laboratory Biomarker Analysis|Correlative studies
1478823|NCT03128619|Drug|Letrozole|Given PO
1478824|NCT03128619|Drug|Palbociclib|Given PO
1478825|NCT03128619|Other|Pharmacological Study|Correlative studies
1478835|NCT03128567|Device|Stimulation of the subthalamic nucleus|Stimulation of the subthalamic nucleus
1478836|NCT03128554|Other|Intervention with Training and Materials|Peer-Led Continuing Medical Education Session and Provider/Patient Handouts
1478837|NCT03128541|Diagnostic Test|Ultrasound spine|A ultrasound of the lumbar spine of each patient will be performed in both positions to identify vertebral levels
1478840|NCT03128515|Drug|Hydroxyurea|Administered once a day in tablet form (100mg or scored 1000mg) for 24 months
1478841|NCT03128489|Biological|Infanrix™ -IPV/Hib|Subjects will receive (Infanrix™ -IPV/Hib) as three-dose primary vaccination course at 6, 10 and 14 weeks of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the anterolateral side of the thigh on the right side. The vaccine should not be administered in the buttock.
1478842|NCT03128476|Dietary Supplement|Essence of Chicken|Brand's Essence of Chicken (BEC) is produced via a water extraction process from chicken meat for several hours under high-temperature, followed by centrifugation to remove fat and cholesterol, vacuum concentration to 3- to 4-fold, sterilization by high temperature and pressure before bottling. This kind of chicken essence is rich in protein, and low in sugar and fat, conveniently available and consumable, and easy for household storage.
1478843|NCT03128476|Dietary Supplement|Placebo (Energy matched)|
1478844|NCT03128463|Drug|Intravitreal injection of conbercept|We observe and collect patients with macular neovascular diseases who had intravitreal injections of conbercept. We do not interfere patients' treatment plan.
1478845|NCT03128450|Biological|human neural stem cell|human neural stem cell: 100ul/vessel，2 vessel/one bag，≥2×10 6cells/vessel
1478884|NCT03128216|Procedure|Blind Local Anesthetic infiltration|Patients of this group received blind local anesthetic infiltration on surgical site. Local anesthetic infiltration are performed by surgeon.
1478885|NCT03128216|Procedure|Transversals Fascia Block|Patients of this group received ultrasound guided omolateral Transversals Fascia Block.
1948761|NCT01695941|Drug|Alisertib|Given PO
1948762|NCT01695941|Drug|Bortezomib|Given SC
1948763|NCT01695941|Other|Laboratory Biomarker Analysis|Correlative studies
1948764|NCT01695941|Biological|Rituximab|Given IV
1478846|NCT03128437|Behavioral|Aerobic Exercise|At each of the six exposure sessions, participants will be invited to engage in 2-minute warm-up on the treadmill. Following this warm-up period, participants will be asked to briskly walk or jog on the treadmill at a speed that maintains their heart rate at 60-80% of maximum age-predicted heart rate for 20 minutes using the formula: (220-age) x (0.60 [lower bound] or 0.80 [upper bound]). Participants will be fitted with a heart rate monitor, which will be checked by a research assistant at 5-minute intervals in order to ensure adherence to this prescription; participants will be asked to adjust treadmill speed in order to remain in this range. Following each 20-minute exposure, participants will complete 5 minutes of cool down walking on the treadmill. Assessments will take place at baseline, week 2 (post-intervention), week 4, and week 8.
1478847|NCT03128424|Device|PQ Bypass Stent Graft System|The PQ Bypass™ Stent Graft System is indicated to improve luminal diameter in the treatment of patients with symptomatic de novo or restenotic native lesions or occlusions of the superficial femoral artery (SFA) and/or proximal popliteal artery, with reference vessel diameters of 5.0 to 6.7 mm and lesion lengths up to 180 mm.
1478849|NCT03128398|Drug|Domperidone|Availability of Domperidone to patients with serious gastrointestinal diseases or conditions when there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the patient's disease or condition.
1478850|NCT03128385|Other|Intensive CIT Model Program: Day Camp Model|"Thdelivered in group-based design (8-10 children), 6 hours a day for 6 days (36 hours in total)
constraint of the unaffected hand to encourage the use of the affected hand
massed and repetitive practice of the affected hand during the period of constraint
use of behavioral techniques termed shaping to train the affected hand"
1478851|NCT03128385|Other|Distributed CIT Model Program: Home-Based Model|"The participants will receive individualized interventions, 2.25 hours a day, two times a week for 8 weeks (36 hours in total).
constraint of the unaffected hand to encourage the use of the affected hand
massed and repetitive practice of the affected hand during the period of constraint
use of behavioral techniques termed shaping to train the affected hand"
1478852|NCT03128372|Device|Desaturation|The delivered gas mixture will be adjusted to decrease the displayed saturation of peripheral oxygen. Each desaturation steps are of approximately 5 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
1478853|NCT03128359|Drug|Busulfan|Given IV
1478854|NCT03128359|Drug|Cyclophosphamide|Given IV
1478855|NCT03128359|Drug|Fludarabine Phosphate|Given IV
1478856|NCT03128359|Procedure|Hematopoietic Cell Transplantation|Undergo PBSC HCT
1478857|NCT03128359|Other|Laboratory Biomarker Analysis|Correlative studies
1478858|NCT03128359|Drug|Melphalan Hydrochloride|Given IV
1478859|NCT03128359|Drug|Mycophenolate Mofetil|Given IV or PO
1478860|NCT03128359|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC HCT
1478861|NCT03128359|Other|Quality-of-Life Assessment|Ancillary studies
1478862|NCT03128359|Drug|Tacrolimus|Given IV
1478863|NCT03128359|Radiation|Total-Body Irradiation|Undergo TBI
1478864|NCT03128346|Procedure|Transthoracic Transversus Plane Block|The investigator (RF or DV) will administer bilateral TTP block under dynamic ultrasound guidance with an echogenic needle using a total of 40mL of 0.5% ropivacaine (200mg), 20mL on each side. If the patient is less than 70kg, the total dose administered will be 40mL of 0.3% ropivacaine (150mg). The patient will not require sedation or analgesia for the performance of the block. The projected time for block completion is 20 minutes after appropriate patient positioning (supine) and exposure (upper chest). After block administration, the patient will be monitored for local anesthetics toxicity, hemodynamic instability, and allergic or unexpected adverse reactions for 20 minutes. Standard intensive care monitors are sufficient.
1478865|NCT03128346|Drug|Hydromorphone Hydrochloride|IV, Hydromorphone
1478866|NCT03128346|Drug|Aspirin|Oral Aspirin
1478867|NCT03128346|Drug|Acetaminophen|Oral acetaminophen
1478868|NCT03128346|Drug|Fentanyl|IV, fentanyl
1478869|NCT03128333|Other|RunKeeper app + physiotherapy coaching|RunKeeper app for half a year to self-monitor leisure-time PA.
1478870|NCT03128333|Other|Usual care|In the UMCG, patients who receive cancer treatment or in surveillance after treatment are normally advised to live healthy, stay active, and to maintain their weight.
1948765|NCT01687738|Other|communication intervention|Because of the gaps between documented outcomes of lung cancer surgery and patient communication barriers identified in our recent work, our communication intervention will focus on improving presentation of risk information and confirmation of understanding of patient medical.
1478875|NCT03128294|Other|Retrospective, cross-sectional descriptive analysis|This study is a retrospective, cross-sectional descriptive analysis, and concerns the extraction of data from anonymised patient files. A database will be constructed and descriptive statistics will be used to summarise the data.
1478876|NCT03128281|Behavioral|Questionnaires|"Questionnaires completed 30 days before surgery, two (2) hours after surgery, when leaving the post-anesthesia care unit (PACU), and at hospital discharge.
Questionnaires ask about pain level and any drugs taken for it. It should take about 5 minutes to complete."
1478877|NCT03128281|Device|Conventional Insufflation System (CIS)|CIS with pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
1478878|NCT03128281|Device|ConMed AirSeal Insufflation System (AIS) at Low Pressure|AIS with an insufflation pressure target of 9±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
1478879|NCT03128281|Device|ConMed AirSeal Insufflation System (AIS) at Higher Pressure|AIS with an insufflation pressure target of 15±1 mmHg used for pneumoperitoneum during laparoscopic/robotic surgery.
1478881|NCT03128255|Other|Assessment of already preacquired I-124 PET/US|Assessment of preacquired I-124 PET/US by review of anonymous digital case files
1478882|NCT03128242|Drug|Oxytocin|intranasal administration of oxytocin (24IU)
1478883|NCT03128242|Drug|placebo|intranasal administration of placebo (24IU)
1478886|NCT03128216|Procedure|Spinal Anesthesia|Patients of this group received Spinal Anesthesia
1478887|NCT03128216|Drug|Ropivacaine|Local anesthetic used for local infiltration and Transversals fascia block
1478888|NCT03128216|Drug|Bupivacaine|Local anesthetic used for Spinal Anesthesia
1478889|NCT03128203|Drug|Oxytocin|Oxytocin, intranasally administrated
1478890|NCT03128203|Drug|Placebos|Saline, intranasally administrated
1478891|NCT03128190|Other|Pulse pressure variation monitoring|fluids boluses of colloids were given to maintain continuously measured PPV at 10% or less
1478892|NCT03128177|Dietary Supplement|Dietary sodium|High (6 g) versus low (1.5 g) sodium diet
1478893|NCT03128164|Drug|HMPL-689|Two strengths of HMPL-689 capsules (2.5 mg and 10 mg) will be used for clinical studies. The drug products are capsules.
1478894|NCT03128151|Behavioral|Educational program for clinicians: implementation of a package of clinical prevention measures of NMB|Intraoperative neuromuscular monitoring and pharmacological reversion of NMB according to data sheet
1478895|NCT03128138|Drug|SPH3127|"Drug: SPH3127 Tablet
Drug: Placebo Tablet"
1478896|NCT03128125|Other|clinical examination in neurology|This examination is based on the movement of the child in a standing position (forward and backward on a straight line, jumping on a foot ...), seated (visual continuation ...) and elongated (tone, patellar and achillian reflexes, superficial sensitivity ...) . This makes it possible to evaluate all the neurological systems.
1478897|NCT03128125|Other|neuropsychological examination|This examination is based on the use of standardized psychometric tools and validated with children, usually used in clinical practice.
1478898|NCT03128125|Other|anamnestic elements|Several elements will be collected during the clinical interview to inform the history of the child's development, such as neonatal data (term of pregnancy, APGAR score ...), age of appearance of the first words , seating, walking, possible care, level of education ans level of education of the parents.
2000852|NCT03323450|Behavioral|CogMed®|"It consists of 25 training sessions which can all be completed online and at home. Each session lasts 30-45 minutes. They must have a computer at home compatible with the CogMed® program.
Brief neuropsychological evaluations will be conducted at 4 time points (these assessments are standard of care):
Baseline before the participant is introduced to the CogMed® training program
Within 2 weeks of completion of the CogMed® program
At 3 months of completion of the CogMed® program to establish maintenance of gains
At 6 months of completion of the CogMed® program to establish longer-term maintenance of gains"
1478900|NCT03128099|Behavioral|Virtual reality social skills training|Participants play a virtual reality video game involving social interactions with various characters ( avatars) at a bus stop, a cafeteria and a grocery store. The games become progressively more complex as the participant improves task performance. Eye tracking patterns are recorded throughout the game to observe the patterns of social attention
1478901|NCT03128086|Procedure|Protocol-directed weaning|A protocol-directed weaning in neurological patients undergoing mechanical ventilation will reduce the rate of extubation failure and associated complications comparing with a conventional weaning (control group)
1478902|NCT03128073|Device|Carry life system, ultrafiltration (CLS UF)|The addition of Glucose-salt intermittently to a volume of the intraperitoneal fluid in the device which is then returned to the subject.
1478903|NCT03128060|Other|Home-based palliative care|The HBPC model consists of home visits by an interdisciplinary primary palliative care team (a physician, nurse, social worker, and chaplain). This team provides pain and symptom management, psychosocial support, advance care planning, spiritual counseling, grief counseling, and other services to meet patient and caregiver needs. Within the first week of a patient's enrollment, team members separately visit the patient at home to assess his/her needs as well as the needs of his/her caregiver. Following the patient's initial assessment, subsequent home visits are based on the patient's and caregiver's needs. At a minimum, a core team member visits the patient at home once per week. Additionally, a 24/7 helpline provides access to nurse counseling and after-hours home visits as needed. As a patient's health declines and he/she becomes eligible for hospice care, HBPC clinicians will refer the patient to hospice.
1478904|NCT03128060|Other|Enhanced usual care|"Usual primary care consists of appointment-based access to primary care providers (PCPs) as requested by the patient. These PCPs provide family/internal medicine services as well as access to specialist care. They also offer disease case management and pain and symptom management.
These usual care services are enhanced through training in palliative care provided to PCPs. The training addresses core elements of palliative care, specifically these 6 topics: a palliative care overview; strategies for improving patient-provider communications; instruction in ACP; instruction in managing patients' pain and symptoms; care coordination; and preventing medical crises."
1478905|NCT03128047|Device|Optune NovoTTF-200A System|Optune NovoTTF-200A System receive treatment with 200kHz for a minimum of 18 hours per day in 28 day cycles.
1478906|NCT03128047|Drug|Bevacizumab|Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each cycle 28 day cycle
1478907|NCT03128047|Drug|Temozolomide|Temozolomide(Alkylating agent) will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Days 1-5 of each 28-day cycle
2000853|NCT03323437|Drug|Risperidone|Participants will meet with a study doctor physician once per week (about 3 times total) to monitor progress and side-effects of risperidone, which includes taking 4 assessments each time. After 4 weeks of taking Risperidone, participant will be assessed and scanned with the MRI/MRS scanner again.
1478917|NCT03128021|Drug|Escitalopram Pill|Randomly assigned in Phase 1. Voluntary in Phase 2.
1478918|NCT03128021|Other|Placebo|Randomly assigned
1948766|NCT01687738|Other|Real Time Registry and data feedback only|This group of patients will not received the enhanced communication intervention
1948767|NCT01683019|Device|NeoSync EEG Synchronization Therapy|Generate low-energy sinusoidal magnetic field above the scalp with frequency equal to the subject's intrinsic alpha frequency (IAF). Treatment is 30 minutes, administered 5 days per week for 4 weeks.
1948768|NCT01683019|Device|Sham NeoSync EEG Synchronization Therapy|A device that looks and sounds similar to the active treatment, but no magnetic field is generated.
1948769|NCT01673763|Device|Stent insertion into the main pancreatic duct|Stent insertion into the main pancreatic duct
1478924|NCT03127982|Behavioral|Unified Protocol|The Unified Protocol (UP) is a trans-diagnostic cognitive-behavioral therapy (tCBT) for individuals diagnosed with anxiety disorders, depression and related disorders (which we refer to as emotional disorders).
1478925|NCT03127969|Other|Fluidotherapy treatment|fluidotherapy and joint protection and exercise
1478926|NCT03127969|Other|Joint protection and exercise|joint protection and exercise
1948770|NCT01667354|Behavioral|Academic Detailing|"The intervention design is based on academic detailing, an effective method of changing physician behavior. The aim of the training is effective communication with parents who are hesitant about childhood vaccinations."
1478928|NCT03127943|Drug|Lidocaine|Efficacy for mandibular molar and canine anesthesia
1478929|NCT03127930|Behavioral|Intervention|Participants receive 5 individualized contacts (home visits and phone calls) with either a social worker or a nurse to develop problem solving skills as applied to medication management.
1478930|NCT03127917|Dietary Supplement|L-citrulline|L-citrulline capsules given at 6 g/day
1478931|NCT03127917|Other|Placebo|Maltodextrin capsules given as placebo
1478932|NCT03127904|Procedure|Vein Fitness|Vein fitness is a combination of whole-limb exercises, manual lymphatic drainage, and usual care (wound care and compressive therapy).
1478933|NCT03127904|Procedure|Compressive therapy and wound care|"Compressive therapy consists in the application of pressure to the inferior limb. Investigators describe the specifics in the arm section.
As previously described, a trained nurse will be in charge of keeping the wound healthy, verifying the surface is clean, debriding it, and removing biofilm from it."
1478938|NCT03127709|Behavioral|Trail Making Test, Parts A & B|Part A is a timed measure of visual scanning and graphomotor speed. Part B is a timed measure of cognitive flexibility.
1478939|NCT03127709|Behavioral|Brief Test of Attention|Assesses auditory working memory
1478940|NCT03127709|Behavioral|Symbol Span|Assesses visual working memory
1478941|NCT03127709|Behavioral|Controlled Oral Word Association Test|The COWA timed test of phonemic verbal fluency. It requires the subject to generate as many words as possible, beginning with a given letter of the alphabet (i.e., F, A, and S).
1478942|NCT03127709|Behavioral|The Hopkins Verbal Learning Test-Revised|HVLT-R is a test of verbal learning and memory. Scores obtained are the total number of words.
1478943|NCT03127709|Behavioral|Brief Visuospatial Memory Test-Revised|The BVMT-R is a test of visuospatial learning and memory.
1478944|NCT03127709|Behavioral|Hospital Anxiety and Depression Scale|The HADS is a brief assessment validated in many cancer populations.
1478945|NCT03127709|Behavioral|McGill Quality of Life Scale|This is a questionnaire that is a validated 17-item QOL instrument validated for ill patients and in the particular context of the ancer.
1478946|NCT03127709|Diagnostic Test|MR Brain Imaging|Standard of care brain MR imaging includes high-resolution 3D T1-weighted images in the axial plane. The axial T1-weighted images will be isotropic with a typical matrix size of 256 x 256, 256 mm field-of-view (FOV) and 1 mm slice thickness covering the whole brain.
1478947|NCT03127709|Diagnostic Test|Resting state functional MRI|Scanning will be performed on a 3 Tesla General Electric scanner (Optima 750W) with a GEM HNU 24-channel head coil. rsFMRI matching the FLAIR and T1 post-contrast images will be obtained. For resting state fMRI, T2*-weighted images will be acquired with a single-shot gradient echo echo-planar imaging (EPI) sequence in the axial orientation (TR = 2500 ms, TE = 30 ms, FA = 80°, slice thickness = 4 mm, FOV= 240mm2, matrix=64×64) covering whole brain. For the resting state fMRI portion of the scan, patients will be instructed by the technologist or research staff to leave eyes open, focus on looking at a crosshair, and not think about anything during the scan.
1478948|NCT03127696|Procedure|Fecal Microbiota Transplantation|FMT solution will be infused into the distal duodenum or jejunum via OGD.
1478949|NCT03127696|Behavioral|Lifestyle Modification Program|Dietitian will guide and correct subjects in terms of their dietary habits, physical activity patterns, and other lifestyle habits.
1478950|NCT03127696|Procedure|Sham|Normal saline will be infused into the distal duodenum or jejunum via OGD.
1478951|NCT03127683|Other|Neutral position|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
1478952|NCT03127683|Other|Extension|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
1478953|NCT03127683|Other|Flexion|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
1478954|NCT03127683|Other|Rotation|The expiratory tidal volume, peak inspiratory pressure, oropharyngeal leak pressure, and ventilation score will be assessed at this position
1478955|NCT03127683|Device|Ambu AuraGain TM|Single Use Laryngeal Mask Sterile
1478956|NCT03127670|Drug|Solanum melongena peel extract 0.05%|Administered topically twice daily for 12 weeks
1478957|NCT03127657|Drug|Cock's comb extract 0.01%|Applied topically twice daily for 12 weeks
1478961|NCT03127631|Behavioral|Nutrition|Standardized advice on healthy diet practices.
1478962|NCT03127631|Behavioral|Exercise|Standardized advice on exercise including strength training and resistance training exercises.
1479085|NCT03126916|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
1478963|NCT03127631|Behavioral|Smoking cessation|Advice to quit smoking, if applicable, and on available aids to quit smoking,
1478964|NCT03127631|Drug|Antiplatelet agent, such as Aspirin, or other low-dose antiplatelet agent|Prescription for a low-dose antiplatelet agent, such as aspirin 81-100mg daily or if intolerant of aspirin, other low-dose antiplatelet agent
1478965|NCT03127631|Drug|Statin, such as Simvastatin, Atorvastatin, Rosuvastatin, Pravastatin)|Prescription for a low to moderate dose statin, such as simvastatin 10-40mg daily, atorvastatin 10-40mg daily, rosuvastatin 5-20mg daily or pravastatin 10-40mg daily.
1478966|NCT03127631|Drug|ACE inhibitor|Prescription for an ACE-I (preferable) or an angiotensin receptor blocker for baseline systolic blood pressure greater >120mmHg, or other blood pressure lowering medication as applicable.
1478967|NCT03127618|Drug|Lorlatinib|
1478968|NCT03127605|Drug|Inotuzumab Ozogamicin|
1478969|NCT03127592|Drug|Fixed Dose Combination|Fixed Dose Combination of Etodolac 400 mg + Cyclobenzaprine 10 mg
1478970|NCT03127592|Drug|Etodolac|Individual drug
1478971|NCT03127592|Drug|Cyclobenzaprine|Individual drug
1478972|NCT03127579|Behavioral|Longer meal duration|Participants have 50% more time to eat than usual
1478973|NCT03127553|Dietary Supplement|Low-sodium diet with standard bread|low-sodium diet (2300 mg Na/die) with use of standard bread (750 mg Na/100g) for 6 months
1478974|NCT03127553|Dietary Supplement|Low-sodium diet with low-sodium bread|low-sodium diet (2300 mg Na/die) with use of low-salt bread (280 mg Na/100g) for 6 months
1478977|NCT03126734|Other|Infant Massage course|"Infant massage courses consist of 5 sessions. Investigators explain parents how to make an infant massage technique to their babies and which should be the general conditions of the environment.
This massage is based on the methodology of the International Association of infant massage (IAIM) created by Vimala Schnneider. The courses will make individually."
1478978|NCT03126721|Drug|midazolam|a single oral dose of 2 mg midazolam
1478979|NCT03126721|Drug|PF-06751979|multiple oral doses of PF-06751979 100 mg a day
1478980|NCT03126708|Drug|cetuximab|cetuximab (EGFR monoclonal antibody) plus standard chemotherapy
1478981|NCT03126708|Drug|cisplatin plus paclitaxel|Chemotherapy
1478982|NCT03126695|Drug|Ticagrelor granule|A P2Y12 receptor inhibitor provided as granule for suspension.
1478983|NCT03126695|Drug|Ticagrelor pediatric tablets|A P2Y12 receptor inhibitor provided as pediatric tablets to be swallowed whole.
1478984|NCT03126695|Drug|Ticagrelor pediatric tablets suspended in water|A P2Y12 receptor inhibitor provided as pediatric tablets suspended in water.
1478985|NCT03126695|Drug|Ticagrelor immediate release (IR) tablets (Commercial tablet)|A P2Y12 platelet inhibitor indicated to reduce the rate of thrombotic cardiovascular events in patients with acute coronary syndrome (unstable angina, non-ST (S and T waves) elevation MI or ST elevation MI) and in patients with a history of MI
1478986|NCT03126682|Drug|Wellbutrin SR 300Mg Extended-Release Tablet|Wellbutrin SR 300Mg Extended-Release Tablet
1478987|NCT03126669|Device|Hyperbaric oxygen|Breathing 100% oxygen at 2ATA in the hyperbaric chamber
1478988|NCT03126669|Device|Hyperbaric chamber, normal air|Hyperbaric chamber with normal air
1478989|NCT03127475|Device|Transcranial direct current stimulation|A consecutive 5-days course of tDCS will be delivered. In treatment group, true stimulation will be administrated and sham stimulation will be delivered in control group.
1478990|NCT03127462|Behavioral|Nurse-led educational intervention|Patients in the intervention group will receive an individual face-to-face conversation with a duration of 45 min. All patients will have access to telephone counselling by their primary nurse when needed and able to arrange a new face-to-face conversation. After 4-6 weeks the face-to-face the nurse will of conversation reach out to the patient by phone to follow up on the earlier conversation. Three months after the face-to-face conversation the nurse will offer the patient a closing face-to-face conversation of 15 min at the same time where the patient has a doctor appointment at the department. Those who are in the control group will continue standard care and not receive any conversation and be used as the control group.
1478991|NCT03127449|Drug|Alflutinib|patients take Alflutinib orally once per day at different dose
1478992|NCT03127436|Drug|Acarovac|House dust mite sensitized Patients receive increasing doses of subcutaneous immunotherapy with Acarovac. During the up-dosing phase, patients will receive 4 injections in 1-2 week intervals with increasing allergen amount up to the individual maximum tolerable dose. After reaching the individual maximum tolerable dose patients will receive one maintenance dose in a 4 - 8 week interval.
1478993|NCT03127423|Procedure|Hybrid ablation|This intervention includes totally thoracoscopic surgical ablation and percutaneous catheter ablation simultaneously.
1478994|NCT03127423|Procedure|Thoracoscopic surgical ablation|This intervention only includes totally thoracoscopic surgical ablation without percutaneous catheter ablation.
1478995|NCT03127410|Other|Lumbar traction|Lumbar traction is used to decompress the spinal structures and relieve pressure and may stretch the spine.
1478996|NCT03127397|Behavioral|Praise message phone call|Praise message phone calls after each completed ART appointment, up to two calls per month.
1478997|NCT03127384|Device|Restylane Lidocaine|Hyaluronic acid based filler
1478998|NCT03127384|Other|No-treatment control|No-treatment control
1478999|NCT03127371|Drug|Nitrous Oxide|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
1479000|NCT03127371|Drug|Oxygen|Patients undergoing incision and drainage of abscess will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive 100% oxygen gas via the Nitrous Oxide gas mixer device while undergoing standard incision and drainage of cutaneous abscess . The device will deliver only oxygen at a fixed concentration of 100%. The on demand valve requires patient inspiration to trigger dosing.
1479033|NCT03127137|Drug|Experimental Group 2 triamcinolone and saline|Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL preservative saline (total volume 4 cc)
1479001|NCT03127358|Behavioral|Automated Directly Observed Therapy|Participants will be randomized to either a-DOT or TAU. Participants randomized to the a-DOT group will receive treatment for HCV with Elbasvir-Grazoprevir using a cellphone app to monitor adherence, w
1479002|NCT03127358|Behavioral|Control, TAU|Participants in the control group (TAU), will receive treatment for HCV with Elbasvir-Grazoprevir as per standard of care.
1479003|NCT03127345|Drug|Omegaven|Intravenous omega 3 fatty acid administration
1479004|NCT03127345|Drug|Intralipid|Standard of care
1479005|NCT03127332|Other|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their metastatic breast cancer patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and generated by clinical staff and/or peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
1479006|NCT03127319|Drug|apatinib docetaxel zoledronic|apatinib 500 mg qd p.o.docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
1479007|NCT03127319|Drug|docetaxel zoledronic|docetaxel 60mg/m² iv q3w;zoledronic 4mg iv>15min q4w until disease progression or intolerable toxicity or patients withdrawal of consent
1479008|NCT03127306|Diagnostic Test|Assessment of Polish version of BPS|Validation of Polish Version of BPS.
1479009|NCT03127293|Diagnostic Test|DEXA|Blood samples (10 mL) were drawn at the time of DEXA scans in postpartum period
1479010|NCT03127280|Other|Fast Track foley removal|Foley catheter is removed at 4 hours after surgery
1479011|NCT03127267|Drug|Masitinib Mesylate|treatment per os
1479012|NCT03127267|Drug|Riluzole 50Mg Tablet|treatment per os
1479013|NCT03127267|Drug|Placebo Oral Tablet|treatment per os
1479014|NCT03127254|Behavioral|Video narrative|create a 10-15 minute video intervention about teen experiences after being diagnosed with cancer
1479015|NCT03127254|Behavioral|PedsQL|A generic 23-item Health Related Quality of Life measure initially developed using pediatric cancer patients
1479016|NCT03127254|Behavioral|Ten Item Personality Inventory|The TIPI consists of ten items and measures personality based the subject's agreement of descriptions of themselves taken from the Big-5 model of personality
1479017|NCT03127254|Behavioral|Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test|The D-KEFS Verbal Fluency Test consists of three subtests, which take approximately 6 minutes to complete
1479018|NCT03127254|Behavioral|The Cognitive Log|The Cog-Log is a 5-10 minute assessment designed to measure basic cognitive functioning and orientation
1479019|NCT03127241|Device|Assistive device (Armon Ayura) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.
Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
1479020|NCT03127241|Device|Assistive device (Jaeco Wrex) test|"Short Training (T0-T1) - each subject will undergo a 3-day training at the clinical center during which technicians, along with a physiotherapist will adjust and customize the device and explain possible independent use at home.
Domestic use (T1-T2) - Subjects will use the device during their daily life activities for two weeks at home. They will perform task-oriented movements (e.g. reaching a mouse and objects on a table, moving back to the wheelchair, drinking), free movements, playful activities (e.g. playing chess, leafing through a book), and self-care activities, accordingly to subject's residual capability, for a minimum period of 5 hours/day. They will keep a structured diary where all the problems, achievements and comments will be reported."
1479021|NCT03127228|Other|Standard mechanical debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with dental scalers prior to bone grafting regenerative therapy
1479022|NCT03127228|Device|Er:YAG laser-assisted debridement|Implantoplasty will be performed for peri-implant suprabony defect and infrabony defect will be debrided with the aid of the laser prior to bone grafting regenerative therapy
1479023|NCT03127215|Drug|Olaparib|Olaparib 150 mg tablet
1479024|NCT03127215|Drug|Physician's choice|treatment according to current guidelines
1479025|NCT03127215|Drug|Trabectedin|Trabectedin 1.1mg/m² infusional solution
1479026|NCT03127202|Device|Cardiac Resynchronization Therapy -Defibrillator (range PARADYM, LivaNova, Clamart, France)|Patients were implanted with a Cardiac Resynchronization Therapy -Defibrillator (model PARADYM RF SONR CRT-D 9770 or PARADYM RF CRT-D 9750, Sorin) having 3 left ventricular polarities. The choice of the right atrial, right ventricular and bipolar left ventricular leads was left to investigators' discretion.
1948771|NCT01662050|Drug|Rituximab, Bendamustine, Cytarabine.|6 cycles of 28 days with Rituximab, Bendamustine and Cytarabine (R-BAC). Rituximab 375mg/mq; Bendamustine 70mg/mq; Cytarabine 500mg/mq.
1479029|NCT03127176|Other|Genome sequencing of fecal samples|Fecal samples will be collected and then frozen in the morning pre-prandial after having fasted overnight. DNA will be separated and stored at −80°C in our center (Biobanc) until assayed. Sequencing will be performed with the most appropriate platform.
1479030|NCT03127163|Device|Intraestromal corneal ring|The patients underwent surgery to implant the intrastromal corneal ring (Ferrara Ophthalmics, Belo Horizonte, Brazil) using a manual technique. The procedures were performed by a single surgeon with extensive training in corneal surgery. All patients received the same ring, and the number (1 or 2 segments), thickness, and arc size were calculated using the nomogram provided by the manufacturer.
1479031|NCT03127137|Other|Control cohort group|Control cohort group will receive medications not predetermined by the set protocol.
1479032|NCT03127137|Drug|Experimental Group 1 triamcinolone and lidocaine|Experimental Group 1 will receive Interlaminar cervical ESI at the C7-T1 level with triamcinolone 80 mg + 2 mL 1% lidocaine (total volume 4 cc)
1479078|NCT03126916|Radiation|External Beam Radiation Therapy|Undergo EBRT
1479079|NCT03126916|Radiation|Iobenguane I-131|Given IV
1479034|NCT03127124|Drug|NANT-008|Paclitaxel: benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI)
1479035|NCT03127124|Drug|Fluorouracil Injectable Product|5-fluoro-2,4 (1H,3H)-pyrimidinedione.
1479036|NCT03127124|Drug|Avastin Injectable Product|Recombinant humanized monoclonal IgG1 antibody
1479037|NCT03127124|Drug|Leucovorin Calcium Injection|Calcium N -[p -[[[(6RS )-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1).
1479038|NCT03127124|Drug|Eloxatin Injectable Product|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum.
1479039|NCT03127111|Genetic|Gene mutations analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for KRAS mutations, BRAF mutations, PIK3A mutations, and EGFR mutations, etc., by sequencing and for MSI analysis by PCR and capillary electrophoresis.
1479040|NCT03127111|Genetic|Gene methylation analysis|Genomic DNA extracted from paired fresh-frozen tumor and normal tissues is used for specific gene methylation or CIMP status analysis by MethyLight or bisulfite sequencing. Whole-genome bisulfite sequencing will be used to identify novel candidate set of predictive markers.
1479041|NCT03127111|Genetic|Gene expression analysis|RNA extracted from paired fresh-frozen tumor and normal tissues or serum is used for specific gene expression analysis by real-time reverse-transcription PCR (RT-qPCR). RNA-seq will be used to identify novel candidate set of predictive markers.
1479042|NCT03127111|Genetic|SNP analysis|Genomic DNA extracted from serum is used for specific SNP analysis by using sequencing. GWAS with SNPs array will be used to identify novel candidate set of predictive markers.
1479043|NCT03127111|Genetic|Protein expression analysis|Tissue microarray made from formalin-fixed paraffin-embedded (FFPE) paired tumor and normal tissues is used for specific protein expression analysis by immunohistochemistry staining.
1479044|NCT03127098|Biological|ETBX-011|ETBX-011 immunization will be administered by subcutaneous (SC) injection.
1479045|NCT03127098|Biological|ALT-803|ALT-803 will be administered by SC injection.
1479046|NCT03127072|Device|Radiofrequency Ablation (RFA)|The radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue
1479047|NCT03127072|Drug|chemotherapy ± target therapy|chemotherapy ± target therapy
1479048|NCT03127059|Other|Breathing Exercises|"Key points in the intervention are
Reduction (or normalising) of the respiration rate; use of rhythmic, nasal inspiration, diaphragmatic breathing; reduction of depth of breath, longer expiration; breath-holding at functional residual capacity.
Relaxation, especially the neck, jaw, tongue, and shoulders. Emphasizing the impact of gravity to the body.
Inclusion of the breathing modification into walking and other physical activities.
Daily home exercise of BrEX."
1479049|NCT03127059|Other|Usual care|Participants will receive only short information given initially at recruitment. No instruction or booklet will be distributed in the Usual care-Group.
1479050|NCT03127046|Drug|Aceclofenac|Oral single dose administration of aceclofenac 200mg
1479051|NCT03127046|Drug|Esomeprazole|Oral single dose administration of aceclofenac 200mg
1479052|NCT03127046|Drug|Aceclofenac and Esomeprazole|Oral single dose administration of aceclofenac 200mg and esomeprazole concomitant
1479053|NCT03127033|Other|Soft liner telescopes|"Soft liner telescopes: Overdenture will be adjusted by relieving acrylic opposite to the abutment about 2 mm using a metal stone. The relieved areas will be painted with an adhesive and the rest of the fitting surface of the denture will be painted with a separating medium.
The soft liner (Silicone based soft liner, mollosil, chairside soft relining-long term, DETAX, Germany) will then be applied in the relieved areas to act as a secondary coping The base and catalyst will be mixed according to the manufacturer's instructions on a glass slab. The mix will be placed on the relieved area, seated in the patient's mouth, the patient is asked to bite in centric relation and the excess liner is removed with a lancet."
1479054|NCT03127020|Drug|PQR309|taken continuously on daily basis (60mg, 80mg) or intermittent dosing (120mg, 140mg, 160mg)
1479055|NCT03127007|Drug|Atezolizumab|Atezolizumab is given on day 1 of week 3, 6, 9 and 12 at 1200 mg IV.
1479056|NCT03127007|Drug|5-FU based radio-chemotherapy|IV protracted 5-FU given at 225mg/m2 over 24h 5 days/week for 5 weeks associated to radiotherapy.
1479057|NCT03126981|Other|1.5 oz of whole, natural almonds|1.5 oz of whole, natural almonds
1479058|NCT03126981|Other|Low-fat, high refined starches/sugars|Low-fat foods, high in refined starches and added sugars
1479059|NCT03126968|Drug|Topical epinephrine|Prophylactic topical epinephrine
1479060|NCT03126968|Drug|Placebos|Topical placebo (normal saline)
1479061|NCT03126955|Diagnostic Test|Pre-Operative CISS-MRI Sequences|Compare pre-operative MRI diagnosis to intra-operative findings on if both are in agreement
1479062|NCT03126955|Diagnostic Test|Pre-Operative Interictal Laryngoscopy|Compare pre-operative laryngoscopy diagnosis to intra-operative findings on if both are in agreement
1479063|NCT03126955|Diagnostic Test|Pre-Operative Unilateral and Contralateral Botox|Compare pre-operative diagnosis using Botox to intra-operative findings on if both are in agreement
1479064|NCT03126942|Device|Novaloc|Attachment composed by a polyetheretherketone (PEEK) capsule and carbon-coated abutment. The yellow (medium) retentive component will be used
1479065|NCT03126942|Device|Locator|Traditional cylindrical attachment (Locator system) with pink (medium) retentive components
1479066|NCT03126929|Diagnostic Test|Coma Recovery Scale-Revised and Glasgow Coma Scale|Patients have been assessed with both the Coma Recovery Scale-Revised(CRS-R) and the Glasgow Coma Scale(GCS)
1479067|NCT03126916|Biological|Aldesleukin|Given IV
1479068|NCT03126916|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HSCT
1479069|NCT03126916|Drug|Busulfan|Given IV
1479070|NCT03126916|Drug|Carboplatin|Given IV
1479071|NCT03126916|Drug|Cisplatin|Given IV
1479072|NCT03126916|Drug|Crizotinib|Given PO
1479073|NCT03126916|Drug|Cyclophosphamide|Given IV
1479074|NCT03126916|Drug|Dexrazoxane Hydrochloride|Given IV
1479075|NCT03126916|Biological|Dinutuximab|Given IV
1479076|NCT03126916|Drug|Doxorubicin Hydrochloride|Given IV
1479077|NCT03126916|Drug|Etoposide Phosphate|Given IV
1479089|NCT03126903|Device|KeraKlear Non-Penetrating Keratoprosthesis|The KeraKlear is a flexible non-penetrating artificial cornea designed to be implanted through small corneal incisions in subjects with corneal opacity.
1479090|NCT03126877|Drug|Mitomycin C|The surgical procedure includes a low dose, short duration mitomycin C (MMC) treatment on the exposed stromal bed of the non-dominant eye, before the unilateral implantation of the corneal inlay. This treatment is at a concentration of 0.2 mg/mL (0.02%) applied for 10 to 30 seconds on the stromal bed as well as the stromal side of the corneal flap or pocket.
1479091|NCT03126877|Device|Raindrop Near Vision Inlay|The surgical procedure includes the unilateral implantation of the Raindrop Near Vision Inlay in the non-dominante eye for the improvement of uncorrected near vision.
1479092|NCT03126864|Procedure|Leukapheresis|After enrollment, steady state leukapheresis performed to collect apheresis material. The goal is to achieve a target total nucleated cell (TNC) yield of at least 5 x 10^9 (expected range 5 x 10^8 - 5 x 10^10), for up to two days.
1479093|NCT03126864|Drug|Fludarabine|25 mg/m2 administered by vein on Days -5 to -3.
1479094|NCT03126864|Drug|Cyclophosphamide|900 mg/m2 administered by vein on Day -3.
1479095|NCT03126864|Biological|CD33-CAR-T Cell Infusion|CD33-CAR-T cell infusion administered by vein on Day 0. First group of participants receive the lowest dose level. Each new group will receive a higher dose than the one before it, if no intolerable side effects were seen. This will continue until the highest tolerable dose of T-cells is found. Starting dose level is > 1.5 x 105/kg but ≤ 4.5 x 105/kg.
1479096|NCT03126851|Other|Label|Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.
1479097|NCT03126825|Device|CP910/CP920 with noise reduction on|This intervention uses the approved Nucleus 6 system (CP910/CP920 and accessories) but adds the investigational noise reduction algorithm.
1479098|NCT03126825|Device|CP910/CP920|The approved CP910 or CP920 Sound Processor.
1479099|NCT03126812|Drug|Carboplatin|Carboplatin AUC=6
1479100|NCT03126812|Drug|Paclitaxel|paclitaxel 80 mg/m2
1479101|NCT03126812|Drug|Pembrolizumab|200 mg flat dose, starting cycle 2
1479102|NCT03126799|Drug|Erlotinib plus Bevacizumab|Erlotinib 150mg, po, daily, q 3weeks plus Bevacizumab 15mg/kg, IV, on D1 Q 3 weeks
1479103|NCT03126799|Drug|Erlotinib|Erlotinib 150mg, po, daily, Q weeks
1995267|NCT02811575|Other|Biopsy|Ileon and colon biopsy
1479107|NCT03126760|Drug|Repository Corticotropin Injection|Administered subcutaneously once a day for 14 consecutive days
1479108|NCT03126760|Drug|Placebo|Administered subcutaneously once a day for 14 consecutive days
1479110|NCT03126656|Drug|Testosterone Undecanoate|just hypogonadic patients enrolled received hormone replacement therapy with testosterone undecanoate 1000 mg/4ml intramuscular (IM) at baseline, after 6 weeks and 12 weeks after the first evaluation
1479111|NCT03126643|Biological|Nivolumab|"Opdivo (nivolumab) is a programmed death receptor-1 (PD-1) blocking antibody approved by the US Food and Drug Administration (FDA) on an accelerated basis for some types of cancer. Please contact your physician for more details."
1479112|NCT03126630|Biological|Anetumab Ravtansine|Given IV
1479113|NCT03126630|Other|Laboratory Biomarker Analysis|Correlative studies
1479114|NCT03126630|Biological|Pembrolizumab|Given IV
1479115|NCT03126630|Other|Pharmacological Study|Correlative studies
1479116|NCT03126617|Biological|Elotuzumab|Elotuzumab (Empliciti) is a Signaling Lymphocytic Activation Molecule Family member 7 (SLAMF7) directed immunostimulatory antibody approved by the US Food and Drug Administration (FDA) and indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Please contact your physician for more details.
1479117|NCT03126604|Diagnostic Test|female sexual function index|evaluation of sexual functions questionnaire about Desire, Arousal, Orgasm,pain , lubrications, satisfactions
1479120|NCT03126578|Drug|LEO 32731|LEO 32731 is being developed by LEO Pharma.
1479121|NCT03126578|Drug|Midazolam|Benzodiazepine
1479122|NCT03126565|Other|Lifeline CareSage Flagging|Patients in the intervention group will receive active monitoring by the CareSage risk assessment platform and clinical interface, including nurse triage calls and tailored PHH interventions. Beginning at month 4, the CareSage algorithm will assess patients' risk for emergency transport every 30 days. Patients identified as high risk will receive nurse triage calls and, depending on their needs, tailored care according to a stepped-care approach. The principal goals will be to reinforce the patients' education, ensure compliance with medications and diet, and identify recurrent symptoms amenable to treatment on an outpatient basis to avoid readmissions
1479123|NCT03126552|Biological|Necator americanus L3 larvae|50 Necator americanus L3 larvae
1479124|NCT03126539|Drug|Sulforaphane|Isothiocyanate sulforaphane (SF), derived from broccoli sprouts, has been known to induce an antioxidant response through the Keap1-Nrf2-antioxidant response element pathway.
1479125|NCT03126539|Radiation|Narrow-band Ultraviolet B exposure|The investigators will use a Lumera UVB light phototherapy device which allows for targeted delivery of controlled doses of UVB radiation (emission spectrum 290-320 nm).
1479126|NCT03126539|Procedure|4 mm skin punch biopsy|All areas will be biopsied using standard punch biopsy tools and following standard clinical protocols, including cleansing the skin with an alcohol wipe and injecting local anesthesia with lidocaine and epinephrine. No more than four total skin biopsies will be obtained from a volunteer over the course of the study. After removal of the tissue sample, one or two sutures are placed to close the circular opening. Sutures are removed and a scar is formed, but typically heals well without complications and blends well with the surrounding skin.
1479386|NCT03124316|Behavioral|Problem solving|Analyze or prompt the person to factors that influence the behaviour and select strategies that help overcome barriers
1479127|NCT03126526|Behavioral|Food specific Inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include photos of food and non-food.
1479128|NCT03126526|Behavioral|Implementation intentions|"It involves designing if-then strategies of behaviour. Participants will be asked to describe situations in which they feel they are more prone to behave in a way that is not congruent to their long term goals, and then to plan strategies to behave differently when faced with this situation in the future."
1479129|NCT03126526|Behavioral|General inhibitory control training|It involves a go/no-go task in which participants are requested to respond by clicking a particular button when a specific stimulus appears and requested to withhold their response when another particular stimulus appears. Stimuli in this intervention include only non-food pictures.
1479130|NCT03126513|Procedure|G-POEM|After confirmation of refractory gastroparesis, participants will undergo to gastric POEM. Participants will be admitted to hospital 24hrs before procedure and IV antibiotics will be given and then the procedure will be done. Technique consist of 4 steps: First: a submucosa injection of saline solution with methylene blue at 3-4cms from pylorus. Second: a submucosa incision and tunnel creation up to pyloric area. Third: Myotomy of the circular and longitudinal muscular layers of the pylorus and the antrum. Fourth: closure of the mucosal incision with hemoclips. After procedure they will be kept on surveillance and will be followed-up with clinical, endoscopic and scintigraphic studies up to 1 year after procedure.
1479131|NCT03126487|Procedure|HIGH INTENSITY FOCUSED ULTRASOUND|HIGH INTENSITY FOCUSED ULTRASOUND GUIDED BY MRI AS THERMIC DESTRUCTION
1479132|NCT03126461|Radiation|SAbR|"For patients treated on the GRID A regimen, a dose of 15-20 Gy will be delivered with the GRID device in either a single field, with prescription to dmax, or with parallel opposed GRID fields (matching beamlets from the opposed directions). For patients treated on the GRID B regimen, this same dose will be delivered, with a subsequent regimen of 3 Gy X 10 fractions, with the first of these fractions following the GRID dose."
1479133|NCT03126461|Drug|Ipilimumab|ipilimumab 3mg/kg IV q3wk x 4
1479134|NCT03126461|Drug|Nivolumab|nivolumab 1 mg/kg IV q3wk x 4
1479135|NCT03126448|Diagnostic Test|Highly Sensitive Assays|Tissue will be collected at the time of surgery from patients in each arm of the study. In addition to tissue stored in RNAlater and sent to a research laboratory, cultures will also be sent to Quest Diagnostics for independent culture results.
1479136|NCT03126435|Drug|EndoTAG-1|twice weekly
1479137|NCT03126435|Drug|Gemcitabine|once weekly
1479138|NCT03126435|Drug|Gemcitabine|once weekly
1479139|NCT03126422|Drug|Dexmedetomidine|Pretreatment of different doses of dexmedetomidine
1479140|NCT03126409|Procedure|No-Touch vein harvesting technique|The No-Touch technique focuses on saphenous vein graft harvesting, featured by preserving the surrounding tissue of the vein while at the same time avoiding manual distension.
1479141|NCT03126409|Procedure|Conventional vein harvesting|During saphenous vein harvesting, surrounding tissue of the vein is stripped off, and manual distension is routinely performed
1479142|NCT03126396|Device|Urgo 310 3166 dressing|Experimental: Urgo 310 3166 dressing
1479143|NCT03126370|Drug|LDV/SOF and TAF|"Subjects will be switched from tenofovir disoproxil fumarate to tenofovir alafenamide and then once on tenofovir alafenamide for 12 weeks, subjects will be given concominant ledipasvir/sofosbuvir for 12 weeks
Other: Blood draws for tenofovir PK, renal function assessment"
1479144|NCT03126357|Other|Product A|Usual Brand Cigarette
1479145|NCT03126357|Other|Product B|FT21039 an electronic tobacco vapor product
1479146|NCT03126357|Other|Product C|FT21092 an electronic tobacco vapor product
1479147|NCT03126357|Other|Product D|FT21018 an electronic tobacco vapor product
1479148|NCT03126357|Other|Product E|4mg nicotine gum
1479149|NCT03126344|Device|King Vision video laryngoscope|nasal intubation using King Vision video laryngoscope Device after general anesthesia induction
1479150|NCT03126344|Device|McGrath MAC video laryngoscope|nasal intubation using McGrath MAC video laryngoscope Device after general anesthesia induction
1479151|NCT03126344|Device|Macintosh laryngoscope|nasal intubation using Macintosh laryngoscope Device after general anesthesia induction
1479152|NCT03126331|Drug|Nivolumab|240mg every 2 weeks. At 12 weeks reassess. If tumor decreases by 10% or more, then hold drug for 12 week and test tumor again. Continue treatment if tumor is not decreased by 10% or more
1479153|NCT03126318|Drug|COR-001|Anti-inflammatory therapy
1479154|NCT03126318|Drug|Placebo|Sterile water with a final buffer of 25 mM Histidine, 8.5% (w/v) trehalose and 0.05% PS80
1479155|NCT03126305|Other|OC-Go|OC-Go, a HIPAA-compliant web-based clinician portal and patient-side mobile application that allows clinicians to create and push tailored treatment assignments to patients on their mobile devices
1479156|NCT03126292|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
1479157|NCT03126292|Other|Child Safety Handout|Handout regarding early child safety
1479158|NCT03126279|Procedure|Total Knee Replacement Surgery|All chronic knee osteoarthritis patients will be recruited as they are on the NHS waiting list for a total knee replacement. Only this group will undergo the procedure
1479160|NCT03126253|Diagnostic Test|Anemia|"Hemoglobin level will be used as the parameter for diagnosing anemia. The HemoCue system was used to estimate the concentration of hemoglobin in capillary blood. WHO guidelines for the diagnosis of anemia that were adopted by the Demographic Health Surveys will be used in this study. Briefly, a hemoglobin concentration of less than 70 g/L will be consider to define severe anemia, 70-99 g/L for moderate anemia, and 100-109 g/L will be presumed to correspond to mild anemia. The above-mentioned classification of anemia as severe moderate and mild categories is based on blood hemoglobin cutoffs (will be adjusted for altitude and smoking) recommended by the Center for Disease Prevention of United States; this classification has also been adopted by the World Health Organization."
1479164|NCT03126188|Drug|Sertraline|Tab. Sertraline 50 mg/day, which will be optimized to 75mg/day after 2 weeks if required, and maintained on the same dose for a minimum period of 6 weeks.
1479165|NCT03126188|Drug|Dosulepin|Tab. Dosulepin 25mg/day, which will be gradually hiked up to 75mg/day over 2 weeks,and the patients will be continued on the same dose for a minimum period of 6 weeks.
1479166|NCT03126188|Drug|Venlafaxine|Tab. Venlafaxine 75mg/day, which will be hiked to 112.5 mg/day after 2 weeks, and the patients will be continued on the same dose for a minimum period of 6 weeks.
1479167|NCT03126175|Device|short radial splint|20cm wide gypsum in the forearm cut to fit the thumb associated a elbow splint made with a 15cm width on the ulnar aspect of the forearm that begins at the middle of the forearm and extends into the armpit.
1479168|NCT03126175|Device|Short radial splint + elbow splint|20cm wide gypsum in the forearm cut to fit the thumb.
1479169|NCT03126162|Procedure|InstilIing normal saline into bladder|Backfilling the bladder with 200 mL of normal saline immediately postoperatively, prior to foley catheter removal, after same-day total laparoscopic hysterectomy can potentially increase time to first spontaneous void and time to discharge.
1479170|NCT03126162|Procedure|Removal of foley catheter|Removal of the foley catheter is routinely performed after same-day laparoscopic hysterectomy
1995270|NCT02809729|Drug|Cefazolin|2 g of cefazolin diluted in 0.9% saline by endovenous, once, at the moment of anesthetic induction
1479174|NCT03126123|Procedure|acetic acid test|Patients will receive acetic acid on the mucosa of the anal canal before the surgical procedure
1479175|NCT03126110|Drug|INCAGN01876|In Phase 1 subjects will receive INCAGN01876 administered intravenously (IV) at the protocol-defined dose according to cohort enrollment. In Phase 2, subjects will be administered IV study drug at the recommended dose from Phase 1.
1479176|NCT03126110|Drug|Nivolumab|Nivolumab will be administered IV at the protocol-defined dose according to assigned treatment group.
1479177|NCT03126110|Drug|Ipilimumab|Ipilimumab will be administered IV at the protocol-defined dose according to assigned treatment group.
1479178|NCT03126097|Drug|JNJ-64155806 150 mg|JNJ-64155806 150 mg (3*50 mg tablet) twice daily will be administered under fed conditions on Days 1 to 7 [JNJ-64155806 Alone Phase] and on Days 60 to 66 [JNJ-64155806 + COCP Coadministration Phase].
1479179|NCT03126097|Drug|Ethinylestradiol/drospirenone 0.02 mg/3 mg|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol administered as combined oral contraceptive pill (COCP) given on Days 18 to 41 (lead-in phase), Days 46 to 69 (coadministration phase - Days 59 to 66 under fed conditions).
1479180|NCT03126097|Drug|COCP Placebo|Participant will receive COCP placebo tablets once daily on Days 42 to 45 (lead-in phase) and Days 70 to 73 (JNJ-64155806 + COCP coadministration phase).
1479181|NCT03126084|Drug|Acetaminophen|1000 mg of intravenous acetaminophen will be administered twice a day
1479182|NCT03126084|Drug|0.25% Bupivacaine|20 ml of 0.25% bupivacaine will be administered to the fascia of the transversus abdominis muscle under ultrasound guidance.
1479183|NCT03126084|Drug|0.5% Bupivacaine+Glucose|15mg of 0.5% bupivacaine will be administered to subarachnoid space through 25G spinal needle
1479184|NCT03126084|Drug|Tramadol HCl|50mg of intramuscular tramadol will be administered when pain score is greater than 3 according to NRS
1479185|NCT03126084|Procedure|Inguinal Hernia Repair|Patients will undergo open inguinal hernia repair with one of the tension free mesh techniques
1479186|NCT03126084|Drug|0.25% Bupivacaine|10 ml 0.25% bupivacaine will be administered quadratus lumborum muscle and erector spinae muscle
1479187|NCT03126071|Drug|Raltitrexed|Raltitrexed:3mg/m2,iv 15min,d1,q3w.
1479188|NCT03126071|Drug|Irinotecan|Irinotecan:250mg/m2,iv 90min,d1,q3w.
1479189|NCT03126071|Drug|Oxaliplatin|Oxaliplatin:130mg/m2,iv 120min,d1,q3w.
1479190|NCT03126071|Drug|Bevacizumab|Bevacizumab:75mg/kg,iv 30min,d1,q3w.
1479191|NCT03126058|Procedure|enhanced recovery after surgery|Patients will undergo enhanced recovery after surgery programs.
1479192|NCT03126045|Device|Standard needle|"Patients will perform a spinal punction with a standard needle, used in the usual practice. The standard needles have the following characteristics : BD 22 G x 3 ½ in, 90mm, Quincke spinal needle, Black hub.
When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
1479193|NCT03126045|Device|Atraumatic needle|"Patients will perform a spinal punction with an atraumatic needle, used in the hematological service of the Lucien Neuwirth Cancerology Institute. The atraumatic needles have the following characteristics : Vygon 24 G × 3 ½ in, 90mm, Whitacre Pencil Point Spinal Needle, Purple hub.
When more than 2 attempts for lumbar puncture fail, the investigator will proceed with standard techniques (BD 20G x 3 ½ in, Quincke spinal needle, 90mm, yellow hub). This is a failed lumbar puncture."
1479195|NCT03126019|Drug|INCB050465|INCB050465 at the protocol-defined starting dose for 8 weeks, followed by INCB050465 at the protocol-defined dose QD
1479196|NCT03126019|Drug|Idelalisib|Idelalisib 150 mg BID
1479197|NCT03126019|Drug|INCB050465|INCB050465 at the protocol-defined starting dose for 8 weeks, followed by INCB050465 at the protocol-defined dose once weekly
1479198|NCT03126006|Procedure|NSPT plus oral hygiene|Non-surgical periodontal therapy under local anesthesia to remove plaque and calculus
1479199|NCT03126006|Other|Oral hygiene alone|It includes pregnant women (with periodontal disease) who will not be given any mechanical treatment such as non-surgical periodontal therapy during pregnancy. However, oral hygiene instructions will be given.
1479392|NCT03124238|Other|Massage|Massage therapy localized to the back of the individuals for a duration of 30 minutes
1995271|NCT02809729|Drug|sterile saline|0.9% saline sterile by endovenous, once, at the moment of anesthetic induction
1995272|NCT02809729|Procedure|oncologic breast surgery|The patient will be submitted to a conservative oncologic breast surgery
1997892|NCT01848548|Procedure|Superior Laryngeal Nerve Block using the Thyrohyoid Membrane as an Anatomic Landmark|The needle is introduced just lateral to midline above the thyroid notch in a slightly medial direction so as to enter the thyrohyoid membrane, and inserted about 1-1.5 cm. Three milliliters of 2% lidocaine is injected.
1479200|NCT03125993|Behavioral|>10000 steps brisk walking|This study is a prospective 4-month follow-up scheme in which patients were treated with the following intervention: > 10000 steps, > five days, per week brisk walking.
1479201|NCT03125980|Drug|capecitabine plus oxaliplatin before and after surgery|"Subjects will receive systemic CapeOX chemotherapy both before and after the radical surgery for at most 4 cycles respectively. They shall have rest after the surgery for at least four weeks before the post-operative chemotherapy. CapOX regimen will be administered as follows:
Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1
Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14
Repeat every 3 weeks (Q3W)"
1479202|NCT03125980|Drug|capecitabine plus oxaliplatin after surgery|"Subjects will first receive radical surgery, then have rest for at least four weeks. Thereafter, subjects will receive systemic CapeOX chemotherapy for at most 8 cycles. CapOX regimen will be administered as follows:
Oxaliplatin 130 mg/m2 iv continue for 2 hours.D1
Capecitabine 1000mg/m2/d PO Bid,once every morning and evening D1-14
Q3W"
1479203|NCT03125967|Other|Philips GoLite Blu HF3429/60|Exposure to daily morning colored light in the 440-485 nm wavelength range
1479204|NCT03125967|Other|Philips LivingColor Aura 70998/60/48|Exposure to daily morning colored light in the 625-740 nm wavelength range
1479205|NCT03125954|Other|standardized exercise treatment for knee OA in Denmark (GLAiD)|objective measurement of physical activity before, during af after the GLAiD intervention
1479206|NCT03125941|Drug|Dexamethasone|pre-operative intravenous administration
1479207|NCT03125928|Drug|Atezolizumab|Monoclonal antibody
1479208|NCT03125928|Drug|Paclitaxel|Chemotherapy
1479209|NCT03125928|Drug|Trastuzumab|Monoclonal antibody
1479210|NCT03125928|Drug|Pertuzumab|Monoclonal antibody
1479211|NCT03125915|Behavioral|Communication skills training video|This video includes 4 scenes of gay couples discussing issues related to HIV prevention, testing, sexual agreements, and drug use. Each scene is viewed twice. The first viewing includes common communication errors. The second viewing portrays more skillful interpersonal communication and a more adaptive resolution to the conversation.
1479212|NCT03125915|Behavioral|substance use module|This activity involves completion of a calendar detailing partners' substance use in the past month and a structured debriefing activity designed to facilitate the formation of couples' goals and limits around substance use.
1479213|NCT03125915|Behavioral|Couples HIV Testing and Counseling|CHTC delivered as per the CDC protocol.
1995273|NCT02809729|Other|Microbiology|Samples for quantitative cultures will be obtained in the operating room before antisepsis and the end of surgery. A sample is also collected with the same patterning, on the first postoperative day, immediately after the removal of the dressing placed in the operating room. Will be passed in a standardized manner, a sterile swab soaked in saline over a standard 5cm by 10cm area determined by a field fenestrated sterile filter paper.
1479217|NCT03125889|Device|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
1479218|NCT03125876|Drug|CT053PTSA|receive oral CT053PTSA once daily until disease progression or unacceptable toxicity occurs, each cycle is defined as 28 days
1479219|NCT03125863|Device|AquaBeam System|The AquaBeam system delivers a high-velocity saline stream under precise electromechanical control and live ultrasound guidance to ablate prostatic glandular tissue without the production of heat. The physician uses ultrasound imaging to plan the treatment contour and depth to define the treatment region. The AquaBeam ablates the target tissue, adhering to the pre-defined treatment zone.
1479220|NCT03125850|Other|routine treatment, care, education of day-ward|routine treatment, care, centralized education of glaucoma knowledge by nurse after admission
1479221|NCT03125850|Other|routine treatment, care, education of inpatient|routine treatment, care, centralized education of glaucoma knowledge by nurse after admission
1479223|NCT03125811|Other|Inhaled Isopropyl Alcohol (IPA)|Three doses within 60 minutes. Doses will occur at 0 minutes, 30 minutes, and 60 minutes. Each dose consists of 3 inhalations of one IPA prep pad. A new prep pad is used at each dose.
1479224|NCT03125811|Drug|Oral Dissolvable Tablet Zofran (ondansetron)|Single dose 4 mg tablet at 0 minutes.
1479225|NCT03125798|Device|LigaSure™|LigaSure™ is supposed to provide improved closure of lymphatic and blood vessels during mediastinal lymph nodes dissection.
1479226|NCT03125798|Device|Monopolar electrocautery|Monopolar electrocautery will be used according to the standard technique for the mediastinal lymph node dissection.
1479227|NCT03125772|Device|TAXUS Element™ Paclitaxel-Eluting Stent System|Texus Element is the next generation Boston Scientific paclitexel-eluting coronary sten and received DCGI approval on April 13th, 2010.
1479228|NCT03125772|Device|Xience PRIME Everolimus-Eluting Stent System|The Everolimus-eluting stent manufactured and distributed by Abbott Vascular Santa Clara, CA, as Xience Prime.
1479229|NCT03125746|Drug|LXI-15029|The investigational product for this study is LXI-15029 capsule, which can be administered orally and the specification included 10 mg and 50 mg. There will be about 6 cohorts during the monotherapy period. LXI-15029 capsules will be administered in a therapeutic cycle of 28 days twice a day orally. The patients will be given LXI-15029 continuously, in a therapeutic cycle of 28 days. Patients will continue therapy with LXI-15029 if good safety and tolerability were assessed by investigators after 1 cycle treatment. The treatment will continue until progression or occurrence of unmanageable toxicity.
1479230|NCT03125746|Drug|LXI-15029+Exemestane|The combined drug in the combined therapy period of this study (investigational product) is Exemestane tablet (specification 25 mg). Exemestane should be taken at similar time every day in case of multiple doses (Cycle 1 Day 1 to Cycl 1 Day 28). If one dose was missed (e.g., forgetting, vomiting, etc.), this dose could not be made up and should be administered at next scheduled time point. And the dose of LXI-15029 will be determinated by safety review committee after dose escalation
1479387|NCT03124303|Procedure|High Density-Electroencephalogram|EEG is a safe non-invasive technology without complications that may be used to help diagnose delirium
1479388|NCT03124303|Procedure|Magnetic Resonance Imaging|MRI scan of brain
1479231|NCT03125733|Procedure|Submucosal tunneling endoscopic septum division|"STESD includes 4 steps:
Mucosal incision: submucosal injection of normal saline-indigo carmine solution is performed 2-3cm proximal to the diverticular septum and a 1.5-2cm longitudinal mucosal incision is made using the endoscopic knife.
Submucosal tunneling: a submucosal tunnel is created using the same technique as applied by Peroral Endoscopic Myotomy (POEM) at both sides of the septum until 1-2cm distal to the bottom of the diverticulum.
Septum Division: cricopharyngeal myotomy is performed longitudinally along the mid-line of the septum and ends in the normal esophageal muscle.
Mucosal Closure: the mucosa incision, as well as any accidental mucosotomy if present, is closed with hemostatic clips."
1479232|NCT03125720|Other|Image fusion of SPECT MPI and fluoroscopy venography|In this study, MPI-Fluoro Fusion tool is used to help the implanting physicians to precisely implant LV lead to the optimal/suboptimal venous segments in the guided group.
1479233|NCT03125707|Other|Registry study|not available
1479234|NCT03125694|Drug|Sitagliptin 100mg|Sitagliptin arm took sitagliptin 100 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
1479235|NCT03125694|Drug|Pioglitazone 30 mg|Pioglitazone arm took pioglitazone 30 mg daily in combination with metformin 500 mg QID and gliclazide 80 mg TDS for 52 weeks
1479236|NCT03125681|Procedure|Remote ischemic conditioning|In the RIC group, RIC is performed before and after coronary anastomoses by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
1479237|NCT03125681|Procedure|Control|In the control group, all the procedures will be same with RIC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
1479238|NCT03125668|Behavioral|Educational Program|At the hospitalization, patients receive the educational program with Power Point®Slides, booklets and orientation about the use of warfarin.
1479239|NCT03125668|Behavioral|Telephone follow-up|"After hospital discharge they receive a telephone follow-up (five calls for six months: 1st call in one week and the others calls month by month until six months).
During the telephone calls the researcher talk with the patient about the topics that were approach in the educational intervention and motivate the patient to follow the recommendations for they have a successful treatment."
1479240|NCT03125668|Behavioral|Face to face counseling|They receive two face to face counseling (1st meeting in three months and the 2nd meeting in six months after hospital discharge). In the face to face counseling the researcher collect the data about anxiety and depression again, health-related quality of life and adverse events related to oral anticoagulation therapy.
1479241|NCT03125655|Diagnostic Test|Inflammatory markers|
1479242|NCT03125642|Drug|Etoposide|"BEAM: 100 mg/m^2 IV over 2 hours BID on Days -5, -4, -3, -2 | CBV: 150 mg/m^2 intravenously over 4 hours every 12 hours starting at 6 a.m. and 6 p.m. on Days -6, -5, -4"
1479243|NCT03125642|Drug|BCNU|BEAM & CBV: 300 mg/m^2 IV over over 2 hours on Day -6
1479244|NCT03125642|Drug|AraC|BEAM: 100 mg/m^2 IV over 1 hour BID on Days -5, -4, -3, -2
1479245|NCT03125642|Drug|Melphalan|BEAM: 140 mg/m^2 IV over 20 minutes on Day -1
1479246|NCT03125642|Procedure|Peripheral blood stem cell transplantation|All Arms: Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF.
1479247|NCT03125642|Biological|G-CSF|All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day +5 until the ANC is >2500 x 10^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm^3
1479248|NCT03125642|Drug|Cyclophosphamide|"CBV: 1.5 gm/M^2 over 2 hours at 10 a.m. on Days -6, -5, -4, -3 | CY/TBI: 60 mg/kg IV over 2 hours on Days -7, -6"
1479249|NCT03125642|Radiation|Total Body Irradiation|CY/TBI: 165 cGy bid on Day -4, -3, -2, -1
1479250|NCT03125629|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
1479251|NCT03125629|Procedure|Positron Emission Tomography|Undergo PET/CT and PET/MRI
1479252|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 2 months
1479253|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 3 months
1479254|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 4 months
1479255|NCT03125616|Biological|4CMenB Vaccine|The infants will receive an intramuscular injection of the 4CMenB vaccine at 12 months
1479256|NCT03125603|Other|Consultation of the patient's medical files at the hospital|Gradation of the adverse events according to CTCAE scale 4.03 (June 2010).
1479257|NCT03125590|Other|Testing the PEQ (Personalized Exercise Questionnaire)|Administer the questionnaire to 114 participants to classify their facilitators, barriers and preferences to exercise
1479258|NCT03125577|Biological|4SCAR19 and 4SCAR22|4SCAR19 and 4SCAR22
1479259|NCT03125577|Biological|4SCAR19 and 4SCAR38|4SCAR19 and 4SCAR38
1479260|NCT03125577|Biological|4SCAR19 and 4SCAR20|4SCAR19 and 4SCAR20
1479261|NCT03125577|Biological|4SCAR19 and 4SCAR123|4SCAR19 and 4SCAR123
1479262|NCT03125564|Procedure|Fecal Microbiota Transplantation|Feces from healthy donor will be diluted with sterile saline, blended and filtered. Supernatant will be infused to subject.
1479263|NCT03125564|Procedure|Sham|Infusion of saline water.
1479264|NCT03125564|Procedure|Fecal and Mucosal Microbiota Assessment|To assess the fecal and mucosal microbiota before and after Fecal Microbiota Transplantation
1479265|NCT03125551|Dietary Supplement|Ginger|Ginger dosage at daily recommended allowance
1479266|NCT03125551|Dietary Supplement|Garlic|Garlic dosage at daily recommended allowance
1479267|NCT03125551|Dietary Supplement|Ginkgo Biloba|Ginkgo Biloba dosage at daily recommended allowance
1479268|NCT03125551|Dietary Supplement|Ginseng|Ginseng dosage at daily recommended allowance
1479269|NCT03125551|Other|Placebo|Daily dosage strategy
1479270|NCT03125538|Other|Motor Imagery|"Together with physical rehabilitation performed with physiotherapists, participants from the experimental group will mentally rehearse 3 different locomotor exercises that they already physically performed beforehand.
Exercise 1: 10m Walk
Exercise 2: Timed Up and Go test (rise up from a chair, walk 3 meters, turn around, come back to the chair, turn around and sit down)
Exercise 3: Stairs climbing test (climb up 4 stairs, turn around, climb down the for stairs)
Two min of MIP will be scheduled 5 times/day, during rest periods, so that patients complete 10min of MIP per day."
1479271|NCT03125538|Other|Control Task|"Together with physical rehabilitation performed with physiotherapists, participants from the control group will spend equivalent time focusing on a cognitive task without impact on motor rehabilitation ((word scramble game).
Two min of this cognitive task will be scheduled 5 times/day, during rest periods, so that patients complete 10min of control task per day."
1479272|NCT03125525|Device|Cefaly device|Use of Cefaly based upon the protocol of the approval study of the device, in which it is used once every day on the migraine prevention program
1479273|NCT03125512|Device|Night Shift positional device|Night Shift is a small, positional therapy device that is worn at the back of the neck using a latex free silicone rubber strap. The strap is adjustable and is secured with a magnetic clasp. When a supine position is detected, the device vibrates with increasing intensity till the subject changes to a non-supine position.
1479274|NCT03125512|Device|continuous positive airway pressure|Automated adjusting continuous positive airway pressure
1479275|NCT03125499|Other|Previous treated with TPX-100|No intervention, only observational
1479276|NCT03125486|Drug|SC belimumab 200 mg|Belimumab subcutaneous 200 mg will be supplied for compassionate use for the identified individual subject.
1479277|NCT03125473|Biological|VXA-G1.1-NN Oral Vaccine|The drug product will be provided as small white enteric-coated tablets. Multiple tablets will be administered to deliver the high total doses.
1479278|NCT03125460|Device|Xpert Bladder Cancer Monitor|in vitro diagnostic test for the recurrence of bladder cancer in patients that have been previously diagnosed with bladder cancer
1479279|NCT03125447|Other|speed and accuracy answer to visual stimuli|A yellow fish swimming over a blue-green background will appear on the screen of virtual glasses. The child will have to give as fast as possible the direction of the fish pushing the left or right button of a computer mouse
1479280|NCT03125434|Other|EOS full-spine, MRI, gait analysis|full-spine stereoradiography, high-resolution spine muscle MRI and 3D gait analysis will be performed
1479281|NCT03125421|Procedure|standard preventive methods of pressure sores|"During the control period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be these ongoing in each center and involve the following components: lower eyelid and ocular protection by any method, inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left, and no use of specific device to prevent pressures sores at the head and/or thorax, and/or knees, and/or feet.
The following nonspecific methods to prevent pressures sores will be performed at the discretion of each center according to its usual practice: mattress, upper eyelid protection, main devices securely fasten, arms position, abdomen supported or not, mouth care, enteral nutrition continued in the prone position, skin protection and/or massage."
1479282|NCT03125421|Procedure|experimental multifaceted preventive methods of pressure sores|"During the experimental period, the following specific methods to prevent pressure sores in the prone position (in ARDS patients mechanically ventilated via tracheal route) will be systematically applied: lower eyelid protection by horizontal strap, ocular protection by methylcellulose, 15° inclination of the body from the horizontal position, intermittent head mobilization to the right or to the left every four hours, and use of specific device to prevent pressures sores at the head, thorax, knees, and feet.
The following nonspecific methods to prevent pressures sores will be applied as in the control period described above except for the following: the abdomen will not be supported and the skin will not be protected."
1479283|NCT03125408|Diagnostic Test|HCV Assay|Molecular diagnostic test to detect Hepatitus C
1479284|NCT03125395|Drug|Lumacaftor|LUM/IVA will be administered q12h
1479285|NCT03125395|Drug|Ivacaftor|LUM/IVA will be administered q12h
1479286|NCT03125382|Device|Carelink System|Patients start to perform device data transmission through Carelink system
1479287|NCT03125382|Device|In office standard visit|Patients start or mantain in office standard visits
1479288|NCT03125369|Procedure|Sleeve gastrectomy + duodeno-jejunal bypass|
1479289|NCT03125369|Procedure|Roux-Y gastric bypass|
1479290|NCT03125356|Other|Diet Soda|Subjects will be asked to consume diet soda three times daily for eight weeks.
1479291|NCT03125343|Procedure|endoscopy|"Continuous follow-up. All patients with complete response will be followed for ten years. Details from the follow-up schedule will be registered in clinical record forms including information on the endoscopic findings, MRI findings and digital examination.
They will be followed ever third month for the first two years as follows:
PET-CT is optional, but can be performed at inclusion
Pelvic MRI including diffusion weighted imaging according to appendix C.
Clinical examination
Endoscopy (flexible sigmoidoskopy) with photodocumentation
CEA
After two years the patients will be followed every six month with:
Pelvic MRI including diffusion weighted imaging according to appendix as at baseline
Clinical examination
Endoscopy with photodocumentation
CEA"
1479292|NCT03125343|Procedure|Surgery|Surgery according to recommendations from the multidisciplinary group in patients that prefer surgery to a watch and wait strategy
1479293|NCT03125343|Device|MRI|
1479294|NCT03125330|Behavioral|Professional coaching|Professional coaching is provided by the Principal Investigator via video conference.
1479295|NCT03125317|Other|Music|a kind of music which the participant likes will be listened using speakers
1479296|NCT03125317|Other|Valsalva maneuver|Participant will be asked to take a deep breath and exhale the air out in 15 seconds
1479297|NCT03125317|Other|control|No intervention
1479298|NCT03125304|Other|acupuncture|They will be treated seven days before expected menstrual onset with once a day and three times a week for therapy. During the menstrual period,they will be treated everyday when they are having pain.Every treatment lasts 30 minutes. The trial period will consist of three menstrual cycles of treatment and three menstrual cycles in the follow-up period.
1479299|NCT03125291|Behavioral|Bridges 4-week Program|Participants receive 4, 2-hour sessions over a 6-week period.
1479300|NCT03125278|Other|Medication knowledge|Participants will be asked questions over the phone about their medications
1479301|NCT03125265|Other|dietary intake of omega-3 and omega-6 polyunsaturated fatty acids|
1479302|NCT03125252|Other|Bundle|"Awakening and Breathing Coordination Delirium monitoring and management (detection and management of delirium) Early mobility
Factors of environment:
thirst
noise
pain and well-being
sleep
isolation"
1479393|NCT03124225|Drug|DMARD|
1997894|NCT01841736|Other|Laboratory Biomarker Analysis|Correlative studies
1479303|NCT03125252|Other|Standard Paramedical and Medical practices|"The current recommendations recommend the following scheme:
Identification and correction of an organic cause / factors (sepsis, metabolic disorders, withdrawal syndrome, pain)
Use of non-pharmacological means (early mobilization, correction of sensory deficits, temporo-spatial reorientation strategies)
Use of reference antipsychotic pharmacological means"
1479304|NCT03125239|Drug|Merestinib|Oral, once a day, Merestinib Only- Lead in period on week. The followed by cycles on combination therapy with Merestinib and LY2874455 (28 days long)
1479305|NCT03125239|Drug|LY2874455|This will be followed by cycles of combination therapy with merestinib and LY2874455. Each of these cycles are 28 days long. • LY2874455 will be taken by mouth twice a day. You may take LY2874455 twice daily for 14 days, 21 days, or 28 days each cycle depending on the dose level you are assigned.
1479310|NCT03125200|Drug|ADCT-502|intravenous infusion
1479311|NCT03125187|Biological|Sodium heparin UQ Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
1479312|NCT03125187|Biological|Sodium heparin FK Intravenous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the intravenous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
1479313|NCT03125161|Drug|HAI|HAI
1479314|NCT03125161|Drug|chemotherapy ± target therapy|chemotherapy ± target therapy
1479315|NCT03125148|Device|Enteral stenting|Enteral stent for malignant duodenal obstruction
1479316|NCT03125083|Biological|Biological dosage from plasma|The purpose of this study is to determine the role of inflammation in the high prevalence of psychiatric disorders in skin-restricted lupus (SRL) patients. SRL is an inflammatory disease. Inflammation can lead to a decrease in the synthesis of neurotransmitters via the activation of the IDO enzyme and to induce the synthesis of neurotoxic molecules (kynurenin pathway). This leads to the development of psychiatric disorders.
1479317|NCT03125070|Other|Best Practice|Receive usual care
1479318|NCT03125070|Other|Internet-Based Intervention|Receive INSPIRE and survivorship care plan
1479319|NCT03125070|Other|Survey Administration|Correlative studies
1479320|NCT03125057|Drug|Hemoporfin PDT|Photodynamic therapy is performed using hemoporfin. Hemoporfin（5mg/kg）is infused for 20 minutes, followed by light illumination at 10 minutes from the start of infusion. Different light dose of PDT is applied to the patients.
1479321|NCT03125031|Device|Rainbow adhesive adult/pediatric sensor|
1479322|NCT03125031|Device|Rainbow adhesive adult/neonatal sensor|
1479323|NCT03125018|Device|LNCS ADTX Sensor|Noninvasive pulse oximeter sensor.
1479324|NCT03125005|Device|Rainbow Universal Pulse Oximeter Sensor|
1479325|NCT03124524|Drug|estradiol valerate/dienogest|oral, 28 tablets including 2 tablets of 3mg estradiol valerate, 5 tablets of 2mg estradiol valerate plus 2mg dienogest, 17 tablets of 2mg estradiol valerate plus 3mg dienogest, 2 tablets of 1mg estradiol valerate and 2 non hormonal tablets as placebo, respectively
1479326|NCT03124524|Drug|ethinylestradiol and drospirenone|oral,0.03 mg ethinylestradiol and 3 mg drospirenone (21 tablets)
1479327|NCT03124511|Procedure|Surgery for breast cancer|Breast cancer resection performed via lumpectomy or mastectomy with or without sentinal node biopsy and axillary lymph node dissection.
1479328|NCT03124498|Biological|CIK Cell|Autologous cytokine-induced killer (CIK) cell
1479329|NCT03124979|Device|LNCS DBI Sensor|Noninvasive Measurement of SpO2
1479330|NCT03124966|Device|Pulse Oximeter sensor|
1479331|NCT03124927|Device|DCI pulse oximeter sensor|
1479332|NCT03124914|Other|Neuromuscular tests|Neuromuscular tests
1479333|NCT03124901|Device|DCI pulse oximeter sensor|
1479334|NCT03124875|Device|LimFlow Stent Graft System|Creation of an AV fistula in below-the-knee vasculature for the treatment of critical limb ischemia.
1479335|NCT03124836|Device|Pulse Oximeter Sensor|
1479336|NCT03124823|Device|Rainbow DCI Sensor|Noninvasive pulse oximeter sensor
1479337|NCT03124485|Procedure|Endoscopic Sleeve Gastroplasty|An oesophageal overtube is then inserted to facilitate passage of the endoscope mounted with Overstitch device. A series of full thickness sutures done with Overstitch in the triangular stitch pattern as mentioned by Lopez-Nava[29] will be placed according to the APC markings. The suturing is initiated from the antrum distally and moved proximally towards the gastric fundus. A total of 6 to 8 plications are placed to reduce the gastric lumen. Five sham dressings would also be applied to patient's abdominal wall during the first week to minimize the bias in pain scoring.
1479338|NCT03124485|Procedure|Laparoscopic Sleeve Gastrectomy|Sleeve gastrectomy is then performed using lapaorscopic linear staplers, starting from a point 5-6cm proximal to the pylorus up to the angle of His along the left side of the Mid-sleeve tube. Haemostasis of the staple line is secured by suture plication with the Mid-sleeve tube in situ to ensure no compromise of the gastric tube lumen. All the wounds are closed with staples after local anaesthetic infiltration and covered with non-transparent dressings.
1479339|NCT03124472|Procedure|uterine artery ligation|Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged
1479389|NCT03124290|Other|paced auditory serial addition test (PASAT)|A number between 1 to 9 is called every three seconds through a speaker, and the performer calculates the last two numbers and shouts the answer.
1479394|NCT03124212|Other|CASCADE genetic screening|Family-based cohort of mutation carriers, blood relatives who test negative, and untested blood relatives
1483269|NCT03095326|Biological|PCV Vaccine|Pneumococcal conjugate vaccine
1479340|NCT03124472|Procedure|Lower segment Cesarean section|"Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.
- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.
Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.
Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.
Closure of the anterior abdominal wall in layers"
1948772|NCT01653535|Behavioral|Fast Track|First grade intervention included a weekly two-hour curriculum-based day that was attended by high-risk children, parents, program staff, and teachers of the high-risk children. During each session, the staff modeled academic tutoring with target children in the presence of their parents. In 3rd and 4th grades, intervention consisted of monthly parent and child curriculum-based sessions during the academic year, home visiting, and teachers implementing the in-class PATHS prevention program. In 5th and 6th grades, intervention included monthly parent and child groups and home visiting. In grades 8, 9 and 10 staff developed sessions on an as needed basis to cover topics like transition to high school, note-taking, and study skills.
1479342|NCT03124446|Behavioral|Mindfulness-Based College|MB-College is an 8-week, 9-session curriculum providing systematic and intensive training in mindfulness meditation practices, applied to health behaviors relevant to college students. The curriculum is based on the manualized and standardized Mindfulness-Based Stress Reduction. The course builds a foundation of mindfulness self-regulation skills, including attention control, self-awareness and emotion regulation. It then directs those skills towards participants' relationships with health-related factors particularly salient in college undergraduates, including physical activity, diet, alcohol consumption, sleep, stress, social relationships, cognitive performance, and emotion regulation. Health behavior goal setting, and support for behavior change are integrated in the curriculum.
1479343|NCT03124446|Behavioral|Health education wait list control|In the health education wait list control, participants will be offered a 15-30 minute, one-on-one meeting with the MB-College instructor. There, participants will learn about the MB-College curriculum, and have opportunities to share their relationship with common determinants of undergraduate student health and performance, described above. Together, the student and instructor will explore ways the course may assist in shifting these parts of their lives, as they see best. A deliberate relationship will be formed with the instructor.
1479344|NCT03124433|Drug|Apalutamide|Participants will receive oral apalutamide 240mg daily for 12 weeks
1479345|NCT03124420|Drug|Lansoprazole|Group A: lansoprazole 30 mg b.i.d. for 7 days Group B: lansoprazole 30 mg b.i.d. for 14 days
1479346|NCT03124420|Drug|Amoxicillin|Group A: amoxicillin 1 g b.i.d. for 7 days Group B: amoxicillin 1 g b.i.d. for 14 days
1479347|NCT03124420|Drug|Clarithromycin|Group A: clarithromycin 500 mg b.i.d. for 7 days Group B: clarithromycin 500 mg b.i.d. for 14 days
1479348|NCT03124407|Drug|Capsaicin Topical Solution|OTC TFM compliant product with 0.25% capsaicin
1479349|NCT03124407|Other|Drug product vehicle|This is the vehicle for the active treatment drug product
1479350|NCT03124797|Device|RD DCI Sensor|Noninvasive pulse oximeter sensor
1479351|NCT03124784|Device|RD Disposable Sensors|Noninvasive pulse oximeter sensor
1479352|NCT03124771|Device|Rainbow Resposable Adhesive Sensors|Noninvasive Measurement of SpHb
1479353|NCT03124758|Device|Hemoglobin Sensor ((Rainbow Reusable DCI, DCIP))|Measurement of Noninvasive Hemoglobin (SpHb)
1479354|NCT03124693|Device|Rainbow DCI pulse oximeter sensor|
1479355|NCT03124680|Combination Product|Opioid free|Peroperative opioid free anesthesia will be obtained via a combination of dexmedetomidine, ketamine, lidocaine and magnesium sulfate
1479356|NCT03124680|Combination Product|opioid group|Opioid anesthesia will follow the current standard approach of our hospital.
1479357|NCT03124667|Behavioral|Games|The game training will emphasize general and exercise-specific dual task processing, self-priming and certainty training.
1479358|NCT03124667|Behavioral|Videos|The video training will emphasize health and educational information.
1479359|NCT03124654|Behavioral|Education|Patients will receive several questionnaires to fill in. Knowledge about NOACs will be assessed with a newly developped questionnaire and an educational program will be dispensed while analysing the answers (reactive educational program).
1479362|NCT03124628|Other|Flywheel resistance exercise|Flywheel resistance exercise, originally designed to maintain function, size and quality of skeletal muscle during spaceflight, employs iso-inertial technology rather than gravity dependent weights, which allows for coupled accommodated concentric and eccentric muscle actions, and brief episodes of eccentric overload.
1479363|NCT03124628|Other|Weight-stack resistance exercise|Conventional weight-stack resistance exercise
1479364|NCT03124615|Drug|Enzalutamide|Enzalutamide is a FDA and Therapeutic Goods Administration (TGA, Regulatory Authority of therapeutic goods in Australia) approved treatment for castration resistant prostate cancer
1479365|NCT03124589|Behavioral|Online Gambling Internet Intervention|CAMH's online gambling intervention which includes self-help materials as well as a personalized feedback component.
1479366|NCT03124576|Device|Implantable loop recorder|Continuous rhythm monitoring Medtronic
1479390|NCT03124277|Dietary Supplement|Fortifit®|Best local diet + two servings (40 grams each) of powder (Fortifit®; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
1948780|NCT01639040|Drug|Dupilumab|Dupilumab 300 mg once weekly (QW) for 4 weeks
1948781|NCT01639040|Drug|Placebo (for Dupilumab)|Placebo (for Dupilumab) once weekly (QW) for 4 weeks
1948782|NCT01639040|Other|Topical Corticosteroid (TCS)|TCS such as methylprednisolone aceponate 0.1%, mometasone furoate 0.1%, or betamethasone valerate 0.1%
1997895|NCT01841736|Drug|Pazopanib Hydrochloride|Given PO
1997896|NCT01841736|Other|Placebo|Given PO
1997897|NCT01841736|Other|Quality-of-Life Assessment|Ancillary studies
1479369|NCT03124550|Behavioral|Exergame Experience|Fitbit Charge HR will be used to measure physical activity and sedentary behavior during waking hours. Each participant will wear a Fitbit for a period of one week at baseline and during the entire 4-week pilot study. Data on step counts, heart rate, and moderate/vigorous activity from the Fitbits will be transmitted wirelessly to our secure research server and will be used to assess changes in physical activity and sedentary behavior over the course of the study. Participants will be instructed to wear the monitor continuously on the wrist and will be provided with a log to document the exact times of day when they wore the monitor and took it off. Data will be analyzed using previously validated accelerometer count cut-points for adults after accounting for invalid data and wear time.
2000854|NCT03323424|Radiation|Systemic treatment + Stereotactic Body Radio-Therapy (SBRT)|"According to the usual practice, patients will receive their systemic treatment, composed of :
Taxane + trastuzumab +pertuzumab for metastatic breast cancers;
FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;
5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.
If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice.
In addition to the systemic treatment, patients randomized into this experimental group will receive a SBRT of 45Gy in 3 fractions for hepatic and pulmonary metastasis, 27Gy in 3 fractions for bone metastasis and 33 Gy in 3 fractions for intra-cranial metastasis."
2000855|NCT03323424|Other|Systemic treatment|"According to the usual practice, patients will receive their systemic treatment, composed of :
Taxane + trastuzumab +pertuzumab for metastatic breast cancers;
FOLFOX or FOLFIRI + cetuximab for metastatic colorectal cancers;
5FU-Platine + cetuximab for metastatic head and neck cancers; for six cycles and a maintenance of the targeted therapy until progression or unacceptable toxicity.
If progression occurs before the 6th cycles, patients could receive a different line of treatment, according to the usual practice."
2000856|NCT03323411|Behavioral|Advance Care Treatment Plan|subjects in experimental group are taught information on dementia mechanical ventilation tube feeding and cardiopulmonary resuscitation
1479373|NCT03124368|Drug|ACH-0144471|Participants will receive study drug for 14 days (Treatment Period), followed by a taper over the next 7 days (Taper Period)
2000857|NCT03323398|Biological|mRNA-2416|mRNA-2416 escalating dose levels
2000858|NCT03323385|Drug|N1539|Once Daily
2000859|NCT03323385|Drug|Placebo|Once Daily
1479379|NCT03124342|Other|VANDERBILT ICU RECOVERY PROGRAM|"10-component ICU Recovery Program intervention, including:
Nurse Practitioner In-Person Visit at the time of transfer from the ICU
Provision of an ICU Recovery Program Pamphlet describing post-intensive care syndrome and providing online resources
Performance of formal medication reconciliation at the time of transfer from the ICU
Access to a dedicated 24-hour a day, 7-day a week contact line
ICU Recovery Clinic Visit Medical Examination.
ICU Recovery Clinic Medication Reconciliation and Counseling
ICU Recovery Clinic Cognitive/Mental Health Assessment and Psychoeducation. A brief session of psychotherapy conducted by a clinical psychologist
ICU Recovery Clinic Case Management. A brief case management consultation
ICU Recovery Clinic Patient Centered Consultation. A final consultation with patients and families by a PCCM physician
Directed Subspecialty Referrals"
1479380|NCT03124329|Procedure|Coronally Advanced Flap|Coronally advanced flap will be performed. Briefly, sulcular incisions will be made. Oblique incisions will be made on each papilla requiring root coverage. In the region coronal to the mucogingival junction (MGJ), mucoperiosteal flap will be elevated. Apical to the MGJ, sharp dissection will be performed to the periosteum allowing split-thickness flap elevation to be performed. Epithelium is removed from the papillae adjacent to the recession and the flap is coronally positioned and stabilized with interproximal sutures and apico-coronal interrupted sutures to close the vertical releasing incisions.
1479381|NCT03124329|Procedure|Intrasulcular Tunneling|Initial sulcular incisions are made and small, contoured blades and mini curettes are used to create the recipient pouches and tunnels. The tunnel will be subperiosteal in location. The incision is extended to one adjacent tooth both mesially and distally. This incision maintains the full height and thickness of the gingival component and enables access beneath the buccal gingiva. The connective tissue beyond the mucogingival line will be dissected and free the buccal flap from its insertions to the bone around each tooth. Muscle fibers and any remaining collagen fibers on the inner aspect of the flap, which prevent the buccal gingiva from being moved coronally, are cut. The papillae are kept intact and undermined to maintain their integrity and carefully released from the underlying bone, which allows the coronal positioning of the papillae. An envelope, full-thickness pouch, and tunnel are created and extended apically beyond the mucogingival line by blunt dissection
1479382|NCT03124329|Biological|Vestibular Incision Subperiosteal Tunnel Access (VISTA)|The VISTA approach begins with a Vestibular Incision Subperiosteal Tunnel Access. Through this incision a subperiosteal tunnel is created, exposing the facial osseous plate and root dehiscence. This tunnel will be extended at least one or two teeth beyond the teeth requiring root coverage to mobilize gingival margins and facilitate coronal repositioning. Additionally, the subperiosteal tunnel is extended interproximally under each papilla as far as the embrasure space permits, without making any surface incisions through the papilla. The mucogingival complex is then advanced coronally and stabilized in the new position with the coronally anchored suturing technique, which entails placing a horizontal mattress suture apical to the gingival margin of each tooth. The suture is tied to position the knot at the midcoronal point of the facial aspect of each tooth, which is secured with help of composite resin to prevent apical relapse of the gingival margin during initial stages of healing.
1479383|NCT03124329|Device|Leukocyte-Platelet Rich Fibrin (L-PRF)|"Immediately prior to surgery, 72 mL of blood should be drawn from each patient by venipuncture of the antecubital vein and collected in a sterile glass test tube without any anticoagulant. Tubes should be centrifuged at 2,700 rpm for 12 minutes within 2 minutes after blood draw. For individuals on anti-coagulant therapy or supplements to interfere with coagulation, centrifugation will be for 18 minute. After centrifugation, each L-PRF clot will be separated from the portion of red blood cells (red thrombus), obtaining a fibrin clot with a red small portion in order to include the buffy coat richer in leucocytes. The L-PRF clot is condensed and modeled on a sterile surgical plate. L-PRF will be used within 60 minutes after the preparation."
1479384|NCT03124316|Behavioral|Anticipated regret|Induce awareness of future regret about the unwanted behaviour
1479385|NCT03124316|Behavioral|Material incentive|Inform that valued objects will be delivered if and only if that has been progress in performing the desired behaviours
1479391|NCT03124277|Other|Control Group|Best local diet
1479396|NCT03124186|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
1479397|NCT03124173|Other|Training session|The subjects will be trained to realize several versions of a learning task of conditional visuo-motor associations.
1479398|NCT03124173|Other|First fMRI session|In this session (involving a condition specific to man and a condition that we are certain to obtain in the monkey), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and three Manual responses (3 MRI-compatible mouse buttons).
1479399|NCT03124173|Other|Second fMRI session|In this session (involving a condition specific to man and a condition that we are almost certain to obtain in monkeys), subjects will have to learn by trial and error during successive trials, the conditional associations between three abstract stimuli and Three orofacial responses (3 movements of the mouth).
1479400|NCT03124173|Other|Third session of fMRI|In this session (involving a human-specific condition and a condition we hope to achieve in the monkey), subjects will have to learn by trial-error in successive trials, conditional associations between three abstract stimuli and three verbal or Vocals.
1479401|NCT03124160|Drug|Mona Lisa® NT Cu380 Mini|Mona Lisa® NT Cu380 Mini
1479402|NCT03124160|Drug|ParaGard® CuT380A|ParaGard® CuT380A
1479403|NCT03124147|Device|Neuroconn Eldith stimulator by Magstim|Transcranial direct current stimulation to the ipsilesional hemisphere, contralesional hemisphere, or both, paired with task-oriented therapy.
1479404|NCT03124134|Device|Gelesis200|Encapsulated hydrogel
1479405|NCT03124134|Other|Water, only (placebo)|300 mL of water
1479406|NCT03124121|Drug|Golimumab|A biologic agent which acts by antagonising the effects of tumour necrosis factor (TNF) alpha
2000860|NCT03323372|Drug|3% potassium nitrate and 0.25% sodium fluoride|
2000861|NCT03323372|Drug|5% potassium nitrate and 2% sodium fluoride|
1479410|NCT03124095|Behavioral|Combined exercise Group|The subjects of the combined training group will undergo the intervention three times a week for eight weeks. The combined group will carry out both resistance and aerobic exercises in the same session. The resistance training will be comprised by ten exercises which will alternate body segments with maximum repetitions in the first set and the lower limit of the repetitions interval in the next sets. Along the training, the number of series will be increased whereas the number of repetitions will be decreased. The intensity of the aerobic exercises will be based on the percentage of the heart rate of the anaerobic threshold on the first weeks and on the speed of the anaerobic and aerobic threshold on the last weeks
1479411|NCT03124082|Drug|Remifentanil|continuous infusion intraop
1479412|NCT03124082|Drug|Ketamine|bolus 0,5 mg/kg + infusion 0,25 mg/kg/h
1479413|NCT03124082|Drug|Lidocaine|lidocaine bolus 1 mg/kg + infusion 1 mg/kg/h
1479414|NCT03124082|Drug|Clonidine|clonidine 4 mcg/kg
1479415|NCT03124056|Device|Extracorporeal photopheresis|Extracorporeal photopheresis using non-open system
1479416|NCT03124043|Other|Livongo for Diabetes program|See description in arm/group description.
1479417|NCT03124030|Procedure|simple dental extraction|dental extraction is performed by an expert oral surgeon within 20 minutes. Non-resorbable suture are applied
1479418|NCT03124017|Other|Electronic alert and the Geneva Risk Score calculation tool issued in the electronic patient chart|
1479419|NCT03124004|Procedure|periodontal debridement|with ultrasonic device supragingival and subgingival full-mouth debridement is provided
1479420|NCT03123991|Behavioral|UP-A adapted as a preventive intervention|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
1479421|NCT03123991|Behavioral|Same than experimental group (EG), after EG finishes|The Spanish Version of the Unified Protocol for the Transdiagnostic Treatment of Emotional Disorders in Adolescents (UP-A) adapted as a school-based anxiety and depression preventive intervention. The UP-A (Ehrenreich-May et al., 2016) is a transdiagnostic anxiety and depressive disorders treatment protocol that implement a set of core principles to address common factors underlying youth anxiety and depressive symptoms in an individual setting. Core modules of the UP-A include: (1) Building and Keeping Motivation; (2) Getting to Know Your Emotions and Behaviors; (3) Behavioral Activation; (4) Sensational Awareness; (5) Being Flexible In Your Thinking; (6) Awareness of Emotional Experiences; (7) Situational Emotion Exposures and (8) Keeping it Going - Maintaining Your Gains.
1479422|NCT03123978|Drug|Enzalutamide|Given PO
1479423|NCT03123978|Drug|Niclosamide|Given PO
1479424|NCT03123328|Device|Radical-7 Pulse CO-Oximeter and sensor|Noninvasive device that measures hemoglobin.
1479425|NCT03123315|Device|Ureteral Illuminating Catheter|This is a very thin tube that goes into a ureter to more effectively find and track the ureter during surgeries
1479426|NCT03123289|Drug|68-Gallium citrate PET/CT scan|After establishment of an intravenous access, approximately 5 mCi of 68Ga-citrate (Zevacor Molecular, Somerset, NJ, USA) will be administered intravenously. Whole body PET/CT scan will be performed after 60 minutes of uptake phase.
1479427|NCT03123289|Drug|18F FDG PET/CT scan|Subjects will undergo FDG PET/CT scan using the same imaging parameters either on the same day or within the next 24-48 hours. The subjects will be requested to fast for a minimum of 4 h prior to PET acquisition. After confirmation of a blood glucose level ≤200 mg/dl, technologists will establish the intravenous access and the subject will receive approximately 10 mCi of 18F-FDG (Zevacor Molecular, Somerset, NJ, USA) intravenously. The subject will be placed in uptake room for 60 minutes to allow for optimal localization of the compound. The subjects will be requested to void prior to administration of 18FDG and again prior to image acquisition.
1479428|NCT03123276|Drug|Pembrolizumab|humanized IgG4 PD-1 blocking antibody
1479429|NCT03123276|Drug|Gemcitabine|Doses of 800, 1000 and 1200 mg/m2 will be used in dose escalation phase.
1479430|NCT03123250|Device|Aquablation|To utilizes proprietary heat-free high-velocity waterjet technology to resect and remove prostate tissue using the AQUABEAM system, which is a personalized image-guided tissue removal system.
1479431|NCT03123237|Diagnostic Test|DMSA scan|We explore the possible role of DMSA to detect renal affection in diabetic &/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control & diabetic &/or hypertensive patients.
1479432|NCT03123224|Behavioral|Combined Aerobic and Resistance Exercise + Caregiver Skills Training|The combined moderate to high intensity combined aerobic and resistance exercise training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
1479433|NCT03123224|Behavioral|Stretching Balance and Flexibility + Caregiver Skills Training|The stretching, balance and flexibility training + skills training group consists of six months of physical exercise + caregiver skills training followed by an additional six months of follow-up for a total study duration of twelve months. All aspects of these combined interventions will be delivered through mobile technology thus obviating some of the obstacles to caregivers face in meeting their own needs. Caregivers will be provided with study issued equipment (e.g., exercise equipment, activity monitoring devices, and tablets) to complete all elements of the intervention.
1479434|NCT03123211|Drug|Veliparib|Veliparib will be administered orally.
1479435|NCT03123198|Behavioral|Dialectical Behavior Therapy|DBT is a multimodal comprehensive psychosocial treatment.
1479436|NCT03123185|Drug|Placebo|Tablet and solution formulation
1479437|NCT03123185|Drug|BI 705564|Tablet and solution formulation
1479438|NCT03123185|Drug|BI 705564 (Test)|Fed state
1479439|NCT03123185|Drug|BI 705564 (Reference)|Fasting state
1479440|NCT03123172|Diagnostic Test|arterial and central venous blood gases|withdrawal of arterial and central venous blood gases to measure Co2 gap
1479441|NCT03123159|Diagnostic Test|DxN HBV Assay|Molecular diagnostic test to detect Hepatitis B
1479442|NCT03123146|Behavioral|Functional Behavior-Based Cognitive Behavioral Therapy|Fb-CBT involved nine 2-hour weekly sessions with three to four children in each group and two therapists. Therapy consisted of group activities, individual work in parent-child dyads, group parent training, and social skills exercises.
1479443|NCT03123965|Drug|glecaprevir|It will be administered orally.
1479444|NCT03123965|Drug|pibrentasvir|It will be administered orally.
1479445|NCT03123952|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
1479446|NCT03123939|Genetic|CTL019|2 to 5 x 10(6) autologous CTL019 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
1479447|NCT03123913|Drug|Testosterone Enanthate|Testosterone enanthate in oil (140mg) delivered via intramuscular injections every 2 weeks.
1479448|NCT03123913|Drug|Somatropin|Genotropin (5.0 μg/kg/day) delivered via subcutaneous injections.
1479449|NCT03123900|Behavioral|Physical exercise|The structured physical activity plan consists of a walking program with an initial progressive phase (first week: 30 minutes/session and second week: 45 minutes/session, with a Borg scale of perceived exertion between 9 and 10) and an improvement and maintenance phase (10 weeks, 45 minutes/session with a Borg scale of perceived exertion between 11 and 14).
1479450|NCT03123900|Behavioral|Cognitive training|We use a computerized cognitive training tele-medicine tool, designed by the Guttmann Institute: Guttmann Neuro Personal Trainer (PREVIRNET). Sessions will consist in activities of attention, memory and executive functions, also put in place progressively and parallel to the physical activity.
1479451|NCT03123900|Behavioral|Combined training|Subjects included in this group receive both types of intervention.
1479452|NCT03123887|Other|salvage therapy|VDC(L)P regimen or High-dose cytarabine based regimen or High-dose methotrexate based regimen or Hyper-CVAD regimen or FLAG (Flu, Ara-C, G-CSF) ± anthracyclines based regimen or Repeated original induction regimen or VDP or other
1479456|NCT03123861|Drug|Gabapentin|Patients randomized to this arm will receive 2 weeks of gabapentin post-operatively.
1479457|NCT03123861|Drug|Placebo oral capsule|Patients randomized to this arm will receive 2 weeks of placebo post-operatively..
1479458|NCT03123848|Drug|Darunavir/Cobicistat|Participants will receive a FDC tablet of darunavir 800 mg and cobicistat 150 mg orally in the morning of Day 1.
1479459|NCT03123835|Procedure|Endoscopic Intervention|After reviewing all therapeutic options the patient will be offered the best therapeutic option to treat their condition. Surgical interventions include open laparotomy, diagnostic/therapeutic laparoscopy or endoluminal therapies. After the patient is consented for the related surgical intervention the patient will be given the option to participate in the clinical study to measure outcomes after surgery.
1479460|NCT03123822|Device|Glasses|Glasses traditionally prescribed for refractive error
1479461|NCT03123809|Device|Gastric Electrical Stimulation (GES) system|Implantable GES system will be turned ON in half of gastroparetic patients, while other half will have GES devices turned OFF for 3 months after surgery.
1479462|NCT03123783|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody
1479463|NCT03123783|Drug|Nivolumab|Nivolumab is an immune checkpoint (PD-1) blocking antibody
1479464|NCT03123770|Drug|Pegylated liposomal doxorubicin|a new kind of doxorubicin
1479465|NCT03123770|Drug|Cyclophosphamide|traditional chemotherapy drug
1479466|NCT03123770|Drug|Epirubicin|traditional chemotherapy drug used in breast cancer
1479467|NCT03123770|Drug|Docetaxel|traditional chemotherapy drug used in breast cancer
1479505|NCT03123484|Drug|β-elemene|β-elemene：400-600mg + 5%GS 500ml,ivgtt,qd, continuously 45days
1483705|NCT03092336|Other|Strength training|strength training group
1479468|NCT03123757|Other|6 Minute Walk Test|The 6 minute walk test measures the distance walked in 6 minutes without sitting and without the use of a walker or the help of another person (a cane may be used). The walk was conducted in a wide hallway, specifically designed for this type of assessment, with a defined 20-meter course. The subject walked back and forth in the hallway for six minutes and the distance covered was recorded.
1479469|NCT03123757|Other|EQ-5D Survey|The EQ-5D is a self-reported questionnaire that describes a respondent's health using a descriptive system comprised of five items, each representing a different health dimension (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression). For each dimension, respondents state whether they have no problems, slight problems, moderate problems, severe problems, or are unable to perform the activity.
1479470|NCT03123757|Other|Short Physical Performance Battery|The SPPB is a brief performance battery based on timed short distance walk, repeated chair stands and balance test administered by trained examiners. The measurement goal for this battery is to assess lower extremity functional limitations, which indicate functional abilities and are a strong measure of risk for future disability.
1479475|NCT03123718|Drug|Intrathecal methotrexate|Intrathecal administration of 2nd, 3rd, and 4th doses of methotrexate 15 mg and hydrocortisone 50mg on day 2 or 3 of 2nd, 3rd, and 4th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
1479476|NCT03123718|Drug|High-dose intravenous methotrexate|"Intravenous administration of 1st and 2nd doses of methotrexate 3g/m2 on day 15 of 2nd and 6th cycles of immunochemotherapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (RCHOP), respectively.
* Dose of intravenous methotrexate will be reduced to 2g/m2 for patients aged >70 years."
1479477|NCT03123692|Drug|Emeramide|Lipophilic, membrane passing Metal chelator and anti oxidant
1479478|NCT03123692|Drug|Placebo|14 days treatment with placebo
1479479|NCT03123679|Radiation|pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT|"Patient referred to radiotherapy treatment are evaluated with a baseline PFT [Forced expiratory volume in 1 second (FEV1), Forced vital capacity (FVC), diffusing capacity of the lung for carbon monoxide (DLCO), Alveolar gas volume (VA)].
RT simulation at the radiotherapy department and treatment planning.
Baseline evaluation of pulmonary perfusion/reserve with Tc-99m-MAA SPECT/ Low dose CT.
Radiotherapy."
1479480|NCT03123666|Drug|GMCSF|GM CSF (Sargamostatim-250mcg/M2) over 4 hour and inhalation of same dose by micronebulizer
1479481|NCT03123666|Other|Placebo|Placebo identical to GMCSF will be given
1479482|NCT03123653|Drug|Peg IFN 2b|Peg IFN 2b 1.5mcg/kg once every week for 48 weeks
1479483|NCT03123640|Other|Medication reconciliation and medication review|Pharmacist performed medication reconciliation and medication review
1479484|NCT03123627|Drug|New profilaxis|Primary endpoint: incidence of CMV disease at 12 months after transplantation. Study the predictive value of the assay of CD8 + T cell immunity specific for defined CMV-patients in which they can stop prophylaxis. The definition of CMV disease was based on those recommended by the American Society of Trasnplantation for use in clinical trials (Humar A. Am J Transplant 2006; 6:262-74) criteria.
1479485|NCT03123627|Drug|Profilaxis recommended|Secondary end points: percentage of patients developing T cell immunity in CMV-specific transplantation after receiving timoglubulina induction and valganciclovir prophylaxis. T cell development inmnunidad CD8 + CMV-specific is defined as production of γ> 0.2 interferon by CD8 + T cells stimulated by CMV-specific CMV antigens (QF reagent).
1479486|NCT03123614|Drug|Loteprednol Etabonate 0.5% Oph Gel|
1479487|NCT03123614|Drug|Prednisolone Acetate 1% Oph Susp|
1479488|NCT03123601|Device|Risk sign displays|"Set of sign displays designed to communicate fall, dehydration and pulmonary aspiration risks and reflect on tailored interventions to manage these events in nursing homes. Risk sign displays are:
Small, lightweight rubber coloured bracelets with phrases related with the different risks: prevent rather than fall, contain to protect, drink to hydrate and avoid choking.
Small and coloured signposts next to head of patients bed that are believed to offer some key advantages and increase technically the quality of immediate communication of information and data regarding procedures. It is expected to have greater subject compliance once they will have discrete messages with thoughtful design and colour."
1479489|NCT03123588|Drug|Ruxolitinib|Ruxolitinib administered orally twice daily (BID) at the protocol-defined starting dose.
1479490|NCT03123588|Drug|Anagrelide|Anagrelide administered orally at a starting dose of 1 mg BID.
1479491|NCT03123588|Drug|Placebo|Anagrelide-placebo administered orally BID
1479492|NCT03123588|Drug|Placebo|Ruxolitinib-placebo administered orally BID.
1479493|NCT03123562|Combination Product|Stem cell transplantation|Transplantation of Autologous Bone Marrow Mononuclear Cells
1479494|NCT03123549|Device|Simplify Disc|Simplify Disc at two levels of the cervical spine
1479495|NCT03123536|Device|Point-of-care Ultrasound|Patients' management in the point-of-care ultrasound group will be adjusted according to the results of ultrasound, whereas patients in the control group the decisions about the management were made by the experience of clinical team.
1479496|NCT03123523|Diagnostic Test|Echocardiography at T0|
1479497|NCT03123523|Diagnostic Test|Exercise test|
1479498|NCT03123523|Biological|Biological assays|Creatinin, hematocrit and BNP assays
1479499|NCT03123523|Device|MRI with contrast agent injection|With injection of gadolinium
1479500|NCT03123523|Device|MRI without contrast agent injection|Without injection of gadolinium
1479501|NCT03123523|Diagnostic Test|Echocardiography at M24|
1479502|NCT03123510|Dietary Supplement|Bifidobacterium spp plus bimuno- galacto-oligosaccharides|Volunteers will be asked to take one probiotic capsule and one prebiotic satchel daily.
1479503|NCT03123510|Dietary Supplement|Placebo|Volunteers will be asked to take one placebo capsule and one placebo satchel daily.
1479504|NCT03123497|Other|completion of questionnaire|completion of questionnaire for patient and parent
1479506|NCT03123484|Drug|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib)|EGFR-TKIs(Erlotinib, Gefitinib and Icotinib) as usual
1479507|NCT03123471|Drug|Apremilast|Apremilast 30 mg Twice Daily (BID)
1479508|NCT03123471|Other|Placebo|Placebo Twice Daily (BID)
1479509|NCT03123458|Biological|clonal fetal MSCs|
1479510|NCT03123445|Drug|Endostar|Endostar,30mg continuous intravenous injection pump, d1-d7,21 days as one cycle, 4 cycles in total
1479511|NCT03123445|Drug|Gemcitabine|Gemcitabine,1000mg/m2, i.v, d1 and d8 in each cycle, 21 days as one cycle, 4 cycles in total
1479512|NCT03123445|Drug|Cisplatin|Cisplatin,75mg/m2, i.v, d1 in each cycle, 21 days as one cycle, 4 cycles in total
1479513|NCT03123432|Dietary Supplement|immunomodulating nutrients enriched diet|
1479514|NCT03123432|Dietary Supplement|standard diet|
1479516|NCT03123406|Drug|Cinacalcet HCl|Administer Cinacalcet HCL to all subjects from 1st to 32nd week. Subjects choose to buy and take Cinacalcet HCL in real-world period from 33rd to 52nd week.
1479517|NCT03123393|Drug|TAK-659|TAK-659 Tablets
1479518|NCT03123367|Device|Group 1: Nella VuSleeve|Sleeve to keep tissue back
1479519|NCT03123367|Device|Group 2: Nella NuSpec|Designed to keep tissue back while maximizing patient comfort during procedures when a vaginal speculum is used
1479520|NCT03123367|Device|Group 3: NellaSpec|Ergonomically designed for clinician comfort
1479521|NCT03123367|Device|Group 4: Nella Insert|DIY sleeve for patient comfort
1479522|NCT03123354|Device|O3 regional oximeter sensor|Noninvasive sensor that is placed on the forehead for measurement of oxygenation in the area under the sensor
1479525|NCT03123107|Drug|Ascorbic Acid|Ascorbic acid doses will be mixed in 100 mL normal saline and infused over 60 minutes. The postoperative dose will be given on postoperative day #1.
1479526|NCT03123094|Drug|BI 655130|single dose
1479527|NCT03123094|Drug|Placebo|single dose
1479528|NCT03123081|Procedure|Umbilical Cord Milking|At birth the cord of a depressed newborn is clamped immediately and cut 30 cm from the umbilicus. After completion of initial steps, if required, positive pressure ventilation (PPV) is given for 30 seconds, along with UCM. The cord is untwisted and held in a vertical position. It is milked 3 times towards the baby at a speed of 10 cm/s and then clamped 3 cm from the umbilicus. After completion of PPV along with UCM, if the baby requires further resuscitation, the NRP 2015 guidelines will be followed. Depressed newborns who respond to initial steps of resuscitation with normal breathing and heart rate of 100 bpm or higher, will receive UCM after this.
1479529|NCT03123068|Drug|CocoaVia®|CocoaVia® is manufactured by Mars, Inc. It is a dietary supplement of cocoa bean extract, containing 125 mg cocoa flavanols per capsule.
1479530|NCT03123068|Other|Placebo|The placebo capsules will contain an inert ingredient packaged to be indistinguishable from the active treatment.
1479531|NCT03123055|Drug|B-701|B-701 is a human IgG1 monoclonal antibody that is highly specific for the FGFR3 receptor.
1479532|NCT03123055|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy. It blocks a protective mechanism on cancer cells, and allows the immune system to destroy those cancer cells. It targets the programmed cell death 1 receptor.
1479533|NCT03123042|Procedure|Sentinel basin dissection|Sentinel basin detection using endoscopic detector (Tc99m plus indocyanine green) injection and laparoscopic sentinel basin dissection. Then conventional gastrectomy
1479534|NCT03123029|Drug|Venetoclax|Venetoclax will be administered orally.
1479535|NCT03123016|Drug|Apremilast|Apremilast 30 mg orally, twice daily. (oral tablet)
1479536|NCT03123016|Procedure|NB-UVB phototherapy|treatment with narrowband UVB two to three times weekly to one half of their body for a total of 16 weeks
1479537|NCT03123003|Device|SonicBone Ultrasound|Bone age assessment by SonicBone Ultrasound. The patient needs to put his/her wrist in 3 positions.
1479538|NCT03123003|Device|Wrist X-ray|Bone age assessment by Wrist X-ray
1479539|NCT03122990|Procedure|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
1479540|NCT03122990|Procedure|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented.Performed in 3 weeks time frame."
1479541|NCT03122977|Procedure|FM-SRP|Supra- and sub-gingival mechanical instrumentation of the root surface of the whole dentition within 24 hours.
1479542|NCT03122977|Procedure|Q-SRP|"Supra- and sub-gingival mechanical instrumentation of the root surface will be performed in all dentition subdivided in four appointments. Each appointment will be performed in one week interval. In each appointment only a quadrant of the dentition will be instrumented."
1479543|NCT03122964|Diagnostic Test|AssureMDx|combined panel of methylation and mutation markers for the detection of bladder cancer
1479544|NCT03122951|Diagnostic Test|ovulation test use|Normal use of The Clearblue® Advanced Ovulation Test according to Information for use instructions
1479545|NCT03122938|Dietary Supplement|lactoferrin-supplemented formula|Subjects consume lactoferrin-supplemented formula (85mg lactoferrin per 100g) 3 times a day (81g totally).
1479546|NCT03122938|Dietary Supplement|formula without lactoferrin supplementation|Subjects consume formula without lactoferrin supplementation (<6mg lactoferrin per 100g formula) 3 times a day (81g totally).
1479547|NCT03122925|Device|MR|MR
1479551|NCT03122886|Dietary Supplement|Fat Emulsion|Given IV
1479552|NCT03122886|Other|Placebo|Given IV
1479703|NCT03121859|Other|IFC|Interferential current therapy(IFC)
1479553|NCT03122860|Drug|SM04690|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
1479554|NCT03122860|Drug|placebo|Healthcare professional-administered intra-articular injection performed once on Day 1 of the study
1479555|NCT03122847|Drug|Methylprednisolone|Intravenous methylprednisolone
1479556|NCT03122821|Other|Transcranial direct stimulation|"The electrodes will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral hemisphere.Transcranial direct current stimulation (tDCS), (or Transcranial Micropolarization), is the most commonly used type of tCS [2, 19-25]. It employs a battery-driven stimulator to deliver weak direct currents (0.5-2.0 mA) through contact electrodes over the scalp. The current flow modulates neuronal excitability by altering the resting membrane potential of the neurons and produces aftereffects.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 6 weeks.Transcranial direct stimulation for 30 minutes, 5 days a week for 6 weeks"
1479557|NCT03122821|Other|Transcranial Magnetic stimulation|The Magnet will be placed at the premotor cortex over the scalp corresponding to the topographical representation of upper limb on the contralateral cerebral.Transcranial magnetic stimulation for 30 minutes, 5 days a week for 6 weeks
1479558|NCT03122821|Other|Transcranial direct stimulation with mental imagery|The subject will be practicing mental imagery along with trans-cranial direct stimulation.A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.
1479559|NCT03122821|Other|Transcranial magnetic stimulation with mental imagery|The subject will be practicing mental imagery along with trans-cranial magnetic stimulation.A video of the task will be played in front of the patient and the subject will be asked to perform the mental practice of the activity.The video will be played thrice.
1479560|NCT03122808|Diagnostic Test|Uterine Activity Analysis|Analysis of components of uterine activity; contraction rate, length of contraction, length of relaxation and other values based off these measurements.
1479561|NCT03122808|Diagnostic Test|Partogram Analysis|Analysis of slope of partogram
1479562|NCT03122795|Procedure|Microbiome transplant|A raw microbiome, collected from a donor without any sinonasal health problems, as a nasal lavage.
1479563|NCT03122782|Drug|Topical application Tranexamic acid|Tranexamic acid (TXA) will be injected to distinction media during hysteroscopy in myomectomy
1479564|NCT03122782|Drug|Placebo (Normal saline)|5ml of normal saline will be added to every 500 ml of distension media
1479565|NCT03122769|Radiation|11C-metformin|200 MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Positron Emission Tomography
1479566|NCT03122756|Drug|Dexamethasone|Intravenous injection of dexamethasone 0.1 mg/kg maximum 8 mg (diluted with distilled water to 2 mL) just prior to administration of spinal anesthesia.
1479567|NCT03122756|Other|Normal Saline|Intravenous injection 2 mL intravenous normal saline (0.9 %) just prior to administration of spinal anesthesia.
1479568|NCT03122743|Procedure|Biospecimen Collection|Undergo collection of serum samples
1479569|NCT03122743|Other|Laboratory Biomarker Analysis|Correlative studies
1479570|NCT03122743|Other|Questionnaire Administration|Ancillary studies
1479574|NCT03122704|Procedure|GBS screening|Vaginal and anal swabs of patients will be screened for GBS screening
1479575|NCT03122691|Drug|cannabis|Cannabis will be self-administered by study participants
1479576|NCT03122678|Drug|Thiamine|
1479577|NCT03122678|Drug|Placebos|
1479580|NCT03122652|Drug|Teriflunomide 14 MG Oral Tablet [Aubagio]|1 tablet once a day
1479581|NCT03122652|Drug|Placebo Oral Tablet|1 tablet once a day
1479582|NCT03122639|Drug|Atorvastatin 10mg|Atorvastatin 10 mg daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
1479583|NCT03122639|Drug|Placebo|Placebo daily for 28 days will be randomly allocated to OSA patients regardless of adherence with CPAP. CPAP is a standard of care for OSA and will be prescribed by care providers not associated with this study based on clinical indications. The investigators will have no role in prescribing CPAP. Atorvastatin and placebo will be encapsulated to appear identical and dispensed by the research pharmacy.
1479584|NCT03122626|Behavioral|Together in Movement and Exercise (TIME) Program|The TIME program is an evidence-based, standardized, progressive, licensed exercise program developed by physical therapists at the Toronto Rehabilitation Institute-University Health Network.
1479585|NCT03122613|Dietary Supplement|Curcumin|3g of Curcumin per day
1479586|NCT03122613|Drug|Placebo|3g of Curcumin Placebo per day
1479587|NCT03122587|Device|Transcranial Alternating Current Stimulation at 10 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 10 Hz to target alpha oscillatory activity
1479588|NCT03122587|Device|Transcranial Alternating Current Stimulation at 40 Hz|Non-invasive, safe transcranial alternating current stimulation administered at 40 Hz to target gamma oscillatory activity
1479589|NCT03122587|Device|Active sham transcranial alternating current stimulation|Active sham (placebo)
1479590|NCT03122574|Other|Lavender Aromatherapy|100% pure lavender aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet.
1479704|NCT03121846|Drug|Apatinib|Apatinib 500 mg is administered orally daily, until disease progression or untolerable toxicity.
1479705|NCT03121833|Drug|Endostar|Recombinant Human Endostatin Injection
1479591|NCT03122574|Other|Jojoba Aromatherapy|100% pure jojoba aromatherapy was administered using person essential oil diffusor sachets, consisting of three drops of oil on a surgical sponge covered in a sealed plastic packet. This colorless, odorless oil was used as a placebo comparator.
1479592|NCT03122561|Drug|Paracetamol 500 mg tablet at morning|Single dose oral paracetamol will be administered at 8.00 am
1479593|NCT03122561|Drug|Paracetamol 500 mg tablet at midday|Single dose oral paracetamol will be administered at 2.00 pm
1479594|NCT03122561|Drug|Paracetamol 500 mg tablet at night|Single dose oral paracetamol will be administered at 8.00 pm
1948783|NCT01638104|Drug|ANX-042|Reconstituted in Sterile Water for Injection, United States Pharmacopeia (USP) and administered by 12 hour continuous intravenous infusion with 5% dextrose in water (D5W), United States Pharmacopeia (USP)
2000862|NCT03323359|Device|Hemopatch|For patients included Hemopatch is applied upon the verification made by the surgeon of the presence of an appropriate target bleeding site in the hepatic parenchyma. At the time point of application a stopwatch starts simultaneously. Time to hemostasis is defined as the time required to obtain successful haemostasis in a single bleeding site. At 3 minutes the inspection will be made and, if haemostasis is not achieved, the treatment is considered failed and the Principal Investigator and/or his delegates is allowed to use additional haemostatic measures.The time to haemostasis will be recorded in the patient's medical record and in the eCRF. The bleeding site will be observed for 1 additional minute at the end of the haemostatic procedure and, of the surgery to confirm the haemostasis.
1479597|NCT03122535|Device|FS-LASIK 70 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
1479598|NCT03122535|Device|FS-LASIK 110 degree side-cut angle|FS-LASIK surgical procedures will be performed according to the surgeons' standard practices. Patient will be masked as to the treatment they receive in either eye so as not to influence their subjective responses and visual measurements. Patients will be discontinued from the study if, on the day of surgery, both eyes cannot be randomized and operated as per protocol.
1479599|NCT03122522|Drug|ipilimumab|ipilimumab 3mg/kg
1479600|NCT03122522|Drug|nivolumab|nivolumab 1mg/kg
1479601|NCT03122509|Drug|durvalumab|1500 mg durvalumab via IV infusion
1479602|NCT03122509|Drug|tremelimumab|75 mg tremelimumab via IV infusion
1479603|NCT03122509|Radiation|Radiotherapy (RT)|Radiotherapy (RT) will be performed using external beam ionizing radiation as standard therapy in accordance with institutional standard practice.
1479604|NCT03122509|Procedure|ablation|Ablation will be performed percutaneously under image guidance as standard therapy at the discretion of the interventional radiologist in accordance with institutional standard practice.
1479605|NCT03122496|Drug|durvalumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
1479606|NCT03122496|Drug|tremelimumab|Patients will receive durvalumab (MEDI4736) and tremelimumab together every 4 weeks.
1479607|NCT03122496|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT at 9Gy x 3 delivered every other business day given within 2 weeks after the completion of Cycle 1 of durvalumab (MEDI4736) and tremelimumab
1479608|NCT03122483|Diagnostic Test|blood biomarker|
1479611|NCT03122457|Drug|lindamycin phosphate and benzoyl peroxide 1.2%/3.75% combination|At Day 15, patients will be re-assessed and dispensed the investigational product and instructed on its daily use. Patients will continue to return every 14 days to have their skin assessed until their final visit on day 99, one week after their 3rd menses on treatment (4th menses on study).
1479613|NCT03122431|Drug|Thalidomide|Thalidomide 100mg/day
1479614|NCT03122431|Drug|Hydroxychloroquine reduced|Hydroxychloroquine 400mg three times a week
1479615|NCT03122431|Drug|Hydroxychloroquine high|Hydroxychloroquine 800mg/day for three months
1479616|NCT03122418|Behavioral|Personal Fitness Device|Subjects will be given a personal fitness device to use to encourage exercise routinely. The impact this has on the individual perception of their quality of life will be the primary outcome for this study
1479619|NCT03122353|Drug|Calcipotriene and betamethasone suspension|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
1479620|NCT03122353|Drug|Taclonex|Calcipotriene hydrate and betamethasone dipropionate topical suspension 0.005%/0.064%
1479621|NCT03122353|Drug|Placebo|vehicle used as placebo
1479622|NCT03122340|Drug|Ropren|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
1479623|NCT03122340|Other|Oil|Per os 8 drops 3 times per day for 3 weeks, then 5 drops 3 times per day for 5 weeks
1479624|NCT03122327|Other|Questionaires|Questionaires of cGA assessment. No other interventions would be carried out aside from the standard treatment for MM.
1479625|NCT03122314|Drug|Paracetamol|1000 mg of paracetamol (perfalgan 10mg/ml solutionBristol-Myers Squibb_UK) intravenous (IV) was given 100patients
1479626|NCT03122314|Drug|Dexketoprofen|Second group: dexketoprofen 50 MG (Arveles ampoule -Ufsa- Istanbul) intravenous (IV) was given 100 patients
1479627|NCT03122301|Drug|Stellate Ganglion Block injection with bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
1479628|NCT03122301|Drug|Saline|sham injection with saline
1479631|NCT03122275|Other|Customized text message invitation ( Step 1a)|Personalized text messages, automatically sent by Smart Message v.3.1 software. These text messages intend to invite women to cervical cancer screening
1479632|NCT03122275|Other|Customized automatic phone call invitation (Step 1b)|Personalized phone call, not operator dependent, automatically sent by Smart-Interactive Voice Response v.1.1 software These phone calls intend to invite women to cervical cancer screening
1479633|NCT03122275|Other|Secretary phone call (Step 2)|Manual phone call, performed by a trained secretary. These phone calls invite women to cervical cancer screening, but will only be used after automatic strategies (customized text messages and phone calls)
1479634|NCT03122275|Other|Health professional face-to-face appointment (Step 3)|"Women randomized to experimental arm, who do not undergo cervical cancer screening after automatic invitation or manual phone call, receive this intervention. First, women are contacted through a phone call, performed by a health professional, inviting them for a face-to-face appointment at her primary care unit.
During appointments, the health professional understands possible barriers felt by women for not undergoing cervical cancer screening. Health professionals will try to overcome these barriers, using pre-defined arguments and facts. Finally, women are invited to perform screening."
1479635|NCT03122275|Other|Written Letter|"A written letter will be used to invite eligible women to cervical cancer screening.
This intervention will be used only for women randomized to active comparator arm."
1479636|NCT03122262|Drug|Dolutegravir|DTG 50mg Oral Tablet once daily
1479637|NCT03122262|Drug|Tenofovir Alafenamide|TAF/FTC 25/200mg Oral Tablet once daily
1479638|NCT03122262|Drug|Truvada|
1479639|NCT03122262|Drug|Atripla|
1479640|NCT03122249|Behavioral|Advanced Cancer Symptom Management|For a period of eight weeks patients will use the OASIS web-application daily to help them get better control of their cancer symptoms. In addition, to daily symptom and strategy tracking, participants will have eight e-visits with the nurse-coach via the Zoom application through the UIHC eHealth and eNovation Center to evaluate their progress with managing their symptoms, assess for barriers to implementing strategies, and offering coaching on how to improve symptom management. Questionnaires and blood samples will be collected at baseline (week 0) and follow-up (weeks 4, 8, and 12).
1479641|NCT03122236|Behavioral|Neurorehabilitation of Standard Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of standard walking will focus on the use of typical steady state walking.
1479642|NCT03122236|Behavioral|Neurorehabilitation of Complex Walking|Neurorehabilitation is a behavioral therapeutic approach for enhancing the neural control of task performance by: Restoration of function, specificity of training, Sensory input to the nervous system, Intensity, Repetition and Progression of training. Neurorehabilitation of complex walking will focus on the use of walking tasks that require increased attention and executive functions. The following walking tasks will be used: over obstacles, navigating around obstacles, changing speeds, on soft surfaces (exercise mat), in dim lighting, while conversing with the therapist, up/down ramps and climbing/descending stairs.
1479643|NCT03122236|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Sham stimulation is performed with the same device used for active stimulation, and all procedures will be identical except for the duration of stimulation.
1479644|NCT03122236|Device|Active Transcranial Direct Current Stimulation (tDCS)|"tDCS will be used to induce positive neuromodulation of frontal/executive circuits to make them more amenable to the activity-dependent neuroplasticity that is known to occur with behavioral neurorehabilitation. Specifically, tDCS may facilitate the efficacy of our walking neurorehabilitation intervention by strengthening the synaptic connections within the recruited circuits."
1479645|NCT03122223|Biological|ALVAC-HIV (vCP2438)|expresses the gene products 96ZM651 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and Gag and Pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a viral titer ≥ 1 × 10^6 cell culture infectious dose (CCID)50 and < 1 × 10^8 CCID50 (nominal dose of 10^7 CCID50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%), administered IM as a single 1 mL dose.
1479646|NCT03122223|Biological|Bivalent subtype C gp120/MF59|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered IM as a single 0.5 mL dose.
1479647|NCT03122223|Biological|Bivalent subtype C gp120/AS01(B)|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 20 mcg or 100 mcg, mixed with AS01B adjuvant, administered IM as a single 0.75 mL dose.
1479648|NCT03122223|Biological|Placebo|Sodium Chloride for Injection, 0.9%, administered IM.
1479649|NCT03122210|Device|oxygen administration|
1479650|NCT03122197|Drug|Letrozole Oral Tablet|Daily treatment 1-5 days preop and resuming post op
1479651|NCT03122184|Behavioral|Positive Psychology + Goal Setting|For the positive psychology portion of the intervention, the study trainer will (a) review the week's positive psychology exercise, (b) discuss the rationale of the next week's positive psychology exercise through a guided review of the positive psychology manual, and (c) assign the next week's positive psychology exercise. For the goal setting portion, participants will (a) review their physical activity goal from the prior week, (b) discuss techniques for improving physical activity, and (c) set a physical activity goal for the next week. Study trainers will use motivational interviewing techniques to facilitate goal setting.
1479652|NCT03122184|Behavioral|Health Behavior Education|Each week, participants will learn about a different health behavior topic related to cardiac health. They will also be introduced to motivational interviewing topics in concert with the health behavior education topics. The intervention is divided into five sections, focusing on five different important cardiac health-related topics (recovery from an acute cardiac illness, physical activity, a heart-healthy diet, medication adherence, and stress reduction).
1479653|NCT03122171|Other|Occupational Therapy Treatment|Each occupational therapy treatment will be a one-hour standardized session that will include the following: stretching/strengthening (approximately 20 minutes), bimanual training (approximately 20 minutes), and activities of daily living (approximately 20 minutes).
1479654|NCT03122158|Drug|Escitalopram|Escitalopram treatment will be given to the arms with a starting dose of 2.5 mg day. The treatment dose will be gradually increased up to 20 mg day (if necessary) and the maximal treatment dose was determined as 30 mg day in each group.
1479706|NCT03121833|Drug|Placebo|500ml 0.9% sodium chloride
1479707|NCT03121833|Drug|AIM regimen / GT regimen|"Pirarubicin (THP) + Ifosfamide (IFO) / Docetaxel (TXT) + Gemcitabine (GEM)"
1479655|NCT03122145|Drug|Capsaicin|Participants will inspire deeply through the nebulizer coupled to the facemask and pneumotachograph. Each test inhalation will be separated by an interval of 2 minutes. This experimental trial consists of six (instead of 8) test solutions: 0, 25, 50, 100, 200 and 500 μM capsaicin in 80% physiological saline, 20% ethanol. Participants will inhale single vital capacity breaths of capsaicin solution via an air-powered dosimeter (KoKoDigidoser; Pulmonary Data Services Instrumentation Inc; Louisville, CO). The reflex cough test ends when the participant coughs at least 2 times in response to one inhalation dose, or receives a dose of the highest concentration (500 μM).
1479656|NCT03122145|Device|Videofluoroscopic swallow study|The swallowing systems core laboratory is fully equipped to perform videofluoroscopy with a c-arm (OEC 9900) that is dedicated solely to research purposes. Videofluoroscopy recordings will be kept to a minimum and turned on only during completion of a specific testing task. Video recording and images captured during the videofluoroscopy will be synced and saved for data analysis. Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks. The physiological swallowing measures (temporal and kinematic movement of the base of tongue and hyolaryngeal complex during swallowing) to be analyzed cannot be visualized with any other technique. All swallowing tasks will be completed using barium in order to visualize the bolus during movement of various swallowing muscles and structures.
1479657|NCT03122132|Drug|ombitasvir/paritaprevir/ritonavir 8 weeks|Spanish cohort with HCV treated in real practice with ombitasvir/paritaprevir/ ritonavir 8 weeks
1479658|NCT03122132|Drug|dasabuvir 8 weeks|Spanish cohort with HCV treated in real practice with dasabuvir 8 weeks
1479659|NCT03122119|Drug|Platelet Rich Plasma Joint Injection|30 to 50 milliliters of venous blood will be drawn from the patients arm with a 19 gauge ¾ inch needle using universal precautions. The venous blood will be mixed with 8 milliliters of anticoagulant citrate dextrose solution-A (ACD-A). The anti-coagulated blood will then be centrifuged for 15 minutes at 3200 revolutions per minute in the office centrifuge. This will allow plasma to separate from blood cells. The portion of centrifuged blood deficient in platelets will be extracted and discarded. Once the needle is visualized entering the joint capsule via ultrasound guidance and the physician feels resistance provided by the capsule and ligaments, 3 milliliters of PRP extract will be injected (3 inch, 22 gauge needle) into the sacroiliac joint. The needles will be properly disposed.
1479660|NCT03122119|Drug|Corticosteroid Injection|"Ultrasound evaluation will be utilized to correlate the site of injection consistent with the point of maximal tenderness (Fortin Finger Test). With ultrasound guidance, a 22 gauge 3.5 needle will be advanced into the maximally tender area, located in the articular junction between the iliac crest and the SI joint. After negative aspiration and Doppler clearance, 2 milliliters of 1% lidocaine, 2 milliliters of .25% bupivacaine and 1 milliliter of triamcinolone 40 milligrams/milliliter will be injected in the posterior capsular wall of the SI joint into the overlying sacroiliac ligaments. The injection will continue while slowly withdrawing the needle to appropriately infiltrate the sacroiliac ligamentous structures. Following the injection, the patient will be monitored for 20 - 30 minutes to assess concordance and adverse reactions."
1948784|NCT01638104|Drug|Placebo|Administered once by 12 hour continuous intravenous infusion with D5W (USP)
1948785|NCT01630278|Drug|Ibuprofen|Very premature infants with a large ductus, selected by an early echocardiogram, will receive ibuprofen before 12 hours of life
1948786|NCT01630278|Drug|Placebo|Very premature infants with a large ductus, selected by an early echocardiogram, will receive placebo before 12 hours of life
1479664|NCT03122080|Device|Electroacupuncture(EA)|"Participants in EA group will receive electroacupuncture treatment. Acupuncture will be applied at Baihui (GV20), Shenting (GV24), Yintang (GV29), bilateral Anmian (EX-HN22), Shenmen (HT7), SanYinjiao (SP6) and Neiguan (PC6). After needle insertion, rotating or lifting-thrusting manipulation will be applied for Deqi sensation. The EA apparatus (CMNS6-1, Jianjian Medical Device CO., LTD, China) will be connected to the needles at GV20 and GV29 for 30 minutes and deliver a continuous wave. The frequency will be set at about 30 Hz and the amplitude will be less than 20V. Participants can regularly take the antidepressants or sedative-hypnotics as before during the intervention. Besides, the investigators will strengthen health education about insomnia and depression for the patients."
1479665|NCT03122080|Device|Placebo acupuncture|Participants in the control A group will receive placebo acupuncture treatment with streitberger needles at the same acupoints as the electroacupuncture group. When the tip of the blunt needles touches to the skin, the patient will get a pricking sensation but there is no real needle inserted into the skin. The electroacupuncture apparatus will be set beside the patients, with no connection to the needles. Inform the patients when removing the needles after 30 minutes. Use the dry cotton ball to press the acupoints so that patients can feel the withdrawal of the 'needles'. Same health education and regular administration of antidepressants or sedative-hypnotics will be given to the participants during the intervention.
1479666|NCT03122080|Other|Standard care|Participants in the control B group will keep their standard medical care for the first 8 weeks. Participants will take their regular antidepressants and the sedative-hypnotics during the whole intervention period. Same health education will be conducted as well for the participants. And after waiting for two months, these patients will be treated with the same electroacupuncture treatment as the EA group.
1479667|NCT03122080|Other|Standard care|
1479668|NCT03122067|Drug|oxytocin treatment|intranasal administration of oxytocin
1479669|NCT03122067|Drug|placebo treatment|intranasal administration of placebo
1479670|NCT03122054|Procedure|laparoscopic cholecystectomy|First trocar was inserted with Hasson method (Subumbilical 1 cm vertical incision was made and first 10-mm trocar (VersaportTM plus V2, Covidien, USA) inserted under direct vision) and pneumoperitoneum was created with 12 mm Hg pressure. Second 10-mm trocar was inserted from subxyphoid area. Two 5-mm trocars were inserted in the right upper quadrant area. After general intrabdominal exploration, dissection was started to ensure safe-view of Calot triangle. In case of quite tough gallbladder for griping, gallbladder was drained with a gray intravenous cannula. Cystic artery and cystic duct were separately dissected and twice ligated with Endo Clip™ II ML (Covidien, USA). Gallbladder was dissected from liver bed carefully. Gallbladder was taken out from abdomen through the subumbilical incision.
1479671|NCT03122041|Drug|Sitagliptin|
1479672|NCT03122041|Behavioral|Lifestyle intervention|
1948787|NCT01629056|Procedure|ablation|RF ablation to the left atrium of the heart, guided by ECI-contact information (active arm)
1479673|NCT03122028|Device|LAA closure system|Patients with non-valvular paroxymal, persistent or permanent atrial fibrillation with long-term sustainability and cannot be treated with anticoagulation and scheduled for interventional left atrial appendage closure.
1479674|NCT03122015|Other|Therapeutic clown distraction|The presence of the therapeutic clown, which can adapt his interventions of distraction to the state of health of the patient and the culture of the child, is a multimodal and multi sensorial distraction intervention and can have an impact on health status, procedures, family and multidisciplinary team members. The results of five studies evaluated the effects of distraction by the clown therapy demonstrate a decrease in pain and anxiety in children aged 2 to 17 years, as well as parental anxiety in painful procedures involving needles such as venipuncture.
1479675|NCT03122002|Drug|Drug Therapy|For this observation research, anti platelet drugs, statins and ect. would be used as clinical guidelines as usal, and statical ananysis of the relationship between these drugs and the final outcomes
1479676|NCT03122002|Diagnostic Test|Routine Blood Test and Image Scan|Routine blood test(HCY, LDL and ect.) and image scan (DWI, DSA and ect.)
1479677|NCT03122002|Other|Intravascular therapy|Intravascular therapy including thrombectomy
1479678|NCT03122002|Other|Emergency Treatment|Emergency treatment including time to self-diagnosis of stroke, time to call for help, devices used to hospital and ect.
1479679|NCT03122002|Other|Medical history|Medical history including hypertension, diabetes, hyperlipemia and ect.
1479680|NCT03121989|Drug|Hyperpolarized Pyruvate (13C) Injection|The new imaging method being tested in this study is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast medicine, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The Participants in the active comparator arm will be injected with study drug Hyperpolarized Pyruvate (13C) Injection at a dose of 0.43/ml/kg.
1479681|NCT03121989|Other|Coil Testing|Participants will receive an MRI with a 1 cm diameter plastic ball that contains 13C-urea that will act as a test object. The test object provides a signal that will be used to ensure that the MRI system is functioning properly for participants in Group 2 . The plastic ball does not come in contact with you and there are no known risks associated with it.
1479682|NCT03121989|Drug|NAC|Participants will be receiving NAC as part of their clinical treatment.
1479683|NCT03121976|Device|Ultrasound|Femoral catheter inserted using ultrasound only
1479684|NCT03121976|Device|Ultrasound + Nerve Stimulation|Femoral catheter inserted using ultrasound and nerve stimulation
1479685|NCT03121963|Drug|Oxycodone|oxycodone tablet
1479686|NCT03121963|Drug|Acetaminophen|acetaminophen tablet
1479687|NCT03121963|Drug|Gabapentin|gabapentin tablet
1479688|NCT03121963|Drug|Celecoxib|celecoxib tablet
1479689|NCT03121963|Drug|Hydrocodone-Acetaminophen|hydrocodone 5 mg/acetaminophen 325 mg tablet
1479690|NCT03121950|Other|Dance|The primary intervention is a dance class
1479691|NCT03121950|Other|music|the secondary intervention is listening to live music
1479692|NCT03121937|Behavioral|Mobile App|"The mobile app mConnect is an app designed to facilitate psychotherapy for depression and includes mood tracking, goal setting, and communication"
1479693|NCT03121924|Procedure|timing for oocyte denudation and Intracytoplasmatic Sperm injection|"Donated oocytes were randomly allocated to two groups concerning the time of cumulus corona removal.
The first group: After oocyte retrieval, cumulus cells were immediately removed and then ICSI was performed; in the second group, the oocyte-cumulus complexes were incubated for 4 hours. Afterwards, the granulosa cells were removedand ICSI was immediately performed."
1479694|NCT03121911|Other|Interval Training (IT)|"Each exercise session will consist of:
warm up (10 minutes)- stretches and calisthenics exercises of low to moderate intensity;
interval training (IT) - 30 minutes of IT performed in a cycle ergometer, divided into 6 levels of intensity based on the ventilatory anaerobic threshold (VAT) found in CPET: Level 1 - 5 minutes in moderate intensity, at 80% of power reached in VAT; Levels 2 and 4 - 5 minutes of moderate to high intensity, at 100% of VAT; Levels 3 and 5 - 5 minutes of moderate to high intensity, 110% of VAT; Level 6 - 5 minutes in moderate intensity, at 70% of VAT.
cooling down (10 minutes) - stretching, and breathing exercises. An CPET will be performed every four weeks to adjust the intensity of training."
1479695|NCT03121911|Other|Inspiratory Muscle Training (IMT)|"The IMT session will take place just after the warm-up exercises and consist of 2 series of 12 inspirations with a 60% of Maximal Inspiratory Pressure (MIP) with the equipment POWERbreathe Plus Medic® (POWERbreathe International Ltd, Warwickshire, UK). The patient will be instructed to remain seated with a nasal clip during the IMT series to avoid nasal air leakage and will be asked to inhale quickly and deeply, as quickly as possible, with a 2 minute interval between series. The training load will be adjusted weekly by a new evaluation of MIP to maintain the intensity of the exercise within the proposed value.
All the others exercises will be identical between group 1 and 2."
1479696|NCT03121898|Device|Platelet function test|Measurement of P2Y12 and PAR-dependent platelet function activity before and after cardiac surgery by ADPtest and TRAPtest
1479697|NCT03121885|Behavioral|30-minute movement activity|The subjects arrive in the CRU after a 12 hours overnight fast to perform a 30-minute movement activity with individually adapted exercise intensity on the treadmill.
1479698|NCT03121885|Other|Hypoxia|The 30-minute movement activity on the treadmill will be completed by each subject once under normobaric normoxic and once under normobaric hypoxic conditions (equivalent to approximately 3000 meters above sea level) in a randomized episode.
1479699|NCT03121872|Procedure|Root Coverage Surgery with T-PRF|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
1479700|NCT03121872|Procedure|Root Coverage Surgery with CTG|Root surfaces in the multiple gingival recession regions were made smooth using Gracey curettes. To remove the smear layer, 24% EDTA solution was applied to the tooth surfaces for approximately 2 minutes and then washed with physiological saline. The receiver region was prepared using the modified tunnel method. After passive stabilization of the flap in the coronal aspect, the preparation of the donor region was initiated
1479701|NCT03121859|Other|Neck stabilization exercise|Exercise
1479702|NCT03121859|Other|TENS|Transcutaneous electrical nerve stimulation (TENS)
1948788|NCT01629056|Procedure|RF ablation|RF ablation to the left atrium of the heart, without the use of ECI-contact information (control arm)
1479710|NCT03121807|Other|Oliclinomel N4 Per bag 1.5 L|Home parenteral nutrition with 910 kcal/day , including 33 g amino acid/day, 120 g glucose/day, 30 g lipid/day and electrolyte, micro-element and vitamin according to the nutritional status of subjects and followed the standard procedure of the hospital (Oliclinomel N4 Per bag 1.5 L), was infused continuously daily in an infusion time ranged between 18-24 hours.
1479711|NCT03121807|Drug|Oxaliplatin|
1479712|NCT03121807|Drug|5Fluorouracil|
1479713|NCT03121807|Drug|Leucovorin|
1479714|NCT03121794|Procedure|Ultrasonographic exam|The study team will perform an ultrasonographic exam of the proximal humerus to identify six anatomical landmarks
1479715|NCT03121794|Device|ultrasound machine|Regular ultrasound machine used at Cleveland Clinic
1479716|NCT03121781|Other|respiratory support- interface|change interface to RAM cannula
1479717|NCT03121781|Other|respiratory support- interface|change interface to binasal prongs
1479718|NCT03121742|Behavioral|Ecological Momentary Intervention|Patients will be taught four therapeutic intervention skills based on positive psychology and cognitive behavioral therapy. They will then be prompted to complete these interventions on a smartphone four times per day (and as needed) for the duration of their inpatient care and for 28 days afterwards.
1479719|NCT03121742|Behavioral|Treatment as Usual|Standard care as part of inpatient hospitalization.
1479720|NCT03121729|Procedure|enhanced recovery after surgery|Undergo an enhanced recovery after surgery program
1479721|NCT03121716|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody.
1479722|NCT03121716|Drug|Gemcitabine|gemcitabine
1479723|NCT03121716|Drug|cis-platinum|cis-platinum
1479724|NCT03121703|Other|lumbar stabilization exercise|lumbar stabilization exercise
1479725|NCT03121703|Other|trunk muscle strengthening exercise|trunk muscle strengthening exercise
1479726|NCT03121690|Drug|Prednisone|prednisone 40 mg/day for 7 days
1479727|NCT03121690|Drug|placebo|5ml saline / day for 7 days
1479728|NCT03121677|Biological|Personalized synthetic long peptide vaccine|-The synthetic long peptide vaccine is reconstituted in up to four pools (A, B, C, and D). At each vaccination time point, each of the up to four pools will be administered to one of the four limbs (A - Right Arm, B - Left Arm, C - Right Leg, D - Left Leg) by subcutaneous injection.
1479729|NCT03121677|Drug|Poly ICLC|-The synthetic long peptide vaccine will be co-administered with poly-ICLC.
1479730|NCT03121677|Biological|Nivolumab|-Nivolumab will be administered at a dose of 240 mg intravenously
1479731|NCT03121677|Procedure|Peripheral blood draws|-Cycle 1 Day 15, Cycle 2 Day 1, Cycle 3 Day 1, Cycle 4 Day 1, Cycle 6 Day 1, Cycle 12 Day 1, Time of response, and Time of progression or relapse
1479732|NCT03121677|Procedure|Leukapheresis|"At baseline (prior to initiation of treatment) and up to five days prior to the start of Cycle 6, patients will undergo apheresis according to standard institutional procedures for non-mobilized collection.
Peripheral blood leukocytes will be cryopreserved for later assessment for the presence of T-cells that recognize tumor specific mutant antigens and immunophenotype, and the presence of other lymphocytes or regulatory populations."
1479733|NCT03121677|Biological|Rituximab|-Other anti-CD20 mAb treatment can be used
1479734|NCT03121677|Procedure|Biopsy|"Prior to start of treatment
This biopsy may be performed as an excisional biopsy of a lymph node involved with follicular lymphoma or as 6 core biopsies from two separate lymph nodes involved with follicular lymphoma (12 core biopsies total)"
1479735|NCT03121664|Drug|PF06649751, Itraconazole|PF-06649751 0.25 mg on Days 1,2,3 PF-06649751 0.5 mg on Days 4,5,6 PF-06649751 1 mg on Days 7 to Day 25 Itracoanzole 200 mg on Days 12 to Day 25
1479736|NCT03121651|Device|RL-adaptive application|"Up to 6 dyads of individuals with disabilities and their caregivers will be recruited to collaborate in defining the features and content of the RL-adaptive support. The steps in developing the RL-adaptive support include having the dyads use for approximately 6 weeks each:
young adult uses an electronic medication pillbox that sends its pillbox openings within one hour of opening to the research team,
young adult uses the electronic medication pillbox + both use a commercially available medication reminder app + caregiver uses a pillbox opening notification app, and
young adult uses the electronic medication pillbox + the RL-adaptive support including push notifications in the form of text messages + caregiver uses the pillbox opening notification app.
The goal is to reduce the number of caregiver prompts necessary for the medication pillbox to be opened."
1479737|NCT03121638|Biological|VARIVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
1479738|NCT03121638|Biological|ZOSTAVAX|Preparation of Oka/Merck strain of live, attenuated varicella zoster virus
1479739|NCT03121638|Biological|NBP6081|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
1479740|NCT03121638|Biological|NBP6082|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
1479741|NCT03121638|Biological|NBP6083|Preparation of Oka/SK strain of live, attenuated varicella zoster virus
1479742|NCT03121625|Biological|Autologous CAR-T|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
1479743|NCT03121612|Device|CPAP|CPAP therapy
1479744|NCT03121599|Device|Diagnostic (18F-FLT PET/CT)|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
1479745|NCT03121586|Drug|Pimavanserin|Pimavanserin 10 mg, tablet, taken as one 10 mg tablets, once daily by mouth, OR Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
1479746|NCT03121573|Drug|Duloxetine|duloxetine 30 to 60 mg tablets by mouth, QD to BID per day,
1480428|NCT03116867|Other|sonosalpingography|transvaginal ultrasound with saline infusion
2000863|NCT03323359|Procedure|Common Surgical Techniques|Patients undergoing liver resection for any underlying disease and with resectable mass. The list of the underlying diseases is the following (but might not be limited to): Hepatocellular carcinoma, Hilar cholangiocarcinoma, Adrenal cancer metastasis, Breast cancer metastasis, Colorectal cancer metastasis, Ovarian cancer metastasis, Biliary carcinoma, Hemangioma, Hepatic adenoma, Focal nodular hyperplasia, Unilocular hydatid cyst, Multilocular, hydatid cyst.
2000864|NCT03323346|Drug|Disulfiram|"Patients will take one pill of disulfiram (Antabus) daily at a dose of 400 mg continually during the treatment phase (from day 0 till End of treatment Visit). In case of intolerance, lower dose up to 200 mg per day is allowed.
Copper supplementation will be given separately from disulfiram; in the morning with patients´breakfast. Patients will take one pill of copper dietary supplement (for instance Copper Star, STARLIFE) corresponding to 2 mg of elementary copper."
1479749|NCT03121547|Drug|Tapentadol 50 MG Oral Tablet|1 tablet adminstered
1479750|NCT03121547|Drug|Tramadol Hydrochloride 100 MG Extended Release Oral Tablet|1 tablet adminstered
1479751|NCT03121547|Drug|Placebo Oral Tablet|calcium tablet
1479752|NCT03121534|Drug|Blinatumomab|"Induction phase consists of a single cycle of Blinatumomab therapy. Blinatumomab initiated at 9 mcg/day from day 1-7, followed by 28 mcg/day from day 8-14 (week 2). This is followed by 112 mcg/day from day 15-56. The induction cycle is 8 weeks in duration.
Patients who achieve an objective response after induction are eligible to receive one further cycle of Blinatumomab consolidation, delivered at 112 mcg/day by continuous vein infusion from day 1-28 (total of 4 weeks). Consolidation may be initiated 4-8 weeks after completion of the induction infusion of Blinatumomab."
1479753|NCT03121534|Drug|Dexamethasone|Dexamethasone 20 mg by mouth or vein 24 hours prior to and within 1 hour before start of treatment in each treatment cycle. If treatment is interrupted for >4 hours at any point, Dexamethasone treatment given before re-initiation of therapy. Dexamethasone 8 mg by mouth or vein every 8 hours given for 48 hours at the commencement of the infusion and after each dose increment.
1479754|NCT03121521|Drug|Melatonin 10 mg|melatonin 10mg daily p.o.
1479755|NCT03121521|Drug|Placebo|Placebo 10mg daily p.o.
1479756|NCT03121508|Behavioral|Taking on Diabetes to Advance You (TODAY) Project|This is an individualized educational intervention with activity components designed to assist in modifying habits, roles, and routines to promote healthy lifestyle patterns for individuals with type 2 diabetes.
1479757|NCT03121495|Diagnostic Test|Second forward view (SFV) examination of the right colon|The colonoscope will be advanced to the cecum again when hepatic flexure was reached the first time, where a second forward view (SFV) examination of the right colon will be performed
1479758|NCT03121482|Device|HFNC|Gas flow of 50 l/min and FiO2 adjusted to obtain SpO2 ≥ 92%
1479759|NCT03121482|Device|NIV|Pressure-support level to achieve an expired tidal volume between 6 and 8 ml/kg and PEEP level of 5 cm H2O with FiO2 adjusted to obtain SpO2 ≥ 92%
1479760|NCT03121469|Device|Papillon +TM|Technique of Per-Operative Radiotherapy (RPO) by Papillon +TM
1479761|NCT03121456|Other|18F-FDG PET SCAN|REALIZATION OF INITIAL 18F-FDG PET SCAN (PRE THERAPEUTIC), THEN BETWEEN CYCLE 2 DAY 10 AND CYCLE 3 DAY 1
1479762|NCT03121456|Other|MRI DIFFUSION|REALIZATION OF INITIAL MRI DIFFUSION WITHIN 7 DAYS AFTER INITIAL 18F-FDG PET SCAN, THEN WITHIN 7 DAYS AFTER 18F-FDG PET SCAN 1.
1479763|NCT03121443|Other|Perfusion index|supine,prone, trendelenburg,reverse trendelenburg,45 degrees back up sitting position, 45 degrees legs lifted supine position.
1479764|NCT03121430|Device|Drug eluting peripheral vascular stent system|Drug eluting peripheral vascular stent system、Color Doppler Ultrasonography (CDU) imaging、Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
1479765|NCT03121430|Device|Nitinol Stent System|Nitinol Stent System、Color Doppler Ultrasonography (CDU) imaging and Dual Fluoroscopic Imaging、Digital subtraction angiography（DSA）
1479766|NCT03121417|Biological|Nivolumab|240 mg given IV
1479767|NCT03121404|Procedure|Rectus abdominis muscle biopsy|Patients who will already be having either liver transplant surgery or abdominal surgery will have a biopsy of their rectus abdominis muscle during the time of surgery.
1479768|NCT03121391|Procedure|Ventilator withdrawal algorithm|"Steps and decision trees in the algorithm include in descending order:
Ascertain patient consciousness, perform cuff-leak test, evaluate for indications for pre-medication, select a withdrawal method, assess for respiratory distress with Respiratory Distress Observation Scale, medicate for respiratory distress with morphine, make an extubation decision, ascertain need for continuous morphine, ascertain need for supplemental oxygen, assess for post-extubation stridor, treat post-extubation stridor"
1479769|NCT03121378|Other|Blood sample 1|Blood taken before prosthesis implantation
1479770|NCT03121378|Other|Blood sample 2|Blood taken after prosthesis implantation
1948789|NCT01622348|Drug|IMO-3100|IMO-3100 at 0.16 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 20 mg per injection
2000865|NCT03323333|Behavioral|psychosocial counseling|A problem-solving and psychosocial skill-building intervention.
1479773|NCT03121352|Drug|Carboplatin|AUC 6 IV day 1 of 21-day cycle
1479774|NCT03121352|Drug|Nab-paclitaxel|100mg/m2 IV days 1, 8 and 15 of 21-day cycle
1479775|NCT03121352|Drug|Pembrolizumab|200 mg IV every 21 days
1479776|NCT03121339|Biological|VXA-A1.1 H1 Tablet Vaccine (small)|Tableted oral H1 vaccine (~140 mg tablet)
1479777|NCT03121339|Biological|VXA-A1.1 H1 Tablet Vaccine (large)|Tableted oral H1 vaccine (~275 mg tablet)
1479778|NCT03121326|Diagnostic Test|blood and urine sampling|Ten mL blood and 15mL urine are collected.
1479779|NCT03121313|Drug|tegafur-uracil|
1479780|NCT03121300|Other|CT Scan|Quantitative lung SPECT-CT
1479781|NCT03121300|Other|Lung CT|CT lung ventilation
1479782|NCT03121300|Other|MRI|DCE MRI
1479783|NCT03121300|Other|Walk Test|6 minute hall walk test
1479784|NCT03121300|Other|SGRQ|St. George Respiratory Questionnaire
1479785|NCT03121300|Other|Biological Sample Collection|Blood Draw
1479786|NCT03121300|Other|Toxicity|Toxicity Evaluation
1479787|NCT03121300|Other|Cardiac Assessment|Cardiac MRI Scan
1479792|NCT03121274|Procedure|vaginal delivery|vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded
1479795|NCT03121248|Radiation|WBI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
1479796|NCT03121248|Radiation|WBI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
1479797|NCT03121248|Radiation|LNI 5 fractions|External beam radiotherapy in 5 fractions of 5,4Gy
1479798|NCT03121248|Radiation|LNI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
1479799|NCT03121248|Radiation|SIB 5 fractions if needed|Simultaneous boost of 5 x 6,2Gy (6,5Gy in case of involved resection margins) if needed
1479800|NCT03121248|Radiation|SIB 15 fractions if needed|Simultaneous boost of 15x3,12Gy (3,33Gy in case of involved resection margins) if needed
1479801|NCT03121248|Radiation|TWI 5 fractions|External beam radiotherapy in 5 fractions of 5,7Gy
1479802|NCT03121248|Radiation|TWI 15 fractions|External beam radiotherapy in 15 fractions of 2,67Gy
1479803|NCT03121235|Diagnostic Test|PCR based detection of azole resistance in A. fumigatus|Diagnosis and treatment of IA will be based on the results of a standardized diagnosis and treatment protocol that includes the use of the AsperGenius® PCR.
1479804|NCT03121222|Drug|N-acetylcysteine|The antioxidant group received orally two N-acetylcysteine tablets (each tablet contained 600 mg of NAC; Lamberts Health Care Ltd, Kent, United Kingdom). The participants were instructed to receive the capsules every twelve hours in order to achieve high concentration of N-acetylcysteine throughout the 24 h. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for N-acetylcysteine.
1479805|NCT03121222|Drug|Lactose|The placebo group received orally two lactose tablets per day. The participants were instructed to receive the capsules every twelve hours. Each individual received the capsules pre-packed in daily doses labeled with the day of consumption. The supplementation period was 30-day for placebo.
1479806|NCT03121196|Other|Epices score|Association between EPICES score and the adverse perinatal outcomes will be assessed by quantile regression
1479807|NCT03121183|Device|Laser sheath|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
1479808|NCT03121183|Behavioral|Implantable Cardiac Device lead extraction|Patients who have undergone an extraction of implantable pacemaker or defibrillator leads whatever the indication for the period march 2015-2017
1479809|NCT03121170|Other|extracorporeal shock wave therapy|Intervention group is by extracorporeal shock wave therapy.A radial shock wave device (EMS Swiss Dolor, Munich, Germany) was used. Radial shock wave is created ballistically with the pressurized air source accelerating a bullet to strike a metal applicator. The kinetic energy produced is transformed into radially expanding shock waves from the application site into the tissue to be treated. The treatment of area is lower abdomen which has some acupuncture points such as Shenque(CV8) ,Qihai(BL24), Guanyuan(CV4), Zhongji(CV3), Tianshu(ST25, Guilai(ST29) and Zigong(EX-CA1). All acupuncture points should be placed according to participants' feedback during treatment.
1479810|NCT03121170|Other|hot compress paste|Hot compress pastes will be sticked on the lower abdomen.
1479811|NCT03121157|Behavioral|Multi-Component Technology Based Intervention|The intervention group receives two sessions of computer-delivered MI via software programmed to target adherence to medications and text messaged adherence reminders between sessions. Sessions are provided by an avatar. The intervention engages the youth with the avatar's communication of empathy, optimism, and autonomy support. The intervention focuses the youth on adherence and relevant health behaviors with feedback on adherence, asthma symptoms, and tailored education. Participants are guided in the planning process through goal setting activities. The length of the intervention sessions are about 30 minutes each, with the total duration of the visit (assessment and intervention) lasting about 1.5 hours.
1479812|NCT03121131|Other|Clinical Exam Findings|Findings found on clinical exam of a patient the radiologist will be reading CT scans of.
1479813|NCT03121131|Other|Inaccurate Clinical Exam Findings|Inaccurate findings are given to the radiologists
1479814|NCT03121131|Other|No clinical exam findings|No clinical exam findings are given to the radiologists
1479815|NCT03121118|Other|Scan Opportunity|Participants in the scan group are provided the option of having an amyloid PET brain scan and receiving their results which can inform them of risk for developing Alzheimer's Disease.
1479816|NCT03121092|Drug|ACEI or ARB|Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
1479817|NCT03121079|Drug|Interferon-alpha|patients in Interferon-alpha group will receive Interferon-alpha injection since the third month after transplantation for six months.
1479818|NCT03121066|Device|Active Transcranial Magnetic Stimulation|The intervention consists of a 2-week treatment during which TMS will be applied for 10 days (every working day). The stimulation protocol will be intermittent TBS (iTBS). 600 pulses in each area will be applied at intervals of 2 seconds of stimulation and 8 seconds of rest; the total number of pulses per session will be 1200. The stimulation duration is 3 minutes and 12 seconds. This protocol allows the induction of long-term potentiation effects, promoting plasticity in the stimulated areas. To perform the stimulation a 70 mm, figure of 8-coil will be used. In order to precisely locate the stimulated areas a stereotactic image guidance will be used during the stimulation (Brainsight™ 2)
1479819|NCT03121066|Device|Sham Transcranial Magnetic Stimulation|The Sham intervention will be carried out using the same stimulation protocol as in the active condition but with the coil rotated 90º to prevent the magnetic field inducing electrical activity in the cortex.
1479820|NCT03121053|Drug|sodium bicarbonate|
1479821|NCT03121053|Drug|hypotone saline|
1479822|NCT03121040|Dietary Supplement|Vespa amino acid mixture|17 kinds of amino acids mixture in specific proportion
1479823|NCT03121014|Drug|Fludarabine|40 mg/m^2 IVBP daily for day -5 (5 days before stem cell infusion) through Day -2
1479824|NCT03121014|Drug|Busulfan|targeting a 4800μM/min/ day from day -5 through day -2
1479825|NCT03121014|Drug|ATG|0.5 mg/kg IV on day -3, and 2 mg/kg on days -2 and day -1
1479826|NCT03121014|Radiation|Total Marrow Irradiation|dose of 3Gy on days -3, -2 and -1
1479827|NCT03121014|Procedure|Stem Cell Product Infusion|Day 0 according to BMT unit policy
1479911|NCT03120442|Drug|Propofol|target-controlled infusion starting for Cet 0.1 mcg/ml to achieve MOAA/S 3-4
1479828|NCT03121014|Drug|Tacrolimus|The starting dose is at 0.03 mg/kg/day IV continuous infusion over 24 hr from 4 PM on day -2. Dose will be adjusted to target trough levels of 5-15 ng/mL. More information is available in the protocol document.
1479829|NCT03121014|Drug|Methotrexate|10 mg/m^2 on Day 1, 8 mg/m^2 on Days 3, 6 and 11
1479830|NCT03121001|Drug|ATG|0.5 mg/kg IV on day -9, and 2 mg/kg on days -8 and day -7
1479831|NCT03121001|Drug|fludarabine|30 mg/m2 IVPB daily for day -6 (6 days before stem cell infusion) through day -2
1479832|NCT03121001|Drug|cyclophosphamide|14.5 mg/kg IV on days -6 and -5 and 50 mg/kg/d on days +3 and +4
1479833|NCT03121001|Radiation|Total body irradiation|3 Gy on day -1
1479834|NCT03121001|Procedure|Stem cell infusion|Stem cell product infused according to BMT unit policy on day 0.
1479835|NCT03121001|Drug|Sirolimus|loading dose of 15 mg followed by 5 mg per day on day +5
1479836|NCT03121001|Drug|mycophenolate mofetil|1 g every 8 h (until day 35) will be started on day 5
1479837|NCT03120988|Biological|Lavage with Platelet Poor Plasma (PPP)|Lavage of 50cc PPP
1479838|NCT03120975|Other|Computerized decision support and audit & feedback|"suggestion of guideline concordant antimicrobial treatment based on indication entry in the computerized physician order entry system
mandatory reevaluation of antimicrobial therapy therapy on calendar day 4 of treatment
suggestion of standard antimicrobial treatment duration according to indication"
1479839|NCT03120975|Other|Audit & Feedback|* regular (at least monthly) feedback of antibiotic use quality indicators (on the ward level)
1479840|NCT03120975|Other|Standard antibiotic stewardship|"Infectious diseases consultation on demand
Review of positive blood cultures
Availability of a antibiotic use guidelines (on paper and as PDF)"
1479841|NCT03120962|Drug|Oxycodone|Oxycodone 20mg/day, for 4 weeks
1479842|NCT03120962|Drug|Gabapentin|Gabapentin 900mg/day, titrated up to max tolerated dose or 1800mg/day, for 4-12 weeks
1479843|NCT03120962|Drug|Famciclovir|Famciclovir 500mg three-times daily for 7 days
1479844|NCT03120949|Drug|Olokizumab 64 mg SC q4w|Treatment Arm 1, Experimental, Olokizumab 64 mg Subcutaneous q4w + Methotrexate (oral)
1479845|NCT03120949|Drug|Olokizumab 64 mg SC q2w|Treatment Arm 2, Experimental, Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)
1479846|NCT03120949|Drug|Methotrexate|"Treatment Arm 1, Experimental, Olokizumab 64 mg Subcutaneous q4w + Methotrexate (oral);
Treatment Arm 2, Experimental, Olokizumab 64 mg Subcutaneous q2w + Methotrexate (oral)"
1479847|NCT03120936|Drug|Emtricitabine / Tenofovir Disoproxil Oral Tablet|Open-label emtricitabine 200mg/tenofovir 300mg
1479848|NCT03120936|Behavioral|PrEP support|HIV/STI testing and counseling, adherence counseling, medical exams, safety monitoring, short message system (SMS), ie text message, and peer support, panel management.
1479852|NCT03120884|Procedure|ICSI|A technique that involves microinjection of spermatozoa into mature oocytes.
1479853|NCT03120884|Procedure|IVF|A process of fertilisation where an an egg is combined with sperm outside the body, in vitro.
1479854|NCT03120858|Behavioral|Determine what the imagery levels are|Determine the motor imagery: kinesthetic and visual imagery
1479855|NCT03120845|Procedure|One visit RCT|Root canal treatment in one vist
1479856|NCT03120845|Procedure|Post operative pain in two-visits RCT|Root canal treatment in Two visits
1479857|NCT03120832|Biological|PAN-301-1|
1479858|NCT03120819|Behavioral|Oncologist Recommendation|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist
1479859|NCT03120819|Behavioral|Oncologist Recommendation + DVD|Patients in this arm receive a 2-3 minute verbal recommendation about exercise from their treating oncologist and then be sent an instructional exercise DVD to follow at their home three times per week for eight weeks
1479860|NCT03120806|Procedure|Interrupted subcuticular skin closure|skin is closed with interrupted mattress subcuticular sutures using non-absorbable polypropylene after elective cesarean section
1479861|NCT03120806|Procedure|continuous subcuticular skin closure|skin is closed with continuous subcuticular sutures using non-absorbable polypropylene after elective cesarean section
1479863|NCT03120780|Drug|Fentanyl 20 mcg|20 mcg fentanyl in 10 mL 0.125% bupivacaine
1479864|NCT03120780|Drug|Fentanyl 100 mcg|100 mcg fentanyl in 10 mL 0.125% bupivacaine
1479865|NCT03120767|Behavioral|Risk and Resilience|"The Risk and Resilience course is a 14-week undergraduate seminar that is grounded in the current understanding of adolescent and young adult development, neuroscience, and positive psychology. Students will learn about key areas proven to enhance wellness, including communication, executive functioning, social support, self-efficacy, emotion regulation, and sense of purpose. Students will learn about healthy exercise, nutrition, and sleep habits, and develop skills in core components of cognitive-behavior therapy, mindfulness, and organizational skills."
1479866|NCT03120767|Behavioral|Coordinated Wellness Programming|"During the Fall of 2017, wellness activities will be provided within Founders Hall that support the theories and skills being taught in the Risk and Resilience course occurring in the same semester."
1479867|NCT03120754|Procedure|Place the peritoneal drainage|In the experimental group, the abdominal drainage was not placed
1479868|NCT03120754|Procedure|No peritoneal drainage|Intraoperative placement of peritoneal drainage as control group.
1479869|NCT03120728|Drug|Etonogestrel/ethinyl estradiol contraceptive vaginal ring|"Placement of a contraceptive vaginal ring with subsequent assessment of ovulation disruption. Timing of placement depends on leading follicle size, as described in Arms section."
1479870|NCT03120715|Drug|estrogen|The oral estrogen replacement is 4mg per day (2 mg twice daily), 4 days; 6 mg per day, 4 days. Then, the patient's endometrial thickness is evaluated through vaginal ultrasound and if the endometrial thickness is <7 mm, increasing estrogen by 2 mg is given to patients until the endometrial thickness is >9 mm.
1479912|NCT03120442|Drug|Dexmedetomidine|Incremental titration of dexmedetomidine starting from 0.1 mcg/kg/hr to achieve MOAA/S 3-4
1479913|NCT03120442|Drug|Fentanyl|0.25 mcg fo Fentanyl for anxiolysis
1479871|NCT03120715|Drug|Low Molecular Weight Heparin|If the endometrial thickness is greater than 9 mm, hCG 10000 IU will be administered via intramuscular injection.And low molecular weight heparin (LMWH) will be injected subcutaneously 4100 IU (WHO) every other day before FET.Then on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
1479872|NCT03120715|Drug|hCG|If the endometrial thickness is greater than 9 mm, Human Chorionic Gonadotropin（hCG） 10000 IU will be administered via intramuscular injection.
1479873|NCT03120715|Drug|progesterone|on the next day(D0), progesterone in oil 60 mg will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later(D3).
1479874|NCT03120689|Other|Live Surgery using VITOM|The vaginal operative field will be filmed with a VITOM® camera and the image from the VITOM® camera will be projected live within the operating room, so that the operating team can reference the image during the surgery.
1479875|NCT03120689|Other|Live Surgery without VITOM|The vaginal operation will not be filmed and learner observation will take place in the traditional way, with them looking at the physical surgical field.
1479876|NCT03120689|Other|Video viewing with VITOM|They will view the 10-minute standardized video filmed with the VITOM® camera.
1479877|NCT03120689|Other|Video viewing with standard handheld high-definition camera|They will view the 10-minute standardized video filmed with the standard, handheld high-definition camera.
1479878|NCT03120676|Drug|Atezolizumab|All patients will receive atezolizumab 1200 mg via IV infusion on D1 of each 21-day cycle.
1479879|NCT03120663|Drug|amoxicillin-clavulanic acid|"During one dosing interval at steady state of the involved antimicrobials (ABs), AB plasma concentrations will be determined.
Besides, the measured creatinine clearance based on an 8-hour urinary collection (CrCl8h) will be used as the primary method for determining kidney function. Based on these values, CrCl8h will be calculated according to the standard formula and normalized to a body surface area (BSA) of 1.73m² ."
1479880|NCT03120650|Other|Scalp acupuncture|Acupoint selection: Shenting (DU24; Baihui (DU20; and upper 1/5 and middle 2/5 in the contralateral motor area (upper: 0.5 cm posterior to the midpoint of the front and rear midline; middle 2/5: intersection between the eyebrow line and the leading edge of the temple hairline.
1479881|NCT03120650|Other|Conventional rehabilitation|Rehabilitation plans will be made according to the Guidelines for Stroke Rehabilitation in China (Cerebrovascular Disease Association and the Neurological Rehabilitation Association of Neurology Branch of the Chinese Medical Association, 2012), including physical therapy and occupational therapy.
1479882|NCT03120637|Drug|Methylene Blue|
1479883|NCT03120624|Procedure|Biopsy|Undergo image-guided biopsy
1479884|NCT03120624|Procedure|Computed Tomography|Undergo SPECT/CT
1479885|NCT03120624|Other|Laboratory Biomarker Analysis|Correlative studies
1479886|NCT03120624|Other|Pharmacological Study|Correlative studies
1479887|NCT03120624|Procedure|Planar Imaging|Undergo whole body planar imaging
1479888|NCT03120624|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
1479889|NCT03120624|Drug|Technetium Tc-99m Sodium Pertechnetate|Given IV
1479890|NCT03120624|Biological|VSV-hIFNbeta-NIS|Given IV
1479891|NCT03120611|Other|Virtual Reality Exercise|Game developed by the Kinect, adapted to the lying position of participants.
1479892|NCT03120611|Other|Conventional exercise intradialysis|Aerobic exercise (cycling) and strengthening exercise for lower limbs using elastic bands and gravity
1479893|NCT03120598|Behavioral|ATTC strategy|Addiction Technology Transfer Center (ATTC) strategy: A staff-focused strategy that includes 10 discrete strategies (e.g., centralized technical assistance, conduct educational meetings, provide ongoing consultation).
1479894|NCT03120598|Behavioral|ISF strategy|Implementation & Sustainment Facilitation (ISF) strategy: An organization-focused strategy that includes 7 discrete strategies (e.g., use of an implementation advisor, organize implementation team meetings, conduct cyclical small tests of change).
1479895|NCT03120585|Other|Fluid Management Intervention|Fluid management intervention is fluid restriction to 60 mL/kg/day on Day of Life (DOL) 1 for preterm and 40 mL/kg/day on DOL 1 for term neonates, calculated as total of IV and enteral fluid intake. Infants randomized to low infusion with be placed on 10% dextrose and the Infant will be monitored by obtaining serum glucose levels by point of care testing. Glucose infusion rates (GIR) would be calculated to the corresponding serum glucose and recorded. After 24 hours, infusion rate will be increased to 60ml/kg/d providing minimum GIR >4mg/kg/d. . Total fluid intake will be increased by 20 mL/kg/day until 150 mL/kg/day .
1479896|NCT03120559|Device|New Floss Holder - Gum Chucks|Dental inter-proximal control with GumChucks floss holder
1479897|NCT03120559|Device|New Floss Holder - Gum Chucks/SMS|Dental inter-proximal control with GumChucks floss holder and receiving 16 SMS during first 4 months.
1479898|NCT03120546|Device|rigid video stylet intubation|intubation using rigid video stylet
1479899|NCT03120546|Device|video laryngoscope intubation|intubation using video laryngoscope
1479902|NCT03120520|Drug|Plecanatide|
1479903|NCT03120520|Drug|Matching placebo|
1479904|NCT03120494|Drug|Emtricitabine and Tenofovir|All subjects will be provided study drug for use daily for one year.
1479905|NCT03120481|Other|no intervation|no intervention
1479906|NCT03120468|Drug|Topiramate and N-Acetyl Cysteine|Topiramate up to 200 mg/day and N-Acetyl Cysteine 600 mg twice a day for 12 weeks
1479907|NCT03120468|Drug|Topiramate and Placebo|Topiramate up to 200 mg/day and Placebo for 12 weeks
1479908|NCT03120455|Behavioral|Almond Group|Obese or overweight female adults will be randomly allocated to have almond as afternoon snacks, while they have a hypoenergetic diet.
1479909|NCT03120455|Behavioral|Pistachio Group|Obese or overweight female adults will be randomly allocated to have Pistachio as afternoon snacks, while they have a hypoenergetic diet.
1479910|NCT03120455|Behavioral|Nut free group|Obese or overweight female adults will be asked to avoid nuts, seeds and nut products, while they have a hypoenergetic diet.
1480429|NCT03116841|Drug|Vonoprazan|Vonoprazan 20 mg
1479914|NCT03120429|Behavioral|Fish group|Fish group will have hypoenergetic diet in which subjects will have 3 x 150 g lean fish/ week at main meal
1479915|NCT03120429|Behavioral|Control group|Control group will have hypo-energetic diet in which subjects have no seafood.
1479916|NCT03120416|Behavioral|Resistance exercise training|12-week resistance exercise training program, 2 times per week, 45 min per session. Eight exercises will be used to include large upper and lower body muscle groups (leg press, leg extension, leg curl, chest press, shoulder extension, biceps curl, abdominal crunch and back extension). The baseline one repetition maximum will be used to set initial training loads.
1479917|NCT03120403|Procedure|intrathecal morphine|
1479918|NCT03120390|Other|Best Practice|Undergo usual care
1479919|NCT03120390|Behavioral|Exercise Intervention|Undergo AE
1479920|NCT03120390|Behavioral|Exercise Intervention|Undergo RE
1479921|NCT03120390|Other|Laboratory Biomarker Analysis|Correlative studies
1479922|NCT03120390|Device|Monitoring Device|Receive Polar heart rate monitor
1479923|NCT03120390|Other|Quality-of-Life Assessment|Ancillary studies
1479924|NCT03120390|Other|Questionnaire Administration|Ancillary studies
1479925|NCT03120377|Other|Platform|Whole body vibration training will consist of 12 consecutive weeks with two sessions per week on alternate days. Initially, before training with the vibratory platform, stretches lasting 5 to 10 minutes will be performed, with a series of 60 seconds for each of the following muscle groups: pectorals, sternocleidomastoids, scalenes, quadriceps and ischiatibial muscles. Patients will be monitored through vital signs for follow-up.
1479926|NCT03120377|Other|Platform sham|will receive the treatment without the therapeutic effect of the platform, but with vibrating platform connected with the display lit and a sound device coupled with a noise recording generated by the vibration, but without therapeutic purposes.
1479927|NCT03120364|Biological|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
1479928|NCT03120364|Biological|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
1948790|NCT01622348|Drug|Saline for Injection|Saline for Injection 0.01 mL/kg SC q wk x 4 wk based on body weight at screening, not to exceed 1.25 mL
1948791|NCT01622348|Drug|IMO-3100|IMO-3100 at 0.32 mg/kg SC q wk x 4 wks based on body weight at screening, not to exceed 40 mg per injection
1479931|NCT03120338|Diagnostic Test|The Development and Wellbeing Assessment|The Development and Wellbeing Assessment (DAWBA: http://www.dawba.com/) is a computerised structured instrument for gathering diagnostic data from parents or guardians, teachers and young people themselves.
1479933|NCT03120312|Procedure|total hip replacement|primary hip replacement patients during past 5 years．
1479934|NCT03120299|Drug|Omega-3 fatty acid|Omega-3 fatty acids capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
1479935|NCT03120299|Drug|Placebos|Matching placebo capsules, 1 gram gel capsule, 2 capsules orally administered twice a day for 12 weeks
1479936|NCT03120273|Drug|Dexlansoprazole Injection|15mg q12h,30mg q12h,15mg qd,30mg qd for 5 days
1479937|NCT03120273|Drug|Lansoprazole Injection|30 mg q12h for 5 days.
1479938|NCT03120260|Other|Diet|Intervention 'Diet+ short sleep versus normal sleep
1479939|NCT03120247|Drug|OTM Dexmedetomidine 1µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
1479940|NCT03120247|Drug|OTM Dexmedetomidine 0.75µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
1479941|NCT03120247|Drug|OTM Dexmedetomidine 0.5µg/ kg.|Oral transmucosal dexmedetomidine pharmacologically prepared as a jel substance will be administered to the buccal mucosa 30 mins before the operative procedure.
1479942|NCT03120234|Drug|Dexmedetomidine|
1479943|NCT03120234|Drug|Ketamine|
1479944|NCT03120234|Drug|Fentanyl|
1479945|NCT03120234|Drug|Placebos|o.9% normal saline will be used instead of ketamine
1479946|NCT03120221|Diagnostic Test|Urine sample for iodine measurement|Women will be required to give a urine sample for iodine measurement
1479947|NCT03120208|Behavioral|• The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.|The Edinburgh postnatal depression scale (EPDS), validated in French, with a discrimination threshold ≥ 11.
1479948|NCT03120208|Behavioral|The GAD-7 with a discrimination threshold ≥10.|The GAD-7 with a discrimination threshold ≥10.
1479949|NCT03120208|Behavioral|• Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46|Spielberger's State-Trait anxiety inventory, Form Y (validated in French), with a STAI (form Y-A) discrimination threshold ≥ 46
1479950|NCT03120208|Behavioral|The IES-R, validated in French, with a discrimination threshold ≥ 30.|The IES-R, validated in French, with a discrimination threshold ≥ 30.
1479951|NCT03120195|Device|The EndoRotor®|The EndoRotor® is in automated mechanical endoscopic mucosal resection system for use in the gastrointestinal tract. The EndoRotor suctions up the tissue and cuts it, automatically sending the tissue to a collection trap for histological evaluation.
1479952|NCT03120182|Drug|Acetylsalicylic acid|Patients will receive acetylsalicylic acid 100mg daily for 12 days after randomization
1479953|NCT03120182|Drug|Placebo Oral Tablet|Patients will receive placebo medication 100mg daily for 12 days after randomization
1479954|NCT03120169|Other|treadmill endurance training|n = 15 patients with COPD. Walking intensity will be initially set at 80 percent of 6-minute Walking test Speed with progressive increase in Duration and intensity.
1479955|NCT03120169|Other|cycling endurance training|n=15 patients with COPD. Cycling intensity will initially be set at 60 percent of Peak work rate with progressive increase in Duration and intensity
1486036|NCT03074019|Dietary Supplement|Xylooligosaccacharide|XOS95 powder
1479956|NCT03120156|Device|sensomotoric insoles|sensomotoric insoles were published by Jahrling (2007) and have a certain shape that could improve balance abilities. The toes 2-4 are higher that toe 1, so that the tendons of the toe-flectors are pre-stressed.
1479957|NCT03120156|Device|normal standard insoles|Normal standard insole like you will get them by receipe from an orthotic shop
1479958|NCT03120156|Other|No insoles|control group with no insoles in the shoes
2000866|NCT03323632|Device|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non‐damaged pathways of the central nervous system.
1479961|NCT03120130|Biological|Amblyomin-X|Intravenous drug administration, with different doses in each cohort
1479962|NCT03120117|Procedure|Cough Test following Sling Surgery|Enrolled subjects will undergo sling surgery who present with stress-dominated urinary incontinence. While in the operating room, the subject will be asked to stand and cough to determine if there is still leakage once the sling has been placed.
1479963|NCT03120104|Other|pelvic floor muscle exercise before stoma closure|pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just one month before the stoma closure
1479964|NCT03120104|Other|pelvic floor muscle exercise after stoma closure|pelvic floor muscle training for one month (2~3 times a week, for 4 weeks) just two weeks after the stoma closure
1479965|NCT03120091|Device|Real-time continuous blood glucose monitoring system(CGMS)|A total of 20 patients were enrolled for the place of CGMS.CGMS were placed on the right chest wall of each patients and recorded the interstitial glucose. Arterial blood glucose (ABG) were recorded every four hours. The duration of monitoring set was 5 days.CGMS were compared with ABG at the same time point. A total of 600 pairs of glucose level were collected
1997903|NCT01836237|Device|Alexis - a wound protector|Alexis is a double ring, self-retaining circumferential device that is designed to protect incision site during surgical manipulation.
1479967|NCT03120026|Dietary Supplement|Experimental product|Two servings (40 grams each) of powder (Fortifit; Nutricia) which has to be dissolved in 125 ml of water. Per serving, 20 g whey protein, 3 g total leucine, 9 g carbohydrates, 3 g fat, 800 IU vitamin D, and a mixture of vitamins, minerals, and fibers.
1479968|NCT03120026|Dietary Supplement|Isocaloric placebo|Two servings (40 grams each) of an isocaloric (maltodextrins) powder which has to be dissolved in 125 ml of water.
1479969|NCT03120013|Device|Anodal cerebellar and cathodal spinal tDCS|10 sessions of anodal cerebellar and cathodal spinal transcranial direct current stimulation (5 days/week for 2 weeks)
1479970|NCT03120013|Device|Sham cerebellar and sham spinal tDCS|10 sessions of sham cerebellar and sham spinal transcranial direct current stimulation (5 days/week for 2 weeks)
1479971|NCT03120000|Drug|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
1479972|NCT03119987|Diagnostic Test|Red cell distribution widths|Measured value of Red cell distribution widths in initial laboratory result of blood cell counts at emergency department
1479973|NCT03119974|Drug|Tpo-RA discontinuation|a standardized strategy of dosage reduction will be implemented according to a predetermined scheme on persistent and/or chronic ITP patients who have previously achieved a stable and prolonged (> 2 months) complete response (platelets counts > 100 x 109/L) period on Tpo-RA treatment.
1479974|NCT03119961|Device|SONOCLOUD®|BBB opening by ultrasound
1479975|NCT03119948|Drug|Placebo injection|"Placebo in soleus and placebo in rectus femoris, and placebo in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
150U (x 7.5 ml) placebo Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) placebo distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment"
1479976|NCT03119948|Drug|Botulinum toxin injection|"Botulinum toxin type A in soleus and in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus.
150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) Xeomin® 20U/ml RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
1479977|NCT03119948|Drug|Placebo injection and botulinum toxin injection|"Botulinum toxin type A in soleus and placebo in rectus femoris, and Botulinum toxin type A in additional muscles as per investigator's choice among tibialis posterior, toe flexors (long or short), gastrocnemius muscles or peroneus longus..
150U (x 7.5 ml) Xeomin® 20U/ml Sol + 150U (x 7.5 ml) placebo RF + 100U (5ml) Xeomin® distributed between tibialis posterior, FHL (flexor hallucis longus), FCB (flexor digitorum brevis), gastrocnemius muscles or peroneus longus, based upon investigator clinical judgment."
1479978|NCT03119935|Device|Amflow|Amflow deviced was developed for monitoring ventiation rate and ventilation volume. Participants ventilated the simulated patients by Amflow-device assist ambu bag
1479979|NCT03119935|Device|Ambu bag|Participants ventilated the simulated patients by ambu bag
1479980|NCT03119922|Other|No intervention|
1479981|NCT03119909|Other|First session of fMRI: localization of the premotor areas of the medial frontal cortex|Subjects should perform simple tasks to map the premotor areas of the medial frontal cortex. In this context, they will have to perform hand, tongue, ocular movements for about 20s. Additionally, as part of a control condition, they will need to perform eye fixation on a cross shown at the center of the screen for about 20s.
1479982|NCT03119909|Other|Second fMRI session|The subjects will position their left and right thumbs on response buttons. Each trial will begin with the appearance of one of 2 possible indexes. It will be an unknown abstract visual stimulus). After a variable delay of 0.5 to 6s (average = 2s), a blue or yellow circle will appear on the left or right of the screen.
1479983|NCT03119909|Other|Third fMRI Session|This session is identical to the second session but the subject will have to respond by performing saccadic ocular responses.
1486037|NCT03074019|Dietary Supplement|Maltodextrin|Maltodextrin powder
1479984|NCT03119909|Other|Training fMRI session|The training session will consist in training the subject to carry out the different behavioral tasks that he will then have to perform during the sessions of fMRI.
1479985|NCT03119909|Other|Pilot behavioral study|In a pilot study, 30 subjects will participate in a behavioral study (2 sessions of 2 hours each) aimed at establishing the learning characteristics of the different types of rare events unrelated to actions (visual and sensorimotors on the hand).
1479986|NCT03119909|Other|fMRI Study|Each subject will participate in 2 fMRI sessions of about 2 hours each: a first session in which a first version of the task will be presented and a second session in which the second version of the task will be presented.
1479987|NCT03119896|Other|The Navigator Tool Intervention|The intervention consists of two parts; a training session on self-management of chronic conditions for the healthcare professionals, and a paper-based tool for the patients. Both parts aim to inform and prepare the two parties as to what self-management entails in order to facilitate a constrictive consultation.
1479988|NCT03119883|Other|Infusion of 13-Carbon labeled Glutamine|Intravenous infusion of 13-Carbon labeled glutamine followed by bone marrow aspiration
1479989|NCT03119870|Other|Train|Each subject will be trained to perform a trial-error learning task. In this task, three visual stimuli will be presented to the subject. The subject will have to find by trial-error, the one associated with positive feedback, the other stimuli being associated with negative feedback (search period). Once the stimulus is associated with positive feedback, the subject will perform a period of repetition during which he will choose the stimulus associated with positive feedback. Two variants of the task will be used: a variant in which feedback will be visual (ie positive feedback = green square, negative feedback = red square) and a variant in which feedback will be fruit juice (ie positive feedback = Fruit juice (but less than 2ml), negative feedback = no volume or small volume of fruit juice).
1479990|NCT03119870|Other|MRI|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained. For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
1479991|NCT03119870|Other|EEG|Once the tasks are learned, each subject will participate in an MRI session during which an anatomical scan will be obtained and then an EEG session during which he will perform the task learned.For each task, the time of presentation of the stimuli will be 2s. During this time, the subject should indicate his choice of stimulus. After a delay of 2s, feedback will be presented for 1s. Each test shall be separated by an inter-test delay of 3s. The presentation of the stimuli and the control of the answers will be managed by the E-prime or Presentation software.
1479992|NCT03119857|Drug|Antiandrogen|
1479993|NCT03119857|Drug|Antiandrogen+docetaxel|"Antiandrogen (bicalutamide 150 mg x 1) + docetaxel (Taxotere®) 75mg/m2 (max 2.0m2) i.v. in 60 minutes on day 1. One cycle is 21 days. Docetaxel will be given for up to 8-10 cycles or until unacceptable toxicity or consent withdrawal whichever comes first.
Antiemetic therapy may be used if necessary."
1479994|NCT03119844|Other|Exercise|The exercise will be performed in a cycle ergometer, intermittently, during 40 minutes, in a moderate intensity and prescribed by the perceived exertion Borg (PEB) scale.
1479995|NCT03119844|Other|Placebo Phototherapy|Patients will receive the placebo application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
1479996|NCT03119844|Other|Active Phototherapy|Patients will receive the active application of low level laser therapy (parameters: 808nm, 100mW, 28J) in the rectus Femoris and gastrocnemius muscles of both lower limbs before the performance of the cycle ergometer exercise protocol.
1479997|NCT03119831|Drug|Alcohol-based Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
1479998|NCT03119831|Drug|Alcohol-free Chlorhexidine Gluconate 0.12%|Rinsing with 15ml for one minute twice daily for 14 days
1479999|NCT03119831|Drug|C31G|Rinsing with 15ml for one minute twice daily for 14 days
1480000|NCT03119818|Device|Phosphorus (31P) magnetic resonance spectroscopy|Phosphorus MR spectroscopy realized using a 3-Tesla MR imaging system. A twenty-cm circular surface coil will be set to the 31P resonance frequency and placed over the leg muscle region to obtain spectroscopy acquisitions. 31P MR spectra will be acquired before, during (every 160 seconds), and 30 minutes after dialysis. 31P MR system data will be analyzed using jMRUI Software. Five different peaks will be analyzed: inorganic phosphate, phosphocreatine, α-, β-, and γ-ATP.
1480001|NCT03119818|Other|Hemodialysis|Hemodialysis realized using a 5008 generator, a portable plant, a FX80 Dialyzer, a dialyzing solution with a standard electrolytes composition. The dialysis generator will be placed outside of the MRI examination room. The dialysis lines will pass through a wave guide to connect patients positioned on the bed of the MRI. A suitably trained nurse will proceed to the cannulation of the fistula, the connection of the catheter, and the monitoring of the clinical tolerance of the session.
1480002|NCT03119792|Other|Education Intervention|The education intervention will help increase the children's knowledge of attitudes, and habits of healthy lifestyles. The program will cover self care of the body and heart, emotional management, healthy diet, and physical activity.
1480003|NCT03119792|Other|Control|"The control will not receive an education program relating to knowledge, attitudes, nor habits of healthy lifestyles. Instead, these sessions will occur twice a month, and will last an hour and forty-five minutes. The control program is titled Life's Challenges, which will focus on helping children develop skills necessary for day to day life, is divided into four modules: Person, Family, School, and Environment. There will be four different types of activities used throughout the program including: Lets Think, Lets Experiment, We will finish with...or synthesis, and Not here."
1480004|NCT03119779|Drug|MTA-Anglus|MTA-Anglus freshly mixed according to manufacturer instructions over glass slap and applied to pulp stump and application of wet cotton for 15 min. till initial setting occur.
1480005|NCT03119779|Drug|TheraCal|TheraCal directly applied from the syringe container tip to pulp stump over incremental layers each layer should not exceed 1 mm thickness and each layer will be light cured for 20 sec.
1480006|NCT03119766|Drug|Kolofort|Safety and Efficiency
1480007|NCT03119766|Drug|Placebo|Safety and Efficiency
1486305|NCT03071822|Drug|dexamethasone|PIGLETs
1480008|NCT03119753|Device|Rapid Prototyping method of fabrication of complete denture|For Rapid Prototyping Method of fabrication of complete denture : the master casts will be scanned using DENTAL WINGS eco-scan 3, using laser technology for scanning, after spraying the stainless steel pins with scanning spray to be recorded into the denture base. Virtual model will be obtained for fabrication of denture bases. Denture base will be designed and modified on the virtual model, then it will be printed using ZENITH-3D Printer using Urethane acrylate oligomer based photo-polymerized resin.
1480009|NCT03119753|Device|Conventional method of fabrication of complete denture|For Conventional Method of fabrication of complete denture: Self-cured acrylic resin trial denture bases will be constructed on the obtained master casts, then processing of the final denture bases by conventional clamping method cured by long curing cycle (74º C for 8 hours) using heat-cured poly-methyl methacrylate (PMMA) resin material. The position of the pins will be recorded into the denture bases so that the linear changes could be measured.
1480010|NCT03119727|Device|FreeO2|All include patients will have automatic administration of oxygen by FreeO2 up to 3 day or until weaning of oxygen adminisatrion
1480011|NCT03119714|Drug|Pemirolast|Treatment with pemirolast 200 mg bid for 14-16 days
1480012|NCT03119714|Drug|Placebo Oral Tablet|Treatment with placebo bid for 14-16 days
1480013|NCT03119701|Drug|Interferon Beta-1A|Lyophilisate for solution for injection.
1480014|NCT03119701|Drug|Placebo|Lyophilisate for solution for injection as placebo.
1480015|NCT03119688|Other|Test Product|Micellar cleanser (0.09 ml)
1480016|NCT03119688|Other|Positive Control|Bar Soap (rubbed for 6 seconds to generate a lather)
1480017|NCT03119688|Other|Reference Product|Sterile Water (0.09 ml)
1480018|NCT03119675|Device|GoCheck Kids (iOS)|Photorefraction method is used to screen amblyopia risk factors.
1480019|NCT03119675|Device|GoCheck Kids (Windows)|Photorefraction method is used to screen amblyopia risk factors.
1480020|NCT03119662|Drug|Visipaque|100 mL iodixanol (Visipaque Injection 320 mg I/mL), followed by a 10 mL saline flush to ensure delivery of the full dose of Visipaque.
1480021|NCT03119662|Drug|Placebos|100 mL saline, followed by a 10 mL saline flush.
1480022|NCT03119649|Drug|GLPG2222 dose 1 for cohort A|One oral tablet containing GLPG2222 and two oral tablets containing placebo
1480023|NCT03119649|Drug|GLPG2222 dose 2 for cohort A|one oral tablet containing GLPG2222 and two oral tablets containing placebo
1480024|NCT03119649|Drug|Placebo 1|Three oral tablets q.d.containing placebo
1480025|NCT03119649|Drug|GLPG2222 dose 1 for cohort B|Two oral tablets containing GLPG2222 each and one oral tablet containing placebo
1480026|NCT03119649|Drug|GLPG2222 dose 2 for cohort B|Two oral tablets containing GLPG2222 and one oral tablet containing GLPG2222
1480027|NCT03119649|Drug|Placebo 2|Three oral tablets q.d. containing placebo
1480028|NCT03119636|Biological|NPC transplantation|The cells are stereotactically implanted in the striatum.
1480029|NCT03119636|Drug|Levodopa|Levodopa is used depending on the patient's condition
1480030|NCT03119623|Drug|sacubitril/valsartan|Sacubitril/valsartan 100mg titrated up to sacubitril/valsartan 200mg
1480031|NCT03119623|Drug|Enalapril|enalapril 5mg, titrated up to 10mg po BID
1480032|NCT03119610|Drug|Oxytocin nasal spray|Self administered Oxytocin nasal spray q.i.d. for 8 weeks versus placebo (normal saline nasal spray)
1480033|NCT03119610|Drug|Placebo nasal spray|Self administered Placebo nasal spray q.i.d. for 8 weeks (normal saline nasal spray)
1480034|NCT03119597|Dietary Supplement|Wild Blueberry Powder-13g|Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
1480035|NCT03119597|Dietary Supplement|Placebo|Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
1480036|NCT03119584|Drug|linaclotide or placebo|
1480037|NCT03119571|Procedure|Initial CCL admission|Admission to the cardiac catheterization lab to evaluated coronary artery disease and if present fix the culprit lesion/lesions
1480038|NCT03119571|Diagnostic Test|Initial ICU admission|Evaluate for additional testing and/or procedures
1997904|NCT01833520|Drug|Ra-223 Dichloride|"Phase I Starting Dose of Ra-223 Dichloride: 50 kBq/kg by vein over several minutes on Day 1 of each 4-week cycle.
Phase II Starting Dose of Ra-223 Dichloride: MTD from Phase I."
1480040|NCT03119545|Behavioral|Beardslee family centered intervention|The method entails six meetings. The time for the meeting is 1-2 hours and is usually held once per week. Meetings 1 and 2) include only the parents and focus firstly on the ill parent's history and secondly on the well parent/relative. Meeting 3) includes interviews with each child aged 6-19 years, without the parents being present, concerning the child´s understanding of the disease, potential worries and questions. During the interview the child can formulate his or her own questions for the family meeting. Meeting 4) includes the parents and focuses on the planning of the family meeting. The child's thoughts and questions serve as a guide for the upcoming family meeting. Meeting 5) is the family meeting. Meeting 6) is a follow-up with all of the family members.
1480041|NCT03119532|Other|Receive metric feedback email|If the provider received an email about the participants performance metrics
1480042|NCT03119519|Radiation|Local Definitive Radiotherapy|three-dimensional conformal therapy or intensity modulated radiation therapy
1480043|NCT03119519|Drug|Chemotherapy or Targeted Therapy|platinum doublet therapy，or erlotinib or gefitinib for patients with EGFR mutations，or crizotinib for patients with ALK rearrangements
1480044|NCT03119506|Behavioral|Recess|Recess timing and duration effects on lunch intake
1480045|NCT03119493|Behavioral|Periodized aerobic interval training|The periodized training program consist in 3 phases: light (I) (training range varying between 20 to 39% of heart rate reserve and active recuperation of 19% of heart rate reserve); moderate (II) (training range varying between 40 to 59% of heart rate reserve and active recuperation of 30% of heart rate reserve) and high (III) (training range varying between 70 to 90 % of heart rate reserve and active recuperation of 50% of heart rate reserve).
1480046|NCT03119480|Device|electronic alerts|electronic alerts for AKI
1480047|NCT03119467|Drug|RP4010|Escalating doses starting at 25 mg
1480049|NCT03119441|Device|Dental Water Jet|Dental Water Jet will be used by subjects to clean their teeth in the interproximal areas.
1480519|NCT03116113|Biological|AAV-RPGR|Comparison of different dosages of AAV-RPGR
1997905|NCT01832610|Device|HVAD® System|
1480050|NCT03119441|Device|Dental Floss|Dental Floss will be used by subjects to clean their teeth in the interproximal areas.
1480051|NCT03119428|Drug|OMP-313M32|OMP-313M32 is a monoclonal antibody which binds to the human TIGIT receptor on T cells.
1480052|NCT03119415|Behavioral|Cooperative Learning|CL is an umbrella term that includes peer tutoring, reciprocal teaching, collaborative reading, and other methods in which peers help each other learn in small groups. CL is not prescriptive but rather is a conceptual framework within which teachers design their own small-group activities. Johnson, Johnson, and Holubec's approach to CL combines positive interdependence with individual accountability, a high degree of face-to-face social interaction among youth, and support for the development of cooperative social skills. The Johnsons' approach offers teachers the combination of specific cooperative activities and the conceptual tools to create their own lesson plans using positive interdependence.
1480053|NCT03119402|Behavioral|Rhythmic Reading Training|RRT is a computerized reading training program designed for Italian students with dyslexia. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
1480054|NCT03119402|Device|Transcranial direct current stimulation|tDCS (transcranial direct current stimulation) is a noninvasive weak-current brain stimulation technique that can facilitate (anodal electrode) or inhibit (cathodal electrode) cortical activity, thus offering exciting possibilities for the enhancement and treatment of impaired cognitive abilities.
1480055|NCT03119389|Behavioral|Directly gloving before non-sterile glove use|Current practice is to perform hand hygiene before donning of non-sterile gloves. In units assigned to the intervention, healthcare workers within the units will be educated that performing hand hygiene before donning non-sterile gloves is not necessary.
1480056|NCT03119376|Other|COBPEER|At the end of the online training, they can participate in the study and so peer review 1 manuscript randomly selected from our sample with our tool (COBPeer).
1480057|NCT03119363|Device|Litebook Edge (Experimental)|"The Litebook Edge is a small (5 x 5 x 1) and lightweight (4.6 oz.) box designed to be placed on a table about 18 from the participant's head and within 45º visual field. The Litebook uses 60 premium light emitting diode (LED) lights which mimic the visible spectrum of sunlight for minimum glare and maximum eye comfort. For purposes of safety, the Litebook emits no ultraviolet (UV) light."
1480058|NCT03119363|Device|Litebook Edge (Comparator)|"The Litebook Edge is a small (5 x 5 x 1) and lightweight (4.6 oz.) box designed to be placed on a table about 18 from the participant's head and within 45º visual field. The Litebook uses 60 premium light emitting diode (LED) lights which mimic the visible spectrum of sunlight for minimum glare and maximum eye comfort. For purposes of safety, the Litebook emits no ultraviolet (UV) light."
1480059|NCT03119350|Other|Physical Training|"Intervention with concurrent physical training: strength and aerobic exercises in the same session.
Duration: 2 weeks of adaptation to physical exercise, 8 weeks of training. Frequency: 3 times a week. Time: 55 minutes each session. Intensity: 75 to 90% of maximum heart rate."
2000867|NCT03321786|Other|The University of Pennsylvania Smell Identification Test (UPSIT)|"This standardized test, the most widely used olfactory test in the world, is derived from basic psychological test measurement theory and focuses on the comparative ability of subjects to identify odorants at the suprathreshold level. The UPSIT consists of four envelope-sized booklets, each containing ten scratch and sniff odorants embedded in 10- 50-µm polymer microcapsules positioned on brown strips at the bottom of the pages of the booklets."
1480061|NCT03119324|Device|B-Cure® diode laser|B-Cure laser® (Good Energies, Haifa, Israel) 808nm diode laser application in contact mode over painful area twice a day for 7 consecutive days
1480062|NCT03119324|Device|B-Cure® diode laser sham device|B-Cure laser® (Good Energies, Haifa, Israel) application by sham device twice a day for 7 consecutive days
1480063|NCT03119324|Drug|Nimesulide Ratiopharm® and Flexiban®|Five consecutive days assumption of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm® 50mg twice a day, followed by five consecutive days assumption of Myorelaxant, Flexiban®, 10mg once a day, followed by five consecutive days assumption of 50mg of Non Steroidal Anti Inflammatory drug, Nimesulide Ratiopharm®, twice a day
1480064|NCT03119311|Diagnostic Test|Video-oculography|Diagnostic Method for Exotropia Using Video-oculography
1480065|NCT03119311|Diagnostic Test|APCT|alternative prism cover test
1480066|NCT03119259|Behavioral|ABC Clinical Program|The goal of the ABC Clinical Program is to help primary care physicians achieve the standard of care in the diagnosis, evaluation and management of patients with ADRD. The ABC Clinical Program is delivered by an interdisciplinary team led by a care coordinator. The informal caregiver is also enrolled in the program and caregiver burden is assessed and managed. The ABC team collects all relevant data and formulates an individualized care plan in collaboration with the informal caregiver. The care coordinator communicates the team's recommendations to the primary care physician and finalizes a collaborative plan of action. During the next year, the ABC team uses face-to-face and telephone interactions with the patient and caregiver to monitor and modify implementation of the care plan.
1480067|NCT03119259|Behavioral|HABC 2.0|"HABC 2.0 is a mobile health information technology application whose primary user is the informal caregiver of a patient suffering from ADRD. It is integrated with the electronic medical record system (eMR-ABC) in operation in the ABC Clinical Program. HABC 2.0 performs the following functions:
supports informal caregivers in managing the behavioral and psychological symptoms of dementia (BPSD) by delivering on-demand, around the clock feedback and personalized self-management support without any intervention from the ABC team; and
elicits frequent, real-time, longitudinal assessments of patients and informal caregivers, enabling the ABC team to monitor BPSD data and informal caregiver health, intervening as needed in between scheduled visits."
1480068|NCT03119246|Other|CAPIT-HD beta|New assessment protocol for assessment of complex therapies in Huntington's disease for both groups
1480069|NCT03119233|Device|PQ Bypass System|The PQ Bypass System is intended to improve blood flow in patients with symptomatic peripheral arterial disease due to >15 cm long occlusions and diffuse stenoses of femoro-popliteal arteries, including in-stent re-stenosis, with reference vessel diameters ranging from 5.0 - 6.7 mm
1480520|NCT03116087|Drug|Testosterone patch|300 mcg testosterone patches or placebo applied twice weekly
2000868|NCT03323047|Drug|Acetaminophen|Oral acetaminophen (15 mg/kg) 1 hr pre-operatively
2000869|NCT03323047|Drug|Low-dose Dexamethasone|Intravenous low-dose dexamethasone (0.15 mg/kg, max. 8 mg) immediately after induction of anesthesia
1480070|NCT03119220|Device|Fitbit One|Participants will receive a Fitbit device and a detailed user manual as well as diary materials to record daily steps taken, miles walked, and flight of stairs walked for a total of 12 weeks. An in-person follow-up meeting will be scheduled 7 days after the initial meeting to establish the baseline activity level of the participant and to determine the target number of daily steps for the subsequent 5 blocks of 2 weeks.
1480071|NCT03119207|Behavioral|Naptime Protocol|Between midnight and 4:00 every attempt will be made to limit staff entrance into the patient room.
1480072|NCT03119194|Drug|[14C]-BIA 9-1067|1 × 100 mg capsule, Oral
1480073|NCT03118089|Dietary Supplement|Biscuit style oral nutritional supplement|
1480074|NCT03118076|Drug|0.3% ropivacaine and 50 μg dexmedetomidine|Nerve blocks were administered with 0.3% ropivacaine and 50 μg dexmedetomidine.
1480075|NCT03118076|Drug|Ropivacaine|Nerve blocks were administered with 0.3% ropivacaine.
1480076|NCT03118063|Diagnostic Test|Evaluation of pain by algometry|Assessment of the level of pain and function of asymptomatic individuals, compared with the time that they evolve with acute and chronic low back pain
1480080|NCT03118037|Device|Sonata System|Transcervical access for radiofrequency ablation of uterine fibroids
1480081|NCT03118024|Drug|Crystalloid Solutions|crystalloid restrictive anesthesia protocol
1480082|NCT03118024|Drug|Catecholamines|catecholamine restrictive anesthesia protocol
1480083|NCT03118011|Other|No smoking|No smoking
1480084|NCT03118011|Other|Smoking|Ability to go out to smoke
1480085|NCT03117998|Biological|REMD-477|Administered as repeated SC doses in subjects with Type 1 Diabetes
1480086|NCT03117998|Biological|Placebo Comparator|Administered as a repeated SC doses in subjects with Type 1 Diabetes
1480087|NCT03119168|Drug|Simethicone Solution|Patients will be assigned randomly to take Simethicone Solution plus polyethylenglycol
1480088|NCT03119168|Other|Polyethylenglycol|Patients in this arm will be randomly assigned to take polyethylenglycol as their regular bowel preparation
1480089|NCT03119129|Behavioral|Ho'ouna Pono Drug Prevention Curriculum|Ho'ouna Pono is a school-based, culturally grounded drug prevention curriculum tailored to Native Hawaiian and Pacific Islander youth on Hawai'i Island.
1480090|NCT03119116|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Oral direct factor Xa inhibitors, 15mg and 20mg tablets QD
1480091|NCT03119116|Drug|Dabigatran|Oral direct thrombin inhibitors, 75mg and 150mg capsules BID
1480092|NCT03119116|Drug|Apixaban|Oral direct factor Xa inhibitors, 2.5mg and 5 mg tablets BID
1480093|NCT03119103|Device|Functional Bed Sheet|All participants sleep on the functional bed sheet that is placed under a normal bed sheet. The device collects pressure sensor information and informs on body position, respiration rate, and respiration patterns.
1480094|NCT03119077|Drug|BAY1161116|Escalating doses of BAY1161116; single dose administration; redosing of BAY1161116 at dose group 1 together with itraconazole; redosing of BAY1161116 at dose group 2 as liquid service formulation, redosing of BAY1161116 at dose group 3 together with food
1480095|NCT03119077|Drug|Placebo|Escalating doses of respective placebos; single dose administration; redosing of placebo at dose group 1 together with itraconazole; redosing of placebo at dose group 2 as liquid service formulation, redosing of placebo at dose group 3 together with food
1480096|NCT03119077|Drug|Itraconazole|Redosing of BAY1161116/placebo at dose group 1 together with itraconazole
1480097|NCT03119064|Drug|Nanoliposomal Irinotecan|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
1480098|NCT03119064|Drug|Temozolomide|Three patients will be accrued to level 1. If no dose limiting toxicities are observed following completion of 4 weeks (2 cycles) of treatment then accrual to dose level 2 will proceed (patients must be evaluated prior to their cycle 3 treatment and this will be used to confirm DLTs). If a DLT is observed in one of the first 3 patients in a dose level, then accrual for that level will be expanded to 6 patients. Accrual will continue in this way until the MTD of nanoliposomal irinotecan with temozolomide 50mg/m2/day is determined. Two or more instances of DLT in a cohort of 6 patients will result in the preceding dose level being defined as the MTD. If two or more instances of DLT in a cohort of 6 patients occurs in dose level 1 then dose level -1 of nanoliposomal irinotecan will be investigated. After determination of the MTD, the final cohort will be expanded so that a total of 25 patients are treated on study. The final cohort will be treated at the MTD.
1480099|NCT03119051|Behavioral|Online cognitive training|A variety of cognitive domains will be involved in the training including memory, calculation, attention, visuospatial and executive skills. The difficulty level of each game will be adjusted automatically according to patients' last training results so that patients' correction rate will be kept between 70% and 80%.
1480100|NCT03119038|Drug|Bupivicaine + epinephrine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine with epinephrine
1480101|NCT03119038|Drug|Bupivacaine|Intraoperative periarticular injection of 30 mL of a 0.25% solution bupivacaine without epinephrine
1480102|NCT03119038|Drug|Ropivacaine|Intraoperative periarticular injection of 300 mg of 0.5% ropivacaine
1480103|NCT03119038|Drug|Ketorolac|Intraoperative periarticular injection of 30 mg
1480104|NCT03119038|Drug|Clonidine Injection|Intraoperative periarticular injection of 100 mcg clonidine in a 100 mL 0.9% saline solution
1480185|NCT03118453|Behavioral|Passive implementation clinics|Physical therapy treatment as the physical therapist chooses
1480105|NCT03119025|Biological|Autologous DC-vaccines|"Patients will be vaccinated via intracutaneous injection of autologous DCs (5×106) combined with adjuvant subcutaneous injection of recombinant hIL-2 (250 000 IU).
Initiating course: one vaccination per week, during 1 month. Maintaining course: one vaccination per month, during 6 month. Patients will be monitored in a 2 months (after completing of initiating course), 7 months (after completing of maintaining course) and 13 months (in a 6 months post-vaccination follow-up)."
1995276|NCT02808247|Drug|Nintedanib|Pharmaceutical form: Soft gelatine capsule Pharmaceutical code: Nintedanib (BIBF1120) Source: Boehringer Ingelheim Pharma GmbH & Co. KG Unit strength: 100 mg and 150 mg capsules Daily dose: 400 mg (200 mg twice daily p.o.) Route of administration: oral
1995277|NCT02808247|Drug|Ifosfamide|Ifosfamide will be given at a dose of 3 g/m2 intravenously on days 1, 2 and 3 every 21 days. The total dose per cycle is 9 g/m2
1480109|NCT03118999|Dietary Supplement|Period 1|OM3 derivatives 1 or OM3 derivatives 2 or OM3 derivatives 3
1480110|NCT03118999|Dietary Supplement|Period 2|OM3 derivatives 1 or OM3 derivatives 2 or OM3 derivatives 3
1480111|NCT03118999|Dietary Supplement|Period 3|OM3 derivatives 1 or OM3 derivatives 2 or OM3 derivatives 3
1480112|NCT03118986|Drug|Olanzapine|olanzapine 0.1 mg/kg/dose (maximum 10 mg/dose) by mouth as a single daily dose based on actual body weight
1480113|NCT03118986|Drug|Placebo Oral Tablet|Placebo tablets that look like olanzapine and will be dosed as if they are olanzapine
1480114|NCT03118973|Procedure|Goff trans-pancreatic septotomy vs. Double wire technique|Goff trans-pancreatic septotomy vs. Double wire technique for achieving biliary access when biliary cannulation is challenging.
1480115|NCT03118960|Device|Freedom Bed|This is an automatic rotational system in a bed designed to disburse capillary pressure
1480116|NCT03118960|Device|Group II Low Air Loss/Alternating Pressure Mattress|Subjects placed on the Group II Low Air Loss/Alternating Pressure Mattresses will require manual repositioning every 2 hours
1480117|NCT03118947|Drug|Pimavanserin|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth, OR Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
1480118|NCT03118934|Device|Lotrafilcon B multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily wear basis and cared for with participant's habitual lens care solution
1480119|NCT03118934|Device|Nelfilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
1480120|NCT03118934|Device|Delefilcon A multifocal contact lenses|Contact lenses for near, intermediate, and distance correction worn on a daily disposable basis (removed every night and discarded) with a new pair of study lenses every morning
1480121|NCT03118921|Device|Virtual reality|The first session aims to present the virtual reality material that will be used. The second session will take place 2 weeks after the first session and will consist of the use of the immersion software.
1480125|NCT03118895|Device|BioFreedom™ BA9™ drug-coated stent|Drug-coated stent for coronary arteries
1480126|NCT03118882|Behavioral|Diet group|A meeting where an expert illustrates the scientific basis of a proper diet. Moreover, clear and practical indications for dietary habits improvement and for suggested food purchase are provided. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module:hree theoretical and practical cooking meetings (total of 10 hours) held by cooks with an expertise in natural cuisine and by trained dieticians.
1480127|NCT03118882|Behavioral|Physical activity group|A meeting where an expert illustrates the benefits of a constant PA. Moreover, indications are given on sport opportunities and walking groups in the city organised by public authorities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: three theoretical and practical lessons (total of 10 hours) held by expert physical trainers.
1480128|NCT03118882|Behavioral|Physical activity and diet group|A meeting where the indications given to the previous groups are presented simultaneously. Particular attention is paid to the interaction between the two activities. After having completed the basic module, participants are offered the opportunity of deepening the educational process through an advanced module: four theoretical and practical meetings (total of 12 hours), two lessons focus on diet and two on PA.
1480129|NCT03118856|Diagnostic Test|Prediction of Histology|The accuracy of predicting the histology of colorectal polyps will be assessed with HD-WLE and EC
1480131|NCT03118830|Drug|Triptorelin|daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG triggering.
1480132|NCT03118830|Drug|cetrorelix|Flexible GnRH antagonist protocol was done with daily s.c administration of cetrorelix 0.25 mg started when one or more of the following criteria were achieved: (i) one or more follicle reached 14 mm diameter; (ii) The level of serum E2 reached 600 pg/ml; and (iii) The level of serum LH levels reached 10 IU/l .
1480133|NCT03118830|Drug|Recombinant Follicle Stimulating Hormone|Daily sc rFSH (Gonal-f; Merck Serono , Darmstadt, Germany) injections was started on 2nd day of the cycle in the antagonist protocol. Continuation of rFSH and GnRH antagonist daily until triggering day was done.
1480134|NCT03118817|Drug|HM95573|"Dose: 450 mg BID
Regimen: twice daily (BID), continuous dosing
Duration: until progression disease or unacceptable toxicity develops"
1480135|NCT03118804|Diagnostic Test|Assessment of Lung Tidal Distribution With EIT|Changes of lung tidal distribution during SBT with mechanical ventilation were recorded by EIT can be used to predict weaning success or failure
1480136|NCT03118791|Dietary Supplement|anthocyanins|Acute intake of capsules
1480137|NCT03118765|Drug|GSP304 (tiotropium bromide) Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
1480138|NCT03118765|Drug|GSP304 Placebo Inhalation Solution|Once daily (QD) oral inhalation using a nebulizer
1480139|NCT03118765|Drug|Spiriva® Respimat® inhalation spray|Once daily (QD) oral inhalation
1480186|NCT03118440|Procedure|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
1480521|NCT03116087|Drug|Placebo|Placebo patch
2000870|NCT03323047|Drug|Placebo Oral Tablet|Oral placebo 1 hr pre-operatively
2000871|NCT03323047|Drug|High-Dose Dexamethasone|Intravenous high-dose dexamethasone (0.5 mg/kg, max. 10 mg) immediately after induction of anesthesia
2000872|NCT03322982|Behavioral|Low-fat diet|less than 20% calories from fat daily
2000873|NCT03322930|Diagnostic Test|Rod sensitivity|diagnostic test for rod loss in central retina
2000874|NCT03322852|Other|Vascularization indices observation|The mid-luteal endometrial thickness and volume, uterine vascularization indices of uterine artery pulsatility index and resistance index, endometrial and subendometrial vascularization index, flow index, and vascularization flow index, and serum estradiol and progesterone levels were calculated in spontaneous then stimulated cycles in the same group of infertile patients
2000875|NCT03322826|Procedure|systematic sampling of the lymph-node|Systematic Sampling of lymph nodes
2000876|NCT03322826|Procedure|lymphadenectomy|Routine lymph nodes dissection in lung cancer
1480148|NCT03118687|Other|Biospecimen and survey collection|Blood, microbiota, surveys/questionnaires, electronic medical records.
1480149|NCT03118674|Drug|Harvoni|One capsule of Harvoni/ ledipasvir, 90 mg + sofosbuvir, 400 mg administered daily for 8, 12, or 24 weeks
1480152|NCT03118648|Diagnostic Test|Scale Action Research Arm Test (ARAT)|Measuring the functional recovery of the paretic upper limb rehabilitation outing with the scale ARAT
1480153|NCT03118635|Behavioral|Intervention|Physical activity programming in accordance with the SPARK - After School curriculum as well as engaging activities provided by local community partners. The intervention proceeded the SFSP lunch meal service, so that children received approximately three hours of physical activity programming daily.
1480154|NCT03118622|Device|Intubation using Pentax video laryngoscope|Intubation using Pentax video laryngoscope in Pentax group
1480155|NCT03118609|Other|Understanding Needs Survey|"2-hour Focus Group
Mailed or E-mailed Survey"
1480156|NCT03118596|Device|I-gel|Fibreoptic guided tracheal intubation is going to be performed through the I-gel supraglottic airway.
1480157|NCT03118596|Device|LMA Protector|Fibreoptic guided tracheal intubation is going to be performed through the LMA Protector supraglottic airway.
1480158|NCT03118583|Dietary Supplement|300 mg/day of dietary supplement containing carrageenan|300 mg/day of dietary supplement containing carrageenan.
1995283|NCT02804880|Behavioral|HAR|Smokers will be introduced to various smoking cessation (SC) services in Hong Kong (using the referral card) and be motivated to use the services. Field research staff will assist on-site booking SC services for smokers. Tailored messages, including: harm of smoking, benefit of smoking cessation, importance of adherence to smoking cessation appointment and encouragement on abstinence will be sent via instant messaging (IM) services (e.g. WhatsApp, WeChat) to smokers after initial contact.
1995284|NCT02804880|Behavioral|LTM|Fix-schedule SMS messages will be sent to encourage them to book the smoking cessation services appointment. Smokers are required to book the SC appointments by themselves.
1480161|NCT03118557|Other|Pilates pelvic floor strengthening|Pilates pelvic floor strengthening.
1480162|NCT03118544|Device|DyeVert System|The DyeVert System (Osprey Medical, Inc) consists of a Contrast Monitoring Wireless Display (CMW) and the DyeVert Plus Disposable Kit which is inclusive of a disposable single-use sterile Smart Syringe and DyeVert Plus Module.
2000879|NCT03322670|Other|Signs of CAP and a positive chest X-Ray|"collection of clinical examination data
biological and bacteriological examinations (blood, urine, sputum, nasopharyngeal)
self-reported questionnaires on duration of symptoms and restriction of activity
telephone contact on day 28 and day 90 if hospitalized before day 28"
1480164|NCT03118518|Device|Cryoablation|Pulmonary vein isolation via ablation with cryoballon catheter
1480165|NCT03118518|Drug|Antiarrhythmic drug|Antiarrhythmic drug initiation
1480166|NCT03118505|Device|Infuse Bone Graft|Infuse Bone Graft + Mastergraft Strip + local bone autograft + posterior fixation
1480167|NCT03118505|Device|Medtronic DBM|Medtronic DBM + local bone autograft (and supplemented with iliac crest bone graft (ICBG), if needed) + posterior fixation
1480168|NCT03118492|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
1480169|NCT03118492|Drug|Cyclophosphamide|Given IV
1480170|NCT03118492|Drug|Fludarabine|Given IV
1480171|NCT03118492|Biological|Glycosylated Recombinant Human G-CSF AVI-014|Given IV
1480172|NCT03118492|Other|Laboratory Biomarker Analysis|Correlative studies
1480173|NCT03118492|Drug|Melphalan|Given IV
1480174|NCT03118492|Drug|Mycophenolate Mofetil|Given PO
1480175|NCT03118492|Drug|Tacrolimus|Given IV or PO
1480176|NCT03118492|Radiation|Total-Body Irradiation|Undergo TBI
1480177|NCT03118479|Drug|Anastrozole Pill|10 mg of Anastrozole to be taken daily for 3 months.
1480178|NCT03118479|Drug|Testosterone|Androgel 7.5 g to be applied transdermally daily for 3 months.
1480179|NCT03118479|Drug|Placebo Oral Tablet|One tablet to be taken daily for 3 months
1480184|NCT03118453|Behavioral|Active implementation clinics|Physical therapy treatment as the physical therapist chooses
2000880|NCT03322670|Other|Patients directly hospitalized|"collection of clinical examination data
telephone contact on day 28 and retrieval of hospitalization report
telephone contact on day 90"
2000881|NCT03322670|Diagnostic Test|Control patients|- bacteriological examinations (urine)
2000882|NCT03322670|Other|Patients with partial participation|- collection of clinical examination data
1480187|NCT03118440|Procedure|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
1480188|NCT03118427|Procedure|zero-fluoroscopy 3D navigation|Pacemaker implantation will be performed without fluoroscopy using 3D navigation systems.
1480189|NCT03118427|Procedure|conventional x-ray navigation|Pacemaker implantation will be performed with fluoroscopy using conventional X-ray navigation.
1480190|NCT03118414|Other|Physical Exercise|"Participants were trained by exercise program based on their initial muscle strength and balance condition.
They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
1480191|NCT03118414|Other|Virtual Reality|"Participants were trained with the guidance of VR system.The participants will be asked to choose 6 games from the list before each 30-minute session, and were asked to choose the games to include the upper limbs, lower limbs, and also for both strength and balance challenges instead of choosing the games that need to use only upper limbs or lower limbs, and only for strength or balance gain.
They received a 30-minute exercise for 3sessions per week for 8 weeks in this study."
1480192|NCT03118414|Other|Brain Exercise|Brain Exercise (BE) BE stimulates the executive function, planning, concentration, visual memory and eye-hand co-ordination of the participants throughout the training.For the brain exercise, participants needed to play cognitive stimulating games; Chinese Checker, Janga and Memory Matched pair game; in the sitting position. The participants needed to paly 10 minutes for each gamed and total duration of all 3 games was about 30 minutes in each session for 3sessions per week for 8 weeks in this study.
1480193|NCT03118401|Other|Ritual of stool|During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start the implementation period of ritual of stool. From the stool diary: - will be determined the stool profile of each resident over 1 week and application of the ritual of stool the following week At the end of this second period, data will be collected on an individual stool diary in for 4 weeks
1480194|NCT03118401|Other|Usual practice|"During the first 4 weeks, data will be collected on an individual stool diary with usual care of the resident After randomization will start 2 weeks without data collection. Patient will be follow in usual practice.
At the end of this second period, data will be collected on an individual stool diary in for 4 weeks"
1480195|NCT03118388|Behavioral|Social Enterprise Intervention|The SEI model was implemented in four stages: 1) Vocational skill acquisition (4 months); 2) Small business skill acquisition (4 months); 3) SEI formation and product distribution (12 months); and 4) Clinical/case-management services, (ongoing for 20 months).
1480196|NCT03118388|Behavioral|IPS|To implement the IPS at the host agency, one employment specialist, two case managers, and two clinicians were assigned the 22 available IPS cases among them at baseline. Over the 20 months, all IPS participants met individually with the employment specialist, one case manager, and one clinician at least weekly. Regarding job development in the community, the IPS employment specialist also spent about 40% of each week out in the community building relationships with new and existing employers.
1480197|NCT03118375|Device|super-power BAHA processor|The super-power BAHA processor will be provided for use at the study visit only to run different types of hearing tests, speech understanding tests in quiet, and speech understanding tests in noise. The same tests will be performed with the use of the subject's current BAHA processor for comparison.
1480198|NCT03118362|Drug|Plasmalyte|"Parenteral administration of Plasmalyte initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.
Each patient will receive this solution up to 5 days."
1480199|NCT03118362|Drug|Ringer lactate|"Parenteral administration of Ringer lactate initiated immediately after inclusion at a dosage of 4 ml / kg per percentage area of skin burned for the first 24 hours after burn injury and adjusted based on hemodynamic monitoring.
Each patient will receive this solution up to 5 days."
1480200|NCT03118349|Drug|MVT-1075|MVT-1075 is administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
1480201|NCT03118349|Drug|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
1480202|NCT03118336|Drug|Empagliflozin 10Mg Tab|1 tablet of 10 milligrams per bone 1 time a day during 12 weeks
1480203|NCT03118323|Other|Questionnaire|Patients are given a questionnaire with items related to personality and their willingness-to-pay for different treatment options.
1480204|NCT03118310|Behavioral|5:2 diet|Dietary intervention according to 5:2 diet during three months.
1480205|NCT03118310|Behavioral|LCHF|Dietary intervention according to LCHF diet during three months.
1480206|NCT03118310|Behavioral|Placebo diet|Placebo diet: normal dietary advice
1480207|NCT03118297|Drug|Ulipristal Acetate|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
1480208|NCT03118297|Drug|Placebo oral capsule|Women who have bothersome bleeding with the etonogestrel implant will be randomized to receive ulipristal acetate versus placebo daily for 7 days.
1480209|NCT03118284|Other|urine collection|
1480210|NCT03118284|Other|Blood collection|
1480211|NCT03118284|Behavioral|NRS|
1480212|NCT03118271|Device|lumbar traction|
1480213|NCT03118271|Procedure|spinal manipulation|
1480214|NCT03118271|Procedure|surgery|
1480215|NCT03118258|Behavioral|"Arm Pap test"|"Arm Pap test: Woman is invited to participate in a prevention consultation. The health prevention staff informs the woman in her language and with adapted tools on cervical cancer, causes, consequences, ways of prevention. He proposes an appointment in a health center partner, to realise a pap smear test"
1480216|NCT03118258|Behavioral|"Arm HPV self-sampling + Pap test"|"Arm HPV self-sampling + Pap test: Woman is invited to participate in a prevention consultation. The health prevention staff informs the woman in her language and with adapted tools on cervical cancer, causes, consequences, ways of prevention. The woman is invited to make a vaginal HPV self-sampling, immediately after the consultation on site or at home if more convenient. She has to come back 10 days after to receive results and to take an appointment in an health center partner, to make a pap smear test"
1480217|NCT03118245|Device|AuraGain|After anesthetic induction, AuraGain is inserted in children
1480218|NCT03118245|Device|I-gel|After anesthetic induction, I-gel is inserted in children
1480566|NCT03115749|Other|Intestinal biopsies during colonoscopy|Intestinal biopsies during colonoscopy
1480219|NCT03118232|Drug|Chlorhexidine gluconate (CHG)|2% no-rinse chlorhexidine gluconate (CHG) for bed bathing and 4% rinse-off CHG showering. Bathing frequency will be per routine plus admission bathing.
1480220|NCT03118232|Drug|Iodophor (10% povidone-iodine)|Nasal decolonization using topical 10% povidone-iodine nasal swabs will be applied to all residents on admission for 5 days twice daily plus every other week Monday-Friday using a twice daily regimen.
1480221|NCT03118219|Other|Positive adjustment coping intervention|see arm description
1480222|NCT03118219|Other|Brainteaser|see arm description
1480223|NCT03118206|Device|lumbar traction|
1480224|NCT03118206|Procedure|spinal manipulation|
1480225|NCT03118206|Procedure|surgery|
1480226|NCT03118193|Other|olfactive tests|olfactive tests: odor identification, odor discrimination and olfactory threshold
1480227|NCT03118193|Biological|blood test|one sample of 4mL
1480228|NCT03118193|Biological|Collection of faeces|Collection of faeces by patient at home - optional
1480229|NCT03118193|Device|Tissue Pulsatility imaging|Ultrasound exploration of brain pulsatility - optional
1480230|NCT03118180|Biological|CD19 targeted chimeric antigen receptor T cells|CD19 targeted chimeric antigen receptor T cells for refractory and relapsed B cell lymphoma
1480231|NCT03118167|Dietary Supplement|Tea polyphenols|Tea polyphenols 0.05g, 0.1g, 0.2g (starches filled up to 0.35g), edible capsule
1480232|NCT03118167|Dietary Supplement|AOB-w|Water-soluble antioxidant of bamboo leaves 0.35g, edible capsule
1480233|NCT03118167|Other|Placebo|Edible starches 0.35g, edible capsule
1480234|NCT03118167|Other|Acrylamide (Potato Chips)|Potato Chips bought from market, corresponding to acrylamide (12.6μg/kg b.w. )
1480235|NCT03118154|Other|Manual Physical Therapy|Manual Physical Therapy intervention using the Clear Passage Approach (CPA). The focus of the CPA is to deform adhesions throughout the body using a variety of manual therapy techniques and modalities.
1480236|NCT03118141|Procedure|blastocyst morphologic score|Blastocysts will be scored by Gardner morphologic criteria.
1480237|NCT03118141|Procedure|blastocyst biopsy and sequencing|Three blastocysts will be biopsied on trophectoderm, sequenced with next-generation sequencing (NGS). Euploidy will transferred one by one according to morphologic score.
1480238|NCT03118141|Procedure|freeze-all and single thawed blastocyst transfer|All blastocysts will be vitrified in fresh cycle. Single blastocyst will be thawed and transferred.
1480239|NCT03118128|Drug|Metformin|Metformin 850 mg PO three times a day plus prednisone in one 7-days cycle as pre-treatment and during the 28 days induction remission treatment, consolidation therapy and maintenance
1480240|NCT03118115|Device|Measurement of the flap bioimpedance|Measurement of the flap bioimpedance before and after clamping of the artery or the vein. For information: All patients will have the vein and the arterial section simulating venous or arterial thrombosis.
1480241|NCT03117985|Other|no drug|Stopping antiretroviral therapy
1480242|NCT03117972|Drug|FOLFOXIRI|12 cycles
1480243|NCT03117972|Drug|FOLFOX|12 cycles
1480244|NCT03117972|Drug|FOLFIRI|12 cycles
1480245|NCT03117972|Drug|Bevacizumab|12 cycles
1480246|NCT03117972|Drug|LV5FU2|Maintenance chemotherapy
1480247|NCT03117972|Drug|Capecitabine|Maintenance chemotherapy
1480248|NCT03117959|Device|Stryker ShapeMatch Technology|Will use this patient-specific guide for alignment with Stryker Triathlon Custom Fit Knee.
1480249|NCT03117959|Device|Stryker Triathlon Custom Fit Knee|
1480250|NCT03117946|Other|Biological samples|blood and tumor tissue sample
1480251|NCT03117933|Drug|Olaparib|Tablet, 100mg and 150mg
1480252|NCT03117933|Drug|Cediranib|Tablet 15mg and 20mg
1480253|NCT03117933|Drug|Paclitaxel|Intravenous (IV)
1480254|NCT03117920|Drug|Minnelide|Minnelide will be administered at the dose of 0.67 mg/m2 as a 30 min infusion intravenously daily on days 1-21 of each cycle followed by a 7 day rest period (days 22-28).
1480255|NCT03117894|Drug|Ropivacain 5 mg/ml, 35 ml|Regional Anesthesia. The deposition of local anesthetics in proximity of nerves with the aim of blocking nerve transmission. This is used to block pain as an alternative to systemic treatment of pain.
1480256|NCT03117894|Drug|Remifentanil 50 mikrog/ml|The intravenous administration of anesthetics aiming to induce analgesia (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
1480257|NCT03117894|Drug|Betametason 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered preoperatively.
1480258|NCT03117894|Drug|Paracetamol 1,5 g|Administered preoperatively to prevent pain postoperatively.
1480259|NCT03117894|Drug|Propofol|The intravenous administration of anesthetics aiming to induce sleep (part of the general anesthesia). No fixed dose, administered in relation to the study participants need at the moment.
1480260|NCT03117894|Drug|Arcoxia, 120 mg|Administered preoperatively to prevent pain postoperatively.
1480261|NCT03117894|Drug|Ondansetron 4 mg|Are meant to decrease the risk of so called postoperative nausea and vomiting (PONV). Administered peroperative.
1480262|NCT03117894|Drug|Morphine|Administered peroperative, at the end of the surgery, before awakening the study participant. The aim is to prevent pain.
1480263|NCT03117881|Behavioral|DirectCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at a clinic with a therapist. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using handouts.
1480264|NCT03117881|Behavioral|TeleCAM|The intervention consists of a 60-minute Complementary Alternative Medicine (CAM) program that includes yoga, Pilates and dual-functioning exercises, which is delivered 2 times per week for the first 8 weeks and 1 time per week for the following 4 weeks at home via videos. At the end of week 12, participants will be asked to continue the program in their home for up to 1 year post-intervention using the videos.
1480265|NCT03117868|Other|Study of mortality at 6 months|The objective is to provide strong arguments for establishing a dynamic of collective care for patients suffering from an EFSF
1480266|NCT03117855|Drug|Capecitabine|Given PO
1480267|NCT03117855|Other|Laboratory Biomarker Analysis|Correlative studies
1480268|NCT03117855|Radiation|Radioembolization|Undergo yttrium Y-90 radioembolization
1480269|NCT03117842|Other|Automated text and voice messages|Participants will receive 3x weekly SMS or VM theory-based behavioral messages that will be designed to enhance and increase utilization of existing HIV and SRH services by reminding clients about safe sex methods available to them and providing a conduit for additional support. Participants will also be reminded in each message that they can talk to a peer counselor at any time by responding to the message. Participants who indicate they would like to talk to a counselor will receive a call from a Mobile Link community partner. The counselor will provide individualized information on HIV prevention and care and advice.
2000883|NCT03322670|Other|Signs of CAP and a negative chest X-Ray|"collection of clinical examination data
telephone contact on day 28"
1480271|NCT03117816|Drug|AOP2014 / Pegylated-Proline-interferon alpha-2b|AOP2014 as pre-filled auto-injection pen for subcutaneous injection, containing 250 µg AOP2014 / 0.5 ml. The solution also contains inactive ingredients (sodium chloride, polysorbate 80, benzyl alcohol, sodium acetate, and acetic acid). The solution is colorless to light yellow.
1480272|NCT03117816|Other|Surveillance|For patients randomized into this treatment arm stopp their standard treatment and will just be under observation.
1480273|NCT03117790|Drug|Dexmedetomidine|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Dexmedetomidine (200 ug) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
1480274|NCT03117790|Drug|Placebo|Morphine (0.5 mg/ml, in a total volume of 160 ml) is used for patient-controlled analgesia. Placebo (normal saline) is added to the formula of patient-controlled analgesia. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with patient-controlled bolus of 2 ml each time and a lockout time from 6 to 8 minutes.
1480275|NCT03117777|Behavioral|group cognitive behavioral therapy for insomnia|cognitive behavioral therapy for insomnia delivered in group setting for older adults
1480276|NCT03117764|Device|Microfet Dynamometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.
The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.
Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
1480277|NCT03117764|Behavioral|1 minute sit to stand test|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.
The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.
Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
1480278|NCT03117764|Device|Accelerometer|"To evaluate muscular strength, the investigators will measure quadriceps force at the beginning of the cure and at the end with a functional test, the 1-minute Sit-to-Stand test, and a maximal isometric force test, with the Microfet2dynamometer. Those tests are not invasive and easy to realise.
The investigators will estimate the physical activity of the patients with an accelerometer that they will each carry 72 hours, during the cure.
Patients who undergo their cure at the hospital will follow a specific training program with the physiotherapist."
1480279|NCT03117751|Drug|Prednisone|Given orally (PO).
1480280|NCT03117751|Drug|Vincristine|Given intravenously (IV).
1480281|NCT03117751|Drug|Daunorubicin|Given IV.
1480282|NCT03117751|Drug|Pegaspargase|Given IV.
1480283|NCT03117751|Drug|Erwinase®|To be used in case of hypersensitivity or intolerance to Pegaspargase. Given IV or intramuscularly (IM).
1480284|NCT03117751|Drug|Rituximab|Given IV.
1480285|NCT03117751|Drug|Cyclophosphamide|Given IV.
1480286|NCT03117751|Drug|Cytarabine|Given IV.
1480287|NCT03117751|Drug|Mercaptopurine|Given PO.
1480288|NCT03117751|Drug|Dasatinib|Given PO.
1480289|NCT03117751|Drug|Methotrexate|Given IV.
1480290|NCT03117751|Drug|Blinatumomab|Given IV.
1480291|NCT03117751|Drug|Ruxolitinib|Given PO.
1480292|NCT03117751|Drug|Bortezomib|Given IV or subcutaneously (SQ).
1480293|NCT03117751|Drug|Dexamethasone|Given PO.
1480294|NCT03117751|Drug|Doxorubicin|Given IV.
1480295|NCT03117751|Drug|Etoposide|Given IV.
1480296|NCT03117751|Drug|Clofarabine|Given IV.
1480297|NCT03117751|Drug|Vorinostat|Given PO.
1480298|NCT03117751|Drug|Idarubicin|Given IV
1480299|NCT03117738|Drug|AstroStem|Autologous adipose tissue derived mesenchymal stem cells (AdMSC)
1480300|NCT03117738|Other|Placebo-Control|Saline with 30% auto-serum
1480301|NCT03117725|Drug|Melatonin adminstration|The drug, melatonin will be takenevery night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: Melatonin 2mg once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
1480302|NCT03117725|Drug|placebo administration|the drug, placebo pill will be taken every night from the time of COH to the date of oocyte retrieval. The method of administration is as follows: placebo pill once a day, 1 to 2 hours before bedtime for about 2 weeks until the date of oocyte retrieval.
2000885|NCT03322345|Drug|Dopamine|Initiation of continuous dopamine infusion
2000886|NCT03322319|Procedure|Tissue biopsies|"It is commonly accepted that the diagnosis of cardiac amyloidosis may be based on presence of characteristic cardiac abnormalities in echography, associated with the detection of bi-refractive appearance deposits in polarized light after congo red staining of a biopsy fragment.
Usually a biopsy of the abdominal fat or salivary glands can suffice. More rarely, in case of persistent doubt (eg negativity of congo red despite a characteristic appearance, which may occur in 20 to 30% of cases), it will be necessary to perform an endomyocardial biopsy (EMB)."
1480384|NCT03117127|Other|Whole Eggs|Participants will ingestion whole eggs immediately after resistance exercise
1480306|NCT03117699|Device|New device for seated-standing passages|"Phase 1 : The subject perform different seated-standing passages (see Arm)
Phase 2 : After being seated, the subject performs a course comprising:
A standing pass from sitting on a chair
A straight line movement
A succession of left and right turns
An upward and downward travel of less than 1%.
Standard doorway
Standing on the toilet
A sitting pass from the toilet
One way to a bed
A sitting pass on the bed
A passenger seat sitting upright from the bed
A return to the starting point
A sitting pass on the starting chair"
2000887|NCT03322137|Drug|SNA-120|Pegcantratinib ointment
2000888|NCT03322137|Drug|Vehicle|Placebo ointment to mimic Pegcantratinib ointment
2000889|NCT03321799|Device|Negative Pressure Wound Therapy (NPWT)|A computer randomization system will be used on the day of surgery to allocate patients to either the conventional or NPWT dressing. Due to the nature of this study, blinding of patients and surgeons to their allocated cohort will not be possible.
1480310|NCT03117647|Procedure|Mansoura-VV compression suture|two compression suture both are v shaped apex of each suture placed 2 cm below suture line of C.S and 3 cm from the lateral border of the uterus on the right and left side
1480311|NCT03117634|Drug|Treat and Extend with Aflibercept 2mg|Drug treatment regime which allows extension of treatment interval based on disease activity
1480312|NCT03117634|Drug|Fixed Dosing with Aflibercept 2mg|Fixed 8 weekly dosing regime throughout the study duration
1480313|NCT03117608|Biological|injection of autologous micro-fragmented adipose tissue (aMAT)|adipose tissue will be obtained from abdominal region or buttocks and aMAT, and processed with Lipogems® technology.
1480314|NCT03117608|Biological|injection of Platelet-rich Plasma (PRP)|injection of platelet-rich plasma
1480315|NCT03117595|Drug|Bupivacaine-fentanyl|Dosages as previously written
1480316|NCT03117595|Drug|Bupivacaine-fentanyl morphine|Dosage as previously written
1480317|NCT03117582|Other|Stool specimen|"The following stool specimen will be collected for this study:
4, 3mL stool specimen from patient
1, 25mL stool aliquot from donor"
1480318|NCT03117569|Drug|glecaprevir (300mg)/pibrentasvir (120mg)|glecaprevir (300mg)/pibrentasvir (120mg) for 8 weeks
1480319|NCT03117556|Procedure|Bilateral Thoracoscopic Splanchnicectomy|BTS will be performed on all patients under general endotracheal anesthesia. Patients will be placed in the prone position. A 5 mm trocar should be placed at the inferior scapular apex on the patient's left side. After confirmation of trocar placement with a 30 degree 5 mm thoracoscope, a second trocar will be placed two intercostal spaces below and two cm medial to the first trocar. After the splanchnic nerves are identified inferior and medial to the sympathetic trunk, the pleura will be incised on both sides of each of the nerves. Skin incisions are then closed and the procedure will then be repeated on the patient's right side.
1480320|NCT03117530|Drug|Minocycline|Following initial baseline PET-CT imaging and clinical evaluation, adults with ASD will undergo a 12- week open-label treatment trial of minocycline to be conducted at UCLA under supervision of the UCLA IRB. During weeks 1-6, ASD subjects will be treated with 50 mg minocycline twice daily (low dose). From weeks 7-12, dosing will be increased to 100mg twice daily (typical clinical dosage). Every two weeks during this phase, a treating clinician will measure vital signs, assess safety, record adverse effects, and monitor compliance. Compliance will be obtained as an index of tolerability and will assessed through weekly medication diaries and pill counts.
1480321|NCT03117517|Drug|Metformin|Metformin (1000 mg)
1480322|NCT03117517|Drug|Metformin, Pioglitazone|Metformin (1000 mg) Pioglitazone (30 mg)
1480323|NCT03117504|Other|questionnaire|a questionnaire is given to each woman to determine the urinary incontinence and it's impact on quality of life.
1480324|NCT03117491|Procedure|GGNB injections|The patients received two GGNB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
1480325|NCT03117491|Procedure|IANB injections|The patients received two IANB injections of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
1480326|NCT03117491|Procedure|GGNB + IANB injections|The patients received one GGNB injection plus one IANB injection of 1.8 mL 2% lidocaine with 1:100,000 epinephrine
1480327|NCT03117478|Other|Magneto-encephalography (MEG)|Magneto-encephalography
1480328|NCT03117478|Other|Electro-encephalography (EEG)|Electro-encephalography
1480329|NCT03117478|Other|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging
1480330|NCT03117478|Other|Anatomical Magnetic Resonance Imaging (aMRI)|Anatomical Magnetic Resonance Imaging
1480331|NCT03117478|Other|Meditation|Meditation
1480332|NCT03117465|Other|the experimental group|Stroke hemiplegia patients are randomly assigned to the experimental group (scalp acupuncture + low frequency repetitive transcranial magnetic stimulation + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
1480333|NCT03117465|Other|the control group|Stroke hemiplegia patients are randomly assigned to the control group (scalp acupuncture + routine rehabilitation treatment). All patients in the day of inpatient and the fourteenth day received DTI magnetic resonance examination twice to study the change in white matter fiber microstructure.
1480334|NCT03117452|Behavioral|Visual Training|The computerized visual training (VT) program that is being evaluated was developed by Aaron Seitz, who is a co-investigator on this project; it includes 1) ULTIMEYES, which targets broad-based visual functions, including low-level processes (e.g., visual acuity, contrast sensitivity), and 2) visual perceptual organization exercises, which target mid-level visual processes. Both elements of the program also involve higher-level visual functions, such as visual search and visual attention.
1480335|NCT03117439|Other|duration of antifungal therapy|Patients in the study group will stop antifungals in presence of a negative result of Beta Glucan Test
1480336|NCT03117426|Device|SYMFONY IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. EDOF IOL.
1480337|NCT03117426|Device|AT LISA tri 839MP IOL|IOL for presbyopic treatment in patients undergoing cataract surgery. Trifocal IOL
1480338|NCT03117413|Other|Positron emission tomography scan|"Binaural hearing assessments: speech recognition in noise and sound source localization
Voice perception assessment: voice/non-voice discrimination task, free categorization task
Positron emission tomography examinations under ecological auditory stimuli (voice/non-voice discrimination task)"
1480339|NCT03117387|Other|no intervention|This study contains no interventions
2000890|NCT03321799|Device|Sterile Antimicrobial Dressings|Control group, current hospital standard.
1480340|NCT03117374|Behavioral|Team Nutriathlon intervention|8 wk web-based nutrition intervention program aimed at increasing the consumption of fruits, vegetables and dairy products.
1480344|NCT03117348|Other|Enteral nutrition|Patients in Gradual Goal-dose EN group will receive increased calories gradually by EN and will reach the 80% of target energy by EN at day 8 while patients in immediate Goal-dose EN group will receive 100% of target energy by EN at day 3 after abdominal surgery. Both of the two group will receive EN for 5 days except 80% of target energy delivered by oral feeding or patients are discharged from hospital, whichever arrives first.
1480345|NCT03117335|Drug|Placebos|"Drug 1:
Placebo(Sodium Chloride Injection),7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）
Drug 2:
Vinorelbine-Cisplatin:
Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
1480346|NCT03117335|Drug|Sulijia|"Drug 1:
Sulijia(Recombinant Endostatin Injection) Sulijia, 7.5mg/m2 on d1-d14 in each 21-day cycle（stop interventing until the disease progress）
Drug 2:
Vinorelbine-Cisplatin:
Vinorelbine, 25mg/m2, iv, on d1 and d8 in each 21-day cycle (no more than 4 cycles); Cisplatin,75mg/m2, iv, on d1 in each 21-day cycle(no more than 4 cycles)"
1480347|NCT03117322|Biological|agave inulin|Duration: four weeks Dosage: powder 4 g/d
1480348|NCT03117322|Biological|Lactobacillus reuteri DSM 17938|Duration: four weeks Dosage: 5 drops/d
1480349|NCT03117322|Other|maltodextrin|Duration: four weeks Dosage: powder 4 g/d
1480350|NCT03117322|Other|Oil mix (medium chain triglycerides and sunflower oil)|Duration: four weeks Dosage: 5 drops/d
1480351|NCT03117309|Drug|Nivolumab 240 mg|PART A Nivolumab 240 mg IV every 2 weeks x 6 then initial disease assessment
1480352|NCT03117309|Drug|Ipilimumab 1mg/kg|Ipilimumab 1 mg/kg every 3 weeks x 4
1480353|NCT03117309|Drug|Nivolumab 3mg/kg|In combination with Ipilimumab
1480354|NCT03117309|Drug|Nivolumab 360mg|Continue Nivolumab 360 mg IV every 3 weeks
1480355|NCT03117296|Other|Post procedure daily PT and OT|PT evaluation and treatment on post procedure day zero: Nurses mobility patient using egress testing one time
1480356|NCT03117296|Other|PT post procedure|post procedure day one: PT and OT assessment, education and intervention.
1480357|NCT03117296|Other|OT post procedure|PT and OT Daily until goals met or patient discharge.
1480358|NCT03117296|Other|Routine PT or OT|Routine PT or OT consulted by physician when identified discharge disposition of home
1480359|NCT03117283|Procedure|Laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach|Patients with advanced posterior gastric wall cancer including in the laparoscopic total gastrectomy (LTG) with bursectomy group will undergo laparoscopic D2 radical total gastrectomy with bursectomy using a left outside bursa omentalis approach.
1480360|NCT03117283|Procedure|Laparoscopic D2 radical total gastrectomy without bursectomy|Patients who are included in the laparoscopic total gastrectomy (LTG) without bursectomy group will undergo laparoscopic D2 radical total gastrectomy without bursectomy in a conventional manner.
1480363|NCT03117257|Drug|Lobaplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: Lobaplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
1480364|NCT03117257|Drug|Cisplatin|Device: Chrono-chemotherapy Drug: induction Chrono-chemotherapy Drug: cisplatin chrono-chemotherapy Radiation: intensity-modulated radiation therapy
1480365|NCT03117244|Other|Exercise for Foot Strengthening|Stabilization exercises of the longitudinal arch of the foot
1480366|NCT03117244|Other|Exercise for Foot Strengthening and Electrostimulation|Exercise for the Strengthening of the Foot associated with Electrostimulation
1995285|NCT02804880|Behavioral|AWARD|Ask about smoking history, Warn about the high risk of smoking, Advise to quit as soon as possible, Refer to the smoking cessation services, and Do it again: to repeat the intervention during tel. follow-ups.
1995286|NCT02804880|Other|Referral card|"The 3-folded Smoking Cessation Services card consists of brief information and highlights of existing smoking cessation services, contact methods, motivation information and strong supporting messages or slogans."
1480369|NCT03117218|Diagnostic Test|Coronary MR angiography|Quantitative analysis of coronary MR angiogram
1480370|NCT03117205|Other|Application of Kinesio Taping®|The technique was applied following the methods described in the original method for patellofemoral instability
1480371|NCT03117205|Other|Kinesio Taping® placebo application|Simulation of the application of the Kinesio Taping® technique.
1480372|NCT03117192|Drug|Zinc Sulfate|Zinc supplementation in syrup form
1480373|NCT03117192|Drug|Sucrose Syrup|Sucrose as placebo, with same taste and consistency as zinc
1480374|NCT03117179|Other|Discharge from patient after consultation in emergency department|Discharge from patient after consultation in emergency department
1480375|NCT03117166|Drug|lidocaine|A one time bolus of lidocaine 0.5 mg/kg iv will be administered just prior to IV propofol injection,then successful defibrillation will be ascertained
1480376|NCT03117166|Drug|Placebo|A control group will get an IV bolus of 0.9% NS just prior to IV bolus of propofol, then successful defibrillation will be ascertained
1480377|NCT03117153|Other|DA-5502 liquid toothpaste|6 weeks study, brush three times daily, liquid toothpaste
1480378|NCT03117153|Other|placebo|same flavor solution, brush three times daily
1480379|NCT03117140|Drug|Ropivicaine 0.75%|Only ropivicaine 0.75% is administered for this arm of the interscalene block
1480380|NCT03117140|Drug|Ropivicaine 0.75% + 300 mcg Buprenorphine|Ropivicaine 0.75% + 300 mcg Buprenorphine is administered for this arm of the interscalene block
1480381|NCT03117140|Drug|Ropivicaine 0.75% + 75 mcg clonidine|Ropivicaine 0.75% + 75 mcg Clonidine is administered for this arm of the interscalene block
1480382|NCT03117140|Drug|Ropivicaine 0.75% + 8 mg dexamethasone|Ropivicaine 0.75% + 8 mg Dexamethasone is administered for this arm of the interscalene block
1480383|NCT03117127|Behavioral|Resistance Exercise|Participants will perform leg extension and leg press immediately prior to ingestion of whole eggs or egg whites
1995287|NCT02804880|Other|A4 leaflet|The 2-side color printed A4 leaflet, which systematically covers the most important messages to motivate smoking cessation
1995288|NCT02804880|Behavioral|Brief advice|Very brief, minimal and general smoking cessation advice
1480385|NCT03117127|Other|Egg Whites|Participants will ingestion whole eggs immediately after resistance exercise
1480386|NCT03117114|Device|Endocuff Vision assisted polypectomy|EVD mounted to the tip of the endoscope, therefore EVD assisted polypectomy
1480387|NCT03117114|Other|Standard polypectomy|Absence of an EVD, standard polypectomy
1480388|NCT03117101|Drug|Lucitanib|
1480389|NCT03117088|Other|Checklist ISBAR3|"Checklist ISBAR 3
Use of an online based checklist for handovers with the following items:
Identification Situation Background Assessment Recommendation Read- back Risk
Established Checklist as communication tool"
1480390|NCT03117088|Other|Checklist VICUR|"Checklist Vicur
Use of an online based alternative checklist for handovers with the following items:
Vaccination status Insurance status Contact person Utilisation Rehabilitation Organ donor? Patient decree?
alternative checklist missing communication tool"
1480391|NCT03117075|Device|"using device for scoring pain scale, named ANAPA®"|wearable device for scoring pain scale
1480392|NCT03117062|Other|occlusal reduction|relief of occlusion following endodontic treatment
1480393|NCT03117049|Drug|ONO-4538|360 mg solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
1480394|NCT03117049|Drug|Carboplatin|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
1480395|NCT03117049|Drug|Paclitaxel|Carboplatin at AUC 6 and Paclitaxel at 200 mg/m2 intravenously in every 3 weeks for up to 4 cycles and if deemed safe, Carboplatin and Paclitaxel may continue for up to a maximum of 6 cycles until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
1480396|NCT03117049|Drug|Bevacizumab|Bevacizumab at 15 mg/kg intravenously in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
1480397|NCT03117049|Drug|Placebo|Placebo solution intravenously for 30 min in every 3 weeks until RECIST 1.1 defined PD, unacceptable toxicity, or withdrawal of consent.
1480398|NCT03117036|Drug|Chemotherapy|Systemic chemotherapy with curative intent
1480399|NCT03117023|Drug|dexmedetomidine|sufentanil 0.05ug/kh/h + dexmedetomidine 0.1ug/kg/h for 48h after surgery
1480400|NCT03117010|Drug|Steroids|High dose dexamethasone 20 mg PO or IV
1480401|NCT03117010|Drug|Etoposide|Etoposide 150mg/BSA
1480402|NCT03116997|Drug|Neostigmine+glycopyrrolate|At the conclusion of surgery neuromuscular blockade reversed with neostigmine/glycopyrrolate
1480403|NCT03116997|Drug|Sugammadex|At the conclusion of surgery neuromuscular blockade reversed with sugammadex
1480404|NCT03116984|Procedure|Transcatheter arterial chemoembolization|Transcatheter arterial chemoembolization (TACE) is performed via an injection into the hepatic artery of agents by puncturing the common femoral artery.Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion. The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.
1480405|NCT03116984|Radiation|external- beam radiotherapy|We have reported a series of retrospective clinical trials in which transarterial chemoembolization (TACE) combined with external- beam radiotherapy (EBRT) was a better treatment method than TACE alone for unresectable HCC in the same period and organization, no matter in aspects of the regression rate of carcinoma or survival.Patients who were randomized to the EBRT 3-5 weeks after the completion 2 times TACE.
1480406|NCT03116984|Drug|Adriamycin|Adriamycin(30 to 60 mg) is considered as basic chemotherapy drugs in the process of transcatheter endovascular perfusion.
1480407|NCT03116984|Drug|Lipiodol|The dose of lipiodol was determined by diameter and blood supply type of HCC, generally 5-20ml, and no more than 30ml once.
1480415|NCT03116958|Device|CPAP + Standard care|CPAP device + Standard management at Sleep Unit. According to Spanish Respiratory Society guidelines during 6 months
1480416|NCT03116958|Device|CPAP + Telemedicine|CPAP+ telemedicine approach. Patients followed up at Sleep Unit according to Spanish Respiratory Society guidelines during 6 months.
1480417|NCT03116945|Drug|68Gallium Citrate|Procedure: PET/CT Imaging
1480418|NCT03116932|Behavioral|PrEP knowledge and acceptability questionnaire|This questionnaire consists of 187 items and evaluates socio-demographic variables, sex conducts, PrEP knowledge and PrEP acceptability.
1480419|NCT03116919|Other|Potato|Participants will be given an extra serving of potato a day
1480420|NCT03116919|Other|Non-starchy vegetable|Participants will be given an extra serving of a non-starchy vegetable
1480423|NCT03116893|Drug|BI 685509 After Standardised Breakfast|High-fat high calorie breakfast
1480424|NCT03116893|Drug|Itraconazole|Administration of itraconazole together with BI 685509
1480425|NCT03116893|Drug|Rifampin|Administration of rifampicin together with BI 685509
1480426|NCT03116893|Drug|BI 685509 Fasted Conditions|BI 685509, given alone
1480427|NCT03116880|Procedure|Endovascular aortic repair|Endovascular aortic repair
2000891|NCT03321734|Drug|Caffeine Citrate|Infants will be started on oral caffeine citrate at 10 mg/kg/day or equiv. vol.of placebo (0.9% normal saline, NS). At 36 weeks PMA, drug dose will be increased to 10 mg/kg BID or placebo. Dose will be weight-adjusted weekly until NICU (neonatal intensive care unit) discharge. The research pharmacy will prepare syringes for oral administration with either active drug (caffeine) or placebo (NS) in a blinded fashion. Commercially available vials of caffeine citrate oral solution (20 mg/mL) will be used for active doses; 0.9% sodium chloride (pharmacy stock) will be used for placebo doses. A daily 24-hour supply will be prepared and dispensed. For home administration of study drug, the research pharmacy at each clinical site will prepare a stock solution for outpatient administration, either caffeine or placebo.
1480432|NCT03116815|Other|Direct input of home blood pressure readings via MyChart|Participants will record home blood pressure readings directly into the electronic health record via the MyChart application
1480433|NCT03116802|Drug|Stamaril (live attenuated yellow fever vaccine)|They will receive a single dose of 0.5ml of Stamaril (live attenuated yellow fever vaccine)
1480434|NCT03116789|Dietary Supplement|probiotics|Two capsules for daily
1480435|NCT03116776|Procedure|Walnut Shell Glasses Moxibustion|Participants in experimental group will receive 12 sessions of walnut shell glasses moxibustion, each for 30 minutes,3 times per week, and administered over 4 weeks.
1480436|NCT03116776|Drug|Sodium hyaluronate eye drops|One drop for each eye, four times per day for over 4 weeks.
1480437|NCT03116763|Behavioral|iPeer2Peer Mentorship|10 sessions of 20-30 minute Skype calls conducted over 5-12 weeks.
1480438|NCT03116763|Other|Active Comparator: Control Group|The control group will receive standard care but without the iPeer2Peer program.
1995289|NCT02804880|Other|12-page booklet|12-page smoking cessation self-help booklet
1480441|NCT03116724|Procedure|central venous catheterization through Rt. IJV|"insertion at the intersection of the cricoid cartilage level and the triangular point where the sternal head of the SCM muscle meets the clavicular head
placement of the tip of the catheter 2 cm away from the junction between right atrium and superior vena cava using TEE
measurement of the depth of the catheter at insertion point"
1480442|NCT03116711|Other|Positive CIQ plus High Carbohydrate Diet|Positive Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
1480443|NCT03116711|Other|Positive CIQ plus High Protein Diet|Positive Carbohydrate Intolerance Questionnaire plus High Protein Diet
1480444|NCT03116711|Other|Negative CIQ plus High Carbohydrate Diet|Negative Carbohydrate Intolerance Questionnaire plus High Carbohydrate Diet
1480445|NCT03116711|Other|Negative CIQ plus High Protein Diet|Negative Carbohydrate Intolerance Questionnaire plus High Protein Diet
1480446|NCT03116698|Drug|Low dose DFD07 once daily|Low dose DFD07 once daily
1480447|NCT03116698|Drug|High dose DFD07 once daily|High dose DFD07 once daily
1480448|NCT03116698|Drug|High dose DFD07 twice daily|High dose DFD07 twice daily
1480449|NCT03116698|Drug|Placebo twice daily|Placebo twice daily
1480450|NCT03116685|Biological|Oxabact OC5 - Oxalobacter formigenes HC-1|Active study drug
1480451|NCT03116685|Other|Placebo|Placebo
1480452|NCT03116672|Drug|one dose ketorolac 10 mg|Administration of ketorolac 10mg, (Dolac) 15 minutes before the clinical procedure.
1480453|NCT03116672|Drug|One dose Diclofenac|Administration of diclofenac, (Diclofenaco) 15 minutes before the clinical procedure.
1480454|NCT03116672|Drug|Placebo oral capsule|Administration of Placebo, 15 minutes before the clinical procedure.
1480457|NCT03116646|Diagnostic Test|Chewing evaluation|Children with chewing disorders will be recruited. Each child is required to bite and chew a standardized biscuit for chewing evaluation. The chewing function of each child is scored with the Karaduman Chewing Performance Scale by a physical therapist. Then, the chewing function of each child is also scored with the Karaduman Chewing Performance Scale-Family report by their families.
1480458|NCT03116620|Other|Chewing evaluation|Children with neuromuscular disorders (NMD) will be participated. Children will be asked to chew a standardized biscuit while video recording. Two physical therapists will assess all video recordings independently and score each video according to the KCPS. The correlation between the KCPS scores of two therapists will be used for interobserver reliability. One therapist will rescore the recordings after an interval of 2 weeks for intraobserver reliability.
1480459|NCT03116607|Other|patient education/ recommendations to the health team|The intervention group will receive a Pharmaceutical Intervention Program during their stay in the Service and discharge that includes an analysis of the therapy indicated by the physician, evaluating the safer alternatives for the type of patient and the special conditions of their pathology, with emphasis on Assessments of effectiveness, safety and tolerability of medication, drug interactions, possible adverse events, dose adjustments as necessary according to patient conditions; Verification that the administration is optimal, including the choice of the best route for this and the time in which the drugs are infused to the patient.
1480460|NCT03116594|Biological|NBP608|Preparation of Oka/SK strain of live, attenuated zoster virus
1480461|NCT03116594|Biological|Zostavax|Preparation of Oka/Merck strain of live, attenuated zoster virus
1480462|NCT03116581|Other|Behavior|"Random-dots tasks: dots appear and move, most have a random trajectory but a given proportion of them move coherently to the same direction.
Vicarious reward Each trial begins with a cue, showing 'me' or 'him' and filled rectangle filled proportionally to the payoff. The cue and the square are depicted in yellow (oneself) or blue (other), depending on the beneficiary. The moving dots are then presented and the subjects respond. At the end of dots motion, the feedback is presented. If the response was correct, a pile of coins proportional to the payoff is shown. For incorrect responses and misses, a red-colored cross is displayed.
Audience effect Each trial begins with the display of two eyes (public) or a padlock (private). The moving dots are shown and the participant answers. Audience condition changes the information available on accuracy when submitting comments. In the observed condition, an arrow shows the response. In the observed condition, no feedback is displayed."
1480514|NCT03116152|Biological|paclitaxel/ irinotecan|paclitaxel 175mg/㎡ Intravenous drip every three weeks； irinotecan 180mg/㎡ Intravenous drip every two weeks
1480463|NCT03116581|Other|fMRI (functional Magnetic Resonance Imagery)|"Both behavioral task (audience effect and vicarious reward) will be studied in fMRI (functional Magnetic Resonance Imagery). The same paradigms used in the behavioral experiment will be adapted for fMRI.
Audience Effect experiment: trials will last for 10 seconds maximum. With 80 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 320 trials and have a 54 minutes duration, in 3 runs of 17 minutes each.
Vicarious Reward experiment: trials will have a 10 seconds maximum duration. Using 40 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 200 trials and last for 54 minutes, in 6 runs of 9 minutes each."
1480464|NCT03116581|Other|MEG (MagnetoEncephaloGraphy)|"Both behavioral task (audience effect and vicarious reward) will be studied in MEG (MagnetoEncephaloGraphy). The same paradigms used in the behavioral experiment will be used in MEG.
Audience Effect experiment: trials will last for 7 seconds maximum. With 100 trials for each condition (public easy, public difficult, private easy and private difficult), the task will count a total of 400 trials and have a 47 minutes duration. Every 100 trials (about 12 minutes of tasks), a break will be proposed to the participants.
Vicarious Reward experiment: trials will have a 7.2 seconds maximum duration. Using 75 trials for each condition (other low payoff, other high payoff, self low payoff, self high payoff, control condition), the task will have a total of 375 trials and last for 45 minutes. Every 125 trials (every 15 minutes), a break will be proposed to the participants."
1480465|NCT03116555|Drug|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
1480466|NCT03116555|Drug|Irinotecan|Irinotecan was used as second line treatment with AGC
1480467|NCT03116542|Device|Diagnostic (18F-FLT PET/CT)|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours.
1480468|NCT03116529|Combination Product|Combination Radiation, Immunotherapy, Surgery|"Three doses of Durvalumab (1500 mg) and Tremelimumab (75 mg) given intravenously once every four weeks during radiotherapy prior to surgery.
Radiation therapy delivered with a minimum dose of 50 Gy and 1.8-2 Gy per fraction. Bulky sarcomas, defined as >10 cms in greatest dimension, receive a single 15 Gy fraction of high-dose spatially fractionated (GRID) radiation therapy within 1-3 days prior to radiation therapy
Surgical resection is performed at least 5-8 weeks after cessation of radiotherapy and 4 weeks after completion of neoadjuvant immunotherapy.
Patients with no evidence of disease following surgical resection receive four additional doses and patients with evidence of disease receive nine additional doses of Durvalumab (1500 mg IV) once every four weeks unless there is clear progression of disease."
1480469|NCT03116516|Drug|Temisartan/Amlodipine+Rosuvastatin|All subjects will receive a single oral dose of temisartan/amlodipine+rosuvastatin administered in the morning.
1480470|NCT03116516|Drug|YHP1604|All subjects will receive a single oral dose of YHP1604 administered in the morning.
1480471|NCT03116503|Other|diagnosis of bipolar disorder and comorbid depression|Evaluation of the number of diagnosis of bipolar disorder and comorbid depression
1480472|NCT03116490|Procedure|Anesthesia type|RA group uses regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) ,and GA group uses general anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) .
1480473|NCT03116464|Behavioral|Telemental Health Family Intervention|"Approximately 12-16 session family intervention that will include the following specific strategies, the implementation of which will be tailored by clinicians to the specific interpersonal deficits identified in an assessment: (1) psychoeducation on dementia, (2) communication and problem solving skills, (3) safety building skills, (4) relationship satisfaction enhancement skills, (5) meaning making (i.e. collaboratively identifying the personal significance of events), (6) identification of core patterns from dyad relationship history, (7) techniques to shift emotional responses, (8) techniques to increase emotional attunement, and (9) techniques to increase attunement to care-recipient needs"
1480474|NCT03116451|Behavioral|Foot Health Promoting Program|An electronic intervention for 8 weeks consisting of foot self-care guidance targeted to nurses.
1480475|NCT03116438|Device|CADence|The CADence device collects acoustic (sound) data from locations on the chest for the purpose of identifying coronary artery turbulence, which may be indicative of coronary artery disease. The test will take approximately 15 minutes to complete. There are no follow-up procedures associated with the study.
1480476|NCT03116425|Device|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.
To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).
Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.
Patients will have 4 sessions per day on 5 successive days per arm."
1480477|NCT03116425|Device|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.
To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).
Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.
Patients will have 4 sessions per day on 5 successive days per arm."
1480478|NCT03116425|Device|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.
Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
1480479|NCT03116425|Procedure|Individualized rTMS on VERUM 1's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.
To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).
Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.
Patients will have 4 sessions per day on 5 successive days per arm."
1480515|NCT03116139|Diagnostic Test|V/Q imaging|Standard of care
1480516|NCT03116139|Diagnostic Test|Computed tomography scan|Standard of care
1480517|NCT03116126|Drug|Guanfacine|2mg oral daily tablet
1480480|NCT03116425|Procedure|Individualized rTMS on VERUM 2's region or network|"To increase cortical rCBF, iTB (intermittent theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 2 sec with an inter-train interval of 8 sec.
To decrease cortical rCBF, cTB (continuous theta burst) will be used: triplet at 50 Hz repeated at 5 Hz in trains of 40 sec. Intensity 120% of passive threshold (or 150% of active threshold).
Stimulation protocol will be used up to 5 times per session to allow a reasonable regional or network coverage.
Patients will have 4 sessions per day on 5 successive days per arm."
1480481|NCT03116425|Procedure|Individualized rTMS on PLACEBO region|"Region will be modulated up or down according to the stimulation protocol used in VERUM 1 and 2 conditions.
Stimulation will be replicated up to 5 times per session. Patients will have 4 sessions per day on 5 successive days per arm."
1480482|NCT03116412|Procedure|CT or PET scans|Scans and blood tests are scheduled at baseline, months 6, 12, 24 and 36.
1480483|NCT03116399|Behavioral|PRISM 2.0 Condition|Access to the PRISM 2.0 program
1480484|NCT03116399|Behavioral|Tablet Condition|Access to the tablet
1480485|NCT03116386|Other|run-in period|observational time i.e. baseline situation
1480486|NCT03116386|Device|Control period|neither activation of any lighting environment when the resident gets up from his bed nor alert if the resident did not return to bed after 15 minutes Etolya-F ® devices will only permit detection and recording of the moment of the elderlly will leave his/her bed and recording of the moment the elderly will be found by caregivers
1480487|NCT03116386|Device|Etolya-F ® devices|Etolya-F ® devices will permit detection of absence in the bed, activation of a lighting environment when the resident gets up from his bed, transmission of alert to caregivers through the centralized system of sick call if the resident do not return to bed after 15 minutes and recording the time when caregivers will find the resident out of bed, distinguishing between a fall and a night wandering in the room or corridors without a fall
1480490|NCT03116360|Diagnostic Test|Diagnostic Ultrasound|The physician performing the ultrasound will be blinded to the results of the x-ray and MRI. The physician performing the ultrasound will be informed of the bone in question (ex. Tibia) and will be able to perform a focused history and exam. The bone in which acute stress fracture is suspected will then be scanned throughout its length in two orthogonal views. The criteria for diagnosing acute stress fracture on ultrasound include displaying 2 out of 3 of the following: hypoechoic periosteal elevation of cortical bone, visible cortical disruption, hyperemia surrounding the periosteal lesion on power Doppler. The ultrasound physician will then be asked to make a determination whether the ultrasound study is positive for acute stress fracture or negative/indeterminate.
1480494|NCT03116321|Drug|Eslicarbazepine acetate (ESL)|Oral Tablet of 800 mg and 200 mg of ESL
1480495|NCT03116308|Drug|Opicapone (OPC)|50 mg OPC capsules; oral route
1480496|NCT03116295|Drug|Opicapone (OPC)|Test treatment: 25 mg or 50 mg of OPC hard capsule (new API source NF) Reference treatment: Ongentys® 25 mg or 50 mg of OPC hard capsule (current API source - AF).
1480498|NCT03116269|Drug|Cilostazol 100mg|
1480499|NCT03116269|Drug|Aspirin|
1480500|NCT03116256|Dietary Supplement|Very low calorie diet (VLCD)|All participants (including exercise group) will be using full daily meal replacement during the 6-week interventional period. The total meal supplement is 600 kcal/day.
1480501|NCT03116256|Other|High intensity interval training (HIIT)|Participants in this group will be having HIIT session three times per week under close medical supervision. This involves 60 sec high intensity cycling at 95-125% Watt Max, with 90s recovery, repeated 5 times, with 2 minutes warm up and cool down.
1480502|NCT03116256|Other|Resistance exercise training (RET)|The exercise format will be 2 sets of 12 repetitions at 70% 1-RM for each resistance regime, with 1-2 minutes rest between sets after a prescribed warm-up 3 sessions/week. The resistance regimes are: (3 upper body)chest press, latissimus pull down, seated lever row; (3 lower body) leg extension, leg curl, leg press. Participants will be alternating between upper and lower body exercise during each training session.
1480503|NCT03116230|Device|Cutaneous Stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
1480504|NCT03116230|Device|Knee Sleeve|Commercially-available knee sleeve.
1480506|NCT03116204|Other|Assessment of score SAS|Assessment of a score assessing physical and cognitive activities of patients in follow-up care and rehabilitation departments
1480507|NCT03116191|Drug|SK-1404|4 weeks of repeated administration of SK-1404 to the patients of nocturia
1480508|NCT03116191|Drug|Placebo|4 weeks of repeated administration of Placebo to the patients of nocturia
1480509|NCT03116178|Other|Group G -PVI( Masimo co oximeter) guided fluid therapy|"goal directed fluid therapy maintaining pvi 4-11. when pvi<4 fluid rate is 50-60ml/hr and pvi>11 200ml colloid bolus transfusion till pvi value achieves normal range.
In the control group crystalloid was administered @ 6-8 ml/kg and blood loss was replaced by colloids. Hourly urine output was measured and if less than 0.5ml/hr bolus crystalloid 100-200ml was administered"
1480510|NCT03116178|Other|Group B- Body weight guided intravenous fluid @6-8ml/kg|Intravenous fluid @6-8ml.kg and blood loss replacement with colloids maintaining urine output of 0.5ml/kg
1480511|NCT03116165|Behavioral|Modified prolonged exposure therapy|Participants will receive three sessions of modified prolonged exposure therapy.
1480512|NCT03116165|Behavioral|Attention control|Participants will receive three sessions of supportive counselling and psychoeducation
1480513|NCT03116152|Biological|IBI308|IBI308 200mg Intravenous drip every three weeks；
1480518|NCT03116126|Drug|Placebo|inactive oral daily tablet
1480522|NCT03116074|Behavioral|Patient-centered discharge toolkit|Pre-discharge checklist, safety dashboard enhanced with discharge preparation indicator, secure patient-provider messaging
1480523|NCT03116061|Other|Questionnaire|This questionnaire was to explore potential decompensation risk factors within themes and subthemes of multimorbidity
1480524|NCT03116048|Other|Chronic pain evaluation|Chronic pain assessment with study questionnaire
1480525|NCT03116035|Other|Web-based decision aid|Patients were randomized to receive links to a commercially available decision aid.
1480526|NCT03116035|Other|Standard websites|Patients were randomized to receive links to standard, high-quality websites.
1480527|NCT03116022|Drug|Estriol|Women using drug 1 mg / 1g in the proximal third of the vagina every other night for 12 weeks
1480528|NCT03116022|Drug|Distal estriol|Women using drug 1 mg / 1g at the distal third of the vagina every other night for 12 weeks
1480529|NCT03116022|Drug|Vaginal Gel|Women using a base water gel lubricant during intercourse
1480530|NCT03116009|Diagnostic Test|Screening for diabetes mellitus before 20 weeks of gestation and then undergo diagnostic test|They will receive 50gm oral glucose tolerance test before 20 weeks and if abnormal, they will do the diagnostic test with 100gm OGTT with HbA1C.
1480531|NCT03115996|Drug|REGN3918|Intravenous (IV) or Subcutaneous (SC)
1480532|NCT03115996|Drug|Placebo|Matching Placebo
1480533|NCT03115983|Device|LimiFlex|LimiFlex implantation at a single level after surgical decompression.
1480534|NCT03115983|Device|Fusion Instrumentation|Titanium alloy top-loading, polyaxial pedicle screws and cylindrical, titanium alloy rod instrumentation using autogenous bone graft with or without synthetic extenders and a single PEEK TLIF cage cleared by FDA for this indication
1480535|NCT03115983|Procedure|Decompression|Surgical decompression of a single level L1-S1.
1480536|NCT03115983|Procedure|Fusion|Transforaminal lumbar interbody fusion (TLIF) with concomitant posterolateral fusion (PLF) at a single level after surgical decompression.
1480537|NCT03115970|Procedure|capillary and venous lactate level measurement|capillary and venous lactate level measurement
1480538|NCT03115957|Other|Parenteral Nutrition|Patients who can not tolerate 30% of target energy EN will receive supplemental parenteral nutrition at day 3 or at day 8 after abdominal surgery.
1480539|NCT03115944|Device|Alma vShape Ultra|UltraSpeed ultrasound treatment, a series of four treatments
1480540|NCT03115931|Other|no intervention|no intervention
1480541|NCT03115918|Device|Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm to have a PD stent placed.
1480542|NCT03115918|Other|No Pancreatic Duct Stent Placement|Patients will be randomly allocated to either treatment arm and not receive PD placement.
1480543|NCT03115892|Drug|Green Tea With Aloe Vera mouthwash|measuring Tool/device Smell identification test ( organoleptic score ) (human nose) to measure of malodor which its unit 0-5 score
1480544|NCT03115892|Drug|Chlorhexidine mouthwash|chlorohexidine mouthwash take two times per day for one week
1480545|NCT03115879|Other|Hip mobilization|High velocity low amplitude hip mobilization of the experimental group
1480546|NCT03115879|Other|Hip manipulation simulation|Hip manipulation simulation
1480547|NCT03115866|Behavioral|FRUVEDomics|FRUVEDomics is a behavioral nutrition intervention in young adults 'at risk for metS' and young adults 'with metS' to identify modifiable metabolomics and microbiome risk. Group nutrition education including basic nutrition for the prescribed intervention, culinary tool kit distribution, sample budget and grocery shopping tips were delivered to each participant group prior to the start of the intervention. Participants underwent individual weekly consultations with a Registered Dietitian Nutritionist using food logs, food pictures and receipt management, to assess adherence and cost of the intervention.
1480548|NCT03115853|Drug|Aliskiren 150 mg|Aliskiren 150 mg daily for 2 weeks
1480549|NCT03115853|Drug|Placebo|Placebo tablet for Aliskerin
1480550|NCT03115853|Drug|HCTZ|HCTZ 25mg every day for 18 weeks
1480551|NCT03115853|Drug|Aliskiren 300 mg|Aliskiren 300 mg for 4 weeks
1480552|NCT03115827|Drug|Droxidopa|Droxidopa will be started at 100mg twice a day and titrated up to a maximum of 600mg twice a day
1480553|NCT03115827|Drug|Carbidopa|Carbidopa 200mg twice a day
1480554|NCT03115801|Drug|Nivolumab|Nivolumab will be given to patients with renal cell carcinoma on days 1,15, 29, 43 and 57.
1480555|NCT03115801|Drug|Atezolizumab|Atezolizumab will be given to patients with urothelial carcinoma on days 1,22,43,64.
1480556|NCT03115801|Radiation|Radiation & immunotherapy|Radiation is given to one lesion, 30 Gray (Gy) in 3 fractions of 10 Gy each. over a one week interval (with a minimum of 36hrs between each fraction). On the day of radiation (Day 1) immunotherapy is administered and repeated on the scheduled days. Patients will receive radiation on Day 1 and immunotherapy will be given ± 24hr from Day 1.
1480557|NCT03115788|Other|Heat induced pain|For the heat induced thermal pain, the research nurse will train the subject to estimate pain quantitatively using a 2 cm 2 Peltier controlled thermode (TSA®) applied to the skin of the arm. Typically, the subject is exposed to temperatures between 41° and 49° C using a random staircase method. After the volunteer learns to qualitatively estimate the thermal pain, pain will be established by heating the the leg with a 4 cm2 Peltier controlled thermode (TSA®) for 90 seconds with the probe clamped at a thermal intensity of 47°C.
1480558|NCT03115788|Other|Cold Induced Pain|Cold pain will be induced by placing a foot in a container of circulating water maintained at 10°C for 90 seconds (n=20). Half (n=20) of the subjects will have the foot placed in body temperature water of 38°C.
1480559|NCT03115788|Device|iPad|
1480560|NCT03115775|Dietary Supplement|Conjugated linoleic acid|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) daily.
1480561|NCT03115775|Dietary Supplement|Vitamin D|Intervention will last up to 8 weeks. Subjects will receive vitamin D3 (2000 IU) daily.
1480562|NCT03115775|Dietary Supplement|Conjugated linoleic acid and Vitamin D|Intervention will last up to 8 weeks. Subjects will receive conjugated linoleic acid (4000 mg Tonalin FFA 80) and vitamin D3 (2000 IU) daily.
1480563|NCT03115775|Other|Corn oil (placebo)|Intervention will last up to 8 weeks. Subjects will receive corn oil (4000 mg) daily.
1480564|NCT03115762|Biological|bevacizumab|recombinant humanized monoclonal antibody produced by DNA technology in Chinese Hamster Ovary cells
1480565|NCT03115762|Biological|ASKB1202|
1480567|NCT03115749|Other|Biopsies taken on surgical specimen|biopsies taken on surgical specimen after intestinal resection
1480568|NCT03115736|Drug|Tenofovir Alafenamide|Patients are switched to either Genvoya (TAF/FTC/EVG/COB) or another FTC/TAF-containing ART regimen
1480569|NCT03115723|Procedure|Percutaneous coronary intervention|
1480570|NCT03115723|Procedure|Coronary angiography|
1480571|NCT03115710|Diagnostic Test|Rotating Scheimpflug camera (Pentacam HR)|One visit to Ophthalmology Department is required from participant. Parents or legal guardians must attend with their child. The interview and test during visit take approximately 15 minutes. Interview includes filling out a questionnaire about risk factors of the disease and double check on understanding the consent form. The child will sit in front of the instrument (Pentacam HR Scheimpflug imaging system). The rotational measuring procedure generates Scheimpflug images in three dimensions. The images taken during the examination are digitalized, and all image data are transferred to the computer. It calculates a 3D virtual model of the anterior eye segment, from which all additional information is derived.
1480572|NCT03115697|Drug|Lactulose|Lactulose 20 mL
1480573|NCT03115697|Drug|Rifaximin|Rifaximin 550 BD
1480574|NCT03115697|Biological|Plasmapheresis|Plasmapheresis 8 hrly duration
1480575|NCT03115671|Dietary Supplement|Vayarin|Vayarin capsule
1480576|NCT03115658|Behavioral|Physical Activity|12 week print based intervention
1480577|NCT03115645|Other|Dynamic Work|The intervention consists of the introduction of sit-stand workstations and desk bikes in the participants work environment in a ratio of 1:2 with traditional desks and chairs. Employees will receive a half hour intervention session at the start of the intervention from an occupational physiotherapist, who will provide further intervention support in the ensuing 12 weeks. Intervention participants will also receive an activity tracker which provides feedback on sitting time and physical activity levels.
1480578|NCT03115619|Drug|Pirfenidone|Participants will receive pirfenidone therapy as per clinical practice or summary of product characteristics (SmPC).
1480579|NCT03115606|Device|C-Mac D Blade|Videolaryngoscope
1480580|NCT03115606|Device|Fastrach LMA|Laryngeal mask airway
1480581|NCT03115593|Procedure|Blind biopsy with a pipette|Patients willing to participate to the study will benefit from a double biopsy. The first biopsy will be a blind biopsy performed by aspiration with a Cornier pipette.
1480582|NCT03115593|Procedure|Targeted biopsy using hysteroscopy|During the same consultation, patients will benefit from a diagnostic hysteroscopy with vaginoscopy and saline (allowing a wash of the debris caused by the pipette biopsy), using a rigid hysteroscope of 4.3 mm equipped with an operator channel allowing the passage of a biopsy tong.
1480583|NCT03115580|Device|Rotational atherectomy|"Rotational atherectomy for the treatment of bifurcation lesions to remove plaque with minimal injury to adjacent normal arterial segments and potentially reduce plaque shifting, the snow plow effect."
1480584|NCT03115580|Device|Cutting Balloon Angioplasty|Cutting balloon is a special balloon catheter with three or four microsurgical blades attached longitudinally to its surface, suitable for creating discrete longitudinal incisions in the atherosclerotic target coronary segment during balloon inflation. Lesion preparation will be performed using Cutting Balloon or conventional balloon
1480585|NCT03115567|Drug|Triamcinolone|6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
1480586|NCT03115554|Procedure|PVI Plus Catheter Ablation|Patients with sustained AF following PVI will receive additional linear or focal intracardiac catheter ablation for AF.
1480587|NCT03115554|Procedure|PVI Alone|Patients with sustained AF following PVI will not receive additional linear or focal intracardiac catheter ablation for AF.
1480589|NCT03115515|Drug|levothyroxine|To compare two different methods of adjusting thyroid hormone replacement during pregnancy to maintain TSH within the normal reference range for pregnancy.
1480590|NCT03115489|Drug|Traditional Treatment (Group T)|Patients will receive traditional drug infusions
1480591|NCT03115489|Drug|Ketamine Infusion (Group K)|Patients will receive loading dose of 2.5 mg/kg of ketamine followed by a continuous infusion with a starting dose of 3mg/kg/hr with titration in 1mg/kg/hr increments until burst suppression is achieved or a maximum dose of 10mg/kg/hr is reached
1480592|NCT03115476|Drug|ingenol disoxate gel 0.018%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
1480593|NCT03115476|Drug|ingenol disoxate gel 0.037%|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
1480594|NCT03115476|Other|Vehicle gel|Ingenol disoxate gel is a novel ingenol derivative being developed for field treatment of AKs on treatment areas of up to 250 cm2 (40 in2) on the face, chest and scalp.
1480595|NCT03115463|Other|Titration of oxygen during neonatal resuscitation|Resuscitation will be initiated at 30% O2 and target goal saturations will be the 10th to 25th percentile saturations in OX25 and 75th percentile in OX75 group. The control group will be resuscitated with the OX50 strategy in which resuscitation will be initiated with 30% O2 and target goal saturations will be the approximated median SpO2 observed in healthy term newborns as per current NRP guidelines. For the first 6 minutes after birth, target ranges of of all 3 arms are different. After 6 min, the target ranges are are identical.
1480596|NCT03115450|Device|Ultrasound|Type of imaging technology to look at organs and structures inside the body
1480597|NCT03115450|Device|Pupilometer|A device that measures pupil size and how it changes.
1480598|NCT03115437|Other|Hard cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by hard cushioning.
1480599|NCT03115437|Other|Soft cushioned running shoes|The participants allocated to this experimental group will have to perform all their running sessions with the study shoes they received the day of their inclusion to the study and characterized by soft cushioning.
1480660|NCT03115008|Behavioral|Video-based terminal feedback|Terminal feedback is given after skill performance using video-based coaching coupled with a validated polypectomy assessment tool
1480661|NCT03114995|Drug|Tirofiban|
1995296|NCT02803541|Behavioral|12 day mainstream summer camp experience|see arm description
1480600|NCT03115424|Drug|Saxenda|Saxenda is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management in adult patients. Subjects will be recruited and screened prior to undergoing bariatric surgery. Subjects undergoing SG will be randomized 1:1 at month 3 post surgery to Saxenda, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
1480601|NCT03115424|Drug|Placebos|Subjects will be recruited and screened prior to undergoing bariatric surgery.Subjects undergoing SG will be randomized 1:1 at months 3 post surgery to Placebo, 0.6mg SQ daily, with weekly titration of 0.6mg until maintenance dose of 3mg/daily reached. Subjects will remain on study drug for duration of study (33 months). After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
1480602|NCT03115424|Procedure|RYGB|Subjects will be recruited and screened prior to undergoing bariatric surgery. After undergoing surgery, study visits will be timed to coincide with the standard clinical follow-up visits at months 3, 6, 9, 12, 18, 24, 30 and 36.
1480603|NCT03115411|Device|Winged biliary stent (ViaDuct™)|Placement of winged biliary stent at ERCP for management of benign biliary stricture.
1480604|NCT03115398|Behavioral|Pedometer-based Walking Program|Patients will be instructed to meet the daily step count goal displayed on their fitness tracker. If goal is not being met, study team will intervene and reinforce the importance of meeting this goal. Intervention will include a conversation with the patient, led by a study coordinator, to identify any challenges present in meeting the prescribed goal. Solutions to such challenges may be offered by the coordinator or necessary provider, such as a dietitian, when applicable.
1480605|NCT03115385|Dietary Supplement|VSL#3|VSL#3 will provide active packets. Subjects will take 2 to 3 packets per day with for 16 weeks. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. VSL#3 probiotic is provided in powder form and needs to be mixed with cold, non-fizzy liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero with stevia).
1480606|NCT03115385|Dietary Supplement|Placebo|A matched placebo to VSL#3 will be provided. The placebo will be identical to the active VSL#3 probiotic in aspects such as packaging, color, taste, texture, shape, and odor. The placebo will not contain active ingredients. The study team will supply each participant with all necessary packets on a weekly or bi-weekly basis within 1-2 weeks after their first visit. The placebo is provided in powder form and needs to be mixed with liquid for consumption. For this reason, the study team will also provide participants with zero calorie sugar fee beverages to mix their packet with (e.g., vitamin water zero).
1480607|NCT03115372|Other|Educational Intervention|Attend CRC education session
1480608|NCT03115372|Other|Educational Intervention|Attend healthy nutrition session
1480609|NCT03115372|Other|Informational Intervention|Receive CRC screening brochure
1480610|NCT03115372|Other|Survey Administration|Ancillary studies
1480611|NCT03115372|Behavioral|Telephone-Based Intervention|Receive telephone reminder about CRC screening
1480612|NCT03115372|Behavioral|Telephone-Based Intervention|Receive telephone reminder about healthy nutrition
1480613|NCT03115359|Behavioral|Mindfulness Meditation|"The Mindfulness Meditation intervention will teach participants the mindfulness meditation-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.
In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
1480614|NCT03115359|Behavioral|Cognitive Behavioral Therapy|"The Cognitive Behavioral Therapy (CBT) intervention will teach participants the CBT-based strategies, tailored to the needs of those with opioid-treated chronic lower back pain. It consists of eight weekly 2-hour group sessions guided by trained therapists. In addition to session attendance, participants are asked to practice at home at least 6 days/week, 30 minutes/day during the study.
In addition to the intervention, the participants will receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
1480615|NCT03115346|Other|Decision aid|Decision aid for repair type for aortic abdominal aneurysms
1480616|NCT03115333|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
1480617|NCT03115320|Drug|Human chorionic gonadotropin|Human chorionic gonadotropin (Pregnyl, 5000IU) is used in the medication group to confirme the ovulation.
1480618|NCT03115320|Other|Home ovulation test|The ovulation in the natural menstrual cycle is confirmed by the home ovulation tests from the urine.
1480619|NCT03115307|Drug|Triptorelin|Triptoreline 0,1mg/ml subcutaneously once in a luteal phase in insemination cycles.
1480620|NCT03115294|Drug|Theophylline|iv injection
1480621|NCT03115294|Procedure|Ventilator positive end expiratory pressure adjustment|Positive end-expiratory pressure variation
1480622|NCT03115281|Device|PCI|PCI
1480623|NCT03115268|Behavioral|Social support groups delivered in EVA Park|Intervention will comprise support group meetings delivered in EVA Park, a virtual island created for people with aphasia. Scheduled meetings will be held every two weeks, led by the group co-ordinator and volunteers. Participants will have unlimited access to EVA Park, so will be able to meet up with other group members between meetings.
1480624|NCT03115255|Drug|intravitreal ranibizumab|0.25 mg intravitreal ranibizumab to either 1 eye (unilateral cases) or both eyes (bilateral cases)
1480625|NCT03115242|Other|Contrast injection Sonovue®|In addition to standardized assessment routine care, a contrast injection will be performed during the neck vessels doppler ultrasound.
1480662|NCT03114982|Biological|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
1480663|NCT03114982|Biological|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
2000892|NCT03321734|Drug|Placebos|0.9% sodium chloride (pharmacy stock) will be used to prepare placebos in a 2:1 simple syrup/cherry syrup mixture for the control group infants. The volume of the placebo will match the volume of the study drug.
1480626|NCT03115229|Behavioral|Protective Nursing Interventions for Reduction Obesity Risk|"Applications for the experimental group for 11 weeks are grouped under three headings.
These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.
Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.
Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks."
1480627|NCT03115216|Procedure|FLA-CEIOL|Femtosecond laser-assisted cataract extraction and intraocular lens placement
1480628|NCT03115216|Procedure|CEIOL|Manual cataract extraction and intraocular lens placement
1480629|NCT03115203|Other|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in patients with sequelae of facial paralysis
1480630|NCT03115203|Other|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle, in healthy subjects|Carry out the morphometric evaluation of the muscles of the skin, especially the large zygomatic muscle in healthy subjects (data obtained from the SIMOVI project being published).
1480631|NCT03115190|Diagnostic Test|General Practitioner diagnosis with Heart score|All patients seen by the general practitioner (GP) at the GP cooperation and agreeing to participation will be evaluated with the Heart score. This is a score including history, electrocardiogram, age, risk factors and troponin to assess whether a patient is at high risk for acute coronary syndrome. The troponins asked for in the Heart score are at arrival of the patient, not regarding the time of onset of chest pain. We shall use point of care (POC) troponin, thereby modifying the Heart score. The GP must realize that the POC troponin is not reliable on its own with one test. If the Heart score is low, it is acceptable and safe to not refer the patient, it is however not safe to refer the patient solely on negative troponin result.
1480632|NCT03115177|Drug|Doxycycline|The treatment group will receive 100mg of doxycycline IV in addition to cefazolin within 1 hour of incision for total shoulder arthroplasty.
1480633|NCT03115177|Drug|Cefazolin|
1480634|NCT03115164|Other|To study the characteristics of patients with DIA / DIG|Describe the characteristics of patients with DIA / DIG treated in French SFCE pediatric oncology centers according to whether these tumors behave in a benign or malignant manner.
1480635|NCT03115151|Drug|Bupivacaine|Bupivacaine (0.0625%) will be combined with fentanyl for postoperative epidural analgesia via a lumbar epidural catheter
1480636|NCT03115151|Drug|Hydromorphone|Hydromorphone will be given continuous infusion for intravenous patient controlled analgesia (syringe 25 mg/50 mL).
1480637|NCT03115151|Drug|Fentanyl|Fentanyl (2 mcg/ml) will be given via epidural route together with bupivacaine.
1480638|NCT03115138|Other|Correlation between molecular anomalies of the primary tumor and circulating tumor DNA|The presence of a specific abnormality initially identified on the primary tumor and which can be quantified in the cDNA during the management will allow a better follow-up of the patient.
1480639|NCT03115125|Other|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 of hospitalization in medical reanimation.|Describe for the first time the kinetics of evolution in proportion of the circulating Brég in patients with severe septic state, at times D0, D2, D7 and D14 (or on leaving the service if before D14) of hospitalization in medical reanimation.
1480640|NCT03115112|Drug|Bexagliflozin|20 mg, tablet
1480641|NCT03115112|Drug|Sitagliptin|100 mg, tablet
1480642|NCT03115112|Drug|Placebo for sitagliptin|100 mg inactive tablet to match active comparator
1480643|NCT03115112|Drug|Placebo for bexagliflozin|20 mg inactive tablet to match active comparator
1480644|NCT03115099|Drug|LY3325656|Administered orally
1480645|NCT03115099|Drug|Placebo|Administered orally
1480646|NCT03115099|Drug|Liraglutide|Administered subcutaneously
1480647|NCT03115099|Drug|Sitagliptin|Administered orally
1480648|NCT03115073|Drug|Candiplus|Administration of Candiplus
1480649|NCT03115073|Drug|Clotrimazole|Administration of Clotrimazole
1480650|NCT03115060|Drug|intravenous fluid administration WITH NORMAL SALINE, PLASMALYTE A, OR RINGER LACTATE|intravenous fluid to be used for maintainance and replacement during renal transplant surgery will be normal saline, ringer lactate or plasmalyte A depending on the arm of intervention
1480651|NCT03115047|Drug|Dexmedetomidine Injection|0.35 mcg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
1480652|NCT03115047|Drug|Meperidine Injection|0.35 mg/kg intravenous in 2 minutes if shivering 5 minutes after delivery
1480653|NCT03115034|Drug|Melatonin|Patients under CEA taking 6mg/day melatonin orally from 3 days before operation to 3 days after operation.
1480654|NCT03115034|Drug|placebo|Patients under CEA taking placebo orally from 3 days before operation to 3 days after operation.
1480655|NCT03115034|Other|blank|Patients under CEA without taking melatonin or placebo
1480656|NCT03115021|Device|Active tPCS|A current intensity of 2na and a stimulation frequency range of 6-10 Hz will be used with a peri-auricular ear-clip electrode montage for 20 minutes.
1480657|NCT03115021|Device|Active tDCS|A current intensity of 2mA will be used for 20minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be place over the left prefrontal cortex and the cathode over the right supraorbitofrontal area.
1480658|NCT03115021|Device|Sham tPCS|Sham tPCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tPCS condition and the electrodes placement as well.
1480659|NCT03115021|Device|Sham tDCS|Sham tDCS will consist of applying the same parameters as for active but the corresponding device will be turned off after 30 seconds as to simulate the initial sensation of the active current. A current of 2mA will still be used (but turned off after 30 sec). The electrodes that will be used will be the same as for the active tDCS condition and the electrodes placement as well.
1480669|NCT03114956|Procedure|Gauze|Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
1480670|NCT03114956|Procedure|Titanium brush|Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
1480671|NCT03114956|Procedure|Air powder abrasion|Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
1480672|NCT03114956|Procedure|Comprehensive|A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
1480673|NCT03114943|Biological|NBP608|Preparation of the Oka/SK strain of live, attenuated varicella virus
1480674|NCT03114943|Biological|Varivax|Preparation of the Oka/Merck strain of live, attenuated varicella virus
1480675|NCT03114930|Other|"To study the absence of increased complications and events occurring in the mother-newborn"|"To study the absence of increased complications and events occurring in the mother-newborn couple who made a standard exit compared to the mother-newborn couples who had benefited from an extra day of  Hospitalization in maternity."
1480676|NCT03114917|Other|Cognitive AppRoaches to coMbatting Suicidality (CARMS)|The investigators' psychological therapy is a recovery-focused, structured, time-limited, socio-cognitive intervention. It is based upon the investigators' recently developed treatment manual (Tarrier et al., 2013) and pilot RCTs in the community (Tarrier et al., 2014) and in prison (Tarrier et al., accepted). The intervention modifies negative appraisals of emotional regulation, social support, and interpersonal problem-solving. As a consequence, perceptions of defeat, entrapment, and hopelessness will be improved indirectly. In addition, perceptions of defeat, entrapment, and hopelessness will be worked on directly during the therapy.
1480677|NCT03114904|Other|Variation of Jasinski score between H0 (stop of sedatives) and H6|To compare the effectiveness of a withdrawal management protocol with the usual management in cerebral patients (Subarachnoid haemorrhage (HSA), stroke and head trauma (CT))
1480678|NCT03114891|Procedure|Theta-burst stimulation|A normal, FDA-approved clinical application of TMS involves long trains of repetitive TMS applied for approximately 40 minutes, 5 days/week, over 2-6 weeks, for a total of 10-30 TMS visits. The present study utilizes the same FDA-approved devices (Magventure Cool-Coil B65, MagVenture X100 Stimulator) to administer treatment. We will be modifying the FDA-approved protocol to stimulate in a well-replicated protocol, theta-burst stimulation (Huang et al., 2005), which will result in a greatly reduced number of total pulses delivered to the subject in any given TMS session.
1480679|NCT03114878|Other|TRT / EMDR|"Tinnitus Retraining Therapy:
TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.
Eye Movement Desensitization and Reprocessing:
This is a scientifically, psychotherapeutic approach, developed in 1987 by Francine Shapiro. EMDR represents a specific method within a wider theoretical model called 'Adaptive Information Processing (AIP)'. Within the treatment bilateral stimulation is used i.e. visual, auditory and tactile stimuli can be used to stimulate both the left - and the right hemisphere."
1480680|NCT03114878|Behavioral|TRT / CBT|"Tinnitus Retraining Therapy:
TRT is a therapy developed by Prof. Pawel Jastrebroff and Dr. Jonathan Hazell. During the counseling, the patient is educated about the work mechanism of tinnitus and how to deal with the emotional and physical responses. The main goal is to habituate to the sound of the ringing in the ears.
Cognitive Behavioral Therapy:
CBT is the combination of behavioral therapy with interventions that have been developed from cognitive psychology. The founders of CBT are Aaron Beck and Albert Ellis. The core idea is the assumption that so-called negative cognitions are responsible for dysfunctional behavior. The techniques used in the cognitive behavioral therapy focus on changing the content of these irrational cognitions."
1480685|NCT03114852|Diagnostic Test|blood collection|They will have blood tested to renal genetic diseases
1480686|NCT03114839|Dietary Supplement|Lactobacillus casei strain Shirota (LcS)|A fermented milk containing LcS, 65 ml for oral administration, 1 bottle per day for 7 days. One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10^9 colony-forming units of LcS.
1480687|NCT03114826|Genetic|To study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker|Study the polymorphism of the gene encoding VEGF (rs699947) as a predictive marker of the occurrence of renal cell carcinoma in renal transplant patients.
1480688|NCT03114813|Drug|Carvedilol|Non-selective beta-blocker as per routine clinical care
1480689|NCT03114813|Other|MRI scan|One hour non-invasive MRI scan
1480690|NCT03114813|Procedure|Hepatic Venous Pressure Gradient (HVPG)|Second HVPG to evaluate treatment response
1995297|NCT02802176|Device|INVOcell device|intra-vaginal culture of embryos using INVOcell device
1480692|NCT03114787|Other|Study on patients with respiratory resuscitation|Patient intubated with mechanical ventilation in VS-AI mode, whose weaning is difficult
1480693|NCT03114774|Device|The bispectral index (BIS) monitoring|
1480694|NCT03114774|Behavioral|Ramsay Sedation Scale (RSS) Score monitoring|
1480695|NCT03114761|Radiation|CT angiography|Patients are subjected to a standard abdominal CT scan and (additional in this study) to abdominal CT angiography (CTA)
1480696|NCT03114748|Other|EEG|
1480697|NCT03114748|Other|DBS switched OFF and ON|
1995298|NCT02802176|Other|Traditional IVF|traditional culture of embryos in-vitro
1995299|NCT02802995|Drug|PRP/thrombin mixture|Mixture of platelet rich plasma and thrombin applied topically on the wound surface
1995301|NCT02801422|Other|fMRI|
1995302|NCT02801357|Drug|lofexidine administration in subjects seeking buprenorphine dose reduction|
1995303|NCT02800941|Drug|Oral anticoagulant treatment|The treatment is delivered according to the usual practice.
1480698|NCT03114722|Drug|Citrate 4%|In patients randomised to the citrate arm, the PICC line will be locked with a total of 1.6ml of citrate 4% (0.8ml per lumen in a double-lumen PICC), between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
1480699|NCT03114722|Drug|Heparinised saline (10U/ml)|In patients randomised to the heparinised saline arm, the PICC line will be locked with 10U/ml heparinised saline between each use. Lines will also be flushed with 20ml of normal saline and locked with the locking agent twice a week, if the time elapsed between each use is more than one week. This is part of the standard local protocol. Patients will be followed for up to 6 months or until the catheter is removed, or until the study ends
1480700|NCT03114709|Other|Mindful Movement|The program focuses on enhancing individuals' mindfulness capabilities and skills, specifically attention regulation, body awareness, emotional regulation, and shifts in self-perception, by providing opportunities for education, practice, and social support in mindfulness meditation and physical activity.
1480701|NCT03114709|Other|10 Keys to Healthy Aging|This community-based educational program provides participants useful content focused on general health related topics including common chronic conditions, social support, social participation, cancer screening, immunization and keeping active.
1480702|NCT03114696|Dietary Supplement|IQP-AO-101|1 dose (sachet) to be consumed 30 - 60 mins before bedtime
1480703|NCT03114696|Dietary Supplement|Placebo|1 dose to be consumed 30 - 60 mins before bedtime. (Identical to investigational product)
1480704|NCT03114683|Drug|PD1|IBI308 200mg/3 weeks
1480705|NCT03114670|Biological|CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells|a single dose of CD123CAR-41BB-CD3zeta-EGFRt-expressing T cells will be infusion after preconditioning.
2000893|NCT03321682|Other|Functional Training|Exercises performed in circuit, using weights, elastic bands, suspension tapes, cones and on unstable surfaces.
2000894|NCT03321682|Other|Strength Training|Exercises carried out using weights and involving the main muscle groups.
1480708|NCT03114644|Other|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.|Physiologically evaluate the impact of reading history on the mother-baby synchronies in a context of premature birth requiring hospitalization in neonatal medicine.
1480709|NCT03114631|Biological|Dendritic cells pulsed with tumor lysate|
1480710|NCT03114631|Biological|Dendritic cells pulsed with MUC-1/WT-1 peptides|
1480711|NCT03114605|Behavioral|Mindfulness-based Intervention|
2000895|NCT03320291|Device|Regjoint|Implant of poly-L / D-lactide (Regjoints®) in the treatment of trapezo-metacarpal osteoarthritis
1480713|NCT03114579|Device|Intraoperative heart rate measurement (reference method)|Measurement of cardiac output by both monitors: NEXFIN HD and oesophageal doppler, blood pressure measurement by the catheter and NEXFIN HD monitor, and cardiac output and blood pressure measurements after treatment administration (vasoconstrictor or filling)
1480714|NCT03114579|Device|NEXFIN HD|
1480715|NCT03114566|Other|Leukapheresis|Blood is removed together with an anticoagulant from a vein and separated into white cell rich and red cell rich fractions by centrifugation. The white cells are then saved to generate immune cells and the red cells are reinfused back through the donor's vein.
1480716|NCT03114553|Genetic|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
1480717|NCT03114540|Drug|GBT440|Oral
2000896|NCT03321461|Drug|TMTP1|Fluorescent sites will be removed
2000897|NCT03321461|Drug|ICG|Fluorescent sites will be removed
1480720|NCT03114514|Biological|PRP|PRP will be injected subcutaneously around the eyes at three different time points with one-month interval
2000898|NCT03321448|Drug|TMTP1-ICG|Detection of SLN
1480726|NCT03114462|Radiation|Stereotactic Hypofractionated Radioablation|Starting dose is 8.0 Gy per fraction for 5 fractions (total dose = 40.0 Gy). Subsequent cohorts of participants receive an additional 0.5 Gy per fraction.
1480727|NCT03114462|Behavioral|Questionnaires|Quality of life and symptom questionnaires completed at: Baseline, on days receiving HYDRA, 6 weeks after last dose of HYDRA, 3 months after last dose of HYDRA, and 6 months after last dose of HYDRA. Also after the 6 month follow-up visit, every 3 months for the first 2 years, and then every 6 months after that for up to 5 years.
1480728|NCT03114449|Device|Auricular acupuncture|Auricular acupuncture with indwelling fixed needles at specific AA points
1480729|NCT03114449|Device|Sham auricular acupuncture|Sham auricular acupuncture (AA) with indwelling fixed needles applied at non-AA points
1480730|NCT03114436|Other|Observational Data Collection|All aspects of deceased donor care in the ICU.
1480731|NCT03114423|Other|EMDR-Therapy|The EMDR-protocol from Hase (2008) was used
1480732|NCT03114423|Other|Sham Intervention|For the training the COGPACK-program from Marker (2008) was used
1480787|NCT03113981|Device|Total Hip Arthroplasty|Implanting THA grafted with PolyNass or not
1995304|NCT02800473|Device|Strorz (commercial)|
1995305|NCT02800473|Device|CyPaM2 (experimental)|
1995306|NCT02800096|Behavioral|Gambling Internet intervention|The gambling Internet intervention consists of a new online version of self-change tools that have previously been translated successfully into an online form and shown to have a significant impact on gambling in three trials. A major focus of this intervention is to provide individuals with clear and concise behavioral and cognitive strategies for meeting the goal of reducing or quitting gambling.
1995307|NCT02800096|Behavioral|MoodGYM|Internet intervention for depression and anxiety - MoodGYM, an extensively evaluated intervention found to be effective in a variety of different settings.
1995308|NCT02798757|Drug|Dapagliflozin|Urine samples will be collected for 1HNMR spectroscopies
1995309|NCT02798289|Device|Oculeve Intranasal Neurostimulator|Neurostimulation device
1995310|NCT02797171|Biological|VRC01|Administered by intravenous (IV) infusion
1995311|NCT02797171|Biological|VRC01LS|Administered by intravenous (IV) infusion
1995312|NCT02797002|Other|Assessment|
1995313|NCT02796625|Other|Painful Stimuli|warm or painful heat administration
1995314|NCT02796001|Biological|human rhinovirus|human rhinovirus
1480733|NCT03114410|Behavioral|Re:MIX, a multi-layer comprehensive teen pregnancy prevention intervention aimed at reducing pregnancy and STIs among youth ages 13-17|Re:MIX is a comprehensive in-school health curriculum and teen pregnancy prevention program for adolescents covering a broad range of topics related to sexual health and youth development, including healthy relationships, communication, gender, consent, reproductive anatomy, contraception, sexual decision making, clinics, parenthood, and life planning. Re:MIX also aims to connect students and peer educators with community resources and service linkages. The Re:MIX curriculum teaches mixed-gender groups of students in grades 8 to 10 to delay sex and use protection if they have sex. A co-facilitation team of peer educators (who are young parents) will deliver the information with professional health educators using non-traditional approaches, such as game-based tools, technology, and storytelling. Youth receive roughly nine hours and 10 minutes of group sessions during the school day over one semester (55 minutes per week for 10 weeks).
1480734|NCT03114397|Device|transcranial direct current stimulation - active|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes.
1480735|NCT03114397|Device|transcranial direct current stimulation - sham|transcranial direct current stimulation will be applied over the left dorsolateral at 2 mA for 20minutes. The sham intervention consists of 30 seconds of stimulation at the beginning and the end of the 20minutes of intervention.
1480736|NCT03114384|Other|Creation and detection of patient-respirator asynchronies|The provocation of leaks on the Ventilation circuit and expiratory trigger modulation will generate a number of asynchronies between the subject and the respirator
1480737|NCT03114371|Drug|Oxytocin|The study drug is oxytocin in intra-nasal administration, Syntocinon®, reconditioned as a placebo-like spray. The dosage administered will be 8 International Unit, ie 1 spray (4 International Unit per spray) in each nostril per day for the first 12 weeks, in 3 and 6 years old patients. The dosage administered will be 16 International Unit or 2 sprays in each nostril per day for the first 12 weeks, in 3 to 6 years old patients.
1480738|NCT03114371|Drug|Placebo|Placebo should be used as a spray, similar to that of the oxytocin. The dosage administered will be 1 spray in each nostril per day for the first 12 weeks in 3 to 6 years old patients. The dosage administered will be 2 sprays in each nostril per day for the first 12 weeks, in 7 to 12 years old patients.
1480739|NCT03114371|Drug|Oxytocin|Each patient will receive oxytocin in open label (Syntocinon® not reconditioned) from week 13 to week 24 according to the same dosages.
1480740|NCT03114358|Other|Early Carbapenem de-escalation|The intervention group is de-escalation carbapenems early within 24 hours or no later than 72 hours of prescription by ID specialist (early de-escalation).
2000899|NCT03321448|Drug|ICG|Detection of SLN
2000900|NCT03321019|Drug|Capsaicin|Participants will inhale aerosolized capsaicin with the goal of this inducing cough and an urge-to-cough.
1480743|NCT03114332|Procedure|Subcutaneous Drain|A closed drainage system for the subcutaneous tissue was used (Redivac) through a separate stab wound. Drains were left in place for 24 h or until drainage was less than 50 ml.
1480744|NCT03114319|Drug|TNO155|TNO155 for oral administration
1480745|NCT03114306|Procedure|local infiltration analgesia|Patient receive an infiltration of local anaesthetics around the knee directly after total knee replacement for postoperative pain control.
1480746|NCT03114306|Procedure|regional-anaesthesiological catheter analgesia|Patients receive a single shot nerve block of the proximal Nervus ischiadicus and a catheter placed closed to the Nervus saphenus for perioperative pain control using ultrasound guided techniques.
1480747|NCT03114293|Behavioral|Smartphone App|The app includes an EBPI and physical activity feedback
1480748|NCT03114280|Drug|TPF2|Combination drugs : docetaxel (T), cisplatin (P), 5 Fluorouracil (F) and pembrolizumab every 21 days
1480749|NCT03114280|Other|Radiotherapy with carboplatin|Radiotherapy (RT) combined with carboplatin
1480750|NCT03114267|Other|Comparison of the prevalences of the parvovirus genome|Comparison of the prevalences of the parvovirus genome between cases and controls and then of other viruses according to the results of parvoviruses and data from the literature
1480751|NCT03114254|Drug|Cabazitaxel|"Six cycles of chemotherapy comprising:
Cabazitaxel 25mg/m2 to be repeated at intervals of 21 days."
1480752|NCT03114241|Behavioral|Intervention|Patients allocated to the intervention group receive a pedometer. They are encouraged to be more active by using the pedometer to measure the number of steps walked daily. An increase in step count of 15% compared to baseline will be set as the minimal goal for each patient. Monthly telephone calls are indicated to encourage compliance with the protocol and motivate patients to enhance their level of activity. The coached program ends after three months but patients keep their pedometer and are encouraged to sustain an increased level of daily physical activity for additional 9 months (end of study).
2000901|NCT03321019|Device|Resistive respiratory loads|Participants will breath through a mouthpiece. Every 3-5 breaths in, a respiratory load will be applied. Participants will be asked to rate the magnitude of the load.
1480754|NCT03114215|Drug|MD1003|capsules 100mg 3 times per day
1480755|NCT03114215|Drug|Placebo oral capsule|capsules 100mg lactose 3 times per day
1480756|NCT03114202|Other|intensive nutritional counseling|Individualised nutrition intervention in the form of regular and intensive nutrition counselling by a dietitian, following a predetermined standard nutrition protocol, the Medical Nutrition Therapy (Cancer/Radiation Oncology) protocol of the American Dietetic Association (ADA) every week during radiotherapy. Individually tailored sample meal plans, recipe suggestions and hints to minimise the side effects of the tumour and therapy will be provided.
1480757|NCT03114202|Other|Standard care|Nutritional counseling / education performed by hospital nurses and nutritional care performed by the hospital nutritionist.
1480758|NCT03114189|Procedure|footbath|
1480759|NCT03114189|Behavioral|care of sleep|
1481102|NCT03111641|Diagnostic Test|Lung ultrasonography|Lung ultrasound scan during preoperative anaesthesia consultation
2000902|NCT03321019|Other|Event-related evoked potential using electroencephalography (EEG).|The study team will use EEG time-locked to a respiratory occlusion to measure the brain's response to respiratory sensation.
2000903|NCT03321019|Procedure|Fluoroscopic swallow evaluation|Participants will swallow various consistencies of barium under fluoroscopy (moving-picture x-ray) in order to assess swallowing safety and efficiency.
1480760|NCT03114176|Dietary Supplement|Ketogenic Diet|Diet consisted of a very low carbohydrate ketogenic diet (for 7 days) with the use of some phytoextracts as previously described. The consumed diet was primarily made of beef and veal, poultry, fish, raw and cooked green vegetables without restrictions, cold cuts (dried beef, carpaccio and cured ham), eggs and seasoned cheese (e.g., parmesan). The allowed drinks were infused tea, moka coffee and herbal extracts. The foods and drinks that subjects had to avoid included alcohol, bread, pasta, rice, milk, yogurt, soluble tea, and barley coffee. To facilitate adherence to the nutritional regime, a variety of special meals based on protein and fibers were given to each subject. KD characteristics are protein intake 1.3g/kg/day, to maintain skeletal muscle mass; carbohydrates intake less than 40 g/day and 50-60% of total kcal to induce ketosis. In accordance with a hypocaloric profile, total energy intake was calculated with 200 kcal more than basal metabolic rate.
1480761|NCT03114163|Other|Non-Interventional|Non-Interventional
1480762|NCT03114150|Behavioral|Cardiorespiratory fitness training|Physical exercise of moderate intensity designed to improve cardiorespiratory fitness
1480763|NCT03114150|Behavioral|Functional fitness training|Physical exercise of light intensity designed to improve functional fitness
1480764|NCT03114124|Device|MIFI Catheter|Multielectrode Catheter: standard ablation catheter that has the ability to record low and high frequency signals with high fidelity
1480765|NCT03114124|Device|Standard Ablation Catheter|Standard of care for patients with certain cardiac arrhythmias.
1480766|NCT03114111|Drug|aminolevulinic acid (ALA)|
1480767|NCT03114111|Drug|Placebo|
1480768|NCT03114098|Other|gene abnormalities|A salivary sample (2 ml sample) Blood sampling will be performed to assess treatment tolerance (6 ml)
1480769|NCT03114085|Drug|Capecitabine|Capecitabine 1000mg/m2 po bid, d1-d14, every 21 days for a cycle;
1480770|NCT03114085|Drug|Apatinib|Apatinib 500 mg po qd, d1-d21, every 21 days for one cycle
1480771|NCT03114072|Device|Blue-blocking glasses|Wear the BB-glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
1480772|NCT03114072|Device|Light grey control glasses|Wear the light grey glasses from three hours before bedtime, and if needed to turn on the light, also during the night.
1480773|NCT03114059|Diagnostic Test|Glaucoma diagnostics|Heidelberg, Retinal Topography, Visual field, intraocular pressure, medication anamnesis, Retinal Nerve Fibre Layer Thickness, Pachymetry, Sonography, full ophthalmological determination
1480774|NCT03114046|Behavioral|Lower extremity Constraint-induced movement therapy(LE-CIMT)|"Both phases (A and B) will last 10 weekdays, and during baseline and treatment phases, the data will be collected on 5 different odd days. Considering the long period of data collection. During the baseline phase, no assessment will be administered on even days. The treatment will be delivered daily, along 10 weekdays, 3.5 hours per day. The motor training will be delivered during 3 hours and 30 minutes will be allocated to the administration of the TP.
Both caregivers and participants will be individually interviewed before and after treatment."
1480775|NCT03114033|Other|Targeted therapeutic mild hypercapnia|Patients allocated to the TTMH protocol will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of -4). Arterial blood gases and end- tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 50-55 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change >5 mmHg
1480776|NCT03114033|Other|Targeted normocapnia (Standard care)|Patients allocated to the standard care (TN) protocol will be managed according to current practice and in accordance with ILCOR guidelines which recommend maintaining normocapnia in these patients. They will be sedated to achieve moderate to deep sedation (a target Richmond Agitation Scale Score of - 4). Arterial blood gases and end-tidal carbon dioxide levels will be measured at baseline and then used to guide respiratory rate adjustments of minute ventilation to remain within the target PaCO2 range of 35-45 mmHg. Arterial blood gases will be repeated every 4 hours for 24 hours following randomisation or if end-tidal carbon dioxide values change >5 mmHg.
1480777|NCT03114020|Drug|Hyaluronic Acid Inhalation Solution|twice a day 3 mL of 0.03% Hyaluronic Acid Inhalation Solution
1480778|NCT03114020|Drug|Placebo Inhalation Solution|Twice a day 3 ml of placebo inhalation solution
1480779|NCT03114007|Behavioral|Preventure program|Personality-targeted interventions conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural components. They include real life 'scenarios' shared by local youth with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
1480780|NCT03114007|Behavioral|Equipe program|"Parent training program designed to be delivered in community settings accessible to large groups of parents of 13 to 18 year olds. It uses a coping modeling problem solving process in which parents are the key players in developing problem solving strategies.
Parents participate in group workshops with themes related to communication, conflict resolution, cooperative transitions, negotiating, house rules, monitoring, consequences for serious problems and problem solving. Parents are guides to establish solutions to common problems. Readings and videotapes are used in the workshops to guide parents in identifying common challenges in child management, parenting errors, discussing possible consequences and alternative strategies as well as rationales supporting these strategies."
1480781|NCT03114007|Behavioral|Inter-Action services|An intervention model designed to provide integrated services for youth with significant symptoms of mental health problems, substance misuse and/or psychosocial difficulties. Young people with such difficulties will benefit from stepped and collaborative care involving interventions of varied intensity adapted to their needs and the severity of their problems. These will include cognitive behavioral therapy, motivational interviews, dialectic behavioral therapy and family interventions provided by multidisciplinary teams of professionals. A case navigator will be in charge of initiating service provision and ensuring a fast and smooth flow of information between indicated services providers.
2000904|NCT03320993|Other|Mixed meal with different macronutrient composition|A mixed meal with identical amount of carbohydrates but different content of protein, fat and alcohol will be given
1585448|NCT02343536|Drug|Vincristine|
1480788|NCT03113968|Procedure|electroconvulsive therapy (ECT)|ECT is a procedure done under general anesthesia where small electric currents are passed through the brain, intentionally triggering a brief seizure. Patients who have not responded to antidepressant medications may be candidates for ECT. ECT is FDA approved for treatment resistant depression.
1480789|NCT03113968|Drug|Ketamine|Ketamine is a medication that is used as a short acting anesthetic in pediatric and adult medicine. Subanesthetic (low) doses will be given to patients via infusion in order to assess whether it helps with depression symptoms in patients who have not responded to antidepressant therapy. Ketamine is not FDA approved for this indication and its effectiveness in treatment resistant depression has not been proven. Prior studies have indicated that subanesthetic doses of ketamine may be helpful for treatment resistant depression.
1480790|NCT03113955|Device|Tandem Microsphere loaded with Epirubicin|The primary objective of this study is to evaluate the safety and efficacy of transcatheter arterial chemoembolization with Tandem Microspheres loaded with Epirubicin in the treatment of patients with localized hepatocellular carcinoma (HCC)
1480791|NCT03113942|Drug|Pomalidomide 2 MG Oral Capsule [Pomalyst]|Pomalidomide is an oral immunomodulatory derivative of thalidomide. Thalidomide and its derivatives are small molecules with broad effects on immune activation, including T-cell activation and responsiveness. Pomalidomide augments T cell responsiveness and proliferation by several mechanisms, many mediated by transcriptional regulation downstream of its primary target, cereblon. Effects include increased production of IL-2 and interferon-γ (IFN-γ), enhanced CD4+ and CD8+ T cell co-stimulation.
1480792|NCT03113929|Radiation|MRI|Research MRI
1480793|NCT03113916|Behavioral|Behavioural Lifestyle Intervention|A culturally tailored behavioral intervention.
1480794|NCT03113903|Behavioral|Psychophysical exploration|Psychophysical exploration (multimodal sensitivity, including pain sensitivity) Electronic von Frey applied on forearm; thermal heat applied on forearm; foot immersion in 2°C cold water; exposure to a one-frequency noise up to uncomfortable loudness ; exposure to a halogen-lamp-generated light up to uncomfortable brightness.
1480795|NCT03113890|Genetic|Phlebotomy - Folate|This will be a blood draw performed at Visit 1 for Folate (one 7mL tube)
1480796|NCT03113890|Genetic|Cheek Swab|Participants will undergo a cheek swab to then be analyzed using the Genecept Assay created by Genomind, Inc. This will occur once during Visit 1.
1480797|NCT03113890|Other|Self-report surveys|At visit 1 and at visit 3 and 4, participants will be asked to complete self report diagnostic surveys and surveys related to the objective aims of the study.
1480798|NCT03113877|Other|Autonomic Dysfunction Testing|The participants with CdLS will complete the COMPASS-31 survey and will complete standard clinical testing for autonomic dysfunction including an autonomic reflex screen (tilt table and quantitative sudomotor axon reflex testing) and thermoregulatory sweat test (TST).
1480799|NCT03113864|Dietary Supplement|Placebo|Daily supplementation for 9 months
1480800|NCT03113864|Dietary Supplement|Lutein|Daily Supplementation for 9 months
1480801|NCT03113851|Radiation|Radiotherapy|One lesion received radiotherapy for 35 Gy in 10 fractions and rested for one week; then another metastatic lesion were treated with radiotherapy for 35 Gy in 10 fractions.
1480802|NCT03113851|Drug|rhGM-CSF|Patients were injected subcutaneously rhGM-CSF 125mg/m2 per day from day1 to day 14, every three weeks, concurrent with radiotherapy
1480803|NCT03113825|Device|Investigational Imaging device|Fluorescence imaging of the of the primary tumor specimen, any secondary breast specimens, and lymph nodes will be performed.
1480804|NCT03113825|Drug|AVB-620|AVB-620 will be administered IV before the surgical procedure.
1480805|NCT03113812|Drug|ABvac40|
1480806|NCT03113812|Drug|Placebo|
1480807|NCT03113799|Device|Smart External Drain - SED|Subject will be treated on Day 2 with the SED. ICP and CSF volumes will be recorded at prespecified intervals while subject is stationary and while subject is engaged in protocol-driven directed movements.
1480808|NCT03113786|Biological|CLARIX™100|CLARIX™100 is Amniox's processed and cryopreserved human amniotic membrane tissue retrieved from donated placental tissue after elective Cesarean Section delivery. Amniox's Amniotic Membrane is designated by the FDA as a tissue product under PHS 361 HCT/P (human cells, tissues and cellular and tissue-based products).
1480809|NCT03113786|Biological|CLARIX CORD 1K|CLARIX CORD 1K is made from cryopreserved human umbilical cord, utilizing the patented CRYOTEK™ process. CLARIX CORD 1K is considered a Human Cells, Tissues & Cellular and Tissue-based product (HCT/P) by U.S. FDA standards.
1480810|NCT03113773|Drug|Proleukin|Patients will be treated with subcutaneous injections of IL-2 (range 0.3 X 10^6 - 3.0 X 10^6 IU) or placebo once daily for five consecutive days during the trial.A maximum dose of 3.0 X 10^6 IU will be allowed per day.
1480811|NCT03113773|Drug|Placebo Injection|Dextrose 5%
1480812|NCT03113760|Drug|Tadekinig alfa|Tadekinig alfa is a soluble glycoprotein of 164 amino acids produced from Chinese Hamster Ovary cell line. Tadekinig alfa is supplied as a colorless to slightly yellow, sterile solution for injection in glass vials containing sodium chloride, and 0.02M sodium phosphate buffer as excipients. It is available in a concentration of 20mg/0.5mL.
1480813|NCT03113760|Drug|Placebo|To ensure that the treatment remains blinded for the entire study period, the placebo solutions will be supplied in identical vials and similar labelling as the active drug and will be indistinguishable in terms of their texture, color, and smell.
1480814|NCT03113747|Biological|ALLO-ASCs|1). Cryopreserved cell suspension of early passages of cultured allogeneic MSCs isolated from SVF obtained from lipoaspirate, a total of 10 mln. of cultured cells; 2).The TE-construct consisting of collagen- or fibrin-derived hydrogels and cells of early passages (up to P5) suspension of allogeneic cultured MSCs isolated from SVF obtained from lipoaspirate; Biological is applied by surface application over perforated (1:3) autologous skin graft following the covering with hypoadhesive bandage. This procedure is carried out twice - once simultaneously with a skin grafting procedure and 2-3 days following autodermoplasty, while bandaging.
1480885|NCT03113214|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
1480886|NCT03113201|Behavioral|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation and medication according to a stepped care model
1995315|NCT02796339|Dietary Supplement|Mastiha|
1585449|NCT02343536|Drug|Prednisone|
1995316|NCT02796339|Dietary Supplement|Placebo|
1480815|NCT03113734|Other|Construction and validation of a functional score|"All patients will be treated at the same way:
Completion of questionnaire by the physician with him. Once the consultation has been completed, the physician will issue prescriptions for the usual medical treatment, laximetry prescription (GNRB) to be performed when the knee is indolent and the prescription of the MRI to be performed .The physician will inform the patient that they should consult with the investigator's orthopedic surgeon once the results of GNRB and MRI are available.The study will end there for the patient. The surgeon will then follow his usual diagnostic procedure to decide on the future care of the patient."
1480816|NCT03113708|Drug|Heparin Sodium|Heparinisation 2-4 mg/kg will be done according to actual body weight or lean body weight.
1480818|NCT03113682|Behavioral|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
1480819|NCT03113669|Behavioral|CBT-GSH|
1480820|NCT03113656|Other|Weighted Blanket|Weighted blanket placed on infant for 30 minutes
1480821|NCT03113656|Other|Non-Weighted Blanket|Non-Weighted blanket placed on infant for 30 minutes
1480822|NCT03113643|Drug|Azacitidine|Chemotherapy
1480823|NCT03113643|Drug|SL-401|SL-401 works by targeting leukemia cells (blasts), and also possibly by stopping or slowing the growth of cancer stem cells, which are the undeveloped cells which can develop into cancer cells.
1480824|NCT03113630|Device|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
1480825|NCT03113630|Device|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
1480826|NCT03113630|Device|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
1480827|NCT03113630|Device|Acquisition on TouchScreen Control Group|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
1480828|NCT03113630|Device|Acquisition on Kinect Control Group|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
1480829|NCT03113630|Device|Acquisition on LeapMotion Control Group|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
1480830|NCT03113617|Procedure|Computed Tomography|Undergo PET/CT
1480831|NCT03113617|Drug|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Given IV
1480832|NCT03113617|Other|Laboratory Biomarker Analysis|Correlative studies
1480833|NCT03113617|Procedure|Positron Emission Tomography|Undergo PET/CT
1480834|NCT03113604|Other|Study on samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma|"Retrospective study of samples of tumor and peri-tumor tissues from patients with hepatocellular carcinoma (HCC): three groups of samples will be selected:
Group 1: Tumor and peri-tumor tissue samples from patients with non-treated sorafenib CHC (surgical resection or other) Group 2: Tumor and peri-tumor tissue samples from tumor and peritumor tissues of patients not responding to sorafenib treatment Group 3: samples from patients responding to treatment with sorafenib"
1480835|NCT03113591|Procedure|Minimum invasive total hip arthroplasty|Minimum invasive total hip arthroplasty using the osteo introducer system
1480836|NCT03113591|Procedure|Common total hip arthroplasty|Common total hip arthroplasty using common instruments
1480837|NCT03113578|Device|DiLumen|The study device is placed over a compatible endoscope to facilitate endoscopic diagnosis and treatment of any large intestine pathology with the use of double balloons
1480838|NCT03113565|Behavioral|Count daily number of footsteps.|Using a connected electronic wristband to mainly quantify daily number of footsteps.
1480839|NCT03113539|Other|Modified Low-dose, EKG-gated CT without contrast for the evaluation of aortic aneurysm|"On the same day, the subject will do :
Modified low-dose, EKG-gated CT without contrast
Usual high-dose, EKG-gated CT with contrast
Comparing aortic diameters from the two protocols."
1480840|NCT03113526|Procedure|remove drain|remove drain when output is less than 30ml or less than 100ml per 24-hour
1480841|NCT03113513|Procedure|fixation of the vaginal apex|In the course of vaginal hysterectomy the vaginal cuff is either fixed to the sacrospinous ligament or to the uterosacral ligament.
1480848|NCT03113487|Other|Laboratory Biomarker Analysis|Correlative studies
1480849|NCT03113487|Biological|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
1480850|NCT03113487|Biological|Pembrolizumab|Given IV
1480851|NCT03113474|Other|Food palatability|Food palatability is modulated
1480853|NCT03113448|Drug|0.075% Capsaicin Lotion|To apply 3-4 times per day, every day until 8 weeks then stop
1480854|NCT03113448|Drug|placebo|To apply 3-4 times per day, every day until 8 weeks then stop
1480855|NCT03113435|Other|Oxygen consumption optimization|hemodynamic stability will be achieved through exploration of oxygen consumption need of the patient based on CO2gap/CaO2-CvO2 ratio
1480887|NCT03113201|Behavioral|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
1480889|NCT03113175|Behavioral|Collaborative care|Collaborative care provided by the general practitioner and the care manager. Treatment modalities: Cognitive-behavior Therapy, psychoeducation, medication according to a stepped care model
1995320|NCT02796573|Behavioral|cognitive behavioural therapy|
1995323|NCT02793037|Device|Zirconia resin bonded bridge|
1480856|NCT03113422|Drug|Induction Venetoclax|"1 cycle = 28 days. Venetoclax 800 mg by mouth daily on Days 1-14 of each cycle. On Cycle 1, some patients may start venetoclax on Day 8. After reviewing scans and laboratory results, the study doctor will decide if venetoclax should start on Cycle 1 Day 1 or Cycle 1 Day 8. The first dose of venetoclax may require hospital admission to monitor for tumor lysis syndrome.
Obinutuzumab IV after venetoclax. Cycle 1, Day 1 obinutuzumab 100 mg and Cycle 1, Day 2 obinutuzumab 900 mg for total dose of 1000 mg. On Cycle 1, Day 8 and Day 15 obinutuzumab 1000 mg. Starting with Cycle 2, obinutuzumab 1000 mg on Day 1 only of each cycle.
Bendamustine 90 mg/m² IV on Days 1 and 2 of each cycle over 15 minutes after obinutuzumab."
1480857|NCT03113422|Drug|Maintenance Venetoclax|Patients whose disease is the same or improved will receive venetoclax 800 mg by mouth daily and obinutuzumab 1000 mg IV every 2 months for 2 years. Patients with no evidence of disease will receive obinutuzumab 1000 mg every 2 months for 2 years
1480858|NCT03113409|Drug|Buprenorphine|Buprenorphine will be administered daily
1480859|NCT03113409|Drug|Naltrexone|On study day 2, participants will receive increasing doses of oral naltrexone prior to administration of XR-NTX
1480860|NCT03113409|Drug|Vivitrol|Participants will receive one 380 i.m. injection on Study day 5 or 10, and another injection 4 weeks later.
1480861|NCT03113396|Drug|Baclofen|baclofen oral, 10mg, tid for 2 weeks (or placebo, identically looking capsules) after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
1480862|NCT03113396|Drug|Placebo oral capsule|placebo oral, tid for 2 weeks after 2 weeks, patients undergo a High Resolution Impedance Manometry measurement with a meal period. Patients will fill out questionnaires concerning overall wellbeing.
1480863|NCT03113383|Device|Thoracoabdominal Aortic Aneurysm Repair|Thoracoabdominal aortic aneurysm repair
1480864|NCT03113370|Dietary Supplement|Fish Oil|Fish Oil capsules
1480865|NCT03113370|Dietary Supplement|Placebo|Olive Oil
1480866|NCT03113357|Other|Myofascial release technique|myofascial release technique take along about 3 minutes. This phase repeated 3 times in each session. At the end, for more release, sub-occipital traction will commence. The subject lies supine with head supported and therapist places the three middle fingers just caudal to the nuchal line, lifts the finger tips upward resting the hands on the treatment table, and then applies a gentle cranial pull, causing a long axis extension. The procedure is performed for 2 to 3 minutes. Subjects in each group received ten physical therapy treatment sessions. Treatment frequency was six times per week for MFR group and every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist
1480867|NCT03113357|Other|conventional exercise therapy|"All exercises were performed to a count of 7 seconds and subjects were instructed to perform all exercises daily, 15 repetitions each (twice a day). Treatment frequency was every day for exercise group which three times per week have been come to clinical center for checking of exercise by physiotherapist. They also could be taught active muscle stretching exercises to address any muscle tightness assessed to be present."
1480868|NCT03113344|Drug|cephalosporins,penicillins,macrolides and carbapenems|According to the models of population pharmacokinetics,the investigators and want to correlate use of antibiotics with treatment effectiveness and safety in neonates.
1480869|NCT03113318|Procedure|Total mediastinal lymph node dissection and pulmonary metastasectomy|Total mediastinal lymph node dissection where all lymph nodes and fatty tissues is removed conjunction with pulmonary metastasectomy
1480870|NCT03113318|Procedure|Only pulmonary metastasectomy|
1480871|NCT03113292|Other|Pilates|The protocol will be composed by the following exercises, structured in each session according to progression, difficulty and focus (respiration, stability, muscle strength and joint mobility): Arm Arcs, Bent Knee Opening, Sidelying, Dead Bug, Femur Arcs, Quadruped Series, Single Leg Stretch, Prone Press Up, Sidekick (Front to Back 1 e 2), Leg Pull Front, Mermaid, Spine Stretch, The Hundred, Pelvic Clock, Bridging, Stanging Roll Down, Swan, Saw, Dart, Swimming, Book Opening.
1480872|NCT03113292|Other|Home Exercises|The protocol will be divided into 3 phases, each one composed by the following exercises and structured according to difficulty progression and focus (postural reeducation, muscle strength, balance, joint flexibility): Muscle strength exercises composed by abdominal exercises; back extension exercises; gluteus maximus exercises. Stretching exercises for the lower back, pelvis, iliopsoas muscle, tensor fascia latae muscle).
1480874|NCT03113253|Drug|Tranexamic Acid|
1480875|NCT03113253|Drug|Placebo|0.9% sodium chloride to mimic tranexamic acid
1480876|NCT03113240|Drug|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs.
1480877|NCT03113240|Other|Maltodextrin|Maltodextrin mixed with water given via NG tube q 4 hours.
1480878|NCT03113227|Diagnostic Test|Transvaginal ultrasound|Transvaginal ultrasound will be made for assessment of posterior cervical angle and cervical length
1480879|NCT03113227|Diagnostic Test|Vaginal examination|Vaginal examination will be done for assessment of Bishop score
1480880|NCT03113214|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
1480881|NCT03113214|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
1480882|NCT03113214|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
1480883|NCT03113214|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
1480884|NCT03113214|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid to residual tumor volume as defined by PET/CT;
1480890|NCT03113175|Behavioral|Consultations-Liaison|Consultation-Liaison provided by general practitioner involving a educational relationship with the Collabri Flex team (care manager and psychiatrist).
1480891|NCT03113162|Biological|Autologous Hematopoietic Stem Cell|
1480892|NCT03113162|Drug|BEAM Regimen|Reduced-intensity BEAM for Immunoablation
1480893|NCT03113136|Behavioral|Low wattage E cigarette device|The low wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
1480894|NCT03113136|Behavioral|HIgh wattage E cigarette device|The high wattage E cigarette device will be provided to the participant and they will be instructed to vape ad libitum for 12 weeks and then be assessed at 6 months and 12 months for continued use of device.
1480895|NCT03113136|Behavioral|Usual brand cigarette|The usual brand of cigarettes will be provided to the participant and they will be instructed to smoke ad libitum for the duration of the study.
1480896|NCT03113123|Drug|PrEP with Truvada®|"Associated with:
STD screening/treatment for syphilis, gonorrhoea and chlamydiae
HIV screening/therapy
Questionnaire
Addiction, social or psychological follow-up care if needed
Peer interactive counselling (peer counselors/nurses/physicians experienced with therapeutic education) at the baseline visit and at every follow-up visit up to 6 months. After 6 months, counselling will be provided at the request of participants if they need it. Counselors will remain in contact with the participants between visit to answer any questions relative to PrEP, treatment and prevention, and to facilitate participants interactions with study sites."
1480897|NCT03113110|Drug|Empagliflozin 10 mg|PTDM patients on previous antidiabetic treatment (<40 IU insulin (in some cases plus oral antidiabetics)) receive Empagliflozin, ideally as monotherapy
1480898|NCT03113097|Other|Embryo transfer|Transfer of different qualities of embryos at blastocyst stage
1480899|NCT03113084|Biological|Sodium Heparin UQ subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin UQ experimental medication or Sodium heparin FK comparator medication. They will receive the Subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
1480900|NCT03113084|Biological|Sodium Heparin FK subcutaneous drug administration|The participants will be hospitalized one day to receive the Sodium heparin FK comparator medication or Sodium heparin UQ experimental medication. They will receive the subcutaneous medication and start the blood collection at the programmed time. After 7 days, the participants will return to receive the other medication and have their blood collected. The last visit will be to collect safety datas
1480901|NCT03113071|Drug|Decitabine|Decitabine will be administered in combination with Digoxin
1480902|NCT03113071|Drug|Digoxin|Decitabine will be administered in combination with Digoxin
1480903|NCT03113058|Combination Product|Adoptive transfer of γδT cells|Patients are treated via intravenous infusion of in vitro-activated allogeneic γδ Tcells every two weeks, 12 times in total (6 months).
1480904|NCT03113045|Other|seated time|Pt will be seated for a predetermined time period. All Patients will receive intrathecal bupivacaine and morphine.
1480905|NCT03113032|Other|P-SEC Pre-Surgical Care|The P-SEC protocol is designed to deliver a focal mode of exercise-conditioning for motor performance to the knee extensor musculature. The latter requires a brief, machine-based gravity-resisted joint' movements (<2 seconds). An exercise session (6-minutes, approximately) will require a patient to undertake 4 sets of movement, with sets separated by 60-seconds recovery (delivering a total of 36 exercises across 3 interspersed days).
1480906|NCT03113032|Other|Normal pre-surgical care|Routine pre-surgical care
1480907|NCT03113019|Biological|Immunotherapy based on dendritic cells|Intravenous injection of cells
1480908|NCT03113006|Procedure|Panretinal Photocoagulation|Panretinal laser treatment of the retina in patients with proliferative diabetic retinopathy.
1480909|NCT03112993|Drug|sugammadex|once at the end of the surgery
1480910|NCT03112993|Drug|Neostigmine|once at the end of the surgery
1480913|NCT03112967|Other|low-volume preparation, oral sulfate solution|Oral Sulfate solution (Suprep) in day before and split-dose regimens In the OSS arm: between 17:00 and 18:00 hours on the day before colonoscopy, subjects were instructed to pour one 180-ml bottle of the study medication into a provided 480-ml mixing cup and fill it with water and then drink the entire volume, followed by two additional 480 ml of water. At approximately 6:00 a.m. on the following morning, the subjects took the second dose of OSS by same formulation protocol.
1480914|NCT03112967|Other|large-volume preparation, 4L polyethylene glycol|4L PEG solution in day before and split-dose regimens In the 4L PEG arm: subjects had the first 2L between 18:00 and 19:00 hours (250mL every 15 minutes) in the evening before the colonoscopy. And the second 2L was given between 07:00 and 08:00 on the day of colonoscopy.
1480915|NCT03112954|Drug|Buccal-relaxant formula|Following physical examinations, 60 patients were randomly allocated to 2 groups of 30 patients each, who had been diagnosed with sleep bruxism. Each patient received a small amber glass bottle containing the floral remedy and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group F, the group of patients who received the floral remedy.
1480916|NCT03112954|Drug|Placebo|30 patients diagnosed with sleep bruxism received a small amber glass bottle containing the saline solution and was instructed to use four drops sublingually 4 times a day for 22 days. All examiners were different professionals, with no contact among each other, as follows: an examiner who conducted the physical examination, an examiner who randomly divided the patients, and an examiner who prepared the floral and placebo remedies. At the end of the study, each group of 30 patients was re-named: Group P, the group of patients who received the placebo.
1480917|NCT03112941|Procedure|control group|Patients with traumatic incomplete spinal cord injury (SCI) in the control group are treated with pedicle screw fixation and decompressive laminectomy.
1481140|NCT03111290|Device|Direct Cortical Stimulation|A train of periodic electrical pulses is delivered between two local electrodes implanted in the brain
1480918|NCT03112941|Other|hyperbaric oxygen group|Patients with traumatic incomplete spinal cord injury (SCI) in the hyperbaric oxygen group are treated with pedicle screw fixation and decompressive laminectomy, and are given 0.2 MPa hyperbaric oxygen (HBO), once a day, 10 times as a course, with 5-7 days of resting between two courses, totally four courses.
1480919|NCT03112928|Device|Phantom Motor Execution|"Neuromotus - PME decodes motor volition applying machine learning to surface electromyography. Once the intention of movement is known, this is use to control serious games in virtual and augmented reality.
A treatment session of MPE consists of:
Pain evaluation
Placement of the electrodes and fiducial marker
Practice of motor execution in Augmented Reality (AR)
Gaming using phantom movements
Practice of motor execution by matching random target postures of a virtual limb.
Step 3 to 4 are repeated for different phantom joints, initially one at the time progressing to several joints simultaneously. A treatment session last 2 hours."
1480920|NCT03112928|Device|Phantom Motor Imagery|The only difference between PME and PMI is that in the former myoelectric signals are used to give the participants control over the virtual environments, whereas in PMI the presence of myoelectric activity is used as an alarm to remind the participant that it must imagine rather than execute the phantom movement. In PMI the virtual environments act autonomously to guide the participant in imagination of movement.
1480921|NCT03112915|Procedure|quadratus lumborum block|QLB: Quadratus lumborum block : 20 mL of 0.25% bupivacaine will be administered between the quadratus lumborum and the psoas major muscle bilaterally in the lateral decubitus position
1480922|NCT03112915|Procedure|Transversus abdominis plan block|TAP: transversus abdominis plan block: 20 mL of 0.25% bupivacaine will be administered between the internal oblique muscle and the transversus abdominis muscle bilaterally in the supine position
2000905|NCT03320954|Behavioral|Anomia treatment|Phase II participants will attend two-hour, group intervention sessions one day per week for eight weeks. Participants will engage in multiple word game activities throughout each intervention session. Games will include Facts in Five, Anomia, Boggle, and Bananagrams as well as variations on these, as appropriate.
1480925|NCT03112876|Other|Skin Surface Lipid Collection and Skin Barrier Function|All five groups will undergo the same study intervention: skin surface lipid collection via tapes and skin barrier function evaluated with non-invasive painless devices.
1480926|NCT03112863|Drug|Bakuchiol|This group will receive bakuchiol
1480927|NCT03112863|Drug|Retinol|This group will receive retinol
1480928|NCT03112850|Device|Hearing aid|LOF hearing aid
1480929|NCT03112850|Behavioral|Auditory Training|
1480930|NCT03112837|Other|Lactobacillus, Bifidobacterium and Enterococcus|3 pills two times a day during the whole treatment
1480931|NCT03112824|Drug|Ashwagandha Root Extract Capsule|Participants will take one 300 mg capsule of Ashwagandaha Root Extract orally twice a day for 12 weeks.
1480932|NCT03112824|Drug|Placebo Capsule|Participants will take one placebo capsule orally twice a day for 12 weeks.
1480933|NCT03112811|Device|Autogenic drainage|The manual technique of the chest physiotherapy to move the secretions
1480934|NCT03112811|Device|Intrapulmonary percussive ventilation|The instrumental technique of the chest physiotherapy to move the secretions
1480935|NCT03112785|Device|Total hip arthroplasty (Fitmore or CLS uncemented femoral stem made by Zimmer-Biomet, Warshaw, USA)|The most symptomatic side is randomised to one of the two stem types studied. If the patient has equal amount of symptoms on both sides, the one with most pronounced degenerative Changes on plain radiographs will be randomised. On the second side the type of stem not used on the first one will be inserted. All patients and allhip will receive the same type and design of cup.
1480936|NCT03112772|Other|Puros® Allograft|It is a type of bone grafting materials used for enhancing bone formation
1480937|NCT03112772|Other|CopiOs® Cancellous Particulate|It is a type of bone grafting materials used for enhancing bone formation
1480938|NCT03112759|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy (CBT) uses pain coping skills as a method of managing symptoms associated with chronic pain.Cognitive behavioral therapy teaches patients to identify and modify negative thoughts and behaviors that increase pain intensity, distress, and pain-related disability
1480939|NCT03112746|Behavioral|Cognitive Orientation to Daily Occupational Performance|In CO-OP Approach, therapists use mediational techniques to teach cognitive strategies - GOAL, PLAN, DO, CHECK - to improve occupational performance in goals chosen by the children in collaboration with them and their parents.
1480940|NCT03112733|Diagnostic Test|TFF3, SFRP4, Romo1, NFKB|Blood samples of all participants will be collected.
1480941|NCT03112720|Device|Epidural Blood Patch|A device: 17 gauge Touhy needle will be placed to the epidural space using the loss of resistance technique. Once positioned a sterile stylet will be replaced within the needle to maintain the sterility of the epidural space. A tourniquet may be used to identify a peripheral venous site, which will be sterilely prepped with betadine x3 and then chloroprep. Venipuncture will be performed with a device: 20gauge or larger needle. 20mL of blood will be aspirated in a sterile system into an appropriately sized syringe. After sterile transfer, this autologous blood will be slowly injected into the epidural space.
1480942|NCT03112720|Drug|Sphenopalatine Ganglion Block|The drug: 5% lidocaine ointment, a local anesthetic, will be applied to the end of a device: long channeled cotton tipped applicator inserted into both nares and placed over the mucosa in the area of posterior aspect of the middle ethmoid, toward the presumed anatomic location of the sphenopalatine ganglion, evidenced by a slight resistance at the appropriate depth. 5mL of drug: 1% lidocaine solution will then be injected into the hollow shaft of the device: applicator and allowed to topically anesthetize the ganglion by gravity flow for 30 minutes.
1480943|NCT03112707|Drug|Aspirin|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
1480977|NCT03112551|Drug|Adminstration of magnesium Sulphate for treatment of eclampsia|A total of 100 eclamptic patients are suspected to be approached alternately and subcategorized into two groups - one group will be treated with 24 hours maintenance dose of magnesium sulphate (Group-1; n=50), and the other with 12 hours maintenance dose of magnesium sulphate (Group-2; n=50).
1480944|NCT03112707|Drug|P2Y12 inhibitor|After percutaneous coronary intervention with bioresorbable polymer-coated everolimus-eluting Synergy® stent implantation, dual antiplatelet therapy with aspirin 100 mg od and a P2Y12 inhibitor will be continued for a duration of 1 month, after which single antiplatelet therapy with aspirin will be recommended indefinitely. In case of need for oral anticoagulation, patients will receive an oral anticoagulant in addition to a P2Y12 inhibitor without aspirin for 30 days.
1480945|NCT03112694|Other|Data collection|This is a non-interventional study, the decision to prescribe the product would have been taken prior to, and independently from the decision to enrol the patient.
1480946|NCT03112681|Drug|Saroglitazar magnesium 2 mg|Saroglitazar magnesium 2 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
1480947|NCT03112681|Drug|Saroglitazar magnesium 4 mg|Saroglitazar magnesium 4 mg once daily in the morning before breakfast without food, for a period of 16 weeks.
1480948|NCT03112681|Drug|Placebo Oral Tablet|Placebo once daily in the morning before breakfast without food, for a period of 16 weeks.
1480949|NCT03112668|Behavioral|Cognitive Behavior Therapy|Undergo ACT
1480950|NCT03112668|Other|Quality-of-Life Assessment|Ancillary studies
1480951|NCT03112668|Other|Questionnaire Administration|Ancillary studies
1480952|NCT03112668|Other|Survey Administration|Ancillary studies
1480953|NCT03112655|Diagnostic Test|RNA and neopterin detection|Detection of spliced leader RNA will be performed on blood and cerebrospinal fluid taken before treatment, 11 days after treatment, 6, 12 and 18 months after treatment. Neopterin will be quantified in cerebrospinal fluid taken at the same time points.
1480954|NCT03112642|Procedure|Local anesthetic block [0.35% marcaine]|In the absence of paresthesia and after negative aspiration, the 40 ml of local anesthetic block [0.35% marcaine] will be administered.
1480955|NCT03112642|Device|Braun DIG-R-C Stimuplex Blockade Monitor System|The blockade system will be initially set at 1 milliamp. As the proximity of the tip of the needle to the components of the brachial plexus becomes evident by ultrasound approximation and the stimulation pattern of the hand and wrist, the output of the system will be reduced to .3-.5 milliamps. With use of the Braun DIG-R-C Stimuplex Blockade Monitor System.
1480956|NCT03112616|Other|Vibration sessions|The patients will undergo a program of 10 sessions of vibrations of the neck muscle, each of 10 minutes, during a period of 15 days at the rate of one session per day.
1480957|NCT03112603|Drug|Ruxolitinib|Ruxolitinib twice daily at the protocol-defined starting dose.
1480958|NCT03112603|Drug|Extracorporeal photopheresis (ECP)|Best available therapy (BAT) will be selected by the investigator for each participant. BAT may not include experimental agents (ie, those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements. The BAT in this study will be among the following treatments currently used in this setting (no other types or combinations of BATs are permitted in this study).
1480959|NCT03112603|Drug|Low-dose methotrexate (MTX)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
1480960|NCT03112603|Drug|Mycophenolate mofetil (MMF)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
1480961|NCT03112603|Drug|mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus)|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
1480962|NCT03112603|Drug|Infliximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
1480963|NCT03112603|Drug|Rituximab|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
1480964|NCT03112603|Drug|Pentostatin|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
1480965|NCT03112603|Drug|Imatinib|Patients will receive BAT based on the Investigator's opinion, taking into account the manufacturer's instructions, labeling, subject's medical condition, and institutional guidelines for any dose adjustment.
2000906|NCT03320694|Drug|Metformin|metformin 500mg twice daily & increased until 2500mg till normoglycemia was achieved and was continued till delivery
2000907|NCT03320694|Drug|Insulin|The insulin group was given 3 S/C injections of regular insulin & one intermediate acting injection at night till normoglycemia was achieved and was continued till delivery
1480971|NCT03112577|Drug|REGN3500|
1480972|NCT03112577|Drug|Dupilumab|
1480973|NCT03112577|Drug|Placebo|
1480974|NCT03112577|Drug|Fluticasone propionate|
1480975|NCT03112564|Other|Avoidance of rocuronium/cisatracurium|Anesthesia induction was performed at tidal volume, avoiding the use of analgesics and/or muscle relaxants with FGF of 6 L/min. Induction time was shortened as the FGF was increased. Once 5% sevoflurane end-tidal volume was reached, ventilation with facial mask was maintained for three more minutes. The time lapsed until the loss of blink reflex was achieved and orotracheal tube (OTT) was placed, difficulties in OTT placement, sevoflurane end-tidal volume after OTT placement, complications related to OTT insertion (movement, coughing, rigidity, apnea), mean arterial pressure (MAP) variations were measured. No muscle relaxants were given during surgery.
1480976|NCT03112564|Drug|Sevoflurane 8% + Intravenous fentanyl|Sevoflurane 8% + Intravenous fentanyl was the regimen used for induction and maintenance of anesthesia
1480978|NCT03112538|Device|Insulin Pump|Medtronic Minimed Paradigm Veo Insulin Pump
1480979|NCT03112538|Drug|Multiple daily injections of insulin|Multiple daily injections which consist of a single injection of basal insulin(insulin Glargine) and 3 injections of bolus insulin(rapid acting insulin Glulisine or Aspart) before each meal
1480980|NCT03112525|Diagnostic Test|CYP3A4/5 and P-gp phenotyping|Phenotyping using a simplified version of the Geneva cocktail
1480981|NCT03112525|Genetic|CYP3A4/5 and P-gp genotyping|Selected CYP3A4, CYP3A5, CYP3A7 and ABCB1 single nucleotide polymorphism (SNP) determination
1480982|NCT03112512|Device|optimal PEEP guided by EIT|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
1480983|NCT03112512|Device|optimal PEEP guided by G5 ventilator|Patients are randomly assigned to EIT group or G5 group. PEEP selected in EIT group is based on GI index and regional compliance. PEEP decided in G5 group is based on the ventilator.
1480984|NCT03112499|Procedure|PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is fluoroscopically recognized to access the renal pelvis using the Bull's-eye technique. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using either balloon (20 atm) or Amplatz serial dilators a 30F access channel is created. Lithotripsy is performed using ultrasound lithotripter and stone fragments are removed by grasping forceps. At the end of the operation a 18F Council type catheter is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Council and JJ catheter are removed,in the absence of complications, the second and tenth postoperative day, respectively.
1480985|NCT03112499|Procedure|mini-PCNL|Under general anesthesia and patient in prone position, with the use of a flexible cystoscope an open-ended ureteral catheter 5F / 70cm is positioned to the proximal ureter. Retrograde pyelography is performed and the most appropriate calyx is fluoroscopically recognized to access the renal pelvis using the Bull's-eye technique. A 0.035 guide wire is inserted into the ureter and then replaced with an extra stiff wire. Using Amplatz serial dilators a 16F access channel is created. Lithotripsy is performed using using 270mm Ho: YAG laser fiber and stone fragments are removed by grasping forceps. At the end of the operation a 10F nephrostomy tube is placed into the kidney for drainage of urine and an indwelling JJ catheter is inserted in the ipsilateral ureter. Nephrostomy tube and JJ catheter are removed, in the absence of complications, the second and tenth postoperative day, respectively.
1480986|NCT03112499|Procedure|RIRS|Under general anesthesia and patient in lithotomy position, a 0.035 hydrophilic safety wire is inserted in the ureter under fluoroscopic guidance. Subsequently 8-10 F dilators are used for dilation of the ureter.Insertion of a second working wire follows above which a 14F ureteral sheath is placed. Lithotripsy with a flexible ureteroscope using 270mm Ho: YAG laser fiber follows.Remaining stone fragments are removed by a 2,2F nitinol basket. At the end of the operation a JJ indwelling ureteral catheter is placed over the safety wire. Discharge is performed in the absence of complications, the first postoperative day while JJ catheter is removed on the 10th postoperative day.
1480988|NCT03112473|Behavioral|Task-orientated training|Bi/Uni/Placebo TENS and Task-orientated training on upper limb
1480989|NCT03112473|Device|Transcutaneous electrical nerve stimulation (TENS)|
1480990|NCT03112473|Device|Sham electrical nerve stimulation|
1480991|NCT03112460|Device|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software|cardiopulmonary resuscitation with Zoll R Series defibrillator and defibrillator pads with a real-time CPR feedback option and CodeReview case analysis software
1480992|NCT03112447|Procedure|absorbable cartilage nail|The experiment group patients were fixed with absorbable cartilage nails
1480993|NCT03112447|Procedure|traditional Kirschner wires|The control group were fixed with traditional Kirschner wires
1480995|NCT03112408|Behavioral|Forward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in the same direction as the saccade in order to induce an adaptive increase of saccade amplitude ('forward adaptation')
1480996|NCT03112408|Behavioral|Backward adaptation of reactive saccades|Protocol of reactive saccade where the target is displaced in a direction opposite to the saccade in order to induce an adaptive decrease of saccade amplitude ('backward adaptation')
1480997|NCT03112408|Behavioral|Execution of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in forward and backward adaptation conditions)
1480998|NCT03112408|Behavioral|Generation of reactive saccades|Control protocol of reactive saccade with no displacement of the saccadic target (controlling for non specific factors possibly involved in adaptation condition)
1480999|NCT03112395|Device|Pio Medical Device|The Pio device combines the technologies of pulse modulated magnetic fields and light emission locally applied to the wound area.
1481000|NCT03112382|Drug|zinc supplement plus vitamin A and E|
1481001|NCT03112382|Drug|vitamin A and E|
1481002|NCT03112369|Behavioral|Narrative Exposure Therapy (NET)|An international evidence-based program (EBP) for PTSD based on exposure therapy, an oral tradition of story-telling, and use of tactile medium of natural elements.
1481003|NCT03112369|Behavioral|Motivational Interviewing w/Skills Training (MIST)|Motivational interviewing (MI) coupled with skills training is based on enhancing motivation to change and building skills to address substance use behaviors.
1481004|NCT03112356|Drug|99mTc-Leukoscan® scintigraphy|Gated single photon emission computed tomography with co-registered computer tomography (gated SPECT-CT) 6 hours and 24 hours after infusion of 99mTc-Leukoscan (1000 MBq)
1481005|NCT03112343|Device|Algorithm-based feedback messages|ICT-based intervention group have algorithm-based feedback messages in addition to conventional intervention
1481006|NCT03112343|Device|Personal Health Record|Subjects will save and send their health information to the server via the personal health record app
1481009|NCT03112317|Other|Prevention of hypothermia|Patients are routinely warmed with forced air warming blankets, regular blankets, pre warmed intravenous fluid. Routines are ensured with use of the WHO Surgical Safety Checklist. The intervention is the use of operating theatre care measures to prevent mild hypothermia in surgical patients.
1481010|NCT03112304|Behavioral|MATCH-ADTC|MATCH - ADTC (Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems; Chorpita & Weisz, 2009) is a psychosocial intervention designed to treat children with multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. It is recommended for children aged 6-15. MATCH is composed of 33 modules—i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
1481011|NCT03112304|Other|TRAC|"TRAC (Treatment Response Assessment for Children) is a web-based system that provides weekly monitoring of the MATCH modules used and the child's response to treatment. Child's response to treatment is based on caregiver and child reports of (a) changes in problem severity on the standardized Brief Problem Checklist, and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, TRAC provides a complete record of modules used, and child treatment response, across all the weeks of treatment, as illustrated in the client dashboard."
1481012|NCT03112291|Procedure|Apexification|Apexification forms a calcified barrier in teeth with open apexes and pulp necrosis. It is used to treat immature teeth, but it does not promote the continuity of root formation.
2000908|NCT03320655|Other|Combined Aerobic Training|The subjects will perform in ST part, always only 1 set in the 6 machines early mentioned. During the first and second week they will do 12 repetitions at 40% - 50% of 1 RM. In the third and fourth week progress to 10 repetitions at 60%-70% of 1 RM, and in the second and third month, 8 repetitions at 70%-80% of 1 RM. In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of 10 interval training periods (2 min of high intensity at 85% - 90% of heart rate reserve (HRreser) and 9 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 5 intervals of HIIT, and in the second and third months they are doing the 10 stages of HIIT.
2000909|NCT03320655|Other|Combined Strength Training|During the first and second week subjects will perform 1 sets with 12 repetitions at 40% - 50% of 1 RM in the 6 machines mentioned before. In the third and fourth week strength exercises progress to 2 sets of 10 repetitions, at 60%-70% of 1 RM, and in the second and third month consists of 3 sets at 8 repetitions, at 70%-80% of 1 RM. . In the AT part the HIIT protocol is based on a ratio 2 min : 1 min. Consisted of of 5 interval training periods (2 min of high intensity: 85% - 90% of HRreser) and 4 pauses (1 min in passive pause) between interval training periods. During the first week of training will start with a continuous training, in the second week will start with 3 intervals of HIIT, and after the third/fourth week they are doing the 5 stages of HIIT.
1481015|NCT03112265|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules—i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
1481016|NCT03112265|Other|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
1481017|NCT03112265|Behavioral|Treatment as usual|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
1481019|NCT03112239|Device|Light-Emitting Diode Therapy (LEDT)|Light-emitting diode, has effects similar to the photobiomodulation by low-level laser intensity.
1481020|NCT03112226|Other|GnRHant + E2|GnRH antagonist with estradiol add-back
1481021|NCT03112226|Other|GnRHant + Placebo|GnRH antagonist with placebo add-back
1481022|NCT03112213|Drug|Tocilizumab|Tocilizumab (SC or IV) will be prescribed according to local clinical practice and the SPC.
1481023|NCT03112213|Drug|NSAIDs|Participants may receive NSAIDs, as prescribed by the treating physician or by self medication. Study protocol does not enforce any particular NSAID.
1481027|NCT03112174|Drug|Ibrutinib|Administered orally once daily
1481028|NCT03112174|Drug|Venetoclax|Administered orally once daily
1481029|NCT03112174|Drug|Placebo Oral tablet to match Venetoclax|Administered orally once daily
1481030|NCT03112161|Other|Eucaloric Feeding Period|
1481031|NCT03112161|Other|Overfeeding Feeding Period|
1481032|NCT03112161|Other|Underfeeding Feeding Period|
1481034|NCT03112135|Drug|Tranexamic Acid|TXA of 10-15 mg i.v over 30 min. followed by infusion in adose of 1 mg / kg /hr
1481035|NCT03112135|Drug|Tranexamic Acid|Topical TXA 1 gm diluted in 200 ml saline
1481036|NCT03112135|Drug|Adrenalin|Topical adrenaline 1 mg diluted on 200 ml saline
1481037|NCT03112122|Biological|autologous bone marrow concentrate|injection of autologous bone marrow concentrate
1481038|NCT03112122|Biological|bone substitute i-FactorTM|subchondral injections of i-FactorTM
1481039|NCT03112122|Procedure|core decompression|subchondral anterograde drilling
1481040|NCT03112109|Other|'New care'|Frail elderly receiving care within new organisational models delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform) as provided by pilot sites individually.
1481041|NCT03112096|Drug|[18F]THK-5351|Imaging for evaluating the biodistribution, pharmacokinetics and safety of abnormal tau protein in the brain
1481042|NCT03112083|Dietary Supplement|Nutritional counseling A|Krill powder capsules
1481043|NCT03112083|Dietary Supplement|Nutritional counselling B|Placebo capsules
1481044|NCT03112070|Other|Water aerobic exercise session (WATER)|A continuous session of dynamic water aerobic exercise which consist of a dynamic warm-up period (5 minutes), an active exercise period (35 minutes), and a cooldown period (5 minutes) to total 45 minutes. Heart rate (HR) will be continuously measured with heart monitors (Polar) to confirm the intensity of the WATER session. The WATER intensity will be calculated according to the formula proposed by Kruel for exercise in an aquatic environment18 as follows: HR for exercise = % x (HRmax - ΔHR); % is the intensity of exercise; HRmax is the maximum HR (estimated by 220 - age); ΔHR represents the difference between resting HR on land and resting HR in the water environment. Exercise intensities: 55-60% HRmax during warm-up; 70-75% HRmax during active exercise; and 55-60% HRmax during cooldown.
2010535|NCT02941770|Other|Exercise|Experimental group II will participate accordingly with their availability in two exercise sessions per week (≈60 min/session) directed by one exercise physiologist. The ability to exercise will be assessed in order to customize the exercise plan. All the sessions will include: 10 minutes of warm-up, 5 minutes of agility exercises, 15 minutes of resistance training (including the major upper and lower muscles, 12-15 sets of 15 repetitions), 20 minutes of aerobic exercise, and 10 minutes of cool-down (50-80% heart rate reserve - Polar Vantage NV, Polar Electro Oy, Kempele, Finland). All the participants will have to attend at least 80% of the scheduled sessions.
1481046|NCT03112044|Drug|Sofosbuvir-velpatasvir (400 mg/100 mg)|Patients will have standard monitoring with HCV RNA and liver panel assessment at 2 week intervals until HCV is undetectable and then at the end of treatment and 3 and 6 months following its completion. Post-operative transplant care and immunosuppression will be carried on as usual transplant practice at Toronto General Hospital.
1481047|NCT03112044|Device|Ex Vivo Lung Perfusion (EVLP)|Normothermic EVLP is a method of donor lung preservation, assessment, treatment, and repair of injured organs. This method allows donor lungs to be treated for at least 12h under protective physiological conditions.
1481048|NCT03112031|Drug|Tamoxifen|Tamoxifen will be given orally in a dose of 300mg/day for the first 14 days following randomization. It will be administered by nasogastric tube where patients are unconscious. The Tamoxifen will be administered in the morning combined with amphotericin and fluconazole dose.
1481049|NCT03112031|Drug|Amphotericin B|Patients will receive amphotericin 1mg/kg/day i.v. once daily orally for the first 2 weeks.
1481050|NCT03112031|Drug|Fluconazole|Patients will receive fluconazole 800mg once daily orally for the first 2 weeks. Amphotericin and fluconazole will be administered simultaneously. After the first 2 weeks of study treatment, all patients will receive fluconazole 800mg/day for 8 further weeks, until the study end.
1481051|NCT03112018|Behavioral|data strengthening|Data strengthening: initial training, monthly data collection and feedback on data quality, access to dashboards, periodic Data Quality Assessments
1481052|NCT03112018|Behavioral|modified Safe childbirth checklist - control|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, limited feedback and mentoring on its use
1481053|NCT03112018|Behavioral|modified Safe childbirth checklist - enhanced|modified Safe Childbirth Checklist (mSCC) implementation: provision of the mSCC to facilities, ongoing intensive feedback and mentoring on its use
1481054|NCT03112018|Behavioral|PRONTO training|Health provider training (PRONTO): initial 2-days modular training followed by a 6-week mentoring sessions (Kenya) or periodic modular refreshers and supplemental mentoring (Uganda), each over a 9-12 month period
1481055|NCT03112018|Behavioral|QI cycles|Quality Improvement Cycles (QI): facility teams performing PDSA cycles with mentoring support and twice annual Learning Collaborative sessions, plus opportunities to apply for small amounts of funds to support change efforts
1481056|NCT03112005|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
1481057|NCT03112005|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
1481058|NCT03111992|Drug|PDR001|Anti-PD1 antibody
1481059|NCT03111992|Drug|CJM112|Anti-IL-17A antibody
1481060|NCT03111992|Drug|LCL161|Oral small molecule SMAC-mimetic
1481061|NCT03111979|Dietary Supplement|beta-alanine|
1481062|NCT03111979|Dietary Supplement|Placebo|
1481063|NCT03111966|Other|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir|Spanish cohort with HCV treated in real practice with Elbasvir/Grazoprevir
1481064|NCT03111953|Procedure|Roux-en-Y Gastric Bypass Surgery|"In Roux-en-Y Gastric Bypass Surgery a small gastric pouch is created and connected to a segment of jejunum. Bowel continuity is restored by reconnecting the Roux limb and the biliopancreatic limb approximately ~75-150 cm distal to the gastrojejunostomy. Therefore, ingested food bypasses most of the stomach, the entire duodenum, and a short segment of the jejunum."
1481065|NCT03111953|Procedure|Biliopancreatic Diversion Surgery|In Biliopancreatic Diversion Surgery a horizontal gastrectomy is conducted leaving a portion of the stomach, which is connected to the small intestine, ~250 cm from the ileocecal valve and the biliopancreatic limb is connected to the ileum, ~50 cm from the ileocecal valve. Digestive secretions from the biliopancreatic limb mix in the common channel, where ingested food is also delivered by the alimentary limb.
1481066|NCT03111940|Procedure|Optimisation of the result of intracoronary stenting according to specific algorithm|
1481067|NCT03111927|Other|Infant Formula: enriched level of myelin-relevant nutrients|"Feeding with the assigned infant formula can begin as soon as the child is enrolled in the study (from 2 weeks up to 5 weeks of life) and will last up 12 months of age (+/- 2 weeks).
The volume of feed required by the child per day will depend upon age, weight, and appetite. The product should be given daily ad libitum to the child from enrollment up to 12 months."
1481141|NCT03111290|Device|Direct Cortical Stimulation Sham|Sham trials where no electric pulse is delivered
1481202|NCT03110822|Drug|Lenalidomide 5Mg Oral Capsule|Lenalidomide 5Mg Oral Capsule will be administered at the dose of 5mg QD on Days 1-21 of the treatment cycle.
2010536|NCT02939989|Drug|ABT-493/ABT-530|Tablet
1481068|NCT03111927|Other|Infant formula: standard level of myelin-relevant nutrients|"Feeding with the assigned infant formula can begin as soon as the child is enrolled in the study (from 2 weeks up to 5 weeks of life) and will last up 12 months of age (+/- 2 weeks).
The volume of feed required by the child per day will depend upon age, weight, and appetite. The product should be given daily ad libitum to the child from enrollment up to 12 months."
1481069|NCT03111914|Diagnostic Test|Dual Energy Computed Tomography|"The subject's diagnostic scan will be preceded by a not clinically indicated non enhanced dual energy scan. The overall radiation dose to the patient for the first and second acquisition will be twice the radiation dose of a conventional CT of the chest, abdomen and pelvis. The non enhanced dual energy scan will be repeated during a clinical follow-up after the subject's first three months of enrollment and at a clinical follow-up after six months of enrollment.
The clinically-indicated, contrast-enhanced diagnostic scan will be performed according to standard of care."
2010537|NCT02939989|Drug|Sofosbuvir|Tablet
2010538|NCT02939989|Drug|Ribavirin|Tablet
1481072|NCT03111888|Device|Silicone Stent Airway Implant|The Patient-Specific Tracheobronchial Stent is a silicone stent indicated for use in adults that have stenosis of the airway. The subject device takes a CT scan, thresholds out the airway from the other anatomy, and allows the physician to digitally build the stent to his/her desired dimensions. According to the physician's design, a patient‐specific stent can be manufactured using rapid prototyping technology. The patient‐specific stent is indicated for use with any rigid bronchoscopy/stent application system that fits the design envelope.
1481073|NCT03111875|Procedure|aggressive warming|Patients will be pre-warming 30 minutes before induction of anesthesia and aggressively warmed during surgery to a target intraoperative core temperature between 37 and 37.5°C.
1481074|NCT03111875|Procedure|routine thermal management|A forced-air cover will be positioned but will not initially be activated. The warmer will be activated when core temperature decrease to 35.5°C.
1481075|NCT03111862|Diagnostic Test|NSTEMI Rule-Out according to hs-TnT|Rule-Out according to the rapid rule-out protocol of the current ESC Guidelines
1481076|NCT03111849|Other|sarcopenia|Prevalence of sarcopenia in hospitalized chronic obstructive patients
1481077|NCT03111836|Behavioral|Control Group|Received general information about blood pressure control. All subjects will be sent 16 e-messages on a weekly schedule.
1481078|NCT03111836|Behavioral|Expert-Driven Group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
1481079|NCT03111836|Behavioral|User-driven group|The user-driven e-Counselling group will receive a lifestyle program where the user are able to choose areas of focus. All subjects will be sent 16 e-messages on a weekly schedule.
1481080|NCT03111823|Behavioral|Exercise Intervention|Undergo aerobic exercise sessions
1481081|NCT03111823|Other|Quality-of-Life Assessment|Ancillary studies
1481082|NCT03111823|Other|Questionnaire Administration|Ancillary studies
1481083|NCT03111810|Drug|AZD4017 and prednisolone|The drug AZD4017 will be given together with prednisolone 20mg daily for 7 days to compare its effects on metabolic tissues against the placebo arm where the participants will take placebo and prednisolone 20mg daily for 7 days.
1481084|NCT03111810|Drug|Placebo Oral Tablet and prednisolone|Placebo Oral tablet will be given together with prednisolone 20mg daily for 7 days to compare the effects on metabolic tissues of AZD4017 and prednisolone 20mg daily against the placebo arm.
1481085|NCT03111797|Drug|Morphine|we observe the self-patient controlled morphine consumption during the first 48h after surgery
1481086|NCT03111797|Other|Cardiac output measure|we observe the cardiac output during surgical procedure using a non-invasive cardiac output monitoring device (ClearSight from Edwards lifescience laboratory )
1481087|NCT03111784|Other|Fish consumption and lipid profiles|
1481088|NCT03111771|Procedure|carcinological surgery|carcinological surgery for Group K +
1481089|NCT03111771|Procedure|cervical surgery|cervical surgery for Group K-
1481090|NCT03111758|Device|Flow augmentation|Augmenting venous flow following deep venous stenting in patients with Postthrombotic syndrome
2010539|NCT02938884|Device|HidrateSpark Water Bottle|HidrateSpark water bottle is a smart water bottle that glow when its time to drink water. It is run through an app on a smart phone
1481094|NCT03111706|Procedure|Cesarean section|During Cesarean delivery the lower uterine segment (LUS) was defined as the part of the uterus below the uterovesical peritoneal reflection. After opening the visceral peritoneum and performing the bladder dissection, the LUS was assessed for integrity of the CS scar by the operating surgeon to avoid bias by the sonographic findings. Scar dehiscence was defined as the presence of either transparent LUS with visible contents, presence of well-circumscribed scar defect or presence of frank uterine rupture.
1481095|NCT03111693|Other|Unenhanced Coro-CT|All unenhanced coroCT examinations are performed on the same 64-Row CT scanner (discovery CT 750 HD scanner, GE Helthcare), using prospective ECG-triggerring.
1481096|NCT03111680|Other|environmental intervention|a multi component environmental intervention
1481097|NCT03111667|Behavioral|Teen Marijuana Check Up|Two session Motivational Enhancement Therapy intervention. The first MET session relies on the use of motivational interviewing skills to hear the student's history and current concerns with marijuana. The second session involves the provision of a personalized feedback report based on the student's baseline assessment that reviews normative feedback on marijuana use, consequences experienced, money spent on marijuana, other drug and alcohol use, social supports for quitting and life goals.
1481098|NCT03111667|Other|Treatment as Usual|Referral to community resources
1481099|NCT03111667|Behavioral|Gold Standard Coaching|Weekly coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in a group setting.
1481100|NCT03111667|Behavioral|As Needed Coaching|As needed coaching and feedback about adherence to Motivational Interviewing Skills and intervention delivery in an individual setting.
1481101|NCT03111654|Diagnostic Test|Compare the risk of a vascular event|"Collected in a post-stroke follow-up consultation, patient clinical outcome data, functional and cognitive disability, standardized, using validated scales.
Analysis of selected therapeutic options for the prevention of AF ischemic events."
1481104|NCT03111615|Drug|Aromatase Inhibitors|"Aromatase Inhibitor to start immediately after diagnosis of a Luminal Invasive Breast Carcinoma Patients will be given Letrozol 2.5 mg or Anastrazol1 mg, every 24H and all of them will be given Calcium + Vit D supplement.
Venlafaxin 75 mg is to be administrated cases indicated"
1481105|NCT03111602|Other|restrict polyphenol-rich foods|dietary orientation to restrict polyphenol-rich foods
1481106|NCT03111589|Biological|Inactivated influenza A (H1N1) virus vaccine|All groups of patients and the control group will receive the new annually recommended inactivated influenza A (H1N1) virus vaccine.
1481107|NCT03111589|Diagnostic Test|Blood sampling|Testing of the different humoral immune responses to vaccines or to erythrocyte alloantigens.
1481108|NCT03111563|Other|Warm saline distension media in office hysteroscopy|warm saline distension media in office hysteroscopy
1481109|NCT03111537|Other|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
1481110|NCT03111537|Other|Snus|Use of Camel Snus: Winterchill or Robust flavors
1481111|NCT03111537|Other|E-Cigarette|Use of E-cigarette: multiple flavors offered.
1481112|NCT03111537|Other|Nicotine Gum or Lozenge|Subject choice: Use of nicotine gum or nicotine lozenge, multiple flavors offered
1481113|NCT03111524|Other|Classroom Communication Resource|The Classroom Communication Resource intervention is a classroom- and group-based interventions administered by teachers. It includes a social story, role-play and teacher-led discussion
1481114|NCT03111524|Other|No intervention|No intervention is administered in this group as these are control groups
1481115|NCT03111511|Drug|Drospirenone/Ethinylestradiol|A single dose of drospirenone/ethinylestradiol 3 mg/0.02 mg (OC) tablets on Days 1 and 21.
1481116|NCT03111511|Drug|Midazolam|Midazolam 2 mg orally on Days 1 and 21.
1481117|NCT03111511|Drug|JNJ-56136379|JNJ-56136379 dose will be administered orally at a dose of 250 mg (as 2 tablets of 100 mg + 2 tablets of 25 mg) on Days 6 and 7 and at a dose of 170 mg (as 1 tablet of 100 mg+ 2 tablets of 25 mg + 4 tablets of 5 mg) on Days 8 to 25.
1481118|NCT03111498|Other|practice-based training programme (one-to-one teaching)|practice-based training programme (one-to-one teaching) for conducting VAD
1481119|NCT03111498|Other|theory-based training programme|theory-based training programme for conducting VAD
1481120|NCT03111485|Drug|Sinemet CR|Capsule 250 mg / 50 mg taken at bedtime
1481121|NCT03111485|Drug|Placebo oral capsule|Capsule taken at bedtime
1481123|NCT03111459|Device|Medtronic Valiant Thoracoabdominal Stent Graft System|The Medtronic Valiant Thoracoabdominal Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components The system is comprised of two investigational devices that include the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
1481124|NCT03111446|Procedure|Spinal Anesthesia|Spinal needle 25G with Quincke's bevel will be used. It will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 20 mcg fentanyl (total volume 2.4 ml) at the L3-4 interspace. The parturient will be returned to the supine position with a left lateral tilt of 15° to facilitate left uterine displacement. The upper sensory block level will be checked 5 min after the spinal injection by assessing the loss of cold sensation from alcohol swabs, to ensure that a Th6 sensory block level has been achieved.
1481125|NCT03111446|Procedure|General Anesthesia|Pre-oxygenation with oxygen 100% via a tight fitting mask rapid sequence technique. Induction is by thiopental (5 mg kg lean body weight) and succinylcholine1.5 mg kg body weight), cricoid pressure should be applied before consciousness is lost and kept in place until confirmation of tracheal intubation with capnography and the cuff of the tracheal tube is inflated. Auscultating the chest helps exclude endobronchial intubation. At this point, surgery may commence.
1481126|NCT03111433|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 soft gelatin capsule 100mg
1481127|NCT03111433|Drug|Insulin|multiple dose insulin injection therapy
1481130|NCT03111407|Procedure|total knee arthroplasty|surgical procedure in which damaged parts of the knee joint are replaced with an implant.
1481131|NCT03111381|Drug|Toradol|IV toradol
1481132|NCT03111368|Procedure|Endoscopic ultrasound-guided fine needle aspiration|pancreatic solid mass punctured with a 22G endoscopic ultrasound needle
1481133|NCT03111355|Dietary Supplement|Brazil nut|one nut a day for 2 months, no intervention for 2 months
1481134|NCT03111342|Drug|Anesthesia|A 2% lidocaine without vasoconstrictor injection into the cervix
1481135|NCT03111342|Procedure|Dry-needling|A placement of thin needle into the cervix without substance injection
1481137|NCT03111316|Drug|Cervidil 10 MG Vaginal Insert|Dinoprostone vaginal insert is a thin, flat, polymeric slab which is rectangular in shape with rounded corners contained within the pouch of an off-white knitted polyester retrieval system, an integral part of which is a long tape. Each slab is buff colored, semitransparent and contains 10 mg of dinoprostone in a hydrogel insert. An integral part of the knitted polyester retrieval system is a long tape designed to aid retrieval at the end of the dosing interval or earlier if clinically indicated. The finished product is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
1481138|NCT03111316|Device|Foley Catheter|The balloon on the end of the Foley catheter will be inflated with 30 mL of sterile water, pulled back against the internal os of the cervix, and taped to the maternal thigh under minimal tension.
1995328|NCT02792192|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in respective arm.
1481142|NCT03111277|Device|Experimental: ExAblate Transcranial treatment|Patients' head will be placed in a device to hold it still for the treatment. Patients will lie headfirst on the ExAblate table. The ExAblate Transcranial helmet will be placed on their head. A device will be placed over their head to hold it and the helmet still. The investigators will measure the study participant's heart, blood pressure, temperature, and breathing rate before the treatment begins. MRI scans will be taken to make sure the ultrasound waves will be aimed exactly within the target. The space between the rubber diaphragm and the helmet will be filled with water. The water will be chilled to avoid heating of the scalp and skull during the ultrasound treatment. A series of MR images will be taken to identify the target area, and plan the study treatment. The study investigators will decide on the area of participant's brain that will be treated. The ExAblate Transcranial system will compute a plan to cover the treatment area.
1481143|NCT03111264|Behavioral|EWE Only Group|"The EWE Only Group intervention is based on Food Friends & Mighty Moves, a nutritional program designed to introduce new foods over the course of 12 weeks to preschoolers to create positive eating experiences. In conjunction with the nutritional program, the intervention also consists of an 18 week physical activity program designed to develop gross motor skills."
1481144|NCT03111264|Behavioral|EFE Group|The EFE component is comprised of a curriculum of parenting, wellness, physical activity, and feeding in the home environment. The EFE intervention will span over the course of the EWE intervention.
1481145|NCT03111251|Behavioral|Provider assessment and feedback|Tailored immunization reports highlighting adolescent vaccination rates at the individual, clinic and network levels are distributed by clinic champions every quarter. Reports track vaccination rates over time and allow physicians to compare their rates to the national goal.
1481146|NCT03111251|Behavioral|Provider reminders|An EHR-based reminder system informs providers when patients are due or overdue for HPV vaccination.
1481147|NCT03111251|Behavioral|Provider education|Provider education is being delivered through a comprehensive online continuing education activity that is tailored specifically to physicians, nurses, and clinical staff at TCP practices. It focuses on HPV vaccination best practices and communicating with parents about the HPV vaccine.
1481148|NCT03111251|Behavioral|Patient reminders|Patient reminders are delivered through MyChart, the clinics' online personal health record system, to inform patients (parents) that they are due or overdue for HPV vaccination.
1481149|NCT03111251|Behavioral|Parent education|The parent education intervention (currently in development) will employ innovative strategies to identify and overcome barriers to HPV vaccination.
1481150|NCT03111238|Drug|Rexmyelocel-T|Rexmyelocel-T is administered through an intra-arterial catheter.
1481151|NCT03111238|Drug|Placebo|Placebo is administered through an intra-arterial catheter.
1481152|NCT03111225|Diagnostic Test|massage|a 15 minutes thoracic massage will be added to the regular physical therapy treatment
1481153|NCT03111212|Drug|Iloprost|Iloprost nebulized
1481154|NCT03111212|Drug|control|sodium chloride 0,9% nebulized
1481155|NCT03111199|Other|Cryotherpy|Cryotherapy will be used by means of ice packs over a painful region. The ice will be crushed inside a bag so that it is in an ideal size that provides a coupling in a painful column in the lumbar spine; Once it has been inserted in the plastic bag and before closing it all the air must be removed to avoid a faster thawing of the ice and have difficulties of coupling.
1481156|NCT03111199|Other|TENS Burst|The TENS Burst therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be at the maximum amplitude To generate visible muscle contraction without generating pain / discomfort. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
1481157|NCT03111199|Other|TENS Burst Placebo|The TENS Burst placebo therapy will be performed using the KLD Sonophasys EUS 0503 electrotherapy device connected in the current therapy mode with the following parameters: 4Hz frequency, high pulse duration of 200 μsec and the current intensity will be on but without Produce the effects of visible muscle contractions because the channel will not be properly coupled in the apparatus so that the stimulation does not reach the patient. A channel will be used using self-adhesive electrodes arranged parallel to the erector muscle of the spine, so that the region to be treated is between the electrodes.
1481158|NCT03111199|Other|Education|After the electrophysical intervention, a moment of education and awareness will be held, in which the participants will receive information about the purpose of the treatment; Anatomy and biomechanics of the lumbar spine; Chronic non-specific back pain; Cognitive, emotional, genetic, social, and lifestyle factors; Intrinsic and extrinsic physical factors, biopsychosocial model: beliefs of pain and hypervigilance; Concepts of joint protection; Energy conservation and general guidelines.
1481159|NCT03111186|Drug|Oxycodone Hcl 5Mg|oxycodone HCl 5 mg up to six times daily as needed for pain
1481160|NCT03111186|Drug|Ibuprofen 400 mg|Ibuprofen 400 mg up to six times daily as needed for pain
1481161|NCT03111186|Drug|Acetaminophen 650 mg|Acetaminophen 650 mg up to four times daily as needed for pain
1481163|NCT03111160|Procedure|SMILE procedure using lower energy (100, 105, and 110 nJ)|Based on the review of literature, we regarded SMILE using energy levels of 115 nJ or higher as 'conventional' energy-SMILE (C-SMILE). Since 500kHz VisuMax femtosecond laser used in this study had a threshold photodisruption energy level of 100 nJ, lowest energy level of L-SMILE was set at 100 nJ. Because the spot distance must be changed by approximately 1 μm when laser energy changed by 50 nJ, we could set the maximum laser energy to 150 (100 + 50) nJ as highest one of C-SMILE while keeping the spot distance constant. Finally, we established two groups divided by different laser energies: L-SMILE group using lower energy levels of 100, 105, and 110 nJ, and C-SMILE group using 'conventional', not higher, energy levels of 115 to 150 nJ.
1481198|NCT03110848|Drug|Atorvastatin|Atorvastatin 20 mg daily
1481199|NCT03110848|Drug|Methylprednisolone|500 mg of methylprednisolone weekly for 6 weeks, followed by 250 mg weekly for another 6 weeks, for a total dose of 4.5 mg.
1481200|NCT03110835|Radiation|Radioiodine|Administration of radioiodine
1481201|NCT03110822|Drug|Ruxolitinib Oral Tablet [Jakafi]|Ruxolitinib will be administered at the dose of 5mg BID on days 1-28 of the treatment cycle.
1481733|NCT03106805|Procedure|early insertion|insertion at 4th postpartum week
1586238|NCT02337907|Drug|Donepezil|
1481164|NCT03111160|Procedure|SMILE procedure using conventional energy (115 to 150 nJ)|The SMILE procedures were conducted in the Eyereum Eye Clinic (Seoul, South Korea). The target postoperative refraction was emmetropia. The surgery, using standardized techniques, was performed by an experienced surgeon (D.S.Y.K.) using the VisuMax system. The surgical parameters used during SMILE were as follows: repetition rate of 500 kHz, pulse energy 100 to 150 nJ (100, 105, and 110 nJ, L-SMILE; 115 to 150 nJ, C-SMILE), spot distance 4.5 μm (regardless of FSL energy), cap thickness 120 μm, and side-cut width 2 mm in the 12-o'clock position with an angle of 90°. After the anterior (upper) and posterior (lower) delineated plane of the intrastromal lenticule were well defined, the anterior and posterior interface were dissected with a micro-spatula with a blunt circular tip and extracted with micro-forceps. The integrity of the lenticule was also checked subsequently.
1481165|NCT03111147|Device|0 degrees humeral component version|RTSA with humeral component positioned in 0 degrees of version
1481166|NCT03111147|Device|30 degrees humeral component retroversion|RTSA with humeral component positioned in 30 degrees of retroversion
1481167|NCT03111134|Procedure|modified component separation technique|a new abdomen closure technique based on component separation technique
1481168|NCT03111121|Drug|Sugammadex|receive reversal with sugammadex 4mg/kg
1481169|NCT03111121|Drug|neostigmine|receive reversal with neostigmine 0.04 mg/kg
1481170|NCT03111121|Drug|glycopyrrolate|receive reversal with glycopyrrolate (0.01 mg/kg)
1481172|NCT03111095|Other|Mobile Health|Subjects will submit blood pressure and weight measurements daily for 6 weeks postpartum. Subjects will have a video telehealth visit with the mobile health nurse at 48 hours and 7 days after discharge from the hospital.
1481173|NCT03111069|Procedure|Abdominal Surgery|"Resectable Intra-Abdominal/Pelvic Tumors Group: Participants receive peritonectomy, omentectomy, cytoreduction, (complete surgical tumor resection, no gross residual disease).
Unresectable Intra-Abdominal/Pelvic Tumors Group: Participants receive debulking surgery (90% resection) , with no more than 5mm thick residual implants, totaling no more than 2.5cm2 of residual tumor."
1481174|NCT03111069|Drug|Doxorubicin|"Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.
Dose Expansion Starting Dose: MTD from Dose Escalation."
1481175|NCT03111069|Radiation|Intra-Operative Radiation|Standard dose brachytherapy delivered to the residual pelvic tumor sites.
1481176|NCT03111056|Behavioral|Alc-ERDT|Web-based cognitive behavioral skills-based alcohol intervention that incorporates emotion regulation and distress tolerance skills
1481177|NCT03111043|Diagnostic Test|Head to pelvis CT scan|Introduction of early head to pelvis CT scan within 6 hours of out of hospital arrest as an adjunct to standard of care (no randomization)
1481178|NCT03111030|Behavioral|ProacTive SCI|"Participants will receive weekly physical activity coaching sessions. Each session will be 10-15 minutes, delivered either face to face, over Skype, or over the phone. Additional resources may be emailed to participants based on need throughout the intervention (for example, a goal, list of places to exercise, contact information to reach mentoring services). A typical session may include:
An assessment of motivated the participant is to be physically active
A: If motivated, a physical activity goal will be set, strategies will be reviewed, and resources to accomplish that goal will be provided.
B: If not motivated, questions will be asked to understand why the reasons for lack of motivation. If it is for any reasons including barriers, fear, confidence, or knowledge, the interventionist will discuss strategies to overcome these obstacles.
Progress and barriers will be reassessed and discussed."
1481180|NCT03111004|Other|New Care|All settings that are in any way relevant to the provision of health and social care are integrated, including: out-of-hospital (community) services as well as hospitals, GPs' offices, community nurses, and any type of care practitioners, users' homes and volunteer service providers' offices
2010540|NCT02938533|Behavioral|Intervention|The intervention includes a clinic-based component and a take-home component. All components include the priming image of a Baobab tree. The clinic-based component is an interactive poster that rewarded appointment attendance. Patients who attend three consecutive on-time visits are congratulated and given a colored sticker to place on a poster that is publicly displayed at the clinic. In one clinic, the take-home component is a 2015 calendar in Kiswahili that contained the priming Baobab image. In the other clinic, the take-home component is a small plastic pillbox featuring the Baobab logo.
2010541|NCT02935894|Drug|Ibuprofen|400 mg ibuprofen given to inhibit cyclooxygenase metabolism
1481183|NCT03110978|Radiation|Stereotactic Ablative Radiotherapy|Standard SABR (50 Gy in 4 fx, BED=113 Gy; or, if plans for 50 Gy/4 fx cannot meet normal-tissue dose-volume constraints, 70 Gy in 10 fx, BED=119) to the tumor.
1481184|NCT03110978|Drug|Nivolumab|240 mg given by vein given within 36 hours before or after the first fraction of SABR. Then given every 2 weeks for 12 weeks, for a total of 7 doses.
1481185|NCT03110965|Behavioral|Yoga poses|Patients are asked to perform one or two yoga poses daily for 4-10 months
1481186|NCT03110952|Biological|TDENV-PIV|Single-dose vial with pre-filled syringe, subcutaneous injection
1481187|NCT03110952|Biological|TDENV-F17|Single-dose vial with pre-filled syringe 0.5 mL administered intramuscularly
1481188|NCT03110952|Other|Placebo|0.5 mL vial
1481189|NCT03110939|Other|hyperthermic perfusion|hyperthermic perfusion 1800-2000ml, normal saline, 45-48℃, 1 hour, speed 300-600ml/min (after surgery of advanced lung cancer/esophageal cancer)
1481190|NCT03110926|Drug|mFOLFOX6|Induction Chemotherapy
1481191|NCT03110926|Combination Product|Chemoradiation|Chemoradiation
1481192|NCT03110913|Other|dietary intakes|Four levels of methionine intakes will be provided by the reference protein drinks, 3 levels of methionine from lentils and 3 levels from lentils with rice.
2010542|NCT02935894|Other|Physiological induction of sweating|15 minutes exercise at 60-80% oxygen consumption to induce sweating
1481195|NCT03110874|Drug|one-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : one-way education'
1481196|NCT03110874|Drug|two-way education|'Fluterol Inhalation Capsule(fluticasone propionate 250 μg, salmeterol xinafoate 72.5 μg) : two-way education'
1481197|NCT03110861|Device|Transcatheter Pulmonary Valve (TPV)|Transcatheter Pulmonary Valve Replacement
1481203|NCT03110822|Drug|Methyl Prednisolonate|Methyl-prednisolone will be administered at the dose of 40mg QOD on Days 1-28 of the treatment cycle.
1481204|NCT03110809|Dietary Supplement|Capsinoid|Capsinoids are nunpungent analogs of capsaicin that activate BAT by stimulating sensory neurons in the gastrointestinal tract. Chronic ingestion of capsinoids may stimulate the development or recruitment of new BAT from precursor stem cells within white adipose tissue depots.
1481205|NCT03110809|Dietary Supplement|Placebo|Placebo for capsinoid. Capsule contains no active ingredients.
1481206|NCT03110796|Device|Dressing with LU3103209 - Dose 1|Dressing with LU3103209 - Dose 1
1481207|NCT03110796|Device|Dressing with LU3103209 - Dose 2|Dressing with LU3103209 - Dose 2
1481208|NCT03110796|Device|Dressing without LU3103209|Dressing without LU3103209
1481209|NCT03110783|Biological|Bioseal|Upon completion of the sutured dural repair, the closure will be evaluated for intra-operative CSF leakage with a baseline Valsalva maneuver to 10-20 cm H2O for 5-10 seconds. Subjects who have a CSF leak will be enrolled into the study. If randomized to receive Bioseal, a thin layer will be applied to the entire length of the suture line and the adjacent area to approximately 5mm away, including all suture holes. Up to two layers of Bioseal may be used for each application. While Bioseal achieves complete coagulation, CSF leakage will be re-evaluated with the Valsalva maneuver to 10-20 cm H2O for 5 to 10 seconds.
2000910|NCT03320083|Behavioral|Educational care derived from POSSUMS|Intervention group were offered a sleep education session on healthy practices for parent-baby sleep which included information on sleep needs, sleep hygiene, training in strategies to remove obstacles that get in the way of healthy sleep. Information were provided to guide the parent in forming an action plan based on cued care which included aligning the circadian clock with real time, removing the obstacles that get in the way of healthy sleep, physical activity, mindfulness, and relaxation techniques for mothers derived from the POSSUMS approach. However, we could not use Acceptance and Commitment Therapy, because none of the investigators had sufficient training on ACT at the time the study was conducted.
2000911|NCT03320603|Other|Expert eCRF|An expert eCRF will be used to guide physicians during the management of patients treated with Vitamin K Agonist or Direct Oral Anticoagulant admitted in emergency units for severe bleeding.
2000912|NCT03320603|Other|Prothrombin Complex Concentrate|Prothrombin Complex Concentrate given as standard of care
2000913|NCT03319940|Drug|AMG 757|AMG 757
2000914|NCT03318562|Drug|eFT508|200 mg eFT508 dosed BID for 3 week cycles
1481215|NCT03110744|Drug|Palbociclib|application on 21 consecutive days of a 28 days cycle
1481216|NCT03110731|Behavioral|Physical training|Physical training (2x / week) was performed for 12 weeks
1481217|NCT03110718|Device|ArmeoP+real MV|All the subjects assigned to the experimental received a focal belly-muscle vibration on the spastic antagonist muscles (i.e. triceps brachialis-TB, deltoid-DE, and supraspinatus-SS) during shoulder abduction and elbow extension. MV was delivered by a pneumatic vibrator powered by compressed air (Vibraplus; @Circle, San Pietro in Casale, Italy) (fig. 2) wired to appropriate-muscle probe diameter (up to 2cm2). MV was set at a frequency of 80Hz and an individually adjusted vibration amplitude (approximately 2mm in indentation depth, mean pressure of 250mBar, which effectively induce inhibition of the monosynaptic reflex) so that it was just below the threshold for perceiving an illusory movement. We chose such set up to avoid any signs of muscle contraction potentially reflecting either possible voluntary movement or occurrence of the tonic vibration reflex (TVR).
1481218|NCT03110705|Behavioral|sport|recreaational sport : diving or multisport
1481219|NCT03110692|Behavioral|Default initiation|A default prescription template will be introduced in the palliative setting in order to reduce unnecessary daily image guided radiation.
1481220|NCT03110679|Biological|injection of autologous bone marrow concentrate|
1481221|NCT03110679|Biological|injection of hyaluronic acid.|
1481222|NCT03110666|Biological|Injection of autologous concentrated bone marrow aspirate|Percutaneous injections at the bone-cartilage interface (distal femur and proximal tibia)
1481225|NCT03110640|Biological|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
1481226|NCT03110640|Drug|Fludarabine|Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.
1481227|NCT03110640|Drug|Cyclophosphamide|Patients were given cyclophosphamide 500mg/m2/day on day -4.
1481228|NCT03110627|Device|VDD ICD (experimental group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).
The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
1481229|NCT03110627|Device|Single chamber VVI ICD (control group)|"Patients who are identified on clinical grounds for a single-chamber ICD will randomized to a VDD ICD (experimental group) or single chamber ICD (control group).
The study will compare the Dx-ICD system (experimental) to standard VVI-ICD (control) on the ability to diagnose silent AF in patients without prior AF receiving an ICD for standard indications."
1481231|NCT03110588|Drug|PACE with Cabazitaxel (15 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 15 mg/m2.
1481232|NCT03110588|Drug|PACE with Cabazitaxel (20 mg/m2)|Prednisone, Abiraterone, and Enzalutamide are administered orally; Cabazitaxel is be administered intravenously @ 20 mg/m2.
1481233|NCT03110575|Drug|TNX-102 SL|2 x TNX-102 SL, 2.8mg tablets taken daily at bedtime for 12 weeks
1481234|NCT03110562|Drug|Selinexor|oral 100 mg dose
1481235|NCT03110562|Drug|Bortezomib|subcutaneous dose of 1.3 mg/m2
1481236|NCT03110562|Drug|Dexamethasone|oral dose of 20mg
1481237|NCT03110549|Drug|TMB-607|
1481238|NCT03110549|Drug|Placebo|
1481239|NCT03110536|Diagnostic Test|Copenhagen Burnout Inventory|"A questionnaire based on Copenhagen Burnout Inventory will be completed by each participant to the study, at the beginning of the triage shift and after 2, 4 or 6 hours.
The questionnaire also contains clinical cases that require triage coding."
1481240|NCT03110536|Other|Triage scoring efficacy|The triage scores of the first 5 and the last 5 cases assessed by the investigated nurse will be compared with the triage codes of an expert evaluator (nurse involved in designing The National triage Protocol).
1481734|NCT03106805|Procedure|late insertion|insertion at 6th postpartum week
1587597|NCT02327780|Other|FODMAP diet|
1948792|NCT01614275|Behavioral|Technology-Enhanced Parent Training|"The training for the parents of children with autism assigned to the EIBI group will begin with completion of a structured parent-training program for 6 weeks that includes 16 to 18 sessions (three, 90-minute sessions per week). When a new topic is introduced, the initial training will include viewing a Power Point presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a parent recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
1992801|NCT03294928|Other|progressive increasing of PEEP level.|"four-step measurements of central artery blood pressure evaluating contour wave analysis during a progressive increasing of PEEP level First step (Baseline) Subjects spontaneously breathe in air at atmospheric pressure during applanation tonometry.
Second step (PEEP=5 cm H2O) Applanation tonometry was performed during the application of PEEP = 5 cmH2O (Oxygen flow = 8lt.- Air flow = 10 lt.).
Third step (PEEP= 10 cm H2O) Applanation tonometry was performed during the application of PEEP = 10 cmH2O (Oxygen flow = 15lt.- Air flow = 20 lt.).
Fourth step (Recovery) Subjects spontaneously rebreathe air at atmospheric pressure during applanation tonometry."
1481243|NCT03110510|Drug|Fluorouracil|5FU 400mg/m2 bolus and then 2400mg/m2, continuous infusion D1-2
1481244|NCT03110510|Drug|Irinotecan Hydrochloride|Irinotecan 180 mg/m2
1481245|NCT03110510|Drug|leucovorin calcium|Leucovorin 200 mg/m2
1481246|NCT03110497|Radiation|Single application multi-fraction brachytherapy|Single application brachytherapy procedure to deliver high dose rate fractions of 9Gy, 7Gy and 7Gy with 6-12 hours apart under strict image guidance
1481247|NCT03110484|Drug|Pemetrexed 500 MG|Pemetrexed 500 mg/m2
1481248|NCT03110484|Drug|Erlotinib|Erlotinib 100mg once daily
1481249|NCT03110471|Behavioral|West Wales Adverse Drug Reaction (WWADR) Profile|Nurse-led medicines' monitoring in care homes: a process evaluation of the impact and sustainability of the West Wales Adverse Drug Reaction (WWADR) Profile and pharmacist involvement
1481250|NCT03110471|Behavioral|usual care|usual care
1481251|NCT03110458|Drug|SENS-111 100mg|2 ODT (1 ODT SENS-111 and 1 ODT placebo)
1481252|NCT03110458|Drug|SENS-111 200mg|2 ODT (2 ODT SENS-111)
1481253|NCT03110458|Drug|Placebo Oral Tablet|2 ODT (2 ODT placebo)
1481254|NCT03110445|Biological|rVV-740CTA|non replicating recombinant vaccinia virus expressing 7 Cancer Testis Antigen (CTA) epitopes together with CD80 and CD154(40L)
1481255|NCT03110432|Drug|PCSK9 Inhibitor [EPC]|drug use according to the respective product labelling
1481256|NCT03110432|Drug|Standard lipid lowering therapy|drug use according to the respective product labelling
1481257|NCT03110419|Other|Physical Exercise|The intervention program will follow the recommendations of the American College of Sports Medicine (ACSM, 2009), including aerobic, muscle strength, flexibility and balance exercise. The duration of the intervention will be 16 weeks with sessions 60 min performed in three alternate days.
1481258|NCT03110406|Other|whole-body vibration training|Training on the Vibrating platform will be performed with the patients in the static position.The exercises will be performed in the first two weeks for 10 minutes consisting of 60 seconds of low intensity and 30 seconds of standing rest in the anatomical position. From the second week to the end of the twelfth week (24 sessions) will be performed 15 minutes corresponding being 60 seconds of high intensity interspersed with 30 seconds of rest standing in the anatomical position. In the second month, the patient should be well adapted to the stimuli of the platform keeping the frequency of 35Hz and the amplitude 4mm. Monitoring of blood pressure, heart rate and peripheral oxygen saturation should be done every 5 minutes.
1481259|NCT03110393|Device|Ambu AuraGain|Insert and intubation of an Ambu® AuraGain™ laryngeal mask
1481260|NCT03110393|Device|Intersurgical i-gel|Insert and intubation of an Intersurgical i-gel®
1481269|NCT03110354|Drug|DS-3201b|DS-3201b is supplied as 25 and 100 mg capsules packaged in high-density polyethylene (HDPE) bottles.
1481270|NCT03110341|Drug|Erythropoietin|rhEPO 750U/kg was injected within 72h after birth, subsequent injection was given every other day for 2 weeks (a cumulative dose of 5,250U/kg over the course of 7 separate intravenous injections.
1481271|NCT03110341|Drug|Normal saline|placebo (Normal saline 3 ml/kg birth weight) was injected within 72h after birth, subsequent injection was given every other day for 2 weeks.
1481272|NCT03110328|Drug|MK3475|anti-PD1 immunotherapy
1481273|NCT03110315|Drug|Suvorexant|See detailed information in associated Arm Description.
1481274|NCT03110315|Drug|Placebo|Sugar pill manufactured to mimic suvorexant 10 mg tablet.
1481275|NCT03110302|Behavioral|Prolonged exposure|PE is a manualized treatment developed by Dr. Edna Foa and her colleagues. In all three treatment modalities, 7-15 weekly, 90 minute individual sessions of PE will be provided. PE is based on emotional processing theory, which proposes that avoidance and negative thoughts about the self and the world maintain PTSD symptoms over time. According to emotional processing theory, effective treatment requires repeated activation of the trauma memory (as through memory and in vivo exposure) and incorporation of corrective information into the trauma fear structure. PE has several primary components: (1) psychoeducation about PTSD and avoidance; (2) imaginal exposure with processing, wherein the participant describes the traumatic memory aloud many times and discusses it with the therapist afterward; and (3) in-vivo exposure, wherein the participant engages in feared, but safe, activities that have been avoided since the traumatic event (e.g., crowded places, driving).
1481276|NCT03110289|Other|superdonor FMT|"Fecal microbiota transplantation (FMT) is the transfer of feces from a healthy superdonor to the patient."
1481277|NCT03110289|Other|autologous FMT|Fecal microbiota transplantation (FMT) with feces from the patient him/herself
1481278|NCT03110276|Drug|EYP001a|10 mg and 100 mg capsules. Number of capsules to be ingested will depend on the dose cohort. Administered orally once daily. Single dose (SAD) or 14 days treatment (MAD).
1481279|NCT03110276|Drug|Placebo|Placebo capsules, identical in appearance to the EYP001a 10 mg and 100 mg capsules.
1481280|NCT03110263|Other|Multicomponent internet-based self-help|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., & Posner, D., 2006). The self-help program consists of eight text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
1481281|NCT03110263|Other|Internet-based sleep restriction|Internet-based self-help on the basis of (Perlis, M. L., Jungquist, C., Smith, M. T., & Posner, D., 2006). The self-help program consists of five text-based sessions and tasks. All participants in the active conditions receive guidance during 8-weeks treatment.
1481282|NCT03110237|Other|Control Balance Training (BT) class|Circuit training class with 11 stations, including: step-ups, ball kicking, balance beam, sit to stand, walk and carry, tandem walking, walking over a mat, walking up a ramp, walking at different speeds, speed walk, dual task walking.
1481283|NCT03110237|Other|Fallproof Balance Training (BT) class|There are four categories of exercises in this approach including: center of gravity control training (e.g. multi-directional weight shifts in standing, standing with altered base of support), multisensory training (e.g. standing on compliant surfaces, eyes open/closed), postural strategy training (e.g. resisted perturbation to facilitate ankle, hip or step strategy), and gait pattern variation training (e.g. walking with altered base of support , walking over and around obstacles). Each training category will be allocated 5 minutes with two exercises in each category. An additional 5 minutes will be allotted for games to challenge balance (balloon volleyball, pass the potato, circle soccer).There will be opportunity for group discussion and observational learning.
1481284|NCT03110211|Procedure|Physical Therapist Evaluation|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a physical therapist.
1481285|NCT03110211|Procedure|Primary Care Physician|Participants assigned to this group will receive an initial evaluation and treatment recommendations by a primary care physician.
1481286|NCT03110198|Drug|Mesalazine|Mesalazine enema rectal administration at bedtime 4g/100 ml, once daily
1481287|NCT03110198|Drug|hydrocortisone sodium succinate|hydrocortisone sodium succinate rectal administration at bedtime 100mg/100 ml, once daily
1481288|NCT03110198|Drug|Mesalazine with hydrocortisone sodium succinate|Mesalazine with hydrocortisone sodium succinate rectal administration at bedtime 4g，100mg/100 ml, once daily for induction of remission
1481289|NCT03110185|Device|EEG, fcDOT, fcMRI|Brain activity will be recorded using EEG, functional connectivity DOT and MRI will be used to evaluate differences in brain activity between patients with a delirium diagnosis and non-delirious control patients.
1481290|NCT03110172|Drug|Duloxetine Hydrochloride|The treatment group will receive duloxetine 60mg/24h to 8 weeks after operation
1481291|NCT03110159|Drug|Levulan® Kerastick®|Levulan® Kerastick® for Topical Solution will be applied to a designated area for 3 hours without occlusion prior to illumination with blue light
1481292|NCT03110159|Drug|BLU-U Blue Light Photodynamic Therapy|3 hours after Levulan® Kerastick® for Topical Solution is applied blue light illumination of designated area will be performed using the standard FDA approved treatment time of 16 minutes 40 seconds.
1481293|NCT03110146|Device|EnSite Precision|Ablation procedure
2000915|NCT03318367|Other|Educational Intervention|Complete virtual reality education module
2000916|NCT03318328|Other|survey|
2000917|NCT03318276|Drug|SID142|SID142 is administrated to patients with PAD for 12 weeks
2000918|NCT03318276|Drug|Rinexin® Tab|Rinexin® Tab is administrated to patients with PAD for 12 weeks
2000919|NCT03317860|Device|Sham tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
2010543|NCT02935894|Drug|Pilocarpine|Iontophoresis with a 1.5 milliampere (mA) current using a gel disc containing a 5% pilocarpine nitrate solution to induce sweating
1481303|NCT03110094|Other|Adalimumab|It will be an interventional study with minimal risks and constraints, prospective, mono-centric, in current care. Patient management will not be changed during the study. It will be taken at two different tracking points (M0 and M3) 4 additional tubes.
1481304|NCT03110081|Procedure|Quadratus lumborum block|Quadratus lumborum (QL) block for open partial nephrectomy.
1481305|NCT03110081|Procedure|Epidural analgesia|Epidural analgesia for open partial nephrectomy.
1481306|NCT03110068|Diagnostic Test|contrast-enhanced ultrasound|The Aplio SSA-770A or Aplio 500 (Toshiba Medical Systems, Tokyo, Japan) equipped with a 375BT convex transducer (frequency range, 1.9 to 6.0 MHz). CHI is used with a mechanical index that ranged from 0.06 to 0.10. After activating CHI mode, a bolus injection of 2.4 ml of SonoVue (Bracco, Milan, Italy) is administered intravenously via an antecubital vein, followed immediately by a flush of 5 ml of normal saline solution. The targeted lesion should be observed continuously for 5 minutes, and the entire arterial and portal venous phases and several repetitions of the late phase are stored on the hard disk. The arterial, portal venous and late phases are defined as 0-30 s, 31-120 s and 121-360 s after the injection, respectively.
1481358|NCT03109704|Procedure|Sham manipulation|"The sham manipulation will be performed with the patient and the examiner positioned in the same manner as for the seated manipulation, however the examiner will apply only minimal pressure to maintain physical contact and skin lock with the patient. The examiner will then move the patient through the same range of motion but deliver no manipulative thrust."
1481359|NCT03109691|Drug|bupivacaine|group 1
1481360|NCT03109691|Drug|Dexamethasone|group 2
1481307|NCT03110068|Diagnostic Test|contrast-enhanced computed tomography|The Aquilion 64-slice helical CT machine (Tokyo, Japan) is used. The imaging protocol for CT examinations is as follows: 0.5 mm × 64 mm collimation, 120 kV, 150-200 mAs for 64-slice helical CT examination. The standard triphasic scan procedure is used. An unenhanced helical sequence scan through the liver will be performed first; thereafter nonionic iodinated contrast material (Ultravist, Schering, Berlin, Germany) (1.5 mL/kg) will be administered via antecubital vein with power injection at a rate of 4 mL/s for 64-slice helical CT. The arterial phase sequence is obtained 25-32 s after contrast material administration, followed by a portal venous phase sequence 70 s after contrast agent administration.
1481308|NCT03110055|Drug|Grazoprevir/Elbasvir|anti-viral treatment for HCV
1481309|NCT03110055|Other|Medical records|Medical records of patients who underwent Transarterial Chemoembolization only, in the past.
1481310|NCT03110055|Procedure|Transarterial Chemoembolization|A minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply. Small embolic particles coated with chemotherapeutic drugs are injected selectively through a catheter into an artery directly supplying the tumor. These particles both block the blood supply and induce cytotoxicity, attacking the tumor in several ways.
1481311|NCT03110029|Drug|Efinaconazole 10% (Jublia)|Topical efinaconazole 10% solution
1481312|NCT03110029|Other|Application of nail polish|Application of nail polish only
1481313|NCT03110016|Device|Smartphone Application|The participants use SPSRS to watch the motion picture for at least 10 min a day for 5 weeks.
1481314|NCT03110003|Drug|10 mg Bupivacaine|10 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl injected to the epidural space
1481315|NCT03110003|Drug|5 mg Bupivacaine|5 mg of preservative-free isobaric bupivacaine with 12.5mcg of fentanyl in combination with 10 mL of sterile saline injected into the epidural space.
1481316|NCT03109990|Drug|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
1481317|NCT03109990|Drug|Saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
1481318|NCT03109977|Drug|Zr-DFO-pertuzumab PET/CT|Zr-DFO-pertuzumab studies will be performed as hybrid PET/CT examinations with known HER2-positive malignancy
2000920|NCT03317860|Device|Active tDCS|"Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand. tDCS is a form of noninvasive brain stimulation. Electrodes will be placed on the scalp but in the sham condition they will not deliver direct current (2mA). Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
Repetitive task-specific practice (RTP). Participants will practice using their paretic arm/hand to complete functional movements during the 30 minute train"
2000921|NCT03317158|Drug|Durvalumab|Durvalumab 1120 mg intravenously Day 1 every 21 days x 8 cycles.
1481321|NCT03109951|Drug|Colonoscopy preparation using polyethylene glycol|Colonoscopy preparation using standard preparation with 2L of polyethylene glycol.
1481322|NCT03109925|Device|DC Lumi Bead, BTG|Embolic agent which is radio-opaque
1481323|NCT03109912|Behavioral|Personalized-Coaching Interventions|At the baseline fitness assessment, participants receive exercise prescriptions based upon their individual assessment. One of the ultimate exercise prescription goals is to achieve 30-minutes of an endurance-style exercise 5 times/week which may vary depending upon baseline fitness assessment. Aside from team sports, endurance-style exercise prescriptions may include simply walking, jump roping or stair climbing to more complex Tabata-style workouts. Two additional physical therapy (PT) 30-minute appointments are scheduled about 4-6 weeks and 8-10 weeks from enrollment. These 30-minute PT follow-up appointments will vary based on initial assessment and previous exercise prescription success but will include strength training for major muscles groups and/or flexibility exercises with yoga as well as reinforcement of previously learned techniques. PT will add additional individualized recommendations.
1481324|NCT03109912|Behavioral|Motivational Messages|Intervention participants are enrolled to receive motivational messages starting 14 days after enrollment via preferred contact method (SMS, telephone call and/or email) every 3-4 days over the 6-month study period.
1481325|NCT03109912|Behavioral|Online Exercise Tutorials|Participants are given access to Do More, B'More, Live Fit webpage which includes spotlighted exercises, instructional exercise photos and videos.
1481326|NCT03109912|Behavioral|Social Support and Peer Challenges|Participants are invited to join the Do More, B'More, Live Fit Activity Group via the FitBit Dashboard and are invited to friend the study team members and other exercise-intervention participants in order to take part in FitBit step-goal challenges.
1481327|NCT03109899|Behavioral|Sex Pro mobile Application|Mobile mHealth app that provides HIV risk assessment, home HIV/STI testing options, and PrEP uptake support for young Black MSM.
2000922|NCT03317158|Radiation|External Beam Radiotherapy (EBRT)|EBRT 6 Gy x 3; Cycle 1 Day 1, 3, and 5
1481329|NCT03109873|Radiation|External Beam Radiation Therapy|Undergo External Beam Radiation Therapy
1481330|NCT03109873|Drug|Metformin Hydrochloride|Given orally
1481331|NCT03109873|Other|Placebo|Given orally
1481332|NCT03109860|Behavioral|Open-hidden|Administration of a treatment openly (in full view of the patient) vs hidden (without the patient's knowledge).
1481333|NCT03109847|Drug|Metformin Hydrochloride|Given Orally
1481334|NCT03109847|Other|Radioactive Iodine|Undergo radioactive iodine treatment
1481335|NCT03109847|Other|Placebo|Given orally
1481336|NCT03109834|Dietary Supplement|Meal replacement (MR)|"MR-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d and was advised to replace two meals, i.e. breakfast and dinner, every day with two MR shakes, soups or bars and to prepare their own lunch during 3-month weight loss phase (phase 1).
During 3-month weight stabilization phase (phase 2) MR-S group (MR group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The MR-S group was instructed to continue the implemented nutrition advice of weight loss phase.
Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
1481361|NCT03109691|Other|normal saline|group 3
1481362|NCT03109691|Device|ultrasound|in all groups
1481426|NCT03109249|Drug|Reference1613|Single intravenous infusion of 260 mg/m2 of Reference1613 delivered over 30 minutes in either of two periods (Period 1 or 2)
1481337|NCT03109834|Other|Control (C)|"During 3-month weight loss phase (phase 1) C-WL group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1200 kcal/d without MR for weight control.
During 3-month weight stabilization (phase 2) phase C-S group (C group during weight stabilization phase) were encouraged to consume a self-directed well-balanced variety of nutrient-dense foods without meal intervention. MR counted to food choice option. The C-S group was instructed to continue the implemented nutrition advice of weight loss phase.
Duration: 6 months (phase 1 and phase 2: baseline I - 6.month)"
1481338|NCT03109834|Dietary Supplement|Verum|"Verum: Specific micronutrient composition with omega-3 fatty acids (capsules)
Verum group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 verum-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase (phase 3).
Duration: 6 months (6.month / baseline II - 12.month)"
1481339|NCT03109834|Other|Placebo|"Placebo group followed an energy-restricted diet with a balanced variety of nutrient-dense food of approximately 1500 kcal/d and was advised to consume 3 placebo-capsules twice a day (with breakfast and dinner) with 200 ml water during 6-month weight loss maintenance phase.
Placebo contains no micronutrients and omega-3 fatty acids.
Duration: 6 months (6.month / baseline II - 12.month)"
1481340|NCT03109821|Other|Home-based exercise|"The intervention reflects the standard rehabilitation practice at Elective Surgery Centre. 3 weeks after surgery the patients will receive a thorough instruction and supervision in the strength training exercises that they are to perform without supervision at their own homes the following 7 weeks. The instruction is conducted one-to-one by physiotherapists and supported by an instruction booklet with written and illustrated exercise descriptions. The exercises included are: hip abduction, flexion and extension with elastic band resistance and sit-to-stand and one-legged stance. The prescribed training load will be two sets with repetitions to failure and a relative load of 10 to 20 RM (Repetition Maximum), performed every second day (3-4 times a week).
Exposure: Performed exercise dose will be quantified as the total physiological exercise stimulus (Time under tension summary dose) recorded by a sensor (BandCizer) attached to the elastic exercise band."
1481341|NCT03109808|Other|e-health strategy|"First, a personalized video of the patient's oral hygiene routine (toothbrushing and interdental hygiene) is recorded and made available to him-her via a cloud-based system. The patient is instructed to view it with his-her smartphone and/or tablet when brushing his-her teeth.
Second, the patient is registered in a text-based recall system. This recall system will remind him-her the oral hygiene regimen suited to his-her personal situation and contains a link to his cloud-hosted video. 12 text messages for each patient will be sent over the course of the study (8 weeks). This is a two-way system as patients will be inquired about their compliance to oral hygiene. If the patient declare compliance, he-she will be congratulated (positive reinforcement). If the patient declares non-compliance, he-she will be informed he-she will be offered additional counselling at the next appointment."
1481342|NCT03109808|Other|Traditional Oral Hygiene Education|traditional oral hygiene education
1481343|NCT03109795|Drug|Clonidine Pill|sympathetic nerve activity blockade
1481344|NCT03109795|Drug|Hydrochlorothiazide|Blood pressure-lowering control condition
2000923|NCT03317158|Biological|Bacillus Calmette-Guérin (BCG)|"Dose level 0 (starting dose) = Full-dose
Dose level-1 = 1/3rd-dose BCG"
2000924|NCT03316521|Drug|AMY-101|AMY-101 is a selective inhibitor of complement activation, which binds to the complement component C3.
1481347|NCT03109756|Drug|OV101|Single-dose 5 mg OV101
1481348|NCT03109743|Behavioral|Sisters-GPS: Group Clinical Visits|Sisters-GPS will be involve group clinical visits where by the same group participants with meet with a clinician and behaviorist to receive education, self-management skills development, and clinical assessment over the seven weekly group visits. The content will focus specifically on HIV medications and medication adherence. Additionally, the intervention will involve a private social media website where participants will be able to engage with one another between group clinical visits. Participants will receive food and a roundtrip Metrocard at each group clinical visit.
1481349|NCT03109743|Behavioral|Control: One-on-one Adherence Counseling|For participants in the control arm, the counselor will provide standard-of-care adherence counseling, which includes education about ARVs and the importance of adherence, and addressing non-adherence including assessment of psychosocial barriers to adherence. For visits to the adherence counselor, participants will receive round-trip MetroCards as per clinic policy. Control arm participants will be expected to attend a minimum of three visits with the adherence counselor.
2000925|NCT03316690|Drug|Metformin treatment|"Daily treatment with metformin tablets for 101 days according to the following scheme:
Day 1-4: Metformin tablet 500 mg x 2 Day 5-8: Metformin tablet 1000 + 500 mg Day 9-101: Metformin tablet 1000 mg x 2"
2000926|NCT03316690|Drug|Placebo treatment|"Daily treatment with placebo tablets for 101 days according to the following scheme:
Day 1-4: Placebo tablet 500 mg x 2 Day 5-8: Placebo tablet 1000 + 500 mg Day 9-101: Placebo tablet 1000 mg x 2"
1481355|NCT03109717|Drug|Monoamine Oxidase Inhibitor (MAOI)|Monoamine Oxidase Inhibitor
1481356|NCT03109704|Procedure|Supine upper thoracic spine thrust manipulation|The supine thrust manipulation will target the upper thoracic spine and will be performed as previously described. The patient will be asked to lace his or her fingers behind the neck and bring his or her elbows close together in front of the chest. The therapist will place one hand just below the targeted upper thoracic region (at either the T3 or T4 level) using a pistol grip or loose fist to make contact with both transverse processes of the T3 or T4 vertebrae. The therapist will then use his or her body to push down through the patient's upper arms to provide a high-velocity, low-amplitude thrust in the anterior-to-posterior direction.
1481357|NCT03109704|Procedure|Seated upper thoracic spine thrust manipulation|The seated thrust manipulation will target the cervicothoracic junction with the patient sitting with fingers laced behind the neck. The therapist will stand behind the patient and thread his or her arms through the patient's arms and clasp his or her hands near the C7-T1 level. The therapist will make contact with his or her chest against the patient's upper thoracic region to serve as a fulcrum. The patient will then be instructed to take a deep breath, and upon exhalation the therapist will apply a high-velocity, low-amplitude distraction thrust in a cephalad direction.
1481363|NCT03109678|Device|Crossover Ambu Aura-i™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the Ambu Aura-i™ / Rüsch Super Safety Silk™ group: crossover design using the Ambu Aura-i™ mask in combination with the LMA ETT™ tracheal tube
1481364|NCT03109678|Device|Crossover Ambu Aura-i™ / LMA ETT™|After unsuccessful blind intubation in the Ambu Aura-i™ / LMA ETT group: crossover design using the Ambu Aura-i™ mask in combination with the Rüsch Super Safety Silk™ tracheal tube
1481365|NCT03109678|Device|Crossover FASTRACH™ / Rüsch Super Safety Silk™|After unsuccessful blind intubation in the FASTRACH™ / Rüsch Super Safety Silk™ group: crossover design using the FASTRACH™ mask in combination with the LMA ETT™ tube
1481366|NCT03109678|Device|Crossover FASTRACH™ / LMA ETT™|After unsuccessful blind intubation in the FASTRACH™ / LMA ETT™ group: crossover design using the FASTRACH™ mask in combination with the Rüsch Super Safety Silk™ tube
1481367|NCT03109665|Diagnostic Test|SD-OCT Angiography|SD-OCT Angiography
1481368|NCT03109665|Diagnostic Test|SD-OCT|SD-OCT
1481369|NCT03109652|Drug|Tranexamic Acid|"On the day of operation, same dose of IV tranexamic acid(TXA) is given to all subjects in three study groups. Oral TXA is given from postoperative day 1 only to experimental groups. Duration of oral TXA administration is different between two experimental groups. (5 days in IV TXA and Oral TXA 5 days group and 2 days in IV TXA and Oral TXA 2 days group)"
1481370|NCT03109639|Device|Conventional EUS FNA needle|Participants randomised to Group A will undergo tissues acquisition using the Conventional EUS FNA needle and then crossed over to receive the experimental Acquire EUS- FNB device.
1481371|NCT03109639|Device|Acquire FNB device|Participants randomised to Group B will undergo tissue acquisition using the experimental Acquire EUS FNB device and then crossed over to receive the conventional EUS FNA needle
1481372|NCT03109626|Dietary Supplement|DHA|
1481373|NCT03109613|Device|Positive end-expiratory pressure (PEEP)|level changes as per arm description
1481374|NCT03109600|Biological|Vi-DT (Bio Farma)|Typhoid Conjugate Vaccine
1481375|NCT03109600|Biological|Vi polysaccharide vaccine|Vi polysaccharide vaccine
1481376|NCT03109600|Biological|Influenzae vaccine|1 dose of Influenzae vaccine
1481377|NCT03109600|Biological|Pneumococcal conjugate vaccine|1 dose of Pneumococcal conjugate Vaccine
1481378|NCT03109587|Dietary Supplement|Synbiotic (Probio-Tec® ABCG + Inulin)|Bifidobacterium BB-12: 2.4x1010 colony forming units (CFU)/day; lactobacillus LGG: 2.4x1010 CFU/day; lactobacillus acidophilus LA-5: 2.4x1010 CFU/day, lactobacillus casei 431: 2.4x1010 CFU/day, and 5 g inulin (prebiotic), maltodextrin, microcrystalline cellulose, sodium alginate, silicon dioxide and magnesium stearate.
1481379|NCT03109587|Dietary Supplement|Placebo|maltodextrin, microcrystalline cellulose, sodium alginate, silicon dioxide and magnesium stearate (non-active ingredients)
1481380|NCT03109574|Device|BioFlo DuraMax Chronic Hemodialysis Catheter|
1481381|NCT03109574|Device|Standard of Care Catheter|
1481382|NCT03109561|Other|Resting State Indirect Calorimetry|The investigator will measure the amount of oxygen participants breathe in and the amount of carbon dioxide they breathe out using a portable unit. Participants will be asked wearing a loose-fitting face mask that measures oxygen intake and carbon dioxide output.
1481383|NCT03109561|Genetic|ApoE|The investigator will conduct a genetic test on DNA isolated from from the participants blood. Participants will be asked to provide about 2 tablespoons.
1481384|NCT03109561|Diagnostic Test|Metabolism|To more accurately measure the amount of carbohydrates, fats and proteins that the participants bodies metabolize, participants will be asked to provide two urine samples (one at the beginning, and one at the end, of the study). The total amount of urine to be collected is approximately 4 teaspoons.
1481385|NCT03109561|Other|Cognitive Challenge|Participants will be asked to follow simple instructions that are displayed on computer screen.
1481386|NCT03109548|Other|Standard care initiated by the general practitioner|Patients are treated based on their symptoms and the research group does not interfere with this.
1481387|NCT03109535|Behavioral|Fitbit + Maptrek|Users receive a Fitbit Zip to wear daily. Users aslo receive the mHealth MapTrek game that places users in weekly walking races and sends automated text messages to users on a daily basis for the purpose of increasing daily physical activity.
1481388|NCT03109535|Behavioral|Fitbit only|Users receive a Fitbit Zip to wear daily.
1481389|NCT03109522|Procedure|axillary reverse mapping (ARM)|"ARM/SLNB: patient will be injected with technetium-99 radiolabelled colloid (Tc-99) into the subareolar area of breast, then 1-2 mls of blue dye (patent blue dye) injected subcutaneously into the medial ipsilateral arm, just proximal to the medial epicondyle of the elbow, at the start of the surgical procedure. the SLN(s) will be identified (hot node) and removed, and any blue lymph nodes and lymphatics will be preserved intact, and only removed or disrupted if there is 'crossover (i.e. the blue node is also the SLN) or if clinically suspicious for metastatic disease. ARM/ALND: 1-2 mls of blue dye will be injected subcutaneously into the medial ipsilateral arm at the start of the surgical procedure. Surgeons will perform a standard level I and II axillary dissection and any blue lymph nodes or lymphatics will be preserved intact, and only removed or disrupted if blue nodes are suspicious for metastatic disease."
1481390|NCT03109522|Procedure|Standard axillary surgery (SLNB or ALND)|The control group will have standard SLNB or ALND surgery without identifying or sparing upper-limb lymphatics and nodes (blue dye is not injected).
1481391|NCT03109509|Behavioral|Fitbit + Pokemon Go|Participants received a Fitbit Zip to wear daily for 8 weeks. Participants also received access to the Pokemon Go game.
1481392|NCT03109509|Behavioral|Fitbit Only|Participants received a Fitbit Zip to wear daily for 8 weeks.
1481393|NCT03109496|Other|Collection of body fluids/swabs|Middle ear, ear duct, anterior nare, nasopharynx, adenoids. Niches depend on accessibility for each individual participant.
1481394|NCT03109483|Other|Geriatric Activation Program Pellenberg|intensive multicomponent physical therapy week program
1481395|NCT03109457|Other|oral squamous cell carcinoma|Histological diagnosis of H&E stained sections will be performed according to WHO guidelines by 2 independent pathologists.
1481421|NCT03109275|Other|Single complete MRI intervention|MRI examination will comprise conventional T1 and FLAIR sequences, and advanced sequences such as rs-fMRI and High angular resolution MRI (HARDI).
1481422|NCT03109262|Diagnostic Test|Computed Tomography|Undergo PET/CT
1481423|NCT03109262|Diagnostic Test|Positron Emission Tomography|Undergo PET/CT
1481424|NCT03109262|Device|Yttrium Y 90 Glass Microspheres|Standard of care
1481425|NCT03109249|Drug|SPARC1613|Single intravenous infusion of 260 mg/m2 of SPARC1613 delivered over 25 minutes in either of two periods (Period 1 or 2)
2000927|NCT03316690|Behavioral|Physical training|Twelve weeks of supervised physical training (4 times per week, 45 min per session, mean intensity at 70% of maximal oxygen consumption rate)
1481397|NCT03109431|Behavioral|Level 1|"Youth will receive 1-5 text messages per day for 24 months. Banks of about 750 messages (70-120 messages per domain) focus on the HIV Treatment Continuum, with messages focused on dedicated to healthcare, wellness, sexual health, drug use and medication reminders. Youth will be able to choose the time and frequency that they receive daily texts. Preferences for the timing and type of messages can be updated at 4-month assessment points.
Youth will complete weekly monitoring surveys by text message. The survey will cover six domains related to the HIV Treatment Continuum. If YLH do not respond to the text, reminder messages will be sent to the youth. After three days of non-response a follow-up call by an interviewer will be made to the YLH."
1481398|NCT03109431|Behavioral|Level 2|"Youth will be enrolled in online, private discussion groups.
Peer Support will be offered by fellow participants and/or Youth Advisory Board members that have been trained in basic information on HIV, STI, drug use, mental health, homelessness, and stigma; using social media to create wall posts and use chat functions; and, how to initiate conversations on sensitive topics. By posting and responding to messages, Peer Supporters will encourage and broadly guide conversation related to the HIV Prevention Continuum, and other relevant topics.
Coaches and Project Coordinators will be available to provide factual information (as needed), and remove inappropriate content."
1481399|NCT03109431|Behavioral|Level 3|Youth will have be assigned to a Coach trained in a strengths--based Coaching intervention, as well as common foundational theory, principles and skills used in adolescent HIV Evidence-Based Interventions (EBI). Youth preferences will drive the intervention delivery - whether in-person, electronically via the phone, email, text message, social media private messaging.
1481400|NCT03109418|Drug|Ketamine|OSA patients receiving standard inhaled anesthesia combined with a low-dose ketamine infusion in which dosage will be based on ideal or adjust body weight
1481401|NCT03109418|Procedure|Control|OSA patients receiving standard inhaled anesthesia combined with normal saline
1481402|NCT03109405|Device|Stimulation-assisted venous access|Stimulation-assisted venous access
1481403|NCT03109405|Other|20 guage cannula for IV, tourniquet optional|Standard IV cannulation using 20 ga needle, and use of tourniquet at discretion of nurse performing IV cannulation
1481404|NCT03109392|Drug|Nebulized Lignocaine|2.5 ml of 4% lignocaine will be administered via nebulization prior to bronchoscopy
1481405|NCT03109392|Drug|Lignocaine spray|10 puffs of 10% (10mg/puff) lignocaine spray will be sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
1481406|NCT03109392|Drug|Combined spray and nebulization|Combination of 2.5 ml of 4% lignocaine via nebulization prior to bronchoscopy and 2 puffs of 10% (10mg/puff) lignocaine spray sprayed at 10 seconds intervals into the pharynx immediately prior to bronchoscopy
1481407|NCT03109379|Drug|Trospium-Releasing Intravesical System (TAR-302-5018)|TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.
1481408|NCT03109366|Behavioral|Online patient-provider communication service|
1481409|NCT03109353|Drug|ECP with 5-aminolevulinic acid|extracorporeal photopheresis (ALA-ECP) using 5-aminolevulinic acid instead of psoralen (8-MOP) in a maximum of 10 treatment cycles
1481410|NCT03109340|Other|Supervised treadmill group (Group I)|An exercise prescription was developed for each woman on the basis of the data acquired from the baseline treadmill exercise test. Target HR corresponding to values of 50-70% VO2max (moderate-intensity) was determined by the submaximal treadmill test.The participants were instructed walking exercise at their target HR on a treadmill in Sports Rehabilitation Unit of Pamukkale University. HR was monitored by a Polar HR monitor (Polar Beat, Port Washington, NY).During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
1481411|NCT03109340|Device|ECE PEDO pedometer (Group II)|Following a 10-minute rest after treadmill test, the participants were instructed to walk on the treadmill while maintaining their target heart rate. The number of steps taken in a minute was calculated using a criterion pedometer when target HR responses were reached. In this way, we determined the steps per minute required to moderate intensity walking for each participant. Detected individual step numbers were recorded to ECE PEDO for each person. Then participants were given the walking program with ECE PEDO giving audible feedback in case of any deviation from the range of steps per minute.During 12 weeks, 5 days in a week and 30 minutes per day walking program was applied.
1481412|NCT03109327|Diagnostic Test|Melanoma Detection System -MDS|Imaging of lesion using the MDS test.
1481413|NCT03109314|Drug|Donepezil|Donepezil will be administered to subjects three days before each training, and during training, to evaluate if donepezil improves the effectiveness of training.
1481414|NCT03109314|Behavioral|Single-letter training|Subjects will undergo training to identify single letters (10,000 trials, or 10 blocks per session for 10 sessions).
1481415|NCT03109314|Behavioral|Uncrowd training|Subjects will undergo training to identify letters closely flanked by other letters (10,000 trials, or 10 blocks per session for 10 sessions).
1992802|NCT03294603|Drug|CC-220|1mg [14C]-CC-220 will be administered as a single dose
1481417|NCT03109288|Drug|Pioglitazone|15-45 mg po qd
1481418|NCT03109288|Drug|Montelukast|10mg qd
1481419|NCT03109288|Drug|Losartan|50-100mg/day (can be divided bid)
1481420|NCT03109288|Drug|Hydroxychloroquine|200-400 mg qd/bid
1481493|NCT03108742|Device|INSORB|dermal stapler for skin closure
1591607|NCT02296671|Drug|Fluorouracil|
1992803|NCT03294603|Radiation|[14C]|Single dose of [14C]-CC-220 will contain approximately 1.4 μCi of radioactivity
2010544|NCT02935374|Drug|Amoxicillin|The children with acute otitis media will be treated with amoxixillin mixture, 100mg/ml, 40mg/kg/d, divided to two daily doses for 7 days.
2010545|NCT02935374|Drug|Amoxicillin-Potassium Clavulanate|The children with acute otitis media will be treated with amoxixillin-clavulanate mixture, 80mg/ml, 45mg/kg/d, divided to two daily doses for 7 days.
2010546|NCT02935374|Drug|Macrolide|The children with acute otitis media with a know allergy to amoxicillin or amoxicillin-clavulanate will be treated with macrolide and monitored separately
2010547|NCT02935179|Dietary Supplement|White sweet potato meal replacement|White sweet potato meal replacement
1481427|NCT03109236|Drug|Neupogen|5 doses of GCSF injection will be injected under the skin on the abdomen to mobilize the bone marrow cells.
1481428|NCT03109236|Procedure|CD133 Cells Transplantation|Endothelial progenitor cells are harvested by CD133+ MACS (magnetic activated cell sorting) sort selection of bone marrow and a minimum of 1x 10^6 and up to 50-100 x 10^6 cells are transplanted to one lobe of the liver via a percutaneous catheter inserted into the portal venous system by percutaneous transhepatic approach for engraftment.
1481429|NCT03109223|Other|sole source nutrition|Infant formula
1481430|NCT03109210|Behavioral|Online Cognitive Behavioral Therapy (OCBT)|Cognitive behavioral therapy delivered via commercial online software.
1481431|NCT03109210|Behavioral|Therapist-directed Cognitive Behavioral Therapy (TCBT)|Cognitive Behavioral Therapy delivered via traditional, in-person interaction with a licensed mental health professional.
1481432|NCT03109197|Other|Biospecimin Collection|
1481433|NCT03109184|Behavioral|Project STRONG|The web-based program consists of a number of games, activities, and didactic information that teens move through with their parent. Didactic information introduces teens and parents to specific emotion management, communication, and problem solving strategies as well as sexual health and healthy relationship information. Games and activities allow parents and teens to practice and apply strategies to developmentally appropriate situations.
1481434|NCT03109171|Other|Laryngopharyngeal sensory test|The sensory measurements will include thresholds for laryngeal adductor reflex, cough reflex, gag reflex, and psychophysical sensory thresholds at the velopharynx and hypopharynx.
1481435|NCT03109158|Drug|NC-6004|NC-6004 provided by NanoCarrier
1481436|NCT03109158|Drug|Cetuximab|Commercially Available
1481437|NCT03109158|Drug|5-FU|Commercially Available
1481438|NCT03109145|Other|Menopause educational secure messaging|Participants read educational material about menopause and treatment option for menopause symptoms once a week using secure messaging on a electronic patient portal.
1481439|NCT03109132|Device|Oridion Smart CapnoLine® H Plus with Wedge cannula|The subjects will assess the comfort level of the different cannulas
1481440|NCT03109132|Device|Oridion Smart CapnoLine® Plus with Non-Wedge cannula|The subjects will assess the comfort level of the different cannulas
1481441|NCT03109132|Device|Experimental sample line Model 3|The subjects will assess the comfort level of the different cannulas
1481442|NCT03109132|Device|Experimental sample line Model 4|The subjects will assess the comfort level of the different cannulas
1481443|NCT03109132|Device|Experimental sample line Model 5|The subjects will assess the comfort level of the different cannulas
1481444|NCT03109132|Device|O2/CO2 cannula w/female luer (Westmed comfort plus #0504)|The subjects will assess the comfort level of the different cannulas
1481445|NCT03109119|Drug|Sevoflurane|The patients in the group S will be exposed to routine concentrations of sevoflurane during anaesthesia.
1481446|NCT03109119|Drug|Propofol|These patients will be induced with propofol 1.5 mg / kg and maintained with propofol infusion.
1481447|NCT03109106|Device|PCT Arm|PCT-guided antibiotic therapy per study protocol
1481448|NCT03109093|Drug|Blinatumomab|"Patients will receive blinatumomab at a dose of 28 µg/day as continuous intravenous infusion at constant flow rate for four weeks, followed by a two-week infusion free interval, defined as one treatment cycle. Up to of four cycles will be performed.
In case of defined toxicities, the dose of blinatumomab may be reduced to 9µg/day.
Patients with an MRD relapse may qualify to receive additional treatment with blinatumomab."
1481451|NCT03109067|Other|Standardized meal|Blood samples performed at 5 different times : H0 before the meal, H2, H4, H6 and H8 after the meal
1481452|NCT03109054|Diagnostic Test|State-Trait Anxiety Inventory Test|All patients will take a State-Trait Anxiety Inventory Test. After the test patients will enroll low or high anxiety level.
1481453|NCT03109041|Device|CivaSheet|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiation source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
1481454|NCT03109028|Behavioral|Peer-to-Peer-Groupintervention|"Target group: Adult participants with mild to moderate depressive symptoms who prefer therapists with the same cultural background.
Therapists: Recruitment of psychosocial counselors within refugee community who have sufficient German or English language knowledge. Counselors will be trained for a time period of two months.
Content: Vulnerability and resilience factors; Self-efficacy strategies; Causes and consequences of stress; Possibilities on accelerating the integration process; Strategies preventing violence and radicalization Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two psychosocial counselors."
1481455|NCT03109028|Behavioral|Smartphone-based-Intervention|"Target group: Participants with moderate depressive symptoms who prefer an internet-based intervention.
Content: Five modules with 20 exercises elaborating on psycho-education, treatment options, self-management and diagnostics.
Form of therapy: Participants receive regular emails and sms to encourage steady participation via the internet-based smartphone-application. Weekly questionnaires ascertain the degree of participants symptomatology."
1481456|NCT03109028|Behavioral|Gendersensitive-Groupintervention|"Target group: Vulnerable group of adult women while taking cultural characteristics into account Therapists: Recruitment of psychosocial counselors (similar to Peer-to-Peer-Intervention); Training and supervision of gender-specific aspects.
Content: Focus on psycho-education which consider women specific topics such as gender-differences in symptoms and prevalence in psychic stress related and trauma disorders; physical, psychic and psychosocial consequences of traumatic and violent experiences; gender-specific risk and safety factors; stress and emotional self-regulation Form of therapy: Group-based intervention for a time period of three months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants; Headed by two female psychosocial counselors."
1481494|NCT03108742|Procedure|classic intradermal suture|intradermal suture for skin closure
1481735|NCT03106792|Dietary Supplement|Hairfinity #1|Main Hairfinity formulation
1481457|NCT03109028|Behavioral|Empowerment-Groupintervention|"Target group: Gender-balanced group with mild to moderate depressive symptoms. Therapists: Psychologists and doctors in psychotherapeutic advanced training; The therapist-training lasts for two months with continued supervision during the intervention.
Content: Low-threshold intervention based on the treatment of depression; psycho-education about psychic burdens, trauma, stress and grief as well as vulnerability and resilience factors; Problem solving and self-actualization strategies.
Form of therapy: Group-based intervention for a time period of two months; Two times per week with each session enduring 90 minutes; Group size between 8-10 participants;"
1481458|NCT03109028|Behavioral|Adolescent-Groupintervention|"Target group: Adolescent participants with moderate depressive symptoms. Therapists: Two child and adolescent psychiatrists with translators or two native speaking child and adolescent psychotherapists.
Content: Elements which are based on the START-Manual13 teaching emotion recognition and emotion regulation; Foundations are based on Dialetical behavior therapy; Specific focus lies on the use of mindfulness; Additionally the social network of the participants will receive psycho-education; Professional helpers in facilities will acquire E-learning elements of the SHELTER-program (Safety and Help for Early Adverse Life events and Traumatic Experiences in minor refugees)"
1481459|NCT03109028|Other|Treatment as Ususal|Participants will receive the currently conducted routine and standard psychiatric health care. This involves ambulatory and stationary treatment by board certificated psychiatrists and psychotherapists.
1481460|NCT03109015|Drug|Sunitinib|Patients randomized to sunitinib schedule 4/2 will receive sunitinib at 50 mg daily for 4 weeks on, followed by 2 weeks off, per standard of care. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 4 weeks and 12 weeks.
1481461|NCT03109015|Drug|Sunitinib|Patients randomized to sunitinib schedule 2/1 will receive sunitinib 50 mg daily for 2 weeks on, followed by 1 week off. Cardiopulmonary Exercise Testing (CPET) will be performed at baseline, 5 weeks and 12 weeks.
1481462|NCT03108989|Drug|Sugammadex|After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
1481463|NCT03108989|Drug|Neostigmine|After the end of surgery, neostigmine will be administered to reverse neuromuscular blockade.
1481464|NCT03108976|Other|Behavioral assessments|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
1481465|NCT03108976|Other|Magnetoencephalography (MEG)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
1481466|NCT03108976|Other|Magnetic Resonance Imaging (MRI)|Kinematics measures, concomitant to Magnetoencephalography (MEG, measures oscillatory rhythms in the brain) and Magnetic Resonance Imaging (MRI, used to provide an anatomical image of each participant's brain to be coregistered with oscillatory measurements) recordings, enable to track sensori-motor learning based on performance, and oscillatory changes (with high temporal and spatial resolution).
1481467|NCT03108963|Drug|L-carnitine and Metformin|L-carnitine plus Metformin was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
1481468|NCT03108963|Drug|placebo|placebo was given Obese PCOS Women trying induction of ovulation with clomiphene citrate.
1481469|NCT03108950|Behavioral|Movement to Music|The Movement to Music classes are composed of a set of exercises tailored to the specific needs and capabilities of each target group. The class will consist of and aerobic component and a strength component performed to varying music tempos. All movements will be choreographed by qualified dance instructors. Intervention is delivered using video-conferencing to connect the participant to their instructor.
2010548|NCT02935205|Drug|Enzalutamide|Given PO
1481472|NCT03108924|Drug|Gefapixant|After an overnight fast participants receive a single oral dose of 50 mg gefapixant, in one 50 mg tablet.
1481473|NCT03108911|Other|Best Practice|Receive standard diet
1481474|NCT03108911|Procedure|Biospecimen Collection|Provide stool sample
1481475|NCT03108911|Other|Dietary Intervention|Receive GFD
1481476|NCT03108911|Other|Laboratory Biomarker Analysis|Correlative studies
1481478|NCT03108872|Device|left atrial appendage occlusion|Percutaneous exclusion of left atrial appendage with Watchman or ACP devices
1481479|NCT03108872|Drug|New oral anticoagulants|Include dabigatran, rivaroxaban, apixaban and edoxaban
1481480|NCT03108846|Drug|Escitalopram|5-15 mg/day (target: 15mg/day if tolerated)
1481481|NCT03108846|Drug|Placebo|Masked placebo
1481482|NCT03108833|Drug|Recombinant Human Prourokinase|The drug is used for intravenous thrombolysis therapy
1481483|NCT03108833|Drug|Alteplase|The drug is used for intravenous thrombolysis therapy
1481484|NCT03108820|Behavioral|TMH Intervention|Home visits and close interaction with injured patient to assure plan for care is being followed.
1481485|NCT03108820|Other|Usual Care|Review hospital discharge and rehabilitation plan, identification of primary care provider, provision of educational materials on communication skills, caregiver coping skills, and legal and financial advice.
1481486|NCT03108807|Diagnostic Test|D-dimer test|D-dimer test
2010549|NCT02935205|Drug|Indomethacin|Given PO
2010550|NCT02932605|Drug|Placebo|Placebo
1481489|NCT03108768|Device|Hearing Aid (Successor of Phonak Virto V)|The successor of Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
1481490|NCT03108768|Device|Hearing Aid (Phonak Virto V)|Phonak's In-The-Ear (ITE) hearing aid Virto V will be fitted to the participants individual hearing loss.
2010551|NCT02932605|Drug|Cannabidiol|Cannabidiol
2010552|NCT02930018|Drug|NA-1, 2.6 mg/kg|Single intravenous infusion of NA-1 over 10 ± 1 minutes
2010553|NCT02930018|Drug|Placebo|Placebo Comparator: Placebo
2010554|NCT02928224|Drug|Encorafenib|Orally, once daily.
2010555|NCT02928224|Drug|Binimetinib|Orally, twice daily.
2010556|NCT02928224|Drug|Cetuximab|Standard of care.
2010557|NCT02928224|Drug|Irinotecan|Standard of care.
1481495|NCT03108729|Drug|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, taken once daily for 1 year. The daily maintenance dose will be within the range of 300 mg to 1600 mg ESL, and is determined by body weight, clinical response and tolerability.
1481496|NCT03108716|Procedure|hamate hook removal|The patients were assigned to treat with hamate hook removal.
1481497|NCT03108716|Procedure|microscrew internal fixation|The patients were assigned to treat with microscrew internal fixation after open reduction.
1481498|NCT03108716|Other|short-arm tube-type plaster fixation|The patients were assigned to treat with short-arm tube-type plaster fixation (conservative treatment).
1481499|NCT03108703|Radiation|SBRT|35-40 Gy delivered in 5 fractions
1481500|NCT03108690|Drug|Continuous infusion of beta-lactam antibiotics .|Beta-lactam antibiotic will be administered as continous infusion.
1481501|NCT03108690|Other|Therapeutic drug monitoring of beta-lactam antibiotics.|Dosage of beta-lactam antibiotics will be adjusted according to serum concentration.
1481502|NCT03108677|Other|Blood samples|15 ml peripheral blood
1481505|NCT03108651|Other|Case|Motivational message will be administrated.
1481506|NCT03108638|Behavioral|R3 Supervisor Implementation Strategy|Supervisors will be trained to provide supervision to their caseworkers using R3 principles and strategies. Monthly monitoring and remote coaching will be provided.
1481508|NCT03108612|Diagnostic Test|Análisis de carga de trabajo (ACT)|Semi-structured interview for detecting possible occupational etiology of an upper limb musculoskeletal disease that has been reported (by the worker) as possibly of occupational origin. The instrument is called Workload Analysis Instrument (WAI) or Análisis de Carga de Trabajo (ACT).
1481509|NCT03108599|Other|Enhanced Cab|The cab engineering intervention includes the introduction of an active suspension seat and a therapeutic mattress system. After a baseline phase, the intervention arm will receive the enhanced cab intervention alone, and then the enhanced cab plus a behavioral sleep intervention.
1481510|NCT03108599|Behavioral|Fit4Sleep|The behavioral sleep intervention includes a friendly dyad-based physical activity competition; self-monitoring and logging of physical activity, sleep hygiene behaviors, and sleep; and individual coaching. The intervention arm will receive the behavioral sleep intervention in combination with the enhanced cab intervention.
1481511|NCT03108586|Procedure|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
1481512|NCT03108586|Procedure|Dental treatment|Dental treatment of all dental needs present in adults related or not to the dental caries
1481513|NCT03108560|Procedure|sublobar resection|Patients receive sublobar resection, which includes wedge resection and segmentectomy.
1481514|NCT03108560|Procedure|lobectomy|patients receive lobectomy
1481515|NCT03108547|Other|Determination of scalp hair steroids|
1481516|NCT03108534|Drug|CHF1535 NEXThaler|Rescue treatment
1481517|NCT03108534|Drug|CHF1535 pMDI|Rescue treatment
1481518|NCT03108534|Drug|Placebo|Rescue treatment
1481519|NCT03108521|Drug|Sitagliptin|Januvia
1481520|NCT03108521|Drug|Liraglutide|
1481521|NCT03108508|Dietary Supplement|Prod1|60 mL of product (water, silicic acid, Equisetum Arvense, Rosmarinus officinalis) (Silicic acid) equivalent to 21.6 mg of elemental silicon.
1481522|NCT03108508|Dietary Supplement|Prod2|1.4 g of product (Orthosalicic acid) equivalent to 21.6 mg of elemental silicon
1481523|NCT03108508|Dietary Supplement|Prod3|120 mL of product (Aloe barbadensis Miller, organic silicon, potassium sorbate, cítric acid) (Organic silicon) equivalent to 21.6 mg of elemental silicon
1481525|NCT03108482|Drug|Co-crystal E-58425 (Tramadol/Celecoxib)|Co-crystal E-58425 (Tramadol/Celecoxib): Two immediate release oral over-encapsulated tablets of 100 mg, every 12 hours for 48 hours.
1481526|NCT03108482|Drug|Tramadol (Ultram®)|Tramadol: One immediate release oral over-encapsulated tablet of 50 mg, every 6 hours for 48 hours.
1481527|NCT03108482|Drug|Celecoxib (Celebrex®)|Celecoxib: One immediate release oral over-encapsulated capsule of 100 mg, every 12 hours for 48 hours.
1481528|NCT03108482|Drug|Placebo|Placebo 100 mg or 200 mg oral over-encapsulated tablets every 6 hours for 48 hours.
1481529|NCT03108469|Drug|IONIS-PKKRx (ISIS 546254)|Those randomized to IONIS-PKKRx (ISIS 546254) will receive subcutaneous injections containing 1.00 mL (200mg) of IONIS- PKKRx (ISIS 546254) weekly for weeks 1-16.
1481530|NCT03108469|Other|Placebo|Those randomized to placebo will receive subcutaneous injections 1.00 mL (200mg) weekly for weeks 1-16.
1481533|NCT03108443|Diagnostic Test|Optical Coherence tomography angiography|All subjects will have OCT angiography imaging performed
1481534|NCT03108430|Other|Risk factors and incidence of IP after inhalation|Calculate the annual incidence of PI, the incidence of PI in inhaled patients (in each subgroup), and analyze the risk factors by logistic regression, based on the number of patients hospitalized during the study period.
1481535|NCT03108417|Device|continuous negative external pressure|continuous negative external pressure will be applied to the anterior neck at night
1481536|NCT03108404|Other|Validation of a diagnostic test|Validation of a diagnostic test
1481537|NCT03108391|Device|Ambu AuraGain|
1481538|NCT03108391|Device|LMA Supreme|
1481539|NCT03108378|Procedure|Surgery|hip, shoulder or knee replacement surgery, limb amputations or other orthopedic surgical procedures
1481540|NCT03108365|Device|Axiostat|"Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.
Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
1992812|NCT03293407|Drug|Iloprost (Ventavis, BAYQ6256)|Using Breelib device
1481544|NCT03108339|Other|Guideline recommended physiotherapy care|The intervention will follow current care i.e. guideline informed intervention used by physiotherapists in the treatment of LBP in primary health care. The intervention will use a pragmatic approach and follow a framework of: 1) information of return to activity and to stay active 2) instruction on posture in loaded and unloaded positions 3) information on work and leisure based positions in activity and sitting 4) information on good sleeping position 4) instruction of an individualized exercise program based on findings from the examination enhancing core control 5) a choice of exercises as a home training program. Manual methods may if necessary be used. Choice of treatment, choice of exercises (loaded, unloaded) and also number of treatments is logged and noted.
1481545|NCT03108326|Biological|Stelara, Remicade, Entyvio, Humira, Remsima, Flixabi, Inflectra|The data of Crohn´s Disease (CD)-patients on Ustekinumab will be compared in an explorative analysis with CD-patients on other Biologics.
1481546|NCT03108313|Drug|aloe vera toothpaste|herbal toothpaste used to decrease salivary streptococcus bacterial count
1481547|NCT03108313|Drug|fluoride toothpaste|chemical toothpaste used to decrease salivary streptococcus bacterial count
1481548|NCT03108300|Drug|Propranolol Hydrochloride|propranolol hydrochloride is a beta-adrenergic receptor blocker
1481549|NCT03108300|Drug|Doxorubicin|Doxorubicin is a chemotherapy which will be injected by a dose 60 mg per meter square of body surface area to be repeated every 21days
1481550|NCT03108287|Drug|RAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily
1481551|NCT03108287|Drug|RBAK therapy|rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily
1481552|NCT03108274|Drug|Part 1, Period 1|Midazolam single oral dose
1481553|NCT03108274|Drug|Part 1, Period 2|Multiple doses ACH-0144471 Single dose Midazolam
1481554|NCT03108274|Drug|Part 2, Period 1|Fexofenadine single oral dose
1481555|NCT03108274|Drug|Part 2, Period 2|Multiple doses ACH-0144471 Single dose Fexofenadine
1481556|NCT03108274|Drug|Part 3, Period 1|Mycophenolate Mofetil single oral dose
1481557|NCT03108274|Drug|Part 3, Period 2|Multiple doses ACH-0144471 Single dose Mycophenolate Mofetil
1481558|NCT03108248|Drug|ethiodized oil; doxorubicin;Gelfoam;|Conventional TACE was performed in both groups as follows. First, multiple angiographies were performed to detect the hepatic arterial anatomy and the possible feeding arteries of tumor, selective catheterization of the artery feeding the tumors was performed. A mixture of ethiodized oil was injected, followed by injection of Gelfoam particles.
1481559|NCT03108248|Device|stent; idoine-125|In the ISP-TACE group, stent placement was performed one week before TACE. Under fluoroscopic and ultrasonic guidance, the outer stent was firstly placed at the site of the obstructed portal vein, and a self-expandable nitinol stent was immediately followed through a same 10-F sheath.
1481560|NCT03108235|Behavioral|HOM-HEMP|a 6-week nurse-led, home-based self-management psychosocial education programme comprising of a specifically developed Heart education toolkit, one education session and six weekly home visits.
1481561|NCT03108235|Behavioral|HOM-HEMP with smartphone app|a 6-week nurse-led, home-based self-management psychosocial education programme (HOM-HEMP), comprising of a specifically developed Heart education toolkit, one education session and six weekly home visits with Smartphone app. Your smartphone will be used to monitor your health data (such as weight, and blood pressure). The data will be synchronized to a web-connected portal on a remote server. The research nurse would be able to access your data through the web-connected portal and provide consultation through scheduled tele or video conference.
1481562|NCT03108235|Behavioral|Standard Care|standard care provided by the hospital. It consists of all nursing, medical, and follow-up services as needed.
1481563|NCT03108222|Other|Phosphorus Absorption Test|Subjects will undergo a radiophosphorus (P-33) absorption test over two days, that will include an oral administration of P-33 on the 1st day of the test, and an IV administration of P-33 on the 2nd day of the test. P-33 activity from serial serum and urine collections will be determined by scintillation counting, and fractional phosphorus absorption calculated by kinetic modeling.
1481564|NCT03108209|Other|Photoderm Max lait SPF50+|Subjects apply Photoderm Max lait SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
1481565|NCT03108209|Other|Photoderm Max Stick SPF50+|Subjects apply Photoderm Max Stick SPF50+ at the beginning of their treatment by Vemurafenib/Cobimetinib in prevention of phototoxicities
1481566|NCT03108196|Procedure|sigmoid|The serosal layer with smooth muscle was detached from a 15 cm sigmoid segment submucosal layer and removed continuously. Only the mucosal and submucosal layers were preserved. Approximately 2 cm of the taeniae and serosal layer were preserved to strengthen the urethra-neobladder anastomosis at the central portion of the isolated sigmoid and at the two ends for the ureter-neobladder anastomosis. The ureters were subsequently implanted in antirefluxing fashion in a submucosal tunnel. The ureter-neobladder anastomoses were protected with a 6Fr Single J® stent. The two ends of the sigmoid were closed with the embedded seromuscular layer. The neobladder was anastomosed to the urethra after that.
1481567|NCT03108196|Procedure|ileal|The isolated 70 cm terminal ileum segment is arranged in either an M or W shape and is opened along the antimesenteric border except for a 5 cm section where the incision is curved to make a U-shaped ﬂap. The four limbs of the M or W are then sutured to one another with a running absorbable suture. A small full-thickness segment of bowel is excised for the urethral anastomosis. Once the ileal neobladder is situated and the urethral sutures are tied, the ureters are implanted from inside the neobladder through a small incision in the ileum. The remaining portion of the anterior wall is then closed with a running absorbable suture. Ureteroileal anastomosis were performed with a freely refluxing, open end-to-side method at each end of the W.
1481568|NCT03108183|Diagnostic Test|x-rays|To get further and actual information about periapical lesions, different x-rays will be done (panoramic radiographic, small picture ray, cone beam computed tomography). Furthermore a periodontal status will be performed.
2010558|NCT02928224|Drug|Folinic Acid|Standard of care.
2010559|NCT02928224|Drug|5-Fluorouracil|Standard of care.
1481736|NCT03106792|Dietary Supplement|Hairfinity #2|Variation to main formulation
1481737|NCT03106792|Dietary Supplement|Hairfinity #3|Variation to main formulation
2010560|NCT02928107|Other|Tele-HS|Patients will be given information on the Tele-HS and given access to take the screening at home or in-office, depending on arm.
2010561|NCT02928107|Other|PCP encouragement|Patients will or will not either receive PCP encouragement to do the Tele-HS.
1481572|NCT03108157|Procedure|Endometrial scratch|Patients included in the study group will be performed an endometrial scratch with Pipelle Cournier 3 to 4 weeks before embryo transfer.
1481573|NCT03108144|Behavioral|Brief alcohol intervention|The intervention is a clinical decision support system (CDSS) that provides a computerized prompt in the clinic's online portal. The CDSS prompts a practitioner to intervene when a patient is screening above recommended drinking guidelines. The prompt appears as an alert message, recommending intervention. The portal suggests scripted brief intervention language, designed based on the College of Family Physicians of Canada and Canadian Centre on Substance Abuse's resource on conducting evidence-based Screening, Brief Intervention, and Referral to Treatment (SBIRT) guidelines.
2010562|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for Acquired AA|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3
Cyclophosphamide: Dose: 60mg/kg/day Days: -5, -4
Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2
Bone marrow infusion: Day 0"
2010563|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for iBMF with trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -7, -6, -5, -4, -3
Cyclophosphamide: Dose: 10 mg/kg/day Days: -6, -5, -4, -3
Thymoglobulin: Dose: 3mg/kg/day Days: -4, -3, -2
Bone marrow infusion: Day 0"
1481576|NCT03108105|Device|AOS-C2001-B|A new 2-piece appliance composed with 2 parts: a base plate and an ostomy collection special pouch (1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day)
1481577|NCT03108092|Other|STRIP intervention|The STRIP intervention consists of 9 steps: 1. structured history taking of medication 2. recording medication and diagnoses in STRIPA 3. structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria 4. communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation 5. shared decision-making with the patient with possible adaptation of the recommendation 6. optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions) 7. generation of general practioner (GP) report 8. delivery of the report to the patient and to the GP (optional additional direct communication) 9. follow-up
1481578|NCT03108092|Other|Control|Standard care in the department where the trial is conducted
1481579|NCT03108079|Device|Cystosure Urinary Access System|"Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms
The traditional Foley catheter (Catheter A)
The novel FDA approved Cystosure catheter (Catheter B)
Compare the fluid flow pattern during bladder drainage for
The traditional Foley catheter (Catheter A)
The novel FDA approved Cystosure catheter (Catheter B)
Compare the 3D bladder wall anatomy after emptying the bladder with
The traditional Foley catheter (Catheter A)
The novel FDA approved Cystosure catheter (Catheter B)"
1481580|NCT03108079|Device|Foley Catheter|"Demonstrate the 3D bladder wall anatomy with 300 cc of fluid infused with each of the following bladder drainage mechanisms
The traditional Foley catheter (Catheter A)
The novel FDA approved Cystosure catheter (Catheter B)
Compare the fluid flow pattern during bladder drainage for
The traditional Foley catheter (Catheter A)
The novel FDA approved Cystosure catheter (Catheter B)
Compare the 3D bladder wall anatomy after emptying the bladder with
The traditional Foley catheter (Catheter A)
The novel FDA approved Cystosure catheter (Catheter B)"
1481581|NCT03108066|Drug|PT2385 Tablets|PT2385 inhibits HIF-2α and is a novel approach to treatment of VHL disease-associated ccRCC.
1481582|NCT03108053|Procedure|Semirigid Ureteroscopy (URS) With Guide Wire|Semirigid URS is the operations used for ureteral stone disease. In routine practice it is most commonly done with the use of a guide wire. It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
1481583|NCT03108053|Device|Semirigid Ureteroscopy (URS) Without Guide Wire|Semirigid URS is the operations used for ureteral stone disease . It is conducted with ureteroscope and stone is disintegrated most commonly with lasers.
1481584|NCT03108027|Drug|Treatment A: Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)|Matching placebo (morning dose) and QVM149 150/50/80 μg (evening dose)
1481585|NCT03108027|Drug|Treatment B: QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)|QVM149 150/50/80 μg (morning dose) and matching placebo (evening dose)
1481586|NCT03108027|Drug|Treatment C: Placebo (morning dose) and placebo (evening dose)|Placebo (morning dose) and placebo (evening dose)
1481587|NCT03107988|Drug|Lorlatinib|Lorlatinib will be given orally once daily continuously in 28-day cycles. Lorlatinib will be provided as 5 mg or 25 mg tablets.
1481588|NCT03107988|Drug|Cyclophosphamide|Cyclophosphamide 250mg/m2/day will be administered as a 30 minute IV infusion on days 1-5 of each cycle
1481589|NCT03107988|Drug|Topotecan|Topotecan 0.75mg/m2/day will be administered as a 30 minute IV infusion immediately following cyclophosphamide on days 1-5 of each cycle
1481590|NCT03107975|Biological|human amniotic epithelial cells|intrathecal injection of human amniotic epithelial cells
1481591|NCT03107962|Drug|Pembrolizumab (PD-1 Blocking Antibody)|pembrolizumab 2mg/kg, ivgtt (intravenously guttae), d1. Every three weeks for one cycle and two cycles are required at least. Efficacy and safety were evaluated every two cycles.
1481592|NCT03107949|Device|Lungpacer DPTS (Diaphragm Pacing Therapy System)|Lungpacer Diaphragm Pacing therapy (DPTS) will be conducted in daily sessions until the patient has been extubated or day 30 if not extubated.
1481593|NCT03107936|Behavioral|game prototype|PlayForward: smokeSCREEN videogame to focus on smoking and use of tobacco products (electronic cigarettes (e-cigarettes) and flavored tobacco products) prevention in teens.
1481594|NCT03107923|Diagnostic Test|Dobutamine stress test|Test of myocardial reserve
1481595|NCT03107910|Behavioral|Stigma and Structural Interventions|Stigma focused counseling to address HIV anticipated stigma and online video chatting for HIV/STI testing will be assessed. Stigma and Structural Interventions
1481596|NCT03107910|Behavioral|Health Information Seeking|Seeking and evaluating online health information will be assessed.
1481597|NCT03107897|Other|Pre-habilitation|Eight - Twelve visits to physical therapy prior to their TAVR procedure.
1481738|NCT03106792|Dietary Supplement|Placebo|No active ingredients
1481600|NCT03107871|Drug|Valganciclovir|Valganciclovir is supplied as a powder for reconstitution into an oral solution. The reconstituted solution formulation comprises the following excipients: Povidone K30, fumaric acid, sodium benzoate, saccharin sodium, mannitol, flavor, and purified water.
1481601|NCT03107871|Drug|Simple Syrup|Simple Syrup contains sucrose 85% weight by volume, purified water, and methyl paraben as a preservative along with natural preservatives. It will be flavored to match the flavor of valganciclovir.
2000928|NCT03316443|Device|Glidescope|"The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter).
For endotracheal intubation with glidescope, size 3 blade will be used in all of the cases. Glidoscope will be advanced gently in the oral cavity (in the midline) and walked down the tongue. The scope will be further advanced into the vallecula and gentle lifting force will be applied for visualization of the glottis. Endotracheal tube will be loaded on specific rigid stylet with 60 degree bent and will be advanced into the trachea by the same operator.
Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation."
1481604|NCT03107845|Behavioral|Cognitive Behavior Therapy|Treatments are conducted by cognitive-behavioral therapists in training with different levels of experience as well as licensed cognitive-behavioral therapists with several years of experience. The treatment approach is based on cognitive-behavioral manuals and principles.
1481605|NCT03107845|Behavioral|CBT plus Feedback|Therapists of the IG1 are provided with information about the initial status concerning symptoms (BSI & OQ-30), interpersonal functioning (IIP-32 & OQ-30) as well as diagnoses specific symptoms (GAD-7 or PHQ-9). Beside the status measures, also individual progress information on the symptom level (HSCL-11 each session) is provided to the therapist. Randomized controlled trial to evaluate the effects of personalized prediction and adaptation tools on treatment outcome in outpatient psychotherapy. This group is a matched sample.
1481606|NCT03107845|Behavioral|CBT plus Feedback plus CST|"Additional to the intervention group CBT and Feedback therapists will be provided with additional clinical support tools (CST) which are designed to facilitate treatment selection and treatment adaptation. The causes of deterioration will be assessed and therapists will be provided with additional treatment recommendations and material to help preventing treatment failure for a specific patient. During treatment the clinical support tools will be provided in the problem fields: risk/suicidality, motivation / treatment goals, therapeutic relationship, social support / critical life events, and emotion regulation / self regulation."
1481607|NCT03107832|Procedure|thoracic epidural anesthesia procedure|general anesthesia procedure
1481609|NCT03107806|Device|OptiScanner®|"Glucose monitoring by OptiScanner® for 48 h
Glucose lowering intervention (insulin) guided by OptiScanner®"
1992813|NCT03293407|Device|Breelib nebulizer|Used for inhalation of Ventavis
1481615|NCT03107767|Procedure|PRO-malleol algorithm|An evidence based algorithm for ankle fractures
1481616|NCT03107754|Drug|Lidocaine|Paracervical block will be injected at 4 points at the cervicovaginal junction to decrease pain
1481617|NCT03107754|Drug|Lidocaine-Sodium Bicarbonate|Paracervical block will be injected at 4 points at the cervicovaginal junction to decrease pain
1481618|NCT03107741|Other|Generic Fitness|Subjects in this groups will receive three fitness lessons in a week while each session last for 1 hour throughout the 12 weeks experimental period
1481619|NCT03107741|Other|Tai Chi|Subjects in this groups will receive three Tai Chi lessons in a week while each session last for 1 hour throughout the 12 weeks experimental period
1481620|NCT03107728|Device|Advanced orthotic brace|Participants will use an advanced exoskeletal orthosis.
1481621|NCT03107728|Device|Conventional orthotic brace|Participants will use the standard of care orthosis
1481622|NCT03107715|Behavioral|Breastfeeding Champion|iPad-based behavioral intervention facilitated by researcher
1481623|NCT03107715|Behavioral|Positive Messaging|iPad based behavioral intervention facilitated by researcher
1481624|NCT03107702|Diagnostic Test|melatonin|the relationship between melatonin level and analgesia requirement.
1481625|NCT03107689|Other|administration of intravenous lipid emulsion|all patients receive intravenous lipid emulsion at the discretion of the treating provider. This registry prospectively collects detailed information on such patients
1481626|NCT03107676|Other|trunk extensors endurance training|endurance training
1481627|NCT03107663|Drug|89Zr-Df-IAB22M2C Infusion|A single dose of 3 (±20%) mCi of 89Zr-Df-IAB22M2C (0.2 mg to 1.5 mg of protein) will be administered intravenously over 5-10 minutes.
1481628|NCT03107650|Procedure|Transanal total mesorectal excision of rectal cancer|To perform a total mesorectal excision through a transanal approach
1481629|NCT03107611|Drug|Pimecrolimus Cream, 1%|
1481630|NCT03107611|Drug|Placebo Cream|
1481631|NCT03107598|Drug|colloid preload|coparaison between colloid and crystalloide loading in spinal anesthesia for cesarean section
1481632|NCT03107585|Procedure|bilateral cervical plexus block|with a linear probe and after disinfection vascular neck axis are identified at first. At the cricoid cartilage we conducted an apical scan to locate the carotid bifurcation.at this level is carried out a lateral translation to the visibility of the deep cervical space below the sternocleidomastoidien muscle then a needle 50 is introduced in plane. we proceed in inundation of cervical space
1481633|NCT03107559|Diagnostic Test|perfüsion index|Determination of the relationship between VAS values and PI in patients with normal delivery who undergo epidural analgesia
1481634|NCT03107546|Device|Hyalomatrix|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
1592583|NCT02289768|Drug|Vehicle|
1992814|NCT03293043|Device|NPV-EVLP|Lungs deemed marginal based on standard lung donor criteria that meet study eligibility will be physiologically assessed during ex-vivo perfusion. NPV-EVLP of these lungs will be performed with the addition of numerous pre-determined additives. With respect to the decision of lung utilization post-EVLP, eligibility criteria listed in the Post-NPV-EVLP section of the trial will need to be met. Lungs will also be excluded if they are deemed unsuitable based on the clinical judgment of the lung transplant surgeon.
1481635|NCT03107546|Other|Skin graft|We are comparing two techniques for covering the open area of the finger at the end of syndactyly release surgery. We would like to compare the current technique, a skin graft, with a new technique called Hyalomatrix.
1481636|NCT03107533|Other|Video recording of clinical visit|For patients and parents that are considering scoliosis surgery, a video recording of the encounter will be obtained during their routine clinical visit to discuss surgery/options.
1481637|NCT03107520|Diagnostic Test|Intraoperative contrast-enhanced ultrasound (CEUS)|An intraoperative CEUS of the dysplastic femoral head will be performed after surgical reduction of the femoral head and during placement of the spica cast.
1481638|NCT03107520|Drug|Lumason|Administration of Lumason contrast agent to improve visualization of epiphyseal vascularity in the femoral head.
1481639|NCT03107507|Drug|Levetiracetam|Given in a bolus dose first 50mg/kg as levetiracetam reaches a therapeutic serum level rapidly in 1.3 hours. Titration will not be attempted in our study to reach drug level rapidly and consequent rapid effective control of seizures. Maintenance dose is then given at a dose of 10 - 40mg/kg/day divided every 12 hours.
1481640|NCT03107507|Drug|Phenobarbital|Phenobarbital is given intravenously in the form of a loading dose of 15mg/kg that can be repeated after a 20 minute interval not to exceed 30mg/kg then a maintenance dose 2-4 mg/kg/day divided every 12 hours.
2000929|NCT03316443|Device|Macintosh|The patient will be intubated by suitable sized tube (in males 8 mm and in females 7.5 mm internal diameter). In Macintosh group we will use a blade size 3 at first. The laryngoscope will be advanced in patient mouth displacing the tongue laterally till the laryngoscope reach the vallecula and then gentle lifting will be applied till visualization of the laryngeal inlet then the tube will be advanced.Systolic, diastolic, mean arterial blood pressure and heart rate will be recorded at the following time points: T1: before anesthesia, T2: after induction and immediately before intubation, T3: immediate after completion of intubation, T4: after 1 minute of intubation, T5: after 2 minutes of intubation, T6: after 3 minutes of intubation, T7: after 5 minutes of intubation, T8: after 10 minutes of intubation.Maximal arterial blood pressure and heart rate changes will be recorded
1481642|NCT03107481|Drug|Acetaminophen|Acetaminophen 1g IV
1481643|NCT03107481|Drug|Hydromorphone|Hydromorphone 1mg IV
1481644|NCT03107468|Other|Mokhuri intensive treatment|Patients in this arm will be treated with acupuncture, Chuna and patient consultation during 5 weeks. For acupuncture therapy, disposable sterile needles will be placed on LI4, ST36, LV3, B22, B23, B24 and B25 of both sides of a patient for 15 minutes. For Chuna therapy, the patient lies on the Ergo Style™ FX-5820 Table in the prone position and back muscles will be relaxed by manual manipulation during flexion and extension movement of the table for 5 to 6 minutes. Patient consultation regarding the precautions for everyday life, the precautions for activity in bed, the precautions for walking, the precautions for particular movements and the exercises will be offered for 5 minutes.
1481645|NCT03107468|Other|Non-surgical conventional standard treatment|Patients in this arm will be treated with 10 sessions of non-surgical conventional standard treatment including conventional drug treatment and injection treatment under the consultation of neurosurgeons or doctors of anesthesiology or rehabilitation medicine during 5 weeks. For drug therapy, muscle relaxants, NSAIDs, gabapentin, pregabalin or tricyclic antidepressants will be prescribe. For epidural steroid injection, 3cc of epidurals will be injected at the affected lesion once or twice. For physical therapy, participants shall participate in conventional physical therapy with the aid of physical therapists, including heating pad, deep tissue heating device and transcutaneous electrical nerve stimulation (TENS) twice a week during the five weeks of participation.
1481646|NCT03107455|Device|MitraClip|MitraClip consists in two clip arms and opposing grippers, which can be opened and closed against each other in order to grasp and gain cooptation of MV leaflets at the origin of the regurgitant jet
1481647|NCT03107442|Behavioral|Aerobic exercise|12-weeks aerobic exercise intervention based on the physical activity guidelines from the American College of Sports Medicine (≥150 min/week of moderate to vigorous [40-85% of the individual's heart rate reserve] exercise). Participants will perform the exercise on treadmills at the hospital. The volume and intensity of the exercise will progressively increase throughout the 12 weeks.
1481648|NCT03107429|Drug|Acetazolamide|Acetazolamide tablets were placed in capsules to make them look similar to placebo.
1481649|NCT03107429|Drug|Placebo|Placebo was a sugar based placebo placed in a capsule.
1481650|NCT03107429|Other|Trendelenburg Position|Placed in Trendelenburg Position
1481651|NCT03107416|Procedure|Hepatic artery embolization (HAE)|The intervention being studied is HAE for the treatment of HCC in combination with Bumetanide. HAE is a standard of care procedure.
1481652|NCT03107416|Drug|Bumetanide|Intra-arterial (IA) injection of 0.01mg/kg of Bumetanide in the first cohort, 0.02 mg/kg in the second cohort and 0.1 mg/kg of IA Bumetanide in the final cohort patients during standard HAE until stasis is evident.
1481653|NCT03107403|Behavioral|web form|The scale assessing the bereavement process is the one reported in Teissier 2010
1481654|NCT03107390|Other|Evaluate the blood level of NTproBNP|Evaluate the blood level of NTproBNP in patients with MICI compared to a healthy control population.
1481657|NCT03107364|Other|Hospital stay|Collection of hospital lengths of stay and readmissions
1481658|NCT03107351|Device|Cardiac contractility assessments with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device. Echocardiography will also be used for the experimental arm
1481659|NCT03107351|Device|Cardiac assessment repeatability with Kino-cardiograph|Cardiac contractility will be assessed with Kino-cardiograph device only, at different times of the day to assess the repeatability of the measures.
1481660|NCT03107338|Drug|DEXKETOPROFEN TROMETAMOL|Patients who were administered a single dose of 25 mg of DKT 15 minutes before surgery
1481661|NCT03107338|Other|Placebo|Patients who were administered a single dose of 500 mg of Vitamin C 15 minutes before surgery
1481664|NCT03107312|Procedure|Single blood sample collection|Collection of single blood sample of 10 ml volume by venepuncture
1481665|NCT03107299|Other|Communication methods to encourage adherence|Prospective randomized controlled study in intention to treat in open monocentric in 3 arms: all patients benefiting from the current management (medical consultation every 4 to 6 months in the department of rheumatology)
2000934|NCT03315793|Drug|Duloxetine Hydrochloride|Administered orally
1481668|NCT03107273|Other|Dynamic cultures of in vitro hematopoietic stem cells|Improvement of prognostic scores used in myelodysplastic syndromes by identifying by dynamic in vitro culture of hematopoietic stem cells dynamic factors, reflections of ineffective haematopoiesis
1481669|NCT03107260|Other|To evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in emergency surgery in elderly patients|Evaluate the relationship between oxygen saturation and the incidence of postoperative cognitive dysfunction in non-cardiac, thoracic and vascular emergency surgery in patients 65 years of age and older. The occurrence of POCD will be defined by the MMSE decrease of at least 4 points at 24, 48 or 72 hours
2000935|NCT03315793|Drug|Placebo|Administered orally
2000936|NCT03315689|Drug|Vehicle|Vehicle Topical Solution
1481672|NCT03107234|Other|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues|Assess the level of expression of IP3R3 in cancerous tissues and healthy tissues
1481673|NCT03107221|Behavioral|"Smart Eating internet-based self-help programme"|An internet-based self-help programme using cognitive behavioural therapy principles to treat individuals receiving input from a specialist eating disorders service. The programme takes 3 months to complete.
2000937|NCT03315689|Drug|ATI-50002|ATI-50002 Topical Solution
2000938|NCT03315455|Drug|Emicizumab|Emicizumab will be administered via SC injection.
2000939|NCT03315390|Other|"Narrative Exposure Therapy-oriented intervention"|Narrative Exposure Therapy (NET) in an Primary-care adapted Version in 3 sessions (S) 6 weeks (S1), 8 weeks (S2) and 12 weeks (S3) after baseline data collection at T0.
1481677|NCT03107182|Drug|nab-paclitaxel|All enrolled patients will receive three 21-day cycles of nab-paclitaxel (100 mg/m2 on days 1, 8, 15; 9 doses total)
1481678|NCT03107182|Drug|Carboplatin|All enrolled patients will receive three 21-day cycles of carboplatin (AUC 6 on day 1; 3 doses total).
1481679|NCT03107182|Drug|Nivolumab|"All enrolled patients will receive three 21-day cycles of nivolumab (360 mg on days 1; 3 doses total).
Adjuvant nivolumab will be offered to all patients for 6-months post completion of locoregional therapy for a total of 7 doses."
1481680|NCT03107182|Drug|Cisplatin|Cisplatin will be given on an every 3 weeks basis at a dose of 100 mg/m2 IV over 3-4 hrs day 1 (or 2) and 22 (or 23). Only for patients on the Intermediate Dose Arm and additionally on day 43 (or 44) for patients on the Regular Dose Arm.
1481681|NCT03107182|Drug|Hydroxyurea|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 patients will start hydroxyurea at 500 mg PO q 12 hours x 6 days (11 doses). The first daily dose of hydroxyurea on days 1 - 5 is given 2 hours prior to the first fraction of daily radiotherapy.
1481682|NCT03107182|Drug|5-FU|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On day 0 at 1800 patients will start continuous infusion of 5-FU at 600 mg/m2/day x 5 days (120 hours).
1481683|NCT03107182|Drug|Dexamethasone|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive dexamethasone 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel
1481684|NCT03107182|Drug|Famotidine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive famotidine 20 mg PO (IV) in am Day 1, 1 hr prior to paclitaxel.
1481685|NCT03107182|Drug|Diphenhydramine|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will receive diphenhydramine 50 mg PO (IV) in am Day 1, 30 mins prior to paclitaxel.
1481686|NCT03107182|Drug|Paclitaxel|Patients on the Intermediate or Regular Dose Arms will receive chemoradiation for 3-5 cycles (6-10 weeks). On days 1-5 patients will start paclitaxel 100 mg/m2 after first RT fraction on day 1 of each cycle. Paclitaxel should be administered in 250 ml 0.9% NaCl over 60 minutes.
1481687|NCT03107182|Procedure|Transoral robotic surgery (TORS)|Patients with low risk and small volume tonsillar disease (T1-T2, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) or base of tongue disease (T1-2 with lateralized primary ≤3 cm, non-bulky N2A-N2B with ≤2 non-lower neck lymph nodes measuring ≤5 cm in size) who have ≥50% reduction by RECIST following induction chemotherapy will undergo TORS and selective nodal dissection. Patients may refuse TORS treatment. Patients will receive RT or TORS.
1481688|NCT03107182|Radiation|Adjuvant RT|Patients with low risk, who do not qualify for TORS (due to volume of disease or poor visualization/access) or refuse TORS, who have ≥50% reduction by RECIST following induction chemotherapy will be given de-intensified treatment with radiation alone to 50 Gy. Patients will receive RT or TORS.
1481689|NCT03107182|Radiation|Chemoradiotherapy|"Patients who have low risk disease with <50% but ≥30% reduction, or patients who have high risk disease and ≥50% reduction of tumor by RECIST with induction chemotherapy will receive CRT to 50 Gy with concurrent bolus cisplatin (x2 doses) or TFHX to 45 Gy (3 cycles).
Patients who have low risk disease and <30% reduction of tumor, patients who have high risk disease and <50% reduction of tumor by RECIST, or any patient who has progressive disease with induction chemotherapy will receive CRT to 70 Gy with concurrent bolus cisplatin (x3 doses) or TFHX to 75 Gy (5 cycles)."
1481690|NCT03107169|Other|FMT|Patients in the FMT group received FMT-FURM
1481691|NCT03107169|Drug|Vancomycin|Patients in the vancomycin group received oral vancomycin (250 mg every 6 h for 10-14 days)
1481741|NCT03106766|Drug|Acne cream 2X|Twice daily application of facial acne cream 2X after facial cleansing
1481742|NCT03106766|Drug|Acne cream 1X|Twice daily application of facial acne cream 1X after facial cleansing
2000940|NCT03315390|Other|improved treatment as usual (iTAU)|improved standard primary care for PTSD according to Guidelines, customized to patients' needs and symptoms during 3 consultations between T0 and T1
2000941|NCT03312933|Device|Wearing CAM Walking Boot|Each arm will be given a different amount of time to wear the CAM walking Boot for their injury.
1481692|NCT03107156|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of treatment decision making, enabling providers to deliver evidence-based and personalized treatment care plans to their NSCLC patients on active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROS) and clinical data, reported and generated by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is drive by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by cancer clinicians and researchers.
1481693|NCT03107143|Device|Q2 System|
1481694|NCT03107117|Behavioral|Computer Counseling|two computer counseling online programs for a teen and a parent
1481695|NCT03107117|Behavioral|Standard Care|A referral for substance use counseling
1481696|NCT03107104|Device|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT with a fundus camera used for diagnostic purposes
1481697|NCT03107104|Device|TRC-50DX retinal camera|The TRC-50DX retinal camera is a fundus camera used for diagnostic purposes
1481698|NCT03107091|Drug|Terlipressin acetate continuous infusion|Low-dose continuous infusion of Terlipressin administered via ambulatory pump over 28 days
1481699|NCT03107078|Drug|Glucocorticoids|Intravenous Glucocorticoids (GCs)
1481700|NCT03107065|Device|Thermi Radiofrequency|Percutaneous-Temperature Controlled-Radiofrequency Electrocoagulation
2000942|NCT03313531|Diagnostic Test|Thrombin Generation Assay|Inter lab variation and level of agreement will be determined
1481702|NCT03107039|Behavioral|Exercise|A 12 week resistance exercise curriculum
1481703|NCT03107039|Behavioral|Health Education|A 12 week health education curriculum
2000943|NCT03313531|Drug|Treatment with recombinant coagulation factor|To obtain a wide range of thrombingeneration levels, one person (Treated HA person) will recieve one injection of Advate and one injection of Adynovate respectively
2000944|NCT03312062|Other|Foam Rolling Exercise|We can think that it is type of exercise. These exercise will done by actively. Participants will use a foam roller for exercise. They will position the foam roller on the chair. Afterwards, they will use their body weights to rub the elbow area (biceps brachii muscle) with this foam. It will be 2 sets. Each set will be 1 minute.Foam rolling exercise will be applied 10 times each for 1 minute. Will be resting period for 30 seconds between sets.
2000946|NCT03311724|Drug|LY3298176|Administered SC
1481708|NCT03107000|Procedure|Trabeculectomy|Incisional surgery for glaucoma
1481709|NCT03107000|Procedure|Phako-trabeculectomy|Incisional surgery for glaucoma plus cataract
2000947|NCT03311724|Drug|Placebo|Administered SC
2000948|NCT03311217|Behavioral|Healthy retail strategies|
1481712|NCT03106974|Device|orotracheal intubation Macintosh Laryngoscope|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
1481713|NCT03106974|Device|orotracheal intubation Totaltrack VLM|orotracheal intubation (OTI) after induction of anesthesia and complete relaxation
1481714|NCT03106961|Device|Bioresorbable vascular scaffolds, OCT, non-compliant ballooning|Measure the effect of high-pressure, NC ballooning on scaffold embedding by OCT
1481715|NCT03106948|Drug|Placebo|Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
1481716|NCT03106948|Drug|Ascorbic Acid|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
1481717|NCT03106948|Drug|Cuprimine Oral Product|Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
1481718|NCT03106935|Drug|Levothyroxine|Levothyroxine is an orodispersible tablet.For the LT4 treatment group, 50μg LT4 (Merck Serono, Geneva,Switzerland) was administered every morning from the first day of diagnosed as subclinical hypothyroidism and continued up to the day of serum β-HCG measurement.If pregnancy was confirmed, levothyroxine dose need to increase 25-30% and adjusted according to the pregnancy specific reference range ( T1 0.1－2.5mIU/L,T2 0.2-3.0mIU/L, T3 0.3-3.0mIU/L) .
1481719|NCT03106922|Drug|PMF104|"Powder for oral solution:
Sachet A: macrogol 4000 52.500 g, anhydrous sodium sulphate 3.750 g, simeticone 0.080 g;
Sachet B: sodium citrate 1.863 g, anhydrous citric acid 0.813 g, sodium chloride 0.730 g, potassium chloride 0.370 g;
One sachet A + 1 sachet B in 500 ml of water"
1481720|NCT03106922|Drug|Klean-prep|"Powder for oral solution:
macrogol 3350 59.000 g, anhydrous sodium sulphate 5.685 g, sodium bicarbonate 1.685 g, sodium chloride 1.465 g, potassium chloride 0.7425 g.
One sachet to be dissolved in 1 L of water"
1481721|NCT03106909|Radiation|pulmonary computed tomography (CT)|Pulmonary CT imaging
1481722|NCT03106883|Behavioral|Affective training|3 sessions of active training using affective faces to modify the negative attention bias in depression
1481723|NCT03106883|Behavioral|Sham training|3 sessions of sham attention training using non-affective stimuli
1481724|NCT03106870|Drug|Insulin Mixtard|"Insulin dose:
0.7 IU/Kg (at the second trimester of pregnancy).
0.8 IU/Kg (at the third trimester of pregnancy). Insulin dose was raised at a rate of 1 IU for every 10 mg/dl higher than the target blood glucose concentration."
1481725|NCT03106870|Drug|Metformin|"Oral metformin at a dose of 1500 mg divided into three doses, were taken with meals, in addition to insulin.
If the target blood glucose concentrations were not attained, the dose of metformin was raised to 2000 mg per day."
1481726|NCT03106857|Other|Group A|Group A Physical activity and low caloric diet for
1481727|NCT03106844|Drug|Fecal Microbiota Transplantation|Patients with at least 2 episodes of CDI and IBD will undergo a single FMT
2000949|NCT03310944|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablets
Route of administration: oral"
1481730|NCT03106818|Drug|bupivacain with magnesium sulphate|will receive bupivacain 0.125% and magnesium sulphate 5% infusion in the presternum , for 48 hours
1481731|NCT03106818|Drug|Bupivacaine only|will receive bupivacain 0.125% infusion in the presternum , for 48 hours
1481732|NCT03106818|Drug|conventional|only conventional post operative analgesics will be used
1481745|NCT03106740|Drug|Minocycline Hydrochloride 100mg Capsule|Minocycline 100mg will be administered by mouth daily for 2 weeks
1481746|NCT03106740|Diagnostic Test|Magnetic Resonance-Positron Emission Tomography Imaging|Up to 15 millicuries of [11C]PBR28 will be administered to each subject at each imaging visit, for a total of 2 imaging visits.
1481747|NCT03106740|Other|Placebo Capsule|1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
1481748|NCT03106727|Behavioral|Household model|The proposed intervention is a 'Household Model' where, instead of being assigned to HIV or TB patients, CHWs will rather be assigned to households and will be trained to provide support for a wider range of conditions including HIV, hypertension, diabetes and pediatric malnutrition. The new model is designed to improve retention in care for clients with chronic, non-communicable diseases, along with increased uptake of women's health services and treatment for pediatric malnutrition, while sustaining the high retention rates for clients in the HIV program.
1481749|NCT03106714|Diagnostic Test|RT-PCR|Persistence of detectable Zika virus (by RT-PCR test) in all selected body fluids
1481750|NCT03106701|Procedure|Ablation|Epicardial Radiofrequency ablation
1481751|NCT03106688|Diagnostic Test|fMRI imaging|Using blood oxygenation level dependent (BOLD) echo-planar imaging, fMRI will be used for characterising individual differences in the brain circuits.
1481752|NCT03106688|Diagnostic Test|[11C]carfentanil PET scan|[11C]carfentanil is used to measure μ-opioid receptor (MOR) availability in brain.
1481753|NCT03106688|Diagnostic Test|[18F]FMPEP-d2 PET scan|[18F]FMPEP-d2 is used to measure cannabinoid receptor type 1 (CB1) availability in brain and body.
1481754|NCT03106688|Diagnostic Test|[18F]-FDG PET scan|Brain and body insuin stimulated glucose uptake is measured with radioligand [18F]-FDG.
1481755|NCT03106688|Diagnostic Test|Physical activity measures and fitness tests|Physical activity will be measured over one week following the screening check-up, before the PET measurement days. For the measurement, subjects will wear Polar M600 GPS Sports Watch for the measurement period. The fitness tests will be performed at the Paavo Nurmi Centre.
1481756|NCT03106688|Diagnostic Test|Laboratory measurements|Weight, height, blood pressure, medical history, and current medication are determined. Body fat percentage will be assessed using BodPod plethysmograph.
1481757|NCT03106688|Diagnostic Test|Questionnaires|All the participants will complete a self-administered questionnaire at baseline, and at 12 months, for assessment of leisure-time physical activity (LTPA). The following questionnaires will be completed: Behavioural inhibition / activation, Dutch Eating Behaviour Questionnaire, Yale Food Addiction Scale, PCL-Revised, Food craving State / Trait (FCS-FCST) questionnaires, Autism Spectrum Quotient, State-Trait Anxiety Questionnaire and Pain Sensitivity Questionnaire.
1481758|NCT03106688|Diagnostic Test|Hyperinsulinemic euglycemic clamp|Low-dose hyperinsulinemic euglycemic clamp technique will be used to promote glucose uptake and measure insulin sensitivity of the subjects. In the clamp study subjects are administered intravenous insulin at a steady rate of 0.25 mU/kg/min and normoglycemia is maintained using a variable rate infusion of 20 % glucose based on plasma glucose measurements, which are performed every 5-10 min from arterialized venous blood.
1481759|NCT03106675|Device|Thermal ablation of bone metastasis with MR-HIFU device Philips Sonalleve coupled with Philips Ingenia 3.0T|"Procedure is performed under proper analgesia (general or local anesthesia). The intervention can be performed in areas accessible with ultrasound with no critical structures (nerves, vasculature, bowels) in proximity. Limbs and pelvis are most usually accepted locations.
Patient is adjusted on top of the HIFU-transducer connected to MRI. First a MR-scan is performed and the treatment procedure is planned on consol. Then under MRI-guidance a point by point ablation of the target tumor is performed. During the treatment a real-time thermometry is obtained in order to avoid unwanted heating of related structures and to observe sufficient effect on treatment zone. After treatment MR-scan with gadolinium is performed to evaluate the size of ablated area."
1481760|NCT03106675|Device|Varian Truebeam Radiotherapy System|Conventional radiotherapy focused on bone tumor. Pretreatment planning images acquired with computer tomography
1481761|NCT03106662|Biological|mesenchymal stem cells|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day. At +6 post transplant day, 2-8x10^8 cell/kg mesenchymal stem cells will be infused.
1481762|NCT03106662|Drug|cyclophosphamide administration|After preferred conditioning regimen for the patient, cyclophosphamide 50 mg/kg/day will be administered at +3 and +4 post transplant day.
1481763|NCT03106649|Device|Echocardiography|Before administration of spinal anesthesia, Echocardiography will be performed to determine the LVEDA. If the LVEDA is more than 10 square cms, the patient will be considered as volume replete and spinal anesthesia will be administered. If the LVEDA is less than 10 square cms, a fluid bolus of 250 ml of a balanced salt solution will be given and LVEDA reassessed. This will be repeated till the LVEDA is more than 10 square cms or fluid bolus has been given twice and still the LVEDA is less than 10 square centimeters, in which case phenylephrine 1-2µg/kg will be given before administering spinal anesthesia.
1481764|NCT03106649|Device|Treatment of spinal hypotension|For treatment of spinal hypotension, in the event of hypotension(defined as a mean arterial pressure less than 60 mm Hg or decrease in mean arterial pressure of more than 20% from the baseline value) after spinal anesthesia, the LVEDA will be assessed. If more than 10 square centimeters, the patient will be considered volume replete and a vasopressor in the form of phenylephrine 1-2µg/kg will be given. If the LVEDA is less than 10 square centimeters, a volume bolus of 250ml will be given. On reassessment if the LVEDA is still less than 10 square centimeters the volume bolus can be repeated. In the event of hypotension persisting in spite of volume resuscitation, phenylephrine 1-2µg/kg will be given.
1481765|NCT03106636|Behavioral|KEEP-P|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P is a basic version that employs a curriculum of 12 weekly psychoeducational caregiver support groups Across four waves of data collection (baseline, postintervention, and 12 and 18 months postbaseline), we will examine the extent to which this intervention condition shows improved parenting, reduced rates of disrupted placements, and improved child outcomes.
1481802|NCT03106376|Other|26% O2 gas in breathed air|"Inspiratory gas mixtures: Hyperoxic inspiratory gas will be obtained by adding oxygen (O2) to normobaric, normoxic air with medical O2 tanks.
Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
1486818|NCT03067935|Drug|glembatumumab vedotin|
1481766|NCT03106636|Behavioral|KEEP-P+|The KEEP-P program is a low-cost, manualized, group-based intervention for caregivers of preschool aged children. This trial is evaluating 2 versions of the intervention. KEEP-P+ is an augmented version that consists of the caregiver support groups with extended curriculum including information about recent findings in early brain development and the elements of the Filming Interactions to Nurture Development video coaching program. Across four waves of data collection (baseline, postintervention, and 12 and 18 months postbaseline), we will examine the extent to which this intervention condition show improved parenting, reduced rates of disrupted placements, and improved child outcomes.
1481767|NCT03106623|Drug|ONO-8577|Oral administration of ONO-8577 once a daily for 4 weeks
1481768|NCT03106623|Drug|solifenacin succinate + mirabegron|Oral administration of solifenacin succinate and mirabegron once a daily for 4 weeks
1481769|NCT03106623|Drug|Placebo|Oral administration of Placebo once a daily for 4 weeks
1481770|NCT03106610|Drug|Nivolumab|3 mg/kg of body weight by vein over about 60 minutes on Day 1 of Cycles 1-3.
1481771|NCT03106610|Behavioral|Questionnaires|2 quality-of-life questionnaires completed on Day 1 of Cycles 1-3, at the visit before surgery, and 4 weeks after surgery.
1481772|NCT03106597|Drug|Manidipine 20mg|"After a 1~2-week run-in period, patents will be randomized to receive manidipine (20 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.
BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
1481773|NCT03106597|Drug|Amlodipine 10mg|"After a 1~2-week run-in period, patents will be randomized to receive amlodipine (10 mg/day; n=50) for a 8-week open-labeled phase. Study drugs will be administered orally and once daily between 8:00am and 10:00am.
BP, heart rate, adverse events and concomitant therapy are assessed and a physical examination is performed at each visit. A 12-lead standard ECG is obtained and hematology, clinical biochemistry and urine analysis investigations performed at the screening visit. A Bioelectrical Impedance Analysis (BIA) is undertaken at the screening visit and at the end of the 8-week treatment course. Patients have to attend the clinic visit every 4 weeks during the treatment period."
1481774|NCT03106584|Dietary Supplement|Aquamin-Plus|"Aquamin (a calcium-rich marine multi-mineral) - 666.7mg magnesium hydroxide - 66.66mg pine bark - 30mg vitamin d3 - 2.5μg
Dosage:
4 Capsules is equal to effective dose"
1481775|NCT03106584|Dietary Supplement|Glucosamine sulphate|"The Glucosamine sulphate supplement contains 500mg of the active ingredient Glucosamine sulphate per serving (one capsule).
Dosage:
4 Capsules is equal to effective dose"
1481776|NCT03106571|Drug|Pomaglumetad methionil|Tablets twice daily
1481777|NCT03106571|Drug|Placebo|1-4 tablets twice daily
1481778|NCT03106571|Drug|Methamphetamine|intravenous methamphetamine
1481779|NCT03106558|Device|Total Knee Arthroplasty using Manual Instrumentation|
1481780|NCT03106558|Device|Total Knee Arthroplasty using Robotic Arm|
1481781|NCT03106545|Drug|Liposome bupivacaine|
1481782|NCT03106532|Drug|PHP-201 0.25% ophthalmic solution|3 drops daily, 28 days
1481783|NCT03106532|Drug|PHP-201 0.5% ophthalmic solution|3 drops daily, 28 days
1481784|NCT03106532|Drug|Placebo ophthalmic solution|3 drops daily, 28 days
1481785|NCT03106519|Drug|Liposome bupivacaine + bupivacaine|
1481786|NCT03106506|Procedure|Connective tissue graft|Implant installation surgery with cone morse system with the concomitant placement of autogenous connective tissue.
1481787|NCT03106493|Other|None (observational)|None (observational)
1481788|NCT03106467|Procedure|Single-port laparoscopic appendectomy|Single-port laparoscopic appendectomy: A 1.5 cm skin incision is made inside the umbilicus and single port is introduced through it. The appendix is manipulated by a combination of a 5-mm scope, angulated, and straight instruments. The periappendiceal vessels and appendix are ligated and divided. Specimen is delivered via the transumbilical port. Umbilical fascia and skin are routinely closed.
1481789|NCT03106467|Procedure|Three-port laparoscopic appendectomy|Three-port laparoscopic appendectomy: CLA requires the introduction of a 30-degree 5-mm or 10-mm rigid scope through a 0.5 - 1.0 cm intra umbilical incision. Two additional 5-mm incisions are made outside umbilicus. Appendectomy is performed in the same manner as described for the SLA above. The umbilical fascia and skin are routinely closed.
1481790|NCT03106454|Drug|Ethinyl Estradiol, Norethindrone acetate, ferrous fumarate|Combination Oral Contraceptive Pill. Ethinyl Estradiol 10mcg/Norethindrone acetate 1mg/ferrous fumarate 75mg
1481791|NCT03106454|Drug|Norethindrone|Norethindrone 1.05mg
1481792|NCT03106441|Device|High flow oxygen therapy by nasal cannula. Optiflow®|Patients randomized in interventional group will received a four minutes preoxygenation period with High Flow nasal cannula (60 l/mn FiO2 = 1) before orotracheal intubation. The device will be maintained in place throughout the intubation procedure in order to achieve apnoeic oxygenation.
1481793|NCT03106441|Device|Facial mask oxygenation in BIPAP ventilation|Patients randomized in BIPAP group will receive a four minutes preoxygenation with EPAP 5, IPAP 15 FiO2 = 1 for a pressure support of 10 cm H2O. The facial mask with be removed after before crash induction enabling laryngoscopic vision
1481795|NCT03106415|Drug|Binimetinib|Given PO
1481796|NCT03106415|Other|Laboratory Biomarker Analysis|Correlative studies
1481797|NCT03106415|Biological|Pembrolizumab|Given IV
1481798|NCT03106402|Drug|topical bromfenac sodium hydrate|
1481799|NCT03106389|Drug|Misoprostol|400 micro grams misoprostol administered vaginally followed every 6 hours by 400 micro grams orally until complete expulsion
1481800|NCT03106389|Device|Misoprostol/Transcervical catheter|Foleys' catheter introduced into the cervix and inflated with 30 ml. of fluid; weighted traction applied by using a 1000 ml fluid-filled bag
1481801|NCT03106376|Other|16% O2 gas in breathed air|"Inspiratory gas mixtures: Hypoxic inspiratory gas will be obtained by adding nitrogen (N2) to normobaric, normoxic air with medical N2 tanks.
Delivery of gas mixture: The gas mixture will be delivered by standard tight facemask."
1481968|NCT03104894|Device|Meibomian Massage device|Meibomian glands expression with applicator
1481803|NCT03106363|Drug|delta 9 tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
1481804|NCT03106363|Drug|placebo delta 9 tetrahydrocannabinol|A single placebo cannabis cigarette (<0.03% delta 9 tetrahydrocannabinol) will be given to participants to smoke over a 10 minute period, ad libitum. If the placebo cannabis cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
1481805|NCT03106363|Drug|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol to tonic water to obtain a target blood alcohol content of 0.08mg%.
1481806|NCT03106363|Drug|Placebo alcohol|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
1481807|NCT03106350|Other|Questionnaire|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is a copyrighted instrument, which has been translated and validated in over 100 languages and is used in more than 3,000 studies worldwide.
1481808|NCT03106337|Device|Shear-Wave Elastography|Shear-Wave Elastography was performed on patients scheduled for partial/total thyroidectomy. Results were compared with pathology from surgical excision.
1481809|NCT03106324|Drug|Revlimid (lenalidomide)|Treatment with first line Revlimid containing regimen as prescribed in routine clinical practice
1481810|NCT03106311|Diagnostic Test|assessment of beta subunit of human chorionic gonadotropin|Vaginal washing fluid will be collected and sent for measurement of beta subunit of human chorionic gonadotropin
1481811|NCT03106298|Drug|Iron Sucrose|All participants will be given intravenous iron sucrose (200 mg) weekly for 5 weeks. Iron sucrose is infused over 60 minutes.
1481812|NCT03106285|Dietary Supplement|Lactobacillus reuteri DSM17938|5 drops of active oil drops. The active dose consists of 10^8 CFU L retueri DSM17938
1481813|NCT03106285|Dietary Supplement|Placebo|5 drops of placebo drops
1481814|NCT03106259|Drug|FURESTEM-RA Inj.|Non-interventional observational study
1481815|NCT03106233|Procedure|LTP flap|A flap is harvested from the upper lateral thigh region based on septocutaneous perforators located in the posterior septum between the tensor fascia latae and gluteus medius muscles.
1481816|NCT03106220|Behavioral|exercise|home exercise program
1481817|NCT03106220|Other|placebo|encourage walking and physical therapy per standard care.
1481818|NCT03106207|Procedure|Upper gastric endoscopy (UGE)|UGE will be performed before the gastric bypass surgery and post-surgery at two, six and 12 months of clinical visit.
1481819|NCT03106194|Other|case management|
1481820|NCT03106181|Device|iStent inject®|Insertion of iStent inject®
1481821|NCT03106181|Procedure|Phacoemulsification and intraocular lens implant|Conventional phacoemulsification cataract surgery and intraocular lens implant
1481822|NCT03106168|Procedure|Extraction of mandibular molar|Patients who require extraction of mandibular molars will be submitted to surgery
1481823|NCT03106155|Drug|vistusertib (AZD2014)|vistusertib(AZD2014): 50 mg BID per os every 12 hours administration daily. One cycle is consisted of 3 weeks.
1481824|NCT03106142|Procedure|Academic detailing visit arm|General Practitioners in the intervention group will receive one academic detailing visit. During this visit the GPs will receive information about the importance of physical therapy in the non-surgical management of knee osteoarthritis. The information will be summarized on an information leaflet for the GP.
1481825|NCT03106116|Device|Experimental: Enhanced External Counterpulsation|Enhanced External Counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy has been approved by the United States Food and Drug Administration (FDA) for the treatment of refractory angina and heart failure. Administration of 35-36 hours EECP therapy over a 7 week period, one hour session every working day.
1481826|NCT03106116|Drug|Standard medical therapy|Guideline- driven standard medical treatment for 7 weeks
1481827|NCT03106090|Other|educational materials|The eSCP includes a treatment summary section, a section detailing follow-up and test recommendations, a section on anticipated and potential side effects, as well as additional information specific to their experience/concerns. They will receive a patient education notebook outlining symptoms and their management that is tailored to those that the subject may be likely to experience during their survivorship care trajectory.
1481828|NCT03106077|Drug|Mirvetuximab Soravtansine|6 mg/kg by vein, once every 3 weeks.
1481829|NCT03106064|Behavioral|Promoting independence in self-care|The intervention will consist of an twice daily walking training, plus privileging trips to the toilet by walking (with support devices or with support from people) and all daytime meals seated (not in bed). Attending of the particular and unexplored characteristics of the proposed intervention, namely the use of the toilet and meals, the proposed intervention extends throughout the 24 hours of the day, seven days a week.
1481830|NCT03106064|Other|Usual Care|Usual hospital care
1481831|NCT03106038|Drug|Investigational Imaging Agent|Procedure: routine minimally invasive pelvic surgery.
1481832|NCT03106025|Device|Ultrasound|Each participant will receive an ocular ultrasound which poses minimal to no harm to the participant and the ultrasound results compared to final diagnosis.
1481833|NCT03106012|Procedure|Hysteroscopy|rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30o panoramic optic which is 4mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
1481834|NCT03106012|Procedure|Laparoscopy|Veress needle was placed through the umbilicus and into the peritoneal cavity,After a pneumo-peritoneum has been achieved with a Veress needle, the primary trocar with sleeve (5mm in diameter) was placed at a similar angle in to the Veress needle
1481835|NCT03105986|Drug|JNJ-64041575|Two 500-mg tablets administered as a single oral dose under fasted conditions on Day 1 or Day 22.
1481836|NCT03105986|Drug|Probenecid|One 500-mg tablet administered as a single oral dose with a total of 30 doses (2 doses on Day -1/21 starting in the evening followed by 4 doses per day on the rest of the days).
1481837|NCT03105973|Other|Technology-Enabled CBT Treatment|CBT-based modules delivered via tablet over 4 weeks.
1481963|NCT03104920|Procedure|ERAS Program|An ERAS pathway comprises of optimized management of diet, mobilization, multimodal perioperative analgesia and GI function recovery modalities.
1481838|NCT03105960|Drug|garlic with lime mouth wash|garlic with lime juice is herbal antimicrobial 10 ml (undiluted) for 30s and then expectorate for 14 days.o prepare garlic with lime mouth rinse, 100 g of fresh, washed garlic cloves was macerated in a sterile, ceramic mortar and water was added to obtain a homogenate which was then filtered off with a sterile muslin cloth. the final concentration of the solution was determined to be 1 g/100 ml. About 100 ml of lime juice was extracted from fresh lemons using a juice extractor and added to the garlic extract.
1481839|NCT03105960|Drug|chlorhexidine|hlorhexidine is antimicrobial, antiplaque mouthwash 10 ml (undiluted) for 30 second twice daily and then expectorate for 14 days.
2000951|NCT03306953|Procedure|Rectus muscle approximation|The surgeon will take sutures to approximate rectus muscles at the end of cesarean delivery.
2000952|NCT03306901|Procedure|Esophagectomy|Ivor Lewis esophagectomy or McKeown esophagectomy and systematic lymphadenectomy
1481843|NCT03105934|Procedure|Patients with Pulmonary Arterial Hypertension|2 repeated measurement session to enable assessment of technical and medium-term reproducibility of IV-US and IV-OCT.
1481844|NCT03105921|Device|NanoKnife|The aim of the treatment is to sourround the tumour with two to six needles and to deliver a very high voltage current (3000 volts in 70 to 80 microseconds pulses) by a generator synchronized with an electrocardiogram.
1481845|NCT03105908|Behavioral|Internet delivered Acceptance and Commitment therapy|The main component in the treatment is exposure to symptoms and feared situations. The iACT program is adapted from the evidence based face-to-face treatment at the Behavioral Medicine unit at Karolinska University Hospital. The iACT program has a different structure but is equal in content to face-to-face treatment, and is to be completed within ten weeks. Participants receive texts, audio files, movies and exercises and have online contact with their psychologist via an internet platform or a smart phone application. The treatment aims to encourage valued behaviors in the presence of inner discomfort.
1481846|NCT03105908|Behavioral|Waiting list control condition|After a ten week wait list period, the control condition receive same treatment as the intervention group, but without therapist support.
1481847|NCT03105895|Procedure|Mesh group|An onlay PDVF mesh will be placed as abdominal wall reinforcement
1481848|NCT03105882|Device|Neuro-Spinal Scaffold|Experimental: Neuro-Spinal Scaffold
1481849|NCT03105869|Diagnostic Test|fluorocholine PET/CT|standard diagnostic PET/CT procedure
1481850|NCT03105856|Biological|CERVARIX|- HPV16/18 L1 VLP AS04 vaccine (Cervarix®) group according to a two-dose schedule (0-12 month). This group will receive the HPV16/18 vaccine containing HPV16 and HPV18 L1 virus-like-particles (20 μg of each) adjuvanted with 50 μg 3-O-desacyl-4'-monophosphoryl lipid A and 0.5 mg aluminum hydroxide (GlaxoSmithKline Biologicals, Rixensart, Belgium). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
1481851|NCT03105856|Biological|GARDASIL|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) (Gardasil®) recombinant vaccine according to a two dose schedule (0-12 month). This group will receive amorphous aluminum hydroxyphosphate sulfate adjuvanted quadrivalent HPV (types 6, 11, 16, 18) L1 VLP vaccine (Merck Sharp & Dohme Corp. Whitehouse Station, NJ, USA). A 0.5-mL dose of the vaccine will be administered in the non-dominant arm.
1481852|NCT03105843|Drug|Methacholine (MCh) Challenge Testing|Visit 1: Informed consent, Baseline screening and pulmonary function tests and Low-dose methacholine challenge testing using partial and full flow-volume loops.
1481853|NCT03105843|Diagnostic Test|Eucapneic Voluntary Hyperventilation (EVH) and Hypertonic Saline (HS) Challenge Tests|Visit 2 or 3: Will be conducted in random order and subjects will perform one of the two challenge tests at either visit.
1481854|NCT03105830|Drug|iv paracetamol|iv paracetamol
2000953|NCT03306901|Drug|5-fluorouracil|3,200 ~ 4,000mg/m2 intravenously for 4 to 5 days.
2000954|NCT03306901|Drug|Cisplatin|60mg/m2 intravenously over 1 hour on day 1
2000955|NCT03306901|Radiation|Radiation therapy|45 Gy irradiation (5 days a week for 5 weeks)
2000956|NCT03306654|Behavioral|Happify|An online platform for conveying techniques from positive psychology, cognitive-behavioral therapy, and mindfulness-based stress reduction.
1481860|NCT03105791|Other|Formal education regarding opioid usage|Participannts watched a 2 minute video and were given educational materials
1481862|NCT03105765|Drug|Placebo|Normal saline applied by bolus before operation started, followed by a continuous application of normal saline for 24 hours.
1481863|NCT03105765|Drug|Ketamine|Application of Ketamine 0,2mg/kg ideal Body weight by Bolus before the Operation started, followed by application of 0,2 mg/kg ideal Body weight for 24 hours.
1481864|NCT03105752|Other|Questionnaire of understanding|"The study involved 12 clinical trials conducted in the Clinical Research Center Paris Est. Twenty participants per trial were offered to answer the Qualité de Compréhension des Formulaires d'information et de consentement questionnaire (QCFic) at the inclusion visit after receiving the information by the investigator and signed or refused to sign the form of consent.
Participants filled out the questionnaire in an isolated location, with no possibility of re-reading the information contained in the consent form. The questionnaire was immediately retrieved."
1481865|NCT03105739|Other|LMA removal|According to randomization, LMA device was removed at the end of surgery, either in deeply anesthetised patients or after consciousness recovery.
1481866|NCT03105713|Other|Patient Safety Checklist|The intervention is to be developed and implemented over three stages: 1) develop patient safety checklists for patients to use, 2) pilot testing of the checklists in 5 surgical clusters in two hospitals 3) a stepped wedge cluster randomized controlled trial of the patient safety checklists for patients to use.
1481867|NCT03105700|Device|Transcranial Magnetic Stimulation|Repetitive transcranial magnetic stimulation (TMS) is a focal, nonpharmacological, noninvasive method for stimulating the brain and modulating neural network activity. To administer TMS, an electromagnetic coil is placed on the scalp, and uses electrical current to create magnetic fields that depolarize or hyperpolarize neurons in the brain.
1481964|NCT03104920|Procedure|Traditional treatment|A traditional perioperative management for HCC.
1481868|NCT03105687|Behavioral|SMS reminders of medicines intake|The intervention consists of daily SMS reminders of blood pressure-lowering medication provided by a pharmacist for a period of 3 months.
1481869|NCT03105674|Drug|Multi-drug local anesthetics (Combination)|"Ropivacaine 0.5% - 30 ml
Ketorolac 30mg/ml - 1 ml
Kenalog 10 mg/ml - 5 ml
Lidocaine 1% with Epinephrine 1:100,000 - 20ml"
1481870|NCT03105674|Drug|Standard local anesthetics (Combination)|Marcaine and Lidocaine
1481871|NCT03105661|Drug|Labetalol Hydrochloride 200 mg|Anti-hypertensive prescribed for increased cardiac output as determined by Impedance Cardiography
1481872|NCT03105661|Drug|NIFEdipine 60 mg|Anti-hypertensive medication prescribed for increased systemic vascular resistance as determined by Impedance Cardiography
1481873|NCT03105661|Drug|Atenolol 25 mg|Anti-hypertensive prescribed for increased cardiac output with tachycardia or maternal pulse rate 110 or greater
1481874|NCT03105648|Other|computerized cytomorphometry|use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination
1481875|NCT03105635|Other|Mixed method feasibility study|"Participating practices will receive the following:
Training on community resources : An orientation regarding the availability of the local community health and social resources, and the existing navigation services that can support individuals identify the appropriate resource.
Facilitation to enhance referrals: help support practices to make the desired adaptations to enhance referrals
Promotional material to engagement patients: Practices will provide an area in the waiting room where promotional material on the benefit and availability of community resources will be displayed.
Navigator: The services of a Navigator"
1481876|NCT03105622|Behavioral|TV and music|Watching TV or listening to music while running on a treadmill
1481877|NCT03105609|Device|Hyperspectral imaging|Hyperspectral retinal images will be taken at baseline (before treatment with Lucentis) and then at 3 and 9 months after treatment.
1481878|NCT03105596|Drug|Chidamide plus DICE Regimen|Chidamide 20mg orally d1, 4, 8, 11, 15, 18; Dexamethasone 10mg，ivg, d1-4; ifosfamide 1g/m2, ivg, d1-4, given over 4 hours; Mesna 0.4g, 0,4,8,12 hours during Ifosfamide transfusion, ivg, d1-4; Cisplatin 25mg/m2, ivg, d1-4; Etoposide 60mg/m2, ivg. d1-4.
1481879|NCT03105583|Drug|Medication use during pregnancy|
1481880|NCT03105583|Dietary Supplement|Supplement use during pregnancy|
1481881|NCT03105583|Other|Vitamin status of a pregnant woman|Haemoglobin, RBC count + hematocrits, thrombocytes count, folate (serum), vitamin B12, WBC count, ferritin, iron (serum), transferrin % and saturation, TSH, T4, free glucose, LDH, ALT, AST, GGT, bilirubin (total), CRP, albumin, total protein, ureum, uric acid, creating, calcium (total), 25-hydroxy vitamin D, Na, K, Mg
1481882|NCT03105570|Procedure|Areola Sparing Mastectomy|A small circular incision would be made to separate nipple from breast and an additional incision directly extended from nipple or located at other part of breast such as infra-mammary fold and subaxillary area would be made to remove the total mammary parenchyma. Routine implant based or flap base reconstruction would be performed subsequentially. Nipple reconstruction is optional.
1481883|NCT03105557|Device|Urinary collecting device|Urinary collecting device
1481884|NCT03105544|Other|simulation-based training|As described under group descriptions
1481888|NCT03105505|Drug|Permethrin 5%|Facial skin application once a night for 3 months.
1481889|NCT03105505|Drug|Synthomycine 5%|Eye ointment, eyelids and eyelashes application (chloramphenicol), once a night for 3 months.
1481890|NCT03105505|Drug|Fusidic Acid 1% M/R Eye Drops|viscous eye drops application once a night for 3 months.
1481891|NCT03105479|Drug|Cadazolid|Granules for oral suspension to be administered twice daily
1481892|NCT03105479|Drug|Vancomycin capsule|Capsule containing 125 mg of vancomycin to be administered orally 4 times a day
1481893|NCT03105479|Drug|Vancomycin solution|Vancomycin powder to be administered as oral solution at a dose of 40 mg/kg/day, 3 to 4 times a day
1481894|NCT03105466|Procedure|Deep anterior lamellar keratoplasty|Deep anterior lamellar keratoplasty using acellular porcine cornea; 0.05%Tacrolimus eye drops, four times a day for at least one year; 0.3% Tobradex eyedrops, four times-one times a day for one year.
1481895|NCT03105466|Device|Acellular Porcine Cornea|
1481896|NCT03105466|Drug|Tacrolimus eye drops|
1481897|NCT03105466|Drug|Tobradex eyedrops|
1481898|NCT03105453|Other|3 Sampling points|When entering the in-vitro fertilization/intracytoplasmatic sperm injection 4 samples will be harvested: a rectal swab, a cervical swab, a vaginal swab and an intra-uterine sample using an empty embryo catheter. After the ovarian stimulation treatment, the same patients will be sampled two more times: once at the moment of oocyte retrieval (rectal, cervical, vaginal and intra-uterine samples) and again just before the embryo transfer (at this stage, the embryo culture medium will be harvested, as well as an intra-uterine sample using the tip of an empty embryo inner catheter before the embryo transfer and a rectal sample)
1481899|NCT03105440|Other|Virtual reality|"This virtual reality of projection software, which uses Kinact®, captures the patient's picture and transfers to the monitor. The exercises provided by game are similar to those performed in conventional therapy; however, in a more entertaining form.
Comprised 8 exercises to upper limbs and trunk. The patient should reach the red circle until it becomes green."
1481900|NCT03105440|Other|Vibration therapy|"The vibration mat used in this study was developed by the members of the Laboratory of Sensory and Motor Engineering Rehabilitation together with mark Vibra Ind. e Com. Prod. Electronics Ltda.
Will participate 20 woman, that stay in supine position, with the enveloped member of the vibration mat, elevated and supported. The volunteer will be submitted to 15 minutes of vibration with frequency of the 40 hertz, in both upper limbs."
1481901|NCT03105440|Other|Hand cycling|Will participate 20 woman, submitted hand cycling through of the adapted bicycle to upper members. The protocol will be comprised by track without obstacle, comprised by 10 turns. The cyclic movement velocity will be realized according to the physical fatigue of patients.
1481902|NCT03105440|Other|Canoeing|Will participate 20 woman, submitted canoeing activates, through rowing realized in therapeutic pool, with the aid and supervision of the therapeutic. It is important highlight that the exercises intensity will be to realized according to the physical fatigue of patients.
1481969|NCT03104881|Device|3D exoskeleton type robot|3 dimension exoskeleton type upper extremity robot
1481903|NCT03105440|Other|Robotic rehabilitation|It Will be used a exoskeleton Armeo®Spring, to training to affected upper limb, the protocol of the treatment is constituted for 8 games. The equipment arm will be adjusted the volunteers height, in sitting position, allowing support against the action of gravity of the arm and forearm, supporting 45° of the shoulder flexion, which will be facilitation the member movement.
1481904|NCT03105440|Other|Control group|Will participate 20 healthy woman, that won't pass to the treatment physiotherapeutic, only will be collected the electromyography and dynamometer.
1481905|NCT03105414|Device|Mechanical ventilation|Mechanical ventilation
1481906|NCT03105401|Other|Assessment of hallucinations in Parkinson's disease|Patients participating to the study will be asked to answer a semi-structured questionnaire searching for hallucinations of all modalities, minor psychotic symptoms and delusions. Psychometric scales will be assessed to search for depressive symptoms, cognitive impairment and specific personality characteristics.
1481907|NCT03105375|Drug|Single ascending dose of X842|Each subject in a the same cohort will be assigned to the same single dose of X842. The subjects in the subsequent cohort will be assigned to a single dose of X842 based on safety and efficacy data generated from the previous cohort.
1481908|NCT03105375|Drug|Multiple ascending dose of X842|Each subject in a the same cohort will be assigned to the same dose of X842 once daily for five days. The subjects in the subsequent cohort will be assigned to same dose of X842 once daily for five days based on safety and efficacy data generated from the previous cohort.
1481909|NCT03105375|Drug|Losec|Each subject in one cohort will be assigned to a standard dose of omeprazole once daily for five days.
1481910|NCT03105362|Dietary Supplement|Enterade® oral rehydration solution|Commercially available amino acid based oral rehydration solution
1481911|NCT03105349|Drug|elbasvir/grazoprevir|16 weeks treatment
1481912|NCT03105349|Drug|Sofosbuvir|16 weeks treatment
1481913|NCT03105349|Drug|Ribavirin|16 weeks treatment
2000957|NCT03303547|Diagnostic Test|MRI mapping to guide pathological sampling of extranodal tumour deposits|Radiologist to mark areas where extranodal disease is identified on MRI. The pathologist will use this to take additional samples for analysis. This will allow better pathological staging and will affect treatment decisions for patients.
1481915|NCT03105310|Drug|Pegylated interferon alfa|Pegylated interferon alfa
1481916|NCT03105310|Drug|Ezetimibe|Ezetimibe
2000958|NCT03301090|Other|Placebo|Placebo
2000959|NCT03301090|Biological|REGN3048|REGN3048 is a fully monoclonal antibody (mAbs) which binds to the S protein of MERS-CoV.
2000960|NCT03301090|Biological|REGN3051|REGN3051 is a fully human monoclonal antibody (mAb) which binds to the S protein of MERS-CoV. It can reduce virus titers and ameliorate MERS-CoV-induced lung pathology when given post infection.
1481920|NCT03105245|Other|Electroconvulsive Therapy (ECT) time interval + Anaesthetic (Thiopentone)|The intervention in this study is the time interval between anaesthetic administration and ECT stimulus
1481921|NCT03105219|Drug|Ivabradine|Ivabradine 5mg twice a day (on day 0), heart rate evaluated at day 14 and 28 repeatedly, and the targeted value of heart rate 50-60bpm, the largest dosage 7.5mg twice a day.
1481922|NCT03105219|Other|Sham Comparator|Urinary albumin excretion (UAE) assessment will be performed before randomization (Day 0), 28-day after randomization (Day 28), and 90-day after randomization (Day 28).
1481923|NCT03105206|Procedure|Flexible Ureteroscopy|the Treatment of Low Pole Renal Calculus by Flexible Ureteroscope
1481928|NCT03105180|Other|A mixture of 2.7% sorbitol-0.54% mannitol solution|Venous blood was taken from 12 healthy volunteers and divided into four specimen bottles, which were diluted with different levels (0%, 10%, 20%, and 40%) using a mixture of 2.7% sorbitol-0.54% mannitol solution.
1481929|NCT03105167|Procedure|cortical bone trajectory screws|cortical bone trajectory screws fixation takes the place of traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
1481930|NCT03105167|Procedure|pedicle screws|traditional pedicle screws fixation will be used in transforaminal lumbar interbody fusion.
1481931|NCT03105154|Other|Prevena Dressing|Prevena dressing is applied on one groin
1481932|NCT03105154|Other|Conventional Dressing|Conventional dressing is applied on the contralateral groin
1481933|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to a given pressure followed by deflation, twice daily for 12 months.
Two different magnitude of limb ischemia pressure will be set: 200 mmHg and 40 mmHg above systolic pressure (60 patients for each).
Optimal inflating pressure will be determined based on the results."
1481934|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of a given cycle of 5-min bilateral upper limb ischemia intervened by 5-min reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.
The number of cycles of limb ischemia will be set as: 4, 5 and 6 (60 patients for each).
Optimal cycles for application will be determined based on the results."
1481965|NCT03104907|Procedure|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
1481966|NCT03104894|Procedure|Meibomian Glands Massage|Meibomian gland expression
1481935|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of a given duration of bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, twice daily for 12 months.
The duration of each cycle for limb ischemia will be set as: 4, 5 and 6-min (60 patients for each).
Ischemia duration algorithm will be determined based on the results."
1481936|NCT03105141|Device|Remote ischemic conditioning|"Remote ischemic conditioning is composed of 5 cycles of 5-min bilateral upper limb ischemia intervened by reperfusion, which is induced by an automated cuff-inflator (Doctormate®) placed on both upper arms and inflated to 200 mmHg pressure followed by deflation, once or twice daily for 12 months.
The method for application will be set as: once daily for 12 months and twice daily for 12 months (60 patients for each)."
1481937|NCT03105128|Drug|placebo for risankizumab|Placebo for risankizumab administered by intravenous infusion
1481938|NCT03105128|Drug|risankizumab IV|Risankizumab administered by intravenous infusion
1481939|NCT03105128|Drug|risankizumab SC|Risankizumab administered by subcutaneous (SC) injection
1481940|NCT03105115|Drug|fentanyl|intrathecal fentanyl will be added as adjuvant for spinal anesthesia using heavy bupivacaine, while dexmedetomidine will be infused intravenously during operation
1481941|NCT03105115|Drug|bupivacaine only|heavy bupivacaine will be injected intrathecally during spinal anesthesia, without fentanyl, while dexmedetomidine will be infused intravenously during operation
1481942|NCT03105102|Drug|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
1481943|NCT03105102|Drug|placebo for risankizumab SC|placebo for risankizumab administered by subcutaneous (SC) injection
1481944|NCT03105102|Drug|risankizumab IV|risankizumab administered by intravenous (IV) infusion
1481945|NCT03105102|Drug|placebo for risankizumab IV|placebo for risankizumab administered by intravenous (IV) infusion
1481947|NCT03105076|Other|Decision aids|Shared decision making with decision aids
1481948|NCT03105063|Diagnostic Test|ultrasound scan of the hip|validation of Ultrasound test as a tool for diagosing AIIS morphology
1481949|NCT03105050|Other|Access to bariatric surgery|All countries representatives will be interviewed on their Healthcare systems
1481950|NCT03105024|Other|Self-efficacy enhancement|specific instructions regarding the retrieval of mastery experiences during exposure will be given (e.g., pointing out discrepancies between expected negative consequences and actual outcome during exposure; focus on achievements)
1481951|NCT03105024|Other|Control intervention|specific instructions regarding the retrieval of the exposure session will be given without an emphasis on personal mastery experience (e.g., description of details regarding the virtual reality environment)
1481952|NCT03105011|Behavioral|EpxDiabetes software|Subjects will interact daily with a commercially available telemedicine product, Epharmix Diabetes (EpxDiabetes). They will each undergo a baseline blood draw to establish the control HgbA1C associated with standard of care. Three months later they will undergo an experimental blood draw to establish the HgbA1C associated with the use of EpxDiabetes. Between those procedures, the patient will interact with the intervention daily.
1997907|NCT01831544|Device|HeartWare MVAD® System|The HeartWare MVAD® System consists of a small, wearless, continuous flow pump and associated surgical tools and implant accessories, peripheral components which control and power the system, and a monitor which allows for programming and monitoring of the system
1481957|NCT03104972|Device|tDCS|Stimulation would be applied using semi-dry 5X5 cm electrodes. The current would be 0.75mA, which based on previous computational modeling of tDCS in children and is estimated to equal that of 1-1.5 mA in adults. This decision was made after considering the parameters that would influence current distribution and density at the site of stimulation such as thinner scalp, less cerebrospinal fluid, and smaller head size of the paediatric population. A similar dosage using tDCS was well tolerated by children, and was not associated with adverse effects29. The anodal electrode will be positioned above the dlPFC (F3 based on the International 10-20 system, while the cathodal electrode would be placed over the right supraorbital.
1481958|NCT03104972|Device|tRNS|Children in the active tRNS group will received 0.75mA of tRNS (100-640Hz) to their left dorsolateral prefrontal cortex (dlPFC) and the right inferior frontal gyrus (IFG) via semi-dry 5cm X 5cm electrodes, attached under designated electrode positions (F3, F8) of a tES cap that followed the International 10-20 system (InnoSphere Inc., Haifa). The left dlPFC and right IFG were chosen, based on their contribution in executive control and inhibition. tRNS will be applied for 20 minutes per session during an iPad cognitive training. Similar duration has also been used in paediatrics using tDCS29. Similar to a previous tRNS study in children, and the rational provided for tDCS we will apply 0.75mA.
1481959|NCT03104972|Device|sham|For sham-tRNS we will use the same montage as in active tRNS. For sham-tDCS we will use the same montage as in active tDCS. The only difference between active and sham tES would be that in the case of the sham tES the 30 sec of ramp up of the current from 0 to 0.75mA would not be followed by 19 min of stimulation at 0.75mA as in active tES, but would immediately be followed by 30 sec ramp down period to 0mA. Such method has been shown to provide effective blindness of the stimulation condition as both active and sham tES would lead to slight itching sensation that would disappear due scalp habitation. No further stimulation would be provided in the sham group during the daily session.
1481960|NCT03104959|Dietary Supplement|N-acetyl cysteine|
1481961|NCT03104959|Other|placebo|
1481962|NCT03104946|Diagnostic Test|Mental Development Index;Auditory Brainstem Response;okineticnystagmus|mental development index(MDI）<70:cognitive delay do not pass auditory brainstem response(ABR）：hearing impairment do not pass okineticnystagmus:visual impairment Patent Ductus Arteriosus
1481967|NCT03104894|Procedure|Sham Meibomian Glands Massage|Touching the eyelids gently
1481970|NCT03104881|Device|2D end-effector type robot|2 dimension end-effector type upper extremity robot
1481971|NCT03104868|Behavioral|TAKE IT Strategy|"The TAKE IT Strategy includes:
Programming the electronic health record (EHR) to organize/simplify daily regimen schedules and generate electronic, tangible, print, low literacy medication education materials at every clinical encounter.
SMS text-messaging to remind patients when to take all their medicine.
A web-based patient portal that requests patients to periodically report upon their medication use, providing a continuous link between the transplant center and patient beyond routine in-person visits.
EHR notifications directed to the transplant center nurse coordinator if an adherence-related problem is identified by the web-based portal assessment, who then can activate appropriate staff to respond."
1481972|NCT03104855|Drug|d6-25-hydroxyvitamin D3|intravenous administration of stable isotope-labeled D6-25(OH)D3
1481977|NCT03104829|Behavioral|Motivational interviewing|
1481978|NCT03104829|Drug|DSME participants in this arm will receive standard care for diabetes (DSME) at the beginning of the study and 3 months later|
1481979|NCT03104816|Drug|Acetaminophen IV Soln 10 MG/ML|
1481980|NCT03104816|Drug|Acetaminophen|
1481981|NCT03104816|Drug|Hydromorphone|
1481982|NCT03104803|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered several times per week for 6 weeks to one hand. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
1481983|NCT03104790|Biological|Fluenz Tetra (The two groups are defined by immunisation history, all receive the same intervention in the study)|live attenuated influenza vaccine (LAIV)
1481984|NCT03104777|Behavioral|Behaviourally Informed Intervention Materials|"The intervention consists of 7 separate components. The intervention components are to be delivered at three time-points (referred to as bundles). The bundles consist of:
Bundle 1a - Letter to parents of children bringing a packed lunch to school, 'spot the difference' lunch box tag (attached to all lunchboxes) and a Handy Swaps Card.
Bundle 1b - Letter to parents of children only having school meals and a Handy Swaps Card.
Bundle 2 - Lunch box mixer with ideas for creating nutritious packed lunches. Bundle 3 - Shopping list, packed lunch planner and reward chart to support planning and monitoring progress."
1481985|NCT03104764|Device|Scalpel|Labial frenulum removed by scalpel
1481986|NCT03104764|Device|Er:YAG laser|Labial frenulum removed by Er:YAG laser
1481988|NCT03104725|Dietary Supplement|N-Acetylcysteine|Oral
1481989|NCT03104725|Procedure|Lumbar Puncture|procedure
1481990|NCT03104725|Radiation|Fluoroscopy|If needed for lumbar puncture
1481991|NCT03104712|Other|Glucose #1|50g available carbohydrate
1481992|NCT03104712|Other|Glucose #2|50g available carbohydrate
1481993|NCT03104712|Other|Glucose #3|50g available carbohydrate
1481994|NCT03104712|Other|Spaghetti|50g available carbohydrate
1481995|NCT03104712|Other|Rice|50g available carbohydrate
1481996|NCT03104712|Other|Spaghetti + Tomato Sauce|50g available carbohydrate
1481997|NCT03104712|Other|Rice + Tomato Sauce|50g available carbohydrate
1481998|NCT03104712|Other|Spaghetti + Pesto|50g available carbohydrate
1481999|NCT03104712|Other|Rice + Pesto|50g available carbohydrate
1482000|NCT03104699|Drug|AGEN2034|anti-PD-1 antibody
2000962|NCT03298867|Biological|Teprotumumab|Approximately 38 participants will receive 8 infusions of Teprotumumab q3W for a total of 21 weeks. Teprotumumab 10 mg/kg will be administered on Day 1 and Teprotumumab 20 mg/kg will be administered q3W for the remaining 7 infusions.
2000963|NCT03298867|Other|Placebo|Approximately 38 participants will receive 8 infusions of placebo q3W for a total of 21 weeks.
1482005|NCT03104660|Device|CE certified mitral valve repair systems|Patients receive a transcatheter mitral valve repair with CE certified transcatheter mitral repair systems.
1990595|NCT01946074|Drug|ABT-165|ABT-165 will be administered by intravenous infusion at escalating dose levels in 28-day dosing cycles on Day 1 and 15.
1482007|NCT03104634|Drug|Aclidinium bromide/formoterol fumarate dihydrate|Cross-over design with washout interval. Randomized order of active and placebo arm
1482008|NCT03104634|Drug|Placebo|Placebo and delivery device matched to active intervention
1482009|NCT03104621|Drug|Benzalkonium chloride (BAK)|Benzalkonium chloride (BAK) is the most used preservative and is excellent for safety and stability of drug. However, it causes dry eye, corneal oedema, corneal erosion, and corneal toxicities, thus lowering the long-term tolerability for patients. A critical component when managing glaucoma patients is ensuring compliance.
1482010|NCT03104621|Drug|0.0015% tafluprost|Tafluprost (trade names Taflotan or Taflotan-S by Santen Pharmaceutical) is a prostaglandin analogue. It is used topically (as eye drops) to control the progression of open-angle glaucoma and in the management of ocular hypertension. In this study, tafluprost was used in all experimental group with equally concentration(0.0015%), only measured whether BAK was included or not.
1482011|NCT03104608|Other|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation is a class of meditation that helps quiet the mind and induces physiological and mental relaxation whilst the eyes are shut. It utilizes a specific sound value (mantra) to draw attention inward and permit the mind to experience a restful but alert state of consciousness. Research suggests that ASTM is easier to learn and to teach in comparison to other meditation techniques. Further, studies have shown that ASTM confers large effect sizes as an anti-depressant.
1482012|NCT03104608|Other|Treatment as Usual|Participants randomized to Treatment as Usual (TAU)) will continue to receive their treatment as usual.
1990596|NCT01946074|Drug|paclitaxel|Paclitaxel will be administered by intravenous infusion in 28-day dosing cycles on Day 1, 8, and 15. Paclitaxel may also be administered on Day 22 depending on the dose level the subject receives.
1482014|NCT03104582|Procedure|ERCP Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform endoscopic drainage after informed consent.
1482015|NCT03104582|Procedure|PTBD Drainage|When advanced Klatskin Tumor patients need biliary drainage, they choose to perform percutaneous transhepatic biliary drainage after informed consent.
1482016|NCT03104569|Procedure|Injection of 37℃ contrast agent|Nonionic contrast agent is heated to 37℃ in a incubator when injection of contrast agent
1482017|NCT03104543|Behavioral|Education|30 minute education session; 15 minute booster session at 4 months
1482018|NCT03104543|Behavioral|Test results only|The control group will receive a copy of test results upfront but not experimental educational materials; those will be available at 1 year
1482019|NCT03104530|Other|Brown crabmeat|Those exposed to higher levels of cadmium due to habitual consumption of 40 grams or more per week of brown meat from crab
1482020|NCT03104517|Biological|AMDC-USR|Autologous Muscle Derived Cells for Urinary Sphincter Repair
1482021|NCT03104517|Other|Placebo|Placebo control is the vehicle solution used for the study product.
1482022|NCT03104504|Behavioral|Suicide Risk Screening|Suicide risk screening will be implemented as the standard of care for all patients who present for treatment.
1482023|NCT03104504|Behavioral|Safety Planning|Suicide screen-positive patients who are to be discharged from the hospital will receive personalized safety planning by a mental health clinician or nurse that includes means restriction counseling as a step in the safety plan.
1482024|NCT03104504|Behavioral|Care transition facilitation|Include post-acute telephone phone call follow-up to foster engagement with outpatient care and problem solving within 24 hours of discharge
1482025|NCT03104504|Behavioral|A Lean Implementation Strategy|The Interventions will be implemented using Lean performance improvement strategies
1482026|NCT03104491|Drug|Inotuzumab Ozogamicin|Participants will begin at 0.6mg/m2 and will be adjusted in 0.1mg/m2 increments using a dose escalation scale depending on tolerability. Total range of dose levels is 0.1-0.6mg/m2
1482027|NCT03104478|Procedure|Biological samples collection|In addition to collection and characterization of tumor biopsy samples done for diagnosis (standard care), collection of blood samples at study entry for further biological analyses.
1482028|NCT03104465|Behavioral|Mindfulness Training|interactive. web-based mindfulness training complemented with mobile application
1482029|NCT03104439|Drug|Nivolumab|The antibodies in nivolumab work by causing programmed cell death of the cancer cells
1482030|NCT03104439|Drug|Ipilimumab|The antibodies in ipilimumab work by not allowing cancer cell growth
1482031|NCT03104439|Radiation|Radiation Therapy|Radiation therapy is believed to increase the likelihood of response of immunotherapy
2000964|NCT03297931|Dietary Supplement|Control|Non-pulse chip + non-pulse dip
1482033|NCT03104413|Drug|risankizumab IV|risankizumab administered as intravenous (IV) infusion.
1482034|NCT03104413|Drug|placebo for risankizumab IV|placebo for risankizumab administered as intravenous (IV) infusion.
1482035|NCT03104413|Drug|risankizumab SC|risankizumab administered by subcutaneous (SC) injection
1482036|NCT03104400|Drug|ABT-494|Oral tablet
1482037|NCT03104400|Drug|Placebo for ABT-494|Placebo oral tablet
1482038|NCT03104400|Drug|Adalimumab|Adalimumab subcutaneous injection
1482039|NCT03104400|Drug|Placebo for Adalimumab|Placebo subcutaneous injection
1482040|NCT03104387|Other|Electric train|Exposure to air with low level of ultrafine particles (Electric train)
1482041|NCT03104387|Other|Diesel train|Exposure to air with high level of ultrafine particles (Diesel train)
1482042|NCT03104374|Drug|ABT-494|Oral tablet
1482043|NCT03104374|Drug|Placebo|Oral tablet
1482044|NCT03104361|Biological|Platelet-Rich Plasma|Patients who meet all eligible requirements for entry into the study will be treated with intravesical injection of PRP (extracted from 50ml whole blood ) at 20 sites
1482045|NCT03104348|Diagnostic Test|COPD screening|Self-questionnaire with 5 questions Fagerström's test Spirometry
1482046|NCT03104335|Drug|Apatinib|750 mg daily once oral administration of apatinib for body surface area (BSA) > 1.5 and 500mg daily for BSA <1.5. Half an hour after meal and everyday at the same time is usually advised.
1482047|NCT03104322|Other|patientMpower platform|electronic health journal for patient to record compliance, spirometry, impact on daily life and symptoms
1482048|NCT03104322|Other|usual care|usual care
1482049|NCT03104309|Device|Levonorgestrel intrauterine system|Levonorgestrel intrauterine system for adenomyosis
1482050|NCT03104296|Diagnostic Test|Griffiths Mental Development Scales|"Griffiths Mental Development Scales investigate 5 main areas (locomotor, personal and social skills, hearing and language, eye and hand coordination, performance), providing a general developmental quotient (DQ) of infant's abilities and five sub-scale quotients (SQ) for each developmental area.
The assessments are performed individually in a quiet room, over a 45-min period, by the same professional trained psychologist for the whole study period and are implemented in the presence of the infant's parent. The obtained results are adjusted for corrected age, in order to consider the neurobiological maturation of the enrolled infants."
1482051|NCT03104283|Drug|Apatinib|take apatinib orally until disease progression or appearance of unbearable toxicity
1482052|NCT03104270|Drug|Elotuzumab|Elotuzumab IV at 10mg/kg once a week.
1482053|NCT03104270|Drug|Pomalidomide|Pomalidomide capsules will be administered per Orem (PO) at 3 mg daily
1482054|NCT03104270|Drug|Carfilzomib|Carfilzomib will be given as an IV infusion over 30 min at 20 mg/m2 on days 1 and 2 of cycle 1 and at 27 mg/m2
1482055|NCT03104270|Drug|Dexamethasone|28 mg of dexamethasone administered PO in the morning the day before of ELO infusion.
1482056|NCT03104257|Other|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
1482057|NCT03104231|Other|three-dimensional (3D) movie|Brief VR-3D will be shown using the oculus glasses and a smartphone. Then, patients will be asked several questions from the prepared questionnaire.
2000965|NCT03297931|Dietary Supplement|Yellow pea chip + hummus|Novel pulse chip + pulse spread
1482212|NCT03103152|Drug|Aspirin placebo, Vitamin D placebo|Aspirin 1 x 100mg placebo tablet daily & Vitamin D 4,000IU daily. (8 drops).
1593671|NCT02281630|Drug|Placebo|
1482058|NCT03104218|Other|tDCS group|Interventions: movement training, strengthening, patient education. tDCS will be delivered using a direct current stimulator (constant current of 1.5 mA) via two 35cm2 (5 x 7 cm) saline-soaked surface sponge electrodes (parameters shown effective to enhance training).40 The center of the active electrode will be positioned over C3/C4 (international 10-20 EEG system; corresponding to the cortical representation of upper limb muscles)57, contralateral to the side of pain and the reference electrode over the contralateral supraorbital region. Current intensity will be ramped up (0-1.5 mA) and down (1.5-0 mA) over 15 seconds at the beginning and end of the 30 minutes stimulation period.
1482059|NCT03104218|Other|Placebo group|"Interventions: movement training, strengthening, patient education. The sham tDCS involves electrodes placed in an identical position to that used for active stimulation; however the stimulation will be turned on for 15 seconds and then off to provide participants with the initial itching sensation but without current for the remainder of the period. This procedure has been shown to effectively blind participants to the stimulation condition."
1482060|NCT03104205|Behavioral|Evaluate home-based MOWI|MOWI will be delivered via video-conferencing in the subject's home in a 3x per week, 26-week program from the coordinating center. It will include an individual dietician-led weekly nutrition session; 2x/week physical therapist-led group exercise session; and Amulet monitoringWe plan 5 cohorts of 8 subjects (n=40). In-person Research Assistant-led assessments will occur at 0, 4, 8, 12 and 26 weeks. Recruitment, screening, selection criteria, and usability parallel Aim 2.
1482061|NCT03104192|Behavioral|Develop & Refine MOWI without Amulet|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits. A dietician and physical therapist will lead the in-person sessions. Two waves of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks.
1482062|NCT03104192|Behavioral|Develop & Refine MOWI with Amulet|The mHealth Obesity Wellness Intervention (MOWI) will be informed by the previous Aim (Aim 1) of this proposal. It will consist of a 12-week, 3x/week program of: weekly nutrition counseling; 2x/week group exercise visits; and Amulet to monitor activity. A dietician and physical therapist will lead the in-person sessions. Two waves of 8 individuals each will be assessed at 0, 4, 8 and 12 weeks and will also be given Amulet to measure steps, activity type, duration and distance.
1482063|NCT03104179|Device|Cytosorb Adsorber|Cytokine adsorption during CPB
1482064|NCT03104166|Device|Medium Cut-Off (MCO) dialysis membrane|Patients will be treated with a CE-certified dialysis membrane that provide enhanced clearance for middle-sized molecules, call Medium Cut-Off membrane.
1482065|NCT03104166|Device|High-Flux dialysis membrane|Control: Patients will be treated with a CE-certified High-Flux dialysis membrane.
1482066|NCT03104153|Procedure|Early-drain removal|Drain removal at hospital discharge
1482067|NCT03104140|Drug|Ketamine|After fluid resuscitation, patients will receive :1 mg/Kg ketamine + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
1482068|NCT03104140|Drug|Thiopental|After fluid resuscitation, patients will receive :2 mg/Kg Thiopental + 0.5 ug/Kg fentanyl + 0.05 mg/Kg midazolam for induction of anesthesia
1482069|NCT03104127|Device|Alter G Bionic Leg|Participants are randomized to a 10 week, community-based bionic leg programme. Participants must use the leg for a minimum of 1 hour per day and continue to have active physical therapy sessions.
1482070|NCT03104127|Other|Normal therapy (physiotherapy)|Participants are randomized to a normal therapy (physiotherapy) only program. Participants are also advised to undertake 1 hour a day of physical activity and have active physical therapy (physiotherapy) sessions.
1482071|NCT03104114|Behavioral|pharmacist-intervention|A clinical pharmacist provides patients with motivational counseling regarding their cancer treatments. Patients will be asked to complete three different surveys throughout the study; surveys focus on social support systems and both provider- and pharmacist-patient relationships
1482072|NCT03104114|Behavioral|Historical control|Patients that did not receive in-person motivational counseling support from a clinical pharmacist prior and during treatment
1482073|NCT03104101|Combination Product|TPTNS+Drug|one tablet Trospium Chloride 20 mg once daily Plus TPTNS
1482074|NCT03104101|Device|TPTNS|Surface adhesive electrodes placed on the skin above medial malleolus
1482075|NCT03104088|Diagnostic Test|CANTAB|CANTAB Cognitive Assessment (tablet based cognitive testing from CAMCOG)
1482076|NCT03104088|Diagnostic Test|MOCA|Montreal cognitive assessment (MOCA) in German
1482077|NCT03104075|Biological|Pneumococcal 13valent Conj Vaccine Diphtheria CRM197 Protein|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Pneumovax 23
1482078|NCT03104075|Biological|Pneumococcal Vaccine Polyvalent|One to two years after receiving the randomly-assigned vaccination, participants may opt to receive administration of a second pneumococcal vaccine with Prevnar-13
1482079|NCT03104062|Diagnostic Test|Microbubble Contrasted Echocardiography|Myocardial Perfusion Score Index (MPSI) obtained using Microbubble Contrasted Echocardiography
1482080|NCT03104049|Device|Neuromuscular taping|"NMT applications:
rhomboid major muscle
muscles abdominals
spinal muscles
pectoralis major muscles
gastrocnemius muscle
upper trapezius muscle
anterior muscles of the neck"
1482081|NCT03104036|Other|Faecal bacterial transplantation|Enema prepared from 50 g of stool of examined donor dissolved in 150 ml of normal saline
1482082|NCT03104036|Drug|Mesalazine 4G Enema|Standard mesalazine enema
1482083|NCT03104023|Procedure|Staple line inversion|A staple line inversion will be performed with a running suture of Polypropylene 2/0
1482084|NCT03104023|Combination Product|Staple line buttressing|The gastric section will be performed with a stapler with preloaded buttress material
1482085|NCT03104010|Drug|Somatropin Injection|Recombinant human growth hormone injection, 15IU/5mg/3ml/bottle. The first stage , 0.17mg/d(0.5IU/d), subcutaneous injection ,daily, 26weeks. The second stage(extension period study), 0.17mg/d(0.5IU/d), maximum ≤0.68mg/d (2IU/w),52 weeks.
1482086|NCT03103997|Procedure|EUS-guided liver biopsy|EUS-guided liver biopsy using needles with various preparations
1482087|NCT03103984|Other|Weight loss diet|Weight loss diet composed of 30% lipids, 30% proteins and 40% carbohydrates.
2000966|NCT03297931|Dietary Supplement|Pinto bean chip + hummus|Commercial pulse chip + pulse spread
2000967|NCT03297931|Dietary Supplement|Pinto bean chip + onion dip|Commercial pulse chip + non-pulse spread
1482094|NCT03103958|Dietary Supplement|Probiotic|"Probiatop is a live microbial preparation saches containing 1g of the formulation composed by Lactobacillus acidophilus NCFM, 10⁹, Lactobacillus rhamnosus HN001 10⁹, Lactobacillus paracasei LPC-37 10⁹, Bifidobacterium lactis HN019 10⁹ combined with Polydextrose.
Subjects will take two sachets per day after diluting them in 100 ml of water"
1482095|NCT03103958|Dietary Supplement|Placebo|"The placebo sachets were prepared by substituting equivalent amounts of Maltodextrin for the probiotic powder.
Subjects will take two sachets per day after diluting them in 100 ml of water"
1482096|NCT03103945|Device|CDS box connection of the Niobe™ Remote Magnetic Navigation System|For all subjects included in the study, the ablation procedure will be started per standard of care. First mapping, pacing and electrocardiograms of the right atrium will be evaluated without the CDS box connected. Second the CDS box will be connected to the catheter and mapping, pacing and electrocardiograms will be recorded again. Next, ablation will be conducted per standard of care.
2000968|NCT03297931|Dietary Supplement|Yellow pea chip + onion dip|Novel pulse chip + non-pulse spread
1482098|NCT03103919|Device|Kinesia-ONE™|Kinesia-ONE™ wearable sensor uses a subject-worn finger sensor and iPad mini application (APP) to objectively measure specific motor tasks related to Parkinson's disease symptoms such as tremor, bradykinesia (slowed movements), and dyskinesia (involuntary movements) in the Investigator's office. Subjects should wear the Kinesia-ONE™ device on the most affected side.
1482099|NCT03103919|Device|Kinesia-360™|Kinesia-360™ wearable sensor includes a wrist and ankle device, along with a cell phone, which is also APP-based, and is designed for continuous day time monitoring of Parkinson's disease symptoms. Subjects will wear Kinesia-360™ while they go about their daily lives, and symptom severity is continually captured to enable objective assessment of Parkinson's disease symptoms. Subjects should wear the Kinesia-360™ device bands on the most affected side.
1482100|NCT03103919|Drug|Rotigotine|All subjects will start Neupro treatment at a dose of either rotigotine 2 mg/24 h or 4 mg/24 h (according to the disease stage of the subject) which will then be adjusted based on symptom assessment either via standard care alone or via a combination of standard care and evaluation of the recordings made available by the Kinesia wearable technologies.
1482101|NCT03103906|Other|Cream (Test product)|Moisturizing cream with SPF (Sun protecting factor) 20
1482102|NCT03103906|Other|Cleanser (Reference Product)|Moisturizing facial cleanser
1482103|NCT03103906|Other|Sunscreen (Reference Product)|SPF 50 sunscreen
2000969|NCT03297931|Dietary Supplement|Corn chips + hummus|Non-pulse chip + pulse spread
1482105|NCT03103880|Device|mHealth Asthma Adherence System|This Intervention includes the use of the mobile application and connected sensors to track adherence and engage patients in their care.
1482106|NCT03103880|Device|Remote Mobile Pulmonary Function Testing|This intervention includes remote patient monitoring of lung function using a connected spirometer used to capture pulmonary function testing (PFTs) monthly.
1482107|NCT03103880|Device|Remote Mobile Peak Flow Capture|This intervention includes remote patient monitoring of lung function using a connected spirometer used to capture peak flow and FEV1 metrics weekly.
1482108|NCT03103867|Device|CGM augmented pump with PLGS ,|5 weeks treatment CGM augmented pump with PLGS compared with 5 weeks treatment with insulin pump with CGM , without integration
1482109|NCT03103867|Device|Insulin pump with CGM|5 weeks treatment continuous subcutaneous insulin infusion pump with CGM without data integration,
1482110|NCT03103854|Behavioral|BURST physical activity|BURST is a novel exercise regimen consisting of three daily periods of 10 minutes of high intensity physical activity spread throughout the day.
1482111|NCT03103854|Behavioral|Text Message Reminders|Patients were sent daily text message reminders to remind them to exercise.
1482112|NCT03103854|Behavioral|Moderate Intensity Continuous Training|This is the current standard of care for cardiac rehabilitation patients. It consists of 1 daily period of 30 minutes of moderate intensity physical activity.
1482113|NCT03103841|Procedure|Sleep studies [Polysomnography]|Undertaking of sleep measurements by polysomnography and use of validated sleep questionnaires
1482114|NCT03103828|Behavioral|Computer-Tailored Intervention|CTI will receive telephone contact at three time points: baseline, two, and four months. Each contact consists of an integrated assessment and intervention feedback report, using an expert system. Participants are assessed for four different behaviors that together represent complete ACP engagement: communication with loved ones about views on quality of life versus quantity of life, communication with clinicians about views on quality of life versus quantity of life, assignment of a health care surrogate, and completion of a living will. The system takes the results of the assessment and results in an individualized feedback report.
1482115|NCT03103828|Behavioral|Motivational Interviewing|MET will receive telephone contact at three time points: baseline, two, and four months. They will undergo the assessment as described above receive and they will receive a second a telephone contact within two weeks of the assessment, which will consist of an MET session. If the surrogate has been enrolled in the study, the MET will be conducted with both the Veteran and the surrogate in a dyadic telephone interview. The goal of the interview is to strengthen commitment to engage in ACP and promote self-efficacy. The interviewer will also help the Veteran to reflect on the pros and cons of ACP engagement as elicited in the assessment process, to understand how to build on ACP behaviors already engaged in, and, if appropriate, to help the Veteran create a change plan for further ACP engagement.
1482116|NCT03103828|Behavioral|Motivational Enhancement Therapy|Participants assigned to CTI+MET will receive the CTI intervention at baseline, two months, and four months as described above. with a follow-up MET session as described above occurring within two weeks of each contact.
1482117|NCT03103815|Drug|Amivita|In each course, Amivita solution (500ml) will be administrated i.v. once daily for 4 weeks. After an interval of 2 weeks, the participants will be treated again. A total of 7 courses will be given,
1482118|NCT03103802|Device|intra-oral digital scanner and extra-oral digital scanner|intra-oral and extra-oral digital scanners used to obtain digital models
1482119|NCT03103789|Diagnostic Test|single catheter mucosal impedance testing|
1482120|NCT03103789|Diagnostic Test|balloon assembly mucosal impedance testing|
1482211|NCT03103152|Drug|Aspirin Placebo, Vitamin D|Aspirin 1 x 300mg placebo tablet daily & Vitamin D 4,000IU daily. (8 drops).
1482362|NCT03101969|Other|Call|not called, not reached, and spoken to
1482121|NCT03103776|Other|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto|Comparison of Positive PCR Frequencies for Polyomavirus in Blood, Urine and / or Thyroid Tissue vs Basedow / Hashimoto
1482122|NCT03103763|Drug|Warfarin|Patients on warfarin for atrial fibrillation
1482123|NCT03103750|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic resonance imaging (MRI) scans (3 T) will be collected in each subject for the purposes of excluding participants with anatomical abnormalities and anatomically co-registering PET and MRI for image analysis
1482124|NCT03103750|Drug|Raclopride|Used as a tracer for in vivo imaging.
1482125|NCT03103750|Dietary Supplement|calcitriol|three 0.5 mcg capsules
1482126|NCT03103750|Drug|Placebo oral capsule|three 0.5 mcg capsules
1482127|NCT03103750|Procedure|high-resolution research tomography|A functional imaging technique that is used to observe metabolic processes in the body.
1482128|NCT03103750|Drug|Dextro Amphetamine|Dexedrine 0.3 mg/kg, to a maximum dose of 30 mg
1482129|NCT03103737|Behavioral|Virtual Reality (VR) and Reminiscence Intervention|First and third sessions are dedicated to remember positive and meaningful personal experiences. Second and fourth sessions are oriented to positive emotions by the use of VR. Participants can choose the virtual environment to work with.
1482130|NCT03103724|Drug|Xtandi|Enzalutamide 160 mg (4 x 40 mg capsules), orally once daily
1482131|NCT03103711|Behavioral|Virtual Reality Intervention|"Participants receive two sessions oriented to joy and two focused on relax. In the first 2 sessions patients can choose the environment (Emotional Parks or Walk through Nature) and in the following ones participants visit the alternate environments."
1482132|NCT03103698|Device|To demonstrate the monitoring of perioperative analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
1482133|NCT03103698|Other|Standard preoperative evaluation of analgesia|To demonstrate that the monitoring of perioperative analgesia by the ANI device decreases intraoperative morphine consumption compared with conventional monitoring based on haemodynamic variations.
1482134|NCT03103685|Drug|Clopidogrel|The patient s in experimental arm will not be ask to stop P2Y12 inhibitor such as Clopidogrel, Prasugrel or Ticagrelor
1482135|NCT03103672|Procedure|Percutaneous transhepatic cholangiography|Percutaneous transhepatic cholangiography (PTC) can be performed via the right midaxillary approach, though a subxiphoid approach is occasionally needed
1482136|NCT03103659|Other|personalised care plan|Quality of life assessement in elderly cancer patients
1482137|NCT03103646|Drug|Lu AF35700|Tablets for oral use, single dose in a fasted state. EMs: 10 mg/day, PMs: 5 mg or 10 mg/day.
1482138|NCT03103646|Drug|Itraconazole (200 mg)|100 mg Capsules for oral use, 200 mg/day. In a fed state
1482139|NCT03103646|Drug|Itraconazole (300 mg)|100mg Capsules for oral use, 300 mg/day. In a fasted state.
1482140|NCT03103633|Procedure|mean artery pressure|mean artery pressure declined with less than 20% of baseline
1482141|NCT03103633|Procedure|bispectral index|BIS maintained 45-60
1482142|NCT03103633|Procedure|Brain oxygen saturation|Brain oxygen saturation declined with less than 20% of baseline
1482143|NCT03103633|Other|Controlled|Receiving standard measures to maintain oxygenation (SpO2≥94%), haemoglobin (>80 g/L), core temperature (≥36°C), and heart rate (<120 beats per min)
1482144|NCT03103620|Device|COBRA PzF Coronary Stent System|COBRA PzF Coronary Stent System
1482145|NCT03103607|Diagnostic Test|Ophthalmological evaluation|exophthalmometry, evaluation of the Clinical Activity Score (CAS), assessment of diplopia, measurement of visual acuity, assessment of the corneal status; examination of the fundi
1482146|NCT03103607|Diagnostic Test|Questionnaire|Patients were asked to fill a questionnaire on self-perception related to GO with the following questions: i) are your eyes identical to the way they were before GO appeared?; ii) are your eyes normal? iii) do you have any limitations in daily activities related to your eyes?; iv) do you have any limitations in social life related to your eyes?
1482147|NCT03103594|Drug|DMSO|DMSO will be instilled intravesically.
1482148|NCT03103594|Drug|Botox|Botox will be instilled intravesically with DMSO.
1482149|NCT03103581|Drug|BLI4700|BLI4700 Bowel Preparation
1482150|NCT03103568|Drug|Nitisinone in Arm A|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 17 days.
1482151|NCT03103568|Drug|Tolbutamide|A 500 mg tablet is given as single oral dose 2 weeks apart.
1482152|NCT03103568|Drug|Metoprolol|A 50 mg tablet of metoprolol tartrate is given as single oral dose 2 weeks apart.
1482153|NCT03103568|Drug|Chlorzoxazone|A 250 mg tablet is given as single oral dose 2 weeks apart.
1482154|NCT03103568|Drug|Furosemide|A single intravenous dose of 20 mg administered as an i.v. infusion is given 2 weeks apart.
1482155|NCT03103568|Drug|Nitisinone in Arm B|4 capsules of 20 mg nitisinone (80 mg) is given once daily for 16 days.
1482156|NCT03103555|Drug|Bortezomib|Bortezomib will be subcutaneously administered in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
1482157|NCT03103555|Drug|Cyclophosphamide|Low dose cyclophosphamide will be given orally for 4 month after completion 2 cycles of bortezomib
1482158|NCT03103542|Biological|Recombinant coagulation factor (rFVIIIFc)|"rFVIIIFc 200 IU/kg/day during ITI Period and thereafter adjusted according to the Investigator's judgement
administered intravenously."
1482159|NCT03103529|Other|Active Rehabilitation|
1482160|NCT03103516|Procedure|early epidural decompression group|The patients will be assigned to early (within 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
1482161|NCT03103516|Procedure|delayed epidural decompression group|The patients will be assigned to delayed (exceed 24 hours after spinal cord injury) epidural decompression group (n=100) according to the patient's condition and operation time.
1482162|NCT03103490|Drug|F18 FSPG|Patients will receive 8mCi of F18 FSPG and undergo PET/MRI imaging to determine the ability of F18 FSPG to localize to cardiac sarcoidosis or myocardial inflammation and the utility of PET/MR to detect these conditions.
1482163|NCT03103477|Other|Urine stability|This study is proposing to assess PAF and PAF-AH activity in urine after using various handling methods of the urine specimen. Better understanding of PAF stability will allow for better design of future experiments involving PAF in interstitial cystitis patients.
1482164|NCT03103464|Other|Standard-of-Care Therapy + Sit-to-Stand Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time + sit-to-stand training using the Movi chair 3x/wk for approximately 10 minutes each time.
1482165|NCT03103464|Other|Standard-of-Care Therapy|Standard-of-care physical therapy 3x/wk for approximately 30 minutes each time.
1482166|NCT03103451|Drug|BCD-121|
1482167|NCT03103451|Other|Placebo|
1482168|NCT03103438|Biological|BCD-089|
1482169|NCT03103412|Drug|TD-3504|TD-3504
1482170|NCT03103412|Drug|15N2-tofacitinib|15N2-tofacitinib
1482171|NCT03103412|Drug|Placebo|Placebo
1482172|NCT03103399|Drug|Comtan®|200 mg entacapone were to be taken concomitantly with each levodopa/DDCI dose.
1482173|NCT03103399|Drug|Nebicapone|50 mg, 100 mg and 150 mg doses of nebicapone were to be taken concomitantly with each levodopa/DDCI dose.
1482174|NCT03103399|Drug|Levodopa/DDCI|"Prior to the study, all patients were to have been receiving levodopa/DDCI therapy for at least 1 year with clear clinical improvement. At entry to the study, patients were to be receiving levodopa/DDCI therapy of at least 4 but not more than 8 (inclusive) standard daily doses.
All patients were to continue receiving levodopa/DDCI during the study. Levodopa and DDCI were prescribed by the investigators and purchased locally by patients."
1482175|NCT03103399|Drug|Placebo|Administered orally as encapsulated tablets, which were identical in appearance to the study drugs
1482176|NCT03103386|Dietary Supplement|intake of food product with a patented fermented rye bran|During the treatment period, participants will be provided 2 packages of puff（fermented rye bran）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day to facilitate compliance.
1482177|NCT03103386|Dietary Supplement|intake of food product with common refined wheat|During the treatment period, participants will be provided 2 packages of puff （common refined wheat）and 2 packages of crisp bread to be included in the daily diet. Participants are free to consume the product any time during the day, but will be advised to facilitate compliance.
1482178|NCT03103373|Device|Conventional monitor|Patients underwent non-cardiac surgery will be monitoring by regular monitors
1482179|NCT03103373|Device|Echocardiography|Patients will be monitoring by regular monitors plus echocardiography
1482180|NCT03103360|Device|videopupillometer|Measure of pupillary diameter and pupillary pain index via an infrared camera Each measure lasts approximately 20 seconds
1482181|NCT03103360|Procedure|skin incision|performed under general anesthesia by the surgeon, at the beginning of an elective or emergency surgery.
1482182|NCT03103334|Other|Zeneo® - Methotrexate|0.625 mL of methotrexate solution 40 mg/ML for subcutaneous injection with a prefilled and needle-free delivery system
1482183|NCT03103334|Drug|Methotrexate Biodim®|1 mL of methotrexate solution 25 mg/mL for subcutaneous injection with a conventional needle and syringe injection
1482184|NCT03103321|Other|Internet-Based Intervention|"Receive Knowing your Options decision aid"
1482185|NCT03103321|Other|Internet-Based Intervention|"Receive Prostate Choice decision aid"
1482186|NCT03103321|Other|Best Practice|Undergo usual care
1482187|NCT03103321|Other|Quality-of-Life Assessment|Ancillary studies
1482188|NCT03103321|Other|Questionnaire Administration|Ancillary studies
1482189|NCT03103321|Other|Survey Administration|Ancillary studies
1482190|NCT03103321|Other|Laboratory Biomarker Analysis|Correlative studies
1482191|NCT03103308|Other|Walk Training and Transplant|Subjects will receive free activity monitors and have three training sessions per week for the duration of their bone marrow transplant treatment
1482192|NCT03103308|Other|Activity Monitoring and Transplant|Subjects will receive free activity monitors for the duration of their bone marrow transplant treatment
1482193|NCT03103295|Biological|3D-Tissue Engineered Bone Equivalent|Administrated for operative delivery of 3D-Tissue Engineered Bone Equivalent
1482194|NCT03103282|Device|PuraStat®|Synthetic haemostatic material
1482195|NCT03103269|Behavioral|Challenge! Small Group Intervention|The Challenge! Small Group intervention consists of curriculum related to health behavior goal setting, healthy eating, and staying active, working out with Health Educators, and receiving a year-long membership to the YMCA.
1482196|NCT03103269|Other|Challenge! Environmental Intervention|The environmental intervention involves the formation of a Health and Activity Committee composed of community members, teachers, parents, school staff, and 8th grade girls from the school. Together, this group comes up with ways to make their school environment healthier.
1482197|NCT03103256|Drug|YHP1701|PO, Once daily (QD), 8 weeks
1482198|NCT03103256|Drug|YHR1703|PO, Once daily (QD), 8 weeks
1482199|NCT03103256|Drug|YHR1704|PO, Once daily (QD), 8 weeks
1482200|NCT03103243|Behavioral|Mindfulness Based Group Sessions|In-person group intervention sessions conducted with a combination of meditation, group exercise (yoga), group discussions, deep breathing and other mindfulness based practices.
1482201|NCT03103230|Device|Cortical magnetic stimulation|Motor Evoked Potentials of lips and hand recorded after cortical magnetic stimulation
1482202|NCT03103217|Behavioral|brief CBT for anxious pregnant women|one off 3 hour session including psychoeducation, exploration of cognitions and experiential practice of behavioural techniques.
1482203|NCT03103204|Combination Product|One-stage full-mouth disinfection with chlorhexidine|"Mechanical procedures, composed of full-mouth dental scaling and root planning and dental prophylaxis, will be completed within 24 hours (2 appointments in 2 consecutive mornings or afternoons).
Chlorhexidine will be used as the antimicrobial agent in different concentrations (0.2%, 1% and 2%) and vehicles (solution, gel).
Oral hygiene instructions will be given for all participants."
1482204|NCT03103191|Diagnostic Test|KL-6 levels|Measure of KL-6 in serum
1482205|NCT03103178|Other|Quality of life questionnaire|Measurement of quality of life
1482206|NCT03103165|Behavioral|SimCoach Intervention|
1482207|NCT03103152|Drug|High dose Aspirin & Vitamin D|Aspirin 1 x 300mg tablet daily & Vitamin D 4,000IU daily. (8 drops).
1482208|NCT03103152|Drug|High dose Aspirin, Vitamin D placebo|Aspirin 1 x 300mg tablet daily & Vitamin D placebo (8 drops).
1482209|NCT03103152|Drug|Low dose Aspirin , Vitamin D|Aspirin 1 x 100mg tablet daily & Vitamin D 4,000IU daily. (8 drops).
1482210|NCT03103152|Drug|Low dose Aspirin, Vitamin D placebo|Aspirin 1 x 100mg tablet daily & Vitamin D placebo 8 drops daily.
1482213|NCT03103139|Procedure|Transpapillary Stent|ERCP with placement of short stent
1482214|NCT03103139|Procedure|Stent across bile leak|ERCP with long stent
1482216|NCT03103100|Drug|1% Lidocaine|10 mL of 1% lidocaine
1482217|NCT03103100|Drug|0.25% Bupivacaine|10 mL of 0.25% bupivacaine
1482218|NCT03103100|Drug|Bupivacaine plus Lidocaine|5 mL of 1% lidocaine and 5 mL of 0.25% bupivacaine
1482219|NCT03103087|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
1482220|NCT03103087|Drug|Low-dose Hormonal Add-back|Estradiol and norethindrone acetate
1482221|NCT03103087|Drug|Relugolix Placebo|Placebo relugolix manufactured to match relugolix in size, shape, color, and odor
1482222|NCT03103087|Drug|Low-dose Hormonal Add-back Placebo|Placebo capsule designed to match the active low-dose hormonal add-back therapy in size, shape, color, and odor
1482223|NCT03103074|Drug|Botulinum B Toxin|Intradermal injections
1482224|NCT03103074|Other|Placebo Saline|Intradermal injections
1482225|NCT03103061|Drug|Lexiscan|Coronary vasodilator
1482226|NCT03103048|Diagnostic Test|Without bandages|All volunteers will be held the grasping force measurements without application of elastic adhesive bandage or micropore
1482227|NCT03103048|Diagnostic Test|With placebo|All volunteers will be held the grasping force measurements with application of micropore (placebo) on his forearm in both upper members
1482228|NCT03103048|Diagnostic Test|With bandage|All volunteers will be held the grasping force measurements with application of bandage without tension in the forearm in both upper members
1482229|NCT03103048|Diagnostic Test|With tensioned bandage|All volunteers will be held the grasping force measurements with application of bandage with twenty five percent tensioned on the forearm in both upper members
1482230|NCT03103035|Other|Blog|Participants randomised to the experimental group are exposed to one blog post each week for a period of 6 months. Blog posts focus on the improvement of fruits and vegetables consumption targeting four main determinants of the behavior: (1) knowledge; (2) attitude; (3) self-efficacy; and (4) motivation/goals. Each post included a step-by-step recipe developed by the research team and featuring fruits and vegetables. Recipes were described textually and also using pictures and/or video. Twenty-six posts were created over the six-month intervention.
1482231|NCT03103022|Drug|Acetaminophen|Oral acetaminophen [160 mg/5ml concentration] will be administered every 6 hours with dose of 15 mg/kg/dose for a total of twelve doses
1482232|NCT03103022|Drug|ibuprofen|Oral ibuprofen [100 mg/5 ml] at 10 mg/kg/dose on first day followed by 5 mg/kg/dose at 24 and 48 hours for a total of three doses
1482233|NCT03103009|Drug|Pasireotide|Somatostatin analogues are a last resort for medical intervention in hyperinsulinemic hypoglycemia (HH). The hypoglycemia is very debilitating and can be even life threatening. There is limited experience with pasireotide in hyperinsulinemic hypoglycemia (only one publication); there is more experience with octreotide, both in adults and children and successful interventions with octreotide in hyperinsulinemic hypoglycemia have been published. Pasireotide via its different somatostatin receptor binding profile has clear effects on insulin, glucagon and incretin secretion and can ultimately lead to hyperglycemia. This mode of action (especially the effects on insulin and incretin secretion) could be very useful in the setting of hyperinsulinemic hypoglycemia.
1482234|NCT03102996|Drug|Nephrotrans|Sodium hydrogen carbonate, ATC-Code: A02AH
1482235|NCT03102996|Other|Placebo|Identical capsules without active substance.
1482236|NCT03102983|Other|MRI functional|vowels records and MRI session
1482237|NCT03102957|Other|functional MRI|
1482239|NCT03102931|Drug|Reduced ROS/RNS content products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
1482240|NCT03102931|Drug|Typical to high (ROS/NOS) products|Participants will be given and asked to spoke only the cigarettes provided for them. Biosamples and surveys will be collected every 2 weeks throughout the study.
1482241|NCT03102918|Drug|Cannabidiol|Participants will receive either up to 800 mg Epidiolex over a 6-week treatment period.
1482242|NCT03102918|Drug|Placebo|Participants will receive placebo over a 6-week treatment period.
1482243|NCT03102905|Other|Measurement of the prevalence of the positivity of cutaneous HHV6 quantitative PCR in the cohort studied.|To evaluate the prevalence of the positivity of HHV6 PCR in the skin, during the exanthema in patients hospitalized for haemopathy.
1482244|NCT03102892|Procedure|Scaling root planing|Treatment by scaling and root planing alone.
1482245|NCT03102892|Procedure|Antimicrobial photodynamic therapy|Treatment with methylene blue dye and red laser
1482246|NCT03102879|Procedure|Regenerative Endodontic Procedure|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with stem cells.
1482247|NCT03102879|Procedure|Conventional Root Canal Treatment|Coronary access, conductometry, mechanized instrumentation, irrigation with sodium hypochlorite, intracanal calcium hydroxide medication and obturation with gutta-percha.
1482248|NCT03102866|Other|Best Practice|Receive usual care
1482249|NCT03102866|Behavioral|Exercise Intervention|Undergo aerobic and strength training exercise
1482250|NCT03102866|Other|Quality-of-Life Assessment|Ancillary studies
1482251|NCT03102866|Other|Questionnaire Administration|Ancillary studies
1482252|NCT03102853|Other|Nordic diet|
1482253|NCT03102853|Other|Control diet|
1482254|NCT03102840|Diagnostic Test|Nasopharyngeal swab|Nasopharyngeal swab will be performed in all participants
1482255|NCT03102840|Diagnostic Test|blood sampling|Blood sampling will be done by finger-prick in a sub-set of participants
1482256|NCT03102827|Drug|Oxygen|Patients will receive oxygen with humidified air, fully saturated at 37° C at a flow rate of 20- 50 L/min. The ratio of oxygen and ambient air (FiO2) will be increased stepwise depending on patient's oxygen saturation.
1482257|NCT03102827|Other|Placebo|Ambient air without high-flow therapy administered during first night
1482422|NCT03101566|Drug|Ipilimumab|Ipilimumab 1 mg/kg over 30 minutes
1482258|NCT03102814|Behavioral|Current rehabilitation|The control group will receive the rehabilitation currently offered at each of the participating centers.
1482259|NCT03102814|Behavioral|The BRIDGE program|The experimental group will additionally receive the BRIDGE program, which comprises motivational interviewing, structured goal-setting, tailored follow-up, plans for self-management, and individualised written feedback that participants can use to monitor their progress and share with important care givers.
1482260|NCT03102801|Drug|Humulin S|
1482261|NCT03102788|Behavioral|Rheumatologist-led care.|"Rheumatologist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, and, for some patients, Intra-articular injection of long-acting Corticosteroid.
The rheumatologist may also refer participants to occupational therapy if needed."
1482262|NCT03102788|Behavioral|Occupational therapist-led care.|Occupational therapist-led care comprises confirmation of diagnosis, information about hand osteoarthritis and symptom modifying medication, teaching of hand exercises and ergonomic working methods, and, for some patients, provision assistive devices and orthoses/splints. The occupational therapist will refer patients to a short rheumatologist consultation if confirmation of diagnosis or intra-articular injections of long-acting Corticosteroid are needed.
1482263|NCT03102775|Other|Comprehensive follow-up program for low-income families|The main follow-up areas within the HOLF-program is to improve employment, housing, financial situation of the children. Beside manuals, family coordinators participate in five seminars with home-based tasks in between. Alo a comprehensive supervision structure is implemented that follow the train the trainer model. Coordinators ought to work directly with th families, but also with other actors important to the family, such as child-welfare and school. Coordinators should use specific tools improving the quality of the meetings, such as forms for preparation of meetings, being goal-focused and empowering.
1482264|NCT03102775|Other|local family projects|The control group offices will develop local family projects, depending on local needs. they will also recruit and follow-up families.
1482265|NCT03102762|Drug|Botulinum Toxin Type A|Drug: Botulinum Toxin Type A The treatment group will be injected with 100 units BTX-A one day following penile colour doppler assessment.
1482266|NCT03102762|Drug|Normal saline|The treatment group will be injected with 1 ml normal saline one day following penile colour doppler assessment.
1482267|NCT03102749|Other|metacholine provocation test and CT-scan low dose|Investigators perform a metacholine provocation test where expiratory CT slices were acquired at each dose
1482268|NCT03102736|Drug|Placebos|Placebo saline
1482269|NCT03102736|Drug|Ketamine|0.5 mg/kg ketamine
1482270|NCT03102736|Drug|Nitroprusside|0.5 mcg/kg nitroprusside
1482271|NCT03102723|Drug|Cangrelor|"Cangrelor treatment: IV Cangrelor as a single IV bolus (30 μg/kg) followed by an infusion (4 μg/kg/min) of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI. This dosing regimen is identical to that used in the CHAMPION trials.
Or
Placebo control: IV normal saline as a single IV bolus followed by an infusion of at least 120 minutes duration or until PPCI procedure has ended (whichever is longer) - this will be initiated prior to PPCI."
1482272|NCT03102710|Device|transcranial direct current stimulation (tDCS)|tCDS safely applies a weak electrical current to your scalp using two sponge electrodes that look like flat circular pads. The pads will be held in place on your head with a neoprene cap. The pads will be attached to a generator that will send a weak stimulus to your scalp. This current influences the way that your brain cells work. When the stimulus starts, you might feel a tingling sensation underneath the electrode pads. That sensation is not painful and goes away in seconds.
1482273|NCT03102710|Other|Lidocaine cream|Lidocaine cream will be applied on the arm to reduce pain sensitivity (analgesia).
1482274|NCT03102710|Other|Capsaicin cream|Capsaicin cream will be applied on the arm to increase pain sensitivity (hyperalgesia).
1482275|NCT03102710|Other|Control cream|A neutral cream will be applied on the arm as a control.
1482276|NCT03102697|Device|Air-filled Intragastric balloon|Weight loss system that consists of an air balloon that occupies space in the stomach, thus reducing the gastric capacity and leaving less volume for food.
1482277|NCT03102684|Other|Secondhand exposure to e-cigarette aerosols (low)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with low resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.
All study subjects will participate in this arm as the study has a cross-over design."
1482278|NCT03102684|Other|Secondhand exposure to e-cigarette aerosols (high)|"Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with high resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.
All study subjects will participate in this arm as the study has a cross-over design."
1482279|NCT03102671|Other|Use of HeartHab application followed by usual care|use of a mobile, app based multidisciplinary telerehabilitation program (2 months) followed by usual care (two months)
1482280|NCT03102671|Other|Usual care followed by the use of HeartHab application|Usual care (2 months) followed by the use of HeartHab application (two months)
1482281|NCT03102658|Drug|Micafungin|Administration of study drug
1482282|NCT03102645|Drug|Placebo Oral Tablet|Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc
1482283|NCT03102645|Drug|Imipramine Hydrochloride 25 MG|Two Imipramin DAK film coated tablets 25 mg each, single dose
1482284|NCT03102632|Other|High Water Intake|After 6 months of usual, unchanged diet and fluid intake, participants will be asked to increase the daily fluid intake based on the principal investigator's prescription. The actual amount of extra water prescribed will depend on the results of the participant's 24 hour urine test.
1482285|NCT03102606|Drug|Plinabulin|Plinabulin (BPI-2358) is a synthetic, low molecular weight, new chemical entity that belongs to the diketopiperazine class of compounds. Plinabulin is intended for intravenous (IV) infusion and is diluted in D5W and administered for 30 minutes (± 5 minutes).
1482286|NCT03102606|Drug|Pegfilgrastim|PEGFILGRASTIM is a long-acting granulocyte colony-stimulating factor that stimulates the growth of neutrophils, to reduce the incidence of fever and infection in patients with certain types of cancer who are receiving chemotherapy that affects the bone marrow.
1482287|NCT03102606|Other|Saline Placebo|Placebo Syringe 0.6 ml Saline to match the 0.6 ml pegfilgrastim administration
1482288|NCT03102606|Other|D5W Placebo|Placebo 250 ml D5W to match the administration of plinabulin diluted in 250 ml D5W
1482289|NCT03102593|Drug|ARGX-113|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
1482290|NCT03102593|Other|Placebo|ARGX-113 (Dose A or Dose B) or matching placebo will be administered IV weekly
2000973|NCT03293303|Behavioral|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
1482292|NCT03102567|Drug|GLPG1205 50mg q.d.|oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo
1482293|NCT03102567|Drug|Placebo oral capsule|oral gelatin capsule containing placebo to match study arm 1 - q.d. administration
1482294|NCT03102567|Drug|GLPG1205 250 loading dose and 50mg q.d. maintenance dose|Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration
1482296|NCT03102541|Other|None intervention|
1482297|NCT03102528|Other|No intervention|No intervention
1482298|NCT03102515|Drug|USG-TAP block|
1482299|NCT03102515|Drug|CIC|
1482300|NCT03102502|Device|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is a technique for assisting the circulation by decreasing the afterload of the left ventricle and augmenting the diastolic pressure externally by applying a negative pressure to the lower extremities during cardiac systole. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. EECP enhances the aortic diastolic blood flow and coronary perfusion, leading to increased arterial wall shear stress in a pulsatile manner.
1482301|NCT03102502|Drug|Standard medical therapy|Guideline- driven standard medical treatment
1482302|NCT03102489|Drug|BP101|Nasal spray
1482303|NCT03102489|Drug|Placebo|Nasal spray
1482304|NCT03102476|Drug|Humalog|Subcutaneous injection of Humalog and assessing Pharmacokinetics and Pharmacodynamics properties of Humalog under different environmental conditions
1482305|NCT03102463|Dietary Supplement|Water Control|120mL water given as a control, followed by a hyperinsulinemic-euglycaemic clamp
1482306|NCT03102463|Dietary Supplement|Milk derived hydrolysate|Milk derived hydrolysate made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
1482307|NCT03102463|Dietary Supplement|Parent Protein|Parent protein made up as a milkshake in 120mL water, followed by a hyperinsulinemic-euglycaemic clamp
1482308|NCT03102463|Other|Lipid Load|100mL oral lipid load
1482309|NCT03102450|Drug|Benzalkonium Chloride Spermicide Cream|"One dose of Pharmatex vaginal cream (benzalkonium chloride) must be used systematically before each intercourse, regardless of the cycle period, even during menstrual periods. In case of repeated acts of intercourse, an additional dose of cream must be used before each new act.
Duration of treatment : 6 months (12 months optional)"
1482311|NCT03102424|Device|Transcutaneous Electrical Nerve Stimulator (DW1330)|The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
1482312|NCT03102424|Device|Sham DW1330 device|The Sham DW1330 device will be masked by the same appearance as the study device (DW1330). The usage of time and location of Sham DW1330 device will be completely the same with study device (DW1330). However, the electronic model, including the frequency and time consistence of electronic stimulation are different between the Sham DW1330 device and the study device (DW1330). The 20 weeks of treatment of the DW1330 device, all the patients enrolled should perform 1 treatment within 1 hour after dinner 5 days a week.
1482313|NCT03102398|Drug|Vardenafil, 2.5mg, q.d.|Vardenafil, 2.5mg, topical gel, 2 drops (50ul, 2.5mg)/time, once daily
1482314|NCT03102385|Behavioral|Motivational Interview|A web-based computer-tailored intervention that includes open-ended questions, reflective responses, affirmations, and summarizing, as well as informing and advising. Specific topics include 1) individual motivations for giving, 2) the relationship between past donation behavior and the individual's personal goals/values, 3) donation importance and confidence rulers, 4) addressing donor concerns, and 5) summarizing.
1482315|NCT03102385|Behavioral|Knowledge Interview|A web-based interview that includes open-ended questions regarding blood donation knowledge.
1482316|NCT03102372|Dietary Supplement|Whey protein supplementation|
1482317|NCT03102372|Other|walking program|
1482318|NCT03102372|Other|Very Low Calorie Diet|
1482319|NCT03102359|Drug|Dexmedetomidine|Using dexmedetomidine at anesthesia induction and maintain until the end of the surgery
1482320|NCT03102359|Device|Cooling Helmet|Using cooling helmet for selective head cooling group and Selective Head Cooling and Dexmedetomidine group
1482321|NCT03102346|Other|home-based cardiac rehabilitation|The exercise training includes aerobic exercise (fast walking or cycling ,30-40 minutes per day,5-6 times a week), stretching exercise (15 minutes every time, 5-6 times a week), and resistance and balance training (each of 15 minutes every time, twice to 3 times a week).
1482322|NCT03102333|Device|Variable-rate Feedback Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time. It can increment or decrement rate(0.2ml/hr) by press bolus button during a 48 h period
1482323|NCT03102333|Device|Constant-rate Infusion mode|The PCA regimen consisted of fentanyl 20 μg/kg and Ramosetron Hcl 0.3 mg (total volume including saline: 100 ml) and was programmed to deliver 1 ml /h as a background infusion and a bolus of 1.5 ml on-demand, with a 15 min lockout time during a 48 h period
1990597|NCT01946074|Drug|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion in 28-day dosing cycles on Day 1 and 15.
1482423|NCT03101566|Drug|Nivolumab|Nivolumab 360 mg or 240 mg IV over 30 minutes
1486939|NCT03067064|Other|no intervention|Clinical examination
1990600|NCT01941589|Drug|oral 5-ASA+/-topical 5-ASA+IV corticosteroids / PO Methylprednisolone|maximal oral 5-ASA+/-topical 5-ASA+IV corticosteroids
1990601|NCT01941589|Drug|corticosteroids only|IV corticosteroids only
2000974|NCT03293160|Other|Care management services|Patients who receive care management services will interact with a care manager who will take an inventory of the patient's needs (including social determinants of health such as housing) and provide guidance about available social supports and clinical resources.
1482327|NCT03102307|Other|Not suitable for TAD|Registry of the rate of patients not suitable for TAD as initial CNB with clip placement of axillary lymph nodes is not possible and underlying medical contraindications, technical obstacles or miscellaneous reasons why needle biopsy and/or clip labeling of clinically affected lymph nodes cannot be done
1482328|NCT03102307|Procedure|Suitable for TAD|Registry of surgical outcome measures of targeted resection of the clipped node with optional sentinel node biopsy or axillary lymph node dissection with or without preceding neoadjuvant chemotherapy
1482329|NCT03102294|Other|inspiratory muscle training|inspiratory muscle training with 50% of MIP
1482330|NCT03102294|Other|"Placebo training"|placebo training with PowerBreathe (without inspiratory load)
2000975|NCT03293485|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, 30-minute IV infusion once every 6 hours
2000976|NCT03294174|Drug|Ropivacaine injection|Ropivacaine administered to provide nerve block
1482333|NCT03102242|Drug|Atezolizumab|Single arm phase II trial of induction immunotherapy with anti-PD-L1 for patients with unresectable stage III NSCLC and PS 0-1.
1482334|NCT03102229|Other|Enhanced Supportive Care - Status Checks|Would occur everyday during treatment when a patient is deemed high-risk.
1482335|NCT03102229|Other|Enhanced Supportive Care - Referrals|On an as-need basis, high risk patients can be referred to our nutritionist or palliative care doctor.
1482336|NCT03102229|Radiation|Radiation Therapy|Radiation therapy per standard of care. Must be given concurrently with chemotherapy.
1482337|NCT03102229|Drug|Chemotherapy|Chemotherapy per standard of care. Must be given concurrently with Radiation therapy.
1482338|NCT03102216|Diagnostic Test|iSTAT|iSTAT troponin, INR, CG4+ and Chem8
1482339|NCT03102216|Diagnostic Test|CBC|Complete Blood Count
1482340|NCT03102216|Diagnostic Test|ECG|ElectroCardioGram
1482341|NCT03102216|Diagnostic Test|Lodox|Low dose x-ray
1482342|NCT03102190|Drug|Verapamil Hydrochloride Intranasal|Verapamil solution for injection, supplied in vials, will be utilized in a Neil Med Sinus Rinse of 240mL buffered normal saline.
1482343|NCT03102177|Drug|Administration of stable Isotope labeled levothyroxine|Administration of single dose of stable isotope carbon-13 labeled levothyroxine and measurement of blood levels of stable isotope-labeled levothyroxine
1482344|NCT03102164|Procedure|cardiac rehabilitation|The rehabilitation protocol comprises respiratory, assisted, active dynamic, and relaxation exercises, as well as short-term isometric exercises and general strength exercises of very low intensity, short duration and properly adjusted recovery phase; they are conducted in a lying, sitting, or standing position.
1482345|NCT03102151|Other|Community Campaign La CLAVE|A community campaign to teach community residents and professional networks the signs and symptoms of psychosis using social media, community talks, and advertising.
1482347|NCT03102112|Other|MRI examination|A noninvasive medical diagnostic technique in which the absorption and transmission of high-frequency radio waves are analysed as they irradiate the hydrogen atoms in water molecules and other tissue components placed in a strong magnetic field. This computerized analysis provides a powerful aid to the diagnosis and treatment planning of many diseases, including cancer.
1482348|NCT03102099|Procedure|contrast-enhanced ultrasound group|The contrast-enhanced ultrasound patients will undergo biopsy with contrast-enhanced ultrasound guidance.
1482349|NCT03102099|Procedure|conventional ultrasound group|The conventional ultrasound group will undergo biopsy with conventional ultrasound guidance.
1482350|NCT03102086|Procedure|Scaling|Scaling of dental calculus
1482351|NCT03102073|Diagnostic Test|Radner test|"The A5 reading booklet is held by the subject
The subject is instructed to read sentence by sentence, by turning consecutively the pages of the booklet (on the first side is the number of sentence and the backward side contains the sentence)
The subject is instructed to read the sentences aloud as quickly and accurately as possible to the end, and to not correct reading errors.
One assessor is writing the reading time and records any reading errors on the scoring sheet while the second assessor is audio recording the operation
Stop criterion: reading time longer than 20 seconds or severe errors."
1482352|NCT03102060|Other|Dietary Intervention|Undergo gluten free diet
1482353|NCT03102060|Other|Laboratory Biomarker Analysis|Correlative studies
1482354|NCT03102047|Drug|durvalumab|Within 3−7 days after completion of chemoradiation, patients will receive durvalumab (750 mg IV infusion) every 2 weeks for 4 doses on Day 1(Dose 1), Day 15 (Dose 2), Day 29 (Dose 3), and Day 43 (Dose 4)
1482357|NCT03102021|Drug|erythropoietin|500 units/kg daily for 3 days at onset of acute kidney injury
1482358|NCT03102021|Drug|saline|saline 10 ml for 3 days
1482359|NCT03102008|Behavioral|Unified Protocol for Emotional Disorders in Adolescents (UP-A)|The Unified Protocol for Emotional Disorders in Adolescents (UP-A), is a transdiagnostic therapeutic intervention employing core dysfunction approaches, defined as such due to their attendance to features of various (emotional) disorders. The treatment may work to ameliorate symptoms more broadly by targeting cross-cutting features common to the range of disorders targeted. Specifically, the UP-A might lead to the successful treatment of an array of emotional disorders in youth by targeting processes common across these frequently co-occurring problems including poor distress tolerance, limited cognitive flexibility, and heightened avoidance.
1482360|NCT03101995|Drug|Gemcitabine|"Gemcitabine 300 mg/m2, prepared in 0.5 liters of sodium chloride 0.9%, IV administered in 30 minutes weekly for a maximum of 6 weeks.
Radiotherapy will start the first week, or as soon as the blood count is normal or the patient has recovered after blood transfusion. Radiotherapy will be applied, using an external beam releasing 40-50.4 Gy in 20-28 fractions: 1.8 Gy/day for 5 days/week, during 4 to 6 weeks.
Intracavitary brachytherapy will be added to reach a total EQD2 dosage (α/β=10) of 78-86 Gy."
1482361|NCT03101982|Drug|HBO|Hyperbaric oxygenation (HBO) is defined as breathing of 100% oxygen under elevated ambient pressure in a hyperbaric chamber. HBO is considered a pharmacological therapy.
1594141|NCT02278250|Drug|Gemcitabine|
1482363|NCT03101956|Procedure|Lumbar Spine Manipulation|• The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position the subject's superior thigh in flexion and rotate the subject's upper trunk to the opposite side. The therapist will place his cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
1482364|NCT03101956|Procedure|Lumbar Spine Manipulation Placebo|The subject will be placed in sidelying on a treatment table. Facing the subject, the therapist will position both hips and knees in approximately 45° of flexion. The therapist will place his or her cephalad forearm along the subject's superior lateral trunk and the caudal forearm along the subject's iliac crest and lateral hip. Lastly, the therapist will roll the subject towards himself or herself.
1482365|NCT03101943|Behavioral|Family Spirit Nurture (FSN)|The FSN intervention will be conducted over a 6-month period. Participants in the intervention group will receive 6- 45 minute lessons in their home or a private place of their choosing. The lessons focus on elimination or reduction of Sugar Sweetened Beverages (SSBs) among infants while teaching mothers complementary feeding and responsive parenting practices
1482366|NCT03101943|Other|Control Program|The control group will receive three home-based lessons with home safety information.Lessons will be delivered monthly (at 3, 4 and 5 months postpartum) in the same format as the FSN lessons, by trained FHCs in the home of the participant or in a private place of their choosing.
1482367|NCT03101943|Other|Water Delivery|Drinking water will be delivered to the household of each participant (both in the FSN intervention and control groups) from 6 to 9 months postpartum. The amount of water will be determined by the number of children and adults living in the household at the time of water delivery. The first delivery of water will occur at the time of the 6-month evaluation and the last delivery will occur at the time of the 9-month evaluation. Water will be delivered as often as weekly. Those families who do not need weekly water delivery (based on their preference and their usage of the first delivery of water) will receive water less frequently.
1482368|NCT03101930|Drug|Liraglutide|subcutaneous liraglutide daily
1482369|NCT03101930|Drug|Sitagliptin|oral sitagliptin daily
1482370|NCT03101930|Other|hypocaloric diet|Reduced calorie intake to achieve weight loss.
1482371|NCT03101930|Drug|Placebos|Subjects in the liraglutide arm will receive a placebo for sitagliptin. Those in the sitagliptin arm will receive a placebo for liraglutide. All subjects will receive a placebo for Exendin 9-39.
1482372|NCT03101930|Drug|Exendin (9-39)|All subjects will receive Exendin (9-39) or matching placebo in crossover fashion during study days on the first and third days of the second week after randomization and again on the 5th and 7th days of the 14th week of treatment.
1482373|NCT03101917|Device|The Microtable® Stereotactic System|x
2000977|NCT03292510|Other|GO-OUT Group|Following a baseline assessment, eligible participants will be stratified by site, and randomly assigned to receive the 1-day educational workshop and 3-month outdoor mobility program (GO-OUT intervention)
1482376|NCT03101891|Procedure|Serial amnioinfusions with normal saline|Amnioinfusions will be performed by an expert in fetal procedures with a 20 or 22 gauge needle using sterile technique and ultrasound guidance. Local anesthetic will be employed. The fluid will consist of warmed normal saline. Infusions may take up to 1 hour.
1482377|NCT03101891|Device|Spinal needle|A 20 or 22 gauge spinal needle will be used with sterile technique to access the uterus under ultrasound guidance and to infuse normal saline..
1482378|NCT03101891|Drug|Normal Saline, 0.9% injectable solution|Normal Saline is a sterile isotonic fluid that will be infused into the uterus through a spinal needle under ultrasound guidance using sterile technique. This fluid will act as replacement amniotic fluid.
1482379|NCT03101878|Drug|Ionis AGT-LRx|Ascending single and multiple doses of Ionis AGT-LRx administered subcutaneously
1482380|NCT03101878|Drug|Placebo|Saline .9%
1482381|NCT03101878|Drug|Spironolactone|The challenge drug spironolactone will be given orally to mild hypertensive patients following multiple doses of Ionis AGT-LRx
1482382|NCT03101865|Device|FlorenceM|The automated closed loop system (FlorenceM) will consist of: Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature. An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
1482383|NCT03101852|Dietary Supplement|Plumpy Nut|
1482384|NCT03101852|Dietary Supplement|Plumpy Sup|
1482386|NCT03101826|Behavioral|Listening Project Protocol|The filtered music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
1482387|NCT03101800|Drug|Azathioprine and Allopurinol|Low dose Azathioprine in combination with allopurinol 100 mg for 1 year
1482388|NCT03101800|Drug|Azathioprine|Standard weight based azathioprine dosage
1482389|NCT03101787|Procedure|Extracorporeal cardiopulmonary resuscitation (ECPR)|"In addition to the routine response team, the ECLS team are called to the ED while the patient is transported to the hospital.
The team consists of a physician skilled and qualified in femoral cannulation, a perfusionist and a scrub nurse.
Upon the patient's arrival at the emergency department, CPR will be continued, with continuation of mechanical chest compressions with minimization of interruptions.
Time from arrest to start of cannulation is < 60 minutes."
1482390|NCT03101774|Device|Threshold inspiratory muscle training|Threshold inspiratory muscle training device (Threshold Inspiration Muscle Trainer, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
1482391|NCT03101774|Device|Resistive inspiratory muscle training|Resistive inspiratory muscle training device(PFLEX, Respironics Inc; Pittsburgh, Pennsylvania, USA). The intensiy of IMT was adjusted and verification using Pm measurement in laboratory. Patients spontaneously breathed using resistive-IMT and their Pm were measured simultaneously. Adjusted the intensity of resistive-IMT from small to large according to the Pm waveform. Adjustment completed while mean Pm achieved 60% of MIP and maintained at least 15 minute. Likewise, eligible patients in these group used the resistive IMT device for 15 minutes, twice per day, with an inspiratory load at 60% of PImax as previously adjustment. Training loads were adjusted to maintain 60% of the PImax every week.
1482392|NCT03101774|Other|Control group|Conventional therapy without any inspiratory muscle training program
1482393|NCT03101748|Drug|Neratinib|"Group A - Phase 1b: Participants take starting dose of Neratinib 80 mg, 1 time a day by mouth for the first week as a 1-week pre-cycle. After that, all study cycles are 21 days long. Participants take neratinib tablets 1 time a day by mouth with food at the same time each day (in the morning, if possible) during Cycles 1 - 4.
Group A - Phase II: Participants take Neratinib at the maximum tolerated dose from Phase 1b.
Group B: Participants receive Neratinib at the recommended phase II dose for 4, 21 day cycles.
Group C: Participants receive Neratinib 200 mg by mouth daily in a 21 day cycle for 12 cycles."
1482394|NCT03101748|Drug|Paclitaxel|"Group A: Participants receive Paclitaxel 80 mg by vein over about 1-3 hours on Days 1, 8, and 15 of Cycles 1 - 4.
Group B: Participants receive Paclitaxel 80 mg by vein over about 1-3 hours on Days 1, 8, and 15 of Cycles 1-4.
Group C: Participants receive Paclitaxel 80 mg by vein over about 1 - 3 hours on Days 1, 8, and 15 of Cycles 1 - 4."
1482395|NCT03101748|Drug|Pertuzumab|"Group A: Participants receive Pertuzumab by vein over about 1 hour on Day 1 of Cycles 1 - 4. Loading dose 840 mg, followed by 420 mg by vein on Day 1 of Cycles 1 - 4.
Group B: Participants receive Pertuzumab by vein over about 1 hour on Day 1 of Cycles 1 - 4. Loading dose 840 mg, followed by 420 mg by vein on Day 1 of Cycles 1 - 4."
1482396|NCT03101748|Drug|Trastuzumab|"Group A: Participants receive Trastuzumab by vein over about 1-2 hours on Day 1 of Cycles 1 - 4. Loading dose 8 mg/kg, followed by 6 mg/kg by vein on Day 1 of Cycles 1 - 4.
Group B: Participants receive Trastuzumab by vein over about 1-2 hours on Day 1 of Cycles 1 - 4. Loading dose 8 mg/kg, followed by 6 mg/kg by vein on Day 1 of Cycles 1 - 4."
1482397|NCT03101748|Drug|Doxorubicin|"Group B: Participants received Doxorubicin 60 mg/m2 by vein over about 90 minutes on Day 1 of Cycles 5 - 8.
Group C: Participants received Doxorubicin 60 mg/m2 by vein over about 90 minutes on Day 1 of Cycles 5 - 8."
1482398|NCT03101748|Drug|Cyclophosphamide|"Group B: Participants receive Cyclophosphamide 600 mg/m2 by vein over about 90 minutes on Day 1 of Cycles 5 - 8.
Group C: Participants receive Cyclophosphamide 600 mg/m2 by vein over about 90 minutes on Day 1 of Cycles 5 - 8."
1482399|NCT03101735|Drug|Dimethyl Fumarate (DMF)|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
1482400|NCT03101722|Device|digital hearing aids,|"hearing aids intervention
experimental arm: both hearing aid and huperzine A Placebo Comparator:control"
1482401|NCT03101722|Drug|Huperzine A|huperzine A intervention
1482402|NCT03101722|Other|digital hearing aids and Huperzine A|both digital hearing aids and Huperzine A intervention
1482403|NCT03101722|Other|placebo|placebo Comparator
1482404|NCT03101709|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
1482405|NCT03101709|Drug|Fludarabine|Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).
1482406|NCT03101709|Biological|CART-19|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
1482407|NCT03101683|Radiation|Partial chest wall radiation therapy|A dose of 40 Gy in 16 fractions (2.5 Gy per fraction) is delivered in the area at risk of local recurrence (skin and the pectoralis muscles) delineated by surgical clips and 3D-MRI reconstruction for a precise localization of the tumor excised
1482410|NCT03101644|Drug|Darunavir|The investigated drugs are Prezista (darunavir 600 mg twice-daily or 800 mg once-daily) and Rezolsta (darunavir 800 mg/cobicistat 150 mg once-daily)
1482411|NCT03101631|Diagnostic Test|Comprehensive Geriatric Assessment (CGA)|"CGA includes a set of evaluations to determine therapeutic decision based on mortality risk, toxicity risk and frailty group. Evaluations includes:
Nutritional Assessment: Mini Nutritional Assessment (MNA)
Functional Assessment: Get up and Go, Activities of Daily Living (ADL), Instrumental Activities of Daily Living (IADL), Karnofsky Scale, Walking one Block, Number of Falls in last 6 months and Hearing Loss.
Cognitive Assessment: Mini-Mental State Examination (MMSE-30)
Psychological status: Geriatric Depression Scale (GDS)
Social Support: Medical Outcomes Study Social Support Survey (MOS-SSS)
Comorbidity and Severity of Comorbidities: Charlson Comorbidity Index and Adult Comorbidity Evaluation (ACE-27)
Age
Haemoglobin
CrCl
Presence of geriatric syndromes"
1482412|NCT03101618|Other|Animal allergy|Allergic symptom occurs during exposure to laboratory or pet animal
1482413|NCT03101618|Other|Non-animal allergy|Allergic symptom does not occur during exposure to laboratory or pet animal
1482414|NCT03101605|Other|e-learning teaching module|As described
1482415|NCT03101605|Other|Standard teaching method|As described
2000978|NCT03292510|Other|Workshop Group|the 1-day workshop plus reminders. Follow-up evaluations will occur at 3, 5 and 12 months from baseline
2000979|NCT03291002|Biological|CV8102|CV8102 alone
2000980|NCT03291002|Biological|CV8102 + anti-PD-1 therapy|CV8102 in combination with standard of care anti-PD-1 therapy
1482420|NCT03101566|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV over 30 minutes
1482421|NCT03101566|Drug|Cisplatin|Cisplatin 25 mg/m2 IV over 30 minutes
1482424|NCT03101553|Behavioral|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to negative evaluation.
1482425|NCT03101553|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
1482426|NCT03101540|Drug|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g of docosahexaenoic acid (DHA) daily for the duration of the study.
1482427|NCT03101527|Drug|Omega-3 PUFA supplementation|Subjects received 2.2g of eicosapentaenoic acid (EPA) and 1.2g docosahexaenoic daily for the duration of the study
1482428|NCT03101514|Drug|Kanglaite|Kanglaite injection 200ml is injected intravenous from the first day to the last day of radiotherapy.
1482429|NCT03101501|Drug|Mitomycin c|Low dose mitomycin C at a concentration of 0.02% will be applied a duration of 10 to 20 seconds at the time of the surgical procedure.
1482430|NCT03101501|Device|Raindrop Near Vision Inlay|Implanted to improve near vision in Presbyopic subjects.
1482431|NCT03101488|Drug|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
1482432|NCT03101475|Drug|Durvalumab (MEDI4736)|Durvalumab (MEDI4736) 1500mg Q4W in combination with tremelimumab for up to 4 doses/cycles, followed by durvalumab (MEDI4736) 1500mg Q4W for up to a maximum of 8 months with the last administration on week 48 unless there is unacceptable toxicity.
1482433|NCT03101475|Drug|Tremelimumab|Tremelimumab (75 mg IV Q4W) in combination with durvalumab (MEDI4736) (1500mg Q4W) for up to 4 doses/cycles
1482434|NCT03101475|Radiation|Sterotactic body radiation therapy (SBRT)|delivered in 3 fractions of 10 Gy over 1 week starting 8 to 14 days after first dose of immunotherapy
1482435|NCT03101475|Other|Radiofrequency ablation (RFA)|performed percutaneously under CT, MRI or sonographic guidance 8 to 14 days after start of immunotherapy
2010564|NCT02928991|Other|MRD-BMT with Fludarabine-based RIC for iBMF without trilineage aplasia|"Fludarabine: Dose: 30mg/m2/day (<10kg will receive 1mg/kg/day) Days: -6, -5, -4, -3, -2
Busulfan: Dose: every 6 hours for a total of 12 doses with dosing adjustments to achieve a steady state concentration of 900-1200ng/mL Days: -7, -6, -5, -4
Thymoglobulin: Dose: 3mg/kg/day Days: -10, -9, -8
Bone marrow infusion: Day 0"
1482438|NCT03101449|Other|Finnish tube|Practice the exercise with Finnish tube before choir practice once a week for a period of 14 weeks.
1482439|NCT03101449|Other|Staw phonation|Practice the exercise straw phonation before choir practice once a week for a period of 14 weeks.
1482440|NCT03101436|Dietary Supplement|Extra Virgin Olive Oil and Red Wine|"Phase I: Extra VIrgin Olive Oil 80 grams per day (1 month)
Washout Period: 15 days
Phase II: Red Wine (270 ml per day) (1 month)"
1482441|NCT03101423|Drug|Interleukin-2|On +60 day after transplantation,check patients with STR more than or equal to 90%. transplantat interleukin-2 treatment per month
1482442|NCT03101423|Drug|Donor Regulatory T-Lymphocytes|On +60 day after transplantation,check patients with STR less than 90%. Donor Regulatory T-Lymphocytes infusion (DLI) treatment per month
1482443|NCT03101410|Behavioral|Gluten|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
1482444|NCT03101410|Behavioral|Gluten free|Selected participants will be randomly allocated to treatment group (gluten or gluten free).
1482445|NCT03101384|Other|Diagnostic error|There is no intervention in our study. Patient will be managed with usual care. We will divide patients in the 2 groups according to the presence of diagnostic error.
1482446|NCT03101371|Drug|Catheter insertion with Povidone Iodine|The catheter will be treated with Povidone Iodine prior to insertion.
1482447|NCT03101371|Procedure|Standard of care catheter insertion|Catheter inserted right out of package.
1482449|NCT03101345|Other|Peptamen® 1.5 vanilla|Administration orally
1482450|NCT03101332|Behavioral|Virtual Reality cognitive behavior therapy|"Cognitive interventions targeted to change catastrophic misinterpretations of the physiological symptoms that occur during a panic attack.
Exposure via Virtual Reality to filmed sequences of environments typically feared by agoraphobic patients such as underground station/train, a tunnel, a lift and a public square, as well as exposure to the feared symptoms that occur in a typical panic attack.
Interventions are delivered by a psychologist in face-to-face sessions."
1482451|NCT03101319|Drug|Vitamin D3 cholecalciferol|As mentioned in the description of the study arm
1482452|NCT03101319|Drug|Placebo Oral Tablet|As mentioned in the description of the study arm
1482453|NCT03101306|Other|MR scans|Additional imaging using MR scans.
1482454|NCT03101293|Drug|TAK-831|TAK-831 film-coated tablet
1482455|NCT03101280|Drug|Atezolizumab|Atezolizumab 1200 mg (equivalent to an average body weight-based dose of 15 milligrams per kilogram [mg/kg]) will be administered by IV infusion once every 3 weeks, corresponding to a 21-day treatment cycle. Participants will receive atezolizumab starting on Cycle 1, Day 1. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
1482456|NCT03101280|Drug|Rucaparib|The starting dosage level of rucaparib for Part 1 is 400 mg PO BID during a 21-day treatment cycle. During Part 1 of the study, the rucaparib doses will be increased up to a maximum of 600 mg PO BID using a standard 3 + 3 dose escalation until the RP2D for the two-drug combination of rucaparib and atezolizumab is defined. During Part 2 of the study, rucaparib will be dosed at the RP2D determined in Part 1. Participants in Part 1 of the study will receive rucaparib starting on Cycle 1, Day 1. During Part 2, participants will receive rucaparib monotherapy during a 21-day run-in period. After completion of the rucaparib run-in period and the first on-treatment biopsy between Days 15 and 21 of the run-in period, participants will begin Cycle 1, Day 1 of the rucaparib. Participants deriving clinical benefit will be allowed to continue on study treatment until the absence of unacceptable toxicity or compelling evidence of disease progression.
1482457|NCT03101267|Drug|ASP4070|Intradermal vaccination at 2-week intervals
1482458|NCT03101267|Drug|Placebo|Intradermal vaccination at 2-week intervals
1482459|NCT03101254|Drug|LY3022855|LY3022855 is a colony-stimulating factor-1 receptor (CSF-1R) inhibitor
1482460|NCT03101254|Drug|Vemurafenib|Vemurafenib is a BRAF inhibitor that works by blocking altered BRAF proteins from stimulating the growth of melanoma cancer cells
1482461|NCT03101254|Drug|Cobimetinib|Cobimetinib works by blocking a protein called MEK that has been known to promote melanoma growth
1482463|NCT03101228|Behavioral|Reduced sitting|Subjects are guided to limit their sitting time during the day for 1 hour/day, by adding light activity with the help of an activity monitor. Subjects are not encouraged to increase their moderate to vigorous physical activity levels.
1482464|NCT03101215|Dietary Supplement|phosphorus|adding of phosphorus to high carbohydrate meal
1482465|NCT03101202|Device|SSD tube|The SSD tube allows the suction of subglottic secretions that collect above the cuff of the endotracheal tube
1482466|NCT03101189|Drug|ACT-541468|Capsule
1482467|NCT03101189|Drug|placebo|Matching placebo capsule
1482468|NCT03101176|Drug|SonoVue|The ultrasound contrast agent used for the CEUS specific ultrasound mode
1482469|NCT03101163|Biological|Autologous peripheral blood stem cells and hyaluronic acid|Regimen of intra-articular PBSC and HA injections and postoperative physiotherapy
1482470|NCT03101163|Other|Hyaluronic acid|Regimen of intra-articular HA injections and postoperative physiotherapy
1990616|NCT01924845|Drug|BMN 701|
2010565|NCT02927262|Drug|gilteritinib|Tablet to be taken orally once daily.
1482473|NCT03101137|Drug|Caudal block with dexmedetomedine|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexmedetomidine 1 μg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
1482474|NCT03101137|Drug|Caudal dexamethasone|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg bupivacaine 0.25% along with dexamethasone 0.1mg/kg (diluted with normal saline to 1ml) is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
1482475|NCT03101137|Drug|Control (bupivacaine)|After induction, the electrical cardiometry is applied in supine position and a measurement for the baseline cardiac output, systemic vascular resistance and stroke volume is taken. In left lateral position, the back is sterilized. The block is done by introducing a 23-gauge hypodermic needle perpendicular to the sacrococcygeal membrane. The needle is inserted until there is release of resistance as it pierces the sacro-coccygeal membrane. Then, it is directed upwards to make an angle of 20-30° with the skin about 2 mm. 1 ml/kg the control (bupivacaine) 0.25% is injected over about 60s. Then, another measurement for the hemodynamics is taken at 5, 10, 20 and 30 minutes after caudal block.
1482476|NCT03101124|Drug|Tranexamic Acid 25 mg/ml for wound surface moistening|Wound surface moistened with 20 ml of tranexamic acid 25 mg/ml (total dose 500 mg) prior to wound closure
1482477|NCT03101124|Drug|Tranexamic Acid 5 mg/ml as bolus in wound cavity|200 ml of tranexamic acid 5 mg/ml (total dose 1 g) as a bolus instilled into the wound cavity after wound closure, which will remain in the cavity until the activation of drains one hour later
1482478|NCT03101124|Drug|Tranexamic Acid Injectable Solution|1 g of tranexamic acid administered intravenously in accordance with prevailing routines directly prior to planned surgical procedure.
1482479|NCT03101111|Biological|MV-CHIK|Lyophilized, life attenuated, measles vectored Chikungunya vaccine; 5E+05 TCID50 (+/- 0.5 log) per dose
1482480|NCT03101111|Biological|MMR-vaccine|Lyophilized mixture of life attenuated Measles, Mumps, and Rubella viruses; 1000, 12500, and 1000, respectively, TCID50 per dose
1482481|NCT03101098|Procedure|Retroperitoneal liagation of uterine artery|the site of ligation of uterine artery is the area that it originates from the internal iliac artery during TLH
1482482|NCT03101098|Procedure|Classical ligation of uterine artery|the site of ligation of uterine artery is the area alongside the cervix
1482483|NCT03101085|Drug|S-equol|S-equol is an estrogen receptor β (ERβ) agonist. Provided in capsules.
1482484|NCT03101085|Other|Placebo|Placebo capsules matched in size and color to S-equol capsules.
1482485|NCT03101072|Other|"Fixed long antibiotic course of 14 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
1482486|NCT03101072|Other|"Fixed short antibiotic course of 7 days"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
1482487|NCT03101072|Other|"Individualized duration of antibiotic therapy"|Only the duration of antibiotic therapy will be investigated in this study. (In all arms, the choice and mode of administration (IV vs. PO) of antibiotic(s) will be left to the patient's attending physician and consulting infectious disease specialist and thus will follow usual standards of care.)
2010566|NCT02927262|Drug|Placebo|Matching placebo tablet to be taken orally once daily.
1482489|NCT03101046|Drug|Cabazitaxel|Experimental treatment arm: patients will be treated with intravenous cabazitaxel 20 mg/m2 every 3 weeks for 6 cycles (D1=D22).
1482490|NCT03101046|Drug|Docetaxel|standard treatment arm and cohort: Docetaxel is administered at the dose of 75 mg/m² over 1 hour every 3 weeks for 6 cycles (D1=D22).
1482532|NCT03100851|Dietary Supplement|Lactobacillus casei strain Shirota|a bottle of 100 mililiter probiotic dairy beverage containing 10^8 CFU Lactobacillus casei strain Shirota every day after lunch.
2010567|NCT02927873|Biological|RSV vaccine (GSK3389245A) low dose|2 doses of 0.5 ml of ChAd155 5x10^9 vp, administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
2010568|NCT02927873|Biological|RSV vaccine (GSK3389245A) middle dose|2 doses of 0.15 ml of ChAd155 5x10^10 vp administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
1948793|NCT01614275|Behavioral|Technology-Enhanced Tutor Training|"The training for the tutors to work with children diagnosed with autism, who were assigned to the EIBI group, will complete a 40-hour structured training program for 4 to 8 weeks that includes approximately 32 sessions. When a new topic is introduced, the initial training will include viewing a PowerPoint presentation, with embedded video and audio, that explains, in laymen's terms, the basic principles and processes related to the topic. The second part of the training involves a tutor recruiting an adult friend, who will play the role of a child with autism. The adult playing the child with autism will wear a Bluetooth earpiece connected to a computer, which in turn will be connected to a UNMC expert. The expert will guide the actions of the adult playing the role of the child such that this confederate child will exhibit a variety of target behaviors relevant to the target skill, which will provide an opportunity for immediate feedback."
1990619|NCT01923181|Drug|semaglutide|Once-daily oral administration as tablets.
1990620|NCT01923181|Drug|semaglutide|Once-weekly,injected s.c./subcutaneously (under the skin) using a pen
1990621|NCT01923181|Drug|oral placebo|Once-daily oral administration as tablets.
1482495|NCT03101020|Other|Active Visceral Manipulation|Visceral manipulation techniques consists of deep manual pressure in certain points of the abdomen and the amount of pressure will be respected according to the participant discomfort or pain. It will be performed cardia mobilization, pylori mobilization, Oddi's sphincter mobilization, dueodeno-jejunal valve mobilization, ileocecal valve mobilization, global technique for the liver, global hemodynamic technique. Each technique will last 1 minutes, with the two last ones repeated 10 times.
1482496|NCT03101020|Other|Standard care physiotherapy|The care includes advice for correct postures to perform daily activities; abdominal, pelvic and lumbar muscles re-training and strengthening; and advice to perform at least 20 minutes' walk three times a week. The therapist will treat the participants once a week for a 5-week period. All treatment session will last 40 minutes.
1482497|NCT03101020|Other|Placebo Visceral Manipulation|The placebo intervention involves light touch at the same regions of the techniques the active visceral manipulation, and no intention on the part of the therapist to impart any therapeutic technique
1482498|NCT03101007|Device|ATTUNE Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with cementless ATTUNE rotating platform Knee Prosthesis by DePuy
1482499|NCT03101007|Device|LCS Knee Prosthesis by DePuy|Total Knee Replacement Surgery with cementless LCS rotating platform Knee Prosthesis by DePuy
1482500|NCT03100994|Drug|Bupivacaine|injecting anesthetics to different local
1482501|NCT03100994|Device|Ultrasound|Ultrasound guided nerve block
2010569|NCT02927873|Biological|RSV vaccine (GSK3389245A) high dose|2 doses of 0.5 ml of ChAd155 5x10^10 vp administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
2010570|NCT02927873|Drug|Placebo LD|2 doses of 0.5 ml administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
1482504|NCT03100968|Procedure|Palpation|Traditional epidural methods used for the identification of the midline using palpation prior to procedure
1482505|NCT03100968|Device|Ultrasound|Lumbar spinal ultrasound performed for identification of the midline prior to procedure.
1482506|NCT03100955|Drug|cisplatin, etoposide|The recommended regimen is cisplatin plus etoposide. cisplatin 75 mg/m2 iv on day 1, etoposide 120 mg/m2 iv on day 1-3, 3 weeks a cycle, total for 6 cycles is allowed.
1482507|NCT03100955|Drug|cisplatin, etoposide, apatinib|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Platinum drug=cisplatin 75 mg/m2 iv on day 1; topoisomerase inhibitor=etoposide 120 mg/m2 iv day 1-3, 3 weeks a cycle, total numbers of cycles 6.Used drugs=cisplatin and etoposide. Numbers of cycles 6. In addition to this, subjects will receive VEGF-TKI apatinib oral daily after chemotherapy treatment. Apatinib 500mg oral, once a day, until disease progression or death or un-tolerated toxicites.
2010571|NCT02927873|Drug|Placebo MD|2 doses of 0.15 ml administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
2010572|NCT02927873|Drug|Placebo HD|2 doses of 0.5 ml administered intramuscularly at Day 0 and Day 30 in the left anterolateral thigh or deltoid.
2010573|NCT02926040|Procedure|Irreversible electroporation|
2010574|NCT02925494|Drug|Elagolix|Oral administration
2010575|NCT02925494|Drug|Estradiol/Norethindrone Acetate|Oral administration
2010576|NCT02926911|Other|Guideline Concordant Care|Surgery +/- radiation choice for endocrine therapy
1482514|NCT03100929|Diagnostic Test|Ultrasound|Pre-operational ultrasound for the detection of fetal heart rate, fetal presentation and presence of nuchal cord.
1482515|NCT03100916|Drug|BI 690517|once daily
1482516|NCT03100916|Drug|Placebo|once daily
1482517|NCT03100916|Drug|BI 690517 (Reference)|Fasting
1482518|NCT03100916|Drug|BI 690517|Non- fasting
1482519|NCT03100903|Drug|BI 655130|single dose
1482520|NCT03100890|Other|Preoperative training (hospital)|Preoperative hospital training
1482521|NCT03100890|Other|Preoperative training (home)|Preoperative in-home training
1482522|NCT03100877|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
1482523|NCT03100877|Drug|Cyclophosphamide|Given IV
1482524|NCT03100877|Biological|Filgrastim|Given SC or IV
1482525|NCT03100877|Other|Laboratory Biomarker Analysis|Correlative studies
1482526|NCT03100877|Drug|Lenalidomide|Given PO
1482527|NCT03100877|Procedure|Leukapheresis|Undergo apheresis
1482528|NCT03100877|Drug|Melphalan|Given IV
1482529|NCT03100877|Biological|Palifermin|Given IV
1482530|NCT03100877|Radiation|Total Marrow Irradiation|Undergo TMI
1482531|NCT03100864|Drug|BI 655130|12 weeks treatment
1997911|NCT01827384|Drug|Carboplatin|Given IV
1997912|NCT01827384|Drug|Everolimus|Given PO
1997913|NCT01827384|Other|Laboratory Biomarker Analysis|Correlative studies
1997914|NCT01827384|Drug|Temozolomide|Given PO
1997915|NCT01827384|Drug|Trametinib|Given PO
1997916|NCT01827384|Drug|Veliparib|Given PO
1997917|NCT01827384|Drug|WEE1 Inhibitor AZD1775|Given PO
1997918|NCT01827241|Other|Chart Review|Retrospective and prospective data review of colonoscopy procedures, examination findings, resection techniques, and pathology reports.
2010577|NCT02926911|Other|Active Surveillance|Choice for endocrine therapy
2010578|NCT02923726|Device|Arm 1 (ATP+Shock)|Subjects will be randomized and device programmed to the respective arm.
2010579|NCT02923726|Device|Arm 2 (shock only)|Subjects will be randomized and device programmed to the respective arm.
1482537|NCT03100825|Drug|QVM149|QVM149 (indacaterol acetate/glycopyrronium bromide/mometasone furoate)
1482538|NCT03100812|Behavioral|More intensive CHW Intervention|Group A participants will attend 4 monthly 90 minute group health education sessions that provide the tools and strategies to promote heart health to Filipino American individuals, families, and communities on high blood pressure and CVD. The CHWs will lead these sessions utilizing NHLBI's Healthy Heart Healthy Family, A CHW's Manual for the Filipino Community. Each of the group health education sessions will discuss different content related to CVD, hypertension, and other CVD risk factors. The first session focuses on assessing heart disease risk and recognition of heart attack signs. The second session focuses on physical activity and weight management and blood pressure control. The third session addresses control of cholesterol, and diabetes. The final 4th session teaches participants about nutrition and living smoke free.
1482539|NCT03100812|Behavioral|Less Intensive CHW Intervention|Individuals randomized to the less intensive CHW intervention will have the baseline, 4 month, and 8 month interviews and blood pressure measurements will be collected in those succeeding time points. Participants will also receive a 30 minute one on one session from the CHW and a referral to a physician if needed.
1482540|NCT03100799|Procedure|Arthroscopy|Arthroscopy of the target knee
1482541|NCT03100799|Procedure|Arthrocentesis|Arthrocentesis of the target knee and contralateral knee (if patient consents)
1482542|NCT03100799|Diagnostic Test|MRI|MRI with and without a gadolinium-based contrast agent
1482543|NCT03100786|Drug|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): Dexamethasone for intravenous injection and dexamethasone for oral ingestion
1482544|NCT03100786|Other|Placebo|Treatment with matched placebo: Standard saline for intravenous injection and placebo oral tablets containing cellulose
1482545|NCT03100773|Other|Oral health educational strategy|Oral health educational strategy consisted of four consecutive sessions (once a week) about etiological factors of caries (using visual aids), oral hygiene instructions (using models), supervised toothbrushing and explanation of atraumatic restorative treatment (indications and stages).
1482546|NCT03100773|Procedure|Atraumatic Restorative Treatment|Atraumatic Restorative Treatment was performed using hand instruments for opening and cleaning the cavities and a high-viscosity glass-ionomer for restoration.
1482547|NCT03099668|Other|Visit to a multidisciplinary clinic|Visit to a multidisciplinary clinic
1482548|NCT03099655|Device|Attain Stability Quad Left Ventricular Pacing Lead|cardiac stimulation
1482549|NCT03099642|Radiation|ultrasound-assisted lumbar puncture|The ultrasound probe type will be selected by the treating pediatric emergency physician who has been trained according to standards outlined below. They will first identify the conus medullaris and make a horizontal marking with a sterile pen on the patient's back. Using a transverse view, they will then identify the midline of the patient's spine (using adjacent spinous processes) and will make 2 vertical skin markings on either side of the probe. Next, they will orient the probe in a longitudinal view to identify the desired vertebral interspace and will make 2 horizontal skin markings on either side of the probe at this level. Finally the 4 lines will be joined together at an intersection point, which will be the predetermined site for puncture attempt.
1482550|NCT03099629|Behavioral|inspiratory muscle training|inspiratory muscle training will start with an intensity of 30% of maximal inspiratory pressure, 15 times/set, 3 sets/day, 7 days/week and training will continue until surgery is scheduled or 2 weeks after the completion of treatment if surgery is not suitable.
1482551|NCT03099616|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient.
1482552|NCT03099616|Drug|Desflurane|Desflurane delivery will be controlled using a agent specific vaporiser. The dial concentration of the vaporiser will be adjusted to maintain a BIS of 50-55 in the patients.
1482554|NCT03099590|Dietary Supplement|kudzu extract, puerarin|Capsules containing 500 mg of a crude kudzu extract (NPI-031, Alkontrol-herbal; Natural Pharmacia International, Burlington, MA) will be used, containing 19% puerarin, 4% daidzin and 2% daidzein, so each capsule contains a total of 25% active isoflavones or 125 mg.
1482555|NCT03099590|Dietary Supplement|Placebo control|Matched sugar beet placebo capsules will serve as placebo.
1482556|NCT03099577|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 60 Gy at 2 Gy/Fx/d, then 4.8 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
1482557|NCT03099577|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 2: 60 Gy at 2 Gy/Fx/d, then 9.6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
1482558|NCT03099577|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 3: 60 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
1482559|NCT03099577|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 4: 60 Gy at 2 Gy/Fx/d, then 19.2 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
1482560|NCT03099577|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 5: 60 Gy at 2 Gy/Fx/d, then 4.8x5 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
1482561|NCT03099577|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 6: 60 Gy at 2 Gy/Fx/d, then 4.8x6 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
1482562|NCT03099577|Radiation|radiochemotherapy 7|concurrent radiochemotherapy: radiotherapy dose level 7: 60 Gy at 2 Gy/Fx/d, then 4.8x7 Gy at 1.2 Gy/Fx/bid concurrent concurrent chemotherapy :carboplatin area under the curve (AUC) 2; paclitaxel: 45-50 mg/m2, weekly
1482563|NCT03099564|Drug|Pembrolizumab|pembrolizumab 200mg IV every three weeks
1482564|NCT03099564|Device|Y90 radioembolization|The first Y90 radioembolization treatment will be administered one week after the first dose of pembrolizumab. If a second Y90 radioembolization treatment is required for bilobar disease, this should occur within 4 weeks of the initial procedure (between Cycles 2 and 3 of pembrolizumab).
1482565|NCT03099551|Device|Group using manual toothbrush Curaprox 5460 Ultra Soft|Manual toothbrush usage with Bass technique twice a day during 2 minutes
1482566|NCT03099551|Device|Group using sonic toothbrush Edel White|Sonic toothbrush usage twice a day during 2 minutes
2000985|NCT03287661|Behavioral|Acceptance-based Behavioural Therapy|The treatment program is an eight module (8-week) ABBT for chronic pain. The online treatment material is administered via the WebCAPSI Therapy program. This online program allows participants to progress through the treatment modules at their own pace. Each module is designed to cover a specific component of ABBT and will facilitate understanding of the components through audio files, veteran, military and RCMP-specific vignettes, text-based material, and homework exercises/assignments. Each module is designed to be completed in 60 minutes or less. On the completion of each module, and facilitated through the WebCAPSI Therapy program, the participants are asked to complete a homework exercise to which they answer questions previously encountered throughout the module. The principle therapist responds to each homework exercise within 24-hours of its online submission.
1482572|NCT03100721|Behavioral|PNE+Physiotherapy|Physiotherapy cover kinesitherapy, electrotherapy, thermotherapy and exercises techniques. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
1482573|NCT03100721|Procedure|Physiotherapy|Physiotherapy cover kinesitherapy, electrotherapy, thermotherapy and exercises techniques.
1482574|NCT03100708|Procedure|PIPAC|"Cisplatin 7.5 mg/m2 body surface in 150 ml NaCl 0,9% + Doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% in patients with ovarian, gastric, pancreatic cancer and in primary peritoneal tumors.
Oxaliplatin 92 mg/m2 body surface in 150 ml dextrose solution in patients with colorectal cancer.
The chemotherapeutics will be admitted to the abdomen by a nebulizer at a pressure of 200 psi and 12 mmHG with 0.5 mL/sec. Afterwards the chemotherapeutics can react for 30min before the abdominal gas will be drained to the clinics filtering system."
1482575|NCT03100695|Other|Concentrated autologous PRP-BMA|Injection of autologous, concentrated platelet-rich plasma and bone marrow aspirate at the site of fixation.
1482576|NCT03100669|Procedure|Pectus surgery|Patients undergoing surgical repair of pectus excavatum or carinatum
1482577|NCT03100656|Other|A meat-based breakfast sandwich|A meat-based breakfast sandwich
1482578|NCT03100643|Other|mHealth N'Gage mobile application|To enhance HIV care engagement among couples using mobile technology.
1482579|NCT03100630|Drug|BMS-986089|Specified dose on specified days
1482580|NCT03100617|Behavioral|Psychosocial caregiver intervention|Modified version of the REACH-VA intervention for family caregivers of persons with dementia. The intervention has several components including 1) caregiver education, 2) risk assessment, 3) caregiver needs assessment, 4) caregiver skill building and problem solving, and 4) caregiver stress reduction.
1482583|NCT03100591|Drug|14C-radiolabeled ACT-132577|Single oral dose of 3.7 megabecquerel (MBq) (100 microcurie [μCi]) 14C-radiolabeled ACT-132577 administered as 1 capsule of 25 mg
1482584|NCT03100578|Device|EUS-GUIDED TRANSMURAL DRAINAGE OF PANCRETIC COLLECTION|ENDOSCOPIC ULTRASOUND- GUIDED TRANSMURAL DRAINAGE OF WALLED-OFF PANCREATIC NECROSIS
1482585|NCT03100565|Drug|local lidocaine spray|The lidocaine spray will be introduced to the cervix just before the biopsy procedure
1482586|NCT03100565|Other|forced coughing|The patients will be asked to forced coughing during the biopsy procedure
1482587|NCT03100552|Diagnostic Test|Endoscopic imaging|Analysis of the presence of dysplasia within sessile serrated polyps (SSP) using endoscopic imaging (high definition white light +- narrow band imaging)
1482588|NCT03100539|Other|Care giver treatment|"The caregiver -assisted massage (CG-M) intervention will consist of 3 treatment components:
An in-person training workshop
An instructional DVD recording to reinforce concepts taught during the in-person training session
A written treatment manual with illustrations and images to serve as a reference for participants.
Participants will be asked to engage in at least 3 care giver-assisted massage sessions (30 minutes each) every week at home for the 3-month intervention period. To standardize delivery and facilitate reproducibility of CG-M, the content and general structure of the caregiver-delivered massage routine is established and will be taught during the training workshop"
1482589|NCT03100539|Other|Therapist treated massage|Participants randomized to the therapist-treated massage (TT-M) arm will receive a standardized Swedish massage protocol tailored to chronic neck pain. Massage sessions will involve a maximum of 60 minutes of hands-on, table time and occur twice a week (a frequency which balances practicality and efficacy) for 3 months.
1482590|NCT03100526|Behavioral|PACT Intensive Management|"Purpose: Implement a Patient Aligned Care Team (PACT) model that identifies and proactively manages Veterans at the highest risk for hospital admission and death while they are still in the ambulatory care setting.
Goal:
Reduce emergency department and urgent care utilization, hospitalization, and mortality in complex, high risk patients
Improve Veteran and staff satisfaction
Objectives:
Maintain the patient in the home setting as much as possible
Secure appropriate home environment to facilitate health and well-being
Utilize comprehensive team-based care
Engage appropriate VHA programs to provide interdisciplinary, coordinated, and timely management of complex medical issues"
1482591|NCT03100513|Drug|Lactulose|(lactulose) (20 to 30 g administered orally or by nasogastric tube (3 or more doses within 24 hours) or 200 g by rectal tube if oral intake was not possible or inadequate
1482592|NCT03100513|Drug|Polyethylene Glycol|PEG as single dose of (3sachets if patient <75Kg over 3 hours or 4 sachets if patient >75Kg over 4 hours) dministered orally or via a nasogastric tube (each sachet 64g/25Kg must be dissolved in one liter of water).
1482593|NCT03100500|Drug|QMF149|QMF149 150/320 μg once daily, delivered as powder in hard capsules via Concept1 inhaler
1482594|NCT03100487|Device|Apple iPod Shuffle|One session at least 5 days a week for a total of 8 weeks
1482595|NCT03100461|Other|I2|"A touch screen computer delivered implementation intentions (I2) intervention on CRC screening. Implementation intentions are the exact steps (the when, what, where, how) one will take to complete a test (the date and time, at home or at the doctor's office, with what supplies, etc.)."
1482850|NCT03098420|Drug|2mg Dexamethasone|0.5 mL (2mg) of dexamethasone and 0.5 ml of normal saline
1482596|NCT03100461|Other|Health Education|Standard of care approach that will provide basic information on CRC screening.
1482597|NCT03100448|Device|On1 Concept|NobelActive implant placement with simultaneous On1 Base placement
1482598|NCT03100435|Device|Er:YAG Laser|Titanium disks will be decontaminated ex-vivo with the Er:YAG laser.
1482599|NCT03100435|Other|Carbon Fiber Curette|Titanium disks will be decontaminated ex-vivo with carbon fiber curettes
1482600|NCT03100422|Device|ARMin|arm therapy robot
1482601|NCT03100422|Other|Occupational Therapy|bilateral arm training
1482602|NCT03100409|Other|Dietary modification|"Dietary intervention will consist on a low residue diet: 20% kcal from fat, 5g lactose/day, 20g fiber/day (5g from insoluble fiber).
Dietary intervention will be adapted to the patient's individual requirements, according to the presence of comorbidities or renal deterioration.
No comorbidities. Energy: 20-30 kcal/kg of body weight/day. Protein: 1.3 g/kg of body weight/day.
Comorbidities (diabetes, hypertension), or geriatric patient. Energy: 25-30 kcal/kg of body weight/day. Protein: 1.5 g/kg of body weight/day.
Renal deterioration. Energy: 30-35 kcal/kg of body weight/day. Protein: 1 g/kg of body weight/day. Sodium: 2000-2300 mg/day. Potassium: 1900-2730 mg/day. Phosphorus: 800-1000 mg/day."
1482603|NCT03100370|Device|tsDCS-Anodal Stimulation|2.5mA anodal tsDCS over cervical spine for 20 minutes followed by robotic-assisted training of arm and hand functions for 70 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder. Robotic-assisted training will be provided by using the MAHI Exo-II device.
1482604|NCT03100370|Device|tsDCS-Cathodal Stimulation|2.5mA cathodal tsDCS over cervical spine for 20 minutes followed by robotic-assisted training of arm and hand functions for 70 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder. Robotic-assisted training will be provided by using the MAHI Exo-II device.
1482605|NCT03100370|Device|tsDCS-Sham Stimulation|2.5mA sham tsDCS over cervical spine for 20 minutes followed by robotic-assisted training of arm and hand functions for 70 minutes, five days a week, for two weeks. tsDCS electrodes will be placed over cervical spine and shoulder. Robotic-assisted training will be provided by using the MAHI Exo-II device.
1482606|NCT03100357|Other|Thyroidectomy|Thyroid surgery for benign nodular goiter
1482607|NCT03100344|Drug|Nemolizumab|Injection every 4 weeks during 24 weeks (last injection at week 20)
1482608|NCT03100344|Drug|Placebo|Injection every 4 weeks during 24 weeks (last injection at week 20)
1482609|NCT03100331|Other|Neuropsychological testing|Comprehensive neuropsychological assessment and implementation of appropriate support and resources.
1482610|NCT03100318|Drug|FYU-981|Oral daily dosing for 14 weeks
1482611|NCT03100318|Drug|Benzbromarone|Oral daily dosing for 14 weeks
1482612|NCT03100305|Other|Collection of blood and urine|Collection of blood and urine within 24 hours after birth, during total parenteral nutrition, during partial parenteral nutrition and during enteral nutrition
1482613|NCT03100292|Other|Sleeve gastrectomy or Roux-en-Y gastric bypass|
1482614|NCT03100279|Behavioral|Coping Cat/CAT Project|"The Coping Cat program, developed by Kendall and colleagues (Kendall, 1994; Kendall, 2000; Kendall, Kane, Howard, & Siqueland, 1989; Kendall, Flannery-Schroeder et al., 1997), involves (1) teaching children to identify their own anxious feelings and physiological signs of anxiety, (2) teaching children to identify their own anxiety-provoking cognitions, (3) developing a plan to guide coping - a plan that involves changing the child's thoughts (into positive self-talk) and actions (into self-initiated exposures), and (4) self-evaluation and self-reward. The therapist uses modeling (e.g., revealing therapist's own anxiety and sharing successful coping experiences), in vivo exposure tasks, role-playing (e.g., to prepare for exposure tasks), relaxation training, and contingent reinforcement (e.g., for trying and for succeeding at exposure tasks), in developing these four themes."
1482615|NCT03100279|Behavioral|Primary and Secondary Coping Enhancement Therapy|PASCET is a brief (11-15 sessions) CBT program for depressed youths typically aged 8-15. Sessions and practice assignments are built on findings concerning cognitive and behavioral features of youth depression (e.g., Lewinsohn et al., 1990; Stark et al., 1987), and on the two-process model of perceived control and coping (Rothbaum, Weisz, & Snyder, 1982; Weisz et al., 1984a,b). In this model, primary control involves efforts to cope by making objective conditions (e.g., one's activities, one's peer status) conform to one's wishes. In contrast, secondary control involves coping by adjusting oneself (e.g., one's expectations, interpretations) to fit objective conditions, so as to influence their subjective impact without altering the actual conditions. The goal is for youngsters to build their skills in primary and secondary control coping, and apply those skills to events and conditions that can trigger depression. Therapists are guided by a Therapist's Manual and use a youth workbook.
1482616|NCT03100266|Dietary Supplement|Probiotic|Lactobacillus rhamonosus GG
1482617|NCT03100266|Other|Inactive capsules|Placebo
1482618|NCT03100253|Drug|Tocilizumab|8 mg/kg i.v. every 4 weeks OR 162 mg s.c every seven days
1482619|NCT03100253|Drug|Etanercept|a. Etanercept if initial failure to monoclonal antibodies: infliximab, adalimumab, golimumab or certolizumab
1482620|NCT03100253|Drug|Infliximab|infliximab if initial failure to the receptor fusion protein, etanercept.
1482621|NCT03100253|Drug|Adalimumab|adalimumab if initial failure to the receptor fusion protein, etanercept.
1482622|NCT03100253|Drug|Golimumab|golimumab if initial failure to the receptor fusion protein, etanercept.
1482623|NCT03100253|Drug|Certolizumab Pegol|Certolizumab Pegol if initial failure to the receptor fusion protein, etanercept.
2000986|NCT03285594|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet
Route of administration: oral"
1482625|NCT03100227|Other|PET [18F] FDG|Measurement of carbohydrate metabolism at the individual level. Standardization of the individual imaging data in a standard anatomical space and then calculation of an average image through the group-level controls.
1482626|NCT03100227|Other|Anatomical MRI|All subjects will benefit from a 3D anatomical MRI to control the normality of their MRI and an automatic segmentation of 73 brain regions by multi-atlas segmentation.
1482627|NCT03100214|Other|intervention|Patients randomized to the intervention group, in addition to routine physical therapy follow-up, will receive an early rehabilitation program, which will begin within the first 48 hours after admission. The patient will perform physical training (aerobic and anaerobic) 5 times a week during the hospitalization period, with sessions about an hour. The professional who supervises the training will be blinded to the results of the measurements.
1482628|NCT03100214|Other|Control|Patients randomized to the control group will continue to receive the physiotherapeutic follow-up performed by the physiotherapist of the Program for Adults with CF during the hospitalization period. Supervision includes respiratory physiotherapy involving inhalation therapy and techniques for removal of secretions
1482629|NCT03100201|Other|Intervention Armeo®Spring|The robotic-assisted training will be performed using the clinically evaluated Armeo®Spring medical device (Hocoma AG, Zurich, Switzerland). By means of a sensory orthosis, arm movements will be supported and transmitted to a computer system and visually shown on a screen.
1482630|NCT03100201|Other|Control Group|The control group will receive conventional occupational- and physiotherapy over 3 weeks
1482631|NCT03100188|Other|modified PD prescription|For patients on CAPD, fewer daily exchanges or fewer total weekly exchanges are prescribed. Patients on CCPD are prescribed shorter cycler time or fewer total cycles during the week.
1482632|NCT03100175|Behavioral|physiotherapy|strength training for upper and lower limbs fitness and balance work out
1482633|NCT03100162|Dietary Supplement|Probiotic|
1482634|NCT03100162|Dietary Supplement|Placebo|
2000987|NCT03285594|Drug|insulin glargine (HOE901)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2000988|NCT03285594|Drug|Placebo|"Pharmaceutical form: tablet
Route of administration: oral"
2000989|NCT03284411|Device|Spinal Cord Stimulation|Programming
1482638|NCT03100136|Drug|[11C]PF-06809247|PET Tracer
1482639|NCT03100123|Drug|Aspirin 81 mg|Aspirin 81 mg po daily in tablet form.
1482640|NCT03100123|Drug|Low-molecular-weight heparin|The LMWH regime will be at the discretion of the treating physician, with a suggested regime as follows: tinzaparin 4,500 IU sc daily until 20 weeks gestation, and then 4,500 IU sc twice daily until 37 weeks gestation.
1482641|NCT03100110|Device|NeuroCognitive Communicator|Comprises an electrode array in prefrontal cortex, another in motor cortex, Blackrock NeuroPort system and connectors, augmentative assistive communication application, robotic arm, and virtual reality environment.
1482642|NCT03100097|Device|Aspen Horizon 627 LSO|
1482643|NCT03100084|Other|Blood sampling|Maternal blood sampling
1482644|NCT03100071|Drug|Apixaban|Patients will be treated with Low Molecular Weight Heparin (LMWH) for 1 week and then with apixaban 5 milligram (mg) twice daily for 11 weeks.
1482645|NCT03100058|Drug|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally.
1482646|NCT03100058|Drug|Placebo|Placebo
1482647|NCT03100045|Drug|Artesunate Suppositories|Artesunate suppositories for the treatment of (AIN2/3) Anal Intraepithelial Neoplasia
1482648|NCT03100032|Biological|NVD-001|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with NVD-001.
1482649|NCT03100032|Procedure|Standard of Care|At the Investigator's discretion, one or two interbody polyetheretherketone (PEEK) cage(s) filled and surrounded with autologous locally cancellous bone (laminectomy)
1482650|NCT03100019|Dietary Supplement|Resveratrol|
1482651|NCT03100019|Drug|Placebo|
1482652|NCT03100006|Drug|Nivolumab|240mg of IV Nivolumab is administered over 30 mins every 2 weeks
1482653|NCT03100006|Drug|Oregovomab|IV Oregovomab is administered over 20 mins every 4 weeks at dose levels: 2mg, 1mg, or 0.5mg
1482654|NCT03099993|Other|Measurement of maximal forces of elbow pronosupination and flexion-extension|Maximal forces of elbow pronosupination and flexion-extension will be measured with a portable dynamometer.
1482655|NCT03099980|Biological|secukinumab|secukinumab 300 mg (2 x 150 mg pre-filled syringe) administered at Baseline, Weeks 1, 2, 3, 4, and then Q4W for 24 weeks via subcutaneous injections
1482656|NCT03099967|Device|Transcatheter closure of an atrial septal defect or patent foramen ovale.|In a prospective study in adults troponin T (TnT) serum concentrations were determined before and the day after transcatheter closure of an atrial septal defect (ASD) or patent foramen ovale (PFO).
1482657|NCT03099941|Other|Biofeedback|The aim of this study is to investigate effects of a biofeedback application that is alternative to physical therapist feedback in core stabilization training of patients with CNLBP.
1482658|NCT03099915|Other|completion of self-reported questionnaires|Single completion: Participants will have to complete self-reported questionnaires based on gina criteria and 12-item general health questionnaire
1482659|NCT03099902|Diagnostic Test|Lung function|Spirometry test
1482660|NCT03099902|Diagnostic Test|White blood cell DNA extraction|GSTP1 and TNFa polymorphisms with PCR
1482661|NCT03099902|Diagnostic Test|Urinary testing|Urinary nicotine and cotinine detection
1482662|NCT03099889|Behavioral|Physical Activity|Physical activity intervention based upon stage of change and social cognitive theory based interventions
1482663|NCT03099876|Procedure|treatment period|7 days treatment or 10 days treatment
1482664|NCT03099863|Drug|Cystoscopic Fluid containing Neosporin G. U. Irrigant|Normal saline cystoscopic fluid containing Neosporin G. U. Irrigant 1mL/1000mL
1482665|NCT03099863|Procedure|Cystoscopy|Diagnostic cystoscopy performed during pelvic floor surgery
1482666|NCT03099863|Drug|Cystoscopic Fluid/Placebo|Normal saline cystoscopic fluid
1482667|NCT03099850|Other|Data Management and Monitoring|The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer Center responsible for monitoring protocol and regulatory compliance for consortium. CDMC responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study.
1482668|NCT03099824|Drug|GC4711 Oral Capsule|Part 1: Planned dose levels of the GC4711 Oral Capsule include 82 mg (1 capsule), 164 mg (2 capsules), 246 mg (3 capsules), 328 mg (4 capsules), and 410 mg (5 capsules).
1482669|NCT03099824|Other|Placebo oral capsule|Part 1: Placebo Oral Capsule to mimic appearance of active GC4711 Oral Capsule
1482670|NCT03099824|Drug|IV GC4419|GC4419 will be infused IV as a single dose of 27 mg in 247 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump.
1482671|NCT03099824|Other|Fasting Condition|For the fasting condition, GC4711 will be administered following an overnight fast of at least 10 hours, with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
2000990|NCT03284125|Other|Swallowing disorders evaluation|Self-administered questionnaires and non-invasive clinics tests
1482672|NCT03099824|Other|Fed Condition|Subjects assigned to the fed condition will receive a standard meal per U.S. FDA guidelines consisting of high calorie/high fat meal prior to dosing consisting of total calories of 800-1000 of which 150, 250 and 500-600 calories are from protein, carbohydrate, and fat, respectively. Subjects will start the standard meal 30 minutes prior to administration of GC4711, and will be instructed to eat the meal in 30 minutes or less; however, the GC4711 will be administered 30 minutes after the start of the meal, with 240 mL (8 fluid ounces) of water.
1482673|NCT03099824|Drug|GC4711 Oral Capsule|Part 2: After completion of the single-ascending dose portion of the study, a separate cohort of subjects will receive a single dose of GC4711 (at a dose no higher than previously found to have an acceptable safety profile), under fasted or fed conditions, followed, after a 7-day washout period, of a second single dose of oral GC4711, at the same dose as before, under the opposite condition (fed or fasting)
1482674|NCT03099811|Behavioral|Incentive plan|The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval. Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
1482675|NCT03099811|Behavioral|Smoking cessation|Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH). The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
1482676|NCT03099798|Other|Questionnaires|"All patients will complete a number of questionnaires at different time points.
SF-12, WHOQoL-Bref, EQ-5D-5L, iPCQ, iMCQ
1 week, 1 month, 3, 6 and 12 months after treatment"
1482677|NCT03099798|Diagnostic Test|MRI abdomen|Patients who were treated with splenic artery embolization will also undergo an MRI one month and one year after treatment.
1482678|NCT03099785|Drug|Rifamycin SV 600mg t.i.d.|Morning: one 600 mg tablet Afternoon: one 600 mg tablet Evening: one 600 mg tablet
1482679|NCT03099785|Drug|Rifamycin SV b.i.d. + Placebo|Morning. one 600 mg tablet Afternoon: one matching placebo tablet Evening: one 600 mg tablet
1482680|NCT03099785|Drug|Placebo t.i.d.|Morning. one matching placebo tablet Afternoon: one matching placebo tablet Evening: one matching placebo tablet
1482681|NCT03099772|Behavioral|CBT-IU|Cognitive-behavioral therapy for intolerance of uncertainty
1482682|NCT03099759|Dietary Supplement|Vitamin D|Vitamin D2/D3
1482683|NCT03099746|Behavioral|INVOLVE|Interactive content and decision coaching with tailored framing of messages to subject's informational processing style and stage of change to promote participatory decision making behavior. Consideration of options, consequences, values, and preferences to formulate an informed decision.
1482684|NCT03099746|Behavioral|Informational Support|Passive, non-tailored informational support. Screen-based education (videos) with information content on advance care decisions that occur in the intensive care unit.
1482685|NCT03099746|Behavioral|Usual Care|Routine decision support practices by the healthcare team. Family meetings, bedside updates, and access to printed or electronic decision aids.
1482686|NCT03099733|Other|text message|Participants will receive text message assessment and tailored intervention messages daily over the 14-day/two-week study period.
1482687|NCT03099720|Drug|Ropivacaine|local anesthetic will be given locally at the site of operation to decrease the level of pain after operation
1482688|NCT03099720|Drug|Placebo|placebo fluid will be given at the site of operation locally
1482689|NCT03099707|Behavioral|Treatment Ambassador|"This multi-component intervention, titled the Treatment Ambassador Program, will target people living with HIV who have not initiated ART within 3 months of testing positive. Our intervention will last for 8 sessions over 8-14 weeks, and will aim to address the three steams of influences on decision-making through a system of patient navigation and support with an assigned partner living with HIV who is trained in motivational interviewing. It will be aimed at addressing barriers to ART initiation identified through our prior qualitative research, as framed through the Theory of Triadic Influence, by addressing the three streams of influences on decision-making through a system of patient navigation and support."
1482690|NCT03099694|Procedure|noninvasive high-frequency ventilation (nHFOV)|NHFOV will be provided by a high frequency ventilator (CNO, Medin, Germany or SLE 5000, UK). NHFOV will be provided via binasal prongs. All participating centers have expertise with using these HFO ventilators. Guidelines for initial and maximum settings were provided to all sites. Initial nHFOV settingswill be: MAP of 6cmH2O, which will be equivalent with NCPAP group, frequency of 8 Hz, and amplitude will be adjusted until the infant's chest showsadequate chest wall vibrations. The FiO2will be adjustedto target oxygen saturation (SpO2) from 89% to 93% in preterm infants <30 weeks GA and 90-94% in infants >30 weeks GA by pulse oximeter
1482691|NCT03099694|Procedure|nasal continuous positive airway pressure (nCPAP)|Infants assigned to the NCPAP group will be started on a pressure of 6 cmH2O (range: 6-8 cmH2O) by CPAP system (CNO Medin, Germany, Carefusion, USA), with FiO2 adjusted to target SpO2 from 89% to 93% in preterm infants <30 weeks GA and 90-94% in infants >30 weeks GA by pulse oximeter.
1482692|NCT03099681|Other|Treatment for Epitheloid Sarcoma|Treatment Epitheloid Sarcoma according the disease guideline
1482693|NCT03099538|Drug|Ixekizumab|Subcutaneous injection
1482694|NCT03099525|Other|ILD|This is an observational study without any intervention.
1482695|NCT03099512|Other|SFE|The 'short foot exercise' has been described as a means to isolate contraction of the plantar intrinsic muscles.
1482696|NCT03099512|Other|Exercise|Exercises which improves muscle strength, ROM...
1482697|NCT03099499|Drug|ONC201|ONC201 will be administered at a dose of 625 mg by mouth weekly until disease progression, unacceptable toxicity, or if the patient discontinues for any other reason. Radiologic tumor assessment would be performed at baseline, Cycle 3 Day 1, Cycle 5 Day 1, and at the end of every 3 cycles beyond cycle 5. All patients including those removed from the study due to unacceptable toxicity, will undergo radiologic tumor assessment at the time of discontinuation (End of treatment).
1482698|NCT03099486|Drug|Regorafenib|The dose of Regorafenib is 160 mg PO daily D1-D21 of 28-day cycle or last tolerated dose while on Regorafenib monotherapy.
1482699|NCT03099486|Drug|5-FU|5-FU dose D1 and D15 of 28 day cycle i400 mg/m2 bolus over 10 mins followed by 2400 mg/m2 continuous infusion over 46 hours
1482700|NCT03099486|Drug|Leucovorin|D1 and D15 of 28 day cycle Leucovorin 400 mg/m2 over 2 hours,
1482851|NCT03098420|Drug|4mg Dexamethasone|1 mL (4mg) of dexamethasone
1482701|NCT03099473|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
1482702|NCT03099473|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
1482703|NCT03099473|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
1482704|NCT03099460|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
1482705|NCT03099460|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
1482706|NCT03099460|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
1482707|NCT03099447|Other|ocular electroacupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm. The electropuncture apparatus is used, each group of electrodes are distinguished with different colors of wires to generate current stimulations of current 1.0~1.5 milliampere (mA), voltage 9 volt(V), frequency 1.5 hertz (Hz), and duration of 40 minutes.
1482708|NCT03099447|Other|ocular acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm needle is inserted slowly. Piercing depth is about 20mm.The duration of intervention is 40 minutes.
1482709|NCT03099447|Other|sham acupuncture|During intervention period, patients will continue to keep medications for primary condition. Patient's skin located in the extraocular muscles projection area is routinely disinfected. A diameter of 0.20 mm and length of 25 mm sham needle set is stick onto insertion area without piercing into the skin. The duration of intervention is 40 minutes.
1482710|NCT03099434|Behavioral|Facebook App|This web-based mobile application allows candidates to write a simple and effective story to share with their previously built network on Facebook to help share their story and identify a potential live donor.
1482711|NCT03099434|Behavioral|Live Donor Champion + Facebook App|"A Live Donor Champion (LDC) is a friend, family member, or community member who serves as an advocate for the candidate in their pursuit of live donation. The investigators have developed a six-month program that provides education and advocacy training to waitlist candidates and their LDCs."
1482712|NCT03099421|Procedure|Prostatic Artery Embolization|The procedure is performed with the patient under local anaesthetic and if necessary sedation. We will be using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation will be done using microspherical embolic material.
1482713|NCT03099408|Drug|Metronidazole Oral|Oral metronidazole 400 mg BID for 7 days at first month.
1482714|NCT03099408|Drug|"Metronidazole and Lactobacillus"|Oral metronidazole metronidazole 400 mg BID for 7 days at first month and Lactobacillus vaginal suppositories for 10 days at first month,second month and third month.
1482715|NCT03099382|Biological|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 200mg on Day 1 every 2 weeks
1482716|NCT03099382|Drug|Docetaxel|Subjects receive Docetaxel intravenous at the dose 75mg/m2 on Day 1 every 3 weeks
1482717|NCT03099382|Drug|Irinotecan|Subjects receive Irinotecan intravenous at the dose 180mg/m2 on Day 1 every 2 weeks
1482718|NCT03099369|Behavioral|Daily Step-based Exercise|A 12-week step-based exercise prescription with the eventual goal of walking at least 5,000 steps a day.
1482719|NCT03099369|Behavioral|Symptom-based Exercise|A 12-week symptom-based exercise prescription adapted from clinical practice guidelines.
1482720|NCT03099369|Device|Fitbit Fitness Monitor|Used by the experimental group to assess outcome and to guide exercise therapy; used by the active comparator group to assess outcome only
1482721|NCT03099356|Drug|Cyclophosphamide|Cyclophosphamide 100 mg, PO, days 1-5 and 15-19
1482722|NCT03099356|Drug|Sirolimus|Sirolimus 4 mg, PO, days 1-28
1482723|NCT03099343|Behavioral|Location-based Tailored Messaging|The mobile application works by providing tailored messages targeted to participant locations that can help individuals to choose lower sodium foods.
1482724|NCT03099330|Drug|TQ-B3139|TQ-B3139 p.o. qd
1482725|NCT03099317|Other|Sinew acupuncture|Sinew acupuncture: subject will sit on chair with knee joint flexion with a most comfortable angle nearest to 90 degrees. Acupoints (1-2cm away from the point of tenderness or pain) near the knee will be punctured through the skin by using sterile needles of size 0.30mm × 40mm at the angle of 0-10 degrees pointing along the pain direction and meridian sinew. Immediately, needles will be retreated back just under the skin and inserted 10mm-20mm forward smoothly with minimal pain sensation. Walking and stepping will be advised and governed during acupuncture. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject. The treatment will last 20 minutes for each session.
1482726|NCT03099317|Other|Sham acupuncture|Sham acupuncture: subject will receive the same procedures as the sinew acupuncture without penetrating the skin. The needle will be used to puncture on the acupoint slightly without passing through the skin. The acupoint will be covered with non-allergic bandages to ensure sufficient blinding to the subject.
1482727|NCT03099304|Drug|INCB018424 cream|INCB018424 cream is a topical formulation applied as a thin film to affected areas.
1482728|NCT03099304|Drug|Vehicle cream|Vehicle cream is matching in appearance to INCB018424 cream and is to be applied in the same manner as INCB018424 cream.
1482729|NCT03099291|Biological|RSV D46/NS2/N/ΔM2-2-HindIII Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
1482730|NCT03099291|Biological|Placebo|Administered as nose drops
1482731|NCT03099278|Drug|Ezetimibe|Ezetimibe 20 mg oral daily
1482732|NCT03099265|Drug|neoadjuvant mFOLFIRINOX|Patients will receive 8 cycles of mFOLFIRINOX every 2 weeks. mFOLFIRINOX will be dosed as follows: Oxaliplatin 85 mg/m2, followed by folinic acid 400 mg/m2 infused over 120 minutes and irinotecan 135 mg/m2 infused over 90 minutes, followed by 5-fluorouracil 300 mg/m2 IV bolus, followed by 2,400 mg/m2 continuous infusion for 46 hours. Levoleucovorin may be substituted for folinic acid at a dose of 200 mg/m2 infused over 120 minutes.
1482733|NCT03099265|Drug|Stereotactic body radiotherapy (SBRT)|Stereotactic body radiotherapy (SBRT) will be delivered to the primary tumor and any adjacent involved nodes to 33 Gy in 5 fractions over the course of 2 weeks, and within 4 weeks of chemotherapy.
2000991|NCT03277313|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
2000992|NCT03277313|Biological|GAMMAGARD LIQUID|GAMMAGARD LIQUID IGI (Human), 10% Solution
2000993|NCT03277768|Device|Resonance Raman Spectroscopy (RRS)|Pre and post-ductal RRS measurements will be obtained daily for a maximum of 14 days in infants with and without PDAs.
1482737|NCT03099226|Drug|Placebo|Placebo blue hard gelatine capsules
1482738|NCT03099226|Drug|BIA 5-453|Etamicastat (BIA 5-453) blue hard gelatine capsules - 50 Strength (mg)
1482739|NCT03099213|Drug|RAMIPRIL HOE498|Pharmaceutical form:Tablet Route of administration: Oral
1482740|NCT03099200|Other|No Intervention|
1482741|NCT03099187|Drug|Pirfenidone|Pirfenidone 267 mg capsules three times in a day.
1482742|NCT03099187|Drug|Placebo|Matching placebo capsules three times in a day.
1482743|NCT03099174|Drug|Xentuzumab|Once weekly administrated through one hour intravenous infusion
1482744|NCT03099174|Drug|Abemaciclib|Treatment/28-day cycle p.o. Q12H on Days 1-28 (Starting dose Cohort A) Abbreviations: PO = orally; Q12H = every 12 (± 2) hours
1482745|NCT03099174|Drug|Letrozole|once a day
1482746|NCT03099174|Drug|Anastrozole|once a day
1482747|NCT03099174|Drug|Fulvestrant|once a month, with an additional dose given two weeks after the first dose. Each dose is given as two slow injections lasting one to two minutes, with one injection being given into the muscle of each buttock
1482748|NCT03099161|Drug|preladenant|Administered p.o., BID every day of each 21-day cycle
1482749|NCT03099161|Biological|pembrolizumab|Administered as IV infusion Q3W on Day 1 of each cycle
1482750|NCT03099148|Drug|LY3337641 (R)|Administered orally
1482751|NCT03099148|Drug|LY3337641 (T1)|Administered orally
1482752|NCT03099148|Drug|LY3337641 (T2)|Administered orally
1482753|NCT03099135|Drug|No Treatment|No treatment will be given tp participants during this follow-up study of previous phase II and Phase III in which they have received Odalavir and AL-335 with or without Simeprevir.
1482754|NCT03099122|Biological|Rabbit Anti-thymocyte Immunoglobulin|"Pharmaceutical form: creamy-white powder
Route of administration: intravenous"
1482755|NCT03099122|Drug|Tacrolimus|"Pharmaceutical form: tablet
Route of administration: oral"
1482756|NCT03099122|Drug|Methylprednisolone|"Pharmaceutical form: powder
Route of administration: intravenous"
1482757|NCT03099122|Drug|Mycophenolate mofetil|"Pharmaceutical form: capsule
Route of administration: oral"
1482758|NCT03099122|Drug|Mycophenolate Na|"Pharmaceutical form: capsule
Route of administration: oral"
1482759|NCT03099122|Drug|prednisone|"Pharmaceutical form: tablet
Route of administration: oral"
2000994|NCT03277222|Biological|IN insulin|IN insulin twice daily taken after breakfast and again after dinner using the a nasal delivery device. Each escalated dose will be given for 1 week.
2000995|NCT03277222|Biological|IN saline|IN saline twice daily taken after breakfast and again after dinner using the a nasal delivery device.
2000996|NCT03274934|Behavioral|Experimental: face-to-face and online support group:|5-week intervention according to Acceptance and Commitment Therapy principles with the web-and mobile-based Youth COMPASS program, face-to-face support (2 meetings) and weekly online mobile support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
1482763|NCT03099070|Behavioral|Stress|Trier Social Stress Test
1482764|NCT03099070|Other|Fasting|12-hour fasting prior to study visit
1482765|NCT03099057|Other|follow-up of patients after interventional rhythm operation|The follow-up will take place at 3 months postoperatively, then at 1 year and then annually for 5 years.
1482766|NCT03099044|Other|Placebo comparator|Subjects consume 2 placebo beverages daily for 10 days. The dose-response controls for volume consumed.
1482767|NCT03099044|Other|Single Active dose|Subjects consume 1 placebo + 1 Active beverages daily for 10 days. The dose-response controls for volume consumed.
1482768|NCT03099044|Other|Double Active dose|Subjects consume 2 Active beverages daily for 10 days. The dose-response controls for volume consumed.
1482769|NCT03099031|Drug|Tinzaparin|Subcutaneous injection of 175 IU/kg once daily for 6 months
1482770|NCT03099018|Diagnostic Test|Sofia Strep A FIA|Patients who presented with sore throat will be performed throat swab for the new fluorescent immunoasssay (Sofia Strep A FIA), for a standard RADT (Alere Testpack Strep A) and for culture and backup PCR in case of discrepant results.
1482771|NCT03099005|Drug|Cannabis|vaporization of cannabis
2000997|NCT03274934|Behavioral|Experimental: only online support group:|5-week intervention according to ACT principles with the web-and mobile-based Youth COMPASS program, no face-to-face support, weekly mobile online support and feedback from the individually assigned coach (one third of the participants is randomly assigned to this group)
1482772|NCT03098992|Device|Fotona Dynamis Er:YAG Laser System|Treatment of urodynamic proven stress urinary incontinence using the Fotona Dynamis Er:YAG Laser System in the active arm
1482773|NCT03098992|Device|Fotona Dynamis Er:YAG Laser System with sham handpience|Sham treatment with a sham handpiece and parameter presentations masked
2000998|NCT03274934|Behavioral|Control|Control group, no intervention, school counseling as usual. (one third of the participants is randomly assigned to this group)
2000999|NCT03273790|Other|Non-interventional|Non-interventional
2001000|NCT03272334|Drug|HER2 BATs with Pembrolizumab|8 infusions of HER2 BATs with 1-3 infusions of Pembrolizumab
2001001|NCT03270527|Other|High SFA diet (Diet 1)|'Diet 1' will contain ~18% of its total energy as SFA .
2001002|NCT03270527|Other|Low SFA diet (Diet 2)|'Diet 2' will contain ~10% of its total energy as SFA. The SFA-replacement fats will be mixture of PUFA/MUFA.
2001003|NCT03269695|Drug|PF-06687234|SC QW
1482780|NCT03098953|Drug|Loteprednol Etabonate|one drop per eye for each eye
1482781|NCT03098940|Drug|Chewing Gum|During the study healthy subjects will receive single doses of the various strengths of dronabinol
1482782|NCT03098927|Behavioral|Motor imagery training|Motor imagery training
1482783|NCT03098914|Other|Cohort Study； pathogen； clinical features|Cohort Study； pathogen； clinical features
1482784|NCT03098901|Diagnostic Test|Tc99m-labeled pyrophosphate scan|Intravenous injection of Tc99m-labeled pyrophosphate with consecutive whole body scan using gamma ray scanner for assessment of radioactive uptake in the heart. The results of the scan will be evaluated by a specialist in the field. The uptake will be graded using Perugini scale (0- no uptake, 1- uptake in heart less intense than in bones, 2-uptake in heart as intense as in bones, 3-uptake in heart more intense than in bones).
1482785|NCT03098888|Procedure|bronchoalveolar lavage|bronchoalveolar lavages performed for cytological assessment in critically ill patients with lung diseases, intubated or not
1482786|NCT03098875|Drug|Sevoflurane|General anesthesia using sevoflurane as a hypnotic agent
1482787|NCT03098875|Drug|Propofol|General anesthesia using propofol as a hypnotic agent
1482788|NCT03098875|Drug|Remifentanil|General anesthesia using remifentanil as an analgesic.
1482789|NCT03098849|Other|Buteyko Breathing Technique|Patients are trained in various exercises aiming at breath reduction and breath control as introduced by Dr. K. Buteyko
1482790|NCT03098836|Drug|ARN-509|240 mg orally daily
1482791|NCT03098836|Drug|Abiraterone Acetate|1000 mg orally daily
1482792|NCT03098836|Drug|Prednisone|5 mg orally twice daily (for total daily dose 10 mg)
1482793|NCT03098823|Drug|RAYOS|FDA approved RAYOS for indication of fatigue in Lupus.
1482794|NCT03098823|Drug|Prednisone|FDA approved corticosteroid frequently used for SLE.
1482795|NCT03098810|Drug|Zinc sulphate|Oral syrup zinc sulphate
1482796|NCT03098810|Other|Placebo|Oral syrup placebo
1482798|NCT03098784|Other|Exposure to aircraft exhaust|The exposed group is made up of Air France personnel mainly working in physical proximity to the runways of the Marseille Marignane or Parisian airports. These people are subject to direct exposure to exhaust from aircraft engines.
1482799|NCT03098784|Other|Non exposure to aircraft exhaust|The non-exposed group is made up of Air France personnel working mainly inside buildings at the Marseille Marignane or Parisian airports. These people are not subject to direct exposure to exhaust from aircraft engines.
1482800|NCT03098771|Procedure|the cell transplantation group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the cell transplantation group, which peripheral blood CD34+ cells transfected with ActiveMax® recombinant human vascular endothelial growth factor 165 (VEGF165) gene will be transplanted into the muscles of ischemic limbs in elderly patients with atherosclerotic lower limb ischemia.
1482801|NCT03098771|Drug|the control group|Patients with atherosclerotic lower limb ischemia will be randomly assigned to the control group, which 9% physiological saline will be injected into the muscles of ischemic limbs.
1482802|NCT03098745|Device|Omafilcon A|contact lens
1482803|NCT03098745|Device|Somofilcon A|contact lens
1482804|NCT03098745|Device|Omafilcon A - Proclear (PC)|contact lens
1482805|NCT03098732|Device|Magnetically Enhanced Diffusion (MED)|Treatment of Acute Ischemic Stroke with IV tPA and the adjunctive Magnetically Enhanced Diffusion (MED) System Procedure.
1482806|NCT03098732|Device|MED Workstation Magnet Sham Control|Treatment of Acute Ischemic Stroke with IV tPA and Sham use of the MED Workstation only, without the injection of MED MicroBeads.
1482807|NCT03098719|Behavioral|Active Mobility|see detailed discription
1482808|NCT03098706|Procedure|Procedure control: normothermia|Temperature will be maintained between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming will be introduce to maintain temperature between the range of 36.5 - 37.5°C.
1482809|NCT03098706|Procedure|Procedure active|Therapeutic hypothermia ie targeted controlled temperature between 34° and 35°C will be induced in the active group. Usual method of controlled temperature will be used in ICU: internal active method or external active method.
1482810|NCT03098693|Behavioral|HIV Self-Testing|Access to home-based HIV self-testing kits for stable couples.
1482811|NCT03098693|Behavioral|Immediate Access to ART for HIV infected couple members|Immediate access to ART for HIV infected couple members (per current Tanzanian standard of care).
1482812|NCT03098693|Behavioral|Access to PrEP for HIV uninfected couple members|Access to PrEP for HIV uninfected couple members.
1482813|NCT03098680|Drug|Albuterol Sulfate|see arm/group descriptions
1482814|NCT03098680|Drug|Nicardipine Hydrochloride|see arm/group descriptions
1482815|NCT03098680|Drug|Dobutamine Hydrochloride|see arm/group descriptions
1482816|NCT03098680|Drug|Phenylephrine Hydrochloride|see arm/group descriptions
1482817|NCT03098680|Drug|Verapamil Hydrochloride|see arm/group descriptions
1482818|NCT03098680|Drug|Phentolamine Mesylate|see arm/group descriptions
1482819|NCT03098680|Drug|Placebo|see arm/group descriptions
1482852|NCT03098420|Drug|Ropivacaine (TAP blocks)|20mL of 0% ropivacaine with 20mL of 0.5% ropivacaine
1482853|NCT03098420|Drug|Morphine|
1482854|NCT03098420|Drug|Bupivacaine Hydrochloride|
1488601|NCT03054532|Drug|Lenali|Lenalidomide oral 20 mg/day
1482820|NCT03098667|Device|LMA Protector|After induction of general anesthesia, the LMA Protector will be applied for airway management. The size of the laryngeal mask will be chosen according to the manufacturer's instructions. Lubricant gel will be applied to the dorsal side of the mask to ease the insertion to the oropharynx. The cuff of the mask will be filled with air by syringe until the indication of the integrated cuff pressure indicator is appropriate according to the manufacturer (green indication). If the indication changes during surgery, air will be added or removed accordingly. If the ventilation of the patient is inadequate at the beginning or anytime during the operation, the mask will be removed and the patient will be intubated.
1482821|NCT03098667|Device|Endotracheal tube|After induction of general anesthesia, the endotracheal tube be applied for airway management. The size of the tube will be 7.5 for female and 8.5 for male patients. The cuff of of the tube will be filled with 10ml air.
1482822|NCT03098654|Diagnostic Test|Blood glucose and blood pressure testing|Diabetes will be assessed using a 6-question risk assessment on a 10-point scale (based on a field-tested and culturally adapted International Diabetes Federation formula on DM risk factors and symptoms) and a random blood glucose test with a portable finger stick glucose monitor. Those with either: (1) a risk score of 5 or more, or (2) a random blood glucose with a value greater than 140 mg/dl, will be asked to return after fasting for at least 8 hours to have a fasting glucose test taken. Blood pressure will be assessed using a portable battery operated automatic BP cuff. The BP test will include three values taken at least 5-minutes apart and the 3 will be averaged to determine the final value.
1482823|NCT03098654|Behavioral|Diet and lifestyle counseling|All participants with elevated glucose or BP will receive personalized lifestyle counseling by trained counselors informed by lab results and that includes education on diabetes, hypertension, dietary assessment and recommendations, advice on physical activity, and the need to regularly monitor their glucose, BP, and adjust their diet, activity level, as needed. Personalized risk reduction plans will be negotiated with the client during their scheduled visits.
1482824|NCT03098654|Drug|DM/HTN medications as needed|Subjects will receive DM or HTN medications prescribed by the CTC clinician as needed.
1482825|NCT03098641|Procedure|pelvic organ prolapse repair|Surgery to repair pelvic organ prolapse through the vagina using stitches with the addition of surgical mesh.
1482826|NCT03098628|Biological|PCV Vaccine|PCV vaccination
1482827|NCT03098615|Drug|Jublia (Efinaconazole 10% Topical Solution)|Efinaconazole 10% Topical Solution will be applied to the great toenail with the DLSO and dermatophytoma.
1482828|NCT03098589|Drug|Revlimid|Revlimid
1482829|NCT03098576|Other|Matched targeted drug treatment|Matching a specific genetic abnormality (i.e. mutation) with the appropriate targeted drug.
1482830|NCT03098576|Other|Unmatched standard of care|"All patients with either no identified mutation or no available matching treatment but undergoing a systemic treatment will be enrolled in the control group."
1482831|NCT03098563|Drug|Blinded study medication|Blinded study medication: This is a double-blind within-subject Phase II trial. Study medications will remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications or placebo (sugar pill). All subjects will serve as their own control. Study medication administration will be randomized within each participant.
2001005|NCT03265470|Drug|Dexmedetomidine|Patients will receive Loading dose of dexmedetomidine (0.8μg/kg) over 20 minutes, followed by intravenous infusion (0.4μg/kg/h) during intra-operative period till end of procedure.
1482834|NCT03098537|Drug|enteral nutrition + proton pump inhibitor|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive enteral nutrition and proton pump inhibitor
1482835|NCT03098537|Other|enteral nutrition only|Critically ill patients receiving any form of enteral nutrition will be included into the study. The patients will be randomized either enteral nutrition only group or enteral nutrition and proton pump inhibitors group. This group will receive only enteral nutrition.
1482836|NCT03098524|Procedure|Low tidal volume ventilation (LTV arm)|During cardiopulmonary bypass, mechanical ventilation is maintained with settings described above.
1482837|NCT03098524|Procedure|No ventilation (noV arm)|During cardiopulmonary bypass, no mechanical ventilation is performed.
1482838|NCT03098524|Procedure|Lung recruitment manoeuver|"An insufflation with positive end-expiratory pressure +30 cmH20 during 5 seconds.
At the end of cardiopulmonary bypass, in the operative room. And after transfer to the ICU (intensive care unit)."
2001006|NCT03265470|Drug|Fentanyl|Patients will receive Loading dose of fentanyl (1μg/kg), followed by intravenous infusion (1μg/kg/h) during intra-operative period till end of procedure.
1482840|NCT03098498|Procedure|Subgingival Debridement|Removal of subgingival bacterial biofilms and subgingival calculus from periodontal lesions
1482841|NCT03098485|Drug|Levofloxacin|5 days of levofloxacin administration
1482842|NCT03098485|Drug|Azithromycin|5 days of azithromycin administration
1482843|NCT03098485|Drug|Cefpodoxime|5 days of cefpodoxime administration
1482845|NCT03098446|Behavioral|Prolonged sitting with exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial with the acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
1482846|NCT03098446|Behavioral|Prolonged sitting without exercise|Subjects will have a 2-day control period during which step count and diet will be controlled for and recreated for the other trial. Following this 2-day period, they will undergo the prolonged sitting trial, but will not be asked to complete an acute bout of exercise on day 4. Day 5 will consist of the lipid tolerance test to determine the ability of the body to clear triglycerides.
1482847|NCT03098433|Drug|Liothyronine|Single dose
1594142|NCT02278250|Drug|Cisplatin|
1482855|NCT03098420|Drug|Normal saline 1ml|1.0 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
1482856|NCT03098420|Drug|Normal saline 0.5ml|0.5 ml of normal saline split between 2 sites with standard intrathecal bupivacaine and morphine
1482857|NCT03098407|Drug|Buprenorphine|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
1482858|NCT03098407|Drug|Methadone|This is a pilot study to establish the feasibility and acceptability of a randomized comparative effectiveness clinical trial comparing office-based buprenorphine vs. federally licensed methadone treatment programs for OD pregnant women.
1482859|NCT03098394|Device|Cepheid Xpert CT/NG Rapid Turnaround Test|This diagnostic test will be used to help clinicians determine the need for antibiotic prescriptions in patients with a suspected sexually tract infection.
1482860|NCT03098394|Device|Polymerase chain reaction (PCR)|This is the standard of care for diagnosis of a suspected sexually transmitted infection.
1482861|NCT03098368|Drug|Rotigotine|
1482862|NCT03098368|Drug|Placebo|Placebo of rotigotine patch
1482863|NCT03098355|Biological|4SCAR19/22 T cells|CD19/CD22-targeted 4th Generation CAR-T Cell (4SCAR19/22)
1482864|NCT03098355|Drug|Interleukin-2|Interleukin-2 of 250,000iu/m^2 every other day for 2 weeks and then rest for 2 weeks for up to 6 months.
1482865|NCT03098342|Procedure|Methylene blue-mediated photodynamic therapy|Using the 2% MB aqueous solution as a photosensitiser. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
1482866|NCT03098342|Drug|Amorolfine 5% Nail Lacquer|Patients will be detailed instruction regarding the use of 5% Amorofine Nail Lacquer (Loceryl®) as its recommended protocol.
1482867|NCT03098329|Other|Ct/GC screening|Men aged 15-24 years old will be tested for chlamydia and gonorrhea at community based venues; positive men and their sexual partners will be offered expedited treatment at participating pharmacies; positive men will be asked to be rescreened for Ct/GC at 3 months post treatment.
1482868|NCT03098316|Diagnostic Test|Metabolomics analysis of patient samples|Metabolomics analysis of patient samples by mass spectrometry and nuclear magnetic resonance spectroscopy.
1482869|NCT03098277|Device|Accelerometer|Wear Microsoft Band 2
1482870|NCT03098277|Other|Laboratory Biomarker Analysis|Correlative studies
1482871|NCT03098277|Other|Physical Activity Measurement|Perform physical activities recorded by Microsoft Kinect 2
1482872|NCT03098277|Behavioral|Telephone-Based Intervention|Complete PRO questionnaires
1482873|NCT03098264|Procedure|Simultaneous surgery|Simultaneous surgery in complicated hepatolithiasis
1482874|NCT03098264|Procedure|staged surgery|staged surgery in complicated hepatolithiasis
1482875|NCT03098251|Procedure|3D typing|typing the patient with 3D typing system and give specific treatment
1482876|NCT03098251|Procedure|routine typing|typing the patient with routine typing system and give specific treatment
1482878|NCT03098225|Radiation|Orbital radiotherapy|A high-voltage linear accelerator will be used and a cumulative radiation dose of 20 Gy will be delivered to each eye in 10 fractionated doses over a period of 2 weeks. All patients will be treated in both eyes.
1482879|NCT03098225|Drug|Methylprednisolone|Methylprednisolone pulse therapy for 12 weeks as follows: 500 mg IV once weekly for 6 weeks, then 250 mg IV once weekly for a further 6 weeks. Cumulative dose 4.5 g.
1482880|NCT03098212|Other|Aromatherapy|On the day of admission for labor. Pregnant women select type of essential oil. Aroma diffuser is used during labor. Pain score was record during latent, early active and late active phase.
1482881|NCT03098199|Drug|Gonal-F|
1482882|NCT03098199|Drug|Menopur|
1482883|NCT03098186|Behavioral|Intervention SMS|The active treatment will consist of SMS that are aimed to modified behavioral factors associated with poor adherence to cardiovascular medications used in secondary prevention. The SMS will be delivered daily during the first month, increasing one day of interval for each week during the second month , and weekly thereafter until end of month 12th. In addition, they will receive SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
1482884|NCT03098186|Behavioral|Control SMS|Participants will only receive the SMS thanking for their participation in the trial, reminders of trial appointment and informing if they have changed contact details. The frequency of this SMS will be monthly.
1482885|NCT03098173|Procedure|Early colonoscopy|Performance of prepared colonoscopy within 24 h of arrival
1482886|NCT03098173|Procedure|Elective colonoscopy|Performance of prepared colonoscopy between 24 and 96 h after arrival
1482889|NCT03098134|Behavioral|Behavior Therapy|Virtual Reality and Video based Exposure Therapy
1482890|NCT03098134|Other|Health Education|Video based health education covering common myths and false believes about dental surgeries
1482891|NCT03098121|Drug|grazoprevir and elbasvir|For patients with chronic genotype 1a, with or without resistance associated variant (RAV) of NS5A, are expected to receive grazoprevir 100mg and elbasvir 50mg in a fixed-dose combination tablet once daily with ribavirin for 16 weeks, and for patients with chronic genotype 1b are expected to receive grazoprevir 100mg and elbasvir 50mg in a fixed-dose combination tablet once daily for 12 weeks.
1482892|NCT03098108|Radiation|Concurrent chemo-proton therapy|Proton therapy with simultaneous integrated boost technique Gross tumor volume 70.4 gray (Gy)/ 16 fractions and clinical target volume 44.8 Gy/16 fractions Capecitabine twice a day 825 mg/body square meter
1482893|NCT03098095|Behavioral|Physical Activity|Moderate physical activity
1482894|NCT03098082|Device|Actim Pancreatitis|Actim Pancreatitis (Medix Biochemica) is a urine trypsinogen-2 dipstick test (UTDT) that uses trypsinogen-2 as a biomarker for acute pancreatitis.
1595668|NCT02266927|Drug|Flovent HFA|
1482895|NCT03098056|Other|PROG2|"Nutritional Supplements to be administered:
Protein Shakes: one shake po twice daily
Phytosterol supplement: one capsule po twice daily
Cinnamon: one tablet twice daily
Fiber supplement; one shake twice daily
Antioxidant supplement: 2 capsules daily with dinner
Fish Oil supplement: 1 capsule twice daily with food
Probiotic supplement: 1 capsule twice daily with food"
1482896|NCT03098030|Biological|Dinutuximab|Dinutuximab injection, for intravenous (IV) use
1482897|NCT03098030|Drug|Irinotecan|Irinotecan injection, IV infusion
1482898|NCT03098030|Drug|Topotecan|Topotecan for injection
2001007|NCT03264131|Drug|Brentuximab Vedotin|Brentuximab Vedotin will be given at 1.8 mg/kg IV over 30 minutes on D1 every 21 days for 4-6 cycles. Responders (CR, PR or SD) who are not eligible for BMT and have CD30-positive ATLL will continue maintenance therapy with BV alone (1.8 mg/kg IV for 30 minutes, every 21 days).
2001008|NCT03264131|Drug|CHEP|"Cyclophosphamide- 750 mg/m^2 IV over 1 hour on D1 every 21 days for 4-6 cycles
Doxorubicin- 50 mg/m^2 IV over 3-5 minutes on D1 every 21 days for 4-6 cycles.
Etoposide - 100 mg/m^2 IV over 1 hour each day for 3 days every 21 days for 4-6 cycles.
Prednisone - 100 mg, orally once daily for 5 days every 21 days for 4-6 cycles."
1482903|NCT03098004|Other|e-Cigarette|Participants will self-administer an experimenter-provided e-cigarette.
1482904|NCT03097991|Behavioral|Focused Coparenting Consultation|Six 90-minute sessions over 10 weeks address importance of coparenting for child development; overcoming challenges to coparenting collaboratively; anger and conflict management and communication skills. Parents develop a coparenting plan to support one another's involvement as parents to the baby. A 90-minute booster session one month after the baby's birth reinforces lessons learned in the 6-session intervention.
1482905|NCT03097978|Device|Commercial system|Transhumeral amputees who have had TMR will use a commercially available prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
1482906|NCT03097978|Device|RIC arm system|Transhumeral amputees who have had TMR will use the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct and pattern recognition - based control.
1482907|NCT03097978|Other|Direct Control|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for both direct control.
1482908|NCT03097978|Other|Pattern Recognition|Transhumeral amputees who have had TMR will use either a commercially available prosthesis or the RIC arm system prosthesis with an elbow,wrist, and a hand with custom electronics and software for pattern recognition control.
1482909|NCT03097965|Dietary Supplement|PROGRAM|
1482910|NCT03097965|Other|DIET|
1482911|NCT03097939|Drug|Ipilimumab|1 mg/kg of IV Ipilimumab is admistered over 90 minutes every 6 weeks
1482912|NCT03097939|Drug|Nivolumab|3 mg/kg of IV Nivolumab is administered over 30 minutes every 2 weeks
1482913|NCT03097926|Procedure|Long alimentary limb BPD-DS|BPD-DS with a long strict alimentary limb and a 100-cm common channel.
1482914|NCT03097913|Device|video-stylet|recording each video-stylet endotracheal tube assembly advanced through the selected nasal cavity
1482915|NCT03097900|Drug|Caffeine Citrate|25 patients after elective colorectal surgery will be given 100 mg caffeine citrate orally diluted in 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
1482916|NCT03097900|Other|Water|25 patients after elective colorectal surgery will be given 50 ml apple flavored water three times per day starting on the morning of postoperative day 1 after surgery until flatus will occur for the first time or to a maximal period time of 7 days, whichever comes earlier.
1482917|NCT03097887|Procedure|Omega Loop Gastric Bypass|Bariatric/metabolic surgical procedure
1482918|NCT03097887|Device|Bilitec 2000™|The Bilitec 2000™ device will be used to measure the intensity of biliary reflux in the pouch.
1482919|NCT03097887|Device|V-Loc|Sewing device to perform the anti-reflux sutures.
1482920|NCT03097874|Behavioral|Family Based Treatment|Family Based Treatment of adolescent Anorexia Nervosa
1482921|NCT03097874|Behavioral|Family Based Treatment + Intensive Parental Coaching|Family Based Treatment of adolescent Anorexia Nervosa plus an Intensive Parental Coaching component.
1482922|NCT03097861|Drug|Lubiprostone|24 mcg administered orally twice daily (BID)
1482923|NCT03097861|Drug|Placebo|24 mcg administered orally twice daily (BID)
1482924|NCT03097848|Procedure|RFA|for eligible cases, radiofrequency ablation will be given only.
1482925|NCT03097848|Drug|Sorafenib|for eligible cases, combination treatment with RFA and Sorafenib will be given.That is sorafenib for 2 week,then radiofrequency ablation
1482926|NCT03097835|Drug|Hyper-Diluted Botox|"0.1ml of hyper-diluted Botox® Cosmetic will be administered in the superficial dermis using a 1ml luer lock syringe coupled with a 33g ½ needle"
1482927|NCT03097835|Drug|Topical anesthesia|Topical anesthesia will be bilaterally applied to the mid-face region for 20 minutes
1482928|NCT03097835|Other|0.9% saline solution|0.1ml of 0.9% saline solution will be administered to the side of the face
1482929|NCT03097809|Other|SEEG Recordings|To directly record brain activity from the frontal-limbic circuitry of subjects in the resting state and while they engage in behavioral tasks designed to assess emotional response to negative stimuli and different aspects of impulse control and emotional processing
1482930|NCT03097796|Drug|PUL-042|PUL-042 Inhalation Solution
1482931|NCT03097783|Device|Restylane Perlane Lidocaine|Intradermal injection
1482932|NCT03097770|Biological|anti-CD19/20-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
1482933|NCT03097757|Diagnostic Test|Ultrasound|Ultrasound will be used as a real-time imaging modality to guide forearm fracture reduction.
1482934|NCT03097744|Device|Ceterix NovoStitch|The device allows the physician to place a circumferential compression stitch around meniscal tears. This stitch is placed by passing suture from the tibial side to the femoral side of the meniscus and across the tear. This allows compression across the entire tear surface.
1482935|NCT03097705|Diagnostic Test|OCT (Optical coherence tomography)|RNFL AND IOP MEASUREMNTS
1482966|NCT03097406|Procedure|Global Unite total shoulder arthroplasty|A total shoulder prosthesis used for osteoarthritis
1596263|NCT02262598|Drug|Telmisartan|
1482937|NCT03097679|Device|Pulsar Stent|Percutane transluminal stent angioplasty with a Pulsar Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
1482938|NCT03097679|Device|LifeStent Flexstar Vascular Stent|Percutane transluminal stent angioplasty with a LifeStent Flexstar Vascular Stent of the superficial femoral artery for the treatment of peripheral arterial occlusive disease.
1482939|NCT03097666|Device|C2 CRYOBALLOON SWIPE ABLATION SYSTEM|"The C2 CryoBalloon Swipe Ablation System (CryoBalloon Swipe) is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal diagnostic endoscopes."
1482940|NCT03097653|Other|Decision-aid|Web platform with a multilevel information and an aid for the decision to be taken. The content is splitted in 16-20 screens; each screen contains the answer to a common question (i.e. What is mammography screening? What are its benefits and harms? What results can be expected from the participation to mammography screening? What is breast cancer?). The information covers also controversial topics as overdiagnosis, overtreatment and the disagreement among scientists about harms and benefits' quantification.
1482941|NCT03097653|Other|Standard information|Web platform with a standard brochure. This standard brochure represents a combination of the best information available from the three participate centre' brochures.
1482942|NCT03097640|Other|CHAMP|CHAMP team members visit patients in the ED and on inpatient floors. Along with the patient's input, the team develops an Individualized Care Plan outlining the patient's medical and social history and providing recommendations to other providers on specific aspects of their care. Care plans are reviewed with patients on an individual basis and reviewed periodically by the CHAMP providers. CHAMP-enrolled participants are scheduled for physician and social worker follow-up appointments at the CHAMP clinic; this time is used to provide intensive case management, medical care, and psychosocial support.
1482943|NCT03097627|Drug|ICG Intervention|The intervention to be administered is the drug indocyanine green.
1482944|NCT03097601|Diagnostic Test|ELR+CXCL cytokines levels are of sunitinib response|Demonstrate on independent cohorts of patients that ELR+CXCL cytokines levels are of sunitinib response
1482945|NCT03097588|Drug|Netupitant|Given PO
1482946|NCT03097588|Drug|Palonosetron Hydrochloride|Given PO
1482947|NCT03097575|Drug|ICG Intervention|Patients enrolled in the study will undergo injection of near infrared dye indocyanine green around the lung lesion or within the adjacent segmental bronchus at the time of surgery via navigational bronchoscopy, or if not amenable to navigational bronchoscopy injection, then injection will be carried out via a transthoracic approach through the incision or under CT-guidance.
1482948|NCT03097575|Device|Near Infrared Imaging|A near-infrared camera device will be used to detect indocyanine green following injection.
1482949|NCT03097562|Procedure|Femtosecond cataract surgery|Catalys create a circular opening for accessing and removing the cataract.
1482950|NCT03097549|Device|Tät®II Information app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence.
1482951|NCT03097549|Device|Tät®II Treatment app|Information about pelvic floor muscle training and bladder training for urgency and mixed urinary incontinence. Information about psychological factors and life style factors that might interfere with incontinence .Exercises for the pelvic floor muscles, for bladder training, and for behaviours of avoidance due to fear of leakage, a statistic function and possibility to set reminders. Individual advices regarding life style factors and training based on findings from the bladder diary and answers in the questionnaires.
1482952|NCT03097536|Other|Luna Bar|Luna Bar (blueberry bliss or lemon zest flavor) product of Clif
1482953|NCT03097523|Device|Custom Thigh Cuff|The aim is to achieve positive and near normal forward arterial vascular blood flow to the lower extremities. Milder cuff pressures up to 65 mmHg will be used to limit venous return to the upper body.
1482954|NCT03097510|Behavioral|Transcendental meditation|The TM technique was taught as a standard 7 step course over 4 consecutive days. Thereafter, subjects attended bimonthly group meetings for more advanced knowledge over the four month intervention period.
1482955|NCT03097497|Other|Physiotherapy re-education program|Physiotherapy Program based on the Re-education of Pre-activation of the Transverse Abdominal Muscle
1482956|NCT03097497|Other|Conventional treatment by GP|Patients will follow the general practitioner's advice including medication if needed
1482958|NCT03097471|Device|BPK-S Integration (Ceramic)|primary total knee endoprosthesis
1482959|NCT03097458|Behavioral|Short-term Counselling for Families|Counselling for Families which can take up to 6 weeks, with regular meetings under the guidance of a trained psychotherapist.
1482960|NCT03097445|Drug|Nicotine patch|mailed 5-week course of Habitrol® transdermal nicotine patches
1482962|NCT03097419|Procedure|Remote post-ischemic conditioning|"A manual sphygmomanometer will be inflated over the brachial artery of the participants' arm that does not have an intravenous catheter actively infusing medications. If both arms are in use, then the participant's non-dominant arm will be used.
The sphygmomanometer will be inflated to a pressure at least 20 mmHg greater than the participants' last recorded systolic blood pressure.
The sphygmomanometer will be inflated for 5 minutes then rapidly deflated for 5 minutes, thereby concluding one iteration.
Five (5) total iterations constitute the treatment.
The left arm will be preferentially used instead of the right arm, unless the left arm is receiving medication administration."
1482963|NCT03097406|Procedure|Global Unite hemiarthroplasty|A hemiarthroplasty used for complex fractures of the proximal humerus.
1482964|NCT03097406|Procedure|Global Advantage|A total shoulder prosthesis used for osteoarthritis
1482965|NCT03097406|Procedure|Global FX|A hemiarthroplasty used for complex fractures of the proximal humerus.
1489403|NCT03048136|Drug|Ipilimumab|Specified dose on specified days
1482967|NCT03097393|Diagnostic Test|measure Serum procalcitonin level|measuring procalcitonin level
2001009|NCT03263325|Other|Discarded urine sample|Collection of discarded urine during surgery and following surgery
2001010|NCT03262350|Behavioral|Yoga|The yoga classes will be adapted to all levels of experience, mobility, and body size. Specific breathing techniques and body positive language will be incorporated into a body-positive yoga training done by Ms. Lisa Diers, RDN, E-RYT, YACEP. Less focus will be placed on precision of the poses, instead focus will be on body feelings, except where physically dangerous. Thus, the overall focus will be on listening to one's own body. List of messages will be carefully designed to be related to eating and weight, but to not be directly discussed. Ms. Diers will travel to Delaware to lead the intervention training for yoga instructors prior to the study taking place.
1482971|NCT03097367|Diagnostic Test|bladder neck level on cystography|All patients had investigated by retrograde cystography after LRP and were grouped according their bladder neck position: Level 0: bladder neck at or above the superior margin of the symphysis pubis (SMSP), Level -1: bladder neck at <2 cm below SMSP, and Level -2: bladder neck at >2 cm below SMSP.
1482972|NCT03097354|Other|no intervention/observational survey study design|no intervention/observational survey study design
1482973|NCT03097341|Drug|xisomab 3G3|xisomab 3G3 specified dose on specified day administered as a single intravenous injection
1482974|NCT03097341|Other|placebo|placebo specified dose on specified day administered as a single intravenous injection
1482976|NCT03097315|Combination Product|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 4 mg in 100 microliters, will be administered as a single injection at 2 timepoints
1482977|NCT03097302|Procedure|Laser keratotomy|Penetrating femtosecond laser assisted keratotomy to treat preexisting corneal astigmatism during lens surgery.
1482978|NCT03097289|Device|Trima Accel system|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 5 day storage. The entire procedure is painless and should take 90 to 120 minutes.
1482979|NCT03097276|Procedure|blood simple|blood simple will be collected
1482980|NCT03097276|Radiation|CT scan|CT scan
1482981|NCT03097263|Other|Physical Rehabilitation program|
1482982|NCT03097237|Other|Wholegrain rye|Cereal products based on wholegrain rye
1482983|NCT03097237|Other|Refined wheat|Cereal products based on refined wheat
1482984|NCT03097224|Behavioral|Prehabilitation|Four weeks of tele-supervised prehabilitation
1482985|NCT03097211|Drug|Placebo|Placebo capsules. Orally, with 240 mL of potable water.
1482986|NCT03097211|Drug|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 75 mg, 100 mg. Orally, with 240 mL of potable water.
1482987|NCT03097211|Drug|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg. Orally, with 240 mL of potable water.
1482988|NCT03097211|Drug|Nebicapone|Nebicapone 150 mg tablets. Orally, with 240 mL of potable water.
1482989|NCT03097198|Other|Plum-blossom Needle|"acupoint selection: Zhengguang 1, Zhengguang 2, GB20, GV14, LI4.
plum-blossom needle manipulation methods: After the skin has been wiped with 75 % alcohol, plum-blossom needles will be tapped perpendicularly on the skin at the selected acupoints with wrist force and then lifted immediately. Each point will be tapped repeatedly for 20 to 50 times and both sides of cervical vertebra and temporal region, Suprao-infraorbital margin will be tapped repeatedly. Acupuncturists should tap the points gently to make patients feel only a little pain and stop when the skin gets flushed but is not bleeding."
1482990|NCT03097198|Drug|Tropicamide Eye Drops|Instill one drop in both eyes every night before bed.
1482991|NCT03097159|Procedure|Costoclavicular block|Group C for costoclavicular block Group S for supraclavicular block
1482992|NCT03097146|Other|comprehensive multidisciplinary stroke care|"Patients will be treated in the pathological domain. Some of this treatment will be applied by the outpatient clinic itself (i.e. changes in medical secondary prevention or additional prescriptions, social work interventions), whereas most of it will be referred to other providers, if possible in vicinity to the patients' home. In order to ease treatment prescriptions and allow to measure treatment uptake, patients will also enrol in the case management system Ambulanzpartner. This allows the outpatient center to streamline prescription processes and measure uptake of therapies."
1482996|NCT03097120|Drug|0.625 mg of conjugated equine estrogen|one tablet containing 0.625 mg of conjugated equine estrogen and a placebo tablet daily
1482997|NCT03097120|Drug|0.625 mg of conjugated equine estrogen plus 2.5 mg of medroxyprogesterone acetate|one tablet of 0.625 mg of conjugated equine estrogen plus one tablet 2.5 mg of medroxyprogesterone acetate daily
1482998|NCT03097120|Drug|placebo tablets|two placebo tablets daily
1482999|NCT03097107|Drug|Saroglitazar Magnesium 1 mg|Randomly assigned patients will receive saroglitazar magnesium 1 mg orally once each morning before breakfast for 12 weeks
1483000|NCT03097107|Drug|Saroglitazar Magnesium 2 mg|Randomly assigned patients will receive saroglitazar magnesium 2 mg orally once each morning before breakfast for 12 weeks
1483001|NCT03097107|Drug|Saroglitazar Magnesium 4 mg|Randomly assigned patients will receive saroglitazar magnesium 4 mg orally once each morning before breakfast for 12 weeks
1483002|NCT03097107|Drug|Placebo|Randomly assigned patients will receive placebo orally once each morning before breakfast for 12 weeks
1483003|NCT03097094|Diagnostic Test|Male dog|Male dog extract
1483004|NCT03097094|Diagnostic Test|Female dog|Female dog extract
1483005|NCT03097081|Other|No orthosis|The intervention consists of a deviation of the standard protocol; patients do not receive a post-operative orthosis
1483006|NCT03097081|Device|Orthosis|Patients receive post-operative care following the standard protocol and wear an orthosis for 10-12 weeks.
1483007|NCT03097068|Drug|Lucentis|0.3mg Lucetnis
1483008|NCT03097055|Procedure|Traditional Acupuncture|"widely ongoing traditional acupoints in scalp and limbs with traditional deqi manipulation, for stroke patient"
1483009|NCT03097055|Procedure|Minimal Acupuncture|non-traditional acupoints in scalp and limbs, with minimal manipulation
1483010|NCT03097042|Procedure|Embryo transfer any further manipulation|The catheter will be pulled back slowly and without rotation with the plunger still pushed forward
1483011|NCT03097042|Procedure|Embryo transfer with catheter Manipulation|catheter rotation during withdrawal
1483012|NCT03097029|Drug|Pancreatic Enzyme|All subjects will take pancreatic enzymes at a dose appropriate for their weight. Pancreatic enzymes are used to help digest fat and other nutrients.
1483013|NCT03097016|Drug|CC-122|All subjects will receive one 3 mg CC-122 capsule the morning of Day 1 which will be administered in the fasted state.
1483014|NCT03097003|Drug|Apremilast|Psoriasis patients treated with Otezla® (Apremilast) in Belgium
1483015|NCT03096990|Drug|apremilast|Psoriatic arthritis patients treated with Otezla® (apremilast) in Belgium
1483016|NCT03096977|Diagnostic Test|Scale for the assessment and rating of ataxia (SARA)|Clinical evaluation of the manual dexterity through the SARA scale.
1483017|NCT03096977|Device|JAMAR hand dynamometer|"Clinical evaluation of the prehension force using a JAMAR Dynamometer.
The prehension effort is made with the arm along the body, forearm horizontal, elbow flexed at 90 degrees, wrist in neutral position. The handle of the dynamometer is set to the second notch. The effort required is maximum effort.
Verbal encouragement is given during four successive tentative: the last three are averaged.
Each effort will be separated by a rest period of one minute. Interval: 1 min - Repeat: 3 times per hand"
1483018|NCT03096977|Device|Vibratory sensibility testing|"Test carried out using a tuned fork applied to the styloid radial process.
Position of the evaluated: elbow to the body with forearms horizontal and the wrist in neutral position. Stimulate the tuning fork and apply it to the styloid process of the radius. Ask the patient to say when he no longer feels the vibration.
Repeat 3 times for each hand."
1483019|NCT03096977|Device|Sermes and Weinstein test|"Instrumental, quantitative method of tactile pressure sensation (dermal contact at constant pressure) using monofilaments. The monofilaments bend when a threshold force is applied to them.There is a kit of 5 monofilaments, each one corresponding to a different functional level.
Familiarize the patient with the test, eyes open, on a normal healthy side. Determine the level of perception of the healthy side, eyes closed. Start with the finest monofilament. If the answer is negative, go to the next monofilament.
The monofilaments applications are randomly made in the Wynn Parry areas, 3 times / area for blue and green filaments, then 1 time / zone for others.
The monofilament must be applied in 1.5 sec, held 1.5 sec, removed in 1.5 sec. The patient must give a verbal response yes when he perceives the contact and the response time must be less than 3 sec."
1483020|NCT03096977|Device|Weber test|"Evaluate the discrimination of 2 motionless points. The tactile discrimination threshold is the smallest distance separating 2 simultaneous stimulations that are located and perceived separately.
The pressure stops at the whitening of the skin. The patient should specify if he feels one or two spikes.
To determine the discrimination threshold:
Perform 10 stimulations of the same spacing in the same area. The smallest interval for which 7 correct answers are obtained is retained as threshold value.
Perform the test 3 times."
1483021|NCT03096964|Other|Free walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
1483022|NCT03096964|Other|Nordic walking training|The training period begin for both groups, will be comprised of eight weeks of duration, with frequency of three weekly sessions. Volume (session duration in minutes) and intensity (percentage of the heart rate at second threshold ) were the same for both groups, only differing in the use (NW) or not of the poles (FW). Each session will have of the Initial Part or warming-up, the Main Part and Final Part or cooling-down.
1483023|NCT03096951|Behavioral|Prehabilitation|Prehabilitation group will receive a 4-week tele-supervised prehabilitation and a 8-week tele-supervised postoperative rehabilitation.
1483024|NCT03096951|Other|Rehabilitation|Rehabilitation group will receive World Health Organization recommendations on physical activity for health before surgery and a 8-week tele-supervised postoperative rehabilitation.
1483025|NCT03096938|Diagnostic Test|methylation markers screening|Cell-free DNA extraction from plasma samples-Bisulfite conversion of cfDNA-Determination of DNA methylation levels by deep sequencing-Sequencing data analysis
1483026|NCT03096925|Behavioral|Guided self-help|Web-based guided self-help intervention
1483028|NCT03096899|Other|Observational|Best Supportive Care
1483030|NCT03096873|Behavioral|Combined Exercise Training|The combined exercise training were consisted with 5 minutes of warm-up, 20 minutes of resistant band exercises (Upper: seated rows, biceps curl, shoulder flexion, elbow flexion, pushup; Lower: hip flexion, hip extension, calf raise, leg press, squat), 30 minutes of treadmill walking, and 5 minutes of cool-down. Intensity of the training was gradually increased from 40-50% heart rate reserve in 1-4 weeks to 60-70% HRR in 9-12 weeks.
1491403|NCT03033134|Device|BSJ003W|BSJ003W implant
1992816|NCT03292185|Drug|insulin degludec/liraglutide|Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh.
1992817|NCT03292185|Drug|insulin degludec|17 U Insulin Degludec, single dose administration under the skin in the thigh.
1992818|NCT03292185|Drug|liraglutide|0.6 mg Liraglutide, single dose administration under the skin in the thigh
1483036|NCT03096834|Biological|Pre-Filled Syringe (PFS)|subcutaneous injection of AMG 334
1483037|NCT03096834|Biological|Placebo Pre-Filled Syringe (PFS)|Subcutaneous injection of placebo
1483038|NCT03096821|Drug|ngFDS selected treatment|Treatment based on next-generation functional drug screening (ngFDS). Treatment with commercially available treatments (per package insert instructions) selected by functional drug screening. For drug screening tumor cells from bone marrow aspirates, peripheral blood, pleural effusion, or excised lymph node samples are purified over Ficoll gradient (bone marrow, peripheral blood, pleural effusion) (GE healthcare) or homogenized and filtered (lymph tissue).
2001018|NCT03253796|Biological|Golimumab QM: Period 1 (OL)|OL monthly injections of active golimumab 50 mg or 100 mg (two 50 mg injections) from Month 0 to Month 9 (Period 1, run-in)
2001019|NCT03253796|Biological|Golimumab QM: Period 2 (DB)|"DB monthly injections of active golimumab 50 mg or 100 mg (two 50 mg injections) for 12 months, or until flare (Period 2, full treatment)"
2001020|NCT03253796|Biological|Golimumab Q2M: Period 2 (DB)|"DB monthly injections of golimumab 50 mg or 100 mg (two 50 mg injections), alternating with placebo, for 12 months, or until flare (Period 2, reduced treatment)"
2001021|NCT03253796|Other|Placebo QM: Period 2 (DB)|"DB monthly injections of placebo for golimumab for 12 months, or until flare (Period 2, treatment withdrawal)"
2001022|NCT03253796|Biological|Golimumab QM: Period 2 (OL)|"OL golimumab 50 mg or 100 mg (two 50 mg injections) for 12 months (Period 2, full treatment re-started after flare)"
1483055|NCT03096769|Other|Ergonomist|The intervention consists of each surgeon meeting with an ergonomist where the ergonomist will adjust the console settings and chair height to an ergonomically optimal position.
1483056|NCT03096756|Drug|GC4702 dry powder|5 mg GC4702 mixed with approximately 270 mg of Prosolv 90 LM - SMCC (siliconized microcrystalline cellulose). Planned dose levels of GC4702 encapsulated dry powder formulation are 50, 100, and 150 mg
1483057|NCT03096756|Drug|GC4702 lipid suspension|112 mg GC4702 mixed with Miglyol 812 plus 0.5% by weight BHA plus 1% by weight of Aerosil 200. Planned dose levels of GC4702 encapsulated lipid suspension formulation are 112, 224, and 336, 448, and 560 mg
1483058|NCT03096756|Other|GC4419 IV|infused IV as a single dose of 27 mg (3 mL GC4419 at 9 mg/mL) in 247 mL normal (0.9%) saline, totaling 250 mL, over a 60minute period using a programmable pump.
1483059|NCT03096756|Other|Placebo Dry Powder|Product matches appearance of the GC4702 dry powder formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
1483060|NCT03096756|Other|Placebo lipid suspension|Product matches appearance of the GC4702 lipid suspension formulation. The Placebo will be 500 mg Miglyol 812 oil containing up to 1% of colloidal silicon dioxide in size 1 capsule.
1483061|NCT03096756|Other|Fed Condition|with 240 mL (8 fluid ounces) of tap water following a high calorie/high fat meal. Subjects assigned to the fed condition will receive a standard meal per U.S. FDA guidelines7 consisting of high calorie/high fat meal prior to dosing consisting of total calories of 800-1000 of which 150, 250 and 500-600 calories are from protein, carbohydrate and fat, respectively.
1483062|NCT03096756|Other|Fasting Condition|For the fasting condition, GC4702 will be administered following an overnight fast of at least 10 hours, with 240 mL (8 fluid ounces) of water. No food will be allowed for at least 4 hours post-dose. Water will be allowed as desired except for one hour before and after drug administration.
1483063|NCT03096756|Drug|GC4702 lipid suspension - Part 2|Two single doses of GC4702 (dose level to be selected based on Part 1 results), separated by a 7-day washout period
1483064|NCT03096743|Radiation|MR elastography|MR elastography image acquisition will be conducted on the Compact 3T MRI scanner using a modified single-shot spin-echo echo-planar imaging pulse sequence.
1483065|NCT03096743|Radiation|MRI structural brain imaging|MRI structural brain imaging will be done on the Compact 3T MRI at the same time as MR elastography.
1483066|NCT03096743|Procedure|Lumbar puncture|All patients with papilledema will get lumbar punctures with opening pressure as part of their work-up for papilledema. A small number of patients without increased intracranial pressure will receive a lumbar puncture.
1483067|NCT03096743|Other|Optical Coherence Tomography (OCT) imaging|Optical Coherence Tomography (OCT) imaging will measure the peripapillary retinal nerve fiber layer (RNFL) thickness measurements The images with enhanced depth imaging will be obtained to measure the Bruch's membrane orientation.
1483068|NCT03096743|Radiation|Optic nerve B-scan ultrasound|Ultrasound will be used to measure the optic nerve sheath diameter 3 mm posterior to the posterior scleral surface.
1483069|NCT03096730|Drug|Normal saline|Normal saline is intravenously administrated before anesthesia induction
1483070|NCT03096730|Drug|Remifentanil|Remifentanil is intravenously administrated
1483071|NCT03096730|Drug|Sufentanil|Sufentanil is intravenously administrated
1483072|NCT03096730|Drug|Dexmedetomidine|Dexmedetomidine is intravenously administrated before anesthesia induction
1483073|NCT03096730|Drug|Nalmefene|Nalmefene is intravenously administrated before anesthesia induction
1483074|NCT03096717|Diagnostic Test|colonoscopy and histology|colonic biopsies for detection of dysplasia
1483075|NCT03096704|Diagnostic Test|vitamine d dosage|dosage of vitamine D in slow transit time constipation
1483076|NCT03096691|Device|cervical pessary|Silicone rings known as arabin pessary are used to support the cervix in women with a sonographic short cervix.
1483077|NCT03096678|Diagnostic Test|Cardiac Magnetic Resonance Imaging|Using a comprehensive MR study (Function, LGE, Tissue Characterization, Strain, T1/T2 mapping) to predict the outcome of LBBB with different cardiac function.
1483078|NCT03096665|Diagnostic Test|blood test|Point of care blood analysis obtained from skin puncture
1483079|NCT03096652|Procedure|Approach for cancer resection|
1483080|NCT03096639|Device|Diaphragmatic Pacing Therapy DPTS|Subjects will undergo DPTS 3 times a day until successfully extubated with no reintubation within 48 hours.
1483081|NCT03096613|Drug|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
1483082|NCT03096587|Device|XP Endo Finisher|a flexible single use NiTi file with small diameter and no taper, changes from straight M-phase to A-phase in body temperature
1483083|NCT03096587|Device|ultrasonic activated irrigation|by Satelec,Acteon, France
1483085|NCT03096561|Diagnostic Test|blood draw from three different vessels|Patient in cardiac-arrest and cold exposure, diagnostic test: blood draw from three different vessels (central vein, artery, peripheral vein) and measuring of PR
1483086|NCT03096548|Behavioral|Sun Safety Ink! Program|The intervention will be comprised of an online skin cancer prevention training for all tattoo artists of participating studios. The training will include skin cancer rates and risk factors, tattoo rates, recommendations for sun protection practices, a rationale for the relationship of tattoo care and sun safety, and recommended communication strategies for artists to communicate skin cancer prevention to their clients. Additional printed materials (tip-card for clients, posters) to be displayed in tattoo studios, a Sun Safety Ink! website, and social media messages for tattoo studios' Facebook and Pinterest pages will be provided.
1483087|NCT03096548|Behavioral|Attention Control|Studios and artists in this attention control group will not receive the Sun Safety Ink! program. They will continue to provide standard aftercare instructions to clients. The program will be provided to them at the end of the study.
1483088|NCT03096535|Procedure|Cooling|Individualized cooling protocol.
1483089|NCT03096535|Procedure|Thermoneutral|Thermoneutral control day.
1483090|NCT03096522|Drug|Phenytoin 2% spray|Patients will undergo anal fistulotomy then they will use phenytoin 2% spray topically on the anal wound resulting from fistulotomy with each sitz bath (twice per day) untill the anal wound heals completely
1483091|NCT03096522|Procedure|Anal fistulotomy|Probing of the fistula tract followed by lay open of the tract and curettage of granulation tissue in its base
1483092|NCT03096509|Other|MISSION ABC Integrated Care clinic|The Investigators have developed a model of care incorporating key innovations for patients with asthma, COPD and undifferentiated breathlessness. This service is being implemented within Wessex CCGs.
1483094|NCT03096483|Device|OEC Elite system|Adults undergoing vascular, gastrointestinal (GI), urology or pain management procedures
1483095|NCT03096470|Procedure|anesthesia|no anesthesia
1483096|NCT03096457|Drug|Paromomycin Sulfate|topical application 2 times a day during 20 days
1483097|NCT03096457|Drug|Pentamidine Isethionate|3 Intralesional injections at days 1,3 and 5
1483098|NCT03096457|Other|Placebo|topical application 2 times a day during 20 days
1483099|NCT03096444|Drug|Ketamine Hydrochloride|2g of topical 10% Ketamine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
1483100|NCT03096444|Drug|Amitriptyline Hydrochloride|2g of topical 5% Amitriptyline will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
1483101|NCT03096444|Drug|Lidocaine Hydrochloride|2g of topical 5% Lidocaine will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
1483102|NCT03096444|Combination Product|Ketamine hydrochloride, Amitriptyline hydrochloride, and Lidocaine hydrochloride|2g of topical KeAmLi-combo (ketamine 10%, amitriptyline 5%, and lidocaine 5%) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
1483103|NCT03096444|Drug|Lipoderm Cream|2g of topical vehicle (Lipoderm) will be applied for 30 minutes on one 4x4cm area on the volar forearm in one of two study visits.
1483104|NCT03096431|Behavioral|Physical Activity|"Self-exercise: number of steps per day, per fitness tracker; self-report of daily activity.
One-to-one intervention: 30 minute sessions with licensed therapist to include warm-up, generalized strengthening, stretching."
1483105|NCT03096431|Behavioral|Cognitive rehabilitation|One-to-one intervention: 45 minutes sessions with licensed therapist to include graded cognitive tasks designed to improve executive functioning with focus on both restorative and compensatory approaches.
1483106|NCT03096418|Drug|Paclitaxel|Paclitaxel is an FDA approved medication for treatment of curable breast cancer and is available by prescription at pharmacies throughout the United States.
1483107|NCT03096405|Diagnostic Test|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus|Polymerase Chain Reaction of Methicillin Resistant Staphyloccus Aureus
1483108|NCT03096392|Drug|HDV insulin lispro 100 UNT/ML|HDV is the active excipient, added to insulin lispro. HDV binds to a portion of the insulin lispro.
1992821|NCT03292484|Biological|AR101|AR101
1483109|NCT03096392|Drug|Insulin Lispro 100 UNT/ML|Sterile Water for Injection is added to the insulin lispro, to dilute the insulin lispro equal to the HDV insulin lispro
1483110|NCT03096379|Diagnostic Test|Magnetic resonance imaging|Enterography performed via magnetic resonance imaging
1483113|NCT03096340|Drug|IT-141|Escalating doses administered in mg/m2, IV (in the vein) on days 1 and 15 of each 28 day cycle until progression or unacceptable toxicity develops.
1483116|NCT03096314|Drug|Vitamin D3|540,000 IU vitamin D3
1483117|NCT03096314|Drug|Placebo|A single, liquid enteral dose administered either orally or via naso/orogastric tube
1948794|NCT01614275|Behavioral|Technology-enhanced Early Intensive Behavioral Intervention|After training, the ABA tutor and parents will assist in the implementation of early intervention services that will be tailored to the particular needs of the family's child. These programs could include conducting a paired-stimulus preference assessment, using a natural language program to increase spoken communication, and using matching-to-sample methods to teach categorization skills. We will record and review at least an hour of the ABA tutor's and parents' interactions with the child per week during unstructured and structured teaching situations. The purpose of these observations is to determine whether the parents are implementing the teaching strategies or behavior-management programs as designed (i.e., treatment integrity measures). If the ABA tutor or parent implements a program with less than 80% accuracy across two consecutive observations, an additional scripted role-play will be conducted as a booster session for the targeted skills.
1948795|NCT01614275|Behavioral|No-Intervention|The ABA tutors, parents/caregivers, and children will be randomly assigned to a wait-list control group.
1948796|NCT01612351|Drug|Carboplatin|Weekly carboplatin given intravenously for 6 weeks during induction chemotherapy.
1483121|NCT03096288|Drug|Evolocumab|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
1483122|NCT03096288|Other|Placebo|Patients will be randomly assigned to receive a single dose of either evolocumab 420 mg s.c. or placebo (0.9% sodium chloride s.c. injection).
1483123|NCT03096275|Drug|MMF|Patients were treated with Glucocorticoids combined with methotrexate and mycophenolate mofetil
1483124|NCT03096275|Drug|CYC|Patients were treated with Glucocorticoids and cyclophosphamide sequentially with azathioprine
1483125|NCT03096275|Drug|Glucocorticoids|Patients in the experimental group and comparator group were treated with Glucocorticoids and then gradually tapered
1483126|NCT03096275|Drug|MTX|Patients in the experimental group are treated with Glucocorticoids combined with MTX and MMF
1483127|NCT03096275|Drug|AZA|Patients in the active comparator group were treated with Glucocorticoids combined with CYC followed by AZA
1483128|NCT03096262|Behavioral|Output-Focus Condition|Users are asked to tag more, and force feedback is exerted the more points the user has
1483129|NCT03096262|Behavioral|Input-Focus Condition|Users are asked to tag more and force feedback is exerted based on the number of images the user has analyzed.
1483130|NCT03096249|Drug|Oxytocin|Syntocinon nasal spray: single dose of 24IU (3 puffs of 4IU per nostril)
1483131|NCT03096249|Other|Placebo|Placebo spray: single dose (3 puffs per nostril).
1483132|NCT03096236|Device|EFTR|EFTR with the FTRD developed for gastric resection (gFTRD).
1483133|NCT03096223|Drug|KHK4083|IV administration
1483134|NCT03096210|Procedure|Titanium-Prepared Platelet Rich Fibrin|Blood samples were collected from the each participant's arm in the test group by 20 ml syringe and then was transferred into 10ml grade IV titanium tube without anticoagulant. After centrifugation of blood samples (2800 rpm, 12 minutes) at room temperature, the T-PRF clot was removed from the tubes with sterile tweezers. 6 blood tubes were collected for a sinus floor elevation/lifting operation and 6 T-PRFs were prepared for each participant.
1483135|NCT03096210|Procedure|Allograft|After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
1483136|NCT03096197|Device|Exoskeleton-Assisted Walking|Exoskeleton-Assisted Walking (EAW) is an activity based therapy. Each group will receive 60 minutes of robotic intervention training per session, for a total of 80 sessions.
1483137|NCT03096197|Device|Transcutaneous Lumbosacral Stimulation (TLS)|EAW+TLS. This group will receive 60 minutes of exoskeleton assisted overground walking with simultaneous Transcutaneous Lumbosacral Stimulation (TLS) followed by 15 minutes of overground training without exoskeleton.
1483138|NCT03096184|Drug|Apatinib Mesylate Tablets|500 mg qd.p.o. every day for 21 days as a cycle
1483139|NCT03096184|Drug|Tegafur Gimeracil Oteracil Potassium Capsules|50mg bid p.o. every day for 14 days as a cycle
1483140|NCT03096171|Behavioral|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 16 weeks, with trainings of 20 minutes, four times a week.
1483141|NCT03096158|Other|Functional Electrical Stimulation (FES)|"Early cardiac rehabilitation after coronary artery bypass graft:
FES (Physiological Electrical stimulator - LYNX - FMUSP, São Paulo, Brazil) will be applied at a frequency of 80 Hz with a 0.5 ms pulse width, a 5 s contraction time, a 10 s rest time and at the maximum tolerable intensity for 20 minutes/session during the period of hospitalization of the participants, to perform a full knee extension. Self-adhesive electrodes will placed on the inguinal region and on the vastus medialis and vastus lateralis of the femoral quadriceps of both thighs, which caused alternating contractions between the lower limbs to full extension of knees, placed at 60o of flexion. It will be occur once per day until the hospital exit."
1597545|NCT02254122|Drug|Placebo|
1483142|NCT03096158|Other|Ventilatory Muscle Training (TREMVEN)|"Early cardiac rehabilitation after coronary artery bypass graft:
The enrolled participants will perform IMT or P-IMT for 20 minutes during the period of hospitalization, using the Power Breathe device (POWERbreathe International LTD). During training, subjects will be instructed to maintain diaphragmatic breathing at a rate at 15 to 20 breaths/min. The inspiratory load will be set at 30% of maximal static inspiratory pressure (PImax). It will be occur once per day until the hospital exit."
1483143|NCT03096158|Other|Aerobic Training (AERO)|"Early cardiac rehabilitation after coronary artery bypass graft:
It will consist of supervised walking, lasting 20 minutes a day, during the period of hospitalization of the participants. Heart rate (HR) will be constantly monitored through a cardiac monitor (Polar), with the objective of maintaining between 50 and 60% of the maximum HR predicted by age; Similar to 40 to 50% of VO2max. Blood pressure, SpO2 and level of dyspnea (Borg's effort perception scale) will also be monitored constantly. It will be occur once per day until the hospital exit."
1483144|NCT03096158|Other|Isometric Handgrip Training (ISO)|"Early cardiac rehabilitation after coronary artery bypass graft:
Study participants will perform 5 x 2 min alternating bilateral contractions of the hand flexor muscles at 30% maximum voluntary contraction with one minute rest between contractions, in a total of 20 minutes training during the period of hospitalization. It will be occur once per day until the hospital exit."
1483145|NCT03096145|Behavioral|Telephone counseling 1 session|1 call coaching session for nonsmokers that will be piloted and adapted in this study
1483146|NCT03096145|Behavioral|Mobile texting|nonsmokers will receive 3-5 text messages for 4 weeks
1483147|NCT03096145|Behavioral|Health incentive|Smokers receive a $25 gift card if they call the quitline
1483148|NCT03096132|Behavioral|Family Based Behavioral Treatment|Treatment includes 20 90 minute visits over 6 months which include 60 min parent and child separate groups and 30 min behavioral coaching. FBT includes information regarding nutrition and physical activity, as well as behavior therapy skills, including parenting skills, self-monitoring, problem solving skills, motivation systems, emotional regulation, stress management, stimulus control, and relapse prevention.
1483149|NCT03096132|Behavioral|Guided Self-Help Fam. Based Bx Treatment|Treatment includes 14 20 minute visits over 6 months. gshFBT is delivered to parent/child dyads and includes the same content in the FBT groups but it is provided in a manual. The 20-minute visits focus on clarifying information in the manuals, collecting weight and self-monitoring logs, and problem solving any barriers to implementation.
1483150|NCT03096119|Other|home blood pressure measurement|We ask participants to measure their home blood pressure 7 days or more.
1483151|NCT03096093|Biological|ACIT-1|Cell suspension
1483152|NCT03096080|Drug|Tesevatinib|One dose of the study drug in liquid form
1483153|NCT03096067|Other|Heavy slow resistance training|Resistance training for knee extensors. The exercise will be performed at 90% of 1 RM and slowly (6 s/repetition).
1483154|NCT03096067|Other|Moderate slow resistance training|Resistance training for knee extensors. The exercise will be performed at 55% of 1 RM and slowly (6 s/repetition).
1483155|NCT03096054|Drug|LY3143921 hydrate|LY3143921 hydrate will be administered orally on a daily schedule. Each cycle of treatment will consist of 21 days, and patients may initially receive up to 12 cycles. If the patient is benefitting, they may continue beyond 12 cycles.
1483156|NCT03096041|Device|Auriculotherapy for analgesic use|The ASP will be applied to specific pain points
1483157|NCT03096041|Device|Placebo auriculotherapy|The ASP will be applied to placebo points (not specific to pain)
1483158|NCT03096028|Other|maternal vitamin B12 folate level during pregnancy|Maternal Vitamin B12 and folate level at 18&28 weeks of pregnancy is the primary exposure of interest
1483159|NCT03096015|Behavioral|Intensive Comprehensive Aphasia Program|
1483160|NCT03096002|Behavioral|Lifestyle change|The 3-week lifestyle change program will introduce participants to a regular healthy lifestyle including exercise and dietary changes for reducing sugar intake, reducing refined/processed carbohydrate intake, increasing vegetable consumption. The 3-week program will include six supervised exercise sessions and three exercise sessions performed independently (e.g., at home or outside of the lab). The supervised session will include brief behavioral counseling sessions that teach participants self-regulatory skills to promote independence and long-term adherence to exercising and dietary changes.
1483161|NCT03095989|Behavioral|Mindfulness|The structure of the protocol incorporates key features of Langer's mindfulness theory. Many of the tasks and exercises have demonstrated increased mindfulness in the general population and have been modified to incorporate ALS-specific exercises that make sense from patients and caregivers' points of view. The intervention provides easily understood multimedia (video and written) presentations of the framework of mindfulness and the aims of the planned tasks. The general structure of the protocol mixes different mindfulness elements; for every week there is a specific topic examined in depth. These topics are: Attention to variability; Positive and negative events; Unpredictability; Sense Making; and Novelty seeking / novelty producing. The overall duration of the protocol is 5 weeks.
1483162|NCT03095976|Procedure|Amnion-Chorion allograft membrane on the root surface of periodontally diseased site.|Application of Amnion-Chorion allograft membrane (ACM) on the root surface of periodontally diseased teeth in conjunction with corticocancellous allograft bone substitute covered by ACM in a combination GTR treatment of periodontal intrabony and furcation defects
1483163|NCT03095963|Other|a mixture of highly charged Lactobacilli and Bifidobacteria (VSL#3®)|Patients assigned to the study group took the probiotic supplement VSL#3® for two months, in addition to levothyroxine
1483164|NCT03095963|Drug|levothyroxin|replacement therapy for hypothyroidism
1483165|NCT03095950|Other|News items with spin|Interpretation of news items with spin
1483166|NCT03095950|Other|News items without spin|Interpretation of news items without spin
1483167|NCT03095924|Other|News items with spin|Interpretation of news items with spin
1483168|NCT03095924|Other|News items without spin|Interpretation of news items without spin
1483169|NCT03095911|Other|News items with spin|Interpretation of news items with spin
1483170|NCT03095911|Other|News items without spin|Interpretation of news items without spin
1483171|NCT03095898|Device|Electroacupuncture|Acupuncture is a form of alternative medicine and is used worldwide for different indications, mainly for pain management. It relies on the stimulation of specific acupuncture points along the skin of the body using thin needles.
1483172|NCT03095885|Other|Oxalate-rich Test Meal|
1483173|NCT03095872|Device|CO2-laser|Patients with photo-damaged skin are treated with the CO2 laser to remove damaged skin layers.
1483174|NCT03095872|Drug|Vaseline|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Vaseline, and be marked V. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Vaseline. In the next seven days the patient will repeat the treatment every day at home."
1483175|NCT03095872|Drug|Bepanthen|"After the laser treatment, the wound area will be divided into two parts with a sterile skin marker. One area will be treated with Bepanthen® Wund- und Heilsalbe, and be marked B. Thus, it is ensured that the care product will be applied correctly to the defined area. Postoperatively, this area of the wound will be treated with Bepanthen® Wund- und Heilsalbe. In the next seven days the patient will repeat the treatment every day at home."
1483177|NCT03095846|Procedure|Cooling|Individualized cooling protocol
1483178|NCT03095833|Other|Odors|"Four odors are available: milk chocolate, dark chocolate, pineapple and apricot.
In addition, a neutral odor will be used clean air, a control odor transmitted during the task by the olfactometer in the same way as the other 4 odors, the only variant being that no odor will be deposited in the U-tube containing the smells. The images corresponding to the odors will be displayed after the odor has been proposed."
1483179|NCT03095833|Other|Visual stimulation|Concerning behavioral passes, the subjects will be in front of a computer screen on which the task will be presented. For fMRI passes, the visual stimulation of the participant is done by a mirror system placed about 10 cm from the participant's eyes, allowing him to watch a translucent screen on which the visual stimuli are projected. The latter have an intensity similar to that of television images, and therefore below the maximum permitted by labor legislation. The stimuli will be projected via a video projector located at the back of the imager.
1483180|NCT03095833|Other|Experimental Task|"The olfactory sensitivity and the olfactory identification capacities of the subjects will be evaluated using the ETOC test. Subjects will have to define his state of hunger/satiety thanks to a questionnaire of hunger. Finally, subjects should assess the hedonic nature of the odor and the edibility of the odor source. The task to be performed will be the same for the behavioral study as for the imaging study. The subject will receive instruction from the following three: indulge yourself, the subject must think of the desire to eat the food that will be presented to him in olfactory and visual form; Be natural, the subject must act as naturally as possible; Or hold back, the subject must distance themselves from their desire to eat and control themselves. In a second step, an odor will be presented for 5 seconds. This will be based on the subject's inspiration, then an image associated with the odor will be presented for two seconds."
1483181|NCT03095833|Other|Blood tests|Before and after the imaging examination, a blood sample will be taken by a medical imaging manipulator affiliated with the CERMEP whose actions will be remunerated in accordance with the usual hygiene and safety rules. The samples taken will then be annotated with the subject code and kept at the CERMEP. The volume of ghrelin sampling is 5 ml (10 ml for two samples). The volume of the leptin is 5 ml (ie 10 ml for two samples).
1483182|NCT03095833|Other|Questionnaires and test administered|The proposed questionnaires respond to all ethical aspects established by international and national standards to undertake studies on human subjects. Two types of questionnaires will be used in this experiment: Inclusion of the Subjects and Exploratory Tests.
1483183|NCT03095833|Other|fMRI|The purpose of the imaging part is to determine how high-level cognitive control (the setpoint) can affect the price of a food and the olfactory and visual perception of these foods in healthy subjects and Prader-Willi patients.
1483184|NCT03095833|Other|Odors 2|To modify the floral character of the wine used, the investigators will use the β-ionone odorant molecule (4 (2,6,6-trimethyl-1-cyclohexenyl) -3-buten-2-one (CAS number 14901-07-6) Purity ≥97.0% (Fluka) This molecule is commonly found in wines with a violet odor.
1483185|NCT03095833|Other|Images|The visual stimulation of the subject will be done by a system of mirrors placed about 10 cm from the subject's eyes allows him to look at a translucent screen behind the MRI scanner and on which the visual stimuli are projected.
1483186|NCT03095833|Other|Experimental Task fMRI|For each test the subjects will receive at the same time an image on the screen and a sample of wine (2 ml) delivered in the mouth of the subject thanks to the system of programmable pumps.
1483187|NCT03095833|Other|Genotyping for susceptibility to β-ionone|Sampling will be done by the subject himself by scratching and firmly pressing into the oral cavity, specifically at the cheeks and tongue for one minute, being careful not to touch the teeth and gums.
1483188|NCT03095833|Other|Experimental Task 2|The investigators will determine how perceptual judgments are modulated by cross-modal stimuli, as well as metacognitive judgments (how individuals judge their own sensory performance). In addition, they will determine how perceptual judgments are modified in the context of group decisions and how language influences performance.
1483189|NCT03095820|Behavioral|Usual care management|Usual care management (UCM) which is a standard mental health care management in the community was a telephone(once a week) and home-delivered(once a month) supportive psychotherapy administered in 12 weekly sessions that focus on non-specific therapeutic factors such as facilitating expression of affect, conveying empathy, and imparting optimism.
1483190|NCT03095820|Behavioral|Lifestyle modification with contingency management|Based on SIGN guidelines for non-pharmaceutical management of depression, the investigators developed 4 area of lifestyle modification with contingency management including physical activity, healthy diet, social activity and emotional regulation. To maintain the motivation of participants, the investigators applied prize-based contingency management for each lifestyle modification goal. The investigators provided once a week of telephone-check and once a month of visit-check during the follow-up period for 12 weeks.
1483191|NCT03095807|Drug|NNC9204-1706 A|Administered subcutaneously (s.c., under the skin) Up to 7 dose cohorts will be investigated.
1483192|NCT03095807|Drug|Placebo|Administered subcutaneously (s.c., under the skin)
1483266|NCT03095339|Other|Educational package|The educational package was offered to 30 villages post randomization. The field team completed the SARAR PHAST with community members for 2-3 days in each intervention village. The movie was projected every night for 2-3 days in each intervention village.
1597546|NCT02254122|Device|Respimat®|
1483193|NCT03095794|Other|How people learn another's value preference during decision under risk|The aim of this study is to investigate how an agent learns another's value preference when they should make decisions on behalf of another. This experiment consists of 3 parts(i) measuring individual's loss aversion; (ii) feedback based learning of another's value preference; (iii) and decisions on behalf of others.
1483194|NCT03095794|Other|Neural mechanism of making a group decision under risk that influences on in-group members|how individuals evaluate the risk and the outcome when they should make a single agreement decision in a group that will influence every member's payoff regardless of individuals' decisions. For the first part of the experiment, we will measure the individual level of loss aversion which will be used as the parameter for controlling individual differences.
1483195|NCT03095794|Other|Neural mechanism of making a group decision that influences on out-group members|Human is decimated with other species by delegation of one responsibility. Although the person who has no-interests with the outcome of decision, they should make a delegated decision. Therefore, this decision has influences on others who are not part of the group. The third party punishment (Juries decision making) is one example of the decision made by a group influencing the out group members.
1483196|NCT03095794|Other|fMRI|For neuroimaging passes, the expected duration of each of the experimental protocols is about 1h30 for tasks 1 and 2 and about 2h for task 3. The maximum period foreseen for neuroimaging tests is 3 years and will start as soon as possible. Completion of the behavioral tests.
1483197|NCT03095781|Drug|XL888|Given PO
1483198|NCT03095781|Biological|Pembrolizumab|Given IV
1483199|NCT03095768|Other|Lifestyle Education and Cooking Demonstration|Participants will receive an interactive cooking demonstration as well as healthy lifestyle education
1483200|NCT03095755|Other|Ischemic Conditioning|Inflation of blood pressure cuff to 225 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
1483201|NCT03095755|Other|Sham|Inflation of blood pressure cuff to 25 mmHg on paretic leg. 1 session: 5 minutes of inflation, 5 minutes deflation, repeated 5 times. Maximum 12 sessions over 4 weeks.
1483202|NCT03095742|Diagnostic Test|Low MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
1483203|NCT03095742|Diagnostic Test|High MAP|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein
1483204|NCT03095729|Other|Neuropsychological tests|A battery of tests to evaluate the overall cognitive performance of the subjects (memory, executive, attentional or instrumental functions)
1483205|NCT03095716|Other|laparoscopic surgery|Impact of intraperitoneal pressure and warmed, humidified CO2 gas on clinical outcomes after laparoscopic surgery for uterine prolapse in patients aged ˃75 years
1483206|NCT03095703|Drug|Sirolimus|Participants will be given sirolimus tablets. The starting dose is 2 mg once daily which will be given in 1mg tablets. On day 7 the first trough level is measured (using the LC-MS/MS method) and if not within the target range of 5-8ng/ml, dosing adjustments are made. In case of dosing adjustments, the next trough level is measured seven days later and this is repeated weekly until the target range is achieved. In case trough levels are within the target range, the next trough level measurement is at month 3, after which dosing adjustments are made if necessary, and at month 6. The maximum daily dose is 40mg. No placebo is given.
1483207|NCT03095690|Other|High resolution peripheral scanner (HRpQCT).|radius and tibia osteodensitometry measurement
1483208|NCT03095677|Other|Program of training with exercises including apnea|16 training session on cycle ergometry with exercises including apneas.
1483209|NCT03095677|Other|Program of training with exercises without apnea|16 training session on cycle ergometry with exercises without apnea
1483210|NCT03095664|Behavioral|Intervention group|A behavior change program with 4 monthly 90-min sessions about healthy eating and physical activity.
2001026|NCT03251313|Combination Product|JS001 120mg+GP|In this arm, JS001 120mg will be given at d1; Gem 1000mg/m2 d2,9; DDP(cisplatin) 75mg/m2 d2
2001027|NCT03251313|Combination Product|JS001 240mg+GP|In this arm, JS001 240mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
2001028|NCT03251313|Combination Product|JS001 480mg+GP|In this arm, JS001 480mg will be given at d1; Gem 1000mg/m2 d2,9; DDP 75mg/m2 d2
1483218|NCT03095638|Drug|Conventional dolutegravir 10 mg tablet|Single dose of five 10 mg DTG tablets will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
1483219|NCT03095638|Drug|Conventional dolutegravir 50 mg tablet|Single dose of one 50 mg tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 1. DTG will be a white, round shaped, biconvex tablet.
1483220|NCT03095638|Drug|Dispersible dolutegravir 5 mg tablet|Single dose of five 5 mg DTG tablets will be administered as dispersed in water or direct to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
1483221|NCT03095638|Drug|Conventional dolutegravir 25 mg tablet|Single dose of one 25 mg DTG tablet will be administered directly to mouth with 240 mL of water in the morning to randomized subjects in fasting state present in Part 2. DTG will be a white, round shaped, biconvex tablet.
1483222|NCT03095612|Drug|Selinexor|Oral XPO1 inhibitor selinexor (KPT-330) in combination with Docetaxel
1483223|NCT03095599|Biological|IVACFLU-S|Trivalent inactivated split virion influenza vaccine
1483224|NCT03095599|Other|Placebo|PBS
1483225|NCT03095586|Other|News items with spin|Interpretation of news items with spin
1483226|NCT03095586|Other|News items without spin|Interpretation of news items without spin
1483227|NCT03095573|Device|Lateral-viewing CapsoCam device|Small bowel capsule endoscopy examination with the Lateral-viewing CapsoCam device
1483228|NCT03095573|Device|Axial-viewing capsule|Small bowel capsule endoscopy examination with the Axial-viewing capsule device
1483267|NCT03095326|Dietary Supplement|Zinc|formula of ZnSO4, usually used to treat zinc deficiency.
1483229|NCT03095560|Device|NIRVANA|Nirvana is the first device based on optoelectronic infrared sensors, though which the patient can simply interact through his movements. The rehabilitation exercises with audio-visual stimuli and feedback involve the perceptual-cognitive skills of patients, resulting in a motivational training. Several modes and increasing levels of difficulty characterize each exercise, so the therapist can use a pre-defined rehabilitative solution or new ones, according to patient's needs. The results achieved during rehabilitation allow the therapist to evaluate the patient's actual progress, and then to modify the rehabilitation program. The system is connected to a projector or a big screen (put in front of the patient), reproducing an interactive series of exercises (for trunk, upper and lower limbs, and cognition), thanks to an infrared video camera analyzing the patient's movements, it creates interactivity.
1483234|NCT03095534|Behavioral|3-Step Workout for Life|a 10-week moderate exercise program
1483235|NCT03095521|Drug|Angal, lozenges [menthol],|Angal, administered per 1 lozenge, with an interval 2 hours or more, 6-10 lozenges per day, for a maximum 4 days or until full illness resolution.
1483236|NCT03095521|Drug|ANTI-ANGIN® FORMULA|"0,2 mg + 2 mg + 50 mg (LLC Valeant, Russia). Administered per 1 lozenge, with an interval 2 hours or more, up to 6 lozenges per day, for a maximum 5 days or until full illness resolution."
1483237|NCT03095508|Drug|Angal S, topical spray [Menthol]|0,5 mg + 2 mg (Sandoz d.d., Slovenia), administered as three to five consecutive presses on the actuator button, 6-10 times per day, for a maximum 4 days or until full illness resolution
1483238|NCT03095508|Drug|ANTI-ANGIN® FORMULA, topical metered spray|"0,12 mg + 0,24 mg (LLC Valeant, Russia) administered as one to two consecutive presses on the actuator button, up to 6 times per day, , for a maximum 5 days or until full illness resolution"
1483239|NCT03095495|Device|Heated Humidified High Flow Nasal Cannula|HHHFNC therapy is a simple to use system that delivers warm and moist air/oxygen mixture at high flow rates that generate positive airway pressure
1483240|NCT03095495|Device|Standard Therapy (Low Flow Nasal Cannula)|will be used only if the patient needs oxygenation and Rescue HHHFNC will be used if the patient needs PICU
1483241|NCT03095482|Device|Transcranial Direct Current Stimulation (tDCS)|Participants will receive 20 minutes of either active or sham tDCS prior to in vivo exposure to feared targets.
1483242|NCT03095482|Behavioral|In vivo exposure therapy|Participants will receive 30 minutes of in vivo exposure to feared targets following either active or sham tDCS
1483243|NCT03095469|Drug|Dexmedetomidine|when the operation begin,dexmedetomidine will be pumped at 0.4μg/kg•h for 15 minutes ,then reduce the dose to 0.2μg/kg•h until 24h after PCI.
1483244|NCT03095469|Drug|0.9%NaCl solution|when the operation begin,0.9%NaCl solution will be pumped at 0.1ml/kg•h until 24h after PCI.
1483245|NCT03095456|Drug|Revefenacin|Revefenacin is administered via nebulization. Tiotropium is administered via HandiHaler®.
1483246|NCT03095456|Drug|Tiotropium|Tiotropium is administered via HandiHaler®. Revefenacin is administered via nebulization.
1483247|NCT03095443|Other|Music Therapy - Personalized Playlist|Participant receives personalized playlist.
1483248|NCT03095443|Other|Music Therapy - Standard Playlist|Participant receives a standard low beats per minute playlist.
1483249|NCT03095443|Other|Attention Control|Participant receives an audio-book.
1483250|NCT03095430|Device|Monitoring|Monitoring
1483251|NCT03095417|Behavioral|Physical Exercise Intervention|In home exercise intervention.
1483252|NCT03095417|Behavioral|Cognitive Training Intervention|Online cognitive training modules.
1483253|NCT03095417|Behavioral|Stretching Control|In home stretching and healthy aging discussion.
1483254|NCT03095417|Behavioral|Cognitive Control|Online puzzles and games.
1483255|NCT03095404|Drug|Low Dose Lidocaine|60 cc syringe with 2 vials of 1% lidocaine (40cc's) low dose solution using adjusted body weight formula
1483256|NCT03095404|Drug|High Dose Lidocaine|60 cc syringe with 2 vials of 2% lidocaine (40 cc's) high dose solution using adjusted body weight formula
2001029|NCT03251313|Combination Product|GP followed by JS001|In this arm,Patients receive 6 cycles of GP without JS001 and then receive JS001 maintenance therapy for up to approximately 2 years. JS001 will be given at RP2D.
1483258|NCT03095378|Procedure|Control|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with scaling and root planing
1483259|NCT03095378|Procedure|citric acid plus tetracycline|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with citric acid plus tetracycline
1483260|NCT03095378|Procedure|antimicrobial photodynamic therapy|Periodontal plastic surgery aiming root coverage by palatal connective tissue graft. Root treatment with antimicrobial photodynamic therapy
1483261|NCT03095365|Other|Dry needling|Insertion of solid filament needles in the muscle
1483262|NCT03095365|Other|Pain neuroscience education|Explanation of the functioning of the central nervous system, the differences between acute pain and chronic pain and the importance of thoughts and beliefs in the processing and chronification of pain
1483263|NCT03095365|Other|Conventional treatment|Electrotherapy: Transcutaneous electrical nerve stimulation and microwaves
1483264|NCT03095352|Drug|Carboplatin, Pembrolizumab|Treatment will be continued until clear progression is documented using RECIST, or until unacceptable toxicity or withdrawal of consent. Patients who are believed to have pseudoprogression based on irRECIST may continue on study therapy after consultation with the study PI. Patients on Arm A may stop carboplatin after a minimum of 6 cycles to minimize toxicity if they have stable or responding disease per physician discretion and will continue maintenance pembrolizumab 200 mg IV every 3 weeks. If patients on Arm A discontinue carboplatin before 6 cycles due to reasons other than progressive disease, the possibility of continuing pembrolizumab 200 mg IV every 3 weeks should be discussed with the study PI.
1483265|NCT03095352|Drug|Carboplatin|Treatment will be continued until clear progression is documented using RECIST, or until unacceptable toxicity or withdrawal of consent. Patients who are believed to have pseudoprogression based on irRECIST may continue on study therapy after consultation with the study PI.
1597549|NCT02254096|Drug|BIRT 1696 BS|
1483270|NCT03095326|Biological|PPV Vaccine|Pneumococcal polysaccharide vaccine
1483271|NCT03095313|Other|18F-NaF PET and CT scanning|"At baseline all subjects will undergo dual cardiac and respiratory-gated PET-CT imaging of the heart and aortic valve. A target dose of 125 MBq 18F-NaF will be administered intravenously. 125ml of iodine-based contrast agent (iohexol [Omnipaque™]) will be given for the CT. Nitroglycerin will be given to increase the size of the coronary arteries and a possible dose of metoprolol may be given to control target heart rate.
Repeat contrast-enhanced CT of the heart and aortic valve will be conducted at Year 2 to investigate to investigate whether 18F-NaF activity predicts progression of calcification in prosthetic valves."
1483274|NCT03095274|Drug|Durvalumab|Durvalumab, 1500 mg Q4W for 12 months.
1483275|NCT03095274|Drug|Tremelimumab|Tremelimumab 75 mg Q4W for up to 4 doses/cycles.
1483276|NCT03095261|Behavioral|Web-based exercise diary|All participants will have access to a web-based exercise tracking tool called ExTracker. Individuals will be asked to submit their exercise diaries daily for 52 weeks, using the ExTracker program. Upon entering exercise information, participants will receive individual (e.g., You've completed 50% of your exercise sessions this week!) and group-level (e.g., You and the other people in this study are walking across Canada! Next stop - Toronto!) feedback. Should participants cease to use the platform for one week, they will receive an email reminder to re-engage with the platform. Three such emails will be sent to lapsing participants.
1483277|NCT03095261|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, and track the steps per day and bout minutes of MVPA per day measured by the device. Additionally, participants will be mailed an accelerometer (and asked to return their used ones) at study weeks 26 and 52 in order for the researcher to confirm the data inputted into the ExTracker from the device.
1483278|NCT03095261|Behavioral|Virtual Reward|"Participants will earn 'virtual rewards' (i.e. a heart badge) each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'financial incentive' therapy, for six months."
1483279|NCT03095261|Behavioral|Financial Incentive|"Participants will earn financial incentives each day they track their exercise, for the first six months of the study. In the second six months, participants will crossover to the other therapy, the 'virtual rewards' therapy, for six months."
1483280|NCT03095248|Drug|Selumetinib|Continuous twice daily dosing; oral agent
1483281|NCT03095235|Dietary Supplement|Dietary riboflavin|Dietary riboflavin is vitamin B2. It has been shown to be safe in children in the treatment of migraines at doses of 400 mg per day. There are no known documented side effects
1483282|NCT03095222|Drug|Ketamine|To be given as intravenous infusion. Ketamine infusions will be started at 5 mg/hr and can be increased by nursing staff based on patient-reported pain relief up to a maximum hourly rate of 20 mg/hr.
1483283|NCT03095222|Drug|Opioids|Standard of care for pain management.
1483284|NCT03095209|Drug|Carboplatin|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
1483285|NCT03095209|Drug|Paclitaxel|chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks (maximum 12 weeks post-CRT) after finishing CRT with surgical aspects determined by the treating surgical oncologist.
1483286|NCT03095209|Radiation|Radiation Therapy|The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer.
1483287|NCT03095196|Device|Multipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via multipolar left ventricle lead, in failing heart patients treated by maximal drug therapy.
1483288|NCT03095196|Device|Bipolar CRT-d, plus conventional drug therapy for HF.|A random CRT-d implant performed via bipolar left ventricle lead (group B), in failing heart patients treated by maximal drug therapy.
1483289|NCT03095196|Drug|HF drugs|full medical therapy to treat HF symptoms and its progression.
1483290|NCT03095183|Device|Grape flavored Puritan Junior tongue depressor|
1483291|NCT03095183|Device|Traditional unflavored Puritan Regular Tongue Depressor|
1483292|NCT03095170|Behavioral|Computerized brain fitness training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program.
1483293|NCT03095170|Behavioral|Yoga|Will use adapted Hatha Yoga where participants sit on armless chairs placed on sticky mats for some asana (poses) and use the chair for support throughout. This adapted Hatha Yoga style is appropriate for older adults including those who have limited mobility, use walkers or are in wheelchairs. The appropriately sequenced yoga practice meets the American College of Sports Medicine recommendation for older adults for muscle strengthening and flexibility. Instructions are modeled for the participants
1483294|NCT03095170|Behavioral|Wellness Education|The education component will involve daily 60-minute group sessions with topics such as Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
1483295|NCT03095170|Behavioral|Support Group (patient and partner)|Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
1483296|NCT03095170|Behavioral|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.
Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
1483349|NCT03094780|Behavioral|Quality of life counseling|Will receive quality of life counseling from PI, social workers, and physical therapists
1483297|NCT03095157|Dietary Supplement|fractionated marine lipid concentrate derived from anchovy and sardine oil|Patients will be randomized to receive perioperative treatment versus placebo
1483298|NCT03095144|Device|Spinal anesthesia|Pyloromyotomy under spinal anesthesia
1483299|NCT03095144|Device|General anesthesia|Pyloromyotomy under general anesthesia
1483300|NCT03095131|Device|Heart Spectrum Blood Pressure Monitor|The Heart Spectrum Blood Pressure Monitor provides a convenient and effective filtering application compared with traditional methods that require a visit to a physician for a 12-lead ECG.
1483302|NCT03095105|Drug|200 mg BIA 6-512|capsules containing BIA 6-512 200 mg was administered orally, with 240 mL of mineral water without gas at room tempera¬ture
1483303|NCT03095092|Drug|BIA 6-512 400 mg|4 capsules of BIA 6-512 100 mg / oral administration with 240 mL of potable water .Subjects were administered a 400 mg BIA 6-512 single-dose on two different occasions. In one treatment period subjects were dosed with a single oral dose of 400 mg after a fasting of at least 8 hours, and in the other treatment period subjects were dosed with a single oral dose of 400 mg after a standard meal. Subjects were requested to fast overnight for at least 8 hours before product administration.
1483304|NCT03095079|Drug|recombinant human endostatin|"Cisplatin:dose was based on patient's weight and could be adjusted for weight change,75 mg/m^2 by IV infusion separated in 3 different days Dacarbazine:250mg/m2,administered by intravenous (IV) infusion on the 1 to 5 day of each cycle
Hr-endostatin:dose based on body surface area as 15mg/m2,continuous intravenous infusion from day 1 to day 14"
1483307|NCT03095053|Procedure|comprehensive chromosome screening|"Biopsy Blastocysts with morphological grades of ≥2BB will be biopsied on day 4 or day 5 of in vitro embryo culture. Biopsies will be performed using using a Hamilton Thorne Zilos laser (Hamilton Thorne, MA, USA), with 3-10 trophectoderm cells removed from the blastocysts.
Comprehensive chromosome screening All trophectoderm biopsies will be processed for analysis by Next-Generation Sequencing (NGS, illumina, California, USA)."
1483308|NCT03095040|Drug|CM082 combined with everolimus|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles
1483309|NCT03095040|Drug|CM082|CM082 tablets (200 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for everolimus (2 tablets) taken orally once a day on 28-day cycles
1483310|NCT03095040|Drug|Everolimus|Everolimus tablets (10 mg, 2 tablets) taken orally once a day on 28-day cycles, dummy tablets for CM082 (2 tablets) taken orally once a day on 28-day cycles
1483311|NCT03095014|Procedure|Cesarean Myomectomy|Myomectomy was done during Cesarean section
1483312|NCT03095014|Procedure|Cesarean section|Cesarean delivery
1483313|NCT03095001|Drug|Bevacizumab|Bevacizumab 5mg/kg intraperitoneal administration every 3 weeks for 4-6 cycles
1483314|NCT03095001|Drug|Carboplatin|carboplatin AUC=5 intraperitoneal administration every 3 weeks 4-6 cycles
1483315|NCT03095001|Drug|paclitaxel|paclitaxel 175mg/m2, iv d1, every 3 weeks for 4-6 cycles
1483316|NCT03094988|Behavioral|Cognitive and physical prehabilitation|Participants engage in cognitive and physical training daily for approximately 2-4 weeks prior to surgery.
1483317|NCT03094988|Other|Active attention control|Participants will be provided with personal health educational materials and access to the control version of cognitive training program.
1483318|NCT03094962|Other|Motion capture|Capture kinematics of finger movements
1483319|NCT03094962|Diagnostic Test|MR scan|Capture MR images of hand and fingers in three postures
1483320|NCT03094962|Diagnostic Test|CT scan|Capture CT images of hand and fingers in three postures
1483321|NCT03094949|Procedure|Partial Nephrectomy|The renal capsule is cut in a monopolar fashion around the tumor. After the renal artery is clamped with a bulldog clamp, cold cutting by scissors into the renal parenchymal boundary of the tumor is performed with an optimal surgical margin (a few millimeters). After retrograde injection of diluted indigo carmine, continuous suturing of the opened collecting system and transection of the major vessels is performed with intracorporeal knot-tying. Parenchymal suturing is performed in a continuous fashion. The 20-30 cm length of thread is used, and a knot is made at the end of the thread. A large Hem-o-lok polymer clip (Weck Closure System, Research Triangle Park, NC) is attached on the proximal side of the knot. Before the thread is tightened or cinched, the parenchyma is sutured in a running fashion with three or four stitches without any bolster so that the renal bed is kept in its natural position during the suturing.
1483322|NCT03094949|Procedure|microwave ablation|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.Antenna in the microwave ablation device was percutaneously inserted into the tumor and placed at designated place under US guidance. For tumors less than 1.5 cm, one antenna was inserted and for tumors measuring 1.5 cm or greater, two antennae were inserted in parallel with an inter-antenna distance of 1.0-2.5 cm, which were used simultaneously during MWA to obtain larger ablation zone. A 20G thermocouple was inserted about 0.5-1 cm away from the tumor for real-time temperature monitoring during MWA. MW emission didn't stop until the heat-generated hyperechoic water vapor completely encompassed the entire tumor and the measured temperature reached 60°C or remained above 54°C for at least three minutes.
1483323|NCT03094936|Procedure|APC|Ablation of the dilated gastro-jejunal anastomosis with Argon Plasma Coagulation. This procedure induces cicatrization process around the stoma and propitiates its reduction.
1483324|NCT03094936|Device|Endoscopic Suture Technique (OverStitch TM)|OverStitchTM Endoscopic Suturing System. Stitches will be placed per-orally with the aforementioned device around the dilated stoma in order to reduce the diameter of the anastomosis. In this group, ablation with APC will be done immediately before suturing.
1483350|NCT03094780|Other|Video-conference quality of life counseling|Participants may video-conference to other sites to participate in group session dependent on Florida, Northfield and Arizona enrollment
1483351|NCT03094767|Other|Cardiovascular Rehabilitation|Aerobic and anaerobic exercises performed for 12 weeks, 3x/week, of 60 minutes each.
1483352|NCT03094767|Other|Initial and Final assessment|Measuring blood preassure, heart rate, Borg scale, respiratory rate, oxygen saturation and HbA1C in the first day of assessment and after 12 weeks.
1483353|NCT03094754|Procedure|nevi excision|After general anesthesia, nevi excision in children is performed.
1483325|NCT03094923|Other|Inspiratory Muscle Training|"The inspiratory muscle training (IMT) will be carried out in the IG with Threshold® IMT (Respironics New Jersey, Inc) consisting of a unidirectional flow control valve which assures the constant resistance (linear load) between 7 and 41cmH20.
The IMT will be carried out in the sitting position with a load of 30% of the MIP during the two weeks preceding the surgery, seven days a week, twice daily in three series of ten repetitions with a 30 second interval between series, under the supervision of a physiotherapist. A load of 15% of the MIP was used only on the first day of training in order for the individual to adapt to the equipment. Subsequently, the 30% MIP load will be applied and readjusted according to the new MIP values determined every four days."
1483326|NCT03094910|Diagnostic Test|Examination of vibration perception threshold in fingertips|Vibration perception threshold is examined for 7 different frequences. All fingers are examined except for the thumbs.
1483327|NCT03094910|Diagnostic Test|Ewing's tests|A battery of tests invented to diagnose the cardiac autonomic neuropathy in diabetics. Heart rate and blood pressure are measured during Valsalva maneuver, deep breathing, active standing and prolonged handgrip.
1483328|NCT03094910|Diagnostic Test|Tilt table test|Blood pressure and heart rate are measured continuously while the participant is brought to a 60 degree position and held there for 15 minutes.
1483329|NCT03094910|Diagnostic Test|Thermography|An infrared thermographic camera is applied to record temperature of the fingers of the participant before and after cooling in 10 degree water for 1 min.
1483330|NCT03094910|Diagnostic Test|123I-MIBG|123I-MIBG is injected into a vein, and an early and a late scan is performed. Regions Of Interest are selected for the heart and mediastinum, and the ratio as well as well as the Washout Rate can be determined. MIBG is a noradrenaline analogue and the examination is performed to visualize a potential imbalance of the autonomic nervous system of the heart.
1483331|NCT03094910|Diagnostic Test|Blood samples|"The blood samples will be assayed for hemoglobin, long-term blood sugar, C-reactive protein, sodium, potassium, magnesium, albumin, TSH, vitamin B and D, and ionized calcium.
Patients with suspected Raynaud's disease will be tested for anti-nuclear antibodies (ANA) to screen for underlying rheumatic illness.
Blood samples will also be drawn during tilt table testing and assayed for plasma catecholamines."
1483332|NCT03094897|Drug|18F-Al-NOTA-MATBBN PET/CT|18F-Al-NOTA-MATBBN(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
1483333|NCT03094897|Device|PET/CT|Imaging with 18F-Al-NOTA-MATBBN PET/CT.
1483334|NCT03094884|Radiation|Pulsed Low Dose Radiation|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
1483335|NCT03094884|Drug|Carboplatin|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
1483336|NCT03094884|Drug|Paclitaxel|Treatment naïve patients with non-small cell lung cancer or esophageal cancer whose planned treatment regimen is concurrent CRT followed by surgery. The total radiation dose will be 50.4 Gy in daily fraction of 1.8 Gy for esophageal cancer and 60 Gy in daily fraction of 2 Gy for non-small cell lung cancer. The concurrent chemo regimen will carboplatin-paclitaxel managed by the treating medical oncologist. Patients are planned to receive surgery at approximately 6 to 9 weeks after finishing CRT with surgical aspects determined by the treating surgical oncologist.
1483337|NCT03094871|Behavioral|FACE-PC|
1483338|NCT03094858|Device|Smartphone with prompts|Smartphone will be used to prompt randomly selected participants in intervention group to be active
1483339|NCT03094858|Device|Wristband|Wristband will monitor activity of all participants
1483340|NCT03094858|Device|Smartphone|Smartphone will be used to monitor activity but prompts will not be given to randomly selected participants
1483341|NCT03094845|Biological|Placebo solution|15 injections over 7 weeks
1483342|NCT03094845|Biological|hdmASIT+TM|15 injections over 7 weeks
1948797|NCT01612351|Drug|Paclitaxel|Weekly paclitaxel given intravenously prior to carboplatin infusion for 6 weeks during induction chemotherapy.
1483344|NCT03094819|Behavioral|Financial Incentive|Participants will receive usual care and a $25 payment if they obtain a confirmed eye examination.
1483345|NCT03094819|Behavioral|Retinal Care DR|Participants will receive: (1) point of care risk assessment for vision- threatening diabetic retinopathy, (2) retinal specialist interpretation of their risk assessment data, and (3) care coordination designed to improve the eye examination rate for patients with diabetes at increased risk for vision- threatening diabetic retinopathy.
1483346|NCT03094806|Device|Acapella Vibratory PEP Therapy Device plus usual care|The acapella® Vibratory PEP Therapy System (PEP-FV) device is a handheld device that operates in same principle as standard FV. Unlike standard FV, it is not gravity dependent. It comes in two different devices to accommodate for different flows rates of the patient. It has similar properties of a standard FV and may be better tolerated.
1483347|NCT03094806|Device|Sham Acapella Vibratory PEP Device plus usual care|The Sham Acapella Vibratory PEP Device is the same as the Therapy Device, except the flutter valve has been removed from the device.
1483348|NCT03094793|Other|abnormal EEGs|"This study consists in a scalp EEG to detect, in real time, based on measurements of reaction time and accuracy of responses (recorded every two seconds), the level of attention given by the participant in a repetitive task of constant difficulty and correlate the behavioral results to AIC identified on the EEG recording. A computer equipped for the realization of the STABILO test is already available, its connection / synchronization with standard acquisition systems EEG data is already effective through an RS232 serial port.
Included patients will see their EEG extended for fifteen minutes, during which they will carry out a computerized attentional task to evaluate the stability of the attention."
1491606|NCT03031548|Device|Point-of-care ultrasound exam|No intervention
1483354|NCT03094741|Other|CancerLife|CancerLife is a mobile digital solution that allows patients to broadcast their health status inside a private invitation only group, text, email or publicly in Facebook or Instagram. By doing, so the patient collects his/her own patient-reported outcomes data and then share this data with their doctor or care team.
1483355|NCT03094728|Diagnostic Test|HLA cross matching|"HLA Typing and Mismatch
Cross matching (total and autocross):
Cross match involves placing recipient serum onto donor lymphocytes and a cytotoxic reaction (deemed 'positive') suggests the presence of preformed donor specific antibodies (DSAs),Second, the original crossmatch should be repeated with the addition of the agent Dithiothreitol (DTT). DTT reduces the disulfide bonds in IgM thereby preventing IgM antibodies from generating a positive result."
1483356|NCT03094715|Device|Thrombectomy|Mechanical thrombectomy with state of the art thrombectomy devices (i.e. stent-retrievers, aspiration catheters). Devices will be used per instructions for use (IFU).
1483357|NCT03094715|Other|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.). If applicable, the reason for iv tissue plasminogen activator (tPA) ineligibility has to be documented on the eCRF.
1483358|NCT03094689|Other|Cold water immersion|
1483359|NCT03094689|Other|Water immersion|
2001030|NCT03251963|Drug|Fixed Dose Enoxaparin|Eligible patients will be administered 40 mg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
2001031|NCT03251963|Drug|Variable Dose Enoxaparin|Eligible patients will be administered 0.5 mg/kg enoxaparin daily and will have steady state peak and trough anti-Xa levels drawn after the third enoxaparin dose. For patients in-range (levels 0.3-0.5IUmL), no intervention will be undertaken. For patients out of range, enoxaparin dose will be adjusted according to an established dose adjustment algorithm. Repeat levels will be checked after the third administration of the new dose.
1483362|NCT03094663|Drug|Bupivacaine|0.5% with epinephrine 30cc
1483363|NCT03094663|Drug|Methylprednisolone|40 mg/ml, 1 ml
1483364|NCT03094663|Drug|Cefazolin|500 mg in 10 ml
1483365|NCT03094663|Device|8 MHz. Chiba needle|22G/ 4 inches
1483366|NCT03094663|Drug|15 cc of bupivacaine 0.25% with 2 mg of preservative free Dexamethasone|15 cc of bupivacaine 0.25% with 2 mg of PF Dexamethasone
1483367|NCT03094663|Drug|25 cc 0.25% bupivacaine|25 cc 0.25% bupivacaine
1483368|NCT03094663|Drug|20cc 0.25% bupivacaine|20cc 0.25% bupivacaine
1483369|NCT03094663|Drug|2 mg IV dexamethasone.|2 mg IV dexamethasone.
1483370|NCT03094663|Drug|bupivacaine 0.5% with epinephrine 30cc|bupivacaine 0.5% with epinephrine 30cc
1483371|NCT03094650|Device|MindMotion PRO|Patients will receive five weeks of therapy with 2 sessions (minimum) per week lasting for 45-60 minutes each minimum. The training sessions are based on the MindMotion PRO's virtual reality exercises.
1483374|NCT03094624|Other|Neuropsychological and neurophysiological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons. Neurophysiological tests consist in the recording of EEG and/or MEG signals or MRI images while realizing the neuropsychological tests, as well as anatomical MRI scanning to characterize the participants' brain anatomy and reconstruct the brain sources of surface EEG/MEG signals.
1483375|NCT03094624|Other|Experiment 1|Experiment 1 are interested in perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language.
1483376|NCT03094624|Other|Experiment 2|Experiment 2 focuses on perception and musical memory vs. Language and contribute to our understanding of the functional and structural organization of the brain to perceive and memorize music and language. The second experiment will also study short-term memory networks for musical and verbal materials, but the specificity will be the inclusion of a verbal material sung, thus representing the combination of both information. Experiment 2 is divided into two sub-parts. Indeed, the investigators will develop the musical and verbal materials during a first experimental part in experiment (experiment 2a) and then apply them in experimentation MEG (experiment 2b). Experiment 2a will allow us to test new equipment in a short term memory task under conditions that are less restrictive for the participants. Then the investigators will apply the optimal material that emerges for the MEG experiment.
1483377|NCT03094624|Other|Experiment 3|Experiment 3 will use Discordant Negativity (MMN; Mismatch Negativity) protocols in coupled EEG-MEG (experiment 3a) and EEG alone (experiment 3b) to investigate memory traces of sensory information. The MMN is used to probe auditory sensory memory (pre-requisite for short- or long-term storage), and has the advantage of being measured without requiring an active task from the participant.
1483378|NCT03094624|Other|Experiment 4|"Experiment 4 will study the neural correlates of long-term memory for musical and verbal material with fMRI. The testimonies of the amusicians suggest a deficit of the musical lexicon which contrasts with that the musical lexicon elaborated of the non-musician listeners."
1483380|NCT03094598|Other|Leaflet|The length is 1.5 A4 pages, Flesch's Reading Ease Score (RES) is 57 (fairly difficult, comparable to a quality magazine), and Human Interest Score (HIS) is 37 (interesting, comparable to a digest magazine).
1483381|NCT03094598|Other|Brochure|The length is 2.5 A4 pages, RES is 43 (difficult, comparable to an academic magazine), and HIS is 25 (interesting, comparable to a digest magazine).
1483382|NCT03094598|Other|Booklet|The length is 12 A4 pages, RES is 11 (very difficult, comparable to a scientific magazine), and HIS is 22 (mildly interesting, comparable to a trade magazine).
1483383|NCT03094585|Other|Written and oral information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.
1483384|NCT03094585|Other|Written information|The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
1483502|NCT03093753|Dietary Supplement|Test (study 3)|The test meal will comprise whole-meal bread plus 50 mg oleuropein from olives dissolved in 200 ml water
1483385|NCT03094572|Other|visual motor tasks|"This exercise involves manipulating an object that corresponds to a racket, this racket has a virtual avatar that animated a virtual ball. The purpose is to make it bounce to a given height. This comes close to ping-pong game."
1483386|NCT03094559|Device|FlowMet|The FlowMet device will be placed on the index finger of the right hand. Signal fidelity will be assured by confirming the presence of a pulse waveform if one is expected and by assuring that an appropriate amount of light is be detected by the FlowMet device. Following placement of the FlowMet device, a period of 10 seconds will be allowed to elapse to allow transient changes in perfusion due to device placement to diminish. FlowMet blood flow data will be recorded for 20 seconds using the FlowMet data acquisition software. These steps will be repeated for digits 1 and 2 on the limb with diagnosed or suspected CLI, or on both limbs if both are diagnosed or suspected of having CLI.
1483387|NCT03094546|Dietary Supplement|Polyamine|12 months of polyamine supplementation (6 capsules/day)
1483388|NCT03094546|Dietary Supplement|Placebo|12 months of placebo intake (6 capsules/day)
1483389|NCT03094533|Drug|TIVA|total intravenous anesthesia with propofol
1483390|NCT03094533|Drug|VIMA|volatile induction and maintenance anesthesia with sevoflurane
1483391|NCT03094520|Device|tDCS|Transcranial direct current stimulation (tDCS)
1483392|NCT03094520|Device|sham-tDCS|sham stimulation
1483395|NCT03094494|Other|none intervention|none intervention
1483396|NCT03094481|Procedure|SCPB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Superficial Cervical Plexus Block at C4 or C5.
1483397|NCT03094481|Procedure|ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided Interscalene Brachial Plexus Block at C5 or C6.
1483398|NCT03094481|Procedure|SCPB + ISB|Bupivacaine hydrogen chloride Inj 0.5% epinephrine. 10ml injected for US guided SCPB at C4 or C5 + 10ml injected for ISB at C5 or C6.
1483399|NCT03094481|Drug|Bupivacaine hydrogen chloride , epinephrine|Bupivacaine hydrogen chloride Inj 0.5% (1:200,000) epinephrine
1483400|NCT03094468|Drug|P-3058 (terbinafine hydrochloride 10%)|Patients will apply the P-3058 nail solution once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
1483401|NCT03094468|Drug|Vehicle of P-3058|Patients will apply the Vehicle of P-3058 once weekly in a double blind fashion. The overall treatment phase is of 48 weeks.
1483402|NCT03094455|Other|Experimental group|Observation of video sequences showing uni¬manual or bimanual goal-directed actions followed by the execution of the observed actions either with plegic upper limb for unimanual or with both upper limbs for bimanual actions.
1483403|NCT03094442|Drug|Dexamethasone|An 8 mg dose of Dexamethasone is administered at the time of induction of general anesthesia. The medication is provided by the pharmacy in a blinded syringe.
1483404|NCT03094442|Drug|Normal saline|Normal saline contains 0.9% weight/ volume of sodium chloride. It is used routinely for intravenous resuscitation and fluid maintenance. Patients in the placebo arm will receive 2 ml of normal saline in the blinded syringe provided by the pharmacy.
1483405|NCT03094429|Drug|NaBen®|2000 mg/day or 1000 mg/day, twice daily
1483406|NCT03094429|Other|Placebo|0 mg total, twice daily
1483407|NCT03094416|Drug|levothyroxine sodium capsule|patients will be switched from their current levothyroxine sodium tablet to levothyroxine sodium capsule
1483408|NCT03094403|Drug|Azelaic Acid 15% topical gel|Gel
1483409|NCT03094403|Drug|Finacea® (azelaic acid) Gel, 15%|Gel
1483410|NCT03094403|Drug|Placebo|Gel
1483411|NCT03094377|Other|Multisensory therapy|Sensory stimulation, motor training and ADL training
1483412|NCT03094377|Other|Conventional training|Motor training and ADL training
1483413|NCT03094364|Behavioral|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
1483414|NCT03094351|Procedure|esophagectomy|Robot assisted thoraco-laparoscopic esophagectomy with extended two field lymphadenectomy.
1483415|NCT03094351|Procedure|esophagectomy|Conventional thoraco-laparoscopic esophagectomy with extended two field lymphadenectomy.
1483416|NCT03094338|Behavioral|stress, psychological|students respond to questionnaires
1483417|NCT03094325|Device|Pre Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
1483418|NCT03094325|Device|Pre Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
1483419|NCT03094325|Device|Post Operative On-pump intraoperative echocardiography|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
1483420|NCT03094325|Device|Post Operative Transesophageal echocardiography (TEE) imaging|Center tendency parameters(mean, standard deviation) will be reported for each outcome.
1483421|NCT03094312|Procedure|Dynamic Spectral Imaging (ISD)|cerebral stimulation: dynamic spectral imaging (ISD)
1483422|NCT03094286|Drug|Durvalumab|Durvalumab monotherapy of 1500mg every 4 weeks in solid tumors in HIV-1-infected patients until progression significant clinical deterioration, unacceptable toxicity, any criterion for withdrawal from the trial or trial drug is fulfilled
1483423|NCT03094273|Procedure|Saucerization biopsy|2 mm saucerization biopsy of dysplastic nevi
1483424|NCT03094260|Device|High intensity bright light therapy|"Treatment with light therapy in high intensity (10,000 lux), daily for 30 days between 6 am and 9 am for 30 minutes.
Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subject is sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
1483503|NCT03093753|Other|Control (study 4)|Control meal will comprise 50 g sucrose in 200 ml water, to which the response of the test meals will be compared to
1483504|NCT03093753|Dietary Supplement|Test (study 4)|The test meal will comprise 50 g sucrose in 200 ml water plus 50 mg oleuropein from olives
1483820|NCT03091504|Drug|Albuterol Sulfate|Albuterol is a short acting inhaled bronchodilator
1483425|NCT03094260|Device|Low intensity light therapy|"Treatment with light therapy in low intensity (<500 lux), daily for 30 days between 6 am and 9 am for 30 minutes.
Le device is placed at arm's length (at approximately 50-75cm from the eyes) within the field of vision. The light must bathe the face To ensure the light reaches your eyes, this appliance has a stand that can be set to a variable angle. If subjectis sitting higher or standing and the top edge of the appliance is below eye level, the appliance will be placed in a tilted position so that its light points further upwards and reaches the eyes. If subject is sitting at a table or desk and the top edge of the appliance is above eye level. The appliance can be placed in a more upright position."
1483426|NCT03094247|Drug|Amoxicillin|All patients with severe acute malnutrition will receive a course of amoxicillin.
1483427|NCT03094247|Dietary Supplement|HO-RUTF|HO-RUTF: Milk, linseed oil, palm oil, white sugar, high oleic peanuts
1483428|NCT03094247|Dietary Supplement|D-HO-RUTF|D-HO-RUTF: DHA, milk, linseed oil, palm oil, white sugar, high oleic peanuts
1483429|NCT03094247|Dietary Supplement|C-RUTF|C-RUTF: Milk, linseed oil, palm oil, white sugar, standard peanuts
1483430|NCT03094234|Device|8mm-TIPS|Patients in this group would underwent TIPS placement with 8mm-diameter ePTFE-covered stents.
1483431|NCT03094234|Procedure|endoscopic variceal ligation (EVL)|Patients in this group would underwent sequential endoscopic variceal ligation and propranolol treatment.
1483432|NCT03094234|Drug|Propranolol|Appropriate dose of propranolol was administered to the patients.
1483433|NCT03094221|Device|Rhythmia Mapping System|Arrhythmia mapping will be performed using the Rhythmia mapping system, including its mapping catheter, either in the atria or ventricles depending on the clinical arrhythmia being treated. Detailed mapping will be performed to determine tissue voltage and arrhythmia mechanism/location according to standard clinical practice. This part of the study will take approximately 90-120 minutes. The catheter position and contact will be visualized with intra-cardiac echocardiography, which is also routinely used during these procedures, and to monitor for potential clinically related complications. Images will be recorded to establish criteria for mapping.
1483434|NCT03094208|Other|dual task balance training|balance exercises with cognitive and motor dual tasks
1483435|NCT03094208|Other|traditional balance training|balance exercises
1483438|NCT03094182|Drug|Iron Isomaltoside 1000|Randomly selected patients of the monofer group are given 1000mg of iron isomaltoside, which are mixed in 100ml normal saline, intravenous after induction for 30 minutes.
1483439|NCT03094182|Drug|Normal saline|Randomly selected patients in the control group receive an equivalent volume of normal saline as a placebo.
1483440|NCT03094169|Drug|AVID100 IV|AVID100 is administered once every 3 weeks
1483441|NCT03094156|Drug|Placebo|1 capsule of placebo [to be taken orally, with 240 mL of potable water]
1483442|NCT03094156|Drug|BIA 6-512|1 capsule of BIA 6-512 25mg or 1 capsule of BIA 6-512 50 mg or 1 capsule of BIA 6-512 75 mg or 1 capsule of BIA 6-512 100 mg [to be taken orally, with 240 mL of potable water]
1483443|NCT03094156|Drug|Madopar® 250|Levodopa/benserazide immediate release tablets 200mg/50mg [to be taken orally, with 240 mL of potable water]
1483444|NCT03094156|Drug|Comtan®|Entacapone 200 mg tablets [to be taken orally, with 240 mL of potable water]
1483445|NCT03094143|Procedure|Aortic valve intervention|The choice of either surgical aortic valve replacement or transcatheter aortic valve implantation (TAVI) will be made by the local clinical team according to local policies. In patients undergoing surgical replacement the choice of surgical technique and type of valve replacement used will be at the discretion of the operating surgeon. Patients found to have significant coronary artery disease requiring concomitant coronary artery bypass surgery will not be excluded. Similarly the choice of TAVI valve and need for percutaneous coronary intervention will be made by the TAVI heart team. The procedure should be performed as soon as possible and ideally within four months of randomisation and allocation to group A.
1483446|NCT03094130|Other|News items with spin|Interpretation of news items with spin
1483447|NCT03094130|Other|News items without spin|Interpretation of news items without spin
1483448|NCT03094117|Other|News items with spin|Interpretation of news items with spin
1483449|NCT03094117|Other|News items without spin|Interpretation of news items without spin
1483450|NCT03094104|Other|News items with spin|Interpretation of news items with spin
1483451|NCT03094104|Other|News items without spin|Interpretation of news items without spin
1483452|NCT03094091|Other|News items with spin|Interpretation of news items with spin
1483453|NCT03094091|Other|News items without spin|Interpretation of news items without spin
1483454|NCT03094078|Other|News item with spin|Interpretation of news item with spin
1483455|NCT03094078|Other|News item without spin|Interpretation of news item without spin
1483456|NCT03094065|Other|News items with spin|Interpretation of news items with spin
1483457|NCT03094065|Other|News items without spin|Interpretation of news items without spin
1483458|NCT03094052|Drug|Neratinib|
1483459|NCT03094052|Drug|Trastuzumab|
1483460|NCT03094052|Drug|Crofelemer|
1483461|NCT03094052|Drug|Loperamide|
1483462|NCT03094039|Procedure|Ventilatory support while attached to the cord|Infants will receive active resuscitative care (intubation and ventilation) using a specific designed platform for 120 seconds during delayed cord clamping. Then the cord will be clamped forgoing resuscitation care.
1483463|NCT03094039|Procedure|Immediate cord clamping|Infants will receive immediate cord clamping, transferred to the resuscitation table, intubated and mechanical ventilated according to our current Congenital Diaphragm Hernia protocol.
1483464|NCT03094026|Behavioral|Lumosity|Computer-based online cognitive training program using the Lumosity cognitive training program.
1483465|NCT03094026|Behavioral|Lumosity (waitlist control)|Computer-based online cognitive training program using the Lumosity cognitive training program. The control group will receive the intervention after a waiting period of 12 weeks.
1483466|NCT03094013|Other|Assessment|Assessment
1483505|NCT03093753|Other|Control (study 5)|Control meal will comprise 25 g sucrose in 200 ml water, to which the response of the test meals will be compared to
1483506|NCT03093753|Other|Test (study 5)|The test meal will comprise 25 g sucrose in 200 ml water plus 160 mg oleuropein from olives
1597550|NCT02254096|Drug|Placebo|
1483467|NCT03094000|Behavioral|MIND|"Both experimental and control groups receive 20 weekly sessions (1.5 hours each), based on principles of CBT-E (Fairburn, 2008), adapted for a group format .
The experimental group will receive in addition to CBT-E a mindfulness based intervention comprising of 4 weekly group sessions (1.5 hours each) during the month prior to the CBT-E program. The mindfulness skills intervention will also be practiced throughout the CBT-E program at the beginning of every group session and independently as homework. Mindfulness intervention includes formal mindfulness practice (brief mindfulness meditation - 10 minutes each) and informal mindfulness practice (Other non meditation exercises, also known as mindfulness in everyday life- eg STOP)."
1483468|NCT03094000|Behavioral|CBT-E|The comparison group (control) will receive 4 weekly supportive-educational group sessions (1.5 hours each) prior to the group CBT-E program, with no mindfulness content or training.
1483470|NCT03093974|Drug|Colistimethate Sodium|1 M units equivalent to 80 mg colistimethate sodium diluted in 1 mL saline solution 0.45%
1483471|NCT03093974|Drug|Saline Solution|1 ml saline solution 0.45%
1483472|NCT03093961|Device|IASD implant|Single arm for implant
1483473|NCT03093948|Procedure|Remote ischemic post-conditioning|Remote ischemic post-conditioning will undergo in both thighs at the beginning of targeted temperature management. This will be done with noninvasive measurement of blood pressure, with cuffs inflated to 200 mmHg for four 5 min cycles and interrupted three times for 5 min with cuff deflation.
1483474|NCT03093935|Device|StimRouter Neuromodulation System|The StimRouter Neuromodulation System is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medications). The StimRouter is not intended to treat pain in the craniofacial region.
1483475|NCT03093922|Drug|Atezolizumab|1200 mg/m^2
1483476|NCT03093922|Drug|Gemcitabine|1000 mg/m^2
1483477|NCT03093922|Drug|Cisplatin|70 mg/m^2
1483478|NCT03093909|Drug|Gemcitabine|Nebulized dose of aerosol GCB twice a week continuously (escalating treatment dose schema, starting at 0.75 mg/kg to 3.0 mg/kg). Participants receive a pre-determined volume of nebulized solution, according to the dose level and weight of the participant, with each aerosol GCB administration. One cycle is 4 weeks in duration.
1483479|NCT03093896|Dietary Supplement|snack mix|commercial cereal mix with bits of beef jerky and coconut
1483480|NCT03093896|Dietary Supplement|almonds, 1.5 oz|almonds, 1.5 oz/day
1483481|NCT03093896|Dietary Supplement|almonds, 3 oz|almonds, 3.0 oz/day
1483482|NCT03093883|Drug|Ferrinemia|Test product Ferrinemia will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
1483483|NCT03093883|Drug|Venofer|Reference product Venofer will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
2001032|NCT03249857|Behavioral|cognitive tasks + IQ + MINI|"Patients will perform different tasks:
cognitive tasks : reaction time (Alert TEA, Zimmermann and Fimm, 2005) + Edinburgh laterality questionnaire (Oldfield,1971) + hamilton and young's scale (Tohen et al., 2009) + Montreal Cognitive Assessment (MoCA) (Nasreddine et al., 2005) + experimental task (approach/ avoidance and affordance task).
Intelligence Quotient (IQ) test (PM38, Raven, 1960)
Mini International Neuropsychiatric Interview (MINI, Van Vliet et al., 2006)"
1483487|NCT03093857|Diagnostic Test|Determination of biomarker|Liquor, blood, and urine samples will be drawn and measured at different time points.
1483488|NCT03093844|Device|Miltenyi CliniMACS® CD34 Reagent System|Miltenyi CliniMACS® CD34 Reagent System will be used to prepare CD34+ enriched/T-cell depleted cells from haploidentical mobilized peripheral blood.
1483489|NCT03093831|Drug|Ibrutinib|560mg administered orally once daily.
1483490|NCT03093818|Other|Pharmacogenomic testing|"The pharmacogenomic panel to be used incorporates 50 genetic variants for the following 13 pharamacogenes: CYP1A2 (cytochrome P450), CYP2B6, CYP2C19, CYP2C9, CYP2D6,CYP3A4, DPYD (dihydropyrimidine dehydrogenase), FVL (factor five Leiden), HLA-B (human leukocyte antigen), SLCO1B1 (solute carrier organic anion transporter), TPMT (thiopurine methyltransferase), UGT1A1 (UDP-glucuronosyltransferase), and VKORC1 (vitamin K epoxide reductase complex)."
1483491|NCT03093805|Dietary Supplement|Calcipotriene|Topical vitamin D cream will be applied to affected areas of the skin.
1483492|NCT03093792|Other|Control|
1483493|NCT03093792|Other|American Heart Association plus exercise|
1483494|NCT03093792|Other|Curves Complete - I plus exercise|
1483495|NCT03093792|Other|Curves Complete - II plus exercise|
1483496|NCT03093779|Other|Health Information Assessment|Assess how hearing loss and health literacy alters the ability to access and comprehend online health information
1483497|NCT03093753|Other|Control (study 1)|Control meal will comprise of 50 g glucose dissolved in 200 ml water, to which the response of the test meals will be compared to
1483498|NCT03093753|Other|Test (study 1)|The test meal will comprise 50 g glucose in 200 ml water plus 50 mg oleuropein from olives
1483499|NCT03093753|Other|Control (study 2)|Control meal will comprise 109 g white bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
1483500|NCT03093753|Dietary Supplement|Test (study 2)|The test meal will comprise 109 g white bread plus 50 mg oleuropein from olives dissolved in 200 ml water
1483501|NCT03093753|Other|Control (study 3)|Control meal will comprise whole-meal bread to give 50 g available carbohydrate and 200 ml water, to which the response of the test meals will be compared to
1483566|NCT03093324|Drug|Dimethyl Fumarate|Oral capsules, administered twice daily
1483507|NCT03093753|Other|Control (study 6)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
1483508|NCT03093753|Other|Test (study 6)|High carbohydrate diet (23% fat, 55% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
1483509|NCT03093753|Other|Control (study 7)|Normal diet 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
1483510|NCT03093753|Other|Test (study 7)|High fat diet (44% fat, 34% carbohydrates and 22% protein) 3 days prior to the visit day and 109 g bread with 200 ml water on the study day
1483511|NCT03093740|Drug|Zepatier|Based on negative viral resistance testing of the donor treatment will be Zepatier
1483512|NCT03093740|Drug|Zepatier plus Sofosbuvir|Based on positive viral resistance testing of the donor treatment will be Zepatier with Sofosbuvir
1483515|NCT03093701|Drug|TLC399 (ProDex)|TLC399-DSP with TLC399-Lipid
1483516|NCT03093688|Biological|Infusion of iNKT cells and CD8+T cells|The eligible patients receive twice infusions of iNKT cells(1E8~1E10) and CD8+T cells(1E7~1E9) in one course of treatment.
1483517|NCT03093675|Device|TELELAP ALF-X Robotic Surgical System|The surgical procedures will be performed using the innovative TELELAP ALF-X robotic system, equipped with multiple independent arms. Initial entry will be through a classic open in which the arm with the video camera will be inserted. The device has four independent arms (one for the video camera and three for surgical instruments). Patients will be in the lithotomy position, supported by Allen stirrups and under general anesthesia. The uterus will be manipulated with a multi-use uterine manipulator. After having induced a pneumoperitoneum, high-definition 3D-technology optics will be inserted. Three laparoscopic instruments will be used to complete the procedure. Standard techniques will be used.
1483518|NCT03093662|Device|Ventilation with nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear) while simultaneously wearing nasal cannula (Carefusion AirLife Standard Nasal Cannula) with 15 L/min oxygen flow. Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
1483519|NCT03093662|Device|Ventilation without nasal cannula|Subject is fitted with a face mask and undergoes three continuous minutes of positive pressure ventilation (Respironics AF521, EE with CapStrap headgear). Subject then removes mask and immediately exhales into an oxygen sensor (Maxtec Max-250E).
1483520|NCT03093649|Other|adverse events using patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|The intervention was administrated through APP
1483521|NCT03093649|Other|do not report adverse events through patient-reported outcomes version of common terminology criteria for adverse events (PRO-CTCAE) questionaire|patients receive normal care and visit
1483522|NCT03093636|Device|Continuous Glucose Monitor (CGM)+Decision Support System (DSS)|"Continuous Glucose Monitor (CGM)+Decision Support System (DSS) study participants will use the inControl Advice APP and a study CGM at home for 12 weeks. The DSS contains a smart bolus advisor that adjusts the size of the correction insulin boluses based on short-term blood glucose predictions. It is able to complete this function by evaluating CGM values, insulin usage and carbohydrate intake record. It also contains an exercise advisor, a bedtime advisor, hypoglycemia risk and long-term tracker of HbA1c. Subjects will use study basal and bolus insulin during the study."
1483523|NCT03093636|Other|Continuous Glucose Monitor (CGM) alone|Continuous Glucose Monitor (CGM) alone study participants will use a study CGM at home for 12 weeks. Subjects will use study basal and bolus insulin during the study.
1483524|NCT03093623|Behavioral|Physical activity|In physical activity experimental group, trained study nurses will interview with patients,give health education,teach how to use and record the Activity meter.Professionals will calculate Metabolic Equivalent of Task(MET) with formula weekly.MET = (intensity level 9 points * time of each exercise (hours) * Number of times per week + moderate level 5 points * time per activity (hours) * number of times per week + low level 3 points * time per activity (hours) * number of times per week),investigators hope patients in the first month MET can reach (3.75-7.49 MET-h/ week), and reach moderate or more than moderate activity (>= 7.5-16.49 MET-h/ week) at the starting of second month for at least one year.
1483525|NCT03093610|Procedure|Traditional|Removal of the chest tube after air leakage has ceased and fluid drainage is 200ml/24h or less.
1483526|NCT03093610|Procedure|Test|Removal of the chest tube after air leakage has ceased and fluid drainage is 5ml/kg/24h or less.
1483527|NCT03093597|Other|virgin coconut oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin coconut oil application twice daily for 2 weeks.
1483528|NCT03093597|Other|virgin jojoba oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin jojoba oil application twice daily for 2 weeks.
1483529|NCT03093597|Other|virgin almond oil|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive virgin almond oil application twice daily for 2 weeks.
1483530|NCT03093597|Other|white petrolatum ointment|One of the four locations (right proximal forearm, right distal forearm, left proximal forearm, left distal forearm) on the forearm will be selected to receive white petrolatum ointment application twice daily for 2 weeks.
1483531|NCT03093584|Device|Auricular acupuncture|Auricular acupuncture with indwelling fixed auricular acupuncture needles
1483532|NCT03093584|Behavioral|Expressive writing|Expressive writing is a standard psychological method in treatment of exam anxiety
1483533|NCT03093571|Device|Auricular stimulation|Auricular stimulation with indwelling fixed needles
1483534|NCT03093571|Behavioral|Relaxation|Progressive muscle relaxation
1483535|NCT03093558|Behavioral|ECA/Kardia|Use of the ECA and Kardia daily for 30 days.
1483536|NCT03093545|Biological|Equine Rabies Immunoglobulin|40 IU per kg of body weight of ERIG at Day 0
1483537|NCT03093545|Biological|Purified chick-embryo cell rabies vaccine|1 ml of PCEC Rabies vaccine on days 0, 3, 7, 14 and 28.
1483608|NCT03093077|Device|DePuy ATTUNE total knee arthroplasty system|A standard midvastus approach will be used for both alignment technique groups. This is a standard approach for exposing the knee joint for TKA.
1597773|NCT02252809|Drug|methylprednisolone|
2001033|NCT03249857|Behavioral|cognitive tasks|Healthy volunteers will perform only the cognitive tasks = reaction time alert TEA, Zimmermann and Fimm, 2005 + Edinburgh laterality questionnaire (Oldfield, 1971) + experimental task (approach/ avoidance and affordance task).
2001034|NCT03250585|Diagnostic Test|Exhaled Breath Condensate (EBC)|Serial EBC samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
1483540|NCT03093519|Drug|KHK6640|Intravenous administration
1483541|NCT03093519|Drug|Placebo|Intravenous administration
1483542|NCT03093506|Drug|Low-dose rhEpo|60IU/kg/week
1483543|NCT03093506|Drug|Micro-dose rhEpo|20IU/kg/week
1483544|NCT03093506|Other|Placebo Control|Saline
1483545|NCT03093493|Diagnostic Test|Genotyping|Genotyping by next generation sequencing
2001035|NCT03250585|Diagnostic Test|Plasma Sample|Serial plasma samples will be collected within 48 hours of acute chest syndrome (ACS) diagnosis and at 2 week follow up
1483547|NCT03093467|Behavioral|ASCENSO|Internet-based program: an adjunct support and monitoring system for the treatment of depression.
1483548|NCT03093467|Drug|Antidepressants or in combination with anxiolytics, neuroleptics or mood stabilizers.|Usual psychiatric treatment which may include drugs: antidepressant monotherapy or antidepressants in combination with anxiolytics, neuroleptics or mood stabilizers as needed, according to the psychiatric evaluation. Monthly controls during 5 months in average.
1483549|NCT03093467|Behavioral|Psychotherapy|Usual treatment: brief psychotherapy. One session per week, a total of 9 sessions in average.
1483550|NCT03093454|Drug|Lavender Essential Oil|Lavender essential oil will be applied topically and by inhalation to the lavender group.
1483551|NCT03093441|Other|Multimodal High-Intensity Interval Training Intervention|The intervention will occur 3 times per week for 12 weeks and include a warm-up, MM-HIIT or R-HIIT training protocol, and a cool down.
1483552|NCT03093428|Drug|Radium-223|Radium-223 is a calcium mimetic that hones in on bone metastases. It binds to new bone stroma and emits alpha particles, which induce double-stranded DNA breaks that result in tumor cell death.
1483553|NCT03093428|Drug|Pembrolizumab|Pembrolizumab is a PD-1 inhibitor
1483554|NCT03093415|Drug|elbasvir-grazoprevir (50 mg/100 mg)|12 week treatment of elbasvir-grazoprevir (50 mg/100 mg)
1992822|NCT03291899|Combination Product|FOLFIRINOX|combination chemotherapy using Oxaliplatin, Irinotecan, Leucovorin and Fluorouracil, given every 15 days for a total of 12 cycles
1992823|NCT03290898|Behavioral|High Intensity Interval Training|Training (HIIT)
1483557|NCT03093389|Drug|BIA 6-512|The investigational products consisted of capsules containing BIA 6-512 25 mg, 50 mg, 100 mg and 150 mg. Products were administered orally, with approximately 240 mL of water in case of Doses 1 and 13, and at least 150 mL of water in case of Doses 2 to 12. First dose (Dose 1) and last dose (Dose 13) were administered in fasting of at least 8 hours and subject remained fasted until to 2.5 h post-dose. Meals were not served within 1 hour prior and 1 hour after investigational product administration in Doses 2 to 12
1483558|NCT03093389|Drug|Placebo|Matching placebo capsules
1483559|NCT03093376|Behavioral|Effortful Control Camp|"An interactive, child-friendly camp. Effortful control (EC) camp is comprised of short, game-like exercises taught by camp counselors to groups of approximately 4-6 children. In total, 12 different exercises that teach inhibitory and attentional control, as well as visuospatial and working memory skills, will be administered.
Tasks will allow for scaffolding (Halperin et al, 2013), or incremental increases in difficulty of the games over time. EC camp will occur over 4 mornings from 9AM to 12PM, on two consecutive weekends."
1483560|NCT03093376|Behavioral|Waitlist|Participants randomized to the control group will be given a set of written materials to complete at home with their caregivers after the post-wait list assessment. These materials will be adapted from the EC camp protocol and will include detailed instructions on how to perform the training tasks in a home setting. No additional neurophysiological, behavioral, or clinical data will be collected in subjects who complete the home EC training.
2001036|NCT03248310|Behavioral|Quality of Life Assessments|Upper Limb Lymphedema (ULL-27), Lymphedema Life Impact Scale, version 2 (LLISv2), LYMQOL-Leg.
1483563|NCT03093350|Biological|TAA-specific CTLs|"Each patient will receive 2 injections at a fixed dose, 28 days apart, according to the following dose schedule: The expected volume of infusion will be 1 to 10 cc.
Dose schedule:
Day 0: 2 x 10^7 cells/m2
Day 28: 2 x 10^7 cells/m2
If patients have stable disease or a partial response by the Response Evaluation Criteria in Solid Tumors (RECIST) criteria at their 6 week evaluation after the 2nd cell dose, they will be eligible to receive up to 6 additional doses of CTLs, At least one month should have passed before each additional dose.. Each additional infusion will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
1483564|NCT03093337|Other|Early post hospital discharge psychomotor therapy|The intervention consisted on 20 psychomotor therapy sessions between 2 and 9 months, in order to support infants' development, and parent-infant interactions and adjustment. The therapy was based on body and emotional positive feelings and experiences, leading to improve sensory motor and perceptive integration, interactive and exploratory behaviors, physiological and tonic-emotional self-regulation, motor organization and early coordination. The intervention was a partnership with the parents, leading to decode the baby needs and expectations, for the parents to experiment more positive feelings, to become more confident in their own skills and more sensitive, and in synchrony with their baby. Intervention was supported by a detailed assessment scale implemented in the regional network related to the follow-up for vulnerable babies.
1483565|NCT03093324|Drug|ALKS 8700|Oral capsules, administered twice daily
1992824|NCT03291613|Other|Pinpoint App|Tablet app with pain assessment and communication education, and pain assessment tool.
1992829|NCT03290820|Radiation|Radiotherapy|Technique: intensity-modulated radiotherapy; Dose: GTVnx 6810cGy/30Fr, GTVnd 6400-6600cGy/30Fr, CTV1 6000cGy, CTV2 5400cGy.
1992830|NCT03290820|Drug|Concurrent chemotherapy|Nedaplatin 80mg/m2 d1+5-flurouracil 500mg/m2 d2-5, every 3 weeks; a total of 2-3 cycles.
1483567|NCT03093311|Other|NIRS based protocol|Each desaturation episode will be managed according to a standardized protocol - correction of extreme head position will be followed by optimisation of mean arterial pressure (MAP), arterial hemoglobin oxygen saturation, end tidal carbon dioxide concentration and a level of hemoglobine concentration.
1483568|NCT03093298|Other|Enteroscopy with biopsy sampling and mixed meal test|Enteroscopies with biopsy retrieval and mixed meal tests with blood sampling before and after Roux-en-Y gastric bypass surgery
1483569|NCT03093272|Drug|Leuprolide Acetate|a GnRH agonist
1483570|NCT03093272|Drug|Prednisone|Prednisone is a corticosteroid
1483571|NCT03093272|Drug|Docetaxel|Docetaxel is an antineoplastic agent that acts by disrupting the microtubular network in cells that is essential for mitotic and interphase cellular functions. Docetaxel binds to free tubulin and promotes the assembly of tubulin into stable microtubules while simultaneously inhibiting their disassembly.
1483572|NCT03093272|Drug|Apalutamide|The apalutamide drug substance is an almost white to slightly brown powder. The tablet formulation of apalutamide is an immediate release oral tablet containing 60-mg of drug substance, with a non-functional green film coat
1483573|NCT03093259|Drug|ABX464|ABX464 is a new Anti-inflammatory drug
1483574|NCT03093259|Drug|Placebo oral capsule|Placebo matching with ABX464
1483575|NCT03093246|Dietary Supplement|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
1483576|NCT03093246|Drug|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
1483577|NCT03093246|Other|Placebo|Placebo pills over a period of 180 days
1483578|NCT03093246|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
1483579|NCT03093233|Other|no intervention|only descriptive data analysis
1483580|NCT03093207|Procedure|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
1483581|NCT03093207|Other|Placebo|Placebo pills over a period of 180 days
1483582|NCT03093207|Dietary Supplement|Omega-3 polyunsaturated fatty acids|3 g of omega-3 polyunsaturated fatty acids daily supplementation over a period of 180 days
1483583|NCT03093207|Drug|Aspirin|100 mg of aspirin daily supplementation over a period of 180 days
1483584|NCT03093194|Other|vaginal preparation before CS with Septal soap and septol.|vaginal preparation before CS with Septal soap and septol.
1483585|NCT03093194|Other|No vaginal preparation before CS with Septal soap and septol.|No vaginal preparation before CS with Septal soap and septol.
1483586|NCT03093181|Other|Washout / Standard Cleanser|Participants will apply standard cleanser (Simple Kind to Skin Moisturising Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the standard cleanser in a 5-7 day washout period and during the test phase of the study
1483587|NCT03093181|Other|Test product|Participants will apply 0.6 gram (g) of Test product (Moisturising Cream with Niacinamide) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the test product during the test phase of the study.
1483588|NCT03093181|Other|Positive control cleanser|Participants will apply positive control cleanser (Neutrogena Visibly Clear Spot Clearing Facial Wash) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control cleanser during the test phase of the study.
1483589|NCT03093181|Other|Positive control moisturiser|Participants will apply 0.6 g of positive control moisturiser (Vivatinell Acnecinamide Gel Cream) twice daily (morning and night) with at least 8 hours between product applications. Participants will use the positive control moisturiser during the test phase of the study.
1483590|NCT03093168|Biological|Anti-BCMA CAR-T cells|Retroviral vector-transduced autologous T cells to express anti-BCMA CAR
1483591|NCT03093168|Drug|Fludarabine|dose: 25mg/m2/d
1483592|NCT03093168|Drug|Cyclophosphamide|Dose: 40mg/kg
2001037|NCT03247712|Drug|Nivolumab|Nivolumab 240mg IV q2wks.
2001038|NCT03247712|Procedure|Surgical Resection|Surgical Resection of Tumor
1483595|NCT03093142|Device|tDCS & neurofeedback|tDCs and neurofeedback
1483596|NCT03093142|Device|neurofeedback|Neurofeedback
1483597|NCT03093142|Device|sham neurofeedback|sham neurofeedback
1483598|NCT03093129|Drug|artesunate|"Artesunate (Trade name : Arinate®)
Artemisinins are a family of sesquiterpene trioxane anti-malarial agents derived from Sweet wormwood (Artemisia annua L) that have been used in traditional Chinese medicine for centuries to treat fevers. Artesunate, artemether and arteether are derivatives of artemisinin that are converted into their active metabolite dihydroartemisinin (DHA). Artesunate is approved for the treatment of uncomplicated and multidrug-resistant malaria and is on the WHO list of Essential Medicines (WHO., 2015)."
1483599|NCT03093129|Other|placebo|The matching placebo tablets contain lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, colloidal anhydrous silica and a magnesium stearate blend.
1483600|NCT03093116|Drug|Oral TPX-0005|Oral TPX-0005 capsules.
1483601|NCT03093103|Drug|Empagliflozin 10 mg|Prescription of empagliflozin 10 mg once a day Follow-up of renal parameters including BOLD MRI
1483602|NCT03093103|Drug|Placebo|Prescription of a placebo once a day Follow-up of renal parameters including BOLD MRI
2001039|NCT03247712|Radiation|Radiation|8Gy x 5 (Mon-Fri) GTV+3mm, BED 72
2001040|NCT03247439|Device|Cartiva|Synthetic Cartilage Implant
2001041|NCT03242928|Drug|AFQ056|Tablets
2001042|NCT03242928|Drug|Placebo|Tablets
2001043|NCT03241810|Drug|Seribantumab|Seribantumab is a human monoclonal antibody that targets ErbB3, a cell surface receptor that is activated by the ligand heregulin. Heregulin-driven ErbB3 signaling has been implicated as a mechanism of tumor growth and resistance to targeted, cytotoxic and anti-endocrine therapies. When used in the combination setting, seribantumab is designed to block ErbB3 signaling in order to enhance the anti-tumor effect of a combination therapy partner.
2001044|NCT03241810|Drug|Fulvestrant|Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast cancer in post-menopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works both by down-regulating and by degrading the estrogen receptor.
2001045|NCT03241810|Drug|Placebo|Placebo
2001046|NCT03242252|Drug|Placebo|"Pharmaceutical form: Tablet
Route of administration: Oral"
1483609|NCT03093064|Drug|Natalizumab|Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.
1483610|NCT03093064|Other|Placebo: normal saline|Normal saline, intravenous infusion
1483611|NCT03093051|Other|Unpinning Termination therapy|Electrotherapy comprised of standard biphasic and monophasic pacing pulses
1483612|NCT03093038|Device|H-MAX stem & Delta-TT cup + polyethylene|H-MAX femoral stem & Delta-TT cup with a polyethylene insert
1483613|NCT03093038|Device|H-MAX stem & Delta-TT cup + ceramic|H-MAX femoral stem & Delta Delta-TT cup with a Ceramic insert
1483614|NCT03093038|Device|C2 stem & Delta-TT cup + ceramic|C2 femoral stem Delta Delta-TT cup with a Ceramic insert
2001047|NCT03242252|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet
Route of administration: Oral"
2010580|NCT02924688|Drug|FF/UMEC/VI (100/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation once-daily [QD] in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
1483618|NCT03092999|Drug|Vilaprisan (BAY1002670)|2 mg tablet, single dose, oral administration
1483619|NCT03092986|Drug|Paclitaxel|paclitaxel 200 mg/m2 i.v over 3 hrs on day 1, every 21 days for 2 cycles followed by radiotherapy on day 42
1483620|NCT03092986|Drug|Carboplatin|carboplatin AUC 6 iv over 1 hr on day 1 , every 212 days for 2 cycle followed by radiotherapy on day 42
1483621|NCT03092986|Drug|Cisplatin|cisplatin 100 mg/m2 i.v over 2 hrs on day 1 and 29 followed by radiotherapy on day 50
1483622|NCT03092986|Drug|Vinblastine Sulfate|Vinblastin 5mg/m2 i.v on day 1,8,15,22 and 29 followed by radiotherapy on day 50
1483623|NCT03092986|Radiation|three dimensional conformal radiotherapy|three dimensional conformal radiotherapy would be given at day 42 after completion of paclitaxel and carboplatin 2 cycle and at day 50 after completion of cisplatin and vinblastin from d1 to d29
1483625|NCT03092960|Behavioral|Minimal intensity intervention|The minimal intensity intervention control includes the Group Lifestyle Balance (GLB) videos (DVD or online), standardized messages, and access to a lifestyle coach if initiated by the participant.
1483626|NCT03092960|Behavioral|HOMBRE|HOMBRE is a Group Lifestyle Balance (GLB)-based intervention tailored for men and available in 3 delivery modalities (coach-facilitated individual approach, coach-led online virtual groups, and coach-led in-person groups). A lifestyle coach will support men in making an informed choice of modality and will provide ongoing individualized feedback. All delivery modalities provide the same evidence-based curriculum and include self-monitoring and individualized feedback from the lifestyle coach.
1483627|NCT03092947|Other|No intervention|
1483628|NCT03092934|Drug|AK-01|Oral capsules
1483629|NCT03092921|Device|F&P Mask Seal|Investigative Mask Seal to be used for OSA therapy
1483630|NCT03092921|Device|F&P Mask|Investigative Mask to be used for OSA therapy
1483631|NCT03092908|Dietary Supplement|mature vinegar|Administer 5 ml mature vinegar (Brand: Ninghuafu) three times a day.
1483632|NCT03092908|Dietary Supplement|placebo (water)|Administer 5 ml placebo (water) three times a day.
1483633|NCT03092895|Biological|SHR-1210|Subjects receive SHR-1210 intravenous at the dose 3mg/kg on Day 1 every 2 weeks
1483634|NCT03092895|Drug|Apatinib|Subjects receive Apatinib orally every day with a dose escalation
1483635|NCT03092895|Drug|FOLFOX4|Subjects receive FOLFOX4 treatment every 2 weeks
1483636|NCT03092882|Behavioral|Diabetes Self-Management Program|The Diabetes Self-Management Program is a platform that includes a smart meter, access to coaching 24/7, and a mobile app and website that help members manage their diabetes. The program offers diabetes education and coaching delivered entirely through the smart meter and mobile app or website.
1483637|NCT03092869|Other|Feet and Ankle Mobilization|A set of manual therapy mobilization in feet and ankle joints
1483638|NCT03092869|Other|Proprioceptive Training|A set of proprioceptive exercises oriented to improve balance abilities
1483639|NCT03092856|Biological|Anti-OX40 Antibody PF-04518600|Given IV
1483640|NCT03092856|Drug|Axitinib|Given PO
1483641|NCT03092856|Other|Laboratory Biomarker Analysis|Correlative studies
1483642|NCT03092856|Other|Placebo|Given IV
1483643|NCT03092830|Genetic|Molecular testing of DNA/RNA from skin tumors, SCC/BCC|Molecular testing of DNA/RNA from skin tumors, SCC/BCC
1483644|NCT03092817|Drug|Dexamethasone|Active treatment with dexamethasone from randomisation (IV followed by oral according to disease severity at the start of treatment): dexamethasone for intravenous injection and dexamethasone for oral ingestion
1483645|NCT03092817|Other|Placebo|"Treatment with matched placebo:
Standard saline for intravenous injection and placebo oral tablets containing cellulose"
1483646|NCT03092804|Procedure|ventriculo-peritoneal shunting|A mainstream therapy for NPH. It involves the device of CSF flow control of shunts and accessories(CFDA(I)20143665605)
1483650|NCT03092778|Procedure|Cryoablation|"A computed tomography (CT) scan will be completed to map out where to insert the cryoablation needle. Numbing medicine will be used to numb the skin and deeper tissues before inserting the needle.
The cryoablation needle will be inserted and directed toward the target area of the vagal nerve. A CT scan will be done during the procedure to help guide the needle which will be held in position by the study doctor(s) once it reaches the target area. With the needle in place, the study doctor(s) will freeze the zone over 3 minutes, a 2 minutes thaw will follow, then 2 more cycles of 3 minutes freeze and 2 minute thaw will complete the procedure. This portion of the procedure can last from 25 to 35 minutes. Once the targeted area has been properly treated, the cryoablation needle will be withdrawn."
1483653|NCT03092752|Drug|oral antidiabetic drugs|OADs usage conditions and dose selection in T2DM patients
1483654|NCT03092739|Diagnostic Test|PD-L1 Immunocytochemistry (ICC)|PD-L1 expression in the cytological specimens will be assessed using different antibodies.
1483655|NCT03092739|Diagnostic Test|PD-L1 Immunohistochemistry (IHC)|PD-L1 expression in the histological specimens will be assessed using different antibodies.
1483656|NCT03092726|Drug|ASP8062|oral
1483658|NCT03092713|Behavioral|Combined cognitive (Compensatory Cognitive Training - CCT) and vocational rehabilitation (Supported Employment)|The CCI-SE Group receives a manualized Group-based cognitive psycho-educational intervention (10 sessions), combined with supported employment at their work-place.
1483659|NCT03092713|Behavioral|Control Group|The Control Group receives usual assessment and treatment at Oslo University Hospital.
1483660|NCT03092674|Drug|Azacitidine|Given SC or IV
1483661|NCT03092674|Drug|Cytarabine|Given IV
1483662|NCT03092674|Drug|Decitabine|Given IV
1483663|NCT03092674|Other|Laboratory Biomarker Analysis|Correlative studies
1483664|NCT03092674|Drug|Midostaurin|Given PO
1483665|NCT03092674|Biological|Nivolumab|Given IV
1483666|NCT03092648|Biological|Bronchial basal cell|autologous bronchial basal cell transplantation
1483667|NCT03092635|Drug|Metformin Hydrochloride|Metformin is a drug typically given for the treatment of type II diabetes
1483668|NCT03092635|Other|OPC|OPC is a derivative of grape seed extract
1483669|NCT03092622|Other|Exercise|Exercise training intervention as described earlier.
1483670|NCT03092609|Behavioral|Attention Bias Modification|Attention bias modification (ABM) sessions will consist of a modified dot-probe task that only contains incongruent trials (i.e., target-dot - neutral stimulus 100% pairing).
1483671|NCT03092609|Behavioral|Attention Control|Attention control (AC) sessions, will consist of a standard dot-probe task (i.e., target-dot - neutral/threat stimulus 50% pairing). Thus, for AC participants, bias should remain the same, while ABM participants should show a reduced bias to threat.
1483672|NCT03092596|Behavioral|Patient-administered screening tool|screener for drug and alcohol misuse - NIDA Quick Screen combined with AUDIT and DAST
1483673|NCT03092596|Behavioral|Patient health navigator-administered screening tool|patient health navigator-administered screener
1483674|NCT03092596|Behavioral|Patient health navigator-assisted linkage to treatment|patient health navigator-assisted linkage to substance abuse treatment
1483675|NCT03092583|Other|Blood sample|35 mL, 7 tubes
1483679|NCT03092544|Drug|dimethyl fumarate|Active drug
1483680|NCT03092531|Behavioral|Positive STEPS|Step 1: 2 way SMS text messages; Step 2: Five in-person, counseling sessions. Each counseling session will last approximately 50 minutes.
1948798|NCT01612351|Drug|Lapatinib|Lapatinib (1000mg) taken by mouth once a day either one hour before or one hour after a meal for 6 weeks during induction chemotherapy. Participants deemed high risk following transoral surgery will additionally take lapatinib daily concurrently with their chemoradiation therapy.
1992831|NCT03290820|Drug|Aspirin|Daily aspirin of 75mg, from the starting date of radiotherapy.
1483685|NCT03092479|Behavioral|Behavioral Intervention|Eight bi-weekly small group sessions of approximately 10 participants with session content focused on addressing psychosocial changes after surgery, strategies for postoperative diet and adherence and preventing weight regain.
1483686|NCT03092466|Procedure|femoral nerve catheter|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
1483687|NCT03092466|Drug|femoral group|femoral block with Ropivacaine 0.75% (15 ml) in femoral catheter
1483688|NCT03092466|Drug|control group|infusion of saline solution (15ml) in femoral catheter
1483689|NCT03092453|Biological|Mature dendritic cell (DC) vaccine|Mature DC 7.5-15 million/peptide followed by 2 booster every six weeks of 1-5 million/peptide followed by standard of care anti PD-1 therapy.
1483690|NCT03092453|Drug|Cyclophosphamide 300mg/m^2|administered prior to subject's first DC dose
1483691|NCT03092453|Drug|Pembrolizumab|administered 7-8 weeks after subject's last DC dose
1483692|NCT03092440|Other|serious game|"During three hours, each learner will play with the three different cases of the LabForGames Warning serious game."
1483693|NCT03092427|Dietary Supplement|VSL#3|Dietary Supplement
1483694|NCT03092427|Other|Placebo|Placebo
1483695|NCT03092414|Procedure|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
1483696|NCT03092414|Procedure|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
1483697|NCT03092388|Diagnostic Test|Multi Frequency Bioimpedance Analysis (mfBIA)|Multi Frequency Bioimpedance Analysis (mfBIA) uses very small electric current at different frequencies (5, 50, 100 kHz) to measure the resistance and reactance of the entire body and different segmental body compartiments. With a special software total body fluid can be calculated. By analyzing raw data at different frequencies a detailed view on body and segments fluid distribution is possible.
1483698|NCT03092388|Diagnostic Test|Polysomnography/Polygraphy (PSG/PG)|Sleep is digital recorded by using PSG/PG in hospital and manually analyzed by physicians according to current AASM guidelines.
1483699|NCT03092388|Diagnostic Test|Capillary Blood Gas Analysis (CBGA)|CBGA is a less invasive method to gain arterial blood like gas samples without the punctation of an artery. After inducing a good capillary perfusion, capillary blood is taken by a small punctation of the tip of one ear. The sample is automatically analysed in a blood gas analyzer.
1483700|NCT03092388|Diagnostic Test|Tilting Table with Hemodynamic Monitoring|A tilting table offers the opportunity to turn a study subject automatically from vertical into horizontal position and back. By using non-invasive monitoring technique, hemodynamic parameters are recorded permanently.
1483703|NCT03092349|Device|Vector optimisation|Evaluation of hemodynamically best LV Stimulation vector and device programming according to measurements
1483704|NCT03092336|Other|Electrical Stimulation|electrical stimulation training
1598930|NCT02244255|Drug|FLOMAX® capsules|
1992834|NCT03289936|Device|NIPPV|Non invasive ventilation technique in which PIP and PEEP administration is not synchronized with newborn's respiratory efforts
1992835|NCT03289936|Device|sNIPPV|Non invasive ventilation technique in which PIP and PEEP administration is synchronized with newborn's respiratory efforts through an algorithm based on flow detection
2001048|NCT03242044|Procedure|Congenital diaphragmatic hernia resuscitation with an intact umbilical cord|10 infants with left or right sided congenital diaphragmatic hernia will be intubated and ventilation initiated while still attached to the placental circulation through the umbilical cord. In addition, at the same time, a nasogastric tube will be placed in the stomach to drain entrained air and secretions. After 5 minutes of resuscitation with the umbilical cord intact, the umbilical cord will be cut, infants separated from the placenta and resuscitation performed per routine neonatal resuscitation protocols. Feasibility, the optimal approach and maternal and infant tolerance to the procedure will be assessed as part of the study.
1483707|NCT03092310|Device|Artificial Pancreas Device|Artificial Pancreas Device
1483708|NCT03092284|Biological|Cardiology Stem Cell Centre Adipose Stem Cell (CSCC_ASC)|Direct intramyocardial injection of CSCC_ASC
1483709|NCT03092284|Biological|Placebo|Saline
1483710|NCT03092271|Behavioral|Stepped Care for Suicide Prevention|ZSQI plus Stepped Care for Suicide Prevention
1483711|NCT03092271|Behavioral|Zero Suicide Quality Improvement|ZSQI
1483712|NCT03092258|Other|Questionnaire|Questionnaire to be completed by staff
1483713|NCT03092245|Drug|OctaplasLG|OctaplasLG is given as an infusion when resuscitation fluids are required.
1483714|NCT03092245|Drug|Ringer-Acetate|Ringer-acetate is given as an infusion when resuscitation fluids are required.
1483715|NCT03092232|Drug|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 5 mg, 50 mg, 500 mg, TBD (to be determined)/2000 mg.
1483716|NCT03092232|Drug|PF-06865571|Single ascending dose of PF-06865571 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 15 mg, 150 mg, 1000 mg, TBD/2000 mg.
1483717|NCT03092232|Drug|PF-06865571|Single repeated (TBD mg) dose as extemporaneously prepared solution/suspension of PF-06865571.
1483718|NCT03092232|Drug|Placebo|Matching Placebo for PF-06865571 for each cohort.
1483719|NCT03092206|Drug|F/TAF|antiretroviral therapy
1483720|NCT03092206|Drug|E/C/F/TAF|antiretroviral therapy
1483721|NCT03092206|Drug|R/F/TAF|antiretroviral therapy
2001049|NCT03242018|Drug|Placebo|"Pharmaceutical form: Tablet
Route of administration: Oral"
1483724|NCT03092180|Drug|Intravenous Infusion|Intravenous infusion of follow medicine at disease onset: methyprednisolone and/or human intravenous immunoglobulin
1483725|NCT03092167|Other|Physical exercises|Physical exercises
1483726|NCT03092154|Drug|Lipid-lowering agents (Artovastatin)|Artovastatin 20 mg /day, orally, 12 consecutive weeks.
1483727|NCT03092141|Other|Physical training|
1483728|NCT03092115|Device|HIV medication adherence app|A medication adherence mobile application for HIV+ youth. It is a theory-driven, patient-centered, mobile phone-based intervention targeting medication adherence and engagement in care among HIV+ youth with features including, but not limited to: custom avatar, medication reminders, calendar tracking of medication adherence, and anonymous chat function for social support.
1483729|NCT03092102|Drug|HEC585|HEC585, a pyrimidone compound, is structurally related to pirfenidone, a pyridine compound.
1483730|NCT03092089|Drug|Definity, (Lipid Microspheres) Intravenous Suspension|Sonothrombolysis (High Impulse therapeutic ultrasound with infusion of ultrasound contrast agent Definity) will be applied before and after standard of care reperfusion therapy with PPCI
1483731|NCT03092089|Device|Myocardial Contrast Echocardiography|Myocardial contrast echocardiography will be applied before standard of care reperfusion therapy as well as prior to discharge and at 3 month follow up
1483732|NCT03092089|Procedure|Repurfusion therapy with PPCI|Patients will receive reperfusion therapy with PPCI as standard of care
1483733|NCT03092076|Drug|Ticagrelor|180 mg loading dose
1483734|NCT03092063|Behavioral|Tomando Control-Nurse|Tomando Control de su Diabetes-Nurse is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained Registered Nurses. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
1483735|NCT03092063|Behavioral|Tomando Control-Promotora|Tomando Control de su Diabetes-Promotora is a community-based intervention given in six 2.5 hour sessions. The Spanish-language sessions are led by two trained promotoras. Subjects covered in these sessions include: 1) techniques to deal with the symptoms of diabetes and associated conditions; 2) appropriate exercise; 3) healthy eating; 4) correct use of diabetes medications; and 5) working more effectively with health care providers in a collaborative partnership. Participants make weekly action plans, share experiences, and help each other solve problems they encounter in creating and carrying out their self-management strategies.
1483736|NCT03092063|Behavioral|Enhanced engagement|The Tomando Control clinician (either a promotora or a Registered Nurse, depending on the original group assignment), will conduct up to three home visits that are designed to explain the purpose of the TC intervention to a key relative so as to re-engage the family member in the group process
1483737|NCT03092063|Behavioral|Multifamily Group|"The multifamily group consists of three components: three initial joining sessions conducted with each of the families separately; a one-day (six hour) educational workshop; and ongoing multifamily group sessions."
1483738|NCT03092050|Behavioral|Guided Imagery and Mindfulness|This is a behavioral intervention using guided imagery and mindfulness techniques.
1483739|NCT03092050|Behavioral|Facilitated Discussion|This is a behavioral intervention that involves discussion and group support.
1483740|NCT03092037|Procedure|Blood draw|The Investigators will collect serum and whole blood from participants.
1483789|NCT03091712|Device|Glooko Mobile Insulin Dosing System(MIDS)|Mobile Insulin Dosing System (MIDS) for all long acting insulin degludec titration management
1483790|NCT03091699|Drug|Nicotine|Participants will be required to smoke a cigarette to completion in a 20 minute time frame.
1483791|NCT03091699|Behavioral|Moderate Intensity Exercise|Participants will be required to perform 20 minutes of acute moderate intensity exercise (brisk walk) on a treadmill.
1483821|NCT03091491|Drug|Ipilimumab|Ipilimumab 1 mg/kg administered every 6 weeks as a 30 min IV infusion
1483742|NCT03092011|Drug|Clonidine|Clonidine at 0.38 mcg/kg/dose every 3 hours or 0.5 mcg/kg/dose every 4 hours Clonidine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
1483743|NCT03092011|Drug|Morphine Sulfate|Morphine at 0.03 mg/kg/dose every 3 hours or 0.04 mg/kg/dose every 4 hours Morphine dose will be increased by 25% of the previous dose if needed. It will be decreased by 10% of the highest dose using the original/birth weight (same amount each time) every 24 to 48 hours, provided the scores remain below 8.
1483744|NCT03091998|Drug|CD-NP|Participants will receive a subcutaneous injection of CD-NP (5 mcg / kg) daily for 3 days
1483745|NCT03091998|Other|Placebo|Participants will receive an ~ 1mL subcutaneous injection of normal saline, in lieu of Study Drug, for 3 days
1483746|NCT03091985|Device|PersonalFit - Breast shield|Subjects are to pump 15 min with the comparator device
1483747|NCT03091985|Device|Brownie - Breast shield|Subjects are to pump 15 min with the investigational device
1483748|NCT03091972|Procedure|Pulmonary vein isolation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation with contact force monitoring.
1483749|NCT03091972|Procedure|Contact force assisted left atrial linear ablation|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation monitoring contact force.
1483750|NCT03091972|Procedure|left atrial linear ablation without contact force monitoring|Left atrial linear ablation (Roof line and Anterior line) after pulmonary vein isolation during catheter ablation for persistent atrial fibrillation without monitoring contact force.
1483751|NCT03091946|Other|Overnight oats with additional dried fruits, nuts and seeds|Oatmeal
1483752|NCT03091946|Other|Cooked cream of rice with additional dried fruits, nuts and seeds|Cooked cream of rice
1483753|NCT03091933|Biological|GLIDE|Gudide Lymphocyte by Immunopeptide Derived Expansion (GLIDE) is an anti- Minor histocompatibility (MiHA) cell line
2001050|NCT03242018|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: Tablet
Route of administration: Oral"
2001051|NCT03240354|Device|Saline cuff|Cuff of endotracheal tube inflated with saline rather than air (control)
2001052|NCT03240354|Device|Control|Cuff of endotracheal tube inflated with air
1483757|NCT03091894|Drug|Propofol|propofol intravenous infusion via syringe pump with loading dose of 0.5 mg/kg over 3 minutes then continuous infusion in a dose of 25-75 ug/kg/minute
1483758|NCT03091894|Drug|Dexmedetomidine|dexmedetomidine intravenous infusion via syringe pump with loading dose of 0.5ug/kg over 5 minutes the continuous infusion in a dose of 0.2-0.7ug/kg/hour in addition to the propofol infusion as in propofol group
1483759|NCT03091881|Drug|Granisetron|Prevention of intraoperative hypotension in diabetic parturients with Granisetron
1483760|NCT03091868|Drug|Placebo oral capsule|Matching placebo capsules. Oral administration.
1483761|NCT03091868|Drug|Sinemet® 100/25|Single-dose of immediate release levodopa/carbidopa 100/25 mg consisted of 1 tablet of Sinemet® 100/25. Route of administration: Oral.
1483762|NCT03091868|Drug|Comtan®|Single-dose of entacapone 200 mg consisted of 1 tablet of Comtan®. Route of administration: Oral.
1483763|NCT03091868|Drug|BIA 6-512 25 mg|BIA 6-512 capsules strengths 25 mg. Oral administration.
1483764|NCT03091868|Drug|BIA 6-512 100 mg|BIA 6-512 capsules strengths 100 mg. Oral administration.
1483765|NCT03091855|Other|Questionnaire|Alzheimer's Disease Assessment Scale (ADAS-cog11) and Disability Assessment for Dementia (DAD) Questionnaires
1483766|NCT03091842|Behavioral|Exercise Intervention|Undergo supervised CARE program
1483767|NCT03091842|Behavioral|Exercise Intervention|Undergo supervised TARE program
1483768|NCT03091842|Behavioral|Exercise Intervention|Undergo home-based stretching program
1483769|NCT03091842|Other|Informational Intervention|Receive instructional DVD and booklet of the flexibility exercises
1483770|NCT03091842|Other|Laboratory Biomarker Analysis|Correlative studies
1483771|NCT03091842|Other|Quality-of-Life Assessment|Ancillary studies
1483772|NCT03091842|Other|Questionnaire Administration|Ancillary studies
1483773|NCT03091816|Device|Computed Tomography Perfusion Imaging|Undergo DPCT
1483774|NCT03091816|Other|Laboratory Biomarker Analysis|Correlative studies
1483775|NCT03091816|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1483776|NCT03091803|Device|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo GOCART DCE MRI
1483777|NCT03091803|Drug|Gadobenate Dimeglumine|Given IV
1483778|NCT03091803|Drug|Gadoterate Meglumine|Given IV
1483779|NCT03091803|Device|Magnetic Resonance Imaging|Undergo QSM and T1WI imaging
1483780|NCT03091790|Device|Synthetic Mesh|Synthetic mesh used during open ventral hernia repair
1483781|NCT03091790|Device|Biologic Mesh|Biologic mesh used during open ventral hernia repair
1483782|NCT03091777|Drug|GDC-229|GDC-229 is a vaginal gel.
1483783|NCT03091777|Drug|Metronidazole Vaginal Gel 0.75%|Metronidazole Vaginal Gel 0.75% is an FDA-approved drug
1483784|NCT03091777|Drug|Placebo|Inactive arm of the study
1483785|NCT03091751|Drug|BeneFIX|BeneFIX is a recombinant FIX that contains nonacog alfa, reconstituted in solvent and administered as a single dose of 65-75 IU/kg.
1483787|NCT03091725|Procedure|Roux-en-Y gastric bypass surgery|A bariatric surgery procedure which will help individuals achieve 16-18% weight loss
1483788|NCT03091725|Behavioral|Very low-calorie diet|Subjects will meet with a dietitian over 4-6 months to lose 16-18% of their body weight.
1599327|NCT02241187|Device|DW & DCE-MRI|
1483792|NCT03091686|Behavioral|HAPA SB Intervention Slideshow|In the experimental condition, participants will receive sedentary behaviour and diabetes information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. For the experimental group, the intervention material will target risk perceptions (RP) related to sitting by presenting evidence supported by research on sedentary behaviour and diabetes risk; outcome expectancies (OE) by presenting research on the effectiveness of breaking up sedentary time for improving blood sugar and insulin levels; and self-efficacy (SE) by providing strategies on how to reduce and break up sitting time.
1483793|NCT03091686|Behavioral|HAPA MVPA Attention-Control Slideshow|In the attention-control, participants will receive information in the form of a slide show that will be viewed online. The intervention aims to address all components of the Health Action Process Approach. The attention-control slide show will take the same approach as the Experimental group slideshow but the slides will be geared towards meeting moderate-vigorous physical activity guidelines.
2001053|NCT03241082|Device|ultrasound|validation of portable ultrasound to measure body composition
1483795|NCT03091660|Biological|BCG Solution|Given intravesically
1483796|NCT03091660|Biological|BCG Tokyo-172 Strain Solution|Given intravesically
1483797|NCT03091660|Biological|BCG Tokyo-172 Strain Vaccine|Given ID
1483798|NCT03091660|Other|Laboratory Biomarker Analysis|Correlative studies
1483799|NCT03091647|Behavioral|acupressure intervention|Women in the acupressure intervention group will learn how to press three chief energy acupoints on each side of the body through an 11-minute Chinese-language video and press three acupoints (1 minute per acupoint) on both sides of the body every day for a total of 6 minutes per day for an 8-week intervention period and record their practice on daily logs. Women will be asked to return the logs every week by email or self-addressed envelopes.
1483800|NCT03091647|Behavioral|usual care|Women in the usual care group will receive primary and oncology care from their doctors as usual, and complete daily logs recording their fatigue and daily functioning levels. They also need to return the logs every week by email or self-addressed envelopes.
1483801|NCT03091634|Drug|xue-fu-zhu-yu capsule|participants are given to 6 xue-fu-zhu-yu capsule per time, twice a day. The duration is 7 weeks
1483802|NCT03091634|Drug|xue-fu-zhu-yu capsule simulated agent|participants are given to 6 xue-fu-zhu-yu capsule simulated agent per time, twice a day. The duration is 7 weeks
1483803|NCT03091595|Drug|15 mg E4/3 mg DRSP|15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
1483804|NCT03091595|Drug|20 mcg EE/3 mg DRSP|20 mcg EE/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles
1483805|NCT03091582|Behavioral|Cognitive factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. CBT emphasizes the role of cognitive and behavioral factors on affective distress
1483806|NCT03091582|Behavioral|Behavioral factors|The Cognitive-Behavioral Therapy (CBT) intervention will focus on catastrophizing and rumination. Behavioral factors on affective distress.
1483807|NCT03091582|Behavioral|Increase engagement of pleasant events|Behavioral Activation is grounded in learning theory and posits that lack of positive/active engagement of the person with his/her environment contributes to an increase in avoidant or passive behaviors and decreased reinforcement. An empirically validated treatment, behavioral activation reduces depressive symptoms and increase engagement of pleasant events.
2010581|NCT02924688|Drug|FF/UMEC/VI (100/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
1483810|NCT03091543|Drug|Madopar® HBS 125|1 capsule of Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) in an open label manner, concomitantly with BIA 6-512/Placebo.
1483811|NCT03091543|Drug|Placebo|2 capsules of placebo
1483812|NCT03091543|Drug|BIA 6-512 25 mg dose|1 capsule of 25 mg plus 1 capsule of placebo
1483813|NCT03091543|Drug|BIA 6-512 50 mg dose|2 capsules of 25 mg
1483814|NCT03091543|Drug|BIA 6-512 100 mg dose|1 capsule of 100 mg plus 1 capsule of placebo
1483815|NCT03091543|Drug|BIA 6-512 200 mg dose|2 capsules of 100 mg
1483816|NCT03091530|Other|Sleeper Stretch|The sleeper stretch protocol will follow the process described by Wilk with the subject lying on his throwing shoulder side, with the lateral border of the scapula on the table, and the glenohumeral and elbow joints both at 90 degrees of flexion. Participants will be instructed to passively internally rotate the shoulder with gentle overpressure applied on the dorsum of the dominant arm wrist by the nondominant hand to the point of stretch on the posterior aspect of the shoulder. Stretches will be held for 20 seconds each and repeated 4 times for optimal sustained collagen elongation. This protocol will be performed on days 0-4 after the throwing session.
1483817|NCT03091530|Other|90/90 Hip Lift with Balloon Blow Exercise|The 90/90 Hip Lift with Balloon Blow Exercise (BBE) will follow the guidelines described by the Postural Restoration Institute. The subjects will lie supine with hips and knees flexed to 90 degrees, the right arm flexed to end range and resting on the floor. Using the left arm to hold the balloon, subjects will inhale fully and exhale into a balloon while holding a posterior pelvic tilt. The subjects inhale and then exhale into the balloon fully, then hold their breath for 5 seconds while putting their tongue on the roof of their mouth.
1483818|NCT03091517|Behavioral|GlycoLeap|"GlycoLeap is a 24-week programme includes the following features:
Interactive Education Lessons: Beginning week 1, the participant will be presented with a diabetes self-management education curriculum. These lessons are divided into 6 phases, and each lesson is fully accessible online from a computer or mobile phone, and takes approximately 10 - 15 minutes to complete.
The Glyco Mobile Application: During the 24 week intervention period, the participant will use the Glyco mobile application that allows them to track their weight (measured on the wireless weighing scale), self-tested glucose readings (measured using the glucometer kit), and log their foods and meals by taking photos using their phone. A health coach will review the participant's data regularly, provide personalised feedback."
1483819|NCT03091504|Device|High flow nasal cannula|High flow nasal cannula is a soft and flexible nasal prongs with adjustable head strap fits over the patient's ears, it delivers a broad variety of gas flows directly into the nares without gas jetting.
1600192|NCT02234804|Procedure|Angiography|
1483822|NCT03091491|Drug|Nivolumab|Nivolumab 3 mg/kg administered every 2 weeks as a 30 min IV infusion
1483823|NCT03091478|Drug|Pembrolizumab|200mg every 3 weeks
1483824|NCT03091439|Drug|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8.
1483825|NCT03091439|Drug|Standard-of-Care|Patients will receive an antibiotic (oral of IV) consistent with Standard of Care (SOC) for osteomyelitis based on Investigator judgment. The duration of treatment will be 4-6 weeks.
1483826|NCT03091426|Drug|Omiganan|Omiganan 1%
1483827|NCT03091426|Drug|Omiganan|Omiganan 1.75%
1483828|NCT03091426|Drug|Omiganan|Omiganan 2.5%
1483829|NCT03091426|Drug|Placebo|Vehicle
1483830|NCT03091413|Diagnostic Test|diaphragm ultrasound|"For each patient intubated and ventilated in our ICU we will performed diaphragm ultrasound during the weaning process.
We will performed the measurement of diaphragmatic maximum excursion during a maximal inspiration using an abdominal standard preset with M-mode, with the so called anatomical M-mode.
We will put the probe in the right subcostal window to use the hepatic window to assess the movement of the diaphragm. We will performed the measure of the diaphragm excursion with patient in semi-recumbent position and through a transhepatic transverse oblique scan while the patient is on mechanical ventilation and undergo a Pimax maneuver, that consists in a temporary occlusion of the airway with an expiratory pause.
We will performed the measure three times, and we will take into account the best one made by the patient."
1483831|NCT03091400|Drug|Atomoxetine|Atomoxetine (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
1483832|NCT03091400|Drug|Placebo|Identically encapsulated placebo, with dose matched to experimental agent (40 mg qd titration dose for first seven days, followed by 80 mg qd target dose for remaining five weeks)
1483833|NCT03091387|Diagnostic Test|Spontaneous Breathing Test|subjects when ready for extubation will be given a three minute spontaneous breathing test on ET-Cpap mode of the ventilator
1483834|NCT03091374|Drug|Somatotropin (Human)|
1483835|NCT03091361|Other|imaging, no intervention|no intervention
1483836|NCT03091348|Drug|Testosterone|Testosterone cypionate injection
1483837|NCT03091335|Other|Music-listening|Patients listen to music on headphones
1483838|NCT03091322|Device|Pacemaker of the Edora Family (Edora/ Evity/ Enitra/ Enticos) 8|Assessment of the AV Opt and LV VectorOpt features
1483839|NCT03091309|Other|Interactive educational video|A web-link to an educational video on IBD and pregnancy tailored to emphasize the importance of optimal disease control and medication adherence.
1483840|NCT03091309|Behavioral|Initial in-person counseling with an IBD nurse|This session will emphasize key points from the educational video and the nurse will answer any additional questions the subject may have. The nurse will assess subjects' medication adherence and specifically query any concerns subjects may have regarding specific medications and discuss their intentions to be adherent throughout pregnancy.
1483841|NCT03091309|Behavioral|Motivational interviewing|The nurse will be trained in a technique known as motivational interviewing (MI) specifically adapted for optimizing medication adherence during pregnancy.
1483842|NCT03091309|Behavioral|Telemedicine-based follow-up|The IBD nurse will arrange follow-up visits with each subject on a monthly basis with additional ad-hoc sessions as needed. The encounter will focus on monitoring disease activity adherence and applying MI communication skills to reinforce and improve the latter.
1483843|NCT03091309|Other|Monthly follow-up questionnaires|Web-based short questionnaires, administered monthly, will be used to assess medication adherence [self-reported using the 8 item Morisky Medication Adherence Scale (MMAS-8)] and IBD related disease activated [self-reported using PRO-2 scale for Crohn's Disease related disease activity and 6-Point Mayo Score for Ulcerative Colitis related disease activity].
1483844|NCT03091309|Other|Comprehensive questionnaires|Web-based detailed questionnaires, administered at enrolment and gestational week 34, will be used to assess medication adherence [self-reported using the Morisky Medication Adherence Scale (MMAS-8)], patient trust in physician [self-reported using the Trust in Physician Scale (TIPS)], IBD related disease activated [self-reported using the PRO-2 or 6-Point Mayo Score], IBD-specific health related quality of life [self-reported using the Inflammatory Bowel Disease Questionnaire (IBDQ)], patient satisfaction [self-reported using the Patient Satisfaction with Healthcare in Inflammatory Bowel Disease (CACHE) questionnaire]and IBD specific knowledge [self-reported using the Crohn's and Colitis Knowledge (CCKNOW) questionnaire].
1483847|NCT03091231|Diagnostic Test|mpUS multiparametric Ultrasound|compare the mpUS to other methods
2010582|NCT02924688|Drug|FF/UMEC/VI (200/31.25/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 31.25 mcg and VI 25 mcg in each blister.
1483850|NCT03091179|Device|THRIVE|active nasal oxygen delivery system
1483851|NCT03091179|Device|Endotracheal tube|a plastic tube for mechanical ventilation
1483852|NCT03091166|Drug|Dexmedetomidine|
1483853|NCT03091153|Other|Medication Review|In depth medication review with a focus on deprescribing
1483854|NCT03091101|Device|Scleral lens wearing keratoconics|Cohort of keratoconics fitted with scleral lenses and monitored over 6 months
1483855|NCT03091088|Other|walking at an intense pace|Participants walk 6 kilometers in 1 hour at least 3 times per week
1483856|NCT03091088|Other|osteoporosis specific-oriented training|1 hour of physical activity, 2 times per week, based on the Asociación Española con la Osteoporosis y la Artrosis (AECOS) recommendations. Sessions are divided in 15 minutes of warmup (8 to 10, 60-second exercises), 30-35 minutes of combined exercises with loads and weights, as well as high intensity exercises, and 10-15 minutes of cooldown activities (based on Frederick relaxation techniques)
1483857|NCT03091075|Drug|Oxandrolone Pill|Treatment group will receive 24 mg Oxandrolone per day if male and 12 mg Oxandrolone per day if female, with dosing starting at time of surgery and continuing 12 weeks postoperative
1483858|NCT03091075|Drug|Placebo Oral Tablet|Placebo group will receive a placebo oral tablet, beginning at the time of surgery and continuing 12 weeks postoperative
1600193|NCT02234804|Procedure|OCT|
1483859|NCT03091062|Device|Vest® Airway Clearance System|High frequency chest wall oscillation (HFCWO) therapy is commonly prescribed to provide routine airway clearance in patients with a need for regular airway clearance therapy. HFCWO generates high velocity expiratory airflow that is thought to mobilize secretions by the sheer force created.
1483860|NCT03091062|Device|Monarch™ System|Generates airflow at frequencies similar to those provided by HFCWO and also provides direct percussive therapy.
1483861|NCT03091036|Other|Proactive healthcare intervention|There is an intervention in the coordination of health resources, and monitoring readmissions and know the benefit in total cost of care in 4 month.
1483862|NCT03091023|Procedure|Endometrial Biopsy and endometrial fluid collection|
1483863|NCT03091010|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation will be given 100mL of suspension. It will given for a period of 7 days
1483864|NCT03091010|Drug|Steroids|Oral steroids 40 mg (prednisolone) will be given for a period of 7 days in hospital followed by 3 weeks on OPD basis
1483865|NCT03090997|Dietary Supplement|vitamin C (500 mg / day) + placebo|Adminstration of vitamin C (500 mg / day/orally) + placebo (same presentation like resveratrol)
1483866|NCT03090997|Dietary Supplement|resveratrol (500 mg / day) + placebo|Adminstration of resveratrol (500 mg / day/orally) + placebo (same presentation like vitamin C)
1483867|NCT03090997|Dietary Supplement|vitamin C (500 mg / day) and resveratrol (500 mg / day)|Adminstration of resveratrol (500 mg / day/orally) + vitamin C 500 mg/day/orally)
1483868|NCT03090984|Device|PMMA (BKU)|At serial time points before, during and after each study hemodialysis session using a BKU dialyzer, blood samples will be drawn for coagulation activation analyses.
1483869|NCT03090984|Device|PS (Phylter)|At serial time points before, during and after each study hemodialysis session using a Phylter dialyzer, blood samples will be drawn for coagulation activation
1483870|NCT03090984|Device|AN69ST (Evodial)|At serial time points before, during and after each study hemodialysis session using an Evodial dialyzer, blood samples will be drawn for coagulation activation
2010583|NCT02924688|Drug|FF/UMEC/VI (200/62.5/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains UMEC 62.5 mcg and VI 25 mcg in each blister.
1483873|NCT03090958|Behavioral|AllyQuest|AllyQuest is a novel, high impact secondary prevention intervention delivered via mobile phones to improve linkage and engagement in care among newly diagnosed HIV+ YMSM. The development of this intervention is both timely and vital given the urgency of the ongoing HIV epidemic among YMSM. The features of the intervention aim to target previously identified barriers to care among newly diagnosed youth, namely, low HIV health literacy, lack of social support, and internalized stigma related to their diagnosis.
1483874|NCT03090945|Other|This is an obsevational cohort study|no intervention
1483875|NCT03090932|Other|Blood draw|Research subjects will have one tube of blood drawn, approximately 10mL.
1483876|NCT03090919|Other|Platelet transfusion|
1483877|NCT03090919|Other|Saline|
1483878|NCT03090906|Procedure|Soft tissue augmentation palate|"Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.
Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.
Palate (CG) The double incision was made approximately 2 to 3 mm apical to the gingival margins of premolars. The donor tissue was removed and cross-mattress sutures were used to approximate the wound on the palate.
In both groups the epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick."
1483879|NCT03090906|Procedure|Soft tissue augmentation tuberosity|"Recipient site: Intrasulcular incision at the buccal side of the implant extending in one adjacent tooth for each side and a partial-thickness mucosal ﬂap raised. The connective tissue was secured with suture. Allocation to either treatment was performed according to a randomization table.
Donor site A double-bladed scalpel handle 1,5mm was used in both areas to obtain the same thickness.
Tuberosity (TG) The double incision was made from the distal of the terminal tooth. A second incision was made perpendicular to the linear incision at a distal point, which joined the two linear incisions. The graft was removed and a crossed horizontal suspension suture was used.
Epithelial collar removed. Graft required dimensions for both groups:10mm height, 12mm length and 1,5mm thick."
1483880|NCT03090906|Device|Intraoral optical scan|Intraoral optical scan was performed at both groups at baseline, 3 months, 4 months and 12 months to be able to compare volumetric changes.
1483882|NCT03090880|Drug|Tinzaparin Sodium|Subcutaneous tinzaparin 4,500 IU once daily for six months.
1483883|NCT03090867|Other|Relatives or surrogates are encouraged to perform care|"The relative or surrogate will perform at least two cares a week among feeding, mouth care, hair wash, shaving, eye care, hand, foot and face massage.
All care are planned and perform under the supervision or/and in collaboration with a caregiver.
The relative or surrogate will give his opinion by completing the study questionnaires."
1483884|NCT03090867|Other|Conventional ,care|The relative or surrogate will not be encouraged to perform care. The management of the relative or surrogate wi ll not changed from the regular standard of the ICU.
1483885|NCT03090854|Diagnostic Test|ADASCog|Neuropsychological test
1483886|NCT03090841|Biological|Bio-specimen collected|
1483887|NCT03090828|Behavioral|app-based therapeutic education|Patients will connect to a platform providing information on end-stage renal disease and to contact health care providers.
1483888|NCT03090828|Behavioral|enhanced app-based therapeutic education|Patients in the enhanced app group will also have access to a social network. (forum, chat room)
1483889|NCT03090815|Genetic|Sequencing of ctDNA in plasma|Sequencing of ctDNA in plasma
1483890|NCT03090802|Behavioral|Mentoring Adolescent Mothers at School (MAMAS)|Through the MAMAS program, 12 older mentor mothers, who themselves were pregnant adolescents, will mentor 240 younger adolescent mothers to provide ongoing psychosocial support, navigate re-admission to school, and facilitate access to an existing State-sponsored cash transfer, the child support grant (CSG), in the early postpartum period.
1483891|NCT03090776|Drug|Ketamine|low dose bolus and infusion ketamine, administered under general anesthesia
1483892|NCT03090776|Other|Placebo saline|bolus and infusion saline, administered under general anesthesia
1483893|NCT03090763|Genetic|PCR and sequencing|Blood will be subsequently added into a test tube containing RNA solution of a stabilizer, necessary for preservation of the circulating miRNAs. Subsequently, centrifugation will be performed in a cooled centrifuge and the material thus processed will be kept for the subsequent isolation. The isolation of miRNA will be performed using the High Pure miRNA Isolation Kit (Roche, Basel, CHE) according to the manufacturer's standardized procedure. Presence and quality of the miRNA isolated will be spectrophotometrically confirmed using the NanoDrop device (ThermoScientific, Wilmington, DE, USA). By means of the data available in the on-line gene data basis, primers that are necessary for amplification of miRNA through the RT-PCR method using fluorescent dyes will be suggested.
1483894|NCT03090750|Drug|Lavender Oil|Lavender essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
1483895|NCT03090750|Drug|Bergamot Oil|Bergamot essential oil applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
1483896|NCT03090750|Other|Water|Tap water applied to cotton ball (3 drops) and placed in a medicine cup on bedside table
1483897|NCT03090737|Biological|Nivolumab|Specified Dose on Specified Days
1483898|NCT03090724|Drug|BIA 5-453|100 mg of BIA 5-453 (combination of two 50 mg capsules); Oral, once-daily (QD), in the morning in fasting conditions
1483899|NCT03090711|Device|Transcranial Magnetic Stimulation (TMS)|The investigators recently showed that the repeated application of the so-called continuous theta burst protocol (cTBS) over the contralesional hemisphere resulted in a long-standing improvement of visual hemineglect (Cazzoli et al., 2012). The cTBS protocol was developed by Huang et al. (Huang et al., 2005) and modified by the investigators' group (Nyffeler et al., 2006). TBS protocol consists of a burst of 3 pulses at a frequency of 30 Hz, repeated at 6 Hz. One continuous train includes 801 pulses, the duration of one cTBS train is 44 seconds.
1483900|NCT03090711|Device|Transcranial Alternating Current Stimulation (tACS)|TACS stimulation involves two electrodes placed on either side of the desired site of cortical stimulation. The mode of stimulation used in this experiment is identical to previous studies using tACS in sleep ( Marshall et al., 2006; Prehn-Kristensen et al., 2014 ). Stimulation follows a sinusoidal pattern from 0 to 260 μA. This pattern is delivered at 0.75 Hz and is repeated for 225 cycles; a total of 5 minutes of stimulation. This 5 minute pattern is again repeated 5 times, with a minute of no stimulation between each; thus for a total of 30 minutes.
1483901|NCT03090711|Device|sham Transcranial Magnetic Stimulation (TMS)|Sham coil will be used to exclude possible nonspecific effects of the TMS. The sham coil is shielded i.e., the magnetic field output is weakened and therefore insufficiently powerful to stimulate the cortex.
1483902|NCT03090711|Device|sham Transcranial Alternating Current Stimulation (tACS)|Sham stimulation will be used to exclude possible nonspecific effects of the tACS. Sham tACS stimulation will involve actual stimulation for the first 30 seconds of the ramp-up period (stimulation power is gradually increased until its final level), and then immediately gradually decreased until zero (without the intermediate 4 minutes of actual stimulation). This procedure will be repeated 5 times every 6 minutes and shall induce similar cutaneous sensations as real stimulation.
1483903|NCT03090698|Drug|Hylan G-F 20|intra-articular administration
1483904|NCT03090698|Drug|Triamcinolone|Intra-articular administration
1483905|NCT03090685|Procedure|True auriculotherapy with seeds|Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape in 4 to 5 specific body points to control musculoskeletal pain.
1483906|NCT03090685|Procedure|Placebo Auriculotherapy with seeds|Roasted edible mustard seeds with ~ 2mm diameter fixed with adhesive tape at 4 points located in the auricular lobe not specific for musculoskeletal pain.
1483907|NCT03090672|Drug|Normal Saline|Normal Saline IV delivery
1483908|NCT03090672|Procedure|Tissue Stromal Vascular Fraction|tSVF
1483909|NCT03090672|Biological|Platelet Rich Plasma|PRP
1483910|NCT03090672|Procedure|Cellular Stromal Vascular Fraction|cSVF
1483911|NCT03090659|Biological|LCAR-B38M CAR-T cell injection|
1483912|NCT03090646|Other|Financial Incentive|A financial incentive of up to three gift cards to a major online retailer.
1483913|NCT03090633|Device|Fetoscopy|Minimally invasive in-utero surgery
1483914|NCT03090620|Drug|Physostigmine|Administration of physostigmine bolus followed by an infusion
1483915|NCT03090620|Drug|Lorazepam|Administration of lorazepam bolus followed by normal saline infusion
1483916|NCT03090607|Device|Aluvra™|Endoscopic injection of bulking agent to the lower esophageal sphincter
1483917|NCT03090607|Drug|Saline|Endoscopic injection of saline
1483918|NCT03090594|Procedure|Biopsy|Is to obtain pulmonary parenchyma samples using a flexible bronchoscope.
1483919|NCT03090581|Procedure|Biopsies CP|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a cryoprobe.
1483920|NCT03090581|Procedure|Biopsies FC|Transbronchial biopsies will be obtained with a flexible bronchoscope, using a forceps.
1483921|NCT03090568|Drug|BIA 5-453|BIA 5-453 capsules 50 mg. Route of administration: Oral. In one period subjects received 4 capsules of 50 mg of BIA 5-453 after a fasting of at least 10 hours, and in the other period subjects were dosed with 4 capsules of 50 mg of BIA 5-453 after a standard high-fat and high-calorie meal
1483922|NCT03090555|Procedure|Translational manipulation|After the patient receives an interscalene block on the affected side, a physical therapist performs a series of thrust manipulations on the participant's affected shoulder. The participant's identified limitations of physiological and accessory motion revealed during manual examination guided the physical therapist's choice of technique, which primarily consisted of an accessory superior to inferior accessory gliding motion performed in a physiological position of limited motion. Additional gliding manipulations in combined movement positions such as increased flexion or abduction plus internal or external rotation were utilized until full passive physiologic motion was restored.
1483923|NCT03090555|Procedure|Manual therapy|The first clinic treatment session for all study participants included instruction in the home program of static stretching, resistive exercise, and ice, issue of an illustrated handout and digital video disc detailing the same program, and manual therapy (MT) by a physical therapist that included all indicated grades of non-thrust manipulation of the joints and soft tissue. The MT intervention was targeted toward any identifiable upper quarter pain or movement impairments. Subsequent clinic treatment sessions included additional MT, progression of the strengthening exercises, and reinforcement of the home program.
1484032|NCT03089775|Drug|BBI-2000|Experimental
1600847|NCT02229747|Drug|Diclofenac|
1483925|NCT03090529|Other|Exercise Group|The 12-week exercise-training program will include three sessions of aerobic exercise per week
1483926|NCT03090516|Drug|Ginkgo biloba dispersible tablets|Arm C：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.
1483927|NCT03090516|Drug|Donepezil|Arm A：Aricept 5mg/day
1483928|NCT03090516|Drug|Ginkgo biloba dispersible tablets and Donepezil|Arm B：Ginkgo biloba dispersible tablets，0.15g at a time， three times a day.Aricept 5mg/day.
1483929|NCT03090503|Drug|Aripiprazole|Initial dose: 10 mg.
1483930|NCT03090503|Drug|Risperidone|Initial dose: 2 mg.
1483931|NCT03090490|Other|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients
1483932|NCT03090490|Other|Maintenance treatment discontinuation|Maintenance antipsychotic medication to stabilized patients
1483933|NCT03090477|Behavioral|Pharmaceutical care and adherence aids|Medication review including drug-interaction check, individual patient counseling to improve understanding of treatment rationale and to elicit and address treatment-related concerns, provision of information booklets and adherence aids (calender blister packaging and smartphone medication reminder application), phone calls and face-to-face visits to follow-up on medication-related issues scheduled over a period of 6 months.
2010584|NCT02924688|Drug|FF/VI (100/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 100 mcg in each blister and the second strip contains VI 25 mcg in each blister.
1483935|NCT03090451|Behavioral|Aerobic Exercise|Aerobic physical exercise on treadmill, with intensity based on prior VO2-max testing during the screening visit.
1483936|NCT03090438|Procedure|Varicocele embolization|Ultrasound guided right internal jugular vein access with placement of a vascular sheath. Fluoroscopically guided selective catheterization of the left and right (if bilateral) spermatic veins to the level of the inguinal ligament. Occlusion of the spermatic vein(s) by embolization coils and a sclerosing agent (sodium tetradecyl sulphate 3%).
1483937|NCT03090412|Drug|HPPH|Given IV
1483938|NCT03090412|Other|Laboratory Biomarker Analysis|Correlative studies
1483939|NCT03090412|Drug|Photodynamic Therapy|Undergo PDT
1483940|NCT03090412|Other|Quality-of-Life Assessment|Ancillary studies
1483941|NCT03090412|Procedure|Therapeutic Conventional Surgery|Undergo standard of care surgery
1483942|NCT03090399|Device|FloTrac|For patients belonging to case group a Pulse Contour Analysis was adopted for optimize fluid administration
1483943|NCT03090386|Other|Cognitive Surveys|Complete the Cognitive Communication Survey, standardized cognitive and language assessments, and the Follow-up Cognitive Communication Survey after treatment
1483944|NCT03090373|Device|UroShield|The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
1483945|NCT03090360|Dietary Supplement|Infant formula (CF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
1483946|NCT03090360|Dietary Supplement|Infant Formula (EF)|Formula-fed infants will be randomly assigned to receive one of the study formulas (CF or EF) orally, ad libitum, each day from Study Day 1 until Study Day 180, for a treatment duration of approximately 180 days.
1483947|NCT03090347|Other|Overconsumption of specific dietary nutrient|Subjects will be studied before and then after the consumption of a diet where specific nutrients are provided in excess.
1483948|NCT03090334|Diagnostic Test|De-escalation|Antifungal therapy will be stopped according with BG results
1483949|NCT03090321|Behavioral|Stand Prompt|The participant will receive a notification asking them to stand or walk if they have been sitting for longer than 60 minutes
1483950|NCT03090321|Behavioral|Step Prompt|The participant will receive a notification if they are below 5000 steps by 3pm each day asking them to get to 10000 steps.
1483951|NCT03090321|Behavioral|Cluster Prompt|The participant will receive daily information notifications specific to the activity cluster they fall into based on the activity data collected in phase 1 of the study
1483952|NCT03090321|Behavioral|Newsfeed|Daily reminder to read the newsfeed article provided in the app, this is a control arm
1483953|NCT03090308|Other|Noninvasive positive pressure ventilation|All patients were ventilated using NIPPV (Engstrom Carestation), which was delivered to the patient through full-face mask and was started with pressure support of 8-12 cmH2O and PEEP of 3-5 cmH2O and gradually increased in 2 cmH2O steps. When patients tolerate FiO2 ≤ 0.5 with pressure support ≤ 8 cmH2O and PEEP ≤ 5 cmH2O for > 6 consecutive hours, withdrawal from NIPPV was attempted daily in 30 minutes spontaneous breathing trials.
1483954|NCT03090295|Device|Palpation and Accuro|Identify placement for spinal
1483955|NCT03090282|Procedure|mechanical treatment(mainly scaling and root planing), periodontal surgery(if indicated), implant placement.|The investigators shall follow the regular procedure to these patients.
1483956|NCT03090269|Drug|Methylphenidate Pill|3-month follow-up to study the effective dose as a treatment for cocaine dependence in toxicity and reduction in cocaine use
1483957|NCT03089164|Diagnostic Test|Right heart catheterization|Each patient will have variables measured supine, sitting and standing positions
1483958|NCT03089151|Behavioral|Community Garden Intervention|"The investigators will recruit 30 prospective gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. DUG randomly assigns people on each garden wait list to available plots, using a lottery. This creates a natural randomized experiment. Participants randomized to the garden intervention will receive a standardized garden resource package, which includes the following:
A garden plot in a Denver Urban Garden
Seeds and plant starts
Introductory gardening workshop
Social events including garden-specific events and garden mentoring.
The non-gardening group will remain on the DUG wait lists and will not receive these resources.
Duration of the intervention is 1 year."
1483959|NCT03089138|Drug|Regan Tangjiang|The treatment duration is 3 consecutive days.
1483960|NCT03089125|Behavioral|Dyspnea Intervention|"Dyspnea intervention will be administered over two sessions
Patients will receive:
Psychoeducation
Relaxation training for reducing physiological stress
Behavioral techniques for managing acute breathlessness"
1483961|NCT03089125|Other|Usual Care|Patients will receive any usual care for their dyspnea as deemed appropriate by their clinicians
1483962|NCT03089112|Drug|HGP1607|
1483963|NCT03089112|Drug|HGP1501|
1483964|NCT03089112|Drug|HGP1607+HGP1501|
1483965|NCT03089099|Other|Blood drawing|Blood drawing
1483966|NCT03089086|Biological|Licensed 4CMenB vaccine|Two doses (0.5 mL each) of Bexsero ® vaccine at least 1 month to <3 months apart in adolescents.
1992836|NCT03290326|Device|Transcranial Alternating Current Stimulation (tACS)|tACS will be applied at a frequency of 40Hz and targeting the area of maximal tracer uptake on amyloid PET imaging using an individualized multielectrode design to maximize the induced electrical current to the target region.
1483968|NCT03089060|Device|Silicone Finger cap|Treatment with silicone finger cap
1483969|NCT03089060|Device|Film Dressing|Treatment with conventional film dressing
1483970|NCT03089047|Biological|Transfusion of rejuvenated and washed autolgous RBCs|Rejuvenation refers to the process of adding a mix of solutes (Rejuvesol®, Citra Labs, Braintree, MA; consists of sodium pyruvate, inosine, adenine, mono- and dibasic sodium phosphate) to older, stored (i.e., 2-3 DPG-depleted) blood to immediately restore 2,3-DPG and ATP levels in the stored red blood cells15. Rejuvenation was originally developed to prolong the storage life of rare-phenotype RBC units. It is FDA-approved for use in RBC units stored in CPD, CPDA-1, and AS-1. The major contraindication for the use of Rejuvesol® is in RBC units stored for fewer than 6 days due to high baseline 2,3-DPG and ATP levels. Rejuvenated units must be washed prior to administration to remove residual Rejuvesol that is not approved for iv administration in such concentrations.
1483971|NCT03089047|Biological|Transfusion of washed autolgous RBCs|Autologous RBCs will be washed prior to transfusion to maintain blinding and equalize volume and Hct with the rejuvenated and washed intervention arm
1483972|NCT03090243|Device|Virtual colonoscopy|Inserting a Foley catheter through the anus, and gas inflating of the bowel.
1483973|NCT03090230|Device|Relay Pro Thoracic Stent-Graft System|RelayPro Thoracic Stent-Grafts are designed for the management of patients with aneurysms and penetrating ulcers within the descending thoracic aorta (DTA). The device is designed specifically for use in the thoracic aorta.
1483974|NCT03090217|Behavioral|Pelvic Physiotherapy|1) daily pelvic floor muscle training (PFMT).
1483975|NCT03090217|Behavioral|Standard care (SC)|1) daily vaginal dilator therapy (10 to 15 minutes) and 2) usual care management.
1483976|NCT03090204|Procedure|ultrasound measurements|ultrasound measurements of myocardial deformation of free wall right ventricle at 4 time points during a session of intermittent hemodialysis : before the intermittent hemodialysis connection, just after starting hemodialysis, after 1 hour of hemodialysis and 5 minutes before restitution
1483979|NCT03090178|Other|electronic-Patient Report Outcome and wear of a wristband actigraph|Measurement of sleep quality and quantity with wristband actigraph and evaluation of quality of life with electronic-Patient Report Outcome
1483980|NCT03090165|Drug|ribociclib|400mg PO
1483981|NCT03090165|Drug|ribociclib|600mg PO
1483982|NCT03090165|Drug|Bicalutamide|150mg PO
1483983|NCT03090152|Procedure|Periarticular injection (Deep injection)|"Deep injection of cocktail containing Bupivacaine with Epi, 30mL; Morphine, 8mg/mL, 1mL; Methyprednislone, 40mg/mL, 1mL; Cefazolin, 500mg in 10 mL; saline, 22mL into the anterior capsule, the periosteum, the gluteus maximus, and the abductor muscles and fascia lata."
1483984|NCT03090152|Procedure|Periarticular injection (Superficial injection)|Superficial injection of 40mL 0.25% Bupivacaine into subcutaneous tissue prior to wound closure.
1483985|NCT03090152|Drug|Bupivacaine|EPCA: Bupivacaine 0.06%.
1483986|NCT03090152|Drug|Placebo|EPCA: Saline.
1483987|NCT03090139|Drug|Anti-TNF Therapy|Anti-TNF therapy.
1483988|NCT03090126|Other|Therapeutic education|Questionnaires
1483989|NCT03090113|Drug|Shuxuetong Injection|intravenous drip
1483990|NCT03090113|Drug|Placebo Injection|intravenous drip
1483991|NCT03090100|Drug|Guselkumab|Participants will receive 1 injection of active guselkumab at Weeks 0, 4, 12, 20, 28, 36, and 44.
1483992|NCT03090100|Drug|Placebo|Participants will receive 1 injection of placebo at Weeks 0, 4, 12, 20, 28, 36, and 44 and 2 injections of placebo at Weeks 1, 2, 3, 8, 16, 24, 32, and 40.
1483993|NCT03090100|Drug|Secukinumab|Participants will receive 2 injections of active secukinumab at Weeks 0, 1, 2, 3, 4 and every 4 weeks (q4w) thereafter through Week 44.
1483994|NCT03090087|Biological|Hypoxia|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
1483995|NCT03090087|Drug|Regadenoson|The purpose is to test the effect of A2A adrenoceptor stimulation on the diameter of retinal arterioles during hypoxia in vivo
1483996|NCT03090074|Behavioral|Diet regime|Randomization to moderate or extreme low-carbohydrate Mediterranean diet advice.
1483997|NCT03090074|Behavioral|Type of psychological support|Randomization to group-based psychological support according to ACT or to traditional cognitive behavioral therapy
1483998|NCT03090061|Diagnostic Test|Light induced fluorescence intraoral camera|assessment of marginal integrity of resin composite restorations by light induced fluorescence intraoral camera
1483999|NCT03090061|Diagnostic Test|Visual-tactile assessment method according to FDI criteria|assessment of marginal integrity of resin composite restorations by visual-tactile method that includes the use of mirror, FDI probe under good illumination condition,
1484000|NCT03090048|Drug|Vitamin A|Vitamin A 2-3 % concentration
1484001|NCT03090048|Drug|Azithromycin|azithromycin monohydrate
1484002|NCT03090035|Drug|Pegylated Interferon α2|Peg-INF was given in a dose of 180 μg/week
1484003|NCT03090035|Drug|Ribavirin|ribavirin 1200 mg/day to every patient for the period of 24 weeks for HCV genotype 2 & 3
1484004|NCT03090022|Procedure|Strattice|Intra-abdominally Fixation
1484005|NCT03090022|Procedure|Single running suture of abdominal fascia|Intra-abdominal suture
1484006|NCT03090009|Drug|Flurbiprofen|100 mg twice a day for 14 days
1484007|NCT03090009|Drug|Placebo Oral Tablet|placebo group
1484033|NCT03089775|Drug|Vehicle|Vehicle Comparator
1484034|NCT03089775|Other|Multiple treatments|BBI-2000, Vehicle, Clobetasol Propionate, No treatment
1484035|NCT03089762|Biological|Intra-articular injection of SVF plus PRP|administering SVF and PRP intra-articularly into patients with osteoarthritis grade 1 and 2
1484008|NCT03089996|Procedure|Piezocision|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil). The retraction of the canines will begin using closed nickel-titanium spring (120g). The piezocision surgery will be performed only in one side of the mouth. Three vertical piezo-incisions will be performed near the edentulous region and mesially to the canine root, in the vestibular alveolar cortical bone with the Ultrasonic instrument (BS1 insert Piezotome ™, Satelec Group Acteon Merignac, France) in depth of 3 mm. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months. The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
1484009|NCT03089996|Procedure|Corticotomy|The first maxillary premolars will be extracted with orthodontic purpose. After 3 months of extraction, the orthodontic alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli, Sorocaba, SP, Brazil).The retraction of the canines will begin using closed nickel-titanium spring (120g).The corticotomy surgery will be performed at the day of begining of canine retraction only in one side of the mouth.A mucoperiosteal flap will be raised from the extraction region to the mesial of the canine.Perforations will be performed using a number 2 spherical drill bit in low speed handpiece under irrigation, only in the cortical none depth.The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.The patients will be advised to take analgesics (paracetamol or dipyrone) only if necessary.
1484010|NCT03089996|Device|Control Side|The first maxillary premolars will be extracted with orthodontic purpose. Fixed orthodontic appliance will be bonded (0.022x0.025 slot with MBT prescription in incisors and Standart in the other teeth) with a power arm welded in the bracks upper canines brackets. After 3 months of extraction, the alignment and dental leveling will be obtained and a 0.016x0.022 stainless steel wire will be placed, as well as orthodontic mini-implants (Morelli®, Sorocaba, SP, Brazil) between the roots of the second premolars and molars. At that time an intra-oral digital scan will be performed. The retraction of the canines will begin using closed nickel-titanium spring (120g of force) from the power arm to the mini-implant. No surgery will be done at this side. The intraoral digital scans will be performed with 7 and 14 days after the start of retraction, and then 14 in 14 days to a maximum period of 6 months.
1484011|NCT03089983|Drug|Naltrexone|A naltrexone implant lasting 90 days will be used to deliver naltrexone.
1484012|NCT03089983|Drug|Methadone|Participants will receive daily or weekly doses of oral methadone.
1484013|NCT03089983|Drug|Isoniazid|Participants will be randomized to receive standard INH as TB treatment in prison for 26 weeks.
1484014|NCT03089983|Drug|Rifapentine|Participants will be randomized to receive short course INH + RIF as TB treatment in prison for 12 weeks.
1484015|NCT03089970|Diagnostic Test|Exhaled breath condensate collection|Breath from humans is cooled, condensed, and collected
1484016|NCT03089957|Drug|Ulinastatin|200,000 IU ulinastatin will be dissolved in 100 mL of 0.9% normal saline by continuous intravenous infusion for 1h, 3 times per day for 5 days.
1484017|NCT03089957|Other|Usual care|Usual care in ICU.
1484018|NCT03089944|Drug|Glecaprevir/Pibrentasvir|Tablet
1484019|NCT03089931|Procedure|Cervical spinal surgery|Cervical laminoplasty or anterior discectomy and fusion
1484021|NCT03089905|Drug|Sevoflurane|Experimental arm: end tidal concentration of 0.6 -0.8% or less. Active comparator arm: end tidal concentration of 2.5-3.0% or greater.
1484022|NCT03089905|Drug|Remifentanil|Experimental arm: loading dose: 1 mcg/kg, infusion starting at 0.1 mcg/kg/min or greater.
1484023|NCT03089905|Drug|Dexmedetomidine|Experimental arm: loading dose:1mcg/kg, infusion: 1 mcg/kg/hr.
1484024|NCT03089879|Biological|GVGH Shigella sonnei 1790GAHB vaccine|Single dose administered at Day 1, by intramuscular injection.
1484025|NCT03089866|Drug|Midazolam (0.02mg/kg)|Quantify the effects of sedation with midazolam on auditory activation and cognitive performance (mini Mental State exam and complex reaction time).
1484026|NCT03089853|Device|Neuromuscular electrical stimulation (NMES)|Bipolar self-adhesive neuromuscular stimulation electrodes will be placed over the quadriceps femoris muscle group. Stimulation pulses (30 Hz trains of 300 μsec biphasic pulses) will be delivered using the neuromuscular electrical stimulator. A 5 sec on/25 sec off work/rest ratio will be used initially, progressing to 10 sec on/30 sec off. The patient will be fully supported while knee extensions are performed as the participant sits in a chair. Current from the stimulator will be manually increased and determined by patient tolerance. The goal for each patient will be to reach the highest tolerable amplitude (up to 100mA). Training will be performed on each quadriceps femoris muscle, 30 minutes/day, for 2 weeks including hospital stay till return to the COPD Clinic. This will be followed by pulmonary rehabilitation exercises delivered at home via a smart phone for an additional 10 weeks. Rehabilitation will involve aerobics, strength training as well as breathing exercises.
1484027|NCT03089840|Device|OrganOx metra|Following the routine retrieval procedure at the donor hospital the liver will be flushed with cold preservation solution and prepared for cannulation. The donor organ is then placed on the OrganOx metra device and will be perfused with warmed solution. The OrganOx metra device containing the donor organ is then transported to the recipient transplant centre. The donor liver is then removed from the device and flushed with standard of care preservation solution. Alternatively, where more practical, the livers will be transported to the University of Alberta hospital with ≤ 6 hours of cold storage and then placed on the metra™ for ≥ 4 hours. Implantation and reperfusion of the liver proceed as per the usual practice of the recipient transplant centre.
1484028|NCT03089814|Procedure|ischemic conditioning|Four cycles of 5-min inflation of pneumatic cuff on upper extremity up to 200 mmHg, followed by 5-min deflation with no pressure.
1484029|NCT03089801|Other|Tablet-Enabled Video Telehealth|Veterans referred for tablet-enabled video telehealth will receive a VA-issued tablet that can be used to communicate via video with health care providers (e.g., for chronic disease management, mental health treatment, palliative care).
1484030|NCT03089788|Other|Home-based test|Home-based tests in which the participant pets his/her cat until he/she reaches a certain symptom strength.
1484031|NCT03089788|Other|Skin test|Skin Prick Tests will be performed with registered cat allergen extract.
1484036|NCT03089736|Behavioral|Education|Six education areas was offered: pain and pain physiology, pain medication, side effects and prevention of side effects, abuse of medications, sleep advice and advice on anxiety.
1484037|NCT03089736|Behavioral|Self Care|The following instructions on self-care for pain relief: apply ice or crushed ice in the oral cavity, lubricating and antiseptic mouth rinses, pain relieving gel, tongue movements and gaps exercises. Prevention of dryness in the mouth and throat; saliva stimulants and saliva substitute agents in different preparations, increased measures of good oral hygiene. Physical activities and regular rest once to several times per day. Sleep restriction and measures to treat sleep disorders.
1484038|NCT03089736|Other|Treatment as usual (TAU)|pharmacological treatment + advices
1484039|NCT03089723|Behavioral|Visual Analog Scale (VAS)|Answer Visual Analog Scale (VAS) questionnaire at baseline, 1 month, 3 months and 6 months
1484040|NCT03089723|Behavioral|Range of Motion (ROM)|submitted to ROM at at baseline, 1 month, 3 months and 6 months
1484041|NCT03089723|Behavioral|Palmar grip strength|submitted to palmar grip strength at at baseline, 1 month, 3 months and 6 months
1484042|NCT03089723|Behavioral|Lateral grip strength|submitted to lateral grip strength at at baseline, 1 month, 3 months and 6 months
1484043|NCT03089723|Behavioral|Pulp-pulp pinch strength|submitted to pulp-pulp pinch strength strength at at baseline, 1 month, 3 months and 6 months
1484044|NCT03089723|Drug|Lavage with physiologic saline solution|Joint lavage with physiologic saline solution. After emptying of the joint, 1mL saline solution will be injected.
1484045|NCT03089723|Drug|Lavage with physiologic saline solution and Osteonil® Mini|Joint lavage with physiologic saline solution and Osteonil® Mini
1484046|NCT03089723|Behavioral|Quick Dash|Answer Quick Dash questionnaire at baseline, 1 month, 3 months and 6 months
1484047|NCT03089723|Behavioral|Sollerman Test|Perform Sollerman Test at baseline, 1 month, 3 months and 6 months
1484048|NCT03089710|Other|Mini-fluid challenge|Mini-fluid challenge test with 100mL colloid infusion in 1 min
1484049|NCT03089697|Biological|N-Rephasin® SAL200|A single dose of SAL200 (SAL-1, 3mg/kg) intravenous administration of the study drug, in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
1484050|NCT03089697|Other|Placebo|A single dose of the formulation buffer (placebo), excluding the main ingredient of the study drug in addition to the conventional standard treatment (antibiotics) for MRSA/MSSA
1484051|NCT03089684|Other|No intervention|No intervention
1484052|NCT03089671|Other|Vitamin B (riboflavin, vitamin B2)|Vitamin B is a natural health product approved as a colouring agent.
1484053|NCT03089671|Other|5% Dextrose in Water (D5W)|5% Dextrose in Water is an irrigation/instillation fluid, commonly used in intravenous lines.
1484054|NCT03089658|Drug|Avelumab|Avelumab should be administered intravenously as per the recommended dose. Administration of Avelumab should continue according to the recommended schedule until disease progression or unacceptable toxicity.
2001054|NCT03240900|Device|Electrical Stimulation|Electrical stimulation - a needle attached to an cathode polarity will be placed within the intercostal space near the 4th intercostal nerve. A second needle attached to the anode polarity will be inserted into the serratus anterior muscle. Both electrodes will then be attached to a Grass SD9 stimulator and the voltage and frequency of the stimulation will be titrated to the point where contraction of the intercostal muscles is palpable. It will be maintained at this level for one hour at which point the wires will be removed. This technique is part of the standard of care for peripheral nerve surgeries of the extremities and is proven to be safe in humans.
1484057|NCT03089632|Other|Gluten-free diet|One-month gluten-free diet
1484058|NCT03089619|Drug|Human-Spongiosa|after tooth extraction, the dental alveolus is filled with the bone substitute material (Human-Spongiosa) and covered with a membrane (mucoderm®)
1484059|NCT03089619|Device|collacone®|after tooth extraction, the dental alveolus is filled with the bone substitute material (collacone®) and covered with a membrane (mucoderm®)
1484060|NCT03089606|Diagnostic Test|FDG PET/CT scan|FDG PET/CT scan with IV contrast prior to treatment and C11-AMT PET scan co-registered with CT scan without IV contrast
1484061|NCT03089606|Diagnostic Test|C11-AMT PET scan|C11-AMT PET scan co-registered with CT scan without IV contrast after FDG PET/CT scan with IV contrast before pembrolizumab
1484062|NCT03089606|Drug|Pembrolizumab|200 mg Pembrolizumab IV administered over 30 minutes on day 1. Repeat every 3 weeks for 4 cycles, until progression, or subject withdrawal for other reasons
1484063|NCT03089606|Diagnostic Test|FDG PET/CT scan with IV contrast|At end of Pembrolizumab treatment
1484064|NCT03089593|Other|Extract of ginger|The volunteers will receive two capsules containing 200mg of extract of ginger with 5% of gingerols (20 mg). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
1484065|NCT03089593|Other|Placebo (Cellulose)|The volunteers will receive two capsules containing cellulose (placebo). Breakfast will be offered (bread, butter, turkey ham and industrialized fruit juice) and the participants will have 15 minutes to eat it.
1484066|NCT03089580|Device|Intense Pulsed Light Therapy|Intense pulsed light therapy is a non-invasive and non-laser light treatment that was approved in 1995 by the FDA for dermatology. Participants will receive a total of 4 treatments over the course of the study.
1484067|NCT03089580|Procedure|Sham Treatment|The sham treatment will mimic the IPL treatment but no light will be delivered. Sham treatment will be administered 4 times throughout the study.
1484068|NCT03089567|Drug|Sodium Fluoride|5% Sodium Fluoride Varnish used for dental caries prevention and desensitizer
1484069|NCT03089567|Drug|Silver diamine fluoride|38% Silver Diamine Fluoride used for dental caries prevention and desensitizer
1484070|NCT03089554|Drug|Therapeutic Intervention|Therapeutic Intervention
1484072|NCT03089528|Device|Videolaryngoscopy|the trachea will be intubated with a videolaryngoscope
1484073|NCT03089528|Device|laringoscope|the trachea will be intubated with a laringoscope
1484074|NCT03089515|Diagnostic Test|Cardio-Pulmonary Exercise Testing (CPET)|This test helps determine if the decreased tolerance to exercise or shortness of breath with activity a patient is experiencing is caused by a cardiac disease, versus a pulmonary disease.
1484247|NCT03088124|Drug|Apalutamide|Patients will take orally everyday 240 mg of Apalutamide.
1600848|NCT02229747|Drug|Nimesulide|
1484076|NCT03089489|Diagnostic Test|lung biomarkers in organ donor for PGD in lung recipient|Lung biopsies in organ donor before and after cold ischemia
1484077|NCT03089476|Other|Evaluating atopy in infants|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
1484078|NCT03089476|Other|Evaluating TEWL and STS in adults|This study does not have an intervention. There is the evaluation of the predictive value of TEWL and STS in atopic infants at risk of developing eczema and TEWL and STS in parents of infants.
1484079|NCT03089463|Diagnostic Test|Observation|The primary objective is to employ the measurements of neuropathy, micro/macro-perfusion, and biomechanics of the foot mainly tissue stiffness and plantar pressure to determine the vulnerability of foot to mechanical trauma and ulceration. From the data collected it is proposed that a prognostic risk stratification system will be developed based on the range of parameters collected to identify those that are at highest risk of ulceration incident. Those that are classed as high risk are to be sub-stratified to increase the accuracy of the system in predicting ulceration. This will allow a patient-specific approach to be taken in the prevention of ulcers by providing adequate information to predict ulceration incident.
1484080|NCT03089450|Device|CGBio stent|Percutaneous Coronary Intervention
1484081|NCT03089450|Device|Biomatrix flex|Percutaneous Coronary Intervention
1484082|NCT03089437|Behavioral|Prolonged Standing|Subject will stand for 12 hours and undergo a high fat tolerance test the subsequent day
1484083|NCT03089437|Behavioral|Prolonged Sitting|Subject will sit for 12 hours and undergo a high fat tolerance test the subsequent day
2001055|NCT03240900|Procedure|Placebo|This breast will receive no electrical stimulation; the mastectomy and reconstruction will proceed with no intervention.
1484086|NCT03089398|Procedure|Hybrid Coronary Revascularization|sternal-sparing, off-pump, isolated LIMA-LAD revascularization
1484087|NCT03089398|Device|Hybrid Coronary Revascularization|percutaneous revascularization of at least one non-LAD target
1484088|NCT03089398|Device|Percutaneous Coronary Intervention|Multi-vessel PCI with metallic drug-eluting stents (DES) including the LAD and or LM. Only FDA approved commercially available metallic drug-eluting stents may be used in this protocol.
1484089|NCT03089385|Other|Hypertension tool|An algorithm developed by staff at UHN to help manage hypertension in hemodialysis patients.
1484090|NCT03089372|Device|ARIES-ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
1484091|NCT03089346|Diagnostic Test|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE)|Magnetic Resonance Imaging (MRI) with Ultrashort Echo Time (UTE) pulse sequences on a 1.5T magnet (Avanto dot, Siemens) with 3D reconstruction of the bronchial tree using Neko-MR software in asthma in order to assess bronchial thickness.
1484092|NCT03089346|Diagnostic Test|Computed tomography (CT)|Computed tomography (CT) on a Definition 64 (Siemens) with 3D reconstruction of the bronchial tree using Neko-3D software in asthma in order to assess bronchial thickness.
1484093|NCT03089333|Drug|Dapagliflozin 10mg|Dapagliflozin at a dose of 10mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
1484094|NCT03089333|Drug|Glibenclamide 5Mg Tablet|Glibenclamide at a dose of 5mg daily in combination with metoformin and current antihypertensive therapy for 12 weeks
1484095|NCT03089320|Behavioral|Contingency Management Counseling|Contingency management (CM) is an efficacious treatment for individuals with substance use disorders. In line with operant conditioning, CM typically provides reinforcers (rewards) contingent upon attaining specified goals such as decreased substance use and/or abstinence.
1484096|NCT03089320|Behavioral|Addiction Physician Management|Patients in the CM plus stepped care arm who have PEth > 8 ng/ml at 3 months will progress to Step 2 and receive onsite treatment from an Addiction Psychiatrist (APM) in the HIV clinic. APM will provide care that is typically provided by physicians in specialty referral programs.
1484205|NCT03088371|Other|Pajunk Needle|For local anaesthesia application in psoas sciatic block
1484206|NCT03088371|Other|Portex combined spinal epidural kit|For combined spinal epidural anaesthesia
1484207|NCT03088371|Drug|Lidocaine 1%|For psoas sciatic block.
1484208|NCT03088371|Drug|Bupivacaine 0.5%|For spinal anaesthesia in combined spinal epidural anaesthesia.
1484209|NCT03088371|Drug|Lidocaine 2 %|For psoas sciatic block in the post-operative period
1601284|NCT02226458|Drug|EPI-743|
2001057|NCT03239561|Drug|[18F]MNI-1020|Participants will receive a single intravenous bolus injection of [18F]MNI-1020 at a dose of not more than 10 millicurie (mCi), with a maximum mass dose of 10 microgram (mcg) and maximum volume of 10 milliliter (mL) at imaging visit.
2001058|NCT03235739|Drug|Naloxegol 25 MG|Oral Naloxegol 25 MG
2001059|NCT03235739|Drug|Placebo|matching oral placebo
2001060|NCT03236311|Drug|SAR407899|Pharmaceutical form:Capsule Route of administration: Oral
2001061|NCT03236311|Drug|Placebo|Pharmaceutical form:Capsule Route of administration: Oral
2001062|NCT03236311|Drug|Adenosine|Pharmaceutical form:Solution for injection Route of administration: Intravenous
2001063|NCT03236311|Drug|Regadenoson|Pharmaceutical form:Solution for injection Route of administration: Intravenous
2001064|NCT03233776|Drug|Anakinra|Subjects will be treated with a daily dose of anakinra, intravenously, starting on day -2, until day +12 (day 0 is day of SCT). Predefined doses are 100 mg , 200 mg and 300 mg.
2001065|NCT03234361|Dietary Supplement|High Phosphate Phase|2 capsules of sodium phosphate with 500mg/day of phosphate.
1484097|NCT03089320|Behavioral|Motivational Enhancement Therapy|"Patients in the CM plus stepped care arm who have PEth > 8 ng/ml at 3 months will progress to Step 2 and receive onsite Motivational Enhancement Therapy (MET) from the Social Worker in the HIV clinic.
MET is grounded in research on processes of natural recovery during which patients move through stages of change - precontemplation, contemplation, determination, action, and maintenance. The Social Worker's role is to assist the patient in moving through the stages of change. MET uses motivational interviewing and reflective listening to help patients identify internal sources of motivation to support reductions in alcohol."
1484098|NCT03089307|Device|Dornier Aries- ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites).
1484099|NCT03089294|Device|Aries ED device|The Dornier Aries-ED device will be used for the purpose of the study. LI-ESWT will be applied to the penile shaft 3 areas, and the 2 crura (two sites)
2001066|NCT03234361|Dietary Supplement|Low Phosphate Phase|2 capsules of sodium chloride.
1484101|NCT03089268|Procedure|Colonoscopy|A colonoscopy will be performed to all individuals.
1484102|NCT03089268|Procedure|Polypectomy or biopsy|All lesions will be removed or biopsied during the procedure
1484103|NCT03089268|Genetic|Molecular analysis|"Molecular analysis will be performed in all colorectal cancers and in those polyps diagnosed with serrated lesion"
1484104|NCT03089242|Other|observation of microRNA expression|no intervention
1484105|NCT03089229|Drug|HAT01H Cream|HAT01H Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
1484106|NCT03089229|Drug|Vehicle Cream|Vehicle Cream will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
1484107|NCT03089216|Procedure|Combined Bleaching(2x20)|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
1484108|NCT03089216|Procedure|Combined Bleaching(2x20) with arginine|one clinical session with two applications of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
1484109|NCT03089216|Procedure|Combined Bleaching (1x20)|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
1484110|NCT03089216|Procedure|Combined Bleaching(1x20) with arginine|one clinical session with one application of 35% hydrogen peroxide of 20 minutes each. 10% carbamide peroxide for two hours daily over the course of two weeks.
1484111|NCT03089216|Drug|8% arginine and calcium carbonate|using during all the treatment.
1484112|NCT03089203|Biological|CART T cells|1-3x10^7
1484113|NCT03089203|Biological|CART T cells|1-3 x 10^8
1484114|NCT03089203|Drug|Cyclophosphamide 1g/m^2|day -3 of cohort 3 subjects only
1484115|NCT03089203|Biological|CART T cells|MTD given in Cohort 3 only
1484116|NCT03089190|Dietary Supplement|DC7-2|Effects on appetite
1484117|NCT03089190|Dietary Supplement|DC7-2 + potato protein isolate|Effects on appetite
1484118|NCT03089190|Dietary Supplement|Potato protein isolate|Effects on appetite
1484119|NCT03089190|Dietary Supplement|Placebo|Inactive whey protein, not expected to affect appetite.
1484120|NCT03089177|Behavioral|Community Garden Intervention|"The investigators will recruit prospective adult gardeners who have not been gardening for the past two years and who are listed on Denver Urban Gardens (DUG) wait lists. Individuals randomized to the garden intervention will receive a standardized garden resource package, which includes the following:
A garden plot in a Denver Urban Garden
Seeds and plant starts
Introductory gardening workshop
Social events including garden-specific events and garden mentoring.
The Wait List Control group will remain on the community gardening wait lists and will not receive these resources.
Duration of the intervention is 1 year."
1484121|NCT03089021|Other|mulligan mobilization|mobilization with movement for spinous process or facet joint.
1484122|NCT03089021|Other|maitland mobilization|posterioanterior of spinous process or facet joint.
1484123|NCT03089008|Other|Eccentric exercises|
1484124|NCT03089008|Other|Stretching exercises|
1484125|NCT03088995|Diagnostic Test|Pilot study|Pilot study of HIV and viral hepatitis B and C screening in surgery
1484126|NCT03088982|Other|Questionnaire|"FPs who had agreed to participate worked according to the following plan: first, the multimorbid patient was asked to give his/her consent to participate in the study once the terms had been explained to him/her. After that, FPs completed a questionnaire about their patient.
The purpose of this questionnaire was to explore potential decompensation risk factors within the themes and subthemes of multimorbidity."
1484127|NCT03088969|Other|questionnaire RTWSE|The evaluation of the self-efficiency perceived of return in the work of the patients by a validated auto-questionnaire is thus an additional objective parameter determining the risk factors of unfavorable evolution of the patients with Low Back Pain. This parameter also allows highlight other levers of actions in the therapeutic education.
1484128|NCT03088956|Other|Assessments|Cognitive, Behavioral and Functional as described in the Outcome Measures
1484129|NCT03088943|Other|TTE Apical 4 Chamber View|We will measure a number of echocardiography parameters by TTE (apical 4 Chamber View) prior to and after induction
1484130|NCT03088943|Other|TEE dTG View|We will measure a number of echocardiography parameters by TEE (dTG View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
1484131|NCT03088943|Other|TEE ME 4C View|We will measure a number of echocardiography parameters by TEE (ME 4C View) prior to cardiopulmonary bypass and after cardiopulmonary bypass (atrially paced at 80, 100, and 120 bpm)
1493092|NCT03020030|Drug|DASATINIB|Standard of Care
1484133|NCT03088904|Biological|FluMist® Quadrivalent|LAIV4 vaccine dosage is 0.2 mL Vaccine will be administered as an intranasal spray. Each sprayer contains a single dose of FluMist® Quadrivalent; approximately one-half of the contents should be administered into each nostril. 0.1 mL (i.e., half of the dose from a single FluMist sprayer) is administered into each nostril while the recipient is in an upright position. Insert the tip of the sprayer just inside the nose and rapidly depress the plunger until the dose-divider clip stops the plunger. The dose divider clip is removed from the sprayer to administer the second half of the dose (0.1 mL) into the other nostril.
1484134|NCT03088904|Biological|Fluzone® Quadrivalent vaccine|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
1484135|NCT03088891|Other|Antioxidant-rich snacks|Bama Smoothies (Bama, Oslo, Norway), Freia Premium Dark Chocolate (Freia, Oslo, Norway), Walnuts (Eldorado, Norway), Dried fruits and berries (Cranberries, Gojiberries, apricots)(Bama, Oslo, Norway and Rema 1000, Norway)
1484136|NCT03088891|Other|Control snacks|Milkshake (Tine, Oslo, Norway), YT restitusjonsdrikk (Tine, Oslo, Norway), Bixit (Sætre, Oslo, Norway), Ritz (Mondelez, Oslo, Norway), White chololate (Freia, Oslo, Norway)
1484137|NCT03088878|Drug|Cirmtuzumab|Administered IV every 2 weeks for 5 administrations and then every 4 weeks thereafter
1484138|NCT03088878|Drug|Ibrutinib|Self-administered orally once daily
1484139|NCT03088878|Drug|Cirmtuzumab plus ibrutinib|"Cirmtuzumab: Administered IV every 2 weeks for 3 administrations and then every 4 weeks thereafter
Ibrutinib: Self-administered orally once daily"
1484140|NCT03088865|Diagnostic Test|aspirating first blood volume into a regular blood collection tube|order of blood drawing
1484141|NCT03088852|Drug|Magnesium Citrate 100 MG|initial intravenous treatment: Patients with magnesium levels 1-1.5 mg/dL will receive 2-4 grams of magnesium sulfate in the first 24 hours. Patients with magnesium levels 1.6-1.9 mg/dL will receive 1 gram of magnesium sulfate. participants with magnesium level ≥1 mg/dL, will be randomized, and oral magnesium therapy, Magnesium Citrate, ( or no treatment) will be started, and continued for at least three months. The experimental group will receive 400mg magnesium daily in two divided doses.
1484142|NCT03088826|Drug|Morphine Sulfate|15mg PO morphine sulfate
1484143|NCT03088826|Drug|Oxycodone|10mg Oxycodone
1484144|NCT03088826|Drug|Acetaminophen|650 mg Acetaminophen
1484145|NCT03088813|Drug|Irinotecan liposome injection|IV
1484146|NCT03088813|Drug|Topotecan|IV
2001070|NCT03233217|Biological|QIV-HD by IM|IM, injected into the upper arm (deltoid area)
1484149|NCT03088787|Device|Nexfin measuremtents|There will be only observational recordings, no interevntion
1484150|NCT03088774|Other|Information material|Online web-application developed together with patients with low back pain
1484151|NCT03088761|Device|cuffed tracheal tube|the changes in cuff pressure will be determined using a cuff manometer
1484152|NCT03088748|Device|Journey II posterior cruciate retaining total knee arthroplasty|
1484153|NCT03088748|Device|Journey II posterior bi-cruciate retaining total knee arthroplasty|
1484154|NCT03088735|Procedure|Blastocyst-stage embryo transfer strategy|Intra-uterine transfer of blastocist if in cleavage embryo stage the oocyte recipient has a mínimum of 3 availables embryos with at least one of good quality to transfer and also the inta-uterine transfer of cleavage embryo (day 3) when the recipient doesn't have the previous criteria.
1484155|NCT03088735|Procedure|Cleavage-stage embryo transfer strategy|Inta-uterine transferring of cleavage embryo transfer (day 3 of develpment) in oocyte recipients
1484156|NCT03088722|Other|Training CHEWs to provide contraceptive implants|Training CHEWs to provide contraceptive implants
1948799|NCT01612351|Drug|Cisplatin|Weekly cisplatin given intravenously for 6 weeks concurrent with ipsilateral radiation. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
1948800|NCT01612351|Drug|Cisplatin|Cisplatin given once every 3 week cycle intravenously for 5-7 weeks concurrent with bilateral radiation and daily lapatinib. Alternative regimens may be substituted for cisplatin in patients who are not candidates for cisplatin at the discretion of the investigator. If carboplatin is used, a maximum of 125 mL/min must be used, as per standard of care.
1484163|NCT03088683|Device|Nathanson Retractor|Liver will be retracted with Nathanson retractor
1484164|NCT03088683|Device|Reveel Retractor|Liver will be retracted with Reveel retractor
1484165|NCT03088670|Drug|Gosogliptin|20 mg per day, dose titration to 30 mg per day at Week 4 as required Administration: orally
1484166|NCT03088670|Drug|Vildagliptin|50 mg per day, dose titration to 100 mg per day at Week 4 as required (50 mg twice a day) Administration: orally
1484167|NCT03088670|Drug|Metformin|"1000 mg per day starting Week 12 (500 mg twice a day), dose titration to 2000 mg per day at Week 16 as required (1000 mg twice a day).
Administration: orally"
1484168|NCT03088644|Drug|JNJ-54175446|JNJ-54175446 up to 600 mg suspension for oral dose administration.
1484169|NCT03088644|Drug|18F-JNJ-64413739|18F-JNJ-64413739 fluid for injection administered intravenously.
1484170|NCT03088631|Drug|Metformin|will receive metformin (1500 mg)/day starting from day of ultrasonographic evaluation of the patient, continuing till the day of human chorionic gonadotropin triggering.
1484171|NCT03088631|Other|Placebo|will receive corn-flour placebo tablets (three tablets daily).
1484172|NCT03088618|Procedure|Nasal septoplasty|Type of surgery
1484173|NCT03088605|Drug|TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
1484174|NCT03088605|Drug|Placebo to TOP1630 Ophthalmic Solution|Bilateral ocular drug administration
1484210|NCT03088371|Drug|Bupivacaine 0.125 %|For combined spinal epidural in the post-operative period.
1484211|NCT03088358|Drug|TeaRx|
1484212|NCT03088358|Drug|Enoxaparin|
1484282|NCT03086772|Behavioral|Light Exercise|Individuals in the exercise control group will meet for a twice weekly class involving walking, weight training, stretching and health education (one hour per class, two classes per week for 12 weeks, taught by a trained graduate research assistant, assisted by an undergraduate research assistant.
1484283|NCT03086759|Procedure|platelet rich plasm|intra-articular infiltration with platelet rich plasm
1484175|NCT03088592|Device|Deep Brain Stimulation|Subjects will have awake or asleep DBS surgery with STN or GPi placement. Microelectrode recordings will define the electrophysiological target prior to lead implantation. Cortical recordings will be done using µECoG grids (2.0 x 0.8 cm) placed over the cortex through the same burr hole used for lead implantation. Neural recordings will be made continuously throughout the procedure: before, during, and after DBS, and at all levels of anesthesia. A pulse generator will be connected and implanted either during the operation or within 7-10 days post-operatively. Subjects will be admitted overnight for observation with anticipated discharge the next morning. The researchers will also be collecting other routine data points (length of surgery, stereotactic accuracy, length of hospital stay, and post-operative complications).
1484176|NCT03088579|Device|GammaTile seed loader|Patients are chosen based on symptomatic tumor/radiographic finding of a surgically accessible mass. Surgery will be done in usual fashion. A cavity will be left where the tumor was. Size of operative bed will be measured using a surgical dissector and standard operating room ruler. A sheet of surgical fabric may be used to estimate size of cavity. If pathology is positive the study treatment will continue. If not, patient will not be on trial. If patient is eligible, radiation oncologist will form custom implants using a seed(s) of Cesium-131, with other biocompatible materials used to achieve maximum dosimetric conformality. Surgeon will place constructs into cavity until the operative bed is fully addressed. Implant is not expected to migrate. Surgicel, bioglue or similar material may be used to secure seeds. Wound will be closed in standard fashion. The last 10 patients will be asked to participate in an effort to gauge costs related to radiation portion of treatment.
1484177|NCT03088566|Procedure|The D-Foot method|The D-Foot method is a standardised routine of foot screening. The D-Foot i web program aimed to be used on a surf plate.
1484178|NCT03088566|Procedure|Conventional foot screening|The foot screening is performed with clinical conventional methods.
1484179|NCT03088553|Drug|Therapeutic Drug Monitoring|Trough concentration of ganciclovir and viral load measurement at each follow-up visit.
1484180|NCT03088540|Drug|Pemetrexed|Patients will be administered pemetrexed chemotherapy as per protocol with either cisplatin or carboplatin
1484181|NCT03088540|Drug|Paclitaxel|Patients will be administered paclitaxel chemotherapy as per protocol with either cisplatin or carboplatin
1484182|NCT03088540|Drug|Gemcitabine|Patients will be administered gemcitabine chemotherapy as per protocol with either cisplatin or carboplatin
1484183|NCT03088540|Drug|Cisplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
1484184|NCT03088540|Drug|Carboplatin|Administered with either Pemetrexed, Paclitaxel or gemcitabine.
1484185|NCT03088540|Drug|REGN2810|Patients will be administered REGN2810 as per protocol.
1484186|NCT03088527|Drug|RAD140|RAD140 will be supplied as formulated drug-in-capsules for oral administration.
1484187|NCT03088514|Dietary Supplement|Beetroot juice|Beetroot juice (70ml daily) with or without inorganic nitrate
1484188|NCT03088501|Behavioral|Interactive voice response system|IVR allows the pregnant women, their family members to interact with a computer system using a telephone.Through IVR, women receive a 2-3 minute call that reminds them of lab test, their next follow-up visit and also provides information on child care attendance, breastfeeding, introduction of solid foods, motor development, and sleep.
1484189|NCT03088501|Behavioral|Mother and baby affairs workshop|Mother and baby affairs workshop will involve antenatal workshop and counseling for parents. The intervention will involve brief talk by health professionals, quiz activities, role-plays on personal hygiene, nutritional food, institutional delivery, precautions at the time of delivery, caring for the baby, feeding of colostrum, homemade baby food, immunization, and family planning measures.
1484190|NCT03088488|Diagnostic Test|fasting venous blood samples|
1484191|NCT03088475|Behavioral|nurse-led smartphone-based self-management programme|The participants in the experimental group will undergo nurse-led smartphone-based self-management programme (NSSMP), a 6-month programme comprising an individual education session, and a newly developed smartphone App as a self-help education resource
1484192|NCT03088475|Behavioral|exiting nurse-led diabetes service|the patients in the control group will receive the exiting nurse-led diabetes service (i.e. NDS) provided by the hospital
1484193|NCT03088462|Other|Psychiatric management|Routine treatment for bipolar disorder with a psychiatrist including prescription of medications and potentially other treatments such as individual, group or light therapy.
1484194|NCT03088462|Behavioral|Psychosocial treatment|Any psychosocial treatment participant is involved in such as individual therapy, group therapy, or support groups.
1484195|NCT03088462|Behavioral|LiveWell Program|Participants work with a health coach to facilitate use of a smartphone application designed for people with bipolar disorder.
1484196|NCT03088436|Device|preoperative prone MRI and supine second-look ultrasound data|Patients were examined using a standard clinical MRI protocol in the prone position with both arms placed above the head. Second-look ultrasonographies were performed. Patients were instructed to lie supine, with their hands behind their heads.
1484197|NCT03088423|Radiation|SBRT delivers high dose selective irradiation with millimeter precision to a small volume. The Cyberknife® is a robotic SBRT dedicated device that can deliver 100 to 200 photobeams to the target|Seven to ten days before the scheduled CT, 2-4 fiducial markers were implanted percutaneously 2 to 5 cm next to the lesion under sonographic guidance following administration of local anesthesia, thus allowing real-time tracking during treatment. The total dose delivered was 45 Gy on the 80% isodose, in three fractions over 10 days. Gross tumor volume (GTV) was defined as the tumor mass that could be discerned by diagnostic imaging. An isotropic margin of 5 mm was added to account for the microscopic extension (clinical target volume, CTV) and another 3 mm margin was added to compensate for uncertainties regarding the position (previsional target volume, PTV)
1484198|NCT03088410|Drug|Zidovudine|neonatal 4 weeks prophylactic
1484199|NCT03088410|Drug|Nevirapine|neonatal 4 weeks prophylactic
1484200|NCT03088397|Behavioral|Patient Decision Aid|One sheet of postpartum contraceptive information arranged in a grid.
1484201|NCT03088397|Behavioral|Website|Patient directed to website with information on various contraceptive methods.
1484202|NCT03088397|Behavioral|Shared- Decision Making Counseling|Counseling using principles of shared-decision making
1484203|NCT03088384|Drug|Ketamine|Psychological survey instruments administered before and after a series of six low-dose infusions of ketamine.
1484204|NCT03088371|Drug|Bupivacaine 0.25%|For psoas sciatic block.
1484213|NCT03088345|Drug|Vasopressin, Arginine|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
1484214|NCT03088345|Drug|Placebos|Subjects will be started on a blinded continuous infusion of study drug/placebo in the OR, immediately following the completion of the MUF at 0.3 mU/kg/min. All caregivers will be blinded to the arm assignment. The infusion will run for 20 hours, at which time it will be weaned off at 0.1 mU/hr, over 3 hours.During the active study period, the care team will treat subjects per SOC, using any preferred medication to correct low cardiac output; there is no restriction on using open-label vasopressin during the active study treatment period.
1484215|NCT03088332|Procedure|Endoscopic gastroplasty|Vertical endoscopic gastroplasty
1484216|NCT03088306|Drug|Standard analgesia use [Oxygen]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
1484217|NCT03088306|Drug|Standard analgesia use [Hydromorphone]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
1484218|NCT03088306|Drug|Standard analgesia use [Volatile Anesthesia]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
1484219|NCT03088306|Drug|Standard analgesia use [Fentanyl]|A protocol directed and clinically appropriate post-operative analgesia. In this study, standard post-operative analgesia is defined as: oxygen, volatile anesthesia, fentanyl, hydromorphone.
1484220|NCT03088306|Drug|Multi-modal pain management [Acetaminophen + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
1484221|NCT03088306|Drug|Multi-modal pain management [Fentanyl]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
1484222|NCT03088306|Drug|Multi-modal pain management [Intravenous Ketamine]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
1484223|NCT03088306|Drug|Multi-modal pain management [Valium + Gabapentin]|Administration of acetaminophen (1 gm po) plus gabapentin (600-1200 mg po) in the preparation area prior to surgery; pre-induction opioid titration with fentanyl until pain is relieved and/or respiratory depression ensues; intravenous ketamine (1 mg/kg load prior to incision then 10 mcg/kg/min) during surgery; acetaminophen, valium plus gabapentin during hospitalization; and prescription for acetaminophen, valium plus gabapentin at discharge.
1484224|NCT03088293|Drug|Infliximab|Patients will receive prednisone and infliximab (5 mg/kg at week 0, 2, 6, 11 and 16 as an intravenous (IV) infusion) in association with low-dose methotrexate (10 mg/week) for 16 weeks.
1484225|NCT03088293|Drug|Cyclophosphamide|Patients will receive prednisone and cyclophosphamide intravenously (700 mg/m2 every 4 weeks intravenously) (n=25) for 16 weeks.
1484226|NCT03088280|Drug|Thymoglobulin|reduced dose (3mg/Kg)
1484229|NCT03088254|Drug|Group I (Telmisartan 80 mg, Amlodipine 10 mg, Rosuvastatin 20 mg)|
1484230|NCT03088254|Drug|Group II (Telmisartan 80 mg, Amodipine 10 mg)|
1484231|NCT03088254|Drug|Group III (Telmisartan 80 mg, Rosuvastatin 20 mg)|
1484232|NCT03088241|Other|switch|switch to second-line ART
1484233|NCT03088228|Diagnostic Test|gingival crevicular fluid collection|
1484235|NCT03088202|Other|Educational program|E-learning lectures, group exercises, skills training
1484236|NCT03088202|Other|Standardized care pathways|Pathways for systematic follow-up
1484237|NCT03088202|Other|Early palliative care|Compulsory referral to palliative care at inclusion
1484238|NCT03088176|Drug|Talimogene Laherparepvec 1 Million Pfu/Ml Inj,Susp,1Ml,Vil|Up to 4mL administered on C1D1 intratumorally
1484239|NCT03088176|Drug|Talimogene Laherparep 100 Mil Pfu/Ml 1Ml|Up to 4 ML administered on Week 4 Day 1 and every 2 weeks thereafter
1484240|NCT03088176|Drug|Dabrafenib|150mg PO qday
1484241|NCT03088176|Drug|Trametinib|2mg PO qday
1484242|NCT03088163|Device|Diffusion weighted magnetic resonance imaging|The enrolled colorectal liver metastases patients will receive DWI-MRI screening to evaluate the liver metastases before the chemotherapy, after the first cycle of chemotherapy and in the regular efficacy evaluation time, respectively.
1484243|NCT03088150|Procedure|Thermal ablation|Patients will undergo either radiofrequency ablation (RFA) or microwave ablation (MWA).
1484244|NCT03088150|Procedure|Surgical resection|In case of randomization to surgical resection, the surgeon will remove all target lesions as well as all additional unablatable lesions.
1484245|NCT03088137|Drug|Follitropin alfa (Gonal-f)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
1484246|NCT03088137|Drug|Follitropin alfa (Primapur)|Subcutaneous injection, fixed starting dose 150 IU for 5 days, maximum of 16 days of ovarian hyperstimulation
1601503|NCT02224768|Drug|Ipilimumab|
1484248|NCT03088111|Other|Collection of samples|To the extent possible, blood samples will be collected from all subjects prior to infusion and at specified time points post-infusion to determine serum obiltoxaximab concentrations and ATA titers. Scavenged blood samples can be utilized, if acceptable, to maximize sample analyses for pharmacokinetic and other investigational parameters. Data on other relevant laboratory testing will only be collected and evaluated if available in the subject's record (eg, protective antigen (PA), anti-PA, anti-lethal factor (LF), anti-edema factor, IgG antibodies, anthrax lethal toxin neutralizing activity, presence of anthrax LF, incidence and duration of B. anthracis bacteremia, and demonstration of B. anthracis antigens in tissues).
1484249|NCT03088111|Biological|Obiltoxaximab|Obiltoxaximab standard of care
1484250|NCT03088098|Device|LAAO|Left atrial appendage occlusion for stroke prevention
1484251|NCT03088085|Procedure|Self-mobilization|Subjects will mobilize thoracic spine and ribs with a foam roller every night before going to bed.
1484252|NCT03088085|Procedure|Sleep Education|Subjects will be educated on sleep hygiene in order to improve likelihood of having good sleep.
1484253|NCT03088072|Drug|Edoxaban|"Edoxaban 60mg once daily in patients with CrCl >50- ≤95 mL/min, or 30mg once daily in patients with CrCL 15-50 mL/min.
If at 6 week TEE LAA closure is deemed acceptable by the operator (i.e., peri-device flow <5mm), edoxaban will be discontinued. Aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up, then clopidogrel will be discontinued.
If LAA unacceptable on 6-week TEE due to peri-device flow ≥5mm, edoxaban will be continued for an additional 6 weeks, and LAA reassessed by TEE If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference."
1484254|NCT03088072|Device|WATCHMAN LAA Closure|Per Inclusion Criteria, enrolled subjects must have a successful Left Atrial Appendage (LAA) Closure using the WATCHMAN Device
1484255|NCT03088072|Drug|Aspirin and Clopidogrel|"If at 6 week TEE LAA closure is deemed acceptable by the operator edoxaban will be discontinued, and aspirin 81mg daily and clopidogrel 75mg daily will be administered until 6-month follow-up. Then clopidogrel will be discontinued.
Aspirin 325mg daily rather than 81mg daily can be administered according to operator preference after the 6-week follow-up visit."
1484256|NCT03088072|Drug|Aspirin and Warfarin|If device thrombus is present at 6-week TEE, patient will be transitioned to aspirin 81 mg daily and adjusted-dose warfarin (goal INR, 2.0-3.0), and LAA reassessed by TEE in 6 weeks; further warfarin will be continued according to operator preference.
1484257|NCT03088059|Drug|Afatinib|Afatinib 40 mg given orally, once daily, 1 cycle is 28 days
1484258|NCT03088059|Drug|Palbociclib|Palbociclib 125 mg given orally, once daily, 1 cycle is 28 days (21 days on treatment, then 7 days off)
1484259|NCT03088059|Drug|standard of care|Methotrexate, Paclitaxel, Docetaxel, 5-Fluorouracil, Bleomycine, Gemcitabine, Mitomycine or Best supportive care
1484260|NCT03088059|Drug|IPH2201|Monalizumab given via intravenous injection, 10mg/kg, every 2 weeks
1484261|NCT03088046|Drug|Micronized Progesterone|"Anovulatory women with Polycystic ovary syndrome and clinical hyperandrogenism attended in our Hospital will participate in the study. A patient information sheet will be provided and written consent will be obtained. Patients who give written consent will participate in the trial. All patient information will be confidential and only be available to researches involved in the study.
Blood samples will be collected at baseline (Sample #1) and between the 3rd and the 5th day of withdrawal after 7 days of 100mg vaginal MP every 12 hours of administration(Sample#2)."
1484262|NCT03088033|Device|IASD System II implant|The primary component of the system is an implant placed in the atrial septum designed to allow left to right flow between the left atrium and right atrium to reduce the elevated left atrial pressure.
1484263|NCT03088033|Other|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE)|intra-cardiac echocardiography (ICE), or transesophageal echocardiography (TEE) for examination of the atrial septum and left atrium.
1484264|NCT03088007|Other|Cognitive, adaptive, behavioral and academic assessment|Cognitive, adaptive, behavioral and academic assessment will be performed if not available in the records, using WISC-IV, VABS, GECEN and an academic skills rating form.
1484265|NCT03087994|Behavioral|Nutritional guidance intervention|participants in this group will attend 12 meeting of nutritional guidance
1484266|NCT03087994|Behavioral|Nutritional guidance intervention|Participants in this group will only receive nutrition guidance twice during the study
1484267|NCT03087968|Drug|GS-4997|Experimental drug
1484268|NCT03087968|Drug|Prednisolone|Control drug that is also administered with the Experimental drug, GS-4997. This drug is used in both arms.
1484269|NCT03087968|Device|HepQuant SHUNT Test|"The HepQuant SHUNT Liver Diagnostic Kit is intended for use in the quantitative detection of 13C-cholate and d4-cholate in blood serum, collected after the intravenous administration of 13C-cholate and the oral ingestion of d4-cholate. The device is indicated to assess the severity of liver disease.
For use by health care professionals. Administer the test under a physician's supervision. The HepQuant Analytical Testing Laboratory must analyze the serum samples."
1484270|NCT03087968|Drug|Placebo|Placebo
1484271|NCT03087955|Drug|SCYX 7158|
1484272|NCT03087942|Drug|QAW039|450 mg
1484273|NCT03087942|Drug|QAW39A|450 mg
1484274|NCT03087942|Drug|QAW39A2107|450 mg
1484275|NCT03087942|Drug|QAW39A2107|450 mg
1484276|NCT03087929|Other|Follow up|
1484277|NCT03087903|Dietary Supplement|Grape Seed Extract|Patients will take 150 mg of Grape Seed Extract (GSE) product by mouth twice daily (in the form of 75 mg capsule of Leucoselect Phytosome preparation). Total oral dosage is 300 mg of GSE per day for one year. Patients will be evaluated every 6 weeks for 3 months, then every 3 months thereafter for up to one year. PSA measurements will be obtained at these scheduled visits.
1484278|NCT03087890|Drug|Cotrimoxazole|Patients will receive preventive treatment with 2 tablets cotrimoxazole (80 mg trimethoprim, 400mg sulfamethoxazole) daily for 48 weeks
1484279|NCT03087890|Drug|Placebo|Patients will receive 2 tablets placebo daily for 48 weeks
1484280|NCT03086785|Drug|Apatinib|apatinib 500mg qd po or combined capecitabine 1000mg/m2 bid d1-14 q3w
1484281|NCT03086772|Behavioral|Tai Chi|Individuals in the Tai Chi intervention group will participate in a 12-week Tai Chi program (one hour per class, two classes per week, plus home practice for 12 weeks) led by an experienced Tai Chi Instructor, assisted by an undergraduate research assistant.
1484284|NCT03086759|Drug|Triamcinolone Hexacetonide|intra-articular infiltration withTriamcinolone Hexacetonide
1484285|NCT03086759|Procedure|Isotonic Saline Solution|intra-articular infiltration with Isotonic Saline Solution
1484286|NCT03086733|Drug|Metformin|850 mg tablets v/o OD for first 5 days 850 mg tablets v/o BID until day 21
1484287|NCT03086720|Procedure|Sodium hypochlorite|Application of 10% sodium hypochlorite (60 seconds) after the etching procedure and before the adhesive system.
1484288|NCT03086720|Procedure|Water|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
1484289|NCT03086707|Other|Cigarette|After enrollment, and between Visit 2 and Visit 3, the subjects will abstain from smoking for a period of 8 hours. At Visit 3, after the 8-hour smoking abstinence period, the subjects will smoke 1 single cigarette.
1484290|NCT03086681|Drug|Endostar|Endostar: 7.5mg/m2 d1-10, repeat every 15 days, for 4 cycles
1484291|NCT03086681|Drug|DDP|DDP: 40mg /m2，per week, for 5 cycles
1484292|NCT03087864|Drug|Atezolizumab|Atezolizumab 1200 mg i.v. day 1-22-43-64-85
1484293|NCT03087864|Drug|Carboplatin|Chemotherapy
1484294|NCT03087864|Drug|Paclitaxel|Chemotherapy
1484295|NCT03087864|Radiation|Radiotherapy 23 x 1.8 Gy|Radiotherapy
1484296|NCT03087851|Drug|Zoledronic Acid|Intravenous infusion of 5 mg zoledronic acid
1484297|NCT03087825|Procedure|preoxygenation without inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes
1484298|NCT03087825|Procedure|preoxygenation with inward leak|breathing a 100% inspired oxygen gas flow during 3 to 10 minutes with an inward air leak made possible through a specific calibrated piece on the inspiratory branch
1484299|NCT03087799|Behavioral|Brief Behavioral Treatment for Sleep|The BBT arm will consist of 2 in-person treatment visits and 2 telephone check-in visits. Treatment will involve psychoeducation about sleep hygiene and stimulus control as well as sleep schedule modification and sleep restriction. The treatment manual is attached for clarification. This manual is used solely to guide clinical decision making and will not be provided to participants.
1484300|NCT03087786|Drug|Nicotine Bitartrate Lozenge 4mg|Test Product
1484301|NCT03087786|Drug|Nicotine Polacrilex 4Mg Lozenge|Active Comparator
1484302|NCT03087773|Drug|Empagliflozin 10 mg|The subject will receive Empagliflozin 10 mg orally once daily for 26 weeks.
1484303|NCT03087773|Drug|Placebo Oral Tablet|The subject will receive Placebo orally once daily for 26 weeks.
1484304|NCT03087760|Drug|Pembrolizumab|
1484305|NCT03087747|Procedure|Percutaneous cholecystostomy|Placement of drainage catheter into gallbladder lumen in order to evacuate inflamed content.
1484306|NCT03087734|Device|Implantation of new model of bar with oblique stabilizers|Implantation of new model of bar with oblique stabilizers
1484307|NCT03087734|Device|Implantation of regular bar with perpendicular stabilizers|Implantation of regular bar with perpendicular stabilizers
1484308|NCT03087721|Behavioral|HIIT-LV|"Supervised endurance treadmill training as walking/running uphill, 3 times/week during 12 weeks starting at 85-90% of previously determined maximum oxygen consumption (VO2 max). Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week."
1484309|NCT03087721|Behavioral|CAE|Supervised moderate intensity treadmill training, 3 times/week for 12 weeks starting at 70% of VO2 max. Warm-up 3 min at 30% of VO2 max, 3 min cool-down. Progression in intensity every 3erd week.
2001071|NCT03233217|Biological|QIV-SD by SC|SC, injected into the upper arm (posterior region)
2001072|NCT03233217|Biological|QIV-HD by SC|SC, injection into the upper arm (posterior region)
1484314|NCT03087695|Diagnostic Test|Plasma EBV DNA|Parameters analyzed will include (1) the change pattern of plasma EBV DNA concentrations, (2) various half-life values (t1/2) of plasma EBV DNA clearance rate calculated over different time periods.
1484315|NCT03087682|Diagnostic Test|Optical Coherence Tomography (OCT)|OCT is used to measure thickness (numbers) of retinal nerve fibres in different areas of the retina
1484316|NCT03087669|Device|LVAD flow velocity setting-Rounds per Minute(RPM) on HeartMate III®|Increase in LVAD RPM setting induces an actual increase in LVAD outflow to the patient.This gives the patient an increased systemic Cardiac Output(CO)
1484317|NCT03087669|Drug|MAP intervention using Noradrenalin|At a fixed RPM rate for the LVAD the Mean Arterial Pressure (MAP) is increased to preset levels of 60-70-80-90 mmHG using Noradrenalin
1484318|NCT03087656|Drug|Ceftriaxone|Intravenous Ceftriaxone will be given during the procedure.
1484319|NCT03087656|Drug|Levofloxacin|Oral Levofloxacin will be given for 3 days after the procedure.
1484321|NCT03087630|Behavioral|Reasoned-Based Intervention|Receives personalized feedback based on the reasoned pathway of the Prototype Willingness Model.
1484322|NCT03087630|Behavioral|Social-Based Intervention|Receives personalized feedback based on the social pathway of the Prototype Willingness Model.
1484323|NCT03087630|Behavioral|Integrated Intervention|Receives personalized feedback based on both the reasoned and social pathways of the Prototype Willingness Model.
1484324|NCT03087630|Behavioral|Attention Control|Receives personalized feedback related to nutrition and exercise, unrelated to drinking behavior.
1484325|NCT03087617|Device|Imbio Smoking Cessation Report|Research coordinators at the University of Michigan and HealthPartners will be provided access to the research version of LDA via an Imbio website. Following consent and lung screen, research coordinators will manually upload the study participants' images and download a resulting Report. Radiologists have been designated at both sites to review and approve the Report prior to mailing to participants. The Report will include information including the percent of damaged lung volume.
1484326|NCT03087617|Behavioral|Smoking Cessation Counseling|45 minute counseling session with a tobacco treatment specialist.
1484327|NCT03087617|Other|Usual Care|Usual Care for Lung Cancer Screening patients.
1484328|NCT03087604|Procedure|Thoracic epidural block|Thoracic epidural block with epidural placed with a loss of resistance technique alone.
1484400|NCT03086915|Drug|Neuromuscular Blocking Agent|Administration of neuromuscular blockers during anesthesia
1484401|NCT03086902|Device|Radiofrequency Ablation Catheter|Ablation of PVC with RF energy
1484402|NCT03086902|Device|Cryo Ablation catheter|Ablation pf PVC with Cryo enerygy
1601738|NCT02223104|Device|Sensura|
1484329|NCT03087604|Procedure|Electrical Nerve stimulation|In the electrical stimulation group, following the location of the epidural space with a loss of resistance technique (using air), nerve stimulation will be utilized to elicit a myotomal contraction of the abdominal or thoracic wall.stimulating peripheral nerve catheters(19 Ga. x 90 cm StimuCath® Continuous Nerve Block Catheter with SnapLock™ Adapter (Arrow by Teleflex Medical, Morrisville, NC), and stimulation will be achieved using a B Braun Stimuplex HNS12 Nerve Stimulator product id 4892098.
1484330|NCT03087604|Drug|Solution For Thoracic epidural block|Dose of 3+2 ml of 1.5% lidocaine with 1:200,000 epinephrine
1484331|NCT03087591|Other|Laboratory Biomarker Analysis|Correlative studies
1484332|NCT03087591|Biological|siRNA-transfected Peripheral Blood Mononuclear Cells APN401|Given IV
1484333|NCT03087578|Other|electroacupncture|Patients will receive electroacupuncture treatment for 30 minutes per weekly session for 6 weeks.
1484334|NCT03087578|Drug|Mirabegron 50 MG [Myrbetriq]|Patients will receive 50 mg of mirabegron daily for 6 weeks.
1484335|NCT03087565|Procedure|subtotal hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The corpus is amputated just below the level of the isthmus and then the endocervical canal is electrocoagulated using monopolar electrocautery. The cervical stump is closed using vicryl 0 sutures.
Revision of all pedicles to ensure hemostasis. Intraoperative antibiotics . The abdomen is closed in layers; the wound is covered with a sterile dressing."
1484336|NCT03087565|Procedure|Total hystrectomy|"A transverse lower abdominal incision (Pfannenstiel incision) The urinary bladder is dissected off the lower uterine segment of the uterus and cervix by blunt or sharp dissection. Revision of all pedicles to ensure hemostasis.
The abdomen is closed in layers; the wound is covered with a sterile dressing."
1484337|NCT03087552|Procedure|Transradial balloon aortic valvuloplasty|Mini-invasive balloon aortic valvuloplasty consisting in transradial access
1484338|NCT03087552|Procedure|Transradial balloon aortic valvuloplasty|Rapid pacing using the 0.035-in. retrograde left ventricular support wire
1484339|NCT03087539|Biological|Abciximab|
1484340|NCT03087539|Biological|Placebo|
1484341|NCT03087526|Genetic|Non invasive prenatal diagnosis|Search for the familial mutation on isolated circulating fetal trophoblastic cells from maternal blood
1484344|NCT03087474|Other|Non-Interventional|Non-Interventional
1484345|NCT03087461|Behavioral|Exercise and self-management|The intervention will include aerobic exercise and self-management education using technology.
1484346|NCT03087448|Drug|Ceritinib|"ALK tyrosine inhibitor, 300 mg - 450 mg PO daily.
Phase I dose escalation:
Ceritinib 300mg
Ceritinib 450mg
Ceritinib 450mg
The Phase II doses will be determined by Phase I dose escalation study"
1484347|NCT03087448|Drug|Trametinib|"MEK kinase inhibitor, 1.5 mg - 2.0 mg PO daily.
Phase I dose escalation:
Trametinib 1.5mg
Trametinib 1.5mg
Trametinib 2.0mg
The Phase II doses will be determined by Phase I dose escalation study"
1484348|NCT03087435|Device|Well-Being questionnaire|Development and validation of a tool to access residents well-being.
1484349|NCT03087422|Behavioral|Text message intervention|The intervention consists in sending text messages with orientation that helps in homecare, specifically attempting to minimize chemotherapy side effects.
1484350|NCT03087396|Device|Treatment of insufficiency fractures|Filling of micro fractures or insufficiency fractures with a bone substitute material
1484351|NCT03087370|Other|No intervention|No intervention
1484353|NCT03087344|Device|Fibroscan and Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
1484354|NCT03087344|Device|Fibroscan|Liver stiffness will be measured before and after a standard meal is administered
1484355|NCT03087344|Device|Acoustic Radiation Force Impulse|Liver stiffness and spleen stiffness will be measured before and after a standard meal is administered by Fibroscan and Acoustic Radiation Force Impulse
1484356|NCT03087331|Other|medication reviews, assessment, recommendations, education.|
1484357|NCT03087318|Behavioral|Physical activity|"Physical activity:
3 sessions / week at least
at least during 30 minutes each session
at least at 50% of the maximal heart rate measured during the exercise stress testing (from the screening)
during 3 months."
1484358|NCT03087305|Diagnostic Test|Supraclavicular lymph node ultrasound|Patients will have supraclavicular lymph node assessed prior to EBUS-TBNA
1484359|NCT03087292|Other|Resistance training with vascular occlusion|Patients will perform unilateral leg extension resistance training with vascular occlusion 2 times per week for a period of 8 weeks. Each training session will consist of 3 sets of 15 repetitions at the intensity of 30% 1 RM with 30 s of rest period between sets.
1484360|NCT03087279|Behavioral|Texas I-CAN!|physically active, academic lessons in the elementary school classroom
1484361|NCT03087266|Procedure|FM-SRP|Non surgical periodontal treatment performed in all dentition within 1-2 appointments in a 24 hour time frame.
1484362|NCT03087266|Procedure|Q-SRP|Non surgical periodontal treatment performed in 4 sessions comprising of a quadrant (1/4) of the dentition each. Performed in 3 weeks time frame.
1484363|NCT03087240|Procedure|Dental Prophylaxis|Prevention and treatment of periodontal diseases by cleaning of the teeth in the dental office using the procedures of dental scaling and dental polishing. The treatment includes plaque detection, removal of supra- and subgingival plaque and calculus, as well as motivation and demonstration for establishing a sufficient oral hygiene.
1484364|NCT03087227|Device|NEUTROSIS|evaluate a shared health information system (NEUTROSIS) for home-hospital management of febrile neutropenia after anti-tumor chemotherapy
1484365|NCT03087201|Drug|nabiximols|"starting dose (1 puff): 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD), maximum dose (12 puffs): 32.4 mg THC/30 mg CBD, no target dose is defined
Duration of treatment: 13 weeks"
1484366|NCT03087201|Drug|placebo|analogous to experimental intervention
1484471|NCT03086265|Device|Endotracheal tube|Plastic tube for supporting ventilation during surgery
1484472|NCT03086252|Procedure|Red Blood Cell Transfusions (RBCT)|Undergo patient-driven RBCT
1601959|NCT02221414|Drug|Metformin|
1484367|NCT03087188|Other|Utilization of inhalator|"After written consent patients will be asked whether they know how to use the inhalator and for how long therapy has been already conducted. Patients using the inhalator correctly have completed the study at this point. If patients have demonstrated incorrect use of the inhalator, a film sequence with instructions will be shown via a tablet. The learning success will be assessed subsequently. When patients show correct application, they will be asked to come back for a follow-up visit within 2 to 8 weeks, otherwise they will be retrained by study staff. At the follow-up visit another demonstration evaluation will be performed.
While demonstrating patients will use the inhalator without any drug that could have any medicinal effect on them."
1484368|NCT03087175|Device|MGuard stent|MGuard micronet mesh-covered stent in treatment of NSTE-ACS
1484369|NCT03087175|Device|Drug eluting stent and bare metal stent|Drug eluting stent and bare metal stent in treatment of NSTE-ACS For example, Resolute Onyx
2001075|NCT03227731|Drug|Truvada|Truvada (Truvada (emtricitabine 200mg/tenofovir disoproxil fumarate 300mg) is in a fixed-dose combination (FDC) tablet formulation and is proven safe for the prevention and treatment of HIV in non-pregnant and non-lactating women.
1484371|NCT03087149|Dietary Supplement|monitored vit D supplementation|The vit D supplementation dose start from dose 500IU from 7th day of age and is modified based on vit D measurement at 4 week of age for infants born <30 GA, at 8 week of age for infants born <26 GA at 35+/-2 weeks PMA(postmenstrual age), +/-at 40+/-2 weeks PMA according to the protocol.
1484372|NCT03087149|Dietary Supplement|standard vit D supplementation|The vitamin D supplementation dose is 500IU from 7th day of age.
1484373|NCT03087136|Diagnostic Test|anti-aquaporin-4 antibody|Serum anti-aquaporin-4 antibody
1484374|NCT03087136|Diagnostic Test|anti-myelin oligodendrocyte glycoprotein|Serum anti-myelin oligodendrocyte glycoprotein
1484375|NCT03087123|Behavioral|P-Mobile App|The behavioral strategies are based on Social Cognitive Theory. The following topics will be covered: self-monitoring, goal setting, stimulus control, making time for exercise, exercising in- and outdoors, problem-solving, reinforcing PA, reducing sedentary behaviors, relapse prevention, parental modeling, lifestyle exercise, self-efficacy, self-management, parental PA modeling, parental co-participation, and establishing PA rules. Parents will be provided with adapted step goals (based on principles of shaping). Text messages will be designed to prompt PA, remind parents of concepts from the lessons, and motivate behavioral change.
1484376|NCT03087110|Biological|Matched sibling donor cord blood cell infusion|Single dose intravenous infusion of 12/12 HLA matched sibling donor cord blood cells (>1x10^7 cells/kg)
1484377|NCT03087097|Biological|Fecal Microbiota Transplant|The investigational agent consists of screened-donor fecal material prepared for FMT. FMT will be administered using frozen screened-donor liquid stool (the investigational agent) in the form of enemas (60mL preparations) as per the published protocol in infants. 10mL/kg (maximum 60mL) of donor fecal material will be infused.
1484378|NCT03087097|Biological|Placebo|Placebo will be administered via enema as per delivery of FMT, using standardized placebo preparation. 10mL/kg (maximum 60mL) of placebo material will be infused.
1484379|NCT03087084|Device|Cardiac Pacing and Impedance Measurement system|Subjects indicated for ICD or CRT-D device implant will be requested to perform some respiratory manevures while impedance and electrogram signals are recorded by the system
1484382|NCT03087058|Drug|Patiromer|4.2 g/day, 8.4 g/day and 16.8 g/day
1484383|NCT03087058|Drug|Patiromer|2 g/day, 4 g/day and 8 g/day
1484384|NCT03087058|Drug|Patiromer|1 g/day, 2 g/day and 4 g/day
1484385|NCT03087032|Drug|Liraglutide|Patients will receive adding Liraglutide to prandial insulin Lispro. The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week. The dose was maintained until study completion. Dose of insulin Lispro will be instructed on a titration schedule, adjusted every 3 days.
1484386|NCT03087032|Drug|Insulin Glargine|Individuals randomized to adding insulin Glargine to prandial insulin Lispro will be instructed on a titration schedule, adjusted every 3 days. Patients subcutaneously self-injected once-daily at approximately the same time each day.
1484387|NCT03087019|Radiation|Radiation|Standard use of radiation is administered
1484388|NCT03087019|Drug|Pembrolizumab|Pembrolizumab is designed to restore the natural ability of the immune system to recognize and target cancer cells.
1484389|NCT03087006|Other|Automatic Self Transcending Meditation (ASTM)|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
1484390|NCT03087006|Other|Treatment as Usual|Usual Care includes usual care of the participants including dry eye disease medications
1484391|NCT03086993|Combination Product|Melphalan/HDS|Melphalan/HDS treatment for up to six cycles, followed by a re-induction of CisGem.
1484392|NCT03086993|Drug|Cisplatin and Gemcitabine|continuous treatment with Cis/Gem until disease progression
1484393|NCT03086980|Other|Automatic Self Transcending Meditation|Automatic Self Transcending Meditation (ASTM) is a class of meditation that helps quiet the mind. Research suggests that ASTM helps reduce depression, anxiety, stress, and may improve health related quality of life. Further, ASTM is easier to learn and to teach.
1484394|NCT03086980|Other|Treatment as Usual|Usual Care will be provided.
1484395|NCT03086967|Device|Double-lumen balloon catheter|introduction of catheter into cervix for ripening prior to induction of labor following standard of care practices
1484396|NCT03086954|Biological|The Chimeric Antigen Receptor T Cell Immunotherapy (CAR-T)|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
1484397|NCT03086941|Device|I-gel|To compare between use of I-gel as a conduit for blind intubation and as a conduit for fiberoptic guided intubation in children. We also aim to validate the use of I-gel as conduit for blind intubation in absence of fiberoptic or lack of experience of its use.
1484398|NCT03086928|Other|lava ultimate|resin nano ceramic material
1484399|NCT03086928|Other|E.max cad|Lithium disilicate glass ceramic
1484473|NCT03086239|Drug|Rovalpituzumab tesirine|Intravenous
1484403|NCT03086889|Other|immersion virtual reality (VR)-based rehabilitation|Intervention group received VR-based rehabilitation,including Virtual kitchen and so on.The patients took part in the exercise program for 30 minutes each day, five times per week, for 3 weeks. All subjects received physiotherapy, which accounts for an average of 30 minutes of physiotherapy per day on tolerance.
1484404|NCT03086889|Other|traditional rehabilitation training|The traditional rehabilitation training included occupational therapy and physical therapy, patients took part in the traditional rehabilitation training for 60 minutes each day, five times per week, for 3 weeks.
1484405|NCT03086876|Behavioral|Level 4 Stepping Stones Triple P (SSTP)|Stepping Stones Triple P is a system of psychoeducational and behavioural approaches to parenting a child with LD and challenging behaviour that aims to increase parental confidence and skills so that parents are able to manage the child's behavior effectively. SSTP comprises different levels based on increasing family complexity.
1484406|NCT03086863|Device|electroacupuncture|All the patients in verum electroacupuncture group will receive acupuncture on the six adjacent acupoints (LI4, LI15, TE14, SI9, SI11, and GB21) in unilateral side. Acupuncture needles (stainless steel, 0.25 mm × 40 mm, Dong Bang Acupuncture Inc., Republic of Korea) will be inserted 10-15 mm in depth and de qi sensation will be elicited. Park sham guide tubes will be used in verum group, too. Low frequency stimulate (STN-111, Stratek, Republic of Korea) will be connected to the tips of needles to provide electrical stimulation at middle frequency (30 Hz). Needles with electrical stimulation will be retained for 20 minutes. Patients should take this procedure 3 times a week for 3 weeks (9 sessions in total).
1484407|NCT03086863|Device|sham electroacupuncture|We selected a non-penetrating sham needling, i.e., Park sham device, which has been developed and validated in preceding studies as comparison. On the exactly same 6 acupoints as verum electroacupuncture group, needles will be installed with Park sham guide tubes and the same electrical stimulators will be connected the tips of needles. Since the needles do not penetrate the skin, the stimulation is not electrically conducted. To be sure of patient blinding, the low frequency stimulate will be turned on with the same frequency (30 Hz), which makes a fake noise, resulting in letting patients believe that they are taking real electroacupuncture therapy for 20 minutes. Sham group will also 9 session for 3 weeks (3 sessions a week).
1484408|NCT03086850|Behavioral|Promotion of daily physical activity with a pedometer|"Patients will receive an ONwalk 100 pedometer (GEONAUTE, France) and will be instructed how to use it. They will be encouraged to be more active by using the pedometer to measure the number of steps walked daily and to record this in a diary, together with any information related to their clinical condition. Based on the cumulative step count for each day and the mean value since the last visit, patients will receive a task to increase their steps per day by the next appointment according to the next protocol:
<6000 steps/day: increase by 3000 steps/day
6000 - 10000 steps/day: reach 10000 steps/day
> 10000 steps/day: maintain or increase steps"
1484409|NCT03086850|Other|Conventional treatment|Treatment and follow-up according to conventional clinical practice (SEPAR guidelines), including standard recommendations on healthy habits and lifestyle.
1484410|NCT03086837|Behavioral|Mobile phone based intervention|Participants will receive supporting messages through a mobile phone based intervention.
1484411|NCT03086824|Device|magnetic resonance-guided focused ultrasound|
1484412|NCT03086811|Behavioral|Mother Infant Feeding Interaction very early training|"weekly training meetings on 4 topics:
What - proper nutrition and supplements for solid feeding phase (dietitian); What - the meaning of feeding to mother and infant (social worker).
Who - feeding skills - knowledge and actual practices
From anxiety to serenity - knowledge concerning growth patterns and common physical and emotional issues troubling parents of infants 4-12 months old.
Prevention of obesity and emotional eating - practical advise and tips."
1484413|NCT03086798|Procedure|Magill forceps|Magill forceps techniques to facilitate nasotracheal tube advancement into trachea
1484414|NCT03086798|Procedure|cuff inflation|cuff inflation techniques to facilitate nasotracheal tube advancement into trachea
1484415|NCT03086668|Procedure|Conventional Jaw thrust Group|a video-stylet assisted nasotracheal intubation and facilitate by conventional jaw thrust technique
1484416|NCT03086668|Procedure|Fingers hook Group|a video-stylet assisted nasotracheal intubation and facilitate by fingers-hook technique
2001076|NCT03228199|Other|Intervention group|Immediate provision of a free pair of presbyopic glasses to correct the worker's vision for optimal picking distance as measured using a chart placed at the top of a typical tea bush, and for cylindrical errors >= 0.5D
2001077|NCT03228199|Other|Control Group|Will be deferred to receive spectacles as above, after the 12 week evaluation period.
2001078|NCT03227770|Device|hemoperfusion combined with hemodialysis|Hemoperfusion combined with hemodialysis treatment will perform once every two week. The hemoperfusion apparatus will use type HA130 resin hemoperfusion apparatus (Zhuhai Jafron Biomedical Co., Ltd, China)
1484420|NCT03086629|Other|Patient Concerns Inventory|
1484421|NCT03086629|Other|No Patient Concerns Inventory|
1484422|NCT03086616|Drug|Convection Enhanced Delivery (CED) of Nanoliposomal irinotecan (nal-IRI)|Nal-IRI will be given directly into the tumor using CED.
1484423|NCT03086564|Biological|ADCC & TACE|Experimental groups will be given TACE as well as Activated-Dendritic Cells(1-2*10^8,intravenous drip),simultaneously.Cyclophosphamide(250mg/cm2,intravenous drip) will be used two days before TACE performed.
1484424|NCT03086564|Procedure|TACE|TACE solely in the first day of a clinical course.
1484425|NCT03086551|Device|Active continuous theta burst stimulation (cTBS)|Active cTBS over dorsolateral prefrontal cortex that has an effect upon dorsolateral prefrontal cortex brain activity.
1484426|NCT03086551|Device|Placebo (Sham) continuous theta burst stimulation|Sham stimulation over dorsolateral prefrontal cortex that looks and sounds like active cTBS but does not have any effect upon dorsolateral prefrontal cortex brain activity.
1484427|NCT03086551|Behavioral|Motor Practice|Upper limb reaching task to be practiced. Practice will be paired with Active/Sham stimulation. Twenty trials will occur before Active/Sham stimulation. 40 trials will be practiced after Active/Sham stimulation.
1484543|NCT03085758|Biological|Adrecizumab|Single i.v. dose of 2 mg/kg (treatment arm A) or 4 mg/kg (treatment arm B)
1484544|NCT03085758|Biological|Placebo|Single i.v. dose of placebo (control group)
2001079|NCT03227770|Device|hemodialysis|Regular blood purification treatment（including HD, HDF and HFHD）, 3 times a week, at least 4 hours per session
1484428|NCT03086538|Drug|Pemetrexed|Pemetrexed is a multitarget antifolate (MTA) whose mechanism of action relies mainly on the inhibition of TS, with weaker secondary effects on glycinamide ribonucleotide formyltransferase (GARFT) and dihydrofolate reductase (DHFR), leading to impairment of DNA synthesis and repair.
1484429|NCT03086538|Drug|Tarceva 100Mg Tablet|Erlotinib (tarceva) is oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI).
1484430|NCT03086525|Other|Diagnosis/Prognosis|The present study will be a prospective observational study of 4 years that will be carried out between September 2017 and September 2020 at the University of Malaga. Several questionnaires assessing different beliefs associated with pain will be administered to participants. The results will be evaluated at baseline (t1) and in 4 follow-ups (at 12 (t2), 24 (t3), 36 (t4) and 48 (t5) months.
1484431|NCT03086512|Device|Acutrak 2® - 7.5 Screw|"The Acumed Acutrak 2® - 7.5 is a fully-threaded headless screw fixation, composed of 17 unique screw size options. The Acutrak 2® - 7.5 is available in sizes from 40 mm to 120 mm and is inserted using a 4.0 mm hex driver over a .094 guide wire. The Acutrak 2 Part Number is 30-0XXX and 30-0XXX-S."
1484432|NCT03086512|Device|Synthes® 7.3 Cannulated Screw|The Synthes® 7.3 mm Cannulated screws are available in three thread options: 16 mm, 32 mm or fully threaded. This study will use the partially threaded options. The screws can be placed by small diameter guide wires. They are composed of 316L stainless steel or titanium alloy (Ti-6Al-7Nb).
1484433|NCT03086486|Drug|Pretomanid|200mg tablets
1484434|NCT03086486|Drug|Linezolid|Scored 600mg tablets
1484435|NCT03086486|Drug|Bedaquiline|100mg tablets
1484436|NCT03086486|Drug|Placebo Linezolid|Scored 600 mg tablets
1484437|NCT03086473|Drug|Caffeine Citrate|The intervention in this study is timing of the initial caffeine dose. In the Caffeine arm, participants will receive Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) within 2 hours of life, and Normal Saline (0.9% NaCl) 1ml/kg IV at 12 hours of life.
1484438|NCT03086473|Drug|Placebo (Normal Saline)|The intervention in this study is timing of the initial caffeine dose. In the Placebo arm, participants will receive Normal Saline (0.9%NaCl) 1ml/kg IV within 2 hours of life, and Caffeine Citrate 20mg/kg IV (volume dose 1ml/kg) at 12 hours of life.
1484439|NCT03086460|Drug|CHF 1531|Dose Response: Test one of five different doses of CHF 1531
1484440|NCT03086460|Drug|Formoterol Inhalation Solution|Active Control
1484441|NCT03086460|Drug|Placebo|Matched Placebo
1484442|NCT03086447|Device|Investigational Contact Lens|Senofilcon C Toric
1484443|NCT03086447|Device|Marketed Contact Lens|Air Optix for Astigmatism
1484444|NCT03086434|Other|Culturally Tailored Intervention|School-based substance use prevention
1484445|NCT03086434|Other|Standard Substance Abuse Education|Class room program
1484446|NCT03086421|Behavioral|Questionnaires|Participants, their parent/legal guardian, and if consented to another adult caregiver will be asked to complete several questionnaires evaluating the participant's social cognitive skills, social experience, neurocognitive functioning, and neurocognitive skills.
1948801|NCT01612351|Radiation|Ipsilateral Radiation|After transoral surgery, subjects deemed medium risk will receive ipsilateral radiation as per standard of care 5 days/week for 6 weeks concurrent with weekly cisplatin.
2001080|NCT03226431|Drug|Glutathione|ARINA-1 (inhaled L-glutathione 150 mg/ml, 4 ml) will be nebulized twice daily for 3 months using a PARI eFlow nebulizer
1484449|NCT03086395|Drug|Obinutuzumab|Patients will be treated with a total of 2 cycles of obinutuzumab. Cycle 1 obinutuzumab dose is 1000 mg given intravenously (IV) on day 1, 8, 15. Cycle #1 day #1 dose of 1000 mg of obinutuzumab will be administered over 2 days. During Cycle 1, Day 1, 100 mg will be administered. On the following day (Cycle 1, Day 2), 900 mg will be administered. During cycle 2 patients will receive a single dose of obinutuzumab1000 mg IV on day 1. Cycle #2 will be given 21 days after the first cycle.
1484450|NCT03086382|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 200 mg given as 2 tablets of LCM 100 mg
1484451|NCT03086382|Drug|Lacosamide (LCM) syrup|Treatment B: Single dose of Lacosamide (LCM) 200 mg given as syrup
2001081|NCT03226041|Device|transcutaneous monitor (TCM-4 monitor)|TCM-4 monitor, which had changed new electrode membrane and was calibrated by the same person(who had been trained systematically) before each placement. The electrode should be heated to 44℃, then fixed it to the anterior part of chest in the location of lateral position after remove grease by alcohol. The positon of electrode must be changed every 2 hours in order to avoid thermal injury, and should be calibrated again.
1484456|NCT03086356|Drug|Dabigatran etexilate|Days 1-4 and Day 8-11
1484457|NCT03086356|Drug|Idarucizumab|Day 11
1484458|NCT03086343|Drug|ABT-494|Oral Tablet
1484459|NCT03086343|Drug|Abatacept|IV infusion
1484460|NCT03086343|Drug|ABT-494 matching placebo|Oral tablet
1484461|NCT03086343|Drug|Abatacept matching placebo|IV infusion
1484466|NCT03086304|Device|transcutaneous acupoint electrical stimulation|Transcutaneous acupoint electrical stimulation is same to the traditional Chinese medicine acupuncture treatment,treat diseases by stimulate different acupuncture point.
1484467|NCT03086304|Device|no transcutaneous acupoint electrical stimulation|the choice of acupoints are same with TEAS group,tape over the electrode but don't give electroacupuncture stimulation.
1484468|NCT03086291|Drug|Simvastatin|Simvastatin 5-10mg/kg bid for 7 days and 14 days off treatment for 21 days
1484470|NCT03086265|Device|THRIVE|active nasal oxygen delivery system
1484474|NCT03086226|Drug|Fosravuconazole|Fosravuconazole will be given in two arms either as 300mg or 200mg. The drop-the loser design adaptive clinical trial design will allow two stages of the trial separated by a data based decision. In the first stage a decision will be taken on which arm to drop either the Fosravuconazole 200 or the Fosravuconazole 300 arm. The best treatment will be compared against the standard of care, itraconazole. At the end the focus will be comparing the best treatment against standard of care.
1484475|NCT03086226|Drug|Itraconazole|This will be the active comparator
1484476|NCT03086213|Drug|Propofol|anaesthetic
1484477|NCT03086213|Drug|Sulfentanyl|anaesthetic
1484478|NCT03086213|Drug|Dexmedetomidine|anaesthetic
1484479|NCT03086213|Drug|Lidocaine|local anaesthetics
1484480|NCT03086213|Drug|Ropivacaine|local anaesthetics
1948802|NCT01612351|Radiation|Bilateral Radiation|After transoral surgery, subjects deemed high risk will receive bilateral radiation as per standard of care 5 days/week for 5-7 weeks concurrent with cisplatin every 3 weeks and daily lapatinib.
1484482|NCT03086187|Device|Hephaistos unloading orthosis|The Hephaistos unloading orthosis greatly reduces plantarflexor muscle torque and plantarflexor muscle activation during any gait activity.
1484484|NCT03086161|Behavioral|Interpersonal Psychotherapy for the Prevention of Excess Gestational Weight Gain|Six individual 1-hour sessions delivered over the course of pregnancy to address interpersonal problems areas that may lead to emotional eating, physical inactivity, and increased stress during pregnancy, which are drivers of excess weight gain in pregnancy
1484485|NCT03086161|Behavioral|Treatment-as-usual|Routine prenatal care as part of multidisciplinary adolescent pregnancy clinic, including medical (ob/gyn), nutrition, and social work
2010585|NCT02924688|Drug|FF/VI (200/25) mcg|Dry white powder delivered via the ELLIPTA DPI (one inhalation, QD in the morning). The ELLIPTA DPI holds 2 individual blister strips with 30 blisters on each strip: the first strip contains FF 200 mcg in each blister and the second strip contains VI 25 mcg in each blister.
2010586|NCT02924688|Drug|Fluticasone/salmeterol (FSC)|Dry white powder delivered via the DISKUS DPI (one inhalation twice daily: one in the morning and one in the evening). The DISKUS DPI holds a strip of 60 blisters; each blister contains FP 250 mcg and 50 mcg of salmeterol.
1484488|NCT03086135|Device|Osia System|An external Sound Processor captures and digitize the sound which is transferred to the internal implant where it is converted to an electrical signal. The electrical signal is further transferred as a vibration through an osseointegrated implant to the mastoid bone and eventually to the cochlea.
1484489|NCT03086122|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment for patients randomized to CPAP treatment group. Treatment duration: 3 months.
1484490|NCT03086109|Other|Risk factors|Risk factors associated bone degenerative diseases
1484491|NCT03086096|Device|LifePearl Microspheres loaded with Irinotecan|LifePearl Microspheres are embolisation microspheres for transcatheter chemoembolisation (TACE), that can be loaded with chemotherapeutic agents. In this registry, LifePearl Microspheres will be loaded with Irinotecan.
1484492|NCT03086083|Behavioral|EMDR standard protocol|Patient have only one standard EMDR session about a traumatic situation remembered by him.
1484493|NCT03086083|Behavioral|protocol without brain stimulation|Patient have only one standard EMDR session about a traumatic situation remembered by him, however, without the bilateral brain stimulation.
1484494|NCT03086070|Drug|Omeprazole 20mg|omeprazole 20 mg capsules were administered per os half an hour before breakfast for 8 weeks
1484495|NCT03086070|Drug|Placebo oral capsule|Matching placebo oral capsules were administered per os half an hour before breakfast for 8 weeks
1484496|NCT03086057|Behavioral|PrEPare for Work: Strength Based Case Management (Stage 1)|Support, facilitate, and assist in linkage to PrEP clinic and to facilitate initiation of, and obtaining, PrEP medications.
1484497|NCT03086057|Behavioral|PrEPare for Work: Adherence Training and Counseling (Stage 2)|Up to three adherence training and counseling intervention sessions (once per week for two to three weeks) with a clinical interventionist.
1484498|NCT03086044|Drug|Sofosbuvir/velpatasvir|4 weeks of treatment beginning on the day of transplant or as soon as the recipient is able to tolerate oral medications after transplantation.
1484499|NCT03086044|Other|Monitoring|Close HCV viral load monitoring Will receive direct acting antiviral treatment with 6 weeks of sofosbuvir/velpatasvir if the recipient develops HCV viremia during the post-transplant HCV viral load testing
1484500|NCT03086031|Behavioral|Program -based vocational rehabilitation intervention|"The VR intervention lasts for a total of 6-9 months with first six different modules (3-month) that are individually planned, and second a work placement program (approximately 3-6 months). Each of the different modules follows a comprehensive standard operating procedures (SOP's). The six modules will be grouped into (a) individual therapies which includes neuropsychological sessions (10-hours), balance between work and everyday life (20-hours), and job matching (10-hours), (b) grouped-based therapies which includes psycho education (18-hours), mindfulness (15-hours), and physiotherapy training (15-hours), (c) an manualized family intervention program (8 sessions of 90 minutes), and an individual caregiver coaching (12-hours), (d) a work placement program including work practice (3-6 month), supported employment by the rehabilitation team (30-hours), and the development of a post rehabilitation plan (4-hours)."
1484501|NCT03086031|Behavioral|Conventional vocational rehabilitation (controls)|Treatment as usual delivered by the municipalities.
1484502|NCT03086018|Device|Successor hearing aid to Juna|The participants will all be experienced hearing instrument device users and will be switched from their current (control) devices to the new test device which succeeds the Juna device.
1484503|NCT03086005|Drug|Metformin|
1484504|NCT03085992|Drug|FOLFOXIRI plus Bevacizumab|"BEVACIZUMAB 5 mg/kg over 30 minutes, day 1
IRINOTECAN 165 mg/sqm IV over 1-h, day 1
OXALIPLATIN 85 mg/sqm IV over 2-h, day 1
L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1
5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1 administered every two weeks for 6 cycles (3 months)."
1948803|NCT01612351|Procedure|Transoral Surgery|Transoral resection by robotic or microscopic approach, which will be at the discretion of the treating surgeon.
1948804|NCT01610492|Drug|belimumab|10mg/kg administered intravenously
1948805|NCT01604187|Drug|Fentanyl|Ten minutes before the procedure fentanyl sublingual tablet (Abstral ® 100 µg, ProStrakan) will be given to the patient.
1484505|NCT03085992|Other|Chemoradiotherapy plus Bevacizumab|"FLUOROURACIL 225 mg/sqm/day by protracted IV continuous infusion or -CAPECITABINE 825 mg/sqm/bid p.o. continuously without interruption for all the duration of radiation treatment;
EXTERNAL-BEAM IRRADIATION 50.4 GY in 28 daily fractions over 5.5 weeks;
BEVACIZUMAB 5 mg/kg over 30 minutes, starting on day 1 of radiation treatment day 1 and then every two weeks (for 3 cycles)."
1484506|NCT03085979|Procedure|Burch Colposuspension|Anti-incontinent surgery
1484507|NCT03085979|Procedure|trans obturator tape|Anti-incontinent surgery
1484508|NCT03085979|Procedure|tension free vaginal tape|Anti-incontinent surgery
1484509|NCT03085966|Biological|autologous immune cell therapy|Luteinizing Hormone Releasing Hormone Agonists (LHRH-a) and Autologous dendritic cells (DC) and central memory T cells (Tcm cells)
1484510|NCT03085953|Behavioral|Veteran Supportive Supervisor Training|"The family supportive supervisor behavior (FSSB) training intervention developed by Hammer and colleagues (2011) will be used as the basis for the development of the VSST intervention in the present study. In addition, we will draw on critical elements of training provided by the Employer Support of the Guard and Reserve (ESGR), information about potential mental and physical health effects of being in combat, and information to help reduce the stigma associated with returning veterans; in other words, de-clinicalizing their symptoms. Furthermore, this intervention study falls under the more general rubric of soldier resilience, but more specifically addresses both veteran and family resilience upon return from combat. The details of the training content will be researched and developed during the funded project period."
1484511|NCT03085953|Other|Waitlist Control|Control group will receive training following all measurements points to serve as a comparison group
1484512|NCT03085940|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg once daily initially
1484513|NCT03085940|Drug|Placebo|Placebo
1484514|NCT03085927|Behavioral|Active Music Engagement|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. During the first visit, parent and child will receive information on common responses of young children to cancer treatment and how parents can use music play activities to support their child during treatment. The music therapist will lead parent and child in a variety of music play activities. Parent and child will receive a music kit that includes items such as hand-held rhythm instruments, puppets, and a music CD. During the second and third visit the music therapist will lead parent and child child through the music play activities, answer questions, and make suggestions for using these activities in the hospital and at home.
1484515|NCT03085927|Behavioral|Audio Storybooks|Three 45-minute sessions with a board-certified music therapist delivered over three days. Sessions are delivered in a private setting during in-patient hospitalization. Each session children/parents will choose and listen to one of three illustrated children's books with audio recorded narration.
1484516|NCT03085914|Drug|Epacadostat|Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose
1484517|NCT03085914|Drug|Nivolumab|Nivolumab 240 mg IV on Days 1 and 15
1484518|NCT03085914|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks
1484519|NCT03085914|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 IV on Days 1 and 15
1484520|NCT03085914|Drug|Leucovorin|Leucovorin 400 mg/m^2 IV on Days 1 and 15
1484521|NCT03085914|Drug|5-Fluorouracil|5-Fluorouracil total dose of 2400 mg/m^2 on Days 1 and 15
1484522|NCT03085914|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 IV on Days 1, 8, and 15
1484523|NCT03085914|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m^2 IV on Days 1, 8, and 15
1484524|NCT03085914|Drug|Carboplatin|Carboplatin AUC 6 IV on Day 1 every 3 weeks
1484525|NCT03085914|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 every 3 weeks
1484526|NCT03085914|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 IV on Day 1 every 3 weeks
1484527|NCT03085914|Drug|Cyclophosphamide|Cyclophosphamide 50 mg orally once daily
1484528|NCT03085914|Drug|Carboplatin|Carboplatin AUC 5 IV on Day 1 every 3 weeks
1484529|NCT03085901|Device|Precizon toric intraocular lens|Phacoemulsification and implantation of Precizon toric intraocular lens
1484530|NCT03085901|Device|Tecnis toric intraocular lens|Phacoemulsification and implantation of Tecnis toric intraocular lens
1484531|NCT03085849|Drug|Durvalumab|1500 mg IV on day 8 (flat dose) until progression
1484532|NCT03085849|Drug|Tremelimumab|75 mg IV on day 8 (flat dose) x 4 doses
1484533|NCT03085849|Drug|SGI-110|"SC daily for 5 days (days 1-5) until progression or toxicity
Dose escalation scheme:
Dose level -1 - SGI-110 20 mg/m2 SC daily; Dose level 0 - SGI-110 30 mg/m2 SC daily; Dose level 1 - SGI-110 45 mg/m2 SC daily; and SGI-110 given on days 1-5 of every 28 day cycle"
1484534|NCT03085836|Drug|TAK-438|TAK-438 Tablets
1484535|NCT03085823|Device|Sirolimus Coated Balloon|
1484536|NCT03085810|Drug|Ocrelizumab|Ocrelizumab will be administered via IV infusion as specified throughout the treatment period.
1948806|NCT01604187|Drug|Placebo|Ten minutes before the procedure placebo sublingual tablet will be given to the patient.
1948807|NCT01596959|Procedure|Radiofrequency ablation utilising the ECI contact software|irrigated radiofrequency ablation to the right atrium using the ECI contact data
1948808|NCT01596959|Procedure|Radiofrequency ablation without the use of ECI contact data|irrigated RF ablation without the use of ECI contact data
1484540|NCT03085784|Drug|Aflibercept|The investigational product is intravitreal aflibercept injection (IAI), which will be supplied by Regeneron Pharmaceuticals, Inc. in sterile vials for intravitreal (IVT) injection. The study duration will be 52 weeks. Vials of drug must be used (defined as entered with needle) only once. All drug supplies are to be kept under recommended storage conditions. The injection volume will be 50μL (0.05 mL) and will be administered to the patients by IVT injection.
1484541|NCT03085771|Drug|desferal|It is a blinded randomized cross-over study that investigates the efficacy of DFO (50mg/kg) given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
1484542|NCT03085771|Drug|Isotonic saline|It is a blinded randomized cross-over study that investigates the efficacy of isotonic saline given i.v before intermittent hypoxia (IH) to improve the cardiorespiratory and angiogenetic response in patients with diabetes.
1604213|NCT02205047|Drug|Pertuzumab|
1948809|NCT01578902|Radiation|Hypofractionated radiotherapy|35Gy/5 fractions/29 days
1484545|NCT03085745|Other|Transcranial Magnetic Stimulation (TMS)|TMS is a non invasive brain stimulation technique which allows to measure corticospinal excitability from peripheral muscles.
1484546|NCT03085732|Drug|Irrigation with Saline Solution|During hysterectomy after vaginal cuff closure 500-1000 mL saline irrigation will be done.
1484547|NCT03085719|Drug|Pembrolizumab|Keytruda is designed to restore the natural ability of the immune system to recognize and target cancer cells
1484548|NCT03085719|Radiation|Radiation|Radiation is used to shrink the cancer
1484549|NCT03085706|Biological|PBMC autotransplantation|Fourteen amyotrophic lateral sclerosis (ALS) patients are received peripheral blood mononuclear cell (PBMC) autotransplantation.
1484550|NCT03085680|Drug|Curcumin|Participants will be given curcumin (1000 mg/day), and will be instructed to consume two 500 mg capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
1484551|NCT03085680|Drug|microcrystalline cellulose|Participants will be instructed to consume two capsules prior to breakfast every morning with a glass of water. Participants will be instructed to follow this dosing regimen throughout the entire three-month treatment period. Compliance with the dosing regimen will be monitored both through interview and by counting capsules left at monthly clinic visits.
1484552|NCT03085654|Drug|Oxytocin nasal spray|Intranasal administration of oxytocin 24 international units per dose.
1484553|NCT03085654|Drug|Placebo nasal spray|Intranasal administration of placebo 24 international units per dose.
1484555|NCT03085628|Drug|Oxytocin|40IU
1484556|NCT03085628|Drug|Placebo|40IU
1484557|NCT03085615|Other|Jevity 1.5|Jevity 1.5 is an enteral nutrition product delivering 1.5 kcals/mL and 0.06 g protein/mL.
1484558|NCT03085602|Behavioral|Cognitive behavioral therapy|Therapy focused on explaining the physiological and psychological effects of nicotine. Training is focused on adherence to smoking instructions, physiological and psychological effects of nicotine, reviewing reasons for quitting, and coping with smoking urges. Smokers will be asked to begin smoking on a set schedule leading up to their quit day.
1484559|NCT03085602|Behavioral|Health education|Therapy that provides health education on the importance of healthy eating. Participants will be instructed to smoke as usual.
1484560|NCT03085563|Drug|Nitrous Oxide|Nitrous oxide will be delivered in one of two ways, using the titration method or rapid infusion method. Which ever method is used will be recorded. When using the titration method, starting at 20%, nitrous oxide will be added in 10% increments every 60 seconds until the ideal level of sedation has been met (not to exceed 70% nitrous oxide). Using the rapid infusion method, after the proper flow rate has been achieved with oxygen, the flowmeter will be increased to obtain 50% concentration of nitrous oxide. After 2-3 minutes if the patient does not have adequate sedation, nitrous oxide concentration will be increased to 70%.
1484561|NCT03085563|Drug|Midazolam|Intranasal midazolam with mucosal atomizer device administration will follow the Children's Hospital Colorado (CHCO) established policy 'Intranasal Administration (atomization) of Medications'. As per standard of care, each patient will receive a standardized dose of 0.4mg/kg (maximum dose of 10mg) of intranasal midazolam with the mucosal atomizer device for all procedures.
1484564|NCT03085524|Diagnostic Test|Platelet function testing|The investigators will test platelet reactivity at the beginning and midpoint of the first year after revascularization
1484565|NCT03085524|Diagnostic Test|Vascular ultrasonography|The investigators will test bypass graft and stent patency at 30 days, 6 months, and 1 year.
1484566|NCT03085511|Behavioral|Egg breakfast (EB)|Breakfast is considered as high quality protein diet, but has similar weight, energy, and macronutrients as the active comparator. The details are as follows: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.6%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
1484567|NCT03085511|Behavioral|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics will include portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, as well as behavioral strategies including self-monitoring, motivational interviewing, goal setting, and problem solving.
1484568|NCT03085511|Behavioral|Weight Loss Diet|Participants will have a 1200-1500kcals diet based on each individual's body weight during the study.
1484569|NCT03085511|Behavioral|Cereal Breakfast (CB)|Breakfast is considered as low quality protein diet, but has similar weight, energy, and macronutrients as that in experimental group. The details are as follows: weight 293 g, energy 398 kcal, energy density 1.36 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
1484570|NCT03085498|Other|No intervention|no intervention
1484571|NCT03085485|Drug|Ivacaftor 150 MG|Ivacaftor is a CFTR potentiator
1484572|NCT03085485|Drug|Placebo|placebo pills
1484573|NCT03085459|Behavioral|work Time|nurse got qualification certificate and the working time
1484574|NCT03085446|Behavioral|PDM nutritional intervention|personalized, diet-induced alterations in microbiota (PDM) for six months. (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3).
1484575|NCT03085446|Behavioral|General information on nutrition and health|General information on nutrition and health for six months: (1) A 14-day running-in, no-treatment baseline assessment of all outcomes (T0); (2) A 6-month intervention period, with repeated assessments of all outcomes during the last two weeks of months 3 (T1) and 6 (T2). (3) A 12 month follow up (T3),
2001088|NCT03224117|Drug|DWJ211|inject the Drug into submental fat via subcutaneous
2001089|NCT03224117|Drug|Normal saline|inject the Drug into submental fat via subcutaneous
1484578|NCT03085420|Diagnostic Test|Echocardiogram|A baseline Echocardiogram test (ECHO) will be done one week from admission and monthly (+/- 1 week) or as ordered by a cardiologist.
1484579|NCT03085407|Procedure|early cholecystectomy|cholecystectomy was done within 48 after admission
1484580|NCT03085407|Procedure|delayed cholecystectomy|cholecystectomy was done after 30 days after randomization
1948810|NCT01575106|Device|Heat pain applied using TSA or CHEPS|TSA-2001 Thermal Sensory Analyzer (Medoc LTD Advanced Medical Systems) or the Pathway Medoc (CHEPS model, Contact Heat-Evoked Potential Stimulator, Medoc LTD Advanced Medical Systems)
1484583|NCT03085381|Biological|HPV vaccine|
1484584|NCT03085381|Biological|Placebo|
1484585|NCT03085368|Drug|lapatinib/herceptin|Lapatinib produced by glaxosmithkline. Oral small molecule epidermal growth factor tyrosine kinase inhibitor. Mainly used for combined with capecitabine in the treatment of ErbB-2 over expression, including received prior anthracycline, paclitaxel and trastuzumab (Herceptin) in the treatment of advanced or metastatic breast cancer. Our clinical trial want to see its benefit in early breast cancer
1484586|NCT03085355|Procedure|Exercises and PNE|Exercise for stretching and strength for neck muscles and pain neuroscience education
1484587|NCT03085355|Procedure|Osteopathic manipulative treatment|Osteopathic manipulative treatment associated exercise for stretching and strength for neck muscles and pain neuroscience education
1484588|NCT03085342|Diagnostic Test|Liver MRI|Multiparametric Liver MRI including following sequences: DCE, DWI, MRE, precontrast flow measurement, fat quantification.
1484589|NCT03085329|Device|Seattle-PAP|Seattle-PAP is a modified bubble CPAP device that has been given 510(k) clearance by the US FDA (K131502, October 11, 2013) and is thus recognized as substantially equivalent to other approved devices on the market. Results of a recently completed study in infants indicate that Bn-CPAP is associated with lower effort to breathe by spontaneously breathing premature infants.
1484590|NCT03085329|Device|Conventional bubble nasal CPAP|Infants enrolled in the study and randomized to this arm will be given respiratory support by bubble nasal CPAP using the Fisher & Paykel bubbler device, which is the standard of care at Nationwide Children's.
1484591|NCT03085316|Device|Investigational device|Device is an implantable neuromuscular system designed to deliver low-intensity electrical impulses to nerve and muscle targets.
1484592|NCT03085303|Device|Full Body Blue Light Device|Full body blue light irradiation (phototherapy) of atopic dermatitis patients.
1484593|NCT03085290|Other|Autologous serum eye drops|Autologous serum eye drop doses will be 6 times daily in each eye
1484594|NCT03085290|Other|Allogeneic serum eye drops|Allogeneic serum eye drop doses will be 6 times daily in each eye
1484595|NCT03085277|Dietary Supplement|Bovine colostrum|Bovine colostrum (BC) is the first milk from cows after birth and we suggest that BC may be used to supplement MM, instead of infant formula or DM. BC is a rich source of protein (up to 150 g/L) and bioactive components, including lactoferrin, lysozyme, lactoperoxidase, immunoglobulins, and various growth factors, such as, IGF-I and -II, EGFs, and TGF-β. BC has repeatedly been shown to have beneficial effects in a well-established piglet model of preterm infants, using various feeding regimens, including a gradual regimen that would mimic enteral feeding for preterm infants without access to MM during the first week.
1484596|NCT03085277|Dietary Supplement|Preterm formula|Preterm formula is a type of infant formula designed for preterm infants. It is used when mother's own milk is not available or not in sufficient amount as the enteral feeding for preterm infants in hospitals that do not have donor human milk.
1484597|NCT03085264|Behavioral|Community Health Worker|Community Health Workers calls, texts and visits patient to support them in pre-established care plans as well as medication compliance/appointment attendance
1484598|NCT03085251|Device|Blood glucose monitoring systems for self-testing (BGMS)|"Measurement procedure
Subjects will be asked to wash and dry their hands before the measurements.
The measurement procedure for each reagent system lot of a BGMS will be as follows:
Study personnel will collect a capillary blood sample from the subject's fingertip by skin puncture.
Duplicate measurements on the sample will be consecutively performed with 2 test meters using reagent system units from the same vial / package.
Capillary blood for measurements with all 3 test strip lots and for both comparison measurements will be taken from the same finger puncture.
The sample will be applied to the reagent system units following specifications in the manufacturer's labelling."
1484599|NCT03085238|Device|M-Trap|Device(s) will be surgically implanted in the peritoneal cavity.
1484600|NCT03085225|Drug|Combination of trabectedin with durvalumab|"Dose Escalation : 3 doses of trabectedin given in combination with durvalumab (fixed dose) will be investigated.
A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.).
Expansion cohorts: Once the Maximum Tolerated Dose (MTD) has been defined, the expansion cohorts will be opened. All patients will be treated at the MTD of Trabectedin (as defined in the dose escalation part of the trial) given in association with Durvalumab with the same schedule as in the dose escalation part of the trial."
1484601|NCT03085212|Behavioral|Stress Free Now|Online stress management program developed by the Cleveland Clinic that uses mindfulness and cognitive-behavioral therapy to help individuals manage their stress.
1484602|NCT03085199|Procedure|Laparoscopic reinforcement suture|After cutting of duodenal stump of about 2 cm length using linear stapler, LARS commenced from upper to lower part on staple-line of duodenal stump. Continuous suture with invagination was performed using a barbed suture. In case of patient with short duodenal stump because of chronic ulcer or ectopic pancreas at duodenal bulb, 2 or 3 interrupted sutures without invagination of duodenal stump was conducted using barbed sutures.
1484603|NCT03085186|Drug|Crizotinib|
1484644|NCT03084861|Drug|Conventional treatment|"Artificial tears: Lubristil ®
Therapeutic Contact lens: Air Optix Night&Day"
1484604|NCT03085173|Biological|EGFRt/19-28z/4-1BBL CAR T cells|Cohorts of 3-6 patients will be infused with escalating doses of EGFRt/19-28z/4-1BBL CAR T cells to establish the maximum tolerated dose (MTD). There are 4 planned dose levels: 1 x 10^5, 3 x 10^5, 1 x 10^6, and 3 x 10^6 CAR T cells/kg.
1484605|NCT03085160|Behavioral|Learning to Breathe|Six-session group program that involves meditation and interactive activities to learn mindfulness skills for coping with stress
1484606|NCT03085160|Behavioral|Health Education|Six-session group program that covers topics important for healthy living such as avoiding drug use, conflict resolution, bullying, sun safety and others
2001092|NCT03219164|Drug|AZLI|75 mg/ml of aztreonam administered thrice daily via the PARI Altera® Nebulizer System. Participants < 2 years will receive via the SmartMask® Baby, 2 to < 6 years via the SmartMask Kids® and > 6 years via the nebulizer mouthpiece.
1484608|NCT03085134|Other|Test infant formula with HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) with HMOs intended for management of CMPA.
1484609|NCT03085134|Other|Control infant formula without HMOs|Extensively hydrolysed (whey protein) specialty infant formulas (FSMP) intended for management of CMPA.
1484610|NCT03085121|Procedure|Distal femoral resection in total knee arthroplasty|EM and IM alignment systems are used to make the distal femoral cut in a random order.
1484611|NCT03085108|Other|No Intervention|No Intervention
2001093|NCT03219164|Drug|Placebo|Placebo administered thrice daily via the PARI Altera® Nebulizer System. Participants < 2 years will receive via the SmartMask® Baby, 2 to < 6 years via the SmartMask Kids® and > 6 years via the nebulizer mouthpiece.
2001094|NCT03219255|Drug|RELVAR 100 ELLIPTA|RELVAR 100 ELLIPTA contains fluticasone furoate, an inhaled corticosteroid and vilanterol, an ultra-long-acting Beta-2 agonist and it is indicated for the treatment of COPD (bronchitis chronic/emphysema). Post-marketing investigation of RELVAR 100 ELLIPTA will be carried out in this analysis.
1484614|NCT03085082|Diagnostic Test|blood type test|a blood sample will be withdrawn from the subjects tested by anti A anti B and anti D antigens to detect the individuals blood group and RH. then statistical analysis to detect presence of a relationship between skeletal types of malocclusion and ABO blood groups
1484615|NCT03085069|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
1484616|NCT03085056|Drug|Trametinib|trametinib orally 2mg daily during each 4 week cycle
1484617|NCT03085056|Drug|Paclitaxel|paclitaxel 80mg/m^2 weekly for 3 out of 4 weeks
1484618|NCT03085043|Procedure|Whole Body Magnetic Resonance Imaging (MRI)|Whole body MRI with diffusion-weighted imaging performed at baseline and in 6 months.
1484619|NCT03085043|Procedure|Standard of Care Pelvic MRI|Standard of care pelvic endorectal coil MRI performed at baseline and in 6 months.
1484620|NCT03085043|Procedure|Bone Scan|Standard of care bone scan performed at baseline and in 6 months.
1484621|NCT03085043|Procedure|Computed Tomography (CT)|CT abdomen and pelvis performed at baseline and in 6 months.
1484622|NCT03085030|Drug|Antioxidant Formula|Antioxidant tablet will be taken by the patients
1484623|NCT03085030|Drug|Placebo|The placebo will be taken by the patients
1484624|NCT03085017|Device|BoneSeal|BoneSeal® is an absorbable synthetic bone hemostats that also contains of PLA, PEG and hydroxyapatite which supports bone re-growth. Product code MTJ. FDA number K142348.
1484625|NCT03085017|Device|Ostene|OSTENE is a synthetic, biodissolvable implant material that, provides immediate bone hemostasis, can be used on all bleeding bone surfaces, is completely biocompatible and water-soluble polymer, is a mechanical barrier that does not act biochemically.
1484626|NCT03085004|Drug|Ethanol|The cyst will be lavaged for 3 minutes with ethanol
1484627|NCT03085004|Drug|Normal Saline|The cyst will be lavaged for 3 minutes with Normal Saline
1484628|NCT03085004|Drug|Paclitaxel|Following Lavage with 98% ethanol cysts will be infused with 3mg/ml paclitaxel.
1484629|NCT03085004|Drug|Paclitaxel/ Gemcitabine|Following lavage with normal saline ,The cysts will be infused with an admixture of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
1484630|NCT03084978|Procedure|General Anesthesia|General anesthesia by standard endotracheal intubation.
1484631|NCT03084978|Procedure|Conscious Sedation|Conscious sedation
1484632|NCT03084952|Drug|18-Methoxycoronaridine|Drug under evaluation for leishmaniasis treatment
1484633|NCT03084952|Drug|Glucantime|Leishmaniasis standard drug in Brazil
2010587|NCT02924688|Drug|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) which will be used when needed during the study.
2010588|NCT02924688|Device|ELLIPTA DPI|The ELLIPTA device will be used during the stabilization period and the treatment period. The ELLIPTA DPI is a moulded plastic two-sided device that can hold two individual blister strips which contain powder formulation for oral inhalation.
1484638|NCT03084913|Other|Plant- based, olive oil diet|used as part of daily diet, followed for 8 weeks
1484639|NCT03084913|Other|Prostate Cancer Foundation diet|followed for 8 weeks
1484640|NCT03084900|Other|Arm 1|Patient-Centered Decision Support to Improve Diabetes Mgmt. We will use a computerized decision support system to aid clinicians to provide standard of care management while introducing patient-centered guidelines and outcomes measures.The intervention is the use of an electronic decision support tool. The decision support tool consists of a series of questions answered by the patients that will then allow the health care provider to address specific needs during the visit.
1484641|NCT03084887|Behavioral|manuals and follow-up|distribute manuals for patients before discharge and telephone follow-up per week until secondary hospital
1484642|NCT03084874|Behavioral|Physical activity and sedentary behavior coaching program|The intervention group will receive an individualized coaching program. During a motivational interview an experienced physiotherapist will asses participant's usual exercise habits, possible barriers and facilitators, self-efficacy and motivation to increase physical activity and reduce sedentary time. Based on these data (and baseline physical activity/sedentary information) an individualized, progressive program with specific goals setting and self-monitoring will be established (patients will be active participants and decision makers in this process).
1484643|NCT03084861|Drug|Cord Blood Eye Drops|Eye drops plasma from cord blood diluted v/v with Plasmalyte®, without antimicrobial preservatives
1484960|NCT03082469|Device|CytoSorb|Two consecutive 24h treatments with the CytoSorb-device
1484645|NCT03084848|Other|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of crystallised intelligence
1484646|NCT03084848|Other|Training|25 training sessions of 15 minutes per day, 5 days a week for a month of inhibitory control
2001095|NCT03215745|Behavioral|Delirium prevention program|Delirium prevention program Placard with the names of the care team and the calendar days; cognitively stimulating activities three times a day. Pictures, radio, robe. Visual aids large print books, with daily reinforcement of use Maintain adequate lighting opening blinds and curtains during the day, and darken their environment at night. Dissipation wax and special techniques of communication, with daily reinforcement of these adaptations. Go to the patient by name and tone of voice appropriate. Always listen. Use simple and clear language, face-to-face. Avoid excessive familiarity and childish. Promote family involvement in self-care and caregivers and the reorientation of the patient, contact with extended family during the stay.
2001096|NCT03215277|Drug|Bimekizumab|One Bimekizumab dose will be applied.
2001097|NCT03215277|Drug|Certolizumab Pegol|Two Certolizumab Pegol dosages will be applied.
1484650|NCT03084822|Behavioral|FAITH! App digital intervention|The digital app will include 10 education modules addressing the major CVD risk factors to be delivered on-demand through an innovative, interactive video series. The digital app will also support the multi-media education modules, interactive surveys/quizzes, self-monitoring (diet, physical activity), and social networking (discussion board) functionality.
1484651|NCT03084809|Drug|Cytokine-induced killer cells+ FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks. Collected CIK cells were suspended with 100ml saline (containing 5ml 20% human serum albumin) and given continuously over 2 hours/ day for 3 days.
1484652|NCT03084809|Drug|FOLFOX4|Day 1: Oxaliplatin 130 mg/m² IV infusion in 500 mL D5W. Day 2-6: leucovorin 200mg/m² IV infusion in D5W both given over 2 hours at the same time in separate bags Day 2-6: 5-FU 500 mg/m² IV bolus given continuously over 4-6 hours. The treatment is given for 4-6 cycles, every 3 weeks.
1484653|NCT03084796|Drug|CHF 5259|Dose Response: Test one of four different doses of CHF 5259
1484654|NCT03084796|Drug|Placebo|Placebo Control
1484655|NCT03084796|Drug|Tiotropium Bromide 18 MCG Inhalation Capsule|Active Control
1484656|NCT03084783|Drug|Dexamethasone|Participants receive dexamethasone 10mg intravenously 6 hourly for 4 days.
1484657|NCT03084770|Diagnostic Test|Radiological imaging studies|Patients will be submitted to radiological imaging studies (CT scan and/or MRI and/ or 68Gallium PET/CT and/or Octreoscan and/or EUS+FNAand/or Octreoscan and/or EUS+FNA) at diagnosis, and then every 6 months for the first two years and yearly thereafter for five years in the absence of significant changes on imaging or symptoms appearance. Every 12 months (or 6 months for patients with Ki67> 2%) a high quality imaging (CT scan or MRI) is required.
1484658|NCT03084770|Other|Quality of Life Assessment|quality of life and the perceived burden of surveillance or follow-up after surgery for participants, will be investigated by administrating HADS questionnaire and EORTC QLQ-C30 (version 3) and EORTC QLQ-GI.NET21 Module.
1484659|NCT03084757|Diagnostic Test|research of druggable molecular alterations on tumor biopsy|The study will run in 2 steps. Before starting a new treatment, patients with advanced cancer will undergo a tumor biopsy of a metastatic site in order to perform molecular analyses seeking for druggable molecular alterations
1484660|NCT03084744|Behavioral|Schema therapy|Schema therapy for chronic depression, a face-to-face psychological intervention by clinical psychologists.
1484661|NCT03084744|Behavioral|Active monitoring|Active tele-monitoring by clinical psychologists.
1484662|NCT03084731|Dietary Supplement|Microbiota Directed Complementary Food (MDCF)|"For Study 1: Investigators will test 3 prototype MDCFs and the current RUSF standard of care for MAM to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.
Study 2: From study 1 Investigators will select most efficacious MDCF and compare with 2 additional MDCF prototypes to establish the effect size of each on MAZ repair in a 4 week twice daily intervention, with a 2 week post-intervention phase.
Study 3: Investigators will select the lead MDCF from study 2 and examine the effects between the final MDCF versus current RUSF and also examine the impact dispensing of the lead MDCF once versus twice per day with a 4 week post-intervention period."
1484663|NCT03084718|Drug|CHF 781|Dose Response: Test one of three different doses of CHF 781
1484664|NCT03084718|Drug|Placebos|Placebo Control
1484665|NCT03084718|Drug|Beclomethasone Dipropionate|Active Control
1484666|NCT03084705|Device|Manumeter|A manumeter is a first-of-its-kind magnetic sensor to wirelessly detect hand and arm movement in a socially acceptable and easy to don package. The study participants will wear a small magnet as a ring, and a sensing/logging wristband detects changes in the magnetic field as the ring moves; the wristband can detect arm accelerations.
1484667|NCT03084692|Behavioral|Therapeutic Yoga and Resistance Exercise|Combined Program of Yoga and Resistance Exercise
2001098|NCT03215277|Other|Placebo|Placebo will be provided to keep the blinding.
2001099|NCT03211793|Drug|Mesenchymal stromal cells|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
1484671|NCT03084666|Device|Zimmer ATS tourniquet system|The tourniquet is the same kind that is used in orthopedic surgeries to limit blood loss in arm or leg surgery. It can be inflated to a set pressure for a set amount of time.
1484672|NCT03084653|Other|Survey|Close-ended survey will be performed to the participants. The survey consisted of 18 questions (Appendix). The first six questions (#1-6) were related with respondent's demographical and educational data and experiences of surgical and laparoscopic practices. There were five questions to determine preferred technique for first entry (#7-11), three questions for complications (#12-14), and remaining four questions for safety maneuvers (#15-18).
1484707|NCT03084354|Other|Semi-structured interviews|Semi-structure interviews to gain a deep understanding of women's experiences of maternity bladder care. Interviews will last between thirty minutes to a couple of hours and they will be digitally recorded and transcribed verbatim.
1604785|NCT02200978|Drug|Ara-C|Given IV
1484675|NCT03084627|Behavioral|Tailored dietary advice|The nutrient adequacy of the diet of each patient will be evaluated, at baseline, by a diet quality index: the PANDiet. Then, tailored dietary advice aiming at improving the nutrient adequacy of the diet will be generated for each patient in the arm #2. Patients will choose 3 tailored dietary advices among 3 options during three appointments with a research project team member (the first in person and the second and the third by phone). Each appointment will be spaced of 2 weeks. In total, each patient in the arm #2 will choose nine tailored dietary advice. Tailored dietary advices are of two kinds: substitution of a consumed food item by a food item in the same food subgroup or modification of the consumed amount (increase or decrease) of a food item. Tailored dietary advices cannot generate an increase of more than 190 kcal or a decrease as compared to the observed energy intake.
1484676|NCT03084601|Drug|Calcium Hydroxide, Iodoform, paste|mixture of calcium hydroxide and iodoform
1484677|NCT03084601|Drug|3-mixtatin|3-mixtatin mixture of ciprofloxacin, metronidazole, cefixime, and simvastatin
1484678|NCT03084588|Drug|methadone|Patients will be given methadone at induction of anesthesia
1484679|NCT03084588|Procedure|Interscalene block|Patients will be given an interscalene block prior to induction of anesthesia
1484680|NCT03084575|Procedure|Thermal radio Frequency, selective (unilateral S3, bilateral S4 and S5) saddle rhizotomy|Thermal RF lesioning is done using Bailys RF generator. TRF parameters are 80 C, 120 seconds the TRF lesion is repeated after 180 rotation of the needle tip again after sensory and motor pre-stimulation.
1484681|NCT03084575|Drug|hyperbaric chemical saddle Rhizotomy (6 % pherol in glycerin)|L5-S1 intrathecal injection of 0.5-1 ml of 6 % pherol in glycerin. The patient is seated in the sitting position with 30-45o leaning backwards to make the posterior sensory roots lowermost.
1484682|NCT03084575|Device|Thermal RF lesioning is done using Bailys RF generator|
1484683|NCT03084562|Other|collect examination time, functional and clinical tolerability|Examination time : time from patient setup and launch of the pre-test to the end of the patient monitoring Functional tolerability : functional assessed by the patient Clinical tolerability : clinical score by the cardiologist
2001100|NCT03211793|Other|Placebo|8 intramuscular injections at designated sites in the hand/forearm muscles of the most affected side. Blinded syringes will be used. Injections will be administered by an experienced clinician (plastic surgeon or hand surgeon).
2001101|NCT03211858|Drug|SAR341402|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1484686|NCT03084536|Drug|Bupivacaine|-Given after general anesthesia
1484687|NCT03084536|Drug|Gabapentin|"As per routine care
Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years."
1484688|NCT03084536|Drug|Celecoxib|"As per routine care
Will not be prescribed for any patient with preexisting kidney disease or ≥ 65 years.
Naproxen will be substituted for celecoxib in patients with sulfa allergies."
1484689|NCT03084536|Drug|Acetaminophen|-As per routine care
1484690|NCT03084536|Drug|Midazolam|-As per routine care
1484691|NCT03084536|Drug|Fentanyl|-As per routine care
1484693|NCT03084510|Device|Lotus™ Valve System|"The Lotus™ Valve System consisting of two main components:
a bioprosthetic bovine pericardial aortic valve, and
a delivery system Device sizes include 23 mm, 25 mm, and 27 mm diameter."
1484694|NCT03084497|Procedure|Infant Massage|"The first day, investigators will make the initial assessment of the baby through Psychomotor Development Scale of Early Childhood Brunet- Lézine. Participants will keep the sessions early attention and will participate in the course of Infant Massage, which develop for 5 weeks.
Infant Massage course will take place with families and is based on the methodology and program of the International Association of Infant Massage ( IAIM ), created by Vimala McClure. The course will consist of 5 sessions (one per week) approximately 90 minutes. Parents will practice everyday the movements learned during the time of the study.
When the course of Infant Massage finished, Investigators will conduct the final evaluation of the baby, the same way as in the initial evaluation."
1484695|NCT03084484|Dietary Supplement|Kiwifruit addition to the diet|Subjects were instructed to eat two kiwifruit per day during the whole study period. No recommendation on the type of kiwifruit, brand or origin was delivered. Kiwifruit was suggested to be taken as a whole and not mixed with sugar or other ingredients. No changes to their routinely dietary habits were suggested.
1484696|NCT03084484|Procedure|Non Surgical periodontal treatment|Non-surgical treatment of periodontal pockets with hand and ultrasonic instrumentation
2001102|NCT03211858|Drug|insulin aspart|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2001103|NCT03211858|Drug|insulin glargine (HOE901)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1484699|NCT03084458|Behavioral|Fitbit|The Fitbit device will allow experimental group participant access to their daily step count.
1484700|NCT03084432|Diagnostic Test|Dual Energy X-ray Absorptiometry|Dual Energy X-ray Absorptiometry done for both studied groups
1484701|NCT03084419|Drug|Abatacept|"The IV dose varies according to weight:
<60kg=500mg
≥60 but≤100kg=750mg >100kg=1g
This equates to approximately 10mg/kg."
1484702|NCT03084406|Other|Centervention-ATOD (CV-ATOD)|A customizable suite of online tools specifically designed to support quality implementation and sustainability of any ATOD-EBP within real-world service settings.
1484703|NCT03084380|Biological|Retroviral vector-transduced autologous T cells to express anti-GPC3 CARs|transcatheter arterial chemoembolization + CAR-T infusion
1484704|NCT03084380|Drug|Fludarabine|Fludarabine will be administered at dose of 25mg/m2/d
1484705|NCT03084380|Drug|Cyclophosphamide|Cyclophosphamide will be administered at dose of 40mg/kg for 1 day and then fludarabine will be given for the next 5 days and then the T cells will be administered
1484706|NCT03084367|Diagnostic Test|iFR pullback|iFR pullback assessment post angiographically successful PCI
1485058|NCT03081663|Procedure|Medial Para-Patellar Approach|Medial para-patellar approach for total knee arthroplasty
2001104|NCT03207815|Drug|Filgotinib|200 mg tablet(s) administered orally once daily
2001105|NCT03207815|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
2001106|NCT03207815|Drug|Prednisone|Tablet(s) administered orally once daily
1484708|NCT03084341|Procedure|Neuromuscular Electrical Elongation|Electrotherapy equipment will be used, choosing an interferential current through bipolar application,with a frequency of 4 kHz and a frequency modulation amplitude of 100 Hz.
1484709|NCT03084341|Procedure|Proprioceptive Neuromuscular Facilitation|Hold-relax technique that involves lengthening the muscle to the point of limitation, at which point the individual performs an isometric contraction for up to 10 s, followed by a passive movement of the limb into the new end-range.
1484710|NCT03084328|Dietary Supplement|Vitamind D|Patients will be given an over the counter vitamin D supplement of 2000 units of D3 daily for 6 months
1484711|NCT03084315|Device|E-Cig Zero Nicotine|E-Cig Zero Nicotine
1484712|NCT03084315|Device|E-Cig 24mg Nicotine|E-Cig 24mg Nicotine
1484713|NCT03084289|Biological|ChAd63-METRAP|The candidate vaccine applicable to the clinical trial is the Chimpanzee adenovirus 63 expressing Multiple epitopes and thrombospondin related adhesion protein.
1484714|NCT03084276|Other|High-fat meal|High-fat meal
1484715|NCT03084276|Other|Low-fat meal|Low-fat meal with the same physical and organoleptic characteristics as the high-calorie meal.
1484716|NCT03084263|Procedure|Arthroscopic Assisted Open Reduction Internal Fixation|Surgical fixation of ankle fractures with use of arthroscopy.
1484717|NCT03084263|Procedure|Open Reduction Internal Fixation|Surgical fixation of ankle fractures.
1484718|NCT03084250|Drug|Peginterferon Alfa-2A|180μg/week, 48 weeks; 135μg/week,48weeks
1484719|NCT03084250|Drug|Adefovir, entecavir,tenofovir, either of them|Adefovir, entecavir,tenofovir, either of them is ok
1484720|NCT03084237|Biological|HLX02|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles.
1484721|NCT03084237|Biological|Herceptin®|8 mg/kg administered intravenously over 90 minutes as a loading dose on Day 1, Cycle 1 then 6 mg/kg every 3 weeks for subsequent cycles
1484722|NCT03084237|Drug|docetaxel|75 mg/m2 will be administered on Day 2, Cycle 1.then be given every 3 weeks on Day 1 of each subsequent cycle
1484723|NCT03084224|Genetic|neurological and neurodegenerative diseases|NGS on a large scale of Patients with complexes phenotypes
1484724|NCT03084211|Other|Light exercise discharge instructions|Participants in the intervention group will receive discharge instructions prescribing light exercise following mild traumatic brain injury.
1484725|NCT03084198|Procedure|hiHep Bioartificial Liver Support System|Continuous treatment with the hiHep bioartificial liver support system for a minimum of 3 days to a maximum of 14 days. The subject's ultrafiltrated blood is circulated through 4 cartridges. The parameter is set to Circuit 1：120-200ml/min；Circuit 2：30-50ml/min；Circuit 3：200 ml/min.
1484726|NCT03084198|Procedure|Standard care for ALF|A standard of care for subjects with acute liver failure.
1484727|NCT03084159|Behavioral|Education worksheet|Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
1484728|NCT03084146|Other|12-week elimination diet|individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
1484729|NCT03084133|Behavioral|Therapeutic Education Strategy|"In the experimental arm of the study (intervention group), a screening information and education system will be implemented. The particularities of the index cases likely to require an adaptation of the device will be collected, analyzed and taken into account (level of health literacy, socio-economic status, level of education, professional activity ...). The analysis and intervention frameworks derived from theories on health behaviors will be mobilized (theory of reasoned action, theory of planned behaviors) and applied in order to reinforce the intention of the target audience. The analysis and intervention frameworks resulting from the educational sciences will be integrated with a competence approach (Aizen, 1991, Denovel, Dufour, Prochaska, 1983, Le Boterf, 2002)."
1484730|NCT03084120|Other|Collection of bloods samples for the mother|-During pregnancy, childbirth and after delivery
1484731|NCT03084120|Other|Retrieval of umbilical cord blood.|-During childbirth
1484732|NCT03084120|Other|Retrieval of placenta.|-During childbirth
1484733|NCT03084120|Other|Collection of newborn's and mother's lock of hair.|-During childbirth
1484734|NCT03084120|Other|Dietetic Patient Outcomes Questionnaires for the mother.|-During pregnancy and after delivery
1484735|NCT03084120|Other|Parental questionnaires : ASQ (Ages & Stages questionnaires) and CFQ (Child Feeding Questionnaire).|-At 2 years of age
1484736|NCT03084107|Other|Questionnaire|The elderly participated in the application of smart devices and requested to complete technology acceptance model (TAM) questionnaires for these devices.
1484737|NCT03084094|Device|Transcranial Direct Current Stimulation|Non invasive brain modulation at a 2mA current during 20minutes
1484738|NCT03084081|Device|CO2 standard therapy|Standard therapy using carbon dioxide for freezing of tissue
1484739|NCT03084081|Device|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
1484740|NCT03084081|Device|Thermocoagulator|Thermoablation
1484741|NCT03084068|Other|Human dehydrated umbilical cord allograft|human dehydrated umbilical cord allograft
1484742|NCT03084068|Other|Placebo|Open rotator cuff surgery with standard suture repair
1484743|NCT03084055|Behavioral|eMotion|eMotion is comprised of a series of weekly audio visual modules designed to increase exposure to positive activities and physical activity
1484744|NCT03084042|Device|fMRI|
1484745|NCT03084029|Drug|Oxytocin|40 international units
1484746|NCT03084029|Drug|Placebo|40 international units
1484749|NCT03083990|Biological|IBI305(Bevacizumab)|3mg/kg, infusion in 90minutes
1484750|NCT03083990|Drug|Avastin(Bevacizumab)|3mg/kg, infusion in 90minutes
1484751|NCT03083977|Other|Safe and Sound Protocol|The intervention features music processed based on the resonating frequencies of the middle ear
1485059|NCT03081650|Device|Airvo Humidifier|
1484752|NCT03083964|Behavioral|Usual Care|Usual care is not considered an intervention. This arm of the study involves a lifestyle coaching intervention delivered in primary care sites to the subjects.
1484753|NCT03083964|Behavioral|Priming|The intervention is a just in time eating or physical activity reminder. Each individual participant reports physical activity goals as well as times that they most often eat. This information is used to select for that individual the best time to send an eating or physical activity reminder. The reminders come to the participant's smartphone or a study provided smartphone. Participants will receive reminder 2 to 4 times per day depending on their goals and behavior pattern.
1484754|NCT03083951|Procedure|Complete mesocolon excision|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric vein and a high tie ligation of the inferior mesenteric artery (complete mesocolon excision)
1484755|NCT03083951|Procedure|Conventional locoregional lymphadenectomy|Laparoscopic sigmoidectomy with lymphadenectomy of the lymphatic tissue that accompanies the inferior mesenteric artery and a high tie ligation of the inferior mesenteric artery with or without section of inferior mesenteric vein.
1484756|NCT03083938|Procedure|Omental Roll-up|Using omentum roll-up pancreato-jejunal anastomosis
1484757|NCT03083925|Device|TIPS|Transjugular Intrahepatic Portosystemic Shunt
1484758|NCT03083912|Dietary Supplement|Fortimel Complete|The residents included receive 2 bottle por day.
1484759|NCT03083899|Other|Out-patient clinic on demand|Free use of any resources in the out-patient clinic
1484760|NCT03083899|Other|Scheduled out-patient clinic|Scheduled use of the out-patient clinic
1484761|NCT03083886|Other|Identify, Coordinated, Enhanced (ICE) Decision Making + PCP led care|Subjects seeking care at a clinic assigned to this arm will receive the ICE care model through referral by their primary care provider. The ICE care model was developed by the Clinical Excellence Research Center at Stanford University based on a review of the peer-reviewed literature for adult subjects with incident neck or back pain less than six weeks in duration who are not using high-dose opioid medications or receiving spine-related long-term disability payments.
1484762|NCT03083886|Other|Individualized Postural Therapy (IPT) + PCP led care|IPT involves the evaluation of a subject's posture to identify postural and alignment deviations and, based on this, a personalized corrective exercise program is prescribed. This method does involve the use of prescription medications, surgery, or manipulation. A treatment course typically lasts eight sessions over eight weeks. In order to allow for the consistent delivery of this arm of the study at multiple study-sites across the country, IPT will be delivered by The Egoscue Method. Egoscue was founded in 1971 and has 25 clinics worldwide.
1484763|NCT03083886|Other|Usual PCP led care|Primary care provider will direct patients' care pathway.
2010589|NCT02924688|Device|DISKUS DPI|The DISKUS device will be used during the run-in period. The DISKUS DPI is a plastic inhalation delivery system containing a single-foil blister strip of a powder formulation of FSC for oral inhalation.
1484765|NCT03083860|Device|BEI|BrainMARC Ltd. has demonstrated in recent years the ability to extract effective attention markers from averaged ERP waves sampled with a single EEG channel (two electrodes). In addition, BrainMARC has developed a template matching method to extract the attention-related markers at the single-trial level. An index (termed Brain Engagement Index - BEI) can then be generated from a 1-minute, single-channel sample.
1484766|NCT03083847|Drug|Chloroquine Phosphate|Chloroquine phosphate is FDA approved for suppressive treatment(prophylaxis) and for acute attacks of malaria due to P. vivax, P. malariae, P. ovale, and susceptible strains of Pf. Chloroquine is a bloodstage schizonticide, highly active against replicating forms of bloodstage drug-sensitive parasites
1484767|NCT03083847|Drug|Pyrimethamine|Pyrimethamine is a folic acid antagonist that has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide (Organization April 2013 (rev. January 2014 )). Similar to chloroquine, pyrimethamine (in combination with sulfa drugs) was a drug of choice for malaria treatment and prophylaxis for decades because it was safe, well tolerated, affordable and highly effective; however, due to widespread resistance, pyrimethamine and pyrimethamine combinations have fallen out of favor for clinical use.
1484768|NCT03083847|Biological|Sanaria PfSPZ Challenge|Sanaria Inc has manufactured two strains of Sanaria PfSPZ Challenge: NF54 and 7G8. The Sanaria PfSPZ Challenge contains fully infectious PfSPZ purified from the salivary glands of Anopheles stephensi mosquitoes raised under aseptic conditions. The infectious PfSPZ are formulated in cryoprotectant to maintain potency for an extended period. Sanaria PfSPZ Challenge (NF54) is known to be susceptible to chloroquine, pyrimethamine, atovaquone, artesunate, but not mefloquine. Sanaria PfSPZ Challenge (7G8) is known to be susceptible to mefloquine, atovaquone, artemether and artesunate but not to chloroquine or pyrimethamine.
1484769|NCT03083834|Diagnostic Test|Cosyntropin stimulation test|At 0800h to 0900h, a 25 mm plastic intravenous line will be inserted in an antecubital vein. Then, 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). Serum cortisol and salivary free cortisol will measured just before ACTH administration and 30 minutes later.
1948816|NCT01567462|Device|Monopolar electrocautery loop in Transurethral resection of bladder tumors|Standard monopolar electrocautery loop in transurethral resection of bladder tumors (TURBT)
1484771|NCT03083808|Drug|Pembrolizumab|"Pembrolizumab 200mg IV every 21 days
Physician's choice chemotherapy with one of the following every 21 days:
Docetaxel 75mg/m2 IV
Pemetrexed 500mg/m2 IV (non-squamous only)
Gemcitabine 1000mg/m2 IV on days 1 and 8"
1484772|NCT03083795|Behavioral|Social relationships intervention|Participants randomized to the social interaction cohort will meet on a monthly basis for a two hour group session designed to build social connections. In addition, participants will be paired with another study participant in this group, and will be asked to meet on a monthly basis for a minimum of 45 minutes. All participants in the social support cohort will continue to receive best standard diabetes management.
1948817|NCT01567462|Device|PK Button Vaporization Electrode in transurethral resection of bladder tumors|PlasmaKinetic (PK) Button Vaporization Electrode in transurethral resection of bladder tumors (TURBT)
1948818|NCT01561027|Drug|CNV1014802|Administered as specified in treatment arm.
1948819|NCT01561027|Drug|Placebo|Administered as specified in treatment arm
1948820|NCT01548404|Drug|REGN668/SAR231893|REGN668/SAR231893 for SC dosing will be evaluated in this study.
1485060|NCT03081611|Device|Ram cannula|Ventilatory support for preterm infants using Ram cannula
1484778|NCT03083743|Biological|Recombinant human Apo-2 ligand for Injection|150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
1484779|NCT03083743|Biological|Placebo|150μg/kg/d IV (in the vein), on day 1 to 7 of each 21 day cycle
1484780|NCT03083730|Other|Narrow band UVB treatment (NB-UVB)|NB-UVB light treatment NB-UVB light treatment for 3x/week for 12 weeks (36 visits)
1484781|NCT03083717|Diagnostic Test|Collection of breath samples, followed by analysis of exhaled breath using nanomaterial-based sensors (NaNose)|2-3 liters of breath sample will be collected in chemically inert Mylar bags. The breath samples will then be immediately transferred from the Mylar bags to Tenax sorbent tubes using a dedicated pump. Tubes will be sealed and kept in 4˚C until NA-NOSE analysis.
1484782|NCT03083704|Biological|Andexanet alfa (Gen 1 Process 2)|factor Xa inhibitor antidote
1484783|NCT03083704|Drug|Apixaban 5 MG|factor Xa inhibitor
1484784|NCT03083704|Drug|Rivaroxaban 20 MG|factor Xa inhibitor
1484785|NCT03083704|Drug|Enoxaparin sodium|low molecular weight heparin
1484786|NCT03083704|Drug|Edoxaban 60 MG|factor Xa inhibitor
1484787|NCT03083704|Biological|Andexanet alfa (Gen 2)|factor Xa inhibitor antidote
1484788|NCT03083704|Biological|Andexanet alfa (Gen 1 Process 3)|factor Xa inhibitor antidote
1484789|NCT03083704|Drug|Apixaban 10 MG|factor Xa inhibitor
1484790|NCT03083704|Drug|Rivaroxaban 10 MG|factor Xa inhibitor
1484791|NCT03083691|Drug|Nivolumab, Ipilimumab|Cohort 1: addition of ipilimumab in case of progression on nivolumab monotherapy.
1484792|NCT03083691|Drug|Nivolumab, Ipilimumab|Cohort 2: upfront combination therapy of nivolumab and ipilimumab for four cycles, followed by nivolumab monotherapy.
1484793|NCT03083678|Drug|Afatinib|Afatinib will be given daily in a dose of 40 mg orally in a 4 week cycle until disease progression or patient withdrawal.
1948821|NCT01548404|Drug|Placebo|Placebo matching REGN668/SAR231893
1948822|NCT01539759|Device|Immediate Postplacental Placement of an IUD during cesarean delivery|Women randomized to this arm will have an IUD placed during their cesarean delivery, immediately after delivery of the placenta
1484796|NCT03083652|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (30 minutes per day, 5 days/week) of the quadriceps femoris and gluteus maximus
1484797|NCT03083652|Other|Sham|Conventional physiotherapy with NMES device NOT activated
1484798|NCT03083639|Drug|Esomeprazole Capsule|Esomeprazole Capsule
1484799|NCT03083639|Drug|Esomeprazole Tablet|Esomeprazole Tablet
1484800|NCT03083626|Other|Cold pressor test|"The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached."
1484801|NCT03083613|Drug|Raltitrexed|Raltitrexed:3mg/m2,iv,d1, Every 3 weeks
1484802|NCT03083613|Drug|Paclitaxel|Paclitaxel:80mg/m2,iv,d1,d8, Every 3 weeks
1484803|NCT03083600|Dietary Supplement|Plant-based Protein Hydrolysate 1|Plant-based Protein Hydrolysate 2 for 12-weeks
1484804|NCT03083600|Dietary Supplement|Plant-based Protein Hydrolysate 2|Plant-based Protein Hydrolysate 2 for 12-weeks
1484805|NCT03083600|Dietary Supplement|Placebo|Cellulose Placebo for 12-weeks
1484806|NCT03083587|Behavioral|Normal lifestyle|Normal lifestyle
1484807|NCT03083587|Behavioral|Exercise|Mild exercise 3 min every half hour
1484808|NCT03083587|Procedure|muscle and fat biopsy|Biopsy under local anesthesia
1484809|NCT03083587|Device|Continuous glucose monitoring|Glucose concentrations during the study period
1484810|NCT03083587|Device|Activity monitoring (ActivePal)|Objective measurements of standing and sitting time
1484811|NCT03083574|Device|Photopheresis Theraflex ECP™|The Macopharma (Theraflex ECP™) approach is based on a multistep procedure involving (1) standard mononuclear cell apheresis, (2) injection of the 8-Mop in the apheresis bag, (3) UVA exposure of the bag in the Macogenic illumination device, and (4) reinfusion of the cells into the patients.
1484812|NCT03083561|Drug|LY3337641|Administered orally.
1484813|NCT03083561|Drug|Placebo|Administered orally.
1484814|NCT03083548|Diagnostic Test|Imaging|Conventional radiographs (hands/feet), CT of dominant hand, MRI of dominant hand, ultrasound (hands/shoulder/feet/hips/knees), fluorescence optical imaging of hands
1484815|NCT03083548|Diagnostic Test|Physical examinations|Joint assessment of hands and feet, pain sensitization test and functional tests of the hands
1484816|NCT03083548|Diagnostic Test|Questionnnaires|Self-reported demographic factors, clinical variables and OA history and symptoms
1484817|NCT03083535|Procedure|Tooth Brushing|Tooth Brushing with Dentifrice Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
1484818|NCT03083535|Procedure|aloe vera Massaging|Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with aloe vera gel
1484819|NCT03083535|Procedure|SRP with aloe vera massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with aloe vera ge; shall be carried out by the patients/subjects
1484820|NCT03083522|Drug|Ojeok-San|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
1484821|NCT03083522|Drug|Placebo|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
1484822|NCT03083509|Other|Resistance exercise weight training session|A resistance exercise session was performed. Following a warm-up that consisted of five-minutes cycling at a self-selected intensity, as well as three progressive lifts at 50, 75, and 90% 6 rep max (RM), participants performed four sets of six repetitions at 100% of 6RM (as determined by the maximal weight lifted during the maximal strength assessment) of the following lifts; back squat, front squat, good mornings, and Bulgarian split-squat. Two minutes rest was afforded between sets and exercises.
1485061|NCT03081611|Device|Short nasal prongs|Ventilatory support for preterm infants using short nasal prongs
1484823|NCT03083509|Other|High-Intensity stochastic cycling session|A high-intensity stochastic cycling session was performed. The cycling protocol was performed using a magnetically-braked cycle ergometer (Velotron, RacerMate). Following a 10 minute standardised warm-up including 3 × 3s sprints, participants completed a simulated road-race, consisting of sprints of varied length, differing work to rest ratios and short time-trials.
1484824|NCT03083509|Other|Simulated Team sport protocol|A simulated team sport protocol was performed. Participants performed a standardised warm-up consisting of performing three laps of the circuit jogging, and three laps at 50, 75, and 90% of perceived maximal speed. Participants were then afforded five minutes to perform self-selected stretching prior to commencing the session. Participants performed two sets of 45 minutes of the simulated team sport protocol, separated by 15 minutes rest. Each 45 minute period consisted of a one minute circuit repeated 45 times that replicates typical movement patterns observed during team sports and includes walking, jogging, jumping, sprinting, agility, and decelerations. Each circuit was initiated on the minute, therefore enabling participants to rest following the completion of each circuit. Pilot testing showed participants completes each circuit in approximately 48-55 seconds (sec) therefore enabling 5-12sec rest after each circuit.
1484825|NCT03083496|Drug|Potassium Oxalate 5%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
1484826|NCT03083496|Drug|Potassium Oxalate 10%|Prophylaxis, apply uniformly on the teeth, friccion for 10 seconds, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
1484827|NCT03083483|Device|transcranial direct current stimulation (tDCS)|tDCS will apply a low, direct current for the duration of the study session while the subject is training the specific laparoscopic tasks.
1484828|NCT03083483|Other|gaze training|Gaze training will consist of gaze tracking and then review of performance or the use of an implicit map to train an expert gaze pattern.
1484829|NCT03083470|Drug|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|SOR007 will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of SOR007 that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
1484830|NCT03083470|Other|SOR007 Ointment Vehicle|SOR007 ointment vehicle will be applied topically to a target AK lesion test field twice daily for up to 28 days, or until all lesions resolve. The maximum total amount of Ointment vehicle that will be applied daily will be 1 finger-tip unit (FTU), approximately 0.5g. No more than 25cm2, approximately 0.15% of the total body surface area, will be treated.
1484831|NCT03083457|Drug|Fluid resuscitation or amine administration|Fluid administration or amine administration if deemed necessary by the attending physician. Haemodynamics will be monitored through noninvasive cardiac output assessment by arterial pulse contour analysis
1484832|NCT03083457|Drug|General anesthetic|Total intravenous anesthesia with a standard protocol
1484833|NCT03083457|Drug|Fluid administration|3-5 ml/kg of balanced crystalloids will be administered throughout the whole surgical procedure
1484834|NCT03083457|Procedure|Low-tidal volume ventilation|Volume-control ventilation with tidal volume=7 ml/kg of predicted body weight for the entire surgical procedure. Respiratory rate will be set to maintain EtCO2 within a physiological range and kept unchanged for the entire duration of the study
1484835|NCT03083457|Procedure|Scheduled recruiting maneuvers|Pressure-control ventilation inspiratory pressure=10 cmH2O. Steplike 5-cmH2O-PEEP increase every 30 seconds to achieve a peep of 35 cmH2O, followed by 5-cmH2O-PEEP reduction every 30 seconds to set PEEP
1484836|NCT03083444|Diagnostic Test|Ultrasound|Measurement of thickness of radial artery wall thickness by ultrasound
1484837|NCT03083431|Drug|Propranolol|Oral propranolol (1.6 mg propranolol-hydrochloride/kg.d in 4 divided dosages)
1484838|NCT03083431|Drug|Placebo|Oral solution containing the same excipients as propranolol solution
1484839|NCT03083418|Device|control group|No EDP treatment
1484840|NCT03083418|Device|EDP|Turn on the device, and clean the skin where the patch will be located according to the screen tip. Paste the two groups of small electrodes to the inferior 1/3 of the outer edge of bilateral sternocleidomastoid, and the large electrodes are pasted to the corresponding 2nd intercostal skin surface of pectoralis major at midclavicular line.Adjusting the stimulus intensity according to the daily maximum tolerance (patients with no pain and tension).30 minutes continuous stimulation each time, twice a day, a total of one weeks of treatment .
1484841|NCT03083405|Drug|Clonidine|The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
1484842|NCT03083405|Drug|Buspirone|The study group will get a drug to decrease bruxism activity. Group will be evaluated using polysomnography included rhythmic masticatory muscle activity registration before and after intervention.
1484843|NCT03083392|Procedure|treatment of chronic maxillary sinusitis using DIVA system|chronic maxillary sinusitis treatment utilizing DIVA system for antral lavage
1484844|NCT03083392|Device|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply saline lavage to the maxillary sinus
1484845|NCT03083379|Device|Volumetric Incentive Spirometry|"A study investigator will provide instruction on Incentive Spirometry procedure performance before supervised therapy and monitoring begins.
Five minutes of eupneic ventilation EIT monitoring will occur before I.S. therapy commences.
Study participants will be asked to take 10 deep breaths through the incentive spirometer's mouthpiece, followed by a 60 second pause.
The 10-breath cycle will be repeated three times with respiratory therapist coaching.
Five minutes of eupneic ventilation EIT monitoring will occur following the last I.S. lung expansion therapy breath cycle.
Incentive Spirometry therapy and monitoring session will last about 15 minutes"
1484846|NCT03083379|Device|EzPAP® POSITIVE AIRWAY PRESSURE|"A study investigator will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins. A second study investigator will perform EIT device set-up and monitoring only.
Five minutes of eupneic ventilation EIT monitoring will occur before EzPAP® therapy commences.
Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.
The 10-breath cycle will be repeated three times with respiratory therapist coaching.
Five minutes of eupneic ventilation EIT monitoring will occur following the last EzPAP® lung expansion therapy breath cycle.
EzPAP® therapy and monitoring sessions will last about 15 minutes"
1484847|NCT03083366|Device|PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)|Bilateral s S3 sacral neuromodulation delivered via the PrimeAdvanced Surescan 97702 Neurostimulator - Medtronic (Minneapolis, MN)
1484848|NCT03083353|Drug|Isradipine|In the first CET session, participants will receive a dose of ISR and begin the session after waiting 75 minutes.
1484849|NCT03083353|Behavioral|CET|Two 90-minute CET sessions will be conducted to expose participants to interoceptive and situational cues for tobacco use and craving.
1484850|NCT03083353|Drug|Placebos|In the first CET session, participants will receive a dose of PBO and begin the session after waiting 75 minutes.
1484851|NCT03083340|Behavioral|Deprexis|Participants will complete an 8 week self-help computerized treatments through a web-based online Deprexis program.
1484852|NCT03083327|Dietary Supplement|Parenteral nutrition.|Nutrition support will be provides as per usual, but oral and enteral intake will be topped up with a standard parenteral nutrition solution. The standard parenteral nutrition solution will contain approximately 40 grams of amino acids/L, 40 g lipids/L and 100g dextrose/L).
1484853|NCT03083327|Other|Pragmatic standard care.|Nutrition support will be provided as per usual care.
1484854|NCT03083314|Procedure|SELECTIVE AXILLARY LYMPH NODE DISSECTION (SAD)|
1484855|NCT03083314|Procedure|COMPLETE AXILLARY DISSECTION (ALND)|
1484856|NCT03083301|Other|Medical Files data extraction|Medical Files data extraction
1484857|NCT03083288|Drug|[18F]FluorThanatrace|
1484858|NCT03083275|Other|Resistance Training|
1484859|NCT03083262|Other|no intervention|None, there is no intervention
1484860|NCT03083249|Other|Gardasil|None-data gathering only
1948823|NCT01532089|Biological|Bevacizumab|Given IV
1948824|NCT01532089|Drug|Erlotinib Hydrochloride|Given PO
1484863|NCT03083223|Other|position|Subjects were placed consecutively in random order in five different positions. SaO2 and vital signs were measured at each position after 10, 25, and 40 minutes.
1484864|NCT03083210|Drug|Lanreotide|Lanreotide, at a dose of 120mg subcutaneous injection every 28 days.
1484865|NCT03083197|Drug|Doxycycline 7 days|loading dose 200mg PO, then 100mg PO every 12 hours for 7 days
1484866|NCT03083197|Drug|Doxycycline 3 days|loading dose 200mg PO, then 100mg PO every 12 hours for 3 days
1484867|NCT03083197|Drug|Azithromycin 3 days|loading dose 1000mg PO on day 1, then 500mg PO every 24 hours on days 2 and 3
1484868|NCT03083184|Drug|Ethanol|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
1484869|NCT03083184|Drug|enoxaparin|An ethanol 40 % v/v - enoxaparin 1000 U/mL (Ethenox) interdialytic lock solution
1484870|NCT03083171|Drug|Endotoxin|At T=0 1 ng/kg E. Coli type O113 lipopolysaccharide is administrated intravenously as a bolus, followed by 1 ng/kg/hour for 3 hours.
1484871|NCT03083171|Drug|Placebo|At T=1 hour, placebo will be administered intravenously over a 1 hour period. Placebo is indistinguishable from Adrecizumab.
1484872|NCT03083171|Drug|Adrecizumab|At T=1 hour, Adrecizumab will be administered intravenously over a 1 hour period.
1484873|NCT03083158|Drug|Hepatitis B vaccine|1.0 ml (20 micrograms) suspension of hepatitis B surface antigen for intramuscular injection
1484874|NCT03083145|Dietary Supplement|Whey Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
1484875|NCT03083145|Dietary Supplement|Pea Protein Beverage|Beverage administered and postprandial appetite assessed for 2 hours followed by 1 hour monitoring of food intake from ad libitum snack tray.
1484876|NCT03083145|Behavioral|Snack Tray Choices|Items were selected from a snack tray filled with healthy and unhealthy snacks in order to determine if educational messaging influenced snack choices. Shack choices wre recorded on a check list by a third party observer.
1484877|NCT03083132|Drug|modafinil 50mg|1 capsule oral daily
1484878|NCT03083132|Drug|Placebo oral capsule|1 capsule oral daily
1484879|NCT03083119|Drug|Xuesaitong soft capsule|Panax Notoginseng Saponins, Specification:0.33 per bag, once take two pills and twice a day during a month.
1484880|NCT03083119|Drug|Placebo oral capsule|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
1484881|NCT03083093|Diagnostic Test|The initial CTPA will be reviewed|The initial CTPA will be reviewed
1484882|NCT03083080|Procedure|VATS|VATS is the abbreviation of video-assisted thoracic surgery, which aims to minimize the wound for thoracic surgery and to enhance patient recovery after surgery
1484883|NCT03083080|Drug|Ropivacaine|30 mL 0.5% ropivacaine is used to achieve VATS block
1484884|NCT03083080|Drug|Epinephrine|1:400000 epinephrine is mixed with ropivacaine (local anesthetic) to reduce the risk of local anesthetic systemic toxicity
1484885|NCT03083067|Drug|Budesonide/formoterol|On the foundation of basic treatment strategies, inhaled budesonide/formoterol（160ug/4.5ug）will be used as an intervention drug for patients in PIC group. When air quality index (AQI) is above 200, they will temporary add one inhalation of budesonide/formoterol（160ug/4.5ug）twice a day until the third day after AQI drops below 200.
1484886|NCT03083067|Drug|tiotropium bromide|Inhaled tiotropium bromide(18ug) will be used as routine medicine according to doctor's advice.
1484888|NCT03083041|Biological|SHR-1210|SHR-1210 will be administered as a 30-minute IV infusion Q2W at a dose of 200mg
1484889|NCT03083041|Drug|Apatinib|Apatinib tablet will be administered orally,once daily until progression
1484890|NCT03083028|Procedure|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
1484928|NCT03082716|Drug|Custodiol Solution|After cross clamping patient will receive single dose of HTK custodiol cardioplegia. at temperature of 4-8°C and will be perfused for 6-8 minutes. Dose will start from 400 up to 1000 ml according to the child's body weight. Perfusion pressure will be kept at 70 - 80 mmHg until the heart is arrested.
1485062|NCT03081598|Drug|PBI-4050|Soft gelatine capsule containing 200 mg of the active ingredient per capsule
1604786|NCT02200978|Drug|MTX|Given orally
1484891|NCT03083028|Procedure|Open reduction internal fixation of the ankl|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
1484892|NCT03083015|Procedure|revascularization|a sterile sharp needle was used to irritate the apical tissue until bleeding occurred apically in the root canal space so as to create a biological scaffold for the regenerative process
1484893|NCT03083015|Procedure|Apexification|a 3-5 mm thickness of MTA using a hand plugger and was verified radiographically.
1484896|NCT03082963|Device|Electrogram Morphology Mapping (EMR)|Fifteen second AF recordings will be made using a multipolar electrode catheter to map the entire right atrium & then the left atrium.
1484897|NCT03082950|Diagnostic Test|polymerase chain reaction|PCR is performed with all patients. The result (hpv positive or negative) will define the patiens Group Affiliation.
1484898|NCT03082937|Drug|3 mg [14C]-A4250 capsule|Each subject will receive a single administration of 3 mg [14C]-A4250 capsule for oral administration containing not more than 4.3 MBq (116 μCi), in the fasted state.
1484899|NCT03082924|Device|Control group|Neither cycle training nor inspiratory muscle training.
1484900|NCT03082924|Device|Calibrated cycle ergometer|The most common device to perform cycle training is calibrated cycle ergometer.
1484901|NCT03082924|Device|Threshold loading device|Threshold loading device is used to perform inspiratory muscle training.
1484902|NCT03082924|Device|Calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
1484903|NCT03082911|Other|Phone call|"A brief telephone intervention at the same time of sending the invitation letter plus the habitual invitation process used in the screening program (described in control group). Each phone call will last approximately 5 minutes.
Calls will be made by the administrative staff of the Screening Technical Office, which is experienced in telephone attention."
1484904|NCT03082911|Other|Invitation letter|The habitual invitation strategy used in the screening program . Three letters are send by post: 1- An invitation letter plus an information leaflet and a list of pharmacies in which people can obtain the screening test. 2- A reminder letter for those who have not participated after 5 weeks of sending the first letter. 3- A second reminder letter for those who have collected the kit in the pharmacy but have not returned it with the sample
1484905|NCT03082898|Device|Indego Exoskeleton|Regular dosing of Indego Exoskeleton walking.
1484906|NCT03082885|Drug|Thymosin-α1|1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.
1484907|NCT03082872|Device|Cemented K-wire|Fracture of proximal phalanx was treated with Cemented K-wire.
1484908|NCT03082872|Device|Transfixion Pinning|Fracture of proximal phalanx was treated with transfixion pinning.
1484909|NCT03082859|Behavioral|Exercise|This a randomised cross-over study involving three different modes of exercise which will be compared to a no-exercise control.
1948825|NCT01532089|Other|Laboratory Biomarker Analysis|Correlative studies
1948826|NCT01524705|Drug|"GLIPULIN: [insulin glargine, metformin, exenatide (GLP-1-agonist)]"|Glargine-injectable, variable, QD, 6 months Metformin-oral, up to 1000mg, BID, 6 months Exenatide-injectable, 5mcg, BID, 6 months
1484912|NCT03082833|Drug|AZD2014|AZD2014 is a selective dual mTOR kinase inhibitor targeting both mTORC1 (rapamycin sensitive) and mTORC2 (rapamycin insensitive) complexes of mammalian Target Of Rapamycin (mTOR).
1484913|NCT03082820|Diagnostic Test|Pain-related evoked potentials (PREP)|PREP were performed bilaterally with a concentric surface electrode at twice the individual pain threshold.
1484914|NCT03082820|Diagnostic Test|Quantitative Sensory Testing (QST)|QST was performed bilaterally following the protocol of the German Network on Neuropathic Pain.
1484915|NCT03082820|Diagnostic Test|Nerve conduction studies (NCS)|NCS were performed with patients only.
1484916|NCT03082807|Dietary Supplement|NCDsport|Negative Calorie Diet supplemented with exercise
1484917|NCT03082807|Dietary Supplement|LCDsport|Low-Calorie diet with exercise
1484918|NCT03082794|Dietary Supplement|NCD|Negative Calorie Diet
1484919|NCT03082794|Dietary Supplement|LCD|Low Calorie Diet
1484920|NCT03082781|Dietary Supplement|NCDsport|Negative Calorie Diet supplemented with exercise
1484921|NCT03082781|Dietary Supplement|LCDsport|Low-Calorie diet with exercise
1484922|NCT03082768|Drug|[18F]MNI-968|Healthy volunteers recruited for the study will undergo two [18F]MNI-968 injections and PET scans.
1484923|NCT03082755|Drug|Gabapentin Enacarbil|1 to 2 GEn tablets (300 milligrams per tablet) will be administered once a day in the evening (about 5pm) for 8 weeks.
1484924|NCT03082755|Drug|Placebo Oral Tablet|1 to 2 Placebo Oral Tablets will be administered once a day in the evening (about 5pm) for 8 weeks.
1484927|NCT03082729|Drug|Apremilast|Apremilast (brand name Otezla) is a medication for the treatment of certain types of psoriasis and psoriatic arthritis.
1604787|NCT02200978|Drug|6MP|Given orally
1948827|NCT01524705|Drug|Insulin glargine, metformin, prandial insulin|Approximately 60 type 2 DM participants will be instructed in AHA/ADA meal plan. Insulin Glargine, metformin and one of 3 prandial insulins will be used as combination strategy to control individual HBA1Cs between 6.7 and 7.3%. Prandial Insulins (aspart, glulisine or lispro)
1484929|NCT03082716|Drug|Blood cardioplegia|After cross clamping patient will receive blood cardioplegia, delivered by microplegia delivery system by adding potassium to the blood (K= 35 ml eq/L) . The initial dose will be 35ml/ kg, and subsequent doses 20-15 ml/kg given every 20 minutes at a Temperature of 10 - 15 °C, while maintaining a perfusion pressure of 100-125 mmHg.
1484930|NCT03082703|Behavioral|Text Messaging|Subjects contacted 3 times weekly via text messaging for the study period.
1484931|NCT03082690|Drug|DuoGel|1% IQP-0528 in gel formulation
1484932|NCT03082677|Drug|Ixazomib|Ixazomib beginning between day +100 to +150 at a dose of 4 mg orally once per week (3 weeks on/ 1 week off).
1484933|NCT03082664|Device|PICO Single Use Negative Pressure Wound Therapy|The PICO device will be placed over the closed cesarean section incision.
1484934|NCT03082651|Other|Alternating run training load|Runners will perform a variation of workouts, consisting of interval/speed work, tempo runs, and long-slow distance runs throughout each 7-day period
1484935|NCT03082651|Other|Alternating footwear|Runners will be assigned identical training sessions over a 7-day period but will alternate use of two different models of running shoes across successive workouts (Nike Pegasus and Nike Zoom Streak). The Zoom Streak has 10mm less midsole material, a less supportive heel counter and more flexible forefoot providing a more responsive feel to the runner.
1484936|NCT03082651|Other|Constant training|Runners will be assigned identical training sessions over a 7-day period.
1484937|NCT03082651|Other|Constant footwear|Runners perform runs in two pairs of the same assigned neutral-cushioned running shoe (Nike Pegasus).
1484938|NCT03082625|Drug|Transdermal Magnesium|Magnesium
1484939|NCT03082625|Drug|Placebo|
1484940|NCT03082612|Behavioral|Overcoming Psychological Distress through Hymns Intervention|The intervention will consist of participants viewing a selection of video recorded vignettes during 3 weekly sessions. There will be 5 vignettes included in each session with each vignette edited to a real time of 3-4 minutes (each session is 30 minutes). Since the intervention is designed to be self-administered, there will be a video recorded introduction and instructions for use narrated by the PI. The vignettes are of actual African American cancer survivors narrating stories of ways in which hymns can be used to overcome their anxieties and depressed moods through the use of a hymn. The hymns included represent exemplars from the 5 themes prevalent in the PI's previous research
1484941|NCT03082612|Behavioral|Usual care|Usual care includes education to increase cancer knowledge, treatment coaches, and psychological services.
1484942|NCT03082599|Device|Presbyopia and astigmatism correcting intraocular lens|The Symfony Toric IOL (ZXTx) is an extended depth of focus (EDOF) IOL design to improve the sharpness of vision at near, intermediate and far distances reducing the need of glasses after cataract surgery in patients with astigmatism.
1484943|NCT03082586|Radiation|radiochemotherapy 1|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 7.2 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2, weekly; paclitaxel, 45-50 mg/m2, weekly
1484944|NCT03082586|Radiation|radiochemotherapy 2|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 14.4 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
1484945|NCT03082586|Radiation|radiochemotherapy 3|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 21.6 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
1484946|NCT03082586|Radiation|radiochemotherapy 4|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 28.8 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
1484947|NCT03082586|Radiation|radiochemotherapy 5|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 36 Gy at 1.2 Gy/Fx/bid; concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly;
1484948|NCT03082586|Radiation|radiochemotherapy 6|concurrent radiochemotherapy: radiotherapy dose level 1: 50 Gy at 2 Gy/Fx/d, then 43.2 Gy at 1.2 Gy/Fx/bid concurrent chemotherapy: carboplatin, area under the curve (AUC) 1.5-2,weekly; paclitaxel, 45-50 mg/m2, weekly
1484949|NCT03082573|Drug|H.P. Acthar gel|H.P. Acthar gel in treatment of Refractory RA
1484950|NCT03082560|Diagnostic Test|Boston Grade of Activity in Lichen Planopilaris|A clinical assessment tool to objectively and accurately measure activity and severity in lichen planopilaris over time.
1484951|NCT03082534|Drug|Pembrolizumab, Cetuximab|"Pembrolizumab (KEYTRUDA®; MK-3475) is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, programmed cell death ligand 1 (PD-L1) and programmed cell death ligand 2 (PD-L2). This blockade enhances functional activity of the target lymphocytes to facilitate tumor regression and ultimately immune rejection.
Cetuximab (Erbitux®) binds specifically to the epidermal growth factor receptor (EGFR) on both normal and tumor cells, and competitively inhibits the binding of EGF and other ligands, such as transforming growth factor-alpha. Cetuximab can mediate antibody-dependent cellular cytotoxicity (ADCC), with in vitro assays and in vivo animal studies demonstrating that cetuximab inhibits the growth and survival of tumor cells expressing EGFR."
1484953|NCT03082508|Device|Algisyl|Algisyl device (implants) administered during a surgical procedure
1484954|NCT03082508|Drug|Standard Medical Therapy|as per protocol
1484955|NCT03082495|Behavioral|Exercise|Supervised high-intensity aerobic interval training (HIT) during NACRT followed by unsupervised moderate-to-high intensity aerobic exercise after the completion of NACRT and before surgery
1484956|NCT03082482|Behavioral|Self-help materials|Self-help smoking cessation materials
1484957|NCT03082482|Drug|nicotine patch|Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches. Participants who smoke <10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
1484958|NCT03082482|Behavioral|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
1484959|NCT03082482|Other|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
1484961|NCT03082456|Diagnostic Test|Molecular breast imaging|Molecular breast imaging will be performed at 5-10 minutes after intravenous injection of 15-20 mCi Tc-99m sestamibi. Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
1484962|NCT03082456|Diagnostic Test|Mammography|During the procedure, the breast is compressed using a dedicated mammography unit. Parallel-plate compression evens out the thickness of breast tissue to increase image quality by reducing the thickness of tissue that x-rays must penetrate, decreasing the amount of scattered radiation, reducing the required radiation dose, and holding the breast still (preventing motion blur). Both craniocaudal (CC) view and mediolateral oblique (MLO) images of the breast are taken.
1484963|NCT03082456|Diagnostic Test|Breast ultrasound|Ultrasound investigation of breast is performed by members of breast cancer team. If abnormality is found by the procedure, biopsy will not be performed directly.
1484964|NCT03082443|Other|Therapeutic group|"The group will take place in six meetings lasting one hour. At the end of the intervention, a new group will be started.
Issues related to illness, cardiopulmonary rehabilitation, aroused feelings and aspects of food education will be addressed, with the objective of improving nutritional profile, quality of life and reduction of stress level. During the meeting they will be constantly encouraged to express their feelings, doubts and exchanges of experiences.
In the first individual care (both groups) an initial consultation will be performed when the sociodemographic and anthropometric data will be collected and the instruments will be applied: Lipp Adult Stress Inventory, SF-12 Quality of Life Assessment Questionnaire and Questionnaire Of Food Frequency. After three months, all participants will be reassessed by the psychologist and nutritionist and anthropometric data will be collected and the instruments applied again."
1484965|NCT03082430|Biological|autologous PRP.|one autologous PRP patient in this study and monitor and follow the evolution of pain and the knee function
1484966|NCT03082417|Other|Implementation|"The PAINFREE Initiative is a Multifaceted intervention:
Educating and providing point-of-care tools to nurses working at Emergency Department to improve pain management in older adults with fractures
Educating and providing point of care tools to Emergency Departments physicians working at Emergency Department to improve pain management in older adults with fractures
Inform the patients and their family about how to better manage the pain after a fracture"
1484967|NCT03082404|Other|Inspiratory muscle training|Inspiratory muscle training will be performed during the first hour of hemodialysis treatment and the protocol will consist of five series with 10 repetitions, each series with a two-minute interval of according to patient tolerance. The overload will be adjusted weekly, beginning with 50% of the maximum inspiratory pressure, during the first week, 60% of maximum inspiratory pressure in the second and third week and 70% of maximum inspiratory pressure in the fourth and fifth weeks. Maximum inspiratory pressure will be evaluated before the protocol period and adjusted weekly by manovacuometry.
1484968|NCT03082391|Device|Heavyweight Mesh|Patients will undergo ventral hernia repair with heavweight mesh.
1484969|NCT03082391|Device|Mediumweight Mesh|Patients will undergo ventral hernia repair with mediumweight mesh.
1484970|NCT03082352|Drug|BF-Metoprolol Tablet 100mg|BF-Metoprolol Tablet 100mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
1484971|NCT03082352|Drug|Betaloc Tablet 100mg|Betaloc Tablet 100mg will be used as a comparator drug for the BE study
1484972|NCT03082339|Other|Cortisone|Observation of QTc-interval
2001111|NCT03205124|Procedure|Electrical Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is given at a fixed continuous frequency of 20Hz. The stimulus intensity is the maximum tolerable limit. The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.
The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
1484974|NCT03082300|Drug|naquotinib|Oral
1484975|NCT03082287|Device|Fecal Calprotectin Level|Measurement of calprotectin in feces
1484976|NCT03082274|Diagnostic Test|ConfirmMDx|ConfirmMDx is a molecular diagnostic assay which utilizes DNA isolated from biopsy tissues to determine if aberrant DNA methylation is occurring in three genes: GSTP1, RASSF1 and APC. ConfirmMDx is currently available to clinicians for use in cancer-negative extended-core biopsies to determine if occult cancer is present in the prostate.
1484977|NCT03082274|Diagnostic Test|SelectMDx|SelectMDx for Prostate Cancer is a reverse-transcription PCR (RT-PCR) assay performed on post-DRE, first-void urine specimens from patients with clinical risk factors for prostate cancer, who are being considered for biopsy. The test measures the mRNA levels of the DLX1 and HOXC6 biomarkers, using KLK3 as internal reference gene, to aid in patient selection for prostate biopsy.
2010590|NCT02924688|Device|METERED-DOSE INHALER (MDI)|Albuterol/salbutamol (rescue medication) will be delivered via metered-dose inhaler (MDI) will be used for reversibility testing.
1484979|NCT03082248|Other|Physical Therapy|Patients allocated to the conservative treatment group will receive physical therapy according to the treatment-based classification approach and also educational leaflets and folders.
1484980|NCT03082248|Procedure|Spinal Surgery|Patients allocated to the surgical procedure group will undergo spinal surgery procedures and techniques specific for the low back region.
1484981|NCT03082235|Drug|E6742|gelatin capsules
1484982|NCT03082235|Drug|Placebo|gelatin capsules
1484983|NCT03082209|Drug|ABBV-621|Intravenous
1484984|NCT03082196|Drug|Test varnish|Topical application of test varnish to the teeth 4 times per year.
1484985|NCT03082196|Drug|Standard varnish|Topical application of test varnish to the teeth 4 times per year
1484986|NCT03082183|Drug|Rifampicin|once daily
1484987|NCT03082183|Drug|BI 425809|once daily
1484988|NCT03082170|Device|FEES|FEES test. During this test the investigators look at the pharynx and larynx of the participant while he eats and drinks Economy using number of textures aim to identify swallowing pathology.
1485063|NCT03081598|Other|Placebo|Placebo soft gelatine capsule
1493093|NCT03020030|Drug|DEXAMETHASONE|Standard of Care
2010591|NCT02923921|Biological|AM0010|AM0010 plus FOLFOX
2010592|NCT02923921|Drug|FOLFOX|FOLFOX Alone
1484989|NCT03082170|Diagnostic Test|SDQ|The participant will fill a questionnaire containing 14 questions.These Questions rigorously test all aspects of the swallowing. High score in this test is consistent with swallowing disorder.
1484990|NCT03082170|Behavioral|data review|Reviewing the data from the test summary of participants who have already undergone post operative swallowing assessment.
1484991|NCT03082157|Behavioral|Mighty Men Intervention|African American men assigned to this condition will receive: tailored goals/ messages, self-monitoring, small group meetings and educational and community-based information and resources.
1484992|NCT03082144|Drug|MTX|MTX 15 mg,via lumbar puncture,once per week, 4 weeks in total
1484993|NCT03082144|Drug|Ara-C|Ara-C 50mg,via lumbar puncture,once per week, 4 weeks in total
1484994|NCT03082144|Radiation|Radiotherapy|The sites of symptomatic disease, bulky disease observed on MRI, including the whole brain and basis cranii, 40 Gy in 20 fractions;and/or segment of spinal canal received 40-50 Gy in 20-25 fractions.
1484995|NCT03082131|Dietary Supplement|Resistant Starch Wheat|The investigators will be testing high amylose wheat varieties developed by Arcadia Biosciences that have high levels of RS in the endosperm, the source of refined flour. Compared to regular wheat varieties with RS levels of less than 1%, Arcadia's wheat varieties contain between 16% and 34% RS.
1484996|NCT03082118|Device|Vesair Bladder Control System|Intravesical balloon
1484997|NCT03082105|Other|Breathing in snow|Breathing in snow with different physical properties
1484998|NCT03082092|Drug|Methylprednisolone Sodium Succinate|single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement
1484999|NCT03082092|Drug|Placebos|0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
1485000|NCT03082079|Procedure|ESD|Patient in ESD group undergo ESD for GIST, and regular follow-up are carried out for these patients on 72 ±3h,7±2d,14±2d,3 month,6 month,1 year,2 year,3 year,4 year,5 year after the treatment. The investigators record the success rate of operation,en bloc resection,operation time,complication rate,hospitalization days,hospitalization expenses,pathology results and tumor recurrence rate
1485001|NCT03082066|Other|CT or MRI scan|CT or MRI performed for underlying disease. CT and MRI scans used to asses bone and soft tissue diameter
1485002|NCT03082053|Drug|varlitinib|IMP
1485003|NCT03082053|Drug|capecitabine|Companion Medication
1485004|NCT03082040|Behavioral|home-based breathing training|The intervention group will undergo a home-based breathing training 20 minutes twice daily for four weeks. Participants in the control condition will participate the same breathing training after a four-week waiting list period.
1485006|NCT03082014|Drug|Amlodipine|blood pressure lowering agent - dihydropyridine Ca2+-channel blocker
1485007|NCT03082014|Drug|Losartan|blood pressure lowering agent - angiotensin-receptor blockers
1485008|NCT03082014|Drug|Atenolol|blood pressure lowering agent - beta-blocker
1485009|NCT03082001|Drug|12% Sucrose|
1485010|NCT03082001|Drug|24% Sucrose|
1485011|NCT03081988|Other|chemoradiotherapy|concomitant chemoradiotherpay is routine treatment in locally advanced and advanced esophageal cancer and it is not for research.
1485012|NCT03081975|Device|HD white light or NBI|Use of NBI or HD white light
1485013|NCT03081962|Drug|Bundle|Combination of antibiotic intraperitoneal irrigation with gentamicin and clindamycin solution, use of Triclosan-impregnated sutures and mupirocin application over the skin staples.
1485014|NCT03081962|Procedure|Standard care|Standard care measures include decontamination of the skin during surgery with chlorhexidine alcohol solution, administration of systemic antibiotic prophylaxis and application of thermal blanket to avoid hypothermia. In the standard care protocol, the fascial closure will be performed with a polyglactin suture (without Triclosan impregnation).
1485015|NCT03081949|Drug|Oral Sodium Selenite 200 µg/day for 3 months|PPCM patients with selenium deficiency, who have not achieved LV reverse remodelling (LVRR) (LV end-diastolic dimension indexed to body surface area (LVEDDi) ≤33.0 mm/m2) at 6 months after diagnosis.
1485016|NCT03081936|Dietary Supplement|Oral consumption of Nutricia Aptamil Stage 1 formula|Daily oral consumption of Nutricia Aptamil Stage 1 formula
1485017|NCT03081936|Dietary Supplement|Oral consumption of a2® Platinum Stage 1 formula|Daily oral consumption of a2® Platinum Stage 1 formula
1485018|NCT03081936|Dietary Supplement|Oral consumption of breast milk|Daily oral consumption of breast milk
1485019|NCT03081923|Drug|Durvalumab|anti-PD-L1 mono therapy
1485020|NCT03081923|Drug|Tremelimumab|anti-CTLA4 drug Tremelimumab mono therapy
1485021|NCT03081910|Genetic|CD5.CAR/28zeta CAR T cells|"Three dose levels will be evaluated:
Dose level one: 1×10^7 cells/m2
Dose level two: 5×10^7 cells/m2
Dose level three: 1×10^8 cells/m2
The first six (6) patients treated on the study will be adults (>18 yrs of age). Six adolescents (age 12-18) will be treated before children (>3 yrs of age) are eligible."
1485022|NCT03081910|Drug|Fludarabine|Patients will receive 3 daily doses of fludarabine (30 mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion. Infusions should be given following hospital/pharmacy recommendations (including dose adjustments as appropriate per institutional guidelines) however at a minimum the fludarabine should be infused over 30 minutes. Mesna, IV hydration and anti-emetics should also be provided following local institutional guidelines.
1485023|NCT03081910|Drug|Cytoxan|Patients will receive 3 daily doses of cyclophosphamide (500 mg/m2/day) to induce lymphopenia, finishing at least 24 hours before T cell infusion. Infusions should be given following hospital/pharmacy recommendations (including dose adjustments as appropriate per institutional guidelines) however at a minimum the cyclophosphamide should be infused over 1 hour. Mesna, IV hydration and anti-emetics should also be provided following local institutional guidelines.
1485024|NCT03081897|Drug|SPRANC Block group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional anaesthesia (cervical plexus block) with an long acting local anesthetic according to clinical estimation of the treating anesthetist (about 15 ml Ropivacaine 0,75% around the carotid bifurcation, 5 ml Ropivacaine in the region of Erb´s Point of the superficial cervical plexus and 10 ml Ropivacaine at the area of skin incision on the tumor side); unilateral neck dissection.
1485064|NCT03081585|Behavioral|Satiety State|Participants were scanned twice: once after a meal and once after fasting for 24 hours
1605285|NCT02197026|Procedure|Physiotherapy|
1485025|NCT03081897|Drug|SPRANC Control group|General anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); additional regional Patient Control Group (no Intervention planned), general anaesthesia with Propofol (2mg/kgKG) and Remifentanil (0,1-0,4 µg/kg/min); unilateral neck dissection.
1485026|NCT03081884|Drug|FACBC PET-CT Imaging|"Participants will fast for 4 hours to normalize their neutral amino acid levels. One hour prior to the scan, participants will drink up to 450ml of standard oral contrast. Participants will lie on the scanning bed while the bed moves through the PET/CT scanner for the CT portion of the exam. After completion of the CT scan, approximately 10 units of FACBC will be injected for the PET scan portion of the exam. The bed will move through the scanner again and the PET portion of the exam will take 30 minutes. The entire visit will take about two hours.
Standard of care procedures include conventional imaging (CT and/or MRI; bone scan and/or NaF PET per institutional standards) and radical prostatectomy with extended pelvic lymph node dissection."
1485027|NCT03081871|Other|Pharmacist-led cardiovascular risk service (CVRS)|CVRS pharmacists will access the study database including patient baseline information obtained from the medical record and patient entered data to make their assessments and recommendations to onsite physicians and onsite clinical pharmacists and individualize their communication with patients. The intervention will provide patient-centered counseling and education to improve medication adherence, lifestyle modifications and/or smoking cessation. The CVRS pharmacist does not make changes to therapy independently but, rather, provides the physicians and on-site pharmacists with action plans and status updates about adherence to Guideline metrics, which should markedly reduce the gaps in guideline-concordant therapy that place patients at risk for CVD events.
1485028|NCT03081871|Other|Mobile access to study Personal Health Record|Only subjects assigned to the intervention arm will have access to the mobile app version of the study personal Health Record.
1485029|NCT03081871|Other|Web access to study Personal Health Record|Subjects assigned to both the intervention and control arms will have access to the standard website version of the study personal Health Record.
1948828|NCT01517022|Drug|nicotine replacement therapy|nicotine replacement therapy 2mg for patients cessation arm for period of 6 weeks
1485031|NCT03081845|Dietary Supplement|Oral consumption of milk A1 in study phase 1|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
1485032|NCT03081845|Dietary Supplement|Oral consumption of milk A2 in study phase 1|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 1.
1485033|NCT03081845|Dietary Supplement|Oral consumption of milk A1 in study phase 2|Oral consumption of 250 ml of milk containing both A1 and A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
1485034|NCT03081845|Dietary Supplement|Oral consumption of milk A2 in study phase 2|Oral consumption of 250 ml of milk containing only A2 type beta casein 2 times per day after meal for 5 days in study phase 2.
1485035|NCT03081832|Drug|Oxytocin|Infant included in the ancient study (repeated administrations of oxytocin in infants with Prader Willi Syndrome aged from 0 to 6 months)
1485036|NCT03081832|Other|Control|Not treated.
1485037|NCT03081819|Drug|SH003|Herbal medicine for cancer treatment
1948829|NCT01516515|Drug|Vehicle gel|placebo
1485039|NCT03081780|Biological|FATE-NK100|"Preparative regimen:
Fludarabine 25 mg/m2 x 5 days start Day -6
Cyclophosphamide 60 mg/kg x 2 days on Day -5 and -4
Apheresis cell collection (collected from the Donor Day - 8) will be enriched for FATE-NK100 per CMC. IL-2 at 6 million IU subcutaneously (SC) every other day (EOD) for 6 doses with Dose 1 on Day 0 (no sooner than 4 hours post NK cells) and last dose no later than Day +12."
1485040|NCT03081767|Diagnostic Test|Digital PET/CT scan|The Division of Nuclear Medicine and Molecular Imaging at Stanford has installed the first ever GE-made digital PET/CT scanner worldwide. The investigators wish to determine if the digital PET/CT scanner offers equivalent image quality as the standard PET/CT scanner.
1485041|NCT03081754|Radiation|Doppler velocimetry|Doppler studies were performed within the last week before delivery using a 3.5-Mhz transducer, all measurements were performed with the mothers in a semi recumbent position. Color-flow imaging was used to visualize the ascending branch of the uterine arteries. Pulsed Doppler velocimetry was performed with a sample volume of 5 mm.
1485042|NCT03081728|Device|Interscalene Block with Ropivacaine Hcl 0.2% Inj Vil 10Ml|bolus 10ml of 0.5% ropivacaine followed by infusion @ 2ml/hr of 0.2% ropivacaine
1485043|NCT03081728|Drug|IV diclofenac and IV paracetamol|iv diclofenac 75 mg TDS iv paracetamol 1gm TDS
1485044|NCT03081715|Drug|Cyclophosphamide|20 mg/kg single dose will be administered 3 days i.v.
1485045|NCT03081715|Drug|Interleukin-2|720000 international unit（IU）/Kg/day
1485046|NCT03081715|Other|PD-1 Knockout T Cells|Programmed cell death protein 1(PD-1) gene will be knocked out by CRISPR Cas9
2010593|NCT02921919|Drug|Talazoparib|Maximum starting dose: 1mg/day or last tolerated dose in the originating protocol
2010594|NCT02921256|Drug|Capecitabine|Given PO
1485049|NCT03081689|Drug|Nivolumab 360 mg|Nivolumab 360 mg IV Q3W + Followed by adjuvant treatment for 1 year with Nivolumab 240 mg IV Q2W for 4 months and Nivolumab 480mg Q4W for 8 months
1485050|NCT03081689|Drug|Paclitaxel 200mg/m2|Paclitaxel 200mg/m2 IV Q3W
1485051|NCT03081689|Drug|Carboplatin AUC 6|Carboplatin AUC 6 IV Q3W
1485052|NCT03081676|Drug|Glimepiride 1Mg Tablet|Glimepiride
1485053|NCT03081676|Drug|Glucagon-like Peptide-1|GLP-1 infusion
1485054|NCT03081676|Drug|Glucose-Dependent Insulinotropic Polypeptide|GIP-infusion
1485055|NCT03081676|Drug|Placebo Oral Tablet|Placebo
1485056|NCT03081676|Drug|Placebo infusion|Placebo (saline)
1485057|NCT03081663|Procedure|Quadriceps Sparing Mid-Vastus Approach|Quads-sparing approach for total knee arthroplasty
1605286|NCT02197026|Procedure|Hydrotherapy|
1948830|NCT01516515|Drug|SR-T100 with 2.3% of SM|2.3% of SM in Solanum undatum plant extract
1948831|NCT01506479|Behavioral|Moderate Exercise|Endurance exercise at 60 - 65% heart rate (HR) max,4x/wk for 6 months.
1948832|NCT01506479|Behavioral|Vigorous Exercise|Endurance exercise at 80-85% HR max, 4x/wk for 6 months.
1948833|NCT01506479|Behavioral|No Intervention|No-exercise control (i.e., usual care);
2010595|NCT02921256|Drug|Fluorouracil|Given IV
2010596|NCT02921256|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity modulated radiation therapy
1485065|NCT03081572|Diagnostic Test|Platelet aggregation|Platelet aggregation
1485066|NCT03081559|Behavioral|Healthy Divas|Peer-based counseling to improve medication adherence and engagement in care
1485067|NCT03081533|Behavioral|Circle Dance Program|The Circle Dances consist of a simple way of dancing choreographies of various peoples and cultures, adapted for a circle dance, hand in hand, where it is not necessary to know how to dance, because no technique or experience is required. The choreographies challenges balance, motor coordination, cognitive function and could improve mobility; muscle strength of legs; walking speed and fatigue.
1485068|NCT03081520|Behavioral|Affective response MIT|Examine acute affective responses during and after five sessions of endurance training with moderate intensity continuous training
1485069|NCT03081520|Behavioral|Affective response HAIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity aerobic interval training
1485070|NCT03081520|Behavioral|Affective response HIIT|Examine acute affective responses during and after five sessions of endurance training with high-intensity sprint interval training
1485071|NCT03081507|Behavioral|SM-LHW|Will not receive additional follow-up from the LHW, but will be encouraged during the session to make an appointment with their provider to schedule a mammogram and Pap test, or to consult the MARHABA webpage for information on low-cost and culturally appropriate referral sources of screening. Individuals assigned to this arm who did not attend an educational seminar will be mailed a packet containing a palm card, brochure, and letter encouraging them to speak with their provider about breast and cervical cancer screening and/or going to the MARHABA webpage. LHWs will complete a follow-up survey with participants by phone or in-person at 4 months after baseline
1485072|NCT03081507|Behavioral|PN-LHW|PNLHW participants will receive three planned contacts with LHWs that focus on navigation for obtaining mammogram and/or Pap testing.The initial contact will be made by phone and will focus on motivating participants to make an appointment with their primary care provider and/or obstetrician/gynecologist (OB/GYN), as well as provide information on low-cost or free care if necessary. The second contact will discuss the process of going to the appointment and the third contact will focus on the process of obtaining and interpreting. The second and third contacts will be either made by phone or in-person, depending on participant needs.
2010597|NCT02921256|Other|Laboratory Biomarker Analysis|Correlative studies
2010598|NCT02921256|Drug|Leucovorin Calcium|Given IV
1485076|NCT03081468|Device|Binocular OCT prototype|Participants in the study will undergo pupil measurement using a prototype binocular OCT imaging system (Envision Diagnostics, Inc., CA). For the binocular OCT imaging system, testing will be performed twice in the same session, by the same examiner, to allow assessment of repeatability (test-retest variability).
1485077|NCT03081468|Device|Konan RAPDx|Participants in the study will undergo pupil measurement using a validated, commercially available pupilometer (RAPDx; Konan Medical USA, Inc., Irvine, CA).
1485078|NCT03081455|Diagnostic Test|Diagnostic Test|Genetic Diagnostic Testing
1485079|NCT03081442|Drug|Misoprostol|600 micrograms of misoprostol vaginally as deep as possible six hours before IUD insertion
1485080|NCT03081442|Device|Intrauterine contraceptive device IUCD|"bimanual examination. The cervix was exposed by introducing a vaginal speculum, the cervix and vaginal vault were cleaned with povidone- iodine solution.
The Next step was to sound The IUD was folded into the insertion tube immediately prior to insertion. The cervix was grasped with a tenaculum, and gently pulled downward The insertion tube was advanced into the uterus to the correct depth as marked on the tube by a sliding plastic flange.
The outer sheath of the insert was withdrawn ashort distance to release the arms of the T and was then gently pushed inward again to elevate the opened T against the fundus of uterus ."
1485081|NCT03081416|Drug|Ketamine|Intranasal ketamine administration
1485082|NCT03081416|Drug|Normal saline|
1485083|NCT03081416|Drug|Metoclopramide|
1485084|NCT03081416|Drug|Ketorolac|
1485085|NCT03081416|Drug|Dexamethasone|
1485086|NCT03081416|Drug|Benadryl|
2010599|NCT02921256|Drug|Oxaliplatin|Given IV
1485088|NCT03081390|Other|Mixed meal tolerance testing|An intravenous catheter is placed for serial blood draws for inflammatory markers and ancillary studies. The participant consumes a test meal, and measurements are made for 4 hours.
1485089|NCT03081390|Other|Skin conductance & cold pressor test|Skin conductance will be monitored continuously with 2 electrodes placed on the plantar surface of the foot. To induce pain, we will use the cold pressor test. Participants submerge one hand in a bath with iced water (2-4ºC) for 2 minutes. Blood pressure and heart rate are monitored every minute starting 5 minutes before the cold pressor test and for 10 minutes after the participant withdraws the hand from the bath. This testing will be performed at baseline and post-meal.
1485090|NCT03081390|Other|Flow-mediated dilation testing|At baseline and post-meal, we will assess flow-mediated dilation at the brachial artery using well-validated ultrasound techniques.
1485091|NCT03081364|Other|Initiate ACLS protocol if lethal arrythmia develops|Cardiac Rhythm Management
1485092|NCT03081351|Procedure|extended lymphadenectomy and nerve clearance|"The investigators will implement the pancreaticoduodenectomy using the principle of Total Peripancreas Excision to resect the lymph node and nerve plexus. The lymph node include standard 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b and extended 8p,9,12a,12p,14a-d,16a2,16b1 of the abdominal lymph node."
1485093|NCT03081351|Procedure|standard lymphadenectomy|The investigators will implement the pancreaticoduodenectomy using the standard lymphadenectomy. The lymph node include 5,6,8a,12b1,12b2,12c,12a-b,14a-b,17a-b of the abdominal lymph node.
1485094|NCT03081325|Procedure|URSA patients treated by active immunotherapy with small amount of lymphocytes.|
1485095|NCT03081286|Procedure|Liposuction|Liposuction is performed on the abdomen or thighs as determined before randomization by the surgeon.
1485096|NCT03081286|Procedure|Fat graft|The harvested lipoaspirate is injected at the site of pain.
1485097|NCT03081286|Procedure|Sham graft (saline injection)|Saline will be injected at the site of pain instead of fat
1485169|NCT03080701|Behavioral|Auto Mailing Plus Money|Participant receives money as a thank you for completing CRC screening within 6 months.
1606171|NCT02190188|Device|Knee Brace|
2010600|NCT02921256|Drug|Veliparib|Given PO
1485098|NCT03081260|Other|Patellar resurfacing|The resurfacing of the patella is generally done at the end of the surgery, after having ejected the patella. A frontal bone cut is made using a dedicated ancillary to remove the entire cartilage. Orifices are then made in the patella so that the polyethylene implant can be accommodated with studs which will be cemented on the joint face of the ball joint.
1485099|NCT03081260|Other|Patellar non-resurfacing|Non-resurfacing of the patella does not involve any additional surgical action
2010601|NCT02920034|Device|Radiofrequency denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Spyral™ Catheter (Medtronic, MN, USA)
2010602|NCT02920034|Device|Radiofrequency denervation of renal arteries and branches|Catheter based renal sympathetic denervation of the main renal arteries and its branches using the Spyral™ Catheter (Medtronic, MN, USA)
1485102|NCT03081234|Drug|Ribociclib|Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Ribociclib will be supplied in the form of 200 mg tablets.
1485103|NCT03081234|Drug|Placebo|Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months). Placebo will be supplied in the form of 200 mg tablets.
1485104|NCT03081234|Drug|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy may include GnRH agonist administered every 28 days.
1485105|NCT03081221|Diagnostic Test|USG|
1485108|NCT03081195|Behavioral|MFG|The MFG is a series of weekly meetings guided by a protocol.Over the course of 16 weeks, groups are held weekly and are facilitated by trained and supervised group leaders (in this case either parent peers or community health outreach workers). Groups can consist of up to 20 families involving adult caregivers and all children over six years of age in the family. The protocols have been designed to provide opportunities during each session to directly apply content to the realities of family life, emergent cultural and values perspectives, as well as tailor messages to age of child. Redundancy for missed appointments and opportunities for reinforcement is built in. We aim for families to attend at least 8 meetings or more (out of 16 sessions in total), as findings suggests this dose is needed to reduce child conduct problems and the majority of families reach this goal.
1485109|NCT03081182|Other|Data Management and Monitoring|"The Coordinating and Data Management Center (CDMC) at MD Anderson Cancer responsible for monitoring protocol and regulatory compliance for all consortium studies.
CDMC responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study."
1485110|NCT03081169|Drug|Enoxaparin Sodium 150 MG/ML Prefilled Syringe|The same drugs and dosages will be used in both groups, with only the timing being different
1485111|NCT03081169|Drug|Heparin|The same drugs and dosages will be used in both groups, with only the timing being different
1485112|NCT03081156|Drug|Glycopyrrolate / Formeterol|Exercise Tolerance
1485113|NCT03081143|Drug|FOLFIRI|Irinotecan 180 mg/m2; i.v. bolus of 5-FU 400 mg/m2, i.v. infusion of leucovorin* 400 mg/m2 , followed by a 46-hour continuous administration of 5-FU 2400 mg/m2 on day 1 and 15 of a 28-day cycle
1485114|NCT03081143|Drug|Ramucirumab|8 mg/kg i.v. infusion on day 1 and 15 of a 28-day cycle
1485115|NCT03081143|Drug|Paclitaxel|80 mg/m2 on day 1, 8, 15
1485116|NCT03081130|Procedure|Intravenous laser irradiation treatment|control group
1485117|NCT03081117|Drug|Insulin, intranasal|Regular insulin administered by specialized, non-commercial intranasal drug delivery device
1485118|NCT03081117|Drug|Placebo, intranasal|Saline solution administered by specialized, non-commercial intranasal drug delivery device
1485119|NCT03081104|Device|hystroscopy|The uterine cavity will be distended with saline or glycine, depending on the polarity of the resection system.with a maximum irrigation pressure of 110mmHg. The retained products will be resected from top to bottom with surgical resector without electric power. The use of forceps or curettes to facilitate the removal of material is permitted. If active bleeding occurs , elective coagulation by hystroscope is done to stop intrauterine bleeding. The deficit of distending media should be calculated at the end of procedure.
1485120|NCT03081104|Device|ultrasound|The transducer was held on the abdomen to obtain a longitudinal image of the uterus and cervix and provide the surgeon with a visual reference of the gestational sac, cervical canal and any instruments passed into the uterus.The progress of the operation was continuously monitored as the uterine contents were evacuated under visual control.
1485121|NCT03081104|Procedure|Aspiration|The cervical canal was dilated gradually with Hegar dilators up to the size corresponding to the weeks of gestation. The uterine cavity was evacuated using a plastic cannula attached to an electric suction apparatus. Negative pressure of 75 mmHg was used.
1485122|NCT03081091|Device|Acupuncture|"The needles used for the treatments will be single-use needles of two different gauge sizes. One size or the other will be used depending on the area to be treated and the physical condition of the patient. The needles and gauge sizes used in the study are as follows:
Dong Bang siliconized needle 0.25 mm x 40 mm Dong Bang siliconized needle 0.20 mm x 30 mm
The therapist will assess the patient's condition according to traditional Chinese medicine and will look at the relationship between the patient's most affected areas and the paths of the acupuncture meridians. Subsequently, the combination of Yuan and Luo points to be treated will be determined. This procedure will be followed before every acupuncture session, in such a way that the combination of the points used will depend on the evolution of the symptoms."
1485123|NCT03081091|Device|Sham Acupuncture|"It will follow the validated technique of sham acupuncture with the Park device, without needle penetration in the patient's body.
The Park device for the performance of sham acupuncture consists of two plastic tubes, one sliding within the other, and inside which the needle created for the device slides. The longest tube is attached to a circular base, which has an adhesive surface that sticks to the skin so that the device and the needle cannot fall. Blunt ended needles will be used for this technique and thus the needle does not get to pass through the skin but produces a cutaneous stimulation similar to conventional acupuncture needles. These needles are supplied with the kit that contains the Park sham acupuncture device and are registered in the European Union as CE 0120."
1485170|NCT03080701|Behavioral|Auto Mailing Plus Lottery|Participant has a 1 in 10 chance of winning money in a lottery for completing CRC screening within 6 months.
1485477|NCT03078387|Diagnostic Test|imaging|imaging before and after treatment
2001112|NCT03205124|Procedure|Sham Stimulation|"The experimental treatment involves implantation of 2 sterilized fine-gauge Teflon coated wires percutaneously. The ends of the wire are stripped for conductivity. Electrical stimulation is begun until the patient senses the stimulation, then the stimulation is discontinued.The wires are then taped to the skin with surgical wound tape at a location away from the wound for strain relief. To ensure sterility, care is taken to dress the sutured wound and hand, as well apply the splint.
The wires are removed either immediately at the conclusion of the pre-operative appointment and immediately after surgery or at the first surgical follow-up with dressing change, within one week of surgery."
2001113|NCT03204773|Diagnostic Test|EuroQol five dimensions questionaire (EQ-5D)|Testing quality of life.
1485126|NCT03081065|Dietary Supplement|Mediterranean Diet|Nutritional advice to follow a Mediterranean diet and supplementation with extra virgin olive oil and nuts
1485127|NCT03081052|Drug|iNO|Subject will receive inhaled Nitric Oxide in this intervention
1485128|NCT03081052|Drug|iEPO|Subject will receive inhaled Epoprostrenol in this intervention
2001114|NCT03204773|Diagnostic Test|Modified Fatigue Impact Scale (MFI)|Screening for fatigue
2001115|NCT03204773|Diagnostic Test|Brief Pain Inventory (BPI)|Testing for pain
2001116|NCT03204773|Diagnostic Test|Becks Depression Inventory (BDI)|Screening for depression
1485132|NCT03081026|Diagnostic Test|Bilateral hip to ankle x-ray, exam and strength testing.|Only an X-Ray is performed and reviewed to identify any growth disturbances.
1485133|NCT03081013|Behavioral|Social information|Social comparison information will be provided to the study participants weekly via SMS
1485134|NCT03081013|Device|Fitbit|Fitbit is a wireless pedometer that tracks steps of participants and will be offered in conjunction with a tailored website with customised information for participants.
1485135|NCT03080987|Drug|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion on Day 1.
1485136|NCT03080987|Drug|JNJ-64179375 1.0 mg/kg|JNJ-64179375 1.0 mg/kg on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
1485137|NCT03080987|Drug|JNJ-64179375 2.5 mg/kg|JNJ-64179375 2.5 mg/kg IV infusion on Day 1.
1485138|NCT03080987|Other|Placebo|Matching placebo on Day 1 administered as IV infusion (for Part 1) and SC injection (for Part 2).
1485139|NCT03080987|Drug|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined).
2001117|NCT03204773|Diagnostic Test|Restless-leg Questionaire (RLS diagnostic criteria)|Testing for restless-legs
2001118|NCT03199469|Genetic|AT132|AT132 is an AAV8 vector containing a functional copy of the human MTM1 (hMTM1) gene.
1485142|NCT03080961|Device|VIBLOK barrier cream|VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
1485145|NCT03080935|Drug|Evolocumab|Subjects will receive Evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
1485146|NCT03080922|Biological|hematopoietic stem cell|high dose of donor G-CSF mobilized peripheral blood hematopoietic stem cell are infused to patient received normal chemotherapy
1485147|NCT03080909|Dietary Supplement|Encapsulated nutrients|Amino acid + Lipid; Probiotic bacteria; Lipid; Amino acid selected on their ability to stimulate release of GLP-1 and PYY
1485148|NCT03080909|Dietary Supplement|Placebo|Maltodextrin, which is not expected to stimulate release of GLP-1 and PYY
1485149|NCT03080896|Device|King Vision video-laryngoscope with #3 disposable blade and endotracheal tube stylet|intubation using King Vision video-laryngoscope with #3 disposable blade with stylet convert to intubation with video-laryngoscope and fiber-optic bronchoscope bronchoscope (aScope III) for failure to intubate after three attempts
1485150|NCT03080896|Device|fiberoptic bronchoscope aScope III|Intubation using the videolaryngoscope/fiberoptic bronchoscope (aScope III)
1485152|NCT03080870|Other|Art|Multicomponent art intervention
1485153|NCT03080857|Other|Virtual Platform|The platform will direct patients to review the Canadian Cardiovascular Guidelines and the Heart & Stroke website for commonly asked questions relating to atrial fibrillation, as well as recommendations regarding nutrition and activity.
1485154|NCT03080844|Behavioral|Delay time to first cigarette|Participants asked to delay time until they smoke first cigarette of the day.
1485155|NCT03080844|Behavioral|Therapy|Participants receive tips on how to resist the urge to smoke and control cravings to smoke.
1485156|NCT03080831|Drug|NaCl 0.9% in Glucose 5% + 40mmol/L Potassium|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
1485157|NCT03080831|Drug|Glucion 5%|Study fluid used at maintenance rate of 27 mmol per kg of body weight per day from beginning of surgery until end of study.
1485158|NCT03080818|Dietary Supplement|Probiotic - Lactobacillus Rhamnosus GG|2 capsules per day for 90 days
1485159|NCT03080818|Other|Placebo|2 placebo capsules per day for 90 days
1485160|NCT03080805|Drug|Pyrotinib Plus Capecitabine|pyrotinib(400 mg once daily) + capecitabine (2000 mg/m^2 daily, 1000 mg/ m^2 BID)
1485161|NCT03080805|Drug|Lapatinib Plus Capecitabine|Lapatinib (1250 mg once daily)+ capecitabine (2000 mg/m^2 daily, 1000 mg/m^2 BID)
1485162|NCT03080792|Behavioral|Experimental: moderate to high-intensity exercise|2x per week endurance exercise (continuous moderate and high intensity intervall training on a cycle ergometer) and progressive resistance training (machine based hypertrophy training)
1485163|NCT03080766|Drug|Decitabine|Decitabine (trade name Dacogen®) is a cytidine deoxynucleoside analogue, which selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation that can result in reactivation of tumor suppressor genes, induction of cellular differentiation or cellular senescence followed by programmed cell death.
1485164|NCT03080753|Device|Sphinkeeper|Intersphincteric implants in the anal sphincter
1485165|NCT03080740|Drug|Clindamycin palmitate hydrochloride dispersible tablet|300mg, oral after meal, twice daily, a total of 7days
1485166|NCT03080740|Drug|Metronidazole Tablet|400mg, oral after meal , twice daily, a total of 7days
1485167|NCT03080714|Device|Topcon DRI OCT Triton (plus)|The Topcon DRI OCT Triton (plus) is an OCT machine used for diagnostic purposes
1485168|NCT03080714|Device|3D OCT-1 Maestro|The 3D OCT-1 Maestro is an OCT machine used for diagnostic purposes
1485171|NCT03080688|Device|Prizma Oxygen Saturation Measurement|"A radial arterial cannula was placed in either the left or right wrist of each subject.
Blood gas analysis to determine oxyhemoglobin saturation was performed on an OSM-3® multi-wavelength oximeter (Hemoximeter, Radiometer, Copenhagen). No subject was anemic (Hemoglobin ≤ 10gm•dl-1)."
1485172|NCT03080675|Dietary Supplement|Nutrional blend of ingredients including vitamins and fish oil|
1485173|NCT03080675|Dietary Supplement|Control|
1485174|NCT03080662|Device|ORYGEN DUAL Sham Valve|Training of the inspiratory muscles during 5 weeks
1485175|NCT03080662|Device|ORYGEN DUAL Valve|Training of the inspiratory muscles during 5 weeks
1485176|NCT03080649|Device|excavated with rotary bur|One of two identified caries lesions in the patient were randomly allocated to be excavated with rotary bur
1485177|NCT03080649|Device|Er:YAG laser|One of two identified caries lesions in the patient were randomly allocated to be excavated with Er:YAG laser
1485178|NCT03080636|Other|Aerobic exercise|30 minutes of treadmill exercise at 60-70% of heart rate reserve
1485179|NCT03080636|Other|Resistance exercise|30 minutes of circuit resistance session at 40% of 1 maximun repetition test
1485180|NCT03080636|Other|Control session|30 minutes seated resting
1485181|NCT03080597|Device|PrEP Smart app|"English-speaking males, between the ages of 18-30, who are enrolled at a HBCU or identify as Black/African American, who are currently prescribed PrEP (Truvada) for HIV Prevention, and owners of either an Android or iOS smartphone, will be asked to use an application on their smart phones called PrEP Smart.an application on their smart phones called PrEP Smart."
1485182|NCT03080584|Other|acupuncture|12 weeks of acupuncture comprising basic acupuncture, ear acupuncture and Moving cups. On top of the basic acupuncture, additional locations can be added.
1485183|NCT03080571|Biological|autologous BMMNC stem cells|Autologous BMMNC injected in the ipsilateral MCA
1485184|NCT03080571|Other|standard care|
1485185|NCT03080558|Drug|Indocyanine green|Use of Indocyanine Green during Rectal shaving by laparoscopy.
1485186|NCT03080545|Drug|Enstilar 0.005%-0.064% Topical Foam|Topical foam
1485187|NCT03080532|Other|dietary habits|
1485188|NCT03080519|Procedure|Endovascular Therapy|Balloon angioplasty and stenting for renal artery stenosis
1485189|NCT03080506|Device|Elastic abdominal binder|Participants will be fitted with an elastic abdominal binder at the time of procedure completion just before leaving the operating room. The binder will be placed snuggly tight on top of the hospital gown at the infraumbilical level with the incision positioned at the middle part of the binder. The patients will be encouraged to wear binders at all time. However, periods of break from wearing the binder will be allowed at their convenience.
1485190|NCT03080493|Drug|Gabapentin 600mg|Gabapentin 600 mg PO (two total doses, thereby lasting duration while osmotic dilators are in place)
1485191|NCT03080493|Drug|Placebo oral capsule|Packaged identical to gabapentin dosing
1485192|NCT03080493|Drug|acetaminophen/codeine and ibuprofen|Over the counter analgesic medications
1485193|NCT03080480|Drug|Pioglitazone|"Pioglitazone is PPARγ agonist that may be enhance ROS production and partially restore host phagocytes in CGD.
pioglitazone is administered at a starting dose of 1 mg/kg and given the absence of adverse effects is progressively increased up to 3 mg/kg or 30 mg/daily."
1485194|NCT03080454|Device|Pathmaker MyoRegulator neuromodulation system|
1485195|NCT03080441|Device|pressure stockings|pressure stockings worn during dialysis throughout treatment period
1485196|NCT03080441|Drug|Midodrine|administered Midodrine before each dialysis treatment during treatment period based on PI's judgement. Including consideration of blood pressure.
1485197|NCT03080441|Other|pressure stockings and midodrine|combination of Midodrine and pressure stocking before each dialysis treatment throughout treatment period
1485198|NCT03080428|Diagnostic Test|Genomic test|genomic test realized on surgery block or formalin-fixed paraffin-embedded slides
1485199|NCT03080415|Drug|Combined Therapy SOF and DCV|"1 whole or half tablet sofosbuvir and 1 whole or half tablet daclatasvir per day
SOF dosage: 400 mg/day for greater than 45 kg weight patients; 200 mg/day for 17 kg to 45 kg patients
DCV dosage: 60 mg/day for greater than 45 kg weight patients; 30 mg for 17 kg to 45 kg patients"
1485200|NCT03080402|Device|Mechanical Perturbation Training|The training program will consist of three stages and subjects will progress through each neuromuscular training stage.The training will consist of double- to single-limb movements with progression of jumping, hopping, and pivoting maneuvers on the perturbation device with an emphasis on proper technique and landing. The initial four sessions will focus on primarily on jumping and hopping maneuvers on double- and single-limb in the sagittal plane. The intermediate four sessions will incorporate additional medial and lateral maneuvers with the plyometric tasks. The final four sessions will incorporate rotational and pivoting activities with the maneuvers. The resultant protocol has been derived and optimized from previous published research studies and prevention techniques.
1485201|NCT03080389|Procedure|Extended Urine Culture|"Extended Urine Culture Standard cultures will include 0.001 ml of specimen plated on sheep blood agar and MacConkey agar. Plates were inoculated and incubated at 35 degrees Celsius for 24 hours. Samples were considered positive if there were 10^3 cfu or greater. The extended urine culture will be spun down by centrifuge (3000 rpm for 5 min) and 0.1 ml of the sediment will be cultured for 48 hours.
The participants will fill out the Bother, UDI-6, and PUF questionnaires before the cultures. If a patient has a positive urine culture, the patient will be asked to repeat the questionnaires 7-30 days post treatment with antibiotics. A comparison will be made between the standard and extended urine cultures to assess for a difference in identification and treatment of uropathogens."
1485202|NCT03080376|Other|Web-based intervention with support|Web-based combined aerobics and muscular strength exercises.
1485203|NCT03080376|Other|Web-based intervention without support|Web-based combined aerobics and muscular strength exercises.
1485204|NCT03080376|Other|Traditional intervention|3 months of Printed-based combined aerobics and muscular strength exercise intervention.
1485205|NCT03080363|Drug|Bupivacaine|10 ml %0.5 bupivacaine
1485206|NCT03080363|Drug|Lidocaine|10 ml %2 lidocaine
1485207|NCT03080350|Drug|Fentanyl sublingual|Fentanyl sublingual
1485208|NCT03080350|Drug|Fentanyl ev|Fentanyl ev
1485209|NCT03080350|Drug|Placebo sublingual|Placebo sublingual
1485210|NCT03080350|Drug|Placebo ev|Placebo - NaCL 0,9% ev
1607097|NCT02183467|Drug|Moxifloxacin|
1485211|NCT03080337|Other|Group Care|Participation in 12 group sessions with 6-10 women who are also pregnant and have diabetes.
1485212|NCT03080324|Drug|Fentanyl sublingual|Fentanyl sublingual
1485213|NCT03080324|Drug|Fentanyl ev|Fentanyl ev
1485214|NCT03080324|Drug|Placebo sublingual|Placebo sublingual
1485215|NCT03080324|Drug|Placebo ev|Placebo - NaCL 0,9% ev
1485216|NCT03080311|Drug|APG-1252|"Multiple dose cohorts, 30 minute IV infusion, twice weekly for 3 weeks of a cycle with 28 days.
cycle"
1485217|NCT03080298|Drug|BP101|
1485218|NCT03080298|Drug|Placebo|
1485219|NCT03080285|Device|over-glasses patch|Over-glasses patch (Tomato Eye Patch, Tomato Inc., Busan, South Korea) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
1485220|NCT03080285|Device|Conventional patch|Conventional patch (Opticlude Eye Patch, 3M, Maplewood, MN, USA) is applied to the patients. They were prescribed 2 hours of patching per day for the sound eye.
1485221|NCT03080272|Other|no intervention will take place|Only registration and data collection of patients' care and treatment will take place. There will be no changes in patients' treatment. No intervention will take place
1485222|NCT03080259|Behavioral|Stimulant Diversion Prevention|provider training, patient/parent education and counseling, strategies for use by patients and parents, and treatment adjustments
1485223|NCT03080246|Behavioral|Strength Training Exercise|
1485224|NCT03080220|Device|Astym|therapeutic massage instrument
1485225|NCT03080220|Device|Stick|massage instrument
1485226|NCT03080220|Device|Massage|massage instruments
1485227|NCT03080207|Other|PRP method|It will first be placed on a 25 cc venous blood centrifuge in anticoagulated tubes containing acid citrate dextrose (ACD), and autologous venous blood will be centrifuged at 3200 rpm for 15 minutes. Using the PRP kit, the plasma rich in platelet volume of about 3 cc volume will be removed. This will be activated by the addition of platelet agonists such as thrombin, calcium gluconate or calcium chloride. Injections should be administered subcutaneously for 2-3 weeks, 3-4 times for inguinal, popliteal region and ankle for a total of 12 weeks.
1485228|NCT03080207|Other|Complex Decongestive Physiotherapy|Complex Decongestive Physiotherapy (CDP) consists of four basic components and two phases. Four basic components; Manual lymph drainage (MLD), skin care, compression therapy and therapeutic exercise. Phase I (intense phase): It is also referred to as the phase of reducing the remission. In this phase, skin care and compression bandages are renewed after daily MLD application. The patient is taught how to bandage on his own. (Phase I, 4 weeks) The duration of phase I may vary according to the patient. In Phase II, MLD can be administered 2 or 3 times per week depending on the needs of the individual. In this case, the patient is followed by home program. Our cases will be treated in Phase I every day for 12 weeks in total and 2 days / week in Phase II according to KBF phases.
1485229|NCT03080207|Other|Low Level Laser|"Low Density Laser treatment will be applied for the first 4 weeks every 12 weeks, the remaining 8 weeks 2 days / week. A total of 9 regions (6 point inguinal region and 3 points popliteal region) are to be applied by applying the laser head close to the skin (20000 Hz, 1.5 J / cm2) with the laser device and the regions where lymph nodes and lymph pathways are dense.
During the application, the patient will be in the supine position for the popliteal region, with the patient in the supine position for the inguinal region and the legs free in the abdomen."
1485230|NCT03080194|Drug|paliperidone palmitate|Subjects in experimental group will be injected with 150mg eq and 100mg eq paliperidone palmitate in the deltoid at the 1st and 8th day, and afterwards a flexible dose of paliperidone palmitate from 75 to 150mg eq will be administrated monthly according to clinical judgement. Previous oral antipsychotics could be continued or withdrawn in 2-4 weeks after first paliperidone palmitate administration according to doctors' clinical judgement.
1485231|NCT03080194|Drug|control group|Subject in control group will be applied with oral antipsychotics or other conventional medication.
1485233|NCT03080168|Device|Actigraph|This is NOT an intervention but a monitoring device. All participants will wear an Actigraph for the duration of their inpatient stay, as well as complete paper and computer assessments.
1485234|NCT03080155|Device|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
1485235|NCT03080142|Drug|Exparel|Patients will receive an injection of 30ml of volume to each abdominal side with a total of 60 ml for bilateral TAP blocks.
1485236|NCT03080142|Drug|Ropivacaine|Patients will receive 30ml of ropivicaine. Peripheral nerve catheters will be placed approximately 3-5cm into the TAP space and secured to the skin with tegaderm tape. Infusions will be ordered with CADD pumps and will be initiated at a rate of 8ml/hr of 0.2% ropivicaine on the inpatient floor.
1485237|NCT03080129|Dietary Supplement|Fresubin energy|dietary protein energy supplement
1485238|NCT03080116|Drug|ARN-509|240mg/day (4x60mg tablets, Oral administration: OS)
1485239|NCT03080116|Drug|Degarelix|1st injection: 120mg Subcutaneous administration (SC) x2, 2nd-3rd SC injection 80mg monthly
1485240|NCT03080116|Other|Placebo|4 tablets, per OS
1485241|NCT03080103|Procedure|Laparoscopic or Open appendectomy|Laparoscopic three-port or single-port appendectomy; or conventional McBurney laparotomic appendectomy; or open appendectomy performed through midline incision
1485242|NCT03080103|Drug|Antibiotic-first therapy|Patients treated with antibiotics as first-line approach
1485243|NCT03080090|Behavioral|Aerobic exercise|Individuals will work with a YMCA personal trainer to engage in aerobic exercise 3 times a week (25 mins each) for 15 weeks.
1485244|NCT03080090|Behavioral|Smoking Cessation Intervention|Individuals will work with a national quitline to help them with their smoking cessation goals and make a quit attempt at week 5 of the program.
1485245|NCT03080077|Drug|Ricrolin+|The IONTOPHOR CXL iontophoresis applicator and the associated blepharostat will be placed onto the cornea to be treated. The applicator will be secured to the cornea and filled with Ricrolin+ which as been aspirated from the bottle using a syringe with a needle. The generator will be switched on and set to 1 mA for 5 minutes. The generator will then be disconnected and the applicator will be removed from the cornea.
1485314|NCT03079492|Device|Magnetic resonance imaging|Magnetic resonance imaging will be used to estimate brain temperature and cerebral blood flow
1485315|NCT03079479|Diagnostic Test|Muscle Strenght assesment|Muscle Strenght assesment of the hip muscles
1485246|NCT03080077|Drug|Epi-Off|Using topical anesthesia (proparacaine), the surgeon will create a complete corneal abrasion to facilitate riboflavin diffusion into the cornea. The epithelium will be removed by gently brushing the cornea with a scalpel. A corneal abrasion diameter of ~9mm is recommended, which may be adjusted as needed at the discretion of the investigator to accommodate individual eye geometry. Ultrasound corneal pachymetry should be performed before dis-epithelialization and after dis- epithelialization. Local anesthetics will be administered as needed to maintain patient comfort during the CXL procedure.
1485247|NCT03080064|Behavioral|Health Coach Intervention|Please see arm description.
1485248|NCT03080051|Drug|[18F]MNI-952|Subjects will undergo PET imaging using [18F]MNI-952, a PET radioligand for imaging tau.
1485249|NCT03080051|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-952.
1485250|NCT03080038|Other|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.
Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Documented intravascular hypovolemia.
Intervention end: Patient is free from vasoactive medication support and shock is reversed."
1485251|NCT03080025|Behavioral|CBCT® (Cognitively Based Compassion-Training)|"The CBCT® (Cognitively Based Compassion-Training) as a secular approach was established as a structured protocol.
The therapeutic tools are based on systemic approaches & techniques, which contains a resource- & solution orientation and the approach of Gottman's model of healthy relationships (e.g. trust and commitment - based on that - elements like the positive perspective).
Four dyadic exercises are introduced to enhance positive reciprocity between the romantic partners (based on concepts of couple communication training):
a) Building mindful ability to talk, b) building mindful ability to listen (without reacting initially), c) appreciation in action - indulging the partner, d) noticing, how the partner is doing something good for me - gratefulness in action verbally/non-verbally. Finally, the empathy exercise has been added inspired by CBASP therapy for chronic major depression."
1485252|NCT03080012|Other|Saliva sampling|Stimulated saliva samples are taken using cotton rolls.
1485253|NCT03080012|Other|Plasma/serum sampling|Simultaneously with saliva sampling.
1485254|NCT03079999|Drug|Aspirin|Twice daily aspirin
1485255|NCT03079999|Drug|Placebo|Twice daily placebo
1485256|NCT03079986|Other|Standard care irrespective of CL|Removal of surgical drains despite persistent CL, without dietary restrictions or dietary treatment for CL.
1485257|NCT03079986|Other|Dietary treatment (MCT-diet)|Dietary treatment with MCT-diet until resolution of CL.
1485258|NCT03079973|Drug|P-3073 (calcipotriene 0.005%)|Topical solution P-3073 (calcipotriene 0.005%) once daily for 24 weeks.
1485259|NCT03079973|Drug|Vehicle of P-3073|Once daily for 24 weeks.
1485260|NCT03079960|Device|Electrophysiological recording and measurement devices|Externalization of DBS connectors and macroelectrodes for simultaneous STN stimulation LFP recordings by the use of electrophysiological recording and measurement devices.
1485261|NCT03079934|Device|Absorb-BVS|BVS patients undergoing optical coherence tomography examination at follow-up
1485262|NCT03079921|Drug|Phentolamine|Physiologic receptor blockade (α1-receptor).
1485263|NCT03079921|Drug|Propranolol|Physiologic receptor blockade (β2-receptor).
1485264|NCT03079921|Drug|Placebo|100mL bag of Normal Saline Solution (NSS).
1485265|NCT03079908|Other|da Vinci Skills Simulator®|Initial robotic virtual reality surgical simulator Training (da Vinci Skills Simulator ® System), then laparoscopic dry box evaluation
1485266|NCT03079908|Other|LapSim®|Initial laparoscopic virtual reality surgical simulator training (LapSim ® System), then laparoscopic dry box evaluation
1485267|NCT03079908|Other|Dry lab box laparoscopic training|No initial simulator training. Dry lab box laparoscopic Training only.
1485268|NCT03079895|Behavioral|Thrive|Thrive is an online self-help tool designed to assess for depressive symptoms and give therapeutic suggestions based on Cognitive Behavioral Therapy principals.
1485269|NCT03079869|Drug|Ferric Citrate|One to two tablets of Ferric Citrate phosphorus binder administered by mouth before every meal to prevent dietary phosphorus absorption.
1485271|NCT03079843|Other|exposure to particulate matter with N 95 facemask|2 hours' / day exposure to particulate matter face mask worn during exposure.
1485272|NCT03079843|Other|exposure to particulate matter with no face mask|2 hours'/ day exposure to particulate matter with no face mask
1485273|NCT03079830|Drug|Piritramid|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
1485274|NCT03079830|Drug|Saline|Piritramid will be administered i.v., if the patients feel pain after receiving a bolus of Ropivacaine or saline through the catheter.
1485275|NCT03079817|Other|Yoga Meditation|Yoga meditation using motor imagery to perceive movement patterns
1485276|NCT03079817|Other|Proprioceptive Drills|Active balance and proprioception drills
2001121|NCT03195140|Device|Predictive Low Glucose Suspend|Application of Predictive Low Glucose Suspend
2001122|NCT03195166|Diagnostic Test|FloTrac sensor/Vigileo|blood pressure (systolic, diastolic and mean), stroke volume cardiac output ephedrine consumption after bupivacaine continuous spinal anesthesia
1485316|NCT03079479|Diagnostic Test|2D Kinematics Analysis|2D Kinematics Analysis of the gait
1485280|NCT03079778|Procedure|transarterial chemoembolization|Transcatheter arterial chemoembolization (also called transarterial chemoembolization or TACE) is a minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
1485281|NCT03079778|Radiation|TACE plus RT|radiobiologically guided radiation
1485282|NCT03079765|Behavioral|Behavioral skills training|Participants will receive feedback and error correction on their implementation of the assessment procedures. Feedback will take the form of the experimenter pointing out components of the assessment that are not being conducted accurately and error correction will take the form of the experimenter reviewing the correct way to implement that component of the assessment.
1485283|NCT03079765|Behavioral|Protocol Only|Participants will be given a written protocol describing how to conduct the target assessment procedure.
1485284|NCT03079752|Behavioral|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment of suspected problems at 12 and 24 months of age
1485285|NCT03079752|Behavioral|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
1485286|NCT03079752|Behavioral|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
1485287|NCT03079752|Behavioral|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment for suspected problems at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
1485288|NCT03079739|Diagnostic Test|fractional flow reserve|assessment with FFR in at least one coronary lesion
1485289|NCT03079713|Device|Handheld vibrator triggered during intravitreal injection for wet ARMD|A vibratory device cleaned with alcohol swabs between each use will be attached to the injectors' finger, placed on the lower eyelid of the treatment eye, and triggered during intravitreal injection
1485290|NCT03079713|Device|Normal eye esthesiometry with and without vibration|Healthy patients will undergo corneal and conjunctival esthesiometry with and without triggering of the wearable vibrator placed upon the lower lid of a single eye.
1485291|NCT03079713|Device|Handheld vibrator not triggered during intravitreal injection for wet ARMD|Control group undergoing standard intravitreal injection without triggering of the vibrator.
1485292|NCT03079700|Biological|Trichuris suis eggs|Live eggs from swine whipworm, Trichuris suis
1485294|NCT03079674|Other|observational only- no intervention|observational only- no intervention
1485295|NCT03079648|Dietary Supplement|Angelica gigas N. extract|capsules (2cap/d, 1,000mg/d) for 8 weeks.
1485296|NCT03079648|Dietary Supplement|Placebo|Placebo for 8 weeks
1485297|NCT03079635|Dietary Supplement|Control|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
1485298|NCT03079635|Dietary Supplement|Omega 3 fatty acids|Beverage provided and a four hour postprandial assessment of energy metabolism using a metabolic cart and appetite using a visual analog scale follows.
1485299|NCT03079622|Procedure|Electric Vacuum Aspiration|
1485300|NCT03079622|Procedure|Manual Vacuum Aspiration|
1485301|NCT03079609|Procedure|subinguinal microscopic varicocelectomy|During the procedure approximately 1cm long fragment of varicose vein will be taken for further investigation.
1485302|NCT03079609|Procedure|open hernia repair|During the procedure approximately 1cm long fragment of spermatic cord vein will be taken for further investigation.
1485303|NCT03079596|Procedure|ERAS perioperative cares|Patient's preoperative counseling & education before surgery No Bowel preparation Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Fluid restriction & Management by pulse contour analysis or transesophageal doppler Early mobilization Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD)) Epidural patient controlled analgesics (no opioids analgesics) Postoperative Nausea Active Control Thromboembolism prophylaxis by low molecular weighted heparin (LMWH) Perioperative High content Oxygen therapy No drain insertion No Levin tube Patients will be discharged at POD#4 if there's no problem.
1485304|NCT03079596|Procedure|Conventional perioperative cares|No Patient's preoperative counseling & education before surgery Bowel preparation No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery Conventional Fluid Management by clinical signs (Urine output, heart rate etc.) Conventional Mobilization Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD) IV PCA Postoperative Nausea Control if needed No Thromboembolism prophylaxis No or Low Content Oxygen therapy Routine drain insertion Levin tube insertion if needed
1485305|NCT03079583|Dietary Supplement|Intervention-group|Biofortified Rice is grown by foliar Zn application and is therefore biofortified
1485306|NCT03079583|Dietary Supplement|Control-group|control Rice with normal zinc levels
1485307|NCT03079557|Drug|Intragastric botulinum toxin type A|200 units Botulinum toxin A (Allergan) injected intragastrically in the antrum every six months
1485308|NCT03079544|Combination Product|L-Asparaginase or or Pegaspargase containing chemotherapy|Patients receive at least one cycle of combinational chemotherapy containing L-asparaginas or Pegaspargase.
1485309|NCT03079531|Drug|Secukinumab|We will be giving secukinumab to patients with papulopustular rosacea
1485310|NCT03079518|Drug|Ferric Carboxymaltose|single shot infusion
1485311|NCT03079518|Other|blood withdrawal|for determination of serum and urinary biomarkers of chronic kidney disease metabolism and other parameters
1485312|NCT03079505|Drug|Dasatinib 100 MG [Sprycel]|Dasatinib (Sprycel) 100 milligram, once-daily (QD) will be given to 25 patients orally
1485313|NCT03079505|Drug|Nilotinib 150mg oral capsule [Tasigna]|Nilotinib (Tasigna) 300 milligram, twice-daily (BID) will be given to 25 patients orally
1607617|NCT02180087|Drug|Ketoprofen|
1485317|NCT03079466|Other|CPAP|This is a randomized study where patients are included consecutively under a randomization order that will be given to the investigators. Patients will continue to be treated with CPAP and other treatment with no CPAP for a duration of 3 months and with intention-to-treat analysis And by protocol.
1485318|NCT03079453|Drug|Dexamethasone|The patients in Group 1 were injected with dexamethasone (1 ml, 8 mg) through the uvula and soft palate tissue directly before tonsillectomy
1485319|NCT03079440|Drug|TEMCAP|Oral capecitabine 750 mg/m2 twice a day, Day 1 to 14 and oral temozolomide 200 mg/m2 once a day, Day 10 to 14
1485320|NCT03079427|Drug|Gemcitabine plus cisplatin|Gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 Day 1 and 8, every 3 weeks
1485321|NCT03079427|Drug|Capecitabine|Capecitabine 1,250 mg/m2 Day 1 to 14, every 3 weeks
1485322|NCT03079414|Procedure|Invasive Electrophysiology Study|Invasive electrophysiology studies will be performed using four catheters placed in the right ventricular apex, the coronary sinus, the His bundle region, and the high right atrium. Standard induction protocols for supraventricular and ventricular arrhythmias will be utilized in the absence and presence of isoproterenol. Long-short ventricular extra-stimuli will also be delivered to screen for bundle branch reentrant ventricular tachycardia. The study is considered observational as the participating sites perform electrophysiology studies in this patient population as part of standard clinical care.
1485324|NCT03079388|Dietary Supplement|Ready-to-use-supplementary food|Specially formulated supplementary food for pregnancy
1485325|NCT03079388|Dietary Supplement|Corn-soy-blend|Standard of care for malnutrition in pregnancy in Sierra Leone
1485326|NCT03079388|Drug|Monthly intermittent preventive treatment of malaria during pregnancy (IPTp)|Sulfadoxine-pyrimethamine (500 mg / 25 mg) given every 4 weeks, beginning at enrollment or at 13 weeks' gestation, whichever is later.
1485327|NCT03079388|Drug|Standard intermittent preventive treatment of malaria during pregnancy (IPTp)|Standard of care for Sierra Leone is 2 doses of sulfadoxine/ pyrimethamine (500mg/ 25mg).
1485328|NCT03079388|Other|Insecticide-treated mosquito net|An insecticide-treated mosquito net at the time of enrollment into the study.
1485329|NCT03079388|Drug|Azithromycin|Azithromycin 1 gram given once in second trimester and again during weeks 28-34 of gestation.
1485330|NCT03079388|Drug|Albendazole|Single dose albendazole 400mg given in the second trimester.
1485331|NCT03079388|Combination Product|Bacterial vaginosis testing and treatment|Testing for bacterial vaginosis at enrollment and again at weeks 28-34 using a rapid diagnostic test for sialidase. Those with positive tests will receive extended release metronidazole 750mg daily for 7 days.
1485332|NCT03079375|Other|basic intervention|medication review
1485333|NCT03079375|Other|extended intervention|medication review, medication interview before discharge and follow-up
1485334|NCT03079349|Other|Medical Education|All candidates in the Active Comparator: Traditional Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in the Active Comparator: Traditional Classroom will take a post course test.
1485335|NCT03079349|Other|Medical Intervention|All candidates in the Experimental: Online Synchronous Classroom will take a pre course test of the subject material followed by two 9-hour and one 8-hour educational sessions given over 3 consecutive days. Following the educational sessions all candidates in theExperimental: Online Synchronous Classroom will take a post course test.
1485336|NCT03079336|Behavioral|Implementation - SOTA|The implementation of an evidence-based treatment is largely principle-based - allowing considerable therapeutic flexibility in determining and timing of different treatment aspects. In this condition progress, subtle changes and sudden gains may be an explicit topic and there is no restraint to avoid such topics. However, the therapists are not obligated to take a systematized focus on potential subtle changes and they may use the timing of the sessions to involve the patients into the other tasks of therapy.
1485337|NCT03079336|Behavioral|Implementation - Prolonged focus on changes|Systematized sequence of exploration of subtle changes at a prolonged check-in phase: (1) the precise change situation, (2) related emotional states, (3) related helpful thoughts and self-verbalizations, (4) reinforcement of generalized self-efficacy and treatment motivation, (5) benefit for the upcoming session goals (Flückiger, Grosse Holtforth, et al. 2013, 2014).
1485338|NCT03079336|Behavioral|Mastery your Anxiety and Worry (MAW)|"In the present study, the MAW-packet will be applied within a usual 16-session individual therapy format and up to 3 further booster sessions.
The session format of 50-60 minute usually consists of (a) a check-in phase of 5 to 15 minutes that includes a patients welcoming, reviewing self-help and agenda setting, (b) a working phase around 35-45 minutes that focuses on the previously agreed session goals, (c) a feedback phase of 5 to 10 minutes that summarizes the session and previews the upcoming self-help assignment."
1485339|NCT03079323|Radiation|PART-trial|Elective radiation to the para-aortic lymph nodes 45 Gy / 1.8 Gy
1485340|NCT03079310|Device|Spinal cord stimulation|Range of pulse widths (200-500 microseconds) and frequencies (30-130 Hz) will be assessed for each patient
1485341|NCT03079297|Drug|L-Leucine|L-leucine is an essential amino acid which will be provided as an effervescent powder mixture to participants.
1485342|NCT03079297|Other|Maltodextrin|Maltodextrin is a nonsweet carbohydrate which will be provided as an effervescent powder mixture similar in taste and appearance to the L-leucine containing effervescent powder mixture
1485343|NCT03079284|Other|Holding during cooling|An initial set of vital sings will be recorded before the infant is removed from the isolette. The mother will sit in a reclining chair next to the isolette and place a thermal barrier over her chest and abdomen. The infant will be transferred to the mother by placing the hands under the cooling blanket so as to move the infant and cooling blanket together as one unit. The mother will be allowed to hold for thirty minutes provided that the infant's temperature does not increase by greater than one degree centigrade and the oxygen saturation does not drop below 90%. After thirty minutes, the infant will be returned to the isolette.
1485344|NCT03079271|Drug|Lacrisert, 5 Mg Ophthalmic Insert|
1485345|NCT03079258|Other|Exercise|Previously inactive pregnant women will be asked to complete 3-4 sessions of aerobic exercise each week for 24 weeks of 15-30 minutes in duration.
1485478|NCT03078374|Drug|Warfarin|Reduced dosage to obtain lower INR range
1609708|NCT02164812|Drug|Efavirenz|
1948837|NCT01472965|Drug|ethanol|70% ethanol catheter lock therapy
1485346|NCT03079245|Other|Education Plus (E+)|Education Plus was an intervention developed by the study team based on the Center for Disease Control (CDC) 12 Step Campaign to Prevent Antimicrobial Resistance in Healthcare Settings. The study team provided Education Plus quarterly to prescribers at the three sites (NICU A, B, C) randomized to this intervention. Examples of topics presented were an overview of antimicrobial stewardship principles, epidemiology of healthcare-associated infections (HAIs), prevention of surgical site infections, antimicrobial susceptibility testing, and pharmacokinetic principles. Educational formats included didactic lectures, participation via the audience response system, case vignettes, and panel discussions.
1485347|NCT03079245|Other|Clinical Decision Support|The CDS tool was an intervention developed in consultation with neonatologists and pediatric infectious disease physicians from NICU A and B. Algorithms for empiric and targeted antimicrobial therapy for common pathogens and common clinical scenarios using local antimicrobial susceptibility patterns were developed. The CDS tool also provided additional components to facilitate antimicrobial prescribing, e.g., patient weight, day of life, previous culture results, antimicrobial orders, and selected laboratory results including white blood cell and platelet count, C-reactive protein, creatinine, and therapeutic drug levels. NICUs A and B also received E+
1485348|NCT03079245|Other|Prescriber Audit and Feedback|The prescriber audit and feedback (PAF) intervention was developed by the study team which held focus groups with neonatologists at NICU A (the site randomized to this intervention) to determine the feedback parameters and feedback format as previously described. Neonatologists at NICU A were provided aggregated prescribing data bimonthly that described inappropriate use as described below and prolonged therapy (>7 days) for culture-negative late onset sepsis. NICU A also received CDS and E+.
1485349|NCT03079232|Device|OCTAV|In vivo skin imaging performed by placing the tip of the OCTAV device directly in slight contact with the skin of the patient.
1485350|NCT03079219|Drug|Experimental drug: Aprepitant|Day 1: 125mg QD; Day 2 to Day 3: 80mg QD
1485351|NCT03079219|Drug|Experimental drug: Ondansetron|Day 1: 8mg BD
1485352|NCT03079219|Drug|Experimental drug: Dexamethasone|Day 1: 12mg QD
1485353|NCT03079219|Drug|Experimental drug: Olanzapine|Day 1 to Day 5: 10mg QD
1485354|NCT03079219|Drug|Standard: Aprepitant|Day 1: 125mg QD, Day 2 to Day3: 80mg QD
1485355|NCT03079219|Drug|Standard: Ondansetron|Day 1: 8mg BD
1485356|NCT03079219|Drug|Standard: Dexamethasone|Day 1: 12mg QD ; Day 2 to Day 3: 4mg BD
1485357|NCT03079206|Diagnostic Test|Food challenge|food challenge with hazelnut
1485358|NCT03079206|Diagnostic Test|skin testing|Skin testing with hazelnut extract
1485359|NCT03079206|Diagnostic Test|blood sampling|blood sampling to perform basophile activation tests
1485360|NCT03079180|Other|Strength training at 80% 1RM|Detailed in Arms section's
1485361|NCT03079180|Other|Strength training at 55% 1RM|Detailed in Arms section's
1485362|NCT03079167|Drug|Epoetin Alfa|
1485363|NCT03079167|Drug|Normal saline|
1485364|NCT03079154|Other|Teacher-led MBCT course|9 x 2 hour group sessions following national guidelines for mindfulness-based cognitive therapy
1485365|NCT03079154|Other|Self-guided MBCT course|9 weeks of self-guided mindfulness-based cognitive therapy, following an audiobook covering the same material and exercises as the teacher-led intervention
1485366|NCT03079141|Drug|Eplerenone|"Patients will receive 25 milligrams oral eplerenone once daily for a week, and - when no abnormalities during blood testing for potassium and renal clearance can be detected both before treatment and during the first week of treatment - will receive 50 milligrams oral eplerenone for another 11 weeks thereafter.
When patients are randomized to the eplerenone arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, eplerenone treatment can be initiated in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after PDT treatment."
1485367|NCT03079141|Other|Photodynamic therapy|"In the PDT treatment arm, all patients will receive an intravenous drip through which half-dose (3 mg/m2) verteporfin (Visudyne®) is administered, with an infusion time of 10 minutes. At exactly 15 minutes after the start of the infusion, PDT laser treatment is performed with standard 50 J/cm2 fluency, a wavelength of 689 nm, and a treatment duration of 83 seconds.
When patients are randomized to the PDT arm of this study, they will receive this treatment as a first cCSC treatment. Moreover, PDT can be performed in patients in whom SRF is still present on OCT at the Evaluation Visit at 3 months after the start of eplerenone treatment."
1485368|NCT03079128|Behavioral|Intervention|Weight Watchers Intervention
1485369|NCT03079115|Drug|High-dose Atorvastatin|high-dose Atorvastatin (80 mg QD from 3 days before to 3 days after CAS, and thereafter 20mg QD until 30 days after CAS)
1485370|NCT03079115|Drug|Conventional-dose Atorvastatin|conventional-dose Atorvastatin(20 mg QD from 3 days before to 30 days after CAS).
2001124|NCT03192345|Biological|SAR439459|"Pharmaceutical form: powder for solution for infusion
Route of administration: intravenous infusion"
2001125|NCT03192345|Drug|REGN2810|"Pharmaceutical form: solution
Route of administration: intravenous infusion"
1485373|NCT03079089|Drug|Sequential Packaging (SET)|Sequential chemotherapy: - Thiotepa 5 mg/kg/day for 1 day (D-13) -Cyclophosphamide 400 mg/m²/day for 4 days (J-12 to J-9)- Etoposide 100 mg/m²/day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)-Fludarabine 30 mg/m²/day for 5 days (J-5 to D-1)- Busulfan IV 3.2 mg/kg/day for 2 days (J-5 and J-4)- Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)
1485374|NCT03079089|Drug|Transfusion graft|Graft of peripheral stem cells is preferred at DO
1485375|NCT03079089|Drug|Prevention of GVHD|"Cyclophosphamide 50mg/ kg/day on days D + 3 and D + 5 - Cyclosporine A (CSA; 3 mg / kg / day IV from D+6)
Mycophenolate mofetil (MMF; 30 mg/kg/ day, maximum x2 1g / day from day J+6)"
1485376|NCT03079089|Drug|Care supports|According to the protocols of each center
1485377|NCT03079089|Drug|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90
- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade> II."
1485378|NCT03079076|Drug|Bupivacaine|20 ml %0,25 bupivacaine bilaterally
1485379|NCT03079076|Drug|Saline|2 ml saline subcutaneously bilaterally
1610423|NCT02159352|Drug|Ritonavir|
1485380|NCT03079063|Biological|Eptacog alfa, biosimilar and reference medicinal product Novoseven|Either a single dose of eptacog alfa biosimilar 30 μg/kg and one single dose of NovoSeven 30 μg/kg, or vice versa, with doses separated by a washout period. Then, in an open follow up phase of 12 months, for every bleeding episode eptacog alfa biosimilar 30 μg/kg, on demand, for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
1485381|NCT03079063|Biological|Eptacog alfa biosimilar|Additional patients will receive eptacog alfa biosimilar, on demand, for treatment of every bleeding episode in a 12 months period, at dose 30 μg/kg for one of more days until resolution of bleeding, based on the Investigator's decision - or - prophylaxis with eptacog alfa biosimilar, with dose, frequency, and duration of treatment based on the Investigator's decision. The modality of treatment (on demand or prophylaxis) will be decided by the Investigator.
1485382|NCT03079050|Drug|Dexlansoprazole 60 MG|This drug will be given to 34 random patients during the 2nd, 3rd, and 4th weeks of the month of Ramadan to assess its ability to relieve GERD symptoms
1485384|NCT03079024|Behavioral|Neuroadaptive cognitive training|TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). [Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
1485385|NCT03079011|Drug|Palbociclib 125mg|Palbociclib 125 mg once daily for 21 days followed by 7 days off to complete a 28-day cycle
1485386|NCT03079011|Drug|Aromatase Inhibitors|Letrozole: 2.5 mg once daily on a continuous scheme (tablets, per os) Anastrozole:1 mg once daily on a continuous scheme (tablets , per os) Exemestane: 25 mg once daily on a continuous scheme (tablets, per os)
1485387|NCT03079011|Drug|Fulvestrant Injectable Product|500 mg by intramuscular injection on days 1 and 15 of cycle one and then on day one of each subsequent cycle (28 days)
1485388|NCT03078998|Device|Leap Motion Based Exercises|Game based exercise
1485389|NCT03078985|Procedure|ablation for typical atrial flutter|Typical atrial flutter is treated by catheter ablation.
1485390|NCT03078985|Device|catheter ablation with study device|The study device is used inside the MRI environment to localize the cavotricuspid isthmus (CTI). The CTI is then treated with radiofrequency energy to achieve complete isthmus block.
1485391|NCT03078959|Other|immunohistochemistry|Samples will be stained using the SP263 antibody clone against PD-L1
1485392|NCT03078946|Drug|Dexmedetomidine Hydrochloride|30 patients received a loading dose of 1 μg/kg dexmedetomidine (Precedex; Hospira, Precedex 200 mcg/2 ml, Hospira. Inc, Lake Forest, USA) diluted in 100 ml 0.9% saline infused over 10 min immediately postoperative, followed by continuous infusion of 0.2- 0.7 μg/kg/h
1485393|NCT03078946|Drug|Morphine and Midazolam|30 patients received morphine in a dose of 10-50μg/ kg/hr as an analgesic (Morphine Sulphate ampoule; 10 mg/ 1ml, Misr Co.- Egypt) with midazolam in a dose of 0.05mg/kg up to 0.2 mg/kg (Dormicum; Roche; USA; ampoule containing 15 mg/3 ml mixed in sugar-free apple juice limiting the total volume mixed with a double volume of apple juice) repeated as needed.
1485394|NCT03078933|Device|Standard of Care|Standard of Care arm which includes wound care, dressings and debridement.
1485395|NCT03078933|Device|Nitric Oxide Therapy 2x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
1485396|NCT03078933|Device|Nitric Oxide Therapy 2x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound twice a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
1485397|NCT03078933|Device|Nitric Oxide Therapy 4x week 6 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 6 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
1485398|NCT03078933|Device|Nitric Oxide Therapy 4x week 12 min. plus standard of care|Active Therapy Nitric Oxide delivered topically to the wound four times a week for 12 minutes plus standard of care. Standard of care includes wound care, dressings and debridement.
1485399|NCT03078920|Device|Naída CROS|At fitting Naída CROS and a loaner Naída CI processor are used for the duration of the study. The fitting software allows to enable a HIBAN link between the CI processor and the Naída CROS. The fitting of the CI processor is based on the clinical programming of the subject. No changes are made to the fitting parameters unless the subject requests changes. The fitting is done according to the clinical routine. The Naída CROS is pre-configured to communicate with the Naída CI when switched on.
1485400|NCT03078907|Drug|Selexipag|Film-coated tablets for oral use; one tablet (200 mcg) to eight tablets (1600 mcg) are administered depending on the individual tolerability.
1485401|NCT03078907|Drug|Placebo|Matching film coated tablets
1485402|NCT03078894|Diagnostic Test|Zika|Zika Diagnostic test
1485403|NCT03078894|Diagnostic Test|Chikagunya|Chikagunya Diagnostic test
1485404|NCT03078894|Diagnostic Test|Dengue|Dengue Diagnostic test
1485405|NCT03078868|Device|Magnetic Resonance Scanner|MRI
1485409|NCT03078842|Dietary Supplement|Zinc tablets, 20 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 20 mg of zinc
1485410|NCT03078842|Dietary Supplement|Zinc tablets, 10 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 10 mg of zinc
1485411|NCT03078842|Dietary Supplement|Zinc tablets, 5 mg per day|Participants will receive rehydration, dietary counseling, and 1 tablet per day for 14 days of zinc-tablets, each of which contains 5 mg of zinc
1485412|NCT03078829|Drug|Treatment with a GnRh agonists|All patients will be treated with GnRH agonists
1485413|NCT03078816|Device|Activa PC Primary Cell Neurostimulator - (Model 37601)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
1485414|NCT03078816|Device|Activa RC Rechargeable Neurostimulator - (Model 37612)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
1485415|NCT03078816|Device|Activa SC Single Cell Neurostimulator (Models 37602/37603)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
1485416|NCT03078816|Device|DBS Lead - (Model 3387|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
1485417|NCT03078816|Device|DBS Extension - (Models 37085/6)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
1485418|NCT03078816|Device|Patient Programmer - (Model 37642)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
1485419|NCT03078816|Device|Test Stimulator - (Model 3625)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
1485420|NCT03078816|Device|N'Vision Clinician Programmer - (Model 8840)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
1485421|NCT03078816|Device|N'Vision Software Application Card - (Model 8870)|Deep Brain Stimulator system will be implanted using standard neurosurgical techniques. The device will deliver constant stimulation to the thalamus using settings programmed by study team.
1485422|NCT03078803|Biological|Fecal Microbiota Transplant (FMT)|FMT delivered by colonoscopy and oral capsules
1485423|NCT03078803|Biological|Placebo|Transfer of water only
1485425|NCT03078777|Drug|Fexofenadine|Fexofenadine will be administered to patients.
2001132|NCT03190369|Drug|Hylan G-F 20 (GZ/SAR402662)|"Pharmaceutical form: Solution for injection
Route of administration: Intra articular"
2001133|NCT03190369|Drug|Placebo|"Pharmaceutical form: Solution for injection
Route of administration: Intra articular"
2001134|NCT03187639|Diagnostic Test|FFRct|In the test group all patients who are eligible for CTA will undergo CTA as their default test. Those patients with any coronary stenosis of equal or > 40% data in at least one major epicardial vessel of stentable/graftable diameter will be referred for FFRct. (NB Lesions in distal vessels or vessels of a diameter not suitable for stenting/grafting will not qualify for FFRct if there are no other more significant lesions). In patients in whom FFRct analysis is performed, FFR will be derived for all vessels. The data derived from this test will determine their management strategy. The patients in this arm will not follow the NICE guideline algorithm. Those patients randomised to FFRct with contraindications for CTA will be asked to take part in a trial registry.
1485431|NCT03078738|Drug|OMT-28|OMT-28 is a fully synthetic small molecule that belongs to the family of 17,18-epoxyeicosatetraenoic acids (17,18-EEQ) analogs, a natural metabolite of the omega-3 fatty acid eicosapentaenoic acid (EPA).
1485432|NCT03078738|Other|Matching Placebo|Microcrystalline cellulose
1485433|NCT03078725|Drug|Glyburide|oral hypoglycemic agent
1485434|NCT03078725|Drug|Metformin|oral hypoglycemic agent
1485435|NCT03078712|Other|Peripheral Perfusion guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to peripheral perfusion.
1485436|NCT03078712|Other|Lactate guided resuscitation|Sequential approach with fluids (guided by dynamic predictors of fluid responsiveness), vasopressors titration, and inodilators according to lactate decrease.
1485437|NCT03078699|Radiation|stereotactic body radiation therapy|A total radiation dose of 35-50 Gy was delivered to the 50% isodose line covering at least 95% of the PTV (3.5-5Gy/fraction), and a total radiation dose of 49-70 Gy was delivered to the 70% isodose line covering at least 95% of GTV (4.9-7 Gy/fraction).
1485438|NCT03078686|Procedure|tSVF by lipoaspiration|Lipoaspiration Harvest tSVF closed syringe microcannula harvest, Tulip GEMS microcannula syringe system
1485439|NCT03078686|Procedure|PRP Concentration|Preparation of High Density PRP Centrifugation per manufacturer directive, Emcyte II PurePRP System
1485440|NCT03078686|Procedure|Emulsification tSVF|Preparation of emulsified tSVF harvested adipose; Use of ACM Device; Micronization of tSVF through Sterile Screen
1485441|NCT03078686|Procedure|cSVF isolation and concentration|Healeon Centrifuge (CC1000) enzymatic digestion, incubation, isolation and neutralization to prepare cSVF concentrates
1485442|NCT03078686|Procedure|cSVF in Normal Saline IV|cSVF + NS for IV Placement
1485443|NCT03078673|Other|training intervention, motor skill training|cross country specific motor skill strength training
1485444|NCT03078673|Other|training intervention, maximal strength training|general maximal strength training
1485445|NCT03078673|Other|control group|regular training
1485446|NCT03078660|Behavioral|Smartphone Application|The smartphone Application generates a shopping list for participants, based on a low caloric diet (energy requirements minus 500 kcals), taking into consideration the Dietary Guidelines for Americans' recommendations and also considering the available budget for each shopping event and the weekly discounts from major supermarkets.
1485475|NCT03078426|Other|Thoracic HRCT (standard reference)|It will be performed on a 16 (Sensation 16, Siemens®) or 64 channels (Definition 64, Siemens®), without contrast agent injection.
1485447|NCT03078660|Behavioral|Traditional Nutritional Counseling|Participants will have a face-to-face counseling session with a registered dietitian, who will provide recommendations for a low caloric diet (energy requirements minus 500 kcals) using the food group sheets from the Dietary Guidelines for Americans.
1485448|NCT03078647|Device|Profound|The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
1485449|NCT03078634|Other|Multi-disciplinary clinic model|Clinic model incorporating multiple disciplines for the treatment of functional gut disorders. Disciplines include: gastroenterologists, psychiatrists, psychologists, hypnotherapists, behavioural therapists and dieticians. End of clinic case conference involving clinical disciplines will also occur to coordinate care.
1485450|NCT03078634|Other|Standard outpatient care|Standard care provided in outpatient clinics staffed by GI doctors only
1485451|NCT03078621|Biological|Stem Cell Therapy|Intravenous and Intrathecal transplantation of purified autologous bone marrow-derived stem cells and mesenchymal stem cells.
1948838|NCT01472965|Drug|heparin-saline placebo|heparin-saline placebo catheter lock therapy
2010603|NCT02920034|Device|Ultrasound denervation of the main renal arteries|Catheter based renal sympathetic denervation of the main renal arteries using the Paradise™ Catheter (ReCor Medical, CA, USA)
1485454|NCT03078582|Drug|RA101495|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
1485455|NCT03078569|Drug|Testosterone gel|treatment with testosterone gel
1485456|NCT03078556|Drug|Dolutegravir|Single dose of DTG 50 mg tablet along with 3TC (EPIVIR) tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water. DTG will be a white, film coated, round tablet engraved with SV 572 on one side and 50 on the other side.
1485457|NCT03078556|Drug|Lamivudine|"Single dose 3TC (commercial name: EPIVIR) 300 mg tablet along with DTG tablet will be given to randomized subjects in parts 1 and 2 with 240 mL of room temperature water.<br>3TC will be gray, diamond shaped tablet, engraved GX EJ7 on one side and plain on the other side."
1485458|NCT03078556|Drug|Dolutegravir + Lamivudine FDC Formulation 1|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 1 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) of Part 1 and the first 16 subjects in treatment period 3 (under fed) of Part 1 with 240 mL of room temperature water. &lt;br&gt;FDC formulation 1 tablets will be oval, biconvex, white, film coated tablet engraved 'SV H7I' on one face.
1485459|NCT03078556|Drug|Dolutegravir + Lamivudine FDC Formulation 2|Single dose of DTG 50 mg combined with 3TC 300 mg in a FDC formulation 2 tablet will be administered to randomized subjects in treatment periods 1 and 2 (under fasted state) and the first 16 subjects in treatment period 3 (under fed) of Part 2 with 240 mL of room temperature water. &lt;br&gt;FDC formulation 2 tablets will be oval, biconvex, white, film coated tablet engraved 'SV 13N' on one face.
1485460|NCT03078543|Device|ANTHEM™ Total Knee System implant|"The ANTHEM™ Total Knee System is a comprehensive system which allows surgeons to address simple to complex knee arthroplasties. The ANTHEM™ Total Knee System consists of the following components:
Cobalt-Chrome (Co-Cr) femoral components
Titanium primary tibial components
Posterior-stabilised cross-linked polyethylene tibial inserts
Polyethylene patella components The resulting product is sufficient to accommodate a wide range of clinical applications."
1485461|NCT03078530|Drug|Placebo|This is a pill with inactive ingredients
1485462|NCT03078530|Drug|Visbiome|This is a probiotic mixture
1485463|NCT03078517|Device|I-gel|After the induction of anesthesia, i-gel is inserted along the palatopharyngeal curve.
1485464|NCT03078517|Device|Laryngeal mask airway protector|After the inudction of anesthesia, laryngeal mask airway protector is inserted along the palatopharyngeal curve, and the cuff is inflated.
1485465|NCT03078504|Device|continuous renal replacement therapy using System One (TM) setup (Nxstage)|Participants who have been prescribed continuous renal replacement therapy will have hemodynamic parameters measured at various blood flow rates
1485466|NCT03078491|Other|eCGM (enhanced CGM)|Glucose (CGM and Bluetooth BG meter), insulin (pump or Bluetooth insulin pen) and activity data will be automatically uploaded via the subjects' tablet computers, and analyzed by the CDS. The CDS will, if indicated generate adjustable insulin dosing recommendations that will compensate for different insulin requirements following high vs low activity days. The recommendations of the CDS will be used by the clinical team in their therapeutic decision-making about insulin dosing adjustments at the scheduled study follow up visits and the remote visits between these in-person visits. In addition, study staff will provide recommendations regarding hypoglycemic warning symptoms, causes, and appropriateness of treatment.
2010604|NCT02919371|Drug|Sunitinib|Oral therapy ( Anti-vascular endothelial growth factor Tyrosin Kinase Inhibitor): given as 50 mg daily from day 1 to day 28- cycle repeated every 42 days
1485469|NCT03078465|Drug|Ticagrelor|Daily administration of ticagrelor 180mg for 12 months
1485470|NCT03078465|Drug|Clopidogrel|Daily administration of clopidogrel 150mg for 12 months
1485471|NCT03078452|Device|Power drill|Undergo bone marrow biopsy using power drill
1485472|NCT03078452|Device|Jamshidi needle|Undergo bone marrow biopsy using Jamshidi needle
1485473|NCT03078439|Other|Medical and neuropsychological assessments|"Assessment of health status and development will be performed in specific centers at 5 and a half years. This check-up includes a complete medical examination to look for visual, hearing, motor impairment and health problems, and psychological tests using standardized tools (WPPSI IV ((Wechsler Preschool and Primary Scales Intelligence)) and NEPSY 2 tests) to assess cognitive development of very preterm children.
A parental questionnaire will be fulfilled to investigate family's social conditions, maternal health, autism spectrum disorders (Social Communication Questionnaire), the child's quality of life and behavioral development (Strengths and Difficulties Questionnaire)."
1485474|NCT03078426|Device|MRI|It will be performed on a 1.5-Tesla MR scanner (MAGNETOM Avanto, Siemens Healthcare, Erlangen, Germany). Acquisitions will be obtained in the axial plane using a 12-channel thorax/spine coil. Investigators will use previously published sequence parameters for each MRI sequence. PETRA will be acquired under free-breathing with respiratory gating at functional respiratory capacity.
1485476|NCT03078400|Drug|SPL-108|Subcutaneous injection of 150 mg administered either one time or two times per day.
1485479|NCT03078361|Other|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Both intervention groups will receive an I-FOBT kit (by study coordinator) with verbal and written instructions in Spanish on how to complete the stool sampling at home within 1 week, and mail the completed kit in the pre-addressed, postage paid mailer. Patients with abnormal results will receive a call explaining the meaning of an abnormal I-FOBT and encouraging them to take specific next steps.
1485480|NCT03078361|Behavioral|LATINOS CARES Toolkit|DVD + photonovella booklet), about colorectal cancer screening (CRCS) targeted for a Latino medically underserved population.
1485481|NCT03078361|Behavioral|Standard Intervention|Standard intervention (CDC brochure) on colorectal cancer screening in community health clinics.
1485482|NCT03078348|Other|Fecal Immunochemical Test (FIT) Kit|Free FIT Kits distributed at study entry.
1485483|NCT03078348|Behavioral|Culturally targeted Photo Novella Booklet|Culturally targeted Photo Novella Booklet + culturally targeted reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
1485484|NCT03078348|Behavioral|Screen for Life Brochure|Screen for Life Brochure + standard reminders. Print materials developed by the Centers for Disease Control and Prevention (CDC)) to provide information about CRC, importance of screening and available screening tests. Timed reminder letters and/or emails intended as a cue to action and as educational boost to facilitate participant screening decision making and screening uptake.
1485485|NCT03078335|Other|Glove based care|Described in Experimental Arm: Glove based care
1485486|NCT03078335|Other|Standard of Care - Hand Hygiene|Hand Hygiene - hand washing with soap and water, or alcohol based hand rub
1485487|NCT03078322|Drug|AV-101|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
1485488|NCT03078322|Drug|Placebo|Oral capsules taken once daily (in addition to open-label treatment with a commercially available antidepressant)
1485489|NCT03078309|Drug|cannabis|single dose sublingual cannabis (THC:CBD 1:1, THC:CBD 1:40)
1485490|NCT03078296|Other|survey respondents|all survey participants will be asked to complete a questionnaire
1485491|NCT03078283|Other|high-fiber food type|In 3 successive experiments, usual diet will be supplemented with snack foods containing fiber of plant, fruit or grain origin.
1485494|NCT03078257|Drug|tirofiban in PV|"a loading dose of 10ug/kg tirofiban is given in 3 min through PV,followed by a maintenance dose of 0.15ug/kg*min for 48h.
(clopidogrel 600 mg+aspirin( ASA) 300 mg)x1 day."
1485495|NCT03078257|Drug|tirofiban in IC|"a loading dose of 10ug/kg tirofiban is given in 3 min through IC,followed by a maintenance dose of 0.15ug/kg*min for 48h.
(clopidogrel 600 mg+ ASA 300 mg)x1 day."
1485496|NCT03078257|Drug|antiplatelet thrombolysin|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.
(clopidogrel 600 mg+ ASA 300 mg)x1 day."
1485497|NCT03078257|Drug|placebo|"a loading dose of 5 IU/60kg in 5 min through PV,followed by a maintenance dose of 0.002 IU/kg/h for 48h.
(clopidogrel 600 mg+ ASA 300 mg)x1 day."
1485498|NCT03078257|Drug|Clopidogrel|loading dose of 300 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
1485499|NCT03078257|Drug|Aspirin|loading dose of 300 mg aspirin followed by a maintenance dose of 100 mg/d for at least 5 days.
1485500|NCT03078257|Drug|Clopidogrel|loading dose of 600 mg clopidogrel followed by a maintenance dose of 75 mg/d for at least 5 days
1485501|NCT03078244|Other|N/A, observational study|
1485502|NCT03078231|Procedure|Color fundus photography|Subjects will undergo fundus photography before and after administration of mydriatic agent.
1485503|NCT03078231|Drug|Mydriatic Agent|Subjects will be administered mydriatic medication to dilate their pupils.
1485504|NCT03078218|Diagnostic Test|Pulse oximetry|The tool evaluated will be the assumption of peripherical arterial oxygen saturation by pulse oximetry. The pulse oximetry will identify hypoxemic CCHD and hypoxemic non-cardiac disease before discharge.The test will be realised before 24 hours of life in a newborn aged at least of 35 weeks of gestation.
1485505|NCT03078205|Other|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
1485506|NCT03078205|Other|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
1485507|NCT03078192|Drug|GE-141, Hyperpolarized 129Xenon gas|XeMRI scans will provide 3D images of ventilation and gas exchange. Subjects will inhale HP 129Xe from the dose delivery bags. Then the subject will be moved into the scanner and they will undergo basic 1H localizer and anatomical scans. Once localization is complete, subjects will under-go several MRI scans after inhalation of HPXe
1485508|NCT03078192|Device|MRI|Perform MRI scans with administration of GE-141, Hyperpolarized 129Xenon
1485509|NCT03078179|Dietary Supplement|Commercial Cow Milk with Probiotic|The children will initiate the milk intake with probiotic one week after having ingested the milk without probiotics.They will drink the milk with probiotic during 3 months. Clinical and microbiological testing of saliva will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and desmineralization in early Stage Decay and Established decay tooth (according ICDAS) and quantification of Streptococci of the mutans group.
1485510|NCT03078179|Dietary Supplement|Commercial Dairy Cow Milk|After obtaining parent´s informed consent and the baseline examination, from 3 to 5 years old, will start commercial dairy cow milk intake without probiotic (placebo) during 3 months. Clinical and microbiological testing of saliva at baseline and at the end will be performed. Differences in salivary pH (before and after a sugar solution), remineralization and desmineralization in early Stage Decay and Established decay tooth (according ICDAS) and quantification of Streptococci of the mutans group.
1485511|NCT03078153|Behavioral|Financial Incentive|Participants will receive a $50 gift card at 3- and 6- month follow-up visits.
1485512|NCT03078153|Behavioral|Social Media Group|Participants will be invited to a study Facebook group which will have links to PrEP information and provide a forum for participants to ask questions and communicate their experience with PrEP
1485513|NCT03078140|Dietary Supplement|Triferdine|Triferdine 1 tablet daily Start from 14 weeks of gestation until delivery
1485514|NCT03078140|Dietary Supplement|Triferdine/Ferli-6|"For the participants assigned to this group, urine iodine level will be checked first.
For participants with normal urine iodine level, Ferli-6 1 tab daily will be given.
For those with low urine iodine level, Triferdine 1 tab daily will be given. Medication will be started from 14 weeks of gestation until delivery."
1485515|NCT03078127|Other|Huff-Cough alone|"Subjects will provide two huffs (forced expiratory maneuver with open glottis) followed by a cough every six minutes for a total of six Huff-Coughs."
1485516|NCT03078127|Device|Oscillatory Positive Expiatory Pressure Device|Subjects will use an Areobika® branded OPEP device (10 breaths through highest tolerated resistance) prior to undergoing a Huff-Cough. Subjects will use the device six times every six minutes.
1485517|NCT03078127|Device|Whole-Body Vibration Platform|Subjects will be seated on a PowerPlate® whole-body vibration platform for 90 seconds prior to Huff-Cough. Six intervals on the platform will be completed six minutes apart.
1485518|NCT03078127|Device|High Frequency Chest Wall Oscillatory Vest|"Subjects will use TheVest® using a standardized Minnesota Protocol divided into six, four-minute segments, each followed by a Huff-Cough."
1485519|NCT03078114|Other|Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to manipulate the spine.
1485520|NCT03078114|Other|Placebo Spinal Manipulation|The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to simulate manipulating the spine.
1485521|NCT03078101|Drug|Empagliflozin 10 MG [Jardiance]|administered orally once daily
1485522|NCT03078101|Drug|Placebo Oral Tablet|administered orally once daily
1485523|NCT03078088|Drug|Tham|alkalinizer
1485524|NCT03078088|Drug|Saline|Placebo
1485525|NCT03078075|Drug|Active Medication Combination (AMC)|Naltrexone: 380 mg vial, 4 intramuscular injections administered every 3 weeks ; Bupropion: 450 mg oral dose daily
1485526|NCT03078075|Drug|Placebo (PLB)|injectable matching placebo plus once-daily oral placebo tablets
2001135|NCT03187639|Diagnostic Test|Standard care|All patients in the standard care group will be assessed according to their current conventional pathways that are based upon NICE guidelines for Chest Pain of Recent Onset. The trial will encourage the routine and standard assessment and management of all patients at these sites… (anticipated outcomes include ETT, stress echo, stress MR, nuclear perfusion, CTA, CT calcium, invasive CA, reassurance), in accordance with the local application of the NICE guideline for chest pain of recent onset.
2001136|NCT03186495|Drug|Somapacitan|All subjects will receive three (0.08 mg/kg) consecutive once-weekly s.c. (under the skin) administrations of somapacitan
2001137|NCT03187106|Drug|Cephalexin|Other name(s): Keflex (cephalexin) Cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
2001138|NCT03187106|Drug|Placebo|Placebo representing standard of care
2001139|NCT03187106|Drug|Metronidazole|Other name(s): Flagyl (metronidazole) Metronidazole at 500 mg per oral every 8 hours for a total of 6 doses
1485532|NCT03078023|Device|swallowed sponge device|Swallowed sponge: Subjects having a clinical upper endoscopy will be asked to swallow the sponge 2 hours prior to EGD
1485533|NCT03078010|Drug|Piperacillin-tazobactam|piperacillin-tazobactam (4.5 gm IV q 6 hrs)
1485534|NCT03078010|Drug|cefepime|(2 gm IV q 8 hrs)
1485535|NCT03077997|Behavioral|Space from Diabetes|Space from Diabetes is an internet-delivered cognitive behaviour therapy-based programme for symptoms of depression, anxiety, & diabetes distress in people with type 2 diabetes mellitus.
1485536|NCT03077984|Combination Product|Chinese medicine treatment|The cohort of Chinese medicine treatment uses its comprehensive program of TCM on the basis of treatment with western medicine, including Chinese Herbs, acupuncture and acupoint application therapies.
1485537|NCT03077971|Behavioral|ACT Self-Help|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach
1485538|NCT03077971|Behavioral|ACT Self-Help with Telephone Support|Self-Help Intervention Workbook using an Acceptance and Commitment Therapy approach alongside weekly telephone support calls
1485539|NCT03077958|Procedure|Total Knee Replacement (2 different design)|Patients will randomely receive either Attune or PFC Sigma TKR
1485540|NCT03077945|Behavioral|heart rate variability biofeedback and cognitive reappraisal|
1485541|NCT03077945|Behavioral|control tasks|
1485542|NCT03077932|Other|App Development and Open Pilot|"Other: App Development and Open Pilot Phase 1 (app development) will consist of: 1) development of the BetterOFF prototype; and 2) series of usability studies with patients with OUDs.
Phase 2 (open pilot) will involve conducting a 4-week open pilot trial (n=50) to test the feasibility and acceptability of the BetterOFF app with patients tapering from opiate replacement therapy"
1485543|NCT03077919|Drug|Ropivacaine|0.5% ropivacaine
1485544|NCT03077919|Drug|Sham treatment|preservative-free normal saline
1485545|NCT03077906|Other|Medical Files data extraction|Medical Files data extraction
1485546|NCT03077893|Device|Active Provant Therapy System|Treatment with active Provant Therapy System
1485547|NCT03077893|Device|Inactive (sham) Provant Therapy System|Treatment with Inactive (sham) Provant Therapy System
1485548|NCT03077880|Procedure|intra-operatory measurement during implant placement|mucoperiosteal flap, soft tissue thickness measurement, implant insertion
1485549|NCT03077867|Procedure|sinus floor augmentation with bone graft|sinus floor augmentation with lateral approach with bone graft
1485621|NCT03077412|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
2010605|NCT02919371|Drug|Bevacizumab|Monoclonal antibody against vascular endothelial growth factor: given intravenously on day 29 of each sunitinib cycle
2010606|NCT02917941|Drug|Ixazomib 4.0 mg, lenalidomide 25 mg, dexamethasone 40 mg|Patients will receive study drug (ixazomib 4.0 mg) on Days 1, 8, and 15 plus lenalidomide (25 mg) on Days 1 through 21 and dexamethasone (40 mg) on Days 1, 8, 15, and 22 of a 28-day cycle.
2010607|NCT02917798|Behavioral|Assessments|
2010608|NCT02917902|Other|Food boxes|Box of approximately 50 pounds of nutritious foods provided by food pantry, including fresh fruits and vegetables as well as shelf-stable items selected for diabetic patients, along with brief education provided by food pantry staff.
1485550|NCT03077854|Radiation|Functional Lung Avoidance Thoracic Radiotherapy|"Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)
Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)
Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
1485551|NCT03077854|Radiation|Standard Thoracic Radiotherapy|"Chemoradiation for non-small cell lung cancer: 60 Gy in 30 once-daily fractions (Dose reduction to 54 Gy in 30 once-daily fractions is allowed)
Radiation alone for non-small cell lung cancer: 60 Gy in 25 once-daily fractions (Dose reduction to 55 Gy in 25 once-daily fractions is allowed)
Chemoradiation for small-cell lung cancer: 45 Gy in 30 twice-daily fractions"
1485552|NCT03077841|Radiation|External Radiation Therapy|Prescription dose is 35 Gy in 10 daily fractions delivered on consecutive treatment days. A treatment day is defined as a normal business day, typically Monday - Friday excluding institutional holidays. A 3 Gy in 3 fraction boost should be delivered if a close (less than 2 mm) margin is present and should not be delivered if margins are negative at a minimum of 2 mm or greater.
1485553|NCT03077841|Behavioral|Questionnaires|Questionnaires completed at baseline, and at 6 months and 1, 2, 3, 4, and 5 years after receiving radiation. Questionnaires ask about how participant's breast currently looks and feels. It should take about 10 minutes to complete the questionnaires.
1485559|NCT03077815|Other|Systematically intermittent arm exercise|While holding a rubber ball for 5 minutes a day, together with strappy elastic compression arm veinElastic bandages defined for using this research provides of standard bandages, according to research personnel Guide, reached hand elbow near heart end 4 (2~6) cm at of arm local pressure strong 50 mm-Hg (+/-10 mm-Hg) (about equivalent to provides pressure strong 6.67 thousand PA (kPa), also about equivalent to 0.97 PSI (pound per square inch)), to reached 5 minutes arm movement Shi short reduced vein return, promotion pathway vein extended of effect
1485560|NCT03077802|Other|Modified Seldinger Techniques|This is a technique for central venous catheterization. Use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel. This technique is performed under ultrasound guidance. Long axis or short axis approach was chosen at the discretion of anesthesiologist's decision.
1485561|NCT03077802|Other|Seldinger Techniques|This is a technique for central venous catheterization. The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel. This technique is performed under ultrasound guidance. Long axis or short axis approach was chosen at the discretion of anesthesiologist's decision.
1485562|NCT03077789|Procedure|TRABECULOTOMY|Evaluation of the prognosis of different surgery in congenital glaucoma
1485566|NCT03077763|Drug|Sodium Nitrite|
1485569|NCT03077737|Behavioral|Choose to Change|Population-based letter outreach automated via the electronic health record system and text messaging targeted to low-income smokers. Paired with automated electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy).
1485570|NCT03077737|Behavioral|Enhanced usual care|Enhanced usual care based on Ask, Advise and Refer in which an electronic referral for proactive quitline treatment (behavioral counseling plus nicotine replacement therapy) is made during a clinic visit.
1485571|NCT03077724|Drug|Fish oil|Fish oil supplementation
1485572|NCT03077724|Drug|Placebos|Olive Oil capsules
1485573|NCT03077711|Drug|Trimethoprim|suppressive antibiotic. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
1485574|NCT03077711|Drug|Methenamine hippurate|antiseptic used in the prevention of recurrent UTIs. Estrogen cream may be prescribed if the patient is post-menopausal (but not as a part of this study).
1948839|NCT01471522|Procedure|cardiac catheterization|Narrowed blood vessels can be opened without surgery using stents or can be bypassed with surgery. To determine which is the best approach for you the doctor needs to look at your blood vessels to see where the narrowings are and how much narrowing there is. This is done by a procedure known as a cardiac catheterization.
1485579|NCT03077646|Behavioral|Be SMART|An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART
1485580|NCT03077646|Behavioral|Control: TSE|"A video called Kids and Smoke Don't Mix and handouts on tobacco smoke exposure (TSE) developed by the New York state quit-line."
1485622|NCT03077399|Device|SCALA|All items of SCALA are applied
1485876|NCT03075176|Device|Topography-guided LASIK|Topography-guided laser vision correction
1485581|NCT03077646|Behavioral|Be SMART + MD review|"An educational campaign that is non-political reviewing gun safety measures for preventing firearm injuries in children. There is both a video and written materials reviewing the information. The acronym SMART stands for: Secure all guns in your home, Model responsible behavior, Ask about unsecured guns in other homes, Recognize the risks of teen suicide, Tell your peers to be SMART.
After being presented to parents/guardians via video and handouts, this information will be reviewed in person with a Physician."
1485582|NCT03077633|Procedure|Cervical Cerclage placement|Cervical Cerclage placement
1485583|NCT03077633|Drug|Vaginal Progesterone|200mg tab of vaginal progesterone administered daily from time of randomization until delivery.
1948840|NCT01471522|Procedure|coronary artery bypass graft surgery|"Artery narrowing is bypassed during surgery with a healthy artery or vein from another part of the body. This is known as coronary artery bypass grafting, or CABG (said, cabbage). The surgery creates new routes around narrowed and blocked heart arteries. This allows more blood flow to the heart."
1485589|NCT03077594|Device|Mucosal Impedance|Mucosal impedance will be measured by an endoscopic probe 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation.
1485590|NCT03077594|Other|Research Biopsies|Research biopsies will be obtained at 1 cm above the gastroesophageal junction, 5 cm above the gastroesophageal junction, and in the proximal esophagus in an area not exposed to the index therapeutic radiofrequency ablation.
1485591|NCT03077581|Drug|Transevrsus abdominus plane block|a blunt needle was advanced in the midaxillary line to reach the fascial layer between the internal oblique and transverse abdominis muscles detected by facial click sensation. The LA was slowly injected so as to detect any sign of toxicity or incorrect needle tip position (as resistance) requiring needle repositioning then TAPB was repeated on the opposite side.
1485592|NCT03077581|Drug|Rectus sheath block|In RSB group, 2-3 cm from midline, about 3-5 cm above the umbilicus, the needle was advanced at right angle to the skin. The needle reaches the space between the posterior layer of the rectus sheath and rectus abdominis muscle detected by firm resistance of the posterior wall, The LA was slowly injected then the same steps were repeated on the other side.
1485593|NCT03077581|Drug|local anesthesia infiltartion|40 mls of 0.255 bupivacaine will be infiltrated at skin incision
1485594|NCT03077568|Behavioral|My Stress Control|"The web-based program is designed to educate the users in how stress can affect their health, provide tools to handle stress and also educate the users in a problem-solving method to prevent and manage stress-related problems in the future.
The program is tailored for each user. The stress-management techniques included are: assertiveness training, change negative thinking, pleasant activity scheduling, relaxation, time-management, stimulus control and sleep restriction to improve sleep and physical activity.
Central techniques to support behaivor change in My Stress Controll are encourage intention formulation, specific goal-setting, feedback on performance and reevaluation of goals."
1485595|NCT03077555|Drug|Zoely|quick start of combined hormonal contraception containing 1.5 mg estradiol /2.5 mg nomegestrol acetate
1485596|NCT03077555|Drug|Meliane ED|quick start of combined hormonal contraception containing 20 mcg ethinyl estradiol /75 mcg gestodene
1485597|NCT03077542|Procedure|haploidentical stem cell transplant|haploidentical stem cell transplant
1485598|NCT03077542|Drug|sirolimus|conditioning regimen
1485599|NCT03077542|Drug|campath|conditioning regimen
1485600|NCT03077542|Drug|pentostatin|conditioning regimen
1485601|NCT03077542|Drug|cyclophosphamide|conditioning regimen
1485602|NCT03077529|Dietary Supplement|Galacto-oligosacchride|During this period subjects will receive 5.65 grams of Vivinal GOS supplements three times daily for four weeks
1485603|NCT03077529|Dietary Supplement|Maltodextrin|During this period subjects will receive 7.24 grams of maltodextrin supplements three times daily for four weeks
1485604|NCT03077516|Device|Mobi-C|Device for cervical intervertebral disc replacement at one or two contiguous levels
1485605|NCT03077503|Drug|Dexmedetomidine|Dexmedetomidine 1 µg/kg diluted to 20 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
1485606|NCT03077503|Drug|Fentanyl|Fentanyl 1 µg/kg diluted to 2 ml with 0.9% normal saline was administration. If adverse events were occurred, the patient will receive rescue drugs.
1485607|NCT03077503|Drug|0.9% normal saline|0.9% normal saline was use to dilute the study drugs
1485608|NCT03077503|Device|Skull pins|Skull pins were use to stabilized the patent' s head during surgery
1485609|NCT03077490|Device|Transvaginal mesh Uphold TM Vaginal Support System|
1485610|NCT03077490|Device|Transvaginal mesh Uphold TM Vaginal Support System.|
1485611|NCT03077477|Drug|AMXT 1501|Study treatment will be provided in tablet form; each containing 128 mg AMXT 1501 dicaprate salt, 80 mg of which is AMXT 1501 freebase (active drug), plus excipients and are orally administered.
1485612|NCT03077477|Drug|Placebo Oral Tablet|"Reference Therapy, Dose and Route of Administration:
Placebo Tablets, orally administered"
1485613|NCT03077464|Behavioral|Behavioral nutrition education|Education aimed at improving knowledge, attitudes, and practices related to dietary intake, with a focus on impacting theorized mediators of nutrition-related behavior.
1485616|NCT03077438|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate|0.5 mL, Intramuscular
1485617|NCT03077438|Biological|Meningococcal (Groups A, C, Y and W 135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine|0.5 mL, Intramuscular
1485618|NCT03077425|Behavioral|Enhanced Usual Care (EUC)|Per Arm/Group Description, CHWs will provide a pamphlet and dental referral list to participants both groups.
1485619|NCT03077425|Behavioral|Intervention|Per Arm/Group Description, CHWs will a) conduct 6 home visits with mothers/families over a 12 month period along with follow-up phone support, and b) patient navigation support for child to receive 2 dental visits: one by 12 months of age and one by 18 months of age.
1485620|NCT03077412|Drug|Filgotinib|Tablet(s) administered orally once daily
2001143|NCT03185481|Drug|1 mg QD to 15 mg QD PF-06649751|Up titration from 1 mg QD to 15 mg QD PF-06649751
1485624|NCT03077373|Behavioral|Counseling letter|"The brief counseling letter intervention aiming to reduce physical inactivity, sedentary time in leisure time as well as smoking is based on behavior change theories (Transtheoretical model of health behavior change and Health Action Process Approach).
The computerized intervention system includes up to six interactions with participants. Recurrent assessments are initiated by the system and provide data for scheduling the proceeding intervention steps and selection of relevant content. Physical activity, sedentary time, smoking, and motivational measures to change or maintain behaviors according to the recommendations will be monitored over time and used to provide feedback in the form of letters."
1485625|NCT03077360|Behavioral|Lifestyle|Lifestyle changes to lose weight or become more fit
1485626|NCT03077347|Device|Transcranial Direct Current Stimulation|In tDCS, saline-soaked electrodes are temporary affixed to the scalp and connected to a battery-powered current generator. A weak (2 mA) constant current is then briefly applied (~20 minutes) to stimulate the targeted brain area (e.g. the DLPFC). To control for placebo effects, the study will utilize a sham stimulation protocol that consists of very brief constant stimulation (~1 minute). Subjects usually cannot discern the difference between the sham and experimental stimulation protocols due to habituation.
1485627|NCT03077334|Device|PET-CT|PET-CT will be done before operation and that is routine treatment procedure for pancreatic cancer.
1485628|NCT03077321|Behavioral|CARE plus Peer Mentor|A parent who has completed the standard CARE program will be recruited to be a peer mentor. The peer mentor will attend the CARE training for group leaders and will also be trained in motivational interviewing. These skills will then be used strategically in weekly phone discussions between the peer mentor and parent about practicing the CARE parenting skills in the home setting and planning for attending the 6 training sessions. The parent mentor will co-facilitate the CARE groups in the peer mentor arm along with 2 additional CARE therapists. The peer mentor will also call the parents in the peer mentor arm before each session to discuss progress on homework, and to address barriers for program attendance.
1485629|NCT03077321|Behavioral|CARE|CARE involves 6 weekly 90-minute sessions administered to 6-10 parents by 2 therapists. The initial phase focuses on developing parenting skills aimed at increasing attention to children's pro-social behaviors while ignoring minor attention seeking misbehaviors. The second phase teaches techniques for giving children effective commands in order to set age-appropriate limits and increase compliance. Children do not attend the training but parents are expected to practice the skills with their children between sessions.
1485630|NCT03077308|Procedure|Auditory and Visual Event-related Potentials and EEG|Specifically, through up to three standardized sessions (i.e., annual [every 10-14 months]), we will assess AEP and VEP. ERP recordings will also provide data for specific rhythms/band (gamma and alpha) pattern analyses as secondary measures as well as technical control data, which will help to exclude those with co-current seizures.
1485631|NCT03077295|Other|High Fibre|High fibre/carbohydrate (50% CHO, 35% fat and 15% Protein) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Total dietary fibre will be at least 30g/d for 2000kcal intake and provided as a mixed soluble and insoluble fibre sources to maintain palatability of the diet (e.g. wheat bran, fava bean, lentil, buckwheat).
1485632|NCT03077295|Other|High Protein|• High protein diet (30% protein, 35% fat and 35% CHO) with 45% calories at breakfast and 20% evening meal provided and buffet lunch. Protein will be a mixed meat matrix to include poultry, fish, red meat, prawns, eggs, dairy. Total dietary fibre will be no more than 15g/d for 2000kcal intake.
1485633|NCT03077282|Drug|Prasaprohyai|Prasaprohyai 95% ethanolic extract capsules will take three times a day before meals
1485634|NCT03077256|Device|BioBurst Fluid, Burst Allograft|BioBurst Fluid, Burst Allograft in Foot and Ankle Surgery
1485635|NCT03077243|Radiation|Intensity Modulated Radiotherapy (IMRT) - deintensified|60 Gy at 2 Gy/fx
1485636|NCT03077243|Radiation|Intensity Modulated Radiotherapy (IMRT) - standard|70 Gy at 2 Gy/fx
1485637|NCT03077243|Drug|Cisplatin (or alternative) - deintensified|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 6 total doses.
1485638|NCT03077243|Drug|Cisplatin (or alternative) - standard|The acceptable weekly chemotherapy regimens are Cisplatin 30 to 40 mg/m2 (first choice), Cetuximab 250mg/m2 (second choice), Carboplatin AUC 1.5 and paclitaxel 45 mg/m2 (third choice), Carboplatin AUC 3 (fourth choice). Chemotherapy will be given intravenously weekly during IMRT, 7 total doses.
1485639|NCT03077243|Procedure|Assessment for surgical evaluation|Decision for surgical evaluation will be based on the results of the PET/CT and clinical exam 10-16 weeks after CRT. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon. Patients with a negative PET/CT scan will be observed.
1485640|NCT03077230|Behavioral|Pre/Post Test of a Lung Cancer Screening Decision Aid|After completing the baseline survey, the research team member will ask each participant asked to view the lung cancer screening decision aid on a tablet. The following areas regarding lung cancer screening: What is lung cancer?, Why is lung cancer a problem?, What is screening?, What is low-dose CT screening, Recommended frequency of screening, Screening factors, lung cancer risks and benefits (magnitude of benefit, harms, false positive, invasive procedures, radiation, stress/anxiety), Summary, Values Clarification, Screening Choice, and Smoking cessation messaging for current smokers OR positive reinforcement for former smokers.
1485641|NCT03077217|Drug|Rifaximin|The investigators use low-dose rifaximin for the treatment of patients with covert hepatic encephalopathy
1485962|NCT03074578|Behavioral|Watching Video-clip 1|Video -clip 1 contains violent images and text
2001144|NCT03185481|Drug|3 mg QD to 15 mg QD PF-06649751|Up titration from 3 mg QD to 15 mg QD PF-06649751
2001145|NCT03185481|Drug|7 mg QD to 15 mg QD PF-06649751|Up titration from 7 mg QD to 15 mg QD PF-06649751
2001146|NCT03185481|Drug|15 mg QD PF-06649751|15 mg QD PF-06649751 remaining at 15 mg QD PF-06649751
2001147|NCT03185481|Drug|1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study)|Up titration from 1 mg QD to 7 mg QD PF-06649751 for subject at 1 mg QD who were blindly de-escalated in the parent study
2001148|NCT03185481|Drug|3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|Up titration from 3 mg QD to 7 mg QD PF-06649751 for 3 mg QD subjects who were blindly de-escalated in parent study
1485642|NCT03077204|Biological|1 or 2-Level ACDF utilizing BIO4 with Bio AVS Cervical Allograft (with graft window).|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
1485643|NCT03077204|Device|Aviator Anterior Cervical Plating System|The study will utilize the BIO4 on label as a 361 HCT/P (human cell, tissue and cellular and tissue-based product) for homologous use for the repair, replacement or reconstruction of bone defects. Interbody fusion (1 or 2-level fusion) in conjunction with an allograft (hct/p) interbody spacer (anterior approach in the cervical spine with hardware). Investigators will also use the Aviator Anterior Cervical Plating System for anterior intervertebral screw fixation of the cervical spine at levels C2-T1. The Aviator Anterior Cervical Plating System is intended for use as an aid in cervical spinal fusion and is intended for unilateral fixation. The Aviator plates are intended to be used with the Aviator bone screws.
1485644|NCT03077191|Other|Quality of life measurement|The quality of life of breast cancer patients treated with conservative surgery and adjuvant whole breast hypofractionated radiotherapy, without boost, will be evaluated.
1485645|NCT03077178|Procedure|Geriatric assessment|Geriatric assessment, questionnaire assessment
1485646|NCT03077165|Drug|S42909 100 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
1485647|NCT03077165|Drug|S42909 200 mg|50 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
1485648|NCT03077165|Drug|S42909 400 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
1485649|NCT03077165|Drug|S42909 800 mg|200 mg Film-coated tablets per os administration,twice a day taken at the end of the morning and at evening meals.
1485650|NCT03077165|Drug|S42909 1200 mg|200 mg Film-coated tablets per os administration, twice a day taken at the end of the morning and at evening meals.
1485651|NCT03077165|Drug|Placebo Oral Tablet|Matching placebo tablets, per os administration, twice a day taken at the end of the morning and at evening meals.
1485652|NCT03077139|Device|Cardiac Resynchronization Therapy (CRT)|A CRT device sends small electrical impulses to both lower chambers of the heart to help them beat together in a more synchronized pattern.
1485653|NCT03077126|Other|Fleet Enema|Since a probe will be introduced into the participant's rectal area, participants will be instructed to give themself one regular Fleet enema.
1485654|NCT03077126|Device|Aixplorer® ShearWave Elastography (SWE™)|Pre-surgery ultrasound: Aixplorer® ShearWave Elastography (SWE™) Ultrasound System (made by SuperSonic Imagine, Inc.). The device is used transrectally. This device (ultrasound system) has been cleared by the United States Food and Drug Administration (FDA) for the indication for use as described in this consent form.
1485655|NCT03077126|Diagnostic Test|Pre-surgery Ultrasound|The ultrasound procedure referenced above will be performed at the participant's pre-op visit one to two weeks before their surgery.
1485656|NCT03077126|Procedure|Prostatectomy|Participants will undergo radical prostatectomy as currently performed at our Moffitt Cancer Center. This procedure is performed under general anesthesia in the operating room. This is considered standard of care.
1485657|NCT03077113|Diagnostic Test|4-D CT Scan|The 4-D CT scan shows how the tumor moves when patients breathe so that motion can be taken into account when planning the radiation. This is the usual way of planning lung radiation and everyone in this study will be planned using a 4-D CT scan.
1485658|NCT03077113|Diagnostic Test|SPECT-CT Scan|It may be possible to make a more accurate plan by using a SPECT-CT scan for planning that would result in less damage to healthy lung tissue. This is not yet proven. A SPECT-CT scan uses a special camera to detect radioactivity to produce pictures which can lead to more precise information.
1485659|NCT03077100|Other|Laboratory identification of positive cultures|Laboratory identification of positive cultures
1485660|NCT03077087|Device|thin Integra® (125 cm2)|125 cm2 represents approximately 0.7% of an average sized patient's total body surface area. The remaining injury areas would be covered with standard-thickness Integra® only. The donor graft, a 4 cm x 10 cm sheet of skin, would be meshed in a 3:1 ratio to be expanded to cover the 125 cm2 sheet of thin Integra®. The patient's post-operative care would be largely unchanged, although the patient would have a donor site of 40 cm2 that would be dressed and managed in the usual fashion.
1485661|NCT03077074|Other|low carbohydrate consumption|consumption of up to 60 grams of carbohydrate a day for 10 days FMRI will be performed prior and after the intervention during the luteal cycle phase
1485662|NCT03077061|Procedure|Open flap debridement|Open flap debridement using saline as irrigation
1485663|NCT03077061|Device|Bone replacement graft|Open flap debridement using saline as irrigation including a grafting procedure withBio-Oss Collagen®.
1485664|NCT03077048|Drug|Ketosteril®|Patients will be randomised to receive isonitrogenous and isocaloric LPD providing 0.6 g protein/kg BW/day and an energy intake of 30-35 kcal/kg BW/day with (test group) or without (control group) intake of Ketosteril® (1 tablet/5 kg BW/day). The control group will get additional food protein to balance the nitrogen content of Ketosteril® The mainly vegetarian diet will be maintained for 10 days.
1485665|NCT03077035|Other|glass ionomer sealants|
1485666|NCT03077035|Other|resin-based sealant|
1485667|NCT03077009|Drug|Hyaluronic Acid|Ultrasound guided injection for plantaris friction syndrome
1485697|NCT03076736|Behavioral|Singing group + resource pack|SPA is a community-based, 10 weekly singing group. Each SPA session comprises 30 minutes of settling in/wrap-up and departure, and 60 minutes of group singing. Sessions will be led by a community music leader, co-facilitated by a person with aphasia, and involve the group singing from a songbook. Musical accompaniment will be provided by the facilitator(s). Small percussion instruments will be available for participants, enabling involvement of those with limited singing ability. Intervention content integrates the Information-Motivation-Behavioural (IMB) skills model of health behaviour change to support individuals in developing the social skills and confidence needed to improve psychosocial outcomes. Participants will also receive the resource pack.
1485668|NCT03076996|Behavioral|Online support group|"Participants will be enrolled to form five groups of 8 to 10 participants, and then participants will participate in the 6 sessions of the structured educational and group counseling curriculum through the online platform.
The m/eHealth intervention components include:
Informational messages that reflect the content of the structured group counseling curriculum, Positive Connections, and are posted to the group wall on a regular basis
Moderated, closed group chats where ALHIV can interact with their peers and with a trained health counselor on a biweekly basis
Access to a trained counselor via Facebook Messenger (during normal business hours) for the duration of the intervention who will be able to provide information or basic counseling on ART/HIV care related issues, with referral to health care services as needed"
1485669|NCT03076983|Device|Lung Monitoring with EIT device (PulmoVista 500)|"Patient's lungs will be monitored during clinical routine interventions with Dräger's EIT device (PulmoVista 500).
No medical interventions to routine patient care required."
1485670|NCT03076970|Drug|lasmiditan 200 mg|drug including single placebo tablet
1485671|NCT03076970|Drug|Sumatriptan|drug including single placebo tablet
1485672|NCT03076970|Drug|matching placebo|single oral tablet -given with single lasmiditan tablet and with single sumatriptan tablet.
1485673|NCT03076957|Drug|CKD-516 Tablet|CKD-516 PO for 5 consecutive days and 2 days off in Combination with Irinotecan inj.
1485674|NCT03076944|Drug|UltraEZ|Prophylaxis, apply uniformly on the teeth, wait 15 minutes, remove the gel from the teeth with cotton and abundant water.
1485675|NCT03076944|Drug|Enamelast|Prophylaxis; dry the teeth; apply uniformly on the teeth with a thin layer.
1485676|NCT03076931|Procedure|Microlaryngoscopy|Standard clinical procedure, used to perform airway sizing and vocal fold calibration. Controls receive one as a research procedure, while study patients receive one as part of standard of care.
1485677|NCT03076931|Procedure|Voice Evaluation|Standard clinical procedure that includes aerodynamic, acoustic, and perceptual voice assessments, a pediatric voice handicap index questionnaire, videostroboscopy, and high-speed videoendoscopy. Controls will receive one as a research procedure, while study patients will receive three, one before their airway reconstruction, and two more in the year afterward, as part of standard of care.
1485678|NCT03076931|Procedure|Airway Reconstruction|This includes many types of invasive surgical procedures such as Laryngotracheoplasty to repair a patient's compromised airway. Only study patients will be receiving one, and it will be as part of standard of care unrelated to this study, but the data from surgery and outcomes being pertinent to the study.
1485679|NCT03076918|Device|FLEXITHERALIGHT PDT|Preparation of lesions, MAL application+occlusive dressing during 30 minutes+illumination 2.5 hours
1485680|NCT03076918|Device|Aktilite® Galderma|Preparation of lesions, MAL application+occlusive dressing during 3 hours+illumination 7 to 10 minutes
1485682|NCT03076892|Device|Aktilite® Galderma|preparation of the lesions, Metvixia application + occlusive dressing during 3 hours + illumination: 7 to 10 minutes
1485683|NCT03076892|Device|PHOS ISTOS PDT|preparation of the lesions, Metvixia application + occlusive dressing during 30 minutes + illumination: 2.5 hours
1485684|NCT03076879|Behavioral|Promoting participation in cervical cancer screening|"Nursing education: Women in the experimental group will be trained three times in total, one for the cervical cancer screening and the other two for the individual.
Reminders by phone; Short messages and calls will be reminiscent of women's participation in cervical cancer screenings.
Home visit; The content of the training is the key to cervical cancer and screening. After the group training, it is aimed to be an interactive education and counseling service in the form of question-answer method which is not understood by home visiting method.
Brochure; The brochure for cervical cancer and screening will be given after group training."
1485685|NCT03076866|Other|observational follow-up:clinical, radiological et biological|
1485686|NCT03076853|Other|Opening of the Pharmaceutical Record|After a first prescription without the pharmaceutical record, the study investigator has to open the pharmaceutical record to obtain some additional data. After, he has to choose between maintain or modify his first prescription.
1485687|NCT03076840|Other|Kinesio tape|Kinesio Taping is another option for the treatment of poor hamstring extensibility, It was developed by Kenzo Kase in 1970 and gained a wide popularity by the elite athletes during the various championships and Olympic Games
1485688|NCT03076827|Procedure|Total hip replacement|Total hip replacement starts in the morning in group A and starts in the afternoon in group P.
1485689|NCT03076827|Procedure|Hemi-arthroplasty|Hemi-arthroplasty starts in the morning in group A and starts in the afternoon in group P.
1485692|NCT03076801|Behavioral|Choral Singing|In addition to usual medical care, participants in the intervention group will participate in weekly 60-90 minute singing sessions led by professional musicians over a 12-week period. Sessions will begin with a 5-minute physical warm-up of gentle stretching and a 5-minute vocal warm-up. Music will be selected from a variety of genres and eras. Attendance will be taken weekly.
1485693|NCT03076788|Other|electrocardiogram and echocardiography|"We retrieved all electrocardiograms and echocardiography made during the clinical examination of each athlete and each sedentary control.
Standard 12 lead ECG
Trans-thoracic echocardiography examination of cardiac function, morphology and intracardiac flow."
1485694|NCT03076775|Other|Maternal glycemic control|Maternal capillary blood glucose testing will be performed according to oral intake status: every 2 hours if NPO or fasting and 1-hour postprandial if eating regular meals. Hyperglycemia, defined based on ADA and ACOG recommendations as well as current practice at study sites, will be treated according to study guidelines based on oral intake status: insulin infusion if NPO and subcutaneous insulin if eating regular meals.
1485695|NCT03076762|Drug|intravesical onabotulinumtoxinA injection|Each vial of onabotulinumtoxinA will be diluted with 10 ml of normal saline, resulting in 10U onabotulinumtoxinA per 1.0 ml. Patients assigned for suburothelial BoNT-A injections received 20 injections in the bladder body whereas those assigned trigonal injections will receive 10 sites injections at the trigonal area (5 injections behind interureteric ridge and 5 inside the trigone).
1485696|NCT03076749|Other|Creating models for the diagnosis of BL allergy|
1485698|NCT03076736|Behavioral|Resource pack|Resource pack with information on living with aphasia and local community activities.
1485877|NCT03075176|Device|Topography-guided Photorefractive Keratectomy|Topography-guided laser vision correction
2001149|NCT03185481|Drug|7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study)|7 mg QD to remain at 7 mg QD PF-06649751 for subjects who were blindly de-escalated in parent study
1485701|NCT03076710|Drug|Opioids delivered through PCA|IV up to 1 mg. morphine every 10 minutes on request and oral opioids up to 2 tablets of Percocet every 4 hours
1485702|NCT03076710|Drug|EXPAREL® infiltration|"22 gauge / 3.5 needle, into dermal/fascial/muscular/subcutaneous layers and up to 4mg IV morphine every 60 minutes on request and standardized oral opioids on request"
1485703|NCT03076697|Diagnostic Test|Fundus photography|Fundus photographs will be taken with our smartphone-based camera along with the standard of care, including traditional desktop fundus photography. We will test the feasibility and accuracy of a smartphone-based camera for diagnosing disease along with the stage of disease. Several ophthalmologists will grade the smartphone fundus photographs, the traditional retinal photographs, and the documented eye examination. We will assess the agreement between the graders for the diagnosis of eye disease. We will also assess the sensitivity and specificity of diagnoses with the smartphone, using traditional retinal imaging as the reference standard and in a separate analysis using the ophthalmologist's examination as the reference standard.
1485704|NCT03076684|Other|low-fructose diet|Subjects will consume a four-month diet with the goal of reducing added sugar intake from ≥13% of energy to <5% of energy and keeping their weight stable.
1485705|NCT03076684|Drug|Allopurinol|Subjects in the drug arm will take the drug allopurinol daily.
1485706|NCT03076671|Behavioral|Palliative Care|Palliative care training for community neurologists and use of telemedicine for team-based support of patients
1485707|NCT03076658|Radiation|EOS imaging|The EOS imaging system will be utilized to obtain full-body radiographs in frontal and sagittal projections obtained in the upright standing position. Measurements will include a coronal plumb-line, sagittal vertebral axis (SVA), external auditory meatus plumb-line, cervical lordosis, thoracic kyphosis, lumbar lordosis, hip flexion/extension, knee flexion/extension, ankle flexion/extension, T1 tilt, T1 spino-pelvic instance, acetabular index, pelvic tilt (PT), pelvic incidence (PI), and sacral slope (SS).
1948841|NCT01471522|Procedure|percutaneous coronary intervention|Percutaneous coronary intervention may be done as part of the cardiac catheterization procedure. With this procedure a small, hollow, mesh tube (stent) is inserted into the narrowed part of the artery. The stent pushes the plaque against the artery wall, and opens the vessel to allow better blood flow.
1948842|NCT01471522|Behavioral|Lifestyle|diet, physical activity, smoking cessation
1485710|NCT03076632|Device|Cervical plus transcranial stimulation|Conditioning pulses of cervical electrical stimulation will be delivered before or after test pulses of transcranial magnetic stimulation.
1485711|NCT03076632|Device|Cervical stimulation plus hand/wrist exercise|Pulses of cervical stimulation will be delivered while the subject performs finger and wrist motor tasks.
1485712|NCT03076632|Device|Electromyographic (EMG)-triggered (closed-loop) stimulation|Force and EMG activity of specific hand muscles will be used to trigger peripheral nerve electrical stimulation or transcranial magnetic stimulation.
1485713|NCT03076619|Other|clinical ophthalmoscopy|To study the role of clinical ophthalmoscopy in PIH in diagnosis, prognosis, differential diagnosis, line of treatment and effect of treatment.
1485714|NCT03076606|Diagnostic Test|ophthalmologist examination|ophthalmologist examination after geriatric consultation
1485715|NCT03076593|Other|Exposure: Fall|Participants will be asked about prior falls
1485717|NCT03076541|Device|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
1485718|NCT03076528|Other|Sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based lower extremity training including repetitive ankle movements in multiple directions. Wearable sensors will provide real-time feedback from foot and ankle position and allow perception of motor-errors during each motor-action
1485719|NCT03076528|Other|Non-technology foot and ankle exercise program|Subjects are asked to perform non-technology based foot and ankle exercises, which include plantar flexion and extension.
1485720|NCT03076515|Device|Nerivio Migra neurostimulation|transcutaneous electrical stimulation
1485721|NCT03076515|Device|Sham Nerivio Migra|electrical stimulation- shame mode
1485722|NCT03076489|Other|First Visit|blood sample , morpho-anatomic measures (height, weight, hip and size), impedancemetry and resting energy expenditure by indirect calorimetry, sample of urine and faeces previously collected at home
1485723|NCT03076489|Other|on-line questionnaires|The two on-line questionnaires (hedonic and caloric evaluation of foods and beverages on photos) will have to be completed by the volunteers between the first and the second visit to the University-Hospital.
1485724|NCT03076489|Device|fMRI|a cognitive two-choice test based on food and drink pictures, during fMRI. Before and after the fMRI session, an assessment of the state of hunger, thirst, and general status of the volunteer will be carried out using a numerical scale ranging from 1 to 10.
1485725|NCT03076476|Device|Bioresorbable Vascular Scaffolds (BVS)|Bioresorbable Vascular Scaffold. Introduced after the interim analysis (phase 2) for comparison with DES-slow.
1485726|NCT03076476|Device|Drug-Eluting Stent (DES) - slow|"Slow device inflation (mandated in the BVS IFU). To be compared with the DES-std group at interim analysis at the end of phase 1 stage.
After the interim analysis DES-slow to be compared with BVS."
1485727|NCT03076476|Device|Drug-Eluting Stent (DES) - standard(std)|Metallic DES implanted in standard fashion. To be compared with the DES-slow group at interim analysis at the end of phase 1 stage.
1485728|NCT03076463|Dietary Supplement|GRAPOM|The whole intervention will be divided in 2 periods, control (CTR) and dried and milled grape pomace (GRAPOM). The two periods will have a duration of 6 weeks. During the CTR period, subjects will follow their normal dietary habits and samples will be collected at the beginning and at the end. No proper placebo could be found for the product, so this CTR period was chosen. During the GRAPOM period, the subjects will daily consume 8 g of the product solved in water and samples will be collected at the beginning and at the end.
1485729|NCT03076450|Device|Lung Ultrasound|Adjust PEEP real-time in term of LUS-RAS chang.
1485730|NCT03076450|Diagnostic Test|Maximum Oxygenation|Adjust PEEP real-time in term of PaO2+PaCO2≥400mmHg whether or not.
1493094|NCT03020030|Drug|Dexrazoxane|Standard of Care
1485731|NCT03076437|Combination Product|Drugs and Anti-CD19-CAR transduced T cells|"Drug: Fludarabine On days -4 through -2, Fludarabine 30mg/m2 IV will be infused over 30 minutes. Drug: Cyclophosphamide On days -4 through -2, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
Biological: Anti-CD19-CAR transduced T cells Modified cells will be infused IV over 30 minutes (1-3 days after the last dose of fludarabine)."
1485732|NCT03076424|Other|no intervention used|Patients will be giving a blood sample after 8 hours of fasting.
1485733|NCT03076411|Drug|Pepsin|
1485734|NCT03076385|Biological|VAL-506440|Escalating dose levels
1485735|NCT03076385|Other|Placebo|
1485736|NCT03076372|Drug|MM-310|MM-310
1485737|NCT03076359|Behavioral|Traditional Healer Support Program|"Traditional Healers will provide the traditional healer support program assistance, as previously described, to all newly diagnosed patients."
1485738|NCT03076359|Drug|Standard of Care|First-line ART will consist of two nucleoside reverse-transcriptase inhibitors (NRTIs) plus a non-nucleoside reverse-transcriptase inhibitor (NNRTI)- TDF + 3TC (or FTC) + EFV as a fixed-dose combination to be taken twice a day for the rest of the patient's life), clinic-based counseling, and community searches if lost to follow up.
1485739|NCT03076333|Diagnostic Test|PET/MR|Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant radiation therapy per the direction of the radiation oncologist. At the end of the second week of radiation therapy the patient will undergo a mid-treatment PET/MR. The patient will the complete their radiation therapy. Four weeks after radiation therapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery at 6-8 weeks post radiation if they are still surgical candidates.
1485740|NCT03076320|Combination Product|PDF+M-DDO|Participants with moderate and severe acne will be treated two times a day on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Zaxcell (Pirfenidone with M-DDO) in form of a gel. Patients have to wait 20 min without cover those sites.
1485741|NCT03076320|Combination Product|A+PBO|Participants with moderate and severe acne will be treated once a day (at night) on the face and superior back with a smooth layer (standard finger tip unit 0.5 g for an area of 100 to 120 square centimeters) of Effezel (Adapalene with benzoyl peroxide) in form of a gel. Patients have to wait 20 min without cover those sites
1485742|NCT03076307|Behavioral|Procedural Motor Skills with mirror-drawing of figures|Evaluation of error rate and speed for completion of a procedural motor task
1485743|NCT03076294|Device|TMS|Repetitive TMS involves application of electric currents in the patient's cortex by a magnetic field applied to the scalp of the patient through an eight-coil connected to a magnetic stimulator (MagStim Rapid² magnetic stimulator-UK). In a small percentage of patients, it may cause minimal discomfort with a mild headache sensation, which usually disappears after a few seconds. Depending on the parameters, rTMS can increase or decrease corticomotor excitability and by the connection of the motor cortex with the thalamus, influencing pain control. The patients will respond to an adverse effects questionnaire and will report the perception of real or sham stimulation.
1485744|NCT03076294|Other|Manual therapy (MT)|This intervention uses manual contact for diagnosis and treatment, its practitioners use an enormous amount of manual techniques to preserve the homeostasis through the recovery of dysfunctions, which may cause limitations in the physiological movements, in the accessory movements of the joints (WHO , 2010).
1485745|NCT03076281|Drug|Metformin Hydrochloride|Given orally
1485746|NCT03076281|Drug|Doxycycline|Given orally
1485747|NCT03076281|Drug|Metformin +Doxycycline|Given orally
1485748|NCT03076268|Behavioral|Treinta Millones de Palabras - Visitas al Hogar|TMP-Visitas al Hogar is a cultural and linguistic adaptation of the TMW-Home Visiting curriculum into Spanish. The 12-module curriculum has been translated into Spanish and adapted to address concerns that are vital to mono- and bilingual Spanish-speaking families, including the broadening research base for when to introduce a second language to a child and the benefits of bilingualism.
1485749|NCT03076255|Procedure|Computed Tomography|Undergo CT simulation
1485750|NCT03076255|Device|Medical Device|Given thermoplastic mask
1485751|NCT03076255|Device|Medical Device|Given MID
1485752|NCT03076255|Procedure|Cone-Beam Computed Tomography|Undergo CBCT imaging
1485753|NCT03076242|Other|GEM Registry|Men with a personal history of PCA; Unaffected males who are at higher risk for prostate cancer
1485754|NCT03076229|Behavioral|Healthy Marriage Program|Provide the following allowable activities 1) marriage and relationship education/skills, 2) relationship enhancement, 3) premarital education, and 4) divorce reduction.
1485755|NCT03076216|Device|OncoSil™|The implantation of OncoSil™ under EUS
1948843|NCT01471522|Drug|Medication|antiplatelet, statin, other lipid lowering, antihypertensive, and anti-ischemic medical therapies
1485758|NCT03076190|Behavioral|Psychoeducational My Surgical Success Video|The 90-minute video includes instruction by Dr. Beth Darnall, PhD, a pain psychologist at the Stanford Pain Management Center. She teaches the viewer about the relationship between stress, pain, and catastrophizing and provides instruction and skills to reduce catastrophizing, decrease stress, and increase relaxation.
1485759|NCT03076177|Other|Taping application|Kinesio taping application will be applied for experimental group; non specific taping application for control
1485760|NCT03076164|Drug|Trametinib|Trametinib 1.5mg once daily by mouth
1485761|NCT03076164|Drug|Erlotinib|Erlotinib 75mg once daily by mouth
1485763|NCT03076138|Device|Gene-activated matrix (OCP + plasmid DNA with VEGF gene)|Bone grafting procedure with investigated medical device
1485764|NCT03076125|Behavioral|SCORRE|3 components based on the Health Belief Model
1485765|NCT03076125|Behavioral|Attention-Control Activity|sexual health education
1485766|NCT03076112|Drug|Ipragliflozin|Ipragliflozin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
1485767|NCT03076112|Drug|Sitagliptin|Sitagliptin as add-on to Metformin and Sulfonylurea in patients with poorly controlled type 2 diabetes
1485768|NCT03076099|Drug|Dexmedetomidine|1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.
1485769|NCT03076099|Other|normal saline|equal volume of normal saline was administered intravenously constantly after tracheal extubation.
1485770|NCT03076086|Other|Induced sputum procedure|induced sputum is a sputum specimen produced for diagnostic tests by aerosol administration of a hypertonic saline solution.
1485771|NCT03076073|Other|Impact of physical activity on tendons|Single vs. multiple (up to 12 weeks) of different types of physical exercises (aerobic vs. anaerobic activities).
2001150|NCT03185481|Drug|15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD|7mg QD PF-06649751 for subjects assigned to 15 mg QD who were blindly de-escalated to 7 mg QD PF-06649751 in parent study
2001151|NCT03185442|Device|Pulsed Radiofrequency|Pulsed Radiofrequency is performed if the sensory threshold is below 0.5 volts, the PRF consists of 380 pulses
1485774|NCT03076047|Procedure|end-tidal CO2 (ETCO2) monitoring with Smart CapnoLine Plus O2|monitor end tidal CO2 levels while patients recover in post-anesthesia care unit (PACU) using the Smart CapnoLine Plus O2
1485775|NCT03076034|Device|Reference Point Indentation|"The Osteoprobe: Since these first reports of indentation measurements in humans in vivo, a more 'user-friendly' device, the Osteoprobe® has been developed by Active Life Scientific (Santa Barbara, CA) (10). The Osteoprobe®, which we will use in the current study, is smaller than the previous reference point indentation (RPI) instrument and is designed to be used in a hand-held fashion to allow for rapid measurements. The new instrument does not require a reference probe, because the inertia of the instrument keeps it adequately fixed in space during the short time of the indentation impact (~0.25 milliseconds). The main parameter measured is the distance that the probe further indents into the bone from the reference point. Key components of the Osteoprobe® include an impact generation mechanism, a displacement transducer, and a probe made of hardened stainless steel with a 90 degree conical tip, with a tip diameter of ~375 µm."
2001152|NCT03184480|Drug|Arnuity Ellipta|The active component of Arnuity Ellipta is fluticasone furoate and it is indicated for the treatment of bronchial asthma. Post-marketing investigation of ARNUITY ELLIPTA will be carried out in this analysis.
2001153|NCT03184246|Device|GlideScope|videolaryngoscopy (GlideScope) will be used for intubation
1485778|NCT03076008|Other|Observational|No intervention
1485779|NCT03075995|Other|hight-fat breakfast|It's divided into two stages.For the first stage,the subjects take lapatinib on an empty stomach,the steady state plasa concentration is examined on the 9th and 10th days after lapatinib is administered.The second stage,the subject take lapatinib with hight-fat breakfast,the steady state plasa concentration is examined as the first stage.
1485780|NCT03075956|Drug|5 mg E4 single-dose|A single oral dose of 5 mg E4 will be administered during Period 1 of the study.
1485781|NCT03075956|Drug|15 mg E4 single-dose|A single oral dose of 15 mg E4 will be administered during Period 1 of the study.
1485782|NCT03075956|Drug|45 mg E4 single-dose|A single oral dose of 45 mg E4 will be administered once orally during Period 1 of the study
1485783|NCT03075956|Drug|15 mg E4 multiple-dose|15 mg E4 will be administered once daily orally for 14 consecutive days during Period 2 of the study
1485784|NCT03075943|Dietary Supplement|InSea2|Daily supplement: 2 capsules of InSea2
1485785|NCT03075943|Dietary Supplement|Placebo|Daily supplement: 2 capsules of Placebo
1485786|NCT03075930|Device|Extended Electrocardiogram|ECG with 3 additional leads and a 5 minute recording
1485787|NCT03075930|Device|Body surface potential map|ECG with 184 leads and a 5 minute recording
1485788|NCT03075917|Other|Self Questionnaire|self questionnaire for allergic rhinitis control
1485789|NCT03075904|Drug|SYNT001|IV in 250 mL over 1 hour administered on Day 0, 7, 14, 21, and 28
1485790|NCT03075891|Drug|Ivermectin 1% cream|Topical to the face, approximately one small pea size amount per facial region (right and left cheeks, forehead, chin, and nose) once a day for 12 weeks
1485791|NCT03075891|Drug|Doxycycline 40 mg MR (30 mg Immediate Release & 10 mg Delayed Release beads) capsules|1 Capsule once-daily for 12 weeks
1485792|NCT03075891|Other|Oral placebo capsules|1 Capsule once-daily for 12 weeks
1485793|NCT03075878|Drug|SYNT001|IV in 250 mL over 1 hour administered on Day 0, 7, 14, 21, and 28
1485794|NCT03075865|Device|OmniMax MMF system|OmniMax MMF system consists of arch bars and screws that work together to achieve temporary fixation of the maxilla and mandible to provide indirect or passive stabilization of fractures and maintenance of occlusion in the oral and maxillofacial region. The arch bars have hooks designed to accommodate either wires or elastic bands for temporary maxillomandibular fixation (MMF) either intraoperative or postoperative.
1485795|NCT03075852|Device|Heads- Up Display Surgery|Patient undergoes VR surgery with visualization using heads up display 3D monitor viewed by the operating surgeon.
1485796|NCT03075839|Other|Cigarette Brand Switching|Adult smokers will be switched from smoking menthol cigarettes to non-menthol cigarettes
1485797|NCT03075826|Drug|SGI-110|subcutaneously at a dose of 60 mg/m2
1485798|NCT03075813|Other|Intervention Cluster|Surgical surveillance date will be analyzed by optimized SPC methods. if signal is generated, study personnel in DICON will be notified to adjudicate the signal and determine if further action is needed.
1485799|NCT03075800|Behavioral|Assertive Community Treatment (ACT) + Illness Management and Recovery (IMR)|The integrated ACT+IMR model was developed and manualized prior to the start of this evaluation (27). The model incorporates the following key features: a) ACT staff provide IMR in office-based group and/or individual sessions in office or community settings; b) regular community follow-up by ACT staff to assist clients with practicing IMR skills and achieving their goals; c) regular communication within ACT team (e.g., during daily meetings) on IMR client goals and progress; and d) supervision and consultation on IMR within ACT.
1485800|NCT03075787|Device|standard 24-h ambulatory polysomnography|A standard 24-h ambulatory ad libitum polysomnography including EEG, electro-oculography (EOG), electromyography (EMG), EKG, was performed by a standard clinical.
1485801|NCT03075761|Device|Fitbit|The Fitbit will be utilized in the intervention arm to improve adherence to a 12-week activity regimen.
1485802|NCT03075761|Behavioral|30-minute education session|
1485842|NCT03075423|Drug|Ipilimumab plus nivolumab|Ipilimumab every 3 weeks for 4 times Nivolumab every 3 weeks for 4 times followed by maintenance therapy with nivolumab every 2nd week
1485843|NCT03075423|Drug|Sunitinib|Sunitinib is administered orally 50 mg tablets for 4 weeks on and 2 weeks off
2001154|NCT03184246|Device|Direct laryngoscopy|direct laryngoscopy will be used for intubation
2001155|NCT03183141|Drug|SER-109|SER -109 is an ecology of bacteria in spore form, enriched from stool donations obtained from healthy, screened donors
1485804|NCT03075722|Device|Saturn nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
1485805|NCT03075709|Other|Clinical Pathway (CPW)|CPWs bring the available evidence to a range of healthcare professionals by adapting guidelines to a local context and detailing the essential steps in the assessment and care of patients.
2010609|NCT02916745|Drug|Porfimer sodium|After injection of porfimer sodium (Photofrin®), a flexible bronchoscopy with navigation guidance will be performed to confirm the location and the size of the lesion with the use of radial probe endobronchial ultrasonography (REBUS). A light dose of 200 J/cm of diffuser length for an exposure time of 8 minutes and 20 seconds will be delivered.
2010610|NCT02916745|Device|Fiber optic|A fiber optic diffuser length matching the tumor length will be placed in the lesion under fluoroscopy guidance.
2010611|NCT02915744|Drug|NKTR-102|
1485809|NCT03075683|Behavioral|Cognitive behavioural therapy|Eight sessions of internet-based CBT for insomnia comorbid with chronic pain, with active therapist support.
1485810|NCT03075683|Behavioral|Applied relaxation|Eight sessions of internet-based applied relaxation for insomnia comorbid with chronic pain, with active therapist support.
2010612|NCT02915744|Drug|Eribulin|
2010613|NCT02915744|Drug|Ixabepilone|
1485813|NCT03075657|Drug|Risperidone|Risperidone will be prescribed at dose of 2 mg per day
1485814|NCT03075657|Drug|Risperidone and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Risperidone 2 mg per day
1485815|NCT03075657|Drug|Haloperidol|Haloperidol will be prescribed at dose of 2 mg per day
1485816|NCT03075657|Drug|Haloperidol and Ramelteon|Ramelteon will be prescribed 8mg/day as an add-on therapy to Haloperidol 2 mg per day
1485817|NCT03075644|Drug|somapacitan|Once weekly subcutaneous injections (s.c., under the skin)
1485818|NCT03075644|Drug|Norditropin|Daily subcutaneous injections (s.c., under the skin)
1485819|NCT03075631|Other|Questionnaire|Questionnaires
1485820|NCT03075618|Behavioral|Questionnaires|Questionnaires
1485821|NCT03075579|Drug|Medication Other|medication of atomoxetine
1485822|NCT03075579|Device|motor measurement and saliva collection|motor measurement by actometer and saliva collection for measurement of saliva cortisol and saliva alpha amylase
1485823|NCT03075566|Biological|Healthy subjects|- 207 healthy subjects were donors,(33.2±12.2 years) recruited from the Blood Bank Department of the University Hospital (Mahdia, Tunisia).
1485824|NCT03075566|Biological|Patients|- 310 subjects with CAD (60.3±11.0 years) were admitted to the Department of Cardiology, University Hospital (Monastir, Tunisia).
1485825|NCT03075553|Other|Laboratory Biomarker Analysis|Correlative studies
1485826|NCT03075553|Biological|Nivolumab|Given IV
1485827|NCT03075540|Behavioral|Genetic Counseling and Testing YouTube Video|Participants (n=40) will watch a 15-minute YouTube video that will describe the genetic counseling and testing process and risk/benefit information in a telenovela style format. Participants will complete pre- and post-assessments. After the session, participants interested in pursuing genetic counseling and testing services will be referred to the patient navigator at their respective sites, who will navigate participants to identified no cost or low cost services
1485828|NCT03075527|Drug|Tremelimumab|Tremelimumab blocks a receptor on immune cells that normally suppresses immune attack.
1485829|NCT03075527|Drug|Durvalumab|Durvalumab is a drug that blocks a protein often produced by cancer cells or surrounding cells to suppress immune cells from attacking cancer cells.
1485830|NCT03075514|Other|MKD|Modified ketogenic diet
1485831|NCT03075514|Other|MCT|Medium chain triglyceride ketogenic diet
1485832|NCT03075501|Behavioral|Paired|Administration of a rewarding drug is paired with a given context to assess whether we can change liking and preference for that environment.
1485833|NCT03075501|Drug|Methamphetamine|20mg methamphetamine is the conditioning stimulus.
1485834|NCT03075501|Drug|Placebo|20mg is the non-drug conditioning stimulus.
1485835|NCT03075488|Device|Accuro|spinal anesthesia injection based on identification of entry site with pre-procedural ultrasound scan with Accuro device
1485836|NCT03075488|Procedure|cutaneous landmarks|spinal anesthesia injection based on identification of entry site with palpation of cutaneous landmarks
1485837|NCT03075475|Behavioral|Common Elements Treatment Approach|The Common Elements Treatment Approach (CETA), is a trans-diagnostic psychotherapy that is based on common evidence-based treatments for depression, anxiety, trauma and stress related disorders. This treatment can be used to treat individuals with any of these mental health problems and with any combination of these problems. CETA expands upon traditional treatment approaches that are designed to focus on one specific disorder and has been proven through multiple rigorous trials to reduce the burden of multiple common mental health problems and improve functionality among men and women living in low resource settings. CETA can be provided to people in their own communities by trained and supervised lay providers, for example community health workers.
1485838|NCT03075462|Drug|Fluzoparib|Fluzoparib either at 40,60,80mg twice daily,capsule oral.
1485839|NCT03075462|Drug|Apatinib|Apatinib at 250mg once daily, tablet oral
1485840|NCT03075436|Behavioral|Enhanced demand-side sanitation, hygiene|The enhanced, demand-side sanitation and hygiene intervention package will be informed by findings from formative research, and will consist of interventions designed to enhance sanitation and hygiene messaging to better facilitate behavior change, and intensify implementation of related community-based interventions via engagement of various delivery modalities.
1485841|NCT03075436|Behavioral|Standard of care|The comparison group will receive the current standard of care, including potential implementation of government-led policies and programs.
1485875|NCT03075176|Device|Wavefront optimized Photorefractive Keratectomy|Wavefront optimized laser vision correction
1485844|NCT03075410|Drug|GSK3036656|GSK3036656 is available as capsules (for oral administration) containing 5 mg, 25 mg or 100 mg of GSK3036656 as free base equivalent.
1485845|NCT03075410|Drug|Placebo|Placebo is a matching capsule containing Avicel PH (Suitable for Pharmaceutical Use) 102, for oral administration.
1485846|NCT03075397|Other|blood sample|A sample of HIV-1 infected patients's blood is collected
1485847|NCT03075397|Other|sperm sample|A sample of HIV-1 infected patients's sperm is collected
1485848|NCT03075384|Procedure|computer-assisted navigation system|The computer-assisted navigation system was applied in treatment of unilateral complicated zygomatic fractures
2010614|NCT02915744|Drug|Vinorelbine|
2010615|NCT02915744|Drug|Gemcitabine|
1485851|NCT03075358|Drug|Lidocaine spray|Patients are locally anesthetized with 8 puffs (80 mg, 10mg/puff, 0.8 ml) of 10% lidocaine spray applied thoroughly to the cervix, 3 minutes before starting the procedure.
1485852|NCT03075358|Other|Normal saline spray|0.8 ml of normal saline spray is applied to the cervix, 3 minutes before starting the procedure
1485853|NCT03075345|Behavioral|Acceptance and commitment therapy|Four sessions of the ACT protocol will be psychoeducational in nature, with brief experiential exercises in the class and in-between session practice. It's aim is to allow individuals to be able to sit with difficult experiences (rather than fight against them) and in turn this may allow them to live towards what they value in life.
1485854|NCT03075345|Behavioral|Treatment as usual (dietetic intervention)|Six sessions of a dietetic intervention will be psychoeducational in nature around weight and nutrition, delivered by professionals working in the service.
1485855|NCT03075332|Other|combined training|Combined training consisting of aerobic and resisted training in the same training session for 15 weeks followed by 5 weeks of detraining
1485856|NCT03075319|Procedure|Received perioperative photograph|"All participants in experimental group were adviced to see periopertive knee photograph before rehabilitation everyday.
Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.
The outcome assessors were blinded to treatment groups."
1485857|NCT03075319|Procedure|Didn't receive perioperative photograph|"All participants in active comparator group didn't receive perioperative knee photograph.
Postoperative knee ROM were recorded at day 3, 6 week, 3 month and 6 month. Flexion and extension angle were measured with long arm goniometer.
The outcome assessors were blinded to treatment groups."
1485858|NCT03075306|Behavioral|intervention|the 12-month CHAMPION intervention with 1) a health coach, a trained mental health program employee, who provides healthy lifestyle counseling and support for weight management, a healthy diet and increased physical activity incorporating techniques to engage both the youth and parents; and 2) support from health providers who will provide basic weight management messages and encouragement for behavior change.
1485859|NCT03075293|Other|Determination of pain management|Determine of pain management given to children with appendicitis in ER according to their medical records
1485860|NCT03075280|Procedure|400ml high carbohydrate liquid diet before ERCP|400ml high carbohydrate liquid diet uptake 2 hours before ERCP
1485861|NCT03075267|Drug|PT010 (BGF MDI) 320/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
1485862|NCT03075267|Drug|PT010 (BGF MDI) 160/14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
1485863|NCT03075267|Drug|PT003 (GFF MDI) 14.4/9.6 µg|A single dose of study drug will be administered on Day 1 and BID doses will be administered Day 2 through Day 7 of the Treatment Period, with a final single administration of study drug occurring on the morning of Day 8.
1485864|NCT03075254|Device|A Peltier for Sensory testing|Subjects will be trained to rate the magnitude of late sensations elicited following brief (700 msec) contact of a preheated thermode with the glabrous (palmar) skin of either hand/foot either numerically or using a visual analogue scale.
1485865|NCT03075254|Device|functional magnetic resonance imaging for Brain Neuroimaging|to evaluate baseline changes in regional cerebral blood flow to nociceptive thermal stimuli applied to the extremities of FM patients and healthy volunteers.
1485866|NCT03075254|Device|fMRI for Spinal Cord Neuroimaging|The subjects will be positioned supine and immobilized by means of a padded head support. The spinous process of the first thoracic vertebra (T1) will be aligned with the center of surface Neuro - coil. This coil will be employed for both transmission of radio-frequency (RF) pulses and detection of the magnetic resonance (MR) signal. A modified FLASH sequence will be employed to obtain Blood Oxygen Level Dependent (BOLD)-sensitive images of the spinal cord.
1485867|NCT03075241|Drug|Zolpidem|Zolpidem tablets, 10mg, 10pm (before bedtime) for 14 nights
1485868|NCT03075241|Drug|Zoplicone|Zoplicone tablets, 7.5mg, 10pm (before bedtime) for 14 nights
1485869|NCT03075241|Drug|Placebo|Inactive or inert pill which will be used as a comparator
1485870|NCT03075228|Device|IntelliCap|Sampling of the small intestine using a samling capsule.
2010616|NCT02915744|Drug|Paclitaxel|
1485872|NCT03075202|Device|e-cigarette, brand name JUUL|This is not an experimental study/trial, rather a prospective observational study. Device will be offered to cohort, but they are not mandated to take or use the device.
1485873|NCT03075189|Dietary Supplement|Whey protein supplement|"During hospitalization the intervention group will receive a whey protein enriched snack/meal in the morning and before bedtime. They will be given 15 gr of protein every morning, and the meal before bedtime will vary in protein content according to the individual needs. Diet registration will be carried out every day during hospitalization. At discharge, participants in the intervention will be instructed and advised with focus on consuming more protein at home.
The control group are having the ordinary hospital diet and are following normal guidelines. They are not offered the protein focused counseling at discharge.
Both groups have diet registration and testing at baseline, discharge and follow-up."
1485874|NCT03075176|Device|Wavefront optimized LASIK|Wavefront optimized laser vision correction
1493095|NCT03020030|Drug|Doxorubicin|Standard of Care
2010617|NCT02915744|Drug|Docetaxel|
2010618|NCT02915744|Drug|Nab-paclitaxel|
2010619|NCT02915510|Dietary Supplement|Glycomacropeptide-based protein substitute|
1485878|NCT03075163|Procedure|Acupressure|"Specifically trained personnel will apply pressure on the wrists bilaterally at the P6 point for up to 3 minutes. The P6 point is located three fingerbreadths from the wrist crease on the volar surface of the arm between the palmaris longus and flexor carpi radialis.
In the event of failure in the acupressure group, further treatments will be identical to the control group. Since Ondansetron is the standard Post Anesthetic Care Unit treatment, it will be first line rescue therapy except in the case that the patient has received 8mg in the past 6 hours. If needed, further antiemetic pharmacologic treatments may include, but are not limited to, phenergan, metoclopramide, haloperidol, diphenhydramine or propofol at the clinical discretion of the patient's anesthesiology care team."
1485879|NCT03075163|Drug|Ondansetron|Ondansetron is a medication that belongs to the drug class known as antiemetic and selective 5-HT3 receptor antagonist. Ondansetron is prescribed for the treatment of nausea and vomiting due to cancer chemotherapy and also used to prevent and treat nausea and vomiting after surgery.
1485880|NCT03075150|Device|Masimo Rainbow sensor|The Masimo Rainbow is a portable handheld device connected to a sensor that measures SpHb, SpO2, pulse rate (PR) and perfusion index (PI) in addition to pleth variability index (rPVI).
1485881|NCT03075137|Device|External counter pulsation (ECP)|standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
1485882|NCT03075124|Device|External Counter Pulsation|A standard ECP protocol involves 35 one-hour sessions (once per day, 5 days a week) and continuous for 7 weeks. ECP consists of three sets of pneumatic cuffs attached to each of the patient's legs at the calf and lower and upper thigh. The inflation of the cuffs is triggered by a computer, and timing of the inflation is based on the R wave of the electrocardiogram. The ECP therapist adjusts the inflation and deflation timing to provide optimal blood movement per a finger plethysmogram waveform reading.
1485883|NCT03075111|Diagnostic Test|ImmunoXpert|Host based immune response test distinguishing viral versus bacterial infection
1485884|NCT03075098|Device|Digital colposcope|Diagnostic accuracy of colposcopic examination; Swede scoring system will be used to evaluate the colposcopic examination. Then, the specificity (%) and the sensitivity (%) of colposcopic examination will be calculated using the cutoff value of 8 to segregate dysplastic from non-dysplastic lesions.
1485885|NCT03075085|Behavioral|WISE (We Inspire Smart Eating)|An enhanced implementation strategy for evidence-based obesity prevention in childcare
1485886|NCT03075072|Radiation|Whole brain radiation|Treatment of the whole brain radiation with radiation. When possible the hippocampus will be spared from radiation.
1485887|NCT03075072|Radiation|Stereotactic radiation (SRS)|Focused radiation to each individual brain metastasis without treatment of the remainder of the brain.
1485888|NCT03075059|Behavioral|Child Life|For patients randomized to the intervention group, the Child Life specialist will reach out via telephone to offer support and expertise in helping prepare their child and themselves for outpatient surgery to help decrease anxiety and increase coping. Concepts covered will include: developmentally appropriate language for explaining surgery and related procedures, potential coping skills to ease separation for caregivers and pediatric patients. Additionally, written materials (attached) covering the same information will be sent via mail or email covering the same information discussed in the phone conversation to serve as a refresher and resource before the day of surgery. On the day of surgery, the patient will receive standard of care (SOC) Child Life Services available to all patients.
1485889|NCT03075046|Device|Blue LED 405 nm|It will be applied a 405 nm blue Tonderm LED with a power of 1.66 W / m2, in a closed room by a physiotherapist for 30 minutes. The apparatus shall be supported on a tripod, statically, externally, 5 cm away from the vulva and vagina region, with the patient naked, in gynecological stretcher and lithotomy position. The protocol will consist of only one session.
1485890|NCT03075046|Other|Questionnaire of anamnesis|The participants will answer the anamnesis Questionnaire that will be applied by the physiotherapist
1485891|NCT03075033|Device|Shikani optical stylet|Tracheal intubation is performed using Shikani optical stylet. The shikani optical stylet was bent to the same bend as a Mackintosh laryngoscope blade, lubricated and the endotracheal tube was mounted on it. The tube was settled to the stylet by the 'adjustable tube stop' so that the tip of the stylet did not project beyond the end of the tube. After intubation the 'tube stop' was released and the tube was unmounted into the trachea; the stylet was removed.
1485892|NCT03075033|Device|Flexible fiberoptic bronchoscope for|AwakeRracheal intubation using flexible fiberoptic bronchoscope in patients with cervical spine instability
1485893|NCT03075020|Other|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass
1485894|NCT03075020|Other|AIR|Room air will be administered as placebo
1485895|NCT03075007|Radiation|Florbetaben F18|10Meq of Florbetaben F 18 via intravenous injection is to be used. Visit duration is approximately 3 hours.
1485896|NCT03075007|Procedure|Transcranial Doppler|All participants will undergo Doppler ultrasonography that measures the velocity of blood flow through the brain's blood vessels. Visit duration is approximately 45 minutes and will be scheduled for either the same day or another day as the PET scan.
1485897|NCT03074994|Drug|Peri-articular TXA (15 mg/kg)|combined with multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg) mixed NSS up to 75 mL
1485898|NCT03074994|Drug|Intraarticular TXA 2 g (40 mL)|inject separate from multimodal local anesthetic infiltration (0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 75 mL)
1485899|NCT03074994|Procedure|TXA combined with multimodal local anesthetic infiltration inject into peri-articular area|(Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to capsular closure and tourniquet deflation
1485900|NCT03074994|Procedure|TXA 40 mL inject into intraaricular knee capsule|after multimodal local anesthetic infiltration (Anterior soft tissue 25 mL+Medial gutter area 25 mL+Lateral gutter area 25 mL) prior to tourniquet deflation
1485932|NCT03074760|Diagnostic Test|H. pylori|Diagnostic test for the presence of H. pylori infection in the population groups
1485901|NCT03074981|Device|Combined TopClosure & Vcare Alpha|"Combined TopClosure & Vcare Alpha Treatment. The investigators will debride the wound if necessary. Wound biopsies will be taken to determine the existing pathogens and direct the antibiotic treatment.
Wound measurements will be taken. Afterwards the wound will be approximated by the TopClosure device and the patient will be connected to a Negative Wound pressure device Vcare Alpha.
The investigators will change dressings according to schedule. If the wound is clean the investigators will change dressings every 3-5 days, If the wound is infected the investigators will change dressings every 2-4 days, If the investigators encounter a severe infected wound with a lot of pus the investigators will change dressings every 1-3 days, The investigators will determine the time to heal when the wound is clean and there is no further need for Negative Pressure Wound Treatment (ROI-NPT) up to 10 weeks."
1485902|NCT03074968|Drug|Benzydamine Hydrochloride|Benzydamine Hydrochloride application
1485903|NCT03074968|Drug|Normal saline|normal saline application
1485904|NCT03074955|Device|leg wrapping with tension|"Apply elastic bandages with tension to both legs before injecting propofol.
After 3 minutes, remove elastic bandages."
1485905|NCT03074955|Procedure|Trendelenburg position|"Apply Trendelenburg position positon of 10 degree after injectin propofol
After 3 minutes, change to supine position"
1485906|NCT03074955|Device|leg wrapping without tension|"Apply elastic bandages without tension to both legs before injecting propofol.
After 3 minutes, remove elastic bandages"
1485907|NCT03074955|Procedure|supine position|1.maintain supine position
1485909|NCT03074929|Behavioral|Novel risk communication|The investigators will develop novel risk communication messages to communicate the risks of childhood obesity to parents of children with obesity. The investigators will consider several novel approaches around message content and framing, but primarily, we propose using microsimulation models to forecast a child's long-term health risks, based on his age, race, gender, BMI, and family history of CVD.
1485910|NCT03074916|Device|DIP arthroplasty or arthrodesis|Arthroplasty of the DIP Joint or arthrodesis of the DIP joint
1485911|NCT03074903|Device|Intrauterine system|Women having the Skyla intrauterine system at different times during their menstrual cycle report their bleeding patterns through daily texts.
1485912|NCT03074890|Device|Application Protocol|Application lMassive Transfusion Protocol
1485913|NCT03074877|Behavioral|Family Check-Up|The Family Check-Up (FCU) is a brief, family-based program to prevent Substance Use/Substance Use Disorder (SU/SUD) with replicated efficacy
1485914|NCT03074864|Drug|Erlotinib Hydrochloride|Subjects receive erlotinib tablet 150mg orally once daily, after 12 weeks of induction phase, local radiotherapy is intercalated, and followed by 24-week erlotinib maintenance phase. At the end of maintenance, the subjects enter into the follow-up period.
1485915|NCT03074851|Dietary Supplement|low sodium salt|To give free low sodium salt intervention for 2 months
1485916|NCT03074851|Other|informational intervention|to give reporter informational intervention.
1485917|NCT03074838|Procedure|Transarterial aortic valve implantation - TAVI|After insertion of a guidewire, either through the femoral artery or through the ascending aorta, the aortic ostium is dilated by a balloon and the valve is introduced through a catheter and expanded in the ostium.
1485918|NCT03074838|Procedure|Surgical aortic valve replacement - SAVR|The patient is operated through a sternotomy and coupled to a heart lung machine. The aorta is opened and the native valve excised. Then a biological artificial heart valve is sutured in place.
1485919|NCT03074825|Drug|Chiauranib|Take 50mg orally once daily
1485920|NCT03074812|Device|Transcranial Direct Current Stimulation|Transcranial direct current stimulation (tDCS) is a commonly used non-invasive form of brain stimulation for studying motor functions in health and disease [36]. It involves the attachment of surface electrodes to the scalp through which very small electric currents (1 or 2mA) are applied via a current regulated device. The currents do not produce any sensation. The applied current affects excitability of underlying neural tissue.
1485921|NCT03074799|Other|Symptom -based Screening(Child Contacts)|"Aim 1: Determine the number of child contacts per adult index case of tuberculosis to assess quality of contact tracing.
Aim 2: Determine the percentage of child contacts initiated on IPT or antituberculous therapy (ATT) and compare between intervention (symptom-based, nurse-led initiation of IPT) vs control clinics (TST-based screening with referral to hospital, current standard of care).
Aim 3: Compare outcomes of children initiated on IPT between both groups including: completion of therapy, discontinuation due to side effects, lost to follow up, and adherence while on therapy."
1485922|NCT03074799|Other|Clinical based Decisions|the child is symptomatic, they will be referred to the hospital for further evaluation of TB disease including both chest X-ray and testing of either sputum or swallowed sputum. If the child is asymptomatic, the TB nurse at the local clinic will initiate them on weight-appropriate dosing of IPT
1485923|NCT03074786|Drug|Dapivirine|Silicone elastomer vaginal matrix ring
1485924|NCT03074786|Drug|Truvada|Tablets to be taken orally daily
1485925|NCT03074773|Drug|Dexamethasone|"Dexamethasone is commonly used in the perioperative period to reduce postoperative nausea and vomiting. Additionally, it has been reported to have analgesic effects.
The analgesic effect of epidural or perineural dexamethasone administration is not clear. Dexamethasone might have a local anesthetic effect on nerve by direct membrane action"
1485926|NCT03074773|Device|ultrasound|The growth of ultrasound technology and, with it, our ability to visualize the pleura and other structures in and around the paravertebral space has fueled a tremendous increased interest in performing thoracic paravertebral blocks. These blocks may be used for acute pain control, as an adjunct to general anesthesia for peri-operative pain control and, in some practices, as the primary anesthetic
1485927|NCT03074773|Procedure|paravertebral block|paravertebral block is an effective analgesic technique used in various types of surgery, trauma and chronic pain. it decreases postoperative pain and reduces opioid consumption which in turns improve postoperative pulmonary function hoping for early extubation.
1485928|NCT03074773|Drug|Bupivacaine|it is an amino amide local anesthetic drug
1485929|NCT03074773|Other|isotonic saline|sterile sodium chloride solution at physiological concentration (0.87%); used as diluting agent when added to local anesthetic drug
1485930|NCT03074760|Diagnostic Test|Adenovirus|Diagnostic test for the presence of the adenovirus in the population groups
1485931|NCT03074760|Diagnostic Test|Rotavirus|Diagnostic test for the presence of the Rotavirus in the population groups
1485933|NCT03074747|Diagnostic Test|questionnaires|After filled the questionnaires, the patients will receive the PSG monitoring
1485934|NCT03074734|Other|Exposure to secondhand tobacco smoke|The intervention is exposure to secondhand smoke of COPD and asthma patients in outside smoking areas (no specific drugs or devices are tested in this study). Study subjects will be asked to spend at least 15 minutes in the outdoor smoking area, a preferable time of 30-60 mins. During the exposure period (15-60 min) subjects´ respiratory rates will be recorded using RESpeck/leosound device, as well as the air quality which will be monitored using AirSpeck/SidePak device.
1485935|NCT03074721|Device|PCI Suite Software|PCI with PCI Suite Software
1485936|NCT03074721|Other|conventional PCI|conventional PCI without PCI Software
1485937|NCT03074708|Other|3D visualization and 3D printing|From January 2016 to December 2018,the clinical data of 200 patients with the hepatobiliary and pancreatic diseases will be collected.All the patients received abdominal CT scanning and 3D reconstruction. Then we used the 3D reconstruction model and the 3D printed model based on the 3D reconstruction model in the operation planning and the operation.The clinical data include operative time, intraoperative blood loss,and postoperative complications after surgery.
1485938|NCT03074695|Procedure|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm cerebral spinal fluid (CSF) position. No intrathecal dosing
1485939|NCT03074695|Procedure|Standard Epidural (EPL)|Standard epidural placement
1485940|NCT03074695|Drug|Dural puncture epidural (DPE)|Epidural with spinal needle placed to confirm CSF position. No intrathecal dosing. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
1485941|NCT03074695|Drug|Standard Epidural (EPL)|Standard epidural placement. Ropivacaine 0.1% and Fentanyl 2mcg/mL.
1485942|NCT03074682|Device|Lifeflow|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
1485943|NCT03074682|Device|Push/Pull|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
1485944|NCT03074682|Device|Pressure Bag|Following a 5-minute training video where instructions on device are presented to participants, participants are given the device, a 1L NS bag, tubing and a 22g IV. Prior to beginning the simulation, they will demonstrate ability to set up the device and fill an empty container with fluid.
1485945|NCT03074669|Behavioral|ACT program|ACT program consists of seven modules that have been adapted for the online environment. Each module is structured like a therapy session with at least two homework assignments.
1485946|NCT03074656|Other|Therapeutic drug monitoring|Treatment algorithm based on assessments of serum drug levels and anti-drug antibodies
1485947|NCT03074656|Other|Standard care|Treatment algorithm based on standard clinical assessments, without knowledge of serum drug levels and anti-drug antibodies
1485948|NCT03074643|Behavioral|Weight loss intervention months 0-6|All participants will undergo a dietary weight loss intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass. The weight loss intervention will incorporate nutrition education (via group and individual meetings with the study dietitian), self-monitoring skills, cognitive-behavioral strategies for promoting lifestyle behavior modifications, and planned meals. Behavioral and educational group and individual sessions will be held weekly in a 3:1 ratio (3 group and 1 individual session per month).
1485949|NCT03074643|Behavioral|Exercise intervention months 0-6|All participants will be expected to participate in a supervised, center-based exercise program involving moderate-intensity aerobic exercise (e.g., treadmill walking) 3 days/wk during the 6-month weight loss intervention in accordance with the American Heart Association and the American College of Sports Medicine physical activity recommendations for older adults.
1485950|NCT03074643|Dietary Supplement|Carbohydrate supplement for months 0-6|Participants in the lower protein / higher CHO diet group (RecProt) will be provided a carbohydrate supplement (~50 g of carbohydrate and 220 calories) to consume daily during the 6 month weight loss intervention.
1485951|NCT03074643|Dietary Supplement|Protein supplement for months 0-6|Participants in the higher protein / lower CHO diet groups (6-mon HiProt and 18-mon HiProt) will be provided a protein supplement (~50 g of protein and 220 calories) to consume daily during the 6 month weight loss intervention.
1485952|NCT03074643|Dietary Supplement|Protein supplement for follow-up months 7-18|Participants in the higher protein / lower CHO diet (18-mon HiProt) will be provided a protein supplement (~50 g of protein and 220 calories) to consume daily during the 12-month follow-up.
1485953|NCT03074630|Drug|Dapagliflozin|5 weeks 10mg dapagliflozin once daily
1485954|NCT03074630|Drug|Rosuvastatin|9 weeks 10mg dapagliflozin once daily
1485955|NCT03074617|Other|LTE field|electromagnetic field of the latest standard in mobile communication (long term evolution, LTE)
1485956|NCT03074617|Other|sham field|no electromagnetic field
1485957|NCT03074604|Procedure|aortic no-touch OPCABG|(Study arm 1) In this intervention only the internal mammary artery grafts will be used (i.e. left internal mammary artery graft, right internal mammary artery graft, or a Y-graft that uses right internal mammary artery graft anastomosed onto left internal mammary artery graft to allow for a wide territory of myocardial revascularization). However, in the rare event that the aforementioned approach is insufficient to reach all target vessels, a reversed (great) saphenous vein graft may be used to extend the left internal mammary artery graft or the right internal mammary artery graft.
1485958|NCT03074604|Procedure|OPCABG with partial clamp applying carbon dioxide|(Study arm 2) In this intervention chest cavity will be insufflated with carbon dioxide at a flow above 5 l/min during the entire surgical procedure.
1485959|NCT03074604|Procedure|OPCABG with partial clamp|"(Study arm 3) This is the control arm undergoing traditional OPCABG with partial clamp."
1485960|NCT03074591|Drug|Ferric Carboxymaltose 50Mg/Ml Inj 15Ml|After baseline assessments patients will be randomised in a 1:1 ratio to receive Ferric Carboxymaltose IV or placebo/saline (normal saline: 0.9% w/v NaCl). In the Treatment group, Ferric Carboxymaltose will be administered according to the dosing schedule.
1485961|NCT03074591|Drug|Saline Solution for Injection|In the placebo/saline group, patients will receive the aequivalent number of normal saline infusions.
1493096|NCT03020030|Drug|ETOPOSIDE|Standard of Care
1485963|NCT03074578|Behavioral|Watching Video-clip 2|Video -clip 2 contains neutral images and text
1485964|NCT03074565|Device|Ultrasonic alone|Sanative therapy using ultrasonic instrumentation alone
1485965|NCT03074565|Device|Ultrasonic+|Sanative therapy using ultrasonic plus hand instrumentation
1485966|NCT03074552|Dietary Supplement|LactoLevure|The probiotic preparation will consist a combination of four probiotics: Lactobacillus acidophilus LA-5 1.75 × 109 CFU, Lactobacillus Plantarum 0.5 × 109 CFU, Bifidobacterium lactis BB-12 1.75 × 109 CFU και Saccharomyces boulardii 1.5 × 109 CFU per capsule (LactoLevure, UniPharma, Athens, Greece).
1485967|NCT03074552|Other|Placebo|Placebo will consist of identical capsules of powdered glucose polymer
1485968|NCT03074539|Drug|Riociguat|Patients will be treated with Riociguat according to guidelines (2015 ERS/ESC guidelines for the diagnosis and treatment of pulmonary hypertension) and manufacturers recommendation.
1485969|NCT03074539|Procedure|Pulmonary Endarteriectomy|Patients will receive Pulmonary Endarteriectomy if they are suitable for this procedure according to the recommendation of the local CTEPH board. Patients must also consent to this surgical procedure.
1485970|NCT03074539|Procedure|Ballon Pulmonary Angioplasty|Patients will receive Ballon Pulmonary Angioplasty if they are suitable for this procedure according to the recommendation of the local CTEPH board (e.g. not suitable for PEA). Patients must also consent to this procedure.The BPA will be accomplished in several interventions.
1485971|NCT03074526|Other|Amniotic Fluid|Amniotic Fluid
1485972|NCT03074526|Drug|Saline Placebo|Saline Placebo
1485973|NCT03074513|Drug|Atezolizumab|1200 mg by vein on Day 1 of each 21-day cycle. Atezolizumab administered prior to Bevacizumab, with a minimum of 5 minutes between dosing.
1485974|NCT03074513|Drug|Bevacizumab|15 mg/kg by vein every 3 weeks on Day 1 of each 21-day cycle.
1485975|NCT03074513|Behavioral|Phone Call|About every 3 months after end-of-treatment visit, participant or caregiver called by study staff.
1485976|NCT03074500|Device|Kinesio taping|Kinesio tape will be applied by using space correction and fascia correction technique on forearm of the patients for the treatment of lateral epicondylitis
1485977|NCT03074500|Other|Sham taping|Sham taping will be performed without using any technique
1485978|NCT03074500|Other|Exercise|Stretching exercises of wrist 30 seconds to one minute, twice a day and strengthening exercises will performed be 10 repetitions in 2 or 3 series. .
1485979|NCT03074487|Device|Near-infrared spectroscopy|
1485980|NCT03074487|Device|Long loop reflex measurements|
1485981|NCT03074474|Device|OviTex Permanent 1S|OviTex 1S is a reinforced bioscaffold consisting of layers of extra-cellular matrix derived from sheep stomachs. The layers are embroidered together with a monofilament polypropylene. One side of the mesh has blue polypropylene stitching, which provides a surface conducive to native tissue growth. The other side of the mesh is a smooth surface intended to minimize tissue attachment (adhesions).
1485982|NCT03074461|Procedure|Side-to-End Anastomosis|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a side-to-end colorectal anastomosis.
1485983|NCT03074461|Procedure|Transverse Coloplasty|During the scheduled low anterior resection (LAR) in patients with distal rectal cancer and anticipated anastomosis in the mid or distal rectal third, the reconstruction phase of the LAR consists of the implementation of a transverse coloplasty pouch. For this purpose an end-to-end colorectal anastomosis is initially performed, followed by a longitudinal incision of approx. 8-10 cm length proximal of the anastomosis and a subsequent transverse suture in terms of the coloplasty technique.
1485984|NCT03074448|Device|Aquanet|Aquanet bowel cleansing devices
1485985|NCT03074448|Drug|Sodium Picosulfate|Sodium Picosulfate solution (Picoprep)
1485986|NCT03074435|Device|Insecticidal paint|Houses will be painted with insecticidal paint
1485987|NCT03074435|Device|Larvicide|Larval breeding sites will be treated with larvicide
1485988|NCT03074435|Biological|Ivermectin|Doses of Ivermectin will be injected to peri-domestic animals
1485989|NCT03074435|Behavioral|IEC|A reinforced information, education and communication strategy will be implemented.
1485990|NCT03074422|Procedure|Hypnosis|Hypnosis session performed by a board certified senior anesthesiologist during the frame fixation on the patient's head.
1485991|NCT03074409|Drug|oxytocin|self-administration of oxytocin (nasal spray)
1485992|NCT03074409|Drug|placebo|self-administration of placebo (nasal spray)
1485993|NCT03074396|Device|Use of DialysisNet for doctor|DialysisNet is mobile application for physicians for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record standard.
1485994|NCT03074396|Device|Use of Avatar Beans for patient|Avatar Beans is mobile application for haemodialysis patients. Patient-centred data integration and exchange were based on the American Society for Testing and Materials Continuity of Care Record.
1485995|NCT03074383|Behavioral|Workshop|A 15-minute Individual meetings with each professional (nurse, pharmacist, nutritionist, physical educator, physiotherapist and social worker) of the multidisciplinary team in which diabetes education and self-care topics will be approached.
1485996|NCT03074383|Behavioral|Usual Care|Usual care at outpatient Diabetes clinic AND 3 brief meetings with research team to receive printed educational material.
1485997|NCT03074344|Device|XLHA+CoQ10|XLHA+CoQ10 for four times a day for 12 weeks.
1485998|NCT03074344|Device|Hyaluronic acid (HA)|Hyaluronic acid (HA) for four times a day for 12 weeks.
1948844|NCT01467843|Behavioral|Cognitive Behavioral Therapy|The Cognitive Behavioral Therapy Intervention will be delivered during 8 weekly classes each lasting 2 hours. The classes will be held at a conveniently located Group Health Facility.
1486000|NCT03074318|Drug|Avelumab|Given IV
1486001|NCT03074318|Other|Laboratory Biomarker Analysis|Correlative studies
1486002|NCT03074318|Drug|Trabectedin|Given IV
1486004|NCT03074292|Procedure|phototherapy|estimate oxidative stress and trace elements in neonates with unconjugated hyperbilirubinemia after exposure to phototherapy
1486005|NCT03074279|Other|Interview with a psychologist and self-reported questionnaires|The family members or patients who decide to participate in the study will be asked to complete an interview with a psychologist (semistructured interview, standard form, questionnaires) and self-reported questionnaires
1486006|NCT03074266|Diagnostic Test|Blood coagulation test|Baseline blood coagulation test pre heparin administration and Blood coagulation test after heparin administration
1486007|NCT03074253|Diagnostic Test|Echocardiography|Patients are undergoing echocardiography
1486008|NCT03074253|Diagnostic Test|magnetic resonance imaging|Patients are undergoing magnetic resonance imaging
1486009|NCT03074253|Diagnostic Test|computed tomography|Patients are undergoing computed tomography
1486010|NCT03074253|Diagnostic Test|blood withdrawl|Peripheral blood samples are being collected from all patients
1486011|NCT03074240|Procedure|TAPB Group|Subjects allocated to the TAPB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
1486012|NCT03074240|Procedure|RSB Group|Subjects allocated to the RSB group will be monitored for instances of intraoperative local anesthetic supplementation, analgesic administration, or conversion to general anesthesia will be compared.
1486013|NCT03074240|Procedure|conversion to general anesthesia|For those who do not respond to TAPB or RSB to allow for completion of the intended procedure.
1486014|NCT03074227|Other|Allogeneic faecal transplantation|"Patients will get bowel lavage through a nasoduodenal tube. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with allogeneic faecal microbiota transplantation via the nasoduodenal tube.
Faeces will be collected from a donor."
1486015|NCT03074227|Other|Autologous faecal transplantation|Patients will get bowel lavage through a nasoduodenal tube at our centre. This bowel lavage consists of 2-3 litres of macrogol electrolytes (Klean-Prep) solution. After that, patients will be treated with autologous faecal microbiota transplantation via the nasoduodenal tube.Faeces will be collected from the patient him/herself, in which their own faeces (autologous) will be used as a placebo.
1486016|NCT03074214|Procedure|percutaneous coronary intervention|"All STEMI patients enrolled will at first receive Device(such as: stent or balloon) treatment for their coronary artery."
1486017|NCT03074201|Procedure|Cholangioscopy|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
1486018|NCT03074201|Device|Spyglass DS Cholangioscope|Cholangioscopy used instead of fluoroscopy-based ERCP to facilitate clearance of bile duct stones.
1486019|NCT03074175|Radiation|radiotherapy|The patient in supine position with hands catch the plate column by crossing the head, and body fixed by vacuum mould. An enhanced 4DCT scan is conducted with a layer thickness and a distance each of 5 mm. the imaging information is input into the Eclipse program system,the gross tumor volume of the primary tumor (GTVt) and pathological lymph nodes (GTVn) are delineated,GTV is expanded in all 3D direction to create PGTV by 5mm margin for squamous cell carcinoma, or an 8mm margin for adenocarcinoma.Radiaion therapy is delivered by 5F-IMRT.For conventional fractionated radiotherapy,the prescribed dose covering 95% of PGTV is 60Gy/30F/6W.For hyperfractionated radiotherapy,the prescribed dose covering 95% of PGTV is 50Gy/11F/2W.lung V20 <25%, lung V30 <18%, spinal cord <36 Gy.
1486020|NCT03074162|Drug|Diclofenac Sodium|twice daily
1486021|NCT03074162|Drug|Diclofenac & Capsaicin|twice daily
1486022|NCT03074162|Drug|Diclofenac Sodium Topical Gel|twice daily
1486023|NCT03074136|Device|Photodinamic therapy|Dentin sealant (HELBO® Endo Seal, Bredent, Senden, Germany) will be applied over the crown area and light cured. The root canals will be filled with the phenothiazine chloride (HELBO® Endo Blue, Bredent, Senden, Germany), agitated with a size 15K-file and left in the canal for 2 min. After this time, the root canals will be rinsed with distilled water to remove the excess of the photosensitizer, dried with paper points. The disposable 450 µm fiberoptic tip (3D HELBO® Endo Probe, Bredent, Senden, Germany) will be placed in the apical portion of the root canal at the point where resistance to the fiber will be felt, and root canal will be irradiated with HELBO® TheraLite Laser (λ = 660 nm, power = 100 mW) for 60 s (total energy, 6 J) in a continuous wave mode.
1486024|NCT03074136|Device|Diode laser|High-power diode laser therapy will be applied by using Epic diode laser (Biolase® Technology, Inc., San Clemente, CA, USA) with settings determined in laboratory researches (λ = 940 nm, maximal power 10W).
1486025|NCT03074136|Drug|0.5% Sodium hypochlorite|Chemomechanical preparation will be completed by hand instruments, with minimal instrumentation, and usage of sodium hypochlorite with minimal bactericidal concentration (0.5%, pH 12), on room temperature (21 degrees Celsius).
1486026|NCT03074123|Diagnostic Test|low-dose cosyntropin stimulation test|Each subject recruited in the study will undergo low dose cosyntropin stimulation test via intravenous short 2.5 cm plastic tube. 1 μg/ml ACTH aliquot stock solution will be pushed through, followed by 5 ml physiologic saline (0.9%). For each subject, serum and salivary cortisol will be measured just before cosyntropin administration and 30 minutes later.
1486027|NCT03074110|Device|Isocapnic hyperventilation|Mechanical hyperventilation to enhance elimination of inahalation anesthetics. Administration of a precalculated flow of CO2 according to gender and weight into the inspiratory limb of the breathing circuit in order to avoid hypocapnia.
1486028|NCT03074097|Drug|Bupivacaine 0.125%|Before induction of general anesthesia. Lumber epidural Catherine was inserted,Bupivacaine 0.125% epidural infusion started.
1486029|NCT03074097|Drug|Bupivacaine 0.25%|After induction of general anesthesia, bilateral Ultrasound-guided Rectus Sheath Block was done by bupivacaine 0.25%
1486030|NCT03074071|Behavioral|Hope Enhancement Workshop|Participants in the workshops will be prompted and guided through exercises that help them get in touch with goals that are not explicitly related to cure of disease. These goals will include symptom relief and other personal and or professional objectives.
1486031|NCT03074058|Drug|Fosrenol ODT (Lanthanum Carbonate, BAY77-1931)|Fosrenol orally disintegrating tablet, ODT (Lanthanum Carbonate, BAY77-1931) 500 mg, TID
1486032|NCT03074058|Drug|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931)|Fosrenol chewable Tablet (Lanthanum Carbonate, BAY77-1931) 500mg, TID
1486035|NCT03074032|Drug|ONC1-0013B|ONC1-0013B per os daily
1486038|NCT03074006|Drug|TEW-7197|20mg tablets (doses will be determined through dose-escalation part)
1486039|NCT03073993|Procedure|feeding tube insertion|Feeding tube was inserted in hemodynamically stable babies for purpose of feeding
1486040|NCT03073980|Drug|IV Acetaminophen|IV Acetaminophen for pain control during procedure
1486041|NCT03073980|Drug|PO Acetaminophen|PO Acetaminophen for pain control during procedure
1486042|NCT03073980|Drug|IV Fentanyl|IV Fentanyl for pain control during procedure
1486043|NCT03073980|Drug|Propofol|Propofol for IV conscious sedation
1486044|NCT03073980|Other|Placebo IV Acetaminophen|Placebo IV Acetaminophen
1486045|NCT03073980|Other|Placebo PO Acetaminophen|Placebo PO Acetaminophen
1948845|NCT01467843|Behavioral|Mindfulness Based Stress Reduction|The Mindfulness Based Stress Reduction Classes will be delivered in 8 weekly classes each lasting 2 hours.
1486048|NCT03073954|Other|Working memory training|"The working memory intervention training programme consists of a domain-general cognitive working memory training programme. One training session will take 20 to 30 minutes, and participants will have to complete approximately 40 cognitive training sessions.
The sham treatment is the same as the intervention training however it does not increase in difficulty. Participants are presented with the same task at the same level of difficulty over and over again. Thus a training effect is not expected."
1486049|NCT03073954|Behavioral|Standardised healthy lifestyle coaching|Participants will receive standardised healthy living coaching focusing on healthy diet and daily physical activity.
1486050|NCT03073941|Device|Persona total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
1486051|NCT03073941|Device|Nexgen total knee system|314 participants with knee osteoarthritis set to receive primary total knee arthroplasty will receive either Persona knee or the Nexgen
1486052|NCT03073928|Procedure|Interscalene Block|Regional Anesthesia procedure in the neck
1486053|NCT03073928|Procedure|Paracoracoid SPB|Regional anesthesia procedure under the collar bone
1486054|NCT03073928|Drug|Ropivacaine|Amide local anesthetic Ropivacaine will be used in same concentration (milligrams) in both active comparator and experimental group
1486055|NCT03073902|Other|Liquid biopsy|
1486056|NCT03073889|Procedure|Scalp Nerve Block|A scalp nerve block involves regional anesthesia to the nerves that innervate the scalp, including the supraorbital and supratrochlear nerves, branches of the ophthalmic branch of the trigeminal nerve; the zygomaticotemporal nerves, terminal branch of division two of the trigeminal nerve; the auriculotemporal nerves, terminal branch of the mandibular division of the trigeminal nerve; the greater and lesser occipital nerves. The scalp block is performed bilaterally with 10 solution of 0.75% ropivacaine.
1486057|NCT03073889|Procedure|Scalp infiltration|Scalp infiltration before incision. Neurosurgeons infiltrate the planned incision by a 22-gauge needle penetrated deeply to the skin at a 45°angle with 10ml solution of 0.75% ropivacaine throughout the entire thickness of the scalp.
1486058|NCT03073889|Drug|Ropivacaine|
1486061|NCT03073863|Drug|Atorvastatin|Analysis
1486062|NCT03073850|Drug|Antiplatelet|ASA or clopidogrel
1486063|NCT03073850|Drug|Anticoagulants|Edoxaban
1486064|NCT03073837|Other|Rhinovirus Challenge|Challenge with HRV-16 virus
1486065|NCT03073824|Device|vSculpt|Pelvic Floor Toning and Vaginal Rejuvenation Device
1486066|NCT03073811|Dietary Supplement|Protein enhanced nutrition intervention|Participants will be provided 30 grams of high quality protein (20 grams from Ensure Enlive and 10 grams of whey protein powder) three times a day for two weeks before surgery and two weeks after surgery.
1486067|NCT03073811|Other|Education Control|provided educational on the role of nutrition to prepare for and heal from surgery, and Registered Dietitian will instruct participant to follow instruction on handout.
1486070|NCT03073785|Drug|Capecitabine|Given PO
1486071|NCT03073785|Drug|Fluorouracil|Given IV
1486072|NCT03073785|Other|Laboratory Biomarker Analysis|Correlative studies
1486073|NCT03073785|Other|Pharmacological Study|Correlative studies
1486074|NCT03073785|Radiation|Stereotactic Body Radiation Therapy|Undergo hypofractionated stereotactic radiotherapy
1486075|NCT03073785|Drug|Zoledronic Acid|Given IV
1486076|NCT03073772|Behavioral|Computer-based cognitive training|A total of 36 training sessions, approximately 20 minutes long each. Five different tasks were used in training all tapping different aspects of cognitive control such as updating, shifting, visuo-spatial working memory and episodic memory binding.
1486077|NCT03073772|Behavioral|Physical fitness training|A total of 36 training sessions, approximately 40 minutes long each, with physical fitness training performed as group indoor cycling. The participants were instructed to attain a load of approximately 65-80% of their maximum heart rate.
1486078|NCT03073759|Device|dTCS|Direct current (DC) (maximum of 2 mA) stimulation delivered through surface electrodes. One electrode will be positioned above the left or right primary motor cortex, the other electrode over the forehead.
1486079|NCT03073746|Other|Health Search|
1486080|NCT03073746|Other|Standard Search|
1486083|NCT03073707|Behavioral|Sample collection|Stool samples will be collected from household members of children diagnosed with NTS infection. In addition stool samples of animals and rats will be collected as well as samples of the water supply of the household.
1486113|NCT03073460|Other|Ultrasound examination|This exam is performed at 40 weeks gestation
1486306|NCT03071796|Dietary Supplement|multivitamin supplement|supplement includes 97 natural extracts
1486084|NCT03073694|Drug|Mitomycin c|Mitomycin-c will be given to participants in Treatment Arm 1 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes. 45 minutes into the perfusion, a maintenance dose will be administered.
1486085|NCT03073694|Drug|Melphalan|Melphalan will be given to participants in Treatment Arm 2 as a one-time, intraoperative, intravenous administration for a duration of 90 minutes.
1486086|NCT03073681|Device|Survey|Patients will complete a survey describing their satisfaction with vision after cataract surgery that was performed at least 2 months prior to study enrollment.
1486087|NCT03073668|Procedure|Anterior pericardiotomy|The surgical team will perform anterior pericardiotomy. This will not be a complete pericardiectomy but rather a limited anterior incision to gain access to the heart for surgical exposure.
1486088|NCT03073668|Drug|Saline|During the measurement of cardiac hemodynamic tests, a saline bolus of 300 ml will be administered over 1-2 minutes.
1486089|NCT03073655|Other|Negative Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been limited evidence of KT is effective during application.
1486090|NCT03073655|Other|Neutral Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been not known that KT is effective or not during application.
1486091|NCT03073655|Other|Positive Verbal Input|The treatment group received a standardized therapeutic KT application. The physical therapist said that it has been known that KT has excellent result during application.
1486092|NCT03073642|Other|Pain Education|Together with hydrotherapy, patients will receive pain therapeutic education
1486093|NCT03073642|Other|Hydrotherapy|Hydrotherapy sessions, lasting 45 minutes, twice a week for 12 weeks.
1486094|NCT03073629|Diagnostic Test|Clinical Pathway|Patients will be evaluated and managed in a specialized cardiovascular clinic to determine the etiology of right heart failure and begin treatment.
1486095|NCT03073616|Device|Lung ultrasound|Lung ultrasound and chest RX
1948846|NCT01435538|Behavioral|Care pathway.|The intervention group will implement a care pathway for PFF or COPD containing three active components: a formative evaluation of the actual teams' performance, a set of evidence based key interventions and a training in pathway-development.
1948847|NCT01422005|Other|Simultaneous Bimanual training|"Patients who have had a stroke and are in the Device group will undergo 12 weeks of training using the devices.
Patients who have had a stroke and are in the Control group, will undergo 12 weeks of conventional therapy."
1486098|NCT03073590|Combination Product|Intervention factory with hot lunch|A nutritionally enhanced lunch meal program (increased dietary diversity plus inclusion of multi-nutrient fortified rice), provision of once weekly iron/folate supplement to female workers, and a BCC program conducted in the factory setting focused on improving health and nutrition for women and children, with a focus on anemia prevention.The BCC program will be enhanced to include modules on nutrition (balanced diets/dietary diversity, iron/folate rich foods), infant and young child nutrition (IYCN), and an overview module on anemia prevention, hand-washing with soap and dietary diversity at the very beginning of the intervention.
1486099|NCT03073590|Combination Product|Intervention factory without lunch program|In a selected garment factory that does not have a lunch program, the intervention will consist of the twice weekly provision of iron/folate supplements to female workers, and the enhanced BCC program, as described above.
1486100|NCT03073590|Combination Product|Control factory with lunch program|One control factory who provides regular lunch meal and a nutrition and health behavior change communications (BCC) program.
1486101|NCT03073590|Behavioral|Control factory without lunch program|One control factory was selected where only the standard Behavior change communication (BCC) was implemented.
1486102|NCT03073577|Drug|Antiaging Glycopeptide|Antiaging Glycopeptide (PKX-001) will be supplemented to islet preservation medium during islet isolation process. On the day of transplantation, preserved islets supplemented with PKX-001 are collected and washed with Transplant Media, which does not contain PKX-001, as a standard procedure. The isolation team will evaluate the final islet product based on standard assays used in standard of care practice. When product release minimal criteria are met, islets will be clinically transplanted into patients intraportally by percutaneous transhepatic access.
1486103|NCT03073564|Diagnostic Test|Endurance test for upper limbs|Subjects will initially perform maximal incremental cardiopulmnar test of upper limbs to assess the suggestion of dynamic hyperinflation (DH). After that, it will be randomized, for those who presented DH, to perform the endurance test with and without the use of positive expiratory pressure mask.
1486104|NCT03073564|Diagnostic Test|Functional test|The 6-min pegboard and ring test (6PBRT) will be performed under usual breathing and during application of the EPAP mask. In this condition will be evaluated the presence of dynamic hyperinflation, perception of effort and dipnea, in addition to exercise capacity.
1486105|NCT03073551|Other|Wii Group|Participants in the Wii group will be given a Wii console and video game to take home. The console includes a Wii balance board and remote controller. The Wii Fit game allows participants to choose different types of exercise such as yoga, aerobics, balance training, and more. Participant movements are shown on screen as they move with the balance board and remote control.
1486106|NCT03073525|Biological|Vigil|Vigil is composed of autologous tumor cells harvested from the patient at the time of initial de-bulking surgery which are then transfected extracorporeally, with a plasmid encoding for the gene for GM-CSF, an immune-stimulatory cytokine, and a bifunctional, short hairpin RNA which specifically knocks down the expression of furin, the critical convertase responsible for production of the two TGβ isoforms (TGFβ-1 and TGFβ-2).
1486107|NCT03073525|Drug|Atezolizumab|Atezolizumab is provided in a single-use, 20-cc USP/Ph. Eur. Type 1 glass vial as a colorless to slightly-yellow, sterile, preservative-free clear liquid solution intended for IV administration. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. The atezolizumab drug product is formulated as 60 mg/mL atezolizumab in 20 mM histidine acetate, 120 mM sucrose, 0.04% polysorbate 20, pH 5.8 (Phase III formulation).
1486108|NCT03073512|Other|Ultrasound examination|Participants will undergo ultrasound examination at 32 weeks gestation
1486109|NCT03073499|Procedure|Oncological Home Hospitalization|
1486112|NCT03073473|Diagnostic Test|NantHealth GPS Cancer Test|Quantitative targeted proteonomics detected by mass spectrometry with whole genome (DNA) and whole transcriptome (RNA) sequencing.
1486114|NCT03073447|Other|Specific blood sample of women under 50 years with acute MI|The specific assays, corresponding to the tests carried out as part of the WAMIF study will be sampled before discharge. Some assays, including hormonal and thrombophilia will be centralized in order to standardize the results and their interpretation. All the biological data will be pooled and analyzed by IVS. a sample of blood will be made for later analysis in the context of a serum bank.
1486115|NCT03073421|Other|Qualitative interview|This interview will be 2 hours in length and will be conducted with a Peer Research Assistant (PRA). The PRAs will be women living with HIV.
1486116|NCT03073408|Drug|Propofol|Closed loop control for propofol administration guided by the BIS.
1486117|NCT03073408|Drug|Propofol|Manual control group: Propofol administration adjusted manually.
1486118|NCT03073395|Drug|[68Ga]P16-093|Imaging by Positron Emission Tomography after iv injection of [68Ga]P16-093
1486119|NCT03073382|Other|Chart review|This is a chart review of all patients who have underwent open prenatal repair of fetal myelomeningocele. Although prenatal repair is associated with improved neurologic outcomes and a decreased need for cerebrospinal fluid shunting after birth, one of the major risks is preterm delivery. This study is intended to identify maternal, fetal or intraoperative risk factors associated with preterm delivery.
1486120|NCT03073369|Drug|Ergocalciferol 50000 UNT|Oral Ergocalciferol 50000 IU once daily for 6 weeks
1486121|NCT03073369|Drug|Placebo|Oral Placebo - one capsule once daily for 6 weeks
1486122|NCT03073356|Biological|Infusion of 3-OHB|Increase in 3-OHB levels
1486123|NCT03073356|Biological|Infusion of placebo|NaCl
1486124|NCT03073343|Dietary Supplement|Betaine (trimethyglycine)|Betaine (trimethyglycine) is a food supplement that is approved for sale in the United States without a prescription. In this study, betaine will be provided to patients as a powder that can be mixed with aqueous solutions and consumed orally.
1486125|NCT03073330|Diagnostic Test|GDM screening with 75 g 2 hour GTT|Patients will be diagnosed with gestational diabetes if they have one abnormal value: Fasting ≥ 92; 2 hour ≥ 180 mg/dl;1 hour ≥ 153 mg/dl.
1486126|NCT03073330|Diagnostic Test|GDM screening with two step approach|1 hour glucola with 50 g glucose load followed by 100 g glucose load if 1 hour glucola positive
1486127|NCT03073317|Diagnostic Test|FullPIERS and sFlit/PLGF (Soluble fms-Like Tyrosine Kinase-1-to-Placental Growth Factor Ratio)|Once the centre is randomised to receive the intervention, all eligible women will have serum sFlt1/PlGF measurement performed and fullPIERS assessment and both results will be revealed to the care providers. This will include all women with pre-eclampsia or suspected pre-eclampsia cared for at the main hospital centres (and not be limited to women referred to the hospital from the community health centres). sFlt-1/PlGF will be tested by immunoassays (Roche Platform®). The result read out is provided by specific machines provided by Roche in less than one hour, which permits rapid clinical decision-making. Risk stratification using fullPIERS will be performed on tablet computers using a pre-defined risk scoring system integrated within the MedSciNet database.
1486128|NCT03073304|Drug|Crystalloid based prime solution|Crystalloid based prime solution
1486129|NCT03073304|Drug|Erythrocyte based prime solution|Erythrocyte based prime solution
1486130|NCT03073291|Behavioral|Responsible Marijuana Vendor Training|Employees at retail recreational marijuana stores assigned to the the responsible marijuana vendor training will register them on TrainToTend online training program, create a user profile, and complete the training within four weeks from initial registration. Personnel who complete the training will receive a certificate of completion. New hires at the stores during the trial will be registered and complete the training within four weeks of commencing work. Separate versions of the training will be available reflecting differences in the laws/regulations on recreational marijuana sales in Colorado, Oregon, and Washington State and the content will be reviewed and approved by state regulators.
1486131|NCT03073278|Radiation|Stereotactic Body Radiotherapy|Each group will have different dose of stereotactic body radiotherapy (SBRT). Depending on which group patients are in.
1486132|NCT03073265|Device|STA-Apixaban Calibrator & Control|Measurement of apixaban level will be done using anti-Xa assay (IVD).
1486133|NCT03073252|Other|Normal Protein|Consumption of a normal protein (NP), egg-based (13 g protein; whole eggs) breakfast bowl
1486134|NCT03073252|Other|HIgh Protein|Consumption of a high protein (HP), egg-based (30 g protein; whole eggs) breakfast bowl
1486135|NCT03073239|Other|study ALS patients|Characterization of epidemiological features and genetic.
1486136|NCT03073226|Device|Olympus Elite|New generation Olympus endoscope
1486137|NCT03073226|Device|Olympus Spectrum|Current generation Olympus endoscope
1486138|NCT03073213|Drug|Ixekizumab|Administered as SC injection
1486141|NCT03073135|Behavioral|Psychodrama Group Therapy (PGT)|"The psychotherapeutic focus is on the here and now aspect of the patient's relationships. Conflicts are acted out during the sessions, yielding intense emotional re-experience in a safe environment, which will bring further cognitive understanding of past distressful life experiences and hopefully new adaptive ways of expressing and dealing with the problem."
1486142|NCT03073135|Behavioral|Supportive Group Therapy (SGT)|SGT is a form of treatment in which the therapist maintains a therapeutic relationship and a working alliance based on reality, support, clarification, assistance in troubleshooting, strong leadership, partial gratification of dependency needs, legitimating independence, development of pleasurable activities and adequate rest, guidance and advice to deal with current problems. This approach uses techniques to help patients feel safe, accepted, protected, encouraged and not anxious.
1486143|NCT03073122|Diagnostic Test|Brain MRI, neurocognitive and psychological testing|MRI of the brain and multiple tests of neurocognitive and psychological function including executive function, anxiety and depression
1486144|NCT03073096|Procedure|LVA at time of nodal dissection|Patients will receive a lymphatic-venous anastomosis at time of their required nodal dissection
1486145|NCT03073083|Procedure|Hamstring tendon autograft|ACL reconstruction surgery with hamstring tendon
1486146|NCT03073083|Procedure|Pattella tendon autograft|ACL reconstruction surgery with patella tendon
1486147|NCT03073083|Procedure|Quadriceps tendon autograft|ACL reconstruction surgery with quadriceps tendon
1486185|NCT03072771|Procedure|Peripheral blood draws|-Day +42, Day + 43, Day +56 (4-week infusion) or Day +70 (8-week infusion), and Day +100 (4 week infusion) or Day + 128 (8 week infusion)
1486149|NCT03073057|Drug|Budesonide/formoterol|2 inhalations as a single dose
1486150|NCT03073057|Other|Charcoal|
1486151|NCT03073057|Drug|Symbicort Turbuhaler|2 inhalations as a single dose
1486152|NCT03073044|Diagnostic Test|BELASTUNGSFRAGEBOGEN PARKINSON KURZVERSION (BELA-P-K)|"we proposed the translation and validation of Bela-p-K, a questionnaire that evaluates the Quality of Life in parkinsonian patients.
we applied the method of translation and back-translation at dutch version of questionnaire. after, we evaluated 103 PD patients with Bela-p-K and PDQ39.
The internal consistency of questionnaire was analyzed calculating alpha-Chronbach. We also evaluated the construct validity correlating Bela-p-K and PDQ39"
1486153|NCT03073031|Device|Tablet: Samsung Galaxy Tab A|
1486154|NCT03073018|Drug|Fosinopril|oral administration, capsules
1486155|NCT03073018|Drug|Pravastatin|oral administration, capsules
1486156|NCT03073018|Drug|Fosinopril Placebo|oral administration, capsules
1486157|NCT03073018|Drug|Pravastatin Placebo|oral administration, capsules
1486158|NCT03073005|Other|Simulation-based Mastery Learning (SBML)|The SBML training group will first 1) watch the VAD video, then 2) participate in a SBML intervention using the simulator for a) driveline exit site sterile dressing changes; b) performing controller self-tests; c) changing power sources; d) troubleshooting emergent VAD-related malfunction; and e) recognizing specific signs and symptoms requiring immediate contact with the VAD team.
1486159|NCT03072992|Drug|Curcumin|Curcumin (CUC-01), 300mg i.v. , once weekly for 12 weeks.
1486160|NCT03072992|Drug|Paclitaxel|Paclitaxel (colorless solution) 80 mg /m2 BS, i.v., once weekly for 12 weeks.
1486161|NCT03072992|Drug|Placebo|Placebo i.v. solution, once weekly for 12 weeks
1486162|NCT03072979|Radiation|Stereotactic body radiotherapy|Stereotactic body radiotherapy
1486163|NCT03072966|Device|Wearable device (Fitbit Charge®)|Physical activities will be monitored by wearable device.
1486164|NCT03072953|Drug|APD334|APD334 active treatment
1486165|NCT03072940|Other|Clinical investigations|Clinical examination, motor, cognitive, autonomous, psychological, olfactory and color vision tests, and rapid eye movement sleep characterization using video-polysomnography and 3 T magnetic resonance imaging
1948848|NCT01422005|Other|Conventional Occupational Therapy|Conventional Occupational Therapy will be given to patients in the control group.
1486167|NCT03072914|Procedure|RIPC with RIPostC|The sphygmomanometer is closed to the lower limb and the cuff is inflated and the pressure is increased by 30 mmHg higher than the systolic blood pressure of each patient for 5 minutes. The loss of the distal pulse is confirmed by Doppler in the dorsalis pedis pulse. If there is a pulse, increase the pressure until it disappears. After 5 minutes of ischemia time, the cuff is deflated to confirm that the pulse has returned and has a reperfusion time of 5 minutes. A total of 4 cycles of 5 cycles of ischemic time and 5 minutes of reperfusion time are performed. (Estimated total 40 minutes) When the skull is started to close, RIpc with RIPostC group performs RpostC and the method is the same as the above RIPC method. (Estimated total 40 minutes)
1486168|NCT03072901|Device|EndoBarrier Gastrointestinal Liner|The EndoBarrier Gastrointestinal Liner (EndoBarrier) is a nonsurgical metabolic intervention for the treatment of Type 2 diabetes and obesity. By bypassing the duodenum and proximal jejunum, the device may alter signaling pathways that control metabolic processes.1, 2 The effect on patient's glucose levels is immediate as evidenced by meal tolerance testing.3 Since the device also promotes reduced appetite resulting in weight loss, the effect is maintained as the patient loses weight over the implant period. Most patients achieve normal HbA1c and fasting plasma glucose (FPG) levels rapidly within 3-6 months.
1486169|NCT03072888|Device|TENS|Transcutaneous Electrical Nerve Stimulation will be apply
1486170|NCT03072875|Device|CAMS-RAS|
1486172|NCT03072849|Procedure|Pulmonary function testing|Each enrolled patient will receive pulmonary function testing every three months. Pulmonary function testing includes spirometry, plethysmography, and diffusion capacity measurements.
1486173|NCT03072849|Drug|FAM Therapy|All patients who have evidence of early airflow obstruction on pulmonary function testing will be started on FAM therapy. Early airflow obstruction is defined by a FEV1 decline of ≥10% predicted in addition to a FVC <0.8.
1486174|NCT03072836|Other|analysing microbiota|16SRNA gene sequencing of feces
1486175|NCT03072823|Dietary Supplement|n-3 Polyunsaturated fatty acid|2 g of Eicosapentaenoic acid (EPA) and 1 g of Docosahexaenoic acid (DHA)
1486176|NCT03072823|Dietary Supplement|placebo|olive oil ethyl esters
1948849|NCT01410630|Diagnostic Test|FLT-PET/CT|Standard of Care
1486178|NCT03072784|Procedure|aortic cross clamping|duration of cross clamping, less than 90 minutes, or more than 90 minutes
1486179|NCT03072771|Drug|Blinatumomab|-Blinatumomab is a bispecific T cell engaging antibody
1486180|NCT03072771|Procedure|Autologous stem cell transplant|-Standard of care
1486181|NCT03072771|Drug|Carmustine|-Carmustine is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of carmustine.
1486182|NCT03072771|Drug|Etoposide|-Etoposide is a semi-synthetic podophyllotoxin derivative. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of etoposide.
1486183|NCT03072771|Drug|Cytarabine|-Cytarabine, commonly known as Ara-C, is a synthetic nucleoside. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of cytarabine.
1486184|NCT03072771|Drug|Melphalan|-Melphalan is an alkylating agent. It will be sourced from commercial supply. Institutional guidelines will be followed for storage, preparation, and administration of melphalan.
1486252|NCT03072173|Drug|Xylometazoline|Patient will be given a nasal decongestant (Xylometazoline) prior to their 2nd or 3rd night of PSG.
1948850|NCT01410630|Diagnostic Test|FDG-PET/CT|Standard of Care
1948851|NCT01410630|Drug|FLT|5 mCi IV
1486187|NCT03072745|Diagnostic Test|Neuropsychological assessment|Assessment with a neuropsychological test battery examining different aspects of memory and executive functioning
1486188|NCT03072719|Drug|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
1486189|NCT03072719|Drug|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
2001158|NCT03179813|Procedure|Hydrocortisone|During the third molar extraction the hydrocortisone solution will be used in the test group
2001159|NCT03179813|Procedure|Control|During the third molar extraction the saline solution will be used in the control group
1486192|NCT03072693|Procedure|Home-based remote heart failure management|For patients randomized to Group 1, the home-based remote heart failure management system will be connected via the internet for active intervention. In Group 2 patients, the system will not be activated although all data will continue to be stored and reviewed at clinic visits. For patients in Group 1, clinically-assigned targets and alert thresholds of individual physiological parameters including blood pressure, pulse rate, and body weight will be decided before discharge and at entry into the three management modes. Site investigators will review individual patient physiological parameters upon clinic visits, and treatment can be initiated through instant communication (electronic communication and/or phone).
1486193|NCT03072693|Procedure|Home-based heart failure monitoring with no remote management|For patients randomized to Group 2, the home-based remote heart failure management system will continuously record and store patients information to be reviewed at clinic visits but not connected to internet. Site investigators will review individual patient physiological parameters upon clinic visits, and no treatment will be initiated through instant communication.
1486194|NCT03072680|Behavioral|BPS PAST|"Participants think about themselves in a past when they displayed their best self. Then, they visualize this with the help of audio instructions.
They will practice within a mobile app."
1486195|NCT03072680|Behavioral|BPS FUT|"Participants think about themselves in the future after everything has gone as well as it possibly could. Then, they visualize this with the help of audio instructions.
They will practice within a mobile app."
1486196|NCT03072680|Behavioral|DAILY ACTIVITIES|"Participants think about the activities they did during the last 24 hours. Then, they visualize this with the help of audio instructions.
They will practice within a mobile app."
1486197|NCT03072667|Drug|Omegaven|Omegaven™ will be initiated at 0.5 gm fat/kg of body weight per day (5cc/kg per day of Omegaven™) for 2 days. On day 3, the rate of Omegaven™ will be increased to 1g/kg (10cc/kg) per day and will remain at this level thereafter unless otherwise indicated.
1486198|NCT03072654|Procedure|Thyroidectomy|Remove the nodular goiter on the neck by thyroidectomy (standard procedure)
1486199|NCT03072641|Dietary Supplement|ProBion Clinica|
1486200|NCT03072628|Other|e-cig with nicotine|use an e-cig with nicotine for 30 minutes
1486201|NCT03072628|Other|e-cig without nicotine|use an e-cig without nicotine for 30 minutes
1486202|NCT03072628|Other|nicotine inhaler|use a nicotine inhaler for 30 minutes
1486203|NCT03072628|Other|sham control|use an empty e-cigarette for 30 minutes
1486204|NCT03072615|Diagnostic Test|Stiffness measurement|Transient Elastopgraphy (TE) or Shear-Wave-Elastography
1486205|NCT03072602|Dietary Supplement|Study diet|Participants will consume the study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
1486206|NCT03072602|Other|Glucose Challenge|Participants will come in fasting state on the main study visit day and will be given 75 gm oral glucose solution to drink, followed by blood collection every hour for next 8 hours.
2001160|NCT03178864|Drug|Rivaroxaban|Rivaroxaban 20 mg daily (15 mg daily in participants with a GFR of <50 mL/min as per the Cockroft-Gault equation)
1486208|NCT03072576|Device|Xpert MTB/RIF Ultra|Next generation Xpert MTB/RIF assay, this cartridge is intended for the detection of M. tuberculosis in sputum as well as the detection of M. tuberculosis mutations associated with resistance to rifampin
1486209|NCT03072550|Device|RenewalNail™ Plasma Treatment System|application of cold atmospheric plasma to a fungal infected toenail
1486210|NCT03072524|Diagnostic Test|FAST PLUS test|FAST PLUS test consists of two parts: the first one is the standard FAST test, which evaluates Speech (0-1), Facial palsy (0-1), Arm motor function (0-1), Time (0-1). The second part of the FAST PLUS test evaluates only the presence of severe arm or leg motor deficit (0-1), and unilateral occurrence of this motor function deficit (0-1).
1486211|NCT03072511|Behavioral|Spotlight on Smoke-Free Living: Mindsets and Decisions|Intervention will consist of elements to help quit smoking. All intervention elements will be informed by Construal Level Theory.
1486212|NCT03072511|Drug|Transdermal Nicotine Patch|TNP serve as nicotine replacement for individuals who are attempting to stop smoking. They are safe for use and dosing will be determined for each participant based off of manufacturer's recommendations.
1486213|NCT03072485|Drug|Sirolimus|Topical sirolimus applied to the skin
1486214|NCT03072485|Drug|Metformin|Topical metformin applied to the skin
1486215|NCT03072485|Drug|Diclofenac|Topical diclofenac applied to the skin
1486253|NCT03072173|Drug|placebo (saline)|Patient will be given a placebo nasal spray (saline) prior to their 2nd or 3rd night of PSG.
2001161|NCT03178864|Drug|Standard of care|Accepted standard of care as per American Heart Association/American Stroke Association Guidelines (initial use of unfractionated heparin or low-molecular weight heparin with transition to an oral vitamin K antagonist or continuation with low-molecular weight heparin) with choice of agent at the treating physician's discretion.
1486216|NCT03072472|Device|Endocuff Vision|The EndocuffTM (ARC Medical Design Ltd and Diagmed, UK) is a device (CE marked in UK) made of a soft plastic material with a unique dynamic shape. Endocuff Vision™ is placed snugly around the colonoscope tip prior to insertion. It does not project beyond the tip of the scope, providing an unrestricted view. It helps anchor the scope tip against the bowel wall to provide a stable platform of access. The soft, elastic projections are pushed back (recoiled) towards the scope shaft during insertion but evert during withdrawal to hold colon folds away from the field of view.
2001162|NCT03177850|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
1486218|NCT03072433|Behavioral|Counseling Intervention Package|Daily 45 minutes of group teaching for primary caregivers, followed by 45 minutes of supervised play and stimulation with their children for a total of four days. Teaching modules consist of psychosocial stimulation, nutrition and feeding, and water, sanitation and hygiene practices.
1486219|NCT03072433|Behavioral|Standard of Care|Nutrition and water sanitation and hygiene counseling at any point prior to discharge from hospital as per the local nutrition rehabilitation unit standard of care. In addition, primary caregivers will be stimulated to play with their children in a play area.
1486220|NCT03072420|Other|Compression of the fingertip under MRI.|Compression of the fingertip by a static loading on the phalanx distal of the index of the subjects; Then also a shear stress in the transverse direction of the finger. The data provided by the MRI images will be geometric information such as the thickness of the skin and its possible variation as a function of the area of the finger, the total thickness of soft tissues in compression as a function of the variation in l The angle between the axis of the phalanx and the plane of contact; Mechanical type information relating to the displacements and reaction forces, to the internal deformations of the different areas of the finger.
1486221|NCT03072407|Biological|PB-119 injection|
1486222|NCT03072407|Biological|PB-119 injection placebo|
1486223|NCT03072394|Drug|Local anesthetic|Local skin anesthesia during radial coronary artery catheterization by EMLA anesthetic ointment
1486224|NCT03072394|Drug|local anaesthetic injection|Local skin anesthesia during radial coronary artery catheterization by lidocaine injection
1486225|NCT03072381|Biological|Platelet Rich Plasma - Group 1|Subjects in Group 1 (PRP) will receive a single ultrasound-guided intratendinous (common extensor tendon origin) injection of up to 3 mL autologous PEAK platelet-rich plasma at week 0 (baseline).
1486226|NCT03072381|Drug|Corticosteroid Control - Group 2|Subjects in Group 2 (corticosteroid control) will receive a single ultrasound-guided intratendinous injection approximately (may be limited by tendon/soft tissue limitations of the subject) of 2 mL 1% lidocaine + 1mL of him 40mg Kenalog (triamcinolone hexacetonide, 40mg/mL) at week 0.
1486227|NCT03072368|Other|Photograph|Babies will be photographed and eye color will be observed and documented at birth, 3 months and one year of age
1486228|NCT03072355|Other|Elastic Band|Localized muscle resistance test for shoulder
1486229|NCT03072355|Other|Isokinetic dynamometer|Localized muscle resistance test for shoulder
1486230|NCT03072342|Procedure|Intensive Periodontal Treatment|
1486231|NCT03072342|Procedure|Control Periodontal Treatment|
1486232|NCT03072329|Procedure|Pudendal nerve block|
1486233|NCT03072329|Drug|Bupivacaine|
1486234|NCT03072316|Other|3D surface imaging|3D photography
1486235|NCT03072316|Other|semi-structured interview|qualitative analysis using semi structured interview
1486236|NCT03072316|Other|applanation tonometry|measurement of breast compressibility
1486237|NCT03072303|Other|Web-based Survey|Patients will be sent an email invitation describing the study. If the participant wants to participate and is eligible, she will follow the survey link in the email message, which directs her to an IRB-approved online consent form. A unique survey link will be generated for each participant and included in the survey invitation, which is a customized email message. This link will allow the investigators to determine who completed the survey. The investigators will send repeat email invitations every two months (total of 3 invitations) to those invitees who have not yet participated. The investigators will allow approximately 6 months for enrollment and survey completion and expect that the study will close soon thereafter.
1486238|NCT03072290|Drug|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) or 40 mg (40 mg/ml) triamcinolone acetonide (Shincort)
1486239|NCT03072290|Drug|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
1486240|NCT03072277|Dietary Supplement|Docosa Hexaenoic Acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through 6 months postpartum.
1486241|NCT03072277|Dietary Supplement|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through 6 months postpartum.
1486242|NCT03072264|Behavioral|Body in Mind Training (BMT)|Session 1 - Stop; Session 2 - Intention; Session 3 - Attention; Session 4 - Scientist Myself; Session 5 - Self-Compassion; Sessions 6, 7, 8 - Practice.
1486243|NCT03072264|Drug|Fluoxetine|In this group, individuals will consult with a psychiatrist weekly and will receive fluoxetine in a dosage of 20 to 60mg/dia according to clinical response.
1486244|NCT03072264|Behavioral|Quality of Life Group|Session 1 - Psychoeducation; Session 2 - Substance Use; Session 3 - Sleep; Session 4 - Physical Exercise; Session 5 - Healthy Eating; Sessions 6, 7,8 - discussions.
2001163|NCT03177850|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
2001164|NCT03177837|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
1486248|NCT03072225|Drug|Herbal Medicine C-117|Herbal Medicine C-117 formula including 2 herbals and 2 insects
1486249|NCT03072225|Drug|The Placebo of Herbal Medicine C-117|The Placebo of Herbal Medicine C-117 formula including 4 herbals
1486250|NCT03072212|Other|Observational study|No intervention
1486251|NCT03072199|Drug|RiTUXimab Injection|Single dose of Rituximab given intravenously within 48hours of myocardial infarction
1486303|NCT03071822|Drug|L-asparaginase|PIGLETs
1486304|NCT03071822|Drug|etoposide|PIGLETs
1486254|NCT03072160|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
1486255|NCT03072147|Drug|Teriparatide|20 mcg of teriparatide injected in thigh or abdomen once a day for 24 weeks.
1486256|NCT03072147|Drug|Placebo|20 mcg of saline injected in thigh or abdomen once a day for 24 weeks.
1486257|NCT03072134|Biological|Neural stem cells loaded with an oncolytic adenovirus|The primary objectives are to evaluate the safety of the combined therapy and determine the maximum tolerated dose (MTD) for a future Phase II study.
1486258|NCT03072121|Drug|Shexiang Baoxin pill|Conventional western medicine & shexiang baoxin pill
1486259|NCT03072121|Drug|SBP placebo|Conventional western medicine & placebo (for shexiang baoxin pill)
1486260|NCT03072121|Drug|Aspirin Enteric-coated Tablets|100mg tablet, one tablet daily.
1486261|NCT03072121|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|one tablet daily. (for patients who can't use aspirin)
1486262|NCT03072121|Drug|Atorvastatin Calcium|10 mg tablet, two tablets each night.
1486263|NCT03072121|Drug|Isosorbide Mononitrate Tab 20 MG|1 tablet two times daily.
1486264|NCT03072121|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
1486265|NCT03072121|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
1486266|NCT03072108|Dietary Supplement|Bonolive|2 caps per day of Bonolive
1486267|NCT03072108|Dietary Supplement|Placebo|2 caps per day of Placebo
1486268|NCT03072095|Behavioral|Text-only|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit.
1486269|NCT03072095|Behavioral|Text + Lottery|Subjects will receive a text communication indicating they are overdue for colon cancer screening with the option to elect to receive a free, at-home FIT kit and a 1 in 5 chance to win a $100 gift card for completing the kit.
1486270|NCT03072082|Drug|Danlou Tablet|Conventional western medicine & Danlou Tablet
1486271|NCT03072082|Drug|DanLou Tablet placebo|Conventional western medicine & placebo (for Danlou Tablet)
1486272|NCT03072082|Drug|Aspirin Enteric-coated Tablets|100 mg tablet, one tablet daily.
1486273|NCT03072082|Drug|Clopidogrel Hydrogen Sulfate 75 MG Oral Tablet|One tablet daily. (for patients who can't use aspirin)
1486274|NCT03072082|Drug|Atorvastatin calcium|10 mg tablet, two tablets each night.
1486275|NCT03072082|Drug|Isosorbide Mononitrate Tab 20 MG|One tablet two times daily.
1486276|NCT03072082|Drug|Metoprolol Tartrate Tab 25 MG|12.5 mg or 25 mg two times daily.
1486277|NCT03072082|Drug|Trimetazidine Dihydrochloride Tablets|20 mg tablet, one tablet three times daily.
1486278|NCT03072056|Drug|MIN-101|
2001165|NCT03177837|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
2001166|NCT03177811|Drug|ACETAZOLAMIDE oral capsule|Administration of 125mg acetazolamide in the morning, 250mg in the evening, starting 24 hours before departure to 3200m
1486281|NCT03072030|Biological|GamEvac-Combi (vaccine)|vaccination
1486282|NCT03072030|Biological|Placebo|vaccination
1486283|NCT03072017|Behavioral|MBAT|Breathing-based intervention
1486284|NCT03072004|Device|LLLT|The LLLT will be applied using a diode laser device (Recover Laser MMOptics, São Carlos/SP- Brazil) with parameters: 808nm, continuous output, 100mW, 8J. Laser probe will be applied directly and perpendicularly in skin contact (5 points), the time of irradiation will be 80 seconds per point, and treatments will be applied for three times a week for 12 sessions.
1486285|NCT03072004|Device|Sham LLLT|"That group receive application sham LLLT. The laser will be turned off, but the procedure will be the same as with the LLLT group"
1486286|NCT03071991|Procedure|study group|local anesthetic drug will be used
1486287|NCT03071991|Procedure|control group|no local anesthetic drug will be used
1486288|NCT03071965|Biological|Ciliary neurotrophic factor (CNTF)|The investigational product is the NT-501 encapsulated cell system, which consists of cells encapsulated within a semi-permeable polymer membrane and supportive matrices. NT-501 contains NTC-201 cells that secrete recombinant human CNTF, which were derived from genetically modified NTC-200 cells.
1486289|NCT03071965|Procedure|Surgery|Surgery to implant device for NT-501 or sham surgery
1486290|NCT03071939|Other|Assessment of the insight of schizophrenic patients by themselves, their relatives and caregivers|"This study will evaluate the insight of the patient, something carried out in common practice within the Eastern Pole (CH Le Vinatier). This assessment will take place in the specific services where patients are cared for. It will make it possible to evaluate insight more closely by comparing the opinions of the three actors. There is no risk in this study.
The study will be carried out over 2 years with a recruitment of 119 patients responding to the diagnosis of schizophrenia, taken care of within the Eastern Pole (Intra and Extrahospital services)."
1486291|NCT03071926|Drug|Pegylated Liposomal Doxorubicin|20 mg, qw, first 6 weeks ,every 8 weeks
1486292|NCT03071913|Procedure|Biospecimen Collection|Undergo collection of tissue and blood samples
1486293|NCT03071913|Other|Laboratory Biomarker Analysis|Correlative studies
1486294|NCT03071900|Diagnostic Test|circulating tumor cell analysis|Detect circulating tumor cells with CellCollector in SCCHN and control group.
1486295|NCT03071887|Behavioral|Relaxation Response Resiliency Program (3RP)|The 3RP blends stress management principles, cognitive behavioral therapy, and positive psychology. The 3RP focuses on 3 major areas: (1) eliciting the relaxation response; (2) increasing stress awareness; and (3) promoting adaptive strategies. The 3RP intervention currently consists of eight, 90-minute weekly group sessions. The investigators plan to adapt the intervention to address common concerns for older, HIV-infected women, including: stress of managing a chronic long-term, life threatening illness; additional medical comorbidities; pain and fatigue; stigma and social isolation; depression and anxiety; and sexuality concerns.
1486296|NCT03071874|Drug|AZD2014|AZD2014 is a dual mTORC1/mTORC2 inhibitor
1486297|NCT03071861|Drug|Darbepoetin Alfa|Single dose of 10 mcg/kg Darbepoetin Alpha given IV at less than 24 hours of age
1486298|NCT03071861|Drug|Normal Saline|Single dose of normal saline, IV, given at less than 24 hours of age
1486299|NCT03071848|Other|No Intervention|This was an observational study.
1486300|NCT03071822|Drug|cisplatin|PIGLETs
1486301|NCT03071822|Drug|ifosfamide|PIGLETs
1486302|NCT03071822|Drug|gemcitabine|PIGLETs
1486307|NCT03071796|Dietary Supplement|Placebo|liquids with similar appearance and taste like multivitamin supplement for 12 weeks
1486308|NCT03071783|Device|Vacuum extraction intelligent system|Vacuum extraction intelligent system - this is the intervention
1486309|NCT03071770|Drug|ivosidenib (AG-120)|A single-dose of ivosidenib (AG-120) administered in healthy Japanese and Caucasian subjects
1486310|NCT03071757|Drug|ABBV-368|Intravenous
1486311|NCT03071757|Drug|Nivolumab|Nivolumab will be administered according to standard or approved doses and dosing schedules.
1486312|NCT03071744|Drug|Lazanda|Lazanda is supplied in glass bottles, containing 8 sprays of 100 mcL containing 100 mcg/100 mcL or 400 mcg/100 mcL concentration solution.
1486313|NCT03071731|Drug|Bronchodilators|Administration of a nebulized combination of bronchodilators before the administration of a functional test.
1486314|NCT03071731|Drug|Placebos|Administration of a nebulized placebo before the administration of a functional test
1486315|NCT03071718|Other|Mediterranean diet|"Subjects in the Med-D group will be assigned a personalized diet prepared on the basis of own eating habits as established by 7-d food diary recalls. Energy values of habitual diets will be kept unchanged during Med-D intervention. Briefly, Med-D will be prepared so as to achieve a weekly consumption of:
7 portions of milk or yogurt plus whole grain cereals,
7 portions of nuts (30g)
At least 3 portion of absolute legumes
14 portions of vegetables
21 portions of fruit
4 portions of whole grain pasta
3 portions of whole grain pasta with vegetables or legumes
7 portions of whole grain bread
3 portions of fish
Extravirgin olive oil as unique source of discretional fats All subjects will be requested not to change physical activity levels during the 8 week intervention period."
1486316|NCT03071718|Other|Control Diet|Control subjects will not change their habitual diet during intervention. All subjects will be requested not to change physical activity levels during the 8 week intervention period.
1486317|NCT03071705|Drug|Metformin|500 mg PO BID
1486318|NCT03071705|Drug|TKI|standard dose
1486319|NCT03071692|Drug|K-877|0.2mg tablet
1486320|NCT03071692|Drug|Placebo|K-877 matching placebo tablet
1486321|NCT03071679|Drug|Omiganan|Omignan 1%, 2.5%
1486322|NCT03071679|Drug|Imiquimod|Imiquimod 15mg
1486323|NCT03071679|Drug|Omiganan 1% and Imiquimod|Omiganan 1% and Imiquimod
1486324|NCT03071679|Drug|Omiganan 2.5% and Imiquimod|Omiganan 2.5% and Imiquimod
1486325|NCT03071679|Drug|Placebo|Vehicle
1486326|NCT03071666|Dietary Supplement|cobalamin|Vitamin supplment tablet containing 50µg cobalamin
1486327|NCT03071666|Dietary Supplement|placebo|A tablet identical to the vitamin supplement but containing no vitamin B12
1486328|NCT03071653|Procedure|Left Cardiac Sympathetic Denervation (LCSD)|The procedure involves the surgical removal of the lower half of the left stellate ganglion (T1) and thoracic ganglia (T2-T4), thereby removing the pro-arrhythmic noradrenergic input to the ventricles
1486329|NCT03071653|Other|Optimal Medical Therapy|"All eligible patients with heart failure and depressed left ventricular systolic function will receive guideline and evidence based optimal tolerated medical therapy. The level of risk associated with optimal medical therapy is considered very low. For the majority of patients with heart failure and depressed left ventricular systolic function this will include:
A renin angiotensin system blocker at highest tolerated doses (e.g., enalapril 10mg twice daily or equivalent)
A mineralocorticoid receptor antagonist (e.g., Spironolactone 25-50mg daily or equivalent)
A Beta-blocker (e.g., Carvedilol 25mg twice daily or equivalent)
The use of a loop diuretic and digitalis will be clinically driven and used at the discretion of the attending clinician"
1486330|NCT03071627|Other|New items with spin|Interpretation of news items with spin
1486331|NCT03071627|Other|New items without spin|Interpretation of news items without spin
1486332|NCT03071614|Other|News items with spin|Interpretation of news items with spin
1486333|NCT03071614|Other|News items without spin|Interpretation of news items without spin
1486334|NCT03071601|Drug|Lidocaine-Prilocaine Cream 2.5-2.5%|Topical anesthesia using a cream containing 2.5% Lidocaine and 2.5 % Prilocaine for at least 30 minutes on and around the wound before suture
1486335|NCT03071601|Drug|Lidocaine 1% Epinephrine 0.005mg/mL solution|Local anesthesia by subcutaneous injection of a solution containing 1% Lidocaine and 0.005mg/mL Epinephrine in and around the wound in the minutes preceding the suture of the wound
1486336|NCT03071588|Device|Mechanical rotary burs|A rotary drill made of steel or diamond impregnated materials attached to a steel shank, available in varying degree of sharpness, lengths and sizes used conventionally in preparation of teeth to receive a dental restoration.
1486337|NCT03071588|Device|Carisolv gel|A chemical gel made of a combination of amino acids and sodium hypochlorite used with hand instruments to soften and remove the decay to prepare the tooth to receive a dental restoration.
1486338|NCT03071575|Biological|Measles-rubella (MR) vaccine at 6 and 9 months|Arm A will receive MR vaccine dose at 6 and 9 months of age
1486339|NCT03071575|Biological|Measles-rubella (MR) vaccine at 9 months|Arm A will receive MR vaccine dose at 9 months of age
1486340|NCT03071562|Other|Yoga-mindfulness|"Sample class:
Warm-up
(15 minutes) Standing poses
(15 minutes) Balance poses
(15 minutes) Abdominals & back bends (10 minutes) Cool-down
(5 minutes) Seated meditation Alternate nostril breathing Bellows breath Shoulder/neck stretches Cat-cow Forward fold Sun salutations Warrior 1 Warrior 2 Triangle Extended side angle Reverse warrior High lunge with twist Tree pose Standing holding knee Modified warrior 3 (chair support) Half moon
Bird-dog Side plank Bridge Cobra Sphinx Corpse pose Side-lying Seated om
Every month, a smudging ceremony will take place with an Aboriginal Elder for 5-10 minutes at the start of the class."
1486341|NCT03071549|Drug|Trichloroacetic acid peel|Skin degreasing will be performed before every session using acetone. Trichloroacetic acid 25% will be applied on one side of the face.
1486342|NCT03071549|Drug|combined azaleic and salicylic acids|Skin degreasing will be performed before every session using acetone. Azaleic acid 20% with salicylic acid 20% will be applied to the other side of the face.
1486371|NCT03071276|Drug|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
1493097|NCT03020030|Drug|HYDROCORTISONE|Standard of Care
2001167|NCT03177811|Drug|Placebo oral capsule|Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
2001168|NCT03175042|Device|Masimo spot hemoglobin non-invasive monitor|This non-invasive monitor measures hemoglobin using LED light technology. We will be using it to determine if it is as accurate as routine CBC in anemic obstetric patients.
1486346|NCT03071510|Device|Atlas Genetics io® system|Specimen Collection
1486347|NCT03071497|Diagnostic Test|Non-invasive analysis of Zinc protoporphyrin|In patients fitting the inclusion criteria Zinc protoporphyrin will be measured non-invasively as proxy for iron deficiency. Results will be compared to ZnPP reference values measured via HPLC and with spectroscopical measurements performed on whole blood as well as with blood values (HB, MCH, MCV, ferritin, CRP, transferrin saturation, soluble transferrin receptor) assessed during clinical routine.
1486348|NCT03071484|Device|Transcranial Direct Current Stimulation|The tDCS is a non-invasive neuromodulatory technique that delivers low-intensity, direct current to cortical areas facilitating or inhibiting spontaneous neuronal activity.
1486349|NCT03071471|Device|MID-C|"The MID-C system is designed to correct the deformity step by step along a period of time, giving the skeletal and soft tissues accommodate any incremental correction.
The MID-C System inherent benefits are:
Only two screws are used
Incision size is much smaller
Simpler operation with shorter operative time
Less complication thanks to the three points above.
Minimal spinal mobility loss"
1486350|NCT03071432|Diagnostic Test|Paced breathing at 6, 10 and 15 breaths per minute|
1486351|NCT03071419|Behavioral|Nutrition and Parenting Intervention|The proposed intervention will evaluate and explore the unique influences that low-income fathers have on their preschool age children's obesogenic behaviors and obesity risk.
1486352|NCT03071406|Drug|Nivolumab|Nivolumab 240 mg/dose intravenously (IV) every 2 (q2) weeks.
1486353|NCT03071406|Drug|Ipilimumab|Ipilimumab 1 mg/kg/dose IV q6 weeks.
1486354|NCT03071406|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic Body Radiation Therapy 24Gy in 3 fractions.
1486355|NCT03071393|Device|Hypoxico Hyp-123|During acute intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of low oxygen air (9-15% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
1486356|NCT03071393|Device|Hypoxico Hyp-123|During sham intermittent hypoxia, subjects will undergo 15 brief exposures (60-120 seconds) of normal oxygen air (21% inspired oxygen) delivered by an air generator, alternated with 15 brief exposures (60-120 seconds) of ambient room air.
1486357|NCT03071380|Drug|Repatoxaban|1 tablet contains 10 mg rivaroxaban
1486358|NCT03071380|Drug|Xarelto|1 tablet contains 10 mg rivaroxaban
1486359|NCT03071367|Other|Clinical Simulation|
1486360|NCT03071354|Dietary Supplement|HMB protein supplement (3g)|HMB 3g/day or iso-nitrogenous control (discussed below) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward. The dose of HMB was chosen based on multiple studies revealing efficacy of 3g/day improving muscle mass and demonstrating an excellent safety profile. Feeding will be initiated as per local practice. Enrolled patients will be randomized to supplementation with HMB (3g) or control will begin within 72 hours of admission to ICU.
1486361|NCT03071354|Dietary Supplement|Nutritional Supplement|Control patients will receive 2 x 237mL bottles of the commercially available nutritional supplement (Ensure® Original) in addition to standard enteral, and parenteral nutritional supplementation and standard nutrition when transferred to the ward throughout the study. While the patient is intubated, the control nutritional supplement will be delivered via the enteral feeding tube. The participant will switch to oral administration once extubated
1486362|NCT03071341|Drug|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
1486363|NCT03071328|Drug|Isovue-M 200|Diluted iodinated contrast will be injected under CT fluoroscopy guidance into bone, lymph node, and liver metastases in subjects with metastatic castrate resistant prostate cancer, and pre and post-injection CT images will be obtained to characterize the parameters needed for optimal distribution throughout metastases of a given size. To validate the expression of CD155 in prostate cancer, a biopsy of the metastatic site (liver, lymph node) will be obtained at the time of contrast injection and will be stained for CD155 expression. Due to the sclerotic nature of prostate cancer bone metastases, a biopsy of the bone metastasis to be injected will be performed up to 2 weeks prior to study enrollment, in order to confirm tumor is present. Bone metastases will not be re-biopsied at the time of contrast injection.
1486364|NCT03071315|Other|CCT|CCT focuses on behavioral approach, mainly punitive punishment measures.
1486365|NCT03071315|Other|MMT|MMT is a combination of pharmaceutical and behavioral intervention.
1486366|NCT03071302|Other|EVALUATION OF VSX1, SOD1, and TIMP3 genes|Evaluation of VISX1, SOD1, TIMP3 genes in corneal epithelium, and in peripheral blood. Evaluation of pentacam parameters
1486367|NCT03071289|Radiation|Radiation Method B|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and included all the lymphocyst. The CTV is given a dose of 45Gy.
1486368|NCT03071289|Drug|Cisplatin|The regimen of chemotherapy is cisplatin 30mg/m2 every week.
1486369|NCT03071289|Radiation|Radiation Method A|The gross tumor volume (GTV) is the residual lesion after radical resection and given a dose of 60Gy. The clinical target volume (CTV) is delineated according to the lymph drainage pathway and given a dose of 45Gy.
1486370|NCT03071276|Drug|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
1486451|NCT03070678|Drug|Mefenamic acid|"Pharmaceutical form: capsule
Route of administration: oral"
1493098|NCT03020030|Drug|LEUCOVORIN CALCIUM|Standard of Care
2001171|NCT03174132|Device|Restylane Perlane Lidocaine|Intradermal injection
2001172|NCT03174132|Device|Restylane Perlane|Intradermal injection
2001173|NCT03170440|Other|Transcutaneous vagal nerve stimulation|Non-invasive stimulation provided by transcutaneous electrical nerve stimulation device at 20Hz, 100 μs pulse width
2001174|NCT03170440|Other|Sham stimulation|Sham stimulation will be performed using electrodes placed on earlobe
1486372|NCT03071276|Drug|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
1486373|NCT03071276|Drug|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
1486374|NCT03071263|Drug|Patiromer|2 packets/day starting dose, administered orally
1486375|NCT03071263|Drug|Placebo|2 packets/day starting dose, administered orally
1486376|NCT03071263|Drug|Spironolactone|25 mg tablet/day starting dose, administered orally
1995329|NCT02792192|Biological|Bacille Calmette-Guérin|For Cohort 1B, BCG will be administered (intravesically) at de-escalated doses. De-escalation will be allowed for up to three dose levels of BCG: full dose (50 mg), 66% of full dose, and 33% of full dose. After the MTD or MAD is determined for Cohort 1B, MTD/MAD will be used for all subsequent participants enrolled into Cohorts 1B, 2, and 3 (provided MAD or MTD is determined to be either full dose or 66% of a full BCG dose).
1486378|NCT03071237|Procedure|Gastrectomy|Paitents with gastric cancer that needs receiving total or distal gastrectomy. During the surgery, IPA needs to be exposed and transected.
1486381|NCT03071211|Device|Plug-unplug catheter management|Transurethral catheter is plugged with a plastic cap and participants are taught to unplug during the day when they feel the urge to void or at least every 4 hours.
1486382|NCT03071211|Device|Continuous drainage catheter management|Transurethral catheter is attached to a continuous drainage bag.
1486383|NCT03071198|Procedure|TME|"Find the hypogastric nerve trunk in front of sacral promontory and protect it,be careful to use electrocautery hemostasis biased toward the side of rectal when handle lateral ligament of rectum and middle rectal artery and avoid to damage the pelvic plexus.
At least a 2-cm margin to the lower edge of the tumor is adequate for distal bowel resection. Resect 5cm length distal rectal or all of the mesorectum.Check the integrity of the mesorectum in postoperative routine examination. Double stapling method is used for all low anastomosis operations."
1486384|NCT03071198|Radiation|Concurrent chemo-radiotherapy|Three-dimensional conformal radiotherapy as following: CTV 44Gy/22 times＋GTV1 6Gy/3 times(2Gy/time/day，5 days a week，totally 5 weeks),if rectal tumors do not regress obviously, additional GTV2 is necessary, 5.4Gy/3 times (1.8Gy/time/day). At the same time, Capecitabine (850mg/m2, two times every day) will be taken on radiotherapy day
1486385|NCT03071198|Drug|neoadjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
1486386|NCT03071198|Drug|adjuvant CT|CAPEOX protocol:Oxaliplatin 130mg/m2 ivgtt 2-6h dl;(Capecitabine 1000mg/m2 2 times a day lasts for 14 days Repeat every 3 weeks
1486387|NCT03071185|Procedure|femoral nerve block, common peroneal nerve block|For patients with fibular flaps harvested, femoral nerve block and common peroneal nerve with ropivacaine were administered. For patients with ALT flaps harvested, femoral nerve block with ropivacaine was administered.
1486388|NCT03071172|Drug|Triptorelin for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
1486389|NCT03071172|Drug|Recombinant Human Choriogonadotropin alfa Solution for Injection|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
1486390|NCT03071172|Drug|Progesterone Soft Capsules|Drugs for IVF-ET (in vitro fertilization and embryo transfer).
1486391|NCT03071159|Device|FreeStyle Flash Libre glucose monitoring system|glucose monitoring system with sensors
1486392|NCT03071146|Device|Bard® LifeStent® 5F Vascular Stent System|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
1486393|NCT03071120|Behavioral|Parent-Mediated Intervention|Children with ASD will participate in a 6-month parent-mediated intervention that will include direct intervention and parent education.
1486395|NCT03071094|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec (pexastimogene devacirepvec) will be administered as 3 bi-weekly intratumoral (IT) injections of 10^9 pfu at day 1 and weeks 2 and 4
1486396|NCT03071094|Drug|Nivolumab|Nivolumab will be administered intravenously every 2 weeks (from week 2)
1486397|NCT03071081|Drug|TOP1288|Oral TOP1288
1486398|NCT03071081|Drug|Placebo to TOP1288|Oral placebo to TOP1288
1486399|NCT03071068|Drug|Anti-PlGF recombinant monoclonal antibody, 4mg dose|3 intravitreal injections of THR-317 4mg approximately 1 month apart
1486400|NCT03071068|Drug|Anti-PlGF recombinant monoclonal antibody, 8mg dose|3 intravitreal injections of THR-317 8mg approximately 1 month apart
1486401|NCT03071055|Drug|Ranibizumab Injection [Lucentis]|intravitreal injection
1486402|NCT03071042|Drug|Apatinib|Apatinib Mesylate Tablets 425mg (500mg，675mg or 750mg) po. qd continuous;
1486403|NCT03071042|Drug|Docetaxel|Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
1486404|NCT03071029|Behavioral|Monthly PAFP rates displayed at clinics.|Providers will receive visual and text feedback on their centre's PAFP uptake rates as they compare to the uptake rates of other centres. The feedback will be delivered monthly in a physical paper format.
1486405|NCT03071003|Drug|SENS-401|Oral Administration
1486406|NCT03071003|Drug|Placebo|Oral Administration
2001176|NCT03168776|Device|BuMA Supreme DES|Implant BuMA Supreme stent only
1486407|NCT03070990|Drug|Enfortumab vedotin|All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
1486408|NCT03070977|Other|Interprofessional clinical study unit|"In 2015, Psychiatry in Slagelse established an interprofessional clinical study unit. The aim was to create a new environment for learning, where students could learn from each other and develop competence in interprofessional collaboration. In the study unit there are more students than in the other standard psychiatric wards and several professions are included.
A facilitator team is responsible for the interprofessional training. In autumn 2016 seven professionals participate in course of facilitating interprofessional collaboration and training. The intervention involved the total staff participation in an initial workshop.
The study unit is based on two educational interventions: Student participation in clinical care teams and interprofessional group tuition sessions."
1486409|NCT03070964|Drug|plitidepsin|
1486410|NCT03070951|Drug|Placebo + Placebo Add-back|Placebo tablets and Placebo Add-back for oral administration once daily
1486411|NCT03070951|Drug|OBE2109 + Placebo Add-back|OBE2109 tablets and Placebo Add-back for oral administration once daily
1486412|NCT03070951|Drug|OBE2109 + Add-back|OBE2109 tablets and Add-back for oral administration once daily
1486413|NCT03070938|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylenbiguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
1486414|NCT03070925|Device|PuraPly™ Antimicrobial Wound Matrix|PuraPly AM consists of a collagen sheet coated with polyhexamethylene biguanide hydrochloride (PHMB) intended for the management of wounds. PuraPly AM is supplied dry in sheet form. The device is packaged in sterile, sealed single patches.
1486415|NCT03070899|Drug|Placebo + Placebo Add-back|Placebo tablets and Placebo Add-back for oral administration once daily
1486416|NCT03070899|Drug|OBE2109 + Placebo Add-back|OBE2109 tablets and Placebo Add-back for oral administration once daily
1486417|NCT03070899|Drug|OBE2109 + Add-back|OBE2109 tablets and Add-back for oral administration once daily
1486418|NCT03070886|Drug|Bicalutamide|Given orally
1486419|NCT03070886|Drug|Docetaxel|Given IV
1486420|NCT03070886|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
1486421|NCT03070886|Drug|Flutamide|
1486422|NCT03070886|Drug|Goserelin Acetate|
1486423|NCT03070886|Other|Laboratory Biomarker Analysis|Correlative studies
1486424|NCT03070886|Drug|Leuprolide Acetate|
1486425|NCT03070886|Drug|Nilutamide|
1486426|NCT03070873|Device|Perigee and Apogee Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
1486427|NCT03070873|Device|Gynecare Prolift Mesh|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
1486428|NCT03070873|Procedure|Traditional Surgery|The investigators divided the patients randomly into three groups :the group A received Perigee and Apogee polypropylene mesh(PA)；the group B received Gynecare prolift polypropylene mesh；the group C was without any mesh.
1486429|NCT03070860|Radiation|PET scan 18-FDG and 18-NAF|"Positron emission tomography (PET) is a medical imaging test performed in a nuclear medicine department.
PET scan is performed by IV injection of a mildly radioactive tracer (NAF and FDG)."
1486430|NCT03070847|Drug|Tranexamic Acid|Dose: 5mg/kg
1486431|NCT03070847|Drug|Tranexamic Acid|Dose: 10mg/kg
1486432|NCT03070847|Drug|Sodium Chloride|Tranexamic Acid would be diluted in 0,9% Sodium Chloride (0,9% NaCl) to cumulative volume of 20 ml.
1486433|NCT03070834|Device|Cook 'Celect' retrievable inferior vena cava filter|Cook 'Celect' device will be deployed If randomized to rIVCF insertion
1486434|NCT03070821|Other|rtfMRI neurofeedback training|Information about the state of brain activation was given to subjects. That information was visualised as a thermometer bar. Subjects tried to modulate that activation while performing a mental imagery task.
1486435|NCT03070821|Device|3T MRI|A 3T Siemens MRI scanner was used to implement rtfMRI neurofeedback training.
1486436|NCT03070795|Procedure|early feeding|start oral sips four hours after cesarean section
1486437|NCT03070795|Procedure|delayed feeding|start oral feeding on post operation day 1 (>12hours) after surgery
1486438|NCT03070782|Drug|ISIS 681257|Randomly assigned to one of the dosing cohorts.
1486439|NCT03070782|Drug|Placebo|Randomly assigned to one of the dosing cohorts. Dose of placebo in each cohort will match volume of active in that cohort.
1486440|NCT03070769|Procedure|Venous blood collection for biomarkers measurements|Venous blood was collected in all subjects for measurements of hs-C-reactive protein (hs-CRP), fibrinogen, erythrocyte sedimentation rate (ESR) and Uric Acid (UA) between 8:00 and 9:00 AM, following an overnight fast, shortly after the conclusion of the overnight polysomnography (PSG).
1486441|NCT03070756|Device|Minimal-Intervention - Specification of device settings|- device settings for auto-CPAP treatment night: therapy mode=APAP, Pmin=5hPa,Pmax=20 hPa, Soft-Start duration <=15 min, softPAP Level is selected based on patient comfort
1486442|NCT03070743|Procedure|Posterior Approach Compression Distraction Reduction Surgery|Posterior Approach Compression Distraction Reduction Surgery is performed.All of patients received this procedure routinely in the department of neurosurgery at Xuanwu Hospital.
1486443|NCT03070730|Drug|Droxidopa|Droxidopa: 100 mg or 300 mg t.i.d
1486444|NCT03070730|Drug|Atenolol|Atenolol: 50 mg Q.D.
1486445|NCT03070730|Drug|Placebos|Placebo: t.i.d
1486446|NCT03070717|Procedure|Observation & Diagnosis|SD-OCT, fundus autofluorescence, fundus photography, optional microperimetry, ophthalmic exams (BCVA, optical biometry), blood sampling.
1486447|NCT03070704|Drug|insulin degludec/liraglutide|Patients will be treated with commercially available Xultophy™ (insulin degludec / liraglutide) according to routine clinical practice at the discretion of the treating physician
1486448|NCT03070691|Drug|LDE225B|Cream, 2x daily
1486449|NCT03070691|Drug|Vehicle|cream, 2x daily
1486450|NCT03070678|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet
Route of administration: oral"
1486452|NCT03070665|Drug|Norepinephrine|Increasing blood pressure up to 150mmHg for 5min using norepinephrine pump as initial dose 0.05μg/Kg.min during ESD operation, meanwhile check out the potential hemorrhage spot which is not obvious and then use the hot biopsy forceps to coagulate the bleeding spot, after that withdraw the norepinephrine and record the potential bleeding spot's location. The other procedures are the same as control groups'.
1486453|NCT03070652|Behavioral|NBO, Newborn behavioral observation|
1486454|NCT03070652|Behavioral|Practice as usual|
1486455|NCT03070639|Behavioral|Safe Sleep Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on the baby's sleep practices. Participant will also receive a free pack'n play, sleep sack, and educational resources on safe sleep.
1486456|NCT03070639|Behavioral|Scald Prevention Intervention|A health educator will visit participant during their 2-week well visit in the clinic, to deliver a tailored intervention based on practices regarding scald risks in the home. Participant will also receive a bath thermometer, candy/frying thermometer, and educational resources on scald prevention.
1486457|NCT03070626|Dietary Supplement|PreOp®|No preoperative drink.
1486458|NCT03070613|Drug|Fluorescent Lectin Application|Fluorescein conjugated wisteria floribunda (a lectin).
1486459|NCT03070600|Drug|Universal PrEP Counseling|Counseling at universal sites, will use a standardized counseling script to state that PrEP is available for women at risk for HIV, explain that HIV prevalence in the region is high, and will note that women with HIV positive partners or who don't know their partner's status may be at risk. Counseling will specify that women may have their own reasons to feel at risk or to want PrEP. Following standardized counseling, women will select PrEP at the same visit or will be allowed to deliberate on the decision and come back at the next visit with a decision. Women will be informed that it is advisable to use PrEP if they know their partner is HIV positive or if they do not know their partner's status and will be encouraged to bring untested partners to clinic if status is unknown.
1486460|NCT03070600|Drug|Targeted PrEP Counseling|"Following enrollment, the targeted PrEP clinics will provide two inter-related innovations over two ANC visits. In the targeted PrEP clinics, any of the following three criteria can trigger enhanced PrEP counseling. A participant that meets any one of these criteria will receive PrEP counseling during the study visit where the criteria is met:
Risk Score >5 (Risk score includes male partner status known/unknown, syphilis infection, and lifetime number of male partners).
participant declines partner self-tests regardless of partner HIV status, and/or
their partner declines self-testing or tests positive."
1486461|NCT03070587|Behavioral|Positive Affect Training for SAD|The PAT-S protocol will teach the participants the basics of mindfulness and how to be aware of their physical sensation, thoughts, and emotion at present moment by a nonjudgmental way in breathing, standing, or eating. After two mindfulness sessions, lovingkindness meditation (LKM) will be introduced. The participants will be taught to identify and focus the positive feelings such as gratitude, love, kindness, peacefulness, or friendliness when they wish their benefactor and beloved ones who they feel grateful or respectful, and transfer these feelings first to themselves, then to a neutral individual, to people whom they dislike, and finally to all living beings.
1486462|NCT03070574|Drug|Mesalamine 2400 MG|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers, each 1200mg of IMP (= 2400 mg), every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
1486463|NCT03070574|Drug|Mesalamine 1200 MG|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (1200 mg/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
1486464|NCT03070574|Other|Placebo|For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
1486465|NCT03070561|Biological|sublingual film with peanut extract|
1486466|NCT03070548|Drug|Talazoparib|1 mg of talazoparib containing100 μCi of 14C-radiolabeled talazoparib
2001177|NCT03168776|Device|Xience or Promus DES|Implant XIENCE family or Promus family only
1486468|NCT03070522|Drug|Prednisone|oral prednisone for 7 days during pulmonary exacerbation
1486469|NCT03070522|Drug|Placebos|Placebo
1486470|NCT03070509|Drug|Lisdexamfetamine|lisdexamfetamine 50 mg single dose
1486471|NCT03070496|Biological|Blood sampling|Blood sampling will be performed at 6 months after myocardial infarction to analyse diagnostic and prognostic biomarkers
1486472|NCT03070496|Procedure|ECG|ECG will be performed at 6 months after myocardial infarction
1486473|NCT03070496|Device|MRI|MRI will be performed at 1, 12 and 36 months after myocardial infarction to analyse ventricular remodeling and reperfusion.
1486474|NCT03070496|Other|Quality of life questionnaire|Patients will pass a quality of life questionnaire at 12, 24 and 36 months after myocardial infarction
1486475|NCT03070483|Drug|Cholecalciferol|5000 IU cholecalciferol with 1000 mg calcium citrate daily
1486476|NCT03070470|Drug|Ranolazine|Ranolazine 1500 mg orally two times per day for 2.5 days
1486477|NCT03070470|Drug|Verapamil|Verapamil 120 mg immediate release (IR) morning and afternoon doses on Days 1 and 2, 240 mg extended release (ER) evening dose on Days 1 and 2, and 120 mg IR morning dose on Day 3 (all oral doses)
1486478|NCT03070470|Drug|Lopinavir / Ritonavir|Lopinavir / Ritonavir 800 mg / 200 mg orally two times per day for 2.5 days
1486479|NCT03070470|Drug|Chloroquine|Chloroquine 1000 mg on Day 1, 500 mg on Day 2, 1000 mg on Day 3 (all oral doses)
1486480|NCT03070470|Drug|Placebo|Placebo (administered orally)
1486552|NCT03069950|Drug|Irinotecan (CPT-11)|Irinotecan (CPT) (150 mg/m2 IV over 30 min to an hour) on Day 1 and Day 15.
1493099|NCT03020030|Drug|MERCAPTOPURINE|Standard of Care
2001178|NCT03168438|Genetic|NY-ESO-1ᶜ²⁵⁹T cells|NY-ESO-1ᶜ²⁵⁹T cells administered by infusion on Day 1
2001179|NCT03168438|Drug|NY-ESO-1ᶜ²⁵⁹T in combination with pembrolizumab|NY-ESO-1ᶜ²⁵⁹T cells administered on Day 1, then pembrolizumab administered on Day 22 (3 weeks after initial infusion of NY-ESO-1ᶜ²⁵⁹T cells)
1486481|NCT03070470|Drug|Dofetilide and Diltiazem|"In one period subjects receive Dofetilide 0.125 mg on Day 1, 0.375 mg on Day 3.
In a second period (randomized cross-over) subject receive Diltiazem 120 mg IR morning dose on Day 8, 240 mg ER evening dose on Days 8 and 9, and 120 mg IR on Day 10 with coadministration of 0.25 mg dofetilide on Day 10."
1486482|NCT03070457|Other|Early discharge|Patients randomised to early discharge or not
1486483|NCT03070457|Other|Conventional protocol|Discharge as usually done 48-72 hours after surgery
1486484|NCT03070444|Device|CTC retainer|The CTC retainer consists of 0.8 hard Remanium® wire (Dentaurum, Germany) and is bonded with Tetric Flow (Ivoclar Vivadent, Liechtenstein) to the lower canines directly after debonding.
1486485|NCT03070444|Device|Essix retainer maxilla|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
1486486|NCT03070444|Device|Essix retainer mandible|The Essix retainer is made of 1 mm Essix C+® Plastic (Dentsply, USA) and is handed out to the patient the same day after removal of fixed appliances.
1486487|NCT03070444|Procedure|Alginate impression|Alginate impressions are taken to made the cuspid-to-cuspid and Essix retainers, respectively. Dental casts are obtained at the debond appointment and at the follow-up visits after 6, 18 and 60 months.
1486488|NCT03070444|Other|Questionnaire|A questionnaire is completed at the follow-up visits.
1486489|NCT03070431|Radiation|High-precision RT 5x5 Gy in 1 week|Patients included in this study will receive a high-precision radiotherapy with 5x5 Gy in 1 week
1486490|NCT03070418|Procedure|Mini Incision Dynamic Hip Screw Technique|This technique is the same of AO Dynamic Hip Screw (DHS) technique using 4 holes plate or smaller, in this case it is enough to make just a 3 cm skin incision over the guide wire that is inserted parallel to the anteversion wire by using the 135° guide fixed on the T-handle; (step 2-2), and continuing AO technique steps, until step 3-4, for the plate assembling we remove the guide wire, and insert the plate sliding it through the skin cut over the femur shaft under the muscles using the plate for dissection the soft tissue above the bone surface non using any tool as periosteal elevator but the plate itself by holding it from its DHS screw canal and in 180 degree rotation position in axial aspect (transvers aspect) using the plate end for soft tissue gentle dissection over the bone, then turning the plate 180 degree over the bone shaft to the right position and sliding the DHS screw plat canal over the DHS screw using the measuring bar. Two skin stitches are enough.
1486491|NCT03070405|Drug|Tenofovir disoproxil fumarate 300mg|Single oral dose on the first day of each period
1486492|NCT03070405|Drug|Para-aminosalicylic acid Ca granule 5.28 g|Twice daily oral administration from the first day of each period to the seventh dose
1948852|NCT01408732|Drug|Sodium tetradecyl sulfate (sotradecol)|3% Sodium tetradecyl sulfate (STS) is mixed with air at a ratio of 4 parts air to 1 part STS for injection into the affected vessels in the nose. Topical anesthetic is applied to the nasal mucosa prior to injections. Once the mixture is ready for injection, the needle is placed into the vessel, in a submucosal fashion, penetrating 1-2 mm, and very small quantities of foam are injected The amount of foam injected into each lesion varies between 0.1 cc to 0.25 cc. Individual injection amounts vary between lesions, patients and treatment sessions. No more than a total of 3 ml of solution is used in each session. During each session, several lesions can be treated, but the total amount of STS used does not exceed 3 cc.
2001180|NCT03165539|Device|Cerebral oxygen saturation monitoring|Intraoperatively, patients will have baseline cerebral oxygen saturation monitoring while breathing room air. Cerebral oxygen saturation monitoring will continue throughout the entire operation including the time on one-lung ventilation.
2001181|NCT03165071|Drug|ACT-132577|Capsule
1486497|NCT03070379|Procedure|Topical lidocaine pharyngeal anesthesia|Topical pharyngeal anesthesia by lidocaine was administrated 4-5 min before propofol sedation in patients who underwent esophagogastroduodenoscopy.
1486498|NCT03070366|Drug|Chemotherapy|"cisplatin
5FU
carboplatin
cetuximab"
1486499|NCT03070366|Radiation|Stereotactic radiotherapy|Stereotactic radiotherapy
1486500|NCT03070353|Drug|Dextran 40|Dextran-40 infusion with the dose of 1 g/kg/day (10 ml/kg/day) for 2 days.
1486503|NCT03070327|Biological|EGFRt/BCMA-41BBz CAR T cell|Modified T cell infusions will be administered 2-7 days following the completion of conditioning chemotherapy.There are 3 planned dose levels for this study: 1x10^6, 3x10^6, and 1x10^7 EGFRt/BCMA-41BBz CAR T cells/kg, and a dose -1 level at 3x10^5 EGFRt/BCMA-41BBz CAR T cells/kg, if needed; each dose cohort will consist of 3-6 patients.
1486504|NCT03070327|Drug|Cyclophosphamide|Cyclophosphamide 3000 mg/m2 IV once on day -7 to -2 or low intensity cy/flu (cyclophosphamide 300 mg/m2/day x 3 + fludarabine 30 mg/m2/day x 3) with the last day occurring on day -7 to -2 are the default options for is the default conditioning chemotherapy.
1486505|NCT03070327|Drug|Lenalidomide.|A cohort of patients will be treated with CAR T cell therapy and concomitant Lenalidomide. 10mg PO 21/28 days will be started no less then 1 week prior to clinical apheresis.
1486506|NCT03070314|Drug|Echinaforce junior|Echinacea Purpurea Extract Pill, sweetened and with orange flavour
1486507|NCT03070301|Drug|LEE011|LEE011 300 mg daily, 3 weeks on and 1 week off
1486508|NCT03070301|Drug|everolimus|everolimus 2.5 mg daily
1486509|NCT03070288|Other|Red-green-blue measurements of nasal mucosa image|Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in the selected area
1486510|NCT03070275|Biological|Biocomplex: aBM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
1486511|NCT03070275|Procedure|Two-stage surgical implant placement|Implants are surgically placed on the alveolar crest following a two-stage protocol and the manufacture's guidelines with no adjunctives.
1486512|NCT03070262|Drug|CA|caffeic acid, 300mg, tid, po
1486513|NCT03070262|Drug|placebo group|placebo tablet, 3 tablets, tid, po
1486553|NCT03069950|Drug|FLUOROURACIL|5-Fluouracil (5FU) (1200 mg/m2/day continuous infusion over two days)
1486554|NCT03069950|Drug|PANITUMUMAB|Panitumumab (6 mg/kg IV over 60 min)
1486555|NCT03069950|Drug|DEXAMETHASONE|flat dose of 25 mg on Day 1
1493100|NCT03020030|Drug|METHOTREXATE|Standard of Care
2001182|NCT03163433|Behavioral|Feedback in the consultation|Patients will complete electronic Patient Reported Outcome Measures (PROM) before the consultation at the hospital. The results are fed back to physicians. In the consultation patients will systematically participate in a dialogue with their physician about issues that are most important for the patients.
1486515|NCT03070236|Other|Survey|Select questions will be ask in the survey
1486516|NCT03070223|Drug|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
1486517|NCT03070223|Drug|Placebos|One tablet taken once daily, orally with or without food
1486518|NCT03070210|Procedure|EUS-celiac ganglia block (EUS-CGB)|The intervention technique of EUS-CGB is the realization of EUS-guided celiac block with injection of bupivacaine directly into the ganglia for patients with chronic pancreatitis.
1486519|NCT03070210|Procedure|EUS-celiac plexus block (EUS-CPB)|In the arm of EUS-CPB, the procedure is going to be performed with the standard EUS-guided celiac plexus block with injection of bupivacaine into the retroperitoneal space.
1486520|NCT03070197|Other|Exposure of interest: Brain MRI|Brain MRI will be conducted in all participants
1486521|NCT03070197|Other|Exposure of interest: neurodevelopmental assessments|neurodevelopmental testing will be conducted in all participants.
1486522|NCT03070184|Other|Exercise capacity VO2 max determination|Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
1486523|NCT03070184|Dietary Supplement|Standardized meals|Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
1486524|NCT03070184|Other|Exercise challenge|Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
1486525|NCT03070184|Drug|Metoprolol Succinate ER|Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
1486526|NCT03070171|Drug|dabigatran etexilate|single dose
1486527|NCT03070158|Behavioral|Attachment Promotion|"Attachment Promotion consists of:
Education session about newborn and mother care.
Training in multisensory stimulation using the ATVV Intervention (auditory, tactile, visual and vestibular)
Two domiciliary visits to follow up and to give education about newborn care and ATVV Intervention.
Daily Phone follows up."
1486528|NCT03070145|Other|Exercise Intervention|12-week moderate-intensity aerobic and strength training exercise intervention
1486529|NCT03070132|Drug|BIIB074|Administered as specified in the treatment arm
1486530|NCT03070132|Drug|Placebo|Matched placebo
2001183|NCT03162874|Drug|Placebo oral capsule|BID
1486532|NCT03070106|Dietary Supplement|Functional Medicine|Subjects randomized to the Functional Medicine plus the usual care arm will receive nutrition therapy and dietary supplements. Functional Medicine labs will be used in part to determine which supplements will be prescribed.
1486533|NCT03070093|Drug|gilteritinib|oral
1486534|NCT03070080|Procedure|restrictive fluid strategy|restrictive lactated ringers as intraoperative fluid therapy in a dose of 6ml/kg/hour
1486535|NCT03070080|Procedure|conservative fluid strategy|conservative lactated ringers as intraoperative fluid therapy in a dose of 12ml/kg/hour
1486536|NCT03070067|Other|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
1486537|NCT03070054|Drug|20ml 0.25% bupivacaine-epinephrine|Extra-capsular local infiltration analgesic (LIA) administration of 20ml 0.25% bupivacaine-epinephrine
1486539|NCT03070028|Procedure|crystallised phenol|crystallised phenol will be applied to sinus cavity
1486540|NCT03070028|Procedure|Platelet rich plasma|platelet rich plasma will be applied to sinus cavity
1486541|NCT03070015|Behavioral|Nutrisystem|The Nutrisystem Diet was 1000 kcal/day for week 1,and 1200 calories/day for women and 1500 calories/day for men after week 1.Subjects with BMI > 40 added 200 extra calories/day through grocery food add-ins.Subjects received 7 breakfast,7 lunches,7 dinners, and 14 shakes for week 1.Subjects added in vegetables & no-calorie beverages in week 1.After week 1,Nutrisystem provided 7 breakfasts,6 lunches,6 dinners, and 7 (women) or 14 (men) snacks/week.Subjects prepared 1 lunch & 1 dinner on their own weekly. Guidelines were given to allow subjects to select foods that fit within plan guidelines (~50% kcal from carbohydrate,~25% from protein,~25% from fat). Nutrisystem foods were about 60% of kcal target; grocery additions made the balance.Subjects received guidance as typical on Nutrisystem throughout the study period.Subjects were encouraged to call Nutrisystem counselors. Subjects randomized to this participated in Part A (4 weeks) and Part B (additional 8 weeks) of the study.
1486542|NCT03070015|Behavioral|Self-Directed DASH|The self-directed Dietary Approaches to Stop Hypertension group received instruction/education with handouts & sample meal plans, which met guidelines for DASH. All subjects followed a 1000 kcal/day DASH diet for week 1. After week 1, women ate 1200 kcal/day & men ate 1500 kcal/day. Subjects with BMI >40 added an extra 200 kcal/day. Subjects randomized to this group received one additional educational session beyond the Randomization visit on how to follow their prescribed meal plan. Subjects in this group only participated in Part A (4-weeks) of the study.
1486543|NCT03070002|Biological|Denosumab|Given SC
1486544|NCT03070002|Other|Laboratory Biomarker Analysis|Correlative studies
2001184|NCT03162874|Drug|PXT002331 - dose 1|Oral
2001185|NCT03162874|Drug|PXT002331 - dose 2|Oral
2001186|NCT03161964|Drug|Propranolol 80 Mg Oral Capsule, Extended Release|Propranolol capsule over-encapsulated to match placebo for blinding
1486549|NCT03069963|Drug|Z0063|"Pharmaceutical form: chewable tablets
Route of administration: oral"
1486550|NCT03069963|Drug|Gaviscon|"Pharmaceutical form: chewable tablets
Route of administration: oral"
1486551|NCT03069950|Drug|Floxuridine (FUDR)|5-Fluouracil (5FU) (1000 mg/m2/day continuous infusion over two days)
2001187|NCT03161964|Drug|Placebo oral capsule|Placebo capsule over-encapsulated to match propranolol for blinding
2001188|NCT03161912|Drug|Aflibercept (Eylea, BAY86-5321)|As per the treating physicians discretion
1486556|NCT03069950|Drug|Leucovorin|Leucovorin (LV) (400 mg/m2 IV over 30 min to an hour)
1486557|NCT03069937|Drug|Docetaxel|The docetaxel dose is a 75mg/m2 intravenous (given through the vein) injection.
1486558|NCT03069937|Drug|Degarelix|Degarelix will be given as a subcutaneous (given under the skin) injection in the abdomen. The first dose will be a 240mg dose; all other doses will be 80 mg.
1486559|NCT03069924|Behavioral|Gain-framed messaging|counseling plus gain-framed messaging
1486560|NCT03069924|Drug|Nicotine replacement therapy|counseling plus NRT
1486561|NCT03069924|Combination Product|Gain-framed messaging plus NRT|counseling plus gain-framed messaging and NRT
1486562|NCT03069924|Behavioral|Counseling alone|Counseling only
1486563|NCT03069911|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (29 units for women; 40 units for men) diluted with 0.9% sodium chloride (saline) solution to 40 units per milliliter (mL) (0.725 mL for women, 1 mL for men)
1486564|NCT03069911|Biological|Control|0.9% sodium chloride solution (saline) solution injections (0.725mL for women, 1mL for men)
1486565|NCT03069898|Behavioral|TRUE Dads|The TRUE Dads intervention consists of a set of 12 3-hour workshops that focus on enhancing fathers' role as co-parent, parent, and provider
1486566|NCT03069885|Device|Prevena|Incisional negative pressure wound therapy (iNPWT), is a new approach for surgical site closure using negative pressure wound therapy (NPWT). Recently, PrevenaTM have been approved as an iNPWT-system applied at the end of surgery, while still in a sterile environment. PrevenaTM consist of a sponge foam with a bactericidal silver lining dressed with an adherent film, connected to a vacuum device, producing a vacuum of 125 mm Hg. The PrevenaTM foam and dressing is placed over the suture line, and is recommended to be kept in place for a continuous period lasting between 2 and 7 days.
1486567|NCT03069885|Other|Standard Postoperative dressing|The standard postoperative dressing, using steri strips placed over the suture line.
1486568|NCT03069872|Diagnostic Test|Transvaginal ultrasound|Access to fast transvaginal ultrasound through general practice Develop and conduct training for general practicioners in the latest knowledge of ovarian cancer symptomatology
1486569|NCT03069859|Drug|TXA (1g)|1 gram of TXA (10 mL) diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
1486570|NCT03069859|Drug|Placebo (0.9% saline)|0.9% saline (10 mL), diluted into 0.9% saline, 50 ml mini-bag (a total of 60 mL)
1486571|NCT03069846|Device|Spectra-Scope|"The Spectra-Scope consists of the light collection module and the spectral analysis module.
The light collection module is attached to the handpiece of short pulse Nd:YAG laser, and the analysis module is placed on the laser.
Each potential skin cancer site, which has previously been identified as requiring biopsy, should be assessed using five laser shots that last approximately 10 milliseconds per shot and measurement. The laser shots must be made before the scheduled biopsy.
All potentially cancerous lesions (or lesions that would usually undergo complete biopsy of the lesion or require follow up within three months) should be sampled. The Spectra-Scope will not provide a diagnosis at the time of sampling. Sites should record the spectra reported for each laser shot in the CRF."
1486572|NCT03069833|Diagnostic Test|Computer-aided diagnosis|computer-aided diagnosis to assist colonoscopists
1486573|NCT03069820|Drug|docetaxel and cisplatin|Patients receive TP (docetaxel and cisplatin) chemotherapy
1486574|NCT03069807|Other|Community/Primary Care|The treatment of Latent Tuberculosis Infection (LTBI) in the community by General Practitioners (Family Doctors) and Pharmacists
1486575|NCT03069807|Other|Hospital/TB Clinic|The treatment of Latent Tuberculosis Infection (LTBI) in the Hospital TB Clinic by specialist doctors and nurses
1486576|NCT03069794|Diagnostic Test|Use of stable force platform|Use of stable force platform to appreciate the posture before and after spinal surgery
1486577|NCT03069781|Other|Breg Knee Brace|Participants will have one leg immobilized by means of knee bracing (http://www.breg.com/products/knee-bracing/post-op) thus the contralateral limb will act as an internal control. The leg to be immobilized will be chosen in a random counterbalanced manner to result in equal numbers of participants having their weaker or stronger legs being immobilized. The brace (http://www.breg.com/products/knee-bracing/post-op) will be worn in a fixed flexion position at 140° (i.e., 40° from full extension) with a plastic band that is removed to check for pressure points daily and resealed with a custom-modified plastic strap that is melted to seal the strap
1486578|NCT03069781|Drug|17β-estradiol|1mg/day for 3-days and 3mg/day for 7-days of Estrance
1486579|NCT03069768|Device|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
1486580|NCT03069768|Drug|Chantix|For the first 3 days smokers in this group will receive treatment with Chantix at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12-week active treatment duration.
1486581|NCT03069755|Other|No intervention|No intervention
1486582|NCT03069742|Other|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
1486583|NCT03069742|Other|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
1486584|NCT03069729|Other|no intervention|This study evaluates s system intended to detect bio-markers of DPN. No interventions are involved in this non-invasive study.
1486585|NCT03069716|Device|Smartphone Text Messaging|A HIPPA compliant text messaging platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network. Subjects will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule (defined at enrollment). These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.
1486613|NCT03069482|Drug|Nicotine lozenge|Each participant will be given a 1-week course of 4mg Nicotine lozenges to be taken orally as nicotine cravings arise (about 10 lozenges per day). They will be directed to use them for the week following their quit date, using no more than once every 1-2 hours. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
1486586|NCT03069716|Device|Fitbit Charge HR|The Fitbit Charge HR tri-axial accelerometer will be used to continuously gather data on physical activity, heart rate, and sleep. This device provides feedback in units of activity (steps, stairs climbed, activity time, and exercise time) and heart rate (per second when active, per 5 seconds when inactive). It has been validated against research devices in free-living conditions and is relatively inexpensive.
1486587|NCT03069703|Biological|PCV13|
1486588|NCT03069703|Biological|PPV23|
1486589|NCT03069703|Drug|Rituximab|375 mg/m2/week for 4 consecutive weeks, at Days 0 ± 2 days, Day 7 ± 2 days, Day 14 ± 2 days and Day 21 ± 2 days, as induction therapy of vasculitis flare, followed by 500 mg-rituximab infusion every 6 months as maintenance therapy, i.e. at Month 6, Month 12 and Month 18
1486590|NCT03069690|Behavioral|HABITpreg|Treatment during pregnancy will consist of up to 10 in person sessions taking place at regularly scheduled obstetric appointments, at the investigator's research building, or a nearby location. Participants in the HABITpregnancy group will also receive texts and phone calls between sessions. HABIT will focus on weight, physical activity, eating and psychosocial issues. Women will receive consultation about nutritional balance, dietary guidelines for pregnant women and advice to maintain an optimal rate of weight gain according to prepregnancy BMI. Women will use self-monitoring forms to identify and modify cues for unhealthy behaviors. Beliefs about body weight and eating during pregnancy will be addressed and effects of physical activity on body weight, health, and mood will be included.
1486591|NCT03069690|Behavioral|HABITpost|Treatment during the postpartum period (HABITpost) will consist of an intervention over the 24 weeks immediately following delivery. Treatment will include 12 biweekly sessions completed over the phone or in person. In person sessions will be done at the participant's home or another convenient location. Additionally, participants will receive calls and texts between sessions. Sessions will focus on weight, physical activity, eating and psychosocial issues.
1486592|NCT03069677|Other|music|patients in this group will receive research-selected music for a minimum of 20 minutes after the golden moment has been completed between the patient, provider, and nursing staff
1486593|NCT03069677|Drug|Midazolam|patients in this group will receive IV midazolam (0.5mg to 2mg max) after the golden moment has been completed
1486594|NCT03069664|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
1486595|NCT03069664|Device|Covered Self-expandable Metal Stent|Pancreatic duct stent
1486596|NCT03069651|Other|Virtual Care|The use of Videoconferencing software to enable remote access to monitor patients in the 'Virtual Care' cohort.
1486597|NCT03069638|Drug|Dexmedetomidine|Intranasal administration of dexmedetomidine as a procedural sedation (intra-articular joint injection)
1486598|NCT03069638|Drug|Sedatives/Hypnotics,Other|Inhaled dinitrous oxide as procedural sedation (intra-articular joint injection)
1486599|NCT03069625|Behavioral|Sit-to-stand test|CF young patients will perform 2 STS tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
1486600|NCT03069625|Behavioral|6-Minute Walk Test|CF young patients will perform 2 6MWT tests. Number of repetitions, cardio-respiratory response and physiological adaptations during the second test will be monitored.
1486601|NCT03069612|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS administered bilaterally to the DLPFC at 20 Hz, 90% RMT, 25 trains
1486602|NCT03069599|Procedure|irreversible electroporation (IRE)|Irreversible electroporation is an emerging, mainly non-thermal ablative modality. It circumvents some downsides of thermal ablation and has the potential for broad application among patients with pancreatic cancer.
1486603|NCT03069586|Procedure|Pulmonary recruitment|At the end of surgery a manual pulmonary recruitment (5 sec, max 40 cmH2O) is given to the patiënt
1486604|NCT03069586|Procedure|No pulmonary recruitment|At the end of surgery no intervention was completed
1486605|NCT03069560|Device|SMS|SMS contact from the caregiver with patient after discharge in intervention group
1486606|NCT03069547|Other|Quadriceps Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.
The program details can be requested rom the responsible party. In brief the QE-program consists of:
- A short warm-up and 3 specific exercises for the quadriceps muscle
Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, free weights, etc."
1486607|NCT03069547|Other|Hip Exercise program|"The exercise program is initiated at an individual clinical visit. An experienced physiotherapist introduces the participant to the exercise program and provides instructions to the individual exercises. An experienced physiotherapist provides the monthly supervision visits.
The program details be requested rom the responsible party. In brief the HE-program consists of:
- A short warm-up and 3 specific exercises for the hip abductor and extensor muscles
Progression of the exercise intensity is done by adding (additional) external loads, such as elastic rubber bands, body weight etc."
1486608|NCT03069534|Drug|RhIL-2|RhIL-2 treatment intervention was consisted of four courses of low-dose rhIL-2 plus standard anti-tuberculosis chemotharapy. rhIL-2 (500,000 U/m)regimen was given subcutaneously (SC) once every other day (q.o.d.) for 30 days and four courses were carried out separately during months 1, 3, 5, and 7.
1486609|NCT03069521|Device|EndoArt™ Artificial Endothelial Layer|device is intended for use as an endothelial kearatoprosthesis
1486610|NCT03069508|Drug|Clemizole Hydrochloride|Clemizole Hydrochloride will be administered orally for up to 24 weeks
1486611|NCT03069482|Device|Learn to Quit App|A smartphone app designed for individuals with serious mental illness. The main intervention components of the app are skills based on an intervention called Acceptance and Commitment Therapy that will (a) teach smoking cessation skills and (b) help cope with mental health symptoms. The app incorporates gaming features to keep users engaged, and a tracking component to record smoking habits and moods.
1486612|NCT03069482|Drug|Nicotine patch|Participants enrolled in the study will be given an 8-week course of Nicotine patches. The 8-week course of trans-dermal nicotine patches starting at 21mg/24h for 4 weeks, then transitioning to 14mg/24h for 2 weeks, and finally to 7mg/24h for the last 2 weeks. This dosing will follow recommendations contained in the US DHHS Clinical Practice Guidelines.
1486650|NCT03069170|Biological|Stem Cell Transplantation|Intravenous and Intrathecal injections of purified autologus bone marrow-derived stem cells.
1614463|NCT02128360|Drug|Gonadotropins|
1486614|NCT03069482|Behavioral|Technical Coaching|Coaching to assist the user on the use of each assigned smartphone app. This coaching will be delivered by research staff following a coaching procedure. These in-person coaching meetings will be brief (~15 minutes), done on a weekly basis for 4 weeks, and will have a focus on providing technical assistance.
1486615|NCT03069482|Device|NCI QuitGuide App|A smartphone app developed by the National Cancer Institute which uses recommendations contained in the US DHHS Clinical Practice Guidelines and smokefree.gov. NCI QuitGuide has the following intervention components: (a) psycho-education about the impact of smoking in health, (b) tracking of smoking habits, and (c) Tips for quitting (e.g., distraction strategies).
1486616|NCT03069469|Drug|DCC-3014|CSF1R inhibitor
1486617|NCT03069456|Device|BIS|
1486618|NCT03069456|Device|ADMS|
1486619|NCT03069443|Other|IHG home training|Participants of the intervention group will follow the IHG home training protocol for 20 weeks. The IHG training consists of isometric contractions applied with the hands on a Wii.
1486620|NCT03069430|Behavioral|SELFY (Self Management for Youth with SCD)|The intervention will be delivered via a mobile device (tablet) and consists of three components. 1. Education, will consist of continuous access to electronic educational resources on the SCD process, treatment, home management strategies, symptom prevention and management strategies. To address potential literacy barriers, an application that reads PDF files aloud will be downloaded onto devices. 2. symptom monitoring and tracking, will consist of an application for tracking and monitoring pain in SCD that also permits upload of symptom logs and text alerts to a health care provider. 3. caregiver-provider communication, consists of SMS messaging with a nurse who will: respond to alerts, monitor pain symptoms delivered via the mHealth application, and respond to text messages.
1486621|NCT03069417|Behavioral|Integrating Nuanced Support for Perinatal adherence and Depression|A 5-8 session intervention to decrease depressive symptoms and improve antiretroviral adherence among HIV-infected pregnant and postpartum women
1486622|NCT03069391|Behavioral|physical exercise alone (PES) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week physical exercise-only intervention, then 2-week cognitive exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
1486623|NCT03069391|Device|cognitive exercise alone (iCE) first|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
1486624|NCT03069391|Device|interactive Physical and Cognitive Exercise (iPACES™)|following 2-week placebo for all participants, participants in this arm will then start their active intervention with a randomly assigned 2-week cognitive exercise-only intervention, then 2-week physical exercise-only intervention, then 2-week and 3 month intervals of iPACES™ (interactive physical and cognitive exercise)
1486625|NCT03069378|Drug|Talimogene Laherparepvec (T-VEC)|Talimogene laherparepvec treatment will be given at Day 1 Week 1, and every 3 weeks thereafter .
1486626|NCT03069378|Drug|Pembrolizumab|Pembrolizumab will be given at Day 1 week 1 and every 3 weeks thereafter.
1486627|NCT03069365|Drug|Glecaprevir/Pibrentasvir|Film-coated tablet
1486628|NCT03069352|Drug|Venetoclax|tablet
1486629|NCT03069352|Drug|Placebo|tablet
1486630|NCT03069352|Drug|Cytarabine|Subcutaneous
1486631|NCT03069339|Drug|Carvedilol|Carvedilol will start at starting dose of 3.125 mg BD followed by 6.25 mg BD followed by 12.5 mg BD if BP 90/60 mmHg and HR 55/min
1486632|NCT03069339|Procedure|Endoscopic Variceal Ligation|EVL will be done every 3 weeks till eradication
1486633|NCT03069326|Drug|Ruxolitinib|Ruxolitinib will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. Ruxolitinib will be given continuously orally daily in 28-day cycles.
1486634|NCT03069326|Drug|Thalidomide|Thalidomide will be given orally in an outpatient setting unless the patient is being seen inpatient for another reason. thalidomide will be given continuously orally daily in 28-day cycles.
1948853|NCT01401231|Behavioral|Behavioral activation psychotherapy|Up to 10 sessions of behavioral activation psychotherapy delivered in person or by telephone.
1486636|NCT03069300|Drug|N-acetyl cysteine (NAC)|
1486637|NCT03069287|Behavioral|Benjamin Rose Institute (BRI) Care Consultation™ Program|The BRI Care Consultation™ can be delivered via face-to-face contact, telephone, mail, and/or email by a Care Consultant and caregiver who assists with daily activities, tasks, and health-related issues. BRI CareConsultation™ uses a secure, web-based Care Consultation Information System (CCIS) to guide the delivery of the intervention.
1486638|NCT03069274|Behavioral|Intervention|General nutritional recommendations, change drinking habits
1486639|NCT03069274|Behavioral|General nutritional recommendations|Only general nutritional recommendations were given
1486641|NCT03069248|Drug|Rituximab|
1486642|NCT03069248|Drug|Alpha Interferon|
1486643|NCT03069235|Behavioral|Family member / peer support|supplemental individualized counselling
1486644|NCT03069235|Behavioral|Enhanced intervention with counselor support|"hands on EBF demonstrations"
1486645|NCT03069235|Behavioral|standard of care|one on one and in-group counselling
1486646|NCT03069222|Other|Standard Rehabilitative Treatment|The patients will participate in standard but comprehensive SCI specific rehabilitation therapy provided by the SCI program at KIR. The therapy consists of 3 hours per day, 5 days a week. Motor function therapy includes standardized procedures for range of motion, passive and active muscle activities, and therapies to improve mobility. The treatment program for the enrolled patients will be standardized by Dr. Kirshblum, Director of the SCI program at KIR and a Co-Investigator of the study. Patients usually receive 4 weeks of rehabilitation treatment; however, if any of them are discharged earlier from KIR, their out-patient treatment activities will be monitored and the patients will be tested based on the planned schedule.
1486647|NCT03069209|Biological|Stem Cells|Intraovarian transplantation of autologous purified bone marrow-derived stem cells and mesenchymal stem cells.
1486648|NCT03069183|Drug|0.5% Ropivacaine|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
1486649|NCT03069183|Drug|Normal saline|Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls normal saline.
1486651|NCT03069157|Procedure|lung recruitment maneuver|lung recruitment manoeuvre will be performed in patients using continuous positive airway pressure( CPAP) (30) cm H2O for (40) seconds after induction of anesthesia then patient will be converted to pressure controlled mode again with PEEP 5 cm H2O
1486652|NCT03069144|Drug|HAT1 topical solution|HAT1 topical solution will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
1486653|NCT03069144|Drug|Calcipotriol|Calcipotriol ointment (0.005%) will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
1486654|NCT03069131|Drug|Rifaximin|twice daily administration of 1 tablet containing 550 mg of active rifaximin
1486655|NCT03069131|Other|Placebo|twice daily administration of 1 rifaximin placebo tablet
1486656|NCT03069118|Behavioral|Treatment - Workit Health Online Program|"The Workit Health program is an adaptive recovery in your pocket harm reduction and sobriety solution that provides 24-hour access to adaptive lessons, mentorship, written and audio driven therapeutic exercises and tools, and peer-to-peer coaching. Users access our online site and enter an initial 90-day program that takes a holistic approach to recovery by addressing the physical, mental, emotional, and social aspects of addiction. As they advance, they move through successive levels that include lessons, activities, and assignments. Bonus materials, such as meditations and suggested reading, give users timely opportunities to dive deeper into a problem they are struggling with that day. Workit Health implements evidence-based strategies such as CBT, DBT, and MI."
1486657|NCT03069118|Behavioral|Control - Resource List|Tailored list of resources.
1486658|NCT03069105|Other|Questionnaire|Participants will complete paper and pencil or electronic questionnaires at the cancer center or in the privacy of their own homes.
1486659|NCT03069092|Behavioral|aerobic exercise|AE training will consist of 60 min of treadmill, elliptical, or bike exercise at a moderate to vigorous intensity (50-80% of heart rate reserve). Intensity of the exercise sessions will be built up gradually. Sessions will occur 3 times per week for the duration of the 1 year trial.
1486660|NCT03069092|Behavioral|resistance exercise|RE will consist of 3 sets of 8-15 repetitions at 50-80% of 1 rep-max of each exercise for 12 exercises (chest press, shoulder press, pull-down, back extension, abdominal crunch, torso rotation, biceps curl, triceps extension, leg press, leg extension, leg curl, and calf raise). Weight loads will be increased gradually. With one minute of rest between sets, this plan is estimated to take approximately 60 minutes per session. Sessions will occur 3 times per week for the duration of the 1 year trial
1486661|NCT03069092|Behavioral|Combined resistance and aerobic exercise|Participants will perform exactly the same AE and RE exercises as listed previously; however, the time of AE and RE will each be reduced to 30 min (for 60 min/session total). For the RE aspect, participants will perform 2 sets of 8-15 repetitions of 9 exercises (excluding biceps curl, triceps extension, and calf raise, as these are minor muscle groups). Exercise intensity and resistance will be increased gradually. Combined AE and RE sessions will take place 3 times per week for the duration of the trial.
1486662|NCT03069079|Procedure|Oral hygiene advice, non surgical periodontal treatment|For children affected by periodontal disease, oral hygiene advice, non surgical periodontal treatment will also be performed according to needs. This can be accompanied, when appropriate, by the use of local anaesthesia and adjunctive antimicrobials (systemic or locally applied subgingivally), according to the clinical presentation and the child's medical conditions. Accurate supra- and sub-gingival removal of calculus and dental plaque will be performed both with ultrasonic and/or manual instruments. The necessary sub-gingival debridement will be performed in 1 to 4 visits (either full mouth treatment, half-mouth treatment or quadrant-wise treatment) depending on patient preference and practical considerations, using manual (Gracey curettes, Hu-Friedy) and ultrasonic devices (EMS). .
1486663|NCT03069066|Device|Bioresorbable vascular scaffold. Absorb GT1 (Abbott)|
1486664|NCT03069040|Procedure|nerve sparing radical hysterectomy|Type C1 radical hysterectomy,that is nerve sparing radical hysterectomy, requires separation of two parts of the dorsal parametria: the medialpart , which entails recto -uterineandrecto-vaginal ligaments, and the lateral laminar structure, also called mesoureter, which contains the hypogastric plexus. Furthermore, type C1 requires only a partial dissection of the ureter from the ventral parametria, which is usually asymmetric towards more extensive resection of the medial leaf of the cranial (above the ureter) part of the ventral parametria .
1486665|NCT03069040|Procedure|radical hysterectomy|In the C2 type, the ureter is completely dissected from the ventral parametria up to the urinary bladder wall. Defining the resection limits on the longitudinal (deep parametrial or vertical) plane is crucial for distinguishing between types C1 and C2.
1486666|NCT03069027|Procedure|External nasal nerve block|Three single (midline injection) and 4 paired (bilateral injection) sites to block the external nasal sensation.
1486667|NCT03069027|Drug|saline adrenaline|
1486668|NCT03069027|Drug|Xylocaine, adrenaline|
1486669|NCT03069014|Drug|400mg LM11A-31-BHS|2 Oral Capsules (200mg of LM11A-31-BHS and 200mg of placebo) twice daily (morning & evening) for 26 weeks
1486670|NCT03069014|Drug|800mg LM11A-31-BHS|2 Oral Capsules (200mg of LM11A-31-BHS) twice daily (morning & evening) for 26 weeks
1486671|NCT03069014|Drug|Placebos|2 Oral Capsules (200mg of Placebo) twice daily (morning & evening) for 26 weeks
1486672|NCT03069001|Drug|Sofosbuvir-Simeprevir|-Sofosbuvir-Simeprevir group included 50 patients who received sofosbuvir 400 mg orally once-daily plus simeprevir 150 mg orally once-daily for 12 weeks.
1486673|NCT03069001|Drug|Sofosbuvir-Ribavirin|-Sofosbuvir-Ribavirin group included 40 patients who received sofosbuvir 400 mg orally once-daily plus ribavirin orally twice-daily for 24 weeks.
1486674|NCT03068988|Biological|mesenchymal stem cells|mesenchymal stem cells concentrate into the supraspinatus footprint during the surgery
1486675|NCT03068988|Procedure|without mesenchymal stem cells|rotator cuff surgery without mesenchymal stem cells
1486676|NCT03068975|Drug|Alvimopan|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive Alvimopan ( post operative dose only) and will monitor for post operative ileus.
1493101|NCT03020030|Drug|NELARABINE|Standard of Care
1486677|NCT03068975|Drug|Placebo|Patients who sustained abdominal trauma with resection of bowel and anastomosis will receive the Placebo Pill (post operative dose only) and will monitor for post operative ileus.
1486678|NCT03068962|Other|beetroot Juice|Beetroot Juice
1486679|NCT03068962|Other|Buxton water|natural mineral water
1486680|NCT03068962|Other|antiseptic mouthwash then beetroot juice|Chlorhexidine glocunate
1486681|NCT03068949|Biological|FluBlok|FluBlok trivalent Influenza Vaccine .5 mL given Intramuscularly
1486682|NCT03068949|Biological|Fluzone|Fluzone Quadrivalent Influenza Vaccine .5 mL given intramuscularly
1486683|NCT03068949|Biological|FluCelVax|FluCelVax Quadrivalent Influenza Vaccine .5 mL given intramuscularly
1486684|NCT03068936|Radiation|Intensity modulated radiotherapy|Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
1486685|NCT03068936|Drug|Cisplatin|Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
1486686|NCT03068910|Drug|Spironolactone|Spironolactone is an androgen-receptor blocker commonly used (off-label) for hyperandrogegism. The spironolactone dose will be 50 mg taken orally twice daily (for two weeks before admission to the Clinical Research Unit).
1486687|NCT03068910|Drug|Placebo|The placebo has only inactive ingredients and is not expected to exert any direct physiological effects. Placebo will be taken twice daily (for two weeks before admission to the Clinical Research Unit).
1486688|NCT03068910|Drug|Micronized progesterone solution|Micronized progesterone solution will be given orally at 1000, 1600, and 2200 h on the day of admission to the Clinical Research Unit. Each dose of micronized progesterone will be 0.8 mg/ per kg body weight.
1486689|NCT03068897|Drug|Metaxalone|Metaxalone 400-800mg
1486690|NCT03068897|Drug|Tizanidine|Tizanidine 2-4mg
1486691|NCT03068897|Drug|Baclofen|Baclofen 10-20mg
1486692|NCT03068897|Drug|Ibuprofen 600 mg|Ibuprofen
1486693|NCT03068897|Behavioral|Educational intervention|Research personnel will provide each patient with a 15-minute educational intervention. This will be based on NIAMS's Handout on Health: Back Pain information webpage (available at http://www.niams.nih.gov/Health_Info/Back_Pain/default.asp) Research personnel will review each section of the information sheet with the patient and elicit questions.
1486694|NCT03068884|Device|Cathodal Transcranial direct current stimulation|Cathodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
1486695|NCT03068884|Dietary Supplement|L-Tyrosine|Administration of 2 grams tyrosine
1486696|NCT03068884|Device|Transcranial direct current stimulation (sham)|Sham tDCS
1486697|NCT03068884|Dietary Supplement|Cellulose (placebo)|Administration of 2 grams cellulose
1486698|NCT03068871|Other|ACT|Psycho-educational group
1486699|NCT03068871|Other|CET|Psycho-educational group
1486701|NCT03068845|Device|Drug-eluting balloon angioplasty (DEBA)|"DEBA will be performed after pre-dilatation of the target lesion for subjects allocated to the experimental arm.
If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.
High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).
All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
1486702|NCT03068845|Device|Conventional Balloon Angioplasty (CBA)|"CBA will be performed for the target lesion for subjects allocated to the active comparator arm.
If there is more than 1 stenosis, only the most severe stenosis will be designated the target lesion and treated according to treatment allocation. All other stenoses will be treated with conventional balloon angioplasty.
High pressure balloon angioplasty may be performed if there is poor angioplasty results (significant residual stenosis of more than 30%).
All patients will be started on dual antiplatelets (aspirin and clopidogrel) for 1 month after intervention, followed by 5 months of aspirin."
1486703|NCT03068832|Biological|Personalized peptide vaccine|-It may take 3-4 months for sequencing, neoantigen prediction, and peptide manufacturing
1486704|NCT03068832|Drug|Poly ICLC|-Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension.
1486705|NCT03068832|Procedure|Peripheral blood draw|"After trial enrollment and up to 7 days after the 1st vaccine dose
2 weeks after last dose
Time of progression or discontinuation"
1486709|NCT03068806|Diagnostic Test|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|We will use these techniques combined with attention tests, memory tests, and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
1486710|NCT03068793|Diagnostic Test|Electroencephalography (EEG) and Magnetic Resonance Imaging (MRI)|We will use these techniques combined with tests of reward anticipation and clinical interviews to explore connections between these measures and activity in the brain in patients with a diagnosis of schizophrenia and healthy controls.
1486711|NCT03068780|Drug|Oleogel-S10|10% birch bark extract in 90% sunflower oil
1486712|NCT03068780|Drug|Placebo|Sunflower oil gel
1486713|NCT03068767|Dietary Supplement|Vitamin D|
1486714|NCT03068754|Drug|Acthar|Repository corticotropin injection administered subcutaneously once a day
1486715|NCT03068754|Drug|Placebo|Placebo gel injection administered subcutaneously once a day
1486716|NCT03068741|Drug|Comparison 1: Prehospital Ceftriaxone|Paramedics will administer 1g of intramuscular ceftriaxone.
1486717|NCT03068741|Drug|Comparison 1: Placebo|Paramedics will administer an identical volume of reconstituted intramuscular placebo.
1486718|NCT03068741|Drug|Comparison 2: Liberal fluids|Paramedics will administer up to 2 litres of intravenous saline (0.9%) to all patients regardless of systolic blood pressure, and reassessing this infusion after each 250ml are infused.
1486719|NCT03068741|Drug|Comparison 2: Conservative fluids|Paramedics will administer intravenous saline (0.9%) according to the Medical Directive, which allows for infusion of fluids if systolic blood pressure is <90mmHg and continued until systolic blood pressure is >=100mmHg.
1486720|NCT03068728|Device|Arista|
1486721|NCT03068728|Device|Nexafoam|
1486722|NCT03068728|Device|Sinufoam|
1486723|NCT03068728|Device|Nasopore|
1486724|NCT03068728|Device|Posisep Hemostat Dressing|
1486725|NCT03068728|Device|Posisep X Hemostat Dressing|
1486726|NCT03068715|Device|Active TBS-DLPFC|"Participants in the active stimulation group will receive intermittent TBS (intermittent TBS-1800 pulses/session). They will receive 1800 stimuli of iTBS to left DLPFC per session per session. The L-DLPFC will be targeted utilizing the Localite neuronavigation system. Stimulation intensity will be standardized at 80% of RMT and adjusted to the skull to cortical surface distance (see Nahas 2004).
Sessions will be delivered using the MagPro stimulator, with 3-pulse 50-Hz bursts given every 200ms (at 5 Hz). In the intermittent TBS, a 2s train of bursts will be given every 10 s for a total of 570 s (1800 pulses) over the L DLPFC."
1486727|NCT03068715|Device|Sham TBS-DLPFC|The parameters in the active arms will be as above with the internal randomization of the device internally switching to sham in a blinded fashion.
1486728|NCT03068715|Device|Open label TBS-DLPFC|Patients will have the option of receiving active, open label aTBS treatment following sham.
1486729|NCT03068702|Device|Optical Coherence Tomography Angiography|
1486730|NCT03068689|Procedure|RIPC|RIPC is delivered with a standard blood pressure cuff placed on the upper arm and another standard blood pressure cuff placed on the upper thigh. The cuffs are then simultaneously inflated to 200 mm HG and left inflated for 5 minutes, then deflated to 0 mmHG and left uninflated for 5 minutes. This cycle is repeated twice, so that the RIPC protocol takes 20 minutes in total. If the systolic blood pressure is > 185mm HG the cuffs are inflated to 15 mmHG above that level.
1486731|NCT03068689|Other|Placebo|Placebo
1486732|NCT03068676|Behavioral|Space from Depression|internet-delivered CBT
1486733|NCT03068676|Behavioral|Space from Anxiety|internet-delivered CBT
1486734|NCT03068663|Other|Sampling|"Patients will receive their standard treatments, surgery with/without chemotherapy. A patient intervention consists in taking samples of blood, saliva, faeces, lung/tumour tissue, and bronchoalveolar lavage fluid.
We intend to search for a possible influence of lung cancer on patient's microbiota at different sites, and to see if and in which way does chemotherapy add to this change. The significant number of 20 patients per group was based on the study of Montassier et al., 2015, considering the results of difference in abundance of bacterial phylum Firmicutes in human faecal microbiota."
1486736|NCT03068637|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
1486741|NCT03068611|Behavioral|Standard Web-based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
1486742|NCT03068611|Behavioral|Alcohol-focused Web-Based Smoking Cessation|A website and text messaging program that is publicly available through BecomeAnEX.com. Participants have access to the website whenever they wish.
1486743|NCT03068598|Device|PulseOn watch|The PulseOn watch and a smartphone will be given to the patient after discharge. After a brief training on how to use the sleep tracker, patient will monitor his sleep with watch during the five nights following the discharge. All data will be transmitted directly to the smartphone. Each morning, the patient will complete a questionnaire to assess the quality of his sleep and on day 5, during a standart follow up visit, he will complete a questionnaire evaluating the acceptability of the sleep recording device.
1486744|NCT03068585|Drug|Neovasculgen (Cambiogeneplasmid)|treatment
1486745|NCT03068533|Other|8% L-Arginine/calcium carbonate containing toothpaste|use of 8% L-Arginine/calcium carbonate containing toothpaste to relieve hypersensitivity
1486746|NCT03068533|Other|use of strontium acetate toothpaste|use of strontium acetate toothpaste to relieve hypersensitivity
1486747|NCT03068520|Diagnostic Test|PET MR|PET MR with 18 Fluorodopa ([18F]-DOPA) will be performed on patient at set intervals
1486748|NCT03068507|Behavioral|Trimodal prehabilitation management|Trimodal prehabilitation strategy includes physical exercise (moderate aerobic exercise combined with resistance exercise and respiratory training ), nutritional suggestion and optimization（whey protein supplement）, and psychological therapy, as well as conventional guidance (including preoperative anesthesia assessment, drug treatment recommendations for chronic disease, quit smoking and abstinence).
1486749|NCT03068481|Drug|KDT-3594|
1486750|NCT03068481|Drug|Placebo|
1948854|NCT01401231|Other|Usual care|Continued usual care (could include referral for medication or psychotherapy)
2001202|NCT03153150|Drug|Apixaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
2001203|NCT03153150|Drug|Rivaroxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
1486755|NCT03068442|Drug|Imaging with flutemetamol F 18 PET/CT|All subjects will undergo diagnostic imaging as the intervention. This imaging will be with flutemetamol F 18 PET/CT
2001204|NCT03153150|Drug|Edoxaban|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
1486757|NCT03068416|Biological|CAR T cells|Autologous CD19-targeting, 3rd generation CAR T cells
1486758|NCT03068403|Procedure|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration|Dynamic contrast enhanced ultrasound (D-CEUS) with Sonovue® administration
1486759|NCT03068390|Behavioral|RICHH Intervention|Whole health cardiovascular disease (CVD) self-care risk reduction intervention
1486760|NCT03068390|Behavioral|Usual care|Referral to primary care provider
1486761|NCT03068377|Dietary Supplement|phytonutrient and vitamin supplement|dietary supplement (soft gel capsulr) containing tomato extract as well as other phytonutrient and vitamin
2001205|NCT03153150|Drug|Dabigatran|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
2001206|NCT03153150|Drug|Acenocoumarol|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
1486764|NCT03068338|Device|Robotic Sock|Soft robotic actuator used in a sock design technology to perform plantarflexion and dorsiflexion of the foot about the ankle joint.
1486765|NCT03068338|Device|Intermittent pneumatic compression|Conventional device used by hospitals
1486766|NCT03068325|Other|TF-EAT|
1486767|NCT03068312|Drug|Ivacaftor|Ivacaftor, 150 mg every 12 hours (q12h)
1486768|NCT03068312|Drug|Placebo|Placebo matched to Ivacaftor
1486769|NCT03068299|Other|Dance|Sessions of sixty minutes each, which will take place weekly, totaling 24 weeks (6 months). Ten minutes from the start of each session will be reserved for initial exercises, with movements of the upper limbs, lower, accompanied by a motivational music. The process of identifying and memorizing the movements will be carried out as many times as the group deems necessary. The rhythms include combinations of circular and ballroom dances, including waltz, cha-cha-cha, cancan, among others. In all the sessions, the last fifteen minutes are reserved for a conversation about the dance learned/practiced in the day. It is expected to have reached the proposal of a practice of 15 different choreographies and that this was a pleasant moment for all the participants.
1486770|NCT03068299|Other|Health care guidance|Control group will receive attention, through guidelines for care and health practices for the caregiver and the elderly care recipient. This attention should occur in the same number of sessions of the dance and group intervention group. The control group should follow the same subdivision of the intervention group, in terms of the number of participants per subgroup. The subjects of the guidelines will be raised by the demand of the participants themselves and then worked in an interdisciplinary way.
1486771|NCT03068286|Behavioral|Space in Diabetes|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Psychoeducational content in the diabetes programme focusses on the impact that mood can have on self-management and self-care when living with diabetes.
1486772|NCT03068286|Behavioral|Space in COPD|The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored.Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
1486773|NCT03068286|Behavioral|Space in Chronic Pain|"The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. A module on health anxiety, titled Anxiety and your Health, has been added to the chronic pain programme. This module provides psychoeducational content on health anxiety, the unhelpful behaviours that accompany it and how these can negatively impact on the experience of pain."
1486774|NCT03068273|Device|Real-time CGM data|
1486775|NCT03068260|Drug|Ropivacaine|30 ml ropivacaine 0,375% administered on each side as bilateral TQL blocks
1486776|NCT03068260|Drug|Saline|30 ml saline 0,375% administered on each side as bilateral TQL blocks
1486777|NCT03068260|Drug|Acetaminophen|1 g orally administered postoperatively
1486778|NCT03068260|Drug|Ibuprofen 400Mg Tablet / Celebra 100 Mg tablet|orally administered postoperatively
1486779|NCT03068260|Device|ultrasound-guided nerve block|Transmuscular quadratus lumborum block, ultrasound-guided
1486780|NCT03068260|Drug|Morphine|intravenously administered morphine via PCA-pump
1486781|NCT03068260|Device|Patient-controlled analgesia|PCA-pump with IV-Morphine. 5 mg administered per bolus. Lock-out time and max. dosage standardized.
1486782|NCT03068247|Drug|Duloxetine|10 week treatment
1486783|NCT03068247|Drug|Placebo|10 week treatment
1486784|NCT03068234|Drug|Pirfenidone|A chemical synthesized agent showing anti-fibrotic effects in idiopathic pulmonary fibrosis.
1486785|NCT03068234|Drug|Placebo oral capsule|Placebo for pirfenidone capsule
1486786|NCT03068234|Drug|Steroids|Low dose of glucocorticoids, a basic treatment for patients with systemic sclerosis
1486787|NCT03068221|Other|anaerobic exercise|assessing anaerobic exercise status
1486788|NCT03068208|Procedure|Methylene blue-mediated photodynamic therapy|The 2% MB aqueous solution was applied to the lesion until saturation occurred, followed by a occlusive dressing and rest period of 30 minutes. After the rest period, the lesion was immediately illuminated with incoherent red light (peak emission spectrum at 630-640 nm)
1486789|NCT03068195|Procedure|microwave ablation|KY2000 microwave ablation system was used in the experimental group. A power output of 60 W for 1-3 min for 1-3 cycles to treat the renal cysts according to the cysts size and classification.Percutaneous microwave ablation will be performed under the guidance of ultrasound while the laparoscopic microwave ablation will be performed under direct vision
1486790|NCT03068195|Procedure|laparoscopic decortication|conventional laparoscopic decortication will be performed to treat the renal cysts
2001207|NCT03153150|Drug|Phenindione|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
2001208|NCT03153150|Drug|Warfarin|The participant will be allocated to start this oral anticoagulant drug, if the participant's doctor indicated it before randomisation.
2001209|NCT03153293|Drug|rAAV2-ND4|a Single IVT Injection
2001210|NCT03153293|Drug|normal saline|a Single IVT Injection
1486791|NCT03068182|Device|Arm crank|Each participant practiced on arm crank (Hudson) from long sitting position for 40 minutes. Seat's height and distance were adjusted to achieve full extension of subject arms at horizontal shoulder-level position
1486792|NCT03068182|Device|Treadmill|Participant practiced on an electronic computerized treadmill for 40 minutes . participant began warming up with lowest speed treadmill exercise for 5 minutes at zero inclination. Treadmill speed was increased gradually to achieve the pre-determined individualized moderate intensity for 30 minutes
1486793|NCT03068182|Other|Exercise|
1486794|NCT03068156|Radiation|308-nm excimer laser|monochromator UVB laser (308nm)
1486795|NCT03068130|Drug|Bardoxolone methyl|Capsules of Bardoxolone methyl
1486796|NCT03068117|Other|Regular Early Specialist Symptom Control Treatment (RESSCT)|"Participants will be seen within three weeks of randomisation by the Specialist Palliative Care Team (SPCT), (regardless of, and in addition to, all other treatments being offered). The initial meeting will be an approximately 1 hour consultation with a member of the Specialist Palliative Care team. This may be either a Consultant or Specialist Palliative Care Clinical Nurse Specialist (SPCCNS).
Patients will then continue to be seen regularly on at least a 4 weekly basis (regardless of other treatments, interventions and symptoms) by a member of the SPCT, with consultations lasting approximately 30 minutes. These monthly reviews will continue until end of trial (EOT) or patient death."
1486797|NCT03068104|Other|No intervention|
1486798|NCT03068091|Device|Chest CT|Inspiration and expiration chest CT
1486799|NCT03068091|Diagnostic Test|Pulmonary Function Testing|Measure lung function
1486800|NCT03068078|Dietary Supplement|Low carbohydrate diet high in monounsaturated fats|Participants will have to change their diet during 6 months
1486801|NCT03068065|Drug|Liraglutide|the dosage of liraglutide was 0.6 mg/day during the first week, 1.2 mg/day during the second week, and 1.8 mg/day from the third week to the conclusion of the study
1486802|NCT03068065|Drug|Metformin|the dosage of metformin was 250 mg thrice a day during the first week, 500 mg thrice a day during the second week, and 1000 mg twice a day from the third week to the conclusion of the study
1486803|NCT03068065|Drug|Gliclazide|the initial dosage of gliclazide was 30 mg before breakfast, which was gradually titrated to a maximum of 120 mg/day to achieve a fasting capillary plasma glucose of <7.0 mmol/L
1486804|NCT03068052|Behavioral|No incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment.
1486805|NCT03068052|Behavioral|Incentive|Each participant will receive an email describing the importance of colorectal cancer screening and that they have been selected to receive a risk assessment, for which they will received a loss-framed incentive. They will directed to an online platform where they will be asked about age, family history, and prior screening history. Those who are eligible for screening will be offered the VIP access phone number to schedule an appointment and will receive an additional unconditional pro-social incentive.
1948855|NCT01400581|Behavioral|Collaborative Care Intervention|See description of Intervention arm
1486808|NCT03068026|Device|VitaBreath|The VitaBreath devise will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
1486809|NCT03068026|Other|Pursed Lip Breathing technique|Pursed Lip Breathing technique will be applied during the 1st minute of each resting period between exercise bouts and during the 1st minute of recovery.
1486810|NCT03068013|Behavioral|CALM|CALM intervention covers four domains, namely: 1) Symptom management and communication with health care providers; 2) Changes in self and relations with close others, 3) Spiritual well-being, sense of meaning and purpose, 4) Preparing for the future, sustaining hope and facing mortality
1486811|NCT03068013|Behavioral|SPI|Active Comparator: Supportive psycho-oncology intervention Supportive psycho-oncology intervention (SPI) includes counseling, information, crisis intervention, which is the usual care intervention provided in our center.
1486812|NCT03068000|Behavioral|Judo Training|Judo intervention is divided into general exercises: warm-up and stretching specific to the sport; Specific exercises of the sport: shock absorption, falls cushioning (Ukemi-waza), immobilization techniques (hon-kesa-gatame and tate-shiho-gatame) and projection (o-soto-gari, o-goshi, ashi-guruma, koshi-guruma, tai-otoshi and others); And fight simulation: randori.
1486813|NCT03068000|Behavioral|Ball Games|The Ball Games is divided into general exercises: heating and specific stretching with ball; Specific exercises of the sport: fundamentals of sports with ball, exercises with ball; And games: games will be given at the end of the lesson to work out all the fundamentals and specific exercises in general.
1486814|NCT03067987|Device|Low Intensity Linear Shockwave Device for the Treatment of Erectile Dysfunction.|"This is a prospective, randomized, clinical study aimed to evaluate the safety and efficacy of the two treatment schedules on symptomatic erectile dysfunction patients. The patients are randomized in a 1:1 ratio into two active treatment groups.
Group A: 5 daily sessions within a week (Monday, Tuesday, Wednesday, Thursday, Friday), in which 720 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura).
Group B: Three sessions per week (Monday, Wednesday, Friday) for 2 consecutive weeks, in which 600 shocks of treatment energy will be applied in every session to each treated region (left and right corpora cavernosa and crura)"
1486816|NCT03067961|Other|Salmonella Typhi (S. Typhi)|Investigating the role of typhoid toxin in the pathogenesis of enteric fever
1486817|NCT03067948|Behavioral|Patient Designated Positive Screen Shared with Provider|Patient Designated Positive Screen Shared with Provider -- In the intervention, participants will be given the opportunity to determine which positive screen, if any, that the participant would like to discuss with the participant's provider at the next HIV primary care appointment. The participant will be notified that all positive screens will be shared with the provider prior to their next HIV primary care visit, and that any positive screen the patient has chosen to discuss with the provider will be specified. The provider will receive the PROs result (score, interpretation, and recommendation) prior to their next HIV primary care visit
1486819|NCT03067922|Other|Non interventional study|Not applicable. No intervention will be done. it is an observational study assessing pain after mastectomy and the quality of life as assessed from validated questionnaires given to the patients at regular intervals
1486820|NCT03067909|Other|CIED surgery|
1486821|NCT03067896|Drug|Bupivacaine|Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml
1486822|NCT03067896|Drug|Dexmedetomidine|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline
1486823|NCT03067896|Drug|Magnesium Sulfate|Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml magnesium sulfate 50 mg in 0.5 ml normal saline
1486824|NCT03067883|Drug|Ombitasvir, Paritaprevir and Ritonavir|"A total of 40 HCV treatment naïve patients with or without compensated cirrhosis on regular hemodialysis will be enrolled in the study.
These patients will receive an intervention of '25 mg ombitasvir, 150 mg paritaprevir, and 100 mg ritonavir' (2 capsules Qurevo®) plus ribavirin 200 mg daily for 12 weeks.
Qurevo will be given once daily (on the day of dialysis, it will be given after dialysis session).
Ribavirin will be given once daily (on the day of dialysis, it will be given 4 hrs before dialysis session )."
1486825|NCT03067870|Biological|Stem Cell Transplantation|"Intravenous administration of autologous bone marrow derived stem cells for immunomodulation.
Transplantation of autologous bone marrow derived stem cells in joints."
1486826|NCT03067857|Biological|Stem Cells|Autologous bone marrow-derived stem cell populations injected via the intravenous and intrathecal routes.
1486827|NCT03067844|Drug|Alirocumab 150 mg/mL|Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50.
1486828|NCT03067844|Drug|Placebo|Pre-filled auto-injector pen every second week, starting at day 1 and up to week 50
1486829|NCT03067831|Biological|Stem Cells|Transplantation of purified autologous bone marrow-derived stem cells.
1486830|NCT03067818|Procedure|Unaffected Transcranial Magnetic Stimulation|Non-invasive brain stimulation to unaffected hemisphere site prior to practice
1486831|NCT03067818|Procedure|Affected Transcranial Magnetic Stimulation|Non-invasive brain stimulation to affected hemisphere site prior to practice
1486832|NCT03067818|Procedure|Control Transcranial Magnetic Stimulation|Non-invasive brain stimulation to control site prior to practice
1486833|NCT03067805|Behavioral|Sexual Infidelity Condition|
1486834|NCT03067805|Behavioral|Emotional Infidelity Condition|
1486835|NCT03067805|Behavioral|Neutral Condition|
1486836|NCT03067805|Behavioral|Player in Jealousy Condition|
1486837|NCT03067805|Behavioral|Player in Non-Jealousy Condition|
1486838|NCT03067792|Drug|5-fluorouracil, irinotecan and leucovorin|In FOLFIRI group, patients received irinotecan 180 mg/m2 and 5-fluorouracil 400mg/m2 intravenously bolus injection on days 1 and leucovorin 200mg/m2 for 2 hours and 5-fluorouracil 600mg/m2 for 22 hours intravenously infusion on day 2 of a 14-day cycle.
1486839|NCT03067792|Drug|docetaxel and cisplatin|In DP group, patients received docetaxel 75 mg/m2 and cisplatin 75mg/m2 intravenously on days 1 of a 21-day cycle.
1486840|NCT03067779|Other|mHealth Tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing common patient safety themes in CKD and includes a pre- and post-test knowledge assessment. Topics of emphasis included NSAID risk awareness, hypoglycemia awareness, avoidance of volume depletion when ill (Sick Day Protocol) and avoidance of contrast-induced nephropathy."
1486841|NCT03067766|Procedure|Art Therapy|Participate in a comic art creation workshop
1486842|NCT03067766|Other|Interview|Undergo qualitative interviews
1486843|NCT03067766|Procedure|Quality-of-Life Assessment|Ancillary studies
1486844|NCT03067766|Other|Questionnaire Administration|Ancillary studies
1486845|NCT03067753|Drug|Monosialoganglioside Ganglioside|Monosialoganglioside ganglioside was given at 100 mg/time, once a day for 2 months.
1486846|NCT03067753|Drug|Methylprednisolone (Steroid Hormone)|Pulse steroid, methylprednisolone, was administered by intravenous infusion over 3 consecutive days. Three grams of methylprednisolone was given in each cycle. Administration of 1 g was infused over 1 h daily for 3 days on an in-patient basis, which then tailed off in 10 days with administration of oral prednisolone.
1486847|NCT03067753|Drug|Prednisolone|
1948857|NCT01379573|Drug|Hydroxychloroquine|Nineteen women meeting eligibility criteria will receive 400mg per day of HCQ beginning as soon as pregnancy is established and informed consent obtained. Mothers already on HCQ will remain on 400mg, or escalate to 400mg if on 200mg. Hydroxychloroquine is taken in 200mg pill form - 400mg = 2 200mg pills.
1948858|NCT01373580|Device|The Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay is implanted in the cornea for treatment of presbyopia
1486852|NCT03067714|Other|Infant formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
1486853|NCT03067714|Other|Standard infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
1948859|NCT01371344|Drug|Tacrolimus granules|oral
1486855|NCT03067688|Drug|Temisartan+Amlodipine+Rosuvastatin (Combination drug)|PO, Once daily(QD), 8weeks
1486856|NCT03067688|Drug|Temisartan+Amlodipine|PO, Once daily(QD), 8weeks
1486857|NCT03067688|Drug|Temisartan+Rosuvastatin|PO, Once daily(QD), 8weeks
1486858|NCT03067675|Device|Topcon DRI OCT Triton (plus)|OCT Machine used for diagnostic purposes
1486859|NCT03067662|Other|Aerobic exercise|
1486860|NCT03067649|Behavioral|Motivational Interview|90-minute interview to discuss their concerns and possible barriers to seeking treatment for themselves
1486861|NCT03067649|Behavioral|Information only control|Participants are provided with a pamphlet containing referral information
1486862|NCT03067636|Behavioral|Physical Exercise|Physical exercise: Amount of time exercising gradually titrated from 90-minutes in week one to 180-minutes in week eight. Intensity titrated concurrently from 40 - 60% VO2 max in week one to 40 - 90% VO2 max in week eight. Eight week gym membership provided to all participants to facilitate engagement in exercise.
1948860|NCT01371344|Drug|Tacrolimus|oral
1486863|NCT03067636|Behavioral|Stress management training A|Stress management training A: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
1486864|NCT03067636|Behavioral|Stress management training B|Stress management training B: Daily stress management training for eight weeks with training activity delivered via app. Session lengths titrated from 10-minutes per day in the first week to 20-minutes per day in week eight.
2001211|NCT03152773|Procedure|MRI Right Heart guidewire catheterization|To conduct right heart guidewire catheterization using real-time MRI fluroscopy in human research subjects already undergoing medically necessary right heart catheterization. We will use only passive MRI -compatible catheters and a specific guidewire shown to be safe under specific conditions. Under the conditions of use, the guidewire is not susceptible to heating.
2001212|NCT03151811|Drug|Melflufen|Intravenous infusion
1486867|NCT03067610|Radiation|Intensity Modulated Radiation Therapy|The radiotherapy plan wil be delivered in 2 sequential courses. The first course involves 20 fractions of 2 Gy per fraction to the entire volume (gross disease and elective). The second course involves 15 fractions (thus, total of 35 fractions), at either 2 Gy (gross disease) or 1.6 Gy (microscopic disease and suspicious node) per fraction.
1486868|NCT03067610|Drug|chemotherapy|chemotherapy (if given, either cisplatin, cetuximab, or carboplatin-paclitaxel) per physician discretion
2001213|NCT03151811|Drug|Pomalidomide|Oral capsules
2001214|NCT03151811|Drug|Dexamethasone|Oral tablets
1486871|NCT03067558|Diagnostic Test|Children's automated respiratory rate monitor|"The Children's Respiration Monitor system comprises of an accelerometer based device, with a belt to attach the device to the child.
The device measures the respiration rate in children under 5 years old and automatically classifies the breathing rate according to the IMNCI guidelines set by the World Health Organization. The device is intended to be used by health workers at the community level in low resource settings, clinical officers, nurses, midwives, clinicians (Professional Health Workers) at primary or secondary care facilities."
1486872|NCT03067558|Diagnostic Test|MK2 Acute Respiratory Infection (ARI) Timer|The MK2 ARI timer is a manual respiratory rate (RR) counting device used to assist frontline health workers in measuring the length of time to count the RR in children. It is the second generation of ARI timers (succeeding MK1 ARI timer). The ARI timer is the standard practice for measuring and classifying RR at community level.
1486874|NCT03067532|Procedure|existed simulation system user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery intrument.
1486875|NCT03067532|Procedure|home made simulator user|Investigator will divide the subject by the two groups. Each group will take about 15 minutes for exercising drive robotic surgery instrument by each simulation system. After 15 minutes, both group will take an short exam to check the ability to manage the robotic surgery intrument.
1486876|NCT03067519|Other|Fast track surgery|early feeding and mobilization after surgery
1486877|NCT03067519|Other|Conventional management|Management per the primary surgeon
1486878|NCT03067506|Other|No intervention|No intervention
1486879|NCT03067493|Biological|Neo-MASCT|Patients assigned to Neo-MASCT treatment will receive 18 cycles of neo-MASCT (6 courses), with one cycle every month for the first year and one cycle every 2 months for the second year. Each cycle includes one DCs subcutaneous injection and one CTLs infusion.
1486880|NCT03067480|Device|iPro2 Professional CGM|Professional CGM measures interstitial glucose every 5 minutes via a glucose-oxidase-impregnated membrane during a 3 day period. The patient wearing professional CGM is blinded to the repeated measurements and the data is stored for retrospective analysis.
1486881|NCT03067467|Drug|Hyperpolarized 13C-Pyruvate|Hyperpolarized 13C-pyruvate IV bolus followed by brain MRSI.
1486882|NCT03067467|Drug|Gadolinium|Brain MRI performed with and without gadolinium-based contrast.
1486883|NCT03067454|Procedure|Early mobilisation|"Conservative treatment with early mobilisation
The patient is instructed to do a fist and is not allowed to leave the clinic before. Active mobilisation under control (doctor or physiotherapist) is performed until healing of the fracture is documented."
1486884|NCT03067454|Procedure|Operation|Operation of the fracture. Usually open reduction and internal fixation with plates and screws or just screws within 2 weeks of injury. Immobilisation in a cast for two weeks followed by physiotherapy.
1486885|NCT03067441|Drug|bempedoic acid|bempedoic acid 180 mg tablets taken orally, once per day.
1486886|NCT03067428|Dietary Supplement|Glucose|Participants will adhere to a fructose restricted diet for a period of six weeks (<7.5 grams/meal and/or <10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as glucose powder three times daily during the meal.
1486887|NCT03067428|Dietary Supplement|Fructose|Participants will adhere to a fructose restricted diet for a period of six weeks (<7.5 grams/meal and/or <10 grams/day; ad-libitum intake). In addition, the amount of fructose that will be restricted - which is based on the average individual fructose intake assessed prior to randomization - will be supplemented as fructose powder three times daily during the meal.
1486888|NCT03067415|Drug|D565H(Latanoprost 25㎍/㎖)|D565H twice daily
1486889|NCT03067415|Drug|D565(Latanoprost 50㎍/㎖)|D565 once daily
1486890|NCT03067402|Other|Observation|Patient receives standard observation i.e. only do a nuclear imaging stress test if symptoms present themselves over the course of 3 years
1486891|NCT03067402|Diagnostic Test|Nuclear Perfusion Imaging Stress Test|Patient receives routine nuclear image perfusion stress test
1486892|NCT03067389|Diagnostic Test|Diagnostic test|Genetic diagnostic test
1486893|NCT03067376|Drug|[14C]-CORT125134|ADME Study
1486894|NCT03067363|Drug|MOR107|MOR107 solution for injection
1486895|NCT03067363|Drug|Placebo|Solution for injection manufactured to match MOR107 solution for injection
1486896|NCT03067363|Other|Low sodium diet|Diet designed to restrict sodium intake to 40 mmol/day
1486897|NCT03067337|Device|Stainless Steel Crown (Group A)|Full coverage restoration for multi-surface carious teeth
1486898|NCT03067337|Device|NuSmile Zirconia Crowns (Group B)|Full coverage restoration for multi-surface carious teeth
1486899|NCT03067311|Behavioral|I-CAT|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).
1486900|NCT03067311|Behavioral|Treatment as Usual|Treatment as usual defined by participant clinician at OASIS clinic.
1486901|NCT03067285|Drug|ELV/COBI/FTC/TAF|Treatment with ELV/COBI/FTC/TAF during 24 weeks since randomized.
1486902|NCT03067285|Drug|DTG/3TC/ABC + ELV/COBI/FTC/TAF|Patients continuing on treatment with DTG/3TC/ABC after the randomization for 4 weeks, and then switch to ELV/COBI/FTC/TAF for 24 weeks
1486903|NCT03067272|Device|FemBloc® Permanent Contraceptive System|The FemBloc Permanent Contraceptive System consists of treatment with a Delivery System and Biopolymer, and a confirmation test with the FemChec® Tubal Occlusion Confirmation device as part of a sonographic hysterosalpingogram (Sono HSG).
1486904|NCT03067259|Other|Exposure Group|Surgeries of high or low impact. They could be local , regional o general anesthesia; sedation or a combination of both.
1486905|NCT03067246|Device|VBM Intubating Laryngeal Tube|The position of the VBM Intubating Laryngeal Tube will be assessed using a fibreoptic scope following balloon inflation of the cuff. Seal pressure will be assessed with the presence of the inflated cuff. Endotracheal intubation through the intubating laryngeal tube with a size 7 VBM reinforced tube will be assessed using a fiberoptic scope.
1486906|NCT03067246|Device|I-Gel|The position of the I-Gel will be assessed using a fibreoptic scope. The seal pressure will be assessed with the specified design of the I-Gel in the absence of a cuff. Endotracheal intubation through the I-Gel with a size 7 reinforced endotracheal tube will be assessed using a fiberoptic scope.
1486907|NCT03067233|Other|Polysomnography|Complete polysomnography with : Electroencephalogry, electro-oculography, surface electromyography (chin muscle, anterior tibial muscles), nasal pressure, respiratory movements (plethysmography of thoracic and abdominal inductance), pulse oximetry and electrocardiography.
1486908|NCT03067220|Other|Virtual outpatient clinic appointment|Patients will be sent an appointment letter stating a specific day approximately 6 weeks after their discharge from hospital in which they will be contacted by telephone for a review by a junior doctor from the discharging team.
1486909|NCT03067220|Other|Standard outpatient clinic appointment|Patients will be sent an appointment letter to return to a scheduled outpatient clinic for review approximately 6 weeks after their discharge from hospital
1486910|NCT03067207|Behavioral|MARS-A|The intervention will consist of the 8-week mindfulness meditation program designed for adolescents with chronic health conditions.MARS-A is based on two established mindfulness-based interventions for adults: MBSR and MBCT. The content of the program will be the same for in-person and e-health groups: all participants will receive eight 90-minute weekly evening sessions led by two trained and experienced mindfulness providers. Sessions will include short meditation practices, breathing exercises, guided discussion, mindful movements and inquiry, adapted to the context of chronic illness. Every session will start with a brief review of home practice and will close with a discussion of the home practice for the following week.
1486911|NCT03067194|Drug|Celecoxib 100 MG|Celecoxib 100mg, Oral, BID(twice per day), During 6 weeks
1486912|NCT03067194|Drug|Celecoxib 200mg|Celecoxib 200mg, Oral, QD(once daily), During 6 weeks
1486913|NCT03067181|Other|Best Practice|Undergo observation
1486914|NCT03067181|Drug|Bleomycin|Given IV
1486915|NCT03067181|Drug|Carboplatin|Given IV
1486916|NCT03067181|Drug|Cisplatin|Given IV
1486917|NCT03067181|Drug|Etoposide|Given IV
1486918|NCT03067181|Other|Laboratory Biomarker Analysis|Correlative studies
1486919|NCT03067181|Other|Pharmacogenomic Study|Correlative studies
1486920|NCT03067181|Other|Quality-of-Life Assessment|Ancillary studies
1486921|NCT03067181|Other|Questionnaire Administration|Ancillary studies
1486922|NCT03067168|Drug|Bupivacaine|5 mL of 0.5% bupivacaine will be injected into 2 locations bilaterally.
1486923|NCT03067168|Drug|normal saline 0.9%|5 mL of 0.9% normal saline will be injected into 2 locations bilaterally.
1486924|NCT03067155|Genetic|CMV-specific T cells|
1486925|NCT03067155|Drug|Standard anti-viral therapy|Continue with the anti-viral treatment as per standard of care.
1486926|NCT03067142|Other|Observational|Not an interventional study. Analyses of previously collected urine specimens and data on estimated kidney filtering function.
1486927|NCT03067129|Drug|Glecaprevir/Pibrentasvir|Film-coated tablet (100 mg/40 mg)
1486928|NCT03067129|Drug|Glecaprevir/Pibrentasvir|Oral pediatric formulation
1486929|NCT03067116|Diagnostic Test|Posturography Evaluation|Posturography testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, with eyes open or closed
1486930|NCT03067116|Diagnostic Test|Anthropometrics|measurement of height, minimum stance width (feet together or as close as they can be), circumference of the torso at the breast level, of the abdomen, of the hip, and of each thigh, and supine fundal height
1486931|NCT03067116|Diagnostic Test|Vitals|measurement (bilateral and seated/standing if applicable) of temperature, respiration rate, heart rate, blood pressure, pulse oxygenation and heart rate variability
1486932|NCT03067116|Other|Health and daily activity questionnaires|one time general health questionnaire as well as session questionnaires asking the subjects if they have fallen since their last testing session and how comfortable they are in doing daily activities
1486933|NCT03067103|Drug|Tramadol|Patients will receive injections in peritonsillar fossa of tramadol (2 mg/kg-2 ml)
1486934|NCT03067103|Drug|Ketamine|Patients will receive injections in peritonsillar fossa of ketamine prior to surgery
1486935|NCT03067103|Drug|Placebos|Patients will receive 2mL of saline solution in peritonsillar fossa prior to surgery
1486936|NCT03067090|Device|Aquamid Reconstruction|"AR contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape or effect. AR is biocompatible, non-biodegradable, stable and sterile.
The gel is provided in a sterile, pre-filled 1 ml sealed syringe. The gel is intended to be injected intra-articularly with a sterile 21G x 2 inch (0.8 x 50 mm) needle."
1486937|NCT03067077|Procedure|SMILE|SMILE surgery
1486938|NCT03067077|Procedure|LASIK|LASIK surgery
1486940|NCT03067051|Drug|Verteporfin|In the last decade a clinical interest of developing new methods for minimally invasive treatments of organ-confined prostatic malignancies has been pursued. In this study the drug verteporfin for injection (VFI) is to be used with the SpectraCure P18 System (Interstitial multiple diode lasers and IDOSE® Software).
1486941|NCT03067051|Device|SpectraCure P18 System|Interstitial Photodynamic therapy is provided with the the SpectraCure P18 system
1486942|NCT03067038|Device|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy with single port device
1486943|NCT03067038|Device|Three port laparoscopic cholecystectomy|Laparoscopic cholecystectomy with three port
1486944|NCT03067012|Other|Oncometabolic reconstruction|The length of biliopancreatic limb is 50cm and the length of Roux limb is 100cm. (long limb uncut Roux-en-Y gastrojejunostomy) These limbs are longer than the conventional uncut Roux-en-Y reconstruction for gastric cancer patients.
1486945|NCT03066999|Procedure|Cystoscopy|Patients will assign to either Group Cystoscopy (catheter placement via cystoscopy)
1486946|NCT03066999|Device|DirectVision|Patients will assign to either Group DirectVision (catheter placement via DirectVision)
1486947|NCT03066986|Drug|Delta-inulin|Addition of adjuvant, delta-inulin to JJA VIT regime, to determine if this will allow lower doses and shorter regimes to promote protective responses, reducing costs and morbidity of JJA VIT.
1486948|NCT03066986|Biological|Dose finding comparison|"Define minimum effective maintenance dose (50mcg vs 25mcg). In real world sting challenges after 12 months of JJA VIT objective systemic reaction rates after 50 and 100 mcg maintenance doses respectively 14/130 and 12/126 subjects vs reaction rates to stings in similar subjects without JJA VIT 70-76%. Venom delivery in sting likely <20mcg. Therefore minimum effective maintenance dose not yet defined."
1486949|NCT03066973|Behavioral|BREATHING EXERCISE|The intervention group was instructed on breathing exercise according to the established trial protocol.
1486950|NCT03066960|Procedure|Radiofrequency neurotomy|RF neurotomy represents a nerve destructive, coagulating technique affecting the conduction through all nerve fibers.
1486951|NCT03066960|Procedure|Sham treatment|Sham treatment represents no coagulation of the nerve and will not affect the nerve conduction.
2001215|NCT03151395|Other|Sputum and blood sampling|Evaluation of the occurrence of potential bacterial and viral pathogens in the sputum of stable COPD patients and at the time of AECOPD.
2001216|NCT03150862|Drug|BGB-290|BGB-290
2001217|NCT03150862|Drug|TMZ|TMZ
1948861|NCT01339546|Other|no intervention|
1948862|NCT01302080|Drug|sertraline|Non interventional study - drug, dose, duration etc as per USPI and clinician discretion
1486957|NCT03066908|Device|Sinopsys® Lacrimal Stent|Transcaruncular paranasal sinus or nasal cavity access for the purpose of irrigating the ethmoid sinus with saline
1486958|NCT03066895|Device|BabyGentleStick|Experimental device.
1486959|NCT03066895|Device|Standard Lancing Device|HMC standard of care.
1486960|NCT03066882|Dietary Supplement|NCD|negative calorie diet
1486961|NCT03066882|Dietary Supplement|LCD|low calorie diet
1486962|NCT03066869|Drug|H.P. ACTHAR GEL|H.P. Acthar Gel is an adrenocorticotropic hormone (ACTH) analogue indicated for ophthalmic diseases.
1486963|NCT03066856|Other|Dietary intervention|"The main aim of the trial is to reduce serum levels of IGF-I and IRm with a a low- calorie and low-protein diet. In humans, calorie restriction alone does not seem to significantly lower IGF-I; protein restriction is also required. In detail, recommendations for participants included in the intervention arm include:
reducing protein intake, mainly milk and animal protein (except fish), down to 10-12% of total calorie intake.
reducing high glycemic index food and high insulinemic foods.
reducing sources of saturated fat (red and processed meat, milk and dairy products).
eating mostly food of plant origin, with a wide variety of seasonal products."
1486964|NCT03066843|Drug|ALA (5-aminolevulinic acid)|ALA (5-aminolevulinic acid) will be applied to subjects' skin for either zero time incubation or one hour incubation
1486965|NCT03066843|Device|Blue light therapy|Subjects will be exposed to blue light
1948863|NCT01302080|Behavioral|psychotherapy|Non-interventional study- as above
1948864|NCT01294020|Drug|Tacrolimus|Oral
1948865|NCT01288053|Biological|Allogeneic Stem Cell Therapy|Donor stem cells will be given to subject diagnosed with Crohn's disease
1948866|NCT01286272|Drug|Bendamustine Hydrochloride|Given IV
1486970|NCT03066817|Drug|Ergocalciferol 8000 IU/ML Oral Liquid [DRISDOL]|50cc of ergocalciferol 8000 IU/ml will be given to participants as a one-time dose.
1486971|NCT03066817|Drug|Propylene Glycol|50cc of propylene glycole will be given to participants as one-time dose, used as placebo
1486972|NCT03066804|Drug|sacubitril/valsartan|Sacubitril/valsartan is available as 24 mg/26 mg, 49 mg/51 mg, 97 mg/103 mg, respectively in tablet form to be taken orally
1486973|NCT03066804|Drug|Enalapril|Enalapril is available as 2.5 mg, 5 mg, and 10 mg tablet form to be taken orally
1486974|NCT03066804|Drug|Valsartan|Valsartan is available as 40 mg, 80 mg, 160 mg tablet form to be taken orally
1486975|NCT03066804|Drug|Placebo to match sacubitril/valsartan|Placebo to match LCZ696 50 mg, 100 mg, 200 mg tablet form to be taken orally
1486976|NCT03066804|Drug|Placebo to match enalapril|Placebo to match enalapril 2.5 mg, 5 mg, 10 mg tablet form to be taken orally
1486977|NCT03066804|Drug|Placebo to match valsartan|Placebo to match valsartan 40 mg, 80 mg, 160 mg tablet form to be taken orally
1486978|NCT03066791|Dietary Supplement|Turmeric tablets|
1486979|NCT03066791|Dietary Supplement|Curcumin and Bioperine tablets|
1486980|NCT03066791|Dietary Supplement|Placebo tablets|
1948867|NCT01286272|Drug|Bortezomib|Given IV or SC
1948868|NCT01286272|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET
1948869|NCT01286272|Other|Laboratory Biomarker Analysis|Correlative studies
1948870|NCT01286272|Biological|Ofatumumab|Given IV
1948871|NCT01286272|Procedure|Positron Emission Tomography with Radiolabeled Targeting Agent|Undergo FDG-PET
1948872|NCT01281488|Procedure|fluorescence imaging|Undergo NIR fluorescence imaging with ICG on the da Vinci surgical system
1948873|NCT01281488|Procedure|laparoscopic surgery|Undergo standard approach robot-assisted laparoscopic partial nephrectomy
1948874|NCT01281488|Drug|indocyanine green|Given IV
2001218|NCT03150862|Radiation|Radiation|Up to 60 Gy (total) over 6 - 7 weeks
2001219|NCT03150810|Drug|BGB-290|BGB-290
1486986|NCT03066765|Device|Linguaflex Tongue Retractor|Tongue implant
1486987|NCT03066739|Drug|Remifentanil|0.1 micrograms/kg/mL
1486988|NCT03066739|Drug|Remifentanil+ Placebo|high dose remifentanil (0.4 mg) combined with placebo (HI, 0.4 micrograms/kg/mL)
1486989|NCT03066739|Drug|Remifentanil +ultra-low dose naloxone|high dose remifentanil (0.4 mg) combined with ultra-low dose naloxone (HN, 0.004 micrograms/kg/mL naloxone
1486990|NCT03066713|Other|Skin Off French Fry|Skin Off French Fries will be provided at breakfast and lunch
1486991|NCT03066713|Other|Skin On French Fry|Skin On French Fries will be provided at breakfast and lunch
1486992|NCT03066713|Other|Hash brown|Hash brown potatoes will be provided at breakfast and lunch.
1486993|NCT03066713|Other|Carbohydrate control|A pancake will be provided at breakfast, and pretzels will be provided at lunch.
1486994|NCT03066700|Device|Hemostatic powder|HemosprayTM (Tc-325) is an endoscopic hemostatis powder that came onto market recently. It is made of an inorganic, non-absorbable powder which acts locally at the mucosa. When spraying the powder on to the bleeding site, it creates an adherent stable barrier sheath that allows for at least temporary hemostasis. Neither luminal nor systemic side effects have been reported to date.
1486995|NCT03066687|Drug|Erdafitinib|Erdafitinib 9 mg (provided as one 4-mg tablet [G-024] and one 5-mg tablet [G-025]) will be administered orally on Day 1 in each Treatment Period of assigned sequence.
1486996|NCT03066674|Other|McKenzie group|Mobilization for lumbar spine,TENS,Exercises,Postural education ,Home exercises program.
1486997|NCT03066674|Other|Control group|TENS,Exercises,Postural education ,Home exercises program.
1486998|NCT03066661|Drug|Entrectinib|Open-label expanded access, capsules
1486999|NCT03066648|Drug|Decitabine|Decitabine is a cytidine deoxynucleoside analogue that selectively inhibits DNA methyltransferases at low doses, resulting in gene promoter hypomethylation.
1487000|NCT03066648|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 monoclonal antibody directed against PD-1 that blocks the binding of PD-L1 and PD-L2.
1487001|NCT03066648|Drug|MBG453|MBG453 is a high-affinity, humanized anti-TIM-3 IgG4 monoclonal antibody which blocks the binding of TIM-3 to phosphatidylserine (PtdSer).
1487002|NCT03066635|Drug|Botulinum Toxin Type A 25 IU|injection with 25 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
1487003|NCT03066635|Drug|Botulinum Toxin Type A 12.5 IU|injection with 12.5 IU botulinum toxin towards the otic ganglion (symptomatic side) using image-guided navigation and the MultiGuide device
1487004|NCT03066622|Drug|Standard of Care as per attending physician|Patients are randomized to standard of care medication (as determined by attending physician)
1487005|NCT03066622|Drug|5mg rapidly dissolving olanzapine|5mg rapidly dissolving olanzapine
2001220|NCT03150810|Drug|Temozolomide|TMZ
2001221|NCT03150810|Drug|BGB-290|Dose/schedule selected based on dose escalation phase.
2001222|NCT03150810|Drug|Temozolomide|Dose/schedule selected based on dose escalation phase.
1487009|NCT03066596|Behavioral|PRAGMATIC|Provider educational seminar, EHR prompt, outreach-worker care coordination
1487010|NCT03066583|Biological|trephination with placebo|trephination under US guidance and placebo injection
1487011|NCT03066583|Biological|trephination with platelet rich plasma|trephination under US guidance and platelet rich plasma injection
1487012|NCT03066570|Behavioral|Graded Exposure|Graded Exposure in vivo (GEXP) is a second-generation cognitive-behavioural intervention, and is characterized by systematic and repeated exposure to feared movements, activities and/or sensations in order to decrease fear and subsequently increase physical activity.
1487013|NCT03066557|Procedure|TACE and Apatinib|TACE and Apatinib 250mg po qd
1487014|NCT03066557|Procedure|TACE|TACE
1487015|NCT03066544|Drug|Bupivacaine|Nerve blocks with bupivacaine will be performed at initial visit
1487016|NCT03066544|Drug|Naratriptan Pill|one pill will be administered twice each day for 5 days
1487017|NCT03066544|Drug|Dexamethasone|one tablet will be administered twice each day for 3 days
1487018|NCT03066544|Drug|Ketorolac|ketorolac will be administered intramuscularly (IM) or intravenously (IV) at initial visit
1487019|NCT03066531|Behavioral|ACT-based intervention|
1487020|NCT03066531|Behavioral|CBT-based intervention|
1487021|NCT03066518|Drug|Melatonin 5 mg|
1487022|NCT03066518|Other|Placebo|
1487023|NCT03066505|Device|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
1487024|NCT03066505|Device|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
1487025|NCT03066492|Other|Northwestern Follow Up Care Coordination|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at the Northwestern Transitional Care Follow Up Clinic.
1487026|NCT03066492|Other|Federally Qualified Health Center|Each patient is provided with information by telephone and mail, offering assistance to receive a follow-up appointment at a nearby Federally Qualified Health Center.
1487027|NCT03066479|Device|Fitbit|Wearable activity & sleep tracker.
1487028|NCT03066479|Other|OSA questionnaire|Parents will complete a questionnaire assessing the potential symptoms their child is experiencing that are related to obstructive sleep apnea (OSA).
1487029|NCT03066479|Diagnostic Test|Polysomnography|All participants will be undergoing a sleep study as part of their clinical care.
1487030|NCT03066466|Drug|Atorvastatin|Oral medication given to prevent graft versus host disease in bone marrow transplant.
1487031|NCT03066466|Drug|Methotrexate|IV medication given to prevent graft versus host disease in bone marrow transplant.
1487178|NCT03065192|Drug|VY-AADC01|Single dose, neurosurgically infused, bilaterally into the striatum.
2001223|NCT03150043|Device|Masimo Rainbow Pulse CO-oximeter|Masimo Rainbow Pulse CO-oximeter will be used to measure hemoglobin values of pregnant women during primary cesarean delivery
1487032|NCT03066466|Drug|Tacrolimus|IV or Oral medication given to prevent graft versus host disease in bone marrow transplant.
1487033|NCT03066453|Drug|Tobi Inhalant Product|inhaled tobramycin 300 mg twice per day
1487034|NCT03066453|Drug|Nebcin|10 to 12 mg/kg/day in 1 injection for adults and 10 to 12 mg/kg in 1 pediatric injection (combined with another IV antibiotic)
1948885|NCT01262898|Drug|GSK962040 (5 mg tablet)|5 mg tablet
1948886|NCT01262898|Drug|GSK962040 (25 mg tablet)|25 mg tablet
2001224|NCT03147222|Behavioral|Hip Care at Home|This is a graduated, functionally-based intervention, paired with caregiver interactions for enhancing functional abilities. Caregivers are encouraged to have the hip fracture participant actively participate in their own activities of daily living and incorporate functional activities into daily routines. An intervention coach will discuss care related challenges with the caregiver to identify dependency problems, motivate the caregiver to help foster independence in the care recipient, and provide guidance in addressing behavioral symptoms associated with cognitive limitation that may occur during caregiving. The coach is guided by interventions designed by PTs, OTs, and a nurse practitioner expert in FFC. The intervention includes 1) initial assessment of participant, caregiver, and environment, 2) coaching and mentoring of caregivers regarding use of effective motivational strategies, 3) goal setting, and 4) on-going motivation and evaluation.
1487038|NCT03066414|Procedure|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
1487039|NCT03066401|Procedure|echography|The inferior vena cava and the internal jugular vein diameters were measured by echography before and after blood withdrawal during a standardized respiratory maneuver
1487040|NCT03066388|Other|Pulse pressure variations|Stroke volume and, pulse pressure variations obtained by noninvasive (ΔPPCNAP) and invasive (ΔPPART) devices are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin.
1487041|NCT03066375|Device|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
1487042|NCT03066362|Other|Echocardiography-Doppler|Ultrasonographic recordings are recorded immediately before and after volume expansion (VE), performed as a 30-minute infusion of 500 mL of 4% gelatin. Inferior Vena Cava diameters are measured during spontaneous and standardized respiratory cycles. Stroke volume is measured during spontaneous respiratory cycles.
2001225|NCT03135249|Drug|Alemtuzumab|Alemtuzumab is a humanized monoclonal therapeutic antibody that rapidly depletes cluster of differentiation 52 (CD52)+ cells.
1487044|NCT03066336|Device|Erchonia LunulaLaser|Active Low Level Laser Light Therapy
1487045|NCT03066323|Other|Rice with tea extract|Rice with tea extract
1487046|NCT03066323|Other|Rice without tea extract|Rice without tea extract
1487047|NCT03066310|Diagnostic Test|Next generation sequencing|The obtained DNA from the urine, blood and tumor (optional) will be tested by next generation sequencing for each arm.
1487048|NCT03066297|Procedure|Extent of pulmonary resection|Extent of pulmonary resection selected based on the institutional decision-making algorithm
1487049|NCT03066271|Other|Exercise +|Usual care
1487050|NCT03066271|Other|Control +|Usual care
2001226|NCT03133208|Procedure|Blood draws|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72 (7 draws total). Each draw would be up to 20 mL of blood (but no less than 10 mL).
1487052|NCT03066245|Biological|MSC-PLGA|Bone marrow derived MSC seeded on biodegradable PLGA, supplemented with PL.
1487053|NCT03066219|Drug|BRM421|A topical solution containing BRM421 active
1487054|NCT03066206|Drug|Poziotinib|Poziotinib given at a dose of 16 mg by mouth daily (two tablets of 8mg).
1487055|NCT03066193|Drug|Dronabinol|Participants will receive Dronabinol which will be slowly titrated in the first week of the study. They will be followed for a total of 12 weeks.
1487056|NCT03066193|Dietary Supplement|Palmotoyletahnolamide|Participants will receive the PEA in a standing dose of 400mg. They will be followed for a total of 12 weeks.
1487057|NCT03066180|Device|Viveve SUI treatment|Non-ablative radiofrequency treatment with surface cooling
1487058|NCT03066167|Other|Validation of different dysphagia scores|
1487059|NCT03066154|Drug|oral docetaxel (ModraDoc/r)|Weekly once- or twice daily ModraDoc/r
1487060|NCT03066154|Drug|androgen deprivation therapy|ADT according to the standard of care
1487061|NCT03066154|Radiation|high-dose intensity-modulated radiation therapy|77 Gy in 35 fractions of 2.2 Gy, 5 fractions a week
1487062|NCT03066128|Diagnostic Test|Point-of-care viral load testing|Point-of-care viral load testing will be performed while the participant is in the clinic to ensure that participants receive the viral load results on the same day
1487063|NCT03066128|Other|Lab-based viral load testing|Viral load testing will be lab based and follow standard of care procedures
2001227|NCT03130959|Biological|Nivolumab|Specified dose on specified day
2001228|NCT03130959|Biological|Ipilimumab|Specified dose on specified day
1487069|NCT03066102|Other|muscle fatigue|"Modified push-up plus exercise:
the participants first supported by both knees and the single elbow, and then performed sustained scapular protraction for three minutes with ten repetitions in males and two minutes with five repetitions in females with forty-five seconds rest between."
1487070|NCT03066089|Drug|Fenfuro|
1487071|NCT03066076|Drug|Antithyroid Drug|Antithyroid drug
1487072|NCT03066076|Procedure|Total thyroidectomy|Operation
1487073|NCT03066050|Other|MV Repair|Participants underwent mitral valve repair with annuloplasty and a sub-valvular procedure for severe tethering.
1487074|NCT03066050|Other|MV Replacement|Participants underwent mitral valve replacement and complete preservation of the sub-valvular apparatus.
1487075|NCT03066050|Other|CABG|Participants underwent coronary artery bypass grafting
1487138|NCT03065517|Device|VillageWhere App|VillageWhere is a mobile phone app for use on both Android and iOS platforms by youth with conduct disorders and their parents.
1948887|NCT01262898|Drug|GSK962040 (125 mg tablet)|125 mg tablet
1948888|NCT01262898|Drug|Placebo|matching placebo tablet
1948889|NCT01257750|Drug|Pazopanib (5mg/ml)|Topical pazopanib, 4 times per day for 3 weeks
1487076|NCT03066037|Procedure|regional-anaesthesiological infiltration|Patients with therapy refractory chronic pain are treated with local infiltration techniques using e.g. local anaesthetics, opioids or drug combinations. Targeted structures are e.g. Ganglion stellatum, Ganglion pterygopallatinum, Trigeminal nerve branches (V1-V3). Patients receive a context- sensitive number of blocks in a series of infiltrations depenting on their pain course.
1487077|NCT03066011|Drug|Isavuconazonium sulfate|Oral and Intravenous
1487078|NCT03066011|Drug|Voriconazole|Oral and Intravenous
1487079|NCT03066011|Drug|Posaconazole|Oral and intravenous
1487080|NCT03065998|Drug|Opipramol|PO
1487081|NCT03065998|Drug|Baclofen|PO
1487082|NCT03065985|Device|3 radiofrequency ablation procedures (Habib™ EUS-RFA)|"Patients in the treatment group will receive standard chemotherapy plus 3 radiofrequency ablation procedures, each one month apart.
Investigators will use the Habib™ EUS-RFA, product number 6700, which is a 1 Fr wire (0.33 mm, 0.013) with a working length of 200 cm, which can be inserted through the biopsy channel of an echoendoscope and is compatible with a 19G or 22G echoendoscopic needle. RF power is applied to the electrode at the end of the wire to coagulate tissue in the pancreas at 10 Watts for 2 minutes for each application. It has a CE mark and FDA 510(k) approval."
1487083|NCT03065985|Drug|Standard chemotherapy|Standard chemotherapy
1487084|NCT03065985|Other|Best Medical Care|Best Medical Care
1487085|NCT03065972|Procedure|Surgical fistula creation from patient's anatomy|Patient will be randomized via computer system, to receive the fistula or graft. If fistula, surgeon creates fistula for hemodialysis access from patient's anatomy.
1487086|NCT03065972|Device|Surgical Graft implant|Patient will be randomized via computer system, to receive the fistula or graft. If graft, surgeon implants hemodialysis access using an FDA approved graft.
1487087|NCT03065959|Drug|CK-2127107|oral
1487088|NCT03065959|Drug|Placebo|oral
1487089|NCT03065946|Other|Early wakening|By using an intravascular device to administer mild TH for 24 hours, patients can safely have their medically induced coma reversed early at 12 hours, allowing an accurate neurological assessment to be performed
1487090|NCT03065933|Drug|extended-release clonidine|Subjects will received 0.2 mg extended-release clonidine twice on second day of this three-day study.
1487091|NCT03065907|Other|Vision rehabilitation|A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.
1487092|NCT03065894|Other|Matched Physical Therapy Intervention|"Patients who are medium-risk will receive up to 6-8 physical therapy (PT) visits over a 3 month period that is guided by published evidence based practice guidelines. The PT treatment will be tailored to the physical findings and specific patient needs, and appropriate exercises, spinal mobilization/manipulation, strengthening/stretching as well as a home program will be given to improve patient pain and function and reduce disability.
Patients who are high-risk will receive the evidence based PT treatment as deemed necessary. In addition, the PT treatment will incorporate principles of psychologically informed practice to address psychosocial barriers (e.g., fear avoidance, anxiety, etc) that may be impeding disability reduction. This may include instruction on chronic pain rehabilitation techniques such as the use of: pacing in order to maintain or increase activity; graded activity principles in order to increase function; and pain education and understanding responses to pain."
1487093|NCT03065894|Other|Current Care in Family Medicine|Patient education, medication management
1487094|NCT03065881|Device|RETeval|The RETeval device measures the retina's electrical response to light, called an electroretinogram (ERG). The standards body ISCEV [1] recommends collecting normative data for ERGs to provide waveforms and statistically relevant measurements representing the range of ERGs from people with normal vision. LKC Technologies provides this information with their UTAS product line and wishes to collect such a database for the newest device: the RETeval device. As the RETeval device uses a different electrode to measure the ERG, the normal data for the UTAS product line is not transferable to the RETeval device. Ophthalmic practitioners would also like ERG examples of specific retinal disorders to help diagnose patients with abnormal ERGs. The RETeval device is FDA cleared (K142567),
1487095|NCT03065868|Drug|H. pylori eradication (Amoxaxillin, Lanston, Clarithromycin)|H. pylori eradication (Triple Therapy) as first line treatment if eradication failure, quadruple therpy will be provided as 2nd line treatment
1487096|NCT03065855|Procedure|Early removal group|Participants assigned to the experimental arm will have their urethral catheters removed at 2 days after after laparoscopic anterior resection of the rectum.
1487097|NCT03065855|Procedure|Normal removal group|Participants assigned to the control group will have their urethral catheters removed at 7days following surgery, as is standard practice in our institution.
1487098|NCT03065842|Behavioral|Abortion- and contraceptive-use stigma reduction program|"An abortion- and contraceptive-use stigma reduction intervention (1-month program), capturing i. Negative stereotypes associated with girls who have had an abortion. ii. Discrimination/exclusion of girls who have had an abortion. iii. Fear of coming in contact with a girls who have had an abortion. iv. Negative stereotypes about girls using a contraceptive method. v. Misconceptions about contraceptive use.
The pedagogy will be based on that gender stereotypes, intent to control female sexuality, compulsory motherhood, are social constructs that can be deconstructed. Pedagogical methods will include role modelling, practice of desired behaviours, activities for building self-efficacy, and didactic instructions."
1487099|NCT03065842|Behavioral|Usual Standards|Usual standards according to the school curriculum in Kenya.
1487100|NCT03065829|Behavioral|ASSIST|Wearable sensor technology delivering mindfulness meditation training (MMT) and health promotion (sleep hygiene and physical activity) .
1487101|NCT03065829|Behavioral|Attention-Control|Wearable sensor technology only viewing biophysical sensor data.
1487102|NCT03065816|Drug|Z0063|Pharmaceutical form: chewable tablets Route of administration: oral
1487103|NCT03065816|Drug|Gaviscon|Pharmaceutical form: chewable tablets Route of administration: oral
1487139|NCT03065517|Device|Attention-Control Placebo App|Mobile phone app for use on both Android and iOS platforms.
1487140|NCT03065504|Dietary Supplement|Turmeric|
1487141|NCT03065504|Dietary Supplement|Turmeric-containing combination tablet|
1487142|NCT03065504|Dietary Supplement|Placebo tablets|
1487104|NCT03065803|Procedure|Buccal plate expansion technique for dental socket preservation|"An internal osteotomy of the socket buccal plate will be performed with a piezotome (SurgyStar).
Two vertical osteotomies and one horizontal osteotomy will be made to push the buccal plate outward from the socket. Two small cervical releasing incisions will be made in the mesiobuccal and distobuccal aspects of the socket to permit the displacement of the osteotomies in the area of keratinized tissue. The socket will be loaded with natural bovine bone mineral (cerabone). The biomaterial will be pressed to push the released buccal plate outward. A collagen bio absorbable membrane will be utilized to cover the socket. The collagen membrane plug will be stabilized on the top of the socket with a cross suture (silk 4/0)."
1487105|NCT03065803|Procedure|Guided bone regeneration technique for post-extraction dental socket preservation|After full‑thickness flap reflection on buccal and lingual sides, atraumatic tooth extraction utilizing periotome will be performed.The periosteum of buccal flap will be incised; this would permit coronal advancement of facial flap and a tension‑free primary closure. Extraction sockets will be grafted with natural bovine bone mineral (cerabone). Collagen membrane will be trimmed and placed on the grafted socket and alveolar bone.. Buccal and lingual/palatal flaps will be approximated utilizing interrupted simple loop and vertical mattress sutures (4/0)
1487106|NCT03065790|Diagnostic Test|2-Deoxy-2-[18F]fluoro-D-glucose (FDG)|
1487107|NCT03065777|Device|ONE ENDO|single file rotary system
1487108|NCT03065777|Device|F6 SKYTaper|single file rotary system
1487109|NCT03065777|Device|ProTaper Universal|multi-file rotary system
1487110|NCT03065764|Drug|89Zr-Pembrolizumab|"eligible subjects will undergo two whole body immuno-PET scans with a non-therapeutic tracer dose (2 mg) of 89Zr-pembrolizumab; one with and one without a preceding cold therapeutic dose of pembrolizumab."
1487111|NCT03065751|Device|Plasmaexchange|TPE against fresh frozen plasma
1487112|NCT03065738|Other|tibial reduction osteotomy in total knee replacement|reduction osteotomy :downsizing of tibial tray with lateralization
1487113|NCT03065725|Procedure|late FDG|In addition to regular FDG-PET/CT 60 minutes post injection, an extra scan 180 minutes post injection is made.
1487114|NCT03065712|Drug|18F-Fluoroestradiol|18F-Fluoroestradiol will be administered for PET/CT scan.
1487115|NCT03065699|Device|DIALIVE Liver Dialysis Device|ACLF patients will receive dialysis treatment for 8-12 hrs/day and on three to five consecutive days over a 10-day time period. Dialysis treatment is performed by using the DIALIVE device provided by YAQRIT Ltd.
1487116|NCT03065686|Genetic|identification of genetic factors|Clinical questionnaire and analysis of genetic data obtained by exome high-throughput sequencing
1487117|NCT03065673|Procedure|Potassium oxalate 5% gel|"Teeth will be cleaned using rubber cups associated to pumice and water
Relative isolation with roller cotton will be done;
Prior to each bleaching session, the patients will receive the potassium OXALATE 5%
Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.
A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
1487118|NCT03065673|Procedure|Placebo gel|"Teeth will be cleaned using rubber cups associated to pumice and water
Relative isolation with roller cotton will be done;
Prior to each bleaching session, the patients will receive the placebo gel
Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.
A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
1487119|NCT03065660|Drug|Mifepristone, Oral, 200 Mg|The Investigational Medicinal Product (IMP) is a single dose of 200mg mifepristone to be taken orally after confirmation of missed miscarriage by pelvic ultrasound scan.
1487120|NCT03065660|Drug|Placebo Oral Tablet|The placebo will be an oral tablet in the same form as the IMP, and identical in appearance.
1487121|NCT03065647|Device|Expedited Transport With Mechanical CPR|Patients with OHCA refractory to initial BLS and ACLS will be transported by EMS with ongoing mechanical CPR and ACLS to an emergency department capable of initiating ECPR.
1487122|NCT03065634|Behavioral|Return to work and living healthy after head and neck cancer|Return to work and living healthy after head and neck cancer (RELIANCE) is a 2-months group intervention for head and neck cancer patients delivered by a trained psychotherapist and a peer in eight sessions. The individual sessions aim to improve work ability, quality of life and psychological well-being
1487123|NCT03065634|Behavioral|socio-legal counseling|"Non-manualized socio-legal counseling
two socio-legal counseling sessions delivered by a social worker"
1487124|NCT03065621|Drug|Palbociclib|Each cycle will be 28 days. Patient will take study drug daily during 21 days and then have a rest period of 7 days.
1487125|NCT03065595|Dietary Supplement|Ophiochepalus striatus extract|each sachet of ophiochepalus striatus extract is poured into 50 mL normal water and drink two times/day
1487126|NCT03065595|Other|Placebo|each sachet of placebo drug is poured into 50 mL normal water and drink two times/day
1487127|NCT03065582|Other|Topical Product A|topical application sunscreen containing topical antioxidants and sunscreen filters
1487128|NCT03065582|Other|Topical Product B|topical application of product A without topical antioxidants
1487129|NCT03065582|Other|Topical Product C|Topical application of antioxidants only
1487130|NCT03065582|Other|Control|No product applied
1487131|NCT03065569|Drug|Bupivacaine|16 mL of 0.125% bupivacaine
1487132|NCT03065556|Drug|188-0551 Solution|Topical solution containing active drug
1487133|NCT03065556|Drug|Vehicle Solution|Topical solution containing no active drug
2001229|NCT03130439|Drug|Abemaciclib|Abemaciclib (LY2835219) has been shown in vitro to be a selective ATP-competitive inhibitor of CDK4 and CDK6 kinase activity that prevents the phosphorylation and subsequent inactivation of the Rb tumor suppressor protein, thereby inducing G1 cell cycle arrest and inhibition of cell proliferation.
2001230|NCT03130049|Procedure|Popliteal plexus block|10 mL Marcain-adrenalin 5 mg/mL + 5 microgram/mL. Ultrasound-guided injection into the distal part of the adductor canal
2001231|NCT03128034|Drug|Cyclosporine|Given PO or IV
2001232|NCT03128034|Drug|Fludarabine Phosphate|Given IV
2001233|NCT03128034|Other|Laboratory Biomarker Analysis|Correlative studies
2001234|NCT03128034|Drug|Mycophenolate Mofetil|Given PO or IV
2001235|NCT03128034|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
1487143|NCT03065491|Dietary Supplement|Combined nutraceutical|Plant sterols 800 mg + Red Yeast Rice containing 5 mg monacolin K + L-Tyrosol 50 mg per daily dose Oral administration: 1 tablet per day
1487144|NCT03065491|Other|Placebo|Oral administration: 1 tablet per day
1487145|NCT03065478|Dietary Supplement|OnLife|Daily dosing of dietary supplement OnLife
1487146|NCT03065465|Device|Over-the-scope hemoclipping device|A endoscopic entrapment of tissue for control of bleeding or other applications.
1487147|NCT03065465|Other|Standard endoscopic treatment|Standard therapy includes injection of dilute epinephrine, thermal coagulation with multipolar electrocautery (MPEC) probe, and/or hemoclips.
1487148|NCT03065439|Diagnostic Test|Static balance testing|Postural sway will be measured using a force plate (Metitur Good Balance System®).
1487149|NCT03065400|Drug|Pembrolizumab|200 mg of Pembolizumab administered via intravenous infusion over 30 mins given every 3 weeks
2001236|NCT03128034|Other|Pharmacological Study|Correlative studies
2001237|NCT03128034|Radiation|Pretargeted Radioimmunotherapy|Given 211^At-BC8-B10 IV
2001238|NCT03128034|Drug|Sirolimus|Given PO
2001239|NCT03128034|Radiation|Total-Body Irradiation|Undergo TBI
1487154|NCT03065374|Biological|IMM-529|IMM-529
1487155|NCT03065374|Other|Placebo|Matching placebo
1487156|NCT03065348|Dietary Supplement|oral whey protein|This substance is specifically formulated to target the nutritional needs of the elderly when they require increased energy and strength, such as following a fall or fracture or for the management of under nutrition and frailty. It provides 300 kcal, 20g of protein and increased levels of vitamin D, calcium. Available in vanilla, caramel and strawberry-biscuit
1487157|NCT03065348|Dietary Supplement|Immunonutrition|This substance is a clinically proven nutritional solution for the dietary management of major elective surgery patients, to improve clinical outcomes, and reduce postoperative complications and length of hospital stay. IMPACT formulation contains omega-3 fatty acids, arginine and nucleotides, and is suitable for use as a sole source of nutrition. Oral IMPACT is a powdered sip feed that provides 303kcal per portion when reconstituted with water (74g powder plus 250ml water) and is enriched with omega-3 fatty acids, arginine, nucleotide, 3 gr of soluble fibre 321mg sodium, 402 mg potassium, 216 mg phosphate per portion.
1487158|NCT03065348|Dietary Supplement|Carbohydrate Drink|"Resource® preload™ contains the following elements:
Per portion à 50gr 47.5 gr carbohydrate, < 10mg sodium, 190kcal"
1487159|NCT03065348|Other|Preoperative hydration|If urine specific gravity is >1.020 then additional tap water drinking will be encouraged (1% of ideal body weight)
1487160|NCT03065348|Other|continous spinal anesthesia|Surgery will be performed under continuous spinal anesthesia without general anesthesia
1487161|NCT03065335|Drug|Ketamine|N-methyl-D-aspartate (NMDA) glutamate receptor (NMDA-R) antagonist
1487162|NCT03065335|Other|Placebo|0.5 mg/kg IV saline
1487163|NCT03065322|Other|To assess risk of OSA|The risk of OSA will be assessed using the Berlin questionnaire and the Epworth Sleepiness Scale (ESS). Women with at high risk of OSA will have home-based sleep studies performed. Study participants will be divided based on the results of the Berlin and ESS questionnaires and sleep studies into two groups: 1) PCOS low risk OSA: women with normal ESS and normal Berlin questionnaire (no sleep studies performed), or women with normal sleep studies; and 2) PCOS OSA: women with OSA proven by sleep studies.
1487164|NCT03065309|Drug|Remifentanil|bolus dose
1487165|NCT03065296|Behavioral|Musculoskeletal (MSK) Prescription Didactic Lectures|In between phase 1 and phase 2 there will be a series of didactic lectures to educate resident on home exercise prescription and get them familiarized with the handouts.
1487166|NCT03065296|Other|Musculoskeletal (MSK) home exercise hand-outs|In between phase 1 and phase 2, residents will use home exercise hand-outs readily available and educate their patients in regards to those.
1487167|NCT03065283|Procedure|Diaphragm lift|The purpose is to generate the stretch of the peripheral fibers of the diaphragm, being performed with the patient in the supine position and the physiotherapist standing on the patient's head and Pulling the Your costal arch In the cephalic direction, for one minute, twice
1487168|NCT03065283|Procedure|Relaxation of the diaphragm pillars|Second technique aims to promote the rhythmic stretching of the double psoas diaphragm pillars, being performed with The patient in the ventral position and the therapist standing at his side placing the ulnar border of his cephalic hand on the last ribs and his caudal hand flattened in front of the popliteal fossa of the popliteal fossa, stretching was done for one minute
1487169|NCT03065270|Other|Use unstable shoes Masai Barefoot Technology (MBT)|Use of unstable shoes during 9 weeks, at least four hours per day.
1487170|NCT03065270|Other|Use conventional sport shoes|Use of conventional sport shoes during 9 weeks, at least four hours per day.
1487171|NCT03065257|Procedure|Endoscopic Resection|Any Endoscopic resection for Gastrointestinal disorders including neoplasms.
1487172|NCT03065244|Drug|IVIG|Subjects randomized to this arm will receive IVIG 2g/kg over 10-12 hours
1487173|NCT03065244|Drug|Infliximab|Subjects randomized to this arm will receive infliximab 10 mg/kg over 2 hours
1487174|NCT03065231|Device|Extraventricular Drain|As mentioned above, intervention will take place to promote subarachnoid blood diversion from cerebrospinal fluid after ruptured intracranial aneurysm.
1487175|NCT03065231|Device|Lumbar Drain|
1487176|NCT03065218|Radiation|99mTc sestamibi|The patient will receive an injection into the vein of a radioisotope 99mTc sestamibi dose 25mCi and will be imaged in 1 day.
1487177|NCT03065205|Device|Propeller Health device + asthma navigator|The patients will be monitored using the propeller health device for 6 months. The patients will be contacted at 2 month intervals by an asthma health educator to discuss barriers to adherence to asthma medications
1487179|NCT03065179|Drug|Nivolumab/Ipilimumab|IV immunotherapy
2001240|NCT03122665|Drug|Nefopam Low dose|Continuous intravenous infusion at 0.5 mg/ml for three hours.
2001241|NCT03122665|Drug|Nefopam High dose|Continuous intravenous infusion at 1.0 mg/ml for three hours.
2001242|NCT03121560|Device|Hysteroscopy|Hysteroscopy allows a direct visualization of the interior of the uterine cavity in order to invalidate or confirm the presence of uterine pathologies.In the pre-menopausal period, it is preferable to perform a hysteroscopy at the beginning of the follicular phase (just after the menstruations, when the endometrium is atrophic). Use of a rigid hysteroscope comprising a 2.9 mm optics and a 4.3 mm sheath with a 5 - bit operator channel allowing the realization of a biopsy.
1487180|NCT03065179|Radiation|SBRT|SBRT will be delivered in conjunction with immunotherapy
1487181|NCT03065166|Other|Raisin Treatment|Subjects will consume 3.2oz of dried Cabernet grapes during a single intervention time point.
1487182|NCT03065166|Other|Bagel Control|Subjects will consume 95g of whole wheat bagel during a single intervention time point.
1487183|NCT03065140|Other|Training or detraining|A period of detraining or a supervised exercise program.
1487184|NCT03065127|Behavioral|Cognitive Training|Training the cognitive domain may be accomplished by training various cognitive and executive functions with guided practice focusing on specific skills (e.g. visuospatial processing, executive function, memory, language, and attention). Cognitive training has been demonstrated to be efficacious in several studies in individuals with PD. Given the potential cognitive contribution to FOG episodes, this type of therapy may alleviate FOG by potentially improving upon planning, set-shifting, and/or response inhibition.
1487185|NCT03065127|Behavioral|Cognitive Behavioural Therapy|CBT has been demonstrated to be effective in the remediation of anxiety in individuals with PD. This may be beneficial to individuals experiencing FOG, given the evidence that anxiety may provoke FOG. During periods of elevated anxiety (e.g. walking in a threatening environment), freezers will be able to more efficiently process this limbic load resulting in greater resources available for movement control.
1487186|NCT03065127|Behavioral|Proprioceptive Training|Currently, studies investigating proprioceptive training as a treatment in PD are limited. However, this type of training has potential by improving proprioceptive processing. It would be expected that due to this training, when sensorimotor processing is challenged during locomotion (e.g. by removing visual feedback and preventing compensation of proprioception deficits), freezers would experience less decrements to gait due to an enhanced ability to process sensorimotor demands.
1487187|NCT03065114|Other|PGS|chromosome abnormality test from PGS and relationship between embryo development
1487188|NCT03065101|Device|Trigen Intertan|While both the Trigen InterTAN and Sliding Hip Screw are marketed and demonstrated to be suitable for treatment of the study indication, the randomisation is considered an intervention as it may be contrary to the treatment chosen by the surgeon were the patient not a study subject.
1487189|NCT03065101|Other|Post-Surgery Follow Up|The current clinical trend is for minimal follow up post-surgery, unless indicated by complications. The study protocol indicated that follow up telephone visits are to be performed at 8 weeks, 12 weeks and 12 months post-surgery and an outpatient follow up visit at 6 months post-surgery. While most outcome measures are conducted via questionnaire, the increase in follow up means that subjects may be exposed to increased ionising radiation.
1487190|NCT03065101|Device|Sliding Hip Screw|
1487191|NCT03065088|Behavioral|aLIFE|The aLiFE programme is taught by an instructor during six home visits and 3 phone calls during the 6-month intervention period. The programme will be personalised by use of an initial balance and strength assessment (aLiFE assessment tool). The participants assigns activities to his or her daily activities, and during subsequent home visits, the number of activities and task demands are upgraded. Participants will be taught how to select opportunities themselves to embed activities into their individual daily routine, and how to progress over time.
1487192|NCT03065088|Behavioral|eLIFE|The eLIFE includes a personalised ICT-administered training schedule using the activities developed in aLiFE, delivered in the form of video clips, pictures and text/verbal instructions on a smartphone and smartwatch application. Personalisation of activity content will be decided based on a phenotype tool and initial difficulty level is decided through the aLiFE assessment tool. In addition, a virtual instructor teaches the participants how to carry out the eLiFE programme. The user receives motivational messages and feedback, and there will be a possibility for social interaction between the participants. The instructors teach the eLiFE participants the programme during 4 home visits and 3 phone calls during the 6 month intervention period.
1487193|NCT03065088|Behavioral|control|The control group follows the World Health Organization's recommendations of physical activity. The control participants will receive one home visit and be given a written letter with the activity recommendations.
1487194|NCT03065075|Drug|Phenazopyridine|Phenazopyridine on morning of postoperative day 1
1487195|NCT03065062|Drug|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for part 1 of the study will be 100 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered with food.
1487196|NCT03065062|Drug|Gedatolisib|Gedatolisib will be administered once weekly on the first day for each of the four weeks during the 4-week cycle. The initial dose for part 1 of the study will be 110 mg. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for gedatolisib are required.
1487197|NCT03065049|Behavioral|TREC|Participants will engage in a 12-week physical activity intervention guided by a peer-facilitator at the methadone clinic they receive treatment. Participants will attend weekly groups, engage in a guided walking group, and utilize the Fitbit to self-monitor physical activity.
1487198|NCT03065036|Drug|prestudy topical glaucoma medications|Reintroduction of prestudy topical glaucoma medications, introduced one medication at a time during each study visit, as necessary.
1487199|NCT03065023|Drug|RGT100-PEI|RGT100-PEI with a fixed concentration of 0.2 mg/mL
1487200|NCT03065010|Drug|BCD-115|Inhibitor of CDK8/19
1487201|NCT03064997|Dietary Supplement|Synergy 1|a daily dose: 7 g/day of Synergy1 (oligofructose enriched inulin) consumed for 12 weeks together with a strict gluten-free diet
1487202|NCT03064997|Dietary Supplement|Placebo|a daily dose: 7 g/day of placebo (maltodextrin) consumed for 12 weeks together with a strict gluten-free diet
1487203|NCT03064984|Other|CBS eyedrops|CBS eyedrops (prepared from umbilical cord blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
1487204|NCT03064984|Other|PBS eyedrops|PBS eyedrops (prepared from adult peripheral blood serum) will be provided as frozen vials containing 0.8 ml of the product and will be administered at a regimen of 1 drop / 8 times day / each eye during the waking period, with the last administration to take before bedtime.
1487205|NCT03064971|Behavioral|Standard Care|Standard of care provided by QuitlineNC includes Quit Coaches, counseling calls, nicotine replacement therapy, and written materials
1487206|NCT03064971|Behavioral|smoking cessation DVD|"The evidence-based How to Quit DVD contains 60 minutes of smoking cessation information and strategies"
1487207|NCT03064971|Behavioral|PTF DVD|Culturally specific smoking cessation DVD. This DVD contains 60 minutes of material.
1487208|NCT03064958|Other|Herbs and spices|Mix of commonly used herbs and spices
1487209|NCT03064958|Other|High fat meal|Meal containing 1000kcal and 45g fat
1487210|NCT03064945|Device|Livia|Livia® Transcutaneous Electrical Nerve Stimulation (TENS) is a novel pain management device for women suffering from dysmenorrhea
1487211|NCT03064932|Other|Controlled feeding diet|Average American diet with different levels of spices
1487212|NCT03064919|Behavioral|Curriculum Testing|An evidence-based curriculum for teaching preschool children to eat in response to internal hunger and fullness signals was developed by refining an existing curriculum. State-of-the art theories in early childhood science education, innovative virtual technology to provide more realistic simulations of hunger and fullness, and a parent training component to improve long-range sustainability were incorporated. This 9-wk intervention will be tested by forty children (ages 4-5). Key outcomes will be children's adjustment in intake in response to a first course (energy compensation) and children's intake of tasty snacks when not hungry (eating in the absence of hunger). Additionally, the investigators will measure other variables likely to impact the success of the curriculum, for example: child gender/age, parent feeding practices, parent education, infant feeding practices, child/parent weight status, and others.
1487213|NCT03064906|Device|Insulet AP (artificial pancreas) System|Insulet AP (artificial pancreas) system, using the Omnipod® insulin management system, Dexcom G4 Share® AP System and personalized model predictive control algorithm.
1487214|NCT03064893|Device|Alloderm|Reconstruction material
1487215|NCT03064893|Device|Dermacell|Reconstruction material
1487216|NCT03064880|Other|SV maximization|Voluven solution 250 mL infusion per 5 minutes up to the platau of Flank-starling law: status to SV change < 10% and maintained for 20 minutes
1487217|NCT03064867|Drug|Venetoclax|Beginning with 400mg daily on days 1-10 of cycle 1-3
1487218|NCT03064867|Drug|RICE|rituximab, ifosfamide, carboplatin, etoposide on day 1-3 every 21 days
1487219|NCT03064854|Drug|PDR001|Powder for solution for infusion
1487220|NCT03064854|Drug|Cisplatin|Intravenous infusion
1487221|NCT03064854|Drug|Gemcitabine|Intravenous infusion
1487222|NCT03064854|Drug|Pemetrexed|Intravenous infusion
1487223|NCT03064854|Drug|Carboplatin|Intravenous infusion
1487224|NCT03064854|Drug|Paclitaxel|Intravenous infusion
1487226|NCT03064828|Radiation|CT colonoscopy(normal dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 100-200mA
1487227|NCT03064828|Radiation|CT colonoscopy (low dose)|Perform CT colonoscopy with full bowel preparation and inflated colon,CT Scans on subjects with normal-dose protocol by setting scanning parameters as 120-140 kVp, 20-100mA
1487228|NCT03064815|Device|Videocapsule endoscopy|"Capsule endoscopy is a procedure that uses a tiny wireless camera to take pictures of your digestive tract. A capsule endoscopy camera sits inside a vitamin-size capsule you swallow. As the capsule travels through your digestive tract, the camera takes thousands of pictures that are transmitted to a recorder you wear on a belt around your waist.
Capsule endoscopy helps doctors see inside your small intestine — an area that isn't easily reached with more-traditional endoscopy procedures."
1487229|NCT03064815|Procedure|colonoscopy|Colonoscopy is a test that allows your doctor to look at the inner lining of your large intestine (rectum and colon). He or she uses a thin, flexible tube called a colonoscope to look at the colon.
1487230|NCT03064815|Diagnostic Test|PROMETHEUS® IBD sgi Diagnostic™|This test combines serologic, genetic, and inflammation markers in a proprietary Smart Diagnostic Algorithm to provide added IBD diagnostic clarity. This test helps physicians differentiate IBD vs. non-IBD and CD vs. UC in one comprehensive blood test.
1487231|NCT03064815|Diagnostic Test|Fecal calprotectin|A stool test to measure inflammation in the gut.
1487232|NCT03064802|Device|BioBurst Fluid, Burst Allograft|BioBurst Fluid or Burst Allograft used to augment spinal fusion
1487233|NCT03064776|Device|m-RESIST Patients|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
1487234|NCT03064776|Device|m-RESIST Caregivers|A mobile system based on Information and Communications Technology (ICT), which is addressed to empower patients suffering from TRS and to involve their caregivers
1487235|NCT03064763|Drug|Talimogene laherparepvec|T-VEC will be administered by intralesional injection only into injectable cutaneous, subcutaneous, and nodal tumors, with or without image ultrasound guidance. On day 1 (week 0) the first dose of talimogene laherparepvec will be up to 4.0 mL of 106 PFU/mL. The second injection up to 4.0 mL of 108 or 107 PFU/mL, should be administered 3 weeks (+ 5) days after the initial injection (no sooner than day 22 but should not be delayed more than 5 days after the 21-day time point). The dose of 108 PFU/mL will be diluted 1:10 to obtain a concentration of 107 PFU/mL immediately prior to injection. Subsequent injections up to 4.0 mL of 108 or 107 PFU/mL should be given every 2 wks (± 3) days. The maximum volume of talimogene laherparepvec to be administered at each treatment visit is 4.0 mL
1487236|NCT03064750|Behavioral|pelvic floor exercises|In preparation for surgery, patients receive individual information by a physiotherapist on pelvic floor anatomy and correct pelvic floor contraction. Patients are told to do the following pelvic floor exercises 3 times a day: 8-12 maximal contractions, hold contractions during 10 seconds, and 3 fast contractions after each long contraction. In addition exercise in groups with skilled physical therapists once a week during 12 weeks.
1487237|NCT03064750|Other|Waiting list|patients wait as usual until surgery without special treatment.
1487238|NCT03064737|Other|Skin biopsy for genetic analyze|"It will be offered to a subgroup of adult patients carrying genetic markers predisposing to the severity of the LD infection, a skin biopsy in order to realize genetic analyses.
This visit will be conducted once the results of genetic markers obtained (between 30 and 36 months), a specific consent will be required to patients.
The skin biopsy will be performed according to the Clinical Department use."
1487271|NCT03064399|Procedure|lateral ligament repairment|microfracture combined with repairment of the lateral ligament
1487239|NCT03064724|Behavioral|"Interactive Mobile Doctor (iMD)"|"iMD delivers tailored interactive video education via a mobile tablet to smoking patients right before their clinic visit with a provider. iMD delivers the 5 A's (ask, advise, assess, assist, and arrange) and generates a bilingual tailored printout, which aims to increase patient-provider discussion on tobacco use and to promote smoking cessation. This version of iMD delivers the intervention in Korean or Vietnamese languages as preferred by the patient."
1487240|NCT03064711|Diagnostic Test|Electronyugraphy|Surface electromyography (sEMG) recorded diaphragmatic muscle activity during rest and while performing maximal voluntary ventilation
1487241|NCT03064698|Other|Post-partum Doppler ultrasound|Participants will undergo one uterine artery Doppler ultrasound at 6 weeks post-partum.
1487242|NCT03064672|Device|transcervical Balloon Catheters|induction of labor by transcervical Balloon Catheters insertion
1487243|NCT03064646|Other|Organ Preservation|Patients with a complete response or a almost complete response after neoadjuvant treatment will be offered an organ preservation strategy
1487244|NCT03064633|Drug|dexamethasone 8 mg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both side using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexamethasone group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexamethasone 8 mg.
1487245|NCT03064633|Drug|dexmedetomidine 80 µg|At the level of the umbilicus, the high-frequency ultrasound linear array probe (L 4 - 12) will be placed transversely on the anterolateral abdominal wall between the subcostal margin and the iliac crest. localization of the fascial plane between the internal oblique and the transversus abdominis muscles will be done. The local anesthetic solution mixture will be injected with short bevel needle. The TAP block will be performed on the both sides using the same technique and the same local anesthetic solution mixture volume. For the patients randomized to dexmedetomidine group, the local anesthetic solution mixture will consist of a total volume of 40 ml containing bupivacaine 0.25 % and dexmedetomidine 80 µg.
1487246|NCT03064633|Drug|Bupivacaine 0.25% Injectable Solution|38 ml of the solution will be prepared to be used in transversus abdominis plane block
1487247|NCT03064620|Biological|PCV|PCV7 was introduced in Israel (IL and EJ) in July 2009 PCV13 replaced PCV7 in IL and EJ on Oct 2010 PCV10 was introduced in PA in 2011
1487248|NCT03064607|Other|Fluid collection|Fluids tested for biomarker S100beta
1487249|NCT03064594|Procedure|Cornual pregnancy|we will get the information of operative time, blood loss and postoperative pregnancy and delivery rate.
1487250|NCT03064581|Behavioral|Intervention|The educational session consisted of a one-hour small group discussion (5-10 people). Gender-specific community health educators facilitated sessions for Pacific Islander women and for their spouses/significant others that included an educational video and other materials (brochure, calendar, and resource list). The video emphasized the importance of Pap testing for Pacific Islander women, and showed men supporting their women to get tested. Women's sessions provided basic information on cervical cancer and pap testing, and ended with verbal commitments and target screening dates by women to get screened. The men's education sessions contained similar information, with supplemental information on how to provide support for their wives to get tested and exercises on showing their support.
1487251|NCT03064568|Drug|Misoprostol 100Mcg Tab|
1487252|NCT03064568|Drug|Placebo|
1487253|NCT03064542|Drug|carbimazole (CMZ) or thiamazole (TMZ)|CMZ or TMZ will be used to treat the hyperthyroidism till the FT4/TSH is in normal range.
1487254|NCT03064529|Device|Accelerometer|All participants receive a wrist worn accelerometer to measure physical activity continuously before and after surgery
1487255|NCT03064516|Procedure|Endocrown|In experimental group, the researches will be performed in the Endocrown group- only the ceramic restoration will fill the pulp chambre in teeth treated endodontically. Cusps will be preserved.
1487256|NCT03064516|Procedure|Onlay and fiber pin|In control group, the researches will be performed in the onlay ceramic restorations with glass fiber pin group in endodontically treated teeth- the teeth receive a fiberglass pin in the main root canal and composite resin filling. Cusps will be preserved.
1487257|NCT03064503|Biological|Blood sampling|Blood sampling will be performed at inclusion to investigate some biological eligibility criteria, and the day of MRI in order to analyse fibrosis biomarkers and collagen synthesis biomarkers
1487258|NCT03064503|Device|MRI|MRI will be performed to measure interstitial fibrosis
1487259|NCT03064503|Biological|Skin auto-fluorescence|Skin auto-fluorescence measures will be performed to measure advanced glycation end-products (AGE) produced by collagen degradation
1487260|NCT03064490|Drug|Pembrolizumab|Neoadjuvant Pembrolizumab ( 3 cycles) administered concurrently with weekly Carboplatin and Paclitaxel and daily radiation therapy; followed by surgical resection and adjuvant Pembrolizumab ( 3 cycles)
1487261|NCT03064477|Behavioral|Unified Protocol|Intervention group that carries out the Unified Protocol in a group format
1487262|NCT03064477|Behavioral|Cognitive Behavioral Therapy (TAU)|TAU group that carries out Cognitive Behavioral Therapy in an individual format
1487263|NCT03064464|Other|None Intervention|It is observational study, no interventios to any of the three study arms
1487264|NCT03064451|Procedure|cartofinder guided ablation followed by PVI|cartofinder guided ablation followed by PVI
1487265|NCT03064438|Drug|ACCU-D1|ACCU-D1
1487266|NCT03064438|Drug|Placebo Comparator|Placebo Comparator
1487267|NCT03064425|Biological|Vaginal and blood sample collection|The researchers will obtain approximately 20 mL of blood from participants. Participants will also undergo a pelvic exam where a sample of cells will be collected from the cervix using two small cytobrushes. In addition, a cervicovaginal lavage will be collected using saline.
1487268|NCT03064412|Biological|Urine sample collection|A urine sample will be collected in each of the 3 trimesters of pregnancy, and also at 6 weeks post partum.
1487269|NCT03064412|Biological|Saliva collection|A saliva sample will be collected at one time point during the study - likely at the initial baseline visit.
1487270|NCT03064399|Procedure|without lateral ligament repairment|microfracture without repairment of the lateral ligament
1487272|NCT03064386|Procedure|Plate fixation|internal fixation with the plate
1487273|NCT03064386|Procedure|Screw fixation|internal fixation with the screw
1487274|NCT03064360|Other|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline and study exit. Finger sticks at baseline, interim, and study exit.
1487275|NCT03064360|Device|Patient Activity|Continuous monitoring of Patient Reported Informatics (PRIs) at study entry to study completion.
1487276|NCT03064360|Behavioral|Questionnaires|Symptom and quality of life questionnaire at baseline, and every week following to study completion
1487277|NCT03064347|Dietary Supplement|Sucrose plus Whole Milk Powder in Enteric Coating|Single dose enteric coated sucrose plus whole milk powder will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
1487278|NCT03064347|Dietary Supplement|Non coated Sucrose plus Whole Milk|Single dose sucrose plus whole milk powder with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
1487279|NCT03064347|Dietary Supplement|Sucrose in Enteric Coating|Single dose enteric coated sucrose will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
1487280|NCT03064347|Dietary Supplement|Sucrose with Separate Enteric Coating Materials|Single dose sucrose with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
1487281|NCT03064347|Dietary Supplement|Whey Protein in Enteric Coating|Single dose enteric coated whey protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
1487282|NCT03064347|Dietary Supplement|Whey Protein with Separate Enteric Coating Materials|Single dose whey protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
1487283|NCT03064347|Dietary Supplement|Pea Protein in Enteric Coating|Single dose enteric coated pea protein will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
1487284|NCT03064347|Dietary Supplement|Pea Protein with Separate Enteric Coating Materials|Single dose pea protein with separate enteric coating materials will be consumed by mouth. Blood will be drawn at baseline and then at 15 minute intervals for 3 hours from ingestion for measurement of GLP-1, PYY, C-peptide, insulin and glucose.Visual analog score will be used to record satiety and adverse symptoms every 15 minutes.
1487285|NCT03064334|Procedure|Total Knee Arthroplasty|surgical knee joints Arthroplasty
1487286|NCT03064321|Behavioral|Insomnia Intervention|The SHUTi intervention is based on a cognitive behavioral treatment for insomnia (CBT-I) and organized into six structured, weekly online sessions. Each week the participants will complete a 30-minute interactive learning module and to complete daily online sleep diaries will be used.
1487287|NCT03064321|Other|Information Control|Information on websites that are general health promoting
1487289|NCT03064295|Device|Myocardial Perfusion Cardiac MRI.|MRI with administration of a contrast drug and a stress agent, if no contraindications are present. The gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg) The IV stress agent is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
1487290|NCT03064295|Drug|Contrast|The intravenous gadolinium based contrast agent to be used in this study is either Gadavist (up to 0.2 mL/kg body weight (0.2 mmol/kg) or MultiHance (0.2 mmol/kg)
1487291|NCT03064295|Drug|Pharmacologic Stress Agent|The stress agent administered intravenously is regadenoson (0.4mg/5ml bolus) or adenosine (dosage based on subject's weight and is set at 140mcg/kg/min
1487292|NCT03064282|Other|Placebo|observation of skin changes if any
1487293|NCT03064282|Drug|papaverine|observation of symptoms
1998266|NCT01541215|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks. Subjects will continue treatment in a 26 week open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
1487295|NCT03064256|Behavioral|Physical training program|Physical training program consisted of three weekly sessions lasting up to one hour over a period of twelve weeks. and will be carried out respecting the traditional training principles: biological individuality, Specificity, overload, adaptation and reversibility
1487296|NCT03064256|Behavioral|Physical training program|All sessions were started with stretches for lower and upper limbs lasting 10 minutes for warm-up, and after trekking on treadmill using the predetermined critical velocity (Vcrit). The exercises were completed with cooling of the muscle groups for one minute still on the treadmill, plus 10 minutes of relaxation exercises on the mat at the end of aerobic exercise.
1487297|NCT03064243|Drug|apatinib|apatinib 500mg po. qd.
1487298|NCT03064230|Other|QoL questionnaire SF-12 and and a screening questionnaire|patient were asked to fill questionnaires
1487299|NCT03064217|Procedure|CLP and 12 weeks waiting|Restorative treatments will be initiated 12 weeks after clinical crown lengthenings (CLPs).
1487300|NCT03064217|Procedure|Digital impression taken at surgery|The final impression will be made at surgery.
1493102|NCT03020030|Drug|Vincristine|Standard of Care
1998267|NCT01541215|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks. Subjects will discontinue placebo treatment in the open-labelled extension. Rescue treatment will be allowed if rescue criteria are met.
1487301|NCT03064191|Combination Product|calcium hydroxide chlorhexidine combination|Endodontic intra-canal medicament used for decreasing postoperative signs ans symptoms
1487302|NCT03064191|Other|calcium hydroxide intra-canal medicament|Endodontic intra-canal medicament used for decreasing postoperative signs and symptoms.
2001243|NCT03121560|Device|Hysterosonography|Hysterosonography (SIS) is an endovaginal ultrasound performed along with an injection of saline in order to observe the uterine cavity and detect any endometrial pathology. A 3D image can be associated with it to define the topography of a lesion. It is ideally performed in the first part of the cycle. Use of the GE Voluson E8 Ultrasound System.
2001244|NCT03120533|Drug|Iontophoresis of treprostinil|the participant will receive 10 days of iontophoresis of treprostinil on a first site
1487308|NCT03064139|Behavioral|Mindful walking|Community-based in person group training n mindful walking over 11 sessions in 6-months+ Activity monitor with feedback on activity levels
1487309|NCT03064139|Behavioral|Education|Community-based in person group education in management of knee osteoarthritis (importance of physical activity, weight management, etc.) over 11 sessions in 6 months + Activity monitor with feedback on activity levels
1948890|NCT01213914|Device|An FDA approved continuous renal replacement device|"70ml/kg/hr for treatment group for 48 hours with the following requirements:
double lumen dialysis catheter should be placed in the internal jugular or femoral vein
Anticoagulation will be determined by prescribing physician
Use of 1.4 m2 or larger biocompatible synthetic hollow-fiber dialysis membrane that is changed every 24 hours
Blood flow rate will be set to ensure a filtration fraction of no more than 25%
Monitoring for electrolytes (specifically K+, Mg, Ca, and phos) during HVHF must be performed at least every 6 hours
Replacement fluids will be bicarbonate-buffered with appropriate adjustments when citrate-anticoagulation is utilized
All antibiotics will be dose adjusted for renal replacement therapy"
1948891|NCT01213914|Other|Control Group|Both groups will receive 'contemporary' care via consideration of the Burn-specific Sepsis Bundle adapted from the most recent Surviving Sepsis Campaign (SSC) (1) recommendations and specifically modified to our patient population
1948892|NCT01213329|Drug|Alemtuzumab|All kidney transplant recipients received one 30mg dose (IV push) of Alemtuzumab in operating room per Standard of Care.
1948893|NCT01205152|Biological|asfotase alfa|
1948894|NCT01204918|Drug|Riluzole|Riluzole 100mg PO for up to 8 weeks
1487317|NCT03064100|Other|Observational Study|Exclusion from the study
1487318|NCT03064087|Device|Colli-Pee|First, two first-void urine samples will be collected with the Colli-Pee device (Novosanis NV, Wijnegem, Belgium) at home, the day before a visit to the colposcopy centre at a gynecology clinic.
1487319|NCT03064087|Device|Multi-Collect Swab|At the colposcopy clinic, one vaginal self-sample will be collected with the Multi-Collect Swab (Abbott GmbH & Co. KG, Wiesbaden, Germany).
1487320|NCT03064087|Device|Evalyn Brush|Another vaginal self-sample will be collected also at the colposcopy centre either with the Evalyn Brush (Rovers Medical Devices B.V., Oss, Netherlands)
1487321|NCT03064087|Device|Qvintip|or with Qvintip (Aprovix AB, Uppsala, Sweden).
1487322|NCT03064087|Diagnostic Test|Abbott RealTime High Risk HPV|The hrHPV assay used, will be the Abbott PCR (Abbott GmbH & Co. KG, Wiesbaden, Germany), which detects separately DNA of HPV16 and HPV18, as well as the pool of twelve other hrHPV types (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66 and 68). The accuracy of this PCR assay for the detection of CIN2+ will be determined on all samples: on the mixed two urine samples and on the vaginal and cervical samples. Furthermore, it is possible that in the future other assays will be validated.
1487323|NCT03064074|Drug|Fresolimumab|The purpose of this study is to determine if fresolimumab is safe as a treatment for OI. We will evaluate the safety of a single dose of fresolimumab in the 1st stage of the study. We will evaluate the safety of multiple doses of fresolimumab in the 2nd stage of the study. The Investigators will evaluate the effect of the two doses of fresolimumab in Stage 1 on markers of bone turnover and determine the dose that shows the greatest reduction in bone turnover markers compared to no treatment. This dose will be chosen for the repeat dose studies. If there were no significant changes between the bone turnover markers with either dose, the 4 mg/kg dose will be chosen for the repeat dose study.
1487324|NCT03064061|Device|Virtual reality|a device with virtual reality is given to the patients with a film of 18 minutes
1487325|NCT03064048|Dietary Supplement|Neo-ASA|Dietary supplement with nitric oxide in the form of a lozenge called Neo-ASA.
1487326|NCT03064048|Dietary Supplement|Placebo|Dietary supplement with no nitric oxide in the form of a lozenge to look and taste like the dietary supplement Neo-ASA
1487327|NCT03064035|Drug|4-factor prothrombin complex concentrate (4FPCC)|4-factor prothrombin complex concentrate (4FPCC) contains all of the vitamin K-dependent clotting factors inhibited by warfarin, making it desirable for use in warfarin reversal for emergent bleeds. Multiple guidelines currently recommend 4FPCC for warfarin reversal in vitamin K-dependent major bleeding or intracranial hemorrhage. 4FPCC has a fast onset of action and has demonstrated significant reversal of INR within 10 minutes. Its duration of action is up to 8 hours, and for this reason it should be given concurrently with vitamin K. Vitamin K has a delayed onset of action due to its need to stimulate the synthesis of clotting factors so its effects begin as the effects of 4FPCC diminish. 4FPCC is the standard of care treatment for this clinical population in the Regions Hospital Emergency Department.
1487329|NCT03064009|Other|Infection|This is an observational trial
1487330|NCT03063996|Procedure|peripheral IV access procedure|standard of care guided IV access into peripheral vein excluding IJ
1487331|NCT03063996|Procedure|Peripheral IJ access procedure|standard of care guided IV access into IJ
1487332|NCT03063983|Drug|Cyclophosphamide|Continuous oral cyclophosphamide
1487333|NCT03063983|Drug|Methotrexate|Continuous oral methotrexate
1487334|NCT03063970|Device|Dynamic Lycra Orthosis|Dynamic lycra orthoses: made to measure fabric lycra compression gauntlets individually tailored to correct upper limb movement and positioning. Worn for eight hours per day but may be removed for therapy and washing.
1487335|NCT03063970|Other|Usual Rehabilitation|Physiotherapy or Occupational Therapy delivered as routine part of rehabilitation
1487336|NCT03063944|Drug|STAT Inhibitor OPB-111077|Given PO
1487337|NCT03063944|Drug|Decitabine|Given IV
1487380|NCT03063645|Drug|AC-SD-01 (50 g)|50 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
1487338|NCT03063931|Drug|Magnesium: Magnésium UPSA Action Continue®|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
1487339|NCT03063931|Drug|Placebo: Lactose|This clinical trial compares magnesium and placebo for the prevention of neuropathic pain induced by mastectomy assessed with a (0-10) numerical pain rating scale
1487340|NCT03063918|Other|Informational Intervention|Receive a workbook
1487341|NCT03063918|Other|Quality-of-Life Assessment|Ancillary studies
1487342|NCT03063918|Other|Questionnaire Administration|Ancillary studies
1487343|NCT03063918|Other|Survey Administration|Ancillary studies
1487344|NCT03063918|Behavioral|Telephone-Based Intervention|Receive personalized dietary intervention
1487345|NCT03063905|Drug|Buprenorphine|Patients taking buprenorphine to wean off an opiate addiction
2001245|NCT03120533|Drug|Iontophoresis of placebo|the participant will receive 10 days of iontophoresis of NaCl on a second site, but the same time than treprostinil; it's like a design of cross-over study
2001246|NCT03120143|Other|Small-sided ball game training with high protein intake|In the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation high in protein consists of 18 g protein consumed immediately after and 3 h post exercise
1487348|NCT03063879|Drug|Sofosbuvir 400 mg and daclatasvir 60 mg|Daily fixed dose combination pill (Sovodak) containing 400 mg sofosbuvir and 60 mg daclatasvir for 12 weeks if not cirrhotic (liver stiffness < 12 KPa) or 24 weeks if cirrhotic
1487349|NCT03063866|Drug|Propofol|Propofol 1 mg/kg i.v
1487350|NCT03063866|Drug|Midazolam|Midazolam 3 mg i.v
1487351|NCT03063866|Drug|Fentanyl|fentanyl 0.5 ug/kg
1487352|NCT03063853|Other|Removal of surgical clips at day 4 postop vs day 8|
1487353|NCT03063853|Procedure|Elective cesarean delivery|
1487354|NCT03063840|Device|Microwave ablation|Microwave ablation (MWA): Emprint Microwave Ablation system with 2.45 GHz microwave generator
1487355|NCT03063827|Drug|OnabotulinumtoxinA 200 UNT|Patient in the treatment arm received a single injection of onabotulinumtoxinA 200 UNT to the detrusor muscle at 20 sites of the bladder body.
1487356|NCT03063827|Diagnostic Test|Urothelial sensory protein levels|Bladder tissues were investigated for urothelial barrier and inflammation proteins as well as urothelial sensory protein levels by Western blotting, between SCI patients and 10 controls, as well as successful and failed treatment groups.
1487357|NCT03063814|Behavioral|APP|See arm description
1487358|NCT03063814|Behavioral|PHY|see arm description
1487359|NCT03063801|Other|Data extraction in medical files|Data extraction from medical files, countraverified by the bloodbank database for accuracy.
1487360|NCT03063788|Drug|3BNC117-Copper-64|3 mg/kg 3BNC117 combined with radio-isotope Copper-64
1487361|NCT03063775|Device|BioOss® + Mucograft Seal®|Placement of BioOss®-Collagen into the extraction socket. The Mucograft Seal® Membrane is then applied to the socket.
1487362|NCT03063775|Other|FGG + Bio-Oss®|Placement of BioOss®-Collagen into the extraction socket. The FGG is then attached to the socket.
1487363|NCT03063775|Other|FGG + Gelatine sponge (Spongostan®)|Placement of a Gelatine sponge into the extraction socket, then attaching the FGG to the socket.
1487364|NCT03063775|Device|Spongostan®+ Mucograft® Seal|Placement of a Gelatine sponge into the extraction socket, then attaching the Mucograft® Seal Membrane to the socket
2001247|NCT03120143|Other|Small-sided ball game training with low protein intake|n the present study, small-sided ball game training consists of repeated intervals of floorball and cone ball training on small areas and 3-4 participants on each team. The supplementation low in protein consists of 3 g protein consumed immediately after and 3 h post exercise.
2001248|NCT03118700|Other|Aerobic Interval Exercise|Subjects will perform an interval exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time
1487370|NCT03063736|Drug|Entolimod|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
1487371|NCT03063736|Biological|Td Vaccine|The objective is to compare adverse events and anti-tetanus (TT) antibody levels between patients getting entolimod vs no entolimod combined with tetanus-diphtheria (Td) vaccine. This clinical trial in 40 normal health subjects compares a single dose of 4 ug Td (2 ug of TT and 2 ug of diphtheria toxoid + 3000 ug of alum) with or without entolimod (1μg).
1487372|NCT03063723|Drug|Ledipasvir-Sofosbuvir|8 CHC patients were treated with Sofosbuvir (400mg, qd)/Ledipasvir (90mg, qd) for 12 weeks
1487373|NCT03063723|Drug|Daclatasvir-Sofosbuvir|7 CHC patients were treated with Sofosbuvir (400mg, qd)/Daclatasvir (60mg,qd) for 12 weeks.
1487375|NCT03063684|Device|Fractional / Pixel CO2 Laser|"The laser energy is transferred in a fractioned manner: the laser beam splits while passing through a lens to 81 dots (9 x 9 pixels) onto approximately 1 cm2, so the laser rays hit the tissue in small spots.
For gynecological applications, the treatment is performed by a transducer, which was specifically designed for vaginal application."
1487376|NCT03063671|Drug|Ketamine, bupivacine,dexmedetomidine|thoracic epidural catheter insertion at T4-5
1487377|NCT03063658|Drug|Paracetamol|The first dose of 1 gr intravenous paracetamol will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
1487378|NCT03063658|Drug|Ibuprofen 800 mg|The first dose of 800 mg intravenous ibuprofen will be administered preoperatively and the remaining three doses will be given each six hours in the early postoperative period.
1487379|NCT03063645|Drug|AC-1202|60 g AC-1202 mixed in 240 mL of water at Hour 0 Day 1
1487381|NCT03063645|Drug|AC-SD-01 (75 g)|75 g AC-SD-01 mixed in 240 mL of water at Hour 0 Day 1
2001249|NCT03118700|Other|Continuous exercise|Subjects will perform a 30-minute continuous exercise bout on a cycle ergometer. To warm up, they will cycle at a work rate associated with 50% of their max heart rate (HR) for 10 minutes. Wattage will then increase and they will perform a 30-minute exercise bout at a work rate associated with 75%-80% of their max HR. They will be given a 5-minute cool-down period at a work rate associated with 50% of their max HR. After the exercise, they will remain in the lab for 4 hours and their blood pressure will be measured every 10 minutes using an automated blood pressure monitor and cardiac output will be measured using the PhysioFlow. They will remain seated during this time.
2001250|NCT03118661|Other|For Step 2: Structured treatment interruption|-Accepted tool in the evaluation of immunological interventions, gene therapy, or therapeutic vaccines for the treatment of HIV infection
2001251|NCT03118661|Procedure|Peripheral blood draw|-Screening, entry for Step 1, Step 1 visit 2, entry for Step 2, weekly, week 16, monthly through week 52, week 52, quarterly through year 5, year 5, and viral relapse
1487385|NCT03063619|Drug|Afimoxifene|Applied topically
1487386|NCT03063619|Other|Laboratory Biomarker Analysis|Correlative studies
1487387|NCT03063619|Other|Placebo|Applied topically
1487388|NCT03063619|Other|Questionnaire Administration|Ancillary studies
1487389|NCT03063606|Behavioral|Cognitive-Behavioral Therapy (CBT)|CBT specialist treatment
1487390|NCT03063606|Drug|NB Medication (on-going from acute treatment)|Naltrexone/bupropion combination (on-going blinded pharmacotherapy from acute treatment consisting of either naltrexone/bupropion or placebo)
1487391|NCT03063580|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablets
Route of administration: oral"
1487392|NCT03063580|Drug|Rifampicin|"Pharmaceutical form: capsules
Route of administration: oral"
1487393|NCT03063567|Device|CPAP interfaces|All patients in study underwent crossover prospective trial of the same 3 types of CPAP interfaces (nasal mask, oronasal mask, nasal pillows) in randomized order. Trial was 1 month duration for each interface.
1487394|NCT03063554|Procedure|Endoscopic Ultrasound Guided Biliary Drainage|Endoscopic Ultrasound Guided biliary drainage with stent placement;
1487395|NCT03063554|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography with transpapillary biliary stent placement
2001252|NCT03116828|Drug|Eslicarbazepine acetate|eslicarbazepine acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
2001253|NCT03116828|Drug|Eslicarbazepine Acetate|eslicarbazepine acetate acetate tablets, taken once daily. Subjects begin 2-week Titration Phase starting on Day 1 (Week 1), by initiating treatment with ESL 400 mg/day. Subjects titrate to minimum dose of 800 mg/day for the 24-week Maintenance Phase beginning at Week 3. In the Maintenance Phase, subjects may titrate in weekly increments of 400 mg/day as medically indicated at the discretion of Investigator up to a maximum dose of 1200 mg/day (Canadian sites) or 1600 mg/day (US sites)
2001254|NCT03116282|Behavioral|E-alcohol therapy|Conversational therapy sessions provided via video conference by a professional alcohol therapist.
1487400|NCT03063515|Drug|Pyridostigmine|single oral dose of 60 mg pyridostigmine tablet
1487401|NCT03063489|Drug|Loteprednol Etabonate Ophthalmic Gel|Formulated LE into a gel (loteprednol etabonate ophthalmic gel, [Lotemax® gel])
1487402|NCT03063476|Drug|C-13 labeled Lysine|Carbon-13 is a stable naturally occurring heavy isotope of carbon. Inclusion of a 13C label on lysine allows for subsequent differentiation between endogenous and exogenous lysine and 2-AAA for calculation of clearance and excretion of the lysine bolus.
1487403|NCT03063476|Drug|Normal saline|Because patients will have multiple blood draws during the course of the study, subjects will have an IV placed to reduce the number of needle sticks. To keep the vein open for blood collections, we will infuse Normal (0.9%) Saline (NS) at a rate of approximately 10ml/hr in order to keep the line open.
1487404|NCT03063463|Procedure|pneumatic dilation|Pneumatic dilation of the lower esophageal sphincter (LES) consists of inserting a guide wire under visual control into the stomach and to pass the balloon over the guide wire. The balloon is inflated, disrupting the muscle fibers of the sphincter.
1487405|NCT03063463|Procedure|surgical myotomy|This procedure destroys the muscles at the gastroesophageal junction, allowing the valve (LES) between the esophagus and stomach to remain open.
1487408|NCT03063437|Biological|Encapsulated fecal microbiota preparation|30 capsules
1487409|NCT03063437|Biological|Encapsulated placebo|30 capsules
1487410|NCT03063424|Diagnostic Test|Eucapnic voluntary hyperventilation|
1487411|NCT03063424|Diagnostic Test|Exercise challenge on a cycle ergometer|
1487412|NCT03063411|Other|Executive Function Intervention|In the executive function training group, children will complete computerised tasks requiring working memory and inhibitory control over four weekly sessions lasting 15-20 minutes. The aim is to improve their executive function skills. In the active control group, children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
1487413|NCT03063411|Other|Active Control Group|This is the active control condition. Children will complete computerised tasks requiring simple decision making and visual search skills over four weekly sessions lasting 15-20 minutes.
1487414|NCT03063398|Diagnostic Test|No intervention, this is an observational study|Assessment for exocrine pancreatic insufficiency
1487415|NCT03063385|Behavioral|Parental Communication intervention|In this intervention, we focus on providing parents with basic knowledge about pregnancy, HIV/AIDS, and STDs as a basis for effectively communicating with their adolescents. We work to support attitudes and develop skills to facilitate communication in general and specifically sexual communication. Based on our prior work we focus on prevention beliefs, reaction beliefs, and communication efficacy. Importantly, we include a component on HIV/AIDS stigma as we conceptualize this to impact attitudes and communication about sex. We will program the intervention in such a way so that parents will have to view the Cuídalos program sequentially and in its totality before being able to review any content.
1948895|NCT01204918|Drug|placebo|placebo
1487416|NCT03063385|Behavioral|Health promotion control condition|"In this intervention, we provide a web-based program relying on existing Spanish language web-sites to provide participants with helpful information to prevent significant health problems affecting Puerto Rican adolescents that are related, not to sexual behavior, but to other behaviors. Similar to the experimental condition, we will develop a set of homework related to diet and exercise that we will ask parents to complete with their adolescents."
1487417|NCT03063372|Dietary Supplement|Pomella pomegranate extract|Participants will take a 500 mg capsule of pomegranate extract twice daily for 28 days.
1487418|NCT03063372|Other|Placebo|Participants will take a gelatin placebo twice daily for 28 days.
1487419|NCT03063359|Drug|intranasal fentanyl|Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
1487420|NCT03063359|Drug|Oral Morphine|Administration of oral morphine (0,4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
1487421|NCT03063359|Drug|oral placebo|Administration of intranasal fentanyl (1.5µg/kg) and oral placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
1487422|NCT03063359|Drug|intranasal placebo|Administration of oral morphine (0,4mg/kg) and intranasal placebo in children with acute pain in traumatic context on arrival in emergency pediatric department.
1487423|NCT03063346|Dietary Supplement|Protein hydrolysate high dose|
1487424|NCT03063346|Dietary Supplement|Protein hydrolysate low dose|
1487425|NCT03063346|Dietary Supplement|Placebo|
1487426|NCT03063333|Other|Coping-oriented hypnosis|Hypnosis using coping-oriented suggestions based on reversal of statements from the pain catastrophizing scale plus current treatment.
1487427|NCT03063333|Other|Neutral hypnosis|Hypnosis using neutral suggestions plus current treatment
1487428|NCT03063320|Other|Spice blend|Test spices include cardamom, coriander, cumin, ginger, paprika, red pepper, turmeric, cinnamon
2001255|NCT03114969|Device|ELLIPTA Inhaler|ELLIPTA inhaler will be used by subjects as their primary treatment to control COPD.
2001256|NCT03114969|Device|TURBUHALER|TURBUHALER inhaler will be used by subjects as their primary treatment to control COPD.
1487431|NCT03063294|Other|Online Toolkit|The online toolkit provides a set of tools that clinics can use to improve their care coordination processes.
1487432|NCT03063294|Other|Distance-based coaching|The distance-based coach supports included clinics in carrying out a quality improvement project focused on care coordination, either using the online toolkit or other resources determined by the clinic.
1487433|NCT03063281|Other|BIological analysis|Biological analysis : ficolin-2 et anti-ficolin-2 antibodies
1948896|NCT01204684|Biological|autologous tumor lysate-pulsed DC vaccination|
1948897|NCT01204684|Biological|Tumor lysate-pulsed DC vaccination+0.2% resiquimod|
1948898|NCT01204684|Biological|Tumor-lysate pulsed DC vaccination +adjuvant polyICLC|
1487437|NCT03063255|Drug|Obturator block|Subjects allocated to the obturator block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to post-anaesthesia care unit (PACU) or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
1487438|NCT03063255|Drug|Neuromuscular block|Subjects allocated to the neuromuscular block group will be monitored for the incidence of block and procedure-related adverse events. In addition to clinical observation, a Nerve Integrity Monitor (Medtronic) will be used to detect adductor spasm using continuous electromyography. Electrodes will be placed on the thigh to objectively detect and record instances of adductor spasm. One hour after arrival to PACU or when discharge criteria are met (whichever comes first), repeat dynamometer measurements and TUG tests will be performed. Patients will be called 24-48 hours post procedure to inquire about falls or evidence of nerve injury, as well as patient satisfaction.
2001257|NCT03114969|Device|DISKUS Inhaler|DISKUS inhaler will be used by subjects as their primary treatment to control COPD.
2001258|NCT03114969|Device|HANDIHALER|HANDIHALER inhaler will be used by subjects as their primary treatment to control COPD.
1487441|NCT03063229|Device|Accelerometer|Attach a monitor to participants thigh to measure their physical activity for 7 days. The monitor is called the Activpal Micro.
1487442|NCT03063229|Other|Anthropomentry|Take skinfold measurements of participants using Harpenden skinfold calipers.
1487443|NCT03063229|Procedure|Blood tests|Taking standard clinical blood tests to measure HbA1c, Glucose, FBC, U&E's, LFT's, Coagulation Screen, Lipid Profile, Thyroid Function, and Tacrolimus for transplant patients.
1487444|NCT03063229|Device|BODPOD|Measure body composition using a BODPOD machine. This uses Air displacement plethysmography.
1487445|NCT03063229|Procedure|MRI (Magnetic Resonance Imaging)|MRI Scans of abdomen, particularly the livers of islet transplant and insulin pump patients.
1487446|NCT03063229|Other|Food Diary|Participants will keep a 7 day weighed food diary.
1487447|NCT03063229|Device|CGMS (Continuous Glucose Monitoring System)|Participants will wear a CGMS for 7 days to measure their glucose control and pattern over a 7 day period.
1487448|NCT03063229|Other|Questionnaire and Hypo Score|Participants with Type 1 Diabetes will fill in 3 short questionnaires about their Diabetes.
1487449|NCT03063229|Procedure|Mixed Meal Tolerance Test (MMTT)|"The patients will under go a test which involves taking 30 minute glucose and C-peptide levels (blood test from a cannula) for 3 hours. They will consume 150ml of a mixed meal supplement drink Fortisip Compact at the start of the 3 hours, after having no morning insulin, breakfast and not eating anything from midnight the night before."
2001259|NCT03114969|Device|BREEZHALER|BREEZHALER inhaler will be used by subjects as their primary treatment to control COPD.
1487450|NCT03063229|Procedure|Indirect Calorimetry|During the Meal Tolerance Test, the patients will be resting on a bed in the research facility and breathing normally into a clear plastic hood. The machine connected to the hood (GEM) will analyse their resting energy expenditure from the gases expired in their breath. They will have the hood on for 2 hours.
1487451|NCT03063229|Drug|Doubly Labelled Water|The Doubly Labelled water will be prescribed for the participants and they will drink their 100ml dose of the stable isotope. Dose depends on the eight of the participant. The participant will then collect urine samples at home on day 5, 10 and 14 after drinking the water. They will store them in the freezer until they can bring them back to us.
1487452|NCT03063229|Drug|Hepatic Mitochondrial Oxidation breath test|Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
1487453|NCT03063203|Drug|Decitabine|"After 2 cycles, patients with progressive disease or relapse (a clear progression with at least >40% bone marrow blasts and an increase of at least 50% from prior biopsy) should be removed from protocol and proceed to salvage treatment according to center preference
Transplant eligible patients who achieve CR, CRc, or CRi, after 3 cycles with a suitable donor will proceed to conditioning regimen and transplant
Transplant eligible patients with PR after 3 cycles may be removed from protocol and proceed to salvage treatment according to center preference
Transplant eligible patients with a suitable donor who achieve mLFS, CR, CRc, or CRi, may proceed to transplant after at 3 cycles
Transplant ineligible patients with (CR, CRc or CRi, PR) will continue on maintenance doses
Transplant ineligible patient with SD after cycle 4 may be removed from protocol and proceed to alternative treatment or continue on protocol according to treating physician's preference."
1487454|NCT03063203|Procedure|Bone marrow biopsy|-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression or relapse
1487455|NCT03063203|Procedure|Peripheral blood draw|-Baseline, Cycle 1 Day 10, Cycle 1 Day 28, Cycle 2 Day 28, Cycle 3 Day 28, and Progression/Relapse
1487456|NCT03063203|Procedure|Skin biopsy|"Optional but if refuse skin biopsy then must do buccal swab
If WBC at time of enrollment is < 30,000/µl, skin biopsy should be collected during enrollment bone marrow biopsy.
If WBC at time of enrollment is >30,000/µl, skin biopsy should be collected at the time of C1D28 bone marrow biopsy."
1487457|NCT03063203|Procedure|Buccal swab|-Baseline (if skin biopsy declined) and Cycle 2 Day 28
1487458|NCT03063190|Drug|Vitamin D|patients will receive vitamin D supplementation according to guidelines
1487459|NCT03063190|Drug|Placebo Oral Tablet|patients will receive placebo oral tablets
1487461|NCT03063164|Device|Intralase IFS150|Intralase flap creation
1487462|NCT03063164|Device|Visumax|Visumax flap creation
1487464|NCT03063112|Device|Radiofrequency generator device|sympathetic blockade or ablation of thoracic splanchnic nerves
1487465|NCT03063112|Drug|Lidocaine|sympathetic blockade or ablation of thoracic splanchnic nerves
1487466|NCT03063112|Device|C arm fluoroscopic device|sympathetic blockade or ablation of thoracic splanchnic nerves
1487467|NCT03063112|Drug|Ethyl alcohol|sympathetic blockade or ablation of thoracic splanchnic nerves
1487468|NCT03063099|Other|ReNu™ Injection|Injection into the hip for the treatment of Osteoarthritis.
1487469|NCT03063086|Drug|QVM149 150/50/80 μg o.d.|A
1487470|NCT03063086|Drug|QVM149 150/50/160 μg o.d.|B
1487471|NCT03063086|Drug|salmeterol/fluticasone FDC 50/500 μg b.i.d.|C
1487472|NCT03063073|Drug|Dexmedetomidine Injection [Precedex]|ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine (markyrene R sigma -Tec, Egypt) plus (1 µg/kg) Dexmedetomidine Injection [Precedex]
1487473|NCT03063073|Drug|Bupivacaine|
1487474|NCT03063060|Other|vitamin D levels and Calcium levels examination|observational
1487475|NCT03063047|Other|PD21871AA|A 100s size menthol cigarette.
1487476|NCT03063047|Other|PD21872AA|A 100s size menthol cigarette.
1487477|NCT03063034|Other|PD21864AA|A king size menthol cigarette.
1487478|NCT03063034|Other|PD21864AB|A king size menthol cigarette.
1487479|NCT03063021|Drug|N-Acetyl Cysteine (NAC)|Oral tablets of N-acetyl-cysteine
1487480|NCT03063008|Device|PEEK|"Procedure/Surgery:
TLIF fusion with common PEEK cages."
1487481|NCT03063008|Device|TiPEEK|"Procedure/Surgery:
TLIF fusion with titanium coated PEEK cages."
1487482|NCT03062995|Other|Infant Formula with added synbiotics|Intervention group: Infant Formula / Follow-On formula with partially hydrolysed cow's milk protein supplemented with prebiotics and probiotics.
1487483|NCT03062995|Other|Standard Infant formula|Control group: Standard Infant Formula / Follow-On formula with intact cow's milk protein (only standard ingredients, without addition of pre- and probiotics).
1487484|NCT03062982|Drug|Fluzoparib|2 doses separated by 7 days.
1487485|NCT03062969|Procedure|Cleavage stage biopsy group|"intracytoplasmatic sperm injection (ICSI)- (Invitro Fertilization)IVF
Time lapse embryo culture
Cleavage stage biopsy
aCGH analysis
Fresh euploid embryo transfer"
1487486|NCT03062969|Procedure|Trophectoderm biopsy group|"ICSI-IVF
Time lapse embryo culture
Day 3 zona pellucida opening
Trophectoderm biopsy
aCGH analysis
Frozen-thawed euploid embryo transfer"
1487487|NCT03062956|Drug|MYK-491 or placebo|Oral suspension
1487488|NCT03062943|Drug|Nintedanib|
1487489|NCT03062930|Behavioral|Track 1|Training of non-paretic arm followed by sham condition
1487490|NCT03062930|Behavioral|Track 2|Same procedures as track 1, but completed in opposite order, starting with sham condition followed by the non-paretic arm training
1487491|NCT03062917|Diagnostic Test|Nasal and Bronchial Sampling|Nasal Absorption sampling, Bronchial sampling, Nasal Pharageal Aspirates, Blood sampling.
1487492|NCT03062904|Drug|Inhaled Bronchodilators +/- Inhaled Methacholine|"Combined Salbutamol 200μg and Ipratropium bromure 80μg (2 inhalations) if paradoxal answer
Inhaled Methacholine based on international recommendations"
1487493|NCT03062891|Procedure|Online CBT for insomnia|See CBT arm description for information about the CBT intervention. More details can be found in source 4 in the reference list.
1487494|NCT03062878|Other|Arterial blood pressure|Continuously monitored for 5-30 minutes via finger photoplesmography
1487495|NCT03062878|Other|Vascular Ultrasound|Assessment of carotid artery cross sectional area and intima-media thickness. Assessment of brachial artery diameter
1487496|NCT03062878|Other|Venous blood sample|Evaluation of oxidative stress via serum lipid hydroperoxide
1487497|NCT03062878|Other|Skin microcirculatory blood flow|Assessed non-invasively in the forearm skin via Laser Doppler flowmetry in response to locally delivered acetylcholine (ACh) and sodium nitroprusside (SNP) via iontophoresis.
1487498|NCT03062865|Other|No intervention|
1487499|NCT03062852|Device|Medication safety vest|"The nurses preparing and administering medication will wear a medication safety vest. On the back of the vest, the sentance Do not disturb me. I am preparing medications is written to inform others professional, patients and visitors. A informational flyer will be put in the units to inform patients and visitors about the intervention."
1487500|NCT03062839|Drug|Melatonin 5 mg|Melatonin 5 mg taken 30 minutes before bed time
1487501|NCT03062813|Drug|Tacrolimus &entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
1487502|NCT03062813|Drug|placebo & entecavir|HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
1487503|NCT03062800|Drug|Thalidomide|100-200mg/d,oral ,qn
1487504|NCT03062800|Drug|pemetrexed|(500mg/m^2) on day 1 of 21-days cycle,ivgtt
1487505|NCT03062800|Drug|cisplatin|(75mg/m^2) on day 1 of 21-days cycle, ivgtt
1487506|NCT03062800|Drug|carboplatin|(AUC=5) on day 1 of 21-days cycle, ivgtt
1487507|NCT03062787|Device|Cingal® (Sodium hyaluronate with Triamcinolone Hexacetonide)|Intra-articular injection
1487508|NCT03062787|Device|Monovisc® (Sodium hyaluronate)|Intra-articular injection
1487509|NCT03062774|Biological|PB-119 injection|
2001263|NCT03111732|Drug|Pembrolizumab (MK-3475)|200 mg will be administered as an IV infusion on Day 1 of each 21 day cycle
1487512|NCT03062735|Other|Inspiratory Muscle Training|The Inspiratory Muscle Training (IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 50% of maximal inspiratory pressure.
1487513|NCT03062735|Other|Sham Inspiratory Muscle Training|The Sham Inspiratory Muscle Training (Sham-IMT) group will perform 30 inspiratory efforts, 5 times a week, twice a day, for 12 weeks, against a pressure threshold load equivalent to 15% of maximal inspiratory pressure.
1487514|NCT03062722|Procedure|keyhole approach|The surgical procedure was a direct microsurgical approach with a 1.5 cm incision in the thenar sulcus, under local anesthesia (3cc, 2% lidocaine) administered with an insulin needle. The keyhole approach applied to this anatomical region is based on a 1.5 cm skin incision from where the 0.5 cm dissection is completed in the subcutaneous plane in the side borders and 1cm in the distal and proximal borders. Thus, the subcutaneous phase of the dissection is completed with separation of the carpal ligament and resection of its borders. Once the transverse fibers are open, the perineural micro adhesions of the median nerve are resected and 3mm of the free borders of the carpal fibers found on the nerve are removed to avoid fibrosis. The wound is checked for hemostasis and closed in apposition with Vicryl 3-0 and a single subdermal 3-0 Nylon stitch.
1487515|NCT03062709|Behavioral|Breathe Easy Coalition written materials|written materials about secondhand and thirdhand environmental smoke exposure in children
1487516|NCT03062709|Behavioral|Maine Tobacco Helpline|referral to tobacco cessation counselor, helpline calls adult referred to provide counseling over the phone.
1487517|NCT03062709|Diagnostic Test|Urine cotinine testing|the child's urine is tested for cotinine, which is produced when the body absorbs nicotine. These results are communicated to the child's parent/guardian.
1487518|NCT03062696|Behavioral|CBT-RD|5-8 sessions of cognitive behavioral therapy for rumination disorder (CBT-RD), held once per week in an outpatient setting.
1487519|NCT03062683|Other|Lactate, prolactin and creatine kinase conc.|Lactate, prolactin and creatine kinase conc. in blood samples were measured
1487520|NCT03062670|Other|Retreat|Full day off-site training session
2001264|NCT03111732|Drug|Oxaliplatin|130mg/m^2 IV Infusion will be administered as an IV infusion on Day 1 of cycles 1-6
1487522|NCT03062644|Drug|MR308|two times daily; Mode of Administration:oral
1487523|NCT03062644|Drug|MR308|four times daily; Mode of Administration:oral
1487524|NCT03062644|Drug|MR308|two times daily; Mode of Administration:oral
1487525|NCT03062644|Drug|MR308|given four times daily to maintain the blind; Mode of Administration:oral
1487526|NCT03062631|Drug|3,4-Diaminopyridine|The investigator will prescribe an initial dose of 3,4 diaminopyridine (DAP) by mouth based on the participant's weight. This initial dose may be modified later according to the participant's response to treatment.
1487529|NCT03062605|Drug|Iodine (Betadine)|
1487530|NCT03062605|Biological|NaOCL|
1487531|NCT03062592|Dietary Supplement|Pine nut oil|Subjects are supplemented with either no oil, hydrolyzed oil or non-hydrolyzed oil in combination with an OGTT
1487532|NCT03062579|Drug|Tocilizumab|Tocilizumab will be intravenously administered as the dosage of 8 mg/kg every 4 weeks, 6 weeks if possible, without concurrent other immunosuppressive treatments.
1487533|NCT03062566|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
1493103|NCT03020017|Other|Laboratory Biomarker Analysis|Correlative studies
2001265|NCT03111732|Drug|Capecitabine|750 mg/m^2 will be administered orally twice a day on Days 1-14 of cycles 1-6
2001266|NCT03112902|Device|Application of Transcranial Alternating Current Stimulation for Modulation of Sleep and Cognitive Performance|Transcranial Alternating Current Stimulation will be applied during slow wave sleep to assess effects on memory and sleep architecture.
2001268|NCT03111173|Device|Holter Device|MyECG E3.80 Holter Recorder
1487537|NCT03062540|Drug|TNX-102 SL|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
1487538|NCT03062540|Drug|Placebo SL Tablet|Patients will take 2 tablets of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks
1487539|NCT03062527|Other|Dietary Intervention: Low vs. moderate glycemic index|
1487540|NCT03062514|Device|PINS Vagus Nerve Stimualtor|PINS Vagus Nerve Stimualtor
1487541|NCT03062501|Drug|Hydroxyurea|Patients hospitalized for uncomplicated pain crisis with a pain scale of ≥ 6 during the last 24 hours will receive a dose of 30-40 mg / kg hydroxyurea. This same dose of hydroxyurea will be repeated at 24 h and 48 h after the first dose of hydroxyurea, with dose suspension if the patient is discharged within 48 hours. Patients will also receive the center's usual practice and analgesia protocol.
1487542|NCT03062488|Drug|IV acetaminophen|multi-modal analgesia with IV acetaminophen
1487543|NCT03062488|Drug|Fentanyl|single modal analgesia
1487544|NCT03062488|Drug|PO acetaminophen|multi-modal analgesia with PO acetaminophen
1487545|NCT03062475|Behavioral|lifestyle intervention with dietary and exercise recommendation|"With the dietary intervention we aimed to promote a healthy pattern of eating but not necessarily to restrict energy intake.For example we suggested exchanging carbohydrate-rich foods with a medium-to-high glycaemic index for those with a lower glycaemic index to reduce the glycaemic load, and restricting dietary intake of saturated fat.
With respect to advice on physical activity, we focused on incremental increases in walking from a pedometer assessed, or encourage them to do moderate cycling during pregnancy."
1487546|NCT03062462|Drug|Clopidogrel|double standard-dose clopidogrel treatment (300 mg loading dose, then 75 mg twice daily) for 7 days
1487547|NCT03062462|Drug|ticagrelor|half-dose ticagrelor treatment (90 mg loading dose, then 45 mg twice daily) for 7 days
1487548|NCT03062449|Drug|L-Serine|Gummy containing L serine dose
1487549|NCT03062449|Other|Placebo Gummy|Gummy with no dosing of L Serine
1487550|NCT03062436|Other|Stopping the standard drug therpy|Stopping the standard drug therapy of CML patients and monitoring their treatment free remission status
1487551|NCT03062423|Drug|Sofodelevier|1 tablet contains 400 mg sofosbuvir
1487552|NCT03062423|Drug|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
1487553|NCT03062423|Drug|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
1487554|NCT03062410|Other|Electronic PRO in daily clinical practice|All patients diagnosed with mRCC initiating TKI anti-VEGF treatment (Sunitinib or Pazopanib) will be invited to complete the European Organisation for Research and Treatment of Cancer (EORTC) QLQ-C30 cancer specific questionnaire and the EQ-5D before each visit with the physician. Questionnaires completion will be done by patients on tablets and/or computer terminals via the CHES software (Computer-based Health Evaluation System) at hospital before consultation or at home via secured portal. Physician will immediately have access to a visual summary of HRQOL evaluation.
1487555|NCT03062397|Drug|JPI-289 Low-dose|JPI-289 Low dose will be intravenously administered during 24 hours
1487556|NCT03062397|Drug|JPI-289 High-dose|JPI-289 High dose will be intravenously administered during 24 hours
1487557|NCT03062397|Drug|Placebo|Same dosage of JPI-289 Low and Hogh dose will be intravenously administered during 24 hours
1487558|NCT03062384|Dietary Supplement|AT-001|
1487559|NCT03062384|Dietary Supplement|Placebo|
1487560|NCT03062371|Behavioral|Playgroup|A semi-structured gathering of caregivers and their children in a community setting developed and implemented by a skilled provider.
1487561|NCT03062358|Biological|pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
1487562|NCT03062358|Drug|placebo|Normal saline solution administered as an IV infusion Q3W
1487563|NCT03062358|Other|best supportive care (BSC)|BSC will include pain management and management of other potential complications including ascites per local standards of care.
1487564|NCT03062345|Other|Single-User Virtual Reality Upper Extremity Therapy|Virtual Reality games with the user as the only person required for participation
1487565|NCT03062345|Other|Multi-User Virtual Reality Upper Extremity Therapy|Virtual reality games in which more than one user is required for participation. Users interact in the virtual environment.
1487566|NCT03062332|Genetic|Faecal genome|Sequencing faecal genome is not the intervention measure.It is the Observational method to detect the component of faecal microbiota.
1487567|NCT03062319|Drug|Oral Anticoagulant|warfarin, dabigatran, rivaroxaban, apixaban, or edoxaban
1487568|NCT03062319|Drug|Antiplatelet Drug|aspirin, clopidogrel, prasugrel, ticlopidine, or cilostazol
1487569|NCT03062293|Device|Functional Re-adaptive Exercise Device|Exercise intervention 3 times per week for up to 30min. Difficulty and time will be progressed as indicated by clinical presentation, assessed by the Physiotherapist team.
1487570|NCT03062280|Drug|Hydrocortisone|Modified release hydrocortisone
1487605|NCT03061877|Other|Anxiety or depression|The presence of anxiety or depression measured by the Hospital Anxiety and Depression Scale (HAD)
2001269|NCT03110757|Biological|GLA-AF|Previously referred to as Gluco-pyranosylphospho-lipid A aqueous formulation (GLA-AF). It is a toll-like receptor-4 agonist
2001270|NCT03110757|Biological|Hepatitis B Virus Vaccine|A non-infectious subunit viral vaccine derived from hepatitis B surface antigen (HBsAg) produced in yeast cells.
2001271|NCT03110757|Biological|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel
1487571|NCT03062267|Other|Mobile interventionist|A mobile interventionist is a trained clinician who provides supportive messaging through text messages via mobile devices (i.e. basic / smartphones)
1487572|NCT03062254|Drug|radium-223 dichloride|6 doses of Radium-223
1487573|NCT03062241|Procedure|Cryoablation|After left atrial appendage (LAA) thrombus exclusion, the transseptal puncture will be performed and intravenous heparin will be administered to achieve Activated Clotting Time (ACT) ≥300 seconds.The pulmonary vein (PV) isolation will be performed. Optimal cryoballoon positioning will be confirmed by PVs angiography. Pulmonary veins isolation will be confirmed by entrance/exit block using appropriate catheter. During cryoablation of the right PVs, high-output right phrenic nerve stimulation will be performed using a diagnostic catheter placed in the superior vena cava. Whenever decrease/loss of pacing capture will be observed, cryoablation will be immediately terminated.
1487574|NCT03062215|Behavioral|Space from Depression|Space from Depression programme (Yo puedo sentirme Bien -Spanish version) consists of seven modules of cognitive-behavioural therapy. The treatment includes self-monitoring, behavioural activation, cognitive restructuring, and challenging core beliefs. All modules have the same structure and format, which consist of quizzes, videos, educational content, activities with homework suggestions and a module review page.
1487575|NCT03062202|Behavioral|SilverCloud|SilverCloud Health is a leading provider of online therapeutic solutions to support and promote positive behavior change and mental wellness. SilverCloud delivers interventions for all of the anxiety disorders (panic disorder, social anxiety, phobias, GAD, health anxiety, OCD), depression and also comorbid depression and anxiety. The programs for the treatment of depression and anxiety employ several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social. Research on the SilverCloud interventions has yielded significant clinical outcomes (Richards et al., 2015).
1487576|NCT03062176|Drug|Anakinra|Anakinra (Kineret)
1487577|NCT03062163|Other|Resveratrol lipoic Acid|Transdermal patch loaded with resveratrol and lipoic acid
1487578|NCT03062163|Other|Placebo|Transdermal patch loaded with normal saline
1487579|NCT03062150|Drug|Placebo|Placebo
1487580|NCT03062150|Drug|Fludrocortisone|Fludrocortisone
1487581|NCT03062150|Drug|D-Cycloserine|D-Cycloserine
1487582|NCT03062137|Diagnostic Test|blood gas sampling|
1487583|NCT03062124|Procedure|SpyGlass pancreatoscopy|During the SpyGlass pancreatoscopy procedure visually guided biopsies and flushing liquid are collected from the pancreatic duct
1487586|NCT03062098|Device|ultrasound imaging|Ultrasound imaging during embryo transfer using a small vaginal probe.
1487587|NCT03062085|Other|Cataract|The genetic and environmental factors concerning to the pathogenesis of cataract in the three groups.
1487588|NCT03062072|Drug|Chemotherapy|Chemotherapy containing glucocorticoid as anti-emetics or anti-cancer agent except for targeted agents
1487589|NCT03062059|Drug|Intravesical 2000mg/52.6ml gemcitabine instillation|Intravesical 2000mg/52.6ml gemcitabine instillation during operation to prevent intravesical recurrence after radical nephroureterectomy in upper urinary tract urothelial carcinoma
1487591|NCT03062020|Device|QUIPP|Information required by QUIPP tool will be introduced ( obstetrical history, cervical length and quantitative fetal fibronectin value) and a percentage of risk of preterm birth will be given. Women with a high-risk value will be managed in Preterm Birth Prevention Clinic and women with low-risk value will be followed-up in a low-risk unit.
1487592|NCT03062007|Drug|BI-CON-02|BI-CON-02 prescribed as intravenous infusion once per 3 weeks. Investigational product therapy during 1 year (up to 18 cycles, duration of 21 days each).
1487593|NCT03061981|Drug|Placebo|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period.
1487594|NCT03061981|Drug|Metformin|Subjects in the IE cohort will receive 500 mg metformin (IR formulation) at 12 hours on Day 1 and a single oral dose of the IMP with 500 mg metformin (IR formulation) after an overnight fast on Day 1, in Treatment Period 2.
1487595|NCT03061981|Drug|DA-1241|After pre-dose assessments on Day 1, subjects will receive a single oral dose of IMP after an overnight fast in each Treatment Period .
1487596|NCT03061968|Behavioral|acupressure|The babies in experimental group will be observed for one day, and then intervene the simplified acupressure three times a day for fifteen days, and continuously recoding the observation and records until discharge.
1487597|NCT03061955|Biological|influenza vaccination|administration of influenza vaccination
1487598|NCT03061942|Other|Arthroscopic rotator cuff repair without synovectomy|30 subjects will undergo conventional arthroscopic rotator cuff repair without synovectomy.
1487599|NCT03061942|Other|Arthroscopic rotator cuff repair with synovectomy|30 subjects will undergo arthroscopic rotator cuff repair with synovectomy. Synovectomy is an operation performed to remove inflamed synovial membrane of a joint. Arthroscopic synovectomy will be performed with the use of a shaver and a cautery device through the portals for arthroscopic rotator cuff repair.
1487600|NCT03061916|Dietary Supplement|Cinnamon|Cinnamon 20% will be given to participants after baseline collection of saliva
1487601|NCT03061916|Dietary Supplement|Ginger|Ginger 20% will be given to participants after baseline collection of saliva
1487602|NCT03061916|Drug|Chlorhexidine Gluconate|Chlorhexidine Gluconate will be given to participants after baseline collection of saliva
1487603|NCT03061903|Device|Prevena|"Closed Incision Negative Pressure Therapy (bandage over the incision sealed with negative pressure of a vacuum) to be placed on after surgery for 7 days.
Prevena™, by KCI, is currently being used selectively in high-risk patients and a FDA-approved device."
1487604|NCT03061903|Device|Aquacel|"Water resistant, silver-impregnated, antimicrobial hydrofiber dressing that is placed on after surgery for 7 days.
AQUACEL® Ag, by Convatec, is currently the standard of care for postoperative wound dressing and a FDA-approved device."
1487606|NCT03061864|Behavioral|Periviable Birth Plan|
1487607|NCT03061851|Behavioral|conventional treatment|the treatment plan by the investigators according to the patient's condition may be, this study does not interfere.
1487608|NCT03061851|Other|Maltose app|"Weekly diabetes-related science articles.
Patients reported hypoglycemia or other adverse reactions, the competent physician to deal with.
Questionnaires published out the hospital (2 weeks 1), the feedback for the problem.
monitoring of abnormal blood glucose data or the presence of related discomfort, can communicate with the competent physician online.
Personalize the development of diet, exercise program.
different insulin and oral hypoglycemic drug medication time to remind.
hypoglycemic drug side effects query."
1487609|NCT03061838|Drug|MabThera®|1000 mg intravenously
1487610|NCT03061838|Drug|Ritumax®|1000 mg intravenously
1487611|NCT03061825|Device|Zenith Alpha™ Abdominal Endovascular Graft|Zenith Alpha™ Abdominal Endovascular Graft for the treatment of abdominal aortic or aorto-iliac aneurysm.
1487612|NCT03061812|Drug|Rovalpituzumab tesirine|Administered on Day 1 via intravenous infusion in a 42-day cycle for 2 cycles.
1487613|NCT03061812|Drug|Topotecan|Administered on Day 1-5 via intravenous infusion in a 21-day cycle.
1487614|NCT03061799|Dietary Supplement|HPC-03|HPC-03 is extracts of danggui (angelica gigas nakai), taeunggung (cnidium rhizome), and broilers (cinnamon bark).
1487615|NCT03061799|Dietary Supplement|Placebo|Placebo is constituted of crystalline cellulose(50.5%), corn starch(33.10%), caramel color(1.90%), anhydrous citric acid(1.25%), silicon dioxide(1.90%), carboxymethylcellulose calcium(6.25%), magnesium stearate(2.50%), and coater (3.10%).
1487616|NCT03061773|Other|Exercise|Physical training: The combined training program consisted of 12-week aerobic, resistive and flexibility exercises, with 3 sessions per week of aerobic and resistive training in the same session (supervised by physical exercise coaches) and 2 sessions per week of Flexibility training (unsupervised). As stretching sessions were interspersed with sessions of aerobic and weathered training in the daytime period.
1487617|NCT03061773|Behavioral|Conventional hospital treatment|Conventional hospital treatment: The patients did not perform physical training
1487618|NCT03061760|Procedure|Radical prostatectomy|Radical prostatectomy due to prostate cancer.
1487619|NCT03061760|Diagnostic Test|Initial evaluation|Questioners, Ultrasound, Uroflowmetry
1487620|NCT03061760|Diagnostic Test|Evaluation after 1,3,6,9,12 months|Questioners, Ultrasound, Uroflowmetry
1487621|NCT03061747|Device|Assesment of outcome of implantable device patients|Evaluation during follow-up of the occurrence of atrial arrhythmias, hospitalizations, and of death.
1487627|NCT03061721|Drug|Saroglitazar magnesium 1 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 1 mg tablet orally once daily for 16 weeks.
1487628|NCT03061721|Drug|Saroglitazar magnesium 2 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 2 mg tablet orally once daily for 16 weeks.
1487629|NCT03061721|Drug|Saroglitazar magnesium 4 mg|Patients randomly assigned to this group will receive Saroglitazar magnesium 4 mg tablet orally once daily for 16 weeks.
1487630|NCT03061721|Drug|Placebos|Patients randomly assigned to this group will receive placebo tablet orally once daily for 16 weeks.
1487631|NCT03061708|Drug|AZD2014|mTOR inhibitor
1487632|NCT03061682|Device|"Scharioth macula lens A45sml/A45smy"|Implantation of an add on intraocular lens to low vision patients
1487633|NCT03061656|Drug|Cyclophosphamide|1st HDCT
1487634|NCT03061656|Drug|Carboplatin|1st HDCT
1487635|NCT03061656|Drug|Etoposide|1st HDCT
1487636|NCT03061656|Radiation|131I-MIBG|2nd HDCT
1487637|NCT03061656|Drug|Thiotepa|2nd HDCT
1487638|NCT03061656|Drug|Melphalan|2nd HDCT
1487639|NCT03061643|Drug|Docetaxel|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
1487640|NCT03061643|Other|Androgen-Deprivation Therapy (ADT)|docetaxel 40 mg/m2 IV every 2 weeks plus ADT
1487641|NCT03061630|Drug|Gemcitabine|D1.8.15 : GEMCITABINE 1000MG/M2
1487642|NCT03061630|Drug|Cisplatin|D1: CISPLATIN 60G/M2
1487643|NCT03061617|Other|VCV mode|set fixed 6ml/kg tide volume
1487644|NCT03061617|Other|PCV mode|adjust pressure to achieve tide volume of 6ml/kg
1487645|NCT03061604|Device|Hemospray|Hemospray is a novel hemostatic powder licensed for endoscopic hemostasis of non-variceal upper gastrointestinal bleeding which has been shown to be effective in preliminary studies for the management of patients with peptic ulcer bleeding, including those on anticoagulant or antithrombotic therapy . Recently, two case reports and a pilot study reported that hemostatic powder may be useful in emergency management of variceal bleeding as a bridge towards more definitive therapy
1487646|NCT03061604|Drug|Octreotide|"Octreotide will be administered to all patients at time of admission and will be continued for 24 hours
• Dosage: 50 mcg bolus at admission then 25 mcg/hour"
1487647|NCT03061604|Biological|Blood transfusion|Blood transfusion will be administered to all patients if needed
1487648|NCT03061604|Drug|Ceftriaxone|Ceftriaxone will be administered to all patients on daily basis
1487649|NCT03061591|Dietary Supplement|Wholistic Turmeric capsules|Oral capsules of wholistic Turmeric capsules (Pukka herbs) curcumin (each capsule 0.5100 m gr curcumin) for a total of 4 gr/d divided twice daily.
1487650|NCT03061591|Other|Placebo|Placebo capsules
1487651|NCT03061578|Diagnostic Test|Tear Film Imager|Ocular surface imaging assessment by the Tear Film Imager (TFI)
1487652|NCT03061578|Diagnostic Test|Low Humidity Environmental Exposure Chamber (LH-EEC)|Subjects will enter the LH-EEC (<15% relative humidity (RH), temperature 22±5ºC, and 5±3ft/s directed air flow velocity) and remain for approximately 120 min.
1487653|NCT03061565|Drug|erythropoietin|Patients were given erythropoietin during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
1487687|NCT03061266|Behavioral|E-health Education|E-health education on shared care program will be established by different type's professionals including diabetes physicians, pharmacists, dietitians and diabetes health teacher.
1487654|NCT03061565|Drug|Placebos|Patients were given placebo during the EPO-TBI study in 2010-2014. In the current follow-up we will evaluate any possible long term differences between patients treated with etrythropoietin compared to placebo.
1487655|NCT03061552|Diagnostic Test|sonographic measurement of inferior vena cava diameter|pre-dialysis measurement of inferior vena cava diameter using echocardiography
1487656|NCT03061539|Drug|Nivolumab & Ipilimumab|"Nivolumab 1 mg/kg + ipilimumab 3 mg/kg every three weeks for a maximum of 4 doses.
6 week gap after last combination dose.
480 mg flat dose of nivolumab every 4 weeks for up to one year, or until progression, unacceptable toxicity or withdrawal of consent."
1487657|NCT03061526|Other|optical coherence tomography|measurement of reflectivity in different retinal layers based on optical coherence tomography findings
1487658|NCT03061513|Drug|Ubiquinol|Ubiquinol caplets 600mg/day
1487659|NCT03061513|Dietary Supplement|Placebo|placebo
1487660|NCT03061487|Procedure|Open Surgical Treatment of Aneurysm (Aneurysmectomy)|Aneurysmectomy is a surgical procedure in which a localized, dilated, weakened section of an artery (aneurysm) is removed (resected). The artery is either replaced with a synthetic graft, as seen in an aneurysm in the chest (thoracic aneurysm), abdomen (abdominal aneurysm) or leg (femoral or popliteal aneurysm).
1487663|NCT03061461|Device|rESWT|"All patients will receive standard care as follows:
Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.
The clean wounds will be assessed using the TIME concept.
Treatment with rESWT.
Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin, Smith & Nephew, Inc. Advanced Wound Management; Fort Worth, TX, USA).
In addition, patients in arm rESWT will receive rESWT between Steps 2 and 3 of standard care as outlined in arm description rESWT."
1487664|NCT03061461|Device|Sham rESWT|"All patients will receive standard care as follows:
Wounds will be cleaned with distilled water and applied with collagen gel or collagen sheet on the wound and then closed with foam/gauze or gamgee.
The clean wounds will be assessed using the TIME concept.
Treatment with sham rESWT.
Subsequently the wounds will be cleansed with distilled water, and collagen and glycerine gel will be applied and covered with adhesive dressings (Melolin).
In addition, patients in arm Sham rESWT will receive sham rESWT between Steps 2 and 3 of standard care as outlined in arm description Sham rESWT."
1487665|NCT03061448|Behavioral|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into eight modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
1487666|NCT03061435|Procedure|Screening anal Pap smear - No high-resolution anoscopy|75% of patients with negative cytology on their anal Pap smear will not receive high-resolution anoscopy
1487667|NCT03061435|Procedure|Screening anal Pap smear - High-resolution anoscopy|25% of patients with negative cytology on their anal Pap smear will receive high-resolution anoscopy. All patients with positive (abnormal) cytology on their anal Pap smear will receive high-resolution anoscopy.
1487668|NCT03061422|Other|Xylitol|caries prevention chewing gum
1487669|NCT03061422|Other|xylitol with bicarbonate|caries prevention chewing gum
1487670|NCT03061422|Other|paraffin|chewing gum
1487671|NCT03061409|Dietary Supplement|Pharmavite Nature Made Multi for Him 50+|To examine whether one tablet a day of Pharmavite Nature Made Multi for Him 50+ will increase micro-nutrient status in older people taking multiple medications as compared to placebo
1487672|NCT03061409|Dietary Supplement|Placebo|served as placebo
1487673|NCT03061396|Other|Matching points PC6+CV12|Choose both Neiguan(PC6) and Zhongwan point(CV12).The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
1487674|NCT03061396|Other|Single points PC6|Choose Neiguan(PC6)of double upper limb.The needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a electrode.Frequency is 2/10 hertz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10 milliampere. And plus 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron，Granisetron or Ondansetron) and dexamethasone.
1487675|NCT03061383|Other|8% Arginine based toothpaste|toothpaste
1487676|NCT03061383|Other|8% strontium acetate based toothpaste|toothpaste
1487677|NCT03061383|Other|placebo|toothpaste
1487678|NCT03061370|Procedure|Esophagectomy or Gastrectomy|Surgical resection
1487679|NCT03061357|Behavioral|Activity tracker|Misfit Flash (Misfit Wearables Co., Burlingame, CA) activity tracker
1487680|NCT03061344|Biological|DVIU treated with liquid buccal mucosal graft|DVIU treated with liquid buccal mucosal graft; internal urethrotomy for urethral stricture followed by injection of morcellated buccal mucosal graft mixed with fibrin glue (Tisseel, Baxter)
1487681|NCT03061331|Drug|LUM/IVA|LUM 400 mg/IVA 250 mg every 12 hours (q12h)
1487682|NCT03061331|Drug|Placebo|No Active Drug
1487683|NCT03061292|Procedure|Pectoral Nerve Block|
1487684|NCT03061292|Procedure|Without Pectoral Nerve Block|
1487685|NCT03061279|Device|Fixation by Acutrak headless screw|The fixation provided by the Acutrak headless compression screws provide sufficient fixation to achieve union and a favorable clinical outcome in both horizontal and vertical medial malleolus fractures when compared to bicortical and unicortical screw fixation, tension band wiring, and mini-fragment or buttress plating
1487686|NCT03061279|Device|Fixation by headed screws, plates, and or wires|DePuy-Synthes Cannulated Cancellous Screws, DePuy-Synthes Cancellous Screws, DePuy-Synthes Cortical Screws, DePuy-Synthes 1/3 Tubular Plate, DePuy-Synthes Locking contrast dynamic compression (LC-DCP) Plate, DePuy-Synthes Pre-contoured Plate, and/or 18g Wire are the alternative methods of treatment of medial malleolus fracture.
1487688|NCT03061266|Other|Routine care|Routine care on shared care program as advised by clinical professionals, which included medications, dietary control and general physical activities.
1487689|NCT03061253|Other|Electronic Cigarette and behavioural change support.|The nicotine strength of Group A (nicotine-inclusive e-cigarettes) cartridges will be 18 mg/ml of nicotine strength. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
1487690|NCT03061253|Other|Nicotine-Free Electronic Cigarette and behavioural change support.|Group B participants will receive nicotine-free cartridges for the period of the intervention. All participants will receive up to 6 behavioural change support sessions over the 3-month intervention period.
1487691|NCT03061253|Other|Nicotine Replacement Therapy and behavioural change support.|Group C participants will be referred to smoking cessation services where they will be expected to receive Nicotine Replacement Therapy and up to 6 behavioural change support sessions over the 3-month intervention period, as per current guidelines.
1487692|NCT03061240|Device|Smart pain assessment tool|We record and analyze multiple bio-signals from post-operative patients in the attempt to evaluate their experienced pain.
1487693|NCT03061227|Drug|Intravenous glucagon|Randomized application of glucagon or saline during oral glucose tolerance test
1487694|NCT03061227|Drug|Intravenous saline|Randomized application of glucagon or saline during oral glucose tolerance test
2001272|NCT03109444|Diagnostic Test|Hip Ultrasound|Both hips will be examined. The diagnostic examination for developmental dysplasia of the hip (DDH) incorporates 2 orthogonal planes: a coronal view in the standard plane at rest and a transverse view of the flexed hip at rest. It is acceptable to perform the examination with the infant in a supine or a lateral decubitus position. The anatomic coronal plane is approximately parallel to the posterior skin surface of an infant. The imaging plane is through the deepest part of the acetabulum (which includes visualization of the triradiate cartilage and the ischium posteriorly), the resulting image will be a coronal view in the standard plane. The standard plane is defined by identifying a straight iliac line, the tip of the acetabular labrum, and the transition from the os ilium to the triradiate cartilage. Acetabular morphology is assessed in this view and may be validated by measuring the acetabular alpha angle (≥60°). The femoral head coverage by the bony acetabulum should be >50%.
2001273|NCT03105947|Other|Coconut oil|50g extravirgin coconut oil daily for four weeks
2001274|NCT03105947|Other|Butter|50g butter daily for four weeks
2001275|NCT03105947|Other|Olive oil|50g extra virgin olive oil daily for four weeks
1487702|NCT03061188|Other|Laboratory Biomarker Analysis|Correlative studies
1487703|NCT03061188|Biological|Nivolumab|Given IV
1487704|NCT03061188|Other|Pharmacological Study|Correlative studies
1487705|NCT03061188|Drug|Veliparib|Given PO
1487706|NCT03061175|Other|Internet-Based Intervention|Receive web-based CPM-DA
1487707|NCT03061175|Other|Laboratory Biomarker Analysis|Correlative studies
1487708|NCT03061175|Other|Survey Administration|Ancillary studies
1487709|NCT03061162|Radiation|pulsed low dose rate radiation therapy|Pulsed low dose rate 3-dimensional conformal radiation therapy
1487710|NCT03061149|Other|Low-level laser therapy|
1487711|NCT03061149|Other|Ultrasound treatment|
1487712|NCT03061136|Drug|Clonazepam|
1487713|NCT03061136|Drug|Placebo|
1487714|NCT03061123|Other|Questionnaire|
1487717|NCT03061097|Biological|Autologous fecal microbiota transplant|Fecal Microbiota Transplant (FMT) FMT is the process by which processed donor microbiota material is transplanted into recipients, by either upper or lower gastrointestinal delivery. The aim is to reconstitute the normal intestinal microbial flora in recipients. FMT can be administered by either enema or capsule depending on eligibility criteria. In this study, the fecal microbiota preparation will be made from the participant's own stool (autologous FMT).
1487718|NCT03061097|Other|Placebo|Placebo FMT material delivered via enema or capsule.
1487719|NCT03061071|Device|NightBalance Sleep Position Trainer (SPT)|Subject to sleep with the SPT for a 6 week home use period followed by in-lab PSG.
1487720|NCT03061071|Device|Automated Adjusting Positive Airway Pressure (APAP)|Subject to sleep with the APAP for a 6 week home use period followed by in-lab PSG.
1487721|NCT03061058|Drug|Docetaxel|intraperitoneal and/or intravenous
1487722|NCT03061058|Drug|Oxaliplatin|intravenous
1487723|NCT03061058|Drug|Cisplatin|intraperitoneal
1487724|NCT03061058|Drug|Irinotecan|intraperitoneal and/or intravenous
1487725|NCT03061058|Drug|Pemetrexed|intraperitoneal and/or intravenous
1487726|NCT03061058|Drug|S1|oral
1487727|NCT03061045|Drug|Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Intravenous Powder for Suspension [LUMASON]|All patients enrolled in this study will undergo contrast enhanced ultrasound examination for assessment of brain perfusion.
1487728|NCT03061032|Drug|Sofosbuvir/Ledipasvir 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 12 weeks.
1487729|NCT03061032|Drug|Sofosbuvir/Ledipasvir plus Ribavirin 12W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 12 weeks.
1487730|NCT03061032|Drug|Sofosbuvir/Ledipasvir 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) for 24 weeks.
1487731|NCT03061032|Drug|Sofosbuvir/Ledipasvir plus Ribavirin 24W|Daily fixed dose combination of Sofosbuvir (400mg)/Ledipasvir (90 mg) plus Daily Ribavirin (1000-1200 mg) for 24 weeks.
1487732|NCT03061019|Procedure|Oral Myofunctional Therapy with exercices|Oral-Motor training of oral muscles (tongue, lips) associated with nasal hygiene with daily repetition of exercices and parental support.
1487733|NCT03061019|Procedure|Oral Myofunctional Therapy with soft oral appliance|Ora-Motor training of oral muscles (tongue, lips) associated with nasal hygiene, with reduced parental support.
1487734|NCT03061006|Drug|Dabigatran Etexilate|150 mg BID (CrCL > 30 mL/min) or 75 mg BID (CrCL > 15 to 30 mL/min); Assessment of kidney function every 6 months.
1487735|NCT03061006|Drug|Warfarin|Dose-adjusted (INR 2.0 - 3.0); Standard warfarin follow-up and education based upon system criteria.
1487736|NCT03060993|Drug|Cannabis|Patients will be administered cannabis (THC/CBD) in vaporized form.
1487737|NCT03060993|Drug|Placebo|Patients will be administered placebo (cannabis stripped of cannabinoids) in vaporized form.
1487741|NCT03060967|Behavioral|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities of food and control images
1487742|NCT03060954|Device|MINI WELL READY ®|BILATERAL IMPLANTATION OF MINI WELL READY®, A PROGRESSIVE EXTENDED DEPTH OF FOCUS INTRAOCULAR LENS IN PATIENTS WITH CATARACT SURGERY
1487743|NCT03060954|Device|FINE VISION®|FINE VISION®, A TRIFOCAL INTRAOCULAR LENS IMPLANTATION IN PATIENTS WITH CATARACT SURGERY
2001276|NCT03104738|Other|25% reduction of basal insulin dose|"Subjects will be instructed to reduce their basal insulin dose to 75% instead of our institutional 50%.
Subject must check their own blood sugar before reporting to the hospital for their surgery. If the value is less than 70 or subjects are having symptoms of hypoglycemia, subjects will be instructed to immediately ingest 4-8 oz of fruit juice (without pulp) and call their doctor or the hospital."
2001277|NCT03104647|Other|VRP-Clinic|Subjects will perform a series of neck movements guided by graphic instructions appearing in the virtual reality environment
2001278|NCT03102580|Other|OA Care Plan|Patient and surgeon will receive the OA Care Plan (currently under development). This Care Plan will inform Shared Decision for treatment of moderate to sever OA, including surgical and non-surgical options.
2001279|NCT03099603|Drug|HTD1801|A small molecular compound for the treatment of primary sclerosing cholangitis
1487749|NCT03060928|Procedure|Arthroscopic Rotator Cuff Repair|Arthroscopic Rotator Cuff Repair
1487750|NCT03060928|Procedure|Micro-perforations|Biological stimulation with micro-perforations
1487751|NCT03060928|Procedure|Artelon®|Biological stimulation with Artelon® Tissue Reinforcement
1487752|NCT03060915|Device|Polysomnography|Patient's undergo a polysomnography
1487753|NCT03060915|Device|Actigraphy|Patient's wear an actigraphy while doing the polysomnography
2001281|NCT03098797|Drug|Elamipretide|40 mg daily subcutaneous injection for 12 weeks
1487755|NCT03060889|Drug|Tranexamic acid|10 mg/kg body weight will be given with induction of anesthesia by intravenous infusion
1487756|NCT03060863|Behavioral|2. Executive Functioning|Interventions will occur in 3 biweekly visits plus technology-based practice. The investigators will use computer-based working memory training to improve Executive Functioning (EF) and will use a working memory training game that has been used with children this age (N-back task).
1487757|NCT03060863|Behavioral|3. Food Bias|The investigators will use attention-bias retraining techniques that have been tested in adults that have children practice approach and avoidance attentional strategies using a joystick and food images (healthy and unhealthy foods). Interventions will occur in 3 biweekly visits. Children in this arm will use a computer-based approach avoidance task to reduce attentional biases for food by using a joystick to push away images of nonhealthy foods and pull closer images of healthy foods.
1487758|NCT03060863|Behavioral|4. Emotion Regulation|Interventions will occur in 3 biweekly visits plus home practice. The investigators will use assisted relaxation training where children are trained to monitor and control their heart rate and skin conductance using biofeedback in a computer-game context (Journey to Wild Divine).
1487759|NCT03060863|Behavioral|5. Future orientation|"Interventions will occur in 3 biweekly visits. Children will participate in an interview protocol designed to enhance their capacity to visualize upcoming future events and describe them in detail, with the goal to make the future become present."
1487760|NCT03060850|Drug|AC0010MA|Participants in the dose escalation cohorts will be treated with AC0010MA every 28 days
2001282|NCT03098511|Diagnostic Test|Neurological Diagnostic Evaluation|"Clinical Data:
Demographic data
Daily data (clinical exams, laboratory data)
Drug administration
Additional clinical or ancillary neurological determination test
Diagnostic Intervention:
CT-Perfusion
CT-Angiography reconstructions
Reference Standard:
- Clinical Neurological Exam
Blood Samples (Pharmacokinetics, Inflammatory & Nanovesicles Parameters):
At the time of patient enrolment
6 hours after patient enrolment
At the time of the clinical neurological exam
Secondary Outcome measures at 6 months:
extended Glasgow Outcome Scale (GOSe)
modified Rankin Scale (mRS)"
2001283|NCT03095300|Procedure|Prone position|Patients are rotated from the supine to the prone position for a period of 2 hours.
2001284|NCT03095066|Drug|AVP-786|oral capsules
2001285|NCT03095066|Drug|Placebo|oral capsules
1487767|NCT03060824|Other|Blood sampling|To explore changes in osmolality during coronary artery bypass grafting surgery with the aid of Cardiopulmonary Bypass by repeated measurements of osmolality and concentration shifts of sodium, glucose and urea in plasma.
1487768|NCT03060798|Drug|Desflurane|general anesthesia using desflurane.
1487769|NCT03060798|Device|Near-infrared spectroscopy monitor|tissue oxygen saturation monitoring combined with vessel occlusion test
1487770|NCT03060785|Drug|Tenofovir Disoproxil Fumarate/Emtricitabine|
1487772|NCT03060759|Device|Light Therapy box|"The light box used for LT (SunRay by The Sunbox Company, Gaithersburg, Maryland, USA) is approximately 15.5 tall x 23 wide x 3.25 deep and is designed to stand on a desk or tabletop. It can be used both in the home or office. The light is delivered at a downward angle to maximize the effectiveness. The box runs on 124 watts and contains full spectrum 5000k 10,000 lux bulbs."
1487773|NCT03060746|Other|Newly Diagnosed|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
1487774|NCT03060733|Other|Post-Therapy|Gastric biopsy tested by composite reference method (CRM) (histology, urease, culture) and stool sample
1487775|NCT03060707|Drug|Rocuronium Bromide|Continuously infuse, or bolus administer rocuronium.
1487776|NCT03060694|Other|diabetes|"a history of diabetes and using anti-diabetic medicines.
fasting serum glucose level greater than 7.1mmol/L, or glycosalyted hemoglobin percentage greater than 6.5%."
1487812|NCT03060395|Dietary Supplement|A2 milk 200|Days 5 and 6: 200 mL A2 milk twice a day
1487813|NCT03060395|Dietary Supplement|A2 milk 250|Days 7 to 14: 250 mL A2 milk twice a day
1487814|NCT03060395|Dietary Supplement|A1/A2 milk 100|Days 1 and 2: 100 mL A1/A2 milk twice a day
1487815|NCT03060395|Dietary Supplement|A1/A2 milk 150|Days 3 and 4: 150 mL A1/A2 milk twice a day
1493104|NCT03020017|Other|Pharmacological Study|Correlative studies
1487777|NCT03060681|Drug|Bupivacaine 0.5% injected in the thoraco-lumber inetrfacial plane block|After attaching basic monitors (ECG, SpO2, NIBP), the patient will take the prone position. Using the superficial probe of the ultrasound machine, the probe will be placed in transversally in midline position at selected level. The spinous process and interspinalis muscles will be identified. The probe was then moved laterally to identify the mulifidus muscle (MF) and the longissimus muscles (LG) where the local anesthetic will be injected. The needle will be advanced under real-time in-plane ultrasound guidance till it reaches the interface between the two muscles then a 1-2 ml of saline will be inserted to confirm needle site. 15 ml of bupivacaine 0.25 will be injected each side.
1487778|NCT03060668|Other|Peptamen intense|Study group will receive a nutritional formula containing 1.0 kcal/ml and 93 g/L of protein
1487779|NCT03060668|Other|Novasource senior|Control group will receive a nutritional formula containing 1.2 kcal/ml and 65 g/L of protein
1487780|NCT03060655|Biological|PLGA-Mg material|The PLGA-Mg material was used to accomplish the fixation of fragments. Then, the clinical outcome was assessed.
1487781|NCT03060655|Biological|titanium alloy|Traditional fixation was titanium alloy. the clinical outcome was assessed.
1487782|NCT03060642|Device|Tethered capsule sponge|Subjects swallow a tethered capsule sponge sampling device, which is then withdrawn through the mouth after an interval of 5 minutes.
1487783|NCT03060642|Device|Electronic nose device|Subjects breathe into the device, which then records an exhaled volatile organic compounds (VOC) signature.
2001286|NCT03093870|Drug|Varlitinib|Varlitinib:300mg, oral tablets, twice daily for 2 weeks, followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
2001287|NCT03093870|Drug|Capecitabine|1000mg/m2, oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
2001288|NCT03093870|Drug|Placebo (for Varlitinib)|oral tablets, twice daily for 2 weeks followed by a 1-week rest period in 3-week cycles. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death
1487787|NCT03060603|Drug|Erythropoietin|Recombinant Human Erythropoietin, three times in a week, until the correction of anemia, approximately two months.
1487788|NCT03060577|Drug|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
1487789|NCT03060577|Drug|Evolocumab|Evolocumab is a fully human monoclonal antibody that inhibits PCSK9.
1487790|NCT03060564|Procedure|tendon graft|JRF Orthopedics Tendon Graft
1487791|NCT03060564|Other|No intervention|No intervention
1487792|NCT03060551|Procedure|Adipose tissue-derived stromal vascular fraction (SVF)|SVF is increasingly recognised as an easily accessible source of regenerative cells with therapeutic potential in ischaemic or autoimmune disease. We aimed to measure for the first time the safety, tolerability and potential efficacy of autologous SVF cells local injections in patients with systemic sclerosis
2001289|NCT03090542|Dietary Supplement|clinoptilolite|randomized, open-label, cross-over study of control vs clinoptilolite with a washout period separating the 2 phases
1487795|NCT03060525|Behavioral|Deaf Weight Wise 2.0|"Deaf Weight Wise 2.0 is a group or individual intervention lead by trained, American Sign Language fluent Deaf counselors, who utilize an existing evidence-based curriculum that emphasizes healthy eating, exercise, and lifestyle components. It is a behavior change intervention that uses motivational interviewing techniques to help participants identify/recognize their own unhealthy behaviors, help individuals build skills that will promote behavior change, and help group members to support each other to make behavior changes. The Curriculum includes group exercise activities (Do It!), experiential learning activities (Try It! such as learning how to read a nutrition label or modify a recipe to make it healthier), and group activities related to food preparation or sampling healthy foods (Taste It!). Self-monitoring using daily food diaries and weekly weigh-ins is also a key component. The intervention also includes a 6-month follow up and maintenance phase."
1487796|NCT03060512|Drug|Polyethylene Glycol 3350|"Polyethylene Glycol 3350, 17 grams of powder to be dissolved in 4 to 8 ounces of water, juice, soda, coffee or tea to be taken once a day.
Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
1487797|NCT03060512|Drug|Movantik|"Movantik 25 mg, 1 tablet taken once a day on an empty stomach at least 1 hour prior to the first meal of the day or 2 hours after the meal.
Bisacodyl 5mg, 1-3 tablets may be taken by subject who does not experience a bowel movement within 72 hours."
1487798|NCT03060486|Device|HYBENX®|"The mixture was then introduced inside the root canal using the pre-dosed syringe for 20 seconds with a sterile paper point with and up and down movement.
Finally, the canal was rinsed with sterile saline water using a syringe with a side-vented 30 G needle."
1487799|NCT03060473|Drug|Azithromycin|Azithromycin 1 gm PO once
1487800|NCT03060473|Drug|Erythromycin|Erythromycin 250 mg IV every 6 hours for 48 hours followed by 500 mg PO every 8 hours for 5 days.
1487801|NCT03060473|Drug|Ampicillin|Ampicillin 2 gm IV every 6 hours for 2 days
1487802|NCT03060473|Drug|Amoxicillin|Amoxicillin 500 mg PO every 8 hours for 5 days
1487803|NCT03060460|Diagnostic Test|Ultrasound guided sheath insertion|ultrasound is used routinely for sheath insertion
1487807|NCT03060434|Drug|Pentoxifylline Oral Tablet|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid; pentoxifylline 400 mg bid
1487808|NCT03060434|Drug|Ibuprofen|patient will receive for 15 days: Ibuprofen 600 mg bid; pregabalin 75 mg bid; paracetamol 1 g tid
1487809|NCT03060421|Device|Aquamid reconstruction|Aquamid Reconstruction is a Polyacrylamide hydrogel that contains 2.5% polyacrylamide and 97.5% non-pyrogenic water, with a unique molecular structure that allows the normal water exchange with the surrounding tissue without losing shape. Aquamid Reconstruction is biocompatible, non-absorbable non-biodegradable, stable, and sterile. T Aquamid Reconstruction is injected into the knee joint cavity.
1487810|NCT03060395|Dietary Supplement|A2 milk 100|Days 1 and 2: 100 mL A2 milk twice a day
1487811|NCT03060395|Dietary Supplement|A2 milk 150|Days 3 and 4: 150 mL A2 milk twice a day
1948914|NCT01158690|Other|resource card|the intervention group receives an envelop with resource card
1487816|NCT03060395|Dietary Supplement|A1/A2 milk 200|Days 5 and 6: 200 mL A1/A2 milk twice a day
1487817|NCT03060395|Dietary Supplement|A1/A2 milk 250|Days 7 to14: 250 mL A1/A2 milk twice a day
1487818|NCT03060382|Device|balanced buttress absorbable spacer|For the patients of study group, a balanced buttress absorbable spacer was placed into the gap after the osteotomy of tibia and fibula to modify the lower limb line.
1487819|NCT03060382|Biological|total knee arthroplasty|Total knee arthroplasty was conducted for the patients of control group
1487820|NCT03060369|Device|CareGuide™ device|CareGuide™ is a minimal risk, non-invasive device that uses near-infrared spectroscopy to measure skeletal muscle oxygen saturation.
1487821|NCT03060356|Biological|T cells modified with RNA anti -cMET CAR|Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains
1487822|NCT03060343|Biological|Zeushield Cytotoxic T Lymphocytes|"Three dose levels will be evaluated. Dose Level One: 1.0×10^5 cells/kg, Dose Level Two: 1.0×10^6 cells/kg, Dose Level Three: 1.0×10^7 cells/kg.
At the discretion of the investigator, if patients with active disease have stable disease or a response at week 8 or on subsequent evaluations, they are eligible to receive up to 6 additional infusions at 8 to 12 week intervals."
1487823|NCT03060330|Procedure|Laparoscopic Ventral Mesh Rectopexy|This group will undergo laparoscopic ventral mesh rectopexy alone
1487824|NCT03060330|Procedure|Laparoscopic Ventral Mesh Rectopexy Combined with Stapled Trans-anal Rectal Resection|This group will undergo laparoscopic ventral mesh rectopexy combined with stapled trans-anal rectal resection
1487825|NCT03060317|Behavioral|Examination with neurological scales.|Coma Recovery Scale, Glasgo Coma Scale, FOUR scale
1487826|NCT03060304|Drug|Tamoxifen|Patients in study group will receive tamoxifen at a daily dose of 40 mg from day 3 to day 8.
1487827|NCT03060304|Drug|estradiol valerate|Patients in control group will receive estradiol valerate at a dose of 3 mg twice per day from day 3.
1487828|NCT03060291|Behavioral|FCU-Online, web/ mobile only|Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior.
1487829|NCT03060291|Behavioral|FCU-Online, web/ mobile + coach|"Participants will be invited to complete the FCU via the FCU-Online website. They will complete an assessment, receive computer-generated feedback, and access to skills units designed to teach parents the importance of using specific parenting skills, provide practice opportunities to try these skills, and tools to track their use of these parenting skills and any associated changes in child behavior. Participants will also have access to a family coach who will motivate parents to enhance parenting skills and provide support while they are learning to use these skills."
1487830|NCT03060278|Behavioral|Self-help materials|Self-help smoking cessation materials.
1487831|NCT03060278|Drug|nicotine patch|Participants who smoke >10 cigarettes per day will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg nicotine patches. Participants who smoke < 10 cigarettes per day will receive 6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches.
1487832|NCT03060278|Other|Smartphone-delivered automated treatment|Tailored video clips, text and graphical messages delivered automatically each week to the participant.
1487833|NCT03060278|Behavioral|Counseling|Proactive phone counseling with a Certified Tobacco Treatment Counselor
1487834|NCT03060265|Drug|Paracetamol|Administrating Paracetamol IV pre-cesarean section
1487835|NCT03060265|Drug|PLACEBO|Administrating SALINE IV pre-cesarean section
1487836|NCT03060239|Other|Near Infrared Spectroscopy|Use of the near-infrared-spectroscopy (NIRS) to explore the cortical mechanism by which this sleep disorder would allow a disappearance of parkinsonian signs at night
1487837|NCT03060226|Diagnostic Test|blood sample|Search of blood predictive marker (s)
1487838|NCT03060213|Behavioral|Fun For Wellness (FFW)|FFW consists of videos, games, and content teaching 14 skills to support seven drivers of change that promote well-being in I COPPE domains. The drivers form the acronym BET I CAN, which stands for: Behaviors, Emotions, Thoughts, Interactions, Context, Awareness, and Next Steps. B teaches basics of habit formation, including antecedents, behaviors, and consequences and techniques like goal setting, behavior tracking and rewards. E teaches how to build positive emotions and cope with negative ones. T teaches lessons from cognitive behavioral therapy. I builds communication skills such as empathy, listening and assertiveness. C teaches how to create healthier environmental contexts. A aims to increase insight. N emphasizes the need to make plans and anticipate barriers.
1487839|NCT03060200|Other|Self-administered online CBT plus therapist check in|The app being tested is comprised of courses, exercises and a behavioural activation component. Courses represent the psycho-educational background of the program, comprising topics such as: information on depression, what is CBT, healthy/unhealthy negative emotions, rational/irrational thoughts, behaviour, social support, relaxation techniques, sleep hygiene, relapse prevention, treatment adherence, and suicide prevention plan. Exercises use the information presented in the courses and follow the structure of a regular therapy session/ therapeutic homework. The following exercises are included in the app: Emotional Pulse, Find Irrational Thoughts, and Change Irrational Thoughts. The behavioural activation component consists in two main exercises: My goals and My Activities.
1487840|NCT03060200|Other|Sham self-administered online CBT plus therapist check in|The active placebo intervention will be delivered via the same platform and largely in the same format as the tested app: it will include the same sections and features as the original app, except for the complete exercises. In addition, the psychoeducation section, although mirroring the structure of the corresponding section in the original app, will include different content, elaborating on common sense psychological well being aspects.
1487841|NCT03060187|Other|KU Score|Exam with a max score of 10 and min score of 0. Designed as a preoperative assessment of the patient's airway.
1487842|NCT03060174|Other|monitoring and non-medical prophylaxis of delirium|
1487843|NCT03060161|Behavioral|Health in the right measure|Nutritional monitoring and individual guidance on regular physical exercise.
1487844|NCT03060148|Device|Medtronic neurostimulation system|Dual leads for spinal cord stimulation will be performed at 90% of the motor threshold for 24 hours/day at 50 Hz and pulse width 0.2 ms
1487930|NCT03059667|Drug|Etoposide|In accordance with the summary of product characteristics.
2001290|NCT03084549|Drug|Administration of Ropivacaïne|Administration of Ropivacaïne in the margins of the episiotomy
2001291|NCT03084549|Drug|Administration of placebo|Administration of placebo in the margins of the episiotomy
1487847|NCT03060122|Device|NIN|The InterX device will be applied by a trained therapist along the course of the dermatomes in the affected area, paying special attention to the location of major cutaneous nerves ensuring optimal treatment points are identified and treated within the neurologically related area.
1487848|NCT03060122|Device|Sham CES|The sham CES is identical to the regular device but ear clips will emit a dose at 100 mA, a sub-sensory level.
1487849|NCT03060122|Device|CES|Cranial Electrical Stimulation (CES) Alpha-Stim is a noninvasive medical treatment device that delivers a microcurrent (100 to 500 microamperes) via ear clip electrodes connected to a handheld device.
1487850|NCT03060109|Other|Blood draw within 12 hours of injury|
1487851|NCT03060096|Other|Severe Anxiety/depression: High Intensity Stepped Care|The stepped-care Telehealth high intensity intervention is tailored to participants with severe anxiety and depression. Ppts randomized to this group will have 12 weekly psychotherapy sessions delivered by phone with a licensed therapist. Participants will also receive a CBT (cognitive behavioral therapy) workbook including daily exercises to supplement understanding.
1487852|NCT03060096|Other|Moderate Anxiety/depression: Low Intensity Stepped care|The stepped care Telehealth low intensity intervention is tailored to participants with moderate anxiety and depression. Ppts randomized to this group will receive a self-guided CBT workbook and biweekly (every 2 weeks) check-in calls from a research staff person to assess changes in symptom severity and need for treatment/support.
1487853|NCT03060096|Other|Moderate Anxiety/depression: Enhanced Usual Care Control|"Participants with moderate anxiety/depression that are randomized to EUC will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study."
1487854|NCT03060096|Other|Severe Anxiety/depression: Enhanced Usual Care Control Group|"Participants with severe anxiety/depression that are randomized to EUC will receive information about referrals/resources in their local area (support groups, mental health providers), NCI materials (Facing Forward: Life after Cancer Treatment, self-help workbooks, copy of the CBT (cognitive behavioral therapy) workbook on completion of the study."
1487855|NCT03060083|Other|Very low nicotine content (VLNC) cigarettes and nicotine replacement therapy (NRT)|Participants will switch to very low nicotine content (VLNC) cigarettes with the aid of nicotine replacement therapy (NRT)
1487856|NCT03060083|Other|Reduce cigarettes per day (CPD) with nicotine replacement therapy (NRT)|Participants will reduce cigarettes per day (CPD) with the aid of nicotine replacement therapy (NRT)
1487857|NCT03060070|Drug|Ketamine|Ketamine at a dose of 0.5mg/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
1487858|NCT03060070|Drug|dexmedetomidine|dexmedetomidine at a dose of 1ug/kg will be added to bupivacaine 0.25 (total volume 20ml) in each side using sonar guided TAP block
1487859|NCT03060070|Drug|control group|20ml of 0.25% bupivacaine will be injected in each side of the TAP block
1487860|NCT03060057|Device|U2 Knee™ System|The United U2 Knee™ System consists of several components and for this clinical evaluation it includes the (1) Femoral Component, (2) Tibial Insert, 3) Tibial Baseplate, and the 4) Patella.
1487861|NCT03060044|Drug|Salmeterol/fluticasone Easyhaler|
1487862|NCT03060044|Drug|Salmeterol/fluticasone Easyhaler with charcoal|
1487863|NCT03060044|Drug|Seretide Diskus|
1487864|NCT03060044|Drug|Seretide Diskus with charcoal|
1487865|NCT03060031|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 45 minutes prior to pain tasks.
1487866|NCT03060031|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 45 minutes prior to pain tasks
1487867|NCT03060018|Device|Sentec (SenTec) Digital Monitoring System with OxiVenT Sensor|The sensor will be attached to four anatomical positions (thoracic left and right; abdominal left and right), starting with the left thoracic position followed by 4-hourly clockwise position rotation. In case of severe oedema, the ear lobes will be used as anatomical measurement sites and changes to the contralateral ear lobe are made every 4 hours.
1487868|NCT03060005|Drug|Tears Naturale Forte|This medication is used to relieve dry, irritated eyes
1487869|NCT03060005|Drug|liposic|Liposic eye gel contain the active ingredient carbomer, which is a type of medicine known as an eye lubricant. It is used for the treatment of the symptoms of dry eye.
1487870|NCT03059992|Drug|SCY-078|Experimental Study Drug
1487871|NCT03059979|Drug|Methylprednisolone|methylprednisolone 1000 mg dissolved in 100 cc of NaCl 0.9%, by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
1487872|NCT03059979|Other|sodium chloride|100 cc of NaCl 0,9% , administered by intravenous infusion in 30 minutes on three consecutive days Three-day treatment courses are given at week 0, week 4 and week 8.
1487873|NCT03059966|Procedure|Microsurgery technique for root coverage|Microsurgery technique for root coverage adapted for macrosurgery
1487874|NCT03059966|Biological|Microsurgery technique for root coverage associated to EMD|Microsurgery technique for root coverage adapted for macrosurgery associated to Enamel Matrix Derivative
1487875|NCT03059940|Behavioral|Questionnaires|Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
1487876|NCT03059940|Procedure|Low Dose Computed Tomography Scan|Participants have a CT scan of chest to look for signs of lung cancer.
1487877|NCT03059940|Other|Shared Decision Making + Video|Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
1487878|NCT03059940|Behavioral|Cessation Counseling|Brief cessation counseling given by LDCT provider.
1487879|NCT03059940|Behavioral|Quitline|Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
1487931|NCT03059654|Procedure|tracheostomy|
1488310|NCT03056742|Biological|Stempeucel(R)|Ex vivo cultured adult bone marrow derived allogeneic mesenchymal stem cells
1487880|NCT03059940|Behavioral|Pharmacotherapy Discussion|Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
1487881|NCT03059940|Drug|Nicotine Patch|Nicotine patch dispensed. Dosing at physician's discretion.
1487882|NCT03059940|Drug|Anti-Smoking Drug|Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
1487883|NCT03059940|Behavioral|Tobacco Treatment Program|Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
1487884|NCT03059940|Other|Carbon Monoxide (CO) Level Test|Participant asked to blow air through a CO-measuring device.
1487885|NCT03059927|Procedure|Knee arthroplasty, Cruciate retaining|Legion total knee arthroplasty implant component, Smith & Nephew, Cruciate Retaining design
1487886|NCT03059927|Procedure|Knee arthroplasty, Anterior stabilized|Legion total knee arthroplasty implant component, Smith & Nephew, Anterior Stabilized design
1487887|NCT03059927|Procedure|Knee arthroplasty, Posterior stabilized|Legion total knee arthroplasty implant component, Smith & Nephew, Posterior Stabilized design
1487888|NCT03059914|Device|InterOss|Anorganic bovine bone mineral - Xenograft
1487889|NCT03059914|Device|Bio-oss|Anorganic bovine bone mineral ( Xenograft)
1487890|NCT03059901|Other|Caminamos App|Mobile phone that encourages Latina women to walk together through social support.
1487891|NCT03059888|Drug|Abatacept Injection|Subcutaneous administration of abatacept
1487892|NCT03059875|Behavioral|Medical consultation for a Standardized Geriatric Evaluation|
1487893|NCT03059862|Dietary Supplement|L-tryptophan|3 g/day of L-tryptophan added to the standardized low-tryptophan diet. Duration: 3 weeks.
1487894|NCT03059862|Dietary Supplement|Placebo|A placebo will be added to the standardized low-tryptophan diet. Duration: 3 weeks.
1487895|NCT03059849|Drug|Adalimumab|Dose of adalimumab will be increased by 40mg every 2 weeks.
1487896|NCT03059836|Dietary Supplement|n3 PUFA-enriched fish oil|3000mg of Eicosapentaenoic acid per day and 1800mg of Docosahexaenoic acid per day
1487897|NCT03059836|Dietary Supplement|Placebo|Organic Sunflower Oil 5000mg per day
1487898|NCT03059823|Drug|MGA012|Anti-PD-1 monoclonal antibody
1487899|NCT03058718|Other|Procalcitonin|The application of antimicrobial agents is determined by PCT results.
1487900|NCT03058718|Other|Clinical Experience|The application of antimicrobial agents is determined by clinical experience of doctors.
1487901|NCT03058705|Drug|Hexaminolevulinate HCL|Intravesical instillation of 100 mg hexaminolevulinate HCL will be performed via foley catheter at the initiation of the procedure. Although NIRF is more sensitive than bluelight cystoscopy, the current FDA approved dose will be used. Hexaminolevulinate has a favorable safety profile at this dose.
1487902|NCT03058705|Device|Near Infrared Fluorescence (NIRF)|NIRF is a highly sensitive multi-spectral imaging modality that speeds the detection of bladder cancer fluorescence after infusion of hexaminolevinulate.
1948915|NCT01158690|Other|no resource card|the control group receives an envelop without resource card
1487908|NCT03058666|Drug|Aerosolized Calfactant|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
1487909|NCT03058666|Device|Solarys|Aerosolization of Infasurf at 6ml/kg via the modified Solarys aerosol generator.
1487910|NCT03058653|Procedure|Small fluid boluses of 50 ml|Participants will receive small 50ml boluses of fluid up to 250ml in total. The remainder will be given as infusion pump method at a rate of 1000ml/hour which will complete in 15 minutes. In total, the 500ml will be given over 25 minutes.
1487911|NCT03058653|Device|LIDCORapid Monitor|Addition of the LIDCORapid Monitor to measure stroke volume
1487912|NCT03059797|Drug|Anlotinib|Anlotinib p.o. qd
1487913|NCT03059797|Drug|Placebo|Placebo p.o. qd
1487914|NCT03059784|Other|APP-based multifaceted management|Patients after PCI will be regularly given education materials, medication reminders, life-style behaviors instruction through APP. Cardiologists can interact with patients on advice provision and clinical support after discharge through APP.
1487915|NCT03059771|Behavioral|Mobile Enhancement of Motivation (MEMS)|The MEMS group will engage in a goal-setting session and then receive personalized text-messages to support goal attainment.
1487916|NCT03059771|Behavioral|Control|The control group will only engage in a goal-setting session.
1487917|NCT03059758|Other|fMRI|All participants are scanned while evaluating deductive reasoning problems. Their math skill is also assessed.
1487918|NCT03059745|Procedure|Cholecystectomy|Single Port and Multi-Port approaches trans-laparoscopic approaches with or without the use of the daVinci Surgical Robotic System.
1487919|NCT03059732|Other|Treatment|Observe the treatments of gastric cancer in each group
1487920|NCT03059719|Biological|Exenatide injection(Byetta)|
1487921|NCT03059719|Biological|PB-119 injection|
1487922|NCT03059706|Device|RegenoGel-OSP™|intra-articular injection of RegenoGel-OSP™ after arthroscopic surgery
1487923|NCT03059706|Other|saline|intra-articular injection of saline after arthroscopic surgery
1487924|NCT03059693|Drug|HAT1 topical cream|
1487925|NCT03059693|Drug|Vehicle cream|
1487926|NCT03059680|Other|High potassium diet|An increase in consumption of high potassium fruits and vegetables
1487927|NCT03059667|Drug|Atezolizumab|Atezolizumab at 1200 mg IV every 3 weeks
1487928|NCT03059667|Drug|Topotecan|oral 2.3 mg/m² or IV 1.5 mg/m² day 1-4 recommended
1487929|NCT03059667|Drug|Carboplatin|In accordance with the summary of product characteristics.
1493105|NCT03020017|Drug|Targeted Molecular Therapy|Given NU-0129 IV
1487932|NCT03059628|Other|Personalized Normative Feedback|"This PNF technique use information designed to correct normative misperceptions to reduce heavy drinking. Much of the alcohol consumption among college students stems from the fairly widespread perception that one's peers expect regular and sometimes extreme drinking participation (subjective drinking norms). The PNF approach is designed to counter this perception by giving students accurate figures on how much their peers actually drink (actual drinking norms). It also aims to improve students' understanding of alcohol use in general and the firmly established negative outcomes associated with short - and long-term patterns of excessive drinking."
1487933|NCT03059628|Other|Brief Therapeutic Intervention|BTI are brief (typically one session 20-30 mns) and incorporate some or all of the following elements:feedback on the person's alcohol use and any alcohol-related harm; clarification as to what constitutes low risk alcohol consumption; information on the harms associated with risky alcohol use; benefits of reducing intake; motivational enhancement; analysis of high risk situations for drinking and coping strategies; and the development of a personal plan to reduce consumption.
1487934|NCT03059628|Other|Evaluation questionnaire|The patient have to fill the same evaluation questionnaire at J0, M6 and M12
1487935|NCT03059615|Drug|Nerofe|Nerofe is a first-in-class hormone-peptide with cancer suppressive properties. Nerofe is a derivative of the human hormone-peptide Tumor-Cells Apoptosis Factor (TCApF). It contains 14 amino-acids. Binding Nerofe to the T1/ST2 receptor caused a rapid activation both of Caspase 8 and Bcl-2 mediated downstream in proliferating cancer cells.
1487936|NCT03059602|Other|No specific treatment based intervention-health measurement instrument|Caregivers will receive a series of standard health measurement tools/survey from NIH's Patient Reported Outcome Measurement Information System (PROMIS)
1487937|NCT03059576|Other|Chronobiological status of the subjects|"Participation was completely voluntary and not remunerated. The subjects were organized into groups of 5 pairs, and were given an appointment at a university facility located in the city center, where informed consent was signed prior to the procedures indicated below. An informational letter was sent to pre-selected individuals. Later a phone call confirmed their availability.
Temperature rhythm was assessed continuously for 7 days using a temperature sensor and programmed to collect information every 10 min.
Body position and rest-activity rhythm were assessed over the same 7 days using a Acceleration Data Logger that record data every min and placed on the non-dominant arm by means of an elastic band, with its X axis parallel to the humerus bone.
Diet and sleep record were completed over the same week, their sleep schedules and their nutritional status."
1487938|NCT03059563|Drug|Varenicline|Varenicline is an FDA-approved medication to facilitate smoking cessation. it is also a promising candidate to enhance dopamine signaling by upregulating dopamine D2/D3 (type 2) receptors in the striatum and improve cognitive function.
1487939|NCT03059563|Other|Placebo|A placebo containing no active ingredients will be used as a control to assess the effects of varenicline on dopamine D2/D3 receptor availability and cognitive function.
1487940|NCT03059537|Drug|Oral chenodeoxycholic acid stimulation|oral intake of chenodeoxycholic acid to stimulate the ileal bile acid transporter and farnesoid X receptor
1487941|NCT03059511|Drug|Nalbuphine|Opioid Pain Medicine
1487942|NCT03059498|Procedure|Unilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Unilateral. Using Bupivacaine
1487943|NCT03059498|Procedure|Bilateral PECS I and II block|A truncal block called the pectoralis nerve block (PECS I and II block). Bilateral. Using Bupivacaine.
1487944|NCT03059498|Drug|Bupivacaine|Bupivacaine solution 0.25%. At the PECS I site each patient will receive 10 cc of local anesthetic solution, and at the PECS II site an additional 20 cc of local anesthetic solution will be placed.
1487945|NCT03059485|Drug|Durvalumab|It is a monoclonal antibody, which is known to take the brakes off the immune system to restore immunity
1487946|NCT03059485|Biological|DC/AML Fusion Vaccine|The Dendritic Cell Fusion Vaccine is an investigational agent that tries to help the immune system to recognize and fight against cancer cells
1487947|NCT03059485|Other|Observation|Traditional care provided by the hospital.
1487948|NCT03059472|Behavioral|Group 1 (Intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
1487949|NCT03059472|Behavioral|Group 2 (Delayed intervention)|"The investigators will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized delayed intervention trial. They will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 5 intervention and 6 delayed intervention communities. In addition, the investigators will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
1487950|NCT03059446|Drug|Cenicriviroc|Cenicriviroc 150 mg tablet once daily in the morning with food.
1487951|NCT03059433|Other|AVID Intervention|Advancement via Individual Determination (AVID) is a college preparatory program that participating high schools have available to students.
1487952|NCT03059407|Behavioral|Dog therapy only|Canine assisted therapy only during echocardiogram
1487953|NCT03059407|Behavioral|Dog plus standard distraction tech|Canine assisted therapy plus standard distraction techniques during echo
1487954|NCT03059407|Behavioral|Standard distraction techniques only|Standard distraction techniques (such as watching a movie) only during echocardiogram
1487955|NCT03059394|Device|Non intervention study|Test - Retest of measurements
1487956|NCT03059381|Drug|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
1488026|NCT03058939|Drug|FEC|Only administered to patients who received paclitaxel and carboplatin, and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
1493859|NCT03014791|Other|Blood sample & spot urine sample|Core Measurement
1487957|NCT03059368|Device|new bone fixation plate with screw|Fracture ends and injured posterior cruciate ligament will be exposed in twenty patients with tibial avulsion fracture of posterior cruciate ligament of knee through posterior approach. Open reduction will be conducted. The posterior cruciate ligament will be reconstructed with a new bone fixation plate with screw(cancellous bone screw).
1487958|NCT03059355|Biological|UCMSCs|Allogeneic Umbilical Cord Tissue derived MSCs (UCMSCs)
1487959|NCT03059355|Biological|BMMSCs|Bone Marrow derived Mesenchymal Stem Cells (BMMSCs)
1487960|NCT03059355|Other|Placebo|a single administration of placebo delivered via peripheral intravenous infusion.
1487961|NCT03059342|Procedure|single event multilevel surgery|
1487962|NCT03059329|Drug|Fycompa|The usual oral dosage for adults and children 12 years of age or older is initially 2 milligrams (mg) once daily as perampanel at bedtime, and the daily dose may then be increased by 2 mg at intervals of 1 week or longer. The maintenance dose is 8 mg once daily in the absence of concomitant antiepileptic drugs that accelerate the metabolism of this product, or 8 to 12 mg once daily in the presence of such concomitant drugs. The dosage may be increased or decreased as necessary by 2 mg at intervals of 1 week or longer depending on symptoms, but the maximum daily dose should not be over 12 mg.
1487963|NCT03059316|Combination Product|Massimo device|Massimo is a newly introduced device which can measure the peripheral organ perfusion and expressed it as perfusion index(PI).
1487964|NCT03059316|Drug|Nitroglycerin drug|Nitroglycerin is a drug used as an hypotensive agent through its vasodilation effect on veins
1487965|NCT03059316|Drug|Labetalol|Labetalol is an antagonist of adrenergic receptors (a1, b1, b2) which is used as an hypotensive inducer. This drug targets the beta receptors 5 to 10 times more specific than alpha receptors so that minor tachycardia happens
1487966|NCT03059303|Drug|Simeprevir 75 mg|"Part 1: Simeprevir (SMV) 75 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent capsule in Treatment C.
Part 2: SMV 75 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 37.5 mg each), and G (2 tablets of 37.5 mg each), and as a single agent capsule in Treatment C2."
1487967|NCT03059303|Drug|Odalasvir 25 mg|"Part 1: Odalasvir (ODV) 25 mg taken orally as a component of FDC tablet in Treatment A, D and E and as a single agent tablet in Treatment C.
Part 2: ODV 25 mg taken orally as a component of FDC tablet in Treatment A2 and F (2-tablets of 12.5 mg each), and as a single agent tablet in Treatment C2."
1487968|NCT03059303|Drug|Odalasvir 12.5 mg|Part 1: ODV 12.5 mg taken orally as a component of FDC tablet in Treatment B.
1487969|NCT03059303|Drug|Odalasvir 75 mg|Part 2: ODV 75 mg taken orally as a component of FDC tablet (2 tablets of 37.5 mg each) in Treatment G.
1487970|NCT03059303|Drug|AL-335 800 mg|"Part 1: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A, B, D and E and as a single agent tablet in Treatment C.
Part 2: AL-335 800 mg taken orally as a component of FDC tablet in Treatment A2, F (2 tablets of 400 mg each), and G (2 tablets of 400 mg each) and as a single agent tablet in Treatment C2."
1487971|NCT03059303|Drug|Lansoprazole 30 mg|30 mg lansoprazole once daily from Day 1 to Day 5.
1487972|NCT03059303|Drug|Omeprazole 20 mg|20 mg omeprazole once daily from Day 1 to Day 5.
1487973|NCT03059290|Device|neolix file|first file used is C1 file size 25 taper 12% as orifice opener and for coronal flaring for 2/3 of canal length the A1 file size 25 taper 8% in narrow or curved canals if size 10 K file (Mani ,Japan ) is loose or pass easily in the canal , but in case of K-file size 20 loose in the canal so we choose large file size 40 taper 4% either of them to the full working length to the full working length with (X-Smart, Dentsply Maillefer, USA.), with speed 300-500 rpm and torque 1.5 N.cm
1487974|NCT03059277|Drug|Intravitreal Aflibercept|Intravitreal Aflibercept 2mg
1487975|NCT03059264|Other|Natural history|Longitudinal disease progression
1487976|NCT03059251|Biological|Obinutuzumab|Obinutuzumab will be administered as intravenous infusion for 6 cycles (28 days per cycle): 100 milligrams (mg) on day 1 Cycle 1, 900 mg on day 2 Cycle 1, 1000 mg on days 8 and 15 of Cycle 1, and 1000 mg on day 1 of Cycles 2-6.
1487977|NCT03059238|Drug|Celecoxib 200mg oral capsule|
1487978|NCT03059238|Drug|parecoxib sodium|
1487979|NCT03059238|Drug|controlled-release oxycodone|
1487980|NCT03059225|Device|repetitive transcranial magnetic stimulation (rTMS)|undergo 10-min of contralesional 1Hz repetitive transcranial magnetic stimulation(rTMS) or 10-min ipsilesional 5-Hz rTMS for 10 daily sessions
1487981|NCT03059225|Device|Sham stimulation|2-week inhibitory non-dominate hemisphere rTMS program
1487982|NCT03059225|Behavioral|Computer-integrated Speech Training|Computer-integrated Speech Training program for 20 mins
1487983|NCT03059212|Device|rTMS|Device: rTMS 5Hz rTMS over M1 or inferior frontal lobe
1487984|NCT03059212|Device|Sham stimulation|Device: rTMS Sham stimulation over M1 or inferior frontal lobe
1487985|NCT03059199|Behavioral|Single-Arm Feasibility Study|Participants are provided with the HAT TRICK Playbook, a resource manual including weekly healthy eating and physical activity challenges and tracking logs. Each face-to-face session is facilitated by trained research staff, community partners, and health care professionals. Weekly sessions include information on physical activity, healthy eating, and behaviour change techniques (e.g., social support, goal setting, self-monitoring) and include an opportunity to be active/exercise.
1487986|NCT03059186|Behavioral|Gratitude diary|"The intervention involves keeping a record of three things that the individual feels grateful for during that day.
This can be completed daily, and for the purpose of this study will be completed every evening for the duration of one week."
1487987|NCT03059173|Dietary Supplement|Inofolic (r)|Dietary supplement Inofolic containing myo-inositol (0.6 g) and folic acid (0.2 mg) in a same caps Supplementation started on average one month before treatment with Clomiphene citrate and continued throughout cycles of Clomiphene citrate (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle.
1487988|NCT03059173|Drug|Clomiphene Citrate|Clomiphene citrate 50 mg. taking D2 to D6 of each cycle (maximum 9 cycles). Treatment will be delivered during ultrasound visit at D12 of each cycle and the dose will be increased if necessary.
1487989|NCT03059173|Dietary Supplement|placebo|Placebo Dietary supplement containing placebo substance and folic acid (0.2 mg)in a same caps
1487990|NCT03059160|Drug|Tridecanoic Acid|3 times daily oral doze of the drug for 20 weeks with 4 weeks of baseline and 4 weeks of washout
1487991|NCT03059147|Drug|SF1126|SF1126 is a dual PI3 kinase/BRD4 inhibitor small molecule. It will be administered IV twice weekly (900 mg/m2 starting dose with escalation to 1000 mg/m2 per dose and 1100 mg/m2 per dose) at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
1487992|NCT03059134|Drug|Mirabegron 25mg|We compared the therapeutic effects and adverse events (AEs) in overactive bladder (OAB) patients receiving different combination of mirabegron and solifenacin.
1487993|NCT03059108|Procedure|Early Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 4 weeks earlier. The device (dental implant) is of the same type in both groups.
1487994|NCT03059108|Procedure|Conventional Loading|The procedure in this group will consist on placing implant-supported restorations over the implants placed 8 weeks earlier. The device (dental implant) is of the same type in both groups.
1487995|NCT03059095|Behavioral|Yoga & Meditation|Yoga is an ancient Indian science and way of life that includes the practice of specific postures, regulated breathing, and meditation.mindfulness-based stress reduction, an intervention that teaches individuals to attend to the present moment in a nonjudgmental, accepting manner
1487996|NCT03059082|Device|Recovery Navigator on an as needed basis up to 6 months|"This group will undergo contact with Recovery Navigator on an as needed basis up to 6 months and then have a 3 month and 6 month follow-up visit."
1487997|NCT03059082|Device|Recovery Navigator prior to hospital discharge|This group will undergo one interaction with Recovery Navigator prior to hospital discharge and then have a 3 month and 6 month follow-up visit.
1487998|NCT03059082|Other|No interaction with Recovery Navigator|This group will not have any interaction with Recovery Navigator. They will have a 3 month and 6 month follow-up visit.
1487999|NCT03059069|Drug|Chonline Alphoscerate|Patients treated with Chonline Alphoscerate as add on therapy to their medication
1488000|NCT03059069|Drug|Placebo Oral Tablet|Patients maintain their medication with either Gliatamin or placebo for 6 months.
1488001|NCT03059056|Drug|Empagliflozin 25mg|Samples from six, healthy, adult, male, smoking, Egyptian volunteers (age: 22-33 years, Average weight: 77.8 kg, Average BMI: 29.2) will be collected at 0, 0.5, 1, 1.5, 2, 3, 4, 8 and 12 h after administration of Empagliflozin 25 mg
1488002|NCT03059043|Device|viscoelastic-free implantation system|Viscoelastic-free implantation system use balanced salt solution irrigation during the implantation
1488003|NCT03059043|Device|standard viscoelastic-assisted Implantation system|This method utilize the viscoelastic agent to fill and maintain the anterior chamber during the implantation
1488004|NCT03059030|Device|TheraSphere® Yttrium-90 Glass Microspheres, BTG International Inc.|The Interventional Radiologists will inject a dose of Yttrium 90 into your spleen through a small catheter placed in your femoral artery.The entire treatment visit is an outpatient procedure. You will only be admitted to the hospital if the physician deems it necessary due to any symptoms you may experience after the treatment is given. This visit may take 6 to 8 hours.
1488005|NCT03059017|Drug|Salbutamol Sulphate|salbutamol sulphate packaged as aerosol
1488006|NCT03059017|Drug|Niosomes|Niosomes
1488007|NCT03059004|Behavioral|TeMPO Home Exercise Program|This exercise program includes quadriceps, gluteus medius, gluteus maximus, and core exercises. The program includes a DVD and multi-page instruction pamphlet.
1488008|NCT03059004|Behavioral|Motivational SMS Messages|The motivational SMS messages will be sent three times per week encouraging participants to complete their exercises.
1488009|NCT03059004|Behavioral|In-Clinic Topical Therapy|Subjects will be assigned to a physical therapist and will attend 16 in-clinic topical therapy sessions. Sessions will include application of ultrasound, gel, and manual therapy.
1488010|NCT03059004|Behavioral|In-Clinic Exercise Therapy|Subjects will be assigned to a physical therapist and will attend 16 in-clinic exercise and manual therapy sessions. Sessions will include the same exercises from the Home Exercise Program but the in-clinic therapy setting will allow for more personalization.
1488011|NCT03058991|Behavioral|Distress Tolerance Intervention|See arm/group description.
1488012|NCT03058991|Behavioral|Working Memory Intervention|See arm/group description.
1488013|NCT03058991|Behavioral|Control Informational Intervention|See arm/group description.
1488014|NCT03058978|Device|Etonogestrel Implant|Ovarian function will be assessed with weekly serum progesterone levels. Participants will undergo weekly venipuncture for a total of four draws over a 30 day period. Participants will also complete a bleeding diary to assess daily bleeding patterns for the 30 day study period.
1488015|NCT03058965|Drug|[18F]MNI-958|Subjects will undergo PET imaging using [18F]MNI-958, a PET radioligand for imaging tau.
1488016|NCT03058965|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-958.
1488017|NCT03058965|Drug|DaTscan|DaTscan SPECT imaging will be completed in those PSP subjects who have not previously had DATScan imaging as part of the screening procedures.
1488018|NCT03058952|Behavioral|Mindfulness-Based Stress Reduction|An 8-week standardized group program to teach mindfulness skills. In MBSR, participants meet for 2.5 hours per week for 8 weeks in a group format. Participants receive instruction in mindfulness meditation according to a standardized curriculum and have the opportunity to ask questions.
1488019|NCT03058952|Behavioral|Chronic Disease Self-Management Program|The CDSMP is a structured program to teach self-management skills based on self-efficacy theory. CDSMP teaches self-management strategies and attempts to modify illness beliefs, enhance self-management capabilities and reinforce successful management strategies. CDSMP is based on self-efficacy theory, which posits that key determinants of behavior are: 1). self-efficacy (confidence in the ability to carry out an action) and 2). outcome expectancy (expectation that a particular goal will be achieved).
1488020|NCT03058939|Drug|Paclitaxel|Administered to all patients for a minimum of 8 doses with a possible maximum of 16 doses.
1488021|NCT03058939|Drug|Perjeta|Only administered to patients with HER2-positive disease.
1488022|NCT03058939|Drug|Herceptin SC|Only administered to patients with HER2-positive disease.
1488023|NCT03058939|Drug|Tamoxifen|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
1488024|NCT03058939|Drug|Letrozole|Only administered to hormone-receptor positive patients. Patients will receive tamoxifen or letrozole.
1488025|NCT03058939|Drug|LHRH agonist|Administered to all premenopausal patients.
1488027|NCT03058939|Drug|Carboplatin|Only administered to patients who receive paclitaxel and were assessed as having poor response (defined as stable disease or progressive disease or partial response inoperable).
1488028|NCT03058926|Other|Data Management and Monitoring|"Clinical Research Support Center's Data Management and Multicenter Study Support (MCSS) teams responsible for monitoring protocol and regulatory compliance for all consortium studies.
MCSS responsible for maintaining and tracking IRB approval and regulatory documents from each site throughout the life of the study."
1488029|NCT03058900|Drug|Fecal microbiota transplantation (FMT)|One fecal microbiota transplantation is performed at baseline using gastroscopic guidance. The transplant consists of 50 g feces obtained from a healthy non-related donor. The donor feces is suspended into NaCl (0.9%) and glycerol (10%), and will be stored at minus 80 degrees celsius until use. The total volume of the suspension is 250 mL and its temperature will be 37 degrees celsius when infused into the small intestine of the recipient.
1488030|NCT03058900|Other|Drug: Placebo (saline)|One identical appearing sham procedure is performed at baseline using gastroscopic guidance. 250 mL saline (NaCl 0.9%) is infused into the small intestine of the recipient.
1488031|NCT03058900|Drug|Methotrexate (MTX)|Weekly s.c. methotrexate in maximum tolerable dosis
1488032|NCT03058887|Other|Exercise intervention - Cycling|The patients that will be randomly allocated to the exercise group - cycling will be requested to perform an exercise session on a cycle ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
1488033|NCT03058887|Other|Exercise intervention - arm cranking|The patients that will be randomly allocated to the exercise group - arm cranking will be requested to perform an exercise session on an arm crank ergometer. Each training will be consisted of high intensity interval training for 30 minutes (30s 100% PPO/ 30s passive recovery) twice per week for 3 months. Patients will perform two visits for the baseline measurements prior the exercise intervention by repeating them at the end of the exercise intervention (follow up measurements).
1488034|NCT03058874|Device|Extra-vascular lung water measurements by ultrasound|Lung congestion measured by lung ultrasound (US-B lines) to guide dry-weight probing and UF intensification
1488035|NCT03058874|Other|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
1488037|NCT03058848|Dietary Supplement|PKU Start|"PKU Start is a powdered, phenylalanine-free, infant formula, containing essential and non-essential amino acids, carbohydrate, fat, vitamins, minerals, trace elements and long chain polyunsaturated fatty acids (LCPs); Arachidonic acid (AA) and Docosahexaenoic acid (DHA). It is suitable for use from birth.
The recommended amount of the product for each participant will be determined and prescribed by a dietitian."
1488038|NCT03058835|Drug|tenofovir disoproxil and emtricitabine|Pre-exposure Prophylaxis with Truvada will be distributed to all participants eligible to receive PrEP.
1488039|NCT03058822|Drug|BMS-931699|
1488040|NCT03058809|Device|Oncopheresis|Oncopheresis is a type of apheresis incorporating an extracorporeal blood circuit and a filter to separate circulating tumor cells from normal blood components.
1488041|NCT03058796|Device|Neuromuscular electrical stimulation (NMES)|The use of electrical current to activate paretic muscles through surface electrodes.
1488042|NCT03058796|Device|Hand Therapy Video Games|The use of video games with NMES to encourage therapeutic hand movement at home
1488043|NCT03058783|Drug|IDP-124 Lotion|Lotion
1488044|NCT03058783|Drug|IDP-124 Vehicle Lotion|Lotion
1488045|NCT03058770|Other|Sensorimotor retraining|Subjects will receive education regarding sensation and sensory retraining; practice in detection and localization of touch and in discrimination of hardness, texture and temperature in sitting and standing with vision obscured; proprioception training; and practice of these sensations in functional activities.
1488046|NCT03058770|Other|Relaxation technique|Subjects will perform guided relaxation by using the Jacobson technique.
1488047|NCT03058757|Drug|neoadjuvant intravesical mitomycin-C 40mg/20ml instillation|"Intravesical mitomycin-C 40mg/20ml instillation
one day before surgery
four hours before surgery"
1488048|NCT03058744|Drug|IDP-118 Lotion|Lotion
1488049|NCT03058744|Drug|HP Monad Lotion|Lotion
1488050|NCT03058744|Drug|Ultravate Cream|Cream
1488051|NCT03058744|Drug|Tazorac Cream|Cream
2001295|NCT03085641|Device|Nasal high flow oxygen therapy|nHFT will be titrated during a first titration night and used at home during the night for 4 weeks consecutively
2001296|NCT03084471|Biological|MEDI4736 (Durvalumab)|A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).
1488054|NCT03058640|Other|PKSA karate class|"Participants will attend at least 20/24 PKSA karate classes over a 12 week period, completing standard karate training lessons. Participants will also be encouraged to practice on their own at home.
• Participants must attend at LEAST 20/24 classes"
2001297|NCT03084471|Biological|MEDI4736 (Durvalumab) + Tremelimumab|"Durvalumab: A human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that blocks the interaction of PD-L1 (but not programmed cell death ligand-2) with PD-1 on T cells and CD80 (B7.1) on immune cells (IC).
Tremelimumab: A human immunoglobulin (Ig) G2 mAb that completely blocks the interaction of human CTLA-4 (cluster of differentiation [CD]152) with CD80 and CD86 and increase release of cytokines (interleukin [IL]-2 and interferon [IFN]-γ) from human T cells, peripheral blood mononuclear cells and whole blood."
1488059|NCT03058588|Genetic|Analysis with molecular biology|Molecular screening by next generation sequencing (NGS) platform, for known and unknown mutations potentially associated with the disease
1488060|NCT03058575|Dietary Supplement|Dietary MACs|"All subjects will have a dose-escalation period when randomized to the active arm that will occur as follows:
Day 1: 1 scoop of product (morning, in the clinic)
Day 2: 1 scoop of product (morning)
Day 3: 2 scoops of product (morning and evening)
Day 4: 2 scoops of product (morning and evening)
Days 5-60: 3 scoops of product (morning, afternoon, evening)
Other Names:
Dietary fiber supplement"
1488061|NCT03058575|Other|Control|No Intervention for 8 weeks
1488062|NCT03058562|Drug|ABX-1431|ABX-1431, capsules, 40 mg in the fasting state
1488063|NCT03058562|Drug|Placebo Comparator|Matching Placebo
1488064|NCT03058562|Drug|ABX-1431|ABX-1431, capsules, 20 mg with a high fat meal
1488065|NCT03058549|Behavioral|Family Expectations|Relationship education and referral services for expectant couples.
1488066|NCT03058536|Device|Arabin Pessary|The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner.
1488067|NCT03058536|Drug|Vaginal Progesterone|Treatment with 400 mg micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
1488068|NCT03058536|Other|Arabin Pessary and Progesterone|Arabin Pessary and Progesterone The cervical pessary will be inserted at the randomization and removed during the 36 week of pregnancy, unless labour occurs sooner. Treatment with 400 mg Micronized progesterone daily, until the day of randomization to 36 weeks of pregnancy.
1488069|NCT03058510|Procedure|Frequency domain optical coherence tomography|OCT is an established medical imaging technique that uses light to capture high-resolution, three-dimensional images of blood vessels
1488070|NCT03058497|Device|Temperature-Controlled Laminar Airflow Device (Airsonett®)|
1488071|NCT03058484|Behavioral|Community Health Worker intervention|The intervention included four integrated components: 1) formal linkage of CHWs to health facilities; 2) CHW-led antiretroviral therapy (ART) adherence counseling; 3) loss to follow-up tracing by CHWs; and 4) distribution of Action Birth Cards (ABCs), a birth planning tool.
1488072|NCT03058471|Drug|Methotrexate|methotrexate arm will be given methotrexate starting at 10 mg weekly to be increased to 25 mg maximum in subsequent visits gradually
1488073|NCT03058471|Drug|NSAID|this arm will be given NSAID to the tolerable full dose with pantoprazole
1488074|NCT03058471|Drug|Steroids|inj. depot methyl prednisolone 80 mg ,2 doses deep intramuscularly given one week apart to all patients who have 5 or more swollen or tender joints
1488075|NCT03058458|Drug|PIN201104|IV or SC administration
1488076|NCT03058458|Drug|Placebo|IV or SC administration
1488077|NCT03058445|Device|Echocardiography|Substernal 4 chamber view obtained, then MMode applied to RA, then 5ml of saline is injected
1488078|NCT03058445|Device|CVC|Injection of 5 ml of saline
1488079|NCT03058432|Radiation|Radiotherapy alone|
1488080|NCT03058432|Radiation|Concurrent chemoradiotherapy|
1488081|NCT03058419|Drug|JNJ-54175446 150 mg|Subjects will receive JNJ-54175446 150 mg capsules orally (1*100 mg + 1*50 mg) under fasted conditions on Day 7, 9, 10 and 11.
1488082|NCT03058419|Drug|JNJ-54175446 600 mg|Subjects will receive JNJ-54175446 600 mg (6*100 mg capsules) orally on Day 8.
1488083|NCT03058419|Drug|Midazolam 2 mg|Subjects will receive midazolam 2 mg oral emulsion [2 (milligram per milliliter (mg/mL)] as a drug cocktail on Day 1, 7 and 11.
1488084|NCT03058419|Drug|Warfarin 10 mg|Subjects will receive warfarin 10 mg tablets (2*5 mg) orally as a drug cocktail on Day 1, 7 and 11.
1488085|NCT03058419|Drug|Caffeine 50 mg|Subjects will receive caffeine 50 mg tablet (1*50 mg) orally as a drug cocktail on Day 1, 7 and 11.
1488086|NCT03058419|Drug|Dextromethorphan 30 mg|Subjects will receive dextromethorphan 30 mg capsule (1*30 mg) orally as a drug cocktail on Day 1, 7 and 11.
1488087|NCT03058419|Drug|Bupropion 150 mg|Subjects will receive Bupropion 150 mg tablet (1*150 mg) orally as a drug cocktail on Day 1, 7 and 11.
1488088|NCT03058419|Drug|Omeprazole 20 mg|Subjects will receive omeprazole 20 mg capsule (1*20 mg) orally as a drug cocktail on Day 1, 7 and 11.
1488089|NCT03058406|Drug|Eribulin mesylate|Participants will receive 1.4 milligrams per square meter (mg/m2) administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle and beyond.
1488090|NCT03058393|Other|Teach-Back Lesson|A teach-back lesson will be given to providers (teach-back group) who have challenging clinical discussions with patients
1488091|NCT03058380|Other|Stated-Preferences Evaluation Instrument|A discrete choice experiment (Stated-Preferences Evaluation Instrument) will be electronically configured using best practice stated-preference methods to quantify preferences for total knee replacement versus unicompartmental knee replacement surgery.
1488092|NCT03058367|Dietary Supplement|IQP-AE-103 (330mg)|High dose capsules
1488093|NCT03058367|Dietary Supplement|IQP-AE-103 (165mg)|Low dose capsules
1488094|NCT03058367|Dietary Supplement|Placebo|Placebo identical to verum capsules
1488095|NCT03058354|Drug|Propofol|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using intraoperative TIVA with propofol.
1488096|NCT03058354|Procedure|general anaesthesia|Patient undergoing surgery at Queen Mary Hospital, Hong Kong between 2014 to 2016 using general anaesthesia methods other than intraoperative TIVA with propofol.
1488097|NCT03058341|Drug|propofol|Monitoring and other anaesthetic procedures including the management of hypertension and hypotension will be the same as group S. The only difference is that induction and maintenance of general anaesthesia will be conducted using total intravenous infusion of propofol. Sevoflurane will not be used, and oxygen and air would be given to provide a FiO2 of 30-50%.
1488098|NCT03058341|Drug|Sevoflurane|
1488099|NCT03058328|Other|Cognitive testing, testing of heart rate variability and blood samples|
1488100|NCT03058302|Behavioral|CETA (Common Elements Treatment Approach)|The Common Elements Treatment Approach, or CETA, is a transdiagnostic psychotherapy based on cognitive behavioral elements for mood, anxiety and trauma related problems. CETA is based on the fact that most evidence-based mental health treatments (EBTs) consist of similar components. The objective of CETA is to provide a single training in a range of therapy components that are similar across EBTs and to then teach counselors how to design a specific course of treatment for each client based on the client's presenting problems.
1488201|NCT03057548|Procedure|Cryo or RF Ablation only of Pulmonary Veins|"Artic Front Advance Cardiac Cryoabltion System used to ablate the Pulmonary Veins
OR
FDA Approved RF Ablation Catheter used to ablate the Pulmonary Veins.
Ablation of the Pulmonary Veins alone"
1488101|NCT03058289|Drug|INT230-6|"INT230-6 is clear sterile solution administered by injection directly into the tumor to be treated.
The product contains a cell permeation agent with cisplatin and vinblastine sulfate at fixed concentrations.
The drug is stored frozen and must be dosed at room temperature.
Escalation of the drug dose and number of injected tumors is possible in subsequent treatment sessions.
The drug dose to be administered is set by the tumor volume of the target lesions - not the subject's body surface area"
1488102|NCT03058289|Biological|anti-PD-1|A concomitant anti-PD-1 will be added in cohort D
1488103|NCT03058289|Biological|anti-PD-1 antibody|A concomitant anti-PD-1 antibody could be added for cohort E
1488104|NCT03058276|Behavioral|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
1488105|NCT03058276|Other|rTMS|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with Magstim Rapid coil. rTMS is performed at 10 Hz, during 4.9 seconds,for each set of stimuli (20), with a interval between sets of 30 seconds.
1488106|NCT03058276|Other|SAM|Previous to rTMS completion, MRI scans were performed in order to determinate the motor threshold trough 1Hz stimuli and locate the desired area with the neuronavigator. Motor threshold is defined as the stimulus with less intensity, able to generate a motor potential of at least 50 µV in 10 trials. Next, patients were called for 5 times per week, along 2 weeks, for receiving brain stimulation with SAM coil.
1488107|NCT03058263|Drug|Dose of Neostigmine|Subjects were given partial dose of neostigmine as rocuronium reversal after the surgery had finished; subjects were given TOF ratio-based dose of neostigmine after the surgery had finished
1488108|NCT03058250|Other|Transesophageal echocardiography|
1488109|NCT03058237|Drug|Arbaclofen Placarbil SR|One low dose oral tablet of Arbaclofen Placarbil sustained release (SR) in the fasted state.
1488110|NCT03058237|Drug|Arbaclofen Placarbil MR Prototype A|One low dose oral tablet pf Arbaclofen Placarbil modified release (MR) Prototype A in the fasted state; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
1488111|NCT03058237|Drug|Arbaclofen Placarbil MR Prototype B|One low dose oral tablet of Arbaclofen Placarbil modified release (MR) Prototype B; this formulation may also be tested with 0.6 g/kg beverage diluted in orange juice
1488112|NCT03058237|Drug|Arbaclofen Placarbil IR|One low dose oral capsule of Arbaclofen Placarbil immediate release (IR) in the fasted state.
1488113|NCT03058224|Drug|IGN-ES001|Only active product will be compared with placebo as described in Arms and Interventions.
1488114|NCT03058224|Drug|Parol 500 mg Tablets (acetaminophen)|Analgesic Rescue Medication
1488115|NCT03058211|Diagnostic Test|Echocardiography|Standard protocols
1488116|NCT03058211|Diagnostic Test|Cardiac Magnetic resonance|MRI with late gadolinium increase and T1 mapping
1488117|NCT03058198|Diagnostic Test|89Zr-ABT806 PET|Patients will be given IV bolus injection of 89Zr-ABT806(1-2mCi). The first 89Zr-ABT806 PET scan will be performed about 72 to 120 hours after injection of tracer. The second 89Zr-ABT806 PET scan will be performed about 120 to 168 hours after injection of tracer. Semi-quantitative analysis was performed using the maximum standardized uptake value (SUVmax) and T/N ratio.
1488118|NCT03058172|Other|Odor presentation (for participants' perception)|Several different odors will be diffused by an olfactometer under the participants' nostrils, though a controlled airflow, and synchronously with the participants' respiration. fMRI designs require repeated stimulus presentation. Odors will also be presented (in flasks or in odor pens) outside the scanner.
1488119|NCT03058172|Other|Image presentation (for participants' perception)|Several different pictures will be displayed in front of the participants' face, though a through a mirror system in the scanner, or on a computer screen outside the scanner.
1488120|NCT03058159|Other|fMRI|fMRI scans will be acquired before and after a 40 min nap slot in the afternoon. Functional connectivity between brain region will be assessed analyzing the scans with the CONN toolbox of the Statistical Parametric Mapping (SPM) software.
1488121|NCT03058146|Behavioral|Mobile Health Walking Condition|Physically inactive older adults in this condition (N=30) will perform 3 months of prescribed brisk walking (to increase cardio respiratory fitness) in their real world environments, using mobile health (mHealth) devices during each exercise session to achieve and maintain a minimum of 150 minutes of moderate to vigorous physical activity (MVPA) per week.
1488122|NCT03058146|Behavioral|Healthy Aging Education Condition|The education control condition (N=30) will provide participants with printed materials and homework assignments on issues related to successful aging, such as nutrition, social activity, cognitive and social engagement.
1488123|NCT03058133|Other|fMRI study|Functional brain activations of face-voice processing during a gender task
1488124|NCT03058120|Other|Deferral of admission for stress test|Early discharge; admission and stress test are deferred.
1948916|NCT01154101|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
1948917|NCT01154101|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule, packaged in dosing bottles containing a single daily dose.
1488306|NCT03056768|Behavioral|Active control|Health promotion activities provided by local health bureau.
1948918|NCT01141478|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
1948919|NCT01141478|Drug|Sorafenib|400 mg po bid
1948920|NCT01139060|Behavioral|organized care program for chronic or recurrent depression|
1948921|NCT01130493|Drug|IPX066|experimental product
1948922|NCT01130493|Drug|CLE|active comparator
1998268|NCT01541215|Drug|metformin|Tablets administered for 26 weeks. Maximum tolerated dose (MTD) between 1000-2000 mg at the discretion of the investigator. Subjects will continue treatment in a 26 week open-labelled extension.
1488127|NCT03058094|Drug|Pemetrexed|Pemetrexed will be administered as an intravenous infusion over 10 minutes on Day 1 of each 21-day cycle. Folic acid will be administered 1-2 weeks prior to the 1st dose, then daily during the treatment period until 21days post the last dose. Vitamin B12 will be administered on the same day of pemetrexed infusion during the treatment period. Corticosteroid will be adminstered on the day prior to, on the day, and on the day after infusion.
1488128|NCT03058094|Drug|Cisplatin 75mg/m2|Cisplatin will be administered as an intravenous infusion.
1488129|NCT03058094|Drug|AC0010|300mg, orally, BID
1488130|NCT03058081|Device|High Flow nasal cannula|High intensity Constant Work-Rate exercise test with High Flow Nasal Cannula in COPD patients involved in a Pulmonary Rehabilitation Program after an exacerbation (< 7 days after hospital discharge). High Flow nasal will be administered through nasal cannula using the Airvo2 (Fisher&Paykel)
1488131|NCT03058068|Biological|Allo-hMSCs|1 peripheral intravenous infusion of allogeneic human mesenchymal stem cells (hMSCs)
1488132|NCT03058068|Biological|Placebo|1 peripheral intravenous infusion
1488133|NCT03058055|Behavioral|Placebo|The placebo group will have unstructured lifestyle activities (normal lifestyle activities without restraint).
1488134|NCT03058055|Behavioral|Origami|Origami lessons (one hour/week) with daily take home Origami activities to complete
1488135|NCT03058055|Behavioral|Reading|Book club that includes weekly one hour meetings and daily reading assignments
1488138|NCT03058029|Device|Gelesis200|Subject would take active Glesis200 capsules 3 times per day.
1488139|NCT03058029|Device|Placebo|Subject would take placebo capsules 3 times per day.
1488140|NCT03058016|Other|Personalized recommendations for diet|Personalized recommendations for effective diet, lifestyle and activities based on the patient's parameters measurements and reactions
1488141|NCT03058003|Diagnostic Test|Posturography Evaluation|Posturography testing using the extended modified Clinical Testing of Sensory Integration in Balance (ext_mCTSIB) protocol: the subjects will be required to stand on a hard or compliant surface in a comfortable posture, feet shoulder width, with eyes open or closed, arms to the side and free to move, gazing forward, and breathing normally, with head straight, turned right or left, flexed or extended
1488142|NCT03058003|Other|Central Sensitization Inventory|Standard chronic pain questionnaire: the subjects will be required to score each of the 25 items on a scale from 0 (never) to 4 (always)
1488143|NCT03057990|Drug|Pyrimethamine|Pyrimethamine will be administered 50mg/100mg/150mg once daily on days 1-28 of each 28-day cycle. Administered using intra-patient dose escalation, starting at 50 mg and up to 150 mg.
1488146|NCT03057964|Device|PDL (Pulsed Dye Laser)|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
1488147|NCT03057964|Device|Fractional Photothermolysis Laser|For those in the experimental group, at each treatment visit, the subject's scar will be treated with PDL followed by fractional photothermolysis.
1488150|NCT03057938|Drug|18F-Florbetaben (FBB)|All participants will receive a single intravenous dose of 300 MBq of FBB followed by PET scan.
1488151|NCT03057925|Device|Microwave Ablation|Ultrasound-guided Percutaneous Microwave Ablation
1488152|NCT03057912|Biological|TALEN|TALEN gel consists of TALEN plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
1488153|NCT03057912|Biological|CRISPR/Cas9|CRISPR/Cas9 gel consists of CRISPR/Cas9 plasmid, C32-447, Poloxmer 407 and distilled water as solvent.
1488154|NCT03057899|Drug|TFG capsules (200 mg /capsule)|TFG capsules were prepared using extracts from Trigonella foenum-graecum seed and Lespedeza cuneata. During the study period, two capsules were taken daily for 8 weeks.
1488155|NCT03057899|Drug|Placebo oral capsule|During the study period, two capsules were taken daily for 8 weeks. Placebo and TFG capsules were identical in shape, color, and taste.
1488156|NCT03057886|Device|Comparative thermometers to compare with a new device|The made up for the choice of the thermometer to be to general anesthesia the oral and new device (Spot On thermometers) before anesthesia induction, after anesthesia induction the Spot On, and oral, and esophageal thermometers and after surgery in PACU the Spot On and oral thermometer. In group submitted to spinal anesthesia the made up for the choice of the thermometer to be the oral and Spot On thermometers before anesthesia induction, after anesthesia induction the Spot On and oral thermometers and after surgery in PACU the Spot On and oral thermometer.
1488157|NCT03057873|Dietary Supplement|High protein, high fiber dietary supplement|Dry powder to be mixed with 10 ounces of cold water
1488158|NCT03057873|Dietary Supplement|Placebo|Dry powder to be mixed with 10 ounces of cold water
1488159|NCT03057860|Other|No study intervention|
1488160|NCT03057847|Drug|Sofosbuvir/Velpatasvir|Sofosbuvir/Velpatasvir One tablet (400 mg of sofosbuvir and 100 mg of velpatasvir) taken orally once daily for 12 weeks in the postpartum period
1488161|NCT03057834|Behavioral|Pelvic floor muscle exercise|Standardized pelvic floor muscle exercise regimen
1488162|NCT03057821|Other|3% hydrogen peroxide|The treatment group will also undergo skin preparation with 3% hydrogen peroxide.
1488163|NCT03057808|Behavioral|Gestational weight gain intervention|This intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. The intervention will focus on self-monitoring, clear goals (i.e., GWG, caloric intake exercise), and problem solving.
1488164|NCT03057808|Behavioral|Postpartum weight loss intervention|The PPWL intervention will provide individual, telephone-based sessions (20-30 minutes each) by trained interventionists. (The number of possible telephone sessions will depend on the level of support needed by each participant to meet her weight loss goals). The PPWL intervention will focus on self-monitoring; weight, dietary intake and exercise goals; and problem solving.
1488165|NCT03057795|Drug|Brentuximab Vedotin|Given IV
1488166|NCT03057795|Other|Laboratory Biomarker Analysis|Correlative studies
1488167|NCT03057795|Biological|Nivolumab|Given IV
1488168|NCT03057782|Device|Waveguard (TM) EEG cap|The device is an EEG cap - a non-invasive EEG positioning system used to quickly place a large number of surface electrodes in a quick and consistent manner on the head. The device will measure electrophysiological signals from the scalp at the time points in the study listed in the protocol.
1488169|NCT03057782|Device|Micro Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor breathing and movement in children; the device is not used for validation purposes.
1488170|NCT03057782|Device|Pico Movement Sensor|This device is not FDA approved. This device is in clinical use for all age groups and used for research purposes by neurologists, physiologists and anesthesiologists. In this study, the device is used to monitor respiration rate and gross body movement in children. The device will not be used for validation purposes.
1488171|NCT03057782|Device|QS Piezostimulator|This device is not FDA approved. This device is used for research purposes by neurologists and physiologists. It is a mechanical tactile stimulator for use in functional imaging experiments like MEG, fMRI or EEG. The stimulation is realized by using several different pin matrices. In this study, the device is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
1488172|NCT03057782|Device|tactileTM sensory evaluator|This device is not FDA approved. This device is used for clinical and research purposes by neurologists and physiologists. It is used to stimulate the children's extremities in order to elicit somatosensory evoked responses.
2001298|NCT03085433|Device|Microfluidic Sperm Sorting|Microfluidic technology isolates healthy sperm by laminar flow, creating gradients through channels. The microfluidic chip we plan to study in our randomized clinical trial utilizes space-constrained microfluidic sorting to select highly motile and morphologically normal sperm in a flow and chemical-free design. Unlike the standard of density gradient centrifugation, no manipulation of sperm is required in this process. Raw semen is introduced into the inflow and only motile and morphologically normal sperm are able to swim through the chip to the outflow where it is collected for use.
2001299|NCT03085433|Procedure|in vitro fertilization|ivf/icsi
2001300|NCT03085550|Procedure|Fat grafting|Single treatment fat grafting infiltrated into diabetic ulcer wound
1488176|NCT03057756|Combination Product|Km+ Mfx+ Pto + H + Cfz +E+Z|Second generation of anti tuberculosis Kanamycine, Moxifloxacine,Prothionamide, isoniazide,Clofazimine, Ethambutol,Pyrazinamide
1488177|NCT03057743|Device|Positron emission tomography (PET/CT) imaging|
1488178|NCT03057743|Device|radiotracer [18F]ISO-1|
1488179|NCT03057730|Biological|Acellular Dermal Matrix|ADM is a human-derived allograft material, treated to remove all cellular components so that only the connective tissue matrix remains.
1488180|NCT03057717|Other|2D ultrasound assessment|2D ultrasound assessment of fetal thymus size with measurements of the maximum transverse diameter and thymus perimeter
1488181|NCT03057704|Drug|Lidocaine injection flushed|The investigator administers IV lidocaine and flushes it into the subject prior to administering propofol.
1488182|NCT03057704|Drug|Lidocaine injection tourniquet|Intravenous lidocaine: tourniquet
2001301|NCT03085550|Procedure|Fat grafting + platelet rich plasma|Single treatment fat grafting mixed with autologous platelet rich plasma infiltrated into diabetic ulcer wound. Autologous PRP is obtained using the ANGEL(TM) Concentrated Platelet Rich Plasma (cPRP) Separation Device which is FDA-regulated and CE certified
1488184|NCT03057678|Other|Testing of Pre-Positioning Frame|Placement of bone screws, CT scanning, Surgical planning, Robot motion planning
1488185|NCT03057665|Device|Atomic Biomagnetometer|Measure magnetic field of fetal heartbeat
1488186|NCT03057652|Device|ReWalk|"ReWalk is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.
ReWalk training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. ReWalk phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
1488187|NCT03057652|Device|EKSO|"EKSO is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.
EKSO training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. EKSO phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
1488188|NCT03057652|Device|REX|"REX is a type of wearable robotic exoskeleton (WRE). Subjects will be randomly assigned the order of participation in the exoskeleton devices.
REX training sessions will be scheduled for one hour to include don/doff of device, sit to stand, standing balance and walking. REX phase will require 2 hours pre and 2 hours post training for outcome measurement assessments, plus a minimum of 5 training sessions, with the possibility of up to 15 training sessions to reach a minimal assistance level. The total time commitment for each subject will range from 14-20 weeks and cover 27-72 hours."
1488189|NCT03057639|Other|Quality-of-Life Assessment|Ancillary studies
1488190|NCT03057639|Other|Questionnaire Administration|Ancillary studies
1488191|NCT03057626|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine
1488192|NCT03057626|Other|Laboratory Biomarker Analysis|Correlative studies
1488193|NCT03057626|Other|Quality-of-Life Assessment|Ancillary studies
1488194|NCT03057613|Drug|Pembrolizumab|200mg every 3 weeks for 16 weeks given by IV infusion
1488195|NCT03057613|Radiation|IMRT 60-66Gy|60-66Gy for 6 weeks
1488196|NCT03057600|Drug|Pac-CB|CB-839 administered as oral tablets twice daily (BID) in combination with standard weekly paclitaxel in 28-day cycles
1488197|NCT03057587|Device|NIRS Monitoring|NIRS data will be collected throughout the surgery
1488198|NCT03057574|Drug|Follitropin Alfa|Patients must be prescribed Follitropin Alfa (Gonapure®)
1488199|NCT03057561|Drug|Dotarem® (Gd-DOTA)|Gadolium based contrast agent
1488200|NCT03057561|Drug|Magnevist® (Gd-DTPA)|Brand of Gadopentetate Dimeglumine
1488202|NCT03057548|Procedure|Cryo or RF Ablation of Pulmonary Veins plus Ablation of the PLAW|"Cryoablation of the Pulmonary Veins plus RF Ablation of the PLAW
OR
RF Ablation of the Pulmonary Veins plus RF Ablation of the PLAW
Ablation of the Pulmonary Veins plus RF ablation of the Posterior Left Atrial Wall (PLAW)"
1488203|NCT03057535|Drug|Sodium Bicarbonate|
1488204|NCT03057535|Drug|Sodium Chloride|
1488205|NCT03057522|Behavioral|Change in running cadence|The intervention will involve a home exercise program designed to increase the running cadence in recreational runners.
1488206|NCT03057509|Drug|Ga-68-DOTA-TOC|Ga-68-DOTA-TOC is a imaging radiotracer that is used for positron emission tomography imaging of a variety of the neuroendocrine tumors. This radiotacer in the body binds to several subtypes of the somatostatin receptor and accumulates in the tissue with high expression of these receptors. Therefore neuroendocrine tumors that express somatostatin receptors can be imaged using this radiotracer.
1488207|NCT03057509|Device|Siemens PET/MR scanner|Positron emission tomography-magnetic resonance (PET/MR) is a hybrid imaging technology that incorporates magnetic resonance imaging (MRI) soft tissue morphological imaging and positron emission tomography (PET) functional imaging. The Siemens PET/MR system (Biograph mMR) received a CE mark and FDA approval for clinical diagnostic imaging.
1488208|NCT03057509|Other|Standard Siemens Software|The Siemens PET/MR scanner are equipped with a standard clinical visualization software with the advanced application tools based on the Siemens image interpretation engine called syngo.via. This software allows for visualization and interpretation of the image data-sets in the clinical environment.
1488209|NCT03057509|Drug|LAR Octreotide|LAR octreotide is a man-made protein that is similar to a hormone in the body called somatostatin. LAR Octreotide lowers many substances in the body such as insulin and glucagon, growth hormone, and chemicals that affect digestion. LAR octreotide is used to treat a variety of clinical conditions but most importantly to reduce flushing episodes and watery diarrhea caused by cancerous tumors such as neuroendocrine tumors.
1488210|NCT03057496|Device|Collision warning device|The collision warning device is a pocket-sized, electronic system that includes a micro-computer, a clip-on miniature camera, a gyro-sensor, an accelerometer, and a rechargeable battery. It is about the size of a smart phone. When a potential collision is detected by the device it emits a warning to the user, either in the form of an audible beep or a tactile warning through bracelets worn on the wrist. The time to collision will be coded in both the auditory and tactile domains. As the time to collision decreases, the rhythm of auditory beeps and the tactile vibrations will increase. The device is designed to only give warnings about high risk collisions, so the users will not be continually bombarded by warnings for every potential collision object in the environment.
1488211|NCT03057483|Biological|Seasonal Influenza vaccine|Seasonal Influenza vaccine
1488212|NCT03057470|Drug|50% bolus insulin correction|Patients will receive 50% of their usual bolus insulin correction for post-exercise hyperglycemia
1488213|NCT03057470|Drug|100% bolus insulin correction|Patients will receive 100% of their usual bolus insulin correction for post-exercise hyperglycemia
1488214|NCT03057470|Drug|150% bolus insulin correction|Patients will receive 150% of their usual bolus insulin correction for post-exercise hyperglycemia
1488215|NCT03057470|Other|0% bolus insulin correction|Patients will receive no bolus insulin correction for post-exercise hyperglycemia
1488216|NCT03057457|Device|NGAL Test|The purpose of this study is to demonstrate that BioPorto Diagnostic's NGAL test is able to assist in determining the risk for acute kidney injury for patients who have been admitted to the intensive care unit.
1488217|NCT03057444|Dietary Supplement|SymbioIntest|The intervention is 2x 5g per day the food supplement SymbioIntest (resistant starch types III) over 8 weeks.
1488218|NCT03057431|Drug|Placebo oral capsule|Once daily for 3 years
1488219|NCT03057431|Drug|12.5 mg hydrochlorothiazide|Once daily for 3 years
1488220|NCT03057431|Drug|25.0 mg hydrochlorothiazide|Once daily for 3 years
1488221|NCT03057431|Drug|50.0 mg hydrochlorothiazide|Once daily for 3 years
1488222|NCT03057418|Drug|Aurixim|Administration will be performed once a week during 4-week induction period, and then once per 12 weeks during supporting period, if necessary. Total maximum duration of the investigational therapy - 1 year, during which patients will receive up to 8 infusions of Aurixim.
1488223|NCT03057392|Other|immersion|participants will sit in a 34-35C while receive dialysis
1488224|NCT03057392|Other|sham session|dialysis while sitting in the dialysis chair
1488225|NCT03057379|Other|Vaccine Reminder Recall|The investigators will be sending recall notices via phone call to 11-17 year olds who are eligible but lacking HPV vaccine doses recorded in the New York State Immunization Information System (NYSIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention)
1488226|NCT03057366|Drug|Pevonedistat|Pevonedistat intravenous infusion
1488227|NCT03057366|Drug|[14C]-Pevonedistat|[14C]-Pevonedistat intravenous infusion
1488228|NCT03057366|Drug|Docetaxel|Docetaxel intravenous infusion
1488229|NCT03057366|Drug|Carboplatin|Carboplatin intravenous infusion
1488230|NCT03057366|Drug|Paclitaxel|Paclitaxel intravenous infusion
1488231|NCT03057353|Device|lumbar CT imaging|Collecting lumbar CT imaging data of 104 patients with lumbar spinal stenosis to observed the incidence of ligamentum flavum hypertrophy of patients with different nationalities, sexes, heights, ages, and weights and explored risk factors affecting ligamentum flavum hypertrophy.
1488232|NCT03057340|Biological|Dribble vaccine|DRibble vaccine with DC/CIK(The experimental group) DRibble vaccine will be administered at day1,22,55
1948923|NCT01122823|Behavioral|chronic disease self-management program (online)|The online CDSMP is an internet-based program for people with 1 or more chronic conditions. It's built on self-efficacy theory, facilitated by lay leaders, and uses a curriculum emphasizing problem solving, decision making, and confidence building in weekly sessions over six weeks. It addresses generic topics and skills relevant to managing any chronic condition, including: action plans; problem solving; nutrition; exercise; fatigue; breathing; managing medications; managing stress and emotions; working with health care providers. The structure includes: 1) password-protected, interactive web-based instruction; 2) web-based bulletin board discussion groups to enable participatory learning and support; 3) and a reference book that contains the program content and supplemental information.
1948924|NCT01122836|Other|Massage|Therapeutic Massage
1488235|NCT03057314|Drug|Amorphous Calcium Carbonate|"Subjects will be administered with:
ACC tablets, containing 200 mg elemental calcium
1% ACC (i.e. 0.3% calcium) + 5 mL Water for Injection, as a sterile suspension"
1488236|NCT03057301|Device|iCare home tonometer|All subjects will be taught to use the home care tonometer.
1488237|NCT03057288|Device|fiducial markers placement|The main objective of this study is to evaluate the feasibility of fiducial markers placement under EUS guidance for patients with esophageal or rectal cancer with an indication of radiotherapy
1488238|NCT03057275|Device|Abdominal fetal/maternal monitoring|A single patch placed on the abdomen that incorporates 5 electrodes and a monitoring device
1488239|NCT03057262|Device|Repositioning splint|Application of repositioning splint in the study group.
1488240|NCT03057249|Other|Dynamic infrared thermography (DIRT)|Evaluating abdominal skin perfusion with DIRT
1488241|NCT03057236|Behavioral|Cognitive Behavior Coping Skills|The CBCS-HCV is a psychosocial intervention delivered in group format. Through 9 group sessions, patients will learn coping skills, relaxation techniques and other new cognitive and behavioral skills based on several empirically-supported cognitive behavioral interventions.
1488242|NCT03057223|Device|3D-printed patient-specific titanium plates|3D-printed patient-specific titanium plates will be used in patients.
1488243|NCT03057210|Other|Stress Protocol|Participants will be submitted to an exercise protocol consisting of a jumping program and a maximum short cycle test (ALMEIDAetal). The jumping program consists of 10 sets of 10 jumps with one minute interval between sets. The participants will then perform the Wingate Anaerobic Test protocol, which will be performed on a Biotec 2100 cycle ergometer (Cefise, Nova Odessa, Brazil). A 5-minute warm-up will be carried out where the participant will pedal at a speed of 60 to 90 rpm with a fixed load of 1.0 kg and perform sprints in the 2nd and 4th minute and the test itself, which consists of a maximum of pedals In 30 seconds with a stipulated load of 0.075 kP · kg-1 of the participant's body mass.
1488244|NCT03057210|Other|Massage Protocol|"the present protocol will have a total of 12 minutes duration, being six minutes in the anterior region of the thigh (three minutes for each limb) and six minutes in the posterior region of the trunk.
Surface and deep sliding techniques will be used, the latter being presented in two intensities, moderate or intense, gradually increased. The massage will be performed towards the muscle fibers, from distal to proximal and following the lymphatic flow. In addition to the standardization of the intensity of the massage performed by the physiotherapist, in order to avoid causing discomfort and possible variations in the application of the technique, participants should report their level of comfort from a scale that considers the technique light, moderate or Intense, corresponding respectively to surface slip, Deep Slip 1 and Deep Slip 2."
1488245|NCT03057197|Procedure|new caudal injection technique|new caudal injection technique is applied to the Group B, which is that the needle only penetrates the sacrococcygeal ligament without being inserted into the sacral canal
1488246|NCT03057184|Behavioral|Intervention|The intervention will consist of 8 weekly sessions, with a duration of 90 minutes. Although each intervention is adapted to the specific behavioral problems
1488247|NCT03057145|Drug|Prexasertib|LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
1488248|NCT03057145|Drug|Olaparib|Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.
1488249|NCT03057132|Device|Cavilon Advanced Skin Protectant|Cavilon Advanced Skin Protectant
2001302|NCT03083873|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After NMA lymphodepletion, patients are infused with their autologous TIL (LN-145) followed by IL-2 administration.
2001303|NCT03080181|Drug|Pasireotide 0.6 MG/ML|The aim of the study was to evaluate the effect of pasireotide on β -cell and adipose function in patients with Cushing's disease (CD).
1948925|NCT01118741|Drug|Disulfiram|Cohort 1: 250mg PO daily for 28 days Cohort 2: 500mg PO daily for 28 days
1488258|NCT03057093|Other|Non interventional study|retrospective noninterventional study
1488259|NCT03057080|Procedure|Percutaneous transluminal angioplasty (PTA)|The main goal of the angioplasty (which was also the definition of technical success) was to achieve straight-line flow (SLF) from the aorta down to either a patent dorsalis pedis or plantar arch.
1488260|NCT03057067|Procedure|Embolization of pelvic vein varicosities|Embolization of pelvic vein varicosities
1488261|NCT03057054|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo alloHCT
1488262|NCT03057054|Other|Laboratory Biomarker Analysis|Correlative studies
1488263|NCT03057054|Drug|Lactobacillus plantarum strain 299|Given PO or via NG or G tube
1488264|NCT03057054|Drug|Lactobacillus plantarum strain 299v|Given PO or via NG or G tube
1488265|NCT03057054|Other|Placebo|Given PO or via NG or G tube
1488266|NCT03057041|Drug|Fentanyl|100 mcg of intranasal fentanyl, 50 mcg/ mL in each nostril via mucosal atomizer 15 minutes prior to procedure start
1488267|NCT03057041|Drug|placebo|1 mL of sterile saline in each nostril via mucosal atomizer 15 minutes prior to procedure start
1488268|NCT03057028|Drug|Anakinra|
1494114|NCT03012880|Drug|Dexamethasone|Given PO
1998273|NCT01538199|Device|Near-infrared radiation via Transcranial LED Therapy|"The subject will lie down comfortably on a exam bed . The sites of application of TLT (left and right forehead) will be inspected for any skin lesions (e.g. laceration or signs of inflammation) which would contraindicate the treatment. The subject will wear protective eyewear in the form of goggles or eye pads.
The staff administering the TLT will be careful not to shine the light in or near the eyes of the subject. The two OLS devices will be secured in position with the use of a Hair Net. The delivery of the TLT is expected to last 20 min total (simultaneous application on the left and right forehead). The subject will be asked to rest for five minutes after the delivery of TLT. The skin at the sites of the application will be inspected again prior to dismissing the subject."
1998274|NCT01538199|Device|Sham device|The sham device does not emit near-infrared radiation.
2001304|NCT03078062|Drug|Dexamethasone|Administration of a single-dose of intravenous dexamethasone 8 mg during spinal anesthesia
2001305|NCT03078062|Drug|Normal saline|Administration of a single-dose of Normal saline during spinal anesthesia
2001306|NCT03075371|Other|Glucose|75 g of glucose dissolved in 300 ml of water
1488274|NCT03057002|Drug|Hyperpolarized 13C-Pyruvate|All subjects will be observed for myocardial hyperpolarized [1-13C]pyruvate flux during magnetic resonance spectroscopic imaging.
1488275|NCT03056989|Drug|SPX-101|Inhalation solution twice daily for 7 days.
1488276|NCT03056976|Device|Single-implant mandibular overdenture|Complete mandibular denture retained by a single midline implant
1488277|NCT03056976|Device|Two-implant mandibular overdenture|Complete mandibular denture retained by two implants in the canine region
1488278|NCT03056976|Device|Fixed mandibular denture|A fixed mandibular denture retained by four implants
1488279|NCT03056963|Behavioral|Positive Self-Reference Training|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on positive self-referent material.
1488280|NCT03056963|Behavioral|Neutral Training Control|Participants in this intervention will review a brief psychoeducational video describing the training, and then be given cues every other day designed to practice skills. Participants will then practice visualizing and describing scenes based on these cues. This training will be focused on neutral, non-self-referent material.
1488281|NCT03056950|Device|DELFI PTS ii portable tourniquet|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with doppler ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
1488282|NCT03056937|Other|Bariatric surgery|evaluations pre and post bariatric surgery.
1488283|NCT03056937|Other|Control|without intervention, it will be performed only evaluations
1488284|NCT03056924|Biological|Pneumococcal Pneumonia vaccine|Vaccination for pneumococcal pneumonia will be carried out with either the PSV-23 (Pneumovax, Merck, Whitehouse Station, NJ) or the PCV-13 (Prevnar 13, Pfizer, Philadelphia, PA). Either vaccine is administered in a single dose of 0.5 mL intramuscularly.
1488285|NCT03056924|Biological|Influenza vaccine|Influenza vaccination will be carried out with the 2017-2018 trivalent component vaccine (Afluria, Seqirus USA Inc., King of Prussia, PA) or for patients over 65 years of age (Fluzone, Sanofi Pasteur, Swiftwater, PA). Both of these vaccines are administered in a single dose of 0.5 mL intramuscularly.
1488286|NCT03056924|Biological|Hepatitis B vaccine|Hepatitis B vaccination with be carried out with a single antigen, recombinant hepatitis B vaccine (Energix B, GlaxoSmithKline, Research Triangle Park, NC). This vaccine is administered in a three dose series with 1.0 mL given intramuscularly at 0, 1, and 6 months. For patients receiving a booster, a single intramuscular dose of 1.0 mL will be given.
1488287|NCT03056911|Drug|Ozone|Pain relief with chemonucleolysis by using ozone regard to age, sex, ASA score, and complications.
1488288|NCT03056885|Other|Conventional One-Lung Ventilation|Vt 10 ml/kg
1488289|NCT03056885|Other|Protective One-lung ventilation|Vt 5 ml/kg
1488290|NCT03056859|Device|Extravascular blood pressure transducer|Listed device is included in central venous catheter placement apparatus for consenting patients, according to manufacturer directions
1488291|NCT03056846|Dietary Supplement|Placebo|Placebo will be taken as a capsule twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
1488292|NCT03056846|Dietary Supplement|Probiotic Combination|A capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
1488293|NCT03056846|Dietary Supplement|Bifidobacterium bifidum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
1488294|NCT03056846|Dietary Supplement|Bifidobacterium longum|A capsule containing Bifidobacterium bifidum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
1488295|NCT03056833|Drug|ribociclib|Ribociclib (LEE-011) will be given on days 1-4, 8-11, and 15-18 of a 28 day cycle at 200, 400, or 600mg/day during the dose escalation phase. During the maintenance phase, ribociclib (LEE-011) will be given at 600mg/day, 3 weeks on, 1 week off until progression.
1488296|NCT03056833|Drug|Paclitaxel|During the escalation phase Paclitaxel will be given on days 1, 8, and 15 of a 28 day cycle.
1488297|NCT03056833|Drug|Carboplatin|During the escalation phase Carboplatin will be given on days 1, 8, and 15 of a 28 day cycle.
1488298|NCT03056820|Other|25° head-up position|Participant will be positioned at 25° angle for procedure.
1488299|NCT03056820|Other|55° head-up position|Participant will be positioned at 55° angle for procedure.
1488300|NCT03056807|Other|25° head-up position|Angle person is positioned for procedure.
1488301|NCT03056807|Other|55° head-up position|Angle person is positioned for procedure.
1488302|NCT03056794|Other|No intervention|This is an observational study. The investigators will collect data about exposure to responses to dietary supplements, medications, and the ketogenic diet.
2001307|NCT03075371|Other|Placebo|300 ml of tap water
2001308|NCT03070535|Other|HIGH and LOW meal ingestion|The study will examine CSF biomarker responses to HIGH and LOW meals in 80 men and women with and without the E4 allele in a cross-over design. After an overnight fast, participants will ingest either a HIGH or LOW meal on separate days 3-5 weeks apart in random order. Three hours after meal ingestion, participants will undergo a cognitive battery, followed by spinal fluid collection. Blood samples will also be taken at 7 time points before and after meal ingestion.
1488305|NCT03056768|Behavioral|Multidomain intervention|1-year multidomain health promotion (physical, cognitive, nutritional intervention)
1488313|NCT03056716|Procedure|Silastic vs conventional drain in thoracic surgery|Apical drains will be identical in size and material, and the basal drains will be different in groups. The patients will be followed for daily amounts of fluid drainage, duration of air leaks and fluid drainage, and duration of hospitalization, and the results will be compared statistically to asses any possible relationships with the outcome and the type of basal drain used.
1488314|NCT03056703|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One Fast Release Tablet containing 1000 mg acetylsalicylic acid
1488315|NCT03056703|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|Two Fast Release Tablets containing 500 mg acetylsalicylic acid each
1488316|NCT03056690|Drug|ASP0819|oral
1488317|NCT03056690|Drug|Placebo|oral
2001309|NCT03068429|Drug|Sertraline Hydrochloride|first week: sertraline hydrochloride 50mg/day, second week: sertraline hydrochloride 100mg/day, third week: sertraline hydrochloride 150mg/day, fourth week: sertraline hydrochloride 200mg/day OBS.: Other SSRIs (fluoxetine, paroxetine, escitalopram) with equivalent dosage schedules can be used if patients report prior intolerance to sertraline
2001310|NCT03066778|Biological|Pembrolizumab|IV infusion on Day 1 of each cycle prior to chemotherapy
2001311|NCT03066778|Drug|Normal saline solution|IV infusion on Day 1 of each cycle prior to chemotherapy
1488321|NCT03056664|Procedure|Routine drainage surgery|
1488322|NCT03056664|Biological|MSC injection 01|Local MSC injection in peri-anal with a dose of 3×10E6/kg
1488323|NCT03056664|Biological|MSC injection 02|Local MSC injection in peri-anal with a dose of 6×10E6/kg
1488324|NCT03056664|Other|placebo|NS injection instead of MSC
1488325|NCT03056651|Other|treatment in day-care heart failure unit|
2001312|NCT03066778|Drug|Carboplatin|IV infusion on Day 1 of each cycle
1488328|NCT03056625|Other|Vitamin A fortified rice|Lactating women will receive fortified rice one meal per day on weekdays for a period of 14 weeks.
1488329|NCT03056625|Other|Normal rice|Lactating women will receive normal rice one meal per day on weekdays for a period of 14 weeks.
1488330|NCT03056612|Other|Observation protocol|The whole cohort will be followed for 3 months, while Group 1 will be followed more closely.
1488331|NCT03056599|Drug|Multiple drug microinjection|This is a feasibility study in patients with localized or metastatic soft tissue sarcoma undergoing surgery to determine how sarcoma in situ responds to injected microdoses of anti-cancer therapeutics.
1488332|NCT03056599|Device|CIVO device|Feasibility of assessing drug response to precise local injection of anti-cancer drugs using Presage's CIVO™ device in soft tissue sarcoma patients undergoing surgery.
1488333|NCT03056586|Device|vaginal pessary|A vaginal pessary will be inserted at the end of the operation, for genital prolapse, and will be sutured to the vaginal wall. The pessary will stay in the vagina for 4 weeks.
1488334|NCT03056573|Device|TAVI|Transcatheter Aortic Valve Implantation
1488335|NCT03056560|Behavioral|TakeCARE (video bystander program)|brief video encouraging active responses to high-risk situations for campus violence
1488336|NCT03056547|Other|Induced dyspnea|"Biological samples will be assessed during and after breathing discomfort induced by laboratory models of dyspnea (work/effort, air hunger)."
1488337|NCT03056534|Device|R3 Biolox Delta Ceramic Acetabular System|All study related procedures with the R3 delta Ceramic Acetabular System must be performed according to the recommended surgical technique described in the labeling and in the instructions for use (IFU).
1488338|NCT03056521|Other|preoperative information about pain|It is information about analgesics, post operative pain, complications of pain, benefits of pain treatment and non pharmacologic treatment options.
1488339|NCT03056508|Behavioral|Exercise plus nutrition|On the same day as the exercise class, participants will also receive nutrition support. Participants will alter their overall diet to be consistent with recommendations outlined in our brain health food guide (BHFG) and receive diet counseling and strategy training to promote retention and enable this dietary change. For the first two months, diet group sessions will be held on a weekly basis. For the remaining four months, sessions will be divided between group sessions and individual meetings with study dietitians, on a predefined schedule. Participants will submit weekly logs outlining diet goals, plans, successes and obstacles to help direct identification of sequential goals.
1488340|NCT03056508|Behavioral|Exercise|Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise (4 additional aerobic and 2-3 resistance training sessions per week) will be monitored by an exercise diary. The initial walking prescription will be set at ~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% VO2-peak. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of VO2-peak and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
1488341|NCT03056495|Drug|N-hydroxy-N'-phenyl-octanediamide (Vorinostat)|N-hydroxy-N'-phenyl-octanediamide capsules once a day, three weeks of treatment; dose escalation with different dosages per cohort; One cohort of three subjects
1488342|NCT03056482|Drug|Ondansetron 8mg|Ondansetron 8 MG prepared in a 100 mL normal saline min-bag
1488343|NCT03056482|Drug|Haloperidol 0.05mg/kg|Haloperidol 0.05 mg/kg prepared in a 100 mL normal saline min-bag
1488344|NCT03056482|Drug|Haloperidol 0.1mg/kg|Haloperidol 0.1 mg/kg prepared in a 100 mL normal saline min-bag
1488345|NCT03056469|Other|Completion of patient-reported outcome (PRO) questionnaires|Patient-reported outcome (PRO) questionnaires are completed at home within one week before a patient-physician consultation at the outpatient clinic. The questionnaires are submitted online or on paper depending on the participants choice.
1488346|NCT03056456|Drug|LY900014|Administered subcutaneously (SC)
1488347|NCT03056456|Drug|Insulin Lispro|Administered SC
1488348|NCT03056443|Device|Continuous Positive Airway Pressure (CPAP)|The auto-CPAP group will be scheduled for follow-up with a phone call at 2 - 3 weeks post discharge, then in sleep medicine clinic at 1 month (+2 weeks) and 6 months (+2 weeks) to assess their progress on CPAP.
1488349|NCT03056430|Behavioral|Training|
1488350|NCT03056417|Behavioral|The Complete Health Improvement Program|The Complete Health Improvement Program is a nationally recognized program that encourages a diet of whole plant based foods, moderate exercise, stress reduction, and social support.
1488351|NCT03056404|Other|additional blood sample|
1488352|NCT03056404|Other|respiratory functional exploration|
1488353|NCT03056391|Drug|Paracetamol|">50kg: Paracetamol 1gm PO/NG 6 hourly for 72 hours (maximum dose 4g/24h) plus IV artesunate or oral artemether/lumefantrine.
<50kg: Paracetamol 12.5-15mg/kg/dose 6 hourly for 72 hours (maximum total dose 5doses/24hours;75mg/kg) plus IV artesunate or oral artemether/lumefantrine."
1488354|NCT03056378|Biological|Standard RBCs|Transfusion of standard pRBCs that are matched for C, E and K
1488355|NCT03056365|Procedure|Advanced Nurse (AN)|Protocoled AN-based management of detox
1488356|NCT03056365|Procedure|General Practitioner (GP)|'As usual' medical management of detox
1488357|NCT03056352|Drug|Metoclopramide|Intravenous medication drip
1488358|NCT03056352|Drug|Diphenhydramine|Intravenous medication drip
2001313|NCT03066778|Drug|Cisplatin|IV infusion on Day 1 of each cycle
2001314|NCT03066778|Drug|Etoposide|IV infusion on Days 1, 2 and 3 of each cycle
2001315|NCT03065530|Drug|Normal Saline|Drug: Normal saline control group receive NS after delivery. Drug: butorphanol tartrate PCA: butorphanol tartrate after cesarean section.
2001316|NCT03065530|Drug|Dexmedetomidine 0.03ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.03ug/kg/h Dexmedetomidine after cesarean section.
2001317|NCT03065530|Drug|Dexmedetomidine 0.05ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.05ug/kg/h Dexmedetomidine after cesarean section.
1488364|NCT03056326|Drug|CHF6333 (Part 1 - SAD)|Single doses of CHF6333 at each period
1488365|NCT03056326|Drug|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6333 at each period
1488366|NCT03056326|Drug|CHF6333 (Part 2 - MAD)|once daily multiple doses of CHF6333 for 14 days
1488367|NCT03056326|Drug|Placebo (Part 2 - MAD)|once daily multiple doses of placebo matching CHF6333 for 14 days
1488368|NCT03056313|Behavioral|Proactive support of labor|In case of delayed labor, active labor is defined at an earlier stage; labor support is given with 1 cm opening of the cervix and painful contractions. Labor support interventions are started then.
1488369|NCT03056313|Behavioral|support of labor as usual|In case of delayed labor, active labor start is defined as usual at 3-4 cm opening of the cervix and regular contractions. Labor support interventions are started then.
1488370|NCT03056300|Device|Video-Assisted Thoracoscopic Lobectomy with powered vascular stapler|Powered Vascular Stapler used on vessels
1488371|NCT03056287|Behavioral|Aerobic exercise|treadmill aerobic exercise; 3 sessions per week, 40 minutes per session
1488372|NCT03056287|Other|Repetitive transcranial magnetic stimulation|Repeated non-invasive brain stimulation to the left dorsolateral prefrontal cortex.
1488373|NCT03056274|Drug|Metformin|Metformin Hydrochloride (HCl) Tablets, is an oral antihyperglycemic drug used in the management of type 2 diabetes
1488374|NCT03056274|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid (UDCA) is used to treat gallstones and primary biliary cirrhosis. UDCA is also used to treat obstetric cholestasis (OC), a liver condition that occurs specifically in pregnancy.
1488375|NCT03056261|Procedure|Combined general and epidural|Combined general and epidural anaesthesia
1488376|NCT03056261|Procedure|General anaesthesia|General anaesthesia
1488377|NCT03056248|Drug|Placebo oral capsule|On day 0, the day of the cardiac surgery placebo will be given once On day 1, one day after cardiac surgery placebo will be given once On day 2, two days after cardiac surgery placebo will be given once
1488378|NCT03056248|Drug|Lithium Carbonate|On day 0, the day of the cardiac surgery oral lithium will be given at dose 900mg once On day 1, one day after cardiac surgery oral lithium will be given at dose 900mg once On day 2, two days after cardiac surgery oral lithium will be given 900mg once
1488379|NCT03056235|Device|ELAPR002f|30mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
1488380|NCT03056235|Device|ELAPR002g|40mg/ml Tropoelastin cross-linked with derivatised hyaluronic acid
1488381|NCT03056235|Device|Saline|Saline control
1488382|NCT03056222|Device|Ablation catheter|Ablation of paroxysmal atrial fibrillation
1488383|NCT03056209|Drug|KL1333 25 mg|oral administration, single dose, 25mg 1tab
1488384|NCT03056209|Drug|KL1333 50 mg|oral administration, single dose, 25mg 2tab
1488385|NCT03056209|Drug|Placebo|oral administration, single dose
1488386|NCT03056196|Diagnostic Test|point of care ultrasound|want to assess the ability of d-dimer test and point of care ultrasound to role out lower leg DVT
1488387|NCT03056183|Behavioral|Depression Care Transitions (DCT)|DCT Intervention group - Patients in the DCT intervention will have a Transitional Care Social Worker (TCSW) who will maintain daily phone contact, home visits, and will attend with the patient medical and psychiatric appointments for an average of three months following discharge. Patients in the usual care group will proceed as usual (scheduled follow-up visits). These subjects will also be asked to complete questionnaires relating to quality of life and physical and mental health status.
1488388|NCT03056170|Device|real tDCS|"In active stimulation, the Transcranial Direct Current Stimulation device will produce a direct current of 1 mA from one electrode to the other for 30 min with a ramp up at the beginning and a ramp down at the end of the stimulation of 30 s. The sham or active mode is chosen by a numeric code."
2001318|NCT03065530|Drug|Dexmedetomidine 0.08ug/kg/h|Drug: Dexmedetomidine This group receive Dex 0.5ug/kg after delivery. Drug: butorphanol tartrate and Dexmedetomidine. PCA: butorphanol tartrate with 0.08ug/kg/h Dexmedetomidine after cesarean section.
2001319|NCT03063710|Drug|olaparib|Initial dose is 300mg twice daily. Study treatment can be dose reduced to 250 mg bd as a first step and to 200 mg bd as a second step. There is no maximum duration for taking study treatment. Patients may continue to receive study treatment until disease progression as assessed by the investigator according to local standard clinical practice or any other discontinuation criteria.
1488504|NCT03055247|Drug|Mozobil|Mozobil (Plerixafor): 0,24 mg/kg daily. When CD34+ are ≥ 10 /μL Plerixafor will be administered subcutaneously from the next day (or from day 24 if CD34+ are < 10 /μL) to the day of the last LP.
1488505|NCT03055234|Drug|Oral Treprostinil|Extended-release oral tablet for TID administration
1488506|NCT03055234|Drug|Placebo|Matching placebo for TID administration
2001320|NCT03063450|Drug|Nivolumab|Nivolumab at a dose of 240mg as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
1488391|NCT03056144|Device|whole body vibration therapy|"The whole body vibration therapy regime is as follows:
Day Vibration 1 Rest 1 Vibration 2 Rest 2 Vibration 3 Rest 3
st 1 min;12Hz 3 min 1 min;12Hz 3 min 1 min;15Hz 3 min
nd 1 min;15Hz 3 min 1 min;15Hz 3 min 2 min;15Hz 3 min
th 2 min;15Hz 3 min 3 min;15Hz 3 min 3 min;15Hz 3 min
th 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min 2 min;24-25Hz 3 min >5th 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min 3 min;24-25Hz 3 min
The participants will perform mini-squats during Vibrations 1 and 3 and weight-shifting between right and left legs during Vibration 2 on the vibration platform under the supervision of a trained research assistant."
1488392|NCT03056131|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
1488393|NCT03056118|Drug|6-month dual anti-platelet therapy|Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 6 months
1488394|NCT03056118|Drug|12-month dual anti-platelet therapy|Aspirin and P2Y12 inhibitor after percutaneous coronary intervention continues for 12 months
1488395|NCT03056118|Device|Zotarolimus eluting stent|Zotarolimus eluting stent is applied to coronary stenotic lesion
1488396|NCT03056118|Device|Biolimus eluting stent|Biolimus eluting stent is applied to coronary stenotic lesion
1488397|NCT03056105|Other|Residential Insight Meditation Retreat|"Retreats at Spirit Rock Meditation Center were led by teams of 6 experienced teachers. Participants practiced noble silence—refraining from eye contact as well as verbal and written communication—except during meetings with teachers. Teachers lead guided Insight meditation practices, as well as meditations on loving-kindness, compassion, empathetic joy, and equanimity. The daily schedule consisted of sitting and walking meditation sessions (30-45 mins) totaling 8-10 hours/day, meals, and short work meditations (sweeping, dishes, etc.). Seated meditation was practiced as a group in a meditation hall with approximately 80 participants. Walking meditation took place in adjoining halls or on the grounds. Participants lived on-site during the retreat and were provided with a vegetarian diet."
1488398|NCT03056092|Drug|Intravitreal ranibizumab|Patients will be treated with intravitreal ranibizumab and have their aqueous humor obtained for cytokine analysis at every visit that an intravitreal injection is done
1488399|NCT03056079|Drug|Intravitreal aflibercept|Patients will receive intravitreal aflibercept on a variable dosing regimen and have aqueous humor sample obtained for cytokine analysis at every visit when an intravitreal injection is done.
1488400|NCT03056066|Device|Plethysmograph|A full Body Plethysmography examination
1488402|NCT03056040|Biological|ALXN1210|"Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
≥ 40 to <60 kg: 2400 mg loading, then 3000 mg every 8 weeks
≥ 60 to <100 kg: 2700 mg loading, then 3300 mg every 8 weeks
≥100 kg: 3000 mg loading, then 3600 mg every 8 weeks"
1488403|NCT03056040|Biological|Eculizumab|"Regular maintenance dosing beginning on Day 1, then every 2 weeks to Day 183.
Single loading dose of ALXN1210 on Day 183, followed by regular maintenance dosing beginning on Day 197, based on weight.
≥ 40 to <60 kg: 2400 mg loading, then 3000 mg every 8 weeks
≥ 60 to <100 kg: 2700 mg loading, then 3300 mg every 8 weeks
≥100 kg: 3000 mg loading, then 3600 mg every 8 weeks"
1488404|NCT03056027|Diagnostic Test|Ecocolordoppler ultrasound testicular evaluation|Ecocolordoppler ultrasound testicular evaluation
1488405|NCT03056014|Drug|N-acetyl cysteine|giving varying doses of NAC in order to determine which reduces oxidative stress.
1488406|NCT03056014|Dietary Supplement|omega 6 Fish oil ( PUFA)|giving varying doses of PUFA in order to determine which reduces oxidative stress.
1488407|NCT03056014|Dietary Supplement|Placebo|L-alanine placebo pill to determine if effect is supplement related or random effect.
1488408|NCT03056001|Drug|Pembrolizumab|IV infusion on day 1 of each 3 week cycle, at dose of 200 mg
1488409|NCT03056001|Drug|Doxorubicin|IV injection on day 1 of each 3 week cycle, starting at dose of 60 mg/m2 (may be escalated to 75 mg/m2 per investigator discretion after Cycle 1
1488410|NCT03055988|Drug|Tiotropium|Fixed Dose Combination
1488411|NCT03055988|Drug|Olodaterol|Fixed Dose Combination
1488412|NCT03055988|Drug|Fluticasone propionate|Fixed Dose Combination
1488413|NCT03055988|Drug|Salmeterol|Fixed Dose Combination
1488414|NCT03055975|Diagnostic Test|Detection of residual vital bacteria in the root canal space|Detection of residual vital bacteria in the root canal space. No intervention, as it is an observational study. Vital bacteria are looked for in the samples taken from the root canal space.
1488415|NCT03055962|Drug|E2609|tablet
1488416|NCT03055962|Drug|Placebo|tablet
1488417|NCT03055949|Behavioral|Early rehabilitation program|The investigators evaluated patients who were admitted SICU for more than 3 days for an early rehabilitation program and delivered one of 5-stepped rehabilitation program if the patient was eligible.
1995337|NCT02791230|Drug|Tafamidis meglumine|Soft gel capsules administered once a day for 60 months
1488421|NCT03055923|Device|The Inflammacheck Device|A new hand-held, Non-invasive breathing test, that only requires tidal breathing.
1488422|NCT03055910|Diagnostic Test|Fractional Flow Reserve Measurement|Wire-based invasive measurement of the fractional flow reserve in the context of coronary angiography and percutaneous coronary intervention in order to assess the hemodynamic relevance of coronary artery stenoses
1488425|NCT03055871|Behavioral|Habit formation intervention|In addition to the control content and the planning content, this intervention will include material provided to the family that assists with creating physical activity support habits. The material contains a discussion of what habits are, straightforward examples, planning and pointers for forming habits. A key component of the habit intervention will be planning for context-dependent repetition.
1488507|NCT03055221|Drug|Intravenous Treprostinil|Intravenous treprostinil supplied in 20-mL vials and diluted to the appropriate concentration for administration.
1488508|NCT03055208|Radiation|gamma knife radiosurgery (15 Gy to 50% isodose)|Radiosurgery with a gamma knife resembles the application of a precisely focused, high single dose of ionizing irradiation.
1488426|NCT03055871|Behavioral|Physical activity planning intervention|This arm will receive the control education content, but will also be provided with family PA planning material. This material will include skill training content (workbook on how to plan for family PA). The material includes a brainstorming exercise for parents where they list physical activities they think their children have found fun in the past, as well as activities that they would find enjoyable to do as a family. We also have Canadian parental survey data on the most preferred co-physical activities for children 3-6. We will provide this material as prompts/suggestions. This list helps create the template for PA planning by contextualizing what the parents would like to do with their kids.
1488427|NCT03055858|Device|ADO II AS (PDA closure)|Closure of PDA using Amplatzer Duct Occluder II Additional Sizes (ADO II AS).
1488428|NCT03055845|Drug|STA363|STA363, containing 3 different doses of active ingredient, in a volume of 1.5 mL. Administered as intradiscal injection.
1488429|NCT03055845|Drug|Placebo|Matching placebo solution with identical appearance to the test product, used as reference treatment. Administered as intradiscal injection.
1488430|NCT03055819|Device|Brow Lift|Minimally Invasive Brow Lift
1488431|NCT03055806|Drug|IX-01 400 mg|IX-01 400 mg caplet
1488432|NCT03055806|Drug|Placebo|Placebo caplet
1488433|NCT03055806|Drug|IX-01 800 mg|IX-01 800 mg (Two 400 mg caplets)
1488434|NCT03055806|Drug|IX-01 1200 mg|IX-01 1200 mg (Three 400 mg caplets)
1488435|NCT03055793|Other|budesonide formoterol fixed combination|Asthmatic patients who will be on budesonide formoterol fixed combination treatment administered by Elpenhaler device.
1488436|NCT03055780|Device|CT-FFR. CTA. FFR|Study is to compare results of CT FFR against CTA and interventional FFR
1488437|NCT03055767|Drug|OnabotulinumtoxinA|The AB subject group will receive OnabotulinumtoxinA in the first treatment and saline placebo in the second.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
1488438|NCT03055767|Other|Placebo (Saline)|The BA subject group will receive saline and then Onabotulinumtoxin. A.Both groups will then receive OnabotulinumtoxinA in the last two treatments. There will be one treatment at the beginning of each 12 week block, meaning 4 treatments over the 48 week study period total. Progress check-ups will occur every 6 weeks during the study. Randomization will be via selection of sealed envelope.
1488439|NCT03055754|Procedure|Argon randomized arm|Endoscopic argon plasma coagulation
1488440|NCT03055754|Procedure|Control arm|No Endoscopic procedure
1488441|NCT03055741|Drug|Donepezil|5mg or 10mg, once a day, 24 weeks
1488442|NCT03055741|Drug|DHP1401|Total 500mg or 1,000mg was administrated in two divided doses a day for 24 weeks
1488443|NCT03055741|Drug|Placebo|Placebo was administrated in two divided dosed a day for 24 weeks
1488444|NCT03055728|Diagnostic Test|Rapid strep antigen detection test|Pharyngeal swab for rapid antigen detection of streptococcus
1488445|NCT03055728|Diagnostic Test|throat culture|Pharyngeal swab for culture for bacteria (specifically streptococcus) presence
2001321|NCT03063450|Other|Placebo|Matched placebo consisting of sterile 0.9% sodium chloride as a 30-minute IV infusion, on Day 1 of every 14 day treatment cycle
1488447|NCT03055702|Other|Mobile phone text message reminder|an SMS remind subjects to come for scheduled clinic appointment 24-72 hours before
1488448|NCT03055689|Behavioral|Educational telephone intervention|Subjects will receive a nurse-led educational telephone intervention for bowel preparation 24-48 hours before the colonoscopy
1488449|NCT03055689|Behavioral|Standard education for colonoscopy|Standard education for bowel preparation at the time of colonoscopy scheduling
1488450|NCT03055676|Other|Early drain removal|Removing drain(s) on postoperative day 3
1488451|NCT03055676|Other|Late drain removal|Removing drain(s) on postoperative day 5 or later
1488452|NCT03055663|Other|Sedation by watching virtual reality sedative program|Patients watch three-dimensional virtual reality program with headset and headphone during surgery.
1488453|NCT03055663|Procedure|Sedation by using intravenous sedative|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
1488454|NCT03055663|Drug|Midazolam|Patients receive intravenous sedative (midazolam 1-2 mg bolus with 1 mg maintenance dose every 10- 30 minutes)
1488455|NCT03055637|Procedure|Furlow double opposing z-plasty|* Furlow, (1986) has described a technique for palatoplasty combining the principles of mucosal lengthening with creation of an intact muscular sling in the palate with double opposing Z-plasty. On the soft palate, mirror image Z-plasties are drawn, one for the nasal musoca and the other oral flaps, the nasal flaps are developed and closed first .The oral flaps are then approximated. The defect created usually closes readily. The closure lines of the two soft plate layers do not overlap, minimizing the potential for contracture. Also, this repair permits closure of the hard palate without lateral incisions
1488456|NCT03055637|Procedure|Two flap palatoplasty|design the 2-flap palatoplasty, with a 2-layer closure in the hard palate and 3-layer closure in the soft palate,
1488457|NCT03055624|Device|Embosphere microparticles for prostate artery embolization|Pelvic angiograms will be performed and microspheres delivered to the arteries supplying the prostate to alleviate symptoms of benign prostatic hyperplasia.
1488458|NCT03055611|Drug|ELOCTA|Extended half-life factor VIII product
1488459|NCT03055611|Drug|ALPROLIX|Extended half-life factor IX product
1488460|NCT03055598|Drug|Ferric Citrate|Doses can be adjusted as needed by 1 to 2 tablets up to a maximum of 12 tablets daily. Dose can be titrated at 1-week or longer intervals.
1488461|NCT03055585|Biological|Wolbachia-infected Aedes aegypti mosquitoes|Deployment of Wolbachia-infected Aedes aegypti mosquitoes
1488462|NCT03055585|Other|standard practice dengue control|standard practice dengue control activities conducted by dengue control program
1488463|NCT03055572|Other|Olfactory Training with Essential Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Essential oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
2001322|NCT03063151|Diagnostic Test|Surface Electromyography (EMG)|
1488464|NCT03055572|Other|Olfactory Training with Pure Fragrance Oils|Participants will be instructed to sniff one of four provided odors for approximately 10 seconds followed by a 10 second break before repeating with each successive odor for a total of 5 minutes. Pure fragrance oils will be used for the odors. The intervention will be completed in the morning before breakfast and in the evening before bed. Participants will document compliance by completing a log of olfactory training sessions.
1488465|NCT03055559|Dietary Supplement|Globifer Forte|
1488466|NCT03055546|Drug|Oxytocin|intranasal administration of oxytocin
1488467|NCT03055546|Drug|Placebo|intranasal administration of placebo
1488468|NCT03055533|Behavioral|Headsprout reading program|Headsprout is a commercially available, computer-based program reading intervention that can be tailored to meet the individual needs of each child. Participants will have treatment sessions with a trained therapist lasting one to two hours, two to four days a week, for approximately twelve weeks.
1488469|NCT03055520|Other|cognitive training|The Kumon method (www.kumon.com) of arithmetic calculation employs the errorless-learning (EL) strategy and consists of a structured, hierarchical series of exercises, beginning with simple ones (e.g. addition and subtraction) and then proceeding to more complex exercises (e.g. advanced algebra, calculus).
1488470|NCT03055520|Other|placebo|nonspecific recreation including befriending and free simple activities.
2001323|NCT03060772|Drug|Pioglitazone|Participants will take 30 mg of pioglitazone once daily for a total of two to four weeks for those randomized to therapy, until the next bronchoscopy is performed. Participants will receive 14 to 28 tablets of active pioglitazone, which is enough to complete the minimum 14-day course of therapy.
1488474|NCT03055494|Biological|Secukinumab|Secukinumab 300 mg s.c. at randomization, Weeks 1, 2, 3, and 4 followed by monthly dosing up to Week 48
1488475|NCT03055494|Biological|Placebo|Placebo s.c. at randomization, Weeks 1, 2, 3, 4, and 8; secukinumab 300 mg s.c. at Weeks 12, 13, 14, 15, and 16 followed by monthly dosing up to Week 48
1488476|NCT03055481|Other|High irradiance level of phototherapy|High irradiance level of phototherapy: the target irradiance level is 30-35uW per square centimeter per nanometer of wavelength.
1488477|NCT03055481|Other|Low irradiance level of phototherapy|Low irradiance level of phototherapy: the target irradiance level is 12-15uW per square centimeter per nanometer of wavelength
1488478|NCT03055468|Behavioral|Peer support|Peer support and antidepressant medications
1488479|NCT03055455|Diagnostic Test|MR imaging|Conventional structural imaging will be combined with advanced neuroimaging modalities to evaluate integrity of white matter tracts, regional brain perfusion, and the 3-dimensional volume of specific brain structures.
1488480|NCT03055442|Other|Dosage of myo-inositol|Quantitative analysis of myo-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
1488481|NCT03055442|Other|Dosage of D-chiro-inositol|Quantitative analysis of D-chiro-inositol was performed by gas chromatography-mass spectrometry (GC-MS)
1488482|NCT03055429|Other|Full Scale Unit|Pre-test, usability, post-test
1488483|NCT03055416|Other|Mobile Men App Prototype|Testing of app functionality
1488484|NCT03055403|Drug|M201-A Injection|Active Substance: M201-A Route of administration: continuous intravenous injection
1488485|NCT03055403|Drug|Placebo|Saline Placebo for M201-A Route of administration: continuous intravenous injection
1488486|NCT03055390|Drug|hyoscine butylbromide|Intravenous administration of hyoscine butylbromide during first stage of labor
1488487|NCT03055390|Drug|placebo|2ml of saline intravenous
1488488|NCT03055377|Drug|N-acetyl cysteine|N-acetylcysteine 1200 mg twice daily for 12 weeks (administered orally)
1488489|NCT03055377|Drug|Placebo oral capsule|Placebo (matched in appearance to N-acetylcysteine to preserve double-blind) twice daily for 12 weeks (administered orally)
1488490|NCT03055351|Behavioral|Stop&Go Intervention|Stop&Go intervention will be based on Self-determination theory. Patients will participate in four practically-oriented training sessions, focused on (1) nutrition and oral hygiene, (2) sleep habits and self-care, (3) physical activity and exercise, and (4) smoking cessation. In addition, the entire inpatient detoxification centre will be adapted to encourage autonomous physical activity and to reinforce the ideas presented in the training sessions.
1488491|NCT03055338|Drug|MK-8189|Dose strengths: 4 mg (1 tablet); 8 mg (2 tablets); 12 mg (3 tablets)
1488492|NCT03055338|Drug|Risperidone|Dose strengths: 2 mg (1 capsule); 4 mg (2 capsules); 6 mg (3 capsules)
1488493|NCT03055338|Other|Placebo|Double dummy matching placebo for the MK-8189 tablet and Risperidone capsule treatment arms
1488494|NCT03055325|Other|Observational study of patients undergoing surgery|Cognitive testing, testing of heart rate variability and collection of blood samples
1488495|NCT03055312|Drug|TPC|"Conventional chemotherapy(choose a):
TX:(Docetaxel 75mg/m2 iv day1 and Capecitabine 950mg/m2 po twice daily days 1-14)every 3 weeks.
GT:(Paclitaxel 175mg/m2 iv day1 and Gemcitabine 1250mg/m2 iv days 1 & days 8)every 3 weeks.
GC:(Gemcitabine 1000mg/m2 on days 1 & days 8 and Carboplatin by Area Under Curve (AUC) 2 iv on days 1 & days 8) every 3 weeks"
1488496|NCT03055312|Drug|Bicalutamide 150 mg|Bicalutamide 150mg/day,every 28 days
1488497|NCT03055299|Other|COMEX intervention|Comprehensive Exercise
1488498|NCT03055286|Drug|CWP232291|For all cohorts, a fixed dose of ara-C at 1 G/m2 will be administered IV over 2 hours daily from Day 1 to Day 5 following CWP232291 infusion.
1488499|NCT03055273|Behavioral|SOCIABLE|SOCIABLE services involve a nurse, and occupational therapist and a handyman to support function among older adults with end stage renal disease. There is particular emphasis on supporting the social function and the physical and everyday living function.
1488500|NCT03055260|Device|Blood flow restriction cuff|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
1488501|NCT03055260|Device|Blood Flow restriction Cuff-Placebo|The intervention is the wearing of a cuff-like band around the affected limb, of which partially restricts blood flow to the limb.
1488502|NCT03055247|Drug|Ibuprofen|Ibuprofen: 3 mg/kg tid (total daily dose: 9 mg/kg); administered orally from day 1 to day 5 and then from day 14 to the day before the last LP.
1488503|NCT03055247|Drug|Myelostim|Myelostim (G-CSF): 5 µg/kg bid (total daily dose 10 µg/kg); administered subcutaneously from day 19 to the day of the last LP.
2001324|NCT03062553|Behavioral|Metacognitive Training (MCT)|MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions.
1488511|NCT03055182|Other|Physical rehabilitation program|Patients participate during 4 weeks to a physical rehabilitation program.
1488512|NCT03055169|Genetic|genetic analysis|
1488513|NCT03055169|Biological|blood and stools samples|
1488514|NCT03055156|Device|Low rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
1488515|NCT03055156|Device|High rebound mattress toppers|Patients will sleep on this mattress topper during their diagnostic sleep study.
1488516|NCT03055143|Drug|SPARC-08-038|2 mg/ml intravenous infusion
1488517|NCT03055143|Drug|Ref-08-038|2 mg/ml intravenous infusion
1488518|NCT03055130|Other|Thinprep Cytology Test (TCT) and HPV infection types were tested by gynecologist|
1488519|NCT03055117|Behavioral|Group-based exercise rehabilitation|Group- based physiotherapy-led exercise rehabilitation
1488520|NCT03055117|Behavioral|Individual exercise rehabilitation|Individual physiotherapy-led exercise rehabilitation
1488521|NCT03055117|Behavioral|Home exercise|Supervised home exercise
1488522|NCT03055104|Other|management of severe malnutrition|multidisciplinary assessment; guideline for the management of severe malnutrition in PUTH
1488523|NCT03055091|Other|Xylitol syrup|Each dose will be 5 mL of 400 g/L and subjects will receive Three to 5 doses will be given each day.
1488524|NCT03055091|Other|Placebo|Each dose looks and tastes like the xylitol syrup but it is not microbial. Each dose will be 5 mL of 300 g/L of sorbitol. Three to 5 doses will be given each day.
1488525|NCT03055078|Biological|mesenchymal stem cells|Patients in the cell treated group were given umbilical cord derived mesenchymal stem cells by intravenous infusion besides conventional therapy. There was only conventional treatment in the control group. All patients after treatment for 1months, 3months, 6months and 9months were evaluated respectively the therapeutic effect.
1488526|NCT03055052|Other|Standard formula for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
1488527|NCT03055052|Other|Formula with higher protein and new fat blend for preterm infants|Reconstituted in water and given to infants at more than 50% of feedings.
1488528|NCT03055026|Drug|Rivaroxaban|Tablets
1488529|NCT03055026|Drug|Placebo|Tablets
1995338|NCT02790892|Behavioral|Art therapy - pre and post test measures|12 weeks of 90 minutes of art therapy with pre and post test measures to determine changes in social support and levels of diabetes distress
1995339|NCT02789813|Drug|Valproic Acid|Once oral administration of 500mg before exposure therapy.
1995340|NCT02789813|Drug|Placebo|Once oral administration of 500mg before exposure therapy.
1995341|NCT02789813|Behavioral|Fear reactivation|Fear reactivation before exposure therapy.
1995342|NCT02789813|Behavioral|No fear reactivation|No fear reactivation before exposure therapy.
1488536|NCT03055000|Biological|AGS-v|AGS-v (unadjuvanted) as a suspension in WFI (0.5mL) on Day 0 and on Day 21
1488537|NCT03055000|Biological|AGS-v + adjuvant|ISA-51-adjuvanted AGS-v emulsified in WFI (0.5mL) on Day 0 and on Day 21
1488538|NCT03055000|Other|Placebo|WFI (0.5mL) on Day 0 and Day 21
1488539|NCT03054987|Procedure|Endoscopic Balloon Sphincteroplasty|EBS is a technique in which an 8 to 20mm balloon is used to enlarge (dilation) the opening of the bile duct. Following dilation, the stone is removed using routine methods, such as a ballon or basket.
1488540|NCT03054987|Procedure|Laser Lithotripsy|This technique helps to directly see the bile duct stone. A catheter is inserted to reach the stone. Using this catheter, the energy from laser (laser lithotripsy) can be accurately focused onto the stone to cause stone break-up. After the stone is broken to small pieces it can be removed by usual methods such as use of a balloon or a basket
1488541|NCT03054974|Other|Modern rehabilitation treatment|PT 1 hour per day and OT 30min per day
1488542|NCT03054974|Other|Modern rehabilitation &TCM|Traditional Chinese Medicine, including massage and medicated bath
1488543|NCT03054974|Other|modern rehabilitation &Baimai Ruangao|modern rehabilitation treatment with Baimai Ruangao and massage
1488544|NCT03054974|Other|modern rehabilitation &Tibetan medicine|modern rehabilitation treatment and Tibetan medicine(medicated bath with wuweiganlu and rub with baimairuangao)
1488545|NCT03054961|Device|Near-infrared spectroscopy|Measurement of CCO redox state and cerebral oxygenation during epileptic seizures.
1488546|NCT03054948|Drug|SMOFLipid|SMOFlipid is a lipid emulsion formed using soybean oil, medium chain triglycerides, olive oil, and fish oil.
1488547|NCT03054948|Drug|Standard therapy|In most cases standard therapy will be IntraLipid.
1488548|NCT03054935|Other|Indirect Calorimetry|Measurement of resting energy expenditure
1488549|NCT03054922|Drug|Normal Saline|
1488550|NCT03054922|Drug|Lactated Ringer|
1488551|NCT03054922|Drug|Normosol-R Inj|
1488554|NCT03054896|Drug|Venetoclax|Venetoclax is an Antineoplastic Agent; BCL-2 Inhibitor
1488555|NCT03054896|Other|DA-EPOCH-R|Intensive chemotherapy regiment
1995343|NCT02789553|Other|First starch meal then meal with glucose syrup|Before bypass surgery, patients will take randomized meal. One day a starch meal and another day a glucose syrup meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
1488558|NCT03054857|Drug|Dexmedetomidine|After skin incision, the dexmedetomidine group received a loading dose of 0.5 mcg/kg of Dexmedetomidine in 20 minutes followed by a continuous IV infusion at 0.4 mcg/kg/hr until the end of operation.
1488559|NCT03054857|Drug|Placebo|The control group received a loading dose and continuous IV infusion of normal saline at the same volume and rate as in the dexmedetomidine group
1488563|NCT03054831|Drug|liquid oxycodone|"The group will include 25 patients (children 2-5 years old). In this group the children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube before the procedure at the beginning of general anesthesia (after intubation).
In this group 25 children will be randomized to receive 0.1mg/kg of liquid oxycodone via an orogastric tube after the procedure at the end of general anesthesia (before extubation).
The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally before the surgery in pre-op holding.
The group will include 25 patients (children 6-8 years old). In this group the children will be randomize to receive 0.1 mg/kg of liquid oxycodone orally after surgery in the Post Anesthesia Care Unit (PACU)."
1995344|NCT02789553|Other|First meal with glucose syrup then starch meal|Before bypass surgery, patients will take randomized meal. One day a meal with glucose syrup and another day a starch meal. 3 months after surgery, they will take these 2 randomized meal again, one day the first one, and the day after the other one.
1998518|NCT01285037|Drug|Cisplatin|Cisplatin given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, cisplatin may be continued as monotherapy until progression of disease. Participants discontinuing cisplatin therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
1488566|NCT03054792|Drug|18F-FAZA (F18-Fluoroazomycin Arabinoside)|Intravenous administration of a hypoxia marker, 18F- Fluoroazomycin arabinoside (FAZA), before a PET-MR imaging in order to identify areas of lower oxygen content on samples of a tumour.
1488567|NCT03054792|Diagnostic Test|Blood Oxygen Level Dependent [BOLD] MRI|BOLD is a non-invasive T2*-weighted MRI technique that is sensitive to the microvascular deoxyhemoglobin concentration. BOLD has the potential to monitor changes in tissue oxygenation in response to a gas breathing challenge to induce contrast.
1488568|NCT03054792|Diagnostic Test|Diffusion-Weighted [DW] MRI|DW MRI is a non-invasive technique that provides quantitative biophysical information about the movement of water in tissues and reflects the anisotropy of normal and pathologic cells
1488569|NCT03054792|Diagnostic Test|Magnetic Resonance Spectroscopy [MRS]|MRS is a non-invasive imaging technique that enables the generation of spectral profiles of low molecular weight metabolites that reflect status of a tissue
1488570|NCT03054779|Other|Canola Oil|Regular canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
1488571|NCT03054779|Other|High oleic acid canola oil|High oleic acid canola oil will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily.
1488572|NCT03054779|Other|Western diet oil combination|"A typical Western diet fat intake as a control treatment, comprised of 11% MUFA, 11% PUFA (9% omega-6 fatty acids and 2% omega-3 fatty acids), and 13% SFA, will be iso-calorically incorporated into fruit smoothies made with milk and consumed twice daily"
1488573|NCT03054766|Procedure|Ranibizumab combined macular laser|subjects in one group receive both macular laser photocoagulation and ranibizumab injections but ones in the other group just received ranibizumab injection.
1488574|NCT03054766|Drug|Ranibizumab|all subjections received 3+PRN ranibizumab injections by BCVA stabilization
2001325|NCT03062553|Behavioral|Sham/MCT|"The Sham/MCT group will include application of random patterns of low-grade currents to the same brain region as the neuromodulation condition.
MCT is a group-based program developed directly from current cognitive neuropsychiatry research findings on schizophrenia and psychosis. MCT shares knowledge gained in research labs to help individuals experiencing psychosis become more aware of the thinking patterns involved in their illness. The main purpose of the metacognitive training is to help people change the thinking patterns that cause delusions, thereby avoiding relapse into illness or reducing the impact of delusions."
1488576|NCT03054740|Drug|Gebauer Ethyl Chloride|Will be administered according to manufacturers recommendations which is to spray the aerosol can for 4-10 seconds from a distance of 3 to 9 inches. Do not spray longer than 10 seconds.
1488577|NCT03054740|Drug|Nature's Tears|Sterile water mist will be administered 1-2 sprays prior to intravenous access
1488580|NCT03054714|Device|catheter replacement|catheter removal and delayed replacement, versus exchange over a guidewire
1488581|NCT03054701|Other|Hip specific resistance exercise|Hip specific resistance exercise
1488582|NCT03054701|Other|Knee specific resistance exercise|Knee specific resistance exercise
1488583|NCT03054688|Device|Somnotouch NIBP|Somnotouch NIBP in addition to standard blood pressure measurement
1488584|NCT03054675|Diagnostic Test|Spirometry|Absolute FEV1 is measured in every patient using a handheld spirometer
1488585|NCT03054662|Other|Education|Education of patients and caregivers about haemophilia and carriers of haemophilia.
1488586|NCT03054662|Diagnostic Test|Improve biological diagnosis and follow-up of haemophilia|train the laboratory to the diagnosis ans follow-up un haemophilia
1488587|NCT03054662|Drug|Implement haemostatic non substitutive care of haemophilia|Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers
1488588|NCT03054662|Other|Implement non haemostatic care of haemophilia|Implement regular physiotherapy, develop dental care, promote the regular use of pain killers
1488589|NCT03054623|Procedure|DRIL procedure|The DRIL procedure involves creation of a bypass from an arterial inflow site (usually mid brachial artery) proximal to the fistula inflow, to the bifurcation of the brachial artery distal to the fistula, with ligation of the intervening native vessel, thus restoring distal flow while preserving flow through the fistula.
1488590|NCT03054610|Drug|Betamethason Sodium Phosphate|
1488591|NCT03054610|Drug|Ropivacaine|
1488592|NCT03054610|Drug|Botulinum Toxins, Type A|
1488593|NCT03054597|Device|Circular light motion|Exercise with circular light motion
1488594|NCT03054597|Device|Diagonal light motion|Exercise with diagonal light motion
1488595|NCT03054597|Device|Peripheral light motion|Exercise with peripheral light motion
1488596|NCT03054597|Procedure|Exercise|
1488597|NCT03054584|Other|Collecting Nevi|Will be collecting Nevi and completing a DNA analysis, no intervention will be made.
1488598|NCT03054558|Other|Pelvic ultrasound both two dimensional and three dimentional|
1488599|NCT03054545|Drug|Iguratimod|Iguratimod 25mg twice a day, oral administrated.
1488600|NCT03054532|Drug|Durvalumab|Durvalumab intravenous 1500 mg
1488602|NCT03054519|Drug|Metformin|Participants will be prescribed up to 2,000 mgs daily of metformin
1488603|NCT03054519|Drug|Placebo|Placebo pills will appear identical to the metformin to maintain blinding of participants and investigators.
2001326|NCT03062553|Device|transcranial alternating current stimulation (tACS)|tACS is a non-invasive brain stimulation technique in which a weak electrical current is applied to the head. The current passing through the brain produces small changes in the excitability of the brain regions falling within the current flow. The current occur in an alternating manner (University of California-Berkeley, 2015).
2001327|NCT03058692|Biological|Influenza Multimeric-001 Vaccine|The M-001 vaccine consists of 3 repetitions of 9 conserved linear epitopes that are prepared as a single recombinant protein. The M-001 vaccine is expected to protect against existing as well as future seasonal and pandemic virus strains.
2001328|NCT03058692|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
1488607|NCT03054493|Behavioral|no intervention|no intervention
1488608|NCT03054480|Device|Fractional Micro-Needle Radiofrequency|
1488609|NCT03054480|Drug|Botulinum toxin type A|
1488610|NCT03054467|Drug|Caduet 10Mg-20Mg Tablet|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
1488611|NCT03054467|Drug|NorvasC® 10 mg Tablets|Patients are randomly assigned to receive either amlodipine therapy (NORVASC 10 mg/day) or amlodipine/atorvastatin combination (CADUET 10/20mg) for 6 months. The starting dose of the drung is either 5mg amlodipine or 5/20mg CADUET. After 4 weeks, if the 5mg amlodipine is well tolerated, the dose is titrated to 10mg and 10/20mg CADUET
1488612|NCT03054454|Procedure|Podiatry|Podiatry treatments and care from the multidisciplinary team.
2001329|NCT03058692|Biological|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
2001330|NCT03058692|Other|Placebo|Placebo is saline injection
2001331|NCT03057769|Drug|Papillary epinephrine spraying|All patients in this group receive 20 ml of 0.02% epinephrine sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
1488616|NCT03054415|Procedure|endoscopy|colonic biopsies during endoscopy and anal manometry with barostat and anal endoflip
1488621|NCT03054376|Other|Immobilization|Full length cast of one leg R/L randomized
1488622|NCT03054376|Other|Training with non immobilized leg|Exercise training will be conducted with the non-immobilized leg during the immobilization period of two weeks
1488623|NCT03054376|Other|Exercise training with both legs|Exercise training will be conducted regularly on a cycle ergometer during a four week period
1488624|NCT03054363|Drug|Tucatinib in Combination with Palbociclib and Letrozole|"Starting dose of combination therapy :
Tucatinib 300 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily
Dose modifications, if necessary:
If Palbociclib toxicity increased:
Tucatinib 300 mg PO BID Palbociclib 100 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily
If Tucatinib toxicity increased:
Tucatinib 250 mg PO BID Palbociclib 125 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily
If Palbociclib and Tucatinib toxicity increased:
Tucatinib 250 mg PO BID Palbociclib 100 mg PO daily 21 day on, 7 days off Letrozole 2.5 mg PO daily
Additional dose levels per protocol if PKs indicate a significant change to the metabolism of Tucatinib regardless of clinical toxicity."
1488625|NCT03054350|Drug|Vadadustat|Daily oral dose
1488626|NCT03054350|Drug|Placebo|Daily oral dose
1488627|NCT03054337|Drug|Vadadustat|
1488628|NCT03054337|Drug|Placebo|
1488629|NCT03054324|Diagnostic Test|Fractional Flow Reserve|Coronary fraction flow reserve (FFR), the ratio of the mean coronary pressure distal to a coronary stenosis to the mean aortic pressure during maximal coronary blood flow (hyperemia), defines the hemodynamic significance of coronary artery narrowing.
1488630|NCT03054311|Behavioral|Lifestyle Matters|
1488631|NCT03054298|Biological|Hu-CART meso cells|Intravenous or intrapleural lentiviral transduced huCART-meso cells in 5 cohorts with and without cyclophosphamide in a 3+3 dose escalation design.
1488632|NCT03054285|Drug|Levetiracetam|Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
1488633|NCT03054272|Behavioral|Video|A 13-minute video based on a suggested CICO algorithm from the Difficult Airway Society that was produced at the University of Montreal Simulation Centre using high-fidelity settings.
1488634|NCT03054259|Drug|Rituximab|1000mg rituximab infusions on days 1 and 15 (monoclonal antibody)
1488635|NCT03054259|Drug|Methylprednisolone|100mg infusion on days 1 and 15
1488636|NCT03054259|Drug|Normal Saline|250ml infusion on days 1 and 15
1488637|NCT03054246|Other|Evaluation of chewing side preference|"The visual analog scale (VAS) is used. The individual will be asked to make 1 mark on a 10-cm line with  always left and always right at either end and with  no preference in the middle."
1488638|NCT03054233|Procedure|Crossed leg sitting position|Spinal anesthesia done in crossed leg sitting position
1488639|NCT03054220|Drug|Dextromethorphan 5 MG|
1488640|NCT03054220|Drug|Tramadol 10 mg|
1488641|NCT03054220|Drug|Duloxetine 60mg|
1488642|NCT03054220|Drug|Paroxetine 20 mg|
1488643|NCT03054207|Drug|Clopidogrel 300Mg Tablet|
1488644|NCT03054207|Drug|Prasugrel 60Mg|
1488645|NCT03054194|Drug|E2730|capsules
1488646|NCT03054194|Drug|Placebo|capsules
1488647|NCT03054181|Biological|HyQvia|
1488648|NCT03054168|Drug|Sustanon 250|The frequency of the injection will be every 2 weeks, 250mg of testosterone, intramuscular injection.
1488649|NCT03054168|Drug|Zoladex|The frequency of the injection will be just one injection, 3.6 mg of Zoladex, Subcutaneous injection (abdomen).
1488650|NCT03054168|Other|Placebo|
1488651|NCT03054155|Device|Alexandrite Laser|Alexandrite 755nm hair removal laser
1488652|NCT03054142|Other|no intervention|
1488757|NCT03053336|Behavioral|App-technology to increase physical activity|Access to the smartphone-app during 12 weeks. A personal step goal is set for each individual in the app.
1488653|NCT03054129|Other|Rehabilitation and balance training|"Firstly, we will use heat pack as a modality to affected shoulder. Then, stretching will be applied as hold-relax technique in PNF for shoulder flexion, abduction, internal and external rotations. Isotonic exercises will be done with elastic bands for strengthening.
Home exercises will include postural, stretching and strengthening exercises. Balance exercises will receive as non-supervised program."
1488654|NCT03054129|Other|Rehabilitation program|Rehabilitation program will be same in this group except balance exercises.
1488655|NCT03054116|Diagnostic Test|Airflow pertubation device|Participants have airway resistance measured at the mouth by tidal breathing into a mouth-piece connected to the airflow perturbation device.
1488656|NCT03054103|Drug|Ketamine 10 MG/ML: 0.5 ML|5 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
1488657|NCT03054103|Drug|Ketamine 10 MG/ML: 1 ML|10 mg ketamine IV given just prior to onset of case. Then titrated midazolam up to 2 mg IV at beginning and during case.
1488658|NCT03054103|Drug|Normal saline|Preoperative control: Normal saline placebo given preoperatively. Then protocol followed for titration of midazolam up to 2 mg IV at beginning and during case.
1488659|NCT03054090|Other|Quality Improvement Support|Practices will receive a blended strategy of quality improvement facilitation to help participating practices incorporate PCOR clinical and organizational findings while building their overall practice capabilities. Primary care practices will be provided tools and training to improve the rates of screening and treatment of risk factors for heart attacks and strokes, as well as other chronic illnesses and the delivery of preventive services.
2001332|NCT03057769|Drug|Papillary saline spraying|All patients in this group receive 20 ml of saline sprayed on the duodenal papilla, over a period of 10-15 seconds using sphincterotome, at the end of procedure, just before the withdrawal of endoscope.
1488661|NCT03054064|Device|Indego Exoskeleton|Six study sessions including five Indego training sessions over two weeks.
1488662|NCT03054051|Behavioral|Tumaini Mobile Phone Game|Tumaini is a scenario-based role-playing game application, optimized for use on low-cost Android smartphones. Participants will be invited to play the game for at least ten hours over a period of three weeks. The game is designed to: educate players about sexual health and HIV/AIDS; build risk-reduction skills and related self-efficacy for prevention of HIV/STIs and unintended pregnancy; challenge HIV stigma and harmful gender norms; and promote parent-child dialogue.
1488663|NCT03054038|Drug|Afatinib|Given by mouth
1488664|NCT03054038|Biological|Necitumumab|Given IV
1488665|NCT03054038|Other|Laboratory Biomarker Analysis|Correlative studies
1488666|NCT03054025|Device|Smart Phone Monitoring Device|Use activity tracker application
1488667|NCT03053999|Other|Genome Sequencing|Analyses includes genome sequencing based analysis to identify novel germline variations in blood DNAs and somatic changes in tumor DNAs, which may contribute to the development of pancreatic tumors.
1488668|NCT03053999|Other|Data Review|Clinical information retrieved from the patients' medical record including: de-identified demographic data (age, gender, race/ethnicity), medical history, family history, disease status, treatment response, survival information, and selected clinical data from medical record (calcium levels, calcitonin levels).
1488669|NCT03053986|Dietary Supplement|Apple polyphenols|1 tablet per day at evening before sleeping
1488670|NCT03053986|Other|Placebo|1 tablet per day at evening before sleeping
1488671|NCT03053973|Device|nocturnal noninvasive ventilation|Patients will be initiated on bilevel positive pressure non-invasive ventilation via a mask according to regular clinical practice.
1488672|NCT03053973|Other|Standard Care|Standard COPD care is given to all patients (pharmacological management, oxygen, rehabilitation if neccesary, etc.)
1488673|NCT03053960|Device|Computed Tomography|Undergo helical CT scan
1488674|NCT03053960|Device|Positron Emission Tomography and Computed Tomography Scan|Undergo PET/CT scan
1488675|NCT03053960|Device|Cone-Beam Computed Tomography|Undergo CBCT scan
1488676|NCT03053960|Device|Magnetic Resonance Imaging|Undergo MRI scan
1488677|NCT03053960|Procedure|Therapeutic Conventional Surgery|Undergo resection of tumor
1488678|NCT03053960|Procedure|Histopathologic Examination|Correlative studies
1488679|NCT03053947|Drug|Intranasal Ketamine|Administration of intranasal ketamine at a dose from 3 to 9 mg/kg for safe and effective procedural sedation for laceration repair in the ED for children aged 1 to 12 year-old.
1488680|NCT03053934|Behavioral|Online video-based counselling|Videoconferencing facilitates communication between individuals (i.e., the counsellor and the client) in different geographical locations enabling them to interact simultaneously with each other on a computer monitor in real time. In other words, both the client and the therapist communicate live using both visual and audio aids simulating in-person therapy albeit from two separate geographical locations.
1488681|NCT03053934|Behavioral|Traditional in-person counselling|"Traditional in-person counselling is often referred to as face-to-face and can be loosely defined as any mental health intervention, whereby the clinician is in the same room with a client. The terms in-person and same room are used less frequently, but it has been argued that these terms are more descriptive (since in videoconferencing, clients are also seen face-to-face on screen). Therefore, the current study uses the term in-person to describe traditional, face-to-face counselling."
1488682|NCT03053921|Procedure|recession coverage|recession coverage done using Zuchellis technique
1488683|NCT03053921|Procedure|recession coverage and membrane|recession coverage done using Zuchellis technique with placental membrane
1488684|NCT03053908|Procedure|Actigraphy|Recording of sleep/wake cycle and TST by actigraphy to be completed at home by subject over 7 days
1488685|NCT03053908|Procedure|Nocturnal Polysomnograpahy (NPSG)|N1 habituation and N2 data collection
1488686|NCT03053895|Procedure|CSDH - Bedside twist drill technique|For patients randomized to bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic
1488687|NCT03053895|Procedure|CSDH - Operating Room Burr-hole technique|For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
1488688|NCT03053882|Other|mouthwash|mouthwash containing herbal peppermint or green tea
1488689|NCT03053869|Drug|Benzodiazepine - limited use strategy|"No routine use of any intraoperative benzodiazepines.
Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.
Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia."
1488690|NCT03053869|Drug|Benzodiazepine - Ad libitum strategy|"Administration of some benzodiazepine to most patients undergoing cardiac surgery.
Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy)."
1488691|NCT03053856|Drug|Pembrolizumab|Adjuvant pembrolizumab 200 mg every 3 weeks for up to 24 months. (treated with neoadjuvant concurrent chemoradiotherapy followed by curative resection)
1488692|NCT03053856|Procedure|Curative resection|Neoadjuvant concurrent chemoradiotherapy followed by curative resection
1488693|NCT03053856|Procedure|Neoadjuvant concurrent chemoradiotherapy|RT 44 Gy/22 Fractions for 5 weeks With Chemotherapy (Cisplatin 25mg/m2 once weekly, Paclitaxel 50mg/m2 once weekly)
1488694|NCT03053856|Drug|Cisplatin|25mg/m2 once weekly
1488695|NCT03053856|Drug|Paclitaxel|50mg/m2 once weekly
1488696|NCT03053843|Dietary Supplement|Mediterranean diet plus extra virgin olive oil|The patients in the intervention group will receive 1 liter of EVOO per week free of charge and dietary advice on how to follow a Mediterranean diet with contacts every two months. Dietary intervention will be carried out by nutritionists with previous experience in the PREDIMED study. All of them were registered, trained and certified for developing the PREDIMED intervention protocol that is similar to the one to be carried out in this study. The theoretical sessions with patients about dietary education shall be conducted in telephone form, using the internet and sending comprehensive written material to their homes that includes recipes, shopping lists, menus and explanations of typical food in the Mediterranean diet
1488697|NCT03053830|Drug|Ketamine|0.5mg/kg ketamine in normal saline. Infusion will be delivered during a 40 minute interval
1488698|NCT03053817|Other|Exercise group|Interval training will be performed for 21 minutes including a 3 minute warm-up and cool-down period. The interval program will be 15 minutes at 65-75% of maximal heart rate with 30 sec. bursts of exercise to 80-85%; intervals. Resistance training will be done as a circuit and will make use of weight machines and functional exercises. Resistance will be done in 2 sets of 15 repetitions and will last 24 minutes. The work load of the program is calibrated and is conducted at a specified rhythm. All exercise sessions will be supervised.
1488699|NCT03053804|Radiation|MR/PET|MR/PET with contrast media and FDG-18
1488700|NCT03053791|Procedure|Deep brain stimulation in mesencephalic locomotor region|Implantation of Electrodes in the Mesencephalic Locomotor Region for improvement of Locomotion and Gait
1488701|NCT03053791|Device|Implantation of a Deep brain stimulation system|Implantation of a Medtrinic Activa SC Impulse Generator for chronic Stimulation of the selected target.
1488702|NCT03053778|Other|Early follow-up|Early follow-up until 4 weeks after discharge
1488703|NCT03053765|Other|training in IPT|Follow-up training in IPT to determine which best enhances fidelity
1488704|NCT03053752|Procedure|Transcutaneous Electric Nerve Stimulation|Eight sessions were held, once a week, lasting twenty minutes. For this purpose, the electrodes of the acoustic surface Taichong (LR-3), Hé gǔ (Ll-4), Yanglingquan (GB-34) and Neiguan (PC-6) connected to the TENS equipment (EL 608, brand NKL). The current of choice for a BURST type, with intermittent pulses, isolated at a frequency of 2 Hz, ranging from 1 to 10 mA.
1488705|NCT03053739|Drug|Sildenafil 20mg and Bosentan 62.5mg|Sildenafil 20 mg three times a day and bosentan 62.5mg two times a day
1488706|NCT03053739|Drug|Sildenafil 20mg and Placebo|Sildenafil 20 mg three times a day and placebo (matched for bosentan)two times a day
1488707|NCT03053726|Procedure|Variable Frequency Stimulation|vary the frequency of the stimulation paremeter
1488708|NCT03053713|Behavioral|Mediterranean diet pattern|Subjects assigned to the Mediterranean diet pattern arm will receive nutrition advice from a Registered Dietitian (RD). The RD will meet with the subjects (in-person) to provide diet education at randomization, week 3 and week 6 of the intervention. Phone and e-mail follow-up will occur at week 2 and week 9 to provide cooking tips, recipes, videos and answer questions.
1488709|NCT03053713|Behavioral|Habitual diet (control)|Subjects assigned to follow their habitual group will be instructed to make no changes to their diet over 12 weeks.
1488710|NCT03053700|Drug|Bromonide 0.33% gel|Patients would be treated with full face application of bromonide 0.33% gel once daily for three months.
1488711|NCT03053700|Device|Intense Pulsed Light (M22)|Half of the patients' face would be subjected to three IPL treatment sessions three weeks apart from each other.
2001333|NCT03057769|Drug|Indomethacin|All patients without contraindications should be administrated with rectal indomethacin within 30 min before ERCP.
2001334|NCT03057106|Drug|Durvalumab|MEDI4736
1488714|NCT03053674|Other|Oral and written explanation|Oral and written explanation on importance of post-partum influenza vaccination for the health of their newborn infant
1488715|NCT03053674|Other|Follow-up questionnaire|Follow-up questionnaire to determine whether participants have receive post-partum vaccination
1488716|NCT03053648|Other|Self-acupressure|The subjects will be told to perform self-acupressure 30 min before sleep for 20 min every night for 4 weeks. Telephone follow-up will be made twice a week by the trained student research assistant during the 4-week treatment period to remind subjects to practice self-acupressure.
1488717|NCT03053648|Other|Sleep hygiene education|A training hand-out will be provided to each subject. The hand-outs included manualized sleep hygiene instructions. A registered nurse who has been trained by a clinical psychologist will be the instructor on sleep hygiene and activity scheduling. To enhance interaction and ensure the quality of teaching, each course will be conducted in a group of 5 participants.
1488718|NCT03053635|Drug|TLD1433 infusion and photodynamic therapy (PDT) treatment|TLD1433 is infused into the bladder, followed by repeated rinsing and treatment of bladder wall with photodynamic therapy (PDT).
1488719|NCT03053622|Biological|Mirikizumab Test|Administered SC
1488720|NCT03053622|Biological|Mirikizumab Test|Administered IV
1488721|NCT03053622|Biological|Mirikizumab Reference|Administered SC
2001335|NCT03057106|Drug|Tremelimumab|Tremelimumab
2001336|NCT03057106|Drug|Platinum-Based Drug|Pemetrexed, cisplatin, carboplatin or gemcitibine
1488722|NCT03053596|Device|DEB-TACE using anthracyclin loaded LifePearl™|The main purpose of this registry is to assess liver toxicity, treatment efficacy, and safety of DEB-TACE using anthracyclin loaded LifePearl™ for treatment of patients with unresectable hepatocellular carcinoma allocated to TACE treatment at multidisciplinary tumor board.
1488723|NCT03053583|Device|Laryngoscope blade|The POGO score assesses the percent of the glottic opening that can be seen with each blade
1488724|NCT03053570|Device|Cryoballoon|use Cryoballoon to isolation the Pulmonary Vein
1488725|NCT03053570|Device|Radiofrequency Energy(Contact Force)|use Radiofrequency Energy(Contact Force) to isolation the Pulmonary Vein
2001337|NCT03057015|Drug|Clonidine|50 mcg Clonidine added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the treatment group.
2001338|NCT03057015|Drug|Placebo|Normal saline added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in the placebo group.
1488728|NCT03053531|Device|"PockeTalker Hearing Assistive Device (HAD)"|Investigators will test impacts of the provision of the HAD on hearing and understanding, and preparation for discharge. Just prior to going home, consented subjects will answer a set of survey questions, using an electronic tablet to support impaired hearing.
1998519|NCT01285037|Drug|Gemcitabine|Gemcitabine given via IV infusion once a week for 2 weeks and then every 3 weeks. If the LY2801653 is terminated for LY2801653-related toxicity after a minimum of 4 cycles, gemcitabine may be continued as monotherapy until progression of disease. Participants discontinuing gemcitabine therapy may be allowed to continue single agent LY2801653 if they are receiving clinical benefit.
2001339|NCT03057015|Drug|Ropivacaine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
1488731|NCT03053505|Biological|faecal human microbiota transplant (FMT)|"Non-randomized group R: Patients with recurrent CD infection are treated with FMT in this group.
Randomized group FFMT: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with FMT."
1488732|NCT03053505|Drug|Vancomycin or Fidaxomicin|"Randomized group FAB: patients with initial CD infection who have severe disease or who are at high risk of recurrence or high risk of developing severe disease are treated with antibiotics (vancomycin per os 125mg four times a day for 10 days) in this group. In case of treatment failure changes in antibiotic regime (e.g. fidaxomicin per os 200mg per two times a day for 10 days) will be allowed in the line with the recommendations of current CDI treatment guidelines(13)."
1488733|NCT03053492|Device|Duck Duck Punch Play|The behavioral intervention will include playing a hands-free video game custom designed for stroke survivors.
1488734|NCT03053492|Behavioral|Commercially Available Game Play|The behavioral intervention will include playing a hands-free video game available off-the-shelf.
1488735|NCT03053479|Procedure|Laparoscopic sacrocolpopexy|see arm/group descriptions
1488736|NCT03053479|Procedure|Transvaginal mesh procedure|see arm/group descriptions
1488737|NCT03053479|Procedure|Amreich-Richter procedure|see arm/group descriptions
1488738|NCT03053466|Drug|CBT-501|Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). Each treatment cycle is comprised of 2 doses of study drug administered by IV infusion on Days 1, 15 on a 28-day cycle.
1488739|NCT03053453|Procedure|Spinal Surgery|TKA under standard of care spinal surgery.
1488740|NCT03053453|Device|Verasense Knee System device|Sensor measures and localizes peak load at the medial and lateral tibiofemoral joint interfaces. Loading data is thereby captured intra-operatively through the full range of movement (ROM) using the sensor system.
1488743|NCT03053427|Drug|Gabapentin enacarbil|Oral administration
1488744|NCT03053427|Drug|Placebo|Oral administration
1488745|NCT03053414|Dietary Supplement|Vitamin D (ergocalciferol and/ or cholecalciferol)|To evaluate effective repletion and supplementation for Vitamin D levels in patients with inflammatory bowel disease.
1488746|NCT03053401|Procedure|Adductor Canal Block|Under guidance of a linear ultrasound transducer probe (General Electric; GE). Performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg ( maximum of 40 mg ).
1488747|NCT03053401|Procedure|Femoral Nerve Block|Under guidance of a linear ultrasound transducer probe (General Electric;GE).Block will be performed using a 22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany).Solution to be injected will be a combination of Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) and methylprednisolone acetate 1 mg/kg (maximum of 40 mg ).
1488748|NCT03053401|Device|Ultrasound|Use of linear ultrasound transducer probe (General Electric;GE) to guide needle placement for both Adductor Canal Block and Femoral nerve Blocks
1488749|NCT03053401|Device|Stimuplex A needle|22-gauge 2-inch Stimuplex A needle ( B. Braun Medical Inc., Melsungen, Germany) used to perform both Adductor Canal Block and Femoral nerve Blocks.
1488750|NCT03053401|Drug|local anaesthetic injection|Ropivacaine 0.2 % ( 0.5 ml/kg, maximum of 30 ml) for either Adductor Canal Block and Femoral nerve Blocks.
1488751|NCT03053401|Drug|Steroid Drug|Methylprednisolone acetate 1 mg/kg (maximum of 40 mg ) for either Adductor Canal Block and Femoral nerve Blocks.
2001340|NCT03057015|Drug|Dexamethasone|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
1488754|NCT03053375|Device|MDCure|Battery powered portable pulsed electromagnetic therapy device
1488755|NCT03053362|Drug|Vortioxetine|Observing change in cognition using THINC-it tool in patients with MDD.
1488756|NCT03053362|Other|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:
Digit Symbol Substitution Test (DSST) Choice Reaction Time (CRT) One-back working memory tool Trail Making Test B (TMT-B) Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
1488758|NCT03053323|Behavioral|Lifestyle Intervention|The lifestyle intervention consists of three components: nutrition, physical activity, and other areas of wellness. The intervention is administered individually each week for 10 weeks and is tailored for women with a history of depression who are in the first trimester of pregnancy or trying to conceive.
2001341|NCT03057015|Drug|Epinephrine|Clonidine or Placebo added to the solution of 0.5% ropivacaine, 2 mg dexamethasone and 5 mcg/ml epinephrine for adductor canal block-present in both treatment and placebo groups.
1488760|NCT03053284|Drug|Pasireotide 0.6Mg Solution for Injection|Pasireotide 0.6Mg Solution for Injection will be given once per study visit
1488761|NCT03053284|Drug|Saline Solution|Saline Solution injection will be given once per study visit
1488762|NCT03053271|Drug|ATR-101|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks at the same dose level being used at the completion of the open-label dose-escalation period.
1488763|NCT03053271|Drug|Placebos|During the 4-week randomized withdrawal period, subjects will be dosed for 4 weeks with placebo that matches the same ATR-101 dose level being used at the completion of the open-label dose-escalation period.
1488764|NCT03053258|Device|Collection of exhaled breath sample|Collect exhaled breath sample from patients with suspected VAP
1488765|NCT03053245|Behavioral|Mobile Critical Care Program|The m-CCRP revolves around the central figure of a care coordinator who will organize and align recovery resources. The care coordinator is a registered nurse whose scope of practice includes health coaching, case managing, community organizing, and nursing care provider. The m-CCRP support team will consist of a critical care physician (Dr. Khan), a geriatrician with expertise in collaborative care (Dr. Boustani), an ICU collaborative care nurse (Dr. Lasiter), and a psychologist (Dr. Unverzagt). This team will meet weekly with the care coordinator. Drs. Khan and Boustani will be accessible to the coordinator through phone or pager at all times.
1488766|NCT03053245|Behavioral|Attention Control|Patients in this group will receive regular wellness calls from the research team.
1488767|NCT03053232|Device|Purse string suture device|Using purse string suture device to close gastrointestinal perforation under endoscopy.
1488768|NCT03053232|Device|Endoclips|Using endoclips to close gastrointestinal perforation under endoscopy.
1488769|NCT03053219|Drug|AC0010|Oral dose of 300mg bid,the two doses are advised to be administered at an interval of 12 hours
1488770|NCT03053206|Drug|ADE Protocol|"ADE chemotherapy
Cytarabine (100mg/m2 d1-d10 BD), Daunorubicin (50mg/m2 d1-d3) and Etoposide (100 mg/m2 d1-5) over a period of 10 days"
1488771|NCT03053193|Diagnostic Test|MammaPrint, BluePrint, and Full-Genome Testing|Agendia will run MammaPrint and BluePrint tests using the DiscoverPrint testing array.
1488772|NCT03053167|Drug|Irinotecan|Irinotecan: 180mg/㎡+NS250ml, ivgtt, 90min, d1 Every 3 weeks
1488773|NCT03053167|Drug|Raltitrexed|Raltitrexed: 3mg/㎡+NS100ml，ivgtt，15min, d1 Every 3 weeks
1488774|NCT03053154|Other|Sagittal pelvic tilt assessment|Each group passed by three phases of assessment. Firstly assess the pelvic tilt angles from sitting position. Secondly assess the pelvic tilt angles from dynamic sit to stand task. Thirdly, assess the ability to perform sit to stand task of each participant.
1488775|NCT03053141|Device|Rhythmia Mapping System|The Rhythmia Mapping System is a 3D electro-anatomical mapping system.
1488776|NCT03053128|Device|Cardiac shock wave therapy|Patients in CSWT group will receive CSWT for a 3-month therapy, located in their ischemia area with a energy of 0.09mJ/mm2. Patients will get therapy on every first week of the month and rest for following three weeks.
1488777|NCT03053128|Other|Sham cardiac shock wave (Control group)|Patients in sham CSWT group will receive sham cardiac shock wave, which is segregated by an air cushion.
1488778|NCT03053115|Drug|Liothyronine|Cases will take liothyronine drops in the morning and two hours after dinner
1488779|NCT03053115|Drug|Levothyroxin|Both cases and controls will take levothyroxine in the morning (entire dose for controls, reduced dose for cases)
1488780|NCT03053115|Drug|Placebos|Controls will take placebo two hours after dinner
1488781|NCT03053102|Drug|ACH-0144471|ACH-0144471 will be administered to all patients enrolled in the study.
1488782|NCT03053089|Drug|AGT-181|Human Insulin Receptor Monoclonal Antibody-Human alpha-L-iduronidase (HIRMAb-IDUA) Fusion Protein
1488783|NCT03053076|Other|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for safety and effect evaluation
1488784|NCT03053076|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
2001342|NCT03056781|Behavioral|social interaction|Participants will engage in a social interaction with another person
2001343|NCT03056781|Behavioral|food consumption|Participants will be offered food stuffs to eat/drink
1488789|NCT03053037|Procedure|final apical size instrumentation|root canal instrumentation to two different final preparation sizes
1488790|NCT03053011|Other|Vibrating bracelet|A bracelet with vibrations triggered randomly overnight. The sleeper's awakening capability will be evaluated each time the bracelet vibrates (5 times in the night).
1488791|NCT03052998|Drug|Ivermectin|Effect of Ivermectin on frequency of seizures
1488792|NCT03052985|Procedure|urinary incontinence, pelvic organ or rectal prolapse surgery|The observatory is planned for following women after surgery for urinary incontinence, pelvic organ prolapse, or rectal prolapse whatever the type of surgery (by laparoscopy, laparotomy or vginal route) or the use of a mesh
1488793|NCT03052972|Drug|18F-AV-1451|Subjects will receive single IV administration of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18FAV- 1451.
1488822|NCT03052712|Behavioral|social cognition|battery of tests of social cognition
1488823|NCT03052699|Procedure|vaginal Cesarean Section|follow-up to patients operated for vaginal Cesarean Section
1488824|NCT03052686|Other|Childbirth with uterine rupture|No intervention. Follow-up of women with rupture uterine at the childbirth.
1494115|NCT03012880|Drug|Ixazomib Citrate|Given PO
1488794|NCT03052959|Behavioral|Immediate Intervention|The 'BETTER' prevention practitioner intervention involves assessment of a person's current participation, or lack of participation, among domains of evidence-based chronic disease prevention and surveillance (CDPS) actions. The assessment is followed several days later by a supportive meeting with a prevention practitioner nurse, using principles of shared decision making and health coaching, to establish goals for accomplishing CDPS activities of the individual's choice during the subsequent six months to develop personal goals and targets for participating in CDPS actions during the following six months. In BETTER HEALTH: DURHAM, the prevention practitioner nurse will be a public health nurse from the Durham Region Health Department.
1488795|NCT03052959|Other|Wait List Intervention|The control arm will receive the prevention practitioner intervention 6 months after the intervention arm. Their outcomes will not be assessed in the study.
1488796|NCT03052946|Procedure|Bulking agent|Filling bulking agent in the anal canal
1488797|NCT03052946|Procedure|Endoanal electrostimulation|The technique used will be with a frequency of 30 to 40 Hz with pulse width of 200 ms with maximum intensity of 800mAmp and duration of 30 minutes
1488798|NCT03052933|Drug|Copanlisib|"For phase I study, participants will receive copanlisib (in combination with gemcitabine) IV infusion at a dose of 45 mg or 60 mg on Days 1, 8, and 15 of each 28-day treatment cycle. During phase I study, participants will be treated at the level of 45 mg/dose (level1), or 60 mg/dose (level II) of copanlisib. Maximal tolerated dose will be determined by standard 3+3 dose escalation design For phase II study, copanlisib dose level, determined during phase I study, will be administered on Days 1, 8, and 15.
Maximum 6 cycles of gemcitabine and copanlisib combination and subsequent copanlisib monotherapy in participants with ≥ SD to copanlisib and gemcitabine until maximum 12 cycles will be given for this study."
1488799|NCT03052933|Drug|Gemcitabine|For phase I/II study, participants will receive gemcitabine (in combination with copanlisib) IV infusion at fixed dose of 1,200 mg/m2 on Days 1 and 15 of each 28-day treatment cycle until maximum 6 cycles.
1488801|NCT03052907|Behavioral|BSPAN|"Identify readiness assessment criteria (RAC) essential in determining a rural county's capacity to support comprehensive mammography and appropriate follow-up services.
Using the RAC, we will determine which of the five BSPAN1 counties have capacity to manage and sustain the Outreach & Health Promotion and Delivery & Navigation components of the program (High Capacity), and which have the capacity to manage and sustain only the Outreach & Health Promotion component (Medium Capacity).
Expand BSPAN to 12 new rural and underserved counties according to RAC score and evaluate each county's ability to implement program components and increase comprehensive mammography and appropriate follow-up."
1488802|NCT03052894|Device|Hydraulic Monitoring Device|"The hydraulic monitoring device externally measures the pressure associated with thumb strength applied to the device to determine the depth of neuromuscular blockade during general anesthesia.
This will be compared to measurements using a current monitoring device in the same patient."
1488803|NCT03052894|Device|Standard EMG Monitoring Device|"Standard and in current usage, the electromyographic monitoring (EMG) device externally measures the action potential of the muscles of the thumb to determine the depth of neuromuscular blockade during general anesthesia.
This will be used as the clinical monitoring device and as a comparator."
1488804|NCT03052881|Device|Robot assisted surgery|The PRECEYES Surgical System is a robotically assistive device developed by PRECEYES Medical Robotics, a Dutch-based research group at the Technische Universiteit Eindhoven. It has been designed to enhance surgical precision, specifically for vitreoretinal eye surgery. The device provides accuracy beyond human capabilities of <10μm in all directions (x, y, z planes). The surgeon is always in control of the instrument by manipulating the motion controller.
1488805|NCT03052868|Other|Cognitive Assessment|Cognitive testing session
1488806|NCT03052855|Other|Magnetic Resonance Imaging (MRI) and biological samples|Participants will have to do a MRI and biological samples.
1488807|NCT03052842|Drug|C16G2 Strip|Antimicrobial Peptide
1488808|NCT03052842|Other|Placebo Strip|Placebo
1488809|NCT03052829|Behavioral|Physical activity counseling|Subjects in this arm will receive counseling on how to increase their physical activity level.
1488810|NCT03052829|Behavioral|Usual care|Subjects will undergo their usual care without intervention
1488811|NCT03052816|Drug|Ice T|Ice/Tylenol/Toradol with dilaudid for breakthrough
1488812|NCT03052816|Drug|Motrin/Percocet/Dilaudid for breakthrough|Standard regimen
1488813|NCT03052803|Device|Fractional flow reserve measure|Comparison of different devices measuring fractional flow reserve
1488814|NCT03052790|Procedure|manually instrumented total knee arthroplasty|Manually instrumented implantation of a total knee prosthesis involves use of cutting guides or jigs that are secured to the femur and the tibia. The femoral guide is secured to the femur after an intramedullary referenced guide is placed into the femur and the rotational alignment is then assessed with use of the epicondylar axis. An extra-medullary tibial alignment guide will be used to create the tibial cut.
1488815|NCT03052790|Device|robotic assisted total knee arthroplasty|Robotically assisted surgery is used in conjunction with the preoperative CT scan and intra-operative bony registration of the patient's knee. Femoral and tibial trackers are placed and then the bone is registered using bony landmarks to allow the computer and robot to know where the patients' femur and tibia are in space. Once this is complete the preoperative templated surgical plan (performed by the PI) is used to register where to make the bony cuts in order to implant the knee components. The cutting process is performed by the surgeon with the robot assisting in guiding the cuts based on the registered CT anatomy. The surgeon has complete control of the cutting process with the assistance of the robot for placement of the cuts.
1488816|NCT03052777|Behavioral|Telephone counselling|The intervention is a 12 week telephone counselling exercise program where participants will receive weekly telephone counselling that targets key theoretical behavior change constructs. Participants will also receive a copy of Canada's Physical Activity Guideline.
1488825|NCT03052673|Drug|Fentanyl|Fentanyl 1mcg/kg will be given at induction of anaesthesia followed by intraoperative infusion of 0.5 mcg/kg/hr in both the arms . Postoperatively IV-PCA pump containing fentanyl will be attached to patients in both the arms
1488826|NCT03052673|Drug|ketamine|Ketamine 0.5 mg/kg will be given post-induction of anaesthesia followed by infusion of 0.5 mcg/kg /hr in the Ketamine + Fentanyl group arm
1488827|NCT03052660|Drug|Midazolam|Oral administration preoperatively
1488828|NCT03052660|Drug|Placebo oral capsule|Oral administration preoperatively
1488829|NCT03052647|Device|Dermaclip|Dermaclip is an adhesive latch device used for skin closure
1488830|NCT03052647|Device|Subcuticular suture|subcuticular suture will be used as the device to close the skin in this arm
1488831|NCT03052634|Drug|RC48-ADC|
1488832|NCT03052634|Drug|Lapatinib plus capecitabine|
1488833|NCT03052621|Procedure|Omental transposition|Harvesting the omentum to cover irradiated defects of breast cancer
1488836|NCT03052595|Diagnostic Test|Oral glucose tolerance test|Oral glucose tolerance test to measure glucose and insulin concentrations after oral glucose load
1488837|NCT03052582|Other|Milk type|
1488838|NCT03052569|Drug|RXDX-105|Oral Capsules
1488839|NCT03052556|Procedure|Pap smear test and HPV test|"Included women will attend a consultation with a gynaecologist. Pap smear test with HPV test will be performed. Samples collected by cervical scrape with a brush, will be prepared for liquid-based cytology. A sample of the sample will be used for research on HPV (Multiplex DNA PCR).
This method allows detection of 35 different HPV genotypes: high risk (HPV-16, -18, -26, -31, -33, -35, -39, -45, -51, -52, 53, -56, -58, -59, -66, -68, -70, -73, -82, and -85); and low risk (HPV-6, -11, -40, -42, -43, -44, -54, -61, -62, -71, -72, -81, -83, -84, and -89).
Patients with an initial abnormal pap smear or a positive HPV test will be monitored:
In case of an abnormal smear and / or positive HPV test, pap smear and HPV testing will be renewed every 6 months during the study period
In case of an abnormal smear:
ASC-US: the attitude will depend on the result of the HPV test ASC-H, LSIL, HSIL, AGUS, AGC, AIS, carcinoma: a colposcopy will be performed"
1488840|NCT03052543|Device|BIS™ Complete 2--Channel Monitor|monitor depth of anesthesia
1488841|NCT03052530|Device|Sapphire II PRO|To pre-dilate coronary arteries or bypass grafts during the subject's index procedure with Sapphire II PRO 1.0 and 1.25 PTCA dilatation catheters.
1488845|NCT03052504|Other|Registration of complications|Prospective registration
1488846|NCT03052491|Dietary Supplement|Stem Cell 100+|Open-Label 10-Component Dietary Supplement
1488847|NCT03052478|Drug|Vismodegib 150 mg|Vismodegib 150 mg will be administered orally once a day for 21 days as one cycle.
1488849|NCT03052452|Other|My Nutritional Health App|The My Nutritional Health app will be used as the data collection platform for this study. We will use the data collected in the app testing to develop population level FAST scores.
1488850|NCT03052439|Other|FODMAP|After 2 weeks on a low FODMAP diet, subject will undergo a reintroduction period. 5 different FODMAPs will be reintroduced (1 week at a time, followed by 1 week washout) in a blinded, randomized fashion.
1488851|NCT03052426|Device|Ergotron WorkFit - TL|A sit to stand work station.
1488852|NCT03052413|Dietary Supplement|Nutrafol|Eligible subjects will receive Nutrafol® to take daily for 180 days
1488853|NCT03052413|Dietary Supplement|placebo|Eligible subjects will receive Placebo to take daily for 180 days
1488854|NCT03052400|Drug|Mifepristone 600 mg daily|Glucocorticoid receptor antagonist
1488855|NCT03052400|Drug|Placebo|Matching placebo
1488856|NCT03052387|Other|assigned intervention|"* Local anesthesia with vasoconstrictor(V.C) used for hemostasis.
chin block graft
Scrubbing and draping of the patient will be carried out in a standard fashion using betadine surgical scrub.
The donor site is usually the chin area, its approached using local anesthesia with VC at symphysis region.
Low vestibular incision exposing the symphysis area to the inferior border of the mandible.
Using fissure bur to harvest the graft for the defect.
Closure using vicryl 3-O sutures."
1488857|NCT03052374|Behavioral|VID-KIDS Intervention Program|"Investigators created VID-KIDS for mothers with PPD to improve sensitivity and positive responsiveness towards their infants. Video-feedback has the advantage of being visually concrete yet distant because the action and the feedback are not concurrent; this helps mothers maintain an element of objectivity that may minimize guilty feelings associated with potential perceived lack of parenting skills. Video-feedback interventionists are trained by investigators with manualized modules. Including: Introduction to Video-feedback; NCAST Keys to Caregiving Program; Infant Engagement and Disengagement Cues; Video-feedback Intervention Protocol; Overview of Behaviours of Interest; Case Studies; and Examples of Strengths-Based Feedback. VID-KIDS intervention follows an 8-step protocol."
1488858|NCT03052361|Drug|Ondansetron|Patients allocated to this arm will receive ondansetron in the ED triage.
1488859|NCT03052361|Drug|Placebos|similar looking and tasting liquid placebo
1488860|NCT03052348|Other|Polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid
1488861|NCT03052348|Other|Fusidic acid, polyethylene glycol hexadecyl ether & Betamethasone valerate cream 0.1%|Polyethylene glycol hexadecyl ether -Moisturizer. Betamethasone valerate cream 0.1% -Topical steroid Fusidic Acid - Topical Antibiotic
1488892|NCT03052023|Procedure|dual approach laparoscopic inguinal hernioplasty|after pneumoperitoneum is done preperitoneal pneumo-dissection is done and then peritoneal incision done . dissection preperitoneally and sac dissection will be easy approached
1488893|NCT03052023|Procedure|TAPP|pneumoperitoneum is done and then through abdominal approach peritoneal dissection in done and sac reduction and then mesh fixation
1488957|NCT03051503|Drug|The Transdermal Therapeutic System-Fentanyl (TTS-F)|(TTS-F) group (n=30) 50ug/h patch, placed 12 hours preoperatively
1488862|NCT03052335|Device|Pillcam® COLON 2 Capsule|The second generation of PillCam colon capsule endoscopy (CCE-2) is 11.6 mm × 31.5 mm in size and has two imagers, that each have a 172° angle of view, allowing for almost 360° visual coverage of the colon. CCE-2 has an adaptive frame rate from 4 to 35 images per second. This means that the camera is able to capture up to 35 pictures while in motion whereas 4 images per second are captured when it is virtually stationary. During the examination the patient wears a sensor array which is attached to the abdomen and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the workstation and a video is generated.
1488863|NCT03052335|Procedure|Colonoscopy|Optical colonoscopy is the standard method for evaluating the colon
1488864|NCT03052322|Drug|MSB11022|MSB11022 will be administered at a dose of 40 milligram (mg) subcutaneously at every other week starting at Baseline (Week 0), last dose at Week 48.
1488865|NCT03052322|Drug|Humira®|Humira® will be administered at a dose of 40 mg subcutaneously at every other week starting at Baseline (Week 0), last dose at Week 48.
1488866|NCT03052309|Device|Passeo-18 Lux DCB|The decision to treat the patient with Passeo-18 DCB is at the investigator discretion. The endovascular procedure is performed as per standard of care and device Instructions For Use (IFU)
1488867|NCT03052296|Device|Passeo-18 Lux DCB|The endovascular procedure is conducted as per the local standard practice and device instruction for use
1488868|NCT03052283|Other|Questionnaire|non-interventional
1488869|NCT03052270|Device|Arabin Pessary|Insertion of Arabin pessary for the prevention of preterm delivery
1488870|NCT03052257|Behavioral|Educational|Video testimonial from a glaucoma patient; Discussion of glaucoma and the potential for blindness, facilitated by the glaucoma educator using a 3-dimensional model eye and photographic representation of glaucomatous vision loss; One-one-one demonstration of eye drop instillation techniques, Provision of a mnemonic aid which alerts the participant to missed doses; Review of the participant manual: An illustrated brochure on glaucoma and eye drop instillation. An individualized schedule for dosing of glaucoma medications. Individualized suggestions for improving adherence based on the subject's responses to the (SASES).
1488871|NCT03052257|Behavioral|Dose reminder|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened. For participants in the intervention arm only, a reminder through AdhereTech will be activated."
1488872|NCT03052257|Behavioral|Educational|The control information session will include review of a Powerpoint presentation on general eye health, including but not specific to glaucoma.
1488873|NCT03052257|Behavioral|dose monitoring|"Participants will be provided with a smart bottle to house one of their glaucoma medications. The smart bottle records the date and time that the bottle is opened."
1488874|NCT03052244|Device|tDCS+VI|2mA will be delivered over 20min to M1 via neuroConn DC stimulator combined with video presenting walking legs.
1488875|NCT03052244|Device|tDCS Sham+VI Sham|2mA will be delivered up to 30 sec to M1 via neuroConn DC stimulator combined with video presenting graphical illustration or nature movie for total duration of 20 min.
1488876|NCT03052231|Device|caremessage|Central to the mobile health information service is the interactive and personalized text-based message system that delivers actionable and tailored health content to participants: office visit appointment reminders; medication adherence reminders; and general health education messages.
1488877|NCT03052218|Device|Pupillometry|Pupillometry performed before administration of tramadol, at T0 and then 1 to twice per hour, during the stay of the patient in the emergency department
2001355|NCT03053297|Other|Patient Reported Outcomes|"HRQoL will be assessed using questionnaire EORTC QLQ-C30 and the questionnaire EORTC QLQ-LC 13.
These two questionnaires are validated instruments, translated in various languages and are not used as an intervention but rather to track patient quality of life and symptom reduction in real-life settings. Data for these patient reported outcomes will be collected prospectively from the time of enrolment until the end of follow-up. The two questionnaires will be self-administered by the patients in both cohorts at the enrolment visit and subsequently every 3 months (±1 month) at routine standard of care scheduled visits. The questionnaires are expected to take about 15 minutes to complete"
1488879|NCT03052179|Dietary Supplement|Poly-biotic|Before-after treatment
1488880|NCT03052166|Device|QT Ultrasound scan|QT Ultrasound scan
1488881|NCT03052153|Other|No investigational intervention performed for this study|No investigational intervention for the purpose of this study was performed; data collected is retrospective data previously collected for non-research purposes.
1488882|NCT03052140|Device|Lamelleye Dry Eye Drops|Liposomal multi-dose preservative-free sterile suspension which contains soy lecithin phospholipids, sphingomyelin and cholesterol, suspended in saline.
1488883|NCT03052140|Device|Optive Plus|Multi-dose sterile solution which contains sodium carboxymethylcellulose, glycerine, Castor Oil, Polysorbate 80, levocarnitine, and erythritol, preserved with PURITE® which breaks down into natural tear components in the eye
1488884|NCT03052127|Drug|Light-activated AU-011|Study treatment
1488885|NCT03052114|Device|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt.
1488886|NCT03052075|Other|Retrospective Data Review|Retrospective, uncontrolled pre- and post-test design in a case series of approximately 250 patients who underwent parathyroidectomy at MD Anderson Cancer Center (years 1990 - 2013 ) and had bone density measures recorded at baseline and at one year post-surgery. Data extracted from the surgical oncology database for bone mineral density measures for each patient at multiple sites including the lumbar spine, total hip (right/left), femoral neck (right/left), and distal 1/3 radius. All measures recorded from two time points: presurgical (baseline) and postsurgical (all follow-up available dates beginning at 1 year post-parathyroidectomy).
2001356|NCT03052062|Dietary Supplement|Lipidrive|LipiDrive, 4 to 8 capsules per day, oral administration. Dose 1: 2.6 g Lipidrive per day Dose 2: 5.2 g Lipidrive per day
1488888|NCT03052049|Device|Prostate Artery Embolization|The PAE procedure will be completed on all enrolled patients in Interventional Radiology includes a pelvic/prostate angiogram and embolization with Bead Block microspheres to slow/block blood flow to the prostate.
1488894|NCT03052023|Procedure|(lichtenstein) repair|inguinal incision is done and inguinal canal approach anteriorly and then sac dissection and excision then mesh fixation to posterior wall and closure the incision in layers
1488895|NCT03052010|Other|Integrated PrEP as a bridge to ART HIV-1 prevention strategy|The PrEP as a bridge to ART intervention will be introduced into clinics according to Kenya national guidelines using a stepped wedge design, stratified by region. The components of the intervention are: a) Couples' HIV-1 counseling and testing; 2) PrEP as a bridge to ART: PrEP offered prior to ART initiation in couples in which the HIV-1 infected partner is not on ART due to refusal/delay, during the first 6 months after ART start during viral decline, and then discontinuation; 3) ART at any CD4 count, offered to all HIV-1 infected partners, with ongoing promotion/counseling for those delaying/declining;4) Standard of care HIV-1 prevention services
1488896|NCT03052010|Drug|PrEP|A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.
1488897|NCT03052010|Drug|ART|ART medications will be provided according to Kenya national ART policies and will come from clinic stocks.
2001357|NCT03052751|Drug|UCB7665|UCB7665 will be administered in 2 different dosages (dose 1 and dose 2) in dosage regimen 1 and 2.
2001358|NCT03052751|Other|Placebo|Placebo will be administered in period 1 of dosage regimen 2.
1488900|NCT03051984|Device|Neuromuscular electrical stimulation|NMES will be conducted on the quadriceps of the operative leg using a portable stimulation device, starting within 48-72 hrs of surgery. The operative leg will be immobilized at a neutral angle (~30º), with electrodes affixed to the anterior surface of the thigh. Symmetrical, biphasic pulses (400 µs duration at 50 Hz) will be used, with a duty cycle of 25% (10 s on, 30 s off), with patient-selected stimulation intensity to cause visible contractions below pain threshold. NMES sessions will occur 5 d/week, twice daily for 45 min (5 min warm-up) for 5 wks.
1488901|NCT03051971|Device|Vibrating Mesh Nebulizer|short-acting bronchodilator medication delivered with a vibrating mesh nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
1488902|NCT03051971|Device|Jet Nebulizer|short-acting bronchodilator medication delivered with a jet nebulizer via mouthpiece, valved facemask or non-invasive ventilation mask
1488903|NCT03051958|Behavioral|Internet mindfulness&exposure treatment|"See description under Arm."
1488904|NCT03051958|Other|Treatment as usual|Written information about standard treatment for atopic dermatitis, that is information regarding how to use moisturizers and anti-inflammatory treatment such as Topical steroids.
2001359|NCT03051932|Drug|Ofiramev® (IV Acetaminophen)|Post -op pain medication
2001360|NCT03051932|Drug|Placebo IV administration|Post -op pain
2001361|NCT03050801|Device|rTMS|Altering the connectivity of trans-synaptic pathways
2001362|NCT03050320|Other|Exercise|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
1488909|NCT03051919|Other|observation|
1488910|NCT03051906|Biological|Durvalumab|Durvalumab given intravenously at 1500 mg every 4 weeks; first two cycles concurrent with RT + cetuximab, 6 cycles after the end of RT as adjuvant treatment; treatment will be continued for a maximum of 8 months (concurrent phase included).
1488911|NCT03051906|Biological|Cetuximab|Cetuximab given intravenously weekly at 400mg/m2 loading dose 1 week before RT start, then 250 mg/m2 weekly thereafter.
1488912|NCT03051906|Radiation|Intensity modulated radiation therapy (IMRT)|A total dose of 69.9 Gy will be given with 2.12 Gy dose per fraction, delivered in 33 fractions over 7 weeks.
1488913|NCT03051893|Drug|Chronocort|Modified formulation of hydrocortisone
1488914|NCT03051880|Drug|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 8 weeks. Also, to evaluate the preventive effect of paronychia, patients applied same cream on the finger tips of one side hand, twice a day for 8 weeks.
EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
1488915|NCT03051880|Drug|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 8 weeks. Patients applied same cream on the finger tips of the other side hand, twice a day for 8 weeks.
Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
1488916|NCT03051854|Behavioral|Interaction Competencies with children - for teachers|Core training components include teacher-student interaction, maltreatment prevention, effective discipline strategies, identifying and supporting burdened students and implementation of the training materials into the school setting.
1488917|NCT03051841|Drug|CKD-581|Intravenously on Days 1, 8 of each 21-day treatment cycle.
1488918|NCT03051828|Procedure|fencing|No intervention: practice fencing
1488919|NCT03051802|Device|Navigated Endoscopy|Navigated endoscopy used to guide the placement of HDR applicators in the esophagus or lung as a replacement to current standard of practice using fluoroscopic imaging.
1488920|NCT03051789|Device|Menstrual Cup|Menstrual cups are reusable bell-shaped receptacles made of high grade medical silicone which collect ~30 ml of menstrual blood when inserted into the vaginal canal
1488958|NCT03051503|Device|Intravenous patient-controlled analgesia (PCA) morphine|IV PCA morphine for pain in the postoperative period.
2001363|NCT03050320|Other|No Exercise|A no exercise (control) group will be asked to maintain their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
2001364|NCT03049488|Biological|VRC-RSVRGP084-00VP|VRC-RSVRGP084-00-VP is an investigational vaccine that is intended to prevent respiratory synctial virus.
2001365|NCT03049293|Drug|Midazolam|The impact of Midazolam levels in follicular fluid.
1488921|NCT03051789|Other|Cash transfer|A small stipend of Ksh 1500 (US$15, Dec15 exch) per term will be provided to girls, through a safe and secure mobile money transfer system provider, like M-Pesa, Equity, or Postbank. Monies will be transferred at the beginning of a term, based on school registry statistics confirming participants attended for at least 80% of the previous term.
1488922|NCT03051789|Other|Cups and Cash|Combination of both interventions, using the same interventions and implementation methods.
1488923|NCT03051776|Other|Kinesio Taping|
1488924|NCT03051776|Other|Compression Garment|
1488925|NCT03051750|Other|Complex Physical Therapy plus Pressotherapy|
1488926|NCT03051750|Other|Kinesio Taping|
1488927|NCT03051724|Other|Telematic follow up|Follow-up of OSA patients through automatic CPAP with data transmission (Dreamstation; Philips Respironics), a 24-hour voice mailbox available for questions or problems, and an Internet-connected (4G) tablet with a friendly mobile application for simple questionnaires.
1488928|NCT03051711|Drug|GBT440|Capsules which contain GBT440 drug substance in Swedish Orange
1488929|NCT03051698|Drug|C1-inhibitor|100 Unit/kg IV, one gift prior to broncho provocation.
1488930|NCT03051698|Other|Saline|0.9% NaCl
1488931|NCT03051698|Drug|Antibiotics|vancomycin, ciprofloxacin, metronidazole
1488932|NCT03051685|Drug|DFN-15 Dose 1|
1488933|NCT03051685|Drug|DFN-15 Dose 2|
1488934|NCT03051685|Drug|DFN-15 Dose 3|
1488935|NCT03051685|Drug|Active Comparator|
1488936|NCT03051672|Drug|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells
1488937|NCT03051672|Radiation|Palliative radiotherapy|Treatment to shrink a cancer, slow down its growth, or control symptoms
1989729|NCT02405455|Procedure|Cerclage|Surgical procedure which consists of a strong suture being inserted into and around the cervix to close it.
1989730|NCT02405455|Device|Cervical pessary|The Arabin cervical pessary, which is CE-certified for preventing spontaneous preterm birth (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC). It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain.
1488942|NCT03051633|Behavioral|Be Under Your Own Influence|School based anti-drug use communications campaign
1488943|NCT03051620|Drug|Discontinuation with alendronate|140 patients with osteoporosis stopping treatment with alendronate.
1488945|NCT03051594|Device|fluorescent camera|used too detect residual caries depending on the bacterial byproducts.
1488946|NCT03051594|Other|caries detector dye|dye used to detect the residual caries.
1488947|NCT03051594|Diagnostic Test|visual tactile assessment|method usually used to detect the residual caries.
1488948|NCT03051581|Device|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
1488949|NCT03051568|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
1488950|NCT03051555|Device|18F-FDG PET/ CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10min/bed).
1488951|NCT03051542|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/￼￼￼￼dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
1488952|NCT03051529|Other|combined spinal epidural anesthesia|After approval by local research ethics committee of the Faculty of Medicine, and informed written consent obtained from all patients, 24 patients having dilated cardiomyopathy, subjected to vascular surgery in the lower half of the body under CSEA
1489197|NCT03049618|Biological|Pembrolizumab|Given IV
1948926|NCT01106027|Drug|Eculizumab|"At the time of deceased donor kidney transplantation, patients will undergo one plasmapheresis prior to surgery.
Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.
Patients will be given 900 mg of eculizumab on Day 1 post-transplant.
Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant
At week 4, patients will be assessed for DSA. Patients with total DSA normalized values <5000 will stop eculizumab treatment. Patients with total DSA normalized values >5000 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52."
1948927|NCT01094587|Procedure|Gastroschisis closure with suture|
1488961|NCT03051477|Drug|Helixor® M|3 hour IV infusion on Mon, Wed, and Fri each week.
1488962|NCT03051464|Procedure|Complete responders and Non-complete responders|Patients that are complete responders will not have surgery. Patients that are non-complete responders will have surgery.
1488963|NCT03051464|Radiation|Chemoradiation + EBRT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and an external beam boost of 9 Gy in 5
1488964|NCT03051464|Radiation|Chemoradiation + HDRBT Boost|45 Gy in 25 with concomitant 5-FU or Xeloda chemotherapy) and followed by a brachytherapy boost of 30 Gy in 3 fractions
1488965|NCT03051451|Drug|combination metformin hydrochloride/ fluoxetine 500/20 mg|"Group A will receive metformin 1000 mg and 40 mg of fluoxetine; after the increment phase.
All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
1488966|NCT03051451|Drug|combination metformin hydrochloride/ fluoxetine 1000/20mg|"Group B will receive metformin 1700 mg and 40 mg of fluoxetine; after the increment phase.
All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition"
1488967|NCT03051451|Drug|Placebo Oral Tablet|Group C will receive placebo oral tablet; All treatment groups will receive, in addition to the intervention, recommendations of a diet based on a hyper protein, hypo caloric and low carbohydrate diet as well as an exercise routine according to age and physical condition
1948928|NCT01094587|Procedure|Gastroschisis closure without suture|
1948929|NCT01088243|Drug|Mesalamine|Mesalamine (5-ASA) 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
1488970|NCT03051425|Dietary Supplement|Probiotic yogurt|120 mL of Yogurt containing Lactobacillus delbrueckii subsp. bulgaricus, Streptococcus thermophilus, Lactobacillus casei, Bifidobacterium animalis ssp. lactis, and Lactobacillus plantarum
1488971|NCT03051425|Dietary Supplement|Placebo|120 mL of low-fat milk
1488972|NCT03051412|Other|No Intervention|No intervention
1488973|NCT03051399|Dietary Supplement|Placebo|The participants will be asked to orally ingest one capsule per day (500 mg maltodextrin, single serving), in combination with 200mL water.
1488974|NCT03051399|Dietary Supplement|EpiCor|The participants will be asked to orally ingest one capsule per day (500 mg EpiCor, single serving), in combination with 200mL water.
1488976|NCT03051373|Drug|nanoparticle albumin-bound paclitaxel, S-1|Nanoparticle albumin-bound paclitaxel is given at 120mg/m2 intravenously over 30 minutes on day 1 and 8, in combination with S-1 which is orally administered (40-60 mg according to the body surface, Bid) on day 1-14 of each 21-days cycle. Number of cycle: 6 cycles.
1488977|NCT03051373|Drug|Gemcitabine, cisplatin|Gemcitabine is given at 1000mg/m2 combination with cisplatin 75mg/m2 intravenously on day 1 and 8 of each 21-days cycle. Number of cycle: 6 cycles.
1488978|NCT03051360|Drug|PCSK9 Inhibitor [EPC]|Patients will receive PCSK9 inhibitor by a biweekly injection
1488979|NCT03051360|Drug|Placebos|Patients will receive Placebo by a biweekly injection
1488980|NCT03051347|Other|Itch Questionnaire and Interview|
1488981|NCT03051347|Other|Stigma Questionnaire and Interview|
1488982|NCT03051334|Other|diagnosed as bicuspid aortic valve|
1488983|NCT03051321|Device|Wellness toilet system|Water-based toileting with capacity to apply zinc oxide barrier spray to treat incontinence associated dermatitis
1488984|NCT03051308|Combination Product|NPT and UW Solution|Tissue preservation solutions for transplantation
1488985|NCT03051295|Other|Dental health information form|The format in which dentists receive information about diagnostic test results and efficacy of treatment.
1488986|NCT03051282|Drug|Enalapril|Study participants in both arms will be treated with 10 mg enalapril orally once daily for seven consecutive days
1488987|NCT03051269|Drug|Calcium chloride|Tumour site is injected with a solution of 9 mg/ml calcium chloride and afterwards the tumour site is given electroporation to facilitate calcium to enter the cell cytosol.
1488988|NCT03051269|Device|Electroporation|"Performed by single use electrodes attaches to a device called Cliniporator provided from IGEA, ITALY."
1488989|NCT03051256|Drug|REL-1017|REL-1017 will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
1488990|NCT03051256|Drug|Placebo|Placebo will be administered as an oral solution. Patients will continue to take the same, stabilized antidepressant medication that they were taking at screening throughout the course of the study.
1488991|NCT03051243|Drug|Linagliptin and Basal Insulin|Linagliptin and bed time insulin glargine linagliptin (trajenta) once daily combined with bed time basal insulin (glargine Lantus; sanofi) before meals
1488992|NCT03051243|Drug|Basal Insulin and Bolus Insulin|Basal bolus insulin regimen and insulin based therapy with glargine once daily before bedtime and glulisine (Apidra; sanofi) before meals
1488993|NCT03051217|Other|Placebo|"Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 0.9 % saline
Route of Administration: Subcutaneous use Q2W"
1488994|NCT03051217|Drug|Certolizumab Pegol|"Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 200 mg/mL
Route of Administration: Subcutaneous use"
1488995|NCT03051191|Diagnostic Test|micro RNA|micro RNA, cell free DNA and 16S rRNA genes will be explored cross-sectionally at enrollment.
1488996|NCT03051178|Device|Responsive deep brain stimulation|Responsive deep brain stimulation (R-DBS) therapy will be delivered responsively based on the level of their symptoms as detected by wearable EMG and inertia (acceleration) sensors.
1948930|NCT01088243|Drug|Placebo|Sugar pill 500 mg capsules four times per day for 6 weeks in Chronic Beryllium Disease subjects.
1488998|NCT03051152|Procedure|D1 gastrectomy|Gastrectomy with limited lymph node dissection
1488999|NCT03051152|Procedure|D2 gastrectomy|Gastrectomy with extended lymph node dissection
1489000|NCT03051139|Behavioral|Multi-component LTVV implementation strategy|Multicomponent LTVV implementation strategy consisting of: 1) physician orientation, 2) physician audit and feedback, and 3) clinical decision support comprised of a) an ARDS screening tool using a natural language processing (NLP) algorithm, b) EHR-based tasks for clinicians to complete, and c) a clinician reminder system.
1489001|NCT03051126|Other|Tissue Samples|Fresh residual tissue samples will be obtained during parathyroid and/or pancreas tumor intervention (for pancreas tumor intervention in MEN1 patients with hyperparathyroidism and pancreatic lesions).
1489002|NCT03051100|Drug|Bempedoic acid 180mg|bempedoic acid 180 mg
1489003|NCT03051100|Drug|Ezetimibe 10mg|ezetimibe 10 mg
1489004|NCT03051100|Drug|Atorvastatin 20mg|atorvastatin 20 mg
1489005|NCT03051100|Other|Placebo|placebo
1489006|NCT03051087|Drug|Ganirelix acetate|
1489007|NCT03051074|Behavioral|Floating|Floating supine in a pool saturated with Epsom salt for up to 90 minutes
1489008|NCT03051074|Behavioral|Comparison|Watching a relaxing film for up to 90 minutes
1489009|NCT03051048|Procedure|Reperfusion|
1948931|NCT01077388|Behavioral|Dietician electronic support|Dietitian-delivered behavioral intervention, that uses a patient shared EMR and e-communications, will be integrated into routine healthcare and will result in improved control of modifiable CVD risk.
1489011|NCT03051022|Drug|Dexamethasone 8 mg|Dexamethasone 8 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
1489012|NCT03051022|Drug|Morphine 2 mg|Morphine 2 mg was given via epidural catheter as an adjuvant to 12.5 mg of 0.125% bupivacaine in 10 cc syringe and added with 0.9% sodium chloride until the volume was 10 cc.
1489013|NCT03051009|Drug|Desmopressin ODT 25 μg|
1489014|NCT03051009|Drug|Desmopressin ODT 50 μg|
1489015|NCT03050996|Procedure|robotic radical prostatectomy|Urodynamic evaluation during robotic radical prostatectomy
1489016|NCT03050983|Device|IPI|Enable the IPI algorithm and IPI alarm algorithm
1489017|NCT03050957|Dietary Supplement|menthol|Alimentary bolus supplemented with menthol
1489018|NCT03050944|Other|Lifestyle behaviour and dietary habits assessment|Lifestyle behaviour and dietary habits assessment
1489019|NCT03050931|Device|Electrical Impedance Tomography|EIT comprises of a box of electronics similar in size to a video recorder, laptop computer and leads which link typically to 16 or 32 external ECG-like electrodes placed around the subject. Images are generated by applying tiny electrical signals through some electrodes and recording the resulting signals at others. The signals applied are completely safe, within established British and EU safety limits and cannot be felt. For intracranial electrode studies, the EIT systems will be linked to the existing EEG video recording systems and EIT will be recorded at the same time using some or all of the available intracranial electrodes.
1489020|NCT03050918|Behavioral|Follow-up Phone Call|Patients will first be called within 72 hours discharge.
1489021|NCT03050905|Drug|VEKIRAX|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).
Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)"
1489022|NCT03050905|Drug|EXVIERA|"Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Dasabuvir (Exviera).
Study Regimen: dasabuvir (250 mg twice daily)"
1948932|NCT01057862|Drug|Naltrexone|Targeted dosage of 50mg PO daily
1489024|NCT03050866|Drug|Cabazitaxel|25mg/m2 q3w
1489025|NCT03050866|Other|Antihistamine|As intravenous premedication (dexchlorpheniramine 5 mg, diphenhydramine 25 mg, or equivalent)
1489026|NCT03050866|Other|Corticosteroid|As intravenous premedication (dexamethasone 8 mg or equivalent)
1489027|NCT03050866|Other|H2 antagonist|As intravenous premedication (ranitidine or equivalent)
1489028|NCT03050866|Other|Antiemetic|Antiemetic prophylaxis is recommended and can be given orally or intravenously if necessary
1489029|NCT03050853|Behavioral|E-cigarette|The e-cigarette arm will be provided with 8 weeks of free e-cigarettes based on self-report of regular tobacco use. Participants assigned in this arm will be asked to switch combustible tobacco with e-cigarettes. The appeal of e-cigarettes and health impacts will be measured, but we are not targeting quitting combustible tobacco or reducing craving.
1489030|NCT03050840|Behavioral|Way to Health|An online platform (Way to Health) will be used to test if self-monitoring plus gamification principles can increase steps per day and lower sugar sweetened beverage consumption per day, among obese children and adults, compared to self-monitoring alone.
1489031|NCT03050827|Drug|3% oxybutynin|TI1e FDA approved drug Gelnique 3% TM (3% oxybutynin), which is used to treat overactive bladder, may also improve nerve function in type 2 diabetic subjects with established peripheral neuropathy.
1489032|NCT03050827|Drug|Placebo|Non-active placebo for 3% oxybutynin
1489033|NCT03050814|Drug|Avelumab|Intravenous infusion over 1 hour (-10 minutes/+20 minutes, i.e., 50 to 80 minutes).
1489034|NCT03050814|Biological|Ad-CEA vaccine|Administered as a subcutaneous injection in the thigh on Day 1 of specific cycles, prior to Avelumab. It will be administered on cycles 1, 2, and 3; 5,7, and 9; and every 6 cycles thereafter.
1489035|NCT03050814|Drug|Bevacizumab|5mg/kg IV over 30-90 min on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
1489036|NCT03050814|Drug|5-FU|400mg/m2 IV bolus on day 1 (Arm A) or 2 (Arm B), or 2400mg/m2 IV over 46 hours to start on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
1489037|NCT03050814|Drug|Leucovorin|400mg/m2 IV over 2 hours on day 1 (Arm A) or 2 (Arm). Part of the standard of care therapy.
1489038|NCT03050814|Drug|Oxaliplatin|85mg/m2 IV over 2 hours on day 1 (Arm A) or 2 (Arm B). Part of the standard of care therapy.
1489039|NCT03050814|Drug|Capecitabine|625 mg/m2 twice a day every day by mouth. Part of the standard of care therapy.
1948933|NCT01057862|Other|Placebo|Sugar pills daily PO
1489041|NCT03050788|Device|Smartphone confocal microscopy|Imaging of skin lesion using the smartphone confocal microscopy
1489042|NCT03050775|Device|Heated Ventilator Circuit|active heat and humidification during anesthesia by warming inspire gases without a heat-moisture exchanger
1489043|NCT03050775|Device|Standard Ventilator Circuit|no active heat and humidification during anesthesia
1489044|NCT03050762|Other|Data Collection|Participant information collected from either source document or direct participant response.
1489045|NCT03050762|Behavioral|Follow Up|Participants followed up at the return to clinic visits. If participant cannot come to clinic, either a questionnaire mailed requesting follow-up, or participant called. Participants followed for a length of 15 years at intervals of every 2-3 years.
1489046|NCT03050749|Device|Princess® VOLUME|Princess® VOLUME injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
1489048|NCT03050723|Device|Princess® FILLER|Princess® FILLER injections up to 10 ml applied to the eligible subjects at the baseline visit, and the touch-up visit, if applicable.
1489049|NCT03050710|Device|Princess® VOLUME Lidocaine|Princess® VOLUME Lidocaine injections up to 10 ml given to the patients at baseline, and touch-up at week 2, if applicable
1489050|NCT03050684|Procedure|vaginal lavage group|
1489051|NCT03050684|Procedure|Control Group|
1489052|NCT03050671|Device|Intermittent Pneumatic Compression, Rapid|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a sharp and rapid way
1489053|NCT03050671|Device|Intermittent Pneumatic Compression, Slow|Cyclic external compression in both calves through a cuff connected to a device which pumps venous blood in a smooth, slow and progressive way
1489054|NCT03050632|Behavioral|N-back|The N-back task is a measure of working memory in which individuals need to make a response to targets which are repeated letters either in a row (i.e., one-back) or in every-other-letter format (i.e., two-back).
1489055|NCT03050632|Behavioral|White Bear Task|For this thought suppression task, participants are instructed to inhibit thoughts of a white bear, and to indicate with a pencil mark every time the thought of the white bear occurs to them.
1489056|NCT03050606|Other|Pilates|Exercises performed on the mat and apparatus, following the six principles of the Pilates method. The exercises will be performed in three levels of difficulty: basic, intermediate and advanced, according to the capacity of the patient.
1489057|NCT03050606|Other|Aerobic|Aerobic exercise will be carried out individually on treadmills or stationary bikes. The intensity of the training will be mild to moderate (57% to 76% of the maximal heart rate monitored by the frequencymeter).
1489058|NCT03050593|Diagnostic Test|MRI scan, Echo scan|
1489059|NCT03050580|Behavioral|self-esteem enhancement group|Subjects in the treatment group will join a six-session treatment for recognizing their strengths and resources through group activities and sharing. Each session is 1.5-2 hours long, and all sessions are designed for 4-8 abused women. The activities are designed and led with an aim to improve their self-esteem, general health, as well as to reduce the level of depression. This service is provided by registered social workers.
1489060|NCT03050580|Behavioral|Standard care for abused women|The shelter standard care and services will be provided to the abused women in one randomized shelter. Besides, standard care in shelters includes residential accommodations, emotional support, legal, housing and financial advice and referrals will be given to survivors who reported being abused.
1489061|NCT03050567|Diagnostic Test|Transcranial Doppler Ultrasound|Transcranial Doppler will be performed on the symptomatic (ipsilateral to an index event) middle cerebral artery in a quiet temperature controlled room. The middle cerebral artery will be identified through the temporal window in a supine position with a flow direction towards the probe. The subject will have a head frame (Marc 600 Spencer Technologies, USA) fitted to reduce motion and to secure a constant angle of the middle cerebral artery insonation depth at 50-60 mm from the skull surface. All recordings will be made using the ST3 Transcranial Doppler Ultrasound System (Spencer Technologies, USA) with a 2-MHz transducer for 1 hour. Emboli will be detected by listening for their characteristic short audible sound (range 10-100 ms, intensity threshold above 7 dB) and spectral appearance using the International Consensus Group microembolus identification criteria and an automated Embolus Detection Software (Spencer Technologies, USA).
1489062|NCT03050554|Drug|Avelumab|Avelumab 10mg/kg IV infusion every 2 weeks for 6 cycles
1489063|NCT03050554|Radiation|SBRT|SBRT: 12Gy x 4 fractions or 10Gy x 5 fractions (4-5 radiation doses given over 10-12 days every other day.)
1948934|NCT01052922|Other|3 sample g-SENSA|Participants will be mailed to a 3 sample g-SENSA FOBT kit to complete at home and mail back to the lab for screening.
1948935|NCT01052922|Other|2 sample InSure|Participants will be mailed to a 2 sample InSure FOBT kit to complete at home and mail back to the lab for screening.
1489066|NCT03050528|Behavioral|Supervised Exercise|Participants will attend the weekly supervised exercise sessions for a period of eight weeks. The classes will be delivered to groups of up to ten participants and will be led by a physiotherapist. The classes will be one hour and thirty minutes in duration and will feature two components: education/advice and exercise. The education/advice sessions will cover topics such as pacing and goal setting and the physiotherapist will answer any queries from the participants in relation to physical activity over the course of the eight weeks. The exercise component will involve the provision of individualised exercises based on each participant's personal goals and the sessions will feature a combination of aerobic, stretching and strengthening exercise in a pool and a gym setting.
1489067|NCT03050528|Behavioral|Acceptance and Commitment Therapy|Participants will attend weekly group psychology sessions for an eight-week period. Each session will be two hours in duration and will delivered by a Senior Psychologist trained in Acceptance and Commitment Therapy (ACT). The sessions will feature an ACT treatment process that is designed to promote psychological flexibility through various methods including acceptance and values awareness. The overall aim is to promote behaviour change, enhancing patient engagement in meaningful activities and reducing pain-avoidant behaviours. There is an emphasis on mindfulness, experiential learning and the use of metaphor which is unique to ACT.
1489068|NCT03050515|Biological|Fecal Microbiota Transplantation|This is a single arm study. All participants will receive a single fecal transplant to determine effectiveness in treating refractory recurrent urinary tract infections.
1489198|NCT03049618|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
1489071|NCT03050489|Procedure|On-Pump CABG.|Standard On-Pump CABG.
1489072|NCT03050489|Procedure|Off-Pump CABG.|Standard Off-Pump CABG.
1489073|NCT03050489|Procedure|BH-CABG MSC.|Patients with coronary artery bypass graft (CABG) surgery performed on beating heart with mechanical support of circulation
1489074|NCT03050476|Drug|bRESCAP|intravenous application before, during, and for 24 hours after heart surgery
1489075|NCT03050476|Drug|placebo|intravenous application before, during, and for 24 hours after heart surgery
1489076|NCT03050463|Procedure|Biospecimen Collection|Undergo blood and saliva sample collection
1489077|NCT03050463|Procedure|Functional Magnetic Resonance Imaging|Undergo fMRI related tasks
1489078|NCT03050463|Other|Questionnaire Administration|Ancillary studies
1489079|NCT03050450|Drug|25 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 25 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
1489080|NCT03050450|Drug|50 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 50 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
1489081|NCT03050450|Drug|100 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 100 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
1489082|NCT03050450|Drug|150 mg/m2 Lenalidomide (Revlimid®) and 180 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 180 mg/m2 days 1-7 and 15-21 of a 28 day cycle
1489083|NCT03050450|Drug|150 mg/m2 Lenalidomide (Revlimid®) and 230 mg/m2 Vorinostat (Zolinza®)|Drug: Lenalidomide 150 mg/m2 days 1-21 of a 28 days cycle Drug: Vorinostat 230 mg/m2 days 1-7 and 15-21 of a 28 day cycle
1489084|NCT03050437|Drug|Cisplatin|cisplatin is added to Pem/cis arm
1489085|NCT03050437|Drug|Pemetrexed|Pem is applied to both arms
1489086|NCT03050424|Drug|Ferric Carboxymaltose|Ferric Carboxymaltose injectable Product
1489087|NCT03050424|Drug|Sodium Chloride 0.9%|Sodium Chloride 0.9%
1489088|NCT03050411|Drug|Apatinib Mesylate Tablets|250mg, 500mg, 750mg, q.d., p.o.
1489089|NCT03050411|Drug|EGFR-TKIs (Erlotinib, Gefitinib and Osimertinib)|EGFR-TKIs include but are not limited erlotinib, gefitinib and osimertinib
1489090|NCT03050398|Drug|Ribociclib|ribociclib + letrozole
1489091|NCT03050398|Drug|letrozole|ribociclib + letrozole
1489092|NCT03050385|Device|transcranial direct current stimulation|
1489093|NCT03050372|Device|LFMS - Active|A non-invasive form of brain stimulation administered from a device resembling a bird cage. The device covers the top part of the head for the duration of stimulation (in the current study, 20 minutes)
1489094|NCT03050372|Device|LFMS - Sham|A simulation of the LFMS-Active intervention, using the same device that produces a sound similar to the sound made by the device during the active treatment, for a similar duration (in the current study, 20 minutes)
1489095|NCT03050359|Drug|TAK-438|TAK-438 tablets
1489096|NCT03050359|Drug|Lansoprazole|Lansoprazole capsules
1489097|NCT03050359|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets.
1489098|NCT03050359|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
1489099|NCT03050359|Drug|Bismuth-Containing Quadruple Therapy|Amoxicillin, clarithromycin and bismuth potassium citrate.
1948936|NCT01052922|Other|1 sample OC-Micron|Participants will be mailed to a 1 sample OC-MICRON FOBT kit to complete at home and mail back to the lab for screening.
1948937|NCT01038193|Other|Cognitive assessment|Cognitive and functional assessments at 2-4 weeks, 3 months and 12 months.
1489102|NCT03050307|Drug|TAK-438|TAK-438 tablets
1489103|NCT03050307|Drug|Lansoprazole|Lansoprazole capsules
1489104|NCT03050307|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
1489105|NCT03050307|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
1489106|NCT03050307|Drug|Bismuth-Containing Quadruple Therapy|Bismuth-Containing Quadruple Therapy
1489107|NCT03050294|Behavioral|Phone calls|Phone calls twice daily
1489108|NCT03050294|Drug|Desoximetasone 0.25% spray|Desoximetasone 0.25% spray applied twice daily
1489109|NCT03050281|Other|Simulation/Cadaver lab|The primary focus of this study is to determine whether the use of a comprehensive, combined, and simplified approach of using cadavers and simulation laboratories to train third-year medical students will have a beneficial effect on student performance in the OB-GYN and surgical clerkships.
1489110|NCT03050281|Other|Lectures|Standard Anatomy lectures were offered.
1489111|NCT03050255|Other|Medical air|
1489112|NCT03050255|Other|Oxygen (2Liter/min)|
1489113|NCT03050255|Other|Oxygen (4Liter/min)|
1489114|NCT03050242|Drug|Glycopyrrolate|Intramuscular administration of glycopyrrolate 0.005mg/kg 1 hour before the surgery
1489115|NCT03050229|Drug|Empagliflozin|Empagliflozin 10mg/day once daily before or after breakfast
1489116|NCT03050229|Drug|Placebo|Placebo once daily before or after breakfast
1489117|NCT03050216|Biological|ALT-803|"Preparative Regimen:
Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4
ALT-803 Stimulated Donor NK Cells:
The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be stimulated by overnight incubation with 36.1 ng/mL ALT-803 under GMP conditions and infused on day 0.
ALT-803 to Facilitate NK Cell Survival and Expansion:
ALT-803 at 10 mcg/kg subcutaneously (SC) with the 1st dose administered on day 0 (no sooner than 4 hours post NK cells), day +5 and day +10 for 3 doses total"
1494116|NCT03012880|Other|Laboratory Biomarker Analysis|Correlative studies
1489118|NCT03050203|Other|custom pack|Preparation of the surgical field using a custom pack. The use of a custom pack provides much of the material provided for the preparation of the surgical field with a single opening of the package , reducing the risk of contamination of the material.
1489119|NCT03050203|Other|standard care|The scrub nurse prepares the surgical field opening all the sterile packs it deems necessary for the surgery
1489120|NCT03050190|Genetic|Therapeutic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
1489121|NCT03050177|Drug|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered under fed conditions after a 10-hour overnight fast.
1489122|NCT03050177|Drug|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered under fed conditions after a 10-hour overnight fast.
1489123|NCT03050164|Drug|Gefitinib Tablet 250mg of Hunan Kelun|Single dose of Gefitinib Tablet 250mg of Hunan Kelun was administered after a 10-hour overnight fast.
1489124|NCT03050164|Drug|Iressa® Tablet 250mg of AZN|Single dose of Iressa® Tablet 250mg of AZN was administered after a 10-hour overnight fast.
1489125|NCT03050151|Drug|Dupilumab|Administration of dose of Dupilumab as per protocol by auto-injector or prefilled syringe
1489126|NCT03050151|Device|Auto-injector Device|Delivery of Dupilumab by auto-injector device
1489127|NCT03050151|Device|Prefilled syringe|Delivery of Dupilumab by prefilled syringe
1489128|NCT03050125|Device|Hypo-osmolar drop 1|180 mOsmol sterile saline drops used as a contact lens rewetting drop.
1489129|NCT03050125|Device|Hypo-osmolar drop 2|240 mOsmol sterile saline drops used as a contact lens rewetting drop.
1489130|NCT03050125|Device|Iso-osmolar drop|300 mOsmol sterile saline drops used as a contact lens rewetting drop.
1489131|NCT03050112|Other|MacNew questionnaire|Patients will be asked to fill in the MacNew questionnaire on quality of life (phone contact).
1489132|NCT03050099|Other|Non-Interventional Study|This is a non-interventional study. However, several blood samples will be taken which would not be taken as part of standard of care.
1489133|NCT03050086|Drug|1 or 2% minocycline topical gel|once daily administration of topical minocycline gel to face
1489134|NCT03050060|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
1489135|NCT03050060|Other|Laboratory Biomarker Analysis|Correlative studies
1489136|NCT03050060|Drug|Nelfinavir Mesylate|Given PO
1489137|NCT03050060|Biological|Nivolumab|Given IV
1489138|NCT03050047|Biological|BCD-100|Anti-PD1 monoclonal antibody
1489139|NCT03050034|Device|WIN @ Hospital system|WIN @ Hospital system is a wearable and wireless system (Medical Class IIA) that allows continuous and real-time vital signs monitoring, automatically calculating the NEWS score with a personalized alert system for the patient. It does not require the continuous presence of the nurse in front of the control room, but is working with alert on portable devices (ipad).
1489140|NCT03050034|Other|Traditional monitoring|Vital signs control performed by nurse staff each 6 hours or more, according to medical advice.
1489141|NCT03050008|Other|FLACS USFREE|Cataract Surgery with Femtosecond Laser Without Ultrasound
1489142|NCT03050008|Other|Traditional Surgery|Traditional phacoemulsification cataract surgery using ultrasound.
1489143|NCT03049995|Procedure|Left ventricular contractile reserve SE|Stress protocols (either physical or pharmacological) will be performed according to recent guidelines recommendations (1,2,3). with special focus on Wall Motion Score Index.
1489144|NCT03049995|Procedure|B-lines SE|SE will be performed with special focus on lung sonography and B-lines score (3,4).B-lines will be scored with the 28-regions antero-lateral chest assessment as previously described at baseline and immediately after stopping exercise. A simplified 8-region scan is also allowed in order to save time without loss of critical information.
1489145|NCT03049995|Procedure|Left ventricular outflow tract gradient SE|SE will be performed with special focus on left ventricular outflow tract obstruction (3,4).
1489146|NCT03049995|Procedure|Diastolic function SE|SE will be performed with special focus on E/e', pulmonary artery systolic pressure, B-lines and left ventricular end-diastolic volume (3,4).
1489147|NCT03049995|Procedure|Mitral regurgitation SE|SE will be performed with special focus on mitral regurgitation and aortic valve gradients assessment (3,4).
1489148|NCT03049995|Procedure|Pulmonary hemodynamics SE|SE will be performed with special focus on pulmonary artery systolic pressure and pulmonary artery hemodynamics.
1489149|NCT03049995|Procedure|Coronary flow reserve SE|SE will be performed with special focus on regional wall motion + coronary artery flow velocity reserve.
1489150|NCT03049982|Device|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
1489151|NCT03049969|Device|tDCS stimulation|up to 2.0 mA, dorsolateral prefrontal cortex (dlPFC) motage) while completing cognitive training tasks
1489152|NCT03049956|Diagnostic Test|Ocular vestibular evoced myogenic potentials|The oVEMP technique is an accepted standard for testing otolith function in vestibular patients. It represents a quick, simple and non-invasive technique utilizing repetitive stimulation of the otolith organs with bone-conducted vibration to elicit an extraocular muscle response. Repetitive oVEMP stimulation leads to a characteristic decrement in patients with myasthenia, which can be quantified with surface electromyography from the inferior oblique muscle underneath the eye.
1489153|NCT03049943|Device|low level laser|
1489154|NCT03049930|Drug|Ketamine|Ketamine is a medication used for starting and maintaining anesthesia. Participants randomized to the ketamine arm will receive 1 mg/ml solution infused at 0.2 mg/kg/hour (0.2 ml/kg/h) for a maximum of 20 ml/hour.
1489155|NCT03049930|Drug|Sodium chloride|Participants randomized to the placebo arm will receive 0.9 mg/ml sodium chloride, infused at a rate of 0.2 ml/kg/hour
1489156|NCT03049917|Behavioral|Financial incentive|Conditional cash transfer upon HIV testing
1489269|NCT03049163|Drug|vitrectomy under topical anesthesia [Proparacaine HCL (Alcaine®)]|to observe the anesthesia effect of topical anesthesia of 27-gauge vitrectomy for vitreous floaters
1489433|NCT03047928|Drug|Nivolumab|Nivolumab 3 mg/kg is administered biweekly as long as there is clinical benefit.
1489157|NCT03049904|Behavioral|Vr2L 2Spirit|"Three weeks exploring the Vr2L 2Spirit island.
Week 1: Learning Level. Contains the Vr2L 2Spirit island orientation, the learning paths covering HIV testing, harm reduction, safer sex, and condom use & condom use negotiation, the lodge, the in-world Motivational Interviewing (MI) counseling, and leisure activities.
Week 2: Skills Building Level. The purpose of the city level is for participants to practice the knowledge gained in the Learning level through quests, challenges, and role play scenarios.
Week 3: Experiential Level. Experiential interactions with other participants where they can practice the knowledge and skills they gained in the previous levels."
1489158|NCT03049891|Other|Data abstraction|The investigators will abstract clinical data from down-referral sites and from NHLS to determine whether children made it to their down-referral sites or whether children are in care at a different facility.
1489159|NCT03049891|Other|Tracing questionnaire|The investigators will attempt to contact and visit caregivers of children who are determined to be LTF from DNH or from down-referral sites. If located and after providing consent, caregivers will be administered a tracing questionnaire, or a verbal autopsy if their child has died.
1489160|NCT03049891|Other|Tier.net|For all children who started ART at DNH between 2004 and 2013, the investigators will abstract data on these children from the electronic medical system in South Africa called Tier.net.
1489161|NCT03049878|Drug|Paracetamol Codeine|preoperative administration
1489162|NCT03049878|Drug|Placebo Oral Tablet|preoperative administration
1489163|NCT03049852|Drug|CBT-001|One drop in the study administered three times daily (TID)
1489164|NCT03049852|Drug|Vehicle|One drop in the study administered three times daily (TID)
1489165|NCT03049839|Behavioral|Intervention_ S|One year Structured intervention program for members of high-risk group (Subjects with FINDRISC score ≥12 points and impaired glucose tolerance (IGT))
1489166|NCT03049839|Behavioral|Intervention_ I|One year Informative intervention program for members of moderate risk group (People with normotolerant or impaired fasting glucose in the OGTT and a FINDRISC score ≥12 points)
1489167|NCT03049839|Behavioral|Intervention_ C|One year, Intervention program at Community level. People with a FINDRISC less than 12 points
1489168|NCT03049826|Other|Nutritional status|Body composition and nutrient status
1489169|NCT03049813|Behavioral|Virtual Reality Job Interview Training|Job interview training using virtual reality software created by SIMmersion, Inc, in addition to standard supported employment services.
1489170|NCT03049813|Other|Supported Employment (Services as Usual)|Standard supported employment services.
1489171|NCT03049800|Device|Magnetic Resonance Imaging|Functional, structural, and diffusion weighted imaging conducted with a 7T-PS scanner.
1489172|NCT03049800|Behavioral|Treatment as Usual|patients who receive treatment as usual while participating in a randomized controlled trial examining the effect of computerized cognitive training.
1489173|NCT03049800|Behavioral|Targeted Cognitive Training|patients who receive targeted training while participating in a randomized controlled trial examining the effect of computerized cognitive training.
1489174|NCT03049800|Other|Healthy Controls|age and gender matched controls who are psychologically and physically healthy will be recruited from the community to participate in this cohort.
1489175|NCT03049787|Other|Home Exercise Protocol|Home physical therapy protocol given to patient to be completed at home.
1489176|NCT03049787|Other|Formal Physical Therapy Protocol|Formal physical therapy protocol to be given to physical therapist working with patient to direct formal intervention along with a home therapy protocol.
1489177|NCT03049761|Device|Water Flosser|Power interdental cleaner
1489178|NCT03049761|Device|String Floss|Mechanical interdental cleaner
1489179|NCT03049761|Device|Manual Toothbrush|ADA standard soft bristle toothbrush
1489180|NCT03049748|Device|Mobile phone app (VAD Care App)|"VAD Care App is a novel self-management tool being tested for patients with implantable LVADs. The app has daily push notifications (alerts), cues for daily self-management tasks, two-way communication using text messages and videoconferencing (virtual clinic), and links to LVAD self-management skills and videos easily accessible for self-management skill review."
1489181|NCT03049748|Other|Usual LVAD Care|Routine clinic follow-up visits over 6 months. Patients and caregivers will both receive self-management education post discharge and as needed throughout the duration of the study.
1489182|NCT03049735|Drug|Relugolix|Relugolix 40 mg tablet administered orally once daily
1489183|NCT03049735|Drug|Low-dose Hormonal Add-back|Estradiol and norethindrone acetate.
1489184|NCT03049735|Drug|Relugolix Placebo|Placebo relugolix manufactured to match relugolix in size, shape, color, and odor
1489185|NCT03049735|Drug|Low-dose Hormonal Add-back Placebo|placebo capsule designed to match the over-encapsulated active low-dose hormonal add-back therapy in size, shape, color, and odor
1489186|NCT03049722|Device|Pacemaker|
1489187|NCT03049696|Behavioral|ENCOURAGEING START|16-week physical activity and behaviour modification/education program. CMBS approved bariatric surgery patients participate in structured, supervised physical activity sessions (2 per week) and behaviour modification-education classes during weeks 1 through 8. During weeks 9 through 16, patients will be given access to attend drop in physical activity sessions or can opt to complete physical activity at home.
1489188|NCT03049683|Other|Vestibular evoked myogenic potentials (VEMPs)|The c- and oVEMPs will be assessed in three different sessions including conventional sequential recordings and two different simultaneous recording methods, i.e., unilateral simultaneous recording of cVEMPs and oVEMPs during monaural stimulation (Figure 1A) and bilateral simultaneous recording of each VEMP during binaural stimulation (Figure 1B).
1489189|NCT03049670|Device|latent available chlorine (LAC)|local application on the necrotic infected tissue
1489190|NCT03049657|Device|Angiolite|Percutaneous coronary intervention
1489191|NCT03049657|Device|Xience|Percutaneous coronary intervention
1489192|NCT03049644|Procedure|Mechanical Diagnosis and Therapy|Identification of directional preference.
1489193|NCT03049644|Procedure|Manual Therapy|Mechanically based treatment based on taking joint to end range and thrusting or soft tissue manipulation.
1489194|NCT03049631|Dietary Supplement|Raspberry and fructooligosaccharide|Red raspberries (1 cup equivalent) with fructooligosaccharide (8 g)
1489195|NCT03049631|Dietary Supplement|Raspberry|Red raspberries (1 cup equivalent)
1489196|NCT03049618|Other|Laboratory Biomarker Analysis|Correlative studies
1948938|NCT01032824|Behavioral|Individual Telephone Counseling Intervention|10-session, 5-month HIV adherence and chronic disease self-management individual telephone counseling intervention.
1948939|NCT01032824|Other|Group Arm|10-session didactic telephone group
1948940|NCT01032824|Other|Book Arm|Book only.
1489202|NCT03049592|Other|HIBISCUS counseling|Third trimester prenatal appointment with a family planning specialist for contraceptive counseling utilizing the Contraceptive CHOICE counseling script - emphasizing the WHO birth-to-pregnancy recommendation of 18 months, and a follow up postpartum contraception visit with a family planning specialist.
1489203|NCT03049579|Dietary Supplement|Weiquan Yogurt with probiotics|150 ml daily consumption for a total of 12 weeks
1489204|NCT03049579|Dietary Supplement|Weiquan Yogurt without probiotics|150 ml daily consumption for a total of 12 weeks
1489205|NCT03049566|Other|preoperative questionnaires|no intervention, cross-sectional survey in a single group
1489206|NCT03049553|Device|Cobas HPV-DNA test|"Cobas HPV-DNA testing device from Roche is already in standard use in the Danish screening program for purpose of triage and primary screening of women 60+. It has four signals; HPV-negative, HPV-16, HPV-18 and other"
1489207|NCT03049553|Device|Liquid-based cytology|Liquid-based cytology (LBC) is the standard screening test in the Danish cervical screening program.
2001366|NCT03048370|Procedure|Left body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
1489210|NCT03049527|Behavioral|Education, Incentives and Feedback|The study participants will receive additional educational activities, including low-literacy fact sheets on liquid intake guidelines, cards with instructions on how to self-monitor urine color and volume, and flyers and posters placed throughout the worksite. All consenting study participants will be offered incentives to start the work day hydrated and then to maintain or improve their hydration status over the work shift. Participants who do not meet hydration goals will receive additional coaching and feedback on ways to improve hydration.Feedback will also be provided to all groups about their productivity level to help participants recognize the connection between improved health and function.
1489211|NCT03049501|Behavioral|Caregiving condition|
1489212|NCT03049501|Behavioral|Nutrition condition|
1489214|NCT03049462|Drug|Mirabegron|Women will take 100mg daily for 4 weeks. Men will take 200mg daily for 4 weeks. The medication is available in 50mg tablets.
1489215|NCT03049462|Other|Placebo|Males will be randomized to take placebo versus active drug (mirabegron). Those taking placebo will take 4 tablets each day to mirror to active group (taking 4 tablets of 50 mg each).
1489216|NCT03049449|Biological|Anti-CD30-CAR T cells|Dose-escalation trial starting dose: 0.15x106 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x106 CAR+ T cells/kg)infuse on day 0
1489217|NCT03049449|Drug|Cyclophosphamide|300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3
1489218|NCT03049449|Drug|Fludarabine|30 mg/m2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
1489219|NCT03049436|Other|Program of adapted physical activity|
1489220|NCT03049423|Device|MRI scans|30 patients with ankle ligament and tendon injury were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the trial group. Each participant was required to undergo MRI scans in normal position and during complete plantar flexion and complete dorsiflexion.
1489221|NCT03049423|Diagnostic Test|MRI scans and general physical examination|30 patients with normal ankle joint were selected in accordance with the diagnostic criteria of ankle ligament and tendon injury in the control group. Each participant was required to undergo MRI scans and general physical examination in normal position and during complete plantar flexion and complete dorsiflexion.
1489222|NCT03049410|Procedure|Intracorporeal Robot Assisted Radical Cystectomy|Intracorporeal robot assisted radical cystoprostatectomy or anterior exenteration
1489223|NCT03049410|Procedure|Open Radical Cystectomy|Removal of bladder and adjacent organs
1489224|NCT03049397|Other|Communication Intervention|Complete Enhancing Connections program
1489225|NCT03049397|Other|Questionnaire Administration|Ancillary studies
1489226|NCT03049384|Other|Traditional Exercise|The traditional exercise group will undertake a supervised exercise intervention involving aerobic exercise and light resistance training, in line with published guidelines for exercise in cancer survivors.
1489227|NCT03049384|Other|Tailored Exercise|The tailored training group will be prescribed an individualized exercise intervention designed specifically to counteract deficits (e.g. neuromuscular) of difficulties (e.g. sleep disturbance) identified during pre-intervention testing.
1489228|NCT03049371|Other|No Intervention for both groups|No Intervention for both groups However, computer-administered questionnaire will collect quantitative demographic information and details about surgical history, neovaginal health, neovaginal practices, and sexual behavior including neovaginal intercourse and drug use history from each participant
1489229|NCT03049358|Other|Physiologic Testing|Undergo UPSIT smell test
1489230|NCT03049358|Other|Quality-of-Life Assessment|Ancillary studies
1489231|NCT03049358|Procedure|Sham Intervention|Undergo sham training
1489232|NCT03049358|Procedure|Therapeutic Procedure|Undergo olfactory training
1489233|NCT03049358|Other|rose essential oil|patient smells rose oil in vial
1489234|NCT03049358|Other|lemon essential oil|patient smells lemon oil in vial
1489235|NCT03049358|Other|clove essential oil|patient smells clove oil in vial
1489236|NCT03049358|Other|eucalyptus essential oil|patient smells eucalyptus oil in vial
1489237|NCT03049358|Other|canola oil placebo|patient smells canola oil in vial
1494117|NCT03012880|Drug|Lenalidomide|Given PO
1948941|NCT01026623|Biological|Cixutumumab|Given IV
1948942|NCT01026623|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1948943|NCT01026623|Drug|Temsirolimus|Given IV
1489238|NCT03049345|Procedure|Sentinel Lymph Node Sampling|The day before surgery, 2mL of endoscopically-placed technetium 99m sulfur colloid solution will be injected submucosally at 4 points around the tumour. At the time of surgery, 2cc of 1% isosulfan blue dye will be similarly injected. Laparoscopically, the gastrocolic ligament will be opened to expose all gastric lymph node drainage basins. Using visual inspection and a laparoscopic gamma probe, blue nodes and those emitting 10x greater than background activity will be considered sentinel nodes and extracted. Sentinel lymph nodes and resected specimens will be analyzed by permanent section.
1489239|NCT03049345|Drug|Radioactive Tracers|see above
1489240|NCT03049345|Drug|Methylene Blue 20 MG/ML|see above
1489241|NCT03049332|Behavioral|self- and family-management intervention sessions|The self- and family management intervention will have six elements: (a) biofeedback for relaxation; (b) family support; (c) coping skills; (d) anxiety, stress, and depression management; (e) cognitive-behavioral management skills; and (f) psycho-educational classes.
2001367|NCT03048370|Procedure|Right body temperature VS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
2001368|NCT03048370|Procedure|Left warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
2001369|NCT03048370|Procedure|Right warm CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
2001370|NCT03048370|Procedure|Left cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
2001371|NCT03048370|Procedure|Right cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
1489252|NCT03049267|Drug|Apremilast|Fifteen patients will be supplied of apremilast for daily oral use; 16 weeks.
1489253|NCT03049267|Drug|Placebo Oral Tablet|Five patients will be supplied with placebo tablets with identical labeling as apremilast for daily use; 16 weeks.
1489254|NCT03049241|Other|neuromuscular fatigue|The main aim of the present protocol is to compare the effect of knee extensors and ankle plantarflexors length on the development and aetiology of neuromuscular fatigue, in children and adults
1489255|NCT03049228|Diagnostic Test|31P-MRS scan and cardiac MRI scan|"31P-MRS measurement of the heart: Phosphorous magnetic resonance spectroscopy (31P-MRS) will be used for the determination of the energy status of the heart in vivo. The localization of phosphorus energy metabolites in the heart will be performed by one-dimensional spectroscopic imaging, resulting in spectra from slices through the heart of 1 cm thickness. The peaks of PCr and ATP will be fitted in order to calculate the ATP/PCr ratio.
The measurement of cardiac function is a standardised protocol. In the 4 chamber view setting a T1 mapping sequence will be performed for the detection of fibrosis. Hereafter patients will receive contrast for T2 mapping and late enhancement studies for determining extracellular volume and ischemia."
1489256|NCT03049228|Diagnostic Test|Atrial biopsy for high-resolution respirometry|Mitochondrial respiration rates are ex vivo measured in tissue homogenates under exposure of different substrates, stimulating different complexes of the electron transport chain of the mitochondria.
1489257|NCT03049228|Diagnostic Test|Blood analysis|To determine blood glucose metabolism and renal function.
1489258|NCT03049228|Diagnostic Test|Body composition|This device uses air displacement plethysmography for determining percent fat and fat-free mass in adults and children. The 5-minute test consists of measuring the subject's mass (weight) using a very accurate electronic scale, and volume, which is determined by sitting inside the BOD POD chamber. From these two measurements, the subject's body composition is calculated.
1489259|NCT03049228|Diagnostic Test|Indirect Calorimetry|As basal energy metabolism might be related to cardiac metabolism and mitochondrial function, and basal metabolic rate shows inter-individual variance, it is an important subject characteristic of the patients. Resting substrate oxidation rates are measured with indirect calorimetry for 30 minutes. A ventilated hood is connected to indirect calorimetry equipment, which measures concentrations of oxygen consumption and CO2 production. From these parameters, the respiratory quotient (RQ), as well as energy expenditure and substrate metabolism will be computed. During this measurement, every 10 minutes (so 4 times) one tube of blood (10ml) will be drawn for the analysis of lipid and glucose metabolites.
1489260|NCT03049215|Device|Lumen Apposing Metal Stent (LAMS)|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst.
1489261|NCT03049215|Device|LAMS plus double pigtail stent|The AXIOS Stent and Electrocautery-Enhanced Delivery System is an endoscopic device designed to enable the ultrasound trained interventional endoscopist to deliver a transenteric stent between the gastrointestinal tract and a pancreatic pseudocyst. The double pigtail stent is a routinely used plastic biliary stent.
1489265|NCT03049176|Drug|PrEP (Truvada)|oral, daily Truvada for HIV-negative participants
1489266|NCT03049176|Drug|Antiretrovirals|oral daily antiretrovirals and frequent viral load monitoring for HIV-positive participant
1489267|NCT03049176|Procedure|Semen washing|collection of semen from an HIV-positive man, processing semen to remove HIV, followed by intrauterine insemination
1489268|NCT03049176|Procedure|Artificial vaginal insemination|collection of semen from an HIV-negative man, followed by intravaginal insemination
1494118|NCT03012880|Other|Questionnaire Administration|Ancillary studies
1489270|NCT03049137|Procedure|Computer Guided Stent Augmentation|Defective alveolar ridge is to be replaced by simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) using computer guided stent and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 Revolution Per Minute (RPM) for 10 minutes.
1489271|NCT03049137|Procedure|Free Hand Augmentation|Defective alveolar ridge is to be replaced by Free Hand simultaneous implant placement with ring graft augmentation (Trephine Drill to obtain the ring graft autogenous bone) and covered with Platelet-rich fibrin (PRF), by using venous blood from the patient, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM for 10 minutes.
1489272|NCT03049137|Drug|Platelet-rich fibrin (PRF)|
1489273|NCT03049137|Device|implant|
2001372|NCT03048370|Procedure|Left ice cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
1489276|NCT03049098|Behavioral|Simulation|A 9-minute scenario based on an ACLS bradycardia algorithm in which a high-fidelity mannequin requires external pacing
1489277|NCT03049085|Drug|Aspirin|preoperative uncoated 75 mg Aspirin is administered 2 hours prior OPCAB
1489278|NCT03049085|Drug|vitamin C|preoperative 75 mg Vit. C (Placebo) is administered 2 hours prior OPCAB
1489279|NCT03049072|Radiation|Protons and Carbon Ions|
1489280|NCT03049059|Device|Fractional Picosecond 1,064 nm laser|Fractional Picosecond 1,064 nm laser and daily application with 4% hydroquinone cream
1489281|NCT03049059|Drug|4% hydroquinone cream|
1489282|NCT03049046|Drug|CC100|synthetic caffeic acid phenethylester
1489283|NCT03049046|Drug|Placebos|Diluent
1489284|NCT03049033|Other|Neurologic Music Therapy|Neurologic Music Therapy uses rhythms to change brain activity and function.
1489285|NCT03049033|Other|Occupational Therapy|Occupational Therapy uses traditional motor training.
1489286|NCT03049020|Procedure|laparoscopic sacrocolpopexy|standard laparoscopic sacrocolpopexy for prolapse treatment
1489287|NCT03049007|Diagnostic Test|Survey|Completion of surveys with diagnostic measurements (e.g., PGD, depression, anxiety, PTSD).
1489288|NCT03048994|Dietary Supplement|Glutamine|"Patients randomised to receive glutamine supplementation will receive IV glutamine (0.5g/kg body weight/day) continuously over 24 hours.
IV glutamine will be administered for 5 days or less if death ensues prior to 5 days or transferred to another hospital prior to 5 days. IV glutamine will be continued even if the patient is transferred outside the ICU but within the hospital.
An intravenous saline solution that is identical in volume, color and consistency will be administered to the placebo group with the same dosing regimen and duration."
1489289|NCT03048994|Dietary Supplement|Placebo|"Nutritional support will be continued as per managing ICU team discretion.
Management of severe sepsis will be continued as per managing ICU team discretion.
Weaning patients from mechanical ventilation will be done as per managing ICU team discretion.
To minimise differences between centers, active dissemination of practice guidelines for nutritional support, sepsis management and weaning will be carried out."
1489290|NCT03048981|Drug|Fish oil|Blood samples before and after 10 day intake of maximum dose fish oil
1489295|NCT03048955|Device|Superion® IDS|Device is a non-fusion, spinal column load-sharing device used to stabilize the spine at the implanted leve
1489296|NCT03048955|Procedure|Direct decompression Surgery|A surgical procedure - the control
1489297|NCT03048942|Drug|Cabazitaxel|3 weekly cyctotoxic chemotherapy
1489298|NCT03048942|Drug|Paclitaxel|Weekly cyctotoxic chemotherapy
1489299|NCT03048929|Biological|Typhoid Vi Polysaccharide Vaccine|Salmonella typhi capsular polysaccharide vaccine (Typhoid Vi Polysaccharide Vaccine): Each dose of 0.5ml Salmonella typhi capsular polysaccharide vaccine (Sanofi Pasteur, SA) is formulated to contain 25μg of purified Vi polysaccharide in a colorless isotonic phosphate buffered saline (pH 7±0.3), 4.150mg of sodium chloride, 0.065mg of disodium phosphate, 0.023mg of monosodium phosphate and 0.5ml of sterile water for injection. It is indicated for use by humans aged 2 years and older for protection against typhoid fever.
1489300|NCT03048929|Biological|Placebo|The placebo injection will consist of 0.5mL of saline.
1489301|NCT03048916|Other|general swallowing therapy|including a session of oral exercises, tactile stimulation, compensatory techniques, swallowing maneuvers that are taught to the participants by a speech therapist.
1489302|NCT03048916|Other|NMES therapy|he NMES therapy with VitalStim therapeutic device will be done by one physician who is licensed practitioner and certified in use of the VitalStim device. The placement of 2-channel electrodes is depended on the dysphagic types and the findings on VFS.
1489328|NCT03048760|Other|MRI scan|All participants will undergo 2 MRI scans - 1 at the time of their radiotherapy planning scans & 1 after approx. 2 weeks of radiotherapy treatment.
1489303|NCT03048903|Drug|Rheum Palmatum Root|Rhubarb is commercially certified rhubarb(Rheum palmatum , Sichuan origin, provided by the pharmacy of my hospital), ground into a powder, over 80 mesh steel mesh.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
1489304|NCT03048903|Drug|Starch Corn|Starch Corn is harmless to people .The use dosage is same as Rheum Palmaturn Root.The dose is 6g in the first 2 days, 3 times / day, oral or nasal feeding,two days later the dose is reduced to 3g, three times / day, oral or nasal feeding.
1489305|NCT03048890|Behavioral|Physical activity levels|Patients with severely low physical activity levels will be notified to consult their physician.
1489306|NCT03048877|Drug|Apatinib Oral Tablet|Apatinib Mesylate Tablets
1489307|NCT03048877|Drug|Placebo Oral Tablet|Placebo Oral Tablet
1489308|NCT03048851|Device|Low dosage SES group|The participants were randomly assigned to one of the five intervention groups. Low dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 45 minutes and arm with wrap for 45 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
1489309|NCT03048851|Device|High dosage SES group|The participants were randomly assigned to one of the five intervention groups. High dosage SES group received the SES (Micro-Z Mini, Prizm Medical Inc., USA) training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted twice per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove (Electro-Mesh Glove-Sleeve Electrode Kit) for 90 minutes and arm with wrap for 90 minutes. The pulse width was set to 300us for all stimulation levels. The frequency was set to 100 Hz and 10 Hz.
1489310|NCT03048851|Device|VRCIT group|The participants were randomly assigned to one of the five intervention groups. VRCIT group received the VRCIT training plus traditional rehabilitation, conducted twice per week for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, plus home program, and restraint of the less affected UE for 1.5 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training. The VRCIT combined CIT and commercially available VR-based systems including Sony Playstation EyeToy and Nintendo Wii.
1489311|NCT03048851|Device|VRCIT+SES group|The participants were randomly assigned to one of the five intervention groups. VRCIT+SES group executed VR programs by affected UE in Mesh-gloves (Electro-Mesh Glove-Sleeve Electrode Kit) with the optimal SES (Micro-Z Mini, Prizm Medical Inc., USA) protocol formulated from the 1st phase study. The VRCIT program was conducted 1.5 hours/time, twice/week for 12 weeks. The VRCIT combined CIT and commercially available VR-based systems. Some commercially programs, such as Sony Playstation EyeToy (Sony Computer Entertainment America, Foster City, Calif., USA), and Nintendo Wii (Nintendo Domestic Distributor, College Point, N.Y., USA).
1489312|NCT03048851|Procedure|traditional rehabilitation program|The participants were randomly assigned to one of the five intervention groups. The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
1489313|NCT03048838|Behavioral|Risk reduction behavioral intervention|
1489314|NCT03048838|Behavioral|Wellness Promotion Intervention|
2001373|NCT03048370|Procedure|Right ice cold CVS|Caloric vestibular stimulation (CVS), which involves the irrigation of cold or warm water into the external ear canal, induces a temperature gradient across the semicircular canals of the vestibular apparatus stimulating the vestibular nerve. It is commonly used in both otolaryngology to assess vestibular function and neurology to test brain stem function
2001374|NCT03047213|Other|Laboratory Biomarker Analysis|Correlative studies
2001375|NCT03047213|Drug|Sapanisertib|Given PO
1489320|NCT03048812|Device|O'Ring Attachment (A)|Attachment A will be inserted in three months of follow up,followed by treatment B in a random order
1489321|NCT03048812|Device|Equator Attachment (B)|Attachment B will be inserted in three months of follow up,followed by treatment A in a random order
1489322|NCT03048799|Device|Radiofrequency|The radiofrequency application protocol will be used in the form of capacitive electrical transfer, bipolar configuration, with CAPENERGY device (Figure 1), which has two electrodes: an active one, which will be introduced into the anal region, using a condom and gel to The emission of radiofrequency and another electrode, dispersive, coupled to the patient's hip, which will function as earth. The active electrode has at its end a sensor capable of capturing the temperature. The temperature used in the treatment will be 41 ° C, which this parameter will be placed in the equipment. Upon reaching the desired heating, the apparatus maintains the temperature and thus the application of the radiofrequency will be maintained for 2 minutes.
1489323|NCT03048786|Behavioral|Control|Participants will receive automated text messages used by SmokefreeTXT. The messages are designed to provide encouragement, support, and information about quitting smoking. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date.
1489324|NCT03048786|Behavioral|Peer Mentoring|"Participants will receive a modified version of the automated text messages sent to the control arm plus random assignment to a peer mentor. The modified messages include automated conversation starters, designed to stimulate conversation with the peer mentor. The peer mentor will then send personalized, tailored responses. The peer mentor is a former smoker who has completed a training program developed by the investigator team. Participants will receive 1-5 automated messages per day for 6-8 weeks depending on choice of quit date."
1489325|NCT03048773|Device|shockwave therapy|Intervention with shockwave therapy
1489326|NCT03048773|Other|PT|Physical therapy 3 times per week for 3 weeks
1489327|NCT03048773|Other|placebo|sham shockwave therapy
1489329|NCT03048747|Drug|Tolvaptan Oral Tablet|Tolvaptan tablets at 7.5, 15, 30 (one tablet each), or 60 mg (two 30 mg tablets) will be orally administered once daily after breakfast for up to 30 days.
1489330|NCT03048721|Procedure|Skin Tape Stripping|For psoriasis group, tape-stripping will be done in both involved and uninvolved skin. The tape-stripping will be performed within 2.5 cm of the first punch biopsy. For healthy control group, tape-stripping will be performed on normal skin, within 2.5. cm of the first punch biopsy.
1489331|NCT03048721|Procedure|Punch Biopsy|For psoriasis group, one punch biopsy will be taken from each of the following areas: involved skin, tape-stripped involved skin, uninvolved skin, and tape-stripped uninvolved skin. For healthy control group, one punch biopsy will be taken from each of the following areas: normal skin and tape-stripped normal skin (within 2.5 cm of the first punch biopsy).
1489332|NCT03048708|Procedure|Bariatric surgery|patients who had received treatment with bariatric surgery for medical reasons
1489333|NCT03048695|Behavioral|GMT|Metacognitive strategy training where the primary objective is to stop ongoing behavior to define goal hierarchies and monitor performance
1489334|NCT03048682|Device|Foley catheter - Early Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.
Subjects in the Early Voiding group will have their repeat voiding trial on post-op day #2, 3, or 4 will undergo an in-office voiding trial. The experimental group will return for an in-office voiding trial sooner than the active comparator."
1489335|NCT03048682|Device|Foley catheter - Late Voiding Trial|"All subjects that are discharged home with a Foley catheter will need an in-office repeat voiding trial.
Subjects in the Late Voiding group will have their repeat voiding trial on post-op day #7 or after. This is our current practice"
1489336|NCT03048669|Other|Continuous quality improvement|A quality improvement team at the health district and at the clinics levels. A clinic level QI team will include at least one staff each from antenatal care (ANC), delivery/maternity, and well-child services. The head of the each QI team plus a supervisor from the health district bureau and a study team member constitute the district QI team. Immediately following randomization, we will bring together QI teams to review program and quality indicators from their clinics and across districts to identify key bottlenecks in the care delivery system and agree on an action plan to modify them. QI teams will be responsible for the implementation of the action plan at the level of their respective clinics. Every three months, using data from the monitoring system, the process will be repeated for a duration 18 months. To limit possible contamination, all staff from a randomized district/clinic who may have a dual appointment in another facility will be excluded from QI teams.
1489337|NCT03048656|Other|static posturography|The measurement of the weight distribution and the static posturography was performed on the balance platform Good Balance by Metitur . The device is comprised of the triangular force platform with electronic system and computer software. The body weight distribution was evaluated in the upright standing with eyes open, feet placed 20 cm from each other.The individual stood motionlessly for 15 s, then the measurement was recorded. The static posturography was performed with 3 various positions of feet, both with eyes open and eyes closed. (1) Position : normal standing - an upright standing with feet placed parallel 20 cm apart for 30 s. (2) Position: tandem - a stance with one foot placed ahead of the other. for 20 s. (3) Position: one leg standing: stance on the one leg for 20 s.
1489338|NCT03048643|Drug|Buprenorphine/naloxone|Subjects in both groups will receive buprenorphine/naloxone according to published guidelines for induction, stabilization, and maintenance dosing.
1489339|NCT03048643|Other|Outpatient parenteral antibiotic therapy|Subjects randomized to OPAT plus buprenorphine will complete IV antibiotic therapy for infective endocarditis as an outpatient according to published guidelines.
1489340|NCT03048630|Behavioral|Education|Owner-to-Worker training about reducing chemical exposures in nail salons
1489341|NCT03048604|Device|Genio(TM) bilateral hypoglossal nerve stimulation system|Subjects will be consented, enrolled and eligibility criteria checked. If the subject is eligible, subject will proceed with the Genio(TM) implant implantation. Four (4) weeks after implantation, the implant will be activated and the subject will be assessed at 1 month plus 1 week, 2, 3, 4 and 6 month(s) after implantation.
1489342|NCT03048591|Device|electroacupuncture|Acupoint selection: Bilateral Hegu (LI4), Qu-chi (LI1) of upper limbs and bilateral Zusanli (ST36) ,Taichung (LR3)of lower limbs.
1489343|NCT03048578|Drug|Saxenda|Week 1: 0.6mg/day Week 2: 1.2mg/day Week 3: 1.8mg/day Week 4: 2.4mg/day Week 5 and Onward: 3.0mg/day
1489344|NCT03048578|Drug|Placebo|Subcutaneous Saline Solution
1489345|NCT03048565|Behavioral|MBSR|Mindfulness is a skill that helps people manage their thoughts so that the stressful impact of unhelpful thoughts can be limited. The aim of the mindfulness based intervention in this study is to help caregivers manage stressful thoughts and events and help them respond to life stressors in a positive way.
1489346|NCT03048552|Behavioral|Family CONNECT|Linkage specialists, who are clinical social workers and embedded within the probation departments, will work with specifically caregiver-youth dyads in the Family CONNECT arm to link youth to substance use services.
1489347|NCT03048539|Procedure|Transoral endoscopic thyroidectomy|This procedure will remove thyroid lobe through oral vestibule. Aim to avoid scar at anterior neck.
1489348|NCT03048526|Device|NovaTears®|Topical eye drops for lubrication of the ocular surface
1489349|NCT03048526|Device|Hydrabak®|Eye drops
1489350|NCT03048513|Other|Patient who presented with melioidosis in head and neck|Investigators assess the patients who had the pus culture positive with Burkholderia pseudomallei.
1489351|NCT03048500|Other|Laboratory Biomarker Analysis|Correlative studies
1489352|NCT03048500|Drug|Metformin Hydrochloride|Given PO
1489353|NCT03048500|Biological|Nivolumab|Given IV
1489354|NCT03048474|Drug|nivolumab and ipilimumab|
1489355|NCT03048461|Device|Platelet Rich Plasma Prep System|intradermal injections of platelet rich plasma to an area of alopecia
1489356|NCT03048461|Drug|Placebo|intradermal injections to an area of alopecia
1489357|NCT03048448|Drug|Fevipiprant|Single 450mg dose
1489358|NCT03048435|Other|EORTC QLQ CX-24|Disease specific Patient Reported Outcome measurement tool developed by the European Organization for Research and Treatment of Cancer (EORTC). This questionnaire covers symptoms common to women with cervical cancer and captures the impact of disease and/or treatment on domains including: urologic and gastro-intestinal symptoms, sexual functioning and body image.
1489402|NCT03048136|Drug|Nivolumab|Specified dose on specified days
1489359|NCT03048435|Other|Physician Feedback Form|This Feedback form to be completed by oncologists who have had at least one consenting patient participating in this study.
2001376|NCT03045289|Behavioral|Plant-Based Diet|Women will be provided with free prepared food for 6 weeks, along with a multivitamin, and will attend weekly office visits. Women will have baseline assessment and 6 week assessment, in addition to a 3 week blood test.
2001377|NCT03044418|Other|application of ET laser tube in propofol anesthesia|The special endotracheal laser tube covered by aluminum tape is used during anesthesia of endolaryngeal laser surgery.
2001378|NCT03044236|Procedure|Stretching|The novel stretching technique will be done on a supine position. subjects will be asked bridge as high as possible. After That, Participants will then flex their shoulder and elbow to 90°. Participants will use the other hand to push to the point of mild discomfort and simultaneously maintain contraction while progressing the stretch.
2001379|NCT03036514|Device|Sublingual sufentanil tablet system|Usage of a new patient-controlled SSTS in the postoperative phase after laminectomy or spinal fusion.
1489364|NCT03048409|Other|Enteral Formula|Enteral feeding with a peptide-based formula.
1489365|NCT03048396|Procedure|Uterus transplantation|
1489366|NCT03048383|Drug|OnabotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
1489367|NCT03048383|Drug|AbobotulinumtoxinA Injectable Product|Administered to treat facial synkinesis
1489368|NCT03048383|Drug|Incobotulinumtoxin A Injectable Product|Administered to treat facial synkinesis
2001380|NCT03036514|Drug|Patient-controlled intravenous analgesia|Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
2001381|NCT03036592|Behavioral|Early OGTT|Test glucose tolerance using identical mixed 75 gr of glucose under early condition (4 hours before habitual bedtime)
2001382|NCT03036592|Behavioral|Late OGTT|Test glucose tolerance using identical mixed 75 gr of glucose under late condition (1 hour before habitual bedtime)
1489377|NCT03048357|Device|Freedom Bed|Fully Integrated Lateral Rotation Bed System that automatically turns the patient to a specific angle in degrees between from 15-25 with dwell times between 1-120 minutes.
1489378|NCT03048357|Other|Standard hospital bed|Caregiver turning patients to one side then the other every 2 hours for pressure relief over bony prominence's.
1489383|NCT03048331|Device|Functional Electrical Stimulation|"Functional electrical stimulation is applied with stimulators according to the lesion. In case of a upper motor neuron lesion the stimulation operates via nerve. For the stimulation surface electrodes are placed on the skin over the muscle belly. The stimulation of the innervated muscles will be conducted using the following conditions:
300-400 usec, 20-50 Hz, amplitude depends on the quality of muscle contraction (20-80 mA). the duty cycle of the stimulation is 3 sec. ramp up, 5 ec. plateau, 2 sec. ramp down, 10 sec. pause."
1489384|NCT03048318|Procedure|Arterial Flushing|
1489385|NCT03048318|Procedure|Portal Flushing|
1489386|NCT03048292|Other|Acute Endovascular Stroke Treatment|
1489387|NCT03048279|Behavioral|Questionnaires|"Multiple Endocrine Neoplasia Syndromes: MEN1/MEN2 Group: Participants interviewed by phone and/or mail to obtain medical history specific to their diagnosis of either MEN1 or MEN2.
Close Relatives of Registered MDACC MEN Patients Group: Participants asked to complete a health and family history questionnaire. This questionnaire process may be completed by phone or mail."
1489388|NCT03048253|Biological|OrienX010|Beijing biological technology co., LTD. Research and development of the source and force of recombinant human GM-CSF herpes simplex virus injection (OrienX010), is a genetically engineered type 1 herpes simplex virus (HSV - 1) as the carrier insert GM-CSF gene therapy drug.Its carrier is made of isolated from patients with oral Chinese wild single blister virus type I (CL1), after gene recombination technology successively removing ICP34.5, ICP47 and insert the deactivation ICP6 gene, and at the site of the original ICP34.5 insert guided by IE promoter of hCMV human GM-CSF gene.
1489389|NCT03048240|Device|"perPDT"|"The protocol requires the realization of specific procedures in addition to the usual care.
The per-operative photodynamic therapy (perPDT) added to surgery for glioblastoma excision. The patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery + lighting of the tumor bed by a light source (laser) at the end of resection (Prolonged surgery of 45 minutes)."
1489390|NCT03048240|Drug|GLIOLAN|patient will receive 5-ALA (5- alanine ,GLIOLAN drinkable) 4h before surgery
1489391|NCT03048227|Device|Continuous Glucose Measurement (CGM)|Patients will manage their diabetes with the help of Continuous Glucose Measurements (Abbott Freestyle Navigator II).
1489392|NCT03048214|Procedure|Infraclavicular nerve block|Infraclavicular nerve block is a relatively safe and straightforward brachial plexus nerve block that can be used to provide intraoperative regional anaesthesia for upper limb surgeries from the elbow to fingers.
1489393|NCT03048214|Procedure|General anaesthesia|Usual practice for upper limb surgeries.
1489394|NCT03048201|Device|Physica Kinematic Retaining Knee System|Modular total knee prosthesis with a Kinematic Retaining mechanism and posterior cruciate ligament (PCL) preservation
1489395|NCT03048201|Device|Physica Cruciate Retaining Knee System|Total knee prosthesis with posterior cruciate ligament (PCL) preservation
1489396|NCT03048201|Device|Physica Posterior Stabilized Knee System|Total knee prosthesis that sacrifices the posterior cruciate ligament (PCL) and replaces the functionality of the PCL with a post-cam mechanism.
1948961|NCT00994916|Drug|3,4 diaminopyridine|3,4 diaminopyridine up to 80 mg daily in divided doses
1489398|NCT03048175|Procedure|Wisdom tooth removal|After inferior dental and buccal nerve anesthesia a triangular full thickness flap with releasing incision on the mesio-buccal aspect of the second molar is designed. Ostectomy is then performed and tooth is sectioned and gently elevated. Once all the tooth components are extracted, the socket is carefully inspected and flap is sutured with interrupted sutures.
1489399|NCT03048162|Drug|sodium chloride|500 ml of 0.9% isotonic sodium chloride
1489400|NCT03048162|Drug|Hydroxyethylstarch|500 ml of 6% Hydroxyethylstarch
1489401|NCT03048162|Drug|Ringer-Lactate Infusion Solution Bag|500 ml of Ringer-Lactate Infusion Solution Bag
1489404|NCT03048123|Procedure|Hepatic arterial infusion|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially
1489405|NCT03048123|Procedure|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
1489406|NCT03048123|Drug|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
1489407|NCT03048123|Drug|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
1489408|NCT03048110|Drug|BAY1841788 (ODM-201)|In Period 1, 600 mg single dose administered as 2x300 mg tablets on Study Day 1, In Period 2, 600 mg single dose administered as 2x300 mg tablets on Study Day 5 In Period 3, 600 mg single dose administered as 2x300 mg tablets at Study Day 8
1489409|NCT03048110|Drug|Itraconazole|200 mg twice daily (BID) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Day 1 200 mg once daily (QD) administered as 2 x 100 mg capsules per dose in treatment period 2 on Study Days 2 to 7
1489410|NCT03048110|Drug|Rifampicin|600 mg QD administered as 1 x 600 mg tablet per dose in treatment period 3 on Study Days 1 to 10
1489411|NCT03048097|Drug|Fluorodeoxyglucose|a radiopharmaceutical used in the medical imaging modality positron emission tomography (PET)
1489412|NCT03048097|Drug|Rubidium|used in PET scans
1489413|NCT03048097|Diagnostic Test|FDG-PET/CT with Rb82 Myocardial Perfusion Imaging|A 18-20 gauge catheter equipped with a 3-way stopcock will be inserted preferably in the antecubital vein. Cardiac FDG-PET imaging will be performed on the YNHH GE Discovery ST PET/CT scanner following a high fat/low carbohydrate diet and a prolonged fast as is current clinical protocol. Resting ECG-gated dynamic Rb-82 PET imaging will be performed using 20-30 mCi of Rb82 as per YNHH clinical imaging protocol and established clinical guidelines. FDG-PET imaging will be performed following a high fat/low carbohydrate diet (instructions provided to patient) and a fast of greater than 12 hours. The patient will be injected with the same dose of FDG (8-10mCi) as they received for their index clinical examination. Cardiac FDG imaging will be performed using a single 3D acquisition over the heart. Low-dose CT images (120 kV, 50-150 mA based on BMI) for the purposes of attenuation correction will be performed before Rb82 and FDG imaging sequences.
1489414|NCT03048084|Drug|Levetiracetam|Antiepileptic drug levetiracetam
1489415|NCT03048084|Drug|Valproic Acid|Antiepileptic drug valproic acid
1489416|NCT03048071|Other|Data collection within medical files|Data collection within medical files
1489419|NCT03048045|Procedure|Supportive Periodontal Treatment (SPT)|Assessment of Gingival Bleeding Index and Plaque Control Record, re-instruction and re-motivation to effective individual plaque control, professional tooth cleaning, application of a fluoride gel. Twice a year a periodontal charting with probing pocket depths (PPD) and vertical attachment Level (PAL-V) are obtained at 6 sites per tooth. Thirty seconds after probing bleeding on probing (BOP) is recorded. Sites exhibiting PPD = 4 mm and BOP as well as sites with PPD >/= 5 mm are scaled subgingivally. Assignment of SPT intervals is performed according to the periodontal risk assessment (PRA).
1489420|NCT03048032|Procedure|Blood sampling|Besides routine clinical, laboratory and instrumental evaluation, blood samples will be taken within 4 hours of presentation to the hospital. Plasma samples, stored and frozen at -80°C, will be analyzed at the INSERM UMR942 institute in Paris. Up to 15 novel will be measured during the study: copeptine, proenkephalin, high sensitivity troponin T, troponin I, brain natriuretic peptide (BNP), N-terminal pro-BNP, adrenomedullin, soluble ST2, galectine 3, C-reactive protein, interleukine 6, procalcitonin, cystatin C, neutrophil gelatinase associated lipocalin.
1489421|NCT03048032|Procedure|Echocardiography exam|A standard echocardiography as well as examination focused on right ventricle (RV) will be performed in a period of 48 hours of admission. Novel qualitative and quantitative parameters of right ventricle function and structure will be measured. These include RV diameter at base and midlevel, a measure of RV fractional area change (FAC), tissue doppler imaging derived tricuspid lateral annular systolic velocity wave (S'), tricuspid annular plane systolic excursion (TAPSE), velocity and gradient of tricuspid regurgitation, estimated systolic RV and RA pressure, RV wall strain and strain rate.
1489422|NCT03048019|Drug|Tirofiban|Patients will receive Tirofiban during the PCI procedure
1489423|NCT03048019|Drug|Cangrelor|Patients will receive Cangrelor during the PCI procedure
1489424|NCT03048006|Procedure|MRI with Dotarem|
1489427|NCT03047980|Drug|Sirolimus|Low dose oral sirolimus
1489428|NCT03047967|Diagnostic Test|lung function tests|baby-body plethysmography
1489429|NCT03047967|Diagnostic Test|Nasal brushing|Epithelial sample collecting for in vitro study
1489430|NCT03047954|Drug|Broncho-Vaxom|BV is an orally administered immunostimulating preparation, which consists of a lyophilised bacterial extract prepared from 8 bacterial species (Haemophilus influenzae, Streptococcus pneumoniae, Klebsiella pneumoniae and ozaenae, Staphylococcus aureus, Streptococcus pyogenes and viridans, Neisseria catarrhalis)
1489431|NCT03047954|Drug|Placebo - Cap|Matching Placebo capsule administered
1489432|NCT03047941|Diagnostic Test|Determination of optimal cutoff values.|The results of the four scores will be compared with the results of the polysomnography (PSG). A statistical analysis will be performed to determine the optimal cutoff value of each of the four scores to detect severe OSA patient with hypoxemia.
1494644|NCT03009058|Biological|Ipilimumab|Standard of Care immunotherapy
1489434|NCT03047928|Biological|PD-L1/IDO peptide vaccine|The vaccine is administered biweekly for a total of 6 times, then every fourth week up to 47 weeks, whereupon no additional vaccinations will be given. A total of 15 vaccines will be administered. A vaccine consists of 100 μg PD-L1 long1 peptide, 100 μg IDO long peptide and 500 μl Montande as adjuvant.
1489435|NCT03047915|Other|Music|The intervention consists of listening to a choice of music for 30 to 60 minutes on a loaned iPad with disposable headphones.
1489436|NCT03047902|Other|Group 1 - Parents will be present for the Questionnaire.|"In Group 1 the parents will be present for the questionnaire. The information on the questionnaire will be disclosed to them.
In Group 2 the parents will not be present for the questionnaire and the information will not be disclosed to them."
1489437|NCT03047902|Other|Group 2- Parents will not be present for the Questionnaire|
1489438|NCT03047889|Drug|standard therapy|standard therapy for advanced/metastatic breast cancer
1489440|NCT03047863|Drug|Repair Control EGF®|"A Split face study was done. Patients applied 1 finger tip unit of EGF cream on one side of face, twice a day for 4 weeks.
EGF cream(Repair Control EGF®) containing 10 ppm of rhEGF was prepared at D.N. Co., Ltd. (Seoul, South Korea)"
1489441|NCT03047863|Drug|Cream without rhEGF|"A Split face study was done. Patients applied 1 finger tip unit of cream on the other side of face, twice a day for 4 weeks.
Placebo cream was prepared at at D.N. Co., Ltd. (Seoul, South Korea), consisted of same ingredient with EGF cream except rhEGF"
1489442|NCT03047850|Diagnostic Test|Comparison of Delta Down and Delta Pulse Pressure|Comparison of Delta Down and Delta Pulse Pressure Before and After Sternotomy.
1489443|NCT03047837|Drug|Aspirin (ASA) + Metformin (MET)|Arm D (experimental arm) Treatment: active ASA + active MET Dose: 100 mg, 1 tablet daily + 850 mg,1 tablet twice a day (BID) Duration: 12 months
1489444|NCT03047837|Drug|ASA|Arm C (experimental arm) Treatment: active ASA + placebo MET Dose: 100 mg, 1 tablet daily + 1 tablet twice a day (BID) Duration: 12 months
1489445|NCT03047837|Drug|MET|Arm B (experimental arm) Treatment: placebo ASA + active MET Dose: 1 tablet daily+ 850 mg, 1 tablet twice a day (BID) Duration: 12 months
1489446|NCT03047837|Drug|Placebos|Arm A (control arm) Treatment: placebo ASA + placebo MET Doses: 1 tablet daily +1 tablet twice a day (BID) Duration: 12 months
1489447|NCT03047824|Device|Intravascular continuous monitoring|Bedside usual insulin therapy guided by continuous glucose monitoring
1489448|NCT03047824|Other|Standard of care|Bedside usual insulin therapy guided by intemittent glucose monitoring
1489449|NCT03047811|Other|TCR - T cell therapy|Low dose group: 1 x 10 ^8 /kg T cell total reinfusion. High dose groups: 10 x 10 ^ 8 / kgT cell total reinfusion.
1489450|NCT03047798|Drug|Mouthrinse|"A randomized clinical intervention study was planned with a cross-over design. The 34 subjects were randomly allocated to one of the three experimental groups: 1) the control; 2) ASM group for aqueous single-phase mouthrinse; 3) OTM group for oil-water two-phase mouthrinse.
Subjects were instructed to use the prescribed mouthrinse to gargle their mouth for one minute, twice daily for two weeks. The completion of each experiment regimen was followed by a 2-week washout period, after which the subjects of each group were permutated to the next mouthrinse trial until all three groups underwent the three mouthrinse trial regimen."
1489451|NCT03047772|Drug|Atorvastatin|Routine dose of Atorvastatin therapy
1489452|NCT03047772|Drug|Intensive Atorvastatin|Intensive dose of Atorvastatin therapy
1489453|NCT03047772|Drug|Low dose BMMSC|Low dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
1489454|NCT03047772|Drug|Middle dose BMMSC|Middle dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
1489455|NCT03047772|Drug|High dose BMMSC|High dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
1489456|NCT03047772|Drug|Transplantation|Optimal dose autologous Bone Marrow Mesenchymal Stem Cells transplantation
1489457|NCT03047759|Device|water flosser|Powered
1489458|NCT03047759|Device|air floss|Powered
1489459|NCT03047746|Device|CliniMACs|Peripheral blood stem cells from closely matched unrelated or partially matched related donors will be processed using the CliniMACS device to remove TCRalpha/beta T cells and B cells, in accordance with the Investigator Brochure and Technical Manual following the laboratory standard operating procedures (SOPs) and using aseptic technique
1489460|NCT03047733|Device|The XTRAC Excimer Laser System|Initial irradiation dose was 50 mJ/cm2 on face and 100 mJ/cm2 on trunk and extremities. If there had not been minimal asymptomatic erythema, energy level was escalated by 50 mJ/cm2.
1489461|NCT03047733|Drug|Topical tacrolimus 0.1% ointment|Application of topical tacrolimus 0.1% ointment on the both lesions once daily.
1489462|NCT03047720|Other|Behavioral Modification|Will follow behavior modification guidelines presented in Wetting Accidents Voiding Education Booklet and Bedwetting Brief handout
1489463|NCT03047720|Other|Lully|6 weeks of scheduled awakening protocol using Lully Sleep Guardian: each night, a partial scheduled awakening will be performed with a vibrating mattress pad placed below the mattress. This will be used to reliably produce a partial awakening by titrating the device to a minimal awakening stimulus during the first night of use. If a partial awakening cannot be produced using the mattress pad, the parent will gently awaken the child
1489465|NCT03047694|Other|tablet therapy|stimulation of the lexico semantic system on a tactile tablet therapy for 3 months
1489466|NCT03047694|Other|usual care|speech therapy
1489467|NCT03047681|Diagnostic Test|venous blood withdrawl|patients will be asked for a venous blood sample
1489468|NCT03047668|Dietary Supplement|diet with/without supplementation|diet with/without supplementation with PUFAs
1489469|NCT03047655|Behavioral|Lifestyle intervention (physical activity)|Dietary treatment with or without additional motivation on more physical activity
1489470|NCT03047655|Dietary Supplement|Lifestyle intervention (PUFA/isomaltulose-enriched muffin)|
1489471|NCT03047642|Device|CRP|Prospective case series of febrile children and adults. The results of the fever triage assay tests will not be provided to the treatment teams nor used to inform patient care.
1489472|NCT03047629|Drug|ENT-01|Daily dosing with ENT-01. ENT-01 is an orally administered proprietary substance formulated as a small 25mg coated tablet. Dosing will range from 25-200mg, and the dose will be taken upon awakening on an empty stomach with 8oz water simultaneous to dopamine.
1489473|NCT03047629|Other|Placebo|Daily dosing with a placebo
1489474|NCT03047616|Other|Blood and Urine Collection|
1489475|NCT03047603|Diagnostic Test|PIVKA-II|Serum samples are tested for tumor markers including PIVKA-II,AFP,AFP-L3% and biochemical tests.
1489476|NCT03047590|Behavioral|Choice-based Exercise Intensity|Participants are instructed to choose whichever intensity they want, rather than regulate their intensity based on heart rate.
1489477|NCT03047590|Behavioral|Positive Affect Focus|Participants are instructed to focus on feeling good while exercising.
1489478|NCT03047590|Behavioral|Heart rate-based Exercise Intensity|Participants are instructed to regulate their exercise intensity based on their heart rate.
1489479|NCT03047577|Behavioral|Brief intervention|A 15-20minute discussion about the patients alcohol use and its association with current health conditions, option for a discussion with social worker and written material (information about how alcohol affects health and contact details for seeking more support)
1489480|NCT03047564|Device|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
1489481|NCT03047564|Device|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
1489482|NCT03047551|Device|Ultrasound Device|Ultrasound machines vary by site. At Planned Parenthood and Columbia University Medical Center, providers utilize the LOGIQ P5 ultrasound machine, manufactured by General Electric Healthcare.
1489483|NCT03047538|Drug|Atorvastatin, Amlodipine, Perindopril|To compare free and fixed combination of atorvastatin, perindopril, amlodipine
1489484|NCT03047525|Biological|Cytokine-induced Killer Cells|Concurrent of chemotherapy plus 4 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment and 4 cycles of Cytokine-induced Killer Cells(CIK) treatment
1489485|NCT03047512|Behavioral|Experimental: Internet-based program|"The website have the following modules:
What is 'CUIDA TU ÁNIMO': Description and definition of the program
Psycho-educational information: Information about depression, its treatment, and opportunities for prevention.
How is your mood? (Monitoring): a) Online assessment of symptoms every two weeks during three months with the PHQ-3. b) Feedback
Forums.
Blog.
Appointment (Chat or Phone call).
Contact."
1489486|NCT03047499|Drug|Botulinum toxin type A|Botulinum toxin type-A injection
1489487|NCT03047473|Biological|avelumab|add on of avelumab 10mg/kg IV to standard therapy
1489488|NCT03047460|Other|multimodal evoked potentials|
1489489|NCT03047447|Behavioral|Dietary Ketosis: Regulator of Obesity and Metabolic Syndrome|30 adults previously diagnosed with MetS randomly prescribed to one of three groups: a sustained ketogenic diet with no exercise, the participant's normal diet with no exercise, or participant's normal diet with 3-5 days per week of exercise for 30 minutes
1489490|NCT03047421|Diagnostic Test|Comparison of accuracy of DES-OSA and P-SAP scores|Comparison of accuracy of DES-OSA and P-SAP scores with the result of the PSG (polysomnography)
1489491|NCT03047408|Procedure|Video polysomnography|the main objective of our study is to longitudinally evaluate clinical and vPSG features of RBD, including measure of RSWA, in patients with PD-RBD, after three years from the diagnosis of RBD, in order to ascertain whether RBD features remain stable over time. The possible remission of RBD with the progression of PD would question indeed its reliability as prognostic bio-marker.
1489492|NCT03047395|Biological|risankizumab|Risankizumab 150 mg administered by subcutaneous injection every 12 weeks.
1489493|NCT03047382|Other|AKI Care Bundle|Patients identified as high risk of AKI by the electronic clinical prediction model will be managed with a care bundle of best practice.
1489494|NCT03047356|Behavioral|"If-then plans"|"If-then plans (or implementation intentions) involve linking in memory critical situations (e.g., temptations) with appropriate responses (e.g., substitution)"
1489495|NCT03047356|Other|Control|Exposure to critical situations (e.g., temptations) and appropriate responses (e.g., substitution) but not linked in memory
1489496|NCT03047343|Other|Retrospective data extraction in medical files|Retrospective data extraction in medical files
1489497|NCT03047330|Drug|Leuprolide Acetate|one injection of open-label intramuscular dose of leuprolide (3.75-mg depot), a gonadotropin-releasing hormone agonist that rapidly suppresses estradiol and temporarily achieves ovarian suppression.
1489498|NCT03047330|Other|Fragmented sleep|Fragmented sleep will be experimentally induced.
1489499|NCT03047317|Biological|MABp1|Single dose of intravenous MABp1
1489500|NCT03047304|Diagnostic Test|Trans abdominal sonography|Trans abdominal sonography in order to measure fetal PR interval.
1489501|NCT03047291|Drug|Probiotic|30 probiotic tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
1489502|NCT03047291|Device|Placebo Oral Tablet|30 placebo tablets were given after the mechanical debridement of implants with mucositis and periimplantitis.
1489503|NCT03047278|Procedure|Serial Blood Samples|Serial blood samples are being collected at times 0, 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 24 and 36 hours after gabapentin administration, for all patients.
1489504|NCT03047278|Procedure|Serial Urine Samples|Serial urine samples are being collected at intervals 0-8 hours, 8-16 hours, 16-24 hours and 24-36 hours after gabapentin administration, for all patients.
1489505|NCT03047278|Drug|Gabapentin 300 mg|All patients are being treated with oral single dose of gabapentin 300 mg.
1489506|NCT03047278|Drug|Cetirizine Hydrochloride 10 mg|Patients of control group are being treated with cetirizine hydrochloride, 10 mg, twice as day, orally, for five days.
1489507|NCT03047265|Drug|Paclitaxel|Paclitaxel 135mg / m2 D1, DDP 20mg / m2 D1-4, D1,D29 of RT, a total of 2 courses.
1489508|NCT03047265|Drug|Cisplatin|Cisplatin 100mg / m2 , D1,D22,D43 of RT, a total of 3 courses.
1489537|NCT03046992|Drug|YH25448|"Dose Escalation: YH25448 20mg~160mg, PO
Dose Expansion: YH25448 40mg~160mg, PO
Dose Extension: Recommended Dose of YH25448"
1489538|NCT03046979|Drug|Apatinib|500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
1489574|NCT03046667|Dietary Supplement|Control|The control beverages is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks
1489511|NCT03047239|Device|SENSIMED Triggerfish|Smart contact lens based device indicated to detect the peak patterns of variation in intraocular pressure over a maximum period of 24 hours
1948962|NCT00992264|Behavioral|Message Tone|All participants receive an tailored, online smoking cessation program. Participants in this intervention group either receive content written in a prescriptive tone or a motivational tone.
2001388|NCT03034967|Drug|Danirixin|Danirixin is available as 5, 10, 25, 35 and 50 mg white, film-coated, oval or round shaped tablets for oral administration.
2001389|NCT03034967|Drug|Danirixin matching placebo|Danirixin matching placebo will be available as white, film-coated, oval or round shaped tablets for oral administration.
1489515|NCT03047200|Biological|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
1489516|NCT03047187|Diagnostic Test|ACLR|"quadriceps and hamstring isometric muscles test
single hop for distance
IKDC, KOOS, Tampa and ACL-RSI Questionnaires"
1489517|NCT03047174|Other|Mepitel® Film|Mepitel® Film is a gentle, sterile, transparent, breathable film dressing consisting of polyurethane film coated with a special contact layer. The film dressing is supported with a paper frame for ease of application. Mepitel® Film is an ultra thin, transparent, breathable soft silicone film dressing.
1489518|NCT03047174|Other|Standard Care|"Cream: Fatty cream with 2-5% urea is applied to the irradiated skin 3-4 times daily.
Mometasone furoate cream: In addition to the fatty cream with 2-5% urea, mometasone furoate cream (solution 0.1%) is applied to the irradiated skin once daily."
1489519|NCT03047161|Device|fetal MCG|assess fetal heart rate and rhythm
2001390|NCT03034967|Drug|Standard of care|Participants will continue with their standard of care inhaled medications (i.e. long acting bronchodilators with or without inhaled corticosteroids) during the study treatment.
1489521|NCT03047135|Drug|Olaparib|Olaparib will be dispensed to patients on Day 1 and every 28 days thereafter until the patient completes the study, withdraws from the study or closure of the study.
1489522|NCT03047109|Drug|Phenylephrine|50 patients will receive Phenylephrine 30 µg/minute by syringe pump infusion for 30 minutes.
1489523|NCT03047109|Drug|Ephedrine|50 patients will receive Ephedrine 3 mg/ minute by syringe pump infusion for 30 minutes.
1489524|NCT03047096|Drug|hyaluronic acid|intra-Articular injection
1489525|NCT03047096|Drug|hyaluronic acid and corticosteroids|intra-Articular injection
1489526|NCT03047083|Other|Treatment patterns among AML patients|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
1489527|NCT03047083|Other|AML-related healthcare resources|This is a retrospective cohort study of AML patients with or without FLT3 mutation who were exposed to treatments for AML per treating physician's decision between 1 January 2013 and 31 December 2015.
1489528|NCT03047070|Drug|Lidocaine|IV Lidocaine infusion
1489529|NCT03047070|Drug|Normal saline|IV normal saline infusion
1489530|NCT03047057|Drug|Lidocaine|IV Lidocaine infusion
1489531|NCT03047057|Drug|IV normal saline|IV normal saline infusion
1489532|NCT03047044|Other|Optimizing basal infusion (B.I)|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.4 ml by pressing bolus button (The interval: ~ 6 hr: 60 minutes, 6-18 hr: 90 minutes, 18 hours: 120 minutes). Conversely, if the bolus button is not used for 120 minutes, the administered amount of drug per hour is setted to be reduced by 0.2 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 1 ml).
1489533|NCT03047044|Other|Conventional PCA mode|Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes
1948963|NCT00992264|Behavioral|Navigation|Persons in this arm either have their ability to navigate the site dictated for them based on their readiness to quit smoking or they are able to freely navigate through the website.
1489535|NCT03047005|Drug|NB medication (Naltrexone Bupropion combination)|NB medication
1489536|NCT03047005|Other|Placebo|Placebo
1494645|NCT03009058|Drug|Cyclophosphamide|Standard of Care chemotherapy
1948964|NCT00992264|Behavioral|Proactive Outreach|Persons receive periodic, proactively delivered email reminders to visit the intervention website.
1948965|NCT00992264|Behavioral|Testimonials|People receive a personally-tailored testimonial as part of their online smoking cessation program.
2001391|NCT03034967|Drug|Rescue medication|Participants will continue to use rescue medication(s). The following rescue medications may be used: short acting beta agonists, short acting muscarinic antagonists, or short acting combination bronchodilators.
2001395|NCT03033121|Drug|Growth Hormone|
2001396|NCT03030391|Other|PET|
2001397|NCT03030391|Other|MRI|
2001398|NCT03030859|Other|Usual Care|Undergo usual care only
2001399|NCT03030859|Other|Usual Care plus LEF-SCP|Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, as well as review LEF self-care educational manual and videos
2001400|NCT03030859|Other|Usual Care plus LEF-SCP plus Follow-up|Undergo Motivational Interviewing sessions and LEF Self-Care Training sessions, and review LEF self-care educational manual and videos, as well as meet with the study lymphedema therapist
1489539|NCT03046966|Procedure|Intervention: Receives Training|"• Complete a Hands-on Intubation in the Simulation Lab with PI instructing:
Using state of the art technology, a Storz C-MAC video laryngoscope
Identifying anatomical landmarks
Practice on the manikin until intubation occurs within 15 seconds"
1489540|NCT03046966|Other|Intervention: Control No Training|• Does not receive simulation training with PI. Only standard training.
1489541|NCT03046953|Drug|Avelumab|anti-PDL1 antibody
1489542|NCT03046940|Other|Patient-centered style of communication|Different doctor-patient communication
1489543|NCT03046940|Other|Doctor-centered style of communication|Different doctor-patient communication
2001401|NCT03030352|Behavioral|How-to Parenting Program|The How-to Parenting Program addresses all three key dimensions of optimal parenting; autonomy support, affiliation and structure. With weekly workshops, the How-to-Parenting Program optimizes learning by (1) linking group content with parents' needs, (2) facilitating awareness with perspective taking activities, (3) offering concrete parenting skills, (4) modeling the skills and providing practice in a predictable and non-judgmental environment, (5) emphasizing the importance of implementing these skills at home for long term behavioral change, and (6) offering tools (i.e., exercise booklet, skill summary) that facilitate information retention.
2001402|NCT03029247|Drug|Daprodustat|Daprodustat will be available as 2, 4, 6, 8, and 10 mg oral tablets to be administered once daily
1489546|NCT03046914|Genetic|HLA-B*5801 test|Check whether a participant has HLA-B*5801 allele or not, before administration of allopurinol
1489547|NCT03046901|Drug|Vancomycin|Vancomycin belongs to the family of medicines called antibiotics.When taken by mouth, is used to treat Clostridium difficile-associated diarrhea (also called C diff). C diff is a type of bacteria that causes severe diarrhea. Oral Vancomycin is also used to treat enterocolitis caused by a certain bacteria (e.g., Staphylococcus aureus). Subjects enrolled in the study will take 500 mg capsule, 3 times per day for 3-12 weeks.
2001403|NCT03029247|Drug|Epoetin alfa|Epoetin alfa will be administered according to local labelling and clinical practice guidelines to keep Hgb in the target range (10.0-11.0 g/dL)
1489549|NCT03046875|Other|Transcutaneous Spinal Cord Stimulation|Transcutaneous Spinal Cord Stimulation is a non-invasive mechanism to enhance excitation of spinal neural circuitry and represents a promising supplement to existing physical therapy programs. Transcutaneous Spinal Cord Stimulation will be applied (via the Vectra Neo) using a 5cm x10cm oval electrode placed midline on the skin between spinous process T11 -T12 as a cathode and two 7.5cm x 13cm rectangular electrodes placed symmetrically on the skin over the lower abdomen as anodes.7,9 A symmetrical biphasic rectangular waveform, at 50Hz and 1millisecond, will be used to provide 30 continuous minutes of stimulation.
1489550|NCT03046875|Other|Sham stimulation|Sham procedures, well documented in Transcranial DC Stimulation (tDCS), will be used. Electrodes will be placed as they are in the Transcutaneous Spinal Cord Stimulation condition. Stimulation will be applied at subject's maximum intensity for 30 seconds and then discontinued.
1489551|NCT03046862|Drug|Durvalumab|Durvalumab 1.12 g iv on D1 every 3 weeks
1489552|NCT03046862|Drug|Tremelimumab|Tremelimumab 75mg iv on D1 every 3 weeks
1489553|NCT03046862|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 iv on D1& D8 every 3 weeks
1489554|NCT03046862|Drug|Cisplatin|Cisplatin 25 mg/m2 iv on D1& D8 every 3 weeks
2001404|NCT03028441|Other|Placebo|Placebo
1489556|NCT03046836|Drug|Oxytocin|40 IU oxytocin nasal spray
1489557|NCT03046836|Drug|Placebo|Saline
1489558|NCT03046810|Device|Wellness toileting system|This group will use the wash, dry, cleanse, and apply zinc oxide barrier spray routinely for all toileting.
1489559|NCT03046797|Device|Fibroptic intubation through Boussignac valve opening|After patients being put in HELP position to facilitate both ventilation and intubation, mask ventilation will be continued and FOB intubation will be performed from Boussignac valve opening.
1489560|NCT03046797|Device|Classic Fibroptic intubation|After patients being put in HELP position to facilitate both ventilation and incubation, mask ventilation will be terminated then FOB intubation will be done by an experienced anesthetist.
1489561|NCT03046784|Other|haemodynamic evaluation|continous haemodynamic monitoring is performed with digital Nexfin captor in two positions. in the same time transthoracic cardiac ultrasonography is performed to calculate cardiac output using velocity time index of aortic outflow chamber.
1489562|NCT03046771|Behavioral|Transport PLUS group|The Transport Plus EMTs will offer to perform the FHA and DCA for all transports of patients aged 65 or older, who are being transported from The Mount Sinai Hospital to a private residence.
1489563|NCT03046758|Drug|A combination of fosfomycin, metronidazole and GM-CSF i.p.|All drugs will be administered together intraperitoneally at the end of the surgery after the appendix has been removed.
1489564|NCT03046732|Other|"Implementing Explore Transplant Education"|"The Explore Transplant Ontario (ETO) education program"
1489565|NCT03046719|Drug|Bupivacaine 0,5%|Bupivacaine 0,5% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
1489566|NCT03046719|Drug|NaCl 0,9%|NaCl 0,9% was given on the subconjunctiva, in between stitches by the surgeon after finishing the last stitches
1489567|NCT03046706|Behavioral|post operative voice rest|After surgery, a week of total silence. In the second week after surgery talking is allowed for 20 minutes a day.
1489568|NCT03046706|Behavioral|No voice rest|No limitations regarding post operative speech. Members can talk indefinitely after surgery with no special restrictions
1489569|NCT03046693|Drug|Group A Citicoline 1000 mg oral tablet|Citicoline 1000 mg will be repackaged and given to Group A for 60 days
1489570|NCT03046693|Drug|Group B placebo oral tablet|Placebo will be repackaged and given to Group B for 60 days
1489571|NCT03046680|Other|Health Coaching|
1489572|NCT03046680|Other|Multiprofessional Team|
1489573|NCT03046667|Dietary Supplement|Barley β-glucan|The test beverages with Barley β-glucan is consumed by the participants for the first time at the trial site, followed by a 1 week running-in period were the participants was ingesting half a dose of test drinks. Subsequent were a full dose of the test drinks consumed for 5 weeks. In total was the test drinks consumed for 6 weeks.
2001405|NCT03028441|Biological|VRC-CHKVLP059-00-VP|Measles-vectored Chikungunya vaccine
1489575|NCT03046654|Diagnostic Test|Trans vaginal sonography|Trans vaginal sonography performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and distance from internal and external os`.
1489576|NCT03046654|Diagnostic Test|Vaginal examination|Vaginal examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cervical conditions including cervical dilatation, cervical effacement and pressure on the cerclage.
1489577|NCT03046654|Diagnostic Test|Speculum examination|Speculum examination performed once every 4 weeks from the time of cerclage placement until the time of cerclage removal to evaluate cerclage position and vaginal bleeding.
1489578|NCT03046641|Other|Continuous training|Study group I (42 participants) received the continuous training.
1489579|NCT03046641|Other|The interval training|Study group II (40 participants) received the interval training.
1489580|NCT03046628|Device|TcPO2|
1489581|NCT03046628|Device|Green laser (at 532nm) and a fast camera|
1489582|NCT03046615|Device|EEG Electrode Patch|The additional electrodes are modified EEG electrodes (used in clinical practice on the head already) placed in a silicone molding. These are placed lateral to the eye with the patient asleep. These are then wired to the same recording apparatus that we would commonly use for recording.
1489583|NCT03046615|Device|Standard Needles|Needles are placed in the muscles surrounding the eye to measure eye movements.
1489584|NCT03046589|Drug|DP13|dose escalation
1489585|NCT03046589|Drug|placebo|control to dose-escalation
1489586|NCT03046576|Diagnostic Test|plasma DPP4 activity|DPP4a was determined by enzymatic assays.
1489587|NCT03046563|Other|Acupressure and Abdominal Massage|Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes
1489588|NCT03046563|Other|Pressing the Sham points|Pressing the sham points for eight minutes
1489589|NCT03046550|Drug|NTM-1634|NTM-1634 drug product is a mixture of four human monoclonal IgG1 antibodies (XC41, XC42, XC44, and XC84) which bind to non-overlapping epitopes on BoNT/C/D. Three dose cohorts (A: 0.33 mg/kg B: 0.66 mg/kg, and C: 1 mg/kg).
1489590|NCT03046550|Drug|Placebo|placebo
1489591|NCT03046537|Diagnostic Test|Breath test|Collecting breath test from participants
1489592|NCT03046524|Other|Chart Review|Data between the years of 1/1/2002 and 12/31/2013 analyzed.
1489593|NCT03046511|Drug|Cefazolin|A post- procedure administration of Cefazolin will be compared with a pre-operative intravenous dose
1489594|NCT03046498|Behavioral|Evidence-Based Program|DSMP and DPP
1489595|NCT03046485|Behavioral|Self management program 'Living with Vision Loss'|group met for 6 weeks, 2 hours per week, to discuss strategies for living with low vision
1489596|NCT03046472|Other|Physical Therapy treatment for Postural Behavior|"Physical Therapy treatment for Postural Behavior: intervention program will include physical awareness by using a mirror and practice for good posture, and exercises for flexibility, strength and muscle endurance.
All participants will get 10-15 minutes of exercise for performing every day."
1489597|NCT03046459|Biological|BNZ132-1-40|pegylated peptide inhibiting IL-2, IL-9 and IL-15
1489599|NCT03046420|Other|Chart review|This is a retrospective chart review study. The charts of patients who meet the inclusion criteria will be abstracted into a standardized electronic case report form, as described in Section 5. A standardized case report form for each patient will be created so as to collect uniform data. Charts data for one year back to the start date of data abstraction will be included in the study
1489600|NCT03046407|Biological|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
1489601|NCT03046394|Device|C-SACH|Solid Ankle Cushion Heel by Otto Bock, advertised for activity category 1
1489602|NCT03046394|Device|B-DER|Dynamic Motion by Otto Bock, advertised for activity category 2-3
1489603|NCT03046394|Device|A-DER|Triton by Otto Bock, advertised for activity category 3-4
1489604|NCT03046381|Drug|Tocilizumab|Tocilizumab 162mg 1x weekly s.c.
1489605|NCT03046368|Behavioral|Targeted cover letter|The intervention Group will receive a cover letter with targeted content with the purpose of increasing participation
1489606|NCT03046355|Procedure|Labor induction at 37.0 to 37.6 weeks of gestation|Diagnosis of FGR with induction at 37 weeks 0 days of gestation to 37 weeks and 6 days
1489607|NCT03046355|Procedure|Expectant monitoring until delivery|Diagnosis of FGR managed with expectant monitoring and delivery as indicated
1489608|NCT03046342|Diagnostic Test|Molecular method (PCR)|"Stool samples are being processed through molecular method (PCR) for children with GE.
Epidemiology of acute Gastroenteritis in the pediatric population in Qatar"
1489609|NCT03046329|Behavioral|Carevive CPS|This intervention will focus on the use of the Carevive CPS at the point of care to enable providers to deliver evidence-based and personalized supportive care and symptom management plans to their MM patients receiving active treatment. The Carevive CPS collects electronic patient reported outcomes (ePROs) and clinical data, reported and entered by clinical staff and/or extracted from the electronic medical record (EMR), and uses these to auto-generate the personalized care plans. Care plan content is driven by practice guidelines and other peer-reviewed evidence, and includes patient education, resources, and referrals developed by expert cancer clinicians and researchers.
1489610|NCT03046316|Other|local consolidative treatment|local consolidative treatment to primary or metastases, which includes surgery, radiotherapy or interventional therapy
1489611|NCT03046303|Procedure|ERAS|optimized pain control, restricted I.V. fluids, early initiation of post-operative oral feeding and enforced mobilization
1489612|NCT03046290|Procedure|circumcision|
1489613|NCT03046290|Drug|Lidocaine|
1489614|NCT03046290|Drug|Ropivacaine|
1489615|NCT03046277|Other|No intervention|No intervention
1489616|NCT03046251|Drug|Natalizumab|
1489617|NCT03046238|Drug|Dexmedetomidine|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine plus Dexmedetomidine (1 µg/kg)
1489618|NCT03046238|Drug|placebo|preoperative ultrasound guided modified Pecs block with 30 mL of 0.25% bupivacaine
1489684|NCT03045770|Drug|Irinotecan|Irinotecan was used as first line treatment with AGC.
1489685|NCT03045770|Drug|Paclitaxel|Paclitaxel was used as first line treatment with AGC.
1948966|NCT00988754|Behavioral|School children and adolescents as health experts|Experimental group: Weekly health lesson for children; Monthly training for teacher; 2-3 trainings/year for the parents
1948967|NCT00987116|Drug|Prednisone - Azathioprine|"Rapid strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for improvement or minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 0.75 mg/kg/day.
Classical strategy consists of decreasing the prednisone dose if at each monthly consultation the patient fulfils the criteria for minimal manifestation state, in order to discontinue it before twelve months. The starting dose is 1.5 mg/kg/2days."
1948968|NCT00972478|Drug|Cyclophosphamide|Given IV
1948969|NCT00972478|Drug|Doxorubicin Hydrochloride|Given IV
1948970|NCT00972478|Other|Laboratory Biomarker Analysis|Correlative studies
1489624|NCT03046199|Other|Questionnaire|Targeted screening of COPD by GPs via the GOLD / HAS questionnaire. The questionnaire includes 4 questions for patients over 40. At least one positive response is an indication to perform a spirometry.
1489625|NCT03046199|Other|Coordination|Information of the GPs of the existence of a coordination of the care of proximity to facilitate the access to the spirometry (identification of a referent specialist, making appointments).
1489626|NCT03046186|Diagnostic Test|Mixed meal test with double tracer technique|
1489627|NCT03046173|Other|concentrated growth factors|These patients were randomly assigned to receive concentrated growth factors, hydroxyapatite and autogenous bone at bone defect sites in the experimental group.
1489628|NCT03046173|Other|hydroxyapatite and autogenous bone|These patients were randomly assigned to receive hydroxyapatite and autogenous bone at bone defect sites in the control group.
1489629|NCT03046160|Other|Manual therapy (Mobilization with movement)|grade III mobilizations with movement, performed in sitting for 6-10 repetitions for 3 sets
1489630|NCT03046160|Other|neck and scapular exercises.|A program of 12 neck and scapular exercises.
1489631|NCT03046160|Other|corrective tape|elastic tape used to correct the anterior tilt of the scapula
1489632|NCT03046147|Procedure|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery for morbid obesity
1489633|NCT03046134|Biological|PCV13|Conjugated pneumococcal vaccine
1489634|NCT03046121|Behavioral|Family-centered Function-focused Care (Fam-FFC)|"An educational empowerment model for family CGs that includes a care pathway, provided within a social-ecological in-patient framework promoting specialized care to patients with ADRD. The intervention creates an enabling milieu for the person with ADRD through environmental and policy assessment/modification, staff education, unit-based champions, and individualized goal setting that focuses on functional recovery during hospitalization and the immediate post-acute period."
2001406|NCT03024606|Behavioral|text messages focused on smoking cessation and pregnancy|The impact of a text-message service on smoking cessation in medically underserved, obstetric patients when added to the usual care of pharmacist-driven CBT smoking cessation program and smoking cessation pharmacotherapy with either the nicotine replacement patch or bupropion.
2001407|NCT03023631|Biological|GARDASIL 9|GARDASIL 9 administered as 3 separate 0.5-mL doses under the skin in the arm or thigh at about 6 months (+/- 8 weeks) after the stem cell transplant, then again about 2 months after the first injection, and then again about 4 months after the second injection.
2001408|NCT03023878|Drug|Blinatumomab|Blinatumomab monotherapy
2001409|NCT03023878|Drug|Investigator's Choice Chemotherapy|Investigator's Choice Chemotherapy
1489641|NCT03046095|Other|Unilateral Resistance Exercise|Unilateral Resistance exercise will include training three days per week and each session will include 3 sets of leg extension and 3 sets of leg press. In each set, the participant will complete a maximum of 12 repetitions.
1489642|NCT03046095|Procedure|Immobilization|During the last two weeks of the study (week 8-10), a Don Joy adjustable knee brace will be applied to the participant's leg randomized to immobilization. The brace will be applied at a 40 degree angle relative to complete extension.
1489643|NCT03046082|Drug|Antibiotics|Observation of antibiotic types given to patients with pneumonia.
1489649|NCT03046056|Drug|Filgotinib|Tablet(s) administered orally once daily
1489650|NCT03046056|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
1489686|NCT03045770|Drug|calcium levofolinate|Calcium levofolinate was used as first line treatment with AGC.
1494646|NCT03009045|Drug|Tedizolid|200mg oral tedizolid one pill per day
1948971|NCT00972478|Drug|Prednisone|Given IV
1948972|NCT00972478|Biological|Rituximab|Given IV
1948973|NCT00972478|Drug|Vincristine Sulfate|Given IV
1948974|NCT00972478|Drug|Vorinostat|Given PO
1948975|NCT00962910|Other|PFF evidence based pathway|A care pathway, as complex intervention, will be implemented.
1948976|NCT00962468|Other|COPD evidence based care pathway|A care pathways, as complex intervention, will be implemented.
1948977|NCT00952380|Drug|dalteparin|dalteparin subcutaneous injection
1489653|NCT03046030|Other|Real acupuncture|Verum acupuncture will be applied on the right SP6 and SP9. For each subject, leg position, acupoint location, and needling parameters (1-2 cm depth, 120 rotations / minute, 90˚ insertion angle, moderate deqi sensations on a 0-10 scale) will be kept constant. For the low dose acupuncture group, needles will be rotated at one point and then the other in 15-second rotations with 20-30 second breaks. The specific starting acupoint will be randomized across subjects but kept consistent for each subject across sessions.
1489654|NCT03046030|Other|Sham acupuncture|Placebo acupuncture will be applied at two sham points using specially designed sham acupuncture needles [20, 35, 104-106]. The sham needles differ from regular needles by possessing blunt and retractable tips. Instead of penetrating the skin, the point of the Streitberger needle retracts up the handle shaft when the acupuncturist presses it against the skin. This sham device has been validated by studies showing that subjects cannot distinguish between genuine and sham needling [20, 35, 104]. Two sham points will be used during placebo acupuncture: sham point 1 is located 1 cun posterior to the superior 1/3 of K9 and K10. Sham 2 is located 1 cun posterior to K8. Both points are located on the leg where there is no meridian passing through. Sham acupuncture treatment will be the same as verum acupuncture.
1489655|NCT03046030|Other|VGAIT|In Session 1, all patients will first be introduced to acupuncture treatment, particularly the sensation evoked by acupuncture needles. This will be followed by a five-minute acupuncture exposure applied by a licensed acupuncturist. The exposure will include multiple acupuncture needle manipulations across the two acupoints (SP 6 and SP 9) used in this study. The paradigm applied will be identical to real acupuncture treatment, and the procedure will also be video recorded for the following session. At the beginning of the VGAIT session, patients will be trained for imagery acupuncture outside the fMRI scan. Subjects will first read a script introducing the imagery acupuncture treatment. Then, VGAIT will be applied during scanning. Identical to the acupuncture treatment, there are two fMRI scans during VGAIT, each lasting about 10 minutes. We will ask the patient to measure the sensations they feel during treatment using the MGH Acupuncture Sensation Scale (MASS) after treatment.
1489656|NCT03046030|Other|VGAIT control|The control condition will be the same as VGAIT, except we will use cotton swabs repeatedly touching at non-acupoints with a frequency of about 1 Hz using the same paradigm of verum / sham acupuncture. They will also read a script describing what they are about to see. Then, VGAIT control will be applied during scanning. We will ask the patient to measure the sensations they feel during treatment using the MASS after treatment.
1489657|NCT03046017|Device|tDCS|Electrical stimulation will be applied on the head to temporarily influence brain activity in specific regions.
1489658|NCT03046017|Other|Lidocaine cream|Lidocaine cream will be applied to reduce pain sensitivity (analgesia).
1489659|NCT03046017|Other|Control cream|A neutral cream will be applied as a control.
1489660|NCT03046004|Other|Decision aid for breast cancer screening|Women in the intervention arm will receive a leaflet with detailed information on the benefits (breast cancer mortality reduction, less intensive treatments) and harms (false positive results and overdiagnosis).
1489661|NCT03046004|Other|Standard leaflet|Women in the control arm will receive a standard leaflet that does not mention harms and recommends accepting the invitation to participate in the biennial exams of the EDBCP.
1489662|NCT03045991|Behavioral|Sequential combination of aerobic exercise and cognitive training|
1489663|NCT03045991|Behavioral|non-aerobic exercise training and unstructured mental activities|
1489664|NCT03045965|Procedure|Salpingectomy|The intervention is a routine salpingectomy, performed laparoscopically, through laparotomy or vaginally.
1489665|NCT03045952|Procedure|microwave ablation device|Microwave ablation is a technique that uses thermal therapy to induce complete necrosis of tumor in situ by using microwave ablation device.
1489666|NCT03045939|Device|cervical ripening device|insertion of the double balloon device for 12 hours (standard care) vs 6 hours, following oxytocin IV infusion according local protocol guidelines as mentioned above
1489667|NCT03045926|Drug|Diosmectite (Smecta®)|
1489668|NCT03045913|Device|Genoss DES|The Genoss DES (Genoss, Korea) L-605 cobalt chromium (CoCr) platform with a strut thickness of 70 µm Sirolimus drug with concentration of 1.15µg/mm2 Abluminal biodegradable PLA and PLGA polymers.
1489669|NCT03045900|Other|Shaded bulk-fill resin composite|Dental bulk-fill resin composite with shades A1, A2, A3
1489670|NCT03045887|Drug|GSK2292767 50 μg|GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
1489671|NCT03045887|Drug|GSK2292767 500 μg|GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
1489672|NCT03045887|Drug|Placebo|Lactose as powder for inhalation
1489673|NCT03045861|Drug|GSK2838232|GSK2838232 capsules will be supplied as swedish orange, unmarked capsule (50 mg), and white, unmarked capsules (10 mg) in high-density polyethylene bottles.
1489674|NCT03045861|Drug|Cobicistat|Cobicistat tablets 150 mg will be supplied as an orange, round, biconvex, film-coated tablet in bulk containers for individualized dosing.
1489675|NCT03045848|Device|Biofreedom drug-coated stent|BioFreedom (Biosensors International Technologies, Singapore) is the only polymer- and carrier-free drug coated stent with Biolimus A9 in a selectively micro-structured abluminal surface. It is a stainless steel bare metal surface with 120 micron thick corrugated ring strut.
1489676|NCT03045835|Device|BASKA mask|Baska mask will be inserted during induction of anaesthesia and once patient is in an adequate anaesthetic depth
1489677|NCT03045835|Device|Endotracheal intubation|Endotracheal intubation will be carried out during induction of anaesthesia and once patient is in an adequate anaesthetic depth
1489678|NCT03045822|Drug|Bioimpedance analysis|
1489679|NCT03045809|Diagnostic Test|Urogenital infection point-of-care tests|Instead of syndromic management of symptomatic women, the study offers screening of high risk women regardless of symptoms using point-of-care tests for HIV, TV, and BV (all women), syphilis, NG, and CT (when risk score positive), and UTI (when symptomatic).
1489680|NCT03045796|Device|Oxygen Saturation measured by WristOx|Patients will be hooked up to finger cuffs as well as ECGs to monitor oxygen saturations in different part of the body.
1489681|NCT03045783|Drug|Cefotiam|Prophylactic use of antibiotics group：Prophylactic use of antibiotics during endoscopic treatment, cefotiam 2.0g intravenous
1489682|NCT03045770|Drug|Fluorouracil|Fluorouracil was used as first line treatment with AGC.
1489683|NCT03045770|Drug|Oxaliplatin|Oxaliplatin was used as first line treatment with AGC.
1489687|NCT03045744|Device|long-term paired associative stimulation|Paired associative stimulation (PAS) administered 3 times per week. PAS comprises transcranial magnetic stimulation (eXimia magnetic stimulator, Nexstim Ltd, Helsinki, Finland) and peripheral nerve stimulation (given with Dantec Keypoint® electroneuromyography device (Natus Medical Incorporated, Pleasanton, CA, USA)).
1489688|NCT03045718|Behavioral|Horticultural Therapy|The Horticultural Therapy intervention will be delivered by trained facilitators at the Therapeutic Garden at Hort Park, and consists of 1 hour sessions weekly for 9 months. The Horticultural Therapy program is designed to stimulate the senses through interaction with the tasks and the environment, promote social interaction and also to promote a sense of self-worth through completion of projects. It encompasses a range of activities including general gardening and also project-based craft activities.
2001410|NCT03021915|Other|OvaPrime Treatment|The treatment is based on identified EggPC cells in the outer-most layer of the ovary. During OvaPrime, the EggPC cells are isolated from biopsy tissue obtained from the outer layer of the ovary. OvaScience separates the EggPC cells and these isolated cells are then returned to the IVF clinic - there is no culture or expansion of the EggPC cells during this process. Upon receipt of the autologous EggPC cells, the clinic initiates the process of reintroducing the cells into the follicular development zone of the woman's own ovary using a laparoscopic procedure. Once in the ovary, the EggPC cells have the opportunity to develop and mature into fertilizable eggs naturally or with controlled ovarian hyperstimulation (when stimulated by exogenous gonadotropins) using standard IVF protocols.
2001411|NCT03020745|Drug|GSK3389404|GSK3389404 is available as Clear colorless to slightly yellow solution for injection.
1489691|NCT03045692|Diagnostic Test|kidney function assessment by 4 hour creatinine clearance|4 hour creatinine clearance is used to decide colistin maintenance dosage.
1489692|NCT03045692|Diagnostic Test|kidney function assessment by creatinine based eGFR|creatinine based eGFR (which is not revised value with standardized body surface area, that is, 1.73m2) are used to decide colistin maintenance dosage.
1489693|NCT03045679|Other|RYGB|laparoscopic RYGB
1489694|NCT03045679|Other|OAGB/MGB|laparoscopic OAGB/MGB
1489695|NCT03045666|Other|Exercise program|patients who are stable on Macitentan therapy (received in both groups before enrollment) and will exercise at a pulmonary rehabilitation program twice a week for 12 weeks
1489696|NCT03045653|Drug|Tamoxifen Oral Product|Tamoxifen 100 mg/d
1489697|NCT03045640|Other|FSI ECD|The FSI ECD intervention was delivered in a structured curriculum format, covering a range of topics from health, water and sanitation, good hygiene, early stimulation, conflict resolution, to good communication. It was designed to improve vulnerable households home environment and engagement with their children in order to improve child development outcomes. The curriculum was delivered by bachelor-level trained staff with beneficiaries on an individual, one on one basis, using active coaching to promote child well being and behaviors with caregivers.
1489698|NCT03045627|Drug|AraC|ARA-C subcutaneously in a 12-hour infusion on days 1 through 14
1489699|NCT03045627|Drug|Aclarubicin|Aclarubicin(Acla) 5～7mg/m2/d，intravenously on days 1 through 8
1489700|NCT03045627|Drug|Peg-G-CSF|PEG-G-CSF 6mg subcutaneously on days 0.
1489701|NCT03045627|Drug|G-CSF|G-CSF 200 μg·m-2·d-1, subcutaneously on days 0 through 14.
1489702|NCT03045614|Other|No intervention|No intervention
1489703|NCT03045601|Diagnostic Test|CT-FFR|Invasive FFR and CCTA With CT-FFR
1489704|NCT03045601|Diagnostic Test|Stress echocardiography|Stress echocardiography and invasive FFR
1489705|NCT03045588|Other|Combined exercise and diet intervention|Both groups exercise 6 times per week in 4 weeks conducted as 3 evening and 3 morning sessions per week. Both groups receive dietary products to be consumed immediately before and after each evening and morning session, respectively. One group conduct morning sessions in a fasted state, the other conduct the morning sessions in a fed state. Performance pre and post is measured, and muscle biopsies are obtained.
1489706|NCT03045562|Drug|Normal saline|Patients will be assigned to receive 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
1489707|NCT03045562|Drug|Salvianolate injection|Patients will be assigned to receive Salvianolate injection dissolved in 100ml of normal saline in catherter room setting,and following similar medicine once daily for 7 days.
2001412|NCT03020745|Drug|Placebo|Placebo is available as a Clear colorless solution.
2001413|NCT03019406|Drug|GZ402666|Pharmaceutical form:powder for concentrate for solution for infusion Route of administration: intravenous
1489710|NCT03045536|Device|MML (Fa. ESKA/Orthodynamics)|Classification of complications according to MSTS
1489711|NCT03045523|Drug|GLPG2222 150 mg q.d.|GLPG2222 150 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
1489712|NCT03045523|Drug|GLPG2222 300 mg q.d.|GLPG2222 300 mg administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
1489713|NCT03045523|Drug|Placebo|Placebo administered as a ready-to-use oral suspension, once daily (q.d.) for 29 days
1489714|NCT03045510|Drug|decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 5d, every four weeks for one cycle. It will be given six cycles.
1489715|NCT03045497|Drug|Perflutren Lipid Microspheres|Given IV
1489716|NCT03045497|Device|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
1489717|NCT03045497|Device|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced Magnetic Resonance Imaging
1489718|NCT03045484|Drug|Controlled-release oxycodone|CRO is effective for 12 h. Patient takes it only twice a day. The minimum oral unit of CRO is a 10 mg tablet, so the minimum daily dose was 10 mg.
2001414|NCT03019406|Drug|alglucosidase alfa GZ419829|Pharmaceutical form:powder for concentrate for solution for infusion Route of administration: intravenous
2001415|NCT03017326|Drug|Cisplatin|Arms A and B - cisplatin is used alone Arms C, D, E and F - cisplatin us used in combination
2001416|NCT03017326|Drug|Doxorubicin|Arms C, D and E used in combination
2001417|NCT03017326|Drug|Carboplatin|Arms C and D used in combination
2001418|NCT03017326|Drug|5Fluorouracil|Arm C used alone
2001419|NCT03017326|Drug|Vincristine|Arms C and D used in combination
2001420|NCT03017326|Drug|Etoposide|Arm D used in combination
2001421|NCT03017326|Drug|Irinotecan|Arm D used in combination
2001422|NCT03017326|Drug|Gemcitabine|Arm F used in combination
1489719|NCT03045484|Other|Chemoradiotherapy|Radiotherapy were administered intensity modulated radiation therapy wiht a dose of 1.8-2.2Gy per fraction, 30-32 fraction for various tumor locations. Chemotherapy drugs platinum was used once a weak with 100mg/㎡.
1489720|NCT03045471|Drug|R-EPOCH|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Etoposide: a topoisomerase inhibitor from the group of epipodofyllotoxins; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
1489721|NCT03045471|Drug|R-CHOP|Rituximab: an anti-CD20 monoclonal antibody, which has the ability to kill B cells, be they normal or malignant; Prednisolone: a glucocorticoid hormone that can cause apoptosis and lysis of both normal and malignant lymphocytes; Oncovin, also known as vincristine: a vinca alkaloid that binds to the protein tubulin, thereby preventing the formation of microtubules and mitosis; Cyclophosphamide: an alkylating antineoplastic agent; Hydroxydaunorubicin, also known as doxorubicin: an anthracycline antibiotic that is able to intercalate DNA, damaging it and preventing the cell division.
1489722|NCT03045458|Device|tissue level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 tissue-level implants 12 mm in length and 4.8 mm in diameter were inserted in Group I. Cover screw was removed and replaced with healing abutments.
1489723|NCT03045458|Device|Bone level dental implant|After local anesthesia, full thickness flaps were reflected, and osteotomies were prepared in the first mandibular molar sites. In these surgical operations, 20 bone-level dental implants 12 mm in length and 4.8 mm in diameter were inserted inGroup II. Three months later, second-stage surgery was performed and implant exposed into the oral cavity. Cover screw was removed and replaced with healing abutments. Three months waited for second surgery in bone level implants.
1489724|NCT03045445|Diagnostic Test|Double Low-Dose protocol CT|Double low-dose protocol CT (Low radiation dose quadriphasic liver CT and low dose of iodine contrast media) at spectral dual energy CT scanner
1489725|NCT03045445|Diagnostic Test|Standard protocol CT|standard protocol CT (standard dose quadriphasic liver CT and standard dose of iodine contrast media) at spectral dual energy CT scanner
1489726|NCT03045432|Other|video-teaching|By watching a video specially designed by a rehabilitation team, the participants may learn how to position their affected arm properly (30 minutes per time, twice a day for five days in a week), how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly (15 minutes per time, twice a day for five days in a week), and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy.
1489727|NCT03045432|Other|oral-teaching|The nurses will teach patients how to position their affected arm properly, how to transfer safely with the help from the caregivers, how to execute appropriate passive range of motion exercises regularly, and be taught to be aware of not doing insecure pulley exercises nor carrying stuffs which are too heavy on the admission date of hospitalization.
1489728|NCT03045432|Other|regular rehabilitation program|Regular occupational therapy program and regular physical therapy program in the rehabilitation department of the hospital.
1489729|NCT03045419|Procedure|gadoxetic acid-enhanced liver MRI|liver MRI using a standard dose (0.025mmol/kg) of gadoxetic acid
2001423|NCT03017326|Drug|Oxaliplatin|Arm F used in combination
2001424|NCT03017326|Drug|Sorafenib|Arm used in combination
1489732|NCT03045393|Drug|Mirvetuximab Soravtansine (IMGN853)|Mirvetuximab Soravtansine is a targeted drug for tumors that express high levels of folate receptor alpha.
1489733|NCT03045380|Other|Game based physical activity training|Based on the physical levels of the patients, appropriate games will be selected and video game based physical activity training will be started. Video games will be played with Xbox One with motion sensor (Microsoft) and a 50'' Liquid Crystal Display. Depending on the prognosis of the patients, the grades of the games and types of the games will be changed. A game based physical activity training session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
1489734|NCT03045380|Other|Conventional physiotherapy|A conventional physiotherapy program including balance, upper extremity, and core stabilization exercises will be implemented. A conventional physiotherapy session takes 30 to 45 minutes. The program will be administered once a week for 8 weeks.
1489735|NCT03045367|Procedure|Phacoemulsification, intraocular lens implant, vitrectomy.|Cataract extraction, intraocular lens implant, vitrectomy, epiretinal membrane and inner limiting retinal membrane peeling.
1489736|NCT03045354|Other|Mashed potatoes|Isocaloric (450 kcal) breakfast treatments of eggs with a side of mashed potatoes
1489737|NCT03045354|Other|Traditional breakfast|Isocaloric (450 kcal) control breakfast treatments of cereal, milk, toast and jam
1489738|NCT03045354|Other|Breakfast skipping|No breakfast
1489739|NCT03045354|Other|French fries|Isocaloric (450 kcal) breakfast treatments of eggs with a side of French fries
1489740|NCT03045354|Other|Beans|Isocaloric (450 kcal) breakfast treatments of eggs with a side of beans
1489741|NCT03045341|Drug|NB medication (Naltrexone Bupropion combination)|NB medication
1489742|NCT03045341|Behavioral|Behavioral Weight Loss (BWL) counseling|BWL counseling
1489743|NCT03045341|Other|Placebo|Placebo
1489744|NCT03045328|Drug|Ibrutinib|Given PO
1489745|NCT03045328|Other|Laboratory Biomarker Analysis|Correlative studies
1489746|NCT03045328|Other|Pharmacological Study|Correlative studies
1489747|NCT03045328|Drug|Venetoclax|Given PO
1489748|NCT03045315|Other|IVF Procedure|
1489749|NCT03045302|Drug|BIM23B065|Subcutaneous twice a day or three times a day administration of BIM23B065. Dose will be 0.4, 0.6, 0.8 or 1 mg (twice a day or three times a day).
2001425|NCT03015649|Device|SAVI SCOUT Surgical Guidance System|SAVI SCOUT Surgical Guidance System is a non-wire system, which uses nonradioactive light-activated radar, to provide breast surgeons with real-time guidance to locate and remove the target lesion in the breast and/or axillary tissue.
2001426|NCT03015194|Device|Edwards SAPIEN 3 transcatheter heart valve|Used to relieve aortic stenosis in patients with symptomatic heart disease
2001427|NCT03015194|Device|ASHI INTECC Astato XS 20|"The Astato 0.014 guidewire is used for transcatheter electrosurgery in two steps in this procedure. First it is used for leaflet traversal during electrification. This procedure is similar to the use of the Astato XS20 and an amputated Asahi Confienza Pro 12 in the transcaval IDE investigation recently published. Second, the midshaft is focally denuded and electrified for the leaflet traversal step."
1489752|NCT03045276|Behavioral|Behavioral Feedback and Economic Incentives: Arm 1|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 1, participants will not receive personalized feedback, nor will they receive the extra incentive of $10 for meeting their adherence goal."
1489753|NCT03045276|Behavioral|Behavioral Feedback and Economic Incentives: Arm 2|"The purpose of this study is to determine the effectiveness of behavioral feedback plus economic incentives to promote treatment adherence among a large diverse population of adolescents and young adults (AYA) with kidney transplants (KT) or spina bifida (SB). In Arm 2, participants will receive personalized feedback, and an extra incentive of $10 for meeting their adherence goal."
1489754|NCT03045263|Behavioral|Pivotal Response Treatment|Behavioral intervention for autism
1489755|NCT03045250|Device|Corneal confocal microscopy|Confocal miscroscopy will be used to assess corneal nerve changes due to hyperglycemia.
1489756|NCT03045250|Procedure|Skin biopsy|Skin biopsy will be used to assess the appearance of nerve fibers in subjects with type 1 diabetes.
1489757|NCT03045250|Procedure|Nerve conduction study|Nerve conduction studies will be use to assess for neuropathy.
1489758|NCT03045250|Other|Blood draw|Subjects will undergo a one time blood draw for biomarkers.
1489759|NCT03045237|Other|physical exercises classes|3 physical exercises classes, one of them in the pool.
1489760|NCT03045224|Device|PTA, balloon angioplasty, stent|
1489761|NCT03045211|Device|Dynamic Standing Table|The dynamic standing table is a height-adjustable standing table with an oscillating tabletop system. The tabletop system moves automatically and slowly (velocity of approximately 3 mm/s) from side-to-side in the horizontal plane (in a linear movement pattern) and facilitates stepping by the user to stay centered in front of the working table surface.
1489762|NCT03045198|Drug|Azithromycin|
1489763|NCT03045185|Procedure|RET using Ciprofloxacin 100mg, and Metronidazole 100mg.|"First Treatment Visit: Tooth isolation, access, pulp extirpation and root canal irrigation with 0.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the Bi antibiotic paste (mixture of Bi antibiotic paste (Ciprofloxacin 100mg and Metronidazole 100mg with sterile water). Sealing tooth access with glass ionomer cement.
Second Treatment Visit: Tooth analgesia using plain local analgesics, isolatation and re-access as described above. Irrigation of root canal system using normal saline followed by paper point dying. Initiation of bleeding through insertion of a sterile 23-gauge needle with a length of 2 mm beyond the working length into the periapical tissues. Access sealed using Portland cement, followed by glass ionomer and then composite resin."
1489764|NCT03045172|Biological|Platelet Rich Plasma|
1489765|NCT03045172|Drug|Saline|Placebo
1489766|NCT03045159|Behavioral|Strong Families Strong Forces|Parenting program
1489767|NCT03045159|Behavioral|Strong Parents|self-care program
1489768|NCT03045146|Other|Multimodal brain imaging|Comparison of the Rate of Good Neurological Functional Outcome defined by Modified Rankin Scale 0-2, 3 Months after an acute ischemic stroke treated by thrombectomy according to the presence or not of a Target Mismatch on Baseline imaging (MRI or CTP).
1948984|NCT00923624|Other|attention control|9 informational email messages sent by study staff about the features of the shared electronic medical record system and how to use them.
1948985|NCT00923624|Behavioral|adherence intervention|9 messages tailored by the study nurse and guided by the IMB model
1489771|NCT03045107|Procedure|Laparoscopic right colectomy with intracorporeal ileocolic anastomosis (IIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the proximal transverse colon and the terminal ileum are transected with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The antimesenteric side of the stapled ends of the transverse colon and terminal ileum are approximated by a stay suture tied intracorporeally and then held by the assistant. An antimesenteric enterotomy and an antimesenteric colotomy are made about 10 cm distal to the stapled ends of the transverse colon and terminal ileum, respectively. A side-to-side anastomosis is fashioned with a laparoscopic EndoGIA TM stapler (Covidien Medtronic). The enterotomies are then closed by two layers of reabsorbable sutures tied intracorporeally. The specimen is delivered through a small Pfannenstiel or a median incision. A big dressing covering all incisions will be applied, similar to that used for the EIA group.
1489772|NCT03045107|Procedure|Laparoscopic right colectomy with extracorporeal ileocolic anastomosis (EIA)|After complete right colon mobilization and ileocolic and right colic vessels ligation, the terminal ileum, right colon, and proximal transverse colon are exteriorized for bowel division through a small midline skin incision in the upper abdomen. A primary ileocolic side-to-side handsewn or mechanical (with GIA stapler - Covidien Medtronic) anastomosis is fashioned and the bowel returned to the abdominal cavity. After reinduction of pneumoperitoneum, the lack of twists of the ileocolic anastomosis is checked. A big dressing covering all incisions will be applied.
1489773|NCT03045081|Behavioral|PainTracker Self-Manager|Interactive web-based educational and assessment program supported by a nurse care manager
1489774|NCT03045068|Biological|Platelet Transfusion|"Post CPB- Platelet transfusion 20ml/kg via a central venous line is continued at a rate of 100 ml/hour till completion.
Initial transfusion to occur proximal to the hemofilter on the MUF circuit for as long as MUF lasts
Subsequent platelet transfusion continued till completion via central venous access to the patient"
1489775|NCT03045068|Biological|FFP and Cryoprecipitate|"1 unit of cryoprecipitate administered during MUF and or after MUF as needed
FFP transfusion 10ml/kg during MUF and or after MUF as needed"
1489776|NCT03045068|Biological|PRBC and cell saver Transfusion|1. Transfuse for target Hematocrit > 40 in neonates with SV physiology; Transfuse for Hematocrit> 33 for 2-Ventricle physiology
1489777|NCT03045068|Biological|Factor Concentrate (Bebulin)|1. Based on clinical bleeding and achievement of hemostasis
1489778|NCT03045055|Device|Remote ischemic conditioning.|RIC is a physical strategy performed by an electric autocontrol device with cuffs placed on bilateral arms and inflated to 200 mmHg for 5-min followed by deflation for 5-min, the procedures is performed repeately for 5 times.
1489779|NCT03045055|Procedure|Endovascular treatment.|Endovascular treatment of acute ischemic stroke is performed by experienced neuroradiologist according to the latest guideline from American Heart Association and American Stroke Association.It includes thrombectomy, intra-arterial thrombolysis, thrombus aspiration, stenting and balloon angioplasty.
1489780|NCT03045042|Drug|Enzyme Replacement Agent|Patients will be treated following the decision of their doctors. The investigators are going to analyze serum samples of these patients
1489781|NCT03045029|Drug|Oral treprostinil|Sustained-release oral tablets for TID administration
1489782|NCT03045016|Drug|Prazosin, ALPRESS® LP 2,5 et 5 mg|"Patients will take Prazosin during 28 days ; there are two periods of treatment (escalation of doses):
PERIOD 1 (Day 0 - Day 7): 1 tablet of ALPRESS LP 2.5 mg (Prazosin) at bedtime for 7 days
PERIOD 2 (Day 8 - Day 27): 1 morning tablet of ALPRESS LP 5 mg (Prazosin) at bedtime for 21 days."
1489783|NCT03045003|Behavioral|RESIL Intervention|Interventions tested in this study are the following: i) educational sessions with oncologists and nurses, ii) direct, electronic feed-back of resilience and needs screening in a monitoring sheet including intervention propositions and iii) consultation provided by a clinical nurse specialist to patients (in intervention B only) Interventions have been developed based on previous studies on the efficacy of screening of patient reported outcomes and direct feed-back to health care professionals and on previous studies on interventions to enhance resilience in nursing or psycho-oncology with proven efficacy. Interventions provided in the monitoring sheet have been validated by experienced Swiss oncology nurses, oncologists and psycho-oncologists.
1489784|NCT03044977|Drug|90Y-DOTA-3-Tyr-Octreotide|Peptide receptor radiotherapy (PRRT) using Yttrium-90 as the active radionuclide. For intravenous administration only.
1489785|NCT03044977|Drug|131I-MIBG|Peptide receptor radiotherapy (PRRT) using Iodine-131 as the active radionuclide. For intravenous administration only.
1489786|NCT03044964|Drug|Ranolazine|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
1489787|NCT03044964|Drug|Placebo|Patients will be started on 500mg twice daily and may be increased to 1000mg twice daily after 1 week. Patients will or may remain on the 1000mg for 5 weeks.
1489788|NCT03044951|Procedure|cryoballoon ablation|cryoballoon ablation：pulmonary vein isolation by cryoballoon
1489789|NCT03044951|Procedure|radiofrequency ablation|radiofrequency ablation: pulmonary vein isolation by radiofrequency energy
1489790|NCT03044938|Drug|salbutamol|Salbutamol or albuterol is a short-acting β2 adrenergic receptor agonist used for the relief of bronchospasm in conditions such as asthma and chronic obstructive pulmonary disease.
1489791|NCT03044938|Drug|Placebo|Neutral preparation for pharmacological effects, given in substitution of a medicine, for the purpose of provoking or controlling reactions, ger. Of a psychological nature, accompanying such a therapeutic procedure.
1489792|NCT03044925|Procedure|Remote magnetic navigation|Pulmonary vein isolation and other areas ablation guided by remote magnetic navigation
1489793|NCT03044925|Procedure|Cryoablation|Pulmonary vein isolation and other areas ablation used by cryoballoon
1489794|NCT03044912|Drug|mirabegron|To evaluate the efficacy and safety of Mirabegron 50 mg vs 25 mg in Taiwanese patients with overactive bladder syndrome
1489795|NCT03044899|Procedure|All surgeries in adult patients|All surgeries in adult patients
1489796|NCT03044886|Dietary Supplement|vitamin D|Subjects took vitamin D or placebo
1489797|NCT03044873|Drug|BMS-986165|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
1489798|NCT03044873|Drug|Rosuvastatin|Rosuvastatin on Day 1. BMS 986165 on Days 5-8 and Days 10-12. On Day 9, BMS 986165 coadministered with an oral dose of rosuvastatin.
1489799|NCT03044860|Procedure|Double-balloon enteroscopy (DBE) with biopsy retrieval|With the use of a double-balloon enteroscopy device, study participants underwent upper and lower enteroscopies with mucosal biopsy mucosal biopsy retrieval from every ~30 cm of the small intestine and specific locations in the large intestine
1489800|NCT03044847|Other|COPD group|The treatments will be determined by their treating physicians and no additional investigational drugs will be applied to the patients included in this study.
1489802|NCT03044821|Procedure|Open-Uterus Fetal Repair|Single arm study. All patients will receive the open-uterus fetal repair.
1489803|NCT03044808|Drug|Lidocaine|
1489804|NCT03044808|Drug|Saline|
1489805|NCT03044795|Drug|Veliparib|Subjects in part A and part B will all start treatment with oral veliparib monotherapy twice a day. Patients will receive oral veliparib BID on days 1- 21, q3 weeks. All subjects will start with veliparib 300 mg, if the subject tolerates 300 mg BID for 2 weeks, veliparib may be increased to 400 mg BID at the investigator's discretion. Subjects will self-administer the morning dose and the evening dose of veliparib approximately 12 hours after the morning dose with or without food. ANC must be above 1.5 × 109/L in order to commence a new cycle.
1489807|NCT03044769|Procedure|Malformations resection|Resection of the malformation lung sections with a healthy adjacent part
1489808|NCT03044756|Drug|Omit Citrotide 0.25 dose on the day of triggering of ovulation|Omit Citrotide 0.25 dose on the day of triggering of ovulation
1489809|NCT03044743|Drug|Fludarabine|To modify immune micro-environment
1489810|NCT03044743|Drug|Cyclophosphamide|To modify immune micro-environment
1489811|NCT03044743|Drug|Interleukin-2|To sustain the survival of infused T cells
1489812|NCT03044730|Drug|Capecitabine|Given PO
1489813|NCT03044730|Other|Laboratory Biomarker Analysis|Correlative studies
1489814|NCT03044730|Biological|Pembrolizumab|Given IV
1489815|NCT03044717|Other|Nutrition survey|Survey will be done prior to the initiation of the education
1489816|NCT03044717|Other|Educational Conference|A prevention educational conference will be available to attend once every 5 weeks.
1489817|NCT03044717|Other|3-hour nutrition module|Nutrition module will be provided by the Gaples Institute to participants as part of this study. This will be completed online via e-mail
1489818|NCT03044691|Other|Parent Brief Questionnaire|The PBQ was developed using questions recommended by the American Academy of Pediatrics. Parents are one of the most important sources of a child's tobacco smoke exposure. Therefore screening parents is a recommended best practice.
1489819|NCT03044691|Other|Eligibility Questionnaire|Upon checking in at the clinic the front desk staff will provide parents with an iPad that will ask the parent to enter their child's age to determine if s/he is eligible to participate in the study.
1489820|NCT03044691|Other|Adaptive Reserve and Change Process Capability Questionnaire|The Change Process Capability Questionnaire (CPCQ) will be administered to all participating practices at the beginning and end of the study (baseline and 9 months). The CPCQ is designed to assess three domains: (1) the practices' history of change; (2) capacity for internal improvement and refinement; and (3) capacity to initiate and sustain change.
1489821|NCT03044691|Other|Clinician Survey|Each clinician in the practice who will be participating in the study will be asked to complete a 10 minute survey about their knowledge of and current practices related to tobacco and nicotine product screening and interventions with their patients. These data will be collected at baseline and at 3 months post the intervention (9 months).
1489822|NCT03044691|Other|Youth Tobacco and Nicotine Product Questionnaire|At baseline, approximately 190 patients per practice in the intervention and control groups will be asked to complete a set of tobacco/nicotine product use questions while waiting for their clinician visit (either in the waiting room or another area designated by the practice without the parent being present). The questions were taken from the National Youth Tobacco Survey, a national survey designed to measure middle and high school youth's attitudes toward and behaviors related to tobacco and nicotine products.
1489823|NCT03044691|Other|Youth Tobacco and Nicotine Product Primary Care Survey|At 30 days post primary care visit, children with parental consent and their assent will be contacted via telephone to complete a 10 minute survey about their recollection of the tobacco and nicotine product discussions held with the clinician during the primary care visit. The YTNP-PCQ is adapted from the questionnaire used in the Adolescent Health Risk Assessment in Primary Care Study.
1489824|NCT03044678|Behavioral|REACH for Success|Exposure-based cognitive behavioral with social skill training (cognitive self control, relaxation, skills for conversations and assertiveness)
1489825|NCT03044678|Behavioral|Self-Study|Books for youth about anxiety management
1489826|NCT03044665|Drug|Rosuvastatin|Subjects will start rosuvastatin 20 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level as current US guideline.
1489827|NCT03044665|Drug|Rosuvastatin plus ezetimibe|Subjects will start single combination pill of rosuvastatin 10 mg plus ezetimibe 10 mg a day irrespective of previous lipid-lowering treatment or LDL-cholesterol level.
1489828|NCT03044652|Device|WO2085 Moisturising Cream|2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. After improvement of the symptoms the frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
1489829|NCT03044652|Drug|Estriol Cream 0.1%|0.5 g of the reference product Estriol Cream 0.1% will be applied intravaginally once daily in the evening for the first 3 weeks. Subsequently, the frequency will be reduced to twice a week for the last 3 weeks for all patients in this treatment group.
1489830|NCT03044639|Drug|Lipid Emulsions, Intravenous|The every day provision of lipid emulsion as a part of parenteral nutrition along with dextrose, amino acids, electrolytes, trace elements, vitamins and water in the dose of 0.8-1.0 g/kg/day.
1948986|NCT00921713|Other|Oncology Nurse Care Management|
1948987|NCT00921713|Other|Patient-centered materials|
1489833|NCT03044613|Drug|Nivolumab|240mg or 1 mg/kg administered IV
1489834|NCT03044613|Drug|Ipilimumab|3mg/kg administered IV
1489835|NCT03044613|Drug|Carboplatin|standard care dose
1489836|NCT03044613|Drug|Paclitaxel|standard care dose
1489837|NCT03044613|Radiation|Radiation|standard care dose
1489838|NCT03044600|Other|Chart Review|Patient charts will be reviewed to collect demographic data, pre-operative and post-operative clinical and laboratory data, operative reports, and pathology reports.
1489839|NCT03044600|Other|HRPT2 Mutation Evaluation|Archived formalin-fixed paraffin-embedded (FFPE) tissue blocks from surgical specimens of patients stained for parafibromin to evaluate for HRPT2 mutations.
1489840|NCT03044587|Drug|Arm NaI-IRI + 5-FU + Leucovorin (Arm A)|Nal-IRI (80 mg/m2 as a 1.5 hour infusion), 5-FU (2400 mg/m2 as 46 hour infusion) and Leucovorin (400 mg/m2 as 0.5 hour infusion) Cycle q2w
1489841|NCT03044587|Drug|Arm Cisplatin + Gemcitabine (Arm B)|Cisplatin (25 mg/m2 as 1 hour infusion on D1, D8) and Gemcitabine (1000 mg/m2 as 0.5 hour infusion on D1, D8) Cycle q3w
1489842|NCT03044574|Device|SCD|IPC with Kendall SCD™ Sequential Compression System 700 used continuously when the patient is in bed with 6-hours night interval free of compression: from 0 a.m. to 6 a.m. In the ICU SCD used continuously all day, and in surgery department - all time of bed resting. SCD used until discharge.
1489843|NCT03044574|Device|GCS|Thigh-length graduated compression stockings with pressure of 18-21 mm. Hg at the ankle used all the time until discharge plus one month after discharge
1489844|NCT03044574|Drug|LMWH|LMWH enoxaparin (Clexane) 40 mg once a day subcutaneously started on 1st or 2-5th postoperative day according to the bleeding risk and used until discharge.
1989731|NCT02403310|Drug|Selinexor|"Induction: Oral selinexor on days 1, 3, 8, 10, 15 and 17.
Dose Level 2: 80 mg twice weekly.
Dose Level 1 (starting dose): 60 mg twice weekly.
Dose Level -1: 40 mg twice weekly.
Consolidation: Selinexor same dose as induction (days 1,3,8,10) unless dose limiting toxicity (DLT) dictates a dose reduction.
Maintenance: Selinexor at the same dose as induction on days 1 and 8 a 21 day cycle. They will continue for a maximum of 12 months."
2001428|NCT03012061|Drug|Placebo|Placebo is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, both of which contains lactose monohydrate blended with magnesium stearate.
1489847|NCT03044548|Other|Supportive supervision|" Supportive supervision. The specific characteristics of the supportive supervision as intended in this project are outlined below.
Frequency: Biweekly in the first 3-5 months, than monthly. Duration: approximately 2 hours in each HC at each visit. Provider: local staff (nutritionist, DHO) trained in integrated management acute malnutrition (IMAM) guidelines and in methods of  supportive supervision.
Receivers: nurses working at HC level with children with malnutrition.
Reference guidelines:
• Current National IMAM guidelines
Attitude and philosophy:
• Participatory peer-to-peer model based on the Plan - Do- Study- Act quality improvement (QI) Cycle ."
1489848|NCT03044522|Other|Opioid Education|
1494647|NCT03009032|Dietary Supplement|PMT25341|
1489849|NCT03044509|Diagnostic Test|Secreted cytokine assay|Blood collected in a sodium-heparin tube will be used for the assay using novel TB-specific antigens. After incubation the supernatant will be harvested and cryopreserved at -80 °C for further testing of cytokines. Cytokines will be measured using a bead-based multiplex assay reader (MAGPIX, Luminex Crop., Austin, USA).
1489850|NCT03044509|Diagnostic Test|Intracellular cytokine assay|Blood will be stimulated with recombinant MTB-specific antigens, ESAT-6, CFP-10, positive control or left unstimulated. Following an initial duration of stimulation, Brefeldin-A will be added and the blood incubated for a further 5 hours. White cells will be fixed and cryopreserved at - 80°. Batched analysis within 6 months of cryopreservation will be done using multi-colour flow cytometry.
1489851|NCT03044496|Drug|Supraclavicular nerve block|Supraclavicular nerve block using ultrasound and 10ml ropivacaine 0.5% with 20ml mepivacaine 1%
1489852|NCT03044483|Other|Measurement of sublingual microcirculatory parameters|Measurement of the sublingual microcirculatory function using the CytoCam-IDF imaging device to establish the normal range for each age group noted.
1489853|NCT03044470|Other|cryotherapy|Role of cryotherapy in reduction of post operative pain
1489854|NCT03044457|Procedure|TKA|"femoral and tibial positioning using the reversed gap technique"
1489855|NCT03044444|Dietary Supplement|citrus extract|Participants will receive either a low or high dose citrus extract
1489856|NCT03044444|Other|placebo|participants will receive 500mg of maltodextrin
1989732|NCT02403310|Drug|Daunorubicin|"Induction: Daunorubicin 60 mg/m^2/day (days 1-3).
Consolidation: Daunorubicin 45 mg/m^2/day (days 1-2)."
1989733|NCT02403310|Drug|Cytarabine|"Induction: Cytarabine 100 mg/m^2/day (days 1-7).
Consolidation: Cytarabine 100 mg/m^2/day (continuous infusion on days 1-5)."
1489859|NCT03044405|Diagnostic Test|Fluid challenge|Fluid bolus of 500 ml of crystalloids is given over 15 minutes. Positive fluid responsiveness is defined by an increase in SV of at least 15%.
1489860|NCT03044405|Diagnostic Test|Focused transthoracic echocardiography|Focused transthoracic echocardiography is performed to assess expansion of stroke volume after fluid challenge. Also mitral E and A waves, left ventricle outflow tract velocity time integral (LVOT VTI) and its variability, inferior vena cava diameters during breathing cycles are measured.
1489861|NCT03044392|Drug|Next Bolus Interval|Next Bolus Interval 15, 30 or 45 minutes
1489862|NCT03044379|Drug|Dapivirine gel (0.05%)|MTN-026/IPM 038 will use the HTI pre-filled applicator, the same applicator that has been utilized in other rectal studies.
1489863|NCT03044379|Other|Universal HEC placebo gel|
1489864|NCT03044366|Other|general anesthesia management of preterm infants|general anesthesia management of preterm infants
2001429|NCT03012061|Drug|UMEC|UMEC is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GSK573719 blended with lactose blended with magnesium stearate and another one contains lactose monohydrate blended with magnesium stearate.
2001430|NCT03012061|Drug|Fluticasone Furoate|FF is a white powder to be administered using ELLIPTA DPI which hold two individual blister strips, one of which contains GW685698 blended with lactose monohydrate and another one contains lactose monohydrate with magnesium stearate.
1489867|NCT03044340|Other|impedance measurement and pain evaluation|Measurement of chlorine ions impedance by SUDOSCAN and pain due to temperature evaluation with THERMOTEST
1489868|NCT03044327|Procedure|LPS challenge|LPS inhalation and bronchial instillation
1489869|NCT03044314|Drug|Illoprost and nitric oxide administration|Iloprost will be administered by the I-neb ultrasonic nebulizer (Respironics, Cedar Grove, New Jersey) with a disposable attachment that allows for administration to a supine patient at a concentration of 10 µg/ml with a 10 minute dose of 2.5 µg and then repeated to a cumulative dose of 5.0 µg if tolerated.
1489870|NCT03044301|Combination Product|Intramuscular ZENEO® injection|Sodium Chloride (0.9 %)
1489871|NCT03044301|Combination Product|Subcutaneous high ZENEO® injection|Sodium Chloride (0.9 %)
1489872|NCT03044301|Combination Product|Subcutaneous low ZENEO® injection|Sodium Chloride (0.9 %)
1489873|NCT03044288|Other|New adhesive strip|This is a strip made of a newly developed adhesive. This adhesive might in the future be part of an ostomy product.
1489874|NCT03044288|Other|Standard adhesive strip|this is a standard adhesive strip (hydrocolloid). This adhesive is currently used in marketed ostomy devices.
1489875|NCT03044275|Other|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
1489876|NCT03044275|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid). The adhesive is a part of an ostomy device
1489877|NCT03044262|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid) that is part of an ostomy device
1489878|NCT03044262|Other|New adhesive strip|This is a newly developed adhesive strip that in the future might be part of an ostomy device
1489879|NCT03044249|Drug|MP-101|Capsules
1489880|NCT03044249|Drug|Placebo|Capsules
2001431|NCT03012061|Drug|Albuterol/salbutamol|Albuterol/salbutamol is to be administered via metered-dose inhaler as a rescue drug on need basis throughout the study.
1489882|NCT03044210|Other|Metabolic evaluation|"diet assessment
biological evaluation
clinical evaluation
metabolic evaluation (calorimetry)"
1489883|NCT03044197|Device|MRI/ultrasound transperineal fusion-guided prostate biopsy|3-6 targeted biopsy cores from each prostate region of interest
1489884|NCT03044197|Device|Systematic transrectal ultrasound-guided prostate biopsy|12 systematic biopsy cores
1489885|NCT03044184|Drug|Tranexamic Acid|Transamine is an antifibrinolytic medication given systemically via the intravenous route
1489886|NCT03044171|Device|Low Level Laser Therapy|Laser therapy: it was used the infrared spectrum with wavelength of 808 nm in its active environment AsGaAl, in two points: cervical and central-medial region of the incisors, canines and premolars.
1489887|NCT03044171|Drug|1.1% Sodium Fluoride|Fluoride therapy: 1.1% sodium fluoride 5000 ppm was applied for 5 minutes on the vestibular surface of all pre-bleached dental elements.
1489888|NCT03044171|Drug|In-office dental bleaching|Both groups received the in-office bleaching treatment. Three 15-minute applications of the 35% hydrogen peroxide gel were performed, totaling 45 minutes in each of the 4 sessions, with a 7-day interval.
2001432|NCT03006913|Behavioral|In-person|At all sites, patients randomized to/preferring in-person counseling will meet with a counselor.
1489892|NCT03044145|Behavioral|The Cultural Formulation Interview-Engagement Aid|Culture affects how all people communicate and understand the world. Culture is important because patients and clinicians from different cultural backgrounds may have different preferences for communication. Mismatch in the clinician's approach and the patient's expectations of care can lead to patient dissatisfaction and discontinuation with treatment. Patients and clinicians may also have different views about what caused an illness, how it functions, what makes it better or worse, and the types of treatment needed. The CFI-EA is a series of questions over three sessions that clinicians can use to clarify patient views about treatment and communication so that patients stay in treatment longer. Clinicians can use the CFI-EA to customize their current treatment plans.
1489893|NCT03044145|Behavioral|The Cultural Formulation Interview-Engagement Aid (Revised)|The study team will revise the CFI-EA based on patient and clinician feedback. The study team expects that the revisions will consist of changes to the questions such as adding or subtracting specific items or revising the wording of the content. The study team do not anticipate other changes, though we will let our empirical data analyses guide revisions in consultation with the K23 mentor team.
1489894|NCT03044145|Behavioral|Treatment as usual|Standard mental health treatment at FHMC
1489895|NCT03044132|Other|DermACELL AWM|Decellularized regenerative human tissue matrix allograft (dermis) processed using proprietary Matracell® technology
1489896|NCT03044119|Biological|Dental Implant with PRFM|placement of a minimum of two adjacent dental implants being randomly assigned into (G1) - Dental implant with PRFM
1489897|NCT03044119|Biological|Dental Implant with PRFM and PBMSCs|placement of a minimum of two adjacent dental implants being randomly assigned into (G2) - Dental implant with peripheral blood mesenchymal stem cells embedded in PRFM.
2001433|NCT03006913|Behavioral|By phone|Patients in the phone arm will receive a scheduled call at their home.
2001434|NCT03006913|Behavioral|By video|Because low income patients are not likely to have video conference capability at home, this service will be offered at all three hospitals, and patients will have scheduled appointments to come to the hospital to receive counseling delivered through a computer.
1489900|NCT03044093|Drug|Mifepristone|The group that will get in addition to Misoprostol also Mifepristone
1489901|NCT03044093|Drug|Placebo|The group that will only get Misoprostol
1489902|NCT03044093|Drug|Misoprostol|Both groups will get think drug
2001435|NCT03004612|Drug|Linagliptin + metformin|Linagliptin-Metformin 2.5/850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
2001436|NCT03004612|Other|Metformin|Metformin 850mg twice daily plus a lifestyle modification program based on nutritional assesment, physical activity prescription and general counseling
1489905|NCT03044067|Other|Pain neuroscience education + Exercise|A session of Pain neuroscience education + Exercise covers the activity, strength and endurance of lower and upper muscles of the extremities. Besides that it will be covered the understanding and acknowledgement about how pain is processed.
1489906|NCT03044067|Other|Exercise|A session of exercise covers the activity, strength and endurance of lower and upper muscles of the extremities.
1489907|NCT03044054|Device|ECHOPULSE|HIFU Under ultrasound guidance
1489908|NCT03044041|Drug|Tranexamic Acid|IA (intra-articular) tranexamic acid after capsule closure
1489909|NCT03044028|Device|CyMedica Orthopedics QB1 e-vive™ system|a multifunctional electrotherapy device providing neuromuscular electrical stimulation (NMES), for improving quadriceps strength and improving functional outcomes accelerating functional recovery in patients managed with total knee arthroplasty (TKA).
1489910|NCT03044015|Behavioral|community based integrated strategy for secondary prevention of OF|Educational programme on pharmacological treatment, diet recommendations, physical activity programme on OF prevention in primary care
1489911|NCT03044015|Behavioral|as usual|
1489912|NCT03044002|Device|Biotronik 4 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
1489913|NCT03044002|Device|6 French Portfolio|Ambulatory intervention by femoral access for endovascular treatment of lower-extremity peripheral artery disease
1489914|NCT03043989|Drug|Docetaxel|6 infusions of Docetaxel with 18 doses clarithromycin
1489915|NCT03043989|Drug|Cabazitaxel|6 infusions of Cabazitaxel with 18 doses clarithromycin
1489916|NCT03043989|Drug|Clarithromycin|18 doses of clarithromycin with either Docetaxel or Cabazitaxel
1489917|NCT03043976|Device|Actigraph GT9X Link device|"Assessment of the level of physical activity of PH patients using the Actigraph GT9X Link device that includes a triaxial accelerometer and can be enabled to show on its display the number of steps taken for the day, so that it can also be used by the patients as a common pedometer.
Evaluation of the effects of an 8 week step count-based light touch training programme to see if activity can be increased"
1489918|NCT03043963|Behavioral|Sleep Extension|Lengthen the duration of sleep time.
1489919|NCT03043963|Behavioral|Sleep Timing|Regularize the timing of the sleep period.
1489920|NCT03043950|Drug|Panitumumab + FOLFIRI|Patients will be scheduled to receive first line therapy with the combination of Panitumomab (6 mg / kg i.v, given once every two weeks) and FOLFIRI, according to current SmPC Germany.
1489921|NCT03043937|Other|registry|
1489922|NCT03043924|Drug|Cyproterone Acetate + estradiol|"PCOS will receive:
50mg cyproterone acetate (Androcur®) in combination with p.o. 2mg estradiol daily"
1489923|NCT03043924|Drug|Levonorgestrel, Ethinyl Estradiol 0.1-0.02Mg Oral Tablet|Healthy volunteers receive combined oral contraceptive (COC) consisting 0.02 mg ethinylestradiol and 0.1mg of progestins (Leeloo Gé®)
1490000|NCT03043469|Other|Respiratory muscle function|Breathing through a mouth-piece in many different ways in order to measure the function of the respiratory muscles (non-invasively).
2001437|NCT03003936|Behavioral|Dinner timing|Glucose tolerance after a late diner (1 hour before habitual bedtime) differs from early dinner (4 hours before habitual bedtime) due to the concurrence of meal timing with different levels of endogenous melatonin. This effect can be different among risk allele carriers (G) or non-rick allele carriers (C) of the MTNR1B.
2001438|NCT03001011|Drug|Placebo|"Pharmaceutical form: tablet
Route of administration: oral"
2001439|NCT03001011|Drug|Sevelamer Carbonate (GZ419831)|"Pharmaceutical form: tablet
Route of administration: oral"
1489924|NCT03043898|Other|Lung sound transmission measurement|Sound at chest wall is recorded using a sensor array during the bronchoscopy procedure, while a sound is played down the working channel of the bronchoscope.
1489925|NCT03043898|Other|Lung sound recording|Lung sounds are recorded using a sensor array.
1489926|NCT03043885|Device|FDBA|Graft material used to graft extraction socket
1489927|NCT03043885|Device|PRF|Autologous blood product used to graft extraction socket
1489928|NCT03043885|Procedure|Blood Clot|Surgical treatment of extraction socket without addition of graft material
2001440|NCT02997852|Behavioral|Therapy dog visitation|The TDV will consist of a 10-minute visit from the same Faithful Paws animal handler and her dog. Each therapy dog meets obedience, temperament, and health standards appropriate to therapy dog visitation in hospital settings. The dog will be leashed and under control of the animal handler and the TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Visual and tactile contact with the dog will be promoted by the animal handler. Per hospital protocol, the patient will be assisted in washing his/her hands before and after the TDV and the dog will be placed on the bed or remain at the bedside in close proximity allowing petting. A clean sheet will be placed over the patient when the dog is placed on the bed. The research staff will collect data before and after each arm of the study.
2001441|NCT02995733|Drug|PARTICS using QVAR|Patient takes inhaled corticosteroid at the time of rescue inhaler use
2001442|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
2001443|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
2001444|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
1489934|NCT03043859|Behavioral|Pure Prairie Living Program|Education session (n=5) on healthy eating, menu planning and skill building for effective diabetes management
1489935|NCT03043846|Other|Follow-up every 3 months during 1 year (data collection in eCRF)|
1489936|NCT03043846|Other|Follow-up every month to follow the pre-defined strategy|
2001445|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
1489938|NCT03043820|Drug|Raloxifene|Oral selective estrogen receptor modulator (SERM).
1489939|NCT03043820|Drug|Placebo|Tablets identical in form and color to intervention.
1489940|NCT03043807|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
1489941|NCT03043807|Drug|Docetaxel|75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
1489942|NCT03043807|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
1489943|NCT03043807|Radiation|Radiation|Radiation will be delivered in 1 to 5 fractions, and the dose and fractionation schedule will depend on the size and location of the lesion and the surrounding normal tissue constraints in accordance with AAPM Task Group 101 recommendations. Typical doses include 16 - 24 Gy in 1 fraction, 48 - 50 Gy in 4 fractions, and 50 - 60 Gy in 5 fractions.
1489944|NCT03043794|Radiation|Stereotactic Body Radiation SBRT|Stereotactic Body Radiation to the breast to 21 Gy
1489945|NCT03043781|Other|Continuous epidural infusion|Continuous infusion, 5 ml/h
1489946|NCT03043781|Other|Intermittent epidural bolus|Intermittent bolus 5 ml every hour
1489947|NCT03043742|Drug|Bone Marrow Derived Autologous CD133+ Selected Cell Product|Injection of bone marrow derived autologous CD133+ cell product into laser channels during Trans-Myocardial Revascularization
1489948|NCT03043729|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2, as 2h infusion on Day 1 (Arm A + Arm B)
1489949|NCT03043729|Drug|5-FU|5-FU 400 mg/m^2 i.v. as bolus on Day 1 and 2400 mg/m^2 as 46 h infusion q2w (Arm A + Arm B)
1489950|NCT03043729|Drug|Leucovorin|Leucovorin 350 mg/m^2 i.v. as 2h infusion on Day 1 (Arm A + Arm B)
1489951|NCT03043729|Biological|Aflibercept|Aflibercept 4 mg/kg BW i.v. on Day 1 q2w (Arm B, Cycles 1 to 5)
2001446|NCT02992288|Drug|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
2001447|NCT02992288|Drug|Placebo|Orally once daily for 20 weeks
2001448|NCT02990338|Drug|isatuximab SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
2001449|NCT02990338|Drug|pomalidomide|Pharmaceutical form:capsule Route of administration: oral
1489956|NCT03043677|Biological|Ex-vivo stimulation of cells with infliximab, golimumab, adalimumab, vedolizumab and ustekinumab|"Ex-vivo conditioning of lamina propria and peripheral blood mononuclear cells.
Here, we will address whether the current available biological therapies for IBD patients (infliximab, golimumab, adalimumab, vedolizumab and ustekinumab) elicit a differential effect on the mucosal capacity to recruit circulating leukocytes on an ex-vivo approach using transwell culture systems."
1489957|NCT03043664|Drug|Somatuline Depot|Somatuline depot (Lanreotide depot) 90mg SQ every 3 weeks
1489958|NCT03043664|Drug|Keytruda|Keytruda (pembrolizumab) 200mg IV every 3 weeks
2001450|NCT02990338|Drug|dexamethasone|Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
1489960|NCT03043638|Procedure|CAF+ADM+PRP|CAF+ADM+PRP group treated with coronally advanced flap technique including ADM placement, In CAF+ADM+PRP group, ADM was hydrated in the platelet-poor plasma (PPP) and the PRP was applied to surgical sites prior to final suturing.
1489961|NCT03043638|Procedure|CAF+ADM|CAF+ADM group treated with coronally advanced flap technique including ADM placement without PRP application
1489997|NCT03043469|Other|Heart rate variability analysis|Measurement of the variation in the beat-to-beat interval (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
1489998|NCT03043469|Other|Continuous measurement of arterial blood pressure|Measurement of blood pressure based on the peripheral pulse using a finger cuff (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
1489999|NCT03043469|Diagnostic Test|Lung function test|Breathing through a mouth-piece in many different ways in order to measure the function of the lungs (non-invasively).
1490166|NCT03042208|Other|Self guided handout|Written handout with basic weight management strategies
2001451|NCT02988011|Procedure|Gastric by-pass surgery|Gastric by-pass surgery is expected to achieve a mean weight loss of 7-8kg in 4 weeks, which is similar weight-loss achieved in the other arm (low-caloric diet) during this time period.
2001452|NCT02988011|Dietary Supplement|Low-caloric diet|Energy restricted diet with a total energy intake of 800-1200kcal/day
1489962|NCT03043625|Other|Visceral manipulation|Participants will be instructed to lie down comfortably on a stretcher in the supine position, with lower limbs flexed and abdomen exposed, and the physiotherapist positioned to the right side of the patient. The therapeutic intervention will be began with the left hand of the physiotherapist in contact with the lower region of the stomach, to which a force will be applied so that the organ was moved in an upper and lateral left direction while the right hand controlled and directed the knees of the patient to the right side until the moment when the physiotherapist notice an increase in tension in the stomach region. For the liver manipulation, the same procedures will be followed, however, with contact in the right epigastric region and the knees directed to the left side. The same position will be maintained for each organ treated until the physiotherapist could feel, through touch, a decrease in the tension of the viscera. The mean treatment time will 5 minutes.
1489963|NCT03043625|Other|Control group (CG)|The CG will be received placebo treatment. In the placebo treatment, the therapist should place the hands over the navel region without exerting any local tension for 1 minute.
1489964|NCT03043612|Device|Cook Sof-Flex® Double Pigtail Ureteral Stent coextruded with doxazosin|Placement of drug-coated ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
1489965|NCT03043612|Device|Cook Sof-Flex® Double Pigtail Ureteral Stent|Placement of a commercially available ureteral stent when temporary ureteral stenting is indicated following ureteroscopy for urolithiasis
1489966|NCT03043599|Radiation|Thoracic Radiation Therapy|All participants will receive radiation therapy (3Gy x 10 fractions) to the chest for 10 days (Monday through Friday for 2 weeks).
1489967|NCT03043599|Drug|Ipilimumab|Ipilimumab 3 mg/kg (90 minute IV infusion) will be administered every 3 weeks for 4 doses.
1489968|NCT03043599|Drug|Nivolumab|Nivolumab 1 mg/kg (30 minute IV infusion) will be administered every 3 weeks for 4 doses, followed by nivolumab 480 mg every 4 weeks.
1489969|NCT03043573|Behavioral|PATH-MCI|Problem Adaptation Therapy for Mild Cognitively Impaired Adults (PATH-MCI) differs from standard of care psychotherapy by offering a combination of emotion regulation techniques with the provision of environmental adaptation tools (notes, checklists, calendars, etc.), the use of the WellPATH app, and the participation of a willing and available caregiver.
1489970|NCT03043573|Behavioral|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors.
1489971|NCT03043560|Drug|Ezogabine|daily for 5 weeks
1489972|NCT03043560|Drug|Placebos|placebo pill daily for 5 weeks
1489973|NCT03043547|Drug|nal-IRI|nal-IRI [Irinotecan liposome] (80 mg/m2 as a 1.5 hour infusion)
1489974|NCT03043547|Drug|5-FU|5-FU [5-Fluorouracil] (2400 mg/m2 as 46 hour infusion)
1489975|NCT03043547|Drug|leucovorin|leucovorin (400 mg/m2 as 0.5 hour infusion)
1489976|NCT03043534|Other|shave gel|"Non marketed pre-shave gel with the following INCI list of ingredients:
WATER, GLYCERIN, DIMETHICONE, LAURETH-23, PETROLATUM, ACRYLAMIDE/SODIUM ACRYLOYLDIMETHYLTAURATE COPOLYMER, ISOPROPYL PALMITATE, HYDROXYETHYLCELLULOSE, FRAGRANCE, PEG-23M, C13-14 ISOPARAFFIN, DMDM HYDANTOIN, DISODIUM EDTA, LAURETH-7, IODOPROPYNYL BUTYLCARBAMATE"
1489977|NCT03043534|Other|Brush|All subjects randomized to brush will use the brush with each shave
1489978|NCT03043521|Drug|Dexlansoprazole 60 MG|
1489979|NCT03043521|Drug|CJ-12420 50mg|
1489980|NCT03043521|Drug|CJ-12420 100mg|
1489981|NCT03043521|Drug|CJ-12420 200mg|
1489982|NCT03043508|Other|Chart Review|Database reviewed to obtain patient and disease characteristics, laboratory values, imaging results, hormone parameters (menopausal status, bioidentical hormone use, oral contraception use, gestational status and diagnosis of a prolactinoma) and vital status.
1489983|NCT03043508|Behavioral|Questionnaire|Participants sent an email questionnaire to complete regarding their pregnancy and hormone use history.
1489984|NCT03043495|Procedure|Ultrasound guided supraclavicular brachial plexus block|ultrasound guided Supraclavicular brachial plexus block
1489985|NCT03043495|Drug|Dexamethasone|Various doses of Dexamethasone (2, 4 & 8 mg) to be used as an Adjuvant to Local anesthetic drugs
1489986|NCT03043482|Drug|Single VS-105/placebo to healthy|In Part 1, single ascending doses of VS-105 or placebo will be administered to approximately 5 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo.
1489987|NCT03043482|Drug|Multiple VS-105/placebo to healthy|In Part 2, multiple ascending doses of VS 105 or placebo will be administered each morning over 7 consecutive days to approximately 3 cohorts of 8 healthy subjects in each cohort with 6 receiving active and 2 receiving placebo..
1489988|NCT03043482|Drug|Multiple VS-105/placebo to HD subjects|In Part 3, multiple ascending doses of VS 105 will be administered over 14 consecutive days to approximately 3 cohorts that will each include 4 hemodialysis subjects with 3 receiving active drug and 1 receiving placebo.
1489989|NCT03043469|Other|Short-form survey instrument|Questionnaire with questions about quality of life. Takes about 5 minutes to be completed.
1489990|NCT03043469|Other|Demographic data|height, weight, age, gender, list of comorbidities, health history, level of physical activity, medicines in use. Takes about 10 minutes to be completed.
1489991|NCT03043469|Other|Hospital Anxiety and Depression Scale|Questionnaire with questions about anxiety and depression. Takes about 5 minutes to be completed.
1489992|NCT03043469|Other|Nijmegen questionnaire|Answering questions about symptoms related to breathing. Takes about 5 minutes to be completed.
1489993|NCT03043469|Other|The Self-evaluation of breathing questionnaire|Answering questions about self-evaluation of breathing. Takes about 5 minutes to be completed
1489994|NCT03043469|Other|six-minute exercise test|Cycling against certain load in a bicycle for 6 minutes. Takes about 16 minutes to be completed together with indirect calorimetry, oxygen saturation monitoring, heart rate variability analysis and continuous monitoring of arterial blood pressure).
1489995|NCT03043469|Other|Indirect calorimetry|Breathing through a mask that measures levels of oxygen, carbon dioxide, breathing frequency and others (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
1489996|NCT03043469|Other|Oxygen saturation monitoring|The measurement of the amount of oxygen which is attached to haemoglobin molecules (non-invasively). Takes about 16 minutes to be completed, together with the 6-minute exercise test.
1490229|NCT03041857|Radiation|Observational use of fluoroscopy|
1490001|NCT03043469|Other|Manual assessment of respiratory motion|Measure of the movements of the thorax while the participant is breathing (non-invasively).
1490002|NCT03043469|Other|Breath-hold test|Holding the breath a few times for as long as possible.
1490003|NCT03043469|Other|Physical Activity monitoring|Wearing a light-weight activity monitor to be wore on the hip for 7 consecutive days during, at least, 8 hours per day.
1490004|NCT03043469|Other|Asthma Control Questionnaire|Only for asthmatics: answering questions about the control the participant has over this respiratory condition/symptoms.
1490005|NCT03043456|Device|Thermoplastic complete denture|A device used to substitute the teeth for edentulous patients made of thermoplastic resin
1490006|NCT03043456|Device|Conventional acrylic resin complete denture|A device used to substitute the teeth for edentulous patients made of acrylic resin
1490007|NCT03043443|Other|Melatonin|Natural health product
1490008|NCT03043443|Other|Placebo|starch containing pills
1490009|NCT03043430|Drug|Ketamine 100 MG/ML|Administer ketamine via mucosal atomization device
1490010|NCT03043430|Drug|Midazolam 5 MG/ML|Administer midazolam via mucosal atomization device
1490011|NCT03043417|Behavioral|CHC's given the intervention|CHC's NOT given the intervention
1490012|NCT03043404|Device|Transcatheter aortic valve replacement|TAVR with Lotus Valve Flex System
2001453|NCT02987764|Other|cord milking|For infants in the cord milking group, the cord will be clamped at the longest distance possible and neonatal team will bring the infant to the resuscitation table for further care. The clinical care will be provided by the clinicians taking care of the infant. The research team will be trained and be responsible for requesting the obstetrician in advance to provide the maximum length of umbilical cord.
2001454|NCT02986607|Drug|parathyroid hormon 1-84|Hypoparathyroidism patients will receive Natpara in continous subcutaneous infusion delivered by a pump for 4-7 days.
1490015|NCT03043365|Drug|control fish oil|4 capsules, 3 times a day after meals
1490016|NCT03043365|Drug|LCMUFA-rich saury oil|4 capsules, 3 times a day after meals
1490017|NCT03043352|Dietary Supplement|Management of SAM at home|LHWs will identify and treat all cases of severe acute malnutrition (SAM) in children under-five years at household level compared with the standard CMAM program
1490018|NCT03043352|Dietary Supplement|Management of SAM at facility|LHWs will identify SAM as per 'Standard CMAM program' (MUAC < 11.5cm) and will refer all cases to the health facility BHU/ satellite site (ACF) for further management and counselling by health workers (ACF CMAM Nurse) at facility level.
1490019|NCT03043339|Other|Stool Specimen Collection|Participants will provide a stool sample at baseline (pre-operation) and 30 days after the transplant operation. Stool specimens will be self-collected by the participant.
1490020|NCT03043339|Other|Anal Swab Sampling|Anal swabs will be collected prior to surgery (baseline) and at post-operation days 2, 15, and 30. Participants whose planned hospitalization duration is extended from the pre-surgical plan will have an additional, optional, anal swab collected 2 days prior to their anticipated hospital discharge date. Anal swabs will be collected by the study team, except for the standard of care post-operative appointment (30 days after the operation) for the living donors who will collect their own samples.
1490021|NCT03043339|Other|Short Diet Assessment (SDA)|The study coordinator will administer the Short Diet Assessment (SDA) to participants prior to surgery at baseline and post-operation days 2, 15, and 30. Participants whose planned hospital length of stay is extended from the pre-surgical plan will complete the questionnaire 2 days prior to their anticipated hospital discharge date.
1490022|NCT03043339|Other|NHANES Dietary Screener Questionnaire (DSQ)|The National Health and Nutrition Examination Survey (NHANES) 2009-2010 Dietary Screener Questionnaire will be completed on Post-Operative Day 2. The questionnaire asks about foods consumed during the past 30 days. There are 25 items on the questionnaire and additional questions may be asked depending on responses provided. The questionnaire will be self-administered or administered by a study team member.
1490023|NCT03043326|Drug|Tenofovir Disoproxil Fumarate and Emtricitabine|This is an observational study. Pre-exposure Prophylaxis with TDF/3TC will be distributed to all participants elegible to receive PrEP.
2001455|NCT02986854|Biological|Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo)|One intramuscular injection of MenACWY at Day 1.
2001456|NCT02984514|Radiation|Positron emission tomography with tracer 18F-deoxy glucose|Assessment of activity of brown adipose tissue with positron emission tomography using the tracer 18F-deoxy glucose
1490026|NCT03043300|Other|Screening Criteria Review|"The screening criteria review is an 8 item instrument collecting information during screening about overall health, including self-reported chronic intestinal conditions, immunocompromising conditions, the use of certain medication types (immunosuppressives and antibiotics), and pregnancy status. The instrument will also collect dates of planned travel to South(east) as well as preferred dates for study visits and reminder contacts.
This instrument will be administered verbally by the study team and completed no more than 4 weeks prior to travel departure from the United States."
1490027|NCT03043300|Other|Pre-Travel Questionnaire|"The pre-travel questionnaire is a 29 item instrument collecting information about baseline characteristics, dietary habits, travel plans, and health history.
This questionnaire will be administered verbally by the study team and completed 1 week prior to travel departure from the United States."
1490028|NCT03043300|Other|Pre-Travel Stool Specimen Collection|"The pre-travel stool specimen collection will occur 1 week prior to travel departure from the United States.
The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
1490029|NCT03043300|Other|Short-Term Post-Travel Questionnaire|"The short-term post-travel questionnaire is a 19 item instrument collecting information about dates and locations of travel, food and beverages consumed while traveling, and illnesses during or following traveling.
This questionnaire will be administered verbally by the study team and completed 2 weeks after returning to the United States from travel."
1490030|NCT03043300|Other|Short-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 2 weeks after returning to the United States from travel.
The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
1490103|NCT03042741|Biological|atherosclerosis vaccine|Atherosclerosis vaccine, V6, formulated as an oral pill made from from pooled antigens derived from adipose tissue
1490031|NCT03043300|Other|Long-Term Post-Travel Questionnaire|"The long-term post-travel questionnaire is a 16 item instrument collecting information about illnesses since last study visit, dietary habits since last study visit, and any traveling since the last visit.
This questionnaire will be administered verbally by the study team and completed 14 weeks after returning to the United States from travel."
1490032|NCT03043300|Other|Long-Term Post-Travel Stool Specimen Collection|"The short-term post-travel stool specimen collection will occur 14 weeks after returning to the United States from travel.
The processing and analyses of this stool specimen will be performed by the Centers for Disease Control and Prevention."
1490033|NCT03043287|Biological|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX®)100 to 200 U
1490034|NCT03043274|Drug|Cangrelor|Cangrelor 30 mcg/kg bolus followed by a 4 mcg/kg/min intravenous infusion prior to PCI will be given. It will be continued for ≥ 2 hours or for the duration of the procedure, whichever is longer.
1490035|NCT03043261|Behavioral|Williams LifeSkills|Online multi-media interactive training modules which address 10 core skills to improve coping, stress management and interpersonal relationships.
1490036|NCT03043261|Drug|SSRI|Eligible participants who score 9 or higher on the PHQ-9 and who opt in will be given a prescription from the study PI for one of four SSRI medications (sertraline, citalopram, paroxetine or escitalopram).
2001457|NCT02983370|Procedure|Minicraniotomy|The surgical method for the implantation of the intracortical microelectrodes is straightforward and follows the standard neurosurgical procedures. Briefly, after the scalp is prepped with an antiseptic, a small skin incision is made. Then the skin and muscles are lifted off from the bone and folded back. Next, one small burr hole or a minicraniotomy of approximately 1.5 cm is made in the skull. This is a minimally invasive procedure that allows an easy access to the brain and is a standard procedure widely used in neurosurgery.
2001458|NCT02982733|Other|ABS|Ankaferd Blood Stopper
2001459|NCT02982733|Device|TR Band|Transradial band
2001460|NCT02982733|Other|CS|Sterile Gauze
2001461|NCT02977403|Behavioral|Attention Bias Retraining|Attention retraining program on smartphone where the probe always replaces the neutral picture. There is a perfect correlation between picture type and probe location.
1490042|NCT03043209|Genetic|Genomic sequencing|Genomic sequencing of DNA in Blood sample and myectomy tissue
1490043|NCT03043196|Drug|SRP plus Rosuvastatin gel|SRP followed by Rosuvastatin placement into intrabony defect
1490044|NCT03043196|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
1490045|NCT03043183|Procedure|perioperational nutrition surpport|Oral enteral nutrition support（25 kcal/kg or 1.5 g protein/kg） for 3 days before operation
1490046|NCT03043170|Device|Ultrasound Cardiac Output Monitor|a device for assessing haemodynamics continuously and non-invasively using Doppler wave ultrasound
1490047|NCT03043157|Drug|rocuronium|intravenous rocuronium infusion
1490048|NCT03043144|Other|Worsening of olfaction from enrollment visit to 6 months|Worsening of olfaction from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
1490049|NCT03043144|Other|Worsening of taste from enrollment visit to 6 months|Worsening of taste from enrollment visit to 6 months will be evaluated for association with the primary and secondary outcomes
1490050|NCT03043144|Other|Serum Zinc|Serum zinc will be evaluated for association with taste and/or smell impairment
1490051|NCT03043144|Other|Chronic rhinosinusitis|Chronic rhinosinusitis will be evaluated for association with smell impairment
1490052|NCT03043144|Other|Dialysis adequacy|Dialysis adequacy will be evaluated for association with taste and/or smell impairment
1490053|NCT03043144|Other|Decayed missing filled teeth index (DMFT)|DMFT will be evaluated for association with taste impairment
1490054|NCT03043131|Drug|Plasmalyte A|Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
1490055|NCT03043131|Drug|Ringer Lactate|Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
1490056|NCT03043118|Other|Variety Intervention|Vegetable flavor variety created with multiple herb and spice blends
1490057|NCT03043105|Drug|Thalidomide, cyclophosphamide and prednisone|"Thalidomide: 100mg QN for 1 year; And maintained with 100mg QN for the second year;
Cyclophosphamide: 300mg/m2 on Day 1, 8, 15, 22 every month for 1 year;
Prednisone: 1mg/kg on Day 1-2, 8-9, 15-16, 22-23 every month for 1 year."
1490058|NCT03043079|Diagnostic Test|Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity|Abdominal Ultrasound Acoustic Radiation Forced Impulse Shear Wave Velocity (ARFI-SWV)
1490059|NCT03043066|Procedure|Scaling and root planing|subjects underwent full mouth supragingival and subgingival scaling
1490060|NCT03043066|Drug|scaling and root planing along with antibiotic intervention|subjects underwent full mouth supragingival and subgingival scaling along with antibiotic intervention of amoxicillin of 500 mg and metronidazole of 400 mg thrice daily for 7 days
1490061|NCT03043053|Drug|oxytocin nasal spray|oxytocin intranasal spray
1490062|NCT03043053|Drug|Placebo|Placebo nasal spray
1490063|NCT03043040|Behavioral|Telephone follow up|Already described in previous page
1490064|NCT03043040|Behavioral|Treatment as usual|Already described in previous page
1490065|NCT03043027|Drug|liposomal bupivicaine|local anesthetic
1490066|NCT03043027|Drug|Bupivacaine|local anesthetic
1490067|NCT03043027|Drug|Saline Solution|saline injection
1490104|NCT03042741|Biological|Placebo pills|Half of the patients will be randomly assigned to receive placebo pill
1490105|NCT03042728|Behavioral|Dog Interaction|A therapy dog will visit the patients.
1490106|NCT03042728|Behavioral|Human Interaction|A human will visit the patients.
1490107|NCT03042715|Behavioral|Qualitative Interviews|phase 1 of the study entail refining the psychological intervention based on caregivers' feedback
1490108|NCT03042702|Drug|Kevetrin|Kevetrin dose to associated cohort
1490109|NCT03042702|Drug|Kevetrin|Kevetrin dose to associated cohort
2001462|NCT02977403|Behavioral|Booster Attention Retraining|All subjects can opt to undergo attention bias training after the randomized phase of the study is complete
1490068|NCT03043014|Drug|Mifépristone versus Misoprostol|The women will be randomized into two groups: Mifépristone group and Misoprostol group. The main endpoint will be the per-operating pain. The other endpoints are the pre and post-operative pain, the complications (cervical tearing, uterine perforation, hemorrhage requiring the use of blood products or an hemostatic intervention), the surgical time necessary to terminate the pregnancy, the side-effects of the drugs. The amount of per-operating bleeding and the duration of the intervention . The investigators assume that the use of Mifepristone in the cervical preparation of the surgical abortion under LA would reduce the per-operating pain. The number of patients required is 55 in each arm.
1490069|NCT03043001|Drug|Memantine|All the subjects will receive add-on memantine for 12 week
1490070|NCT03042988|Other|Heating pad|Heat stress applied on the trunk for up to 8 hours
1490071|NCT03042988|Other|Sham control|heating pad turned off applied on the trunk for up to 8 hours
1490072|NCT03042975|Other|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
1490073|NCT03042975|Procedure|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies.
1490074|NCT03042962|Other|MRI|Functional and structural MRI of the brain will be conducted to identify disorder specific neural markers
1490075|NCT03042962|Procedure|Blood draw|Blood samples will be collected, the DNA will be extracted and banked for genetic studies
1490076|NCT03042949|Device|Blood pressure measurement|Blood pressure measurement with a standard plethysmograph
1490077|NCT03042949|Device|Blood pressure measurement with the new device|Blood pressure measurement with the optical sensor, Elfor -1 device.
1490078|NCT03042936|Behavioral|Insulin Superheroes Club Curriculum|This curriculum promotes healthier physical activity, nutrition, sleep, and stress coping practices. The intervention lasts 12-months: registration, six evaluation sessions (2-3 hours per evaluation: Weeks 1, 8, and 16, 6-month, 9-month, and 12-month), and 16-weekly, 3-bi weekly, 6-monthly educational and physical activity sessions each lasting 90 minutes.
1490079|NCT03042923|Drug|lactulose:mannitol (L:M) oral challenge|
1490080|NCT03042910|Drug|Talazoparib|Talazoparib 1 mg orally once daily.
1490081|NCT03042897|Dietary Supplement|Dietary Intervention|Undergo DASH diet
1490082|NCT03042897|Behavioral|Exercise Intervention|Undergo in aerobic exercise
1490083|NCT03042897|Other|Laboratory Biomarker Analysis|Correlative studies
1490084|NCT03042897|Other|Quality-of-Life Assessment|Ancillary studies
1490085|NCT03042884|Behavioral|Questionnaires|"Inpatient Group: Participants complete a questionnaire about any symptoms they may have had in the past 24 hours. The questionnaire should take about 5 minutes to complete.
Within 24 hours of being discharged, same questionnaire about symptoms and a questionnaire about experience with the wearable exercise tracker. These questionnaires should take about 10 minutes total to complete.
Outpatient Group: Participants complete 2 questionnaires about any symptoms they may have had in the past 24 hours and their current level of physical function. These should take about 10 minutes total to complete.
At the end of the 14-day period, participant called by the study staff to remind them to complete the same 2 questionnaires about symptoms and level of physical function. Participants complete another questionnaire about their experience with the wearable exercise tracker. These questionnaires should take about 15 minutes total to complete."
1490086|NCT03042884|Device|Wearable Exercise Tracker Watch|"Inpatient Group: Participants receive a wearable exercise tracker watch upon admission to acute inpatient rehabilitation unit. Participant to wear the exercise tracker watch on their wrist for 24 hours a day. Device to be returned within 24 hours before being discharged.
Outpatient Group: Participants receive a wearable exercise tracker watch to wear on their wrist for 24 hours a day for 14 days. Device to be returned at next visit."
1490087|NCT03042871|Drug|0.5mg intravitreal ranibizumab|Patients received ranibizumab (0.5mg, Novartis AG, Basel, Switzerland) via a pars plana transcleral injection through 30-gauge needle at 3.5 to 4mm of inferotemporal limbus. Levofloxacin eye drops ( Cravit Eye Drops, Santen, Japan) was instilled 4 times a day in the study eye before the treatment at least 1 day. Povidone-iodine (5%, Luofushan Pharmaceutical Co., China) was applied to the conjunctiva bulbi and the fornices for at least 3 minutes before injection. Patients were instructed to continue the levofloxacin eye drops 4 times a day for 3 days
1490088|NCT03042858|Other|Infants with PPV|Data will be collected for up to 18 years to monitor for inguinal hernia.
1490089|NCT03042858|Other|Infants without PPV|Basic data will be collected regarding the surgery and the subject's study participation will be complete.
1490090|NCT03042845|Device|Tiger cardiac catheter|Tiger cardiac catheter
1490091|NCT03042845|Device|Judkins 3.5L/4R cardiac catheters|Judkins 3.5L/4R cardiac catheters
1490092|NCT03042832|Behavioral|LOCI|Leadership development with coaching and organizational change support
1490093|NCT03042832|Behavioral|WEBINAR|Webinar leadership training
1490094|NCT03042819|Drug|Selinexor|Selinexor is a Selective Inhibitor of Nuclear Export (SINE) compound that binds and inactivates Exportin 1 (XPO1), thereby forcing the nuclear retention of key tumor suppressor proteins (TSPs).
1490095|NCT03042819|Drug|Doxorubicin|Doxorubicin is currently approved for various cancers. Doxorubicin inhibits DNA synthesis and repair by inhibiting topoisomerase II and also by intercalation between base pairs on the DNA helix. These actions result in the blockade of DNA and RNA synthesis and fragmentation of DNA.
1490096|NCT03042806|Behavioral|questionnaire|all the COPD patients will be ask to complete the questionnaire
1490097|NCT03042793|Biological|PD-L1 peptide vaccine|PD-L1 peptide given subcutaneously with Montanide ISA-51
1490098|NCT03042780|Drug|FOLFIRINOX|The FOLFIRINOX regimen consists of oxaliplatin given as a 2-hour intravenous infusion, immediately followed by leucovorin given as a 2-hour intra-venous infusion, with the addition, after 30 minutes, of irinotecan given as a 90-minute intravenous infusion. This study treatment is immediately followed by a continuous intravenous infusion of 5-Fluorouracil (5-FU) over a 46-hour period every 2 weeks.
1490099|NCT03042780|Drug|Granulocyte colony-stimulating factor (G-CSF)|The use of G-CSF will not be mandatory as primary prophylaxis, but will be allowed at investigators' discretion. If febrile neutropenia occurs, than the use of G-CSF will be mandatory after each following cycle of treatment.
1490100|NCT03042767|Biological|IMM-124E|IMM-124E is a hyper-immune, bovine colostrum (milk) powder with flavoring.
1490101|NCT03042767|Other|Placebo|Matched Placebo
1490102|NCT03042754|Diagnostic Test|XpertMTB/RIF|
1490111|NCT03042663|Procedure|USG stellate ganglion block|After verification of proper needle position and aspiration to exclude vascular spread, 1mL of the injectate will be injected to see proper tissue spread as well as patient response. After one minute the remaining volume will be injected under real time ultrasound imaging.
1490112|NCT03042650|Behavioral|Intensive Referral Intervention Group|The Intensive Referral Intervention Group will review a series of pamphlets regarding participation in 12-step meetings as well as smoking cessation that will be presented in a group setting to probationers in 3 sessions.
1490113|NCT03042650|Behavioral|Standard Practice Facilitated Group|The Standard Practice Facilitated Group will receive 3 sessions of the current standard practice for facilitated groups.
1490114|NCT03042637|Drug|Acthar Gel and Tacrolimus|Combination therapy with Acthar Gel and Tacrolimus (0.5-3.0 mg BID) following 6 months of ACTH therapy only
1490115|NCT03042624|Dietary Supplement|Fermented rice|7 g of powder obtained from Lactobacillus paracasei CBA L74
1490116|NCT03042624|Dietary Supplement|Maltodextrins|7 g of maltodextrins powder
1490117|NCT03042611|Drug|Apatinib|Daily oral dose of Apatinib plus Best Supportive Care defined as palliative non-cancer therapy at the Investigator's discretion
1490118|NCT03042611|Other|Placebo|Daily oral dose of Placebo with Best Supportive Care defined as palliative non-cancer therapy at the Investigator's discretion
1490119|NCT03042598|Device|Biphasic Cuirass Ventilation|The RTX Respirator will be applied to the patient's chest to provide non-invasive ventilatory support using a Biphasic Cuirass Ventilation technology to increase the safe apnic period during intubation.
1490120|NCT03042585|Radiation|Total body irradiation|When radiation is given in a way to cover the whole body, it is called total body irradiation.
1490123|NCT03042559|Device|Protonics Knee brace|"Protonics Therapy Program is separated into three phases for a period of 4 weeks. In each phase the patients will learn how to perform the Protonics neuromuscular repositioning technique, Protonics gait and open-chain exercise. All subjects will be asked to perform the exercise 3 times a week, 3 sets a day; every set is 10-15 repetitions for 4 weeks.
In phase one, the subjects will perform Protonics Neuromuscular repositioning Techniques, Protonics gait through walking for up to 5 minutes or as tolerated, and preform warming up exercise.
In phase two, the subjects will perform Protonics Neuromuscular repositioning Techniques, Protonics gait through walking for up to 8 minutes or as tolerated, and preform three specific exercises in prone, supine and sitting position.
In phase three, the subjects will perform Protonics Neuromuscular repositioning Techniques, Protonics gait through walking for up to 10 minutes or as tolerated, and preform one specific exercise in standing position."
1490124|NCT03042559|Device|Sports Cords|"Sports Cord Therapy Program is separated into three phases for a period of 4 weeks. In each phase the patients will learn how to perform the sports cord gait and open-chain exercise. All subjects will be asked to perform the exercise 3 times a week, 3 sets a day; every set is 10-15 repetitions for 4 weeks.
In phase one, the subjects will perform the sports cord gait through walking for up to 5 minutes or as tolerated, and preform warming up exercise.
In phase two, the subjects will perform the sports cord gait through walking for up to 8 minutes or as tolerated, and preform three specific exercises in prone, supine and sitting position.
In phase three, the subjects will perform the sports cord gait through walking for up to 10 minutes or as tolerated, and preform one specific exercise in standing position."
1490125|NCT03042546|Drug|Calcium Sulfate|Calcium Sulfate with abx will be used in the defect
1490126|NCT03042546|Drug|PMMA|PMMA with abx will be used in the defect
1490127|NCT03042546|Other|No treatment|The defect will not be treated
1490128|NCT03042533|Device|Conventional Compression|Method of Nail fitting
1490129|NCT03042533|Device|Standard Backslapping|Method of Nail fitting
1490130|NCT03042533|Device|Dynamic Locking with Backslapping|Method of Nail fitting
1490131|NCT03042520|Other|Observation only|
1490132|NCT03042507|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|The existing CBIT protocol includes a functional assessment procedure designed to identify relevant contextual variables (both antecedent and consequent) impacting tic expression and guide the development of an individualized behavioral program to neutralize these contextual influences in the service of tic reduction and psychoeducational component. Given the central role that negative social reactions typically play in tic exacerbation and maintenance, psychoeducation about tics is systematically provided to parents, siblings, and other caretakers and prominent individuals in the child's life. The other primary CBIT component, Habit Reversal Training (HRT), is used to weaken or eliminate the negative reinforcement cycle created by tic-contingent reduction in premonitory urge.
1490133|NCT03042494|Dietary Supplement|Control|Isocaloric food without the test prebiotic.
1490134|NCT03042494|Dietary Supplement|Prebiotic|Prebiotic consumed as 7 g/d in a snack food in Group 1 and consumed as 2.5-3 g/d in a snack food in Group 2.
1490135|NCT03042468|Drug|177Lu-PSMA-617|177Lu-PSMA-617 [50mCi (1.85GBq) - 300mCi (11.1GBq)] intravenous X2 doses, 2 weeks apart (Visit 1 and 2)
1490136|NCT03042468|Drug|68Ga-PSMA-HBED-CC|68Ga-PSMA-HBED-CC [5 ±2mCi or 185 ±74MBq] intravenous during screening and at 12 weeks with standard imaging
1490164|NCT03042234|Other|Group II|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
1490165|NCT03042234|Other|Group III|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
1490137|NCT03042455|Device|Armeo and rTMS|"The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. rTMS is a magnetic method used to stimulate small regions of the brain.
The Robot and rTMS group will receive the robot-assisted upper arm training and rTMS for 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks."
1490138|NCT03042455|Device|Armeo|The Armeo, a robot with a spring mechanism allowing adjustable arm weight support, can generate assistive forces of up to 66N in flexion/extension and up to 30N for the arm and forearm respectively. This robot integrates seven angle sensors and one pressure sensor that allow direct interaction between the motion of the patient's arm and the associated therapy software. The Robot group will receive the robot-assisted upper arm training for 30 minutes daily 5 times per week, for 4 weeks. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
1490139|NCT03042455|Other|Control group|The conventional group will receive occupational therapy for 30 minutes daily 5 times per week, for 4 weeks instead of Robot or rTMS. And all patients of three groups will receive the additional conventional occupational therapy for 30 minutes daily 5 times per week, for 4 weeks.
1490140|NCT03042442|Diagnostic Test|Point-of care biomarkers|Point-of care biomarkers(Activin,Midkine) assessed by WB and IHC
1490141|NCT03042442|Other|Clinical, venous blood samples, pancreatic tissue|Clinical evaluation, venous blood samples and pancreatic tissue needed for determining point-of-care biomarkers.
1490142|NCT03042442|Other|Follow-up|Participants will be assessed (by telephone) over a period of 2 years
1490143|NCT03042429|Drug|Cycles N8, N5 and N6|two chemotherapy cycles N8 followed by standard arm therapy
1490144|NCT03042429|Drug|Cycles N5 and N6|Standard arm six chemotherapy cycles (3xN5 and 3x N6) followed by myeloablative therapy with stem cell support and isotretinoin
1490146|NCT03042403|Other|Breath stacking|During initial rest period, the volunteer remained seated for 10' in spontaneous breathing. Right after, the measurement of arterial pressure, of SpO2 (%), of heart rate, of respiratory frequency and applied to a modified effort perception Borg. During carrying out of the breath stacking technic, the volunteer remained seated, being requested to hold the mask on his/her face not allowing air scape, The volunteer was oriented to inhale normally and exhale all the air during expiration for 20 seconds, and the variables were assessement again the same variables of control. In the final rest period, right after technic end, the volunteers remained seated for 10 minutes in spontaneous breathing and again the same variables of control at the 10th minute were assessed.
1490147|NCT03042377|Other|Single-Visit Retreatment|The teeth in this group were treated according to the guidelines for root canal retreatment in single-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were obturated with gutta percha and coronal restoration was made using composite and/or fully crown if necessary.
1490148|NCT03042377|Drug|"Multiple-Visit-Calcium Hydroxide"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with calcium hydroxide and the cavity was filled with temporary restorative material.
1490149|NCT03042377|Drug|"Multiple-Visit-Corticosteroid Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with corticosteroid & antibiotic paste and the cavity was filled with temporary restorative material.
1490150|NCT03042377|Drug|"Multiple-Visit-Antibiotic Paste"|The teeth in this group were treated according to the guidelines for root canal retreatment in multiple-session. The filling was removed and cavity was opened. Then root canal filling was removed from the root canals completely using retreatment kit. After irrigation protocol, root canals were treated with an antibiotic paste and the cavity was filled with temporary restorative material.
1490151|NCT03042364|Other|Pipelle de Cornier|RCT with endometrial scratching prior to hormone treatment in ART. Aspiration of uterine secretion at transfer day
1490152|NCT03042351|Device|Magic Kegel app|Pelvic floor muscles recover exercises with a specific device and Magic Kegel App
1490153|NCT03042338|Behavioral|CET: Central Executive Training|CET: Central Executive Training
1490154|NCT03042338|Behavioral|CET: Comparison Executive Training|CET: Comparison Executive Training
1490156|NCT03042312|Drug|Lu177-PSMA-617|Lutetium (177Lu) -DOTA (1,4,7,10-tetra-azacyclododecane-N,N',N'',N'''-tetraacetic acid )-PSMA has three components: PSMA is the targeting vector , DOTA (1, 4, 7, 10-tetraazacyclododecane-1, 4, 7, 10-tetraacetic acid) is a radiometal chelator and a linking group, and 177Lu is the beta emitter that upon internalization delivers radiation to the nucleus of tumor cells to cause DNA damage [43] [44, 45]. The targeting vector utilizes glu-urea-lys sequence which is an inhibitor capable of binding to the domain of PSMA. These components have been previously used in human subjects and in medical research.
1490157|NCT03042299|Drug|TAK-536 10mg|Period 1: TAK-536 pediatric formulation (granules) 10 mg Period 2:TAK-536 commercial formulation 10 mg
1490158|NCT03042299|Drug|TAK-536 10mg|Period 1:TAK-536 commercial formulation 10 mg Period 2: TAK-536 pediatric formulation (granules) 10 mg
1490159|NCT03042273|Dietary Supplement|High Strength Cranberry|Softgel capsule
1490160|NCT03042273|Dietary Supplement|Placebo|Soy oil to match High Strength Cranberry Softgel Capsule
1490161|NCT03042260|Drug|Trimethoprim-Sulfamethoxazole|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
1490162|NCT03042260|Drug|Placebo Oral Tablet|oral tablets, 3 times a week, for a minimum of 6 months and maximum of 1 year.
1490163|NCT03042234|Other|Group I|High intensity interval training: 3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
1494648|NCT03009032|Dietary Supplement|Placebo|Lactose
1490167|NCT03042208|Behavioral|Weight Watchers|Access to Weight Watchers in-person meetings and online tools
1490168|NCT03042195|Other|Parenteral Nutrition|Supplementary parenteral nutrition to achieve 100% coverage of estimated needs
1490169|NCT03042182|Biological|Oral therapeutic vaccine V3-X to treat cholangiocarcinoma|One single pill of V3-X vaccine administered once per day to patients with cholangiocarcinoma
1490170|NCT03042169|Drug|Preoperative Chemotherapy|Standard chemotherapy regiments according to risk of recurrence
1490171|NCT03042169|Procedure|Surgery|the surgical treatment will undergo gastrectomy between D1 and D30 after randomization.
1490172|NCT03042169|Drug|Postoperative chemotherapy|Chemotherapy should be restarted between D1 and D30 post-randomization
1490173|NCT03042156|Radiation|Palliative Radiation Therapy|
1490174|NCT03042143|Biological|Human umbilical cord derived CD362 +ve MSCs|Infusion of Human umbilical cord derived CD362 +ve MSCs
1490175|NCT03042143|Biological|Placebo (Plasma-Lyte)|Infusion of placebo
1490176|NCT03042130|Other|Standard of care|standard of care
1490177|NCT03042130|Drug|Iron Carboxymaltose|Two IV doses
1490180|NCT03042091|Drug|Polyethylene Glycol|Given orally
1490181|NCT03042091|Drug|Neomycin|Given orally
1490182|NCT03042091|Drug|Metronidazole Hydrochloride|Given orally
1490183|NCT03042091|Procedure|Therapeutic Conventional Surgery|Undergo colorectal resection
1490184|NCT03042078|Device|Zero-fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without the use of fluoroscopy.
1490185|NCT03042078|Device|Conventional fluoroscopic ablation|Catheter ablation will be performed under the guidance of Ensite NavX plus fluoroscopy.
1490186|NCT03042065|Device|vibrating Mesh nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using vibrating Mesh nebulizer
1490187|NCT03042065|Device|jet nebulizer|Receive in the same aerosol solution 5 mg of Salbutamol (Ventolin, Glaxo, 5 mg / ml solution for nebulization) mixed with 0.5 mg Ipratropium Bromide (0.25 mg / ml) by nebulization every 20 min For 3 doses during the first hour of treatment, using jet nebulizer
1490188|NCT03042052|Drug|detrusor infection of Botulinum toxin|detrusor injection
1490189|NCT03042039|Other|New Care|New organisational care model delivering integrated healthcare (IHC) supported by ICT infrastructure (electronically shared-care platform).
1490190|NCT03042013|Drug|ASP8273|Oral
1490191|NCT03042000|Other|non-NCRT|without the preoperative concurrent chemoradiothearpy (no neoadjuvant chemoradiation)
1490192|NCT03042000|Other|NCRT|the preoperative concurrent chemoradiothearpy (neoadjuvant chemoradiation)
1490193|NCT03042000|Drug|capecitabine with oxaliplatin|combined chemotherapy with capecitabine with oxaliplatin
1490194|NCT03042000|Drug|capecitabine|single-agent chemotherapy with capecitabine
1490195|NCT03042000|Procedure|TEM|transanal endoscopic microsurgery (TEM) excision of the lesion
1490196|NCT03042000|Procedure|radical resection|radical resection of rectal cancer
1490197|NCT03041987|Other|Demographic factors, biomedical measurements, drugs used for controlling metabolic disorders, etc|
1490198|NCT03041974|Procedure|Red Blood Cell transfusion|
1490199|NCT03041974|Procedure|Microparticles quantification|Flow cytometric quantification of microparticles in transfused blood
1490200|NCT03041961|Dietary Supplement|Placebo|Identical formulation as the treatment consisting of colored maltodextrin using artificial colors.
1490201|NCT03041961|Dietary Supplement|Aronia full spectrum|Powdered whole fruit obtained from aronia berries (Aronia melanocarpa)
1490202|NCT03041961|Dietary Supplement|Aronia extract|Powdered extract obtained from aronia berries (Aronia melanocarpa)
1490203|NCT03041948|Procedure|Ilioinguinal/iliohypogastric nerve block|See arm description
1490204|NCT03041948|Procedure|Caudal-epidural nerve block|See arm description
1490205|NCT03041948|Drug|Acetaminophen|See arm description
1490206|NCT03041948|Drug|Sevoflurane|See arm description
1490207|NCT03041948|Drug|Remifentanil|See arm description
1490208|NCT03041948|Drug|Propofol|See arm description
1490209|NCT03041948|Drug|Morphine|See arm description
1490210|NCT03041948|Drug|Ondansetron|See arm description
1490211|NCT03041948|Drug|Dexamethasone|See arm description
1490212|NCT03041948|Drug|Ketorolac|See arm description
1490213|NCT03041935|Procedure|Ilioinguinal/iliohypogastric nerve block|See arm description
1490214|NCT03041935|Procedure|Caudal-epidural nerve block|See arm description
1490215|NCT03041935|Drug|Acetaminophen|See arm description
1490216|NCT03041935|Drug|Sevoflurane|See arm description
1490217|NCT03041935|Drug|Remifentanil|See arm description
1490218|NCT03041935|Drug|Propofol|See arm description
1490219|NCT03041935|Drug|Morphine|See arm description
1490220|NCT03041935|Drug|Ondansetron|See arm description
1490221|NCT03041935|Drug|Dexamethasone|See arm description
1490222|NCT03041935|Drug|Ketorolac|See arm description
1490223|NCT03041935|Drug|Ropivacaine|See arm description
1490224|NCT03041909|Drug|GBT440|Oral drug
1490225|NCT03041896|Device|coflex® Interlaminar Technology|Interlaminer Technology
1490226|NCT03041883|Procedure|Crosslinking with riboflavin of the corneal graft-support|Corneal graft support for the KPro will be crosslinked and used with the standard surgical technique
1490227|NCT03041883|Procedure|De-epithelisation of the corneal graft support with instillation of riboflavin|Corneal graft-support will be de-epithelialized and soaked with riboflavin and then used with the standard surgical technique
1490228|NCT03041870|Device|PET-fMRI scan|fMRI scan include MR sequences: BOLD and fMRI. The PET acquisition will be carried out in dynamic for 90 consecutive minutes following intravenous administration of 4 MBq / kg dose of [11C]DASB bolus.
1494649|NCT03009019|Drug|DFN-15|
2001463|NCT02976220|Other|Digital Education|Online videos, illustrations, and text materials designed to improve participants' awareness and understanding of kidney function, kidney disease, kidney failure options, peritoneal dialysis, home hemodialysis, in-center hemodialysis, kidney transplant, medical management, and treatment decision. Also includes online messaging system and discussion board designed to allow participants to message study nurse and peer mentor, as well as to engage in group discussion in an open forum and about specific scenarios.
1490232|NCT03041818|Behavioral|Horseback riding therapy|Apply 30 minutes/session, twice a week for 8 weeks of horseback riding therapy (provided with 1 horse rider, 2 side walkers)
1490233|NCT03041805|Procedure|EVLT|Endovenous laser treatment of great saphenous vein, small saphenous vein, accessorial saphenous vein with different laser wavelength and any bare type
1490234|NCT03041805|Procedure|RFA|Radiofrequency ablation of great saphenous vein, small saphenous vein, accessorial saphenous vein with ClosureFast technique
1490235|NCT03041805|Procedure|USFS|Ultrasound guided foam sclerotherapy of great saphenous vein, small saphenous vein, accessorial saphenous vein with polidocanol or tetradecyl sulphate of any concentration
1490236|NCT03041805|Procedure|HL/stripping|High ligation and stripping of great saphenous vein, small saphenous vein, accessorial saphenous vein
1490237|NCT03041805|Procedure|Miniphlebectomy|Miniphlebectomy of any varicose veins under local, regional or general anaesthesia
1490238|NCT03041805|Procedure|Sclerotherapy|Foam or liquid sclerotherapy of any varicose veins with polidocanol or tetradecyl sulphate of any concentration
1490239|NCT03041805|Device|GCS|Graduated compression stockings may be used after procedure by the decision of the doctor
1490240|NCT03041805|Drug|LMWH|Low-molecular-weight heparin may be used after procedure by the decision of the doctor
1490241|NCT03041792|Drug|Liraglutide|Liraglutide
1490242|NCT03041792|Other|Placebo|Placebo
1490243|NCT03041779|Drug|Diclofenac Sodium 50Mg Suppository|
1490244|NCT03041779|Drug|Paracetamol 500Mg Suppository|
1490245|NCT03041766|Biological|Sm14|Three 0.5 mL intra-muscular injections of the vaccine solution (50µg Sm14) will be administered on D0, W4, W8 (D = day, W = week).
1490246|NCT03041766|Drug|GLA-SE solution|Two (2) adjuvant concentrations will be made and packaged at 0.4 mL/vial, per GMP standards. One lot at the concentration of 10µg/mL for injection in the first cohort at 2.5µg GLA-SE/injection and one lot at the concentration of 20µg/mL for the second cohort intended to receive 5.0µg of GLA-SE/injection
1490247|NCT03041740|Drug|Perfluorooctylbromide(PFOB)|Subjects in the Perfluorooctylbromide (PFOB) Group will be administered a series of doses of Perfluorooctylbromide (PFOB) instilled via the endotracheal tube until a visible meniscus is obtained. Subjects will be evaluated every 2-4 hours for up to 10 days after initial dose of PFOB to maintain a visible PFOB meniscus.
1490248|NCT03041727|Other|Fascial Manipulation|Fascial Manipulation is a manual therapy that focused on deep muscular fascial.
1490249|NCT03041727|Other|Standard exercises protocol|Stretching and strengthening exercises
1490250|NCT03041701|Drug|Dasatinib|Once daily on days -7 through day 27 during cycle 1, and then days 0-27 for subsequent cycles.
1490251|NCT03041701|Drug|Ganitumab|Once every 2 weeks beginning on day 0.
1490256|NCT03041675|Device|Laser Acupuncture group|47 participants receive 10 seconds of Laser Acupuncture(808nM/300mW) on acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
1490257|NCT03041675|Device|Sham Laser Acupuncture group|The investigators apply the Laser Acupuncture pen (without pressing the Laser button) on other 47 participants' acupoints RN6, RN4, and RN12. The whole duration of treatment is 3 times a week, for 8 weeks.
1490258|NCT03041662|Diagnostic Test|MR/MRCP|MR/MRCP
1490259|NCT03041649|Other|GT button change - Mic-Key|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
1490260|NCT03041649|Other|GT button change - Mini One|After 2 months with each button, parents will be asked which button they prefer at the 4-month post-operational follow-up visit.
1490261|NCT03041636|Drug|Ruxolitinib|Ruxolitinib administered twice daily (bid), approximately 12 hours apart. Starting dose 20 mg twice a day for patients with a platelet count of greater than or equal to 200 x10^9/L (dose level 1) and 15 mg twice a day for patients with a platelet count of greater than or equal to 100 x 10^9/L and less than or equal to 200 x 10^9/L (dose level -1).
1490262|NCT03041610|Behavioral|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
1490263|NCT03041597|Procedure|placement of implants|surgical procedure and placement of implants
1490264|NCT03041597|Procedure|immediate loading|cone-anchored implant supported removable dental prostheses placement
1490265|NCT03041597|Procedure|conventional loading|cone-anchored implant supported removable dental prostheses placement in 3mo
1490266|NCT03041597|Device|Ankylos implant|
1490267|NCT03041584|Procedure|Guided placement|implant placement with use of guide
1490268|NCT03041584|Procedure|Non-guided placement|conventional implant placement
1490269|NCT03041584|Device|Astra Tech TX implant|
1490270|NCT03041571|Behavioral|Patient Provider Orientation Scale|Investigators are interested in the impact that our activity has on the students' patient-centeredness. Investigators will use the Patient-Practitioner Orientation Scale (PPOS), which will be completed by both the student and the patient prior to the encounter. Following the interview, the co-investigators will lead a discussion with the patient and student. Investigators will discuss differences in patient and student PPOS scores, and how each party felt the interview went. Investigators will examine if the patients feel the interview differed from typical interactions with health care providers, and how this made the patient feel. The students will describe what was learned from the patients story as well as try to explore reasons why providers may not always learn the patient's illness story.
1490298|NCT03041389|Behavioral|Control Group|Reading material only including recommendations about sleep hygiene, stimulus control and sleep restriction. Access to the CCBT-I program through the internet (Cleveland Clinic Wellness Go! To Sleep six-week online program), if proven effective, after the study is completed.
1494650|NCT03009019|Other|DFN-15 Placebo|
1490271|NCT03041571|Behavioral|Interview performed by MHP student|"The MHP students took a course called Medical Humanities in the fall of 2016. MHP students learned patient interviewing skills and the importance of gathering the patients illness story. The students will conduct an interview with a patient with chronic illness, which will be focused on gather information about how the patients illness affects daily life as well as interactions with the health care system."
1490272|NCT03041558|Behavioral|SafeCare+ (SC+)|SafeCare intervention with the additional Healthy Relationships (HR) module
1490273|NCT03041558|Behavioral|SafeCare (SC)|SafeCare intervention as usual
1490274|NCT03041545|Device|Fitbit|Women enrolled in the study will be asked to wear a Fitbit from one week prior to chemotherapy until six months post-chemotherapy. The Fitbit is a watch-sized, wrist worn, physical activity tracker. A button, when pressed, displays the wearer's accumulated daily steps, mileage, and steps climbed.
1490275|NCT03041532|Procedure|Proximal retroflexion|The investigator explore twice right colon, first front view and second forward viewing or proximal retroflexion depends on randomization
1490276|NCT03041532|Procedure|Frontal view|The investigator explore twice right colon with frontal viewing
1490277|NCT03041519|Procedure|Zero-fluoroscopy ablation|Catheter ablation will be performed under the guidance of Ensite NavX and without fluoroscopy.
1490278|NCT03041519|Procedure|Conventional fluoroscopy ablation|Catheter ablation will be performed under the guidance of fluoroscopy pllus Ensite NavX.
1490279|NCT03041506|Drug|Lidocaine|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.
Lidocaine 2%: 15 -20 ml."
1490280|NCT03041506|Procedure|US guided ISCB|"Infiltration of local anesthetic agents around target nerves (C5, C6 nerve roots), US guidance, for shoulder pain relief and muscle relaxation.
Lidocaine 2%: 15 -20 ml."
1490281|NCT03041506|Drug|Midazolam|IV administration up to a maximum dosage of 0.1 mg/kg (bolus of 1 mg by titration every 30-60 seconds) for sedation and pain relief.
1490282|NCT03041506|Drug|Ketamine|IV administration up to maximum dosage of 100 mg IV (bolus of 25 mg by titration every 30-60 seconds) for sedation and pain relief.
2001464|NCT02974582|Behavioral|exposure to smoking advertising with coupon|direct mail marketing of smoking advertising with discount coupon
2001465|NCT02974582|Behavioral|exposure to smoking advertising|direct mail marketing of smoking advertising without discount coupon
2001466|NCT02974582|Behavioral|exposure to non health related images|control group
1490286|NCT03041480|Diagnostic Test|serum lipid levels and Lp-PLA2|Estimation of Total Cholesterol, triglyceride, High density lipoprotein, Low density lipoprotein, very low density lipoprotein and Lipoprotein associated lipophosphase A2 in chronic periodontitis
2001467|NCT02974582|Behavioral|exposure to smoking advertising no coupon|direct mail marketing of smoking advertising without discount coupon
1490288|NCT03041441|Device|MRI algorithm|MRI sequences have been developed that may be able to estimate intracranial pressure in a non-invasive fashion
1490289|NCT03041441|Procedure|Lumbar puncture|Lumbar puncture according to the standard-of-care treatment plan.
1490290|NCT03041441|Procedure|Epidural patching|Epidural patching will be performed to the standard-of -care treatment plan
1490291|NCT03041428|Device|Ultraprotective ventilation|Adjusting ventilator parameters for 3 ml/kg of tidal volume in order to achieve the ultra protective strategy
2001468|NCT02973321|Drug|SAR425899|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2001469|NCT02973321|Drug|Placebo|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1490294|NCT03041402|Other|PSP|PSP, setting the inspiratory pressure support ≥8 cmH2O to obtain a tidal volume of 6-8 mL•kg-1 of body weight, the fastest rate of pressurization (0.0 sec) and I/E cycling at 35% of peak inspiratory flow
1490295|NCT03041402|Other|NAVA|NAVA, adjusting the NAVA level in order to achieve a comparable peak EAdi (EAdipeak) as during PSP with a safety Paw upper limit of 30 cmH2O
1490296|NCT03041402|Other|PSN|PSN, setting the NAVA level at its maximum (i.e; 15 cmH2O/mcV), and an upper Paw limit such to obtain the same overall Paw applied during PSP
1490297|NCT03041389|Behavioral|CCBT-I Group|Every patient will have a unique password to access to CCBT-I. The program consists of 5 cores: sleep log, day's lesson, activities, relaxation and progress. Each day, the patients fill in sleep logs before getting the day's lesson. Filling sleep log will be reminded daily by the program coach from Sleep Center.
1495200|NCT03005197|Device|Laser Doppler Flowmetry|
2001470|NCT02973321|Drug|Liraglutide|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2001471|NCT02973321|Drug|Metformin|"Pharmaceutical form: tablets
Route of administration: oral"
2001472|NCT02971683|Drug|Abatacept subcutaneous|Specified dose of Abatacept subcutaneous on specified days
2001473|NCT02971683|Drug|Placebo|Placebo of Abatacept subcutaneous
2001474|NCT02969590|Drug|Leuprolide acetate|Administer Lupron to healthy women in order to ovarian supress them
2001475|NCT02969590|Drug|Estrogen and Progesterone Replacement|Replace hormones exogenously to create an artificial cycle
2001476|NCT02969590|Drug|Progestin|Synthetic progestin to assess effects on cervical mucus.
2001477|NCT02967354|Radiation|Positron emission tomography with the tracer [11C]5-hydroxy-tryptophan|Estimation of islet mass by PET using the tracer [11C]5-hydroxy-tryptophan
2001478|NCT02967757|Drug|No treatment given|Patients will be treated according to routine clinical practice at the discretion of the treating physician. The study will gather data over the course of routine treatment for liraglutide 3.0 mg and liraglutide 1.2 mg/1.8 mg treated patients
2001479|NCT02965703|Drug|Aspirin|Given PO
2001480|NCT02965703|Other|Laboratory Biomarker Analysis|Correlative studies
2001481|NCT02965703|Other|Placebo|Given PO
2001482|NCT02965703|Other|Questionnaire Administration|Ancillary studies
2001485|NCT02965573|Biological|ARGX-113|
2001486|NCT02965573|Drug|Placebo|
2001487|NCT02964182|Procedure|Carbon Monoxide (CO) Testing|Carbon monoxide levels measured at Baseline and at Weeks 1, 2, 4, 5, and 8. Participants blow air through a CO-measuring device.
1490299|NCT03041376|Behavioral|Walking intervention|The intervention will be delivered over a six-month period and will consist of: (1) an individualized pedometer-based walking program with weekly step goals, (2) regular visits to the clinic including face-to-face session with the physician, and (3) regular telephone calls with the research nurse in between the face-to-face contacts.
1490300|NCT03041363|Drug|Triheptanoin|Triheptanoin will be administered for 7 days 4 times daily.
1490301|NCT03041350|Other|Smartphone video-assisted ALS(advanced life support)|As an preparation for this study, personnel training in mock advanced life support (ALS) simulation including the smartphone video call methodology was conducted. The smartphones were not separately purchased or produced; commercially available smartphones already owned by the emergency medical service (EMS) personnel and medical directors were used. To facilitate the smartphone video call between the medical director and the EMS personnel and to prevent the caregivers or others nearby from hearing the conversation, Bluetooth earphone sets were used. Data were collected using the cardiopulmonary resuscitation (CPR) recording form uploaded in SNS which consisted of EMS personnel and medical directors, and the quality of CPR was evaluated
1490302|NCT03041337|Diagnostic Test|stress echocardiography|"stress echocardiography will be performed in accordance with the current guidelines on a variable load 45° cycle ergometer with an incremental workload of 25 W every 2 minutes up to the symptom-limited maximal tolerated workload. Echocardiographic measurements will be acquired at baseline, at peak exercise and during recovery of 5 minutes.
The electrocardiogram and blood pressure will be monitored at each workload. Termination criteria and / or positive test criteria for inducible myocardial ischemia will follow the current recommendations"
2001488|NCT02964182|Behavioral|Questionnaires|Participants complete questionnaires about their demographics, physical and emotional health, and smoking behavior at Baseline and at Weeks 1, 2, 4, 5, and 8. These questionnaires should take about 30 minutes to complete.
2001489|NCT02964182|Behavioral|Smartphone Assessments|Using a smartphone, participants answer questions and maintain a daily log every day for up to 75 days. Participants also complete electronic assessments at various points every day for up to 42 days. Participants complete an electronic survey at Weeks 1, 2, 4, 5, and 8.
2001490|NCT02964182|Other|Urine Sample|Urine sample given at Baseline and at Weeks 1, 2, 4, 5, 8, and on or about Day 10 of Phases 1, 2, and 3 to bring to Weeks 5, 8, and 10 study visits.
2001491|NCT02964182|Other|Usual Brand (UB) Cigarettes|Participants smoke their usual brand (UB) during Phase 1 (Baseline; week 1).
2001492|NCT02964182|Other|Very Low Nicotine Content Cigarettes (VLNCC)|Participants smoke VLNCC during Phase 2 (weeks 2-4).
2001493|NCT02964182|Other|VLNCC and e-cigs (VLNCC+ECIG)|During Weeks 5-10, participants smoke only the cigarettes and e-cigarettes provided to them. Participants smoke either low ECIG-Lo 8 mg/ml, or high nicotine content ECIG-Hi 36 mg/ml cigarettes for the first 3 weeks (Phase 3), and then switch to whichever one they had not yet received for the remaining 3 weeks (Phase 4).
1490309|NCT03041298|Procedure|MR mammography with Dotarem|
1490310|NCT03041285|Drug|idronoxil (NOX66) suppository|"Patients in Group 1 will be given 400mg of Idronoxil suppository (NOX66) (1 suppository)daily from Day 14 to Day 26. Group 2 will be given Idronoxil (NOX66) 800mg (2 suppositories) daily from Day 14 to Day 26.
All patients will receive two courses of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 25 Gray in 5 daily fractions on consecutive days for each course.
The first radiotherapy session (WEEK 1) will involve irradiation of Lesion 1 (smallest lesion), 25 Gray in 5 fractions.
The second radiotherapy session will start in week 3. It will involve irradiation to remaining lesions. Patients will receive 25 Gray in 5 fractions."
1490311|NCT03041285|Radiation|Stereotactic Body Radiation Therapy|All patients (Group 1 and Group 2) will receive two courses of Stereotactic Body Radiation Therapy (SBRT), to be delivered in 25 Gray in 5 daily fractions on consecutive days for each course. The first radiotherapy session (week 1) will involve irradiation of lesion 1 (smallest lesion), 25 Gray in 5 fractions. The second radiotherapy session will start in week 3. It will involve irradiation to remaining lesions. Patients will receive 25 Gray in 5 fractions.
1490314|NCT03041246|Procedure|Pelvic floor fascial mobilization|The manual manipulation of the pelvic floor involves intra vaginal superficial as well as pelvic skin area pressure points.
1490316|NCT03041220|Procedure|cesarean section|obese patients (BMI of 30 or greater) who have had a cesarean section
1490317|NCT03041207|Behavioral|Development and implementation of an antibiotic guideline|A consensus conference will develop and then implement a guideline for stopping vs. continuing antibiotics in infants with suspected ventilator-associated infection
1490318|NCT03041194|Other|dietary affects|Dietary affects on urine pH in relation to Interstitial cystitis symptoms
1490319|NCT03041181|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV every 21 days (21 days = 1 cycle)
1490320|NCT03041181|Drug|Nivolumab|Nivolumab 360 mg IV every 21 days (21 days = 1 cycle)
1490321|NCT03041168|Device|Carotid Stenotic Scan|Each subject will have been scheduled for a carotid ultrasound, or other imaging test of the neck (carotids) as ordered by his/her physician for clinical or screening purposes. These studies will be read by a Jefferson radiologist and a report generated for standard clinical purposes. These reports and the images will be collected and de-identified to be used as comparator measurements to the CSS results. The CSS device is shaped like a stethoscope with 3 small gel pads. It is positioned with a gel pad on either side of the neck and one on the front of the chest. The scan takes about 1-2 minutes to provide an image on the screen of the device cart. The scan device pads just lie on the skin and do not use any invasive techniques to provide the image.
1490322|NCT03041155|Behavioral|Muscle respiratory training|Muscle respiratory training during hemodialysis sessions
1490323|NCT03041142|Behavioral|Interdisciplinary intervention|Physical Activity, nutrition and Psychological
1490324|NCT03041142|Other|Routine|The participants continued to maintain their routine
1490325|NCT03041129|Diagnostic Test|oral glucose tolerance test|6 hours OGTT
1490326|NCT03041129|Diagnostic Test|MRI of liver|MRI of the liver and use of DIXON method
1490329|NCT03041103|Other|Food Product 1|50 grams of fortified nutritious product from legumes
1490448|NCT03040167|Procedure|PEC 1 block|Under echoguidance, injection of the substance of interest between the major and minor pectoral muscles.
1490330|NCT03041090|Device|Lucerno ID (identification) System|The Lucerno ID is intended to dynamically measure the uptake of radiotracer in a particular organ or body region during the radiotracer uptake period as part of nuclear medicine (NM) procedures. The Lucerno ID is indicated for use as a tool for trained healthcare professionals (technologists, NM physicians, and radiologists) to help assess whether a radiotracer injection has resulted in an infiltration. The LD ID can be used by healthcare professionals including nuclear medical technologists, nuclear medicine physicians, or any other medical staff in a NM facility, once they have received the necessary training into the use of the system.
1490331|NCT03041077|Dietary Supplement|Instaflex Advanced|Joint function
1490332|NCT03041077|Dietary Supplement|Placebo|Placebo
1490333|NCT03041064|Other|50/100|SPF
1490334|NCT03041064|Other|100/50|SPF
1490335|NCT03041051|Biological|PCV13|
1490336|NCT03041051|Biological|PPV23|
1490337|NCT03041038|Drug|Secukinumab|Anti IL-17A antibody
1490338|NCT03041038|Drug|Placebo|
2001494|NCT02964507|Drug|GSK525762|For Phase I, GSK525762 will be available as 5 mg and 25 mg oral tablets. Subjects will be initially dosed at 60 mg daily (Dose Level 1). Further subjects will be dosed based on the dose limiting toxicity rate, at a higher 'Dose Level 2' (or still higher, based on PK data), same 'Dose Level 1', or lower 'Dose Level 1'.
2001495|NCT02964507|Drug|Placebo|Placebo will match GSK525762 tablets, and will be provided in Phase II only. Dosing will be done until unacceptable toxicity, progression of disease, death, or withdrawal of consent.
1490341|NCT03041012|Drug|Romidepsin|5mg/m2 romidepsin will be administered IV on days 10, 17, and 24 after initiating ART
1490342|NCT03041012|Drug|3BNC117|30 mg/kg 3BNC117 will be administered IV on day 7 and 21 after initiating ART
1490343|NCT03041012|Drug|Antiretrovirals|Combination antiretroviral therapy
1490349|NCT03040986|Other|Laboratory Biomarker Analysis|Correlative studies
1490350|NCT03040986|Drug|Selumetinib Sulfate|Given PO
1490351|NCT03040973|Drug|capmatinib|tablet for oral use 400 mg BID
1490352|NCT03040947|Other|Cardiovascular Magnetic Resonance|
1490353|NCT03040934|Device|Firehawk sirolimus target eluting coronary stent system|98 subjects will be enrolled to receive a test device of Firehawk sirolimus target eluting coronary stent system
1490354|NCT03040934|Device|XIENCE Everolimus-Eluting Coronary Stent System|98 subjects will be enrolled to receive a control device of XIENCE Everolimus-Eluting Coronary Stent System
1490355|NCT03040921|Procedure|Uterine transposition.|Surgical transposition of the uterus to the upper abdomen. After the end of radiotherapy, rectosigmoidectomy is performed and the uterus is repositioned into the pelvis.
1490356|NCT03040895|Other|Group-based ICDP-intervention|Group-based ICDP-intervention for caregivers through a sequence of eight meetings
1490357|NCT03040895|Other|Treatment as usual|Treatment as usual through the data collection period (6 months)
1490358|NCT03040882|Other|cotton sock|Application of a cotton sock in the immediate postoperative period before applied the Walker
1490359|NCT03040882|Other|Elastic Compression Wraps|Application of an Elastic Compression Wraps in the lower limb in the immediate postoperative period before applied the Walker (standard care)
1490360|NCT03040856|Dietary Supplement|Alpha Linolenic Acid|Alpha Linolenic Acid enriched diet
1490361|NCT03040856|Dietary Supplement|Omega 3 enriched diet ( DHA+EPA)|Omega 3 (DHA+EPA) supplementation enriched diet
1490362|NCT03040856|Other|Placebo|Placebo capsules containing olive oil
1490363|NCT03040830|Drug|Progesterone 100 IM/day|Progesterone IM 100 mg /day was started on day of egg retrieval in egg retrieval arm and on day of embryo transfer in the embryo transfer arm
1490364|NCT03040817|Procedure|Gastric peroral endoscopic pyloromyotomy (G-POEM)|"G-POEM procedure:
A. Premixed methylene blue/normal saline were injected into gastric antrum submucosa at greater curvature, 5 cm proximal to the pylorus.
B. Submucosal tunnel was created via endoscopic submucosal dissection. C. A white thick pyloric band, was in contrast to a thin-walled submucosal space of the duodenum observed distally.
D. Pyloromyotomy starts with dissection of the pyloric ring exposing muscular layer underneath.
E. Circular and longitudinal myotomy for 2-3 cm. F. Serosa indicates appropriate depth of myotomy. G. Reevaluation of the mucosotomy site. H. Mucosal entry was closed with clips from distal mucosal incision point."
1490365|NCT03040817|Drug|Esomeprazole + Mosapride|Each participant receive Esomeprazole （Nexium） 40mg bid + Mosapride （Mosapride Citrate Tablets） 5mg tid.
1490366|NCT03040804|Radiation|Low dose Radiotherapy|Subjects in this protocol will only receive radiotherapy directed at one region, typically the region that is most bothersome to the patient. Patients will receive a total radiotherapy dose 7.5 Gy in five daily fractions of 1.5 Gy.
1490367|NCT03040791|Drug|Nivolumab|Nivolumab
1490368|NCT03040778|Drug|Pentoxifylline|Pentoxifylline is a commonly used medication for muscle pain associated with peripheral artery disease. It is a methylated xanthine derivative that improves peripheral blood flow, flexibility of red blood cell membranes, microcirculation, and tissue oxygenation and reduces viscosity of blood.
1490369|NCT03040778|Drug|Placebo|
1490370|NCT03040778|Drug|Tocopherol|Tocopherol (vitamin E) impairs tissue fibrosis and is a potent oxygen radical scavenger that may reduce damage caused by free radicals impacting necrosis.
1490371|NCT03040765|Drug|Denosumab 60 MG/ML Prefilled Syringe|Denosumab 60 MG/ML will be administered to 10 patients with b-thalassemia major
1490372|NCT03040765|Drug|Zoledronic Acid 5Mg/Bag 100Ml Inj|Zoledronic Acid 5Mg/Bag 100Ml Inj will be administered to 10 patients with b-thalassemia major
1490373|NCT03040752|Drug|Nifedipine 20 Mg|nifedipine 20 mg tablets (Epilat Retard®, EIPICO, Egypt) twice daily, starting 12 hours after arrest of threatened preterm labor
1490374|NCT03040752|Drug|Ritodrine Oral Tablet|Ritodrine 5 mg tablets (Yutopar®, PHARCO, Alexandria) every 6 hours, starting 12 hours after arrest of threatened preterm labor
1490375|NCT03040739|Other|use of O'ARM imaging system|use of O'ARM imaging system
1490449|NCT03040167|Drug|Bupivacaine with epinephrine|Treatment group
1490450|NCT03040167|Drug|Normal saline|Placebo group
1490380|NCT03040713|Drug|18F-AV-1451|Subjects will receive single IV administration of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451.
1490381|NCT03040713|Drug|18F-AV-45|Subjects with no qualifying amyloid scan within three years will receive single IV administration of 370 MBq (10 mCi) of 18F-AV-45 prior to enrollment as a screening assessment
1490382|NCT03040700|Other|Myocardial Perfusion Scan|Myocardial perfusion scan will be performed at rest and during pharmacological stress with dipyridamole (99mTc-Sestamibi)
1490383|NCT03040700|Other|Coronary CTA|Coronary CTA will be performed using a 320-detector scanner, 0.5 mm slice thickness, with gantry rotation of 350ms. Prior to each scan, the patient's blood pressure and heart rate will be assessed, and if the heart rate is above 70bpm, beta-blockers will be given orally. Following oral beta blocker administration, if the heart rate is still greater than 64bpm, intravenous metoprolol will be administered. A total of 70-100 mL of iodinated contrast will be administered via an automated injector at a rate of 5mL/s. All coronary CTA images will be transferred to a workstation (Vitrea FX—Vital Image) and analyzed by two experienced cardiac imagers who are blinded to all other data using a standard 18-segment coronary tree model.
1490384|NCT03040687|Biological|Anti CS6 BSIgG product (Lot PD1601105CS)|
1490385|NCT03040687|Biological|Anti B7A BSIgG product (Lot PD1601132ET)|
1490386|NCT03040687|Biological|Bovine Immunoglobin Negative Control (Lot PD161071NC)|
1490387|NCT03040674|Procedure|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day
1490388|NCT03040661|Procedure|Ablation for atrial fibrillation.|Ablation for atrial fibrillation.
1490389|NCT03040648|Device|DSA|DSA was used for detection of intravascular injection
1490390|NCT03040648|Device|RTF|RTF was used for detection of intravascular injection
1490391|NCT03040635|Drug|RO7034067|Single oral doses of RO7034067 will be administered on Day 1.
1490392|NCT03040635|Drug|Placebo|Single oral doses of RO7034067 matching placebo will be administered on Day 1.
1490393|NCT03040622|Device|WATCHMAN Left Atrial Appendage Closure|WATCHMAN Left Atrial Appendage Closure
1490394|NCT03040609|Behavioral|Visual-behavioral Scale at day 1|To perform the classification with the scale by caregiver.
1490395|NCT03040609|Behavioral|Test-retest at the end of 2 weeks|To perform the classification with the scale by orthoptist at the end of 2 weeks
1490396|NCT03040609|Behavioral|Test at 6 months|To perform the classification with the scale by orthoptist at the end 6 months.
1490397|NCT03040596|Drug|Fluticasone propionate|fluticasone inhaler 44mcg/puff, 2 puffs twice a day for 4 weeks
1490398|NCT03040596|Behavioral|Standard voice therapy|Standard voice therapy sessions
1490399|NCT03040583|Other|No intervention|Patients data will be collected during their disease follow-up
1490400|NCT03040570|Procedure|Conservative oxygenation target|Participants allocated to the conservative oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining 88-92% (inclusive).
1490401|NCT03040570|Procedure|Liberal oxygenation target|Participants allocated to the liberal oxygenation target group will receive supplemental oxygen and ventilator settings at the discretion of the treating clinical team with the aim of peripheral oxygen saturations remaining >94%.
1490402|NCT03040557|Device|Flexible footwear|- Arm Flexible footwear: The intervention will be with flexible shoes in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
1490403|NCT03040557|Device|Orthopedic insole|- Arm Orthopedic insole: The intervention will be with orthopedic insole in women with plantar fasciitis (acute and chronic) and will have a duration will be six months, for six hours a day, seven days a week (42 hours / week).
1490404|NCT03040544|Procedure|LTB-Curriculum|The Lübeck Toolbox (LTB) curriculum has a structured training program, in which the laparoscopic basic skills are to be learned in six consecutive exercises. In doing so, the curriculum has precise targets for each of the six exercises based on the abilities of 15 experts of the minimally invasive surgeons demonstrated in the system as a benchmark. The objectives and the learning curves were additionally validated in prospective studies. The LTB curriculum is thus a structured training program with clear objectives that enable the technical learning of laparoscopic basic skills comparable to the expert level.
1490405|NCT03040544|Procedure|Laparoscopic cholecystectomy|Performing Laparoscopic cholecystectomy by physicians in the first year of further education
1490406|NCT03040531|Dietary Supplement|Genistein aglycone|27mg bid in tablets
1490407|NCT03040531|Drug|Alendronate Oral Tablet|70 mg/week in tablets
1490408|NCT03040531|Dietary Supplement|Calcium + vitamin D3 tablet|500mg Calcium + 200 IU Vitamin D3 bid in tablets
1490409|NCT03040518|Behavioral|Narrative SMS|Narrative SMS have been defined as interactive life stories based around a range of characters (varying in age and socio-demographics) which can simulate the processes that make group-based interventions successful: humour, banter, peer support, facts about diet and PA and evidence based BCTs. The narrative form draws on real world learning from the film, television and games industry. When theorised, the narrative enables engagement with characters who convey the message of the intervention, and facilitate the viewer's empathy. Through creating an empathic bond with the character, users pay more attention to and become engaged and immersed within the story. This appears to lead to optimal learning and conceptualisation of the target information.
1490600|NCT03039023|Dietary Supplement|Choline Bitartrate|500mg choline bitartrate tablets
1490410|NCT03040518|Behavioral|Endowment Incentive|All participants will be 'endowed' with an incentive at the start of the trial. It will be placed into a hypothetical personal account which is theirs for a year (no withdrawals). Participants will be able to secure money for verified weight loss at 3, 6, and 12 months.
1490411|NCT03040505|Other|questionnary|Participant's verbalization will be audio recorded and then transcribed by investigators. The investigators will use predefined categories to score the strategies mentioned by participants during the think aloud task.
1490412|NCT03040479|Drug|lasmiditan 200 mg|single dose
2001496|NCT02964507|Drug|Fulvestrant|Fulvestrant will be supplied as a solution for injection in a prefilled syringe, at a strength of 250 milligrams (mg) per 5 milliliters (mL), for slow intramuscular (IM) injection into the buttocks. Two 5 mL injections (total 500 mg of fulvestrant) will be administered, one in each buttock, on Day 1, Day 15, Day 29, and once monthly thereafter.
1490416|NCT03040453|Device|Microwave ablation|
1490417|NCT03040453|Device|Irreversible electroporation|
1490418|NCT03040440|Device|Cylindrical endotracheal tube|Cylindrical endotracheal tube was intubated
1490419|NCT03040440|Device|TaperGaurd endotracheal tube|TaperGaurd endotracheal tube was intubated
1490420|NCT03040427|Drug|F-18 florbetapir|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid).
1490421|NCT03040414|Device|Medtronic 670G hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID) and continuous glucose monitor (CGM).
1490422|NCT03040414|Device|Medtronic 690G hybrid closed loop system|The components of the intervention are the insulin pump with insulin delivery algorithm (PID + Fuzzy Logic) and continuous glucose monitor (CGM).
1490423|NCT03040401|Drug|Cohort 1, Ceplene® and Proleukin®|"Patients in Cohort 1 will be administered only Ceplene® during the first treatment cycles and Ceplene® in combination with Proleukin® during treatment cycles 2-4.
IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
1490424|NCT03040401|Drug|Cohort 2, Ceplene® and Proleukin®|"Patients in Cohort 2 will be administered Ceplene® in combination with Proleukin® during all treatment cycles 1-4.
IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
1490425|NCT03040401|Drug|Cohort 3, Ceplene® and Proleukin®|"Cohort 3 will receive either only Ceplene® during treatment cycles 1-4 or Ceplene® in combination with Proleukin® during treatment cycles 1-4. Treatment will be decided by the study committee based on the safety profile of treatment administered to cohort 1 and 2.
IL-2 will be administered s.c., 1 µg/kg (=16400 IU/kg) body weight twice daily (BID) during treatment periods. Ceplene® will be administered s.c. 0.5 mg BID after IL-2."
1490426|NCT03040375|Behavioral|Peer counselling|
1490427|NCT03040362|Drug|[14C]-lasmiditan|[14C]-lasmiditan as a 200 mg (approximately 100 µCi) oral solution
1490428|NCT03040349|Behavioral|Training|The training program consists of a one-day core session addressing tobacco use with patients in the context of a busy primary care practice setting.The curriculum design was designed to be 2/3 theory and 1/3 practical. The program employs teaching techniques including role-play and case-study approaches known to enhance practice change.
1490429|NCT03040349|Behavioral|Provider and Patient Tools|Provider and patient tools were translated and adapted for use in primary care settings in Greece. A tool kit of resources will be distributed to providers which includes: patient tobacco use survey; provider consult form; provider medication reference sheet; patient quit plan booklet; and, waiting room posters. The provider consult form uses a checklist style set-up and provides real-time reminders for conducting an initial smoking cessation visit and follow-up appointments. The TiTAN Crete tools are available online at www.titan.uoc.gr
1490430|NCT03040349|Behavioral|E-blast and Webinars|In order to develop the network and continue to provide training opportunities for skills development we will develop a communication platform via an email list-serv to proactively communicate with providers who participate in the TiTAN program. A quarterly e-blast will be sent to all health care professionals involved in the TiTAN program. The e-blast will address the latest evidence-base practice, and skill development. Links to videos will also be provided. A webinar series will be scheduled to cover topics identified as interest by the primary health care providers. The webinar series will also be linked the Global Bridges EPACTT project.
1490431|NCT03040336|Behavioral|Prehabilitation|The 6-week long prehabilitation intervention will include (1) strength and balance training; (2) inspiratory muscle training; and (3) nutritional coaching and supplementation.
1490432|NCT03040323|Drug|Lumason 60.7Mg Powder for Injection|Lumason 60.7Mg Powder for Injection injected prior to ultrasound-guided biopsy
1490433|NCT03040323|Drug|Placebos|Placebos injected prior to ultrasound-guided biopsy
1490434|NCT03040310|Other|Back Rx program|The Back Rx program can be viewed via a smartphone app.
1490435|NCT03040297|Device|Tracheal gas insufflation 6 L/min|Endotracheal flow (6 L/min) of respiratory gases with standard FiO2
1490436|NCT03040297|Device|Tracheal gas insufflation 11 L/min|Endotracheal flow (11 L/min) of respiratory gases with standard FiO2
1490437|NCT03040297|Device|Tracheal gas insufflation catheter, without gas flow|Tracheal gas insufflation catheter, without gas flow
1490438|NCT03040284|Device|Echodia® hand-held equipment (ELIOS)|
1490439|NCT03040271|Other|Health-E-PALS-|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
1490440|NCT03040258|Other|Health-E-PALS-Pilot|Intervention to promote Healthy Eating and Physical Activity in Lebanese School-Children It comprises in class-activities, meetings with parents, improvement of school food service
1490441|NCT03040245|Behavioral|Whiplash book|
1490442|NCT03040232|Other|biomechanical assessment|biomechanical and strength assessment of both groups
1490443|NCT03040219|Drug|Folic Acid|Tablets
1490444|NCT03040193|Drug|Lignocaine Nebulization|4% Lignocaine delivered via Nebulization
1490445|NCT03040193|Drug|Saline Nebulization|Normal Saline Delivered via Nebulization
1490446|NCT03040180|Drug|Electrochemotherapy with bleomycin|Systemic injection, once only treatment
1490447|NCT03040180|Device|EndoVE|Electroporation using an endoscopic electroporation device
1490451|NCT03040154|Other|"Video Documentary entitled, Para Sa Kinabukasan ng Mga Anak (For Our Children's Future)"|
1490452|NCT03040154|Other|Usual Care Video that is publicly available|
1490453|NCT03040141|Drug|Low dose of VIS410 in addition to oseltamivir|Single intravenous infusion of fixed low dose of VIS410 in addition to oseltamivir
1490454|NCT03040141|Drug|High dose of VIS410 in addition to oseltamivir|Single intravenous infusion of fixed high dose of VIS410 in addition to oseltamivir
1490455|NCT03040141|Drug|Placebo in addition to oseltamivir|Single intravenous infusion of placebo in addition to oseltamivir
1490456|NCT03040128|Drug|Minocycline|high-dose, intravenous minocycline
1490457|NCT03040128|Other|normal saline infusion|
1490458|NCT03040115|Other|Non-Interventional Study|
1490459|NCT03040102|Other|Hospice Video Educational Tool|it's a 6 minute video regarding hospice care
1490460|NCT03040102|Other|Standard of Care|Standard of Care practice is used
1490461|NCT03040089|Device|PICO+4|picosecond, neodymium-doped yttrium aluminum garnet laser
1490462|NCT03040089|Drug|Neoquine Cream 2%|2% hydroquinone cream
1490463|NCT03040076|Behavioral|Cognitive Bias Treatment|Two computerized tasks will be administered during four intervention sessions. During the first task, the Word Sentence Association Paradigm, participants see a threat or benign word and then an ambiguous sentence. Participants press one if they believe the word and sentence are related and two if they believe the word and sentence are not related. Participants are given feedback that they responded correctly if they state that a benign word is related to the sentence or they state that a threat word is not related to the sentence. The second task is the Ambiguous Scenarios Task. In each trial, an ambiguous scenario, ending in a benign word, appears on the screen. After the scenario is presented, participants respond to a comprehension question and are given feedback on their performance.
1490464|NCT03040076|Behavioral|Relaxation Condition|Participants assigned to the active control group will complete four sessions of progressive muscle relaxation training. Two alternating relaxation scripts will be used. The scripts will be presented as Youtube videos with a blank black screen and will instruct participants to keep their eyes closed for the duration of the training. Participants will access the videos through Qualtrics to ensure that data can be gathered about their compliance. The relaxation scripts used in the present study will be modified versions of those currently being tested by other researchers utilizing cognitive bias modification paradigms. The relaxation training sessions will be matched to the length of the treatment condition and therefore will last approximately 30 minutes.
1490465|NCT03040063|Procedure|Combined endovascular approach (EVAR)|"puncture of SFA in orthograde position if possible
DSA through 4F dilator, proof of occlusion
wire test
Heparin 70-80 IU/kg i.a.
implantation of peripheral stent graft VIABAHN
implantation of peripheral stent SUPERA into stent graft
insertion of strait flush catheter for local thrombolysis
administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTT 1,5-2x) according to the department standards
control angiography in 12 hrs or earlier according to clinical status and symptoms
repeated angiography in 24 hrs"
1490466|NCT03040063|Procedure|Standard optimal therapy (OPT)|"puncture of SFA in orthograde position if possible
DSA through 4F dilator, proof of occlusion
wire test
Unfractionated heparin 70-80 IU/kg i.a.
insertion of strait flush catheter for local thrombolysis
administration of continuous local thrombolysis in the dose of 1 mg/hr., unfractionated heparin continuously (APTTT 1,5-2x)
control angiography in 12 hrs or according to clinical status and symptoms
repeated angiography in24 hrs
Final result review, vascular team consultation and indication for surgical or conservative management of popliteal artery aneurysm."
1490467|NCT03040050|Other|rPCR results|Interventional group: rPCR results will be shared with the clinical provider to determine appropriate standard of care antibiotic treatment at time of standard of care prostate biopsy.
1490468|NCT03040050|Other|Control group|Control group: rPCR results will not be shared with the clinical provider at time of standard of care prostate biopsy. Standard of care antibiotic selection will be up to the discretion of the clinical provider.
1490469|NCT03040024|Drug|Ketamine|Ketamine will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
1490470|NCT03040024|Drug|Placebo|Placebo will be administered intravenously after administration of general anesthesia and prior to the first surgical incision.
1490471|NCT03040024|Device|Electroencephalogram (EEG)|A processed EEG device will be used during the surgical procedure to gather raw EEG data for off line analysis among patients developing post-operative delirium.
1490472|NCT03040011|Drug|Dexamethasone|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
1490473|NCT03040011|Drug|Bupivacaine|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
1490474|NCT03040011|Procedure|Bilateral Pudendal Nerve Block|Performed transvaginally. The ischial spines will be palpated transvaginally and the sacrospinous ligament identified as a firm band running medially and posteriorly from the ischial spine to the sacrum. The needle guide will be inserted and positioned against the vaginal mucosa on the sacrospinous ligament approximately 1 cm medial and inferior to the ischial spine. When the needle guide is properly positioned, the spinal needle is advanced approximately 1cm through the vaginal mucosa into the sacrospinous ligament. The needle will be aspirated to ensure no intravascular needle placement. With a negative aspirate, 5 milliliters of solution are injected. This same procedure will be performed on the contralateral side.
1490475|NCT03040011|Procedure|Bilateral Levator Ani Muscle Injection|Performed transperineally. With thumb, superomedial aspect of obturator foramen is palpated 2-3 cm lateral to the clitoris. The index and middle finger are in the vagina to confirm obturator foramen. A spinal needle is inserted through the the obturator foramen into the obturator internus muscle. The needle is angled slightly posteriorly towards the ischial spine, parallel to the arcus tendineus levator ani and arcus tendineus fascia pelvis. The needle is advanced to the level of the ischial spine, the vaginal hand ensuring that the needle has not perforated the vaginal wall. Once the needle tip is at a depth of the ischial spine, aspiration is performed to ensure no intravascular needle placement. 5 milliliters of solution is injected along the length of the needle tract.
1490476|NCT03040011|Drug|Saline|Pudendal Nerve and Levator Muscle Injection. See additional information in study arm description.
1490477|NCT03039985|Device|Zirconia crowns (Prettau®)|Monolithic zirconia molar crowns are, after randomization, placed in patients with or without bruxism
1490478|NCT03039985|Device|lithium disilicate crowns (IPSe.max®)|lithium disilicate molar crowns are, after randomization, placed in patients with or without bruxism
1490479|NCT03039972|Diagnostic Test|No intervention|No intervention
1490480|NCT03039959|Diagnostic Test|No intervention|No intervention
1490481|NCT03039946|Device|Closed-Loop GDFT|Patients receive fluids in the form of 100ml boluses of crystalloid (Plasmalyte) over 6 minutes via an automated closed-loop goal-directed fluid therapy (GDFT) system guided by non-invasive flow monitoring (Clearsight system). Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
1490482|NCT03039946|Other|Restrictive Fluid Therapy|Patients receive fluids (Plasmalyte) via a restrictive approach with a baseline of of 4ml/kg/h. Additional boluses of colloid or crystalloid can be administered under the attending anesthesiologist's discretion (e.g. to compensate blood loss) .
1490483|NCT03039933|Behavioral|Fear of Hypoglycemia|Participants will receive exposure and response prevention and/or hypoglycemia awareness training.
1490484|NCT03039933|Other|Treatment As Usual|Treatment As Usual
1490485|NCT03039920|Device|Electronic cigarette|
1490486|NCT03039920|Other|Conventional cigarette|
1490487|NCT03039907|Procedure|Total Knee Arthroplasty|Total knee arthroplasty
1490489|NCT03039881|Device|Non-Invasive Respiratory Volume Monitor|The device requires the application of a monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.
2001497|NCT02963909|Biological|IXIARO|An inactivated vaccine indicated for active immunization for the prevention of disease caused by Japanese encephalitis virus (JEV).
1490491|NCT03039842|Drug|Dextromethorphan|
1490492|NCT03039842|Drug|Memantine|
1490493|NCT03039842|Drug|dextromethorphan+memantine|
1490494|NCT03039842|Drug|placebo+valproate|
1490495|NCT03039829|Dietary Supplement|Creatine nitrate, low dose|Creatine nitrate at 3.0 grams (2.0 grams creatine, 1.0 gram nitrate, 3.0 grams dextrose)
1490496|NCT03039829|Dietary Supplement|Creatine nitrate, high dose|Creatine nitrate at 6.0 grams (4.0 grams creatine, 2.0 grams nitrate)
1490497|NCT03039829|Dietary Supplement|Placebo|Placebo at 6.0 grams (6.0 grams dextrose)
1490498|NCT03039816|Device|Nasaleze|Nasaleze cellulose powder
1490499|NCT03039816|Device|Placebo|Lactose powder in the same plastic container as Nasaleze and with the same taste
1490500|NCT03039803|Procedure|uterine closure during cesarean section|
1490501|NCT03039790|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide and with or without monophosphoryl lipid A (MPL), for intramuscular (IM) injection. Vaccine formulations according to the parent trials: NOR-107,210,204 and 222.
1490502|NCT03039764|Device|Rapael|This group will receive virtual reality-based rehabilitation intervention wearing Rapael glove made by Neofect supplemented with standard occupational services per conventional protocols.
1490503|NCT03039751|Drug|AdvVEGF-D|AdvVEGF-D will be injected into 10 sites of the myocardium
1490504|NCT03039751|Drug|Control Rx|Placebo (buffer solution without gene) will be injected into 10 sites of the myocardium
1490505|NCT03039738|Device|Vital Sync IM & VPMP (Surveillance Monitoring)|The Vital Sync™ Informatics Manager (IM) & Virtual Patient Monitoring Platform (VPMP) is an electronic medical record connectivity and remote continuous patient monitoring software solution.
1490506|NCT03039738|Device|Telemetry Monitoring|Continuous ECG monitoring for hospitalized patients at-risk for cardiac events.
1490507|NCT03039725|Other|Observational|Retrospective chart review on vaccine compliance
1490508|NCT03039699|Drug|Ergoferon|
1490509|NCT03039699|Drug|Placebo|
2001498|NCT02963909|Other|Placebo|0.9% Sodium Chloride 5 mcg
1490512|NCT03039673|Drug|Riluzole|"All patients will be treated with Riluzole for a period of three months prior to final inclusion and randomization. Riluzole treatment will continue throughout the 18 months of follow-up planned for in this protocol.
Riluzole treatment is part of routine care for patients with ALS."
1490513|NCT03039673|Drug|IL-2|"The dose of IL-2 to be used in this study will be 2.0 million IU/day.
Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period.
In case of intolerance, a flexible dose-reduction schedule is available."
1490514|NCT03039673|Drug|5% glucose water solution|"The placebo consists of 5% glucose water solution, which is the matrix with which low-dose IL-2 injections are prepared in the experimental arm. Placebo injections are prepared in exactly the same manner as IL-2 injections, just without the IL-2.
Each treatment course will last 5 days (i.e. 1 sub-cutaneous injection per day for 5 consecutive days). The 5-day course will be repeated every 4-weeks over an 18-month treatment period."
1490515|NCT03039660|Behavioral|RefreshMD|Online Sleep Improvement Course
1490516|NCT03039660|Behavioral|Bond Between Us|Online Educational Course
1490517|NCT03039621|Drug|Ergoferon|
1490518|NCT03039621|Drug|Placebo|
1490519|NCT03039608|Drug|combination of local steroid injection（triamcinolone ）with oral steroid administration（prednisone）|local steroid injection and oral steroid
1490520|NCT03039608|Drug|oral steroid administration（prednisone）|oral steroid
1490521|NCT03039595|Other|Ploidy and tumour:stromal ratio measurements|Ploidy and tumour:stromal ratio measurements will be made on specimens of early rectal cancer removed by transanal endoscopic microsurgery (TEM)
1490522|NCT03039582|Diagnostic Test|Bidigital palpation|palpation of the anovaginal distance with two fingers
1490523|NCT03039582|Diagnostic Test|Perineal ultrasound|ultrasound measurement of the anovaginal distance
1490599|NCT03039036|Drug|Misoprostol|Misoprostol is a medication that is commonly used for cervical ripening during labor induction. It is commonly used independently or in combination with mechanical methods, such as a foley catheter. The commonly used dose during term labor induction is 25 mcg. Use of this medication will be decided by the provider.
2001499|NCT02963909|Biological|YF Vax 17D Strain|A stabilised Yellow Fever Vaccine (Live) that is an injectable suspension of the attenuated 17D strain of yellow fever virus. The vaccine is injected by the subcutaneous route.
1490525|NCT03039556|Behavioral|Normal Daily Steps|Complete normal daily ambulation for one week
1490526|NCT03039556|Behavioral|Step-Reduction|Reduce daily ambulation to fewer than 1000 steps per day for two weeks
1490527|NCT03039556|Behavioral|Return to Normal Daily Steps|Increase daily ambulation to 100% of normal daily step-count for two weeks
1490528|NCT03039543|Drug|Rocuronium|Intravenous rocuronium was used to maintain moderate (TOF count of 1 or 2) neuromuscular blockade for patients with moderate neuromuscular blockade whereas intravenous rocuronium was used to maintain deep (TOF count of 0 with post-tetanic count of 2) neuromuscular blockade for patients with deep neuromuscular blockade.
1490529|NCT03039543|Drug|Sugammadex|Patients in moderate neuromuscular blockade are reversed with 2 mg/kg sugammadex at a TOF count of 1 or 2 and patients in the deep neuromuscular blockade are reversed with 4 mg/kg sugammadex at post-tetanic count of 2.
1490530|NCT03039530|Behavioral|Group Cognitive Behavioral Therapy|9 weekly 2-hour group CBT sessions delivered by 2 trained Public Health Nurses.
1490531|NCT03039530|Behavioral|Postnatal Care As Usual|Postnatal care as usual will involve treatment from their family physician and midwife or obstetrician, and voluntary participation in programs offered by Niagara Region Public Health and in the community.
1490532|NCT03039517|Device|ACTitouch|The device is applied to the lower leg (calf, ankle, and foot) and consists of an under-sock worn against the skin, a compression sleeve containing 4 inflatable chambers and a controller unit. The controller provides the airflow to inflate the chambers and monitors and adjusts the chamber pressure to maintain the intended treatment pressures.
1490533|NCT03039517|Device|Compression garments (stockings)|"Compression garments (stockings) now serve as the generally recommended standard of care for patients post DVT and will be utilized as the control compression method in this study. Compression garments utilized in this study will be below the knee style with a pressure range of 30-40 mmHg. If a patient does not have compression garments as indicated, these stockings will be provided."
1490534|NCT03039504|Dietary Supplement|Potensa, a succinate-based dietary supplement|Potensa - a dietary supplement: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
1490535|NCT03039504|Dietary Supplement|Placebo|Placebo: 4 capsules (2 white 200mg each and 2 blue 200 mg each) once a day with a meal or immediately after a meal, preferably after breakfast, for 3 months.
1490536|NCT03039491|Biological|Pneumococcal polysaccharide vaccine 23 valent|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 23 serotypes of Streptococcus pneumoniae
1490537|NCT03039491|Biological|13 valent conjugated pneumococcal vaccine|This is the pneumococcal vaccine consisting of the capsular polysaccharides of 13 serotypes of Streptococcus pneumoniae conjugated to non-toxic diphtheria carrier protein 197
1490538|NCT03039478|Dietary Supplement|Xylitol 7g|Xylitol 7g in 300mL tap water
1490539|NCT03039478|Dietary Supplement|Erythritol 10g|Erythritol 10g in 300mL tap water
1490540|NCT03039478|Dietary Supplement|Xylitol 17g|Xylitol 17g in 300mL tap water
1490541|NCT03039478|Dietary Supplement|Xylitol 35g|Xylitol 35g in 300mL tap water
1490542|NCT03039478|Dietary Supplement|Erythritol 25g|Erythritol 25g in 300mL tap water
1490543|NCT03039478|Dietary Supplement|Erythritol 50g|Erythritol 50g in 300mL tap water
1490544|NCT03039465|Device|Modified Trans-Esophageal Prosthesis|This device is a biomedical grade silicon voice prosthesis with an inner esophageal flange, a stem and an outer tracheal flange. Insertion would be done through a modified 'romovac' inserter set / curved metal inserter (provided with the TEP) and an oesophagoscope in case of secondary insertion would be used. in patients with existing TEP puncture / who require a TEP change, on out-patient basis, the insertion would be done with a novel two-part inserter device (front loading)
1490546|NCT03039439|Other|Biomarker Study|"Each tissue sample will be tested for the following immunohistochemical biomarkers:
Expression Retinoblastoma
PGP 9.5
Parafibromin
Ki67
E-Cadherin
Galectin-3"
2001500|NCT02963909|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
2001501|NCT02962609|Behavioral|Feeding Position|Semielevated side-lying position (ESL): Experimental Group Semielevated supine position (ESU): Control Group
1490549|NCT03039413|Drug|Copper Cu 64 TP3805|Given IV
1490550|NCT03039413|Procedure|Positron Emission Tomography|Undergo Cu-64-TP3805 Positron Emission Tomography scan
1490551|NCT03039413|Procedure|Computed Tomography|Undergo Cu-64-TP3805 Computed Tomography scan
1490552|NCT03039400|Behavioral|Physiotherapist-guided home exercise with web-based support|
1490553|NCT03039400|Behavioral|Physiotherapist-guided home exercise with standard support|
1490554|NCT03039387|Device|anodal transcranial direct current stimulation|
1490555|NCT03039387|Device|transcranial direct current stimulation (sham)|for the placebo control condition, the transcranial direct current stimulation will only last for 30 seconds and will then be ramped down.
1490556|NCT03039374|Other|Magnetic resonance imaging|The extent of obstetric anal sphincter injury will be evaluated using MRI, endoanal ultrasound and anal manometry
1490557|NCT03039361|Behavioral|Equine Assisted Psychotherapy|Therapist will use Equine Assisted Growth and Learning Association (EAGALA) modeled Equine Assisted Psychotherapy.
1490558|NCT03039348|Other|semi-structured interview using a questionnaire|semi-structured interview using a questionnaire
1490559|NCT03039322|Diagnostic Test|Serum Golgi Protein 73|Serum test
1490560|NCT03039309|Procedure|Endoscopic Submucosal Dissection|Endoscopic submucosal dissection is an endoscopic resection technique that utilises an endoscopic knife to remove lesions within the gastrointestinal tract in an en bloc fashion.
1490561|NCT03039296|Procedure|Endoscopic rhizotomy|Endoscopic rhizotomy (facet joint denervation) is carried out through the insertion of an endoscope to the medial spinal nerve area with the help of mobile C-arm x-ray guidance. The tissue surrounding the medial nerves is endoscopically visualized and dissected with a sterile grasper to expose the nerve structure. Finally, a radiofrequency probe is used to ablate the problematic medial branch nerve under direct endoscopic control. The procedure is concluded with the removal of the endoscope and the small incision is closed with 1-2 skin sutures.
1490562|NCT03039283|Device|Nucleus CI532 cochlear implant|Retrospective study of the commercial CI532 cochlear implant
1490563|NCT03039270|Other|With sonic activation (SMART Device®)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM, SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the sonic activation side, immediately after the gel's application, sonic activation(Smart Sonic Device, FGM, SC, Brazil) was performed for 1.5 minutes in total for side (30 seconds per tooth). After the time of 30 seconds in each of the three anterior teeth of the respective side, the gel was removed from teeth with cotton. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
1490564|NCT03039270|Other|Control (Without sonic activation)|The operator applied a desensitizing gel containing 5% potassium nitrate and 2% sodium fluoride (Desensibilize KF 2%, FGM,SC, Brazil) on the vestibular surfaces of the participant's anterior teeth. In the side allocated for application without sonic activation, gel was kept for 10 minutes, after which it was removed from the teeth. After removal of the desensitizing gel, gingival tissues were isolated and the bleaching gel were applied.
1490565|NCT03039257|Dietary Supplement|Vitamin A|Dose administration will start with 2500 IU/kg with maximum dose of 250,000 IU orally.
2001502|NCT02961894|Device|Revolution™ Peripheral Atherectomy System|The Rex Medical Revolution™ Peripheral Atherectomy System is a minimally invasive catheter-based atherectomy system used to treat patients who suffer from PAD. This system is designed to treat a broad range of plaque types both above and below the knee and may address many of the limitations associated with existing treatment options.
2001503|NCT02961751|Drug|Ciprofloxacin|Ciprofloxacin is a broad-spectrum antimicrobial carboxyfluoroquinoline.
2001504|NCT02958085|Drug|NNC0174-0833|Doses of NNC0174-0833, dosed either once daily or once weekly
1490569|NCT03039231|Device|Freespira Breathing System|Following authorization from a study team member, patient will be assigned an FBS to take home and perform 4 weeks of training exercises twice a day for 17 minutes each time. Efficacy of the FBS system will be evaluate over the 4 week period and at 2 and 6 month follow-up periods.
1490570|NCT03039218|Device|Dornier Aries 2|Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
1490571|NCT03039218|Device|Placebo / Sham|Inactive (placebo/sham) Extracorporeal Shock Wave Device for treatment of mild erectile dysfunction
2001505|NCT02958085|Drug|Placebo|Dosed either once daily or once weekly
2001506|NCT02956980|Biological|Blood Plasmacytoid dendritic cells (pDCs) absolute number|Two 7 ml tubes will be necessary to perform the functional assays as well as the quantification of blood pDCs absolute number. Functional assays will be performed on isolated PBMC by Ficoll procedure. Quantification of blood pDCs absolute number will be performed on whole blood. After written parental consent, blood sample will be performed on children participating to the study.
2001507|NCT02957162|Drug|Atorvastatin|
2001508|NCT02957162|Other|Blood samples|3-5 mls of blood is taken at baseline and 3 subsequent timepoints and processed for Endothelial Progenitor Count (EPC).
1490576|NCT03039179|Device|polyurethane foam dress|Application of the polyurethane foam dress at the heel in the immediate postoperative period before applied the Walker
1490577|NCT03039166|Device|MRI 7T|
1490578|NCT03039166|Device|MRI 3 T|
1490579|NCT03039166|Biological|blood sample|
1490580|NCT03039140|Other|Educational Intervention|Attend weekly educational sessions
1490581|NCT03039140|Behavioral|Exercise Intervention|Participate in CR program
1490582|NCT03039140|Other|Quality-of-Life Assessment|Ancillary studies
1490583|NCT03039140|Other|Questionnaire Administration|Ancillary studies
1490584|NCT03039127|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
1490585|NCT03039114|Drug|INCB050465|INCB050465 at the protocol-defined starting dose administered once daily for 8 weeks followed by once weekly.
1490586|NCT03039114|Drug|Hexal|Bendamustine 90 mg/m^2 administered intravenously at protocol-defined timepoints.
1490587|NCT03039114|Drug|Gazyvaro|Obinutuzumab 1000 mg by intravenous infusion at protocol-defined timepoints.
1490588|NCT03039101|Procedure|Nasal lavage|determine frequency of CD49d expressing neutrophils in the nasal lavage by flow cytometry
1490589|NCT03039101|Procedure|Nasal allergen challenge|A small amount of allergen extract will be applied to one naris.
1490590|NCT03039101|Procedure|Epicutaneous skin testing|Skin testing (prick) to determine allergies.
1490591|NCT03039101|Procedure|Peripheral blood|Peripheral blood draw
1490592|NCT03039101|Drug|Montelukast 10Mg Tablet|one pill orally, daily, for 1 week
1490593|NCT03039101|Drug|Placebo Oral Tablet|one pill orally, daily, for 1 week
1490594|NCT03039088|Other|Follow-up after 12 weeks after TNF alpha blockers initiation|
1490595|NCT03039075|Drug|Metformin SR Tablet|Metformin SR Tablet made in Conquer pharmaceutical co., LTD
1490596|NCT03039049|Drug|Triptorelin 0.1 mg|a single dose of Triptorelin 0.1 mg subcutaneously administered 6 days after oocyte retrieval.
1490597|NCT03039036|Procedure|Amniotomy|Artificially rupturing membranes
1490598|NCT03039036|Device|Foley Catheter|Foley catheter device is commonly used for cervical ripening during labor induction. It is used independently or in combination with pharmacologic augmentation. It is inserted in the cervix and the balloon is then inflated with 60 cc of saline. It is removed when either 1. it falls out under gentile traction during labor checks or 2. it is de-inflated at 12 hours after placement. If at the time of de-inflation at 12 hours, the desired affect has not been achieved, the provider may choose to place another foley balloon or use an alternative method of induction (misoprostol). This is an eligibility criteria and only patients who are undergoing induction with a Foley Catheter will be approached for enrollment.
1490601|NCT03039023|Other|Pre-cooked, pre-peeled whole hardboiled eggs|Obtained from a commercial source.
1490602|NCT03039023|Other|Egg whites from pre-cooked, pre-peeled hardboiled eggs|Egg whites from pre-cooked, pre-peeled hardboiled eggs. The yolks are removed and discarded.
1490603|NCT03038984|Behavioral|At Home Screening procedure On demand|Home monitoring is a supportive treatment. Patients are randomized to screen themselves on demand
1490604|NCT03038984|Behavioral|At Home Screening procedure every 3 months|Home monitoring is a supportive treatment. Patients are randomized to screen themselves every 3 months
1490605|NCT03038971|Biological|Dose Level 1|Short and Tall Ragweed Mix
1490606|NCT03038971|Biological|Dose Level 2|Short and Tall Ragweed Mix
1490607|NCT03038971|Biological|Placebo|Saline with 0.4% Phenol
1490608|NCT03038958|Drug|Isobaric 2-chloroprocaine|intrathecal injection of 50 mg isobaric 2-Chloroprocaine
1490609|NCT03038958|Drug|Hyperbaric prilocaine|intrathecal injection of 50 mg hyperbaric prilocaine 2%
1490610|NCT03038945|Other|2/0 barbed suture|Close vaginal vault 2 planes with 2/0 barbed suture in patients with total laparoscopic hysterectomy in benign pathology
1490611|NCT03038945|Other|0/0 Vicryl suture|Close vaginal vault 2 planes with 0/0 Vicryl suture in patients with total laparoscopic hysterectomy in benign pathology
1490612|NCT03038919|Drug|Testosterone cypionate|Bi-weekly intramuscular injection of testosterone cypionate 200mg.
1490613|NCT03038919|Other|Standard nutrition and physical therapy at ICU|follow-up of the patient without use of testosterone cypionate
1490614|NCT03038893|Diagnostic Test|Point Of Care Ultrasound (PODUS)|Patients were first submitted to Point Of Care Ultrasound (POCUS) and then to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
1490615|NCT03038893|Diagnostic Test|Echo Doppler Ultrasound (EDUS)|Patients were submitted only to Echo Doppler Ultrasound (EDUS) for the diagnosis of DVT.
1490616|NCT03038880|Drug|RO6867461|RO6867461 will be administered via IVT injections as specified during the treatment period.
1490617|NCT03038880|Drug|Ranibizumab|Ranibizumab will be administered via IVT injections as specified during the treatment period.
1490618|NCT03038867|Drug|Duloxetine|Duloxetine orally 60mg daily for 5 weeks, then taper to 30mg daily for 1 week
1490619|NCT03038867|Other|Placebo|Placebo orally 2 tabs daily for 5 weeks, then taper to 1 tab daily for 1 week
1490620|NCT03038854|Other|Test GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
1490621|NCT03038854|Other|Standard GUM|Growing up milks (GUMs) are milk-based drinks with vitamins and minerals for toddlers and pre-school children.
1490622|NCT03038854|Other|Cows' milk|Homogenized store-bought full fat cow's milk.
1490623|NCT03038841|Device|Mobile Health|Patients discharged from hospital will be equipped with a tracking bracelet and a smart phone
1490624|NCT03038828|Biological|Leukocyte Interleukin, Injection|Immunotherapy
1490625|NCT03038815|Device|VACOped|restriction of ankle joint motion
1490626|NCT03038815|Device|Ortho Tri-Phase|restriction of ankle joint motion
1490627|NCT03038802|Biological|Therapeutic hepatitis B vaccine|HBV vaccine based on unique combination of recombinant PreS hepatitis B surface antigen particles formulated with Advax-2 adjuvant
1490628|NCT03038802|Biological|Commercial Hepatitis B vaccine|Commercially available prophylactic hepatitis B vaccine formulated with alum adjuvant
1490629|NCT03038776|Biological|Recombinant influenza hemagglutinin|Avian H7N9 influenza vaccine
1490630|NCT03038763|Other|Eligibility Screening|Investigators will call eligible mothers to screen for the possibility that eligible mothers may have passed HCV on to adult children. Investigators will consent these mothers to contact the adult child(ren), as the child(ren) must be informed of the mother's HCV status, if not already known.
1490631|NCT03038763|Diagnostic Test|HCV test|Adult children will be invited to Penn or a Penn affiliate to have labwork, testing HCV antibody and HCV quant. If the quant comes back positive, investigators will also test genotype and fibrosure.
1490632|NCT03038750|Other|Eligibility and lifestyle restrictions check.|Eligibility will be assessed at each study visit and participants will be informed in advance of their visit.
1490633|NCT03038750|Other|Medical history, demographic and lifestyle factors|Medical History, participants demographics and lifestyle factors will be assessed by the participant completion of the medical history and ethnicity questionnaires.
1490634|NCT03038750|Other|Anthropometric measurements: height, weight, and body fat|Height measured by stadiometer. Weight and body fat measured by Tanita scale bioelectrical impedance analysis.
1490635|NCT03038750|Other|Blood pressure and heart rate|Parameters will be measured using a validated, automated device while seated and again after 3-5 min standing. All measurements will be done in triplicate.
1490636|NCT03038750|Other|Forearm blood flow: Visit 1 (EDNRA)|Intra-arterial infusion of Phenylephrine at doses of 0.75, 2.5, and 7.5 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 30 minute washout with saline followed by Endothelin-1 infusion of at a dose of 5 pmol/min for 90 min.
1490637|NCT03038750|Other|Forearm blood flow: Visit 2 (EDNRA)|Intra-arterial infusion of Sodium nitroprusside infusion at doses of 1, 3, and 10 μg/min for 6 min each (18 min in total). FBF measured in the last 3 minutes. There will be a 20 minute washout with saline followed by infusion of BQ-123 at a dose of 10 nmol/min for 90 min.
1490638|NCT03038750|Other|Blood biochemistry (PNPLA3)|25ml blood will be taken from the participant in a glucose fasting state. Following a high carbohydrate meal, a second 25ml blood sample will be taken. Clinical Biochemistry tests and detailed lipid analysis will be performed.
1490639|NCT03038750|Other|Blood EPCR function (PROCR)|Blood sample taken will be analysed via ELISA and FACS.
1490640|NCT03038750|Other|Blood platelet coagulation and function (PROCR)|Blood sample taken will be analysed using a Platelet coagulation and function assay.
1490641|NCT03038750|Other|Blood endothelial permeability (PROCR)|Blood sample will be analysed in vitro using a permeability assay kit.
1490642|NCT03038750|Other|Blood leukocyte-endothelium adhesion (PROCR)|Blood sample will be analysed in vitro using a leukocyte-endothelium adhesion assay.
1490643|NCT03038750|Other|Baseline Venepuncture (PNPLA3, Visit 1)|Up to 25ml Blood will be taken.
1490644|NCT03038750|Other|Deuterium water - Loading dose 1 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
1490825|NCT03037359|Biological|Other|Human immune globulin
1490645|NCT03038750|Other|Deuterium water - Loading dose 2 (PNPLA3, Visit 1)|Loading dose of 3 g/kg body water.
1490646|NCT03038750|Other|Energy-balanced dinner (PNPLA3, Visit 1)|Provided following baseline bloods and loading dose 1.
1490647|NCT03038750|Other|Fasting venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
1490648|NCT03038750|Other|Deuterium water - Maintenance dose (PNPLA3, Visit 2)|every hour, maintenance dose 0.04 g/kg body water
1490649|NCT03038750|Other|Consumption of high carbohydrate meal (PNPLA3, Visit 2)|Provided following fasting blood sample.
1490650|NCT03038750|Other|Postprandial Venepuncture (PNPLA3, Visit 2)|Up to 25ml Blood will be taken.
1490651|NCT03038750|Other|Venepuncture (PROCR)|Up to 50ml Blood will be taken.
1490652|NCT03038737|Other|bre.flex|"In the recent time thermoplastic materials become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus(3).
The major disadvantage of a nylon RDP is the inability for a reline procedure and the lack of occlusal rests as well as rigid frameworks, that could lead to occlusal instability and sinking, especially in Kennedy class I and II cases. On the other hand, acetal resins present adequate mechanical strength to form a frame-work more rigid than nylon with retentive clasps, connectors, and supportive elements; however, the acetal resin material lacks natural translucency and vitality."
1490653|NCT03038737|Other|PEEK|PEEK has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth.Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
1490654|NCT03038724|Diagnostic Test|Rapid HIV test|
1490655|NCT03038711|Drug|BMS-986166|Specified dose on specified days
1490656|NCT03038711|Other|Placebo matching BMS-986166|Specified dose on specified days
1490657|NCT03038685|Behavioral|Strokecoach.be - digital coaching program for stroke patients|The stroke coach gives patients two education sessions during hospitalization (risk factor management, review of medications and clinical evolution). During these sessions, study participation will be proposed. Eligibility will partially depend on their historical use of the internet and e-mail. The aim is to have the digital platform personalized for his/her individual needs, risk factors and remaining neurologic signs/symptoms. Tips and tricks to deal with lifestyle modification will be delivered on regular basis. Meanwhile, patients will be asked to complete on a pre-specified frequency their data regarding their cardiovascular risk profile. Additionally, participants will be contacted at 0.5-1-2 and 6 months by phone calls or videoconsultancy. To standardize, an adapted, digital version of the standardized WSO Post-Stroke Checklist shall be used as a decision-support flowchart. A report of the consultation will be derived after the videoconsultancy.
1490661|NCT03038659|Device|Penile Duplex|Measuring intima media thickness
1490662|NCT03038646|Drug|MIN-101|
1490663|NCT03038633|Other|Novel Medical Food|This medical food takes advantage of the stability and high level of solubility of the human H-ferritin protein to be absorbed by the body as an iron source; indeed H-ferritin is enriched in breast milk as the mechanism for transferring iron from mother to infants. Once the ferritin has been absorbed from the gut, uptake into each organ is regulated by a specific extracellular receptor pathway to deliver iron in the body's preferred bioavailable form.
1490664|NCT03038620|Drug|Liraglutide|Liraglutide is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the liraglutide dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
1490665|NCT03038620|Drug|Placebo|Placebo is administered once daily by subcutaneous injections with the pen-injector, either in the abdomen, thigh or upper arm. Injections can be done at any time of day irrespective of meals. Subjects will be instructed to escalate the placebo dose to 3.0 mg/day over a 4 week period following an initial dose of 0.6 mg/day and weekly dose escalation steps of 0.6 mg/day.
1490666|NCT03038607|Drug|Aspirin|This group were subjected to aspirin 75 mg once daily for 6 weeks.
1490667|NCT03038594|Drug|Somatropin|
1490668|NCT03038594|Drug|0.09% Saline Solution|
1490669|NCT03038568|Diagnostic Test|CT scan|Patients with colorectal liver metastases scheduled for abdominopelvic CECT will be consented to undergo an additional CT of their abdomen (termed add-on CT) within 15 seconds, before or after, their clinical portal venous phase CT (PV CT), which is performed at a fixed delay of 80 seconds at our institution.
1490670|NCT03038542|Behavioral|Gain-framed text messages|
1490671|NCT03038542|Behavioral|Standard care text messages|
1490672|NCT03038529|Procedure|Classic postrolateral extraarticular percutaneous approach for O3 injection|Receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through the classic postrolateral extraarticular percutaneous approach
1490673|NCT03038529|Procedure|Postrolateral transforaminal approach (Yess approach ) for O3 injection|Group B receive 10 ml of ozone oxygen mixture 30 ug O3/ml O2 through postrolateral transforaminal approach (Yess approach ).
1490674|NCT03038516|Drug|Cholecalciferol|To test the hypothesis that vitamin D treatment during 12 weeks to palliative cancer patients is superior to placebo in decreasing opioid consumption, fatigue and infectious burden and increase quality of life.
1490675|NCT03038516|Device|Placebo|To test the hypothesis that placebo is inferior to vitamin D treatment during 12 weeks to palliative cancer patients in decreasing opioid consumption,
1490676|NCT03038503|Drug|Methylene Blue|after defined refractory shock (need NE>0.5 mcg/kg/min) add Methylene blue 1 mg/kg iv drip then 2 hr later drip 0.5 mg/kg/hr*4 hr (intervention add on to standard care)
1490677|NCT03038503|Drug|Terlipressin|after defined refractory shock (need NE>0.5 mcg/kg/min) add terlipressin 1 mg IV then repeated dose 20 min later if unstable BP (intervention add on to standard care)
1490678|NCT03038490|Dietary Supplement|ABOUND|an oral mixture of arginine, glutamine and beta-hydroxy-beta-methylbutyrate
1490680|NCT03038464|Diagnostic Test|Synovial biopsy|Biopsy of jint prior reimplantation of new joint prosthesis
1490681|NCT03038451|Drug|S-NOR (s-amlodipine) 2,5 mg & 5 mg tablet|
1490682|NCT03038425|Drug|Normal Saline|This is the placebo intervention - normal saline infused in the adductor canal via a catheter. There are no anticipated therapeutic effect
1490683|NCT03038425|Drug|Ropivacaine|This is the treatment intervention - ropivacaine 0.2% infused in the adductor canal via a catheter. This will provide analgesia to the knee after TKA
1490684|NCT03038399|Drug|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 months.
1490685|NCT03038399|Drug|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 months.
1490686|NCT03038399|Drug|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 months.
1490687|NCT03038399|Drug|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 months.
1490688|NCT03038386|Other|Dual Energy CT|In this study all patients undergo DECT scan to assess the value of DECT scan in diagnosing acute arthritis caused by gout. If the DECT scan demonstrates MSU depositions and the diagnosis of gout was not ascertained prior to DECT scanning by MSU crystals in the synovial fluid, then additional ultrasound guided aspiration will take place, with knowledge of DECT results, followed by repeat microscopy
1490689|NCT03038373|Procedure|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be conducted based on standard protocol.
1490690|NCT03038347|Behavioral|Training|Six modules containing PDF-files with text-based information, video files, case studies with associated questions and practical exercises. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules and associated exercises once a week. After six weeks the training is completed.
1490691|NCT03038347|Behavioral|Education only|Six modules containing only PDF-files with text-based information. Participants can download the modules and associated materials from an online platform they need to register for. They receive access to modules once a week. After six weeks the education is completed.
1490692|NCT03038334|Dietary Supplement|Magnesium sulfate|Transdermal application of Magnesium sulfate 250mg every four hours per day for 90 days.
1490693|NCT03038321|Drug|sofenacin|solifenacin 10 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation
1490694|NCT03038321|Drug|Tavanic|levofloxacin 500 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
1490695|NCT03038321|Drug|Xefo|lornoxicam 8 mg, 6 hours after IVI of BCG and continue for another 2 days post instillation.
1490696|NCT03038308|Drug|Ropinirole|
1490697|NCT03038295|Drug|Propranolol|Oral propranolol:0.25mg/kg daily(every 24 hours)；Eye drop propranolol(0.2%):3 microdrops,in each eye, four times daily (every 6 hours) .Both administration routes will be discontinued until retinal vascularization will be completed, but no more than 90 days.The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:Atropine.Isoproterenol hydrochloride (isoprenaline).Terlipressin.Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular).
1490698|NCT03038295|Drug|placebo|Oral/eye drop placebo will be taken in enrolled newborns. Other treatment will follow the standard treatment schedule of Early Treatment For Retinopathy Of Prematurity Cooperative Group.
1490699|NCT03038282|Dietary Supplement|Chromium Chloride|Transdermal chromium chloride 50 to 600 mcg/day.
1490700|NCT03038282|Other|Individual Exercise|Participants will engage in 150 minutes of exercise over 3-5 days per week for 12 weeks
1490701|NCT03038269|Behavioral|Upper Extremity Robotics, tDCS|Participant will receive 20 minutes of non-invasive brain stimulation followed by one hour of shoulder/wrist robotic training.
1490702|NCT03038256|Drug|concurrent capecitabine-based long-term radiotherapy followed by 4 cycles XELOX and a delayed TME|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.
XELOX:
Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks
Surgery Procedure:
Total Mesorectal Excision"
1490703|NCT03038256|Drug|concurrent capecitabine-based long-term radiotherapy followed by a Regular TME and 6 Cycles XELOX|"concurrent capecitabine-based long-term radiotherapy: capecitabine 825mg/m2,bid,d1-5, q week with Radiation treatment. Radiation treatment was given at 1·8 Gy per day, 5 days per week for 5-6 weeks, after a 45 Gy radiation dose in 25 fractions to the pelvis, a boost dose of 5·4 Gy in 3 fractions to the tumor bed or concurrent boosted.
XELOX:
Oxaliplatin: 130mg/m2,IV,d1; Capecitabine: 1000mg/m2,bid,d1-14; repeated every 3 weeks
Surgery Procedure:
Total Mesorectal Excision"
1490704|NCT03038243|Biological|Shigella flexneri 2a whole cell (Sf2aWC) vaccine and double mutant E. coli heat labile toxin (dmLT)|2.25 x 10^11 Sf2aWC cells +10 µg dmLT administered orally on Days 0, 28, and 56
1490705|NCT03038243|Biological|Shigella flexneri 2a whole cell (Sf2aWC) vaccine|2.25 x 10^11 Sf2WC cells administered orally on Days 0, 28, and 56
1490706|NCT03038243|Other|Placebo|2.0 grams of NaHCO3 dissolved in 150 mL of sterile water
1490707|NCT03038230|Drug|MCLA-117 bispecific antibody|MCLA-117, a human bispecific IgG antibody which targets CLEC12A and CD3
1490708|NCT03038217|Drug|Capecitabine +/- Oxaliplatin|Patients in ACT group will undergo postoperative adjuvant chemotherapy with single agent Capecitabine regimen or combined Capecitabine +Oxaliplatin regimen.
1490709|NCT03038217|Procedure|local resection|Patients in the LR group will undergo local resection of the T1-2N0 rectal carcinoma
1490710|NCT03038217|Procedure|radical resection|Patients in the RR group will undergo radical resection of the T1-2N0 rectal carcinoma
1490711|NCT03038217|Other|No adjuvant chemotherapy|Patients in Non-ACT group will not undergo postoperative adjuvant chemotherapy.
1490712|NCT03038204|Procedure|The papillary muscle approximation|"Surgery is performed through median sternotomy, aortic and bicaval cannulation, normothermic perfusion, and antegrade cardioplegia with the use of cardioplegic solution.
After coronary anastomosis, the mitral valve is exposed by a transseptal incision.
The papillary muscles are approximated through the mitral valve at the level of papillary muscles heads. Nonabsorbable, braided sutures of 2-0 (Ethibond, Ethicon, Inc.) with PTFE felt pledgets are used for this purpose.
Annuloplasty mitral rings of different sizes are anchored using multiple deep U-shaped stitches of Ethibond 2-0 (Ethicon, Inc., USA). After MV repair, the LV is forcefully filled with saline water to test the valve competence. After satisfactory hydraulic test walls of the heart chambers are sutured."
1490713|NCT03038191|Device|Neuroelectrics Enobio 8(R)|Monitoring
1490714|NCT03038178|Drug|LAI plus multi-drug regimen|Liposomal Amikacin for Inhalation (LAI) is the experimental treatment which, in this single arm will be taken in conjunction with standard of care multi-drug treatment regimen
1490715|NCT03038152|Device|Magseed Marker|Magseed marker injected into or near in or near the lymph node under arm up to thirty days prior to surgery.
1490716|NCT03038152|Procedure|Lymph Node Removal Procedure|Handheld device used to scan under arm and locate the marker during lymph node removal procedure.
1490717|NCT03038152|Procedure|Ultrasound/Mammogram|Person injecting the Magseed marker may use an ultrasound or mammogram to position the needle properly.
1490718|NCT03038152|Behavioral|Post-Operative Visit|Participant returns for a routine follow-up visit 2-6 weeks after surgery. During visit, participant asked questions about any side effects or injuries since their surgery and about any drugs they may be taking. It should take about 10 minutes to answer these questions.
1490719|NCT03038152|Device|Magseed® Localization|Magseed® localized using the Sentimag® system during surgery and removed with the targeted lymph node.
1490720|NCT03038139|Other|Cervical exercises|Cervical correction program consist of 3 strengthening and 2 stretching exercises for neck and scapula Lumbosacral correction program consist of strengthening and stretching exercises for lumbar and sacral regions
1490721|NCT03038139|Other|Lumosacral exercises|Cervical and Lumbosacral correction program Lumbosacral program consist of 2 strengthening and 4 stretching exercises
1490722|NCT03038126|Other|CCHT|Veterans Administration (VA) CCHT program available to veterans with difficult to manage chronic conditions and employing an established guideline-based CKD DMP, augmented laboratory monitoring, and decision support from the VA Renal Inter-disciplinary Safety clinic (RISC).
1490723|NCT03038126|Other|Usual care|Standard clinical care
1490724|NCT03038113|Drug|RO7062931|Administered subcutaneously in Parts 1 and 2. Part 1 will be administered in single-ascending doses after 0.1 mg/kg starting dose. Subsequent doses of 0.3, 1, 2 and 4 mg/kg may be administered based upon tolerability. In Part 2a, participants will receive two monthly doses of either 0.4, 0.8, 1.2 times the saturation dose or placebo. In Part 2b a dose selected from Part 2a based on HBsAg decline or the max dose well tolerated, will be administered to participants randomized in 2 parallel cohorts where they will receive either the full dose every two weeks (3 doses), or half the dose weekly (5 doses).
1490725|NCT03038113|Drug|Placebo|Part 1 cohorts: active drug vs placebo 4:1. Part 2a 4 parallel cohorts of 3 active drug doses and placebo in 1:1:1:1. Part 2b active drug vs placebo in 3:1 in 2 parallel cohorts.
1490726|NCT03038100|Drug|Paclitaxel|Paclitaxel 175 milligrams per square meter (mg/m^2) IV infusion on Day 1 of each 21-day cycle
1490727|NCT03038100|Drug|Carboplatin|Carboplatin at a dose to achieve a target area under the curve (AUC) of 6 milligrams per milliliter*minute (mg/mL*min) on Day 1 of each 21-day cycle for a total of 6 cycles
1490728|NCT03038100|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion on Day 1 of each 21-day cycle
1490729|NCT03038100|Drug|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion as per the schedule specified in respective arms
1490730|NCT03038100|Drug|Atezolizumab Placebo|Placebo matching to atezolizumab on Day 1 of each 21-day cycle
1490731|NCT03038087|Device|SENSE Device|"The SENSE device transmits a low power tailored electro-magnetic pulse across the patient's brain and detects changes in the signal that may indicate intracranial hemorrhage. The device consists of two parts:
A molded plastic headpiece containing the antenna array, and
A processing control unit.
The SENSE device will be placed on the subject within 15 minutes of a baseline head CT, or as soon as practicable. The SENSE device will be set to scan every 10 minutes until the device is removed after completion of the SENSE measurement corresponding to the 72 hour CT scan. The investigator will be blinded to the data collected from the SENSE device."
1490732|NCT03038061|Other|Patients undergoing Laparoscopic Surgery|Data are to be obtained at three phases at supine horizontal position (during spontaneous breathing, at mechanically ventilated patient under general anesthesia with muscle relaxation and at mechanically ventilated patient under general anesthesia with muscle relaxation during insufflation of carbon dioxide into the peritoneal cavity to achieve exposure during laparoscopic surgery).
1490733|NCT03038048|Procedure|Varying needle size with intravitreal ranibizumab or aflibercept|Varying gauge of needle, 33 gauge vs 30 gauge
1490734|NCT03038035|Drug|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
1490735|NCT03038035|Drug|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
1490736|NCT03038022|Drug|MGL-3196|Oral
1490737|NCT03038022|Drug|Placebo|Oral
1490739|NCT03037996|Other|patients' response|patients' satisfaction to anesthesia services
1490740|NCT03037983|Device|Repetitive transcranial magnetic stimulation|rTMS is a non-invasive procedure, in which the administration of a transient magnetic field induces electrical currents in specific, targeted brain regions. The intervention will be administered in 20 sessions lasting 50 minutes each over the course of 2-6 weeks. Up to two sessions may be scheduled per day with a one-hour interval in-between.
1490741|NCT03037983|Device|Sham|Subjects will still attend treatment sessions as outlined in the rTMS intervention. However, the device will not deliver any stimulation to the subject.
1490742|NCT03037970|Drug|RhPDGF-BB|One 2x4x.3cm of collagen wound matrix is saturated with 2.0 ml of the rhPDGF-BB solution.
1490743|NCT03037970|Other|Placebo|Collagen Wound Dressing wetted with buffer.
1490744|NCT03037957|Device|ARIES Group A Strep Assay|
1490745|NCT03037944|Drug|Yasmin|(ethinyl estradiol 0.03 mg/ drospirenone 3 mg) tablets
1490746|NCT03037944|Device|Metraplant-E|"Levonorgestrel-releasing Intrauterine System modified levonorgestrel-releasing intrauterine system from the old IUD Metraplant, modified by Azzam 2013"
2001515|NCT02947269|Drug|Prucalopride|Prucalopride 2mg capsule
2001516|NCT02947269|Drug|Placebo Oral Capsule|Placebo capsule
1490749|NCT03037918|Dietary Supplement|Yakult light|A fermented milk drink containing the probiotic Lactobacillus casei Shirota
2001517|NCT02944825|Drug|Ciprofloxacin|first line prophylactic oral antibiotic
1490751|NCT03037892|Drug|Midazolam, Fentanyl|Two minutes before the colonoscopy procedure, a bolus of midazolam 0.03mg/Kg and 1.5microgram/Kg fentanyl will be given intravenously over 60 sec in group 1. 0.5 mg of midazolam intravenously can be given every two minutes till the patient is sufficiently sedated (sleeping but arousable on calling). The colonoscopy can start at this end point. Increments of 0.5mcg/Kg of fentanyl will be given if patient complains of pain, which can be repeated every 5 minutes if there is persistent pain.
1490752|NCT03037892|Drug|Midazolam, Remifentanil|The patient in group 2 Target controlled infusion of Remifentanil to 3.0 ng/ml will be started 2 minutes before procedure. The patient will then be given same doses of midazolam in 0.5 mg increments till sedated sufficiently (sleeping but arousable on verbal command). During Colonoscopy the dose of Remifentanil could be increased by 0.5ng/ml if patient complained of pain upto 4.0ng/ml.
1490753|NCT03037892|Drug|Remifentanil|The group 3 patient will receive only Remifentanil in the same doses as given in group
1490754|NCT03037879|Other|SPT|Participants in the SPT group will receive 10 training sessions over 5 weeks.
1490755|NCT03037879|Other|SPT Control|Participants in the SPT control group will receive 10 computer-based control sessions over a five-week period during which they will engage in computer-based training. However, they will not be exposed to the training materials central to the SPT.
1490756|NCT03037879|Other|mSMT|Participants in the mSMT group will meet with the trainer twice per week for five weeks. Sessions last 45-60 minutes each and are spread over 5 weeks.
1490757|NCT03037879|Other|mSMT Control|Participants in the mSMT control group will meet with the therapist at the same frequency and for the same duration as those in the mSMT experimental group. However, subjects will not be exposed to the training materials central to the mSMT.
1490758|NCT03037866|Behavioral|LifeSkills Training for College|The intervention will consist of e-learning modules (self-guided) and small-group sessions (facilitator led). The intervention is designed for new college students and is aimed at providing tools and strategies to help them maximize opportunities and adeptly handle the challenges ahead. The intervention will teach them the knowledge and skills needed to stay safe from problems that are prevalent among new students on college campuses, such as alcohol and drug abuse and sexual violence.
1490759|NCT03037853|Other|Healthy volunteers|MRI scanner
1490760|NCT03037840|Device|Low intensity amplitude-modulated RF EMFs|Low intensity amplitude-modulated radiofrequency electromagnetic fields,the carrier frequency is 27.12MHz with a power of about 100mW
1490761|NCT03037827|Procedure|Endovenous laser ablation (EVLA)|Endovenous laser ablation with laser wavelength 1470 nm and radial laser fiber
1490762|NCT03037827|Device|Laser|Device for endovenous laser ablation manufactured by Biolitec AG company (ELVeS system) - diode laser with a wavelength of 1470 nm
1490763|NCT03037814|Device|Compomer|Aesthetic resin dental materials that are used to replace structure loss, commonly for dental caries of primary tooth. Compomers designed to combine the aesthetics of traditional composite resins with the fluoride release and adhesion of glass-ionomer cements.
1490764|NCT03037814|Device|RMGIC|Dental restorative materials that are a combination of the desirable properties of glass-ionomer (fluoride release and chemical adhesion) with high strength and low solubility of resins.
1490765|NCT03037814|Device|Giomer|Giomers are dental materials that are hybrid of compomers and glass ionomers, and are used to restore dental caries.
1490766|NCT03037814|Device|Amalgam|Amalgam is a silver-colored dental restorative material that can be used to restore both primary and permanent posterior teeth which have dental caries.
1490767|NCT03037801|Device|Intrapulmonary Percussive Ventilation (Percussionaire Corp, Sandpoint, Idaho)|IPV physiotherapy 3 times a day
1490768|NCT03037788|Drug|WO3979|Application of cream to each axilla
1490769|NCT03037788|Drug|WO3970|Application of cream to each axilla
1490770|NCT03037788|Drug|WO3992|Application of cream to each axilla
1490771|NCT03037788|Drug|Placebo (WO3988)|Application of cream to each axilla
1490772|NCT03037775|Other|Baseline|measurement of baseline hemodynamic parameters
1490773|NCT03037775|Device|e-cigarette without nicotine|measurement hemodynamic parameters during smoking e-cigarette without nicotine
1490774|NCT03037775|Device|e-cigarette with nicotine|measurement hemodynamic parameters smoking e-cigarette with nicotine
1490775|NCT03037775|Device|traditional cigarette|measurement hemodynamic parameters smoking traditional cigarette
1490776|NCT03037762|Procedure|Flexible Endoscopic Evaluation of Swallowing|
2001518|NCT02944825|Drug|trimethoprim/sulfamethoxazole|second line prophylactic oral antibiotic
2001519|NCT02944825|Drug|No Intervention|No intervention
1490779|NCT03037736|Drug|5-Fluorouracil|5-fluorouracil is an antimetabolite that is commonly used in glaucoma surgery to prevent postoperative scaring.
1490780|NCT03037736|Drug|Bevacizumab|Bevacizumab is an anti-VEGF antibody that is commonly used to prevent or treat neovascularization in retinal disorders.
1490781|NCT03037736|Drug|Normal saline|Normal saline will be used as the placebo.
1490782|NCT03037723|Other|CT simulation|
1490783|NCT03037710|Device|HealthPatch|A multi-sensor device to collect continuous vital signs
2001520|NCT02945527|Drug|Acetazolamide|As described above
1491029|NCT03035955|Drug|Azelaic acid|15% gel twice daily for four weeks to one side of face
2001521|NCT02945527|Drug|Dexamethasone|As described above
2001522|NCT02945410|Other|Caloric Restriction|Participants will consume 30 kcal/kg FFM/day.
2001523|NCT02945410|Other|Protein|Participants will consume 1.7 g protein/kg BW/day.
2001524|NCT02945410|Other|Exercise|Participants will conduct aerobic exercise designed to expend 15 kcal/kg FFM/day
1989748|NCT02392429|Drug|Chemotherapy|Given anthracycline IV
2001525|NCT02945410|Dietary Supplement|Calcium and Vitamin D|Participants will be provided calcium and vitamin D supplement in order to maintain calcium and Vitamin D intake constant across all study arms
2001526|NCT02945410|Other|Maltodextrin|Participants will be provided with maltodextrin to supplement the liquid diet in order to meet caloric needs within each study arm
1490786|NCT03037684|Diagnostic Test|neurophysiology|electrophysiologic measurements of peripheral nerves
2001527|NCT02943265|Other|Care Coordination Strategies|Co-located Care coordinator will use EMR-driven registry to facilitate patient transitions between primary care and oncology care and enhance teamwork through coaching and technical assistance.
1490788|NCT03037658|Other|Offering a financial incentive to increase walking|"After a baseline week of walking while wearing a pedometer, participants will be randomly assigned to one of the five conditions. In each of these conditions, participants will have the chance to earn .02/step for each additional step per day (on average across the week, above baseline levels). After a week of incentivized walking, participants will again be asked to wear the pedometer for one final week (with no incentive).
Because the investigators need a week of walking before the incentive week, it is important that participants do not know the specific incentive aspect at the beginning of the study. Therefore, the investigators will not disclose the incentive structure at the beginning of the study. The investigators will debrief participants at the end of the study, and they will be fully informed of the purposes of the study at that time."
1490789|NCT03037645|Drug|SNS-062|SNS-062 will be orally administered twice daily and available in capsules containing either 25 mg or 100 mg of active ingredient.
1490790|NCT03037632|Behavioral|Family Heart Talk Booklet|
1490791|NCT03037619|Behavioral|Fitbit|Participants randomized to Fitbit will be mailed a Fitbit and encouraged to wear it over the next 4 months
1490792|NCT03037619|Behavioral|Fitbit+Support|"Participants will identify a Buddy and both the participant and Buddy will be mailed a Fitbit. Both participant and Buddy will be asked to Friend each other on Fitbit and encouraged to wear the monitor over the next 4 months."
1490793|NCT03037606|Drug|Rabelis DDR 50 mg Capsules|Rabelis DDR 50 mg Capsules once daily for seven days.
1490794|NCT03037606|Drug|Pariet 20 mg Enteric Coated Tablets|Pariet 20 mg Enteric Coated Tablets once daily for seven days.
1490795|NCT03037593|Drug|4000 IU vitamin D3|vitamin D supplementation (4000 IU vitamin D3 +prenatal vitamin
2001528|NCT02941874|Other|Blood sample collection during an OGTT to assess IRAP blood concentration|Blood sample collection during an OGTT to assess IRAP blood concentration. Blood samples will be collected every 15 minutes during 3 hours
2001529|NCT02941835|Radiation|pre-operative irradiation|pre-operative whole breast irradiation of 21 fx of 2.2Gy and boost of 2.66Gy
1490798|NCT03037567|Behavioral|Modified Weight Watchers plan|Weight Watchers is a structured lifestyle modification program that includes a food plan based on balanced diet and healthy eating, activity plan designed to promote progressive physical activity increase, group support and cognitive behavior modification. Participants attend weekly in-person group meetings led by a trained Weight Watchers meeting leader and have a suite of electronic tools available through an iPhone app.
1490799|NCT03037554|Device|Sleepwear with Lateralized Thermal Characteristics|Subjects will wear sleepwear constructed with insulating fabric on one side and conductive fabric on the other side, arranged bilaterally.
1490800|NCT03037554|Device|Sham-Lateralized Sleepwear|Subjects will wear sleepwear constructed with two insulating fabrics arranged bilaterally.
1490801|NCT03037541|Drug|Carac Cream|Carac Cream will be used once daily for seven consecutive days
1490802|NCT03037541|Drug|Placebo Cetaphil cream|Placebo Cetaphil Cream will be used once daily for seven consecutive days
1490803|NCT03037528|Behavioral|diet and lifestyle program|Participants will be taught how to follow a very low carbohydrate, ketogenic diet, become more physically active, and get adequate sleep.
1490804|NCT03037528|Behavioral|positive affect informational materials|Participants will be taught about positive affect skills, such as gratitude, positive reappraisal, and personal strengths.
1490805|NCT03037528|Behavioral|mindfulness informational materials|Participants will be taught about mindfulness and mindful eating techniques.
1490806|NCT03037528|Behavioral|dietary tracking|Participants will be asked to track their diet consistently.
1490807|NCT03037515|Drug|Tranexamic Acid|To identify if intravenous tranexamic acid is superior to oral tranexamic acid in reducing blood loss and need for transfusion in lumbar spine surgery.
1490808|NCT03037502|Behavioral|Intervention|Assess the effectiveness of a person-specific, randomized controlled pilot weight loss study of 120 African American and 120 Latino men; to compare changes in HbA1c, diabetes risk behaviors (e.g., diet and physical activity), adiposity measures (e.g., body fat), and psychosocial mediators (e.g., social support, autonomous motivation) between data collected at baseline and at 6-months
1490809|NCT03037489|Drug|MIV-711|MIV-711 administered orally once daily
1490810|NCT03037476|Behavioral|Web-based PFI|A web-based 5 component Personalized Feedback Tool covering content on: 1) Stimulants, 2) Marijuana, 3) PSM and unwanted effects, 4) Academics, and 5) Alcohol.
1490811|NCT03037476|Behavioral|In-person PFI|A 1.5 hour in-person brief personalized feedback intervention utilizing a motivational interviewing approach to discuss the student's PSM misuse, alcohol and other drug use, and review personalized graphic feedback.
1490812|NCT03037450|Procedure|Miniinvasive corneal neurotization|Neurotization of a neurotrophic cornea
1490813|NCT03037437|Drug|Sorafenib (SOR)|Patients will receive SOR 400 mg by PO twice daily on Cycle1/Day1 (C1D1).
1490814|NCT03037437|Drug|Hydroxychloroquine (HCQ)|400mg by mouth daily
1490815|NCT03037424|Drug|Octafibrin|Octafibrin will be administered when the blood bank receives an order for fibrinogen supplementation
1490816|NCT03037424|Drug|Cryoprecipitate|Cryoprecipitate will be administered when the blood bank receives an order for fibrinogen supplementation
1490818|NCT03037398|Device|Vercise Deep Brain Stimulation System|
1490819|NCT03037385|Drug|BLU-667|BLU-667 is a potent and selective inhibitor of the RET mutations, fusions, and predicted resistant mutants
1490820|NCT03037372|Drug|ART, Atorvastatin|ART, Atorvastatin
1490821|NCT03037372|Drug|ART, Rosuvastatin|ART, Rosuvastatin
1490822|NCT03037372|Drug|ART, No statin|ART, No statin
1490823|NCT03037372|Drug|Healthy-HIV-negative|Age-matched, Healthy HIV-negative
1490824|NCT03037359|Biological|Bivigam|Human immune globulin
2001530|NCT02938923|Drug|Testosterone|Topical testosterone gel 1%
1948988|NCT00896441|Drug|Citalopram|"Refer to Detailed Description Section for full description of intervention. Week 1 (baseline): Subject will complete several tests to assess the subject's memory and concentration. Following visit, they will begin treatment with the antidepressant citalopram.
Week 1 MRI: Subject will have their first MRI. Week 2 visit: Physician will meet with they to assess the subject's overall condition.
Week 2 MRI: Subject will have the subject's second MRI. Week 4 visit: The study physician will meet with the subject to assess their overall condition.
Week 6 (Telephone check-in): The study physician will check in with the subject by telephone to assess the subject's overall condition.
Week 8: (End-of-study visit) Subject will take repeated tests of memory and concentration. The study physician will also discuss recommendations for further treatment of the subject's depression.
Week 8 MRI: Around the time of the subject's week 8 visit they will have the subject's third and final MRI."
1490828|NCT03037333|Procedure|Transvenous cardiac pacing guided by fluoroscopy|Transvenous cardiac estimulation
1490829|NCT03037333|Procedure|Transvenous cardiac pacing guided by ECG/ECHO|Transvenous cardiac estimulation
1490830|NCT03037320|Procedure|comparison of coronally advanced flap and semilunar vestibular incision technique for root coverage in maxillary teeth|
1490831|NCT03037307|Other|Test Product|Five strips of test adhesive cream for upper denture, as per application instructions.
1490832|NCT03037307|Other|Positive Contol|Three dabs of positive control adhesive cream for upper denture, as per application instructions.
1490833|NCT03037307|Other|Negative Control|No adhesive
1490834|NCT03037294|Dietary Supplement|Preoperative protein supplementation|Daily 40 g of pre-sleep protein supplementation during 2-week preoperative period.
1490835|NCT03037294|Drug|Preoperative intra-articular corticosteroid injection|Intra-articular injection of corticosteroid (combination of betamethasone and bupivacaine) 2 weeks before surgery.
1490836|NCT03037281|Diagnostic Test|Septic|30mls of blood will be sampled by venepuncture, or sampled from indwelling lines (in the case of septic patients on intensive care). Blood will be sampled using standard techniques, and transferred to EDTA containing blood bottles, and undergo processing immediately.
1490837|NCT03037268|Device|Lytro Plenoptic Camera and 28D lens|"visual acuity measured, intraocular pressure obtained, eyes dilated as part of a standard exam for intended patient visit
screened and consented for study
subjected to bilateral plenoptic ophthalmoscopy
mydriatic, single-field fundus images obtained
images reviewed for quality and diagnostic utility by a masked grader"
1490838|NCT03037255|Other|long term conditions|Long term conditions including diabetes mellitus, chronic obstructive pulmonary disease or asthma, chronic heart failure, chronic renal failure, cerebrovascular disease or peripheral vascular disease.
1490839|NCT03037242|Procedure|Transtibial pullout technique|
1490840|NCT03037229|Device|Smartphone ECG|
1490841|NCT03037229|Device|Standard 12-lead ECG|
1490842|NCT03037216|Other|Exercise Intervention|10 Week aerobic exercise training
1490843|NCT03037203|Drug|JZP-110|75 mg, 150 mg, 300 mg
1490844|NCT03037203|Other|Placebo|
1490845|NCT03037190|Other|withdrawal of gluten from the diet|Gluten free diet the same recommendations as for patients with diabetes and known celiac disease
1490846|NCT03037164|Device|INTERCEPT Blood System for Red Blood Cells|The pathogen reduction process begins with a unit of RBCs derived from whole blood that is separated according to local regulations and standard operating procedures at the Blood Centers. RBCs are suspended in AS-5. Leukocyte-reduction of whole blood or RBCs will be performed per manufacturer's instructions. The INTERCEPT Blood System process is performed on a single unit of leukocyte-depleted RBC in AS-5.
1490847|NCT03037164|Device|Conventional (Control)|Conventional RBC components ordered and administered to study patients by their treating physicians according to the local standards of care
1490848|NCT03037151|Drug|Grazaoprevir/Elbasavir|treatment naive
1490849|NCT03037151|Drug|Grazaoprevir/Elbasavir/RBV|treatment experienced
1490850|NCT03037138|Other|Blood flow Rate profiling|Blood flow rate profiling during dialysis session
1490851|NCT03037125|Procedure|Split Crest with PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed with PRF closing the gap
1490852|NCT03037125|Procedure|Split Crest without PRF|Narrow ridges are split to increase the ridge width and immediate implants are placed without grafting
1490853|NCT03037112|Behavioral|Education|The first intervention is an educational intervention regarding appropriate diagnosis and treatment of common respiratory infections. This education will be delivered in an interactive lecture format for providers with follow up short informational video clips available over the course of the project.
1490854|NCT03037112|Behavioral|Communication Skills|The second intervention is an education plus communication skills training intervention. This training session will include identical antibiotic education training, good and bad communication examples, training on negative behavioral framing, and education regarding key drivers of patient satisfaction. Additionally providers will be informed of parent's desire for antibiotics rating prior to their consultation with the patient.
1490855|NCT03037099|Behavioral|Enhanced GI Concept Education|
1490856|NCT03037073|Drug|Duloxetine|35 patients will receive duloxetine (Cymbalta; Eli Lilly & Company, Indiana, USA) 30 mg orally with sips of water, 2 h before induction of anesthesia.
1490857|NCT03037073|Drug|Placebo oral capsule|35 patients will receive similar-looking placebo capsules (starch capsules) orally with sips of water, 2 h before induction of anesthesia.
1490858|NCT03037060|Other|[11C]-(+)-PHNO PET scan|PET scan
1490859|NCT03037060|Other|Alcohol Self-Administration|Session for assessing motivation for consuming alcohol.
1490860|NCT03037060|Other|Craving Task|Cue exposure paradigm
1490861|NCT03037060|Other|MRI scan|MRI scan scan to analyze the PET data will be administered.
1490862|NCT03037060|Other|Neuropsychological Assessment|Cognitive questionnaires administered over course of study.
1490863|NCT03037047|Drug|0.9% Sodium Chloride Injection|Patients will treated with 0.9% Sodium Chloride Injection on the basis of conventional therapy for 14 days.
1490864|NCT03037047|Drug|salvianolate injection|Patients will treated with salvianolate injection on the basis of conventional therapy for 14 days.
1490865|NCT03037034|Device|Forcep|"Following the injection around a submucosal tumor, the adjacent mucosa or submucosa was grasped with the forceps and pulled away to form a tent. The tissue was dissected using an electrocoagulating current."
1490866|NCT03037008|Device|Perineal Sonography|In a modified lithotomy position (supine position with elevated legs), probands will get an examination of their pelvic floor by using a common ultrasound probe head on the perineum. During the examination, the bladder should be filled with around 300ml. If patient appear with empty bladder, the examination can be repeated on an other date. During the examination, the pelvic floor will be observed during rest, coughing and valsalva-maneuver. One examination takes around 30minutes. During ultrasound, we want to illustrate the urethral mobility, the bladder neck opening and the urethral angle as well as the distance from the urethra to the symphysis.
1490867|NCT03036995|Drug|Apremilast|Patient will receive narrow UVB treatment and apremilast (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and apremilast during 24 weeks.
1490868|NCT03036995|Other|Placebo|Patient will receive narrow UVB treatment and placebo (2 tablets for day) during 24 weeks. If the patient is responder (response is defined as an increase of at least 30 % in the VASI score at W24 compare to Baseline), he will receive narrow UVB treatment according the and placebo during 24 weeks.
1490869|NCT03036943|Radiation|Fluciclovine|Fluciclovine (18F) PET/CT scan completed >= 48 hours prior to surgical resection for breast cancer
1490870|NCT03036930|Other|Laboratory Biomarker Analysis|Correlative studies
1490871|NCT03036930|Other|Questionnaire Administration|Ancillary studies
1490872|NCT03036930|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
1490873|NCT03036904|Drug|Venetoclax|Venetoclax will be administered orally on days 3-12 in cycle 1, and days 1-10 with all subsequent cycles except dose level -1. If dose level -1 is required, venetoclax will be administered on days 3-7 in cycle 1 and 1-5 with subsequent cycles.
1490874|NCT03036904|Drug|Rituximab|Rituximab will be administered as an IV infusion at 375 mg/m2 on day 1 of each cycle of DA-EPOCH-R, immediately prior to the start of chemotherapy. Oral pre-medication 650 mg of acetaminophen and 50-100 mg diphenhydramine hydrochloride will be administered 30 to 60 minutes prior to starting each infusion of rituximab. The first rituximab infusion should be started at 50 mg/hr, and increased in 50-mg/hr increments every 30 minutes to a maximum rate of 400 mg/hr. If this rate of escalation is well tolerated the second and subsequent infusions can begin at a rate of 100 mg/hr and increase in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr. CAUTION: DO NOT ADMINISTER AS AN INTRAVENOUS PUSH OR BOLUS.
1490875|NCT03036904|Drug|Etoposide|Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
1490876|NCT03036904|Drug|Vincristine Sulfate|Vincristine Sulfate will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
1490877|NCT03036904|Drug|Cyclophosphamide|Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
1490878|NCT03036904|Drug|Prednisone|Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
1490879|NCT03036904|Drug|Doxorubicin Hydrochloride|Doxorubicin Hydrochloride will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
1490880|NCT03036891|Drug|Naloxegol 25 MG Oral Tablet [Movantik]|Patients will be given the study drug (Movantik 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
1490881|NCT03036891|Drug|Placebo Oral Tablet|Patients will be given Placebo (Placebo 25 mg).They will take this daily in the morning 1 hour before breakfast for four weeks.
1490882|NCT03036878|Other|ReNu|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
1948989|NCT00880048|Drug|orvepitant|neurokinin-1 antagonist
1948990|NCT00880048|Other|Placebo|Placebo to match orvepitant 30 mg and 60 mg
2001531|NCT02938923|Drug|Placebo gel|Inactive skin gel
2001532|NCT02938923|Behavioral|Supervised exercise training|Multicomponent exercise program focused primarily on progressive resistance exercise training
1490887|NCT03036826|Drug|Piperacillin/tazobactam|antiinfective therapy with Piperacillin/Tazobactam within routine care
1490888|NCT03036826|Drug|Meropenem|antiinfective therapy with Meropenem within routine care
1490889|NCT03036826|Drug|Vancomycin|antiinfective therapy with vancomycin within routine care
1490890|NCT03036813|Drug|GBT440|
1490891|NCT03036813|Other|Placebo|
1490892|NCT03036800|Drug|Saxenda|standard care plus targeted use of Liraglutide (LIRA) 3mg when pre-specified stopping rules for the medication apply. Liraglutide (Saxenda) 6 mg/mL solution for injection in pre-filled pen, administered by subcutaneous injection. Dose escalation to 3.0 mg daily (or maximum tolerated dose)
1490893|NCT03036800|Other|Specialist Obesity Management Services|Specialist Obesity Management Services standard of care
1490894|NCT03036787|Behavioral|family based intervention|behavioural advises to family for normal motor development
1490895|NCT03036774|Procedure|Ultrasonic measurement of antral area|Ultrasonic measurement of antral area
1490896|NCT03036761|Procedure|Auriculotherapy|
1490897|NCT03036748|Dietary Supplement|Standardized sodium diet|Dietary Supplement: Standardized salt diet 150 mmol NaCl per day given as three meals daily for 6 consecutive days.
1490898|NCT03036748|Drug|Tbl amiloride|Drug: Amiloride Amiloride tablet 10-20 mg two times daily (morning and afternoon) for one day
1490899|NCT03036735|Device|steroid eluting spacer|The Restora Mometasone Furate Eluting Spacer will be compared to the Silastic spacer.
1490900|NCT03036722|Other|Flaxseed|Flaxseed is a member of the genus Linum in the family Linaceae. It is a food and fiber crop and it occurs in two basic varieties: brown and yellow or golden (also known as golden linseeds).
1490901|NCT03036722|Other|Placebo control porridge|control porridge matched for energy and fat content.
1948991|NCT00873366|Drug|dextromethorphan hydrobromide|
1490938|NCT03036475|Device|Sienna+ injection|Subcutaneous injection of Sienna+ in the morning of operation day
1490939|NCT03036462|Drug|Iron|i.v. iron administration
1490940|NCT03036462|Drug|Saline|i.v. NaCl administration
1948992|NCT00873366|Drug|tamoxifen citrate|
1948993|NCT00873366|Other|high performance liquid chromatography|
2001533|NCT02931669|Other|Qualitative Descriptive Study|
1490902|NCT03036709|Drug|VRC-HIVMAB01060-00-AB (VRC01)|"VRC01 will be administered at a dose of 40 mg/kg intravenously every 3 weeks for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first.
The first dose of VRC01 will be administered on the same day that antiretroviral therapy (ART) is interrupted. In the simian model, VRC01 administered intravenously achieved peak serum levels within one hour of infusion and was slowly metabolized with an average half-life of 7.61 days.The second infusion of VRC01 will occur at the midpoint of this highest risk period."
1490903|NCT03036709|Other|Sodium Chloride for Injection USP, 0.9%|Normal saline (Sodium Chloride for Injection USP, 0.9%) will be administered intravenously every three weeks to participants assigned to the placebo arm of the trial for a total duration of 24 weeks or until ART resumption criteria are met, whichever comes first.
1490904|NCT03036696|Other|Pregnant Mothers Interview|"Pregnant mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection and preferences for methods related to non-invasive sample collection.
Data collection for pregnant mothers includes Clinical Health Update (3rd trimester) and Physical Activity questionnaires.
The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
1490905|NCT03036696|Other|Lactating Mothers Interview|"Lactating mothers will be interviewed and asked to provide feedback on common strategies used for recruitment, challenges that would preclude them from enrolling and participating in CRTs, their preferences for incentives, data collection, bio-specimen collection, and preferences for methods related to non-invasive sample collection.
Data collection for lactating mothers includes Clinical Health update (post-natal), Infant Feeding, and Physical Activity questionnaires.
The following will be collected from mothers during the interview: self-reported behavioral data, maternal human milk (HM), stool, urine, saliva, and vaginal swab."
1490906|NCT03036683|Device|Transcranial direct current stimulation|Transcranial direct current stimulation will be administered for 20 minutes using a CE approved stimulator (NeuroConn, Ilmenau, Germany).
1490907|NCT03036683|Device|Sham transcranial direct current stimulation|The same device will be used as in the active stimulation group, but stimulation will be terminated after 30 seconds.
1490908|NCT03036657|Device|MAC acupuncture needles|"Sterile single-use MAC acupuncture needles (0.22 x 25 mm, TianJin Haing Lim Sou Won Medical Equipment Co, Ltd, South Korea. Used for Manual Acupuncture
Used for: Manual Acupuncture to PC3, PC5 or HT3, HT4 for 20 min"
1490909|NCT03036657|Device|Electrostimulator 6c.Pro, Pantheon Research, Venice, CA|"Electrostimulator used for delivery or Low-Frequency or High-Frequency Electroacupuncture
Used for Interventions:
Low-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min AND High-frequency Continuous Electroacupuncture to PC3, PC5 or HT3, HT4 for 20 min"
1490910|NCT03036644|Device|e-cigarette (PG+VG without nicotine; low temperature)|
1490911|NCT03036644|Device|e-cigarette (PG+VG with nicotine; low temperature)|
1490912|NCT03036644|Device|e-cigarette (PG+VG without nicotine; high temperature)|
1490913|NCT03036644|Device|e-cigarette (PG+VG with nicotine; high temperature)|
1490914|NCT03036644|Other|tobacco cigarette|
1490915|NCT03036618|Dietary Supplement|Quinoa|Test wheat bread roll (approximately 160g weight) delivering 20 g quinoa consumed per day.
1490916|NCT03036618|Dietary Supplement|Wheat|Test wheat bread roll (approximately 160g weight) without quinoa.
1490917|NCT03036605|Drug|Bupivacaine|%0.5 bupivacaine
1490918|NCT03036605|Drug|Dexamethasone|8 mg Dexamethasone
2001534|NCT02929043|Other|air puffs|
1490921|NCT03036579|Device|Celtra Duo|Full ceramic crowns will be made from the high strength ceramic, Celtra Duo.
1490922|NCT03036566|Device|Lithium disilicate ceramic (Ivoclar)|Three unit high strength ceramic bridges replacing a single tooth.
1490923|NCT03036553|Other|Diagnosis/Prognosis|The present study will be a prospective multi-centric 12-month study that will be conducted between May 2017 and April 2019 in four primary care centers and a hospital in the province of Malaga. Several questionnaires assessing different psychological factors will be administered to these participants. The results will be evaluated at baseline (t1) and at 3-fold follow-up (after 3 (t2), 6 (t3) and 12 months (t4)).
1490924|NCT03036540|Device|application in midline catheter|The routine insertion of midline catheter for the patients admitted in hospital who needs peripheral venous approach for the period more than 5 days or with the insufficient peripheral veins system
1490925|NCT03036527|Procedure|Activity-based locomotor training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stepping (IRB 07.0066).
1490926|NCT03036527|Procedure|Activity-based stand training|The weight-bearing activity-based intervention will be provided via a standardized locomotor training program that is provided clinically at Frazier Rehab Institute within the NeuroRecovery Network (NRN); or similar interventions in a research protocol of stand only program (07.0268). The stand only intervention may also be provided as part of this study.
1490927|NCT03036527|Procedure|Activity-based upper arm ergometry|The non-weight bearing activity-based upper arm ergometry intervention will be provided via a standardized arm crank therapy provided within this study.
1490930|NCT03036501|Drug|[^14C]-RO7034067|[^14C]-RO7034067 18 mg oral solution with approximately 0.75 megabecquerel MBq (20 microcuries [μCi]) of [14C]-labeled RO7034067.
1948994|NCT00873366|Other|laboratory biomarker analysis|
1948995|NCT00873366|Other|pharmacogenomic studies|
1948996|NCT00873366|Other|pharmacological study|
1948997|NCT00873366|Procedure|fluorescence imaging|
1948998|NCT00871468|Procedure|superior plate|Open reduction internal fixation (ORIF) clavicle with superior plate
1490941|NCT03036449|Behavioral|Education program for NICU caregivers.|"Intervention includes a main initial educational program, maintenance education programs and tools supply
- Main educational program will include 9 hours of courses into NICU (1 hour each week) and @ learning modules validation.
Topics: Main causes of medication errors, How to analyse retrospectively medication errors, Strategies to reduce medication errors, How to improve communication between health professional; Task interruption; Standardisation of preparation…..
Maintenance education program will return on specific topics of main program and will be fitted to each NICU needs.
Examples of Tools: check lists, medication neonatal formulary, Sound alike and Look alike drug lists…"
1490942|NCT03036436|Behavioral|Intervention|A physical activity intervention, delivered remotely using a combination of the Fitbit application and support from a chartered physiotherapist.
1490943|NCT03036423|Behavioral|Online video education|
1490944|NCT03036423|Behavioral|Computerized mental exercises|
1490945|NCT03036410|Device|standard telephone setting|without streaming function
1490946|NCT03036410|Device|DECT|cordless telephone (streaming to both hearing devices)
1490947|NCT03036410|Device|EasyCall|accessories for Bluetooth capable mobile telephones (streaming to both hearing devices)
1490948|NCT03036410|Device|DuoPhone|streaming function, which provides the speech signal to both ears
1490949|NCT03036397|Drug|SRX246|180mg qam/ 120mg qhs for 5-7 days
1490950|NCT03036397|Drug|Placebo|twice daily for 5-7 days
1490951|NCT03036384|Drug|HB Prilocaine 2% (varying dose)|Varying dose of hyperbaric (HB) prilocaine 2% according to sensitive response of previous subjects. The dose of 60mg of hyperbaric prilocaine 2% will be administrated intrathecally with 100µg of morphine and 5µg of sufentanyl
1490952|NCT03036384|Drug|HB Prilocaine 2%|The dose of 60mg of hyperbaric (HB) prilocaine 2% will be administrated intrathecally with 100µg of morphine and 5µg of sufentanyl
1490953|NCT03036384|Drug|Sufentanil|5µg sufentanyl
1490954|NCT03036384|Drug|Morphine|100 µgMorphine
1490955|NCT03036371|Behavioral|High Intensity Interval Exercise|6 week at-home aerobic exercise protocol
1490956|NCT03036358|Other|teledermatology consult|Information from the dermatologic assessment will be entered into the patients chart.
1490957|NCT03036358|Other|Routine Care|The dermatologic assessment will occur but not added to the patients medical record. Dermatology may still be consulted but will be at the prerogative of the treating hospitalist.
1490958|NCT03036345|Device|Dual-monitoring|Monitored using both INVOS and FORE-SIGHT monitors.
1490959|NCT03036332|Behavioral|Aerobic interval training|Carried out 3 times per week for 16 weeks
1490960|NCT03036319|Device|Active tDCS|Participants will receive active tDCS at up to 4mA for up to 40 minutes for up to 30 sessions.
1490961|NCT03036319|Device|Sham tDCS|Participants will receive sham tDCS for up to 30 sessions
1490962|NCT03036319|Behavioral|Cognitively based intervention|Participants may receive a cognitively based intervention that targets the particular cognitive and/or functional abilities of interest. This includes methods of cognitive training, cognitive remediation, and cognitive rehabilitation for up to 30 sessions
1490963|NCT03036319|Device|Active tACS|Participants will receive active transcranial alternating current stimulation at up to 4mA for up to 40 minutes for up to 30 sessions
1490964|NCT03036319|Device|Sham tACS|participants will receive sham transcranial alternating current stimulation for up to 30 sessions
1490965|NCT03036319|Device|Active tRNS|Participants will receive active transcranial random noise stimulation at up to 4mA for up to 40 minutes for up to 30 sessions
1490966|NCT03036319|Device|Sham tRNS|Participants will receive sham transcranial random noise stimulation for up to 30 sessions
1490967|NCT03036306|Drug|SCX-001|Nefopam cream formulation
1490968|NCT03036306|Other|Placebo|Cream formulation without Nefopam
1490969|NCT03036293|Drug|Tenoten|Safety and Efficiency
1490970|NCT03036293|Drug|Placebo|Safety and Efficiency
1490971|NCT03036280|Drug|elenbecestat (E2609)|tablet
1490972|NCT03036280|Drug|Placebo|tablet
1490973|NCT03036267|Behavioral|BREATHE|Primary care providers (PCPs) randomized to BREATHE will be trained to deliver the 7-minute brief shared decision-making intervention using a 4-step motivational interviewing approach.
1490974|NCT03036267|Other|Attention Control Condition|PCPs randomized to the control intervention will not receive any specific training. To control for contact, they will be instructed to engage in a 7-minute diet and exercise discussion as this will not confound results.
1490975|NCT03036254|Device|HBOT intervention|HBOT is a treatment in which oxygen-enriched air (up to 100%) is administered to patients at a pressure above the ambient atmosphere.
1490976|NCT03036254|Device|Sham intervention|"Sham was selected as the control condition rather than usual care to equate intervention groups with respect to other variables that could influence cognition and functional status, such as a new challenge (completing an activity program), peer socialization, and attention from staff."
1490977|NCT03036241|Device|Conventional angioplasty|Angioplasty with conventional balloon
1490978|NCT03036241|Device|Angioplasty with drug-eluting balloon|Angioplasty with drug-eluting balloon
1490979|NCT03036228|Drug|Karonudib|Dose escalation of administration with oral solution of Karonudib.
1490980|NCT03036215|Behavioral|PACT Experimental Arm|The study will employ a self-management program, entitled Personalized Activated Care and Training (PACT) that is a tailored 8-week progressive web-based training program supported by a health coach to enhance understanding, compliance, and success in improving TMD pain. The program provides 8 weeks of structured didactic and experiential training on exercises and cognitive- behavioral training to reduce risk factors that contribute to delayed recovery and enhance protective factors that have evidence of improving TMD pain.
1490981|NCT03036202|Drug|Epinephrine|This is truly an observational study to determine T1/2 for epinephrine and time to peak concentration following a single dose of epinephrine in a cardiac arrest setting
1490982|NCT03036189|Behavioral|baa nnilah|7 meetings in the community led by a trained community facilitator
1491025|NCT03035981|Other|Brown rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
1491026|NCT03035981|Other|Fructooligosaccharide (FOS)|White and brown rice were tested for differences in gastric emptying rate and appetitive response
1491027|NCT03035968|Other|Vojta therapy|
1490983|NCT03036176|Behavioral|Play-based family centered stimulation|Children in the intervention group received routine medical treatment and nutritional rehabilitation services in hospital; their primary caregivers were given basic orientations on child care, feeding and nutrition. Children attended play-based stimulation sessions in which trained nurses demonstrated caregivers on how to stimulate the SAM child using play materials and facilities at playroom and playground of the hospital. After discharge from hospital, they were followed up at home and visited three times over a period of six months. During the visits, new play materials were provided and caregivers were shown how to use them to stimulate the SAM child.
1490984|NCT03036176|Other|no intervention|On the other hand, the control SAM group did not receive the guided psychomotor/psychosocial stimulation services although they had access to the playground facilities. Both the intervention and the control groups received all the routine medical care and dietary rehabilitation services at the hospital.
1490985|NCT03036163|Drug|PBTZ169 - 40 mg|40 mg of PBTZ169 (1 capsule) orally once in fasting state
1490986|NCT03036163|Drug|PBTZ169 - 80 mg|80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
1490987|NCT03036163|Drug|PBTZ169 - 160 mg|160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
1490988|NCT03036163|Drug|PBTZ169 - 320 mg|320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
1490989|NCT03036163|Drug|PBTZ169 - 640 mg|640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
1490990|NCT03036163|Drug|PBTZ169 - 320 mg (multiple administration)|320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
1490991|NCT03036163|Drug|PBTZ169 - 640 mg (multiple administration)|640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
1490994|NCT03036137|Device|Transcranial Direct Current Stimulation|Anodal stimulation of the temporoparietal left area with an cathode over the right dorsolateral prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
1490995|NCT03036137|Device|Sham Transcranial Direct Current Stimulation|Sham tDCS sessions will last 20 minutes
2001541|NCT02924493|Other|Diet low in fermentable carbohydrates (low FODMAP diet)|The participants follow the diet in 4 weeks. They have been provided with some foods (bread, pasta, cereal products), but will by the rest themselves. They have been provided with lists of foods to include and foods to avoid. They have also been provided with suggestions to a 4 week meal plan, based in their individual need for energy.
1490998|NCT03036111|Drug|Trimebutine|Trimebutine suppository will be inserted in the anal canal on completion of hemorrhoidectomy then at six and 12 hours postoperatively.
1490999|NCT03036111|Procedure|Hemorrhoidectomy|Patients will undergo classic Milliagn-Morgan hemorrhoidectomy
1491005|NCT03036085|Drug|Liposomal bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline.
1491006|NCT03036085|Drug|Bupivacaine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
1491007|NCT03036085|Drug|Epinephrine|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with bupivacaine plus epinephrine plus normal saline.
1491008|NCT03036085|Drug|Normal saline|In the operating room after induction of general anesthesia patients will be positioned in a lateral decubitus position, prepared and draped in a sterile fashion. Under thoracoscopic guidance, a posterior intercostal nerve block will be performed with liposomal bupivacaine plus normal saline or with bupivacaine plus epinephrine plus normal saline.
1491009|NCT03036072|Other|Strict normothermia|
1491010|NCT03036072|Device|Delayed Rewarming|Use of the servo-controlled cooling blanket for delayed rewarming to target temperature.
1491011|NCT03036059|Drug|400 μg/kg Ivermectin + 400 mg Albendazole|400ug/Kg, tablet, given orally once or twice a year.
1491012|NCT03036046|Drug|F901318 with fluconazole low dose|adverse events
1491013|NCT03036046|Drug|F901318 with fluconazole high dose|adverse events
1491014|NCT03036046|Drug|F901318 with posaconazole|adverse events
1491015|NCT03036033|Device|SaeboGlove|All participants are given a Saebo glove to use during their stroke recovery.
1491016|NCT03036020|Radiation|CereTom Neurologica Samsung|Diagnosis of acute stroke patients by cerebral CT diagnostics prehospital
1491019|NCT03035994|Other|Real-Time Biofeedback|A custom written MatLab script will sample bilateral peak vertical ground reaction forces and display the magnitude in real time on a screen placed in front of the participant. A target line will be placed in the middle of the screen which corresponds to one of the three loading conditions. Participants will be instructed to alter their movement in an attempt to match each limb's vertical ground reaction force to the target line.
1491020|NCT03035981|Other|White rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
1491021|NCT03035981|Other|White rice, high amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
1491022|NCT03035981|Other|White rice, slow|White and brown rice were tested for differences in gastric emptying rate and appetitive response
1491023|NCT03035981|Other|White rice, resistant|White and brown rice were tested for differences in gastric emptying rate and appetitive response
1491024|NCT03035981|Other|Brown rice, low amylose|White and brown rice were tested for differences in gastric emptying rate and appetitive response
1491028|NCT03035968|Other|conventional physiotherapy|
1491030|NCT03035942|Drug|Dexamethasone|Dexamethasone 8 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
1491031|NCT03035942|Drug|Ondansetron|Ondansetron 4 mg (made up to 5 mL with normal saline) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
1491032|NCT03035942|Other|Saline|Normal saline (5 mL total volume) will be drawn into each syringe which will be offered to the anesthesia provider after the opaque envelope was opened and administered immediately after spinal anesthesia was performed.
1491033|NCT03035929|Drug|Dexamethasone|A single dose of dexamethasone IV 4 mg will be administered.
1948999|NCT00871468|Procedure|anterior-inferior plate|ORIF clavicle with anterior inferior plate
1989749|NCT02392429|Procedure|Computed Tomography|Undergo FLT PET/CT
1989750|NCT02392429|Drug|Cytarabine|Given IV
1491037|NCT03035903|Device|Not holding, then holding the MedGem®|Subjects will have a RMR measurement taken first while not holding the MedGem®, and then while holding the MedGem®
1491038|NCT03035903|Device|Holding, then not holding the MedGem®|Subjects will have a RMR measurement taken first while holding the MedGem®, and then while not holding the MedGem®
1491039|NCT03035890|Radiation|Radiation|Radiation therapy will be administered in 3 or 5 fractions over 3-10 days, at a recommended dose of 8-15 Gy per fraction for 3 total fractions (total dose 24-45 Gy) or 6-10 Gy per fraction for 5 total fractions (total dose 30-50 Gy)
1491040|NCT03035890|Drug|Immuno-Therapeutic Agent|"Immune checkpoint inhibitors that are FDA approved for use in patients with metastatic NSCLC will be acceptable for use concurrently with radiotherapy in this trial. The choice of agents will be at the treating medical oncologist's discretion, and include:
Nivolumab 240mg or 3 mg/kg once every 2 weeks (14 day cycle)
Pembrolizumab 200mg or 2 mg/kg once every 3 weeks (21 day cycle)
Atezolizumab 1200 mg once every 3 weeks (21 day cycle)
These agents should be continued per standard of care until either disease progression or unacceptable toxicity."
1491041|NCT03035877|Behavioral|Multisystemic Therapy-Emerging Adults|MST-EA is a home- and community-based treatment for emerging adults (ages 17-21) that aims to address antisocial behavior and problems caused by substance use disorders. The model also addresses co-occurring mental health problems when present. Therapists work directly with the young adult and his/her social network. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
1491042|NCT03035877|Behavioral|Enhanced Treatment as Usual|With Enhanced Treatment as Usual (E-TAU), emerging adults will get the treatments that they usually receive when they have a substance use disorder and have been in trouble with the law. In addition, they will receive travel vouchers for attending services, a card with an individualized list of contacts when in crisis, and facilitation with identifying need of services and accessing those services.
1491043|NCT03035864|Drug|rhNGF|Eye Drop 20 μg/mL
1491044|NCT03035864|Other|Vehicle|Vehicle Eye Drop
1491045|NCT03035851|Behavioral|Aerobic exercise|
1491046|NCT03035851|Behavioral|Stretch and Strength|
1491047|NCT03035838|Drug|Fosaprepitant|Within 24 hours from injury, IVAMEND (the intravenous formulation of the NK-1 antagonist fosaprepitant) will be administered at a dose of 300 mg, intravenously over 1 hour.
1491048|NCT03035825|Dietary Supplement|Oral moisturizing jelly|Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth
1491049|NCT03035825|Other|Artificial saliva|A non-edible oral lubricating gel for dry mouth patients
1491050|NCT03035812|Drug|Alkali|Oral intake of alkali therapy whatever the formulation (alkali-based water, powder or pharmaceutics)
1491051|NCT03035799|Other|Paleolithic diet|Paleolithic diet
1491052|NCT03035799|Other|General Healthful Diet|General Healthful Diet
1491053|NCT03035773|Behavioral|Care Plan Only|Patient participants randomized to Arm A will be sent a copy of the SCP within 3 months of completion of treatment and a copy will be added to their medical record. A copy of the SCP will also be sent to the PCP on record. The SCP will be completed by a nurse, nurse practitioner, or physician assistant. The SCP will be accompanied by a cover letter that will be signed by a member of the clinical team.
1491054|NCT03035773|Behavioral|Care Plan During a Visit|Patient participants randomized to Arm B will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider on record. The visit will be scheduled after consent is signed and will occur between 1 and 3 months after completion of treatment. The visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues.
1491055|NCT03035773|Behavioral|Care Plan During a Visit with an Additional Visit|Participants randomized to Arm C will receive a copy of the SCP during an in-person 'stethoscope free' visit with a nurse, nurse practitioner, or physician assistant. A copy of the SCP will be added to the medical record and a copy will be sent to the primary care provider. The visit will be scheduled after consent is signed and will occur between 1-3 months after completion of treatment. The initial visit will focus on review of the SCP content and offer an opportunity for patients to ask questions about any aspect of the plan or associated treatment and survivorship issues. Patients will also receive a follow up survivorship visit 7-10 months after the end of treatment that will focus on a review of the SCP and offer the opportunity to ask about any persistent or emerging issues.
1491056|NCT03035760|Drug|Oxfendazole|methyl-5 (6)-phenylsulfiyl-2-benzimidazole carbamate, is a broad spectrum benzimidazole antihelminthic. It is the sulphoxide metabolite of fenbendazole.
1491057|NCT03035747|Procedure|conventional surgery|high ligation and stripping of incompetent saphenous veins
1491058|NCT03035747|Procedure|endovenous laser ablation|endovenous laser ablation of incompetent saphenous veins
1495651|NCT03002012|Drug|Sertraline|sertraline 400mg/day
1989751|NCT02392429|Other|Fluorothymidine F-18|Undergo FLT PET/CT
1989752|NCT02392429|Other|Laboratory Biomarker Analysis|Correlative studies
1989753|NCT02392429|Procedure|Positron Emission Tomography|Undergo FLT PET/CT
1989754|NCT02392806|Device|Bubble CPAP- BabiPlus, Respiralogics|Infant will be randomized to BabiPlus verses B&B Bubbler at time of extubation
1491059|NCT03035747|Procedure|sclerotherapy|ultrasound guided or catheter or or any other methods sclerotherapy of incompetent saphenous or varicose veins
1491060|NCT03035747|Procedure|endovenous radiofrequency ablation|endovenous radiofrequency ablation of incompetent saphenous veins
1491061|NCT03035747|Procedure|phlebectomy|hooks phlebectomy of varicose veins
1491062|NCT03035734|Drug|BMS-986141 Form A Tablet|
1491063|NCT03035734|Drug|BMS-986141 Form B tablet (low dose)|
1491064|NCT03035734|Drug|BMS-986141 Form B tablet (high dose)|
1491065|NCT03035721|Dietary Supplement|Low protein formula|Infants were enrolled to receive low protein formula (energy: 65 kcal/100 mL, protein: 1.2 g/100 mL, protein-to-energy ratio:1.9 g/100 kcal, carbohydrates: 8 g/100 mL, fat: 3.1 g/100 mL) for the firsts 4 months of life.
1491066|NCT03035721|Dietary Supplement|Standard protein formula|Infants were enrolled to receive standard protein formula (energy: 68 kcal/100 mL, protein: 1.7 g/100 mL, protein-to-energy ratio:2.5 g/100 kcal, carbohydrates: 7.1 g/100 mL, fat: 3.5 g/100 mL) for the firsts 4 months of life.
1491067|NCT03035708|Drug|Varenicline|1 mg BID
1491068|NCT03035708|Drug|Placebo oral capsule|1 mg BID
1491069|NCT03035695|Device|Axiostat®|
1491070|NCT03035695|Device|Cotton Gauze|
1491071|NCT03035682|Other|Augmented Media Group|The intervention group will receive traditional PT services deemed clinically appropriate via examination plus home exercise prescription augmented via a mobile health application. The augmented media group will receive digital exercise prescription via a mobile health application source (Physitrack) that includes: high definition video and pictures, education material and written instruction, reminder notification and in-app logging of completion.
1491072|NCT03035682|Other|Traditional Group|The Traditional Group will receive traditional PT services deemed clinically appropriate via examination plus traditional home exercise prescription.
1491073|NCT03035669|Behavioral|Mindfulness group|8 week program
1491074|NCT03035669|Behavioral|Reading group|8 week program
1491075|NCT03035656|Drug|Ropivacaine|Administration of Ropivaciane via epidural injection intra-operatively
1491076|NCT03035656|Other|Saline|Administration of saline via epidural injection intra-operatively
1491077|NCT03035643|Device|Ascyrus Medical Dissection Stent placement|The study is a prospective, non-randomized, non-blinded, single-arm, single center study evaluating the feasibility and safety of this new design of stent. The device will be implanted during already planned surgical intervention for aortic dissection repair. The participant will be observed and data gathered during the surgery and routine standard of care follow up visits.
1491078|NCT03035630|Drug|Avelumab|Avelumab 10mg/kg IV over 60 minutes on D1 and D15 of every 28 day cycle
1491079|NCT03035630|Drug|Sunitinib|Sunitinib 50 mg once daily from D1 to D14 of every 21 day cycle
1491080|NCT03035617|Drug|Bupivacaine|Bupivacaine is long acting local anesthetic drug. Though minimum toxic dose of bupivacaine for intra-peritoneal use is not defined, analgesic effect of its intra-peritoneal use especially after laparoscopic cholecystectomy has been assessed in several interventional studies. Intra-peritoneal use of up to 50ml of .25% , , or up to 20ml of .5% solution has not shown any drug related adverse reactions .
1491081|NCT03035617|Other|Saline|In control arm mesh will be soaked in normal saline solution as is routinely done.
1491082|NCT03035604|Behavioral|Comprehensive Geriatric Assessments|Mini Nutritional Assessment (MNA), Body Mass Index (BMI), weight loss, lean muscle mass, percent weight change assessed at each time point.
1491083|NCT03035591|Drug|ODM-207|
1491084|NCT03035578|Drug|Morphine|Sampling blood for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
1491085|NCT03035578|Drug|Morphine|Sampling saliva for development of Morphine Pharmacokinetic/Pharmacodynamic Model for Neonatal Population
1491086|NCT03035565|Behavioral|Computerized Cognitive Training with Brain HQ|Computerized Cognitive Training Brain HQ activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
1491087|NCT03035565|Behavioral|Computerized Crossword Puzzles|Computerized Crossword Puzzles activities initiated and continued 1 hour/day, 5 days/week for 8 weeks
1491088|NCT03035552|Behavioral|Pacifier activated music player|Therefore the immediate goal of the current proposal is to demonstrate that intensive NNS-training using reinforcement with mother's voice can improve the oral feeding outcomes of infants with CCHD using a randomized controlled trial (RCT) design, with wait-list controls to ensure that infants in the trial all benefit from a treatment with only demonstrated positive effects. Establishment of optimal NNS patterns in the first 6 months after birth in these infants will improve downstream feeding skills and may promote better motor and language outcomes by one year of age.
1491089|NCT03035539|Other|Cardiac rehabilitation|AF specific cardiac rehabilitation Group education 1 hour each week for 3 months Physical training 1 hour each week for 3 months with physiotherapist
1491090|NCT03035539|Other|Standard treatment|Standard treatment
1491091|NCT03035513|Other|Continuous spikes and waves during slow sleep (CSWS)|
1491092|NCT03035500|Other|Educational Intervention|Receive health education
1491093|NCT03035500|Other|Laboratory Biomarker Analysis|Correlative studies
1491094|NCT03035500|Other|Long-term Follow-up|Undergo long-term follow-up using survivorship care plan
1491095|NCT03035500|Other|Quality-of-Life Assessment|Ancillary studies
1491096|NCT03035500|Other|Questionnaire Administration|Ancillary studies
1491097|NCT03035487|Device|Ultrasound guided prostate exam using SOC ultrasound system|
1491098|NCT03035487|Device|mpMRI guided prostate examination using PI-RADS v2|mpMRI guided prostate examination using standard of care MRI system
1491099|NCT03035487|Device|High-resolution micro-ultrasound guided prostate biopsy|
1491249|NCT03034369|Other|Preventive Screening|Analysis of health care claims data for preventive screenings at baseline and 12 months.
2001551|NCT02921230|Device|Peripheral stenting|stent implantation during the index procedure
1491104|NCT03035435|Other|fast-track rehabilitation|
1491105|NCT03035435|Other|standard care rehabilitation|
1491106|NCT03035422|Drug|Sequential Packaging (SET)|"Sequential chemotherapy:
Thiotepa 5 mg / kg / day for 1 day (D-13)
Cyclophosphamide 400 mg / m² / day for 4 days (J-12 to J-9)
Etoposide 100 mg / m² / day for 4 days (J-12 to J-9) Repos days J-8 and J-6 Reduced-intensity conditioning (RIC)
Fludarabine 30 mg / m² / day for 5 days (J-5 to D-1)
Busulfan IV 3.2 mg / kg / day for 2 days (J-5 and J-4)
Anti-lymphocyte serum (Thymoglobuline) 2.5 mg / kg / day for 2 days (J-3 and J-2)"
1491107|NCT03035422|Drug|Transfusion graft|Graft of peripheral stem cells is preferred at D0
1491108|NCT03035422|Drug|Prevention of GVHD|"Cyclophosphamide 50mg / kg / day on days D + 3 and D + 5
Cyclosporine A (CSA; 3 mg / kg / day IV from D + 6)
Mycophenolate mofetil (MMF; 30 mg / kg / day, maximum x2 1g / day from day J + 6)"
1491109|NCT03035422|Drug|Care supports|According to the protocols of each center
1491110|NCT03035422|Drug|Lymphocyte injection of prophylactic donor (PDLI)|"According to the protocols of each center. In the absence of clinical indication against-disease (GVHD), phasing MMF between days D + 35 and D + 56, then phasing APF between D + 62 and D + 90
- PDLI: 3 injections from the D + 120 patients who discontinued immunosuppressive therapy for ≥ 1 month and having no active GVHD or history of acute GVHD grade> II"
1491111|NCT03035409|Drug|Anamorelin|100 mg by mouth 1 time each day for 6 weeks.
1491112|NCT03035409|Behavioral|Physical Activity|Participants perform resistance exercises and a walking program at home for 6 weeks while also taking Anamorelin.
1491113|NCT03035409|Behavioral|Assessment Questionnaires|Assessment questionnaires completed at baseline, on Days 8, 15, 21, 29, 36, and 43.
1491114|NCT03035409|Behavioral|Counseling|Participants meet with a dietitian for nutrition counseling on Day 21, and an exercise specialist on Day 15.
1491115|NCT03035383|Procedure|Purse string technique|Thyroidectomy closure is performed using purse string suturing technique.
1491116|NCT03035383|Procedure|Conventional technique|Thyroidectomy closure is performed using conventional suturing technique.
1491117|NCT03035370|Biological|Viaskin PT 25 mcg|Two applications of Viaskin 25 mcg PT at a 2-week interval (D0 and D14).
1491118|NCT03035370|Biological|Viaskin PT 50 mcg|Two applications of Viaskin 50 mcg PT at a 2-week interval (D0 and D14).
1491119|NCT03035370|Biological|Viaskin PT Placebo|Two applications of Viaskin PT Placebo at a 2-week interval (D0 and D14).
1491120|NCT03035370|Biological|Boostrix™|Four weeks after the second Viaskin application (at Day 42 of the study), all subjects will receive a dose of diphtheria-tetanus-pertussis vaccine (Boostrix® dTpa) to ensure the optimal recall of their immunity against pertussis.
1491121|NCT03035357|Drug|Daratumumab|16 mg/kg by vein once weekly for a total of 4 doses.
1491122|NCT03035344|Other|Metabolome study|Metabolome study in ALL patients compared to healthy controls
1491123|NCT03035331|Procedure|Cryosurgery|Undergo cryosurgery
1491124|NCT03035331|Biological|Dendritic Cell Therapy|Given IT
1491125|NCT03035331|Biological|Pembrolizumab|Given IV
1491126|NCT03035331|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given by injection
1491127|NCT03035331|Other|Quality-of-Life Assessment|Ancillary studies
1491128|NCT03035305|Dietary Supplement|Lipid-based Nutrient Supplement (LNS)|"For each round of SMC distribution (total of 4 rounds):
For children aged 6-11 months: 15 sachets/month or 50g every two days for 4 weeks
For children aged 12-59 months: 21 sachets/month or 50g per day for 3 weeks"
1491129|NCT03035305|Drug|Seasonal malaria chemoprevention|"For each round of SMC distribution (total of 4 rounds):
For children aged 6-11 months: sulfadoxine 250mg/pyrimethamine 12.5mg and amodiaquine 75mg
For children aged 12-59 months: sulfadoxine 500mg/pyrimethamine 25mg and amodiaquine 150mg
D1 : 1 tablet sulfadoxine-pyrimethamine + 1 tablet amodiaquine D2 : 1 tablet amodiaquine D3 : 1 tablet amodiaquine"
1491130|NCT03035279|Drug|SC-006|Intravenous
1491131|NCT03035266|Device|Blood Flow Restriction|Delfi's Personalized Tourniquet System for Blood Flow Restriction has been specifically designed to safely regulate and control tourniquet pressure. Occlusion pressures will be set at 80% of total occlusive pressure as determined by the Doppler sensor. Each subject will perform 4 sets of each exercise (1 set of 30 repetitions followed by 3 sets of 15 repetitions). The pressure will remain through completion of the final set, but not to exceed 5 minutes. One minute rest without tourniquet application will be performed between 5 minute cycles. Sets and repetitions will remain constant for each subject; however, resistance will be incrementally increased after the subject is able to complete all 75 repetitions without loss of proper form.
1491132|NCT03035266|Other|Standard rehabilitation|Standard of care for post-operative condition
1491133|NCT03035253|Drug|OMP-305B83|
1491134|NCT03035253|Drug|FOLFIRI|Treatment will consist of OMP-305B83 and the FOLFIRI chemotherapy regimen.
1491135|NCT03035240|Behavioral|Financial Education|Participants randomized to financial education will undergo a year long financial education. This involves 9 weeks of weekly classes followed by one on one coaching for a year.
1491136|NCT03035227|Procedure|Catheter Ablation|Catheter ablation of atrial or ventricular arrhythmia. The technique and type of ablation will be at the discretion of the treating electrophysiologists.
1491137|NCT03035227|Drug|Anti-Arrhythmics|Anti-Arrhythmic drugs that are deemed to be appropriate for the given participants's arrhythmia by the treating physician.
1491138|NCT03035214|Drug|Dexamethasone (Steroids)|Is to describe the use of integrated assessment of respiratory physiology using Targeted Neonatal Echocardiography, assessment of optimal Functional Residual Capacity and the tolerance of lung oxygen uptake at different oxygen levels, and hence early prediction of Bronchopulmonary Dysplasia and the underlying pathophysiology by periodic application of the oxygen tolerance test; which may help early targeted treatment of this common disease.
1491139|NCT03035201|Dietary Supplement|Cocoa extract|2 capsules/d containing total of 750 mg/d cocoa extract, including 75 mg (-)-epicatechin, and 90 mg theobromine
1491140|NCT03035201|Dietary Supplement|Multivitamin|Daily multivitamin
1491141|NCT03035188|Drug|Vismodegib|1 capsule (150 mg vismodegib) taken once daily for a maximum of 12 weeks.
1491142|NCT03035175|Other|Video Laryngoscopy|Residents intubate using video laryngoscopy.
1491143|NCT03035175|Other|Traditional Laryngoscopy|Residents intubate without using video laryngoscopy.
1491144|NCT03035162|Device|Transcranial direct current stimulation|Dual Active/sham tDCS will be applied over the leg motor area (M1) priori to conventional physical therapy (1 hours). Anodal on affected hemisphere, Cathodal on unaffected hemisphere. Each participant will complete two experiments (active/sham tDCS). The interval between two experiments is at least 48 hours. The two experiments will be performed in random order for each subject.
1491145|NCT03035149|Other|Weight Management Program|Obese subjects partake in a medically supervised weight management program. This lifestyle modification program involves weekly three hour sessions for six months and monthly sessions for six months. The first twelve weeks comprise an initial weight loss phase when patients are placed on a 900 Kcal/day meal replacement. This is followed by a four week transition to a 1200-1800 Kcal diet followed by a ten week maintenance phase of 10 weekly sessions.The majority of weight loss occurs during the first 26 weeks followed by a 26 week period of stabilization of weight loss. Hence subjects are evaluated after the first 26 weeks.
1949000|NCT00869713|Biological|Inactivated, Dried (TSI-GSD 200), RVF Vaccine|All subjects: 1.0-mL (SQ)doses on day 0, once between days 7 & 14, & once between days 28-42. Initial responders: A 6-month mandatory vaccine booster dose (1.0 mL, SQ) will be given if the PRNT80 is ≥1:40 after the primary series. Subsequent booster doses will be given for PRNT80 titer <1:40. Initial non-responders: Individual who has a PRNT80 titer <1:40 following the primary series may be administered a booster dose before 6 months. The individual will not receive the mandatory 6-month booster dose. Once an initial non-responder achieves PRNT80 ≥1:40, additional booster doses will be given for subsequent PRNT80 <1:40). All subjects: RVF booster dose will be administered within 90 days after a PRNT80 result of <1:40.
1491147|NCT03035110|Behavioral|Dialectical Behavioural Therapy (DBT) based skills groups|Dialectical Behavioural Therapy (DBT) involves skills that help people manage their emotions and tolerate distress. This therapy is found effective in reducing self-harm behaviour for outpatients with Borderline Personality Disorder.
1491148|NCT03035097|Other|Biorepository|One-time blood draw for blood to be stored in a biorepositoy
1491149|NCT03035084|Drug|Vitamin D3|Single oral dose of 50,000 IU of vitamin D3
1491150|NCT03035084|Drug|Vitamin D2|Single oral dose of 50,000 IU of vitamin D2
1491151|NCT03035084|Drug|Placebo oral capsule|
1491152|NCT03035071|Procedure|minimally invasive esophagectomy|In the MIE group the laparoscopic procedure was performed for gastric tube formation. The patient was placed in supine position with legs apart. The surgeon stands between the legs using a five-trocar technique. Laparoscopy will be followed by an anterolateral thoracotomy in the fourth intercostal space.
1491153|NCT03035071|Procedure|open esophagectomy|in the open group the gastric mobilization and gastric tube formation will be perfumed with an open surgical approach. Laparotomy will be performed, followed by an anterolateral thoracotomy in the fourth intercostal space.
1491154|NCT03035058|Drug|Vedolizumab|Vedolizumab intravenous infusion
1491155|NCT03035058|Drug|Placebo|Placebo
1491156|NCT03035045|Drug|Paracetamol|
1491157|NCT03035045|Drug|Placebo Oral Tablet|
1949001|NCT00869232|Drug|Velcade|1.0mg/m2 days 1, 5, 8, & 11
1491159|NCT03035019|Behavioral|Lantern|This pilot will evaluate how the availability of a virtual stress management resource can help patients reduce anxiety and improve quality of life.
1491160|NCT03035006|Drug|Lipotecan|Lipotecan based concurrent chemoradiotherapy
1491161|NCT03034993|Behavioral|Text Messaging|"Subjects will receive text messages with reminders of their upcoming outpatient health care appointments at the Boston Health Care for the Homeless Program (BHCHP) clinic. The text message will indicate the time of the appointment and the location (e.g. Remember appointment Friday March 15 at 10am in the Yawkey building). Appointment reminder text messages will be sent 3 days ahead and again 1 day ahead of the appointment date. Medication related texts will be sent every other day and will be educational and motivational (e.g. Keep taking medications that way the doctor prescribed them, even if feeling fine). Mood related texts will also be sent every other day and ask about mood on a 1 to 5 scale. The participant will text back a response."
1491162|NCT03034980|Other|Training intensity (workload) during ergospirometry|The reached workload (W) during each training is noted during 12 weeks of rehabilitation. The relative intensity is expressed as a percentage of VT1 and VT2.
1949002|NCT00869232|Drug|Melphalan|10 mg/m2 day 3
1949003|NCT00869232|Drug|Thalidomide|200 mg days 5-8
1949004|NCT00869232|Drug|Dexamethasone|40 mg day 5-8
1949005|NCT00869232|Drug|Cisplatin|10 mg/m2 day 5-8
2001552|NCT02919267|Device|Double lumen tube|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the L-DLT group.
2001553|NCT02919267|Device|Bronchial blocker|Either gaseous volume quantification or intrapulmonary pressure measurements will be done in patients randomized in the BB group.
1491169|NCT03034941|Drug|Metformin|In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg twice per day per os for 12 weeks
1491170|NCT03034941|Drug|Liraglutide + metformin|In the COMBI group the initial dose of metformin was 500 mg for at least 2 wk and gradually increased to a final dose of 1000 mg twice per day. Liraglutide 1.2 mg once per day s.c. was added after first two weeks of monotherapy with metformin.
1949006|NCT00869232|Drug|Adriamycin|10 mg/m2 day 5-8
1949007|NCT00869232|Drug|Cyclophosphamide|400 mg/m2 day 5-8
1949008|NCT00869232|Drug|Etoposide|40 mg/m2 day 5-8
1491292|NCT03033914|Drug|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
1949012|NCT00813878|Genetic|protein analysis|protein analysis
1949013|NCT00813878|Genetic|protein expression analysis|protein expression analysis
1949014|NCT00813878|Genetic|proteomic profiling|proteomic profiling
1949015|NCT00813878|Other|diagnostic laboratory biomarker analysis|Performed one time on study
1949016|NCT00813878|Other|immunohistochemistry staining method|Performed one time on study
1949017|NCT00813878|Other|liquid chromatography|Performed on samples collected one time on study
1949018|NCT00813878|Other|mass spectrometry|Performed on samples collected one time on study
1949019|NCT00813878|Procedure|fine-needle aspiration|Samples collected one time on study at the appointment for fine-needle aspiration where applicable
1491176|NCT03034863|Behavioral|Safe Actions for Families to Encourage Recovery|A novel, 5-session intervention to enhance currently mandated VA suicide safety planning by involving family members to support its implementation. Incorporation of education about suicide risk factors and teaching communication skills of active listening and making a positive request will supply Veterans and family members with the knowledge and tools needed to 1) identify potential warning signs, and 2) discuss Veteran ideation or family concerns with assurance that such requests will be listened to with validation and support, creating an ally for the suicidal Veteran in his struggle. As discussed above, research has demonstrated compellingly that suicidal desire is motivated by two interpersonal factors; perceived burdensomeness and thwarted belongingness. SAFER aims to increase family support for the Veteran to directly mitigate Veteran loneliness and sense of being a burden to others.
1491177|NCT03034863|Behavioral|Enhanced Treatment-as-Usual|The comparison condition will be an assessment-only enhanced treatment-as-usual (E-TAU), incorporating weekly scripted check-in phone calls to review mood symptoms and use of the safety plan, which will then be given as feedback to the Veteran's primary mental health provider.
1491178|NCT03034850|Procedure|CRS/HIPEC|The generic surgical approach involved peritonectomy procedures and visceral resections called CRS as described by Sugarbaker (1995). Peritoneal disease burden was assessed using the perito- neal cancer index (PCI), which scores 13 intra-abdominal sites on a scale of 0 (no disease) to 3 (lesion size > 5 cm), thus giving a range of possible scores from 0 to 39. The same team performed the surgical procedure of all included patients. Before connection to the patient, the circuit was filled with dextrose 5% (2 L/m2 body surface area) and warmed to 37°C.
1491179|NCT03034837|Drug|resin sealant|Sealing the occlusal surface of the included molars using the market product of SDI conseal f once.
1491180|NCT03034837|Drug|ART sealant|"Sealing the occlusal surface of the included molars using the market product of 3M ESPE KetacTM Molar Easymix glass ionomer cement once."
1491181|NCT03034824|Procedure|SRP+940±15 nm diode laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the 940±15 nm diode laser.
1491182|NCT03034824|Procedure|SRP+Er,Cr:YSGG laser|In addition to Non-surgical periodontal treatment, the individuals diagnosed with Generalized Aggressive Periodontitis were applied the Er,Cr:YSGG laser.
1491183|NCT03034824|Procedure|Scaling and root planing (SRP)-Control|Only Non-surgical periodontal treatment
1491184|NCT03034811|Device|Persona Partial Knee system|Fixed bearing partial knee
2001554|NCT02913755|Behavioral|Preparatory video|5 minute Preparatory video to increase motivation, awareness and engagement in ABI rehabilitation
1491186|NCT03034772|Drug|Dorzolamide-timolol|Topical eye drop (active comparator) used twice daily for study duration
1491187|NCT03034772|Other|Artificial tears|Topical eye drop (placebo comparator) used twice daily for study duration
1491188|NCT03034759|Other|individualized insulin sensitivity index (ISind)|"The new insulin sensitivity index, named SISP is calculated from data derived from insulin pump and glucose monitoring (CGM) uploads."
1491189|NCT03034746|Other|Physical activity (PA)|It will perform a program consist of 15 min of warm-up, 60 min of aerobic and resistance training, and 15 min of cool-down.
1491190|NCT03034746|Other|cognitive treatment (CT)|The cognitive stimulation group will received a rehabilitation program with multimodal repetitive stimulation in order to exercise and reinforce the cognitive skills of the participant to slow/prevent the decline. In particular the treatment will be focused on reorient the patient about his/her-self, his/her history and his/her environment, to improve the memory skill by teaching compensatory and restitutive strategies, to help the patient to the discussion about everyday life and in particular to the everyday problems
1491191|NCT03034733|Drug|Dexamethasone|intravenous dexamethasone, two groups: 0,15 mg/kg, 0,25 mg/kg
1491192|NCT03034733|Drug|Sodium Chloride, (24)NaCl 0,9%|intravenous placebo
1491193|NCT03034720|Behavioral|Collaborative Care|Intervention subjects will receive treatment from an MSW-trained care manager over the course of 6-months after randomization. Intervention team members will work collaboratively with primary care providers to link physical and mental health care longitudinally through outpatient follow-up and community rehabilitation. Intervention subjects and their families and collaborative team members will share information and deliberate treatment decisions with each other in order to develop an individually tailored treatment plan. Stepped, higher intensity care will be available for intervention subjects with recurrent symptoms. Stepped up care will include CBT booster sessions targeting post-concussive and related symptom comorbidity as well as psychopharmacologic assessment and treatment.
1491194|NCT03034707|Dietary Supplement|biotin|
1491195|NCT03034694|Other|teledermatology consult|teledermatology consult
1491196|NCT03034694|Other|Routine Care|The patient will undergo imaging but this report will not be put into the chart.
1491197|NCT03034681|Other|Physiotherapy technique: TENS|
1491198|NCT03034681|Other|Physiotherapy technique: Vojta Therapy|
1491199|NCT03034668|Dietary Supplement|CS16-003 Full dose|350 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts
1491200|NCT03034668|Dietary Supplement|CS16-003 Half dose|175 mg 'Rhodiola rosea L. & Rhaptonticum carthamoides extracts + maltodextrin 175 mg
1491201|NCT03034668|Dietary Supplement|Placebo|Maltodextrin: 350 mg
1491202|NCT03034655|Device|CDP|Vestibular rehabilitation using CDP
1491203|NCT03034655|Device|Mobile posturography|Vestibular rehabilitation using mobile posturography
1491204|NCT03034655|Other|10 sessions|Vestibular rehabilitation, ten sessions
1491205|NCT03034655|Other|5 sessions|Vestibular rehabilitation, five sessions
1491206|NCT03034642|Procedure|Bronchoscopy with bilateral bronchoalveolar lavages|Bronchoscopy with bilateral bronchoalveolar lavages
1491207|NCT03034629|Behavioral|Short-term aerobic exercise|One bout of moderate intensity exercise (75% of maximal predicated heart rate).
1491208|NCT03034616|Device|OLIVA device|"OLIVA device is a laparoscopic device with a standard handle and a tip built of 5 parallel razor blades enclosed by protective cap opened by a separate button.
This device will enable to perform shallow slashes on the ovarian cortex following the grasping of the ovary without damaging other abdominal and pelvic organs"
1491248|NCT03034369|Other|Social support|Patient reported outcome survey administered at baseline and 12 months to assess social support and outlets.
2001555|NCT02914678|Other|Fentanyl|Change in protocol from 2 to a total of 3 μg/kg fentanyl per transport
1491209|NCT03034603|Dietary Supplement|Nutri-jelly with PEITC|Nutri-jelly with PEITC resulted from an addition of tested amount of PEITC, which was shown in animal model to delay cancer growth, into Nutri-jelly.
1491210|NCT03034603|Dietary Supplement|Nutri-jelly|Nutri-jelly is an edible nutritious gel for patients with chewing and swallowing difficulties. One milligram of Nutri-jelly contains approximately 1 kcal.
1491211|NCT03034590|Other|questionnaire|
1949020|NCT00813878|Procedure|needle biopsy|Samples collected one time on study at the appointment for needle biopsy where applicable
1949021|NCT00813878|Procedure|radiomammography|Samples collected one time on study at the appointment for radiomammography where applicable
1491214|NCT03034564|Drug|Northera|
1491215|NCT03034564|Drug|Placebo Oral Tablet|
1491216|NCT03034551|Behavioral|Financial Incentive, Mobile Phone App, and Cellular Scale|Subjects will be provided a cellular-connected digital scale and will be offered $150 to use the app each day to log one daily self-weighing and one medication check-in. Medication check-ins consist of uploading daily photos of pills at the time of self-administration through the Wellth app. If a 2 lb or greater daily increase in weight, or a 5 lb weekly increase in weight is detected in any patient, a UMCPP physician or nurse will be alerted via automatic email and text. A physician or a nurse will then call the patient to assess the patient's symptoms. If there are increasing heart failure symptoms, the physician or nurse will suggest the patient see their doctor within the next 48 hours and will notify the patient's primary care physician and cardiologist.
1491217|NCT03034538|Drug|Zonegran|100mg
1491218|NCT03034538|Drug|Zonegran|200mg
1491219|NCT03034499|Procedure|Single-port sacrocolpopexy|Single-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
1491220|NCT03034499|Procedure|Multi-port sacrocolpopexy|Multi-port sacrocolpopexy surgery for the repair of vaginal apex prolapse.
1491221|NCT03034486|Drug|D930, D565|Period 1: D565 administered 1 time for one day/ Period 2: D930 administered 3 time per day for 9 days/ Period 3: D565(1 time per day) with D930(3 time per day) administered for 9days
1491222|NCT03034473|Other|Translational Research and multimodal treatment|"Blood/biopsy samples (tumor & mucosa) are taken pretherapeutically. Blood samples (serum & plasma) are drawn at 11 time points during RCTx (e.g. for analysis of 5-FU metabolism, genomic DNA extraction). After pathohistological workup of the TME specimen, the formalin-fixed material will be transferred to the central biobank of KFO179. Blood samples (plasma & serum) will be drawn during 5y-follow-up. Treatment (based on CAO/ARO/AIO-94- and CAO/ARO/AIO-04-phase-III trials of the GRCSG):
Preoperative RCT: 28x1.8 Gy (total: 50.4 Gy, 5 fractions per week on d1-d38) combined with 5-FU (1000 mg/m2/d) as 120 h civ during 1st and 5th week.
TME-surgery is performed 6 weeks after RCTx. 4 to 8 weeks after surgery, patients receive either 4 cycles 5-FU (500 mg 5-FU/m2 iv, d1-5, repeat d 29-33) or 3 cycles (6 single appl.) of FOLFOX regimen [(400 mg FA/m2, 2-h civ, d 1; 100 mg oxaliplatin/m2, 2-h civ in 500 ml Glucose 5%, d 1; 2400 mg 5-FU/m2 as 46-h civ) on d1+d15, d30+d45 and d60+d75]."
1491223|NCT03034460|Drug|CD5024 1% cream|500 µL on half-face, five days a week during 6 weeks
1491224|NCT03034460|Drug|CD5024 cream placebo|500 µL on half-face, five days a week during 6 weeks
1491225|NCT03034460|Drug|CD0271/CD1579 gel|500 µL on half-face, five days a week during 6 weeks
1491226|NCT03034460|Drug|CD0271/CD1579 gel placebo|500 µL on half-face, five days a week during 6 weeks
1491227|NCT03034447|Other|Questionnaire|Children and parents are going to inform data regarding socioeconomical status, asthma and rhinitis diagnosis, asthma and rhinitis control, medications, sleep complaints, and sleep habits
1491228|NCT03034447|Other|Lung Function Test|Children are going to blow in a machine that measures how the lung is working
1491229|NCT03034447|Other|Home Sleep Study|Children are going to sleep at home with a device that tells if they stop breathing during sleep
1491230|NCT03034434|Device|Trans-vaginal ultrasound|Three trans-vaginal ultrasounds, the 1st to be performed 8 hours post delivery, the 2nd 24 hours after delivery and the 3rd 48 hours after delivery.
1491231|NCT03034421|Behavioral|Bed rest|Patients will undergo bed rest for 48 hours following endoscopic valve implantation.
1491232|NCT03034408|Drug|Nalmefene|
1491233|NCT03034408|Drug|Baclofen|
1491234|NCT03034408|Drug|Placebo Oral Capsule|
1491235|NCT03034395|Procedure|Wide Local Excision|Surgery
1491236|NCT03034382|Drug|Morphine|5 mg morphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
1491237|NCT03034382|Drug|Nalbuphine|5 mg nalbuphine in 5 ml volume are injected perineurally as adjuvants for 10 ml of lidocaine + epinephrine 1:400,000 in ultrasound guided interscalene block
1491238|NCT03034382|Drug|Bupivacaine 0.5%|10 ml of 1% lidocaine +1:400,000 epinephrine and 5 ml of bupivacaine 0.5% injected perineurally in interscalene block
1491239|NCT03034382|Drug|Lidocaine Hydrochloride 1% and epinephrine 1:400,000|10 ml of 1% lidocaine and 1:400,000 epinephrine were injected perineurally in interscalene block
1491240|NCT03034369|Other|Access to Care|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with access to care.
1491241|NCT03034369|Other|Depression Screening|Analysis of health care claims data for depression screenings at baseline and 12 months.
1491242|NCT03034369|Other|Patient-Provider Relationship|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-provider relationship.
1491243|NCT03034369|Other|Patient-Clinic Interactions|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with patient-clinic interactions.
1491244|NCT03034369|Other|Stigma|Patient reported outcome survey administered at baseline and 12 months to measure perceived stigma.
1491245|NCT03034369|Other|Provider Continuity|Patient reported outcome survey administered at baseline and 12 months to measure satisfaction with provider continuity.
1491246|NCT03034369|Other|Symptom Severity|Patient reported outcome survey administered at baseline and 12 months to measure symptom severity.
1491247|NCT03034369|Other|Diagnoses|Patient reported outcome survey administered at baseline and 12 months to measure diagnoses.
1491324|NCT03033719|Procedure|Laparoscopy|Minimally invasive surgery
1949022|NCT00794040|Drug|Citalopram|
1949023|NCT00794040|Drug|Methylphenidate|
2001556|NCT02913859|Radiation|Radiotherapy to the pelvis|Radiotherapy to the pelvis and prostate
1491250|NCT03034369|Other|Inpatient Hospitalization Utilization|Analysis of health care claims data for Inpatient Hospitalization Utilization at baseline and 12 months.
1491251|NCT03034369|Other|Inpatient Readmissions|Analysis of health care claims data for Inpatient Hospitalization Readmissions at baseline and 12 months.
1491252|NCT03034369|Other|Post-Admission follow-up|Analysis of health care claims data for Post-Admission follow-up at baseline and 12 months.
1491253|NCT03034356|Drug|Levetiracetam|Anticonvulsant drug
1491254|NCT03034356|Drug|Placebo|Placebo
1491255|NCT03034343|Behavioral|Mindfulness|
1491256|NCT03034330|Other|Two-Tier Stroke Family Empowerment|The family-based care management intervention will be implemented in two tiers. The first tier is the Family Care Management that a care manager is responsible for empowering family caregivers to support their stroke survivors through reorganizing family roles, enhancing family functioning, and maximizing their family and community resources. The second tier is led by trained volunteers who are responsible for increasing the capacity of caregivers for the mastery of stroke care by providing psychoeducation, skill-training, and social support. Each caregiver participant will be assigned a care manager and a volunteer. All care managers who are social workers from the participating centres have undergone 4-day training to improve their knowledge of stroke and skills required for the intervention. Similarly, volunteers have undergone 6.5-day training to equip them with the knowledge and skills to conduct the intervention.
1491257|NCT03034330|Other|Volunteer Support Psychoeducation|The active control group will receive a standard, non-family-based psychoeducation intervention provided by the trained volunteers under the supervision of care managers. It will provide 4 in-home visits and 2 telephone follow-up interviews about psychoeducation for caregivers of stroke survivors.
1491258|NCT03034317|Device|NeuRx DPS|Patients who are diagnosed with ALS, have initiated NIV and choose to have the NeuRx DPS implanted.
2001557|NCT02913859|Drug|Hormonal therapy (LHRH agonist and/or antiandrogens)|life-long hormonal therapy (LHRH agonist and/or antiandrogens)
2001558|NCT02913157|Drug|Hydroxychloroquine|Orally administered Hydroxychloroquine
1491261|NCT03034291|Dietary Supplement|Cacao 70%|Consumption for 8 weeks of 50 grams of chocolate per day with 70% cocoa solids.
1491262|NCT03034291|Dietary Supplement|White chocolate|
1491263|NCT03034278|Other|Not applicable - no intervention|Not applicable - no intervention, observational survey study.
1491264|NCT03034252|Procedure|Patients with Liposarcoma|Evaluation of Liposarcoma treated in a single center
1491265|NCT03034239|Dietary Supplement|Protein supplementation|+ insect protein
1491266|NCT03034239|Other|Resistance training|Resistance exercise
1491267|NCT03034226|Other|Glucose clamp technique|Hyperinsulinemic euglycemic and hyperinsulinemic hypoglycemic clamp procedure with infusion of insulin and glucose
1949024|NCT00787826|Biological|Live Francisella Tularensis Vaccine|"Approximately 0.0025 mL of vaccine will be administered percutaneously with a bifurcated needle using 15 pricks on the volar surface of the forearm. Vaccination may be repeated up to two times within the year if successful vaccination is not demonstrated by a positive take reaction and a MA titer of ≥ 1:20."
1491270|NCT03034200|Drug|ONC201|625mg ONC201 will be given every 3 weeks for up to one year or until progression.
1491272|NCT03034148|Diagnostic Test|Platelet Acetyl Coenzyme A Carboxylase analysis in CAD|
1491275|NCT03034096|Drug|Propofol|Maintenance of general anesthesia with propofol infusion
1491276|NCT03034096|Drug|Volatile Agent|Maintenance of general anesthesia with volatile agent (sevoflurane, desflurane, or isoflurane)
1491277|NCT03034083|Behavioral|Elevate|Study participants receive needs assessment and 8 hours of classes over a 4-week period in healthy couple functioning behaviors, relationship quality/stability, and parenting skills.
1491278|NCT03034070|Diagnostic Test|Diagnostic performance 3D T1|"Although non-invasive, the prospective addition of a new MRI sequence to a routine MRI protocol is considered by our ethical committee as an interventional study."
1491279|NCT03034057|Drug|Sayana Press|Sayana Press in the Uniject injection system
1491280|NCT03034018|Drug|suvorexant|10-20 mg taken at bedtime for four weeks
1491281|NCT03034018|Drug|placebo|placebo taken at bedtime for four weeks
1491282|NCT03034005|Drug|Budesonide|1600 ug inhaled daily for 6 weeks
1491283|NCT03033992|Device|Optune System (NovoTTF-200A System, Tumor Treating Fields, TTFields)|The Optune, a.k.a. Tumor Treating Fields (TTFields), will be worn for a minimum of 18 hours a day, with a recommendation of 22 hours/day for at least 23 days in a 28-day cycle. Cycle 1 includes 7 days training period, followed by 28 days treatment (total 35 days). The patients will receive multiple 28-day cycles of continuous Optune treatment. In the absence of treatment related serious adverse events or disease progression, Optune will continue up to 26 cycles.
1491284|NCT03033966|Device|NIRS based Cerebral Oximetry|Cerebral Oximetric measurement before and after decompressive craniectomy
1491285|NCT03033953|Dietary Supplement|Native whey|
1491286|NCT03033953|Dietary Supplement|Milk|
1491287|NCT03033953|Other|Strength training|
1491288|NCT03033940|Radiation|Observational use of fluoroscopy|
1491289|NCT03033927|Diagnostic Test|CTC isolocation and analysis|Circulating tumorigenic cell (CTC) isolation and enrichment will be performed using a proprietary invasion assay.
1491290|NCT03033914|Drug|doxorubicin|Doxorubicin: 25 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
1491291|NCT03033914|Drug|Bleomycin|Bleomycin: 10 units/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
1949028|NCT00764517|Drug|Cladribine|Given IV
1949029|NCT00764517|Other|Laboratory Biomarker Analysis|Correlative studies
1949030|NCT00764517|Biological|Rituximab|Given IV
1949031|NCT00764517|Drug|Vorinostat|Given PO
1949032|NCT00751218|Drug|desloratadine|desloratadine, 5mg oral tablets, once daily for 28 days
2001565|NCT02911714|Drug|Lumason Contrast-Enhanced Ultrasound|In both arms, we will use Lumason to measure kidney allograft perfusion via contrast-enhanced ultrasound.
1491293|NCT03033914|Drug|dacarbazine|Dacarbazine (DTIC): 375 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
1491294|NCT03033914|Drug|Nivolumab|nivolumab 240mg q14 days
1491295|NCT03033901|Device|Polysomnography - Level 1 and Level 3|Participants will undergo simultaneous administration of Level 1 and 3 polysomnography on the rehabilitation unit with study funded sleep technologist present to meet Level 1 standards.
1491296|NCT03033901|Device|Actigraphy monitoring|Participants will undergo actigraphy monitoring to assess habitual sleep duration to determine readiness for polysomnography and examine trajectory and duration of sleep.
1491297|NCT03033901|Other|Sleep Apnea Screening|Participants and their family member or proxy, and clinical staff will be asked to answer questions in order to complete the three standardized sleep apnea screening measures.
1491298|NCT03033888|Behavioral|Health-Literacy Focused Education Session|
1491299|NCT03033875|Behavioral|Tele-Savvy|The Tele-Savvy program engages groups of six dementia family caregivers in a program that extends over 43 days.The program begins with a scheduled 75-minute group videoconference led by facilitators; similar group videoconferences then take place weekly for six weeks. In between the video-conferences, caregivers will receive daily emails with links to 5-15 minute on-line video lessons that can be watched on their own schedule as often as they wish.The videoconferences allow caregivers to report enactment of learned and self-developed management strategy behaviors into their own caregiving and allow them to raise questions. Each daily video presents a teaching point linked to the overall curriculum. The lesson is carried forward by brief, scripted talks by experts or is enacted in vignettes in which a fictional family caring for a father living with Alzheimer's demonstrates effective caregiving techniques linked to the day's teaching points.
1491300|NCT03033875|Behavioral|Healthy Living Education Program|The Healthy Living Education Program contains video and text materials on exercise, diet, and healthy living. Participants will be asked to log into the Canvas site daily over the course of six weeks to view the videos. Each participant will also receive 7 weekly brief scripted phone or video calls from a project facilitator to inquire about participants' use of the materials. Additionally, all participants will convene weekly for a video conference centered on the application of healthy living strategies. Facilitators will greet and check in with each of the caregivers, coach and debrief caregivers on the homework, answer questions and/or respond to feedback about the week's material, review key points and concepts from the week's video sessions and introduce new material, report on any activities that caregivers may have implemented based on the materials, and provide homework assignments.
1491301|NCT03033862|Device|Bioresorbable Vascular Scaffold|Bioresorbable Vascular Scaffold
1491302|NCT03033862|Device|Drug Eluting Stent|Drug Eluting Stent
1491303|NCT03033849|Device|Blood glucose monitoring system for self-testing Contour® Next One|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).
The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.
Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.
Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.
Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.
The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.
An additional skin puncture will be performed by study personnel with single-use lancing devices."
1491304|NCT03033849|Device|Blood glucose monitoring system for self-testing Accu-Chek® Aviva Connect|
1491305|NCT03033849|Device|Blood glucose monitoring system for self-testing FreeStyle Freedom Lite|
1491306|NCT03033849|Device|Blood glucose monitoring system for self-testing OneTouch® Verio|
1491307|NCT03033849|Device|Blood glucose monitoring system for self-testing GlucoMen® areo|
1491308|NCT03033836|Drug|ARV treatment|Dolutegravir 50 mg QD plus co-formulated emtricitabine 200 mg/tenofovir 300 mg QD.
1491309|NCT03033823|Drug|Magnesium|Usual care (i.e. without any restriction of drug therapy) plus oral tablet magnesium supplementation: 426.6mg of magnesium per day three times daily (i.e. 142.2 mg for each shot) throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used (i.e. 189.6mg).
1491310|NCT03033823|Drug|Placebo Oral Tablet|Usual care (i.e. without any restriction of drug therapy) plus oral placebo, totally similar to the verum, three times daily throughout the study (i.e. fifteen days). In case of diarrhea, nearly half-dosage will be used.
1491311|NCT03033810|Device|Fractional flow reserve and instantaneous wave-free ratio|"To explain discrepancies between FFR and iFR using demographic, morphological, genetic and functional indices.
The development of software for the automatic detection of the lowest point of microvascular resistance."
1491312|NCT03033797|Device|MoviLetrando|Half of the participants will play two different levels of the Game MoviLetrando, two minutes each.
1491313|NCT03033797|Device|MoveHero|Half of the participants will play 2 minutes of the game MoveHero.
1491314|NCT03033784|Drug|Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 8IU.
1491315|NCT03033784|Drug|Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 24IU.
1491316|NCT03033784|Drug|Oxytocin|Participants will receive one dose of intranasal oxytocin at a dose of 48IU.
1491317|NCT03033784|Drug|Placebo|Participants will receive one dose of intranasal placebo.
1491318|NCT03033771|Device|Implantation with the Multilayer Flow Modulator (MFM)|Endovascular implantation with the MFM
1491319|NCT03033758|Other|Budesonide/Formoterol treated patients|patients who are eligible to start their treatment with budesonide/formoterol therapy
1491320|NCT03033745|Drug|IgPro20|A liquid formulation of normal human IgG at a concentration of 20% administered as a subcutaneous infusion at a dose prescribed by subject's physician prior to study entry.
1949033|NCT00751218|Drug|placebo|placebo, once daily for 28 days
1949034|NCT00751218|Drug|cetirizine|cetirizine, 10 mg capsules once daily for 28 days
1491323|NCT03033719|Procedure|Laparotomy|Open surgery
1989755|NCT02392806|Device|Bubble CPAP- B&B Bubbler, B&B Medical devices|Infant will be randomized to BabiPlus verses B&B Bubbler at time of extubation
1491325|NCT03033706|Procedure|Pulse pressure variation guided fluid therapy|Pulse pressure variation obtained from invasive blood pressure waveform
1491326|NCT03033706|Procedure|Traditional fluid therapy|4 ml/Kg/hr ringer solution plus rescue fluid bolus of 200 ml Ringer solution if Mean arterial pressure decreased by 20% with central venous pressure less than 4 mmHg.
1491327|NCT03033706|Procedure|Brain tumor excision|Brain tumor excision under general anesthesia
1491328|NCT03033693|Other|Bispectral index will be targeted at 50|The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
1491329|NCT03033693|Other|Bispectral index will be targeted at 35|The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
1491330|NCT03033680|Drug|[F-18]PBR06|PET radiopharmaceutical
1491331|NCT03033667|Dietary Supplement|G group|patients received 500 cc of glucose 10% containing 50 g of glucose proving patients with 200 Kcal with 556 mosmoles/L
1491332|NCT03033667|Dietary Supplement|group L|patients received 100 cc of lipid solution (soybean 30%, medium chain triglycerides 30%,olive oil 25%,fish oil 15% and 20 mg vitamine E) containing 20 g lipid which provided patients with 200 Kcal with osmolarity of 380 mosmoles /L. with a flow rate of infusion of 12.5 cc per hour
1491333|NCT03033667|Dietary Supplement|Group C|Over night fasting with no supplementation
1491334|NCT03033654|Other|Sunscreen, Actinica|Two Consecutive Sunscreen Applications
2001566|NCT02911688|Drug|gamma tocopherol|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after γT dosing.
1491336|NCT03033628|Device|injection using DentalVibe comfort system|giving maxillary infiltration injection of dental local anesthesia using DentalVibe comfort system.
1491337|NCT03033628|Device|traditional dental injection|giving maxillary infiltration injection of dental local anesthesia without using DentalVibe comfort system.
1491338|NCT03033615|Device|PixelShine|Machine learning algorithm
1491339|NCT03033615|Device|Conventional processing|Iterative reconstruction software
1491340|NCT03033602|Behavioral|written exposure therapy|five sessions of writing about traumatic experience.
1491341|NCT03033602|Behavioral|CPT, cognitive only|12 sessions of cognitive therapy related to traumatic experience.
1491342|NCT03033589|Drug|Marcaine 0.25 % Injectable Solution|For the adductor canal block, 20 mL of 0.25% marcaine will be injected with the use of ultrasound guidance into the adductor canal by the attending anesthesiologist on the case in the pre-op holding area.
1491343|NCT03033589|Drug|Marcaine 0.25 % Injectable Solution|For the femoral nerve block, 30 mL of 0.25% marcaine will be injected with the use of ultrasound guidance around the femoral nerve sheath by the attending anesthesiologist on the case in the pre-op holding area.
2001567|NCT02911688|Drug|Placebo|The effect of supplemental with gamma tocopherol on O3 response will be assessed using the difference pre and after placebo dosing.
1491347|NCT03033563|Procedure|Intracytoplasmic sperm injection|Intracytoplasmic sperm injection
1491348|NCT03033550|Behavioral|brief negotiated mobile application|The intervention will supplement the standard of care with the following steps: (1) mobile- based brief negotiated Intervention ( BNI); (2) a customized companion communication vaccine report to be given before AFG sees provider; and (3) automated interactive Electronic Recall/Reminder Messages (Text messaging), including text messaging and access to a website which includes information about HPV, HPV Vaccine, and cervical cancer screening guideline.
1491349|NCT03033537|Drug|Verapamil|Local treatment of erectile dysfunction
1491350|NCT03033524|Drug|TTAC-0001|Calculated amount of drug will be diluted with normal saline and administered intravenously.
1491351|NCT03033511|Drug|Rovalpituzumab tesirine|Rovalpituzumab tesirine 0.3 mg/kg administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
1491352|NCT03033511|Drug|Dexamethasone|Dexamethasone 8 mg administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
1491353|NCT03033511|Drug|Placebo for rovalpituzumab tesirine|Placebo for rovalpituzumab tesirine administered intravenously Day 1 of each 6-week cycle, omitting every third cycle
1491354|NCT03033511|Drug|Placebo for dexamethasone|Placebo for administered orally (PO) twice daily on Day -1, Day 1 (the day of dosing), and Day 2 of each 6 week cycle, omitting every third cycle.
1491355|NCT03033498|Drug|ABBV-951|ABBV-951 administered by subcutaneous infusion.
1491356|NCT03033485|Radiation|18F-P3BZA|18F-P3BZA is a type of 18F labeled Picolinamide targeting melanin which is highly secreted in Melanoma. The toxicity of P3BZA was evaluated by SoBran Bioscience. The final report showed that there no signs of toxicity during the conduct of the toxicity study. No treatment-related differences were noted in mean body weight and body weight changes, clinical chemistry, haematology, or coagulation parameter after a single intravenous dose of P3BZA at 0.0589mg/kg.
1491357|NCT03033472|Drug|600 mg Clindamycin orally|600 mg Clindamycin orally 30 minutes before treatment
1491358|NCT03033472|Drug|Oral Placebo|Oral Placebo 30 minutes before treatment
1491359|NCT03033459|Behavioral|Motivational Interviewing|"Motivational Interviewing (MI) is a psychosocial intervention designed to help individuals increase readiness for behavior change by increasing intrinsic motivation and resolving ambivalence. MI founders MI conversations help clients change behavior through identifying and resolving discrepancies between goal behaviors and actual behaviors. Behavior change is promoted through the elicitation of change talk, or client-verbalized arguments for change. In MI, change talk is elicited through two major components: the therapeutic relationship, or the embodiment of the spirit of MI, and technical skill."
1491360|NCT03033459|Behavioral|Psychoeducation Control|Psychoeducation on infant development, age 0-15 months, brief education on breastfeeding.
1491361|NCT03033446|Radiation|Y-90 Radioembolization|Dose of Yttrium-90 is determined based on BSA, size of liver tumor, and dose modifications required for percent lung shunting between 10-20% on the Tc-99MMA scan
1491362|NCT03033446|Drug|Nivolumab|21 days after Radioembolization, 240mg of IV Nivolumab over 30 minutes will be administered every 2 weeks
1491363|NCT03033433|Drug|DCB-DM101|determination of optimal dose for Stage 2
1491364|NCT03033420|Device|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules|A smartphone-based monitoring system including a) an integrated feedback loop between patients and clinicians and b) context-aware CBT modules
1491365|NCT03033407|Other|Tailored mobile coaching messages|Intervention was adding tailored mobile coaching to current usual diabetes care. The participants received regular mobile messages via Switch app according to entered data, such as self-monitoring of blood glucose, blood pressure, exercise, dietary record, medication record, and body weight. Contents of messages were alert for the unused, weather, behavioral recommendation, education about diabetes, and individualized advices.
1491366|NCT03033394|Drug|Beta-lactam antibiotic|Routine clinical dosing
1491367|NCT03033381|Device|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for operated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
1491368|NCT03033381|Device|Color Doppler Ultrasound|Radiological evaluation was performed by a single radiologist using CDUS for nonoperated side testis of each patient preoperatively and on days 7 and 30 post-surgery. Longitudinal, anteroposterior, and transverse diameters of the testis were measured, and the testicular volume was calculated automatically using the CDUS device (volume = 0.523 × D1 × D2 × D3, where D1, D2, and D3 were the maximal longitudinal, anteroposterior, and transverse diameters defined by CDUS) for both testicles in each patient . Peak systolic velocity (PSV) was calculated using the CDUS system (in cm3/s) for both testicles in each patient.
1491369|NCT03033368|Drug|Rilpivirine|Rilpivirine 25 mg tablet
1491370|NCT03033355|Drug|Intradetrusor injection of Botulinum Toxin-A|Using cystoscopy, Botulinum Toxin-A is injected into the bladder.
1491371|NCT03033342|Drug|Oral single doses of MRX-4|Oral single escalating doses of MRX-4
1491372|NCT03033342|Drug|Oral multiple doses of MRX-4|Multiple ascending doses of MRX-4 given twice daily for 10 days
1491373|NCT03033342|Drug|MRX-4 co-administered with omeprazole|MRX-4 given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
1491374|NCT03033342|Drug|Oral single doses of placebo|Single doses of placebo to match MRX-4
1491375|NCT03033342|Drug|Oral multiple doses of placebo|Oral placebo given twice daily for 10 days to match the oral MRX-4
1491376|NCT03033342|Drug|Placebo co-administered with omeprazole|Placebo given orally on Day 1 and Day 7, co-administered with omeprazole on Day 3 through Day 7
1491377|NCT03033329|Drug|Single intravenous doses of MRX-4|Intravenous single escalating doses of MRX-4
1491378|NCT03033329|Drug|Single intravenous doses of placebo|Intravenous single doses of placebo to match MRX-4
1491379|NCT03033329|Drug|Multiple intravenous doses of MRX-4|Multiple ascending doses of MRX-4 given intravenously twice daily for 10 days
1491380|NCT03033329|Drug|Multiple intravenous doses of placebo|Multiple doses of placebo to match MRX-4 given intravenously twice daily for 10 days
1491381|NCT03033329|Drug|Single dose of intravenous and oral MRX-4|Crossover single dose of intravenous and oral MRX-4 given on Day 1 and Day 4
1491382|NCT03033316|Drug|Dexamethasone|
1491383|NCT03033303|Biological|Hu3F8|Day 1: hu3F8 infused iv over ~30 to 90 minutes. Day 3: hu3F8 infused iv over ~30 to 90 minutes. Day 5: hu3F8 infused iv over ~30 to 90 minutes.
1491384|NCT03033303|Drug|GM-CSF|Days -4 to 0: GM-CSF 250 mcg/m2/day, subcutaneously. Days 1 to 5: GM-CSF 500 mcg/m2/day, subcutaneously.
1491385|NCT03033303|Drug|Isotretinoin|Isotretinoin is administered at 160 mg/m2/d, divided into two doses, x14 days.
1491386|NCT03033290|Drug|Bu-Zhong-Yi-Qi-Tang|Qi-tonifying regimen of traditional Chinese herbal medicine
1491387|NCT03033290|Drug|placebo|placebo control
1491388|NCT03033277|Biological|Placebo transplantation|Intraovarian injection of placebo through vagina under the guidance of ultrasonic.
1491389|NCT03033277|Biological|HUC-MSCs transplantation|Intraovarian injection of HUC-MSCs through vagina under the guidance of ultrasonic.
1491390|NCT03033264|Drug|Dinoprostone|10 mg of a Dinoprostone vaginal insert.
1491391|NCT03033264|Device|Double lumen cervical ripening balloon.|Double lumen cervical ripening balloon.
1491392|NCT03033251|Device|Non Invasive Ventilation|Patients will receive non invasive ventilation as a standard of care.
1491393|NCT03033251|Device|High Flow Oxygen Cannula 50|Patients will receive High Flow Oxygen Cannula with a flow set at 50 L/min
1491394|NCT03033251|Device|High Flow Oxygen Cannula 30|Patients will receive High Flow Oxygen Cannula with a flow set at 30 L/min
1491395|NCT03033225|Drug|Verteporfin PDT|the study drug will be given through an IV infusion. approximately one hour later The physician will direct the endoscope that has an ultrasound to your pancreas, and the treatment laser will be guided to the sites on your pancreas where the tumors are located. This will be done using a ultrasound to find the tumor and place a needle from inside the stomach or small intestine into the tumor. This is a standard procedure for obtaining tissue from a tumor. In this study, a special fiberoptic probe will be placed through the needle to allow light to be delivered to the tumor
1491396|NCT03033212|Other|Therapist-Guided Rehabilitation|Rehabilitation consists of exercises guided by a certified physical therapist. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
1491397|NCT03033212|Other|Self-Guided Rehabilitation|Rehabilitation consists of self-guided exercises with provided instructions. These exercises include: aerobics, walking tests, stability exercises, and strengthening exercises.
1491398|NCT03033199|Drug|Probiotic Agent|probiotic capsules containing three viable and freezedried strains—Lactobacillus acidophilus,Lactobacillus casei, and Bifidobacterium bifidum：2 capsules, bid x 4 weeks for one cycle. It will be given for one or two cycles.
1491399|NCT03033199|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
1491401|NCT03033147|Drug|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|2 gm of amoxicillin/ clavulanic acid combination orally 30 minutes before root canal treatment
1491402|NCT03033147|Drug|Oral placebo|placebo 30 minutes before root canal treatment
1491405|NCT03033108|Drug|Emixustat|Once daily, tablet for oral administration
1491406|NCT03033095|Drug|Etanercept ® 50 mg|The etanercept is not the experimental study drug. Etanercept is a treatment justifying the inclusion of patients and is used in accordance with its marketing authorization.
1491407|NCT03033082|Other|Questionnaire sheets|"A- Marital satisfaction Index (MSI). Interview (Modified Arabic translation)
B- Sexual Satisfaction Scale:(SSS). The Arabic version of the sexual satisfaction scale was used.
C- International Index of Erectile Function Questionnaire (IIEF-5): For male subjects.
D- The Eysenck Personality Questionnaire (EPQ):
The Arabic version of the EPQ was used."
1491408|NCT03033069|Drug|Brexpiprazole (OPC-34712)|
1491409|NCT03033069|Drug|Sertraline|
1491410|NCT03033069|Other|Placebo|
1491411|NCT03033056|Behavioral|Test of fear conditioning|Behavioral and brain correlates of conditioned fear generalization and avoidance will be assessed using fMRI and related to levels of anxiety related psychopathology.
1491412|NCT03033043|Device|Relay Pro Stent-Graft|Endovascular treatment of an aortic dissection
1491413|NCT03033030|Diagnostic Test|Ultrasound|Ultrasound examination
1491414|NCT03033017|Other|Blood Testing|
1491415|NCT03033004|Device|Conventional Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes using the Polarys device. Polarys is a commercially available cryolipolitic device.
1491416|NCT03033004|Device|Contrast Cryolipolysis|Treatment will consist of a heat exposure of the subcutaneous fat for 10 minutes followed by 60 minutes of cold exposure and 10 minutes of heat exposure again. Cold and heat will be provided by the Polarys device. Polarys is a commercially available cryolipolitic device.
1491417|NCT03033004|Device|Reperfusion Cryolipolysis|Treatment will be a cold exposure of the subcutaneous fat for 60 minutes followed by 10 minutes of heat exposure using the Polarys device. Polarys is a commercially available cryolipolitic device.
1491418|NCT03032978|Other|Calcium hydroxide|Pulp capping material
1491419|NCT03032978|Other|Calcium silicate|Pulp capping material
2001568|NCT02910375|Other|Cohort A|Venous sampling (n=13) will be performed in the hospital at D0 (prior to first golimumab injection), D3, D7, D14 (prior to second injection), D28, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D3, M1D7, M2D0 (8 weeks after M0D0, week 14), M3D0 (12 weeks after M0D0, week 18) Dried blood spot sampling (n=39) will be performed at D0 (prior to first golimumab injection), D1, D2, D3, D4, D5, D6, D7, D10, D14, D15, D16, D17, D18, D19, D20, D21, D28, D35, M0D0 (right before injection at week 6), M0D3, M0D7, M1D0 (4 weeks after M0D0, week 10), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, rig week 14), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, week 18)
1491422|NCT03032952|Other|"Feel Stress Free mobile application"|This online and mobile application uses relaxation techniques, thought challenging, mini-games and mood tracking to help reduce feelings of stress, anxiety and depression.
1491423|NCT03032939|Procedure|endotracheal intubation|standard endotracheal intubation of surgical patients after induction of anesthesia
1491424|NCT03032926|Behavioral|Open Trial|Behavioral Intervention
1491425|NCT03032913|Procedure|Blood samples|Blood samples for both group
1491426|NCT03032913|Procedure|Portal vein blood sample|Portal vein blood sample during surgery procedure for the Pancreatic Ductal Adenocarcinoma group
1491427|NCT03032887|Behavioral|voice prompts|voice prompts on disinfectant dispenser
1491428|NCT03032887|Behavioral|agitation|Education, reminders and optimising materials
1491429|NCT03032874|Procedure|Colonoscopy|They all had screening colonoscopy
1491430|NCT03032861|Other|Orange juice|Thirty days before the beginning of trial, women (n= 10; BMI 23.8 kg/m2; 28 years) will be advised to not consumed foods containing prebiotic, probiotic and fibers, and citrus fruits and beverages. After 30 days, the participants will consume 300 mL of orange juice daily during 60 days. After 60 days of orange juice intervention, the participants will be submitted to 30 days of washout. Samples of blood, urine and feces will collect in five different occasions (baseline, 30 day, 60 day, 90 day, and 120 day) in order to evaluate the prebiotic effect of orange juice on gut microbiota and the bioavailability of its flavanones in blood, urine and feces.
1491431|NCT03032848|Drug|Conjugated Estrogen|use of 1 gram per day
1491432|NCT03032848|Drug|Promestriene|use of 1 gram per day
1491433|NCT03032848|Drug|Estriol|use of 1 gram per day
1491434|NCT03032848|Drug|Vaginal Moisturizer - Cream|use of 1 gram per day
1491435|NCT03032809|Other|Vessel Wall MR imaging|Magnetic resonance images of the intracranial arteries will be acquired using the 3 Tesla MR scanners. Intracranial vessels will be imaged by high resolution vessel wall MR imaging to characterize vessel wall enhancement characteristics and wall thickness.
1491436|NCT03032796|Behavioral|Body-Brain Trainer|A novel video game-based intervention that incorporates i) adaptive algorithms critical for cognitive training, ii) physiological measures such as heart rate into the core game mechanics, and iii) motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks.
1491437|NCT03032796|Behavioral|Body Trainer|"A novel video game-based intervention that incorporates physiological measures such as heart rate into the core game mechanics, with motion capture technology to incorporate whole-body kinematics into game play. This group will train for 36 minutes per day, 3 days a week for 8 weeks. The Body Trainer group will train using closed-loop adaptive algorithms to challenge physical performance as guided by heart rate, such that the amount of movement needed to respond on each task will dynamically change depending upon the participant being below/above a predetermined derived level of exertion. During Body Training, participants will only perform a basic reaction task in each level/module to ensure only the most minimal cognitive challenge is present"
1491438|NCT03032796|Behavioral|Brain Trainer|"The Brain Trainer group will train using the aforementioned closed-loop adaptive algorithms to challenge cognitive performance, except while sitting down and playing with an Xbox control pad (thus removing all physical training aspects). This group will train for 36 minutes per day, 3 days a week for 8 weeks."
1491476|NCT03032575|Behavioral|SEARCH010/RV254|
1491521|NCT03032250|Other|Communication Intervention|Attend interventionist sessions
1949038|NCT00697047|Behavioral|Automated Mailing|Usual Care plus Automated mailing
1491439|NCT03032796|Behavioral|Expectancy Matched Control|The placebo-matched control group will engage in a battery of three apps (playing each app 10 minutes per day, 5 days a week for 8 weeks completed in the laboratory that we believe will have no significant impact on the cognitive or physical fitness measures we are assessing: i) an app with 100 different logic games of varying difficulty and length, ii) a language-learning app with 10 language options, and iii) an app that offers a guided Tai Chi program. We have pre-determined that this approach generates matched expectancy compared to our training groups: we asked 100 naïve individuals to predict how they would expect to improve performance on our outcome measures after training on one of these platforms, revealing that placebo training generates equivalent expectations of improvement across each outcome measure as the BBT group.
1491440|NCT03032783|Radiation|Total-Body Irradiation|Undergo Total Body Irradiation
1491441|NCT03032783|Procedure|Donor Lymphocyte Infusion|Undergo Donor Lymphocyte Infusion
1491442|NCT03032783|Drug|Cyclophosphamide|Given IV
1491443|NCT03032783|Drug|Tacrolimus|Given IV
1491444|NCT03032783|Drug|Mycophenolate Mofetil|Given IV
1491445|NCT03032783|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo Hematopoietic Stem Cell Transplantation
1491446|NCT03032770|Device|two-dimensional ultrasound and color Doppler|the eligible participants will be searched for signs suggestive of placenta accreta; low implantation of the gestational sac (<4cm from the external os), presence of placental lakes, Disruption of placental-myometrial interface and trophoblast overlapping a uterine scar by 2 dimensional transvaginal ultrasound and Intraplacental dilated vessels, turbulent blood flows and greatly increased periplacental vascularity by Doppler ultrasound by level II sonographer and co-investigator under his supervision using ultrasound device.
1491448|NCT03032744|Other|Asthma Assessment & Management|Asthma Assessment & Management based on NAEPP-EPR3 guidelines
1491449|NCT03032744|Other|Asthma Education|Asthma education on medications
1491450|NCT03032744|Other|Controllers administered at school|Students will receive the morning dose of their daily preventive asthma medication at school on school days.
1491451|NCT03032731|Behavioral|Website and pedometer intervention|Self-directed, website-based intervention delivered with a pedometer to promote understanding of health and health behaviour change.
1491452|NCT03032731|Other|Control|Standard, publicly available NHS resources for healthy lifestyles.
1491453|NCT03032718|Behavioral|Whole-body vibration training|Whole-body vibration exercise
1491454|NCT03032705|Device|SonicFill™ 2|The intervention in arm 1 is SonicFill™ 2, a sonic-activated, bulk fill dental composite system for posterior restorations that requires no additional capping layer.
1491455|NCT03032705|Device|Filtek™ Supreme|The intervention in arm 2 is Filtek™ Supreme Ultra, a Universal Nanocomposite dental restorative material that is visible-light activated and designed for use in anterior and posterior restorations of any class.
1491456|NCT03032692|Device|SWORD|Both arms will perform two separate sessions consisting of one exercise - shoulder flexion with elbow flexion at 90 degrees - for 4 minutes in two experimental conditions: with and without biofeedback. Group 1 will perform the exercise with biofeedback first and without biofeedback after; group 2 performed the exercise in the opposite order. The SWORD system will be used to record movement data in both sessions.
1491457|NCT03032692|Other|Exercise with biofeedback|
1491458|NCT03032692|Other|exercise without biofeedback|
1491459|NCT03032679|Other|Non interventional study|No intervention
1491460|NCT03032666|Drug|sofosbuvir/velpatasvir|treatment of hepatitis C genotype 1-6 in patients with transfusion-dependent thalassemia.
1491461|NCT03032653|Other|Late Rehabilitation|"Post-0p: Non weight-bearing and no range of motion for 2 weeks post treatment. 2 weeks: Splint removed, removable pre-fabricated walking boot applied. WB as tolerated with boot, range of motion out of boot.
6 weeks: Boot discontinued and full unrestricted and unprotected WB and ROM permitted 6 weeks:"
1491462|NCT03032653|Other|Early Rehabilitation|Weightbearing and range of motion as tolerated within the limitations of participant's own comfort. Use of ambulatory aides of any kind is permitted as needed without restriction. No brace or splint of any kind is permitted
1491463|NCT03032640|Other|Oral Glucose Tolerance Test (OGTT)|Once we test the fasting plasma glucose (after an overnight fast), subject will receive a 75g glucose beverage they will have to drink within 5 minutes. Then after drinking the beverage, 8 blood samples will be collected through the IV catheter, over the next 3 hours.
1491464|NCT03032640|Other|Assessment of dietary compliance|Assessment of consumption of non-caloric artificial sweeteners
1491465|NCT03032640|Other|Stool sampling|Subjects will provide a stool sample.
1491466|NCT03032640|Other|Sodium Saccharin|
1491467|NCT03032640|Other|Placebo|
1491468|NCT03032640|Other|Lactisole|
1491469|NCT03032627|Procedure|Collection of discarded heart tissue|Discarded heart tissue will be collected from patients undergoing the aforementioned cardiac surgeries.
1949039|NCT00697047|Behavioral|Automated Mailing Plus Assisted|If not screened after automated mailing, MA assists with screening.
1949040|NCT00697047|Behavioral|Auto Plus Assisted Plus Navigation|If not screened after automated mailing and assistance by MA, RN begins navigation.
1949041|NCT00685516|Dietary Supplement|green tea|6 cups of green tea daily for 2-8 weeks
1491473|NCT03032601|Dietary Supplement|N-acetyl Cysteine|The study consists of two arms. The first arm of this study will receive intravenous and oral NAC, a strong antioxidant that increases brain glutathione, which may be beneficial in MS. NAC, is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. It is a common over-the-counter supplement that is also available as an injectable pharmaceutical that protects the liver in cases of acetaminophen overdose. It has the potential to reduce markers of oxidative damage, protect against cell death, and to increase glutathione in blood, which might be useful in preventing oxidative damage in MS patients. The second arm will be a waitlist control receiving standard MS care. It should be noted that both arms will receive standard of care while enrolled into the study.
1949042|NCT00685516|Dietary Supplement|placebo|6 cups of water daily for 2-8 weeks
1491522|NCT03032250|Other|Educational Intervention|Watch video on a DVD
1949043|NCT00685516|Dietary Supplement|decaffeinated black tea|6 cups of decaffeinated black tea daily for 2-8 weeks
1491477|NCT03032562|Diagnostic Test|Multimodal measurement of respiratory muscle function and strength|Sleep-studies, capnography, spiromanometry, phrenic nerve conduction studies, magnetic phrenic nerve stimulation, diaphragmatic ultrasound
1491478|NCT03032549|Dietary Supplement|RTD|Ready to Drink Supplement
1491479|NCT03032549|Dietary Supplement|Placebo|Placebo
1491483|NCT03032523|Diagnostic Test|Standard of care glucose test|If the CGM in the remote monitoring group detects a blood sugar less than 46mg/dl, a confirmatory standard of care glucose test will be performed to confirm the low blood sugar.
1491484|NCT03032510|Drug|Eravacycline|
1491485|NCT03032510|Drug|Ertapenem|
1491486|NCT03032510|Drug|Placebo|
1491487|NCT03032510|Drug|Levofloxacin|
1491488|NCT03032497|Device|EEG-based BCI analysis of fear avoidance|Scalp EEG signals that are acquired and recorded from experiment 1 and 2 are analysed for healthy controls, participants with low back pain and participants with lower limb pain. Comparisons of signal patterns are made between groups. Assuming unique signal patterns are obtained for each groups, these signals are further analysed and used to develop a feedback brain training system to better manage pain and ideally reduce fear-avoidant behaviors towards pain.
1491489|NCT03032484|Drug|Bevacizumab|Bevacizumab is FDA approved as a treatment for recurrent Glioblastoma following failure of radiation therapy and temozolomide.
1491490|NCT03032484|Drug|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme.
1491491|NCT03032471|Other|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.|There is no intervention for this study. Patients are allocated to the study groups based on whether or not DCI occurs.
1491492|NCT03032458|Drug|Pethidine|pethidine 25 mg IV bolus injection before start of session plus placebo gel then then IV infusion, so that the total dose doesn't exceed 1mg/kg
1491493|NCT03032458|Drug|Ketorolac|ketorolac IV bolus injection before start of session plus placebo gel then 30 mg IV infusion so that total dose doesn't exceed 60 mg.
1491494|NCT03032458|Drug|Xylocaine Gel|Xylocaine gel locally 15 minutes before session with 10 mg normal saline IV bolus before session then IV normal saline infusion then
1491495|NCT03032445|Other|Alcoholic Beer|Subject will be asked to consume alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
1491496|NCT03032445|Other|Non alcoholic beer|Subject will be asked to consume non alcoholic beer within 30 minutes. Subject will be monitored for 60 minutes at commencement of study beverage.
1491497|NCT03032432|Device|Dynamic Elastic Garment (DEG) brace|Improve function of the shoulder
1491498|NCT03032432|Drug|Corticosteroid injection|Injection to improve rotator cuff tendinosis pain and functional score
1491499|NCT03032419|Biological|IPV-Al SSI|3 primary injections of IPV-Al SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
1491500|NCT03032419|Biological|IPV SSI|3 primary injections of IPV SSI at 6, 10, and 14 weeks of age and 1 booster at 9 months of age
1491501|NCT03032406|Drug|Hydroxychloroquine|
1491502|NCT03032406|Drug|Everolimus|
1491503|NCT03032393|Other|high-power|Subjects will stand with hands on their hips, elbows pointing out and feet approximately one foot apart (high-power) for 20 seconds.
1491504|NCT03032393|Other|low-power|Subjects will stand with hands and arms wrapping around the torso and feet together (low-power) for 20 seconds.
1491505|NCT03032380|Drug|S-649266|2000 mg intravenously every 8 hours for a period of 7 to14 days (dosage adjustment is necessary based on renal function)
1491506|NCT03032380|Drug|Meropenem|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function)
1491507|NCT03032380|Drug|Linezolid|600 mg of Linezolid will be administered intravenously over 30 minutes to 2 hours, every 12 hours.
1491508|NCT03032367|Drug|bedaquiline|
1491509|NCT03032354|Drug|Lactobacillus rhamnosus GG and Bifidobacterium lactis BB12|Combination therapy of probiotics during 6 months
1491510|NCT03032354|Other|Placebo, (Placebo group)|Placebo during 6 months
1491511|NCT03032328|Dietary Supplement|vitamin D supplement|Patients will be given a dose of vitamin D for 2 months
1491512|NCT03032315|Drug|TAH Tablet (Telmisartan80/Amlodipine besylate10/Hydrochlorothiazide12.5)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 12.5 mg combination-drug would be administered orally once
1491513|NCT03032315|Drug|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
1491514|NCT03032315|Drug|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 12.5 mg) would be administered orally once
1491515|NCT03032302|Dietary Supplement|Swisse Womens 50+ Ultivite Multivitamin|Single tablet taken once daily
1491516|NCT03032302|Dietary Supplement|Holland and Barrett Triple Strength Omega-3 Fish Oil|Single capsule taken once daily
1491517|NCT03032289|Behavioral|Active Transport|Active transport, most commonly walking or cycling, is the use of physical activity to commute.
1491518|NCT03032276|Other|Safe motherhood and newborn health promotion package|The intervention package consists of three components: facility, community and linkages between the community and health facilities. Facility based interventions will serve both the comparison and intervention arms. However, other two interventions will serve the intervention arm only. Specific interventions and approaches for the three components will be implemented within the MOH&FW service delivery system to improve MNH practices in families and communities and to increase the use of MNH services from appropriate facilities/providers. The intervention package has been developed based on the experiences from SMPP in Narsingdi district and on the basis of consultations with the International Advisory Body (IAB) that included GoB, JICA, ICDDR,B, other experts and stakeholders.
1491519|NCT03032263|Device|Video Laryngoscopy for nasal intubation|The anesthesia provider will use a video laryngoscope to facilitate the nasal intubation for the procedure.
1491520|NCT03032263|Device|Direct Laryngoscopy|These patients will be nasally intubated for their procedure via direct laryngoscopy
1491523|NCT03032250|Other|Educational Intervention|Complete modules of the Prepare to Care kit
1491524|NCT03032250|Other|Quality-of-Life Assessment|Ancillary studies
1491525|NCT03032250|Other|Survey Administration|Ancillary studies
1491526|NCT03032237|Other|Nutritional intervention - protein-rich|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.
To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.
Intervention group will receive protein-rich meals and protein-rich foods and drinks."
1491527|NCT03032237|Other|Nutritional intervention - standard|"Both groups will receive readymade meals (Sligro) for each day during the 4-week intervention period (28 hot meals in total per participant). They will also receive other food products from FrieslandCampina's assortment to freely consume during the intervention period.
To keep the intervention as close as possible to the real life situation, meals and foods will be home-delivered twice a week as the participants are already used to.
Control group will receive standard (not protein-rich) meals and standard foods and drinks."
1491528|NCT03032224|Procedure|Resection of the esophagus and the gastroesophageal junction|
1491529|NCT03032211|Device|Alfapump|Implant Alfapump® System
1491530|NCT03032198|Device|Imagio Imaging System|The Imagio system is a diagnostic functional and morphologic imaging system intended for the opto-acoustic (OA) evaluation of thyroid in men and/or women who have findings of thyroid nodules.
1491531|NCT03032185|Device|Transcutaneous Elevtrical Nerve Stimulation|
1491532|NCT03032172|Drug|RO7034067|RO7034067 will be administered orally once daily.
1491533|NCT03032159|Behavioral|Text2Breathe Study Group|
1491534|NCT03032146|Procedure|Cardiac Rehabilitation|Cardiac rehabilitation is a multidisciplinary framework which focuses on improving the functioning of heart disease patients to facilitate and optimize the return to a regular routine as early as possible. The rehabilitation program provides the tools for the maintenance of a healthy lifestyle, encouraging participants to take part in recreational activities and includes extending their daily functioning.
1491535|NCT03032133|Procedure|Regional pain control|Regional pain catheter
1491536|NCT03032133|Procedure|Local pain control|Local intraarticular pain catheter
1491537|NCT03032120|Dietary Supplement|Orange juice|Lean and obese subjects drank one single dose (5 mL/kg body weight) of fresh-squeezed orange juice (FOJ) and processed orange juice (POJ) followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
1491538|NCT03032120|Dietary Supplement|Control|Lean and obese subjects drank one single dose (5 mL/kg body weight) of an energy and sugars-matched orange-flavored drink (control), followed by an ad libitum breakfast. A washout period of seven days among each beverage (FOJ, POJ and control) was applied.
1491539|NCT03032107|Drug|T-DM1|-T-DM1 will be administered intravenousely in clinic on day 1 of each 3-week cycle
1491540|NCT03032107|Drug|Pembrolizumab|-Pembrolizumab will be administered intravenousely in clinic on day 1 of each 3-week cycle
1491541|NCT03032094|Procedure|connective tissue graft|palatal connective tissue graft to attain root coverage
1491542|NCT03032081|Other|High intensity exercise|High intensity exercise, defined as an exercise intensity of > 80% of heart rate reserve. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
1491543|NCT03032081|Other|Moderate intensity exercise|Moderate intensity exercise, defined as 50 to 60% of heart rate reserve for 40 to 47 minutes per day, 4 days per week, for 8 weeks. Heart rate reserve is the maximum measured heart rate minus the measured resting heart rate.
1491544|NCT03032068|Other|At-Home Monitoring|Patient reported outcomes, functional measures such as the maximum attainable range of motion (AROM) and the number of steps taken will be tracked using sensors worn by the patient. The AROM sensor values will be verified with range of motion measurements taken using a goniometer during therapy and MD visits.
1491545|NCT03032042|Drug|Azithromycin|
1491546|NCT03032042|Drug|Albendazole|
1491547|NCT03032042|Drug|Delayed treatment|Albendazole+Azithromycin
1491549|NCT03032003|Other|Cysticlean|2 BID for 15 days
1491550|NCT03032003|Other|Placebo|2 BID for 15 days
1491551|NCT03031990|Behavioral|In-person yoga for fertility group|The participants in this group will complete the Yoga for Fertility class at Pulling Down the Moon: An Integrative Center for Fertility. This consists of a 30 minute discussion session followed by a 60 minute Vinyasa style yoga class one time a week for a total of 6 weeks. Participants must attend at least 5 out of the 6 sessions to be included in the analysis.
1491552|NCT03031990|Behavioral|Online yoga for fertility group|The participants in this group will complete an online webinar of the Yoga for Fertility class and engage in a home yoga practice with the Pulling Down the Moon Yoga DVD. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
1491553|NCT03031990|Behavioral|In person discussion only group|The participants in this group will attend an in-person 30 minute discussion session at Pulling Down the Moon. This will occur one time a week for a total of 6 weeks. Participants must complete at least 5 out of the 6 sessions to be included in the analysis.
1491554|NCT03031977|Other|visceral mobilization|
1491555|NCT03031964|Device|revision multihole acetabular cup|post market study of multi hole revision acetabular cup
1491556|NCT03031951|Behavioral|Lifestyle Intervention Group|Subjects will attend 12 educational sessions for a healthy lifestyle in groups of 10-15 participants, for approximately 3 months. Sessions will last 60-90 minutes and will include educational content and practical application classroom exercises in the areas of physical activity and exercise, diet and eating behavior, and behavior modification. The inclusion of self-regulation skills, such as pedometer use, recording food regularly and monitoring weight, is also part of the curriculum.Participants will be instructed and motivated to make small but enduring reductions in caloric intake and to increase energy expenditure to induce a daily energy deficit of approximately 300 kcal. Weight will be monitored weekly.
1491604|NCT03031561|Device|MicoPure ultrasound|Undergo MicoPure ultrasound
1491605|NCT03031561|Procedure|Biopsy of Breast|Undergo breast biopsy or surgical resection
1491558|NCT03031925|Other|ANXA2|serum and urinary concentration
1491559|NCT03031912|Biological|V920 (rVSVΔG-ZEBOV-GP) Ebola Virus Vaccine|The rVSVΔG-ZEBOV-GP vaccine is a live attenuated recombinant virus consisting of a single recombinant VSV isolate (11481 nt, strain Indiana) with the gene for the Zaire ebolavirus GP (ZEBOV GP), Kikwit strain replacing the gene for the VSV GP, which has been deleted. This results in a VSV backbone with the ZEBOV GP constituting the envelope of the virus.
1491560|NCT03031912|Other|Saline|Normal saline (0.9%) has been chosen as an inert substance to serve as placebo control.
1995681|NCT02684903|Behavioral|Parent Child Interaction Therapy|PCIT is a 16-20 session live-coaching parenting intervention. PCIT for Child Welfare families is delivered in two sequential treatment phases following a motivational enhancement training: Phase 1, Child-Directed Interaction (CDI) to enhance positive parenting and interrupt harsh aversive parenting, and Phase 2, Parent-Directed Interaction (PDI) to coach effective parent commands and a consistent time-out protocol when child disobeys.
1995682|NCT02683395|Drug|PLX51107|
1995683|NCT02682862|Drug|olodaterol hydrochloride 2.5mcg, tiotropium bromide 2.5mcg|Inhaler: 2.5 microgram tiotropium (as bromide monohydrate) and 2.5 microgram olodaterol (as hydrochloride) per puff. 2 puffs once daily
1491564|NCT03031886|Other|low glycaemic index intervention|Low GI sweetener would be added to the treatment meals. 30 grams of isomaltulose to dinner and breakfast and 20 grams of isomaltulose to lunch and snack.
1491565|NCT03031886|Other|high glycaemic index intervention|High GI sweetener would be added to the treatment meals. 30 grams of sucrose to dinner and breakfast and 20 grams of sucrose to lunch and snack.
1995684|NCT02682862|Drug|olodaterol 2.5 mcg|Inhaler: 2.5 microgram Olodaterol (as hydrochloride) per puff. 2 puffs once daily
1491567|NCT03031860|Other|Semiquantitative Cough Strength Score|Evaluate extubation outcome according to degree of evaluated Semiquantitative Cough Strength Score
1491568|NCT03031847|Device|Cardiac Resynchronization Therapy Pacemaker|Patients randomized to the pacemaker arm will receive a CRT-P device.
1491569|NCT03031847|Device|Cardiac Resynchronization Therapy Defibrillator|Patients randomized to the defibrillator arm will receive a CRT-D device.
1491570|NCT03031834|Drug|Quinapril|
1491571|NCT03031821|Drug|Metformin|Metformin Duration: 18 months 850 mg PO OD x 30 days then 850 mg PO BID for duration
1491572|NCT03031821|Drug|Placebo Oral Tablet|"Placebo Oral Tablet Duration 18 months
1 tablet (850 mg) PO OD x 30 days then 1 tablet PO BID for duration"
1491573|NCT03031808|Drug|Lidocaine spray (2%)|Spraying trachea from 2 cm above the vocal cords and 5 cm down with a straw with multiple side holes
1491574|NCT03031808|Drug|Muscle Relaxant (Rocuronium)|After induction of anesthesia, the participants are given 0,6 mg/kg bodyweight intravenously.
1491575|NCT03031808|Other|No Muscle relaxant, no Lidocaine|This group get general anesthesia without Rocuronium or Lidocaine
1491578|NCT03031782|Drug|AIN457|Secukinumab (AIN457) is a high-affinity fully human monoclonal anti-human antibody that targets IL-17A and neutralizes activity.
1491579|NCT03031782|Other|Matched placebo|Matched placebo to AIN457 for use in the double blind Treatment Period 2
1491580|NCT03031756|Device|glycine powder air-polishing (Air-Flows)Perio Powder|
1491581|NCT03031756|Device|ultrasonic (Piezon Master 700; EMS, Nyon, Switzerland)|
1491582|NCT03031730|Drug|Carfilzomib|Given IV
1491583|NCT03031730|Drug|Dexamethasone|Given PO or IV
1491584|NCT03031730|Other|Laboratory Biomarker Analysis|Correlative studies
1491585|NCT03031730|Drug|Lenalidomide|Given PO
1491586|NCT03031730|Drug|MDM2 Inhibitor AMG-232|Given PO
1491587|NCT03031730|Other|Pharmacological Study|Correlative studies
1491588|NCT03031717|Procedure|Transjugular intrahepatic portosystemic shunt|
1491589|NCT03031704|Procedure|Endoscopic mucosectomy|Performing adenoma resection through standardized endoscopic mucosectomy of duodenal adenoma.
1491592|NCT03031678|Device|Electric-Acoustic Stimulation (EAS) Cochlear Implant System|Combination of a cochlear implant and a hearing aid
1491593|NCT03031652|Device|Phacoemulsification|The device device used to provide and perform small profile entry for cataract extraction with or without option of insertion of a specified intraocular lens implant
1491594|NCT03031639|Procedure|Endoscopic approach thyroidectomy|Thyroid surgery using endoscopy.
1491595|NCT03031626|Biological|Medical Air vs Oxygen|Medical Air/Oxygen will be given
1491596|NCT03031613|Procedure|PEEP group|Application of 5cmH20 positive end expiratory pressure
1491597|NCT03031613|Procedure|ZEEP group|No application of positive end expiratory pressure
1491598|NCT03031600|Diagnostic Test|Radiodilution via Daxor BVA-100|The BVA-100 measures the hematocrit and residual plasma radioactivity of each sample in a semi-automated process, and the residual radioactivity is compared from that of the pre-injection sample to determine plasma volume. The plasma volume and BVA-100-measured hematocrit are then used to calculate the red cell volume and actual blood volume. The BVA-100 is FDA approved for blood volume measurement in vivo, has a reported precision of ± 2.5%, and has demonstrated accuracy and specificity in blood volume assessment in clinical and research settings (Van, P.Y., et al., 2011, Borovka, M., et al., 2013).
1491599|NCT03031600|Diagnostic Test|Hemodilution via hematocrit measurement|Hemodilution uses the ideal blood volume and serial hematocrit measures drawn before and after administration of a known quantity of IV fluid to estimate blood volume. Ideal blood volume is calculated using the methods described by Feldschuh and colleagues (Feldschuh, J. and Y. Enson, 1977; Feldschuh, J. and S. Katz, 2007). Hematocrit is measured using the Abbot iSTAT point of care testing device and the lab. Urine output is measured in ml. The ideal blood volume, pre and post-bolus hematocrit, fluid bolus volume, and urine output will be used to calculate estimated blood volume using a mathematical model previously described by the investigators (D'Angelo, M., et al., 2015).
1491600|NCT03031587|Other|Additional MRI acquisition sequences|It deals with specific sequences of rapid imaging acquisition in gradient echo (4 to 5 slices/cardiac cycle) with synchronization on the surface ECG systematically included in a cardiac MRI examination, together with update of the slice position depending on the respiratory state (established technique of navigator echo). The acquisition is repeated over 300 cardiac cycles to monitor myocardial temperature changes
1491601|NCT03031587|Device|MRI|cardiac MRI
1491602|NCT03031574|Drug|SUVN-D4010|Tablets
1491603|NCT03031561|Device|Ultrasound|Undergo standard ultrasound
1491607|NCT03031548|Radiation|Reposition ETT|ETT will be repositioned based on CXR by fluoroscopy
1491608|NCT03031535|Drug|Intranasal octreotide acetate|Intranasal spray of octreotide acetate
1491609|NCT03031535|Drug|Subcutaneous octreotide acetate|Subcutaneous injectable solution of octreotide acetate
1491610|NCT03031535|Diagnostic Test|Growth hormone-releasing hormone|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
1491611|NCT03031535|Diagnostic Test|Arginine hydrochloride|Part of the well established GHRH/Arginine challenge to detect GH deficiency.
1491612|NCT03031522|Radiation|18F-IRS|According to experiment, 18F-IRS was non-toxic and stable in serum.
1491613|NCT03031509|Biological|Human Amniotic Epithelial Cells|Human Amniotic Epithelial Cells transplant after debridement
1491614|NCT03031509|Procedure|debridement|debridement
1491615|NCT03031496|Drug|GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets)|"GSK3542503 (HCTZ 50mg/Amiloride HCl 5mg tablets) are cream-colored, circular, flat faced uncoated tablets with beveled edges having break line on one side and BD embossed on the other side."
1491616|NCT03031496|Drug|Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets)|"Moduretic (HCTZ 50mg/Amiloride HCl 5mg tablets) tablets are peach-colored, half scored, diamond shaped tablets marked MSD917."
1491617|NCT03031483|Drug|clarithromycin and lenalidomide|"Each treatment course will consist of:
Oral Lenalidomide (Revlimid) once daily for 21 days at a dose 20 mg; in case of drug-related adverse events the dose can be reduced to 15 and 10 mg/day; Oral Clarithromycin 500 mg twice daily for 28 days. Courses will be repeated every 28 days. After the first 3 courses patients with stable disease or better response will be given another three courses. Patients with complete remission or disease progression after 6 courses will be taken off study, while patients with partial response or stable disease will receive 3 further courses of treatment. Again, patients with complete response or disease progression will stop therapy, while patients with partial response/stable disease will receive 3 further courses up to a maximum of 12 courses in total."
1491618|NCT03031470|Drug|Reparixin|Reparixin 168 hrs continuous infusion
1491619|NCT03031470|Other|Standard care procedures|Standard procedures for administration of Immunosuppressive and support post transplant therapies
1491620|NCT03031457|Diagnostic Test|Duplex ultrasound|Duplex ultrasound of lower extremity venous system
1491621|NCT03031444|Drug|Cetuximab plus FOLFIRI/FOLFOX|cetuximab was added into the routine perioperative chemotherapy(FOLFIRI/FOLFOX) to evaluate its safety and efficacy
1491622|NCT03031444|Drug|FOLFIRI/FOLFOX/CapeOX|to evaluate its safety and efficacy of routine perioperative chemotherapy(FOLFIRI/FOLFOX/CapeOX)
1491623|NCT03031431|Device|Non-Electric Infant Warmer|Electric warmers are the standard of care in developed countries, but are extremely costly, complicated with risk of causing both hypo and hyperthermia with misuse, and often not feasible in settings without stable electricity. Through a multi-institutional collaboration, the investigators have developed an electricity-free infant warmer.
1491624|NCT03031418|Diagnostic Test|ExoDx Prostate Intelliscore|ExoDx Prostate (IntelliScore) is a non-invasive, urinary 3-gene expression validated test in which the results of the assay are adjunctive to the ordering physician's clinical judgment and work-up of the patient in the determination of whether a prostate needle biopsy is necessary. The ExoDx Prostate (IntelliScore) was clinically validated to discriminate patients with higher grade prostate cancer from those with more indolent lower grade cancer and benign disease.
1491625|NCT03031405|Drug|Oxytocin nasal spray|
1491626|NCT03031405|Drug|Placebos|Placebo nasal spray
1491627|NCT03031392|Diagnostic Test|Sensitivity test|Routine clinical and radiographic examination
1491628|NCT03031379|Other|shortened fast|fast of 45 minutes prior to surgery as opposed to standard 6 hour fast
1491629|NCT03031366|Other|3d roadmap guidance|TIPS was established using 3d roadmap
1491630|NCT03031366|Other|conventional TIPS procedure|conventional TIPS procedure using wedged hepatic venography
1491631|NCT03031353|Drug|Misoprostol|Misoprostol is given before elective cesarean section as prophylaxis against post partum hemorrhage
1491632|NCT03031353|Drug|Placebos|placebos tablet will be given before elective Cesarean sections
1491633|NCT03031340|Drug|Pregabalin|On the day of the surgery, 1hour + 15 minutes before the surgery starts, the subject will receive either 300mg of pregabalin or a similarly packaged placebo. On post operative day one, 150 mg of pregabalin or placebo will be given in two doses 12hrs apart.
1491634|NCT03031340|Other|placebo|placebo
1491635|NCT03031327|Device|Lubricin 20µg/ml eye drops|Lubricin 20µg/ml eye drops 3 times per day
1491636|NCT03031327|Device|Lubricin 50µg/ml eye drops|Lubricin 50µg/ml eye drops 3 times per day
1491637|NCT03031327|Device|Sodium hyaluronate (HA) 0.18% eye drops|Sodium hyaluronate (HA) 0.18% eye drops 3 times per day
1491638|NCT03031314|Device|barbed suture|
1491639|NCT03031314|Device|standard suture|
1491640|NCT03031301|Device|Vibrant capsule|One Vibrant capsule will be ingested 5 times per week for 8 weeks of treatment.
1491641|NCT03031301|Device|Sham capsule|One Sham capsule will be ingested 5 times per week for 8 weeks of treatment.
1491642|NCT03031288|Device|A|standard bottle
1491643|NCT03031288|Device|B|vented base bottle
1491644|NCT03031275|Radiation|High-resolution computed tomography|HRCT of the thorax
1491645|NCT03031275|Radiation|Magnetic resonance imaging|MRI of the brain
1491646|NCT03031275|Behavioral|Cognitive testing|Neuropsychological testing
1491647|NCT03031262|Drug|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
1491648|NCT03031262|Drug|Chidamide|Chidamide at a dose of 20mg/d twice a week for 3 months.
1491649|NCT03031249|Drug|Cytarabine|Cytarabine at a dose of 3g/㎡/d on the first, third and fifth day.
1491650|NCT03031249|Drug|all-trans retinoic acid|ATRA at a dose of 30mg/㎡/d on day 1-14.
1491651|NCT03031249|Drug|Arsenic Trioxide|ATO at a dose of 10mg/d on day 1-14
1491652|NCT03031236|Behavioral|Psychosocial stimulation, Cognitive behavioral therapy and positive parenting practice|The mothers of intervention (ECD+HN) group will receive fortnightly group sessions for 12 months that will include combined messages on a) psychosocial stimulation, b) positive parenting to prevent child maltreatment and c) cognitive behavioural therapy (CBT) for positive thinking, d) health and nutrition messages and e) 15 micronutrient sprinkle supplement.(90 sachets of over 6 month-period)
1491653|NCT03031223|Radiation|low-level laser therapy|low-level laser therapy
1491654|NCT03031210|Drug|Amoxicillin|(90 mg/kg/day) twice daily
1491655|NCT03031197|Combination Product|Tailored realtime triggered reminder pkg|"Core intervention: 1) real time, personalized wireless reminder messages when ART doses are not taken on time, and 2) 'feedback' on adherence behavior via monthly interactive counseling sessions informed by summaries of their previous month's behavior. Personalized features of the intervention will be selected by each patient and may include 1) reminders sent to the WPC (light or chimes) or to patient's or caregiver's cell phone if dose is late; 2) content of text messages from a menu of options; 3) use of youth-friendly WPC adherence reports for interactive counseling sessions; 4) additional counseling by clinic staff; 5) a buddy system, by choosing someone to review the adherence report with him/her; and 6) a reward message after a pre-selected time period of excellent adherence."
1491656|NCT03031184|Drug|Carbamazepine|
1491657|NCT03031184|Drug|Mirtazapine|
1491658|NCT03031184|Other|Placebo|
1491659|NCT03031171|Behavioral|Screening patient navigation|The program offered assistance with scheduling, paperwork, arranging transportation, answering questions and providing education about screening and colorectal cancer.
1491660|NCT03031171|Behavioral|Non-Navigated|Randomly matched sample of non-navigated clinic patients
1491661|NCT03031158|Behavioral|SFEX+H|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist), hip-focused strengthening exercises and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
1491662|NCT03031158|Behavioral|SFEX|Participants will receive an intervention consisting of heat to the low back, manual therapy to the hip (including movement of the hip by the therapist) and a trunk muscle training program including exercises for the abdominal and low back muscles. The intervention will be delivered twice weekly for 8 weeks.
1491663|NCT03031145|Biological|Felis Domesticus|Nasal Administration of Felis Domesticus
1491664|NCT03031132|Behavioral|HP-Beverage Breakfast|Participants will consume high protein beverage (shake) breakfast meals each morning.
1491665|NCT03031132|Behavioral|HP-Solid Breakfast|Participants will consume high protein solid (traditional food items) breakfast meals each morning.
1491666|NCT03031132|Behavioral|Breakfast Skipping|Participants will skip breakfast each morning.
1491667|NCT03031119|Drug|Placebo|Tablets administered once or twice daily, with food, in Part A.
1491668|NCT03031119|Drug|PF-06835919|Tablets administered once or twice daily, with food, in Part A. Tablets administered once or twice daily, with food and atorvastatin in Part B.
1491669|NCT03031119|Drug|atorvastatin|In Part B, tablets administered once or twice daily, with food, with and without PF-06835919.
1491670|NCT03031093|Radiation|inhalation protocol|technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution
1491671|NCT03031093|Device|EPAP valve|aerosol solution of technetium labeled diethylenetriaminepenta-acetic acid (99mTc-DTPA) (1mCi) and bronchodilators (fenoterol (2.5 mg) and ipratropium bromide (0.25 mg)) with 0.9% saline solution (total 1,5 ml) using a vibrating MESH inhaler (Aerogen® Solo, Aerogen Ltd, Galway, Ireland). An EPAP valve will be associated to the circuit in the exhalation branch.
1491672|NCT03031080|Device|Thermoplastic Hand Splint|Thermoplastic Night splint created and moulded to the individual patients hand in-house using generic thermoplastic.
1491673|NCT03031067|Device|Machine perfusion|"The graft preservation will be performed perfusing with a oxygenated solution of preservation at 4°C for two hours with Exiper, Bologna Machine Perfusion, developed by Medica s.p.a and our research group.
Flow and pressure values will be set up for the kidney and liver perfusion, differently. The oxygenation of solution will be performed by an oxygenator and a filter for decapneization / oxygenation. During the perfusion the oxygen pressure will be required between 600-750 mmHg (pO2 80-100 Kpa), as reported in the scientific literature. The pH, lactate concentration, and oxygen (PO2) and carbon dioxide (PCO2) partial pressure were measured in the preservation solution at T0 and T1 by means of a standard haemogasanalyzer."
1491674|NCT03031054|Procedure|Sono-guided injection with hyaluronic acid|Sono-guided injection with hyaluronic acid (ARTZDispo, 25 mg/2.5 ml) between carpal tunnel and median nerve
1491675|NCT03031054|Procedure|Sono-guided injection with normal saline|Sono-guided injection with 2.5cc Normal saline (0.9%) between carpal tunnel and median nerve
1491676|NCT03031041|Procedure|Ultrasound-guided short-axis hydrodissection with 3cc normal saline|Ultrasound-guided short-axis hydrodissection with 3cc normal saline between carpal tunnel and median nerve
1491677|NCT03031041|Procedure|Ultrasound-guided long-axis hydrodissection with 3cc normal saline|Ultrasound-guided long-axis hydrodissection with 3cc normal saline between carpal tunnel and median nerve
1491678|NCT03031028|Other|ketogenic diet|Ketogenic Diet is a high fat, low carbohydrate diet.
1491679|NCT03031015|Device|Cemented K-wire Fixation|Fractures were reduced and then fixed with cemented K-wires.
1491680|NCT03031015|Device|Plating|Fractures were reduced and then fixed with Plate.
1491681|NCT03031002|Behavioral|Exposure treatment for spider fear|Two sessions (each session = 60 minutes) of in-vivo exposure treatment (including psychoeducation) with two different spiders. Exposures comprise a hierarchy of 7 steps, to be completed with both spiders.
1491682|NCT03030989|Drug|Chlorhexidine Gluconate 2% Wipe|
1491683|NCT03030989|Drug|Placebo Wipe|
1491684|NCT03030976|Drug|cyclophosphamide|Patients receive cyclophosphamide (Cy) on day -2 and day -1 to reduce B cells. The dose is 0.5g/m2/d.
1491685|NCT03030976|Drug|anti-CD19-CAR-T cells|A 2nd CAR, CD19 as target protein, 4-1BB as co-stimulator, and optimized the spatial conformation by a suitable hinge & transmembrane domain sequences. Patients infused with anti-CD19-CAR-T cells transduced with lentivirus on day 0 in the absence of disease progression or unacceptable toxicity to treatment of SLE. The dose is 1E6~1E7 CD19-CAR positive T cells. The cells infusion process may last for 30 min.
1491686|NCT03030963|Other|Equal ratio ventilation(ERV)|Set the inspiratory to expiratory ratio 1:1 during mechanical ventilation
1491687|NCT03030963|Other|"I:E Ratio 1:2"|Set the inspiratory to expiratory ratio 1:2 during mechanical ventilation
2001569|NCT02910375|Other|Cohort B|Venous sampling (n=8) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D3, M1D7, M2D0 (8 weeks after M0D0, right before next injection), M3D0 (12 weeks after M0D0, right before next injection) Dried blood spot sampling (n=20) will be performed at M0D0 (right before new golimumab injection), M0D3, M0D7, M1D0 (4 weeks after M0D0, right before next injection), M1D1, M1D3, M1D5, M1D7, M1D9, M1D14, M1D21, M2D0 (8 weeks after M0D0, right before next injection), M2D1, M2D3, M2D5, M2D7, M2D9, M2D14, M2D21, M3D0 (12 weeks after M0D0, right before next injection)
1491690|NCT03030937|Drug|Apatinib|Apatinib, a novel targeted inhibitor of VEGF receptor 2 (VEGFR2).
1491691|NCT03030937|Drug|Irinotecan|Irinotecan was used as second line treatment with AGC.
1491692|NCT03030924|Device|Solace|Noninvasive physiologic monitor
1491693|NCT03030911|Drug|Dexmedetomidine|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
1491694|NCT03030911|Drug|Midazolam|The drug will be administered for sedation and its effect on basal metabolic rate will be investigated
1491695|NCT03030911|Drug|Fentanyl|The drug will be administered in both groups
1491696|NCT03030911|Device|Indirect calorimetry|The device will be used for measurement of basal metabolic rate
1491697|NCT03030898|Diagnostic Test|respiratory variation of the right internal jugular vein|respiratory variation of the right internal jugular vein vs respiratory variation of superior and inferior cava vena
1491698|NCT03030885|Drug|131I-MIP-1095|"First Therapeutic Dose with 131I-MIP-1095 to be administered no later than 30 days after dosimetry dose, which will be designated Day 1 of the Treatment Phase 2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 41. 1st Therapeutic Dose with 131I-MIP-1095 to start after qualifying from dosimetry on Day 8 or no later than 30 days after dosimetry dose.
2nd and 3rd Therapeutic Doses with 131I-MIP-1095 to be administered 12 weeks apart Monthly Follow-Up Visits until Week 53"
1491703|NCT03030846|Other|Stabilization exercise|18 sessions during 6 consecutive weeks, three times per week, 30 or 40 minutes per session including: Twenty minutes for receiving hot pack and TENS and 10 or 20 minutes for training the exercises in 7 level : 1.Train the specific contraction of the deep abdominal muscles, multifidus and pelvic floor muscles(PFM). 2.Train the specific contraction of deep abdominal muscles with coactivation of multifidus and PFM in supine, prone, sitting, standing and quadruped position. 3. Segmental control exercises in close kinematic chain. 4. Segmental control exercises in open kinematic chain with limb loading, emphasis on abdominal muscles. 5. Segmental control exercises in open kinematic chain with limb loading, emphasis on back extensor muscles. 6. Progress exercises to functional task. 7. Coactivation of abdominal and multifidus muscles with limb loading in aerobic tasks.
1491704|NCT03030846|Other|Control group|8 sessions during 6 consecutive weeks, three times per week, per session including: Twenty minutes for receiving hot pack and TENS
1491705|NCT03030833|Device|Pulse Oximeter|Comparison of pulse oximetry to blood gas analyzer.
1491706|NCT03030820|Procedure|Dental Cleaning|This is standard of care dental cleaning as is guided by the initial dental evaluation
1491707|NCT03030807|Diagnostic Test|Right heart cathetarization (in case of suspected PH)|
1491708|NCT03030794|Device|Repetitive transcranial magnetic stimulation|A non-invasive method of brain stimulation that emits a magnetic pulse.
1491709|NCT03030794|Device|Repetitive transcranial magnetic stimulation (sham)|No brain stimulation will be administered.
1491710|NCT03030768|Drug|PrEP|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex during the peri-conception period.
1491711|NCT03030768|Behavioral|Counseling on timed condomless sex, ART and PrEP adherence|An integrated, phased safer conception intervention that focuses on ART use by the HIV-1 infected partner, PrEP use by the HIV-1 uninfected partner, and timed condomless sex
1491712|NCT03030755|Other|Optical coherence tomography|
1491713|NCT03030742|Other|Survey|"A survey will be administered at two time points (time of hospital discharge and 2-4 weeks postpartum) to determine:
Satisfaction with pain control 2-4 weeks postpartum
Patient-reported use of opioid medication postpartum (receipt of prescription, filling of prescription, if refill was obtained, and number of opioid pills remaining at the time of follow-up)
Patient characteristics associated with high opioid use
Methods of storage and disposal of unused opioids"
1491714|NCT03030716|Dietary Supplement|95% condensed proanthocyanidins from grape seed extract|0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each
1491715|NCT03030703|Dietary Supplement|phytic acid|350 mg phytic acid (inositol hexaphosphate) three times daily for four weeks
1491716|NCT03030690|Other|Glass Carbomer Cement|Restoration of proximal lesions in primary molars using glass carbomer cement
1491717|NCT03030690|Other|Composite Resin|Restoration of proximal lesions in primary molars using composite resin.
1491718|NCT03030690|Other|Resin Modified Glass Ionomer Cement|Restoration of proximal lesions in primary molars using resin modified glass ionomer cement
1491719|NCT03030677|Procedure|Pectoralis type 2 block and catheter insertion without Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
1491720|NCT03030677|Procedure|Pectoralis type 2 block and catheter insertion with Lidocaine dissection|B Braun Catheter Kit Contiplex with a 18 gauge needle will be used. After topicalization of the skin and sterilization using ultrasound guidance to facilitate performing insertion of the canula. 10 ml of lidocaine 1% will be injected for plan dissection to facilitate the procedure. Confirming the tip position will be done by ultrasonography while performing pectoralis type 2 block for cases undergoing simple mastectomy procedures
1491721|NCT03030677|Drug|Lidocaine|
1491722|NCT03030664|Dietary Supplement|L.reuteri|Each day, at about the same time, the subjects will be given 5 drops (1x10^8 CFU) of the study product in connection with feeding
1491723|NCT03030664|Drug|Placebo|Same formulation as study product, without probiotics.
1491820|NCT03029845|Drug|Propranolol 2|Participants will take 10 mg propranolol twice a day for 2 weeks
1491724|NCT03030651|Behavioral|Breastfeeding Education and Support|Women Development Army (WDA) leaders will function as peers for mothers in intervention group. There will be two visits during pregnancy and 8 visits postnatally. During pregnancy, WDA leaders will cover in detail the importance of EBF, feeding colostrum first, and discouraging prelacteal foods and encourage the mother to deliver at the nearby health center. During Postnatal visits, mothers will be observed positioning, attaching, and feeding the new-born, with appropriate feedback provided, solving any BF problems, encourage the mothers to continue exclusive breastfeeding for 6 months, emphasize nutrition for sufficient breast milk to breastfeed successfully and hands-on guidance only when necessary.
1491725|NCT03030638|Drug|Olodaterol|Drug
1491726|NCT03030638|Drug|Indacaterol|Drug
1491727|NCT03030625|Radiation|IGRT/VMAT focal therapy boost to DIL|Image-guided/VMAT focal Intensification dose to intraprostatic dominant lesion in men with localized prostate cancer (PCa) of intermediate and high risk (criteria NCCN) eligible to receive radiotherapy
1491728|NCT03030612|Drug|ARGX-110 with AZA|
1491729|NCT03030599|Drug|JZP-258|
1491730|NCT03030599|Other|Placebo|
1491731|NCT03030573|Procedure|Reconstruction of the bile duct with the round ligament|In patients who had bile duct defect by injury or resection, the Round ligament will be used to reconstruct the defect. Surgical technique, the early and long term postoperative measures are detailed in the investigators protocol.
1491732|NCT03030560|Drug|Lidocaine|patients (n = 20) will receive a loading dose of lidocaine 2 mg ̸ kg slowly IV just before induction of anesthesia, then the lidocaine infusion started at a rate of 3 mg ̸ kg/h, and continued until the end of the operation.
1491733|NCT03030560|Drug|0.9% Sodium-chloride|patients (n = 20) will receive an equal volume of 0.9% saline (both the loading and the infusion), the infusion will be initiated at the time of induction of anesthesia and continued until the end of the operation.
2001570|NCT02905162|Other|Transitional HIV care for prison releasees|Transitional HIV care program for releasees
1491735|NCT03030534|Combination Product|Educational package and software package|Using Information and communication technology to deliver health promoting activities
1491736|NCT03030534|Other|Health promotion tips|Give general information on health promotion
1491737|NCT03030521|Diagnostic Test|the aortic delamination test|The aortic delamination test will be performed in the dissected tissue of all patient. The processes of this test has been descripted in the summary.
1491738|NCT03030508|Other|No intervention|
1491739|NCT03030495|Device|Comprehensive physiologic evaluation|Comprehensive physiologic evaluation using pressure-temperature sensor wire to measure fractional flow reserve, coronary flow reserve, index of microcirculatory resistance
1491740|NCT03030495|Device|Intravascular imaging devices|Intravascular ultrasound or optical coherence tomography
1491741|NCT03030482|Procedure|touch massage|
1491742|NCT03030469|Other|Change in electronic health record default for new opioid analgesic prescriptions|
1491743|NCT03030456|Device|Power Plate®|Training of elderly women with Whole Body Vibrations through the use of a vibratory platform.
1491744|NCT03030430|Biological|BAT1706|1mg/kg, IV on day 1
1491745|NCT03030430|Biological|EU-sourced Avastin|1mg/kg, IV on day 1
1491746|NCT03030430|Biological|US-sourced Avastin|1mg/kg, IV on day 1
1949044|NCT00666952|Other|Video Decision Aid|Participants randomized to the video decision aid group will be asked to view the video portion of the decision aid, Weight loss surgery: Is it right for you? in a private room The content of the video and accompanying booklet was based on a systematic-review of the efficacy and safety of bariatric surgery, input from experts in bariatric surgery, internal medicine, psychology, nutrition, and nursing, and from a series of focus groups and interviews with 30 morbidly obese patients, some of whom had elected not to have bariatric surgery.
2001571|NCT02905591|Drug|Radiation Therapy|Conformal radiation administered daily, Monday through Friday Total dose is 60 Gray (Gy) and is delivered in 2 Gy fractions. One fraction is delivered daily for a total of 30 fractions in 30 days
2001572|NCT02905591|Drug|Paclitaxel|"Administered intravenously (IV) Given the same day as carboplatin, but given before the carboplatin is administered
During concurrent phase:
the dose is 45 mg/m2 (standard dose)
Administered weekly
6 to 7 weeks of therapy, depending on when radiation starts
Standardized dose reductions are used
Consolidation phase:
Begins 3 to 4 weeks after completing radiation therapy
Prescribed at 200 mg/m3 (standard dose)
Given once every 21 days (i.e., one cycle)
Up to 2 cycles are administered
Standard dose reductions are used"
1491750|NCT03030378|Other|Laboratory Biomarker Analysis|Correlative studies
1491751|NCT03030378|Biological|Pembrolizumab|Given IV
1491752|NCT03030378|Biological|Recombinant Interleukin-12|Given SC
1491753|NCT03030365|Device|"Siemens Biograph mMR PET-MR (3T)"|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging. In addition Patients will receive an intravenous injection of 2-5mCi of 18F-FDG prior to PET MRI.
1491755|NCT03030339|Other|High VA intake, recent VAS|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (VAS; 200,000 IU) in the past month, and are identified as being likely to have chronic excessive dietary VA intake.
1491756|NCT03030339|Other|High VA intake|Children who are exposed to multiple VA programs, have received a high-dose VA supplement (200,000 IU) in the past 3-6 months, and are identified as being likely to have chronic excessive dietary VA intake.
1491757|NCT03030339|Other|Low/adequate VA intake|Children who are not exposed to multiple VA programs, have received a high-dose VA supplement in the past 3-6 months, and are identified as being likely to have chronic low to adequate dietary VA intake.
1491758|NCT03030326|Behavioral|heart rate variability biofeedback|Patients learn to increase heart rate variability by breathing at the resonance frequency of the cardiovascular system, at approximately 6 breaths/min, varying among people.
1495652|NCT03002012|Drug|Placebo Oral Tablet|matched placebo tablet
1949045|NCT00666952|Other|Booklet Decision Aid|General educational booklet on gastrointestinal surgery developed by the NIH titled, 'Gastrointestinal Surgery for Severe Obesity'.
1949046|NCT00659230|Drug|Nepicastat|100-800mg
1491759|NCT03030313|Device|Reassure Non-Contact Respiration Monitor|Reassure Respiration Monitor uses very low power radio waves to detect respiratory movements of a person while asleep in bed - without physical contact with the individual. Algorithms analyze the respiratory movement signals and extract information about respiration rate and variability. This data is uploaded to a secure cloud infrastructure for storage.
1491760|NCT03030300|Drug|Novolin 30R;Pioglitazone;Metformin|"Insulin (Novolin 30R) was titrated according to the level of blood glucose until reached euglycemia (FPG≤6.1mmol/L and/or P2hBG≤8.0mmol/L and/or HbA1c ≤6.5%). After glucose was well controlled within these targets for 4 weeks, insulin dosage was gradually decreased until discontinued;
Pioglitazone hydrochloride was discontinued if the glucose was well controlled at the 6th week after the cessation of insulin;
Metformin was the last drug that to be discontinued if the glucose was still well controlled at the 4th week after the cessation of pioglitazone."
1491761|NCT03030287|Drug|OMP-305B83|intravenous (in the vein) infusion
1491762|NCT03030287|Drug|Paclitaxel|administered intravenously
1491763|NCT03030274|Device|Occlutech AFR device|Catheter-guided placement of an AFR device following balloon atrial septostomy.
1491764|NCT03030261|Drug|Elotuzumab|"During induction therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1, 8, 15, and 22 for Cycles 1-2 and Days 1 and 15 for Cycles 3-4. Elotuzumab will be administered intravenously at a dose of 10 mg/kg.
During continuation therapy, elotuzumab will be administered on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 for Cycles 7+. For Cycles 1-6 elotuzumab will be administered intravenously at a dose of 10 mg/kg. For Cycles 7+ elotuzumab will be administered at a dose of 20 mg/kg."
1491765|NCT03030261|Drug|Pomalidomide|During induction therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 4 mg. During continuation therapy, pomalidomide will be taken by mouth daily on Days 1-21 of each 28-day cycle at a starting dose of 2 mg. During continuation, pomalidomide may be dose escalated to 4 mg at the discretion of the treating physician if the 2 mg dose is tolerated.
1491766|NCT03030261|Drug|Dexamethasone|During induction, dexamethasone will be taken by mouth on Days 1, 8, and 15 of each of four 28-day cycles at a starting dose of 40 mg. During continuation therapy, dexamethasone will be taken by mouth at a starting dose of 40 mg. It will be given on a 28-day cycle as follows: on Days 1 and 15 for Cycles 1-6 and on Day 1 only for Cycles 7+. Sufficient quantity of drug for one cycle of therapy will be prescribed to the patient at a time.
1491767|NCT03030261|Procedure|Autologous stem cell transplant|-Standard of care
1491768|NCT03030261|Drug|Melphalan|-Standard of care
1491769|NCT03030248|Drug|Vancomycin Oral Capsule|We have chosen oral vancomycin capsules as it is currently a standard of care for Clostridium difficile infections, is poorly absorbed by the intestines, and is easier to blind compared to oral vancomycin solution.
1491770|NCT03030248|Drug|Placebo Oral Capsule|A capsule containing gelatin, polyethylene glycol, titanium dioxide, iron oxide, and FD&C blue No. 2. Contains the inactive ingredients of the vancomycin oral capsule, as mixed by the Froedtert Health Research Pharmacy.
1491771|NCT03030235|Drug|Dapagliflozin 10Mg Oral Tablet|Dapagliflozin 10Mg Oral Tablet
1491772|NCT03030235|Drug|Dapagliflozin matching placebo|Dapagliflozin matching placebo
1491773|NCT03030222|Drug|Empagliflozin 10Mg Tab|Empagliflozin 10Mg Tab
1491774|NCT03030222|Drug|Placebo Oral Tablet|Empagliflozin matching placebo
1491775|NCT03030209|Procedure|Distal pancreatectomy|Distal pancreatectomy with or without splenectomy using minimal invasive or open approach
1491776|NCT03030196|Drug|Denosumab|NaCl 0.9% injection is used as placebo
1491777|NCT03030183|Drug|RA101495|0.3mg/kg subcutaneously (SC) at Day 1 (loading dose) followed by a starting maintenance dose of 0.1 mg/kg daily SC
1491778|NCT03030170|Device|ENDO GIA X-tra Thick reload with Tri Staple Technology|Suture of the pancreas by normal stapling
1491779|NCT03030170|Device|ENDO GIA Articulating Reinforced Reload with Tri-Staple Technology|Suture of the pancreas by reinforced stapling
1491780|NCT03030157|Drug|pirarubicin(THP)|
1491781|NCT03030144|Other|Evidence based nursing recommendations|The intervention group gets the evidence based nursing interventions for the conservative management of urinary incontinence in female nursing homes.
1491782|NCT03030131|Drug|Durvalumab|durvalumab 750 mg IV Day1, 15, 29
1491783|NCT03030118|Drug|Hydroxychloroquine|Hydroxychloroquine is classified as an anti-malarial and it is has immunomodulatory functions that make it useful for treatment of autoimmune disorders including systemic lupus erythematosus and rheumatoid arthritis.
1491784|NCT03030118|Drug|Placebo Oral Capsule|An oral capsule placebo is made to match the active intervention medication hydroxychloroquine.
1491785|NCT03030105|Drug|BPN14770|investigational drug
1491786|NCT03030105|Drug|BPN14770 placebo|placebo
1491787|NCT03030105|Drug|Donepezil|comparator
1491788|NCT03030105|Drug|Donepezil placebo|placebo
1491789|NCT03030105|Drug|Scopolamine 0.6 MG/ML|cognition impairment
1491790|NCT03030105|Drug|Scopolamine placebo|placebo
1491791|NCT03030092|Other|Maximal Strength Training|leg pres and abduction exercises
1491792|NCT03030079|Device|High intensity electrical stimulation|The electrodes will pass an electrical current through the skin and into the muscle first at a low intensity for 5 minutes to allow the subject to adjust to the sensation. The current will then be gradually increased to a level sufficient to elicit a non-painful motor contraction. The subject will sit in a relaxed position as the electrical stimulator contracts the muscles for a duration of 15 minutes.
1491794|NCT03030053|Dietary Supplement|Cocoa-Flavanol Supplements|3 capsules each containing 300mg cocoa flavanols (total daily dose of 900mg cocoa-flavanols).
1491795|NCT03030053|Dietary Supplement|Control Supplements|3 capsules each containing 0mg cocoa-flavanols
1491796|NCT03030040|Behavioral|The self-help book: Williams, M. & Penman, D. (2011). Mindfulness: A practical guide to finding peace in a frantic world. London: Piatkus.|Participants will be provided with a copy of the self-help book, and asked to read it and follow the activities outlined in it, over eight weeks. They will receive weekly standardized emails, to provide information about mindfulness and encouragement to engage with the self-help book.
1491821|NCT03029845|Drug|Placebo|Participants will take placebo twice a day for 2 weeks
1492395|NCT03025347|Other|Control|Participants complete a resting control condition instead of a run.
1491797|NCT03030027|Behavioral|Connecting Through Caregiving|The Connecting Through Caregiving intervention focuses on reappraisal exercises on intergeneration relationships in caregiving, involving the following: 1) enhancing self-awareness of the caregiver, 2) developing interpersonal empathy for the care-recipient, 3) help-seeking in caregiving, 4) balancing self-care and caring and 5) negotiating action plans.
1491798|NCT03030027|Other|Basic Skills Building|Skill building involves: 1) monitoring activities, 2) pleasant event scheduling, 3) communicating with the care recipient, 4) communicating with family members and 5) review implementation
1491799|NCT03030014|Behavioral|educational programm|Oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
1491800|NCT03030014|Other|no educational program|without oral health education will be done for children and their care givers about various diseases affecting the oral cavity, the effects of bad oral hygiene and tooth decay, importance of tooth brushing, and correct methods of tooth brushing.Three follow up examination is assessed after one week, three weeks and six weeks using questionnaire for evaluation of participant satisfaction about oral health and using OHIS index for evaluating the effect of the dental educational program on the oral health status of deaf children.
1491801|NCT03030001|Biological|PD-1 antibody expressing mesothelin specific CAR-T cells|Patients will receive an IV infusion of PD-1 antibody expressing mesothelin specific CAR engineered peripheral blood leukocyte. On day 21, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
1491802|NCT03029988|Drug|Tilmanocept (Technetium Tc 99m tilmanocept Injection)|Drug: Technetium Tc 99m tilmanocept
1491803|NCT03029988|Procedure|SPECT/CT Imaging|4-6 hours post-injection SPECT/CT will be obtained in the abdominal region.
1491804|NCT03029975|Behavioral|Resistance Training Exercise|Participants will undergo 10 weeks of progressive resistance exercise training while following their randomly assigned nutritional intervention.
1491805|NCT03029975|Behavioral|Beef Protein Consumption|Following each resistance training sessions, participants will consume either a 3oz or 6oz beef patty (corresponding to the randomly assigned nutritional intervention group). Participants will also be provided with beef protein powder and beef snack bars to help them achieve their assigned protein goals during the intervention period.
1491806|NCT03029962|Behavioral|Girl2Girl|"Girl2Girl is a text messaging-based teenage pregnancy prevention program specifically for 14-18 year old LGB adolescent females. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 7 weeks long. A booster is delivered 12-weeks post-intervention end and reviews the topics covered in the intervention. Girl2Girl content is tailored based upon sexual experience (i.e., whether one is abstinent or sexually active) and whether one is same-sex or dually attracted."
1491807|NCT03029949|Behavioral|ACT with VR|6 weekly 120-minute group sessions of acceptance and commitment therapy with vestibular rehabilitation, and brief (approximately 15 minute) individual follow-up sessions at 1 and 3 months after the group treatment
1491808|NCT03029949|Behavioral|self-treatment VR|booklet written on vestibular rehabilitation for self-treatment
1491809|NCT03029949|Other|clinical management|clinical management and pharmacotherapy as usual for chronic dizziness
1491810|NCT03029923|Behavioral|Experimental: Behavioral Activation Treatment for Cardiac Smokers (BAT-CS)|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to BAT-CS condition will receive 5 more counseling sessions over the 12 weeks after discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur by phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and mood management using behavioral activation techniques. Participants will be offered the nicotine patch if medically cleared.
1491811|NCT03029923|Behavioral|Smoking cessation plus Health and Wellness|All participants will receive one hour of standard smoking cessation counseling during their hospitalization for an acute coronary syndrome. Participants will be randomized 1 week after discharge. Those assigned to the Smoking cessation plus Health and Wellness condition will receive 5 more counseling sessions over the 12 weeks after hospital discharge. The first will be up to one hour and will be conducted in person. The next 4 sessions will occur over the phone and will take about 30 minutes. Post-discharge sessions will be focused on smoking cessation and didactic health and wellness education. Participants will be offered the nicotine patch if medically cleared.
1491812|NCT03029910|Other|Cryotherapy and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. Previously subjects should cool their leg in ice water during sixteen minutes at a temperature of 8ºC (+/-2ºC)
1491813|NCT03029910|Other|Vibration and eccentric exercise|12 weeks, 5 days/week, once a day, 2 exercises, 3 sets/exercise, 15 repetition/set. Of excentric exercise of foot plantar flexors. First exercise with knee in extension. Second exercise with knee in flexion. During the exercise subjects will be subjected to vibration. Vibration parameters: Frequency: 35Hz, Amplitude: 4 millimeters, Force: 3,9G
1491814|NCT03029897|Other|My eReport France|"patients are educated to the use of My eReport France application"
2001573|NCT02905591|Drug|Carboplatin|"Administered intravenously (IV) GIven the same day as paclitaxel, immediately after the paclitaxel infusion is done.
During concurrent phase:
Prescribed at area-under-the-curve (AUC) = 2 using the Cockroft-Gault formula (standard)
Administered weekly
6 to 7 weeks of therapy, depending on when radiation starts
Standard dose reductions are used
Consolidation phase:
Begins 3 to 4 weeks after radiation
Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)
Given once every 21 days (i.e., once cycle)
Two cycles are administered
Standard dose reductions are used"
1491818|NCT03029858|Other|No interventions will be taken in this Observational study|TAGRISSO(osimertinib/AZD9291）
1491819|NCT03029845|Drug|Propranolol 1|Participants will take 20 mg propranolol twice a day for 2 weeks
1491822|NCT03029832|Drug|MOXR0916|MOXR0916, 300 milligram (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle.
1491823|NCT03029832|Drug|Atezolizumab|Atezolizumab, 1200 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
1491824|NCT03029832|Drug|Placebo|Placebo matching MOXR0916, 300 mg by intravenous (IV) infusion on Day 1 of each 21-day cycle.
2001574|NCT02905591|Drug|Ascorbic Acid|"Administered intravenously
Concurrent phase:
75 grams per infusion; each infusion is about 2 hours
3 infusion per calendar week
The infusion is actively running for at least 20 minutes when radiation begins
May be given while chemotherapy is delayed due to low counts
Dose reductions are not used
Given for 6 to 7 weeks, depending on when radiation starts
Consolidation phase:
75 grams per infusion, taking about 2 hours
2 infusions per calendar week; the days are normally back-to-back
May be given while chemotherapy is delayed due to low counts
Administered after paclitaxel and carboplatin
Two cycles are administered
Dose reductions are not used"
2001575|NCT02905578|Drug|Gemcitabine|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after nab-paclitaxel and before ascorbate
given for 3 weeks out of the 4 week cycle
standard dose reductions are used
up to 2 cycles are administered before standard of care CT scan
decision to continue therapy is based disease response to therapy as measured from the CT scan
treatment continues until disease progression is identified"
2001576|NCT02905578|Drug|nab-paclitaxel|"Administered intravenously the same day as nab-paclitaxel and ascorbate Administered after before gemcitabine and ascorbate
given for 3 weeks out of the 4 week cycle
standard dose reductions are used
up to 2 cycles are administered before standard of care CT scan
decision to continue therapy is based disease response to therapy as measured from the CT scan
treatment continues until disease progression is identified"
1491829|NCT03029806|Other|Aldosterone response to AngII LS|Change in aldosterone from baseline to after Ang II infusion on a LS diet
1491830|NCT03029806|Other|Renal blood flow response to salt|Change in renal blood flow: High salt to low salt diet
1491831|NCT03029806|Other|Vascular Stiffness|Change in vascular stiffness, baseline compared to AngII
1491832|NCT03029793|Other|Biomarkers Testing|CRT resistance biomarkers will be detected before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
1491833|NCT03029793|Other|Functional Imaging analysis|The SUV value and texture parameters of 18F-FDG PET-CT as well as ADC values DWI-MRI will be measures before CRT, 2-3 weeks after the initiation of CRT, and 4 weeks post-CRT.
1491836|NCT03029767|Other|Aerobic exercise .|The aerobic exercise group will perform brisk walking. Intensity of the aerobic exercise program will be progressively increased throughout the 16-week program. Intensity of aerobic exercise will be 40-65% of maximum heart rate , which is low to moderate.Duration of each session will be 45 minutes. Aerobic exercise will be performed 3 days per week.
1491837|NCT03029767|Other|Resistance exercise|"The resistance exercise group will perform 8 different exercises. Frequency of exercises per week is 3 days and duration of each exercise session is 45minutes. Interval rest among different exercises is 1minute.The intensity and repetition of resistance exercises is progressive. Participants will be exercised at 30% intensity (low intensity) for upper body and 50% intensity (moderate intensity) repetition voluntary maximum for lower body.
Progressive, dynamic and rhythmical, alternative to upper-body and lower-body works and circuit resistance training of low to moderate intensity exercises will be executed."
1491838|NCT03029767|Other|Aerobic and resistance exercise|The aerobic and resistance exercise group will perform 23 minutes aerobic exercises and 22 minutes resistance exercises. The exercises will be performed three days per week . Intensity of aerobic and resistance exercise group for aerobic and resistance exercises are similar with intensity of aerobic group and resistance group exercises respectively.
1491839|NCT03029754|Procedure|Passive leg raise|A baseline vein diameter will be obtained using ultrasound by the sub-investigator. Then a nurse will raise the child's legs using a bolster while a second measurement of the child's vein diameter is recorded by the sub-investigator. The anesthesiologist will then place the IV and rate the degree of difficulty encountered.
1491840|NCT03029741|Drug|AZD0284|Subjects will receive a single oral dose of 4 to 120 mg AZD0284 oral suspension 5 mg/mL in the fasted state
1491841|NCT03029741|Drug|[14C]AZD0284|Following administration of the AZD0284 oral suspension subjects will receive an IV infusion of 20 μg [14C]AZD0284 solution
1491842|NCT03029715|Drug|Propofol|Total intravenous anaesthesia.
1491843|NCT03029715|Drug|Remifentanil|Narcotics
1491844|NCT03029715|Drug|Dexmedetomidine|Total intravenous anaesthesia
1491845|NCT03029715|Drug|Desflurane|Inhalation anaesthesia.
1491846|NCT03029702|Drug|Insulin|Insulin will be used for GDM treatment
1491847|NCT03029702|Drug|Glyburide|Glyburide will be used for GDM treatment
1491848|NCT03029702|Drug|Metformin|Metformin will be used for GDM treatment
1491849|NCT03029689|Drug|Raltegravir|Raltegravir 1200 mg (2 tablets x 600mg) once daily plus current ART during 48 weeks from randomization
1491850|NCT03029689|Drug|Placebo|Placebo (2 tablets of placebo) once daily plus current ART during 48 weeks from randomization.
1491851|NCT03029689|Drug|Current ART|3-drug antiretroviral treatment including PI/r/c or NNRTI
1491852|NCT03029676|Drug|benzodiazepines|sedative
1491853|NCT03029676|Drug|opioid|analgetic, sedative
1491854|NCT03029676|Procedure|spinal anesthesia|
1491855|NCT03029663|Procedure|Transurethral resection of the bladder tumour|
1491856|NCT03029650|Drug|Transderm Scop®|TDDS dosage is 1.5 mg/72 hrs
1491857|NCT03029650|Drug|Intravenous scopolamine hydrobromide|0.4 mg via intravenous injection
1491860|NCT03029624|Device|eCoin|Patients are implanted with active implantable device called eCoin. eCoin is turned ON in order to deliver neuromodulation therapy.
1491866|NCT03029598|Drug|Carboplatin|Given IV
1491867|NCT03029598|Other|Laboratory Biomarker Analysis|Correlative studies
1491868|NCT03029598|Biological|Pembrolizumab|Given IV
1949047|NCT00659230|Drug|Placebo|100-800mg placebo
2001577|NCT02905578|Drug|Ascorbic Acid|"Administered intravenously the same day as nab-paclitaxel and gemcitabine Administered after nab-paclitaxel and gemcitabine
given 3 times weekly
given for 4 weeks out of the 4 week cycle
no dose reductions are used
up to 2 cycles are administered before standard of care CT scan
decision to continue therapy is based disease response to therapy as measured from the CT scan
treatment continues until disease progression is identified"
2001578|NCT02903940|Device|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
2001579|NCT02903316|Procedure|Fluids|
2001580|NCT02902237|Biological|tTF-NGR|tTF-NGR will be given as 1-hour infusion via central venous access once daily for 5 days with a subsequent rest period of 2 weeks and following cycles with dose escalation of 0.5 mg/m2 upon judgement of tolerability and therapeutic activity. Starting dose will be 1 mg/m2/day. Dose-escalation is stopped before the maximum number of 8 escalation steps if tumor response, tumor progression or a Dose-Limiting Toxicity (DLT) is observed.
2001581|NCT02899221|Radiation|High-Dose Rate Brachytherapy|Undergo high dose rate brachytherapy
1491874|NCT03029572|Drug|Diet supplementation|Micronutriment supplementation therapy
1491875|NCT03029572|Procedure|Bariatric surgery|Roux-en-Y gastric bypass provided in both arms.
2001582|NCT02899221|Procedure|Hyperthermia Treatment|Undergo interstitial hyperthermia treatment
2001583|NCT02899728|Drug|Carboplatin|Given IV
1949050|NCT00644995|Behavioral|Step Up Wellness Program|Participants in the Step Up Wellness program will receive weekly phone calls from a study health coach. During these calls, the coach will discuss ways to improve and manage mood, increase physical activity, and prepare to quit smoking.
1491879|NCT03029533|Drug|Leuprolide Acetate|DWJ108J, SC injection, once(Day1)
1491880|NCT03029533|Drug|Leuprolide Acetate|Leuplin DPS Inj, SC injection, once(Day1)
1491881|NCT03029520|Other|Root canal obturation with iRoot SP sealer|Postoperative pain after root canal obturation with iRoot SP sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
1491882|NCT03029520|Other|Root canal obturation with AH Plus Sealer|Postoperative pain after root canal obturation with AH Plus sealer with patients who has (mandibular premolar/molar) vital and devital pulps.
1491883|NCT03029507|Behavioral|ACT Enhanced ShipShape|The ACT components focus on: a) thoughts, feelings, and bodily sensations that are often present in the context of efforts to lose weight or improve fitness; b) limitations of previous efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness of experiences; and e) identification of personal values and setting and pursuing values-consistent goals in order to achieve improved quality of life.
1491884|NCT03029507|Behavioral|Standard ShipShape (SS)|The materials and format of the Standard SS-only protocol are based on recommendations from the Navy and Marine Corps Public Health Center. These include: a) education for nutrition and physical activity; b) creating and documenting goals for weight loss and physical fitness; c) a food diary to track eating habits throughout the program; d) developing behavioral strategies to initiate/maintain an exercise program; e) monitoring of physical activity (pedometer provided by the study); and f) identifying and overcoming personal triggers for over-eating.
1491885|NCT03029494|Device|stabilization splint|Hard acrylic type of splint with full coverage of occlusal surfaces of upper teeth, with a thickness of about 1.5 mm at the level of the first molar.
1491886|NCT03029494|Drug|Placebo Oral Tablet|sugar pill manufactured to mimic 1000 mg Vitamin C
1491887|NCT03029494|Device|placebo splint|Ineffectively designed oral appliance: an acrylic palatal plate will be used (without influence on occlusion, TMJ and masticatory muscles).
1491888|NCT03029494|Dietary Supplement|Vitamin C|1000 mg
1491889|NCT03029481|Drug|Ganitumab|The patient will receive ganitumab, 18 mg/kg/dose intravenously every 2 weeks until clinical progression or decision to move to an alternate therapy.
1949051|NCT00644995|Behavioral|Usual care|Participants will receive referral usual care treatment for depression and smoking cessation, plus self-help physical activity intervention.
1491891|NCT03029455|Drug|VX-659|
1491892|NCT03029455|Drug|Tezacaftor|
1491893|NCT03029455|Drug|Ivacaftor|
1491894|NCT03029455|Drug|VX-659 Matching Placebo|
1491895|NCT03029455|Drug|Triple Combination (TC) Matching Placebos|
1491896|NCT03029442|Drug|Denosumab (Prolia)|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates. The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
1491897|NCT03029442|Other|Placebo (normal saline)|Identical Denosumab volume of normal saline
1491898|NCT03029429|Drug|Theophylline|oral theophylline
1491899|NCT03029429|Drug|Placebos|oral placebo
2001584|NCT02899728|Drug|Cediranib Maleate|Given PO
1491901|NCT03029403|Drug|Pembrolizumab|Given intravenously in clinic, at 200 mg, on Day 1 of every 21-day cycle.
1491902|NCT03029403|Biological|DPX-Survivac|Given by injection under the skin of the upper thigh in clinic. Participants will receive one priming dose of 0.25 mL of DPX-Survivac on Cycle 1 Day 1. After about 6 weeks, participants will receive an additional boosting dose of 0.25 or 0.5 mL DPX-Survivac.
1491903|NCT03029403|Drug|Cyclophosphamide|Given orally, at 50 mg, twice a day, starting about 7 days before Cycle 1 Day 1, then continue 7 days off, 7 days on.
1491904|NCT03029390|Dietary Supplement|Berberine|"Berberine capsules, 500 mg, three per day before each meal during 14 weeks.
The patients will have a running period during two weeks:
First week they will receive one 500 mg capsule before breakfast Second week they will receive two 500 mg capsules (before breakfast and meal) From the third week until the end of the study (14 week), they will be receive three 500 mg"
1949052|NCT00602836|Biological|Rituximab|Cycle 1: 100 mg by IV on day 1, 375 mg/m^2 by IV on day 2 Cycle 2-6: 375 mg/m^2 by IV on day 1 (every 21 days)
1949053|NCT00602836|Drug|Cyclophosphamide|600 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
1949054|NCT00602836|Drug|Lenalidomide|Cycle 7: 5 mg orally daily on days 1-28 Cycle 8: 10 mg orally daily on days 1-28 as tolerability permits Cycle 9 and beyond: 10 mg orally daily on days 1-28
1949055|NCT00602836|Drug|Pentostatin|2 mg/m^2 by IV on day 1 of cycles 1-6 (every 21 days)
1491905|NCT03029390|Drug|Metformin|"Metformin capsules, 850 mg, two per day before breakfast and dinner and one placebo capsule before lunch during 14 weeks.
The patients will have a running period:
First week they will receive one 850 mg capsule before breakfast Second week they will receive one 500 mg capsules (before breakfast) and one placebo capsule (before meal).
From the third week until the end of the study (14 week), they will be receive two 850 mg capsules (before breakfast and dinner) and one placebo capsule (before meal)."
1491906|NCT03029377|Other|Posture Study, Autonomic Function Tests, and a Stress Test|Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
2001585|NCT02899728|Drug|Cisplatin|Given IV
1491908|NCT03029351|Drug|Exenatide Extended Release for Inj Susp 2 MG|Exenatide extended release treatment weekly for 1 year in T2DM patients with micro- and macroalbuminuria
1491909|NCT03029351|Drug|Placebos|placebo treatment weekly for 1 year in type 2 diabetes with micro-and macroalbuminuria
1491910|NCT03029338|Biological|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
1491911|NCT03029312|Device|Galileo M|Motorized board producing side-to-side alternating vertical sinusoidal (rotational) vibrations around a fulcrum in the mid-section of the plate. The vibration frequency can be selected by the user who stands on the board with both feet, wearing shoes. The peak-to-peak displacement to which the feet are exposed increases with the distance of the feet from the centre line of the vibrating board. Three positions marked 1, 2 and 3 are indicated on the vibrating board, corresponding to peak-to-peak displacements of 2, 4, and 6mm. The peak acceleration exerted by vibration exercise increases with higher frequencies and higher amplitudes.
1491912|NCT03029299|Device|FilmArray RP EZ|Patients in the intervention arm will be tested with the FilmArray RP EZ and the results of the test will be provided to the treating clinician
1491913|NCT03029286|Behavioral|Usual Care Arm|Health information provided by the American Cancer Society Website
1491914|NCT03029286|Behavioral|Personalized Web Intervention Arm|Women will be assigned to view a tailored website featuring their personalized risk information for breast cancer related to breast density and other factors.
1491915|NCT03029273|Drug|Cyclophosphamide|Three days prior to infusion of TCR-T cell, subjects receive cyclophosphamide treatment at dose 1 g/day for 2 days and take a rest for one day before infusion.
1491916|NCT03029273|Biological|Anti-NY-ESO-1 TCR transduced T cells|A single dose of Anti-NY-ESO-1 TCR transduced T cells (about 5×109) will be intravenously (i.v.) administered Additionally, following infusion of Anti-NY-ESO-1 TCR transduced T cells, IL-2 subcutaneous injections (250,000 IU/day) will be administered for 14 days concomitantly to each subject.
1491917|NCT03029260|Other|Neural mobilization - tension.|"Neural mobilization in tension consists of using combinations of joint movement known to maximize the tension and lengthening of peripheral nervous structures.
The intervention will be delivered in one session only."
1491918|NCT03029260|Other|Neural mobilization - gliding|"Gliding neural mobilization consists of using combinations of joint movement known to maximize the movement of the peripheral nerves in relation to adjacent structures.
The intervention will be delivered in one session only."
2001586|NCT02899728|Drug|Etoposide|Given IV
2001587|NCT02899728|Other|Laboratory Biomarker Analysis|Correlative studies
1491921|NCT03029234|Drug|Dexamethasone|20 mg intravenous (IV) or oral dexamethasone on Days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day Cycles.
1491922|NCT03029234|Drug|Carfilzomib|Infusion of intravenous (IV) carfilzomib on Days 1, 2, 8, 9, 15 and 16. On Cycle 1, Days 1 and 2, subjects will receive carfilzomib 20 mg/m2. If tolerated (defined as absence of any treatment-related adverse event [AE] requiring dose reduction, delay, or the dose to be held), the dose will be escalated to 27 mg/m2 on Cycle 1 Day 8 and all subsequent doses.
1491923|NCT03029221|Other|PREP 8.0 curriculum developed by PREP|healthy marriage and relationship education
1491924|NCT03029221|Other|Within My Reach curriculum developed by PREP|healthy marriage and relationship education
1491925|NCT03029221|Other|Within Our Reach 8 Hours curriculum|healthy marriage and relationship education
1491926|NCT03029208|Drug|Daprodustat|Daprodustat will be supplied as film coated tablets for oral administration containing 1, 2, 4, 6, 8, or 10 mg of daprodustat. Doses of 12, 16, and 24 mg of daprodustat will be provided using multiples of these tablet strengths.
1491927|NCT03029208|Drug|Darbepoetin alfa|Darbepoetin alfa will be supplied as prefilled syringes (PFS) for SC/IV injection available in strengths: 40, 60, 100 and 150 mcg.
1491928|NCT03029208|Drug|Iron therapy|Iron therapy will be administered if ferritin is <=100 ng/mL and/or TSAT is <=20%.
1491929|NCT03029195|Device|Nasoalveolar molding therapy|Presurgical infant orthopedics
1491930|NCT03029182|Other|Walking+simulated-altitude|Participants will walk on a treadmill for up to 50 minutes at a 16% oxygen level (administered via exercise mask), which is similar in altitude to Flagstaff, AZ. The progression of exercise training will be based on a varying percents of heart rate reserve.
1491931|NCT03029182|Behavioral|Walking (control)|Participants will walk on a treadmill for up to 50 minutes.The progression of exercise training will be based on a varying percents of heart rate reserve.
1491932|NCT03029169|Drug|Propafenone i.v.|Treatment
1491933|NCT03029169|Drug|Amiodarone i.v.|Treatment
2001588|NCT02899728|Drug|Olaparib|Given PO
1491975|NCT03028857|Drug|Choline|Mothers are instructed to take the capsules twice a day, five 450 mg phosphatidylcholine capsules at breakfast and five phosphatidylcholine 450 mg capsules at dinner.
2001589|NCT02898740|Behavioral|Structural exercise|Exercise instruction and encouragement
2001590|NCT02898740|Behavioral|Health education|Provision of general information about a variety of health topics
2001591|NCT02898298|Behavioral|Positive Emotion Regulation Training|Participants will receive a 3-session psycho-educative training on emotion regulation.
2001592|NCT02898194|Other|Survey|Survey that occurs within a focus group led by a moderator
2001593|NCT02896907|Drug|Oxaliplatin|Given IV
2001594|NCT02896907|Drug|Irinotecan Hydrochloride|Given IV
2001595|NCT02896907|Drug|Leucovorin Calcium|Given IV
2001596|NCT02896907|Drug|Fluorouracil|Given IV
2001597|NCT02896907|Dietary Supplement|Ascorbic Acid|Given IV
1491934|NCT03029156|Device|Aeroneb nebulizer|"The Aeroneb Nebulizer System is a portable medical device for single patient use that is intended to aerosolize physician-prescribed solutions for inhalation to patients on and off ventilation.
The Aeroneb Adapter is an accessory specific to the Aeroneb Nebulizer. It facilitates intermittent and continuous nebulization and optional supply of supplemental oxygen to adult patients in hospital use environments via a mouthpiece or aerosol mask. The Aeroneb Nebulizer System and Adapter are FDA approved devices for nebulizing solutions including bronchodilators (albuterol and ipratropium)."
1491935|NCT03029156|Device|Small volume jet nebulizer|The bronchodilators will be administered via small volume jet nebulizer
1491937|NCT03029130|Device|Catheter extension|Foley transurethral catheter placed to allow continuous drainage of urine.
1491938|NCT03029117|Procedure|correction of rheumatic valve lesions|
1491939|NCT03029104|Drug|CXLO Corneal Strengthening Solution and UVA Illumination|CXLO Corneal Strengthening Solution
1491940|NCT03029091|Drug|Losartan Potassium|Participants will receive Losartan potassium for 4 months.
1491941|NCT03029078|Drug|fecal microbiota transplant|We will perform a fecal microbiota transplant for patients harboring XDR bacteria in their digestive tract
1491942|NCT03029052|Behavioral|Reconciliation|In addition to standard healthcare procedures, the pharmacist will analyze discharge prescriptions and proceed to medication reconciliation. A patient's counseling session will also be provided by the pharmacist. A reconciliation mail will be addressed to the PCP.
1491943|NCT03029039|Other|Blood samples|Blood samples will be collected at inclusion.
1491944|NCT03029026|Other|Baseline assessment|Baseline assessment will include clinical history, Quality of Life Questionnaire (EQ-5D/SF-12), a 6-minute-walk test, blood sampling for haematocrit, renal function, biomarkers (NT-pro-BNP and troponin), and biobanking (also for AL exclusions if scanning positive), a urine sample for biobanking (also for AL exclusions if scanning positive), as well as tests performed as the routine pre-operative work-up (clinical electrocardiogram, blood pressure to estimate global LV afterload, valvulo-arterial impedance).
1491945|NCT03029026|Procedure|Transthoracic echocardiography|"Patients will undergo a clinical transthoracic echocardiogram for the assessment of AS severity and diastolic function in line with the British Society of Echocardiography guidance. Simultaneous, optimised 2-chamber, 3-chamber and 4-chamber views will need to be recorded (over 3 cycles) for strain analysis.
Severe AS will be defined using standard echocardiography guidelines in conjunction with MDT consensus."
1491946|NCT03029026|Procedure|99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy|Scanning will use a hybrid SPECT-CT gamma camera after intravenous injection of 700 MBq of DPD (effective dose 4mSv). Acquisition technique: 5-minute (early) and then 3-hour (late) whole body planar scans, followed by SPECT-CT of the heart. Qualitative visual (Perugini) scoring of the cardiac uptake is performed from the 3-hour whole body planar images and the SPECT-CT images.
1491947|NCT03029026|Radiation|CT 3-5-minute post-contrast research sequences|Cardiac CT for ECV will use the dedicated cardiac CT scanner (Somatom FORCE; Siemens Medical Solutions, Germany). 3-5-minute post contrast research images will be taken at the end of the clinically indicated TAVR work-up CT.
1491948|NCT03029026|Procedure|Cardiac Magnetic Resonance|CMR will be performed using a 1.5-T Aera for standard late gadolinium enhancement, as well as T1 mapping and ECV.
1491949|NCT03029026|Procedure|Endomyocardial biopsy|Septal tissue specimens will be taken under direct vision by the surgical team using a 14-gauge coaxial needle system. Biopsies will be screened for amyloid by Congo red staining; if positive, tissue will be fully sub-typed (immunohistochemistry, mass spectrometry).
1491950|NCT03029026|Other|Follow-up assessment|1-year follow-up with clinical echocardiogram (for sAVR and TAVI patients) and/or telephone interview for all patients (if not carried out in person at the time of the echocardiogram). This will include a follow up Quality of Life Questionnaire as per baseline. If attending clinic or echocardiogram a 6-minute-walk test will also be performed.
1491951|NCT03029013|Drug|Apatinib|Apatinib， 250 mg qd，po，after 7 days , paclitaxel (135-175 mg/m2) and platinum two drug standard chemotherapy, 21 days as a treatment cycle，during the chemotherapy of 7-21 days continue to offer the Apatinib. without disease progress, after 4 chemotherapy cycles, patients continue to accept the Apatinib maintenance treatment.
1491952|NCT03029000|Drug|tbo-filgrastim|solution for subcutaneous (sc) injection
1491953|NCT03028987|Biological|Fluzone®|Fluzone® Quadrivalent (IIV4; inactivated influenza virus vaccine)
1491954|NCT03028987|Biological|FluMist®|FluMist® Intranasal Spray (quadrivalent, live, attenuated influenza vaccine)
1491955|NCT03028974|Biological|Fluzone®|Fluzone® Quadrivalent: Quadrivalent influenza virus vaccine
1491956|NCT03028974|Biological|FluMist®|FluMist® Quadrivalent: Quadrivalent influenza virus vaccine live, intranasal spray
1491957|NCT03028961|Other|Stanford Letter|Receive and complete the Stanford Letter
1491958|NCT03028961|Other|Interview|Undergo semi-structured, research staff-led interview
1491959|NCT03028961|Other|Questionnaire Administration|Ancillary studies
1491960|NCT03028961|Other|CA Advance Health Care Directive Form|Receive and complete the CA Advance Health Care Directive Form
1491961|NCT03028948|Other|Internet-Based Intervention|Access ITW
1491962|NCT03028948|Other|Questionnaire Administration|Ancillary studies
1491963|NCT03028948|Other|Survey Administration|Ancillary studies
1491964|NCT03028935|Behavioral|Exercise Intervention|Undergo instructor-led exercise program
1491965|NCT03028935|Behavioral|Nutritional Intervention|Undergo instructor-led nutritional education program
1491966|NCT03028922|Device|creos xenogain|GBR procedure will be performed using creors xenogain bone graft substitute in patients that need horizontal bone augmentation prior to implant placement. The defect should be located in the pre-molar and molar region of the mandible
1491967|NCT03028909|Drug|Oseltamivir|Standard of care for influenza caused by Type A strains
1491968|NCT03028909|Drug|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.
1491969|NCT03028909|Drug|Placebo|Salt-water solution containing no active ingredients.
1491970|NCT03028896|Procedure|90° rotational technique|the LMA FlexibleTM was rotated counter-clockwise through 90°
1491971|NCT03028883|Other|Dose adjustments|Do higher doses of buprenorphine result in a higher rate of neonatal abstinence syndrome as compared to lower doses of buprenorphine
1491976|NCT03028857|Dietary Supplement|Placebo|Mothers are instructed to take the capsules twice a day, five placebo corn oil capsules at breakfast and five placebo corn oil capsules at dinner.
1491977|NCT03028844|Other|Music therapy|The musical intervention will be played for ten minutes prior to venepuncture
1491978|NCT03028831|Dietary Supplement|70g of fully digestible starch amylopectin corn starch|Fully digestible amylopectin corn starch
1491979|NCT03028831|Dietary Supplement|Resistant starch|70g high-amylose maize starch
1491980|NCT03028805|Other|Automatic inclusion of COPD orders in admission orders|Use of real-time data to identify a population of patients with COPD and prompt improved adherence to evidence-based guidelines through the automatic inclusion of a COPD order set in the admission orders.
1491981|NCT03028805|Other|Dynamic, end-user order set design|Use of a dynamic order set that has been end-user tested prior to launch rather than designed centrally by a committee to test use of order set components.
1491982|NCT03028792|Behavioral|Attention Modification Program|"Each trial begins with a fixation cross at the center of the computer screen for 500 ms. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threat material. In this case, the probe always replaces the neutral stimuli. Thus, although there will be no specific instruction to direct attention away from the threat stimuli, on all trials, the position of the neutral stimulus will indicate the position of the probe."
1491983|NCT03028792|Behavioral|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen. The cross is then replaced by a face pair presented in the center of the screen. The face pair disappears and a probe (letter E or F) appears immediately in the location of one of the two previous stimuli. Youth will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threat material. In this case, the probe randomly replaces the threat or neutral stimulus."
1491984|NCT03028779|Procedure|Fast-track Total Hip and knee arthroplasty|To be able to do a total knee or hip arthroplasty and return the patient home in less then 24 hours
1491985|NCT03028766|Drug|AZD1775|AZD1775 is a potent, selective small molecule inhibitor of WEE1
1491986|NCT03028766|Drug|Cisplatin|Chemotherapy drug
1491987|NCT03028766|Radiation|Radiotherapy|Intensity Modulated Radiotherapy
1491988|NCT03028753|Device|Bladder scan post void residual|After voiding on the commode, all subjects will have a post void residual measured by bladder scanner
1491989|NCT03028753|Procedure|Straight catheter post void residual|After voiding on the commode and having a post void residual measured by bladder scanner, all subjects will have a post void residual measured by straight catheter performed with usual sterile technique.
1491990|NCT03028753|Procedure|Back fill voiding trial|Prior to catheter removal, all subjects will undergo a back fill voiding trial. The bag of the foley catheter will be removed and the subjects bladder will be filled with 300cc of normal saline (or as much as they can tolerate). The foley catheter will then be removed and the subject will be asked to void on the commode. The voided volume will be measured.
1491991|NCT03028740|Drug|Cenicriviroc|1 tablet QD
1491992|NCT03028740|Drug|Placebo|1 tablet QD
1491993|NCT03028727|Procedure|Ultrasonic Scaling and root planing|Procedure of scaling and root planing at day 0 and at 1 week
1491994|NCT03028727|Procedure|980 nm diode laser irradiation|Procedure of scaling and root planing and application of 980 nm diode laser at day 0 and at 1 week
1491995|NCT03028714|Behavioral|Technology-based nutrition education|All participants will undertake anthropometric measurements and assessments of blood pressure and blood glucose. They will be also asked to complete online questionnaires with regards to nutrition and physical activity. Participants in the intervention group will receive additional access to a website, providing information about nutrition topics including alcohol and physical activity. Through the website participants will be asked to play online quiz-games related to the nutrition topics. Each play will include game elements such as time, point collection and graphics. Participants will be asked to play the games as much as they want to improve their scores and to use the website as a reference tool.
1491996|NCT03028701|Drug|Formoterol/Budesonide 12/400 mcg Discair|Formoterol/Budesonide 12/400 mcg Inhalation Powder (1 puff) once daily via Discair®
1491997|NCT03028688|Device|High flow nasal cannula oxygen|Participants will receive high flow nasal cannula oxygen delivery during anesthesia. Participants will also have transcutaneous PCO2 measurements performed using a cutaneous electrode.
1491998|NCT03028675|Drug|Gd-DTPA-ST|The contrast agent (Gd-DTPA, Gadavist) will be injected intravenously (IV) in the arm (patients only). The
1491999|NCT03028675|Drug|Control|No Contrast Agent
1492000|NCT03028662|Behavioral|Retrieval-Extinction Learning|The intervention consists of the accomplishment of the task of approach-avoidance of alcohol during 4 days of training. Subjects are instructed to respond with an approach movement (pulling a lever) to neutral images and to respond with avoidance movement (pushing the lever) to images of alcohol.
1492001|NCT03028649|Dietary Supplement|β-hydroxy-β-methylbutyrate and a placebo supplementation|
1492002|NCT03028623|Procedure|Salpingectomy|Bilateral salpingectomy will be performed instead of standard tubal ligation as sterilization during cesarean section.
1492003|NCT03028623|Procedure|Tubal ligation|Standard tubal ligation by either Parkland or Pomeroy technique will be performed at cesarean section
1492004|NCT03028610|Device|radiofrequency generator|
1492005|NCT03028597|Behavioral|Intervention Values Affirmation|Participants are asked to circle the two or three values that are MOST important to them. Next, participants are asked to think about times when the values chosen might be important to THEMSELVES and then write a few sentences to describe when and why they might be important.
1492006|NCT03028597|Behavioral|Control Values Affirmation|Participants are asked to circle the two or three items that are LEAST important to them. Next, participants are asked to think about times when the values chosen might be important to SOMEONE ELSE and then write a few sentences to describe when and why they might be important.
2001599|NCT02891915|Drug|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
1492436|NCT03025061|Other|Assessment of E-nose measurements|Breath sampling through E-nose pneumopipe
1492008|NCT03028571|Drug|Trimethaphan|Trimethaphan 4 mg/min IV will be given as a pharmacological tool to study the role of the autonomic nervous system on the regulation of endogenous glucose production by the liver.
1492009|NCT03028571|Other|Saline|IV saline at a rate of 48 mL/hr, will be given during the insulin clamp to resemble the volume infused in the intact day
1492010|NCT03028545|Behavioral|Collection of the individual narrative, semi-directed interviews|Visit one : individual interview Individual narrative Passing Psychometric Measurement Scales of Recovery: Score at Warwick and Wellness Scale Andreasen scale score Visit two Focus group
2001600|NCT02891915|Drug|Amoxicillin-clavulanate|A fixed-ratio combination of amoxicillin trihydrate, an aminopenicillin, and potassium clavulanate, a beta-lactamase inhibitor, used to treat a broad-spectrum of bacterial infections, especially resistant strains.
1492012|NCT03028519|Drug|Vitamin D3|
1492013|NCT03028506|Other|Carbohydrate intake|By calculating carbohydrate amounts at meals and snacks, as well as classifying meals and snacks as high fat, the investigators will examine the correlation to higher preprandial blood glucose values and large for gestational age infants.
1492014|NCT03028493|Behavioral|Original SAFE Intervention|A CDC recommended, evidence-based falls prevention intervention.
1492015|NCT03028493|Behavioral|Adapted SAFE Intervention|An adapted version of the SAFE intervention meant to target older adults with low vision.
1492016|NCT03028480|Drug|NUCALA Injection|Single dose of NUCALA SC will be administered. Dose unit, daily dose frequency, date of administration will be at the investigator discretion.
1949056|NCT00601094|Biological|autologous dendritic cell-adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
2001601|NCT02891915|Drug|Cefdinir|Cefdinir is a cephalosporin antibiotic used to treat bacterial infections in many different parts of the body.
2001602|NCT02891915|Other|Placebo|Placebo
1492023|NCT03028454|Dietary Supplement|Ginger Root|Capsules containing 250 mg of ginger root extract standardized to contain at least 5% gingerol compounds, as well as an additional 225 mg of regular ginger root.
1492024|NCT03028454|Dietary Supplement|Placebo|Capsules containing rice flour powder.
1492027|NCT03028428|Biological|Placenta Derived Mesenchymal Stem Cell|1ml 1*10^7 Placenta Derived Mesenchymal Stem Cell administered into the knee joint once
1492028|NCT03028428|Drug|Sodium Hyaluronate|Sodium hyaluronate administered into the knee joint once
1492031|NCT03028402|Procedure|C5-C6 arthrodesis|A standard Smith Robinson anterior medial approach to the cervical spine. Vertebral endplates will be prepared by removing the cartilage endplate. Tricortical anterior iliac crest autografts will be harvested with a low-speed oscillating saw. Allografts will be fresh-frozen, vacuum-sealed, nonradiated tricortical grafts. All grafts will be fashioned in a typical Smith-Robinson formation. The motion segment will be distracted approximately 2-mm beyond the graft height before the insertion of each graft. Fusion plate will be contoured to cervical lordosis. Cervical plates will be positioned using surgical midline markers. All rigid anterior plate fixations will be performed using titanium anterior fixed-angle screw systems.
1492032|NCT03028389|Procedure|limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
1492033|NCT03028376|Other|Blood sampling|Blood sampling from peripheral venous catheter routinely inserted in trauma patients during transportation
1492034|NCT03028363|Drug|Olumacostat Glasaretil Gel|
1492035|NCT03028363|Other|Vehicle|
1492036|NCT03028350|Drug|Ifetroban Oral Capsule|Subjects will be treated with oral ifetroban daily for 8 weeks
1492037|NCT03028350|Drug|Placebo Oral Capsule|Subjects will be treated with oral placebo daily for 8 weeks
1492038|NCT03028337|Radiation|Spine Radiosurgery|"Spine Radiosurgery - 1 Dose: For single fraction and multifraction arms, 0.01 cc of the cord allowed to receive 10 Gy and 14 Gy, respectively while 0.01 cc of the cauda equina allowed to receive 14 Gy and 18 Gy, respectively.
Spine Radiosurgery - 3 Doses (3 days): The dose for the multifraction arm is 27 Gy in 3 fractions (9 Gy per fraction)."
1492039|NCT03028337|Behavioral|Questionnaires|"Participants complete 3 questionnaires about any pain they may be having, quality-of-life, and any other symptoms. It should take about 10 minutes to complete these questionnaires.
Questionnaires completed at Baseline and at Months 3,6,9,12,18, and 24 and then every 6 months after that during follow up."
1492040|NCT03028324|Device|Transcranial Magnetic Stimulation (TMS)|Non-invasive brain stimulation, high frequency repetitive TMS delivered in 10 sessions over a 2-week period.
1492041|NCT03028311|Device|SIR-Spheres|"SIR-Spheres - Two Sessions: Participants have SIR-Spheres treatment delivered over 2 sessions within 2-4 weeks.
SIR-Spheres - One Session: Participants have SIR-Spheres treatment delivered in 1 session."
1492042|NCT03028298|Drug|Low dose sildenafil citrate|
1492043|NCT03028298|Drug|High dose sildenafil citrate|
1492044|NCT03028285|Drug|arginine sodium succinate|Healthy volunteers will receive the experimental drug (arginine sodium succinate 1.4% solution; Unifusol) intravenously at 3 different combinations of dose and infusion rate under the close monitoring of vital signs and other safety parameters.
1492045|NCT03028272|Other|Skye Barrier|Substrate derived from amniotic tissue that is FDA-approved for human implantation
1492046|NCT03028272|Other|Fascia|Autologous donor substrate. Examples include tragal cartilage, perichondrium, temporalis fascia, and temporoparietal fascia
1492047|NCT03028259|Other|lab results|Comparison of lab results
1492048|NCT03028246|Device|ExAblate 4000 System|
1492049|NCT03028233|Behavioral|Healthy Lifestyle|A Community Health Worker coaches families regarding healthy eating, physical activity, and obesity prevention, and promotes the use of existing built environment resources.
1492485|NCT03024684|Drug|Atorvastatin|Atorvastatin 10mg daily
1949063|NCT00582504|Biological|VEE TC-83|Subjects will receive a single 0.5 mL dose by subcutaneous route in the upper outer aspect of arm
1492050|NCT03028233|Behavioral|Positive Parenting|A Community Health Worker coaches parents on improving positive parenting skills and promotes the use of relevant community resources.
1492051|NCT03028220|Device|Dexcom G5 Continuous Glucose Monitor|Real time continuous glucose sensor connected to monitor providing data and alarms and alerts for glucose trends and values
1492052|NCT03028220|Device|Abbott Freestyle Libre|Continuous glucose recording device which reports glucose concentration and trend on demand, along with a retrospective review of the last 8 hours glucose data
1492053|NCT03028207|Procedure|Medical tests|During Visit 1, subjects will go through medical tests including spirometry, bronchodilation test, pulse oximetry, cooximetry, and bioimpedance. Additional tests will be performed at up to 9 centers such as pulmonary diffusion test, 6 minute walk test, CT during the same visit.
1492054|NCT03028207|Other|Questionnaire|During Visit 1, subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Health Related Quality of Life (HRQoL) CAT questionnaire, HADS anxiety scale, YPAS physical activity questionnaire, ECSC respiratory symptoms questionnaire, occupational exposure related questionnaire, MMSE questionnaire, Fagerstrom test, Prochaska test.
1492055|NCT03028194|Procedure|Curettage|Postpartum uterine curettage with a sharp curette # 14 or #16, immediately after delivery of the placenta.
1492056|NCT03028194|Procedure|Placebo|No procedure after delivery of the placenta
1492057|NCT03028168|Other|Yôga|Intervention observing respiratory frequency (RF) of 15- 20 respiratory cycles per minute (rcpm). A standardized 7-minute final relaxation .
1492058|NCT03028168|Other|Breathing technique|Intervention uses diaphragmatic breathing, observing slow respiratory frequency, between 5-8 rcpm. A standardized 7-minute final relaxation.
1492059|NCT03028168|Other|Control group|Patients will be oriented to keep their pharmacological routine and daily activities, with no structured exercises. They will have to return to the hospital for post-testing after 8 weeks from randomization
1492060|NCT03028155|Drug|Oxaliplatin: BSA-based HIPEC|oxaliplatin: 460 mg/m2 volume: dependent on the capacity of the peritoneal cavity of the patient
1492061|NCT03028155|Drug|Oxaliplatin: Concentration-based HIPEC|oxaliplatin: 230 mg/L
1492062|NCT03028142|Drug|1.5 mg RPL554 plus tiotropium|
1492063|NCT03028142|Drug|6 mg RPL554 plus tiotropium|
1492064|NCT03028142|Drug|Placebo plus tiotropium|
1492065|NCT03028129|Drug|Isoniazid 900 milligrams|Oral tablet, with the isoniazid 900mg, given two weekly, for 52 weeks. The administration will be supervised.
1492066|NCT03028129|Drug|Placebo|Oral tablet, without the active ingredient, similar in size, weight, color, taste and odor. It will be given two weekly for 52 weeks.
1492067|NCT03028116|Biological|influenza vaccine|"A allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains:
NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes)."
1492068|NCT03028116|Biological|Placebo|water for injection
1492069|NCT03028103|Drug|Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2
1492070|NCT03028103|Drug|Fluconazole|200mg will be orally administered QD for 4 days in order to determine CYP3A4 inhibition when administered concomitantly with tazemetostat
1492071|NCT03028103|Drug|Omeprazole|Using omeprazole as a probe substrate, 20mg will be orally administered for a total of 5 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C19. Omeprazole is also being used to determine the effect of increased gastric pH on metabolism of tazemetostat.
1492072|NCT03028103|Drug|Repaglinide|Using repaglinide as a probe substrate, 25mg will be orally administered for a total of 2 days in order to determine the potential of tazemetostat to inhibit or induce CYP2C8.
1492073|NCT03028090|Device|SHERLOCK 3CG™ Tip Confirmation System with MODUS Software|The SHERLOCK 3CG™ Tip Confirmation System (TCS) is a fully-integrated magnetic tracking and ECG-based PICC tip confirmation technology. It was cleared by the FDA on March 19, 2012 and is indicated for use as an alternative to chest x-ray and fluoroscopy for PICC tip placement confirmation in adult patients. In order to further develop the SHERLOCK 3CG™ platform and simplify the PICC placement for the clinician, Bard Access Systems, Inc. is developing MODUS, a software package.
1492074|NCT03028077|Dietary Supplement|GS-3K8|GS-3K8 (ultrafiltered red ginseng extract) 1 g/day
1492075|NCT03028077|Dietary Supplement|GINst15|GINst15 (hydrolyzed ginseng extract) 1 g/day
1492076|NCT03028077|Dietary Supplement|Placebo|Placebo 1 g/day
1492077|NCT03028064|Other|in this cohort study, we will take blood to examine the platelet function|
1492078|NCT03028038|Drug|Platelet Rich Plasma|"Platelet Rich Plasma (PRP) will be injected beneath the buccal periosteal of the first molar and premolar in one mouth side with a split-mouth design before the beginning of Rapid Maxillary Expansion and after 7 days of it.
High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
1492079|NCT03028038|Drug|No Platelet Rich Plasma|"No Platelet Rich Plasma (PRP) will be injected in the other mouth side with a split-mouth design during Rapid Maxillary Expansion.
High resolution cone beam computed tomography (CBCT) will be taken before treatment and after 3 months when the Hyrax is removed."
1492080|NCT03028025|Device|StatSeal|Patients randomly assigned to the experimental group will have a Statseal Advance (SSA) disc applied after withdrawing the radial sheath 2-4 cm. A Tegaderm dressing will be applied to secure the disc position. The TR band will be applied over the SSA disc with the center of the balloon (the green dot) over the center of the SSA disc. The TR band will be inflated with 8cc of air (which is typically occlusive pressure), and the sheath removed. No deflation will occur immediately. After 20 minutes of pressure, 3 cc of air will be removed from the TR band. After an additional 20 minutes (40 minutes after procedure), the TR band will be completely deflated, and the TR band left in place. After an additional 20 minutes (60 minutes after procedure) the TR band will be removed.
1492081|NCT03028025|Device|TR Band|Patients randomly assigned to the control group will have a TR band applied over the arteriotomy site and inflated with 15-18ml of air. After aspirating and clearing the contents of the sheath, the radial sheath will be removed. The TR band will be deflated until bleeding occurs, and 2 ml of air will be reintroduced to provide hemostasis. Patent hemostasis will be documented with plethysmography and oximetry as described below within 5 minutes after band application and removal, and within 30 min of discharge or after 24 hours. The TR band will be left inflated and in place for 2 hours following the procedure for all patients (regardless of diagnostic or PCI procedure), after which deflation attempts will commence.
1492082|NCT03028012|Drug|Ketorolac|Participants may be randomized to receive Ketorolac for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
1492083|NCT03028012|Drug|Lidocaine|Participants may be randomized to receive Lidocaine for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
1492084|NCT03028012|Drug|Dexamethasone|Participants may be randomized to receive Dexamethasone for their TPI. This randomized study will compare the efficacy of the three substances used in TPIs.
1492085|NCT03027999|Other|tight nursing follow-up|"In addition to the usual follow-up by their rheumatologist tight nursing follow-up patients will benefit of
a training session to self-assess their RA: Self-assessment of the number of painful and swollen joints, of pain and disease activity (global assessment by the patient) (self-DAS). During this session, a scheduled dosage of ESR and CRP levels will be given to the patient.
A monthly call by a nurse who inquires about the results of the patient's self-assessment. As soon as she suspects a relapse of RA, she plans a consultation to confirm or not the relapse. For this purpose, she calculates the DAS28 taking into account the results of the biological test, the articular count and the disease activity. Clinical relapse is documented by a DAS28-CRP > 2.7"
1492086|NCT03027986|Behavioral|postural rehabilitation program|This program is based on sensory-motor control
1492087|NCT03027973|Drug|UPA|
1492088|NCT03027973|Drug|TEA|
1492089|NCT03027973|Drug|Placebo (for UPA)|Sugar pill manufactured to mimic UPA 5 mg
1492090|NCT03027973|Drug|Placebo (for TEA)|Sugar pill manufactured to mimic TEA 500mg
1492091|NCT03027960|Drug|Empagliflozin|10mg empagliflozin for a 2-week period
1492092|NCT03027960|Drug|Placebo Oral Capsule|10 mg placebo for a 2-week period
1492093|NCT03027947|Device|Spinal cord stimulator|Spinal cord stimulator leads (2-3 leads) will be placed in the lumbar epidural space of lower limb amputees to determine if the patient experiences any pain reduction from spinal cord stimulation.
1492094|NCT03027934|Drug|Ticagrelor|Ticagrelor, 90mg twice daily
1492095|NCT03027934|Drug|Prasugrel|Prasurgrel, 10mg once daily
1492096|NCT03027921|Other|elastography|
1492097|NCT03027908|Other|Fluoride Toothpaste 1|Toothpaste containing 1450 ppm F as Sodium Fluoride
1492098|NCT03027908|Other|Fluoride Toothpaste 2|Toothpaste containing 1450 ppm F as Sodium Fluoride
1492099|NCT03027895|Device|Endoscopic Ultrasound-guided Drainage Lumen-apposing metal stent|Endoscopic Ultrasound-guided Drainage of WON with metal stent
1492100|NCT03027895|Device|Endoscopic Ultrasound-guided Drainage Tubular metal stent|
1492101|NCT03027882|Other|No Intervention|This is a reliability/validity study of a functional clinical test. There is no intervention
1492102|NCT03027869|Device|transcranial direct current stimulation|15 minute anodal stimulation 1.5mA
1492103|NCT03027856|Device|Magmaris|Implantation of a sirolimus eluting bioresorbable magnesium stent
1492104|NCT03027843|Drug|Growth Hormone|in GH group, patients have weekly injections of GH dose 14 iu, until the day of hCG.
1492105|NCT03027830|Device|iFR pressure-wire|The instantaneous wave-free ratio (iFR) as an adenosine-independent index of coronary stenosis severity, calculated as the ratio between the distal trans-stenotic pressure and the proximal coronary pressure during a specific diastolic wave-free period
1492106|NCT03027830|Device|Conventional|Other diagnostic devices (including FFR and angiography)
1492107|NCT03027817|Procedure|Prone Positioning|Noninvasive cardiac output monitoring parameters were recorded before and after prone positioning.
1492108|NCT03027804|Procedure|Ross Operation|Replacement of the aortic valve by means of pulmonary artery autograft
1492109|NCT03027791|Behavioral|Virtual Reality|Participation in Virtual Reality experiences focused on a) education about the effects of high sodium foods on coronary arteries, blood pressure, the kidneys, and the cerebral vasculature, and b) stress management.
1492110|NCT03027791|Behavioral|Group Sessions|12 weekly group sessions that will provide education on topics related to hypertension, dietary sodium, physical activity and stress.
1492111|NCT03027778|Other|Exercise|Intradialytic pedalling exercise during regular dialysis sessions (3x per week) for 4 months
1492112|NCT03027752|Procedure|Operation carotid endarterectomy with plastic of xenopericardial patch|Under local anesthesia Sol.Novocaini 0.25%, wires or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Common carotid artery cut then performed a longitudinal arteriotomy on the front of the anterior surface of the internal carotid artery. Under the visual control performs a sequence of endarterectomy of the internal carotid artery. Plastic arteriotomy performed patche of ksenoperikardial (Kemperiplas-Neo) treated with epoxy compounds.
1492113|NCT03027752|Procedure|New method of operation сarotid endarterectomy with autoarterial remodeling of bifurcation CCA|Under local anesthesia Sol.Novocaini 0.25%, or endotracheal anesthesia using the standard access the bifurcation of the common carotid artery, internal carotid artery, isolated on identical distance external carotid artery. Carotid glomus separated and moves downward and backward bifurcation of the common carotid artery. External carotid artery is cut off at an angle of 45º from the mouth with a portion of the common carotid artery, then performed a longitudinal arteriotomy on the front of the medial surface of the internal carotid and posterior-lateral surface of the external carotid artery. Under the visual control performs a sequence of endarterectomy of the internal and external carotid arteries. The final recovery of the arteries is performed by crosslinking of their walls with each other in a side by side type between the internal and external carotid arteries 6/0 Polypropylene thread with two needles.
1492114|NCT03027739|Biological|CART-19|CART-19 cells treated
1492115|NCT03027726|Behavioral|lifestyle and psycho-educational program|The family-based healthy lifestyle education and psychological education program will be followed once every two weeks (11 sessions over 22 weeks) for 90 minutes (45 minutes in the healthy lifestyle education program and 45 minutes in the psycho-educational intervention). The sessions of the healthy lifestyle education and psycho-educational interventions will be developed simultaneously and delivered to both parents (or caregivers) and children, separately. The family-based healthy lifestyle education program will be conducted by experienced nutritionists and the psycho-educational program by experienced psychologists in behavior changes
1492116|NCT03027726|Other|Exercise plus lifestyle and psycho-educational program|The intervention group will attend the same lifestyle education and psycho-educational program plus the exercise program. The exercise group will do exercise 3 days/week, 90 minutes per session, over a 22-week period. The program will be offered to the families five days per week to choose a total of three days/week. Sessions will be designed and supervised by exercise specialists. The duration of training sessions will be 90 minutes of exercise, including warm-up, moderate to vigorous aerobic activities, and strength exercises
1492117|NCT03027713|Procedure|weaning protocol|The patients were allocated in the NAVA weaning protocol group o in the PSV weaning protocol group
1492118|NCT03027700|Device|MRI|MRI scan performed on 1.5T Philips Ingenia MRI scanner.
1492119|NCT03027687|Device|tDCS|tDCS is an electrical brain stimulation method
1492120|NCT03027674|Drug|10% nifedipine cream|Topical treatment for Raynaud
1492121|NCT03027674|Drug|5% sildenafil cream|Topical treatment for Raynaud
1492122|NCT03027661|Drug|Bupivacaine|
1492123|NCT03027661|Drug|0.9% Sodium Chloride|
2001609|NCT02891499|Procedure|Low-level laser therapy|"Immediate post-operative period (implantation day) Red emission (650 nm) Energy density: 2 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 One application, 10 seconds of non-contact irradiation (01 point at the area surrounding the miniscrew) at a distance of 15,5 mm.
Mediate post-operative period (after implantation day) Infrared emission (808 nm) Energy density: 4 J/cm2 Power: 0.1W Irradiation area: 0,5 cm2 6 applications every 48 hours after the day of implantation, 20 seconds of non-contact irradiation (01 point on the area surrounding the miniscrew) at a distance of 15,5 mm."
1492125|NCT03027635|Device|PleurX, peritoneal tunnelated catheter|A permanent catheter
1492126|NCT03027635|Device|Large Volume Paracentesis|Short time drainage
1492127|NCT03027635|Drug|Ciprofloxacin 500Mg Tablet|
1492128|NCT03027622|Behavioral|quality of life in the patients with mild pericoronitis|active surviallence by OHIP-14 TR after treatment
1492129|NCT03027609|Drug|aerubumab|monoclonal antibody
1492130|NCT03027609|Drug|placebo|matching placebo
1492131|NCT03027596|Procedure|Remote ischemic conditioning|
1492132|NCT03027583|Dietary Supplement|Bif195|6 weeks daily oral intake of the probiotic Bif195.
1492133|NCT03027583|Dietary Supplement|Placebo|6 weeks daily oral intake of placebo.
1492134|NCT03027570|Behavioral|Control|Five-month interdisciplinary program, including: twice a week one-hour group exercise activity sessions, 3-5 group meetings with a dietician, 12-13 parent sessions with a social worker, and a healthy cooking workshop, each child will take part in individual sessions including: two appointments with a pediatrician, three sessions with a dietician and two sessions with a physical therapist serving as a consultant for physical activity.
1492135|NCT03027570|Behavioral|Exergame activity_EXG|"In addition to the treatment given to the control group (as described above), the EXG group will obtain home access to the app Just Dance Now and part of a weekly exercise session will include a group activity with the app."
1492136|NCT03027570|Other|Application activity|"The application - Just Dance Now will be downloaded to the cellular phone of the child or parent. Exercise using the app will be used by cell phone connection to the child's home computer and as part of exercise group activity."
1492137|NCT03027557|Drug|Cinacalcet 30 mg Tablet|Participants in one arm will receive 30 mg cinacalcet each day.
1492138|NCT03027557|Drug|Denosumab Inj 60 mg/ml|Participants in two arms will receive 60 mg Denosumab biannually.
1492139|NCT03027557|Other|Placebo tablets|Participants in two arms will receive one placebo-tablet each day.
1492140|NCT03027557|Other|Saline Injection (Placebo)|Participants in one arm will receive saline injections as placebo for denosumab.
1492141|NCT03027544|Radiation|tomotherapy|"Tomotherapy: The regular fraction modes were as follows: a. lesions≥3 cm:52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions<2cm:36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm: 40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem:50-60Gy/2.5-3Gy/20f; 3. multiple lesions with large lesion: whole brain radiation (WBRT) with 40Gy/2Gy/20f and concurrent boost of 60Gy/3Gy/20f of the lesions.
TMZ is used if necessary: concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/ m2*5d, q28d, up to 6cycles."
1492142|NCT03027531|Behavioral|eKISS: electronic KIOSK for Safer-Sex|An interactive computer-based intervention for safer-sex which provides individualized feedback about protective and risky sexual behaviors; offers instructive video modules for safe-sex; elicits change behavior and identification of behavior change goal using elements of motivational interviewing.
1492143|NCT03027518|Other|WILD 5 Wellness|
1492144|NCT03027505|Drug|Ready to Use Therapeutic Food (RUTF)|"MUAC used as the primary admission and exit criteria for children with MUAC <125mm and no medical complication.
Single treatment of RUTF for severe and moderate malnourished children and gradual reduction of doses according to the MUAC and the weight of the child during treatment. MUAC split into 3 categories:
MUAC <115 mm: 175 kcal /kg/day
115 <MUAC <120mm: 125kcal/kg/day
120 <MUAC <125mm: 75kcal/kg/day"
2001610|NCT02891499|Procedure|Mediate force application|Mediate force application protocol: orthodontic force application (150 gF) 4 weeks after the day of the implantation.
2001611|NCT02890888|Other|hyperbaric oxygen treatment|Patients are treated in a hyperbaric oxygen chamber for 1 hour at 2ATA, 10 times over 2 consecutive weeks, 5 times per week
2001612|NCT02889796|Drug|Filgotinib|Tablet(s) administered orally once daily
2001613|NCT02889796|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
2001614|NCT02889796|Drug|Adalimumab|40 mg/mL administered via subcutaneous injection once every two weeks
1492486|NCT03024684|Drug|Placebo Oral Tablet|Placebo one tablet daily
2001615|NCT02889796|Drug|Placebo to match adalimumab|Administered via subcutaneous injection once every two weeks
1949064|NCT00582088|Biological|VEE C-84|Subjects will receive a 0.5 mL subcutaneous injection in the upper outer aspect of arm; maximum of four boosters in 1 year if titer <1:20.
2001616|NCT02889796|Drug|MTX|Commercially sourced tablet(s) administered orally
1492151|NCT03027362|Other|Cognitive behavioral therapy (CBT) and medication|Sixteen sessions over 14 weeks.
1492152|NCT03027362|Other|Psychoeducation and medication|
1492153|NCT03027349|Other|No intervention are provided|
1492154|NCT03027336|Dietary Supplement|Coleosoma|patients will take one tablet of 500mg daily for 12 weeks. No dose titration is foreseen.
1492155|NCT03027336|Dietary Supplement|Placebo|patients will take one tablet daily for 12 weeks.
1492156|NCT03027323|Device|AxoTrack System|The AxoTrack system is a novel ultrasound guidance system intended to facilitate central venous cannulation (CVC) by a single operator as well as to reduce complications and time associated with CVC. The AxoTrack has a small ultrasound scan head which facilitates imaging of the subclavian vein.
1492157|NCT03027284|Drug|Merestinib|Administered orally
1492158|NCT03027284|Drug|Cisplatin|Administered IV
1492159|NCT03027284|Drug|Gemcitabine|Administered IV
2001617|NCT02886728|Drug|Filgotinib|Tablet(s) administered orally once daily
2001618|NCT02886728|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
1492162|NCT03027232|Other|No intervention (drugs) will be given. Purpose: collecting blood for in vitro studies|No drugs or interventions are given. Single purpose is to draw blood from healthy subjects to study immune cell biology in vitro. No records about subjects to be kept.
1492163|NCT03027219|Drug|Alprostadil|Vasodilator for anastomosis-site of free flap
1492164|NCT03027206|Other|Vibration technique|Comparison of different technique
1492165|NCT03027206|Other|Acceleration of expiratory flow|Comparison of different technique
1492166|NCT03027193|Biological|ChAdOx2 HAV|The ChAdOx2 HAV vaccine consists of the replication-deficient simian adenovirus vector ChAdOx2, containing the Mycobacterium avium subspecies paratuberculosis (MAP) antigens ahpC/gsd/p12/mpa expressed from the strong CMV IE promoter.
1492167|NCT03027180|Device|Noninvasive positive airway pressure with different levels|
1492168|NCT03027167|Drug|Aspirin|
1492169|NCT03027167|Device|(Post- discharge) Mechanical Compression Device|
2001619|NCT02886728|Drug|MTX|Capsule(s) administered orally once weekly
2001620|NCT02886728|Drug|Placebo to match MTX|Capsule(s) administered orally once weekly
1492172|NCT03027141|Behavioral|Face recognition task|Inside the MRI scanner and during the experiment, participants will be asked to make judgments about the identity they perceived in each morphed picture.
1492174|NCT03027115|Drug|Tamsulosin|Tamsulosin treatment for 7 days pre-operatively
1492175|NCT03027102|Biological|DNT cells|DNT cells will be expanded (increased in numbers) in the laboratory, in order to enhance their tumour destroying potential before infusion into AML patients.
1492176|NCT03027076|Procedure|Genitourinary Specimen Collection|Collect urethral swab, urine before prostatic massage (pre-M), urine after prostatic massage (post-M) and Expressed Prostatic Secretion (EPS)
1492177|NCT03027076|Procedure|Collect midstream urine samples|Collect midstream urine samples
2001621|NCT02884531|Other|Patient Education and Basic Body Awareness Therapy|Patient education (1/2 day) and a Physiotherapy movement modality (12 times, once a week)
2001622|NCT02884531|Behavioral|Patient Education|Patient education (1/2 day)
1492180|NCT03027050|Procedure|T-PRF|Applied for treatment of periodontal bone loss.
1492181|NCT03027050|Procedure|Open Flap Debridement alone|
1492182|NCT03027024|Device|Implantation of IOL: PhysIOL POD F GF|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
1492183|NCT03027011|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
1492184|NCT03027011|Procedure|Control|Control group without remote ischemic preconditioning
1492185|NCT03026998|Procedure|MRI|MRI will be performed each year during 10 years.
1492186|NCT03026985|Other|Observational cohort|Ultrasound assessment of quadriceps, muscle strength testing, highest mobility level
2001623|NCT02883049|Drug|Clofarabine|Given IV
2001624|NCT02883049|Drug|Cyclophosphamide|Given IV
2001625|NCT02883049|Drug|Cytarabine|Given IT, IV or SC
2001626|NCT02883049|Drug|Dasatinib|Given PO
2001627|NCT02883049|Drug|Dexamethasone|PO or IV
2001628|NCT02883049|Drug|Doxorubicin Hydrochloride|Given IV
2001629|NCT02883049|Drug|Etoposide|Given IV
1949072|NCT00561080|Biological|Zostavax|One dose (0.65 mL)
1949073|NCT00561080|Biological|Zostavax|Two doses (0.65 mL) at one month interval
2001630|NCT02883049|Drug|Hydrocortisone Sodium Succinate|Given IT
2001631|NCT02883049|Other|Laboratory Biomarker Analysis|Correlative studies
2001632|NCT02883049|Drug|Leucovorin Calcium|Given PO or IV
2001633|NCT02883049|Drug|Mercaptopurine|Given PO
2001634|NCT02883049|Drug|Methotrexate|Given IT and IV
2001635|NCT02883049|Drug|Pegaspargase|Given IV
2001636|NCT02883049|Drug|Prednisone|Given PO or IV
2001637|NCT02883049|Radiation|Radiation Therapy|Undergo radiation therapy
2001638|NCT02883049|Drug|Thioguanine|Given PO
2001639|NCT02883049|Drug|Vincristine Sulfate|Given IV
2001640|NCT02883530|Procedure|Bronchoscopy|Flexible bronchoscopy will be performed under conscious sedation (with premedication using a mild sedative such as 1−2.5 mg IV midazolam) followed by use of topical anaesthesia (lidocaine spray) on the throat, vocal cords, and trachea in order to investigate the airways. The procedure allows sampling of the airway tissue to allow for laboratory analysis. Three brushings of a small area of the epithelial surface of an airway will be performed via a specialised channel of the bronchoscope with the use of a sterile cytology brush and up to eight 2-mm endobronchial biopsies.
2001641|NCT02880592|Other|Affinity Allograft|fresh hypothermically stored human amniotic membrane
2001642|NCT02880592|Other|Standard of care|offloading, debridement, infection management using appropriate dressings
1492194|NCT03026959|Behavioral|Mindfulness|The mindfulness intervention follows the structure described by Short, Mazmanian, Ozen, & Bédard, (2015).
1492195|NCT03026946|Drug|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
1492196|NCT03026946|Drug|cyclosporin A|Oral cyclosporine A start dose 5 mg/kg/day (split in 2 doses), decreasing the dose after 8 weeks to 3 - 3.5 mg/kg/day (split in 2 doses). The treatment period is 24 weeks.
1492197|NCT03026933|Drug|KI1107 4 Capsules, QD|KI1107 4 Capsules
1492198|NCT03026933|Drug|Rosuvastatin Calcium 20 MG, QD|Rosuvastatin Calcium 20mg, QD
1492199|NCT03026920|Procedure|less invasive method|The less invasive surgical method was conducted in this study. Then, the clinical results were compared with the patients treated using traditional methods to assess the less invasive method.
1492200|NCT03026907|Drug|Alitretinoin|Oral alitretinoin capsule of 30mg once daily for a total of 24 weeks.
1492201|NCT03026907|Drug|Azathioprine|Oral azathioprine tablets twice daily in a dose of 1.5 or 2.5mg/kg/day, depending on the thiopurine methyltransferase (TPMT) activity.
1492202|NCT03026894|Radiation|Panoramic Radiograph|Measurement of bone resorption
1492203|NCT03026894|Device|T-Scan III occlusal system|Recording percentage of force in maximum intercuspation
1492204|NCT03026881|Drug|Fluzoparib|Fluzoparib either at 20,30,40mg twice daily,capsule oral.
1492205|NCT03026881|Drug|Apatinib|Oral
1492206|NCT03026881|Drug|Paclitaxel|Intravenous injection
1492207|NCT03026868|Procedure|quadrilateral surface plate|Both anterior and posterior approaches were always conducted to manage the fragments of quadrilateral surface. Novel quadrilateral surface plate was used in this study to examine whether the fragments could be fixed through single Stoppa approach.
1492208|NCT03026855|Biological|Autologous PRP Gel and PRP Injection|"Autologous PRP prepared using the Res-Q™ 60 PRP system from patient's whole blood, will be injected subcutaneously around the periphery of the wound/ulcer.
Based on the wound size and area, autologous platelet gel obtained by spraying simultaneously equal volumes of PRP and activator solution (thrombin with calcium chloride) will be applied topically over the ulcer or wound.
Single dose of PRP injections and application of PRP gel will be administered, only on the day of treatment."
1492209|NCT03026842|Drug|Decitabine|20 mg/m2/day for 5 days
1492210|NCT03026842|Drug|Daunorubicin, Cytarabine|Daunorubicin: 45 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
1492211|NCT03026842|Drug|Mitoxantrone, Cytarabine|Mitoxantrone: 8 mg/m2/day for 3 days; Cytarabine: 100 mg/m2/day for 5 days
1492212|NCT03026842|Drug|Aclacinomycin, Cytarabine|Aclacinomycin: 20 mg/day for 5 days; Cytarabine: 100 mg/m2/day for 5 days
1492213|NCT03026829|Device|CART sound therapy|"The study consists of two parts:
Phase 1: laboratory evaluation of CART sound acceptability
Phase 2: take home evaluation of CART sound therapy including baseline without CART"
1492214|NCT03026816|Device|Epidural Spinal Cord Stimulation|epidural spinal cord stimulator
1492215|NCT03026803|Drug|Oxaliplatin|Given IV
1492216|NCT03026803|Drug|Capecitabine|Given PO
2001643|NCT02878486|Device|Jawbone Up|Jawbone Up is a wrist wore water resistant activity monitor.
1492221|NCT03026764|Procedure|Outpatient|Patients in the outpatient group will be discharged from the hospital the same day of surgery following a total hip arthroplasty
1492222|NCT03026764|Procedure|Inpatient|Patients in the inpatient group will be discharged from the hospital the following day after a total hip arthroplasty
1492223|NCT03026751|Procedure|Bone Marrow Aspirate|Bone marrow aspirate
1492224|NCT03026738|Procedure|Laparoscopic anterior mesh rectopexy|fixation of the rectum anteriorly using laparosopy and polypropylene mesh
1492225|NCT03026738|Procedure|Laparoscopic posterior mesh rectopexy|fixation of the rectum posteriorly using laparosopy and polypropylene mesh
1492226|NCT03026738|Device|polypropylene mesh|A strip of polypropylene mesh will be introduced and sutured.
1492227|NCT03026725|Other|Tri-calcium Phosphate|A paste contains Tri Calcium Phosphate & Fluoride
1492228|NCT03026725|Other|Placebo|paste manufactured to mimic Clinpro, without Tri Calcium Phosphate
1492229|NCT03026712|Device|Real dual tDCS + Robotic Arm Therapy|"Dual tDCS (anodic on injured hemisphere, cathodic on healthy hemisphere). Motor cortex will be simultaneously stimulated at an intensity equal to 1-2 mA and for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).
The intervention will be performed 5 times per week for 2 consecutive weeks."
1492230|NCT03026712|Device|SHAM tDCS + Robotic Arm Therapy|"SHAM bilateral tDCS for a maximum duration of 20 minutes just before 30 minutes of arm robotic task oriented treatment performed with an exoskeleton device (Armeo Power).
The intervention will be performed 5 times per week for 2 consecutive weeks."
1492231|NCT03026699|Behavioral|eSNAP|Participants in the intervention group will then be given a tablet loaded with the eSNAP application and asked to create a visualization of their social networks. Upon completion, participants will be asked to review their ecomaps and complete the user experience questionnaire.
1492232|NCT03026699|Behavioral|Questionnaires|Participants will complete demographics and baseline (T1; baseline) questionnaires. For all participants Time 2 (T2; 3 week) and Time 3 (T3; 6 week) questionnaires will be completed either by phone, mail, or email (depending on participant preference) to assess longer-term effects of eSNAP on outcomes versus controls.
1492233|NCT03026673|Other|NSAID use|The purpose of the study is to establish that NSAIDS are an appropriate analgesic to be used in the postpartum period, and thus women in the immediate postpartum period are the focus of this study.
1492234|NCT03026660|Dietary Supplement|Moringa Oleifera|
1492235|NCT03026660|Dietary Supplement|Cabbage Placebo|
1492236|NCT03026647|Procedure|Suture|To examine different types of suture material used for hysterotomy closure in cesarean section and determine if one is preferred above other types due to a complications profile.
1492237|NCT03026634|Behavioral|Sleep-disordered breathing|Prevalence and dynamic of sleep-disordered breathing after heart transplantation
1492238|NCT03026621|Dietary Supplement|Lignite Extract|"The study design is a double-blind case-control trial, whereby half of the participants will be cases and will be asked to take 5mL 'Restore' mineral supplement three times each day. The other half of the participants will be controls and will be asked to take 5mL of a placebo three times each day. Both the study leader and the participants will be blinded to who receives Restore and who receive placebo."
1492239|NCT03026621|Other|Herbal tea|This is an herbal tea that will look like the control
1492240|NCT03026608|Behavioral|Veggie Van Program|This includes 1.) Weekly delivery of fresh local produce; 2.) Cooking and nutrition demonstrations; 3.) Weekly newsletters about cooking, nutrition and local produce mailed to all study participants and distributed at Veggie Van
1492241|NCT03026595|Other|no intervention|no intervention
1492242|NCT03026582|Device|Intestinal ultra-sound monitoring|Children diagnosed with either CD or UC will be enrolled at diagnosis or at any time point during follow-up. Patients' characteristics will be retrieved from their medical files including demographic details, disease phenotype, endoscopic and radiologic variables, anthropometric measures, laboratory evaluation, complication and therapeutic regimens. At enrollment and every 3 months for a total period of 2 years all patients will perform intestinal US during regular clinic visits. All other measures including laboratory exams, anthropometric measurements and disease activity indices (either PCDAI for CD or PUCAI for UC) will be performed as part of standard of care.
1492243|NCT03026569|Other|Orange juice (500 mL/d)|The patients were instructed to drink orange juice in two daily portions during eight consecutive weeks. Patients from both groups were asked to maintain their usual lifestyle, diet, and physical activity, and they were checked weekly by the researcher's team. Assessments of anthropometric data, dietary intake, as well as blood sample collection for biochemical analysis were performed in all participants on the first and last day of the experiment.
1492244|NCT03026556|Drug|Dabigatran vs. Rivaroxaban|observed for 6 years
1492245|NCT03026556|Drug|Dabigatran vs. Apixaban|Observed for 6 years
1492246|NCT03026543|Procedure|Pulmonary Recruitment Maneuver|
1492247|NCT03026543|Procedure|Laparoscopic cholecystectomy|
1492248|NCT03026543|Device|Ventilator|
1492249|NCT03026530|Procedure|Pulmonary recruitment maneuver|The participants in the experimental arm receives 1 minute of ventilator-piloted pulmonary recruitment with positive inspiratory pressure set to 40 cm H2O, at the end of laparoscopic bariatric surgery.
1492250|NCT03026530|Procedure|Laparoscopic bariatric surgery|
1492251|NCT03026530|Device|Ventilator|
1492252|NCT03026517|Drug|Dabrafenib|
1492253|NCT03026517|Drug|Trametinib|
1492254|NCT03026517|Drug|Phenformin|
1492255|NCT03026504|Drug|Baricitinib|4 milligrams oral Baricitinib daily for 52 weeks
1492256|NCT03026491|Other|Chewing evaluation|Each child was required to bite and chew a standardized biscuit while chewing video recording. Chewing function was scored with the Karaduman Chewing Performance Scale (KCPS).
1492257|NCT03026478|Drug|Betamethasone Dipropionate|
1492258|NCT03026478|Drug|Clobetasol Propionate|
1492259|NCT03026465|Device|Polymer-free stent|PCI using a polymer-free dual-drug sirolimus- and probucol-eluting stent (Coroflex ISAR)
1492260|NCT03026465|Device|Biodegradable-polymer stent|PCI using a biodegradable-polymer biolimus-eluting stent (Biomatrix)
1492261|NCT03026452|Procedure|US-guided RFA|The investigators used percutaneously US-guided radiofrequency ablation for patients with small hepatocellular carcinoma,and estimated the safety and efficacy of this treatment through 2-year follow-up of US/CEUS/CT/MRI and the tumor markers.
1492262|NCT03026426|Behavioral|CONEMO|"Participants will be offered a behavioral activation-based intervention delivered by an application for smartphones (CONEMO) oriented to encourage them to be more active and to incorporate more activities in participants' everyday life.
Nurses will train participants to use CONEMO, make phone calls when participants are non-adherent, and provide technical support when necessary. Nurses will be supervised by clinical psychologists."
1492263|NCT03026413|Procedure|pulmonary vein antrum modification|
1492264|NCT03026400|Procedure|Transumbilical incision|While both types of incision were considered equal regarding the potential clinical outcome, the investigators considered the transumbilical incision to be the ''intervention'' and the subumbilical incision to be the ''standard care comparator'' since the transumbilical incision take a few more minutes to be completed.
1492265|NCT03026400|Procedure|Subumbilical incision|Considered here as the ''control'' intervention.
1492266|NCT03026387|Behavioral|Neuropsychological battery tests|"The neuropsychological battery tests is composed with: Continuous Performance Test, Iowa Gambling Test, Verbal fluency (animals), Emotional stroop, Self-injury implicit association test.
The neuropsychological battery assesses domains heavily involved in suicidal behavior: impulsivity, affective dysregulation, alterations in decision-making (risky choices), selective attention and verbal fluidity"
1492267|NCT03026374|Behavioral|Be Resilient to Breast Cancer|This is a supportive-expressive group therapy.
1492268|NCT03026361|Genetic|global proteomic profiling|Global proteomic profiling was performed on OLP and OSCC samples and healthy mucosa. Obtained data was analysed in Uniprot database (http://uniprot.org) with the emphasis on extracellular matrix proteins. In total, 55 extracellular matrix proteins were found to be expressed in analysed samples with very high confidence.
1492269|NCT03026348|Biological|RSV F Vaccine with Aluminum Phosphate Adjuvant|
1492270|NCT03026348|Biological|RSV F Vaccine|
1492271|NCT03026348|Biological|Matrix-M1 Adjuvant|
1492272|NCT03026348|Other|Phosphate Buffer|
1492273|NCT03026335|Behavioral|Positive Action|Based upon a Cognitive Behavioral Therapy model, intervened schools were engaged in providing curriculum, school infrastructure elements, and parent/community involvement activities around a single model aimed to provide positive support for behaviors. Six areas were identified: self-concept, body/mind, responsible self-management, treating others they way you want to be treated, telling yourself the truth, and continual improvement of self.
1492274|NCT03026335|Behavioral|Control|Business as usual with students in non-itervened schools
1492347|NCT03025763|Procedure|Pre-operative CT Scan Image Files.|Optional for those who had a previous CT scan for a prior traumatic event.
1492348|NCT03025750|Biological|IPV-Al SSI|Total of three primary injections of IPV-Al SSI, one at 2, 4 and 6 months of age
1492275|NCT03026322|Other|Manual Ventilation|Beginning after the administration of sedation/neuromuscular blockade, manual ventilation will be provided by bag-valve-mask until the initiation of laryngoscopy. In patients requiring more than one attempt at laryngoscopy, bag-valve-mask ventilation will resume between laryngoscopy attempts.
1492276|NCT03026322|Other|No Manual Ventilation|Between the administration of sedation/neuromuscular blockade and intubation, ventilation will not be provided unless the patient experiences an arterial oxygen saturation less than 90%. For patients who experience an oxygen saturation less than 90% after induction, bag-valve-mask ventilation may be provided.
1492277|NCT03026309|Other|no intervantion|no intervention is being performed, only observational evaluations.
1492278|NCT03026296|Behavioral|Healthy Life Center|Depending on what behavior participants aim to change, they get individual counselling using elements from motivational interviewing, group-based exercise twice a week, diet courses and tobacco secession courses during three months
1492279|NCT03026283|Device|HeartFLow CT-FFR|Patients receiving CCTA to diagnose stable chest pain or stable angina will receive CT-FFR to estimate rate of flow through the coronary arteries. The rate of flow will be compared to the rate found on Invasive FFR (the gold standard) if the subject receives invasive FFR.
1492280|NCT03026270|Other|Paraffin|The application of paraffin wax will be performed with the patient in the supine position at rest for at least 10 min, then with an appropriate brush (5 cm wide), will spend several layers with the brush into two distinct groups, seven or ten layers depending on the outcome of randomisation, in the region of interest of the upper limb, being scarred, surrounded by a plastic film film remaining in the area for 15 minutes, and then discarded
1492281|NCT03026257|Device|Lotrafilcon B contact lenses with added wetting agent|Silicone hydrogel contact lenses
1492282|NCT03026257|Device|Samfilcon A contact lenses|Habitual silicone hydrogel contact lenses
1492283|NCT03026257|Device|POLYQUAD/ALDOX-preserved contact lens solution with added wetting agent|Multi-purpose disinfecting solution for contact lens care
1492284|NCT03026257|Device|Hydrogen peroxide-based contact lens solution with added wetting agent|Solution for contact lens cleaning and disinfecting
1492285|NCT03026257|Device|Senofilcon C contact lenses|Habitual silicone hydrogel contact lenses
1492286|NCT03026257|Device|Senofilcon A contact lenses|Habitual silicone hydrogel contact lenses
1492287|NCT03026257|Device|Comfilcon A contact lenses|Habitual silicone hydrogel contact lenses
1492288|NCT03026257|Device|Habitual Multi-Purpose Solution (HMPS)|Multi-purpose solution for contact lens care according to participant's habitual brand, used per manufacturer's instructions
1492289|NCT03026244|Dietary Supplement|Milk protein, prebiotics, vitamin D|3 weeks supplementation with milk protein only, followed by 3 weeks milk protein + prebiotics, followed by 3 weeks milk protein + prebiotics + vitamin D
1492290|NCT03026244|Dietary Supplement|Placebo product|3 periods of 3 weeks placebo product
1492291|NCT03026231|Biological|PRIM-DJ2727|Thirty eligible subjects with PD will be randomly assigned to receive either PRIM-DJ2727 in orally administered enteric-coated capsules or placebo capsules
1492292|NCT03026231|Drug|Placebo (for PRIM-DJ2727)|Thirty eligible subjects with PD will be randomly assigned to receive placebo capsules
1492293|NCT03026218|Other|GlucoseMama application with blood sugar monitoring and carb monitoring.|
1492294|NCT03026218|Other|Group prenatal care for GDM.|
1492295|NCT03026205|Drug|ARMS-I|
1492296|NCT03026192|Device|near infrared spectroscopy|Near infrared spectroscopy will be placed on infants both with and without hsPDA
1492297|NCT03026179|Behavioral|Play Nicely|Play Nicely is a multimedia program that teaches parents about appropriate methods to discipline.
1492298|NCT03026166|Drug|rovalpituzumab tesirine|Intravenous
1492299|NCT03026166|Drug|nivolumab|Intravenous
1492300|NCT03026166|Drug|ipilimumab|Intravenous
2001644|NCT02878486|Behavioral|Physical Activity Education|A study team member will discuss benefits of changing sitting habits and ways to make changes to personal habits.
2001645|NCT02878486|Device|ActivPAL|Devices measures postural changes over time. Participants will wear device for 7 days. The device measures time sitting, standing, and posture changes (i.e. sit-to-stand).
1492303|NCT03026140|Drug|Nivolumab|Nivolumab 3mg/kg (day 1 and day 15), administered neoadjuvant before surgery
1492304|NCT03026140|Drug|Ipilimumab|Ipilimumab 1 mg/kg (day 1) ,administered neoadjuvant before surgery
1492305|NCT03026140|Drug|Celecoxib 200mg|celecoxib will be administered starting day 1 until 1 day before surgery daily (if patient is randomized to group 2 (only applicable for patients with a MSS tumor)
1492306|NCT03026127|Behavioral|Cognitive Reappraisal Intervention for Suicide Prevention|Cognitive Reappraisal Intervention for Suicide Prevention, or CRISP, is a psychosocial intervention aimed to reduce suicide risk in middle-aged and older adults who have been hospitalized for suicidal ideation or suicide attempt. CRISP offers a combination of emotion regulation techniques, including changing the subject's perspective or the way he/she thinks to improve emotion reactions. Additional strategies taught include the provision of environmental adaptation tools (notes, checklists, calendars, etc), phone calls, and a tablet application called WellPATH.
1492307|NCT03026127|Behavioral|Supportive Therapy|ST focuses on: 1. facilitating expression of affect; 2. conveying to the patient that he or she is understood; 3. offering empathy; and 4. highlighting positive experiences. The ST manual aims to standardize nonspecific therapeutic factors
1492309|NCT03026101|Drug|Nitroglycerin|Intra-arterial adminstration to dilate external carotid artery branches and to replicate migraine pain
1949074|NCT00561080|Biological|Zostavax|Two doses (0.65 mL) at 3 months interval
1492346|NCT03025763|Procedure|Tissues from a Clinically Indicated Procedure|In some instances when there is discarded tissues and specimens (including skin and bone at the time of reconstructive craniofacial surgery), they will be collected by making arrangements with their physicians. Some of these tissues will be used to generate cell lines. Optional.
1949075|NCT00541047|Drug|bicalutamide|
1949076|NCT00541047|Drug|goserelin acetate|
1949077|NCT00541047|Drug|leuprolide acetate|
1492311|NCT03026075|Device|Motus Cleansing System (MCS)|The MCS enables colon cleansing during standard colonoscopy using a standard colonoscope. The cleansing device, which is attached to the tip of the colonoscope and is connected to an external workstation, generates fluid jets within the colon thus dissolving the feces into small parts. The fecal matter & fluids are drained through the evacuation pipe of the cleansing device into a collecting reservoir.
1492312|NCT03026062|Drug|Tremelimumab|Arm 1, Sequential: 3 mg/kg intravenous (IV) every 4 weeks (q4w) for up to 4 doses Arm 2, Combination: 1 mg/kg IV plus Durvalumab for up to 4 doses
1492313|NCT03026062|Drug|Durvalumab|Arm 1, Sequential: 1.5 g IV q4w for up to 9 doses upon progression Arm 2, Combination: 1.5g IV q4w for up to 4 doses and then if disease progresses, by Durvalumab monotherapy 1.5 g IV q4w for up to 9 doses
1492314|NCT03026049|Device|deep venous stenting|Deep venous stent
1492315|NCT03026023|Drug|Combindation treatment with Grazoprevir and Elbasvir fixed dose combination tablet, with or without ribavirin|HCV treatment for 12 to 16 weeks. Treatment length and addition of ribavirin based upon presence of baseline resistance associated variant in the HCV virus. Medications given concurrently.
1492316|NCT03026010|Procedure|central blood pressure|SphygmoCor XCEL will be used to measure both standard blood pressure in the arm and central pressure, the blood pressure at the heart.
1492317|NCT03025997|Dietary Supplement|Active yoghurt|Active yoghurt (containing encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
1492318|NCT03025997|Dietary Supplement|Placebo yoghurt|Placebo yoghurt (containing non-encapsulated lipid) will be ingested after a standardized breakfast, and subsequently satiety and food intake will be measured.
1492319|NCT03025984|Behavioral|Texting|patient adherence to her recommended care regimen after intervention of a text message reminder and education system
1492320|NCT03025971|Device|J-Valve Transcatheter Aortic valve replacement|Transapical Transcatheter Aortic Valve Replacement
1492321|NCT03025958|Drug|Nimotuzumab|
1492322|NCT03025958|Radiation|Radiation|
1492323|NCT03025945|Drug|Nepafenac 0.3%|
1492324|NCT03025945|Drug|Saline Solution|
1492325|NCT03025932|Procedure|repair of giant hiatal hernia with mesh and anterior fundoplication|
1492326|NCT03025906|Drug|Phenobarbital|In the PB group, a loading dose of 20 mg/kg (may give an additional 10 mg/kg) begins at a rate of 50 mg/min followed by IV 100 mg q6 h.
1492327|NCT03025906|Drug|Valproate|In the VPA group, a loading dose of 30 mg/kg (may give an additional 15 mg/kg) begins at a rate of 3 mg/kg per min followed by a continuous infusion at a rate of 1-2 mg/kg per hour.
1492328|NCT03025893|Drug|Sunitinib|Sunitinib, 300 mg administered orally in a weekly schedule.
1492329|NCT03025893|Drug|Lomustine|Lomustine 110 mg/m2, taken orally on day 1 every 6 weeks.
1492330|NCT03025880|Drug|Pembrolizumab|"Pembrolizumab at a dose of 200mg as an intravenous (IV) 30 minutes infusion on day 1 of each 21-day cycle.
Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first. Patients completing 24 months of uninterrupted treatment with pembrolizumab or 35 administrations of study medication will stop pembrolizumab treatment (though may continue with gemcitabine). Subjects who stop pembrolizumab after 24 months may be eligible for up to one year of additional pembrolizumab treatment if they progress after stopping it."
1492331|NCT03025880|Drug|Gemcitabine|"Gemcitabine at a dose of 1,250mg/m2 as an intravenous (IV) 60 minutes infusion on day 1 and 8 of each 21-day cycle.
Treatment will be repeated on day 1 of each 21-day cycle until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first."
1492332|NCT03025867|Drug|Niraparib|
1492333|NCT03025854|Other|laboratory biomarker analysis|
1492334|NCT03025841|Drug|Ceftaroline|
1492335|NCT03025828|Drug|ACTHar|for 6 months
1492336|NCT03025815|Other|Intervention group|Oral stimulation program consists of the a 15 minutes stimulation program, whereby the first 12 minutes involved stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consists of sucking on a pacifier routinely.
1492337|NCT03025815|Other|Control group|sham stimulation program consists of the same researcher placing her hands for 15 minutes.
1492338|NCT03025789|Drug|Fexinidazole|Tablets of 600 mg Patients with a weight between 20 and 34kg: 1200mg for 4 days, then 600mg for 6 days Patients with a weight of 35kg and above: 1800mg for 4 days, then 1200mg for 6 days
1492339|NCT03025776|Behavioral|Reaching|sitting reaching under various task conditions (size, speed, location)
1492340|NCT03025776|Behavioral|Kinematic collection while reaching|sitting reaching under various task conditions (size, speed, location), told how many & which hand to use, kinematic data collected
1492341|NCT03025763|Other|Craniosynostosis Network Environmental Survey|Questionnaire is administered to the mothers of affected participants regarding medical history and environmental exposures during pregnancy, delivery, and neonatal period. Optional.
1492342|NCT03025763|Other|2D/3D Photography|Full frontal and lateral face and other parts of the body may be taken for dysmorphic assessment. There is the risk of identification and loss of confidentiality. Optional.
1492343|NCT03025763|Procedure|Buccal Swab Cell Sampling|One or more swabs, like a Q-tip (for children), or saliva collection kit (for adults) will be used to collect buccal cells. With a swab, they will brush the inside of the mouth several times. With saliva collection kit, they will collect their saliva by spitting into a container several times using a commercially available saliva collection kit. Required.
1492344|NCT03025763|Procedure|Blood sampling|Venipuncture so that one teaspoon to tablespoons (1-20 ml.) of blood is collected. The volume drawn will be dependent on the age and size of the child. Minimal amounts may be required for DNA, but to establish a lymphoblastoid or iPS cell line at least 3 to 10 ml will be required independent of age. In the case of an infant, if 3 to 10 ml cannot be obtained, then a lymphoblastoid or iPS cell line will not be created. Optional.
1492345|NCT03025763|Procedure|Skin Biopsy|For those who do not undergo surgery or the skin removal is not considered part of the surgical procedure. After proper cleaning, a piece of skin the size of a pencil eraser (about 4 mm or 1/8 inch in diameter) will be removed (using a circular blade or scalpel) from the arm (inside of arm or forearm in a spot that is as unnoticeable as). This area will be covered with a Band-Aid. No stitches are usually required. A crust will form and eventually fall off. Optional.
1492349|NCT03025750|Biological|IPV SSI|Total of three primary injections of IPV SSI, one at 2, 4 and 6 months of age
1492350|NCT03025724|Drug|Levulan Kerastick|Intervention group subjects will undergo a surgical excision of the tumor. Then a clear transparency film will be used to trace the clinical margins of the lesion, as well as any other distinctive skin markings such as nevi or birthmarks. Subjects will then undergo the study procedure where the area to be treated will be swabbed with an alcohol wipe and allowed to dry. Next, the investigator will apply topical 20% 5-ALA (Levulan Kerastick; DUSA Pharmaceuticals) to the SCCis. Then, the area will be occluded with Tegaderm film for 3 hours.
1492351|NCT03025724|Device|blue light source|At the end of the incubation period, the Tegaderm will be removed and the patient will be exposed to a blue light source (BLU-U; DUSA Pharmaceuticals).
1492352|NCT03025724|Other|participant satisfaction survey|Participants will be asked to fill out a satisfaction survey.
1492356|NCT03025685|Procedure|RUS technique|A soft hydrophilic wire easily pass through the invisible small vessels in the distal parts of a coronary artery into a heart cavity. It is necessary to pass a wire softly and forward as deep as possible. Quite often the wire goes through the left ventricle to aorta arch, and sometimes distal soft tip can be visible in a descending aorta. Thus the stiffest part of the wire become staying on all length of artery, straightening bends and giving the maximum support. After that balloons and stents can be delivered more easily
1492357|NCT03025685|Procedure|Anchoring Technique|A standard endovascular technique of coronary wire support improvement
1492358|NCT03025685|Procedure|Coronary stenting|A standard endovascular procedure of percutaneous coronary intervention with coronary stenting
1492359|NCT03025659|Other|Pyruvate levels|An additional 1 ml of arterial blood will be drawn at each routine postoperative blood draw (Hour 0, 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, and 48 for participants 10kg and above or only at Hour 0, 2, 4, 6, 8, and 12 for infants under 10 kg) to measure the concentration of pyruvate in blood.
1492360|NCT03025646|Other|Mental Health care services & home based training|"From day 0 of the study period we will initiate setting up the intervention in two schools, which will include two components:
Implementing mental health care services at schools targeting the mothers diagnosed as having depression who have consented to participate in the study (intervention mother).
Psychologists will provide counseling session over 4-6 months period. Every month a psychiatrist will visit each school for reviewing the records of the mothers and mothers will be referred to the National Institute of Mental Health (NIMH) if necessary
Organizing training sessions of the intervention mothers for supporting enhanced child care at home.
Organizing training of the intervention mothers by special educator through a parental training module in the schools. Special educator will conduct refresher training at home every month."
1492361|NCT03025633|Other|PEARL|PEARL, is a commercially available PC-based tool that provides a realistic and functional 3D model of a linac and, having uploaded example treatments it can demonstrate the treatment procedure and also relevant anatomical information.
1492362|NCT03025620|Dietary Supplement|Rapeseed oil|Active comparator arm : Dietary Supplement: rapeseed oil supplementation (10g per day) and margarine with a high level of alpha-linolenic acid (12.5g per day) during 42 days.
1492363|NCT03025620|Dietary Supplement|Sunflower oil|Placebo comparator arm : Dietary Supplement: sunflower oil supplementation (10g per day) and margarine with a high level of inoleic acid (12.5g per day) during 42 days.
1492364|NCT03025607|Device|JOOL Health Mobile Phone Application|JOOL Health is a mobile phone-based application that aims to increase autonomous motivation to prevent T2DM by helping individuals make connections between certain health behaviors and the energy and willpower needed to achieve personal goals. On a daily basis, JOOL Health users chart the following health behaviors: Sleep, Presence, Activity, Creativity, and Eating. On a weekly basis, JOOL Health users are asked to record how well they lived according to their purpose and values. Through the integration of user-entered information with contextual data, JOOL Health provides tailored messaging and daily predictions of individuals' energy and willpower.
1492365|NCT03025594|Drug|Gonyautoxins|Periarticular infiltration of 40mcg of Gonyautoxin diluted in 30cc of Sodium Chloride 0.9%, with pH 6.2 and isosmotic. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue just before wound closure of total knee arhroplasty
1492366|NCT03025594|Drug|Chirocaine ketorolac epinephrine|Periarticular infiltration of 150ml of Chirocaine 2%, 60mg of ketorolac and 0.75mg of epinephrine. This solution will be administer targeting posterior capsule, both retinaculum, collateral ligaments, quadriceps and patelar tendon and subcutaneous tissue jbefore wound closure of total knee arhroplasty.
1492367|NCT03025581|Other|Nipple stimulation|For the intervention group participants will be instructed to gently massage alternate breasts, especially around the nipples for 15 minutes every 6 hours until the appearance of regular contractions but not more than 24 hours. Moist cloth or lubricating or moisturizing cream will be offered to facilitate the procedure according to individual preferences. In the control group all participants will be asked to avoid any breast stimulation during the study period.
1492368|NCT03025568|Other|PEEK|PEEK (poly-ether-ether-ketone) has been successfully used over the last years in the medical ﬁeld, and orthopedics, speciﬁcally. which presents high biocompatibility, good mechanical properties, high temperature resistance, and chemical stability due to a 4 GPa modulus of elasticity, it is as elastic as bone and can reduce stresses transferred to the abutment teeth. Additional advantages of this polymer material are elimination of allergic reactions and metallic taste, high polishing qualities, low plaque afﬁnity, and good wear resistance, it has only recently been used in dentistry.
1492369|NCT03025568|Other|Bre.flex|In the recent time thermoplastic materials (breflex) become quite popular in clinical practice such as nylon and acetal resins. since the 1950, polyamide resin (nylons) provide improved esthetics and reduction of rotational forces on the abutment teeth due to their low elastic modulus.
1492392|NCT03025386|Other|Electroencephalography|Mesure of the mismatch negativity wave
1492393|NCT03025373|Other|Visuo-acoustic stimulation|Controlled visual and acoustic stimulation in a virtual reality setting
1492394|NCT03025360|Drug|larotrectinib|Open-label expanded access, capsules or liquid formulation
1492370|NCT03025555|Other|PEEK|"Polyetheretherketone (PEEK) is a synthetic, tooth colored polymeric material that has been used as a biomaterial in orthopedics for many years but recently used as removable prosthetic material. Advantages of this polymer material are elimination of allergic reactions, high polishing qualities, low plaque affinity, and good wear resistance.
It has been proven that it shows high mechanical and biological properties. Studies evaluating the properties of this material are limited and need more clinical tests."
1492371|NCT03025555|Other|Bre.flex|Bre.flex is a nylon-based thermoplastic material, composed of nylon PA 12 (polyamide).Nylon exhibits high physical strength, heat resistance and chemical resistance. It can be easily modified to increase stiffness and wear resistance. Nylon resin can be semi-translucent and provides excellent esthetics but it is a little more difficult to adjust and polish.
1492372|NCT03025542|Drug|Bimekizumab|Based on their randomization subjects will receive a combination of several injections of Bimekizumab.
1492373|NCT03025542|Other|Placebo|Subjects will receive injections of Placebo.
1492374|NCT03025529|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation or TMS is a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. This magnetic field can pass through the head safely and painlessly. TMS can be used to change activity in the brain.
1492375|NCT03025529|Device|Sham Transcranial Magnetic Stimulation|Sham Transcranial Magnetic Stimulation or sham TMS is like active TMS, a noninvasive procedure (meaning it does not enter the body) that is used to stimulate a part of the brain using a magnetic field. TMS can be used to change activity in the brain but in this intervention, the coil will be angled 90 degrees from the scalp, resting on one wing of the coil, and therefore will not be delivering active TMS.
1492376|NCT03025516|Device|Rapid Biosensor Systems (RBS) TB Breathalyser|Rapid Biosensor Systems (RBS) recently developed a portable, non-invasive, rapid TB diagnostic 'Breathalyser' capable of diagnosing TB in patient breath samples collected while patients cough (Figure 1). The TB Breathalyser comprises a disposable, single-use sample collection tube and a multi-use reader. At the bottom of the collection tube is a glass bio-sensor coated with a biochemical sensor that is formulated to react with TB bacilli. Patients cough into the collection tube after nebulization with 0.9% saline solution. Following sample collection, the tube is placed into the reader, where a diode laser interrogates the biochemical coating in the sample collection tube and reports the presence of TB bacilli. The entire process takes about two minutes.
1492377|NCT03025516|Device|eNose AeonoseTM|The eNose Company has also developed a hand-held, non-invasive rapid TB diagnostic 'electronic nose' (AeonoseTM) for TB detection based upon analysis of exhaled breath. After the device has been calibrated, the patient is instructed to breathe into the device through a mouthpiece for 5 minutes. Within the device is a micro-hotplate, metal-oxide sensor which behaves as a semiconductor at high temperature. Redox-reactions occurring at the sensor surface result in changes in resistance, with results read and interpreted by a phone application to confirm the presence of MTB.
1492378|NCT03025503|Other|nipple stimulation|
1492379|NCT03025490|Device|Capnographic monitoring|Capnographic monitoring is used during the sedation.
1492380|NCT03025477|Drug|CC0 - Carboplatin (IV) - Paclitaxel (IV)|(6 cycles)
1492381|NCT03025477|Drug|CC0 - Cisplatin (IP) - Epirubicin (IV)|(6 cycles)
1492382|NCT03025477|Drug|CC>0 - Carboplatin (IV)- Paclitaxel (IV)|"carboplatin (IV) - paclitaxel (IV) (3 cycles)
Interval surgery
Carboplatin (IV) - paclitaxel (IV) (3 cycles)"
1492383|NCT03025477|Drug|CC>0 - Cisplatin (IP/IV)- Epirubicin (IV)|"Cisplatin (IV) - Epirubicin (IV) (3 cycles)
Interval surgery :
if CC0: Cisplatin (IP) - Epirubicin (IV) (3 cycles)
if CC>0 Cisplatin (IV)- Epirubicin (IV) (3 cycles)"
1492384|NCT03025464|Device|Obstructive Sleep Apnea Screening Device|Assessment of ability of device to detect apneas and hypopneas to screen for OSA
1492385|NCT03025451|Behavioral|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
1492386|NCT03025425|Device|Trilogy 100 ® (Philips Respironics)|Mouth piece Ventilation (MPV) using Trilogy 100 ® (Philips Respironics).
1492387|NCT03025412|Procedure|endoscopic surgery|Ambulatory surgery. Same surgeon for all patients. General anesthesia. Full debridement of the paratenon and crural fascia. Also the plantaris longus tendon is debrided, but no additional tenotomy executed. Postoperative rehabilitation. Oral nonsteroidal anti-inflammatory drugs 7 days postoperatively. Active ankle dorsiflexion and plantar flexion from day 1 postoperative. Partly weight bearing (30 kg) from day 1 postoperative. Full weight bearing allowed from week 3 postoperative. Gradually increased load, both in activity of daily living, stationary bike and stretching, with individually and pragmatic progression due to pain response. From week 6 postoperative the patients start the same exercise regimen as the conservative treatment group.
1492388|NCT03025412|Behavioral|physiotherapy and exercise|Exercise schedule: Weeks 1-6, Eccentric unilateral loading while standing on the step of a staircase performed in two exercises; with straight knee and with bent knee. Weeks 7-9, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions x 3 performed with straight knee, and 15 repetitions x 3 performed with bent knee. 3 - 4 times a week. Weeks 10-12, Eccentric - Concentric loading while standing on the step of a staircase performed with straight knee and bent knee. Dose: 15 repetitions maximum (15RM) x 3 performed with straight knee, and 15 RM x 3 performed with bent knee. 3 - 4 times a week. One leg performance or hand hold weight for extra load is used to obtain the exact number of RM.
1492389|NCT03025399|Drug|Tangwang prescription|A kind of Granule(Tangwang prescription) was composition by five Chinese herbal medicines, every bag has 4.87g granules.
1492390|NCT03025399|Drug|Placebo|Placebo is a simulated drug of tangwang prescription,included weight, appearance, colour, taste,smell and solubility.
1492391|NCT03025386|Other|logatoms test|A forced choice test will evaluate the discrimination of the most confusing logatoms in the cochlear implant users, and representative of the French language.
1492396|NCT03025347|Other|Exercise|Participants complete a 60 minute run at 70% of their maximal oxygen uptake
1492397|NCT03025334|Device|transcranial direct current stimulation|brain stimulation to increase neuronal excitability in the targeted regions
1492398|NCT03025321|Device|transcranial Direct Current Stimulation (tDCS)|tDCS is an electrical brain stimulation method Participants will receive real-tDCS or sham twice daily for 13 min with an interval of 20 min for five consecutive days.
1949078|NCT00541047|Procedure|adjuvant therapy|
1949079|NCT00541047|Procedure|quality-of-life assessment|
1492401|NCT03025295|Drug|Dexmedetomidine|
1492402|NCT03025295|Drug|Saline|
1492403|NCT03025282|Drug|CD10367 3% Solution - Non-desquamated zone|Once daily application for 3 weeks
1492404|NCT03025282|Drug|CD10367 1% Solution - Non-desquamated zone|Once daily application for 3 weeks
1492405|NCT03025282|Drug|CD10367 solution placebo - Non-desquamated zone|Once daily application for 3 weeks
1492406|NCT03025282|Drug|Betneval ointment - Non-desquamated zone|Once daily application for 3 weeks
1492407|NCT03025282|Drug|CD10367 3% Solution - Desquamated zone|Once daily application for 3 weeks
1492408|NCT03025282|Drug|CD10367 solution placebo - Desquamated zone|Once daily application for 3 weeks
1492409|NCT03025269|Drug|Ocrelizumab|This is not a drug intervention study, we are doing an observational study with those who have been prescribed Ocrelizumab by their neurologists during clinical routine appointments
1492411|NCT03025243|Device|computer aided surgical guide|comparing accuracy of surgical guide of printing layer thickness of 50 micron and 100 micron by superimposition of pre-operative and post-operative CBCT
1492412|NCT03025230|Other|Dry needling and electric stimulation|Dry needling technique and the application of electric stimulation of levator scapulae PG
1492413|NCT03025230|Other|Dry needling|Treatment of PG with a filiform needle in levator scapulae muscle
1492414|NCT03025217|Behavioral|Total Lifestyle Coaching (TLC)|
1492415|NCT03025204|Biological|Enamel Matrix Proteins|EMD is composed of different proteins, 90% of which are amelogenins, which has the capacity to induce processes involved in the regeneration of periodontal tissues in a manner similar to normal tissue development (48). Several clinical and animal model studies have demonstrated the use of enamel matrix-derived proteins in regenerative periodontal procedures for the formation of a new periodontium.
1492416|NCT03025204|Procedure|Open Flap Debridement|After administration of local anesthetics, full-thickness flaps will be raised in order to access all defect faces. Sulcular incisions will be performed extending to mesial and distal adjacent teeth, including the entire papilla in the flap. No relaxing incisions will be performed. All granulation tissue will then be carefully removed, and subsequently scaling and root planing will be performed. The surgical area will be irrigated with 0.9% saline and carefully inspected to ensure that all steps have been satisfactorily performed until then.
1492417|NCT03025191|Behavioral|Speaker/Listener technique|Couple will learn taking turns as the speaker and as the listener who paraphrases the speaker's point.The couple will then identify an issue they have faced in their relationship and will role-play using the technique to discuss it.
1492418|NCT03025191|Behavioral|Social Support|Identification of and mapping sources of social support and the types of support provided by members of the network. Participants will also identify the strengths and weaknesses of their support network and think through ways to strengthen those networks.
1492419|NCT03025191|Behavioral|Problem-Solving|Couple will be taught steps to systematically analyze a problem and brainstorm solutions through a short video. Steps include identify the trigger/problem; identify the goal for addressing the problem; brainstorm possible solutions for each partner; evaluate the solutions and pick the best; and act on the best solution.
1492420|NCT03025191|Behavioral|Goal Setting|Couple will be introduced to the concept of short- and long-term goal setting, including components of goal and planning for potential barriers. The couple will then set a goal for themselves that incorporates the skills obtained during the intervention, such as strengthening ties in their social support network. Participants will fill in a worksheet outlining their goal, potential barriers, and solutions to those barriers.
1492421|NCT03025178|Procedure|4Fr central venous catheter insertion|The central venous catheter is placed at left internal jugular vein in infant, and its tip is confirmed by transthoracic echocardiography.
1492422|NCT03025165|Other|Community Adherence Clubs|Provision of ART care in the community to a club of 20-25 HIV+ patients
1492423|NCT03025165|Other|Home-Based ART Delivery|Provision of ART care to an individual at their home
1492424|NCT03025165|Other|Standard of Care|Delivery of ART adherence support, symptom screening and dispensation of medications at the local clinic according to local guidelines.
1492425|NCT03025152|Dietary Supplement|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
1492426|NCT03025152|Other|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
1492427|NCT03025139|Other|Educational Intervention|Attend survivorship education
1492428|NCT03025139|Other|Laboratory Biomarker Analysis|Correlative studies
1492429|NCT03025139|Procedure|Meditation Therapy|Attend mindfulness meditation
1492430|NCT03025139|Other|Questionnaire Administration|Ancillary studies
1492431|NCT03025126|Other|Multimedial Rehabilitation|
1492432|NCT03025126|Other|Usual care program|Usual care at home program according to healthcare professional's advice
1492433|NCT03025113|Drug|ketoprofen and cyclobenzaprine association|The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
1492434|NCT03025113|Drug|Cyclobenzaprine|The patient will take 2 tablets (cyclobenzaprine), oral, per day, each 12h.
1492435|NCT03025087|Drug|Hydroxychloroquine|Participants will be getting hydroxychloroquine
1492605|NCT03023761|Device|laser sham|laser without irradiation
1949080|NCT00541047|Radiation|radiation therapy|
1492437|NCT03025048|Behavioral|A holistic dietary intervention for persons with spinal cord injury|A lifestyle program over 9 weeks combining individual consultations with a dieatitian and interdiciplinary group sessions
1492438|NCT03025035|Drug|Pembrolizumab|Pembrolizumab IV solution administered on Day 1 of each 3-week cycle
1492439|NCT03025022|Drug|14C-JNJ-42847922 40 mg|Participants will receive a single 40 mg oral dose of 14C-JNJ-42847922 containing maximally 100 MicroCurie as a 40 milliLitre (mL) solution.
1492440|NCT03025009|Drug|LY3192767|Administered SC.
1492441|NCT03025009|Drug|Basal Insulin Peglispro|Administered SC.
1492442|NCT03025009|Drug|Insulin Glargine|Administered SC.
1492443|NCT03025009|Drug|Placebo|Administered SC.
1492444|NCT03024996|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion q3w
1492445|NCT03024996|Other|Placebo|Placebo matching to atezolizumab q3w
1492446|NCT03024983|Other|Glucose|Glucose monohydrate (55 g) dissolved with 500 mL of water
1492447|NCT03024983|Other|Semolina soup|Semolina soup (322 g) eaten with 500 mL of water
1492448|NCT03024983|Other|Bread|Bread (122 g) eaten with 500 mL of water
1492449|NCT03024983|Other|Penne (fresh)|Cooked penne (132 g) eaten with 500 mL of water
1492450|NCT03024983|Other|Penne (dry)|Cooked penne (142 g) eaten with 500 mL of water
1492451|NCT03024983|Other|Spaghetti (dry)|Cooked spaghetti (142 g) eaten with 500 mL of water
1492452|NCT03024957|Drug|Morphine Sulfate|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces with injection of morphine sulphate .
1492453|NCT03024957|Drug|Dexmedetomidine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
1492454|NCT03024957|Drug|Bupivacaine|Intrathecal injection as the patients will be placed in the sitting position and a 25-gauge Quincke needle will be placed in the L2-3 or L3-4 interspaces.
1492455|NCT03024944|Drug|18F-THK-5351|Intravenous (IV) catheter (tube) placed in participant arm. A small amount of 18F-THK-5351 will be injected into the IV enough time has passed for this contrast to collect in the tissue in the brain (approximately one half-hour), and participant will lie on a bed which slides into a PET Scanner to complete Tau imaging.
1492456|NCT03024931|Other|observational study|No intervention
1492457|NCT03024905|Behavioral|Village meeting and travel vouchers|"The interventions are:
Village meetings by community health workers to educate women and their families about safe birthing.
Vouchers for free transport by motorcycle taxi drivers to access health facility at delivery."
1492458|NCT03024905|Device|Birth kit with misoprostol|Provision of birth kit with clean delivery supplies (soap, 2 pairs of gloves, 2 cord clamps, surgical blade, and 600 mcg misoprostol for the woman to take immediately after the delivery to prevent postpartum hemorrhage).
1492459|NCT03024892|Procedure|ICG GB|ICG was given by intra-gallbladder injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
1492460|NCT03024892|Procedure|ICG IV|ICG was given by systemic injection, then the near-infrared image guide laparoscopic cholecystectomy were performed.
1492461|NCT03024892|Procedure|LC conventional|simple laparoscopic cholecystectomy was performed under white light image.
1492462|NCT03024892|Procedure|LC conventional and IOC|simple laparoscopic cholecystectomy was performed under white light image and intraoperaitve cholangiography guidance.
1492463|NCT03024879|Drug|Erythromycin|
1492464|NCT03024879|Drug|Saline|
1492465|NCT03024853|Behavioral|BPS PAST|
1492466|NCT03024853|Behavioral|BPS PRESENT|
1492467|NCT03024853|Behavioral|BPS FUTURE|
1492468|NCT03024853|Behavioral|CONTROL|
1492469|NCT03024840|Drug|Sevoflurane|Sevoflurane: 1%~2%
1492470|NCT03024840|Drug|Propofol|Propofol: 9-15 mg/kg/h
1492472|NCT03024814|Drug|Acetaminophen|"The first group will receive acetaminophen as the following
Loading dose: 20 mg/kg in the first 12-24 hours To be diluted in D5W up to 3-5 ml and to be infused over 15 minutes.
Maintenance dose: 7.5 mg/kg after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
1492473|NCT03024814|Drug|Dextrose 5|"The second group will receive placebo (D5W) as the following
Loading dose: 3-5 ml in the first 12-24 hours To be infused over 15 minutes.
Maintenance dose: 3-5 ml after 6 hrs from the loading dose and to be repeat every 6 hours for 3 days."
1492474|NCT03024801|Drug|autologous platelet-rich plasma|The patients with knee cartilage injury were randomized to the intra-articular injection of autologous platelet-rich plasma group.
1492475|NCT03024801|Drug|normal saline|The patients with knee cartilage injury were randomized to the normal saline group.
1492476|NCT03024788|Device|syringe, fundus camera etc|Physical examination, fundus examination, blood and urine samples collection
2001650|NCT02876107|Procedure|Breast Core Biopsy|Breast core biopsy performed before Day 1 of Cycle 1 for biomarker testing.
1492479|NCT03024762|Procedure|targeted Provider-Initiated-Testing and Counseling (tPITC)|The intervention arm involves children and adolescents with unknown HIV status, aged between 6 weeks to 19 years, born to parents living with HIV/AIDS. These children will be identified for HIV testing through their parents diagnosed with HIV or receiving HIV care in the hospital.
1492480|NCT03024736|Other|buprenorphin|"if buprenorphine has better neonatal outcomes compared to methadone in
the treatment of opioid-maintained pregnant women"
1492481|NCT03024723|Device|nasal mask CPAP|CPAP and ventilation administered via nasal mask
1492482|NCT03024710|Behavioral|Intervention cluster|The mother- infant pairs (the infant who has completed his/her 6 month of age from the date of birth along with their mother) of intervention clusters will receive the CF practice counselling in groups as soon as enrolment is completed by CHRW at fixed site clinic and refreshers will be arranged 3 months apart from first training in groups at same place and by same person. However CHRWs will also counsel each participant during her bimonthly household visit.
1492483|NCT03024697|Procedure|Pectoral Plane Block|
1492484|NCT03024697|Procedure|Local Anaesthetic Wound Infusion Catheter|Levobupivicaine 0.1% @10ml/hr via a wound infusion catheter
1492487|NCT03024671|Other|Patch test application|test patch with cosmetic product will be applied to the back
1492488|NCT03024658|Other|positive end expiratory pressure (PEEP)|Positive end expiratory pressure was applied using anesthesia machine at the time of induction in the patients undergoing laparoscopic bariatric surgery
1492492|NCT03024632|Procedure|Trial of labor|trial of labor after 3 or more previous cesarean deliveries
1492493|NCT03024619|Other|Pain and Urinary pH|assess the correlation between urinary pH and Interstitial Cystitis (IC) pain, with emphasis placed on exploring the type and severity of pain
1949081|NCT00515242|Behavioral|massage|therapeutic massage
1492495|NCT03024593|Behavioral|Health- and illness-related internet use|
1492496|NCT03024580|Drug|Megestrol Acetate 160Mg Tablet|Megestrol acetate 160 mg PO daily
1492497|NCT03024580|Drug|Anastrozole 1Mg Tablet|Anastrozole 1 mg PO daily OR
1492498|NCT03024580|Drug|Letrozole 2.5Mg Tablet|Letrozole 2.5 mg PO daily OR
1492499|NCT03024580|Drug|Exemestane 25 MG|Exemestane 25 mg PO daily
1492500|NCT03024580|Drug|Tamoxifen 20Mg Tablet|Tamoxifen 20 mg PO daily
1492501|NCT03024580|Drug|Fulvestrant 50Mg Solution for Injection|Fulvestrant 500 mg IM d1, d14, d28 and q28 days
1492502|NCT03024567|Dietary Supplement|Salt|10 capsules daily for 14 days
1492503|NCT03024567|Dietary Supplement|Placebo|10 capsules daily for 14 days
1492504|NCT03024554|Device|Implantation of the Bifurcated Multilayer Flow Modulator|
1492505|NCT03024528|Behavioral|CPOT assessment|Polish version of Critical care pain observation tool validation.
1492506|NCT03024515|Drug|opioids titration|Standard Practice Arm
1492507|NCT03024515|Drug|predefined titration steps|comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies
1492508|NCT03024502|Drug|EPP-AF Gel 1%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
1492509|NCT03024502|Drug|EPP-AF Gel 2%|Administration intravaginal of EPP-AG Gel 1%, 1x/day, 7 days
1492510|NCT03024502|Drug|Clotrimazole|Administration intravaginal of clotrimazol, 1x/day, 7 days
1492511|NCT03024489|Drug|Palbociclib|Dose Level -1: 100 mg oral every other day 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
1492512|NCT03024489|Drug|Palbociclib|Dose Level 1: 75 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
1492513|NCT03024489|Drug|Palbociclib|Dose Level 2: 100 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
1492514|NCT03024489|Drug|Palbociclib|Dose Level 3: 125 mg per oral daily 3 week-on and 1-week of during IMRT (Day 1-21 and Day 29-49).
1492515|NCT03024489|Drug|Cetuximab|All dose levels: 400 mg/m2 IV at 7 days before (day -7) starting radiation and then 250 mg/m2 IV weekly for 7 weeks.
1492516|NCT03024489|Radiation|Intensity Modulated Radiation Therapy|5 days on/2 days off with a total dose of 70 Gy for 33 fractions.
1492517|NCT03024476|Behavioral|Behavioral intensification|"Suggested algorithm for behavioral intensification:
If frequency of BP measurement ≤5 in a week, send a texting message
If frequency of BP measurement ≤3 in a week, make a telephone contact by research nurse
Target range of home-systolic blood pressure: 110 - 135
If rate of outlier exceeds 50% in a week (based on ≥5 measurements in a week), make a telephone contact by research nurse (applied at least 2 weeks after randomization). A call for breakthrough visit may be issued when clinically required (decided by the institutional investigator)
If frequency of BP measurement ≥ 10 in a week and frequency of outlier = 0 in a week, send a texting message to encourage and compliment on excellent BP management"
1492518|NCT03024476|Drug|Pharmacological intensification based on olmesartan|"Study drug will be provided from the roll-in period.
Step I:
Use olmesartan 20 mg only if mean systolic blood pressure ≤150 mm Hg during the immediate past 2 days
Use olmesartan 40 mg if mean systolic blood pressure >150 during the immediate past 2 days
Step II: olmesartan 20 mg or 40 mg + amlodipine 5 mg
Step III: olmesartan 20 mg or 40 mg + amlodipine 10 mg
Step IV: olmesartan 20 mg or 40 mg + amlodipine 10 mg + hydrochlorothiazide 12.5 mg
If blood pressure profile showed high degree variability to evoke clinical concern, consider discontinuation of hydrochlorothiazide or reduction of olmesartan dose.
Use of beta-blockers is permitted if clinically indicated.
At each clinic visit regardless of regular or breakthrough visit, follow the pharmacological intensification rule."
1492519|NCT03024476|Device|Bluetooth-equipped sphygmomanometer|"Participants will be given a wireless Bluetooth-equipped sphygmomanometer system, which is connected to the main server through the participants' own smartphone. (Identical for both intervention and control groups)
Every blood pressure and heart rate measured will be encrypted and stored in the main server. (Identical for both intervention and control groups)"
1492520|NCT03024463|Procedure|IM-SLNB and IMLN dissection|Internal mammary sentinel lymph node biopsy followed by internal mammary lymph node dissection
1492521|NCT03024450|Drug|H+CT|All patients were treated with trastuzumab plus chemotherapy as the first-line therapy. There were no protocol-specified chemotherapy regimens. This is a prospective observational study. Efficacy and safety of trastuzumab were analyzed, clinical and pathological data were collected to evaluate the potential prognostic factors on progressive free survival.
1492522|NCT03024437|Drug|Atezolizumab|Atezolizumab will be given intravenously every 3 weeks at 1200 mg.
1949082|NCT00515242|Behavioral|thermotherapy|heat therapy
1949083|NCT00515242|Behavioral|relaxing environment|time in a relaxing environment
1949084|NCT00485953|Drug|risedronate|risedronate 35 mg per week
1492523|NCT03024437|Drug|Bevacizumab|Bevacizumab will be given intravenously every 3 weeks at 15 mg/kg.
1492524|NCT03024437|Drug|Entinostat|Entinostat will be given orally every 7 days at 1, 3, or 5 mg depending upon phase. In Phase I, dose levels will be tested in up to 3 cohorts starting at 1 mg. In Phase II, the dose will be the recommended phase II dose that was determined during Phase I (i.e., 1, 3, or 5 mg).
1492525|NCT03024424|Behavioral|Early disclosure|
1492526|NCT03024424|Behavioral|Late disclosure|
1492527|NCT03024411|Other|iPod (Music/video games)|Group 1 patients will be given an iPod to enjoy music/video games during induction of labor.
1492528|NCT03024385|Behavioral|Well Child Visits|Mothers of young infants will be screened for maternal behaviors that affect the outcome of future pregnancies. These behaviors are related to the following: family planning; smoking status, prenatal vitamin use and maternal depression. Mothers with positive screens will be offered appropriate resources. This will all take place during the child's routine well-child visit.
2001651|NCT02876107|Drug|Paclitaxel|80 mg/m2 given by vein on Days 1, 8, and 15 of Cycles 1-4.
2001652|NCT02876107|Drug|Carboplatin|5 AUC given by vein on Day 1 of Cycles 1-4.
1492531|NCT03024359|Dietary Supplement|Extra virgin olive oil|2 liters of extra virgin olive oil will be given to participants to include/use in their daily foods.
1492532|NCT03024320|Behavioral|M2M|An eHealth platform has been designed to deliver a home-based package using the extensive set of movement patterns that have been adapted for people with a range of physical/mobility disability, called Movement-To-Music (M2M). The M2M prescription will be based on the participant's baseline level of health, function and fitness. Each movement pattern will be available in three different positions - standing, standing with support (chair) and seated. The duration of each M2M session will be gradually increased during the Adoption phase from three 20-minute sessions (10 min. aerobic & 10 min. strength) during weeks 1 to 3 (60 min/wk), to 45-min sessions (30 min. aerobic & 15 min. strength) during weeks 4 to 6 (135 min/wk), and to 50-min sessions (150 min/week) during weeks 7 to 12 (excluding 5-min warmup and 5-min cool down).
1492533|NCT03024320|Behavioral|Attention Control|Telecoaching on health-based topics, not including physical activity.
1492534|NCT03024307|Other|pharmacists involved OPCSP|This was an open labelled randomised study. Rheumatic diseases patients were recruited and arbitrarily divided into the intervention group (usual care plus OPCSP) and the non-intervention group (usual care only). Those enrolled in the research were scheduled for follow-up for eight consecutive visits. Improvements in lab results and direct costs were compared longitudinally (pre and post analysis) between the groups.
1492535|NCT03024294|Other|Post-operative care pathway for patients undergoing VATS lobectomy or segmentectomy|To place participants on this specific post-operative care pathway upon the completion of their VATS surgery to determine the discharge rate by midnight on post-operative day (POD) three.
1492536|NCT03024268|Device|Figulla Flex Occluder (Occlutech)|Interventional closure of the iASD with an Figulla Flex Occluder (Occlutech)
1492537|NCT03024255|Drug|BBI-4000 Concentration 1|Lowest test dose
1492538|NCT03024255|Drug|BBI-4000 Concentration 2|Test dose between high and low concentrations
1492539|NCT03024255|Drug|BBI-4000 Concentration 3|Highest test dose
1492540|NCT03024255|Drug|Vehicle (Placebo)|Vehicle without drug
1492541|NCT03024242|Device|Tight vaginoscope|
1492542|NCT03024229|Device|LifePort® perfusion machine|Renal perfusion on LifePort® machine
1492543|NCT03024216|Drug|Atezolizumab1200 mg IV|
1492544|NCT03024216|Drug|Sipuleucel-T|
1492545|NCT03024203|Behavioral|Cognitive Remediation - Executive Training|Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as memory, and problem solving ability.
1492546|NCT03024203|Behavioral|Cognitive Remediation - Perceptual Training|Cognitive remediation is a cognitive and behavioural therapy designed to improve cognitive skills such as attention, and processing speed.
1492547|NCT03024190|Other|Kinesiotaping|The technique of Kinesiotaping for spastic wrists and fingers in stroke patients is performed from the proximal interphalangeal joints of all fingers acted on the extensor carpal and digital muscle groups, with an anchor at the proximal one-third forearm.
1492548|NCT03024190|Other|stretching exercise|15- min stretching exercise for upper extremity twice daily
1492549|NCT03024190|Other|OT rehabilitation program|regular rehabilitation program for 3 weeks
1492550|NCT03024177|Drug|Vapendavir|Vapendavir Tablets, 264 mg
1492551|NCT03024177|Drug|Placebo Oral Tablet|Vapendavir 264 mg matching tablets
1492552|NCT03024164|Other|treatment following current guidelines|treatment following current guidelines
1492553|NCT03024151|Drug|Comthyroid|T4/T3 combination replacement
1492554|NCT03024151|Drug|Synthroid|T4 mono replacement
1492555|NCT03024138|Radiation|Repeat CT scan|
1492556|NCT03024125|Other|High protein|To observe the effect of a high protein (HP) diet over muscle mass, fat mass, and strength changes, focusing in differences between the NP and HP groups.
1492557|NCT03024125|Other|Normal protein|To observe the effect of a normal protein (NP) diet over muscle mass, fat mass, and strength changes
1492558|NCT03024125|Other|Training|The physical strength training will be performed equally by both groups, containing exercises for upper and lower limbs and aiming for hypertrophy.
1949085|NCT00447668|Behavioral|Yoga|Yoga for back pain
1949086|NCT00447668|Behavioral|Exercise|exercises for back pain
1492561|NCT03024099|Other|Hippotherapy once a week|Hippotherapy once a week
1492562|NCT03024099|Other|Hippotherapy twice a week|Hippotherapy twice a week
1492563|NCT03024086|Drug|DWJ1252|DWJ1252 and Placebo of Gasmotin
1492564|NCT03024086|Drug|Gasmotin|Gasmotin and Placebo of DWJ1252
1492565|NCT03024073|Procedure|BB-Phaco|Phacoemulsification with bilateral bifocal lenses implantation
1492566|NCT03024060|Drug|ALA|20% ALA applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
1492567|NCT03024060|Drug|Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to 4-15 lesions on the face or scalp 14-18 hours prior to 10 J/cm2 blue light
2001653|NCT02876107|Drug|Panitumumab|"2.5 mg/kg by vein on Day 1 of a 1-week pre-cycle. Participants then receive it on Days 1, 8, and 15 of Cycles 1-4, before paclitaxel."
2001654|NCT02876107|Drug|Doxorubicin|60 mg/m2 given by vein on Day 1 of Cycles 5-8.
1492568|NCT03024060|Device|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
1492569|NCT03024060|Device|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
1492570|NCT03024047|Device|Pacemaker|
1492571|NCT03024034|Drug|TP-271|single oral dose of TP 271 or placebo, randomized 3:1, doses escalating as 25 mg, 50 mg, 100 mg, 150 mg, 200 mg, and 300 mg, and a final crossover cohort of 50 mg TP-271 and 50 mg TP-271 with 250 mg of EDTA, or placebo and 250 mg of EDTA
1492572|NCT03024021|Device|Near-infrared spectroscopy (NIRS) (INVOS®, Covidien)|As we start the targeted temperature management protocol (24 hours of hypothermia adjusted to 33-36 C and afterwards up to five days of normothermia [36.5 C]) NIRS sensor pads will be placed over the right and left frontal area. Regional cerebral oxygen values will be continuously recorded at the NIRS monitor. Tests to assess neurological outcome will be performed. Patients will be assessed in terms of neurological performance tests and regional cerebral oxygen.
1492573|NCT03024008|Biological|BonoFill-II|"Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion.
A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed.
internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union."
1492574|NCT03023995|Procedure|CAF with Platelet rich fibrin|In test group, preparation of PRF was carried out, after which the flap was coronally positioned over the membrane to completely cover it and secured with 4-0 non resorbable sutures.
1492575|NCT03023995|Procedure|CAF with connective tissue graft|In control group, connective tissue graft was harvested, after which the flap was coronally positioned over the graft to completely cover it and secured with 4-0 non resorbable.
1492576|NCT03023982|Drug|Bupivacaine Hydrochloride|40 cc 0.25% of Bupivacaine Hydrochloride injection using ultrasound approach will be administered between pectoralis minor and serratus anterior muscle at the 3rd and 4th rib
1492577|NCT03023982|Device|Ultrasound|All blocks will be done under ultrasound
1492578|NCT03023982|Procedure|Thoracotomy|The patient population will include patients that undergo either open thoracotomy or thoracoscopy for anatomic and non-anatomic lung resection. The standard thoracoscopy approach in our institute includes three holes technic. There are two incisions of 1 cm and utility incision of 4 cm. The standard thoracotomy is posterior- lateral thoracotomy which divided the latissimus dorsi muscle but spears the serratus anterior muscle.
1492579|NCT03023982|Drug|Opioids|standard pain control with opioids
1492580|NCT03023982|Drug|NSAID|standard pain control with NSAIDs
1492581|NCT03023969|Drug|ozone oxygen mixture|receive 10 ml of ozone oxygen mixture under variable dosing
1492582|NCT03023956|Procedure|Locking plates were used for proximal humeral fractures.|
1492583|NCT03023943|Other|Instrument Assisted Soft Tissue Mobilization|Intervention will be 10 minutes of GT1 instrument application at anterior thigh using sweep technique.
2001655|NCT02876107|Drug|Cyclophosphamide|600 mg/m given by vein on Day 1 of Cycles 5-8.
2001656|NCT02876107|Procedure|Mammogram|Before receiving doxorubicin and cyclophosphamide, a mammogram of the involved breast performed.
1492586|NCT03023917|Procedure|umbilical cord milking|Infants were placed at or below level of the placenta and about 25cm of the umbilical cord was vigorously milked towards the umbilicus two to three times before clamping the cord. The milking speed was about 25cm/2 seconds
1492587|NCT03023917|Procedure|umbilical cord clamping immediately|umbilical cord was cut immediately after birth
1492588|NCT03023904|Biological|Nivolumab|Given IV
1492589|NCT03023904|Other|Laboratory Biomarker Analysis|Correlative studies
1492590|NCT03023891|Drug|Prednisone|Prednisone 60 mg tablet once
1949087|NCT00447668|Behavioral|Self-care book recommendations|Self-care book for back pain
2001657|NCT02876107|Procedure|Ultrasound|Before receiving doxorubicin and cyclophosphamide, an ultrasound of the involved breast and lymph nodes performed.
1492593|NCT03023865|Procedure|Staged stress function|A preoperative staged stress function procedure for elongation of the proximal and distal segments to achieve utilizing the native esophagus to establish esophageal continuity
1492594|NCT03023852|Drug|JNJ-63623872|Participants will receive JNJ-63623872 600 mg (2*300 mg) oral tablets in Panel 1 and 2 under Fasted conditions.
1492595|NCT03023852|Drug|Oseltamivir|Participants will receive Oseltamivir 75 mg (1*75 mg) oral capsule (reference) in Treatment D of Panel 2 and Oseltamivir 75 mg administered as JNJ-63623872/37.5 mg Oseltamivir oral FDC tablet concept formulation (test 3) in Treatment E of Panel 2.
1492596|NCT03023826|Drug|LY3202626 (R-Fasting)|Administered orally
1492597|NCT03023826|Drug|LY3202626 (T1-Fasting)|Administered orally
1492598|NCT03023826|Drug|LY3202626 (T1-Fed)|Administered orally
2001658|NCT02876107|Other|Follow Up|Study staff checks on participant about 1 month after surgery, and once each year for at least 5 years after participant stops taking the study drugs.
2001659|NCT02874924|Drug|Rapamycin|treatment
1492601|NCT03023787|Drug|Hepalatide|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
1492602|NCT03023787|Drug|Placebo|There are three cohorts as follows 4.2mg, 6.3mg, 8.4mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection once a day for seven days and will be monitored for 3 days.
1492603|NCT03023774|Drug|Neupogen|neupogen 30 IU once intrauterine at the time of ovum pickup
1492604|NCT03023761|Device|low level laser|low level laser irradiation
2001660|NCT02874924|Drug|Placebo|control
2001661|NCT02874924|Drug|Rapamycin|No placebo control in this substudy group
2001662|NCT02873936|Drug|Filgotinib|Tablet(s) administered orally once daily
2001663|NCT02873936|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
2001664|NCT02873936|Drug|csDMARDs|csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX is not allowed)
2001665|NCT02870049|Behavioral|Inreach strategy|Inreach strategy: In clinic education and delivery of fecal immunochemical test (FIT) kit
1492606|NCT03023748|Drug|Intravenous Paricalcitol|Twenty four months of intravenous paricalcitol will be given twice or thrice weekly post-hemodialysis depending on frequency of hemodialysis of the patients
1492607|NCT03023735|Other|None. This is an observational study|
1492608|NCT03023722|Drug|anetumab ravtansine|Patients will receive anetumab ravtansine IV infusion at a dose of 6.5 mg/kg (recommended Phase II dose) on Day 1 of a 21-day cycle
1492609|NCT03023709|Biological|Fluzone®|quadrivalent, inactivated influenza virus vaccine, intramuscular
1492610|NCT03023709|Biological|FluMist®|quadrivalent, live, attenuated influenza vaccine, intranasal spray
1492611|NCT03023696|Procedure|Bilateral Cervical Keyhole Foraminotomy|Under microscopic or loop magnification, a high-speed burr is used to perform the foraminotomy. The keyhole foraminotomy begins at the lamina-facet junction, with careful consideration of the amount of facet resection. Typically, only the medial one third is drilled. Then a 1- or 2-mm Kerrison punch can be carefully placed over the nerve root and then used to undercut the facet, ensuring that the spine is not destabilized by the foraminotomy. The amount of facet resection must not exceed 50% in order to preserve spine stability.
1492612|NCT03023696|Procedure|Cervical Decompression|Cervical decompression for myelopathy, including the following procedures: laminoplasty, laminectomy, discectomy and fusion
1492613|NCT03023683|Biological|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
2001666|NCT02870049|Behavioral|Outreach strategy|Outreach strategy: Mailed fecal immunochemical test (FIT) kit and telephone reminders
2001667|NCT02870049|Behavioral|Both Inreach and Outreach strategies|Both Inreach and Outreach strategies: Both In clinic education and delivery of fecal immunochemical test (FIT) kit and Mailed fecal immunochemical test (FIT) kit and telephone reminders
1492616|NCT03023657|Other|Detection of arousal|Detecting facial microexpression before visible facial expressions in patient with disorder of consciousness after severe brain injury
1492617|NCT03023644|Behavioral|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will an iPad with a web-based software program. The 25 sessions will be completed individually by the child with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the child can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
2001668|NCT02870049|Behavioral|Usual care|Usual care: FIT kit delivery as part of usual care
1492619|NCT03023618|Device|FloTrac|Stroke Volume has been maintained at 90% of the maximal Stroke Volume as in NICE protocol 2011
1492620|NCT03023605|Behavioral|Training Intervention for PE Diagnosis|"Focused on the Emergency Department staff and the rotating residents during the months 4 and 5 of 2015, and consisted of:
Clinical Update Sessions for staff ED (20 physicians)
training sessions for residents that rotate in ED (60 physicians )
Development of a triptych, including clinical prediction scales, combination algorithm of scales and D-Dimmer value
Development of posters, with brief information
Dissemination by e-mail of scientific information
Direct reminder during the working day"
1492621|NCT03023592|Drug|Iguratimod|Iguratimod 25 mg orally twice a day for 24 weeks
1492622|NCT03023579|Other|The star excursion balance test|
1492623|NCT03023566|Drug|Dotarem|Dotarem at dose of 0.1 mmol/kg of body weight (routine/standard of care)
1492624|NCT03023553|Biological|Fluzone®|Influenza Virus Vaccine Suspension for Intramuscular Injection
1492625|NCT03023553|Biological|FluMist®|Influenza Virus Vaccine Live, Intranasal Spray
1492626|NCT03023540|Drug|PXT3003|Liquid oral solution, 5 mL bid for 9 consecutive months
1492627|NCT03023527|Drug|Nivolumab|
1492628|NCT03023527|Drug|Pomalidomide|
1492629|NCT03023527|Drug|Dexamethasone|
1492630|NCT03023527|Drug|Elotuzumab|
1492631|NCT03023514|Dietary Supplement|Oral Lipoic acid|300 mg ALA x2 (1pill orally/12h) to the recipient from the day of the donors pick up until 8 week of pregnancy
1492632|NCT03023514|Drug|Vaginal Progesterone|200 mg Vaginal Progesterone (1 vaginal capsule/24h) from the day of the donors pick up until 8 week of pregnancy
1492633|NCT03023501|Drug|Gabapentin|
1492634|NCT03023501|Drug|Placebo Oral Capsule|
1492635|NCT03023488|Procedure|flexible ureteroscopy|Flexible ureteroscopy is an endourological procedure performed for kidney stones. The flexible ureteroscope is a device used to reach the renal cavities through the natural urinary tract in a retrograde fashion. During the operation, irrigation fluid is used to expand the cavities to provide space for movement of the device and also to provide clear vision.
1492636|NCT03023488|Device|Doppler Ultrasound examination|peak systolic velocities (PSV) and end diastolic velocities (EDV) of the arteries will be measured and then resistive index (RI) and pulsatility index (PI) will be calculated.
1492637|NCT03023488|Device|laser lithotripsy|The laser fiber extending into the cavities through the working channel of the ureteroscope is used to fragment the stones. Laser energy is generated by the laser machine and transmitted to the stones via the laser fiber.
1492638|NCT03023475|Device|LigaSure endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the LigaSure system.
1492639|NCT03023475|Device|TLS2 endoscopic vessel harvesting|The radial artery will be harvested endoscopically using the TLS2 system.
1492640|NCT03023462|Drug|Oksykodonhydroklorid|Oksykodonhydroklorid, 5 - 10 mg intravenously or orally postoperatively to reduce pain. Repetition until effect.
1492641|NCT03023462|Drug|Ketobemidone Hydrochloride|In case of insufficient analgesia, judged by the patient.
1492642|NCT03023462|Drug|Ondansetron and Droperidol|When nausea and vomiting: Ondansetron 4mg and droperidol 0,625 mg intravenously
1492643|NCT03023462|Drug|Ropivacaine|Local anesthetic for the block
1492644|NCT03023449|Drug|Nitric Oxide|Inhaled Nitric Oxide gas
1492682|NCT03023150|Other|Ischemic Preconditioning|
1492683|NCT03023150|Other|Sham|
1492759|NCT03022578|Procedure|Laser Interstitial Thermal Therapy|LITT delivered directly to the tumor by a neurosurgeon.
1493049|NCT03020264|Device|glycemic sensor FREESTYLE Libre|Collection of hypoglycemia episodes with glycemic sensor FREESTYLE Libre
2001669|NCT02869698|Procedure|Spectral Dynamic Imaging|
1492645|NCT03023436|Procedure|Cytoreductive surgery|"Gastrectomy with D2 lymph node dissection and Metastasectomy for peritoneal metastatic sites only.
A total, distal, or proximal gastrectomy and the type of reconstruction will be selected according to the surgeon's experience.
Metastasectomy is limited to peritoneal metastatic sites only to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible."
1492646|NCT03023436|Procedure|Hyperthermic Intraperitoneal Chemotherapy|Docetaxel 120 mg diluted in 5.0 L of saline is forced into the abdomen through the inflow catheter by a pump and pulled out through the drains as a heated intraperitoneal perfusion.A heat exchanger keeps the intraperitoneal fluid at 43±0.5℃ and duration limited to 70 minutes.24 hours after cytoreductive surgery no less than 2 cycles postoperative chemotherapy will be recommended.
1492647|NCT03023436|Drug|Fluoropyrimidine|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
1492648|NCT03023436|Drug|Cisplatin|CF regimens or other first line regimens based on Fluoropyrimidine and Platinum according to the NCCN Guidelines（Gastric Cancer，version 3.2016) are recommended.Regimens and dosing schedules are not limited in this trial.
2001670|NCT02869698|Device|Hybride electrode|
2001671|NCT02869698|Device|Macro electrode|
1492651|NCT03023410|Procedure|VERASENSE|Sensor-Assisted Revision TKA
1492652|NCT03023397|Biological|Der f|Nasal administration of Dermatophagoides farinae with 100 allergen units (AU), 500 AU, and finally 1000 AU
1492653|NCT03023358|Drug|chidamide|30mg po twice a week
1492654|NCT03023358|Drug|cyclophosphamide|750mg/m2 iv on day 1
1492655|NCT03023358|Drug|liposomal doxorubicin|30mg/m2 iv on day 1
1492656|NCT03023358|Drug|vincristine|1.4mg/m2 iv on day 1
1492657|NCT03023358|Drug|prednisone|100mg/d po on day 1-5
1492658|NCT03023345|Device|Microwave trans rectal focal treatment|Microwave trans-rectal ablation of the prostatic index tumor using MRI-transrectal ultrasound image registration
1492659|NCT03023332|Behavioral|Resourcefulness Training|A cognitive-behavioral intervention delivered through iPad technology that consists of teaching and reinforcing personal (self-help) and social (help-seeking) resourcefulness skills.
1492660|NCT03023332|Behavioral|Biofeedback training|"Use of a heart-rate variability (HRV) tracking device to enable one to learn to alter physiology to improve health. Devices are used to measure physiological activity, e.g., breathing and heart function, and provide rapid, accurate feedback to the user, thereby enabling desired physiological changes that can endure over time without continued use of the device and continue to influence behavior."
1492661|NCT03023332|Behavioral|Bipolar Education|An educational program designed to teach family caregivers of about the types, causes, symptoms, episodes, warning signs, and treatments for individuals with bipolar disorder, as well as available resources for assisting a family member with bipolar disorder. The content to be presented within an audiovisual format using iPad technology follows the recommendations and guidelines developed through research and by the Depression and Bipolar Support Alliance and the National Institute of Mental Health.
1492662|NCT03023319|Drug|Bosutinib|100mg daily for 4 cycles (21 days per cycle)
1492663|NCT03023319|Drug|Pemetrexed|500 mg/m2 every 21 days for 4 cycles
1492664|NCT03023306|Other|Antiemetic treatment the day before surgery vs intraoperatively|Preemptive group The antiemetic regime thus 2 doses of 10 mg each metoclopramide will be administered the day before surgery Intraoperative group The antiemetic regime thus 2 doses of 10 mg each metoclopramide will be administered intraoperatively
1492665|NCT03023293|Other|n-3 PUFAs consumption and irisin|The investigators plan to collect n-3 PUFAs and irisin information at 24-28 weeks' gestation, 42 days postpartum, 1 year postpartum and 2 years postpartum
1492666|NCT03023280|Procedure|Radiofrequency ablation|
1492667|NCT03023267|Behavioral|Music therapy and Kangaroo care|Mother holding baby in skin to skin position while singing
1492668|NCT03023267|Behavioral|Kangaroo Care alone|Mother holding baby in skin to skin position without singing
1492669|NCT03023254|Other|Hydrotherapy|3-weeks Avène hydrotherapy
1492670|NCT03023241|Procedure|biopsy|cold cup bladder biopsies and bladder washings under anesthesia, blood and urine collection
1492671|NCT03023228|Behavioral|diabetes self-management education|1-group, pre-test/post-test design feasibility and preliminary efficacy evaluation of diabetes survival skills self-management education delivered at the hospital bedside.
1492672|NCT03023215|Procedure|Meditation|Participants guided through 10 minutes of intervention by a mind-body specialist who will follow a standardized script prior to stereotactic breast biopsy (SBB). Mind-body specialist will also accompany participant during SBB to continue intervention.
1492673|NCT03023215|Procedure|Electroencephalogram|Electroencephalogram (EEG) activity recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
1492674|NCT03023215|Behavioral|Questionnaires|Self-report measures (anxiety and pain) assessed at baseline, immediately before, during, and after the SBB.
1492675|NCT03023215|Procedure|Heart Rate|Heart rate (HR) recorded at baseline, for 10 minutes prior to the SBB, throughout the SBB, and immediately following SBB.
1492676|NCT03023202|Other|PMMTB (Precision Medicine Molecular Tumor Board)|PMMTB is a clinical intervention, NOT a research intervention. The research component of this study is to observe the outcomes of the PMMTB.
1492677|NCT03023189|Drug|Tranexamic acid|"At randomisation : loading dose of 1g of intravenous tranexamic acid in 10 min, immediately followed by an intravenous infusion of 3g of TA over 24h.
Total dose : 4 g of TA"
1492678|NCT03023189|Drug|Placebo|At randomisation : loading dose of 10 mL of intravenous isotonic saline over 10 min, immediately followed by an intravenous infusion of 30 mL of isotonic saline over 24h Total dose : 40 mL of Placebo
1492679|NCT03023176|Biological|Fluzone® standard IIV3|Influenza Virus Vaccine Suspension (0.5ml) for Intramuscular Injection
1492680|NCT03023176|Biological|Fluzone® standard IIV3 Pediatric Dose|Influenza Virus Vaccine Suspension (0.25ml) for Intramuscular Injection
1492681|NCT03023163|Other|Longitudinal|Participants that completed the Impact of Age on Cardiovascular, Cerebrovascular, Cerebrovascular and Cognitive Health study, will be re-assessed again to compare longitudinal (3-5 years) change in blood pressure, cerebral blood flow, arterial stiffness and cognitive health.
1492684|NCT03023137|Behavioral|Walking & dietary modification|"Daily walking at a moderate pace (4 km/h) > 40 min, 7/7. Those remaining seated most of the day should walk 25-30 min twice a day, avoiding >12 h of physical inactivity. Walking may be replaced by stationary bicycle rides or swimming when convenient, which often occurred near term and when the mother was obese.
At least two daily servings of protein-rich food (≥ 4 g/kg of meat, poultry, fish or eggs) per day. Avoidance of high-carbohydrate, low-fiber meals, such as snacks, candies, fiber-free juices, coconut water or sugar-sweetened beverages. Sucralose could be used as a sweetener. Participants are recommended to use ondansetron for nausea and vomiting prevention"
1492685|NCT03023124|Drug|Trabectedin|Treatment with trabectedin repeated every 21 days for 6 cycles
1492686|NCT03023124|Drug|Adriamycin|Treatment with Adriamycin at day 1 every 21 days for 6 cycles
1492687|NCT03023124|Drug|Dacarbazine|Treatment with Dacarbazine at days 1 and 2 every 21 days for 6 cycles
1492688|NCT03023111|Drug|Sbv|Standard treatment for CL, parenteral drug used during 20 days.
1492689|NCT03023111|Drug|Miltefosine plus placebo|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. Placebo gel cream will be used topically.
1492690|NCT03023111|Drug|Miltefosine plus GM-CSF|Oral treatment for CL, capsules with 50mg used 3 times a day, during 28 days. GM-CSF gel cream will be used topically.
1492691|NCT03023098|Device|Conventional PTA|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a conventional balloon
1492692|NCT03023098|Device|Drug-eluting balloon|After passing the stenosis it is dilated with a conventional balloon. The patient is randomized to a second dilatation with a drug-eluting balloon
1492693|NCT03023085|Drug|BLI4700|BLI4700 bowel preparation
1492694|NCT03023072|Other|Incontinence Detection System|
2001672|NCT02867111|Device|Sperm Selection Assay|Sperm Selection Assay (SSA) that allow the investigators to select functional spermatozoa, which are capacitated, with intact DNA, reduced oxidative stress and with good viability and motility, on the basis of sperm chemotaxis towards a physiological attractant molecule.
1492705|NCT03023033|Behavioral|mHealth messaging|SMS appointment reminders and health messaging via mobile phones
1492706|NCT03023033|Behavioral|Transport Payments|A payment scaled to reflect the cost of typical return transport fare for residents of the clinic catchment area
1492709|NCT03023007|Procedure|Loco-regional anaesthesia|Loco-regional anaesthesia
1492710|NCT03022994|Other|Duodenum and rectum examination|All subjects will undergo upper gastrointestinal endoscopy and proctoscopy. In addition, it will be also evaluated duodenal and rectal biopsies.
1492711|NCT03022981|Drug|SOF/VEL|FDC tablet administered orally once daily
1492712|NCT03022968|Drug|[18F]T807 PET|Imaging with [18F]T807 PET
1492713|NCT03022955|Dietary Supplement|Dark chocolate bar|Dark chocolate bar (70% cocoa solids (~500kcal, ~50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
1492714|NCT03022955|Dietary Supplement|Dark chocolate mousse|Dark chocolate mousse (150g, ~500kcal, ~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
1492715|NCT03022955|Dietary Supplement|White chocolate bar|White chocolate bar (0% cocoa solids (~500kcal, 50% fat)), 100g / day for 3 days to assess postprandial brain activity and colonic transit by FDG-PET.
1492716|NCT03022955|Dietary Supplement|White chocolate mousse|White chocolate mousse (150g, ~500kcal, ~50% fat) to assess gastric emptying and oro-caecal transit time by scintigraphy.
1492717|NCT03022942|Other|GROUP Costal mobilization & Diaphragm Release|Costal mobilization technique (Rib raising): The patient will be lying. The Therapist supports the last four pulps of both hands at the rib angles, gently traverses the rib angles in the posterior-anterior direction, using the stretcher as a lever to facilitate the elevation of the costal angles. Siting: The Therapist hugs the patient by supporting the ribs of the fingers at the rib angles, gently traverses the rib angles bilaterally in the anterior-lateral direction. Manual Diaphragm Release Technique: The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
1492718|NCT03022942|Other|GROUP Manual Diaphragm Release|The therapist makes manual contact with the underside of the costal border of the common cartilage of the last rib. In the inspiratory phase, the therapist draws the points of contact with both hands in a cephalad direction and slightly Accompanying the movement of the rib cage.
1492719|NCT03022942|Other|GROUP SHAM|The applied technique will only be of support of the therapist's hands, in the same anatomical points being one in each hemithorax without exerting any type of effort and / or pressure in the patient. You will be asked to perform your normal breathing for two sets of ten breathing cycles, with one minute interval between sets.
1492720|NCT03022929|Behavioral|Enhanced Antimicrobial Stewardship Commitment and Feedback|Goes beyond the GetSmart recommendations to discern whether these recommendations can be improved upon.
1492721|NCT03022916|Drug|Jublia|Application of Jublia to the nails of both big toes
1492722|NCT03022916|Other|Nail polish|Application of nail polish to one big toe nail
1492723|NCT03022903|Procedure|Aminolevulinic Acid (ALA)|Photosensitizing
1492724|NCT03022890|Behavioral|hatha yoga|12 weeks of hour-long gentle hatha yoga classes
1492725|NCT03022890|Behavioral|health education|12 weeks of hour-long classes on nutrition, sleep, coping with pain, and other health educaiton topics
1492755|NCT03022604|Dietary Supplement|C4/Generation 4|12 grams of C4/Generation 4
1492756|NCT03022604|Dietary Supplement|C450X|12 grams of C450X
1492757|NCT03022604|Dietary Supplement|Placebo|12 grams of flavored dextrose
1492758|NCT03022591|Other|Management|management of twin pregnancies with a short cervix diagnosed between 16 0/7 WGA to 27 6/7 WGA.
1492831|NCT03022032|Other|HOPE App|HOPE App
1492726|NCT03022877|Drug|Levosimendan|In a prospective randomized setting, patients are included with an acute STEMI of the anterior wall. A bolus administration Levosimendan with/without following continuous infusion over 24 hours compared to a control group (placebo) will be examined. The initiation of therapy is carried out for 10 min. prior to reperfusion. The coronary Intervention is performed immediately after inclusion at the latest within 6 hours after the onset of symptoms. The administration of Levosimendan is based on a fixed schema: Bolus: 12 µg/kg over 10 min I. V., starting 10 min before recanalization and an addition of 0.1-0.2 µg/kg/min i. v. for 24 hours in the continuous infusion group.
1492727|NCT03022851|Device|Occlutech AFR Device|Catheter-guided transeptal placement of an AFR device following balloon atrial septostomy (BAS) -procedure.
1492728|NCT03022838|Drug|Caffeine|From the point of enrollment, patients will substitute their daily dietary caffeine with either placebo- or capsulated caffeine tablets (Recip®, 100mg).
2001673|NCT02867111|Other|Attractant Substance|Capacitated spermatozoa may be oriented by following an increasing concentration gradient of an attractant molecule, a phenomenon called sperm chemotaxis. This is a guidance mechanism observed in vitro, which may transport and retain spermatozoa at the fertilization site. Though several molecules have been suggested to attract human spermatozoa, in the context of gamete interaction prior to fertilization, progesterone has biological importance for several reasons. After ovulation, this hormone is secreted by the cumulus cells that surround the oocyte, diffusing to form a molecular gradient toward the periphery of the cumulus and beyond. Notably, a gradient of very low concentrations (picomolar) of progesterone is sufficient to chemically attract capacitated human spermatozoa
2001674|NCT02867111|Procedure|ICSI|An in vitro fertilization procedure in which a single sperm is injected directly into an egg
1492732|NCT03022799|Drug|KM-819|
1492733|NCT03022799|Drug|Placebo|
1492734|NCT03022786|Other|Order set|Inpatient order set and ambulatory care guide offer guidance on initial compression to decrease edema, obtaining gradient compression stockings, how to access evaluation by vascular medicine for pain or dermatology for evaluation of allergic contact dermatitis if itch persists, etc
1492735|NCT03022786|Other|Motivational Interviewing training for home health aides|"Home Care aides trained about use of compression stockings and use of motivational interviewing as a tool to help patients make behavior changes to reduce leg swelling. This is part of our 'tool kit'.
There will be a focus group comprised of providers. This focus group will explore the perceptions of the providers and what unmet needs remain for the patients."
1492736|NCT03022786|Other|Tools & Education|Engaged physical therapists to evaluate patients for ability to don stockings, to assess need for strengthening exercises or leg exercises to improve venous return. This is part of our 'tool kit'
1492737|NCT03022773|Other|Carotenoid measurements|"Carotenoid measurements of the eye (macula) are obtained through non-invasive ophthalmic photographs using the Heidelberg Spectralis imaging system.
Carotenoid measurements of the skin are measured by a laboratory instrument that uses a painless blue laser light for exposure of the skin and a photodetector for scattered light.
Carotenoid measurements in the blood are obtained through routine venipuncture."
1492738|NCT03022760|Behavioral|Work-related measures|After mapping the patient's psychosocial work situation using tools provided at the one-day training, the patient's employer will be contacted and involved in the rehabilitation planning.
1492739|NCT03022747|Drug|Allopurinol|Allopurinol is added to standard oral 6-mercaptopurine and methotrexate
1492740|NCT03022747|Drug|Standard treatment|Oral 6-mercaptopurine and methotrexate
1492741|NCT03022734|Drug|chemotherapy|cetuximab 250mg/m2 or bevacizumab 5mg/kg, FOLFOX (oxaliplatin 85mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2) or FOLFIRI (irinotecan 180mg/m2, leucovorin 200mg/m2, 5-FU 400mg/m2, 5-FU continuous 1200mg/m2)
1492742|NCT03022734|Radiation|radiotherapy|After FOLFOX 4cycle, subject have short course radiotherapy 5Gy for 5 days.
1492743|NCT03022721|Other|No interventions are planned for this study.|No interventions are planned for this study, it is purely observational.
1492744|NCT03022708|Device|Xeltis Bioabsorbable Pulmonary Valved Conduit|Surgical implantation of Xeltis Bioabsorbable Pulmonary Valved Conduit
1492745|NCT03022695|Device|High Intensity Focused Ultrasound|
1492746|NCT03022669|Behavioral|Text Message|Annie (VA text messaging program) or mobile Health manager (private text messaging program for non-VA female participants recruited at non-VA facility)
1492747|NCT03022669|Behavioral|Mobile Application|TBD
1492748|NCT03022669|Other|Website|American Heart Association patient education website
1492749|NCT03022656|Device|Active Brace system|
1492750|NCT03022643|Behavioral|Interpersonal Social Rhythms Psychotherapy|The treatment involves 8-weeks of individual psychotherapy. Weekly sessions will be 60-minute long and will take place at the Pain Research Center. The treatment focuses on 1) the link between life events, pain severity, sleep disturbances, fatigue, and mood, 2) social and behavioral rhythms and sleep-wake disturbances, 3) identification and management of rhythm dysregulation and the triggers for it, 4) allowing and facilitating the mourning of the loss healthy self, 5) identification and appropriate management of symptoms.
1492751|NCT03022643|Device|Bright Light Device|All patients will be provided with a bright light device (Re-Timer) and will be instructed to use it in the first 2-hours of the day (for a minimum of 30 minutes) throughout the 8-week treatment period.
1492752|NCT03022630|Other|Comprehensive Palliative Care services|Participants who are randomly assigned to the intervention arm will receive informational materials, comprehensive inpatient palliative care consultations with a palliative care physician or nurse practitioner, in addition to standard hepatic care. If the patient is discharged, follow-up consults will be provided by a palliative care nurse via telephone contact. Telephone contacts will occur on a flexible schedule (e.g., weekly, bi-weekly, monthly) based on the needs and wishes of the patient, at a minimum frequency of once a month. If a need for further care is identified from a telephone contact, appropriate follow-up (referral, appointment, clinical communication, etc.) will occur per standard procedures. If the participant is readmitted, the consultation schedule will restart.
1492753|NCT03022630|Other|Usual hepatic care|Participants randomized to the usual care arm will not be scheduled to meet with the palliative care service unless a consult is requested by the patient, the family, or treating physician. These consultations would include the same palliative care services as the intervention arm, excluding the informational patient materials and telephone consultations.
1492754|NCT03022617|Drug|Apremilast|
1492760|NCT03022578|Drug|Lomustine|Lomustine administered by mouth at 90 mg/m2 on Day 1 for the first six week cycle. The dose of Lomustine may be increased to 110 mg/m2 starting with the second six week cycle, at the treating physician's discretion, as long as patient has not required dose modification for toxicity.
1492761|NCT03022578|Behavioral|Quality of Life Questionnaires|Quality of life questionnaires completed at baseline, 14 days after LITT procedure, on Day 1 of each Lomustine cycle, 6 weeks after Lomustine stopped, and every 3 months during follow up.
1492762|NCT03022578|Device|The NeuroBlate System|The NeuroBlate System used for thermal ablation of tumor utilizing the LITT procedure.
1492763|NCT03022565|Drug|Vorinostat|Study participants who meet the criteria of Class 2 uveal melanoma and no radiologic evidence of metastases will be treated with 400 mg of Vorinostat daily for 15 days.
1492764|NCT03022539|Radiation|Repeat CT scan|
1492765|NCT03022526|Procedure|CSE|
1492766|NCT03022526|Procedure|Epidural|
1492767|NCT03022526|Drug|Bupivacaine / fentaNYL|
1492769|NCT03022500|Drug|durvalumab + tremelimumab|Durvalumab: 1.5g Q4W plus Tremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
1492770|NCT03022474|Behavioral|Healthy Lifestyles Intervention|The program included three major components. The first component consists of live lectures to kindergarten staff about basic nutrition and food concepts that attempted to correct false beliefs. The second component was a health curriculum for children that focused on promoting healthy nutrition habits and a healthy living style. Preschools were required to ensure that children received a health education lesson every two weeks. The third component was aimed at educating parents and consisted of lectures every two months, preschool-home communication every week and child growth monitoring every three months.
1492771|NCT03022461|Other|Long term follow-up|
1492772|NCT03022448|Other|No Intervention|This is a NIS. No intervention.
1492773|NCT03022435|Biological|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
1492774|NCT03022435|Biological|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe
1492775|NCT03022435|Biological|LAIV|Live, attenuated influenza vaccine for Intranasal Spray
1492776|NCT03022422|Biological|TIV|Influenza Virus Vaccine Suspension for Intramuscular Injection
1492777|NCT03022422|Biological|High-Dose TIV|High-Dose Influenza Virus Vaccine supplied in a prefilled, single-dose syringe for intramuscular injection
2001675|NCT02862353|Biological|blood sample|15 ml of blood
2001676|NCT02861534|Drug|Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
1492780|NCT03022396|Biological|High Dose Fluzone® (intramuscular)|Licensed seasonal High dose trivalent inactivated influenza
1492781|NCT03022396|Biological|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza
1492782|NCT03022383|Device|DRI OCT Triton plus|OCT Machine used for diagnostic purposes
1492783|NCT03022370|Behavioral|Stepping Stones and Creating Futures|"Stepping Stones consists of 10 sessions. It seeks to strengthen relationships and to transform views on gender and in the process impact on exposure to, or participation in, gender-based violence and HIV risk. These cover gender and peer influences our actions; sex and love; conception and contraception; STIs and HIV; safer sex and condoms; GBV; motivations for behaviour (including influences of alcohol and poverty); and communication skills.
Creating Futures is a facilitated group intervention of eleven sessions. It seeks to strengthen livelihoods. The key sessions include: setting medium term livelihood goals, the need for assets and coping with crises; social resources for livelihoods (trust and community participation); getting and keeping jobs; and savings and spending."
1492784|NCT03022357|Other|Patient assessment|Clinical examination, Examination, Questionnaires
1492785|NCT03022357|Radiation|DATScan|In small subgroup
1492786|NCT03022357|Radiation|Orbital X-Ray|If foreign body in eye needs exclusion
1492787|NCT03022357|Other|Magnetic Resonance Imaging (MRI)|MRI scanning of all subjects
1492788|NCT03022344|Radiation|Cardiac CT|
2001677|NCT02861534|Drug|Placebo for Vericiguat|2.5, 5.0, or 10.0 mg orally once daily
1492790|NCT03022305|Behavioral|Group one - standard therapy|Group two - standard physical therapy treatment for shoulder and hip maladjustment.
1492791|NCT03022305|Behavioral|Group two - neuromuscular therapy|Use of physical therapy treatment for shoulder and hip maladjustment.
1492792|NCT03022292|Drug|Aflibercept Ophthalmic|IAI given for active exudative macular degeneration (CNV, SRF, PED) per SOC
1492793|NCT03022292|Device|optovue angiovue|FDA approved Optovue Angiovue will be used to monitor progression and responsiveness of active exudative macular degeneration to IAI.
1492794|NCT03022279|Procedure|TAP Blocks|ultrasound guided transversus abdominis plane block utilizing 0.25% bupivacaine with 1:200,000 epinephrine
1492795|NCT03022279|Procedure|local wound infiltration|local anesthesia provided at the surgical site utilizing 0.25% bupivacaine with 1:200,000 epinephrine
1492796|NCT03022279|Drug|0.25% bupivacaine with 1:200,000 epinephrine|2.5 mg/kg or 1 mL/kg of 0.25% bupivacaine with 1:200,000 epinephrine
1492797|NCT03022279|Device|ultrasound|ultrasound guidance
1492798|NCT03022266|Behavioral|Financial Incentive and Mobile Phone App|Subjects receiving the Financial Incentive and Mobile Phone App will each participate in a 90-day adherence promotion program. When users first log in to the app, the screen will display an incentive of $150 that participants have earned by enrolling in the program. Participants will be told that each missed medication check-in will result in a $2 deduction from the account before it is paid out. Each $50 portion (minus any penalties) of the $150 incentive will be paid out in 30-day installments by remotely crediting a previously distributed debit card. Adherence will be measured simultaneously by app photos and CleverCap(R) electronic monitoring (EM) devices filled with a 90-day supply of aspirin. Claims data will be analyzed for a 90 day period to account for any hospital admissions.
1492832|NCT03022032|Other|Standard of Care|Standard of Care
1492833|NCT03022032|Device|Fitbit Charge HR|Fitbit Charge HR
1492834|NCT03022019|Device|ReNovaCell|
1492835|NCT03022006|Drug|elbasvir, grazoprevir|
1492799|NCT03022253|Biological|Liberal platelet transfusion|"Liberal platelet transfusion: In Intervention group the investigators will transfuse platelet concentrates to maintain a platelet count above 1,00,000 per microliter until one of the following endpoints is met, whichever is applicable:
PDA closes or
A maximum of 120 hours after the point of randomisation"
1492800|NCT03022253|Biological|Restrictive platelet transfusion|"The investigators will transfuse platelets only if:
(i) Platelet count is < 20,000 per microliter or (ii) Subject has a clinical bleed or (iii) Subject has platelet count < 50000 per microliter and requires a major non-neurosurgical interventional procedure as per the current standard of care, or (iv) Subject has a platelet count < 1, 00,000 per microliter and requires a neurosurgical procedure"
1492801|NCT03022253|Drug|Paracetamol|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:
Paracetamol:
Dosage-15 mg/kg/dose every 6 hourly x 12 doses Route - IV"
1492802|NCT03022253|Drug|Ibuprofen|"As all subjects recruited in the trial will have hemodynamically significant (hs) PDA, they will all be medically treated as per standard of care. Treatment regimens will be as follows, depending on the discretion of the treating physician:
Ibuprofen:
Dosage-10 mg/kg stat followed by 5 mg/kg/dose x 2 doses at 24 hours intervals Route- oral"
1492807|NCT03022227|Other|telemedicine|telemedicine applied to adult cochlear implant users' follow-up
1492808|NCT03022214|Dietary Supplement|Placebo|Microcrystalline cellulose capsules x 5 morning and night with meals for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal
1492809|NCT03022214|Dietary Supplement|Intervention|"Daily capsules will be divided into two servings, one serving to be taken in the morning with breakfast, and one serving to be taken in the evening with dinner. Each serving containing 5 capsules, as follows:
EnduraCell broccoli sprout powder: 3 capsules
Bulk Powders Green tea extract: 1 capsule
Bulk Powders Cinnamon Bark Extract: 1 capsule taken for two days prior to exercise test and 5 capsules taken on the morning of the test with the first meal"
1492810|NCT03022201|Drug|DA-9701|Following 2-week screening period, study participants in this group will be given a standard dose of DA-9701 (30 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
1492811|NCT03022201|Drug|Domperidone|Following 2-week screening period, study participants in this group will be given a standard dose of domperidone (10 mg t.i.d). Concomitant anti-PD medication will be continued without modification during the trial. The investigators will evaluate dyspepsia and constipation symptoms, gastric emptying by MRI, UPDRS and clinical variables at baseline and at the end of the study.
1492812|NCT03022201|Drug|Placebo domperidone|
1492813|NCT03022201|Drug|Placebo DA-9701|
1492814|NCT03022175|Drug|SPR741|"SAD: Double-blind dosing will occur in cohorts 1 through 8. Six participants will receive single doses of SPR741. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.
MAD: The Safety Management Group will evaluate the safety and tolerability data obtained for the participants in Cohorts 1-5 to determine the appropriate dose level of intravenous q8h dosing of SPR741 to be utilized in the first cohort (Cohort 9) in the MAD. Dosing will commence on the morning of Day 1. Three doses will be administered per day at approximately 8 hours apart. Daily dosing will continue for a total of 14 consecutive days."
1492815|NCT03022175|Drug|Placebo|0.9% sodium chloride for injection. SAD: Two participants in each cohort will receive matching placebo. MAD: Two participants in each cohort will receive matching placebo.
1492816|NCT03022149|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
1492817|NCT03022149|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
1492818|NCT03022136|Other|cold sensation method|Complete sensory loss to ice will be evaluated form anterior median line to posterior median line at the end of surgery.
1492819|NCT03022123|Drug|PL-doxorubicin and epirubicin|PL-doxorubicin 35-40 mg/m(2) and epirubicin 70 mg/m(2) were given in combination with standard dosage of prednisone, vincristine, cyclophosphamide, rituximab (according to CHOP-R regimen) every 21 days for six courses.
1492820|NCT03022110|Device|Endoscopic Ultrasound-guided Drainage|Pancratic pseudocyst drainaged under the guide of Endoscopic Ultrasound
1492821|NCT03022097|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination, twice per day via Genuair
1492822|NCT03022097|Drug|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day via Genuair
1492823|NCT03022097|Drug|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day via Turbuhaler
1492824|NCT03022097|Drug|Placebo|Inhaled dose-matched placebo, twice per day via Genuair or via Turbuhaler
1492825|NCT03022084|Device|Desyncra|This group will use the sound-therapy device, Desyncra™ for Tinnitus Therapy System.
1492826|NCT03022084|Other|Cognitive Behavioral Therapy|Standard of Care
1492827|NCT03022071|Other|Cognitive psychotherapy|In this study we want to compare CBT and PDT and examine whether some patients will benefit from CBT and other from PDT. More specifically we want to examine moderators and mediators for improvement in depressive symptoms in the two interventions arms.
1492828|NCT03022058|Device|Ear-EEG system|Measurement of the neural activity in the brain by use of the Ear-EEG device, which is a customized earplug containing 6 embedded dry electrodes placed inside the ear canal and in the concha of the ear.
1492829|NCT03022045|Drug|risankizumab|risankizumab administered by subcutaneous injection.
1492830|NCT03022032|Device|Fitbit Zip|Fitbit Zip
1492836|NCT03021993|Drug|Nivolumab|Nivolumab will be administered on days 1, 15 and 29. If disease has progressed at day 29, the subject will proceed to surgery. If a response or stable disease is present after the third dose, a fourth dose will be given on day 43, then the subject will proceed to surgery.
1492837|NCT03021980|Behavioral|SuperFIT|Behavioural intervention with two components. One component will consist of social and physical environmental changes at the preschools and the other component consists of a family educational program.
1492838|NCT03021954|Biological|Platelet Rich Plasma|Platelet rich plasma is produced by obtaining patient's whole blood and processed by centrifugation and activation by CaCl2.
1492840|NCT03021928|Other|Time-To-Treatment Randomization|The time after symptom onset to initiate treatment will be randomized to one of four possible treatment arms: 60 hours, 132 hours, 228 hours, or 324 hours (+/- 12 hours each).
2001678|NCT02860468|Other|Cranberry juice|cranberry juice cocktail provided by Ocean Spray Cranberries, Inc.
1492842|NCT03021902|Drug|IV amino acids|IV amino acids delivered by continuous infusion, such that the total enteral and IV protein will be between 2.0-2.5 g/kg/day as a combination of amino acid infusion plus standard feeding.
1492843|NCT03021902|Device|In-bed cycle ergometry exercise|"In-bed cycle ergometry exercise delivered in 45-minute sessions once-daily 5 days per week according to a detailed specific protocol that includes a safety check in combination with vigorous verbal encouragement from trained research staff delivering the intervention to promote active cycling.
Cycling is protocolized to provide graduated increases in resistance during each session and between daily sessions. Cycling will continue through ICU discharge or 21 calendar days after randomization. The intervention will specifically occur during ICU stay."
1492844|NCT03021889|Behavioral|Nutritional therapy|The nutritional therapy intervention group received monthly nutritional guidelines for 12 weeks focusing on the diet for dyslipidemia, based on the recommendation of the type I diet of the Clinical Protocol and Therapeutic Guidelines for Management of HIV Infection in children and adolescents. In addition, participants in the intervention group received weekly phone calls for nutritional counseling.
1492845|NCT03021889|Behavioral|Control group|The control group was followed according to the ambulatory care routine, which consists of medical follow-up by the assistant team.
1492846|NCT03021876|Drug|L-carnitine|treatment with oral L-carnitine, 1500 mg/body per day
1492847|NCT03021876|Other|usual intake|baseliner
1492848|NCT03021863|Behavioral|Group A Reminder|Tone of reminder email (duty 14 days followed by duty 28 days for non-responders)
1492849|NCT03021863|Behavioral|Group B Reminder|Tone of reminder email (encouragement 14 days followed by encouragement 28 days for non-responders)
1492850|NCT03021863|Behavioral|Group C Reminder|Tone of reminder email (encouragement 14 days followed by duty for non-responders 28 days)
1492851|NCT03021863|Behavioral|Group D Reminder|Tone of reminder email (duty 14 days followed by encouragement for non-responders 28 days)
1492852|NCT03021863|Behavioral|Group E Reminder|Tone of reminder email (generic reminders 14 days followed by 28 days for non-responders)
1492853|NCT03021863|Behavioral|Group F Reminder|Tone of reminder email (generic 14 days followed by duty for non-responders 28 days)
1492854|NCT03021863|Behavioral|Group G Reminder|Tone of reminder email (generic 14 days followed by encouragement for non-responders 28 days)
1492855|NCT03021863|Behavioral|Group H Reminder|Tone of reminder email ( duty14 days followed by generic for non-responders 28 days)
1492856|NCT03021863|Behavioral|Group I Reminder|Tone of reminder email (encouragement 14 days followed by generic non-responders 28 days)
2001679|NCT02860468|Other|Placebo juice|apple juice added with flavor and colorants provided by Ocean Spray Cranberries, Inc.
1492858|NCT03021837|Other|antenatal corticosteroid|Will look at maternal glucose level after corticosteroids
1492859|NCT03021811|Device|KLOX LumiHeal BioPhotonic System|Real-life use of KLOX LumiHeal BioPhotonic System in combination with standard of care.
1492860|NCT03021798|Other|No Drug and no aspecific intervention|No intervention
1492861|NCT03021785|Biological|TK001|TK001 will be administered intravitreal injection.
1492862|NCT03021772|Drug|Neostigmine|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 0.5 mg neostigmine for Bier block.
1492863|NCT03021772|Drug|Dexamethasone|Patients will receive intravenous 3mg/kg lidocaine 2 % (diluted with normal saline to 40 ml) + 8 mg dexamethasone for Bier block.
1492864|NCT03021759|Behavioral|Active choice|Statin options are framed to physicians as an active choice to prescribe or not prescribe a statin
1492865|NCT03021759|Behavioral|Social comparison feedback|Statin prescribing rates are communicated to physicians and along with how their performance compares to their peers
1492866|NCT03021746|Behavioral|Diabetes Self Management Support (DSMS)|
1492867|NCT03021733|Procedure|Operative management|Rotator cuff surgery
1492868|NCT03021720|Procedure|Arterial access|Location of arterial puncture
1492869|NCT03021694|Dietary Supplement|Testing of micellar casein, blended micellar casein and native whey, versus native whey to determine post-ingestion aminoacidemia, glycemia, and insulinemia in young adult men|
2001680|NCT02860702|Other|Human Milk Derived Fortifier|Human milk derived fortifier will be utilized to increase caloric intake in infants assigned to the exclusive human milk arm
1492964|NCT03020979|Drug|Apatinib|Patients will take 500mg apatinib daily orally.
1492965|NCT03020966|Drug|Acetaminophen|Oral acetaminophen, intravenous placebo
1492966|NCT03020966|Drug|Acetaminophen|Intravenous acetaminophen, oral placebo
2001681|NCT02860702|Other|Human/Bovine Milk|Bovine milk derived fortification
2001682|NCT02859896|Drug|Doxercalciferol (GZ427397)|"Pharmaceutical form: capsule
Route of administration: oral"
2001683|NCT02859896|Drug|Calcitriol|"Pharmaceutical form: capsule
Route of administration: oral"
2001684|NCT02859454|Drug|Avelumab|Avelumab 10 mg/kg IV every 2 weeks for up to 6 doses.
2001685|NCT02858492|Drug|GSK2982772 60 mg|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
2001686|NCT02858492|Drug|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
1492870|NCT03021681|Other|autologous bronchial basal cell transplantation|the investigators obtained extraction bronchial basal cells micro tissue from 3~4 grade bronchus, then purified and selectively amplified bronchial basal cells to reserve . After a period of time, the basal lamina of the bronchial epithelial cells can be stored in the liquid nitrogen cell bank for a long time. Before applied to the patient, bronchial basal cells need to go through a series of strict examination. Then, bronchoscopy was performed again and the bronchial basal lamina suspension was injected directly into the lesion site .
1492871|NCT03021668|Device|Prevena Peel & Place Dressing|Prevena Peel & Place Dressing is a device that can be used for closure of the surgical site. It provides negative pressure to the surgical wound
1492872|NCT03021668|Other|Standard Closure of the Surgical Incision|This would involve standard closure of the incision site
1492873|NCT03021655|Behavioral|Adventure-based intervention group|One-day adventure-based training will be assigned to subjects and the activities include wall climbing, rope course and health talk on mood, pressure management and smoking cessation.
1492874|NCT03021655|Behavioral|WhatsApp intervention group|A WhatsApp group will be opened for the subjects and we will send messages about mood and pressure management to them and encourage them to quit smoking. The subjects can share their unhappy things in the group.
1492875|NCT03021655|Behavioral|Control group|Telephone follow-up will be conducted at 1-week, 1-, 3-, 6-, 9-, 12-, 24-month and smoking cessation counselling will be delivered to the subjects.
1492876|NCT03021642|Drug|Tepotinib test (Treatment Period 1)|Subjects will be administered a single oral dose of test new Phase III film-coated tepotinib tablet (1 * 500 mg tablet) in Treatment period 1 (Day 1)
1492877|NCT03021642|Drug|Tepotinib reference (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of current Phase II film-coated tepotinib tablet (5 * 100 mg tablet) in Treatment period 2 (Day 22)
1492878|NCT03021642|Drug|Tepotinib reference (Treatment Period 1)|Subjects will be administered a single oral dose of current Phase II film-coated tepotinib tablet (5 * 100 mg tablet) in Treatment period 1 (Day 1)
1492879|NCT03021642|Drug|Tepotinib test (Treatment Period 2)|Followed by a 21-day washout after Treatment period 1 (Day 1), subjects will be administered a single oral dose of test new Phase III film-coated tepotinib tablet (1 * 500 mg tablet) in Treatment period 2 (Day 22)
1492880|NCT03021629|Other|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by an enzyme-linked immuno-absorbent assay|
1492881|NCT03021616|Other|energy drink|32oz of commercially available energy drink
1492882|NCT03021616|Other|Moxifloxacin 400mg|400mg moxifloxacin active control drink
1492883|NCT03021616|Other|Placebo|Placebo drink
1492884|NCT03021603|Behavioral|Brief Hope Intervention|"The present Brief Hope Intervention (BHI) is a four-weeks individual intervention:
Hope enhancement strategies included sharing and recalling past successes, hope-based goal mapping exercises, examining possible pathways to reach the targeted goals, hope visualization exercise and positive self-talk.
Purpose: help participants to develop positive thoughts.
The programme consists of four sessions:
Two face-to-face sessions (1-hour) and two telephone follow up (30 mins) Homework: A booklet is prepared for the participants for reviewing their planned goals and recording achieved targets."
1492885|NCT03021590|Drug|Clarithromycin 500Mg Oral Tablet|"Amoxicillin 1000 mg Tablets every 12 hours , Esomeprazole 20 mg Capsule days all
,Clarithromycin 500 mg Tablets and Tinidazole 500 mg Tablets every 12 hours for 14 days all by mouth"
1492886|NCT03021590|Drug|Levofloxacin 500Mg Oral Tablet|Amoxicillin 1000 mg Tablets , Esomeprazole 20 mg Capsule,Levofloxacin 500 mg Tablets and Tinidazole 500 mg Tablets all every 12 hours for 14 days all by mouth
1492887|NCT03021577|Device|Orbital Atherectomy System (OAS)|The Cardiovascular Systems, Inc. (CSI) Diamondback 360 Coronary Orbital Atherectomy System (OAS) is a catheter-based system designed for facilitating stent delivery in patients with coronary artery lesions. The OAS consists of the hand-held CSI DIAMONDBACK 360 Coronary Orbital Atherectomy Device (OAD), the CSI Saline Infusion Pump (OAS pump), the CSI ViperWire Advance Coronary Guide Wire (VIPERWIRE guide wire), and the CSI ViperSlide Lubricant.
1492888|NCT03021577|Device|Rotablator Rotational Atherectomy System|The Rotablator Rotational Atherectomy System is comprised of a Rotablator RotaGlide, a Rotablator RotaLink Plus/RotaWire/Console
1492889|NCT03021577|Procedure|Magnetic Resonance Imaging (MRI)|In a subset of patients (n= 20) a baseline cardiac MRI will be performed prior to PCI and repeated 24 hours after PCI to quantify the total volume of myocardial necrosis secondary to PCI.
1492890|NCT03021564|Other|cardiopulmonary resuscitation|Basic cardiopulmonary resuscitation : external electric shock, external cardiac massage, adrenaline injection ...
1492891|NCT03021551|Device|Masimo Radical-7|The Masimo Radical-7 is a noninvasive Pulse CO-Oximeter monitor that measures arterial oxygen saturation (Sp02), pulse rate (PR)and perfusion index (PI) along with optional measurement of hemoglobin (SpHb), carboxyhemoglobin (SpCO), total oxygen content (SpOC), methemoglobin (SpMet), Pleth Variability Index (PVI), Oxygen Reserve Index (ORI), Acoustic Respiration Rate (RRA), and Pleth Respiration Rate (RRp).
1492892|NCT03021551|Device|Masimo Root|The Masimo Root is a patient monitoring and connectivity platform that has been cleared by the Food and Drug Administration (FDA) for noninvasive patient monitoring.
1492895|NCT03021525|Procedure|Individualized Goal Directed Therapy|The trial intervention period will commence from the induction of anesthesia until 8 hours after surgery, or until discharging from the postoperative intensive or intermediate care unit. All patients in the intervention group receive basic vital sign monitoring. For inotropic support dobutamine, and as vasopressor norepinephrine are drugs of choice. Hemodynamic management is performed according to standard treatment until an arterial line is placed. The signal of the arterial line is then processed either by calibrated or non-calibrated pulse contour analysis for pulse pressure variation (PPV) and cardiac index (CI) measurement. Fluid challenge will be performed by infusion of 500 ml in <15 minute. Choice of fluid in case of indicated fluid loading is determined on basis of the recent guideline for intravasal volume therapy. Patients receive fluids and vasoactive agents following a protocol of individualized parameters regularly achieved by extended hemodynamic monitoring.
1492967|NCT03020953|Other|Resistance exercise|
1492968|NCT03020953|Other|Estrogen Patch|
1492896|NCT03021525|Procedure|Control Group|Patients in the control group will be treated according to established basic treatment goals (heart rate <100 bpm, mean arterial pressure >65 mmHg, SpO2>94%, and core temperature >36° C). Basic anesthesiological monitoring by five-lead-electrocardiogram, pulse oximetry, non-invasive blood pressure monitoring and capnography is performed in every patient of the control group. Placement of an arterial and central venous line, as well as fluid and catecholamines administration, are at the discretion of the treating clinician.
1492897|NCT03021512|Procedure|Phaco with Restor|Phacoemulsification with bilateral bifocal intraocular lenses implantation
1492898|NCT03021512|Procedure|Phaco with Panoptix|Phacoemulsification with bilateral trifocal intraocular lenses implantation
2001687|NCT02859142|Drug|Chantix|Chantix given alongside standard smoking cessation treatment
2001688|NCT02859142|Behavioral|Behavioral Counseling Sessions|One-to-one behavioral counseling sessions with a trained therapist
1492901|NCT03021486|Drug|Haloperidol|"All participants receive Haloperidol 2 mg by vein every 6 hours regularly and every hour as needed upon admission to acute palliative care unit (APCU). If Richmond Agitation Sedation Scale (RASS) scores reach ≥+2, participant randomized.
Haloperidol Group: Haloperidol 2 mg by vein every 4 hours and every hour as needed.
Haloperidol and Chlorpromazine Group: Haloperidol 1 mg by vein every 4 hours and every hour as needed,"
1492902|NCT03021486|Drug|Chlorpromazine|"Chlorpromazine Group: After randomization, Chlorpromazine 25 mg by vein every 4 hours and every hour as needed.
Haloperidol and Chlorpromazine Group: Chlorpromazine 12.5 mg by vein every 4 hours and every hour as needed."
1492903|NCT03021486|Behavioral|Symptom Questionnaire|Symptom questionnaire completed at baseline and every 8 hours during the first 24 hours in the palliative care unit. After the first 24 hours, questionnaire completed 1 time each day until discharge.
1492904|NCT03021473|Device|The Masimo Radical-7|The Masimo Radical-7 is a noninvasive monitor that measures arterial oxygen saturation (SpO2), pulse rate (PR), and perfusion index (PI), along with optional measurements of hemoglobin (SpHb), carboxyhemoglobin (SpCO®), total oxygen content (SpOC), methemoglobin (SpMet), Pleth Variability Index (PVI®), Oxygen Reserve Index (ORI™), Acoustic Respiration Rate (RRa®), and Pleth Respiration Rate (RRp).
1492905|NCT03021473|Device|Masimo Root|The Masimo Root is a patient monitoring and connectivity platform that has been cleared by the Food and Drug Administration (FDA) for noninvasive patient monitoring.
1492906|NCT03021473|Other|Blood draw|0.5 mL blood samples will collected and analyzed in the operating room using point of care standard epoc® blood gas analysis system, for a total volume of 2.5 mL of blood.
1492907|NCT03021460|Drug|Ibrutinib|Given PO
1492908|NCT03021460|Other|Laboratory Biomarker Analysis|Correlative studies
1492909|NCT03021460|Biological|Pembrolizumab|Given IV
1492910|NCT03021434|Other|Community and household water safety education sessions|Data collectors will give a short community presentation on water treatment, as well as safe water handling and storage. Then, data collectors will immediately visit households and review this information. Data collectors will return within 72 hours and review this information once more.
1492911|NCT03021434|Other|Household-specific water quality information|Household specific water quality data will be provided in two ways. In the Standard Testing Arm, water quality data will be analyzed in a laboratory by standard methods and results will be delivered to households. In the Test Kit arm, water quality data will be analyzed in households using provided water test kits.
1492912|NCT03021434|Other|Low-cost microbiological water test kits|Intervention component consists of low-cost, biodegradable that tests for the presence of E. coli in water samples. The test uses Aquatest broth medium with resorufin methyl ester chromogen. Presence of E. coli (positive test) imparts bright red color, making it easy to use/interpret at the household level with minimal training
1492913|NCT03021421|Procedure|intratechal (subarachnoidal )injection|10 mg (2 cc) intrathecal single shot injection
1492914|NCT03021421|Procedure|lombar plexus and sciatic nerve injection|USG -guided lumbar plexus visualised and 20 ml local anaesthetic mixture (15 cc %0,5 Bupivacaine Hydrochloride 5 cc and %2 Lidocaine 5 cc ) for lombar plexus single shot injection
1492915|NCT03021408|Other|MIRT + Treadmill|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill training twice per day, 5 times a week, for 4 weeks.
1492916|NCT03021408|Other|MIRT + Treadmill Plus|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Treadmill Plus group will undergo 10-minutes treadmill-plus training (with visual and auditory cues) twice per day, 5 times a week, for 4 weeks.
1492917|NCT03021408|Other|MIRT + Virtual Reality|PD patients will undergo a 4-week MIRT. All patients in the MIRT+Virtual Reality (VR) group will undergo 10-minutes VR training with enhanced perceptions (visual, auditory, and haptic inputs), twice per day, 5 times a week, for 4 weeks.
1492918|NCT03021395|Drug|Decitabine|Decitabine at a dose of 20mg/㎡/d on day 1-5.
1492919|NCT03021382|Other|data collection, non-intervention|
1492920|NCT03021369|Device|Pleural drainage system|Pleural drainage system is connected to the chest tubes after surgery.
1492921|NCT03021356|Device|Aortic xenograft|After randomization, the aortic xenograft is implanted in the standard fashion
1492922|NCT03021343|Drug|Colchicine|colchicine given as per trial protocol
1492923|NCT03021330|Drug|Daunomycin and Cytarabine (DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-7.
Daunomycin at a dose of 60mg/㎡/d on day 1-3."
1492924|NCT03021330|Drug|Daunomycin and Cytarabine (Intermediate Dose of DA Regimen)|"Cytarabine at a dose of 100mg/㎡/d on day 1-4 and 1g/㎡/d on day 5-7.
Daunomycin at a dose of 60mg/㎡/d on day 1-3."
1492925|NCT03021317|Drug|ACTHar|The patients will be given 80 Units subcutaneously of ACTHAR at the time of MS relapse daily for 10 days.
2001689|NCT02859142|Drug|NicodermCQ|Nicotine patches provided over 12 week participation
1492927|NCT03021291|Device|Gelesis100 (2.25 g)|Three capsules of Gelesis100, each containing a 750 mg mixture of two food-grade materials: carboxymethylcellulose that is cross-linked with citric acid.
1493047|NCT03020290|Device|Endovascular treatment for PAD during medical care (SuperA stent (Abbott))|Long femoropopliteal stenting with SuperA devices during medical care. The endovascular treatment for PAD will be done during the usual medical treatment of patient. The intervention is not carried out within the framework of the research protocol
1493106|NCT03020004|Drug|Danoprevir|Danoprevir (DNV) 100mg tablet administered orally twice daily
1492928|NCT03021278|Other|Saline injection|In the saline injection group, low back pain will be induced via 1.0 ml hypertonic (5% NaCl) saline bolus injection which is a commonly used model of acute low back pain. Saline will be injected into the right (or left) lumbar longissimus muscle 50 mm lateral to the spinous process just above (5 mm) previously marked point. Injections will be performed by a physician under ultrasound imaging guidance to ensure that each single injection will be equally placed at a depth of 30 mm. The side for the pain induction will be randomised across subjects. The place of needle insertion and corresponding point on the opposite side of the body will be covered by placing a small piece of adhesive plaster.
1492929|NCT03021278|Other|Sham injection|In the sham-injection group (placebo comparator), a real needle will be shown to the participants to imitate and produce the anticipation of a pain experience. A pinprick sensation will be produced by a weighted stimulus applied perpendicularly to the skin just above without piercing the skin. A stimulus of 512 mN will be used to produce a pinprick sensation and activation of cutaneous nociceptors. Adhesive tapes covering stimulation points will also be provided.
2001690|NCT02858336|Behavioral|NEA|Neutral Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 45 kcal/kg LBM day.
1492931|NCT03021252|Device|High intensity IEMT|Training load will be the maximum inspiratory / expiratory load defined according to patient tolerance equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations / expirations (x 5 set), twice a day, during 8 weeks. External loads will be increased weekly at intervals of 10 cm H2O as tolerated. Patients will receive standard swallow therapy consisting of swallowing manoeuvres, oral exercises, and compensatory techniques aimed to improve self-management of dysphagia and protect the airway.
1492932|NCT03021252|Device|Sham IEMT|5 sets of 10 inspirations and expirations in a sham IEMT trainer, twice a day, during 8 weeks.
1492933|NCT03021239|Procedure|Echo Guided Testing|
1492934|NCT03021239|Procedure|Hemodynamic-Echo Ramp Testing -|
1492935|NCT03021226|Behavioral|Fatherhood Development|Fatherhood Development is a curriculum based program provided by a facilitator through a skill-based education intervention.
1492936|NCT03021226|Behavioral|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator through a skill-based education intervention.
1492937|NCT03021226|Behavioral|Financial Literacy|Relationship Enhancement is a curriculum based program provided by a facilitator through skill-based education intervention.
1492938|NCT03021200|Device|Green indocianine|Laser fluorescence using green indocianine guiding the surgical procedure.
2001691|NCT02858336|Behavioral|DEA|Deficient Energy Availability: 5-day outpatient intervention of prescribed diet and exercise to elicit an energy availability of 20 kcal/kg LBM day.
2001692|NCT02855684|Drug|Insulin glargine (U300)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2001693|NCT02855684|Drug|Insulin glargine|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2001694|NCT02855684|Drug|Non-insulin antihyperglycemic drugs|"Pharmaceutical form: capsule/tablet
Route of administration: oral"
1492943|NCT03021174|Behavioral|EXCAP Exercise|12 weeks of at-home walking and resistance exercise
1492944|NCT03021174|Behavioral|Nutrition Education Control|12 weeks of implementing eating tips
1492945|NCT03021161|Drug|Probiotic Formula|The intervention group will receive once daily capsules containing 109 CFU of Lactobacillus rhamnosus HN001, Lactobacillus paracasei Lpc-37 and Bifidobacterium animalis ssp. Lactis HN019
1492946|NCT03021161|Other|Placebo Oral Capsule|Capsule containing no probiotic
1492947|NCT03021148|Other|Questionnaire|Administration of questionnaire.
1492948|NCT03021135|Procedure|Conventional Endoscopic Mucosal Resection|
1492949|NCT03021135|Procedure|Underwater Endoscopic Mucosal Resection|
1492950|NCT03021122|Device|PedAMINES™ / Conventional Method|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:
• PedAMINES™ (Period 1) and then Conventional Method (Period 2)"
1492951|NCT03021122|Device|Conventional Method / PedAMINES™|"Each nurse will be asked to prepare a 5 μg/kg/min continuous infusion of dopamine (Period 1) and then to prepare a 0.1 μg/kg/min continuous infusion of norepinephrine (Period 2) for a 25kg boy using the studied delivery devices according to the sequence randomly assigned based on a cross-over design:
• Conventional Method (Period 1) and then PedAMINES™ (Period 2)"
2001695|NCT02854527|Drug|Digoxin|single dose
1492953|NCT03021096|Other|Surveys|The study is just using validated surveys to assess pain and mood states after surgery
1492954|NCT03021083|Device|IONSYS Patch|Patient controlled transdermal fentanyl patch, IONSYS, applied to patient in place of a PCA.
1492955|NCT03021070|Other|Conditional cash transfer|For each honoured and verified health visit that is made on time following enrollment, a woman receives a cash transfer. The value reduces by one quarter for each week of delayed visit, and no reward is offered for any visit made 3 weeks after the appointment date. Transportation cost by a local taxi to the health facility, and is a value that has been approved by the research ethics committee for many studies in the region as reasonable compensation for research participants.
2001696|NCT02854527|Drug|Furosemide|single dose
1492957|NCT03021044|Other|physical activity intervention|30, 60, 90 and 120 days after hospital discharge a clinical visit and session of physical activity training and program
1492958|NCT03021044|Other|standard of care|30, 60, 90 and 120 days after hospital discharge a clinical visit with correct style life recommendation
1492959|NCT03021031|Other|Observational|Observational study
1492960|NCT03021018|Drug|Brivaracetam|"Pharmaceutical Form: Solution for infusion
Concentration: 10 mg/ml
Route of Administration: intravenous"
1492961|NCT03021018|Drug|Lorazepam|"Pharmaceutical Form: Solution for injection
Route of Administration: intravenous"
1492962|NCT03021005|Behavioral|HIV Self-testing|
1493107|NCT03020004|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
2001697|NCT02854527|Drug|Metformin|single dose
2001698|NCT02854527|Drug|Rosuvastatin|single dose
2001699|NCT02854527|Drug|Digoxin|0.25 mg digoxin as single dose (all 4 drugs given together as a cocktail at the same time point)
1492969|NCT03020940|Drug|Cefuroxime Axetil Dispersible Tablets|"Oral. This product can be taken orally, can also be added to the amount of warm water after mixing evenly.
Adult general 0.25g (one time), 2 times a day, the general course of treatment for 5 to 10 days.
Severe Infection or suspected pneumonia, a 0.5g (once 2), 2 times a day; general urinary tract infection, a Times a 0.125g (one and a half tablets), 2 times a day; for patients with no complications of gonorrhea recommended dose of 1g (4 Tablets), a single taking.
Children generally a dose of 0.125g (one-half tablets), 2 times a day; for less than two years of age in the middle ear Inflammatory patients, a 0.125g (one half tablets), 2 times a day; for greater than two years of otitis media patients, one Times a 0.25g (one time), 2 times a day; more than 12 years of age in children, the same dose for adults"
1492970|NCT03020927|Behavioral|Reciprocal Imitation Training (Therapist-Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills.
1492971|NCT03020927|Behavioral|Reciprocal Imitation Training (Therapist + Parent Delivered)|Naturalistic Developmental Behavioral Intervention aimed at improving social imitation skills, using a combination of therapist-delivered intervention and parent training to deliver intervention in the home setting.
1492972|NCT03020914|Device|Audiovisual Distraction|watching a movie using video glasses and headphones
1492973|NCT03020901|Drug|Teicoplanin for Injection|Use Teicoplanin for Injection
1492974|NCT03020888|Device|Magseed and Sentimag|Magseed marker and Sentimag probe for lesion localization
1492975|NCT03020875|Drug|Ofirmev|Intravenously administered acetaminophen.
1492976|NCT03020875|Drug|Per Os Acetaminophen|Orally administered acetaminophen.
1492977|NCT03020862|Dietary Supplement|Dietary beetroot juice|Consumed as concentrated beetroot juice from James White Drinks England (Beet-it) and contained 300 mg dietary nitrate. Dose: 2x70 mL consumed twice a day for six days.
1492978|NCT03020836|Behavioral|Referral to primary care physician for hypertension control|Referral to primary care physician for hypertension control
1492979|NCT03020836|Behavioral|Referral to smoking quit line|Referral to Maryland Tobacco/Smoking quit line for help with smoking cessation
1492980|NCT03020823|Drug|SCB01A|intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1492981|NCT03020810|Drug|Dupilumab|The patient will receive a 600 mg subcutaneous dupilumab loading dose on Day 1, and then 300 mg subcutaneous dupilumab every 2 weeks
1492982|NCT03020797|Drug|Perampanel|
1492983|NCT03020797|Drug|Placebo Oral Tablet|
1492984|NCT03020784|Drug|Placebo|Placebo
1492985|NCT03020784|Drug|PF-06818883|Treatment
2001700|NCT02854527|Drug|Furosemide|1 mg furosemide as single dose (all 4 drugs given together as a cocktail at the same time point)
2001701|NCT02854527|Drug|Metformin hydrochloride|10 mg metformin hydrochloride as single dose (all 4 drugs given together as a cocktail at the same time point)
1492988|NCT03020758|Dietary Supplement|Dried Fruit|
1492989|NCT03020758|Other|High Carbohydrate Snack|
1949092|NCT00419692|Drug|Ropinirole|Subjects will receive ropinirole 0.5 mg for first 7 days, 1 mg from Day 8-14, 2 mg from Day 15-21, 3 mg from Day 22-28, 4 mg from Day 29-35, 5 mg from Day 36-42 and 6 mg from Day 43-51.
1949093|NCT00371384|Procedure|massage|UP to 10 massages over 10 weeks
1492992|NCT03020732|Procedure|test groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Concentrated growth factor(CGF) membranes were placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
1492993|NCT03020732|Procedure|control groups|Coronally advanced flap procedure is a mucogingival surgery technique that was used to prepare recipient sites. Subepithelial connective tissue graft was placed over the exposed root surface. The flap was advanced 1 mm coronally from CEJ to completely cover.
1492994|NCT03020719|Drug|Oral Glutathione|Oral Glutathione oral powder
1492995|NCT03020719|Drug|Placebo|Placebo oral powder
1492996|NCT03020706|Drug|Magnesium Sulfate, Injectable|magnesium sulphate intravenous administration during general anesthesia
1492997|NCT03020693|Procedure|Invasive electrostimulation combined with exercises|Procedure for producing analgesia by introducing the TENS current through a needle combined with a exercises program.
1492998|NCT03020693|Procedure|Placebo electrostimulation and exercises|First: Sham dry needling. After: electrostimulation using surfaces electrodes. Finally a exercises program.
1492999|NCT03020680|Dietary Supplement|Coenzyme Q10|To examine whehter 200 mg/d ubiquinol for 14 days increase coenzyme Q10 status by a larger degree than 200 mg/d ubiquinone
1949094|NCT00344461|Drug|Nevirapine, FTC, and Tenofovir|One arm only - Open label using FTC 200 mg p.o. qd, and Tenofovir 300 mg p.o. qd, and Nevirapine 200 mg b.i.d.
1949095|NCT00325819|Drug|Acetaminophen|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
1493002|NCT03020641|Procedure|Low pressure pneumoperitoneum|
1493003|NCT03020641|Procedure|standard pneumoperitoneum pressure|
1493006|NCT03020615|Drug|Hydroxyurea|Given orally once daily.
1493007|NCT03020602|Other|Laboratory Biomarker Analysis|Correlative studies
1493008|NCT03020602|Other|Pharmacological Study|Correlative studies
1493009|NCT03020602|Drug|Ubidecarenone Injectable Nanosuspension|Given IV
1493010|NCT03020589|Drug|Tacrolimus|See description in arm/group sections
1949096|NCT00325819|Other|placebo|Children were randomized 1:1 to receive up to five doses of acetaminophen (10-15mg per kg) or placebo following routine vaccinations.
1493013|NCT03020563|Drug|Liposomal Bupivacaine|Liposomal Bupivacaine
1493014|NCT03020563|Drug|Bupivacaine|Bupivacaine
1493015|NCT03020537|Biological|Fluzone|Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.
1493050|NCT03020251|Other|preoperative chest physiotherapy|preoperative chest physiotherapy : 5 sessions per week during 3 weeks
1493016|NCT03020524|Biological|Autologous CD4 T-Cells|all participants will receive a single infusion of C34-CXCR4-modified CD4+ T-cells at one of 3 dose levels. The first 3 subjects will receive dose level 1 of 0.8-1x109 transduced CD4+T-cells. Provided no dose limiting toxicity (DLT) is seen at the first dose level, the next 3 subjects will receive infusion at the 2nd dose level of 2.4-3x109 transduced CD4+ T-cells. If no DLT occurs at that dose, the final 3 subjects will receive the 3rd dose level of 0.8-1x1010 transduced CD4+ T-cells. In the event of a DLT (grade 3 or higher unexpected, related AE) recruitment will be paused pending DSMB decision
1493017|NCT03020511|Other|Ancient wheat flours|Ancient wheat flours will be administered in open label for 30 days
1493018|NCT03020498|Biological|Fluzone|Influenza Virus Vaccine Suspension for Intramuscular Injection
1493019|NCT03020498|Biological|FluMist|Influenza Virus Vaccine Live, Intranasal Intranasal Spray
1493020|NCT03020485|Other|Isomaltulose|Isomaltulose is a disaccharide made up of one molecule glucose and fructose with a (α1-6) linkage.
1493021|NCT03020485|Other|Sucrose|Sucrose is normal table sugar
1493022|NCT03020472|Biological|2008-2009 FluMist LAIV (Intranasal)|2008-2009 FluMist vaccine delivered intranasally
1493023|NCT03020459|Procedure|peeling-reposition|"After dying with Brilliant Blue G (Brilliant Peel; Geuder, Germany), a horizontal ILM strip is peeled off in inferior quadrant of macular area. Then the ILM was peeled from inferior to superior area continuously. The ILM roll  was unfolded with assistance of perfluoro-n-octane (PFO). Finally, the position of the fixed ILM flap is adjusted under PFO bubble using flute needle or forceps.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas.Patients are introduced to posture sitting position for 4 hours then maintain facedown position for 7 days postoperatively."
1493024|NCT03020459|Procedure|peeling|After dying with Brilliant Blue G (Brilliant Peel; Geuder, Germany),the ILM was grasped with end-gripping forceps (Grieshaber Maxgrip 723.13; Alcon Laboratories Inc, Fort Worth, Texas, USA).Then, the strand of ILM was peeled off radially from the foveal center to vascular arcade. In result, a round -shaped with 2.5-3.5 disc diameter ILM -peeled area was created.This was followed by a complete fluid-gas exchange using 14% perfluoropropane gas. Patients are encourage to maintain facedown position for 7 days postoperatively.
1493025|NCT03020446|Device|Sorbion Dressing|Sorbion dressing will be placed on venous leg ulcer and changed weekly for 4 weeks
1493026|NCT03020433|Device|rTMS Contralesional M1|1Hz Contalesional M1 repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 90% AMT
1493027|NCT03020433|Device|rTMS Contralesional PMC|5Hz Contralesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
1493028|NCT03020433|Device|rTMS Ipsilesional PMC|5HZ Ipsilesional PMC repetitive transcranial magnetic stimulation (1500 pulses, 10 minutes, 5 trains of 300 pulses each with 1 minute rest in between, 90% AMT)
1493029|NCT03020433|Device|rTMS sham at Ipsilesional M1|1Hz Ipsilesional M1 sham repetitive transcranial magnetic stimulation (1500 pulses, 25 minutes, 50% MSO)
1493030|NCT03020420|Other|Cicatricell Cream|Cream to be applied 2 times a day for 8weeks to 6 months
1493031|NCT03020407|Procedure|IVC Ultrasound-guided|IVC is identified in longitudinal section in the subcostal area of a patient using the curvilinear probe of standard ultrasound. The selected area of IVC diameter measurement is set at 2 centimeters distal to the confluence of hepatic vein by M-mode coupled by two-dimensional mode on frozen screen images using the Sonosite® X-porte.
1493032|NCT03020407|Drug|Antibiotics|Prompt empirical antibiotics will be given to the patients within one hour before the treatment allocation.
1493033|NCT03020407|Drug|Vasopressor|The threshold to the need of a vasopressor is set at mean arterial pressure below 65 mmHg if a patient's condition does not response to the fluid therapy.
1493034|NCT03020394|Device|Noninvasive ventilation|investigators recommended to use bilevel positive airway pressure mode, and adjust the fraction of inspire oxygen(FiO2) or oxygen flow rate to maintain patient's oxygen saturation(SpO2) between 88% to 92%. Parameter adjustment and weaning of NPPV follow the protocols used before. NPPV failure is defined as patient needs intubation and invasive mechanical ventilation, but the decision whether or not should be determined by attending physician, the patient and patient's family.
1493035|NCT03020368|Biological|Leeches|
1493036|NCT03020368|Drug|Diclofenac|
1493037|NCT03020355|Procedure|Placental Blood Drainage|Immediately after vaginal delivery, after clamping and cutting the cord—the cord will unclamped and the blood will drained until the flow ceased.
1493038|NCT03020355|Procedure|not Placental Blood Drainage|In the control group, the clamped cord will not released.
1493039|NCT03020329|Drug|Paclitaxel|"Patients receive paclitaxel (135mg/m2 on day 1),cisplatin (70mg/m2 Separate injection on day 1 to 3) and 5-fluorouracil (700mg/m2 on Days 1 to 5) every three weeks for three cycl es before the radiotherapy.
Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
Radical radiotherapy:Intensive modulate radiotherapy (IMRT),total dose for nasopharynx and nodule of neck:61.2Gy/34F,1.8Gy/daily."
1493040|NCT03020329|Drug|Cisplatin|Cisplatin (70mg/m2 Separate injection on day 1 to 3) with Paclitaxel and 5-fu every three weeks for three cycles before the radiotherapy.Cisplatin(100mg/m2)Separate injection every three weeks for three cycles during radiotherapy.
1493041|NCT03020329|Drug|5-fu|Fluorouracil (700mg/m2 on Days 1 to 5)with Paclitaxel and cisplatin every three weeks for three cycles before the radiotherapy.
1493042|NCT03020329|Radiation|Radical radiotherapy|Intensive modulate radiotherapy (IMRT) will be implement,total dose for nasopharynx and nodule of neck:61.2Gy(Gray)/34F(Fraction),1.8Gy/daily,5 days/week.
1493043|NCT03020316|Behavioral|Peer Mentor|A volunteer with a similar disease as the subject
1493044|NCT03020316|Behavioral|Transcendental Meditation|A meditation technique
1493045|NCT03020303|Drug|Spironolactone 25Mg Tablet|Randomized participants will receive a study supply of spironolactone 25 mg tablets. They will be instructed to take 1 tablet daily.
1493046|NCT03020303|Drug|Placebo Oral Tablet|Randomized participants will receive a study supply of placebo tablets with no active medical ingredients. They will be instructed to take 1 tablet daily.
1493048|NCT03020277|Other|Ecological Momentary Assessment with Smartphone© Application|Filling of the application every 3 days for 6 months by subjects (parents of patients with ASD)
1493091|NCT03020030|Drug|CYTARABINE|Standard of Care
1493051|NCT03020251|Other|preoperative rehabilitation program|exercise training at home : 5 sessions per week during 3 weeks
1493052|NCT03020238|Procedure|BiClamp group|electric energy
1493053|NCT03020238|Procedure|water jet group|water jet energy
1493054|NCT03020225|Dietary Supplement|White cheese|animal protein food source: White cheese (contains 30g protein), intact, plus 250ml mineral water
1493055|NCT03020225|Dietary Supplement|Green peas|Green peas (contains 30g protein), intact, cooked, plus 250ml mineral water
1493056|NCT03020225|Dietary Supplement|Mankai|Wolffia globosa (Mankai, contains 30g protein), intact, cooked, plus 250ml mineral water
1493057|NCT03020212|Drug|Oxygen|The subjects will be randomly assigned to receive or not LTOT and they will be followed for 30 months. At baseline and then at 10, 20 and 30 months, they will be clinically evaluated with arterial blood gases, pulse oximetry, echocardiography, spirometry with bronchodilator, diffusion capacity, quality of life (SGRQ), neurocognitive performance (MMSE) and six minutes walk test. The primary outcome will evaluate the ratio of occurrence of erythrocytosis or pulmonary hypertension. Secondary outcomes will be evaluated quality of life, lung function, neurocognitive performance and exercise tolerance by comparing the groups with and without LTOT.
1493058|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL.
1493059|NCT03020199|Radiation|nbUVB|Narrow-band UVB applied in 1 or 2 cycles, each comprising a period of 12 weeks with 2 to 3 treatment sessions per week totaling 24 to 36 sessions per cycle. The application will be performed according to the investigational site's protocol, taking into account the patient's skin type. A maximum dose of 3 J/cm2 on the body and 1 J/cm2 on the face is recommended
1493060|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
1493061|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
1493062|NCT03020199|Biological|Secukinumab|Secukinumab (AIN457) 300 mg will be administered in an open-label fashion according to label as 2 s.c. injections of secukinumab 150 mg (1-mL liquid formulation in a pre-filled syringe). Each 300-mg dose will be provided as 2 pre-filled syringes of 150-mg secukinumab in a single box. Each syringe is labeled as AIN457 150 mg/1 mL
1493063|NCT03020199|Drug|Calcipotriol|Its a topical treatment for Psoriasis. the concentration it is used is 50mcg/g
1493064|NCT03020199|Drug|Betamethasone|this is topical cream which is used in 0.5mg/g concentration
1493065|NCT03020186|Other|Physical activity|
1493066|NCT03020186|Other|Physical activity+ MED diet|
1493067|NCT03020186|Other|Physical activity+green MED diet|****Sub-study from all 3 main arms: Autologous fecal microbiota supplement intervention derived from the time of maximal weight loss: At the 6-month time period, the time of anticipated greatest weight reduction, participants's feces samples will be processed to capsulized inocula. Samples will be frozen within 2 hours and will be kept at -80c pending analysis. Participants will be randomized to receive either research capsules or identical placebo capsules between 10 and 12 months time period. Placebo capsules will consist of a combination of powdered cocoa and vegetable gelatin in normal saline/glycerol and will be identical in appearance to research capsules.
1493068|NCT03020173|Other|Laboratory study|Laboratory analysis to determine composition of granulosa and oocytes
1493069|NCT03020160|Drug|Emicizumab|Emicizumab will be administered according to dose and schedule described in respective arms.
1493070|NCT03020134|Drug|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
1493071|NCT03020134|Drug|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
1493072|NCT03020134|Drug|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
1493073|NCT03020134|Drug|Placebo|Placebo
1493074|NCT03020121|Procedure|Colposcopy/biopsy|Colposcopy/biopsy will be performed on all subjects
1493075|NCT03020108|Other|Blood sample|2 cc blood samples will be drawn from antecubital vein
1493076|NCT03020095|Drug|Ravidasvir|Ravidasvir 200mg tablet administered orally once daily
1493077|NCT03020095|Drug|Danoprevir|Danoprevir 100mg tablet administered orally twice daily
1493078|NCT03020095|Drug|Ritonavir|Ritonavir 100mg tablet administered orally twice daily
1493079|NCT03020095|Drug|Ribavirin|Ribavirin(RBV)1000/1200 mg/day (bodyweight<75/≥75 kg)administered orally
1493080|NCT03020082|Drug|Danoprevir|Danoprevir (DNV)administered orally 100mg BID for 12 weeks;
1493081|NCT03020082|Drug|Ritonavir|Ritonavir administered orally 100mg BID for 12 weeks;
1493082|NCT03020082|Drug|peginterferon alfa-2a|PEG-IFN abdominal or thigh subcutaneous injection, 180μg, once a week for 12 weeks;
1493083|NCT03020082|Drug|RBV|RBV administered orally 500mg (5 tablets)( body weight ＜75Kg) BID, 600mg (6 tablets) BID body weight ≥75Kg, for 12 weeks.
1493084|NCT03020069|Device|CGMS Device|
1493085|NCT03020069|Other|No Device|
1493086|NCT03020056|Drug|Phacolin eye drops|After enrollment, the participants will be provided antioxidant eye drops, Phacolin (Zhongshan ophthalmic center, China) for free.The eye drops will be administered 4 times per day for 1 year.Then either phacoemulsification or manual small incision cataract surgery will be performed.
1493087|NCT03020056|Procedure|cataract surgery|After enrollment,either phacoemulsification or manual small incision cataract surgery will be performed within 4 weeks.
1493088|NCT03020030|Drug|Pegaspargase|Arm A: Standard/Fixed Dose Pegaspargase (2500 IU/m2 every 2 weeks) Arm B: Reduced Dose (PK-adjusted) Pegaspargase (Starting Dose: 2000 IU/m2) Arm X: Directly Assigned Standard Dose (2500 IU/m2): For all VHR and patients who decline randomization
1493089|NCT03020030|Drug|Erwinia asparaginase|Only for patients with Pegaspargase allergy or silent inactivation.
1493090|NCT03020030|Drug|Cyclophosphamide|Standard of Care
1493108|NCT03020004|Drug|peginterferon alfa-2a|PegIFN subcutaneous injection at 180 mcg weekly
1493109|NCT03020004|Drug|Ribavirin (RBV)|Ribavirin (RBV)1000/1200 mg/day (bodyweight<75/≥75 kg)
1493110|NCT03019991|Drug|Danoprevir|Danoprevir(DNV)administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
1493111|NCT03019991|Drug|Ritonavir|Ritonavir administered orally 100mg QD on day 4 and day 14; 100mg BID on day 5 -day 13
1493112|NCT03019991|Drug|Placebo|ASC 08 Placebo administered orally 100mg QD on day 1, day 4 and day 14; 100mg BID on day 5 -day 13
1493113|NCT03019978|Other|PCAMS assessments|This is a longitudinal study, where data will be collected from 54 individuals who are already enrolled in Pennsylvania's ACAP program. Participants will be required to complete online assessments at baseline and then quarterly over a two-year time period.
1493114|NCT03019965|Drug|Intermittent Piperacillin/tazobactam|Piperacillin/tazobactam administered in 30 minutes infusion.
1493115|NCT03019965|Drug|Continuous Piperacillin/tazobactam|Piperacillin/tazobactam administered in 24 hours infusion.
1493116|NCT03019965|Drug|Intermittent Imipenem|Imipenem administered in 60 minutes infusion.
1493117|NCT03019965|Drug|Extended Imipenem|Imipenem administered in 6 hours infusion.
1493118|NCT03019965|Drug|Intermittent Meropenem|Meropenem administered in 60 minutes infusion.
1493119|NCT03019965|Drug|Extended Meropenem|Meropenem administered in 8 hours infusion.
1493120|NCT03019952|Behavioral|Care Coordination Visit|This is a longitudinal study. Adolescents or young adults with autism will participate in this study. Participants will be required to complete a baseline of assessment measures at enrollment and then monthly assessments (described in the study procedures below) during the first (approximately) 10-15 minutes of each visit with the t-CARE coordinator. The remainder of the visit will focus on care coordination and clinical treatment goals.
2001702|NCT02854527|Drug|Rosuvastatin|10 mg rosuvastatin as single dose (all 4 drugs given together as a cocktail at the same time point)
2001703|NCT02848885|Other|Active TDCS|Participants will receive active tDCS stimulation.
1493123|NCT03019913|Other|Observational cohort|Evaluation of bedside methods to measure muscularity in critically ill patients
1493124|NCT03019900|Procedure|Red blood cells transfusions|The survey was designated to assess the practices of blood transfusion, specifically about the threshold and factors that can modify this threshold.
2001704|NCT02848885|Other|Sham TDCS|Participants will receive sham tDCS stimulation
1493126|NCT03019874|Dietary Supplement|Cranberry Extract|3 x Cystorenal Cranberry plus daily for 6 months (contains 300 mg Cranberry-Extract, 100 mg Pumpkin seeds-Extract, 20 mg Vitamin C und 0,47 mg Riboflavin)
1493127|NCT03019861|Behavioral|Ayurvedic nutritional counseling|
1493128|NCT03019861|Behavioral|Conventional nutritional counseling|
1493129|NCT03019848|Dietary Supplement|Curcumin|
1493130|NCT03019848|Other|Placebo|
1493131|NCT03019835|Drug|Neostigmine (40 mcg / kg) at different time of neuromuscular block's recovery|
1493132|NCT03019835|Other|Spontaneous recovery|just measuring the Train Of Four at 3 6 9 12 and 15 minutes and measure the Train Of Four Ratio
1493133|NCT03019822|Drug|LSD|100ug per os, single dose
1493134|NCT03019822|Drug|MDMA|125mg per os, single dose
1493135|NCT03019822|Drug|Amphetamine|40.3mg per os, single dose
1493136|NCT03019822|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs
1493137|NCT03019809|Biological|G-CSF for Conditioning before HSCT.|Mobilization of hematopoietic stem (HSC) into circulation
1493138|NCT03019809|Biological|Plerixafor for Conditioning before HSCT.|Directed inhibition of CXC chemokine receptor type 4 (CXCR4) for opening enough BM niches for adequate donor HSC engraftment.
1493139|NCT03019796|Behavioral|EXERCISE TRAINING|EXERCISE TRAINING AND ITS INTERACTIONS WITH METABOLIC SYNDROME PARTICIPANT'S HABITUAL MEDICATION (i.e., blood pressure, glucose, cholesterol and triglycerides lowering drugs).
1493140|NCT03019796|Behavioral|NO EXERCISE TRAINING|REMAINING INACTIVE AND ITS INTERACTIONS WITH METABOLIC SYNDROME PARTICIPANT'S HABITUAL MEDICATION (i.e., blood pressure, glucose, cholesterol and triglycerides lowering drugs).
1493141|NCT03019783|Drug|Atazanavir|The active group will switch from a non-atazanavir regimen to an atazanavir-based regimen.
1493142|NCT03019783|Other|Placebo|The control group will stay on their baseline regimen
1493143|NCT03019770|Behavioral|PrEP Decision Aid|All participants will participate in a simulated or actual clinical visit with a healthcare provider. During this visit, they will review the Decision Aid which will give them an HIV risk score and ask questions about their values. The goal of these visits will be to make an informed decision about whether or not to begin using PrEP.
1493144|NCT03019757|Radiation|DaTscan|A functional imaging of the dopamine transporter using the radioligand [123I]FP-CIT
1493145|NCT03019757|Radiation|F18-AV-45|A brain scan to to measure the extent of amyloid deposition
1493146|NCT03019757|Radiation|FDG-PET|a brain scan measuring total and regional cerebral glucose metabolism wtih positron emission tomographs with 2-(18F)
1493147|NCT03019757|Genetic|APOE genotype|10 ml of whole blood will be drawn and shipped to Athena Diagnostics for genetic testing.
1493148|NCT03019757|Procedure|Polysomnogram|Overnight sleep study
1493149|NCT03019757|Behavioral|Clinical Assessment|Clinical assessments include cognitive, behavioral, and motor evaluations
1493150|NCT03019744|Device|MeCFES-assisted task-oriented upper limb rehabilitation|
1493151|NCT03019744|Other|Usual Care task-oriented upper limb rehabilitation|
2001705|NCT02846051|Procedure|venous mapping|clinical examination + doppler echo
2001706|NCT02840630|Other|Tinned mackerel fish|Diabetic fish intervention group will be given two tinned mackerels per week from week 0 until week 16.
1493203|NCT03019393|Other|Beef|200 g beef topside which is fully cooked will be provided to participant after overnight fast. The intervention is one time only.
1493302|NCT03018665|Drug|Exenatide|subcutaneous injection，5ug twice a day the first month，10ug twice a day the second and third month
2001707|NCT02840331|Drug|St. John's Wort|Single oral doses (900 milligram) 2-4 hours before laparoscopy
1949104|NCT00287365|Drug|ozone|2 hour exposure to 0.4 ppm ozone
1493152|NCT03019731|Behavioral|Therapist-directed Behavioral Therapy|The therapist-directed behavioral therapy group will have their first appointment scheduled within one week of assignment. In the Therapist-directed face-face training program, training instructions will be manualized, in order to match the parent instructional guidelines provided in the home-based DVD. This manual will include the specific psychoeducation, awareness training, competing response training, differential reinforcement of incompatible behaviors, and other adaptive behavioral instructions contained within the home-based DVD. The therapist will match the sequence and required components within the behavior-based training DVD. Face-face training will be administered across 10 weeks (6 weekly sessions followed by 2 bi-weekly sessions).
1493153|NCT03019731|Behavioral|Home-based DVD Therapy|In order to mimic the slight delay between randomization and start of the therapist-directed treatment, those assigned to the Home-based DVD cohort will have the DVD and training materials mailed to their homes. Parents will also receive a written instructional form and a log sheet for tracking the use of the DVD and the time and duration of practice sessions. Any questions regarding patient care and treatment will be directed to Dr. Singer.
1493154|NCT03019718|Other|GSA-Online plus|A 12-week online writing intervention based on the Core Conflictual Relationship Theme Method (CCRT) with feedback provided by online therapists.
1493155|NCT03019705|Other|Observation|
2001708|NCT02840331|Device|Photodynamic diagnostic and therapy|Intraoperative irradiation with light (photodynamic diagnosis (PDD) and therapy (PDT), with the appropriate wavelength (390-440 nanometer) over 15 minutes
1493157|NCT03019653|Drug|ANX-042|The first 20 subjects will receive a dose 0.003 µg/kg/min by infusion, the next 20 subjects will receive a dose of 0.006 µg/kg/min, then the next 20 subjects will receive 0.01 µg/kg/min.
1493158|NCT03019653|Drug|Placebo|The pharmacy created a placebo for this study is sterile Dextrose (5%) solution (D5W) 0.9% Sodium Chloride for intravenous administration to match study drug.
2001709|NCT02838745|Drug|Pemetrexed|
2001710|NCT02838745|Drug|Cisplatin|
2001711|NCT02836015|Behavioral|Shared Medical Visit|The Shared Medical Visits are a replacement for standard diabetic visits with PCP, and will occur completely in Spanish, the patients' preferred primary language. An interdisciplinary group including behavioral health, social work, pharmacy, MD, and diabetic educator will be involved in the visit. The focal point of the meeting is a 30 minute session in which all members are seated around a large table in the Midtown SMV area and each patient's blood sugars, labs, and medications are discussed in front of the entire group. Pertinent labs and vaccines are drawn/administered.
2001715|NCT02833844|Drug|Repatha (Evolocumab)|Dose of subcutaneous Repatha (Evolocumab) every 4 weeks (QM)
2001716|NCT02833844|Drug|Placebo|Dose of subcutaneous Repatha (Evolocumab) Matching Placebo every 4 weeks (QM)
2001717|NCT02833844|Drug|Repatha (Evolocumab)|Dose of subcutaneous Repatha (Evolocumab) every 4 weeks (QM)
1493169|NCT03019627|Drug|NGF|Eye Drop 20 μg/mL
1493170|NCT03019627|Other|Vehicle|Vehicle Eye Drop
1493171|NCT03019614|Drug|Hydrocortisone|Generic hydrocortisone
1493172|NCT03019614|Drug|Chronocort|Modified formulation of hydrocortisone
1493173|NCT03019601|Behavioral|Group Education|Structured group education on family planning facilitated by Peer Champions
1493174|NCT03019588|Biological|Pembrolizumab|IV infusion
1493175|NCT03019588|Drug|Paclitaxel|IV infusion
1493178|NCT03019562|Drug|Oxycodone|4mg of oxycodone iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA)
1493179|NCT03019562|Drug|Fentanyl|50ug of fentanyl iv 20 min before the end of surgery, 10ug/kg of fentanyl in Patient-Controlled Analgesia(PCA),
1493180|NCT03019549|Drug|Lanabecestat|Administered orally
1493181|NCT03019549|Drug|Rosuvastatin|Administered orally
1493182|NCT03019536|Drug|LY3303560 - IV|Administered IV
1493183|NCT03019536|Drug|Placebo - IV|Administered IV
1493184|NCT03019536|Drug|LY3303560 - SC|Administered SC
1493185|NCT03019536|Drug|Placebo - SC|Administered SC
1493186|NCT03019536|Drug|Florbetapir F 18|Administered IV during the Positron Emission Tomography (PET) scan performed during screening.
1493187|NCT03019536|Drug|Flortaucipir F18|Administered IV during the PET scan performed during the study.
1493188|NCT03019523|Dietary Supplement|Caffeine Blend|Taken orally in capsule form
1493189|NCT03019523|Other|Sugar Pill|Taken orally in capsule form
1493190|NCT03019510|Behavioral|No exercise|No exercise will be done on the day of the study night to be tested
1493191|NCT03019510|Behavioral|Morning exercise|Early morning exercise will be done on the day of the study night to be tested
1493192|NCT03019510|Behavioral|Evening exercise|Evening exercise will be done on the day of the study night to be tested
1493193|NCT03019497|Behavioral|Specific Modules|Educational session about a specific related problem
1493194|NCT03019497|Behavioral|Cognitive behavioral therapy|PTSD of participants in both conditions will be addressed with cognitive-behavioral intervention strategies. These strategies are: (a) psychoeducation on PTSD, (b) anxiety management training, (c) restructuring irrational thoughts, (d) imaginative and / or in vivo exposure to memories and situations avoided, and (e) strategies for the prevention of relapse.
1493195|NCT03019484|Behavioral|Breastfeeding support|Self-efficacy
1493196|NCT03019471|Genetic|Isolation of tumor DNA|
1493197|NCT03019458|Dietary Supplement|MINGO|6 20oz sachets will be taken daily by intervention group
1493198|NCT03019432|Behavioral|Observational clinical assessment|perception of verticality measures SVV and SPV; somatosensory assessment RASP
1493199|NCT03019419|Drug|Perampanel|4mg/d or 8mg/d
1493200|NCT03019419|Drug|placebo|placebo
1493265|NCT03018899|Procedure|epidural anesthesia|thoracic epidural anesthesia
1949107|NCT00273598|Procedure|Moss Miami Spine Instrumentation System|
1493204|NCT03019380|Device|removing cerumen from external ear (Wondertip)|The wondertip will be coiled into the external ear canal with the purpose of grasping and evacuating the cerumen. Following the evacuation, the depth of the external ear canal will be messured.
1949108|NCT00273598|Procedure|Universal Spine Instrumentation System|
2001718|NCT02831166|Procedure|Transradial primary percutaneous coronary intervention|Transradial coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. To achieve hemostasis in the transradial approach, a radial compression device will be applied, to maintain patent antegrade flow.
1493207|NCT03019354|Device|high-flow nasal oxygen|Using high-flow nasal oxygen 10 L/min before anesthesia induction, then using high-flow nasal oxygen 30-50 L/min during intravenous general anesthesia.
1493208|NCT03019354|Device|Oxygen mask|Using oxygen mask with oxygen flow 10 L/min before and during intravenous general anesthesia.
1493209|NCT03019328|Other|Peanut in diet|
1493210|NCT03019302|Device|Arrow PICC with Chloragard Technology|chlorhexidine is chemically bonded to the intra- luminal catheter surfaces from tip to hub, and extra-luminal catheter body
1493212|NCT03019276|Drug|TQ-B3101|Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .
1493213|NCT03019263|Dietary Supplement|Nutraceutical|Nutritional counseling plus one pill of an active product (Trixy®) containing Berberine, Tocotrienols and Chlorogenic acid
1493214|NCT03019263|Other|Control|Nutritional counseling
1493215|NCT03019250|Dietary Supplement|Colostrum|Enteral colostrum 20g/day powdered colostrum to be mixed in with water and given via nasogastric tube q4 hrs.
1493216|NCT03019250|Dietary Supplement|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours.
1493217|NCT03019237|Drug|anti-IgE|intranasal anti-IgE
1493218|NCT03019237|Other|intranasal allergen|intranasal allergen
1493219|NCT03019237|Other|intranasal saline|intranasal placebo
1493220|NCT03019224|Procedure|Selection and preparation of the volunteers|Patients who sought the postgraduate dental clinic for whitening were invited to participate in the study. They were informed by the researcher (dentist) about all the aspects of the study and who might participate or discontinue the participation at any moment during the treatment. In addition, it was clarified that their participation was voluntary and refusal to participate would not result in any penalty or loss of benefits.
1493221|NCT03019224|Procedure|Evaluation of the tooth color|"The evaluation of the tooth color was performed by using a spectrophotometer (Easyshade, Vident, Brea, CA, USA). The color was analysed with the tooth hydrated before of the start the first whitening session and one week after.
The spectrophotometer was always used in the same position by a silicon guide, which was prepared with dental arch molds by adding high viscosity vinyl polysiloxane material (Express XT, 3M ESPE, Sumaré, SP, Brazil). After polymerization, an opening was made in the mold corresponding to the buccal surface of the upper central incisors, allowing the color of the tooth to be evaluated with the tip of the spectrophotometer at the height of the middle third."
1493222|NCT03019224|Procedure|Relative isolation|The clinical procedures were performed under relative isolation using lip retractor (Arcflex, FGM, Joinville, SC, Brazil) and dental cotton rollers to apply a gingival protection barrier (Top Dam, FGM, Joinville, SC, Brazil) extending from right first molar to left first molar in both arches.
1493223|NCT03019224|Procedure|Gingival protection barrier|The gingival protection barrier was placed over the margins and gingival papilla corresponding to the areas receiving the whitening gel with approximately 3 mm in height and photopolymerized for 20 seconds in each group of three tooth. Photo-activation was performed with high power LEDs (light intensity = 600mw / cm²) (RadiiCal, São Paulo, SP, Brazil).
1493224|NCT03019224|Procedure|Application of desensitizing gel|The desensitizing gel containing 5% potassium nitrate associated with 2% sodium fluoride (Desensibilize KF 2%, FGM, Joinville, SC, Brazil) was applied with a microbrush (Brush KG, KG Sorensen, Cotia, SP) on the buccal surface from right first molar to left first molar in both arches and remaining for 10 minutes. Then, the desensitizer was then removed with water jet and disposable plastic suction cannula.
1493225|NCT03019224|Drug|Hydrogen peroxide|The handling of 35% hydrogen peroxide (Whiteness HP, FGM, Joinville, SC, Brazil) followed the manufacturer's recommendations, which consisted of mixing 3 drops of 35%hydrogen peroxide for 1 drop of thickener, with this mixture being sufficient for application to at least three tooth. The gel remained in contact with the buccal surface of the tooth for 15 minutes and was removed with disposable plastic suction cannula and water wash. This procedure was performed three times per clinical session. The volunteers underwent three whitening clinical sessions with one week interval between them.
1493226|NCT03019224|Procedure|Used a dentifrice|Among the clinical whitening sessions, each volunteer used an unidentified dentifrice corresponding to their experimental group, which was previously defined by means of a draw made by a dentist who did not participate in the study. Thus, the researcher (dentist) who provided the dentifrice and the volunteer were not aware of which experimental group belonged (i.e. double blind).
1493227|NCT03019211|Other|Exercise|
1493228|NCT03019198|Drug|Tranexamic Acid Injectable Solution|Intravenous 15 mg per kilogram tranexamic acid
1493229|NCT03019198|Drug|Placebo - Concentrate|
1493230|NCT03019185|Drug|Placebo Oral Capsule|Capsule containing an inert placebo
1493231|NCT03019185|Drug|Bardoxolone Methyl|Bardoxolone methyl dose escalated from 5 mg to a maximum of 20 or 30 mg, depending on baseline proteinuria status.
1493232|NCT03019172|Combination Product|Lactobacillus reuteri|Sachet one contains a total of 5*10^8 CFU of Lactobacillus reuteri DSM 16666 & Lactobacillus reuteri DSM 17938, mixed with maltodextrin for flowability during production. Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica. The products will be taken twice per day, morning and evening. The daily dose in the active group will be 1*109 CFU of Lactobacillus reuteri (4*108 CFU L.reuteri DSM16666 and 1*108 CFU L. reuteri DSM17938), 72 mg PAC-A and 3 mg zinc
1493300|NCT03018691|Drug|OPA-15406|
1493301|NCT03018691|Drug|Placebos|
1493233|NCT03019172|Dietary Supplement|Sachet with cranberry + placebo|Sachet one contains placebo for probiotics (maltodextrin). Sachet two contains instant cranberry drink composed of Cranberry extract, xylitol, cranberry aroma, monosodium citrate, zink gluconate, silica.
1493234|NCT03019159|Device|Teleconsulting|
1493235|NCT03019146|Other|HIIT|
1493236|NCT03019146|Other|HOLD|
1493237|NCT03019146|Other|HUG|
1493238|NCT03019133|Device|Sound reduction|Subjects will wear noise reduction headphones between the hours of 8:00 pm and 8:00 am.
1493239|NCT03019133|Device|Sound masking|Subjects will wear wear headphones playing relaxing music between the hours of 8:00 pm and 8:00 am.
1493240|NCT03019120|Drug|Vitamin D|"Subjects will undergo a cognitive evaluation using the Montreal Cognitive Assessment (MoCA) screening test and the Neurotrax computerized cognitive assessment battery.
Subjects will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months.
Levels of serum calcium will be repeated monthly (end of month 1, 2, 3).
Subjects will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.
At 3-month follow-up subjects will be asked to complete the Neurotrax computerized cognitive assessment battery."
1493241|NCT03019094|Device|The RENOVA tibial nerve stimulation system|Study participants will be implanted with the RENOVA tibial nerve stimulation system
1493242|NCT03019081|Drug|Isoproterenol|The goal of this experiment is to use isoproterenol in the context of inhibitory fear learning to reduce eating-related anxiety in AN, and to explore whether these changes are related to interoceptive awareness and autonomic reactivity.
1493243|NCT03019081|Other|placebo|placebo
1493245|NCT03019042|Dietary Supplement|Hou Gu Mi Xi|Hou Gu Mi Xi is a dietary therapy form of Shen Ling Bai Zhu San, of which removes atractylodes and platycodon grandiflorum, adds perilla leaf for adapting a dietary therapy.
1493246|NCT03019042|Other|placebo|The placebo has same appearance, taste and smell as Hou Gu Mi Xi.
1493247|NCT03019029|Other|18-F Florbetapir PET/MR scan|18-F Florbetapir PET/MR scan, PET/MR on a GE SIGNA PET/MR scanner
1493249|NCT03019003|Drug|Azacitidine|Demethylating agent
1493250|NCT03019003|Drug|Durvalumab|anti-PD-L1
1493251|NCT03019003|Drug|Tremelimumab|anti-CTLA-4
1493252|NCT03018990|Other|Ethanol|1 milliliter per kilogram body weight adjusted for elevated body mass index
1493253|NCT03018977|Other|The sedative weaning protocol group|After physician decide to wean sedative or analgesic drugs. We divided to 2 groups including high risk group and low risk group. The sedative weaning protocol were used in these patients which rely on the high risk or low risk group.
1493254|NCT03018977|Other|The usual group|After physician decide to wean sedative or analgesic drugs. The sedative/analgesic drugs were weaned depend on physician
1949112|NCT00248586|Behavioral|Standard CBT (S-CBT)|Standard CBT (S-CBT) is a skills-based training program delivered to patients in 10 weekly, 1-hour sessions.
1493257|NCT03018951|Other|Tool Development meeting|Consenting participants will be invited to attend up to four meetings concerning the design of the specialist tool to assess frailty in older adults with a diagnosis of functional mental illness. The meetings will be small with up to three participants and the Chief Investigator present. The Chief Investigator will present the group with plans and ideas for the proposed assessment tool and facilitate discussions relating to these ideas. Participants will be encouraged to share their opinions and any ideas they may have. The chief investigator will take written meeting minutes during each session, which will be checked and agreed on by all meeting attendees. Each meeting will last no more than 90 minutes.
1493258|NCT03018951|Other|Pilot Test 1 assessment session|Consenting participants will engage in a one off assessment session where the newly devised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. Participants will be asked a series of verbal questions related to frailty indicators and asked to engage in basic observational tests of walking speed and both static and dynamic balance. Qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the tool via a questionnaire that includes both Likert scales and open ended questions. To assess the comprehensibility of the tool's questions each participant will also be asked to rephrase a subset of the tools questions. The duration of the assessment session will be 90 minutes maximum.
1493259|NCT03018951|Other|Pilot Test 2 assessment session|Consenting participants will engage in a one off assessment session where the revised specialist tool to assess frailty in older adults with a diagnosis of functional mental illness will be administered. The administration of the tool will follow the same process as in pilot test 1. Participants will then be asked to complete a further self-rated frailty assessment tool: the Tilburg Frailty Indicator. Again, following the administration of the tools, qualitative data will be gathered from the participant to establish the comprehensibility, relevance, acceptability and feasibility of the revised tool as per the methods in pilot test 1. The tool will be scored by a study researcher and the study's chief investigator at the same time to assess inter-rater reliability. The duration of the assessment session will be 90 minutes maximum.
1493260|NCT03018938|Drug|Insulin Analog Mid Mixture|Administered SC
1493261|NCT03018938|Drug|Basal Insulin Analog|Administered SC
1493262|NCT03018925|Drug|Golimumab|
1493263|NCT03018912|Other|Sleep VS|"During check in patients are instructed to complete the Sleep VS survey packet only. The Sleep VS survey packet will take approximately 4 minutes to complete. The packet includes the subjective Sleep VS and additional sleep questionnaires, such as ESS, FOSQ-10, ISI, and sleep-wake pattern questions.
The subjective Sleep VS is composed of the following 2 questions:
How many days a week are you satisfied with your sleep?
How many days a week is sleepiness a problem?"
1493264|NCT03018899|Procedure|paravertebral block|Ultrasound guided two-segment paravertebral block
1493494|NCT03017313|Drug|LHRH analogues|3-or 6-month formulations
1493266|NCT03018886|Other|GHRH plus arginine test|One ug/kg GHRH [GHRH(1-29), GEREF Serono, Italy] was administered as an iv bolus at time 0 min, followed by arginine (L-arginine monohydrochloride, Braun, Melsungen, Germany) 0.5 g/kg (max 30g9 over 30 min. Blood samples were drawn at -15,0,15,30,45,60,75,90 min.
1493267|NCT03018873|Other|remote ischemic preconditioning （RIPC）|once RIPC: three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
1493268|NCT03018860|Procedure|"Moderate management"|"After randomization, women allocated to the intervention group, i.e. moderate pushing, are encouraged to push only 2 times per contractions, to respect contractions without pushing and there is no limit of pushing duration."
1493269|NCT03018860|Procedure|"Intensive management"|This group corresponds to usual obstetrical management of active second stage in France. In France, national guidelines recommend to limit maternal expulsive efforts to 30 minutes (grade C). Thus, physicians (midwives and obstetricians) encourage usually women to push 3 times per contractions and to push on every contraction in order to deliver into a 30 minutes timing.
1493270|NCT03018847|Device|COPD Co-Pilot|The COPD Co-Pilot is a system that guides a patient through a software application (web or mobile app) to collect, track, and trend daily symptoms related to Chronic Obstructive Pulmonary Disease (COPD). The system is intended to be used by patients as a support tool to track COPD symptoms as part of their personal disease management plan. The COPD Co-Pilot allows health care providers to view and triage subject symptoms via the provider web-based application. Health care providers also have the ability to send responses to subjects, like medication recommendations, through preset forms in the system.
1493271|NCT03018834|Drug|ANAKINRA 100 mg/daily subcutaneously|ANAKINRA 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
1493272|NCT03018834|Drug|Placebo|PLACEBO 100 mg/daily subcutaneously once a day until hospital discharge, for a maximum of 14 days, in addition to standard care: ACE and Beta-blocker for 6 months.
1493273|NCT03018821|Drug|Standard - Yinchengao Decoction plus Ganlu Detoxification Pill|Yinchengao Decoction plus Ganlu Detoxification Pill is one Chinese Medicine Formula for the TCM syndrome: Damp-heat blocking middle jiao.
1493274|NCT03018821|Drug|Entecavir or Tenofovir|Western drug for anti-HBV such as Entecavir and Tenofovir
1493275|NCT03018821|Drug|Standard - Ge Xia Zhu Yu Decoction|Ge Xia Zhu Yu Decoction is one Chinese Medicine Formula for the TCM syndrome: internal blood stasis.
1493276|NCT03018821|Drug|Advanced - Supplemented Taohong Huazhuo Decoction|Supplemented Taohong Huazhuo Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Damp-heat blocking middle jiao.
1493277|NCT03018821|Drug|Standard - Chaihu Shugan San|Chaihu Shugan San is one Chinese Medicine Formula for the TCM syndrome: Liver depression and qi stagnation.
1493278|NCT03018821|Drug|Advanced - Soothe the liver and regulate qi Decoction|Soothe the liver and regulate qi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Liver depression and qi stagnation.
1493279|NCT03018821|Drug|Standard - Xiaoyao powder|Xiaoyao powder is one Chinese Medicine Formula for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
1493280|NCT03018821|Drug|Advanced - Supplemented Ganbi Decoction|Supplemented Ganbi Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Stagnation of liver qi and spleen deficiency.
1493281|NCT03018821|Drug|Standard - Yiguan Decoction|Yiguan Decoction is one Chinese Medicine Formula for the TCM syndrome: Yin deficiency of liver and kidney.
1493282|NCT03018821|Drug|Advanced - Supplemented Zimu Dan|Supplemented Zimu Dan is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yin deficiency of liver and kidney.
1493283|NCT03018821|Drug|Standard - Fuzilizhong Decoction plus Jinkui Shenqi Bolus|Fuzilizhong Decoction plus Jinkui Shenqi Bolus is one Chinese Medicine Formula for the TCM syndrome: Yang deficiency of spleen and kidney.
1493284|NCT03018821|Drug|Advanced - Guifu Erxian Decoction|Guifu Erxian Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: Yang deficiency of spleen and kidney.
1493285|NCT03018821|Drug|Advanced - Supplemented Ganji Decoction|Supplemented Ganji Decoction is one Chinese Medicine Formula suggested by national wide known TCM doctors who expertise in chronic hepatitis B for the TCM syndrome: internal blood stasis.
1493289|NCT03018795|Procedure|Decontamination of implant surfaces|Decontamination of implant surfaces in combination with regenerative surgery
1493290|NCT03018782|Other|Brief Pain Inventory Short Form|Brief Pain Inventory Short Form
1493291|NCT03018769|Drug|Chinese Herb|
1493292|NCT03018756|Drug|Fentanyl Citrate|100 mcg fentanyl citrate will be inhaled via nebulizer.
1493293|NCT03018756|Drug|Placebo|0.9% saline solution will be inhaled via nebulizer
1493294|NCT03018743|Drug|Dapoxetine|Patients receive dapoxetine (taken 1-3 hours before sexual intercourse) 30mg as needed. A dose escalation to 60mg will be consented after 1 month in case of low efficacy. Patients will be re-evaluated 1, 3, 6, 12, and 24 months after initiating therapy regarding the treatment status and the reasons for treatment discontinuation in the case of discontinuation. If patients missed any visits, they will be contacted by telephone or mail to collect their treatment data.
1493295|NCT03018730|Biological|PRX-102|PRX-102 1 mg/kg every 2 weeks
1493296|NCT03018717|Other|Telemonitoring Constant|telemedicine of Constant
1493297|NCT03018717|Other|Standard clinical care|The patient will self-monitor heart rate, blood pressure, weight, diuresis, and capillary glycemia (in the case of diabetes)
1493298|NCT03018704|Drug|Topiramate|anticonvulsant medication
1493299|NCT03018704|Drug|placebo|inactive medication
1493303|NCT03018665|Drug|BIAsp30|subcutaneous injection，fit dosage twice a day in three months
1493304|NCT03018665|Drug|Metformin|oral，0.85g，twice a day in three months
1493305|NCT03018652|Drug|Intravenous immunoglobulin|IVIG 0.5 g/kg, up to maximum of 80 grams will be given on the day of randomization and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
1493306|NCT03018652|Drug|Normal Saline|5 mL/kg, up to maximum of 800 mL will be given on the day of randomization (this will match the volume of 0.5g/kg of IVIG product) and then every 4 ± 1 weeks for 44 weeks (Total 48 weeks)
1493307|NCT03018639|Behavioral|Dialectical Behavior Therapy|DBT is a cognitive-behavioral treatment program that was developed to treat suicidal Patients with BPD (Linehan, 1993).
1493308|NCT03018626|Drug|Rituximab|rituximab (375 mg/m2) given intravenously (IV) on day 0
1493309|NCT03018626|Drug|Etoposide|Etoposide(50 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
1493310|NCT03018626|Drug|Doxorubicin|Doxorubicin(10 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
1493311|NCT03018626|Drug|Vincristine|Vincristine(0.4 mg/m2) given continuous intravenously (CIV) from day 1-4(96 hours)
1493312|NCT03018626|Drug|Cyclophosphamide|Cyclophosphamide(750 mg/m2)/dayg IV on days 5
1493313|NCT03018626|Drug|Prednisone|prednisone (100 mg) given orally bid on days 1 through to 5.
1493314|NCT03018626|Drug|Doxorubicin|Doxorubicin (75 mg/m2) given intravenously (IV) on day 1,
1493315|NCT03018626|Drug|Cyclophosphamide|Cyclophosphamide (1,200 mg/m2) given intravenously (IV) on day 1,
1493316|NCT03018626|Drug|Vindesine|Vindesine (2 mg/m2) given on days 1 and 5
1493317|NCT03018626|Drug|Bleomycin|Bleomycin (10 mg) given IV on days 1 and 5
1493318|NCT03018613|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for chronic functional constipation in part 1.
1493319|NCT03018613|Other|Normal Saline|Normal saline and the traditional treatments for chronic functional constipation in part 2
1493320|NCT03018600|Behavioral|diet and exercise intervention|consult nutrious doctors giving specific food and take regular exercise when under steroid therapy
1493321|NCT03018587|Device|TruSculpt|Subject(s) will receive 1 Trusculpt (Radio Frequency) Device Treatment
1493322|NCT03018561|Other|Exercise and Cognitive testing|Maximal cardiopulmonary test Rest cognitive testing
1493323|NCT03018548|Other|blood draw|subjects will have blood drawn done. This blood will then be exposed to blasting with CO2 cartridge
1493324|NCT03018535|Drug|Rituximab|Rituximab,1 g IV, day 1 and day 15
1493325|NCT03018535|Drug|Methylprednisolone|Methylprednisolone 1 g IV daily for 3 doses, then oral methylprednisolone (0.4 mg/kg/day) or oral prednisone (0.5mg/kg/day) for 27 days during Month 1, 3, 5.
1493326|NCT03018535|Drug|Cyclophosphamide|Month 2, 4 and 6: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days
1493327|NCT03018522|Other|Postoperative cognitive dysfunction|Neuropsychological tests of all patients will conduct on the one day prior to surgery, the first day after surgery, and the 30 th day after surgery
1493328|NCT03018509|Drug|JTE-451|Active drug tablets containing JTE-451
1493329|NCT03018509|Drug|Placebo|Placebo tablets identical in appearance to the active drug tablets
1493330|NCT03018496|Dietary Supplement|Beta-Hydroxy-Beta-Methylbutyrate|
1493331|NCT03018496|Other|Placebo|
1493332|NCT03018483|Device|Variable PSV|"Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.
In patients ventilated with variable PSV, the pressure support variability is as high as possible (up to 100%), while not exceeding the maximal inspiratory pressure determined by the treating physician."
1493333|NCT03018483|Device|Conventional PSV|Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O. The adjustment of pressure support until extubation follows these rules for both non-variable and variable PSV groups: pressure support is gradually adjusted in decrements (or increments) of 0 to 5 cmH2O. PEEP is decreased in steps of 0 to 5 cmH2O; PEEP and FiO2 are adjusted to achieve a SaO2 ≥92%, with a PEEP ≥5 cmH2O.
1493334|NCT03018483|Device|Automated PSV|Pressure support is to a targeted mean tidal volume of 6 to 8 ml/kg; the maximal inspiratory pressure ≤40 cmH2O; the flow trigger is set at 2 l/min; inspiratory cycling-off at 25% of peak flow; PEEP and FiO2 for oxygen saturation SaO2 ≥92%, with PEEP ≥5 cmH2O.Smart CareTM as total automated procedure will be used.
1493335|NCT03018470|Other|Analysis of data from NIV built-in software|Analysis of breathing pattern using data obtained from NIV built-in software
1493336|NCT03018457|Device|ISQ|Measured by Osstell.
1493337|NCT03018444|Drug|Atorvastatin|Atorvastatin tablet
1493338|NCT03018444|Other|Placebo|Placebo tablet
1493339|NCT03018431|Other|CT Scan|patients undergoing chest CT scan at admission and repeated lung ultrasonography
1493340|NCT03018418|Radiation|Proton therapy|Primary target volume 50.4-54 CGE in 28-30 fractions; Nodal volumes 42-54 CGE in 28-30 fractions
1493341|NCT03018418|Drug|Chemotherapy|5FU 1000 mg/m2/day as 96 hour infusion days 1-5 and 29-33; Mitomycin 10mg/m2 days 1 and 29
1493342|NCT03018405|Biological|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
1493343|NCT03018392|Device|Stryker Tritanium Spinal System|open transforaminal lumbar interbody fusion (TLIF) utilizing the Stryker Tritanium cages with pedicle screw fixation according to instructions for use and package labeling for on-label indications
1493344|NCT03018366|Drug|17beta Estradiol|Participants will use a dose of transdermal estradiol 0.1 mg/day patch for 12 weeks. PAT index and sphygmoCor vascular measures and serum immune markers will be measured after 6 and 12 weeks on estrogen patches. Patches will be applied by the participant to the lower abdomen twice weekly, alternating sides.
1493345|NCT03018366|Drug|Transdermal placebo patch|Participants will use a dose of placebo patches for 12 weeks. Placebos will be applied by the participant to the lower abdomen twice weekly, alternating sides.
1493346|NCT03018366|Drug|Progesterone|After 12 weeks of transdermal estradiol patch, participants will use estrogen patch plus progesterone for 2 additional weeks.
1495772|NCT03001076|Drug|Ezetimibe|ezetimibe 10 mg tablet
1493347|NCT03018366|Drug|Placebo Pill|After 12 weeks of transdermal placebo patch, participants will use placebo patch plus placebo pill for 2 additional weeks.
1493348|NCT03018353|Drug|Patients receiving Sof/Vel (Epclusa) and Navigation services|Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
1493349|NCT03018340|Drug|Pimavanserin|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
1493350|NCT03018340|Other|Placebo|Placebo, taken as two tablets, once daily by mouth
1493351|NCT03018314|Other|Blood sample|Serum analysis
1493352|NCT03018301|Drug|Ketamine|will receive 0.25 mg/kg intravenous ketamine diluted with normal saline to 20 ml delivered over 10 minutes.
1493353|NCT03018301|Other|Normal saline|will receive intravenous 20 ml of normal saline, delivered over 10 minutes.
2001719|NCT02831166|Procedure|Transfemoral primary percutaneous coronary intervention|Transfemoral coronary angiography will be performed by the Judkins technique using 6 French diameter sheaths and pre-molded catheters for selective catheterization of left and right coronary arteries. Primary percutaneous coronary intervention with stent deployment will be indicated when a culprit lesion is identified, with high probability of angiographic success, being ideally performed immediately after coronary angiography Procedures will be performed according to recommendations of current guidelines. A vascular closure device will be used to achieve hemostasis in the transfemoral approach, preceded by systematic performance of femoral angiography and maintaining absolute bed rest for 60 minutes.
2001720|NCT02831673|Drug|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
2001721|NCT02831673|Drug|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
1949113|NCT00248586|Behavioral|Minimal contact CBT (MC-CBT)|Minimal contact CBT (MC-CBT) covers the same range of procedures featured in S-CBT but relies extensively on self study materials.
1949114|NCT00245518|Drug|Isoflavone|
1949115|NCT00245518|Drug|Placebos|
1949116|NCT00223717|Drug|Clonidine|0.1-0.2mg po. Single dose.
1949117|NCT00223717|Drug|Nitroglycerin transdermal|0.05-0.2 mg patch. 1 application. Alone or in combination with DDAVP.
1493364|NCT03018236|Drug|Alcohol N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with alcohol use disorder
1493365|NCT03018236|Drug|Alcohol Placebo|Flour pills looking exactly the same as the active compound, for subjects with alcohol use disorder
1493366|NCT03018236|Drug|Cocaine N-acetylcysteine|1200 mg of NAC per day, taken in two doses, for subjects with cocaine use disorder
1493367|NCT03018236|Drug|Cocaine Placebo|Flour pills looking exactly the same as the active compound, for subjects with cocaine use disorder
1493368|NCT03018223|Drug|Fludarabine|Myeloablative conditioning: 40 mg/m^2 daily for 4 days. Dose will be adjusted for estimated creatinine clearance. Reduced intensity conditioning: 30 mg/m^2 daily on days -6, -5, -4, -3 and -2. Dose will be adjusted for estimated creatinine clearance.
1493369|NCT03018223|Drug|Busulfan|Myeloablative conditioning: IV dosing targeted for a daily total area under curve (AUC) 5300 mmol*min/L for 4 days. Busulfan AUC will be pharmacokinetically targeted. An AUC 3500 mmol*min/l may be considered in patients over 60 years of age or with multiple comorbidities. Chemotherapy may start on day -6 or day -5 depending on the day of admission (-6 for Wednesday admission, -5 for Sunday admission).
1493370|NCT03018223|Drug|Cyclophosphamide|Reduced intensity conditioning: 14.5 mg/kg/day on days -6, -5. GVHD prophylaxis: 50 mg/kg ideal body weight (IBW) daily dose will be given on days +3 and +4 post-transplant as an IV infusion over 1-2 hours.
1493371|NCT03018223|Radiation|Total body irradiation (TBI)|Reduced intensity conditioning: 200 centigray (cGy) on day -1.
1493372|NCT03018223|Procedure|Peripheral Blood Hematopoietic Cell Transplantation (HCT)|On day 0, patients will receive a peripheral blood hematopoietic cell graft.
1493373|NCT03018223|Drug|Sirolimus (SIR)|GVHD prophylaxis: SIR will be administered as a 9 mg oral loading dose on day +5, followed by maintenance. SIR levels will be monitored and maintenance dosing adjusted as needed for a target trough level 8 to 14 ng/ml, per Moffitt BMT program standard practice. In the absence of acute GVHD, sirolimus taper will start on day +90 (+/- 10 days) and it is suggested to finish by day +180.
1493374|NCT03018223|Drug|Mycophenolate mofetil (MMF)|GVHD prophylaxis: MMF will start on day +5 at a dose of 15 mg/kg every 8 hours IV with the maximum daily dose not to exceed 3 gm. MMF will be changed to orally (PO) and discontinued on day +35 (without taper) in the absence of acute GVHD.
1493375|NCT03018223|Drug|Granulocyte-colony stimulating factor (G-CSF)|Growth factor support: G-CSF will be given beginning on day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose), until absolute granulocyte count (ANC) is > 1,000/mm^3 for three consecutive days. G-CSF may be given IV or subcutaneously.
1493376|NCT03018210|Procedure|Surgical repair of the rotator cuff|
1493377|NCT03018197|Other|Medication Education|Medication education delivered via the personal health record (MyChart) pertinent to the anticoagulation medication dabigatran. Education newsletters will be sent at 4, 6, and 10 weeks post-enrollment.
1493378|NCT03018184|Other|MRI and Muscle Dynamometer|
1493379|NCT03018171|Drug|Clonidine|Intrathecal clonidine addiction
1493380|NCT03018171|Drug|Sufentanil|Intrathecal
1493381|NCT03018158|Device|denture wear.|MR Imaging was collected with or without denture wear.
1493382|NCT03018145|Device|Wagon|
1493383|NCT03018145|Device|Standard stretcher car|
1493384|NCT03018132|Other|mental health screening, education and referral program|"I. Psychosocial assessments:
Mental health screening for: (1) depressive symptoms with the EPDS, (2) post-traumatic stress symptoms with the IES, (3) for perceived stress with the PSS (4) for anxiety with the OASIS.
Exercise, smoking & substance use, sleep and nutrition.
II. If women are above cutoff values the SCID will be conducted.
III. Education and referral information via Maternal Mental Health NOW:
All receive a brochure entitled, Speak Up When You Are Down
If above cutoffs, participants will also receive referral information; and will be scheduled for a SCID
Trained study staff will review the brochure and show the woman how to use the MMHN online referral system to input their zip code and find preferred maternal mental health practitioners.
IV. Follow up with a survey at 3 months postpartum: acceptability of screening, benefit of referral service, and outcome of this referral."
1493385|NCT03018119|Other|Survey|
2001722|NCT02831673|Drug|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
2001723|NCT02829086|Other|Relationship Enhancement|Relationship Enhancement is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
1493388|NCT03018093|Biological|C-CAR-011|CD19-targeted chimeric antigen receptor T cells
1493389|NCT03018080|Drug|Pembrolizumab|IV (in the vein) on day 1 of a 21 day cycle
1493390|NCT03018080|Drug|Paclitaxel|IV (in the vein) on days 1 and 8 of a 21 day cycle
1493391|NCT03018067|Drug|RDX227675|
1493392|NCT03018067|Drug|Placebo|
2001724|NCT02829086|Other|Family Stress and Conflict Management|Family Stress and Conflict Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
2001725|NCT02829086|Other|Financial Management|Family Management is a curriculum based program provided by a facilitator over an 8 hour skill-based education intervention.
1493395|NCT03018041|Drug|Omacor|"As described in Arms."
1493396|NCT03018041|Drug|Placebo Oral Capsule|"As described in Arms."
1493397|NCT03018028|Drug|Semaglutide|Oral administration once daily
1493398|NCT03018028|Drug|Placebo|Oral administration once daily
1493399|NCT03018028|Drug|Liraglutide|Subcutaneous (s.c., under the skin) injection once daily
1493400|NCT03018015|Drug|Ibuprofen 400 mg oral powder|
1493401|NCT03018015|Drug|Ibuprofen 400 mg film-coated tablet|
1493402|NCT03018015|Drug|Ibuprofen 400 mg soft capsule|
1493403|NCT03018002|Other|iSTAR|"Each component of the iSTAR intervention targets a specific point along the HIV continuum: confidential, onsite integrated laboratory tests during baby showers targets HIV diagnosis (b) church-based Health Advisors (CHAs) trained in motivational interviewing and quality improvement skills as promotoras target linkage, engagement and adherence by providing counseling and other support to HIV-infected women and children (c) integrated network of community and clinic case management targets reduction in loss to follow-up.
CHAs will support participants during the study period by being available to accompany them to clinic visits, review laboratory results and medications after clinic visits. They will be available to speak with them at intervals to see how they are doing either by phone or through home visits as they prefer. At each follow-up study visit, the trained CHA will review and collect data on participants' clinic visits, treatment, and laboratory results."
1493404|NCT03017989|Device|NIRF imaging|By using a fluorescence imaging device (with an adapted light source and camera), a fluorescent dye can be made visible. By injecting the fluorescent dye intravenously, the vascularization will be visible. Thereby, structures with altered vascularization are expected to 'light up' differently than the surrounding.
1493405|NCT03017963|Drug|Sodium Thiosulfate Pentahydrate|Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min
1493406|NCT03017950|Drug|CKD-330|
1493407|NCT03017950|Drug|D086|
1493408|NCT03017950|Drug|CKD-330 + D086|
1493409|NCT03017937|Device|Q-collar|capture ultrasound images at each pressure point
2001726|NCT02830347|Drug|Amoxicillin|Extraction
1493411|NCT03017911|Procedure|Piccline|
1493412|NCT03017898|Procedure|Laser Coagulation|Laser coagulation of anal fistula
2001727|NCT02830347|Procedure|Extraction|Extraction of third molars
1493417|NCT03017859|Device|High flow nasal cannula|We shall use the Airvo 2 device to administer humidified and warmed air at high flow during sleep.
1493418|NCT03017846|Drug|Cantharidin|Application of topical cantharidin
1493419|NCT03017833|Drug|Metformin|"Starting dosage of Metformin is 500 mg by mouth daily. Metformin taken by mouth daily (once to three times daily) starting on Cycle 1 Day 1 for 42 days. (Titration)
Each cycle thereafter is 28 days.
Dose Expansion: Maximum tolerated dose from Dose Escalation."
1493420|NCT03017833|Drug|TAK-228|"Starting dosage of TAK-228 is 3 mg by mouth daily starting on Cycle 1 Day 15 for 28 days.
Dose Expansion: Maximum tolerated dose from Dose Escalation."
1493421|NCT03017820|Biological|Biological Therapy|Given VSV-hIFNbeta-NIS IV
1493422|NCT03017820|Procedure|Computed Tomography|Undergo SPECT/CT
1493423|NCT03017820|Other|Laboratory Biomarker Analysis|Correlative studies
1493424|NCT03017820|Other|Pharmacological Study|Correlative studies
1493425|NCT03017820|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT/CT
1493426|NCT03017807|Biological|Recombinant Anti-EGFr Antibody|Low-dose level patients received cetuximab initial dose 100 mg/m2 and 4 weeks later 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.High-dose level patients received cetuximab initial dose 400 mg/m2 and 4 weeks later loading 400 mg/m2 and 250 mg/m2 weekly maintenance to the disease progression or unacceptable toxicity or death or withdraw informed consent.
1493427|NCT03017768|Dietary Supplement|Acute tryptophan depletion|an amino-acid mixture will be administered without tryptophan (active comparator). After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation to evaluate the effect of depleted tryptophan levels on esophageal sensitivity
1493428|NCT03017768|Dietary Supplement|Placebo|an amino-acid mixture with tryptophan (placebo mixture) will be administered. After an incubation period of 5 hours esophageal sensitivity will be assessed by multimodal stimulation
1493429|NCT03017768|Device|Multimodal stimulation probe|The multimodal esophageal probe allows to perform 4 types of stimulations in the esophagus (thermal, mechanical, electrical and chemical stimulation). These 4 modalities will be evaluated to assess esophageal sensitivity.
1493430|NCT03017755|Other|Survey for Patients Treated for Scoliosis and ther Families|Your Scoliosis Journey: A Survey for Patients Treated for Scoliosis and ther Families
1493431|NCT03017729|Drug|AbobotulinumtoxinA|This is an observational study designed to reflect real world clinical practice in the use of abobotulinumtoxinA. AbobotulinumtoxinA injected doses, frequency of injections, number of injection sites and volume injected per site are in accordance with the current USPI and physician's clinical practice.
1493433|NCT03017703|Drug|Eplerenone|
1493434|NCT03017664|Other|Peptide-based enteral formula|Peptide-based, higher protein and higher calorie enteral formula
1493435|NCT03017664|Other|Retrospective review of enteral tube feeding formula|Enteral formula tube feeding will be retrospectively reviewed
1493436|NCT03017651|Dietary Supplement|OM3-supplement 1|1g of OM3-supplement 1 will be given to subjects to look at DHA/EPA blood absorption
1493437|NCT03017651|Dietary Supplement|OM3-supplement 2|1g of OM3-supplement 2 will be given to subjects to look at DHA/EPA blood absorption
1493438|NCT03017638|Procedure|Quadratus lumborum block (QLB)|QLB will be placed in the operating room after induction of general anesthesia and prior to surgery in the supine position. The QLB will be performed under aseptic conditions with constant continuous visualization by the use of a high frequency linear ultrasound (US) probe. Identification of the injection site will be done under US visualization . At Tuohy needle will be inserted into the injection site in plane . After position verification using 0.9% NaCl injection and negative aspiration, 25 mL of 0.5% ropivacaine will be injected , in 3-5 mL aliquots, separated by repeated negative aspirations, to confirm absence of intravascular injection. Additional data will be collected: ASA physical status, demographics, intra- and post operative opiate(expressed as morphine equivalent in mg/kg) and non opiate consumption, numeric verbal analogue scores (VAS), quality of recovery score(QoR) at 1,2 and four weeks after surgery.
1493439|NCT03017625|Other|Blood is drawn|Blood analyses
1949118|NCT00223717|Drug|Dipyridamole/ Aspirin (Aggrenox)|dipyridamole 200 mg and aspirin 25 mg po. Single dose.
1493441|NCT03017599|Device|20-gauge ProCore FNB needle|"The investigators will prospectively collect data base including patients who underwent EUS-guided biopsy with the 20-gauge ProCore histology needle for the evaluation of Pancreatic solid mass.
EUS procedures will be performed under sedation with linear echoendoscopes. Once the lesion will be penetrated, the stylet will be removed, and suction will be applied for 10 to 20 seconds by using a 10-ml syringe while moving the needle to and fro. All samples will processed at the pathology departments for histological analysis with documentation."
1493442|NCT03017586|Device|Beijing Pins Medical Co., Ltd. Deep Brain Stimulator|Deep Brain Stimulation for primary dystonia subjects
1493443|NCT03017573|Procedure|Tumor biopsies / Tumor surgery|"Tumoral tissues samples must be collected at different times points :
at the time of surgery
before first cycle of adjuvant treatment (if possible)
at progression (if possible)
OR
before neoadjuvant therapy
at the time of surgery
before first cycle of adjuvant treatment (if possible)
at progression (if possible)"
1493444|NCT03017573|Procedure|Blood withdrawal|"Blood samples must be collected at different times points :
at the time of surgery
after surgery
before first cycle of adjuvant treatment
before second cycle of adjuvant treatment
at progression
OR
before neoadjuvant therapy
during neoadjuvant therapy (post cycle 1)
at the time of surgery
before first cycle of adjuvant treatment
before second cycle of adjuvant treatment
at progression"
1493445|NCT03017560|Behavioral|Computerized cognitive treatment|Participants will engage in auditory and verbal memory exercises intended to improve verbal memory functioning. The exercises are: Elephant Memory, Words where are you?, Split words, Bird Songs, Sound check, and You've got voicemail. Participants will complete the exercises 1 hour per day, 6 days per week, for 6 weeks. The program automatically adjusts difficulty level according to individual performance. The program captures and reports all relevant data to the primary investigator, including accuracy and reaction time (speed), which will be used to measure progress.
1493446|NCT03017547|Drug|IC14|
1493447|NCT03017547|Other|Placebo|
1949119|NCT00223717|Drug|Desmopressin (DDAVP)|0.2 - 0.6mg po. Single dose. Alone or in combination with nitroglycerin transdermal or nifedipine
1493449|NCT03017521|Drug|TAS-117|TAS-117 16mg, daily
1493450|NCT03017508|Drug|BHV-0223|35mg of sublingual riluzole before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for 3 hours.
1493451|NCT03017508|Drug|Placebo|a sublingual tablet identical to the active drug will be given before performing an anxiety provoking speech task. Participants will then be clinically assessed every hour for three hours.
1493452|NCT03017495|Drug|Midazolam|2 mg/mL oral solution
1493453|NCT03017495|Drug|ACT-541468|Hard gelatin capsules for oral use at a strength of 25 mg
1493454|NCT03017482|Device|Medtronic 670G|"This is an open labeled follow up of a clinical startup of a newly approved FDA closed loop insulin delivery system. It is essentially a prospective chart review of the clinically startup of a FDA closed loop system and has many elements of a quality improvement project with additional features of:
Questionnaires about the utility and impact of the device
Use of the device in children younger than the current FDA approval range"
1949120|NCT00223717|Drug|Sildenafil|25- 100 mg po. Single dose.
1949121|NCT00223717|Drug|Nifedipine|10-30 mg po. Single dose.
1949122|NCT00223717|Drug|Hydralazine|10-50 mg po. Single dose
1949123|NCT00223717|Drug|Hydrochlorothiazide|12.5-100 mg po. Single dose.
1949124|NCT00223717|Drug|Placebo|Po or patch. Single dose.
1493455|NCT03017469|Other|ARISE|"Full day (7.5 hours) workshop consisting of a resilience-focused seminar facilitated by our Employee Assistance Provider (EAP) [Shepell], an introduction to hospital based resources including EAP and health and wellness offerings, and an introduction to self-care and self-care techniques including yoga and stretches, stress relief using the senses and mindfulness
Half day (3.75 hours) workshop focusing on the following self-care techniques: mindfulness, yoga and stretching, and creative and reflective reading and writing
Peer support through social media engagement (closed Facebook group) for 3 months post-intervention participation
Five online, instructor-guided mindfulness sessions (Zoom)"
1493457|NCT03017443|Behavioral|Nutrisystem Turbo 10|Turbo10 plan provided approx. 1000 kcal/d for all subjects and included portion controlled foods/shakes for the first week (week 0). All food, except non-starchy vegetables and no-calorie beverages, was provided for the first week (week 0). Starting week 1, subjects followed the My Way plan intervention through week 16.
1493458|NCT03017443|Behavioral|Nutrisystem My Way|The Nutrisystem My Way plan provided 7 breakfasts, 6 lunches, 6 dinners, and 7 (women) or 14 (men) snacks/desserts as pre-packaged portion controlled foods every week. Subjects were instructed to prepare one lunch and one dinner on their own each week. General guidelines and recommendations were provided by Nutrisystem in order to allow subjects to self-select appropriate foods for these eating occasions that fit within the My Way plan guidelines (~50% kcal from carbohydrate, ~25% from protein, ~25% from fat). Women were assigned to 1200 calories per day and men were assigned to 1500 calories per day. Nutrisystem packaged foods accounted for approximately 60% of daily calorie target; recommended grocery food additions (which subjects purchased on their own) accounted for the balance.
1493459|NCT03017443|Behavioral|Nutrisystem DASH|The Nutrisystem DASH plan was a modification of the My Way plan designed to meet the nutrition profile of the DASH Diet, as described in NIH materials. Key nutritional targets included < 30% fat (< 7% saturated fat), < 150 mg/d of cholesterol, and < 2300 mg/d of sodium. Key dietary targets were consumption of 7-10 servings of fruit/vegetables/day, 2-3 servings of low-fat dairy/day, and 3 servings nuts/seeds/week. The Nutrisystem DASH plan included a subset of the Nutrisystem menu [7 breakfasts, 6 lunches, 6 dinners, plus snacks as portion-controlled foods every week], as well as modified guidelines for grocery additions, to achieve the nutrition targets of the DASH diet. Women consumed 1200 kcal/day and men consumed 1500 kcal/day.
1493460|NCT03017443|Behavioral|Dieting on Your Own (DIY) - DASH|The self-directed diet included publicly available information consistent with the Dietary Approaches to Stop Hypertension (DASH) diet instructing individuals to consume a reduced calorie diet to support self-directed weight loss efforts. Women were assigned to a 1200 calorie diet and men were assigned to a 1500 calorie diet. Information on the self-directed diet was provided at the beginning of the intervention (visit 2, week 0). Subjects randomized to this group did not receive additional dietary counseling throughout the study period.
1493461|NCT03017430|Drug|Pregabalin|Pregabalin 600 mg a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine).
1493462|NCT03017430|Drug|Clonidine|Clonidine 600 micrograms a day for six-seven days along with symptomatic therapy: Doxylamin 30 mg/day, Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)
1493463|NCT03017430|Drug|Doxylamin|
1493464|NCT03017430|Drug|Ketorolac, Loperamide, Metoclopramide, Nefazolin and Phenazepam (benzodiazepine)|
1493465|NCT03017417|Other|Exercise Intervention|Various exercise tests
1493466|NCT03017417|Other|standard of care|standard treatment
1493467|NCT03017404|Drug|Doxorubicin Hydrochloride Liposome Injection|
1493468|NCT03017404|Drug|Cyclophosphamide|
1493469|NCT03017404|Drug|docetaxel|
1493470|NCT03017391|Drug|metoclopramide|metoclopramide 10 mg tablets 3x daily orally or suppositories 10 mg 3x daily rectally, use until toxicity
1493471|NCT03017391|Drug|granisetron|granisetron patch 3.1mg/24 hours, use until toxicity
1493472|NCT03017391|Drug|Dexamethasone|dexamethasone 8 mg, last step in both algorithms
1493473|NCT03017391|Drug|Granisetron 2Mg Tablet|granisetron 2 mg loading dose
1493474|NCT03017378|Biological|TB/FLU-01L|TB / FLU-01L (intranasal application)
1493475|NCT03017378|Biological|TB/FLU-01L|TB/FLU-01L (sublingual application)
1493476|NCT03017365|Other|Stable Resistance Training|traditional machine-based resistance training
1493477|NCT03017365|Other|Unstable Resistance Training|free weight resistance training using unstable devices
1493478|NCT03017365|Other|Adductor/Abductor Resistance Training|machine-based adductor/abductor resistance training
1493479|NCT03017352|Drug|Exenatide|
1493480|NCT03017352|Drug|Placebos|
1493481|NCT03017339|Other|Functional Exercise|
1493482|NCT03017339|Radiation|Low Level Laser Therapy|
1493483|NCT03017339|Radiation|Placebo Low Level Laser Therapy|Low Level Laser Therapy with the device off
2001743|NCT02828306|Other|Patient Specific Implant|Implantation of Patient Specific Implant
2001744|NCT02825069|Other|Early introduction of solid foods|Early introduction of solid foods
2001745|NCT02823613|Dietary Supplement|High salt diet followed by low salt diet|High salt diet (250 mmol/day) in 5 days followed by low salt diet (60-70 mmol/day) in 5 days.
2001746|NCT02823613|Dietary Supplement|Low salt diet followed by high salt diet|Low salt diet (60-70 mmol/day) in 5 days followed by high salt diet (250 mmol/day) in 5 days.
2001747|NCT02821832|Procedure|blood draw|blood draw
1493495|NCT03017300|Device|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
1493496|NCT03017300|Device|PFLEX®|A device used to offer resisive to inspiratory muscle
1493497|NCT03017287|Device|GlucoMe App|Assessment of the the GlucoMe App
1493498|NCT03017274|Other|Abdominal ultrasound examination|All subjects undergone abdominal ultrasonography at the Outpatient of Ultrasonography of the Department of Internal Medicine at the University Hospital of Palermo, Italy.
1493499|NCT03017261|Device|TSolution One®|Total knee arthroplasty with the TSolution One® System for the preparation of the femoral and tibial cuts.
1493500|NCT03017248|Drug|Ketamine|ketamine
1493501|NCT03017248|Drug|Placebos|0.9% normal saline
1493502|NCT03017248|Drug|Morphine|Morphine
1493503|NCT03017235|Drug|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution|Supplied as ready-to-drink without further reconstitution before administration
1493504|NCT03017235|Drug|Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder|Supplied as two packets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
1493505|NCT03017222|Drug|Ondansetron|Ondansetron also has been reported as effective prophylactic and therapeutic 5-HT3 receptor antagonist for the treatment of PONV. Ramosetron has been shown to have a very strong effect for preventing PONV in previous meta-analyses, but in recent report, its clinical significance may be questioned to request for additional study.
1493506|NCT03017222|Drug|Ramosetron|Ramosetron is a newly developed selective 5-HT3 (5 hydroxytryptamine 3) receptor antagonist with longer duration of action up to 48hours and higher receptor affinity, than its previously developed congeners, including ondansetron.
2001748|NCT02821832|Radiation|PET/CT|Radiographic biomarkers using PET/CT as an early marker of treatment response and possibly as a marker for relapse at the end of treatment are being examined. The FDG-PET/CT scan will be performed at a facility local to the study site. The CT portion of the scan will be done without contrast and will be limited to the chest. Subjects will consent to receive a maximum of 4 FDG-PET/CT scans during the study baseline, 1 month, EOT, and at recurrence); however the vast majority of subjects will only receive 2-3 scans. The same scanner at each location will be used for subjects receiving subsequent scans as was used on their first scan. Subjects will be fully briefed with regard to what to expect and any precautions highlighted.
2001749|NCT02821832|Procedure|induced sputum|Sputum induction, if necessary during the study, will take place in a designated area. Hypertonic saline will be administered via the mouthpiece of a nebulizer to induce expectoration.
1949125|NCT00223717|Drug|Bosentan|62.5 -125 mg po. Single dose.
1493511|NCT03017183|Procedure|EBUS-TBNA|Endobronchial ultrasound guided transbronchial needle aspiration
1493512|NCT03017183|Procedure|Endobronchial forceps biopsy|Conventional endobronchial forceps biopsy
1493513|NCT03017170|Drug|Dried Cranberry|"Dried cranberry powder is not an extract of cranberries, but a full spectrum ingredient. It is comprised of a proprietary ratio of dried cranberry fruit, cranberry pomace, and cranberry seeds, each of which is a recognized food and/or dietary ingredient. One 500 mg capsule of dried cranberry powder consists of approximately 25 grams of cranberry fruit."
1493514|NCT03017170|Drug|Placebo Oral Capsule|Colored Maltodextrin: Proprietary mixture of: maltodextrin and food grade colors
1493515|NCT03017157|Other|Echo-cardiogram|Patients will undergo echo-cardiogram to determine improvement in their heart function and this will be compared to thyroid function
1493516|NCT03017157|Other|Blood test|Blood test to determine thyroid function
1493517|NCT03017131|Biological|Aldesleukin|Given SC
1493518|NCT03017131|Drug|Cyclophosphamide|Given IV
1493519|NCT03017131|Drug|Decitabine|Given IV
1493520|NCT03017131|Biological|Genetically Engineered NY-ESO-1-specific T Lymphocytes|Given IV and IP
1493521|NCT03017131|Other|Laboratory Biomarker Analysis|Correlative studies
1493522|NCT03017118|Dietary Supplement|Turmeric|Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.
1493523|NCT03017118|Other|Placebo|Subjects in the control group will receive a placebo 3 times per day for 6 weeks.
1493524|NCT03017105|Other|Cross-education of strength-training|Strength-training exercises using isometric contractions and resistance bands to be performed with the uninjured arm
1493525|NCT03017105|Other|Usual rehabilitation|Exercises to improve range of movement, strength and movement control (as standard for non-operatively managed proximal humerus fractures)
1493526|NCT03017092|Behavioral|Tablet-guided tobacco intervention|This intervention, as guided by a tablet computer, is a brief (20 minute) counseling intervention designed to increase motivation to quit smoking and to increase knowledge of methods of quitting.
1493527|NCT03017079|Dietary Supplement|semi-solid agent|after infusion of semi-solid agent, Intermittent enteral feeding is applied less than 60 mins
1493528|NCT03017079|Other|standard enteral feeding|Intermittent enteral feeding is applied less than 60 mins
1493529|NCT03017066|Device|Ultrasound|Ultrasound assessment of gastric volume is performed three times; just after ingestion of the breast milk, infant formula, or carbohydrate drink; 1 hour prior to the surgery; and before induction of general anesthesia.
1493530|NCT03017066|Other|General anesthesia|Scheduled operation under general anesthesia
1493531|NCT03017053|Radiation|Radiotherapy|Radiotherapy after primary surgery in the treatment of early oral cancer based on adverse pathological factor
1493532|NCT03017053|Procedure|Elective neck dissection|Elective neck dissection after primary surgery in the treatment of early oral cancer based on adverse pathological factor
1493533|NCT03017040|Device|CT scan|A CT scan of the wrist
1493534|NCT03017040|Device|Fluoroscopy Scan|A fluoroscopy scan of the wrist.
1949126|NCT00223717|Drug|Diltiazem|30-60 mg po. Single dose.
2001751|NCT02816229|Device|Insertion of endobronchial valve|One or more endobronchial one- way valves will be inserted into the appropriate lung regions
2001752|NCT02812914|Other|Low-cost gas stove|Women will be provided with a 3-burner liquid propane gas stove and one year's supply of gas
1493535|NCT03017027|Behavioral|Therapy dog visitation (TDV)|The TDV intervention consists of a one-time 10 minute TDV with the dog handler and his/her dog interacting with the patient. The therapy dog visitation program is a currently established program and each therapy dog meets obedience, temperament, and health standards required by the organization and are deemed appropriate to therapy dog visitation. For hygienic reasons, dogs are bathed before visitation and the patient is required to wash hands before and after the visit. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. The therapy dog will be leashed and controlled by the dog handler. If the participant wants the dog to be placed on the bed, a clean sheet will be placed on the bed in between the dog and patient. The TDV will be casual and not restrict the handler with conversing, which is standard practice in TDV. Tactile and visual contact with the dog will be promoted.
1493536|NCT03017027|Behavioral|non-TDV control|Participants randomized to the control condition will receive a new plush stuffed animal for the same 10-min timeframe without any structured activities. At the end of the session, a stuffed animal will be offered to the participant to keep.
1493537|NCT03017001|Dietary Supplement|CHO (carbohydrate)|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia
1493538|NCT03017001|Drug|intravenous w-3 PUFA|Patients in this groups received during the operation (intraoperative) a dose of intravenous w3-PUFA
1493539|NCT03017001|Other|CHO (carbohydrate) plus intravenous w3-PUFA|Patients in this group received a preoperative fast for solids for 6h and a drink containing water plus 12.5% maltodextrine (carbohydrate) 2h before anesthesia, plus an intravenous dose of w3-PUFA intraoperatively
1493540|NCT03016988|Drug|Bortezomib|Bortezomib(V) 1.3mg/m2, subcutaneously,day 1,4,8,11;
1493541|NCT03016988|Drug|Fludarabine|Fludarabine(F) 25mg/m2, intravenously day 1-3;
1493542|NCT03016988|Drug|Cytarabine|Cytarabine(A) 500mg/m2 for 3 days(day1-3)
1493543|NCT03016975|Device|Edwards Cardioband System|Transcatheter mitral valve repair with the Edwards Cardioband System
1493544|NCT03016962|Device|cap-assisted colonoscopy|cap-assisted colonoscopy
1493545|NCT03016962|Device|Standard colonoscopy|Standard colonoscopy
1493546|NCT03016949|Biological|IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
1493547|NCT03016949|Biological|f-IPV|Comparison of different vaccination schedules with 2 different vaccines (IPV and f-IPV) and 2 different types of administration (IM and ID)
1493548|NCT03016923|Device|FES Therapy|FES therapy will be administered over the course of 1 hour sessions that will be take place 3 times per week over 16 weeks, for a total of 48 sessions.
1493549|NCT03016897|Other|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter|Respirometer, Handgrip Meter, Skulpt Chisel, ActigraphyMeter
1493550|NCT03016884|Biological|Zostavax vaccine|After the screening, the eligible patients who provided the informed consent, will be administered the zoster vaccine.
1493551|NCT03016871|Drug|Carboplatin|Given IV
1493552|NCT03016871|Drug|Etoposide|Given IV
1493553|NCT03016871|Drug|Ifosfamide|Given IV
1493554|NCT03016871|Other|Laboratory Biomarker Analysis|Correlative studies
1493555|NCT03016871|Biological|Nivolumab|Given IV
1493556|NCT03016858|Procedure|Thoracoscopic Bullectomy Surgery|undergoing the Thoracoscopic Bullectomy Surgery
1493557|NCT03016832|Drug|Placebo drug that simulates Irbesartan tablets|Placebo drug that simulates Irbesartan tablets 150mg /qd, oral dosing
1493558|NCT03016832|Drug|irbesartan tablets|irbesartan tablets 150mg /qd, oral dosing
1493559|NCT03016832|Drug|Placebo drug that simulates HuangKui capsule|Placebo drug that simulates HuangKui capsule 2.5g/tid, oral dosing
1493560|NCT03016832|Drug|HuangKui Capsule|HuangKui Capsule 2.5g/tid, oral dosing.
1493561|NCT03016819|Drug|AL 3818|Anlotinib (AL3818) 12 mg orally administered once daily in 21-day cycles (14 days on treatment, 7 days off treatment)
1493562|NCT03016819|Drug|Dacarbazine|Dacarbazine 1000 mg/m2 as a 20-120 minute IV infusion on Day 1 of each 21-day treatment cycle
1493563|NCT03016806|Radiation|Total Body Irradiation 1200 cGy|Total Body Irradiation 1200 cGy in 8 fractions
1493564|NCT03016806|Radiation|Total Body Irradiation 200 cGy|Total Body Irradiation 200 cGy in one fraction
1493565|NCT03016806|Drug|Cyclophosphamide|50 mg/kg or 60 mg/kg
1493566|NCT03016806|Drug|Mesna|50 mg/kg or 60 mg/kg plus 10% loading dose
1493567|NCT03016806|Procedure|Cord Blood Infusion|Intravenous infusion of cord blood stem cells
1493568|NCT03016806|Drug|Busulfan|0.8 mg/kg x 16 doses
1493569|NCT03016806|Drug|Fludarabine|30 mg/m2/day x 5 or 40 mg/m2/day x 5
1493570|NCT03016806|Drug|Melphalan|140 mg/m2
1493571|NCT03016793|Drug|Puerarin|purabone (puerarin) is a bone graft used for surgical repair of bony defects.
1493572|NCT03016793|Drug|β- tricalcium phosphate|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
1493573|NCT03016793|Drug|β- tricalcium phosphate alone|β- tricalcium phosphate is a bone graft used for surgical repair of bony defects
1493574|NCT03016780|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation and the traditional treatments for ulcerative colitis in part 1.
1493575|NCT03016780|Other|Normal Saline|Normal saline and the traditional treatments for ulcerative colitisin in part 2.
1493576|NCT03016767|Procedure|Manual oral stimulation protocol|
1493577|NCT03016754|Device|Wearable Cardioverter Defibrillator|LifeVest Wearable Cardioverter Defibrillator
1493578|NCT03016741|Biological|GnRH agonist/antagonist|Given GnRH agonist/antagonist therapy
1493579|NCT03016741|Drug|Prednisone|Given by mouth
1493580|NCT03016741|Drug|Abiraterone Acetate|Given by mouth
1493581|NCT03016741|Drug|Enzalutamide|Given by mouth
1949127|NCT00223717|Drug|Eplerenone|50-100 mg po. Single dose.
1949128|NCT00223717|Drug|guanfacine|1-3 mg po. Single dose.
1949129|NCT00223717|Dietary Supplement|L-arginine|6-17 g po. Single dose
1949130|NCT00223717|Drug|captopril|25-50 mg PO. Single dose.
1949131|NCT00223717|Drug|carbidopa|25-200 mg PO. Single dose.
1949132|NCT00223717|Drug|losartan|25-200 mg PO. Single dose.
1493585|NCT03016702|Other|Cognitive stress tests during functional MRI|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function while undergoing fMRI.
1493586|NCT03016702|Other|Cognitive stress tests during gait task|Subjects will undergo progressively more complex cognitive stress tests that assess memory and executive function both in sitting and while ambulating on a force sensor mat.
1949133|NCT00223717|Drug|metoprolol tartrate|25-100 mg PO. Single dose.
1949134|NCT00223717|Drug|nebivolol hydrochloride|2.5-40 mg PO. Single dose.
1493589|NCT03016663|Procedure|Technique of Breast Lipofilling|"Identification of the donor site Procedure carried out in single sessions under GA. Abdominal site identified and outlined with a skin marker.
Fat Harvesting Berlin autologous lipotransplantation technique used according to the BEAULI protocol described by Ueberreiter et al.
Infiltration solution -Klein'solution contains 1 cc of epinephrine (1:500,000) diluted in 500 cc of 0.001% lactate ringer solution (LRS).
Fat Processing After aspiration of nonviable components of the aspirate, fat graft washed using Lactate Ringer Solution for three times. The fat processing and washing were performed by the same assistant for all patients.
Fat Transfer (Injection) Fat is injected in small amounts as the needle is gradually withdrawn. Periglandular planes and intrapectoral planes are used. Intraparenchymal injection avoided."
1493590|NCT03016650|Drug|Acetaminophen|Patients receive 100 mL of physiologic saline with 1 g IV paracetamol 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
1493591|NCT03016650|Drug|Ibuprofen|Patients receive 100 mL of physiologic saline with 800 mg IV ibuprofen 30 minutes before the end of the operation and postoperatively 6, 12 and 18 hours after PCNL
1493592|NCT03016637|Device|SharkCore (TM) FNB Exchange System|
1493593|NCT03016624|Device|OCT guided PCI|oct guided
1493594|NCT03016624|Device|Angiography guided PCI|angio guided
1493595|NCT03016611|Drug|Chewing Ticagrelor LD|180 mg Chewing Ticagrelor
1493596|NCT03016611|Drug|Chewing Prasugrel LD|60 mg Chewing Prasugrel
1493597|NCT03016598|Drug|Intranasal oxytocin|Each Veteran with CUD and receiving MMT for OUD will receive a oxytocin nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
1493598|NCT03016598|Drug|Intranasal placebo|Each Veteran with CUD and receiving MMT for OUD will receive a placebo nasal spray 40IU to be self administered twice daily over 6 weeks while in the MMT program. The veteran will come in for a total of 7 weekly visits. At baseline and during the last visit the veteran will complete at Trier Social Stress Test (TSST), and psychophysiological and biomarkers of stress will be collected. At every weekly visit a urine sample and self-reported drug use will be collected and therapy attendance will be recorded.
1493599|NCT03016585|Other|Tai Chi Training|Participants practiced, under supervised instruction, 10 forms from the classic Yang style of Tai Chi 3 times per wk for 12 weeks.The Tai Chi sessions lasted approximately 55 minutes and included a 10-minute warm up, 40 minutes of practice and exercise finalizing with a 5-minute cooldown period.
1493600|NCT03016572|Behavioral|Standard of Care|Follow-Up Calls, Questionnaires
1493601|NCT03016572|Behavioral|Crisis Intervention|Frontline Services will be administering follow up phone calls for participants of the study, recently discharged from the emergency room.
1493602|NCT03016572|Behavioral|Wraparound Services|Tapestry will be assigning case management services for participants randomized into the third arm of the study.
1493603|NCT03016559|Other|releasing muscle|At baseline, hip and knee angles were measured. The QL muscle was released. After that, the hip and knee angles were re-measured.
1493604|NCT03016546|Behavioral|BEST-maCARE|Features of the integrated BEST-maCARE intervention approach include: Integration of depression screening and linkages to HIV and mental health treatment in the context of perinatal care; A trained, clinic-based nurse (study nurse) plays a mediating role between the health system and its beneficiaries; scheduling of appointments; and, accompanying the patient as needed to initial appointments if desired, and, follow up. Low cost, mobile phone technology is used for frequent one:to:one patient contact with a health care provider (the study nurse) to facilitate continuity of care (for mental health, HIV and pregnancy across the continuum of care from prenatal through postpartum) and promotion of self-care (adherence) and retention in care with a theory-guided, empirically-supported, standardized counseling intervention that is delivered proactively by the study nurse over 18 weeks.
1493605|NCT03016546|Behavioral|Attention Control Condition|The control group will receive an intervention that is time and attention equivalent to the experimental condition. The attention effect that is likely with provision of a mobile phone in the experimental condition will be controlled by providing mobile phone to the control group participants and, they will receive time matched calls from the study nurse with content of the calls focused on infant and maternal nutritional health education per Indian National Guidelines. The phone will be used for delivery of the interventions and may also be used by study staff for purposes of establishing contact or to collect survey interview data if necessary. Time, date, and content of all phone contacts will be documented by the nurse and evaluated in the analysis.
1493606|NCT03016533|Drug|Dolutegravir film-coated tablets|Dolutegravir film-coated tablets will be provided as 10 mg, 25 mg and 50 mg tablets. It will be administered at the dose of approximately 1 mg/kilogram (kg) with maximum dose of 50 mg to participants as per their age and weight band.
1949135|NCT00223717|Drug|prazosin hydrochloride|0.5-1 mg PO. Single dose.
1949136|NCT00223717|Drug|tamsulosin hydrochloride|0.4-0.8 mg PO. Single dose.
1949137|NCT00223717|Other|Head-up tilt.|Head of the bed elevated 10 degrees (7 inch) or whole bed tilted head-up 5 degrees in reverse trendelenburg (head of the bed elevated 7 inches)
1949138|NCT00223717|Drug|aliskiren|aliskiren (Tekturna) 150-300mg po single dose
1949139|NCT00223717|Other|Local heat stress|Passive heat-stress using a commercial heating pad applied over the abdomen and part of the torso
2001753|NCT02812914|Behavioral|Peer education classes|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution
1493607|NCT03016533|Drug|Dolutegravir film-coated dispersible tablets|Dolutegravir film-coated dispersible tablets will be provided as 5 mg dispersible tablets. It will be administered at the appropriate dose as determined by results of the parent protocol to participants as per their age and weight band.
1493608|NCT03016520|Drug|DWJ1392|
1493609|NCT03016520|Drug|DWC20164|
1493610|NCT03016494|Drug|Co-administration of DWC20155 and DWC20156|
1493611|NCT03016494|Drug|DWJ1386 Tab.|
1493612|NCT03016481|Behavioral|Active Comparator: the Community Health Worker -Personalized Support for Progress|Subjects will meet with their CHW to prioritize their needs detected by the Promote psychosocial screening and identify their preferences for intervention using a secure, online card sorting tool called Optimal Sort. The subject will explain her/his rationale for each decision to the CHW, allowing them both to begin to identify goals. The prioritization survey results provide subjects a personalized package of services that map onto the four main intervention options: legal help, problem solving therapy, medical consultation, or social services.
1493613|NCT03016481|Behavioral|Care as Usual- Social Worker|Based on their assessment and the subjects' needs, brief onsite interventions are provided and consist of empowerment focused advocacy, IPV education, community referrals, and safety planning. Participants determine follow-up. This will be a short-term interaction as routinely practiced across hospital settings.
1493614|NCT03016468|Drug|Parenteral Remodulin (treprostinil) injection|Remodulin will be provided in vial strengths of 1, 2.5, 5, and 10 mg/mL. Subjects will be admitted to the hospital and IV Remodulin will be initiated within 12 hours after the last dose of selexipag. Subjects will remain under observation in the inpatient setting for at least the first 72 hours of Remodulin administration. Subjects will be transitioned to an equivalent dose of SC Remodulin at discharge.
1493615|NCT03016468|Drug|Oral Treprostinil|Oral treprostinil will be provided as 0.125-, 0.25-, 1-, or 2.5-mg extended-release tablets. Oral treprostinil will be dosed three times daily with food.
1493616|NCT03016455|Other|Presence of DSA w/ cAMR|
1493617|NCT03016455|Other|Presence of DSA w/o cAMR|
1493618|NCT03016455|Other|No DSA No cAMR|
1493619|NCT03016442|Device|Cook Double Balloon Catheter|A double- balloon catheter (Cook Cervical Ripener Balloon,Cook OB/GYN,Spencer IN) is inserted into cervical canal under direct visualisation during a sterile speculum examination.İt is placed for 12 hours
1493620|NCT03016442|Drug|Dinoprostone|10 mg of dinoprostone in a hydrogel insert is placed high in the vaginal fornix. İt is placed for 12 hours.It is a controlled release formulation which has been found to release dinoprostone in vivo at a rate of approximately 0.3 mg/hr.
1493621|NCT03016403|Behavioral|Stepped-Care Intervention|The intervention delivered evidence-based CBT and stress management across eight counseling sessions.
1493622|NCT03016403|Behavioral|Enhanced Usual Care|Consists of a list of standard mental health resources offered at the participating hospital, local community, or national non-profit organizations.
1493623|NCT03016377|Biological|iC9-CAR19 cells|Three dose levels are being evaluated: dose level -1 (1 x 10^5), dose level 1 (5 x 10^5), and dose level 2 ( 1x 10^6)
1493624|NCT03016377|Drug|AP1903|Subjects who develop grade 4 CRS or grade 2/3 CRS that is unresponsive to standard of care interventions will be given AP1903 at .4 mg/kg.
1493625|NCT03016377|Drug|Cyclophosphamide|900 mg/m^2 IV over 1 hour on day 4 of lymphodepleting chemotherapy.
1493626|NCT03016377|Drug|Fludarabine|25 mg/m^2/day IV over 30 minutes administered for 3 consecutive days.
1493627|NCT03016364|Device|APP software|A software used to by physicians to adjust the dose of Oxycodone Hydrochloride Prolonged-release Tablets for advanced patient's with cancer pain
1493628|NCT03016351|Other|Aerobic Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
1493629|NCT03016351|Other|Resistance Training|After the subject meets all inclusion and exclusion criteria, the subject will be randomized equally to either the ResistanceTraining group (RT) or Aerobic Training group (AT) for weeks 9-16 of the intervention. The participants will be supervised by physical therapists and/or exercise physiologists. Sessions will occur 3 days a week and will be 45 minutes in duration.
1493630|NCT03016338|Drug|Niraparib|
2001754|NCT02812914|Behavioral|Resource-intensive behavioral intervention approach|Women will participate in four classes on how to safely use gas stoves and methods to reduce exposure to air pollution. Additionally, peer educators will visit each home after group classes to help the woman, and key decision-makers in her family, identify top priority strategies to reduce air pollution. Using a checklist, peer educators will observe whether household members are adhering to tailored strategies at subsequent home visits, and provide ongoing support to women and their families.
2001755|NCT02809222|Other|Samples|Blood samples
1493633|NCT03016312|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg), intravenous (IV) infusion on Day 1 of each 21-day cycle.
1493634|NCT03016312|Drug|Enzalutamide|Enzalutamide capsules will be administered orally at a dose of 160 mg daily.
1493635|NCT03016299|Procedure|microfracture techniques|Drill will be performed in 3 contiguous areas. First Area by Nailing, Second by KW drilling and 3rd area drilled by regular drill obtaining a triangle with the three drilled epicenters.
1493636|NCT03016286|Other|vibration|Whole body vibration at 25Hz frequency
1493637|NCT03016273|Procedure|creation of bladder flap|Creation of the bladder flap, i.e., dissecting the urinary bladder from the lower segment of the uterus is a standard part of cesarean section (CS).
2001756|NCT02809222|Other|Quality of life questionnaire|Questionnaire to assess the quality of life of cancer patients
2001757|NCT02810119|Drug|LO2A|
2001758|NCT02810119|Drug|Placebo|
1493646|NCT03016247|Behavioral|TRUST Intervention|The TRUST intervention will be guided by Rotenberg's Framework of Interpersonal Trust 3. The TRUST group will meet with an interventionist trained in weight self-management for eight 90-minute weekly sessions. Each session will include adolescent/parent trust-building exercises (honesty, reliability, emotional connection), didactic content, experiential skills developing (nutrition label reading), behavior-change goal-setting, and problem-solving.
1493647|NCT03016247|Behavioral|Enhanced Usual Care|Single meeting with a Nutritionist for physical activity and eating counseling.
1493648|NCT03016234|Drug|Desflurane|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with pentothal sodium inj (thiopental sodium 0.53g) 5-6mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with 50% oxygen-air-4~7% desflurane inhalation and intravenous remifentanil continous infusion (effect site concentration 3-6ng/mL) during operation. Desflurane concentration is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
1493649|NCT03016234|Drug|Propofol|On arrival in the operating room, initial intraocular pressure is measured after administration of alcaine 0.5% eye drop and routine monitoring and bispectral index(BIS) are applied. Anesthesia is induced with fresofol MCT 1% inj (1% propofol) 1.5-2.5mg/kg and esmeron inj (rocuronium bromide 50mg/5ml) 1mg/kg. Then endotracheal intubation is performed, anesthesia is maintained with intravenous fresofol MCT 2% inj (2% propofol, effect site concentration 2.5-5μg/mL) and remifentanil (effect site concentration 3-6ng/mL) continous infusion. Effect site concentration of propofol is titrated to maintain BIS values within a target range 40-60 during operation. Mean arterial blood pressure, peak airway pressure, end tidal carbon dioxide, and IOP on both eyes are measured at defined intervals.
1493650|NCT03016221|Other|Axanova hot gel|Axanova hot gel is a topical product with a warming effect. It contains menthol, pine needle oil, wintergreen oil, rosemary oil, eucalyptus oil, incense oil.
1493651|NCT03016221|Other|Axanova activ gel|Axanova activ gel is a topical product with a revulsive effect. It contains menthol, pine needle oil, orange oil, lemon oil, wintergreen oil, glycosaminoglycans.
1493652|NCT03016221|Other|Perskindol Dolo Gel|Perskindol Dolo Gel is a topical product with a warming effect. It contains wintergreen oil, pine needle oil, aromatics, excipients.
1493653|NCT03016221|Other|Perskindol Classic Gel|Perskindol Classic Gel is a topical product with a revulsive effect. It contains menthol, wintergreen oil, pine needle oil, lemon oil, orange peel oil, lemon bergamot oil, rosemary oil, lavender oil, excipients.
1493654|NCT03016221|Other|Perskindol Cool Kühl-Gel|Perskindol Cool Kühl-Gel is a topical product with a cooling effect. It contains levomenthol, color E131, aromatics, excipients.
1493655|NCT03016221|Other|Dolor-X Hot Gel|Dolor-X Hot Gel is a topical product with a warming effect. It contains isopropyl alcohol, water, menthol, hyprolose, camphor, trometamol, paprika, wintergreen oil, excipients.
1493656|NCT03016221|Other|Dolor-X Classic Gel|Dolor-X Classic Gel is a revulsive product. It contains water, isopropyl alcohol, menthol, spruce, hyprolose, trometamol, wintergreen oil, excipients.
1493657|NCT03016221|Other|Dolor-X Cool Gel|Dolor-X Cool Gel is a cooling product. It contains water, isopropyl alcohol, menthol, trometamol, color E131, excipients.
1493658|NCT03016208|Drug|Misoprostol vaginal insert|
1493659|NCT03016182|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
1493660|NCT03016182|Procedure|Control|Control group witnout remote ischemic preconditioning
1493661|NCT03016169|Device|Trifecta GT (Glide Technology) Valve|Surgical aortic valve replacement with Trifecta GT Valve.
1493662|NCT03016156|Other|CRADLE|"A smartphone software application designed to detect leukocoria using a sophisticated photoluminic analysis.
The investigator or designee will perform tests with CRADLE in separate patient cohorts with known diagnosis of retinoblastoma, congenital glaucoma, or cataracts."
1493663|NCT03016156|Other|Red reflex testing|Traditional red reflex testing for leukocoria using a direct ophthalmoscope on routine eye examination. Red reflex testing via direct ophthalmoscope will be performed before dilation, using the ophthalmoscope held close to the examiner's eye, focused on the pupil, viewed at 12 to 18 inches from the patient's eyes, with the room lights dimmed, in accordance with the American Academy of Pediatrics guidelines.
1493664|NCT03016143|Biological|Allantoic Split Inactivated Seasonal flu Vaccine|Allantoic split inactivated seasonal influenza vaccine has been prepared on eggs and is made from inactivated parts of the following influenza virus strains: NIBRG-121xp (A/California/7/2009 (H1N1)v and А/PR/8/34 (H1N1)), NYMC X-217 (A/ Victoria/361/2011(H3N2) and А/PR/8/34 (H1N1)), NYMC BX-49 (B/Texas/06/2011 (Yamagata lineage) - like High Yield Reassortant (1:1:6) With B/Lee/40 NP, B/Panama/45/90 NS genes).
1493665|NCT03016143|Biological|VAXIGRIP|Vaxigrip - Seasonal Influenza, split virion, inactivated vaccine. Sanofi Pasteur Serial Number N3E681V
1493666|NCT03016130|Other|Diet|Diet Intervention: Subjects will undergo stratified randomization to account for the heterogeneous population, to receive one of the two diets: liberalized hospital diet (Diet A) or a neutropenic diet (Diet B).
1493667|NCT03016117|Procedure|Pecs II block and parasternal block|The Pecs II block will be performed under ultrasound guidance, at fourth rib level, on the axillary line, into the fascial plane between pectoralis minor muscle and serratus muscle. The parasternal block will be performed under ultrasound guidance, at the second and fourth intercostal space, between the pectoralis major muscle and the intercostal muscles, near to the external intercostal membrane.
1493668|NCT03016104|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
1493669|NCT03016104|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks
1493670|NCT03016104|Other|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
1493671|NCT03016091|Drug|Pembrolizumab|anti PD-L1
1493672|NCT03016078|Device|Mepilex Border Post-Op Ag|Device: Mepilex Border Post-Op Ag
1493673|NCT03016065|Dietary Supplement|Pea Fiber|Baked goods (2 snacks) with fiber-fortified with 5 g/snack of ground pea hulls
1493674|NCT03016065|Dietary Supplement|Control|Baked goods (2 snacks) without added fiber
1493675|NCT03016052|Behavioral|ABMT|Participants will be trained with a dot-probe task including angry-neutral faces. The task will be adapted for the oddball paradigm, such that in 80% of trials the probe will appear in place of the neutral face, and in 20% of trials in place of the angry face.
1493856|NCT03014791|Other|Blood pressure and arterial stiffness|Core Measurement
1493676|NCT03016039|Dietary Supplement|Curcumin supplementation|use of curcumin supplementation as an additive treatment to the conventional treatment
1493677|NCT03016026|Procedure|ERAS|Undergo an ERAS program
1493678|NCT03016013|Biological|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.Study investigator evaluate the patients of curative effect.The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
1493679|NCT03016013|Biological|RC18 160 mg plus MTX|
1493680|NCT03016000|Drug|Thalidomide|Thalidomide 50mg daily by mouth( increase 25mg after 2 weeks if tolerated Until 200mg/day) until disease progression or intolerance due to AEs.The dose could be reduced if patient experienced grade 2 or higher AEs. Does reductions for AEs were recommended (200 mg daily to 100 mg daily, 100 mg daily to 50 mg daily).In patients intolerant of 50mg/ day, thalidomide discontinuation was allowed.
1493681|NCT03016000|Other|Observation|Just observation
1493682|NCT03015987|Other|diode laser activated irrigation|diode laser became the most common and affordable type of laser used in endodontics for many uses , its disinfection effect is an important issue which not discussed in clinical trial before , So this study is assigned to study that
1493683|NCT03015974|Drug|Corticosteroid|
1493684|NCT03015974|Drug|Cyclophosphamide|
1493685|NCT03015974|Drug|Mycophenolate mofetil|
1493686|NCT03015974|Drug|Dipyridamole|
1493687|NCT03015974|Drug|ACE Inhibitor or Angiotensin receptor antagonist|
1493688|NCT03015961|Drug|Bupivacaine HCl|"Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%
Other Name: bupivacaine HCl"
1493689|NCT03015961|Drug|EXPAREL and bupivacaine HCl|"Drug: EXPAREL EXPAREL and bupivacaine HCl
Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%
Other Name: bupivacaine HCl"
1493690|NCT03015948|Drug|SHR4640|a single dose of SHR4640 (n=8) for each dose cohort
1493691|NCT03015948|Drug|Placebo|a single dose of placebo (n=2) for each dose cohort .
1493692|NCT03015935|Procedure|visual-assisted entry|First trocar entry will be performed with visual-assisted trocar
1493693|NCT03015935|Procedure|Veress entry|First trocar entry will be performed with Veress
1493694|NCT03015922|Drug|Lenalidomide or Pomalidomide|Patients will received either lenalidomide or pomalidomide, depending on which drug they were receiving prior to the trial (they will receive the same as before).
1493695|NCT03015922|Biological|REOLYSIN|Patients will receive Reolysin alongside either lenalidomide or pomalidomide
1493696|NCT03015909|Drug|Somatropin|
1493697|NCT03015896|Other|Laboratory Biomarker Analysis|Correlative studies
1493698|NCT03015896|Drug|Lenalidomide|Given PO
1493699|NCT03015896|Biological|Nivolumab|Given IV
1493700|NCT03015883|Radiation|Diffusing Alpha Radiation Emitters Therapy (DaRT)|An intratumoral insertion of a wire(s), loaded with Radium-224, securely fixed in the wires. The wires release by recoil into the tumor short-lived alpha-emitting atoms.
1493701|NCT03015870|Behavioral|Vocal exercise with real-time feedback|The feedback intervention will use iPads pre-installed with a PDF of vocal exercises for the full duration of the study and with an app which will provide tailored feedback regarding pitch, loudness, and duration of phonation during practice sessions.
1493702|NCT03015870|Behavioral|Vocal exercise with recording|The recording intervention will use an iPad pre-installed with the PDF of vocal exercises for the full duration of the study, but no feedback app.Participants audio record self while performing vocal exercises
1493703|NCT03015857|Drug|phenylephrine|- phenylephrine; a vasopressor drug given to prevent post spinal hypotension
1493704|NCT03015857|Drug|Norepinephrine|- norepinephrine; a vasopressor drug given to prevent post spinal hypotension
1493705|NCT03015857|Drug|Bupivacaine|intrathecal bupivacaine 10 mg will be given in both groups
1493706|NCT03015857|Drug|Fentanyl|intrathecal fentanyl 20 mcg will be given in both groups
1493707|NCT03015857|Drug|Placebo (normal saline)|
1493708|NCT03015844|Drug|131-I-meta-iodobenzylguanidine|
1493709|NCT03015831|Drug|Colchicine|Colchicine will be given to open heart surgery patients
1493710|NCT03015831|Drug|Placebo Oral Tablet|Placebo Oral Tablet will be given to open heart surgery patients according to randomization
1493711|NCT03015818|Other|18F-Fluoride PET-CT ; CT calcium scoring ; 18F-FDG PET-CT|18F-Fluoride PET-CT CT calcium scoring 18F-FDG PET-CT
1493712|NCT03015805|Behavioral|Contingency Management|"Contingency Management (CM) utilizes behavior modification & cognitive behavioral strategies to target adolescent alcohol or other drug (AOD) use. Protocol components are as follows: (a) The provider introduces CM to the family and engages them in the intervention; (b) The provider conducts Antecedent-Behavior-Consequence (ABC) assessments of the youth's AOD use with the youth and caregiver; (c) Based on the results of the ABC assessments, self-management planning and drug refusal skills training are implemented by the provider in collaboration with the caregiver; (d) Concurrently, a point and level system contract is filled in by the family, which provides rewards/privileges for negative drug and alcohol tests and disincentives (e.g., extra chores) for positive tests. Until continued abstinence is achieved, components b through d are repeated; (e) The provider collaborates with the family to develop plans for sustaining long-term abstinence. Typical duration of CM is 12-16 weeks."
1493713|NCT03015805|Behavioral|Probation as Usual|Standard services that a young person would receive while under probation supervision in the state of Oregon.
1493714|NCT03015792|Drug|Dexamethasone|Given PO
1493715|NCT03015792|Drug|Ibrutinib|Given PO
1493716|NCT03015792|Other|Laboratory Biomarker Analysis|Correlative studies
1493717|NCT03015792|Drug|Lenalidomide|Given PO
1493718|NCT03015792|Other|Pharmacological Study|Correlative studies
1493719|NCT03015792|Other|Quality-of-Life Assessment|Ancillary studies
1493720|NCT03015779|Other|cultured autologous oral mucosal epithelial cell sheet|a prospective study,Before and after self control
1493746|NCT03015610|Drug|matched placebo|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily placebo for 24 weeks
1493857|NCT03014791|Other|Cardiac output and lung function|Core Measurement
1493858|NCT03014791|Other|Heart rate variability|Core Measurement
1493721|NCT03015766|Other|auricular acupressure therapy|Auricular acupressure, is a therapeutic method in which specific acupoints on the ear are stimulated to treat various disorders of the body. This practice is based on the theory that there are specific points on the auricle which correspond to major organs or systems of the body; and therapeutic effect on the corresponding target organ or system can be exerted by manipulating auricular acupoints. Auricular acupressure applies stimulation through pressure on specific acupoints by the imbedded beads, usually Semen Vaccaria (Wang Bu Liu Xing) or stainless steel beads. This therapeutic method is non-invasive and can be self-manipulated by the recipients at times required.
1493722|NCT03015766|Other|sham auricular acupressure therapy|The intervention is the same as that in the experimental group only when the points are five Helix points (HX 5-9). These points are clearly remote from the inner ear area and have no evidence for insomnia treatment.
1493723|NCT03015753|Behavioral|Tai Chi training|The 12-week Tai Chi training will be prescribed with three 1-hour instructor-led sessions and two 1-hour self-practice sessions per week. A modified 32-short form Yang-style Tai Chi Chuan will be adopted. The instructor-led sessions will be operated by qualified Tai Chi masters. The training activity will be delivered in group. The group size is 15 to 18 persons.
1493724|NCT03015753|Other|Waiting list control group|At the end of the trial, participants in this arm will be offered Tai Chi training similar as Tai Chi training (TC) group.
1493725|NCT03015740|Drug|MGCD516|"First cohort treated at prespecified dose of 80 mg of MGCD516 by mouth every day.
All successive doses chosen by the Lo- EffTox method, and no untried dose level skipped when escalating."
1493726|NCT03015740|Drug|Nivolumab|240 mg/kg by vein every 2 weeks on Day 1 of Cycles 2 and beyond.
1493727|NCT03015727|Drug|Docetaxel|3 cycles of DOC neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2.
1493728|NCT03015727|Drug|Cisplatin|3 cycles of DDP neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 75mg/m2.
1493729|NCT03015727|Radiation|IMRT/TOMO|intensity modulated radiation therapy or tomotherapy
1493730|NCT03015727|Drug|Chemotherapy|2 cycles of cisplatin concurrent chemotherapy at day 64 and 85 with cisplatin 100mg/m2.
1493731|NCT03015714|Other|MIRT|MIRT consists of a 4-week rehabilitation program in a hospital setting, which entails four daily sessions of physical therapy for five days and one hour of physical exercise on the sixth day. On the seventh day the patient rests. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with a physical therapist. The second session includes aerobic exercises to improve balance and gait, using different devices: a stabilometric platform with visual cues, a treadmill plus and a cycloergometer. The third session consists of occupational therapy, the fourth one includes one hour of speech therapy.
1493732|NCT03015714|Other|MIRT-AT|Patients in the MIRT-AT group will undergo the land-based therapy described in MIRT plus three sessions per week (Monday, Wednesday, Friday) of aquatic therapy. On days of aquatic therapy the first session of MIRT was not provided. The aquatic therapy program included aerobic exercises and physical activities to improve balance, motor skills, coordination and joints mobility. The water sessions were divided into 3 phases: i) Warm Up Exercises, ii) Central session Training, iii) Cool-down.
1493733|NCT03015701|Drug|Mifepristone|a 19 norsteroid with anti-progesterone and anti glucocorticoid activity which competitively inhibits binding of the hormone to its receptor
1493734|NCT03015701|Other|Placebo|placebo matching mifepristone
1493735|NCT03015688|Radiation|x-ray images|
1493736|NCT03015675|Drug|ascorbic acid|20g/day, D1-3, every 2 weeks
1493737|NCT03015675|Drug|mFOLFOX6|"mFOLFOX6
Oxaliplatin 85 mg/m² d1 concurrent with
Leucovorin 400 mg/m², followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
2001759|NCT02807493|Device|Occlusal Support Device|Bite plate
2001760|NCT02807493|Other|Control|Control group
2001761|NCT02806154|Other|DEXA|The appendicular muscle mass measured by DEXA
1493741|NCT03015636|Behavioral|Adjusted CBT-i for ADHD|This is a version of CBT for insomnia (CBT-i) developed during the pilot phase of this Project. Traditional CBT-i is adjusted for use in the adult ADHD population. This behavioral intervention adresses not only traditional aspects of insomnia, but also sleep phase problems and other aspects of sleep specifically relevant to the ADHD-population. Treatment is given as 10 weekly group sessions with telephone calls from the therapist between sessions to increase adherence and adress individual patient needs.
1493742|NCT03015636|Other|Treatment as Usual|Usual care at the ADHD-clinic. This mostly entails managing pharmacological treatment for ADHD, comorbid psychiatric problems and/or sleep problems. The clinic also provides different group treatments, for instance mindfulness groups and groups for developing behavioral strategies for managing ADHD symptoms, and individual therapy.
1493743|NCT03015623|Biological|SBI-101|SBI-101 is a biologic/device combination product that combines two components: allogeneic human mesenchymal stromal cells (MSCs) and an FDA-approved plasmapheresis device. SBI-101 is administered via integration into a Continuous Renal Replacement Therapy circuit and is designed to regulate inflammation and promote repair of injured tissue.
1493744|NCT03015623|Device|Sham|The sham control is an FDA-approved plasmapheresis device, without MSCs, which is integrated into a Continuous Renal Replacement Therapy circuit.
1493745|NCT03015610|Drug|commercially available lansoprazole|these participants will receive a one-time dose of lansoprazole followed by PK analysis and then once daily lansoprazole for 24 weeks
1949145|NCT00190450|Biological|graft intracerebral of foetal neurons|graft intracerebral of foetal neurons
2001762|NCT02805972|Drug|Naloxone|4 mg / 0.1 ml
2001763|NCT02805972|Drug|Placebo|0.1 ml
2001764|NCT02804594|Drug|N-acetyl cysteine|1250 mg of N- acetyl cysteine taken three times daily
2001765|NCT02804594|Drug|Placebo|placebo taken three times daily
2001766|NCT02803918|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2001767|NCT02803918|Drug|Placebo|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2001768|NCT02803918|Drug|Basal Insulin|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2001769|NCT02803918|Drug|Metformin|"Pharmaceutical form: tablet
Route of administration: oral"
1493747|NCT03015597|Behavioral|Contingency Management|Contingency management is a behavioural intervention based on the principals of operant conditioning that is widely used in the addictions field. At the most basic level, contingency management works by providing rewards as reinforcement for desired behaviours. In the current study, the desired behaviours are either attendance at the clinic and abstinence from tobacco smoking, or just attendance at the clinic, dependent on the arm of the trial that participants are randomised to. Participants in the experimental condition will receive shopping vouchers for attending the clinic and providing a breath CO recording of <10ppm. Participants in the control condition will receive shopping vouchers for attending the clinic, regardless of their breath CO recording results.
1493748|NCT03015571|Device|Esophagus inspection in Narrow Band imaging.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection.
1493749|NCT03015571|Device|Standard High definition endoscopy.|Whole procedure will be performed in standard High definition endoscopy.
1493750|NCT03015571|Device|Esophagus inspection in Narrow Band imaging and increased care.|During the endoscope withdrawal after cardia examination NBI will be used for esophagus inspection and with increased care of cervical inlet patches detection.
1493751|NCT03015571|Device|Standard High definition endoscopy and increased care.|Whole procedure will be performed in standard High definition endoscopy with increased care of cervical inlet patches detection.
1493752|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - anodal active tDCS session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
1493753|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - active control session|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
1493754|NCT03015558|Device|transcranial direct current stimulation of opercular-insular cortex - sham control session.|transcranial direct current stimulations of opercular-insular cortex. Three sessions separated by a minimum of 2 weeks, with three different conditions: one session with anodal active tDCS, one with active control, and one with sham control.
1493755|NCT03015545|Device|control|1 single session of standing on the vibration platform, with no vibration signals delivered.
1493756|NCT03015545|Device|whole body vibration intervention|1 single session of whole body vibration therapy at 40Hz
1493761|NCT03015519|Drug|Albiglutide|30 mg of lyophilized albiglutide will be delivered from a prefilled dual chamber glass cartridge (DCC). The pen injector system will deliver 0.5 mL albiglutide as a single subcutaneous injection once a week.
1493762|NCT03015519|Drug|Placebo|Matching placebo will be delivered from a prefilled dual chamber glass cartridge DCC. The pen injector system will deliver 0.5 mL matching placebo as a single subcutaneous injection once a week.
1493763|NCT03015506|Other|Bread|
1493764|NCT03015493|Other|Neural mobilization combined with traction|Neural mobilization techniques combined with cervical traction for the cervical nerve roots
1493765|NCT03015493|Other|Traction|Traction techniques for the cervical spine
1493766|NCT03015480|Behavioral|MyFitnessPal|For an 8 week period, patients will be asked to enter dietary information into the MyFitnessPal mobile application or website. Dietitians will access this information and provide personalized motivational interview phone calls on a weekly basis. After the initial 8 weeks, patients will receive a bi-annual phone call to review progress. The need for further intensive weekly counseling will be assessed by the dietitian and provided if indicated.
1493767|NCT03015480|Other|Control|The control group will receive standard medical care and no intervention.
1493768|NCT03015467|Other|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 1
1493769|NCT03015467|Other|normal saline|normal saline and the traditional treatments for Acute Pancreatitis with gut mucosal barrier dysfunction and unbalance of gut microflora in part 2
1493770|NCT03015454|Other|Severe Sepsis Prediction|Upon receiving an InSight alert, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
1493771|NCT03015454|Other|Severe Sepsis Detection|Upon receiving information from the severe sepsis detector in the UCSF electronic health record, healthcare provider follows standard practices in assessing possible (severe) sepsis and intervening accordingly.
1493772|NCT03015441|Other|Milk product fermented by lactic bacteria or not fermented|2 pots of 125g consumed daily during 28 days
1493773|NCT03015428|Other|psychoeducation|Providing knowledge and skills development in family caregivers of people with dementia, through a structured psychoeducational programme
1493774|NCT03015415|Procedure|Elbow Open Arthrolyses|Elbow arthrolysis by posterior access
1493775|NCT03015415|Procedure|Non-surgical intervention|Rehabilitation with splinting protocols
1493776|NCT03015402|Drug|Sodium Nitrite|40 mg PO (by mouth) TID (three times each day) for 3 months
1493777|NCT03015402|Drug|Placebo Oral Capsule|Placebo capsule that is of identical size, shape, and color to experimental drug capsule PO (by mouth) TID (three times each day) for 3 months
1493778|NCT03015389|Procedure|Diagnostic Test|
1493779|NCT03015350|Drug|Sevoflurane|Measurement of blood desflurane level during one lung ventilation
1493780|NCT03015350|Drug|Desflurane|Measurement of blood desflurane level during one lung ventilation
1493781|NCT03015337|Behavioral|New physical education instructions|
1493782|NCT03015324|Drug|Hydroxychloroquine|Hydroxychloroquine
1493783|NCT03015311|Drug|Intensive BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
1493784|NCT03015311|Drug|Standard BP control|For all participants, Olmesartan Medoxomil tablets or Amlodipine Besylate tablets will be used as an initial therapy. Other drugs, including hydrochlorothiazide and β-blockers, are allowed, in order to achieve the SBP target. If the target BP level is not achieved during the Follow-up periods, adjustment of drug type and dosage will be carried out according to procedures defined in the protocol.
1493785|NCT03015298|Device|PET/MRI|The recruited patients will receive a PET/MRI examination to evaluation the stage and resectability of the cancer.
1493786|NCT03015298|Device|PET/CT|At the next day of PET/MRI examination,A PET/CT examination will be performed.
1493787|NCT03015285|Behavioral|Cognitive Behavioural Therapy|A type of talk therapy called cognitive behaviour therapy (CBT) will be delivered to both groups.
1493788|NCT03015272|Behavioral|Auditory-Motor Mapping Training|AMMT is a novel, intonation-based intervention that is accompanied by simultaneous tapping each spoken syllable on tuned drums, designed to help minimally verbal children between the ages of 5.5 and12.0 years develop and/or improve speech output. AMMT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in the method.
1493789|NCT03015272|Behavioral|Speech-Repetition Therapy|SRT is a novel, non-intonation-based intervention designed to help minimally verbal children between the ages of 5.5 and 12 years develop and/or improve speech output. SRT is administered 1-on-1 for 45 min./day, 5 days/week (25 sessions) by researchers trained in this intervention. SRT serves as a control intervention to AMMT.
1493790|NCT03015259|Drug|Budesonide/Formoterol fumarate dihydrate|Experimental: Treatment 1
1493791|NCT03015259|Drug|Symbicort|Active Comparator: Treatment 2
1493792|NCT03015259|Drug|Placebo|Placebo Comparator: Treatment 3
2001770|NCT02799953|Device|Technology-based self-management model|Participants in the technology-augmented self-monitoring model (intervention group) will use a tablet-based, interactive touch screen self-monitoring system to monitor and manage their chronic conditions. The system is designed to augment patients' abilities to assess, record, and review their health signs while providing text-, audio-, and video-based resources supporting disease self-care.
2001771|NCT02796261|Drug|Eflornithine|Eflornithine 2.8 g/m2 administered orally every 8 hours on a 2 week on, 1 week off schedule
2001772|NCT02796261|Drug|Lomustine|Lomustine 90 mg/m2 administered orally once every 6 weeks
2001773|NCT02796261|Drug|Lomustine|Lomustine 110 mg/m2 administered orally once every 6 weeks
2001774|NCT02794376|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|
2001775|NCT02794376|Behavioral|Waiting Period|
1493799|NCT03015220|Drug|Semaglutide|Oral administration once-daily
1493800|NCT03015220|Drug|Dulaglutide|Subcutaneously administration (s.c., under the skin) once-weekly
2001776|NCT02793778|Drug|CROWN|A nutritionally based therapy, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
2001777|NCT02793778|Drug|CROWN Placebo|Placebo, formulated as a powder, administered twice a day, preferable 1 hour before or more than 2 hours after meals, for up to 24 weeks
2001778|NCT02791945|Behavioral|Medical Management Counseling|Brief alcohol counseling
1493806|NCT03015168|Radiation|capecitabine and concurrent intensity modulated radiotherapy|patients with rectal cancer undergoing capecitabine and concurrent intensity modulated radiotherapy
1493807|NCT03015155|Procedure|Infusion of Cold Saline into Local Infarction Myocardium.|Infusion of Cold Saline into the Area of Ischemic Myocardium by Using Aspirated Catheter Before the Ischemia/reperfusion.
1493808|NCT03015142|Device|New image-guidance software|Patients in this group will undergo spine surgery with new image-guidance software application
1493809|NCT03015129|Drug|Durvalumab|
1493810|NCT03015129|Drug|Tremelimumab|
1493811|NCT03015116|Other|Stretching|Daily foot and ankle stretching protocol
1493812|NCT03015116|Other|Cryotherapy|Daily cryotherapy in conjunction with stretching
1493813|NCT03015116|Device|Photobiomodulation Low Power|Photobiomodulation treatment with 10W power output
1493814|NCT03015116|Device|Photobiomodulation High Power|Photobiomodulation treatment with 25W power output
1493815|NCT03015103|Device|Intimate Lubrificant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
1493816|NCT03015090|Drug|Theophylline|After oral theophylline 200mg per day for one week, blood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2
1493817|NCT03015077|Dietary Supplement|oral glutamine|L-Glutamine and maltodextrin are both nutritional supplements. In the glutamine arm: 10 g L-Glutamine and 5 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
1493818|NCT03015077|Dietary Supplement|placebo|in the placebo arm: 15 g maltodextrin. The patients take their supplements three times a day during the period: 7 days before radiotherapy to 14 days after radiotherapy.
1493819|NCT03015077|Radiation|Radiotherapy|All patients undergo radiotherapy. 5 days a week. All patients had a dental evaluation for good oral hygiene prior to computed tomography simulation for radiotherapy. Post-operative patients received planned course of adjuvant treatment of 60 to 66 Gy in 2-Gy fractions to the surgical bed. The course of radiation was initiated no more than 6 weeks after resection. Patients without operation received definitive treatment to 70 Gy in 2-Gy fractions.
1493820|NCT03015064|Other|Myocardial Infarction|Observational study of myocardial Infarction patients
1493821|NCT03015051|Drug|Oxygen|
1493822|NCT03015025|Genetic|Acenocoumarol|A blood sample was collected for CYP2C9, VKORC1, CYP4F2, APOE and 2 variants of POR genotypes.
1493854|NCT03014791|Other|Brief lifestyle/medical history questionnaire|Core Measurement
1493855|NCT03014791|Other|Anthropometric measures|Core Measurement
2001779|NCT02791945|Drug|N-acetylcysteine|Experimental supplement
2001780|NCT02791945|Drug|Placebo|Placebo comparator
2001781|NCT02792257|Drug|Dronabinol (Marinol®)|5mg -10mg daily dose
2001782|NCT02792257|Drug|Placebo|Daily dose
2001783|NCT02791893|Device|VNS device|Hand held device to use for self administration of vagus nerve stimulation.
1493823|NCT03015012|Genetic|Personalized Nutrigenomics Testing (PNT)|Participants will receive nutrition counselling from a registered dietitian based on the results of their personalized nutrigenomics testing. Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the GLB Program, but will be given personalized nutrition advice based on the results of their nutrigenomics test. Each participant will receive a monthly follow-up email or phone call reviewing their nutrition plan, until 12 months after baseline data collection.
1493824|NCT03015012|Other|Standard Nutrition Intervention (SNI)|Participants will receive standard nutrition counselling from a registered dietitian focused on strategies from the Canadian Diabetes Association's patient resource 'Just the Basics.' Nutrition counselling will focus on weight management. Individuals recruited from The East Elgin Family Health Team will complete the standard GLB Program. Each participant will receive a monthly follow-up email or phone call reviewing their nutrition plan, until 12 months after baseline data collection.
1493825|NCT03014999|Device|High frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Higher cortical representation area of first right dorsal interosseous muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold by finding the lowest stimulator output that elicit motor evoked potential at least 50μV. After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20Hz, 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28s, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
1493826|NCT03014999|Device|Low frequency rTMS (repetitive Transcranial Magnetic Stimulation)|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and at 45 degrees from the midline, will be placed over the right primary motor cortex (C3 - 10/20 System). Then, will be determined the rest motor threshold (RMT) by finding the lowest stimulator output that elicit motor evoked potential (MEP) at least 50 microvolts (μV). After determined the RMT, the coil will be positioned over the scalp (Cz - 10/20 System). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed
1493827|NCT03014999|Device|sham rTMS (repetitive Transcranial Magnetic Stimulation)|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over primary motor area Cz. After each rTMS session, presence of adverse effects will be computed.
1493828|NCT03014973|Biological|intra-prostatic concentration of sexual steroids|
1493829|NCT03014973|Procedure|Trans-rectal biopsy|
2001784|NCT02791893|Device|Inactive device|Hand held device to use for self administration of simulated vagus nerve stimulation.
1493831|NCT03014947|Drug|MSB11022|Subjects will receive single dose of 40 milligram (mg) MSB11022 as a subcutaneous injection in the lower abdomen on Day 1.
1493832|NCT03014947|Drug|US-licensed Humira|Subject will receive single dose of 40 mg US-licensed Humira as a subcutaneous injection in the lower abdomen on Day 1.
1493833|NCT03014947|Drug|EU-approved Humira|Subject will receive single dose of 40 mg EU-approved Humira as a subcutaneous injection in the lower abdomen on Day 1.
1493834|NCT03014921|Other|iron injection|Injection of a 250mL saline solution added with 500mg of iron (Ferinject)
1493835|NCT03014921|Other|saline solution injection|Injection of a 250mL saline solution
1493836|NCT03014908|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
1493837|NCT03014895|Drug|Placebo|Intravenous infusion
1493838|NCT03014895|Drug|E3112|Intravenous infusion
1493839|NCT03014882|Drug|L-Carnitine and N-acetyl cysteine|
1493840|NCT03014869|Device|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
1493841|NCT03014856|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by proton-NMR spectroscopy
1493842|NCT03014843|Drug|Naloxone|20µg/kg/h intravenous infusion after 0.4mg bolus of Naloxone and 0.6mL IM NaCl (0.9%) injection (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
1493843|NCT03014843|Drug|Methylnaltrexone Bromide|12mg/0.6mL subcutaneous injection and 1mL bolus of NaCl (0.9%) followed by intravenous infusion (this step is necessary to keep the subject blinded for the condition since nalaxone and methylnaltrexone have different administration routes)
1493844|NCT03014843|Other|Placebo|0.6 mL of NaCl 0.9% will be injected IM and 1mL bolus injection of NaCl(0.9%) will be administered IV followed by IV NaCl 0.9% infusion
1493845|NCT03014830|Drug|Alirocumab|150 mg SQ every 2 weeks
1493846|NCT03014830|Drug|Placebos|Placebo injections SQ every 2 weeks
1493847|NCT03014817|Procedure|Ultrasonically activated scalpel|Dissection with ultrasonically activated scalpel
1493848|NCT03014817|Procedure|Electrocautery|Dissection with electrocautery
1949146|NCT00169234|Biological|PCV7, Prevnar®|Randomized to receive 0.1mL, 0.5mL, 1.0mL or 2.0mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
1949147|NCT00169234|Biological|Pneumovax 23|Randomized to receive 0.5mL at the enrollment visit, followed by 0.1mL PPV23 12 months later.
2001785|NCT02791204|Device|SPECT/CT imaging following revascularization procedures|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. Heated venous blood sampling will be obtained.
1493860|NCT03014791|Other|24 hour ambulatory blood pressure monitor|Detailed Measurement (Optional for participants).
1493861|NCT03014791|Other|24 hour urine collection|Detailed Measurement (Optional for participants).
1493862|NCT03014791|Other|Echocardiograph: Left ventricular mass|Detailed Measurement (Optional for participants).
1493863|NCT03014791|Other|Large artery structure: Carotid intima-media thickness|Detailed Measurement (Optional for participants).
1493864|NCT03014791|Other|Small artery structure: Minimum forearm vascular resistance|Detailed Measurement (Optional for participants).
1493865|NCT03014791|Other|Large artery endothelial function|Flow- and salbutamol-mediated vasodilatation Detailed Measurement (Optional for participants).
1493866|NCT03014791|Other|Small artery endothelial function: Forearm blood flow|Detailed Measurement (Optional for participants).
1493867|NCT03014791|Other|Dundee step test|Systolic blood pressure response to submaximal exercise Detailed Measurement (Optional for participants).
1493868|NCT03014791|Other|Detailed haemodynamic response to submaximal exercise|Detailed Measurement (Optional for participants).
1493869|NCT03014791|Other|Cardiopulmonary fitness: Maximum oxygen consumption|Detailed Measurement (Optional for participants).
1493870|NCT03014791|Other|Haemodynamic response to mental stress|Detailed Measurement (Optional for participants).
1493871|NCT03014778|Drug|The Chlorhexidine gluconate 0.05%|Washing vagina pre- operatively with Chlorhexidine gluconate 0.05%
1493872|NCT03014778|Drug|10% Povidone iodine|Washing vagina pre- operatively with 10% Povidone iodine
1493873|NCT03014765|Other|EDOP|no intervention
1493874|NCT03014752|Other|Classical ketogenic diet|The classical ketogenic diet with a ratio of 4 to 1 (4:1), each 4 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
1493875|NCT03014752|Other|Modified Atkins diet|The modified Atkins diet with a ratio of 1 or 2 to 1 (1:1, 2:1), each 1 or 2 grams of fat to each gram of carbohydrate plus protein, will be introduced gradually.
1493876|NCT03014739|Other|Supersonic ShearWave Elastography|ShearWave Elastography (SWE) is part of routine ultrasound examination
1493877|NCT03014726|Device|Urotronic Drug Coated Balloon (DCB)|Urotronic Drug Coated Balloon (DCB) is a catheter with a tapered atraumatic tip. The distal end of the catheter has a semi-compliant inflatable balloon coated with a proprietary coating containing the drug and carriers.
1493878|NCT03014713|Drug|Dezocine|Dezocine 0.01mg/kg/h intravenous administration during the first two days after surgery.
1493879|NCT03014713|Drug|Flubiprofen|Flubiprofen 0.5mg/kg/h intravenous administration during the first two days after surgery.
1493880|NCT03014713|Drug|Dexmedetomidine|Dexmedetomidine 0.1μg/kg/h intravenous administration during the first two days after surgery.
1493881|NCT03014700|Biological|Fibrinogen Concentrate|Subject will be administered Fibrinogen Concentrate to control bleeding after open heart surgery when randomized to Fibrinogen Concentrate group
1493882|NCT03014700|Biological|Cryoprecipitate|Subject will be administered Cryoprecipitate to control bleeding after open heart surgery when randomized to Cryoprecipitate group
1493883|NCT03014687|Drug|Placebo|PO BID placebo for 7 days. Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
1493884|NCT03014687|Drug|Oral Antibiotics cefdinir or trimethoprim/sulfamethoxazole|Oral antibiotics (cefdinir [Omnicef®] 300 mg PO BID or trimethoprim/sulfamethoxazole [Bactrim DS™] PO BID for cephalosporin intolerant patients) for 7 days.Postoperative days 1 through 7: patients will administer saline spray (e.g., Ocean nasal spray) to both nostrils four times daily. Postoperative days 8 through 30: patients will begin twice daily sinus irrigation rinse (e.g., Neti-pot) until day 30. After day 30, patients will perform sinus irrigation as needed. If a patient is unable to tolerate nasal rinses, saline spray can be used as an alternative.
1493885|NCT03014674|Biological|Lyophilized mepolizumab|Mepolizumab will be provided as white, uniform, lyophilized cake in vials with unit dose strength of 100 mg/vial for reconstitution in 1.2 mL sterile water for injection (SWFI). Following reconstitution it forms a clear to opalescent, colorless to pale yellow solution for SC injection.
1493886|NCT03014674|Biological|Liquid mepolizumab|Mepolizumab will be provided as a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled autoinjector or safety syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose ethylenediaminetetraacetic acid and polysorbate 80.
1493887|NCT03014674|Device|Prefilled autoinjector|Single use, disposable autoinjector will be assembled with the prefilled syringe containing the drug product. It will enable automatic delivery of the drug product under the power of a spring mechanism following activation of the device. Start and end of injection clicks will inform the user of correct use. A plastic needle will cover shield the needle before and after injection to minimize the potential for needle stick injuries.
1493888|NCT03014674|Device|Prefilled Safety Syringe|Single use, disposable safety syringe with a retracting needle guard and locking system.
1493889|NCT03014661|Other|Quality of life under or after therapy with Pollinex quattro|To measure Quality of life using the DLQI-index in year one, year two, year three or six month after therapy with Pollinex quattro plus.
1493890|NCT03014648|Drug|Atezolizumab|Atezolizumab will be administered through an IV over 60 minutes at a dose of 1200mg on Day 1 of each 21-day cycle. If the first dose is tolerated without any infusion-related adverse events, the following doses can be administered over 30 minutes.
1493891|NCT03014635|Biological|Botulinum Toxins, Type A|Intramuscular injection
1493892|NCT03014635|Biological|Placebos|Intramuscular injection
1493893|NCT03014622|Biological|Botulinum Toxins, Type A|Intramuscular injection
1493894|NCT03014622|Biological|Placebos|Intramuscular injection
1493895|NCT03014596|Other|Assert|The Assert-method is a counselling method used to assess and systematically follow up the individual adolescents' perceived needs.
1493896|NCT03014583|Device|Precision Spectra™ system|
1493969|NCT03013985|Drug|Glargine U300|Glargine U300 is a new generation long-acting insulin.
1493970|NCT03013985|Drug|Glargine U100|Glargine U100 is a long-acting insulin.
1495773|NCT03001076|Other|Placebo|matching placebo tablet
1493897|NCT03014570|Behavioral|EIT-4-BPSD|This arm includes the four step intervention: 1. Assessment of the environment and policies; 2. Education of staff; 3. Establishing person-centered care plans; and 4. Mentoring and motivating staff. We provide the sites with a research nurse who works with an identified stakeholder group and champion within the facility and visits the settings monthly, connects by email weekly to complete the four intervention steps. The implementation process is guided by the Evidence Integration Triangle (EIT) framework. The EIT brings together evidence and key stakeholders from the facility to influence care practices. EIT includes: participatory implementation processes, provision of practical evidence-based interventions, and pragmatic measures of progress toward goals.
1493898|NCT03014570|Behavioral|Education-only Control|This arm includes step 2 only of the EIT-4-BPSD. Facilities are provided with education abouthow to provide behavioral interventions for behavioral symptoms associated with dementia. They can have the education face-to-face or via a powerpoint or webinar.
1493899|NCT03014557|Device|left atrial appendage closure device implantation|to permanently implant a WATCHMAN left atrial appendage closure device through trans-catheter approach
1493900|NCT03014544|Device|Computer- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by computer- administered cognitive test battery.
1493901|NCT03014544|Device|Examiner- administered test battery|Participants in this observational study will only undergo sequential cognitive performance evaluations by examiner- administered cognitive test battery.
1493902|NCT03014531|Other|almond|
1493903|NCT03014531|Other|high-carbohydrate control food|
1493904|NCT03014518|Other|Clinical assessments and blood samples; follow-up for 12 mos|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge and other time points throughout 12 months follow-up. Blood samples taken at baseline (admission to unit) and day of discharge.
1493905|NCT03014518|Other|Clinical assessments and blood samples; no 12mo follow-up|Kiddie-Sads Present and Lifetime Version Diagnostic Interview, Columbia-Suicide Severity Rating Scale, Suicidal Ideation Questionnaire, Children's Depression Rating Scale-Revised, Multidimensional Anxiety Scale for Children (2nd Ed), Adverse Childhood Experiences Questionnaire, Life Events Checklist-5, Pubertal Development Scale. All assessments administered at baseline, and a smaller subset of assessments administered at discharge time point (5-7 days after baseline). Blood samples taken at baseline and discharge time points (5-7 days after baseline).
1493906|NCT03014505|Biological|FMT|Fecal Microbiota Transplantation and the traditional treatments for Decompensated Cirrhosis in part 1
1493907|NCT03014505|Other|traditional treatments|traditional treatments for Decompensated Cirrhosis in part 2
1493908|NCT03014492|Device|Q Collar|Collar designed to mitigate slosh in the brain
1493911|NCT03014466|Device|Video Projector|Bed mounted video projector that plays videos of the patient's choosing prior to induction of anesthesia
1493912|NCT03014466|Device|Video Tablet|7 inch video tablet for displaying videos of the patient's choosing prior to induction of anesthesia
1493913|NCT03014440|Drug|Cannabidiol|
1493914|NCT03014427|Other|Biological Database|Biological Database
1493917|NCT03014401|Procedure|Arthroscopic debridement with stem cell transplantation|Autologous fat pad harvest and transplantation of cells after standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
1493918|NCT03014401|Procedure|Arthroscopic debridement only|standard arthroscopic treatment consisting of: partial meniscectomy, synovectomy, chondroplasty, loose body removal.
1493919|NCT03014388|Other|autogenous bone|Autogenous bone graft (gold standard). sinus lift with autogenous bone.
1493920|NCT03014388|Other|Mineralized plasmatic matrix|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM.
1493921|NCT03014375|Drug|BIA-5-453|Each subject will receive a single oral dose of 100 μCi/ 3.7 MBq 14C labeled BIA 5-453 (600 mg).
1493922|NCT03014362|Device|Neuronetics NeuroStar XPLOR magnetic stimulator - Active|
1493923|NCT03014362|Device|Neuronetics NeuroStar XPLOR magnetic stimulator - Sham|
1493924|NCT03014349|Other|Analysis of medical records|Individuals with primary open-angle glaucoma and/or glaucoma suspects, selected from the electronic records of the VER Hospital. The following variables will be observed: gender, age, race, systemic diseases, intraocular pressure, type of glaucoma, complementary exams and degree of evolution. All patients were given a complete ophthalmologic examination, including Goldmann and pneumatic tonometry.
1493925|NCT03014336|Device|memsorb|memsorb is a CO2 filter replacing current chemical CO2 absorbers
1493926|NCT03014323|Drug|Galantamine|Galantamine 4 mg twice a day for 4 weeks
1493927|NCT03014323|Drug|Placebo|Placebo 1 capsule twice a day for 4 weeks
1493928|NCT03014310|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
1493929|NCT03014310|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
1493930|NCT03014310|Biological|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
1493931|NCT03014297|Drug|everolimus|everolimus
1493932|NCT03014297|Drug|fosbretabulin|fosbretabulin
1493933|NCT03014271|Behavioral|sources of strength|sources of strength suicide prevention program
1493934|NCT03014258|Biological|NF54 P. falciparum malaria challenge|Aseptically-raised A. stephensi female mosquitoes infected with aseptically-raised P. falciparum parasites of the NF54 strain.
1493935|NCT03014232|Procedure|SLED-f with HCO dialyzer|Online SLED-f with high cut-off dialyzers were performed using the Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). Super-flux, Sureflux 150FH (Nipro Corporation, Osaka, Japan; cellulose triacetate material, pore size 78 A◦, Kuf 66.9 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
1493936|NCT03014232|Procedure|SLED-f with HF dialyzer|Online SLED-f with standard high-flux dialyzers were performed using the same Fresenius 5008S hemodiafiltration machines (Fresenius Medical Care, Bad Homburg, Germany). High-flux ELISIO 150H (Nipro Corporation, Osaka, Japan; polynephron material, pore size 50-60 A◦, Kuf 67 mL/hr/mmHg, surface area 1.5 m2) were used. Dialysis time and blood flow rate were 6 hours and 200 mL/min, respectively. The predilution reinfusion fluid rate and dialysate flow rate were 80 and 220 mL/min, respectively (the total dialysis fluid flow rate was 300 mL/min).
1493937|NCT03014219|Drug|Only 1 arm: treatment with MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell. Drug study. Single dose of 20 million cells.
1493938|NCT03014193|Device|Semiquantitative Multi-Level Pregnancy Test|
1493939|NCT03014180|Device|"In-Clinic LVAT"|Algorithm offers automatic threshold measurement of differents vectors of left ventricular stimulation.
1493940|NCT03014167|Drug|Albendazole|All eligible individuals will receive a single dose of 400 mg albendazole.
1493941|NCT03014154|Other|Training|
1493942|NCT03014141|Other|Oat bran (Oatwell 28)|11 g oat bran containing 3.1 gram oat beta-glucan
1493943|NCT03014141|Other|Maltodextrin|
1493944|NCT03014128|Other|Clinical examination and data processing of questionnaires|
1493945|NCT03014115|Dietary Supplement|combination ARA + DHA|combination ARA + DHA supplemented infant formula
1493946|NCT03014115|Dietary Supplement|DHA|DHA supplemented infant formula
1493947|NCT03014102|Drug|Recombinant Human Thrombopoietin|Recombinant human Thrombopoietin is a full length glycosylated molecule identical to endogenous Thrombopoietin.
1493950|NCT03014076|Drug|GP2 peptide + GM-CSF vaccine plus trastuzumab|HLA-A2+/A3+ subjects are given the GP2 peptide vaccine plus trastuzumab
1493951|NCT03014076|Drug|Trastuzumab|HLA-A2-/A3- patients are followed as controls receiving trastuzumab only.
1493952|NCT03014050|Device|e-Tapper TT-R1|"The e-Tapper is a non-invasive, handheld electronic device designed to apply micro current stimulation to a person's hands at specified points representing various body parts, such as the head, leg, or foot. This is one form of Bio-Electro Stimulation Therapy known as the 11-point Hand Treatment System. The current delivered is less than one milliampere."
1493953|NCT03014037|Procedure|Unilateral Bone Marrow Procurement|A total of 60cc of bone marrow will be procured under ultrasound guidance from one posterior superior iliac spine (PSIS) via 3 passes, each at least 1 cm apart, through the bone cortex. In each pass investigators will obtain 20cc of BMA with a 60cc syringes.
1493954|NCT03014037|Procedure|Bilateral Bone Marrow Procurement|30cc of bone marrow will be obtained under ultrasound guidance from each posterior superior iliac spine (PSIS) with 3 passes, at least 1 cm apart, per side (10cc per pass) also using 60cc syringes. The collection from each PSIS will be combined to yield a total of 60cc.
1493955|NCT03014024|Other|Low-Level Laser Therapy|The laser is an infrared (invisible) 60 mW 904 nm, made by Irradia Midlaser
1493956|NCT03014024|Other|Placebo Low Level Laser therapy|This i laser is not giving any irradiation, but is identical to the infrared (invisible) 60 mW 904 nm Irradia Midlaser, made by Irradia.
1493957|NCT03014011|Other|Hypoglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to lower and keep plasma blood glucose levels at 3 mmol/L for outcome measurements.
1493958|NCT03014011|Other|Euglycaemic clamp|The clamp is performed by insulin and adjustable 20% glucose infusions, with the aim to keep plasma blood glucose levels at 6 mmol/L for outcome measurements.
1493959|NCT03013998|Biological|Samalizumab|300 mg/m2, IV, on days 1, 3, and 24; followed by 300 mg/m2, IV, every 21 days for 2 years in the absence of toxicity or disease progression. Dose may be de-escalated to 150 mg/m2 or escalated to 600 mg/m2 based on occurrence of dose-limiting toxicity.
1493960|NCT03013998|Biological|BI 836858|20 mg/m2, IV, on days 9, 16, and 23 of a 28-day cycle; followed 20 by mg/m2, IV, on days 1, 8, 15 and 22 of each 28-day cycle for 2 years in the absence of toxicity or disease progression (reduced to monthly administration in event of complete response or complete response with incomplete blood count recovery). Dose may be escalated to 40 mg/m2 or de-escalated to 10 mg/m2 based on occurrence of dose-limiting toxicity.
1493961|NCT03013998|Other|Laboratory Biomarker Analysis|Molecular genomic assessment to assign patients to targeted therapy (sub-study) based on their specific subtype of acute myeloid leukemia
1493962|NCT03013998|Drug|Daunorubicin|60 mg/m2, IV, on days 4, 5, and 6 of the induction cycle
1493963|NCT03013998|Drug|Cytarabine|100 mg/m2, IV, on days 4 through 10 of the 24-day induction cycle; 1000 mg/m2, IV, on days 2, 4, and 6 of the consolidation cycle 1 and days 1, 3, and 5 of consolidation cycles 2 through 4
1493964|NCT03013998|Drug|Azacitidine (BAML-16-001-S2)|75 mg/m2, IV, on days 1 through 7 of each 28-day cycle for 2 years in the absence of toxicity or disease progression
1493965|NCT03013998|Drug|AG-221|100 mg, oral, daily until time of intolerance or disease progression. Dose may be de-escalated to 50 mg based on occurrence of dose-limiting toxicity.
1493966|NCT03013998|Drug|Azacitidine (BAML-16-001-S3)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle starting with cycle 6 and ending after 12 cycles for patients not attaining complete remission or complete remission with incomplete blood count recovery after 5 cycles of monotherapy with AG-221
1493967|NCT03013998|Drug|Entospletinib|200 mg, oral, twice daily for 5 years until time of intolerance or disease progression. Dose may be escalated to 400 mg or de-escalated to 100 mg based on occurrence of dose-limiting toxicity.
1493968|NCT03013998|Drug|Azacitidine (BAML-16-001-S4)|75 mg/m2, IV or SC, on days 1 through 7 of each 28-day cycle and continuing for 12 cycles. Treatment starts after 1 cycle of monotherapy with AG-221 for patients not attaining complete remission or complete remission with incomplete blood count recovery or after later cycles of monotherapy with AG-221 for patients with disease progression.
1493971|NCT03013985|Drug|Glulisine Insulin|Glulisine is a mealtime insulin taken either 15 minutes before or 20 minutes after a meal.
1493972|NCT03013959|Drug|Pranoprofen|it is an NSAIDs.As is reported, NSAIDs(pranoprofen) eye drops can suppress herpes simplex virus（HSV-1） reactivation and reduce inflammatory reaction in vitro and in vivo. In Clinical, there is no risk of corneal tissue melting, glaucoma, cataract by topical application of NSAIDs.
1493973|NCT03013946|Behavioral|Concomitant coaching|"The corner stones of the pro-active coaching are as follows:
Patient education:
Information on nature and severity of treatment emergent AEs
information about remedies for TEAEs
propagation and explanation of tests and treatment decisions
Patient instruction on self-care and preventive measures
Preemptive AE treatment strategies
Supervision of reported ADR severity, ADR mitigation strategies according to recommendations of the PREPARE protocol and cancer treatment modification by treating physician in close collaboration with the coach"
1493974|NCT03013933|Drug|Brentuximab Vedotin|Given IV
1493975|NCT03013933|Drug|Cyclosporine|Given PO
1493976|NCT03013933|Other|Laboratory Biomarker Analysis|Correlative studies
1493977|NCT03013933|Other|Pharmacological Study|Correlative studies
1493978|NCT03013933|Drug|Verapamil|Given PO
1493979|NCT03013907|Behavioral|UPLIFT|Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping & Relaxing Session 4: Attention & Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure & the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks
1493980|NCT03013907|Behavioral|Usual care|Subjects randomized to UC will be advised to seek help from their primary care physician (PCP) or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study
1493981|NCT03013881|Biological|UB-921|150 mg/vial
1493982|NCT03013881|Biological|Herceptin|440 mg/vial
1493983|NCT03013855|Device|FIT-SOC|Study subjects will be given a standard kit for fecal immunochemical test by their primary healthcare provider. As per standard practice, the patient will take the kit home and use the included FIT applicator to collect a stool sample from spontaneously passed stool during a regular bowel movement. The patient will then mail the stool sample to the lab in a pre-paid envelope, which is provided in the kit.
1493984|NCT03013855|Device|FIT-DRE|Study subjects will have a digital rectal exam completed by their primary care providers during the physical exam portion of a routine clinic visit. The stool collected on the examiner's finger will be applied to the FIT applicator in the standard kit, which will then be sent to the lab for processing.
1493985|NCT03013842|Device|Raydiant Oximetry Sensor System|Administration of Fetal Oximetry Probe on 36 weeks or greater pregnant women
1493986|NCT03013829|Behavioral|KPD Educational Video|Incompatible LKDs and recipients assigned to the video-based KPD education group will receive the same living donation and KPD educational materials as those in the UC group. Also, as in the UC group, they will be encouraged by the site coordinator to review the educational materials. In addition, following randomization to this group, participants will be sent an email encouraging them to watch an embedded KPD education video. This video will be professionally designed and will highlight the operational features of KPD and address the specific barriers highlighted in our formative research. The primary goal of these sessions is to increase living donation and KPD knowledge of risks and benefits and to reduce specific concerns that are based on inaccurate information. The intent is not to persuade LKDs or recipients to pursue living donation or KPD, but to ensure that they have sufficient information to make an informed choice that is consistent with their own values and preferences.
1493987|NCT03013816|Behavioral|Organ Donation Education: Testimonial Messaging|The testimonial messaging video intervention will be shown
1493988|NCT03013816|Behavioral|Organ Donation Education: Informational Messaging|The informational messaging video intervention will be shown
1493989|NCT03013816|Behavioral|Organ Donation Education: Blended Messaging|The blended messaging video intervention will be shown
1493990|NCT03013803|Dietary Supplement|Nutricomp Drink Plus Fibre|
1493991|NCT03013790|Drug|Melatonin|Patients will receive Melatonin at 2 different doses or a placebo
1949148|NCT00169286|Procedure|Telephone care management|
1493993|NCT03013764|Behavioral|activity level|subjects will undergo 10 days of low physical activity while consuming a normal protein diet
1493994|NCT03013751|Drug|Udenafil|Active drug
1493995|NCT03013738|Behavioral|Growing Pro-Social Program|GPS is a structured cognitive-behavioral group program aimed to reduce the prominence of early maladaptive schemas
1493996|NCT03013738|Other|Treatment As Usual|TAU in Portuguese prisons is primarily aimed to increase educational and professional qualifications
1493997|NCT03013725|Other|No intervention|No intervention
1493998|NCT03013712|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EpCAM antigen.
1493999|NCT03013699|Behavioral|Cruciferous and Dark Leafy Green Intervention|Participants receive individual dietary counseling from a Registered Dietitian who will focus on increasing intake of cruciferous and green leafy vegetables while addressing any disease- and treatment-related eating difficulties experienced by the participant.
1494000|NCT03013699|Behavioral|Usual Dietary Care|Participants receive standard educational materials that focus on healthy eating for cancer survivors and the opportunity to briefly discuss nutrition-related concerns with the Registered Dietitian weekly.
1494001|NCT03013686|Procedure|Interval appendectomy|Laparoscopic appendectomy
1494002|NCT03013686|Procedure|Follow-up with MRI|Abdominal MRI
1494004|NCT03013660|Other|Limited Financial Support|Subjects randomized to this arm will be contacted to be informed that they are eligible to receive a weekly financial transfer to help them spend more time with their baby at the NICU. The intervention participants will be eligible to receive this transfer every 7 days, starting on the day of enrollment.
1494005|NCT03013647|Drug|Methyl Aminolevulinate|"Patients will be treated with Daylight Photodynamic therapy, following these steps:
mild curettage of the AK lesions
application of a chemical sunscreen SPF 30
application of methyl aminolevulinate cream (Metvix R, Galderma Laboratories)
exposition to daylight, for 120 minutes
cleaning of the face"
1494006|NCT03013634|Drug|Dexmedetomidine|Dexmedetomidine infusion:loading 0.5ug/kg for 10min, then 0.5 ug/kg/h until the end of operation.
1494007|NCT03013634|Drug|Normal saline|Equal volume normal saline substitute for dexmedetomidine
1494008|NCT03013608|Procedure|Simple relocation of the nail plate in nailbed injuries in paediatric population|Repositioning the nail bed without sutures
1494009|NCT03013595|Behavioral|TRAM feedback|
1494010|NCT03013582|Biological|Amnion Tendon Wrapping|Tendon is wrapped with the allograft
1494011|NCT03013582|Procedure|Surgical Tenolysis|Surgical release of peritendinous scarred tissue
1494012|NCT03013556|Drug|Group A, TDF|TDF for 96 weeks
1494013|NCT03013556|Drug|Group B:TDF then TDF and Peginterferon alfa-2a|Subjects will be treated by TDF in the first 48 weeks, then will be treated by the combination of TDF and Peginterferon alfa-2a for another 48 weeks
1494014|NCT03013556|Drug|Group C:TDF and Peginterferon alfa-2a then TDF|Subjects will be treated by the combination of TDF and Peginterferon alfa-2a for the first 48 weeks, then will be treated by TDF for another 48 weeks.
1494015|NCT03013543|Drug|Setmelanotide|RM-493 once daily subcutaneous injection
1494016|NCT03013530|Procedure|Decision making for ICU patients' care|Study of factors involved in the decision-making for ICU patients' care. Effect of advance directives (AD).
1494017|NCT03013517|Drug|Viaskin Peanut 250µg|
1494018|NCT03013504|Drug|HD201|8/mg kg body weight in cycle 1. 6mg/kg in cycle 2-8. Patients without progression after cycle 8 may continue to receive HD201 with or without docetaxel for a total of 12 months after first treatment administration
1494019|NCT03013504|Drug|Herceptin|8/mg kg body weight in cycle 1. 6mg/kg in cycle 2 - 8. Patients without progression after cycle 8 may continue to receive Herceptin® with or without docetaxel for a total of 12 months after first treatment administration
1494020|NCT03013504|Drug|Docetaxel|75mg/m2 IV in cycle 1-4. Patients without progression after cycle 8 may continue to receive docetaxel for a total of 12 months after first treatment administration
1494021|NCT03013504|Drug|Epirubicin|75 mg/m2 IV in cycle 5-8.
1494022|NCT03013504|Drug|Cyclophosphamide|500 mg/m2 IV in cycle 5-8.
1494026|NCT03013478|Behavioral|Standard Treatment As Usual (TAU)|Treatment normally offered at this primary care clinic
1494027|NCT03013478|Behavioral|CBT4CBT program|
1494028|NCT03013465|Other|Control Diet|Participants will receive a controlled diet with 0 g/d of broccoli. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
1494029|NCT03013465|Other|Base Diet with Broccoli|Participants will receive a controlled diet with 100 g of broccoli at both breakfast and dinner daily. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
1494030|NCT03013452|Device|oPEP|Daily chest clearance (chest physiotherapy) using an oPEP (Aerobika) device.
1494031|NCT03013452|Behavioral|Autogenic drainage|Daily chest clearance (chest physiotherapy) by Autogenic Drainage method.
1494032|NCT03013439|Drug|Iron Isomaltoside|The trial is a dose escalating trial.
1494033|NCT03013426|Drug|NVX-508|Administration of NVX-508 emulsion intravenously
1494034|NCT03013413|Procedure|Shear Wave Elastography|Undergo ultrasound-based elastography imaging using the Aixplorer system
1494035|NCT03013413|Procedure|Ultrasound Elasticity Imaging|Undergo ultrasound-based elastography imaging using the Aixplorer system
1494036|NCT03013413|Procedure|Ultrasound-Guided Prostate Biopsy|Undergo standard of care ultrasound-guided prostate biopsy
1494037|NCT03013400|Drug|Ebselen|Ebselen is an opaque capsule containing 200 mg of ebselen is a selenium-based GPx mimic and IMPase inhibitor.
1494038|NCT03013400|Drug|Placebo oral capsule|Placebo is identical in appearance to the ebselen capsules
1494039|NCT03013387|Radiation|90Y-DOTA-3-tyr-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used l as a treatment for both children and adults with neuroendocrine and other somatostatin receptor positive tumors.
1494040|NCT03013387|Procedure|Positron Emission Tomography (PET) whole body scan|68Ga-DOTATOC is a radiopharmaceutical used in PET scans to identify tumors as it can adhere to Somatostatin Receptors.
1494041|NCT03013387|Drug|Amino Acids|This is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
1494042|NCT03013361|Drug|Bupivacaine|Post operative pain control
1494043|NCT03013361|Drug|Ropivacaine|Post operative pain control
1494044|NCT03013361|Other|Normal Saline|Acts as comparator
1494045|NCT03013348|Device|Brain Sentinel's sEMG Post-processing algorithm|Brain Sentinel has developed a post processing method that identifies sEMG signals (recorded from the biceps brachii or as muscle artifact in electroencephalography [EEG] recordings) that are pathognomonic for PNES activity.
1494046|NCT03013335|Drug|Nivolumab|"The dose and schedule of nivolumab in this study will be 3 mg/kg every 2 weeks. Infusion of nivolumab will be performed in 30 minutes (± 5 minutes).
Nivolumab will be administered every 2 weeks until death, disease progression, unacceptable toxicity or withdrawal of the informed consent"
1494047|NCT03013322|Drug|Physostigmine|
1494048|NCT03013322|Drug|Isotonic Saline|
1494049|NCT03013309|Behavioral|Family Check-Up 4 Health|A parent-training intervention to improve child health and manage obesity
1494050|NCT03013309|Other|Treatment as usual|Treatment as usual
1494055|NCT03013283|Other|self questionnaire|"Interface side effects and degree of satisfaction of the patients
Technician evaluation and device measures."
1494110|NCT03012893|Device|Ultrasound sagittal scan|Convex transducer will be placed at patient's neck using paramedian sagittal scan and pointing toward the chest apex aiming to identify the first rib. Then move the transducer medially to identify the transverse process along with identify C7 transverse process will appear on the image as a hyperechoic shadow without continue to the rib laterally. Place the C7 spinous process on the midpoint of the probe and the spinous process correspondence to the midline will be marked as C7.
1494119|NCT03012867|Other|Diben, Fresenius Kabi|Patients receive Diben continously for 7 days
1494056|NCT03013270|Other|Aerobic-Resistance-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1 Repetition Maximum (1RM) for quads training and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets) for 10 min, combined also with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 20 min (Aerobic (30min) + Resistance (10min) + Inspiratory (20min) = 60 min)
1494057|NCT03013270|Other|Aerobic-Resistance|"Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with resistance training at an intensity of 50% of 1RM for quads training, pectoralis m, serratus anterior m, and latissimus dorsi m and upper limb exercises (elbow flex/shoulder flex/abd) using dumbbells (1-2 kg) (12-15 reps/3sets).
(Aerobic (30min) + Resistance (30min) = 60 min)"
1494058|NCT03013270|Other|Aerobic-Inspiratory|Patients will be submitted to a 12 week, 3 times/week, continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with inspiratory muscle training with a flow-resistive loading system at an intensity of 60% of maximal inspiratory pressure/sustained maximal inspiratory pressure (PImax/SPImax) for 30min (Aerobic (30min) + Inspiratory (30min) = 60 min)
1494059|NCT03013270|Other|Aerobic Training|Patients will be submitted to a 12 week, 3 times/week continuous aerobic (e.g. bike) training programme at an intensity of 60-80% max HR (or peakVO2) for 30 min combined with callisthenics or treadmill (at the same intensity) for 30 min (Aerobic training = 60 min)
1494060|NCT03013257|Device|Echopulse|Replacing HIFU for the Graves' disease patients who traditionally have RAI to remission
1494061|NCT03013244|Behavioral|The Body Project: More Than Muscles|Participants complete a variety of activities designed to counter internalization of the lean, muscular body ideal for men.
1494062|NCT03013231|Behavioral|Brief Resilience Scale|6 months post-op, patients will complete the BRS survey as a method of evaluating resilience.
1494066|NCT03013205|Procedure|Intraarticular triamcinolone injection|triamcinolone 10mg/mL
1494067|NCT03013205|Procedure|Intraarticular Xylocaine injection|Xylocaine 1% 4ml
1494068|NCT03013205|Procedure|Coracohumeral ligament triamcinolone injection|triamcinolone 10mg/mL
1494069|NCT03013205|Procedure|Physiotherapy|
1949149|NCT00169286|Procedure|peer-led chronic disease self-management workshop|
1494071|NCT03013166|Other|Corticosteroid medication|Patients will be grouped into Cohort 1 (IR hydrocortisone), cohort 2 (IR prednisolone), cohort 3 (MR hydrocortisone), or cohort 4 (IR to MR hydrocortisone) depending on which oral corticosteroid medications were received during the observation period.
1494072|NCT03013153|Procedure|Low ligation with apical lymph node dissection|Low ligation with apical lymph node dissection (LAND). Left colic artery (LCA) is identified according to the CT 3D-reconstruction, tie the sigmoid artery and superior rectal artery, preserved LCA while low ligation of the inferior mesenteric artery is performed. Lymphadenectomy to the apical lymph nodes (No.253)is performed around the IMA until 2 cm from the aorta.
1494073|NCT03013153|Procedure|High ligation|High ligation (HL) Open the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The IMA is ligated and divided at 2 cm from its origin. The inferior mesenteric vein (IMV) is divided and ligated below the pancreatic margin.
1494074|NCT03013140|Drug|Fluid therapy|"Goal directed Fluid therapy: Within 30 minutes before spinal anaesthesia, repeat Ringer's Injection 3ml/kg within 3 minutes with 1-min gap until ΔSV<5%"
1494075|NCT03013140|Procedure|Spinal anaesthesia|Inject marcaine and fentanyl to CSF for anaesthesia
1494076|NCT03013127|Drug|Pembrolizumab|Pembrolizumab is a humanized antibody used in cancer immunotherapy.
1494077|NCT03013114|Drug|Bortezomib|Bortezomib was given by intravenous bolus injection at a dose of 1.3 mg/m2 on days 1, 4, 8 and 11, repeated every 21 days. It will be given four cycles.
1494078|NCT03013101|Biological|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
1494079|NCT03013088|Device|CTO Crossing|With confirmation that the target vessel is completely occluded by the target CTO lesion, the operator shall initially attempt crossing the proximal end of the target CTO lesion by advancing ShockWireTM device ≥ 1cm. The SoundBite Crossing device can be activated as needed to perform the procedure and may be used for the entire length of the lesion(s).
1494080|NCT03013075|Procedure|Spinal anesthesia with Bupivacaine heavy and Morphine|Spinal anesthesia with Bupivacaine heavy 40 mg and Morphine 250 micro grams will be given to patient in addition to the routine general anesthesia before the start of surgery
1494081|NCT03013075|Drug|Bupivacaine heavy and Morphine|
1494082|NCT03013075|Drug|General Anesthetics|
1494083|NCT03013049|Procedure|Non cultured epidermal cell suspension|Non cultured epidermal cell suspension Split thickness skin specimen will be transferred under aseptic conditions to a container with normal salineand transferred to laboratory. There, the skin graft will be transferred to Trypsin-EDTA solution (0.25% trypsin and 0.02% EDTA) in a Petri dish and incubated overnight at 4°C in 5% CO2 to separate the epidermis from the dermis.Afterwards, the Trypsin-EDTA solution will be removed and PBS will be added and pipetted well so as to separate the cells from the tissue.The suspension will be centrifuged at 1000 rpm for 5 minutes.The supernatant will then be discarded and Phosphate buffer saline is added to make suspension of non-cultured epidermal cells.
1494111|NCT03012893|Device|Ultrasound transverse scan|Linear transducer will be placed at patient's lateral neck using transverse scan. The unique characteristic of sonography of transvers process of C6 and C7 will be used to identify the transverse process of C6 and C7. C6 transverse process has a very prominence anterior tubercle (known as Chassaignac tubercle). While anterior tubercle of C7 is absent. After identifying the C7 transverse process, simultaneously the color Doppler mode will be activated to identify the vertebral artery for double confirmation.
1494084|NCT03013049|Procedure|Non cultured dermal cell suspension|Non-cultured Dermal Cell Suspension Skin punch will be collected in phosphate buffer saline (PBS) with antibiotics (penicillin and streptomycin). The epidermis will be cut off from dermis carefully using a surgical blade (Epidermal part will be used for the epidermal cell suspension). Dermis will be then cut into small pieces and incubated in collagenase (1mg/ml) overnight at room temperature. Next day content will be diluted with PBS and centrifuged at 1000rpm for 5 minutes. Pellet will be washed three times with PBS to remove collagenase activity. Phosphate buffer saline is added to make suspension of non-cultured dermal cells and will be used for the autologous transplantation.
1494085|NCT03013036|Device|Ultrasonography|
1494086|NCT03013036|Drug|Sevoflurane|
1494087|NCT03013036|Drug|intravenous midazolam|
1494088|NCT03013036|Drug|Propofol|
1494089|NCT03013036|Drug|fentanyl and rocuronium|
1494090|NCT03013023|Behavioral|BS|NNS, FT, positional support, and oral sucrose feeding
1494091|NCT03013023|Behavioral|Routine care|Routine NICU care
1494092|NCT03013023|Behavioral|PITP|Parents will learn to regulate infant responses while implementing caregiving activities.
1494093|NCT03013023|Behavioral|BS+PITP|Parents will learn to regulate infant responses while implementing caregiving activities. Supportive interventions, i.e., NNS, FT, positional support, and oral sucrose feeding, will be provided while infants are undergoing painful procedures.
1494094|NCT03013010|Drug|Tegafur-Gimeracil-Oteracil Potassium|The dose of S-1 is according to body-surface area (BSA): patients with a BSA of less than 1.25 m2 received 80 mg daily; those with a BSA of 1.25 m2 or more but less than 1.5 m2 received 100 mg daily; and those with a BSA of 1.5 m2 or more received 120 mg daily. oxaliplatin 130mg/m2, intravenously, on day 1.
1494095|NCT03013010|Radiation|Chemoradiotherapy|"Chemotherapy: S-1 40-60mg/m2 orally, oral tablet twice daily, days 1-5 of each week of radiotherapy.
Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
1494096|NCT03013010|Procedure|Gastric resection|A standard D2 gastrectomy was recommended. The type of gastrectomy performed depended on the location and extent of the primary lesion. For middle third tumors, the gastric margin was recommended to be more than 5 cm, and a total gastrectomy was performed. For lower third tumors, a 2 cm duodenal margin was recommended and a subtotal or total gastrectomy was considered. For upper third tumors, a 3 cm esophageal margin was recommended and a total gastrectomy or esophagogastrectomy was performed. Billroth I or Roux-en-y gastrojejunostomy was performed for distal gastrectomy patients, Roux-en-y esophagojejunostomy was performed for total gastrectomy patients.
1494097|NCT03013010|Drug|Oxaliplatin|The dose of oxaliplatin is according to body-surface area (BSA): 130mg/m2, intravenously, on day 1.
1494098|NCT03012997|Other|Fraction of inspired oxygen 40%|
1494099|NCT03012997|Other|Fraction of inspired oxygen 100%|
1494100|NCT03012984|Drug|Dexmedetomidine supplemented morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
1494101|NCT03012984|Drug|Morphine analgesia|Patients in this group will receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml each time and a lockout time from 6 to 8 minutes according to patients' condition.
1494102|NCT03012971|Drug|Dexmedetomidine supplemented morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is a mixture of dexmedetomidine (1.25 ug/ml) and morphine (0.5 mg/ml), diluted with normal saline to 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
1494103|NCT03012971|Drug|Morphine analgesia|Patients in this group receive patient-controlled intravenous analgesia for 3 days after surgery. The formula is morphine (0.5 mg/ml), diluted with normal saline to 160 ml. The analgesic pump is set to administer a background infusion at a rate of 1 ml/h, with a bolus dose of 2 ml at each time and a lockout time from 6 to 8 minutes.
1494104|NCT03012958|Other|Lung clearance index (LCI)|LCI is determined by the number of lung volume turnovers necessary to clear the lungs of an inert tracer gas such as nitrogen that is inhaled at the beginning of the test. The LCI is calculated by determining the cumulative expired volume (CEV) and then dividing the CEV by the functional residual capacity. Values of less than7.0 indicate normal values while an LCI greater than 7.0 is associated with heterogeneity in ventilation and distal airway abnormalities. The ability to detect peripheral airway disease may make LCI a better modality for detecting distal airways abnormalities seen on lung histopathology but often missed on traditional pulmonary function testing.
1494105|NCT03012945|Drug|Combined Epi-GA/PCEA|An epidural catheter was placed before the induction of general anesthesia. General anesthesia was induced and maintained as in the control group, with the addition of epidural anesthesia which was maintained with the use of 0.5%-0.75% ropivacaine during surgery. Patient-controlled epidural analgesia with 0.12% ropivacaine and 0.5 ug/ml sufentanil was provided after surgery.
1494106|NCT03012945|Drug|GA/PCIA|General anesthesia was induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia was maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) were administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia with 0.5 mg/ml morphine was provided after surgery.
1494107|NCT03012932|Behavioral|HPV self-sampling|
1494108|NCT03012919|Other|active decision support system|The active decision support system in this study is a goal directed therapy (GDT) protocol where threshold hemodynamic values are defined when to give fluid, vasopressors and inotropes. Hemodynamic values are measured with the LiDCOrapid device, which uses pulse contour analysis to continuously monitor cardiac output and respiratory variations in stroke volume (SVV).
1494109|NCT03012906|Other|the prevalence of ischemic events|
1494112|NCT03012893|Procedure|Fluoroscopic technique|C7 spinous process will be identified by counting down from C1 vertebral body and spinous process.
1494113|NCT03012880|Biological|Daratumumab|Given IV
1494120|NCT03012867|Other|Fresubin original fibre, Fresenius Kabi|Patients receive Fresubin original fibre continously for 7 days
1494121|NCT03012854|Procedure|short-myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).
Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.
Endoscopic myotomy is carried out in a proximal to distal direction to a total length less than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.
Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.
Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
1494122|NCT03012854|Procedure|long-myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).
Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.
Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.
Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.
Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
1494123|NCT03012854|Procedure|full-thickness myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).
Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.
Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.
Myotomy of inner circular muscle bundles and outer longitudinal muscle layer is done.
Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
1494124|NCT03012854|Procedure|circular myotomy|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 8-10 cm proximal to the gastroesophageal junction (GEJ).
Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.
Endoscopic myotomy is carried out in a proximal to distal direction to a total length more than 7 cm. The expected end point of myotomy is 2 cm distal to the GEJ.
Myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact.
Closure of mucosal entry: the mucosal incision is closed using hemostatic clips."
1949150|NCT00169286|Procedure|professionally-led cognitive behavioral psychotherapy group|
1494126|NCT03012828|Drug|Moxidectin|
1494127|NCT03012828|Other|Placebo|
1494128|NCT03012815|Drug|Gabapentin|Gabapentin administered as a taper
1494129|NCT03012815|Drug|Benzodiazepines|Benzodiazepines administered using a symptoms triggered protocol
1494130|NCT03012815|Drug|Divalproex Sodium|Given in addition to gabapentin in high risk patients (i.e. seizures, TBI history, DT history)
1494131|NCT03012802|Procedure|Colorectal Surgery|Postoperative Audit
1494132|NCT03012789|Procedure|Surgery|Surgical excision
1494133|NCT03012776|Device|Total Posterior Spine System (TOPS)|Placement of TOPS System to provide posterior stabilization following decompression to treat lumbar spinal stenosis and spondylolisthesis
1494134|NCT03012776|Procedure|Transforaminal Lumbar Interbody Fusion (TLIF)|Fusion with placement of interbody cage and posterolateral instrumentation
1494135|NCT03012763|Drug|Paracetamol|Oral administration of 250 mg paracetamol
1494136|NCT03012763|Drug|Sulfasalazine|Oral administration of 50 mg sulfasalazine
1494137|NCT03012763|Drug|Fexofenadine|Oral administration of 120 mg fexofenadine
1494138|NCT03012763|Drug|Valsartan|Oral administration of 40 mg valsartan
1494139|NCT03012763|Device|non-caloric water|Oral administration of 240 ml non-caloric water
1494140|NCT03012763|Device|caloric drink|Oral administration of 240 ml caloric drink
1494141|NCT03012763|Device|grapefruit juice|Oral administration of 240 ml grapefruit juice
1494142|NCT03012750|Drug|Indocyanine Green|Perioperative application of 0.1 mg ICG per kg Body weight
1494143|NCT03012737|Device|Trilogy 100 ® (Philips Respironics)|Trilogy 100 ® (Philips Respironics) on MPV mode.
1494144|NCT03012724|Device|H7-Coil|Deep transcranial magnetic stimulation for the treatment of major dispersion disorder with the H7-Coil
1494145|NCT03012724|Device|H1-Coil|Deep transcranial magnetic stimulation for the treatment of major depression disorder with the FDA cleared H1-Coil
1494146|NCT03012711|Other|Neuromuscular exercise training|
1494147|NCT03012698|Device|repeated magnetic stimulation (RMS) treatment to the eye|Patients will be asked to undergo a one-time treatment with Epitech Corneal Magnetic Stimulation Device on one eye. The worst eye will be treated; if both eyes are equal, the right eye will be treated
1494148|NCT03012672|Drug|Cladribine|Given IV
1494149|NCT03012672|Drug|Cytarabine|Given IV
1494150|NCT03012672|Biological|Granulocyte Colony-Stimulating Factor|Given SC
1494151|NCT03012672|Drug|Mitoxantrone Hydrochloride|Given IV
1494152|NCT03012672|Other|Quality-of-Life Assessment|Ancillary studies
1494153|NCT03012672|Other|Questionnaire Administration|Ancillary studies
1494154|NCT03012659|Behavioral|Contraceptive Counseling Training|"Intervention sites will receive:
In person training: All staff at an intervention health center will participate in a one-day counseling training.
On-site shadowing: Trainers will shadow staff in-clinic the day following the training to observe the counseling implementation and provide additional coaching and support.
Technical assistance: A Planned Parenthood clinic operations expert will provide follow-up technical assistance."
1494155|NCT03012646|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
1494156|NCT03012633|Device|Lysis timer|Lysis Timer compared with standard laboratory test to diagnose hyperfibrinolysis during liver transplantation.
1494157|NCT03012620|Drug|Pembrolizumab|Treatment
1494159|NCT03012594|Drug|Lanreotide|Dosage: 120mg Dosage form: subcutaneous injection, pre-filled syringe Dosage frequency: 3 injections over 12 weeks, each dose administered 4 weeks apart
1494160|NCT03012581|Drug|Nivolumab|Treatment
1494161|NCT03012568|Device|SJM Implantable cardiac devices|SJM implantable devices undergoing MRI scan
1494162|NCT03012542|Dietary Supplement|Diet 1|Diet controlled in amount and source of carbohydrates or fiber containing foods.
1494163|NCT03012542|Dietary Supplement|Diet 2|Diet controlled in amount and source of carbohydrates or fiber containing foods.
1949151|NCT00169273|Behavioral|Structured behavioral weight loss group|Structured group weight loss program
1949152|NCT00169273|Behavioral|Weight loss and cognitive-behavioral depression group|Structured group program for weight loss and depression
1494166|NCT03012516|Behavioral|PAP-treatment by physiotherapist|
1494167|NCT03012516|Behavioral|Ordinary PAP-treatment at the health care center|
1494168|NCT03012503|Drug|BioFreeze|The estimated surface area of the average adult's neck is 350cm and the standard dose of Biofreeze® to achieve a clinically significant effect has been sited to be 1ml/200cm2 of skin surface area. Using this data approximately 1.75 ml of the assigned gel was applied to each participant's neck (posterior, anterior, left lateral and right lateral) by the same member of the research team, 5 minutes prior to an independent practitioner performing cervical manipulation on the participant.
1494169|NCT03012503|Drug|Placebos|control gel with a similar packaging, texture, and scent as Brand X but without the active ingredient of menthol
1494170|NCT03012490|Other|CRT-P or CRT-D standard remote monitoring|standard for the control group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system
1494171|NCT03012490|Other|CRT-P or CRT-D full remote monitoring|Full follow-up for the Active group: remote monitoring of ventricular rhythm disorders and technical parameters of the implanted system + supraventricular rhythm disorders, parameters related to heart failure, including symptoms and clinical signs of the patient
1494172|NCT03012490|Other|Symptoms and signs remote monitoring|symptoms and clinical signs of the patient
1494175|NCT03012464|Other|Pathologic and functional assessment|Random biopsies will be taken from the pelvic floor muscles, external anal sphincter, and the lateral supportive ligaments of the rectum during surgical treatment of rectal prolapse whether via the abdominal or perineal approach. Tissue samples will be subjected to immunohistochemistry to calculate the ratio between collagen type I and type III, and to reveal any myopathic or degenerative changes
1494176|NCT03012451|Behavioral|Advancing Adolescents|"The Advancing Adolescents programme is a structured 8-week psychosocial intervention for adolescents in humanitarian crises, based on profound stress attunement processes. It features three elements that are widely viewed as important to support youth adjustment in contexts of complex emergencies: (i) safety: establishment of a 'safe space' within the community as a base for activities and site of protection; (ii) support: facilitation of social support and self-expression; and (iii) structured activities: access to scheduled group activities."
1494177|NCT03012438|Device|NIRF imaging in thyroid surgery|a fluorescence imaging system and 7.5 mg of ICG will be used to visualize the parathyroids glands.
1494178|NCT03012425|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
1494179|NCT03012425|Device|Acupuncture|
1494180|NCT03012425|Behavioral|questionnaires|
1494181|NCT03012425|Other|Diurnal Cortisol|saliva test
1494182|NCT03012412|Behavioral|Mindfulness Based Program for Infertility|The Mindfulness Based Program for Infertility is a manualized group psychological intervention derived from contextual or 3rd wave cognitive-behavioral therapies intended to develop mindfulness and acceptance skills, as well as to promote perceptions of self-efficacy to deal with the demands of an infertility diagnosis and medical treatment. It comprises 10 weekly sessions of approximately 2hr each, run in small groups (ranging from 10 to 13 participants).
1494183|NCT03012399|Behavioral|Hypnosedation|Hypnosedation begins in the pre-op holding area and continue through the end of surgery.
1494184|NCT03012399|Behavioral|Empathic Conversation|Empathic conversation with a hypnotherapist begins in the pre-op holding area. Hypnotherapist remains with the participant until they are unconscious.
1494185|NCT03012399|Behavioral|Questionnaires|Symptom questionnaires completed before surgery, after surgery, and 14 days after surgery.
1494186|NCT03012386|Drug|Sildenafil Citrate|phosphodiesterase 5 inhibitor
1494187|NCT03012386|Other|Placebo Oral Capsule|Placebo capsules
1494188|NCT03012373|Procedure|Ear acupressure alone|The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes then were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
1494189|NCT03012373|Procedure|Electroacupuncture plus ear acupressure|Acupuncture included Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation was conducted. The frequency of electrical stimulation was 5 Hz and wave form was adjustable. The intensities of the stimulation were increased in 1 mA increments to maximal tolerable intensity. At the same time, The magnet pellets were placed with adhesive tape at shenmen point of both ears and were pressed 5 times every 5 minutes for 15 minutes. After 15 minutes treatment, acupuncture needles were removed and magnet pellets were attached until next treatment and change now one. The patients received this treatment 2 times a week for 4 weeks.
1494190|NCT03012360|Drug|ceftriaxone|2 g iv every 24h
1494191|NCT03012360|Drug|ciprofloxacin|400 mg iv every 8h
1494192|NCT03012360|Drug|imipenem|1 g iv every 8h
1494193|NCT03012360|Drug|linezolid|600 mg iv every 12h
1494194|NCT03012360|Drug|placebo|The SSI 0.9% or dextrose 5% used are based on routine procedure in different participating centers.Placebo will be prepared using IV bags, with the same of quantity as IMP
1494195|NCT03012347|Drug|BAY987517|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity. (Formulation: RB# Y73-161)
1494196|NCT03012347|Drug|BullFrog Gel Sunscreen Land Sport SPF-50|Subjects will be instructed to apply the test article in a split-body and face configuration, to the assigned side of the body (face, arms, torso, and legs), as they normally would before going outdoors for a run, walk or other sport related activity.
1949153|NCT00158665|Biological|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine|2 0.5 ml doses of '04-05 Trivalent Influenza Vaccine
1949154|NCT00158639|Behavioral|Home BP;secure messaging;pharmaceutical care;|
1949155|NCT00158275|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy focuses on identifying and eliminating maladaptive beliefs and thoughts.
1494197|NCT03012334|Drug|Lasmiditan|Dose is based on treatment sequence in 5-way crossover.
1494198|NCT03012334|Drug|Alprazolam|Active comparator based on treatment sequence in 5-way crossover
1494199|NCT03012334|Other|placebo|Placebo comparator based on treatment sequence in 5-way crossover
1494200|NCT03012321|Drug|Olaparib|
1494201|NCT03012321|Drug|Abiraterone Acetate|
1494202|NCT03012321|Drug|Prednisone|
1494203|NCT03012282|Device|Computed Tomography Perfusion Imaging|Undergo CT perfusion sequence
1494204|NCT03012269|Behavioral|Working memory training|
1494205|NCT03012256|Other|Cardio-respiratory management model|Includes scheduled nurse-led self-management support (based on a training program, and tool-kit), advanced care and goal planning, clinical pharmacist education reconciliation, team case rounds, Situation, Background, Assessment and Recommendation (SBAR) communication protocol with primary care, and a standardized transition package
1494206|NCT03012243|Procedure|Gallbladder aspiration|Percutaneous ultrasound-guided aspiration of bile from the gallbladder. This is performed without leaving a drain in the gallbladder. The aspiration is performed with the intention to relief the pressure in the gallbladder, without drain.
1494207|NCT03012243|Procedure|Cholecystostomy|Ultrasound-guided insertion of drain in the gallbladder. The drain is left in the gallbladder until clinical assessment and laboratory analyses show that the acute cholecystitis has been successfully treated.
1494208|NCT03012230|Other|Laboratory Biomarker Analysis|Correlative studies
1494209|NCT03012230|Biological|Pembrolizumab|Given IV
1494210|NCT03012230|Drug|Ruxolitinib Phosphate|Given PO
1494211|NCT03012217|Other|Observational Study|
1494212|NCT03012204|Device|real LFrTMS at unaffected M1|"Compare the effect of LFrTMS at unaffected M1 to that of all sham stimulation on motor rehabilitation after cerebrovascular disease .
rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.
The four groups are the combinations of real or sham ①/②/③."
1494213|NCT03012204|Device|real primed LFrTMS at unaffected M1|"Compare the effect of primed LFrTMS at unaffected M1 to that of LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .
rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.
The four groups are the combinations of real or sham ①/②/③."
1494214|NCT03012204|Device|combined rTMS at both M1|"Compare the effect of combined rTMS at both M1 to that of primed LFrTMS at unaffected M1 on motor rehabilitation after cerebrovascular disease .
rTMS: Repetitive Transcranial Magnetic Stimulation. Combination Elements: ①6 hertz(Hz) rTMS at unaffected M1 before LFrTMS at unaffected M1 ;②6 Hz rTMS at affected M1;③1 Hz rTMS at unaffected M1.
The four groups are the combinations of real or sham ①/②/③."
1494215|NCT03012204|Device|all sham stimulation|used as controls to eliminate the placebo effect of all kinds of combinated rTMS
1494216|NCT03012191|Drug|Gentamicin Sulfate|
1494217|NCT03012178|Procedure|Mitral valve surgery|ACC/AHA guideline directed mitral valve repair or replacement
1494218|NCT03012165|Drug|ADX-102 Ophthalmic Drops (0.5%)|ADX-102 Ophthalmic Drops (0.5%) administered twice in two weeks.
1494219|NCT03012165|Drug|ADX-102 Ophthalmic Drops (0.1%)|ADX-102 Ophthalmic Drops (0.1%) administered twice in two weeks.
1494220|NCT03012165|Drug|Vehicle of ADX-102 Ophthalmic Drops|Vehicle of ADX-102 Ophthalmic Drops administered twice in two weeks.
1494221|NCT03012152|Procedure|Standard conservative breast surgery|
1494222|NCT03012152|Procedure|Oncoplastic breast surgery|
1494223|NCT03012126|Behavioral|Healthy Weight Clinic|
1494224|NCT03012126|Behavioral|Healthy Weight and Your Child|
1494225|NCT03012113|Drug|Mirabegron|
1494226|NCT03012113|Other|Short term mild cooling|
1494227|NCT03012113|Drug|Placebo Oral Capsule|
1494228|NCT03012100|Drug|Cyclophosphamide|Given PO
1494229|NCT03012100|Other|Laboratory Biomarker Analysis|Correlative studies
1494230|NCT03012100|Biological|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
1494231|NCT03012100|Other|Placebo|Given ID
1494232|NCT03012100|Biological|Sargramostim|Given ID
1494233|NCT03012087|Behavioral|MyHealthyChoices|My Healthy Choices explains what opioid pain medications are, assesses and explains the patient's risk factors related to taking opioids, assesses patient preferences about pain medications, and produces a tailored patient report based on the answers. The patient is encouraged to show the report to the treating ED clinician so they can discuss medication options for treating the patient's pain. Following discharge from the ED, intervention group participants discharged with a prescription pain reliever receive messages about safe medication use, storage, and disposal and access to an educational web portal that contains more information on prescription pain medications and safety.
1494234|NCT03012087|Other|Health Risk Assessment|The WellSource health risk assessment content focuses on general health promotion, and the participant's overall health and wellness. A summary report based on the participants' answers is sent to their email address.
1494235|NCT03012074|Behavioral|Type 2 Diabetes Self-Management|Patients with Type 2 Diabetes
1949156|NCT00158275|Drug|Antidepressants|Antidepressant drugs try to eliminate symptoms of depression such as persistent sadness and disinterest in normal or pleasurable activities.
1949157|NCT00158275|Behavioral|Problem solving therapy|Problem solving therapy identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment.
1949158|NCT00115037|Drug|Naltrexone|100mg/day, up to 8 weeks during Phase 1, 16 weeks in phase 2.
1949159|NCT00115037|Drug|placebo|placebo comparer for 16 weeks in phase 2.
1494291|NCT03011775|Drug|Bisoprolol Fumarate 2.5 MG Oral Tablet|1 tablet per a day
1494292|NCT03011775|Drug|Rosuvastatin Calcium 20 MG Oral Tablet|1 tablet per a day
1494293|NCT03011775|Drug|ramipril 5 MG|1 tablet per a day
1497022|NCT02991573|Device|Prime & Bond XP|Control
1949160|NCT00115037|Behavioral|Medical Management (MM)|Brief manual-based therapy for up to 8 weeks during phase 1, 16 during phase 2.
1494240|NCT03012048|Device|Silver-impregnated ceramic tablet|A silver-impregnated ceramic disk used for drinking water treatment that was developed by engineers at the University of Virginia. When the ceramic disk is placed in a household water storage container, silver diffuses through the porous ceramic into the water at a release rate that is effective for continual disinfection of waterborne pathogens while remaining below the silver drinking water standard. The disk is effective for daily treatment of 10 to 15 liters for at least six months.
1494241|NCT03012048|Device|Silver-impregnated ceramic water filter|Silver-impregnated ceramic water filter are well-developed, tested, and widely-used devices. In addition to mechanically removing pathogens, the filter is treated with silver to reduce live pathogens that pass through the filter and to provide residual disinfectant to reduce risk of recontamination after treatment.
1494242|NCT03012048|Device|Safe-storage water container|The safe-storage water containers used in this study are plastic buckets with a spigot, purchased locally.
1494243|NCT03012035|Other|positive treatment expectations|Before participants undergo the exposure training their expectation of treatment efficacy is manipulated with different information regarding the following treatment. The experimental group will get positive treatment expectations induced with the accurate information, that exposure training refers to the gold standard in psychotherapy to reduce spider fear (= open administration of treatment).
1494244|NCT03012035|Other|neutral treatment expectations|The comparator group will get neutral expectations regarding treatment outcome. To induce neutral treatment expectations about the following exposure training, it is necessary to tell them they are in the comparator group and that they will receive a comparator condition exposure training for diagnostic purposes only (= hidden administration of treatment).
1494245|NCT03012009|Device|full ablative CO2 laser|ablation to the level of de dermal papilla
1494246|NCT03012009|Device|fractional ablative CO2 laser|180 micron HP, pulse 8ms, 15% overlay, 30 W (943J/cm)
1494247|NCT03012009|Drug|MAL|
1494248|NCT03012009|Device|LED lamp|peak wavelength 630 nm, 37J/cm2
1494249|NCT03012009|Drug|lidocaine hydrochloride 2% with epinephrine|
1494250|NCT03011996|Drug|CLR 500mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
1494251|NCT03011996|Drug|CJ-12420 100mg|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
1494252|NCT03011996|Drug|CJ-12420 50mg|Cohort 2: bid for 7 days
1494253|NCT03011996|Drug|AMX 1g|Cohort 1: bid for 5 days Cohort 2: bid for 7 days
1494254|NCT03011996|Drug|Pantoprazole 40mg|Cohort 2: bid for 7 days
1494255|NCT03011983|Device|MEG|MEG is a non-invasive functional imaging technique that can measure slow-wave neural activity.
1494256|NCT03011983|Device|MRI|MRI is a non-invasive imaging modality that provides measures of brain structure.
1494257|NCT03011983|Behavioral|Neuropsychology assessment|A battery of tests will be administered by a neuropsychologist to evaluate the cognitive function of adolescents with concussion compared to healthy controls.
1494258|NCT03011970|Drug|Oxytocin|
1494259|NCT03011970|Drug|Placebo|
1494260|NCT03011944|Other|Quality Improvement Program|Nutrition screening, Nutrition consult, Oral Nutritional Supplement will be implemented in the Home Health branches as standard of care.
1494261|NCT03011931|Drug|Simvastatin|20 mg Simvastatin given, Blood draw, Urine collection, Celiac serology testing, DNA sampling, Dietary review
1494262|NCT03011918|Other|Data Collection prior to first fall for all fallers|Weight history. Descriptive analysis of weight history in single event fallers compared to multiple event fallers. Information on use of any nutrition supplementation exposure will also be collected
1494263|NCT03011918|Other|Hgb value|Hgb decline. Descriptive analysis of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected
1494264|NCT03011918|Other|Vitamin D|Descriptive analysis of vitamin D status of single event fallers compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure will be collected..
1494265|NCT03011918|Other|C-Reactive Protein|Descriptive analysis of C-RP value status of single event fallers as compared to multiple event fallers will be analyzed. Use of nutrition supplement exposure data will be collected.
1494266|NCT03011905|Drug|Dexamethasone|4 ml DexaGalen 4 mg/ml
1494267|NCT03011905|Drug|NaCl (Control)|4 ml NaCl 9 mg/ml
1494268|NCT03011905|Drug|Paracetamol|Premedication and as needed after operation
1494269|NCT03011905|Drug|EtoriCoxib|Premedication and first 2 postoperative days.
1494270|NCT03011905|Drug|Oxycodone|Total of 3 doses of OxyContin postoperatively. OxyNorm as needed.
1494271|NCT03011905|Drug|Ropivacaine|In brachial plexus block
1494272|NCT03011892|Drug|INCB018424 cream|INCB018424 1.5% cream
1494273|NCT03011892|Drug|INCB018424 cream|INCB018424 0.5% cream
1494274|NCT03011892|Drug|INCB018424 cream|INCB018424 0.15% cream.
1494275|NCT03011892|Drug|Triamcinolone 0.1% cream|Triamcinolone 0.1% cream BID
1494276|NCT03011892|Drug|Vehicle cream|
1494277|NCT03011879|Other|clinical pathway|
1494278|NCT03011866|Drug|Wound topically irrigated with 500mg TXA|
1494279|NCT03011866|Drug|1mg/kg/hr TXA intravenous infusion till the last suture|
1494280|NCT03011840|Other|Information leaflet|Patient information leaflet with instructions to be carried out before procedure under general anesthesia
1494281|NCT03011827|Other|Fibrinogen and/or platelets administration|Fibrinogen and/or platelets administration to maintain clot amplitude at 10 minutes of the thromboelastometry between 35-40 mm along liver transplant procedure
1494282|NCT03011814|Biological|Durvalumab|Given IV
1494283|NCT03011814|Other|Laboratory Biomarker Analysis|Correlative studies
1494284|NCT03011814|Drug|Lenalidomide|Given PO
1494287|NCT03011788|Drug|Golytely Oral Solution|Bowel purge prior to,colonoscopy
1494288|NCT03011775|Drug|Pioglitazone 15 mg Tablet|1 tablet per day in the morning for 6 months
1494289|NCT03011775|Drug|Isosorbide Dinitrate 10Mg Tablet|1-2 tablets 2 times a day
1494290|NCT03011775|Drug|Acetylsalicylic Acid 75Mg Tablet|1 tablet per a day
1494294|NCT03011762|Device|Computer controlled mandibular positioner|Participants in this arm will complete the computer controlled mandibular positioner test. The study participant, study dentist, and PI are all blinded to the outcome of the CCMP test. Those participants predicted to experience therapeutic success with OAT will have their oral appliance set at the predicted protrusive level; those participants predicted to experience therapeutic failure will have their oral appliance set at a default position. Outcome home sleep tests with the oral appliance in place will be used to determine the accuracy of the prediction.
1494295|NCT03011749|Other|FLT PET/CT|FLT PET/CT before first series of Radium-223 and after 2 series
1494296|NCT03011736|Other|Laboratory Biomarker Analysis|Correlative studies
1494297|NCT03011736|Procedure|Parathyroidectomy|Undergo parathyroidectomy
1494298|NCT03011723|Behavioral|Resource oriented music therapy|"10 weeks of tailored individual music therapy for PWD and a caregiver. Pre and post assessment in addition.
The music therapy consists of one or more of the following activities:
Singing
Listening to live music
Listening to recorded music
Dancing
Conversations about memories/reminiscence
Exercising to music
Breathing exercises and relaxing exercises
The treatment is following the principles of resource oriented music therapy as described by Rolvsjord et al (2005)"
1494299|NCT03011710|Device|ProVari v2.5 (E-cigarette)|An electronic cigarette or e-cigarette is a handheld electronic device that vaporizes a flavored liquid. The user inhales the vapor. The fluid in the e-cigarette, called e-liquid, is usually made of nicotine, propylene glycol, glycerine, and flavorings.
1494300|NCT03011710|Device|Marlboro Gold (Conventional cigarette)|Conventional cigarette
1494301|NCT03011710|Device|Cigarette tip|Placebo device
1494302|NCT03011684|Drug|Tamoxifen|For ER Positive Randomization
1494303|NCT03011684|Drug|Letrozole|For ER Positive Randomization
1494304|NCT03011671|Drug|Acetazolamide|ACZ will be initiated at 250 mg twice a day (BID) and then escalated to 500 mg BID. ACZ will be started on the day of TMZ initiation.
1494305|NCT03011671|Drug|Temozolomide|Patients will receive daily oral ACZ concomitant with TMZ. ACZ will be started on the day of TMZ initiation.
1494306|NCT03011658|Procedure|venepuncture|for both the groups, HADS questionnaire will be administered to assess the levels of anxiety and depression. The placebo group ( group A) will not be having subjects suffering from oral lichen planus
1494307|NCT03011645|Drug|Ziprasidone|Given by mouth, single dose of 20 mg.
1494308|NCT03011645|Drug|Lorcaserin|Given by mouth, single dose of 10 mg.
1494309|NCT03011645|Drug|Placebo Oral Tablet|Given by mouth, single dose.
1494310|NCT03011632|Drug|Mometasone Nasal|a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months
1494311|NCT03011632|Drug|placebo mometasone|a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
1494312|NCT03011619|Behavioral|Usual Standard of Care|medication management, group therapy, and individual therapy.
1494313|NCT03011619|Behavioral|Cognitive Behavioral Therapy Condition (CBT)|CBT, including a sequence of sessions that builds upon prior sessions and planned exercises, including worksheets and journal entries.
1494314|NCT03011606|Procedure|Robotic Surgery|Robotic Surgery after Focal Ablation Therapy
1494315|NCT03011593|Other|Nutrition Support Product|Nutrition support product contains macronutrients, micronutrients, glutamine, and prebiotics. Product is in powder form (41 grams per serving) and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
1494316|NCT03011580|Dietary Supplement|Fultium-D3|Fultium-D3 (oral cholecalciferol or vitamin D3) will be given to participants in the immediate supplementation arm at a dose of 9,600 IU/day for 8 weeks at V2. At V3, all participants will be given a supply of Fultium-D3 at a dose of 3,200 IU/day.
1494317|NCT03011580|Dietary Supplement|Placebo|3 capsules of placebo will be given daily to participants in the delayed supplementation arm for 8 weeks at V2.
1494318|NCT03011567|Drug|Acetaminophen|Participants will receive acetaminophen for postpartum mild pain relief
1494319|NCT03011567|Drug|Ibuprofen|Participants will receive ibuprofen for postpartum mild pain relief
1494320|NCT03011554|Device|Implantable Miniature Telescope (IMT)|Monocular implantation of the IMT.
1494321|NCT03011541|Procedure|Arm 1|"Procedure/ Surgery: RB (Retrobulbar)
Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
Procedure/Surgery: ST (Subtenon)
Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
Procedure/Surgery: IV (Intravenous)
Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)"
1494322|NCT03011541|Procedure|Arm 2|"Procedure/Surgery: RB (Retrobulbar)
Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
Procedure/Surgery: ST (Subtenon)
Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
Procedure/Surgery: IV (Intravenous)
Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
Procedure/Surgery: IVIT (Intravitreal)
Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)"
1494323|NCT03011541|Procedure|Arm 3|"Procedure/Surgery: RB (Retrobulbar)
Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
Procedure/Surgery: ST (Subtenon)
Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
Procedure/Surgery: IV (Intravenous)
Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
Procedure/Surgery: IO (Intraocular)
Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells."
1494324|NCT03011528|Drug|VDC-IE x2|"Week 1, 5, 9 and week 13:
Vincristine, IV, D1, 1.5mg/m²
Doxorubicine, IV, D1-D2, 37.5mg/m²
Cyclophosphamide, IV, D1, 1.2g/m²
Week 3, 7, 11 and week 15:
Ifosfamide, IV, D15 to D19, 1.8g/m²/d
Etoposide, IV, D15 to D19, 100mg/m²/d"
1494325|NCT03011528|Drug|VDC-IE|"Week 1 and week 5:
Vincristine, IV, D1, 1.5mg/m²
Doxorubicine, IV, D1-D2, 37.5mg/m²
Cyclophosphamide, IV, D1, 1.2g/m²
Week 3, and week 7:
Ifosfamide, IV, D15 to D19, 1.8g/m²/d
Etoposide, IV, D15 to D19, 100mg/m²/d"
1494326|NCT03011528|Drug|TEMIRI|"Week 9, 12, 15 and week 18:
Temozolomide, PO, D1 to D5, 150mg/m²/d
Irinotecan, IV, D1 to D5, 50mg/m²/d"
1494327|NCT03011528|Drug|Consolidation BuMel|"After induction phase and local treatment (surgery and/or radiotherapy) and before PBSC:
Busulfan, IV, D-5 to D-2, dosa according to the weight
Melphalan, IV, D-1, 140 mg/m²
Peripheral Blood Stem Cell infusion:
- PBSC infusion, D0, at least 3.10^6 CD34/kg"
1494328|NCT03011528|Drug|Maintenance|"1st year : VCC
Vinblastine, IV, 3mg/m², once a week (except during radiotherapy: 1mg/m², 3 times a week)
Cyclophosphamide, PO, 25mg/m² continuously
Celecoxib, PO, according to the weight, twice a day, continuously, (except during radiation therapy)
< 20kg: 100 mg bid
20-50kg: 200 mg bid
> 50kg: 400 mg bid"
1494329|NCT03011528|Procedure|Local treatment by surgery|Surgical excision of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy. Radiotherapy can be added
1494330|NCT03011528|Radiation|Local treatment by radiotherapy|Radiotherapy of whole site of the primary tumour and metastatic sites (outside pulmonary sites) can take place before or after the high dose consolidation chemotherapy
1494331|NCT03011502|Other|Biological samples collection of blood and feces|
1494332|NCT03011489|Device|Vacuum formed aligners|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is a modified step in Figueroa's technique.
1494333|NCT03011476|Drug|Donepezil|"Start with 5 mg/day for 4 weeks
Increased to 10 mg/day for 8 weeks"
1494334|NCT03011476|Drug|Placebos|"Start with 5 mg/day for 4 weeks
Increased to 10 mg/day for 8 weeks"
1494335|NCT03011463|Drug|intravenous infusion of 2 mg trospium chloride|intravenous infusion of 2 mg trospium chloride in 20 ml saline within 60 min and 240 ml tap water p.o
1494336|NCT03011463|Drug|oral administration of 30 mg trospium chloride|oral administration of 30 mg trospium chloride with 240 ml tap water
1494337|NCT03011463|Drug|oral administration of 300 mg ranitidine|oral administration of 300 mg ranitidine with 240 ml tap water
1494338|NCT03011463|Drug|oral administration of 500 mg clarithromycin|oral administration of 500 mg clarithromycin with 240 ml tap water
1494339|NCT03011450|Drug|K-877|
1494340|NCT03011450|Drug|Fenofibrate|
1494341|NCT03011450|Drug|Placebo (for K-877)|
1494342|NCT03011437|Other|Esophagogastroduodenoscopy|Esophagogastroduodenoscopy is an examining method for upper gastrointestinal disease.
1494343|NCT03011424|Device|Extracorporeal liver support therapy (ELS)|ELS by using the Molecular Adsorbent Recirculating System (MARS) is based on a modified haemodialysis that allows the removal of water-soluble and protein bound toxins over an albumin-coated high flux membrane against recycled exogenous albumin.
1494344|NCT03011398|Procedure|Orthobiologic Procedures|To observe the improvement in subject-reported clinical outcomes for percutaneous orthopedic procedures used to treat musculoskeletal disorders.
1494345|NCT03011385|Behavioral|Individual Planning|"Participants are filling in the planning forms, referring to their individual physical activity. Both members of the dyad form their own, interdependent plans.
The following behavior change techniques (BCT) are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/coping planning. Applications of all BCT included references to planning."
1494346|NCT03011385|Behavioral|Dyadic Planning|"Participants are filling in the planning forms jointly. Planning refers to physical activity of only one person in the dyad. The other person in the dyad is actively participating in forming plans by the target person.
The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning."
1494347|NCT03011385|Behavioral|Collaborative Planning|Participants are filling in the planning forms jointly. Planning refers to physical activity of both persons in the dyad. Physical activity may be performed jointly by both persons in the dyad. The following BCT are included in the planning intervention protocol: action planning, barrier identification, prompting self-talk, relapse prevention/ coping planning. Applications of all BCT included references to planning.
1494348|NCT03011385|Behavioral|Education|The education group participants receive extended physical activity and healthy nutrition education program. The education includes: (1) the guidelines for physical activity and healthy nutrition, tailored to age and health status of the participants, (2) the examples of exercises and their metabolic equivalent; (3) information about healthy body mass and body composition.
1494350|NCT03011359|Other|Optimizing B.I (New) PCA mode|In the intervention group, the optimizing B.I PCA mode will be setted. This mode is setted that the amount of administered drug per hour will be increased by 0.4 ml by pressing bolus button (The interval: ~ 6 hr: 60 minutes, 6-18 hr: 90 minutes, 18 hours: 120 minutes). Conversely, if the bolus button is not used for 120 minutes, the administered amount of drug per hour is setted to be reduced by 0.2 ml, and the maximum (or minimum) allowable flow rate is 4 ml (or 1 ml).
1494351|NCT03011359|Other|Conventional PCA mode|(Mode setting; total volume: 150 ml, flow rate: 2 ml, bolus volume: 0.5 ml, and LOT: 10 minutes)
1494352|NCT03011346|Device|Symetis ACURATE neo/TF transfemoral TAVI system|Transcatheter aortic valve implantation of a Symetis ACURATE neo/TF bioprosthesis by transfemoral access, pre-dilatation mandatory.
1494353|NCT03011346|Device|Edwards Sapien 3 Transcatheter Heart Valve|Transcatheter aortic valve implantation of an Edwards Sapien 3 bioprosthesis by transfemoral access.
1494354|NCT03011333|Drug|HTX-011|
1494355|NCT03011333|Drug|Bupivacaine HCl without epinephrine|
1494356|NCT03011333|Drug|Saline Placebo|
1494357|NCT03011320|Drug|EC1456|intravenous (IV) bolus dose
1494358|NCT03011320|Drug|99mTc-Etarfolatide|Injection of unlabeled etarfolatide followed by etarfolatide labeled with 740 to 925 megabecquerels (MBq) [20 to 25 millicuries (mCi)] of sodium pertechnetate Tc-99m injection, followed by a single-photon emission tomography (SPECT) or single-photon emission tomography with in-line x-ray computed tomography (SPECT/CT) scan.
1494359|NCT03011307|Drug|Oxytocin|spinal injection of oxytocin
1494360|NCT03011307|Drug|Placebos|spinal injection of placebo
1494361|NCT03011294|Device|Continuous positive airway pressure (CPAP)|
1494362|NCT03011294|Device|Nasal strip|
1494363|NCT03011281|Drug|Tofacitinib|
1494364|NCT03011268|Other|Discontinuation of anti-TNF treatment|Discontinuation of treatment with Infliximab, Adalimumab, and Golimumab in order to record time to relapse occurrences
1494365|NCT03011268|Other|Continuation of anti-TNF treatment|Continuation of treatment with Infliximab, Adalimumab, and Golimumab for 2 years after randomization, then discontinue
1494443|NCT03010579|Drug|iron supplementation|If necessary, oral ferrous succinate, vitamins B12 and folic acid will be administered.
1494366|NCT03011255|Biological|peptide specific CTL|Radiation: RT to 60 Gy, 5 x per week，for 6 weeks Biological: Peptide specific CTL Peptide specific CTL will be administered by intravenous injection on day 28 of radiation.
1494367|NCT03011229|Device|Pro Core Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
1494368|NCT03011229|Device|medtronic Sharkcore Needle|Needle will be used in standard fashion utilizing a slow pull technique by an expert endoscopist who is familiar with EUS and use of both needles.
1494369|NCT03011216|Behavioral|Adaptive emotional cognitive control training|Is supposed to train ability to continuously update emotional material in working memory.
1494370|NCT03011216|Behavioral|Adaptive non-emotional feature match task|Does not train updating of working memory content; may train reaction time speed, visual search, or concentration abilities.
1494371|NCT03011203|Other|physical exercise|In session II and III participants will perform an exercise test on a bicycle inside and outside the MR scanner.
1494373|NCT03011177|Drug|Teneligliptin|teneliagliptin 20mg qd
1494374|NCT03011177|Drug|Linagliptin|linagliptin 5mg qd
1494375|NCT03011164|Procedure|Walk and Run|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk or run on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk or run on the treadmill in barefoot at selected gait speed.
1494376|NCT03011138|Procedure|Gait velocity|Once participants are eligible, they will undergo the experimental procedure. Before data collection, they will walk on a treadmill in barefoot for ten minutes to adapt the condition. The a gait analysis system will collect the data while they walk on the treadmill in barefoot at selected gait speed.
1494377|NCT03011125|Drug|dexlansoprazole injection|
1494378|NCT03011125|Other|placebo|
1494379|NCT03011112|Procedure|Observational procedure|All the patients will undergo a standard observational procedure: i) diagnosed with KOA; ii) take a radiographic examination (x-ray); iii) assessed by WOMAC; iv) take an physical examination to avoid other disease; iv) take a gait examination on a treadmill in barefoot.
1949161|NCT00115037|Behavioral|Combined Behavioral Intervention (CBI)|45-60 minute sessions with a certified therapist focused on resolving ambivalence and skill building. Number of sessions guided by achievement of goals identified within treatment plan; minimum 9, maximum 20 sessions over 16 weeks.
1949162|NCT00115037|Behavioral|Telephone Counseling|Bi-weekly telephone calls lasting 15-20 minutes focused on the same content as MM.
1494382|NCT03011060|Procedure|Neo-adjuvant Chemotherapy|A preoperative chemotherapy based on anthracyclines and taxanes.
1494383|NCT03011060|Drug|Capecitabine|Capecitabine 1000mg/m2 tablets twice a day for 8 cycles.
1494384|NCT03011047|Procedure|endoscopic trans-antral approach|new surgical approach to repair the orbital floor fractures through the maxillary sinus
1494385|NCT03011047|Procedure|trans-orbital surgical approach|through the lower eyelid below the eyelashes ,then down to bone the herniated orbital content will be reduced through this incision traditional surgical approach to repair orbital floor fractures
1494386|NCT03011034|Drug|Talacotuzumab|Talacotuzumab 9 mg/kg will be administered as an IV infusion.
1494387|NCT03011034|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered as an IV infusion.
1494388|NCT03011021|Drug|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
1494389|NCT03011021|Biological|UCB-Treg|Receive Treg infusion: 1~5*10^6/kg b.w. in 100ml normal saline
1494390|NCT03011021|Drug|Insulin|Receive insulin following clinician's instruction.
1494391|NCT03011008|Drug|Liraglutide|Dose escalation of liraglutide starts from 0.6 mg up to 1.2 mg per day.
1494392|NCT03011008|Drug|Insulin|Receive insulin following clinician's instruction.
1494394|NCT03010982|Drug|Tazemetostat and [14C] Tazemetostat|Tazemetostat is a selective oral small molecule inhibitor of EZH2.
1494395|NCT03010969|Procedure|Acute abdominal surgery|Acute abdominal surgery within 72 hours of admission to the department of surgery
1494396|NCT03010943|Device|Virtual reality headset|Feasibility and tolerance
1494397|NCT03010930|Other|Supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of vegetable broth with added MSG one time per day for 1 month
1494398|NCT03010930|Other|No supplementation of diet with MSG|Subjects eat normal diet and consume 8 ounces of low glutamate vegetable broth without MSG (sodium-matched with NaCl) one time per day for 1 month
1494399|NCT03010917|Drug|Fish Oil with ethanol and placebo ethanol infusions|
1494400|NCT03010917|Drug|Placebo with ethanol and placebo ethanol infusions|
1494401|NCT03010904|Other|Dietary intervention|
1494402|NCT03010891|Behavioral|The bundle of supportive interventions|usual NICU care +positioning + gentle touch + modulating infant states + facilitated tucking + NNS+ oral sucrose+ routine KMC > 45 minutes
1494403|NCT03010891|Behavioral|Usual NICU care|usual NICU care + positioning + gentle touch +routine KMC < 20 minutes
1494404|NCT03010878|Other|Yoga|"The yoga intervention group addressed pain as a primary variable and balance as a secondary variable and how to best manage these symptoms in the clinic and community.
Yoga was delivered in sitting, standing, and floor postures"
1497023|NCT02991573|Procedure|technique 1|
1949163|NCT00115037|Other|Treatment as Usual (TAU)|Responders are informed of the benefits of continued treatment with naltrexone and are given a four week supply of medication as well as a prescription for 3 months.
1949164|NCT00099242|Drug|rivastigmine transdermal patch|
1995686|NCT02681198|Drug|Lofexidine|All subjects will receive two single doses of lofexidine HCl; one 0.4 mg dose taken alone on Day 1 and one 0.4 mg dose taken with 40 mg once daily paroxetine HCl at steady-state on Day 13.
1995687|NCT02681198|Drug|Paroxetine|All subjects will receive daily single doses of paroxetine HCl; one 20 mg dose taken Days 4-6, one 40 mg dose taken Days 7-19, one 20 mg dose taken Day 20, one 10 mg dose taken Days 21-22.
1995688|NCT02680834|Device|Dual Action Pneumatic Compression Device|Dual action pneumatic compression device used to treat chronic VLUs.
1995689|NCT02680834|Device|Multi-Layer Bandaging|Multi-layer bandaging used to treated chronic VLUs
1494405|NCT03010878|Other|Self-management|The self-management education group was provide once a month through University of Colorado Health Fort Collins Family Medicine Residency Program Pain Management Clinic. The program consisted of lifestyle variations, accountability, modifications, and strategies to management pain in daily life.
1494406|NCT03010865|Drug|Sodium Butyrate|Sodium butyrate is being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) in 730 mg capsules. The company asserts that their material is 98% pure and food grade. We will have identical placebo capsules. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 4380 mg/day.
1494407|NCT03010865|Drug|Placebo Oral Capsule|Placebo Oral Capsule is also being supplied by T.E. Neesby (Brain White, T.E. Neesby, Inc.) and there is no difference from appearance, smell and taste. It contains 1.5 mg sodium butyrate per capsule. Subjects will receive 3 capsules twice daily (morning and late afternoon or evening) for a total of 9 mg/day.
1494408|NCT03010852|Behavioral|Focused incentive spirometer education and monitoring|
1494409|NCT03010839|Procedure|Remote Ischemic Preconditioning|RIPC will be induced twice daily for one day before cardiac surgery and once before induction of anesthesia by 3 cycles of 5-min upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200mmHg
1494410|NCT03010839|Procedure|Control|Control group witnout remote ischemic preconditioning
1494411|NCT03010813|Procedure|Robotic single port surgery and NOTES|Robotic single port colorectal surgery; Robotic transanal surgery; Robotic single port urologic surgery; Transoral robotic surgery
1995690|NCT02681263|Drug|Temocillin|Treatment duration with a minimum of 5 days administration of the study drug: Temocillin (Negaban®) 6g/day (2g/tid) and as monotherapy.
1995691|NCT02679274|Drug|Placebo|Intermittent intramuscular injections of saline (males and females).
1494414|NCT03010787|Drug|V565|single ascending dose of V565
1494415|NCT03010787|Drug|V565|Multiple dose
1494416|NCT03010787|Drug|Placebo|Single and multiple dose
1494417|NCT03010787|Drug|V565|Open-label single dose
1494418|NCT03010787|Drug|V565|Open-label single ascending dose
1494419|NCT03010774|Behavioral|Risk Stratification|Every night, subjects will be risk stratified into low-risk or medium- to high-risk using a physiologic risk score, eCART. Subjects who meet the low-risk criteria will not be woken up for routine nighttime vitals (typically at midnight and at 4 am). However, subjects will continue to be woken up for laboratory draws, procedures, or treatments as per usual. Subjects who are medium- to high-risk will continue to be woken up at night for routine nighttime vitals. Alarms for all subjects, including low-risk subjects, will continue to alert nurses in real-time. If the primary nurse of a low-risk subject is alerted of an alarm, the nurse will have to go into the subject's room to turn off the alarm and therefore check on the patient.
1494420|NCT03010774|Behavioral|Usual Care|The subject will continue to receive routine vital sign measurements and charting, standard for the ward or according to the physician orders, including routine spot-check vital signs, regardless of risk level.
1494421|NCT03010761|Drug|escitalopram|antidepressant use for the betel-quid abstinence
1494422|NCT03010761|Drug|Moclobemide|antidepressant use for the betel-quid abstinence
1494423|NCT03010761|Drug|Placebo - Cap|Placebo - Cap
1494424|NCT03010748|Device|Scheimpflug tomography system (Pentacam) measurement|The Scheimpflug tomography system (Pentacam,Oculus GmbH, Wetzlar, Germany) is a rotating Scheimpflug camera that measures 138,000 true elevation points to compute corneal topography. Patients were asked to blink twice and then look at the fixation device. Image acquisition was a 2-second scan of 50 rotational Scheimpflug images through the corneal sighting point, the point where the ray of light from the fovea to the fixation device crossed the cornea. All measurements were performed just after a blink to minimize the effect of tear film alteration on the data. Acceptable maps had at least 10.0 mm of corneal coverage with no extrapolated data in the central 9.0 mm zone.
1494425|NCT03010735|Dietary Supplement|Bifidobacterium animalis A6|Daily take 4.0E+10 CFU of Bifidobacterium animalis A6, 6 months
1494426|NCT03010735|Dietary Supplement|Placebo|
1494427|NCT03010722|Drug|Regorafenib|"Patients meeting all of the inclusion criteria and none of the exclusion criteria will receive regorafenib 160 mg orally (po) od for 3 weeks of every 4-week cycle. Each cycle will comprise 3 weeks of treatment followed by 1 week without treatment, hereafter described as 3 weeks on/1 week off. Each 160-mg dose will include four regorafenib 40-mg tablets."
1494428|NCT03010696|Other|No interventions, questionnaire, collect specimen|
1494429|NCT03010683|Drug|Liraglutide|Stimulation of Glucagon like peptide-1 receptor by liraglutide (Victoza) 1.8mg once daily as a subcutaneous injection
1494430|NCT03010683|Drug|Metformin|Antidiabetic drug-biguanide class (Glucophage) 1000mg twice daily per os
1494431|NCT03010670|Drug|Oxytocin|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
1494432|NCT03010670|Other|Placebo|A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril) will be administered before the assessment of the neurophysiological measures.
1494434|NCT03010644|Other|n/a - observational study|n/a - observational study
1494435|NCT03010631|Drug|Lubiprostone Capsule|48 mcg of capsule administered once orally under fasted condition
1494436|NCT03010631|Drug|Lubiprostone Sprinkle Formulation|48 mcg of sprinkle formulation administered once orally under fasted condition
1494437|NCT03010631|Drug|Lubiprostone Sprinkle Formulation|48 mcg of sprinkle formulation administered once orally under fasted condition
1494438|NCT03010631|Drug|Lubiprostone Sprinkle Formulation|48 mcg of sprinkle formulation administered once orally under fed condition
1494439|NCT03010618|Other|Hall technique stainless steel crowns|Primary carious tooth will be treated with stainless steel crowns without local anesthesia or caries removal and the increase in the occlusal vertical dimension will be monitored in two subsequent appointments with measuring canine overbite.
1494440|NCT03010605|Device|Measuring Every Day Device|
1494441|NCT03010605|Other|Physical Therapy|
1494442|NCT03010579|Drug|erythropoietin|Erythropoietin will be administered subcutaneously (s.c.) at the dose of 10 000 IU, three times a week. If necessary,oral ferrous succinate vitamins B12 and folic acid will be administered.
1494444|NCT03010553|Procedure|Detection and resection of sentinel lymph node|
1494445|NCT03010540|Drug|MORPHINE PLUS FENTANYL|Effect Of Morphine Plus Fentanyl On Emergence Delirium
1494446|NCT03010540|Drug|Fentanyl|Effect Of Fentanyl Only On Emergence Delirium
1494447|NCT03010527|Drug|Bimekizumab|"Subjects with a PASI90 response at Week 12 in PS0010 entering PS0011 will receive the same treatment dose.
Subjects who do not achieve PASI90 response at Week 12 in PS0010 will be assigned to a higher treatment dose.
Subjects that were initially randomized to bimekizumab dosage regimen 4 and 5 in PS0010 will receive bimekizumab dosing regimen 3."
1494448|NCT03010527|Other|Placebo|"Subjects with a PASI90 response at Week 12 in PS0010 entering PS0011 will receive placebo.
Subjects who do not achieve PASI90 response at Week 12 in PS0010 will be assigned to bimekizumab dosage regimen 1."
1494449|NCT03010501|Other|Food Energy Density|Food Energy density manipulated
1494450|NCT03010488|Behavioral|Morning Light Therapy|10,000 Lux light for 30 minutes through a light box each morning at patient's desired wake up time.
1494451|NCT03010488|Behavioral|Assigned Sleep Times|Sleep times will be assigned to subjects that will allow them to drive their regular sleep times closer to those they determine to be optimal at study initiation.
1494452|NCT03010488|Device|Goggles|Subjects will wear goggles during saliva collection and Bright Light Therapy
1494453|NCT03010475|Drug|Furosemide|Oral administration A total of three single doses.
1494454|NCT03010475|Drug|Rosuvastatin|Oral administration. A total of three single doses.
1494455|NCT03010475|Drug|SNAC|Oral administration. A total of five single doses.
1494456|NCT03010475|Drug|Semaglutide|Oral administration. Once daily.
1494457|NCT03010462|Device|Nexstim NBS guided active rTMS|Nexstim NBS guided active rTMS + standardized task-oriented therapy
1494458|NCT03010462|Device|Nexstim NBS guided sham rTMS|Nexstim NBS guided sham rTMS + standardized task-oriented therapy
1494459|NCT03010449|Device|Intra-bronchial valve and blood|Intra-bronchial valve implantation in combination with autologous blood instillation
1494460|NCT03010436|Drug|Benralizumab|one injection 30 mg under the subjects skin every 4 weeks for 8 weeks and then every 8 weeks for 24 weeks for a total of 5 treatments.
2001786|NCT02791204|Device|SPECT/CT imaging|Subjects will undergo resting perfusion imaging of the feet using two separate SPECT/CT systems. Subjects will be injected with a low dose radioisotope. In addition to heated venous blood sampling, arterial blood will be continuously sampled from the radial artery for calculation of a blood input function and K1 values for foot angiosomes.
1494463|NCT03010384|Other|Rehabilitation program|
1494464|NCT03010371|Behavioral|Positive Psychotherapy|Positive Psychotherapy (PP) is designed to treat cancer survivors with moderate/severe adaptation difficulties after completing cancer treatments (Ochoa et al., 2010). The objectives are the facilitation and promotion of post-traumatic growth and quality of life, and the reduction of emotional distress (anxiety, depression and post-traumatic symptoms). Secondary consequences of this psychological improvement is a better transition to daily life and the restoration of a good psychosocial functioning (labor reincorporation, adherence to treatments and follow-up, and the adoption of healthy lifestyles). The program consists of twelve sessions of 90 minutes per week in a closed group (5 to 7 participants). Each session focuses on the different topics and tasks defined in the Positive Psychotherapy for cancer survivors (Ochoa et al., 2010).
1494465|NCT03010371|Behavioral|Positive Online Psychotherapy|The Positive Online Psychotherapy (POP) is based on the PP program, but being adapted to an online version. Patients in this experimental condition will have access to a secure virtual platform (supervised and dependent from the Catalan Health Department). The POP consists of twelve weekly sessions of 90 minutes, in a closed-group format (5-7 participants). Patients have a simultaneous group-connection to the online platform, together with a clinical psychologist who lead the tasks according to the focuses of each session.
1494466|NCT03010371|Behavioral|Online Support Group|The Online Support Group (OSG) consists of a virtual patient community. Individuals assigned to this condition have web access to a private online forum in which they interact asynchronously (supervised and dependent by the Catalan Health Department). The forums have eight pre-defined topics that coincide with those of the previous experimental conditions. The forum is moderated and energized by the webmaster with the aim of increasing participation, solving basic technical problems and ensuring minimum rules of operation and respect. Participants can interact at any time of the day and their participations are registered and analyzed at the end of the group.
1494467|NCT03010358|Drug|Entospletinib|Given PO
1494468|NCT03010358|Other|Laboratory Biomarker Analysis|Correlative studies
1494469|NCT03010358|Biological|Obinutuzumab|Given IV
1494470|NCT03010358|Other|Pharmacological Study|Correlative studies
1494471|NCT03010345|Device|Osmed self inflating tissue expanders|Osmed self inflating tissue expanders will be placed 21 days before bone grafting the cleft to gain soft tissue coverage
1494472|NCT03010345|Other|Iliac bone graft|Bone grafting the cleft without the use of osmed self inflating tissue expander
1494473|NCT03010332|Biological|Cytomegalovirus-specific Cytotoxic T Lymphocytes (CMV-CTLs)|ATA230 (third-party donor-derived CMV-CTLs) are cytotoxic T lymphocytes that specifically kill cells presenting CMV protein antigens.
1494474|NCT03010319|Device|PriMatrix Dermal Repair Scaffold|Application of PriMatrix to ulcer
1494475|NCT03010319|Device|Secondary Dressings|Dressings to ensure moist wound environment
1494476|NCT03010319|Device|Offloading device|Offloading device to decrease pressure to wound area
1494477|NCT03010306|Other|CASITA|
1494478|NCT03010280|Dietary Supplement|Immunonutrition|Balanced high-protein formula enriched with Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
1494479|NCT03010280|Dietary Supplement|Balanced high-protein formula|Balanced high-protein formula, without Omega-3 fatty acids. 200 ml of formula every 8 hours during 10 days preoperatively
1494480|NCT03010267|Drug|DP-R213|Investigational product is prescribed to all of randomized subjects
1494481|NCT03010267|Drug|Raloxifene|Investigational product is prescribed to all of randomized subjects
1494482|NCT03010267|Drug|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
1494523|NCT03009994|Procedure|Non exteriorization of the uterus|
1497024|NCT02991573|Procedure|technique 2|
1494483|NCT03010241|Drug|Tangbi (prescription)|A kind of Granule(Tang bi fang) was made from five kind of Chinese herbs. Other: Standard medical care Standard medical care is in accordance with China Guideline for type 2 diabetes (2013).
1494484|NCT03010241|Drug|Placebo|"Granule(Placebo) is in accordance with Tangbi prescription in appearance, colour, taste.
Other: Standard medical care. Standard medical care is in accordance with China Guideline for type 2 diabetes (2013)."
1494485|NCT03010228|Biological|VLA15 with Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
1494486|NCT03010228|Biological|VLA15 without Alum|I.M. vaccination with a multivalent outer surface protein A (OspA) based vaccine candidate on days 0, 28 and 56; three different doses
1494487|NCT03010215|Other|Distal Metatarsal Minimally invasive Osteotomy (DMMO)|"Percutaneous dorsal incision at the level of the the distal part of the metatarsal bone, a Shannon burr is introduced at the level of metatarsal neck, with orientation of at approximately 45°, keeping the articular cartilage surface of the metatarsal head as reference point on the superior cortex.
In this position, under fluoroscopic control, the osteotomy is started following a distal-dorsal and proximal-plantar direction. In this way the metatarsal head moves proximally and dorsally reducing the metatarsal pressure on the plantar ulcer."
1494488|NCT03010202|Drug|Dexamethasone|Comparing the effect of Rituximab infusion With or without Dexamethasone
1494489|NCT03010202|Drug|Rituximab|Comparing maintenance dose of 500mg Rituximab at week 1 and week 24 to Placebo
1494490|NCT03010189|Device|Actigraphy|A small computer in the shape of a wristwatch, that registers movement and assesses sleep quality.
1494491|NCT03010189|Device|Heart-rate variability monitoring|A small computer that registers variation in heart rate, which reflects cardiac autonomic tone.
1494492|NCT03010189|Device|Pupillometry|A handheld infrared camera that sends out a light flash and records the pupil as it contracts and dilates, as a measure of pupillary autonomic tone.
1494493|NCT03010176|Drug|MK-1454|IT injection
1494494|NCT03010176|Biological|Pembrolizumab|IV infusion
1494495|NCT03010163|Other|Health Fair|Testing includes weight, height, waist and blood pressure testing
1494496|NCT03010163|Other|Pedometer|Tracks participants overall steps on a daily basis
1494497|NCT03010163|Other|Text Messaging|Daily healthy living advice and encouraging messages about walking through text messages
1494498|NCT03010163|Other|Social Network Support|Family or friends will provide encouragement and remind participants to maintain in a healthy lifestyle and increase daily walking activities
1494501|NCT03010137|Procedure|Incisional Negative Pressure Wound Therapy|
1494502|NCT03010137|Procedure|Standard Closure with Skin Glue|
1494503|NCT03010137|Device|PICO (Smith&Nephew)|Off the shelf, disposable negative pressure wound therapy device. Contains sterile dressing as well as an attached small (pager sized) suction device/canister.
1494504|NCT03010137|Device|Dermabond|Final wound closure with skin glue.
1494505|NCT03010124|Procedure|Blood sample|
1494506|NCT03010111|Other|QFT-IT Test and other blood sampling|In all enrolled health care workers, QFT-IT Test and other blood sampling were performed.
1494507|NCT03010098|Device|Dual-Loop TCI|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46
1494508|NCT03010098|Device|Open-Loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
1494509|NCT03010085|Procedure|Open left-sided hepatectomy|Open left-sided hepatectomy Laparotomy (upper midline, inverted 'L', or Benz incision) Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
1494510|NCT03010085|Procedure|Laparoscopic left-sided hepatectomy|Trocar insertion Mobilization of the liver Glissonian approach or individual isolation technique Left lateral sectionectomy or left hemihepatectomy
1494511|NCT03010072|Drug|low-dose sucroferric oxyhydroxide|250 mg suroferric oxyhydroxide
1494512|NCT03010072|Drug|high-dose sucroferric oxyhydroxide|2000 mg suroferric oxyhydroxide
1494513|NCT03010059|Drug|JNJ-64041575 (oral suspension formulation)|Participants will receive 240 mg JNJ-64041575 under fasted and fed conditions in Panel 1 as current/new concept oral suspension formulation.
1494514|NCT03010059|Drug|JNJ-64041575 (oral tablet formulation )|Participants will receive 250 mg JNJ-64041575 under fasted and fed conditions in Panel 2 as current/new concept oral tablet formulation.
1494515|NCT03010046|Drug|ANX005|Single ascending dose intravenous infusion
1494516|NCT03010046|Drug|IVIg|IVIg infusion in Cohorts 4b and 5b only. Randomized to ANX005 followed by IVIg or placebo followed by IVIg.
1494517|NCT03010046|Drug|Placebos|0.9% saline intravenous infusion
1494518|NCT03010033|Other|pulmonary rehabilitation|"pulmonary rehabilitation (preoperative part): lower extremity endurance training (using bike ergometer for 3 days, 2 times/day, 15-20min/time) or stair climbing training (3 days, 2 times/day, 30min/time), keep dyspnea index (Borg) score between 5 to 7 points. And inspiratory muscle training (using threshold inspiratory muscle trainer for 3 days, 5 times/day, 2 sessions/time, every session includes 10-20 cycle respirations).
pulmonary rehabilitation (postoperative part): inspiratory muscle training (using threshold inspiratory muscle trainer until hospital discharge, 3-5 times/day, 1 session/time, every session includes 10-20 cycle respirations)."
1494519|NCT03010020|Behavioral|PCC|Personalized Cognitive Counseling (PCC) sessions will be delivered as described above.
1494520|NCT03010020|Behavioral|Traditional Counseling|GC/CT-infected participants in the standard of care arm (and all GC/CT-negative participants screened for infection) will receive standard post-test counseling in accordance with Peruvian Ministry of Health guidelines.
1494521|NCT03009994|Procedure|Repair of uterine incision|
1494522|NCT03009994|Procedure|Exteriorization of the uterus|
2001787|NCT02788201|Drug|75 approved agents|One or combination of agents: Abiraterone, Arsenic Trioxide, Asparaginase Escherichia coli source, Axitinib, Azacitidine, Bendamustine, Bleomycin, Bortezomib, Busulfan, Carboplatin, Carfilzomib, Carmustine, Chlorambucil, Cisplatin, Cladribine, Clofarabine, Crizotinib, Cytarabine, Dacarbazine, Dactinomycin, Dasatinib, Daunorubicin, Decitabine, Docetaxel, Doxorubicin, Epirubicin, Eribulin, Erlotinib, Estramustine, Etoposide, Exemestane, Floxuridine, Fludarabine, Fluorouracil, Gefitinib, Gemcitabine, Hydroxyurea, Idarubicin, Ifosfamide, Imatinib, Irinotecan, Ixabepilone, Lapatinib, Lomustine, Mechlor, Melphalan, Mercapto, Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Nilotinib, Oxaliplatin, Paclitaxel, Pazopanib, Pentostatin, Romidepsin, Ruxolitinib, Sorafenib, Streptozocinm, Sunitinib, Tamoxifen, Temsirolimus, Teniposide, Thioguanine, Thiotepa, Topotecan, Toremifene, Tretinoin, Vandetanib, Vemurafenib, Vinblastine, Vincristine, Vismodegib, and/or Vorinostat
2001788|NCT02788201|Other|COXEN|The COXEN algorithm will be used to determine the next best therapy from among 75 FDA approved agents (single agent or combination) in patients that have progressed on at least one chemotherapy regimen.
2001789|NCT02788604|Other|Summary of psychosocial risk factors|The treatment team will receive a psychosocial risk summary shortly following diagnosis based on parent report.
1494528|NCT03009968|Other|Post-void residual free voiding trial|Will proceed with voiding trial and assess bladder emptying based on voided amount without checking a post-void residual.
1494529|NCT03009929|Other|Observational study|No intervention, observational only
1494530|NCT03009916|Drug|"cholestagel® (Colesevelam)"|3750mg
1494531|NCT03009916|Drug|Placebos|3750mg
1494532|NCT03009890|Procedure|Surgery (Open Reduction Internal Fixation)|Either volar of dorsal plating or both
1494533|NCT03009890|Procedure|Cast treatment|Hospitals may use their preferred protocol
1494534|NCT03009877|Device|Optiflow F&P 850™ System|"Optiflow™ (Fisher & Paykel Healthcare Limited, East Tamaki, Auckland-New Zealand) offers the ability to comfortably deliver a complete range of oxygen concentrations and flows to extend the traditional boundaries of oxygen therapy.
This will be placed on the patient immediately upon entering the operating room for 5 minutes, at 50 liters per minute then increased to 70 liters per minute after induction."
1494535|NCT03009877|Device|facemask|We will apply the facemask to the patient immediately upon entering the operating room to pre-oxygenate for five minutes.
1494536|NCT03009877|Drug|Rocuronium|Rocuronium will be administered after the ability to mask ventilate is determined.
1494537|NCT03009877|Drug|Propofol|Propofol infusion 50 micrograms to 150 micrograms will be administered immediately on induction to maintain sedation throughout apneic oxygenation.
1494538|NCT03009877|Drug|Fentanyl|Fentanyl will be administered at the beginning of induction, 2 micrograms per kilogram.
1494539|NCT03009877|Drug|Midazolam|midazolam will be given upon induction, 1-2 milligrams at the anesthesiologist's discretion.
1494540|NCT03009877|Device|C-MAC Premium Video Intubation Platform-KARL STORZ|After patient is induced, the 5.5mm flexible intubation video scope (C-MAC Premium Video Intubation Platform-KARL STORZ) will then be introduced into the oropharynx and advanced into the trachea with the assistance of the C-MAC video laryngoscope (3 or 4 blade based on anesthesiologist's discretion).
1494541|NCT03009864|Drug|Tangshen Prescription|The prescription contains granules of five Chinese herbal medicines, every bag weighs 4.87g, take it one bag each time, two times a day.
1494542|NCT03009864|Drug|Placebos|Treatment with placebo corresponding to each dose of Tangshen Prescription , every bag weighs 4.87g, take it one bag each time, two times a day.
1494543|NCT03009851|Behavioral|OBCHI|Occupation-based cultural heritage intervention emphasizing the cultural background of residents in LTC settings.
1494544|NCT03009838|Drug|Letrozole|oral tablets 2.5 mg
1494545|NCT03009838|Procedure|ovarian drilling|laparoscopic electrocauterization
1494546|NCT03009812|Procedure|Longitudinal uterine incision|
1494547|NCT03009812|Procedure|Transverse uterine incision|
1494548|NCT03009799|Drug|Iota-Carrageenan|One drop in each eye 8 times per day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until Day 21
1494549|NCT03009799|Drug|Carmellose|1 drop in each eye 8 times/day for 7 days (mandatory), then 4 to 8 times/day for the next 14 days until day 21
1494551|NCT03009773|Other|rehabilitation multitasking walking.|rehabilitation multitasking walking.
1494552|NCT03009773|Other|Traditional walking rehabilitation|Traditional walking rehabilitation
1494553|NCT03009760|Drug|CJ-12420 50mg(HP-)|CJ-12420 50mg in H. pylori negative subject
1494554|NCT03009760|Drug|CJ-12420 100mg(HP-)|CJ-12420 100mg in H. pylori negative subject
1494555|NCT03009760|Drug|CJ-12420 50mg(HP+)|CJ-12420 50mg in H. pylori positive subject
1494556|NCT03009760|Drug|CJ-12420 100mg(HP+)|CJ-12420 100mg in H. pylori positive subject
1494557|NCT03009734|Drug|ATx201 dermal formulations 2%|Topical application of ATx201 dermal formulations 2%
1494558|NCT03009721|Drug|Other: Not applicable-observational study|
1494559|NCT03009708|Other|Blood samples|Two blood tubes will be collected each week during 8 weeks maximum for the present study. Samples will start at day 30 post-graft and finish at day 90 post-graft maximum.
1494560|NCT03009695|Device|High frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically high-frequency rTMS (18 Hz) enhances cortical excitability.
1494592|NCT03009461|Drug|Sorafenib|400 mg of sorafenib (consisting of two 200-mg tablets) twice daily.
1494593|NCT03009448|Other|Interview|Each subject will be interviewed using a semi constructed interview.
1494594|NCT03009435|Other|prophylactic manual rotation|
1494595|NCT03009422|Drug|Local application pentostam|
1494596|NCT03009422|Drug|intra-lisional pentostam|
1494597|NCT03009422|Device|fractional CO2 laser|
1494844|NCT03007589|Drug|otc sunscreens|Sunscreens of various SPF levels and ingredients
1494561|NCT03009695|Device|Low frequency repetitive dTMS|Focal rTMS will be performed using a Magstim Rapid2 magnetic stimulator (The Magstim Co. Ltd., U.K.) equipped with an H-shaped coil. The used H-coil version is the H-addiction specifically designed to stimulate the insula and the Pre-Frontal Cortex (PFC). This novel H-coil allows direct stimulation of deeper brain regions, like insula (3 cm vs 1.5 cm from the skull). Before each stimulation the resting Motor Threshold (rMT) should be determined. The rMT will be determined over the left primary motor cortex, afterwards the coil will be moved forward 6 cm anterior the motor spot and aligned symmetrically over the PFC and insula. Repetitive dTMS induces long-lasting changes in neural excitability and dopamine release, specifically low-frequency rTMS (1 Hz) inhibits cortical excitability.
1494562|NCT03009695|Device|Sham|Sham stimulation will be performed by an H-sham-coil. The H-sham-coil is designed to mimic the auditory artifacts and the scalp sensation evoked by the real coil, without stimulating the brain itself. As in the other groups, in each patient the rMT will be determined before each repetitive dTMS session. The sham stimulation will be performed either at high frequency (50% of subjects) or at low-frequency (50% of subjects), according to the previously described methodologies. All obese people in this group will be submitted at the sight of food preferred (cue).
1494563|NCT03009682|Drug|Olaparib|"Dosage and Schedule : Olaparib 300 mg BID per os every 12 hours administered daily. One cycle is consisted of 21 days.
Two x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water. The olaparib tablets should be swallowed whole and not chewed, crushed, dissolved or divided. Olaparib can be taken with a light meal/snack."
1494564|NCT03009656|Other|No study specific interventions|
1494565|NCT03009643|Drug|Inhaled Nitric Oxide|Patients are treated with iNO for 3-5 days.The concentration of inhaled Nitric Oxide is around 5-10ppm.
1494566|NCT03009643|Device|lung protective mechanical ventilation|Mechanical ventilation in the SIMV mode (ventilators Evita 2 or 4,Dräger, Lübeck, Germany) with VT 6-8ml/kg
1494567|NCT03009643|Device|Hemodynamic monitoring|Flotrac/Vigileo (Edwards Lifesciences) are used to guide the fluid management.
1494568|NCT03009630|Procedure|RFA|Patients diagnosed with early-stage NSCLC and signing the informed consent will be performed RFA under the guidance of ENB.
1494569|NCT03009630|Device|ENB|ENB will be used to guide bronchoscope into the accurate location of the lesion during RFA.
1494570|NCT03009617|Behavioral|the educational program and counseling|to examine the effectiveness of web-based health education and consultation on health promotion behaviors of adolescents, their e-health literacy, and their information levels.
1494571|NCT03009604|Drug|Simethicone|Simethicone 40mg oral tablets
1494572|NCT03009604|Drug|Enema|sodium dihydrogen phosphate dihydrate 19.2 gram & disodium hydrogen phosphate dodecahydrate 7.2 gram, in addition to purified water
1494573|NCT03009591|Other|Experimental group|"Longitudinal surface sliding maneuver over the superficial fascia in the anterior region of the arm and the forearm. Applied in 3 strokes.
Transverse sliding maneuver of the flexor muscles of the wrist and fingers.
Transverse sliding maneuver for the biceps brachii muscle.
Longitudinal surface sliding maneuver over the superficial fascia in the posterior arm region.
Transverse sliding maneuver over the brachial triceps tendon.
Transverse sliding maneuver for the pectoralis major muscle.
Transverse sliding maneuver for the posterior axillary region pectoralis major muscle.
Induction maneuver of the fascia of the posterior axillary fold.
Induction maneuver (crossed hands over the brachial region and forearm).
Maneuver of transverse planes for the cervicothoracic region.
Upper limb telescopic maneuver."
1494574|NCT03009578|Drug|Iron Sucrose Injection|iron Intramuscular injections
1494575|NCT03009578|Drug|Ferrous Bisglycinate|oral iron tablets
1494576|NCT03009565|Other|coronary artery disease|
1494577|NCT03009552|Procedure|speckle tracking echocardiography|Speckle tracking echocardiography is used for measuring parameters of cardiac mechanics: left ventricle strain and strain rate; left ventricle twist, untwist and torsion; left atrium strain and strain rate; right ventricle longitudinal strain and strain rate. Echocardiography will be performed within 24 hours of admission, 72 hours after admission and 1 month after discharge.
1494578|NCT03009539|Behavioral|eHealth Familias Unidas Primary Care|"The experimental condition will consist of eHealth Familias Unidas Primary Care. eHealth Familias Unidas Primary Care is an adaptation of the face-to-face version of Familias Unidas. As with face-to-face Familias Unidas, eHealth Familias Unidas Primary Care aims to prevent drug use, sexual risk behaviors, and STIs by improving family functioning. Similar to face-to-face Familias Unidas, eHealth Familias Unidas is a multi-level intervention that targets risk and protective factors at the multiple systems affecting the youth and youths' family."
1494579|NCT03009526|Drug|Sulfadoxine-pyrimethamine|
1494580|NCT03009526|Drug|dihydroartemisinin-piperaquine|
1494581|NCT03009513|Drug|Teneligliptin+Glimepiride|
1494582|NCT03009500|Drug|Bupivacaine|
1494583|NCT03009500|Drug|Depo-Medrol Injectable Product|
1494584|NCT03009500|Other|Saline (Sodium Chloride) solution|
1494585|NCT03009500|Drug|Lidocaine|Each injection of study medications will be preceded by subcutaneous injections of 1 mLs of 2% lidocaine at each injection site to reduce discomfort of the study participants from the injections
1494586|NCT03009487|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug), Rosuvastatin 20mg|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Crestor Tab. 20mg(Rosuvastatin 20mg) and placebo of Olmesartan 40mg
1494587|NCT03009487|Drug|Olmesartan 40 mg, Rosuvastatin 20mg|co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Crestor tab. 20mg(Rosuvastatin 20mg) and placebo of Sevikar Tab 10/40mg(Amlodipine/Olmesartan 10/40mg).
1494588|NCT03009487|Drug|Amlodipine/Olmesartan 10/40mg (Combination drug)|co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg) 10/40mg, Placebo of Olmesartan Tab. 40mg and Placebo of Rosuvastatin 20mg
1494589|NCT03009474|Drug|CJ-30060|Fixed-dose combination drug containing Amlodipine 5 mg and Valsartan 160 mg and Rosuvastatin 10 mg
1494590|NCT03009474|Drug|Exforge tab 5/160mg, Crestor tab 10mg|Co-administration of Amlodipine 5 mg/ Valsartan 160 mg(combination drug) and Rosuvastatin 10 mg
1494591|NCT03009461|Procedure|HAIC|Intra-arterial chemotherapy consisted of infusions of oxaliplatin (35 mg/m2 for 2 hours), followed by 5-fluorouracil (600 mg/m2 for 22 hours) on day1-3 every 4 weeks. For each cycle, leucovorin calcium 200 mg/m2 was intravenously administered for 2 hours from beginning of 5-fluorouracil infusion.
1494643|NCT03009058|Biological|Anti-PD1|Standard of Care immunotherapy
1494598|NCT03009409|Drug|Ketamine Injectable Solution|"Once IV access has been obtained and a facemask has been applied for pre-oxygenation, the loading dose (0.5 mg/kg) of the study drug will be given over 60 seconds and the fixed infusion (10 mcg/kg/min to a maximum of 60mg/hour) will be initiated by the anesthetist through the pump interface.
The study drug will be infused at a constant rate of 10 mcg/kg/min throughout the maintenance phase, until the end of the procedure (last suture), up to a maximum cumulative dose of 200 mg. If at any point the anesthesiologist feels that it is clinically necessary to reduce the amount of study drug infusion rate, they may opt to reduce the infusion rate by 50% (to 5 mcg/kg/min), or stop the infusion entirely."
1494599|NCT03009409|Other|Placebo|Participants in the control group will receive an equivalent volume bolus and infusion of normal saline to mimic the ketamine infusion in the ketamine group.
1494601|NCT03009383|Device|A bedside portable endoscopy|
1494602|NCT03009344|Drug|tazemetostat|tazemetostat tablets
1494603|NCT03009331|Procedure|Lungrecruitment manoeuver in prone position.|Postoperative lungrecruitment in prone position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
1494604|NCT03009331|Procedure|Lungrecruitment manoeuver in supine position.|Postoperative lungrecruitment in supine position, pressure-controlled ventilation peak inspiratory pressure 40 cm H2O combined with PEEP 20 cm H2O during 60 seconds.
1494605|NCT03009318|Other|tumors are confirmed by surgery and pathology|Each patient undergoes both MRS imaging and 11C-MET PET/CT scan prior to surgery. The lesion will be considered as a glioma when either MRS or 11C-MET PET/CT results indicated the diagnosis. Pathologic diagnosis will be performed to confirm the final diagnosis.
1494606|NCT03009305|Other|Lower body negative pressure|Model of hypovolemia: Lower body negative pressure down to -80 mmHg (maximum).
1494607|NCT03009305|Device|Continuous positive airway pressure|CPAP of 0, 5 and 10 cm water (H2O).
1494608|NCT03009305|Device|Positive expiratory pressure|PEP of 0, 5 and 10 cm H2O.
1494609|NCT03009292|Drug|lenvatinib|once daily continuous dosing
1494610|NCT03009266|Drug|Sonazoid|Myocardial contrast echocardiography ischemic memory imaging using intravenous administration of Sonazoid
1494611|NCT03009253|Other|order of treatment|the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
1494612|NCT03009240|Drug|Decitabine|Given IV
1494613|NCT03009240|Other|Laboratory Biomarker Analysis|Correlative studies
1494614|NCT03009240|Drug|Pevonedistat|Given IV
1494615|NCT03009240|Other|Pharmacological Study|Correlative studies
1995692|NCT02679274|Drug|Testosterone|Intermittent intramuscular injections of 100 mg Testosterone Enanthate (males) or 25 mg Testosterone Enanthate (females).
1494618|NCT03009214|Drug|AMC303|AMC303 is a CD44v6 inhibitor blocking receptor tyrosine kinase (RTK) pathways
1494619|NCT03009201|Drug|Doxorubicin|Given IV
1494620|NCT03009201|Drug|Ribociclib|Given PO
1494621|NCT03009175|Device|Implantable Cardiac Defibrillator, Cardiac Resynchronization Therapy Defibrillator/Pacemaker|
1494622|NCT03009162|Drug|Lasmiditan|200 mg, single oral tablet
1494623|NCT03009149|Other|Aerobic exercise|Aerobic exercise will perform 3 days per week
1494624|NCT03009136|Drug|SCRT|composed of eight herbs: Glycyrrhiza uralensis Fischer 1g Zingiber officinale Roscoe 0.5g Cinnamomum cassia Blume 0.2g, Ephedra sinica Stapf 0.5g, Pinellia ternata Breitenbach 2.67g, Paeonia lactiflora PALL 1g, Asiasarum sieboldi F. Maekawa 0.5g, Schisandra chinensis 2.67g (per 9g of granules)
1494625|NCT03009136|Drug|Placebos|is made of lactose, corn starch and caramel coloring, and has appearance, shape, weight, taste, and color similar to SCRT
1494626|NCT03009123|Other|Erectile dysfunction|Patients with ED are considered belonging to the exposure group.
1494627|NCT03009110|Device|Prophylactic NPWT|The Prevena NPWT system is a small, lightweight, portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary foam and adhesive dressing. It is supplied as a pump with a sterile dressing kit and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 13 to 20 cm and more. The pump maintains negative pressure of -125 mmHg to the wound surface. The device is placed after skin closure.
1494628|NCT03009110|Device|Standard Dressing|Standard wound dressing is routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
1494629|NCT03009097|Biological|DFDBA|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
1494630|NCT03009097|Drug|DFDBA with atorvastatin|13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel
1494631|NCT03009084|Behavioral|Lifestyle counseling|Lifestyle counseling of modifiable risk factors of chronic kidney disease: telemonitoring of blood pressure, counseling for smoking cessation, losing weight and increasing the physical activity.
1494632|NCT03009071|Procedure|Doin (conduction exercise)|Doin (conduction exercise) will be combined with acupuncture as active and passive movement to the aim of effective treatment of pain and functional disability. Doin (conduction exercise) sessions will be conducted 2 times a week for 5 weeks.
1494633|NCT03009071|Device|Acupuncture|Acupuncture will be performed with manual stimulation (needle twirling) to evoke de-qi sensation. Acupuncture sessions will be conducted 2 times a week for 5 weeks.
1494634|NCT03009058|Biological|IMM-101|A suspension of heat killed whole cell Mycobacterium obuense NCTC 13365
1494635|NCT03009058|Drug|Gemcitabine|Standard of Care chemotherapy
1494636|NCT03009058|Drug|Nabpaclitaxel|Standard of Care chemotherapy
1494637|NCT03009058|Drug|Capecitabine|Standard of Care chemotherapy
1494638|NCT03009058|Drug|Folinic Acid|Standard of Care chemotherapy
1494639|NCT03009058|Drug|Fluorouracil|Standard of Care chemotherapy
1494640|NCT03009058|Drug|Irinotecan|Standard of Care chemotherapy
1494641|NCT03009058|Drug|Oxaliplatin|Standard of Care chemotherapy
1494642|NCT03009058|Biological|cetuximab|Standard of Care immunotherapy
1494651|NCT03009006|Drug|Chlorhexidine 2% gel - Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide Mixed With Chlorhexidin efficacy of calcium hydroxide and 2 % chlorhexidine gel and combination of both on the anaerobic bacteria, It was clear from the study that calcium hydroxide had limited efficacy against facultative anaerobes, but effective against obligate anaerobes while chlorhexidine only and combination group were effective against all species of anaerobic bacteria
1494652|NCT03009006|Drug|Calcium Hydroxide Paste - Non-Setting|Calcium Hydroxide The antimicrobial activity of calcium hydroxide Ca(OH)2 is related to the release of hydroxyl ions in an aqueous environment leading to damage in the bacterial cytoplasmic membrane, protein denaturation and DNA damage
1494653|NCT03008993|Behavioral|HQIS implementation|
1494654|NCT03008980|Other|Diagnostic Test|
1494655|NCT03008967|Other|Arthroplasty and postoperative rehabilitation.|Patients undergoing total knee or total hip arthroplasty and their response to postoperative rehabilitation.
1494656|NCT03008941|Biological|FMT|Capsules with fecal microbiota from healthy donors
1494657|NCT03008941|Other|Placebo|Placebo capsules
1494658|NCT03008928|Behavioral|Alcooquizz|
1494659|NCT03008915|Drug|Aspirin|81mg aspirin taken once per day in the morning
1494660|NCT03008915|Drug|Placebo|placebo taken once per day in the morning
1494661|NCT03008902|Procedure|Near-infrared passive motion capture recording|Full body movement will be recorded during movements using near infrared passive motion capture. This procedure is non-invasive and standard practice in biomechanics labs. Movement will be recorded using an eight-camera system. Retroreflective markers are placed at strategic joint locations to characterize limb movement. Accuracies of the marker positions are sub-millimeter, and allow accurate characterization of limb rotation and translation during movements. Passive reflective marker clusters (3 markers each) will be attached to subjects at 8 locations along the spine. Additional markers will be applied to the manubrium of the sternum, head, pelvis, and extremities. Eight EMG surface electrode pairs will be used to record activation from the left and right erector spinae, latissimus dorsi, trapezius and rectus abdominis muscles during all motions.
1494664|NCT03008876|Drug|Acetaminophen|infants receive acetaminophen for treatment of their PDA
1494665|NCT03008876|Drug|Ibuprofen|infants receive ibuprofen, standard of care in our unit, for treatment of a PDA
1494666|NCT03008863|Other|Education|
1494667|NCT03008850|Drug|MgSo4|"Patients will be randomly allocated to one of two groups:
Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.
Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
1494668|NCT03008850|Drug|Placebo|"Patients will be randomly allocated to one of two groups:
Group (M): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml (25 mg) MgSO4 will be injected intrathecally.
Group(P): 2 ml (10 mg) of 0.5% heavy bupivacaine plus 0.5 ml normal saline will be injected intrathecally."
1494669|NCT03008837|Device|Military Field Stimulator|The Military Field Stimulator (MFS/Neuro-Stim System), a percutaneous electrical neural field stimulation (PENFS) device evolved from PENS, is currently employed by the United States (US) military and used in the VA (contract number V797D-50453). There is some evidence based on a small trial of 20 postoperative patients that suggests PENS may have greater benefit than acupuncture for acute pain.
1494670|NCT03008837|Other|Standard Therapy|Standard therapy for fibromyalgia will include physical therapy, medication management through the Anesthesiology Pain Clinic, and referral to a pain psychologist.
1494671|NCT03008811|Procedure|Pulmonary vein isolation with cryoballoon catheter.|Device: Arctic Front Advance™ cardiac cryoablation catheter system.
1494672|NCT03008811|Procedure|Pulmonary vein isolation with radiofrequency ablation.|Device: TactiCath™ Quartz irrigated ablation catheter (St. Jude Medical) with aid of 3-D mapping system (EnSite Precision, St. Jude Medical).
1494673|NCT03008798|Drug|Herbal Medicine C-117|C117 formula including 2 herbals and 2 insects
1494674|NCT03008798|Drug|The Placebo of Herbal Medicine C-117|
1494675|NCT03008785|Other|exercise|The training program consisted of aerobic and resisted combined physical exercises performed during 10 weeks, three times weekly with 45 minutes sessions: 5 minutes of warm-up on treadmill, 20 minutes of aerobic exercises and 20 minutes of resistance exercises.
1494676|NCT03008785|Other|isoflavone|Daily supplementation in 1 capsule per day of 100mg of isoflavones (containing 3.3% genistein, 93.5% dadzein and 3.2% glycitein).
1494677|NCT03008785|Other|Placebo|Daily supplementation in 1 capsule per day containing starch of corn.
1494678|NCT03008759|Other|Dentifrice 100% Nano-F|Use of few of dentifrice 100% Nanoencapsulated Fluoride on brushing for one week, twice day.
1494679|NCT03008759|Other|Dentifrice 50% Nano-F|Use of few of dentifrice 50% Nanoencapsulated Fluoride on brushing for one week, twice day.
1494680|NCT03008759|Other|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluorid
1494684|NCT03008733|Other|Ultrasound UHF peripheral nerves|
1494685|NCT03008733|Other|Electro myography surface nerves|
1494686|NCT03008720|Device|Transcranial direct current stimulation (tDCS)|
1494687|NCT03008720|Device|Functional electrical stimulation (FES)|
1494688|NCT03008720|Device|Sham stimulation|
1494845|NCT03007589|Other|sun protection fabrics|fabrics
1995694|NCT02678715|Device|Solubrux®|prefabricated device adaptable by temperature
1995695|NCT02678715|Device|Customized Appliance|customized device fabricated in the dental laboratory
1995696|NCT02678715|Device|Somatics®|standard device
1995697|NCT02677922|Drug|AG-120|
1995698|NCT02677922|Drug|Azacitidine|
1995699|NCT02677922|Drug|AG-221|
1995700|NCT02677311|Procedure|Blood draw|Blood draws will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
1995701|NCT02677311|Procedure|Pelvic Ultrasound|Pelvic ultrasound will be performed immediately prior to GnRHa treatment and at 6 and 12 months following treatment completion
1995702|NCT02676050|Other|Optical Imaging Agents (EMI-137, NAP)|Both optical imaging agents (NAP and EMI-137) will be administered to each patient during a bronchoscopy procedure. A novel delivery catheter (to deliver both agents), imaging fibre and endomicroscopy system with viewer software will be used to detect c-MET and activated neutrophil signal in the human lung.
1494689|NCT03008707|Procedure|LPL is done by irrigation with at least 6 L of warm saline throughout the abdominal cavity and after that, putting a drain in Douglas cavity through the port sites|
1494690|NCT03008694|Device|PET/CT|pet/ct is used as radiotherapy simulation
1494691|NCT03008681|Device|Andresen functional removable orthodontic appliance|Included patients were treated for 24 months with a Functional removable orthodontic appliance, the Andresen activator. The initial checks were performed after 6 weeks with subsequent checks being carried out every 8th week, with the final follow-up at 24 months. The patient underwent functional treatment using the activator described in the protocol with midlines coincidence.
1494692|NCT03008668|Other|acupuncture|
1494693|NCT03008655|Procedure|intradermal tranexamic acid|intradermal tranexamic acid injection
1494694|NCT03008655|Device|Nd-YAG|six session at two-week interval of low influence 1064 Nd:YAG laser (6 mm spot size, energy fluence 1.2 - 1.4 J/cm 2 at 10 Hz)
1494695|NCT03008642|Other|using the CO-Rebreathing technique at diagnosis of polycythemia|The intervention consists in one red cell mass determination using the CO-Rebreathing technique at diagnosis of polycythemia, in addition to the regular tests performed in this indication, including RCM isotopic measurement.
1494696|NCT03008629|Device|Podofix nail brace|Podofix nail brace
1494697|NCT03008629|Device|Combiped nail brace|Combiped nail brace
1494698|NCT03008629|Device|Podofix and then Combiped nail brace|Podofix and then Combiped nail brace
2001790|NCT02788604|Other|Control|The treatment team will NOT receive a psychosocial risk summary shortly following diagnosis based on parent report.
2001791|NCT02786797|Behavioral|MBSR(BC) 6 Week Program|The MBSR(BC) is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. It incorporates simple yoga, sitting meditation, body scan, and walking meditation in this program. Classes for this intervention occur on a weekly basis for 2 hours for 6 weeks. The participants will be asked to record their informal/formal practices in a daily diary during the program and from 6 weeks to 6 months after the intervention.
1494701|NCT03008603|Device|XACT Robotic System|The XACT device is a real-time, CT image guided, 3-dimensional robotic system. The XACT device is intended for use as an image guided positioning and steering system for insertion of clinical tools, such as biopsy needles, ablation needles, etc., during minimally invasive percutaneous procedures. The system is defined to guide (i.e., position and steer) the tool according to a predefined trajectory following a registration process between the device's coordinate system and real-time CT images.
1494702|NCT03008590|Drug|Naltrexone|One 4.5 mg capsule each evening
1494703|NCT03008590|Drug|Placebo|One capsule each evening
1494704|NCT03008577|Other|Change in ambient operating room temperature|
1494705|NCT03008564|Other|Ultrasound scanning of the lower limb in volunteers|"Several reference points will be marked by anatomical landmarks and/or ultrasound: the anterior superior iliac spine; base of patella; apex of the femoral triangle A measuring tape will be used to measure the anterior superior iliac spine (landmark); the base of the patella (landmark); apex of femoral triangle (ultrasound); and distal most portion of adductor canal (Point B described earlier; ultrasound). We will then measure the ASIS to: 1) base of patella; 2) apex of femoral triangle; and 3) Point B. We will repeat the same procedure on the opposite leg. Once complete, the volunteer will be allowed to dress and leave. The procedure should take approximately 10-20 minutes for each volunteer. The following things will be recorded for each subject:
Age
Gender
Weight
Height
BMI
Distance of ASIS to base of patella
Distance of Point A to base of patella
Distance of Point B to base of patella
Distance of apex of femoral triangle to base of patella"
1494706|NCT03008551|Drug|Empagliflozin|Each participant will receive empagliflozin 25mg daily for 3 months.
1494707|NCT03008551|Drug|Metformin|Each participant will receive metformin 1500mg daily for 3 months.
1494708|NCT03008538|Other|MPM(Mineralized plasmatic matrix).|Preparation of sticky bone graft by addition of growth factors obtained from patient's vebous blood.
1494709|NCT03008538|Other|Autogenous Bone Graft|Socket preservation using autogenous bone graft for preservation of bone width and height for future implant insertion.
1494710|NCT03008525|Biological|subcutaneous and visceral adipose tissue biopsies|
1494711|NCT03008525|Biological|blood samples analysis|
1494712|NCT03008512|Drug|Genexol-PM|
1494713|NCT03008499|Biological|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
1494714|NCT03008486|Device|Real soft splint (6 cm)|
1494715|NCT03008486|Device|Placebo soft splint (1 cm)|
1494716|NCT03008473|Device|Glidescope and chest CT iminge|
1494717|NCT03008473|Device|Fiberoptic Bronchoscope|
1494724|NCT03008434|Other|Assigned Interventions|Yoga Group: designed for chronic TBI was provided two times a week for 8 weeks.
1494725|NCT03008421|Dietary Supplement|Astarte® (Pizeta Pharma S.p.a., Ponte San Giovanni, Italy)|
1494726|NCT03008421|Other|Placebo|Identical-looking oral potato-maltodextrin-based placebo
1494727|NCT03008408|Drug|Ribociclib|"Phase I Safety Lead-In: Ribociclib 250 mg by mouth daily for 28 days.
Phase II: Ribociclib 250 mg (or dose determined by Safety Lead-In) by mouth daily for a 28 day cycle."
1494728|NCT03008408|Drug|Everolimus|"Phase I Safety Lead-In: Everolimus 2.5 mg by mouth daily for 28 days.
Phase II: Everolimus 2.5 mg (or dose determined by Safety Lead-In) by mouth daily for a 28 day cycle."
1494729|NCT03008408|Drug|Letrozole|"Phase I Safety Lead-In: Letrozole 2.5 mg by mouth daily for 28 days.
Phase II: Letrozole 2.5 mg (or dose determined by Safety Lead-In) by mouth daily for a 28 day cycle."
1494730|NCT03008395|Behavioral|EMMA|Dialogue tools will be used to develop personally relevant behavioural goals consistent with diabetes self-management
1494731|NCT03008395|Other|Treatment as Usual|Participants randomized to this intervention will receive standard diabetes education sessions. These include group education session and follow up session based on clinician-generated recommendations.
1494732|NCT03008382|Drug|Metoprolol Oral Tablet|Metoprolol is a beta-blocker commonly used for mild blood pressure control, and also commonly used for migraine. Subjects with IC/BPS or MPP will start metoprolol at 25 mg once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
1494733|NCT03008382|Drug|Placebo Oral Tablet|Subjects with IC/BPS or MPP will start placebo distributed in a double-blind manner. Subjects will take placebo once daily and increase to the goal dose of 25 mg 2/day after one week and continue for 8 weeks total.
1494734|NCT03008369|Other|Laboratory Biomarker Analysis|Correlative studies
1494735|NCT03008369|Drug|Lenvatinib|Given PO
1494736|NCT03008369|Other|Quality-of-Life Assessment|Ancillary studies
1494737|NCT03008356|Dietary Supplement|L-carnitine 1000 mg twice daily|Oral L-carnitine to be taken twice daily for 8 weeks
1494738|NCT03008356|Behavioral|Weekly health coaching calls|Weekly health coaching calls lasting 10-15 minutes
1494739|NCT03008356|Dietary Supplement|Placebo capsules|
1494740|NCT03008343|Device|Irreversible Electroporation|One kind of electric ablation machine from Angiodynamic company (USA)
1494741|NCT03008343|Biological|Natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
1494742|NCT03008330|Biological|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
1494743|NCT03008317|Device|PEEK|a metallic denture base
1494744|NCT03008304|Drug|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
1494745|NCT03008291|Procedure|CRT-D Implantation|Cardiac resynchronization therapy defibrillator
1494746|NCT03008291|Procedure|CRT-P Implantation|Cardiac resynchronization therapy pacemaker
1494747|NCT03008291|Procedure|Dual Chamber Pacemaker Implantation|
1494748|NCT03008278|Other|Laboratory Biomarker Analysis|Correlative studies
1494749|NCT03008278|Drug|Olaparib|Give PO
1494750|NCT03008278|Other|Quality-of-Life Assessment|Ancillary studies
1494751|NCT03008278|Biological|Ramucirumab|Given IV
1494752|NCT03008265|Other|Postoperative fascial dehiscence|
2001792|NCT02786797|Behavioral|BCES 6 Week Program|"The BCES is an education support program. This 6-week program is based on the published NIH program, Support for People with Cancer: Taking Time Education Support Group. In addition the class sessions consist of group discussion of educational materials and homework assignments; and group processes related to sharing supportive care situations. The participants will record their feelings, coping mechanisms, and questions related to survivorship in a daily diary during the program and from 6 weeks to 6 months after the intervention."
2001793|NCT02787798|Drug|valsartan/sacubitril 100 mg|Treatment with 100 mg tablets during 2 to 4 weeks
1494755|NCT03008239|Device|FiberSense sensor|The FiberSense system is a glucose-monitoring device indicated for continually recording interstitial fluid glucose levels in patients ages 18 and older with insulin dependent diabetes mellitus for the purpose of improving diabetes management.
1494756|NCT03008239|Device|Dexcom Sensor|Dexcom is a continuous glucose monitoring (CGM) system. The display device shows the glucose readings and the trend.
1494757|NCT03008226|Device|Implementation of 9 mm intrabronchial valves|
1494758|NCT03008213|Drug|Netupitant and Palonosetron|300 mg of netupitant and 0.5 mg of palonosetron
1494759|NCT03008200|Device|ultrasound examination|intrauterine fetal pulmonary artery acceleration time to ejection time ratio measurement via ultrasound
2001794|NCT02787798|Drug|valsartan/sacubitril 200 mg|Treatment with 200 mg tablets during 2 to 4 weeks
1494761|NCT03008174|Other|Early one-way speaking valve (OWSV) assessment|The OWSV assessment by speech language pathologists will be completed at 12-24 hours following percutaneous tracheostomy procedure, which is earlier than the current standard of care of 48 hours or later.
1494762|NCT03008161|Drug|NPT088|IgG1 Fc-GAIM fusion protein, a recombinant fusion protein
1494763|NCT03008161|Drug|Placebo|Placebo
1494764|NCT03008148|Radiation|CCRT|CCRT Phase: Radiation(60 Gy in 2 Gy/fx) + daily Temozolomide (75 mg/m²/day for 6 weeks).
1494765|NCT03008148|Drug|Temozolomide|Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles.
1494766|NCT03008148|Drug|Siroquine|"Chemotherapy Phase: Temozolomide 150-200 mg/m² Day 1-5 of 28-Day for a maximum of 6 cycles + Daily JP001(2 tablets once a day) for 24 weeks (4 weeks for each cycle).
Maintenance Phase: JP001(2 tablets once a day) for 48 weeks until disease progression confirmed."
2001795|NCT02787798|Procedure|Microneurography|Microneurography recording of sympathetic nervous system activity in muscle destiny
2001796|NCT02787551|Drug|insulin glargine/lixisenatide fixed ratio combination|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1494769|NCT03008122|Other|Placebo|Placebo
1494770|NCT03008122|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
1494771|NCT03008109|Drug|EGFR-TK Inhibitor|
1494772|NCT03008096|Procedure|Laparoscopic Sleeve Gastrectomy|Routine Laparoscopic Sleeve Gastrectomy is performed on obese patients supported by Left-Ventricular Assist Device in order to reach a Body Mass Index sufficient for heart transplantation listing.
1494773|NCT03008083|Drug|3 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 90 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
1494774|NCT03008083|Drug|12 months DAPT|Subjects will continue DAPT with P2Y12 inhibitors and Aspirin (ASA) up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge.
1494775|NCT03008070|Drug|IVA337 1200mg|
1494776|NCT03008070|Drug|IVA337 800mg|
1494777|NCT03008070|Drug|Placebo|
1494778|NCT03008057|Dietary Supplement|vitamin D|vitamin D supplement, 4000 IU tablet daily , one time a day, for 3 months
1494779|NCT03008057|Dietary Supplement|vitamin D placebo|vitamin D placebo tablet (Containing starch powder), one time a day, for 3 months
1494780|NCT03008044|Device|FiberSense system|A novel CGM system based on a FiberSense system placed through the dermis of the patient.
1494781|NCT03008031|Procedure|CESM with a reduced dose of contrast agent|
1494843|NCT03007602|Other|Upper Extremity Aerobic Exercise|"Range of maximal heart rate is being followed by a polar band during supervised session each week.
Aerobic exercise is being trained for 30 min-per/day, 3 days/week, 6 weeks. All sessions are being performed by a physiotherapist at cardiopulmonary rehabilitation department."
1495196|NCT03005223|Drug|DWC20163|
2001797|NCT02787551|Drug|liraglutide|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1494782|NCT03008018|Drug|KA2507|KA2507, an orally-active new chemical entity, is a potent and selective inhibitor of the HDAC6 enzyme, with potential clinical utility in the treatment of melanoma and other solid tumors. KA2507 has been shown to display potent in vitro activity in a range of cancer cell lines, including melanoma cell lines. KA2507 exerts potent in vivo efficacy in a syngeneic model of B16 melanoma. Here, the combination of the agent's direct tumor growth inhibition and metastasis suppression, coupled with its immunotherapeutic activity - demonstrated by decreased expression of STAT-3 and PD-L1 and increased expression of acetylated tubulin, gp100 and MHC Class I in tumors - have been observed.
1494783|NCT03008005|Drug|Placebo Oral Capsule|Placebo is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules.
1494784|NCT03008005|Drug|Dronabinol Cap 5 milligrams (MG)|Dronabinol (5mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
1494785|NCT03008005|Drug|Dronabinol Cap 10 milligrams (MG)|Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
1494786|NCT03007992|Drug|Vinorelbine|Oral vinorelbine will be administered at a daily dose of 30 mg (flat dose without any adaptation to body weight or body surface area) without breaks. Treatment will continue until disease progression, occurrence of unacceptable toxicity, patient's refusal or investigator's decision to stop the treatment.
1494787|NCT03007979|Drug|Palbociclib|Palbociclib at a dose of 125 mg should be taken by mouth with food on a 5 days on/2 days off schedule
1494788|NCT03007979|Drug|Letrozole|Patients who are receiving letrozole will take it daily by mouth, every day of each 28-day cycle, at a dose of 2.5 mg.
1494789|NCT03007979|Drug|Fulvestrant|Patients who are receiving fulvestrant will receive it at a dose of 500 mg as two 5 mL intramuscular injections (one into each buttock) on Days 1 and 15 of Cycle 1 and then on Day 1 of each cycle thereafter.
1494790|NCT03007979|Procedure|Optional research biopsy|Patients may consent to paired tumor biopsies at baseline and time of progression.
1494791|NCT03007979|Drug|Goserelin|Goserelin is given as a subcutaneous injection every 28 days. It is preferred to be given on Day 1 of each cycle, but it may be administered on any day of the treatment cycle to accommodate its specific Q28-day cycle. It will be given to pre- and peri-menopausal women only.
1494792|NCT03007979|Procedure|Research blood draw|"-Blood will be drawn at the following time points for serum, plasma, cfDNA, and germline DNA (only at baseline):
Baseline
C1D15
C2D1
Every 2-3 months thereafter
Time of imaging"
1494793|NCT03007966|Procedure|Ilioinguinal / Iliohypogastric Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided ilioinguinal / iliohypogastric block technique.
1494794|NCT03007966|Procedure|Quadratus Lumborum Block|Patients randomized to this arm will receive 25cc's of Bupivacaine 0.25% + Epinephrine 1:200k + Clonidine 1.66mcg/cc administered via an ultrasound guided quadratus lumborum block technique.
1494795|NCT03007966|Drug|Bupivacaine 0.25%|Administered as part of the local anesthetic mixture
1494796|NCT03007966|Drug|Epinephrine 1:200k|Administered as part of the local anesthetic mixture
1494797|NCT03007966|Drug|Clonidine 1.66mcg/cc|Administered as part of the local anesthetic mixture
1494799|NCT03007940|Other|Coach Site Visit|The coach will conduct a one-day on site visit and will review the walk-through and DDCAT assessment results, and help the change team design an initial change project with Plan-Do-Study-Act (PDSA) cycles. The site visit will use a standardized agenda to ensure NIATx fidelity.
1494800|NCT03007940|Other|Walk-through|Walk-Through: Provider change teams will participate in a coach-led webinar that introduces how to conduct a NIATx walk-through from the co-occurring patient perspective and how to write up results using a standard report format. The walk-through will be conducted within two months of the initial coach site visit.
1494801|NCT03007940|Other|Learning Sessions|The study includes two one-day coach-led learning sessions. The learning sessions promote peer-to-peer sharing about specific goals and objectives. The agenda is tailored to specific treatment service integration issues. The first coach-led learning session teaches providers how to use NIATx process improvement strategies. Providers share walk-through results and initial change projects. Skill development activities include how to: identify change opportunities, use specific tools (e.g., flowcharting), develop PDSA cycles, effectively use data and learning successful change strategies. At the final session, providers present results, sustainment plans, and identify ways for the group to continue to interact.
1494802|NCT03007940|Other|Coaching|A NIATx coach leads the active 12 month implementation phase. The coach works with executive directors, change leaders and teams. After the site visit, a coach will hold individual monthly coaching calls (10 hours in total), and participate in group coaching calls (2 hours in total). In the individual calls, the coach and change team review change projects; discuss successes; and identify ideas for future change projects. Group coaching calls involve change leaders from multiple providers. On these calls, change leaders will discuss common change-related issues, progress, and exchange innovative implementation strategies with their peers. These calls provide opportunities for the coach to share new strategies and discuss implementation issues such as the development of a sustain plan.
1494803|NCT03007940|Other|Business as Usual|Programs in this intervention will continue with their own plans without coaching support to integrate services for individuals with co-occurring substance abuse and mental health disorders. Once the programs in the wait-list control group receive the NIATx Strategy, they will participate in all of the interventions listed above.
1494804|NCT03007927|Drug|Bupivacaine-Dexamethasone|Bupivacaine 1,5 mg/kg-Dexamethasone 2ml 8 mg
1494805|NCT03007927|Drug|Bupivacaine- physiological solution|Bupivacaine 1,5 mg/kg- physiological solution
1494806|NCT03007901|Behavioral|Mindful Climate Action|Educational and Behavioral Training Curriculum: An article describing our proposed program was recently published in Sustainability (1) and is summarized here. Experienced instructors from the UW Integrative Medicine Mindfulness Program will teach the 8-week program. Classes will meet weekly for 2½ hours, with a 6 hour weekend retreat. Twenty to 45 minutes of daily home practice will be guided by audio recordings leading participants through body scan, sitting meditations, breath awareness, and mindful movement. Each of the 2½ hour weekly classes includes topics (~30 min) relating to climate change, energy use, and carbon footprint.
1494807|NCT03007888|Drug|IR CD-LD|Immediate Release Tablet containing carbidopa-levodopa flexible dosing
1494808|NCT03007888|Drug|ER CD-LD|Extended Release capsules containing carbidopa-levodopa flexible dosing
1494809|NCT03007875|Biological|high-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
1494810|NCT03007836|Biological|High-activity natural killer|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
1494811|NCT03007823|Biological|High-activity natural killer|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
2001798|NCT02787551|Drug|exenatide|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
2001799|NCT02787551|Drug|exenatide extended-release|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1494814|NCT03007797|Behavioral|vaccination rate for influenza|
1494815|NCT03007784|Device|transcranial direct current stimulation (tDCS) / Comparison of current intensities|
1494816|NCT03007771|Device|Magnetic Resonance-guided High-Intensity Focused Ultrasound|-Heating will not be performed in two areas of the body near each other (for example, not heating in two different places of the same thigh) to minimize the risk of overheating any one part of the subject's body. Heating a second target site is not mandatory, even if time allows, and the participant may refuse.
1494817|NCT03007758|Procedure|open ventral hernia repair|An open retromuscular ventral hernia repair involves an incision through your abdominal wall, most often through a prior surgery scar. The contents of the hernia, which may include intestine or fatty tissue, are returned into the abdominal cavity. The posterior (inner-most) layer of the abdominal wall is separated from the muscle and closed, which closes the abdominal cavity. Mesh is then placed over that closed layer, which is outside of the abdominal cavity, but below the abdominal muscles. The anterior (outer-most) layer of the abdominal wall is then closed over the mesh, which closes the hernia.
1494818|NCT03007758|Procedure|robotic ventral hernia repair|A robotic retromuscular ventral hernia repair involves a similar separation of the layers of the abdominal wall, similar mesh placement, and similar closure of the hernia defect. The surgical robot is a tool that allows your surgeon to place long, narrow instruments through small incisions in order to perform surgery from the inside of your abdomen. Rather than one longer incision in the middle of your abdomen, four to six small incisions, about 1 inch, are made along the outer part of your abdomen between the rib cage and hip.
1494819|NCT03007745|Device|autoadjusting continuous positive airway pressure|Participants in both arms who are diagnosed with obstructive sleep apnea will be treated with autoadjusting continuous positive airway pressure
2001800|NCT02787551|Drug|albiglutide|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
2001801|NCT02787551|Drug|dulaglutide|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
2001802|NCT02787551|Drug|metformin|"Pharmaceutical form: tablet
Route of administration: oral"
2001803|NCT02787551|Drug|pioglitazone|"Pharmaceutical form: tablet
Route of administration: oral"
1494824|NCT03007719|Drug|[18F]F-AraG (Cohort 1)|Cohort 1: Administered within 7 days of atezolizumab commencement, and then again within 7 days before surgery
1494825|NCT03007719|Radiation|PET/MRI Scan (Cohort 1)|Cohort 1: Scan done within 7 days of atezolizumab commencement, and then again within 7 days before surgery
1494826|NCT03007719|Drug|[18F]F-AraG (Cohort 2)|Cohort 2: Administered within 7 days of atezolizumab commencement, and then again between Day 14 and Day 21 of Cycle 1 atezolizumab
1494827|NCT03007719|Radiation|PET/MRI Scan (Cohort 2)|Cohort 2: Scan done within 7 days of atezolizumab commencement, and then again between Day 14 and Day 21 of Cycle 1 atezolizumab
1494828|NCT03007719|Drug|Atezolizumab (Cohort 1)|Cohort 1: 1200mg every 3 weeks x 1-3 cycles as per companion study (NCT02451423)
1494829|NCT03007719|Drug|Atezolizumab (Cohort 2)|Cohort 2: 1200mg every 3 weeks until disease progression or unacceptable toxicity
1494830|NCT03007706|Procedure|Women undergo cesarean section delivery|
2001804|NCT02787551|Drug|SGLT2 inhibitor|"Pharmaceutical form: tablet
Route of administration: oral"
1494833|NCT03007680|Other|Core muscle activation|
1494834|NCT03007667|Procedure|The impact of colorectal cancer surgery on localization of ureters; prospective clinical trail|
1494835|NCT03007654|Device|Mediclore|apply medical device fully around intrauterine surgery area
1494836|NCT03007654|Device|Adept|apply medical device fully around intrauterine surgery area
1494837|NCT03007641|Behavioral|Didactic session|This session will include an overview of the approach to and management of older MBC patients through a case-based presentation.
1494838|NCT03007641|Behavioral|Comprehensive Geriatric Assessment|The Comprehensive Geriatric Assessment (CGA) is a composite of assessment scales evaluating physical, psychological, and social well-being, and is the recommended tool for evaluating an older cancer patient and determining appropriateness of therapy.
1494839|NCT03007628|Device|Magpro X100|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
1494840|NCT03007628|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants are supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
1494841|NCT03007628|Other|Treatment as usual (TAU)|Participants will engage in their intpatient treatment program as-usual.
1494842|NCT03007615|Other|Intimate Lubricant Gel|
1494846|NCT03007589|Other|Optical Filters|Optical filters and surfaces used in solar simulators
2001805|NCT02787330|Behavioral|Control Group|Sessions will not be designed around a specific theme related to childhood cancer and sibling relationships. Activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
1494848|NCT03007563|Device|bilirubin concentration estimation from smartphone pictures|pictures taken of the skin covering the breast bone
1494849|NCT03007563|Procedure|bilirubin concentration measured in standard blood samples|
1494850|NCT03007563|Device|bilirubin concentration measured by transcutaneous device|
1494851|NCT03007550|Procedure|Laparoscopic total gastrectomy|LTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
1494852|NCT03007550|Procedure|Open total gastrectomy|OTG with D1+/D2-10 lymphadenectomy for patients with clinical stage I (T1N0M0、T1N1M0、T2N0M0) gastric adenocarcinoma
1494853|NCT03007537|Drug|Erythropoietin|10000 IU erythropoietin, subcutaneous injection
1494854|NCT03007537|Drug|0.9% sodium chloride|0.9% sodium chloride 1ml, subcutaneous injection
1494855|NCT03007537|Procedure|cardiac surgery|included valve, coronary artery bypass graft or surgery for congenital heart diseases
1494856|NCT03007524|Drug|High dose Rosuvastatin|20mg/d qN, at least 6 months
1494857|NCT03007524|Drug|Low dose Rosuvastatin|10mg/d qN, at least 6 months
1494858|NCT03007511|Device|Fidmi enhanced enteral feeding device|Fidmi enhanced enteral feeding device is intended to provide nutrition to a patient directly into the stomach through a stoma. The Fidmi PEG device would be investigated in this study on patients suffering from dysphagia, who are scheduled for PEG procedure in order to improve surgical initial insertion, device replacement and removal.
1494859|NCT03007485|Other|Telehealth Pulmonary Rehabilitation|Exercise bikes equipped with software that enables a respiratory therapist to remotely conduct a pulmonary rehabilitation session with a patient while he or she is at home (or at a local community center). The patient's vital signs are continually monitored and the RT is able to remotely alert 911 if a patient is in distress. Educational videos and stretching exercises are also incorporated into this session to mimic what a standard pulmonary rehabilitation session offers.
1494860|NCT03007472|Device|CI532|Cochlear implant
1494861|NCT03007472|Device|Nucleus 7|Sound processor
1494862|NCT03007459|Other|Psychological health|Observing and measuring baseline, and changes in, psychological health through a fitness contest preparation period
1494863|NCT03007459|Other|Physiological health|Observing and measuring baseline, and changes in, physiological health through a fitness contest preparation period
1494864|NCT03007446|Drug|Apatinib|Apatinib :A starting dose of apatinib was administered 500 mg daily
1494865|NCT03007446|Drug|Oxaliplatin|Oxaliplatin:130 mg/m2，d1，ivgtt，in a 21 day cycle
1494866|NCT03007446|Drug|S-1|S-1:40mg，bid，d1-14，po，in a 21 day cycle.
1494867|NCT03007433|Other|400ml of Liquid Nutrient Drink|12MBq Technetium-99m-DTPA will be added as a non-absorbable marker incorporated into liquid nutrient drink Fortisip Vanilla (Nutricia Clinical)
2001806|NCT02787330|Behavioral|Experimental Group|The experimental group will be detailed, session by session, in the manual written for this purpose. It addresses on topic per session (respecting each other, medical information about cancer, family relationships, sibling's fears and feelings, relationship between siblings, relationships at school, generating hope.
2001807|NCT02784171|Drug|Cisplatin|
1494870|NCT03007407|Drug|durvalumab|Following three doses of hypofractionated palliative radiation (Days −2, −1, and Day 0 prior to Cycle 1), patients will receive durvalumab (1500 mg IV infusion) on Day 1 for 4 cycles (in combination with tremelimumab). Beginning with Cycle 5 through Cycle 12, patients will receive durvalumab alone (1500 mg/IV infusion) on Day 1 of each 28 day cycle.
1494871|NCT03007407|Drug|Tremelimumab|Following three doses of hypofractionated palliative radiation (Days −2, −1, and Day 0 prior to Cycle 1), patients will receive tremelimumab (75 mg IV infusion) on Day 1 for 4 cycles (in combination with durvalumab).
1494872|NCT03007394|Drug|Lorcaserin|Lorcaserin Capsule
1494873|NCT03007394|Drug|Placebo Oral Capsule|sugar pill to mimic lorcaserin 10mg capsule
1494874|NCT03007381|Drug|Ketorolac Tromethamine|Intravenous analgesic
1494875|NCT03007381|Drug|Normal Saline|Sham comparator
1494876|NCT03007368|Other|Rice|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
1494877|NCT03007368|Other|Potato|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response .
1494878|NCT03007368|Other|Pasta|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
1494879|NCT03007368|Other|Sorghum thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
1494880|NCT03007368|Other|Millet thick porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
1494881|NCT03007368|Other|Millet couscous|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
1494882|NCT03007368|Other|Millet thin porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
1494883|NCT03007368|Other|Millet thin monikuru porridge|Different modern and traditional starch-based foods found in Bamako, Mali were tested for differences in gastric emptying rate and appetitive response.
1494884|NCT03007355|Other|peripheral perfusion index measurement|
1494885|NCT03007342|Drug|Amoxicillin/Clavulanate Potassium 875 mg-125 mg oral tablet|
1494886|NCT03007342|Drug|Placebo|
1494887|NCT03007329|Drug|Exenatide|Exenatide will be combined with Dapagliflozin
2001808|NCT02784171|Drug|Pemetrexed|
2001809|NCT02784171|Drug|Pembrolizumab|
2001810|NCT02783651|Other|Other|No intervention other than routine medical care
1494888|NCT03007329|Drug|Exenatide matching Placebo|Exenatide matching Placebo will be combined with Dapagliflozin
1494889|NCT03007329|Drug|Dapagliflozin|Dapagliflozin, in both arms
1494890|NCT03007316|Procedure|VIP graft|
1494891|NCT03007303|Drug|Atypical Antipsychotic|Olanzapine: tablet ,5-20mg, Po q.d. Risperidone: tablet ,1-3 mg, Po q.d. Quetiapine: tablet ,100-400mg, Po b.i.d. ziprasidone : tablet ,40 -80mg, Po b.i.d.
1494892|NCT03007303|Other|atypical antipsychotic combined with MECT|The schizophrenia who matches the indications such as severe negativism, refused to eating or stupor may be treated with antipsychotic combined with MECT, the frequency and times of MECT depend on the state of illness
1494893|NCT03007290|Other|Therapeutic drug monitoring|Therapeutic drug monitoring for colistin
1494894|NCT03007277|Other|PANJO|PANJO consists on a 6 to 12 home visitation intervention aiming at supporting the parents, supporting their upcoming then relationship with their first newbord child and to help them reaching all services they may need.
1494895|NCT03007264|Device|Cold Atmospheric Plasma|CAP will be applied on one volar arm of volunteers for a total of 2 minutes.
1494896|NCT03007251|Other|"Eurythmy Therapy Movement R"|
1494897|NCT03007251|Other|"Eurythmy Therapy Movement L"|
1494898|NCT03007251|Other|"Eurythmy Therapy Movement B"|
1494899|NCT03007251|Other|Normal movements during walking or standing|
1494900|NCT03007238|Biological|Aldesleukin|Given SC
1494901|NCT03007238|Procedure|Extracorporeal Photopheresis|Undergo ECP
1494902|NCT03007238|Other|Laboratory Biomarker Analysis|Correlative studies
1494903|NCT03007238|Other|Quality-of-Life Assessment|Ancillary studies
1494904|NCT03007225|Drug|Trans-arterial chemoembolization (TACE)|"TACE procedures were performed by experienced radiologists by fluoroscopy. The femoral artery was catheterized under local anesthesia, with a 4F catheter with Copra head configuration. Conventional angiography of the Coeliac and Hepatic arteries to delineate the feeding arteries of the tumors and to exclude portal venous shunting. Then vascular catheter was inserted super-selectively into the branch of the hepatic artery that is the main feeder of the tumor. Chemoembolization then was performed.
Ten milliliters of Lipiodol was mixed with 100 mg of Doxorubicin hydrochloride and 5ml of Urografin emulsified to create a milky solution. The emulsion slowly was infused into the tumour Gel foam embolization was performed by cutting gel foam sheets into small pledges mannully then mixed with a contrast material and an impirical antibiotic (gentamycin 80 mg). Injection of the mixture slowly under fluoroscopy guidance till complete stasis was achieved."
1494905|NCT03007225|Drug|TACE with Drug Eluting Beads procedure|"The same was done as cTACE till the super selective catheterization of the feeding artery.
Loading of the beads with Doxorubicin hydrochloride (100-150 mg) was done in vitro an hour before the beginning of catheterization. The loaded beads were then aspirated from the vial into a syringe filled with nonionic contrast medium. Once the feeding artery was identified and catheter was in placement, the loaded beads were infused slowly under fluoroscopic guidance. Two different sizes of DC beads were used, 100-300 μm and 300-500. Starting with the smaller sized beads to occlude the tumoral bed followed by the larger sized one to embolize the proximal vessels. The injection of the loaded beads was performed as selective as possible using either a4F diagnostic catheter (Cobra head catheter; Cordis, USA) or 2.7F microcatheter (Progreat; Terumo, Japan)."
1494906|NCT03007212|Procedure|transarterial chemoembolization versus the standard treatment with sorafinib|TACE procedures were performed by the interventional radiologist through femoral artery approach in all patients. Super-selective cannulation of the main feeders was performed using a microcatheter whenever possible. The c-TACE protocol consisted of intra-arterial infusion of cisplatin 50-100 mg mixed with lipiodol ,Just prior to injection, emulsion is prepared by intensive mixing of equal volumes of cytotoxic drug solution and iodized oil using the pumping method with two syringes and a three way stop cock. Injection is guided by fluoroscopy and results in dense accumulation of the emulsion within the tumor vascular bed. Injection of poor iodized oil up to a maximum volume of 10-20 cc is an option and is followed by embolization of feeding arteries by Gelfoam cubes .Endpoints of conventional TACE are complete filling of the tumor vascular bed with iodized oil and stop-flow in subsegmental and segmental feeding arteries..
1494907|NCT03007173|Procedure|umbilicus preserving surgery|excision of umbilical complex
1494908|NCT03007160|Drug|Potassium Citrate Extended-release Tablets|Daily 3.24g, Po ,Tid, each 1.08g/tablets
1494909|NCT03007147|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
1494910|NCT03007147|Drug|Cyclophosphamide|Given IV
1494911|NCT03007147|Drug|Cytarabine|Given IV, SC, or IT
1494912|NCT03007147|Drug|Daunorubicin Hydrochloride|Given IV
1494913|NCT03007147|Drug|Dexamethasone|Given PO or IV
1494914|NCT03007147|Drug|Dexrazoxane Hydrochloride|Given IV
1494915|NCT03007147|Drug|Doxorubicin|Given IV
1494916|NCT03007147|Drug|Etoposide|Given IV
1494917|NCT03007147|Biological|Filgrastim|Given IV
1494918|NCT03007147|Drug|Ifosfamide|Given IV
1494919|NCT03007147|Drug|Imatinib Mesylate|Given PO
1494920|NCT03007147|Other|Laboratory Biomarker Analysis|Correlative studies
1494921|NCT03007147|Drug|Leucovorin Calcium|Given PO or IV
1494922|NCT03007147|Drug|Mercaptopurine|Given PO
1494923|NCT03007147|Drug|Mercaptopurine|Given PO
1494924|NCT03007147|Drug|Mesna|Given IV
1494925|NCT03007147|Drug|Methotrexate|Given IT
1494926|NCT03007147|Drug|Methylprednisolone|Given IV
1494927|NCT03007147|Drug|Pegaspargase|Given IV
1494928|NCT03007147|Drug|Prednisolone|Given PO
1494929|NCT03007147|Other|Questionnaire Administration|Ancillary studies
1494930|NCT03007147|Drug|Therapeutic Hydrocortisone|Given IT
1494931|NCT03007147|Drug|Thioguanine|Given PO
1494932|NCT03007147|Drug|Vincristine Sulfate|Given IV
1494933|NCT03007134|Other|Retrospective Chart Review|No intervention.
1494934|NCT03007121|Drug|Morphine intrathecal|Administration of intrathecal injection of 0.3 mg preservative-free morphine in 3 ml NS
1494935|NCT03007121|Drug|Bupivacaine + Sufentanil epidural|Continuous epidural infusion of a mixture containing in 1 ml bupivacaine 0,125% and sufentanil 0,4 mcg at 8 ml/h.
1494936|NCT03007121|Drug|Morphine intravenous|Patiernt-controlled i.v. analgesia with morphine
1494938|NCT03007095|Behavioral|Evaluation of the children's social cognitive development|
1494939|NCT03007082|Device|Revive SE intracranial thrombectomy device|"Intra-arterial mechanical thrombectomy with Revive SE；
According to patient condition, the investigator could determine intravenous thrombolysis or not at his/her discretion"
1494940|NCT03007069|Other|Mineralized plasmatic matrix (MPM).|By using venoud blood from the patient, together with bone graft, a centrifuge will be used to obtain the top layer after centrifuging blood at 3000 RPM, for 10 minutes , Which will result if sticky bone graft consistency after mixing.
1494941|NCT03007069|Other|Autogenous bone graft (gold standard).|Exposed implant threads are to be covered with autogenous bone and collagen membrane.
1494942|NCT03007056|Other|High flow nasal cannula|High flow nasal cannula added to the therapeutic arsenal in neonatal care
1494943|NCT03007043|Other|blood sample|
1494945|NCT03007017|Procedure|Deceased donor nephrectomy, prior to cross clamp of donor aorta|"The investigators will perform a prospective investigation of organ recoveries during which the left kidney will be removed prior to cessation of cardiac activity. The second kidney will be removed in the standard fashion. To do this, investigators will adopt techniques used in living donor kidney transplantation. Specifically, a specialized vascular stapler will be used to divide the renal artery at the level of aorta, followed by the vein, at the level of the vena cava. As such, no cuff of abdominal aorta or vena cava will be present on the target kidneys. Once removed from the body, just as is done for living donor kidney transplantation, the kidneys will be immediately flushed. As this ex-vivo flush is already performed for cadaveric kidney transplantation, there should be no additional cost for performing this portion of the procedure. Approximately 15 minutes of additional surgical dissection (prior to stopping the heart) will be required under the proposed study."
1494946|NCT03007017|Procedure|Deceased donor nephrectomy, standard of care|The investigators will remove the right kidney in the stand of care procedures for cadaveric kidney transplantation
1494947|NCT03007004|Drug|Botulinum toxin type B (2500 units / vial)|
1494948|NCT03007004|Drug|Physiological saline|
1494949|NCT03006991|Other|therapeutic drug monitoring|dose of methotrexate can be adjusted by therapeutic drug monitoring.
1494950|NCT03006978|Device|TearCare|
1494951|NCT03006978|Device|Warm Compress|
1494952|NCT03006965|Drug|Octocog Alfa|
1494953|NCT03006952|Drug|Pentoxifylline|pentoxifylline arm took 400 mg pentoxifylline twice daily plus 50mg losartan daily for 12 weeks.
1494954|NCT03006952|Drug|Losartan|losartan arm took 100mg losartan daily for 12 weeks.
1494955|NCT03006939|Procedure|Cytoreductive surgery|Cytoreductive surgery in terms of tumor debulking is performed in order to promote survival
2001811|NCT02782741|Drug|GZ402666|"Pharmaceutical form: powder for concentrate for solution for infusion
Route of administration: intravenous"
2001812|NCT02782741|Drug|alglucosidase alfa (GZ419829)|"Pharmaceutical form: powder for concentrate for solution for infusion
Route of administration: intravenous"
2001813|NCT02780180|Drug|QGC001|
2001814|NCT02780180|Drug|Placebo|Lactose capsule manufactured to mimic QGC001 50 mg and 250 mg
2001815|NCT02774317|Biological|Plasma|FFP (plasma frozen within 8 hrs of collection) or FP24 (plasma frozen within 24 hrs of collection)
1494961|NCT03006900|Other|Pilates|Pilates
1494962|NCT03006900|Other|Massage|Massage
1494963|NCT03006887|Drug|lenvatinib|lenvatinib capsules
1494964|NCT03006887|Drug|pembrolizumab|pembrolizumab intravenous infusion
1494965|NCT03006874|Drug|CJ-12420 100mg QD|CJ-12420 100mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100mg.
1494966|NCT03006874|Drug|Esomeprazole 40mg|Esomeprazole 40mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40mg.
1494967|NCT03006874|Drug|CJ-12420 50mg QD|CJ-12420 50mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 50mg.
1494968|NCT03006861|Dietary Supplement|3.5 mL/d topical creatine|
1494969|NCT03006861|Dietary Supplement|3.5 mL/d topical placebo|
1494970|NCT03006861|Dietary Supplement|21 g/d Oral creatine|
1494971|NCT03006861|Dietary Supplement|21 g/d oral placebo|
1494972|NCT03006848|Drug|Avelumab|Patients will be administered avelumab at a dose of 10 mg/kg intravenously (IV) over 60 minutes on days 1 and 15 of each cycle, with a cycle lasting 28 days. Patients will receive avelumab every 2 weeks in cycles of 28 days for up to 24 months, or 26 cycles.
1494973|NCT03006848|Other|Questionnaires|To assess quality of life, patients will complete questionnaires at four time points.
1494974|NCT03006835|Drug|Clopidogrel|
1494975|NCT03006822|Other|Pressure release 90|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
1494976|NCT03006822|Other|Pressure release 60|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
1494977|NCT03006822|Other|Pressure release 30|This is a massage technique that aims is eliminate myofascial trigger points for to treat muscle pain.
2001816|NCT02773966|Radiation|Kypho-IORT|During kyphoplasty/vertebroplasty a intraoperative radiotherapy of the affected vertebrae is done with a miniature X-ray generator (INTRABEAM®, Carl Zeiss, Surgical, Oberkochen, Germany). The prescription dose will be 8 Gy in a distance of 13 mm from the isocenter of the radiation source. IORT will take about five minutes. After radiation the applicator will be removed and the operation will be finished as usual.
1494980|NCT03006783|Procedure|Cross-face nerve graft|connecting the healthy facial nerve to the affected facial nerve
1494981|NCT03006770|Biological|PLX-PAD|Local intramuscular (IM) injections of PLX-PAD in the index leg.
1494982|NCT03006770|Biological|Placebo|Local intramuscular (IM) injections of Placebo in the index leg.
1494983|NCT03006757|Other|titanium dioxide denture base|
1495197|NCT03005210|Drug|Magicbuvir Plus|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
1494984|NCT03006744|Behavioral|Phonological awareness training|Training on specific ways to improve children's phonological awareness by making them more aware of the sound structure of words.
1494985|NCT03006744|Behavioral|Reading enjoyment training|Training on how to make reading enjoyable for children.
1494986|NCT03006731|Behavioral|High Intensity Interval Training|Supervised HIIT sessions will be conducted on a treadmill at Toronto Rehab's Cardiac Rehabilitation and Secondary Prevention Program. During each of the three supervised HIIT sessions each week, subjects will be prescribed 2 protocols with a combination of short to moderate duration exercise of near maximal intensity alternating longer periods of active recovery. The total duration for each HIT session will be approximately 20 minutes with an additional 5 minutes warm-up and cool down period.
1494987|NCT03006731|Behavioral|Moderate Intensity Continuous Exercise|MICE sessions represent the standard of care exercise prescription at TRI. Participants will be instructed to complete 20-60 minutes of continuous aerobic exercise at or around the ventilatory anaerobic threshold achieved on the cardiopulmonary exercise test.
1494988|NCT03006718|Other|PROMIS for Pain Management App|At hospital discharge, the investigators will collect baseline surveys, a blood sample, and download the PROMIS for Pain Management App onto the subject's mobile device. For five consecutive weeks, PROMIS measures will be collected through weekly surveys. The investigators plan to compensate patients for their time. Patients will come back to the hospital after 35 days for a final blood draw and set of surveys. In the event a patient gets readmitted, the investigators will record that admission. The investigators will also collect Proxy PROMIS measures from parents of participants between the ages of 8 and 17-years who have agreed to participate in the study. It is the goal of the investigators to engage one of the parents in the reporting of weekly validated Proxy PROMIS measures.
1494989|NCT03006705|Drug|Nivolumab|
1494990|NCT03006705|Drug|Tegafur-gimeracil-oteracil potassium|
1494991|NCT03006705|Drug|Oxaliplatin|
1494992|NCT03006705|Drug|Capecitabine|
1494993|NCT03006705|Drug|Placebo|
1494994|NCT03006692|Other|With arterial blood gas, parameters not being normal can be corrected|If arterial blood gas is analysed answers provide the possibility to make more accurate diagnosis and treat specific abnormal parameters (e.g. electrolytes, oxygenation and so forth).
1494995|NCT03006679|Drug|Meropenem-Vaborbactam|
1494996|NCT03006679|Drug|Piperacillin/Tazobactam|
2001817|NCT02773966|Radiation|EBRT|The external beam radiotherapy will be usually carried out as an outpatient procedure. All patients will receive a planning CT before the first irradiation. EBRT will be performed with 30 Gy, added in 3 Gy per fraction or 8 Gy single dose (only for international study centers, not permitted in Germany) on a conventional linear accelerator (LINAC).
1494999|NCT03006653|Behavioral|Assessment only|Mobile ecological assessment only.
1495000|NCT03006640|Drug|Subcutaneous nitroglycrin|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
1495001|NCT03006640|Drug|Subcutaneous saline|In both groups, a 1 ml filled insulin syringe is delivered to a blinded operator who infiltrated it subcutaneously over 1 cm along the radial artery course. In the NTG group, the syringe contains 200 µg of NTG while in control group the syringe is filled with saline
1495002|NCT03006627|Drug|postoperative morphine|Postoperatively, A loading dose of morphine will be given in incremental doses of 1 mg 5 min apart, till the VAS score reached ≤3. The dose of morphine required to reduce the VAS score to ≤3 will be recorded. Subsequently, PCA pump will be configured to deliver a bolus of 1 mg with a lock-out period lasting for 20 min.
1495003|NCT03006614|Drug|NVB|
1495004|NCT03006614|Drug|EPI|
1495005|NCT03006614|Drug|DDP|
1495006|NCT03006614|Drug|CAP|
1495007|NCT03006614|Drug|GEM|
1495008|NCT03006614|Drug|H|
1495009|NCT03006614|Drug|CTX|
1495010|NCT03006614|Drug|T|
1495011|NCT03006601|Other|Office-based accommodative/vergence therapy|Office-based accommodative/vergence therapy (60 minutes per visit, one time per week, 12 weeks) and home reinforcement (15 minutes each time, five times per week, 12 weeks)
1495012|NCT03006588|Procedure|EUS-FNA for RPLN in NPC patients|An EUS probe was introduced to nasopharynx and the retropharyngeal space (RPS) were scanned. The suspicious recurrent RPLN, which was characterized as (1) roughly round and homogeneously hypo-echoic lesion in RPS; (2) located anterior to the carotid sheath which contained the internal carotid artery (ICA) and the internal jugular vein (IJV). Subsequently, guiding by EUS, a dedicated 22G needle was used to puncture into the enlarged RPLN, then the aspiration was conducted The entire EUS-FNA procedure was repeated at least three times till the satisfied strip tissue was obtained. The obtained tissue samples were sent for pathologic detection and the supernatant fluid was for thinprep cytologic test (TCT).
1495013|NCT03006575|Drug|consolidation chemotherapy of pemetrexed/docetaxel|pemetrexed(500mg/㎡) in non-squamous lung cancer or docetaxel(60mg/㎡) in squamous lung cancer
1495014|NCT03006575|Radiation|split-course chest radiation|split-course chest radiation at 51 Gy/17f and 15 Gy/5f
1495015|NCT03006575|Drug|concurrent chemotherapy|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
1495016|NCT03006562|Drug|Subcutaneous Heparin|5,000 units of subcutaneous heparin before surgery and then every 8 hours after surgery until discharge from the hospital.
1495017|NCT03006549|Behavioral|Emergency Manual (Crisis Checklist)|participants will have an Emergency Manual available to them during the crisis simulation scenario.
1495198|NCT03005210|Drug|Harvoni (fist dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
1949178|NCT00074373|Other|No intervention; observational|
1949179|NCT00070915|Behavioral|Tai chi|
1949180|NCT00070915|Behavioral|Mindfulness-based Stress Reduction program|
1949181|NCT00070915|Procedure|Therapeutic massage|
1949182|NCT00060086|Dietary Supplement|pomegranate juice|Subjects receive oral pomegranate juice once daily. Treatment continues for 18 months in the absence of disease progression or unacceptable toxicity.
1949183|NCT00058890|Drug|Gabapentin|Under code, the study drug was started at 100 mg by mouth 3 times a day for 3 days, to be increased, if necessary and in the absence of side effects, by 300 mg every 3 days to a maximum of 2,400 mg daily in divided doses.
1949184|NCT00058890|Drug|Placebo|
2001818|NCT02773368|Drug|insulin degludec/liraglutide|IDegLira will be given subcutaneously ( s.c., under the skin) once daily.
1495019|NCT03006523|Procedure|Intrauterine insemination|IUI will be performed with a Wallace® insemination 2 Catheter (Cooper Surgical, Trumbull, CT, USA) depositing 0.2 or 0.5 ml of the sperm sample at the uterine fundus. All IUIs will be performed between 12 p.m. and 4 p.m. After the procedure, 10 min of bed rest will be prescribed. Inseminations will be performed every day of the week, including weekends.
1495020|NCT03006510|Other|Hypoglycemia prediction alert|"In real time, for a patient with a glucose <90 mg/d, using a hypoglycemia prediction model that takes into account patient weight, renal function, eating and insulin dosing a risk score is produced.
If the Risk score is >35, then the patient is determined to be at risk for hypoglycemia in the next 72 hours.
If a patient is determined to be at risk for hypoglycemia, the following will occur:
Alert will be generated and sent via careweb a pager alert system that sends the alert specifically to the current oncall provider The alert also points the provider to the EMR order section where a formal more detailed alert gives recommendationsd for changes in insulin dosing to potentially prevent hypoglycemia."
1495021|NCT03006497|Other|Exercise program based on motor learning principles|The exercise program will include simple activities exposing volunteers in various environmental conditions with a view to adjust their head posture in such conditions. The progressiveness of exercises will be based on the two-dimensional classification system of Gentile (1987). Furthermore, external attentional focus will be used.
1495022|NCT03006484|Other|No intervention|No intervention will be needed.
1495023|NCT03006471|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
1495024|NCT03006471|Drug|Placebo - Cap|one per day before breakfast during 12 weeks.
1495025|NCT03006445|Drug|FYU-981|
1495026|NCT03006432|Drug|Oxaliplatin|
1495027|NCT03006432|Drug|5Fluorouracil bolus|
1495028|NCT03006432|Drug|5Fluorouracil continu|
1495029|NCT03006432|Drug|Docetaxel|
1495030|NCT03006432|Drug|Folinic Acid|
1495031|NCT03006419|Drug|Basiliximab|Standard induction therapy
1495032|NCT03006419|Drug|Thymoglobulin|Induction therapy
1495033|NCT03006406|Drug|Long term GnRH-a (3.75mg)|patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
1495034|NCT03006393|Drug|Infliximab|One infusion of Infliximab (Remicade) will be administered intravenously (IV) at 5 mg/kg body weight over a two hour period.
1495035|NCT03006393|Other|Placebo|One infusion of placebo treatment will be administered intravenously (IV) over a two hour period.
1495036|NCT03006380|Drug|oxytocin|Ecbolic used to reduce blood loss
1495037|NCT03006367|Drug|NFC-1 100 mg|
1495038|NCT03006367|Drug|NFC-1 200 mg|
1495039|NCT03006367|Drug|NFC-1 400 mg|
1495040|NCT03006367|Drug|NFC-1 800 mg|
1495041|NCT03006354|Device|nHFOV|Ventilator (Leoni-Plus Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
1495042|NCT03006354|Device|nCPAP|Ventilator (Leoni-Plus or Leoni-2 Ventilator, Heinen-Lowenstein, Germany) derived high frequency oscillatory ventilation, using binasal prongs
1495043|NCT03006341|Drug|Dabigatran etexilate|observed upto 12 months
1495044|NCT03006341|Drug|Warfarin|Observed upto 12 months
1495045|NCT03006328|Behavioral|GEM|GEM tool +Health Coaching
1495046|NCT03006328|Behavioral|Enhanced Usual Care|Patients in the EUC arm will similarly arrive prior to their scheduled same-day primary care visit, but receive non-tailored weight management handouts by health coaches. Patients will follow-up with their primary care teams as needed.
1495047|NCT03006315|Device|Garmin Vivofit device|Participants will be bio-monitored using the Garmin Vivofit mobile wearable device at baseline (at least 1-7 days prior to treatment initiation) and during induction chemotherapy up to completion of 6 cycles. For those patients continuing with ASCT, patients will be bio-monitored up to 90 days post ASCT.
1495048|NCT03006315|Behavioral|Mobile Health quality of life assessements|
1495049|NCT03006302|Drug|Epacadostat|50, 100, or 300 mg taken by mouth twice a day, every day of each cycle
1495050|NCT03006302|Drug|Pembrolizumab|200 mg IV on Day 1 of each cycle
1495051|NCT03006302|Biological|CRS-207|1x10^9 CFU given IV on Day 2 of Cycles 3-6 (Arm A) or Day 2 of Cycles 1-6 (Arm B)
1495052|NCT03006302|Drug|CY|200 mg/m^2 given IV on Day 1 of Cycles 1-2 (Arm A only)
1495053|NCT03006302|Biological|GVAX|5x10^8 cells given as 6 intradermal injections on Day 2 of Cycles 1-2 (Arm A only)
1495054|NCT03006276|Drug|DFN-15 Active|
1495055|NCT03006276|Other|DFN-15 Placebo|
1495056|NCT03006263|Procedure|Totally Laparoscopic Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Totally Laparoscopic Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
1495057|NCT03006263|Procedure|Laparoscopy Assisted Total Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,Laparoscopy Assisted Total Gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
1495058|NCT03006250|Drug|Desflurane|Desflurane is the volatile agent with low blood: gas partition coefficient (0.42), its uptake and elimination from the body of a patient are rapid, which results in a fast onset of anesthesia and a fast recovery from anesthesia. This property provides desflurane as an ideal agent for the ambulatory anesthesia. However, its pungent odor is concerned to irritate the upper airway and may cause significant respiratory complications.
1495059|NCT03006250|Drug|Sevoflurane|Sevoflurane has a blood: gas partition coefficient of 0.65, which is slightly greater than desflurane. The major advantage over desflurane is the better scented. It is considered to be less airway irritation in LMA anesthesia with smooth induction and recovery.
1495060|NCT03006237|Drug|IS-001|10mg, 20mg or 40 mg IV IS-001 drug administered during surgery
1495061|NCT03006237|Device|da Vinci® Si/Xi Surgical System|robot-assisted minimally invasive hysterectomy surgery performed with da Vinci® Si/Xi Surgical System with Firefly® Fluorescent Imaging
1495062|NCT03006224|Other|One Lung Ventilation|
1495063|NCT03006211|Other|Nitrogen protoxide|
1495064|NCT03006211|Other|Oxygen|
2001819|NCT02773368|Drug|insulin glargine|IGlar will be given subcutaneously ( s.c., under the skin) once daily.
1495065|NCT03006185|Device|Ablative Fractional Carbon Dioxide (CO2) Laser|Ablative Fractional Carbon Dioxide (CO2) Laser treatment is randomly allocated to one of two tests areas in each study participant. Laser treatment consists of targeted ablation of actinic keratoses and field laser treatment of the entire test area. After laser treatment, application of methyl aminolevulinate (MAL), a topical photosensitising agent, is performed. The test area thereafter undergoes 2 hours of daylight photodynamic therapy.
1495066|NCT03006185|Device|Microdermabrasion|Microdermabrasion (processing of the skin with a sandpaper-like material) is randomly allocated to one of two tests areas in each study participant. Microdermabrasion treatment consists of targeted treatment of actinic keratoses and field treatment of the entire test area. Afterwards, application of methyl aminolevulinate (MAL), a topical photosensitising agent, is performed. The test area then undergoes 2 hours of daylight photodynamic therapy.
1495067|NCT03006172|Drug|GDC-0077|Participants will receive oral GDC-0077 once daily. For dose escalation, the dose will be increased by up to 100% of the preceding dose level for each successive cohort, until a safety threshold is met. Once the safety threshold has been met in a given cohort, the dose will be increased by up to 50% of the preceding dose level for each successive cohort until a second cohort meets the safety threshold. Thereafter, the dose will be increased by up to 33% for each successive cohort.
1495068|NCT03006172|Drug|Fulvestrant|Participants will receive fulvestrant 500 mg, administered intramuscularly on Days 1 and 15 of Cycle 1. For subsequent cycles, participants will receive fulvestrant intramuscularly on Day 1 of each cycle. Participants who received fulvestrant within 4 weeks of initiating study treatment will receive fulvestrant 500 mg on Day 1 of each Cycle starting in Cycle 1.
1495069|NCT03006172|Drug|Letrozole|Participants will receive once daily oral doses of letrozole 2.5 mg on Days 1−28 of each cycle.
1495070|NCT03006172|Drug|Palbociclib|Participants will receive once daily oral doses of palbociclib 125 mg on Days 1−21 of each cycle. Dose modification will be done based on the safety and investigator's discretion.
1495071|NCT03006159|Drug|SHR0534|
1495072|NCT03006159|Drug|Placebo|
1949185|NCT00004467|Drug|N-acetylcysteine (NAC)|Infusion of 5% dextrose with N-acetylcysteine with an initial loading dose of 150 mg/kg/h of NAC over 1 hour, followed by 12.5 mg/kg/h for 4 hours, then continuous infusions of 6.25 mg/kg/h for the remaining 67 hours.
1495074|NCT03006120|Procedure|Retroperitoneal hematoma due to cardiac catheterization|
1495075|NCT03006107|Procedure|intraligamentary injection piroxicam|"intraligamentary injection Piroxicam is another NSAID that which has the ability for the treatment of pain, fever and inflammation in the body , has a half-life of 50h in the plasma , oral piroxicam reaches a peak concentration in the plasma within 2 to 4 hours .
The needle will be placed in the gingival sulcus at a 30- degree angle to the long axis of the tooth then apical pressure is applied until the needle wedged into the periodontal ligament between the tooth and the alveolar crest of the bone"
1495076|NCT03006107|Procedure|Intraligamentary mepevacaine|mepevacaine is an anesthetic (numbing medicine) that blocks the nerve impulses that send pain signals to brain . It is also used as an anesthetic for dental procedures.
1495077|NCT03006081|Drug|Intravitreal Aflibercept injection|Six number of injections at baseline, 1M, 2M, 3M, 4M, and 5M
2001820|NCT02773069|Behavioral|Church Bridge Project|Community-based participatory research combining efforts of academic researchers, church leaders, primary care providers and community stakeholders.
1495079|NCT03006055|Device|Circulating tumor cells|
1495080|NCT03006042|Drug|Bupivacaine|
1495081|NCT03006029|Drug|TAB08|The initial dose of TAB08 will be 1 µg/kg TAB08 will be administered i.v. over 1 hour weekly for 3 weeks followed by 3 weeks of no treatment; with 6 weeks interval between start of each treatment cycle.
1495082|NCT03006016|Drug|Omega-3 Fatty Acid|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
1495083|NCT03006016|Other|Placebo|The enrollment in the study is proposed by an investigator (surgeon) in each centre at the time of a preoperative visit (V0). Randomization takes place the week before the visit with the investigating surgeon in charge of the patient (V1) when the bariatric procedure is scheduled: omega-3 group (1650 mg of omega-3 / day for 4 weeks without caloric restriction) or placebo group.
1495084|NCT03006003|Drug|Raloxifene|Raloxifene tratment more than 4 weeks
1495085|NCT03006003|Drug|Alendronate|Alendronic acid 70mg with Colecalciferol 70mcg
1495086|NCT03005990|Other|Exercise training group|The conditioning period (24 weeks) of the exercise intervention was under the supervision of an exercise physiologist. The conditioning protocol included aerobic exercise sessions 3 times per week with 70-85% of maximal heart rate(max HR) for 30 mins and resistance sessions 3 times per week with an intensity of 80% of one-repetition maximum(1RM), 3 sets of 8 repetitions maximum. Each participant will measured the borg rating of perceived exertion scale and heart rate monitor during exercise. Exercise sessions were conducted in the afternoon (3-5 PM).
1495087|NCT03005977|Procedure|Urodynamics|UDS is to be performed with prolapse reduced by a speculum. The patient will be asked to valsalva three times then cough while seated after 150 ml of fluid is instilled in the bladder and then again at 300 ml. The same provocative measures will be performed at capacity, with the catheter in place and without the catheter if no leak is identified. If the patient leaks at any volume or if the patient leaks during the cough pressure profile (CPP), the test will be considered positive. If the patient does not leak during filling nor during the CPP then the test will be considered negative.
2001821|NCT02773212|Drug|d-amphetamine|Participants in this group will receive 60 mg of d-amphetamine daily for 4 weeks. There will be a 1 week run up dosing and a 1 week run-down medication period.
2001822|NCT02773212|Behavioral|Contingency management|Contingency management is an established cocaine use disorder treatment in which individuals receive monetary rewards for abstinence.
1495090|NCT03005951|Other|A= Yes Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when given breakfast and lunch
1495091|NCT03005951|Other|B=No Breakfast|Study visit will include analysis of cognitive function (CTET), insulin, glucagon, C-peptide, free fatty acids, and GLP-1 when breakfast is skipped and lunch is provided.
1949186|NCT00004467|Drug|Placebo|Infusion of 5% dextrose
2001823|NCT02773212|Drug|Placebo (for d-amphetamine)|60 mg of riboflavin and cornstarch as needed.
1495094|NCT03005925|Device|Smartphone|Smartphone application coupled with a hand dynamometer
1495095|NCT03005925|Other|physical follow up|regular visits with the specialist
1495096|NCT03005912|Device|Conventional acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
1495097|NCT03005912|Device|Conventional bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
1495098|NCT03005912|Device|VoIP acoustic telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
1495099|NCT03005912|Device|VoIP bluetooth telephony|Quantification of speech comprehension by means of the Hochmair-Schulz-Moser sentence test.
1495100|NCT03005899|Drug|SyB P-1501|"After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.
Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed"
1495101|NCT03005899|Drug|SyB P-1501 placebo|Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.
1495102|NCT03005886|Procedure|Periodontal examination|"periodontal examination included the assessment of plaque index (PI), gingival index(GI), probing depth (PD), bleeding on probing (BOP) and clinical attachment level (CAL).
All subjects underwent a periodontal examination performed by the same periodontitis (ZTÇ) Prior to the study, the examiner was calibrated for reproducibility of PD and CAL measurements"
1495103|NCT03005886|Procedure|GCF sampling|GCF samples were collected using commercially available periopaper . The sample site was gently air-dried and all supragingival plaque was removed. The area was carefully isolated with cotton rolls and a saliva ejector was used to prevent the samples from being contaminated by saliva. The paper strips were inserted into the pockets until slight resistance was felt and left in place for 30s.
1495104|NCT03005886|Procedure|phase I therapy|comprehensive proper plaque control program, scaling, subgingival curettage and root Phase I Periodontal Therapy planning
1495105|NCT03005873|Drug|TLC599|Single dose via intra-articular injection
1495106|NCT03005873|Drug|Normal Saline|Single dose via intra-articular injection
1495107|NCT03005860|Drug|2,6-Diisopropylphenol|In Propofol group, anesthesia will be induced with Propofol TCI using Schneider model to achieve a target site concentration of 4 - 6 mcg/ml. Propofol TCI to achieve BIS (Bispectral Index) between 40-60.
1495108|NCT03005860|Drug|Fluoromethyl hexafluoroisopropyl ether|In Sevoflurane group, anesthesia will be induced with 5 - 7mg/kg thiopental, maintenance with O2 with air 50:50%, sevoflurane 2-2.5 %, Further fentanyl, in increments of 1 mcg/kg - and atracurium 0.15 mg/kg, will be given as indicated by the clinical signs and hemodynamic changes.
1495109|NCT03005860|Drug|Fentanyl Citrate|Inj. fentanyl 2 mcg/kg will be used as an adjunct during anaesthetic induction.
1495110|NCT03005860|Drug|Atracurium Besylate|Inj. atracurium 0.5 mg/kg for will be administered for facilitating LMA placement
1495111|NCT03005847|Dietary Supplement|fermented papaya preparation|dietary supplementation with fermented papaya preparation
1495112|NCT03005834|Other|incidence of cancers|With a continuous surveillance system to track all subsequent incidents of CVD and/or non-CVD via direct contact in the outpatient department, hospital records, and a mailed questionnaire at least once a year, an incidence of cancers was identified.
1495113|NCT03005821|Other|Chinese pediatric massage therapy + usual care|
1495114|NCT03005821|Other|Sham massage therapy + usual care|
1495115|NCT03005808|Drug|Ropivacaine|Surgery for appendicitis
1495116|NCT03005795|Device|Headphones|Music can be heard through headphones
1495117|NCT03005795|Other|No Headphones|No Headphones will be used.
1495118|NCT03005782|Drug|REGN3767|
1495119|NCT03005782|Drug|REGN2810|
1495120|NCT03005756|Device|Needle guiding robot|
1495121|NCT03005743|Radiation|Magnetic Resonance Image based Brachytherapy|MRI based BT prescription will be in accordance to the GEC-ESTRO guidelines [Intention will be to treat the whole cervix and the remaining residual tumour tissue at the primary site at the time of BT (high risk-clinical target volume) to a dose level analogue to the dose level previously prescribed for point-A]
1495122|NCT03005743|Radiation|Conventional Radiograph based Brachytherapy|The standard conventional radiography based prescription will be according to Manchester system Point A and bladder & rectum ICRU point dose constraints
1495123|NCT03005730|Other|phototherapy|The portable PainAway® nine-diode cluster (Multi Radiance Medical®, Solon, OH, USA) will be employed. This system has one 905 nm laser diode, four 875 nm LED diodes and four 670 nm LED diodes. The aperture size of device is 4 cm2.
1495124|NCT03005730|Other|phototherapy placebo|The placebo portable. The aperture size of device is 4 cm2 .
2001824|NCT02769832|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2, day 1, 8 q 21 days
2001825|NCT02769832|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, day 1, 8 q 21 days
1495127|NCT03005704|Drug|Antiplatelet treatment|Subjects will be treated with ticagrelor in combination with acetylsalicylic acid for five days. Ticagrelor will be administered at a loading dose of 180 mg, followed by 90 mg twice daily maintenance dose. Acetylsalicylic acid will be administered at a dose of 81 mg daily.
1495128|NCT03005691|Radiation|Spectroscopy|"Spectroscopy is a noninvasive method to assess brain chemistry. The signal of the hydrogen atom attached to a certain molecule or metabolite has a particular frequency associated with a given metabolite. The utility of Spectroscopy is based on the fact thet the nuclei of atoms have magnetic properties that can be used to obtain chemical information regarding both the type of molecule and it is concentration.
The subjects will be scanned on a 3-T Siemens system and an 12-channel phased-array coil will be used to provide an optimum signal-to-noise ratio for spectroscopy data."
2001826|NCT02767934|Other|Laboratory Biomarker Analysis|Correlative studies
1495129|NCT03005691|Other|Questionnaires|Questionnaires are important to assess the chronic pain and their impact in the quality of life. For this reason, we will assess the Brief Pain Inventory (BPI), it is used to evaluate the subject's perception of pain severity and its interference. Moreover, we will assess neuropathic pain symptoms with the NPSI to detect paresthesia/dysaesthesia, evoked pain and paroxysmal pain. The catastrophizing score will be measured with the Pain Catastrophizing Helplessness Subscale. Also,we will assess the disability after whiplash using the Neck Disability Index.
1495130|NCT03005691|Procedure|Conditioned Pain Modulation|Conditioned Pain Modulation over the tenar eminence. The test will be a heat tonic stimulus which evoke a 3-pain intensity. The conditioning stimulus will be a cold water immersion (12ºC)
2001827|NCT02767934|Biological|Pembrolizumab|Given IV
1495133|NCT03005665|Drug|Acetazolamide|
1495134|NCT03005665|Drug|Normal Saline|
1495135|NCT03005652|Behavioral|Mindfulness weekly courses for 8 weeks|The mindfulness intervention combines intensive training in mindfulness and compassion meditations, light movement and yoga activities, and psycho-educational components to promote nonjudgmental awareness of present moment experiences.
1495136|NCT03005652|Behavioral|Health education weekly courses for 8 weeks|The health education intervention is group-based programme has been developed and validated in an SCD population. Each session of the course covers different subjects, which include self-management, problem-solving, sleep, stress, exercise, managing medicines and memory, communicating with healthcare professionals, eating, and planning for the future.
1495137|NCT03005639|Drug|Vemurafenib and Cobimetinib|All participants will receive study treatment for up to 56 days (8 weeks). After completing treatment, they will undergo a lymph node removal surgery. After surgery, they will have follow-up visit 2-4 weeks after surgery.
1495138|NCT03005626|Other|Therapeutic education|
1495139|NCT03005626|Other|Standard follow-up|
1495140|NCT03005613|Procedure|ischial spine fascia fixation|The participants will receive ischial spine fascia fixation.
1495141|NCT03005613|Procedure|sacrospinous ligament fixation|The participants will receive sacrospinous ligament fixation.
1495142|NCT03005574|Behavioral|TSW-HP|TSW-HP involves home practice of cognitive exercises along with the training sessions facilitated by the cognitive specialist at the agency.
1495143|NCT03005574|Behavioral|TSW-T|Participants assigned to traditional TSW will receive the usual TSW program which includes a one hour session per week at BCS for 6 months. This group will not receive home based cognitive practice exercises
1495144|NCT03005561|Behavioral|Play Back Sessions|"100 participants that will be participating in two Play Back meetings. Playback define that improvisation as a theater facilitator asks the audience to share moments, feelings and stories of his daily life, and a group of actors improvise their stories in front of the stage as a kind of play-back. Unlike hobbies such as sports or singing, the method allows not only to unload the tensions but also communication and collaboration. It is very reminiscent of psychodrama, but unlike, is not considered a therapeutic tool."
1495145|NCT03005548|Device|Transcranial direct current stimulation|"Transcranial direct current stimulation. All eligible patients will be treated with patient-controlled IV morphine analgesia by PCA (PCA pump (CADD-Legacy PCA Pump, Deltec, Inc.) IV morphine bolus 1 mg, lockout time 10 mins.).
Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 20 mins."
1495146|NCT03005548|Drug|Morphine|"In Sham comparator group All eligible patients will be treated with patient-controlled IV morphine analgesia (PCA) (PCA pump (CADD-Legacy PCA Pump (Deltec, Inc.) morphine IV bolus 1 mg, lockout time 10 mins).
Device: wireless tDCS (StarStim, NeuroElectrics) non-invasive brain stimulation with a pair of electrodes with saline-soaked pads for delivery of direct current at intensity 2 mA for 30s at the beginning."
1495147|NCT03005535|Other|Vitaminized corn oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
1495148|NCT03005535|Other|Olive oil|Oil consumption at the two main meals, lunch and dinner (15gx2 per day)
1495149|NCT03005522|Drug|oral dexamethasone|Patient will be dosed with either placebo or with the study drug, 10mg oral dexamethasone, to be administered by mouth one time in the ED
1495150|NCT03005522|Drug|Placebo Oral Capsule|dosed with placebo
1495151|NCT03005509|Other|TQIM checklist|"The intervention phase will include an intense training period covering:
Conduct of Trauma Quality Improvement Meeting (TQIM) (and Trauma Quality Improvement program in general). The training will be delivered using the World Health Organization (WHO) Trauma Quality Improvement Programmes short course and online resources.
Implementation of Trauma Quality Improvement Meeting (TQIM) Checklist."
1495152|NCT03005496|Drug|Zinc|included in intervention arm
1495153|NCT03005496|Drug|Nifedipine|included in intervention and control arm
1495154|NCT03005496|Drug|Beta Carotene|included in intervention arm
1495155|NCT03005496|Drug|Vitamin D3|included in intervention arm
1495156|NCT03005496|Drug|Dexamethasone|included in intervention and control arm
1495157|NCT03005483|Drug|Gabapentin|Orthopedic Surgery was applied for the treatment of osseous disorders
1495158|NCT03005483|Other|Placebo|Orthopedic Surgery was applied for the treatment of osseous disorders
1495159|NCT03005470|Device|TELEM|Participants in the telemonitoring home blood pressure (TELEM) group will receive an oscillometric monitor to measure blood pressure at home for six months. Measurements will be made early in the morning (5:00 to 10:00) and in the evening (18:00 to 21:00) for at least five days a week (including one day during the weekend). Each blood pressure measure will be sent to the center of the study coordination center through software downloaded on the participant's smartphone.
1495160|NCT03005470|Device|TELEMEV|In the lifestyle telemonitoring group (TELEMEV), participants will receive customized standardized text messages to stimulate lifestyle changes and adherence to blood pressure lowering medication. The messages will be focused on the adoption of DASH diet, sodium restriction, increase of physical activity, weight control and adherence to drug treatment. They will be sent out on four of the five days of the week at random times. The messages will be sent to the smarphones through a software developed for this study.
1495161|NCT03005470|Device|TELEM-TELEMEV|Participants in the TELEM plus TELEMEV (TELEM-TELEMEV) will receive both interventions as previously described.
1495199|NCT03005210|Drug|Harvoni (second dose)|1 tablet contains 400 mg Sofosbuvir and 90 mg Ledipasvir
1495162|NCT03005470|Other|UCC|Participants in the control group will receive usual clinical care (UCC) on pre-scheduled visits, but will not use any technological tool to stimulate blood pressure control or lifestyle modification.
1495163|NCT03005457|Behavioral|Hemiparesis Therapy with VR|An in-home therapist-as-consultant model of CI therapy in which motor practice with shaping and the Motor Activity Log with problem solving were delivered via a custom avatar-based video game called Recovery Rapids
1495164|NCT03005444|Drug|Low molecular weight Heparin|4000 or 4100 IU/day, subcutaneously for 48 weeks
1495165|NCT03005431|Behavioral|Parent training and support|Parents will be given access to participate in an on-line support forum and a set of on-line parent training modules.
1495166|NCT03005418|Biological|Human Acellular Vessel (HAV)|The investigational medicinal product (IMP) is a Humacyte Human Acellular Vessel (HAV), which is a tissue-engineered vascular prosthesis for arterial bypass or reconstruction in patients with peripheral arterial disease or peripheral arterial trauma. It is a sterile, non-pyrogenic acellular tubular vessel composed of human collagen types I and III and other extracellular matrix proteins, including fibronectin and vitronectin. The vessel is 6 mm in diameter and approximately 42 cm in length. The product is supplied on a silicone mandrel immersed in sterile phosphate buffered saline in a sealed and labeled plastic container. The Humacyte HAV is implanted using standard vascular surgical techniques similar to placement of predicate peripheral vascular prostheses.
1495167|NCT03005405|Procedure|Ionomer Restoration (control)|Restoration of moderate caries lesions after partial caries removal using high viscosity glass ionomer cements
1495168|NCT03005405|Procedure|Ionomer Sealant (test)|Sealing of moderate caries lesions without any caries removal or cavity opening.
1495169|NCT03005405|Procedure|Oral hygiene orientation and professional fluoride application|Oral hygiene orientation and professional fluoride application
1495170|NCT03005392|Other|exercise|"An exercise program will be designed over 16 weeks with 55 sessions, moderately increasing the volume and intensity of the load every 4 weeks. The program will consist of strength exercises, flexibility and aerobic endurance, which will be explained in videos and are going to be available in an online platform.
The physiotherapist will contact the patient and/or tutor weekly so as to answer and doubts they may have with respect to the exercise program and to further supervise their compliance (group with intervention)."
1495171|NCT03005379|Drug|Fecal Microbiota Therapy (FMT)|Oral capsule-delivered FMT
1495172|NCT03005379|Drug|Placebo|Oral capsule-delivered placebo
1495173|NCT03005366|Drug|Vernakalant|Initial infusion: 3 mg/kg intravenously over a 10 minute period. For patients weighing ≥ 113 kg, the maximum initial dose will be 339 mg. If conversion to sinus rhythm does not occur within 15 minutes after the end of the initial infusion, a second 10 minute infusion of 2 mg/kg will be administered. For patients weighing ≥ 113 kg, the maximum second infusion will be 226 mg.
1495174|NCT03005366|Drug|Flecainide|2 mg /kg (max 150 mg) intravenously over 10 minutes.
1495175|NCT03005353|Drug|Cumin seed extract|patients will receive the drug in suppository form
1495176|NCT03005353|Drug|clotrimazole|patients will receive the drug in suppository form
1495177|NCT03005340|Drug|Treatment B|Bazedoxifene 20 mg
1495178|NCT03005340|Drug|Treatment C|Cholecalciferol granule 10 mg
1495179|NCT03005340|Drug|Treatment BC|Bazedoxifene 20 mg, Cholecalciferol granule 10 mg
1495180|NCT03005327|Drug|X4P-001|CXCR4 antagonist
1495181|NCT03005327|Drug|Placebo|Matched placebo capsules
1495182|NCT03005314|Procedure|chemotherapy|chemotherapy before surgery
1495183|NCT03005314|Procedure|Surgery|chemotherapy after surgery
1495184|NCT03005301|Device|intelligent electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.
Trial instrument of this study is the CX-DZ-Ⅱ type intelligent electroacupuncture therapeutic instrument.Choice of acupuncture needle: one-off stainless acupuncture needle, which is 25~40mm in length and 0.30~0,38mm in diameter.Waveform: continuous-wave with frequency of 120~250 times per minute and current intensity within patients' tolerance.Treatment time: each treatment time is 30 minutes."
1495185|NCT03005301|Device|Hwato electroacupuncture instrument|"Choice of major points: GB20, GB21, EX-B2, GV14. Choice of adjunct points based on syndrome differentiation.
The Hwato electroacupuncture treatment instrument. Waveform: continuous-wave with frequency of 120~250 times per minute and current intensity within patients' tolerance.
Treatment time: each treatment time is 30 minutes."
1495186|NCT03005288|Drug|bimagrumab|monthly intravenous infusion
1495187|NCT03005288|Other|placebo|monthly intravenous infusion
1495188|NCT03005275|Other|IVM|"FSH injection: Day 9, 10 and 11 (can be adjusted 1-3 days before or after to avoid Ultrasound and OPU on holidays). Dose: normally 100 IU/day (maybe 75 - 150 IU/day).
Follicle and endometrium can be evaluated: on the day of final injection or one day later.
hCG 10.000 IU: one day after the final FSH injection, at 9 p.m. Can be adjusted HCG injection day (± 1-2 days) to avoid Ultrasound and OPU on vacation.
OPU: 1,5 day after hCG injection (normally 36-42 hours later). Sperm collection: on OPU day (if mature follicle presents) or 1 day after OPU day.
Embryo transfer: 3 days after OPU. Luteal support: progesterone gel (90 mg once daily) intra-vaginally and estradiol (4 mg/day PO, twice daily) initiated on the day of OPU or the day thereafter."
1495189|NCT03005275|Other|ICSI|"Daily SC injections with rFSH (minimum starting dose is around 150 IUI) are started on On day 2 or day 3 of the menstrual cycle (Stimulation Day 1) and continue up to and including Stimulation Day 7.
From Stimulation Day 8 onwards, subjects from ICSI treatment groups will continue with a daily SC dose of rFSH up to the day before GnRH agonist day. The maximum rFSH dose to continue treatment after the first 7 days is 300 IU but the dose could be adjusted when desired.
As soon as three follicles of 17mm are observed by USS at least, a GnRH agonist (Triptorelin 0.2 mg) will be used for final oocyte maturation at the same day. About 34-36 h thereafter, OPU followed by ICSI is performed. Two days after oocyte pick-up 2 fresh embryos will be transferred"
1495190|NCT03005262|Drug|MLN8237|
1495191|NCT03005249|Procedure|neural stem cells therapy group|The patients will be assigned to neural stem cells therapy group for cerebral palsy.
1495192|NCT03005249|Other|the control group|The patients will be assigned to the control group for cerebral palsy.
1495193|NCT03005236|Drug|ENVARSUS|Envarsus is a once-a-day oral formulation of tacrolimus.
1495194|NCT03005236|Drug|Standard twice daily tacrolimus|Standard tacrolimus will include twice-daily formulations that are currently available.
1495195|NCT03005223|Drug|Co-administration of DWC20155/DWC20156|
1495201|NCT03005184|Drug|Valsartan 80 mg bid|oral medication during run-in and washout period
1495202|NCT03005184|Drug|Enalapril 10 mg bid|oral medication
1495203|NCT03005184|Drug|Sacubitril-Valsartan 200 mg bid|oral medication
1495204|NCT03005184|Drug|Icatibant|intravenous medication
1495205|NCT03005184|Drug|Placebo|intravenous medication
2001828|NCT02766361|Behavioral|Cognitive Behavioral Rehabilitation|12 weekly sessions of Combined intervention lasting 90 minutes
2001829|NCT02766361|Other|Treatment as Usual|standard out-patient treatment offered in our clinic, which involves psychopharmacological mood stabilization and regular contacts with mental health nurses.
1495208|NCT03005158|Other|Validation Phase|Standard care across all sites during the validation phase will rule out myocardial infarction in those with presentation troponin below the 99th centile with greater than 6 hours of symptoms at the time of blood sampling. In those with less than 6 hours of symptoms, a second test will be measured 6- 12 hours after presentation.
1495209|NCT03005158|Other|Randomization Phase|Standard care or HighSTEACS pathway.
1495210|NCT03005158|Other|Implementation Phase|Implementation of the HighSTEACS pathway to rule out myocardial infarction in patients with suspected acute coronary syndrome. Myocardial infarction will be ruled out if presentation cardiac troponin concentrations are <5 ng/L in those with at least 2 hours of symptoms at the time of blood sampling. In patients with less than two hours of symptoms, or where cardiac troponin concentrations are between 5ng/L and the 99th centile, repeat testing will be recommended at 3 hours. Myocardial infarction will be ruled out at 3 hours if cardiac troponin concentrations are unchanged (<3 ng/L change) and remain ≤99th centile on retesting. Those remaining ≤99th centile on retesting but demonstrating a significant change will require admission for further testing at 6-12 hours.
1495211|NCT03005145|Other|7 days of adequate antibiotic treatment|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
1495212|NCT03005145|Other|14 days of adequate antibiotic treatment.|The choice of treatment including type, dose, route and interval of antibiotic will be left at the discretion of treating team as long as it is appropriate for the bacteremia
1495213|NCT03005132|Other|Normal brain tissue|The investigators will extract total protein, DNA and RNA from the samples.
1495214|NCT03005119|Drug|PTL201|Two piece acid resistance hard capsule filled with seamless gelatin matrix green beads containing tetrahydrocannabinol (THC) and cannabidiol (CBD). Each capsule contain 5 mg THC and 5 mg CBD
1495215|NCT03005119|Drug|Placebo Oral Capsule|Placebo seamless gelatin matrix green beads containing excipients only
1495216|NCT03005106|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
1495217|NCT03005106|Procedure|Autograft|The current standard of care procedure for the treatment of severe burns. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original burn wound.
1495218|NCT03005093|Other|CAREGIVERS|The Turkish Feeding/Swallowing Impact Survey will be completed by the caregivers
1495219|NCT03005093|Other|CHILDREN OF CAREGIVERS|Chewing performance with Karaduman Chewing Performance Scale, tongue control with Tongue Thrust Rating Scale, dysphagia symptom severity with the Pediatric version of the Eating Assessment Tool will be evaluated. These assessments will be done before and after swallowing rehabilitation program.
1495220|NCT03005067|Drug|Carbomer 980 (1146A)|Test product containing carbomer 980 gel
1495221|NCT03005067|Other|Placebo|Reference product containing vehicle without carbomer 980 gel
1495222|NCT03005054|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable rectangular piece of stratified epithelial tissue composed of a living dermal matrix containing dermal fibroblasts overlaid with human epidermal keratinocytes (NIKS®).
1495223|NCT03005054|Procedure|Autograft|The current standard of care procedure for the treatment of severe complex skin defects. The procedure involves the removal of a sheet of healthy skin from an uninjured site on the patient and using it to cover the original wound.
1495226|NCT03005015|Drug|Lenvatinib|
1495227|NCT03005015|Drug|Doxorubicin|
1495228|NCT03005002|Biological|Durvalumab|Given IV
1495229|NCT03005002|Other|Laboratory Biomarker Analysis|Correlative studies
1495230|NCT03005002|Biological|Tremelimumab|Given IV
1495231|NCT03004989|Behavioral|Programme|The participants of this study had participated in one of three different RTW-GPs. These programmes are designed to enable participants to proactively take action in their daily lives and in collaboration with employers achieve the best possible working conditions. All the group sessions are based on cognitive theory where attention, awareness and reflection on one's own work and life situation is important
1495232|NCT03004976|Biological|Umbilical Cord Blood|Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10^7 TNCC/kg.
1495233|NCT03004976|Other|Placebo|The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 [pink]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.
1495234|NCT03004963|Device|Body composition monitor|Both body composition monitor (BCM) is used to evaluate the volume status of patients.
1495235|NCT03004963|Device|clinical indexes|The investigators evaluate the volume status of patients according to clinical indexes.
1495236|NCT03004937|Other|Family Medicine Hearing Loss Best Practice Alert|A Best Practice Alert, or BPA, was created in the electronic medical record system, which fires when patients meet the inclusion criteria. It reminds providers to ask their patients if they think have a hearing loss and allows them to respond as needed (refer to audiology, add hearing loss to the problem summary list, or dismiss for one year).
1497062|NCT02991287|Procedure|Inguinal hernia repair|
1495240|NCT03004911|Device|ProFibro (Mobile application)|ProFibro, a mobile Android application in Brazilian Portuguese to promote self-care in patients with fibromyalgia
1495241|NCT03004911|Device|Paper booklet|A 64-page booklet with content similar to the mobile application
1495242|NCT03004898|Behavioral|multidisciplinary renal education|multidisciplinary CKD care involving case management nurse, dietitian, social worker, pharmacists.
1495243|NCT03004885|Device|PrismaLung|Low flow Extracorporeal CO2 removal using a 0.32 m² membrane oxygenator
1495244|NCT03004846|Drug|GSK2981278 ointment|"GSK2981278 ointment will be applied topically twice daily for 8 weeks to all subjects in Part A and to randomized subjects in Part B. GSK2981278 will be a white to off-white ointment and a thin layer will be applied to all affected areas for given timeframe.
GSK2981278 is available as white to off-white ointment in unit strength 4% (w/w), 2% (w/w) and 0.8% (w/w), for topical application for application as thin layer to all affected areas ."
1495245|NCT03004846|Drug|Vehicle ointment|It will be supplied as white to off-white vehicle ointment for topical application.
1495246|NCT03004833|Drug|Nivolumab|Infusion of Nivolumab
1495247|NCT03004833|Drug|Adriamycin|Infusion of Adriamycin
1495248|NCT03004833|Drug|Vinblastine|Infusion of Vinblastine
1495249|NCT03004833|Drug|Dacarbazine|Infusion of Dacarbazine
1495250|NCT03004820|Device|Remote Ischemic Conditioning|RIC consist of five cycles of 5-min inflation (200 mmHg) and 5-min deflation of cuff on bilateral upper limbs twice a day. Medication strategy is based on physician's best judgement.
1495251|NCT03004807|Dietary Supplement|Centrum Silver Mens' Formula|Multivitamin/Multimineral dietary supplement produced for Pfizer for use in older men.
1495252|NCT03004807|Other|Control|A matching tablet to the dietary supplement, but without any active ingredients
1495253|NCT03004794|Other|medical records review|
1495254|NCT03004781|Behavioral|Parenting program|
1495255|NCT03004768|Drug|BMS-986165|
1495256|NCT03004755|Other|Post Mortem|
1495257|NCT03004742|Dietary Supplement|Flavonoid|Flavonoid rich supplement
1495258|NCT03004742|Dietary Supplement|Placebo|Placebo
1495259|NCT03004729|Other|CoMiSS questionnaire|
1495260|NCT03004716|Other|Aerobic training|"5 consecutive patients with chronicle obstructive pulmonary disease are offered to participate in the protocol when they have reached 45 min of aerobic training during their pulmonary rehabilitation program.
During 5 sessions of 45 min, they are monitored with an oximeter device (Nonin 3150) which records heart rate (HR) and oxygen transcutaneous saturation (SpO2). The device also communicates with a telemedicine medical gateway which sends these data to a remote telemedicine center. Data are then provided on a secured online platform and compared with data recorded on the device (Nonin 3150)."
1495261|NCT03004703|Drug|Tocilizumab|Active drug: Tocilizumab, 20 mg/ml; 14 ml (280 mg) dissolved in 100 ml NaCl 0.9 % i.v. once.
1495262|NCT03004703|Drug|Sodium chloride 0.9%|Placebo: Sodium chloride 0.9%; 100 ml i.v. once.
1495263|NCT03004690|Device|PPE Suit A|In this randomized study following good clinical practice guidelines nineteen study volunteers were recruited to wear one of two different types of randomly allocated PPE suits. Suit A has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
1495264|NCT03004690|Device|PPE Suit B|Suit B has to be used by randomly selected participants to perform four different tests six times at 22°C on one day and four times at 28°C on another day in the local core facility clinical research center.
1495265|NCT03004677|Behavioral|Continuous skin-to-skin contact|Infants will rest in skin-to-skin contact on parents' chest 24 hours a day alternating between the parents. The parents will note who provides the SSC and if and for how long they are off SSC for any reason.
1495266|NCT03004677|Other|Standard Care|Infants will receive regular care in the NICU. Parents may practice SSC if they like. Parents will note if, with whom, and for how long they provide SSC.
1495267|NCT03004664|Behavioral|Support Empowerment Model|The DSMS combines a series of clinically informed group didactic sessions that use a patient self-determination approach to empower patients to take control of their own diabetes health with follow-up supports to sustain self-management gains achieved during the sessions.
1495268|NCT03004664|Behavioral|The Chronic Care Model|the CCM focuses on addressing social determinants of health by meeting the medical, cultural, and linguistic needs of patients through integration of cultural norms and social relationships from the patient population into program design
1495269|NCT03004651|Other|Power Doppler ultrasound|Mesure of synovitis (≥ grade 1 synovitis on a semi-quantitative scale)
1495270|NCT03004651|Other|Clinical evaluation|swollen joint count (SJC) as componant of SDAI
1495271|NCT03004638|Biological|MEDI6012|MEDI6012
1495272|NCT03004638|Biological|Placebo|Placebo
1495273|NCT03004625|Drug|daclatasvir|to evaluate the treatment efficacy and safety of the drug in HCV patients
1495274|NCT03004625|Drug|asunaprevir|to evaluate the treatment efficacy and safety of the drug in HCV patients
1495275|NCT03004625|Drug|Ribavirin|to evaluate the treatment efficacy and safety of the drug in HCV patients
2001835|NCT02757859|Procedure|Pancreatectomy|Undergo pancreaticoduodenectomy, distal pancreatectomy, or total pancreatectomy
1495278|NCT03004599|Device|SYM-SV-002 Aortic Bioprosthesis and SYM-DS-002 Transfemoral Delivery System|Transcatheter Aortic Valve Implantation via Transfemoral Approach
2001836|NCT02757859|Other|Lavage|Receive extensive intraoperative peritoneal saline (EIPL-S) lavage
1497063|NCT02991287|Procedure|Abdominal hysterectomy|
2001837|NCT02756143|Behavioral|Exercise|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
2001838|NCT02751138|Procedure|Surgery|Tumor resection
2001839|NCT02749214|Other|Blood Sample Collection|Participants will have two to three tablespoons (30 cc) of peripheral blood drawn to test for inflammatory markers.
1495282|NCT03004573|Other|Neuropsychological detailed tests with focus on social cognition|MATTIS, MOCA, BREF, Light points test, PDQ39
1495283|NCT03004560|Procedure|Standard Laparoscopic Approach|Minimally invasive laparoscopic surgery with 5-10 mm incisions.
1495284|NCT03004560|Procedure|Percutaneous Approach|Minimally invasive laparoscopic surgery with 2-3 mm incisions.
1495285|NCT03004547|Other|Measuring sodium content|Sodium MRI measurement of sodium content in the tissues of all participants
1495286|NCT03004534|Drug|ODM-201|Oral 300 mg tablets; 600 mg (2 x 300 mg tablets) taken twice per day, to a daily dose of 1200 mg.
1495287|NCT03004521|Drug|Quetiapine|Quetipatine prescribed in addition to the patient's existing antidepressant treatment.
1495288|NCT03004521|Drug|Lithium|Lithium prescribed in addition to the patient's existing antidepressant treatment.
1989766|NCT02389465|Drug|Escitalopram + Celecoxib|Participants will receive celecoxib in addition to escitalopram
1495291|NCT03004495|Drug|CHF5259 and CHF6001|b.i.d. for 14 days
1495292|NCT03004495|Drug|CHF5259 + placebo|b.i.d. for 14 days
1495293|NCT03004495|Drug|CHF6001 + placebo|b.i.d. for 14 days
1495294|NCT03004495|Other|Placebo|b.i.d. for 14 days
1495295|NCT03004469|Drug|P-3074|
1495296|NCT03004469|Drug|Finasteride|
1495297|NCT03004469|Drug|Vehicle|
1495298|NCT03004456|Other|Distraction|Distraction will be provided by allowing the patient to will choose an age appropriate application (e.g. movie, game) which will be held for them during the blood draw.
1495299|NCT03004443|Drug|Infliximab|Infliximab will be administered intravenously (IV) as 5 mg/kg body weight over a 2 to 2.5 hour period.
1495300|NCT03004443|Drug|Placebo|Saline solution will be administered intravenously over a 2 to 2.5 hour period.
1495301|NCT03004430|Behavioral|Mantra Meditation|Silent mantra meditation with spiritual mantra
1495302|NCT03004430|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation
1495303|NCT03004417|Drug|CHF 6001 Dose1|CHF 6001 plus placebo
1495304|NCT03004417|Drug|CHF 6001 Dose2|CHF 6001 only (high dose)
1495305|NCT03004417|Other|Placebo|Placebo only
1495306|NCT03004404|Drug|Placebo|
1495307|NCT03004404|Drug|BI 730357|
1495308|NCT03004378|Device|Fitbit|
1495309|NCT03004365|Drug|C16G2 Varnish|Antimicrobial Peptide
1495310|NCT03004365|Other|Placebo Varnish|Placebo
1495311|NCT03004352|Other|retrograde flow|Two pneumatic cuffs were placed on the experimental arm, one on the lower forearm, and the other on the upper arm. Two cuffs were simultaneously inflated for 20 minutes. The distal cuff was inflated to 75 mm Hg and the proximal cuff was inflated to 40 mm Hg. The contralateral (control) arm was cuff free during this intervention.
1495312|NCT03004352|Other|oxygen|Supplemental 100% oxygen administered through a nasal cannula.
1495313|NCT03004339|Drug|SOR007 Ointment 2.0%|
1495314|NCT03004339|Drug|SOR007 Ointment 1.0%|
1495315|NCT03004339|Drug|SOR007 Ointment 0.3%|
1495316|NCT03004339|Drug|SOR007 Ointment 0.15%|
1495317|NCT03004339|Drug|SOR007 Ointment Placebo|
1495318|NCT03004339|Drug|Taclonex® Ointment|
1495319|NCT03004313|Procedure|Pet Scan|Subjects will undergo Pet Scanning for 90 minutes
1495320|NCT03004313|Procedure|MRI scan|
1495321|NCT03004313|Procedure|Quantitative Sensory Testing (QST)|
1495322|NCT03004300|Procedure|Rapid maxillary expansion|Device
1495323|NCT03004300|Procedure|Adenotonsillectomy|Surgery
1495324|NCT03004287|Drug|Carfilzomib|Given by vein: days 1 and 2 of Induction; days 1, 8, 15, and 22 of Consolidation 1; and days 1, 8, 15, and 22 of alternating 3-month blocks during Maintenance.
1495325|NCT03004287|Drug|Thalidomide|Given by mouth at bedtime: days 1-4 of Induction
1495326|NCT03004287|Drug|Dexamethasone|Given by mouth or by vein: days 1-4 of Induction; days -4 - -1 of Transplant(s); and days 1, 8, 15, and 22 of every cycle during Maintenance
1495327|NCT03004287|Drug|Daratumumab|Given by vein: day -1 of induction; days 1 and 8 of Immunological Consolidations; and day 1 of each Maintenance cycle
1495328|NCT03004287|Drug|Cisplatin|Given by vein: days 1-4 (continuous infusion) of Induction
1495329|NCT03004287|Drug|Adriamycin|Given by vein: days 1-4 (continuous infusion) of Induction
1495330|NCT03004287|Drug|Cyclophosphamide|Given by vein: days 1-4 (continuous infusion) of Induction
1495331|NCT03004287|Drug|Etoposide|Given by vein: days 1-4 (continuous infusion) of Induction
1495332|NCT03004287|Drug|Melphalan|Given by vein: days -4 - -1 of Transplant(s)
1495333|NCT03004287|Procedure|ASCT|day 0 of Transplant(s)
1495334|NCT03004287|Drug|Lenalidomide|Given by mouth: days 1-21 of alternating 3-month blocks during Maintenance
1495335|NCT03004287|Drug|Bortezomib|Given by vein or subcutaneous injection: may be substituted for carfilzomib throughout the study regimen at the discretion of the treating physician
1495336|NCT03004274|Other|Running sutures|
1495337|NCT03004274|Other|Interrupted sutures|
1495338|NCT03004261|Biological|CMV-CTL|donor derived cytomegalovirus specific T lymphocytes will be transfused to recipients of hematopoietic stem cell transplant when they are sero-positive for CMV-DNA.
1495339|NCT03004261|Drug|Foscarnet|Foscarnet may be used for the treatment of CMV infection before and after the CMV-CTL infusion.
1495340|NCT03004261|Drug|Ganciclovir|Ganciclovir may be used for the treatment of CMV infection before and after CMV-CTL infusion.
1495341|NCT03004248|Biological|Botulinum Toxins, Type A|Intramuscular Injection
1495342|NCT03004235|Device|Observational data collection|Observational data collection
1495343|NCT03004222|Drug|Bupivacaine|20 ml of 0.5% Bupivacaine
1495344|NCT03004222|Drug|Placebos|
1495345|NCT03004209|Drug|Erythropoietin|three times per a week 100IU / k
1989767|NCT02389465|Drug|Escitalopram + Placebo|Participants will receive a placebo in addition to escitalopram.
1989768|NCT02389023|Other|standard gauze dressing|Standard gauze dressing with tape will be placed over the surgical incision in the operating room and left on the incision as dictated by standard of care
2001840|NCT02749214|Other|Breath Sample Collection|Participants will be asked to breathe into the Breath Sampler containing a rapid passive volatile organic compounds (VOC) sampling device. A disposable mouthpiece is placed over a portion of the sampler where the participant placed his/her mouth. The mouthpiece will be disposed of after each use and a new one will be used for each participant. Prior to sample collection, the participant will be asked to rinse his/her mouth with water. Then the participant will breathe deeply into the sampler five times with breaths being five minutes apart to collect the alveolar breath.
1495349|NCT03004183|Biological|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
1495350|NCT03004183|Drug|Valacyclovir|Prodrug of the antiviral drug acyclovir
1495351|NCT03004183|Radiation|SBRT|Low-dose SBRT
1495352|NCT03004183|Drug|Pembrolizumab|Humanized immunoglobulin G4 anti-programmed death-1 (PD-1) monoclonal antibody
1495353|NCT03004170|Behavioral|Telephone-Administered Motivational Interviewing Plus Behavioral Skills Training|
1495354|NCT03004170|Behavioral|Telephone-Administered Coping Effectiveness Training|
1495355|NCT03004157|Procedure|cardiopulmonary resuscitation|CPR for 10 minutes with a chest compression: ventilation ratio of 15:2 according to international CPR guidelines
1495356|NCT03004144|Other|FLOAT|
1495357|NCT03004131|Drug|Azelastine hydrochloride + fluticasone propionate nasal spray|
1495358|NCT03004131|Drug|Placebos|
1495359|NCT03004131|Drug|fluticasone propionate nasal spray + loratadine|
1495360|NCT03004118|Dietary Supplement|Nutridrink|Liquid meal of 200ml
1495361|NCT03004118|Device|High resolution manometry probe|Catheter inserted via the nose into the stomach to measure intragastric pressure.
1495362|NCT03004118|Device|perfusion catheter|Catheter inserted via the nose into the stomach to perfuse the nutridrink intragastricly.
1495363|NCT03004118|Drug|Placebo Oral Tablet|4 week oral intake (daily)
1495364|NCT03004118|Drug|Ursochol oral tablet|4 week oral intake (daily) (dose of 10.5mg/kg/day)
1495365|NCT03004118|Device|Duodenal fluid aspiration catheter|Catheter inserted via the nose into the duodenum to aspirate duodenal fluids for 2.5 hours.
1495366|NCT03004118|Procedure|Duodenogastroscopy|Catheter inserted via the mounth into the duodenum to take duodenal biopsies.
1495367|NCT03004118|Procedure|Blood sample|Blood sample will be taken to measure liver enzyme serum levels and marker for bile acid synthesis.
2001841|NCT02746744|Drug|Rituximab|Infusion of Mabthera/Rituximab every 6 months
2001842|NCT02746744|Drug|Dimethyl fumarate|Intake of Tecfidera/Dimethyl Fumarate daily acc. to clinical practice.
2001843|NCT02746744|Drug|Sodium Chloride solution|Placebo/Sham infusion every 6 months so that the examining physician (blinded) should not know which patient gets Mabthera or Tecfidera
1495371|NCT03004092|Procedure|blood sample|Twice weekly blood sample, and at every outpatient visit
1495372|NCT03004066|Drug|Daptomycin|standard care
1495373|NCT03004053|Device|Reflectance Confocal Microscopy (RCM) endoscope device|
1495374|NCT03004040|Biological|Flu Vaccine|
2001844|NCT02743975|Drug|Bevacizumab-800CW|dose finding: 4.5mg; 10mg; 25mg; 50mg
1495376|NCT03004014|Other|Sleep endoscopy during propofol induced sleep|It will be performed a sleep endoscopy during drug induced sleep endoscopy
1495377|NCT03004001|Drug|Alirocumab|150 mg biweekly
1495378|NCT03004001|Drug|Alirocumab placebo|placebo
1495379|NCT03004001|Drug|Atorvastatin|20 mg/day
1495380|NCT03003988|Dietary Supplement|Creatine monohydrate|Creatine monohydrate (6.0 g) + dextrose (0.5 g)
1495381|NCT03003988|Dietary Supplement|Creatine nitrate|Creatine nitrate (5.0 g creatine monohydrate + 1.5 g. creatine nitrate that provides 1.0 g. of creatine and 0.5 g. nitrate in 2:1 ratio)
1495382|NCT03003988|Dietary Supplement|Placebo|Placebo (6.5 g dextrose)
1495383|NCT03003975|Device|PVI by single cryoballoon application guided by Achieve Mapping Catheter|Pulmonary vein isolation by single cryoballoon application guided by recorded electrogram signals from an internal Mapping Catheter and by temperature drop if mapping of signals is not possible (temperature cutoff < or = -40 degrees C)
1495384|NCT03003975|Device|PVI by 2 routine cryoballoon applications|Pulmonary vein isolation by 2 cryoballoon applications guided by degree of occlusion and by temperature drop according to discretion of physician
2001845|NCT02742298|Device|Muscle ultrasound|Ultrasound images of limb muscles will be collected.
2001846|NCT02742298|Other|Electrical Impedance Myography|A painless current passes through the skin and surface electrodes are used to record the impedance through muscle.
2001847|NCT02742155|Behavioral|Play2Sleep|Behavioral: Video self-modelling
2001848|NCT02742155|Behavioral|Comparison|Behavioral: Information only
2001849|NCT02741596|Drug|DX-2930|Rollover subjects: 300 mg DX-2930 administered by subcutaneous injection at Day 0. No additional DX-2930 doses until their first reported HAE attack. Following this attack subjects will receive open label doses of 300 mg DX-2930 every 2 weeks by subcutaneous injection throughout the duration of the treatment period.
1495391|NCT03003949|Drug|Estradiol|Transdermal Estradiol worn every day for 16 weeks (patch changed every 7 days).
1495392|NCT03003949|Drug|Placebos|Placebo patches to be worn every day for 16 weeks (patch changed every 7 days).
1495393|NCT03003949|Drug|Progesterone|Micronized progesterone (200 mg) will be administered every day for 12 days during weeks 17-18 (8 weeks after randomization to estradiol/placebo) and again at weeks 25-26 (which is the end of the 16 week intervention).
1495394|NCT03003949|Drug|Placebo Oral Tablet|Placebo pills will be administered every day during weeks 17 and 18 and again for weeks 25-26.
1495396|NCT03003923|Behavioral|Taste exposure|Exposure to the same vegetable
1495397|NCT03003923|Behavioral|Nutritional education|Eat Well and Strive for Five nutritional education
1495398|NCT03003910|Behavioral|Best Possible Self|Intervention group which requires people to envision themselves in a future in which all has gone in the best possible way.
1495399|NCT03003910|Behavioral|Daily Activities|Control group which consists of thinking and writing about all the activities and situations that had taken place during the last 24 h.
1495400|NCT03003897|Other|Soluble Fiber|Participants receiving soluble fiber.
1495401|NCT03003897|Other|Placebo|Participants receiving placebo.
1497064|NCT02991287|Procedure|Vaginal hysterectomy|
1495402|NCT03003884|Drug|Remimazolam Tosilate|Initial dose plus supplemental doses as necessary.
1495403|NCT03003884|Drug|Propofol|Initial dose plus supplemental doses as necessary.
1495404|NCT03003871|Device|Powered toothbrush|Oral-B® AdvancePowerTM 400 series
1495405|NCT03003871|Device|Manual toothbrush|Oral-B® Pro-Health All-In-One
1495406|NCT03003871|Other|Toothpaste|Colgate Maximum Cavity Protection®
1495407|NCT03003871|Other|0.2% chlorhexidine gluconate mouth rinse|CorsodylPTMP
1495408|NCT03003858|Device|0.1% HA-based film-forming device (Gengigel Prof® Fluid)|0.1% HA-based film-forming device (Gengigel Prof® Fluid, Ricerfarma, Milano, Italy) administered (oral rinses for 3-5 min.) three to five times a day over a 4-week period as an adjunct to domiciliary care and oral hygiene instructions and motivation
1495409|NCT03003845|Other|Questionnaires|QOL and pain questionnaires will be given to patients at 3, 6, and 12 months post surgery
1495410|NCT03003845|Other|Collection of Blood samples|Blood for PBLs will be collected at 3, 6, and 12 months post surgery
1495411|NCT03003832|Other|Change in electronic health record default for new opioid analgesic prescriptions|
1495412|NCT03003819|Device|Control Collagen Wound Dressing|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
1495413|NCT03003819|Device|Test Collagen Matrix|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic and local anesthetic, minimally traumatic extraction will be performed with periotomes . After degranulation and bone graft placement, control or test biomaterial will be placed according to the randomization schedule and surgical instructions for each biomaterial.
2001850|NCT02741596|Drug|DX-2930|Non-rollover subjects: 300 mg DX-2930 administered every 2 weeks by subcutaneous injection throughout the duration of the treatment period.
1495416|NCT03003780|Behavioral|Mindful Steps|Integrated website, activity tracker, and mind-body training
1495417|NCT03003754|Behavioral|High Intensity Training (HIT) + Resistance Training (RT)|Exercise will be performed at three sessions per week. Post statistical analyses will be including analyses by the 3 sub-groups proposed. All sessions will be supervised by an exercise physiologist during 6 weeks.
1495418|NCT03003754|Behavioral|Control group|Post statistical analyses will be including analyses by the 3 sub-groups proposed Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 6 weeks.
1495419|NCT03003741|Drug|Bupivacaine|One 4 cc intraorbital injection at the end of procedure
1495420|NCT03003741|Drug|EXPAREL|One 4 cc intraorbital injection at the end of procedure
1495421|NCT03003728|Drug|Elotuzumab|Elotuzumab 10 mg/kg via intravenous infusion on days -16, -3, 12, and 26
1495422|NCT03003728|Drug|Melphalan|Melphalan 200 mg/m2 Ivia intravenous infusion on day -3
1495423|NCT03003728|Procedure|Autologous Stem Cell Transplant (ASCT)|ASCT on day -2
1495424|NCT03003728|Biological|Expanded Natural Killer (ENK) Cells|ENK cell infusion on day 0
1495425|NCT03003728|Drug|ALT-803|ALT-803 (Interleukin-15 superagonist) 10 ug/kg via subcutaneous injection on days 1, 8, 15, and 22
1495426|NCT03003715|Procedure|PET Scans|Two 90 minute scans whose maximum radiological dose is 15 mCi [11 C] carfentanil, a selective and specific mu-opioid receptor radioligand. The first one provided baseline data, and the second occurred with the sequence of sham tDCS and tDCS as described in each arm description.
1495427|NCT03003715|Procedure|transcranial direct current stimulation (tDCS)|In active tDCS, a 2 milli-amp transcranial direct current stimulation is for 20 minutes.
1495428|NCT03003715|Procedure|MRI|No radiotracer is used; 3 tesla scanner; all participants have MRI prior to PET scans.
1495429|NCT03003715|Other|sham tDCS (prior to real tDCS)|For sham tDCS, current is applied only for 30 seconds, as sensations arising from tDCS treatment occur only at the beginning of application; however the equipment will be on the participant for 20 minutes to match that of the active tDCS application.
1495430|NCT03003702|Device|Nonin|
1495431|NCT03003689|Procedure|Scaling and Root Planing|Standard of care scaling and root planing using hand instruments and ultrasonic scaler
1495432|NCT03003689|Device|Er:YAG Laser|Er:YAG laser as an adjunct therapy to standard of care scaling and root planing using hand instruments and ultrasonic
1495433|NCT03003676|Biological|ONCOS-102|Engineered oncolytic adenovirus expressing Granulocyte-macrophage colony stimulating factor (GM-CSF)
1495434|NCT03003676|Drug|Cyclophosphamide|Pre-treatment
1495435|NCT03003676|Drug|Pembrolizumab|PD1 blockade
1495436|NCT03003663|Device|SensableCare System|The SensableCare System is evaluated for reducing bed falls.
1495437|NCT03003650|Device|ACURATE TF™|ACURATE TF™Transfemoral Aortic Bioprosthesis is intended for subjects with severe symptomatic Aortic Stenosis and are considered high risk for surgical conventional Aortic Valve Replacement .
1495438|NCT03003637|Drug|Nivolumab|Nivolumab (240 mg flat dose, week 1 and week 3, twice in total) monotherapy, neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
1495439|NCT03003637|Drug|Ipilimumab|Ipilimumab (1 mg/kg) only in week 1, in combination with nivolumab (240 mg flat dose, week 1 and week 3, twice in total), neoadjuvant to SOC (surgery with or without adjuvant (C)RT).
1495440|NCT03003624|Device|Colorado® microdissection needle|The primary feature of the Colorado® microdissection needle is the ultra-sharp tungsten tip that delivers the wave-form from the electrosurgery generator to a very small spot. This allows the use of extremely low wattages, resulting in less tissue necrosis, precision cutting and cautery, and less post-operative pain.
1495477|NCT03003377|Device|laryngeal mask proseal|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml).The LMAP was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAP was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
1495441|NCT03003624|Device|Cautery tip|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
1495442|NCT03003624|Device|BP blade|Studies have shown that, heat generated by electrosurgical devices are influenced by factors like duration of contact between tissue and electrode tip, current intensity, electro section waveform and the electrode tip size. A larger tip causes more tissue damage, increased operating power and more amount of lateral heat production. This led to the development of microdissection needle with fine electrode tip and efficient power usage. The use of microdissection needles does not have any significant difference in wound healing or pain when compared with scalpel.
1495443|NCT03003611|Procedure|hypnose sedation|Patient will be anesthetized with an hypnose sedation and a complement with light anesthesia
1495444|NCT03003611|Procedure|general anesthesia|Patient will be anesthetized with a classical general anesthesia
1495445|NCT03003598|Other|Videolaryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
1495446|NCT03003598|Other|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
1495447|NCT03003585|Other|Direct laryngoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
1495448|NCT03003585|Other|Fiberoptic bronchoscope|This device is used in endotracheal intubation and tonopen device for measuring of intraocular pressure. The investigators want to evaluate which one is better.
1495449|NCT03003572|Other|Blood samples|Blood samples will be collected at inclusion to determine anti-Ro/SSA IgE titers (Enzyme Linked ImmunoSorbent Assay ELISA).
1495450|NCT03003559|Device|High flow nasal cannula|High flow nasal cannula (HFNC) is a new emerging noninvasive respiratory support technology, which mainly includes high flow (15-60 L/min) device, heating humidification device and nasal cannula for high flow. A large number of physiological studies confirmed that HFNC has the following critical physiological effects: promoting airway humidification, improving tolerance of treatment, reducing the physiological dead space on the upper respiratory tract, producing a certain level of positive end expiratory pressure (2-7 cmH2O), decreasing the work of breathing and so on.
1495451|NCT03003546|Other|Laboratory Biomarker Analysis|Correlative studies
1495452|NCT03003546|Drug|Nab-paclitaxel/Rituximab-coated Nanoparticle AR160|Given IV
1495453|NCT03003546|Other|Pharmacological Study|Correlative studies
1495454|NCT03003533|Genetic|SPK-8011|A novel, bio-engineered, recombinant adeno-associated viral vector carrying human factor VIII gene
1495455|NCT03003520|Drug|Durvalumab|Durvalumab
1495456|NCT03003520|Drug|Rituximab|Rituximab
1495457|NCT03003520|Drug|Doxorubicin|Doxorubicin
1495458|NCT03003520|Drug|Vincristine|Vincristine
1495459|NCT03003520|Drug|Cyclophosphamide|Cyclophosphamide
1495460|NCT03003520|Drug|Prednisone|Prednisone
1495461|NCT03003520|Drug|Lenalidomide|Lenalidomide
1495462|NCT03003507|Dietary Supplement|Enteral Formula With Fructose|Low-carbohydrate Enteral Formula With Fructose
1495463|NCT03003507|Dietary Supplement|Enteral Formula Without Fructose|Low-carbohydrate Enteral Formula Without Fructose
1495465|NCT03003468|Drug|Imprime PGG|Arm A: Phase Ib Cohort 1: 2mg/kg IV; Arm A: Phase Ib Cohort 2: 4mg/kg IV
1495466|NCT03003468|Drug|MK-3475|200mg IV
1495467|NCT03003468|Drug|Imprime PGG|Arm B: Phase II treatment: administered at the maximum safe dose of 2mg or 4 mg as established in the Phase Ib cohort study.
1495468|NCT03003455|Procedure|Nasotracheal intubation over a bougie|Nasotracheal intubation over a bougie, placed with videolaryngoscopy assistance, via a nasopharyngeal airway with or without the aid of Magill forceps
1495469|NCT03003455|Procedure|Conventional Nasotracheal Intubation|Blind passage of an endotracheal tube via the nare followed by videolaryngoscopy-assisted passage through the glottis, with or without the aid of Magill forceps
1495472|NCT03003429|Other|Heart rate monitor|The intervention consist in monitoring the heart rate variability during one night by using a heart rate monitor and a Polar RS800CX
1495473|NCT03003416|Drug|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
1495474|NCT03003403|Behavioral|Intervention Program|Balance is testing a pragmatic approach to promote weight maintenance among overweight and obese patients within local community health centers who experience barriers to losing weight. The intervention utilizes the interactive obesity treatment approach, which creates an energy deficit by having participants achieve simple, straightforward, and concrete behavior change goals (e.g., no fast food, no sugary drinks, walk 10,000 steps per day). The Balance intervention involves tailored behavior change goals; self-monitoring using connected scales and mobile technologies; responsive coaching, and tailored feedback and skills training.
1995703|NCT02676050|Device|Delivery Device Cathetar and Miniaturised imaging fibre|Both optical imaging agents (NAP and EMI-137) will be administered and imaged simultaneously during a bronchoscopy procedure using the devices mentioned above.
1495476|NCT03003377|Device|laryngeal mask supreme|Sevoflurane was administered by facial mask with concomitant remifentanil administration (at an effect-site of 4 ng/ml). The LMAS was inserted according to the manufacturer's recommendations with the patient's head in the neutral position. After equilibrium the LMAS was inserted and secured according to the manufacturer's recommendations, without using muscle relaxants. A single measurement will be obtained from each patient. If the patient reacted with movement, a 1-2 mg/kg dose of Propofol was administered.
1497065|NCT02991287|Procedure|Thoracotomy|
1995704|NCT02676050|Device|Optical endomicroscopy system|The signal emitted by both optical imaging agents (NAP and EMI-137) will be visualised using a novel endomicroscopy system.
1995705|NCT02675166|Other|Pediatric cancer young adult survivors|Patients will receive a questionnaire, a consultation with an oncologist and a psychologist will be planned, and two years later, patients will have to answer again to the questionnaire.
1495478|NCT03003364|Drug|XCEL-UMC-BETA|Intrathecal allogeneic cell therapy in a blinded syringe
1495479|NCT03003364|Drug|Placebo|Placebo in a blinded syringe
1495480|NCT03003338|Drug|OBV/PTV/r and DSV|OBV/PTV/r (12.5 mg/ 75 mg/ 50 mg) in combination with DSV (250 mg): Two tablets of OBV/PTV/r in the morning and one tablet of DSV in the morning and one tablet of DSV in the evening orally with a meal without regard to fat or calorie content.
1495481|NCT03003338|Drug|Placebo to match OBV/PTV/r and DSV|Placebo to match OBV/PTV/r and DSV
1495482|NCT03003325|Drug|AOP2014|AOP2014 will be supplied to the patients as pre-filled auto-injection pens, containing 250 µg of active drug (0.5 ml solution for injection). One pen may be used twice within a time period of 4 weeks. Hence investigators will provide one prefilled pen at every monthly visit. AOP2014 will be self-injected subcutaneously by patients once every 14 days at the single doses of 100 µg (0.2 ml).
1495483|NCT03003325|Procedure|Phlebotomies|According to current common clinical practice the regimen must be selected accordingly to maintain the recommended level of HCT< 45%. Once normalization of the hematocrit has been achieved, blood counts at regular intervals (every 4 weeks) will establish the frequency of future phlebotomies. Sufficient blood should be removed to maintain the hematocrit below 45%.
1495484|NCT03003325|Drug|ASA|100 mg/daily of ASA is recommended (when there are not contraindications) according with current guidelines for this risk class of patients
1495485|NCT03003299|Device|Edwards SAPIEN 3 transcatheter valve, Model 9600TFX|Edwards SAPIEN 3 THV system Model 9600TFX with the associated delivery systems.
1495486|NCT03003286|Behavioral|Unstuck and on Target (UOT)|Unstuck and on Target (UOT) is a novel and innovative cognitive-behavioral treatment that directly addresses executive functioning and self-regulation deficits in ASD and ADHD. UOT is the first contextually-based EF treatment that targets flexibility, goal-setting and planning through a cognitive-behavioral program centered on self-regulatory scripts that are consistently modeled and reinforced. Parents, teachers, and interventionists will be taught to model and support flexibility across settings. Children will also participate in a peer group intervention setting.
1495487|NCT03003286|Behavioral|Parents and Teachers Supporting Students (PATSS)|The Contingency Behavior Management (CBM) intervention was developed by the researchers and called Parents and Teachers Supporting Students (PATSS) as a current best practice intervention that was comparable in design to Unstuck and on Target. The goal is to improve child behavioral outcomes by training parents, teachers and interventionists in core principles of behavior management like social learning and behavioral change. Children were also included in small group sessions where they identify their own behavior goals and meaningful reinforcers.
1495488|NCT03003273|Other|stoppage of antibiotics|antibiotics will be stopped in arm - A on randomization, once child is afebrile for at least 24 hours and fulfills the inclusion criteria.
1495489|NCT03003273|Other|amoxycillin/clavulanic acid|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
1495490|NCT03003273|Other|levofloxacin|In arm - B, once the child is randomized, oral antibiotics will be started (Amoxicillin/ Clavulanic acid + Levofloxacin)
1495491|NCT03003260|Other|CBD chewing gum|
1495492|NCT03003260|Other|Placebo|
1495493|NCT03003247|Drug|IDP-120 Gel|IDP-120 Gel is a combination product
1495494|NCT03003247|Drug|IDP 120 Component A Gel|Monad of Component A
1495495|NCT03003247|Drug|IDP 120 Component B Gel|Monad of Component B
1495496|NCT03003247|Drug|IDP 120 Vehicle Gel|Vehicle
1495497|NCT03003234|Procedure|Duodenogastroscopy|Catheter goes through the mouth in the duodenum to take duodenal biopsies.
1495498|NCT03003234|Device|Duodenal aspiration catheter|Catheter goes through the nose in the duodenum to aspirate duodenal fluid in fasted and fed state.
1495499|NCT03003234|Dietary Supplement|Nutri drink|Liquid meal of 200 ml.
1495500|NCT03003221|Behavioral|AIR-P Dental Toolkit|The AIR-P Dental Toolkit is designed to provide caregivers with guidance and information related to dental care and support strategies for children with autism spectrum disorder.
1495501|NCT03003221|Behavioral|Parent Training|The parent-training intervention integrates strategies shown to be efficacious for: 1) improving adherence to dental care, 2) enhancing dental experiences for children with neurotypical development and high levels of dental fear, and 3) evidence-based behavioral techniques established for children with autism spectrum disorder.
1495502|NCT03003208|Other|Pulmonary rehabilitation|An exercise and education program
1495503|NCT03003195|Drug|Montanide ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection for a total of 4 vaccinations.
1495505|NCT03003156|Procedure|25 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 25 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
1495506|NCT03003156|Procedure|50 Hz magnetic seizure therapy|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of 50 Hz MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
1495508|NCT03003130|Device|Restylane Defyne|Intradermal injection
1495509|NCT03003130|Device|Restylane|Intradermal injection
1495510|NCT03003117|Behavioral|Experimental: Intervention Program|"The home based educational component from the 3rd trimester of pregnancy to when the child is aged 24 months seeks to build knowledge, skills and social support (social cognitive theory, anticipatory guidance) to the parents regarding feeding practices (focussing on breastfeeding and complementary feeding), consistent with the French Nutrition and Health Program (PNNS) guidelines (component 1). Fresh fruit and vegetable baskets are made available at a reduced price from the 3rd trimester of pregnancy to when the toddler is aged 24 m (component 2), along with the provision of follow-on formula and baby food vouchers from 6 to 24 m (component 3).
One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m."
1495511|NCT03003117|Behavioral|Active comparator: Usual Care|Usual Care reflects the standard treatment currently provided within the frame of the French health care system. One home visit is scheduled during the 3rd trimester of pregnancy. Another visit will take place in the maternity ward after the child is born. Five further home visits will take place when the child is aged 3, 6, 12, 18 and 24 m. If nutritional questions are raised by parents, dieticians will restrict their responses based on the food guides of the PNNS.
1495512|NCT03003104|Drug|DMT210 Topical Gel 5%|
1495513|NCT03003104|Other|Vehicle Control|
1495514|NCT03003091|Other|Needs-based patient education|
1495515|NCT03003091|Other|Traditional patient education|
1495516|NCT03003078|Device|OncoSil™|The implantation of OncoSil™
1495517|NCT03003065|Drug|Temoporfin|A single treatment with Temoporfin (Foscan) 3 mg given intravenously followed by PDT with laser light at 652 nm (Ceralas, Biolitec, Germany) within 72 hours
1495518|NCT03003052|Procedure|Dental implants|Data collection from pre-implant assessment, implant surgery, and hygiene recall appointments, to assess implant survival and success.
1495519|NCT03003039|Biological|GB241|
1495520|NCT03003039|Biological|Rituximab|
1495521|NCT03003026|Other|Novel task-specific bike skills training program|Participants randomised to the intervention group will participate in a novel task-specific bike skills training program. The intervention involves seven key components: it is group-based, intensive (2 hours per day for 3 days plus a home program for the remaining days of the one week period), task-specific, goal-directed, and therapist led, with parent involvement and conducted in an ecological setting. Each program will be run by a physiotherapist and allied health assistant during the school holidays.
1495522|NCT03003026|Other|Parent-led home-based bike skills training program|The comparison group will involve a parent-led home-based bike skills training program. Parents of children randomized to the comparison group will receive written information and telephone support from a physiotherapist on training bike skills. They will be encouraged to work with their child towards their bike skills goals for at least 30-45 minutes per day over a one week period during the school holidays in home and community environments.
1495523|NCT03003013|Procedure|Biphasic Bone Graft Material (BGM) in Combination With Autologous Platelet-rich Fibrin (PRF)|
1495524|NCT03003000|Drug|ibuprofen|
1495525|NCT03003000|Drug|caffeine|
1495526|NCT03003000|Drug|placebo|
1495527|NCT03002987|Behavioral|Active Pregnancy policy|Education (3 hours) of leaders in how to implement Active pregnancy policy at their departments/work places
1495528|NCT03002974|Drug|Anakinra 100 mg|100 mg/0.67 mL solution in single-use prefilled syringes for subcutaneous injection
1495529|NCT03002974|Drug|Triamcinolone Acetonide 40 mg|1 mL intramuscular injection of a 40 mg/mL injectable suspension
1495530|NCT03002974|Drug|Placebo to Anakinra 100 mg|sterile solution for injection (0.67 mL) in a single-use prefilled syringe identical to the anakinra syringe
1495531|NCT03002974|Drug|Placebo to Triamcinolone Acetonide 40 mg|1 mL intramuscular injectable suspension with identical appearance as the Triamcinolone Acetonide suspension
1495532|NCT03002961|Drug|RBP-6000|single dose of RBP-6000, preceded by a pharmacokinetic (PK) sample followed by serial PK samples post-dose. Additionally subjects to remain in the clinic through Day 21 for safety assessments
1495533|NCT03002961|Drug|Suboxone|RBP-6000 injection after 7 days of SL Suboxone administration. Interventions as above with additional daily PK collections during Suboxone treatment prior to RBP-6000 administration
1495534|NCT03002948|Other|Orgasm|"clitoris volume, suprapubic angle, urethra-levator gap, suburethral triangle area measurement could made using 4 D transperineal ultrasonography. Clitoris fourchette distance, clitoris perineal body distance, clitoris urethra distance could made with special compasses.
Female Sexual Function Index orgasm domain score"
1495535|NCT03002935|Drug|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
1495536|NCT03002922|Drug|BAY987517|Sunscreen formula Y65-158
1495537|NCT03002909|Device|epidural catheter|
1495538|NCT03002909|Device|preperitoneal catheter|
1495539|NCT03002896|Behavioral|Pep-Pal|Pep-Pal is designed to complement the utilization of other resources, provide support when no other resources can be obtained, or provide support in the interim until greater resources can be obtained. In this way, Pep-Pal is a resource for our most hard to reach caregivers.
1495540|NCT03002896|Other|Treatment as Usual|
1495541|NCT03002883|Behavioral|Usual Care|"Participant provided Quit Kit water bottle with small cessation aids (eg. sunflower seeds) and educated about student health as a cessation resource"
1495542|NCT03002883|Behavioral|Brief Motivational Interviewing|Peer educator conducts brief motivational interviewing about smoking cessation and participant goals
1495543|NCT03002883|Behavioral|Direct referral to quitline|Peer educator educates about state quitline services and gets verbal consent to use quitline's direct referral web portal for quitline to contact participant in 1-2 business days about free counseling services to make a quit plan
1495544|NCT03002870|Other|Questionnaires|Patients will receive questionnaires yearly to follow their QOL
1495545|NCT03002857|Device|LMA-C|LMA-C will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
1495546|NCT03002857|Device|Baska Mask|Baska Mask will be placed into the patients airway following anesthesia induction. The placement will be done as suggested in supine position with a standard gel pillow under patients head.
1495547|NCT03002857|Device|I-gel|I-gel LMA placement will be done as suggested in supine position with a standard gel pillow under patients head.
1495548|NCT03002844|Drug|EGFR-TK Inhibitor|EGFR-TKI (gefitinib 250mg per day)
1495549|NCT03002844|Drug|EGFR-TKI|EGFR-TKI (gefitinib 250mg per day)
1495550|NCT03002844|Drug|EGFR-TKI and Chemotherapy|pemetrexed 500mg per kg q3w/gemcitabine 1000mg per kg q3w and carboplatin AUC=5 q3w
1495551|NCT03002831|Biological|Cytokine-induced Killer Cells|
1495552|NCT03002831|Drug|Tegafur-Gimeracil-Oteracil Potassium|
1495594|NCT03002376|Drug|REGN2810|REGN2810 treatment
1496511|NCT02995330|Procedure|Bone marrow transplantation|Bone marrow transplantation followed by post-transplant Cytoxan and testosterone.
1495553|NCT03002805|Drug|CBT-1®|"CBT-1®, oral, on days 1-7 of each cycle 21-day cycle. Participants will be assigned to dose level of CBT-1®:
Dose level 1 - 50 mg/m2/day Dose level 2 - 100 mg/m2/day Dose level 3 - 150 mg/m2/day Dose level 4 - 200 mg/m2/day Dose level 5 - 250 mg/m2/day Dose level 6 - 300 mg/m2/day doxorubicin, 75 mg/m2, IV, on days 5 and 6 of each cycle Study treatment discontinued after 450 mg/m2 lifetime cumulative dose of doxorubicin reached or after 4-5 cycles completed."
1495554|NCT03002792|Procedure|general anesthesia|nitrous oxide, sevoflurane, propofol, cisatracurium, fentanyl for induction and maintenance with sevoflurane
1495555|NCT03002779|Drug|JNJ-53718678|Participants will receive a single 500 milligram (mg) dose of 14C-JNJ-53718678 as an oral liquid solution containing 14C-labeled and unlabeled JNJ-53718678 corresponding to a radioactivity dose.
1495556|NCT03002766|Procedure|Breast conservative surgery|
1495557|NCT03002753|Behavioral|detached mindfulness|Please see detailed study description.
1495558|NCT03002753|Behavioral|cognitive restructuring|Please see detailed study description.
1495559|NCT03002714|Other|Exercise|
1495560|NCT03002701|Behavioral|UNDERPIN-ICU program|UNDERPIN-ICU consists of standardized protocols focusing on several modifiable risk factors for delirium, including cognitive impairment, sleep deprivation, immobility and visual and hearing impairment.
1495561|NCT03002688|Other|Survey|Verbal survey will be given before and after the cataract surgery, and on the day following the second cataract surgery.
1495562|NCT03002675|Drug|Bydureon|exenatide (Bydureon) 2mg s.c. 1x/wk
1495563|NCT03002662|Other|colonoscopy|
1495564|NCT03002649|Drug|Tofacitinib|Tofacitinib comes as an extended-release (XR) (long-acting) tablet to take by mouth. The extended-release tablet is usually taken with or without food once daily.
1495565|NCT03002636|Procedure|anesthesia|Anesthesia : (1) General Anesthesia (GA)(2) Epidural Anesthesia (EA) (3) Combined Spinal-Epidural Anesthesia (CSEA)
1495567|NCT03002610|Other|Pls|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
1495568|NCT03002610|Other|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
1495569|NCT03002610|Other|Scientific abstract|Scientific abstract the text written for the academic population and practitioners, with scientific abbreviations which enables experts to go into more detail about the topic.
1495570|NCT03002597|Device|BrainPort V200 Device|To see if the device can be used in a pediatric population by measuring the subjects' improvement over baseline in any of the following areas: light detection, light localization, movement perception, and standardized object recognition tasks after use of the BrainPort.
1495571|NCT03002584|Other|completion of self-reported questionnaires|"Single completion: Participants will have to complete the IGQ, the generic health status EQ-5D questionnaire, the specific FDDQL questionnaire (Functional Digestive Disorders Quality of Life).
Test-retest: during the second completion within a mean 7-day interval, participants will complete the IGQ and a single global Gastro-Intestinal Well-Being scale"
1495572|NCT03002571|Drug|IDP-124 Lotion|Lotion
1495573|NCT03002571|Drug|IDP-124 Vehicle Lotion|Lotion
1495574|NCT03002545|Dietary Supplement|Magnesium citrate|
1495575|NCT03002545|Dietary Supplement|Placebo|
1495576|NCT03002532|Radiation|whole brain radiotherapy|
1495577|NCT03002519|Biological|PLX-R18|Intramuscular (IM) administration of PLX-R18
1495578|NCT03002506|Drug|Ceftolozane/tazobactam|Single dose of 2 grams/1 gram intravenously administered over 60 minutes.
1495579|NCT03002493|Drug|Eribulin mesylate|"Treatment phase: During Cycle 1, eribulin mesylate was administered as a 2 to 5 minute (min) intravenous (IV) infusion at 1.4 mg/m2 on Day 1 and Day 15 of 21-day cycle. During subsequent cycles, eribulin mesylate administration as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of a 21-day cycle.
Extension phase: Eribulin mesylate was administered continuously as a 2 to 5 min IV infusion at 1.4 mg/m2 on Day 1 and Day 8 of 21-day cycles, as long as the Investigator considered eribulin mesylate therapy to be clinically appropriate."
1495580|NCT03002493|Drug|Eribulin mesylate|
1495581|NCT03002493|Drug|Rifampicin|Treatment phase: Rifampicin 600 mg was administered orally once a day, from Day 9 to Day 20 of 28-day cycle of Cycle 1.
1495582|NCT03002480|Other|Thromboelastography-Guided Treatment Regimen|"The thromboelastograph (TEG) will be used to determine the best bypassing agent for the management of subjects with severe hemophilia A with inhibitors. Patients will be assigned that bypassing agent and dose for the treatment of their bleeding episodes and subsequently will be followed for a period of 6 months to determine their annual bleeding rate."
1495583|NCT03002467|Other|PESI score|
1495584|NCT03002454|Drug|99mTc MDP Injection:neutron-bombardment|Technetium (99mTc) Medronate Injection USP labeled with 99mTc derived from neutron-activation-produced 99Mo.
1495585|NCT03002441|Device|Same-Day Dilapan-S|Dilapan-S cervical dilators placed the same day as the D&E procedure
1495586|NCT03002441|Device|Overnight Dilapan-S|Dilapan-S cervical dilators placed the day prior to D&E procedure
1495589|NCT03002415|Other|Guided water intake|"Verbal and written guidelines will be given for the patient to ingest the daily volume of water calculated by the weight (30 ml / kg / day) for 14 days. Patients will receive an acrylic glass with a mark in 200 ml and will be instructed to take the number of glasses a day corresponding to the calculated volume (30 ml / kg). Patients will also receive a leaflet indicating how many glasses of water they will need to take. They will also be instructed to mark with an X the number of glasses of water that they actually drank daily during the fourteen days of intervention."
1495590|NCT03002415|Other|Placebo - free demand water intake|Patients are instructed to drink water and other liquids on demand. Patients are asked to note on a food record food and liquids and quantities consumed throughout the day. Patients are advised to make a four-day food diary out of the 14 days.
1495591|NCT03002402|Behavioral|Internet-based CBT-I|Internet-based cognitive-behavioral treatment for insomnia
1496512|NCT02995330|Drug|Bone marrow cell|
1495595|NCT03002363|Behavioral|Video Modeling Intervention|Prior to arrival of the audiological evaluation, the child and caregiver will be required to watch one of two videos created by the research personnel. One video, the intervention video, is a behavior modeling video walking through the entire audiological evaluation. It also includes tips for caregivers to practice with their child before the appointment. The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
1495596|NCT03002363|Behavioral|Placebo Video|The other video is a placebo video that discusses hearing, listening and ears, that does not discuss tips for caregivers to practice with their child before the appointment. The placebo video is not related to the audiological evaluation.
1495599|NCT03002324|Behavioral|Baseline Survey|The baseline survey is a combination of the Vaccine Confidence Scale, and a short form of the Parents' Attitudes about Childhood Vaccines (PACV) Scale. Participants will be asked an additional 10 questions developed as a part of a behavioral phenotyping questionnaire to assess behavioral biases at baseline within the study population. Demographic information and intent to vaccinate will also be collected.
1495600|NCT03002324|Behavioral|Current CDC Message|Participants randomized to the current CDC message arm will read a message taken almost directly from the CDC Vaccine Information Sheet (VIS) on HPV. This message was minimally altered for length and clarity.
1495601|NCT03002324|Behavioral|Cervical Cancer Message|Participants randomized to the cervical cancer messaging arm will receive a message developed by the study team to appeal tenants of the Health Belief Model (self-efficacy, perceived benefit) and on the purity tenant of the moral foundations theory.
1495602|NCT03002324|Behavioral|Control Message|Participants randomized to the non-vaccine related control arm will read a bird-feeding passage.
1495603|NCT03002324|Behavioral|Post-Intervention Survey|The immediate post-intervention survey will include questions from the Vaccine Confidence Scale and the PACV short scale. Intent to vaccinate will be assessed.
1495604|NCT03002311|Other|Epharmix|An electronic intervention platform uses SMS text messaging or pre-recorded phone messages for various adherence tracking and data collection applications, in order to supplement clinical care. Specific messages include proactively asking patients or a designated patient advocate if the patient has experienced a medical event recently; requesting specific care-related information, such as glucose values, current mood, or medication adherence; and providing health care education, i.e. what to do if they are experiencing physical symptoms. Patients receiving the messages are also provided with key contact information for their designated health care provider to promote patient engagement, as well as prompt and appropriate medical intervention.
1495605|NCT03002311|Other|Standard of care|Current standard of care as designated by clinical provider or clinic's standard operating practice.
1495606|NCT03002311|Other|Placebo|Depending on the specific disease/condition studied, in addition to standard of care, participants in the control arm may receive text or phone calls requesting clinical data (e.g. mood, weight, blood glucose level, or disease specific events) that a patient can provide on their own. Depending on the disease condition, these answers may trigger a prompt for the patient to call in to the provider, although no alert will be sent to the provider prompting a call to the patient. Patients are able to contact their provider at any time as per standard of care, but are not proactively prompted by the Epharmix system to contact their provider based on responses/values provided for data collection.
1495607|NCT03002298|Behavioral|DMD gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
1495608|NCT03002298|Behavioral|DMD button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
1495609|NCT03002298|Behavioral|Control group gesture task|Timing coincident task in a virtual environment, using motor learning protocol in which a gesture in front of a webcam shoub be done to reach the task
1495610|NCT03002298|Behavioral|Control group button-press task|Timing coincident task in a virtual environment, using motor learning protocol in which the task shoub be done by pressing a button on the keyboard
1495611|NCT03002285|Behavioral|Cerebral Palsy group|Group with Cerebral Palsy that performed the Fitts law in a computer task
1495612|NCT03002285|Behavioral|Control group|Group with typical development that performed the Fitts law in a computer task
1495613|NCT03002272|Device|TAVR|subjects that underwent TAVR more than 3 years ago
1495614|NCT03002272|Device|SAVR|Historical controls will be selected from among patients at the same site who underwent isolated bioprosthetic SAVR more than 3 years ago
1495615|NCT03002259|Drug|Dexamethasone|Dexamethasone administered as a single IV injection after induction of anaesthesia, but before initiation of CPB. Prepare as a 20 mg/mL dexamethasone solution, made up with 0.9% saline to 10 ml.
1495616|NCT03002246|Other|Ultrasound Examination|Research volunteers will be invited to have a 2D/3D ultrasound research scan 4-7 days from delivery.This ultrasound scan will take approximately 30 minutes to complete.
1495617|NCT03002233|Drug|TRK-820|
1495618|NCT03002220|Drug|radium-223|Radium-223 at a dose of 55 kBq
1495619|NCT03002207|Device|Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect of intervertebral disc is repaired with Autologous Bone Marrow Stem Cell (BMSC)/gelatin sponge after discectomy.
1495650|NCT03002025|Drug|Placebo|Participants will receive matching placebo to JNJ-64304500 as SC injection.
1995706|NCT02675946|Drug|CGX1321|
1995708|NCT02673736|Drug|PLX73086|
1995709|NCT02674607|Dietary Supplement|Spirulina|
1995710|NCT02673996|Drug|Phenylephrine|incremental small doses of IV phenylephrine to find the dose that transiently raises systolic blood pressure by 25 mmHg
1995711|NCT02673996|Drug|Isoproterenol|incremental small doses of IV isoproterenol to find the dose that transiently raises heart rate by 25 bpm
1495620|NCT03002207|Procedure|The defect is sutured|Participants with lumbar disc herniation diseases are treated by Microendoscopic discectomy, and the defect is sutured after discectomy.
1495621|NCT03002194|Device|Cutometer|Skin elasticity will be measured by a Cutometer prior to beginning treatment, week 7 and 3 months after completion of the treatment.
1495622|NCT03002194|Other|Photographs|Photographs will be taken prior to beginning treatment, week 7 and 3 months after completion of the treatment.
1495623|NCT03002181|Other|Education|70 minute education session.
1495628|NCT03002155|Other|EnhanceFitness community exercise program|Level I EnhanceFitness class is a seated fitness class that includes warm up, aerobics, cool down, balance training, strength training, and stretching.
1495629|NCT03002142|Device|Hearing aids|Phonak Audéo B-R (Target V 5.0)
1495630|NCT03002142|Device|Placebo|Phonak Audéo B-R (Target V 5.0) without amplification
1495631|NCT03002129|Other|fluid challenge|At two pre-defined time points during the procedure, enrolled patients will receive a fluid bolus of 5 ml/kg during 5 minutes
1495632|NCT03002116|Other|Tissue thermometry using non-invasive microwave radiometry device|In Patients included in the four study groups underwent non-invasive tissue thermometry using microwave radiometry (MWR) device, at the same room temperature and with the same methodology. Specifically, the probe of the RTM-01-RES (University of Bolton, UK) device was by applied on the surface of the foot tissue at an angle of 90o degrees for approximately 8 to 10 seconds in pre-determined sites. Measurements were performed by two independent operators. Three measurements were taken from each site. The mean value of the three values calculated by the 2 different operators was used for the analysis. Measurements were recorded using a dedicated software.
1495633|NCT03002103|Drug|EndoTAG-1|
1495634|NCT03002103|Drug|Paclitaxel|
1495635|NCT03002103|Drug|Gemcitabine Hydrochloride|
1495636|NCT03002090|Dietary Supplement|Iron trained|"Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.
Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
1495637|NCT03002090|Dietary Supplement|Iron Untrained|1. Ferrous sulfate: 100 mg/day of FeSO4 dosed in 2 capsules taken individually by mouth with breakfast and dinner. Capsules were made with FeSO4 and dextrose. Analysis has shown that each capsule contains 11mg of elemental iron, which is expected to be absorbed at roughly 33% bioavailability.
1495638|NCT03002090|Dietary Supplement|BZKL Trained|"BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.
Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate."
1495639|NCT03002090|Dietary Supplement|BZKL Untrained|1. BaZhen KeLi capsules: Traditional Chinese herbal supplement composed of: Radix Paeoniae Alba (White peony root), Rhizoma Atractylodis (Atractylodes), Rhizoma Chuanxiong (Chuanxiong), Radix Angelicae Sinensis (Angelica), Radix Codonopsis Pilosula (Codonopsis), Poria cocos (Poria), licorice, and Rehmannia glutinosa Each pill contained 5g of licorice and 10g of all other ingredients. Dosed in 2 capsules taken individually by mouth with breakfast and dinner. Analysis has shown that each capsule contained 0.5mg of elemental iron.
1495640|NCT03002090|Dietary Supplement|Placebo Trained|1. Aerobic Training: 25 minutes/day, 5 days/week for 8 weeks working at an intensity between 75-85% of age-predicted maximum heart rate.
1495641|NCT03002090|Dietary Supplement|Placebo Untrained|No intervention
1495643|NCT03002064|Drug|Docetaxel|60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles.
1495644|NCT03002064|Drug|Fluorouracil|5-fluorouracil 3750mg per square metre, civ 120 hours every 3 weeks till progression or at most 6 cycles
1495645|NCT03002064|Drug|Cisplatin|Cisplatin: 60mg per square metre on day 1, repeated every 3 weeks till progression or at most 6 cycles
1495646|NCT03002051|Device|EUS-guided drainage|"Ultrasonographic evaluation of the lesion by linear echoendoscope and positioning for transenteric puncture in shortest distance between enteric wall and the target lumen for drainage.
EUS-guided transenteric puncture by using a 19-gauge needle followed by placement of a 0.035 or 0.025-inch guidewire into the target lumen.
After the needle is removed in remaining the guidewire, the tract is dilated over the guidewire by using bougie dilator or needle type cystotome (Endoflex, Voerde, Germany). And then, the tract may be more dilated by using balloon catheter (4-mm).
After dilation of the tract, stent delivery system is inserted over the guidewire into the target lumen.
After complete deployment of the distal flange under EUS and fluoroscopic guidance into the target lumen, proximal retraction of the delivery system until the blue mark on the handle of the introducer is seen. And then, the proximal flange is deployed slowly under endoscopic guidance."
1495647|NCT03002038|Drug|Azathioprine|Patients are started with Azathioprine 50 mg tablets, taken orally twice a day. The medication dose is increased gradually with the aim of lymphocytes count bellow 1500 and to the maximum dose of 3 g Azathioprine per day. Cell blood count is checked once a week in the first month of treatment, once every two weeks in the second month of treatment, and monthly in the third month of treatment to make decision about medication dose.
1495648|NCT03002038|Drug|Rituximab|Patients will receive 1 g of Rituximab (two vials of RediTux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion and this will be repeated two weeks later. This cycle will be repeated every 6 months.
1495649|NCT03002025|Drug|JNJ-64304500|Participants will receive JNJ-64304500 as SC injection.
1495653|NCT03002012|Drug|Fluconazole|Standard of Care Fluconazole per World Health Organization and Ugandan Guidelines (800mg/day x 2 weeks, 400mg/day x10 weeks, 200mg through 6 months).
1495654|NCT03001999|Behavioral|PP-MI health behavior intervention|"The positive psychology exercises include 3 modules:
Gratitude-based activities, Strength-based activities, and Meaning-based activities. Various goal setting exercises will appear in each of the 14 study sessions."
1495655|NCT03001986|Biological|inactivated EV71 vaccine (KMB-17 cells)|3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
1495656|NCT03001973|Other|No Intervention|Registration of all LN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
1495657|NCT03001960|Drug|Preloading before TAVI|Preloading with Aspirin and Clopidogrel before TAVI
1495658|NCT03001960|Drug|Postloading after TAVI|Postloading with Aspirin and Clopidogrel after TAVI
1495659|NCT03001947|Other|No intervention|Registration of all IgAN patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
1495660|NCT03001934|Other|No intervention|Registration of all NS patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals which have signed the contract in China.
1495661|NCT03001921|Other|No intervention|Registration of all HD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospital which have signed the contract in China.
1495662|NCT03001908|Other|glenohumeral mobilization-oscillation|posterior glide mobilizations oscillated at 1hz, 4 x 30 seconds
1495663|NCT03001908|Other|glenohumeral mobilization-sustained|posterior glide mobilization, sustained 4 x 30 seconds
1495664|NCT03001895|Drug|18F-DCFPyL PET/CT|18F-DCFPyL PET/CT
1495667|NCT03001869|Drug|68Ga-HBED-CC-PSMA PET/CT|68Ga-HBED-CC-PSMA PET/CT Scan
1495668|NCT03001856|Procedure|Oblique Intradermal Suture|
1495669|NCT03001856|Procedure|Intradermal Suture|
1495670|NCT03001843|Drug|Ketamine|Anesthesia of only Ketamine
1495671|NCT03001843|Drug|Narcotics|The narcotic group will receive no ketamine but rather a more standard anesthetic
1495672|NCT03001843|Behavioral|pain scale|0-10 pain scale. 0 = no pain and 10 = worst pain
1495673|NCT03001830|Biological|AAV2/8-HLP-FVIII-V3|Infusion of AAV2/8-HLP-FVIII-V3
1495674|NCT03001817|Drug|K-877|
1495675|NCT03001817|Drug|Fenofibrate|
1495676|NCT03001817|Drug|Placebo (for K-877)|
1495677|NCT03001817|Drug|Placebo (for Fenofibrate)|
1495678|NCT03001791|Procedure|Excisional biopsy with Er:YAG laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with Er:YAG laser (Lite TouchTM, Synergon Dental Lasers, Light instruments Ltd., Yokneam Elite, Israel), λ = 2940nnm. Soft tissue biopsy mode with water cooling, frequency 35 Hz, pulse duration 250-390 µsec, pulse energy of 200 mJ, power 7 Watt . Cylindrical sapphire tip, 400 µm in diameter, without contact to the tissue.
1495679|NCT03001791|Procedure|Excisional biopsy with CO2 laser|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with CO2 laser (Spectra DENTA Surgical Carbon Dioxide Laser, MAX Engineering Ltd., Gyeonggi-Do, Korea), λ = 10'600nnm. cf mode (frequency 140 Hz, pulse duration 400 µsec, pulse energy 33 mJ,a power 4.62 watts). Laser beam with a spot size of 0.2 mm, non-contact mode.
1495680|NCT03001791|Procedure|Excisional biopsy with scalpel|Excisional biopsy of fibrous hyperplasia in the buccal mucosa in local anesthesia with scalpel (blade 15C). Polyamide sutures (Seralon 5-DS15, Serag Wiessner KG, Naila, Germany).
1495681|NCT03001778|Other|Usability Testing|"Usability testing of ready made workouts in a group format."
1495682|NCT03001765|Other|"Intensive Monitoring Strategy: Reveal LINQ™ Insertable Cardiac Monitoring System."|Intensive monitoring strategy of discharge from Emergency Department with 30 day SEEQ external monitor, followed by implantable cardiac Reveal LINQ monitor if negative 30 day result.
1495683|NCT03001752|Device|Open flap immediate implant|Post-extraction implants will be inserted through open flap, without bone grafting
1495684|NCT03001752|Device|Open flap immediate implant and bone grafting|Post-extraction implants will be inserted through open flap, adding bone grafting
1495685|NCT03001752|Device|Flapless immediate implant|Post-extraction implants will be inserted without elevating flap or inserting bone grafting
1495686|NCT03001739|Drug|Urapidil Hydrochloride Injection|Urapidil Hydrochloride Injection or other antihypertensive agents to decrease the BP to the target level.
1495687|NCT03001726|Procedure|Gastrectomy|In patients assigned to surgery followed by chemo- therapy, a total, distal, or proximal gastrectomy with metastasis dissection was done depending on tumour location.
1495688|NCT03001726|Drug|oxaliplatin|oxaliplatin 100 mg/m2
1495689|NCT03001726|Drug|S1|S1 40mg/m2
1495690|NCT03001726|Drug|Docetaxel|docetaxel 40 mg/m2
1495691|NCT03001713|Behavioral|CV WIZARD|"This project will determine whether a sophisticated CDS system will be effective in CHCs. The innovative, point-of-care, web-based CDS system we will test (CV Wizard) generates a guideline-based prioritized summary of each patient's major CVD risk factors, then presents patient and provider 'views' of this summary, with individualized care recommendations."
1495692|NCT03001700|Device|Serranator™ Alto PTA Serration Balloon Catheter|The Serranator™ is an over-the-wire (OTW) balloon dilatation catheter designed to perform percutaneous transluminal angioplasty (PTA) for peripheral indications.
1495693|NCT03001687|Dietary Supplement|enteral supplementation with vitamin D|"Patients allocated to the vitamin D + group receive enteral supplementation with high-dose vitamin D (250.000UI)"
1495694|NCT03001687|Other|blood collection 3mL|all patients will have hepcidin levels measured in the first 24 hours after admission and one week after
1495695|NCT03001674|Device|Conductance catheterization|CD Leycom Conductance Catheter
1495734|NCT03001362|Radiation|Radical external beam radiotherapy|All participants will receive pelvic radiotherapy to a dose of 45 Gy in 25 fractions with a tumor boost to a dose of 9 Gy in 5 fractions (thus total of 54 Gy/30 fractions to the primary tumor), combined with radio sensitizing chemotherapy. Patients will then be closely monitored, through endoscopy and imaging, for response to treatment and relapse.
1496513|NCT02995330|Drug|Cytoxan and testosterone|
1497115|NCT02990884|Drug|ketamine|
1495696|NCT03001661|Device|Dilapan-S|DILAPAN-S® is a non-pharmacological synthetic rod, which is inserted into the cervical canal and through the internal os, for cervical ripening prior to induction. Its mode of action consists in the hydrophilic properties of the device absorbing fluids from surrounding tissue structures, thus expanding the volume of DILAPAN-S® sticks, usually within a 12-hour period. Subsequently it exerts radial pressure on the surrounding structures (cervix) to dilate progressively. Endocervical pressure on the cervix results not only in its mechanical dilatation but the pressure on the endocervical structures also stimulates the production of endogenous PGs and promotes cervical ripening through its collagenolytic action.
1495697|NCT03001661|Drug|Dinoprostone|Dinoprostone slow release 10mg vaginal insert is currently the standard method used for induction of labour in the NHS, particularly in nulliparous woman.
1495698|NCT03001648|Procedure|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy|PGS (Preimplantation Genetic Screening) with trophectoderm biopsy using arrays comparative genomic hybridizatioon (aCGH)
1495699|NCT03001635|Drug|Oxytocin|26 patients will receive Oxytocin infusion for 6h while 26 will receive placebo. all other treatments will be the same and up to date with the current guidelines.
1495700|NCT03001635|Drug|Placebos|26 patients will receive 0.9% normal saline infusion for 6h as placebo
1495701|NCT03001622|Biological|IFX-1|chimeric, monoclonal antibody
1495702|NCT03001609|Drug|AC0010|Oral dose of 14C-labeled AC0010 suspension including 200 mg/83μCi[14C]
1495703|NCT03001596|Procedure|Neoadjuvant Chemoradiotherapy|Before surgery, patients in this group receive neoadjuvant chemoradiotherapy. A total dose of 40 Gy is delivered in 20 fractions (5 fractions per week) for 4 weeks. Chemotherapy is delivered concomitantly and composed of four cycles of paclitaxel 50mg per square meter of body-surface area and cisplatin 25mg per square meter of body-surface area weekly at the intervals of radiotherapy. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
1495704|NCT03001596|Procedure|Neoadjuvant Chemotherapy|Before surgery, patients in this group receive neoadjuvant chemotherapy. Chemotherapy is delivered and composed of two cycles of paclitaxel 135mg per square meter of body-surface area and cisplatin 75mg per square meter of body-surface area every 4 weeks. After neoadjuvant therapy of 4-8 weeks, minimally invasive esophagectomy is performed.
1495705|NCT03001596|Procedure|Minimally Invasive Esophagectomy|After neoadjuvant therapy, patients in groups receive minimally invasive esophagectomy
1495706|NCT03001583|Behavioral|Education program with cooking lessons|Structured education program of mediterranean diet and lifestyle changes with cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
1495707|NCT03001583|Behavioral|Education program WITHOUT cooking lessons|Structured education program of mediterranean diet and lifestyle changes WITHOUT cooking lessons delivered in monthly visits for an induction phase of 6 months, with an extension period of up to two years.
1495708|NCT03001570|Drug|Cetuximab plus Radiotherapy|Standard dose of a curative radiotherapy treatment is 70Gy given with conventional fractionation (2G daily) in an overall length of 7 weeks. In this study, the fractionation has been modified accordingly Cetuximab pharmacokinetics. Cetuximab will be administered with standard schedule: charge dose of 400mg/mq a week before the beginning of concurrent treatment, then weekly doses of 250mg/mq intravenous for 7 administration. This schedule to obtain the same biological efficacy on tumour with lower toxicity on healthy tissues.
1495709|NCT03001557|Drug|Lemborexant 2.5 mg|Lemborexant 2.5 mg tablets
1495710|NCT03001557|Drug|Lemborexant 5 mg|Lemborexant 5 mg tablets
1495711|NCT03001557|Drug|Lemborexant 10 mg|Lemborexant 10 mg tablets
1495712|NCT03001557|Drug|Lemborexant 15 mg|Lemborexant 5 mg and 10 mg tablets
1495713|NCT03001557|Drug|Lemborexant-matched placebo|Lemborexant-matched placebo tablets
1495714|NCT03001544|Biological|TS23|comparison of different doses
1495715|NCT03001531|Device|HydroSun|a skin area of the lower limb will be treated three times with ultraviolet light emitted by a halogen lamp
1495716|NCT03001531|Device|Hilotherm|a skin area of the lower limb will be treated three times with heat applied by a sleeve
1495717|NCT03001479|Dietary Supplement|Similac Human Milk Fortifier Hydrolyzed Protein Concentrated Liquid|HMF with additional hydrolyzed protein
1495718|NCT03001466|Drug|urea-loaded nanoparticles eye drops|one drop five times a day for 8 weeks
1495719|NCT03001466|Drug|Balance Salt Solution eye drops|one drop five times a day for 8 weeks
1495720|NCT03001453|Drug|Liposomal Bupivacaine|266mg liposomal bupivacaine
1495721|NCT03001453|Drug|0.25% Bupivacaine with epinephrine|0.25% bupivacaine with epinephrine
1495722|NCT03001453|Drug|Saline|Normal saline
1495723|NCT03001440|Other|KAB survey|The KAB survey will be conducted among study population to evaluate their understanding of the potential serious risk with the use of ZYBAN. The 20 minutes survey can be completed either online or through a telephone interview.
1495724|NCT03001427|Behavioral|Structured center-based lifestyle intervention|
1495725|NCT03001427|Behavioral|Standard education and physician advice|
1495726|NCT03001414|Biological|Placebo followed by Autologous EPCs transfected with human eNOS|
1495727|NCT03001414|Biological|Autologous EPCs transfected with human eNOS followed by Placebo|
1495728|NCT03001414|Biological|Autologous EPCs transfected with human eNOS|
1495729|NCT03001401|Other|iDesign|One group will under go standard LASIK using iDesign platform (J&J, USA). Visual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
1495730|NCT03001401|Other|SMILE|The other group will undergo SMILE for treatment refractive error (Carl Zeiss, Germany). isual acuity, tomography outcomes, biomechanical outcomes and inflammation in myopic eyes treated with iDesign and SMILE are proposed to be evaluated under the study.
1495731|NCT03001388|Procedure|Transient Elastography (TE)|Participants enrolled in Cystic Fibrosis Liver Disease Network (CFLD NET)Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis (PUSH) study in longitudinal follow up at centers with Fibroscan available (currently 8/11 centers)
1495732|NCT03001375|Procedure|Laparoscopic high anterior resection splenic flexure mobilization|
1495733|NCT03001375|Procedure|Laparoscopic high anterior resection without splenic flexure mobilization|
1495771|NCT03001076|Drug|Bempedoic acid|bempedoic acid 180 mg tablet
1497152|NCT02990533|Drug|Testosterone|
1495735|NCT03001349|Drug|68Ga-DOTATOC|Before 68Ga-DOTATOC PET/CT scan performed, 5 mCi (3-5 mCi), in an approximate volume of 1-3 mL, containing 10-50 mcg of 68Ga-DOTATOC injected.
1495736|NCT03001349|Procedure|PET/CT|PET/CT scan performed after 68GA-DOTATOC injection for diagnosing neuroendocrine tumors. The scan will last up to an hour.
1495737|NCT03001336|Other|no intervention|This is a cross-sectional study
1495738|NCT03001323|Drug|Degludec|"Discharge on once a day degludec insulin by pen (supplied by Novo) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.
Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.
Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.
Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
1495739|NCT03001323|Drug|Standard long-acting|"Discharge on once a day long-acting insulin by pen that patient is using at time of enrollment (supplied by clinic) at dose 0.3 U/kg with reduction to 0.2 U/kg for GFR <30 ml/hr.
Fast acting insulin that patient is using will be adjusted so that total daily dose given to cover 2 or 3 meals is equal to the long-acting insulin dose. Patient will have basal bolus regimen either using carb counting or with set doses for meals.
Insulin adjustment if hypoglycemia (less than 60 mg/dl) or if fasting BG over 140 despite insulin compliance. For hypoglycemia, dose will be lowered 0.05 U/kg and for elevated fasting glucose it will be raised 0.05 U/kg.
Phone calls every month and clinic visits every 3 months for 1 year with dose adjustment as above."
1495740|NCT03001310|Biological|AAV - CNGB3|Comparison of different dosages of AAV-CNGB3
1495746|NCT03001284|Other|NO intervention|
1495747|NCT03001271|Drug|Angiotensin 1-7|
1495748|NCT03001271|Other|Placebo|
1495749|NCT03001258|Other|Presbyopia screening training|The training module and the protocol were designed in a way that a layman with limited education could be trained for screening and could sell reading glasses without any hassle, accurately and responsibly. Training module included the general anatomy of eye, common vision problems, aetiologies, determination of proper acuity of vision, sales techniques of the reading glass, marketing of products and services, and management of inventory and referrals. All the providers who participated in the current study, had no prior experience/training of screening presbyopia before the intervention. Each of the intervention arm used letter acuity chart i.e. Snellen chart as it commonly used for as a test of visual acuity
1495750|NCT03001245|Behavioral|Interpersonal Counseling|Interpersonal Counseling 1+6 sessions
1495751|NCT03001245|Behavioral|Standard treatment|Psychosocial treatment 1+6 sessions guided by the professional's standard professional principles and routinely available methods
1495752|NCT03001232|Behavioral|Movement-oriented Dementia Care|The intervention is a new multidisciplinary approach that focuses on optimizing physical activity and independence in daily care and activities. MDC intended to incorporate all persons surrounding the patients. The nursing staff was intensively trained by an expert in MDC, and played a central role in continuously stimulating patients to function as independently as possible. Geriatric physicians and physiotherapists advised the nursing staff about participants' medical and physical limitations to ensure safe stimulation. Consequently, a plan was created for each resident to determine the daily routines they were capable of performing themselves. Caregivers and volunteers were informed about the benefits of an active lifestyle during several open meetings.
1495757|NCT03001206|Device|Master Caution System|"The purpose of this study is to evaluate the effectiveness and usability of the Master Caution System for 12 leads continuous monitoring of ECG signal in the ICCU.
The purpose of the study is to evaluate the effectiveness and usability of using Master Caution 12 leads Garment for stress test.
The purpose of the study is to reassess the adequate size of the Master Caution Garment (MCG)."
1495758|NCT03001193|Drug|DF 01|
1495759|NCT03001193|Drug|Oxytocin|
1495760|NCT03001193|Drug|Placebo|
1495761|NCT03001154|Behavioral|Face-to-face Virtual Reality Exposure Therapy|In session, systematic, hierarchical exposure to feared stimuli with therapist.
1495762|NCT03001154|Behavioral|Internet-administered Virtual Reality Exposure Therapy|Therapist-guided, Internet-administered Virtual Reality Exposure Therapy self-help program
1495763|NCT03001154|Other|Waiting-list|Weekly assessments of public speaking
1495765|NCT03001128|Drug|Antiretroviral treatment pause|Antiretroviral treatment pause
1495766|NCT03001102|Device|4% Chlorhexidine gluconate|Cationic biguanide - antimicrobial action rubbing in the skin.
1495767|NCT03001102|Device|10% PVPI degermante|Polymer soluble in water of iodine with polyvinylpyrrolidone (PVP) - antimicrobial action rubbing in the skin.
1495768|NCT03001102|Device|Soap without antiseptic|Liquid soap with glycerin, neutral pH. Skin cleansing
1495769|NCT03001089|Drug|Oral Fludrocortisone (enteral)|Oral Fludrocortisone (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
1495770|NCT03001089|Drug|Placebo Oral Tablet|oral placebo (enteral) at a dose of 10 mcg 2 times daily (every 12 hours) for 8 days from day 1 (first administration between H24 and H30, and then every 12 hours) until day 8.
1495774|NCT03001063|Other|Supported Self-Management|This Supported Self-Management intervention consists of bibliotherapy (the Antidepressant Skills Workshop) that is provided to a patient by a health or social worker. The patient is supported in the use of the skills found in the workbook over the course of two months. The skills in the workbook are based on the principles of Cognitive Behavioural Therapy.
1495775|NCT03001063|Other|Enhanced treatment as usual|Participants in the control arm will received enhanced treatment as usual in the form of usual care at primary care centres and a leaflet providing information about depression.
2001851|NCT02735577|Drug|Disulfiram|Patients will be hospitalized on an inpatient psychiatric unit for 1-7 days to initiate abstinence. An fMRI scan will be performed to examine neural mechanisms of alcohol motivation. Prior to discharge, patients will receive the first dose of disulfiram 500 mg. They will then attend an outpatient clinic every other day for 14 days. At each clinic visit, they will receive 500 mg of disulfiram under supervision. Another fMRI scan examining alcohol motivation will be performed. Following this, all patients will attend the clinic weekly, and will be prescribed disulfiram 250 mg daily to take at home. This will be followed followed by an optional extension of weekly visits taking disulfiram 250 mg daily for another 28 days, for a total of 70 days of disulfiram treatment.
1495777|NCT03001024|Behavioral|Implementation of WayToServe Español|Following baseline assessment and randomization to experimental condition, premises assigned to the intervention condition will be contacted and recruited to the trial. Managers will provide a list of all servers. All servers will be registered by project staff on the WTS-E website and provided a unique identification code, which will track their use of the training and associate it with the premise. Servers will complete a profile on the program during their first login. Servers will be asked to complete the training within four weeks from initial registration; email and text reminders will be sent to those who do not login within one week of initial registration.
1495778|NCT03001024|Behavioral|Usual and Customary RBS Training|The premises randomized to the UC training condition will be, in effect, blind to the investigation. Server training is mandatory for all servers in New Mexico. Server training is voluntary in Texas but heavily incentivized by TABC's Safe Harbor clause. Under this clause, liquor licensees are held harmless for any service infractions if all servers are trained and certified by an approved RBS trainer; instead, the server is cited for the infraction.
1495781|NCT03000998|Behavioral|Web App Intervention Group|All baseline and follow-up data collection will be conducted via online surveys and a customized web portal and include parent self-reports and clinic records of vaccination of boys
1495782|NCT03000998|Behavioral|Usual Customary Care Group|Participants randomized to the usual and customary care (UC) group will receive a website with a pamphlet on HPV vaccination from the Centers for Disease Control and Prevention (CDC) in Portable Document Format (PDF) format.
1495783|NCT03000985|Behavioral|Psychoeducation|6 session psychoeducation program with the family caregiver of schizophrenics patients.
1495784|NCT03000972|Procedure|Cement augmentation|
1495785|NCT03000972|Procedure|PFN-A Nail|
1495786|NCT03000946|Drug|Somatostatin|Lyophilisate and solution for IV use (glass ampoule of lyophilisate + 1 ml glass ampoule of solvent) 6 mg per day Continuous intravenous infusion for 6,5 days
1495787|NCT03000946|Drug|Octreotide|Solution for SC use 100μg, every 8 hours Subcutaneous injection for 6,5 days
1495790|NCT03000907|Other|Intervention|Diet and physical exercises
1495791|NCT03000894|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This CBT-I is a 4 sessions 60-90 minutes group-based therapy administered by a nurse therapist. Each session has 6-8 participants.
1495792|NCT03000881|Other|standard adhesive|This is a standard adhesive (hydrocolloid)
1495793|NCT03000881|Other|New adhesive strip|This is a newly developed adhesive strip
1495794|NCT03000868|Procedure|Cold endoscopic mucosal resection|Cold endoscopic mucosal resection (EMR) means removing small colorectal polyps (<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
1495795|NCT03000868|Procedure|Hot endoscopic mucosal resection|Hot endoscopic mucosal resection (EMR) means removing small colorectalpolyps (<1cm) with snare without the use of electocautery after injection of normal saline into the submucosa.
1495796|NCT03000855|Procedure|EUS-guided choledocho-duodenostomy|"The CBD would be identified by a linear echoendoscope and a suitable puncture site in the bulb of the duodenum would be located. The common bile duct would be punctured with a 19-gauge needle and the position would be confirmed by aspiration of bile and contrast injection. A 0.025 or 0.035 guide wire would be passed through the needle in to the CBD. A fully covered metal stent would then be inserted after track dilation."
1495797|NCT03000855|Procedure|Endoscopic retrograde cholangiopancreatography with covered metallic stent|After cannulation of the CBD, a cholangiography would be performed to assess the diameter of the CBD, the length and position of the biliary stricture. The endoscopist would decide on the appropriate size of SEMS to be placed. The stents should be visible from the duodenal lumen after deployment.
1495798|NCT03000842|Device|transcutaneous vagal nerve stimulation on|electrical current on positioned in the ear to estimate vagal branch of auricular nerve
1495799|NCT03000842|Device|transcutaneous vagal nerve stimulation off|an electrical current off positioned in the ear to estimate vagal branch of auricular nerve
1495800|NCT03000829|Other|Tele-intensivist consultation|Standardized consultation to on-site cardiac arrest team by off-site intensivist via two-way audiovisual link using a mobile telemedicine cart
1495801|NCT03000829|Other|"Simulated observation by ICU physician"|Display of silent, pre-recorded, non-interactive videotape of an ICU physician. The on-site cardiac arrest team will be told that an intensive care physician is observing the mock code.
1495802|NCT03000816|Radiation|SBRT|Patients with 1-4 metastases located in less than 3 organs/ lymphatic drainage regions that are 5 cm or less from each other and simultaneously treated with SBRT.
1495803|NCT03000803|Behavioral|Early Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
1495804|NCT03000803|Behavioral|Late Total Caloric Intake|Provide subjects a regimented amount of calories at each meal.
1495853|NCT03000426|Procedure|Free gingival graft|Free gingival graft removal from palate for socket preservation
1495854|NCT03000426|Device|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site for photobiomodulation
1495855|NCT03000413|Drug|Ketamine|Active treatment
1495805|NCT03000790|Device|Lingual Ring Splint|"A polyvinyl (polypropylene) material was chosen, which is biocompatible, nontoxic, hypoallergenic, and has a hardness of about 60-70 Shore, The thickness of 3 mm in the occlusive active portion and 2 mm in the other parts was constructed.
The lingual ring consists of Two lateral genal shields that are vertical and symmetric, and have a right- and left-of-oval form, Two interocclusive levels with a roughly triangular form, but with round angles also right and left symmetric, double arch superior arch and inferior archwill make the Ring around the tongue"
1495806|NCT03000777|Dietary Supplement|melatonin plus zinc|Melatonin 1 mg plus Zinc 10 mg o.d. 1 hour before going to bed during 16 weeks
1495807|NCT03000777|Other|Placebo|Isomaltose o.d. 1 hour before going to bed during 16 weeks
2001852|NCT02735044|Drug|insulin glargine (U300)|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
2001853|NCT02735044|Drug|insulin glargine|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1495810|NCT03000751|Other|Simple Audit Report|The simple audit provides comparison and feedback on radiation doses.
1495811|NCT03000751|Other|Multi-Component Intervention|The multi-component intervention gives tailored feedback on needed changes plus guidance using quality improvement methods that facilitate organizational change. Provides access to experts, detailed audit, collaborative calls, and site visits (as needed).
1495812|NCT03000751|Other|In-Person Meeting|Collaborator meeting with an emphasis on quality improvement.
1495813|NCT03000725|Behavioral|Using Practice and Learning to Increase Favorable Thoughts|"Description of the UPLIFT program: Participants who choose to participate in UPLIFT will complete 8 weekly group sessions via telephone.
Session 1: Introduction to UPLIFT/Noticing Thoughts Session 2: Checking and Changing Thoughts Session 3: Coping & Relaxing Session 4: Attention & Mindfulness Session 5: The Present as a Calm Place Session 6: Thoughts as Changeable, Thoughts as Not Fixed Session 7: Focus on Pleasure & the Importance of Reinforcement Session 8: Preventing Lapses and Giving Thanks"
1495814|NCT03000725|Behavioral|Usual Care|Participants randomized to the UC group will receive printed educational materials on management of epilepsy in English or Spanish as preferred.
1495815|NCT03000712|Biological|Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml|biological : Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml drug: saline solution
1495816|NCT03000699|Behavioral|Cognitive Bias Modification|Training paragraphs describe scenarios designed to be ambiguous at the outset and to resolve in a positive direction, with the intention of establishing a learning contingency between the ambiguity at the beginning of the scenario and the positive resolution that becomes clear towards the end of the statement.
1495817|NCT03000686|Biological|GSK2586881|GSK2586881 will be a clear colorless liquid for IV infusion over 3- 5 mins and will be administered as unit dose 0.8 mg/kg.
1495818|NCT03000686|Other|Placebo|Normal saline (0.9%) will be administered as a single IV dose infusion over 3 to 5 min.
1495819|NCT03000673|Drug|Enoxaparin|Specified dose of Enoxaparin on specified days
1495820|NCT03000673|Drug|unfractionated heparin (UFH)|Specified dose of UFH on specified days
1495821|NCT03000673|Drug|BMS-986177|Specified dose of BMS-986177 on specified day
1495822|NCT03000660|Drug|Venetoclax|Venetoclax at one of four escalating doses
1495823|NCT03000660|Drug|Dexamethasone|Dexamethasone 20mg by mouth on days 1, 8, 15, and 22 of each cycle.
1495824|NCT03000647|Procedure|Pelvic floor exercises guided by a physiotherapist|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day and once a week they check it with a physiotherapist (this day only they do it twice at home)
1495825|NCT03000647|Procedure|Non guided pelvic floor exercises|Subjects perform two types of contractions of the pelvic floor in two different positions 3 times a day. They do not attend to meetings with a physiotherapist
1495826|NCT03000634|Drug|Elotuzumab|Administered through a small tube that goes directly into the vein
1495827|NCT03000634|Drug|Bortezomib|Administered as a subcutaneous injection under the skin
1495828|NCT03000634|Drug|Lenalidomide|Capsule taken by mouth
1495829|NCT03000634|Drug|Dexamethasone|Taken by mouth
2001854|NCT02735044|Drug|fast-acting insulin analogue|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
2001855|NCT02729025|Drug|Repatha (Evolocumab)|Dose of subcutaneous Repatha (Evolocumab) every 4 weeks (QM) using 3 auto injector (AI) Pen
1495832|NCT03000595|Drug|SAN007 Cream|A cream containing 5% East Indian sandalwood oil (EISO).
1495833|NCT03000595|Drug|Placebo|The vehicle cream
1495834|NCT03000582|Dietary Supplement|Creatine monohydrate|Creatine monohydrate (5.0 g creatine monohydrate, 1.5 g dextrose)
1495835|NCT03000582|Dietary Supplement|Creatine nitrate-1|Creatine nitrate-1 (1.0 g creatine monohydrate, 0.5 g nitrate, 5.0 g dextrose)
1495836|NCT03000582|Dietary Supplement|Creatine nitrate-2|Creatine nitrate-2 (2.0 g creatine monohydrate, 1.0 g nitrate, 3.5 g dextrose)
1495837|NCT03000582|Dietary Supplement|Placebo|Placebo (6.5 g dextrose)
2001856|NCT02729025|Drug|Placebo|Dose of subcutaneous Repatha (Evolocumab) Matching Placebo every 4 weeks (QM) using 3 auto injector (AI) Pen
2001857|NCT02726750|Procedure|Blood Collection|Blood (about 1-2 tablespoons) collected for biomarker and routine tests and to check the status of the disease.
1495840|NCT03000556|Drug|0.3% Sodium Hyaluronate Eye Drop|The patients need to use 0.3% Sodium Hyaluronate Eye Drop for 3 month.
1495841|NCT03000543|Device|Stable isotope labelled vitamin A|Oral dose of 400 μg 13C10 or 13C3- retinyl acetate (stable isotope labelled vitamin A) dissolved in 0.5 mL of sunflower oil
1495844|NCT03000504|Device|Intercostal tube|
1495845|NCT03000491|Other|No intervention|
1495846|NCT03000478|Behavioral|Prolonged Exposure|
1495847|NCT03000478|Behavioral|Virtual Reality Exposure Therapy|
1495848|NCT03000465|Procedure|Laparoscopic colorectal surgery|Minimizing intra-abdominal insufflation pressure in laparoscopic colorectal surgery as an individualized strategy
1495849|NCT03000452|Drug|DARATUMUMAB|DARATUMUMAB
1495850|NCT03000452|Drug|DURVALUMAB|DURVALUMAB
1495856|NCT03000413|Drug|Fentanyl|
1496514|NCT02995317|Other|Number of falls based on an one year follow-up|
1495857|NCT03000400|Behavioral|The Traumatic Brain Injury Family System Intervention.|Theoretically based intervention consisting of 8 weekly 90 minutes sessions addressing specific topics according to a manual.
1495858|NCT03000400|Behavioral|Psycho-educational session at OUH|2.5 hour psycho-educational session for the patient's family members.
1495859|NCT03000387|Drug|Nicotine Patch|Active nicotine patch of 21 mg, 14 mg and 7 mg
1495860|NCT03000387|Drug|Placebos|Matching placebo patches of 21 mg, 14 mg and 7 mg
1495861|NCT03000374|Drug|Panitumumab|Panitumumab will be administered intravenously (IV) in a dose of 6 mg/kg on day 1 every 14 days. Panitumumab will be supplied to sites by the study sponsor in 5-mL and 20-mL vials, at a concentration of 20 mg/mL.
1495862|NCT03000374|Drug|5Fluorouracil|Once every 14 days. Day 1: 400 mg/m2 in IV bolus and a 46-hour infusion of 5-FU 2400 mg/m².
1495863|NCT03000374|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
1495864|NCT03000374|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
1495865|NCT03000361|Procedure|Motorized Spiral Colonoscopy|For any pathological finding during colonoscopy standard endoscopic techniques, e.g. forceps biopsy, injection, endoscopic mucosal resection, argon plasma coagulation
1495866|NCT03000348|Drug|Cysteamine|Oral Cysteamine Capsule
1495867|NCT03000348|Drug|Placebo Oral Capsule|Placebo Oral Capsule
1495868|NCT03000322|Device|Cooling Vest|A cool therapy device intended to provide moderate, controlled cooling (approximately 15C/59F) by absorbing heat. The material in the vest is safe, non-toxic, and eco-friendly.
1495869|NCT03000309|Drug|Apremilast|
1495870|NCT03000296|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Hematopoietic stem cell transplantation Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
1495871|NCT03000283|Drug|Conivaptan|"Patients will receive 20mg IV of the study drug every 12 hours equaling 40mg/day over 2 days (4 doses total), in addition to the standardized ICH management targets using the PI's version of standardized ICH management targets.Usual standard of care can include sedation and analgesia as needed, elevation of the head of the bed, mannitol and/or saline as needed to reduce ICP, and temperature control with antipyretics such as acetaminophen.
The conivaptan bolus (20mg), which is premixed with 100ml of 5% dextrose in water, is infused (peripherally) over 30 minutes, most commonly through an already placed central line."
1495872|NCT03000270|Device|Impella unloading prior to PPCI|Impella unloading prior to PPCI
1495873|NCT03000257|Drug|ABBV-181|Intravenous infusion
1495874|NCT03000257|Drug|Rovalpituzumab Tesirine|Intravenous infusion
1495875|NCT03000218|Drug|Ursodeoxycholic acid|Ursodeoxycholic acid 300mg bid for 8 weeks
1495876|NCT03000218|Drug|Metformin|Day 29 to 56: Metformin 500mg bid
1495877|NCT03000218|Drug|Placebo|Day 1 to 56: Placebo bid
1495878|NCT03000205|Device|hypertonic dextrose water|20% hypertonic dextrose water injection for chronic shoulder pain at Week0
1495879|NCT03000205|Device|Normal saline and Lidocaine.|Normal Saline injection for chronic shoulder pain at Week0 (Arms:Placebo Comparator: Placebo)
1495880|NCT03000179|Drug|Avelumab|Avelumab through a vein once every 2 weeks
1495881|NCT03000166|Behavioral|Step-Up Intervention|Intervention group participants will meet with a study facilitator during 5 regularly scheduled visits for chemotherapy. The facilitator will provide education about the benefits of physical activity and strategies to overcome barriers to physical activity, help the participants to set physical activity goals based on ability and preferences, and educate the participant on using a physical activity tracker.
1495882|NCT03000153|Other|Completing the Goals Form|The Goals Form is a personalised outcome measure where clients enter their goals in collaboration with their assessor. Goals are then rated at the start of every session and open the therapeutic dialogue.
1495883|NCT03000140|Behavioral|High Intensity Interval Training|High Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
1495884|NCT03000140|Behavioral|Control group|Moderade Intensity Interval Training pre-hypertensive group; Exercise will be performed at three sessions per week. All sessions will be supervised by an exercise physiologist during 16 weeks.
1495885|NCT03000127|Drug|AndroGel 1 % Topical Gel|testosterone gel
1495886|NCT03000127|Drug|Placebos|Placebo gel
1495887|NCT03000114|Procedure|Percutaneous Needle Aponeurotomy|
1495888|NCT03000114|Drug|XIAFLEX|
1495889|NCT03000101|Other|100% pomegranate juice|125 mL of 100% pomegranate juice twice daily for 12 weeks
1495890|NCT03000101|Other|placebo beverage|125 mL of placebo beverage twice daily for 12 weeks
1495891|NCT03000088|Device|intubate with 60° angled stylet|
1495892|NCT03000088|Device|intubate with 60° angled stylet|
1495893|NCT03000075|Drug|risankizumab|
1495894|NCT03000075|Drug|placebo to risankizumab|
1495895|NCT03000062|Behavioral|Intervention group|Please see the preceding section
1495896|NCT03000049|Other|bedside blood culture|
1495897|NCT03000036|Drug|Doxorubicin|Patients had prescribed endovenous doxorubicin as part of their chemotherapy regimen (mean cumulative dose 102,66 mg/m2, administered in 4 doses with 21 days interval).
1495898|NCT03000036|Device|Achieva, Philips Medical Systems (3T magnet)|Patients were imaged in supine position in a 3T magnet (Achieva, Philips Medical Systems, Best, The Netherlands). The protocol consisted of electrocardiographically gated cine imaging with steady state free-precession to assess left ventricular (LV) ejection fraction and LV mass. For imaging of late gadolinium-DTPA enhancement (LGE) we used an inversion-recovery-prepared, gradient-echo sequence with segmented acquisition, which was triggered every other heartbeat. LGE images were acquired during end-expiratory breath-holding, after administration of Dotarem. T1 was performed with a Look-Locker sequence with a non-slice-selective adiabatic inversion pulse, followed by segmented gradient-echo acquisition for 17 times after inversion, covering approximately two cardiac cycles. T1 imaging was repeated in the same LV short-axis slice, once before and five to seven times after the injection of gadolinium to cover an approximately 30-min period of slow contrast clearance.
1495899|NCT03000036|Drug|Gadoterate Meglumine|LGE images were acquired starting within 10 min after bolus administration of a cumulative dose of 0.2 mmol/Kg of gadoterate meglumine (Dotarem, Guerbet, Aulnay-sous-Bois, France).
1495900|NCT03000010|Device|Incisional Wound Vac|
1495902|NCT02999997|Behavioral|Ronnie Gardiner Method (RGM)|RGM includes functional exercises consisting of cognitively challenging multi-task exercises. The exercises are performed sitting down or standing up with weight shifting exercises. The practitioner projects unique symbols shaped as red or blue hands and feet on the wall in specific 'choreoscores' of 2-8 bars. Red symbolizes left side of the body, blue the right side. Each symbol is accompanied with a certain movement and sound code. To the sound of rhythmical music the participants follow the symbols beat by beat, performing the movements and pronouncing the word. The exercises are progressed by increasing the tempo of the music, or by using more symbols. The practitioner uses a shirt with the color red on one side, and blue on the other side, in order to facilitate for the participants.
1495903|NCT02999984|Biological|Infusion of autologous cryopreserved EFS-ADA LV CD34+ cells|Infusion of OTL-101 after reduced intensity conditioning
1495904|NCT02999971|Other|circuit class therapy in water|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
1495905|NCT02999971|Other|circuit class therapy on land|The circuit, the main part of the session, include a series of 10 different workstations, arranged to progress in complexity, in order to work several segments of the body, oriented towards a functional recovery objective. These stations will be made up of task-specific activities for gait, balance and dexterity. Time in each workstation will be 5 minutes divided as follows: 4 minutes work period and 1 minute rest period, of these, last 30 seconds will be change period for crossing from one workstation to the next. After 50 minutes, each patient will have covered the 10 workstations, thus working in all of the objectives pursued in the realization on this CCT: gait, balance and dexterity.
1495906|NCT02999958|Biological|Antioxidants|In the Treatment Arm, the G-Series culture media system will be used with antioxidants
1495907|NCT02999945|Dietary Supplement|SGA-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
1495908|NCT02999945|Dietary Supplement|IUGR-enhanced nutrients|Infants will receive fortified breast milk (>50% meals/d fortified, 1,4 g protein, 85 kcal/100ml, FM85, Nestle ®) or post discharge formula (2g protein; 73-75 kcal/100ml; Aptamil PDF, Milupa® or Beba F Nestle® ) between discharge and 52nd week of gestation (three months after term
1495909|NCT02999945|Other|SGA-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
1495910|NCT02999945|Other|IUGR-standard nutrients|Infants will receive unfortified breast milk (65-70kcal/100ml) or starter formula (1,2- 1,3g protein, 66 kcal/100ml Beba Pre Pro Start, Nestle® or Aptamil Pre, Milupa ®) between discharge and 52nd week of gestation (three months after term)
1495911|NCT02999932|Other|SpO2 directed oxygen therapy|Oxygen therapy was administered to achieve targeted SpO2.
1495912|NCT02999919|Procedure|spinal anesthesia|12.5 mg hyperbaric bupivacaine intrathecally following a successful dural puncture performed with a 27G Quincke spinal needle at the L3-4 or L4-5 intervertebral space in the sitting position
1495915|NCT02999893|Drug|APR-246|APR-246 (also known as PRIMA-1MET), a first-in-class agent targeting mutant p53 resulting in re-expression of wild-type p53 activity.
1495916|NCT02999880|Procedure|Polychromatic layering|Only two composite resin material shades will be used (opaque dentine composite and enamel shade composite).
1495917|NCT02999867|Dietary Supplement|triticale and mung bean|subjects are assigned to intake of triticale and mung bean for 30 days
1495918|NCT02999867|Dietary Supplement|adzuki bean|subjects are assigned to intake of adzuki bean for 30 days
1495919|NCT02999854|Biological|ATIR101|ATIR101 is a T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells using photodynamic treatment; single dose of 2×10E6 viable T-cells/kg body weight between 28 and 32 days after the HSCT (intravenous infusion)
1495920|NCT02999854|Drug|Cyclophosphamide|High dose post-transplant cyclophosphamide 50 mg/kg/day at 3 and 4/5 days after the HSCT (powder for intravenous infusion)
1495921|NCT02999854|Procedure|T-cell depleted HSCT from a related, haploidentical donor|T-cell depleted graft prepared from peripheral blood stem cells using the CD34+ cell selection method; infused after a myeloablative conditioning regimen
1495922|NCT02999854|Procedure|T-cell replete HSCT from a related, haploidentical donor|T-cell replete (full, non-manipulated) graft prepared from either bone marrow or peripheral blood stem cells; infused after a myeloablative conditioning regimen
1495923|NCT02999841|Drug|Acarbose|1-2 week: 50mg tid; 3-24 week: 100mg tid.
1495924|NCT02999841|Drug|Vildagliptin|1-24 week: 50mg bid
1495925|NCT02999828|Biological|inactivated EV71 vaccine (KMB-17)|3.0EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
1495926|NCT02999815|Procedure|Human tetanus immunoglobulin|Adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin. Second, participants will be randomized to receive the addition of 500 IU intrathecal human antitoxin.
1495927|NCT02999815|Procedure|Intramuscular antitoxin|First, adults admitted to ICU at Hospital for Tropical Diseases will be randomized to receive either human (3000 IU) or equine (21,000 units) intramuscular antitoxin including a 0.05ml test dose (ie 75 units equine antitoxin or 12.5 IU human antitoxin). Second, participants will be randomized with sham procedure
1495928|NCT02999802|Behavioral|Exercise|Progressive resistance exercise training
1495929|NCT02999789|Device|SmartInhaler with reminder function turned on|The SmartInhaler is a medication monitoring system that functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
1495930|NCT02999789|Device|SmartInhaler|The SmartInhaler is a medication monitoring system manufactored by Adherium that also functions as a patient reminder device. It monitors asthma medication adherence and also functions by providing an audiovisual reminder.
1495931|NCT02999776|Device|Laser microporation alone|The Er:YAG laser induced microporation of 5 cm2 of a plaque surface, followed by application of an OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment will also be repeated twice weekly for 8 weeks.
1495932|NCT02999776|Drug|Standard of care-daily administration of Daivobet|The other control treatment is Daivobet®, which is applied topically daily for 8 weeks on one pre-selected randomized plaque.
1495933|NCT02999776|Drug|Laser microporation + topical application of Etanercept|Immediately following microporation of a 5 cm² area of the designated plaque with the P.L.E.A.S.E.® Professional laser, 0.0625 ml of Etanercept (50 mg/ml) solution for injection in pre-filled syringes will be applied to the microporated surface of the lesion. The treated area will then be covered with OpSiteTM Flexigrid Transparent Dressing for 4 hours. This treatment procedure will be repeated twice weekly for 8 weeks.
1495934|NCT02999763|Device|SlimShape|SlimShape radiofrequency treatment to the abdomen
1495935|NCT02999750|Other|individual therapy|Patient will be treated with individual therapy.
1495936|NCT02999737|Biological|Platelet Rich Plasma for 4 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every month x 3 sessions then every 3 months x 1 session (total 4 sessions)
1495937|NCT02999737|Biological|Platelet rich plasma for 2 sessions|Injection of autologous platelet rich plasma into areas of alopecia on the scalp every 3 months x 2 sessions (total 2 sessions)
1495938|NCT02999724|Drug|Gabapentin|Gabapentin 300-600 mg 1 hour preop
1495939|NCT02999724|Other|placebo|placebo capsule(s) 1 hour preop
1495940|NCT02999711|Drug|REGN3500|
1495941|NCT02999711|Drug|Placebo|
1495942|NCT02999698|Other|Observational|Observational
1495943|NCT02999685|Behavioral|Home-base Pulmonary Rehab with Health Coaching|
2001858|NCT02719665|Dietary Supplement|SPM Emulsion, Dose-modality|"Phase 1a Dose-Finding oral SPM administration of increasing dose (15ml, 30ml, and 60ml) by the following schedule:
Days 1 to 5: 15 ml; Days 6 to 14: Washout, no SPM administration; Days 15 to 19: 30 ml; Days 20-28: Washout, no SPM administration; Days 29-33: 60 ml"
1495945|NCT02999659|Device|Pupilometer|Device to measure change in pupil diameter due to a defined light stimulus.
1495946|NCT02999646|Other|MVX-ONCO-1|Autologous cells: 1 vial containing 4x106 irradiated tumor cells Capsules: 2 biocompatible capsules loaded with 8x105 MVX-1 cells
2001859|NCT02719665|Dietary Supplement|SPM Emulsion|Oral administration of SPM Emulsion dose determined in Phase 1a, once daily, in the morning, for 5 days.
2001860|NCT02719665|Other|Placebo|Oral administration of placebo, once daily, in the morning, for 5 days.
2001861|NCT02718716|Drug|UCB7665|"Intervention Type: Biological/Vaccine
Pharmaceutical Form: Powder for solution for infusion
Concentration: 100 mg/ml - Route of Administration:
Subcutaneous infusion"
2001862|NCT02715375|Device|CREON2000A|
2001863|NCT02715375|Device|Sham|
1495953|NCT02999620|Dietary Supplement|Alpha-cyclodextrin|Alpha-cyclodextrin (α-CD) is a soluble dietary fiber that has a history of use in foods and as a pharmaceutical excipient. Recently the ability of the fiber to bind to dietary fat has led to further investigation of the possible health benefits of dietary supplementation with this fiber.
1495954|NCT02999620|Dietary Supplement|Placebo|Identical looking placebo tablet to active (Alpha-cyclodextrin)
1495955|NCT02999607|Other|transcranial direct current stimulation|0.5 mA, 1mA, 2mA for 10 minutes each
1495956|NCT02999594|Drug|Tramadol Hydrochloride|50mg intramuscularly
1495957|NCT02999594|Drug|Distilled Water|2ml intramuscularly
1495958|NCT02999581|Dietary Supplement|C4 Extreme, C4 Extreme (without Advantra Z)|
1495959|NCT02999568|Other|Physical exercise|Women who practice high level of physical activity, as defined by International Physical Activity Questionnaire, for the past 3 years will be recruited. These women will will be asked to fulfill the International Physical Activity Questionnaire and additional questionnaire regarding relevant demographic and medical information. Blood samples to anti-mullerian hormone , leptin, and hormonal profile will be obtained in day 3 of menstruation. Ultrasound will be performed to measure Antral Follicular count and ovarian blood flow
1495960|NCT02999555|Procedure|Ovum pickup|Ovum pickup or Egg retrieval, that is performed not for the purpose of the study, but for the purpose of well known in vitro fertilization indications
1495961|NCT02999542|Other|Music|Children will be randomised to receive either music via headphones or silence via headphones
1495962|NCT02999542|Other|No music|Children will be randomised to receive either music via headphones or silence via headphones
1495963|NCT02999529|Other|Educational Video|Participants will be asked if they know the meaning of six words related to cancer treatment. Following the interview, participants will watch a video explaining the meaning of the six words. After viewing the video, participants will be re-interviewed about the meaning of the six words.
1495964|NCT02999516|Other|Motor imaginary|Participants imagine doing a motor task watching a video recording
1495965|NCT02999516|Other|Non Motor imaginary|Participants watch a television documentary
1495966|NCT02999503|Behavioral|Nutritional education|Nutritional education trough a personal online nutritional consultant
1495967|NCT02999490|Radiation|18F-FDG|18F-FDG is positron emission tomography imaging agent which is already widely used in PET/CT examination.
1495971|NCT02999464|Other|Qigong|The experimental group will be required to practice a total of 50 minutes of qigong training 3 times per week and for 16 weeks
1495972|NCT02999464|Other|Fitness exercise|Active control group will be required to practice a total of 50 minutes of fitness training 3 times per week and for 16 weeks
1495973|NCT02999451|Device|snare-assisted POEM|POEM was performed by using snare in place of common knives
1495974|NCT02999451|Device|knife-assisted POEM|POEM was performed by using common knives
1495975|NCT02999438|Device|Actigraph to check activity levels at home|
1495976|NCT02999425|Other|Education|Educational intervention
1495977|NCT02999412|Procedure|Comprehensive medication review|"A thorough medication reconciliation, including a patient/carer interview, by a clinical pharmacist.
The clinical pharmacist performs a comprehensive medication review in collaboration with the ward physician and patient, similar to a level three clinical medication review as earlier described in the literature [4]. This includes a structured, critical examination of all of the patient's medications in relation to the patient's conditions, based on information from the patient and the medical record. The objective is to optimise the impact of medications and minimizing the number of medication-related problems. The effects of medication changes will be monitored during the hospital stay by the physician or pharmacist, depending on the specific situation.
Before discharge, the clinical pharmacist performs another medication reconciliation to check if the patient's prescriptions for medications to be used after hospital stay are consistent with the patient's medical record."
1495978|NCT02999412|Procedure|Comprehensive medication review with active follow-up|"The same as I1 but with the following additions:
In case of any monitoring needs or necessary subsequent actions to be taken after hospital discharge, the clinical pharmacist and the ward physician send an electronic medication review referral to the patient's primary care physician upon discharge.
A first phone call to the patient or carer is made by the clinical pharmacist 2-7 days after the patient is discharged depending on health condition and the pharmacist's availability. This phone call aims to ensure that all information has been understood correctly and to find out if any problems, concerns or questions have arisen after discharge.
A second phone call will be made by the clinical pharmacist approximately 30 days after hospital discharge. This phone call aims to find out how the patient is managing the medication and if any problems, concerns or questions have arisen, and to provide the patient with a motivational boost."
1495979|NCT02999412|Procedure|Usual Care|The control group will receive usual hospital care. According to Swedish legislation, usual care includes medication reconciliation upon admission. Next to that, the law requires a medication report addressing the patient's medication treatment to be given to the patient or carer upon hospital discharge and to be attached to the electronic discharge letter. This report contains a motivation and explanation to the changes in medication treatment that have been made during hospital stay, as well as the patient's updated medication list. These mandatory activities are currently carried out to various degree within the different hospitals and wards. Other activities as described in the interventions above may be carried out to a certain degree as well, but no clinical pharmacist will be involved.
1495980|NCT02999399|Other|Brussel Sprouts|Subjects are given ~150 g of Brussels sprouts once daily for 7 consecutive days.
1495981|NCT02999399|Drug|Deuterated Phenanthrene|Subjects are given 1 microgram of deuterated phenanthrene [D10]phe at baseline and after 7 days of Brussels sprout consumption. Urine is collected for 6 hours after each dose.
1495982|NCT02999373|Other|Autologous Umbilical Cord Blood Mononuclear Cells Therapy|Autologous Umbilical Cord Blood Mononuclear Cells Therapy in preterm for prevention of infection
1495983|NCT02999373|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride in control group
1495984|NCT02999360|Behavioral|Language therapy|1 hour and 15 minutes language therapy
1495985|NCT02999360|Behavioral|Background Music|30 minutes background music only
1495986|NCT02999360|Behavioral|Aerobic Exercise|30 minutes AE with background music
1495987|NCT02999334|Behavioral|Group Antenatal Care|To examine the effect of type of care on completion of the recommended antenatal and postnatal visits as well as perinatal health outcomes, including knowledge, behaviors, psychosocial well-being, pregnancy-related empowerment, satisfaction with ANC care.
1495988|NCT02999321|Other|aspartame|will be given 5mg aspartame or 15 mg aspartame
1495989|NCT02999321|Other|water|control group
1495990|NCT02999308|Other|Observe the patient's condition and then change the regimen|The patients will be assessed every 3 months and the treatment regimen will be modified by the result of assessment.
1495991|NCT02999295|Biological|Ramucirumab|Ramucirumab (8 mg/kg) is administered.
1495992|NCT02999295|Biological|Nivolumab|Nivolumab (3.0 mg/kg or 1.0 mg/kg) is administered.
1495993|NCT02999282|Device|Anodal transcranial direct current stimulation|10 sessions of anodal transcranial direct current stimulation (5 days/week for 2 weeks)
1495994|NCT02999282|Device|Sham transcranial direct current stimulation|10 sessions of sham transcranial direct current stimulation (5 days/week for 2 weeks)
1495995|NCT02999269|Device|MECTA Spectrum 5000Q Amplitude|Current
1495996|NCT02999256|Dietary Supplement|Montmorency Tart Cherry Juice|
1495997|NCT02999256|Other|Placebo|
1496000|NCT02999230|Other|Caries Free 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
1496001|NCT02999230|Other|Caries Free Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
1496002|NCT02999230|Other|Caries Active 1.5% Arginine|Study toothpaste assigned containing 1.5% Arginine. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
1496003|NCT02999230|Other|Caries Active- Placebo Sodium Fluoride|Marketed Toothpaste containing 1100 ppm F as Sodium Fluoride will be assigned. Subjects will also receive a Colgate Wave Comfort Adult Toothbrush to brush their teeth with twice a day.
1496004|NCT02999217|Drug|Iron isomaltoside|"Intravenous injection 1 g given postoperatively in the recovery ward.
Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.
Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.
Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
1496045|NCT02998918|Dietary Supplement|PolyResveratrol Supplementation|Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
1496634|NCT02994264|Radiation|adjuvant concurrent chemoradiation|
1496005|NCT02999217|Drug|Saline|"Intravenous injection given postoperatively in the recovery ward.
Blood tests including red blood cell count, plasma ferritin, haemoglobin, haematocrit, mean corpuscular volume, mean haemoglobin concentration are made 1 day preoperatively, day 1, day 3 postoperatively, day of discharge and 1 month after discharge.
Reticulocyte count and reticulocyte haemoglobin concentration tests are made on the day of discharge and 1 month after discharge.
Count of total consumption of intravenous blood products. Count of total intravenous fluids. Clinical recovery and complications. Duration of hospital stay."
1496006|NCT02999204|Drug|Vitamin D3|Two different doses of Vitamin D3
1496007|NCT02999191|Drug|BI 1467335 (Treatment A)|
1496008|NCT02999191|Drug|BI 1467335 (Treatment B)|
1496009|NCT02999191|Drug|BI 1467335 (Treatment C)|
1496012|NCT02999165|Other|Breast feeding|Infants on respiratory support will be allowed to attempt to breast feed (with a top up nasogastric tube feed if required).
1496013|NCT02999165|Other|Nasogastric feeding|The control intervention is feeding via nasogastric tube
1496014|NCT02999152|Other|blood and urines samples|"For all patients the blood samples must be organized: Before, 4 hours (+/-30 min), 1 day, 2 days, and 3 days after the start of the radiation therapy.
Collections of urine must be organized: Before, 1 day, and 2 days after the radiation therapy."
1496015|NCT02999126|Drug|Propofol|Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model
1496016|NCT02999126|Drug|Remifentanil Hydrochloride|Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.
1989769|NCT02389023|Other|Prevena Incision Management system|The Prevena dressing system over the closed surgical incision. The dressing consists of a sterile sponge that is placed over the incision followed by a plastic adhesive covering that is used to secure it to the skin forming an air-tight seal. The sponge is then connected by tubing to a vacuum that applies negative pressure to the closed system. This allows fluid to drain from the wound and into a container connected to the dressing.
1496021|NCT02999087|Drug|Cetuximab|Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of RT.
1496022|NCT02999087|Drug|avelumab|IV infusion of avelumab (10 mg/kg over 1 hour) once every 2 weeks. Avelumab will start on Day-8 together with cetuximab and subsequently every 2 weeks during the course of RT. Avelumab with be continued every 2 weeks for an additional 12 months following RT.
1496023|NCT02999087|Drug|Cisplatin|100 mg/m² IV after hyperhydration and at a maximal rate of 1 mg/min, on days 1, 22, 43.
1496024|NCT02999087|Radiation|IMRT|RT will be performed using IMRT (intensity modulated radiotherapy), with a simultaneous integrated boost (SIB) technique. RT dose to the GTV will be 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions). Prophylactic dose will be 52.8 Gy in 1.6 Gy daily fractions over 6.5 weeks (33 fractions).
1496025|NCT02999074|Other|Resistance exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The progressive resistance exercise comprises 8 machine-based exercises, each performed in 3 sets, 12 repetitions at 60-80% of one repetition maximum (1-RM).
1496026|NCT02999074|Other|Aerobic exercise|The training will take place twice weekly over the course of neoadjuvant CTx at the NCT Heidelberg or in regional qualified centers under supervision and guidance of experienced exercise therapists. The aerobic exercise will be performed on a cycle ergometer (or alternatively at a treadmill, elliptical, rowing ergometer, or combination) progressing from 60% to 70% VO2max with increasing duration. During weeks 7-18 the goal is to perform an extensive interval training.
1496027|NCT02999074|Other|Usual care during neoadjuvant chemotherapy/Exercise after surgery|The control group receives no exercise intervention during neoadjuvant CTx, which reflects the usual care condition. To investigate effects of different exercise timing, and to provide those patients also a potential health benefit and reduce drop-out and contamination, the control group will receive 18 weeks resistance or aerobic exercise (according to their personal preferences) after breast cancer surgery.
1496028|NCT02999048|Drug|Panax Notoginseng Saponins|Panax Notoginseng Saponins integrated with conventional therapy
1496029|NCT02999022|Drug|Lithium Carbonate|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
1496030|NCT02999022|Drug|Lactose Placebo|Intervention begins 14 days after injury for non-surgical participants and 2 weeks after surgery for participants who have surgical treatment of their fractures.
1496031|NCT02999009|Device|Trident II Tritanium Acetabular Shell|A hemispherical acetabular shell indicated for cementless application.
1496032|NCT02998996|Biological|15 µg HA/strain and 1% Endocine™|intranasal administration
1496033|NCT02998996|Biological|15 µg HA/strain and 2% Endocine™|intranasal administration
1496034|NCT02998996|Biological|15 µg HA/strain|intranasal administration
1496035|NCT02998996|Biological|intramuscular comparator|intramuscular administration
1496036|NCT02998996|Biological|intranasal comparator|intranasal administration
1496037|NCT02998996|Biological|Placebo, Saline|intranasal administration
1496038|NCT02998983|Drug|Racotumomab|
1496039|NCT02998970|Drug|Empagliflozin|single oral tablet once daily.
1496040|NCT02998970|Drug|Placebo|single oral tablet once daily.
1496041|NCT02998957|Device|AcuTENS|Stimulation of acupuncture point Dingchuan using transcutaneous electrical nerve stimulation (TENS) instead of needles
1496042|NCT02998957|Device|Sham AcuTENS|
1496043|NCT02998931|Drug|Glutamin|Enteral Glutamine 0.3g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs
1496044|NCT02998931|Other|Maltodextrin|Maltodextrin mixed with water given via NG tube Q 4 hours
1496674|NCT02994043|Behavioral|Relapse Prevention Therapy|
1496046|NCT02998918|Dietary Supplement|Curcumin Supplementation|Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
1496047|NCT02998905|Drug|NOAC|Apixaban or dabigatran or edoxaban or rivaroxaban at recommended dosing for stroke prevention in atrial fibrillation. The particular agent is at the discretion of the local investigator.
1496048|NCT02998905|Drug|Acetylsalicylic Acid|Acetylsalicylic acid 81 mg/day
1496049|NCT02998892|Behavioral|Traditional Exercise Training|Participants will be asked to perform moderate-intensity exercise (brisk walking) for 45 minutes for 5 days/week for 4 weeks. This intervention corresponds to the current recommendations.
1496050|NCT02998892|Behavioral|Daily Microbursts of Activity|Participants will be asked to break up their sedentary activities of daily living for 5-minutes every hour for 10 hours, 5 days/week, by brisk walking for 4 weeks.
1496051|NCT02998879|Drug|Velmanase Alfa (e.g. Lamazym)|iv infusion treatment
1496052|NCT02998866|Procedure|Esophageal Temperature-Guided Ablation|Esophageal temperature-guided ablation (if esophageal temperatures drop too low during cryoablation, the physician will stop the ablation) in order to increase the safety profile of cryoballoon pulmonary vein (a vein carrying blood from the participants lungs to the left side of the participants heart known as the left atrium) isolation (PVI [means a balloon shaped catheter will be placed at the opening of each pulmonary vein and tissue will be cooled in order to create an ablation line (line of scar tissue) between the left side of the participants heart and each pulmonary vein. This is done to prevent the triggers that typically cause intermittent atrial fibrillation (known as Paroxsymal Atrial Fibrillation) by providing one center's experience.
1496053|NCT02998853|Other|QFR measurement by dedicated workstation on xrays angio selected runs|The patient undergoes coronary angiography; if at least one stenosis from 40 to 90% in non culprit is present and FFR is indicated by guidelines the patient is enrolled to 3d Angio QFR evaluation; no adjunctive invasive procedures are needed for QFR measurements
1496054|NCT02998840|Biological|B244|odorless suspension
1496055|NCT02998840|Biological|Vehicle|odorless suspension
1496056|NCT02998827|Drug|Thalidomide|
1496057|NCT02998827|Drug|infliximab, azathioprine|other treatment include infliximab, azathioprine
1496058|NCT02998827|Other|enteral nutrition|
1496059|NCT02998814|Other|acid-etch|acid-etch
1496060|NCT02998814|Other|self-etch adhesive|Self etch (7th generation ) bonding agent
1496061|NCT02998814|Other|etch-and-rinse adhesive|Total etch bonding agent (5th generation)
1496062|NCT02998814|Other|self-etch adhesive after acid-etch|acid etch + self-etch adhesive Self etch (7th generation ) bonding agent
1496063|NCT02998801|Other|IPAD|Patients undergoing surgery will watch the video using an PAD
1496064|NCT02998801|Other|VR Goggles|Patients undergoing surgery will watch the video using goggles
1496065|NCT02998775|Drug|Plasma Sampling|No lenvatinib will be administered in this study; however, plasma samples will be obtained for assessment of in vitro lenvatinib protein binding.
1496066|NCT02998736|Drug|Cialis|"Cialis 20 mg daily by mouth for 16 day. 5 days prior to surgery, day of surgery and 10 days post surgery.
Influenza vaccine 0.5mL day of surgery"
1496067|NCT02998736|Biological|Influenza vaccine|One 0.5mL intramuscular injection the day of surgery
1496068|NCT02998723|Other|Early Booster Teaching|The early booster group will receive a booster teaching session at 3 weeks post-training followed by feedback.
1496069|NCT02998723|Other|Late Booster Teaching|The late booster group will receive a booster teaching session at 2 months post-training followed by feedback
1496070|NCT02998697|Drug|Ferrous Sulfate|Ferrous sulfate 200 mg t.i.d for 90 days
1496071|NCT02998697|Drug|Placebo Oral Capsule|Lactose 200 mg t.i.d for 90 days
1496072|NCT02998684|Device|Active Transcranial Direct Current Stimulation|
1496073|NCT02998684|Device|Sham Transcranial Direct Current Stimulation|
1496074|NCT02998684|Behavioral|PEERS Social Skills Training|14 weekly social skills training sessions for all participants
1496077|NCT02998658|Device|Vaginal cuff closure using barbed sutures|Vaginal cuff will be closed using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA )
1496078|NCT02998658|Device|Vaginal cuff closure using conventional sutures|Vaginal cuff will be closed using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
1496079|NCT02998645|Drug|eltrombopag|Film-coated tablets (12.5 mg, 25 mg, 50 mg and 75 mg) administered orally, once daily. Dosing is done according to age and ethnicity (East Asian)
1496080|NCT02998645|Drug|Cyclosporine|Supplied in oral soft gel capsules or oral solution and dosage is based on body weight and administered every 12 hours. Dosing is titrated individually according to therapeutic trough level for 6 months.
1496081|NCT02998632|Procedure|Mineralized plasmatic matrix for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using MPM (Mineralized Plasmatic Matrix) bone graft.
1496082|NCT02998632|Procedure|Autogenous bone for bone augmentation|Vertical bone augmentation of defective posterior mandibular alveolar ridge using autogenous bone graft (gold standard) covered by titanium membrane.
1496083|NCT02998619|Radiation|Radiotherapy|Radiation to prostate/seminal vesicles including pelvic lymph nodes Postoperative radiation to prostate bed including pelvic lymph nodes
1496084|NCT02998606|Drug|Naloxegol|MOVANTIK™ 25 mg, daily
1496085|NCT02998606|Drug|Placebo Oral Capsule|Placebo 25 mg, daily
1496086|NCT02998593|Drug|Bahman capsules|Oral Use of Bahman capsules for 3 months by patients.
1496087|NCT02998593|Drug|Placebo|Oral use of placebo capsules by patients for 3 months.
1496088|NCT02998580|Device|LFR followed by HFL|Magventure Cool B70 Coil with RX100 Stimulator
1496089|NCT02998580|Device|cTBS followed by iTBS|Magventure Cool B70 Coil with RX100 Stimulator
1496090|NCT02998567|Drug|Guadecitabine|In arm 1 (escalation) and 2 (expansion).
1496091|NCT02998567|Drug|Pembrolizumab|In arm 1 (escalation) and 2 (expansion).
1496336|NCT02996630|Procedure|Surgical intervention|Congenital Heart Disease repair
1989771|NCT02386670|Other|tDCS + CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).
tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 30 min. per session.
CR sessions will follow the tDCS session and last 2 hours in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory with titrated difficulty levels. Performance feedback will reinforce progress. Strategic monitoring and bridging discussions will promote transfer of cognitive gains to everyday tasks."
2001864|NCT02715245|Procedure|Home-based rehabilitation|Procedure/Surgery: Home-based rehabilitation In the patient's home, the primarily applied treatment has been physical therapy, seeking to achieve the highest possible functionality and gait training. In more than 25% of cases, health education is conducted for families and caregivers. Thus, consistent with the patient's condition and their tolerance to activity and to exercise their self-care independently, rehabilitation interventions are activated that prevent sequelae derived from functional limitations.
1496105|NCT02998515|Device|Companion (Liquid oxygen device)|
1496106|NCT02998515|Device|Activox (concentrator)|
1496107|NCT02998502|Device|Freespira Breathing System|Over an 8-week period the efficacy of the FBS system in youth will be tested, with those in the randomized active device group. The control group will not receive the device until completion of the 8 week baseline.
1496108|NCT02998489|Other|Fast milk advancement|30-40 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
1496109|NCT02998489|Other|Traditional milk advancement|20 cc/kg/d of human milk or formula milk until total enteral feeding has been achieved
1496110|NCT02998476|Drug|INCB050465|INCB050465 once daily for 8 weeks followed by once weekly
1496111|NCT02998463|Device|skin-to-skin facilitating garment|Fabric garment designed to accommodate term neonates having skin-to-skin contact.
1496112|NCT02998450|Drug|IMR-687|1 of 6 possible single doses administered orally following overnight fast
1496113|NCT02998450|Drug|Placebo Oral Capsule|Placebo oral capsule with 50 mg microcrystalline cellulose in capsules identical to those used for the active pharmaceutical ingredient.
1496114|NCT02998437|Drug|Ilaprazole 10mg|Period 1: Ilaprazole 10mg, one a day, one day Period 2: Ilaprazole 10mg, twice a day, 6 days
1496115|NCT02998437|Drug|Clarithromycin 500mg|Period 1: Clarithromycin 500mg 1 tab., twice a day, one day Period 2: Clarithromycin 500mg 1 tab., one a day at 5 day
1496116|NCT02998437|Drug|Amoxicillin 500 Mg|Period 1: Amoxicillin 500mg 2 cap., one a day, one day Period 2: Amoxicillin 500mg 2 cap., one a day at 5 day
1496117|NCT02998424|Drug|Propofol|Continuous infusion
1496118|NCT02998424|Device|Pupillary diameter measurement|Instantaneous measure
1496119|NCT02998411|Other|Titration|
1496120|NCT02998398|Other|Switch from REMICADE® to INFLECTRA®|Treatment with an infliximab biosimilar (i.e. INFLECTRA® ) for all patients which have been treated by REMICADE® for at least 4 months
1496121|NCT02998385|Drug|Cisplatin|intravenous, concomitant to irradiation
1496122|NCT02998385|Radiation|radiotherapy|
1496123|NCT02998359|Device|Hemiarthroplasty|A cemented polished double taper stem hemiarthroplasty inserted via an anterior-lateral surgical approach (Zimmer incorporated, UK).
1496124|NCT02998359|Device|Total hip arthroplasty|A cemented polished double taper stem arthroplasty stem inserted via an anterior-lateral surgical approach with a cemented acetabular cup (Zimmer incorporated, UK).
1496125|NCT02998333|Procedure|Surgical stabilization|Surgical stabilization of the ankle joint, performed as an open or arthroscopic procedure.
1496126|NCT02998320|Drug|Genvoya|Oral use (one tablet each day); 150/150/200/10 mg; 28 days
1496127|NCT02998307|Procedure|CPR Training|Brief CPR assessment and training done during working hours with real-time performance feedback
1496128|NCT02998294|Device|Respiratory Volume Monitor(RVM)|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
1496129|NCT02998294|Device|artificial respirator|The purpose of this study was to determine the accuracy of one-time respiratory volume measured by RVM compared to the one-time respiratory volume measured by mechanical ventilation in post-operative ICU patients.
1496130|NCT02998281|Device|Threshold (IMT)|Training is going to perform by using a pressure threshold- loading device (Threshold, IMT, USA) used to inhale against a same-pressure load every inhalation for strengthening primarily the diaphragm and rib cage muscles. The device pressure is adjusted according to PImax, and reliability/reproducibility has been demonstrated.
1496131|NCT02998268|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
1496132|NCT02998268|Drug|Taxol|Taxol is a novel antimicrotubule agent that promotes the assembly of microtubules from tubulin dimers and stabilizes microtubules by preventing depolymerization. This stability results in the inhibition of the normal dynamic reorganization of the microtubule network that is essential for vital interphase and mitotic cellular functions.
1496133|NCT02998268|Drug|Carboplatin|Carboplatin is a platinum coordination compound that is used as a cancer chemotherapeutic agent. Carboplatin produces predominantly interstrand DNA cross-links rather than DNA -protein cross-links.
1496134|NCT02998255|Drug|Single dose of 2L PEG|Patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. Patients began to drink 2 L of PEG 4-6 hours before colonoscopy at a rate of 250 mL every 15 minutes.
1496135|NCT02998255|Drug|Split dose of 4L PEG|All patients at average risk for inadequate BP were given instructions for bowel preparation through phone call a day before scheduled colonoscopy. the participants began to drink the first 2 L of PEG at 7:00-9:00 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
1496136|NCT02998242|Drug|Apatinib|
1496137|NCT02998242|Radiation|SBRT to symptomatic bony metastatic bony site(s)|
1496138|NCT02998229|Device|Artisse™|Intrasaccular Device
1496139|NCT02998216|Procedure|Bilateral sacrospinous fixation|Bilateral sacrospinous vaginal suspension
1496140|NCT02998203|Dietary Supplement|Organic diet|Full organic diet from certified organic products as obtained from certified producers and cooked by a certified organic restaurant. five meals each day delivered to students.
1496141|NCT02998190|Drug|Single Ascending Doses of EB8018|
1496142|NCT02998190|Drug|Single Ascending Doses of placebo|
1496143|NCT02998190|Drug|Multiple Ascending Doses of EB8018|
1496144|NCT02998190|Drug|Multiple Ascending Doses of placebo|
1496145|NCT02998164|Behavioral|augmentative and alternative communication technology|
1496146|NCT02998164|Behavioral|Usual Care|No change to the therapy care received
1496147|NCT02998151|Drug|Acamprosate|two 666 pills
1496148|NCT02998151|Drug|Lovastatin|two 20mg pills
1496149|NCT02998151|Drug|Minocycline|two 135mg pills
1496150|NCT02998151|Drug|Placebo|
1496151|NCT02998125|Procedure|Total knee arthroplasty|prospective assessments for the functional outcome before and after the total knee arthroplasty
1496152|NCT02998112|Drug|fecal microbiota transplantation|Fecal microbiota which was purified from fresh stool defecated by a healthy donor
1496153|NCT02998112|Drug|Saline|
1496154|NCT02998099|Drug|Rivipansel|A single dose of IV rivipansel over 20 minutes.
1496155|NCT02998086|Behavioral|Promoting Resilience in Stress Management|Skills-based intervention designed to promote resilience resources
1496156|NCT02998073|Behavioral|Stop, Now and Plan Youth Justice Model|SNAP YJ is an adaptation and extension of the original SNAP program and was developed to target justice-involved youth (12 years and older) who have problems with aggression, CD, and/or gang affiliation. Using the SNAP strategy, the SNAP YJ program was adapted to use digitally-based iPad intervention modules that incorporate an interactive learning experience through the use of novel technology. These modules focus on engaging youth in interesting and creative learning modules by providing real life scenarios designed to improve self-control, impulsive behaviors, decision-making skills, and pro-social skills. SNAP YJ treatment is delivered over a 13-week period.
1496157|NCT02998060|Procedure|Pedicle Screw Placement|As a part of the lumbar spinal fusion procedure, posterior pedicle screws will be placed.
1496158|NCT02998060|Device|SpineAssist®/Renaissance® (Mazor Robotics Ltd. Caesarea, Israel)|This robot will be used to guide pedicle screws into their trajectories.
1496159|NCT02998060|Device|3D C-Arm (Ziehm Imaging, Nuremberg, Germany)|This 3D Fluoroscope will be used to navigate pedicle screws into their trajectories.
2001865|NCT02714010|Drug|EGFR-TKI|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid
1496161|NCT02998034|Device|Uncemented Furlong Hemiarthroplasty|A furlong uncemeneted hyroxyapatite coated prosthesis.The hydroxyapatite stimulates bone ingrowth around the prosthesis and is this is thought to reduce loosening of the implant, residual pain and the long-term revision rate.
1496162|NCT02998034|Device|Cemented tapered stem hemiarthroplasty|A cemented double tapered stem hemiarthroplasty
1496163|NCT02998021|Device|Vibrating Dumbbell|Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively, first by increasing the frequency of the vibration (max. 40 Hz) then by the addition of more weight, based on weekly assessments and consultation with the senior investigators.
1496164|NCT02998021|Device|Standard Dumbbell|Supervised training sessions will occur optimally, 3 times per week for a total of 12 consecutive weeks. The sessions will involve nine exercises specifically designed to improve upper limb muscle function. The beginning training intensity for each participant will be based on their one rep max for each exercise, which is determined during baseline laboratory testing in accordance with standard procedures. Training intensity will be adjusted progressively by the addition of more weight, based on weekly assessments and consultation with the senior investigators.
1496165|NCT02998008|Behavioral|high intensity interval training|
1496166|NCT02997995|Drug|Immune-attractant|The first cohort patients will receive tremelimumab (3 mg/kg, single infusion) as immune-attractants combined with exemestane (25 mg daily).
1496167|NCT02997995|Drug|Durvalumab|Durvalumab (lymphocyte activation) will be administrated at a dose of 1500 mg Q4W (equivalent to 20 mg/kg Q4W) IV, combined with exemestane (25 mg daily), for six months
1496168|NCT02997995|Procedure|Biopsy|After three weeks (+/- 3 days) of immune-attractants, a tumor biopsy will be done. Patients who present >10% CD8+ cells in the tumor after 3 weeks will receive the Durvalumab
1496169|NCT02997982|Drug|Valaciclovir 500Mg Tablet|Valaciclovir treatment (oral, 500 mg tablets). First week: 500 mg three times daily, second to fourth week: 1000 mg three times daily.
1496170|NCT02997969|Biological|DNA-HIV-PT123 vaccine|Contains a mixture of 3 DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C ZM96 gag, 2) clade C ZM96 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose 4 mg administered as 1 mL intramuscularly (IM)
1496171|NCT02997969|Biological|Protein/MF59 vaccine|clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered as 0.5 mL IM
1496172|NCT02997969|Biological|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products
1496173|NCT02997956|Drug|Tocilizumab|Participants will receive Tocilizumab (ACTEMRA®) at 4, 6, or 8 mg/kg IV dose escalation on days 1, 29 and 57.
1496174|NCT02997956|Procedure|Transcatheter Arterial Chemoembolization|Minimally invasive procedure performed in interventional radiology to restrict a tumor's blood supply
1496175|NCT02997943|Behavioral|Step 1 Treatment: APP|Participants will receive a smartphone app to track weight, dietary intake and physical activity, and a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker. Participants will use their own smartphone to receive the study smartphone application.
1496176|NCT02997943|Behavioral|Step 1 Treatment: APP + Coaching|Participants will receive a smartphone app to track weight, dietary intake and physical activity; a technology core consisting of web-based weekly lessons, wireless scale, and activity tracker; 12 weekly telephone coaching sessions. Participants will use their own smartphone to receive the study smartphone application.
1496337|NCT02996630|Procedure|Brain monitoring|EEG and continuous brain oximetry before surgery.
2001866|NCT02714010|Radiation|whole brain radiotherapy|30Gy/10F
1496177|NCT02997943|Behavioral|Step 2 Treatment Strategy: Modest Step-up|In addition to first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) for the remaining 12 weeks.
1496178|NCT02997943|Behavioral|Step 2 Treatment Strategy: Vigorous Step-up|In addition to the first line treatment, participants identified as non-responders will be provided an additional mHealth intervention component (push notifications) plus a traditional weight loss intervention component (coaching, meal replacements).
1496179|NCT02997930|Behavioral|fMRI|fMRI for measuring function connectivity and DTI will be done between day 2 to day 5.
1496180|NCT02997930|Behavioral|Montreal Cognitive Assessment (MoCA)|A measure of general cognition
1496181|NCT02997930|Behavioral|Digital Clock Drawing Test Command and Copy|A measure of current cognition using digital pen technology
1496182|NCT02997930|Behavioral|Wide Range Achievement Test reading subtest|A measure of premorbid intellectual estimate
1496183|NCT02997930|Behavioral|Hopkins Verbal Learning Test (HVLT)|A measure of declarative memory
1496184|NCT02997930|Behavioral|General Depression Scale (GDS)|A measure of the of presence of depression.
1496185|NCT02997917|Behavioral|Education|
1496186|NCT02997917|Behavioral|Sham|
1496187|NCT02997904|Device|Apply Liquid Then Comb Out|Apply liquid to dry hair, wait for 5 minutes, then comb out lice and eggs for up to one hour
2001867|NCT02713555|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass surgery entails the formation of a small gastric pouch and the division of the small intestine 60 cm from the duodenum. Formation of a gastrojejunal anastomosis with the distal segment and the formation of a jejuno-jejunal anastomosis 150 cm from the gastrojejunal anastomosis with the biliary segment.
1496189|NCT02997878|Biological|Orbcel-C|Selected Mesenchymal Stromal Cells derived from human ubmical cord
1496190|NCT02997865|Behavioral|Stepped care for depression|Cognitive behavior therapy (CBT), augmented with an antidepressant if indicated.
2001868|NCT02713555|Procedure|Gastric Sleeve|Gastric Sleeve entails a vertical division of the stomach with a stapler.
1496192|NCT02997839|Behavioral|sleep disruption|"Group two will have interrupted sleep at time periods of 2 hours post operatively.
Group two will be woken every 2 hours, which is the standard NCCU protocol."
1496193|NCT02997826|Other|Infantil formula|
1496194|NCT02997800|Drug|Esmolol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of esmolol 30 mg IV (30 mg in 5 ml of normal saline). An intravenous esmolol infusion will be initiated at 5mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5mcg/kg/min each time HR or MAP >20% of baseline. An intravenous bolus of placebo (normal saline 1 ml) will be administered whenever a change to the infusion rate is made.
1496195|NCT02997800|Drug|Labetalol|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of labetalol 10 mg IV (10 mg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of labetalol 5 mg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
1496196|NCT02997800|Drug|Fentanyl|Following induction and intubation, any increase in heart rate (HR) or mean arterial pressure (MAP) >20% of baseline will be treated with an initial intravenous bolus of fentanyl 50 mcg IV (50 mcg in 5 ml of normal saline). Any further increases in HR or MAP >20% of baseline will be treated with intravenous boluses of fentanyl 25 mcg in 1 ml every 5 minutes as needed. An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus dose and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
1496197|NCT02997800|Other|saline infusion|An intravenous placebo infusion (normal saline) will be initiated at 5 mcg/kg/min after the first intravenous bolus drug dose (fentanyl or labetalol depending upon randomization) and will be titrated up by 5 mcg/kg/min each time an additional intravenous bolus is given.
1496198|NCT02997800|Other|1 ml saline infusion|Every time the infusion rate of esmolol is changed, 1 ml of normal saline will be infused.
1496199|NCT02997774|Other|Cooler dialysis|Having dialysis at a slightly cooler temperature (35 vs 36.5 degrees Celsius)
1496200|NCT02997774|Other|Standard Dialysis|Having dialysis at a standard temperature (36.5 degrees Celsius)
1496201|NCT02997761|Biological|Blinatumomab|Given IV
1496202|NCT02997761|Drug|Ibrutinib|Given PO
1496203|NCT02997748|Procedure|Remote ischemic preconditioning (RIPC)|3 cycles or more cycles of 5 to 10-min inflation of a blood-pressure cuff to 200 mm HG (or at least to a pressure 50 mmHG higher than the systolic arterial pressure) to one upper arm followed by 5 min reperfusion with the cuff deflated. In Non-Responder two additional cycles of 10 min cuff inflation will be performed in arm 6.
1496204|NCT02997735|Behavioral|Quitline Delivered Treatment|The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.
1496205|NCT02997722|Drug|Ketamine|Patients randomly allocated to the treatment group will receive a ketamine infusion over the course of 45 minutes. The dose will be 0.5 mg/kg. Patients will be monitored for 30 minutes after the completion of the infusion.
1497018|NCT02991599|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
2001869|NCT02712749|Device|Sound with Binaural Beats|Acoustic frequencies of 256 Hz in one ear and 260 Hz in the opposite ear producing a binaural beat of 4 Hz generated by the special program Gnaural in stereo option
2001870|NCT02712749|Device|Sound without Binaural Beats|Acoustic frequencies of 256 Hz in both ears to perceive one tone without beats generated by the program Gnaural in mono option
1496206|NCT02997722|Drug|Normal Saline|Patients randomly allocated to the control group will receive an infusion of 100 mL of normal saline over the course of 30 minutes. Patients will be monitored for 30 minutes after the completion of the infusion.
1496207|NCT02997709|Procedure|Blood Specimen Collection|Blood specimen collection (plasma and serum) for CTCs and other possible biomarkers pre-radiation therapy at Baseline, during treatment and at various intervals post-treatment, per study protocol.
1496208|NCT02997709|Behavioral|Memorial Anxiety Scale for Prostate Cancer patients|Memorial Anxiety Scale for Prostate Cancer (MAX-PC) patients administered to study participants at Baseline and at intervals during treatment and post-follow-up, per study protocol.
1496209|NCT02997709|Behavioral|Expanded Prostate Cancer Index Composite-SF-12|Expanded Prostate Cancer Index Composite (EPIC) Short Form 12 (SF-12) administered to study participants at Baseline and at intervals during treatment and post-follow-up, per study protocol.
1496210|NCT02997709|Behavioral|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) administered to study participants at Baseline and at intervals during treatment and post-follow-up, per study protocol.
1496211|NCT02997709|Device|MRI-US fusion guided biopsy|MRI-US fusion guided biopsy (MUFgBx) of prostate for research at baseline and 2-2.5 years post-treatment.
1496212|NCT02997709|Device|Multiparametric MRI|Multiparametric MRI at Baseline and various time points post-treatment per study protocol.
1496213|NCT02997696|Drug|ONO-4474|
1496214|NCT02997696|Drug|Placebo matching ONO-4474|
1496215|NCT02997683|Device|Body Vibration platform GALILEO|3 month home based training on whole Body Vibration platform GALILEO
1496216|NCT02997683|Other|exercises at home on the floor|
1496217|NCT02997670|Other|Algorithmic Cardiac Resynchronisation Therapy Optimisation|Use of a computer algorithm to run through multiple combinations of pacing options in patients who have a Cardiac resynchronisation pacemaker with defibrillator where a quadripolar lead has been implanted. These quadripolar leads offer extra options for pacing locations across the heart, as well as for different combinations and sequences of pacing stimuli.
1496218|NCT02997657|Behavioral|Positive Psychotherapy|Exercises designed to boost moods, positive behaviors, and positive cognitions.
1496219|NCT02997657|Behavioral|Standard smoking cessation counseling|Counseling designed to provide support and problem solving for smoking cessation
1496220|NCT02997657|Drug|Transdermal Patch, Nicotine|
1496221|NCT02997644|Behavioral|Video Education|"The content of the education focuses on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage.
The consent, enrollment, and video education will take about 20-30 minutes for patients in this group, and occur at the end of their preoperative visit. The patient will watch the video on a portable Tablet computer."
1496222|NCT02997644|Behavioral|Usual Care Group|Patients that are randomized to usual care will only receive the regular instructions about opioid usage they typically receive from their surgeon.
1496223|NCT02997631|Device|MEDi Robot|Distraction therapy using an interactive humanoid robot
1496224|NCT02997618|Behavioral|Community based exercise programme|20 week community (home or gym based) exercise programme
1496225|NCT02997618|Other|Control|Usual care consisting of advice.
1496226|NCT02997605|Drug|GlucoCorticoid|"After inclusion in the study, the first part of the study will be an open follow-up period where all patients will receive 5 mg of prednisone daily for one month. After one month, if patients still have a DAS28 ≤3.2, they will be randomized into two arms: Group 1: GC tapering group / Group 2: Hydrocortisone replacement group.
After randomisation, there are four scheduled visits: M4, M7, M9 and M12. Furthermore, extra visits can be scheduled in three cases. Patients withdrawing from GC therapy will be instructed, that if they start feeling unwell during or after the GC tapering protocol they should not taper the steroid dose any further, but contact the centre responsible for the protocol. If GC induced adrenal insufficiency is confirmed or strongly suspected, GC replacement will be secured using hydrocortisone. Patients will carry a steroid emergency card, stating the need for GC replacement."
1496227|NCT02997592|Device|SpinCare dressing|The burn wound is dressed using the SpinCare wound dressing
1496228|NCT02997579|Procedure|patellar resurfacing|patellar component insert with cement
1496229|NCT02997566|Other|Autonomic evaluation|
2001871|NCT02712216|Procedure|Laparoscopy|Determine best port sites to insert bariatric trocars
2001872|NCT02710890|Drug|Lacosamide|"Pharmaceutical form: solution for infusion
Concentration: 10 mg/ml
Route of Administration: intravenous"
2001873|NCT02710708|Drug|EE20/DRSP (YAZ, BAY86-5300)|YAZ (DRSP 3 mg/EE 20 µg), oral route, 6 cycles of 28 days per cycle, each cycle comprising 24 days of active tablets followed by 4 days of placebo tablets
2001874|NCT02708433|Drug|Lidocaine|Lidocaine
1496234|NCT02997514|Behavioral|Solution Focused Coaching|SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
1496235|NCT02997514|Behavioral|Intensive Solution Focused Coaching|Intensive SFC is an approach that uses strategic questioning to help the client envision what they would like to be different and how they will take action towards achieving their goals.
2001875|NCT02706392|Other|Laboratory Biomarker Analysis|Correlative studies
2001876|NCT02706392|Biological|ROR1 CAR-specific Autologous T-Lymphocytes|Given IV
2001877|NCT02705963|Drug|Trametinib|Each tablet is 2mg trametinib to be taken orally once daily.
2001878|NCT02705963|Drug|Trametinib|Each tablet is 0.5mg trametinib to be taken orally once daily. 0.5mg tablets may be used if a dose reduction is required.
2001879|NCT02705963|Drug|Oral Contraceptive (1mg norethindrone, 0.035mg ethinyl estradiol)|Combined oral contraceptive to be taken orally once daily.
1496241|NCT02997488|Device|Pentax Airwayscope|intubation using Pentax Airwayscope
1496242|NCT02997488|Device|McGrath Videolaryngoscope|intubation using McGrath Videolaryngoscope
2001880|NCT02705313|Drug|177Lu-DOTA0-Tyr3-Octreotate|The treatment regimen consists of 4 administrations of 7.4 GBq (200 mCi) at the date and time of infusion. The recommended interval between two infusions is 8 weeks, which could be extended up to 16 weeks in case of dose modifying toxicity.
2001881|NCT02700646|Behavioral|Developmental recommendations|
1496244|NCT02997410|Device|Ozone|
1496245|NCT02997410|Device|Placebo (for Ozone)|
1496246|NCT02997410|Device|Dental treatment with occlusal splint|
1496247|NCT02997397|Procedure|tourniquet(+)|A novel atraumatic tourniquet technique, applied via placing a vascular clamp widely on both the infundibulopelvic ligament and uterine arteries.
1496248|NCT02997397|Procedure|tourniquet(-)|
1496249|NCT02997384|Other|Information|information of women about their risk of breast cancer and the screening methods recommended for them
1496250|NCT02997371|Drug|Anakinra Prefilled Syringe|Administration as initially intravenous injection followed by a intravenous infusion
1496251|NCT02997371|Drug|Isotonic saline|Placebo, administration as initially intravenous injection followed by a intravenous infusion
1496252|NCT02997358|Drug|Doxorubicin|
1496253|NCT02997358|Drug|Trabectedin|
1496254|NCT02997345|Other|There is no intervention associated with this study.|There is no intervention associated with this study.
1496255|NCT02997332|Drug|Durvalumab|Durvalumab will be administered every 3 weeks for 3 injections at week 1, 4, 7. Dose levels: the durvalumab first dose level is 1120 mg Q3W, and the dose level -1 is 750 mg Q3W.
1496256|NCT02997332|Drug|Docetaxel|Docetaxel 75mg/m² on D2, IV in 1 hour
1496257|NCT02997332|Drug|Cisplatin|Cisplatin 75mg/m² on D2, IV in 3 hours
1496258|NCT02997332|Drug|5 Fluorouracil|5 Fluorouracil 750mg/m²/day on D2, D3, D4, D5, D6 IV in 24 hours
1496259|NCT02997306|Procedure|Superior/Medial Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Superior/Medial half of the incision, and interrupted sutures being used on the Inferior/Lateral half of the incision.
1496260|NCT02997306|Procedure|Inferior/Lateral Running Sutures|Simple interrupted stitches and running (continuous) stitches are the two most frequently used suturing techniques. The erythema secondary to these suturing techniques will be compared by utilizing them side-by-side for closure of post-Moh's surgical defect repair in each patient. This intervention consists of running sutures being used for closure of the Inferior/Lateral half of the incision, and interrupted sutures being used on the Superior/Medial half of the incision.
1496261|NCT02997293|Other|Enhanced Recovery protocol|The Enhanced Recovery protocol focuses on many areas or perioperative care, including non-narcotic pain management, optimization of fluid balance throughout the perioperative course, early eating, ambulation, early removal of drains postoperatively, and preoperative patient education.
1496262|NCT02997280|Drug|Ruxolitinib Oral Tablet|"Dose reduction criteria for acute GVHD: grade 4 neutropenia or grade 4 thrombocytopenia related to ruxolitinib administration based on the decision of attending physician.
Dose reduction criteria for chronic GVHD: grade 3 neutropenia, grade 3 thrombocytopenia or anemia requiring transfusion, related to ruxolitinib administration based on the decision of attending physician.
Reduced dose schedule: 5 mg bid for adults and children with body weight > 40 kg, 0.08 mg/kg bid for children with body weight < 40 kg.
Treatment discontinuation criteria: complete response; absence of response after 28 days or progressive disease after 7 days for acute GVHD; absence of response after 84 days or progressive disease after 28 days for chronic GVHD; life-threatening complications."
1496263|NCT02997267|Procedure|Closure of the ileostomy|Surgical closure of the protective ileostomy (reconnection of intestinal loops)
1496264|NCT02997241|Biological|OncoCare|Personalized monitoring
1496265|NCT02997241|Drug|chemotherapy for colorectal carcinoma|chemotherapy for colorectal carcinoma
2001882|NCT02700646|Behavioral|Standard care|standard care
2001883|NCT02698254|Radiation|Re-Irradiation Therapy (RRT) to Brain|Participants may receive up to 6 weeks of radiation therapy. Dose of radiation decided by participant's radiation oncologist.
2001884|NCT02698254|Behavioral|Questionnaires|Quality of life and symptom questionnaires completed at baseline, and at months 1, 3, 5, 7, 9, 11, 13, 16, 19, 22, and 25 after radiation therapy.
2001885|NCT02694783|Biological|PyVST|Ex vivo generated polyomavirus-specific T cells from HLA-matched donor.
2001886|NCT02694783|Other|No Intervention|No Intervention
1496273|NCT02997215|Drug|Lidocaine|lidocaine infusion during surgery
1496274|NCT02997215|Drug|Saline Placebo|saline infusion at same rate as intervention group during surgery
1496277|NCT02997189|Drug|OTO-104|12 mg dexamethasone administered intratympanically
1496280|NCT02997150|Drug|IL-2 Low dose|"Patients receive low doses of Interleukin 2: 0.5 million UI/m²/ injection subcutaneously.
The treatment is initiated with an induction phase of one injection per day for 5 consecutive days, followed by a maintenance phase in which patients will receive one injection every 14 days for 6 months.
At the same time, corticoid treatment will be tapered until its complete withdrawal no later than 3 months from the first injection"
1496281|NCT02997137|Dietary Supplement|BOT-01|"Amino acid composition with micronutrients, once a day (in the morning) content of a sachet mixed with 200 ml water.
Duration: 12 weeks"
1496282|NCT02997137|Other|Placebo|"Placebo, once a day (in the morning) content of a sachet mixed with 200 ml water.
Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.
Duration: 12 weeks"
1496283|NCT02997124|Procedure|local infiltration and TAP block|Local infiltration of the iliac crest harvest site along with TAP block using 0.2 % Ropivacaine is done
1496284|NCT02997124|Procedure|local infiltration only|Only local infiltration with 0.2% Ropivacaine of the iliac crest harvest site is done.
1496285|NCT02997111|Device|PFA-100|The PFA-100 will be used to assess platelet function before and after energy drink consumption.
1496338|NCT02996630|Procedure|cord blood sample|Cord blood samples will be taken after birth in both groups.
1496288|NCT02997059|Drug|Fluconazole|200 mg/ day
1496289|NCT02997059|Other|Placebo|
1496290|NCT02997046|Other|Ferumoxytol|Ferumoxytol used as contrast in MRA
1496291|NCT02997033|Other|No intervention|No intervention
1496292|NCT02997020|Other|EDSPD|The equipment & conditions for measuring bioelectric changes across the sinus mucosa are based on the standard NPD protocol, including use of agar-filled PE90 tubing for the probing electrode and limiting perfusion solutions to Ringer, Ringer + amiloride (100 µM), chloride-free gluconate with amiloride + isoproterenol (10 µM). The potential difference will be monitored in actively inflamed areas as judged by endoscopy in comparison to an agar-filled reference butterfly electrode placed in the volar aspect of the forearm. A stable potential with the mean value of a 10-s scoring interval after perfusion of each solution will be recorded by a blinded investigator.
1496293|NCT02997007|Device|active tDCS|
1496294|NCT02997007|Device|sham tDCS|
1496295|NCT02996968|Procedure|Self-removal|Self-discontinuation of a transurethral catheter
1496296|NCT02996955|Behavioral|social support|behaviour change intervention
1496297|NCT02996955|Behavioral|treatment of illness perceptions|educational interview
1496298|NCT02996955|Device|Activ8|wearing a move monitor
1496299|NCT02996955|Other|activity advice|walking or cycling 5 days a week during at least half an hour
1496300|NCT02996942|Biological|Factor VIII replacement|Patients receive their usual treatment
1496301|NCT02996929|Device|LC System|Subjects will undergo CIED lead extraction with the LC system
1496302|NCT02996916|Drug|Olmesartan|10-40mg daily
1496303|NCT02996916|Drug|Amlodipine|2.5-10mg daily
1995765|NCT02658578|Procedure|PNS|Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator. In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
1496306|NCT02996877|Other|Observational no intervention|
1496307|NCT02996864|Other|Healthy Detours App|"The app features:
Immediate and relevant feedback at the point of decision-making to reinforce healthy lifestyle behaviors within a population making crucial lifestyle choices.
User-centered and location-specific tailored information to provide users with information to improve future decision-making through activity tracking.
Multiple health-tracking features (i.e., diet and PA tracking, and accelerometry for PA and sleep) that will aid in self-monitoring."
1496308|NCT02996864|Other|Fat Secret App|Freely available app for weight loss and nutrition. Includes food and exercise diaries; calorie counting.
1496309|NCT02996838|Drug|TQ-B3234|TQ-B3234 p.o. qd
1995768|NCT02657031|Drug|Prochlorperazine|prochlorperazine 10 mg IV
1995769|NCT02657031|Drug|Ketamine|Ketamine 0.3 mg/kg IV
1995770|NCT02657031|Drug|Diphenhydromine|Diphenhydromine 25 mg IV
1496314|NCT02996812|Drug|Exendin (9-39)|
1496315|NCT02996799|Other|Umbilical cord milking|Milking of the umbilical cord at delivery
1496316|NCT02996786|Dietary Supplement|Danggui Buxue Tang|Danggui Buxue Tang purchased from Kaiser Pharmaceutical
1496317|NCT02996786|Other|Placebo|Consisting of corn starch and carboxymethyl cellulose
1496318|NCT02996773|Drug|Bendamustine|"After transplant, on day +4, Cyclophosphamide and Bendamustine will be given intravenously
Dose level 1: 20 mg/m2 Dose Level 2: 60 mg/m2 Dose Level 3: 100 mg/m2"
1496319|NCT02996773|Drug|Cyclophosphamide|"After transplant, on day +4, Cyclophosphamide and Bendamustine will be given intravenously
Dose level 1: 40 mg/kg Dose Level 2: 20 mg/kg Dose Level 3: 0 mg/kg"
1496320|NCT02996760|Drug|Growth Factor, Platelet-Derived|0,5 mL, vaginal use , 3 dose number
1496321|NCT02996747|Procedure|curettage (intralesional surgery)|comparison of two different tumors treated by curettage
1496322|NCT02996734|Procedure|curettage and resection|the investigators analyzed patients with giant cell tumor of bone who underwent curettage or resection with or without denosumab administration
1496323|NCT02996721|Biological|Vitamin D3|Vitamin D3 (cholecalciferol) will be provided to participants of the study.
1496324|NCT02996695|Drug|Artesunate|Artesunate is a succinic ester of artemether.
1496325|NCT02996695|Drug|Chloroquine|4-aminoquinolone, antimalarial agent for oral administration
1496326|NCT02996695|Biological|PfSPZ (NF54)|PfSPZ (NF54) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
1496327|NCT02996695|Other|Placebo|Placebo
1496328|NCT02996682|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
1496329|NCT02996682|Drug|RBV|Capsules administered orally in a divided daily dose
1496330|NCT02996656|Drug|Cefazolin|Antibiotic that will be give before a Trauma or elective open shoulder surgery
1496331|NCT02996656|Drug|Ceftriaxone|Antibiotic that will be give before a Trauma or elective open shoulder surgery
1496332|NCT02996643|Device|Ultrasound Assisted Group|A custom brace standing frame, a medical ultrasound system, a custom pressure measurement system, and in-house Ultrasound measurement software were used to assist brace casting for the intervention group.
1496333|NCT02996630|Procedure|Sonography|Fetal Ultrasound exploration
1496334|NCT02996630|Device|Magnetic Resonance Imaging|Fetal MRI for brain study
1496335|NCT02996630|Other|Bailey Test|Neurodevelopment paediatric assessment test performed at 2 years of age.
1496441|NCT02995902|Device|MRI|
1995771|NCT02657031|Drug|Ondansetron|Ondansetron 4 mg IV
1995772|NCT02657031|Drug|Normal Saline|Normal Saline 500 cc IV Bolus
1995773|NCT02656511|Drug|Dolutegravir|Dolutegravir 50 mg PO daily
1995774|NCT02656511|Drug|Emtricitabine/Tenofovir|Emtricitabine 200 mg/Tenofovir alafenamide 25 mg PO daily
1496339|NCT02996617|Drug|rhG-CSF regimen|Patients weren't preventive use of rhG-CSF.If their WBC≤1×10^ 9/L,they were administered rhG-CSF:5ug/kg/day until their WBC≥4×10^ 9/L.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
1496340|NCT02996617|Drug|Pegylated rhG-CSF regimen|Patients were administered pegylated rhG-CSF 6mg（weight≥45Kg）or 3mg（weight≤45Kg）once 24 hours after the end of chemotherapy drugs of every chemotherapy cycle.Chemotherapy regimen: CHOP: Epirubicin：70 mg/m2 , Cyclophosphamide：750 mg/m2, Vincristine: 1.4 mg/m2 , Prednison：100mg/d; CHOPE: Epirubicin：70 mg/m2, Cyclophosphamide：750 mg/m2,Vincristine: 1.4 mg/m2,Prednison：100mg/d,Etoposide: 100 mg/（m2•d）;EPOCH:etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin;Hyper-CVAD(A):hyperfractionated cyclophosphamide, vincristine,doxorubicin, dexamethasone, cytarabine and methotrexate;GemOx-R:Gemcitabine, Oxaliplatin;GDP:gemcitabine, dexamethasone, and cisplatin
1496341|NCT02996604|Other|acupuncture|Manual acupuncture treatment will be conducted. thirty minutes duration every time, five times per week for one course, a total four courses.
1496342|NCT02996591|Procedure|25 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for popliteal nerve block|
1496343|NCT02996591|Procedure|10 mL of 0.25% bupivacaine plus 2 mg preservative-free (PF) dexamethasone / 30 ml for adductor canal nerve block|
1496344|NCT02996591|Drug|Midazolam, 2-5 mg IV + Glycopyrrolate, 0.1 mg IV + Ketamine, 10-20 mg + propofol as needed|
1496345|NCT02996591|Procedure|45-60 mg of 1.5% mepivacaine for spinal anesthesia|
1496346|NCT02996591|Procedure|LMA insertion + titrated propofol infusion + sevoflurane + ketamine 10 mg/hr for general anesthesia|
2001887|NCT02691351|Other|Prospective Registry|"Survival and disease status follow-up at 1st primary treatment, 1st salvage treatment and 2nd salvage treatment
Regimen
Response Evaluation
SUSAR(Suspected, Unexpected, Serious, Adverse Reaction) collection"
2001888|NCT02689453|Biological|IL-15 plus alemtuzumab|rhIL-15 by s.c. injection Monday-Friday over two weeks; followed by alemtuzumab three times a week for a total of 4 weeks of alemtuzumab treatment.
2001889|NCT02690818|Behavioral|Regularly scheduled LTBI medication reminder text messages|"Regularly scheduled medication reminder text messages Daily LTBI text messages without the option to text back. The messages will read, This is a reminder to take your medication."
1496351|NCT02996565|Other|Best Practice Clinic-Based Care|"Relies primarily on the physician-medical assistant dyad and face-to-face visits to promote:
Improved recognition of uncontrolled BP at primary care encounters,
Therapeutic action to address uncontrolled BP at primary care encounters,
Reliable follow-up visits to re-assess uncontrolled BP every 2-4 weeks."
1496352|NCT02996565|Other|Telehealth Care|"All elements of Clinic-Based Care are performed, plus a telemonitoring and pharmacist case management program is offered, specifically:
Referral to care by MTM pharmacist and receiving a home blood pressure telemonitoring device
Systematic home BP telemonitoring with data transmitted into patient medical record
Systematic home-based care by pharmacist via telephone and/or secure email"
1496353|NCT02996552|Procedure|M & T Repair Group|After the mitral valve repair a device for tricuspid annuloplasty will be implanted.
1496354|NCT02996552|Procedure|Mitral-Only Group|Mitral valve repair alone; after the mitral valve repair no device for tricuspid annuloplasty will be implanted.
1496355|NCT02996539|Other|Clinical examination and laboratory measurements|Subjects were interviewed by a physician regarding their medical history, history of hypoglycemic attacks, smoking status, and alcohol consumption. Concentrations of blood urea nitrogen (BUN) and serum creatinine (SCr) were analyzed by the urease-ultraviolet rate method and picric acid method, respectively. Serum uric acid was determined using the enzymatic colorimetric method. Serum hemoglobin A1c (HbA1c) was measured by liquid enzymatic assay. Urine albumin and urine creatinine were found through immune turbidimetric analysis and the enzymatic method, respectively.
1496356|NCT02996513|Other|Retinol Isotope Dilution (RID)|13C-retinyl acetate will be administered to subjects in order to assess their body retinol pools
2001891|NCT02682290|Other|Expectoration and measurement of sputum rheological properties|
2001892|NCT02678767|Drug|Ferumoxytol|All subjects will receive neurocognitive testing. Subjects will have a brain MRI prior to drug infusion. A one-time ferumoxytol IV infusion will be given at a dose of 4mg Fe/kg up to a maximum of 510mg of elemental iron delivered at a rate of 1ml/sec. A second brain MRI will be completed post-infusion
2001893|NCT02675192|Other|Proof cohort : muscular assessment|Clinical examination, blood appraisal, urinary collection, MVC, checking muscle functional skills and muscular biopsy will be performed.
1496360|NCT02996487|Drug|Vancomycin|
1496361|NCT02996487|Other|Placebo|
2001894|NCT02670616|Drug|Ibrutinib|560 mg by mouth daily on day 1-21 per each cycle
2001895|NCT02670616|Drug|Rituximab|
2001896|NCT02670616|Drug|Cyclophosphamide|
1496365|NCT02996448|Drug|NDV-3A|A vaccine containing recombinant Candida albicans agglutinin-like sequence 3 (rAls3) protein as the antigen, formulated with AlOH adjuvant in phosphate buffered saline. Participants will receive a single 0.5 mL dose containing 300 micrograms of rAls3 and 0.5 mg of aluminum as AlOH, delivered via intramuscular injection.
1496366|NCT02996435|Other|Mobile Application Intervention|Mobile phone application that sends reminders and allows participants to self-manage their medication adherence. Monitoring of participant adherence from this tool will be performed by the central coordinating center, which will send notifications or contact the participant based on the adherence history in accordance with the study protocol.
1496367|NCT02996435|Drug|Rivaroxaban|Rivaroxaban is administered to the participants as part of their standard medical care.
1496368|NCT02996422|Behavioral|School-based water campaign|Includes: 1) the installation of filtered water bottle refilling stations, 2) the distribution of reusable water bottles to all students and teachers, and 3) a social marketing campaign to support the increase of water consumption among students.
1496442|NCT02995889|Device|FLT-PET|
1496443|NCT02995876|Procedure|Glaze layer|A coating of a glaze layer will be used at the inner surface of the bridge to improve adhesion
1496369|NCT02996422|Behavioral|Community cooking classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
1496370|NCT02996409|Drug|HVIGI|High Volume Image-Guided Injection with a saline/lidocain solution
1496371|NCT02996409|Drug|LVIGI|Placebo control with injection of a saline/lidocain solution (low volume)
1496372|NCT02996409|Other|Progressive exercise program|A 12-week during progressive exercise training program consisting of isometric, isotonic and eccentric calf exercises.
1496373|NCT02996396|Device|Nellix Endovascular Aneurysm Sealing System (Nellix®-System)|The Nellix system is comprised of two independent flow channels, one to each iliac artery. Each flow channel consists of a balloon-expanded ePTFE covered stent surrounded by a Polymer-filled EndoBag which fills the blood lumen within the aorta, and seals the aneurysm from side-branch flow.
1496374|NCT02996383|Device|Internal fixation|Internal fixation of the fracture with a Targon FN implant (BBraun Ltd, Germany)
1496375|NCT02996383|Device|Cemented Hemiarthroplasty|Replacement of the femoral head with a cemented hemiarthroplasty
1496376|NCT02996370|Other|papilla fill index|The clinical photographs were taken baseline, 3 and 6 month. Two T shaped full-round hexagonal straight filaments, each 5 mm, were used in the taking of standardized images.
1496377|NCT02996370|Other|crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline, 3 and 6 month with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
1496378|NCT02996370|Other|probing depth|The change of probing depth between baseline, 3 and 6month. Probing depth was measured with a plastic periodontal probe (mm)
1496379|NCT02996370|Other|Modified sulcus bleeding index|Modified bleeding index was measured baseline, 3 and 6 month. Presence of bleeding on probing were performed at four sites of implants.
1496380|NCT02996370|Other|Modified plaque index|Modified plaque index was measured baseline, 3 and 6 month. Presence of plaque index was performed at four sites of implants.
1496381|NCT02996344|Other|Didactic training|Six online training modules pertaining to suicide prevention in primary care.
1496382|NCT02996344|Other|Standardized patient interaction|Two standardized patient practice interactions - 1 face-to-face, 1 remote/telehealth.
1496383|NCT02996331|Other|2 hour repositioning|Current PrU prevention protocols recommend repositioning moderate, high, and severe risk residents a minimum of every 2 hours. We propose to include low risk residents because studies suggest they too develop PrUs. New pressure redistribution mattresses may make 2 hour repositioning unnecessary, but optimal time between repositioning remains unclear. Aim is to determine differences in incidence of new PrUs in NH residents (low, moderate, high risk level) using VE surfaces and repositioned at 2, 3, and 4 hour frequencies.
1496384|NCT02996331|Other|3 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 3 hour repositioning interval.
1496385|NCT02996331|Other|4 hour repositioning|It is expected that repositioning frequency can be extended for NH residents who are low, moderate, and high risk for pressure ulcer (PrU) development and on visco-elastic (VE) high-density foam support-surfaces without compromising PrU incidence. This intervention will include a 4 hour repositioning interval.
1496386|NCT02996318|Device|Paclitaxel coated balloon (SeQuent Please)|Paclitaxel coated balloon (SeQuent Please)
1496387|NCT02996318|Device|Sirolimus coated balloon|Sirolimus coated balloon
1496388|NCT02996305|Drug|OV101 Regimen 1|
1496389|NCT02996305|Drug|OV101 regimen 2|
1496390|NCT02996305|Other|Placebo|
1496391|NCT02996292|Device|Traditional brackets|Treating of crowding using traditional brackets
1496392|NCT02996292|Device|Active self-ligating brackets|Treating of crowding using active self-ligating brackets
1496393|NCT02996292|Device|Passive self-ligating brackets|Treating of crowding using passive self-ligating brackets
2001897|NCT02670616|Drug|Doxorubicin|
2001898|NCT02670616|Drug|vincristine|
1496396|NCT02996253|Procedure|FHL transfer|endoscopic transfer og flexor hallucis longus
1496397|NCT02996240|Dietary Supplement|Omega-3 FFA|Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
1496398|NCT02996227|Procedure|TAP block|Transversus Abdominis Plane (TAP) blocks will be performed preoperatively. An in-plane ultrasound will be used in TAP block procedure.
1496399|NCT02996227|Procedure|Epidural analgesia|Epidural catheters will be inserted preoperatively.
1496400|NCT02996227|Drug|EXPAREL|Once the target area is positioned, plain bupivacaine 0.25%, 20ml will be given to open the space and then single dose (10ml) of liposomal bupivacaine (Exparel) mixed with saline (10 ml) will be injected in each side. Total dose of Exparel will be 20 mL.
1496401|NCT02996227|Drug|Bupivacaine|Once an epidural catheter is successfully positioned, an infusion will be initiated intraoperatively. Bupivacaine standard solution without additives will be prepared for each patient in epidural group.
1496402|NCT02996214|Drug|Paclitaxel Liposome|Paclitaxel liposome injection 175 mg/m2, given on day 1 of a 21-day cycle, for 6 cycles.
1496403|NCT02996214|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, given on days 1 and 8 of a 21-day cycle, for 6 cycles.
1496404|NCT02996214|Drug|Cisplatin|Cisplatin 75 mg/m2, given on day 1 of a 21-day cycle, for 6 cycles.
2001899|NCT02670616|Drug|Prednisolone|
1496406|NCT02996188|Procedure|routine therapeutic paracentesis|
1496407|NCT02996175|Behavioral|Behavioral Sleep Treatment|"Introduction to the treatment program, an overview of common sleep problems in DS, and the basic principles of the behavioral approach as it relates to sleep problems
Information on healthy sleep hygiene, preventative techniques, and use of visual supports
Information on reinforcement and extinction procedures for bedtime struggles, codependence, night waking, early waking
Information on procedures for delayed sleep onset and problematic sleep associations
Feedback on implementation of behavioral sleep treatments and strategies for managing sleep hygiene in the future"
1496510|NCT02995343|Procedure|Hypogastric and/or uterine artery ligation|
2001900|NCT02670044|Drug|Cobimetinib|Cobimetinib will be administered orally daily on Days 1-21 of each 28-day treatment cycle.
1496408|NCT02996175|Behavioral|Standard of care sleep treatment enhanced with psychoeducation|"Introduction to the general-education program, build rapport with family, and review basic information on Down syndrome
Introduction to understanding and interpreting results from clinical evaluations
Introduction to educational planning, expectations, and transition planning
Introduction to lifespan development and advocacy and support services available
Feedback on current concerns and methods for obtaining services to manage concerns"
1496409|NCT02996162|Device|Massimo Root Monitoring System|The Masimo Root system is a patient monitoring and connectivity platform; Root displays patient monitoring information from the connected modules. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
1496410|NCT02996162|Device|ISA-Infrared Sidestream Gas Analyzer|The ISA-Infrared Sidestream Gas Analyzer displays end-tidal carbon dioxide waveforms and measurements and trends of end tidal CO2. This will be used as a non-invasive way to determine infants' pCO2. The equipment will be used in the inpatient portion of the study up to twice weekly for 5 minutes to obtain approximately 150 end tidal CO2 values and recorded over time for each infant. In the outpatient portion, it will be used in each clinic visit in a similar fashion.
1496411|NCT02996149|Procedure|Endoscopic lung volume reduction coil treatment|
1496412|NCT02996136|Device|Flu Symptoms|Flu Symptoms
1496413|NCT02996123|Other|cad/cam maxillary dentures|patients wearing cad/cam designed and milled dentures
2001901|NCT02670044|Drug|Idasanutlin|Idasanutlin will be administered orally daily or twice daily on Days 1-5 of each 28 day treatment cycle.
1496417|NCT02996097|Device|The Lutronic electronic carbon dioxide (eCO2) Plus laser system|CO2 ablative laser plus intralesional triamcinolone acetonide A topical EMLA cream or tetracaine 7%/lidocaine 23% will be applied to the both treatment sites and after sufficient anesthesia is attained, one keloid will be treated with the fractional CO2 laser using standard protocol as practiced in our clinics followed by intralesional triamcinolone acetonide. One lesion would be treated with fractional CO2 ablative laser followed with intralesional triamcinolone acetonide at 4 weeks intervals
1496418|NCT02996097|Drug|Intralesional Triamcinolone Acetonide|
1496419|NCT02996071|Procedure|laparoscopic sleeve gastrectomy|a sleeve gastrectomy operation that is performed laparoscopically.
1496420|NCT02996058|Drug|Dexmedetomidine 0.35µg/kg /h|the infants will receive a maintenance dose of 0.35µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
1496421|NCT02996058|Drug|Dexmedetomidine 0.5µg/kg /h|the infants will receive a maintenance dose of 0.5µg/kg /h of Dexmedetomidne without a loading dose and guided by the assessed sedation scale
1496422|NCT02996045|Other|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-6, and scans scored 7-8 for which an alternative scan scored 8-9 exists.
This screen will show the appropriateness score of the original scan order, and will display up to 7 alternative scans that are scored >4 and greater than or equal to the original score for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication."
1496424|NCT02996019|Drug|Etrolizumab|Etrolizumab will be administered at a dose of 105 milligrams (mg).
1496425|NCT02996019|Device|Auto-Injector (AI)|The pre-filled AI will be used to administer etrolizumab.
1496426|NCT02996019|Device|Prefilled Syringe With Needle Safety Device (PFS-NSD)|The PFS-NSD will be used to administer etrolizumab.
1496427|NCT02996006|Procedure|stepwise vascular control|"Before liver parenchymal resection, we performed total hepatic vascular preparation for occlusion with portal triad (PT), infra-hepatic inferior vena cava (IIVC), and supra-hepatic inferior vena cava (SIVC) preparation in order. Then we performed step-by-step vascular occlusion according to the individual bleeding situation."
1496428|NCT02995993|Drug|Moss-aGal (recombinant human alpha-galactosidase A produced in moss)|Single i.v. Infusion of 0.2 mg/kg moss-aGal over 60 minutes
1496429|NCT02995980|Device|DECE mammography|Contrast mammography
1496430|NCT02995980|Device|digital mammography|routine digital mammography
1496431|NCT02995967|Procedure|Hydrodistention|The hydrodistention will then be performed with the bladder filled at a pressure of 80 cm H2O and noted to be full as evidenced by no further influx of water into the bladder. This volume will be held in the bladder for 5 minutes.
1496432|NCT02995967|Drug|Botulinum toxin-A|Intradetrusor injection of 100 units of botulinum toxin a
1496433|NCT02995954|Drug|Perindopril/Amlodipine|Single table containing Perindopril/Amlodipine
1496434|NCT02995928|Procedure|Decompressive craniectomy|Decompressive craniectomy: All patients in the treatment group will receive decompressive craniectomy of at least 12 cm according to institutional guidelines and a published surgical protocol during the clipping surgery within 48 hours form the onset.
1496435|NCT02995928|Procedure|Best medical treatment|Best medical treatment: Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2012 and 2013 respectively.
1496436|NCT02995915|Drug|Nicotine Replacement Therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum or nicotine lozenge, and will be instructed to use the rescue method as needed to reduce cigarette cravings
1496437|NCT02995915|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
1496438|NCT02995915|Behavioral|Cognitive Behavioral Treatment|Participants will receive 4 60-minute sessions of CBT telephone counseling for alcohol and smoking cessation.
1496439|NCT02995915|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence, and breathalyzer to confirm abstinence from alcohol. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence and alcohol abstinence.
1496440|NCT02995902|Device|FLT-PET|
1496444|NCT02995876|Procedure|E-max Press layer|A coating of E-max Press layer will be used at the inner surface of the bridge to improve adhesion
1496445|NCT02995863|Device|Rigid Rocker Sole Footwear|
1496446|NCT02995863|Device|Therapeutic Footwear|
1496447|NCT02995850|Drug|CRS+HIPEC|"Ib
Dose-escalation of intraperitoneal paclitaxel will follow a modified 3 + 3 dose escalation procedure.
II
① CRS If PCI <12, CRS will be performed by gastrectomy with D2-lymphadenectomy and resection of any involved adjacent structures.
If PCI≥12, instead of CRS, 3 times of IP paclitaxel +cisplatin and oral S-1 chemotherapy every 3 weeks, and then PCI <12, CRS will be done.
② Extensiveintraperitoneal lavage Peritoneal lavage after CRS will be done with 10 L before HIPEC.
③ HIPEC Following surgery HIPEC will be performed using CDDP (60 mg/m2) and PTX (P2RD mg/m2). IP chemotherapy will be performed.
④ Post-operative intraperitoneal chemotherapy Postoperative chemotherapy will be done 8 cycles of IP paclitaxel+ cisplatin and oral S-1 after 4 weeks."
1496448|NCT02995837|Other|Sleep Study|Overnight, video-recorded sleep study will be performed in a dedicated pediatric sleep lab. Sleep architecture, apneas and hypopneas, arterial oxygen saturation and end-tidal carbon dioxide tension will be evaluated during the sleep study. Safety measures including arterial oxygen saturation using pulse oximetry, EEG and EKG will be continuously monitored during the study.
1496449|NCT02995837|Other|Neurocognitive Testing|Cognitive and behavioral measures including intelligence, attention, working memory, and processing speed will be assessed by a trained psychologist.
1496450|NCT02995837|Other|CBF During Wakefulness|Cerebral blood flow (CBF) will be measure using Diffuse optical and correlation spectroscopy (DOS/DCS), a non-significant risk device used to collect data for this study but not being tested as part of the protocol. Light sources and detectors which are embedded in a rubber pad will be attached to the subject's head in order to record right and left hemispheric cerebral blood flow, total hemoglobin concentration and tissue oxygen saturation. Measurements will be continuously recorded during the study and averaged for purposes of statistical analysis. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique, a standard clinical test. While CBF is being measured, subjects will wear nose clips and sit comfortably breathing through a mouthpiece while the level of carbon dioxide is adjusted over a 3-4 minute period. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
1496451|NCT02995837|Other|CBF During Sleep|This is the same as the CBF testing during wakefulness/daytime except that it will be done during a sleep study performed with a continuous positive airway pressure (CPAP) mask not nose clips and a mouthpiece. With DOS/DCS in place, ventilatory response to hypercapnia will be determined using the rebreathing technique. While CBF is being measured, OSAS subjects will receive an individualized positive pressure aimed at treating obstructive sleep apnea and controls will receive a standard pressure. End-tidal carbon dioxide will be measured via a port in the mask. A constant flow of carbon dioxide will be introduced to the circuit, a slowly adjusted until the patient arouses or for a maximum of 3 minutes, whichever occurs first. One trial will be attempted in each sleep stage (slow-wave sleep and rapid-eye-movement) with a minimum of 15 minute of breathing room air between challenges. Oxygen and carbon dioxide levels will be carefully monitored throughout the testing.
1496452|NCT02995824|Other|Raltegravir-based antiretroviral therapy|To analyze retrospectively the efficacy and safety of raltegravir plus 2 nucleoside reverse transcriptase inhibitors (NRTI) [lamivudine (3TC) or emtricitabine.(FTC) plus abacavir (ABC) or tenofovir (TDF)] [Group 1] versus other ART regimens including boosted PI or NNRTIs [Group 2] in 271 HIV/HCV-coinfected patients who underwent liver transplantation between 2002 and 2012 and were followed until December 2016.
1496453|NCT02995811|Other|Observational Cohort|Ultrasound assessment of 4 muscles, activity monitoring, daily global peripheral skeletal muscle strength
1496454|NCT02995798|Other|Cortical Bone thickness and Hounsfield unit (HU) numbers|Cortical Bone thickness and Hounsfield unit (HU) numbers considering BMD
1496455|NCT02995785|Other|simulation-based training|simulation-based training:The first aid skill simulation training with discussion and debriefing(75-min) and TMS online lecture(15-min).
1496456|NCT02995785|Other|traditional training|traditional training:Give TMS online lecture(15-min).
1496457|NCT02995772|Drug|Aromatase Inhibitors (Arimidex)|Comparison of efficacy with chemotherapy
1496458|NCT02995772|Drug|Tamoxifen|Comparison of efficacy with chemotherapy
1496459|NCT02995772|Procedure|SOB|Comparison of efficacy with chemotherapy
1496460|NCT02995772|Drug|FAC|Comparison of efficacy with hormonal therapy
1496461|NCT02995772|Drug|Aromatase Inhibitors (Femara)|Comparison of efficacy with chemotherapy
1496462|NCT02995772|Drug|Aromatase Inhibitors (Aromasin)|Comparison of efficacy with chemotherapy
1496463|NCT02995759|Other|Seizure Action Plan|The action plan will be electronically formatted in the EMR. After electronic creation, the primary neurologist and patient/caregiver will create a patient-specific plan.
1496464|NCT02995746|Drug|Dexamethasone|"On study visit #1 all patients will have a SD-OCT scan and measurement of baseline visual acuity. All patients will receive the 0.7mg dexamethasone intravitreal implant
Subsequent follow-up visits will be at 1 month, 2 months, 3 months, 4 months, 5 months, and 6 months after intravitreal injection of dexamethasone implant
Each visit will consist of measurement of visual acuity, intraocular pressure, dilated fundoscopic examination, and SD-OCT scan
Anticipated duration of the study: 6 months"
2001902|NCT02670044|Drug|Venetoclax|Venetoclax will be administered orally daily on Days 1-28 of each 28 day treatment cycle.
1496466|NCT02995720|Drug|Fimasartan/Amlodipine combination drug, Rosuvastatin|
1496468|NCT02995694|Drug|Estradiol|Estradiol Vaginal Cream
1496469|NCT02995694|Drug|Placebos|Placebo with no active pharmaceutical ingredients. Topical vaginal cream
1496470|NCT02995694|Drug|Reference|Estrace Vaginal Cream
1496471|NCT02995681|Other|Balance training|Balance exercises will include: functional lower extremity training, gait training under challenging conditions and training to increase stability during changes in body positions.
1496472|NCT02995681|Other|Pulmonary rehab|Pulmonary rehab includes: supervised exercise (aerobic exercise, resistance exercise) disease-specific education, and psychological and social support.
1496473|NCT02995668|Other|Strength-Function|Preoperative functional and strength capabilities training.
1496474|NCT02995668|Other|Balance-Proprioception|Preoperative proprioceptive and balance capabilities training
1496475|NCT02995655|Drug|CX-01|CX-01 at a dose of 4mg/kg on Day 1 of each 28-day cycle, followed by a continuous intravenous infusion at a dose of 0.25 mg/kg/hour for Days 1 through 7 of each cycle.
1496476|NCT02995655|Drug|Azacitidine|Azacitidine at a dose of 75mg/m^2 on Days 1-7 of each 28-day cycle.
1496477|NCT02995655|Procedure|Bone marrow biopsy|-Baseline, day 28 of even-numbered cycle through Cycle 6, and end of study
1496478|NCT02995655|Procedure|Peripheral blood draw|-Day 1 of each cycle, day 3 of each cycle, day 7 of each cycle, day 28 of every even-numbered cycle through Cycle 6, and end of study
1496479|NCT02995642|Drug|18F-FPPRGD2|One single intravenous injection.
1496480|NCT02995642|Device|Positron emission tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
1496481|NCT02995642|Procedure|Computed tomography|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
1496482|NCT02995642|Device|Magnetic Resonance Imaging|Undergo 18F-FPPRGD2 PET/CT or PET/MRI
1496483|NCT02995629|Procedure|laser indirect ophthalmoscopy pan retinal photocoagulation|"Prior to procedure, eligible patient is dilated and a topical anesthesia is administered 3 to 5 minutes prior to treatment initiation
Treatment duration is fixed at 50 minutes and power is titrated until moderate gray-white burns are achieved, avoiding long ciliary nerves
Target treatment of 250 spots
Only one eye per eligible patient randomized with regard to whether green or yellow laser utilized first
After treatment,pain assessment conducted:spot count, laser parameters and treatment duration recorded for each respective laser wavelength"
1496484|NCT02995616|Other|Regular therapy settings|Patients will walk in the Lokomat according to their regular therapy settings for 30 minutes (i.e. minimum tolerable guidance force (GF), minimal tolerable body weight support (BWS) and maximum tolerable walking speed)
1496485|NCT02995616|Other|Different levels of guidance force|Patients will walk in the Lokomat with 3 different levels of guidance force (60%, 80% and 100%) for 10 minutes each and with the same amount of body weight support and walking speed as in the first session
1496486|NCT02994667|Device|Permanent Pacemaker Placement|
1496487|NCT02994654|Device|ReCell|"The ReCell-assigned treatment area will be treated as described in the product's Instructions for Use. In summary, 1ml of fluid physically covers a treatment area of 80 cm2. Each milliliter of fluid contains cells harvested from a square centimeter of thin split-thickness skin sample.
The reagents and components of the ReCell kit are used, in a scalable fashion, to facilitate disaggregation of cells from skin samples into filtered cell suspension. Areas to be harvested for skin samples are to be clean and show no evidence of surrounding cellulitis or infection. Treatment area sizes and cell suspension volumes are to be recorded."
1496488|NCT02994641|Procedure|COMA Score Assessment|
1496490|NCT02995577|Other|Feeding tolerant|
1496491|NCT02995577|Other|Feeding intolerant|
1496492|NCT02995577|Other|Necrotizing enterocolitis|
1496493|NCT02995564|Behavioral|social skills therapy|Sixteen week manual based social skills curriculum targeting social fluency and responsiveness.
1496494|NCT02995551|Procedure|Arthroscopic meniscal repair or resection|Arthroscopic meniscal repair or resection following standard procedures.
1496495|NCT02995551|Behavioral|Exercise and education|A 12-week (2 exercise sessions per week) supervised neuromuscular and strengthening exercise program tailored to 18-40 years old patients with a meniscal tear combined with patient education teaching the participants about their disease and how to manage it through exercise and in their daily life.
1496496|NCT02995512|Drug|Colchicine 0.6 mg tablets|1.2 mg PO followed by 0.6 mg PO 1 hour later
1496497|NCT02995486|Other|Exercise|Otago Exercise Program for falls prevention after discharge due to fall-related injuries.
1496498|NCT02995473|Drug|NP000888|270 µg/g topical (BID) for 24 weeks
1496499|NCT02995473|Drug|Vehicle|Topical (BID) for 24 weeks
1496500|NCT02995460|Behavioral|interval training|4x4 high intensity interval training
1496501|NCT02995447|Other|differences between surface and intracerebral EEG|No intervention is performed. Im- and explantation of intracerebral electrodes is performed for clinical and not for study purposes. The only difference between study and non-study patients is that the surface as well as the intracerebral EEG is recorded and stored in the former, while it is discarded in the latter.
1496502|NCT02995434|Device|Virtual Reality Headset|"The following VR experiences will be used:
Virtual Meditative Walk:http://painstudieslab.com/projects/virtual-meditative-walk/ Qualia: Zen Eagle:http://www.mobiointeractive.com/big-picture/index.html Tilt Brush:https://www.tiltbrush.com Call of the Starseed Episode 1 and 2: http://store.steampowered.com/app/270130/"
1496503|NCT02995434|Other|2D PC|"The control group will be exposed to 2D equivalent versions of the same multimedia experiences but on their PC screen (without the VR headset use). these will be functionally similar to the VR experiences. These will include:
Virtual Meditative Walk:http://painstudieslab.com/projects/virtual-meditative-walk/ Qualia: Zen Eagle:http://www.mobiointeractive.com/big-picture/index.html Tilt Brush:https://www.tiltbrush.com Call of the Starseed Episode 1 and 2: http://store.steampowered.com/app/270130/"
1496504|NCT02995408|Behavioral|Relaxation Response Resiliency Program for Parents of Children with ASD|
1496505|NCT02995395|Device|Mucosal Impedance Balloon catheter|"During the clinical endoscopy (a standard procedure that allows your doctor to look at the inside of your swallowing tube), the 2 mm catheter (tiny tube), called an Intraluminal Impedance Balloon, will be passed through the channel of the standard endoscope.
o The catheter (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) for two minutes, readings from the catheter will be recorded."
1496506|NCT02995382|Procedure|Anterior Intramuscular Transposition|Anterior intramuscular transposition technique to decompress the ulnar nerve at the level of the elbow
1496507|NCT02995369|Device|Dryshield|DryShield (DS) is an all-in-one isolation system. It combines the tasks of fluid evacuation, tongue and cheek retraction, and serves as a bite block. Its design allows it to suction and isolate half the oral cavity at a time.
1496508|NCT02995369|Other|Cotton rolls|Cotton Roll Isolation requires placing cotton rolls along the buccal mucosa, especially over the parotid glands ducts for maxillary teeth. For the mandibular teeth, the cotton rolls are placed in the buccal vestibule and the floor of the mouth (between the lower buccal mucosa and underneath and/or between the tongue). With this technique, a high-speed evacuation of saliva and water is used.
1496509|NCT02995356|Other|Collecting cervical liquid and sera samples|
1496515|NCT02995304|Drug|Morphine premedication|30 children will 0.1 mg/kg morphine as a premedication 20 to 30 min before surgical incision.
1496516|NCT02995304|Drug|Midazolam premedication|All children who will receive 0.025 mg/kg midazolam IV as a premedication 20 to 30 min before surgical incision.
1496517|NCT02995304|Drug|Saline premedication (placebo)|30 children in midazolam only group will receive saline after midazolam
1496518|NCT02995291|Drug|OraVerse|1.7ml OraVerse (0.4 mg phentolamine mesylate) will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). Oraverse will be injected at the same site Bupivacaine was injected.
1496519|NCT02995291|Drug|Saline Water (Control)|1.7ml saline water will be injected once after the participants are found to be well anesthetized following an injection of 1.8ml Bupivacaine 0.5% (inferior alveolar nerve block). The water will be injected at the same site Bupivacaine was injected.
1496520|NCT02995278|Other|Does not include a drug needing FDA approval and therefore it is not by definition, a Clinical Drug Trial as defined by FDA.|
1496521|NCT02995265|Other|Exoskeleton Program|Subjects will wear the exoskeleton device at each physiotherapy session to work on improving mobility and walking ability.
1496522|NCT02995265|Other|Usual Care Program|Subjects will receive hands-on physiotherapy to improve their mobility and walking ability. Physiotherapy session will be tailored to subject individually by their therapist.
1496523|NCT02995252|Other|Blood draws|
1496524|NCT02995252|Drug|Tenofovir Alafenamide|25 mg tablet, once a day by mouth.
1496525|NCT02995252|Other|Knowledge Index Questionnaire|
1496526|NCT02995252|Other|Liver transient elastography (FibroScan)|Participants of the hepatitis B treatment sub-study may have FibroScans completed at baseline, during the study with liver enzyme normalization, and at the end of the study.
1496527|NCT02995252|Procedure|Liver Biopsy|40 participants of the hepatitis B treatment sub-study will have liver biopsies prior to starting tenofovir alafenamide, and at years 1 and 2 of receiving treatment.
1496528|NCT02995239|Drug|CJ-12420 formulation 2|CJ-12420 formulation 2
1496529|NCT02995239|Drug|CJ-12420 formulation 1|CJ-12420 formulation 1
1496530|NCT02995226|Other|Clinical and biological examination, Saliva (or blood) test Glycemia, thermal test, cognitive and bike tests, questionnaires|Clinical and biological examination, Saliva (or blood) test, glycemia, thermal test, cognitive and bike tests, questionnaires
1496531|NCT02995226|Other|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires|Clinical examination, Glycemia, saliva (or blood) test, thermal test, cognitive and bike tests, questionnaires
1496532|NCT02995213|Behavioral|Accelerometer based feedback about paretic arm use|
1496533|NCT02995200|Behavioral|Accelerometer Based Feedback|
1496534|NCT02995187|Drug|Apatinib Mesylate tablet|Apatinib 500 mg in tablet once daily
1496535|NCT02995174|Device|Dichoptic video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with 'contrast-balanced' images displayed on the screen of an i-Pod touch device. The eye with weaker eyesight will see the image with high contrast, and the good eye will see the image with low contrast. The subject will play the game one hour per day for 6 weeks.
1496536|NCT02995174|Device|Video game in an i-Pod touch device|Amblyope will wear a pair of red green goggles and play the video game with equal contrast images displayed on the screen of an i-Pod touch device. Both eyes will see the image of same contrast. The subject will play the game one hour per day for 6 weeks.
1496537|NCT02995161|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-106)
1496538|NCT02995161|Drug|SPF control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1496539|NCT02995148|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-104)
1496540|NCT02995148|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1496541|NCT02995135|Drug|BAY987517|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
(Formulation Code: Z43-094)"
1496542|NCT02995135|Drug|SFP Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1496543|NCT02995122|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
(Formulation Code: Z43-090)"
1496544|NCT02995122|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1496545|NCT02995109|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
(Formulation Code: Z11-004)"
1496546|NCT02995109|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1496547|NCT02995096|Procedure|Pre-treatment|Non-transplantation pre-treatments prior to transplantation (e.g. radiofrequency ablation, transcatheter arterial chemoembolization)
1496548|NCT02995096|Drug|Sirolimus based immunosuppression|Immunosuppression regimens containing Sirolimus
1496549|NCT02995083|Drug|40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine|Patients will receive an ultrasound guided intra-articular injection of 40 mg Depo-Medrol in 1 ml, 9 ml of 1% lidocaine
1496550|NCT02995083|Drug|Normal Saline 10 ml|Patients will receive an ultrasound guided intra-articular injection of Normal Saline 10 ml
1496551|NCT02995083|Drug|Air 10 ml|Patients will receive an ultrasound guided intra-articular injection of Air 10 ml
1496552|NCT02995070|Procedure|CTG|Periodontal plastic surgery for root coverage by the trapezoidal flap plus connective tissue graft
1496553|NCT02995070|Device|LLLT|Low Level Laser Therapy on the buccal recipient site of connective tissue graft.
1496554|NCT02995070|Device|SHAM|Simulation of GaAlAs laser to irradiation on connective tissue graft recipient site.
1496555|NCT02995057|Device|Gold- or silver-coated, or uncoated nickel microneedles|The stratum corneum of the participants will be breached with the gold- and silver-coated, or uncoated nickel microneedles.
1496556|NCT02995044|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-180)
1496557|NCT02995044|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1496558|NCT02995031|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-177)
1496559|NCT02995031|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1496560|NCT02995018|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z09-174)
1496561|NCT02995018|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1496562|NCT02995005|Drug|Tenofovir Disoproxil Fumarate|300 mg daily
1496563|NCT02994992|Drug|BAY 987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-100)
1496564|NCT02994992|Drug|SPF Control|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1496565|NCT02994979|Other|Delirium-prevention|"Patients will be seen by an intervention CNA at least once daily 7 days a week. The CNA will be English/Spanish bilingual and will provide intervention components guided by structured protocols and a daily visit form. A typical visit lasts 30 minutes and begins with an introduction and orientation activity followed by provision of water, a reminiscence activity or game, a physical exercise, and a snack and second cup of water. Patients may also receive a relaxation visit at night and given a warm drink, a hand or foot massage, and quiet music. Daily visits will last for the duration of the illness and 7 days following the illness end. Illness end is defined as the last day of illness treatment (e.g., last day of antibiotics) or monitoring (e.g., last day on nursing 24-hour report). During weekly intervention staff meetings patients will be discussed with the primary medical and nursing team. The planned intervention group sample size results in a case load of 4-8 patients."
1496566|NCT02994979|Other|Sham comparator|Usual care plus sham visits by CNA
1496567|NCT02994966|Device|Surrosense|
1496568|NCT02994966|Other|Standard care|
2001903|NCT02667626|Other|Reproductive Health Survivorship Care Plan (SCPR)|The reproductive health survivorship care plan (SCPR) is a web-based educational tool that will include information on how to manage various reproductive health issues such as hot flashes, fertility concerns, contraception practices, and sexual function. The intervention also includes additional web-based information and resource lists, text-based reproductive health and study adherence prompts.
2001904|NCT02667626|Other|Control|Web-based resource lists and text-based study adherence reminders
1496571|NCT02994940|Drug|Acetaminophen|
2001905|NCT02667457|Radiation|99mTc-rhAnnexin V-128|
2001906|NCT02665364|Biological|IFN-Kinoid|
2001907|NCT02665364|Other|Placebo|
2001908|NCT02665364|Other|ISA 51|
2001909|NCT02665468|Behavioral|Supported adoption intervention|An intervention where a healthcare system implements quality improvement by sending patients proactive reminders, motivational messages, and educational support to encourage use of a new service (i.e., secure messaging)
1496578|NCT02994888|Drug|Cetuximab|All patients will be offered cetuximab 500mg/m2 every 2 weeks, until the time of progression
1496579|NCT02994875|Dietary Supplement|N-acetylcysteine|NAC is an FDA-approved dietary supplement with antioxidant properties that is available over-the-counter. NAC has no contraindications.
1496580|NCT02994875|Other|Placebo|Sugar pill
1496581|NCT02994862|Other|Galla Chinnesis|new Remineralizing Agent before Bonding to teeth with amelogenesis imperfecta
1496582|NCT02994862|Other|Conventional Bonding|Normal Bonding Protocol
1496583|NCT02994836|Biological|Anti-TNF: Infliximab (Infusion)|Infliximab (Infusion 5mg/kg milligram(s)/Kilogram-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
1496584|NCT02994836|Drug|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Infusion-Intravenous use)(Visit1,visit 3,visit 4,visit 5, visit 6 and visit 7)
1496585|NCT02994836|Biological|Anti-TNF:Adalimumab (Subcutaneus)|Adalimumab (Subcutaneus 40 mg milligram(s)-subcutaneus)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
1496586|NCT02994836|Drug|Anti-TNF discontinuation: Physiological saline solution|Physiological saline solution (Injection-subcutaneous use)(Visit 1,visit 2,visit 3,visit 4,visit 5, visit 6 and visit 7).
1496587|NCT02994810|Other|Breastfeeding guidance|Breastfeeding guidance
1496588|NCT02994784|Drug|Propylene Glycol-Free Melphalan Hydrochloride|Intravenous Propylene Glycol-Free Melphalan Hydrochloride
1496589|NCT02994771|Drug|Lymfactin® [1 x 10E10 vp]|Lymfactin® [1 x 10E10 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
1496590|NCT02994771|Drug|Lymfactin® [1 x 10E11 vp]|Lymfactin® [1 x 10E11 vp] will be administered as a single dose via perinodal injection in a volume of 2 mL.
1496591|NCT02994758|Other|Personalised treatment|Treatment based on NGS or DSRT
1496592|NCT02994745|Drug|Fimasartan, Atorvastatin|
1496593|NCT02994732|Drug|BVD-523|
1496594|NCT02994719|Drug|Anti-Parkinson medication|During the optional second visit subjects with neurological disease and already on anti-parkinson medication are asked to come off their anti-parkinson medication.
1496595|NCT02994719|Device|Deep Brain Stimulation|During the optional second visit subjects with neurological disease already treated with deep brain stimulation are asked to come temporarily stop deep brain stimulation and resume stimulation, with walking trials done in each condition.
1496596|NCT02994706|Procedure|Home Monitoring|Participants selected to receive home monitoring, in addition to routine CF care, will be given a digital lung function monitor (spirometer) and a modified mobile phone.
1496597|NCT02994706|Other|Clinical Care|Participants selected for this arm will continue to receive routine clinical care.
1496598|NCT02994693|Device|OFDI capsule imaging|Imaging of Barrett's esophagus (BE) using OFDI capsule imaging
1496599|NCT02994680|Device|Three-burner LPG stove|The intervention arm will receive a three-burner LPG stove upon enrollment. The control arm will receive the stove one year after enrollment.
1496600|NCT02994680|Other|Delivery of LPG tanks|One year supply of LPG fuel, in the form of delivery of 20 kg tank that holds 10 kg of LPG. Delivered to homes.
1496601|NCT02994680|Other|Vouchers for LPG tanks|One year supply of LPG, in the form of vouchers to obtain a free LPG tanks from a distribution center. (Beginning one year after enrollment, for one year)
1496602|NCT02994628|Other|Water|Water only without carbohydrate
1496603|NCT02994628|Other|Mini banana|Ingest mini banana containing higher phenolics and carbohydrate concentration
1496604|NCT02994628|Other|Cavendish banana|Ingest Cavendish banana (common banana)
1496605|NCT02994628|Other|6% sugar beverage|Ingest 6% sugar beverage containing same glucose and fructose profile as banana
1496606|NCT02994602|Drug|Nestorone + Testosterone Combination Gel|The combined gel is a transdermal treatment that will be applied as three single applications to a male subject's arms and shoulders on three different treatment days. The formulation will be a hydro alcoholic gel containing about 1.43% T (14.3 mg T/g gel). About 9 to 14% of the steroid (T or NES) in the gel applied is available to the body. The amount of gel to be applied each application will be approximately 5 mL in volume. The gel application volume will contain 62.5 mg of T that will deliver approximately 6 mg T to the body per day (Swerdloff et al., 2000; Wang et al., 2000). This gel volume will also contain 8.3 mg of NES that will deliver about 0.8 mg of NES to the body per day (NES 8 mg/d + T 60 mg/d (NES8/T60) gel).
1496607|NCT02994589|Other|Tegaderm™(Absorbant, 3M)|3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.
1496608|NCT02994589|Device|OASIS® wound matrix|OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).
1496609|NCT02994589|Other|Xeroform™|Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
1496610|NCT02994576|Drug|Atezolizumab|Atezolizumab, 1200 mg administered I.V. once
1496611|NCT02994563|Device|Thrombectomy Device|The Amnis Thrombectomy Device is intended to restore blood flow by removing thrombus from intracranial vessels in patients experiencing ischemic stroke
1496612|NCT02994550|Drug|FSH/LH|
1496613|NCT02994537|Other|Different biochemical results or pathogenesis.|Comparing the pathogenesis,clinical characteristics and treatment effects between the acute autoimmune hepatitis group and the chronic autoimmune hepatitis group. The investigators don't use special intervention.
1496614|NCT02994524|Procedure|Rerouting technique for transsphincteric perianal fistula|
1496615|NCT02994498|Drug|DCB-BO1301|1, 2, or 3 capsules, three times a day, oral, at most 48 weeks
1496616|NCT02994485|Drug|Simvastatin|Simvastatin 20 mg/day for two weeks (increased to 40 mg/day at day 15) for another two weeks plus the routine treatment
1496617|NCT02994485|Other|Placebo|Placebo
1496618|NCT02994472|Radiation|Gastric emptying scintigraphy using 99mTc-DTPA|
1496619|NCT02994446|Device|Saline-Enhanced Radiofrequency Catheter and Ablation System|Ablation of ventricular tachycardia with a saline-enhanced radiofrequency ablation catheter
1496620|NCT02994433|Drug|Nitrous Oxide|Nitrous oxide, an odorless, colorless gas typically used as an induction agent for general anesthesia or for dental sedation, is a known N-methyl-D-aspartate (NMDA) antagonist. It will be given at 50% nitrous oxide/50% oxygen in this study.
1496621|NCT02994433|Drug|Placebo gas|Placebo gas given at 50% nitrogen [inert]/50% oxygen.
1496622|NCT02994433|Device|MRI|MRIs done on all participants, this is a tool we are using to measure outcomes. No treatment is from an MRI.
1496623|NCT02994407|Drug|turoctocog alfa pegol|"Part A: Participants will receive a single dose of turoctocog alfa pegol, administered subcutaneously (under the skin), at a dose of 12.5, 25 or 50 U/kg.
Part B: Participants will receive a daily dose of turoctocog alfa pegol, as identified in Part A, as a subcutaneous (under the skin) injection for a period of 3 months."
1496625|NCT02994381|Drug|RPC1063|
1496626|NCT02994368|Other|Observation|
1496627|NCT02994355|Other|Systems Analysis and Improvement Approach|"Understanding the cascade from FP clinic enrollment to HIV testing
Use process mapping to identify modifiable bottlenecks
Define and implement workflow adaptations to eliminate modifiable bottlenecks
Monitor change in performance
Repeat the analysis and improvement cycle (steps 1-4)"
1496628|NCT02994342|Device|Vaginal gel, Medical Device Class 2A|Application twice a day of vaginal gel for 56 consecutive days
1496629|NCT02994329|Device|OraQuick® HIV Self-Test (Orasure Technologies, Thailand)|All individuals aged 16 and above who are approached by community health workers conducting door-to door HIV testing will be offered the choice to use an oral HIV self test kit or to have standard of care finger-prick rapid HIV testing
1496630|NCT02994316|Other|Copeptine dosage in children with diabetic ketoacidosis at diagnosis|Blood collection of 3 mL for copeptin dosage will be taken at different times in the first hours of management of diabetic ketoacodosis in children under the age of 16 years
1496631|NCT02994290|Drug|HPV vaccine|After the vaccine is administered (or the patient declines the vaccine), a member of the research team (RA) will approach eligible postpartum women and invite them to participate in individual in-depth interviews.
1496632|NCT02994290|Behavioral|Inpatient Postpartum HPV Immunization Quality Improvement Program|"The program coordinator (PC) will screen electronic medical records of Women's Center patients admitted to the inpatient postpartum service for IPP-HPV eligibility: women ≤ 26 years of age who have not received all 3 doses.
Nurses and providers in the Women's Center will be encouraged to discuss the HPV vaccine during prenatal care and recommend postpartum immunization to vaccine eligible women.
All patients will be provided with a Vaccine Information Sheet as is required by law. A postpartum nurse will then administer the HPV vaccine as routine care prior to discharge (unless the patient refuses). A postpartum provider will be available to answer any questions or concerns as needed."
1496633|NCT02994277|Device|1° Phase: UVa algorithm 2° Phase: ITBA/UNLP algorithm|The UVa algorithm is an already established mathematical model that can be programmed in DiAs software to manage glycaemia in T1DM through a subcutaneous insulin pump and a continous glucose monitoring. This algorthm works on a meal announcement basis and will be tested during the first phase of the trial. The ITBA/UNLP algorithm is a new development with safety mechanisms improved and without need of meal anouncement. This algorithm will be tested during the second phase of the trial.
2001910|NCT02665468|Behavioral|Active comparator control|The investigators will use an attention control (a control intended to balance the attention Veterans receive from the facility mailings and to enhance masking of intervention versus control). As an attention control must not have information about the intended intervention, the investigators will mail out general wellness information available on the VHA National Center for Prevention
2001911|NCT02660957|Behavioral|self-determination smoking cessation|a self-help quitting leaflet plus a series of brief interventions using the AWARD model
2001912|NCT02660957|Other|placebo comparator|suggest a healthy life style as a placebo comparator
1496638|NCT02994238|Device|Remote Health Management Sensor Platform|The Propeller sensor monitors the use of inhaled medications, capturing the date, time, and number of uses. The sensor then transmits this information using Bluetooth to a paired smart phone or hub. Data can be uploaded to the caregiver's smart phone and to the patient's web portal, which their healthcare team will have access to help overall management.
1496639|NCT02994225|Drug|Indocyanine Green|"Subcutaneous injection (1 ml) of the indocyanine green into the ipsilateral upper extremity 10 min before the surgery.
Near Infra-red images acquisition is performed during surgery"
1496640|NCT02994212|Dietary Supplement|Monthly distribution of RUTF|115 children eligible for the outpatient treatment of SAM were provided a monthly ration of RUTF.
2001913|NCT02659930|Drug|liposomal doxorubicin|liposomal doxorubicin IV day 1 of a 28-day cycle
1496642|NCT02994186|Procedure|Bariatric Surgery|These are patients who will be having either Vertical Sleeve Gastrectomy or Roux-en-Y Gastric Bypass.
1496643|NCT02994186|Other|Medical Weight Loss Program|These are patients who will be starting a structured medical weight loss program.
1496644|NCT02994173|Drug|Oxycodone|Current clinical practice, used as a control in this study
1496645|NCT02994173|Drug|S-Ketamine 0.25|dosage
1496646|NCT02994173|Drug|S-Ketamine 0.5|dosage
1496647|NCT02994173|Drug|S-Ketamine 0.75|dosage
1496648|NCT02994160|Other|FastLIFE electrode|Implant temporary FastLIFE electrodes and record the nerve signals that control delicate finger motions and play back the nerve signals that give the hand feelings of touch and movement.
1496649|NCT02994147|Drug|Placebo|Placebo-only control study medication is the same formulation as active treatment without active ingredient
1496650|NCT02994147|Drug|AC-201CR|The investigational product is formulated as controlled-release (CR) tablets
1496651|NCT02994134|Behavioral|Moderate intensity exercise.|Moderate intensity aerobic exercise intervention (delivered at 55-64% age-predicted maximal heart rate), 4 times per week for 4 weeks.
1496652|NCT02994134|Behavioral|High intensity exercise.|High intensity aerobic exercise intervention (delivered at 65-90% age-predicted maximal heart rate), 4 times per week for 4 weeks.
1496653|NCT02994108|Behavioral|Txt2Protect|Text messages sharing HIV/STI prevention information with a focus on HPV infection and vaccination.
1496654|NCT02994108|Behavioral|Sexual Health Knowledge Control|Text messages sharing HIV/STI prevention and healthy relationship building information, including information about HPV infection and vaccination.
1496655|NCT02994095|Behavioral|Pilot Study|Trained community health agents used Motivational Interviewing-based counseling and action planning in monthly home visits with adults with diabetes
1496656|NCT02994082|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smokeless tobacco cessation combined with supplemental treatment modules based on individual need and preferences.
1496657|NCT02994082|Behavioral|Behavioral activation for elevated depressive symptoms|Participants with elevated depressive symptoms may receive this six session telephone-based behavioral activation intervention.
1496658|NCT02994082|Behavioral|Post-cessation weight gain management|Participants with concerns about gaining weight after quitting smokeless tobacco use may receive this six session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
1496659|NCT02994082|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six session telephone-based behavioral intervention for reducing alcohol use.
1496660|NCT02994082|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be based on individual participant preferences, medical history, and contraindications.
1496661|NCT02994082|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be based on individual participant preferences, medical history, and contraindications.
1496662|NCT02994082|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be based on individual participant preferences, medical history, and contraindications.
1496663|NCT02994082|Drug|Bupropion sustained release|Medication selection will be based on individual participant preferences, medical history, and contraindications.
1496664|NCT02994082|Drug|Varenicline|Medication selection will be based on individual participant preferences, medical history, and contraindications.
1496665|NCT02994082|Drug|Combination nicotine replacement therapy|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + nicotine lozenge and nicotine patch + nicotine gum.
1496666|NCT02994082|Drug|Combination nicotine replacement therapy + bupropion|Medication selection will be based on individual participant preferences, medical history, and contraindications. Possible combinations include nicotine patch + bupropion, nicotine gum + bupropion, and nicotine lozenge + bupropion.
1496667|NCT02994082|Behavioral|Tobacco quit line|Referral to the Department of Veterans Affairs tobacco telephone quit line.
1496668|NCT02994082|Behavioral|Educational materials|Information regarding the VA tobacco quit line and associated treatment services, self-help materials for tobacco cessation, and information about tobacco cessation medications available in the VA,
1496669|NCT02994069|Drug|Cisplatin|Cisplatin
1496670|NCT02994069|Radiation|XRT|Radiation Therapy
2001914|NCT02659930|Drug|pomalidomide|pomalidomide once a day, days 1- 21 of a 28-day cycle, at the dose levels described in dose escalation plan
2001915|NCT02658084|Drug|Vinorelbine|Administered as an intravenous infusion on Day 1 and Day 8 of every 21-day cycle.
1496673|NCT02994043|Behavioral|Mindfulness Plus Relapse Prevention Therapy|
2001916|NCT02658084|Drug|Trastuzumab Emtansine|Administered as an intravenous infusion on Day 1 of every 21-day cycle.
1496675|NCT02994017|Other|cardiopulmonary exercise testing|The Cardiopulmonary exercise testing (CPET) was performed at the beginning of the study, the same at each center. Each patient underwent a symptom-limited incremental exercise test on an ergometric bicycle (Ergoline-Ergometrics 800®). The protocol included a warm-up period of 3 min at 20 W followed by a progressively increasing work rate (WR) in a ramp fashion and then 3 min recovery. The ramped WR increment was individualized (range,8-30 W/min). during exercise, heart rate (HR) was monitored continuously by 12-lead ECG, and arterial oxygen saturation (SpO2) was measured by pulse oximetry (Nellcor N-395). The expired gases were analyzed with an Ergocard®, focusing on oxygen consumption(VO2), carbon dioxide production (VCO2), minute ventilation (VE), and tidal volume (VT).
1496676|NCT02994004|Other|no intervention|
1496677|NCT02993991|Drug|Mocetinostat|Mocetinostat (MGCD0103) is a potent small molecule HDAC inhibitor that targets human HDAC isoforms. It is an orally bioavailable, second generation benzamide inhibitor of HDAC 1, 2, 3 and 11 with broad spectrum antitumor activity in vitro and in vivo.
1496678|NCT02993991|Biological|Durvalumab|Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against human PD-L1. It is selective for recombinant PD-L1 and blocks the binding of recombinant PD-L1 to the PD-1 and CD80 receptors.
1496679|NCT02993965|Other|Vaccine Reminder/Recall|The investigators will be sending recall notices via phone call or postcard to 11-17 year olds or 11-14 year olds who are eligible but lacking HPV vaccine doses recorded in the Colorado Immunization Information System (CIIS). The investigators will be testing the effectiveness and cost effectiveness of up to 3 notices per dose with usual care (no intervention) for bringing children 11-17 years old up to date on HPV vaccination. They will also be testing the effectiveness and cost effectiveness of using mail vs. phone call reminder notices (as compared to no intervention) for bringing 11-14 year olds up to date on HPV vaccination.
1496680|NCT02993952|Device|Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode. A constant current of 2mA will be applied for 20 minutes.
1496681|NCT02993952|Device|Sham Transcranial Direct Current Stimulation|For electrode placement, the criteria used by the 10/20 electroencephalography system will be obeyed and the electrodes will be positioned area C3 for the anode and Fp2 (contralateral supraorbital area) for the cathode electrode, but the stimulator was turned off after 30 seconds of stimulation. Therefore, patients in the sham group felt the initial itching sensation but received no current for the rest of the stimulation period.
1496682|NCT02993939|Procedure|Interscalene block|Ultrasound guided single shot block above the clavicle
1496683|NCT02993939|Procedure|Infraclavicular-suprascapular block|Combined block of nerves far away from phrenic nerve
1496684|NCT02993926|Drug|Leuprorelin|Leuprorelin suspension for injection
1496685|NCT02993913|Drug|Simmiparib|Simmiparib Tablets, oral administration
1496686|NCT02993900|Device|Image-Guided Brachytherapy|Brachytherapy will be precisely inserted with the assistance of magnetic resonance (MRI) scans
1496687|NCT02993887|Behavioral|Resourcefulness Training|This intervention will include a one time face to face instruction on Resourcefulness Training that entails 8 self-help and help-seeking skills plus viewing short video vignettes of caregivers describing application of the resourcefulness skills. In addition, participants will use daily journaling to describe application of the resourcefulness skills in their daily caregiving with their technology-dependent child.
1496688|NCT02993887|Behavioral|Mindfulness|The mindfulness intervention will include the use of an app daily via Stop, Think, Breathe.
1496689|NCT02993874|Dietary Supplement|Creatine|The experimental group will ingest for seven days (Loading - phase 1), 5g (4x/day) of creatine monohydrate associated with the clinical treatment (30-45 minutes of walking, 3 times a week). Subsequently, they will ingest for 49 days (Maintenance - phase 2), 3g (1x / day) creatine monohydrate associated with clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
1496690|NCT02993874|Dietary Supplement|Placebo|The placebo group will ingest for seven days (Loading - phase 1), 5g (4x / day) of dextrose associated to clinical treatment (30-45 minutes of walking, 3 times per week). Subsequently, they will ingest for 49 days (Maintenance phase 2), 3g (1x / day) of dextrose associated with the clinical treatment (30-45 minutes of walking, 3 times a week). They will be given guidance by telephone, so that they can reach the necessary recommendations for the study.
1496691|NCT02993861|Other|Anti-epileptics|
1496692|NCT02993848|Other|No intervention|
1496693|NCT02993835|Other|Labeled iron salt Fe54|Fe salt enriched with Fe 54 isotopes
1496694|NCT02993835|Other|Labeled iron salt Fe57|Fe salt enriched with Fe 57 isotopes
1496695|NCT02993835|Other|Labeled iron salt Fe58|Fe salt enriched with Fe 58 isotopes
1496696|NCT02993822|Drug|Orvepitant Maleate|Tablet, once daily, oral
1496697|NCT02993822|Drug|Placebo|Tablet, once daily, oral
1496698|NCT02993809|Biological|BM-ECs and PRPE|
1496699|NCT02993809|Biological|BM-ECs|
1496700|NCT02993783|Drug|Vedolizumab|Vedolizumab intravenous infusion
1496701|NCT02993770|Procedure|Endoscopic DCR|Endonasal endoscopic technique as described by Wormold et al.
1496702|NCT02993770|Procedure|External DCR|External DCR
1496703|NCT02993757|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, Month 6 and 12, respectively
1496704|NCT02993757|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Month 1, 7 and 13, respectively
1496705|NCT02993757|Biological|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, intramuscular at Day 0 and Month 6, respectively
1496706|NCT02993757|Biological|Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.|0.5 mL, intramuscular at Day 0 and Month 6, respectively
1995777|NCT02655445|Procedure|Mini-craniotomy|chronic subdural hematoma evacuation through minicraniotomy
1995778|NCT02655445|Procedure|Twist Drill Craniostomy|chronic subdural hematoma evacuation through twist drill craniostomy
1497153|NCT02990533|Dietary Supplement|Protein Supplement|
1496710|NCT02993718|Drug|Dexmedetomidine|As a loading dose, 0.5 μg/kg dexmedetomidine was administered over 10 min, which was then administered continuously at a dose of 0.2-0.8 μg/kg/h. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
1496711|NCT02993718|Drug|Propofol|Propofol was infused continuously via a target-controlled infusion device, and the effect-site concentration was maintained with a range of 0.5-2.0 μg/ml. Sedation was maintained at modified observer's assessment of alertness/sedation scale 3
1496712|NCT02993705|Drug|Trabectedin|
1496713|NCT02993692|Device|Direct laryngoscopy and fiberoptic bronchoscopy|These devices is used in endotracheal intubation and tonopen for measuring of intraoculer pressure. I want to see whcih is better.
1496714|NCT02993679|Procedure|reconstruction of the ACL and anterolateral ligament|reconstruction of the ACL and anterolateral ligament
1496715|NCT02993666|Device|Bair Hugger|forced air warming with Bair Hugger air warmer
1496716|NCT02993653|Radiation|High-dose Intensity-modulated radiotherapy|Pelvic High-dose Intensity-modulated radiotherapy with stereotactic radiotherapy or intracavitary radiotherapy
1496717|NCT02993640|Drug|vasopressin + nitro|vasopressin infusion 4,8 U/h for 20 minutes, thereafter nitroglycerine infusion to a MAP of 60 for 5 minutes.
1496718|NCT02993627|Dietary Supplement|Spirulina|2 g(4* 500 mg tablets) daily intake of Spirulina Platensis
1496719|NCT02993627|Other|diet therapy|low calorie diet (-500 or -300 kcal) composed of 55% carbohydrate, 15% protein and 30% fat
1496720|NCT02993601|Device|Heartfelt-1|The patients will stand in front of the Heartfelt-1 in order for images to be captured and the volume of their lower legs measured.
1496721|NCT02993601|Device|Weighing scales|The patient will be asked to stand on standard medical weighing scales, to measure their weight.
1496722|NCT02993601|Other|Medical grading of oedema|A member of the research team will assess the severity of the peripheral oedema on a scale of 1-5.
1496723|NCT02993601|Other|Baseline assessements|At the point study participants are recruited, their age, sex, diagnosis, aetiology of heart failure, LVEF (Left ventricular ejection fraction), medical and device therapy, time since diagnosis, BNP (B-type Natriuretic Peptide), CRP (C-Reactive Protein), renal function (EGFR), Haemoglobin, albumin and urinalysis will be assessed unless recent (less that 6 months old) results are available. The number of Heart failure hospital admissions in the last 2 years, LACE score, co-morbidities will also be noted.
1496724|NCT02993601|Device|Water displacement method|This will involve filling a gauge with lukewarm water (27-35oC +-2oC) up to the appropriate level. The appropriate level is determined by the water stabilising after some has flown out of the gauge into the waste bucket. Once the water level is stable the patient, who is sitting on a chair will be gently plunging the foot (naked) in the gauge until their foot is flat on the bottom on the gauge. The water flowing out of the gauge into the measuring bucket will be collected until the flow of water stops. Four small marks with non-toxic /non-permanent pen will be made on the lower leg of the patient to indicate where the water level was at. The water which has been collected in the measuring bucket will be weighted with precision scales to determine the volume of water displaced by the insertion of the foot. The patient's foot will then be dried.
1496725|NCT02993601|Device|Callipers measurements|This will involve making 4 marks on one of the foot/lower leg (small cross) using non-toxic / non- permanent pen. The measurement will consist of making 6 measurements between those marks using callipers, and reporting the distance on a calibrated tape.
1496726|NCT02993601|Device|Measuring tape|The measurements taken using a medical tape measure will involve the circumference of the ankle to be measured as well as the circumference at the level of the arch of the foot. The medical tape used will be a CE marked disposable medical measuring tape to minimise the risk of infection. The measurements will be done on both feet.
1496727|NCT02993588|Drug|Melatonin|Melatonin 6 mg tablet once daily
1496728|NCT02993588|Other|Placebo|one tablet once daily
1496729|NCT02993575|Drug|Flucloxacillin|Dose according to summary of product characteristics (SPC) or local protocols: intermittent and continuous infusion
1496730|NCT02993562|Drug|Levothyroxine|Normal treatment with levothyroxine.
1496731|NCT02993536|Other|Biospecimen Collection|
1496732|NCT02993523|Drug|Venetoclax|Tablet
1496733|NCT02993523|Drug|Azacitidine|Solution for subcutaneous or intravenous administration
1496734|NCT02993523|Drug|Placebo|Tablet
1496735|NCT02993510|Procedure|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
1496736|NCT02993510|Device|Chondro-Gide sutured|Implantation of Chondro-Gide membrane using atraumatic sutures following microfracture via mini-arthrotomy
1496737|NCT02993510|Device|Chondro-Gide glued|Implantation of Chondro-Gide membrane using Fibrin glue following microfracture via mini-arthrotomy
1496738|NCT02993497|Device|Infrared camera|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an Infrared camera.
1496739|NCT02993497|Device|RVM(Respiratory Volume Monitor)|In patients undergoing spinal anesthesia, the respiratory parameters are measured using an RVM(Respiratory Volume Monitor).
1496740|NCT02993484|Drug|Dimethyl Malonate|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
1496741|NCT02993484|Biological|Ischemic preconditioning|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
1496742|NCT02993484|Other|Ischemia reperfusion|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
1496743|NCT02993484|Other|Sham|Heart tissue will be obtained from patients undergoing heart surgery. The tissue will be used to test the properties of ischemia and different cardioprotective interventions.
1496744|NCT02993471|Drug|Drug Cocktail|Administered orally
1496745|NCT02993471|Drug|Ixekizumab|Administered SC
1496746|NCT02993458|Other|DASH diet|DASH style diet rich in fruits, vegetables, and low‐fat dairy foods and low in saturated fat and total fat
1497019|NCT02991586|Behavioral|Dialectical Behaviour Therapy|Group of families
1496747|NCT02993458|Other|Low Na diet|Sodium intake of 1500 mg/d (65 mmol, or 0.75 mg/Kcal/d), representing the Adequate Intake recommended by the Institute of Medicine.
1496748|NCT02993458|Other|High Na diet|Sodium intake of 3500 mg/d (152 mmol, or 1.73 mg/Kcal/d, representing the highest sodium intake used for adults in the DASH Sodium trial.
1496749|NCT02993458|Other|Usual Diet|The usual diet will include foods that provide the majority of energy for adolescents in the U.S., i.e. grain based desserts, pizza, sugary drinks,pasta, chicken, and chicken mixed dishes.
1496750|NCT02993445|Other|Alternate Nostril Breathing|
1496751|NCT02993445|Device|Foot Reflexology|
2001917|NCT02657304|Behavioral|Coaching group|patients will have a medical consultation at 2 weeks post-diagnostic and one phone call/month for duration of 5 months. The consultations will use visual support, CPAP device and its accessories.
2001918|NCT02657304|Other|Control group|patients receive only usual care (standard), it's mean: diagnosis with explanation of the disease and benefit of CPAP, entrusts a medical device provider, then an appointment proposed by the doctor or taken by the patient (5 months).
1496754|NCT02993419|Drug|Bacillus licheniformis Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of experimental drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
1496755|NCT02993419|Other|placebo Intervention|On the basis of the use of antibiotics in children with symptomatic treatment, the addition of placebo drugs 1 bag each time, three times a day, for taking seven days; children observed during the test is no longer taking other probiotic preparations, and any other proprietary Chinese medicine preparation
1995779|NCT02655445|Procedure|Burr Hole Craniostomy|chronic subdural hematoma evacuation through burr holes
1995780|NCT02655289|Device|Modulated TENS|"Frequency: 100 Hz
Intensity: individual; TENS should be clearly perceptible but not painful; impulse width is coupled with intensity
Mode: intensity modulation (40% decrease every 0.5 seconds)
TENS device: ARTROSTIM® SELECT
Channels: 2
Electrodes: 4 (5x5cm), placed on site of pain (a little more proximal if allodynia is present)"
1995781|NCT02655289|Device|Placebo TENS|"Frequency: 100 Hz (conventional for High TENS; Placebo is achieved by reduction of intensity, see below)
Intensity: The device is on and will be up-regulated together until the first sensation is perceptible. Then the activated device will be down-regulated minimally (no sensation perceptible) and this configuration will be retained.
Mode: continuous
TENS device: ARTROSTIM® SELECT
Channels: 2
Electrodes: 4 (5x5cm), placed on site of pain (a little proximal if allodynia is present)"
1496760|NCT02993380|Dietary Supplement|Stir-fried olive oil group|Stir-fried olive oil group taking food with extra-virgin olive oil in stir fried food or any food with olive oil in heated under 150 degrees of celsius minimal dose per week is 30gram, providing amount of olive oil with meals is 10gram, three times in a weeks
1496761|NCT02993380|Dietary Supplement|Natural olive oil group|Natural olive oil group taking food with extra-virgin any food with olive oil in , minimal dose per week is 30grams, providing amount of olive oil with meals is 10gram, three times in a weeks
1496762|NCT02993367|Drug|Butylphthalide Soft Capsules|DL-3-n-butylphthalide (NBP) (Fig. 1) is a synthetic chiral compound containing L- and D-isomers of butylphthalide.Butylphthalide Soft Capsules is the oral preparation.
1496763|NCT02993367|Drug|Placebo Butylphthalide Soft Capsules|
1496764|NCT02993354|Device|The EUM300 (electrical uterine myography)|External monitor intended for the evaluation of electrical signals originating in the uterus, thus providing a tool for measuring uterine activity as well as fetal heart rate.
1496765|NCT02993341|Drug|Tranexamic Acid|
1496766|NCT02993341|Other|Saline Wash|
1496767|NCT02993328|Drug|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
1496768|NCT02993328|Drug|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
1496773|NCT02993289|Other|Different well-known treatments|
1496774|NCT02993276|Device|Neurocap®|NEUROCAP®, a bioresorbable nerve capping device based upon the NEUROLAC® nerve guide, is indicated to protect a peripheral nerve end and to separate the nerve from surrounding environment to reduce the development of a symptomatic neuroma.
1496775|NCT02993263|Device|VectraplexECG System with CEB®|The device will be used after noncardiac surgery
1496779|NCT02993237|Drug|DRV/COBI FDC placebo tablet|Participants will receive 1 placebo tablet matching the DRV/COBI 800/150 milligram (mg) FDC
1496780|NCT02993237|Drug|D/C/F/TAF FDC placebo tablets|Participants will receive 1 placebo tablet matching the D/C/F/TAF 800/150/200/10 mg FDC.
1496781|NCT02993224|Drug|deferasirox dispersable tablet (DT)|"DT will be provided as 125 mg, 250 mg, 500 mg dispersible tablets for oral use. The required number of DT should be stirred into water, apple juice or orange juice until fully dissolved once a day before 12 PM on empty stomach. The starting dose on Baseline Day 1 would be as following:
Deferasirox DT of 20 mg/kg/day in transfusion-dependent thalassemia (TDT)
Deferasirox DT of 10 mg/kg/day in non- transfusion-dependent thalassemia (NTDT),"
1496782|NCT02993224|Drug|deferasirox film coated tablet (FCT)|"FCT will be provided as 90 mg, 180 mg, 360 mg dispersible tablets for oral use. FCT should be taken once a day before 12 PM with or after light meal. If there is difficulty in swallowing, pill may be crushed and sprinkled over soft food. The starting dose on Baseline The equivalent FCT starting dose on Week 25 is:
Deferasirox FCT of 14 mg/kg/day in transfusion-dependent thalassemia (TDT)
Deferasirox FCT of 7 mg/kg/day in non- transfusion-dependent thalassemia (NTDT)."
1496783|NCT02993211|Device|Bipolar transurethral standard resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
1496784|NCT02993211|Device|Bipolar transurethral en bloc resection|Olympus TURis Bipolar HF-resection electrode (Model: WA22306D)
1496785|NCT02993198|Drug|Carvedilol|
1496826|NCT02992925|Biological|Hib vaccine|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
1497020|NCT02991573|Device|Prime & Bond Universal|Prime & Bond Universal
1496786|NCT02993185|Behavioral|Your Move|"Your Move (YM) is an interactive sex education intervention. Groups of girls are randomly assigned to YM or Eat Smart (ES), a control interactive nutrition education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months and 9 months after the program ends."
1496787|NCT02993185|Behavioral|Eat Smart|"Eat Smart (ES) is an interactive nutrition education intervention. Groups of girls are randomly assigned to ES or Your Move, an interactive sex education intervention. Each program consist of seven 75-minute sessions, and each session contains 60 minutes of facilitator-led discussion, video clips, activities, and games as well as 15 minutes of personal reflection time during which girls practice the decision making skills they have learned. Participants complete online surveys about their attitudes, knowledge, and behavior related to food and nutrition and relationships and sex at baseline and also 3 months and 9 months after the program ends."
2001919|NCT02654990|Drug|panobinostat capsules|20mg, 10mg or 15mg (for dose reductions only)
2001920|NCT02654990|Drug|bortezomib injection|1.3mg/m2 sub-cutaneous administration; Cycle 1-4: 2 weeks on/1 week off twice a week for patients <=75 years at time of screening; once a week for patient > 75 years Cycle 5+: once a week for all patients
2001921|NCT02654990|Drug|dexamethasone tablets|pre and 24h after BTZ administration; patients <= 75 years at time of screening: 20mg/dose patients > 75 years: 10mg/dose
2001922|NCT02653911|Other|Acupuncture|Hwato Brand, Suzhou Medical Appliance Factory, China
2001923|NCT02653911|Other|Sham-acupuncture group|Hwato Brand, Suzhou Medical Appliance Factory, China
1496798|NCT02993133|Drug|Cellcept® in autoimmune bullous dermatoses|The administration will follow the recommendations for the use of Cellcept® in autoimmune bullous dermatoses
1496800|NCT02993094|Drug|Ixazomib|Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
1496801|NCT02993094|Drug|Carboplatin|Cycles will be repeated every four weeks. Cycles will be repeated every four weeks. All subjects will continue on study drug until disease progression, unacceptable toxicity or treatment discontinuation for any other reason.
1496802|NCT02993068|Behavioral|Questionnaires|"Baseline questionnaires about decision-making, stress and anxiety, well-being, and genetic and cancer- risk knowledge.
Follow up questionnaires completed at 3 months, 1 year, and 2 years after having received the genetic test results."
1496803|NCT02993068|Behavioral|Genetic Video|Participants watch a welcome video, which will provide information about genetics, the genes and genetic mutations that will be tested, and possible test results.
1496804|NCT02993068|Behavioral|Genetic Counselor|Participants in Group C and Group D make an appointment with a genetic counselor before beginning the genetic testing process. Participants in Groups A and B provided with the option to speak to a genetic counselor if they want to, but will not be required to do so for this study.
1496805|NCT02993068|Genetic|Saliva Collection|Participants mailed an FDA-approved saliva collection kit from Color Genomics. A video on the website shows participant how to provide a large enough saliva sample.
1496806|NCT02993068|Behavioral|Genetic Counseling|Participants in Groups B and C need to make an appointment with a genetic counselor before viewing the genetic test results. Participants in Groups A and D are able to view results online without speaking to a genetic counselor, but will be given the option to speak to a genetic counselor if participant would like.
1496807|NCT02993068|Behavioral|Genetic Testing Results|Participants in Groups B and C need to make an appointment with a genetic counselor before viewing the genetic test results. Participants in Groups A and D are able to view results online without speaking to a genetic counselor, but will be given the option to speak to a genetic counselor if participant would like.
1496808|NCT02993055|Drug|Ulimorelin|
1496809|NCT02993055|Other|Placebo|
1496810|NCT02993042|Device|Robot-assisted gait training|Patients should use their belts (Harness) to support their weight when walking in equipment. In the first training session, the patient focuses on fitting and adapting the equipment and helps the patient learn. To minimize skin damage, the patient can wear a protector. The initial walking speed starts at 1.5km / h (0.42m / s) and can be increased gradually to 3.0km / h (0.83m / s) by increasing to 0.2km / h (0.06m / s) per session. The therapist provides appropriate visual and auditory instructions to allow the patient to participate as fully as possible in the walking cycle provided by the walking robot. The treatment time per session is 30 minutes except for the time of wearing and releasing.
1496811|NCT02993029|Drug|99Tc-MDP|99Tc-MDP 15mg in 100ml normal saline intravenously dripped every twice a week for 5 weeks, every 1weeks for 10 weeks, every 2weeks for 10 weeks, every 1 month for 6 months.
1496812|NCT02993029|Drug|Celecoxib|Celecoxib capsule 200mg qd by mouth.
1496813|NCT02993016|Procedure|patient-specific instruments|
1496814|NCT02993016|Device|The Signature™ Vanguard|
1496815|NCT02993016|Procedure|conventional instruments|
1496816|NCT02993016|Device|Vanguard PS(posterior stabilized)|
1496817|NCT02993003|Device|Nasopharyngeal probe|nasopharyngeal probe insertion
1496818|NCT02992990|Procedure|Bladder tumor biopsy|Bladder tumor biopsy performed at the time of the preoperative office flexible cystoscopic evaluation.
1496819|NCT02992977|Biological|AutoSynVax™ vaccine|AutoSynVax™ vaccine + QS-21 Stimulon® adjuvant
1496820|NCT02992964|Drug|Nivolumab|Nivolumab (also referred to as BMS-936558 or MDX1106) is a human monoclonal antibody (HuMAb; immunoglobulin G4 [IgG4]-S228P) that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor.
1496821|NCT02992951|Device|DACC-Coated Post Operative Dressing|
1496822|NCT02992938|Drug|Acetazolamide|
1496823|NCT02992938|Drug|Placebo Oral Tablet|
1496824|NCT02992925|Biological|DPT-IPV-Hib-High (Combined Vaccine)|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
1496825|NCT02992925|Biological|DPT-IPV-Hib-Low (Combined Vaccine)|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
1496827|NCT02992925|Biological|DPT-IPV|0.5mL, subcutaneous injection, 3 times with the 3-8weeks intervals then an additional injection after 6-13 months.
1496828|NCT02992912|Drug|Anti-PD-L1 antibody atezolizumab|1200 mg every 3 weeks
1496829|NCT02992912|Procedure|SABR|Hypofractionated SABR will be delivered at a dose of 45 Gy in 3 fractions of 15 Gy
1496830|NCT02992899|Other|gammaCore/electroCore|Vasal nerve stimulation (VNS) will be self-administered using the electroCore non-invasive VNS device. The intensity of the stimulus (the current amplitude) will be adjusted by the user, to the maximum tolerable level to ensure VNS without causing excessive pain (typically 10-30 V), the burst frequency to 5 kilohertz (kHz), and the envelope frequency to 25 Hz. These are the standard frequency settings that electroCore has demonstrated to be most effective in capturing the vagus nerve based on evoked potential studies. The duration of delivery will be 2 minutes, one minute into which the high-resolution positron emission tomography (HR-PET) scan will be conducted; following an additional 8 minutes, a second VNS delivery will be administered, after which another scan will be obtained.
1496831|NCT02992899|Other|Sham gammaCore/electroCore|Sham vasal nerve stimulation (VNS) will be self-administered using the electroCore non-invasive VNS device. The device will be programmed such that no actual power is delivered. The duration of delivery will be 2 minutes, one minute into which the HR-PET scan will be conducted; following an additional 8 minutes, a second sham VNS delivery will be administered, after which another scan will be obtained.
1496832|NCT02992886|Radiation|Preoperative radiation|Radiation treatment before surgery
1496833|NCT02992886|Drug|Raltitrexed|concurrent chemotherapy
1496834|NCT02992886|Procedure|Pelvic surgery|
1496835|NCT02992873|Device|Layperson allocated to start CPR and fetch nearest AED|Dispatching laypersons to fetch an AED and start CPR in out-of-hospital cardiac arrest
1496836|NCT02992873|Device|Layperson allocated to start CPR|Dispatching laypersons to start CPR out-of-hospital cardiac arrest
1496837|NCT02992860|Drug|JNJ-56022473|JNJ-56022473 will be supplied as a lyophilized product containing 100mg of active pharmaceutical ingredient (50 mg/mL after reconstitution with 2.0 mL sterile water for injection). The JNJ-56022473 dose administered will be dependent upon the subject's weight at baseline. The JNJ-56022473 dose should be adjusted in case the subject's weight changes by > 10%. JNJ- 56022473 will be administered in 250 mL IV infusion over approximately 180 minutes using an infusion pump.
1496838|NCT02992860|Procedure|Bone marrow analyses and CBC with differential|Bone marrow analyses and CBC with differential will be performed by a central laboratory. If the marrow cannot be aspirated, a biopsy should be performed.
1496839|NCT02992860|Other|Flow cytometry analyses|Characterization of LSCs and blasts (including CD123 and CD38 expression) will be performed as study-related analyses in the context of this protocol by central flow cytometry using bone marrow samples.
1496840|NCT02992860|Other|Central biobanking|Central biobanking of study samples (bone marrow, peripheral blood as well as a buccal swab) will be carried out in Dresden.
1496841|NCT02992860|Procedure|Histopathology analysis|A bone marrow biopsy is taken whenever it seems necessary to the investigator.
1496842|NCT02992860|Genetic|Cytogenetic analysis|The cytogenetic analysis with banding analysis (optional FISH) have to be performed at local labs. Therefore 2 - 5 ml of bone marrow will be collected and analysed.
1496843|NCT02992860|Procedure|Serum chemistry|For serum chemistry 15 ml (2 x 7,5 ml) of peripheral blood have to be collected.
1496844|NCT02992860|Procedure|Automated CBC|For CBC a minimum of 3 ml of peripheral blood have to be collected.
1496845|NCT02992860|Procedure|Pregnancy Test|Serum or urine pregnancy testing β-HCG with a sensitivity of at least 25 mIU/mL is to be done not more than 3 days prior to initiation of JNJ-56022473 in female patients with childbearing potential. Furthermore, serum or urine pregnancy testing has to be done after end of treatment (EoT) visit.
1496846|NCT02992847|Other|Unenhanced MRI|
1496847|NCT02992834|Biological|IL-2 pre-treated CD19 cells|IL-2 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
1496848|NCT02992834|Biological|IL-7/IL-15 pre-treated CD19 cells|IL-7/IL-15 stimulated, CD28-ζ-vector transfected T cells(TCRζ chimeric antigen receptor-T cell)， were administered at 1×106/kg by single infusion
1496849|NCT02992821|Procedure|Bed-side pocket size ultrasound imaging|
1496850|NCT02992821|Procedure|High frame rate tracking doppler|
1496851|NCT02992808|Drug|recombinant gonadotropins|
1496852|NCT02992808|Drug|HP-HMG|
1496853|NCT02992795|Device|BrainPulse|JanMedical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to tge brain motion using an array of sensors placed on the head.
1496854|NCT02992782|Behavioral|Standard Care|Home program of decongestive exercise and daily use of a compression sleeve
1496855|NCT02992782|Behavioral|Exercise and Compression Garment|Decongestive progressive resistance exercise using flat-knit garment and daily use of a compression sleeve
1496856|NCT02992782|Behavioral|Exercise and Adjustable Compression Wrap|Decongestive progressive resistance exercise using adjustable compression wrap and daily use of a compression sleeve
1496857|NCT02992756|Drug|Growth Factors|"one dose
1 mL of PRP obtained by PRGF Endoret"
1496858|NCT02992743|Genetic|Autologous genetically modified T Cells, NY-ESO-1ᶜ²⁵⁹T|Cytoreductive chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 1.
1496859|NCT02992730|Behavioral|No Intervention|No Intervention
1496860|NCT02992704|Drug|Peginterferon Alfa-2A|peginterferon alpha 2a 180mcg weekly for either 24 or 48 weeks
1496861|NCT02992691|Drug|20% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
1496862|NCT02992691|Drug|35% w/w sodium bicarbonate|Dentifrice containing 35% w/w sodium bicarbonate.
1496863|NCT02992691|Drug|50% w/w sodium bicarbonate|Dentifrice containing 20% w/w sodium bicarbonate.
1496864|NCT02992691|Drug|67% w/w sodium bicarbonate|Dentifrice containing 67% w/w sodium bicarbonate.
1496865|NCT02992691|Drug|0% w/w sodium bicarbonate|Dentifrice containing 0% sodium bicarbonate and 1450 parts per million (ppm) fluoride.
1496866|NCT02992678|Drug|Pentoxifylline|Pentoxifylline, 400 mg, 3 times daily by mouth the day before ERCP procedure. Subjects received up to a maximum of 3 doses.
1496867|NCT02992678|Drug|Placebo|Placebo, 400 mg, 3 times daily by mouth by mouth the day before ERCP procedure. . Subjects received up to a maximum of 3 doses.
1496868|NCT02992665|Drug|Ca Ionophore A23187|Sibling oocytes are to be randomized to artificially activated using Calcium ionophore in cases with severely compromized semen parameters
1496869|NCT02992665|Other|Placebo|Placebo is used to control Ca ionophore group
1496870|NCT02992652|Drug|Allopurinol|600 mg of allopurinol divided in two oral doses before the procedure (300 mg at 15 hours and 300 mg at 3 hours before ERCP)
1496871|NCT02992639|Behavioral|Control group|The participants who included in control group did not receive any treatment.
1496872|NCT02992639|Behavioral|Weight loss group|The participants who included in weight loss group followed a 12-week weight loss program consisting of a 300 kcal/day reduction of thier usual caloric intakes
1496873|NCT02992626|Other|Human-dog interaction|The tests are completed in the presence of a dog. Further, before starting the tests, the children have 15 minutes to interact with the present dog.
1496874|NCT02992626|Other|Stuffed toy dog|The tests are completed in the presence of a stuffed toy dog. Further, before starting the tests, the children have 15 minutes to play with the stuffed toy dog.
1496875|NCT02992613|Procedure|total knee arthroplasty with ultra-congruent (UC) insert|
1496876|NCT02992613|Procedure|total knee arthroplasty with posterior-stabilized (PS) insert|
1496877|NCT02992587|Other|CAF, Comprehensive assessment of frailty|CAF, Comprehensive assessment of frailty. A scoring system of the patients physical status. By smaller physical test of balance, strength and walking speed.
1496878|NCT02992574|Radiation|Post Mastectomy Radiation therapy|Post mastectomy radiotherapy to the chest wall and ipsilateral supra-clavicular fossa to a dose of 40 Gy in 15 fractions over 3 weeks
1496879|NCT02992561|Behavioral|FORNET (adapted version)|
1496880|NCT02992548|Drug|Pravastatin|
1496881|NCT02992535|Device|Intense Pulse Light Energy delivery (IPL)|
1496885|NCT02992509|Device|EMED detruset(TM) intravesical electrical stimulation|"There will be a total of 8 therapy sessions, each lasting 15 minutes. The sessions will be done in a serial fashion, 2 per week for 4 consecutive weeks. The electrical parameters utilized will be those previously determined to be appropriate for OAB and UUI. As the beneficial effect of electrical stimulation is dependent on a maximal level of stimulation, the stimulation voltage will be increased during the first minute of treatment until the maximum tolerated by the patient is established and then backed-off by 1-2 Volts. The therapy will continue for 15 minutes in total for each session. The VAS will be marked by the patient before each treatment session throughout the therapy period, and other questionnaires will be administered."
1496886|NCT02992496|Drug|Ketamine|
1496887|NCT02992496|Drug|Midazolam Hydrochloride|
1496888|NCT02992483|Drug|MIK665|MIK665
1496889|NCT02992470|Dietary Supplement|Hydrolyzed oyster extract|1 tablet of oyster extract t.i.d. for 8 weeks
1496890|NCT02992470|Dietary Supplement|Placebo|1 tablet of maltodextrin t.i.d. for 8 weeks
1496891|NCT02992457|Drug|Sofosbuvir|Sofosbuvir 400 mg daily.
1496892|NCT02992457|Drug|Ribavirin|Ribavirin 1000-1200 mg daily
1496893|NCT02992457|Drug|Pegylated-interferon alfa-2a|Pegylated interferon alfa-2a once weekly for 3 months
1496894|NCT02992457|Drug|Simeprevir|Olysio once daily.
1496895|NCT02992457|Drug|Daclatasvir|Dakla once daily for three months.
1496896|NCT02992444|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
1496897|NCT02992444|Other|Experimental adhesive strip|This is a strip of a newly developed adhesive.
1496898|NCT02992431|Behavioral|Participatory patient care planning|Intervention includes the patient activation questionnaire form, a visit to the nurse who conducts the measurements (blood pressure, waist measurement, weight and length) and a visit to the general practitioner who discusses and agrees with the patient about the treatment goals and follow-up resulting in the written PPCP.
1496899|NCT02992431|Other|Usual care|Usual care including standard disease specific follow-up with visit to general practitioner.
1496900|NCT02992418|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Month 1, 7 and 13, respectively
1496901|NCT02992418|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Month 1, 7 and 13, respectively
1496902|NCT02992418|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Month 1
1496903|NCT02992418|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly at Day 0
1496904|NCT02992405|Behavioral|FOCUS Resilience Enhancement Program|Each couple or family will have 10 weekly 75 minute sessions comprising the treatment protocol.Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the 10-week treatment is completed (T2).
1496905|NCT02992405|Behavioral|Waitlist (No Study Treatment)|Participants assigned to the Waitlist (No Treatment) group will receive the study intervention only after the 10 weeks of the immediate treatment phase has been completed. Questionnaires will be administered at baseline-before the immediate treatment phase (T1) and after the immediate treatment phase is completed (T2).
1496906|NCT02992392|Drug|Liposic|one eye of the participant recieved Lipoic
1496907|NCT02992392|Drug|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
1496908|NCT02992379|Device|pivot splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of selfcuring acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe.
1496954|NCT02992106|Other|EndoPAT|We will use the EndoPAT device to measure endothelial function, which is a non-invasive and innovative technique (peripheral pulse wave amplitude measurement).
1496955|NCT02992093|Other|all the indicators|BMI、WHR、FSH、LH、PRL、T、E2、TG、CHOL、LDL-C、HDL-C、FBG、OGTT、FINS、insulin release test、HOMA index、identification of metabolites
1496909|NCT02992379|Device|stabilizing splint|A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch . Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position. Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop . Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. intervention: pivot splint
1496910|NCT02992366|Procedure|implant placement|implant placement
1496911|NCT02992353|Procedure|Three-port pulmonary resection surgery|Three-port pulmonary resection surgery
1496912|NCT02992353|Procedure|Single-port or two-port surgery|Single-port or two-port pulmonary resection surgery
1496913|NCT02992340|Drug|Varlitinib|Per oral (PO) Varlitinib BID (starting dose at 200 mg BID)
1496914|NCT02992340|Drug|Cisplatin|On D1 and D8, every 3 weeks. Cisplatin (25 mg per square meter of body surface area) in 1 litre of 0.9% saline with 20 mmol of potassium chloride and 8 mmol of magnesium sulfate intravenous (IV) infusion for 2 hours, followed by 500 mL of 0.9% saline over 30 minutes before the administration of Gemcitabine
1496915|NCT02992340|Drug|Gemcitabine|All patients will receive Gemcitabine (1000 mg per square meter of body surface area) as a 30-minute infusion.
1496916|NCT02992314|Device|Metaqil™ Oral Rinse|Metaqil™ is a proprietary formulation of GRAS ingradients
1496917|NCT02992314|Device|Placebo|Placebo formulation with out the active ingredients
1496918|NCT02992301|Drug|Alirocumab|Injectable prescription medicine called a PCSK9 inhibitor.
2001924|NCT02653781|Behavioral|Realistic simulation|The students enrolled and selected according to the inclusion criteria will be randomized into two groups. The experimental group will experience the combined teaching methodology: dialogue-exhibition and realistic simulation.
2001925|NCT02653781|Behavioral|control group|The control group will have contents exposed solely from the dialogue-exhibition.
1496925|NCT02992275|Other|Neuromuscular electrical stimulation (NMES)|Participants will receive NMES to the hip abductors while performing strength training 3 times per week for 24 weeks
1496926|NCT02992275|Other|Multi-Modality Balance Intervention (MMBI)|Participants will attend a group balance class that focuses on movement and obstacle negotiation 3 times per week for 24 weeks
1496927|NCT02992262|Device|Point of care ocular ultrasound|
1496928|NCT02992236|Drug|VAS203|Infusion of NO-Synthase inhibitor VAS203
1496929|NCT02992236|Drug|Saline|Infusion of saline
1496930|NCT02992210|Genetic|4SCAR-GD2|
1496931|NCT02992197|Biological|Rotarix, dose 1|Rotarix, dose 1
1496932|NCT02992197|Biological|Rotarix, dose 2|Rotarix, dose 2
1496933|NCT02992197|Drug|Placebo (for Rotarix dose 2)|Sterile water to provide volume equivalent as a second dose of Rotarix
1496934|NCT02992184|Device|HCV RNA detection with Genedrive assay|
1496935|NCT02992184|Device|HCV RNA detection with RealTime HCV|
1496936|NCT02992171|Behavioral|care management by oncology nurses|The intervention employs a care management approach to facilitate provision of primary palliative care within existing oncology clinic structures. The intervention is deployed through a series of nurse-led encounters occurring before or after regularly-scheduled oncology clinic visits.
1496937|NCT02992158|Behavioral|behavioral activation|
1496938|NCT02992158|Behavioral|treatment-as-usual|psychotherapy (and potentially medication) as part of treatment-as-usual provided in a community mental health center
1496939|NCT02992132|Drug|Pimavanserin 34 mg|Pimavanserin 34 mg, tablet, taken as two 17 mg tablets, once daily by mouth
1496940|NCT02992132|Drug|Pimavanserin 20 mg|Pimavanserin 20 mg, tablet, taken as two 10 mg tablets, once daily by mouth
1496941|NCT02992132|Other|Placebo|Placebo, taken as two tablets, once daily by mouth
1496942|NCT02992119|Biological|RTS,S/AS01B Fractional dose|RTS,S/AS01B standard dose at Month 0 and Month 1 + RTS,S/AS01B fractional dose (1/5th dose) at Month 2.
1496943|NCT02992119|Biological|Double RTS,S/AS01E Fractional dose|A double dose of RTS,S/AS01E standard dose at Month 0 and Month 1 + a double dose of RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
1496944|NCT02992119|Biological|RTS,S/AS01E Standard dose|RTS,S/AS01E standard dose at Month 0, Month 1 and Month 2.
1496945|NCT02992119|Biological|RTS,S/AS01E + DHA-PIP+PQ Standard dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0, Month 1 and Month 2
1496946|NCT02992119|Biological|RTS,S/AS01E Fractional dose|RTS,S/AS01E standard dose at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) at Month 2.
1496947|NCT02992119|Biological|RTS,S/AS01E + DHA-PIP+PQ Fractional dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 and Month 1 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2.
1496948|NCT02992119|Biological|RTS,S/AS01E + DHA-PIP+PQ Fractional two-dose|RTS,S/AS01E standard dose + DHA-PIP+PQ at Month 0 + RTS,S/AS01E fractional dose (1/5th dose) + DHA-PIP+PQ at Month 2
1496949|NCT02992106|Other|Parental questionnaires|"We will provide parents with questionnaires depending on the age of their children:
Children aged 0-6 years old:
Questionnaire on socio-demographic characteristics
Dutch Eating Behaviour Questionnaire
Food Frequency Questionnaire
Ages and Stages Questionnaire
Strengths and Difficulties Questionnaire
Questionnaire on developmental milestones
Questionnaire on behaviour
Children older than 6 years:
Questionnaire on socio-demographic characteristics
Dutch Eating Behaviour Questionnaire
Food Frequency Questionnaire
Pediatric Quality of Life Questionnaire
Children's Behaviour Questionnaire in Dutch
Questionnaire on developmental milestones
Developmental Coordination Disorder Questionnaire
Strengths and Difficulties Questionnaire"
1496950|NCT02992106|Other|Blood sample|We will determine the following biochemical parameters: glucose, insulin, total cholesterol, LDL, HDL, triglycerides, uric acid, IGF-1, adiponectin, leptin, hs-CRP, IL-6, TNF-α and ICAM-1.
1496951|NCT02992106|Other|Urine sample|We will take a urine sample to evaluate the albumin to creatinin ratio.
1496952|NCT02992106|Other|Anthropometric measurements|We will measure weight, Height, hip, waist and neck circumference, blood pressure, 4-site skinfold measurements and BIA.
1496953|NCT02992106|Other|Ultrasound|We will do an abdominal ultrasound to measure the abdominal fat accumulation
1496956|NCT02992080|Biological|miRNAs isolation from blood samples of patients and control|Blood sample collection in specific PAXGene tubes
1496957|NCT02992054|Other|stimulating activities|
1496958|NCT02992041|Drug|VVZ-149 Injections|A novel analgesic drug candidate, VVZ-149 Injections shows dual antagonistic activity with moderate potency on glycine transporter type 2 (GlyT2, IC50=0.86 uM) and serotonin receptor 2A (5HT2A, IC50=1.3 uM), which are therapeutic targets for pain. GlyT2 inhibitors have been studied by many pharmaceutical companies as a well-known and promising analgesic candidate because of their role in inhibitory (glycine) modulation and regional specificity.
1496959|NCT02992041|Drug|Placebo|Same formulation and appearance with VVZ-149 Injections
1496960|NCT02992028|Drug|Intravenous Nutrition (Vitamins) injection|
1496961|NCT02992028|Drug|Intravenous Saline injection|
1496962|NCT02992015|Drug|Gemcitabine|Participants receive a one time IV dose of gemcitabine prior to having standard of care surgery.
2001926|NCT02653781|Behavioral|Simulation workshop|Check the performance of students in face of simulated situations on medication administration by intramuscular and intravenous routes experienced in the Skills and Care Simulation Laboratory.
1496964|NCT02991989|Behavioral|Exercise Snacking|"Each bout of exercise snacking consists of 5 exercise. Each exercise is performed for one minute, with aim of completing as many repetitions as possible of that exercise in that minute. One minute of rest is observed between each exercise of the exercise snack. The five exercises are; sit-to-stand from a chair, marching on the spot, seated knee extensions alternating legs, standing knee bends alternating legs, and standing calf raises. The sit-to-stand exercise is always performed first, with the number of repetitions achieved recorded, and subsequent exercises performed in any order without recording of repetitions.
Two exercise snacks are completed each day for 28 days; once in the morning and once in the evening, or at least separated by 2 hours."
1496965|NCT02991989|Dietary Supplement|Yogurt|Participants are asked to consume 150 g of yogurt (Arla, Skyr- natural flavour) with their breakfast meal. Participants may substitute the yogurt for another part of their regular breakfast, or add the yogurt to their regular breakfast, with participants asked to record a log book of daily yogurt consumption and to complete a three day food diary during the last week of the 28 day intervention period.
1496966|NCT02991976|Procedure|Oxygen concentration|Shunting, raising concentration of O2 because of improving regional cerebral oxygen saturation (rSO2), keeping blood pressure above 120-130 mmHg, positive end expiratory pressure (PEEP)
1496967|NCT02991963|Other|Interview|A survey will be included patient demographics, information on malaria treatment, bed net use and possible risk factors for acquiring malaria, as well as questions about their travel and usage of mobile phones
1496968|NCT02991963|Other|Blood collection (Dried Blood Spot)|Dried Blood Spot
1496969|NCT02991963|Other|Blood Collection (Venous Blood collection)|Venous Blood collection
1496970|NCT02991963|Other|Blood Smear|Slide blood smear
1496971|NCT02991950|Drug|Parnaparin Sodium|Parnaparin sodium ( Fluxum 4250 anti-Xa IU /0.4 mL or Fluxum 6400 anti-Xa IU /0.6mL; Alfa Wassermann S.p.A.) was administered at a dose of 100 IU/kg/day from the day before the beginning of the stimulation phase of the cycle until the result of the procedure was confirmed by pregnancy and, in the case of evolutive pregnancy, until delivery or the end of pregnancy
1496972|NCT02991937|Drug|Piperacillin/Tazobactam|24 hours of IV antibiotic administration
1496973|NCT02991937|Procedure|Surgical Treatment|Appendectomy
2001927|NCT02653781|Behavioral|Test realistic simulation|Occurs after the end of the three-month intervention. At that time, students from the control and intervention groups will be asked to take a knowledge retention test in cognitive assessment format and OSCE format (objective structured clinical examination).
2001928|NCT02652923|Drug|Sonazoid; Perflubutane for Injection|subdermal injection into the breast of Sonazoid (1 or 2 ml) divided into four individual aliquots at four locations (12, 3, 6, and 9 o'clock)
1496977|NCT02991898|Biological|Infusion of Treg|"Allopurinol on day -7 to day 0 Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 Fludarabine 30mg/m2 IV over 1 hour on day -6, -5, -4, -3, and -2 Total Body Irradiation 200 cGy as a single dose
Sirolimus 8mg-12mg oral loading dose followed by signle dose 4mg/day. Levels are to be monitored 3 times/week in the first week, weekly until day +60, and as clinically indicated until day +100 post-transplantation.
Mycophenolate Mofetil (MMF) 3 gram/day IV/PO divided in 2 or 3 doses. Stop MMF at day +30 or 7 days after neutrophil recovery, whichever day is later, if no acute GVHD.
DUCBT followed Tregs - double umbilical cord blood transplant (FIRST) followed by the Treg cell infusion (SECOND) no sooner than 1 hour, but within 24 hours after the 2nd cord blood infusion.
ULD IL-2 ultra-low-dose IL-2 200,000 IU/m2 SQ three times a week for 4 weeks beginning within 24 hours after Treg product infusion (but no sooner than 1 hour post-infusion)"
1496978|NCT02991885|Biological|HAL-MPE1|Weekly subcutaneous administrations of HAL-MPE1
1496979|NCT02991885|Drug|HAL-MPE1 placebo|Weekly subcutaneous administrations of HAL-MPE1 placebo
1496980|NCT02991872|Procedure|Blood draw|Subjects aged from ≥6 to ≤17 years at the time of enrolment in the parent clinical trial (following the CFDA post-marketing commitment requirement) and who received the full PEP rabies regimen as an intramuscular injection according to the vaccine group to which they were assigned in the V49_24 (NCT01680016) study will be invited to take part in this study. Single blood draw from subjects at Day-1/Visit-1. Subjects will be observed for 15 minutes after the blood draw.
1497015|NCT02991625|Other|Healthy Controls|Healthy control participants will not receive a placebo drug or be put on a waitlist.
1497016|NCT02991612|Drug|Rifaximin|Patients receive Rifaximin 400mg bid for 2 months
1497017|NCT02991599|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
1497021|NCT02991573|Device|Ceram X|
2001929|NCT02652559|Device|Transcutaneous measurements of PCO2|PCO2 will be measured transcutaneously with an ear lobe sensor before initiation of NIV, and during the initiation period (SenTec DM®, Software V-STATS 4.0; SenTec AG; Therwil, Switzerland)
2001930|NCT02652559|Device|Telemonitoring|Telemonitoring will be used to send data from the transcutaneous measurements, data from the EMG measurements and data from the ventilator from home to the hospital.
1496987|NCT02991820|Device|Intubation|Each participant will perform endotracheal intubation on the mannequin using videolaryngoscopes (VL) and traditional direct laryngoscopy (DL).
1496988|NCT02991807|Drug|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. RAD001 tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.
Patients will be instructed to take 4.5 mg/m2 of RAD001 orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
1496989|NCT02991807|Drug|Placebo|"Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. Matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.
Patients will be instructed to take 4.5 mg/m2 of the matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
1496990|NCT02991794|Device|EinsteinVision 3D visualization system|Elective laparoscopic radical prostatectomy due to histologically proven prostate cancer using EinsteinVision® 3D visualization system.
1496991|NCT02991781|Other|Biofeedback and Neurofeedback Training|The protocol will consist of 5 sessions of skin temperature biofeedback and 20 sessions of a neurofeedback training protocol that will consist of Alpha-Theta ratio up-training. The aim of the training is to reach a crossover state, were initially Alpha activity will increase and then in a deeper state, the Theta activity will take over. This state is associated with a reverie and disidentification with problems, stress or traumatic experiences. Therefore, the subjects will learn how to increase their Theta/Alpha ratio.
1496992|NCT02991781|Drug|Varenicline use for smoking cessation|The protocol will consist 1 mg varenicline use twice daily following a 1-week titration for 3 months.
1496993|NCT02991781|Other|Sham Neurofeedback|Subjects will receive equal sessions of sham neurofeedback, and thus serve as a control group for the analysis and design of the study.
1496994|NCT02991781|Other|Passive Control|Subjects will not receive any intervention, but they will be measured via a clinical and psychometric evaluation with a time-difference of 3 months. This is equal to the intervention time. Hence, the subjects in this intervention type will serve as a control group for the analysis and design of the study.
1496995|NCT02991768|Drug|Entocort|A corticosteroid that decreases levels of inflammatory cytokines.
1496996|NCT02991768|Drug|Placebos|Placebo is matched to the study drug.
1496997|NCT02991755|Procedure|Wound closure with 5-0 prolene vs 5-0 fast absorbing gut|
1496998|NCT02991742|Other|contrast media|Compare 2 contrast media
1496999|NCT02991729|Other|iPad-based decision aid|This is a novel decision aid developed by genetic counselors and Maternal Fetal Medicine physicians. It is used via an iPad and is interactive. It is available in English and Spanish has been piloted by 20 English and Spanish speaking women. It takes approximately 15 minutes to complete.
1497000|NCT02991729|Other|Genetic counseling appointment|All participants will undergo an approximately 15 minute educational genetic counseling appointment regarding aneuploidy screening options. Should family history concerns be identified on intake, this visit may be extended to include a discussion of additional issues.
1497001|NCT02991716|Other|recorded patients|No intervention applied, only recording of cutaneous ECG signal from specific points on the torsi
1497002|NCT02991703|Device|pOpmètre®|the pOpmètre® uses saturation sensors,
1497003|NCT02991703|Device|Sphygmocor|the Sphygmocor uses applanation tonometry
1497004|NCT02991690|Other|Hypothermia|To deliver intravascular hypothermia, an Alsius Icy CoolGuard® catheter (US Food and Drug Administration approved, Premarket Notification [510(k), K030421]; Alsius Corporation, Irvine, California) will be inserted through the femoral vein using a sterile technique. Patients will be cooled at a maximum rate (2-2.5 ºC/hr.) until they reach the target temperature (T 33 ºC), which will be maintained for 48 hours, and then re-warmed at 0.1 ºC/hr. until normothermia (T 37ºC) is achieved.
1497008|NCT02991664|Other|Equia Forte|Glass ionomer restorative system
1497009|NCT02991664|Other|G-aenial Posterior|Micro hybrid composite resin
1497010|NCT02991651|Drug|IRX4204|RXR agonist
1497011|NCT02991651|Drug|erlotinib|inhibitor of phosphorylation of the tyrosine kinase associated with the epidermal growth factor receptor
1497012|NCT02991638|Drug|Ibrutinib|Relapsed / refractory chronic lymphocytic leukemia and Waldenstrom macroglobulinaemia (lymphoplasmacytic lymphoma): 420 mg daily Relapsed / refractory mantle cell lymphoma: 560 mg daily Relapsed / refractory indolent B-cell non-Hodgkin lymphoma: 560 mg daily Treatment is continued until disease progression
1497013|NCT02991625|Drug|Placebos|Positive treatment expectations will be induced by giving participants capsules containing inert material and telling them that the capsules contain an effective drug that has been approved for treating Chronic Back Pain. They will be requested to take two capsules twice a day and report their pain on paper forms organized as a calendar.
1497014|NCT02991625|Other|Waitlist|These Chronic Back Pain participants will not be given any placebos and will be requested to report their pain on paper forms organized as a calendar.
1497154|NCT02990533|Other|Placebo Injection|
2001931|NCT02652559|Device|EMG|Surface EMG of the respiratory muscles will be used to monit patients in both groups as a surrogate marker of respiratory muscle unloading and to detect PVA during NIV
2001932|NCT02652559|Other|Home initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
2001933|NCT02652559|Other|Inhospital initiation of NIV|The primary aim of the study is to compare home and inhospital initiation of NIV
1497025|NCT02991560|Other|Strengthening exercises|The exercises consisted of 3 sets with 20 repetitions of wrist and elbow flexion; 2 sets with 10 repetitions of wrist extension strengthening starting with 50% of the maximum strength and density increasing the resistance each week; and finally, 2 sets with 10 repetitions of the wrist flexor and extensor muscle groups comprising 20 sec of stretching and 10 sec of relaxing using the healthy hand.
1497026|NCT02991560|Other|Intensive Physioytherapy|The treatment consisted of a cold pack (enclosed in a moist towel for 12 minutes around the elbow joint), TENS (in an asymmetrical biphasic wave form and burst modulation, current width 150 mms, pulse frequency 5 Hz), and deep transverse friction massage (2 minutes of application to the locally sensitive areas determined through palpation on anterolateral surface of lateral epicondyle) followed by home exercises.
1497027|NCT02991560|Device|Kinesio taping|Kinesio tape has been implemented on forearm of the patients for the treatment of lateral epicondylitis
1497028|NCT02991560|Device|Athletic taping|By athletic taping, similar effects with Kinesio taping were aimed to gain. Considering the McConnel principles
1497029|NCT02991547|Other|Observational|
1497030|NCT02991534|Behavioral|CV Toolkit Components|"Patient completes a CV self screener.
Patient discusses CV risks factors with primary care providers and CV risks are documented and discussed for action steps and referrals.
Patient will be recommended to attend a gender tailored facilitated workgroup - Gateways to Healthy Living to make specific SMART goals and commit to patient preferred services or program"
2001934|NCT02651103|Device|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
1497032|NCT02991508|Drug|Placebo|
1497033|NCT02991508|Drug|Adrecizumab|
2001935|NCT02649426|Device|The Paradise® Renal Denervation Ultrasound System|Randomization will occur following the diagnostic renal angiogram. Blinded patients randomized to treatment will receive the renal denervation procedure using the Paradise System to deliver ultrasound energy to thermally ablate and disrupt the renal sympathetic nerves while sparing the renal arterial wall.
2001936|NCT02649426|Device|Sham Procedure|Randomization will occur following the diagnostic renal angiogram. For blinded patients randomized to control, the diagnostic renal angiogram will be considered the sham procedure.
1497038|NCT02991482|Drug|Pembrolizumab|Pembrolizumab (MK-3475) is a potent and highly selective humanised monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. This blockade enhances functional activity of the target lymphocytes to facilitate tumour regression and ultimately immune rejection.
1497039|NCT02991482|Drug|Gemcitabine|"Gemcitabine replaces one of the building blocks of nucleic acids, in this case cytidine, during DNA replication. The process arrests tumour growth, as new nucleosides cannot be attached to the faulty nucleoside, resulting in apoptosis (cellular suicide)."
1497040|NCT02991482|Drug|Vinorelbine|Vinorelbine is a vinca alkaloid cytotoxic chemotherapy that is available in intravenous and oral preparations with EMA licenses in lung cancer and breast cancer. Vinorelbine blocks mitosis in phase G2-M, causing cell death in interphase or at the following mitosis.
1497044|NCT02991443|Behavioral|Mindfulness based stress reduction|Mindfulness based stress reduction consisted of 8 group sessions for parents of children with IBD
1497047|NCT02991417|Biological|CDVAX|
1497048|NCT02991404|Procedure|Multimodal Peripheral Nerve Block Injection|After successful placement of the adductor canal catheter placed in standard fashion , the patient will receive a one-time 20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine followed by a continuous infusion of 0.125% bupivacaine set at 10ml/hour.
1497049|NCT02991404|Procedure|Single Shot Adductor Canal Block|A total of 20 ml of solution containing a combination of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, 150 micrograms of buprenorphine, 2 mg of dexamethasone, and 1:400,000 epinephrine will be administered underneath the Sartorius muscle. A sham catheter will then be placed subcutaneously into the Sartorius muscle, secured in typical fashion, and connected to a pump containing saline to provide similar shape and weight with an opaque bag covering the pump. The pump will be run at the lowest possible ml/hour rate, which is currently 0.1 ml/hour with the current pump used in our hospital.
1497050|NCT02991404|Drug|Initial Bolus|20 ml bolus of 0.25% bupivacaine, 1.67 mcg/ml of clonidine, and 1:400,000 epinephrine
1497051|NCT02991404|Drug|Continuous infusion|Continuous infusion of 0.125% bupivacaine
1497052|NCT02991391|Other|None, use of a questionnaire|Telephone health survey using 2015 Behavioral Risk Factor Surveillance Survey in Texas, Florida, South Carolina, and Kentucky that includes questions regarding tobacco exposure and respiratory symptoms
1497053|NCT02991378|Behavioral|Children's emotional and stress coping program|Giving the children lessons about the emotional self-regulation skills and stress coping skills, with the psychoeducation books and lectures for the teachers and parents.
1497054|NCT02991365|Other|nasal insulin|
1497055|NCT02991365|Other|placebo spray|
1497056|NCT02991352|Device|Image guided needle placement|Stereotactic MRI based image guidance to aid in the placement of percutaneous needles into vascular malformations using a CE marked navigation system (CAS-One IR, CAScination AG)
1497057|NCT02991339|Drug|Dexamethasone|Dexamethasone 10 mg iv for 2 days; then 5 mg iv for 1 day
1497060|NCT02991313|Device|Endocardial Ablation Procedure|
1497061|NCT02991300|Device|BioPoly RS Partial Resurfacing Patella Implant|
2001937|NCT02648191|Device|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.
For this intervention, the stimulations are active."
1497067|NCT02991261|Drug|SPARC001 type I|Treatment type I
1497068|NCT02991261|Drug|SPARC001 type II|Treatment type II
1497069|NCT02991261|Drug|Reference001 type I|Hydrocodone-acetaminophen
1497070|NCT02991261|Drug|Reference001 type II|Hydrocodone Acetaminophen
1497071|NCT02991248|Device|robotic training|robotic training by applying pelvis force perturbation
1497072|NCT02991248|Device|spinal cord electrical stimulation|Applying direct current electrical stimulation on spinal cord
1497073|NCT02991248|Device|treadmill|conventional treadmill training only
1497074|NCT02991235|Dietary Supplement|PRJ212|6 capsules of study product will be taken daily and orally.
1497075|NCT02991235|Dietary Supplement|Placebo|6 capsules of study product will be taken daily and orally.
1497076|NCT02991222|Drug|SPARC001 type I|Treatment type I
1497077|NCT02991222|Drug|SPARC001 type II|Treatment type II
1497078|NCT02991222|Drug|Reference001 type I|Hydrocodone-Acetaminophen
1497079|NCT02991222|Drug|Reference001 type II|Hydrocodone-Acetaminophen
1497080|NCT02991209|Drug|Testosterone|
1497081|NCT02991209|Drug|Placebos|
1497082|NCT02991196|Drug|DS-8273a + nivolumab|Nivolumab will be administered at 240 mg intravenously (IV) once every two weeks (Q2W) over 30 (± 5) minutes (on Days 1 and 15 of each cycle of 28 days). DS-8273a will be administered [90 (± 15) minutes on Day 1 of Cycle 1, and 60 (± 15) minutes in subsequent infusions] after the end of the nivolumab infusion in ascending doses up to 1200 mg IV Q2W. The regimen is adjusted based on injection site reactions or adverse events. Additional dose combinations may be considered based on the assessment of safety, primary pharmacodynamic (PDy) effects, and preliminary anti-tumor activities.
1497083|NCT02991183|Behavioral|ACT|A psychological therapy to help people i) notice and accept difficult thoughts and emotions; ii) identify what they value in life and iii) make changes to their behaviour to promote these values.
1497084|NCT02991170|Procedure|unipolar or bipolar radiofrequency ablation+CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing unipolar or bipolar radiofrequency ablation and Coronary Artery Bypass Grafts at the same time
1497085|NCT02991170|Procedure|CABG|Patients with myocardial infarction related potential malignant ventricular arrhythmia undergoing Coronary Artery Bypass Grafts
1497086|NCT02991157|Drug|Nimodipine|
1497087|NCT02991144|Genetic|scAAV8OTC|non-replicating, recombinant scAAV8 encoding human ornithine transcarbamylase (OTC)
2001938|NCT02648191|Device|NeuroCoach II Stim|"A noninvasive vagus nerve stimulator consists of two components. An electrode is placed in the left ear concha and will be used by the patient for 4-5 hours per day in segments of 1 hour minimum.
For this intervention, the stimulations are inactive."
1497090|NCT02991118|Drug|bempedoic acid|bempedoic acid 180 mg tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
1497091|NCT02991118|Drug|placebo|Matching placebo tablet taken orally, once daily. Patients remain on ongoing lipid-modifying therapy (not study provided)
1497092|NCT02991092|Procedure|fluid administration|"After surgery, patients in the experiment group were provided with intravenous fluid administration at 1.0ml/Kg/h and encouraged to take food and drink water early after surgery, and the intravenous fluid administration was stopped immediately when the oral intake was more than 1500ml/h; patients in the control group strictly followed the fasting and were provided with the intravenous fluid administration according to Total amount of fluid = physiological requirement + additional loss (fever + gastrointestinal decompression) + amount lost until their intestinal function completely recovered."
1497093|NCT02991079|Other|Intervention group|"Smartphone with APP (EVIDENT) for 3 months, cardio-health rides and feeding workshop.
Counseling on physical activity and Mediterranean diet."
1497094|NCT02991079|Other|Control: Lifestyle counseling|Conseling on physical activity and nutrition (intervention)
1497095|NCT02991053|Drug|ketamine|
1497096|NCT02991027|Device|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical short cavity tunable laser
1497097|NCT02991027|Device|DRI OCT Triton|DRI OCT Triton using micro-electro-mechanical tunable vertical cavity surface emitting laser
1497098|NCT02991014|Behavioral|researcher-selected frequency-modulated music|Music pieces have been selected in advance by the researchers. Furthermore, musical frequencies have been artificially modulated.
1497099|NCT02991014|Behavioral|researcher-selected non-modulated music|The same music pieces as in the active comparator arm have been selected in advance by the researchers, but no artificial frequency modulation.
1497100|NCT02991014|Behavioral|participant-selected non-modulated music|Participants bring their own choice of personally preferred music pieces and listen to them during the intervention sessions. There is no frequency modulation in this condition.
1497101|NCT02991001|Procedure|Ultrasound-guided hydrodissection|Ultrasound-guided hydrodissection with 5cc normal saline between carpal tunnel and median nerve.
1497102|NCT02991001|Procedure|Placebo ultrasound-guided injection|Ultrasound-guided injection with 5cc normal saline at subcutaneous layer beyond carpal tunnel
1497103|NCT02991001|Device|Ultrasound|
1497104|NCT02991001|Drug|Normal Saline|
1497105|NCT02990975|Drug|ketamine|
1497106|NCT02990962|Drug|5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (5cc) between carpal tunnel and surrounding median nerve with hydrodissection.
1497107|NCT02990962|Drug|1cc 2% Xylocaine+4cc Triamcinolone (40mg)|Ultrasound-guided perineural injection with1cc 2% Xylocaine+4cc Triamcinolone (40mg) between carpal tunnel and surrounding median nerve with hydrodissection.
1497108|NCT02990949|Other|Timing of trigger|
1497110|NCT02990923|Device|High-Flow Needleless Valve|
1497111|NCT02990923|Device|DualCap Disinfection Devices|
1497112|NCT02990910|Drug|personalized opioid analgesia|(a）positive result 10μg/kg morphine; negative result 50μg/kg morphine.
1497113|NCT02990910|Device|conventional opioid analgesia|(b) all received 25μg/kg morphine
1497114|NCT02990897|Behavioral|clinical decision support message|The intervention patient's physician is shown an estimate of the patient's 5 year risk of ESRD with a link for further information.
1497116|NCT02990871|Other|early neurological rehabilitation|start of neurological rehabilitation between 3rd and 15th day after ABI
1497117|NCT02990871|Other|no-early neurological rehabilitation|start of neurological rehabilitation between 20th and 90th day after ABI
1497118|NCT02990858|Drug|PRO 140 SC injections|
1497119|NCT02990845|Drug|Pembrolizumab/ Exemestane/ Leuprolide|Dose level 1 (Pembrolizumab 150 mg IV Q2W); Dose level -1 (Pembrolizumab 100 mg IV Q2W); Dose level -2 (Pembrolizumab 50 mg IV Q2W) Combination with Exemestane 25 mg PO QD, and Leuprolide 3.75 mg SC Q4W
1497120|NCT02990832|Device|Exciton|"Exsalt® Wound Dressings will be applied by the physician/nursing staff.
The test product, exsalt® Wound Dressings (0.4 mg Ag/cm2) will be applied after wound cleansing or debridement if required.
Dressings will be changed weekly, either at the out-patient facility or at home with provided dressings. At regular intervals throughout the study, as per the existing Diabetes Foot Care Clinical Care Pathway, wound assessment including size determination, Exsalt Wound Assessment Form, any adverse events will be reported, with tracing and/or photography included where available.
Maximum treatment course will be 28 days (end of study) or until wound closure."
1497121|NCT02990819|Device|Apha/beta T and CD19+ cell depletion using CliniMACS device|Stem cells will be processed using the CliniMACS device for alpha/beta and CD19+ T cell depletion. Processing of cells using the CliniMACS will occur in accordance with the Investigator Brochure and Technical Manual following the laboratory SOPs and using aseptic technique.
1497122|NCT02990806|Biological|NI-071|20 ml vial containing 100 mg for a final reconstitution volume of 10 mg/mL
1497123|NCT02990806|Biological|Infliximab|20 ml vial containing 100 mg for a final reconstitution volume of 10 mg/mL
1497124|NCT02990793|Device|Active MeRT Treatment|A personalized biometrics-guided protocol known as magnetic EEG/EKG resonance therapy (MeRT) treatment that is tailored specifically to each patient's higher harmonic frequency of heart rate, which is nearest to the characteristic frequency of alpha EEG frequency.
1497125|NCT02990793|Device|Sham MeRT Treatment|A personalized biometrics-guided protocol similar to MeRT treatment that mimics magnetic EEG/EKG resonance therapy (MeRT) but does not emit active stimulation.
1497126|NCT02990780|Radiation|Conventionally fractionated concurrent chemo-radiotherapy|5Fx/W,2Gy/Fx,Dt:PTV-G:60Gy/30F/6W.
1497127|NCT02990780|Radiation|Accelerated hypofractionated concurrent chemo-radiotherapy|5Fx/W,2.5Gy/Fx,Dt:PTV-G:55Gy/22F/4.4W.
1497128|NCT02990754|Behavioral|Physical activity education|Instruction in suitable physical activity options and education about physical activity with CHD.
1497129|NCT02990728|Drug|Metformin|The enrolled patient is allocated to either LNG-IUS only or LNG-IUS + metformin by central randomization with study site allocation. A 90-100 days of continuous treatment before first histologic assessment of treatment response is required. The patient will receive endometrial curettage or hysteroscopic evaluation and resection of suspected lesion after 90-100 days of treatment. Patients with good response to assigned treatment will continue the treatment for another 90-100 days and second histologic assessment will be performed. Patients with poor response to assigned treatment at first assessment will receive additive oral progestin therapy, along with the assigned regimen(s) as, Oral progestin, either medroxyprogesterone acetate 500 mg daily or oral megestrol acetate 160 mg daily After a total of at least 6 months treatment period, the patient with good response at first assessment is suggested to keep the Mirena for maintenance until plan to get pregnant
1497130|NCT02990728|Device|Mirena®|
1497131|NCT02990715|Device|C-Scan System|"To establish the efficacy of C-Scan Capsule System and FIT in detecting patients with polypoid lesions ≥ 10mm, compared with Optical Colonoscopy
To evaluate the safety of the C-Scan Capsule System procedure"
1497132|NCT02990702|Other|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
1497133|NCT02990702|Other|Ultrasound guided coracoid infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
1497134|NCT02990702|Drug|Bupivacaine|
1497135|NCT02990702|Device|Ultrasound|
1497136|NCT02990689|Device|Trifocal Intraocular Lens|bifocal intraocular lens (IOL)
1497137|NCT02990689|Device|Bifocal Intraocular Lens|trifocal intraocular lens (IOL)
1497138|NCT02990689|Device|Low Addition Bifocal Intraocular Lens|low near addition intraocular lens (IOL)
1497139|NCT02990676|Behavioral|Computerised cognitive training|Computerised cognitive training regime
1497140|NCT02990663|Other|Use of blood pressure lowering medication at bedtime|Blood pressure lowering medications will be switched (one at a time as tolerated) to bedtime, or maintained at bedtime if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
1497141|NCT02990663|Other|Use of blood pressure lowering medication in the morning|Blood pressure lowering medications will be switched (one at a time as tolerated) to morning, or maintained in the morning if already taken at that time. All decisions related to which, and how many, medications to switch are at the discretion of the care provider.
1497142|NCT02990650|Behavioral|Balance Task Training with therapist guarding support|"Nine balance tasks:
long forward step
forward reach
push forward
push backward
step over hurdle
step up on foam surface
step up on solid surface
sit-to-stand
step onto slippery surface The therapist will provide guarding support"
1497143|NCT02990650|Behavioral|Balance task training with robotic guarding support|"Nine balance tasks:
long forward step
forward reach
push forward
push backward
step over hurdle
step up on foam surface
step up on solid surface
sit-to-stand
step onto slippery surface The guarding support will be provided by a robot"
1497144|NCT02990650|Behavioral|Challneged balance task training with robotic guarding support|"Nine balance tasks where the subject is challenged to perform at a harder level of difficulty:
long forward step
forward reach
push forward
push backward
step over hurdle
step up on foam surface
step up on solid surface
sit-to-stand
step onto slippery surface The guarding support will be provided by a robot"
1497145|NCT02990637|Dietary Supplement|OLECOL|Olive leaf extract
1497146|NCT02990637|Dietary Supplement|Placebo|Maltodextrin
1497147|NCT02990624|Radiation|PUVA|36 sessions of psoralen-ultraviolet A, divided as 3 sessions weekly
1497148|NCT02990611|Other|Non Interventional|
1497149|NCT02990585|Other|Back school|
1497150|NCT02990546|Drug|midodrine|Midodrine will be given to treatment arm as enteral medication
1497151|NCT02990546|Other|Standard of Care|Patients in the control arm will receive standard of care for septic shock
1497155|NCT02990533|Other|Placebo supplement|
2001939|NCT02647944|Drug|Liraglutide|Initiate at 0.6mg S.C. daily for 1 week; subjects will return to the Clinical Research Unit (CRU) each week until an increase by 0.6mg/day in weekly intervals to a dose of 3.0 mg/day is achieved (~4 weeks). Once maintenance dose of 3.0 mg is achieved, subjects will return approximately every 4 weeks to obtain new supply of study medication.
2001940|NCT02647944|Drug|Placebo|
2001941|NCT02646904|Drug|Nasal Beclomethasone Dipropionate|Standard dose (400 µg/daily as 100 µg 1 spray nos bid) of nebulized Beclomethasone Dipropionate nasal spray for 21 days.
2001942|NCT02646904|Drug|CERCHIO 10 mg/ml OS|For Children < 12 years old 10 drops die (5 mg die) for 21 days. For Children > 12 years old 20 drops die (10 mg die) for 21 days.
1497160|NCT02990494|Behavioral|STANDARD|Standard Internet-delivered behavioral weight loss
1497161|NCT02990494|Behavioral|PREVENT|enhanced standard Internet-delivered behavioral weight loss program
1497162|NCT02990494|Behavioral|PROMOTE|enhanced standard Internet-delivered behavioral weight loss program
1497163|NCT02990481|Biological|TRK-950|Initially two dose levels will be explored during dose escalation.
1497164|NCT02990468|Drug|BMX-001|Subcutaneous injection.
1497165|NCT02990468|Radiation|Radiation Therapy|Patients will receive standard dose intensity modulated radiation therapy (IMRT).
1497166|NCT02990468|Drug|Cisplatin|Cisplatin will be administered per institution's standard of care practice.
1497167|NCT02990455|Drug|Reduced nicotine cigarettes|Participants will be assigned to undergo two experimental conditions (i.e., exclusive smoking of RNC Low or Moderate in their home environment for 7 days) in a double-blind, randomized, crossover design. The two experimental conditions will be separated by a 7-day period of return to smoking of participants' own brand of cigarette.
1497168|NCT02990442|Device|rTMS|repetitive transcranial magnetic stimulation, 1Hz protocol to right dorsolateral pre frontal cortex (R_DLPFC)
1497169|NCT02990429|Procedure|Forced Air warmer|"record room temperature
record core temperature (tympanic membrane)
General anesthesia
using forced air warmer (bair hugger)
Intravenous fluid at room temperature
room temperature and core temperature q15 minutes
anesthesia finish, stop bair hugger
record core temperature before recovery room"
1497170|NCT02990429|Procedure|Intravenous Fluid Warmer|"record room temperature
record core temperature (tympanic membrane)
General anesthesia
using ranger warmer
Intravenous fluid at room temperature
room temperature and core temperature q15 minutes
anesthesia finish, stop ranger warmer
record core temperature before recovery room"
1497171|NCT02990416|Biological|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
1497172|NCT02990416|Biological|Pembrolizumab|A humanized monoclonal immunoglobulin (Ig) G4 antibody directed against human cell surface receptor PD-1 (programmed death-1 or programmed cell death-1) with potential immune checkpoint inhibitory and antineoplastic activities.
1497173|NCT02990416|Radiation|Ionizing Radiation|Electromagnetic or corpuscular radiation capable of producing ions, directly or indirectly, in its passage through matter.
1497174|NCT02990403|Drug|Aspirin|
1497175|NCT02990403|Drug|Heparin|
1497176|NCT02990403|Drug|Prednisone|
1497177|NCT02990403|Drug|Immunoglobulin|
1497178|NCT02990403|Drug|Dydrogesterone|
1497179|NCT02990377|Behavioral|RL-supported IVR intervention|Participants in the intervention group receive interactive voice response calls where they are asked to report information about their health and medications using their touch-tone phone. Based on their responses, participants may receive brief or extended motivational messages during the call, or they may be assigned to receive a 20 minute motivational enhancement session with a study therapist over the phone.
1497180|NCT02990364|Drug|Sucrose|Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
1497181|NCT02990364|Drug|Lidocaine|Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
1497182|NCT02990364|Drug|EMLA Topical Product|EMLA cream will be applied 70 minutes to the circumcision to all participants of the study.
1497183|NCT02990351|Procedure|loco regional therapies for HCC|29 HCC patients received locoregonal therapy as a bridging therapy for those who were within milan and as downstaging for those were initially beyond milan. The main LRT types used for our patients were TACE and or RFA and microwave ablation
2001943|NCT02644616|Drug|tolvaptan+torasemide|tolvaptan 15mg/d po(10 days) + torasemide 20mg/d iv
2001944|NCT02644616|Drug|placebo+torasemide|placebo 15mg/d po(10 days) +torasemide 20mg/d iv
1497187|NCT02990325|Drug|ABX464|ABX464 given orally at 150 mg per day from Day 0 to Day 28
1497188|NCT02990312|Drug|Sirolimus + Maraviroc|Patients will be placed on the combination of Sirolimus and Maraviroc starting on Day 0 and followed for 96 weeks during which they will have regular monitoring of both clinical safety labs, Sirolimus levels, and research labs to look at the HIV reservoir, CCR5 density, and immune activation
1497189|NCT02990299|Behavioral|mHealth for Diabetes Adherence Support|Participants will be paired with a health coach who will provide ongoing support and resources in medication and lifestyle adherence and diabetes self-management. The health coach will perform regular home visits, telephone support and tailored text-messages based on the participant's preferences and needs. They will help assess barriers to adherence and use motivational interviewing to help patients set goals and create action plans. They will also facilitate videoconferences with an assigned clinical pharmacist who will provide consultation on medication use, reconciliation and adherence, identify therapeutic goals and formulate an approved plan of care.
1497190|NCT02990286|Drug|Rituximab|Rituximab 500mg concentrate for solution for infusion. One course of IV rituximab consisting of a first infusion of 1000 mg (500 ml solution) rituximab (day 1 infusion), and a second infusion of 1000 mg (500 ml solution) rituximab two weeks later (day 15 infusion)
1497191|NCT02990286|Drug|Placebo of Rituximab|500 ml of saline (0.9% sodium chloride) for infusion One course of intravenous placebo of rituximab consisting of a first infusion of 500 ml of saline (0.9% sodium chloride) infusion (day 1 infusion), and a second infusion of 500 ml of saline infusion two weeks later (day 15 infusion)
1497192|NCT02990286|Drug|Mycophenolate Mofetil|"Mycophenolate Mofetil 500mg film-coated tablets
1 gram twice daily on oral route of MMF (= 2 grams daily) for 6 months."
1497193|NCT02990273|Biological|Blood transfusion|
1497194|NCT02990260|Dietary Supplement|Saccharomyces cerevisiae|Live Saccharomyces cerevisiae
1497195|NCT02990260|Dietary Supplement|Lynside Wall Basic|yeast cell walls
1497196|NCT02990260|Dietary Supplement|Placebo|Maize starch and magnesium stearate
1497197|NCT02990247|Device|anharmonic morphological analysis of the respiratory signals (AMARS)|
1497198|NCT02990234|Procedure|Capsular Repair|
1497199|NCT02990234|Procedure|No Capsular Repair|
1497200|NCT02990221|Drug|Ingenol mebutate|150 mcg / g per day, to be applied on a predetermined area of 25 cm2 of skin of the face or scalp, for 3 days consecutive
1497201|NCT02990221|Procedure|cryotherapy|application with 5 seconds of freezing time of each lesion located in a predetermined skin area of 25 cm2 of the face or scalp
1497202|NCT02990208|Behavioral|Diaphragmatic breathing|Patients trained in the technique of diaphragmatic breathing were instructed to take a breath by contracting the diaphragm and were trained to maintain their respiration frequency. They were told to inhale through the nose for four seconds and exhale through the mouth for six seconds (six cycles per minute). Patients then had five minutes to practice by following verbal breathing instructions provided over headphones. During VR exposure breathing instructions were provided via headphones. Diaphragmatic is thought to reduce arousal on the physiological level (Hazlett-Stevens & Craske, 2009) but at the same time not to divert attention from the feared situation to the same extent as other coping strategies
1497203|NCT02990208|Behavioral|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facilitates the practice of exposure-based treatments especially for situations or places difficult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been conducted or only in a limited manner (Mühlberger & Pauli, 2011)
1497204|NCT02990195|Other|Chyme reinfusion|
1497205|NCT02990169|Device|CATS tonometer prism|IOP tonometer prism for assessment of intraocular pressure
1497206|NCT02990169|Device|Goldmann Tonometer prism|IOP tonometer prism for assessment of intraocular pressure
1497207|NCT02990156|Device|Coil Embolization System|deposits coils in the aneurysm sac by electrolytical detachment; coil types include Complex Finish, Complex Frame, and Helical. The coils are made of a platinum - tungsten alloy, have a minimum diameter of 2 mm and a maximum diameter of 24mm. The intended use of the Microport NeuroTech Coil Embolization System is for the endovascular embolization of intracranial aneurysms.
1497208|NCT02990156|Device|Cotrol device from Medronic|Control device from Medronic (include AxiumTM Detachable Coils and AxiumTM Prime Detachable Coils) are manufactured by ev3 (Medtronic, Irvine, California, USA);
1497209|NCT02990143|Procedure|Ologen|Ologen® CM,a biodegradable scaffold matrix, induces a regenerative non-scarring wound healing process without using anti-fibrotic agents.
1497210|NCT02990130|Other|Observational|
2001945|NCT02644122|Drug|SF1126|
2001946|NCT02643303|Drug|Durvalumab|
1497213|NCT02990078|Drug|Sildenafil citrate|Sildenafil is a potent and specific PDE5 inhibitor, which was initially developed for the treatment of hypertension and angina. Its effectiveness as a treatment for male erectile dysfunction became apparent during Phase I clinical trials, and the focus of drug development shifted to this indication. In patients with cerebrovascular dysfunction, a few preliminary studies have used sildenafil to increase CVR. Participants in the pilot study had CVR tested in response to hypercapnia measured twice, at baseline and then 1 hour after administration of sildenafil citrate, 50 mg by mouth. The investigators have an IND exemption for the uses in this study.
1497214|NCT02990078|Device|Functional Near Infared Spectroscopy|Functional near-infrared spectroscopy (fNIRS) will be used to measure regional cerebral blood flow and cerebrovascular reactivity. are connected to the scalp and surrounding detectors a few cm away detect the light as it scatters through the underlying tissues. The technique is able to detect changes in the absorption spectrum of the tissue corresponding to the concentrations of oxyhemoglobin (HbO2) and deoxyhemoglobin (HbR), and indicate local perfusion changes.
1497215|NCT02990078|Other|Hypercapnia Challenge|The study device is a Douglas Bag that traditionally is designed to measure respiratory exchange. It consists of large bag attached to a mouthpiece utilized to hold either expired air from the subject or filled with different concentrations of air to be aspired. For the purposes of this study, the Douglas Bag will be utilized to induce hypercapnia in the subject. The bag is equipped with a switch that allows rapid shifting from room air to 5% CO2 each minute over 7 minutes.
1497216|NCT02990065|Dietary Supplement|PROTEIN SUPPLEMENTATION|
1497217|NCT02990052|Procedure|Volar plating|Open reduction and volar fixed-angle plate fixation of distal radius fracture
1497218|NCT02990052|Procedure|Conservative treatment|Closed reduction & casting of distal radius fracture
1497219|NCT02990039|Behavioral|Counseling letter|The intervention is based on the Health Action Process Approach. The first letter provides information on knowledge regarding sedentary time and physical activity as well as intervenes on self-efficacy depending on the mindset of participants (non-intender, intender, actor). The second letter focuses on benefits and barriers of physical activity as well as the role of social support for physical activity. In case of actional stage, the third letter intervenes on self-efficacy again and suggests action and coping planning. Otherwise, the letter includes ipsative feedback according to the second letter.
1497306|NCT02989363|Procedure|Not device O-Arm in RAQUIS|Complex back surgeries without the device O-Arm
1497307|NCT02989350|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 vs Placebo
2001947|NCT02643303|Drug|Tremelimumab|
1497220|NCT02990026|Behavioral|Specialty Mental Health Probation|Specialty mental health probation includes the following components: (1) exclusively mentally ill caseload of probationers; (2) reduced caseload of 40-45 probationers; (3) problem-solving supervision orientation; (4) ongoing training and consultation; and (5) greater connection with local mental health services
1497221|NCT02990013|Drug|Avenova|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
1497222|NCT02990013|Drug|Povidone-iodine 5% solution|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
1497223|NCT02990013|Drug|4% chlorhexidine|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
1497224|NCT02990013|Drug|Isopropyl alcohol|Subjects will all undergo the treatment arm where their skin will be cleansed with four different agents: AvenovaTM , povidone-iodine 5% solution, 4% chlorhexidine and isopropyl alcohol
1497225|NCT02990000|Behavioral|Scientific Match|Consecutive consenting patients at each site will be randomly assigned to condition. The project coordinator, unaware of therapist baseline performance, will generate the randomization sequences using an online random generator. Therapists will be crossed—that is, some of their cases will be matched, while others will be non-matched. Within condition, patients will be assigned sequentially to the site-specific therapists until therapists reach their study quota. In the low probability event that there is no therapist meeting minimal match criteria for a patient in the match condition, that patient will be removed from the study protocol (though will, of course, still receive treatment) and replaced with the next patient where a match does exist (this will also be carefully tracked).
1497226|NCT02989987|Behavioral|Narrative Exposure Therapy|
1497227|NCT02989987|Behavioral|Social Support|A local counselors provides social support on demand.
1497228|NCT02989974|Behavioral|KY LEADS Survivorship Care|"Survivor: Survivor questionnaire 1 at enrollment; KY LEADS Survivorship Care Program; survivor questionnaire 2 one week after program completion; survivor questionnaire 3 six months after enrollment.
Caregiver: Caregiver questionnaire 1 at enrollment;KY LEADS Survivorship Care Program; caregiver questionnaire 2 one week after program completion; caregiver questionnaire 3 six months after enrollment"
1497229|NCT02989961|Other|Resticutis|Autologous, Activated-Platelets type of Preparation
1497230|NCT02989961|Other|Platelet-Poor Plasma (PPP)|A preparation of low platelet plasma obtained by a high-speed centrifugation step.
1497231|NCT02989948|Device|Physician-modified fenestrated and branched aortic endograft|Physician-modified fenestrated endografting for the endovascular treatment of asymptomatic, non-ruptured thoracoabdominal aortic aneurysms of any Crawford extent (I-V) meeting traditional size criteria for open surgical repair.
1497232|NCT02989935|Procedure|Ventilation|Measurements of ventilation with subjects seated, and breathing across a pneumotachygraph and pressure transducer to measure inspiratory airflow, during both resting and CO2 stimulated breathing.
1497233|NCT02989935|Procedure|Parasternal EMG|Recordings of electrical activity (EMG) from the parasternal intercostal muscle in the second intercostal space on the upper anterior chest wall adjacent to the sternum.
1497234|NCT02989935|Procedure|Phrenic magnetic stimulation|Bilateral maximal magnetic stimulation (Magstim) of the phrenic nerves.
1497235|NCT02989922|Biological|SHR-1210|SHR-1210 is a humanized anti-PD1 IgG4 monoclonal antibody
1497236|NCT02989909|Device|CATS tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
1497237|NCT02989909|Device|Goldmann tonometer prism|demonstrate that not more than 5% of the paired differences between the reference tonometer (CATS prism) reading and the test tonometer (Goldmann prism) reading for each pressure range
1497238|NCT02989896|Device|perfusion index|
1497239|NCT02989883|Other|peroral endoscopic myotomy|The procedure consists of four steps: 1) mucosal incision 10-15 cm above the esophagogastric junction to allow entry into the submucosa, 2) creation of a submucosal tunnel until the lower esophageal sphincter is reached, 3) myotomy of the circular muscle layer, and 4) closure of the mucosal entry with endoclips.
1497240|NCT02989870|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"Participants will receive 3-5 fractions of radiation as determined by the dose level at time of enrollment. The starting dose level will be Dose Level 1: 8 Gy x 3 fractions for a total of 24 Gy. If sufficient treatment related toxicity is observed at the initial starting dose, then the dose will be reduced to 16 Gy in 2 fractions of 8 Gy. The dose per fraction for each participant will be provided at the time of registration based on the toxicity experience of the previous participants on study. This will be escalated to 40 Gy in 5 fractions of 8 Gy."
1497241|NCT02989870|Drug|Sorafenib|Sorafenib by mouth (PO): 200 mg twice a day (BID) then 400 mg BID.
1497242|NCT02989870|Drug|Bavituximab|Bavituximab intravenously (IV): 3 mg/kg every week (q wk).
2001948|NCT02643303|Drug|Poly ICLC|
1497245|NCT02989844|Drug|ALT-803|ALT-803 6 mcg/kg will be administered subcutaneously once a week on day 1, 8, 15 and 22 followed by 4 weeks of no treatment. Up to 4 treatment cycles (4 weeks on/4 weeks off) are permitted.
1497246|NCT02989831|Device|Vibrating insoles 'on'|Duration: 30-60 seconds
1497247|NCT02989818|Other|Endoscopic Submucosal Dissection|This intervention is part of the subjects standard of care and is a method to remove the Gastrointestinal lesion.
1497248|NCT02989805|Behavioral|Care Management|Professionals and peers will each deliver the same intervention. The intervention combines a traditional medical model of care management with a recovery-based approach.
1497249|NCT02989792|Genetic|Blood sampling for genotyping|Venous punction of maximum 10 millilitres
1497250|NCT02989792|Other|Personality Questionnaires completion|Completion of the following questionnaires: Multidimensional Personality Questionnaire (MPSQ), Interpersonal Reactivity Index (IRI) and Behavioral inhibition system/ Behavioral activation systems (BISBAS) questionnaires
1497251|NCT02989779|Drug|NK1 Antagonist|
1497252|NCT02989779|Drug|Placebo Oral Capsule|
1497253|NCT02989766|Behavioral|Education on Breast Feeding|Subjects in the intervention arm will complete 3 activity sheets prenatally-study related.
2001952|NCT02638935|Device|Ultrasound- Virtual Touch Tissue Imaging Quantification|Siemens Medical Solutions USA, Inc. (Mountain View, CA) has implemented Virtual Touch Tissue Imaging Quantification (VTIQ) technology on a commercially available general purpose US imaging system (trade name: Acuson S2000 or S3000). This system has received clearance under Food and Drug Administration (FDA) 510(k) number K072786 (S3000) and K130881 (VTIQ). The technology uses a set of tailored US pulses (Acoustic Radiation Force Impulse, ARFI) to induce shear waves in breast tissue due to tissue displacement. A set of standard B-mode pulses detect the perpendicular shear waves. The displacement signals can be processed using algorithms on a Virtual Touch IQ-equipped system in order to calculate the shear wave velocity.
1497257|NCT02989740|Procedure|Optical Coherence Tomography|Patients aged ≥ 18 years bearing target lesions that fulfil the inclusion criteria and have undergone FFR and OCT imaging as per clinical practice will be enrolled in the study.
1497258|NCT02989727|Drug|Lamotrigine|Lamotrigine tablets at dosages of 25mg/day for Week 1 and Week 2, 50mg/day for Week 3 and Week 4, 100mg/day for Week 5, and 200mg/day for Week 6, Week 7, and Week 8.
1497259|NCT02989727|Drug|Placebos|Placebo tablets
1497260|NCT02989714|Drug|Interleukin-2|600,000 IU/kg/dose intravenously during two 5-day cycles 9 days apart
1497261|NCT02989714|Drug|Nivolumab|Nivolumab will be administered intravenously at 240 mg/dose over 60 minutes every 14 days, starting 1 week to 3 weeks after the start date of the first cycle of IL2 and continued for up to 48 weeks total in the absence of disease progression
1497262|NCT02989701|Drug|Plerixafor|Dose escalation of Plerixafor for Hematopoietic stem cell mobilization in patients with Sickle Cell Disease
1497263|NCT02989688|Dietary Supplement|Nepro HP (Abbott Nutrition)|oral nutritional supplement drink with modified carbohydrate composition
1497264|NCT02989688|Dietary Supplement|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia)|Fortisip compact protein 125 ml + Calogen 20ml (Nutricia) oral nutritional supplement drink macronutrient matched with standard carbohydrate composition
1497265|NCT02989688|Dietary Supplement|Fortisip compact 125 ml (Nutricia)|Fortisip compact 125 ml (Nutricia) oral nutritional supplement drink - standard
2001953|NCT02638623|Drug|Lactated Ringer|2L Lactated Ringer administered prior to primary knee or hip arthroplasty
1497267|NCT02989662|Drug|Mifepristone|Participants receive 6 doses.
1497268|NCT02989662|Drug|Placebo - Cap|Participants receive 6 doses
1497269|NCT02989649|Drug|Alogliptin|Alogliptin tablets.
1497270|NCT02989649|Drug|Alogliptin FDC With Pioglitazone|Alogliptin FDC with pioglitazone tablets
1497271|NCT02989649|Drug|Alogliptin FDC With Metformin|Alogliptin FDC with metformin tablets
2001954|NCT02638623|Drug|Placebo|No additional fluids will be administered
2001955|NCT02637050|Other|Standard of care|At the discretion of the attending physician.
2001956|NCT02635646|Other|Family and interdisciplinary approach|"Family and interdisciplinary approach that includes:
nutritional counseling,
physical activity counseling,
psychological counseling,
metformin 850mg twice at day for 12 months All this with the purpose to improve insulin resistance and insulin secretion in patients with prediabetes. Patients must attend a monthly session together with his family where they will receive the nutritional, physical activity and psychological counseling."
1497275|NCT02989623|Radiation|Copper Cu 64 TP3805|Given Intravenously
1497276|NCT02989623|Procedure|Positron Emission Tomography and Computed Tomography Scan|Undergo copper Cu 64 TP3805 PET/CT scan
1497277|NCT02989597|Drug|Methadone Hydrochloride|IV administration of methadone intra-operatively for a single dose
1497278|NCT02989597|Other|Standard pain regimen|Control
1497279|NCT02989584|Drug|Atezolizumab|
1497280|NCT02989584|Drug|Gemcitabine|
1497281|NCT02989584|Drug|Cisplatin|
1497282|NCT02989571|Drug|Intravenous normal saline administered at 250ml/hr|Intravenous normal saline administered at 250ml/hr
1497283|NCT02989571|Drug|Intravenous normal saline administered at 125ml/hr|Intravenous normal saline administered at 125ml/hr
1497284|NCT02989558|Drug|Ticagrelor plus ASA|Subjects in the Ticagrelor group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Ticagrelor 90mg bid 1 day prior to the TAVI procedure and for 90 days.
1497285|NCT02989558|Drug|Clopidogrel plus ASA|Subjects in the Clopidogrel group will receive ASA 80mg qd 7 days prior to the TAVI procedure and for 90 days and Clopidogrel as a loading dose of 300 mg 1 day prior to the TAVI procedure and thereafter 75mg qd for 90 days.
1497286|NCT02989545|Device|Anal Tape|
1497289|NCT02989493|Drug|Doxazosin|Doxazosin
1497290|NCT02989493|Other|Placebo|Placebo
1497293|NCT02989467|Drug|Aprepitant|Subjects will receive one tablet daily for 5 consecutive days. On Day 1 subjects will take a 125mg tablet, on Days 2-5, subjects will take an 80 mg tablet.
1497294|NCT02989467|Drug|Placebo|Subjects will receive one placebo tablet daily for 5 consecutive days.
1497296|NCT02989428|Procedure|Early parathyroidectomy group (EPTX-group)|Participants will undergo parathyroidectomy as soon as possible
1497297|NCT02989415|Other|Mechanical Ventilation|Mechanical ventilation during robotic surgery
1497298|NCT02989402|Drug|Rivastigmine|15 cm2 patch sizes loaded with 27 mg of rivastigmine
1497299|NCT02989389|Drug|LY3323795|Administered orally
1497300|NCT02989389|Drug|Itraconazole|Administered orally
1497301|NCT02989389|Drug|Placebo|Administered orally
1497302|NCT02989376|Procedure|After detection of occluded vessels by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment.|When the ratio of the end diastolic velocity in the common carotid arteries is greater than 1.4 or the diastolic flow in the internal carotid artery is not detected by vascular imaging using carotid duplex ultrasound, digital subtraction angiography is immediately performed before acute endovascular treatment. If vessel occlusion is not detected by carotid duplex ultrasound, additional vascular imaging including MR angiography or CT angiography is considered.
1497303|NCT02989363|Procedure|Device O-Arm in DBS|Deep brain stimulation surgeries with device O-Arm
1497304|NCT02989363|Procedure|Device O-Arm in RAQUIS|Complex back surgeries with the device O-Arm
1497305|NCT02989363|Procedure|Not device O-Arm in DBS|Deep brain stimulation surgeries without the device O-Arm
1497308|NCT02989350|Dietary Supplement|Placebo|Lactobacillus reuteri DSM 17938 vs Placebo
1497309|NCT02989324|Drug|MisoprostoL|Vaginal MisoprostoL
1497310|NCT02989324|Device|Foley Catheter|Misoprostol Plus Foley Catheter
1497311|NCT02989311|Dietary Supplement|Fortified maize porridge (MNP and Iron)|Maize porridge fortified with MNP and labelled iron compound
1497312|NCT02989311|Dietary Supplement|Fortified Maize porridge (MNP + Iron + GOS)|Maize porridge fortified with MNP + GOS and labelled iron compound
1497313|NCT02989298|Other|No intervention|Registration of all PD patients in the First Affiliated Hospital of Sun Yat-sen University and other hospitals，which have signed the contract in China.
1497314|NCT02989272|Drug|Sulfate, Magnesium|magnesium group (30 patients) who will receive pretreatment by intravenous infusion of magnesium sulfate 60 mg / kg
1497315|NCT02989272|Other|saline group|saline group (30 patients) who will receive pretreatment by saline solution
1497316|NCT02989259|Drug|Apatinib|apatinib 500mg p.o. qd
1497317|NCT02989246|Other|Ventilator protocol|Open loop ventilator management by a computer based protocol
1497318|NCT02989246|Device|Esophageal Catheter|Esophageal manometry measurements of patient effort of breathing will be used to guide the protocol recommendations
1497319|NCT02989233|Other|Non-surgical periodontal treatment|Scaling and oral hygiene instructions with brochure, model or video
1497320|NCT02989220|Other|Positive Reappraisal Coping Intervention|
1497321|NCT02989207|Procedure|Trabeculectomy|The current standard surgical treatment for glaucoma remains trabeculectomy. Wound healing modulation with antifibrotic agents, like MMC and 5-fluorouracil (5-FU), has been shown to increase the success of glaucoma filtering surgery in high-risk eyes
1497322|NCT02989207|Device|Baerveldt tube surgery|All glaucoma drainage devices consist of a tube which is inserted into the anterior chamber of the eye, draining aqueous humour to a plate which maintains a minimum bleb size and allows the collection of aqueous humour to be absorbed into the surrounding tissue.
1497323|NCT02989207|Drug|mitomycin-C|This is an anti scarring agent whcih is an standard adjunctive treatment in glaucoma surgery
1497324|NCT02989194|Drug|VIS410 low dose|Single intravenous fixed low dose of VIS410
1497325|NCT02989194|Drug|VIS410 high dose|Single intravenous fixed high dose of VIS410
1497326|NCT02989194|Drug|Placebo|Single intravenous infusion of placebo
1497327|NCT02989181|Device|Continues Positive Airway Pressure (CPAP)|Mask with positive airway pressure during exhalation which maintains the airway open
1497328|NCT02989168|Drug|GBT440|
1497329|NCT02989142|Behavioral|INTER-ACT|"Pre-conception coaching sessions: We encourage less motivated women to participate to the trial by collaborating with Kind & Gezin from the very beginning, as most timepoints of the counselling sessions coincide with the time points of the Kind&Gezin vaccine scheme (postpartum week 6, week 8, week 12, 6 months). We will organize the coaching in a mother and baby friendly community-based setting or in the hospitals, as preferred by the mothers.
Pregnancy coaching sessions: take place in hospital, at the time of the three planned ultrasound scans.
By consequence, the applied methodology can be applied as such at the moment of global utilisation in Flanders."
1497330|NCT02989129|Behavioral|Questionnaires|Questionnaires regarding quality of life, pain level, and related symptoms completed at Baseline and at End of Study Visit.. It should take less than 1 hour to complete these questionnaires.
1497331|NCT02989129|Drug|Quercetin|500 mg by mouth twice daily (after breakfast and dinner) for 12 weeks during study.
1497332|NCT02989116|Behavioral|Inhibition training|Inhibition training on a tactile tablet for a month (20 sessions of 15 min)
1497333|NCT02989116|Behavioral|Working memory training|Working memory training on a tactile tablet for a month (20 sessions of 15 min)
1497334|NCT02989116|Behavioral|Mindfulness training|Mindfulness training on a tactile tablet for a month (20 sessions of 15 min)
1497335|NCT02989116|Behavioral|Active control training|Active control training on a tactile tablet for a month (20 sessions of 15 min)
1497336|NCT02989116|Genetic|Saliva collection|Collection of a saliva sample for genotyping
1497337|NCT02989116|Procedure|Brain Magnetic Resonance Imaging|Structural and functional MRI
1497338|NCT02989116|Behavioral|Cognitive testing|Battery of cognitive and academic tasks on executive functions
1497339|NCT02989090|Other|Receive Detailed ICD Information-electronic|Receive Detailed ICD Information (Patient Notification Summary Report) via an electronic Patient Portal vs control
1497340|NCT02989090|Other|Receive Detailed ICD Information-paper|Receive Detailed ICD Information (Patient Notification Summary Report) via paper vs control
1497342|NCT02989051|Other|Restrictive fluid regimen|In this treatment arm, patients will receive a maximal daily fluid intake of 70% of normal requirements (for a healthy child).
1497343|NCT02989051|Other|Liberal fluid regimen|This is considered current standard clinical treatment, wherein patients will receive a fluid regimen of >85% of normal fluid recommendations (for a healthy child).
1497344|NCT02989038|Other|Very Low Nicotine Content Cigarettes|cigarettes with 0.03 nicotine yield with 0.4 mg/g nicotine content and 9.0 mg tar yield
1497345|NCT02989038|Other|Intermediate Nicotine Content Cigarettes|cigarettes with 0.12 nicotine yield with 2.4 mg/g nicotine content and 9.0 mg tar yield
1497346|NCT02989038|Other|Normal Nicotine Content Cigarettes|cigarettes with 0.8 nicotine yield with 15.8 mg/g nicotine content and 10.5 mg tar yield
1497347|NCT02989025|Drug|17 OHPC|The study participant will be given 17 OHPC, 250mg IM at admission and every 7 days thereafter.
1497348|NCT02989012|Drug|GanMaoKangNing Granules|3 times a day, 2 bags each time.
1497349|NCT02989012|Drug|Analogous Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
1497350|NCT02989012|Drug|Oseltamivir Phosphate Capsules|2 times a day,1 capsule each time.
1497351|NCT02989012|Drug|Analogous GanMaoKangNing Granules|3 times a day, 2 bags each time.
1497393|NCT02988700|Drug|Intrathecal hyperbaric bupivacaine 0.25mg/kg 0.5%|The lumber puncture will be made in the lateral position at the L4-5 or L5-S1 interspace with a 25 G pencil point Quincke spinal needle with a short bevel and the orifice of the spinal needle will be turned cephalad.
1497422|NCT02988401|Drug|Placebo|All patients will receive either insulin or placebo through an air spray pump during the first 24 weeks of the study.
1497352|NCT02988999|Dietary Supplement|D-allulose|D-allulose (psicose), a C-3 epimer of D-fructose, is defined one of the rare sugars since it is rarely found in nature. Rare sugars are monosaccharides which present in small quantities in commercial mixtures of D-glucose and D-fructose obtained from hydrolysis of sucrose or isomerization of D-glucose (5). D-allulose (psicose) has been demonstrated to be a non-calorie monosaccharide which has approximately 70% sweetness of sucrose. Various physiological activities of D-allulose (psicose) have been revealed. Of those, its glucose suppressive effect has been proven by both animal and clinical studies.
1497353|NCT02988999|Dietary Supplement|erythritol|non-calorie sweetener
1497354|NCT02988986|Drug|TAK-228|MTORC1/2 inhibitor
1497355|NCT02988986|Drug|Tamoxifen|Non-steroidal anti-estrogen
2001957|NCT02635646|Other|Individual approach|"Individual approach that includes:
nutritional and physical activity counseling in individual appointments,
metformin 850mg twice at day for 12 months, All this with the purpose to improve insulin resistance and insulin secretion. The patients must attend a monthly follow-up individually."
2001958|NCT02634060|Device|Home Based Fecal Calprotectin|Home Based Fecal Calprotectin measurement at weeks 0, 4 and 8
1497358|NCT02988960|Drug|ABBV-927|Intravenous
1497359|NCT02988960|Drug|ABBV-927|Intratumoral
1497360|NCT02988960|Drug|Nivolumab|Nivolumab will be administered according to standard or approved doses and dosing schedules.
1497362|NCT02988921|Device|MRI and CT|
1497363|NCT02988921|Radiation|Ratiotherapy|
1497364|NCT02988921|Drug|Paclitaxel, platinum-based drug|
1497365|NCT02988908|Drug|Donepezil|"Participants received donepezil as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.
Participants also received 2 weeks of memory training at weeks 13-14"
1497366|NCT02988908|Drug|Placebos|"Participants received placebo as 5mg pills per day for 6 weeks, then 10 mg per day for the remainder of the 52-week trial.
Participants also received 2 weeks of memory training at weeks 13-14"
1497367|NCT02988895|Radiation|episcleral brachytherapy|The study intervention is an outpatient, ambulatory procedure performed under local anesthesia with anesthesia assist.
1497368|NCT02988895|Drug|Anti-VEGF|Administered PRN as Standard of Care
1497369|NCT02988882|Drug|OTX-DP (Dexamethasone)|OTX-DP contains 0.4 mg dexamethasone and is designed to provide a sustained and tapered release of therapeutic levels of dexamethasone to the ocular surface for approximately 30 days.
1497370|NCT02988882|Other|Placebo - PV|The control test article, PV, is the same fluorescent PEG hydrogel punctum plug as OTX-DP, except that it does not contain drug
1497371|NCT02988869|Drug|Tiotropium/Formoterol|Tiotropium/Formoterol 18/12 mcg Inhalation Powder (1 puff) once daily via Discair®
1497372|NCT02988869|Drug|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
1497373|NCT02988869|Drug|Formoterol|Formoterol 12 mcg Inhalation Powder (1 puff) twice daily via Aerolizer
1497374|NCT02988869|Drug|Tiotropium|Tiotropium 18 mcg Inhalation Powder (1 puff) once daily via Handihaler
1497375|NCT02988856|Device|Magnetic lid system|Small externally mounted magnetic lid arrays are attached to the eye lid (s). Glasses with a second magnet system may be combined with the arrays depending on the lid condition. The device intends to facilitate eye opening and closing.
1497376|NCT02988843|Drug|Brentuximab Vedotin|Dose level 1: 1.8 mg/kg every 21 days (up to 180 mg) Dose level -1 :1.2 mg/kg every 21 days ( up to 120 mg)
1497377|NCT02988843|Drug|Bevacizumab|15 mg/kg every 21 days
1497378|NCT02988830|Device|Subcutaneous Electric Lumbar Stimulation|
1497379|NCT02988817|Biological|HuMax-AXL-ADC|All arms of the trial (both in escalation and expansion phase) will be administered (HuMax-AXL-ADC)
1497380|NCT02988804|Device|endotracheal tube|"In the Endotracheal group In the ETT group, the procedure will be exactly the same except that the ETT will not be exchanged and the patient will be directly extubated
Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:
baseline, in the operating room before anesthetic induction (non invasive arterial pressure)
end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)
at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
1497381|NCT02988804|Device|Laryngeal mask|"In the LMA group, after aspirating pharyngeal secretions and with the patient still under general anesthesia, we will insert a Proseal LMA (Laryngeal Mask Co. Ltd., Le Rocher, Victoria, Mahe Seychelles) and extubate the trachea using a guided Bailey technique
Hemodynamic variables (blood pressure, HR, CO, rSO2, TCD) will be recorded at 8 moments:
baseline, in the operating room before anesthetic induction (non invasive arterial pressure)
end of surgery, before awakening (ETT group) or before ETT replacement (LMA group)
at 1, 5, 10, 15, 30 and 60 min after extubation or LMA removal (according to group assignment)."
1497382|NCT02988791|Dietary Supplement|probiotic (BIfidobacterium, BB-12®)|probiotic (Bifidobacterium, BB-12®)
1497383|NCT02988791|Dietary Supplement|Placebo|Placebo
1497384|NCT02988778|Drug|Budesonid 50mcg (Noex)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
1497385|NCT02988778|Drug|Budesonid 50mcg (Busonid)|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
1497386|NCT02988765|Procedure|Groin ultrasound +/- fine needle aspiration|"Preoperative ultrasound morphometry (USM) of the inguino-femoral lymph nodes (IFLN).
The FNAC and/or FNAB is performed in case of suspicious nodes, if at least one of the selected criteria is relieved during ultrasound"
1497387|NCT02988752|Device|Electronic Mobile Device|Measure C/D Ratio With An Equipment Attached To A Ophthalmoscope That Will Determine C/D Ratio Without Touching Patient's Eyes. To Perform It We Need Mydriatic Conditions.
1497388|NCT02988752|Device|Optical Coherence Tomography|Measure C/D Ratio With OCT, Considered Gold Standard Equipment
1497389|NCT02988739|Biological|seasonal influenza vaccine|influenza vaccine containing 15 µg haemagglutinin of three seasonal influenza virus strains recommended by WHO
1497390|NCT02988739|Device|fractional Er:Yag laser|Fraction laser device to apply micorpores of defined depth and density into skin.
1497391|NCT02988726|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a recurrent/residual Neurofibroma or Schwannoma will receive Antineoplaston therapy (Atengenal + Astugenal).
1497392|NCT02988713|Device|Programming|Programming spinal cord stimulation (SCS) in patients undergoing a Boston Scientific (BSC) spinal cord stimulation (SCS) temporary trial
1497394|NCT02988700|Drug|caudal plain bupivacaine 2.5mg/kg 0.25%|"The sacral hiatus between the sacral conru will be palpated. While inserting the 23-G needle at 45° to the skin in the midline, a distance give or pop will be felt as the needle passes the sacral ligament into the caudal space, the needle will be tilted more toward the skin surface and inserted 2‑3mm deeper."
1497395|NCT02988661|Behavioral|Chronic Disease Self-Management Program (CDSMP)|The CDSMP consist of 6 weekly classes of two and a half hours each one, for six weeks. A group of 10-16 people with different chronic conditions attend the classes together. Classes are facilitated by two certified leaders, one or both of whom are non-health professionals with chronic diseases. The workshop covers topics such as: 1) how to deal with frustration, fatigue, pain and isolation, 2) exercise for maintaining and improving strength, flexibility, and endurance, 3) communicating effectively with family, friends, and health professionals, 4) nutrition, 5) decision making, 6) appropriate use of medications and how to evaluate new treatments. Participants receive a companion book, Living a Healthy Life with Chronic Conditions, and an audio relaxation CD, Relaxation for Mind and Body.
1497396|NCT02988648|Radiation|Radioiodide (131I-)|The Phase I portion will follow a 3+3 design with 4 dose levels (30, 60, 120, and 200 mCi) of I- treatment. The maximum tolerated dose (from Phase I) will be used in the Phase II efficacy assessment which will follow a Simon's optimal two-stage design.
1497397|NCT02988635|Other|Early Palliative Care|Subjects who are randomized to the Standard Oncology Care with Early Palliative Care will meet with the palliative care team at their next medical oncology or infusion visit. They will meet with the palliative care clinician at least every three weeks. They will complete questionnaire at 12 weeks after enrollment.
2001959|NCT02633306|Device|transcranial magnetic stimulation|Treatment will consist of five daily sessions of transcranial magnetic stimulation of the motor cortex contralateral to the pain.
2001960|NCT02631707|Other|High protein diet|The intervention diet is higher in protein than the control diet.
2001961|NCT02631044|Biological|JCAR017 single-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon successful generation of JCAR017 product, participants will receive treatment with one or more cycles of JCAR017 therapy. Each cycle will include lymphodepleting chemotherapy followed by one or two doses of JCAR017 administered by intravenous (IV) injection. Participants who respond to treatment but who have not achieved a complete response (CR) may receive additional cycles of study treatment on the dose and schedule to which they were initially assigned.
2001962|NCT02631044|Biological|JCAR017 2-dose schedule|Participants will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of JCAR017. During JCAR017 production, participants may receive low-dose chemotherapy for disease control. Upon product availability, participants will receive study treatment consisting of lymphodepleting chemotherapy followed by two IV doses of JCAR017. Participants who respond to treatment but who have not achieved a complete response (CR) may receive additional cycles of study treatment on the dose and schedule to which they were initially assigned.
1497403|NCT02988583|Device|Surgery using low viscosity silicone oil|Pars plans vitrectomy using low viscosity silicone oil
1497404|NCT02988583|Device|Surgery using high viscosity silicone oil|Pars plans vitrectomy using high viscosity silicone oil
1497405|NCT02988570|Behavioral|computer-evaluation of the language|A computer-evaluation of the language will be done for children born very preterm preterm in 2011 in the region of Haute-Normandie in France
1497406|NCT02988557|Procedure|walking on a treadmill with a sloped surface|walking on a treadmill with a sloped surface
1497407|NCT02988557|Device|treadmill|walking on a treadmill with a sloped surface
1497408|NCT02988544|Procedure|Artificial shrinkage|
1497410|NCT02988518|Behavioral|COGMED program|"Patient should connect on his computer at home, 5 times a week, for 5 weeks. Every day, the patient has to do 8 exercises for a total duration of 30 to 45 minutes.
In total, the patient will have to complete 25 sessions. The difficulty level of the proposed items adjust automatically to the patient's maximum capacity to compel him to provide a cognitive effort. A progression index assesses the progress made by the patient.
Every week, the investigator will call the patient for 10 minutes in order to gather the patient's feelings, his difficulties, provide some advice and encourage him.
The investigator will have to analyze the results of curves available for each event, as well as the patient's progress index."
1497411|NCT02988505|Other|Standard care|
1497412|NCT02988492|Device|MRI perfusion imaging|Evaluate the sensitivity and specificity of whole--‐brain CTP in predicting 24 hour DWI--‐MRI infarct in patients with acute proximal anterior circulation occlusions successfully recanalized with endovascular treatment.
1497413|NCT02988479|Other|Out of pocket payments in patients|
1497414|NCT02988466|Biological|Haplo HCT <55 years old|"Fludarabine (Flu)
Cyclophosphamide (Cy)
Melphalan (Mel)
Total body irradiation (TBI)
Non-T-cell depleted donor bone marrow stem cell infusion Day 0"
1497415|NCT02988466|Biological|Haplo HCT ≥55 years old|"Fludarabine (Flu)
Cyclophosphamide (Cy)
Melphalan (Mel): Dose reduction by 30%
Total body irradiation (TBI)
Non-T-cell depleted donor bone marrow stem cell infusion"
1497416|NCT02988466|Drug|GVHD Prophylaxis|"Cyclophosphamide (Cy)
Tacrolimus (Tac)
Mycophenolate mofetil (MMF)"
1497417|NCT02988453|Other|MBT-CD|MBT-CD is a disorder-specific modification of MBT, initially developed for patients with Borderline Personality Disorder. It is a manualized and psychodynamically oriented psychotherapy with the aim to increase the mentalization capacity of adolescents in close relationships. The therapy consists of 6 psychoeducational group sessions, 30 individual therapy sessions and 10 family sessions. The average duration of therapy is 12 months.
1497418|NCT02988453|Other|treatment as usual (TAU)|Patients in TAU will receive standard routine care provided in the German health care system. They will be assessed and advised for treatment at an outpatient clinic for adolescents with self-harming, aggressive or antisocial behavior.
1497421|NCT02988401|Drug|Insulin|All patients will receive either insulin or placebo through an air spray pump during the first 24 weeks of the study.
1497423|NCT02988388|Procedure|Lung biopsy/lobectomy|Lung biopsies and lobectomies are not experimental. Participants will undergo a lung biopsy or a lobectomy as part of standard of care.
1497424|NCT02988375|Behavioral|dCBTI|
1497425|NCT02988375|Behavioral|Sleep Education|
1497426|NCT02988362|Drug|HL068 16/10mg|Candesartan 16mg and Amlodipine 10mg
1497427|NCT02988362|Drug|Candesartan 16mg and Amlodipine 10mg|
2001963|NCT02629120|Drug|Campath|a humanized monoclonal antibody directed against CD52 (which is abundantly expressed on all human lymphocytes), and causes T cell activation in vitro as well as complementmediated lysis and antibodydependent cellular toxicity. for this study, being used as part of the conditioning regimen. Given IV (dose escalation) over 5 days per package insert and and standard of practice
1497429|NCT02988323|Other|Cervicovestibular Physio (CV PT)|See description in CVPT arm
1497430|NCT02988323|Other|Low-Level Aerobic Exercise (LLAE)|See description in LLAE arm
1497431|NCT02988323|Other|Combination (LLAE and CV PT)|See description in LLAE and CVPT arm
1497432|NCT02988310|Other|No intervention|
1497433|NCT02988297|Drug|RNS60|Nebulized RNS60 will be administered by daily inhalation for 24 weeks.
1497434|NCT02988297|Drug|Placebo|Nebulized Placebo will be administered by daily inhalation for 24 weeks.
1497435|NCT02988284|Other|No intervention|
1497436|NCT02988271|Behavioral|Symptom Questionnaires|Questionnaires completed at baseline and at end of study visit. Questionnaires should take about 15-20 minutes total to complete.
1497437|NCT02988271|Behavioral|Meditation Video|On Day 1, participants watch a pre-recorded video on their device app that explains the practice of meditation, and what to expect during meditation.
1497438|NCT02988271|Behavioral|Meditation|Participants to meditate at least 1 time every day for up to 2 weeks using the meditation app on their device.
1497439|NCT02988271|Behavioral|Mood Questionnaires|Participants complete a questionnaire about their mood before and after each meditation session using the app on their device.
1497440|NCT02988271|Behavioral|Interview|At end of study visit, participant has an interview with a member of the study staff. Participant asked questions about their opinions on meditation and if they think they benefited from meditation. Interview should take about 10 minutes to complete.
1497441|NCT02988271|Behavioral|Support Services|Participants will have access to their doctor as well as access to social workers, support groups, spiritual care, and other patient services for two weeks.
1497442|NCT02988258|Genetic|CMV-TCR transduced donor-derived T cells|Dose escalation
1497443|NCT02988245|Drug|Prescription Drugs|Using either Genetics or JNC-8 guidelines for prescribing for patients with hypertension
1497444|NCT02988232|Drug|Sogyeonghwalhyeol-tang|herbal extract
1497445|NCT02988232|Drug|Placebo|extract powder with same appearance, odor and color as SGHH
1497446|NCT02988219|Drug|Bupivacaine-fentanyl|Local anesthetic
1497447|NCT02988219|Device|Holter ECG monitor|3-chanel, CM5 leads
1497448|NCT02988219|Procedure|Open kidney cancer surgery|Lateral position
1497449|NCT02988219|Procedure|General anesthesia|
1497450|NCT02988219|Procedure|Epidural Anaesthesia|
1497451|NCT02988206|Behavioral|Personalized Objects|personalized objects are based on the observation or the reports from family
1497452|NCT02988206|Behavioral|non-personalized Objects|non-personalized objects are based on the suggestion in CRS-R,which are comb and cup
1497453|NCT02988193|Device|optima4BP medication optimization|A clinical reasoning expert system is used to determine the need for a medication treatment optimization. If a treatment optimization is needed, the expert system generates a recommendation that is sent to the treating physician.
1497454|NCT02988180|Other|basic services|The age-matched control children received the basic services such as family-home, food, clothing, health care, protection and education. However, they were not provided with the play-based developmental stimulation.
1497455|NCT02988180|Other|the play-based developmental stimulation|Children in the intervention group received basic services such as family-home, food, clothing, health care, protection and education for older children. In addition, there received play-based developmental stimulation integrated into the services.
1497456|NCT02988154|Other|Simulation training|Simulation training (computer simulation of the procedure, followed by simulation on a dead animal model).
1497457|NCT02988154|Other|''See one, do one'' approach|The participants watch an experienced surgeon perform the EVD placement, after which the participants attempt to perform the procedure independantly on the skull model.
1497458|NCT02988128|Device|Treatment for intracranial aneurysms|Embolization of aneurysms
1497459|NCT02988115|Drug|bempedoic acid|bempedoic acid 180 mg tablet
1497460|NCT02988115|Other|placebo|Matching placebo tablet
1497461|NCT02988102|Other|Following S100B and NSE in head trauma|Following S100B and NSE in head trauma in correlation with Head CT and post concussion syndrome and Lisat11
1497462|NCT02988089|Drug|Clarithromycin susceptibility dependant strategy|"Patients in this group will receive a 14-day bismuth-based quadruple regimen to eradicate H. pylori. Antimicrobial susceptibility testing (AST) will be used to test the susceptibility of clarithromycin.
If clarithromycin is susceptible, amoxicillin 1 g b.i.d and clarithromycin 500 mg b.i.d will be chosen; If clarithromycin is resistant, amoxicillin 1 g bid and furazolidone 100 mg b.i.d will be chosen."
1497463|NCT02988089|Drug|2 susceptible antibiotics (amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline )|Patients in this group will receive a a 14-day bismuth-based quadruple regimen to eradicate H. pylori. The regimen is consist of a PPI, Colloidal Bismuth Pectin and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
1497464|NCT02988089|Drug|proton pump inhibitor (PPI) and Colloidal Bismuth Pectin|all patients need these two drugs.
1497465|NCT02988089|Drug|amoxicillin and clarithromycin or amoxicillin and furazolidone|patients in the 6 antibiotics dependant group will use these intervention.
1497466|NCT02988089|Drug|amoxicillin and furazolidone or amoxicillin and tetracycline|salvage therapy for negative culture when the results of culture are negative
1497467|NCT02988089|Drug|amoxicillin and furazolidone or amoxicillin and Tinidazole or amoxicillin and Levofloxacin|salvage therapy for failed eradication if failed with AST guided eradication therapy
1497468|NCT02988063|Drug|Polidocanol Endovenous Microfoam (PEM)|Polidocanol endovenous microfoam (PEM) is a sclerosing agent indicated for the treatment of incompetent great saphenous veins, accessory saphenous veins, and visible varicosities of the great saphenous vein system above and below the knee. PEM improves the symptoms of superficial venous incompetence and the appearance of visible varicosities.
1497469|NCT02988050|Drug|Remifentanil|Remifentanil used for conscious sedation.
1497470|NCT02988050|Drug|Dexmedetomidine|Dexmedetomidine used for conscious sedation.
1497471|NCT02988050|Drug|Propofol|Used for conscious sedation.
1497472|NCT02988050|Drug|Bupivacaine|Local anaesthetics
1497473|NCT02988050|Drug|Lidocaine|Local anaesthetic
1497474|NCT02988050|Drug|Epinephrine|With local anaesthetic for skin infiltration.
1497475|NCT02988037|Behavioral|A-DBT-A|Adapted Dialectical Behaviour Therapy for Adolescents
1497476|NCT02988024|Drug|LY03005|LY03005
1497477|NCT02988024|Drug|Pristiq|
2001964|NCT02629120|Drug|Busulfan|an alkylating chemotherapeutic agent determined to have broad myelosuppressive effects. On this study is being used as part of the conditioning regimen for its myelosuppressive properties. Given IV over 2 or 3 days depending on donor cells (sibling vs. unrelated donors) per package insert and standard of practice
2001965|NCT02629120|Other|allogeneic peripheral blood allograft infusion|Prepared per the standard of operating procedure established in Department of Transfusion Medicaine and infuse
2001966|NCT02629120|Drug|cyclophosphamide|Cyclophosphamide is an antineoplastic and for this study being used for its immunosuppresive mechanism of action. Patient will be given Cyclophosphamide 50 mg/kg/d IV per package insert and standand of care on Day +3 and 4 after receiving the cells
2001967|NCT02625961|Biological|pembrolizumab|
2001968|NCT02621463|Device|Noninvasive Ventilator (V60, Philips)|The clinician will determine the concentration of oxygen that shall be delivered to the patient. The ventilator is capable of providing concentrations between 21% - 100% of oxygen. Unless otherwise directed by the clinician, the default setting of 40% will be used.
1497484|NCT02987985|Drug|Acetaminophen, gabapentin|acetaminophen 15 mg/kg, gabapentin 10 mg/kg
1497485|NCT02987985|Drug|Acetaminophen|acetaminophen 15 mg/kg
1497486|NCT02987985|Drug|Ketamine , Lidocaine , Dexmedetomidine|Ketamine 0.5 mg/kg, Lidocaine 1 mg/kg, Dexmedetomidine 0.3 mcg/kg
1497487|NCT02987985|Drug|Fentanyl, Dexmedetomidine|Fentanyl 0.5 mcg/kg, Dexmedetomidine 0.3 mcg/kg
1497488|NCT02987985|Drug|Dexamethasone , Ondansetron|Dexamethasone 150 mcg/kg, Ondansetron 50 mg/kg
1497489|NCT02987985|Drug|Sevoflurane|Sevoflurane (dose titrated to effect)
1497490|NCT02987985|Drug|Sevoflurane, Fentanyl|Sevoflurane (dose titrated to effect), Fentanyl as needed (dose at anesthesiologist's discretion)
2001971|NCT02617654|Drug|Liraglutide|Treatment with liraglutide for 52 weeks
2001972|NCT02617654|Drug|Placebo for liraglutide|Placebo for liraglutide. Treatment once daily for 52 weeks
1497494|NCT02987959|Drug|TAK-228|TAK-228 is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128) targets 2 distinct mTOR complexes, mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2).
1497495|NCT02987946|Device|IPD Device delivered by Converis|After randomization patients will be subjected to perioperative (48 hrs) intermittent pneumatic compression.
1497496|NCT02987946|Drug|Fraxiparine|All patients receive Fraxiparine 2850 IE daily, starting preoperatively compatible with current practice.
1497497|NCT02987920|Drug|Dextromethorphan|Additional medication to perioperative analgesic regimen in Group B
1497498|NCT02987920|Drug|Placebo - Concentrate|Additional medication to perioperative analgesic regimen to Group A
1497499|NCT02987920|Drug|Acetaminophen|Multimodal analgesic regimen to Group A and Group B
1497500|NCT02987920|Drug|Oxycodone|Multimodal analgesic regimen to Group A and Group B
1497501|NCT02987920|Drug|Celecoxib|Multimodal analgesic regimen to Group A and Group B
1497502|NCT02987920|Drug|Pantoprazole|Multimodal analgesic regimen to Group A and Group B
1497503|NCT02987920|Drug|Ketorolac|Multimodal analgesic regimen to Group A and Group B
1497504|NCT02987920|Drug|Gabapentin|Multimodal analgesic regimen to Group A and Group B
1497505|NCT02987920|Drug|Hydromorphone|Multimodal analgesic regimen to Group A and Group B
1497506|NCT02987907|Drug|Dexamethasone|use dexamethasone 10mg (2ml) I.A. during TACE
1497507|NCT02987907|Drug|Normal Saline|use normal saline 2ml I.A. during TACE
2001973|NCT02616562|Drug|NNC0195-0092|Administered subcutaneously (s.c., under the skin) once-weekly.
2001974|NCT02616562|Drug|Norditropin® FlexPro® pen|Administered subcutaneously (s.c., under the skin) once daily.
2001975|NCT02615743|Behavioral|Daily Text message reminder|Subjects in the intervention arm will receive once daily text messages at the time of their choice or at a default time of 7am. The text message will remind them to give their child their controller medication and provide a helpful information on asthma controller use.
1497512|NCT02987855|Procedure|Lipoaspiration|Closed syringe harvesting subdermal fat
1497513|NCT02987855|Procedure|ADcSVF isolation|Isolation of AD-cSVF from lipoaspirate via enzymatic digestion
1497514|NCT02987855|Procedure|Normal Saline IV|Normal Saline IV containing autologous AD-cSVF
1497515|NCT02987842|Device|TruScan Neurofeedback|Neurofeedback and quantitative EEG system
1497517|NCT02987816|Device|Sham tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
1497518|NCT02987816|Device|Anodal tDCS|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned over the left primary motor cortex, and the cathode over the contralateral supraorbital area.
1497519|NCT02987803|Other|Data|The intervention is a data tool developed by Ovia Health to display hospital-level cesarean delivery rates from The Leapfrog Group customized to the user's geographic location.
1497520|NCT02987790|Other|C-reactive protein|PCR assays shall be performed daily on serum obtained from blood collected for routine intensive care examinations up to 2 days after antibiotic withdrawal. In the PCR group, antibiotic suspension will be encouraged when levels of this marker are <35mg / L (if peak PCR below 100mg / L); or reduce 50% of the highest value (if PCR peak> 100mg / L), with a limit of seven days, if there is clinical improvement.
2001976|NCT02615743|Device|Inhaled steroid canister monitor|An electronic monitor will be affixed to subjects' inhaled steroid canister and families will be instructed to use the inhaler as directed by their physician. Subjects will not receive daily text messages.The canister monitor, the Propeller sensor (Propeller, Madison, Wisconsin) is an FDA-approved, portable device which affixes to the top of most metered dose inhaler canisters. The devices records the number and time of each inhaler actuation and transmits this information to either a smart phone or cellular modem. Data is then sent via the cellular network to the secure Propeller server. The data will then be downloaded monthly.
1497522|NCT02987751|Drug|Glargine + Glulisine|Glargine should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit and Glulisine should be taken 20 minutes before breakfast/dinner, the dose is adjusted as per postprandial blood glucose during each visit
1497523|NCT02987751|Drug|Premixed analogue insulin (70/30)|Premixed analogue insulin should be taken 30 minutes before breakfast/dinner, the dose is adjusted as per fasting blood glucose during each visit.
1497524|NCT02987738|Drug|Dapagliflozin|two administrations in the evening and 12 hours later
1497525|NCT02987738|Drug|Placebo Oral Tablet|two administrations in the evening and 12 hours later
2001977|NCT02615197|Behavioral|Dialectical Behavior Therapy|Includes all components of standard DBT (individual therapy, group skills training, phone coaching, and therapist consultation team).
1497527|NCT02987712|Other|Thromboelastography based protocol|patients will be treated according to a new thromboelastography based protocol
1497528|NCT02987699|Drug|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dose of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
1497529|NCT02987699|Drug|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 1400 mg/m2 (2) oxaliplatin: 135 mg/m2 (3) leucovorin: 400mg/m2
1497530|NCT02987699|Drug|5-Fu, oxaliplatin , leucovorin|Drug: 5-Fu, oxaliplatin and regular dosage of leucovorin Regimen: (1) 5-Fu: 2800 mg/m2 (2) oxaliplatin: 85 mg/m2 (3) leucovorin: 400mg/m2
2001978|NCT02615197|Behavioral|Dialectical Behavior Therapy Prolonged Exposure protocol|Includes an adapted version of Prolonged Exposure therapy for PTSD.
1497532|NCT02987673|Procedure|MGB/OAGB|
1497533|NCT02987673|Procedure|LSG|
1497534|NCT02987660|Procedure|Topography Guided LASIK|Corneal surgery for refractive error correction
1497535|NCT02987660|Procedure|Small Incision Lenticular Extraction|Refractive surgical procedure for the correction of myopia with or without astigmatism
1497536|NCT02987660|Device|WaveLight EX500 Excimer Laser System|As used for corneal stroma ablation (refractive error correction). The treatment is intended to last the subject's lifetime.
1497537|NCT02987660|Device|VisuMax Surgical Laser|As used for lenticule creation/removal (refractive error correction). The treatment is intended to last the subject's lifetime.
1497538|NCT02987647|Other|Hidrafemme|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
1497539|NCT02987647|Other|Vagidrat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
1497540|NCT02987647|Other|Lubrinat|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
1497541|NCT02987647|Other|Antrofi|The complete treatment will have followed four weeks of duration and application of the product should take place twice a week.
1497542|NCT02987634|Other|PeriActive|mouthwash
1497543|NCT02987621|Device|tDCS|Less than 10V of Transcranial Direct Current Stimulation
1497544|NCT02987621|Device|Sham tDCS|Sham 0V of Transcranial Direct Current Stimulation
1497545|NCT02987608|Device|Power Up|Smartphone phone app
1497546|NCT02987595|Other|Whole-grain rye, high lignan|Intervention week 1-8: 50 g rolled rye + 50 g puffs + 4 pieces of crisp bread + 70 g pasta. Additionally for intervention week 4-8: 4 lignan capsules per day
1497547|NCT02987595|Other|Whole-grain wheat, low lignan|Intervention week 1-8: 100 g puffs + 4 pieces of crisp bread + 70 g pasta.
1497548|NCT02987582|Behavioral|Emotion-focused mindfulness group|Intervention The group will run for 8-weeks. Each group session is 2 and a half hours. Half way through the intervention there will be a 5 hour retreat on the weekend. A typical group format includes 20-40 minutes of meditation, followed by 10 minutes of independent journaling. Then group members will have time to report on recollections from meditation and facilitators will provide feedback. There is a break and the second part of the group focuses on a didactic teaching topic. Topics change each week; groups will run between October 2016 and June 2018.
1497549|NCT02987569|Behavioral|mConnect plus mobile connections to multidisciplinary professionals & peers|mConnect is the integration of evidence-based HPN interventions delivered via professionally moderated iPad visual meetings with peers, and reinforced by HPN related skill-building games (apps) and iPad music guided short naps.
1497550|NCT02987569|Behavioral|iPad use plus one mobile connections to multidisciplinary professionals & peers|iPad with a data plan and one professionally moderated iPad visual meeting with peers.
1497551|NCT02987569|Device|iPad|
2001979|NCT02609672|Other|Exercise|A biomechanical exercise program shown to decrease joint loading was administered 3 times a week for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
2001980|NCT02609672|Other|No Exercise|A no exercise (control) group maintained their existing activity level for 12 weeks. Outcomes included mobility performance; pain; strength; cardiovascular fitness; and resilience.
2001981|NCT02610543|Drug|UCB5857|Active Substance: UCB5857 Pharmaceutical form: Capsule Concentration: 5 mg, 10 mg, 30 mg Route of administration: oral
2001982|NCT02610543|Drug|Placebo|Active substance: Placebo Pharmaceutical Form: Capsule Route of administration: oral
2001983|NCT02610426|Other|Laboratory Biomarker Analysis|Correlative studies
2001984|NCT02610413|Other|Laboratory Biomarker Analysis|Correlative studies
1497566|NCT02987491|Behavioral|Exercise|Participants will perform 2 metabolic study days of either resting or acute bout of cycling exercise in a randomized cross-over design.
1497567|NCT02987465|Drug|Darbepoetin Alfa|Darbepoetin is not a study drug and is prescribed as part of routine treatment of anaemia in CKD1. Darbepoetin is licensed for use for the treatment of anaemia in the context of CKD. It will be provided as part of the standard clinical care of the renal patients in this study. Healthy Volunteers will not be treated with Darbepoetin.
1497568|NCT02987465|Drug|Acetylcholine|Acetylcholine is being used as a challenge agent in this study and assesses NO-mediated vasodilation
1497569|NCT02987465|Drug|Noradrenaline|Noradrenaline is being used as a challenge agent in this study and is an endogenous a1 adrenoceptor agonist
1497570|NCT02987465|Drug|BQ 123|BQ 123 is being used as a challenge agent in this study and is an (Endothelin A) ETA receptor agonist.
1497571|NCT02987452|Other|aerobic exercise|Aerobic exercise (EA): activity on a treadmill lasting 45 minutes with intensity of 50-60% of maximum heart rate (HR) obtained from ergometer test
1497572|NCT02987452|Other|resistance exercise|resistance exercise (RE): 4 series of 12 repetitions of resistance exercises at moderate intensity (until moderate fatigue), for 45 minutes
1497573|NCT02987452|Other|combined exercise|combined exercise (CE): EA (25 minutes) + ER (20 minutes), with an interval of 2 minutes between sessions totalizing 45 minutes
1497574|NCT02987439|Other|Pulmonary rehabilitation|The intervention is pulmonary rehabilitation
1497575|NCT02987426|Behavioral|Mindfulness-oriented intervention|"The 10 minutes daily sessions every weekday, will take place at the inpatient unit in groups of 10 people. The intervention will be alternating between three forms of moving mindfulness-oriented interventions as detailed below:
Seated Tai Chi: patients will slowly move their arms in soft movements coordinated with slow breaths Gentle stretching: patients will slowly stretch their bodies coordinated with the breath and with awareness of physical sensations throughout the body4 Walking meditation: patients will walk slowly in no particular direction, focusing close attention on the act of walking"
1497576|NCT02987413|Biological|Autologous Mesenchymal stem cells (MSCs)|2 intrathecal autologous MSCs infusions (1x10^8 cells) will be performed, escalated from 30 days apart
1497577|NCT02987400|Drug|Venetoclax|3 cycles followed by 9 cycles consolidation if not transplant eligible
1497578|NCT02987400|Drug|Obinutuzumab|3 cycles followed by 9 cycles consolidation if not transplant eligible
2001985|NCT02611310|Other|No intervention|No intervention administered in this study.
1497580|NCT02987374|Biological|2011-2012 Fluzone IIV3 (IM)|2011-2012 Fluzone IIV3 vaccine delivered intramuscularly (IM)
1497581|NCT02987361|Device|DC-STIMULATOR PLUS|2mA for 20minutes a day, 5 days per weeks, totally 2 weeks
1497582|NCT02987348|Drug|exenatide once weekly|patients received exenatide once weekly treatment under their standard care, no intervention was given by the study investigator
1497583|NCT02987348|Drug|exenatide twice daily|patients with exenatide twice daily treatment under their standard care, no intervention was given by the study investigator.
1497584|NCT02987348|Drug|basal insulin|patients with basal insulin treatment under their standard care, no intervention was given by the study investigator
1497585|NCT02987335|Drug|Pancreatic Clamp|We are not performing any interventions; we are only characterizing participants using tests. The hormones that we are administering are not a treatment but are typically used in context of routine care.
1497586|NCT02987322|Dietary Supplement|honey|Ziziphus honey (sider honey) orally in a dose of 1ml (1.2g)/kg/day for 3 months
1497587|NCT02987296|Dietary Supplement|Immunonutrition with arginine|Nutritional beverage containing supplemental arginine taken 3 times per day
1497588|NCT02987296|Dietary Supplement|Immunonutrition without Arginine|Nutritional beverage without supplemental arginine taken 3 times per day
1497589|NCT02987270|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine is an antimalarial in the artemisinin-based combination therapy class of drugs. It is the Kenya Ministry of Health second-line treatment for malaria in Kenya.
1497590|NCT02987257|Drug|cyclosporin A|
1497591|NCT02987257|Drug|Etanercept 50 MG Solution for Injection|
1497592|NCT02987257|Drug|Placebos|Intravenous and subcutaneous saline to match cyclosporine and etanercept in an identical delivery container/syringe
1497593|NCT02987244|Drug|Chidamide|"Six cycles of therapy will be administered,and each cycle of treatment is 28 days.
Phase I: Patients were treated at the following dose levels: 15, 20, and 25 mg twice per week to determine the MDT Phase II: If MTD was not reached at 25mg dose level of Chidamide. The followed study will use 20mg twice per week as experimental dose."
1497594|NCT02987244|Drug|Cyclophosphamide|Cyclophosphamide(750mg/m2) was administered intravenously on d1
1497595|NCT02987244|Drug|Epirubicin|epirubicin (70mg/m2)was administered intravenously on d1;
1497596|NCT02987244|Drug|Vindesine|vindesine (4mg)was administered intravenously on d1;
1497597|NCT02987244|Drug|Etoposide|etoposide (100mg) was administered intravenously on d1,2,3.
1497598|NCT02987244|Drug|Prednisone|prednisone (60mg/m2)was administered intravenously by oral d1-5.
1497599|NCT02987231|Procedure|CAF|Periodontal plastic surgery for root coverage by the trapezoidal flap
1497600|NCT02987231|Device|ES|Local electric stimulation for 120 seconds, once a day for a week
1497601|NCT02987231|Device|SHAM|Simulation of electric stimulation protocol. In Sham stimulation non current will be applied
1497602|NCT02987218|Drug|Propofol|Intravenous hypnotic agent Decrease Cerebral Metabolic reduction Decrease ICP Better cognitive Function preservation
1497603|NCT02987218|Drug|Desflurane|Inhalational agent. Decreases cerebral metabolism Increase /decreases ICP Cognition preservation
2001986|NCT02609594|Other|Weekly application of Amnioband|Weekly application of Amnioband.
1497606|NCT02987192|Device|pen type 27 gauge needles|minimally invasive group patients will receive pen type 27 gauge needles.
1497607|NCT02987192|Device|cutting type 22 gauge needles|traditional group patients will receive cutting type 22 gauge needles.
1497608|NCT02987179|Other|Observational|Collect anthropomorphic, WatchPAT, Crit-line Monitor measurements as well as sleep questionnaires and video records
1497609|NCT02987166|Radiation|High-Dose Conformal Radiation Therapy|"24 Gy in 3 fractions of 8Gy each for bone and/or soft tissue lesions
30 Gy in 5 fractions of 6 Gy each for prostate gland"
1497610|NCT02987166|Drug|Pembrolizumab|200 mg
1497611|NCT02987153|Radiation|Kypho-IORT|The radiation source is inserted into the lesion and switched on for a few minutes to provide intraoperative radiotherapy accurately targeted to the tissues that are at the highest risk of local recurrence. The dosimetric characteristics and clinical applications of this device have been well studied.
1497612|NCT02987140|Behavioral|Clinical evaluations|Participants will receive clinical evaluations, and practice the finger sequence task used to assess context-dependency along with EEG assessment. On the second day, the participants will receive the TMS assessment.
1497613|NCT02987114|Drug|PLT101|PTL 101 (Cannabidiol, CBD) Two piece hard capsules filled with seamless gelatin matrix green beads containing CBD (50 or 100 mg CBD per capsule) The beads should be administered following a meal, mixed with food
1497614|NCT02987101|Procedure|Liposuction|Adipose tissue is harvested by liposuction from either abdomen or thighs.
1497615|NCT02987101|Other|Standard wound care|Patients will receive standard wound care and dressings independent of their participation in this study at the discretion of the wound nurses.
1497616|NCT02987101|Drug|Adipose-Derived Regenerative Cells|Cells isolated from adipose-derived tissue will be injected locally around and under the wound.
1497617|NCT02987088|Drug|Sodium Nitrite|
1497618|NCT02987075|Other|Compacting embryo transferring|transfer of 2 utilizable compacting embryos
1497619|NCT02987075|Other|Non- compacting embryo transferring|transfer of 2 utilizable non-compacting embryos have 7-9 cells with under 20% fragmentation.
1497620|NCT02987036|Device|Aerogen|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by mesh nebulizer
1497621|NCT02987036|Device|Jet nebulizer|Two doses of aerosolized Albuterol sulfate (2.5 mg dissolved in saline) At study start (T l 0) and after 6 hours (Tll0) by Jet nebulizer
1497622|NCT02987023|Procedure|uterus transplantation|Uterus transplantation from live donor
2001987|NCT02609594|Other|Biweekly application of Amnioband|Biweekly application (every two weeks) of Amnioband.
1497624|NCT02986984|Other|There is no intervention|There are no interventions
1497625|NCT02986971|Device|New IMD|The contraceptive implants of the subjects in this arm are removed by the new IMD.
1497626|NCT02986958|Other|Pre-visit patient-family agenda-setting checklist|Pre-visit patient-family agenda-setting checklist
1497627|NCT02986958|Other|Usual care|routine primary care
1497628|NCT02986945|Behavioral|Resiliency App|
1497629|NCT02986932|Device|BBB opening|Open BBB using ExAblate focused ultrasound and (Definity®) contrast agent
1497630|NCT02986919|Drug|CPI-0610|"Optional tumor biopsy will be obtained prior to Day 1 of CPI-0610 administration.
CPI-0610 will be administered 200mg orally once a daily for 14 consecutive days followed by a 7-day break. The 14 days of CPI-0610 dosing and the 7-day break together constitute 1 cycle of treatment. The dose will not be adjusted for body weight or body surface area."
1497631|NCT02986906|Drug|5% dextrose|Ultrasound-guided 5cc 5% dextrose injection between medial epicondyle and ulnar nerve
1497632|NCT02986906|Drug|2cc 2% Xylocaine+3cc Triamcinolone (30mg)|Ultrasound-guided 2cc 2% Xylocaine+3cc Triamcinolone (30mg) injection between medial epicondyle and ulnar nerve
1497633|NCT02986906|Device|Ultrasound|The ultrasound was used for injection guidance
1497634|NCT02986893|Behavioral|Dietary Intervention|Participants will be assigned to follow a specific diet for 6 months. This will involve meetings with the study nutritionist at least monthly as well as regular assessments related to adherence and effects.
1497635|NCT02986893|Behavioral|Non-dietary Intervention Arm|Participants will be requested to follow their usual diet and attend monthly meetings at the MS center to discuss various topics with a focus on wellness in MS for 6 months.
1497636|NCT02986880|Drug|Botulinum toxin A|
1497637|NCT02986880|Procedure|Placebo|Injection of sodium chloride (NaCl) 9/1000
1497638|NCT02986867|Radiation|SAbR Treatment of Lesions|"SAbR will be administered as per the guidelines of UTSW with a single 24-27Gy or three 10-14 Gy/fraction fractions totaling 33-48Gy. Lesions receiving SAbR will be called radiated lesions."
2001988|NCT02609594|Other|Standard of Care|Standard of care for this study is weekly multi-layer compression bandaging.
1497640|NCT02986828|Drug|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
1497641|NCT02986828|Drug|Normal saline|Ultrasound-guided 3cc normal saline injection between proximal carpal tunnel and median nerve.
1497642|NCT02986828|Device|Ultrasound|
1497643|NCT02986815|Other|[11C]Acetate Brain Imaging|Patients will be imaged on a Siemens Biograph 64 slice PET CT scanner. After placing the patient on the scanner and securing the head in a head restraint, a low dose CT of the brain will be acquired. Images with 3 mm slice thickness and spaced at 1.5 mm intervals will be reconstructed in a 300 mm field of view. The purpose of the CT is for image localization and attenuation correction and it is not considered to be a diagnostic quality CT. Following the completion of the CT, the [11C]Acetate will be administered. A dynamic PET image will be acquired in 3D list mode for a total of 30 minutes.
1497644|NCT02986776|Behavioral|Inpatient Care|21 days of inpatient substance misuse treatment
1497645|NCT02986776|Behavioral|Outpatient Care|21 days of outpatient substance misuse treatment
1497646|NCT02986763|Biological|Questionnaire, blood, urine, hair and dust samplings|
1497647|NCT02986750|Device|Thealoz Duo Eye Drops|Manufacturer: Laboratoires Thea, France
1497648|NCT02986750|Device|Optive Eye Drops|Manufacturer: Allergan Pharmaceuticals, Ireland
1497649|NCT02986750|Device|Systane Ultra Eye Drops|Manufacturer: Alcon Pharma GmbH
1497692|NCT02986451|Drug|Lenalidomide|Lenalidomide 25mg PO daily on days 1-21 of a 28-day cycle
1497651|NCT02986711|Behavioral|Motivational Text Messages|Motivational text messages in addition to survey questions about smoking status
1497652|NCT02986711|Behavioral|Control|Only survey questions about smoking status
1497653|NCT02986698|Biological|in utero hematopoietic stem cell transplantation|This is a phase 1 safety study to demonstrate it is safe for both the mother and fetus to perform In utero hematopoietic stem cell transplantation of maternal derived stem cells at the time of intrauterine transplantation of red blood cells to treat fetuses affected with alpha-thalassemia major.
1497654|NCT02986685|Drug|Trimebutine Maleate|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage ,then oral trimebutine maleate 200mg three times daily combined with rabeprazole 20mg once daily were administered to the experimental arm for 4 weeks.
1497655|NCT02986685|Drug|rabeprazole|Rabeprazole 20mg once daily was administered during the 8 weeks' screening stage,and rabeprazole 20mg once daily was administered to other arm for additional 4 weeks.
1497656|NCT02986672|Dietary Supplement|Calanus oil|Omega-3 oil in form of calanus oil
1497657|NCT02986672|Other|Medical Paraffin|2ml per day
1497658|NCT02986659|Drug|Metformin|
1497659|NCT02986659|Drug|Placebo|
1497660|NCT02986633|Other|Echocardiography|
1497663|NCT02986594|Drug|Aspirin|
1497664|NCT02986594|Drug|Heparin|
1497665|NCT02986568|Drug|Cisplatin|If tumor sized ≥ 5cm, undergo neoadjuvant chemotherapy with Cisplatin before surgery. (40mg/m2 on day 1 of each 7 day cycle for 5 cycles)
1497666|NCT02986568|Drug|Cisplatin|Before surgery, neoadjuvant chemotherapy with cisplatin (40mg/m2 on day 1 of each 7 day cycle for 5 cycles) is performed.
1497667|NCT02986568|Procedure|Peritoneal mesometrial resection|Perform Fusion Peritoneal mesometrial resection (PMMR).
1497668|NCT02986568|Procedure|Radical hysterectomy|Type C radical hysterectomy.
1497669|NCT02986568|Radiation|Concurrent chemoradiation therapy (CCRT)|Radiotherapy with Cisplatin 40mg/m2 on day 1 of each 7 day cycle
1497670|NCT02986568|Procedure|Laterally extended endopelvic resection, Total mesometrial resection|"After neoadjuvant chemotherapy, if pelvic wall invasion is absent, perform Fusion Total mesometrial resection (TMMR).
If pelvic wall invasion is present, perform Fusion Laterally extended endopelvic resection (LEER) with preserving bladder, rectum and anus."
1497671|NCT02986568|Procedure|Total mesometrial resection|"If tumor size < 5cm, perform Fusion Total mesometrial resection (TMMR)
If tumor sized ≥ 5cm, perform Fusion TMMR after neoadjuvant chemotherapy with cisplatin as above."
1497672|NCT02986568|Drug|5-fluorouracil, Cisplatin|"After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy with 5-fluorouracil and cisplatin. (5-fluorouracil 1000mg/m2 on day 1-5 and Cisplatin 60mg/m2 on day 1 of each 21 day cycle)
If not, no adjuvant therapy."
1497673|NCT02986568|Drug|5-fluorouracil, Cisplatin|"After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy with 5-fluorouracil and cisplatin. (5-fluorouracil 1000mg/m2 on day 1-5 and Cisplatin 60mg/m2 on day 1 of each 21 day cycle)
If not, no adjuvant therapy."
1497674|NCT02986568|Drug|Doxorubicin, Cisplatin|"After surgery, if resection margin, more than two pelvic lymph node or more than one para-aortic lymph node is positive in pathologic report, undergo adjuvant chemotherapy with doxorubicin and cisplatin. (Doxorubin 60mg/m2 and Cisplatin 50mg/m2 on day 1 of each 21 day cycle)
If not, no adjuvant therapy."
1497675|NCT02986568|Procedure|Staging operation|Perform surgical staging include hysterectomy, bilateral salpingo-oophorectomy, pelvic lymph node dissection and para-aortic lymph node dissection.
1497676|NCT02986568|Radiation|Radiotherapy or Concurrent chemoradiation therapy (CCRT)|Undergo adjuvant therapy after surgical staging. Radiotherapy only or CCRT (radiotherapy with Cisplatin 40mg/m2 on day 1 of each 7 day cycle)
1497677|NCT02986568|Radiation|Concurrent chemoradiation therapy (CCRT)|If risk factor is reported in pathologic report, undergo adjuvant CCRT. (radiotherapy with Cisplatin 40mg/m2 on day 1 of each 7 day cycle)
1497678|NCT02986555|Device|Existing Biofeedback|Using relaxing assisted biofeedback approach
1497679|NCT02986555|Device|Biofeedback accompanied with virtual reality|Using relaxation approach with existing biofeedback accompanied by virtual reality relaxation
1497681|NCT02986529|Drug|GV-971|
1497682|NCT02986529|Drug|Placebos|
1497683|NCT02986516|Other|Randomized Cohort|Surgical treatment with different approach, based on the characteristics of the tumor or definitive high dose radiotherapy (carbon ion radiotherapy, proton-therapy, mixed photons-proton therapy) will be assigned by randomization
1497684|NCT02986516|Radiation|Prospective cohort|Surgical treatment or definitive high dose radiotherapy will be selected by the patients and will be prospectively evaluated
1497685|NCT02986503|Drug|Doxorubicin+cisplatin+ifosfamide|Chemotherapy for Good responder high grade osteosarcoma
1497686|NCT02986503|Drug|Doxorubicin+cisplatin+ifosfamide+methotrexate|Chemotherapy for Poor responder high grade osteosarcoma
1497687|NCT02986490|Biological|Blood sample|Blood sample
1497688|NCT02986477|Other|Contrast Ultrasound|For diagnostic purposes, intravesicle administration of contrast ultrasound agent will be performed to study vesicoureteral reflux.
1497689|NCT02986464|Device|Virtual Reality Prototype|VR prototype installed around the tank in the hydrotherapy room to give the child a sense of immersion in the virtual world with a possibility of interaction depending on the child's age and condition.
1497690|NCT02986464|Other|Standard Pharmacological Treatment|According to the unit's protocol and adjusted to each participant`s age, weight and condition by the anesthetist and the pain clinic nurse.
1497691|NCT02986451|Drug|clarithromycin|Clarithromycin 500mg PO twice daily on days 1-28 for a 28-day cycle.
1497693|NCT02986451|Drug|Dexamethasone|Dexamethasone 40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle.
1497694|NCT02986438|Device|Repetitive Transcranial Magnetic Stimulation|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral.
Each patient will receive consistent treatment in 2 sessions a day for 10 consecutive business days in the first two weeks, then receive 2 weekly sessions, until the year of treatment is completed. Each session will consist of the application of 30 trains of 10 seconds duration separated by intervals of one minute, at a fixed frequency (5Hz or 10Hz), to 100% of the motor threshold."
1497695|NCT02986438|Device|Repetitive Transcranial Magnetic Stimulation (Sham)|"The investigators will use a Magpro R-30 MagVenture quick stimulator, equipped with an 8-reel, 75 mm internal diameter in each spiral with a coil that allows simulated stimulation (Coil AP).
This condition will only last two weeks."
1497696|NCT02986425|Other|STRIP intervention|"The STRIP intervention consists of 9 steps:
structured history taking of medication
recording medication and diagnoses in STRIPA
structured drug review based on the STRIPA with the integrated Screening Tool of Older Person's Prescriptions (STOPP)/ Screening Tool to Alert Doctors to the Right Treatment (START) criteria
communication and discussion of the structured drug review with prescribing physician with possible adaptation of the recommendation
shared decision-making with the patient with possible adaptation of the recommendation
optional revision based on new accumulating data during hospitalisation (e.g. new diagnoses, adverse drug reactions)
generation of general practioner (GP) report
delivery of the report to the patient and to the GP (optional additional direct communication)
follow-up"
1497697|NCT02986425|Other|Control|Standard care in the department where the trial is conducted. To keep the patients and the blinded team members blinded one questionnaire will be conducted by the intervention team in both arms. This is considered a SHAM intervention.
1497698|NCT02986412|Other|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
1497699|NCT02986399|Other|Fast track patient pathway|Admittance: Ambulance - Radiology - Orthopaedic ward. Focus on preoperative information, stress reduction, pain relief, early mobilization and nutritional status.
1497700|NCT02986386|Procedure|Dental occlusion restoration|Placement of dental implants by surgical intervention followed, after a healing period of 2 months, by fabrication and installation of implant supported dental prosthesis
1497701|NCT02986386|Procedure|Orthodontic treatment of malocclusion|Orthodontic therapy to treat malocclusion
1497704|NCT02986347|Procedure|Intravenous regional anesthesia (Bier)|Intravenous regional anesthesia (Bier Technique)
1497705|NCT02986347|Procedure|Local anesthesia with adrenaline|local anesthesia with adrenaline without limber garroting (Lalonde Technique)
1497706|NCT02986334|Drug|Naproxen|Subjects enrolled in the active treatment arm will receive 500mg of Naproxen prescribed twice daily, once in the morning and evening.
1497707|NCT02986334|Drug|Omeprazole|Subjects enrolled in the active treatment arm will receive 20mg of Omeprazole prescribed twice daily, once in the morning and evening. Furthermore, subjects should take this one hour before a meal.
1497708|NCT02986334|Drug|Placebo|Subjects enrolled in the inactive treatment arm will receive two prescriptions, however, there are no active ingredients and are intended to look identical to the active treatment. Therefore, subjects will be instructed exactly the same way as if they were ingesting the active treatment.
1497709|NCT02986321|Drug|CHF6001|Dose response: Test one of 4 different doses of CHF6001
1497710|NCT02986321|Drug|Budesonide|active control
1497711|NCT02986321|Drug|Placebo|placebo control
1497712|NCT02986308|Other|No intervention|
1497713|NCT02986295|Device|BioMimeTM Stent, Ultimaster® Stent|
1497714|NCT02986282|Device|ABI measurement using both doppler and oscillometric method|
1497715|NCT02986269|Procedure|general anesthesia across LMA|general anesthesia across LMA
1497716|NCT02986269|Procedure|Spontaneous breathing(SB)|general anesthesia across LMA under SB without PSV
1497717|NCT02986269|Procedure|Pressure Support Ventilation|general anesthesia across LMA under SB with PSV
1497718|NCT02986256|Behavioral|Taking pictures|Photograph of foot ulcer with transmission to referring nurse 1 time per week
1497719|NCT02986256|Behavioral|Visit at home|Home visit by the referring nurse every 15 days
1497720|NCT02986243|Other|Exercise|6 months worth of exercise regimen
1497721|NCT02986243|Dietary Supplement|Diet Plan|Each subject will receive a personalized diet plan from nutritionist.
1497722|NCT02986230|Other|Cancer prevention wizard (CPW)|The cancer prevention wizard is a point of care clinical decision support system designed to identify patients that are due for preventative cancer services and provides evidenced-based recommendations to the patient and provider.
1497723|NCT02986217|Other|regular structured assessment of surgical performance|
1497724|NCT02986204|Procedure|removal of ENG implant|"the researcher(s) will ask you to: Visit 1 - SCREENING VISIT
questions about your medical/contraception history
Review medical record
physical examination
urine sample for pregnancy test
Visit 2a - Radiology
Have an ultrasound of your arm
The radiologist will mark your arm at the location of the implant.
Visit 2b
ultrasound of your arm to locate the implant. This is done by feeling the area.
Have your ENG implant removed through a numbed small cut. The researcher will apply a pressure bandage to the site(s). This will reduce bleeding/decrease swelling.
Have the removal procedure video recorded.
Visit 3 - FOLLOW UP VISIT approximately 2 weeks after Visit 2:
Provide a urine sample for pregnancy test
Have the implant removal site examined"
1497725|NCT02986204|Procedure|continuation of ING implant|"the researcher(s) will ask you to:
To answer questions about your medical and contraception history
Review your medical record
Have a physical examination by the researcher
Provide a urine sample for pregnancy test
Have an ultrasound of your arm"
1497726|NCT02986191|Procedure|Mucograft|This method of grafting will be used to treat the gingival recession using coronally advanced flaps.
1497727|NCT02986191|Procedure|Connective Tissue Graft|This will be used in the traditional manner to correct gingival recession
1497728|NCT02986178|Biological|PVSRIPO|A single dose of an oncolytic polio/rhinovirus recombinant (PVSRIPO)
1497729|NCT02986178|Drug|Lomustine|A single oral dose of 110 mg/m2 lomustine 8 weeks after PVSRIPO administration
1497730|NCT02986165|Dietary Supplement|Placebo control|The placebo control is water containing a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions
1497731|NCT02986165|Dietary Supplement|Low dose pomace extract|Immediately prior to ingestion, 'drinks' containing 1 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
1497732|NCT02986165|Dietary Supplement|High dose pomace extract|Immediately prior to ingestion, 'drinks' containing 2.5 g of tomato pomace extract will be prepared at the research facility. The water used to dilute the extract will be flavoured using a commercially available orange flavoured powder (Kool aid) which will be diluted according to the manufacturer's instructions before adding to the tomato pomace extract.
1497733|NCT02986152|Behavioral|Cancer Distress Coach Mobile App|"Cancer Distress Coach is a stand-alone symptom management tool with three basic components. The Learn about Distress module provides psycho-education. The Insights module includes an inspiring Quote of the Day, daily activity planning tips, a graph displaying the user's distress level plotted over time, and assessment feedback. The main action of the application is in the Activities module that provides patients with skills to manage their stress in the moment they experience it. Depending on the severity, the patient is routed to any of a number of helpful skills based on cognitive-behavioral principles. The stress management tools include positive imageries, soothing songs and pictures, and the Relax-Identify-Decide tool. Also included is find support and get support now to connect the user to his/her support network and locate informal cancer and non-cancer related support or (immediate) professional care."
1497736|NCT02986126|Behavioral|Resiliency Class|See Arm Description
1497737|NCT02986126|Other|Resource for Services (RS)|See Resource for Services (RS) Description
1497738|NCT02986113|Behavioral|MAPS tailored multimedia patient activation program|
1497739|NCT02986113|Behavioral|Sleep hygiene video|3 minute video on sleep hygiene produced by HealthiNation
1497740|NCT02986113|Behavioral|Telephone evidence-based follow-up care|3 months of suicide-focused collaborative mental health care, directed by a supervising psychiatrist and implemented by a care manager working with the patient and their primary care provider
1497741|NCT02986113|Behavioral|Commitment to Living for Primary Care|Brief (30 minutes total time) video modules presenting participating patients' primary care providers with a patient-centered framework for suicide risk assessment and intervention
1497742|NCT02986100|Drug|C-14 labeled Rucaparib|Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and [14C]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of [14C]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of [14C]-rucaparib
1497743|NCT02986100|Drug|Rucaparib|200 & 300 mg tablet
1497744|NCT02986087|Device|Fetal Tracheal Occlusion|Fetuses with congenital diaphragmatic hernia with an observed to expected lung-to-head ratio of <25%, LHR <1, o/e LHR<30% (moderate), singleton pregnancy, no known other anomalies, gestational age < 29 weeks 6 days, no maternal disease, maternal age > 18 years old meet criteria to be offered tracheal occlusion. We want to test feasibility and efficacy in our center as a requirement to enter the TOTAL trial.
1497745|NCT02986074|Device|Paresthesia mapping lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using paresthesia mapping in the first part of the SCS trial and using the lead implanted using anatomical midline placement in the second part of the SCS trial
1497746|NCT02986074|Device|Anatomical midline lead evaluation first|Subjects will evaluate the clinical efficacy of stimulation delivered using the lead implanted using anatomical midline in the first part of the SCS trial and using the lead implanted using paresthesia mapping placement in the second part of the SCS trial
1497747|NCT02986061|Device|Urinary catheter|
1497748|NCT02986048|Other|Proton Beam Therapy|Intervention is not assigned. Only patient data is being collected
1497749|NCT02986035|Other|ECA cream|
1497750|NCT02986022|Behavioral|Resilience|Self-efficacy, optimism, altruism, goal setting
1497751|NCT02986022|Behavioral|Information|Information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China
1497752|NCT02986009|Behavioral|Parenting|"The parenting intervention consists of four weekly sessions, each lasting two hours. The intervention was designed according to the parenting characteristics of Chinese parents in Hong Kong. The four sessions cover: 1) response modification (stop and rest), 2) relaxation/enhancing positive moods (relax and play), 3) cognitive reframing (think), and 4) using social support (talk and share). Discussion, practice, and questions are involved in each session."
1497788|NCT02985697|Drug|Nitrous Oxide|Nitrous oxide to be administered in conjunction with other interventions, per study design.
1497753|NCT02986009|Behavioral|Information|The information intervention consists of four weekly sessions, each lasting for two hours. The contents cover information and resources about education, medical care, housing, employment, and community facilities available in Hong Kong and Mainland China.
1497754|NCT02985996|Drug|Truvada|Truvada is intended for the treatment of HIV-1 infection. Truvada is a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg in one tablet.
1497755|NCT02985996|Drug|Genvoya|Genvoya is a 1-pill, once-a-day prescription medicine used to treat HIV-1. Genvoya is a combination of 150 mg of elvitegravir, 150 mg of cobicistat, 200 mg of emtricitabine, and 10 mg of tenofovir alafenamid in one tablet.
1497756|NCT02985983|Drug|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 66.
1497757|NCT02985983|Drug|Placebo|Administered Placebo by subcutaneous (SC) injection until week 16. Administered KHK4827 by SC injection from week 17 until week 66.
1497758|NCT02985970|Other|questionnaire|The questionnaire will be send to all members of ČSARIM with the selected 4 controversial clinical scenarios in which the RSI should be used
1497761|NCT02985944|Procedure|Colonoscopy|Colonoscopy performed in adult consecutive patients for different indications
1497762|NCT02985931|Other|Diagnostic imaging scans of SPECT and MRI|
1497763|NCT02985918|Device|High-intensity NPPV|The patients will receive noninvasive positive pressure ventilation using S/T mode. The inspiratory positive airway pressure will be initially set at 10 cmH2O, and will be continuously adjusted by increments/decrements of 1-2 cmH2O, according to subjects' tolerance (up to 30 cmH2O), to obtain a VT of 15 mL/kg of predicted body weight, and to achieve normocapnia as possible as it can.
1497764|NCT02985918|Device|Conventional-intensity NPPV|The patients will receive noninvasive positive pressure ventilation using S/T mode. The inspiratory positive airway pressure will be initially set at 10 cmH2O, and will be continuously adjusted by increments/decrements of 1-2 cmH2O, according to subjects' tolerance (up to 20 cmH2O), to obtain a VT of 10 mL/kg of predicted body weight.
1497765|NCT02985905|Dietary Supplement|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
1497766|NCT02985892|Other|SSASG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.
Patients of segmental stabilization active stretching group (SSASG) will perform stretch exercises in four sets of 30 seconds for each muscle. The active stretching exercises will last 15 minutes. The muscles that will be stretched are pectorals, latissimus dorsi, latissimus dorsi, teres major, rectus abdominis, external and internal oblique."
1497767|NCT02985892|Other|SSPSG|"Both groups will perform segmental stabilization exercises (SS), which emphasis is for the lumbar multifidus muscles (ML) and transversus abdominis (TAR), using protocol proposed by Richardson et al. Four types of exercises will be carried out with four sets of ten exercises. Muscle contractions will be held for ten seconds and followed by ten seconds rest. Between each type of exercise patients will rest for one-minute interval.
Patients of segmental stabilization placebo stretching group (SSPSG) will perform exercises that simulate stretching, but the muscles will not suffer effective stretch. The placebo stretching exercises will last 15 minutes. The muscles that will be stretched are wrist flexors and extensors muscles and fingers flexors and extensors muscles."
1497772|NCT02985840|Drug|Ondansetron|Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes
1497773|NCT02985840|Drug|Dexamethasone|Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
1497774|NCT02985827|Drug|Rohto (r) Hydra|Rohto (r) Hydra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
1497775|NCT02985827|Drug|Systane (r) Ultra|Systane (r) Ultra; Over the counter Eyedrop, 1 gtt OU single-masked in-office dose
1497776|NCT02985801|Drug|Pancrelipase|Lipase 16,000 United States Pharmacopoeia (USP) units, protease 57,500 USP units, and amylase 60,500 USP units
1497777|NCT02985801|Drug|Placebo Oral Capsule|Placebo Oral Capsule
1497778|NCT02985775|Biological|Donor-derived CMVpp65-specific T cells|About 1 million per kg CMVpp65-specific T cells will be infused once acute GVHD ocurred post haploidentical transplantation.
1497780|NCT02985749|Drug|Intranasal Oxytocin|This study is examining the short-term efficacy and tolerability of intranasal oxytocin for the treatment of social impairment in youths and adults with high-functioning ASD (HF-ASD).
1497781|NCT02985736|Drug|Topicort Topical Spray|
1497782|NCT02985723|Device|AT LISA tri toric 939MP|
1497783|NCT02985710|Device|Sudoscan|The Sudoscan is a non invasive procedure and similar to standing on a scale to be weighed. Sudoscan measurements are made in compliance with the manufacturer's recommended procedures. The measurement is rapid and non-invasive, and requires no advance preparation.
1497784|NCT02985710|Procedure|Skin biopsy|For subjects that give additional consent, skin biopsy will be done in standard fashion under sterile conditions. Assessment of nerve fiber density typically involves a 3-mm punch biopsy of skin from the leg (10 cm above the external malleolus).
1497785|NCT02985710|Procedure|QSART|QSRT (quantitative sudomotor axon reflex test) testing involves having a technician wipe the subject's arms and leg with alcohol, then tissue to wipe it dry. Electrodes filled with acetylcholine are put on three areas of the leg and one on the wrist, stimulators are turned on and sweat responses are measured.
1497786|NCT02985697|Drug|Dexmedetomidine|The intervention being tested is intranasal dexmedetomidine
1497787|NCT02985697|Drug|Midazolam Hydrochloride|Oral midazolam is being used as the Active Comparator. It will also be used in conjunction with IN dexmedetomidine in some experimental groups.
1497789|NCT02985684|Device|GORE® CARDIOFORM ASD Occluder|Percutaneous Atrial Septal Defect Closure
1497790|NCT02985671|Drug|orphenadrine, acetaminophen, caffeine and diclofenac sodium|01 tablet, orally, 03 times a day (every 8 hours), for 07 days.
1497791|NCT02985671|Drug|Voltaren® (diclofenac sodium 50mg)|01 tablet, orally, 03 times a day (every 8 hours), for 07 days.
2001991|NCT02606591|Procedure|Electroencephalograph|EEG performed at beginning and end of school year.
1497795|NCT02985645|Procedure|maxillary sinus augmentation with CGF|Graftless maxillary sinus augmentation surgery with CGF application utilizing DIVA system
1497796|NCT02985645|Device|"dynamic implant valve approach - DIVA system"|The DIVA system will be used to apply the CGF to the maxillary sinus.
1497797|NCT02985632|Drug|BMS-986141|
1497798|NCT02985619|Drug|Bevacizumab|
1497799|NCT02985619|Drug|Triamcinolone Acetonide|
1497800|NCT02985606|Other|Caffeine powder -60|
1497801|NCT02985606|Other|Caffeine powder -30|
1497802|NCT02985606|Other|Caffeine powder 0|
1497803|NCT02985606|Other|Placebo powder -60|
1497804|NCT02985606|Other|Placebo powder -30|
1497805|NCT02985606|Other|Placebo powder 0|
1497806|NCT02985593|Drug|KHK4083|
1497807|NCT02985593|Drug|Placebo|
1497808|NCT02985580|Dietary Supplement|Blueberry|
1497809|NCT02985580|Dietary Supplement|Placebo|
1497810|NCT02985567|Other|Intraocular pressure evaluation|Intraocular pressure checked with Icare rebound tonometer at 25 minutes after induction, followed by every 10 minutes until sedation was complete.
1497811|NCT02985554|Drug|Nivolumab|Nivolumab dose escalation will be used for the intensification phase with starting dose at 1m/kg every 2 weeks for 4 doses.
1497813|NCT02985528|Other|further diagnostic|further diagnostic procedures - mainly CHEST CT -
1497814|NCT02985515|Drug|Budesonide|"Phase 1 of the study will consist of 30-days of budesonide saline nasal irrigation treatment. All subjects will be provided with the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle Kit and a one-month supply of USP Grade Sodium Chloride & Sodium Bicarbonate Mixture (pH balanced, Isotonic & Preservative & Iodine Free) commercially prepared packets. Subjects will need to purchase distilled water or boil tap water for five minutes for use with the saline irrigation. Subjects will be required to dissolve the contents of two capsules (0.5mg budesonide each) into the 8-ounce (240 ml) NeilMed Sinus Rinse Regular Bottle along with the saline rinse. All subjects will be instructed to irrigate both right and left nasal cavity with one-half of the contents of the nasal rinse once daily."
1497815|NCT02985515|Other|Smell Training|Subjects will smell 4 odors (phenyl ethyl alcohol, eucalyptus, lemon, eugenol) twice a day for 12 weeks. The odors will be placed in separate jars at the same concentration in each jar. Each jar will be labeled with the specific odor. Subjects will be advised to sniff each of the jars for 10 seconds (~30-second interval in between) twice a day.
1497816|NCT02985502|Other|pancreatogenic diabetes|pancreatogenic diabetes
1497817|NCT02985489|Dietary Supplement|Olimel Parenteral Nutrition|Olimel 5.7% with electrolytes
1497818|NCT02985476|Other|Health reports|Participants were sent 3 sets of individualised, educationally enriched health reports about their diagnosed inflammatory bowel disease history, care plan and updates on their recent health status, results or encounters with health care services.
1497819|NCT02985450|Biological|Energix-B|Hepatitis B Vaccine
1497820|NCT02985437|Drug|Surfactants|
1497821|NCT02985437|Drug|Saline Solution|
1497822|NCT02985424|Other|18F-FDG PET/CT|18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography
1497823|NCT02985411|Behavioral|Immediate Gardening Intervention|Provided with supplies to plan/plant 3 vegetable gardens over the course of a year. Survivors will be paired with a master gardener from their local Cooperative Extension to help guide them and provide mentorship in vegetable gardening,
1497824|NCT02985411|Other|Delayed Gardening Intervention|Subjects will be monitored for 1-year and will then receive the same vegetable gardening intervention as described under the Immediate Gardening Intervention
1497825|NCT02985398|Biological|ALD403 (Eptinezumab)|
1497826|NCT02985385|Other|Palliative management|Diagnostic studies for abnormal fetal ultrasounds
1497827|NCT02985372|Drug|Decitabine|All patients were treated with decitabine of 15 mg/ m2 intravenously over 4h for 5 consecutive days (day 1-5) for priming combined with cytarabine of 10 mg/m2 q12h for 10 days (day 4-13).
1497828|NCT02985372|Drug|Cytarabine|
1497829|NCT02985359|Dietary Supplement|Nutributter|Daily 20g Nutributter provided to children 6 to 24 month of age
1497830|NCT02985359|Behavioral|Social Behavioral Change Communication (SBCC)|Social Behavioral Change Communication (SBCC) activity focused on improving infant and young child feeding (IYCF) practices and water, sanitation, and hygiene (WASH) behaviors through community groups.
1497831|NCT02985346|Biological|Bone marrow mesenchymal stem cells in treatment of Idiopathic pulmonary hemosiderosis|
1497832|NCT02985333|Drug|Paclitaxel|Paclitaxel 170 mg/m(2) IV over 3 h d1
1497833|NCT02985333|Drug|Cyclophosphamide|Cyclophosphamide 200mgmg/m(2) IV d1,3,5
1497834|NCT02985333|Drug|Dexamethasone|Dexamethasone 20mg iv d1-4
1497835|NCT02985320|Biological|Single-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
1497836|NCT02985320|Biological|Single-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
1497837|NCT02985320|Biological|Three-dose regimen of high dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
1497838|NCT02985320|Biological|Three-dose regimen of medium dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
1497839|NCT02985320|Biological|Three-dose regimen of low dosage investigational sIPV|The investigational vaccines were manufactured by Sinovac Biotech Co., Ltd..
1497840|NCT02985320|Biological|Three-dose regimen of commercialized sIPV|The control vaccine was manufactured by Chinese Academy of Medical Sciences.
1497841|NCT02985320|Biological|Three-dose regimen of commercialized IPV|The control vaccine was manufactured by Sanofi Pasteur S.A (IMOVAX POLIO).
1497842|NCT02985307|Behavioral|Short Message Text Service|A service designed by professionals inside the National Health Service (NHS) to provide support and advice for participants to manage weight loss. It combines the expertise of the healthcare team and the convenience of the participant's own mobile phone to give prompts and advice to act on. It makes use of the familiar and convenient mobile phone text service 'SMS' to communicate directly with participants.
1497843|NCT02985307|Behavioral|Standard Weight Management Group|A standard Lothian NHS group programme facilitated by a Dietitian
1497844|NCT02985294|Other|Multiple Excitability Measures of peripheral nerves|The technique of threshold tracking can be used to obtain several measures of peripheral nerve excitability (Multiple Excitability Measures or MEM), such as refractoriness, supernormality, strength-duration time constant and `threshold electrotonus' (i.e. the changes in threshold produced by long-lasting depolarizing or hyperpolarizing current pulses). Each of these measurements depends on membrane potential and on other biophysical properties of the axons. Many of these excitability parameters are very constant among different subjects, while other, such as the current/threshold parameters and the super/sub-excitability parameters, appear to be characteristic of an individual
1497845|NCT02985281|Drug|Sofosbuvir Oral Product|direct acting antiviral drug for HCV infection
1497846|NCT02985281|Drug|Ribavirin|antiviral drug for HCV infection
1497847|NCT02985268|Device|MitraClip|The MitraClip Clip Delivery System is indicated for the percutaneous reduction of significant symptomatic mitral regurgitation (MR ≥ 3+) due to primary abnormality of the mitral apparatus [degenerative MR] in patients who have been determined to be at prohibitive risk for mitral valve surgery by a heart team, which includes a cardiac surgeon experienced in mitral valve surgery and a cardiologist experienced in mitral valve disease, and in whom existing comorbidities would not preclude the expected benefit from reduction of the mitral regurgitation.
1497848|NCT02985268|Drug|Optimal Medical Therapy|Optimal medical therapy administered as per the Guideline Direct Medical Therapy (GDMT) as defined in the 2013 ACCF/AHA Heart Failure Guidelines with maximum tolerated doses of an ACE-inhibitor or Angiotensin Receptor Blocker (ARB) and beta-blocker
1497849|NCT02985268|Device|CRT-D|Cardiac Resynchronization Therapy with defibrillation therapy devices will be implanted according to the Heart Rhythm Society Guidelines for implanted devices.
1497850|NCT02985255|Drug|Docetaxel|Neoadjuvant Arm
1497851|NCT02985255|Drug|Cisplatin|Neoadjuvant Arm
1497852|NCT02985255|Drug|5FU|Neoadjuvant Arm
1497853|NCT02985255|Radiation|Radiotherapy|Neoadjuvant Arm
1497854|NCT02985255|Procedure|Glossectomy|Neoadjuvant Arm
1497855|NCT02985242|Drug|Empagliflozin|
1497856|NCT02985242|Drug|Glimepiride|
1497857|NCT02985242|Drug|Empagliflozin placebo|
1497858|NCT02985242|Drug|Glimepiride placebo|
1497859|NCT02985229|Drug|Mifepristone|The option of home or clinic administration of 200 mg oral mifepristone
1497860|NCT02985229|Drug|Misoprostol|800 μg buccal misoprostol through 70 days LMP following administration of mifepristone
1497861|NCT02985216|Drug|YHD1119|"YHD1119 150mg, PO YHD1119 300mg, PO
YHD1119 600mg, PO"
1497862|NCT02985216|Drug|Lyrica|Lyrica 75mg, PO Lyrica 150mg, PO Lyrica 300mg, PO
1497863|NCT02985203|Drug|Vinorelbine Oral|Oral vinorelbine plus cisplatin Followed by Metronomic oral Vinorelbine
1497864|NCT02985190|Drug|Azacitidine|Azacitidine at 75mg/m²/j for 7 days.
1497865|NCT02985177|Drug|Fentanyl intranasal + Oral Hydromorphone|Analgesics
1497866|NCT02985177|Drug|Fentanyl intranasal + Oral ibuprofen|Analgesics
1497867|NCT02985164|Radiation|PDSa|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSa1 (outside lead apron),PDSa2 (inside lead apron).
1497868|NCT02985164|Radiation|PDSb|After an anesthesiologist administered a narcotic and an induction agent to a patient (total intravenous anesthesia, TIVA), an endoscopist commenced the procedure. A co-researcher turned on Pocket Radiation Dosimeter label as PDSb1 (outside lead apron), PDSb2 (inside lead apron).
1497869|NCT02985151|Device|Syneron-Candela CO2RE Laser|This fractionated ablative laser will administer energy at either a high intensity setting or a low intensity setting to subjects randomized into a particular treatment group. It will be operated by the principle investigator, who has extensive experience with laser therapy.
1497870|NCT02985138|Procedure|TLIF and unilateral pedicle screw fixation|TLIF combined with posterior unilateral pedicle screw fixation
1497871|NCT02985138|Procedure|TLIF and bilateral pedicle screw fixation|TLIF combined with posterior bilateral pedicle screw fixation
1497872|NCT02985138|Device|Pedicle screw and cage|Pedicle screw and cage
1497873|NCT02985125|Drug|LEE011|Treatment cycles are 28 days long. It is taken orally. The dosage varies depending on the study arm.
1497874|NCT02985125|Drug|Everolimus|Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.
1497875|NCT02985112|Device|FFR and IVUS-NIRS|
1497876|NCT02985099|Drug|SRP plus Rosuvastatin gel|SRP followed by 1.2% Rosuvastatin placement into intrabony defect
1497877|NCT02985099|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
1497878|NCT02985086|Drug|Cefoxitin|
1497879|NCT02985086|Drug|oxytocin/misoprostol|
1497880|NCT02985073|Device|Veritas®|Biologic mesh
1497881|NCT02985073|Device|TIGR®|Non biologic mesh
1497922|NCT02984800|Other|Anesthesia induction|All patients will have inhaled induction of anesthesia by facemask using oxygen and 8% sevoflurane for 2 to 4 minutes followed by placement of an IV cannula. After performing PVB injections, the sevoflurane concentration will be decreased to 0.4% to 0.8% and maintained until completion of surgery.
1497882|NCT02985060|Device|Arctic Sun|"Induction phase: At a temperature of 4℃, a saline 500 mL or 1 L is intravenously administered.
Arctic sun (surface freezing equipment) Target temperature: 35±0.5℃ Within 12 hours of the onset of symptoms, the therapeutic hypothermia is performed
Maintenance phase:The use of bedside shivering assessment scale (BSAS) The use of Columbia anti-shivering protocol,Maintenance period: 48 hours
Recovery phase:Rewarming velocity: 0.05~0.1℃ (within 30 hours)"
1497883|NCT02985060|Other|Standard treatment|"All the patients receive standard treatment modalities for stroke, which are applicable to the international treatment guidelines.
In all the patients, neurological assessments and NIHSS scoring are performed on a daily basis for 4 days with the help of board-certified nurses or specialists in stroke.
Blood pressure, respiratory rate and heart rate are measured at least once at a 4-hour interval for 4 days.
Using an esophageal thermometer, the central temperature is measured at a 2-hour interval for 5 days."
1497884|NCT02985060|Drug|Saline|
1497885|NCT02985047|Other|Brief Admission|Participants randomised to Brief admission (BA) will participate in a negotiation together with their out-patient clinician and a representative from the ward. The aim of the negotiation is to form an individualised contract defining how BA will work for them. After signing the contract, will have the possibility to admit themselves to hospital according to the procedure stated in the contract.
1497886|NCT02985034|Procedure|RFA|Radiofrequency ablation (RFA) is performed according to routine practice, and then safety margin is assessed by a) visual side-by-side comparison between pre-RFA MRI and post-RFA CT, and b) registration software for two modalities.
1497887|NCT02985021|Drug|Carboplatin|Chemotherapy
1497888|NCT02985021|Drug|Docetaxel|Chemotherapy
1497890|NCT02984982|Drug|alirocumab SAR236553|"Pharmaceutical form: Solution for injection
Route of administration: Subcutaneous"
1497891|NCT02984982|Drug|atorvastatin|"Pharmaceutical form: tablet
Route of administration: oral"
1497892|NCT02984982|Drug|rosuvastatin|"Pharmaceutical form: tablet
Route of administration: oral"
1497893|NCT02984982|Drug|fenofibrate|"Pharmaceutical form: tablet
Route of administration: oral"
1497894|NCT02984982|Drug|bezafibrate|"Pharmaceutical form: tablet
Route of administration: oral"
1497895|NCT02984982|Drug|ezetimibe|"Pharmaceutical form: tablet
Route of administration: oral"
1497896|NCT02984982|Drug|antiplatelets|"Pharmaceutical form: tablet or capsule
Route of administration: oral"
1497897|NCT02984982|Drug|anticoagulants|"Pharmaceutical form: tablet or capsule
Route of administration: oral"
1497898|NCT02984956|Device|pleth variability index|
1497899|NCT02984943|Device|Hyperbaric Oxygen|30 treatments of Hyperbaric Oxygen.
1497900|NCT02984930|Drug|Administration of study drug (esomeprazole, mosapride)|Esomeprazole(Hanxium®) 40 mg once daily and mosapride (Gasmotin®) 5 mg t.i.d for 4 weeks.
1497901|NCT02984930|Drug|Administration of study drug (esomeprazole, placebo tablet)|Esomeprazole(Hanxium®) 40 mg once daily and placebo tablets that are identical to mosapride tablets t.i.d (3 times a day) for 4 weeks.
1497902|NCT02984930|Procedure|upper endoscopy, scintigraphy|After medication(4weeks), subjects will be undergo upper endoscopy and scintigraphy.
1497903|NCT02984917|Procedure|Anterior transversalis fascia approach|Patients will undergo inguinal hernia repair via the anterior transversalis fascia approach.
1497904|NCT02984917|Procedure|Preperitoneal space approach|Patients will undergo inguinal hernia repair via the preperitoneal space approach.
1497905|NCT02984904|Other|survey|survey
1497906|NCT02984891|Procedure|Optical Coherence Tomography (OCT)|Procedure will be performed using the OCT Dragonfly catheter is a hydrophilic-coated catheter that uses infrared light with a central wavelength between 1,250 and 1,350 nm. Axial resolution with OCT is 10-20 microns, and maximum tissue penetration with OCT is approximately 1.5 mm-3 mm.
1497907|NCT02984891|Procedure|Intravascular Ultrasound (IVUS)|Procedure will be performed using the IVUS Kodama catheter is a hydrophilic-coated catheter that used high-fidelity ultrasound transmission to capture high-definition images of coronary artery anatomy. It uses ultrasound waves with a frequency of 40 or 60 MHz, as opposed to 20 MHz in conventional IVUS, to improve resolution while optimizing tissue penetration. It provides axial resolution of < 40 microns and tissue penetration of 10 mm.
1497909|NCT02984865|Drug|Sulfentanyl|
1497910|NCT02984865|Drug|Nalbuphine|
1497911|NCT02984865|Drug|flubiprofen axetil|
1497912|NCT02984852|Drug|Darunavir (DRV)|Darunavir 800 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/TAF(10mg).
1497913|NCT02984852|Drug|Cobicistat (COBI)|Cobicistat 150 milligram (mg) will be taken orally in FDC together with DRV(800mg)/FTC(200mg)/TAF(10mg).
1497914|NCT02984852|Drug|Emtricitabine (FTC)|Emtricitabine 200 milligram (mg) will be taken orally in FDC together with COBI(150mg)/DRV(800mg)/TAF(10mg).
1497915|NCT02984852|Drug|Tenofovir Alafenamide (TAF)|Tenofovir Alafenamide 10 milligram (mg) will be taken orally in FDC together with COBI(150mg)/FTC(200mg)/DRV(800mg).
1497916|NCT02984839|Device|Stimpod NMS450® Nerve Stimulator, by Xavant™ Technology|Quantitative train-of-four (TOF) ratio will be recorded in the post anesthesia care unit (PACU) via Stimpod NMS450
1497917|NCT02984826|Other|Strength training|The specific ST group trained and fulfilled a 10 week training diary. The ST consisted of 4 shoulder exercises. During the training the relative loading was progressively increased from 12 repetitions maximum (RM) (70% of maximal intensity) at the beginning to 8 RM (80 % of the maximal intensity). ST was performed with slow concentric and eccentric muscle contractions with resistance from the elastic bands.
1497918|NCT02984826|Other|Ergonomic and posture|The control group was instructed in ergonomics and posture correction (EP). They were instructed to pay attention to their sitting posture, and how they used a computer or other working tools. Further they were asked to do a posture correction exercise 3 times a day with 10 repetitions. The EP were seen twice during the 10 week period, and had a phone call every 2 weeks. After 10 weeks they were instructed that they should stop the exercise but continue to be conscious of their ergonomics and sitting position.
1497919|NCT02984813|Drug|GlaucoHealth|Containing alpha lipoic acid, citicoline, Co-enzyme Q10, Ginkgo biloba extract, grape seed extract, N-acetyl-cysteine, curcumin, and green tea extract
1497920|NCT02984813|Drug|GlaucoSelect|Containing curcumin, bilberry extract, and grape seed extract
1497921|NCT02984813|Drug|Placebo|No active ingredients
1497923|NCT02984800|Other|PVB injection at L1-L2|Patients will receive a single PVB injection at L1-L2 and placebo PVB injections at T12-L1 and L2-L3.
1497924|NCT02984800|Other|PVB injections at T12-L1, L1-L2 and L2-L3.|Patients will have PVB injections at T12-L1, L1-L2 and L2-L3.
1497925|NCT02984787|Procedure|3D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 3D laparoscopic-assisted totalgastrectomy (3D-LTG) group, they will received 3D-LTG with spleen-preserving splenic hilum lymph nodes dissection
1497926|NCT02984787|Procedure|2D Laparoscopic total gastrectomy|When participants with advanced proximal gastric cancer are randomized in the 2D laparoscopic-assisted totalgastrectomy (2D-LTG) group, they will received 2D-LTG with spleen-preserving splenic hilum lymph nodes dissection
1497927|NCT02984774|Procedure|Cystectomy|Segment of cystic wall from the patients for planned cystectomy was taken after operation and was preserved at -80º Celsius for further analysis
1497928|NCT02984774|Procedure|Endometrial sampling|Endometrial sampling was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
1497929|NCT02984774|Procedure|Peripheric blood sampling|4 cc peripheric venous blood was sampled into the EDTA(Ethylenediaminetetraacetic acid)-containing tubes during catheterization for anesthesia was preserved at 4º Celsius for further analysis
1497930|NCT02984774|Procedure|Ovarian tissue sampling|2cm linear tissue sample from ovarian cortex was performed at the same operation with the planned operation for the main indication and was preserved at -80º Celsius for further analysis
2001992|NCT02606591|Behavioral|Cognitive Tests|During the EEG, participant asked to wear headphones and do some simple tests on the computer that measure their abilities to see, hear, and understand information.
2001993|NCT02606591|Other|Hair Sample|Participants provide a sample of hair at baseline (near the beginning of school), and follow-up (near the end of school). Sample tested to measure cortisol levels.
1497933|NCT02984748|Device|Cochlear implant|
1497934|NCT02984735|Other|Evaluation|Descriptive characteristics including age, height and weight were recorded. Chewing performance level was determined with the Karaduman Chewing Performance Scale (KCPS). Each child was placed in a sitting position (either on a chair or on his/her mother's arm) with the head upright and with the midline position and arms and legs supported, and required to bite and chew a standardized biscuit, and no clue was given on how to chew. The physical therapist rated the chewing performance according to the KCPS. All children underwent a physical examination by a physical therapist to determine gross motor function by applying the Gross Motor Function Classification System (GMFCS). In addition to GMFCS, number of affected limbs of the children was also noted.
1497935|NCT02984722|Drug|Metformin|
1497936|NCT02984709|Behavioral|Positive Psychology Intervention|Health Behavior Contract - Baseline visit Education Packet - Baseline visit Positive psychology training for teen and parents - baseline visit Parent praise reminder (text message) - one time per week (over 8 week intervention period) Teen PANAS survey (text message) - biweekly every other Sunday (over 8 week intervention period) Teen gratitude message (text message) - every Monday (over 8 week intervention period) Teen positive value message (text message) - every Wednesday (over 8 week intervention period) Teen mood booster (text message) - every Thursday and Saturday and alternative Sundays (over 8 week intervention period)
1497937|NCT02984709|Behavioral|Education|Health Behavior Contract - Baseline visit Education Packet - Baseline visit Teen PANAS survey (text message) - biweekly every other Sunday (over 8 week intervention period)
1497938|NCT02984696|Drug|1 mg of transdermal estradiol daily and 10mg of oral MPA|
1497940|NCT02984670|Behavioral|Cognitive Therapy|Cognitive Therapy involves challenging negative automatic thoughts about sleep and the use of behavioral experiments to challenge and test five cognitive processes (i.e., worry, dysfunctional thoughts, monitoring, safety behaviours, misperception) proposed to perpetuate insomnia.
1497941|NCT02984670|Behavioral|Behavior Therapy|Behavior Therapy involves the use of stimulus control and sleep restriction in order to reverse maladaptive sleep habits (time in bed, napping, bedtime variability, rise time variability) proposed to maintain insomnia. It also involves the practice of sleep hygiene principles.
1497942|NCT02984670|Behavioral|Waitlist.|The waitlist serves as a passive control which will receive the same measures administered to the cognitive and behaviour therapy groups.
1497943|NCT02984657|Procedure|Surgical patients in 2012 with anesthesia and nursing staff less attuned to intraoperative RTP.|RTP, reverse Trendelenburg positioning
1497944|NCT02984657|Procedure|Surgical patients in 2015 with enhanced anesthesia and nursing staff awareness and use of intraoperative RTP.|RTP, reverse Trendelenburg positioning
1497945|NCT02984644|Drug|Dapagliflozin|Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.
1497946|NCT02984644|Drug|Placebo|Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
1497947|NCT02984631|Procedure|Preventing pulm HTN during exercise|Balloon catheter is inflated within the IVC to maintain pulmonary pressures during exercise.
1497948|NCT02984618|Procedure|Sphenopalatine ganglion block|Cotton- tipped applicators inserted up through the nose followed by infusion of ligdocaine through the applicators.
1497949|NCT02984618|Procedure|Epidural blood patch|Autologous sterile blood (20ml) will be infused in the lombar epidural space.
1497950|NCT02984605|Dietary Supplement|nutritional meal replacement|1 times a day with bags of nutritional meal replacement + individualized exercise prescription
1497951|NCT02984592|Behavioral|physical exercise|regular exercise programs in the previous 6 months.
1497952|NCT02984579|Device|YD REBA MTB-MDR|Conducted on stored, de-identified leftover samples. A line probe assay designed for detection of Multidrug-resistant tuberculosis (MDR-TB). The REBA MTB-MDR® assay is a qualitative in vitro test for the identification of Mycobacterium tuberculosis (MTB) complex and its susceptibility to rifampin and isoniazid from cultured samples and smear positive specimens.
1497995|NCT02984254|Device|Womac|Answer Womac questionnaires at baseline, 1 month, 3 months and 1 year
2001996|NCT02595931|Drug|ATR Kinase Inhibitor VX-970|Given IV
2001997|NCT02595931|Drug|Irinotecan Hydrochloride|Given IV
2001998|NCT02595931|Other|Laboratory Biomarker Analysis|Correlative studies
1497953|NCT02984579|Device|Hain Genotype MTBDRplus V1|Conducted on stored, de-identified leftover samples. There is only one Line Probe Assay for molecular MTB drug resistance globally available, the GenoType® MTBDRplus V.1 from Hain Lifescience. This assay includes rpoB gene probes for Rifampin (RIF) resistance, katG gene probes for high level Isoniazid (INH) resistance, and inhA gene probes for determination of low level INH resistance
1497954|NCT02984579|Device|Hain Genotype MTBDRplus V2|Conducted on stored, de-identified leftover samples. An updated version of the Hain Genotype MTBDRplus V1 assay, the Genotype MTBDRplus V.2 line probe assay, showed increased sensitivity for MTB detection in the 2 studies published so far
1497955|NCT02984566|Device|Kilovoltage Intrafraction Monitoring|KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.
1497956|NCT02984540|Other|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
1497957|NCT02984540|Other|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
1497958|NCT02984527|Device|wet wipes|intimate hygiene with disposable wet wipes
1497959|NCT02984527|Device|water and soap|Intimate hygiene with water and soap
2001999|NCT02595931|Other|Pharmacological Study|Correlative studies
1497961|NCT02984501|Radiation|Radiation|Radiotherapy target volumes are established by CT scan and PET-CT scan. Radiotherapy is delivered with a total dose of 54-59 Gy with fractionation of 1.8 Gy daily for 5 days a week. The Planning Target Volume (PTV) is defined by CTV with a safety margin of 1cm in all directions to include organ motion and set-up errors. Organs at risk for radiation-induced side effects are contoured on the dose planning CT and dose volume histograms (DVH) are calculated. All treatments are delivered with a 15-MV linear accelerator (Varian Medical System) with a multifield isocentric technique using a multileaf collimator. A quality-control protocol are applied for all patients with periodical digital portal images to evaluate the precision of the set-up.
1497962|NCT02984501|Drug|Chemotherapy|The induction phase of the treatment plan is designed to administer gemcitabine 1000 mg/mq and oxaliplatin 100 mg/mq every 14 days for four doses. Chemotherapy concurrent to conformal radiation therapy is gemcitabine at the dose of 600 mg/mq weekly.
1497963|NCT02984488|Procedure|single visits|Endodontic treatment is done and completed in a single visit using protaper next rotary system.
1497964|NCT02984488|Procedure|two visits|Endodontic treatment is done and completed in two visits using protaper next rotary system.
1497965|NCT02984475|Drug|Metformin|
1497966|NCT02984462|Procedure|percutaneous Akin osteotomy|The act to AKIN is osteotomy in percutaneous; This technique can be performed with or without fixation, and both methods make reference in the literature. With fixation method to get rid of the risk of loss of the surgical reduction of the misalignment, but requires an additional surgical procedure marked by the implementation of a percutaneous cannulated screw on part of the osteotomy. Without fixing method allows to get rid of this gesture, and risk a possible annoys by osteo-synthesis material. Surgical dressings of surgery of hallux valgus allow to keep the reduction for 15 days. Both techniques give excellent results and are performed in our service of routinely.
1497967|NCT02984449|Behavioral|Pre+post-operative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
1497968|NCT02984449|Behavioral|Postoperative Cardiac rehabilitation|CR has the aim to influence favorably the underlying cause of cardiovascular disease, as well as to provide the best possible physical, mental and social conditions (BACPR, 2012).
1497969|NCT02984436|Procedure|Blood Sample|Blood samples will be collected from study participants for hs-cTnT analysis. Results of hs-cTnT will be used for research purposes only. Providers and participants will be blinded to results and participants will be treated by their healthcare providers per the standard of care.
1497970|NCT02984436|Behavioral|HEART Score|The HEART Score is a prospectively studied scoring system to help emergency departments risk-stratify chest pain patients. Patients score on a scale of 0‒10.
1497971|NCT02984410|Radiation|Intensity-Modulated Radiation Therapy|
1497972|NCT02984410|Procedure|Trans Oral Surgery|
1497973|NCT02984397|Drug|Ketotifen Fumarate|Ketotifen is a second-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis, or the itchy red eyes caused by allergies. In its oral form, it is used to prevent asthma attacks.
1497974|NCT02984397|Drug|Placebo|
1497975|NCT02984397|Other|Standard of Care|
1497978|NCT02984371|Procedure|Coronary artery bypass grafting|
1497979|NCT02984371|Procedure|Epicardial ganglionated plexi ablation|
1497980|NCT02984371|Procedure|implantable loop recorder|
1497981|NCT02984358|Other|Animal protein based diet|
1497982|NCT02984358|Other|Low-nucleotide mycoprotein based diet|
1497983|NCT02984358|Other|High-nucleotide mycoprotein based diet|
1497984|NCT02984345|Other|Mycoprotein beverage|
1497985|NCT02984345|Other|Milk protein beverage|
1497986|NCT02984332|Other|Lower limb immobilisation (leg brace)|
1497987|NCT02984319|Dietary Supplement|Cherry concentrate|
1497988|NCT02984319|Dietary Supplement|Placebo concentrate|
1497989|NCT02984306|Dietary Supplement|Cherry powder|
1497990|NCT02984306|Dietary Supplement|Placebo|
1497993|NCT02984267|Device|Ultrasound|Using ultrasound guidance to evaluate the spine prior to epidural placement
1497994|NCT02984267|Other|Palpation|Using palpation only to evaluate the spine prior to epidural placement
1497996|NCT02984254|Device|Lequesne|Answer Lequesne questionnaires at baseline, 1 month, 3 months and 1 year
1497997|NCT02984254|Device|Timed-up-and-go (TUG)|Perform Timed-up-and-go (TUG) at baseline, 1 month, 3 months and 1 year
1497998|NCT02984254|Device|five-times-sit-to-stand-test (FTSST)|Perform the five-times-sit-to-stand-test (FTSST) at baseline, 1 month, 3 months and 1 year
1497999|NCT02984254|Device|Six-minute walk test.|Perform six-minute walk test at baseline, 3 months and 1 year
1498000|NCT02984254|Device|functional patellofemoral neoprene brace|Use the functional patellofemoral neoprene brace for 2 hours/day minimum - 12 hours/day maximum
1498001|NCT02984254|Device|neoprene sleeve brace.|Use the neoprene sleeve brace for 2 hours/day minimum - 12 hours/day maximum
1498002|NCT02984241|Behavioral|eHealth Coping Skills Training|Access to a specialized coping skills training website
1498003|NCT02984241|Behavioral|eHealth Usual Web Care|Access to a website in which helpful information on coping that is available on the internet has been systematically collected and organized in one place for easy retrieval
1498004|NCT02984241|Behavioral|Coach Support|Access to a professional coach by phone
1498005|NCT02984228|Biological|PRP|
1498006|NCT02984228|Drug|Hyaluronic Acid|
1498007|NCT02984228|Device|Ultrasound|
1498008|NCT02984202|Device|auditory midbrain implant (AMI)|
1498009|NCT02984189|Other|Inspiratory muscle training|The inspiratory muscle training (IMT) will be realized, to compare three intensities differents the training (Inspiratory critical pressure, 60% maximal inspiratory pressure and sham). The IMT will be performed for 11 weeks (33 sessions, 3 times/week, 1-hour duration). The session will consist of 5-min warm-up (50% of the training load) and 3 sets of 15 minutes (breathing against 100% of the training load) with 1-min interval between them, using a linear inspiratory load resistor (Device: PowerBreathe K5).
1498010|NCT02984176|Drug|Simethicone Tab 40 mg|3 tablets of Simethicone Tab 40 mg (one tablet after each meal) and to fast overnight the day before the operation.
1498011|NCT02984176|Drug|Placebo Tablets|3 tablets of Placebo Tablets (one tablet after each meal) and to fast overnight the day before the operation.
1498012|NCT02984163|Behavioral|Exercise|Exercise sessions will include a combination of aerobic, resistance, balance, and flexibility exercises delivered in a circuit-type class setting or group personal training format.
1498013|NCT02984150|Dietary Supplement|dodecanoic acid|
1498014|NCT02984150|Dietary Supplement|saline|
1498015|NCT02984137|Other|testing, evaluation, sampling|neuroimaging biomarkers using positron emission tomography and magnetic resonance imaging, and evaluation of neurological & neurocognitive status by using a predefined neuropsychological assessment battery.
1498016|NCT02984124|Behavioral|Informed Assent Discussion|"Participants randomized to the intervention arm will participate in a discussion about CPR with a study doctor that follows these steps:
Patient's values and preferences for therapies and outcomes elicited from patient and family; overall therapeutic goals formulated
Description of CPR and dying process provided
Personalized explanation provided about probable lack of achieving any reasonable therapeutic goal with CPR (i.e. why s/he is a poor candidate for CPR due to underlying illness)
Patient and family informed that due to severe underlying illness and high likelihood that CPR will be burdensome/harmful and will not provide benefit, CPR will not be offered unless they disagree (except in rare circumstance where overall therapeutic goals from step 1 are to preserve life regardless of quality of that life) Assessment of patient's and family's understanding of issues discussed; patients may actively disagree and request CPR be performed, but CPR not explicitly offered"
1498017|NCT02984124|Behavioral|Usual Care with Attention Control|Participants who are randomized to the usual care arm will receive a friendly visit in the hospital from research personnel to ask if they have any questions or concerns. Follow up assessments and time windows will be explained. Importance of their participation in the study will be emphasized.
2002004|NCT02595866|Other|Laboratory Biomarker Analysis|Correlative studies
2002005|NCT02595866|Biological|Pembrolizumab|Given IV
1498020|NCT02984098|Drug|Dextrose|before heel lance, 2ml oral dextrose gel 25%or 40% was administered, and pain related intensity was evaluated with premature infant pain profile scale
1498021|NCT02984085|Drug|Genetically corrected cultured epidermal autograft (ATMP)|"Genetically corrected cultured epidermal autograft (Hologene 7) is intended for transplantation onto surgically prepared blistering skin areas of RDEB patients and permanent regeneration of a healthy, functional and renewing epidermis sustained by the engraftment of transduced epidermal stem cells.
By taking some autologous epidermal cells, a new layer of transgenic tissue is grown in the laboratory. This layer of tissue is then implanted by a surgeon into the damaged area. The implantation can be done in one or more areas and repeated in case of failure of the first surgery."
1498024|NCT02984059|Genetic|Genomic DNA|blood draw
1498025|NCT02984059|Genetic|RNA analysis|Mucosal Biopsy via colonoscopy
1498026|NCT02984059|Genetic|Microbiome|Stool microbiome
1498027|NCT02984059|Other|Calprotectin|stool or blood analysis for calprotectin
1498028|NCT02984059|Other|Pain questionnaires|PSDS PCS-C/P PBI APPT
1498029|NCT02984059|Other|Anxiety/Depression Questionnaires|RCADS-25 CSI-24 ARCS
1498030|NCT02984046|Drug|Protein CC16|
1498031|NCT02984033|Radiation|Head and Neck patients|Treatment consists of Intensity Modulated Radiation Therapy (until 2.2 Gy) with a total dose of 50-66 Gy in post-operative setting and 66-72 Gy in radical setting.
1498032|NCT02984007|Behavioral|Motivational Interviewing|"Mothers randomized in the intervention group will receive an educational session based on the motivational interviewing (MI) approach with a research assistant (RA). The RA will have first received a standardized training session on the content and techniques of MI.
The MI intervention will be carried out in simple and understandable language in order to allow discussion and questions from parents rather than provide prescriptive and direct information. The intervention will last approximatively 15 to 20 minutes."
1498033|NCT02984007|Other|Information flyer|Mothers randomized in the control group will receive a locally information flyer on childhood vaccines without any oral explanation by the research assistant.
1498034|NCT02983994|Device|TURBUHALER®|
1498035|NCT02983994|Device|SPIROMAX®|
1498036|NCT02983981|Drug|Topicort Topical Spray|open label Topicort spray
1498037|NCT02983968|Other|Description of the cirrhosis management|
1498038|NCT02983955|Device|UPnRIDE Powered Wheelchair|The UPnRIDE Powered Wheelchair device is a product which changes people position from sitting to standing and standing to sitting. The product provides indoor and outdoor mobility.
1498039|NCT02983942|Dietary Supplement|ketogenic diet|Ketogenic diet is given to maintain blood ketone level above 2 mmol/L.
1498040|NCT02983942|Dietary Supplement|Routine diet|Routine diet is given without blood ketone requirement
1498041|NCT02983929|Procedure|Rehabilitation after total knee arthroplasty|All the included patients followed a rehabilitation program in the Polyvalent Geriatric Rehabilitation Clinic after total knee arthroplasty.
1498042|NCT02983916|Procedure|Adhesiolysis|Diagnostic laparoscopy or laparotomy with lysis of adhesions.
2002006|NCT02594735|Drug|Abatacept|Study participation will consist of a screening visit and 5 protocol visits over six months (week 0, week 6, week 12, week 18, and week 24) for each subject, and phone follow-up (week 2, week 4, week 8, week 10, week 14, week 16, week 20, and week 22). At Visit 1, which will be treatment initiation, eligible subjects will be instructed on the use and side effects of subcutaneous abatacept and will be started on the study drug (abatacept 125 mg SQ weekly for subjects with body weight ≥ 50 KG or abatacept 87.5mg SQ for subjects with body weight < 50 KG).
1498044|NCT02983890|Drug|Dicloxacillin|"Tablets containing dicloxacillin are taken 500mg 2x 3 times per day, for 10 days. Followed by test-day nr 1 at day 11.
Both arms receives both treatments, randomly assigned"
1498045|NCT02983890|Drug|Placebos|"No drug are taken for 10 days. Non-blinded. Followed by test-day nr 1 at day 11.
Both arms receives both treatments, randomly assigned"
1498046|NCT02983877|Behavioral|iTAB-CV Stage 2|In the second stage, participants will receive daily texts which will include medication reminders, contextual cues, and immediate reinforcement for medication taking behavior in addition to the content from stage 1.
1498047|NCT02983877|Behavioral|iTAB-CV Stage 1|Stage 1 of the intervention will be introduced. Researchers will conduct an interview in order to customize iTAB-CV for each participant at the baseline session. In the first month, participants will receive alternating daily texts with educational and motivational content and a daily mood rating request to both monitor their mood and to determine adherence to the intervention.
1498048|NCT02983864|Behavioral|BASICS|A one session intervention focused on reducing drinking with motivational interviewing
1498049|NCT02983864|Behavioral|Integrated BASICS|A one session intervention focused on reducing drinking and sexual behavior while drinking
1498050|NCT02983864|Behavioral|Relaxation|A one session intervention focused on increasing relaxation skills
1498051|NCT02983864|Behavioral|Integrated Bystander|A one session intervention focused on reducing sexual assault with a focus on the role of alcohol
1498052|NCT02983851|Procedure|Noninvasive mechanical ventilation|Noninvasive mechanical ventilation will be delivered to the patient through a mask. The mask will be adjusted and connected to a ventilation system.
1498053|NCT02983851|Procedure|Invasive mechanical ventilation|Invasive mechanical ventilation will be initially performed by using the volume controlled mode, and could be adjusted to pressure controlled mode or other modes based on clinical situation.
1498054|NCT02983825|Device|Continuous positive airway pressure (CPAP); level changes|as per arm description
1498056|NCT02983786|Drug|Indocyanine Green|ICG will be injected to derive absolute CBF and calibrate the DCS monitor to yield continuous absolute CBF. During each 12-hour monitoring session, for up to 14 days, the ICG will be injected at baseline(0.2 mg/kg,(4), every four hours (or less if signal is stable).
1498057|NCT02983773|Drug|THC 7.2%|1 smoked marijuana cigarette with 7.2% THC
1498058|NCT02983773|Drug|THC 3.0%|1 smoked marijuana cigarette with 3.0% THC
1498059|NCT02983773|Drug|Placebo|1 smoked placebo marijuana cigarette
1498060|NCT02983760|Device|Planar V/Q-based strategy|Strategy based on planar pulmonary scintigraphy
1498061|NCT02983760|Device|CTPA-based strategy|Strategy based on pulmonary angiography
1498062|NCT02983760|Device|V/Q SPECT-based strategy|Strategy based on pulmonary tomoscintigraphy
1498063|NCT02983747|Other|PRP Treatment(P)|Ultrasound(Philips® iU22 ultrasound system) guided intra-disk injection using 2 ml of platelet rich plasma, containing 0.2 ml of calcium chloride(SINE®, SHANGHAI XINYI PHARMACEUTIAL Co . Ltd .) per treatment
1498064|NCT02983747|Drug|Medication Treatment(Loxoprofen Sodium tablets,M)|Loxoprofen Sodium tablets(LOXONNIN®, DAICHI SANKYO PHARMACEUTIAL (SHANGHAI) Co . Ltd .)，P.O., 60mg, three times a day
1498065|NCT02983734|Drug|D-cycloserine|Partial agonist of N-methyl-D-aspartate (NMDA) receptor
1498066|NCT02983734|Drug|Placebos|Sugar pill
1498067|NCT02983721|Procedure|transradial|transradial route for coronary angiography and PCI
1498068|NCT02983721|Procedure|Transfemoral|transfemoral route for coronary angiography and PCI
1498069|NCT02983708|Biological|Peripheral blood mononuclear cells (mPBMC)|
1498070|NCT02983708|Drug|G-CSF|
1498071|NCT02983708|Drug|Placebo|
1498072|NCT02983695|Drug|TIL-TC150|The active ingredients in TIL-TC150 are tetrahydrocannabinol (THC) and Cannabidiol (CBD), isolated from the Cannabis sativa L. strains produced by Tilray, and formulated into an oral liquid drug product.
1498073|NCT02983682|Drug|Lidocaine Infusion|Patients will receive lidocaine infusion of 42 micrograms/kg/minute over tow hours for a total of 5 mg/kg.
1498074|NCT02983669|Dietary Supplement|Thyme|Thyme capsule 350 mg twice daily
1498075|NCT02983669|Other|Placebo|Placebo capsule 350 mg twice daily
1498076|NCT02983656|Biological|live attenuated varicella vaccine|
1498077|NCT02983630|Other|Penicillin allergy testing|The standard protocol for testing for penicillin hypersensitivity, including initial skin testing with prick and intradermal evaluation followed by oral challenge if skin testing is negative.
1498081|NCT02983604|Drug|GS-5829|Tablet(s) administered orally once daily
1498082|NCT02983604|Drug|Exemestane|25 mg tablet administered orally once daily (or in accordance with locally approved labeling)
1498083|NCT02983604|Drug|Fulvestrant|"Administered every 28 days (± 3 days) intramuscularly in accordance with locally approved labeling
Participants initiating fulvestrant on Cycle 1 Day 1 and have not received any prior dose of fulvestrant will receive a single additional dose of fulvestrant on Cycle 1 Day 15."
1498084|NCT02983591|Drug|Misoprostol after delivery|Patients will receive 1000 mcg Misoprostol per rectum
1498085|NCT02983591|Drug|Oxytocin after delivery|Patients will receive 20 units oxytocin intravenously in one liter of Lactated Ringer solution at a rate of 150ml/h
1498086|NCT02983591|Drug|Oxytocin before delivery|All patients will receive oxytocin 0.5-1 milliUnit/min IV, titrated to 1-2 milliUnit/min every 15-60 min before delivery to induce labor
1498087|NCT02983578|Drug|AZD9150|During the 7-day Lead-in period, AZD9150 3mg/kg IBW administered by vein as a loading dose on Days -7, -5, and -3. Starting with Cycle 1, AZD9150 administered every week on Days 1, 8, 15, and 22 of each 28 day treatment cycle.
1498088|NCT02983578|Drug|MEDI4736|MEDI4736 administered at 20 mg/kg by vein on Day 1 of each 28 day treatment cycle, starting with Cycle 1.
1498089|NCT02983565|Device|Intelligent oxygen therapy system (iO2Ts)|
1498092|NCT02983526|Device|Total hip replacement (2 different designs)|Patients will randomly receive either CFP or Corail stem
1498093|NCT02983513|Behavioral|Early Intervention|
1498094|NCT02983487|Procedure|Nasopharyngeal sampling|Nasopharyngeal sample by aspiration or swabbing
1498095|NCT02983487|Procedure|Blood Sampling|Blood sample by the tip of a finger (fingerprick)
1498096|NCT02983474|Procedure|cholecystectomy|"Laparoscopic surgery
Reverse Trendelenburg position
Skin incision and trocar insertion
CO2 gas insufflation
Intra-abdominal inspection and gallbladder exposure
Gallbladder traction
Calot triangle exposure
Cystic artery and cystic duct isolation
Gallbladder bed dissection
Bleeding control
Gallbladder extraction
Trocar removal and wound closure
Open surgery
Supine position
Skin incision
Intra-abdominal inspection and gallbladder exposure
5. Gallbladder traction 6. Calot triangle exposure 7. Cystic artery and cystic duct isolation 8. Gallbladder bed dissection 9. Gallbladder extraction 10. Bleeding control 11. Wound closure"
1498097|NCT02983461|Drug|Sildenafil|Sildenafil, 20mg x 3 times a day for 10 weeks
1498098|NCT02983461|Drug|Placebo Oral Tablet|Placebo, 3 times a day for 10 weeks
1498099|NCT02983448|Device|transcutaneous vagus nerve stimulation|All patients will receive both active and sham transcutaneous vagus nerve stimulation, with the order being randomized
1498100|NCT02983435|Other|G1 - Thrust manipulation|Osteopathic manipulation with Thrust technique. The Group 1 (G1) will receive the Thrust technique applied at the level of dysfunction. Subject in lateral decubitus, with one lower limb extended and the other in flexion, to the level of the targeted vertebra; upper trunk rotated back until the same vertebra; at the end of the range of movement will be applied the high speed and low amplitude impulse (Thrust).
1498101|NCT02983435|Other|G2 - Muscle Energy|Osteopathic manipulation with Muscle Energy technique. The Group 2 (G2) will receive the Muscle Energy technique applied at the level of dysfunction. Subject in lateral decubitus, with the upper and lower trunk flexed until the target vertebra, and upper trunk rotated back to the level of the same vertebra; lumbar in lateral flexion (using the subject's feet) until the target vertebra. Following the command the subject will perform an isometric contraction of 3-5 seconds against the therapist's hand (pushing the hand towards the floor), repeated 3 times.
1498102|NCT02983422|Drug|aminophylline|To increase the dose of frusemide until 15mg/h with Syringe pumps. If the urine doesn't reach 1ml/kg/h,then combined with Aminophylline(loading dose of 5mg/kg，and maintenance dose of 0.5mg/kg)
1498103|NCT02983422|Drug|frusemide|Use frusemide with Syringe pumps,maximum dose to 15mg/h
1498104|NCT02983422|Drug|normal saline|Placebo bolus followed by IV infusions of normal saline (0.9%) every hour (matched by volume and appearance to the treatment group)
1498105|NCT02983409|Radiation|Pstone|A adult patients who were diagnosed as urinary stone by the urinary CT
1498106|NCT02983396|Device|Diagnostic accuracy of Mini Relf Device|Evaluation of the Mini Relf Device when it is applied on daily basis at home and during coronary angioplasty at 60 second acute coronary occlusion angioplasty
2002007|NCT02594215|Drug|ARQ 092|
2002008|NCT02592551|Drug|MEDI4736|
2002009|NCT02592551|Drug|Tremelimumab|
1498110|NCT02983357|Radiation|CT, X-Ray|2 anterior-posterior (AP) radiographs of the glenohumeral joint, one in internal rotation and the other in external rotation, along with axillary lateral films, will be completed of the affected operated shoulder. Also, a computed tomographic scan without contrast performed of same shoulder.
1498111|NCT02983357|Other|Physical assessment|Physically evaluate for shoulder function and pain using American Shoulder Elbow Score (ASES) Constant score and the Simple Shoulder Test to obtain specific shoulder functional, motion,and strength outcomes.
1498112|NCT02983357|Other|Questionnaire|Rand Short Form Health Survey (Rand SF-36) which is a patient completed quality of life measurement
1498113|NCT02983344|Drug|Ropivacaine|Fascia iliaca compartment block using ropivacaine
1498114|NCT02983344|Drug|Fentanyl|Intravenous fentanyl
1498115|NCT02983344|Device|Ultrasound|Ultrasound-guided fascia iliaca compartment block
1498116|NCT02983331|Procedure|complications during procedure|patients may have anesthesia related complications during procedure
1498117|NCT02983305|Device|Head-Mounted Display|Head-mounted displays (HMD) are a class of technology that are worn on the user's head and project an image either in front of or into the eye.
2002010|NCT02592551|Other|Untreated arm (control)|
2002011|NCT02592525|Behavioral|IP-SDM training for health professionals|Multifaceted SDM training program for providers: i) 1.5-hour online tutorial, ii) 3.5-hour skills building workshop; iii) video-clip demonstrating SDM in the context of an IP home care team with an aging adult making a decision about location of care (to be used with clients and providers as well); and iv) performance feedback to providers (role play during the workshop).
2002012|NCT02592395|Drug|FOLFIRINOX|"The chemotherapy schedule will include administration of FOLFIRINOX (5-Fluorouracil, Irinotecan, Oxaliplatin, and Leucovorin) will be:
Day 1: Oxaliplatin at 85mg/m2 over 120 minutes, Irinotecan 180mg/m2 over 90 minutes, Leucovorin 400mg/m2 over 90minutes, 5-Fluorouracil (5-FU) 1200mg/m2/day continuous infusion (CIV) over 46 hours. Day 3: 5-FU CIV pump will be disconnected. Neulasta injection 6mg subcutaneous"
2002013|NCT02592395|Device|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
1498118|NCT02983292|Device|PyroTITAN™ HRA|Humeral Resurfacing
1498119|NCT02983279|Dietary Supplement|Dietary Intervention|Undergo caloric restriction diet
1498120|NCT02983279|Other|Counseling|Undergo counselor-led dietary counseling
1498121|NCT02983279|Procedure|Therapeutic|Undergo standard of care surgery
1498122|NCT02983266|Device|InTENsity MicroCombo|An electrotherapy device.
1498123|NCT02983253|Other|blood sample|none, only laboratory tests on blood serum
1498124|NCT02983240|Device|Electrical Uterine Pacemaker|The catheter is placed under ultrasound guidance into the posterior vaginal fornix next to the external cervical os. The electrode connectors are attached to the EI device. Activating the EI device involves: 1) turning the current pulse duration rotary dial clockwise to the desired setting; this is an important setting and should be set at 20ms; 2) turning the current frequency rotary dial clockwise to the desired setting; 3) turn on the EI device on with the on/off toggle switch; 4) SLOWLY turning the current strength rotary dial clockwise to the desired setting, at this time the red light should be flashing. Usually 5-10mA of current is sufficient, but 20 mA is a maximum. Based on the tocometer recordings the least amount of EI current is given to inhibit the uterine contractions.
1498125|NCT02983227|Drug|GDC 0853|GDC-0853 tablet will be administered orally BID for 52 weeks.
1498126|NCT02983214|Drug|Clopidogrel|
1498127|NCT02983214|Drug|Cilostazol|
1498128|NCT02983201|Other|filiform needle|Patients will receive filiform needle treatment only.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
1498129|NCT02983201|Other|thumbtack needle|Thumbtack intra-dermal needle will be applied to selected acupuncture points after filiform needle treatment. The thumbtack needle will remain embedded in the patient's dermal part for 2-3 days as per instruction.During the study period, a maximum of two courses of acupuncture therapy, consisting of 7 sessions each, will be administered. Treatment will be given twice per week. After completing the first course of 7 sessions, there will be a break of one week, at the end of which the second course will commence. Treatment will come to a halt as soon as the pain has totally subsided.
1498130|NCT02983188|Drug|Berberine|Berberine pills, 0.4g every time, three times daily
1498131|NCT02983188|Drug|Placebos|Placebo pills, 0.4g every time, three times daily
1498132|NCT02983188|Drug|Antipsychotic Agents|Antipsychotic agents prescribed at the discretion of the patients' psychiatrists with respect to patients' conditions. Concomitant use of other psychotropic drugs will be generally allowed, including benzodiazepines and non-benzodiazepines insomnia and anti-anticholinergics for extrapyramidal symptoms, but anti-hyperlipidemic, antihypertensive and antidiabetic drugs will be not allowed. For those who have been under anti-hyperlipidemic, antihypertensive and antidiabetic treatment, they will be required to discontinue these treatments when they enter the trial.
1498133|NCT02983175|Other|ultrasound assessment of gastric content|"Achievement of gastric ultrasound (specific procedure) :
Gastric ultrasound is performed specifically for the study by a senior anesthetist physician in a patient placed supine, semi-sitting by an angle of 45 ° relative to the horizontal.
Standardised achievement of the antral ultrasound by the following method:
First, a qualitative assessment of antral contents in 3 grades according to the Perlas method [24].
Second, performing a quantitative analysis of antral contents calculating the CSA.
Then, volume of gastric contents calculation as from the CSA."
1498134|NCT02983149|Device|Double lumen tube|Use an double lumen tube to achieve one lung ventilation in thoracic surgeries
1498135|NCT02983149|Device|Fuji blocker|Use the Fuji blocker to achieve one lung ventilation in thoracic surgeries
1498136|NCT02983149|Device|EZ blocker|Use the EZ blocker to achieve one lung ventilation in thoracic surgeries
1498137|NCT02983136|Behavioral|Dialogue and inter-professional learning|"The middle and front-line leaders of the study OR will participate in an intervention based on an iKT model. Components of the intervention will include:
Two workshops, consisting of educational sessions covering the state of the art regarding person-centeredness, prevention of infections, leadership, and implementation. The educational component and results of pre-studies will work as frameworks for the dialogues between the front-line leaders and the research group. In dialogues the participants will be given the opportunity to reflect on barriers to and enablers of change; and
The participants will be supported in creating an action plan aimed at facilitating the anaesthesia providers' change of practice."
1498138|NCT02983123|Procedure|1-hour hs-cTnT|
1498139|NCT02983110|Procedure|Anoscopy with Rectal Tissue Sampling|All subjects will provide 10 pieces of rectal tissue
1498140|NCT02983110|Procedure|Phlebotomy|• Procedure: Blood plasma/serum collection Approximately 17 mL of blood will be taken from each subject just prior to tissue sampling.
1498141|NCT02983110|Procedure|Female Genital Tract Sampling|Cohorts A and B only will have cervical cells, cervical tissue, and vaginal tissue collected
1498142|NCT02983110|Procedure|Semen Sampling|Cohorts D and E will provide a single semen sample
1498143|NCT02983097|Drug|Rituximab|Rituximab 375 mg/m²
1498144|NCT02983097|Drug|Cisplatin|Cisplatinum 100 mg / m²
1498145|NCT02983097|Drug|Carboplatin|Carboplatinum AUC5
1498146|NCT02983097|Drug|Dexamethasone|Dexamethasone 40 mg
1498147|NCT02983097|Drug|Cytarabine|Cytarabine 2000 mg/m², administered twice
1498148|NCT02983097|Drug|Lenalidomide|5-20 mg administered either d1-d7, or d-6-d7
1498149|NCT02983097|Drug|PegFilgrastim|PegFilgrastim 6 mg
1498150|NCT02983097|Procedure|peripheral stem cell collection|collection of peripheral stem cells for autologous stem cell transplantation
1498151|NCT02983084|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed appliance
1498152|NCT02983071|Drug|G1T38|
1498153|NCT02983071|Drug|Fulvestrant|
1498154|NCT02983058|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner
1498155|NCT02983058|Device|MRI Scan|Structural MRI will be obtained to permit co-registration of PET images
1498201|NCT02982681|Drug|Platelet rich fibrin|In the test site the graft was then carefully compacted from the base of the defect coronally. PRF membrane was placed in the test site
1498202|NCT02982681|Drug|Bioactive Glass|The control site were packed with the bioactive glass graft alone
1498156|NCT02983045|Drug|Combination of NKTR-214 + nivolumab|"Phase 1: Patients with select tumor types will receive NKTR-214 doses administered either every 21 days or every 14 days, in combination with 240 mg nivolumab (Opdivo®) every 14 days or in combination with 360 mg of nivolumab every 21 days.
Phase 2: Additional patient cohorts with select tumor types will be dosed at the recommended Phase 2 dose/schedule of NKTR-214 and nivolumab (as determined by Phase 1 of the trial)."
1498157|NCT02983032|Behavioral|BBTI|3 group sessions over 4 weeks
1498158|NCT02983019|Drug|Kagocel|Investigators could prescribe other drugs in frame of routine clinical practice
1498159|NCT02983006|Biological|DS-8273a|"Starting Dose: 4 mg/ kg IVQ 3 weeks (Cohort 1)
Dose Escalation: 8 mg/kg IV Q 3 weeks (Cohort 2), 16 mg/kg IV Q 3 weeks (Cohort 3), 24 mg/kg IV Q 3 weeks (Cohort 4), 2 mg/kg IV Q 3 weeks (Cohort -1), 4 mg/kg IV Q 3 weeks (Cohort -2)"
1498160|NCT02983006|Biological|Nivolumab|5 mg/kg IV Q 3 weeks
1498161|NCT02982980|Procedure|Physiotherapy Guidance|Pre and postoperative assessment and orientation, guidelines for lymphedema prevention and self drainage, follow-up for rehabilitation or maintenance of joint amplitude of shoulder movements and functional return.
1498162|NCT02982980|Procedure|Physiotherapy Muscle strengthening|The exercises performed were active-free, with the aid of a stick or resistance by elastic bands and dumbbells for flexion, extension, adduction, abduction, external and internal rotation of the shoulder, and elbow flexion and extension, besides activities to enable movements Functional. The mode of execution of the exercises was isotonic, done slowly and within the joint amplitude reached by the patient, using resistance according to the muscular capacity of each patient.
1498163|NCT02982967|Other|Physical Activity|Recreational Physical Activity (Duration: 60 minutes; Intensity: 65%-85% heart rate reserve; Frequency: 4 sessions/week).
1498166|NCT02982941|Drug|Enoblituzumab|enoblituzumab administered IV weekly for up to 96 weeks
1498167|NCT02982915|Biological|Longeveron Mesenchymal Stem Cells (LMSCs)|Intravenously delivered
1498168|NCT02982915|Biological|Fluzone High Dose Vaccine|Intramuscular injection
1498169|NCT02982902|Biological|CMV specific adoptive t-cells|It is expected that the cell dose will be in the range of 10^3 - 10^5 virus - specific, antigen selected T cells per kg of recipient weight.
1498170|NCT02982889|Drug|LIQ865A bupivacaine formulation|single subcutaneous injection in medial calf
1498171|NCT02982889|Drug|LIQ865B bupivacaine formulation|single subcutaneous injection in medial calf
1498172|NCT02982889|Drug|Diluent for LIQ865|Sterile diluent composed of 12.5mg/g sodium hyaluronate, 5.8mg/g sodium chloride, 1mg/g polysorbate 80, 6.1mg/g Tris base, in sterile water for injection - single subcutaneous injection
1498173|NCT02982889|Drug|0.5% bupivacaine hydrochoride|single subcutaneous injection
1498174|NCT02982876|Procedure|Dynamic Flexible Bronchoscopy|The bronchoscope will be introduced into the proximal trachea at the level of the cricoid. At that point, patients will be instructed to take a deep breath, hold it and then blow it out (forced expiratory maneuver). Maneuvers will be done at the following six sites: proximal trachea at the level of the cricoid; mid-trachea 5 cm proximal to the carina; distal trachea 2 cm proximal to the carina; right main stem bronchus at the right tracheobronchial angle; bronchus intermedius and left main bronchus at the left tracheobronchial angle
1498175|NCT02982876|Procedure|Rigid Bronchoscopy|Under general anesthesia, a rigid bronchoscope (Bryan-Dumon Series II; Bryan Corporation; Woburn, MA) will be introduced, and respiration will be maintained through jet ventilation.
1498176|NCT02982876|Device|Stent placement|Silicone Y stent or uncovered self-expanding metallic stent will be placed in the standard fashion and good fit will be confirmed visually.
1498177|NCT02982850|Drug|Dabigatran|
1498178|NCT02982850|Drug|Acetylsalicylic acid|
1498179|NCT02982850|Drug|Warfarin|
1498180|NCT02982837|Drug|PEG-IFN & Nucleos(t)tide analogues|Subjects who will be randomized to receive 180 Mcg/ week as an add-on Pegylated Interferon therapy α-2 A with their ongoing NUCLEOTIDE analogues for 48 weeks.
1498181|NCT02982837|Drug|Nucleos(t)tide analogues|Subjects will continue on the same dose of Nucleoside/nucleotide analogues as they started the study.
1498182|NCT02982824|Dietary Supplement|Magnesium|Oral magnesium
1498183|NCT02982824|Drug|Placebo - Concentrate|Placebo will be given
1498184|NCT02982811|Device|i-ACT|3x 45 min training with i-ACT system (analytical and functional training) during 6 weeks, additional to therapy as usual (i.e. occupational therapy, physiotherapy, etc.)
1498185|NCT02982798|Drug|Metformin + Rosuvastatin|administration of Metformin + Rosuvastatin
1498186|NCT02982798|Drug|JLP-1310|administration of JLP-1310
1498187|NCT02982785|Behavioral|Standard post-operative rehabilitation|
1498188|NCT02982772|Other|Combination Therapy|"Brief behavioral intervention
The test product is a transdermal nicotine patch for 12 weeks. The dosage of the test product depends on the new algorithm (amount, addiction, prior attempts) Nicotine Gums for 12 weeks."
1498189|NCT02982772|Other|Standard Care Intervention|"Brief Behavioral Intervention
The test product is transdermal Nicotine replacement patch for 10 weeks.The dosage of the test product follows the product guidelines and depends on the amount of cigarettes used.
Standard Flavored Gums for 10 weeks"
1498190|NCT02982759|Behavioral|Multi-Level Intervention|The multi-level interventions will include activities at the individual level, family level, school level, and community level.
1498191|NCT02982759|Behavioral|Genetic Newsletters|The comparison will receive generic newsletters
1498192|NCT02982746|Other|gPCC (Gothenburg Person Centred Care)|
1498196|NCT02982720|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously.
1498197|NCT02982720|Drug|Sylatron|Sylatron will be administered subcutaneously.
1498198|NCT02982707|Drug|BMS-986177|
1498199|NCT02982694|Drug|Atezolizumab|Atezolizumab will be administered 1200 mg in 250 ml 0.9% NaCl IV infusion bag, on day 1 of each cycle of 21 days.
1498200|NCT02982694|Drug|Bevacizumab|Bevacizumab will be administered 7.5 ml/kg (diluted in 0.9% sodium chloride solution) on day 1 of each 21 days cycle.
1498203|NCT02982668|Other|Initial enteral feeding|
1498204|NCT02982668|Drug|erythromycin|gastrointestinal (GI) motility improving
1498205|NCT02982655|Other|Blood pressure management policies|
1498206|NCT02982642|Drug|1612 capsule|Subjects will be assigned 1612 capsule,3 capsules per time(0.38g per capsule), 3 times per day.1612 capsule is a Chinse herbal medicine,which can tonification of spleen and kidney, mainly contains shudihuang(Rehmannia glutinosa),shanyao(Dioscorea opposita),shichangpu(Uncaria rhynchophylla)and so on,
1498207|NCT02982642|Drug|Placebos|Subjects will be assigned placebo identified to 1612 capsule,3 capsules per time, 3 times per day
1498208|NCT02982629|Behavioral|Reminder letter Intervention|Patients in this group receive letters and phone calls to reschedule missed follow-up appointments.
1498209|NCT02982616|Dietary Supplement|Dodecanoic acid|The middle chain saturated fatty acid that can be widely found in daily food.
1498210|NCT02982616|Behavioral|Positive emotion|Positive emotion induced by facial expressions and classic music.
1498211|NCT02982616|Dietary Supplement|saline|saline
1498212|NCT02982616|Behavioral|neutral emotion|Neutral emotion induced by facial expressions and classic music.
1498213|NCT02982603|Drug|Qinggongshoutao Bolus|Qinggongshoutao bolus and placebo identified to Ginkgo Biloba Extract 761
1498214|NCT02982603|Drug|Ginkgo Biloba Extract 761|Placebo identified to Qinggongshoutao bolus and Ginkgo Biloba Extract 761
1498215|NCT02982603|Drug|Placebos|Placebo identified to Qinggongshoutao Bolus and placebo identified to Ginkgo biloba
1498216|NCT02982590|Drug|Apixaban 5 MG Oral Tablet [ELIQUIS]|Apixaban is licensed for treatment of deep vein thrombosis and pulmonary embolism. Hence, a good study drug for left ventricular thrombosis for possibility of a new indication.
1498217|NCT02982590|Drug|Warfarin Sodium|as controlled arm since warfarin is the standard therapy for LV thrombus
1498218|NCT02982577|Drug|Pilocarpine|Spray the basis of 1.54% pilocarpine, 3 times per day (each 8 hours), during 90 days.
1498219|NCT02982577|Other|Spray without Pilocarpine|Spray without pilocarpine, 3 times per day (each 8 hours), during 90 days.
1498220|NCT02982564|Behavioral|Exercise Program Low Intensity|This arm includes a low-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
1498221|NCT02982564|Behavioral|Exercise Program Moderate Intensity|This arm includes a moderate-intensity intervention and will have a duration of six months. Participants will be provided with a heart rate monitor to train at the intensity according to group assignment. Progression for both programs in the endurance component will be slower and more gradual for deconditioned participants, and may require multiple shorter periods (5-10 minutes) with rest intervals.
1498222|NCT02982551|Drug|Insulin|Insulin will be administered peripherally to observe the effects of circulating insulin on brain activity
1498223|NCT02982551|Other|Taste Task|Participants will taste milkshakes and a tasteless solution to observe the brain responses to palatable taste.
1498224|NCT02982551|Other|Magnetic Resonance Imaging|Participants will complete two MRI scans approximately 60 minutes apart - one under baseline fasting conditions and the second during isoglycemic-hyperinsulinemia. Each functional scan will include a resting-state BOLD sequence followed by a taste-reward task. Functional MRI sequences will last approximately 30 minutes. MRI scanning will also include approximately 30 minutes of structural MRI scans.
1498225|NCT02982551|Drug|Dextrose|During hyperinsulinemic clamp, participants will be infused with a variable rate dextrose infusion will be used to keep the blood sugar level within 5mg/dl of the baseline glucose value.
1498226|NCT02982538|Behavioral|Extended Training in Prolonged Exposure Therapy for PTSD|Extended training in Prolonged Exposure consists of a 4-day PE workshop, followed by expert PE consultation on 2 training cases. PE consultation consists of weekly telephone calls with expert PE therapists at the University of Pennsylvania, who will review video-recordings of providers PE sessions and provide feedback. Consultation is considered complete if the consultant has reviewed a minimum of 12 video-recorded sessions across 2 training cases, and has provided feedback on all of the crucial elements of PE (e.g., rationale, imaginal exposure, in vivo exposure, processing).
1498227|NCT02982538|Behavioral|Standard Training in Prolonged Exposure Therapy for PTSD|Standard training in PE consists of a 4-day professional workshop on Prolonged Exposure Therapy. This is similar to the standard training approach that has been used to train providers in delivery of PE in the Army.
1498228|NCT02982525|Dietary Supplement|No Mussels|Habitual diet only
1498229|NCT02982525|Dietary Supplement|One mussel portion|1 x 75g mussel portions provided per week
1498230|NCT02982525|Dietary Supplement|Two mussel portions|2 x 75g mussel portions provided per week
1498231|NCT02982525|Dietary Supplement|Three mussel portions|3 x 75g mussel portions provided per week
1498232|NCT02982512|Drug|Dexmedetomidine|Administration of dexmedetomidine a different concetrations
1498233|NCT02982499|Device|magnetic resonance image (MRI)|
1498238|NCT02982447|Device|blue laser imaging colonoscopy|Insertion to cecum was performed under white light(WL) and once the cecum was reached, the Blue Laser Imaging mode was switched on during withdrawal of endoscope for complete colonic examination. Second colonoscopic examination was performed in a similar manner after the first complete withdrawal of the colonoscope. WL was used on insertion and WL was used on withdrawal
1498239|NCT02982447|Device|conventional white light colonoscopy|In this arm, WL was used for both insertion and withdrawal of the colonoscope during the first-pass and second-pass examinations.
1498240|NCT02982434|Drug|Pharmaceutical composition containing botulinum toxin|
1498241|NCT02982434|Drug|0.9% normal saline|
1498242|NCT02982434|Procedure|Coronary artery bypass grafting|
1498243|NCT02982421|Behavioral|Group art therapy|Participants will engage in an art therapy group tailored at emotion expression related to the experience of breast cancer survivorship.
1498244|NCT02982421|Behavioral|Control|Participants will receive Psychoeducational material in the form of a lecture and will engage in the coloring of mandalas.
1498245|NCT02982408|Dietary Supplement|High carbohydrate overfeeding|"All participant's individual energy requirement will be determined in mega joules (MJ) per day. The energy requirement will be multiplied by a factor 1.5 for a low physical activity level (PAL). The MJ will be rounded up or down to the nearest whole number.
The participant will receive food corresponding to ~25% additional energy above their calculated energy requirement. The 25% extra energy will be supplied to the participants for 4 weeks in the form of food containing simple carbohydrates. The subjects will be given a daily snack package containing processed foods or refined foods such as sweets, cookies, soft drinks, juice etc. To ensure an adequate energy surplus (i.e. weight gain), physical activity has to be decreased to a low level during the 4 weeks overfeeding period."
1498246|NCT02982408|Behavioral|Exercise|"Half of the participants will be randomized to a 3-month exercise-training program.
The training program consists of combined aerobic training and strength training. The training program is performed unsupervised 3 times per week 45 minutes per session for 3 months in the local fitness center. Before engaging in the training program a maximal oxygen consumption test (VO2 max) are conducted and the maximal heartrate (HR) are determined.Participants are wearing the Polar V800 HR monitor and are asked to note their HR in a training log at the end of the last interval at each training session. The strength training program consist of 6 exercises (2 exercises paired together) involving the large muscle groups. The first training session is completed supervised at Rigshospitalet . After 6 weeks the training program is adjusted. Compliance will be ensured by phone calls, text messages and e-mails from study personnel."
1498247|NCT02982408|Behavioral|Normal physical activity|"The other half of the participants will be randomized to a 3-month with normal physical activity level (control).
The participants will have to return to the physical activity level they had before entering the study (baseline level). Compliance will be ensured by phone calls and text messages from study personnel. The subjects will wear a simple pedometer on the hip showing the number of steps. Once a week a text message (SMS-track) is automatically sent asking the participants to enter the weekly number of steps. The test personnel receive the reply and contact the participant if the number of steps does not match the baseline level. During the first and the last 7 days of the exercise intervention participants are wearing 2 accelerometers measuring their physical activity behavior."
1498248|NCT02982395|Drug|Nanoxel®M|Intravesical
1498249|NCT02982395|Drug|Mitomycin-C|Intravesical
1498250|NCT02982382|Other|Manipulative Therapy|Subjects will receive techniques of High Velocity and Low Amplitude (HVLA) or grade V manipulation to the lumbar region (lumbar roll), and pain education based on the biopsychosocial approach.
1498251|NCT02982382|Other|Pain Education|Individuals will receive pain education based in a biopsychosocial approach
1498252|NCT02982382|Other|Sham|The individuals will receive a simulation of spinal manipulation (sham) involving manual contact over lumbar region totaling 5 minutes.
1498253|NCT02982369|Other|Spinal Manipulation|High-velocity and low-amplitude (HVLA) manipulation techniques to the cervical and thoracic region
1498254|NCT02982369|Other|Pain Education|Subjects will receive pain education based in biopsychosocial approach
1498255|NCT02982369|Other|Sham|A simulation of spinal manipulation (sham), involving manual contact over the cervical and thoracic region totaling 10 minutes.
1498256|NCT02982356|Procedure|Fetal Selective Reduction Technology|Fetal Selective Reduction Technology will be conducted according to different gestational weeks: before 16weeks, 16~24 weeks, 24~27+6 weeks,>28weeks
1498257|NCT02982356|Drug|Potassium Chloride|
1498258|NCT02982343|Behavioral|Falls management plus exercise training|Participants will undergo a session of falls management and education followed by 12 weeks of strength and balance training. Strength training will be performed 4 times per week. Resistance training of the proximal muscles will be prescribed progressing to loads of 60% of 1 repetition maximum, 8-12 repetitions. Weaker muscles will be trained using 2 sets of 8-12 repetitions against gravity. They will also give a selection of exercises targeting balance to challenge stability and sensory feedback using equipment such as foam cushions, though will be individual based on participants' limitations and abilities. Participants will be asked to perform balance exercises daily.
1498259|NCT02982343|Behavioral|Falls management only|Participants will undergo a session of falls management and education.
1498262|NCT02982317|Procedure|Manual palpation identification lumbar spine|
1498263|NCT02982317|Procedure|Automated ultrasound technology identification|This technology involves a standard ultrasound machine and curvilinear probe- what is novel is the software which will be connected to the ultrasound machine
1498264|NCT02982317|Procedure|Lumbar level identification gold standard ultrasound|
1498265|NCT02982304|Device|Deep Brain Stimulation|Deep Brain Stimulation Electrode
1498266|NCT02982291|Procedure|Williams flexion protocol|The Williams flexion protocol group will participate in 15 treatment sessions.
1498267|NCT02982291|Procedure|Focused spinal stenosis rehabilitation|The focused spinal stenosis rehabilitation group will participate in 5 treatment sessions.
1498268|NCT02982278|Behavioral|Community-based Intervention under Nurse Guidance after Stroke|CINGS is a 12-week nurse coordinated, Community Health Worker intervention structure. Intervention home visits will be conducted by the CHW and will include home-based training in self-care and self-management strategies alongside strategies to address risk of negative stroke outcomes that will be determined once these risk factors are identified and community-engaged approaches to their resolution derived. CHW efforts will be guided via televideo interactions with nurse coordinator. During home-visits, self-reported assessments will be collected via RedCap as well as assessments collected by the CHW and research nurse (weight, blood pressure, medication adherence). After baseline, participants randomized to the intervention group will have home visits, once a week for the first month, and biweekly for the other two months, conducted by the CHW. Additionally, there will be post-intervention follow-up assessments at 3, 6, and 12-month time intervals.
1498302|NCT02982057|Drug|O.M.T|
1498411|NCT02981173|Drug|Placebo|Microcrystalline cellulose capsule ingested on each of three test days (5 days apart +/- 1-2 days)
1498269|NCT02982252|Behavioral|CoPILOT|Participants in all groups will receive either six or twelve hours of training in a standard powered wheelchair; however, the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
1498270|NCT02982239|Behavioral|Sleep Diary|All 40 chosen students will be provided a link to complete a daily sleep diary for 10 weeks. Sleep diary will assess activity before bed, bedtime, time to fall asleep, number of awakenings, time awake after sleep onset, time out of bed, time of final awakening, perceived sleep quality. Diary also asks about naps taken during the day, caffeine and tobacco consumption, and an additional space for open-ended comments from the participant.
1498271|NCT02982239|Device|Fitbit|All 40 chosen students will receive a Fitbit. The fit bit will estimate sleep and physical activity as well as adherence to the program. participants will have access to their own data. Data will also be monitored from the lab using Fitabase which provides access to day, hour, and minute-level resolution of data for steps taken, intensity class, calories burned, and sleep (length, movement, and quality).
1498272|NCT02982239|Device|Blue-Blocking Glasses|Half of the 40 chosen students (N=20) will be provided with blue blocking glasses. The blue-blocking glasses will ensure that blue light from electronic devices will not interfere with circadian rhythm or sleep onset, and allow students to fall asleep earlier.
1498273|NCT02982239|Device|LED light|Half of the 40 chosen students (N=20) will be provided with a bright LED light. The bright LED light will provide bright blue light in the morning to help students wake and an amber light to promote earlier bedtimes.
1498274|NCT02982239|Other|Information Sessions|"all 40 participants will attend a 1-hour information session about sleep delivered by the PIs, to be followed by a 1-hour Q&A period.
Peer educators will receive and extra 1-hour training session on how to handle questions and when to refer back to the PIs."
1498275|NCT02982239|Behavioral|Text messages|All participants will receive text messages in the evening that will include adherence reminders, encouraging statements, and tips for improving sleep. Messages will be randomized, with no more than 3 messages of any type per week. Messages will serve as a cue to action without being overly repetitive or predictable.
1498276|NCT02982226|Device|ReNu Injection|ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
1498277|NCT02982226|Device|Corticosteroid Injection|Corticosteroids are considered a standard of care for treatment of Plantar Fasciitis
1498278|NCT02982213|Other|Companion Present|A companion will be present during the epidural catheter placement.
1498279|NCT02982187|Device|Placebo ELLIPTA|It is a dry powder inhaler device that can hold two individual blisters: one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
1498280|NCT02982187|Device|Placebo DISKUS|It is a placebo dry powder inhaler with one blister strip containing lactose monohydrate.
1498281|NCT02982187|Device|Placebo TURBUHALER|It is a placebo dry powder inhaler containing lactose monohydrate.
1498282|NCT02982187|Device|Placebo HANDIHALER|Placebo capsules contain lactose monohydrate in the form of powder for oral inhalation, to be used with HANDIHALER device.
1498283|NCT02982187|Other|PQ1|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
1498284|NCT02982187|Other|PQ2|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
1498285|NCT02982187|Other|PQ3|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
1498286|NCT02982187|Other|PQ4|Consists of 2 questions to assess subjects' preference of device attributes and dosing regimens. The 4 versions of the questionnaire ask the same questions.
1498287|NCT02982174|Device|3D OCT-1 Maestro|Image acquisition of the posterior surface of the eye
1498288|NCT02982174|Device|DRI OCT Triton|Image acquisition of the posterior surface of the eye
1498289|NCT02982161|Drug|MR308|Over-encapsulated tablet, Dosing frequency: two times daily, Mode of administration: oral
1498290|NCT02982161|Drug|Tramadol|Over-encapsulated capsule, Dosing frequency: four times daily, Mode of administration: oral
1498291|NCT02982161|Drug|Placebo|Capsule, Dosing frequency: four times daily, Mode of administration: oral
1498292|NCT02982148|Device|methylene blue intradermal injection|Methylene blue has been prove to be effective and safe as a blue dye for sentinel lymph node biopsy in early breast cancer patient. But it was also reported by some article that adverse skin lesions appeared after methylene blue injections for sentinel lymph node localization. But the effectiveness and safety of methylene blue intradermal injection has not yet been investigated.
1498293|NCT02982148|Device|methylene blue subcutaneous injection|Methylene blue subcutaneous injection has become one of the standard method for sentinel lymph node biopsy for breast cancer patients. In such case, we use this method to be an active comparator for the intradermal injection group.
1498294|NCT02982135|Other|bypass surgery and indrect bypass surgery|bypass surgery ： patients recieved STA-MCA bypass indrect bypass surgery：patients recieved EDAS or mutiple bur holes
1498295|NCT02982122|Other|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.|For both groups, CPP targets will be achieved first by ICP control if this is raised and then by ABP support by titration (up or down) of vasopressors and fluids according to local protocols.
1498296|NCT02982096|Device|Cellutome Device|Use of FDA approved Cellutome treatment on burn wounds
1498297|NCT02982096|Other|Standard of Care|Acellular burn wound management
1498298|NCT02982083|Drug|Raloxifene hydrochloride|20 patients consume raloxifene hydrochloride oral tablet daily for one year.
1498299|NCT02982083|Drug|Placebo Oral Tablet|20 patients consume placebo oral tablets daily for one year.
1498300|NCT02982070|Behavioral|Mental Toughness Training|Behavioral training in goal-building, mindfulness, and the growth mindset.
1498301|NCT02982057|Device|the ABSORB:bioresobable vascular scaffold|
1498303|NCT02982044|Other|Suprasystolic (300 mmHg) cuff compressions|10 minutes of ECG-gated repeated suprasystolic (300 mmHg) cuff compressions, with inflation occurring every other heart cycle. These cuff compressions may be triggered 0 seconds, 0.2 seconds, or 0.4 seconds from the R spike (systole) on the ECG signal.
1498304|NCT02982044|Other|Handgrip exercise|10 minutes of ECG-gated rhythmic handgrip exercise at 30% maximal voluntary contraction, with contraction occurring every other heart cycle
1498305|NCT02982044|Other|Passive heat stress|10 minutes of passive heat stress at 42 degrees Celsius with a commercially available heating blanket
1498306|NCT02982031|Procedure|shamrock|This scanning technique is performed in the lateral decubitus position with the side of interest facing upwards. The transducer is placed in the transverse plane on the flank of the patient cranially to the iliac crest. The quadratus lumborum muscle is identified medial to the aponeurosis of the transversus abdominis muscle. With the psoas muscle anterior to the transverse process, the erector spinae muscle posterior to the transverse process, and the quadratus lumborum muscle attached to the apex of the transverse process of L4.
1498307|NCT02982031|Procedure|paramedian transverse scan|The ultrasound transducer is positioned 4 cm lateral to the midline along the intercristal line and just above the iliac crest. The transducer is also directed slightly medially.
1498308|NCT02982005|Drug|KHK4827|Administered KHK4827 by subcutaneous (SC) injection until week 62.
1498309|NCT02982005|Drug|Placebo|Administered placebo by subcutaneous (SC) injection until week 12. Administered KHK4827 by SC injection from week 13 until week 62.
1498310|NCT02981979|Drug|Leflunomide 10mg Tab|20mg per day for leflunomide group during the entire study; 20mg per day for control group during the maintenance therapy (start from the 25th week till the end of the study).
1498311|NCT02981979|Drug|Prednisone Acetate|basic therapy（start with 0.6mg/kg/d and maintained for 4 weeks, then reducing 5mg every 2 weeks until 10mg per day if the subject achieve clinical remission.）
1498312|NCT02981979|Drug|Placebos|used in control group during the induced remission therapy for 24 weeks.
1498313|NCT02981966|Drug|Dapagliflozin|dapagliflozin, 10mg tablet
1498314|NCT02981966|Drug|Placebo|Placebo for dapagliflozin
1498315|NCT02981953|Device|Cardioband Tricuspid|The Cardioband Adjustable implant is delivered and anchored to the tricuspid valve annulus by a transfemoral delivery system. The Cardioband TR will be deployed and adjusted under trans-esophageal and fluoroscopy guidance.
1498316|NCT02981940|Drug|Abemaciclib|Abemaciclib capsule
1498317|NCT02981940|Procedure|Surgery|Surgery
1498318|NCT02981927|Other|Physical inactivity|
1498319|NCT02981914|Drug|Pembrolizumab|Pembrolizumab will be administered at a fixed dose of 200 mg IV every 3 weeks for a max of 24 months, so long as there is no disease progression.
1498320|NCT02981901|Other|Patient with ovarian epithelial cancer|
1498321|NCT02981888|Radiation|X-Ray|X-ray of the abdomen will be done to look at the motility of the GI tract
1498322|NCT02981875|Other|oculomotor training|a sequence of vision training exercises which focused mainly in oculomotor skill
1498323|NCT02981875|Other|placebo|placebo vision training exercises involving minimal accommodation and vergence eye movement.
2002014|NCT02591472|Procedure|Integrated care (ICare)|The Integrated Care approach provides Usual Care processes plus simultaneous psychosocial support via the Transform-10 Program. The Transform-10 Program will include information regarding emotional well-being, social support, and provides opportunity for the patient to openly discuss their thoughts and concerns regarding their recovery. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
1498327|NCT02981823|Procedure|hip replacement|The patients undergo hip replacement with the collum femoris preserving stem suffered from periprosthetic fractures.
1498328|NCT02981810|Device|Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55*|The treatment was conducted using an Arthrocare® Corporation (ArthroCare Corporation, 7500 Rialto Boulevard Austin, Texas 78735) COBLATION electrode ReFlex Ultra 55* for tonsillar tissue ablation at low temperatures with only one treatment. All the patients underwent tonsil channeling treatment with coblation, and 4-6 channels were done in each tonsil under local anesthesia, in the operating room. The patients were observed overnight.
1498329|NCT02981810|Procedure|tonsillectomy|
1498330|NCT02981797|Other|Blood Collection During Standard of Care Treatment|Blood collection for baseline CTC numeration and H2AX assay. Circulating prostate cancer cell analysis requires blood draw of 7.5 ml (about 1 ½ teaspoons) of blood, to be performed at the screening, 1-2 hours before the third and sixth dose of radium 223 and 24 hours after the first, third, sixth dose of Radium 223. Standard of care Radium 223 treatment is given every 4 weeks for a total of 6 treatments and post Radium 223 follow up at week 24 is also considered standard of care. Other than these standard clinic visits and treatments, the study only requires 3 extra trips to the cancer center for blood draw at 24 hours after the first, third, sixth dose of Radium 223. Blood draws other than circulating tumor cell analysis is considered standard of care and doesn't require extra visits.
1498331|NCT02981784|Drug|Ponatinib (Iclusig®)|Novel tyrosine kinase inhibitor active in patients with an ABL T315I mutation compared to conventional or reduced intensity allogeneic stem cell transplantation.
1498332|NCT02981784|Procedure|allogeneic stem cell transplantation|
1498333|NCT02981771|Behavioral|Balance activity program|Participants will take part in a biweekly, 12 week physical activity program that will include balance and coordination exercises
1498334|NCT02981771|Behavioral|Strength activity program|Participants will take part in a biweekly, 12 week physical activity program that will include traditional strength exercises
1498335|NCT02981745|Drug|CT-1530|Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Waldenstrom's Macroglobulinemia, FL, Diffuse B-cell lymphoma, Mental-cell lymphoma
1498336|NCT02981732|Other|Liuwei Dihuang Pill|
1498337|NCT02981719|Procedure|irreversible electroporation|irreversible electroporation with chemotherapy in pancreatic cancer
1498338|NCT02981719|Drug|chemotherapy：Gemcitabine|Intravenous infusion for 30 minutes
1498868|NCT02977533|Drug|Acyclovir|"Pharmaceutical form: tablet
Route of administration: oral"
1498339|NCT02981706|Procedure|Arteriovenous Fistula (AVF)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous fistula, or connection between a native artery and vein.
1498340|NCT02981706|Procedure|Arteriovenous Graft (AVG)|The location of vascular access placement in the upper extremity will be based on pre-surgery vein mapping and the appearance of the vessels at the time of the surgery, with the most distal clinically acceptable location used. When no contra-indication is present, the vascular access will be placed in the non-dominant arm per standard of care. In this case, the vascular access will be an arteriovenous graft, or synthetic connection between a native artery and vein.
1498341|NCT02981693|Procedure|Root canal sealer|Patients who required root canal therapy were enrolled and allotted into either iRoot SP arm or AH Plus arm randomly.For Test Arm: iRoot SP was used as a sealer. Obturation was performed with Gutta-percha cones and root canal sealer by continuous-wave condensation technique. For Control Arm: AH Plus was used as root canal sealer. The same steps were followed for obturation as in Test Arm.
2002015|NCT02591472|Procedure|Usual Care (UsCare)|Usual Care includes radiographic imaging and administration of pain medication and antibiotics, skin care and range of motion of the injured area. The patient's normal clinical care usually includes a hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit. At the end of the study all of the materials that make up the Transform-10 Program will be provided.
2002016|NCT02591472|Other|Patient-Reported Outcomes Measurement Information System|Questionnaires of Physical Functional quality of life and Emotional Well-being will be performed during the hospital stay, a 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
1498344|NCT02981667|Other|Exercise intensity|Participants were randomized to 1 or 2 exercise intensities, moderate or high (interval training).
1498345|NCT02981654|Device|Alma Lasers Pixel carbon dioxide laser system|The vaginal handpiece sheath is lubricated with baby oil. Set the initial energy level (startup set up recommendations: High mode, 40 millijoule/pixel; according to the patient reaction you can increase up to 120 max. Pulse mode or Repeat mode). The handpiece is inserted as distally as possible, with the laser energy's window oriented to the 12:00 o'clock position. There are position markings on the handpiece. Trigger a laser pulse by pressing the footswitch. Shoot the laser and rotate the probe by one hour at a time. When you reach the 12:00 o'clock position again, withdrawal the headpiece back by one centimeter and repeat the rotational treatment process.
1498346|NCT02981641|Radiation|Intraoperative radiotherapy (IORT)|Total dose: 18~22 Gy; Single dose: 18~22 Gy; Frequency: 1
1498347|NCT02981641|Drug|Sequential chemotherapy|Sequential chemotherapy
1498348|NCT02981641|Radiation|Three dimensional conformal radiation therapy (3D-CRT)|Total dose: 60 Gy; Single dose: 2 Gy; Frequency: 30
1498349|NCT02981641|Drug|Concurrent chemotherapy|Gemcitabine (GEM), 800 mg/m2 weekly on Day 1-21, Q28d; or S-1 orally, 400 mg/d, bid on Day 1-21, Q28d
1498350|NCT02981628|Biological|Inotuzumab Ozogamicin|Given IV
1498351|NCT02981628|Other|Laboratory Biomarker Analysis|Correlative studies
1498352|NCT02981615|Drug|Levofloxacin|one tablet (500mg) a day, from day 10 to day 28 in every cycle of the 4 first cycles
1498353|NCT02981615|Drug|Placebo Oral Tablet|one tablet a day, from day 10 to day 28 in every cycle of the 4 first cycles
1498354|NCT02981602|Drug|IONIS-HBVRx|Ascending multiple doses of IONIS-HBVRx by subcutaneous (SC) injection
1498355|NCT02981602|Drug|Placebo|Placebo
1498356|NCT02981589|Device|Invasive mechanical ventilation|Invasive ventilation was performed to all eligible patients. When patients met predefined criteria, spontaneous breathing trial was performed. Given spontaneous breathing trial passed, patients were extubated; on the contrary, patients would continue to receive invasive ventilation. If patients had respiratory failure after extubation, reintubation and invasive ventilation were necessary.
1498357|NCT02981576|Biological|Autologous Mesenchymal Stem Cells|Autologous Mesenchymal Stem Cells will be collected from patients, prepared in the lab and then injected intrathecally.
1498359|NCT02981537|Device|two-staged endobronchial blocker insertion|positioning endobronchial blockers in two-staged method
1498360|NCT02981537|Device|single-staged endobronchial blocker insertion|positioning endobronchial blockers in traditional single-staged method
1498361|NCT02981524|Drug|CY|CY is administered intravenously at 200 mg/m2
1498362|NCT02981524|Biological|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting
1498363|NCT02981524|Drug|Pembrolizumab|Pembrolizumab is administered intravenously at 200 mg
1498365|NCT02981498|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
1498366|NCT02981498|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
1498367|NCT02981485|Device|Fat Grafting|Treatment of breast cancer related lymphedema by fat grafting
1498371|NCT02981459|Drug|Mirabegron|daily mirabegron 25mg with the option to increase dose based on symptoms to 50mg daily after 4 weeks
1498372|NCT02981446|Drug|DE-117|DE-117 ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
1498373|NCT02981446|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution will be taken one drop, once daily for 3 months in both eyes.
1498407|NCT02981186|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
1498408|NCT02981186|Device|IOL implantation comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
1498409|NCT02981173|Drug|0.143 mg/kg Psilocybin|0.143 mg/kg psilocybin capsule ingested on each of three test days (5 days apart +/- 1-2 days)
1498410|NCT02981173|Drug|0.0143 mg/kg Psilocybin|0.0143 mg/kg psilocybin capsule ingested on each of three test days (5 days apart +/- 1-2 days)
1499857|NCT02970318|Drug|Acalabrutinib (ACP-196)|
1498374|NCT02981420|Behavioral|Safety planning|Safety Planning Intervention. This brief one-session intervention, based on cognitive behavioral principles, is designed to help individuals identify a concrete list of coping strategies and social supports that youth can utilize preceding or during a crisis to lower imminent risk of suicidal behavior. In youth who also report nonsuicidal self-injurious behavior (NSSI), the safety plan will address both suicidal and nonsuicidal behavior. The plan helps youth identify possible triggers to SI/crisis including self-monitoring of suicidal thoughts, feelings, and behaviors; advance planning to remove lethal means; determine distress tolerance/emotion regulation skills that may be helpful; identify accessible social supports to target hopelessness/sense of isolation; reinforce the commitment to seek treatment; and, how and where to access emergency care.
1498375|NCT02981407|Biological|Red Blood Cell Transfusion|Transfusion of packed red blood cell units
1498376|NCT02981394|Procedure|Bone Marrow Aspirate Concentrate Injection|BMAC will be collected in the outpatient setting with local anesthesia. The collection site will be the Posterior Superior Iliac Spine (PSIS). This will be visualized under ultrasound prior to collection. Local anesthesia with 1% lidocaine will be performed prior to the harvest. BMAC harvest will be performed using the Arthrex Angel BMAC System using the Arthrex collection protocol. The Arthrex Angel machine will be used to separate BMAC contents for injection based on Arthrex collection protocol. Machine settings, volume of collection and volume of output have not been standardized and will be based upon harvest and the condition treated. These will be variables recorded for consideration of optimal settings based on the patient-reported outcomes.
1498377|NCT02981381|Device|NEST-1|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be NEST-1 compatible.
1498378|NCT02981381|Device|SHAM|The SHAM NeoSync EEG Synchronized TMS (NEST) is a device, identical to the active NEST-1 device, that is configured to simulate the delivery of active treatment without actively delivering sTMS therapy. The device includes an EEG recording module that is used to record individualized alpha frequency (IAF) on randomized personal passport modules (PPM) pre-assigned to be SHAM compatible.
1498379|NCT02981381|Device|NEST-2|The open-label NeoSync EEG Synchronized TMS (NEST) that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of PTSD. The device is distinct in both color and sound both SHAM and NEST-1 devices. PPMs corresponding with both SHAM and NEST-1 devices are compatible with the NEST-2 device.
1498380|NCT02981368|Drug|18F-DCFPyL Injection|A single dose of 9±1 mCi (333±37 MBq) IV injection of 18F-DCFPyL
1498381|NCT02981355|Procedure|Microfracture treatment|Microfracture is performed by penetrating the subchondral bone beneath the cartilage lesion inducing a bleeding response.
1498382|NCT02981355|Device|BST-CarGel|BST-CarGel is combined with fresh, autologous whole blood and applied to the lesion on the femoral condyle with a syringe following microfracture arthroscopic surgery.
1498387|NCT02981329|Drug|Metformin|"Subjects will be started at a dose of 500 milligrams/day of metformin taken twice a day. After one week dose, the dose will be increased to 750 milligrams/day taken twice a day (total dose 1500 mg/day).
After 3 months on metformin at 1500 milligrams/day, the dose will be increased by 500 milligrams per day per week until a maximum dose of 2500 milligrams/day."
1498388|NCT02981316|Biological|RBX7455|Microbiota capsule(s) given twice daily in the morning, and in the evening.
1498389|NCT02981303|Biological|Imprime PGG|Imprime PGG is a soluble, β-1,3/1,6 glucan isolated from the cell wall of a proprietary Saccharomyces cerevisiae yeast strain. Imprime PGG acts as a Pathogen-Associated Molecular Pattern (PAMP). Imprime will be administered at a dose of 4 mg/kg IV over a 2-hour infusion time on Days 1, 8 and 15 of each 3-week treatment cycle.
1498390|NCT02981303|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody against the programmed death receptor-1 protein. Pembrolizumab will be given at a fixed dose of 200 mg IV over 30 minutes on Day 1 of each 3-week treatment cycle after the Imprime infusion.
1498391|NCT02981290|Drug|Renodapt|Renodapt will be administered as 500 milligrams (mg) tablet orally on Day 1 in any treatment periods.
1498392|NCT02981290|Drug|Mycept|Mycept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
1498393|NCT02981290|Drug|Cellmune|Cellmune will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
1498394|NCT02981290|Drug|CellCept|CellCept will be administered as 500 mg tablet orally on Day 1 in any treatment periods.
1498395|NCT02981277|Drug|Transcricoid injection|Lignocaine delivery using Transcricoid Injection
1498396|NCT02981277|Drug|Spray as you go|Lignocaine delivery using Spray as you go method
1498397|NCT02981264|Drug|Transcricoid Injection|
1498398|NCT02981264|Drug|Spray as you go|
1498399|NCT02981251|Behavioral|Health education with support by trained female health volunteer|Along with usual care four sessions of interactive health education will be provided to the participants by medical officer and/or registered nurse based on a syllabus for six months. Trained female female health volunteer will motivate the participants through their home visit twice a month where they will monitor blood pressure and counsel the family members to support the patient.
1498400|NCT02981238|Dietary Supplement|Phytostandard® Eschscholtzia / Valerian|
1498401|NCT02981225|Dietary Supplement|Phytostandard® Rhodiola-Saffron|
1498402|NCT02981212|Drug|Mycophenolate Mofetil|less than 80 kg: 1,500 mg / day , 80 kg or more: 2,000 mg / day divided twice a day and administered orally
1498403|NCT02981212|Drug|ACE inhibitor|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
1498404|NCT02981212|Drug|Corticosteroid|combination with Mycophenolate Mofetil
1498405|NCT02981212|Drug|ARB|maintain conservative treatment (using ACE inhibitor or ARB for blood pressure regulation and proteinuria suppression treatment) just as before randomization
1498406|NCT02981199|Procedure|stem cell transplantation|conditioning with chemotherapy [VMD regimen(bortezomib, melphalan, dexamethasone) or Mel+Vel regimen(melphalan, bortezomib)], then stem cell transfusion
1499858|NCT02970318|Drug|Rituximab|
1498412|NCT02981160|Other|Dietary|The REE testing will be done with the Breezing device, a breath analyzer developed at Arizona State University. The Breezing device is an indirect calorimetry analyzer that measures the rate of oxygen consumption and carbon dioxide production, and determines how much energy the body is burning (REE), and the type of nutrients the body uses to produce energy (energy source). The Breezing device is a cellphone-size, battery-operated, portable technology that syncs with smartphones and electronic pads. The patients will be asked to breathe into a mouthpiece connected to the Breezing device; the data will be then beamed wirelessly to the device. The breath analysis data will displayed on the screen in conjunction with an estimate of total calories burned each day (total energy expenditure, TEE).
1498414|NCT02981134|Procedure|Computed tomographic scan|after 1year of BVS implantation, computed tomographic scan will be performed
1498415|NCT02981121|Behavioral|Exercise and Diet remedies|
1498416|NCT02981121|Drug|Metformin|
1498417|NCT02981108|Drug|HS-10296|
1498418|NCT02981095|Procedure|Thyroidectomy|Thyroidectomy performed by the same surgical and anesthesia team
1498419|NCT02981095|Drug|Bupivacaine|bupivacaine 0.5%, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
1498420|NCT02981095|Drug|Saline Solution|%0.9 sodium chloride solution, 10cc was administered to surgical field after completion of Thyroidectomy and approximately 15-30 minutes before the extubation.
1498421|NCT02981082|Drug|Dimethyl Fumarate (DMF)|Dimethyl Fumarate (DMF) is a prescription medicine used to treat relapsing multiple sclerosis.
1498422|NCT02981082|Drug|Placebo Oral Tablet|Sugar pill manufactured to mimic Dimethyl Fumarate (DMF)
1498423|NCT02981069|Drug|Dapagliflozin|10mg
1498424|NCT02981069|Drug|Exenatide|Byetta 5 to 10 ug (twice daily) Bydureon 2mg (once weekly)
1498425|NCT02981069|Drug|Placebo|Placebo for Dapagliflozin
1498426|NCT02981056|Other|Johnson's Baby Top-To-Toe Wash|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
1498427|NCT02981056|Other|Johnson's Baby Lotion|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: at least once a day, no more than twice in the same day.
1498428|NCT02981056|Other|Water (in lieu of bathing products)|During the study period, the different intervention products/regimens will be assigned to each group of subjects and replaced their daily wash and or body lotion products. Usage frequency: Ideally 7 times a week, at least 5 times a week, no more than once in the same day.
1498429|NCT02981030|Drug|Mifepristone|Women seeking medical abortion will be offered the option to take mifepristone at home
1498430|NCT02981030|Drug|Misoprostol|Women seeking medical abortion will be offered the option to take misoprostol at home. Misoprostol will be administered buccally.
1498431|NCT02981017|Device|Porcine Intestinal submucosal xenograft|Cook Biodesign ENT repair graft will be used in the experimental group to cover exposed bone in the sinonasal cavity as a result of the Draf III/endoscopic modified lothrop procedure.
1498432|NCT02980991|Drug|Pemetrexed|Two cycles of pemetrexed 500mg/m2 day 1, 21 days per cycle for patients before surgery
1498433|NCT02980991|Drug|Cisplatin|Two cycles of cisplatin 75mg/m2 day 1 (or 25mg/m2 day 1-3), 21 days per cycle for patients before surgery
1498434|NCT02980978|Behavioral|Coaching|Focus on nutrition, activity and appropriate medication use and adherence
1498437|NCT02980952|Other|overfeeding|
1498438|NCT02980952|Drug|Acipimox|Acipimox ingestion
1498439|NCT02980952|Other|Physical inactivity|
1498440|NCT02980952|Dietary Supplement|Eucaloric|
1498441|NCT02980952|Dietary Supplement|Placebo|
1498442|NCT02980952|Dietary Supplement|Hypercaloric|
1498443|NCT02980939|Other|iv fluid infusion|Intravenous isotonic saline infusion
1498444|NCT02980926|Drug|Mepivacaine|This is a shorter acting spinal anesthetic as compared to the current standard of care at this institution.
1498445|NCT02980926|Drug|Bupivacaine|This is the current standard of care at this institution and many centers. This is a longer acting spinal anesthetic compared to the study drug.
1498446|NCT02980913|Device|Thealoz Duo eye drops and Thealoz Duo gel|Thealoz Duo eye drops during the day + Thealoz Duo gel at night (1 drop before going to bed) for 7 days
1498447|NCT02980913|Device|Thealoz Duo gel|Thealoz Duo gel during the day and at night for 7 days
1498448|NCT02980900|Dietary Supplement|Post exercise protein supplement|
1498449|NCT02980900|Dietary Supplement|Post exercise placebo supplement|
1498450|NCT02980900|Dietary Supplement|Pre bed protein supplement|
1498451|NCT02980900|Dietary Supplement|Pre bed placebo supplement|
1498452|NCT02980887|Other|No Intervention|There is no intervention in this observational study
1499859|NCT02970318|Drug|Idelalisib|
2002017|NCT02591472|Other|Lower Extremity Gain Scale (LEGS)|LEGS consists of a 3-meter walk, putting on a sock, putting on a shoe, rising from an armless chair, stepping up and down stairs, getting on and off the toilet, reaching from a sitting position to an object on the ground. In people with traumatic fractures, LEGS has high internal consistency and the content, concurrent and construct validity are high. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
1498455|NCT02980861|Procedure|Laparoscopic total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the laparoscopic totalgastrectomy (LATG) group, they will received LTG with spleen-preserving splenic hilum lymph nodes dissection.
1498456|NCT02980861|Procedure|Open total gastrectomy|When the participants with advanced proximal gastric cancer are randomized in the open total gastrectomy(OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
1498457|NCT02980848|Device|Screening digital mammography|Screening with digital mammography alone
1498458|NCT02980848|Device|Screening digital breast tomosynthesis|Screening with digital mammography plus digital breast tomosynthesis
1498459|NCT02980848|Device|Screening breast magnetic resonance imaging|Screening with digital mammography plus breast magnetic resonance imaging
1498460|NCT02980848|Device|Diagnostic mammography|Pre-operative diagnostic work-up with mammography alone
1498461|NCT02980848|Device|Pre-operative breast magnetic resonance imaging|Pre-operative diagnostic work-up with mammography plus breast magnetic resonance imaging
1498462|NCT02980835|Drug|Normal Saline|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate B contains 10 mL of 0.9% normal saline.
1498463|NCT02980835|Drug|Ropivacaine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate A and C contain 9 and 24 mL of ropivacaine HCl 0.5%, respectively.
1498464|NCT02980835|Drug|Epinephrine|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectate C contains 0.125 mL of epinephrine-1:1000 preparation.
1498465|NCT02980835|Drug|Dexamethasone|Blocking the nerves between the ribs with a local anesthetic is normally done as a part of routine care at the end of the surgery in one set of injections. Intervention group will receive injectate A at the beginning and injectate B and C prior to the closure. Control group receive injectate B at the beginning of surgery and injectate A and C prior to the closure and end of surgery. Injectates A and C both contain 1 mL of dexamethasone 4mg/mL preparation.
1498466|NCT02980809|Drug|Apatinib|
1498467|NCT02980809|Drug|Topotecan|
1498468|NCT02980796|Behavioral|Exercise|Each experimental day participants will complete an acute bout of exercise on a recumbent bike.
1498469|NCT02980796|Behavioral|Practice|Each experimental day participants will complete a session of skilled motor practice.
1498470|NCT02980783|Device|Juvéderm® VOLIFT®™ with Lidocaine|Juvéderm® VOLIFT®™ with Lidocaine is injected into the dynamic radial cheek line skin depressions on Day 0; volume of injection will not exceed 2mL per side. If applicable, a touch-up of Juvéderm® VOLIFT®™ with Lidocaine will be injected on Day 14; volume will not exceed 1mL per side.
1498471|NCT02980757|Drug|Gliclazide 120 mg MR Tablets Formula A|
1498472|NCT02980757|Drug|Gliclazide 120 mg MR Tablets|
1498473|NCT02980757|Drug|Gliclazide 120 mg MR Tablets Formula B|
2002018|NCT02591472|Other|Dynamometer|Isometric handgrip strength will be measured using a hand-held hydraulic dynamometer. Handgrip strength is clinically important as it strongly predicts long-term function capability after orthopedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
1498476|NCT02980718|Behavioral|intensive olfactory training|
1498477|NCT02980718|Behavioral|ordinary olfactory training|
1498478|NCT02980705|Drug|SUNPG1622 I dose|Injection
1498479|NCT02980705|Drug|Placebo dose|Injection
1498480|NCT02980692|Drug|SUNPG1623 I|injection
1498481|NCT02980692|Drug|SUNPG1623 II|injection
1498482|NCT02980692|Drug|SUNPG1623 III|injection
1498483|NCT02980692|Drug|SUNPG1623 IV|injection
1498484|NCT02980692|Drug|PLACEBO|injection
1498485|NCT02980679|Drug|CTC|After injection of CTC, a whole body and thyroid scan will be performed.
1498486|NCT02980679|Drug|G-PERT|After injection of G-PERT, a whole body and thyroid scan will be performed.
1498487|NCT02980666|Drug|Teduglutide|0.05 mg/kg SC once daily for 24 weeks
1498488|NCT02980653|Drug|Megestrol acetate (MA) 400 mg/day|Megestrol acetate (MA) will be given on 400 mg/day as eligible patient begin CCRT. Total treatment period is for a maximum of 12 weeks calculated from the date of first dose.
1498489|NCT02980627|Behavioral|Therapy with Mobile App Enhancement|"Treatment includes 12 weekly therapy sessions with daily RR app use between sessions. Intervention is CBT-based and specifically draws from ACT. ACT is a contextual behavior therapy that emphasizes the function of behavior (e.g., affect regulation) and helps individuals accept (or tolerate) emotional discomfort for a broader purpose (i.e., personal values). Broadly, treatment will focus on improving diabetes management by increasing patients' capacity to effectively cope with psychological barriers to self-care using acceptance and mindfulness strategies."
1498490|NCT02980627|Device|Recovery Record (RR) Mobile app|Treatment includes the use of a mobile application originally designed for eating disorders and adapted to include components specific to Type 1 Diabetes and Acceptance and Commitment Therapy (ACT). Participants will access this app outside of therapy and receive prompts from their therapist related to their current treatment goals.
1498491|NCT02980614|Device|4D flow imaging|
1498492|NCT02980601|Device|Integra plus STSG|A sheet of Integra directly on the wound bed with subsequent removal of the overlying silicone sheet and immediate application of a 0.008mm STSG
1498493|NCT02980601|Procedure|STSG|0.012mm STSG
1498494|NCT02980588|Device|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC
1498495|NCT02980575|Other|Music|
1498496|NCT02980575|Other|Exercise|
1498497|NCT02980562|Drug|Polyethylene Glycols|(Split dose 2L PEG-Asc)
1498498|NCT02980562|Drug|Bisacodyl|(1L PEG-Asc plus bisacodyl)
1498499|NCT02980549|Other|children's sleep habits questionnaire|survey of children's sleep habits completed by parent
2002019|NCT02591472|Other|Active Range of Motion (AROM)|The use of goniometer and a digital inclinometer will be used to assess AROM. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
1498504|NCT02980510|Drug|Panitumumab, oxaliplatin, folinic acid, 5fluoruracil|
1498505|NCT02980510|Drug|Panitumumab, oxaliplatin, folinic acid, 5fluoruracil, irinotecan|
1498506|NCT02980497|Other|Listerine Zero Mouthwash (without alcohol)|20 ml of rinse for 30 seconds, twice a day
1498507|NCT02980497|Other|Listerine Antiseptic Mouthwash (with alcohol)|20 ml of rinse for 30 seconds, twice a day
1498508|NCT02980484|Procedure|Active|Repetitive transcranial magnetic stimulation (rTMS) will be applied to the left dorsolateral prefrontal cortex (DLPFC) (4000 pulses, 10 Hz, 5-sec trains, 25-sec inter-train interval) followed by the right DLPFC (1000 pulses, 1 Hz frequency, single train). The DLPFC will be identified using individual subject-level resting-state network estimation (Hacker et al, 2013). Each treatment will be completed over the course of 1 hour, and each subject will receive a total of 20 treatments over the course of 20 consecutive weekdays.
1498509|NCT02980484|Procedure|Sham|Treatment that looks and feels similar to active rTMS will be administered as a sham treatment.
1498510|NCT02980471|Device|Pulse Oximeter|Blood removal and reintroduction as measured by the plethysmograph of a pulse oximeter
1498511|NCT02980458|Drug|Deferiprone 500Mg Tablet|
1498512|NCT02980458|Drug|Deferiprone 500 MG Oral Tablet [Ferriprox]|
1498513|NCT02980445|Behavioral|Outdoor activity 1|40-minute outdoor activity
1498514|NCT02980445|Behavioral|Outdoor activity 2|Dose 1 plus an additional 40-minute outdoor activities during recesses
1498515|NCT02980432|Other|changes in whole-body roll position and visual/haptic stimuli presented|In different whole-body roll positions subjects will be presented a luminous line or a rod in combination with a moving or stationary background. Participants will be asked to align the line or the rod along perceived direction of gravity.
1498516|NCT02980419|Behavioral|presentation of visual and vestibular stimuli|In each participant the investigators will assess verticality perception in whole-body upright position by use of the SVV, the SPV and the SHV after static roll-tilt at ±90deg over 5min. Measurements will be obtained on a motor-driven turntable and two different roll-tilt positions will be applied (±90°). A visual line (SVV), a rod (SHV) or the turntable itself will be adjusted to indicate perceived direction of vertical. A total of three measuring sessions, each lasting about 60 minutes are scheduled.
1498517|NCT02980406|Dietary Supplement|FODMAP|Fermentable oligo-, di- and monosaccharides and polyols are poorly absorbed carbohydrates that are known to cause symptoms in IBS patients.
1498518|NCT02980406|Dietary Supplement|Glucose (control)|Glucose is not a FODMAP.
1498519|NCT02980393|Behavioral|Lifestyle intervention|The structured lifestyle intervention involves alternating weekly phone calls with two health coaches: a registered dietitian and a fitness specialist. A total of 50 phone calls (25 nutrition-related and 25 physical activity-related) are delivered over the one-year study. After six months in the program, participants are introduced to supporting program-specific software that they can access online, as an additional way to interact with the program, set goals, and record their progress. Client and family-centred nutrition and physical activity counselling includes an initial and regular behavioural assessment, and subsequent conversations (i.e., phone calls) using motivational interviewing techniques intended to increase knowledge or skills, and improve behaviours.
1498520|NCT02980380|Other|Non-invasive brain computer interface|"The hemodynamic change in the motor cortex of the CLIS patient will be recorded across many sessions spread over more than a year and will be used to train a classifier to predict the yes and no answering pattern of the CLIS patient"
1498521|NCT02980367|Other|Non-Surgical Management (Rehabilitation)|Routine ACL rehabilitation protocols used at the participating site will be followed. As part of the site selection process, documentary evidence of the use of or willingness to adopt a rehabilitation protocol that reflects the guidelines of the mandatory aims/goals set for the study rehabilitation intervention will be required.
1498522|NCT02980367|Procedure|Surgical Management (Reconstruction)|All surgical reconstructions will be patella tendon or hamstrings tendon depending on the surgeon's preference. All other care will be routine, including immediate post-operative care.
1498523|NCT02980341|Drug|U3-1402|An investigational drug, not yet approved for marketing.
1498524|NCT02980328|Device|Low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
1498525|NCT02980328|Device|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating overactive bladder. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
1498526|NCT02980315|Other|CAR-T cells|the patients treat with CAR-T cells
1498527|NCT02980302|Procedure|Cutaneous biopsy|Under local anesthesia
1498791|NCT02978222|Biological|FRα peptide plus Adjuvant (GM-CSF)|Intradermal injection FRα peptides, 500μg each - plus GM-CSF 125 μg
1498528|NCT02980276|Drug|Metformin Hydrochloride|Women randomised to the metformin group will receive metformin 500mg OD, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of 2500mg Metformin daily (5 tablets) or maximum tolerated dose, in addition to usual care (exercise and MNT), and taken until delivery.
1498529|NCT02980276|Other|Placebo|Women randomised to the placebo group will receive 1 placebo tablet OD, with the dose titrated upwards every 2 days over 10 days increasing to a maximum of five placebo tablets daily, in addition to usual care (exercise and MNT), and taken until delivery.
1498530|NCT02980263|Drug|Canakinumab|
1498531|NCT02980250|Drug|Low dose|0.2mg group-The premature infant will be fed with 0.2mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
1498532|NCT02980250|Drug|normal dose|0.4mg group-The premature infant will be fed with 0.4mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
1498533|NCT02980250|Drug|over dose|0.6mg group-The premature infant will be fed with 0.6mg/kg/tds domperidone and will be tested the residual glucose everyday in a 7-days period.
1498534|NCT02980250|Drug|Glucose|Glucose group-The premature infant will be fed with glucose and will be tested the residual glucose everyday in a 7-days period.
1498535|NCT02980237|Other|eHealth_additional support|An e-learning education program whose audiovisual content will be implemented. Nine audiovisual e-Health program will be composed of nine video classes addressing the following topics: 1) musculoskeletal health, 2) healthy diet and 3) mental health were identified through focus group. A communication tool will be adopted is the Moodle environment. All the participants will be able to whipping the web platform and questions regarding access and navigation are answered by e-mail. All participants will be monitored, as viewing the videos, and whenever it is identified that the participants not accessed and lack of interest of reasons. A team of tutors will be responsible for online support providing reinforcing stimuli and clarifying any questions (intervention group) on the content.
1498536|NCT02980237|Other|eHealth_program|The comparative group will receive the same eHealth education program that intervention group. But the comparative group will receive only audiovisuals without additional support. .
1498537|NCT02980224|Drug|OmegaD|OmegaD Softgels
1498538|NCT02980224|Drug|Placebo|Placebo Softgels
1498539|NCT02980211|Device|Ridge Reconstruction|Tooth extraction will be attempted in minimally traumatic, flapless, fashion. Following tooth extraction, the existence of the suspected dehiscence defect will be confirmed; absence of a defect will result in subject exclusion from the study and the case will be considered an intent-to-treat. Horizontal and vertical dimensions of the defect will be measured using a UNC-15 probe. After creating a soft tissue 'pouch' using tunneling instruments, a non-absorbable dense-PTFE (dPTFE) [Cytoplast TXT-200, Osteogenics Biomedical] barrier membrane, trimmed to the size and shape that would allow for complete extension over the existing defect, will be tucked between the mucosa and the alveolar bone. The socket will then be grafted using a particulate bone allograft [EnCore, Osteogenics Biomedical] and the socket access will be sealed with an extension of the dPTFE membrane to ensure complete coverage of the bone graft and the crestal bone.
1498540|NCT02980198|Biological|IFN-Kinoid|
1498541|NCT02980198|Other|Placebo|
1498542|NCT02980198|Other|ISA 51|
1498543|NCT02980185|Procedure|Laparoscopic primary cytoreduction|Primary cytoreduction for ovarian cancer performed through a completely minimally-invasive approach
1498544|NCT02980172|Other|Pain evaluation|Evaluation of pain using a numerical scale (1 to 10)
1498545|NCT02980159|Other|Triage liaison physician|A triage liaison physician is present from 7:30 am to 10:30 pm, Monday to Friday, with the mission to evaluate quickly patients who cannot be immediately installed in an ED room
1498546|NCT02980146|Other|Non interventional study|
1498550|NCT02980120|Other|SCID-I|The structured clinical interview for DSM-IV Axis I Disorder (SCID-I, German translation, see Wittchen, Zaudig & Fydrich, 1997) is a semi-structured interview to diagnose AN and BM. It allows a detailed assessment of ED symptoms across different settings and time periods necessary to make an accurate diagnosis.
1498551|NCT02980120|Other|EAT|The Eating Attitudes Test (EAT) is a standardized questionnaire of symptoms and concerns related to ED (Garner & Garfield, 1979, German translation by Steinhausen). The questionnaire consists of 40 items on a six-point Likert scale, providing information
1498552|NCT02980120|Other|EDI-2|The Eating Disorder Inventory 2 (Paul & Thiel, 2004) is a self-report questionnaire on psychological features generally associated with AN and BN.The instrument consists of 91 items on a six-point Likert scale. The 11 scales are drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears, asceticism (provisional), impulse regulation (provisional) and social insecurity (provisional). It was designed as a diagnostic aid; its psychometrics have been tested, with studies demonstrating satisfactory internal consistency reliability coefficients (between .44 and .93), test-retest reliability of .79 to .95 (after one week) and above .80 (after three weeks), and content, convergent and discriminant validity.
1498553|NCT02980120|Other|SCID-II|The SCID-II interview (German, see Wittchen, Zaudig & Fydrich, 1997) is a widely used and researched instrument to assess DSM-IV-TR personality disorders.The interview covers all ten DSM-IV personality disorders (antisocial, avoidant, borderline, dependent, histrionic, narcissistic, obsessive-compulsive, paranoid, schizoid and schizotypal), PD not otherwise specified, and appendix categories (depressive PD and passive-aggressive PD) and is used to make personality disorder diagnoses either dimensionally or categorically (present-absent). Furthermore, it allows the investigation of patterns of PD that co-occur with other mental disorders as well as the analysis of the underlying structure of personality pathology.
1498554|NCT02980120|Other|LoPF|In order to specifically focus on certain personality traits, we use the LoPF as an additional measure. It is a well-validated and reliable self-report questionnaire to measure healthy and pathological personality functioning in adolescents. It is based on the DSM-5 Section III Alternative Model for Personality disorders and covers core impairments in adolescents' personality functioning: identity, self-direction (self-related personality functioning), intimacy/ attachment and empathy/ social-related personality functioning (Sevecke & Krischer, 2011).
1499860|NCT02970318|Drug|Bendamustine|
1498555|NCT02980120|Other|HAWIK-IV|The Wechsler Intelligence Scale for Children (HAWIK-IV, Petermann & Petermann, 2008) will be used assess intelligence. For adolescents older than 16.11 years, we will use the German version of the Wechsler Adult Intelligence Scale (HAWIE-IV).Results from test-retest reliability demonstrate that the mean retest scores for all subtests are higher than the mean test scores from first administration, with effect sizes ranging from .08 (comprehension) to .60 (picture completion). The test has demonstrated an acceptable relationship to other measures of achievement, memory, adaptive behavior, emotional intelligence and giftedness in children and adolescents (Canivez, 2014). For the non-clinical adolescent sample, we will use two subtests of the HAWIK.
1498556|NCT02980120|Device|fMRI|To measure food-related brain activation, event-related fMRI will be used, with phases of high-caloric images alternating with phases of low-caloric images and images of fixation cross (not related to food images). A total of 18 blocks will be performed - see figure below. The duration of each phase will be 30 seconds. In a second run, the patients and control subjects will drink chocolate milk and water, alternating every 30 seconds, through a long silicon tube. This procedure was successfully tested in a previous fMRI study with adult AN patients (Gizewski et al. 2010, Vocks et al. 2011) and has now been adopted in preliminary measurements for young AN patients.
1498557|NCT02980107|Other|Infographics|Cochrane started developing infographics, where short textual information about research is supported by visual representations of the main findings and is also aimed at the lay public The investigators will examine whether this format is better in information uptake than standard PLS.
1498558|NCT02980107|Other|PLS|Text format with simple explanation of the survey topic main findings and is intended for lay audience.
1498559|NCT02980094|Dietary Supplement|Milk Antioxidant group(A)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+selenium and vitamin E (A).
1498560|NCT02980094|Dietary Supplement|Milk Oil group(O)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)+sunflower oil (O).
1498561|NCT02980094|Dietary Supplement|Milk Antioxidant and oil(AO)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets:control (C)+selenium, vitamin E and sunflower oil (AO).
1498562|NCT02980094|Dietary Supplement|Milk Control group(C)|There is no intervention pre-specified before the institutionalized elderly to receive three times per day of milk (total 600ml of milk all day) produced by lactating cows fed with the following diets: control (C)
1498563|NCT02980081|Other|abdominal plain x-ray|Abdominal plain x-ray as prescribed by the emergency physician
1498566|NCT02980055|Procedure|collagen matrix|Surgical procedure for root coverage using collagen matrix
1498567|NCT02980055|Procedure|connective tissue graft|Surgical procedure for root coverage using connective tissue graft
1498568|NCT02980042|Drug|Ocrelizumab|A humanized monoclonal antibody that targets CD20 and selectively depleted CD-20 expressing B cells
1498569|NCT02980042|Drug|Rituximab|A chimeric monoclonal antibody against CD20.
1498570|NCT02980029|Drug|TVB-2640|TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
1498571|NCT02980029|Other|Placebo|Placebo
1498572|NCT02980016|Drug|rifapentine + isoniazid|Rifapentine + isoniazid Once weekly rifapentine (at a dose of 900 mg) plus isoniazid (at a dose of 900 mg), with adjustment for participants weighing ≤50 kg
1498573|NCT02980016|Drug|Isoniazid|Daily self-administered isoniazid (at a dose of 300 mg/daily), with adjustment for participants weighing ≤24 kg
1498574|NCT02980003|Drug|isotonic saline|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure.
1498575|NCT02980003|Drug|i.v. sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. The patient receives solution of 1.4% sodium bicarbonate (167 mEq/L; 334 mOsm/L) one hours and six hours after procedure.
1498576|NCT02980003|Drug|oral sodium bicarbonate|patients will start hydration with isotonic saline 6 hours before angiography and continue for 12 hours after the procedure. One hour before the angiography and 3 hours after patients will receive oral sodium bicarbonate at the dose of 4 g (47.6 mEq) dissolved in 60 mL of water
1498577|NCT02979990|Other|Instructional Video|The experimental group will be asked to view a set of videos that demonstrate proper usage of controlled ovarian stimulation medication. They will have the opportunity to review instructional videos as needed throughout the ovarian stimulation process.
1498578|NCT02979990|Other|Control Video|The control group will have access to a video about the IVF process
1498579|NCT02979977|Drug|cetuximab|30-60 minutes after the recommended pre-medications, cetuximab will be administered intravenously at a dose of 400mg/m2 on cycle 1, day 1 of treatment (loading dose) and at a dose of 250mg/m2 every 7 days (+/- 1 day) thereafter. Doses will be administered on the same day of each week (+/- 1 day).
1498580|NCT02979977|Drug|afatinib|Patients will take a single oral dose of afatinib each day at a dose of 40 mg. Afatinib dose will not be escalated beyond the 40 mg daily oral dose; dose reductions of afatinib can occur to manage treatment related adverse events.
1498581|NCT02979964|Behavioral|Audit and Feedback|
1498582|NCT02979938|Other|Semen analysis and semen PCR for Zika virus|Every two weeks subjects provide a semen sample which is analysed and then frozen for RT-PCR and viral load. Semen sample testing for the presence of ZIKV (Institute of Tropical Medicine, Belgium) will be performed using both a ZIKV-specific, in-house duplex real-time RT-PCR, targeting a 102bp and 121bp sequence of the NS5 gene and the RealStar® Zika Virus RT-PCR Kit (Altona). Quantitative viral load RNA measurements will be expressed utilizing threshold cycle values because a standardized viral load reference method is not available. To test for infectivity of ZIKV in semen, ZIKV isolation will be attempted in semen samples with a high viral ZIKV load (i.e. positive ZIKV PCR result and Ct-values below 30) by inoculation in Vero cells.
1498662|NCT02979288|Other|NO Intervention|NO Intervention
1498585|NCT02979912|Biological|Platelet Lysate|Eye drops of Platelet Lysate
1498586|NCT02979899|Biological|TRC105|TRC105 antibody
1498587|NCT02979899|Drug|Votrient|pazopanib
1498588|NCT02979886|Drug|GnRH-a|the hormone reaction to the down regulation of the patients
1498589|NCT02979886|Drug|Human Menopausal Gonadotropins|the effects on the serum LH level of day of HCG
2002020|NCT02591472|Other|Posttraumatic Stress Disorder (PTSD)|The Posttraumatic Stress Disorder (PTSD) Checklist will be administered to measure posttraumatic stress levels. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
1498591|NCT02979860|Behavioral|Sleep duration 90 min|Sleep duration: time in bed increased by 90 minutes
1498592|NCT02979860|Behavioral|Sleep duration 45 min|Sleep duration: time in bed increased by 45 minutes
1498593|NCT02979860|Behavioral|Sleep timing|Sleep timing: bed time kept consistent
1498594|NCT02979847|Procedure|hybrid catheter ablation|trans-xyphoid epicardial puncture is performed and 20-pole catheter via SL-1 sheath is inserted. Voltage mapping or activation mapping or CFAE mapping is performed as rhythm status. Epicardial and Endocardial side ablation were performed.
1498595|NCT02979847|Procedure|conventional endocardial ablation|trans-femoral puncture is performed. Voltage mapping or activation mapping or CFAE mapping is performed as rhythm status. Endocardial side ablation were performed and Epicardial side is not assessed.
1498596|NCT02979821|Drug|Poziotinib|A cycle of study treatment is defined as 28 days.
1498597|NCT02979808|Device|Navina Smart|Subjects treatment-naïve to transanal irrigation (TAI). Frequency of TAI will be tailored to each subject.
1498598|NCT02979795|Procedure|Preoperative chemoradiotherapy|Preoperative chemoradiotherapy. 2.5 Gray/fraction (Total in 45-54 Gray)
1498599|NCT02979782|Procedure|Endo-CABG|minimal invasive cardiac intervention
1498600|NCT02979782|Procedure|PCI|stenting procedure
1498601|NCT02979769|Drug|Palovarotene dose level 1|Palovarotene will be taken orally once daily at approximately the same time each day.
1498602|NCT02979769|Drug|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
1498603|NCT02979756|Procedure|Decentralized GDM screening and initial management|Screening for GDM and initialization of nutritional therapy at the first level of care
1498604|NCT02979743|Behavioral|Occupational therapy|
1498605|NCT02979743|Other|Occupational therapy puls acupuncture and massage methods|
1498606|NCT02979730|Other|Core Lab Test|For patients randomized to the Core Lab Testing Arm, ED physicians will order an influenza test to be performed in the core lab.
1498607|NCT02979730|Other|ED Point of Care Test|For patients randomized to the ED Point of Care Testing Arm, the Research Assistant will perform influenza testing in the Emergency Department, using the Cobas Liat Influenza A/B assay
1498608|NCT02979717|Dietary Supplement|High protein, high fiber dietary supplement|
1498609|NCT02979717|Other|Low protein, low fiber comparator|
1498610|NCT02979704|Drug|Rosuvastatin|45 patients will be treated with rosuvastatin at a dose of (5-10) mg orally once daily dose for 08 weeks
1498611|NCT02979704|Drug|Atorvastatin|45 patients will be treated with atorvastatin at a dose of (10-20) mg orally once daily dose for 08 weeks
1995796|NCT02653638|Other|Control|"Transcranial Doppler
Blood Pressure
Heart Rate
Oxygen Saturation"
1995797|NCT02653638|Drug|Indomethacin|"Transcranial Doppler
Blood Pressure
Heart Rate
Oxygen Saturation"
1498614|NCT02979678|Other|Questionnaire|The questionnaire should be updated with respect to wording, terminology.
1498615|NCT02979665|Drug|Ranibizumab Ophthalmic|"Ranibizumab (trade name Lucentis among others) is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab. It is an anti-angiogenic that has been approved to treat the wet type of age-related macular degeneration (AMD, also ARMD), a common form of age-related vision loss and diabetic macular edema (DME)."
1498616|NCT02979639|Biological|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm on a 2 month schedule.
1498617|NCT02979626|Procedure|Respiratory nasal swab|Nasal swabs will be obtained for testing by the study nurses. If a respiratory sample has already been collected as part of routine clinical care, this will replace the study collection, and no additional testing will be required.
1498623|NCT02979574|Procedure|Electro-Acupuncture (EA)|Participants will receive 10 treatment of Electro-Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). The acupuncturist will insert acupuncture needles in at least 4 local points around the body with the most pain and at least 4 distant points to address the patient's baseline constitution. The needles will be electrically stimulate at 2 Hz by connecting to a TENS unit. The needles will be in place for 30 minutes.
1498624|NCT02979574|Procedure|Battle Field Acupuncture (BFA)|Participants will receive 10 treatment of Battle Field Acupuncture over the course of 10 weeks (with a maximum of 2 treatments per week). Acupuncture needles will be placed in the participants' ears. The total duration of BFA delivery is about 10 to 20 minutes depending on how many needles are used in the procedure.
1498625|NCT02979574|Device|Wait List Control (WLC)|After the waiting period (12 weeks from randomization), participants in the WLC will receive up to ten treatments of either EA or BFA based on their personal preference.
1498706|NCT02978859|Drug|MGCD516|Administered at 150 mg orally, daily, in continuous 21 day cycles. An orally available, potent small molecular inhibitor of several related receptor tyrosine kinases.
1995799|NCT02650349|Other|fMRI|
1498626|NCT02979561|Drug|Dabigatran Etexilate|All patients in this group continue to receive unfractionated heparin for 5-7 days, and then transferred to the drug Pradaxa dose of 150 mg 2 times a day. Pradaxa administration continued until the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
1498627|NCT02979561|Drug|Warfarin|all patients continue to receive unfractionated heparin intravenously and at the same time (from the date of randomization) start warfarin, accompanied by regular measurement of the INR every day or every other day. As soon as INR reaches the range of 2.0 to 3.0, the administration of the unfractionated heparin should be discontinued. Further measurements of INR should be performed once a month during outpatient visits. The patient continues to receive warfarin under the control of the INR till the end of the treatment period. The treatment period starts on the day of randomization and lasts for 6 months.
1498628|NCT02979548|Drug|Aprepitant|Aprepitant is a non peptide, selective, Neurokinin type 1 (NK 1) receptor antagonist. Group A will receive Aprepitant as an add-on anti-emetic therapy in addition to ondansetron.
1498629|NCT02979548|Drug|Ondansetron|Ondansetron is 5HT3 Receptor antagonist used to treat and prevent chemotherapy induced nausea and vomiting
1498630|NCT02979548|Drug|Metoclopramide|Dopamine receptor antagonist , acts at CTZ. Rescue medication, injection metoclopramide 0.5 mg/kg body weight/day.
1498631|NCT02979535|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, Month 6 and 12, respectively
1498632|NCT02979535|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Month 1, 7 and 13, respectively
1498633|NCT02979535|Biological|Human Papillomavirus Bivalent [Types16 and 18] Vaccine, Recombinant.|0.5 mL, intramuscular at Day 0 and Month 6, respectively
1498634|NCT02979535|Biological|Human Papillomavirus Bivalent [Types 16 and 18] Vaccine, Recombinant.|0.5 mL, intramuscular at Day 0 and Month 6, respectively
1498635|NCT02979522|Drug|Brentuximab vedotin|Brentuximab vedotin infusion
1498636|NCT02979522|Drug|Doxorubicin|Doxorubicin infusion
1498637|NCT02979522|Drug|Vinblastine|Vinblastine infusion
1498638|NCT02979522|Drug|Dacarbazine|Dacarbazine infusion
1498639|NCT02979509|Other|Endoscopic ultrasound- (EUS) guided tissue sampling|EUS- guided tissue sampling of solid and/or cystic pancreatic and non-pancreatic lesions as part of their medical care.
1498640|NCT02979496|Dietary Supplement|0 g pomace (control)|16 oz of juice containing 0 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded)
1498641|NCT02979496|Dietary Supplement|90 g pomace|16 oz of juice containing 90 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
1498642|NCT02979496|Dietary Supplement|180 g pomace|16 oz of juice containing 180 g of citrus pomace will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
1498643|NCT02979496|Dietary Supplement|Flavored water (control)|16 oz of a flavored, calorie-matched water beverage will be consumed each day for 3 weeks by participants in the group receiving this assignment (group is unknown, double-blinded).
1498644|NCT02979483|Procedure|Integrative supportive care|"At the inclusion, the investigator determine a personalized program of supportive care procedures for each patient (for instance : treatment of pain and nutritional support,stenting of bile duct and/or duodenum, tumor biopsy for pathologic diagnosis ,..)
At the end on the integrative supportive care, according to the ECOG-PS of patients , they will be classified into two groups:
Group 1 :Good prognosis - ECOG-PS 0-1 and eligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.
Patient will be treated by : FOLFIRINOX or gemcitabine-nab-paclitaxel or clinical trial
- Group 2 : Poor prognosis - ECOG-PS 2-4 and / or ineligible for clinical trial, FOLFIRINOX or gemcitabine + nab-paclitaxel.
Patients will be treated by: FOLFOX7lightened"
1498645|NCT02979457|Behavioral|Awareness of degree of worry|degree of worry is a definition made for this project. It is roothed in coping psychology but has been influenced by the construct of self-rated health. Will blinding of DOW have an effect on triage outcome.
1498646|NCT02979444|Behavioral|Mothers and Babies Groups|"The Mothers and Babies group intervention is comprised of 6, two hour sessions. It is divided into three overall sections, one on each of the following Cognitive Behavioral Theory components; Pleasant Activities, Thoughts, and Contact with Others. In each of these sections, participants are first taught to understand how the component influences her mood. This teaching of the relationships between CBT components and mood is referred to as psychoeducation. In addition to psychoeducation, participants also receive concrete skills in each of the three sections (pleasant activities, thoughts, contact with others). These skills are intended to provide participants with a toolkit of approaches they can use to improve their mood."
1498651|NCT02979405|Drug|Phenylephrine|prophylactic infusion of phenylephrine 40 mcg/min
1498652|NCT02979392|Drug|TENPA (Targeting-Enhancing Nanoparticles of Paclitaxel)|TENPA IV once every 3 weeks (Phase I starting dose 75 mg/m2)
1498653|NCT02979379|Other|Pain|
1498654|NCT02979366|Drug|S64315|S64315 will be administered via i.v. infusion over 30 minutes once every week (21- day cycle), the starting dose is 50 mg. As data emerge during the study, the infusion duration and alternative dosing regimen may be changed.
1498655|NCT02979353|Behavioral|Shed-Meds: A Patient-Centered Deprescribing Intervention|The goal of the intervention is to safely deprescribe medications, as defined by dose reductions and stopped medications, based on a combination of clinical criteria and patient preferences.
1498656|NCT02979340|Procedure|MRI|non-invasive assessment of hepatic fibrosis and steatosis
1498657|NCT02979327|Drug|Adderall capsule|
1498658|NCT02979327|Drug|Placebo capsule|
1498659|NCT02979314|Device|Galvanic Vestibular Stimulation|The investigators aim to study the influence of Galvanic Vestibular Stimulation on the brain mechanisms underlying illusory self-motion and its influence on egocentric mental transformation. As a control condition sham stimulation will be applied by the same device within the same participants in different trials. Participants should not note the difference.
1498660|NCT02979301|Drug|Tamoxifen|5 mg tam per day for 30 days.
1498661|NCT02979288|Drug|Lactobacillus casei rhamnosus (Lcr 35 regenerans)|Probiotic vaginal tablets vith active probiotic strains
1498663|NCT02979275|Procedure|Open heart surgery on cardiopulmonary bypass.|Brain oximetry and tissue saturation will be measured during operation. NGAL, cystatin-C, and Acute Kidney Injury Network (AKIN) criteria of AKI will be assessed durin first post-op day.
1498664|NCT02979262|Behavioral|Fathers for Change|
1498665|NCT02979262|Behavioral|Parent Education|
1498666|NCT02979249|Drug|Oral Iron|for one year
1498667|NCT02979236|Device|STENTYS Xposition S|
1498668|NCT02979223|Drug|sodium picosulfate and magnesium citrate, polyethylene glycol with ascorbic acid|"sodium picosulfate and magnesium citrate and 2L polyethylene glycol with ascorbic acid are used as combination method.
There is a difference in the order of intake between two group"
1498669|NCT02979210|Other|Artificial Fecal Insult|protease/bile acid cocktail 200 microliters (1500 µg/ml trypsin/chymotrypsin protease mixture, 6.5 mg/ml cholic acid sodium, 6.2 mg/ml deoxycholic acid sodium, and 3.1 mg/ml chenodeoxycholic acid sodium in phosphate buffered saline
1498670|NCT02979210|Other|Phosphate Buffered Saline|200 microliters of phosphate buffered saline
1498671|NCT02979197|Drug|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule|Over-encapsulated 10 mg amlodipine besylate tablet + over-encapsulated 200 mg celecoxib capsule qd for 14 days
1498672|NCT02979197|Drug|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule|Over-encapsulated 10 mg amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule qd for 14 days
1498673|NCT02979197|Drug|Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule|Matched placebo tablet for over-encapsulated amlodipine besylate tablet + matched placebo capsule for over-encapsulated celecoxib capsule qd for 14 days
1498674|NCT02979184|Other|Intensive decongestive physiotherapy|2 weeks of intensive decongestive physiotherapy
1498675|NCT02979171|Device|Laryngeal Mask Airway Classic|
1498676|NCT02979158|Procedure|CPB Low Dose|Performing CPB with low dose heparin and coated equipment
1498677|NCT02979158|Procedure|CPB High Dose|Performing CPB with high dose heparin and uncoated equipment
1498678|NCT02979145|Other|No intervention involved|
1498679|NCT02979132|Drug|Eisensulfat LOMAPHARM 50 mg|oral intake of an 'Eisensulfat LOMAPHARM 50 mg' tablet every morning for 90 days
1498680|NCT02979132|Drug|Ferinject(R)|Single-dose Ferinject(R) administration
1498681|NCT02979132|Dietary Supplement|iron fortified biscuits|consumption of an iron-fortfied biscuit every morning for 90 days
1498683|NCT02979106|Other|Test meal|Assessment of postprandial responses to a mixed meal containing fructose in carriers of one mutated ALDOB allele.
1498684|NCT02979093|Drug|Oxytocin|All women in both groups will receive 2 fMRIs according to our research protocol. Fifty minutes before the first fMRI, the women will administer nasal spray which will randomly contain either oxytocin or placebo. A month later the woman will return for the 2nd fMRI and administer nasal spray containing the substance they did not receive at the first scan. The randomization is double blinded with only the pharmacy knowing which nasal spray to provide at which fMRI visit.
1498685|NCT02979093|Drug|Placebos|All women in both groups will receive 2 fMRIs according to our research protocol. Fifty minutes before the first fMRI, the women will administer nasal spray which will randomly contain either oxytocin or placebo. A month later the woman will return for the 2nd fMRI and administer nasal spray containing the substance they did not receive at the first scan. The randomization is double blinded with only the pharmacy knowing which nasal spray to provide at which fMRI visit.
1498686|NCT02979080|Other|Eisensulfat LOMAPHARM 50 mg|Eisensulfat LOMAPHARM 50 mg administration for 120 days
1498687|NCT02979067|Procedure|Nasal oxygen flow|Nasal oxygen flow during apnoea
1498688|NCT02979054|Device|T4020|
1498689|NCT02979054|Device|Placebo|
1498690|NCT02979041|Behavioral|Interactive virtual reality training|"The proposed VR intervention program will provide active training to be performed individually 4 times a week for 20 minutes a session.
The intervention program will be supervised by qualified, experienced physiotherapists, and will include individual training and two follow up meetings during the study period. The intervention program will include strengthening and endurance exercises for the cervical and shoulder girdle muscles. Training will include sensorimotor control and functional, quick, accurate, neck motion, using interactive VR training systems. This type of advanced training is very relevant to the pilots function in the cockpit as it includes interactive tasks aimed to increase range, speed, smoothness, accuracy, and control of cervical motion."
1498691|NCT02979041|Other|Standard Care|physiotherapy and medical care as provided currently
1498692|NCT02979028|Device|TEAS|Transcutaneous electrical acupoint stimulation
1498695|NCT02978989|Procedure|nonsolo LC|This patient is scheduled to undergo nonsolo laparoscpic cholecystectomy.
1498696|NCT02978989|Procedure|solo LC|This patient is scheduled to undergo solo laparoscpic cholecystectomy.
1498697|NCT02978976|Drug|Betamethasone|will receive two doses of 12mg betamethasone ( Dipropfos ® SCHERING-PLOUGH; Kenilworth, New Jersey, USA) intramuscularly (IM) 24 hours apart.
1498698|NCT02978976|Drug|saline|saline placebo injection in the same regimen.
1498699|NCT02978963|Behavioral|Cognitive behavioral therapy (CBT)|CBT focused on reducing intolerance of uncertainty
1498700|NCT02978950|Other|Duplex ultrasound surveillance|bilateral lower extremity venous duplex
1498701|NCT02978950|Other|No ultrasound surveillance|will have daily exam and history as per normal clinical routine
1498702|NCT02978924|Device|tsDCS|20 min of treatment applied at the thoracic level (active electrode) with reference placed on the right shoulder
1498703|NCT02978911|Procedure|preoperative cerebral MRI and operative findings|
1498704|NCT02978885|Radiation|SPECT-CT imaging|"Injection of AxV-128 labeled with 99mTc followed by SPECT CT
￼￼￼￼"
1498705|NCT02978885|Drug|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
1498707|NCT02978846|Other|Clinical Observation|Undergo side effects evaluation using cards
1498711|NCT02978820|Other|SEAS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The SEAS group received SEAS exercises one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
1498712|NCT02978820|Other|CS exercise|Patient were referred by medical doctor with a prescription of brace and exercise training for their moderate scoliotic curves. Patients were randomly divided into two groups. The CS group received core stabilization exercise training one times in a week for four months. In addition patients in SEAS groups were wearing spinal brace for their scoliosis in this period
1498713|NCT02978807|Procedure|Point of care and venous screening|
1498716|NCT02978768|Other|Exercise|First year, the investigators investigate the effect of 12-week Tai Chi 6-Form accompanied with music rhythm for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
1498717|NCT02978768|Device|Computer-based cognitive training|Second year, the investigators investigate the effect of 12-week computer-based cognitive training games for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
1498718|NCT02978768|Device|Physico-Mental rehabilitation Wii|Third year, the investigators investigate the effect of 12-week Physico-Mental rehabilitation Wii (PM Wii) for patients with mild and moderate AD in behavioral and general health, functional and cognitive decline.
1498719|NCT02978755|Drug|GM102|GM102 escalating doses (phase1)
1498720|NCT02978755|Drug|Paclitaxel + carboplatin|GM102 escalating doses combined with paclitaxel and carboplatin
1498721|NCT02978755|Drug|GM102|GM102 single agent at recommended dose in 3 parallel cohorts (sex cord, epithelial ovarian, cervix cancers)
1498722|NCT02978742|Behavioral|Adaptive Recovery Record App|Participants will use the Recovery Record smartphone app, which is a meal monitoring tool, that incorporates discrete reminders, motivational tools, social support, summative feedback, and coping skill suggestions. Participants will also receive tailored, algorithm-generated content in a structured manner that mimics the progression of psychotherapy (e.g., checking in with users, reminding them of their reasons for wanting to recover, and working towards goals) over the course of 8 weeks.
1498723|NCT02978742|Behavioral|Standardized Coaching|Coaches (dietitians or mental health clinicians) will review patients' logs daily and participants will receive one communication of standardized feedback each day through the app based on their food records. A standardized feedback manual to be used by coaches has been developed by co-investigators (two PhD psychologists and one psychiatrist), and all feedback will be monitored for consistency and quality by co-investigators.
1498724|NCT02978729|Other|Two-way videoconference remote genetic counseling|
1498725|NCT02978729|Other|Telephone remote genetic counseling|
1498729|NCT02978703|Drug|COPD Pharmacologic Substance|COPD patients treated by Fluticasone / Salmetrol via Elpenhaler device
1498731|NCT02978677|Radiation|Radiotherapy 68 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton
1498732|NCT02978677|Radiation|Radiotherapy 72 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 18 Gy(RBE) proton and boost 2 to 4 Gy(RBE) proton
1498733|NCT02978677|Radiation|Radiotherapy 60 Gy(RBE)|Radiotherapy 2.0 to 50 Gy(RBE) photon or proton and boost 2 to 10 Gy(RBE) proton
1498734|NCT02978664|Procedure|Air insufflation|Air insufflation during colonoscopy including insertion phase
1498735|NCT02978664|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy.
1498736|NCT02978664|Procedure|Water exchange|Water will infused and removed during insertion phase of colonoscopy
1498737|NCT02978651|Drug|Pitolisant (BF2.649)|
1498738|NCT02978651|Drug|Placebo Oral Tablet|
1498739|NCT02978638|Device|Finetech Vocare Bladder System|Participants will be implanted with the existing FDA-approved Finetech Vocare Bladder System stimulator and electrodes.
1995801|NCT02650024|Drug|ledipasvir and sofosbuvir|ledipasvir (90 mg) and sofosbuvir (400 mg) in a single tablet
1995802|NCT02650024|Drug|Placebo (for ledipasvir and sofosbuvir)|Sugar pill manufactured to mimic ledipasvir and sofosbuvir (90 mg/400 mg)
1995803|NCT02650362|Other|fMRI|
1498743|NCT02978612|Drug|Capecitabine|Capecitabine is a prodrug to 5-fluorouracil. It is used for adjuvant chemotherapy after surgery for colon cancer. The tablets are either 150 mg or 500 mg
1498744|NCT02978599|Drug|AVL-3288|daily for 5 days
1498745|NCT02978599|Drug|Placebo|daily for 5 days
1498746|NCT02978586|Device|[Ga-68]PSMA PET/MR|All participants will undergo at least 1 baseline [Ga-68]PSMA PET/MR. If participants test positive for [Ga-68]PSMA tumor uptake, they will under up to 2 additional scans
1498747|NCT02978573|Device|Cartiva|Cartiva Synthetic Cartilage Implant
1498748|NCT02978560|Device|fluorescence-mediated photoplethysmography|Indocyanine green dye (ICG) will be injected intravenously as a sterile solution at a dose of 0.5 mg/kg, and then imaging of skin will be done with a fluorescence camera. The ICG-angiogram sequence will consist of 1.5 x 2.0-cm field-of-view ICG fluorescence images acquired at the rate of approximately 30/sec during a period of about 15 seconds. Following acquisition of the initial transit angiogram sequence, several additional 15-second-long image sequences will be acquired during the next half-hour, but without any additional injections.
1498749|NCT02978547|Drug|Metformin Hydrochloride 500Mg Tablet|In the event of any grade 2 toxicities (with the exception of hyperglycemia), metformin will be withheld until improvement to ≤ grade 1, then restarted at a dose of 500 mg daily. In the event of grade ≥ 3 toxicities related to metformin, treatment will be discontinued. Metformin therapy will also be discontinued if serum lactate levels are above normal values.
1498750|NCT02978534|Drug|Quetiapine|Quetiapine concentrations will be observed in women who have already (under the guidance of a physician) decided to continue taking Quetiapine for the treatment of Bipolar Disorder (any subtype) or Schizophrenia during pregnancy.
1498792|NCT02978222|Drug|Adjuvant (GM-CSF) Alone|Intradermal injection 125 μg GM-CSF
1498869|NCT02977520|Procedure|Printing, Three-Dimensional|To establish 3D model of cerebral aneurysms and have preoperative evaluation.
1995804|NCT02649686|Drug|Durvalumab|
1995805|NCT02649686|Drug|Trastuzumab|
1498751|NCT02978521|Other|Pulmonary rehabilitation|Session 1: ventilatory pattern training Session 2,3: ventilatory pattern + respiratory training with incentive spirometer Session 4-6: Sessions 1-3 training continues + training with Positive expiratory pressure device (Threshold PEP) and breathing trainer Threshold IMT) Sessions 7-9: Continue respiratory training + resistance training with RECK MOTOmed2 ergometer at a 30% intensity until 60% is achieved Session 10-12: Continue with previous training + treadmill training
1498754|NCT02978495|Drug|Doxorubicin|Doxorrubicin 60 mg/m2 4 cycles each 21 days
1498755|NCT02978495|Drug|Carboplatin|Carboplatin AUC 1,5 once a week, for 12 weeks
1498756|NCT02978495|Drug|Paclitaxel|80mg/m2 weekly for 12 weeks
1498757|NCT02978495|Drug|Cyclophosphamide|600mg/m2 4 cycles each 21 days
1498758|NCT02978482|Drug|durvalumab|durvalumab (MEDI4736) 20mg/kg via IV infusion every 4 weeks until disease progression or unacceptable toxicity
1498759|NCT02978482|Drug|tremelimumab + durvalumab|20 mg/kg durvalumab (MEDI4736) via IV infusion q4w and 1 mg/kg tremelimumab via IV infusion q4w for up to 4 doses/cycles, and then continue 20 mg/kg durvalumab (MEDI4736) q4w starting on Week 16 for up to confirmed disease progression
1498760|NCT02978469|Other|Life style changing: reducing sedentary behavior|"The program includes 23 meetings held once per week (with holiday breaks). Each meeting lasts 90 minutes, consisting of exercise training.
the group will meet for information providing and discussion. Participants are guided in the process of creating a focussed individualized activity plan.
In the group setting they will experience a variety of activities enabling them to explore activities they prefer: each participant receive three personal consultation meetings. The group will experience sport and recreational activities with persons with physical impairments. Also activities in sport in community facilities."
1498761|NCT02978456|Device|quantitative coronary angiography guided coronary intervention with sirolimus-eluting Orsiro stent|In the quantitative coronary angiography-guided group, sirolimus-eluting Orsiro stent size and length is chosen to cover the entire length of the culprit lesions according to quantitative coronary angiography measurements. Selection of the sirolimus-eluting Orsiro stent size should be guided by both quantitative coronary angiography measurement and visual estimate, and is recommended to be based on distal reference vessel diameter by quantitative coronary angiography (distal reference vessel diameter by quantitative coronary angiography plus ~10% of distal reference vessel diameter).
1498762|NCT02978456|Device|intravascular ultrasound guided coronary intervention with sirolimus-eluting Orsiro stent|In the intravascular ultrasound -guided group, sirolimus-eluting Orsiro stent size and length is selected by intravascular ultrasound measurements.
1498763|NCT02978443|Drug|Nivolumab|
1498764|NCT02978443|Drug|Ipilimumab|
1498765|NCT02978430|Device|Computer-assisted GDFT|Patients receive fluid therapy via a computer-assisted goal-directed fluid therapy (GDFT) prototype closed-loop (automated) system guided by a cardiac output monitor.
1498766|NCT02978430|Other|Standard of care|Patients receive fluid management based only on static variables (e.g. arterial pressure, heart rate, CVP, and urine output). This control group (started retrospectively before the first included patient of the closed-loop goal directed fluid therapy group) consists of the same population undergoing the same surgery as the closed-loop GDFT group.
1498767|NCT02978417|Drug|Naltrexone for extended-release injectable suspension|Opioid-dependent Drug Court clients enrolled in the study will receive monthly injections of Vivitrol for up to 12 months if they continue to be medically eligible and willing.
1498768|NCT02978417|Drug|Oral naltrexone|Opioid-dependent Drug Court clients enrolled in the study will receive prescriptions for oral naltrexone for up to 12 months if they continue to be medically eligible and willing.
1498769|NCT02978404|Drug|Nivolumab|Nivolumab is administered to patients to a maximum of 1 year.
1498770|NCT02978404|Radiation|Radiosurgery|Up to 10 cubic centimeter of brain metastases will be treated with radiosurgery. The dose of radiosurgery depends on the size of individual metastases.
1498771|NCT02978391|Procedure|endoscopic adhesive powder|
1498772|NCT02978391|Drug|epinephrine|
1498773|NCT02978391|Device|Endoscopic Wound Dressing (Next Biomedical)|
1498774|NCT02978378|Other|biomarker levels|The level of the biomarker hyaluronic acid will be measured
1498775|NCT02978365|Other|Questionnaires|Patients will fill self-reported functional shoulder scales (1. Western Ontario Shoulder Instability index - WOSI, and 2. Disabilities of Arm, Shoulder and Hand questionnaire - DASH), as well as a Fear Avoidance Belief Questionnaire (FABQ).
1498776|NCT02978365|Other|Isokinetic Strength Measurement|Isokinetic strength will be measured using a Biodex Isokinetic System 4.0 (Shirley, NY)
1498777|NCT02978352|Other|learning|
1498778|NCT02978339|Drug|Curcumin|Subjects will receive one 750 mg softgel by mouth twice a day for 12 weeks. Each each 750 mg CuraMed® softgel supplies 500 mg of highly bioavailable BCM-95 curcumin.
1498779|NCT02978326|Drug|SAGE-217|
1498780|NCT02978326|Drug|Placebo|
1498781|NCT02978313|Drug|Cetuximab|anti-EGFR monoclonal antibody
1498782|NCT02978313|Drug|mFOLFOX6|Oxaliplatin+LV5FU2
1498783|NCT02978313|Drug|FOLFIRI|Irinotecan+LV5FU2
1498784|NCT02978300|Device|NIV/HFNC|Pressure support level to achieve an expired tidal volume between 6 and 8 ml/kg of predicted body weight Positive end expiratory pressure from 5 to 10 cm H2O, aiming a PEEP level ≥ 8 cm H2O FiO2 set to achieve SpO2 ≥ 92%
1498785|NCT02978300|Device|HFNC|Gas flow of 60 l/min and FiO2 set to achieve SpO2 ≥ 92%
1498786|NCT02978287|Drug|BAVU Solution|Tissue preservation solution for transplantation
1498787|NCT02978274|Drug|MMF engraftment|MMF withdrawal by engraftment post haplo-SCT
1498788|NCT02978274|Drug|MMF 2 month|MMF withdrawal by 2 month post haplo-SCT
1498789|NCT02978261|Drug|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
1498790|NCT02978235|Drug|TAS4464|Intravenous (IV) Infusion
1498793|NCT02978209|Other|Comparing the effect of moisturizers with 5 and 7.5 % carbamide, respectively|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 5 % on one half of the body twice a day while applying the same moisturizer with 7.5 % urea on the other half of the body in the same quantity at the same frequence
1498794|NCT02978209|Other|Comparing the effect of moisturizers with 5 and 10 % carbamide, respectively|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 5 % on one half of the body twice a day while applying the same moisturizer with 10 % urea on the other half of the body in the same quantity at the same frequence
1498795|NCT02978209|Other|Comparing the effect of moisturizers with 7.5 and 10 % carbamide, respectively|Patient untreated with moisturizers for 1-2 weeks will start applying moisturizers containing urea at concentration 7.5 % on one half of the body twice a day while applying the same moisturizer with 10 % urea on the other half of the body in the same quantity at the same frequence
1498796|NCT02978196|Procedure|PD-L1 expression detection in Lung cell|Lung cell biopsies, PD-L1 expresser detection test, Blood test, SPECT/CT with 99m-Tc Labeled Anti-PD-L1 VHH
1498797|NCT02978183|Biological|ST266|One (1) drop of 1X ST266 ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
1498798|NCT02978183|Drug|Saline (0.9% NaCl)|One (1) drop of saline ophthalmic eye drops will be administered to each eye 4 times a day for 8 days.
1498799|NCT02978170|Device|Cone Beam Computed Tomography (CBCT)|During standard of care bronchoscopy, Cone Beam Computed Tomography (CBCT) used to ensure the biopsy instruments are in the proper location.
1498802|NCT02978144|Radiation|SPECT-CT imaging|Injection of AxV-128 labeled with 99mTc followed by SPECT-CT
1498803|NCT02978144|Drug|AxV-128/Tc|Injection of AxV-128 labeled with 99mTc
1498804|NCT02978131|Other|Histopathological study|
1498805|NCT02978131|Other|Molecular study (Polymerase chain reaction)|
1498806|NCT02978118|Device|Immune cell and CTC detection procedures|Immune cell profiling assays (in blood and archival tumor samples) and circulating tumor cell assays (in blood samples)
1498807|NCT02978105|Other|self-conditioning techniques|Self-hypnosis to increase self-control before meals and every food compulsion episode
1498808|NCT02978105|Other|standard care (diet, exercise and behavioral therapy)|dietary recommendations, exercise recommendations, and behavioral recommendations
1498809|NCT02978079|Device|Automated pupillometry|Automated pupillometry will be performed in patients with acute stroke with the intention of diagnosing Horner's syndrome
1498810|NCT02978066|Other|Spinal anaesthesia|
1498811|NCT02978053|Behavioral|Bright light|Bright light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
1498812|NCT02978053|Behavioral|Red light|Red light for 30 minutes during night shifts (between 2 AM and 3 AM the first night, between 3 AM and 4 AM the second night, between 4 AM and 5 AM the third night).
1498813|NCT02978040|Drug|Cangrelor|Cangrelor will be administered as bolus of 30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old).
1498814|NCT02978040|Drug|Tirofiban|Tirofiban will be administrated as 25 µg/Kg bolus followed by infusion at 0.15 µg/Kg/min for 2 h (or to the end of PCI) (infusion rate of 0.075 µg/Kg/min for patients with creatinine clearance < 60 ml/min); at the end of infusion, oral prasugrel at loading dose of 60 mg will be administrated, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old) .
1498815|NCT02978040|Drug|Prasugrel|In the prasugrel arm no intravenous anti-platelet drug will be administered. Patients will be randomized to oral integer prasugrel or chewed oral prasugrel at an identical loading dose of 60 mg, then 10 mg daily (5 mg daily if body weight < 60 kg or age > 75 years old).
1498816|NCT02978027|Behavioral|Brief Advice|
1498817|NCT02978027|Behavioral|NIAAA Clinician's Guide|
1498818|NCT02978027|Behavioral|Motivational Interviewing (MI)|
1498819|NCT02978014|Device|ProSpare|A novel rectal obturator (ProSpare) acting as a non-invasive daily on-line image guided tool, a rectal spacer and a prostate bed stabiliser
1498820|NCT02978001|Other|Stabile Isotope tracers|Non-radioactive tracers used in hyperinsulinaemic euglycaemic clamp
1498821|NCT02977988|Behavioral|Mindfulness Meditation|MBRP-W is delivered in 12 bi-weekly 80-minute group sessions. Facilitators with previous experience in MBSR and trained in MBRP-W will deliver each group. Each session has a central theme and is divided into five segments consisting of: (a) a welcome meditation or other mindfulness practice, (b) a review of session objectives, (c) a brief didactic psycho-educational presentation and discussion based on the session's theme, (d) experiential and formal meditation or other practices, and (e) readings and assignments for the next class. Participants are expected to learn skill building techniques to reducing stress using mindfulness-based principles to complement their recovery treatment program.
1498822|NCT02977988|Behavioral|Brain and Recovery (B&R)|B&R is delivered in 12 bi-weekly 80-minute group sessions delivered by two trained interventionists. The B&R group will receive didactic education on the neurobiology of addiction. B&R contains no information on behavior change, stress reduction, or mindfulness-based or relapse-related content. The intervention was developed over three years with a population similar to those in the study and with input from patients and experts on neurobiology of addiction. Topics include: (1) brain structures and functions related to addiction, (2) effects of various types of substances on the brain, and (3) rewarding effects and how these lead to addiction. Participants are expected to gain knowledge pertaining to the effects of drugs on the brain.
1498823|NCT02977975|Other|Raw sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
1498824|NCT02977975|Other|Pasteurized sauerkraut|Sauerkraut without live bacteria.
1498867|NCT02977533|Drug|Placebo|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2002021|NCT02591472|Other|Beck Depression Inventory-II|The Beck Depression Inventory-II is a broadly-applicable, clinically relevant psychometric instrument with high reliability and consistency which notes depression. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
2002022|NCT02591472|Other|State-Trait Anxiety Inventory (STAI)|The State-Trait Anxiety Inventory (STAI) will be used to measure state anxiety (anxiety about an event) and trait anxiety (anxiety level as a personal characteristic). This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
1498827|NCT02977949|Drug|Raloxifene|
1498828|NCT02977936|Dietary Supplement|Cartimotil Fort|
1498829|NCT02977923|Device|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the site of the injury, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, were adapted for children and tailored to minimize cyber sickness.
1498830|NCT02977923|Other|Standard pharmacological treatment|according to the unit's protocol and adjusted to each participant`s age, weight and condition by the anesthetist and pain clinic nurse.
1498831|NCT02977910|Procedure|repair of deltoid ligament|intraoperative repair of deltoid ligament combined with ORIF
1498832|NCT02977897|Drug|Octreotide Acetate|Octreotide 100mcg SC q12h for 5 days
1498833|NCT02977884|Behavioral|The Complete Health Improvement Program|CHIP focuses on food, diet, activity, exercise, stress management, by viewing videos, cooking demonstrations, discussion, and exercise. Intervention nurtures intelligent self-care through enhanced understanding of the epidemiology, etiology, and risk factors associated with chronic lifestyle related diseases. The primary focus is the consumption of plant-based whole foods, such as fresh fruits, vegetables, whole grains, legumes, and nuts. The goal was to keep dietary fat below 20% of total calories, daily intake of added sugar below 10 tsps, sodium below 2,000 mg, and cholesterol below 50 mg. High fiber food intake (>35 g/day) is encouraged, and flexibility exercises, a daily walk of 30 minutes or 10,000 steps and daily use of stress management techniques.
1498834|NCT02977871|Procedure|Bladder flap|Performing uterine incision and cesarean section with a bladder flap.
1498835|NCT02977858|Other|Educational practice for HCPs,Dissemination only|Study participants are health care professionals (HCPs) who will be provided educational material and complete knowledge assessments
1498836|NCT02977858|Other|Educational practice for HCPs,Spaced Education|Study participants are health care professionals (HCPs) who will be provided educational material via a Spaced Education program; participants will subsequently complete knowledge assessments
1498837|NCT02977845|Behavioral|Qigong|"Qigong has long been regarded as a form of mind-body intervention in Traditional Chinese Medicine (TCM), which simultaneously exercises the mind and the body for treating many chronic diseases and promoting wellness. About a hundred million people are currently practicing Qigong in China. Qigong is now regarded as a form of self-practise mind-body exercise and recently relevant to sports activity, which is officially known as Health Qigong. It is different from Medical Qigong which involves a TCM practitioner to emit Qi to heal the patients."
1498838|NCT02977832|Dietary Supplement|Odyliresin|Odyliresin 2 ml, 20 drops once daily and alpha-antagonist (alfuzosin 10 mg)
1498839|NCT02977832|Drug|Alfuzosin|10Mg Oral Tablet, Extended Release
1498840|NCT02977819|Other|Meditation practice|18 months
1498841|NCT02977819|Other|Learning English as a foreign language|18 months
1498842|NCT02977793|Device|Tomey EM-4000 Specular Microscope|
1498843|NCT02977793|Device|Konan CellChek XL Specular Microscope|
2002023|NCT02591472|Other|Tampa Scale of Kinesiophobia-11 (TSK-11)|Tampa Scale of Kinesiophobia-11 (TSK-11) will be used to assess pain-related fear in orthopaedic trauma. This assessment will be performed during the hospital stay, at the 2 week follow up, 6 week follow up, 12 week follow up, 6 month, and 1 year follow up visit.
2002024|NCT02589522|Drug|ATR Kinase Inhibitor VX-970|Given IV
2002025|NCT02589522|Other|Laboratory Biomarker Analysis|Correlative studies
1498848|NCT02977767|Procedure|Conversational hypnosis|Conversational hypnosis starts since the enter of the nurse in patient's room and last since the nurse leaves the room. Change of canula is performed under conversational hypnosis.
1498849|NCT02977754|Other|This is an observational study|Imaging
1498850|NCT02977741|Drug|Olanzapine|
1498851|NCT02977728|Other|Olfactory Evaluation|The investigators will evaluate the olfactory system of all participants by the use of the Sniffin'Sticks batterie
1498852|NCT02977715|Biological|IMVAMUNE®|Two doses of attenuated live virus smallpox vaccine (IMVAMUNE®) administered on days 0 and 28 via subcutaneous injection (deltoid) (1 x 108 Tissue Culture Infectious Dose 50 [TCID50] per 0.5 mL)
1498853|NCT02977689|Drug|IDH305|study drug used to inhibit IDH1 mutation in these tumors, resulting in anti-tumor activity.
1498855|NCT02977650|Procedure|Endoscopic ultrasonography-guided fine needle aspiration|
1498856|NCT02977637|Procedure|Feraheme MRI/MRA|
1498857|NCT02977624|Behavioral|The Cognitive Orientation to daily Occupational Performance|
1498859|NCT02977585|Device|10 cmH2O peep|positive end expiratory pressure
1498860|NCT02977572|Device|Non-Invasive Ventilation|In arm description
1498861|NCT02977572|Device|Continuous Positive AirwayPressure CPAP|In arm description
1498862|NCT02977559|Device|Laryngeal Tube Suction Disposable|Device for ventilation
1498863|NCT02977559|Device|Laryngeal Mask Airway AuraGain|Ventilation device
1498864|NCT02977546|Device|Noninvasive pulse contour analysis|For noninvasive pulse contour Analysis we use the CNAP-Monitor (CNSystems Medizintechnik AG, Graz, Austria)
1498865|NCT02977546|Device|Pulmonary artery catheterization|As a reference method we use the Goldstandard intermittent thermodilution via a PAC which is regularly performed during the patients Hospital stay
1498866|NCT02977533|Drug|GZ402668|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1498872|NCT02977494|Drug|Daratumumab|Daratumumab (JNJ-54767414) is a novel human IgG1monoclonal Antibody (mAb) that binds with high affinity to a unique epitope on CD38
1498873|NCT02977494|Drug|Bortezomib|
1498874|NCT02977494|Drug|Dexamethasone|
1498875|NCT02977468|Drug|Merck 3475 Pembrolizumab|Participants receive Pembrolizumab by vein over about 30 minutes on Day 1 of two cycles.
1498876|NCT02977468|Radiation|Intraoperative radiation therapy (IORT)|Participants will receive Intraoperative radiation therapy (IORT) on the day of surgery.
1498877|NCT02977442|Behavioral|exercise|
1498878|NCT02977429|Other|standardized fluid therapy|The patients with ScvO2 <70% will receive the standardized fluid therapy for 6 hours.
1498879|NCT02977429|Other|conventional fluid therapy|The patients with ScvO2 ≥ 70% will receive the conventional fluid therapy.
1498880|NCT02977416|Other|anti-TNFα|
2002026|NCT02589522|Other|Pharmacological Study|Correlative studies
2002027|NCT02589522|Other|Quality-of-Life Assessment|Ancillary studies
1498883|NCT02977390|Other|Passive leg raise|By tilting the patient's bed from sitting 45 degrees to supine with legs tilted up 45 degrees we recruit the blood volume in the legs and can measure a reversible fluid challenge on stroke volume.
1498884|NCT02977377|Other|Exercise therapy|Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
1498885|NCT02977377|Other|Whole body vibration|4 sets, 1 min application and 1min rest whole body vibration and after that exercises. Cases will take the treatment 1-hour, 3 days in a week for 8 weeks.
1498886|NCT02977364|Drug|HS-10241|
1498887|NCT02977351|Procedure|Non-surgical periodontal treatment|
1498888|NCT02977338|Other|Retrospective review|
1498889|NCT02977325|Other|water cure|
1498890|NCT02977312|Drug|Imatinib|Observation of chronic myeloid leukemia (CML) patients in chronic phase (CP) treated with Cemivil
1498891|NCT02977299|Drug|Aripiprazole|Oral adjunctive therapy with aripiprazole, dose adjusted for effectiveness and tolerability.
1498892|NCT02977299|Device|Repetitive transcranial magnetic stimulation (rTMS)|Adjunctive therapy with transcranial magnetic stimulation, dose adjusted for effectiveness and tolerability.
1498893|NCT02977299|Drug|Venlafaxine XR|Oral switch therapy with venlafaxine, dose adjusted for effectiveness and tolerability.
1498894|NCT02977286|Drug|Naloxegol Oral Tablet|Naloxegol Oral Tablet 25 mg (or 12.5 mg) po (enteral) daily
1498895|NCT02977286|Drug|Placebo Oral Tablet|Placebo Oral Tablet po (enteral) twice daily
1498896|NCT02977286|Drug|Docusate Sodium 100 Mg oral capsule [Colace]|Docusate Sodium 100 mg po (enteral) twice daily
1498897|NCT02977286|Drug|Senna 217 Mg Oral Tablet|Senna 127 mg oral tablet daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to two senna 127 mg tables if no no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=5 days after scheduled opioid initiation. Repeat two senna 127 mg tablets if no spontaneous bowel movement >/=6 days after scheduled opioid initiation.
1498898|NCT02977286|Drug|Polyethylene Glycols|Polyethylene Glycols 17 g daily if no spontaneous bowel movement >/=3 days after scheduled opioid initiation; increase to 34 g daily if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat 34 g daily if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
1498899|NCT02977286|Drug|Bisacodyl 10 mg Suppository|Insert one suppository if no spontaneous bowel movement >/=4 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation. Repeat if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation.
1498900|NCT02977286|Drug|Magnesium Citrate Oral Liquid Product|Administer one 10 oz bottle if no spontaneous bowel movement >/= 5 days after scheduled opioid initiation.
1498901|NCT02977286|Drug|Methylnaltrexone|Administer 8 mg or 16 mg (depending on subject's weight) subcutaneously x 1 if no spontaneous bowel movement >/= 6 days after scheduled opioid initiation, consult surgery/gastroenterology and discontinue study medication.
1498902|NCT02977273|Other|Thin/100% Portion|Thin textured rice meal (ground rice grains) served in a regular portion size (100 %: 700g)
1498903|NCT02977273|Other|Thin/150% Portion|Thin textured rice meal (ground rice grains) served in a larger portion size (150 %: 1050g)
1498904|NCT02977273|Other|Thick/100% Portion|Thick textured rice meal (whole rice grains) served in a regular portion size (100 %: 700g)
1498905|NCT02977273|Other|Thick/150% Portion|Thick textured rice meal (whole rice grains) served in a larger portion size (150 %: 1050g)
1498906|NCT02977260|Other|Thin/Low Energy|Thin textured rice meal (ground rice grains) with lower energy density (0.57 kcal/g)
1498907|NCT02977260|Other|Thin/High Energy|Thin textured rice meal (ground rice grains) with higher energy density (1.01 kcal/g)
1498908|NCT02977260|Other|Thick/Low Energy|Thicker textured rice meal (whole rice grains) with lower energy density (0.57 kcal/g)
1498909|NCT02977260|Other|Thick/High Energy|Thicker textured rice meal (whole rice grains) and high energy density (1.01 kcal/g)
1498910|NCT02977247|Other|Non-Interventional|Only standard care procedures will be performed for clinical intervention and diagnostic purposes.
1498911|NCT02977247|Device|Automated Whole Breast Ultrasound|Bilateral breast ultrasound images will be captured, but not clinically evaluated for diagnostic purposes by a physician.
1498912|NCT02977234|Drug|Isoamyl 2-Cyanoacrylate|
1498913|NCT02977221|Procedure|Piezosurgery|The device tip will be used to to create small vertical incisions into the cortex of the dento-alveolar process of the lower anterior teeth.
1498914|NCT02977208|Procedure|Sparse blood sampling|Blood samples are being collected at times 0, 90 and 240 minutes after gabapentin administration.
1498960|NCT02976883|Other|[18F]HX4 diagnostic PET/CT scan|Single intravenous injection of [18F]HX4 and PET/CT scan
2002028|NCT02589522|Procedure|Therapeutic Conventional Surgery|Undergo surgery
2002029|NCT02589522|Radiation|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
1498915|NCT02977208|Procedure|Urine sampling|Urine samples are being collected during the dosing interval, only in patients hospitalized at Hospital Estadual de Américo Brasiliense (HEAB).
1498916|NCT02977208|Procedure|DNA extraction|Blood sample are being collected for DNA extraction. DNA are being extracted from the whole blood of all patients for genotyping of the SLC22A2 c.808G>T and SLC22A4 c.1507C>T polymorphisms
1498917|NCT02977208|Drug|Gabapentin|All patients undergoing chronic treatment with gabapentin are being recruited.
1498918|NCT02977195|Drug|NP137|Treatment will be administered as long as patient experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent.
1498919|NCT02977182|Other|Complete Decongestive Therapy (CDT)|CDT is a multimodal therapy consisting of four components: manual lymph drainage, compression wrapping, exercise, and skin care
1498920|NCT02977169|Radiation|PORT|3-dimensional conformal or intensity-modulated radiotherapy, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks, following the standard and consistent PORT CTV delineation guideline
1498921|NCT02977169|Drug|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
1498922|NCT02977156|Biological|Pexa-Vec|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
1498923|NCT02977156|Drug|Ipilimumab|IT Injections will be performed by a radiologist using imaging-guidance, ultrasound or computed tomography (CT). The dose to be injected could be divided between 1 to 5 tumor lesions.
1498924|NCT02977143|Procedure|Fluid loading of volulyte 300 ml|Administration of volulyte 300 ml and measurement of increase in cardiac index
1498925|NCT02977130|Behavioral|Map group|diabetes shared care plus conversation map intervention
1498926|NCT02977130|Behavioral|Control group|diabetes shared care
1498927|NCT02977117|Other|Dialysate magnesium (1.0 mmol/L)|Dialysate magnesium will be increased from 0.5 mmol/L to 1.0 mmol/L for 4 weeks after which subjects will return to dialysate magnesium 0.5 mmol/L for 2 weeks observation.
1498928|NCT02977117|Other|Dialysate magnesium (0.5 mmol/L)|Dialysate magnesium will be maintained at 0.5 mmol/L for the duration of the trial.
1498929|NCT02977104|Other|Maestro ECG|Telemetry is obtained through the Maestro handheld ECG device.
1498930|NCT02977091|Other|change in fitness level|fitness level assessed by the Euro-fit tests for school age children.including 1.body fat 2. single leg balance test 3.Plate Tapping -for speed of limb movement 4.Sit-and-Reach flexibility test 5. Standing Broad Jump - measures explosive leg power. 6.Handgrip Test - measures static arm strength 7.Sit-Ups in 30 seconds - measures trunk strength 8.Bent Arm Hang - muscular endurance/functional strength 9.20 m endurance shuttle-run - cardiorespiratory endurance Wingate anaerobic test which is a 30 seconds maximum pedaling against resistance on bike for evaluating the anaerobic fitness
1498931|NCT02977078|Behavioral|Active feedback on monitored inhaler use|Feedback given on inhaler use by research nurse/ doctor based on mobile application feedback
1498932|NCT02977078|Device|Inhaler casing|Monitors inhaler use
1498933|NCT02977078|Device|Mobile application|Mobile application software linked to inhaler casing
1498934|NCT02977065|Drug|Atorvastatin 20mg|PO daily for 4weeks
1498935|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 50 mg|PO daily for 4weeks
1498936|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 100 mg|PO daily for 4weeks
1498937|NCT02977065|Drug|Atorvastatin 20 mg + CKD-519 200 mg|PO daily for 4weeks
1498938|NCT02977065|Drug|Rosuvastatin 10 mg|PO daily for 4weeks
1498939|NCT02977065|Drug|Rosuvastatin 10 mg + CKD-519 100 mg|PO daily for 4weeks
1498945|NCT02977039|Other|NDPR diet|
1498946|NCT02977039|Other|USDA healthy eating diet|
1498947|NCT02977026|Behavioral|CYD|
1498948|NCT02977026|Behavioral|AHC|
1498949|NCT02977013|Diagnostic Test|Anti-Xa assay|Correlation between anti-Xa assay and the efficacy and safety of enoxaparin in the treatment of pulmonary embolism
1498950|NCT02977000|Drug|Propranolol|Propranolol was administered orally as a dose of 1.5 mg/kg.d divided q8h.investigators used powdered drug, dissolved in 5% dextrose. The treatment was continued until complete development of retinal vascularization, although administration was not permitted for more than 90 days.
1498951|NCT02976987|Drug|Cidofovir|
1498952|NCT02976974|Other|Manual therapy|Application of different manual therapy techniques through posterior and inferior humeral head slides, as well as scapular movements. Also, rotator interval stretching will be done.
1498953|NCT02976974|Other|Therapeutic exercise|"Shoulder extension: Elastic bands.
Shoulder flexion: Elastic bands
Shoulder external rotation: Elastic bands.
Scapulothoracic stability: Movement of scapular adduction guided by the physiotherapist, keeping the position for few seconds ; standing push up on the wall.
Thoracic column movements: Flexion-extension"
1498955|NCT02976948|Other|No intervention|
1498956|NCT02976935|Other|hyperpolarised 129 Xenon|Hyperpolarised 129 Xe to assess lung function
1498957|NCT02976922|Dietary Supplement|Probiotic lozenge|10 patients with RAS are randomised to active treatment with probiotic lozenge, one lozenge twice daily for 3 months and other 10 patients with RAS are randomised to treatment with placebo lozenge, one lozenge twice daily for 3 months.
1498958|NCT02976909|Drug|Paclitaxel+Cisplatin+5fluorouracil|Patients will receive the following chemotherapy: Paclitaxel 135mg/m2 IV over 3 hours on Day 1; Cisplatin 75mg/m2 IV over 1 hours on Day 1; 5-FU 4g/m2 for 5 days continuous infusion from Day 1 to Day 5.
1498959|NCT02976896|Drug|Apatinib Mesylate|Patients will receive Apatinib Mesylate at 500mg/times,oral one times daily for 28 days.
1498961|NCT02976870|Radiation|Ultrasound|Single ultrasound scan of kidney on side of body where ALIF was performed. If hydronephrosis of this kidney is detected, the second kidney will also be scanned.
1498962|NCT02976857|Biological|C-CAR-011|lymphocytes will be transduced with lentiviral vector containing CAR-CD19 gene.
1498963|NCT02976844|Procedure|Positive end-expiratory Pressure|Positive end-expiratory pressure will be used during mechanical ventilation.
1498964|NCT02976831|Drug|AZD0284|Oral solution, concentration: 2 mg/mL and 15 mg/mL
1498965|NCT02976831|Drug|Placebo|Placebo matching AZD0284 in the form of an oral solution with water.
1498966|NCT02976805|Drug|4L PegLyte + 15 mg bisacodyl|Randomized
1498967|NCT02976805|Drug|6L PegLyte + 15 mg bisacodyl|Randomized
1498968|NCT02976792|Procedure|Renal Resistive Index/NephroCheck™test|Renal Resistive Index and NephroCheck™ test before TAVI and after TAVI
1498969|NCT02976779|Drug|OWC MGC cream|Topical cream containing 3% CBD and 3% THC for Psoriasis treatment
1498970|NCT02976779|Drug|OWC Control Cream|
1498971|NCT02976766|Drug|Gypenosides|Participants will receive gypenosides 360 mg/day (120 mg three times a day) for 10 days.
1498972|NCT02976766|Drug|Placebo|Participants will receive placeco three times a day for 10 days.
1498973|NCT02976753|Drug|efmoroctocog alfa|extended half-life factor VIII product
1498974|NCT02976753|Drug|Factor VIII|conventional factor VIII product
1498975|NCT02976740|Radiation|SBRT|Stereotactic body radiotherapy A type of radiation therapy to the Metastasis lesion
1498976|NCT02976740|Drug|Immunological Agent|Subcutaneous injection of human recombined granulocyte-macrophage colony stimulating factor (125ug/m² per day) will be executed from day 1 to day 14 in this cycle. Another metastasis lesion will be treated likewise concurrently with rhGM-CSF in a consecutive cycle.
1498977|NCT02976740|Drug|Immunological Factors|Thymosin Alpha 1(1.6mg Biw)will be executed from the fist Week to the 12th Weeks.
1498978|NCT02976727|Drug|Topical Vitamin D (Calcipotriol) application|Calcipotriol ointment 50 mcg/g (Daivonex, Leo Pharma, Denmark) was applied twice for daily on treatment area for 15 consecutive days.
1498979|NCT02976727|Drug|Placebo cream application|placebo cream (indistinguishable from calcipotriol cream by visual and physical appearance and sense of smell) was applied twice for daily on treatment area for 15 consecutive days.
1498980|NCT02976727|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
1498981|NCT02976727|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
1498982|NCT02976727|Drug|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
1498983|NCT02976727|Other|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by ImageJ program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
1498984|NCT02976727|Device|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
1498985|NCT02976714|Other|spontaneous sputum|"CF patients carry a spontaneous sputum that is made in the context of bronchial drainage sessions conducted as part of usual care (inclusion, 6 months, 12 months, 18 months).
The collection of spontaneous sputum is carried out within the bronchial drainage sessions, which are routinely performed at each visit. The spontaneous sputum is collected in a sterile container. In order not to contaminate the sputum with buccal epithelial cells will be asked patients to rinse the mouth before expectorate."
1498986|NCT02976701|Drug|DLBS1033|
1498987|NCT02976701|Drug|Placebo|
1498988|NCT02976701|Drug|Standard therapy|Standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for four weeks will be given to both arms.
1498989|NCT02976688|Other|Sodium Propionate|Sodium propionate is a non-toxic food additive, confirmed and licensed by the European Food Safety Authority (EFSA) sodium propionate E281. We are planning the oral application of 500 mg SP 2x per day. This dose is about 0.014 mg/kg of the body weight. Therefore, no risk of toxicity is expected in the patients.
1498990|NCT02976675|Biological|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
1498991|NCT02976675|Biological|PEG-somatropin|Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w，once per two weeks for 26 weeks
1498992|NCT02976662|Procedure|Artificial shrinkage|Artificially eliminated blastocoelic fluid before vitrification procedures.
1498993|NCT02976636|Behavioral|Family-based behavioral therapy|Traditional family-based, group-based behavioral therapy for weight loss. Parent and child groups will be held separately. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
1498994|NCT02976636|Behavioral|Parenting training|Parenting skills training for parents. Parent and child groups will be held separately and only parents will receive this training. Children will not receive any additional materials. Intervention will consist of 20 sessions: 16 weekly sessions, and then every other week for 4 sessions.
1498995|NCT02976623|Other|metric-based feedback training|Structured feedback; a trained investigator will give feedback according to a set of metrics and errors previously developed and validated. Trainees will undergo deliberate practice on the volunteer until they demonstrate adequate and objective performance as assessed by the set of metrics and errors provided.
1498996|NCT02976610|Device|Hemolysis Point-of-Care test|Hemolysis measurement of plasma using a point of care test to determine the hemolysis level in plasma
1500014|NCT02969174|Other|zimin Lu,Guo Sa|chengzhong Liu
1498997|NCT02976597|Drug|Bupivacaine 0.25% 20ml on each side Sonar guided TAB|Bupivacaine 0.25% 20ml on each side Sonar guided TAB using Broad and linear array ultrasound probe will be placed in the axial plane across the mid-axillary line midway between costal margin and iliac crest. After careful aspiration injection of 20ml of 0.25% bupivacaine will be performed and hypoechoic layer will be detected on ultrasound then the maneuver will be repeated on the other side
1498998|NCT02976597|Drug|Morphine 10mg|Morphine 10mg will be added to bupivacaine in sonar guided- TAB block divided into 5mg on each side.
1498999|NCT02976597|Drug|Morphine 15mg|Morphine 15mg will be added to bupivacaine in sonar guided- TAB block divided into 7.5mg on each side.
1499000|NCT02976571|Drug|Bupivacaine|Sub cutaneous and/or Intraperitoneal Marcaine application
1499001|NCT02976558|Behavioral|Clown theatrical Performance|
1499002|NCT02976558|Procedure|Acupuncture|Acupuncture according to Traditional Chinese Medicine
1499003|NCT02976558|Behavioral|Music Therapy TaKeTiNa|
2002030|NCT02582866|Drug|Lacosamide|"Pharmaceutical Form: Oral tablets
Concentration: 50 mg
Route of Administration: Oral administration"
1499006|NCT02976532|Other|Electromagnetic tracking unit in femoral derotation surgery|Use of the electromagnetic tracking system during the surgical procedure in addition to the normal measurement with goniometer, the different devices listed are combined to form the EMT system unit
1499007|NCT02976519|Drug|BI 443651|twice daily
1499008|NCT02976519|Drug|Placebo|twice daily
1499009|NCT02976506|Behavioral|Unsupervised exercise program|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to < 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
1499010|NCT02976506|Behavioral|Physical fitness and quality of life|Both control and intervention group undergo clinical evaluation, and anthropometric measurements, blood pressure (casual and ambulatory blood pressure monitoring), physical and laboratorial tests, and the assesment of Quality of Life by Questionnaire SF-36 were done at the beginning and the end of the study.After a period of 12 weeks of unsupervised walking program in which participants were asked to do it three times a week at least, at a moderate intensity (40 to < 60% of heart rate reserve), all participants underwent a complete re-evaluation to compare the results obtained with the proposed program. Data were analyzed using SPPS, v.23.0.
1499011|NCT02976493|Other|No Intervention|
1499012|NCT02976480|Procedure|Irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair and perform the irrigation. Irrigation will be delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. The volume of normal saline used will be calculated as 60 millilitre per centimetre length of laceration for a maximum of 300 millilitre. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
1499013|NCT02976480|Procedure|No irrigation|A designated unblinded medical team member (nurse, emergency room physician or resident/trainee uninvolved in that particular patient's care) will prepare the laceration for repair. The laceration will not directly be irrigated. In order to ensure blinding of the subjects, the surrounding of the wound will be irrigated with a total of 60 millilitre of normal saline delivered through a 20 Gauge 1 inch long catheter mounted on a 60 millilitre syringe. Care will be taken not to enter a margin of 5cm from the laceration edges. Once completed, the treating physician will enter the room and proceed to the laceration closure with the method and equipment of his choice. Both the patient (through eye covering) and the treating physician will remain blinded to the intervention.
1499016|NCT02976454|Behavioral|Guided Self-Help Obesity Treatment|Guided Self-Help obesity treatment will be provided by a health coach in the clinic. The treatment involves 14 sessions: 1 one-hour session and 13 twenty-minute sessions with the health coach who will provide behavioral obesity treatment.
1499017|NCT02976454|Behavioral|Family-based behavioral obesity treatment|Traditional family-based, group-based behavioral weight control program. The treatment involves 20 hourly group-based sessions for parents and children separately, which occurs weekly for 16 weeks, then every other week for the last 2 months (4 session).
1499018|NCT02976441|Radiation|Radiation therapy|
1499019|NCT02976441|Drug|Temozolomide|
1499020|NCT02976441|Procedure|Stem cell collection|
1499021|NCT02976441|Procedure|Stem cell infusion|
1499022|NCT02976428|Procedure|Sensor Guided Soft Tissue Balancing|Primary TKR with soft tissue balancing with a sensor guided device.
1499023|NCT02976428|Procedure|Standard Soft Tissue Balancing|Primary TKR with soft tissue balancing with a standard of care manual tensiometer device.
1499024|NCT02976415|Other|In-Bed Cycling|
1499025|NCT02976402|Radiation|SBRT|"Postoperative RT consisting in:
31 Gy in 5 sessions each of 6.2 Gy (adjuvant intent) delivered in one week
32.5 Gy in 5 sessions each of 6.5 Gy (salvage intent) delivered in one week"
1499026|NCT02976389|Other|Financial Incentive: High|dlParticipants in this group will receive an additional $40/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
1499125|NCT02975557|Drug|Placebo|Placebo (Refresh plus Artificial Tear) dispensed in Brimonidine bottles 2 times a day for 12 weeks.
1499126|NCT02975544|Behavioral|CRECES programme|The first unit of CRECES programme was implemented in 8 sessions. Each session was 40-50 minutes long and delivered during four weeks. Parents were provided with home-extension activities.
1500327|NCT02966795|Drug|Glecaprevir/Pibrentasvir|Film-coated tablet
1499027|NCT02976389|Other|Financial Incentive: Middle|Participants in this group will receive an additional $20/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
1499028|NCT02976389|Other|Financial Incentive: Low|Participants in this group will receive an additional $10/month to use towards the purchase of SNAP eligible fruits and vegetables. They will be able to access these dollars through an electronic wallet (e-wallet) that is tied to their customer loyalty card. They will also have access to the fruit and vegetable promotions that include discount pricing and SNAP-Ed programming (e.g., in-store cooking classes, tours, and healthy food self-labeling system) to educate and support the purchasing behaviors of SNAP-eligible families.
1499029|NCT02976376|Other|The Box|The Box contains four smartphone compatible devices. Patients will measure their vital signs and automatically send them to the hospital.
1499030|NCT02976363|Radiation|Radiotherapy breast cancer|
1499031|NCT02976363|Other|Evaluation Maximal Respiratory Pressures|
2002031|NCT02580071|Dietary Supplement|Sheng-Yu-Tang|"Granulated formula will be prescribed by KO DA Pharmaceutical co., LTD (科達) composition of formula is as follows: Radix Rehmanniae Praeparata 4g Radix Paeoniae Alba 4g Radix Astragali 4g Radix Ginseng 4g Radix Angelice Sinensis 2g Rhizoma Chuanxiong 2g (for preperation method and concentration ratio's please refer to manufacturers information)
patients will be required to take 4.2gr, t.i.d (total of 12.6gr per day)"
2002032|NCT02579226|Drug|AZD2811|The study will be conducted in 2 parts, dose-escalation (A) and dose-expansion (B1, B2, and B3). All patients in both parts of the study with receive AZD2811. In Part B2 and B3 AZD2811 will be combined with Irinotecan.
1499035|NCT02976311|Procedure|cesarean section(C/S) via the modified Misgav-Ladach technique|the first consecutive 44 patients underwent C/S via the modified Misgav-Ladach technique
1499036|NCT02976311|Procedure|cesarean section via the Pfannenstiel-Kerr technique|the second consecutive 44 patients underwent C/S via the Pfannenstiel-Kerr technique
1499037|NCT02976298|Other|transcranial magnetic stimulation|comparison of different conditions of transcranial magnetic stimulation
1499038|NCT02976285|Procedure|arthroscopic rotator cuff repair with a polyester patch|Patients were operated under general anesthesia and a supraclavicular nerve block, in a beach-chair position with 80° forward shoulder flexion and traction between 3-5 kg. After washing and draping a standard viewing portal was placed at the dorsal softspot. Further portals included, a lateral, a dorso-lateral, an antero-lateral and an anterior portal. If additional pathologies were present, they were treated simultaneously and mostly involved the long head of the biceps tendon, treated with tenodesis or tenotomy respectively. After a thorough bursectomy, the rupture was fully visualized and thereafter its size was estimated. Following debridement of the footprint, we used a triple row repair and implanted the patch.
1499039|NCT02976272|Other|bortezomib|
1499040|NCT02976259|Drug|Dolutegravir|All patients included must have treated by dolutegravir. They will have some exams (plasma samples, sperm samples)
1499041|NCT02976246|Dietary Supplement|Vitamin K2 (MK7)|One tablet of vitamin K2 (MK7) 360 micrograms given once daily.
1499042|NCT02976246|Other|Placebo|One tablet of placebo given once daily.
1499044|NCT02976194|Drug|ranibizumab|Ranibizumab 0.5mg is injected into the vitreous cavity through the pars plana using 30 gauge (or narrower) needle-attached syringe.
1499045|NCT02976181|Device|IPG|Patient might require IPG device to be implanted under standard of care
1499046|NCT02976168|Other|12° head down tilt|supine head down tilt
1499047|NCT02976155|Other|A standard enteral nutrition protocol|Patients in the experimental arm, the practice of enteral nutrition will based on a standard protocol. The core content of this protocol includes five step：1. Whether the participants need nutrition therapy? 2. The choice of nutrition way? 3. Nasogastric tube or nasointestinal tube? 4. The choice of enteral nutrition type? 5. The target calorie and protein of the participants? And how to achieve these target？(In this study, the practice of the above protocol is the only intervention).
1499048|NCT02976142|Procedure|neoadjuvant chemoimmunotherapy|
1499049|NCT02976129|Drug|V565|Daily dosing of V565 three times a day orally for 6 weeks
1499050|NCT02976129|Drug|Placebo|Daily dosing of placebo three times a day orally for 6 weeks
1499051|NCT02976116|Drug|Fruquintinib|Fruquintinib will be administered orally once daily from Day 1 to Day 21 per 28-day cycle until disease progression or unacceptable toxicity
1499052|NCT02976116|Drug|Gefitinib|Gefitinib will be administered orally once daily per 28-day cycle or unacceptable toxicity
1499053|NCT02976103|Device|Jacki Recovery jacket|An outer jacket that holds surgical drains and allows access for blood draws
1499054|NCT02976103|Other|Standard Care Pain medicine/management|Standard care pain medicine and management in hospitals where the study enrolls
1499055|NCT02976077|Behavioral|RC2S+|new cognitive remediation program
1499056|NCT02976077|Behavioral|active comparator|cognitive remediation program
1499057|NCT02976064|Behavioral|PreHabilitation|"Case identification: Candidates fulfilling the inclusion criteria will be identified by the anesthesiologist.
Case evaluation: Candidates will be assessed to identify the overall needs and perform a baseline evaluation.
Personalized Work plan definition: Personalization of the plan involves a calendar and planning of face to face visits and remote contacts; intensity of the supervised exercise training program; threshold of steps per day; nutritional intervention; psychological intervention; and integration of the intervention into the overall work plan.
Work plan execution & 5-Follow-up+event handling: Involve the follow-up tasks, including non-scheduled interactions through the personal health folder (PHF)
6-Discharge: Patient will be discharged from prehabilitation and moved to rehabilitation."
1499127|NCT02975531|Other|Simulator's construction|Model to build the mold for the simulator
1499128|NCT02975531|Other|Model Features|Volunteers to determine the elasticity of the skin and cirtometry neck to compare with the simulator.
1499129|NCT02975531|Other|Parameterization technique|Evaluation of the simulator features and parameterization of the Pompage technique in the simulator.
1499130|NCT02975531|Other|Simulator training|Training of pompage technique using the simulator.
1499058|NCT02976064|Behavioral|Rehabilitation in chronic stable patients in primary care|"Case identification: Candidates fulfilling the inclusion criteria will be identified by the general practitioner.
Case evaluation: The primary care team will characterize the candidates, covering: i) patient requirements defining the work plan; ii) aerobic capacity and physical activity; iii) identification of factors modulating adherence.
Personalized work plan definition: The community-based intervention will include reassessment of the patient's work plan aiming at optimization of both pharmacological and non-pharmacological therapies. Consist of a motivational interview and a physical activity (PA) intervention (6-month duration) based on supervised endurance training, promotion of PA and empowerment for self-management using the PHF.
Work plan execution & 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.
6-Discharge: The patient will be discharged or moved to the PA service addressed to citizens at risk & patients with mild disease."
1499059|NCT02976064|Behavioral|Rehabilitation in mild chronic patients and citizens at risk|"Case identification: Candidates fulfilling the inclusion criteria will be identified by the GP.
Case evaluation: i) patient requirements defining the work plan; ii) aerobic capacity and PA; iii) identification of factors modulating adherence.
Personalized work plan definition: i) motivational interview; ii) training for the use of the PHF for self-management; and iii) assign one case manager for off-line remote surveillance. The following optional modules are envisaged: i) basic service (above); ii) endurance training programs; iii) community physical activity group sessions; and/or, iv) upgraded PA program including sensors and close off-line supervision.
Work plan execution & 5-Follow-up+event handling: The ICT-support will facilitate the program follow up.
6-Discharge: The basic version of the promotion of PA program is conceived for a timeless duration. However, the different modules included in the service portfolio will have specific agendas and associated costs."
1499060|NCT02976051|Radiation|HART-CN|HART-CN: Hyperfractionated accelerated radiotherapy with weekly concommitant cis-platin and daily nimorazole
1499061|NCT02976038|Drug|elamipretide|40 mg, subcutaneous injections (in the abdomen) daily for the shortest of the following: 260 weeks; regulatory approval and commercial availability of elamipretide in the subject's respective country; or termination of the clinical development for elamipretide in subjects with PMD.
1499062|NCT02976025|Other|Longitudinal Remote Consultation|Longitudinal Remote Consultation utilizes video conferencing to efficiently link providers to consultants who provide timely feedback and training in collaborative care. LRC will be provided in addition to standard collaborative care training and support
1499063|NCT02976025|Other|Collaborative Care|Standard collaborative care implementation training and support
1499064|NCT02976012|Drug|Aflibercept|. Study eyes will receive one preoperative intravitreal aflibercept injection (IAI) <21 days prior to vitrectomy and one intraoperative intravitreal aflibercept at end of surgery. Eyes will be randomized on the day of surgery or 1-2 weeks post-operatively to either a q8week IAI dosing regimen group or a q16week IAI dosing regimen group.
1499065|NCT02976012|Procedure|Endolaserless Vitrectomy|Endolaserless vitrectomy and intraoperative and postoperative IAI in patients with PDR-related vitreous hemorrhage
1499066|NCT02975999|Drug|Vasopressin|Vasopressin at dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
1499067|NCT02975999|Drug|Normal Saline|Normal saline at starting dose of 0.4mU/kg/min will be started on the assigned group once coming off cardiopulmonary bypass following the Fontan operation.
1499068|NCT02975986|Other|Radioactive isotope|Uptake of radioactive isotope by the kidney
1499069|NCT02975973|Device|transcranial direct current stimulation|transcranial direct current stimulation (tDCS) is a safe, noninvasive, weak electrical current delivery that stimulates brain function. It is a novel therapeutic for cognition in schizophrenia.
1499070|NCT02975960|Biological|injection of autologous stromal vascular fraction|"Acquiring autologous stromal vascular fraction (SVF) from liposuction
purifying SVF from lipoaspirates and making syringe filled with SVF
SVF injection - Inject SVF on fingers subcutaneously."
1499071|NCT02975947|Device|Humidified, warmed CO2 insufflation of open peritoneum using Fisher & Paykel's HUMIGARD (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand)|The study group will receive warmed (37°C), humidified (98% RH) carbon dioxide into the open peritoneal cavity using the Fisher & Paykel's HUMIGARD system (Fisher & Paykel Healthcare Ltd, Auckland, New Zealand). This will create a local atmosphere of 100% carbon dioxide (warmed, humidified) in the open peritoneal cavity.
1499072|NCT02975947|Device|Standard heating|Standard intraoperative warming measures including heated blankets, heating with forced warmed air, warming of fluids, and insulation of limbs and head
1499073|NCT02975934|Drug|Rucaparib|Rucaparib will be administered daily.
1499074|NCT02975934|Drug|Abiraterone acetate or Enzalutamide or Docetaxel|Abiraterone acetate and enzalutamide will be administered daily. Docetaxel will be administered every 3 weeks.
1499075|NCT02975921|Drug|Povidone-Iodine|Intrapleural administration of Povidone-Iodine
1499076|NCT02975895|Device|Hydrophobic IOL: Vivinex (HOYA)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
1499077|NCT02975895|Device|Hydrophilic IOL: INCISE (Bausch+Lomb)|Patients requiring cataract surgery will be randomized to one of the two types of IOLs.
2002033|NCT02579226|Drug|Irinotecan|Irinotecan will be administered in combination with AZD2811 to a select group of patients in the dose expansion segment of this study, Parts B2 and B3.
2002034|NCT02579083|Drug|MB66|10 mg of HSV8-N and 10 mg of VRC01-N monoclonal antibodies per MB66 film
2002035|NCT02579083|Drug|Placebo Film|The placebo film is composed of the identical excipients as MB66 without the monoclonal antibodies.
1499083|NCT02975869|Other|Standard Leukemia Care|
1499084|NCT02975869|Other|Palliative Care|
1499085|NCT02975856|Dietary Supplement|Table Red Wine|
1499086|NCT02975856|Dietary Supplement|Young Port Red Wine|
1499087|NCT02975843|Drug|Beclometasone dipropionate/Formoterol Fumarate/Glycopyrronium|single inhalation of 99mTc radiolabelled CHF 5993 pMDI (4 puffs for a total dose of: Beclometasone diproprionate (BDP) 400 μg, Formoterol fumarate (FF) 24 μg, Glycopirronium bromide (GB) 50 μg)
1499088|NCT02975830|Radiation|Three dimensional CT based images|Right bronchial angle, left bronchial angle
1499089|NCT02975817|Other|Hibler's|Passive body heat retention using multiple-layer tight wrapping of patient
1499090|NCT02975817|Other|Warm Air|Active, convective warming of patient using warm air blanket
1989772|NCT02386670|Other|sham tDCS + sham CR|"First, the intervention sessions will be administered 5 days/week for 8 weeks (induction phase). Then, for 5 days once every 6 months (consolidation phase).
tDCS session: anode over Fz & cathode over Iz; direct current: 2 mA (current density=0.57A/m2) for 1 minute, then the current will be 0 mA for 29 minutes.
CR sessions will follow the tDCS session and last 2 hours in a group supervised by trained interventionists. Participants will also complete CR exercises online at home. CR will consist of computer-based exercises relevant to attention, processing speed, executive function, and verbal and working memory without titrated difficulty levels."
1499092|NCT02975791|Other|Marking the cricothyroid membrane after ultrasound|Ultrasonography is applied to the subjects neck in order to identify the cricothyroid membrane - subsequently the membrane is marked with a pen
1499093|NCT02975791|Procedure|Marking of the cricothyroid membrane after Palpation|Palpation is applied to the subjects neck in order to identify the cricothyroid membrane- subsequently the membrane is marked with a pen
1499094|NCT02975778|Device|Pain Monitor™|Pain measured by Pain Monitor™
1499095|NCT02975765|Procedure|Piezosurgery|The surgical tip is going to be used to make small cuts into the cortex of the alveolar bone between the crowded teeth.
1499096|NCT02975752|Genetic|LC-RT-PCR and NGS|highly sensitive PCR vs. multiplex targeted-resequencing
1499097|NCT02975739|Device|Holmium-166 (poly L lactic acid) microspheres|Intratumoral injections of Holmium-166 (poly L lactic acid) microspheres
1499098|NCT02975726|Device|Peritoneal Dialysis Catheter|Peritoneal dialysis catheter insertion in order to drain access fluid within the belly for patients with liver cirrhosis and refractory ascites.
1499099|NCT02975726|Procedure|Large Volume Paracentesis|Insertion of a needle into the peritoneal cavity where ascites accumulates, then attaching the needle to a collection system that drains the ascites by gravity. This procedure is part of the standard care for the treatment of refractory ascites.
1499100|NCT02975726|Biological|25% Human Serum Albumin injection|Patients will be given Human Serum Albumin after the initial drain of ascites fluid: 100cc for 5-10L drainage, 200cc for 10-15L drainage.
1499101|NCT02975726|Procedure|Bloodwork|Monthly bloodwork will be done as part of usual standard of care.
2002036|NCT02574650|Device|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS)|Mitralign Percutaneous Tricuspid Valve Annuloplasty System (PTVAS) delivered by a percutaneous transcatheter procedure.
1499103|NCT02975687|Biological|CD19 CAR T cells|CD19 CAR T cells was transduced with a lentiviral vector to express anti-CD19 scFv TCRζ:4-1BB.
2002037|NCT02574481|Device|ELUVIA (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
1499106|NCT02975648|Behavioral|educational model + follow up|"educational programme (with booklets and orientation)
telephone follow up (that will be started in preoperative for six months)."
1499107|NCT02975648|Behavioral|usual care|"orientations about the surgery and the rehabilitation by health professionals
one scheduled appointment for evaluation by health professionals at six months after the Percutaneous Coronary Intervention"
1499108|NCT02975635|Other|Questionnaire|Patients are given a questionnaire with items related to personality and behaviour.
1499109|NCT02975622|Procedure|Central venous catheterization|Ultrasound guided central venous catheterization
1499110|NCT02975609|Radiation|Conventional Fractionated Radiotherapy|5Fx/W,3Gy/Fx,Dt:PTV-G:30Gy/10F/2W for metastatic sites, Dt:60Gy/30F for primary tumor and metastatic lymph node.
1499111|NCT02975609|Radiation|Stereotactic Body Radiation Therapy|30Gy/3-5F for the primary and the metastases.
1499112|NCT02975596|Other|Awareness|Awareness: Conduct an awareness campaign throughout Alachua County to alert the community in general to the significance of Serogroup B meningococcal disease in the United States. To inform the material included in the awareness campaign and the education materials, semi-structured interviews with members for each of the key stakeholder groups: students, parents, and medical practitioners will be conducted.
1499113|NCT02975596|Other|Education|Education: This component will be both web-based and in-person to meet the individual needs of the learners. There will be parent and a student (18-23 years old) version of the educational curriculum. National resources of patient -focused materials and guidelines will be adapted. There will be pre- and post-education surveys to assess knowledge and vaccine decision-making.
1499114|NCT02975596|Other|Empowerment|"Empowerment: A guided program for adolescents and young adults on Decision-Making for your Health will be offered on the vaccination days to assist youth in assessing and utilizing health information to guide their personal decision-making for vaccines."
1499115|NCT02975596|Other|Accessibility|Accessibility: MenB vaccine will be offer on the high school and university campuses through a collaborative program between the local schools, university and department of health. We will offer students booster shots of Men ACWY and HPV at the same time. All vaccines will be offered free of charge. Each vaccine administered will be recorded in Florida SHOTS.
1499116|NCT02975583|Drug|Vorapaxar|2.08 mg oral tablet daily
1499117|NCT02975583|Drug|Placebos|Placebo oral tablet daily
1499118|NCT02975570|Drug|Delamanid|Delamanid is a medication used to treat tuberculosis. Specifically it is used, along with other antituberculosis medications, for active multidrug-resistant tuberculosis. It is taken by mouth.
1499119|NCT02975570|Drug|Linezolid|Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics.
1499120|NCT02975570|Drug|Levofloxacin|Levoflaxacin is an antibiotic used to treat a number of bacterial infections including acute bacterial sinusitis, pneumonia, urinary tract infections, chronic prostatitis, and some types of gastroenteritis. Along with other antibiotics it may be used to treat tuberculosis.
1499121|NCT02975570|Drug|Pyrazinamide|Pyrazinamide is a medication used in combination with other drugs such as isoniazid and rifampicin in the treatment of Mycobacterium tuberculosis.
1499122|NCT02975570|Drug|WHO MDR-TB regimen|The WHO guidelines recommend the following 5-agent treatment regimen for MDR-TB: pyrazinamide; a fluoroquinolone; a parenteral agent (typically amikacin or kanamycin); ethionamide (or prothionamide); and either cycloserine or para-aminosalicylic acid, with preference for cycloserine. Short (9 mos) or longer (20-24 mos) treatment schedules can be used.
1499123|NCT02975557|Drug|Brimonidine 0.15%|Brimonidine 0.15% eye drops 2 times a day for 12 weeks
1499124|NCT02975557|Drug|Brimonidine 0.075%|Brimonidine 0.075% (1:1 dilution will be performed using 0.15% Alphagan-P solution with Refresh Plus Artificial Tears solution) eye drops 2 times a day for 12 weeks.
1499131|NCT02975531|Other|Training Evaluation|Evaluation of volunteers from GE group before and after training with the simulator.
1499132|NCT02975518|Biological|Administration of radio labelled endothelial outgrowth cells|Radio labelled endothelial outgrowth cells will be administered to patients undergoing elective coronary angiography and stenting. They will be administered intra-venously and intra-arterially (right radial artery) in separate arms. Migratory behaviour of these cells will be defined using PET CT. Intra-venous and intra-arterial injection of free radio tracer will serve as a control comparator arms.
1499133|NCT02975505|Other|Strict blood pressure control|Systolic Blood Pressure Target < 120 mm Hg (measured at home)
1499134|NCT02975492|Drug|Cholecalciferol|
1499135|NCT02975492|Drug|Ergocalciferol|
1499136|NCT02975479|Drug|ALK Diluent|
1499137|NCT02975479|Drug|ALK Alutard SQ 5-grasses or ALK Alutard Birch|Depot formulation of relevant allergen adsorbed to aluminium hydroxide in a suspension.
1499138|NCT02975466|Device|Insertion of AirQ Blocker and intubation through the device|
1499139|NCT02975466|Device|Insertion of AuraGain and intubation through the device|
1499140|NCT02975466|Device|Insertion of I-Gel and intubation through the device|
1499141|NCT02975453|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by the treating physician
1499142|NCT02975440|Drug|Rifampicin|11 single oral doses of 600 mg Rifampicin resulting in a total dose of 6600 mg Rifampicin.
1499143|NCT02975440|Drug|Midazolam|2 single oral doses of 1 mg Midazolam resulting in a total dose of 2 mg Midazolam
1499144|NCT02975440|Drug|BAY1002670_Vilaprisan|2 single oral doses of 4 mg Vilaprisan resulting in a total dose of 8 mg Vilaprisan
1499145|NCT02975427|Other|Diet group|All participants were prescribed an appropriate diet with caloric restriction and an exercise program and underwent a follow-up examination 3±1 months later.
1499146|NCT02975414|Procedure|rTARUP technique|obot-assisted rTARUP technique
1499147|NCT02975401|Procedure|rTAPP technique|robot-assisted rTAPP technique
1499148|NCT02975388|Drug|RO7079901|Participants will receive a single dose of 1000 milligrams (mg) RO7079901 as a 30-minute intravenous (IV) infusion.
1499149|NCT02975375|Procedure|Preoperative geriatric consult or assessment|A preoperative geriatric consult or assessment will be considered to be present if such a consult or assessment is billed by a geriatrician for a patient in the cohort within 4 months preceding surgery. For the primary analysis we will collapse both geriatric consultations and comprehensive geriatric assessments into a single exposure level.
1499150|NCT02975375|Procedure|No Preoperative geriatric consult or assessment|No assessment or consult billed in the 4 months before surgery
1499151|NCT02975362|Other|Acupuncture Treatment|Acupuncture Treatment Acupoint selection base on disease stage combined adjunct acupuncture acupoint base on syndrome differentiation.①Base on disease stage: Flaccid paralysis period: DU24, DU20, Motor Area , LI15, LI14, LI11, SJ5, LI4, GB31, EX-LE2, GB34, ST36, ST40.Spastic period: DU24, DU20, Motor Area , SJ10, SJ13, LI10, SJ8, SJ5, SJ4, SJ4, BL37, BL40, BL39, BL55, BL57, ST41, GB40, BL60.②Base on syndrome differentiation:Excess syndrome of yang-type: LR3, ST37; Deficiency syndrome of Yang-type: KI3, BL23; Excess syndrome of yin-type: SP9, GB20;Deficiency syndrome of Yin-type: CV6, BL23.③Electroacupuncture acupoint: Flaccid paralysis period: LI15, LI4, GB31, ST40; Spastic period: SJ13, SJ5, BL40, BL57.30minutes each time,twenty times / treatment course，two treatment courses in total.
1499152|NCT02975362|Other|Rehabilitation Treatment|Rehabilitation treatment The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists
1499153|NCT02975349|Drug|M2951|M2951 low dose will be administered for 48 weeks
1499154|NCT02975349|Drug|M2951|M2951 mid dose will be administered for 48 weeks
1499155|NCT02975349|Drug|M2951|M2951 high dose will be administered for 48 weeks
1499156|NCT02975349|Drug|Placebo|Placebo will be administered for 24 weeks
1499157|NCT02975349|Drug|Tecfidera|Tecfidera; 120 mg hard capsule BID for 7 days then 240 mg hard capsule BID for duration of treatment (47 weeks)
1499158|NCT02975349|Drug|M2951|Following Placebo for 24 weeks, M2951 low dose will be administered for 24 weeks
1499159|NCT02975336|Drug|Placebo|Placebo matched to M2951 will be administered for 52 weeks.
1499160|NCT02975336|Drug|M2951|M2951 low dose will be administered for 52 weeks.
1499161|NCT02975336|Drug|M2951|M2951 mid dose will be administered for 52 weeks.
1499162|NCT02975336|Drug|M2951|M2951 high dose will be administered for 52 weeks.
1499163|NCT02975323|Drug|Carvedilol|Single dose of oral carvedilol 12.5 mg and wait till the time there's 20% reduction in hepatic wedge pressure gradient from the baseline.
1499164|NCT02975310|Procedure|Endoscopic polypectomy in clinic (EPIC)|The experimental intervention is endoscopic polypectomy performed in clinic (EPIC) where nasal polyps are removed using a microdebrider under local and topical anesthesia in the outpatient clinic.
1499165|NCT02975310|Procedure|Endoscopic Sinus Surgery (ESS)|The control intervention is endoscopic sinus surgery (ESS), a minimally invasive procedure that is the current standard that involves polypectomy with a microdebrider as well as sinus ostia enlargement of the affected sinuses performed in the operating room under general anesthesia.
1499166|NCT02975310|Other|General Anesthesia|ESS will be performed under general anesthesia in the operating room
1499167|NCT02975310|Other|Local and topical anesthesia|EPIC will be performed under topical and local anesthesia in a clinic setting
1499168|NCT02975297|Drug|Exenatide|Exenatide Injectable Product will be administered at a dose of 2 mg subcutaneously once a week for 6 weeks.
1499169|NCT02975297|Drug|NRT|Nicotine Patch (21mg) / 24 hours.
1499170|NCT02975297|Behavioral|Counseling|Brief individual behavioral smoking cessation counseling.
1499171|NCT02975297|Drug|Placebo|Normal saline.
1499172|NCT02975271|Drug|Serlopitant|
1499173|NCT02975271|Drug|Placebo|Matching placebo
2002038|NCT02574481|Device|Zilver PTX (Stent Implantation)|Drug-eluting self-expanding stent implantation during the index procedure.
1499232|NCT02975011|Procedure|Cupping|Cupping treatment will be administered at 1-2 points using mainly proximal acupuncture points and Ah-shi points.
2002044|NCT02573233|Drug|dupilumab SAR231893/REGN668|Pharmaceutical form:solution Route of administration: subcutaneous
2002045|NCT02573233|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
2002046|NCT02573233|Drug|fluticasone propionate and salmeterol|Pharmaceutical form:inhalation aerosol, inhalation powder Route of administration: inhaled
1499183|NCT02975232|Behavioral|F&V economic incentive|50% off eligible fresh, frozen and canned fruits and vegetables (up to $10/day)
1499184|NCT02975232|Behavioral|Cooking Matters Store Tour|Participants will be asked to attend one Coking Matters store tour during January or February 2017
1499185|NCT02975219|Drug|Bevacizumab-800CW|4.5mg Bevacizumab-800CW will be administered intravenously three days prior to surgery
1499186|NCT02975206|Drug|Serlopitant High Dose|serlopitant tablets - high dose
1499187|NCT02975206|Drug|Placebo Oral Tablet|placebo tablet
1499188|NCT02975206|Drug|Serlopitant Low Dose|serlopitant tablets - low dose
1499189|NCT02975193|Behavioral|Computer task assessing cognition|Participants will complete a short computer game to assess cognition.
1499190|NCT02975193|Behavioral|Impulsive-Compulsive Disorders in Parkinson's Disease|Standard clinical questionnaire
1499191|NCT02975193|Behavioral|Montreal Cognitive Assessment|Standard clinical questionnaire
1499192|NCT02975180|Device|FES|The MyndMove FES System (MyndTec Inc., Mississauga, ON) is a fully programmable FES device with eight channels. This system allows motor practice of 17 different reaching and grasping protocols. The muscles stimulated may include the anterior, middle and posterior deltoid, biceps and triceps brachii, flexor digitorum superficialis and profundus, extensor digitorum, thenar eminence, lumbricals, and interossei. The sophistication of this system is unique. In contrast, many of the MyndMove stimulation protocols involve activation of small muscles that are used for fine motor control. The second FES device that will be used is the Odstock 2-channel Stimulator (FES Mobility Ltd., Vancouver, BC). While less sophisticated than the MyndMove system, it is smaller and more portable.
1499193|NCT02975180|Behavioral|Conventional|Conventional training involves repetitive practice of upper extremity movements with manual assistance provided by a therapist as needed.
1499194|NCT02975167|Other|Outpatient Cervical Ripening|The experimental arm of the study will be subjects randomized to the outpatient group. Once randomized, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with outpatient induction of labor. Following placement of the Foley catheter, the subjects will be given detailed instructions for which to return to the hospital, as well as provided a 24 hour phone number to call if they have questions. They will be instructed to return to the hospital once the catheter falls out or if 24 hours has passed since its placement. Upon returning to the hospital, subjects will complete another survey assessing their satisfaction with their induction process.
1499195|NCT02975167|Other|Inpatient Cervical Ripening|Once randomized to this group, subjects will complete a survey assessing their attitudes, fears, anxiety, satisfaction and expected hours of sleep with inpatient induction of labor. Following placement of the Foley catheter, the subjects will undergo normal labor monitoring until their Foley catheter either falls out or is removed at 24 hours. At this time subjects will complete another survey assessing their satisfaction with their induction process.
1499196|NCT02975167|Procedure|Foley catheter placement|Subjects randomized to both the inpatient and the outpatient arms will receive this intervention following completion of a survey. A Bard(TM) 16G two-way 5cc silicone-coated latex Foley catheter will be placed by a physician-member of the research team using a sterile metal speculum and ring forceps, or by hand, depending on physician preference. Once placed within the cervical canal, the Foley will be filled with 60cc of saline
1499197|NCT02975167|Behavioral|Pre-Foley Questionnaire|Prior to randomization into inpatient or outpatient arms, all subjects will complete a questionnaire assessing their attitudes, opinions, fears and anxiety regarding induction of labor.
1499198|NCT02975167|Behavioral|Post-Foley Questionnaire|Following removal of the Foley catheter (either by a physician at 24 hours or spontaneously), all subjects will complete the same questionnaire as prior assessing their attitudes, opinions, fears and anxiety regarding their induction of labor.
1499229|NCT02975011|Procedure|Pharmacopuncture|Pharmacopuncture consisting of select herbal ingredients will be administered at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
1499230|NCT02975011|Procedure|Acupuncture|Acupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
2002047|NCT02573233|Drug|budesonide and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
2002048|NCT02573233|Drug|mometasone furoate and formoterol|Pharmaceutical form:inhalation aerosol Route of administration: inhaled
2002049|NCT02571244|Behavioral|Motivational Interview plus text message|After discharge the experimental group will receive extended care including a counseling session and text messages. The session will provide basic information about smoking and successful quitting. The counselor will use motivational interview techniques to build coping skills, with the goal of helping the participant build and implement a quit plan. The focus will then shift to increasing motivation to make quit attempt, including confidence building, medication use, and cessation planning.The session will last approximately 30 minutes. Participants in the experimental arm will be offered up to 30 text messages to help the patient implement the quit plan discussed during the phone call. Patients motivated to quit in the next 30 days or that had already quit will receive 30 messages (2 per day) and patients unwilling to quit 16 (2 per day). The messages follows the self efficacy theory.
2002050|NCT02569307|Drug|Minocycline|Minocycline added to TAU Minocycline will be administered in 200mg once daily dose
2002051|NCT02569307|Drug|Omega-3 fatty acids|Omega-3 fatty acids added to TAU Omega-3 fatty acids will be administered in 1.2g once daily dose
2002052|NCT02569307|Drug|Placebo|Placebo added to TAU
1499199|NCT02975167|Procedure|Fetal Non-Stress Test|Following placement of the Foley catheter, all subjects, regardless of arm they are randomized to, will undergo a 20-minute NST. The NST will be read by a physician-member of the research team. If the NST is considered to be suspicious based on the physician's evaluation, subjects randomized to the outpatient arm will be moved to the inpatient arm, but evaluated as part of the outpatient arm on an intent-to-treat basis. All subjects randomized to the inpatient arm will be placed on continuous fetal heart rate monitoring, regardless of physician evaluation of the NST.
2002053|NCT02569307|Drug|Minocycline Plus Omega-3 fatty acids|Minocycline will be administered in 200mg once daily dose and Omega-3 fatty acid 1.2g taken as once daily dose
1499201|NCT02975141|Drug|Afatinib 30Mg Tab|Study Drug
1499202|NCT02975141|Drug|Afatinib 40Mg Tab|Study Drug
1499203|NCT02975141|Drug|Gemzar|Chemotherapy Backbone
1499204|NCT02975141|Drug|Abraxane|Chemotherapy Backbone
1499205|NCT02975128|Device|BLES system and conventional lumpectomy|Each patient undergoes the same procedure. Under general anaesthesia for the normal surgical procedure, the tumor is first removed using the BLES system under US guidance. Next, the normal surgical procedure is performed, excising the BLES excision cavity and a ≥ 1cm margin of surrounding tissue, also guided by the US appearance after the BLES procedure.
1499206|NCT02975115|Other|RQ-PCR RNA Analysis|Conventional Q-RT-PCR every 3 months
1499207|NCT02975102|Device|CBL-101 Eye Drops|CBL-101 Eye Drops 3 to 6 times per day for 3 months.
1499208|NCT02975102|Device|Vismed® Multi|Vismed® Multi 3 to 6 times per day for 3 months.
2002054|NCT02567799|Drug|BIO 300 Oral Suspension|Cohort 1: BIO 300 500 mg Cohort 2: BIO 300 1,000 mg Cohort 3: BIO 300 1,500 mg Cohort 4: BIO 300 Optimal dose (TBD) BIO 300 dose will be given daily, 7 days/week (Week 1, day 1 through week 6) The 2nd and 3rd dosing cohort (1,000 and 1,500 mg/day) will begin following the accrual of a minimum of 6 subjects at the previous dose level, dose escalation to the next BIO 300 dose level will be allowed to occur when a cohort has completed concurrent chemoradiotherapy with fewer than 33% Dose Limiting Toxicities (DLTs) attributed to BIO 300 Oral Suspension.
2002055|NCT02567799|Drug|Paclitaxel|"During the Concurrent Therapy period, paclitaxel 45 mg/m2 will be administered by intravenous drip weekly during weeks 1-6.
During the Consolidation Therapy period, paclitaxel 200 mg/m2 will be administered by intravenous drip two times, 21 days apart."
2002056|NCT02567799|Drug|Carboplatin|"During the Concurrent Therapy period, area under the curve (AUC) = 2mg* min/mL will be administered by intravenous drip weekly during weeks 1-6.
During the Consolidation Therapy period, carboplatin AUC = 6mg*min/mL will be administered by intravenous drip two times, 21 days apart."
1499212|NCT02975076|Drug|Sanchitongshu|The study drugs were manufactured according to Good Manufacturing Practice (GMP) by the Pharmaceutical Factory of Chengdu Huasun Group Inc. Ltd. and presented in the form capsules. Every Sanchitongshu capsule weighed 200 mg, contained 100 mg of panaxatriol saponin (PTS) and 100 mg inactive excipient (starch). PTS comprised of dried extracts from roots of Radix Notoginseng, and had been standardised with respect to Ginsenoside Rg1 (50%), Ginsenoside Re (6%), Notoginsenoside R1 (11%). The amounts of the active ingredients were determined by analytical RP-HPLC using an acetonitrile-water gradient system as mobile hase. The peaks were detected by UV-DAD.
1499213|NCT02975076|Drug|placebo of Sanchitongshu|The Sanchitongshu placebo capsule contained dark brown muscovado sugar and the same inactive excipient (starch).
1499214|NCT02975076|Drug|Aspirin|
1499215|NCT02975076|Drug|Clopidogrel|
1499216|NCT02975076|Drug|placebo of clopidogrel|
1499217|NCT02975063|Behavioral|intensive interpersonal communication|(1) Interpersonal communication through frontline workers/volunteers to increase mothers' knowledge and practice of optimal infant and young child feeding (IYCF) behaviors. Interpersonal communication will involve multiple contacts with mothers and an array of IYCF messages; (2) Community mobilization activities to raise awareness of the benefits of optimal IYCF practices among opinion leaders and family members, and increase their support to mother for IYCF; (3) Training of facility and community-based health workers on IYCF to improve their ability to support mothers and provide timely information on IYCF; and (4) Mass media communication on IYCF.
1499218|NCT02975063|Behavioral|streamlined interpersonal communication|"The streamlined interpersonal communication approach will identify rules of thumb that convey small doable actions related to IYCF for a mother to perform and will address key drivers of those small doable actions, including positive emotion. Alive & Thrive will identify and test three sets of rules of thumb, one set for each of these audiences: (1) pregnant women (on early initiation of breastfeeding and exclusive breastfeeding); (2) mothers of children 0-6 months (on exclusive breastfeeding); and (3) mothers of children 6-24 months (on complementary feeding)."
1499219|NCT02975050|Other|Location|
1499220|NCT02975037|Drug|Sildenafil|sildenafil 25 mg PO
1499221|NCT02975037|Drug|Erythromycin|erythromycin 250 mg PO
1499222|NCT02975037|Drug|Itraconazole|itraconazole 100 mg PO
1499226|NCT02975011|Drug|Herbal medicine|Herbal medicine will be administered in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
1499227|NCT02975011|Procedure|Chuna manipulation|Chuna is a Korean spinal manipulation that incorporates spinal manipulation techniques for joint mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation will be administered to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
1499228|NCT02975011|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture will be administered only after confirming a negative response to hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens will be injected at 4-5 acupoints proximal to the dysfunctional site at the physician's discretion. Each acupuncture point will be injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
1499231|NCT02975011|Procedure|Electroacupuncture|Electroacupuncture treatment will be administered using mainly proximal acupuncture points and Ah-shi points.
1499361|NCT02974101|Other|registration of AdaptiveStim|
1499233|NCT02975011|Other|Other intervention(s)|Patients will be allowed any other additional intervention(s) as deemed necessary by the attending physician regardless of type or dose, and patterns of use will be investigated and recorded as an pragmatic clinical study.
1499234|NCT02974998|Behavioral|Young Women's Health CoOp (YWHC)|Participants will receive HTC and engage in a two-session gender-focused intervention. The intervention will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal. The intervention also encourages positive goal-seeking to access linkages to health care within the larger social ecological framework of where the young women live.
1499235|NCT02974998|Behavioral|Standard HTC|Participants will receive the standard of care available in South Africa for this population.
1499236|NCT02974985|Device|Restylane Lyft and Restylane L|Please see group descriptions
1499237|NCT02974959|Device|gammaCore active device|The nVNS therapy will be performed using the gammaCore-R (electroCore LLC, NJ), which is an external hand-held vagal nerve stimulator. The gammaCore-R produces a low voltage electric signal consisting of five 5000 Hz pulses that are repeated at a rate of 25 Hz. It allows for a 120 second stimulation session. The stimulation will occur twice daily, one time in the morning and one time in the evening. This should be done as close to 12 hours apart as possible and should occur twice daily for the entire 12 week study period.
1499238|NCT02974959|Device|gammaCore sham device|The sham device appears identical to the gammaCore but does not provide a frequency of stimulation powerful enough to stimulate either efferent or afferent fibers of the vagus nerve. However, it does supply a low frequency current which will cause a tingling of this skin to improve blinding of the patients.
1499239|NCT02974946|Device|RenalGuard|
1499240|NCT02974933|Drug|Apatinib combined with pemetrexed|For those pretreated non-squamous non-small cell lung cancer, treat with apatinib 500mg Qd, po.combined with pemetrexed continue until disease progression
1499241|NCT02974920|Drug|Rivaroxaban 10 MG|Rivaroxaban 10 mg once daily for 180 days
1499242|NCT02974920|Drug|Aspirin|Aspirin 100 mg once daily for 180 days
1499243|NCT02974907|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
1499244|NCT02974907|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
1499245|NCT02974894|Dietary Supplement|Probiotic (Lactobacillus Plantarum)|
1499246|NCT02974894|Dietary Supplement|Placebo|
1499247|NCT02974881|Device|Transcatheter Mitral Valve Replacement|Minimally invasive transcatheter mitral valve implantation using the HighLife™ TMVR system
2002057|NCT02567799|Radiation|Radiotherapy|Radiation treatment will be scheduled at the discretion of the investigator provided the subject has completed a minimum of 2 days of BIO 300 dosing. Subjects will receive radiation therapy 5 days per week, once daily fractions, 2.0 Gy per fraction, for 6 weeks.
2002058|NCT02567461|Drug|Edoxaban 60 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
2002059|NCT02567461|Drug|Edoxaban 30 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
2002060|NCT02567461|Drug|Clopidogrel 75 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
1499255|NCT02974842|Device|MAKO 7|Hysteroscopic cell sampling
1499256|NCT02974829|Other|follow-up|
1499257|NCT02974816|Device|Glooko's mobile application|Standard of care and Remote monitoring
1499261|NCT02974777|Drug|DAPT reduction|Reduction of standard dose DAPT due to low platelet reactivity
1499262|NCT02974777|Drug|DAPT on-target|Standard DAPT within the therapeutic window of platelet reactivity
1499263|NCT02974777|Drug|DAPT intensification|Intensification of standard dose DAPT due to high platelet reactivity
1499264|NCT02974764|Other|No intervention/exposures|
1499265|NCT02974751|Procedure|Aquablation|Aquablation is a minimally invasive transurethral surgical procedure using the AQUABEAM system, a personalized image-guided waterject resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue.
1499266|NCT02974738|Drug|PT2977|PT2977 is a highly selective small molecule that inhibits the function of the HIF-2α transcription factor. As a result, hypoxic signaling in cancer cells is impaired, blocking the transcription of several genes involved in oncogenesis
1499267|NCT02974725|Drug|LXH254|LXH254 will be supplied as tablet for oral use.
1499268|NCT02974725|Drug|LTT462|LTT462 will be supplied as hard gelatin capsule for oral use.
1499269|NCT02974712|Drug|Fentanyl|
1499270|NCT02974712|Drug|Saline|
1499271|NCT02974699|Dietary Supplement|Potato Starch (Bob's Red Mill)|Subjects will be assigned to Potato Starch (active) following assessment of their gut microbiome.
1499272|NCT02974699|Dietary Supplement|Pregelatinized Starch (Resource ThickenUp)|Subjects will be assigned to Pregelatinized Starch (placebo) following assessment of their gut microbiome.
1499273|NCT02974686|Drug|Everolimus|
1499274|NCT02974686|Drug|Mycophenolic Acid|
1499275|NCT02974673|Procedure|Ejaculatory test|Measures of sphincter pressures during ejaculation will be registered using a sensor introduced in the urethra on patient with spinal cord injury.
1499276|NCT02974660|Drug|Protamine sulfate|
1499277|NCT02974660|Drug|0.9% NaCl|
1499279|NCT02974634|Other|OSMT group to UC group|Ostomy Self management Training group in which subject will learn using pouches and equipment, skin care, ostomy complications, nutritional needs, Impact on feelings, clothing changes, social relationships, being prepared for emergencies, Intimacy and sexuality, communication skills, tips for travelling and physical activity recommendations
2002061|NCT02567461|Drug|Aspirin 81 mg|Patients will receive randomized treatment for 10±2 days, in order to achieve steady-state anticoagulant effects. Afterwards, patients randomized to any of the edoxaban groups (arms 1 and 2) will stop aspirin therapy. Study treatment will be administered for other 10±2 days.
1499288|NCT02974569|Device|Computer Symptom Capture Tool|"C-SCAT is an investigator developed app that is delivered via an iPad. The original CSCAT included the 30 symptoms from the Memorial Symptom Assessment Scale. The recently updated version includes two additional symptoms feeling bloated and sexual dysfunction that are included in the adult version of the MSAS.21 These symptoms were added based on feedback from the initial AYA sample of 13-29 year olds and in consideration of the developmental perspectives of the AYA population.The CSCAT allows the user to create an image of his or her symptom experience."
2002062|NCT02566512|Other|Tracheostomy cuff inflation.|With the tracheostomy cuff inflated, the peak expiratory flow meter will be attached directly to the tracheostomy tube. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times.
2002063|NCT02566512|Other|Tracheostomy cuff deflation|With the tracheostomy cuff deflated, a one-way valve will be attached to the tracheostomy tube. The patient will use a mouthpiece to connect to the peak expiratory flow meter. The patient will be instructed to take as big a breath as they can and then forcefully cough. This will be repeated four times
2002064|NCT02563808|Other|Survey: Standard|
1499292|NCT02974543|Device|Sham Treatment: unimodal auditory stimulation|All subjects will be told they will receive either Sham or Active Treatment, but will not know which treatment is assigned. Set up for the sham treatment is the same as the active treatment.
1499293|NCT02974543|Device|Active Treatment: Bimodal auditory-somatosensory stimulation|"Somatosensory stimulation will be delivered by pads positioned on the cheek overlying the trigeminal ganglion, the juncture of the temporomandibular joint or on the neck at overlying cervical nerves, c1 or c2, determined by the manner in which the subject can modulate the tinnitus.
The auditory stimulus will be individualized based on subject baseline audiogram and tinnitus test results and is presented through a calibrated earphone."
1499294|NCT02974530|Other|Neurological evaluation|
1499295|NCT02974530|Other|Laryngological evaluation|
1499296|NCT02974530|Other|MRI evaluation|
1499297|NCT02974530|Other|Breathing investigation|
1499298|NCT02974530|Other|MRI and articulatory investigation|
1499299|NCT02974530|Other|Postural investigation|
1499300|NCT02974530|Other|Voice and soundscape investigation|
1499301|NCT02974517|Device|EmbryoScope®|The intervention is EmbryoScope® versus conventional incubators.
1499302|NCT02974504|Drug|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to linagliptin 5mg
1499303|NCT02974504|Drug|Linagliptin|linagliptin 5 mg tablet qd + placebo tablet matching to evogliptin 5mg
1499304|NCT02974491|Other|Fuji apple juice|On two different days, each volunteer consumed 300 mL Fuji apple juice (AJ), immediately after a dialysis section. After a washout period of 3 weeks, the volunteers drank 150 mL Fuji AJ in a similar manner as described above. Before and after 30 and 60 min of AJ consumption, blood samples were withdrawn for biochemical analysis.
1499305|NCT02974478|Dietary Supplement|Orange juice with meals|orange juice (20% of energy requirement/day)
1499306|NCT02974478|Dietary Supplement|Orange juice between meals|orange juice (20% of energy requirement/day)
1499307|NCT02974478|Dietary Supplement|Sugar sweetened beverage between meals|Sugar sweetened beverage (20% of energy requirement/day)
1499308|NCT02974465|Procedure|Biofeedback Electromyography|protocol of sEMG-BFB that consisted of active movements in glenohumeral abduction guided by the visual signal of the register equipment. The protocol was the following: firstly proof active movements were requested in glenohumeral abduction without feeling any pain in order to teach the visual signal of their muscle activity. The therapist dedicated around 10 minutes in each session for subject learned to control the activation of both muscles in the limits that physical therapist marked with each individual in particular (controlling the activation in the upper trapezius). Once integrated information, shoulder abduction were requested following 4 main principles.
1499309|NCT02974465|Procedure|Sham Biofeedback Electromyography|consisted of Sham-EMG biofeedback, in which the electrodes were placed as the same method as the EG (Fig. 2) but the screen emit no signal. The subject performed 3 sequences of 10 abduction contractions (first degrees) without pain feeling and with 5 minutes of rest between sequences.
1499310|NCT02974465|Procedure|Conventional Physical Therapy Treatment|All participants received a conventional daily treatment of neurological physical therapy. Since no evidence has been found about a specific therapy that specially could benefit hemiparesis consequences, the common approach in this center consists of a combination of different specific concepts (Bobath, Brunnstrom, Rood, Johnstone, Propioceptive Neuromuscular Facilitation, Perfetti, Vojta, Motor Relearning Programme,…), exercise programs, electrotherapy, myofascial techniques, etc…
2002065|NCT02563808|Other|Survey: Regret|
2002066|NCT02552212|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol
Pharmaceutical Form: Prefilled syringe
Concentration: 200 mg / ml
Route of Administration: Subcutaneous injection"
1499313|NCT02974426|Radiation|PORT-first|PORT administered at the first day of adjuvant therapy, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
1499314|NCT02974426|Radiation|PORT-last|PORT administered sequentially after participants received adjuvant chemotherapy for four cycles, using 3- dimensional conformal or intensity-modulated radiation, total dose of 50.4 Gy, 1.8 Gy once daily over 5.5 weeks.
1499315|NCT02974426|Drug|Platinum-based two drug chemotherapy (cisplatin/carboplatin + vinorelbine or cisplatin/carboplatin + pemetrexed regimen)|Cisplatin/ carboplatin + vinorelbine regimen for squamous cell lung carcinoma Cisplatin/carboplatin + pemetrexed regimen for lung adenocarcinoma
2002067|NCT02552212|Other|Placebo|"Active Substance: Placebo
Pharmaceutical Form: Prefilled syringe
Concentration: 0.9 % saline
Route of Administration: Subcutaneous injection"
2002068|NCT02549898|Drug|Feraheme|Feraheme is an USPIO agent, which will be applied as a contrast agent to visualize vascular inflammation in unilateral migraine without aura.
2002069|NCT02549898|Drug|Cilostazol|Cilostazol will be applied to provoke migraine attacks in migraineurs
2002070|NCT02549898|Other|USPIO-MRI|USPIO-MRI scans will be performed in order to assess possible vascular inflammation associated with migraine attacks.
1499316|NCT02974413|Behavioral|self-care supported|The intervention to be performed will be based on the principles and steps of supported self-care, guided by Behavior Change Protocol (Behavior Change Protocol - BCP) and consists of an educational program with quarterly meetings, and individual at home, through home visits, and group in the Basic Health Unit (BHU), in addition to telephone monitoring in the interval between two meetings. This intervention will be applied together adult men with type 2 diabetes who are randomized in the intervention group (IG) for six months. Thus, these men will take part in three meetings, individual or group, and will receive four telephone calls in between the face meetings. Our objective is to draw with this intervention by the participant, an individual plan of self-care, based on concretras goals and supports you in the implementation of this plan, in order to improve their self-efficacy in self-care and therefore glycemic control.The study will also include a Control Group (CG).
1499317|NCT02974400|Behavioral|Internet-based, CBT-oriented, guided self-help|The self-help program includes sessions regarding (1) cognitive model, (2) sleep hygiene, (3) mindfulness, (4) meta-cognition, (5) coping with voice hearing, (6) persecutory ideation, (7) worrying, (8) self-esteem, (9) depression, (10) social competence, and (11) relapse prevention.
1499318|NCT02974387|Drug|Fluorometholone(FML)|
1499319|NCT02974387|Drug|Loteprednol (Lotemax)|
1499320|NCT02974374|Drug|PF-06835919|Single or repeated, escalating dose
1499321|NCT02974374|Other|Placebo|Single or repeated, escalating dose
1499322|NCT02974361|Drug|Ibuprofen|
1499323|NCT02974361|Drug|Ibuprofen Lysine|
1499324|NCT02974361|Drug|Ibuprofen-LDH|
1499325|NCT02974348|Drug|Arthemeter-lumefantrine|Randomization codes were computer-generated by an offsite investigator and provided to a study nurse responsible for treatment allocation. All other study personnel were blinded to the treatment assignments, and patients were not informed of their treatment regimen. Participants from Group 1: AL, Group 2 : DHAP, Group3 : ASMQ were also given appointment card for days 1, 2, 3, 7, 14, 21, 28, 35 and 42 for clinical examination and blood smears. Blood was taken on filter paper on each of these visits.
1499326|NCT02974348|Drug|Artesunate mefloquine|Artequin® is an antimalarial drug presented as infant co-formulation of two separate drugs
1499327|NCT02974348|Drug|Dihydroartemisinin piperaquine|Malacur®. is an antimalarial drug presentad as co-formulation of two separate drugs
1499328|NCT02974348|Drug|Paracetamol|Paracetamol, is an antipyretic drug, presented as tablets or syrup in infants formulation
1499329|NCT02974348|Drug|Amoxicillin|Amoxicillin is an antibiotic with no reported activity on plasmodium
1499330|NCT02974348|Drug|Quinine|quinine sulphate is an antimalaria drug administered as a second line or rescue drug
1499331|NCT02974335|Behavioral|Interviews with Stakeholders|The information gained from stakeholders will be applied in an iterative process to develop a best-practice approach to screening patients, and to build the EHR tools (CDEs and CDS) that will be further tailored and tested in Phase 2, and then implemented in one clinic in Phase 3.
1499332|NCT02974322|Drug|GED-0301|GED-0301
1499333|NCT02974322|Drug|Placebo|Placebo
1499334|NCT02974309|Behavioral|Sleep Extension|All youth in this condition are asked to extend their sleep to 10 hours or at least one hour, whichever is longer
1499335|NCT02974309|Behavioral|Routine|All youth in this condition are asked to follow the routines set by their clinical care team.
1499336|NCT02974296|Device|transcranial magnetic stimulation|non invasive brain stimulation approach
1499337|NCT02974283|Other|Normobaric oxygen therapy|"In this study, it is simple to administer via oxygen storage facemask at flow rates of 10 L/min for 4 hours. This therapy start should within 1 hour after diagnosed ischemic stroke and uninterrupted during other treatments including r-tPA thrombolytic therapy and standard clinical treatment. .
Other Names:"
1499338|NCT02974270|Drug|Leuprolide|
1499339|NCT02974257|Drug|Thiamine|Thiamine 500mg IV twice daily for 2 days
1499340|NCT02974257|Other|placebo|100mL normal saline IV every 12 hours for 2 days
1499341|NCT02974244|Drug|exenatide once weekly|exenatide treatment in the customary clinical care in the USA
1499342|NCT02974244|Drug|basal insulin|basal insulin treatment in the customary clinical care in USA
1499343|NCT02974231|Radiation|Intensity-modulated radiation therapy|
1499344|NCT02974205|Procedure|Jack brace|Rehabilitation after acute isolated PCL rupture with orthosis
1499345|NCT02974205|Device|Rehabilitation|Rehabilitation after acute isolated PCL rupture without orthosis
1499346|NCT02974205|Device|össur brace|Rehabilitation after acute isolated PCL rupture
1499347|NCT02974192|Other|Neopterin|Neopterin will be measured by using standard laboratory methods on the first day of admission.
1499348|NCT02974179|Biological|Subjects from Study AG-CLI-0206 who received AMG0001|Subjects from Study AG-CLI-0206 who received the study product AMG0001
1499349|NCT02974166|Other|Conventional Group|Rigid occlusal splints and medication (Ibuprofen and Cyclobenzaprine Hydrochloride) were made and prescribed under the dentist professor supervision. Likewise, speech therapists performed assessments, measurements, massages, stretches and therapeutic exercises for head, neck and mouth regions.
1499350|NCT02974166|Other|Osteopathic Group|Same assistance of Conventional Group, cited above, plus the osteopathic care during 20 to 30 minutes once a week during four weeks. The osteopathic treatment consisted in an individualized assessment of mobility restrictions of myofascial tissues and joints and the application of smooth techniques such myofascial release, membranous strain and counterstrain, muscle energy, cranial and high velocity and low amplitude.
1499351|NCT02974166|Drug|Ibuprofen|The medication was prescribed by the dentist as nonsteroidal anti-inflammatory drug if necessary.
1499352|NCT02974166|Drug|Cyclobenzaprine Hydrochloride|The medication was prescribed by the dentist as muscle relaxer if necessary.
1499353|NCT02974153|Biological|ALD403 (Eptinezumab)|
1499354|NCT02974153|Biological|Placebo|
1499355|NCT02974140|Device|Cataract Refractive Suite (CRS)|Configuration consisting of Verion™ Image Guided System, LenSx® Laser and ORA™ System with VerifEye+™ (with or without VerifEye Lynk), combined for use in surgical pre-op planning and during cataract surgery
1499356|NCT02974140|Procedure|Standard manual technique|Standard biometry for intra-ocular lens (IOL) calculation and cataract removal using phacoemulsification technique
1499357|NCT02974127|Radiation|Radiotherapy|Multisession radiosurgery
1501752|NCT02956590|Drug|Pitavastatin|Statin
1499362|NCT02974088|Device|Neem-based lotion plus louse comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by systematic combing using a head louse detection and removal comb
1499363|NCT02974088|Device|Neem-based lotion plus grooming comb|Neem-based conditioning lotion was applied to washed and towel dried hair followed by combing through using a regular grooming comb
1499364|NCT02974075|Procedure|Salvage lymph node dissection|Open pelvic surgery to dissect pelvic lymph nodes. The landmarks for dissection are: 1. Inferior mesenteric artery 2. Ilioinguinal nerve 3. Inguinal ligament 4. Dorsal pelvic floor 5. Urinary bladder
1499365|NCT02974062|Other|Lumbar stabilization exercise|Participants were trained using lumbar stabilization exercise based on their initial lumbar stability level. They were received a 30-minute exercise for 1 session in this study.
1499366|NCT02974049|Drug|Albendazole|"Subjects in Arms 1, 2, and 4 will receive 400mg of Albendazole
Subjects in Arm 3 will receive 800mg of Albendazole"
1499367|NCT02974049|Drug|Ivermectin|Subjects in Arms 1 and 4 will receive 200mg/kg body weight
1499368|NCT02974049|Drug|Diethylcarbamazine|Participants in Arm 4 will receive 6mg/kg of Diethylcarbamazine per body weight
1499371|NCT02974010|Drug|NRX-101 Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
1499372|NCT02974010|Drug|Placebo + Lurasidone Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
1499373|NCT02974010|Drug|Placebo Oral Capsule|Prospective Randomized Factorial Design Study as per arm/group descriptions
1499374|NCT02973997|Other|Laboratory Biomarker Analysis|Correlative studies
1499375|NCT02973997|Drug|Lenvatinib|Given PO
1499376|NCT02973997|Biological|Pembrolizumab|Given IV
1499377|NCT02973958|Drug|Bupivacaine|See active comparator description
1499378|NCT02973958|Drug|Sevoflurane|See active comparator description
1499379|NCT02973958|Drug|Acetaminophen|See active comparator description
1499380|NCT02973958|Drug|Ibuprofen|See active comparator description
1499381|NCT02973958|Drug|Ketorolac|See experimental arm description
1499382|NCT02973945|Device|High Flow Nasal Cannula|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the intervention arm will receive oxygen trough High Flow Nasal Cannula (HFNC) at 50 lpm and 40% of oxygen.
The aerobic capacity training plan will be conducted three times a week over 24 sessions."
1499383|NCT02973945|Device|The Venturi Mask|"During the pulmonary rehabilitation program, patients will train the aerobic capacity on a treadmill. Patients in the control arm will receive oxygen trough The Venturi Mask (VM) at 40% of oxygen.
The aerobic capacity training plan will be conducted three times a week over 24 sessions."
1499384|NCT02973932|Behavioral|Cognitive-bahavioral psychotherapy|
1499385|NCT02973919|Behavioral|Eye Movement Desensitization and Reprocessing Therapy|In 1989, Shapiro discovered that while talking about negative life events or thoughts, rhythmic eye movements on a horizontal axis can alleviate the associated vividness and burden (Shapiro, 1989). She established the psychodynamic-behavioral Eye Movement Desensitization and Reprocessing (EMDR) Therapy, which includes the induction of rhythmic eye movements as a central feature. EMDR is regarded as an efficient treatment tool. Several times it has also been successfully applied in the field of specific phobias (de Jongh, ten Broeke, & Renssen, 1999; de Jongh, Holmshaw, Carswell, & van Wijk, 2011; Lapsekili & Yelboga, 2014; Muris, Merckelbach, van Haaften, & Mayer, 1997) and there is a standard protocol for using EMDR on specific fears and phobias (de Jongh, 2015).
1499386|NCT02973919|Behavioral|Virtual Reality Exposure Therapy|Exposure to fear-evoking stimuli is conducted more often in virtual environments using simulators or similar computer-technologies (Virtual Reality Exposure Therapy, VRET). One great advantage of using VR-technologies is that it is possible to create an environment which is highly controllable by its creators. Feared stimuli or scenarios can be varied on individual purposes and presented several times. This facili- tates the practice of exposure-based treatments especially for situations or places diffi- cult to access or requiring a considerable amount of time and/or money (e.g. being in war zones or a passenger on a flight), where in vivo exposures have often not been con- ducted or only in a limited manner (Mühlberger & Pauli, 2011).
1499387|NCT02973906|Other|ADAPT Self Directed web|In the self-directed web-only ADAPT condition, participants have access to the full ADAPT website (10 modules, online discussion forum
1499388|NCT02973906|Other|ADAPT individualized web-facilitated|This condition comprises access to the full ADAPT web program as described above, with augmentation of individual facilitator web support (i.e. the facilitator connects via Google Hangout). Facilitators meet with families at a mutually convenient time weekly (10-14 weeks, approximately 3 sessions per month).
1499389|NCT02973906|Other|Group-based ADAPT|Groups will meet weekly for 120 minutes, at a time convenient to participants (usually early evening). Groups cover core ADAPT/PMTO topics:
1499390|NCT02973893|Biological|Placebo|Placebo
1499391|NCT02973893|Biological|VF001-DP LD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
1499392|NCT02973893|Biological|VF001-DP HD|VF001-DP contains parts of normal vitronectin and Insulin-like growth factor 1 (IGF-I) combined in a single protein.
1499393|NCT02973880|Drug|NETILDEX™ ophthalmic gel|
1499394|NCT02973880|Drug|NETILDEX™ eye drops solution|
1499395|NCT02973841|Device|Sono-ease device|insertion of US guided IJV using sono-ease device
1499396|NCT02973828|Procedure|Imaging|This is an observational study only, with no interventions. Volunteers will undergo MRI imaging on the MR Linac, however this will not affect, change or initiate any intervention, or change to their care path.
1499397|NCT02973815|Behavioral|NU-HOME Intervention|The NU-HOME family intervention consists of group sessions, individual goal setting calls and online materials to support the sessions. The intervention focuses on promoting healthful family meals where parents and children cook and eat together, healthful home food and physical activity environments, and being active together as a family.
1501753|NCT02956590|Drug|Placebo|Placebo
1499398|NCT02973802|Biological|ATX-GD-59|Disease specific immune modulating treatment for Graves Disease
1499401|NCT02973776|Drug|LEO 90100 aerosol foam|
1499402|NCT02973776|Drug|Dermoval®/Dermovate®|
1499403|NCT02973776|Drug|Diprosone|
1499404|NCT02973776|Drug|Elocon|
1499405|NCT02973776|Drug|Locoid|
1499406|NCT02973776|Other|LEO 90100 foam vehicle|
1499407|NCT02973763|Drug|Alflutinib|
1499408|NCT02973750|Procedure|Baseline Biopsy|Baseline biopsy (and ascites fluid sampling if applicable). This is done during the normal work-up procedures.
1499409|NCT02973750|Procedure|Tissue Collection|Tissue collection during debulking surgery.
1499410|NCT02973750|Procedure|Blood Draws|Blood samples for paclitaxel and carboplatin plasma levels will be collected in the study. Paclitaxel will be measured on cycle 1 day 1 at predose and then at the end of the infusion, followed by 1, 2, 4, 8 hours after the end of infusion, then on cycle 1 day 2 at 24 hours after the end of infusion. Carboplatin will be sampled for on cycle 1 day 1 at predose and then at the end of the infusion, followed by 0.5, 1.5, 3.5, 7.5 hours after the end of infusion, then on cycle 1 day 2 at 23.5 hours after the end of infusion.
1499411|NCT02973737|Drug|pyrotinib|400 mg once daily
1499412|NCT02973737|Drug|placebo|400 mg once daily
1499413|NCT02973737|Drug|Capecitabine|1000 mg/m2 per day on day 1 through 14, every 21 days.
1499414|NCT02973724|Drug|Remifentanil|The concentration of remifentanil was determined by biased-coin up and down design, starting from 1.0 ng/ml (0.4 ng/ml as a step size)
1499415|NCT02973724|Drug|Propofol anesthesia|Anesthesia was induced with propofol target-controlled infusion at an effect-site concentration of 5.0 μg/ml.
1499416|NCT02973711|Drug|Nilotinib|Nilotinib 300 mg BID
1499417|NCT02973711|Drug|Ruxolitinib|Ruxolitinib, 10, 15 or 20mg BID
1499418|NCT02973698|Other|chin-down posture maneuver|it was performed the training of Chin-down postural maneuver with saliva and water. Besides, the subjects received instructions regarding feeding.
1499419|NCT02973698|Other|Orientations about swallowing|The instructions about feeding were performed. The individuals received all the instructions on a written document.
1499420|NCT02973698|Other|Control|No intervention will do
2002071|NCT02549898|Other|BBI-MRI|Black blood MRI scans will be performed in order to asses changes in vessel wall thickness due to possible vascular inflammation associated with migraine attacks.
2002072|NCT02549534|Procedure|Axon Reflexes|"*Axon reflexes will be evoked in the palmar surface of the right great toe using local skin heating with a 0.33 cm2 heat probe using the following protocol:
Baseline: Heating the skin of the toe for a minimum of 5 minutes at 33*C.
Heat Ramp: Increasing the heat in the heat probe to 42*C at approx. 0.1*C/10 sec.
Skin Heating: Heating the skin of the toe for 30 minutes 42*C.
Heat Ramp: Increasing the heat in the heat probe to 44*C at 0.1*C/10 sec..
Skin Heating: Heating the skin for an additional 5 minutes at 44*C.
The size of the axon reflex during this skin heating protocol will be imaged using Laser Doppler Flowmetry (LDF). In the case that participants develop CIPN on their left side only, the left toe will be substituted."
2002073|NCT02549534|Procedure|Axon Flares|Axon flares will be generated on the palmar surface of the right great toe using the same local skin heating protocol described above, and imaged using a laser speckle contrast imager (LSCI) (also known as full-field laser perfusion imager, or FLPI).
1499425|NCT02973672|Drug|SGM-101|4 days before surgery, SGM-101 will be administered to the patient by intravenous injections.
1499426|NCT02973659|Drug|Oxybutynin|10% oxybutynin gel (one side) Vs placebo aqueous gel (other side) - 2/d application, 1 month
1499427|NCT02973659|Drug|Placebos|
1499428|NCT02973646|Drug|Entecavir or Tenofovir|Patients in nucleos(t)ide analogues treatment for 12 weeks group will receive nucleos(t)ide analogs therapy (Entecavir tablet 0.5mg/d or Tenofovir tablet 300mg/d) from Week 25th to 36th.
1499429|NCT02973646|Drug|Peginterferon Alfa-2B|
1499430|NCT02973633|Device|Diffusion Tensor MRI (DTI)|Diffusion Tensor MRI (DTI) measures the diffusion of water in the heart, which allows the orientation of the muscle fibers in the heart to be determined.
1499431|NCT02973620|Drug|Levosimendan|levosimendan infusion started at 0.1 mcg/kg/min for 6-12 hours, increased to 0.2 mcg/kg/min for 24-36 hours
1499432|NCT02973607|Procedure|Nephrectomy|This is observational in design.
1499433|NCT02973594|Drug|Ivabradine|
1499434|NCT02973594|Drug|Placebo|
1499435|NCT02973581|Drug|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram
1499436|NCT02973581|Drug|Acetaminophen|in group P patients will receive pre-emptive analgesia using intravenous infusion of acetaminophen in a single dose of 10-15 mg per kg of body weight
1499437|NCT02973581|Drug|0,5 % bupivacaine with of 2% lidocaine|in group PBB patients in group BF will receive regional peribulbar block using a solution of 0,5% bupivacaine (2,5 ml) with 2% lidocaine (2,5 ml)
1499438|NCT02973581|Drug|Proxymetacaine|in group T patients will receive topical analgesia using a solution of 0,5% Alcaine
1499439|NCT02973568|Other|Observational Study|
1499440|NCT02973555|Other|PRP injection|autologous intrauterine infusion of PRP
1499441|NCT02973542|Drug|Ethosuximide|
1499442|NCT02973542|Other|Placebo|
1499443|NCT02973529|Device|Absorb|Randomization to implantation of Absorb BVS in bifurcation lesion
1499444|NCT02973529|Device|Desolve|Randomization to implantation of Desolve BRS in bifurcation lesion
1499445|NCT02973516|Drug|P03277|P03277 will be administered at 0.1 mmol/kg BW (corresponding to 0.2 mL/kg BW) by intravenous (IV) bolus injection at 2 mL/s rate without dilution, followed by a 0.9% saline flush.
1499446|NCT02973503|Drug|Elbasvir/Grazoprevir Fixed Dose Combination|Evaluate the efficacy of of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, with non- severe fibrosis as measured by the proportion of subjects with sustained viral response 12 weeks after cessation of treatment (SVR 12).
1499447|NCT02973490|Device|Transanal Tube Drainage|Using transanal tube drainage after colorectal ESD
1499448|NCT02973477|Drug|Dapagliflozin|Dapagliflozin is a sodium glucose transporter-2 (SGLT-2) inhibitor, a new class of glucose lowering agent that reduces hyperglycemia in patients with T2D by reducing renal glucose reabsorption.
1499449|NCT02973477|Drug|Glimepiride|Glimepiride is a sulfonylurea agent that reduces hyperglycemia in patients with T2D by stimulating insulin release from the pancreatic beta cells and reduction of glucose output from the liver.
1499450|NCT02973464|Drug|Valganciclovir|Oral at a dose of 450mg or 900mg per day begin within 10 days till to Day 100 posttransplant
1499451|NCT02973464|Drug|Ganciclovir|intravenous GCV 5mg/kg/d after renal transplantation for the first 14 days, and then oral GCV 1g 3 times daily till to Day 100 posttransplant.
1499452|NCT02973451|Drug|Laparoscopic Guided Bupivacaine|Bupivacaine Laparoscopic GuidedTransversus Abdominis Plane Block
1499453|NCT02973451|Drug|local Bupivacaine|Bupivacaine Trocar Site Infiltration
1499454|NCT02973438|Device|Intermittent Hypoxia (IH)|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute hypoxic intervals (FIO2 = 0.09-0.12) with 3-minute normoxic intervals (FIO2 = 0.21). During hypoxic intervals, oxygen concentration may be adjusted to maintain participants SpO2 levels between 75-90%.
1499455|NCT02973438|Device|SHAM|Administered over a period of 5 consecutive days involving daily, hour long sessions of alternating 6-minute normoxic intervals (FIO2 = 0.21) with 3-minute normoxic intervals (FIO2 = 0.21).
1499456|NCT02973425|Behavioral|NRT Only|NRT sampling & health assessments without feedback
1499457|NCT02973425|Behavioral|NRT & Suite of mHealth motivational tools and mini-games.|NRT sampling experience & Suite of mHealth motivational tools and mini-games.
1499458|NCT02973399|Drug|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
1499459|NCT02973386|Drug|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT.
1499460|NCT02973386|Drug|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1 and day 22) during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles at 4 weeks later after RT.
1499461|NCT02973373|Device|MRI with High-frequency non-invasive ventilation|MRI performed under high-frequency non-invasive ventilation
1499462|NCT02973373|Other|MRI without High-frequency non-invasive ventilation|MRI performed without High-frequency non-invasive ventilation
1499463|NCT02973360|Drug|Docosahexaenoic Acid|Oral Capsule
1499464|NCT02973360|Drug|Placebo|Oral Capsule
1499465|NCT02973347|Other|Intermittent enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube less than 30 mins.
1499466|NCT02973347|Other|Continuous enteral feeding|The intervention is the schedule under which ventilated children are offered enteral feeding attempts: feed administered via the nasogastric tube for 24 hours.
1499467|NCT02973334|Other|Ingestion of artificially-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing non nutritive sweeteners (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
1499468|NCT02973334|Other|Ingestion of sugar-sweetened beverages|From t=60 to the end of the metabolic test, volunteers will ingest 7 beverages containing sugar (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
1499469|NCT02973334|Other|Ingestion of water|From t=60 to the end of the metabolic test, volunteers will ingest 7 water beverages (25 mL / beverage) every 15 minutes after 10-sec mouth rinsing.
2002074|NCT02549534|Procedure|Self-Reported Signs & Symptoms of CIPN|Self-reported signs & symptoms of CIPN such as the presence and location of (1) tingling, (2) numbness, and (3) neuropathic pain, along with information about (4) deficits in vibration thresholds, and (5) loss of deep tendon reflexes will be assessed at each study visit using the 5-item, modified Total Neuropathy Score (mTNS).
2002075|NCT02545686|Behavioral|Chest wall movement assessment without CPAP|While subject is breathing normally, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
1499474|NCT02973308|Other|Observer|Observer A and observer B
1499475|NCT02973295|Drug|Silymarin|Capsules contains 100 mg of silymarin
1499476|NCT02973295|Other|Placebo Oral Capsule|Capsule will be identical in shape, size and color, packed in the same way like verum
1499477|NCT02973282|Other|Recording of Infants and Children's Cough Sounds|Smartphone recordings of the cough sounds of infants and children presenting to a participating site with signs or symptoms of respiratory disease
1499478|NCT02973269|Biological|Botulinum Toxins, Type A|Intramuscular injection
1499479|NCT02973269|Biological|Placebo|Intramuscular injection
1499480|NCT02973243|Device|Automatic RR Measurement|Different newly developed respiration rate sensors are applied at the bedside during the intervention phase which send data to the IntelliVue Guardian System.
1499481|NCT02973230|Other|Dosage of VEGF serum concentration|Blood samples were collected by peripheral venous puncture before treatment; a total 15 mL of blood was withdrawn (2 mL for β-hCG, 3mL for progesterone, 10 mL for VEGF determinations). Blood samples for VEGF were collected in siliconized tubes and were allowed to coagulate at room temperature for 2-6 hours.
1499482|NCT02973217|Device|Immunostimulating Interstitial Laser Thermotherapy|
1499483|NCT02973204|Drug|Sorafenib|
1499484|NCT02973204|Procedure|Radiofrequency ablation (RFA) or surgery|Intended curative surgery or RFA
1499485|NCT02973204|Drug|Everolimus|
1499486|NCT02973204|Drug|Lanreotide|Or other somatostatin analogues (SSTA), eg. Sandostatin
1499487|NCT02973191|Drug|JCAR015|
1499532|NCT02972814|Device|Laboratory based troponin test|acquisition of blood troponin level by Roche Cobas E 603
1499533|NCT02972814|Device|Point of care based troponin test 1|acquisition of blood troponin level by Radiometer EQT 90 Flex
1499534|NCT02972814|Device|Point of care based troponin test 2|acquisition of blood troponin level by Philips Minicare I-20
1499489|NCT02973152|Procedure|Thyroplasty|This medialisation/augmentation technique is a static technique, performed under local anaesthesia that aims to improve the positioning of the paralysed vocal fold. It uses a silastic implant readily available in different sizes according to size of larynx and gender of the patient. The correct size can be determined intraoperatively by using a measuring device while listening and visualising the larynx with flexible fiberoptic scope simultaneously.
1499490|NCT02973152|Procedure|Reinnervation|For laryngeal reinnervation, ansa cervicalis to recurrent laryngeal nerve repair technique will be used. In this technique, the functioning ansa cervicalis nerve that overlies the internal jugular vein and the distal stump of injured recurrent laryngeal nerve (RLN) will be identified and anastomosed without tension (Crumley RL. Teflon versus thyroplasty versus nerve transfer: a comparison. The Annals of otology, rhinology, and laryngology. 1990;99(10 Pt 1):759-63).
1499491|NCT02973139|Other|Medical Thoracoscopy|Medical thoracoscopy will be performed as per standard protocols.
1499492|NCT02973139|Other|Fibrinolytic Group|Patients will receive intrapleural combination of TPA (10 mg) and DNAse (5 mg). Therapy will be given twice daily for a maximum of 6 doses
1499493|NCT02973126|Procedure|FFRct and SPECT|enable the comparison of diagnostic performance of FFRct and SPECT in subjects with suspected stable CAD after abnormal SPECT imaging who have no contraindications to coronary computed tomography angiography (CCTA).
1499494|NCT02973113|Biological|EB-VST Cells|EB-VST cells in an expected volume of 10-20cc will be given by intravenous injection over 2-10 minutes through either a peripheral or a central line.
1499495|NCT02973113|Biological|Nivolumab|Nivolumab 3mg/kg (max dose: 240 mg) will be administered as an intravenous infusion over 60 minutes.
1499496|NCT02973100|Drug|Dulaglutide|Administered SC
1499497|NCT02973100|Drug|Placebo|Administered SC
1499500|NCT02973074|Dietary Supplement|OLEOvital|2sachets with 30mg iron per day for a 4 weeks period
1499501|NCT02973061|Other|Questionnaires|All participants families will fulfill a periodic questionnaire regarding attention, behaviour.
1499502|NCT02973048|Drug|Hyperbaric bupivacaine|The dose of 10 mg of hyperbaric bupivacaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
1499503|NCT02973048|Drug|Hyperbaric prilocaine|The dose of 50 mg of hyperbaric prilocaine will be administered to one of two groups intrathecally and the quality of sensory and motor block as well as side-effects will be observed at precise time points.
1499504|NCT02973035|Drug|Amlodipine|
1499505|NCT02973035|Drug|Valsartan|
1499506|NCT02973022|Other|CC&S|Three educational modules -- Cancer Basics, Cancer Prevention, and Cancer Screening -- intended to increase cancer awareness. The full CC&S curriculum is currently available at http://chdi.wisc.edu/cancer-clear-simple-curriculum-rural-adaptation.
1499507|NCT02972996|Other|Blueberry|22 g freeze-dried whole blueberry powder
1499508|NCT02972996|Other|Placebo|22 g placebo blueberry powder
1499509|NCT02972983|Drug|Daptomycin|Adjuvant therapy for up to five days
1499510|NCT02972983|Other|Placebo|Placebo
1499511|NCT02972970|Device|Aveera|Subjects will use the 3D crafted CPAP mask. All subjects will receive a mask to use
1499512|NCT02972957|Biological|Nasovac-S|one of 0.5ml intranasal dose of trivalent live attenuated vaccine (LAIV)
1499513|NCT02972957|Drug|Azithromycin|a single dose of Azithromycin (liquid formulation - Zithromax) at 20mg/Kg (up to a maximum adult dose 1g) to be given to a subset of subjects
1499514|NCT02972944|Procedure|Laparoscopic cholecystectomy|
1499515|NCT02972944|Procedure|Non-operative treatment|
1499516|NCT02972918|Drug|Levosimendan|24h preoperative infusion of levosimendan (0,1 mcg/Kg/min)
1499517|NCT02972905|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister and 500 mcg per blister.
1499518|NCT02972905|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose
1499519|NCT02971800|Drug|sodium fluorescein injection 10%|
1499520|NCT02971787|Dietary Supplement|Probiotics|Day 1-21: 2 capsules per day
1499521|NCT02971787|Dietary Supplement|Salt|Day 8-21: 10 tablets à 600 mg per day
1499522|NCT02972879|Procedure|Therapeutic modalities: Orthotic (Group 1)|participants will be instructed to remove the orthosis only two hours in the morning, two hours in the afternoon and two hours at night to avoid joint stiffness
1499523|NCT02972879|Procedure|Therapeutic modalities: LLLT (Group 2)|"The LLLT parameters are:
LASER 904nm
P: 1.5W/cm²
30mV/cm²
Area 2 cm²
1 Joule por ponto ( in the A1 pulley)"
1499524|NCT02972879|Procedure|Therapeutic modalities: Paraffin (Group 3)|"Paraffin will be heated and maintained at 50 ° C. Participants will immerse their affected hand 10 times in heated paraffin, then they will roll up their affected hand in a towel that they will bring, after 20 minutes timed by a trained professional, the subjects will remove the towel and paraffin glove:"
1499525|NCT02972879|Procedure|Corticosteroid injection (Group 4)|The injection solution is composed of 1 ml of betamethasone and 1 ml of 2% lidocaine.This group may repeat the procedure in two weeks if they report that there was no improvement of the triggering or pain.
1499526|NCT02972866|Drug|Budesonide|Suspention to nasal use, 2 atomization in each nostril during the morning and at night.
1499527|NCT02972853|Behavioral|Mindfulness Training for Primary Care (MTPC)|"For intervention description see Mindfulness Training for Primary Care (MTPC) in the study MINDFUL-PC: Integrating Mindfulness Into the Patient-Centered Medical Home - A Pilot Study"
1499528|NCT02972840|Drug|Acalabrutinib in combination with bendamustine and rituximab|Acalabrutinib in combination with BR
1499529|NCT02972840|Drug|Placebo in combination with bendamustine and rituximab|Placebo in combination with BR
1499530|NCT02972827|Device|NICOM/FloTrac|Use of noninvasive cardiac output and minimally invasive cardiac output monitors
1499531|NCT02972827|Other|Crystalloid Fluid Challenge|500-1000ml Normal Saline or Plasmalyte intravenous fluid bolus will be given at baseline, and following a positive passive leg raise response as defined by a 10% or greater increase in any of: stroke volume index, cardiac index, or pulse pressure, as measured by the NICOM or FloTrac Monitors.
1499808|NCT02970669|Drug|sacubitril/valsartan (LCZ696)|sacubitril/valsartan tablet taken orally.
1499535|NCT02972801|Procedure|Testicular biopsy|Testicular biopsy is performed to obtain testicular tissue for cryopreservation
1499538|NCT02972775|Other|no interventions. observational study|
1499539|NCT02972762|Drug|Diprivan|anesthesia will be maintained with remifentanil and Diprivan.we use Diprivan close-loop to control the anesthesia depth,and the anesthesia depth will be detected with BIS machine.the usage of remifentanil、ropivacaine、sufentanil and cisatracurium in both arms is no difference.
1499540|NCT02972749|Behavioral|Intervention|Recommendations for lifestyle changes which have shown to reduce IOP. recommendations include: Moderate aerobic exercise, High fiber diet, sleeping with a head elevation and moderating caffeine intake. while continuing prescribed medical therapy.
1499541|NCT02972736|Radiation|Radiation dose expressed as DAP|
1499542|NCT02972723|Drug|Metformin|Oral Metformin 1g bd. (total = 2g per day) for 14 days
1499543|NCT02972710|Other|Supine thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
1499544|NCT02972710|Other|Seated thoracic spine thrust manipulation|The participant will be positioned so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
1499545|NCT02972697|Radiation|11C-acetate ligand|
1499546|NCT02972697|Radiation|FDG ligand|
1499547|NCT02972684|Device|Thrombo-elastometry POC testing|Use of thrombo-elastometry point of care test and algorithm guided predetermined intervention during peri operative haemorrhage
1499548|NCT02972671|Device|MiStent (MT005) Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
1499549|NCT02972671|Device|Xience Coronary Artery Stent|Implantation of a coronary artery stent in an all-comers population, including patients with symptomatic coronary artery disease including patients with chronic stable angina, silent ischemia, and acute coronary syndromes, who qualify for percutaneous coronary interventions
1499551|NCT02972645|Drug|LY3305677|Administered SC
1499552|NCT02972645|Drug|Placebo|Administered SC
1499553|NCT02972632|Drug|Vortioxetine|Vortioxetine tablet
1499554|NCT02972619|Other|Structured Multicomponent Intervention (MCI)|Multicomponent Intervention (MCI) includes 1) algorithm-driven antihypertensive treatment for all hypertensive individuals using fixed-dose combination (FDC) and lipid lowering for high risk hypertensive individuals, 2) motivational conversation for high-risk hypertensive individuals and 3) telephone based follow-ups of all hypertensive individuals by a team of physician supervised nurse, and 4) discounts on FDC antihypertensive medications
1499555|NCT02972593|Biological|Blood and blood products for transfusion|Randomization would not occur until the patient's Hgb dropped below 7 g/dL. If the patient is randomized to the liberal arm, they would be transfused to keep their Hgb >7 g/dL. If the patient is randomized to the conservative arm, they would not be transfused until their Hgb drops below 5.5 g/dL. If the patient's Hgb does not drop below 7.0 g/dL, randomization will not be done.
1499556|NCT02972580|Genetic|Genetic characterization|Longitudinal prospective observational study
1499557|NCT02972567|Dietary Supplement|Lactobacillus spp|9 log10 cfu/capsule. 1 capsule/day for 12 weeks
1499558|NCT02972567|Dietary Supplement|Control|Maltodextrin
1499559|NCT02972554|Drug|Propanolol hydrochloride|We are using 40mg of Propanolol in a single tablet.
1499560|NCT02972554|Other|Placebo|matching active drug
1499561|NCT02972541|Device|Stenting with neoadjuvant chemotherapy|After clinical success of colonic stenting, patients will be given neoadjuvant chemotherapy. Surgery is performed after 3 cycles of mFOLFOX6 or 2 cycles of CapeOx. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 5-9 cycles of mFOLFOX6 or 4-6 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
1499562|NCT02972541|Device|Stenting with immediate Surgery|After clinical success of colonic stenting, patients will undergo surgery 7-14 days later. The choice of surgery performed is up to the individual consultant colorectal surgeon. Patients will receive 8-12 cycles of mFOLFOX6 or 6-8 cycles of CapeoX after surgery. Each cycle of mFOLFOX6 consists of racemic leucovorin 400 mg/m², oxaliplatin 85 mg/m² in a 2-h infusion, bolus fluorouracil 400 mg/m² on day 1, and a 46-h infusion of fluorouracil 2400 mg/m². Each cycle of CapeOx consists of oxaliplatin 130 mg/m2, capecitabine 100 mg/m2 twice daily for 14 days.
1499563|NCT02972528|Biological|Platelet Lysate|Direct injection of allogenic Platelet Lysate
1499564|NCT02972528|Biological|Platelet Poor Plasma|Direct injection of allogenic Platelet Poor Plasma
1499565|NCT02972515|Behavioral|See Me Smoke-Free|See Me Smoke-Free is a multi-behavioral mobile application focusing on increasing smoking cessation, healthy eating, and moderate to intense physical activity. The app tracks the participant's quit date, and eating/physical activity goals. Participants have access to guided imagery audio files that they are instructed to listen to every day for at least 30 days. Participants can earn awards for meeting the study goals.
1499566|NCT02972515|Device|Smart phone|See Me Smoke-Free mHealth app delivered via a smart phone
1499567|NCT02972502|Drug|Metoclopramide|Patients receive 10 mg of intravenous (IV) metoclopramide.
1499568|NCT02972502|Drug|Haloperidol|Patients receive 2.5 mg of IV haloperidol.
1499569|NCT02972502|Other|Normal Saline|All patients receive a 1-liter bolus of normal saline (NS)
1499570|NCT02972502|Drug|Diphenhydramine|All patients receive 25 mg of intravenous (IV) diphenhydramine.
1499648|NCT02971943|Procedure|internal fixation for ankle fractures|The patients with ankle injury underwent internal fixation for ankle fractures and ligament repair. Ankle was observed with X-ray and magnetic resonance imaging.
1499571|NCT02972489|Device|3D OFDI guidance arm|Subjects randomized to 3D-guidance arm will undergo optical frequency domain imaging (OFDI) assessment in the main vessel after re-wiring into the jailed side branch following stent implantation. If the position of the wire is not located in the optimal cell, further attempts to redirect the wire to the optimal cell will be performed, with subsequent OFDI acquisitions to confirm position in 2D and off-line 3D reconstruction. After procedure, OFDI is performed in the main branch.
1499572|NCT02972489|Device|Angio guidance arm|In angiography-guidance group, wire recrossing into the side branch will be performed using conventional fluoroscopic/angiographic guidance. After finishing the procedure, OFDI is performed in the main branch but the results will be blinded to the operators.
1499573|NCT02972476|Drug|Budesonide & formoterol fumarate and Aclidinium bromide|
1499574|NCT02972476|Drug|Fluticasone 500 & salmeterol and Aclidinium bromide|
1499575|NCT02972476|Drug|Fluticasone 250 & salmeterol and Aclidinium bromide|
1499576|NCT02972476|Drug|Aclidinium bromide & formoterol fumarate|
1499577|NCT02972463|Dietary Supplement|Immunoglobulin Y|
1499578|NCT02972463|Other|Placebo|
1499579|NCT02972450|Biological|GTU-MultiHIV B-clade vaccine|
1499580|NCT02972450|Biological|MVA HIV-B HIV vaccine|
1499581|NCT02972450|Biological|Placebo 1: Sodium Chloride|
1499582|NCT02972450|Biological|Placebo 2:S08 buffer|
1499583|NCT02972437|Other|sample taking|throat culture and oral cavity sample
1499584|NCT02972424|Drug|Teriparatide Prefilled Syringe|TPTD 20 mcg
1499585|NCT02972424|Drug|Placebo|Matching placebo as a prefilled syringe with all inactive ingredients
1499586|NCT02972411|Behavioral|Voluntary ventilatory response|Training of the subjects for voluntary increase in the respiratory minute ventilation
1499587|NCT02972411|Drug|Acetazolamide|Acetazolamide 125mg. PO every 12 hours since 24 hours before ascent, until 48 hours at high altitude
1499588|NCT02972398|Drug|N-acetylcysteine|Participants of interventional group receive 1000mg N-acetylcysteine twice daily for 12 weeks.
1499589|NCT02972398|Drug|placebo comparator of N-acetylcysteine|Participants of placebo group receive placebo comparator matching with N-acetylcysteine twice daily for 12 weeks.
1499590|NCT02972385|Procedure|Cheek Swab/ Mouthwash sample|A one time cheek swab or mouthwash sample will be performed.
1499591|NCT02972385|Procedure|Blood Draw|Patients who are receiving a blood draw during their regular clinical appointment will be asked for a blood sample of 15 milliliters. Genomic DNA will be isolated for genotyping and patient plasma samples will also be stored.
1499592|NCT02972372|Procedure|CRT|"Drug: Capecitabine(Aibin) capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
Other Names:
Aibin Drug: Oxaliplatin(Aiheng) Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
Other Names:
Aiheng cisplatin: 75mg/m2 d1，29 or d1, 29, 57, 85. 5-Fu：750mg/m2 CIV24h d1-4，d29-32 or d1-4，d29-32, d57-60, d85-88.
Radiation: Radiotherapy concurrent radiotherapy：IMRT radiotherapy 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity"
1499593|NCT02972372|Procedure|surgery|The patients randomized to receive either standard esophagectomy will have the operation performed in an open manner with two-field lymphadenectomy
1499595|NCT02972346|Drug|ACTH|routine treatment plus ACTH 0.4 Unit/kg/day (Maximum 25Unit) for three consecutive days every 4 weeks
1499596|NCT02972333|Drug|AZD9291 80mg oral each day|All eligible patients will have access to AZD9291 regimen through the ASTRIS study as long as they continue to show clinical benefit.
1499597|NCT02972333|Radiation|Radiation therapy|Radiation therapy will be implemented according to investigator's clinical practice.Based on the guidelines provided for the interruption of ADZ9291 with brain radiation therapy, a 7-10 days washout period before radiotherapy and 1 week period after completion of brain radiothearpy before re-starting AZD9291.
1499598|NCT02972320|Drug|temozolomide|temozolomide maintain therapeutic
1499599|NCT02972307|Other|wheelchair skills|the extent to which caregivers enhance the wheelchair skills of powered wheelchair users
1499600|NCT02972294|Drug|Iron Isomaltoside 1000|Iron Isomaltoside 1000 will be use. Blinding procedure will be put in place for the administration of the treatment
1499601|NCT02972294|Drug|Tranexamic Acid|Tranexamic acid will be use.
1499602|NCT02972294|Drug|Placebos iron isomaltoside 1000|placebo of Iron Isomaltoside 1000 correspond to a saline solution. Blinding procedure will be put in place for the administration of this treatment
1499603|NCT02972294|Drug|Placebos tranexamic acid|placebo of tranexamic acid correspond to a saline solution.
1499604|NCT02972281|Biological|Immunological diagnosis tests|(Non exhaustive list): hemogram, IgG, A, M, IgG subclasses, complement, vaccinal response to protein and polysaccharide antigens, ...
1499605|NCT02972268|Drug|Tamsulosin 0.2mg + Solifenacin 5mg|Tamsulosin 0.2mg + Solifenacin 5mg for 12wks
1499606|NCT02972268|Drug|Tamsulosin 0.2mg + Placebo(Solifenacin)|Tamsulosin 0.2mg + Placebo(Solifenacin) for 12wks
1499607|NCT02972255|Drug|RO7079901|RO7079901 will be administered as per schedule described in individual arm.
1499608|NCT02972255|Drug|Meropenem|Meropenem will be administered as per schedule described in individual arm.
1499609|NCT02972255|Other|RO7049389 Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
1499610|NCT02972255|Other|Meropenem Placebo|Placebo matching to meropenem will be administered as per schedule described in individual arm.
1499611|NCT02972242|Radiation|Field of View|Non-Contrast CT Scan for coronary calcium assessment prior to CT coronary angiography
1499612|NCT02972229|Radiation|10x(3-5) Gy IMRT|10x(3-5) Gy IMRT on partial vertebral body for spinal metastases
1499613|NCT02972229|Radiation|10x3 Gy IMRT|10x3 Gy IMRT on whole vertebral body for spinal metastases
1499614|NCT02972216|Drug|Nolbaxol|
1499615|NCT02972216|Drug|Taxotere|
1499616|NCT02972216|Drug|cisplatin|
1499650|NCT02971917|Radiation|Chest x-ray image acquisition|Obtain a digital X-ray chest image of the patient
1499651|NCT02971917|Radiation|Creation of TRUVIEW ART applied image|"Application of TRUVIEW ART to the original chest x-ray image to create a new set of TRUVIEW ART applied image.
Outcome: 2 versions of chest image
Original Chest X-ray (w/o TRUVIEW ART)
TRUVIEW ART applied image"
1499617|NCT02972203|Behavioral|Mindfulness Training for Primary Care|• MPTC is a primary care adaptation that includes core common Mindfulness-Based Intervention (MBI) elements. MTPC is a referral-based, insurance-reimbursable 8-week group psychotherapy delivered primarily by Patient-Centered Medical Home-integrated behavioral clinicians. MTPC groups are 2 hours long for 8 weeks, with a 7-hour day of silent group practice on a weekend. MTPC also emphasizes psychoeducational skills for self-regulation including a collaborative primary care provider (PCP) action-planning appointment during week 6.
1499618|NCT02972203|Behavioral|Mindfulness Intro. +resources +waitlist|Control arm: Participants receive a 60-minute introduction to mindfulness group plus referral to a list of community mindfulness resources such as private-pay community mindfulness classes, mobile mindfulness applications, books, and online recordings. These participants are added to a 6-month waitlist for a Cambridge Health Alliance mindfulness-based intervention group. All participants are scheduled to meet with their primary care provider during week 6 for a collaborative action planning visit.
1499619|NCT02972190|Procedure|Bilateral decompression with TLIF|Bilateral decompression of neural elements combined with TLIF
1499620|NCT02972190|Procedure|laminectomy with PLIF|Decompression of neural elements using laminectomy combined with PLIF
1499621|NCT02972190|Device|Pedicle screw and interbody cage|Pedicle screw and interbody cage
1499622|NCT02972177|Procedure|Radiofrequency ablation|Transbronchial radiofrequency ablation will be performed under the guidance of navigation bronchoscopy.
1499623|NCT02972177|Procedure|Microwave ablation|Transbronchial microwave ablation will be performed under the guidance of navigation bronchoscopy.
1499624|NCT02972177|Radiation|SBRT|Stereotactic body radiation therapy
1499625|NCT02972164|Behavioral|Weight loss program for school children|"The intervention involves developing social and emotional competences, promotion of healthy lifestyle, use of activity monitoring devices to promote increased activity and enlisting family to maintain weight loss in the long term.
The intervention group receives all program components: 1. Parent information sessions and orientation, 2. Two week intensive weight loss and lifestyle education camp, 3. after school clubs for consolidation (including physical activity and lifestyle education), and 4. wearable sensors and social media modules with parental involvement. Assessed outcomes include pre- and post-measurement at each phase included: weight, height, BMI, waist circumference, blood pressure, physical activity, dietary intakes, self-esteem, and subjective well-being."
1499626|NCT02972151|Drug|Comprehensive treatment of TCM|Subjects were treated with comprehensive treatment of TCM including Oral medicine: 1 dose daily by our hospital pharmacy medicine room Decoction decoction, each agent 200ml, and the 2 ton service. 10 days for a course of treatment, continuous treatment of 3 courses; retention enema with traditional Chinese medicine oral drugs according to different types of concentrated decoction enema, each dose of medicine decocting 2 times, 2 days of external application of Chinese medicine: Chinese medicine enema; break into powder, into the bag, steam for 45 minutes, and so the temperature dropped to appropriate, will be installed a Chinese medicine bag used on patients with lower abdomen for 20 minutes. Above method, a course of treatment for 10 days, continuous treatment of 3 courses.
1499627|NCT02972151|Other|Expectant treatment|Expectant treatment group patients were not treated during the observation period.（3 months after the start of the trial and 1 months after the end of the trial.）From the point of view of medical ethics, the expectant treatment group of patients at the end of the observation period, given the treatment of traditional Chinese medicine treatment group.
1499628|NCT02972125|Drug|Lacosamide (LCM) tablet|Treatment A: Single dose of Lacosamide (LCM) 100 mg tablet
1499629|NCT02972125|Drug|Lacosamide (LCM) dry syrup|Treatment B: Single dose of Lacosamide (LCM) 100 mg given as dry syrup
1499630|NCT02972112|Behavioral|CBT|novel cognitive behavioral protocol for the treatment of tokophobia
1499631|NCT02972112|Other|Sham|standard birth preparation sessions.
1499632|NCT02972099|Device|TcPRF|Transcutaneous Pulsed Radiofrequency is a method that is widely used for control of pain. There are no known complications. In this study a Radiofrequency generator will be used that has a separate outlet for transcutaneous use. It is used in the daily clinical practice in the Pain Center of the Swiss Paraplegic Center.
1499633|NCT02972099|Device|Placebo|In the Placebo Treatment, no current will be delivered. Since no sensations are produced by TcPRF treatment the patients won't recognize the difference.
1499634|NCT02972086|Behavioral|Behavioral Parent Training (BPT)|A specific intervention modality that has been shown to improve key functional outcomes in youth with ADHD.
1499635|NCT02972073|Other|Exercise intervention|Physical therapist will provide exercise for patients with low back pain for 60 minutes per day, 2-3 days per week for the total of 8 weeks.
1499636|NCT02972060|Drug|ODM-201|ODM-201 is a novel, oral, potent nonsteroidal AR inhibitor. ODM 201 will be administered as oral 300-mg tablets. The dose of study drug to be administered is 600 mg (2 x 300-mg tablets) b.i.d. to a daily dose of 1200 mg. It is recommended that ODM-201 be taken with food. Treatment should be initiated within 28 days from randomization.
1499637|NCT02972060|Drug|ADT|"ADT by means of LHRH antagonist for 24 weeks or by LHRH agonist therapy for 24 weeks with 4 weeks of anti-androgen to prevent flare.
This includes leuprolide, goserelin, triptorelin, and degarelix. Beyond week 24, the treatment will be left to the discretion of the treating physician."
1499638|NCT02972047|Behavioral|Diaphragmatic Breathing|Subjects in this are practice diaphragmatic breathing for 30 minutes after each meal.
1499639|NCT02972047|Behavioral|Sham Comparator|Sham therapy (listening to music/watching TV for 30 minutes after each meal
1499640|NCT02972034|Drug|MK-8353|PO capsule
1499641|NCT02972034|Biological|Pembrolizumab|IV infusion
1499642|NCT02972021|Device|High-flow nasal cannula|
1499643|NCT02971995|Device|PET Scan ou TEP-TDM|Performance of the PET/CT using Flurocholine in order to detect the localization of the pathological fixation of the tracer and to determine the place where to take the biopsy
1499644|NCT02971995|Device|mpMRI|Performance of the mpMRI in order to determine the place where to take the biopsy
1499645|NCT02971982|Drug|rituximab /Dexamethasone/cyclophosphamide|rituximab:375mg/m2 ,Dexamethasone 20mg q12h,cyclophosphamide 750mg
1499646|NCT02971982|Drug|Velcade/Dexamethasone/cyclophosphamide|Velcade:1.3mg/m2,Dexamethasone 10mg q12h,cyclophosphamide 750mg
1499647|NCT02971956|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
1499809|NCT02970669|Drug|enalapril|Enalapril tablet taken orally.
1499652|NCT02971917|Radiation|Comparison of TRUVIEW ART image with original image|Comparison of 2 versions of chest image side by side Performance evaluation may consist of detailed categories such as expression of chest structure, visibility level of pulmonary vascular system, etc. For all categories visibility and preference will be scored and each category will be analyzed to point out any statistical difference
1499653|NCT02971904|Other|human milk collection|
1499654|NCT02971891|Drug|Furosemide Topical Gel|
1499655|NCT02971891|Drug|Vehicle Topical Gel|
1499656|NCT02971878|Biological|Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)|Human embryos will be cultured in media that contains 3 antioxidants (Acetyl-L-carnitine (ALC), N-acetyl-L-cysteine (NAC) and α-lipoic acid (ALA)) that can be found in the in vivo Environment.
1499657|NCT02971865|Behavioral|CBT/CMT|Cognitive Behavioral Therapy (CBT - training to change nutritional thoughts and behaviors) and Chiropractic Manipulative Therapy (CMT - High Velocity, low amplitude chiropractic manipulation) were delivered in average total 8 visits in a year. The interventions were comparable in format (individual visit), duration (30 minute visits), frequency (monthly), and number of participants per group (see intervention details). Each intervention was delivered according to a protocol in which all instructors were trained. (Figure 3: Chiropractic/Behavioral health and Primary care Integration Protocol.) Routine care varied with patient complaints at the time of visit.
1499658|NCT02971865|Other|Control group traditional primary care|No change in care usually given
1499659|NCT02971839|Drug|CTP-656, 20 mg (QD)|
1499660|NCT02971839|Drug|CTP-656, 100 mg (QD)|
1499661|NCT02971839|Drug|CTP-656, 150 mg (QD)|
1499662|NCT02971839|Drug|Placebo (QD)|
1499663|NCT02971839|Drug|Kalydeco, 150 mg Tablet (BID; open-label)|
1499664|NCT02971826|Device|REVIVETM SE thrombectomy|Mechanical thrombectomy using the REVIVETM SE device in patient with an ischemic stroke due to an intracranial arterial occlusion
1499665|NCT02971813|Behavioral|Facebook|"Volunteers will be recruited at their intake visit or prior to intake to phase II during inpatient stay.
Participants will be given a baseline BREQ-3 survey and a PNSE scale.
Patients will be randomized to Facebook™ versus comparison groups using a blocked randomization.
The Facebook™ intervention will include peer support, education, provider support and text message prompts when new posts are added.
Educational posts will cover topics that will cover healthcare information.
Provider support will be posted much like the educational posts.
The data collection for this study will take place during the entrance visit for CR or prior to intake while inpatient, at which time the participants will receive the BREQ-3 and PNSE surveys
Post-testing will include a BREQ-3 and PNSE surveys and count of the number of sessions completed in a 3 month period of time."
2002076|NCT02545686|Behavioral|Breath hold assessment without CPAP|While subject is breathing normally, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
2002077|NCT02545686|Procedure|Chest wall movement assessment with CPAP|While subject is breathing via CPAP machine, determine chest wall movement (via RPM waveform) with free breathing, over the course of half an hour.
2002078|NCT02545686|Procedure|Breath hold assessment with CPAP|While subject is breathing via CPAP machine, subject will perform a moderate and a deep inspiratory breath hold. Duration, reproducibility and tolerance of deep inspiratory breath hold will be recorded.
2002079|NCT02544334|Procedure|Dental Plaque|All participants will have dental plaque removed from different tooth surfaces for supragingival.
1499670|NCT02971735|Other|mobile technology of e-learning (M-TEL)|UME students learn the Top 10 emergent ORL-HNS disorders using the M-TEL including the IM module or the PPS module.
1499671|NCT02971722|Drug|JY09|2mg/1ml/bottle
1499672|NCT02971722|Drug|Placebo|1ml/bottle
1499673|NCT02971709|Behavioral|Shade Sail|Shade sails had powder-coated or gout galvanized steel poles and a lighter colored shade cloth to transmit visual light. The shade cloth met Ultraviolet Protection Factor (UPF) ratings to reduce UV under the shade cloth by 94%. The final shade sail designs and sizes were determined with input from parks department staff and complied with all local engineering, building, and planning codes. Shade sails exceeded the minimum safety requirements for strength (for wind and snow load), resistance to light degradation, and UV transmission. The design minimized climbing access points and hazards to adjacent activities.
1499674|NCT02971696|Drug|Sorafenib|Sorafenib will be administrated at a dose of 400 mg twice daily (consisting of two 200-mg tablets).Treatment interruptions and up to two dose reductions (first to 400 mg once daily and then to 400 mg every 2 days) will permitted for drug- related adverse effects. If further dose reductions will required, patients will withdraw from the study
1499675|NCT02971696|Drug|Best Supportive care|Liver Support, pain management
2002080|NCT02544334|Other|Multi-dimensional health assessment questionnaire (MDHAQ)|The RA groups will receive the multi-dimensional health assessment questionnaire (MDHAQ) for physical function, pain, and global status.
2002081|NCT02544334|Other|Saliva Collection|All participants will have a saliva collection.
1499678|NCT02971670|Biological|rTSST-1 Variant Candidate Vaccine|Immunization either according to their former allocated dose (group 4: 3 µg of candidate vaccine or placebo, group 5: 10 µg of candidate vaccine or placebo, group 6: 30 µg of candidate vaccine or placebo) or 3 µg of candidate vaccine or placebo (groups 1 - 3) from Phase I.
1499679|NCT02971644|Device|cobalt alloy pedicle screw implantation|The patients with severe kyphosis deformity undergo cobalt alloy pedicle screw implantation.
1499680|NCT02971631|Other|Exendin 9-39|Complete blockade of action of endogenous GLP-1 by Exendin 9-39. Defined as a physiological study, not a clinical trial as such (as advised by the UK MHRA).
1499681|NCT02971631|Other|Placebo|Infusion of 1% human albumin in normal saline
1499682|NCT02971605|Drug|Psilocybin|25 mg/70 kg Psilocybin
1499683|NCT02971592|Device|MDcure|reception of real working MDcure - device that does apply the electromagnetic field
1499684|NCT02971592|Other|Mock Device|reception of device that does not apply the electromagnetic field
1499685|NCT02971579|Procedure|ERCP|Endoscopic procedure used to manage biliary and pancreatic diseases
1499686|NCT02971553|Device|Upright Resuscitator with PEEP|
1499687|NCT02971553|Device|Upright Resuscitator|
2002082|NCT02538666|Biological|Nivolumab|
2002083|NCT02538666|Biological|Ipilimumab|
2002084|NCT02538666|Other|Placebo|
2002085|NCT02537678|Behavioral|Stepped Care TF-CBT|Stepped Care TF-CBT: Patients will receive Step One: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together),60, 61 scheduled weekly phone meetings (15 minutes), and information from the Stepping Together website and the National Center for Childhood Traumatic Stress website (via web or paper for those without access). Children who do not meet responder status will receive Step Two: 9 (1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks
1499693|NCT02971527|Device|Oste-scan 500A|The investigators will detect the same calcaneus of each subject by experimental ultrasound bone strength device. Experimental ultrasound bone strength device's model number is Oste-scan 500A and report number is Z-Y-2009-2014, Z-E-0530-2014(G).
1499694|NCT02971527|Device|SONOST3000|The investigators will detect the same calcaneus of each subject by control ultrasound bone strength device. Control ultrasound bone strength device's model number is SONOST3000.
1499695|NCT02971514|Behavioral|Flossing before Brushing|
1499696|NCT02971514|Behavioral|Brushing before Flossing|
1499700|NCT02971488|Other|Screening for HCV in PWID and Linkage-To-Care|"Screening, diagnosis and treatment of HCV in PWID, will be part of a harm reduction strategy.
Treatment of HCV infected PWID will be delivered in a multidisciplinary care setting with services to reduce the risk of reinfection and for management of the common social and psychiatric comorbidities in this population."
1499701|NCT02971475|Procedure|extracorporeal shock wave lithotripsy|People in this group would be treated with ESWL only.
1499702|NCT02971475|Procedure|endoscopic drainage of the main pancreatic duct|People in this group would be treated with ESWL followed be endoscopic drainage in 48 hours.
1499703|NCT02971475|Drug|Analgesics|Analgesics administrated include morphine, buprenorphine, pethidine, tramaldol, metamizole and acetylsalicylacid. They will only be administrated as needed.
1499704|NCT02971462|Device|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
1499705|NCT02971449|Device|Amazon Fire Tablet|A generic amazon fire tablet with pre-loaded instructional videos
1499706|NCT02971449|Other|ICCM Traditional Trainins|Standard, Didactic VHT Training intervention as an active comparator
1499707|NCT02971436|Device|FPH Device with SensAwake On + Pressure Support A|FPH Device with SensAwake On + Pressure Support A
1499708|NCT02971436|Device|FPH Device with SensAwake Off + Pressure Support A|FPH Device with SensAwake Off + Pressure Support A
1499709|NCT02971436|Device|FPH Device with SensAwake On + Pressure Support B|FPH Device with SensAwake On + Pressure Support B
1499710|NCT02971436|Device|FPH Device with SensAwake Off + Pressure Support B|FPH Device with SensAwake Off + Pressure Support B
1499711|NCT02971436|Device|Competitor's PAP Released Device + Pressure Support A|Competitor's PAP Released Device + Pressure Support A
1499712|NCT02971436|Device|Competitor's PAP Released Device + Pressure Support B|Competitor's PAP Released Device + Pressure Support B
1499713|NCT02971423|Drug|ETX2514|
1499714|NCT02971423|Drug|Placebo|matching placebo infusion
1499715|NCT02971423|Drug|Sulbactam|
1499716|NCT02971423|Drug|Imipenem/Cilastatin|
1499717|NCT02971410|Other|Laboratory Biomarker Analysis|Correlative studies
1499718|NCT02971410|Other|Quality-of-Life Assessment|Ancillary studies
1499719|NCT02971410|Drug|Simvastatin|Given PO
1499720|NCT02971397|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
1499721|NCT02971397|Drug|Cytarabine|Given IV
1499722|NCT02971397|Drug|Daunorubicin Hydrochloride|Given IV
1499723|NCT02971397|Other|Laboratory Biomarker Analysis|Correlative studies
1499724|NCT02971384|Drug|Echinaforce|
1499725|NCT02971371|Device|Lokomat|"Both the groups performed 40 45min Lokomat sessions, five times a week, between 9am and 11am. The RAGTand VR group received a visual feedback showing a VR run game where the patient had to collect or avoid objects, to motivate him/her to walk actively. Each avatar's leg movement corresponded to that performed by the patient. On the other hand, the RAGT without VR group was not provided an avatar, and a smile indicating the goodness of each leg movement. The biofeedback of the Lokomat gait orthosis is based on the interaction torques between the participant and the orthosis"
1499726|NCT02971358|Procedure|Radical prostatectomy|Standard radical prostatectomy with extended lymph node dissection is performed.
1499727|NCT02971345|Procedure|Stent and Iodine-125 seed strand implantation|The patent second-order branch of the intrahepatic portal vein was punctured with a 22-gauge Chiba needle under ultrasound guidance.Stent and Iodine-125 seed strand are implanted by two 0.035-inch,150-cm-long wire.
1499728|NCT02971345|Device|Stent|Bare stent should be placed through a 7-F, 23-cm-long sheath over the wire.
1499729|NCT02971345|Device|Iodine-125 seed|The number of Iodine-125 seeds planned to be implanted was calculated by the following formula: N = length of obstructed main portal vein (mm)/4.5 + 4. These seeds were arranged linearly and sealed into a 4-F catheter continuously to construct a Iodine-125 seed strand.
1499730|NCT02971345|Drug|Epirubicin|Epirubicin is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: Epirubicin 30-60 mg per patient,depending on the situation of the patient.
1499731|NCT02971345|Drug|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
1499732|NCT02971345|Other|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
1499762|NCT02971098|Procedure|Reduced activity|Participants will reduced their physical activity level to approximately 2000 steps or 75% of their normal activity levels.
1499763|NCT02971085|Procedure|Active surveillance|Active surveillance cohorts are routinely performed the systematic biopsy ≥ 12 cores by TRUS-guided or MR-TRUS fusion according to the protocol based by time path as 1, 2, 4, 7, 10 years and subsequently every 5 years following initial TRUS biopsy.
1499764|NCT02971072|Procedure|Subacromial injection|A subacromial injection consisting up 6 cc 0.5% Marcaine with Epinephrine and 1 cc DepoMedrol will be administered.
1499765|NCT02971072|Other|Physical Therapy|A standardized six-week exercise protocol supervised by a physical therapist
1499733|NCT02971332|Procedure|Stapled Transanal Rectal Resection|"The prolapsed tissue is pulled out through the CAD using e gauze pad and Allis forceps; this allows us to identify the extent of the prolapse to be resected. Four to five parachute stitches are then apposed circumferentially, like parachute cords, at the apex of the prolapse, in order to control the tissue during resection. The prolapse is then opened longitudinally at 3 o'clock with the electric scalpel between two Kocher clamps. Two traction stitches are applied at the deep vertex of the prolapse, one for each Kocher apex.
The longitudinal opening then allows the surgeon to begin circumferential resection of the rectum by pulling on the parachute stitches. This maneuver is performed counterclockwise using an average of 4-6 recharges, with care to always place the stapler at the base of the prolapse. The resected specimen was always inspected before the end of the procedure."
1499734|NCT02971319|Device|Tc-99M-Tetrofosmin SPECT|
1499735|NCT02971319|Device|F-18 FDG PET|
1499736|NCT02971306|Drug|standard medical therapy|Standard medical therapy involves primary treatment with pentoxifylline at a dose of 400 mg three times a day and normal hospital nutrition (1800 to 2000 kcal per day). Diuretics, sodium restriction and albumin for treatment of ascites or fresh frozen plasma for coagulopathy or antibiotics for any focus of infection as spontaneous bacterial peritonitis (SBP), pneumonia, cellulitis, and urinary tract infection as indicated.
1499737|NCT02971306|Drug|G-CSF|G-CSF- 5μg/Kg s.c every 12 hours for 5 consecutive days
1499738|NCT02971306|Drug|n-Acetylcysteine|n-Acetylcysteine at 150, 50, and 100 mg/kg in 250, 500, and 1000 ml of 5% glucose solution over 30 minutes, 4 hours, and 16 hours, respectively; days 2 through 5: 100 mg/kg/day in 1000 ml of 5% glucose solution
1499739|NCT02971293|Drug|AZD8871 100 µg|The subjects will receive one dose of AZD8871 100 µg single dose DPI.
1499740|NCT02971293|Drug|AZD8871 600 µg|The subjects will receive AZD8871, 600 µg single dose DPI.
1499741|NCT02971293|Drug|Placebo|The subject will receive Placebo single dose DPI.
1499742|NCT02971267|Other|Observational|None, observational only
1499743|NCT02971254|Drug|Sevoflurane|
1499744|NCT02971254|Drug|Desflurane|
1499745|NCT02971241|Behavioral|Intergenerational Mobile Technology Opportunities Program|The themes of the 8-week training session are designed based on the objectives of IMTOP: 1) teach skills of tablet use and diabetes self-management behavior tracking app, 2) introduce online community communication to decrease social isolation and obtain social support from family and friends, young volunteers, health care providers, and diabetes peers who have similar condition/interest/ or disease), 3) teach diabetes self-management knowledge and skills based on the evidence-based Chronic Disease Self-Management Program; and 4) teach mobile technology application to healthcare access and daily needs (i.e., online appointment, online refill, appointment reminder, online health information, online training videos, and virtual classes such as e-newspaper, e-books, related sites, apps).
1499746|NCT02971228|Drug|Insulin Lispro|Used to lower blood glucose. Commercially available by prescription and is indicated for patients with T1DM, but not for use in a bionic pancreas. Individualized dose based on metabolic needs and frequent monitoring of blood glucose.
1499747|NCT02971228|Drug|ZP4207 (dasiglucagon)|A glucagon analog not yet approved by the FDA. Subcutaneous administration in one BP arm.
1499748|NCT02971228|Drug|Glucagon|A hormone normally made by the pancreas to raise blood glucose. Used to treat low blood sugar. Commercially available by prescription and is indicated for patients with T1DM in severe hypoglycemia, but not for use in a BP. Subcutaneous administration in one BP arm.
1499749|NCT02971228|Device|iPhone-based bionic pancreas|An experimental device.
1499750|NCT02971228|Device|iLet-based bionic pancreas|An experimental device.
1499751|NCT02971215|Device|iLux Laser|"Treatment during 15 sessions. It is divided in two phases: 1. 12W. 50 Hz 20% duty cycle. 50 J/cm² in painful zone. 2. 15 W. Burst (10 pulses-900 msec each train) 250 J/cm² in painful zone. Trough the iLux Laser (Mectronic Medicale, Italy)
+ Physical Therapy protocol."
1499752|NCT02971215|Device|Sham ilux Laser|Sham treatment during 15 sessions trough the iLux Laser (Mectronic Medicale, Italy), It is applies the same time than experimental one but with 0 W + Physical Therapy protocol.
1499753|NCT02971202|Drug|Hyperinsulinemic, euglycemic clamp|"Participants will undergo an 8-hour hyperinsulinemic, euglycemic clamp to quantify insulin sensitivity at whole-body and tissue-specific levels. The following hormones will be infused in the study:
insulin (12 mU/m^2/min [3x basal] for 150 minutes, then 40 mU/m^2/min [10x basal] for 180 minutes)
glucagon (0.65 ng/kg/min [1x basal] for 330 minutes)
somatostatin (60 ng/kg/min) These infusions will maintain a basal glucagon level and an increased insulin level in the blood that will be equal between all 3 cohorts."
1499754|NCT02971202|Drug|20% dextrose|A variable infusion of 20% dextrose will be used to maintain plasma glucose within the euglycemic range throughout the hyperinsulinemic portion of the clamp. 6,6-H2 glucose will be infused at a low rate (0.033-0.22 µmol/kg/min) to determine glucose flux during the study.
1499755|NCT02971189|Device|Librata Endometrial Ablation|The treatment procedure will be performed in accordance with the physician's routine endometrial ablation practice and in accordance with the requirements of the LibrataTM IFU. The uterine cavity will be systematically inspected using hysteroscopy prior the ablative procedure (after any blind cervical dilatation) and post the ablative procedure to estimate the completeness of endometrial destruction and to exclude uterine trauma including uterine perforation. The patient will undergo standard post-operative monitoring and recovery according to usual hospital practices. An assessment will be made for any ablation procedure or device related serious adverse events.
1499756|NCT02971176|Radiation|Low-dose protocol computed tomography|Radiation dose under the low-dose protocol computed tomography (120 kilovolt, 15 milliampere seconds)
1499757|NCT02971176|Radiation|Standard-dose protocol computed tomography|Radiation dose under the standard-dose protocol computed tomography (120 kilovolt, 150 milliampere seconds)
2002086|NCT02537678|Behavioral|Standard TF-CBT|Standard TF-CBT: Patients will receive 12 (1.5 hr.) standard weekly in-office therapist-directed sessions (2 additional weeks allow for scheduling difficulty). TF-CBT includes child, parent and conjoint parent-child sessions addressing the 10 core trauma treatment components of TF-CBT (e.g., parenting skills, affect modulation, cognitive coping, trauma narrative, etc.).
1499759|NCT02971150|Behavioral|Brief Behavioral Treatment for Insomnia|
2002087|NCT02537756|Behavioral|Project Voice|A tablet-based intervention that directs participants through different activities related to adolescent HPV vaccination based on their assigned condition
1499766|NCT02971059|Dietary Supplement|Phenylalanine intake|Phenylalanine will be provided as graded intakes ranging from 7-40 mg/kg/day
1499767|NCT02971046|Other|varying protein intakes|Four randomly assigned levels of protein intake in a repeated measured design.
2002088|NCT02537106|Procedure|1.5% NaCl|After the infusion of 1.5% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
2002089|NCT02537106|Procedure|3% NaCl|After the infusion of 3% NaCl and dura opening the microcirculation and the brain relaxation score will be measured in the area of healthy brain and perifocal oedema sites. Microcirculation measurement will be repeated at the same sites after tumor resection.
2002090|NCT02535689|Drug|Tofacitinib|Oral administration of tofacitinib, 5 mg
1499771|NCT02971020|Other|Observational/Cognitive Assessment|Montreal Cognitive Assessment (MoCA); Trail Making Test Part A; Trail Making Test Part B; Phonemic Fluency (letter fluency) and Semantic Fluency (category).
1499772|NCT02971007|Drug|Oral Encochleated Amphotericin B (CAMB)|lipid-crystal nano-particle formulation amphotericin B
1499773|NCT02971007|Drug|Fluconazole|
1499776|NCT02970968|Drug|VLY-686 (Tradipitant)|oral capsule
1499777|NCT02970968|Other|Placebo|placebo oral
1499778|NCT02970955|Procedure|Inoperable thoracic nodes metastases|The radiation treatment will be delivered with three possible schedules, with a risk adaptive scheme according to number, site and size of metastatic nodes and based on the possibility to respect the constraints of healthy tissues
1499781|NCT02970929|Drug|SEP-363856|One SEP-363856 capsule (25 mg, 50 mg or 75 mg (flex)) daily for 26 weeks
1499782|NCT02970916|Drug|FOLFIRI+aflibercept|"Aflibercept: 4 mg/kg administered intravenous infusion on day 1
FOLFIRI regimen immediately after aflibercept:
Irinotecan:180 mg/m2 intravenous infusion, folinic acid (dl racemic): 400 mg/m2 intravenous infusion, followed by 5-fluorouracil (5-FU): 400 mg/m2 intravenous bolus, followed by 5-FU: 2400 mg/m2 continuous intravenous infusion over 46 hours.
* folinic acid: 400 mg/m² (racémic) or 200 mg/m² (L-form)"
1499783|NCT02970903|Device|VitalPAD|VitalPAD prototype device
1499784|NCT02970903|Device|Traditional tools|Paper based records, screenshots of monitors and therapy devices
1499785|NCT02970890|Device|Portable Pain Away™|Portable Pain Away™ device (manufactured by Multi Radiance Medical, Solon - OH, USA) - placebo or active phototherapy
1499786|NCT02970877|Biological|Fecal filtrate from 150 g stool from healthy lean donors|150 g stool from healthy lean donors will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
1499787|NCT02970877|Biological|Fecal filtrate from 150 g of the recipient's own stool|150 g stool from the recipient will be diluted in 0.9% normal saline to a total volume of 450 mL. Preparation from frozen stool.
1499789|NCT02970838|Other|Structured weight-loss program|"During the fasting phase, daily consumption consists of five sachets fully replacing normal food and corresponded to an energy content of 800 kcal. This fasting phase is followed by a four-week refeeding phase, during which regular food will be reintroduced and formula diet is gradually replaced until a daily total intake of 1200 kcal is reached. During the last five weeks of the program, energy intake is gradually increased to an individual level between 1200 kcal and 1500 kcal that allowed subjects to keep their weight stable.
Once a week participants visit the study center to monitor health status and taking part in supervised exercises and a nutritional and behavioral counseling."
1499790|NCT02970825|Other|Exercise|Moderate to high intensity physical training
1499791|NCT02970825|Other|Relaxation|Low intensity physical activity and mindfulness
1499792|NCT02970812|Device|EMS|Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
1499793|NCT02970812|Device|TENS|Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
1499794|NCT02970786|Drug|Injection of 68Ga-NODAGA-E(c[RGDyK])2|Following one injection of 68Ga-NODAGA-E(c[RGDyK])2 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
1499795|NCT02970773|Drug|Rivaroxaban|
1499796|NCT02970747|Drug|Carfilzomib|In accordance with SmPC.
1499797|NCT02970734|Behavioral|Breathe|Six web-based cognitive behavioural therapy sessions. Telephone and email support are also provided during the program.
1499798|NCT02970734|Behavioral|Resource Webpage|Static webpage listing anxiety resources.
1499799|NCT02970721|Drug|Mood Stabilising Treatment|Mood stabilizing treatment includes drugs that can be used alone or in combination with antipsychotics
1499800|NCT02970708|Device|EFG group|88 anisometropic amblyopia will be recruited to receive Eyetronix Flicker Glasses treatment.
1499801|NCT02970708|Device|Patching group|88 anisometropic amblyopia will be recruited to receive patching treatment.
1499802|NCT02970695|Device|magneto-auriculotherapy (MAT)|Subjects will then receive MAT. The magnetic pellets will have ~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm.The experimental object will be applied to the seven selected acupoints as detected by an acupoint detector. Only one ear will receive treatment at a time, and the pellets will remain in situ for two days before the next change.
1499803|NCT02970695|Device|Laser auriculotherapy (LAT)|A laser device (Pointer Pulse™)15 will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm,2 and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. 16, 17 This application is a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer. A 1-minute treatment using the continuous mode of the device will be directly applied to the selected acupoints. Laser protective goggles will be provided to the subjects and the researcher for eyes protection
1499804|NCT02970682|Drug|SFX-01|Stabilised Sulforaphane
1499805|NCT02970682|Drug|Fulvestrant|Fulvestrant
1499806|NCT02970682|Drug|Tamoxifen|Tamoxifen
1499807|NCT02970682|Drug|Aromatase Inhibitors|
1499810|NCT02970669|Drug|matching placebo sacubitril/valsartan (LCZ696)|matching placebo sacubitril/valsartan tablet taken orally
1499811|NCT02970669|Drug|matching placebo enalapril|matching placebo enalapril tablet taken orally
1499812|NCT02970656|Behavioral|Teens.Connect|
1499813|NCT02970643|Drug|Olanzapine|Moderate risk chemotherapy induced nausea group in all cancer. D1 Olanzapine 10mg PO D2-3 Olanzapine 10mg PO
1499814|NCT02970643|Drug|Palonosetron|Moderate risk chemotherapy induced nausea group in all cancer. D1 Palonosetron 0.25mg IV
1499815|NCT02970630|Drug|Tacrolimus|once a day
1499816|NCT02970630|Drug|Everolimus|twice daily
1499817|NCT02970617|Other|Memory Intervention|Ring bell after final radiation treatment
1499818|NCT02970617|Other|Questionnaire Administration|Ancillary studies
1499819|NCT02970617|Radiation|Radiation therapy|Radiation therapy with or without chemotherapy
1499820|NCT02970604|Drug|Aspirin|Non enteric coated aspirin
1499821|NCT02970591|Other|Traditional dietary advice and low FODMAP content|Traditional dietary advice according to the Brittish Dietetic Association including reducing the intake of fermentable carbohydrates.
1499822|NCT02970591|Other|Low carbohydrate diet|Diet that contains a maximum of 10 energy percent of carbohydrates, 25 energy % proteins and 65 energy % fat.
1499823|NCT02970591|Other|Optimized Medical treatment|Standard consultation by physician and if needed patients will receive medical treatment based on the most prominent symptom. Constipation: osmotic laxatives, linaclotide. Diarrhea: loperamid, bile acid binders. Pain: anti depressent, antispasmodics, linaclotide.
1499824|NCT02970578|Procedure|3D printed module|The patients underwent 3D printed module-assisted lumbar pedicle screw placement using the Quandrant system, aiming to restore the stability of the spine.
1499825|NCT02970565|Behavioral|Family Nurture Intervention|The mother-child pair will be asked to talk and play with each other as they customarily do. If the child becomes restless and dysregulated the mother will be coached by the Nurture Specialist to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact.
1499826|NCT02970565|Behavioral|Nutrition and Play Intervention|Mothers and children in the Play and Nutrition group will play educational and nutrition-focused games.
1499827|NCT02970552|Drug|Vaginal Progesterone|200 mg micronized vaginal progesterone suppository
1499828|NCT02970552|Drug|Placebo|Indistinguishable placebo vaginal suppository
1499829|NCT02970539|Drug|Oraxol|Oraxol (Paclitaxel and HM30181A) will be dosed orally. Paclitaxel will be supplied as capsules and HM30181A will be supplied as tablets.
1499830|NCT02970539|Drug|Ramucirumab|Ramucirumab will be administered by iv infusion.
1499831|NCT02970526|Drug|Oxaliplatin|Intensity of neuropathy induced by oxaliplatin evaluated by the QLQ-CIPN20 Questionnaire (EORTC).
1499832|NCT02970513|Other|Psychiatric evaluation|
1499833|NCT02970500|Drug|Methylphenidate HCl 10Mg SR|The participants will receive 1 capsule of Methylphenidate HCl 10Mg SR each morning for 14 days in the double-blinded randomized placebo-controlled phase and a dose between 10-20mg in the open trial phase.
1499834|NCT02970500|Drug|Placebo Comparator|In the Placebo comparator intervention, participants from the Placebo group will take1 tablet of placebo each morning for 14 days
1499835|NCT02970487|Device|Intraocular implant of the Precisight|Precisight ismplanted in place of the natural cloudy lens, inside the capsular bag.
1499836|NCT02970474|Device|Conventional Bolus|Conventional bolus is mold made from Super stuff powder, superflab, or paraffin wax and made to fit the contours of the body.
1499837|NCT02970474|Device|3D Printed Bolus|The 3D printed bolus is also made from Super stuff powder, superflab, or paraffin wax, however it uses CT scans to print a molded bolus from the images of the participant's body.
1499838|NCT02970461|Other|Gamified Group|See Gamified Group in Arms description.
1499839|NCT02970461|Other|Control Group|See Control Group in Arms description.
1499840|NCT02970448|Procedure|LITT|MRI-guided laser interstitial thermal therapy uses a gas cooled side-firing (directional) laser and a variety of procedure specific tools to thermally ablate target tissue in-situ.
1499841|NCT02970448|Radiation|Radiation therapy|One treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks. All portals shall be treated during each treatment session. Doses are specified such that at least 95% of the planning target volume (PTV) shall receive 100% of the prescribed dose.
1499842|NCT02970448|Drug|Temozolomide|Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days
2002091|NCT02535689|Drug|Placebo|
2002092|NCT02528071|Other|Diaphragmatic endurance test|This consists of hyperventilation in a flask while maintaining the constant level of Carbon Dioxide (CO2). The patient will realize hyperventilation to increasing levels of Maximum Minute Ventilation (MMV), corresponding to increasing levels of respiratory rate, until exhaustion
2002093|NCT02517515|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
1499846|NCT02970422|Other|Patient Survey|Participants will answer an online survey and their medical chart information will be gathered to compare responses across disease severity.
1499847|NCT02970409|Device|saline|catheter lock using saline
1499848|NCT02970409|Device|Heparin|catheter lock using Heparin
1499849|NCT02970396|Behavioral|self-management|
1499850|NCT02970383|Behavioral|Initial prescription for 10 narcotic tabs|Reduced number of pills in initial prescription post-operatively
1499851|NCT02970383|Behavioral|Inital prescription for 30 narcotic tabs|
1499852|NCT02970370|Other|no intervention|
1499853|NCT02970357|Other|DIAPASON Questionnaire|"50 item questionnaire of the French Youth Diabetes Association to evaluate one's theoretical knowledge about the diabetes disease. 6 main themes are evaluated :
what is diabetes
Monitoring
Hypoglycemia and Hyperglycemia
Nutrition
Insuline"
1499854|NCT02970357|Behavioral|WHO-5|5 item questionnaire of the World Health Organization about quality of life
1499855|NCT02970344|Behavioral|Diabetes Coping Skills Training (DCST)|Diabetes Coping Skills Training (DCST) consist of twelve 50 minutes sessions delivered over 6 months using a faded contact model ( 6 weekly session, 3 biweekly sessions and 3 monthly sessions)
1499856|NCT02970331|Drug|pefcalcitol ointment, 0.005%|
1499861|NCT02970305|Drug|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg, taken as two tablets, once daily by mouth
1499862|NCT02970305|Drug|Placebo|Placebo, taken as two tablets, once daily by mouth
1499863|NCT02970292|Drug|Pimavanserin|Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth
1499864|NCT02970292|Drug|Placebo|Placebo, taken as two tablets, once daily by mouth
1499865|NCT02970279|Behavioral|Behavioural Activation Group (BAG) Psychotherapy|Behavioural activation (BA) is a psychotherapy intervention based on behaviour theory and operant conditioning. It teaches patients to reduce avoidant depressive behaviours and in turn increase the positive reinforcement they receive from their environment for non-depressive behaviours through the use of activity scheduling and pleasant events. For the trial, BA will be delivered in a group format (BAG) and facilitated by two therapists. BAG treatment will consist of eight weekly sessions, lasting two hours and will follow a manualised treatment protocol. Each session will be based on a different topic relevant to the principles of BA and patients will be given between session work to complete to encourage increased participation in rewarding personally meaningful activities.
1499866|NCT02970253|Procedure|Capsular resection|
1499867|NCT02970253|Procedure|Capsular retention|
1499868|NCT02970240|Procedure|Cardiopulmonary testing|A 2-day consecutive testing on an ergometer cycle
1499869|NCT02970227|Other|Observation|None, observation only
1499870|NCT02970214|Other|no intervention, only observational|no intervention, only observational
1499871|NCT02970201|Other|EpxDialysis|The EpxDialysis intervention consists of automated SMS text or voice messages delivered to the patient's preferred phone number three times per week. These messages provide details about the subject's upcoming hemodialysis session, anticipatory guidance regarding clinically-concerning symptoms, as well as the option for direct call routing to the dialysis center for rescheduling sessions.
1499872|NCT02970188|Behavioral|Time Restricted Feeding|consuming all daily calories within an 8 hour feeding window
1499873|NCT02970175|Drug|Terlipressin administration|
1499874|NCT02970175|Procedure|bronchoscopy under local anesthesia|
1499875|NCT02970175|Procedure|Biopsy sampling|
1499876|NCT02970162|Drug|Amifampridine Phosphate|
1499877|NCT02970162|Drug|Placebo Oral Tablet|
1499878|NCT02970149|Other|NA (observational)|
1499879|NCT02970136|Device|OraQuick Swab|OraQuick for oral fluid HIV antibody testing
1499880|NCT02970136|Device|Fecal Immunochemical Test|Fecal Immunochemical stool test specific for human hemoglobin
1499881|NCT02970136|Device|OraQuick Fingerstick|Patients will be tested for Hepatitis C infection using a fingerstick
1499882|NCT02970136|Other|Standard Screening Tests|Patients will be navigated to a local health center for standard screening tests
1499883|NCT02970136|Other|HPV Self-Sampling Test|Patients will be using swab to check for HPV infection
1499884|NCT02970123|Behavioral|Sit Less, Interact, Move More (SLIMM)|
1499885|NCT02970097|Drug|20ml bolus of 0.5% ropivicaine|local anesthetic
1499886|NCT02970097|Drug|10 ml of 0.5% ropivicaine|local anesthetic
1499887|NCT02970097|Drug|Midazolam|1-2 mg of medication given intravenously before nerve block
1499888|NCT02970097|Drug|Fentanyl|50-100 mcg of medication given intravenously before nerve block
1499889|NCT02970084|Other|Nutraceutical product based on vitamin K2 (PLAK2)|
1499890|NCT02970058|Other|Platelet-rich Plasma|
1499891|NCT02970058|Other|Control|
1499892|NCT02970045|Procedure|Biospecimen Collection|Undergo collection of blood, tissue, and other biological samples
1499893|NCT02970045|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
1499894|NCT02970045|Other|Medical Chart Review|Review of medical chart
1499895|NCT02970045|Other|Quality-of-Life Assessment|Ancillary studies
1499896|NCT02970045|Other|Questionnaire Administration|Ancillary studies
2002094|NCT02517515|Drug|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir|Placebo for ombitasvir/paritaprevir/ritonavir and dasabuvir
2002095|NCT02515058|Device|PUROS (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
1499899|NCT02970019|Drug|K0706|Once a day administration after fast
1499900|NCT02970019|Drug|Placebo|Once a day administration after fast
1499901|NCT02970006|Device|neurovisual stimulation|a new system of multisensory stimulation based on virtual and enhanced reality (i.e., neuro-visual stimulation)
1499902|NCT02969993|Other|Questionnaires|evaluating the voice outcome by the fullfilment of the voice handicap index
1499903|NCT02969980|Drug|Cyclophosphamide|Cyclophosphamide 25 mg/kg/day i.v. daily on days 3 and 4 of hematopoietic cell transplantation
1499904|NCT02969967|Device|SaeboFlex|Use of the SaeboFlex orthosis for a set protocol of grasp-release activities for 50 minutes at least 3 times per week, followed by 10 minutes of grasp-release activities without the orthosis for 8 weeks. Will occur in participants' homes after discharge from inpatient rehabilitation with visit from principal investigator to progress program for 1 hour 3 times a week for the first 2 weeks and then once a week for 6 weeks.
1499905|NCT02969954|Other|Self-efficacy for diabetes management|Participants at both sites will watch a 12 minute video featuring the digital stories on diabetes. Following the video, participants will engage in a brief facilitated discussion regarding motivations and barriers to diabetes management, led by a trained Spanish-speaking facilitator.
2002096|NCT02515058|Device|FDBA (Ridge Preservation bone grafting surgery)|Ridge preservation bone grafting after tooth extraction
1499907|NCT02969928|Procedure|Full-mouth ultrasonic debridement|Full-mouth ultrasonic debridement will be performed in order to treat diseased sites
1499908|NCT02969928|Drug|Clarithromycin|Administration of Clarithromycin 500mg bid for 7 days
1499909|NCT02969928|Drug|Amoxicillin|Administration of Amoxicillin 500mg tid for 7 days.
1499910|NCT02969928|Drug|Metronidazole|Administration of Metronidazole 400mg tid for 7 days.
1499911|NCT02969915|Behavioral|Incentives|Treatment incentives are offered to HIV-positive participants for reaching treatment targets, including retention to medical follow-up, initiating antiretroviral therapy, and maintaining high adherence with antiretroviral therapy.
1499912|NCT02969915|Behavioral|Integrated Care Centers|ICCs offer key-population-oriented, vertically-integrated harm reduction, HIV testing, and HIV treatment services
1499913|NCT02969902|Device|Buzzy® device|
1499914|NCT02969902|Device|Hand-held computer|
1499915|NCT02969889|Device|Airtraq|video laryngoscope with a channel
1499916|NCT02969889|Device|ILMA|
1499917|NCT02969876|Drug|Vortioxetine|Vortioxetine is a selective serotonin re-uptake inhibitor (SSRI), a common form of treatment for major depressive disorder.
1499918|NCT02969863|Device|Bihormonal Bionic Pancreas|Participants will wear a Bionic Pancreas that uses glucagon and insulin (bihormonal) to automate their glucose control based on continuous glucose monitor readings.
1499919|NCT02969863|Device|Insulin Only Bionic Pancreas|Participants will wear a Bionic Pancreas that uses just insulin (insulin-only) to automate their glucose control based on continuous glucose monitor readings.
1499920|NCT02969863|Other|Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity and hypoglycemia, and will be notified by study staff any time their continuous glucose monitor reads less than 50 mg/dl for 15 mintues.
1499921|NCT02969863|Other|Not Monitored for Hypoglycemia|During half of the study arms (one each bihormonal bionic pancreas, insulin-only bionic pancreas and usual care) the subjects will be remotely monitored for device connectivity only, not hypoglycemia.
1499922|NCT02969850|Dietary Supplement|Vitamin D Supplementation|Subjects in this group will receive initial dose of 2400, 3600, or 4800 IU of vitamin D3, based on her serum vitamin D level. Dose will be adjusted at 3 month visit to maintain serum vitamin D level at a desirable level.
1499923|NCT02969850|Other|Placebo|Subjects in this group will receive a placebo.
1499924|NCT02969850|Dietary Supplement|Calcium|If dietary calcium intake is insufficient in participants of either group, they will be given a calcium supplement in the form of one 600mg pill of CaCO3 to bring them up to an intake of 1200mg/day.
1499925|NCT02969837|Drug|Elotuzumab|Elotuzumab will be given on Cycles 1-2 on days 1, 8, 15, 22, Cycles 3-8 on days 1, 15, Cycles 9-24 on days 1, 15, and Cycles 24+ on day 1.
1499926|NCT02969837|Drug|Carfilzomib|Carfilzomib will be given on Cycles 1-2 on days 1, 8, 15, Cycles 3-8 on days 1, 8, 15, and Cycles 9-24 on days 1, 15.
1499927|NCT02969837|Drug|Lenalidomide|Lenalidomide will be given on days 1-21 for all cycles.
1499928|NCT02969837|Drug|Dexamethasone|Dexamethasone will be given on days 1, 8, 15, and 22 for all cycles.
1499929|NCT02969824|Behavioral|Aerobic Exercise|The AE protocol will consist of eight sessions that proceed in a stepwise fashion in terms of duration and intensity over 11 days. Exercise will be performed on the Velotron Pro stationary cycle ergometer (RacerMate Inc., WA, USA), which will be digitally connected to a heart rate monitor and programmed to monitor the wattage of the bike based on the participant's heart rate. Exercise duration (10min-20min) and intensity (50%-70% max HR) will increase over the intervention period.
1499930|NCT02969798|Drug|Dapagliflozin|10mg/day
1499931|NCT02969798|Drug|Saxagliptin|5mg/day
1499932|NCT02969798|Drug|Pioglitazone|the dose will increase from 15 mg/day to 30 mg/day at month two
1499933|NCT02969798|Drug|Metformin|starting at 1000 mg/day and increased to 2000 mg/day at month 2.
1499934|NCT02969785|Other|G1: exercises for lumbar stabilization|Specific exercises for lumbar stabilization. The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
1499935|NCT02969785|Other|G2: back strengthening exercises|Specific back exercises. The Group 2 (G2) will perform therapy including back strengthing exercise on a Roman chair machine to perform flexion and extension of trunk with load progressive training.
1499936|NCT02969772|Other|Assessment of upper limb variables|International Standards for Neurological and Functional Classification of Spinal Cord Injuries of American Spinal Injury Association (ASIA); Functional Independence Measure (FIM); The following kinematic variables of arm were studied: shoulder, elbow and wrist angles; percentage of time to peak velocity; movement time; peak velocity and movement smoothness (number of velocity peaks and index of curvature); Capabilities of Upper Extremity instrument (CUE); Spinal cord independence measure (SCIM II); electromyography (Clavicular portion of pectoralis major, long head of biceps brachii, anterior and posterior deltoid, triceps and wrist extensors).
1499937|NCT02969772|Other|Training protocol|The strengthening sessions consisted of 20 minutes of electrical stimulation on triceps, extensor carpi radialis longus, extensor digitorum communis, lumbricalis, flexor digitorum superficialis and opponens pollicis muscles. The functional training sessions was performed through movements the reach and palmar grasp with NMES of the several cylindrical and conical objects of different weights (30 minutes sessions).
1499938|NCT02969759|Other|Skin Biopsy|
1499939|NCT02969746|Drug|Activated Charcoal|"Patients will take oral activated charcoal after randomization in the intervention arm.
A blood sample(TO) will be collected after patient enrollment and before charcoal administration and 4 blood samples will be collected on a 8h length period (T1 to T4)"
1499940|NCT02969733|Drug|Xylocaine|Xylocaine is administered at a dose of 1.5 mg / kg for induction and then relay by syringe pump at a dose of 1.33 mg / kg / hour will be administered throughout the duration of the intervention and for 24 hours after the end of thereof, to obtain deemed effective plasma concentrations of the order of 0.5 to 5 mcg / mL.
1499941|NCT02969733|Drug|Ketamine|Ketamine will be administered at a dose of 0.5 mg / kg and then relay by syringe pump at a dose of 0.05 mg / kg / hour for the duration of surgery and 24 hours after the end thereof.
1499942|NCT02969733|Drug|isotonic saline serum intravenous administration|
1499943|NCT02969720|Dietary Supplement|Phytosterols|Oral daily consumption of 2 grams of phytosterols (8 ml) per 180 days.
1499944|NCT02969720|Dietary Supplement|Titanium Dioxide|Oral daily consumption of Titanium Dioxide (8 ml) per 180 days.
1500015|NCT02969148|Procedure|Laparoscopic bursectomy and D2 lymphadenectomy|The anterior lobe of transverse mesocolon and capsula pancreatis will be dissected with the D2 lymphadenectomy according to the guidelines of National Comprehensive Cancer Network(NCCN) by laparoscopy，this is Laparoscopic bursectomy and D2 lymphadenectomy.
1501763|NCT02956499|Drug|APX001 single dose 4|
1499945|NCT02969707|Device|repetitive Transcranial Magnetic Stimulation|The investigators will perform two applications of 40s of continuous theta-burst stimulation (cTBS) form of rTMS at 80% resting motor threshold (previously determined), with a 15 minute intersession interval. The standardized treatment location for the left DLPFC will be determined by Localite Neuronavigation and targeted at the posterior middle frontal gyrus. The baseline structural scan obtained during the scan 1 will be utilized for this localization process.
1499946|NCT02969707|Device|Sham repetitive Transcranial Magnetic Stimulation|This will be identical to active rTMS except the stimulation will be blocked. Both active and sham repetitive Transcranial Magnetic Stimulation will receive simulation from a specially designed coil which is capable of delivering either active rTMS or sham rTMS in a manner, which is randomized by the system itself and therefore blinded to the treater.
1499947|NCT02969694|Other|G-STAT questionnaire|"Patients will have a consultation with an addiction specialist physician. During the consultation, the physician ask the patient about these sexual practice and the use of psychostimulants. The patient will answer to the G-STAT questionnaire. This questionnaire allows the physician to perform an initial assessment of the patient's sexual addiction.
The entire consultation takes place in the usual practice of consultations for this addiction."
2002097|NCT02514668|Drug|Isatuximab|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
2002098|NCT02513186|Drug|lenalidomide|Pharmaceutical form: tablet Route of administration: oral
1499950|NCT02969655|Drug|Daprodustat small|Available as 7.0 millimeter (mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of daprodustat as active ingredient
1499951|NCT02969655|Drug|Daprodustat small placebo|Available as 7.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
1499952|NCT02969655|Drug|Daprodustat large|Available as 9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of daprodustat as active ingredient
1499953|NCT02969655|Drug|Daprodustat large placebo|Available as 9.0 mm round, standard biconvex, white film coated tablets containing no daprodustat
1499954|NCT02969655|Drug|Darbepoetin alfa|Available as 0.5 mL plastic prefilled syringes (PFS) for IV injection each containing 10, 15, 20, 30, 40 or 60 mcg of darbepoetin alfa in a clear and colorless solution.
1499955|NCT02969655|Drug|Darbepoetin alfa placebo|Available as 0.5 mL plastic PFS for IV injection containing no darbepoetin alfa in a clear and colorless solution.
1499956|NCT02969642|Device|Argus Migraine Treatment device|treatment of Migraines targeting Sphenopalatine ganglion
1499957|NCT02969629|Drug|Apomorphine|
1499958|NCT02969629|Drug|Normal Saline|
1499959|NCT02969616|Biological|Trinity Elite|cell based allograft
1499960|NCT02969603|Other|Magnetic Resonance Imaging|Magnetic Resonance Imaging as reference
1499961|NCT02969603|Other|Magnetic Resonance combined with Positron Emission Tomography|Comparison with MRI only, to assess muscular activity, creation of anatomic images of muscle activity and resolution of metabolic activity distribution within exercising skeletal muscle
2002099|NCT02513186|Drug|bortezomib|Pharmaceutical form: lyophilized powder for subcutaneous injection Route of administration: subcutaneous
2002100|NCT02513186|Drug|cyclophosphamide|Pharmaceutical form: tablet Route of administration: oral
2002101|NCT02513186|Drug|dexamethasone|Pharmaceutical form: tablet or solution for infusion Route of administration: oral or intravenous
1499965|NCT02969577|Behavioral|Exercise Program|Participants will have a personal training session at the first visit. A member of the study team will discuss strength training and cardiovascular workouts for them to complete over the first 6 months of the study. A member of the study team will then talk with the participant every week for the first 3 months and monthly afterwards until month 6. Participants will be sent exercise videos and be given recommendations for the exercise program via phone calls and will be tailored to the individual. Videos and recommendations will be sent directly to the participant's smartphone.
1499966|NCT02969577|Behavioral|Diet and Nutrition Coaching|Diet and nutrition coaching session with an overview of resources on the smartphone. Over the first 6 months, participants will receive healthy recipes and nutritional information on the smartphone.
1499967|NCT02969577|Other|Usual Care with Attention|Participants will receive the usual care for men undergoing ADT. This includes monitoring blood work and answering questions about how they are feeling. Participants will be directed to the IMPACT website for education materials on prostate cancer.
1499968|NCT02969564|Other|scintigraphy 99mTc-MDP-SPECT/CT.|SPECT/CT will be performed for every patient in the frame of their clinical follow up
1499969|NCT02969564|Other|18F-NaF-PET/MR|a 18F-NaF-PET/MR will be performed, in the frame of this clinical study, to the patients to assess the difference of sensitivity of the 2 exams
1499970|NCT02969551|Device|Manometry and possibly DISE|A Manometry is performed on all patients. After it in some Patient DISE is followed
1499971|NCT02969538|Other|Total etching time|Apply 35% phosphoric acid on dentin and enamel by 15 seconds.
1499972|NCT02969538|Other|Half-reduced etching time|Apply 35% phosphoric acid on enamel by 15 seconds and dentin by 7 seconds.
1499973|NCT02969525|Other|Placebo|
1499974|NCT02969525|Drug|Bimekizumab|Bimekizumab in different dosage regimens.
1499975|NCT02969512|Other|HIPPER|"Participants can complete the online educational modules at home or another location with internet access. The total time to complete all of the modules is about 2 hours and 30 minutes. A trainer (an occupational therapist or physiotherapist) will be able to remotely monitor the participant's progression on the HIPPER modules and will phone participants to check in if there is no online activity for 2 weeks. Participants will also be given the phone number and email of the trainer to contact if experiencing difficulty using the modules or with any other aspects of the study.
The total amount one could exercise using this program is 30 hours. However, it is up the participant how much they actually exercise."
1499976|NCT02969512|Other|In-Person Education|2 x 2-hour in-person educational small group sessions
1500016|NCT02969148|Procedure|Laparoscopic D2 lymphadenectomy|D2 lymphadenectomy is carried out according to the guidelines of National Comprehensive Cancer Network(NCCN).
1500017|NCT02969135|Behavioral|Progressive early passive and active movement|
1500018|NCT02969135|Behavioral|Limited early passive movement|
2002102|NCT02513186|Drug|isatuximab SAR650984|Pharmaceutical form: solution for infusion Route of administration: intravenous
1499977|NCT02969473|Drug|Docetaxel|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.
Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the DP group received two cycles of DP regimen (docetaxel 60 mg/m2 delivered on day 1 and cisplatin 80 mg/m2 delivered on day 1) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
1499978|NCT02969473|Drug|Fluorouracil|"Radiotherapy: All patients underwent conventional radiotherapy, 1.8-2.0 Gy per fraction and 5 fractions per week. The prescribed dose was 60-64 Gy to PTV1 and 50 Gy to PTV2. Patients received either three-dimensional conformal radiotherapy (3D-CRT) or intensity-modulated radiation therapy (IMRT). 3D-CRT treatment plans were calculated by Pinnacle planning system and IMRT treatment plans were calculated by Monacle planning system. All patients were treated with a 6-MV or 8-MV linear accelerator.
Chemotherapy: All patients received two cycles of chemotherapy concurrently with radiotherapy. Patients assigned to the PF group received two cycles of PF regimen (cisplatin 80 mg/m2 delivered on day 1 and 5-FU 1000 mg/m2 continuous infusion over 24 hours daily on days 1-4) at a 3-week interval. In cases of grade 4 hematologic toxicity or severe non-hematologic toxicities, dose adjustment was performed in the subsequent chemotherapy cycle."
1499979|NCT02969460|Behavioral|Neurotrack Virtual Cognitive Health Program|
1499980|NCT02969447|Drug|Administration of 10 units of intra venous oxytocin after fetal expulsion|
1499981|NCT02969434|Other|Sleep assessment tools|Interventions are 3 tools to assess sleep: Verran Snyder Halpern sleep scale, the Pain and Sleep Questionnaire 3 Item Index (PSQ-3) and the Pittsburg Sleep Quality Index (PSQI).
1499982|NCT02969421|Other|Cough method for placement of tenaculum|The intervention in this arm is the placement of tenaculum via cough method
1499983|NCT02969421|Other|Slow Tenaculum Placement of tenaculum|The intervention in this arm is the placement of tenaculum via slow method
1995808|NCT02648295|Procedure|Effects of IV TXA on TEG in patients undergoing THA or TKA|Subjects will undergo surgery per standard of care. All subjects will have 3 additional vials of blood drawn to evaluate TEG.
1499987|NCT02969369|Drug|SEP-363856|SEP-363856 (25, 50, or 75mg/day)
1499988|NCT02969369|Drug|Placebo capsule|Placebo once daily
1499990|NCT02969343|Behavioral|Patient Safety health information technology|Patient safety technology toolkits on hospital care units
1499991|NCT02969330|Device|Stimulator|
1499992|NCT02969330|Dietary Supplement|Glucose|300ml tap water with 75g glucose
1499993|NCT02969317|Drug|Tiotropium|Fixed dose combination
1499994|NCT02969317|Drug|Olodaterol|Fixed dose combination
1499995|NCT02969304|Drug|dimethyl fumarate|"Off-Label Use: All participants <18 years of age and participants without an MS diagnosis who are prescribed dimethyl fumarate
On-Label Use: All participants >18 years of age with an MS diagnosis who are prescribed dimethyl fumarate"
1499996|NCT02969291|Behavioral|Reduced Sedentary Time Intervention (RSTI)|Following 7 days of baseline activity monitoring a study investigator will download the information from the monitor, evaluate the periods of sedentary behavior and create a tailored RSTI for each participant. For example, the investigator may notice a long stretch of sitting in the evening following a meal and identify several exercises that can be done indoors during that time, or if the participant is amiable to walking breaks and a period after work is identified the investigator might suggest the appropriate walking activity at that time. This program has been successful in sedentary overweight office workers and investigators will use similar techniques.
1499997|NCT02969278|Procedure|18FDG-PET/TC|Nuclear medicine exam (18FDG-PET/TC) to assess the status of the regional groin and pelvic lymphnodes
1499998|NCT02969278|Procedure|Sentinel node biopsy|Intradermal injection of 0.2 ml 37-148 MBq of radiocolloid and a blue dye near the tumor to locate the position of the sentinel lymph node. Intraoperatively, sentinel node localization is guided by a gamma probe and by the eyes of the surgeon who detects the lymph nodes that are stained with the blue dye.
1499999|NCT02969265|Drug|Amlodipine|Amlodipine Capsules
1500000|NCT02969265|Drug|TCV-116CCB|TCV-116CCB Tablets
1500001|NCT02969265|Drug|Amlodipine Placebo|Amlodipine placebo-matching capsules
1500002|NCT02969265|Drug|TCV-116CCB Placebo|TCV-116CCB 8/5 mg placebo-matching tablets
1500003|NCT02969252|Drug|Rifamycin SV-MMX® 600|
1500004|NCT02969239|Drug|Norepinephrine|bolus administered norepinephrine 5mcg intravenously, if SBP <90mmHg or 20% decrease from baseline
1500005|NCT02969239|Drug|Phenylephrine|bolus administered phenylephrine 100mcg intravenously, if SBP <90mmHg or 20% decrease from baseline
1500006|NCT02969226|Procedure|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
1500007|NCT02969226|Procedure|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
1500008|NCT02969226|Procedure|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS >0 and =< 8 cm H2O with PEEP>0 and =< 5 cm H2O
1500009|NCT02969226|Procedure|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece (off the ventilator)
1500010|NCT02969200|Drug|Enzyme replacement therapy|All patients included in the study have received enzyme replacement therapy with either agalsidase alfa and/or agalsidase beta
1500011|NCT02969187|Drug|Exparel|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Exparel will be injected at port sites.
1500012|NCT02969187|Drug|Bupivacain|6 trocars are placed to perform LRYGB or LSG: two 12 mm trocars and four 5 mm trocars. Bupivacain will be injected at port sites.
1500013|NCT02969187|Drug|Saline|
1500019|NCT02969122|Procedure|standard gastrectomy with D2 lymphadenectomy|standard distal or total gastrectomy and accorded D2 lymphadenectomy
1500020|NCT02969122|Procedure|hyperthermic intraperitoneal chemotherapy|Intraperitoneal docetaxel of 100mg/m2 at 42℃ for 30 minutes
1500021|NCT02969122|Procedure|Extensive intraperitoneal lavage|Lavage of peritoneal cavity with 1000ml saline for 10 times
1500022|NCT02969122|Other|Preoperative chemotherapy|Oxaliplatin 130mg/m2 D1 S-1 40-60mg Bid D1-14 Repeated every 3 weeks.
1500023|NCT02969122|Other|Postoperative chemotherapy|SOX regimen postoperative chemotherapy (Oxaliplatin 130mg/m2 D1, S-1 40-60mg Bid D1-14, Repeated every 3 weeks) for surgery-first arm. Regimen for chemotherapy-first arm is determined according to the postoperative pathologic evaluation of response.
1500024|NCT02969096|Procedure|Targeted Cryoablation Therapy|A cryoprobe is inserted percutaneously under CT guidance into the targeted lesion. Patients undergo ablation using a freeze-thaw-freeze cycle lasting approximately 6-10-6 or 8-10-8 minutes, respectively.
1500025|NCT02969083|Procedure|RNU|Radical surgical removal by open or laparoscopic access
1500026|NCT02969083|Drug|Gemcitabine/Cisplatin|Gemcitabine (1000 mg/m²) day 1 and 8 and Cisplatin (70 mg/m²) day 1
1500027|NCT02969083|Drug|M-VAC Protocol|Methotrexate (30 mg /m²) and Vinblastine 3 (mg /m²) day 1; Adriamycin 30 mg /m² and Cisplatin 70 mg /m² in day2
1500028|NCT02969070|Dietary Supplement|LopiGLIK™ therapy|4 weeks of LopiGLIK™ therapy 1 capsule/day
1500029|NCT02969070|Dietary Supplement|Armolipid Plus® therapy|4 weeks of Armolipid Plus® therapy 1 capsule/day
1500030|NCT02969057|Other|Breakfast with rice bran oil gel|25 grams of rice bran oil gel
1500031|NCT02969057|Other|Breakfast with rice bran oil|25 grams of rice bran oil
1500032|NCT02969057|Other|Breakfast with palm oil gel|25 grams of palm oil gel
1500033|NCT02969057|Other|Breakfast with palm oil|25 grams of palm oil
1500036|NCT02969031|Behavioral|Enhanced SCOPE training|Intervention is integrated into the American Board of Internal Medicine (ABIM) Maintenance Of Certification (MOC) process.
1500037|NCT02969031|Behavioral|Standard Communication training|
2002103|NCT02510300|Drug|Sofosbuvir (SOF)|Exposure of interest for participants who received a sofosbuvir-based regimen in previous Gilead-Sponsored Chronic Hepatitis C Infection Trials
2002104|NCT02510300|Drug|Ledipasvir/Sofosbuvir (LDV/SOF)|Exposure of interest for participants who received a Ledipasvir/Sofosbuvir-based regimen in previous Gilead-Sponsored Chronic Hepatitis C Infection Trials
1500040|NCT02969005|Radiation|surgical treatment|Use of a radiopaque localizer grid and methylene blue staining as an aid to resect the lesions
1500041|NCT02968992|Drug|rhLactoferrin|Eligible participants will be provided with Recombinant Human lactoferrin (rhLF) in 250 mg capsules along with detailed instructions for taking the study drug and they will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
1500042|NCT02968992|Other|Placebo|Eligible participant will be provided with placebo in capsules of 250 mg along with detailed instructions for taking the placebo. Participants will be asked to take six 250 mg capsules twice a day and to keep a daily dosing dairy.
1500043|NCT02968966|Other|Therapy regime|Patient will receive Phenytoin, if no success is obtained, Vimpat is given, if no success is obtained Kinidinsulfat is given. In case of success after one of the treatments, the endpoint is reached. Success is defined as reduction of seizures to 50% compared to baseline.
1500044|NCT02968953|Drug|Triheptanoin|A single patient with Glucose Transporter 1 (GLUT1) Deficiency Syndrome will receive tripheptanoin (UX007).
1500047|NCT02968927|Drug|Everolimus 0.5 MG|
1500048|NCT02968927|Drug|Auranofin 6 MG|
1500049|NCT02968927|Drug|Vitamin D3|
1500050|NCT02968927|Drug|CC-11050|
1500051|NCT02968927|Drug|2HRbZE/4HRb|
1500052|NCT02968914|Biological|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
1500053|NCT02968914|Biological|Benralizumab|A humanized, afucosylated, monoclonal antibody (mAb) that binds specifically to the human IL-5 receptor alpha subunit (IL-5Rα) on the target cell.
1500054|NCT02968901|Drug|macitentan|used in open label
1500055|NCT02968901|Drug|tadalafil|used in open label
1500056|NCT02968888|Other|Strength training|
1500057|NCT02968888|Dietary Supplement|Milk 1%|
1500058|NCT02968888|Dietary Supplement|Whey protein concentrate 80|
1500059|NCT02968888|Dietary Supplement|Native whey|
1500060|NCT02968875|Device|Endurance Training|40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.
1500061|NCT02968875|Other|therapeutic education meetings|Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
1500062|NCT02968862|Other|observational|The study will involve adult patients undergoing elective thoracolumbar-sacral spine surgery involving 1-5 spine levels, at the Brigham and Women's hospital that have an anticipated post surgical hospital stay of one to three days. These patients will be randomly assigned by the BWH Investigational Drug Service to one of three different groups, each consisting of 33 patients. This is an observational studies with subjects in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive a therapeutic intervention, but the investigator does not assign specific interventions to the subjects of the study.
1500063|NCT02968849|Biological|ALVAC-HIV (vCP2438)|Expresses the gene products ZM96 gp120 (clade C strain) linked to the sequences encoding the HIV-1 transmembrane anchor (TM) sequence of gp41 (28 amino acids clade B LAI strain) and gag and pro (clade B LAI strain). It is formulated as a lyophilized vaccine for injection at a dose > 10^6 cell culture infectious dose 50% (CCIDv50) and < 1 × 10^8 CCIDv50 (nominal dose of 10^7 CCIDv50) and is reconstituted with 1 mL of sterile sodium chloride solution (NaCl 0.4%) delivered IM
1500064|NCT02968849|Biological|Bivalent Subtype C gp120/MF59|Subtype C TV1.C gp120 Env and 1086.C gp120 Env proteins, each at a dose of 100 mcg, mixed with MF59 adjuvant (an oil-in-water emulsion) and delivered IM
1500065|NCT02968849|Biological|Placebo|Sodium Chloride for injection, 0.9% delivered IM
1500066|NCT02968836|Dietary Supplement|Blend of amino acids|The product will be poured in bottles containing the enteral nutrition that the patient receives as standard of care.
1500067|NCT02968836|Dietary Supplement|Maltodextrin only|The product will be poured in bottles containing the enteral nutrition that the patient receives as standard of care.
1500068|NCT02968823|Other|Licorice|ExtractumLiquiritiaeFluidum, 1 g diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 2
1500069|NCT02968823|Other|Sugar water|Sugar gargle: Sirupus Simplex (sugar 5 g) diluted in 30cc water, gargle the solution for 60 seconds without swallowing it starting preoperatively, 3 times a day until post-operative day 2
1500070|NCT02968810|Other|Laboratory Biomarker Analysis|Correlative studies
1500071|NCT02968810|Other|Placebo|Given PO
1500072|NCT02968810|Drug|Simvastatin|Given PO
1500073|NCT02968797|Device|SafeSed|Monitor respiratory parameters
1500074|NCT02968784|Device|ExAblate MRgFUS|ExAblate treatment of prostate cancer less than or equal to Grade 7
1500075|NCT02968771|Other|Non intervention|
1500076|NCT02968758|Device|Comparison between GenePOC PCR and Reference Method|Stool specimen will be tested with the GenePOC CDiff test on the GenePOC Instrument. The results will be compared to Reference Method defined as direct and enriched culture method for observation of a toxigenic Clostridium difficile strain.
1500077|NCT02968745|Other|Observational study|Canadian Occupational Performance Measure (COPM) was applied to identify the main occupational performance problems
1500078|NCT02968732|Procedure|Radical Cystectomy|
1500079|NCT02968719|Drug|Donepezil TDS Version A|Donepezil Hydrochloride Transdermal Delivery System (5mg and 10 mg Version B)
1500080|NCT02968719|Drug|Donepezil TDS Version B|Donepezil Hydrochloride Transdermal Delivery System (5 mg and 10 mg Version B)
1500081|NCT02968719|Drug|Aricept|Aricept (5 mg and 10 mg) Donepezil Hydrochloride
1500082|NCT02968719|Drug|Donepezil TDS Version D|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version D)
1500083|NCT02968719|Drug|Donepezil TDS Version E|Donepezil Hydrochloride Transdermal Delivery System (5 mg Version E)
1500084|NCT02968706|Device|High Flow Nasal Cannula|Heated humidified high flow oxygen of 50 L/min at FiO2 of 40%
1500085|NCT02968706|Device|Conventional Nasal Cannula|Supplemental oxygen of 2-5 L/min
1500086|NCT02968706|Other|Patient satisfaction questionnaire|Questionnaire
1500087|NCT02968693|Device|antibiotic-loaded calcium sulfate|To obtain a paste suitable for pellets, the following steps should be used: 1. Empty 10 cc Stimulan® calcium sulfate powder (Stimulan; Biocomposites Ltd; United Kingdom) into a sterile mixing bowl. 2. The calcium sulfate powder was mixed with 2,000 mg of vancomycin powder. 3. Add approximately 5 ml mixing solution into the above mixture. Mix thoroughly until a smooth paste is formed (approximately 30 seconds). 4. The resultant paste is uniformly smooth into the mould provided to form pellets with diameters of 4.8 mm and height of 3.3 mm. 5. Allow paste to cure undisturbed for at least 15 minutes after mixing. Flex mould to release pellets.
1500088|NCT02968693|Device|antibiotic-loaded polymethyl methacrylate|One sachet of 40g PALACOSR®+G power containing 33.6g PMMA and with the addition of 0.5g gentamicin sulphate (Heraeus Medical Gesellschaft mit beschränkter Haftung,Germany) was mixed with 4,000 mg of vancomycin powder in a sterile bowl. The liquid provided was poured into the resultant mixture above. Then, the mixture was stirred carefully for 30 sec. If the dough-like mass no longer sticked to the rubber gloves, it can be progressed. If the required consistency was obtained, the cement can be applied to the bony defect until it hardened completely.
1500089|NCT02968693|Drug|Vancomycin|Vancomycin powder was added into the combination therapy group and PMMA groups
1500090|NCT02968680|Procedure|Sentinel Lymph Node Biopsy|Undergo SLNB
1500091|NCT02968680|Device|Ultrasonography|Undergo sonazoid-enhanced ultrasonography
1500092|NCT02968667|Behavioral|Empowerment|6 weeks of empowerment program and supported face to face discussion
1500093|NCT02968654|Procedure|Restrictive Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Restrictive Transfusion Strategy will receive blood transfusion whenever their Hb concentration is < 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
1500094|NCT02968654|Procedure|Liberal Transfusion Strategy|"Patients will be randomized when hemoglobin levels will be below 9 g/dl. Patients randomized to the Liberal Transfusion Strategy will receive blood transfusion whenever their Hb concentration is < 7 g/dl. All patients should preferably receive one unit of blood transfusion at a time. The duration of the intervention is 28 days after randomization or until hospital discharge. Daily assessment of hemoglobin levels are mandatory only during the ICU stay. No other procedures and or interventions are scheduled. General management of patients will be conducted according to international guidelines; however, local protocols and procedures are allowed."
1500095|NCT02968641|Drug|Lonafarnib|antiviral farnesyltransferase inhibitor
1500096|NCT02968641|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
1500097|NCT02968628|Other|Video Electroencephalogram (EEG)|Single neonatal video EEG at 24 hrs to 5 days of life during birth hospitalization. Neonatal scalp leads, respiratory and nasal leads. Approximately 60 minute recording.
1500098|NCT02968628|Other|Point-of Care Blood Sugar Testing|One-time heel-stick point-of-care blood sugar testing at time of EEG.
1500099|NCT02968628|Other|Medical Record Data Extraction|Medical record data extraction from both maternal obstetric and neonatal medical record for variables known to impact EEG and neurodevelopmental outcomes.
1500100|NCT02968628|Other|Maternal Questionnaire|One-time maternal questionnaire related to smoking practices, ETOH consumption, level of education, and body mass index.
1500101|NCT02968615|Behavioral|Dietary Intervention|Participants were instructed to increase both their dietary fiber intake to 35 g/day and protein intake to 0.8 g per kilogram/day of their ideal body weight. Patients in both conditions will receive intensive dietary instruction for 6 weeks, followed by a 6 weeks maintenance phase. Participants received dietary instructions via individual and group sessions led by registered dietitians.
1500102|NCT02968602|Drug|Minocycline|Minocycline capsules taken twice daily for two weeks.
1500103|NCT02968602|Other|Placebo|Placebo capsules taken twice daily for two weeks.
1500104|NCT02968589|Behavioral|Training|
1500105|NCT02968576|Drug|TENOFOVIR DISOPROXIL FUMARATE 300 Mg / EMTRICITABINE 200 Mg ORAL TABLET [TRUVADA]|
1500106|NCT02968576|Device|Proteus Sensor System|
1500107|NCT02968563|Drug|Tirabrutinib|Capsules or tablets administered orally once daily
1500108|NCT02968563|Drug|Idelalisib|Tablets administered orally once daily
1500109|NCT02968563|Drug|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
1500110|NCT02968537|Behavioral|Alc-IT (50/50) (morning)|This alcohol-specific inhibition-training (Alc-IT) training group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In the morning group, this training will be administered within the first 2 hours after awakening.
1500111|NCT02968537|Behavioral|Alc-IT (75/25) (morning)|This version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In the morning group, this training will be administered within the first 2 hours after awakening.
1500112|NCT02968537|Behavioral|Control-training (morning)|This group will receive an unspecific inhibition training. this training is of the same length and difficulty as the two Alc-inhibition-trainings. In the morning group, this training will be administered within the first 2 hours after awakening.
1500113|NCT02968537|Behavioral|Alc-IT (50/50) (afternoon)|"As in the arm Alc-IT (50/50) (morning), this alcohol-specific inhibition-training (Alc-IT) group will operate with a Go/NoGo ratio of 50/50 (Houben et al. 2011; 2012): This original version of the Alc-inhibition-training will include 80 alcoholic NoGo trials as well as 80 non-alcoholic Go trials. In order to arrive at the same training length while keeping the number of Alc-NoGo-pairings constant and the Go/NoGo-ratio at 50/50, it will additionally include 80 neutral Go-trials as well as 80 neutral NoGo-trials. It will thus consist of 320 trials and take about 10.5 minutes to be completed. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
1500114|NCT02968537|Behavioral|Alc-IT (75/25) (afternoon)|"As in the arm Alc-IT (75/25) (morning), this version of the alcohol-specific inhibition-training (Alc-IT) will operate with a Go/NoGo-ratio of 75/25. It will equally include 80 Alcoholic NoGo-trials and 80 non-alcoholic Go-trials, but now 160 neutral Go-trials will complete the set. This training will also consist of 320 trials and take about 10.5 minutes. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
1500115|NCT02968537|Behavioral|Control-training (afternoon)|"As in the arm Control-training (morning), this group will receive an unspecific inhibition training. This training is of the same length and difficulty as the two Alc-inhibition-trainings. In contrast to the In the morning group, this afternoon group will receive the training in the afternoon."
1500116|NCT02968511|Biological|fecal microbiota transplant|Fecal microbiota transplant for the treatment of severe, complicated C. difficile infection
1500117|NCT02968498|Dietary Supplement|Lactulose crystals 10 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
1500118|NCT02968498|Dietary Supplement|Lactulose crystals 20 g|White or almost white crystalline powder used as food ingredient. The products will be provided in sachets to be dissolved in 250 mL water.
1500119|NCT02968498|Dietary Supplement|Lactulose liquid 10 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
1500120|NCT02968498|Dietary Supplement|Lactulose liquid 20 g|Clear, viscous liquid, colourless or pale brownish-yellow liquid syrup (solution). The products will be provided in sachets to be dissolved in 250 mL water.
1500121|NCT02968498|Dietary Supplement|Oral glucose 20 g|White crystalline powder used as food ingredient. To standardise for 20 g glucose, 22 g glucose monohydrate will be used. The products will be provided in sachets to be dissolved in 250 mL water.
1500122|NCT02968498|Dietary Supplement|Still water|Still water will be used. Water from the same source will be also used to dissolve investigational and control products.
1500123|NCT02968485|Drug|SHR7390|SHR7390 is provided as white, film-coated,immediate release tablets containing SHR7390 at dosage strengths of 0.125 mg and 0.5 mg. Multiple tablets of SHR7390 will be administered daily to achieve targeted doses of SHR7390: 0.25 mg-4 mg. Tablets will be orally administered with 240 ml water, once daily, 2 hours after a meal.
1500124|NCT02968472|Genetic|prophylactic 4SCAR19 cells|Autologous 4th generation withdrawal lentiviral-transduced 4S CAR-T19
1500125|NCT02968459|Other|Umbilical cord MSCs|Participants will receive direct local intramuscular injection of 1*10^7 MSCs (in 1ml of 0.9% saline) in the uterine incision.
1500126|NCT02968459|Other|0.9% Saline|Participants will receive direct local intramuscular injection 1ml of 0.9% saline in the uterine incision.
1500127|NCT02968446|Dietary Supplement|4 placebo|subjects will take orally 4 pills without any active ingredients which are of the same size, shape and color as the study pills
1500128|NCT02968446|Dietary Supplement|4 Vitamin D|subjects will take orally four pills for a single dose of 200,000 IU of Vitamin D (cholecalciferol)
1500129|NCT02968446|Drug|Valchlor|Twice during the study, subjects will be given 0.016% Valchlor at 3 locations (for a total of 6 locations) in the inner arm using Finn ChambersTM
1500130|NCT02968433|Drug|Infusions of young plasma|Participants will receive four weekly infusions of 1 unit young plasma (male, ages between 18-25)
1500326|NCT02966808|Behavioral|cognitive and behavioural questionnaires|
2002105|NCT02505542|Biological|Certolizumab Pegol|"Active substance: Certolizumab Pegol
Pharmaceutical form: Prefilled syringe
Concentration: 200 mg / ml
Route of Administration: Subcutaneous injection"
1500132|NCT02968407|Other|Peer- and self-rating|Participants will be given a print and a e-mail of the modified OSATS global rating scale and will be introduced to how the rating scale is used to rate technical performance. The participant will receive a USB stick each allowing the participant to see a video of his/her own performance and two videos from previous post-test performances from participants enrolled in the course. One video is a video of a participant who performed poorly,the other is from a participant who performed well. The participants will be asked to watch and rate the videos of their peers' performance first and afterwards watch and rate the participants own video performance. The investigators choose to let the participants rate their peers' performances before their own, so the participants will have the best opportunities to self-rate. Participants will be asked to email the results of their ratings to the principal investigator within 3 days. And expert in surgery will also rate the videos using OSATS.
1500133|NCT02968394|Drug|omalizumab|
1500134|NCT02968381|Behavioral|Imagery Intervention|Telephone coaching sessions, use of guided imagery and website.
1500135|NCT02968381|Behavioral|Control Condition|Telephone coaching using standard cognitive behavioral methods
2002106|NCT02505542|Other|Placebo|"Active substance: Placebo
Pharmaceutical form: Prefilled syringe
Concentration: 0.9 % Saline
Route of Administration: Subcutaneous injection"
2002107|NCT02504216|Drug|Rivaroxaban (Xarelto, BAY59-7939)|2.5 mg, twice daily, orally, tablet
1500138|NCT02968355|Other|Observational study|Observational study
2002108|NCT02504216|Drug|Rivaroxaban-Placebo|matching placebo, twice daily, orally, tablet
1500140|NCT02968316|Other|BIA measurement|observation only
1500141|NCT02968303|Drug|Vemurafenib and Cobimetinib|Combination of Vemurafenib with Cobimetinib in BRAF V600E/K mutated melanoma patients to normalize LDH and optimize immunotherapy with Nivolumab and Ipilimumab
2002109|NCT02504099|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet; Ombitasvir coformulated with Paritaprevir and ritonavir
1500145|NCT02968277|Device|LifeWalker Upright|Comparison of three different walker between individuals with without back pain.
1500146|NCT02968277|Device|Predicate Device|Individual's personal walker
1500147|NCT02968277|Device|Standard Rollator|A control rollator device
1500148|NCT02968251|Behavioral|Hand Washing Program (HWP)|HWP consists of integrating hand washing practice in the school health policy, setting up proper hand washing facilities in the intervention schools, training to school teachers, delivering of health talk to schoolchildren and their parents, developing reminders and posters of a simplified 5-step hand washing technique, peer briefing session, take home package (5-steps hand washing, commitment letter, poster, leaflet). The program will be delivered once every week.
1500149|NCT02968238|Behavioral|Cognitive-behavioral therapy|10 weekly sessions of cognitive-behavioral therapy
1500150|NCT02968238|Behavioral|Yoga|10 weeks of biweekly yoga sessions (N = 20)
1500151|NCT02968225|Other|Computer Game|The game involves viewing subtle nonverbal behaviors of game characters for the purpose of executing their own goal-directed behavior in the game related to solving various crimes. The learning involves interpreting nonverbal cues on the animated characters, such as pointing, head turns, eye gaze cues.
1500152|NCT02968212|Drug|Clofazimine|All participants in the experimental/treatment arm on this protocol will take a loading dose of 200 mg daily in soft capsule form of clofazimine for 16 weeks, dropping to 100 mg daily for the next 8 weeks.
1500153|NCT02968212|Other|sugar pill|All participants in the placebo arm on this protocol will take placebo in soft capsule form daily dropping to a smaller dose after 16 weeks to mirror the treatment arm dosing.
1500154|NCT02968199|Behavioral|A brief intervention|The content of the intervention includes: (1) asking about tobacco use; (2) advising cessation; (3) assessing willingness to quit; (4) assisting in the attempt to quit; and (5) arranging follow-up.
1500155|NCT02968186|Behavioral|Implementation program|Health professionals in the intervention arm will receive up to four training sessions in the first three months of the implementation period. Practice support will be continuously available throughout the project. Posters specifically designed for this project will be added to the primary health care units aiming to facilitate eliciting alcohol issues during the consultations, and to help professionals remembering to conduct alcohol screening and brief intervention. Leaflets to be handed-in to patients were also specifically produced for this project, aiming to aid professionals in advising at-risk drinkers to cut down. The research team will schedule with each primary health care unit regular visits for feedback on the progress of the program.
1500156|NCT02968173|Drug|Palivizumab|Palivizumab is a humanized immunoglobulin G1 (IgG1) monoclonal antibody directed to an epitope in the A antigenic site of the F (fusion) protein of respiratory syncytial virus (RSV).
1500157|NCT02968160|Drug|Telmisartan 40mg + Rosuvastatin 20mg|
1500158|NCT02968160|Drug|Telmisartan 80mg + Rosuvastatin 20mg|
1500159|NCT02968160|Drug|Telmisartan 40mg, 80 mg|
1500160|NCT02968160|Drug|Rosuvastatin 20mg|
1500161|NCT02968147|Device|High frequency jet ventilation|General anaesthesia and ventilation with the Acutronic Monsoon III Jet ventilator system
1500162|NCT02968147|Device|Conventional ventilation|General anaesthesia and ventilation with a conventional Phillips intermittent positive pressure ventilator system
1500163|NCT02968134|Drug|Posaconazole|A single dose of 300mg intravenous posaconazole will be administered and blood samples will be taken prior to start of infusion, at 15,45,75minutes, 3,5,8,12,18,24,30,36 and 48 hours.
1500164|NCT02968121|Drug|Brexpiprazole, OPDC-34712|
1500165|NCT02968108|Drug|Ustekinumab|Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects <40 kg or 130 mg for subjects >= 40 kg in Group 1 and 9 mg/kg for subjects < 40 kg or 390 mg for subjects >= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects < 40 kg or 90 mg for subjects >= 40 kg at Week 8.
1500166|NCT02968095|Behavioral|Text Message Craving Program|Text messages targeting cravings delivered 2-3 times per day.
1500167|NCT02968095|Behavioral|Self-Help Manual Plus Control Texts|Self-help manual plus motivational text messages delivered 2-3 times per day.
1500200|NCT02967770|Other|Molecularly Tailored Second Line Therapy|This trial is designed to assess the efficacy of MTT vs. SOC therapy as second-line therapy in patients with metastatic pancreatic cancer.
1500168|NCT02968082|Drug|Scopolamine|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
1500169|NCT02968082|Drug|Placebo|Patch will be applied under the ear of the opposite side of operation, at 9 p.m. of the day before the operation day. Nausea will be assessed by Visual Analogue Scale (VAS) immediate after arrival at a recovery room and the ward. After that, nausea will be continuously assessed every 4 hour (4hr, 8hr, 12hr, 16hr, 20hr, and 24hr after surgery) and a number of vomiting will also be counted. Basic clinical characteristics and the number of antiemetic administration will be identified through medical records.
1500170|NCT02968069|Device|NBI|Endoscopic factors under white light view and simplified narrow band imaging classification assisting in diagnosing cancerous lesions will be recorded.
1500171|NCT02968056|Procedure|Radiofrequency ablation|Radiofrequency energy is used for ablation in both arms of this study (Hybrid group and MIS group)
1500172|NCT02968043|Other|physiotherapeutic scoliosis specific exercises|Physiotherapeutic scoliosis specific exercises (PSSE) is recommended as a first step in the treatment of AIS to halt curve progression by SOSORT guidelines. The PSSE program will be personalized according to the subject's curves characteristics. The program includes patient and family education, 3D self-correction, stabilizing exercises, balance training, breathing exercises, and training in activities of daily living. A physiatrist will give a detailed explanation of the aims, importance, methods, and procedure of an intervention to patients and their parents. Each subject will receive guidance from multiple physiotherapists to ensure that the treatment effects are the result of the protocol and not any particular physiotherapists.
1500173|NCT02968043|Other|generalised physiotherapy exercises|Generalised physiotherapy exercises includes stretching and strengthening activities. Little evidence is in favor of generalised physiotherapy exercises. Each subject will receive guidance from multiple physiotherapists.
1500174|NCT02968030|Other|Muscle strength|"Strength training The strength training for lower limbs muscles occurred twice a week, 40 minutes per session for eight consecutive weeks.
n the first two weeks of training, each elderly performed the exercises with 50% of its load defined in 8RM test, increasing to 60 and 70% of the load in the third and fourth subsequent weeks, respectively. After this period, a new evaluation by 8RM strength test was conducted, adopting the fifth and sixth weeks of training 50% of value of the new load defined in 8RM test and to finalize the program in seventh and eighth weeks applied, respectively, 60% and 70% of the new charge. The exercises were performed for the quadriceps, hamstrings, muscles adductor and abductor hip."
1500175|NCT02968004|Drug|MOD-4023|Once weekly subcutaneous injection using pre-filled pen device.
1500176|NCT02968004|Drug|Somatropin|Once daily subcutaneous injection of Genotropin
1500177|NCT02967991|Device|EUS-guided liver biopsy|Endoscopic ultrasound guided liver biopsy
1500178|NCT02967965|Other|Imagery|MRI at year 3
1500179|NCT02967952|Device|supraglottic airway (SGA) V.S. endotracheal intubation (ETI)|already being described above
1500180|NCT02967939|Drug|DA-2802|DA-2802 319mg tablet qd + placebo tablet matching to Viread® 300mg.
1500181|NCT02967939|Drug|Viread®|Viread® 300mg tablet qd + placebo tablet matching to DA-2802 319mg.
1500182|NCT02967926|Procedure|Endoscopic Retrograde Cholangioscopy by SpyGlass (ERCS)|Digital SpyGlass Cholangioscopy to facilitate common bile duct stone removal
1500183|NCT02967913|Procedure|Bladder flap|bladder is separated from the lower uterine segment prior to making the uterine incision at time of cesarean delivery
1500184|NCT02967887|Drug|cisplatin and 5-fluorouracil|Hepatic arterial infusion of Cisplatin (60mg/m2 for 2h on day 2) and 5-fluorouracil (500mg/m2 for 5h on days 1-3) through implanted port system (chemoport)
1500185|NCT02967874|Procedure|Intra-articular auto-SVFs injection|Liposuction under local anesthesia followed by single intra-articular injection of auto-SVFs under the ultrasound navigation
1500186|NCT02967874|Drug|Hyaluronic Acid|Single intra-articular injection of Synocrom Forte 2% under the ultrasound navigation
1500187|NCT02967861|Behavioral|Pranayama|Pranayama is the breathing exercise through the nostrils. It enhances the systemic immunity which in turn enhances the overall defense mechanism of an individual.
1500188|NCT02967861|Procedure|Scaling and root planing|It is a mechanical debridement of dental plaque.
1500189|NCT02967848|Other|99mTc-mebrofenin hepatobiliary scintigraphy (HBS)|99mTc-mebrofenin HBS is a SPECT imaging procedure that allows evaluation of global and local liver function. Mebrofenin, bound to albumin, is taken up by hepatocytes in a similar manner to organic anions such as bilirubin. After hepatic uptake, the mebrofenin is excreted into the bile canaliculi. Dynamic imaging tools allow measurement of clearance rates for global function, and 3D SPECT imaging with corresponding CT allows visualisation of the local liver function with respect to anatomy. HBS allows direct visualisation of hepatocyte function.
1500190|NCT02967848|Other|Indocyanine Green|ICG is a fluorescent dye injected into the patient. The dye is exclusively excreted by the liver. The ICG clearance rate is measured in the finger of the subject.
1500191|NCT02967848|Other|Liver Elasticity|This is an Ultrasound measurement of the elasticity of the liver.
1500192|NCT02967835|Behavioral|Tele-psychiatry consult|tele-psychiatry consult for evaluation and treatment recommendations
1500193|NCT02967822|Genetic|Biological samples for patients|Blood samples. Sampling of uterine tissue during surgical intervention (collection of samples for the study only if samples remain after the routine care analyses)
1500194|NCT02967822|Genetic|Biological samples for healthy relatives|Blood samples.
1500195|NCT02967809|Device|echography|cardiac and pulmonary echography
1500196|NCT02967796|Dietary Supplement|Proteochoc|
1500197|NCT02967783|Device|ID adaptor|ID adaptor fixed to the end of a standard ID needle and syringe to facilitate ID administration of the inactivated poliovirus vaccine
1500198|NCT02967783|Device|ID Jet Injector (Tropis, Pharmajet)|ID disposable syringe (needle free) jet injector to facilitate ID administration of the inactivated poliovirus vaccine
1500199|NCT02967783|Device|Needle and syringe|Standard ID needle and syringe for ID administration of the inactivated poliovirus vaccine
1500201|NCT02967770|Drug|Standard of Care Second Line Therapy|
2002110|NCT02504099|Drug|Dasabuvir|Tablet
1500203|NCT02967744|Drug|NSAID|NSAIDs are among the most common pain treatments for patients with osteoarthritis.
1500204|NCT02967731|Drug|480 Mometasone Furoate Sinus Drug Depot|Management of Chronic Sinusitis
1500205|NCT02967705|Behavioral|Pain management group|Chronic pain patients participate in a peer group. They are provided information about chronic pain self-management based on biopsychosocial framework.
2002111|NCT02504099|Drug|Ribavirin|Tablet
2002112|NCT02502253|Drug|grape seed polyphenolic extract, resveratrol|Bioactive Dietary Polyphenol Preparation (BDPP) is a combination of two nutraceutical preparations (grape seed polyphenolic extract [GSE], and resveratrol) that contain abundant concentrations of polyphenols.
2002113|NCT02502383|Behavioral|ACTION PAC|Adolescents enrolled in ACTION PAC will meet with SBHC providers. SBHC providers will use Motivational Interviewing to motivate students to adopt strategies for improving nutrition and increasing physical activity. All participants will receive annual BMI results discussion with providers. Overweight/Obese adolescents will meet with providers for 16 sessions over 2 years.
2002114|NCT02502383|Behavioral|Comparison|Annual BMI results will not be discussed with participants in comparison schools; however, a letter containing BMI results and obesity prevention recommendations will be sent to parent/guardians.
1500210|NCT02967679|Drug|MD1003|
1500211|NCT02967666|Radiation|FDG ligand|
1500212|NCT02967666|Radiation|DOTANOC ligand|
1500214|NCT02967640|Drug|Ketamine|
1500215|NCT02967640|Drug|Placebo|
1500216|NCT02967627|Device|Incisional Negative Pressure Wound Therapy (iNPWT)|Incisional Negative Pressure Wound Therapy devices are lightweight, self contained, portable battery powered (or line powered), suction pumps for medical procedures where secretions and other body fluids and infectious materials must be removed through the application of continuous or intermittent negative pressure. The pumps are operated through computer software, having help and alarm features. The device is indicted for management of chronic, acute, traumatic, subacute and dehisced wounds, partial-thickness burns, ulcers (such as diabetic or pressure), flaps and grafts. The pumps may be used at patient's bedside. These are suitable for use in either hospitals or long term care facilities and nursing homes. These devices will be applied to closed laparotomy incisions with the aim to provide three days of continuous negative pressure of - 100mmHg.
1500217|NCT02967627|Device|Sterile Gauze Dressing|In most cases, self-adhesive, absorbent dressings will be used for standard wound therapy. However, surgical teams may decide on alternative forms of sterile gauze dressings, as long as the wound site is kept clean and dry. Dressings should be taken down on the second post-operative day.
1500218|NCT02967614|Drug|[A]|One eye drop(about 40ul) / Day1 ~ Day8 / BID
1500219|NCT02967614|Drug|[B]|One eye drop(about 40ul) / Day1 ~ Day92 / BID
1500220|NCT02967614|Drug|[A]+[B](1)|One eye drop(about 40ul) / Day9 ~ Day100 / BID
1500221|NCT02967614|Drug|[A]+[B](2)|One eye drop(about 40ul) / Day93 ~ Day100 / BID
1500222|NCT02967601|Behavioral|STAI (State Trait Anxiety Inventory) questionaire|Each patient would fill the STAI questionaire before Cesarean Section (on the same day, in the morning)
1500223|NCT02967588|Behavioral|Intervention group|"All stages of the intervention will take place during hospitalization. Patients will complete a questionnaire about their personal beliefs about medicines. Patients responses to this questionnaire will form the basis of Session 1 where beliefs about medicines will be discussed. Any negative beliefs or concerns will be discussed and beliefs about drug necessity will be encouraged.
Session 2 will focus on developing specific action plans for taking medication at home. Patients will be asked to formulate an if-then plan ('If it is time X in place Y and I am doing Z, then I will take my pill dose').
Prior to discharge, patients will complete the beliefs questionnaire again to see if there has been any shift in their beliefs about medications. Patients will also be asked to provide detailed feedback about the study. The investigators want to know whether the intervention setting, timing, content and delivery method seem to be acceptable to patients."
1500224|NCT02967575|Device|cTDR|"The surgical procedure for the Triadyme-C total disc replacement corresponds to the standard surgical technique for cTDR:
Implantation through a standard anterior cervical approach
Midline identification
Routine discectomy with endplate preparation and decompression
Implant sizing and trial implantation
Keel preparation
Implant preparation and loading of the appropriate Triadyme-C implant
Triadyme-C insertion, positioned as close to the midline as possible"
1500225|NCT02967562|Other|Inflation Breaths|
1500226|NCT02967562|Other|Sustained Inflation|
1500227|NCT02967549|Device|NAVA|NAVA delivered by the Servo-n ventilator (Maquet)
1500228|NCT02967549|Device|PAV|PAV delivered by the Stephanie ventilator (Stephan)
1500229|NCT02967536|Device|Continuous Positive Airway Pressure (CPAP)|All participants in both groups will be started on Auto-titrating CPAP treatment, using standard clinical procedures. In order to facilitate the smooth initiation of CPAP all participants will receive a telephone call after 1 week from a member of the research team. This can be followed up by a hospital visit if required. CPAP is the gold-standard treatment for OSA and can be delivered using a number of different masks. Each of these is CE marked and has been shown to be effective in the treatment of OSA, the interface used will be determined by clinical availability and patient preference. Treatment compliance will be considered as a cofactor.
1500233|NCT02967497|Drug|YQ1|Oral administered powder
1500234|NCT02967484|Device|acupuncture|"Huo Xue San Feng acupuncture method: Patients will recieve the acupuncture treatment,choose the bilateral point:Renying(ST9),Hegu(L14),Taichong(LR3),Quchi(LI11),Zusanli(ST36).
Routine care for ischemic stroke :patients will recieve the acupuncture treatment,choose the point:Neiguan(PC6),Renzhong(10),Sanyinjiao(SP6),Jiquan(HT1),Chize(LU5),Weizhong(BL40).
Drugs: Antihypertensive drugs.Patients will be treated 1 of 5 type of antihypertensive drugs,include ARB、ACEI、βreceptor blocker,CCB,Diuretic.
The time of therapy will consist of 6 times per week in Continuous treatment phase(1st-6th week after enrollment) and 3 times per week(once every other day) in Consolidation treatment phase(7th-tewlve week after enrollment)"
1500235|NCT02967458|Drug|Perflutren Lipid Microsphere Intravenous Suspension|The intravenous administration of Perflutren Lipid Microsphere will provide enhancement of vascular tissue when performing subharmonic prostate ultrasound imaging. This enhancement will be used to guide targeted biopsy of the prostate to vascular areas which are more likely to contain aggressive prostate cancer.
1500236|NCT02967445|Device|Arabin Pessary|Arabin silicon pessary
1500237|NCT02967445|Device|Cervical cerclage|
1500238|NCT02967432|Drug|Mupirocin Topical Ointment|Mupirocin ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
1500239|NCT02967432|Drug|Petroleum Jelly|Petroleum jelly ointment 1/2 inch ribbon applied topically to each nare and umbilicus twice daily for 5 days; repeat treatment courses possible.
1500240|NCT02967419|Other|No Intervention|
1500241|NCT02967406|Behavioral|4 x 4 lifestyle modification|Participants in the intervention group will be given 4x4 lifestyle modification intervention, which will address four health behaviors (diet, physical activity, alcohol drinking and smoking) at four different levels: individual, household, knowledge management and community levels. A new computer program called 'iActive' adapted from the GPAQ with add-on functions to allow real-time assessment and presentation of the energy expenditure along with recommendations specific to each individual will be used. Dietary counseling will be given individually following assessment using a new dietary assessment program called Dietary Assessment Scanning Calculator. Home visit will be done every 3 months by responsible nurses and village health volunteers. Knowledge management will be done through meetings between participants and villages with support from trained nurses. Situation analysis and community action will be encouraged to address four health behaviors.
1500242|NCT02967393|Drug|ccIIV4|
1500243|NCT02967393|Drug|IIV4|
1500244|NCT02967380|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
1500245|NCT02967380|Drug|Gadobenate Dimeglumine|Given IV
1500246|NCT02967380|Drug|Gadobutrol|Given IV
1500247|NCT02967380|Radiation|Gadopentetate Dimeglumine|Given IV
1500248|NCT02967367|Device|Jawbone sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
1500249|NCT02967367|Device|Withings sleep tracker|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
1500250|NCT02967367|Device|BodyMedia Sense Wear accelerometer|During one night of polysomnographic recording, investigators are going to place these 3 accelerometers on the wrist of the patient
1500252|NCT02967341|Other|Ciprofloxacin administration|Ciprofloxacin will be administered via the PAC directly followed by a NaCl 0.9% flush to wash the PAC. At least 1 hour afterwards 500 microliter of blood will be drawn via the PAC. Directly hereafter a blood draw of 500 microliter will be performed either via capillary blood sampling or via a venipuncture. If an anaesthesia is foreseen for another procedure (e.g. a lumbar puncture or an osseous punction), we will strive to perform the peripheral blood draw under anaesthesia.
1500253|NCT02967328|Other|RP% Measurement by FCM as a Diagnostic Test for ITP|
1500254|NCT02967315|Procedure|Cardiac Magnetic Resonance Imaging (CMRI)|"There will be 2 CMRIs. The first one will be patient's routine clinically schedule CMRI after the patient has fasted for 12 hours.This CMRI uses contrast.
The second CMRI will be the research CMRI after the fluid administration. This CMRI does not use contrast."
1500255|NCT02967315|Procedure|Central venous line placement|An ultrasound guided central line catheter will be placed in the internal jugular vein (IJV) under local anesthesia.
1500256|NCT02967315|Procedure|Chest X-ray|A chest X-ray will be performed for safety reasons to rule out pneumothorax (< 1% risk) after central line placement.
1500257|NCT02967315|Procedure|Fluid administration|Administration of 15cc/kg of normal saline for fluid hydration through peripheral IV that is placed for the MRI contrast administration.
1500258|NCT02967315|Procedure|Blood Draw|One to two teaspoons of blood will be drawn for basic metabolic panel.
1500259|NCT02967315|Procedure|Pregnancy test|A urine pregnancy test will be performed in female subjects.
1500260|NCT02967315|Procedure|Electrocardiogram|12 lead ECG
1500261|NCT02967302|Drug|Morphine Sulfate|active intervention
1500262|NCT02967302|Drug|Triamcinolone|active control
1500263|NCT02967302|Drug|placebo|placebo control
1500264|NCT02967289|Drug|Irinotecan|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: irinotecan (Campto®) 180 mg/m² on D1, IV infusion over 90 minutes to begin 30 min after folinic acid infusion is started
1500265|NCT02967289|Drug|Folfox Protocol|every 14 days, 12 cycles, 24 weeks, new cycle beginning on day 15: oxaliplatin (Eloxatin®) 85 mg/m² on D1, IV infusion over 2 hours, followed by folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid) IV infusion over 2 hours 5-FU 2400 mg/m²/h IV continuous infusion over 46 hours starting at the end of folinic acid infusion
1500266|NCT02967276|Drug|Metformin XR|500 mg tablet: They take 1-5 tablets of 500 mg after dinner. Starting dose of Metformin XR 500 mg. It will have an increase of 500 mg/day each week up to the maximum tolerance from the 2500 mg / day, during the 6 cycles.
1500267|NCT02967276|Drug|Dexamethasone|4 mg tablet: Patients will use 40 mg per day. They take 5-10 tablets 4mg after breakfast and lunch. Patients over age 75 will use 20 mg / day.
1500268|NCT02967250|Drug|ursodeoxycholic acid|Subjects will be provided ~50mg/kg/day (based on the use of 250 and 500mg capsules) of UDCA to be divided into 3 equal daily doses and titrated up over ~2 weeks to a stable dose for 4 weeks.
1500269|NCT02967237|Drug|insulin glargine (U300)|Pharmaceutical form: solution Route of administration: subcutaneous
1500280|NCT02967198|Device|CT/US fusion|Fusion of pre-procedure cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
1500281|NCT02967198|Device|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in S-shear wave scanner according to guidelines of ultrasound elastography.
1500282|NCT02967185|Behavioral|Brief Behavioral Therapy for Insomnia|Treatment will consist of 4 weekly, 1 hour sessions and will be conducted by a trained graduate assistant on an individual basis. Treatment components will include education about aging and sleep. It will also include instruction in techniques designed to: (a) promote good sleep habits, (b) restrict the use of the bed and bedroom to sleep and sleep-conducive activities, (c) modify bed and wake times to better match the participants sleep needs, and (d) promote relaxation. Daily home practice of these techniques will be encouraged. Participants will maintain logs of their home practice sessions and will continue to record their daily sleep habits throughout treatment.
1500283|NCT02967172|Drug|Ropivacaine|
1500284|NCT02967172|Drug|Epinephrine|
1500285|NCT02967172|Drug|Morphine|
1500286|NCT02967172|Drug|0.9% sodium chloride solution|
1500287|NCT02967159|Drug|Abediterol|Treatment A: Abediterol 2.5 μg via DPI
1500288|NCT02967159|Drug|AZD7594|Treatment B: AZD7594 440 μg via DPI
1500289|NCT02967159|Drug|AZD7594/abediterol|Treatment C: AZD7594/abediterol 440 μg/2.5 μg FDC via DPI
1500290|NCT02967159|Drug|AZD7594 and abediterol|Treatment D: AZD7594 440 μg and abediterol 2.5 μg free combination administered via 2 separate DPIs
1500291|NCT02967146|Device|adhesive barrier|After having axillary dissection, investigator has to inject the mediclore on op site directly and suture the site.
1500294|NCT02967120|Other|no intervention|
1500295|NCT02967107|Procedure|Cold snare polypectomy|Use of a polypectomy snare closed over a polyp without electrocautery
1500296|NCT02967107|Procedure|Endoscopic mucosal resection|Use of injected chromogelofusine solution to raise a lesion prior to snare resection with electrocautery
1500297|NCT02967094|Drug|Administration of mucolytic solution before upper endoscopy (Espumisan, ACC long)|
1500298|NCT02967094|Drug|Administration of water before upper endoscopy|
1500299|NCT02967081|Procedure|Collection of dentinal fluid using a cellulose membrane|After removal of the caries lesion/filling a cellulose membrane (sterile paper point) will be applied with its blunt end to the dentin for 1 min to collect dentinal fluid.
1500300|NCT02967042|Device|18F-PET-TT|can 18F-PET-TT be used as an diagnostic tool in patients with CKD-MBD
1500301|NCT02967029|Drug|Esmolol Hydrochloride|the influence of brevibloc as a hypotensive agent on rSO2
1500302|NCT02967029|Drug|Remifentanil Hydrochloride|the influence of remifentanyl as a hypotensive agent on rSO2
1500303|NCT02967016|Behavioral|Actigraph|following delivery a ActiGraph will be offered to patients to track their steps
1500304|NCT02966990|Device|Hand Orthotic Devices|Orthotic device made to provide the patient with better hand function
1500305|NCT02966977|Other|Conventional microbiological identification by culture plate|Conventional microbiological identification involves a step of overnight-2days growth of bacteria/fungi on culture plates prior to identification by biochemical methods or by mass spectrometry. See also information noted in arm/group description.
1500306|NCT02966977|Other|Direct mass spectrometry identification from urine sample|The urine sample is concentrated and directly measured by a MALDI-TOF mass spectrometer without an intermediary microbiological culture on agar plates.
1500307|NCT02966964|Drug|DWPUR001|
1500308|NCT02966964|Drug|Placebo|
1500309|NCT02966951|Biological|Adipose tissue derived mesenchymal stem cell|Intra-articular adipose tissue derived mesenchymal stem cell injection.
1500310|NCT02966925|Device|Cellular Matrix BCT-HA Kit|Submucosal injections in the vulva, in the posterior vaginal wall and in the perineum of a combination product made of PRP and HA prepared using the Cellular Matrix BCT-HA medical device
1500311|NCT02966912|Dietary Supplement|400 mg of Magnesium Oxide twice daily for 24 weeks|
1500312|NCT02966912|Other|Open label (none)|
1500313|NCT02966899|Dietary Supplement|Omega-3 fatty acids|
1500314|NCT02966886|Procedure|Eccentric Reaming|
1500315|NCT02966886|Procedure|Augmented Component Implantation|
1500316|NCT02966886|Procedure|Reverse Arthroplasty|
1500317|NCT02966873|Drug|N-Acetylcysteine (NAC) Treatment|Participant will receive 12 weeks of Active Treatment NAC (2400 mg) daily. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
1500318|NCT02966873|Behavioral|Cognitive Behavioral Therapy|Participant will receive 12 weeks of weekly cognitive-behavioral therapy, medication management, and AE monitoring.
1500319|NCT02966873|Drug|Placebo Oral Capsule|Participant will receive 12 weeks of inactive placebo. The study medication will be provided in blister packs in the form of 600 mg tablets. Each participant will be asked to take two (2) 600 mg tablets in the morning and two (2) 600 mg tablets in the evening.
1500320|NCT02966860|Drug|Oral solution OC/APAP|
1500321|NCT02966847|Procedure|CBCT acquisition|Acquisitions are performed with the DynaCT function of a C-arm Artis Zeego System® device
1500322|NCT02966847|Procedure|Anesthesia and surgery|The anesthesia and surgery will take place according clinical routine practice
1500325|NCT02966821|Drug|Sulfatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
1500330|NCT02966769|Other|Overall survival|Compare overall survival between both groups.
1500331|NCT02966756|Drug|Venetoclax|tablet
1500332|NCT02966743|Drug|Midazolam|administration of midazolam during spinal anesthesia for target bispectral index 75-80
1500333|NCT02966743|Drug|Dexmedetomidine|administration of dexmedetomidine during spinal anesthesia for target bispectral index 75-80
1500334|NCT02966730|Drug|Ibrutinib|Ibrutinib will be administered orally, on a once daily continuous dosing schedule and in an outpatient setting. Treatment will continue for 2 years and there will be no planned treatment breaks. The dose of Ibrutinib will be initiated at 560mg per day, which will remain constant throughout the study period, unless otherwise specified.
1500335|NCT02966717|Drug|Rituximab|Rituximab is a human-mouse-chimeric monoclonal antibody which was approved in 1997 for the treatment of cancer.
1500336|NCT02966717|Drug|conventional therapy|Intervention of conventional therapy group: controlling blood pressure using amlodipine, valsartan, metoprolol and terazosin and so on , protecting the renal function using bailing capsule, alpha keto acid, low molecular weight heparin and so on.
1500337|NCT02966717|Drug|Mesenchymal stem cells|Mesenchymal stem cells (MSCs), which belongs to mesoderm, is a kind of somatic stem cell with the ability of self-replication and the potential of multi-directional differentiation.
1500338|NCT02966704|Dietary Supplement|intrinsically labeled milk protein|
1500339|NCT02966691|Other|VisioCyt® diagnostic test|The cytology slides obtained from the current practice will be compared to the slides obtained with the Visiocyt protocol, for each arm.
1500340|NCT02966678|Procedure|Color Vision Test|Farnsworth Panel D15/Hue test plus Ishihara charts
1500341|NCT02966665|Other|Maximum Exercise Tests|Graded exercise test to volitional exhaustion (stationary bike or treadmill), maximal handgrip test, maximal leg extension test, and maximal plantar flexion test.
1500342|NCT02966665|Drug|BH4, L-NMMA, Vitamin C, Vitamin E, α-Lipoic Acid and L-Ascorbate|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, passive leg movement test, exercise bouts, electromyography and exercise training regimen at baseline and following treatment with Nitric Oxide blockade via infusion of N-monomethyl-L-arginine (L-NMMA) (0.4 mg/kg/min), antioxidant cocktail (Vitamin C, Vitamin E, alpha-lipoic acid) ingestion, L-ascorbate injection, BH4 ingestion.
1500343|NCT02966665|Drug|BQ-123|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with endothelin-1 receptor antagonist BQ-123 (D-tryptamine-D-aspartic acid-L-proline-D-valine-L-leucine).
1500344|NCT02966665|Drug|Fexofenadine, Ranitidine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test and exercise bouts at baseline and following treatment with Histamine H1 receptor antagonist fexofenadine (Allegra) and Histamine H2 receptor antagonist ranitidine (Zantac).
1500345|NCT02966665|Other|Angiotensin-II, Valsartan|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement, and exercise bouts at baseline and following treatment with Angiotensin-II receptor agonist (angiotensin-II) and antagonist Valsartan (Diovan).
1500346|NCT02966665|Drug|Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine, Phentolamine|Catheter placement in femoral artery and femoral vein; resting measurements of blood pressure, heart rate and blood flow; flow mediated vasodilation test, muscle sympathetic nerve activity measurement; vasodilation with nitroglycerin followed by Angiotensin-II and Alpha Adrenergic blockade with infusions of Acetylcholine, Sodium Nitroprusside, Angiotensin-II, Norepinephrine and Phentolamine (Regitine).
1500347|NCT02966665|Drug|BQ-123, MitoQ, BH4|Catheter placement in femoral artery and femoral vein and muscle biopsy; Nuclear Magnetic Resonance (NMR) scanning and exercise bouts at baseline and following treatment with BQ-123 with or without oral mitochondria-targeted antioxidant (MitoQ) or oral BH4.
1500348|NCT02966652|Drug|DITEST|Lipid formulation of native oral testosterone.
1500349|NCT02966652|Drug|Testosterone undecanoate|Generic treatment for patients with primary or secondary male hypogonadism
1500350|NCT02966613|Device|GMK Medacta Total Knee arthroplasty|Total Knee arthroplasty
1500351|NCT02966600|Other|Progressive resistance exercise|The intervention group participated in sixteen PRE training sessions for eight weeks: two sessions per week on non-consecutive days, sixty-seventy min each one.
1500352|NCT02966600|Other|Physical Activity|The control group followed its usual weekly physical activity routine
1500353|NCT02966587|Biological|Durvalumab|Given IV
1500354|NCT02966587|Other|Laboratory Biomarker Analysis|Correlative studies
1500355|NCT02966574|Device|whole body MRI|The examination will be conducted in the pretreatment assessment of breast cancers with a high metastasis risk and in the monitoring of metastatic breast cancers. The examination is performed without intravenous injection of contrast medium, from the top of the skull to mid-thigh using diffusion weighted sequences in the axial plane, T1-weighted sequences in the coronal plane, STIR T2 weighted sequences in the coronal plane and T1-weighted sequences in the sagittal plane on the spine. Total examination duration is one hour. The interpretation of the results is made by two independent reporters with a complementary expertise, according to a systematic lecture grid.
1500356|NCT02966561|Behavioral|Pedometer-based activity promotion|"The central components of the 2 x 45 minutes lasting pedometer-based physical activity behaviour change intervention BCI are the following behaviour change techniques (BCTs):
Instruction on how, where and when to perform the behaviour
Prompt goal setting for physical activity
Prompt self-monitoring of behaviour
Feedback on behaviour. Participants receive a pedometer and a booklet with a physical activity diary and associated information on the importance of goal setting and keeping a physical activity diary, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
1500394|NCT02966275|Device|Glucagon-only bionic pancreas - placebo|A computer algorithm will automatically deliver placebo based on the signal from a minimally invasive continuous glucose monitor.
1500395|NCT02966262|Device|Optical coherence tomography|Intracoronary imaging device which can precisely observe intracoronary structures
1500396|NCT02966249|Drug|Levobupivacaine|3 ml Levobupivacaine 0.5% (15mg) given intrathecally
1500357|NCT02966561|Behavioral|Short patient education and exercise|"The central components of the 2 x 45 minutes lasting intervention are revisions of knowledge of the pulmonary rehabilitation (standard care) in combination with related exercises:
Revision of knowledge on exercise recommendations
Revision of knowledge on possibilities of self-regulation of endurance training exercise intensity with the rate of perceived exertion (BORG-Scale)
Revision of self-regulation of endurance exercise intensity
Revision of strengthening activities consistent with the exercise recommendations.
Participants receive a booklet with information on the rate of perceived exertion, exercise recommendations, possibilities to stay active after rehabilitation and appropriate physical activities."
1500358|NCT02966561|Other|Pulmonary rehabilitation (Standard care)|Standard care is an in-patient pulmonary rehabilitation (PR) in a specialized German Rehabilitation Clinic. PR is a comprehensive, multidisciplinary intervention based on a patient assessment followed by a combination of patient-tailored therapies. PR lasts on average 25 days. PR includes the following obligatory main components: Checking and, if required, adjusting the current COPD medication according to current COPD-guidelines; physical training (4-5 units/week endurance training [45 min] and 3 units/week of strength training [45 min] per week, 7 units/week whole body vibration muscle training/week); structured COPD-patient education (6 hours patient education COPD + 1 hour device training); respiratory physiotherapy in groups [2-4 units/week with 45 min]. PR is implemented by an interdisciplinary rehabilitation team.
1500359|NCT02966548|Drug|Relatlimab|Specified dose on specified days
1500360|NCT02966548|Drug|Nivolumab|Specified dose on specified days
1500361|NCT02966535|Device|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:2 to 1:1)
1500362|NCT02966535|Device|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)|Adjustment of Mechanical Ventilator Inspiratory to expiratory time ratio (1:1 to 1:2)
2002119|NCT02499029|Drug|N-acetylcysteine|NAC pills were administered each week. NAC is a N acetyl pro-drug of the naturally-occurring amino acid cystine. NAC is a white, crystalline powder with the molecular formula C5H9NO3S and with a molecular weight of 163.2.
2002120|NCT02499029|Drug|Placebo|Identical looking placebo pills were administered each week.
2002121|NCT02497781|Drug|Ceftazidime -avibactam|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
1500366|NCT02966496|Biological|Acri.LISA366D multifocal aspheric IOLs|The implantation of Acri.LISA366D multifocal aspheric IOLs are used in the test group.
1500367|NCT02966496|Biological|TecnisZ9001 multifocal aspheric IOLs|The implantation of TecnisZ9001 multifocal aspheric IOLs are used in the test group.
1500368|NCT02966483|Procedure|TaTME|Transanal Total Mesorectal Excision
1500369|NCT02966483|Procedure|LpTME|Conventional Laparoscopic Total Mesorectal Excision
1500370|NCT02966470|Device|Obtain grip strength from a standardized gripometer|Obtain grip strength from a standardized gripometer, 3 times on each hand
1500371|NCT02966457|Drug|Colistimethate Sodium|Selective oral intestinal decolonization
1500372|NCT02966444|Other|MUFA-rich HF Meal|
1500373|NCT02966444|Other|PUFA-rich HF Meal|
1500374|NCT02966444|Other|SFA-rich HF Meal|
1500375|NCT02966431|Behavioral|Counseling|
1500376|NCT02966431|Behavioral|No Counseling|
1500377|NCT02966418|Procedure|Mild Hypoxia Preconditioning|Patients will be treated with mild hypoxia ( Note: The oxygen concentration decreased from 20% to 18%, and keeping at 18%)×7 days，twice a day in the morning and in the afternoon before surgery.
1500378|NCT02966418|Procedure|Sham preconditioning|Patients will be treated with sham preconditioning (oxygen concentration: 21％) ×7 days，twice a day in the morning and in the afternoon before surgery.
1500379|NCT02966392|Device|Tracoe cuff pressure controller|Participant will be attached to the cuff pressure controller as soon as possible after enrolment. They will remain attached during their intubated stay. If reintubated during same admission they will continue in the intervention arm. If readmitted to ICU they will be managed according to standard care.
1500380|NCT02966379|Device|cochlear implantation|"Surgery is standardized in order to have the same procedure for all patients and to preserve a maximum of residual hearing:
Corticosteroïds (1mg/kg solumedrol) at anesthetic induction ,
mastoidectomy + posterieur tympanostomy ,
insertion through round window,
stop at the first resistance point"
1500381|NCT02966366|Device|Cochlear implant|
1500382|NCT02966353|Drug|ruxolitinib|Ruxolitinib will be supplied to the investigator by sponsor in 5 mg tablets. Ruxolitinib should be taken orally, approximately 12 hours apart (morning and night) without regard to food unless instructed to temporarily hold taking drug by investigator.
1500383|NCT02966340|Drug|Prazosin|2mg Prazosin
1500384|NCT02966340|Drug|Placebo|Placebo
1500385|NCT02966327|Device|Bilateral leg compression stockings|Prescribed Jobst Elvarex compression class 1 (18 to 21 mmHg) standard or custom-made stockings for both lower limbs with or without panty; participants will be recommended to wear the garments for 12 to 16 hours daily for at least 6 months post-operatively.
1500386|NCT02966327|Behavioral|Individualized exercise|Individualized education on exercise according to the Canadian Physical Activity Guidelines and self-lymphatic drainage techniques
1500387|NCT02966327|Behavioral|Lymphedema risk reduction|Standard education on lymphedema risk reduction along with printed materials from the Lymphedema Association of Quebec
2002122|NCT02497781|Drug|Cefepime|Patients randomised (3:1) to the CAZ-AVI or cefepime treatment
1500390|NCT02966301|Drug|Arsenic Trioxide Injectable Solution|"Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).
Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.
The study duration will be 2 years (12 months recruitment + 12 months follow-up)."
1500391|NCT02966288|Drug|Toradol|3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
1500392|NCT02966288|Drug|Oral NSAID|800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
1500393|NCT02966275|Device|Glucagon-only bionic pancreas - glucagon|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
1500397|NCT02966249|Drug|Dexmetomidine intravenously|Continuous infusion of dexdemetomidine at a rate of 0.25 μg/kg/h given intravenously 10 min before spinal anesthesia in total knee arthroplasty
1500398|NCT02966249|Drug|Normal Saline added intrathecally|Normal Saline added to 5μgr dexmetomidine up to 0,5 ml given intrathecally for spinal anesthesia in total knee arthroplasty
1500399|NCT02966249|Drug|Normal Saline intrathecally|0,5 ml Normal Saline given intrathecally given once for spinal anesthesia in total knee arthroplasty
1500400|NCT02966249|Drug|Ringer's Lactate solution intravenously|Continuous infusion of Ringer's Lactate solution given intravenously, starting 10 minutes before spinal anesthesia up to the end of the operation
1500401|NCT02966249|Drug|Dexmetomidine intrathecally|5 μgr dexmetomidine given intrathecally once for anesthesia in total knee replacement
1500402|NCT02966236|Drug|Tranexamic Acid|
1500403|NCT02966236|Drug|Placebos|
2002123|NCT02496143|Drug|EC-18|EC-18 will be supplied as 500 mg Softgel capsules. The study will include up to four sequential dose cohorts. Six subjects in each cohort will be randomized to receive EC-18: 500, 1000, 2000, or 4000 mg by oral administration of 1, 2, 4, and 8 EC-18 capsules, for Cohorts 1, 2, 3 or 4, respectively.
1500405|NCT02966197|Procedure|prophylactic internal iliac artery balloon catheterization|Between June 2015 and August 2016
1500406|NCT02966197|Device|Prophylactic internal iliac artery balloon|
1500407|NCT02966197|Radiation|Radiology operation|
2002124|NCT02496143|Drug|Placebo|Placebo will be supplied as Softgel capsules. The study will include up to four sequential dose cohorts. Two subjects in each cohort will be randomized to placebo and will receive 1, 2, 4 or 8 placebo capsules for Cohorts 1, 2, 3 or 4, respectively.
1500409|NCT02966171|Drug|HMPL-453|oral administration
1500410|NCT02966158|Other|AIT Group|"The AIT Group will begin with a one-month, run-in period where patients will perform current standard of care CR programming, which will involve traditional MICE. MICE at the Cardiac Rumsey Centre will consist of either track walking/jogging or treadmill walking/jogging for approximately 30-40 minutes, performed at an intensity of 60-80% of VO2peak, in addition to a warm-up and cool down period. In the second month of the study intervention, patients will begin to perform AIT three days per week, which involves performing 4-minute intervals at greater than 90% of peak heart rate, separated by 3-minutes of active recovery, with one of those AIT exercise sessions occurring at the Rumsey Centre under supervision, and 2 sessions per week of MICE, which will again consist of the 30-40 minutes of walking/jogging at an intensity of 60-80% of VO2peak, with an allotted warm up and cool down period."
1500411|NCT02966145|Other|Observational Study|
1500412|NCT02966132|Behavioral|iMD|Interactive video education delivered on a tablet computer
1500413|NCT02966132|Behavioral|NPA|
1500414|NCT02966119|Drug|Clopidogrel or Aspirin and/or Dypyridamole|"The physician will prescribe on this antiplatelet agent if the patient is randomized in the arm  restart"
1500415|NCT02966106|Device|Right prefrontal low frequency rTMS|A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
1500416|NCT02966106|Other|Sham-rTMS|Right prefrontal rTMS sham treatment. A treatment session each day in four weeks apart from weekends. Each session is administered with 2 pulse trains of 180 sec with a 2 min interval
1500417|NCT02966093|Drug|Lenvatinib|Participants will received lenvatinib 24 mg (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
1500418|NCT02966093|Drug|Placebo|Participants will received lenvatinib matched placebo (two 10-mg capsules + one 4-mg capsule) orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity, withdrawal of consent, or study termination by sponsor.
1500419|NCT02966080|Drug|HEP-IV|
1500420|NCT02966067|Device|Microneedle Device (Experimental)|Injection of 1.2ml of a standard local dental anaesthetic solution [1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)] at a rate of 1 mL/min.
1500421|NCT02966067|Device|30-gauge Short Hypodermic Needle|Injection of 1.2ml of a standard local dental anaesthetic solution [1.2ml of 2% lidocaine and 1:80,000 epinephrine (lidocaine 20 mg/ml, epinephrine 12.5 mμ/ml)] at a rate of 1 mL/min.
1500425|NCT02966041|Drug|Ondansetron|
1500426|NCT02966041|Drug|Saline/Placebo|
1500427|NCT02966028|Drug|SNF472|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
1500428|NCT02966028|Drug|Placebo|Administered 3 times weekly by intravenous infusion through the dialysis machine in conjunction with the patient's dialysis sessions.
1500430|NCT02966002|Drug|Aspirin|
1500432|NCT02965976|Biological|Botulinum Toxin Type A|Given IM
1500433|NCT02965976|Procedure|Esophagectomy|Undergo esophagectomy
1500434|NCT02965976|Other|Quality-of-Life Assessment|Ancillary studies
1500435|NCT02965963|Drug|Dopamine|
1500436|NCT02965963|Drug|Metoclopramide|
1500437|NCT02965963|Drug|Placebos|
1500438|NCT02965963|Other|Rest|
1500439|NCT02965963|Other|Exercise - 60%|60% of VO2max
1500440|NCT02965963|Other|Exercise - 85%|85% of VO2max
1500441|NCT02965950|Drug|Cyclophosphamide|I.v. infusion
1500442|NCT02965937|Other|Story-centred care intervention program|"Participants in the intervention group received the Story-Centred Care Intervention Program once a week for four weeks."
1500443|NCT02965937|Other|Health consultation control condition|The control group received a health consultation from researchers once a week for four weeks.. The health consultation will be tailored to the participants' needs. Based on a previous study12, the health consultation will include pain management, healthy nutrition, how to make best use of medical services and education and counselling for individual health-related concerns.
1500444|NCT02965924|Drug|Phenylephrine 2.5%|Instilling phenylephrine 2.5% eye drop
1500493|NCT02965638|Other|Administration of placebo gas|The placebo arm (Placebo Group) will receive air via nasal cannula up to 24 hours daily
1500445|NCT02965911|Drug|Fenofibrate|Fenofibrate is a drug of the fibrate class. it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein (HDL) levels and reducing triglyceride levels.
1500446|NCT02965911|Drug|UDCA|Ursodeoxycholic acid，the abbreviation UDCA, is one of the secondary bile acids, which are metabolic byproducts of intestinal bacteria，it is the only FDA approved drug to treat PBC.
1500447|NCT02965898|Dietary Supplement|Vitamin D 100ug|Vitamin D 100 ug from Orion Pharma. Safest highest daily dose of vitamin D.
1500448|NCT02965898|Dietary Supplement|Vitamin D 10ug|Placebo dose. Minimal recommended dose.
1500449|NCT02965885|Drug|TAS-116|TAS-116 is an oral heat shock protein 90 (HSP90) inhibitor investigated in 3 dosing regimens (QD, QOD, 5 days on 2 days off) in patients with advanced solid tumor.
1500450|NCT02965872|Other|No intervention|
1500451|NCT02965859|Drug|Metacavir Enteric-coated Capsules 80mg|Metacavir Enteric-coated Capsules 80mg
1500452|NCT02965859|Drug|Metacavir Enteric-coated Capsules 160mg|Metacavir Enteric-coated Capsules 160mg
1500453|NCT02965859|Drug|Metacavir Enteric-coated Capsules 320mg|Metacavir Enteric-coated Capsules 320mg
1500454|NCT02965859|Drug|Metacavir Enteric-coated Capsules Placebo 240mg|Metacavir Enteric-coated Capsules Placebo 240mg
1500455|NCT02965859|Drug|Metacavir Enteric-coated Capsules Placebo 160mg|Metacavir Enteric-coated Capsules Placebo 160mg
1500456|NCT02965859|Drug|Metacavir Enteric-coated Capsules Placebo 320mg|Metacavir Enteric-coated Capsules Placebo 320mg
1500457|NCT02965859|Drug|Adefovir Dipivoxil Capsule10mg|Adefovir Dipivoxil Capsule10mg
1500458|NCT02965859|Drug|Adefovir Dipivoxil Capsule Placebo 10mg|Adefovir Dipivoxil Capsule Placebo 10mg
1500459|NCT02965846|Drug|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
1500460|NCT02965846|Drug|Vehicle|1 drop of AGN-195263 vehicle(placebo) will be instilled in each eye twice daily.
1500461|NCT02965833|Device|Clear Care® Plus Contact Lens Solution|3% hydrogen peroxide solution with HydraGlyde® Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
1500462|NCT02965833|Device|Habitual Multi-Purpose Contact Lens Solution|
1500463|NCT02965833|Device|Habitual Contact Lenses|Participant's habitual contact lens brand worn in a daily wear modality for 30 days.
1500464|NCT02965820|Device|Opti-Free® PureMoist® contact lens solution|
1500465|NCT02965820|Device|Habitual Multi-Purpose Contact Lens Solution|
1500466|NCT02965820|Device|Habitual Contact Lenses|Participant's habitual contact lens brand worn in a daily wear modality for 30 days.
1500467|NCT02965807|Device|Bronchial Thermoplasty|patients will be under Bronchial Thermoplasty approximately every three weeks.And totally having three surgerys will be considered as completed.
1500468|NCT02965794|Other|Care pathways for colorectal cancer|development of a care pathway for this patient group
1500469|NCT02965781|Drug|SADBE|Topical solution
1500470|NCT02965781|Other|Placebo|Topical solution
1500471|NCT02965768|Drug|Naltrexone HCl|4.5 mg Naltrexone HCl, p.o., nocte (standard-dose); 3.0 mg Naltrexone HCl, p.o., nocte (optional-dose);
1500472|NCT02965755|Other|Treatment recommendation|Depending on the results from the participant's archival tissue, a panel of Johns Hopkins investigators will meet to interpret the molecular and genetic profiling results in order to identify any actionable mutations to provide a personalized treatment recommendation for the patient.
1500473|NCT02965742|Device|Stratos|A machine made by DMS group.
1500474|NCT02965742|Device|"Hologic QDR 4500A"|A machine made by Hologic inc.
1500475|NCT02965729|Behavioral|Family-based weight management|"The Our Lifestyles, Our Lives family-based weight management intervention consisted of 10 weekly 90-minute group sessions focused on physical activity, nutrition, and behavioral modification. Parents and siblings were encouraged to join the participant in these sessions. Sessions were interactive and included cooking demonstrations, light to moderate intensity physical activity that engaged all family members, and behavioral counseling sessions in both mixed (parent and child) and parent-only format."
1500476|NCT02965729|Behavioral|Pedometer|In addition to participating in the family-based weight management intervention, participants were given a pedometer (Omron HJ-324U, Omron Healthcare, Lake Forest, IL) and instructions at session 1. Participants were asked to wear the pedometer every day for the entirety of the program and return at session 10.
1500477|NCT02965729|Behavioral|Individualized step goals|In addition to participating in the family-based weight management intervention, participants were given a step goal to increase their activity by 500 steps each week (above baseline calculated as average daily steps/day during week 1).
1500478|NCT02965716|Other|Laboratory Biomarker Analysis|Correlative studies
1500479|NCT02965716|Biological|Pembrolizumab|Given IV
1500480|NCT02965716|Biological|Talimogene Laherparepvec|Given IL
1500485|NCT02965690|Procedure|NexGen CR|Total Knee Replacement
1500486|NCT02965690|Procedure|GMK Sphere|Total Knee Replacement
1500487|NCT02965677|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
1500488|NCT02965677|Device|Peripheral Balloon Dilatation Catheter|in this group the subject will be treated by Paclitaxel Eluting Balloon Dilatation Catheter
1500489|NCT02965664|Drug|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
1500490|NCT02965664|Drug|Placebo|Placebo drops contain the same ingredients as PresbiDrops except for the active ingredients
1500491|NCT02965651|Behavioral|ECA System|"The ECA system, named Gabby, included content pertaining to stress management, nutrition and physical activity as well as dialogue scripts and media such as meditations. The scripts included motivational interviewing dialogue: dialogue to simulate shared decision making interactions and additional longitudinal interaction using techniques such as goal setting, problem solving, tips, and homework. Gabby was available on a web browser through a username and secure password login."
1500492|NCT02965638|Other|Oxygen|The intervention arm (Oxygen Group) will receive oxygen via nasal cannula at a rate of 4L of FiO2 93-100% from an oxygen concentrator up to 24 hours daily
1500494|NCT02965612|Device|Injex|administration of Specific Immunotherapy (ITS) with car pressure injector without a needle
1500495|NCT02965612|Procedure|SCIT|administration of Specific Immunotherapy (ITS) via traditional subcutaneous
1500496|NCT02965599|Drug|GSK3117391|GSK3117391 (Dose A) is a white, opaque, gelatin capsule.
1500497|NCT02965599|Drug|Placebo|Placebo is a white, opaque, gelatin capsule.
1500498|NCT02965586|Drug|intrathecal|intrathecal block will be performed in sitting position using 25 G spinal needle at either the L3-L4 or L4-L5 intervertebral spaces.
2002125|NCT02496676|Drug|Magnesium L-threonate|Following an initial washout of magnesium-containing supplements, patients with XMEN syndrome will be randomized into 2 arms. Arm 1 will receive 12 weeks of oral magnesium supplementation followed by 12 weeks of placebo. Arm 2 will receive 12 weeks of placebo followed by 12 weeks of oral magnesium supplementation. Magnesium supplementation will consist of escalating doses of daily, orally self-administered magnesium Lthreonate. Dose escalation for oral magnesium L-threonate will be based on patients weight and tolerance of the supplement. Intolerance is defined as gastrointestinal symptoms (eg, diarrhea, nausea) after any dose. Patients experiencing intolerance will revert to the last tolerated dose. Oral magnesium L-threonate capsules will be purchased from commercial sources.
1500501|NCT02965547|Device|Remote ischemic conditioning equipment|The RIPC consisted of 4 cycles of extremities ischemia (5-minute blood-pressure cuff inflation to 200 mm Hg, followed by 5-minute cuff deflation). The tourniquets were applied to one side upper arm and other side thigh. This intervention was undertaken one time in total.
1500502|NCT02965547|Procedure|Intravenous blood collection|Nurses will collect intravenous blood 6ml twice(at baseline and 1h after RIPC).The blood samples will be stored for laboratory test.The blood samples only use for the trial.
1500503|NCT02965547|Procedure|dCA measurement|Serial measurements of dCA were performed at 7 time points, baseline, 1h, 3h, 6h, 9h, 12h, 24h after RIPC.The continuous ABP was measured non-invasively using a servo-controlled plethysmograph (Finometer Pro, the Netherlands) at the middle finger. Two 2 MHz transcranial Doppler probe was used to measure continuous cerebral blood flow velocity (CBFV) simultaneously in the bilateral middle cerebral arteries at a depth of 45-60 mm Endtidal CO2 was monitored using a capnograph (MultiDop X2, DWL, Sipplingen, Germany). The probes were placed over temporal windows and fixed with a customized head frame. CBFV and continuous arterial blood pressure were recorded simultaneously from each subject in the supine position for 10 minutes. All data were recorded for further assessment and analysis.
1500505|NCT02965521|Behavioral|Website and text messages|Participants receive a personalized diet report, access to a digital health dietary intervention, and text messages for 12 weeks.
1500506|NCT02965508|Other|Home-based Primary Care|Care in the programs is inter-professional and team-based. Each physician leads a team charged with the care of a panel of patients and directs the team's activities. New patients are assigned a Mount Sinai Visiting Doctors (MSVD) primary care physician or the Chelsea Village House Calls Program (CVHCP) who makes an initial visit within 2 weeks of the patient's enrollment in the program. The primary care physician completes a comprehensive medical history and physical exam during the initial visit including standardized assessments of physical functioning and cognition. The primary care physician then provides ongoing management of the patients' acute and chronic health problems, including palliative and home hospice care when needed, every 2 to 12 weeks as determined on a case-by-case basis.
1500507|NCT02965508|Other|Usual Care|Office based care
1500508|NCT02965495|Drug|YYD302 2ml|YYD302 2ml
1500509|NCT02965495|Drug|YYD302 3ml|YYD302 3ml
1500510|NCT02965495|Drug|Placebo 3ml|phosphate buffered saline 3ml
1500511|NCT02965482|Device|Wright Nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
1500512|NCT02965482|Device|Aerogen Solo Nebulizer|Aerogen Ltd., Galway, Ireland
1500513|NCT02965469|Behavioral|Breathe2Relax|The app teaches diaphragmatic breathing and has audiovisual coaching
1500514|NCT02965456|Drug|IDP 121 Lotion|Lotion
1500515|NCT02965456|Drug|IDP-121 Vehicle Lotion|Lotion
1500516|NCT02965443|Drug|Dapagliflozin 10 mg + Saxagliptin 5 mg|24 weeks intervention with Dapagliflozin 10 mg + Saxagliptin 5 mg
1500517|NCT02965443|Drug|Placebo 1 10 mg + Placebo 2 5 mg|24 weeks intervention with Placebo 1 10 mg + Placebo 2 5 mg
1500518|NCT02965430|Device|AL-SENSE|A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis
1500519|NCT02965417|Drug|Sym004|Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
1500523|NCT02965378|Drug|FGFR Inhibitor AZD4547|Given PO
1500524|NCT02965378|Other|Laboratory Biomarker Analysis|Correlative studies
1500525|NCT02965352|Device|Door handle device|To evaluate the cylindrical grip movement, it was used a door handle, which evaluated all the strength at the arc of motion
1500526|NCT02965352|Device|Linear switch device|To evaluate the pulp-pulp pinch movement, it was used one linear switch, which evaluated all the strength at the motion displacement.
1500527|NCT02965352|Device|Door key device|To evaluate the pulp-side pinch movement, it was used a door key, which evaluated all the strength at the arc of motion
1500528|NCT02965326|Procedure|Nasal swab; rectal biopsy.|Nasal epithelial cells will be obtained by nasal swabs from patients of the three arms; intestinal epithelial cells will be obtained, by rectal biopsy, only from patients treated by CFTR modulators.
1500529|NCT02965313|Procedure|SSLS Procedure|Synthetic suture repair
1500530|NCT02965313|Procedure|BSSVF-M Procedure|Bilateral sacrospinous vaginal vault fixation with synthetic mesh arms
1500532|NCT02965274|Drug|Torrent's Fluoxetine Tablets|
1500533|NCT02965274|Drug|Warner Chilcott LLC's Sarafem Tablet|
1500534|NCT02965261|Drug|Torrent's Fluoxetine Tablets|
1500535|NCT02965261|Drug|Warner Chilcott LLC Sarafem Tablets|
1500574|NCT02964897|Behavioral|Usual care from the Health Care for Reentry Veterans program|Health Care for Reentry Veterans program provides reentry planning while the veteran is incarcerated. An outreach worker visits the veteran in the incarceration facility to conduct a needs assessment and help create a reentry plan to cover issues such as where they will be housed, what health care appointments they will need in the first 30 days, whether they need legal assistance, etc.
1500575|NCT02964884|Drug|Lovastatin 20 MG|Those in the Lovastatin group will receive 20mg of Lovastatin per day for the first two weeks.
1500536|NCT02965248|Drug|Standard adjuvant systemic chemotherapy|"Patients undergo radical surgery with standard adjuvant systemic chemotherapy (mFOLFOX6/CapeOx/sLV5FU2/Cape).
mFOLFOX6: oxaliplatin 85 mg/m2 IV d1 + leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 continuous IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.
CapeOx: oxaliplatin 130 mg/m2 IV d1 + capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles.
sLV5FU2: leucovorin calcium 400 mg/m2 IV d1 + 5-FU 400 mg/m2 IV bolus d1 + 5-FU 2400 mg/m2 IV over 46-48 hours d1-2. Repeat every two weeks for twelve cycles.
Cape: capecitabine 1000mg/m2 po bid d1-14. Repeat every three weeks for eight cycles."
1500537|NCT02965248|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC) with raltitrexed|Raltitrexed (3 mg/m2) is added to the perfusate after attaining 42 degrees of inflow temperature and last for 60 minutes.
1500538|NCT02965248|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC) with oxaliplatin|Before the beginning of HIPEC, 5-FU 400 mg/m2 and leucovorin calcium 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (130 mg/m2) is added to the perfusate after attaining 42 degrees inflow temperature with a total of 30 minutes perfusion time.
1500539|NCT02965222|Device|the time-lapse videography|The all oocytes will be placed in the Time-Lapes .The third day the top-grade embryo will be selected by time-lapse imaging (TLI) .
1500540|NCT02965209|Procedure|motorized spiral enteroscopy|Novel Motorized Spiral Enteroscopy (NMSE) represents a new technology which offers all of the advantageous options of spiral enteroscopy with a faster and less invasive approach. When the region of interest in the small bowel is reached by NMSE standard endoscopic techniques, e.g. argon plasma coagulation (APC), forceps biopsy or endoscopic mucosal resection (EMR) are performed for treatment and/or tissue acquisition.
1500541|NCT02965196|Drug|IV Dexamethasone Therapy|
1500542|NCT02965196|Other|IV Normal Saline (NaCl 0.9%)|
1500543|NCT02965183|Other|Temperature measurements|
1500544|NCT02965157|Biological|CART20|
1500545|NCT02965144|Other|no treatment|no treatment
1500546|NCT02965131|Procedure|Temporary portocaval shunt|The hepatic artery, bile duct, and portal vein are dissected and clamped. The retrohepatic vena cava is preserved with selective clamping of the hepatic veins during total hepatectomy. Then, temporary portocaval shunt is constructed by end-to-end anastomosis of the portal vein stump to the middle and left hepatic vein trunk or by end-to-side anastomosis of the stump to the infrahepatic vena cava depending on the remaining length of the vessels.
1500547|NCT02965118|Drug|PAC-14028 cream 1.0%|topical application
1500548|NCT02965118|Drug|PAC-14028 cream Vehicle|topical application
1500549|NCT02965105|Device|Coloplast Test Catheter|This is a newly developed intermittent catheter
1500550|NCT02965105|Device|Speedicath|This is a marketed Catheter which is used as comparator
1500551|NCT02965092|Genetic|Second generation CAR-T cells|
1500552|NCT02965079|Device|ECCO2R|The ECCO2R system was developed from the principle of ECMO systems by underscoring the importance of carbon dioxide elimination rather than direct improvement of oxygenation in some patients. The circuit of the ECCO2R system can be set up in venovenous (VV) or arteriovenous (AV). For VV setup, a low flow pump is used to maintain a low extracorporeal flow rate using only 20-30 % of cardiac output. The ECCO2R system does not provide complete pulmonary function as it can achieve only limited oxygenation but provides predominantly carbon dioxide removal. As neither VV nor AV circuit allows full cardiopulmonary bypass, the system provides respiratory function but no cardiac support
1500553|NCT02965066|Device|Coloplast Test Catheter|Newly developed intermittent catheter
1500554|NCT02965066|Device|Coloplast Speedicath|Marketed Coloplast Speedicath catheter
1500555|NCT02965053|Drug|EOS789|
1500556|NCT02965053|Drug|Placebo|
1500557|NCT02965053|Drug|Renvela|
1500559|NCT02965027|Drug|Prazosin|
1500560|NCT02965027|Drug|Placebos|
1500561|NCT02965014|Behavioral|Face-to-Face Women's CoOperative (WC)|Participants will receive HIV counseling and testing (HCT) and engage in a two-session face-to-face WC intervention. The face-to-face sessions will include information addressing the intersection of substance use, sexual risk, and violence through skill building, role-play, and rehearsal.
1500562|NCT02965014|Behavioral|mHealth Women's CoOperative (WC)|Participants will receive HIV counseling and testing (HCT) and training on the mHealth application, which will include all content addressed in the face-to-face WC delivery format. Participants will also receive a tablet to complete the two-session intervention.
1500563|NCT02965014|Behavioral|HIV Counseling and Testing|Participants will receive standard HIV counseling and testing (HCT).
1500564|NCT02965001|Drug|68Ga-NOTA-AE105|The patients are refered to an uPAR-PET/CT scan before initiation of the routine radiotherapy and the prognostic efficacy is assessed by registration of recurrence rate and death at routine clinical follow-up.
1500565|NCT02964988|Drug|Injection of PET tracer 68Ga-NOTA-AE105|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to whole body PET/CT
1500566|NCT02964988|Device|PET/CT|Whole body PET/CT
1500567|NCT02964975|Procedure|Percutaneous coronary intervention|Recanalisation of chronic total occlusion of coronary artery
1500568|NCT02964975|Drug|Optimal medical therapy|Medical threatment according to guidelines
1500569|NCT02964962|Device|29 mm LOTUS Edge™ Valve System|Transcatheter aortic valve replacement
1500571|NCT02964936|Drug|roxadustat|Oral administration
1500572|NCT02964910|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) intramuscularly at 0, 1, 6 month.
1500573|NCT02964897|Behavioral|Peer-support plus usual care from the Health Care for Reentry Veterans program|a peer mentor who is also a veteran will establish a relationship with each subject and provide instrumental and emotional support to the subject during the first 6 months of the subject's release from incarceration. This is in addition to the usual reentry support provided by the Health Care for Reentry Veterans program.
1500654|NCT02964312|Device|Nasal Implant|Latera implant will be placed in stand alone procedure or in conjunction with a turbinate reduction procedure
1500576|NCT02964884|Behavioral|reading tutoring intervention|After the initial 12 weeks of Lovastatin or placebo, children will return for one week tutoring intervention (either reading or sham; Visit 2)
1500577|NCT02964884|Drug|Placebo Oral Tablet|Those in the placebo group will receive a tablet daily
1500578|NCT02964884|Behavioral|sham tutoring|No reading (sham) tutoring
1500579|NCT02964884|Drug|Lovastatin 40 MG|Those in the Lovastatin group will receive 40mg of Lovastatin per day starting at week 3 through week 11.
1500580|NCT02964871|Device|Sofia Fluorescent Immunoassay Analyzer Influenza A+B|The Sofia Influenza A+B Fluorescent Immunoassay (FIA) uses advanced immunofluorescence-based lateral-flow technology to detect influenza A and influenza B viral nucleoprotein antigens.
1500581|NCT02964871|Other|Usual care|Our team will discuss our interest in monitoring influenza antiviral treatment and prophylaxis courses, antibiotic courses, clinician and emergency room visits, respiratory infection-related hospitalizations, all-cause hospitalizations, and deaths during the anticipated 4-month influenza season over 3 years.
1500582|NCT02964858|Radiation|Standard Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT , CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
1500583|NCT02964858|Radiation|Experimental Arm|Radiation will be started within 3-4 weeks of completion of chemotherapy. Computed Tomography (CT)scan will be acquired for treatment planning, which will be done using External Beam Planning System. The target volumes will be defined by clinical examination, staging Positron Emission Tomography with CT (PET-CT) and response PET-CT. The staging PET-CT will be fused and co-registered with the planning CT scans for target volume delineation. For Involved Field Radiotherapy,Clinical target volume (CTV) will include the entire nodal region depending on the site involved. For Involved Site RT,CTV will include the involved nodal volume in the staging PET-CT. For extranodal sites, the CTV will include the involved extranodal region as per the staging PET-CT. The total dose will be prescribed to the Planning Target Volume based on dose uniformity guidelines. All patients will be treated with 3 Dimensional Conformal Radiotherapy or Intensity Modulated Radiotherapy where indicated.
1500584|NCT02964845|Behavioral|WISH with CHW and referral to HFM|6 intervention counseling sessions with a peer CHW, as well as CHW facilitated linkage to primary care and HIV risk reduction.
1500585|NCT02964845|Other|Enhanced Treatment as Usual|Linkage to Primary care.
1500586|NCT02964832|Device|Grasp method|
1500587|NCT02964832|Device|Armband-in-hand method|
1500588|NCT02964832|Device|Armband-on-arm method|
1500589|NCT02964819|Other|exercise|
1500590|NCT02964819|Device|Interferential current therapy|
1500591|NCT02964819|Device|Therapeutic Ultrasound|
1500592|NCT02964806|Dietary Supplement|Ordinary Diet|
1500593|NCT02964806|Dietary Supplement|Modified Atkin's Diet|
1500594|NCT02964806|Dietary Supplement|Ketogenic Diet|
1500595|NCT02964793|Other|intervention group|"The intervention will include
clinician training sessions, designed to raise awareness of the importance of monitoring for FGR and standardizing SFH measurements
the use of SFH charts and EFW customised charts, built with the same software allowing all information to be recorded on an unique document
the use of the EFW values mentioned on US report, to plot EFW on the customised chart
and explicit recommendations about interpretation of longitudinal values of SFH and EFW measurements. If slopes through consecutive plots are not parallel to either of the predicted centile lines (90th, 50th, 10th) on the chart, and either of the centile lines are 'crossed', fetal biometry by ultrasound scan will be recommended."
1500596|NCT02964780|Procedure|Gastric bypass surgery|
1500597|NCT02964780|Behavioral|Conservative weight loss program|
1500598|NCT02964754|Device|CT scan for internal fixation|In the observation group, digital three-dimensional models will be established by CT scan for internal fixation.
1500599|NCT02964754|Procedure|conventional internal fixation|In the control group, patients will undergo conventional internal fixation.
1500600|NCT02964741|Device|Active Comparator|non-invasive brain stimulation (active protocol)
1500601|NCT02964741|Device|Sham Comparator|non-invasive brain stimulation (sham protocol)
1500602|NCT02964728|Drug|Botulinum Neurotoxin Type A|topical injection
1500603|NCT02964728|Other|Normal saline|topical injection
1500604|NCT02964715|Drug|Empagliflozin|25 mg daily for 6 months
1500605|NCT02964702|Device|Thrombectomy Device T-01|
1500606|NCT02964689|Drug|Binimetinib|Binimetinib will be administered in combination with pemetrexed and cisplatin (induction therapy), and with pemetrexed only (maintenance therapy), during the first 2 weeks of each cycle. Cycles will be repeated every 21 days.
1500607|NCT02964689|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. is applied on day 1 of each cycle, before cisplatin administration
1500608|NCT02964689|Drug|Cisplatin|Cisplatin 75 mg/m2 i.v. is applied on day 1 of each induction therapy cycle. The drug must be administered after pemetrexed infusion
1500609|NCT02964676|Procedure|ab interno trabeculectomy with Trabectome|123 PACG will be recruited to receive ab interno trabeculectomy with Trabectome and before this surgery, laser peripheral iridectomy will be performed firstly
1500610|NCT02964676|Procedure|trabeculectomy|123 PACG will be recruited to receive trabeculectomy to reduce IOP
1500611|NCT02964663|Device|esCCO|comparison of non-invasive monitoring esCCO vs VV on cardiac output measurements
1500612|NCT02964650|Device|Personalised rate-response settings|Rate response range fixed to limits suggested by force-frequency curve
1500613|NCT02964637|Other|Observational Study|
1500655|NCT02964299|Device|Mandibular advancement bite block|Mandibular advancement bite block that provides mandibular advancement by 3 mm, 6 mm, or 9 mm from neutral position
1501757|NCT02956538|Drug|placebo(for thalidomide)|sugar pill manufactured to mimic thalidomide 100mg tablet
1500614|NCT02964624|Other|Rehabilitation|Protocol will consist of three exercise/week for eight weeks. Each session will begin with the evaluation of pain by the volunteer. Starting with a warm up exercise in a cycle ergometer (CEE), for 5 minutes at free cadence, then the intensity will be set at 90% of the intensity obtained during the incremental test and maintained for 10 min. Afterward, four sets of three different resistance exercises (RE) will be performed at 70% of the load correspondent to 1RM test with one minute interval between sets and exercises. During CEE Borg scale will be taken every two minutes and during RE the OMNI scale taken at the end of every set to monitor the intensity. At the end of the session, cool down global stretching exercises for inferior members will be performed and the VAS evaluated.
2002126|NCT02496676|Drug|Placebo|Dose escalation for placebo will be based on patients weight and tolerance of the formulation (i.e., absence of gastrointestinal symptoms). The Clinical Center s Pharmaceutical Development Section will formulate matching placebo capsules using clear, unmarked 00 vegetable (hydroxypropyl methyl cellulose) capsules containing lactose. The tablets and packaging for magnesium L-threonate and placebo will be identical in appearance.
1500616|NCT02964598|Behavioral|Gamified intervention|A new mobile application for assisting in sleep regulation, duration 4-6 weeks
1500617|NCT02964598|Behavioral|Sleep coaching|A new personalized program, duration 4-6 weeks
1500618|NCT02964598|Device|Bright light|Morning bright light 10 000 lux maximum duration 4-6 weeks
1500619|NCT02964598|Other|Control|Minimal information on sleep timing and advancing the sleep rhythm
1500620|NCT02964598|Other|Psychoeducation|An extensive information platform in the internet created for this purpose
1500621|NCT02964585|Drug|Canagliflozin|100 mg
1500622|NCT02964585|Drug|Placebo|1 tablet daily for 16 weeks
1500623|NCT02964572|Drug|Glimepiride|In accordance with the standard treatment guidelines of diabetes, glimepiride as a drug of active comparator will be administered to improve blood sugar in patients with poorly controlled blood sugar.
1500624|NCT02964572|Drug|Empagliflozin|Empagliflozin as a drug of experimental will be administered to improve blood sugar in patients with poorly controlled blood sugar.
1500625|NCT02964559|Biological|Pembrolizumab|Given IV
1500626|NCT02964546|Other|Blood sample|2 additional tubes of blood samples are collected during a blood sample realized for the patient's care
1500627|NCT02964533|Other|thunder-fire moxibustion therapy|burn moxa stick and heat shenque acupoint
1500628|NCT02964533|Other|common moxa-stick moxibustion|burn moxa stick and heat shenque acupoint
1500629|NCT02964520|Behavioral|Neurofeedback training|uptraining alpha (8-11 Hz) and theta (5-7.5 Hz) frequency bands, inhibiting beta (15-30 Hz) and delta (2-4 Hz)
1500630|NCT02964520|Behavioral|Sham comparator: Sham neurofeedback training|in UNEVEN neurofeedback sessions (1,3,5,7,9): up-training lobeta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz) in EVEN neurofeedback sessions (2,4,6,8,10): down-training beta (13-16 Hz) and hibeta (16-22 Hz), inhibiting alpha (8-11 Hz), theta (5-7.5 Hz) and hibeta (23-30 Hz)
2002127|NCT02496676|Drug|Magnesium Sulfate (MgSO)|After 24 weeks of study, patients who show < 0.5 log reduction in the number of EBVinfected B cells on oral magnesium as compared to placebo (oral treatment failure) will begin a 2-week washout and proceed to Part II. Such patients will be hospitalized to receive 3 days of IV MgSO4 administered 3 times per day for a total daily dose of 30/mg/kg/day. Then they will restart escalating doses of orally self-administered magnesium L-threonate and continue for the remaining 24 weeks of the study.
1500634|NCT02964468|Radiation|3DCRT treatment (sequential boost)|"Radiotherapy:
3DCRT treatment (sequential boost) 25 fractions fraction 1,8Gy by administering a total dose of 45 Gy on tumor and lymph nodes and lymph node chains more pelvic margin determined according to protocol.
3 fractions fraction 1,8Gy by sequentially administering an additional dose of tumor and lymph nodes 5,4Gy on more margin.
Chemotherapy:
According to routine clinical practice of the participating centers."
1500635|NCT02964468|Radiation|Dose Escalation Intensity Modulated Radiotherapy treatment|"Radiotherapy:
IMRT treatment (concomitant boost technique) 25 fractions fraction 2,15Gy by administering a total dose of tumor and lymph nodes 53,75Gy on more margin. Simultaneously we will proceed to the irradiation of pelvic lymph node chains according to protocol, a division of 1,8Gy per session until a total dose of 45 Gy.
Chemotherapy:
According to routine clinical practice of the participating centers."
1500636|NCT02964455|Drug|Docetaxel|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) of each of the first six weeks during chest radiation
1500637|NCT02964455|Drug|Nedaplatin|5 mg/m², 10 mg/m², or 15 mg/m² given intravenously twice weekly (depending on dose under investigation at time of registration) on days 1,4 (depending on allocation of treatment schedule) of each of the first six weeks of during chest radiation
1500638|NCT02964455|Radiation|chest radiation|continuous chest radiation at 64 Gy/32f
1500639|NCT02964442|Other|Capsinoids|12 mg of Gel capsules
1500640|NCT02964442|Other|Cold Stimulus|Cooling vest maintain at 14 degree Celsius
1500641|NCT02964429|Device|Diacap Pro High-Flux|During dialysis treatment ultrafiltration rate will be changed following a fixed schedule and resulting changes in Transmembrane Pressure (TMP) recorded to generate data for calculation of the in-vivo KUF.
1500642|NCT02964416|Drug|Injection Tramadol|
1500643|NCT02964416|Other|placebo|0.9% Normal saline in 10 ml syringe
1500644|NCT02964403|Drug|Cox-2|
1500645|NCT02964403|Drug|Indomethacin|
1500646|NCT02964390|Procedure|Balloon Pulmonary Angioplasty|
1500647|NCT02964377|Drug|(+)- Epicatechin|
1500648|NCT02964351|Biological|High PSA levels|
1500649|NCT02964338|Drug|Fremanezumab- A|
1500650|NCT02964338|Drug|Fremanezumab- B|
1500651|NCT02964338|Drug|Placebo|Matching Placebo
1500652|NCT02964325|Device|Mirasol platelets (MIR PLTs)|The final product to be transfused to the subject will be leukoreduced (LR), apheresis (Aph) single-donor platelets (PLTs) at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs. MIR PLTs will be treated with the Mirasol pathogen reduction technology system.
1500653|NCT02964325|Device|Reference platelets (REF PLTs)|The final product to be transfused to the subject will be LR-Aph single-donor PLTs at the standard therapeutic dose of 1 unit of Aph PLTs containing ≥ 3.0 × 1.0E11 PLTs.
1500656|NCT02964286|Device|The Electric vibrating massager,SAMPO®|The technique used is The electric vibrating massager ''SAMPO®'', and patients are taught to apply the strong mode on the 15 specific points,5 min each, 3 times a day from Monday to Friday during chemotherapy course. The intervention follow the points are used to stimulate the hematopoietic function. According to their anatomical location: upper extremity are Hegu (LI4), Quchi (LI11); lower extremity are Xuehai (SP10); Sanyin-jiao (SP6), Taixi (K3), Zusanli (ST36), Taichong (LV3); and the top of head is Baihui (GV20). The used of all the points, except for Baihui (GV20), is bilateral.
1500657|NCT02964273|Drug|Tolvaptan|"Tolvaptan 7.5, 15, and 30 mg spray-dried, immediate release tablets with matching placebo. Subjects will be randomized to receive either active tolvaptan or matching placebo for 12 months in Phase A, followed by open-label tolvaptan for 24 months in Phase B. Study medication will be administered orally as a split-dose, with the first dose taken upon awakening and the second dose taken approximately 8 hours later. Phase A and Phase B starting doses will be based on weight. After 1 week, subjects will be asked to up-titrate once from their starting dose. Subjects may down-titrate at any time during the trial; however, subjects will be asked to stay on the highest tolerable dose (by weight group) if possible. The titration schedules for Phase A and Phase B are similar.
Frequency: Twice daily."
1500658|NCT02964273|Drug|Matching Placebo|"Placebo matching Tolvaptan 7.5, 15, and 30 mg spray-dried, immediate release tablets. Subjects will be randomized to receive either active tolvaptan or matching placebo for 12 months in Phase A, followed by open-label tolvaptan for 24 months in Phase B. Study medication will be administered orally as a split-dose, with the first dose taken upon awakening and the second dose taken approximately 8 hours later. Phase A and Phase B starting doses will be based on weight. After 1 week, subjects will be asked to up-titrate once from their starting dose. Subjects may down-titrate at any time during the trial; however, subjects will be asked to stay on the highest tolerable dose (by weight group) if possible. The titration schedules for Phase A and Phase B are similar.
Frequency: Twice daily."
1500659|NCT02964260|Drug|Chemotherapy drug|Doxorubicin/Platinum agents
1500660|NCT02964260|Drug|Embolic agents|Lipiodol/Gelatin sponge/PVA/Blank microspheres
1500661|NCT02964260|Procedure|Simultaneously|1-3 days
1500662|NCT02964260|Procedure|Sequentially|1 month
1500663|NCT02964260|Device|Ablation|Radiofrequency ablation/Microwave ablation
2002128|NCT02490098|Other|6-day intervention with sensor-augmented pump therapy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. Participants will adjust their insulin delivery as per their standard practice; including temporary basal and correction boluses. Participants will have access to their finger-stick glucose measurements and will be advised to measure their glucose level as per their standard practice. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol. Participants will use sensor-augmented pump therapy for 6 days.
2002129|NCT02490098|Other|6-day intervention with single-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
1500666|NCT02964234|Behavioral|Empowerment|Three group sessions (breast cancer education; communication; volunteerism) 1.5 hours 3 times across 3 weeks
1500667|NCT02964234|Behavioral|Education|Three group sessions (breast cancer education; diet; physical activity) 1.5 hours 3 times across 3 weeks
1500668|NCT02964221|Other|Cognitive Testing|Computerized CogState Brief Battery (CBB), Cognigram, assesses changes in four cognitive domains including psychomotor function, attention, learning and memory, and working memory. The CBB is a computerized test based on card games that can be administered online. .
1500669|NCT02964208|Device|AMPLATZER™ Cardiac Plug™ LAA Occluder|The AMPLATZER™ LAA Occluder is intended to prevent thrombus embolization from the left atrial appendage (LAA) in patients who have nonvalvular Atrial Fibrillation (AF). It may be considered for use in patients who have a high risk of stroke and bleeding and are deemed by their physician to have an appropriate rationale to seek a non-pharmacologic alternative to long term anticoagulants.
1500670|NCT02964195|Drug|Rifaximin|ALFA WASSERMANN S.p.A.
2002130|NCT02490098|Other|6-day intervention with dual-hormone closed-loop strategy|One day prior to the intervention, participants will have to install a glucose sensor and the study insulin pump. On the first day of the intervention, participants will be admitted to the clinical research facility in the morning. Participants will have to install a second pump containing glucagon. A team member will review with the participant how to use study devices. Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be allowed to go home in the afternoon. They will be advised to continue with study intervention at home for the next 5 days. Participants will be asked to install a new infusion set every 2 days. Participants will be allowed to eat whatever they want and allowed to drink alcohol.
2002131|NCT02490098|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
2002132|NCT02490098|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
2002133|NCT02490098|Device|Continuous Glucose Monitoring System Enlite sensor®, Medtronic|Enlite sensor®, Medtronic
2002134|NCT02490098|Device|Insulin pump MiniMed® Paradigm® Veo™, Medtronic|MiniMed® Paradigm® Veo™, Medtronic
2002135|NCT02487979|Drug|Glembatumumab Vedotin|Given IV
2002136|NCT02487979|Other|Laboratory Biomarker Analysis|Correlative studies
1500678|NCT02964169|Behavioral|Family Planning Support|
1500679|NCT02964156|Other|Supersole|A 4-mm thin, individually customized insole of a malleable plastic material (CI-Core®) with synthetic textile material on the upper side.
1500680|NCT02964156|Other|No intervention|No intervention
2002137|NCT02487979|Other|Pharmacological Study|Correlative studies
2002138|NCT02486653|Drug|Tamsulosin|"Tamsulosin 0.4mg capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.
Outline of schedule:
Day 1-7: tamsulosin 0.4mg in the evening
Day 8: surgery; tamsulosin 0.4mg in the evening if the subject has not yet completed the bladder management protocol
Day 9-14: tamsulosin 0.4mg in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
2002139|NCT02486653|Drug|Placebo|"Placebo capsule orally once daily, dosed 30 minutes after dinner or before bed, starting 7 days before surgery and continuing for 0-5 days postoperatively.
Outline of schedule:
Day 1-7: placebo in the evening
Day 8: surgery; placebo in the evening if the subject has not yet completed the bladder management protocol
Day 9-14: placebo in the evening until the subject either 1) completes the bladder management protocol (defined by two consecutive voids with post-void residual <200mL), or 2) has an indwelling urinary catheter replaced, or 3) is discharged from the hospital, whichever occurs first. The minimum number of total doses is 7; the maximum number of total doses is 14. The 14th dose will be the final dose regardless of bladder function."
1500684|NCT02964130|Other|No name|
1500689|NCT02964091|Drug|sofosbuvir/ledipasvir|
1500690|NCT02964078|Drug|Pembrolizumab|Pembrolizumab: 200 mg every 3 weeks, 12 doses planned. This is considered the investigational part of the combination. The infusion time is 1 hour.
1500691|NCT02964078|Drug|Interleukin-2|Interleukin-2: 8 admissions to hospital, each with 5 doses planned. This is considered the standard part of the combination. The standard interleukin-2 dose is 600,000 international units per kilogram per dose, with a maximum of 66,000,000 (for patients over 110 kg, which is 242 pounds). The dose is usually set at the start of the treatment and not adjusted. The infusion time is 15 minutes.
1500692|NCT02964065|Biological|Live-Attenuated influenza Vaccine(LAIV)|
1500693|NCT02964065|Biological|Placebo|
1500694|NCT02964052|Other|Brain CT imaging|Investigators will analyzed the CT image that was performed in patients with hyperacute stroke. The CT protocol includes CT thrombus, collateral, core images. Investigators also obtain detailed history and laboratory and imaging result for comorbidity. The comorbidity index protocol is based on the Charlson comorbidity index.
2002140|NCT02487446|Drug|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
2002141|NCT02487446|Drug|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
2002142|NCT02487446|Drug|Placebo (umeclidinium/vilanterol)|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
1500698|NCT02964026|Device|pulmonary artery catheter|PAC must be placed between the day of admission and the day following a qualifying cardiac surgery
2002143|NCT02487446|Drug|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
2002144|NCT02483663|Device|Functional Magnetic Resonance Imaging|Measure brain activity.
1500701|NCT02964000|Device|Low level 1 Watt|The Phoenix Thera-Lase System will be on 1 watt
1500702|NCT02964000|Device|Phoenix Thera-Lase System 42|The Phoenix Thera-Lase System will be on 42 watts
1500703|NCT02964000|Device|Phoenix Thera-Lase System 74|The Phoenix Thera-Lase System will be on 74 watts
1500704|NCT02963987|Other|Food and Beverage Portion Size|Variations of Food and Beverage Portion Size, 100% Baseline portions and increased 50% for 150% portions
1500705|NCT02963974|Device|Cochlear implant|Implantation
1500706|NCT02963961|Behavioral|Preoperative Cognitive Training Battery|Patients will engage in a daily preoperative cognitive training battery (BrainHQ, Posit Science) that aims to improve attention, memory, and visuospatial processing.
1500707|NCT02963948|Behavioral|Meetings with implementation leader(s)|The perceived appropriateness of the intervention to medical staff will affect an intervention's initial adoption as well as sustainability. We will assess this through focus groups with staff, conducted approximately 1-2 months after implementation of the screening and CDS tools.
1500708|NCT02963948|Behavioral|the SAAS survey|Medical staff will be surveyed using the Substance Abuse Attitude Survey (SAAS) to gather information about attitudes from medical staff who do not participate in the focus groups, or may be uncomfortable sharing negative attitudes in a group of their peers. The SAAS is a validated multidimensional instrument that evaluates physician attitudes toward substance-using patients. It includes specific measures of attitudes toward permissiveness, treatment intervention, stereotypes, treatment optimism, and moralism, and has been used in prior studies of primary care physicians. Collecting information on staff attitudes toward substance users and substance use interventions will be helpful to inform about any sources for low adoption of the tools, and any needs for additional provider education and training.
1500709|NCT02963948|Behavioral|Patient surveys|Patient surveys regarding attitudes toward substance use screening and interventions in the primary care clinic will be distributed to patients presenting for care, regardless of whether they completed screening, at regular time periods throughout this study phase. The survey will be conducted for 1 week at the following approximate intervals following successful implementation: 1 month, 4 months, 7 months, and 10 months
1500710|NCT02963935|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
1500711|NCT02963935|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 56 weeks. Dose gradually increased to 3.0 mg
1500712|NCT02963935|Behavioral|CMS IBT|Intensive Behaviour Therapy for obesity
2002145|NCT02483663|Radiation|Dual Energy X-ray absorptiometry|Body composition measurements.
2002146|NCT02483663|Other|Questionnaires|Questionnaires related to: health, weight, sleep, mood, dietary habits, attitudes towards eating, how you describe yourself.
2002147|NCT02483663|Other|Mood and Appetite Ratings|Answer questions about how you are feeling at the moment.
2002148|NCT02483663|Other|Test Meals|Breakfast, a snack, and lunch provided during study visit.
2002149|NCT02483663|Other|Computer Tests|Perform a series of computer tests to determine reaction time.
1500719|NCT02963896|Drug|gentamicin|intratympanic application of gentamicin 2m/80mg - 3x application -0,5 ml
1500720|NCT02963883|Other|SVO2 group / control group|
1500721|NCT02963870|Other|Security Plan|This study compared two groups of adolescents aged 12-17 hospitalized for TS and randomized to a group treated with the Security Plan plus the usual treatment and a group receiving standard treatment only.
1500722|NCT02963844|Other|Inspiratory Muscle Training|
1500723|NCT02963844|Other|Inspiratory Muscle Training Sham|
1500726|NCT02963818|Other|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
1500727|NCT02963818|Other|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
1500728|NCT02963818|Other|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
1500729|NCT02963805|Behavioral|High intensity physical activity (HIPA)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session engaged participants in high-intensity vigorous activity using a combination of playground-style games and circuit training activities that aimed to keep children moving and maintain a mean heart rate above 70% of age-predicted maximum heart rate (~145 beats/min) for the session duration. Intensity was verified by heart rate monitoring. Coaches delivered and monitored sessions and increased the intensity over time to allow for the children to progress. The mean heart rate for HIPA sessions was 150 beats/min, with children spending 52 min at this intensity during the session.
1500730|NCT02963805|Behavioral|Fundamental movement skill (FMS)|This arm consisted of a twice-weekly after-school club at the intervention school for 26 weeks during school term time, delivered by qualified coaches. Each 60 minute session focused on improving two skills from the vertical jump, hop, sprint run, dodge, kick, catch, overarm throw, and strike. All skills were taught in equal quantities. Each session was designed to maximise participation and enjoyment, and consisted of various games, drills, self-learning activities, and offered numerous opportunities for practice. Skill components were taught to the children using simple learning cues, and skill related questions were used to develop purposeful feedback. The mean heart rate for FMS sessions was recorded at 141 beats/min, with children spending 55 min at this intensity during the session.
1500731|NCT02963805|Behavioral|Physical activity signposting (PASS)|A researcher visited participants once per week in 6 weekly blocks to set an activity mission to complete outside school with family and friends. Twenty missions were set over 4 x 6 week blocks, each separated by a 6 week break. Each mission suggests a task as a prompt to participate in physical activity and decrease sedentariness during the week. Children received a sticker on a wall chart for returning the mission; children were rewarded with prizes if all missions were returned in each block. If all missions were returned in a block, a reward was given. 58% of children returned all twenty missions. In addition to the missions, pedometers were issued as a promotional tool for the duration of the project for self-monitoring of activity.
1500732|NCT02963792|Other|Preventing Professionals burnout|
1500733|NCT02963779|Drug|LY2775240|Administered orally
1500734|NCT02963779|Drug|Placebo|Administered orally
1500735|NCT02963779|Drug|Apremilast|Administered orally
1500738|NCT02963740|Behavioral|Supervised Exercise|Participants will take part in supervised exercise activities two times per week at a YMCA. Length of the activity will be increased during participation in study. Participants will start at 40 minutes per week and work their way up to 120 minutes per week.
1500739|NCT02963740|Behavioral|Home-based Exercise|Aerobic exercise activities to be completed at home. Participants will be asked to start out doing 60 minutes at home and work up to 180 minutes of purposeful aerobic home exercise per week.
1500740|NCT02963740|Behavioral|Group Phone Calls|Once weekly phone calls that are group-based. The calls will discuss lifestyle changes specific to participants and cover the effects of diet, physical activity, and weight on breast cancer risk, as well as body image and emotional eating.
1500741|NCT02963740|Behavioral|Diet|Participants will consume a nutritionally balanced, reduced calorie diet as recommended by the Academy of Nutrition and Dietetics.
1500742|NCT02963727|Biological|Wharton Jelly derived mesenchymal stem cell|Intra-articular Wharton Jelly derived mesenchymal stem cell injection.
1500743|NCT02963714|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
1500744|NCT02963714|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
1500745|NCT02963701|Drug|Ibuprofen|Fixed dose combination
1500746|NCT02963701|Drug|Pseudoephedrine-HCl|Fixed dose combination
1500747|NCT02963688|Genetic|Ion AmpliSeq BRCA 1/2 Panel (Life Technologies, Carlsbad, CA, USA) ,Ion PGM platform|BRCA1,2 Germline /Somatic mutation test
1500748|NCT02963675|Other|unspecified|external unexposed reference group
1500749|NCT02963662|Procedure|laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass was one of the interventions pre-specified to be administered to participants. The patients undergo Roux-en-Y gastric bypass (RYGB group) following a comprehensive evaluation for the surgical indication
1500750|NCT02963662|Procedure|laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy was the other intervention pre-specified to be administered to participants. The patients undergo sleeve gastrectomy (SG group) following a comprehensive evaluation for the surgical indication
1500751|NCT02963649|Device|DCB|Drug Coated Balloon
1500752|NCT02963649|Device|PTA|Percutaneous Transluminal Angioplasty
1500753|NCT02963636|Other|Pharmacist clinical intervention|Pharmacists will make a clinical intervention with patients. They will review patient drug therapy already prescribed in their usual care. This includes a medication reconciliation, an assessment of drug related problems, an assessment of the regimen complexity and adherence to treatment. A care plan will be elaborated. Moreover, immediate and future interventions with the patient or other health professionals will be implemented and monitored. There will be no drug or devices tested, it is a human clinical intervention by a pharmacist.
1500754|NCT02963610|Drug|Lenalidomide|Lenalidomide is a thalidomide analogue with immunomodulatory, anti-angiogenic, and antineoplastic effects. It is administered as a pill taken orally. It has completed phase III study evaluation and has FDA indications for use in certain patients with multiple myeloma, myelodysplastic syndrome, and mantle cell lymphoma.
1500755|NCT02963610|Drug|Pembrolizumab|Pembrolizumab is a humanized IgG4 monoclonal antibody which targets the PD-1 receptor, thus inhibiting the interaction between PD-1 and its ligands, PD-L1 and PD-L2 respectively. It is administered as an IV infusion. This drug has several studies in patients with solid tumors and currently has an FDA indication for use in patients with melanoma and non-small cell lung cancer.
1500756|NCT02963597|Device|AirSense™ 10 AutoSet|The AirSense 10 AutoSet is a device that provide non-invasive ventilatory support to treat patients with sleep disordered breathing. The device is intended for home and hospital use. The treatment pressure required by the patient may vary due to changes in sleep state, body position and airway resistance. In AutoSet mode, the device provides only that amount of pressure required to maintain upper airway patency. The AirSense 10 AutoSet provides a minimum and maximum pressure within the range of 4-20 cm of water.
1500757|NCT02963597|Other|Standard Medical Therapy|Standard medical therapy according to current guidelines.
1500758|NCT02963584|Other|decision aid|The related information about CTO and PCI procedures will be told to the patients thoroughly.
1500759|NCT02963571|Procedure|posterior percutaneous pedicle screw internal fixation|The patients underwent minimally invasive posterior percutaneous pedicle screw fixation in acute thoracolumbar vertebral fractures with simple anterior spinal column injury.
1500760|NCT02963558|Device|cycle ergometry|The cycler will provide 3 different possible modes of cycling—passive, active-assisted, and active. The subject will start with passive cycling and may progress to active-assisted and active cycling.
1500761|NCT02963545|Other|Usual care patients in neurology department|patients characteristics, history, clinical signs chronology and usual medical care by the emergency units, cerebral infarction area
1500762|NCT02963545|Biological|blood and urines sampling|Collection samples for biochemical determinations of serotonin pathway and kynurenine pathway parameters determinations
1500763|NCT02963545|Procedure|Psychiatric evaluation|depression scale, impulsivity scale, hostility scale , tobacco consumption questioning
1500764|NCT02963532|Other|We are observing criteria present at extubation|We will not be performing any intervention. We will only be observing what clinical data is present at the time of extubation and how predictive are different pieces of clinical data.
1500765|NCT02963519|Device|VistaCare®|
1500766|NCT02963519|Device|Dressings|
1500767|NCT02963506|Other|Placebo|
1500768|NCT02963506|Drug|Bimekizumab|Bimekizumab in different dosages.
1500769|NCT02963493|Drug|Melflufen|
1500770|NCT02963493|Drug|Dexamethasone|
1500771|NCT02963480|Procedure|Cardiac Surgery|
1500772|NCT02963467|Procedure|cigarette|smoking 4 conventional cigarettes
1500773|NCT02963467|Procedure|"dummy cigarette"|"smoking a dummy cigarette"
1500774|NCT02963454|Device|Microdialysis Probe (Muscle microdialysis)|"Interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were determined at baseline and then every six hours for the following 72 hours after randomization.
During the study period, conventional treatment was continued as per usual practice. Fluid challenges were performed, and repeated as necessary, to maintain central venous pressure (CVP) ≥8 and pulmonary arterial occlusion pressure (PAOP) ≥12 mmHg. Norepinephrine was titrated to maintain mean arterial pressure (MAP) ≥65 mmHg. Packed red blood cells were transfused when Hemoglobin (Hb) concentrations decreased below 7 g/dL, or if the patient exhibited clinical signs of inadequate systemic oxygen supply."
1500775|NCT02963454|Drug|Dobutamine|Dobutamine (5 μg/kg/min) will be used as indicated
1500776|NCT02963454|Drug|Levosimendan|Levosimendan (0.2 μg/kg/min) will be used as indicated
1500777|NCT02963428|Behavioral|Enhanced Care|"In addition to standard of care, the study participants will also receive:
i. An initial consult with a licensed, Registered Dietician Nutritionist (RDN); ii. Regular tele-health check-ups (10-20 mins/check-up) with the RDN until delivery; iii. Exposure to personal GWG chart; iv. Letter from physician stating the recommendations for GWG over the course of the pregnancy."
1500778|NCT02963415|Behavioral|Exergame|Participants will take part in the exergame, 3 times a week for a month. The session will start for 30-35 minutes of cycling on recumbent stationary cycles in session 1 and progress to moderate intensity for 50 minutes a session. Participants will do warm-up and cool-down activities before and after cycling. While cycling, participants will be playing virtual reality based games. An exercise interventionist will supervise the sessions and monitor participant's conditions and responses to ensure safety.
1500779|NCT02963402|Drug|Tocilizumab|
1500780|NCT02963402|Drug|Adalimumab|
1500781|NCT02963389|Drug|Tripegfilgrastim|
1500782|NCT02963376|Drug|0.05 mL/kg DDFPe|
1500783|NCT02963376|Drug|0.05 mL/kg Placebo|
1500784|NCT02963376|Drug|0.10 mL/kg DDFPe|
1500785|NCT02963376|Drug|0.10 mL/kg Placebo|
1500786|NCT02963376|Drug|0.17 mL/kg DDFPe|
1500787|NCT02963376|Drug|0.17 mL/kg Placebo|
1500788|NCT02963363|Other|Home-based Adapted Physical Activity|"Home-based adapted physical activity to attend progressively 150 minutes of physical activity per week at the end of neoadjuvant chemotherapy.
5 times 30 minutes of walking + 3 times 30 minutes of muscle strengthening exercises per week during 18 weeks"
1500789|NCT02963350|Drug|BMN190, recombinant human tripeptidyl peptidase-1 (rhTPP1)|
1500790|NCT02963337|Drug|remifentanil|Remifentanil PCA will be used to deliver intravenous drug boluses from 20 to 40 micrograms per 2 min lockout interval.
1500791|NCT02963337|Drug|combined spinal-epidural analgesia|Patient controlled epidural analgesia will be used to deliver epidural boluses of 6-10 ml of 0,1% bupivacaine with 2 micrograms of fentanyl per ml per 15 min lockout interval.
1500792|NCT02963324|Drug|Ivermectin|
1500793|NCT02963311|Drug|ALN-PCSSC|ALN-PCSSC is a small interfering ribonucleic acid (siRNA) that inhibits PCSK9 synthesis and is given as SC injections.
1500794|NCT02963311|Drug|Standard of Care|Included maximally-tolerated statin therapy and/or other low density lipoprotein-cholesterol (LDL-C)-lowering therapies.
1500795|NCT02963298|Procedure|Continuous renal replacement therapy|
2002150|NCT02483663|Procedure|Intravenous Catheter (IV) placement|Blood samples collected throughout regular intervals during the study visit day to measure levels of hormones involved in regulating appetite and body weight. We will also determine if twins are fraternal or identical and will examine DNA to see if participants carry two genes that affect appetite or body weight, the FTO gene and the MC4R gene.
1500797|NCT02963272|Other|Conventional strategy|Conventional strategy to manage the patients with HF, following the international guidelines.
1500798|NCT02963272|Other|ST2-guided strategy|patients wit ST2 over the median are targeted with higher doses of drugs with putative effects on fibrosis and anti HF pathophysiology
1500799|NCT02963259|Device|SJM Infinity|IPG replacement procedure
1500800|NCT02963246|Behavioral|Mindfulness|"Mindfulness-based therapy has been used effectively to treat a variety of physical and psychological disorders, including depression, anxiety, and chronic pain. Recently, several lines of research have explored the potential for mindfulness-therapy in treating somatization disorders, including fibromyalgia, chronic fatigue syndrome, and irritable bowel syndrome. Mindfulness-based therapies (MBT) are a clinical application involving the key element of nonjudgmental acceptance of physical pain or psychological distress, thereby reducing the tendency to ruminate over and catastrophise these experiences.
In the present study, we propose a mindfulness intervention of 12 months, with sessions either personalized or online."
1500801|NCT02963233|Procedure|Closed reduction and percutaneous pinning and immobilization|
1500802|NCT02963233|Procedure|Non-operative reduction and immobilization|
1500803|NCT02963220|Behavioral|CBT-AR|20-40 sessions of cognitive behavioral therapy for avoidant/restrictive food intake disorder (CBT-AR), held once per week in an outpatient setting
1500804|NCT02963207|Other|Modified Sano's classification|Set of characteristics described by Singh et al. 2013 to evaluate colorectal lesions.
1500805|NCT02963207|Other|NICE classification|Set of characteristics described by Hewett et al. 2012 to evaluate colorectal lesions.
1500806|NCT02963194|Drug|Oxytocin|
1500807|NCT02963194|Drug|Placebo|
1500810|NCT02963168|Drug|Oradoxel|oral docetaxel will be supplied in capsules and oral HM30181A-UK tablets
1500811|NCT02963155|Other|Blood samples|
1500812|NCT02963129|Drug|Mupirocin|Mupirocin ointment in the nose for 5 days
1500813|NCT02963129|Other|Placebo|Placebo ointment in the nose for 5 days
1500814|NCT02963116|Drug|AZD5718 IR tablet|
1500815|NCT02963116|Drug|AZD5718 oral suspension|
1500816|NCT02963116|Drug|Rosuvastatin tablet|
1500817|NCT02963103|Drug|Tacrolimus|Oral
1500818|NCT02963090|Drug|Topotecan|"Topotecan at 1.25mg/m2 on days 1 to 5 every 21-days until progression of disease or unacceptable toxicities.
Patients with progression of disease by RECIST 1.1 will be allowed cross over to receive pembrolizumab 200 mg IV every 21-days for up to 1 year until progression of disease or unacceptable toxicities."
1500819|NCT02963090|Drug|Pembrolizumab|200 mg IV every 21-days until progression of disease or unacceptable toxicities.
1500820|NCT02963077|Drug|A4250|
1500821|NCT02963077|Drug|CRC (A3384)|
1500822|NCT02963077|Drug|Questran|
1500823|NCT02963077|Drug|Placebo|
1500824|NCT02963064|Biological|Humanized anti-CD117 Monoclonal Antibody|Procedure: one time intravenous infusion of anti-CD117 antibody
1500825|NCT02963064|Procedure|Blood Forming Stem Cell Transplant (CD34+CD90+)|Procedure: one time intravenous infusion of donor blood forming stem cells
1500826|NCT02963051|Drug|Copper|1 mg, 3 mg, 5 mg or 7 mg intravenously on cycle 1 day 1, 8 and 15
1500827|NCT02963051|Drug|Disulfiram|"80 mg three times a day
Source of disulfiram: Cantex Pharmaceuticals"
1500828|NCT02963051|Drug|Copper gluconate|"1.5 mg three times a day
Source of copper gluconate: Cantex Pharmaceuticals"
1500829|NCT02963038|Biological|Autologous CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
1500830|NCT02963025|Procedure|PEEP level|
1500831|NCT02963025|Procedure|Use of recruitment maneuvers|
1500832|NCT02963012|Other|ultrasound examination|
1500833|NCT02962999|Drug|Ketamine|After induction, patients will be administered 0,5 mg/kg/hour ketamine infusion intraoperatively.
1500834|NCT02962999|Drug|Saline|After induction, patients will be administered saline infusion intraoperatively.
1500835|NCT02962986|Drug|Norepinephrine|Norepinephrine diluted in 5% dextrose solution to a concentration of 6mcg/mL
1500836|NCT02962986|Drug|Phenylephrine|Phenylephrine diluted in 0.9% normal saline solution to a concentration of 100mcg/mL
1500837|NCT02962973|Device|CARMAT Total Artificial Heart|
1500838|NCT02962973|Procedure|surgical procedure|
1500839|NCT02962960|Drug|Anifrolumab|subcutaneous administration every 2 weeks from week 0 to week 50
1500840|NCT02962960|Drug|Placebo|subcutaneous administration every two weeks from week 0 to week 50
1500841|NCT02962947|Drug|Propranolol|80 mgR propranolol once daily
1500842|NCT02962947|Drug|Placebo|placebo once daily
1500843|NCT02962934|Other|Non CRRT group|Non CRRT group:Blood samples prior to first dose of Ceftolozane-Tazobactam and at 15, 45, 1hr, 2hr 3hr 4h 5h 6h 7h 8h.
1501758|NCT02956525|Drug|Dexibuprofen|200 mg
1501759|NCT02956512|Drug|Dexibuprofen|
1500844|NCT02962934|Other|CRRT group|"CRRT group: Pre and Post dialysis filter blood samples taken prior to first dose of Ceftolozane-tazobactam and at 15min, 45min, 1h 2h 3h 4h 5h 6h 7h 8h.
Ultrafiltrate samples at 1 hr,2h 4h 6h 8h"
1500845|NCT02962921|Drug|Insulin LISPRO intravenous loading|intravenous infusion of insulin Lispro.
1500846|NCT02962908|Biological|FLU-v|Subcutaneous injection in the upper arm with 500 ug of FLU-v as 0.5ml suspension in 0.01M HCl and 0.01M NaOH
1500847|NCT02962908|Biological|adjuvanted FLU-v|Subcutaneous injection in the upper arm with 500ug of FLU-v emulsified in 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
1500848|NCT02962908|Biological|Saline|Subcutaneous injection in the upper arm with 0.5ml of saline
1500849|NCT02962908|Biological|Adjuvanted placebo|Subcutaneous injection in the upper arm with an emulsion made with 0.25ml of Montanide ISA-51 adjuvant (Seppic, France) and 0.25ml of water for injection
1500850|NCT02962895|Biological|VAY736|VAY736
1500851|NCT02962895|Other|Placebo|Placebo control
1500852|NCT02962882|Device|Mepilex Border|Multi-layer Foam Dressings
2002155|NCT02482792|Other|Norwegian Psychomotor Physiotherapy|The recruited patients will after randomization receive either Norwegian Psychomotor Physiotherapy (NPMP) or COPE combined with active individual physiotherapy. In NPMP the treatment is individualized, targeting body-mind awareness through exercise, massage and therapeutic conversation
2002156|NCT02482792|Other|Cognitive Patient Education and PT|The comparison group will receive a combination of education about how to manage pain (COPE) followed by active individual physiotherapy.
2002157|NCT02480088|Drug|Ramosetron|ramosetron 0.3 mg IV 20 min before the end of surgery and 24 h after the surgery
2002158|NCT02480088|Drug|Palonosetron|palonosetron 0.075 mg IV 20 min before the end of surgery and 24 h after the surgery.
1500857|NCT02962843|Behavioral|IY TCM|The Incredible Years Teacher Classroom Management program is a manualized program for teachers and staff in school and day-care settings to strengthen teacher classroom management strategies, to reduce negative behavior and promote prosocial behavior, as well as school readiness in children. Two qualified IY TCM group-leaders (facilitators) train teachers and staff in groups through six full-day workshops (a total of 42 hours).Workshop 1: Building Positive Relationships with Students, Workshop 1b: Preventing Behavior Problems -The Proactive Teacher, Workshop 2: The Importance of Teacher Attention, Coaching and Praise, Workshop 3: Motivating Children Through Incentives, Workshop 4 & 5: Decreasing Inappropriate Behavior and Workshop 6: Emotional Regulation, Social Skills & Problem Solving.
1500858|NCT02962830|Drug|Sufentanil|intra-amniotic injection of 50 micrograms of Sufentanil
1500859|NCT02962817|Other|Educational intervention|
1500860|NCT02962817|Other|Video explaining the clinical practice guidelines on low back pain|
1500861|NCT02962804|Drug|Nivolumab|240 mg per IV infusion over 60 minutes every 14 days (+/- 2 days) until disease progression or participant withdrawal from study
1500862|NCT02962804|Radiation|Radiation|Radiation to at least 1 site (up to 3) of primary or metastasis, 5 fractions - delivered over 2 weeks, starting 1-3 days post-nivolumab administration. Recommended dose range is 6 Gy-12 Gy per fraction.
1500863|NCT02962791|Procedure|Cardiac resynchronization therapy implantation|Cardiac resynchronization therapy implantation will be done for patient with symptomatic heart failure
1500864|NCT02962791|Device|Stimulation of 3 ventricular sites|Cardiac resynchronization therapy with stimulation of 3 ventricular sites
1500865|NCT02962791|Device|Stimulation of 2 ventricular sites|Cardiac resynchronization therapy with stimulation of 2 ventricular sites
1500866|NCT02962791|Device|Echocardiography|Standard Echocardiography will de bone for patient
1500867|NCT02962752|Dietary Supplement|Blackadder Juice|
1500868|NCT02962752|Other|Placebo|
1500869|NCT02962739|Drug|emtricitabine 200 mg/tenofovir alafenamide 25mg|1 tablet of Descovy contains emtricitabine 200 mg/tenofovir alafenamide 25mg
1500870|NCT02962713|Procedure|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
1500871|NCT02962713|Procedure|ART with Giomer Beautifil-Bulk Restorative|Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
1500872|NCT02962713|Procedure|ART with Composite Resin Filtek Bulk Fill (3 M/ESPE).|Occlusal-proximal ART restorations in primary molars using Giomer will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Giomer Beautifil-Bulk Restorative and occlusion will be checked.
1500873|NCT02962700|Device|muscle microdialysis|Systemic haemodynamics and interstitial tissue concentrations of lactate, pyruvate, glucose and glycerol were obtained at baseline, 6, 12,18 and 24 hours after initiation of renal replacement by using muscle microdialysis.
1500874|NCT02962687|Behavioral|Care management via videoconference|12-week nurse care management for medically complex Veterans with CI delivered via videoconference
1500875|NCT02962687|Behavioral|Care management via telephone calls|12-week nurse care management for medically complex Veterans with CI delivered via telephone calls
1500876|NCT02962674|Device|ProstaCare System|
1500877|NCT02962661|Biological|Intravenous Infusion of Human Mesenchymal Stem Cells (hMSCs)|Intravenous Infusion of Mesenchymal Stromal Cells (MSCs) Group: 4 weekly doses of MSCs administered intravenously at a dose of 2 x 10^6 cells/Kg.
1500878|NCT02962661|Other|Routine Heart Failure Medical Therapy|Participants treated with routine heart failure medical therapy, Ace-inhibitors/Non-Selective beta blockers and when necessary diuretics/Aldosterone Inhibitors per institutionally defined standard of care.
1500879|NCT02962661|Biological|Transendocardial Injections of Mesenchymal Stromal Cells|Transendocardial Injections of Mesenchymal Stromal Cells (MSCs) Group: 15 injections of 0.2 ml MSCs at a total dose of 15 x 10^7 cells during one operative procedure using the MyoStarTM injection catheter (Biosense Webster, Inc.).
1500880|NCT02962648|Drug|Iron Isomaltoside|
1500881|NCT02962635|Device|bioelectrical impedance measurement and biomarker measurement|Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
1500882|NCT02962622|Other|High intensity interval training (HIIT)|Six weeks, three days per week (total of 18 sessions) of HIIT cycle ergometer exercise protocol
2002159|NCT02477839|Drug|Lacosamide|Active Substance: Lacosamide Pharmaceutical Form: Syrup Concentration: 10 mg/mL Route of Administration: oral
1500884|NCT02962596|Other|ADNEXMR SCORING system|Scoring system used to standardize the imaging report for sonographically indeterminate adnexal masses.
1500885|NCT02962583|Other|Weight loss|
1500886|NCT02962583|Drug|Probiotic Formula|
1500887|NCT02962583|Drug|Placebos|
1500888|NCT02962570|Device|On Demand Oxygen Delivery|Supplemental oxygen flow is controlled such that it is on only during inhalation.
1500889|NCT02962570|Device|Traditional, Always-On, Oxygen Delivery|Supplemental oxygen flow is constantly on, irrespective of whether the patient is inhaling or exhaling.
1500890|NCT02962570|Device|Oxygen Flow Stopped|Supplemental oxygen flow is stopped completely for a brief period to allow undisturbed end-tidal oxygen and CO2 measurements
1500892|NCT02962544|Procedure|FS-SMILE|The procedure will be performed using an established technique. the patient's eye will be centered and docked with the curved interface cone before application of suction fixation.The laser will be activated for photo-dissection in the following sequence: first the posterior surface of the refractive lenticule then the lenticule border then The anterior surface of the refractive lenticule which extended beyond the posterior lenticule diameter by 0.5 mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the cap near the hinge before the cap is separated. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula. The lenticule is then grasped with forceps through the small incision.
1500893|NCT02962544|Procedure|FS- LASIK|LASIK procedure Each LASIK procedure will be performed using a standard, established technique. Under topical anesthesia and standard draping, a lid speculum is used to retract the eyelids. A superiorly hinged 100 μm thick flap will be created using the WaveLight FS200 (Alcon Laboratories, Inc.) With inverted side cut (115 ̊) .Excimer laser ablation is then performed using WaveLight EX500 excimer laser (Alcon Laboratories, Inc.).After ablation, the flap will be carefully repositioned, and postoperative medications are commenced.
1500894|NCT02962544|Device|Visumax device|
1500895|NCT02962544|Device|FS 200 device|
1500896|NCT02962531|Drug|IX-01 caplets 1600 mg (4 x 400 mg), fasted|oral dose under fasted conditions
1500897|NCT02962531|Drug|IX-01 caplets 1600 mg (4 x 400 mg), fed|oral dose under fed conditions
1500898|NCT02962531|Drug|IX-01 aqueous dispersion 1600 mg (20 mL), fasted|oral dose under fasted conditions
1500899|NCT02962518|Device|Pressure Device|"Patients undergo surgery using the fillet technique and intra-lesional injections of triamcinolone 10mg /ml every 4 to 6 weeks for 6 months and they are additionally treated with a non-customized Pressure Device. The standardized clips (K. Egner, Dental Technique, Neu-Ulm, Germany) used in our study is available in two different sizes for smaller or larger defects. According to the guidelines of the German Society of Dermatology, patients are advised to wear the clip at least 16 hours per day. Medically approved transparent acrylate is used so that change in skin color and therefore amount of pressure can be observed at all times. Allergic or toxic skin involvement can be visualized through the transparent surface. Adjusting of the clip is done with one or two screws."
1500900|NCT02962518|Procedure|Fillet Technique|"Patients undergo surgery using the fillet technique. To prevent the remaining skin from further damage, the meticulous skin preparation is performed either using the microscope or magnifying glasses. The keloid is peeled out of the excessive skin pocket. If necessary skin trimming is performed and non-resorbable monofilament single sutures are placed."
1500901|NCT02962518|Drug|Triamcinolone|All patients received intra-lesional injections of tiamcinolone 10mg/ml every 4 to 6 weeks for 6 months.
1500902|NCT02962492|Drug|Exenatide/Exenatide extended release|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
1500903|NCT02962492|Drug|Dapagliflozin|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
1500904|NCT02962492|Drug|Placebo|Eighty (80) patients with T1D will be enrolled and randomized into 4 groups(20 each) to receive placebo, or dapagliflozin, or exenatide (5µg acutely)/Exenatide extended release (long term), or exenatide (5µg acutely)/Exenatide extended release (long term) and dapagliflozin treatments acutely and for 12 weeks
1500905|NCT02962466|Other|CC-Test|classification of the oocyte based on the expression pattern observed in the cumulus cells
1500906|NCT02962453|Device|Morning walk|gait training with Morning walk three times during 5 minutes with 5 minute break a day over 5 weekdays
1500907|NCT02962453|Device|Ground Walker|gait training with ground walker until corresponding 200 steps during 5 minutes with 5 minute break a day over 5 weekdays
1500908|NCT02962440|Drug|somapacitan|All subjects will receive one subcutaneous (s.c., under the skin) dose of somapacitan containing [3H]-somapacitan
1500909|NCT02962427|Drug|Sphenopalatine ganglion Block|
1500910|NCT02962427|Procedure|Epidural blood patch|
1500911|NCT02962414|Drug|everolimus|everolimus, 2mg dispersible tablets
1501041|NCT02961712|Biological|amniotic epithelial cells|single intrathecal injection of amniotic epithelial cells
1500912|NCT02962401|Drug|Obinutuzumab|"6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15
Cycle 2 - 6 :
Obinutuzumab 1000mg I.V.day 1"
1500913|NCT02962401|Drug|Idelalisib|"6 cycles every 28 days
Cycle 1 :
Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment"
1500914|NCT02962388|Drug|Anagrelide|Anagrelide in the study, according to the investigator decision fom day 1 to 48 months
1500915|NCT02962388|Drug|Ruxolitinib (JAKAVI®)|Ruxolitinib (JAKAVI®) - Novartis. Tablets 5 mg. Starting dose 10 mg BID, orally. To be increased or decreased (5 or 10 mg steps) per standardized dosing Maximum dose 25 mg BID. fom day 1 to 48 months
1500916|NCT02962388|Drug|IFNα/ PegIFNα|IFNα/ PegIFNα in the study, according to the investigator decision fom day 1 to 48 months
1500917|NCT02962375|Dietary Supplement|Active|100% orange juice with orange pomace fiber
1500918|NCT02962375|Dietary Supplement|Control|100% orange juice
1500919|NCT02962336|Drug|Torrent's Olmesartan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|Oral, crossover
1500920|NCT02962336|Drug|Tribenzor Tablets of Daichi Sankyo Inc, USA|Oral, crossover
1500921|NCT02962323|Drug|Torrent's Rosuvastatin Calcium Tablets 40 mg|Oral, crossover
1500922|NCT02962323|Drug|Crestor 40 mg Tablets of AstraZeneca Pharmaceuticals LP, USA|Oral, crossover
1500923|NCT02962310|Drug|Torrent's Rosuvastatin Calcium Tablets 40 mg|oral, crossover
1500924|NCT02962310|Drug|Crestor 40 mg Tablets of AstraZeneca LP, USA|oral, crossover
1500925|NCT02962297|Drug|Vitamin E softgel|All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
1500926|NCT02962297|Drug|Placebo|"All participants receive standardized recommendations for life-style modification (Diet modification, weight loss, exercise).
Height and weight, waist-to-hip ratio Review of diet and exercise"
1500927|NCT02962284|Drug|abiraterone acetate with Methylprednisolone|YONSA 500 mg (4 x 125 mg qd) with Methylprednisolone (4 mg bid)
1500928|NCT02962271|Device|Musculoskeletal Ultrasound|Musculoskeletal ultrasound (MSUS) of the lower limbs' entheses were performed
1500929|NCT02962258|Drug|Torrent's Olmesartaan medoxomil, Amlodipine and Hydrochlorothiazide Tablets|oral, crossover
1500930|NCT02962258|Drug|Tribenzor of Daichi Sankyo Inc. USA|oral, crossover
1500931|NCT02962245|Drug|berberine|
1500932|NCT02962245|Drug|regular treatment|such as 5-ASA,immunomodulating/suppressive agents or Anti-TNF therapy
1500933|NCT02962232|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|treatment group
1500934|NCT02962232|Device|PTA catheter|control group
1500935|NCT02962219|Behavioral|Pre-operative Exercise Programme (my-PEP)|A pre-operative personalised exercise programme (my-PEP) consisting of: 1) actions to promote exercise, using behavioural change techniques (BCTs), 2) home inspiratory muscle training (IMT), 3) a home exercise programme (HEP) - which is also current standard care, 4) a 4 week hospital-supervised aerobic and muscle strengthening programme (Hos-PEP) .
1500936|NCT02962219|Behavioral|Home Exercise Programme (HEP)|Written advice on exercise at home
1500937|NCT02962206|Device|Point-of-care ultrasound|After the fracture reduction maneouver, the physician will assess residual dorsal angulation using point-of-care ultrasound. If deemed adequate, the physician will progress to immobilization. If the reduction is not adequate, the physician will attempt further reduction at their discretion.
1500938|NCT02962206|Procedure|Closed fracture reduction|The distal radius fracture will be reduced with using a combination of local anesthetic, sedation, reduction maneouvers and immobiliazation at the discretion of the treating physician
1500939|NCT02962180|Device|Dermabrasion with dermaroller|o The dermaroller is passed on the treated depigmented area. This technique is based on tiny microwounds performed using 540 microneedles (0.2mm length) which should allow the penetration of the suspension cells into the epidermis to obtain a good repigmentation.
1500940|NCT02962167|Biological|Modified Measles Virus|Administration of MV-NIS either into the tumor bed, if surgery to remove local tumor
1500941|NCT02962167|Biological|Modified Measles Virus Lumbar Puncture|Administration of MV-NIS into the cerebrospinal fluid via lumbar puncture
1500942|NCT02962154|Radiation|Coronary CT Angiography|The coronary CT angiography will assess for coronary artery stenosis, plaque characteristics, calcifications, and other factors.
1500943|NCT02962154|Other|Mood Symptom Scale|"Some or all of the following questionnaires will be conducted to assess mood symptoms:
Beck Depression Inventory, Hamilton Depression Rating Scale (24-item), Montgomery Asberg Depression Rating Scale (MADRS), Mood and Anxiety Symptom Questionnaire (MASQ), QIDS, Young Mania Rating Scale"
1500944|NCT02962154|Other|Anxiety Symptom Scale|"Some or all of the following questionnaires will be conducted to assess anxiety symptoms:
Beck Anxiety Inventory, Spielberger State/Trait Anxiety Inventory (STAI), GAD-7 Anxiety Questionnaire, Penn State Worry Questionnaire (PSWQ)"
1500945|NCT02962154|Other|Chronic Stress Inventories|"Some of all of the following questionnaires will be conducted to assess chronic stress:
Chronic stress inventories: Cohen Perceived Stress Scale, Holmes and Rahe Stressful Life Events Scale, Karasek Job Strain Questionnaire, Conner-Davidson Resilience Scale, PTSD Checklist"
1500946|NCT02962154|Other|Psychosocial Function Questionnaires|"Some of all of the following questionnaires will be conducted to assess psychosocial function:
Type A Personality Scale, NEO Personality Inventory, Positive and Negative Affect Schedule (PANAS), Behavioral Inhibition/Behavioral Approach Scale (BIS/BAS)"
1500947|NCT02962154|Other|General Health and quality of life questionnaires|"Some of all of the following questionnaires will be conducted to assess quality of life:
EQ-5D Health Questionnaire, Seattle Angina Questionnaire, International Index of Erectile Function (ILEF-5), Pittsburgh Sleep Quality Scale, Morningness Eveningness Questionnaire"
2002160|NCT02477839|Other|Placebo|Active Substance: Placebo Pharmaceutical Form: Syrup Concentration: N/A Route of Administration: oral
1501042|NCT02961699|Device|Transpose ® RT System|adipose-derived stem cell therapy
1500948|NCT02962154|Other|Magnetic Resonance Imaging|First, subjects will undergo a resting cardiac MR perfusion study to establish baseline (pre-stress) measures of cardiovascular function. Second, subjects will undergo a series of brain magnetic resonance imaging studies (T1-weighted anatomical MRI, diffusion tensor imaging, resting state functional MRI) to establish baseline (pre-stress) measures of brain function and structural correlates. Third, investigators will use a well-validated cognitive task to induce mental stress by testing subjects' working memory for a series of emotionally arousing or neutral images, while repeating the functional MRI scan. Finally, subjects will undergo a repeat cardiac MR perfusion study while being tested on the same mental stress task.
1500949|NCT02962141|Device|Paclitaxel Releasing Peripheral Balloon Dilatation Catheter|Treatment group
1500950|NCT02962141|Device|Balloon Dilatation Catheter|Control group
1500951|NCT02962128|Dietary Supplement|High Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a high [10% energy] LA-containing diet for 12 weeks.
1500952|NCT02962128|Dietary Supplement|Low Linoleic Acid (LA) Diet|Volunteers will be randomly assigned to consumption of a low [2.5% energy] LA-containing diet for 12 weeks.
1500953|NCT02962115|Behavioral|Decision Aid Invitation|electronic invitation to complete web-based decision aid
1500954|NCT02962102|Drug|Calcifediol|Calcifediol 400mcg PO/NGT/OGT x 1, followed by 200mcg PO/NGT/OGT daily x 4
1500955|NCT02962102|Drug|Calcitriol|Calcitriol 4mcg PO/NGT/OGT daily x 5
1500956|NCT02962102|Drug|Placebos|Placebo (medium chain triglyceride oil) daily x 5
1500957|NCT02962089|Dietary Supplement|Branched chain amino acids (BCAA)|
1500958|NCT02962089|Dietary Supplement|Placebo|
1500959|NCT02962076|Radiation|[C-11] Meta-hydroxyephedrine radioactive tracer (MHED)|
1500960|NCT02962063|Biological|durvalumab|
1500961|NCT02962063|Drug|carboplatin AUC 2/paclitaxel|
1500962|NCT02962063|Radiation|External beam radiation|
1500963|NCT02962063|Procedure|esophagogastrectomy|
1500964|NCT02962050|Procedure|Videofluoroscopic Swallowing Study (VFSS)|Videofluoroscopic swallowing study will be performed to measure oropharyngeal swallowing
1500965|NCT02962050|Procedure|High Resolution Manometry|High resolution manometry will be performed to measure pressures across the various anatomical zones of swallowing.
1500966|NCT02962050|Other|DIGEST|DIGEST will be used to analyze the safety and efficiency of swallowing bolus trials.
1500967|NCT02962050|Other|Penetration Aspiration Scale|The Penetration Aspiration Scale will be used to analyze the safety of the swallowing bolus trials.
1500968|NCT02962050|Other|Normalized Residue Ratio Scale|The Normalized Residue Ratio Scale will be used to analyze the efficiency of the swallowing bolus trials.
1500969|NCT02962050|Device|Voluntary Peak Cough Flow Testing|Voluntary peak cough flow testing will be performed to determine the peak expiratory flow (PEF) and volume of air expelled (FEV1) during voluntary coughing.
1500970|NCT02962050|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
1500971|NCT02962050|Device|Lingual Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
1500972|NCT02962050|Drug|Capsaicin Challenge|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
1500973|NCT02962050|Device|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), maximum inspiratory pressure (MIP), and maximum expiratory pressure (MEP) expressed as a percentage of predicted values.
1500974|NCT02962050|Other|Eating Assessment Tool 10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
1500975|NCT02962050|Other|The Center for Neurologic Study Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
1500976|NCT02962037|Other|Melatonin and light therapy|
1500979|NCT02962011|Device|Knotless barbed suture|uterine incision closure
1500980|NCT02962011|Device|polyglactin 910|uterine incision closure
1500981|NCT02961998|Drug|Celecoxib|Patients from experimental group will take celecoxib, except for sorafenib
1500982|NCT02961998|Drug|Sorafenib|Each group will receive sorafenib as basic treatment.
1500983|NCT02961972|Dietary Supplement|monohydrate and micronized creatine|oral supplementation with creatine
1500984|NCT02961972|Other|placebo|oral supplementation with maltodextrin (control group)
1500985|NCT02961959|Procedure|Surgery|Arthrodesis of SI-joints, Physiotherapy
1500986|NCT02961959|Other|Non-surgery|Physiotherapy
1500987|NCT02961946|Drug|Nitroglycerin|Patients grouped in sublingual administration (group 1 and 2) will receive Nitroglycerin during the cCTA scan by the MD after the Calcium scoring scan and 5 minutes before the actual cCTA scan. Patients categorized to transdermal administration will receive Nitroglycerin 1 hour before the CT examination. The patch will be placed on the chest or the upper arm.
1500988|NCT02961933|Other|Apneic oxygenation|Nasal cannula apneic oxygenation
1500989|NCT02961933|Other|Pre-oxgenation with NRB, NIPPV, BVM|Pre-oxygenation with non-rebreather mask, non-invasive positive pressure ventilation, or bag-valve mask
1500990|NCT02961920|Device|IE ratio 1:1|Set an I:E ratio1:1 in the mechanical ventilator during spine surgery in the prone position in obese patients.
1500991|NCT02961920|Device|IE ratio 1:2|Set an I:E ratio1:2 in the mechanical ventilator during spine surgery in the prone position in obese patients.
1501040|NCT02961712|Biological|NK cells|single intravenous injection of NK cells (0.9~1*10^9)
1501043|NCT02961699|Other|debridement/dressing of wound|standard of care debridement and wound dressing
2002162|NCT02478398|Biological|MK-3641|
1500994|NCT02961881|Drug|blinatumomab|Drug used as a treatment for relapsed/refractory B-cell precursor ALL
1500995|NCT02961868|Other|Abdominal and supra-aortic trunks vascular imaging|Abdominal and supra-aortic trunks vascular imaging (angiography, CT-angiography or MR-angiography) will be performed 3 years after inclusion. This imaging will be compare to initial imaging (which is a part of usual care, not an intervention added by the study) in order to assess FMD progression.
1500996|NCT02961868|Genetic|Blood sampling (genetic)|A sample of blood will be taken to meet the objective of estimating the rate of genetic polymorphism that may influence disease progression or be associated with complications.
1500997|NCT02961868|Other|Blood sampling (biomarkers)|A sample of blood will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
1500998|NCT02961868|Other|Urine sampling|A sample of urine will be taken to biomarkers analysis to meet the primary objective of assessing the risk factors for progression of FMD lesions.
1500999|NCT02961855|Drug|anesthesics plus antiinflammatory, CLIFE1|anesthesics plus antiinflammatory, CLIFE1 topical gel containing lidocaine plus diclofenac anesthesics plus antiinflammatory
1501000|NCT02961855|Drug|local anesthesics, CLIFE2|local anesthesics, CLIFE2 topical gel containing lidocaine local anesthesics
1501001|NCT02961842|Drug|500 mL Colloid Preload|6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven®) 500 mL will be rapidly infused before spinal anesthesia
1501002|NCT02961842|Procedure|Spinal Anesthesia|Performed at the L3-L4 or L4-L5 interspace using 27- or 25-gauge spinal needle
1501003|NCT02961842|Drug|Intrathecal Bupivacaine|Bupivacaine 12.5 mg (2.5 mL 0.5%) will be administered in the subarachnoid space
1501004|NCT02961842|Drug|Intrathecal Fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space
1501005|NCT02961842|Drug|500 mL Crystalloid Coload|Ringer acetate 500 mL will be rapidly infused immediately after intrathecal injection
1501006|NCT02961842|Drug|1000 mL Crystalloid Coload|Ringer acetate 1000 mL will be rapidly infused immediately after intrathecal injection
1501007|NCT02961842|Procedure|Cesarean Delivery|Lower segment cesarean section using the Pfannenstiel incision
1501008|NCT02961842|Radiation|Ultrasound Assessment of the Inferior Vena Cava|The inferior vena cava largest and smallest diameters will be measured proximal to the opening of the hepatic veins in the longitudinal axis with the M-mode using a 5-2 MHz curved array ultrasound probe placed longitudinally in the subxiphoid region
1501009|NCT02961842|Drug|Intravenous Ephedrine|Intravenous ephedrine 3, 5, and 10 mg will be administered when Systolic blood pressure decreases below 90%, 80%, and 70% of baseline, respectively.
1501010|NCT02961829|Drug|Maraviroc|antiretroviral intensification
1501011|NCT02961829|Drug|Dolutegravir|antiretroviral intensification
1501012|NCT02961829|Biological|Dendritic Cell Vaccine|Therapeutic vaccination
1501013|NCT02961829|Drug|Auranofin|purging
1501014|NCT02961829|Drug|Sirtuin Histone deacetylase inhibitor|latency disruption
1501015|NCT02961816|Drug|Palifermin|Palifermin, per standard of care, on Days -13 to -11 and on Days 0, +1, and +2.
1501016|NCT02961816|Drug|Panobinostat|20 mg by mouth daily from Day -9 to -2.
1501017|NCT02961816|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein followed by prolonged infusion over 4.5 hours of 2,700 mg/m2 (total daily dose 2,775 mg/m2) on Days -8 and -3.
1501018|NCT02961816|Drug|Busulfan|"Busulfan test dose administered on Day -10. Test dose of 32 mg/m2 based on actual body weight administrated over 60 minutes. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-8. Doses of Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1. Busulfan adjusted to target a cumulative AUC of 16000 and may be significantly higher or lower than 4000 on the last 2 days depending on first PK."
1501019|NCT02961816|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
1501020|NCT02961816|Drug|Rituximab|375 mg/m2 by vein on Day -9 for patients with CD20+ tumors.
1501021|NCT02961816|Drug|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
1501022|NCT02961816|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
1501023|NCT02961816|Drug|Glutamine|Oral Glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
1501024|NCT02961816|Other|Oral Cryotherapy (ice chips)|Oral cryotherapy (ice chips) from 30 minutes before until 2 hours after each Melphalan infusion.
1501025|NCT02961816|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
1501026|NCT02961816|Biological|Stem Cell Infusion|Stem cells administered by vein on Day 0.
1501027|NCT02961816|Drug|G-CSF|G-CSF administered as an injection just under the skin, per standard of care ,1 time each day starting on Day +5 until blood cell levels return to normal.
2002163|NCT02478398|Biological|Placebo|
2002164|NCT02478398|Drug|Self-injectable epinephrine|Intramuscular (IM) injection with suggested doses of 0.15 mg for participants weighing 15-30 kg (33-66 pounds) or 0.3 mg for participants weighing ≥30 kg (≥66 pounds), as needed for rescue medication
1501030|NCT02961790|Drug|Oxybutynin Chloride|Given PO
1501031|NCT02961790|Other|Placebo|Given PO
1501032|NCT02961790|Procedure|Quality-of-Life Assessment|Ancillary studies
1501033|NCT02961790|Other|Questionnaire Administration|Ancillary studies
1501034|NCT02961777|Other|implementation of care pathway|implementation of a care pathway
1501035|NCT02961764|Drug|Usual Care|Usual care as prescribed by the physician as standard of care in clinical practice for the treatment of ABSSSI.
1501036|NCT02961764|Drug|Dalbavancin|Dalbavancin administered as a single IV dose of 1500 mg over 30 minutes.
2002165|NCT02478398|Drug|Albuterol/Salbutamol|Inhalation albuterol 90 mcg/puff or salbutamol 100 mcg/puff metered dose inhaler (MDI), as needed for rescue medication
1501038|NCT02961738|Behavioral|Cognitive Analytic Therapy (CAT)|Cognitive Analytic Therapy (CAT) is a relational, integrative and time-limited psychotherapy. This is a study with two active arms. Therefore in the full CAT arm the participants receive the full therapy, but in the CAT-NR arm participants get CAT with the narrative reformulation aspect removed.
1501039|NCT02961725|Biological|UCMSC|UCMSC: umbilical cord mesenchymal stem cells 3-5*10^7/5 ml
1501760|NCT02956499|Drug|APX001 single dose 1|
1501044|NCT02961686|Radiation|Patients affected by prostate cancer|Patients affected by prostate cancer and treated with a multidisciplinary approach: it includes exclusive radiotherapy, psychological and andrologic evaluation.
1501045|NCT02961673|Biological|HU-014 Inj|Clostridium botulinum type A
1501046|NCT02961673|Biological|Botox Inj|Clostridium botulinum type A
1501047|NCT02961660|Drug|Odalasvir|Participants will receive odalasvir 25 mg tablet, orally.
1501048|NCT02961647|Procedure|Mitral valve repair|The intervention is NOT related to the study design. It is a description of patients undergoing surgery vs. not undergoing surgery and this decision is made according to current guidelines (patients are not randomized).
1501049|NCT02961634|Device|Nailner 2 in 1|Nailner 2 in 1 is a combination of assets that alter the pH of the nail and is used as an adjunct in the treatment of onychomycosis.
1501050|NCT02961634|Drug|Ciclopirox 8%|Ciclopirox 8% is a glaze used in the treatment of onychomycosis
1501051|NCT02961621|Behavioral|Stress Reduction Training for 9-1-1 Telecommunicators|
1501052|NCT02961608|Drug|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)|Drug conversion from Tacrolimus (Prograf® or Adoport®) to LCP-Tacrolimus (Envarsus®)
1501053|NCT02961595|Biological|Oral Polio Vaccine (OPV)|Serial Oral Polio Vaccine (OPV) was given to intervention group instead of inactivated poliovirus vaccine (IPV).
1501054|NCT02961582|Device|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period. If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted.
Patients in the intervention group are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
1501055|NCT02961582|Other|Personalized Conservative Treatment|The control group will receive the best and least invasive alternative treatment, which is personalized conservative treatment (PCT). PCT includes, a combination of laxative/medication use and/or colonic irrigation, depending on the preferences of the patient. Use of PCT will be documented.
1501056|NCT02961569|Procedure|sputum collection for acid fast bacilli|spontaneous or post fiberoptic bronchoscopy sputa
1501058|NCT02961543|Other|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.
45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
1501059|NCT02961543|Other|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.
45 days after ACL reconstruction, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
1501060|NCT02961530|Other|Isokinetic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.
15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isokinetic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
1501061|NCT02961530|Other|Isotonic eccentric exercises|"The individuals of both groups will be submitted to the same physiotherapeutic protocol with objectives of analgesia, reduction of edema, recovery of range of motion, proprioception and functionality.
15 days after partial menisectomy, subjects randomly allocated to this arm will be submitted to a muscle rehabilitation program based on isotonic eccentric exercise lasting six weeks, with training frequency of two sessions per week, separated by a minimum interval of 72 hours."
1501062|NCT02961517|Other|Questionnaire|Anonymous questionnaire collecting basic sociodemographic data about the participant and information regarding their preferences for the method of delivery format of patient education information
1501063|NCT02961504|Biological|HLCM051|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of 1.2 billion HLCM051 cells to be intravenously administered
1501064|NCT02961504|Biological|Placebo|Within 18 to 36 hours after the onset of ischemic stroke, subjects will receive a single dose of placebo to be intravenously administered
1501065|NCT02961491|Drug|Ultratrace Iobenguane I131|Subjects will receive a dosimetry dose of AZEDRA and will undergo 3 whole body scans. If the scans indicate tumor avidity for AZEDRA, the subjects will receive up to 2 therapeutic doses of AZEDRA each at 500 mCi (or 8 mCi/kg, for subjects weighing 62.5 kg or less) approximately 90 days apart.
1501066|NCT02961478|Drug|IOHEXOL|Estimate iohexol clearance at the end of stay in intensive care for patients who had an episode of acute renal failure.
1501067|NCT02961465|Device|Sacral Neuromodulation|"SNM starts with a screening phase. In this phase a tined lead is inserted into the third sacral foramen and attached to an external stimulator, after which the patient enters a four-week stimulation test period.
If the screening phase is successful (defecation frequency (DF) ≥3 a week), the external stimulator is changed for a pacemaker that is implanted in the buttocks. If the screening phase is unsuccessful (DF <3 a week), the lead is explanted. Patients are asked to limit the use of additional conservative treatments for constipation (such as laxatives and colonic irrigation) to what is necessary to relieve (the most severe) complaints. What is necessary to relieve complaints is determined by the patient."
1501068|NCT02961452|Other|Cross reaction detection|
1501069|NCT02961439|Behavioral|Epworth Richmond's Echocardiography Focused Year|a year long echo teaching program
1501070|NCT02961426|Drug|sofosbuvir|combination sofosbuvir ravidasvir treatment for non cirrhotic and compensated cirrhotic patients
1501071|NCT02961400|Other|PUSH text messages|The intervention is designed to remind participants of treatment components.
1501072|NCT02961400|Other|PULL text messages|The intervention is designed to remind participants to recall treatment components.
1501073|NCT02961400|Behavioral|TranS-C|The Transdiagnostic Sleep and Circadian Intervention (TranS-C) integrates evidence-based treatments derived from basic research on the circadian system.
1501074|NCT02961400|Behavioral|PE|Psychoeducation on the inter-associations between sleep, diet, exercise and stress.
1501075|NCT02961387|Device|Hydrogen generator treatment|The patients mainly used the hydrogen generator with nebulizer for inhalation of hydrogen-oxygen mixed gas.
1501076|NCT02961387|Device|Oxygen-making machine treatment|The patients mainly used medical molecular sieve oxygen-making machine for oxygen inhalation.
1501077|NCT02961374|Drug|Erlotinib Hydrochloride|Given PO
1501078|NCT02961374|Other|Laboratory Biomarker Analysis|Correlative studies
1501079|NCT02961361|Drug|ropivacaine|40 ml 0.375% ropivacaine was injected after Locating brachial plexus.
1501080|NCT02961361|Drug|ropivacaine mixed with dexmedetomidine|40 ml 0.375% ropivacaine mixed with dexmedetomidine was injected after Locating brachial plexus.
2002166|NCT02478398|Drug|Loratadine|5 mg (1 mg/mL syrup or 5 mg tablet) for participants 5 years old or 10 mg (1 mg/mL syrup or 10 mg tablet) for participants 6 to 17 years old, as needed for rescue medication
2002167|NCT02478398|Drug|Olopatadine|Opthalmic solution, 1 drop (0.1%) per affected eye twice daily (BID), as needed for rescue medication
1501083|NCT02961335|Procedure|Bronchoscopy|
1501084|NCT02961335|Procedure|Confocal microendoscopy|Confocal microendoscopy will be performed during this initial bronchoscopy
1501085|NCT02961335|Procedure|Biopsy sampling|
1501086|NCT02961322|Other|lobo-isthmectomy assisted robot|
1501087|NCT02961309|Drug|THC|1 High-Potency THC (Dosage = 10mg) cigarette (oral smoking) on one day and 1 Placebo on the other day.
1501088|NCT02961296|Other|No intervention|No intervention will be needed.
1501089|NCT02961283|Drug|ASN003 ascending doses|
1501090|NCT02961283|Drug|ASN003 MTD|The highest safe and well tolerated dose selected from the doses tested in Part A of the study.
1501091|NCT02961270|Drug|Icotinib|Icotinib will be given orally 250 mg thrice per day until disease progression, or untolerated toxicity
1501092|NCT02961257|Drug|cabazitaxel|"Arm A : cabazitaxel 25 mg/m² on Day 1 of a 3-week cycle plus daily prednisone or
Arm B: cabazitaxel 16 mg/m² on Day 1 and Day 15 of a 4-week cycle plus daily prednisone.
Treatment will be continued for a maximum of 10 cycles unless there is documented disease progression or unacceptable toxicity.
Standard cabazitaxel premedication will be used"
1501093|NCT02961257|Drug|Prednisone|Arm A:plus prednisone 10 mg orally given daily for a maximum of 10 cycles Arm B: plus prednisone 10 mg orally given per day up to 10 cycles
1501094|NCT02961257|Drug|Granulocyte colony-stimulating factor (G-CSF)|Primary prophylaxis with Granulocyte Colony-Stimulating Factor (G-CSF) will be injected from Day 3 to Day 7 after every cycle of cabazitaxel (if neutrophil count is >2000/mm3, only 3 days)
1501095|NCT02961244|Other|Prewarming and perioperative warming with Forced Air Warming device and its blankets.|
1501096|NCT02961244|Device|Forced Air Warming blanket|
1501097|NCT02961231|Biological|PCV 2p+1|introduction of PCV in a reduced dosing 2p+1 schedule
1501098|NCT02961231|Biological|PCV 3p+0|introduction of PCV in a reduced dosing 3p+0 schedule
1501099|NCT02961231|Biological|PCV 1p+1|introduction of PCV in a reduced dosing 1p+1 schedule
1501100|NCT02961231|Biological|PCV 0p+1|introduction of PCV in a reduced dosing 0p+1 schedule
2002168|NCT02478398|Drug|Mometasone furoate monohydrate|Intranasal spray, at doses of 1 spray (50 mcg/ spray) per nostril for participants 5 to 11 years old or 2 sprays (50 mcg/spray) per nostril for participants 12 to 17 years old, as needed for rescue medication
2002169|NCT02475356|Drug|Mirena (Levonorgestrel IUS, BAY86-5028)|The treatment of Mirena should comply with the local product information.
1501103|NCT02961205|Dietary Supplement|Oral Nutritional Supplementation|"Participants randomized to this arm will receive one bottle of Ensure Enlive 2 times per day, for 30 days prior to their cardiovascular surgery, plus continue their usual diet.
After their CVS and throughout their hospitalization they will continue to receive 2 bottles of Ensure Enlive per day, plus the standard hospital menu (3 meals per day, plus snacks or as ordered by the medical team), ending at hospital discharge."
2002170|NCT02474082|Biological|Secukinumab|Secukinumab 150 mg, 1 ml liquid formulation in a pre-filled pen for s.c. injection
1501107|NCT02961179|Behavioral|Increased dairy product|
1501108|NCT02961179|Behavioral|Dietary counselling|
1501109|NCT02961166|Drug|IgM enriched Immunoglobulins|Treatment for 3 days
1501110|NCT02961153|Other|death|
1501111|NCT02961140|Other|Cardiac Output Maximization|According to Frank-Starling law, the investigator will administer Voluven 6% 250 mL every 5 minute until stroke volume maximized (stabilized for 20 minutes), and maintain cardiac index and stroke volume variation during the whole operation.
1501112|NCT02961140|Other|Cardiac Output Normalization|The investigator will administer intravenous fluids to keep cardiac index (CI) ≥ 2.2, and maintain CI and stroke volume variation during the whole operation.
1501113|NCT02961127|Other|Venous blood was collected|Venous blood was collected by standard vein puncture in fasting condition
1501114|NCT02961114|Procedure|Microcannula Harvest Adipose|Use of closed syringe microcannula harvest of autologous AD-tSVF from subdermal adipose deposits to create a AD-cSVF
1501115|NCT02961114|Device|Centricyte 1000|Use of Centricyte 1000 closed system digestion, incubation/agitation, and centrifugation to acquire a concentrated pellet of AD-cSVF
1501116|NCT02961114|Biological|IV Sterile Normal Saline|Sterile Normal Saline deployment of AD-cSVF in suspension of 500cc in IV pathway
1501117|NCT02961101|Drug|Anti-PD-1 antibody|Anti-PD-1 antibody will be given at 1-3mg/kg on day8 by IV every three weeks
1501118|NCT02961101|Drug|Decitabine|Decitabine will be given at 10mg/d on day 1to 5 by IV every three weeks
1501119|NCT02961088|Other|Pasta as part of a low GI/GL diet|
1501120|NCT02961075|Other|local surface anesthesia|Airway anesthesia for Bronchoscopy
1501121|NCT02961075|Device|Laryngeal tube|
1501124|NCT02961049|Procedure|Gingival displacement|Gingival displacement with a gingival cord (#0, #00 or #000) with specific spatula.
1501125|NCT02961049|Procedure|Enamel and dentin etched|Enamel and dentin etched with 35% phosphoric acid for 30 and 15 seconds, respectively.
1501126|NCT02961049|Procedure|Selective enamel etched|Selective enamel etched with 35% phosphoric acid for 15 seconds.
1501127|NCT02961049|Procedure|Wash and dry|Wash and dry with absorbent paper.
1501128|NCT02961049|Device|Total-etch adhesive system|Two layers of pirmer/bond on enamel and dentin with a brush.
1501129|NCT02961049|Device|self-conditioning adhesive system|One layer of acid/pirmer on enamel and dentin with a brush following to one layer of bond with a brush.
1501130|NCT02961049|Procedure|Photoactivated|Photoactivated for 20 seconds
1501131|NCT02961036|Other|Group 1 information|Group 1 prize draw information for participants to win 100% of an Amazon gift card (or currency equivalent) in invitation letter.
1501132|NCT02961036|Other|Group 2 information|Group 2 prize draw information for participants to win 75% of an Amazon gift card (or currency equivalent) in invitation letter.
1501133|NCT02961036|Other|Group 3 information|Group 3 prize draw information for participants to win 50% of an Amazon gift card (or currency equivalent) in invitation letter.
1501134|NCT02961036|Other|Group 4 information|Group 4 prize draw information for participants to win 25% of an Amazon gift card (or currency equivalent) in invitation letter.
1501135|NCT02961036|Other|Group 5 no information|Group 5 no Information for participants to enter a draw to win an Amazon gift card (or currency equivalent) in invitation letter.
1501136|NCT02961036|Other|Group A Reminder|One survey reminder at 14 days
1501137|NCT02961036|Other|Group B Reminders|Two survey reminders one at 14 days and one at 28 days
1501138|NCT02961023|Other|Exercise therapy|"3-week residential phase and 12-week outpatient phase.
Residential phase
Exercise will be supervised by a physiotherapist and prescribed based on cardiopulmonary exercise testing.
A monitored daily program of exercise involving bicycle ergometry, walking, breathing exercises, dumbbell exercises 5 days per week.
1.5 to 2 hours of exercise will be performed daily, with rest intervals.
At weekends, lower intensity, unsupervised exercise mirroring the outpatient phase
Ongoing exercise prescription will be based on tolerability, progress and HR
Outpatient phase
A training manual will be compiled based on the subjects exercise performance during the residential program and tailored specifically to their needs
Participants will be provided with a cycle ergometer, weights and a HR monitor
Weekly telephone contact will be made by the study doctor or physiotherapist, with adjustments made to training prescription as necessary"
1501139|NCT02961010|Behavioral|Keeping Safe|A whole school Preventative Education programme
1501140|NCT02960997|Drug|Sirolimus, 2%|
1501141|NCT02960997|Drug|Vehicle|
1501142|NCT02960984|Other|Task Oriented rehabilitation and aerobic training|Participants in the experimental group will receive 1 hour treatment comprising 30' of aerobic training and 30' of task-oriented training focused on uppper limb rehabilitation for 3 times a week for 20 sessions.
1501143|NCT02960971|Procedure|Thoracic surgery for lung cancer|Lung cancer resection performed via Video-assisted thoracoscopic surgery (VATS) and/or thoracotomy, including lobectomy, bilobectomy, pneumonectomy, resection of the tracheobronchial bifurcation, wedge resection, sleeve resection and combinations hereof.
1501144|NCT02960945|Drug|CTP-543, 16 mg (2 x 8 mg tablet)|
1501145|NCT02960945|Drug|Jakafi 15Mg Tablet|
1501146|NCT02960932|Device|ultrasound scanner|Ultrasound scanner used to the SSI technical reproducibility.
1501147|NCT02960919|Drug|oral amoxicillin or parenteral ampicillin/ penicillin and gentamicin|
1501148|NCT02960919|Drug|parenteral ampicillin/ penicillin|
1501149|NCT02960919|Drug|gentamicin|
1501150|NCT02960906|Drug|Nivolumab|"For Arms 1A and 4A:
Nivolumab alone administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol.
For Arms 1B, 2B, 3B and 4B:
Nivolumab administered IV over 60 minutes at 3 mg/kg combined with ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks for 4 doses followed by nivolumab administered IV over 60 minutes at 240 mg every 2 weeks until disease progression, unacceptable toxicity or other reasons specified in the protocol."
1501151|NCT02960906|Drug|Ipilimumab|"For Arms 1B, 2B, 3B and 4B:
Ipilimumab administered IV over 30 minutes at 1 mg/kg every 3 weeks combined with Nivolumab administered IV over 60 minutes at 3 mg/kg for 4 doses until disease progression, unacceptable toxicity or other reasons specified in the protocol."
1501152|NCT02960906|Drug|Pazopanib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):
Pazopanib 800 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
1501153|NCT02960906|Drug|Sunitinib|"For Arms 2C and 3C (TKI pazopanib or sunitinib):
Sunitinib 50 mg orally QD until disease progression, unacceptable toxicity or other reasons specified in the protocol"
1501154|NCT02960893|Drug|BHV-4157|140mg capsule QD
1501155|NCT02960893|Drug|Placebo Comparator|
1501156|NCT02960880|Drug|Rivaroxaban (Xarelto, BAY597939)|15mg, 20mg
1501157|NCT02960880|Drug|Phenprocoumon (branded and generics)|Individually adjusted dose
1501159|NCT02960841|Other|Intracavitary Manual Lymphatic Drainage|
1501160|NCT02960841|Other|Conventional treatment|
1501161|NCT02960828|Procedure|Subthreshold Laser Photocoagulation|Selective Subthreshold Laser Photocoagulation is applied to the periphery of high-risk macular drusen
1501162|NCT02960828|Drug|intravitreal Anti-VEGF injection|To prevent choroidal neovascularization, intravitreal Anti-VEGF injection is done on a 3 month interval up to 1 year.
1501163|NCT02960828|Device|Subthreshold Laser|
1501167|NCT02960802|Procedure|kidney transplantation|
1501168|NCT02960789|Other|Formalized clinical assessment of hydration status|Undertake and record a standard formalized clinical hydration assessment
1501169|NCT02960789|Other|Take a measurement of body weight on calibrated scales|Standard body weight measurements conducted on calibrated scales
1501170|NCT02960789|Device|"RF wristband hydration status measurement"|"Take measurements with RF wristband radio-frequency non-invasive wrist-based hydration status assessment device"
1501171|NCT02960789|Other|Measure capillary refill time with manual stopwatch|A standard visual assessment of capillary refill time, aided by the use of a stopwatch
1501172|NCT02960789|Device|"CRT device hydration status measurement"|"Take measurements with CRT device for non-invasively quantitatively assessing Capillary Refill Time"
1501173|NCT02960776|Behavioral|Sleep Restriction (SR)|Participants will be asked to keep their habitual wake time constant but delay their bedtime to achieve a reduction of 1.5 hours in total sleep time. A delay in bedtimes was chosen rather than advancing wake-up time because it most closely reflects differences in sleep timing behavior between short and normal sleepers.
1501174|NCT02960763|Drug|Aripiprazole Augmentation|Augment current antidepressant treatment with aripiprazole (tablets). Start at 2 mg daily; increase every two weeks (i.e., to 5, 7, 10 mg) to a maximum of 15 mg daily based on symptom severity and side effects.
1501175|NCT02960763|Drug|Bupropion Augmentation|Augment current antidepressant treatment with bupropion once-daily extended release, starting at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
1501176|NCT02960763|Drug|Switch to bupropion|Taper from current antidepressant therapy. Start bupropion once-daily extended release at 150 mg daily; titrated after four weeks to 300 mg daily based on symptom severity and side effects.
1501177|NCT02960763|Drug|Lithium Augmentation|Augment current antidepressant treatment with lithium carbonate tablets starting at 300 mg daily, titrated per blood level to 0.4-0.6 meQ/L.
1501178|NCT02960763|Drug|Switch to nortriptyline|Taper from current antidepressant therapy. Start on nortriptyline tablets starting at 1 mg per kg of body weight daily, titrated per blood level to 80-120 ng/ml
1501179|NCT02960750|Behavioral|"A workplace sit less and move more web-based program for Spanish office employees"|W@WS encourages office employees to progressively 'sit less and move more' during workdays over 19 weeks. During the first 8 weeks (ramping phase), tips are provided every two weeks to break occupational sitting time through incidental movement during work tasks, introduce short walks (5-10 minutes) during morning/afternoon work breaks and/or commuting time, introduce longer walks at lunchtime and achieve at least 10,000 daily steps as well as increase walking intensity. During weeks 9 to 19, W@WS provides automated guidance with periodic emails encouraging behaviors achieved in the previous phase. Ecological support strategies such as logging daily step counts into a personal account and receiving visual feedback on the achievement of goals are also provided
1501180|NCT02960750|Behavioral|Active Comparison group|The Active Comparison group maintained habitual behavior. The A-CG was given a pedometer and a paper diary to register daily step counts and self-reported sitting time throughout the intervention.
1501181|NCT02960737|Device|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
1501182|NCT02960724|Other|68Ga-NOTA-AE105 PET/CT|One injection of 68Ga-NOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan.
1501183|NCT02960711|Drug|Metformin Hydrochloride 850 MG Oral Tablet [Glucophage]|
1501184|NCT02960711|Drug|Ludipress, mg stereate, micronized hydrated silica, talcum|Tablet
1501185|NCT02960698|Other|IRM and comportemental tasks|
1501186|NCT02960685|Procedure|Echocardiography|
1501195|NCT02960633|Device|Corail with collar.|
1501196|NCT02960633|Device|Corail without collar.|
1501197|NCT02960620|Device|TheraSphere Treatment|TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. The hepatic artery provides the main blood supply to the tumor in the liver, whereas the portal vein supplies blood to normal liver parenchyma. TheraSphere® is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
1501198|NCT02960607|Drug|Icotinib|Icotinib (250mg tid) until disease progression or unacceptable toxicities occurred.
1501199|NCT02960594|Biological|INO-1400|
1501200|NCT02960594|Biological|INO-9012|
1501201|NCT02960581|Biological|PGT121|3mg/kg administered by IV Infusion
1501202|NCT02960581|Biological|PGT121|10mg/kg administered by IV infusion
1501203|NCT02960581|Biological|PGT121|30mg/kg administered by IV infusion
1501204|NCT02960581|Biological|PGT121|"30mg/kg administered by IV infusion
Placebo: None"
1501205|NCT02960581|Biological|PGT121|"10mg/kg administered by IV infusion
Placebo: None"
1501206|NCT02960581|Biological|PGT121|"3mg/kg administered by IV infusion
Placebo: None"
1501207|NCT02960581|Biological|Placebo (0.9% Sodium Chloride Injection USP (Saline))|
1501208|NCT02960568|Drug|Primaquine|30 mg oral primaquine one time
1501260|NCT02960178|Behavioral|Conventional walking training|Over-ground practice of stepping and balance tasks in standing. One hour in duration.
1501261|NCT02960165|Behavioral|Virtual interface group|First practice on virtual interface in order to evaluate the improvement and its influence on real interface performance (second practice).
2002171|NCT02474082|Drug|Fumaric acid|Fumaric acid initial therapy (tablet contains 30 mg dimethylfumarate, 67 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt) and Fumaric acid maintenance therapy (tablet contains 120 mg dimethylfumarate, 87 mg ethylhydrogenfumarate calcium salt, 5 mg ethylhydrogenfumarate magnesium salt, 3 mg ethylhydrogenfumarate zinc salt)
1501215|NCT02960529|Procedure|extra-peritoneal high ligation of hernia|
1501216|NCT02960529|Procedure|intraabdominal high ligation of hernia|
1501217|NCT02960516|Device|MRI of 3.0T|Diffusion Tensor Testing for peripheral nerve monitoring
1501218|NCT02960503|Drug|Azithromycin|Study participants will be randomized to the treatment arm (azithromycin 500 mg three times a week for 6 months).
1501219|NCT02960503|Other|Placebo|Study participants will be randomized to the control arm (placebo three times a week for 6 months).
1501220|NCT02960490|Drug|E6011|subcutaneous administration
1501221|NCT02960490|Drug|Placebo|subcutaneous administration
1501222|NCT02960477|Other|Pain Neuroscience education|A PNE session covers the neurobiology, neurophysiology and processing of pain.
1501223|NCT02960477|Other|Biomedical Education|A biomedical session covers the normal course of shoulder pain, anatomy, physiology and biomechanics of the shoulder, the expected course of postoperative shoulder pain, and the importance of self-care.
1501224|NCT02960464|Device|Transcranial direct current stimulation|
1501225|NCT02960464|Device|Sham Transcranial direct current stimulation|
1501226|NCT02960451|Other|PRIME care|Specialist medication, cognitive behavior therapy, family-focused therapy
1501227|NCT02960451|Other|Usual care|Medication and psychotherapy as available form community providers
1501228|NCT02960438|Drug|E6011|subcutaneous administration
1501229|NCT02960438|Drug|Placebo|subcutaneous administration
1501230|NCT02960425|Dietary Supplement|Delivra TM Livsport preworkout cream|High versus low dose topical creatine
1501231|NCT02960425|Dietary Supplement|Placebo|Topical placebo
1501232|NCT02960412|Drug|furosemide|10mg lasix given intraoperatively
1501233|NCT02960412|Drug|Normal Saline|Normal saline given intraoperatively as placebo
1501234|NCT02960399|Biological|Zostavax®|Zostavax® immunization
1501235|NCT02960386|Other|Machine Learning Algorithm|The algorithm will help participants improve physical activity by sustaining long term engagement with their fitness tracker.
1501236|NCT02960373|Other|White Bread (Control)|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
1501237|NCT02960373|Other|Dried Fruit - Glycemic Index|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
1501238|NCT02960373|Other|Catalytic Fructose Dose Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
1501239|NCT02960373|Other|High GI Displacement Effect|A randomized multiple-crossover acute-feeding trial design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 day washout period.
1501240|NCT02960347|Device|High-definition (HD) transcranial direct current stimulator, HD-tDCS with 4x1 HD adaptor|Non-invasive focal neuromodulation
1501241|NCT02960334|Device|MyDiagnostick|The MyDiagnostick is a compact hand-held device that registers and stores I-lead ECG strips. In one minute, t analyses the rhythm for the presence of AF. It distinguishes AF from normal cardiac rhythms by measuring RR-irregularity.
1501242|NCT02960308|Radiation|Computed Tomography Perfusion Imaging|Undergo WNCTP scan
1501243|NCT02960295|Device|1-Self-monitoring of blood glucose|Self-monitoring of blood glucose 4 times daily: fasting and 1-hour after each meal. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment.
1501244|NCT02960295|Device|2-Self-weighing|Self-weighing on electronic scale at least once a week. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment.
1501245|NCT02960295|Device|3-Self-checking of blood pressure|Self-checking of blood pressure at least weekly with sphygmomanometer. Results will be recorded and transmitted in real-time via a Bluetooth connection to a cellphone app installed on study enrollment.
1501246|NCT02960295|Device|4-Checking fetal heart rate|Patient will record her fetus' heart rate with a Doppler device at least once weekly. The patient will immediately report to Labor and Delivery for any fetal heart rate below 100 beats per minute or greater than 160 beats per minute over a 10 minute observation period.
1501247|NCT02960295|Procedure|5-Visits with caregivers|Telephone visits will alternate with in-office visits
1501248|NCT02960282|Procedure|Biospecimen Collection|Undergo collection of fecal specimens
1501249|NCT02960282|Other|Laboratory Biomarker Analysis|Correlative studies
1501250|NCT02960269|Other|interprofessional back pain assessment|team assessment and education with urban physical therapist and rural nurse practitioner via telehealth
1501251|NCT02960256|Device|ekocardiogram test|ekocardiogram test
1501252|NCT02960243|Device|Deep Brain Stimulation|"DBS System Medtronic
DBS programming settings will be set to maximally alleviate limb tremor, primary reason for referral
These settings will be used to evaluate effects of voice tremor as well"
2002172|NCT02470078|Device|Phagenyx-Catheter, Phagenesis Limited, UK.|Pharyngeal electrical stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
1501256|NCT02960204|Drug|Emricasan|
1501257|NCT02960204|Drug|Placebo|
1501258|NCT02960191|Device|Magnetic resonance imaging (MRI)|
1501259|NCT02960178|Behavioral|Perturbation-based training|Over-ground practice of stepping and balance tasks in standing with perturbations applied by the trainer (pushes and pulls to the safety harness). One hour in duration with 60 perturbations targeted per hour.
1501262|NCT02960165|Behavioral|Real interface group|First practice on real interface in order to evaluate the improvement and its influence on virtual interface performance (second practice).
1501263|NCT02960152|Other|diagnostic|full-mouth periodontal examination
1501264|NCT02960139|Device|Test- Treatment with Sylys Surgical Sealan|Standard closure of stapled anastomosis plus treatment with Sylys Surgical Sealant
1501265|NCT02960126|Drug|Aspirin|
1501266|NCT02960126|Drug|Clopidogrel|
1501267|NCT02960113|Drug|scopolamine patch|Group I (n=80): Will receive scopolamine patch placement on the skin behind the right ear 1 hour before initiation of the regional anesthesia for the duration of surgery. The time of the application of the patch will be recorded, and the time of the start of the surgery will be recorded. The last time point for evaluation of patient's nausea/vomiting will be when the patient arrives to the post anesthesia care unit. A member of the research team will remove the patch from the patient and properly dispose the patch upon arrival to the post anesthesia care unit.
1501268|NCT02960113|Device|acupressure point P6|Group II (n=80): Will receive acupressure point P6 stimulation. This is a stimulation of the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device will be put on the patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device will be removed from the patient in the operating room, before the patient is transported to the recovery room. Patients will receive continuous stimulation at a level that is comfortable for her prior to administration of the standardized regional anesthesia.
1501269|NCT02960100|Other|Informational Intervention|Receive standard HPV vaccine information (HPV VIS)
1501270|NCT02960100|Other|Media Intervention|Receive targeted HPV vaccine narrative-style video
1501271|NCT02960100|Other|Survey Administration|Ancillary studies
1501272|NCT02960087|Radiation|Low dose rate brachytherapy|-125 to a total dose of 144 Gy
1501273|NCT02960087|Radiation|High dose rate brachytherapy|19 Gy in 1 fraction plus intraprostatic boost to GTV
1501274|NCT02960074|Biological|Fecal Microbiota Capsule|We will treat patients with oral encapsulated frozen FMT over 2 days.
1501275|NCT02960061|Drug|Neoadjuvant chemotherapy|Eligible patients receive 4 cycles of mDOF(docetaxel 50 mg/ m2 day 1 + oxaliplatin 85 mg/ m2 day 2 + fluorouracil 400 mg/ m2 bolus iv followed by 600 mg/ m2 22 hours chronic infusion, day 2/3 + leucovorin 200 mg/ m2, day2/3; repeated every 14 days ).
1501276|NCT02960061|Procedure|D2 radical resection|Laparotomy or laparoscopic surgery are chosen according to the preference of the surgeon. Either cases, a throughout peritoneal cavity exploration is required to comfirmed the tumor resectability and peritoneal metastasis. A curative D2 resection is performed if achievable.
1501277|NCT02960061|Drug|Hyperthermic intraperitoneal perfusion chemotherapy|Two cycle of hyperthermic intraperitoneal perfusion chemotherapy is administered to patients who have received neoadjuvant chemotherapy and D2 resection, dosage and the relative parameter setting is described above.
1501278|NCT02960061|Drug|Adjuvant chemotherapy|Adjuvant chemotherapy using SOX or XELOX regimen will be administered as routine within 4-6 weeks.
1501279|NCT02960048|Device|Stabilizing splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .
Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient should be instructed to close in Centric relation . Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .
Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe. All areas, except labial to the mandibular canines, are flattened to the contact marks. This area will create the eccentric guidance."
1501280|NCT02960048|Device|Anterior repositioning splint|"A 2-mm-thick, hard, clear sheet of resin will be adapted to the maxillary arch .
Small amount of self-curing acrylic will be added to the anterior portion of the appliance as a stop for the lower incisor. The area of this stop is approximately 4 to 6 mm. The patient is instructed to protrude the mandible slightly and to open and close the mouth In this position.
Self-curing acrylic will be added to the occluding surface of the appliance. All occluding areas, except the contact on the anterior stop .
Excess acrylic surrounding the centric contacts is removed with a hard rubber wheel on a lathe."
1501281|NCT02960035|Drug|etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
1501282|NCT02960035|Drug|etanercept (half dose)|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
1501283|NCT02960035|Drug|placebo|
2002173|NCT02470078|Device|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for pharyngeal electrical stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual patients. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
2002174|NCT02467738|Radiation|Brachytherapy|Undergo brachytherapy with Cesium-131
2002175|NCT02467738|Drug|Cesium-131|Undergo brachytherapy with Cesium-131
1501287|NCT02960009|Device|HD-tDCS|Different stimulation protocols will be applied to the primary motor cortex of stroke patients
1501288|NCT02959996|Drug|Liposomal bupivacaine|liposomal bupivacaine injection in the Pfannenstiel incision
1501289|NCT02959996|Drug|Placebo|placebo injection in the Pfannenstiel incision
1501290|NCT02959983|Drug|Eluxadoline|Eluxadoline 100 mg oral tablets BID with food.
1501291|NCT02959983|Drug|Placebo|Placebo matching eluxadoline oral tablets BID with food.
1501292|NCT02959970|Drug|dapsone gel|Dapsone (ACZONE) 7.5% gel topically once daily.
1501293|NCT02959957|Drug|Temocillin|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial temocillin administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
1501294|NCT02959957|Drug|Cefotaxime|Total antibiotic treatment 7-10 days, of which at least 72 hours (9 doses) initial cefotaxime administration. In case of bacteraemia at baseline the total antibiotic treatment can be extended up to 14 days.
1501295|NCT02959944|Drug|ibrutinib|Ibrutinib capsules administered orally daily
1501296|NCT02959944|Drug|Placebo|Placebo capsules administered orally daily
1501297|NCT02959944|Drug|Prednisone|Prednisone administered daily
1501761|NCT02956499|Drug|APX001 single dose 2|
1501298|NCT02959931|Other|High Potassium Meal|Breakfast meal that provides ~2400 mg of dietary potassium. Meals are isocaloric.
1501299|NCT02959931|Other|Low Potassium Meal|Breakfast meal that provides ~540 mg of potassium. Meals are isocaloric.
1501300|NCT02959918|Drug|SEL-212|SEL-212
1501301|NCT02959918|Drug|SEL-037|SEL-037, biologic
1501302|NCT02959918|Drug|SVP-rapamycin (SEL-110)|
1501303|NCT02959905|Biological|TSA-CTL(Tumor Specific Antigen Induced Cytotoxic Lymphocyte)|On day 0,cells will be infused intravenously on the Patient Care Unit over 20-30 minutes.
1501304|NCT02959905|Drug|Cyclophosphamide|Cyclophosphamide 30 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
1501305|NCT02959905|Drug|Cyclophosphamide|Cyclophosphamide 30 mg/kg/day X 1 days IV in 250 ml D5W over 1 hr.
1501306|NCT02959905|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 3 days.
1501307|NCT02959892|Drug|Amphetamine|Amphetamine tablets
1501308|NCT02959892|Drug|TAK -041|TAK-041 oral suspension
1501309|NCT02959879|Drug|FOLFOX neoadjuvant chemotherapy|4 cycles of FOLFOX neoadjuvant chemotherapy are administrated to patient
1501310|NCT02959879|Drug|FOLFIRINOX neoadjuvant chemotherapy|4 cycles of FOLFIRINOX neoadjuvant chemotherapy are administrated to patient
1501311|NCT02959879|Procedure|curative surgery for resectable pancreatic duct adenocarcinoma|curative surgery for resectable pancreatic duct adenocarcinoma
1501312|NCT02959879|Drug|Standard adjuvant chemotherapy|12 cycles of standard adjuvant chemotherapy are administrated
1501313|NCT02959879|Drug|adjuvant chemotherapy|8 cycles of standard adjuvant chemotherapy are administrated
1501314|NCT02959866|Other|online income tool|An online tool that uses information about the patient to develop a tailored list of financial benefits that they are eligible to apply for.
1501315|NCT02959853|Drug|Anastrazole|
1501316|NCT02959853|Behavioral|weight loss|
1501317|NCT02959840|Device|Acupressure Point P6 stimulator|This device stimulates the chi channel at the master of the heart (MH8 position) at the small depression of the volar surface of the distal right forearm just above the crest of the wrist. The device is placed on patients in the operating room prior to administration of the regional anesthesia and will be removed after the cesarean section is complete. The device is removed from the patient in the operating room, before the patient is transported to the recovery room. Patients receive continuous stimulation at a level that is comfortable for the patient prior to administration of the standardized regional anesthesia.
1501318|NCT02959840|Drug|Metoclopramide|10 mg Reglan IV immediately prior to administration of the standardized regional anesthesia.
1501319|NCT02959840|Drug|Ondansetron|8 mg of Zofran IV immediately prior to administration of the standardized regional anesthesia.
1501321|NCT02959814|Other|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
1501322|NCT02959801|Procedure|Percutaneous mechanical thrombectomy|Aspirex catheters(Straub Medical AG, Wangs, Switzerland)
1501323|NCT02959788|Other|Heart rate variability|All patients have a 10-minute recording analyzed for indices of heart rate variability.
1501324|NCT02959775|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
1501325|NCT02959775|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
1501326|NCT02959762|Dietary Supplement|Placebo-Control|two placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
1501327|NCT02959762|Dietary Supplement|Low-Dose Vitamin K2 (menaquinone-7; 45-mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
1501328|NCT02959762|Dietary Supplement|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|two 45-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
1501329|NCT02959749|Drug|Osimertinib|80 mg oral daily; until disease progression, intolerable toxicities, or patient death.
1501330|NCT02959749|Drug|docetaxel, bevacizumab|Docetaxel and bevacizumab are common used in third line therapy in non-small cell lung cancer if not used before. Docetaxel (75 mg/m2) intravenous infusion on day 1 and bevacizumab (7.5 mg/kg) on day 1 every 21days a cycle, until disease progression, intolerable toxicities, or patient death.
1501331|NCT02959736|Behavioral|MATADOC ad CRS-R|Behavioural assessments for Disorders of Consciousness
1501332|NCT02959710|Drug|AC-1204 mixed in water|40 g AC-1204 (shaken in 240 mL of water) at Hour 0 on Day 1
1501333|NCT02959710|Drug|AC-1202 mixed in water|60 g AC-1202 (shaken in 240 mL of water) at Hour 0 on Day 1
1501334|NCT02959710|Drug|AC-1202 mixed in Ensure®|60 g AC-1202 (shaken in approximately 8 oz [237 mL of Ensure® Original] at Hour 0 on Day 1)
1501335|NCT02959697|Procedure|Subconjunctival Injection|
2002176|NCT02467738|Procedure|Conventional surgery|Undergo surgical resection
1501337|NCT02959658|Drug|Dimethyl Fumarate|
1501338|NCT02959658|Drug|Placebo Oral Capsule|Manufactured to mimic Dimethyl Fumarate capsules
1501339|NCT02959632|Behavioral|Animal Assisted Therapy|Animal Assisted Therapy is the program where a pet, usually dog will visit and interact with the patients.
1501340|NCT02959619|Drug|Ensartinib|Oral ensartinib was given daily at escalating doses in a 28-day cycle
1501341|NCT02959606|Drug|Sarpogrelate SR 300mg|
1501342|NCT02959606|Drug|Clopidogrel|
1501343|NCT02959593|Device|VISIOR video goggles|View commercially available content through the VISIOR video goggles continuously for thirty minutes.
1501344|NCT02959580|Drug|Hydrocortisone Butyrate|topical use
1501345|NCT02959580|Procedure|extended excision|Lesion extended excision with or without a random breast dermo-glandular flap (BDGF).
1501346|NCT02959567|Device|Aqueduct 100 dilation|
1501347|NCT02959554|Drug|Nivolumab|240 mg i.v. on D1 of every cycle (Q2W) for 16 weeks. After 16 weeks 480 mg i.v. on D1 of every cycle (Q4W) until disease progress, intolerable toxicity, withdrawal of consent or end of study.
1501348|NCT02959554|Drug|Sunitinib|According to Standard of Care (SOC). Recommended dose is 50 mg p.o. once daily for 4 consecutive weeks followed by a 2-week rest period (schedule 4/2) to comprise a complete cycle of 6 weeks (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
2002177|NCT02467621|Drug|Pantoprazole|40 mg x 1 daily intravenously from ICU admission to ICU discharge
1501349|NCT02959554|Drug|Pazopanib|According to Standard of Care (SOC). Recommended dose is 800 mg p.o. daily continuously (until disease progress, intolerable toxicity, withdrawal of consent or end of study).
1501350|NCT02959541|Drug|Leucovorin|
2002178|NCT02467621|Other|Saline (0.9%)|10 ml of isotonic saline x 1 daily intravenously from ICU admission to ICU discharge
1501353|NCT02959515|Procedure|Capnothorax|Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.
1501354|NCT02959515|Procedure|Capnothorax and CPAP|"Insufflation of CO2 at a preset pressure of 10 cmH2O in the right pleural cavity.
Continuous positive airway pressure of 10 cmH2O delivered by CF 800 Continuous flow CPAP, Drager."
1501355|NCT02959502|Other|Receive tDCS+CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'Patient' will receive active tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory. Performance feedback is given to reinforce progress and the exercises are designed to be enjoyable to complete, with titrated difficulty levels over time.
1501356|NCT02959502|Other|Facilitate tDCS + CR|Over the course of 8 weeks, for 5 days a week, participants designated a 'facilitator' will be trained to deliver tDCS &CR at-home. tDCS will be administered during the 2 hour CR sessions for 30 min/day. The tDCS montage will be bifrontal91 with 1 large anode placed over Fz and the cathode over Iz. The direct current will be 2 mA (current density = 0.57 A/m2). CR sessions will utilize didactic and computerized drill-based exercises which focus on practice and repetition of neurocognitive ability areas that are affected in depression such as attention, processing speed, executive function, verbal memory, and working memory.
1501357|NCT02959489|Behavioral|Alzheimer's Disease Risk Disclosure|Subjects will learn a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
1501358|NCT02959489|Behavioral|Amyloid Brain Imaging and Alzheimer's Disease Risk Disclosure|"Subjects will learn their own elevated or not elevated amyloid results and a numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type."
1501359|NCT02959476|Drug|Ropivacaine|Anesthetic
1501360|NCT02959476|Drug|Placebos|Inactive comparator
1501364|NCT02959450|Dietary Supplement|Modified consistency and volume diet|Modified consistency diet, with a certain viscosity and controlled volume, which was designed from recommendations based on the review of different studies. A Chef and a Nutritionist developed and determined the viscosity of the menus with a Brookfield Viscometer (model RV). All the menus were prepared and evaluated at the Food Technology Department of this Institute to achieve the viscosity required with a food thickener. The nectar consistency had a viscosity of 51 to 350 centiPoises (cP) and the pudding consistency menus with a higher viscosity at 1,750 cP. The patient and/or their caregivers in the intervention group must attend to a training workshop to explain how to use the food thickener.
1501365|NCT02959437|Drug|Azacitidine|Five doses of azacitidine will be administered by subcutaneous injection or intravenously (IV) over Days 1 to 7 in Cycles 1 and 2.
1501366|NCT02959437|Drug|Pembrolizumab|Pembrolizumab will be administered in a 30-minute IV infusion every 3 weeks on Day 1 of each 21-day cycle.
1501367|NCT02959437|Drug|Epacadostat|Epacadostat tablets will be administered orally twice daily.
1501368|NCT02959424|Other|Spanish Northwestern Esophageal Quality of Life questionnaire|
1501369|NCT02959411|Drug|Tolvaptan|Tolvaptan is a selective vasopressin receptor antagonist that inhibits activation of the V2 receptor and synthesis and insertion of the aquaporin2 channel into the apical membrane of the renal collecting duct. Tolvaptan inhibits the reabsorption of free water, inducing free water diuresis and increasing serum sodium levels without adversely influencing electrolyte levels or stimulating the sympathetic nervous system or renin-angiotensin system.
1501370|NCT02959411|Drug|Standard of care diuretic therapy|Usual standard of care diuretic therapy for patients hospitalized with acute decompensated heart failure
1501371|NCT02959398|Device|Standard mammography|
1501372|NCT02959398|Device|Standard mammography and tomosynthesis|
1501373|NCT02959385|Radiation|Definitive Radiochemotherapy|Radiotherapy,IMRT, 60Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day
1501374|NCT02959385|Procedure|Neoadjuvant Radiochemotherapy|Concurrent Radiochemotherapy: Radiotherapy,IMRT, 40Gy; Chemotherapy, Docetaxel （25mg/m2）+Cisplatin (25mg/m2) 1st/8th/15th/22nd day; Receive radical surgery 4 to 6 weeks later.
1501375|NCT02959372|Other|lung ultrasound|
1501376|NCT02959372|Other|placebo|lung ultrasound. The attending physician will not know the result
1501377|NCT02959359|Drug|Ledipasvir 90mg/Sofosbuvir 400 mg|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
1501378|NCT02959359|Drug|Ribavirin|A 12 week Harvoni (Ledipasvir 90mg/Sofosbuvir 400 mg ) plus ribavirin will be provided after confirmation of curative treatment.
1501379|NCT02959346|Procedure|Sham Acupuncture|"Procedure:
Sham Acupuncture(ipisilateral side, 0.3cun, No needle sensation (de qi) was elicited) Sham acupuncture will be applied by inserting acupuncture needle into acupoints(1cm away from the true acupoint):upper limb: Waiguan TE5; lower limb: Zusanli ST36.
All procedures were carried out to a depth of 0.5 cm with disposable needles measuring 0.16 mm in diameter (40-gauge) and 12.7 mm in length (Yu Kuang, Taipei, Taiwan).
Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
1501762|NCT02956499|Drug|APX001 single dose 3|
2002186|NCT02466035|Dietary Supplement|Extensively hydrolyzed casein formula plus Lactobacillus rhamnosus GG|Extensively hydrolyzed casein formula containing the probiotic Lactobacillus rhamnosus GG
1501380|NCT02959346|Procedure|Acupuncture|"Procedure:
Acupuncture(ipisilateral side, the needling depth decided by whether patients feel De qi, neutral supplementation and draining) Acupuncture will be applied by inserting acupuncture needle into acupoints: Zhigou TE6, Shousanli LI10, Hegu LI4, Neiguan PC6, Houxi SI3; lower limb: Biguan ST31, Fushe SP13, Zulinqi GB41; axillary area(Remove Needles right away after De qi): Yuanye GB22, Jiquan HT1; local area(Remove Needles right away after De qi): ashi point close to the pain area.
The other needles will be left for 20 minutes and then removed. All procedures were carried out with disposable needles measuring 0.25 mm in diameter (32-gauge) and 44 mm in length (Yu Kuang, Taipei, Taiwan).
Acupuncture treatment will consist of one session per day and consecutive three days after thoracoscopic surgery."
1501381|NCT02959333|Biological|hAEC|hAEC: human amniotic epithelial cells
1501382|NCT02959320|Procedure|Hip Hemiarthroplasty|This single-institution, prospective, randomized clinical trial will be performed on consecutive elderly patients admitted for surgical treatment of displaced femoral neck fractures with hemiarthroplasty (HA).
1501383|NCT02959307|Device|Transcranial Light Therapy|Transcranial light therapy penetrates the skin and brain using light energy; this makes transcranial light therapy noninvasive. Transcranial light therapy may activate under-stimulated brain regions.
1501384|NCT02959307|Device|Sham Transcranial Light Therapy|The same device used for the actual transcranial light therapy is used as the sham device; The device, when set to sham, will mimic the actual transcranial light therapy; however, when set to sham the device does not emit skin and cranium penetrating light emitting diode light energy.
1501385|NCT02959294|Procedure|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
1501386|NCT02959294|Device|Centricyte 1000|Use of Centricyte 1000 Closed System Digestion Autologous AD-tSVF to create AD-cSVF
1501387|NCT02959294|Procedure|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
1501388|NCT02959281|Other|Providing caring physicians with hemodynamic variables|NICAS electrodes are applied to the skin of the forearm bilaterally (similar to EKG electrodes). Conductors, attached to the electrodes, connect the patient with the measuring system.
1501389|NCT02959268|Device|Al-Sense|Liner for diagnosis of amniotic fluid leakage verified by standard clinical diagnostic tests
1501390|NCT02959255|Drug|Esomeprazole|
1501391|NCT02959229|Drug|Lactoferrin|
1501392|NCT02959229|Drug|Placebo (for Lactoferrin)|placebo in form of distilled water
1501393|NCT02959216|Other|Aerobic Exercise|Participants will be given a prescription to exercise at 80% of their threshold heart rate for symptom exacerbation. Heart rate threshold will be monitored weekly in order to increase exercise level accordingly.
1501394|NCT02959216|Other|Stretching Exercise|Participants will be given a prescription to complete a standardized stretching protocol.
1501395|NCT02959190|Drug|Galcanezumab|Administered SC
1501396|NCT02959177|Drug|Galcanezumab|Administered SC
1501397|NCT02959177|Drug|Placebo|Administered SC
1501398|NCT02959164|Drug|Decitabine|"Dose escalation starting at 0.1mg/kg, subcutaneously administered on twice weekly schedule for three weeks of a 28 day cycle.
Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;
*Starting Dose Level"
1501399|NCT02959164|Drug|Gemcitabine|"Fixed infusion rate of 900 mg/m2, IV over 90 min, on Days, 1, 8 and 15 of a 28-day cycle.
Dose Escalation Schedule Dose Level/Dose of Decitabine per cycle Level -2: 0.1 mg/kg SQ twice weekly for 1 week; Level -1: 0.1 mg/kg SQ twice weekly for 2 weeks; Level 1*: 0.1 mg/kg SQ twice weekly for 3 weeks; Level 2: 0.2 mg/kg SQ twice weekly for 3 weeks;
*Starting Dose Level"
1501400|NCT02959151|Drug|CAR-T cell|CAR-T cells are generated by T cells from the patients or a suitable donor transfected by CAR-lentivirus vectors. There are three options for CAR-targets: GPC3 for hepatocellular carcinoma;mesothelin for pancreatic cancer metastatic; CEA for colorectal cancer metastatic.
1501407|NCT02959112|Drug|Epinephrine|
1501408|NCT02959112|Other|Sterile water|
1501409|NCT02959112|Drug|Indomethacin Rectal Suppository|
1501410|NCT02959073|Other|Symptom Recording|Subjects muss record their allergic symptoms after contact with their cats
1501411|NCT02959060|Drug|BMS-986177|Single dose of BMS-986177 and multiple doses of Rifampin
1501412|NCT02959060|Drug|Rifampin|Single dose of BMS-986177 and multiple doses of Rifampin
1501413|NCT02959047|Drug|Alirocumab|150mg SQ every 2 weeks
1501414|NCT02959047|Drug|Matching placebo|SQ every 2 weeks
1501415|NCT02959021|Behavioral|weight loss intervention - self directed|
1501416|NCT02959021|Behavioral|weight loss intervention - peer coach|
1501417|NCT02959008|Device|measure TOI and BP|Both groups measure TOI and BP.
1501418|NCT02958995|Other|No Intervention|
1501419|NCT02958982|Drug|RP3128|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
1501420|NCT02958982|Drug|Placebo|Participants will receive single oral dose of RP3128 in SAD, multiple dose in MAD AND POC
1501421|NCT02958969|Drug|Apixaban|apixaban 2.5 mg orally twice daily for primary prevention of VTE for a duration of 6 months
1501422|NCT02958969|Drug|Placebo Oral Tablet|placebo
1501423|NCT02958956|Drug|Pioglitazone|Participants with diabetes who were members of the KPNC registry, and had received at least 2 prescriptions for pioglitazone within a 6-month period were followed up to 15.5 years (1997-2012) in this observational study 1.
1501424|NCT02958943|Behavioral|On-screen electronic alert|On-screen notification regarding the patient's increased risk of stroke in AF and the lack of an active order for anticoagulation. Providers may then 1) access a template of FDA-approved anticoagulation regimens for stroke prevention in AF, 2) follow a link to evidence based clinical practice guidelines, or 3) proceed onto order entry after providing an explanation for why anticoagulation was not prescribed.
1501425|NCT02958930|Device|MemorEM 1000|The MemorEM 1000 device is self-contained and has been designed for in-home daily electromagnetic treatment in the radiofrequency range, allowing for complete mobility and comfort in performing daily activities during treatment. The device has a custom control panel that is powered by a rechargeable battery. This control panel/battery box is worn on the upper arm and wired to specialized antennas in the head cap worn by the subject. The device provides global RF treatment to the entire forebrain, including deep brain areas. For each of the 60 days of in-home treatment, two one-hour treatment will be given (early morning and late afternoon). Each treatment will be administered by the patient's caregiver, who will position the device on the patient's head and monitor treatment.
1501426|NCT02958917|Drug|Pirfenidone|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 40 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
1501427|NCT02958917|Other|Placebo controlled|This is a single-center, randomized, double-blind, placebo-controlled, efficacy and safety study of pirfenidone in subjects with FHP. Approximately 40 subjects will be randomized in a 2:1 ratio to receive pirfenidone 2403 mg/d or placebo for 52 weeks.
1501428|NCT02958904|Other|using questionnaires|using questionnaires International Index Erectile Function and Beck Depression Inventory.
1501429|NCT02958891|Other|Data collection|Collection epidemiological dental measures
1501430|NCT02958878|Drug|Tamsulosin|
1501431|NCT02958878|Drug|Placebo Oral Capsule|
1501436|NCT02958852|Drug|Letrozole|
1501437|NCT02958852|Drug|Letrozole and atorvastatin|
1501438|NCT02958852|Drug|Fulvestrant|Fulvestrant will be used as second line treatment upon progression on first line treatment with letrozole +/- atorvastatin.
1501439|NCT02958839|Procedure|Catheter ablation|Patients with persistent or paroxysmal atrial fibrillation will go through catheter ablation
1501440|NCT02958826|Other|Questionnaire|Anonymous questionnaire asking patients about their experiences with surgical lights, surgical smoke, and surgical sounds during their outpatient procedure.
1501441|NCT02958813|Behavioral|IMARA|Morning and afternoon sessions begin with an icebreaker and/or poem to enhance ethnic and gender pride. IMARA's goals and motto are presented to emphasize strong mother-daughter relationships, foster sisterhood, build group cohesion, and increase motivation. Ground rules are reviewed, and each woman and girl signs the IMARA pact to confirm her commitment to the program. At the end of day 1, mothers and daughters receive homework for the week. Woven throughout IMARA is the impact of alcohol and drug use on risk behavior, including condom use while high.
1501442|NCT02958813|Behavioral|FUEL|FUEL™ Health Promotion Control Group: mothers and daughters randomly assigned to FUEL™ will participate in separate 2-day workshops identical in length and intensity to IMARA. FUEL™ promotes healthy activities by encouraging good nutrition, exercise, and informed consumer behavior. Investigators will also insert the following sessions from Balance into FUEL: alcohol use, drug/marijuana use, nutrition, exercise, and violence to increase program length.
1501443|NCT02958800|Other|Intervention|"The intervention will be 12-weeks in duration consisting of four blocks resulting from a 1:1 randomization of two different three-week treatment courses of a patient's existing antipsychotic medication. For example, the intervention ABAB means that a participant would undergo three weeks of treatment A, followed by three weeks of treatment B, followed by three weeks of treatment A, and lastly three weeks of treatment B.
Treatment A block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose.
Treatment B block is defined as a mutually agreed upon dose of a participant's antipsychotic medication that is different (i.e. lower) than their enrolment dose and the dose in Treatment A."
1501444|NCT02958787|Radiation|Radiation Therapy|Radiation Therapy Using MRI Based Treatment Planning
1501445|NCT02958774|Radiation|Standard Fractionated Radiation Therapy|Chest/Breast 5000 centigray (cGy)/25 fractions/200 cGy daily Regional nodes 4500-5000 cGy/25 fractions/180-200 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
1501446|NCT02958774|Radiation|Hypofractionated Radiation Therapy|Chest/Breast 4005 centigray (cGy)/15 fractions/267 cGy daily Regional nodes 4005 cGy/15 fractions/267 cGy daily 1000 cGy boost to lumpectomy/scar/undissected nodes 200 cGy daily
1501449|NCT02958748|Other|taking blood sample|
1501450|NCT02958735|Other|Exercise Challenge|Participants randomized to an exercise condition will perform treadmill exercise for 30 minutes. Participants will self-select a comfortable walking speed. The treadmill grade will be adjusted to elicit and maintain the target heart rate.
1501451|NCT02958722|Procedure|diagnostic hysteroscopy|Endoscopic procedure to visualize uterine cavity
1501452|NCT02958722|Drug|physiological solution|
1501453|NCT02958722|Drug|carbon dioxide|
1501454|NCT02958709|Drug|High-dose: RIF, INH, PZA, EMB|high-dose rifampicin plus standard dose H,Z,E, given for 8 weeks in treatment Arms 1 and 2
1501455|NCT02958709|Drug|High dose: RIF, INH, PZA, LEVO|high-dose rifampicin plus standard dose H,Z, with levofloxacin substituted for ethambutol for 8 weeks in treatment Arm 2
1501456|NCT02958709|Drug|Standard of care: RIF, INH, PZA, EMB|standard doses of R,H,Z,E given for 8 weeks in treatment Arm 3, control arm.
1501457|NCT02958696|Drug|HTL0018318|Two single doses of active drug (low, mid or high dose either as aqueous solution or capsule) separated by a washout of at least 12 days.
1501754|NCT02956564|Procedure|intrauterine intervention|choose different surgeries according to different causes
1501458|NCT02958683|Other|Chest wall motion analysis|Assessment of chest wall motion using novel technologies including: optoelectronic plethysmography (OEP), structured light plethysmography (SLP), Microsoft Kinnect
1501459|NCT02958670|Other|18F-AV-1451 (Tau-PET tracer)|Single i.v. administration of 18F-AV-1451 (Tau-PET tracer) and consecutive Positron-Emission-Tomography-Scan
1501460|NCT02958657|Other|Exercise Training|Supervised exercise training program that includes two workouts per week for three months at a rehabilitation unit.
1501461|NCT02958644|Dietary Supplement|Synbiotics|12g / day synbiotics (fructo-oligosaccharide and probiotics) supplemented orally for 90 days
1501462|NCT02958644|Dietary Supplement|Placebo|12g / day placebo (polydextrose) supplemented orally for 90 days
1501463|NCT02958631|Drug|Fimasartan|
1501464|NCT02958631|Drug|Losartan|
1501465|NCT02958618|Procedure|"30 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 30 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
1501466|NCT02958618|Procedure|"60 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 60 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
1501467|NCT02958618|Procedure|"180 group"|A limited sphincterotomy (EST) was performed prior to the EPBD.The length of the sphincterotomy incision was limited to a third of the size of the papilla. A CRE balloon (diameter 10, 12, 15, 18 ) was chosen according to the diameter of bile duct. The balloon was then gradually filled with diluted contrast medium under endoscopic and fluoroscopic guidance to observe the disappearance of the waist. Once the waist disappeared, the balloon remained inflated for 180 seconds. The stones were then retrieved by a basket or retrieval balloon. An ENBD catheter (.) was routinely placed into the CBD after stone removal.
1501468|NCT02958605|Device|Smartphone apps|If already own a smartphone application dedicated to calculate medication dosage for children, the participant will be allowed to use his/her own application. Otherwise, the resident will be offered to chose among a list of applications paid by the research team (PediSafe, PediStat, Palm Pedi, Safedose, EZdrip peds). He/she will be instructed to practice with a few time at home before doing the simulations.
1501469|NCT02958605|Device|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
1501470|NCT02958592|Other|two-dimensional shear-wave elastography (SWE)|performa two-dimensional shear-wave elastography (SWE) for staging hepatic fibrosis in the background liver parenchyma in patients with liver tumors before hepatic resection
1501471|NCT02958579|Other|No intervention will be done. Participants are on standard care and the treatments will be recorded because of observational nature of this study.|
1501472|NCT02958566|Drug|Acetaminophen|
1501473|NCT02958566|Drug|Gabapentin|
1501474|NCT02958566|Drug|Orphenadrine|
1501475|NCT02958566|Drug|Lidocaine|
1501476|NCT02958566|Drug|Marcaine|
1501477|NCT02958566|Drug|Ketamine|
1501478|NCT02958566|Drug|Methadone|
1501479|NCT02958566|Drug|Tramadol|
1501480|NCT02958566|Drug|Ketorolac|
1501481|NCT02958566|Drug|Morphine Sulfate|
1501482|NCT02958566|Drug|Fentanyl|
1501483|NCT02958566|Drug|Dilaudid|
1501484|NCT02958566|Drug|Hydrocodone-Acetaminophen Tab 5-325 MG|
1501485|NCT02958566|Drug|Morphine Sulfate|PCA
1501486|NCT02958566|Drug|Fentanyl|PCA
1501487|NCT02958566|Drug|Dilaudid|PCA
1501488|NCT02958566|Drug|HYDROCODONE/ACETAMINOPHEN 5 Mg-325 Mg ORAL TABLET|Breakthrough
1501489|NCT02958553|Device|emPOWER Ankle|The device is 510k cleared and is intended to replace a missing foot and ankle. The emPOWER Ankle is to be used exclusively for fittings of lower-extremity amputations as prescribed by a healthcare professional.
1501490|NCT02958540|Biological|SynGEM|Prime / boost vaccination in each group
1501491|NCT02958540|Other|placebo|prime /boost vaccination
1501493|NCT02958514|Device|intense pulsed light|Intense pulse light (IPL) has been used in dermatology practices for several years as a treatment for rosacea and acne.IPL uses Xenon flashlamp to emit wavelengths of light from 400 to 1200nm. When placed on the light, a filter restricts the wavelength to the visible light range of *500nm.In 2007-2008, an IPL treatment technology-the Diamond Q4 by DermaMed Solutions-was specifically configured to our specifications with the goal of stimulating secretion of normal meibum via skin treatment effects on the meibomian glands. It was discovered that dry eye patients are better positioned for gland expression, as IPL seems to liquefy the abnormal viscous meibum and dilate the glands.
1501494|NCT02958514|Drug|Tobramycin and Dexamethasone Ophthalmic Ointment|
1501495|NCT02958501|Drug|Colecalciferol|Drug
1501496|NCT02958488|Device|High Flow Nasal Cannula|
1501497|NCT02958475|Behavioral|Social Support Group (Facebook)|The breastfeeding social support group on Facebook will be moderated to facilitate posting of shared experiences. Short videos, photographs, and written blurbs on related topics are posted on the Facebook page to reinforce the messaging and content of the texts.
1501535|NCT02958163|Procedure|Trans-arterial Chemo-Embolization|Trans-Arterial Chemo-Embolization will be performed with Doxorubicin-Eluting-Beads (DEB-TACE). It will be performed in each arm of treatment.
1501536|NCT02958163|Drug|Doxorubicin|Drug-eluting Bead for Trans Arterial Chemo-Embolization will be loaded with Doxorubicin.
1501498|NCT02958475|Behavioral|Breastfeeding messages|The Mother's Milk Messaging app gives participants access to text messages via push notification on the app, as well as access to videos and written material to facilitate knowledge acquisition and skills building. The text messages are targeted at specific theoretical constructs such as outcome expectations/attitudes, barrier self-efficacy, reinforcing a message using peripheral (expert) opinion, eliciting a sense of social currency or providing a cue-to-action.
1501499|NCT02958475|Behavioral|Injury Prevention Messages|The Mother's Milk Messaging app will provide participants in the control group with genetic injury prevention message.
1501500|NCT02958462|Other|follow up|
1501501|NCT02958449|Device|Test - Standard Closure with TissuGlu Surgical Adhesive|Patients randomized into the Test group, TissuGlu® will be applied to the chest wall after removal of the breast tissue using the custom applicator during a standard mastectomy procedure followed by normal wound closure (suturing technique) without drain placement.
1501502|NCT02958436|Drug|REGN3500|
1501503|NCT02958436|Drug|Placebo|
1501504|NCT02958423|Device|Transcranial DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of healthy volunteers
1501505|NCT02958423|Device|Transspinal DCS Healthy Volunteers|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of healthy volunteers
1501506|NCT02958423|Device|Transcranial DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the right primary motor cortex of CPP patients
1501507|NCT02958423|Device|Transspinal DCS CPP patients|The DC stimulator manufactured by NeuroConn (Germany) will be used to deliver anodal direct current stimulation over the D10 spinal process of CPP patients
1501508|NCT02958410|Biological|Anti-CD30-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD30-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
1501509|NCT02958397|Biological|Anti-CD33-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD33-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
1501510|NCT02958384|Biological|Anti-LeY-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived LeY-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
1501511|NCT02958371|Procedure|fMRI|
1501512|NCT02958371|Behavioral|fruit-flavored drink ingestion|
1501513|NCT02958358|Other|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and FDG as radiotracers; images obtained before and 3 months after treatment with ambrisentan.
1501514|NCT02958345|Biological|Zostavax|Vaccination with one dose of Zostavax per Zostavax package insert
1501515|NCT02958345|Other|Placebo|Injection of 0.65 mL of sterile normal saline
1501516|NCT02958332|Other|video game program|Participants will use the Wii console and the Wii balance board, to play different video games which imply shoulder movements. They will receive 5 individual sessions of 30 minutes.
1501517|NCT02958306|Biological|platelet rich plasma|PRP is a portion of the plasma fraction of autologous blood, having a platelet concentration above baseline values
1501518|NCT02958280|Other|App Development and Open Pilot|"Phase 1: Five participants will evaluate the various features of the Fit&Sober app prototype. After an initial period of evaluation of the app, participants will be invited back to participate in a focus group where they will engage in a discussion about the Fit&Sober app.
Phase 2: Twenty patients will be recruited to participate in a 12-week study examining the feasibility and acceptability of the Fit&Sober app."
1501519|NCT02958267|Biological|BMAC injection|60mL of bone marrow will be collected from a bone near the hip. Approximately 5-6mL of the bone marrow aspirate concentrate is then used for injection, under ultrasound guidance, into the target knee by the study physician.
1501520|NCT02958267|Biological|PRP injection|60mL of venous blood will be withdrawn from either arm. Approximately 4-5 ml of platelet-rich plasma will be introduced under ultrasound guidance to the subject's target knee by the study physician.
1501521|NCT02958267|Device|Gel-One® hyaluronate injection|Patients will receive a single injection of Gel-One® (3 ml syringe of Gel-One® - 1% solution [10 mg/mL], 30mg total hyaluronan) into the target knee. Injections will be performed by the study physician under real-time dynamic ultrasound guidance.
1501522|NCT02958241|Other|MRI|Supine and weight bearing MRI
1501523|NCT02958228|Behavioral|Positive Mental Imagery Training (PMIT)|
1501524|NCT02958228|Behavioral|Cognitive Control Training (CCT)|
1501525|NCT02958228|Other|Treatment as Usual|
1501526|NCT02958215|Drug|Phenylephrine|it will be given as a prophylaxis for prevention of hypotension after spinal anesthesia in pregnant patients undergoing cesarean section
1501527|NCT02958215|Other|Placebo|5 ml normal saline will be given before spinal anesthesia
1501528|NCT02958202|Drug|BMN 044 IV 6 mg/kg|
1501529|NCT02958202|Drug|BMN 044 IV 9 mg/kg|
1501530|NCT02958202|Drug|BMN 044 SC 6 mg/kg|
1501531|NCT02958189|Behavioral|Tweet4Wellness|A daily, behavior change theory-based intervention message is sent to a private, 25-person online Twitter-support group to prompt peer-to-peer discussion. Participants receive individual text messages to encourage group participation (e.g. 'thank you for participating' or 'please participate tomorrow'). Participants also receive weekly individual messages giving them daily step goals for the week based on their previous week's daily step average, recorded from Fitbit.
1501532|NCT02958189|Behavioral|Self-monitoring|A Fitbit is provided to the group which tracks participants' daily steps.
1501533|NCT02958176|Behavioral|HRV Biofeedback|At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap
1501534|NCT02958176|Behavioral|Autogenic Training|Autogenic training recording provided on a CD
1501537|NCT02958163|Radiation|Stereotactic Ablative Radiotherapy|"SABR schemes will be adapted according to the CP score and the vicinity of surrounding organs at risk. These are the different schemes proposed in this trial:
48Gy = 3x16Gy BED 124.8Gy ( α/β=10) 50Gy = 5x10Gy BED 100Gy ( α/β=10) 48Gy = 6x8Gy BED 86.4Gy ( α/β=10) 40Gy = 5x8Gy BED 72Gy ( α/β=10)
For patients with Child-Pugh (CP) A cirrhosis : the choice of the scheme will be left to each physician. The highest BED should be favored if dose constraints to the organs at risk are respected.
For patients with CP B cirrhosis : only the latter scheme will be allowed: 40Gy = 5x8Gy."
1501538|NCT02958150|Drug|Dexmedetomidine|
1501539|NCT02958150|Procedure|Standard Clinical Practice|
1501540|NCT02958137|Procedure|Arthroscopic Resection Arthroplasty|Surgical removal of the arthritic joint(s) using a minimally invasive technique.
1501541|NCT02958111|Drug|Capecitabine|Patients will receive capecitabine (650 mg/m2 bid, p.o.，d1-21，q3wks; continued until disease progression, unacceptable toxicity, or over 1 year).
2002210|NCT02462356|Procedure|Uniportal VATS|Uniportal VATS lobectomy and lymph node dissection will be performed in this group
1501544|NCT02958072|Other|LeucoPatch|LeucoPatch is an fully autologous growth factor-containing dressing
1501545|NCT02958059|Biological|Pacetin® (cefoxitin)|1~2g of Cefoxitin (2nd generation cephalosporin) is administered to patients 30 minutes Before ERCP procedure. Cefoxitin is mixed with 10ml of normal saline. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
1501546|NCT02958059|Biological|Placebo|10ml of normal saline is injected to patients as placebo. Patients and caregivers can not distinguish antibiotics and placebo by naked eye.
1501547|NCT02958046|Drug|Lansoprazole/Domperidone|DUOLANS 30/30 mg SR tablet per oral, one tablet daily
1501548|NCT02958033|Radiation|Whole Breast irradiation Plus simultaneous tumor bed Boost|hypo-fractionated irradiation for experimental group and normal fractionated irradiation for comprator group
1501549|NCT02958007|Behavioral|Peer Education on Exercise for Recovery|A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity
1501550|NCT02958007|Behavioral|Enhanced supervised fitness training|A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
1501551|NCT02957994|Drug|Tenofovir alafenamide fumarate|Patients on TDF will be switched to TAF
1501552|NCT02957981|Behavioral|Web-based Counseling|The web-based genetic counseling and education intervention will include standard information typically provided in individual genetic counseling. the intervention will be individually tailored based upon key clinical and demographic characteristics of the participant.
1501553|NCT02957981|Behavioral|Standard Care|Standard care includes access to resource list for men from hereditary cancer families plus access to standard clinical genetic counseling
2002211|NCT02462356|Procedure|Conventional VATS|Conventional VATS lobectomy and lymph node dissection will be performed in this group
2002212|NCT02461550|Device|Irreversible Electroporation Ablation|
2002213|NCT02457598|Drug|Tirabrutinib|Capsules or tablets administered orally
2002214|NCT02457598|Drug|Idelalisib|Tablets administered orally twice daily
2002215|NCT02457598|Drug|Entospletinib|Tablets administered orally
1501559|NCT02957942|Device|1Hz repetitive transcranial magnetic stimulation (rTMS)|1 session of low-frequency rTMS (1Hz, 1200 pulses, 20 minutes)
1501560|NCT02957929|Drug|APX001 single IV dose|
1501561|NCT02957929|Drug|APX001 single oral dose 1|
1501562|NCT02957929|Drug|APX001 single oral dose 2|
1501563|NCT02957929|Drug|APX001 single oral dose 3|
1501564|NCT02957929|Drug|APX001 single oral dose fasted|
1501565|NCT02957929|Drug|APX001 single oral dose fed|
1501566|NCT02957929|Drug|APX001 multiple oral doses 1|
1501567|NCT02957929|Drug|APX001 multiple oral doses 2|
1501568|NCT02957929|Drug|APX001 multiple oral doses 3|
1501569|NCT02957929|Drug|Cytochrome P450 substrates|
1501570|NCT02957929|Drug|Matching placebo control|
1501571|NCT02957903|Drug|Ropivacaine|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
1501572|NCT02957903|Drug|Isotonic Saline|All 20 study participants will receive both treatment A and B in form of a nerve block injection around the lateral femoral cutaneous nerve. Treatment A and B will be randomized to be given in either right or left lower extremity. If the participant is randomized to receive treatment A in the right lower extremity, treatment B will be given in the left lower extremity, and vice versa. Each participant will thus constitute as their own control.
1501573|NCT02957890|Biological|Inactivated influenza vaccine (NH formulation)|Round 1 (November): 0.5mL FluQuadri®, Sanofi Pasteur, containing 60μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the northern hemisphere formulation
1501574|NCT02957890|Biological|Inactivated influenza vaccine (SH formulation)|Round 2 (May): 0.5mL Vaxigrip®, Sanofi Pasteur, containing 45μg antigen - 15μg for each influenza strain included - with strains recommended by the WHO for the southern hemisphere formulation
1501575|NCT02957890|Biological|Placebo|Round 2 (May): 0.5mL normal saline
1501576|NCT02957877|Drug|Nadroparin|A nadroparin infusion regimen (loading dose of 35 IU/kg, followed by 10 IU/kg per hour for 6 hours) is administered as anticoagulation during the 8-hour hemodialysis.
1501718|NCT02956811|Drug|Placebo|Matching Placebo
2002216|NCT02457598|Drug|Obinutuzumab|Administered intravenously
2002217|NCT02454517|Behavioral|Behavioral Dietary Intervention|Undergo DPP lifestyle intervention
2002218|NCT02454517|Behavioral|Exercise Intervention|Undergo DPP lifestyle intervention
2002219|NCT02454517|Other|Informational Intervention|Receive oral and written guidelines and meet with dietician
2002220|NCT02454517|Other|Laboratory Biomarker Analysis|Correlative studies
2002221|NCT02454517|Other|Quality-of-Life Assessment|Ancillary studies
1501577|NCT02957877|Drug|Unfractionated heparin|The individualized unfractionated heparin infusion regimen currently employed by the recruited patients in their home dialysis treatment is administered as anticoagulation during the 8-hour hemodialysis.
1501578|NCT02957864|Drug|tenofovir alafenamide|
1501579|NCT02957864|Drug|abacavir|
1501580|NCT02957851|Drug|Medical Air|
1501581|NCT02957851|Drug|EMONO|
1501582|NCT02957838|Dietary Supplement|C18:0|Receives 24g of C18:0 in a low-fat banana milkshake.
1501583|NCT02957838|Dietary Supplement|mock|Low fat banana milkshake without C18:0 supplement.
1501584|NCT02957825|Device|Continuous wireless monitoring|Continuous wireless monitoring of vital signs
1501585|NCT02957812|Device|Custom-made Foot Orthotics (CFO)|Provides longitudinal arch support
1501586|NCT02957799|Behavioral|Accountable Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive ongoing monitoring and supervision. CHW will monitor mother's health and linkage to care; CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. CHW will also have a mobile phone to record information at each visit. CHW will log their home visits each day, rate the content and skills addressed on the mobile phone, weigh children, and report outcome achievements (e.g., receiving the child grant, immunizations, breastfeeding, and retention/ adherence to HIV care). The CHW in this arm will receive data-informed supervision. CHW will be monitored weekly with review of contact logs, recorded outcomes, and random site visits by supervising in-service training on a monthly basis. The Accountable Condition will last for two years (until the child is 24 months old).
1501587|NCT02957799|Behavioral|Control Condition|Mothers will receive home visits by government-funded CHW who will be trained under Philani as well as receive supervision and monitoring consistent with local government practices. CHW will monitor mother's health and linkage to care. CHW will refer all mothers to local clinics for HIV, blood sugar, and pregnancy testing. The Control Condition will last for two years (until the child is 24 months old).
1501588|NCT02957786|Drug|Cytisine|Cytisine tablets
1501589|NCT02957786|Behavioral|Behavioural support|Withdrawal-orientated cessation support
1501590|NCT02957786|Drug|Varenicline|Varenicline tablets
1501591|NCT02957773|Behavioral|Qigong and art activities|Participants join a 90-minute session of integrated Qigong and art activity consisting of 30 minutes Qigong followed by 60 minutes art activity.
1501592|NCT02957773|Behavioral|Art activities|Participants join a 90-minute session that consists of 60-minute art activities followed by 30 minutes daily activities.
1501593|NCT02957773|Behavioral|Qigong|Participants join a 90-minute session that consists of 30-minutes Qigong exercise followed by 60 minutes daily activities (watching television, reading or sitting together).
1501594|NCT02957773|Behavioral|Daily activities|Participants do their daily activities routine for 90-minutes, such as watching television, reading and sitting together or participants can do free individual activities on their own.
1501595|NCT02957760|Drug|Hydroxycarbamid|20 mg/kg milligram(s)/kilogram per day during 6 month, oral administration (coated tablet).
1501596|NCT02957747|Behavioral|SHE|SHE is a computer-delivered intervention (Safety and Health Experiences Program; SHE) that will provide a screening and brief behavior intervention for women Veterans with any lifetime ST. More specifically, the intervention, SHE, will address interrelated health concerns for women Veterans with ST (i.e. alcohol misuse, IPV, and PTSD). SHE will provide individualized assessment, feedback, and referrals for women Veterans with any lifetime ST. SHE will take place within a primary care setting.
1501597|NCT02957734|Procedure|Rehabilitation of severely worn dentitions|Patients with severely worn dentition and functional problems are included in this study. Teeth are rehabilitated using indirect composite resin restorations in an increased vertical dimension of occlusion in order to optimize function and esthetics.
1501598|NCT02957721|Other|Usual Care|Patients will not be given the intervention but receive usual care for T2D.
1501599|NCT02957708|Other|mCIMT + SR|"Each participant wears a customized cotton sling on the unaffected arm for six hours everyday. Participant is engaged in fifteen unimanual tasks during the three-week training that provides them sufficient challenge and opportunities for repetition.
SR is incorporated on the 1-hour structured practice by using video playback to help participants realize their own performance for better learning. Participant first performs a task with videotaping, then identifies steps with problems or difficulties by video playback of participant's performance. Secondly, participant is asked for possible solutions, prompting is given if needed. Lastly, participant performs the activity by adopting the suggested solutions with videotaping again to facilitate participant's evaluation of new performance."
1501600|NCT02957708|Other|Control|A combination of training on functional and remedial activities on unimanual tasks and bimanual tasks that based primarily on neurodevelopmental approach are provided. The training aims at increasing control, strength and functional use of their affected arm and hand, and improving bimanual coordination in performing daily activities. Each participant receives 1 to 2 hours of training per week at school. Home exercise including both unimanual and bimanual tasks is prescribed to them as well.
1501601|NCT02957695|Device|Placebo-Neurofeedback|The Intervention used for the control-group consists of a sham-neurofeedback, which is based on a previous eeg-recording and doesn't respond to the actual brain activity. The fact, that it is not a real neurofeedback, cannot be recognized by the patient nor the trainer because the eeg recording is not visible and the program reacts to muscle contractions (where feedback reactions would be expected) but not to brain activity.
1501602|NCT02957695|Device|Active-Neurofeedback|"The neurofeedback-method used in our study is called infra-low frequency neurofeedback Training, developed by S. and S. Othmer. NeuroAmpII® is the device and Cygnet® the corresponding Software used for this method, both are approved as an active medicinal device (CE-marked) in the European Union and in USA (www.eeginfo.com). The device and the Software are produced by the Company BEE Medic GmbH, Kirchberg, CH."
1501603|NCT02957682|Drug|Praluent (Alirocumab)|
1501604|NCT02957682|Drug|Placebo|
1501605|NCT02957669|Behavioral|Practice Self-Regulation|PS-R is an in-person, individual-level, clinic-based intervention implemented by mental health professionals trained in the intervention. It is intended to be implemented in ten structured, individual therapy sessions lasting approximately 50 minutes over the course of 18 weeks.
2002222|NCT02454517|Other|Questionnaire Administration|Ancillary studies
1501721|NCT02956785|Drug|10 mg Dinoprostone; CTS, UK|
1501606|NCT02957669|Behavioral|Therapy Practice Group|Therapy Practice Group is the control condition aimed at providing the youth a safe space to work on meeting their mental health goals. It is intended to be at least ten sessions over the course of 18 weeks.
1501607|NCT02957656|Biological|H7N9 pLAIV|10^7.0 fluorescent focus units (FFU); delivered by an Accuspray device
1501608|NCT02957656|Biological|H7N9 pIIV|Administered by intramuscular injection in the deltoid.
1501609|NCT02957656|Biological|AS03 adjuvant|Mixed with H7N9 pIIV vaccine; administered by intramuscular injection in the deltoid
1501610|NCT02957643|Drug|Iron|
1501611|NCT02957630|Drug|15 mg E4/3 mg DRSP|15 mg E4 combined with 3 mg DRSP administered in a 24/4-day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
1501612|NCT02957630|Drug|30 mcg EE/150 mcg LNG|30 mcg EE combined with 150 mcg LNG administered in a 21/7‑day regimen (i.e. 21 days of yellow active tablets followed by 7 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
1501613|NCT02957630|Drug|20 mcg EE/3 mg DRSP|20 mcg EE combined with 3 mg DRSP administered in a 24/4‑day regimen (i.e. 24 days of pink active tablets followed by 4 days of white placebo tablets). One tablet per day orally for 6 treatment cycles.
2002223|NCT02449824|Other|magnetic resonance imaging|early MRI
1501615|NCT02957604|Drug|evolocumab|Pregnant women exposed to evolocumab. Evolocumab is not administered in this non-interventional study.
1501616|NCT02957591|Dietary Supplement|Vivomixx®|Food supplementation with Vivomixx®. Vivomixx® (Mendes SA, Lugano, Switzerland) is a probiotic mixture of 8 strains: Streptococcus thermophiles DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) lactobacilli (L. acidophilus DSM 24735, L. plantarum DSM 24730, L. paracasei DSM 24733, L. delbrueckii subsp. Bulgaricus DSM 24734).
1501617|NCT02957591|Other|Placebo|Subjects in the placebo group will receive a placebo that contains starch but no bacteria. The appearance of the placebo will be indistinguishable in color, shape, size, packaging, smell, and taste from that of the probiotic supplement.
1501619|NCT02957565|Behavioral|Baseline Questionnaires|Participant completes 5 questionnaires during an already-scheduled office visit. Questionnaires ask about symptoms, physical and emotional health, and trust in the medical profession. These questionnaires should take about 17 minutes to complete.
1501620|NCT02957565|Other|Videos|Participant watches 2 short videos that show actors playing doctor and patient roles, discussing different cancer-related symptom treatment options. Each video is about 4 minutes long and discusses the same content, but setting of each video is different.
1501621|NCT02957565|Behavioral|Assessment Questionnaires|"After viewing first video, participant completes assessment questionnaire to evaluate their opinion of the physicians behavior. These questionnaires should take about 5 minutes to complete.
After viewing second video, participant completes the same 3 assessment questionnaires. Participant also completes 2 additional questionnaires asking which physician participant would prefer as a primary physician and the satisfaction with health information technology use in their care."
1501622|NCT02957552|Biological|Mesenchymal Stem Cells|Donor-specific, bone marrow derived mesenchymal stem (stromal) cells
2002224|NCT02442778|Drug|AVP-786|
2002225|NCT02442778|Drug|Placebo|
1501625|NCT02957526|Behavioral|Prompts to report symptoms via study app|Weekly prompts to report aromatase inhibitor use in the previous 7 days and treatment-related adverse symptoms via the web-enabled study app.
1501626|NCT02957526|Behavioral|Clinical Alerts|: Reported symptoms may trigger an email alert to the participant's care team based on predetermined thresholds. Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
1501627|NCT02957513|Behavioral|Text Messaging (TM)|As specified in the arm description above
1501628|NCT02957513|Behavioral|Health Coaching (HC)|As specified in the arm description above
1501629|NCT02957513|Behavioral|Enhanced Usual Care (EC)|As specified in the arm description above
1501630|NCT02957500|Device|Mediclore® (adhesion barrier)|
1501631|NCT02957487|Device|Denture supported by 3 dental implants|Metal-reinforced denture without palatal coverage incorporating nylon rings retained by friction to Locator abutments fitted on top of dental implants
1501632|NCT02957474|Drug|GED-0301|
1501633|NCT02957474|Drug|Omeprazole|
1501634|NCT02957461|Device|BrainScope Battery|The BrainScope Battery consists of 4 components to collect brain electrical activity, a cognitive assessment, a neurocognitive/symptom/balance assessment, and an ocular motor assessment.
1501635|NCT02957448|Drug|BMS 986141|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
1501636|NCT02957448|Drug|Rifampin|Two single doses BMS 986141 (days 1 and 13) and single daily doses Rifampin (days 7-22)
1501722|NCT02956785|Drug|3 mg Dinoprostone vaginal tablet; Pfizer, UK|
2002226|NCT02442765|Drug|AVP-786|
2002227|NCT02442765|Drug|Placebo|
2002228|NCT02439437|Behavioral|Psychosocial Intervention|Telephone-based psychosocial intervention involving Eight telephone encounters. Each encounter will focus on strategies for dealing with pain and stress, and how to apply these strategies to patients own experiences.
2002229|NCT02433379|Device|EMBLEM S-ICD System|The intervention comprises programming the EMBLEM Subcutaneous Implantable Defibrillator (S-ICD) with zone cutoffs at 200 bpm and 250 bmp
2002230|NCT02429791|Drug|DTG 50 mg|Participants will take one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet will contain 52.62 mg dolutegravir sodium salt, which is equivalent to 50 mg dolutegravir free acid.
2002231|NCT02429791|Drug|RPV 25 mg|Participants will take one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet will contain 27.5 mg of rilpivirine hydrochloride, which is equivalent to 25 mg of RPV.
2002232|NCT02429791|Drug|CAR|CAR will include following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI
1501637|NCT02957435|Drug|eplerenone|(Single arm) Sequence 1: one eplerenone coated tablet 25 mg in fasting (period 1), one eplerenone coated tablet 50 mg in fasting (period 2) and two eplerenone coated tablets 50 mg (100 mg of eplerenone) in fasting (period 3)
2002233|NCT02429570|Drug|Meclofenamate|
2002234|NCT02426086|Drug|Imetelstat 9.4 milligram/kilogram (mg/kg)|Participants will receive imetelstat intravenously as 9.4 mg/kg every 3 weeks. Study drug will be administered intravenously until disease progression, unacceptable toxicity, or study end.
1501640|NCT02957409|Drug|sacubitril/valsartan|This study is designed as an observational, naturalistic, multicenter study in patients being treated with sacubitril/valsartan as per the Canadian product label. Treatment initiation with sacubitril/valsartan must be within the last 3 months. Sacubitril/valsartan will be used as commercially available supplies which are available as Film coated tablets in 3 dosage: 1) 24 mg sacubitril / 26 mg valsartan, 2) 49 mg sacubitril / 51 mg valsartan and 3) 97 mg sacubitril / 103 mg valsartan.
1501641|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg intact tablet|20 mg intact finerenone immediate-release tablet; single dose in the fasting condition
1501642|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg crushed and resuspended tablet|20 mg crushed and resuspended finerenone immediate-release tablet; single dose in the fasting condition
1501643|NCT02957396|Drug|Finerenone (BAY94-8862): 20 mg suspension|20 mg finerenone suspension; single dose in the fasting condition or in the fed condition
1501644|NCT02957383|Other|Wavelength|wavelength at two levels: short (SWL)-485 nm (13500k) and long (LWL)-620 nm (4250k)
1501645|NCT02957383|Other|Intensity|Luminance at two levels: low - 80 lux (35mw/cm2) and high - 350 lux (160mw/cm2
1501646|NCT02957331|Drug|Propranolol|
1501647|NCT02957318|Dietary Supplement|FiberBind|Potato pulp consisting of 68% fiber (5.5 soluble, 76.7% insoluble and 17.8% resistant starch), 9.7% water, 0.3% fat, 7.2% protein and 14% carbohydrates (starch).
1501648|NCT02957318|Dietary Supplement|RG-I fiber|Soluble fiber extracted from potato pulp consisting of 95% fiber and 5% water.
1501649|NCT02957318|Dietary Supplement|Placebo|Low-fiber control
1501650|NCT02957305|Drug|Misoprostol 400 µg|Evaluate the required cervix dilation in the moment of the intrauterne suction
1501651|NCT02957305|Drug|Misoprostol 200 µg|Evaluate the required cervix dilation in the moment of the intrauterne suction
1501652|NCT02957292|Drug|Levonorgestrel (13,5 mg) intrauterine device|
1501653|NCT02957292|Device|Cooper (380mm2) intrauterine device|
1501654|NCT02957279|Drug|Antibiotics|In the sepsis group, antibiotics were used when needed.
1501655|NCT02957266|Radiation|Volumetric Arc Radiotherapy|Volumetric Arc Radiotherapy
1501656|NCT02957266|Radiation|Interstitial brachytherapy|Interstitial High Dose Rate Brachytherapy
1501657|NCT02957266|Drug|Cisplatin|Weekly Cisplatin
1501658|NCT02957266|Drug|Gemcitabine|Weekly Gemcitabine
1501659|NCT02957266|Genetic|PIK3CA|PIK3CA mutations rate
1501660|NCT02957266|Genetic|KRAS|KRAS mutations rate
1501661|NCT02957266|Genetic|BRAF|BRAF mutations rate
1501662|NCT02957266|Genetic|RRM1|RRM1 mutations rate
1501663|NCT02957253|Other|risk factors|monitoring risk factors due to deterioration of the liver disease
1501664|NCT02957253|Other|self-care|information and motivation to adherence to self-care instructions and medical treatment
1501665|NCT02957253|Other|nutrition|nutritional assessment and activities to prevent malnutrition
1501666|NCT02957253|Other|lifestyle|motivation of lifestyle changes essential for disease progress and
1501667|NCT02957253|Other|psychosocial needs|psychosocial care.
1501668|NCT02957253|Other|Nurse-led clinic|compensated disease once yearly, decompensated disease twice a month to every third month
1501669|NCT02957240|Behavioral|Standard Care|"This group will partake in 4 clinic-based intervention sessions (one 1-hr. and 3 subsequent 30-minute sessions) where the focus will be on home program competency/advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.
Home program (3x daily, 15 minutes) to include 10 repetitions of active thumb opposition, active thumb radial abduction, intrinsic minus active stretches, flat fist and composite, finger extension, Elbow flexion and extension, Shoulder scapular rolls, and glenohumeral circumduction.
Edema will be addressed through strict elevation when at rest and every 10 minutes on the hour. When resting in a seated or supine position, clients will be instructed to use pillows to accomplish elevation and to keep elbows in an extended position. Instructions for elevation will be provided immediately following orthopaedic intervention. Strict elevation will be recommended for the first 72 hours of the injury."
1501670|NCT02957240|Behavioral|Motor Representation Techniques|"Those in this group will receive 4 clinic-based intervention session (one 1-hr. and three subsequent 30-minute sessions) where the focus will be on home program competency and advancement. Session 1 will occur within 1 week of cast treatment, session 2 in week 2, session 3 in week 4, and session 4 in week 5.
Home Program will be performed 3x daily for 15 minutes. A Motor Representation Technique (i.e., modified GMI) protocol described by Lagueux et al. will be employed. As originally designed the program was broken into three stages 1) Laterality, 2) Explicit Motor Imagery, 3) Mirror therapy with unaffected hand only and 4) Mirror Therapy with bilateral hands. For the purpose of this study, and given the restraint offered by cast immobilization, the 4th phase will not be used. Each phase will require 1-2 weeks and will be progressed at the discretion of the hand therapist interventionist."
1501671|NCT02957227|Device|No intervention is part of this study but patients use an EEG devide during observational data collection.|
1501672|NCT02957214|Behavioral|Pain education|
1501673|NCT02957201|Other|Blood samples|Blood samples at baseline and 3 timepoints for EPC analysis
1501674|NCT02957188|Other|13C eicosapentaenoic acid and 13C arachidonic acid|Each participant orally consumed a single oral dose of 35 mg of 13C-EPA, and after the wash-out, a 50 mg dose of 13C-AA.
1501675|NCT02957175|Other|Immunophenotyping|Multiplex assays for screening pro- and anti-inflammatory markers and RNA will be analysed using a next generation sequencing approach
1501723|NCT02956785|Drug|Aquacryl hydrogel rod; HPSRx Enterprises, USA|
1501755|NCT02956551|Biological|T cells|intravenous administration
1501678|NCT02957149|Other|Autologous Platelet-Rich Plasma|Platelets that are collected from the subject during the radical prostatectomy, for prostate cancer. The platelets are concentrated in a device to 1,000,000 platelets/mL and applied topically once to the neurovascular bundle during the surgery.
1501679|NCT02957149|Device|Angel Concentrated Platelet Rich Plasma System|
1501680|NCT02957136|Device|Rapid respiratory pathogen nucleic acid amplification test|Patients randomized to the rapid respiratory pathogen nucleic acid amplification test (Film Array Respiratory Panel, BioFire Diagnostics), will receive usual physician-directed care plus results from a rapid diagnostic test for 20 common respiratory pathogens. Patients will have a nasopharyngeal swab sample collected and tested during the ED episode of care with results reported in the electronic medical record (EMR) within two hours of sample collection. ED physicians will receive education regarding the rapid respiratory pathogen test prior to commencing the study. During the study, ED physicians will be free to review and interpret the respiratory pathogen test results and make treatment decisions based on their individual clinical judgment without involvement of study personnel.
1501681|NCT02957123|Drug|Intranasal auto-M2-BFs|Delivery is performed with the aerosol inhaler device (nebulizer), 2.0 mL once a day up to 30 days.
1501682|NCT02957110|Behavioral|Laughter Frequency|Relationships between laughter frequency, momentary mood state, and pain will be observed.
1501683|NCT02957097|Drug|Gabapentin|Medication used for management of neuropathic pain conditions
1501684|NCT02957097|Drug|Placebo|Placebo medication. It looks exactly same as the Gabapentin medication in same size, shape, and color.
1501685|NCT02957058|Procedure|SCAR technique|Thermal ablation of the EMR margin using ERBE Soft Coagulation (Effect 4, 80 watts) and the operator choice of endoscopic resection snare
1501686|NCT02957045|Procedure|Cough pressure measurement|
1501687|NCT02957045|Device|Pcough|
1501688|NCT02957032|Drug|F16IL2|"All patients first receive an initial run-in dose of 30 Mio IU of F16IL2 on day 1 and escalating doses of F16IL2 on day 1, 8, 15 and 22.
Treatment will be repeated every 28 days for up to three cycles."
1501689|NCT02957032|Drug|cytarabine|Patients will be treated with cytarabine (5 mg twice daily s.c. for 10 days). Treatment will be repeated every 28 days for up to three cycles.
1501690|NCT02957019|Drug|L19-IL2 - Ph I|Patients will receive increasing doses of L19-IL2 (0.32, 0.43, 0.57 and 0.76 Mio IU/kg of IL-2 equivalents per administration) during Phase I study
1501691|NCT02957019|Drug|L19-IL2 at RD - Ph II|Patients will receive L19-IL2 at the RD defined during the Phase I part of the study
1501692|NCT02957019|Drug|Rituximab|Patients will receive a fixed dose of Rituximab (375 mg/m2) per administration during Phase I and Phase II of the study
2002235|NCT02426086|Drug|Imetelstat 4.7 mg/kg|Participants will receive imetelstat intravenously as 4.7 mg/kg every 3 weeks or at an escalated dose of 9.4 mg/kg based on investigator's discretion. Study drug will be administered intravenously until disease progression, unacceptable toxicity, or study end.
1501694|NCT02956993|Drug|vonapanitase|
1501695|NCT02956993|Drug|Placebo|
2002236|NCT02419573|Device|Endotracheal Intubation|In this traditional model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use ETI as the primary (initial) airway management intervention. If the EMS agency is assigned to this arm, basic-level EMS personnel will use bag-valve-mask ventilation only even if they would normally use an LT.
1501697|NCT02956967|Other|Overall satisfaction questionnaires of home use of Nivestim|
1501698|NCT02956954|Drug|Enzyme replacement therapy (Agalsidase alpha (Replagal®))|Patient treated with Enzyme replacement therapy as usual (Agalsidase alpha (Replagal®)). The treatment is prescribed in routine and not specially for the protocol
1501699|NCT02956954|Procedure|Magnetic Resonance Imaging|Magnetic Resonance Imaging will be assessed every 6 months during 2 years
1501700|NCT02956941|Behavioral|BCC on Essential Nutrition and Hygiene Actions (ENHAs)|The behavioral change communication (BCC) on micronutrient intake messages will be implemented based on Essential Nutrition and Hygiene Actions (ENHAs) on micronutrient deficiencies prevention and control. BCC intervention training workshop will be given to science teachers by principal investigator/ senior health professional in local language. Interventions will be delivered to students by their science teachers under the supervision of principal investigator/ school director for the consecutive three times.
1501701|NCT02956915|Procedure|Transfemoral Transcatheter aortic valve implantation|Transcatheter aortic valve implantation (TAVI): The SAPIEN-3 prosthese are implanted without open heart surgery. The valve delivery system is inserted in the body via the femoral artery.
1501702|NCT02956902|Other|Clinician supported smartphone application intervention|
1501703|NCT02956889|Drug|Vismodegib|Patients will receive a continuous once-daily oral dosing of Vismodegib at a dosage of 150 mg .
1501704|NCT02956889|Radiation|Radiotherapy|Radiotherapy (RT) will be administered with a total dose of 50 Gy/2.5 Gy per fraction over 4 weeks.
1501705|NCT02956876|Drug|standard chemotherapy for colorectal cancer|standard chemotherapy for colorectal cancer
1501706|NCT02956876|Other|Nurse practitioner consultation|Nurse practitioner consultation will be done standard chemotherapy for colorectal cancer
1501707|NCT02956876|Other|Medical practitioner consultation|Medical practitioner consultation will be done standard chemotherapy for colorectal cancer.
1501708|NCT02956863|Procedure|Osteopathic manipulative treatment|Osteopathic manipulative treatment delivered on pragmatic way.
1501709|NCT02956863|Procedure|Exercises|Exercise for stretching and strength for neck muscles
1501710|NCT02956850|Other|Placebo|Placebo matched to RO7020531 will be administered as per schedule specified in the respective arm.
1501711|NCT02956850|Drug|RO7020531|RO7020531 will be administered as per schedule specified in the respective arm.
2002237|NCT02419573|Device|Laryngeal Tube (King)|In this test model of OHCA airway management, advanced-level Emergency Medical Services (EMS) personnel will use LT as the primary (initial) airway management intervention. Basic-level EMS personnel will use bag-valve-mask ventilation. If trained to use LT, basic-level EMS personnel may perform LT insertion.
1501716|NCT02956824|Other|Standard care|Current care
1501717|NCT02956811|Drug|Dapagliflozin|SGLT2 inhibitor
1501756|NCT02956538|Drug|Thalidomide|
1501724|NCT02956772|Drug|TACE|After the puncture of femoral artery via Seldinger method, a catheter was inserted and digital celiac axis or hepatic arteriography performed. Then a microcatheter was used to infuse chemotherapeutic agent (30 to 60 mg of pirarubicin) mixed with 5 to 20 mL of Lipiodol Ultra-Fluid. Embosphere microspheres (size of 100 to 300 um) were inserted for embolization.
1501725|NCT02956772|Drug|Arsenic trioxide|Arsenic trioxide 10 mg is put into 500 ml saline solution and then administrated by continuous intravenous drip for 5 hours during a treatment day.
1501726|NCT02956759|Procedure|Pan-retinal photocoagulation laser treatment|PRP initially consists of 1200 - 1600 burns given over 2-3 sessions and separated by2-3weeks by 532-argon laser machine.
1501727|NCT02956746|Biological|SYN023|The effects of SYN023 on immunogenicity of rabies vaccines Imovax and RabAvert will be compared to the effect of human rabies immune globulin.
1501728|NCT02956746|Biological|Imovax, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of Imovax rabies vaccine
1501729|NCT02956746|Biological|RabAvert, human rabies immune globulin|Subjects will receive HyperRAB ST (human rabies immune globulin) and 5 doses of RabAvert rabies vaccine
1501730|NCT02956733|Procedure|dermotaxis|In dermotaxis (Singhs skin traction) method two parallel kirschner wires (1.5mm) will be passed through the dermis on either side of the wound margins and interconnected by compression device consisting of threaded rod having two blocks and compression knob. Gradual compression will be applied daily at the rate of 1 turn/12hours on both sides of the wound.
1501731|NCT02956733|Procedure|loop suture technique|The loop suture technique involves using corrugated drains and Ethilon no.1. It is an extension of the purse string suture technique where a surgical suture is passed as a running stitch in and out along the edge of a wound in such a way that when the ends of the suture are drawn tight the wound is closed. Two corrugated drains (1 & 2) will be anchored to the skin adjacent to the fasciotomy incision using Ethilon no.1. Then the sutures will be passed from one edge of the wound through the skin and corrugated drain to the other in an alternating fashion.
1501732|NCT02956720|Device|UltraShape Power|non-invasive body contouring procedure
1501733|NCT02956707|Other|No pre-operative steroids|Due to new information provide from previous studies at our center the investigator instituted a clinical practice change remove steroid administration in the pre-operative period for all neonates undergoing surgery with cardiopulmonary bypass. This study is to evaluate this change.
1501734|NCT02956694|Behavioral|Training of clinicians + tools|The clinicians will have access to a distance training program on shared decision making (e-TUDE) during one month. They will also receive five Decision Boxes (DB) dealing with difficult decisions often faced by seniors with dementia and their caregivers in primary care. Each DB will be designed in two versions, one adapted to clinicians (C-DB), and a simplified version adapted to patients/caregivers (P-DB). They will receive the five C-DBs by email, at a rate of 1 per week for 5 weeks. Furthermore, they will also be invited to use the 5 P-DBs with their patients. To this end, they will receive a stack of printed copies of the P-DBs for use in home care consultations, and we will also leave some copies in a wall file in each consultation room of the clinic.
1501735|NCT02956694|Other|Usual care|Healthcare providers from the clinics allocated to the control group will practice as usual and have access to the same training program after the end of the study data collection (delayed intervention).
1501736|NCT02956681|Behavioral|Intervention Group|Callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that a genetic counselor will call them back to offer them a free genetic counseling appointment and that a brochure will be sent. A UCSF/SFGH genetic counseling assistant will call them back within a few days to offer them a free genetic counseling appointment at SFGH.
1501737|NCT02956681|Behavioral|Delayed Intervention Group|This is a randomized delayed intervention control trial in which eligible callers to California's toll-free breast/cervical screening phone service were screened for family history. Callers identified as high risk will be told that they are eligible to speak to a genetic counselor who is available at no charge at SFGH and that they will be sent a brochure with information on where to call.
1501738|NCT02956668|Other|Blindsight Training associated to tDCS|The patient undergo visual rehabilitation while his brain is electrically stimulated with tDCS.
1501739|NCT02956668|Other|Blindsight Training alone|The patient undergo visual rehabilitation
1501740|NCT02956655|Other|Fasting therapy|The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. After intervention, all the accomplished patients undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up.
1501741|NCT02956655|Drug|Insulin intensive therapy: Human Insulin (Novolin-R, Novo Nordisk)|"Human Insulin (Novolin-R, Novo Nordisk)
Device: H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland
The target fasting plasma glucose is set below 6.1mmol/l and the postprandial blood glucose below 8.0 mmol/l. If the glucose target cannot be achieved within 2 weeks or the subjects are not tolerated with this therapy, these members will be exclude from the study and they will receive other treatment according the standard treatment guidelines. After intervention, all the accomplished patients will undergo a 1 year period follow-up. Lifestyle guidance will be offered throughout the follow-up."
1501742|NCT02956655|Other|Exercise|Middle intense exercise for at least 2 hours,e.g. brisk walking or jogging
1501743|NCT02956655|Behavioral|Lifestyle guidance|Lifestyle guidance is provided by specific physicians through phone calls
1501744|NCT02956655|Device|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
1501745|NCT02956642|Device|Livongo Health System|Participants will be asked to use the Livongo Health System to manage their blood glucose.
1501746|NCT02956642|Device|iHealth Glucose Meter|Participants will be asked to use the iHealth Glucose Meter to take blood glucose measurements.
2002238|NCT02417441|Device|EEVA™|Embryos of consented subjects will be assessed with EEVA™ System and morphological assessment and will be followed up after Embryo Transfer until achievement of implantation and confirmation of pregnancy.
2002239|NCT02415413|Drug|carfilzomib|
2002240|NCT02415413|Drug|Lenalidomide|
1501750|NCT02956616|Procedure|Enhanced Recovery Protocol|Postoperative recovery will follow the usual service protocols
1501751|NCT02956603|Other|Fine wire EMG electrodes|Electrodes placed either in partial muscle grafts or in intact muscle to record and stimulate
2002241|NCT02415413|Drug|Dexamethasone|
2002242|NCT02415413|Drug|Melphalan|
1501764|NCT02956499|Drug|APX001 single dose 5|
1501765|NCT02956499|Drug|APX001 single dose 6|
1501766|NCT02956499|Drug|APX001 multiple dose 1|
1501767|NCT02956499|Drug|APX001 multiple dose 2|
1501768|NCT02956499|Drug|APX001 multiple dose 3|
1501769|NCT02956499|Drug|APX001 multiple dose 4|
1501770|NCT02956499|Drug|Matching Placebo|
1501771|NCT02956486|Drug|elenbecestat (E2609)|tablet
1501772|NCT02956486|Drug|Placebo|tablet
1501773|NCT02956473|Device|Supine MRI|
1501774|NCT02956473|Other|Neoadjuvant Therapy|
1501775|NCT02956473|Device|Ultrasound|
1501776|NCT02956473|Device|Mammography|
1501777|NCT02956473|Procedure|Standard of Care|
1501778|NCT02956460|Device|fanfilcon A|contact lens
1501779|NCT02956460|Device|senofilcon C|contact lens
1501780|NCT02956447|Drug|Kisspeptin 112-121|0.313 µg/kg IV
1501781|NCT02956447|Drug|Gonadotropin Releasing Hormone (GnRH)|0.075 ug/kg IV
1501782|NCT02956434|Behavioral|Brief Family Intervention|Two 50-minute sessions aimed at helping family members be most supportive to their loved one's treatment goals.
1501783|NCT02956421|Biological|RABIPUR®|Biological rabies vaccine
1501784|NCT02956421|Biological|PIKA rabies vaccine|Biological rabies vaccine
1501785|NCT02956408|Dietary Supplement|Vitamin D3|Patients will be prescribed either 2000 IU or 6000 IU of vitamin D3 per day. They will go to a pharmacy and purchase a vitamin D3 supplement in their preferred form (eg gummy, liquid, chew, tablet, capsule)
1501786|NCT02956395|Other|Integrated care intervention|"Integrated care intervention is implemented by a multidisciplinary team from the hospital and from the Primary Care.
The intervention after hospital discharge a) Phone call at 24 hours; b) Home visit at 72 hours after discharge by one member of the transitional care team, if is needed; During this visit, the therapeutic plan for each patient will be customized to their individual frailty factors and shared with the primary care team. Reinforcement of the logistics for treatment of co-morbidities and social support will be done accordingly; c) Accessibility to the point of care available 24 hours/day ; d) Accessibility to the individualized PHF, as self-management tool ; d) appointment at 1m after discharge and after 12 m"
1501787|NCT02956382|Drug|Ibrutinib|Ibrutinib is dispensed as a capsule.
1501788|NCT02956382|Drug|Venetoclax|Venetoclax is dispensed as a tablet.
1501789|NCT02956369|Dietary Supplement|Control|Control granulates (maize starch and long-chain fatty acids) with powder
1501790|NCT02956369|Dietary Supplement|SATIOSTAT|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder
1501791|NCT02956356|Dietary Supplement|Control treatment + oral glucose|Control granulates (maize starch and long-chain fatty acids) with powder; 75g oral glucose load
1501792|NCT02956356|Dietary Supplement|SATIOSTAT treatment + oral glucose|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; 75g oral glucose load
1501793|NCT02956356|Dietary Supplement|Control treatment + meal intake|Control granulates (maize starch and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
1501794|NCT02956356|Dietary Supplement|SATIOSTAT treatment + meal intake|SATIOSTAT granulates (hydrocolloids (fibers) and long-chain fatty acids) with powder; test meal (ham sandwiches: 50g bread, 10g butter, 29g ham (pork); 247 kcal/sandwich) and tap water)
1501795|NCT02956343|Device|Five minutes pulse wave recording|Patients will wear a smart watch and a wristband each at one arm. A standard egg (lead I) and pig signals from the wearables will be recorded for five minutes.
1501796|NCT02956317|Drug|STP705|The Cotsiranib drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and Cox-2 mRNA respectively, and formulated in nanoparticles with Histidine-Lysine co-Polymer (HKP) peptide at a ratio of 1:4 in mass weight (siRNA:peptide), which is further formulated into a dry powder drug product. The administration route would be intra-dermal injection.
1501797|NCT02956317|Drug|Placebo|Normal Saline
1501798|NCT02956304|Other|PMv stimulation (iTBS)|PMv stimulation (iTBS)
1501799|NCT02956304|Other|PMv inhibition (cTBS)|PMv inhibition (cTBS)
1501800|NCT02956304|Other|Control (SHAM)|Control (SHAM)
2002243|NCT02415361|Other|Cleft lip and palate|Comparison between Arm A who will receive standard care and Arm B who will receive systematic follow up performed by a special trained nurse will be performed.
1501804|NCT02956265|Device|bimodal optical spectroscopy|an optical fiber will be put in gentle contact with the patient's skin in order to acquire optical spectra
1501805|NCT02956252|Procedure|Spinal anesthesia|Spinal anesthesia was used in patients who underwent LC
1501806|NCT02956252|Procedure|General anesthesia|General anesthesia was used in patients who underwent LC
1501807|NCT02956239|Procedure|Thermocoagulation (device)|Thermocoagulation uses heat injury to destroy the abnormal dysplastic cells of the cervix
1501808|NCT02956239|Procedure|Cryotherapy (device)|Cryotherapy uses cold injury to destroy the abnormal dysplastic cells of the cervix
1501809|NCT02956239|Procedure|LEEP (device)|The abnormal area of the cervix is excised with a thin metallic loop driven by electrosurgical unit
1501810|NCT02956226|Drug|Cannabinoids - 99% pure cannabinoids mix|99% pure cannabidiol (CBD) and 99% pure Δ9-tetrahydrocannabinol (THC) in a 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
1501811|NCT02956226|Drug|Placebo|Olive oil and flavors solution.
1501812|NCT02956226|Drug|Cannabinoids - whole plant extract|Whole plant extract enriched with cannabidiol (CBD) and Δ9-tetrahydrocannabinol (THC) to achieve 20:1 ratio (B.O.L Pharma, Israel), in a 160/8.0 mg per mL (CBD/THC) olive oil-based solution.
1501813|NCT02956213|Other|HEPA portable air filter|A high efficiency (MERV17) portable air filter (HEPA portable air filter) will be placed in the subject's bedroom and will run 24/7 for the duration of the study.
1501814|NCT02956213|Other|Sham Control|A portable air filtering device will be placed with no high-efficiency air filter, but only the basic carbon filter in place.
2002244|NCT02413242|Other|Various observed exposure(s) of interest|A risk prediction model will be developed to assess which risk factors are associated with the development of ICU pneumonia during ICU stay
1501815|NCT02956200|Drug|Fingolimod|Patients randomized to fingolimod will also receive oral fingolimod (Gilenya, Novartis) at a dosage of 0.5 mg once daily, for three consecutive days, with the first dose being given at the time in which patients are enrolled which is about one hour prior to mechanical thrombectomy.
1501816|NCT02956187|Behavioral|Biofeedback|Functional outlet obstruction will be treated by biofeedback: sessions of biofeedback guided by anorectal manometry combined with instructions for daily exercizing for 4 weeks.
1501817|NCT02956187|Dietary Supplement|Fiber supplement|3.5 g plantago ovata per day will be administered for 4 weeks.
1501818|NCT02956174|Device|Co-Cr single crown|
1501819|NCT02956174|Other|Periodontal parameters|
1501820|NCT02956161|Device|Stimulation of up-phase of sleep slow oscillation|
1501821|NCT02956161|Device|Random stimulation of up phase of sleep slow oscillation|
1501822|NCT02956161|Device|No stimulation|
1501823|NCT02956148|Radiation|Radioligand [18F]MNI-659|The effective radiation dose for the injection of [18F]MNI-659 is approximately 5.6 mSv (approximately 2 years of background radiation in Sweden) for an average person weighing 70 kg.
2002245|NCT02408523|Drug|Lacosamide Tablet|"Active Substance: Lacosamide
Pharmaceutical Form: Film-coated Tablet
Concentration: 50 mg
Route of Administration: Oral use"
2002246|NCT02408523|Drug|Lasosamide Oral Solution|"Active Substance: Lacosamide
Pharmaceutical Form: Oral Solution
Concentration: 10 mg/ml
Route of Administration: Oral use"
2002247|NCT02408523|Other|Placebo Tablet|"Active Substance: Placebo
Pharmaceutical Form: Film-coated Tablet
Concentration: 50 mg
Route of Administration: Oral use"
1501827|NCT02956109|Drug|Finerenone (BAY94-8862): 1 0mg tablet|10 mg finerenone immediate-release tablet; single dose in the fasting condition
1501828|NCT02956109|Drug|Finerenone (BAY94-8862): 5 X 0.25 mg oro-dispersible tablets|5 x 0.25 mg (1.25 mg) oro-dispersible tablets; single dose in the fasting condition
1501829|NCT02956109|Drug|Finerenone (BAY94-8862): 1.25 mg oro-dispersible tablet|1.25 mg finerenone oro-dispersible tablets; single dose in the fasting condition or in the fed condition
1501830|NCT02956096|Device|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.
1501831|NCT02956096|Device|training on the running belt|The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
1501832|NCT02956083|Other|Systane Balance eye drops|Propylene Glycol 0.6% Over the counter lipid based artificial tears.
1501833|NCT02956083|Other|Systane Contacts eye drops|Hydroxypropyl methycellulose over the counter non-lipid based artificial tears
1501834|NCT02956083|Other|saline|Saline - no brand name
1501835|NCT02956070|Drug|Dexamethasone acetate|The volunteers in the Dexamethasone acetate group (experimental group) will receive six capsules of dexamethasone 8 mg each to be administered orally, initially two days before the first bleaching query as follows: 8 mg (1 capsule) 9 am two days before the first clinical session whitening; 8 mg (1 capsule) the 9 am to 1 day before session whitening, 8 mg (1 capsule) to 9 am on the day of the first session of whitening.Clinical intervention: 1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A placebo gel will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
1501836|NCT02956070|Drug|Potassium Nitrate|The volunteers in the Potassium Nitrate Group (Placebo group) will receive 6 placebo capsules, who contained the same components of de dexamethasone drug except the active ingredient (starch [50%], lactose monohydrate [35%], dibasic calcium phosphate [14%], and magnesium stearate [1%]).Clinical session:1- Dry teeth and apply Gingival Barrier to both arches. 2- Light cure. 3- Firmly attach a mixing nozzle to the Pola Office+. 4- Apply a thin layer of gel to all teeth undergoing treatment. 5- Leave gel on for 8 minutes. 6- Suction it off. 7- Repeat steps 5-6 twice times. 8- After the last application, suction all the gel off, then wash and apply suction. 9- Remove Gingival Barrier. 10- A desensitizing gel containing 6% potassium nitrate will be applied with a brush on the labial surface of the teeth whitened for 2 to 3 minutes .
2002248|NCT02408523|Other|Placebo Oral Solution|"Active Substance: Placebo
Pharmaceutical Form: Oral Solution
Concentration: 10 mg/ml
Route of Administration: Oral use"
1501840|NCT02956044|Drug|Bexagliflozin|Bexagliflozin tablets, 20 mg
1501841|NCT02956044|Drug|Metformin|1000 mg metformin
1501842|NCT02956044|Drug|Glimepiride|4 mg glimepiride
1501843|NCT02956044|Drug|Sitagliptin|100 mg sitagliptin
1501844|NCT02956031|Other|Screening|Cervical specimen obtained using speculum examination and cervical collection bush.
1501845|NCT02956031|Other|Colposcopy|Vaginal speculum examination followed by application of 2% acetic acid and lugol's iodine with inspection with colposcope and punch biopsies taken of abnormal areas.
1501846|NCT02956031|Procedure|LLETZ|The above (see colposcopy) is followed by local anaesthetic with two dentist's ampoules of lignocaine and large loop excision using coagulation of the abnormal area (usually 2 x 3 x 1 cm).
1501847|NCT02956005|Drug|ENVARSUS®|ENVARSUS XR is a form of the anti-rejection drug, tacrolimus, for people who have had a kidney transplant
1501848|NCT02955992|Behavioral|Improving communication during the end-of-life process|
1501849|NCT02955979|Other|CT scan with iodinated contrast agents|"Before the CT scan, the investigators with iodinated contrast agents, the following data will be collected in the medical record: creatinine prior to injection, comorbidities and child characteristics, associated treatments and risk factors of acute renal failure, as well as the injection pattern.
After the CT scan the investigators will collect the characteristics of the injection type, osmolarity and volume of contrast used and the appearance of a possible allergic reaction.
Then 24 and 48 hours and day 7 will collect serum creatinine, urine output and vital replacement therapies may be necessary."
1501850|NCT02955966|Device|imaging 18F-FDG-PET/CT|18F-FDG PET Scan at Day 0, W6 and W12
1501923|NCT02955472|Drug|GLA5PR GLARS-NF1 tablet 150mg|A new formulation(1st.) of Pregabalin CR tablet
1501851|NCT02955966|Biological|Blood collection|Blood collection at D0, D3, W1, W2, W4, W6, W12, end of treatment.
1501852|NCT02955953|Drug|LY2963016|Administered SC
1501853|NCT02955940|Drug|Ruxolitinib|Ruxolitinib at the same dose provided in the parent study at the time of the rollover.
1501854|NCT02955940|Drug|Capecitabine|Capecitabine at the same dose provided in the parent study at the time of the rollover.
1501855|NCT02955940|Drug|Regorafenib|Regorafenib at the same dose provided in the parent study at the time of the rollover.
1501856|NCT02955927|Drug|0.01% atropine eye drops|
1501857|NCT02955927|Device|ortho-k|
1501858|NCT02955901|Other|3 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
1501859|NCT02955901|Other|1 day low residue diet prior to the colonoscopy|3 day low residue diet prior to the colonoscopy
1501860|NCT02955888|Drug|PBI4050|Investigational Medicinal Product
1501861|NCT02955888|Drug|Placebo|Comparator
1501862|NCT02955875|Behavioral|Pharmaceutical care|Outpatient drug history management, drug regimen review, patient counseling and education before and/or after physician evaluation on the day of facility visit
1501863|NCT02955862|Other|Vietnam Cryptococcal Retention in Care Study (CRICS)|"Drug: Fluconazole HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
Other Names:
• Fluconazole"
1501864|NCT02955849|Device|SLT laser|Patients will be offered initial SLT laser by doctors
1501866|NCT02955810|Drug|Daratumumab|
1501867|NCT02955810|Drug|Cyclophosphamide|
1501868|NCT02955810|Drug|Bortezomib|
1501869|NCT02955810|Drug|Dexamethasone|
1501870|NCT02955797|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
1501871|NCT02955797|Biological|Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine|0.5 mL, Intramuscular
1501872|NCT02955797|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
1501873|NCT02955797|Biological|Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine|0.5 mL, Intramuscular
1501874|NCT02955784|Device|Sinasprite Mobile App|Mobile App
1501875|NCT02955771|Procedure|PDT-Deuteporfin（6 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China） followed by the illumination of the tumor. 6 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China） will be applied to the tumor.The second courses of PDT may be given at 3-month intervals.
1501876|NCT02955771|Procedure|PDT-Deuteporfin（9 hour)|Photodynamic therapy (PDT) involves the i.v. injection of Deuteporfin (7.5 mg/kg，Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd，Shanghai，China) followed by the illumination of the tumor.9 hours after the injection,a laser light ( (wavelength,630 nm; light dose, 180 J/cm(2)；Guilin Xingda Photoelectric Medical Calinstrument Co., Ltd，,Fujian, China) will be applied to the tumor. The second courses of PDT may be given at 3-month intervals.
1501877|NCT02955771|Device|stenting|The stenting procedure consists in the placement of plastic stents （Boston Scientific Corporation, MA,USA；or Cook Medical, Bloomington,USA）above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC).
1501878|NCT02955758|Other|Laboratory Biomarker Analysis|Correlative studies
1501879|NCT02955758|Biological|Pembrolizumab|Given IV
1501880|NCT02955745|Other|Iodine-129|The present study is an observational study and does not therefore include an investigational product in the proper sense because the used tracer (semi-stable iodine isotope) has no physiological effect on the participants. 129I will be used as tracer to measure appearance in plasma, urine and stools after the oral administered of the 129I-tracer.
1501881|NCT02955732|Device|Dexmedetomidine|A 2-4 µg/kg dose of the study drug, 2 µg/kg of intranasal dexmedetomidine, will be administered using a LMA MAD Nasal™ -device approximately 20 min prior to planned sedation/anesthesia.
1501882|NCT02955719|Drug|Sertraline|
1501883|NCT02955719|Drug|Venlafaxine|
1501884|NCT02955719|Other|CBT/Psychological Therapy|
1501885|NCT02955719|Other|Psychiatric Consultation|
1501886|NCT02955719|Other|Lifestyle Intervention Resources|
1501887|NCT02955706|Drug|Acetyl-L-Carnitine|TID
1501888|NCT02955706|Drug|Placebo of Acetyl-L-Carnitine|TID
1501889|NCT02955693|Drug|LAS41008 120 mg / Fumaderm® 120 mg|Single dose of LAS41008 120 mg or Fumaderm® 120 mg in each Period
1501924|NCT02955459|Drug|VNRX-5133|
1501925|NCT02955459|Drug|Placebo|
1502038|NCT02954640|Biological|Blood sampling|Additional blood sampling for the realization of the test on the gene panel
1501892|NCT02955667|Procedure|invivo microscopy group|patients receive invivo micro-colposcopy examination
1501893|NCT02955667|Procedure|normal group|patients receive normal colposcopy examination and the biopsy specimens are sent for pathological HE staining and analysis
1501894|NCT02955654|Behavioral|Acceptance and commitment therapy|Patients randomized to ACT will receive weekly 45-50 minute sessions delivered over 8 weeks by a therapist. ACT will include mindfulness,learning new methods to handle problems，acceptance of thoughts and feelings, learning to disempower thoughts and feelings, and values-based committed action.
1501895|NCT02955654|Drug|Aripiprazole|Patients randomized to aripiprazole group will be treated with aripiprazole at the dose of 10-20mg/day for 8 weeks.
1501896|NCT02955654|Behavioral|Stress management training|Patients randomized to SMT group will be received 2 introductory sessions and 15 treatment sessions. SMT will include training of stress manage-ment skills, progressive muscle relaxation,positive imagery, assertiveness training, and problem solving.
1501897|NCT02955641|Drug|Dexamethasone Disodium Phosphate 0.1%|four drops a day for four days after LPI treatment
1501898|NCT02955641|Drug|Nepafenac 0.1%|four drops a day for four days after LPI treatment
1501899|NCT02955641|Drug|Hydroxyethylcellulose 0.19%|four drops a day for four days after LPI treatment
1501900|NCT02955628|Drug|Ibrutinib-RICE|Ibrutinib will be added to RICE regimen for patients not achieving a complete remission at interim PET-2. Ibrutinib will be continued for up to 1 year after autologous transplantation.
1501901|NCT02955615|Drug|ILT-101|"Induction phase followed by weekly administrations of ILT-101 on top of SLE background therapy.
SLE background therapy includes ..."
1501902|NCT02955615|Drug|Placebo|"Induction phase followed by weekly administrations of placebo on top of SLE background therapy.
SLE background therapy includes ..."
1501903|NCT02955602|Drug|MBX-8025 2 mg Capsule|"Initial 8-week treatment:
• MBX-8025 2 mg
Extension:
The 2 mg group will be started after safety and efficacy review of the 5 mg and the 10 mg groups has been completed.
Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
1501904|NCT02955602|Drug|MBX-8025 5 mg Capsule|"Initial 8-week treatment:
• MBX-8025 5 mg
Extension:
Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
1501905|NCT02955602|Drug|MBX-8025 10 mg Capsule|"Initial 8-week treatment:
• MBX-8025 10 mg
Extension:
Subjects will initially enter the extension on their assigned dose. The dose might be up- or down-titrated after safety and efficacy data review of the first 8 weeks of treatment. During the extension, a subject's dose might be re-adjusted for safety or efficacy reasons."
1501906|NCT02955589|Drug|HBI-8000|Oral, twice weekly
1501907|NCT02955576|Device|Microneedle HA patch|"The microneedle HA patch were made of hyaluronic acid with microneedles which can enhance the drug permeation. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with microneedle HA patches.
Microneedle HA patch (Therapass®, RMD-6.5A) was prepared at Raphas Co., Ltd. (Cheonan, South Korea).
Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
1501908|NCT02955576|Device|Patch|"The patch were made of hyaluronic acid with no microneedles to rule out the occlusion effect of microneedle HA patch. All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment with patches.
Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied.
The hyaluronic acid patch was prepared at Raphas Co., Ltd. (Cheonan, South Korea) for this clinical trial, not for sale."
1501909|NCT02955576|Other|Control|"All lesions were treated with topical calcipotriol - betamethasone dipropionate ointment only.
Daivobet® containing the active ingredients calcipotriol - betamethasone dipropionate was applied."
1501910|NCT02955563|Other|CSDM Web-Based Tool Intervention|Educational sessions on CSDM tool are provided for family members to complete before each family meeting. These sessions help family members become familiar with ICU operations/setting, prepare for the meeting, and learn how to make values based decisions for their loved one. The majority of the educational tool is comprised of video, but there are several interactive components that allows for family members to prepare and answer questions for the clinical team.
1501911|NCT02955550|Drug|rhIL-2|Human recombinant Interleukin-2
1501912|NCT02955550|Biological|PNK-007|PNK-007 is a culture-expanded cell population derived from human cord blood hematopoietic stem/progenitor cells.
1501913|NCT02955537|Other|MI-BP|MI-BP includes the following components: 1) Home blood pressure monitoring 2) Physical activity monitoring 3) Sodium intake self-monitoring 4) Physical activity and sodium intake goal setting 5) Educational messaging via push notification and in-app messaging 6) motivational messaging 7) tailored messaging relevant to individual participants and 8) medication reminders.
1501914|NCT02955524|Drug|Tetracaine 0.5%|One drop of 0.5% Proparacaine to nasolacrimal Duct to numb the ethmoidal nerve in the nasal passage on the side of the eye to be treated.
1501915|NCT02955524|Drug|Lidocaine hydrochloride ophthalmic gel 3.5%|1ml of lidocaine gel is placed over the conjunctivae of the eye to be treated after the patient is under general anesthesia and before the procedure
1501916|NCT02955511|Device|Blade MAC size 3|Patient will be intubated using the DL- Blade MAC size 3
1501917|NCT02955511|Device|Blade MAC size 3.5|Patient will be intubated using the DL- Blade MAC size 3.5
1501918|NCT02955511|Device|Inscope Blade size 3.5|Patient will be intubated using the Inscope Blade size 3.5
1501919|NCT02955498|Drug|Sevikar tab. 10/40mg|Reference drug: Sevikar tab. 10/40mg, 1T, single oral administration in the fasted state
1501920|NCT02955498|Drug|Lodivikar tab. 5/40mg|Test drug: Lodivikar tab 5/40mg, 1T, single oral administration in the fasted state
1501921|NCT02955485|Other|Patients do not undergo any type of interventions, but standard care if offered and accepted.|
1501922|NCT02955472|Drug|GLA5PR GLARS-NF3 tablet 150mg|A new formulation(3rd.) of Pregabalin CR tablet
1502282|NCT02953080|Behavioral|Call for life using M health SMS|
1501926|NCT02955446|Drug|PF-03084014|Two patients enrolled in this study will continue receiving 80mg BID doses of PF-03084014, which was the same dose/schedule of their latest cycle on protocol A8641014. PF-03084014 will be administered twice a day in the morning and evening divided by approximately 12 hours. PF-03084014 should be administered in cycles of 21 days continuously.
1501927|NCT02955433|Other|Rideshare-based transportation|
1501928|NCT02955420|Drug|BC 007|
1501929|NCT02955420|Drug|NaCl 0.9 %|
1501930|NCT02955407|Other|no intervention|observational case-control study
1501933|NCT02955381|Device|Restylane Silk, 1.0 ml|Restylane® Silk was approved in 2014 submucosal implantation for lip augmentation and dermal implantation for correction of perioral rhytids in patients over the age of 21.
1501934|NCT02955381|Device|Saline, 1.0 ml|Simple saline solution. To be used as placebo (control). No active ingredients.
1501935|NCT02955368|Drug|DP-R212|DP-R212 + C1-R212 placebo + C2-R212 placebo
1501936|NCT02955368|Drug|C1-R212|DP-R212 placebo + C1-R212 + C2-R212 placebo
1501937|NCT02955368|Drug|C2-R212|DP-R212 placebo + C1-R212 placebo + C2-R212
1501939|NCT02955342|Other|no intervention|no intervention
1501940|NCT02955329|Drug|Tetrahydrocannabinol|The THC for the study will be obtained from NIDA as either an ~90% THC wax which will need to be diluted after it is obtained or as a 40% THC oil in propylene glycol as the vehicle. If provided as the 40% THC oil, the investigators will use half of the amount as a THC-alone e-liquid and the other half to formulate a 40% THC + 6% nicotine e-liquid in propylene glycol. If obtained as a 90% THC wax, the investigators will utilize a compound pharmacy to dilute to 40% in propylene glycol under Good Manufacturing Practice conditions.
1501941|NCT02955303|Other|TECH: Tablet Enhancement of Cognition and Health|cognitive training using touchscreen tablet gaming applications
1501942|NCT02955290|Other|Laboratory Biomarker Analysis|Correlative studies
1501943|NCT02955290|Biological|Nivolumab|Given IV
1501944|NCT02955290|Biological|Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine|Given CIMAvax IM
1501945|NCT02955277|Other|TECH: Tablet Enhancement of Cognition and Health|TECH protocol - cognitive training using touchscreen tablet gaming applications
1501946|NCT02955264|Dietary Supplement|D-Galactose|
1995815|NCT02647489|Biological|PAMVAC|
1501949|NCT02955238|Behavioral|Special Intervention|"Participants randomized into the SI group will participate in four group health education classes and seven clinical visits per year with the patient care team. The patient care team will be comprised of a mid-level clinician and a Community Health Worker (CHW).
Content and materials utilized in the group health education classes are derived from the validated and translated curriculum Pasos Adelante , developed and refined by the CDC. Methods for training CHWs will be derived from the Pasos Adelante Curriculum."
1501950|NCT02955225|Device|Active Moticon OpenGO insole|A Moticon OpenGO insole measures shoe pressure and connects/sends data to a ANT+ enabled smartphone.
1501951|NCT02955225|Device|Passive shoe insole|A deactivated insole measures shoe pressure only.
1501952|NCT02955212|Drug|ABT-494|Oral formulation once daily
1501953|NCT02955212|Drug|Placebo|Oral formulation once daily
1501954|NCT02955199|Behavioral|Mothering From the Inside Out (MIO)|Mothering from the Inside Out (MIO) is a 12 session individual parenting therapy designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. MIO aims to promote their capacity for parental reflective functioning (the capacity to recognize and make sense of their own and their child's difficult emotions during challenging parenting situations).
1501955|NCT02955199|Behavioral|Parent Education|Parent Education (PE) is a 12 session individual parent counseling intervention designed for mothers enrolled in treatment for drug and/or alcohol addiction and caring for a child between 11 and 60 months of age. PE provides psycho-education about child development and parenting strategies typically available at community agencies on parenting. PE is designed to control for active treatment, treatment dose, and individualized intervention approach.
1501956|NCT02955186|Drug|Saracatinib|Saracatinib 125 mg once per day for 8 days
1501957|NCT02955186|Drug|Placebos|Placebo once per day for 8 days
1501958|NCT02955173|Procedure|Surgery|Laparoscopic or open surgery for resection of gastric or rectal cancer
1501959|NCT02955160|Biological|Multivalent|Pneumococcal conjugate vaccine
1501960|NCT02955160|Biological|Tdap|Tetanus, diphtheria, and pertussis vaccine
1501961|NCT02955147|Drug|Ustekinumab|Ustekinumab is a humanized monoclonal antibody that targets the p40 subunit of IL-12 and IL-23 and inhibits cytokine - cytokine receptor coupling and signaling
1501962|NCT02955147|Drug|Prednisone|Prednisone is an anti-inflammatory medication
1501963|NCT02955134|Drug|Talcid®|Talcid® is allowed to be taken when patients feel stomach pain, acid reflux or heartburn. Continuous taking time should not exceed one week.
1501964|NCT02955134|Drug|Chinese medicine prescription|"The Chinese medicine application prescription is composed of pinellia 9g, radix scutellariae 10g, rhizoma coptidis 8g, rhizoma zingiberis 10g, radix curcumae 10g, rhizoma atractylodis 10g, roasted bighead atractylodes rhizome 10g, radix astragali 15g, spreading hedyotis herb 20g, scutellariae barbatae 20g, salvia miltiorrhiza bge 10g, the stem of noble dendrobium 10g, radix pseudostellariae 10g, fructus aurantii immaturus 10g, cortex magnoliae officinalis 10g, rhizoma curcumae 10g, ginger 3g, jujube 6g.
Patients take 200ml each time, twice a day. Treatment duration are 24 weeks."
1501965|NCT02955134|Drug|Placebo|The placebo is simulate granule of Chinese medicine application prescription. Patients take 200ml each time, twice a day. Treatment duration are 24 weeks.
1501966|NCT02955134|Drug|Compound Azimtamide Entieric-coated Tablets|Compound Azimtamide Entieric-coated Tablets are qualified by China Food and Drug Administration. These tablets are allowed to be taken when patients feel fullness, belching or anorexia. Continuous taking time should not exceed one week.
1501967|NCT02955121|Genetic|CYP2C19 genotyping|
1995816|NCT02647489|Biological|Alhydrogel|
1995817|NCT02647489|Biological|GLA-SE|
1995818|NCT02647489|Biological|GLA-LSQ|
1995819|NCT02647489|Other|Placebo|
1501968|NCT02955108|Procedure|Distractive Auditory Stimuli|"Participants will self-select 1 music piece from a list of choices to keep the rhythm and tempo consistent throughout the 6MWT. The instructions to participants for selecting the music will be standardized. TThe music volume will be standardized to be moderately loud as rated by participants for the music condition. Participants will not be specifically instructed to synchronize their walking movements with the music tempo. The music is based on a cognitive therapy (distraction) strategy conceptual framework. Music will be played during the 6MWT (in-task) only."
1501969|NCT02955108|Procedure|No Distractive Auditory Stimuli|Participants will wear headphones with no music playing
1501970|NCT02955095|Device|Quit Smoking Phone Application|The app will be downloaded on participants' phones, and used by the participant for 30 days to make a quit attempt. Participants will be encouraged to use the app every day and to utilize all of its features, including features such as setting a quit date, taking the assessment section, and entering cigarette use and reasons for cravings
1501971|NCT02955082|Drug|Carboplatin|Intravenous carboplatin infusion every 3 weeks.
1501972|NCT02955069|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized IgG4 antibody directed against Programmed Death-1 (PD-1) receptor that blocks the binding of PD-L1 and PD-L2. PDR001 dose is 400 mg infusion every 4 weeks.
1501973|NCT02955056|Drug|Forsteo|20 micrograms/80 microlitres solution for injection in pre-filled pen
1501974|NCT02955043|Behavioral|Behavioral techniques|"Improve nighttime sleep: Participants will receive a modified form of cognitive-behavioral therapy for insomnia with a primary focus on stimulus control, a set of techniques to strengthen the association between bed and sleep and weaken its association with stimulating behaviors.
Increase daytime activity: Participants will receive instruction in activity management strategies including prioritizing activities, planning activities during peak energy, activity pacing, and alternating between rest and activity. Participants will be provided with a basic step-count pedometer to enhance ability to self-monitor activity and increase motivation for activity.
The intervention will be adapted to individual needs based on assessments of sleep and activity patterns."
1501975|NCT02955030|Biological|NSV0001|sublingual
1501976|NCT02955030|Biological|"Influenza HA vaccine Biken HA"|subcutaneous
1501977|NCT02955030|Biological|Placebo|sublingual
1501978|NCT02955017|Behavioral|traditional follow_up|"Multidisciplinary support with educational face to face family based intervention at 6, 9 and 12 months after inclusion.
Two days of a complete medical check at 9 and 15 months"
1501979|NCT02955017|Behavioral|"distance follow-up new technologies"|"Multidisciplinary support with long distance monitoring Mobile apps.
Two days of a complete medical check at 9 and 15 months"
1501980|NCT02955004|Procedure|Electrical cardioversion|Transthoracic direct current electrical cardioversion
1501981|NCT02954991|Drug|Glesatinib|Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
1501982|NCT02954991|Drug|Sitravatinib|Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
1501983|NCT02954991|Drug|Mocetinostat|Mocetinostat is an HDAC inhibitor.
1501984|NCT02954991|Drug|Nivolumab|nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
1501985|NCT02954978|Drug|Placebo Oral Capsule|"25 patients in group 1 will receive Placebo (sugar pill) one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up."
1501986|NCT02954978|Drug|Nilotinib 150mg oral capsule [Tasigna]|25 patients in group 2 will receive 150mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
1501987|NCT02954978|Drug|Nilotinib 300mg oral capsule [Tasigna]|25 patients in group 3 will receive 300mg Nilotinib one (1) capsule once daily (taken without a meal) for 12 months and 3 months follow up.
1501988|NCT02954965|Behavioral|Reward|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are rewarding and pleasurable and to integrate these activities into their schedule.
1501989|NCT02954965|Behavioral|Approach|Brief behavioral intervention (administered during a 45-minute phone call) that is designed to improve graduate student burnout by helping participants to identify activities that are challenging, but important to their long-term goals and values, and to integrate these activities into their schedule.
1501990|NCT02954939|Drug|MMF-MMF|Class III/IV+/-V lupus nephritis patients to receive PRED+MMF
1501991|NCT02954939|Drug|CTX-AZA|Class III/IV+/-V lupus nephritis patients to receive PRED+CTX followed by AZA
1501992|NCT02954926|Drug|IVIG|IVIG at a dose of 500mg/kg within 12 h and 3 days of birth
1501993|NCT02954913|Procedure|Simultaneous Resection|Resections of 3 or more segments of the liver will be considered a major liver resection.(Reddy) The anesthetic technique and the order of liver resection or rectal resection will be determined by each surgeon's standards. It is recommended that a low central venous pressure be maintained in order to decrease intraoperative blood loss (Chen; Hughes) and that liver resection be performed prior to colorectal resection in order to keep a low central venous pressure during that part of the case.
1501994|NCT02954900|Other|RealRisks|RealRisks is a web-based patient decision aid with modules that present information about risk assessment and chemoprevention.
1501995|NCT02954900|Other|BNAV|Breast Cancer Risk Navigation (BNAV) tool is a web-based decision support tool with modules that present pertinent information for primary care providers regarding breast cancer risk assessment and preventative measures for their patients.
1995823|NCT02643862|Drug|Xolair|Xolair is a monoclonal antibody approved by the FDA for asthma and chronic urticaria
1995824|NCT02643862|Drug|Placebo|Placebo
1502003|NCT02954861|Other|No intervention|No intervention
1502319|NCT02952807|Drug|Misoprostol|vaginal Misoprostol Plus Foley Catheter
1995831|NCT02642432|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
1995832|NCT02642393|Drug|Inosine|capsules containing 500 mg of inosine
1502006|NCT02954835|Device|Prevena|Prevena is a sterile silver dressing. On top of the silver dressing is an adhesive plastic, which is connected to a therapy unit through a short length suction tube.
1502007|NCT02954835|Device|Traditional Dressing|Sterile gauze dressing secured by tape.
1502008|NCT02954822|Drug|Evogliptin→Evogliptin+Glimepiride→Glimepiride|"Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days. After the washout period for 10 days, Glimepiride 4mg will be administered for 2 days.
Glimepiride : Glimepiride 4mg QD
Evogliptin + Glimepiride : Evogliptin 5mg QD + Glimepiride 4mg QD"
1502009|NCT02954822|Drug|Glimepiride→Evogliptin→Evogliptin+Glimepiride|After 2 days of administration of Glimepiride 4mg follows the 10-day washout period. Afterwards Evogliptin 5mg will be administered for 7days and then glimepiride 4mg will be added on and administered with Evogliptin 5mg for 2 days.
1502010|NCT02954809|Device|Morning bright light therapy|Exposure to morning bright light therapy delivered with Green-Blue Re-Timer glasses for 30 minutes in the morning during one week.
1502011|NCT02954809|Device|Dim light|Exposure to dim light with Red-Yellow Re-Timer glasses for 30 minutes in the morning during one week.
1502012|NCT02954796|Drug|SGN-CD352A|On the first day of each 28-day cycle, SGN-CD352A will be given IV. The dose of SGN-CD352A is different in each cohort of the study, with the lowest dose in Cohort 1 (8 mcg/kg) and the highest in Cohort 6 (65 mcg/kg). Patients can only be enrolled into a higher dose level arm if lower doses have proven safe.
1502013|NCT02954783|Behavioral|High Intensity Interval Training|"Supervised aerobic High Intensity Interval Training program consisting of 4 weekly sessions of approximately 35 minutes. Patients will perform a test of maximum cardio-respiratory (VO2 peak test). Using the patient's individual capacity score (VO2peak), a personalized exercise program will be prescribed.
After a light warm-up, patients will perform 25 min of aerobic high intensity interval training on a stationary bicycle, intervals will consist of cycles of HI intervals with 120% of vVO2max for 1 min followed by recovery for 3 min at 30% of vVO2max. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
1502014|NCT02954783|Behavioral|Moderate-Intensity Aerobic and Resistance Training|"Supervised Moderate-Intensity Aerobic and Resistance Training program consisting of 2 weekly sessions of approximately 75 minutes. Using the patient's individual capacity score (VO2peak and 1RM), a personalized exercise program will be prescribed.
After a light warm-up, patients will perform 30 min of moderate-intensity aerobic training (continuous 55-65% of heart rate reserve, HRR) on a stationary bicycle. Resistance training (approximately 35 min) comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load."
1502015|NCT02954783|Behavioral|Usual Care Observational Control|The reference group will receive the standard patient care program as provided by the Department of Urology, Rigshospitalet.This includes information regarding smoking cessation and alcohol reduction and a physiotherapist consultation regarding pelvic floor exercises. This group is allowed to exercise on their own initiative or participate in any standard care hospital- or municipality-based exercise program. This will be monitored by self-report.
1502016|NCT02954757|Procedure|HIFU treatment|High intensity focused ultrasound
1502017|NCT02954744|Procedure|HIFU treatment|High intensity focused ultrasound
1502018|NCT02954731|Behavioral|UP-CBT|"Psychotherapy in groups based on the Unified Procol a third generation CBT-type psychotherapy"
1502019|NCT02954731|Behavioral|Standard-CBT|Psychotherapy in groups based on diagnosis specific, manualized, cognitive behavior therapy
1502020|NCT02954718|Other|activity training|
1502021|NCT02954705|Other|Non interventional study|This is a non interventional study because all levies are performed during visit planned for the care of patients.
1502022|NCT02954692|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: pen for injection
Route of administration: subcutaneous"
1502023|NCT02954692|Drug|metformin|"Pharmaceutical form: tablet
Route of administration: oral"
1502024|NCT02954692|Drug|sulfonylurea|"Pharmaceutical form: tablet
Route of administration: oral"
1502025|NCT02954692|Drug|meglitinides|"Pharmaceutical form: tablet
Route of administration: oral"
1502026|NCT02954692|Drug|thiazolidinediones|"Pharmaceutical form: tablet
Route of administration: oral"
1502027|NCT02954692|Drug|alpha-glucosidase inhibitors|"Pharmaceutical form: tablet
Route of administration: oral"
1502028|NCT02954692|Drug|GLP1 Receptor Agonist|"Pharmaceutical form: pen for injection
Route of administration: subcutaneous"
1502029|NCT02954692|Drug|Dipeptidyl peptidase-IV (DPP-IV) inhibitors|"Pharmaceutical form: tablet
Route of administration: oral"
1502030|NCT02954692|Drug|Sodium-glucose transport-2 (SGLT-2) inhibitors|"Pharmaceutical form: tablet
Route of administration: oral"
1502031|NCT02954679|Other|Online self-administrated and anonymous survey questionnaire|The study will be conducted during a period of 3 years, between September 2016 and September 2019, according to a standardized methodology identical in every school involved and a procedure based on an online self-administrated and anonymous survey questionnaire. The questionnaire, elaborated on Limesurvey®, will be available for two successive academic years for all students aged more than 18 years old.
1502032|NCT02954666|Device|radio-frequency ablation (nMARQ™ or Smart Touch™ catheter)|"Patients will undergo a tailored radio-frequency ablation of the ARGP with the Smart Touch™ catheter or with the nMARQ™ catheter. Radiofrequency applications will be interrupted if no significant P-P interval shortening is observed after 30 seconds or if P-P interval is ≤ 550 ms during ablation.
The ablation procedure is considered complete when one of the following conditions is fulfilled:
P-P interval < 70% baseline procedural P-P interval after 5minute of waiting time; P-P interval < 600 ms after 5 minute of waiting time; 5 radiofrequency applications > 30 seconds have been delivered with the nMARQ™ catheter or 10 applications with the Smart Touch catheter."
1502320|NCT02952807|Device|Foley Catheter|
1502039|NCT02954627|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
1502040|NCT02954614|Behavioral|Active play in after school programs (ASP)|"A 15 hour training-program for ASP-staff aimed to increase active play and physical activity among children in ASPs. The program includes lectures, guided discussions and practical tasks focusing on increasing the staffs competence in how to support active play and PA among all children in the ASP
A 8 hour course for local physiotherapists enabling them to guide ASP-staff during parts of the intervention period"
1502041|NCT02954601|Drug|ORMD-0801 (qd)|Dose 1 = ORMD-0801 (qd)
1502042|NCT02954601|Drug|ORMD-0801 (bid)|Dose 2 = ORMD-0801 (bid)
1502043|NCT02954601|Drug|ORMD-0801 (tid)|Dose 3 = ORMD-0801 (tid)
1502044|NCT02954601|Other|Placebo|fish oil placebo
1502045|NCT02954588|Dietary Supplement|Pyridoxamine|
1502046|NCT02954588|Dietary Supplement|Placebo|
2002249|NCT02408081|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of one months.
1502048|NCT02954562|Other|fMRI|Participants will undergo two to three fMRI scans
1502049|NCT02954549|Dietary Supplement|Vitamin D3|As in Arms
2002250|NCT02408549|Drug|Lacosamide Tablet|"Active substance: Lacosamide
Pharmaceutical form: Tablet
Concentration: 50 mg and 100 mg
Route of Administration: oral administration"
2002251|NCT02408549|Drug|Lasosamide Oral Solution|"Active substance: Lacosamide
Pharmaceutical form: Oral solution
Concentration: 10 mg/ml
Route of Administration: Oral administration"
2002252|NCT02405962|Behavioral|ACT|Four sessions of group-based ACT integrated with asthma education. Each session will compose of pediatric asthma education based on guidelines of Global Strategy for Asthma Management and Prevention Revised 2011, plus group-based Acceptance and Commitment Therapy (ACT). Parents will learn to (1) increase acceptance of subjective experiences, (2) learn mindfulness of the present rather than an over-attachment to the past or future; (3) clarify personally held values and (4) move on in an effort to promote asthma care and parenting.
1502058|NCT02954510|Device|ferumoxytol|ferumoxytol used as imaging contrast agent for MRI
1502059|NCT02954497|Device|Surgical placement of the Jarvik 2015 VAD|The Jarvik 2015 VAD is a miniaturized, fully implantable, continuous flow left ventricular assist device.
1502060|NCT02954497|Device|Surgical placement of the EXCOR® Pediatric VAD|EXCOR® Pediatric VAD is an extracorporeal, pneumatically driven, pulsatile ventricular assist device.
1502061|NCT02954484|Drug|pregabalin|see arm/group description. Lyrica manufacture site: Pfizer Manufacturing Deutschland GmbH, Freiburg, Germany.
1502062|NCT02954484|Drug|Placebo|Placebo capsule containing lactose and MCC (no active ingredients).
1502063|NCT02954484|Drug|Etoricoxib|Etoricoxib 120mg per oral once daily on postoperative days 1,2,3. 'Arcoxia' manufacture site: MSD International GMBH, Singapore
1502064|NCT02954484|Drug|paracetamol|Paracetamol 1g per oral 6hourly on postoperative days 1,2,3. Manufacture site: SM Pharmaceuticals, Malaysia
1502065|NCT02954484|Drug|Morphine|"patient-controlled analgesia intravenous morphine sulphate on postoperative days 1,2,3.
Manufacture site: Hameln Pharma Plus GMBH, Hameln, Germany"
1502066|NCT02954484|Drug|Ropivacaine|Femoral block with ropivacaine 0.5% 30mls. Ropivacaine manufacture site: AstraZeneva AB, Sweden
1502067|NCT02954458|Drug|Teduglutide|0.05 mg/kg subcutaneous once daily
1502068|NCT02954458|Other|SOC|Standard safety assessments and adjustments in nutritional support
1502069|NCT02954445|Biological|Anti-BCMA-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived BCMA-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
1502070|NCT02954432|Device|transcranial Direct Current Stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
1502071|NCT02954432|Device|Transcranial Ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
1502072|NCT02954419|Other|No intervention|No intervention
1502073|NCT02954406|Drug|TAK-659|TAK-659 immediate release tablet
1502074|NCT02954406|Drug|Bendamustine|Bendamustine intravenous infusion
1502075|NCT02954406|Drug|Rituximab|Rituximab intravenous infusion
1502076|NCT02954406|Drug|Gemcitabine|Gemcitabine intravenous infusion
1502077|NCT02954406|Drug|Lenalidomide|Lenalidomide capsule
1502078|NCT02954406|Drug|Ibrutinib|Ibrutinib capsule
1502079|NCT02954393|Procedure|Scaling and root planing|SRP will be performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
1502080|NCT02954393|Drug|Metronidazole active phase|Metronidazole 400 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
1502081|NCT02954393|Drug|Metronidazole healing phase|Metronidazole 400 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
1502082|NCT02954393|Drug|Amoxicillin active phase|Amoxicillin 500 mg thrice a day for 14 days in the active phase of the periodontal treatment (beginning with the first SRP session).
1502083|NCT02954393|Drug|Amoxicillin healing phase|Amoxicillin 500 mg thrice a day for 14 days in the healing phase of the periodontal treatment (3 months after active phase).
1502084|NCT02954393|Drug|Placebos active phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the active phase (beginning with the first SRP session).
1502085|NCT02954393|Drug|Placebos healing phase|Amoxicillin and metronidazole placebos thrice a day for 14 days in the healing phase (3 months after active phase).
1502086|NCT02954380|Device|Zio|long term continuous monitoring
1502087|NCT02954367|Dietary Supplement|PROTEIN|Immediately (<10 min) after completing each training session (resistance training) participants will consume a beverage containing 20g of meat protein (10g) plus whey (10g) mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
1502088|NCT02954367|Dietary Supplement|CARBOHYDRATE|Immediately (<10 min) after completing each training session (resistance training), participants will consume a beverage containing about 20g of maltodextrin mixed with 200 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
1502089|NCT02954354|Drug|S-033188|2 to4 X 20-mg tablets taken orally
1502090|NCT02954354|Drug|Placebo to S-033188|2 to4 X 20-mg tablets taken orally
1502091|NCT02954354|Drug|Oseltamivir|75-mg capsules taken orally
1502092|NCT02954354|Drug|Placebo to Oseltamivir|Placebo capsules matching oseltamivir 75-mg capsules
1502093|NCT02954341|Device|CardioMEMS HF System|
1502094|NCT02954328|Device|tDCS|The active tDCS condition will consist of 20 min of continuous stimulation. This amount of stimulation is safe for healthy young and older adults and has been shown to induce acute beneficial changes in cortical excitability and cognitive functions.
1502095|NCT02954315|Other|Almonds|
1502096|NCT02954302|Procedure|PrPD with proximal Roux-en-y gastrojejunal anastomosis|the distal antrum was divided about 1 to 2 cm proximal to the pylorus ring, preserving more than 95% of the stomach. The proximal jejunum was divided approximately 2 to 4 cm distal to the duodeno-jejunal junction. After completion of the resection, the proximal end of the first loop of jejunum was then brought through the transverse mesocolon, and the gastrojejunal anastomosis (GJA) was performed in two layers by using 3-0 PDS sutures and 4-0 silk sutures in an end-to-side fashion. The jejunum was then divided 35 to 40 cm distal to the GJA, and the distal limb was brought separately through the transverse mesocolon to be placed in the duodenal bed for reconstruction of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA).
1502097|NCT02954302|Procedure|conventional PrPD|After completion of the pancreatojejunal anastomosis (PJA) and hepatojejunal anastomosis (HJA), a hand-sewn, isoperistaltic GJA was performed 25 to 30 cm distal to the HJA in two layers by using 3-0 polydioxanone (PDS) sutures and 4-0 silk sutures.
1502098|NCT02954289|Behavioral|Dietary intervention|"Session 1:The Breakfast Club: ways to increase the healthiness of breakfast and all meals.
Session 2: Calcium and Vitamin D -Keys to Bone Health
Session 3: Fruits and Veggies -Your New Best Friends
Session 4: Let's Talk About Fat
Session 5: Shopping Therapy
Session 6: Celebrity Chefs Share Their Secrets"
1502099|NCT02954276|Drug|Omexa Sublingual Sumatriptan tablet|75 mg
1502100|NCT02954276|Drug|Imitrex Oral Product|100 mg
1502101|NCT02954263|Drug|TD-1439|
1502102|NCT02954263|Drug|Placebo|
1502103|NCT02954250|Behavioral|Mindfulness Based Cognitive Therapy|The 8-week MMBCT protocol combines the practice of specific meditation techniques with cognitive therapy principles applicable to anxiety and depression. Each session will cover a meditation practice, as well as a relevant topic for discussion. The initial sessions will introduce general concepts of mindfulness (non-judgemental awareness, being in the moment, fostering curiosity, etc.), which will be expanded to more elaborate notions that are particularly relevant to anxiety, depression and suicidal ideations (recognizing thoughts are not facts, cultivating loving kindness for oneself, improving communication with others, etc.) Participants will be encouraged to practice the mindfulness techniques between sessions, a process that will be reviewed during groups in an ongoing fashion.
1502104|NCT02954237|Device|AMPLATZER™ Cardiac Plug|The AMPLATZER™ Cardiac Plug is a transcatheter, self-expanding device intended for use in preventing thrombus embolization from the left atrial appendage. The device is constructed from a nitinol mesh and consists of a lobe and a disc connected by a central waist. The device is designed to facilitate occlusion. The lobe has stabilizing wires to improve device placement and retention. The device has threaded screw attachments at each end for connection to the delivery and loading cables. The device has radiopaque markers at each end and at the stabilizing wires. Device Sizes: 16, 18, 20, 22, 24, 26, 28, and 30 mm (lobe diameter) Delivery System: AMPLATZER TorqVue® 45º x 45º (sheath sizes 9, 10, or 13 Fr)
1502105|NCT02954224|Other|CPAP treatment|Patients who are randomized to auto-titrating CPAP will use an auto CPAP device on postoperative days 1, 2, and 3
2002253|NCT02405962|Behavioral|An educational talk|One session of educational talk about pediatric asthma care, as usual practice.
1502177|NCT02953691|Drug|Maltodextrin (Placebo)|Maltodextrin is a polysaccharide commonly used as a food additive. It is produced from starch by partial hydrolysis.
1502178|NCT02953678|Drug|Ruxolitinib|
1502179|NCT02953678|Drug|Prednisone or methylprednisolone|Either oral prednisone or IV methylprednisolone may be used to begin corticosteroid treatment at the investigator's discretion.
1502180|NCT02953665|Drug|Liraglutide|Liraglutide 6 mg/ml once daily at a maximum dose of 1.8 mg
1502181|NCT02953665|Drug|Placebo|Placebo (for Liraglutide) 6 mg/ml once daily at a maximum dose of 1.8 mg
2002254|NCT02404220|Drug|Entospletinib|Entospletinib tablet(s) administered orally
2002255|NCT02404220|Drug|VCR|Vincristine (VCR) administered intravenously
2002256|NCT02404220|Drug|Dexamethasone|Dexamethasone tablet(s) administered orally
2002257|NCT02404220|Drug|CNS Prophylaxis|CNS prophylaxis per institutional standard
2002258|NCT02395094|Behavioral|Child Life|"Child Life preparation in surgical daycare can include:
role-play using dolls and medical equipment (either toy doctor kits or true medical materials)
the use of books/storyboards that show pictures of operating room and daycare routines
teaching & rehearsing coping and relaxation skills such as deep breathing and guided imagery
age-appropriate explanation of what to expect throughout the day in SDCU"
2002259|NCT02395159|Device|Prevena™ IMS|"Prevena™ IMS is intended for the management of the surgical incision environment and surrounding healthy skin in patients with a risk of postoperative complications such as infections. This entails the maintenance of a closed environment around the incision by applying a negative pressure wound therapy system.
The corresponding dressing is known under the name Prevena™ Dressing. The layer closest to the skin comprises silver foil, which reduces the microbial colonisation of cells."
1502108|NCT02954198|Drug|Tacrolimus|goal trough level 5-12ng/mL
1502109|NCT02954198|Drug|Prednisone|goal dose 5mg QD
1502110|NCT02954198|Drug|Mycophenolate mofetil|goal dose 1g BID
1502111|NCT02954198|Drug|Everolimus|goal trough level 3-8ng/mL
1502112|NCT02954185|Device|WellClub|
1502113|NCT02954185|Behavioral|Standard Therapy|
1502114|NCT02954172|Drug|Bevacizumab in combination with Paclitaxel/Carboplatin|Drug Bevacizumab 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
1502115|NCT02954172|Drug|Avastin in combination with Paclitaxel/Carboplatin|Drug Avastin 15mg/kg in combination with Paclitaxel/Carboplatin 6 cycles then maintains at 7.5 mg/kg
1502116|NCT02954159|Drug|Tacrolimus|Oral tacrolimus tablet starting at 0.05mg/kg twice daily, with dose adjustments aiming for serum trough levels of 10-15 ng/ml during the first 2 weeks, and 5-10ng/ml subsequently.
1502117|NCT02954159|Drug|Vedolizumab|Intravenous Vedolizumab 300 mg at week 0, 2 and 6 followed by the same dose every 8 weeks. This drug will be given as per standard of care.
1502118|NCT02954159|Other|Placebo|Patients will be randomized 1:1 in Treatment arm (receive Tacrolimus) and Placebo Arm.
1502119|NCT02954146|Behavioral|Connectd mobile application|Connectd is a mobile application that collects and automatically analyzes input from patients with PTSD/TBI, as well as their families, for clinician review. The app will aggregate patient and family input on current issues, relationship stressors, and situational stressors to better focus (personalize) treatment as well as to more efficiently and accurately understand key factors and root causes. In addition, the app provides informational resources for veterans and family regarding treatment options and mental health supports.
1502120|NCT02954133|Device|Invisalign (7 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 7 days.
1502121|NCT02954133|Device|Invisalign (5 day)|Patients are are fitted with a ClinCheck plan by Align Technology by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office. Aligners are switched every 5 days.
1502122|NCT02954133|Device|OrthoPulse|Daily 10 minute (5 minutes per arch) OrthoPulse treatments are administered at home.
1502123|NCT02954120|Other|no intervention provided|
1502124|NCT02954107|Other|MRI|
1502125|NCT02954107|Other|24h-EEG + video|
1502126|NCT02954107|Other|Neuropsychological tests|
1502127|NCT02954081|Drug|Phase I: Fumaric acid esters. Phase II: Apremilast|
1502128|NCT02954068|Drug|IV Oxytocin + IM placebo|
1502129|NCT02954068|Drug|IM Oxytocin + IV placebo|
1502130|NCT02954055|Drug|Paclitaxel|Arm A
1502131|NCT02954055|Drug|Cyclophosphamide|Arm B
1502132|NCT02954055|Drug|Capecitabine|Arm B
1502133|NCT02954055|Drug|Vinorelbine|Arm B
1502134|NCT02954042|Device|Pelvital probe|Pelvital probe
1502135|NCT02954042|Device|Placebo Probe|Placebo Probe
1502136|NCT02954029|Device|ezClot (hemostasis pad)|ezClot pad uses chitosan, a deacetylated complex carbohydrate derived from the naturally occurring substance chitin, to accelerate blood clotting.
1502137|NCT02954029|Device|BloodSTOP ix pad|BloodSTOP® pad is an etherized and oxidized regenerated cellulose matrix that achieves hemostasis by activating the intrinsic coagulation pathway.
1502138|NCT02954029|Device|Rotary compression device|Rotary compression device consists of a plastic arch and a rotary screw to deliver local pressure by moving the silicone compression pad.
1502139|NCT02954016|Device|ePass|Subject is implanted with the device for up to 3 years.
1502140|NCT02954003|Device|Endo Bypass System|Subject is implanted with the device for up to 3 years.
1502141|NCT02953990|Behavioral|MOMS Program|
1502142|NCT02953977|Behavioral|Diabetes Prevention Program|An adapted version of the Diabetes Prevention Program will be delivered to intervention participants.
1502143|NCT02953964|Other|Behavioral: perceptual-based memory encoding training|Participants are trained in the use of perceptual-based memory encoding strategies, inclusive of visual imagery and the method of loci. Visual imagery involves the creation and encoding of mental images, while the method of loci refers to linking these images with specific places to facilitate memory (Simon et al., 2012). Participants are taught to visualise performing each step of a task in a familiar environment, such as in their home (Liu et al., 2009). After participants can correctly visualise the entire task, they then progress to actually performing the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
1502182|NCT02953652|Drug|HBI-8000|Orally twice weekly
1502183|NCT02953639|Drug|Basmisanil|Participants will receive either 80 milligrams (mg) or 240 mg of basmisanil twice daily orally for 24 weeks.
1502184|NCT02953639|Drug|Placebo|Participants will receive placebo-matched to basmisanil orally twice daily for 24 weeks.
1502224|NCT02953366|Drug|Mometasone spray nasal|The patient should administer 1 spray in each nostril once daily.
1502278|NCT02953106|Drug|Azelastine-Fluticasone Nasal|137 micrograms azelastine hydrochloride / 50 micrograms fluticasone propionate
1502279|NCT02953106|Drug|Placebos|Placebo nasal spray
1502280|NCT02953093|Drug|Acarbose|see arm description
1502281|NCT02953093|Other|Placebo|See arm description
2002260|NCT02395159|Other|sterile plaster dressings|standard wound management method of sterile plaster dressings
2002261|NCT02393001|Other|Dermatology patients|Cleanse an area of unafflicted (control) skin with a cotton 2 x 2 dampened with saline.
2002262|NCT02393001|Other|Dermatology patients|Cleanse a suspicious lesion (potential melanoma) with a saline cotton swab.
1502144|NCT02953964|Other|Behavioral: semantic-based memory encoding training|Participants are asked to encode the steps of a task by forming an association of the steps and sequence. Participants are trained in the use of the chunking association method and honeycomb concept and perform different tasks each week, implementing this encoding strategy (Lim et al., 2012). The chunking association method breaks down information into smaller parts and helps with the encoding and retrieval of information. The honeycomb concept allows the steps to form a story in relation to place, time, characters, problem and solution and the story is verbalised. Participants then complete the task. During the intervention sessions, 2-3 tasks are covered each session, and these tasks become progressively difficult as the weeks progress. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
1502145|NCT02953964|Other|Behavioral: Cognitive stimulation group (control group)|Participants receiving cognitive stimulation intervention. It consists of eight sessions that train participants' visual attention and memory, auditory attention and memory and their application in daily activities. Two sessions are also given which allow for participants to apply the training practically in their daily lives. The intervention lasts for 10 weeks with one session every week. Each session runs for 90 minutes. A follow-up home training program is run once a week for 30 minutes with the participant and their care-giver.
1502146|NCT02953951|Other|blood transfusion|blood transfusion different sources
2002263|NCT02393001|Other|Dermatology patients|This intervention follows the standard of care for patients with a suspicious skin lesion (potential melanoma) the physician plans to biopsy. The alcohol swab used to prep the site will be stored for testing rather than discarded.
2002264|NCT02393001|Other|Dermatology patients|Cleanse an area of unafflicted (control) skin with an alcohol swab.
1502149|NCT02953912|Procedure|Reciproc single-file|The Reciproc is a single-file nickel-titanium systems , made of a special nickel-titanium (NiTi) alloy called M-Wire created by innovated thermal treatment process which increases flexibility and improved resistance to cyclic fatigue
1502150|NCT02953912|Procedure|One Shape single-file|One Shape is one of the few single file made of austenite 55- NiTi alloy characterized by different cross sectional designs ,it is used in continuous clockwise rotation for a quick and safe root canal preparation due to its flexibility and minimal fatigue.In addition to , the electropolished safety tip instrument for enhanced cutting efficiency and it is delivered in a sterile blister for single use.
1502151|NCT02953899|Behavioral|Contingency Management|In addition to Cognitive Behavioural Therapy, this intervention uses small incentives to reinforce study attendance and gambling abstinence.
1502152|NCT02953899|Behavioral|Cognitive Behavioural Therapy|This intervention uses psychoeducation, behavioural strategies, and cognitive restructuring to assist the participant in their efforts to become abstinent from gambling.
1502153|NCT02953886|Device|Silver Diamine Fluoride (SDF)|No caries removal will take place. Bacterial samples will be collected using Gracey curettes at the initial visit before application of SDF and one month after. The tooth will be dried and SDF will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet
1502154|NCT02953873|Drug|Tacrolimus Extended Release Capsule|goal trough 5 - 12ng/mL
1502155|NCT02953873|Drug|Mycophenolate mofetil|≥500mg twice a day
1502156|NCT02953873|Drug|Prednisone|goal dose 5mg daily
1502157|NCT02953873|Drug|Mycophenolate Sodium|≥360mg twice a day
1502158|NCT02953860|Drug|Fulvestrant with Enzalutamide|500mg of Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC) and 160mg of Enzalutamide will be given PO daily. Patients will receive a tumor biopsy at the start of treatment and 4 weeks after the start of treatment, with an optional 3rd biopsy at the end treatment.
1502159|NCT02953847|Drug|Rimactane|150 mg capsules, Sandoz MCC registration # A/20.2.3/784
1502160|NCT02953847|Drug|Rifafour e-275|Rifampicin/isoniazid/pyrazinamide/ethambutol 150/75/400/275 mg This 4-drug FDC is the most widely used 4-drug FDC in South Africa with an estimated 100% of the SA DOH tender.
1502161|NCT02953847|Drug|Rimactazid 150/75|Rifampicin/isoniazid 150/75 mg This 2-drug FDC is one of 2 widely used 2-drug FDCs in South Africa, with an estimated 30% of the SA DOH tender. Rifinah® made by Sanofi-Aventis holds about 70% of the tender, however as the Sanofi-Aventis 4-drug FDC will also be evaluated.
1502162|NCT02953834|Drug|kisspeptin 112-121|Dose: 0.313-12.5 mcg/kg Duration: up to 16 hours
1502163|NCT02953834|Other|Insulin Resistance Test|Eat or drink a standard meal OR drink a standard drink containing 75 grams of sugar
1502164|NCT02953834|Other|Placebo|Receive intravenous fluids for up to 16 hours that do not contain any study drug
1502165|NCT02953821|Drug|Repository corticotropin injection|
1502166|NCT02953821|Drug|Placebo gel|
1502167|NCT02953808|Drug|Placebo|0.9% weight by volume (w/v) saline solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2).
1502168|NCT02953808|Drug|GSK2315698|200 mg/mL stock solution for intravenous infusion over 1 hour (in Cohort 1) or over 15 hours (in Cohort 2). The stock solution will be diluted to obtain dosage levels of 10 mg/hr, 20 mg/hr, or 40 mg/hr.
1502169|NCT02953782|Drug|Hu5F9-G4|Hu5F9-G4 will be administered weekly.
1502170|NCT02953782|Drug|Cetuximab|Cetuximab will be administered weekly.
1502171|NCT02953756|Radiation|Gamma Knife radiosurgery|Gamma Knife radiosurgery will be performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the tumor volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target
1502172|NCT02953743|Drug|Lenvatinib|Lenvatinib 4 mg capsules will be administered orally, once daily continuously 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
1502173|NCT02953730|Drug|PEG-rhG-CSF|
1502174|NCT02953717|Radiation|Gamma Knife radiosurgery|GKRS is performed with a Leksell Gamma Knife® Icon, Elekta Instruments, AB. Depending upon the volume, a dose of 18-25 Gy will be prescribed with 99-100% coverage of the target.
1502175|NCT02953717|Radiation|Whole Brain Radiation Therapy|Patients in the WBRT group will receive 4 Gy x 5 fractions (total of 20 Gy) in one week, which is a commonly utilized treatment schedule according to Dutch guidelines.
1502176|NCT02953691|Drug|Galacto-Oligosaccharide|Mixture produced from lactose utilizing the transgalactosidic activity of Bifidobacterium bifidum NCIMB 41171 beta-galactosidase
2002265|NCT02390752|Drug|PLX3397|Take oral drug daily for a 28 day cycle
1502185|NCT02953626|Behavioral|Mother Matters Online Postpartum Support Group|"Mother Matters is a 10-week online support group for women with postpartum depression. It involves: 1) A private, online forum that can be accessed by participants 24-hours per day. During regular business hours (9:00 am to 5:00 pm on weekdays) it is moderated by a psychotherapist, and there is a weekly moderated live chat hour; 2) Weekly topics with readings are provided with questions to prompt discussion on the online forum. Topics incorporate symptom management (i.e. Interpersonal Therapy, Cognitive Behavioural Therapy) and affect regulation strategies (i.e. Mindfulness, DBT) with a supportive counselling approach. External resources related to each week's topic, are also shared."
1502186|NCT02953613|Device|NIRS/IVUS|Cardiac catheterization using infraredx
1502187|NCT02953600|Dietary Supplement|Standard Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg.
1502188|NCT02953600|Other|Zero Spirulina Platensis|the zero pill-taken group is a comparison for two other groups.
1502189|NCT02953600|Dietary Supplement|Double Dose Spirulina Platensis|As previous small scale of clinical trial results in HBV patients provided by Far East Bio-Tec Company, lamivudine combined with oral Spirulina platensis would also improve the sero-conversion rates of HBeAg. Hence, the investigators would like to see if the investigators could improve sero-conversion rates much faster by taking double dose of Spirulina platensis.
1502190|NCT02953587|Procedure|Oral Glucose Tolerance Test (OGTT)|Subjects will have glucose administered enterally and blood will be drawn to measure its kinetics.
1502191|NCT02953587|Drug|Human Ghrelin|Human ghrelin will be administered by IV at two of the four study visits in conjunction with the OGTT.
1502192|NCT02953587|Drug|Saline|Saline Infusion will be administered by IV at two of the four study visits in conjunction with the OGTT to serve as a placebo comparator for the human ghrelin infusions.
1502193|NCT02953574|Procedure|daily sleep enhancement nursing protocol|
1502194|NCT02953561|Drug|Avelumab|"Approximately 60 minute infusion by vein on Day 1 and day 14 (+/-3 days) of each 5-azacytidine cycle for the first 4 cycles or until CR (whichever occurs earlier) followed by a maintenance regimen (one dose of avelumab on day 1 of each cycle of 5-azacytidine)
Starting dose of Avelumab 3.0 mg/kg."
1502195|NCT02953561|Drug|5-azacytidine|5-azacytidine 75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) for 7 days of every cycle with daily schedule of 7 consecutive days (Days 1-7) or for days 5-2-2 which is 5 consecutive weekdays (Days 1-5) with rest on the 2 weekend days (Days 6 and 7) and then dosing the first two weekdays of the next week (Days 8 and 9) of each 28-day cycle as determined by treating physician
2002266|NCT02391961|Drug|Dalfampridine|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
1502197|NCT02953535|Drug|Magicbuvir|1 tablet contains 400 mg sofosbuvir
1502198|NCT02953535|Drug|Sovaldi (fist dose)|1 tablet contains 400 mg sofosbuvir
1502199|NCT02953535|Drug|Sovaldi (second dose)|1 tablet contains 400 mg sofosbuvir
1502200|NCT02953522|Other|191 mcg/day of Folate|Diet containing 191 mcg / day of Folate
1502201|NCT02953522|Other|90 mcg / day of Folate|Diet containing 90 mcg / day of Folate
1502202|NCT02953509|Drug|Hu5F9-G4|Hu5F9-G4 infusions will be administered weekly.
1502203|NCT02953509|Drug|Rituximab|Rituximab infusions will be administered weekly for one cycle (28 days) and then every 4 weeks up to 6 cycles.
1502204|NCT02953496|Drug|vonapanitase|Vonapanitase will be administered to the target lesion of the SFA or PA via percutaneous needle injection under ultrasound guidance.
1502205|NCT02953483|Other|Red blood cells|Packed red blood cells to final hematocrit of 14%
1502206|NCT02953470|Behavioral|Individual tailored functional exercise|Receive individual tailored exercise to increase ability to perform everyday activities through increased physical function and self-efficacy in relation to be able to exercise and decreased pain-related beliefs such as fear of falling, catastrophizing thoughts and fear of movement.
1502207|NCT02953470|Behavioral|Standard care|Receives written and oral advice about physical Activity and the benefits of being physically active by one visits from a physiotherapist. Than will the participants receive Telephone reminder about following the advice once a week during intervention week 1-8 and 10.
1502208|NCT02953457|Biological|Durvalumab|Given IV
1502209|NCT02953457|Other|Laboratory Biomarker Analysis|Correlative studies
1502210|NCT02953457|Drug|Olaparib|Given PO
1502211|NCT02953457|Biological|Tremelimumab|Given IV
1502212|NCT02953444|Other|Thirty-Second Mindfulness Practice|
1502213|NCT02953444|Other|Three-Minute Mindfulness Practice|
1502214|NCT02953431|Device|Positive Expiratory Pressure|Positive Expiratory Pressure will be administered through a PEEP valve attached to a mask
1502215|NCT02953418|Device|Radiofrequency ablation|RFA
1502216|NCT02953405|Drug|Clopidogrel|
1502217|NCT02953392|Device|Anorganic Bovine Bone Graft Material|Anorganic bovine bone graft material is intended for augmentation or reconstructive treatment of the alveolar ridge, filling periodontal defects, filling defects after root resection, apicoectomy, and cystectomy, filling extraction sockets to enhance preservation of the alveolar ridge, and elevation of maxillary sinus floor.
1502218|NCT02953392|Device|Collagen Membrane|Collagen dental wound dressing is intended for the management of oral wounds and sores, including; dental sores, oral ulcers, periodontal surgical wounds, suture sites, burns, extraction sites, surgical wounds, and traumatic wounds.
1502219|NCT02953392|Device|Shelta Platform Switching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and/or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
1502220|NCT02953392|Device|Shelta Platform Matching Premium Implants|Shelta implant systems are intended for immediate placement and function on single tooth and /or multiple tooth applications when good primary stability is achieved, with appropriate occlusal loading, in order to restore chewing function.
1502221|NCT02953379|Drug|EMS Mometasone gel|The patient should administer 2 spray in each nostril, once daily.
1502222|NCT02953379|Drug|Mometasone spray nasal|The patient should administer 2 spray in each nostril, once daily.
1502223|NCT02953366|Drug|EMS Mometasone gel|The patient should administer 1 spray in each nostril once daily.
1502225|NCT02953353|Device|Active transcranial direct current stimulation (tDCS)|Participants will receive 10 daily sessions (phase 2) and 3 times a week (phase 3) of tDCS (2mA, 30 min per session). The tDCS montage will target the left dorsolateral prefrontal cortex (DLPFC) (anode: F3 based on the 10:20 system; cathode over the right supraorbital area). For stimulation the investigators will use 5x5cm sponge pads that will be soaked in 0.9% saline during the sessions.
1502226|NCT02953353|Other|Hypocaloric diet|During phase 3, participants will undergo a supervised hypocaloric diet intervention for 2 weeks based on a low-calorie diet (LCD) providing a hypocaloric diet based in 20% reduction from total energy expenditure (TEE). The diet will be individualized on the basis of physical activity levels, age for each participant. This intervention will be be conducted at an inpatient, well-controlled setting to guarantee adherence to the diet. Here the diet intervention will be administered in combination with tDCS. tDCS will be applied every other day (Monday, Wednesday, Friday) over the course of these two weeks.
1502227|NCT02953353|Other|Sham transcranial direct current stimulation (tDCS)|Subjects in the control group will receive sham stimulation (placebo) (similar procedure and duration as real tDCS, but here electric current flows for 30 s only, to mimic the subjective sensations that occur with active tDCS).
1502228|NCT02953340|Drug|SPI-2012|Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle
1502229|NCT02953340|Drug|Pegfilgrastim|Subcutaneous injection administered on Day 2 of each cycle.
1502230|NCT02953340|Drug|Docetaxel|75mg/m^2 IV infusion administered on Day 1 of each cycle
1502231|NCT02953340|Drug|Cyclophosphamide|600mg/m^2 IV infusion administered on Day 1 of each cycle
1502232|NCT02953327|Biological|Bacille Calmette-Guerin|
1502233|NCT02953327|Biological|BCG solvent|
1502234|NCT02953314|Drug|VX-661|
1502235|NCT02953314|Drug|Ivacaftor|
2002267|NCT02391961|Drug|Placebo|10-week randomized, placebo controlled, double-blind, crossover trial, which includes a period of wash out of two weeks between treatment with dalfampridine and placebo.
2002268|NCT02388659|Device|3 Tesla scanning|Approximately 38 brain tumor patients with IDH mutated gliomas and 50 patients with non-glioma disease will be scanned.
1502238|NCT02953275|Drug|vedolizumab|standard of care
1502239|NCT02953275|Drug|Pentoxifylline|added to vedolizumab
1502240|NCT02953275|Drug|placebo|added to vedolizumab
1502241|NCT02953262|Behavioral|Supported Adopted Intervention|One on one session, group training session, follow-up support
1502242|NCT02953236|Procedure|Instrumented massage|The first group will receive a 20 min session of instrumented massage on back and neck areas. Subjects will be in prone position and physical therapist will applied instrumental massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
1502243|NCT02953236|Procedure|Manual massage|The second group will receive a 20 min session of manual massage on back and neck areas. Subjects will be in prone position and physical therapist will applied manual massage in a protocolised way from low back until neck muscles, both in left and right side of the body.
2002269|NCT02390635|Drug|18F-FDG|Participants receive an injection of 18F-FDG prior to whole body magnetic resonance imaging.
2002270|NCT02390635|Procedure|Whole Body Magnetic Resonance Imaging (MRI)|Participants receive whole body MRI.
2002271|NCT02390635|Drug|Gadolinium|Participants receive injection of gadolinium contrast agent 2 mL/sec and 0.1 mmol/kg of body weight during whole body MRI.
2002272|NCT02390635|Procedure|Positron Emission Tomography/ Computed Tomography (PET/CT)|PET/CT performed following whole body MRI.
2002273|NCT02384200|Drug|nitrofurantoin monohydrate/macrocrystalline capsules|1 week course of preoperative nitrofurantoin monohydrate/macrocrystalline capsules 100 milligrams twice daily
2002274|NCT02384200|Drug|ampicillin|IV (2 g)
2002275|NCT02384200|Drug|gentamicin|IV (5 mg/kg)
2002276|NCT02384200|Drug|vancomycin|IV (1 g)
2002277|NCT02384200|Drug|ceftriaxone|IV (2 g)
2002278|NCT02380118|Drug|Olanzapine|Intramuscular injection
2002279|NCT02380118|Drug|Haloperidol|Intramuscular injection
1502258|NCT02953197|Radiation|FDG-PET guided radiation dose escalation|Selective dose escalation
1502259|NCT02953184|Drug|Pegylated Liposomal Doxorubicin|35mg/m2 iv drop during the first 4 cycles every three week
1502260|NCT02953184|Drug|Cyclophosphamide|600mg/m2 IV drop during the first 4 cycles every three week
1502261|NCT02953184|Drug|Taxotere|100mg/m2 IV drop during the last 4 cycles every three week
1502262|NCT02953184|Drug|Dexrazoxane (DZR)|DZR will be administrated for protecting Cardiac toxicity in the group of Active comparator.
1502263|NCT02953184|Drug|vitamin B|Vitamin B will be administrated for protecting HFS in PLD group
1502264|NCT02953184|Drug|Doxorubicin|60mg/m2 Doxorubicin IV drop during the first 4 cycles every three week
1502265|NCT02953184|Procedure|Breast Conserved Surgery|Patients will undergo Breast Conserved Surgery if the tumor/breast ratio is proper and she demands to conserve the breast after 8 cycles of chemotherapy
1502266|NCT02953184|Procedure|Modified Radical Mastectomy|Patients will undergo Modified Radical Mastectomy if she does not keep her breast after 8 cycles of chemotherapy
1502267|NCT02953184|Procedure|Sentinel Lymph Node Biopsy（SLNB）|Patients will undergo Sentinel Lymph Node Biopsy（SLNB） if the evaluation of lymph node are negative after 8 cycles of chemotherapy
1502268|NCT02953171|Other|Raw, lacto-fermented sauerkraut|Sauerkraut fermentations have been shown to contain a broad range of microorganisms, including Leuconostoc mesenteroides, Lactobacillus plantarum, Leuconostoc citreum, Leuconostoc argentinum, Lactobacillus paraplantarum, and Lactobacillus coryniformis. Some of these bacteria, such as Lactobacillus plantarum, are classified as probiotics.
1502269|NCT02953171|Dietary Supplement|Mutaflor|The probiotic Escherichia coli Nissle 1917, registered in Germany as the medicinal product Mutaflor, possesses a unique combination of fitness and survival factors.
1502270|NCT02953171|Other|Pasteurized sauerkraut|Sauerkraut without live bacteria.
1502271|NCT02953171|Other|Placebo capsule|Capsules without probiotics
1502272|NCT02953158|Other|Haas Avocado|Hypocaloric weight loss diet
1502273|NCT02953158|Behavioral|Dietary Counseling|Dietary Counseling
1502274|NCT02953145|Drug|Tisseel|
1502275|NCT02953132|Drug|MT-4129|
1502276|NCT02953132|Drug|Placebo|
1502277|NCT02953119|Other|Prehabilitation|
1502283|NCT02953067|Procedure|Open reduction and internal fixation|Stratum 1: Conservative treatment versus open reduction and internal fixation Stratum 2: Open reduction and internal fixation versus arthrodesis
1502284|NCT02953067|Procedure|Primary arthrodesis|Primary arthrodesis versus ORIF
1502285|NCT02953067|Procedure|Conservative treatment|Conservative treatment versus open reduction and internal fixation
2002280|NCT02380118|Drug|Midazolam|Intramuscular injection
1995833|NCT02642393|Drug|Placebo|capsules containing ~500 mg of lactose and appearing indistinguishable from inosine capsules
1502288|NCT02953041|Drug|Glycopyrronium|long-acting muscarinic antagonist
1502289|NCT02953041|Drug|Indacaterol|ultra long-acting beta agonist
1502290|NCT02953028|Device|CPAP|Auto-CPAP-machine for treating Obstructive Sleep Apnea With positive airway pressure
1502291|NCT02953028|Device|Mandibular Advancing Splint|Oral Appliance for providing an open upper airway as a mean of treating Obstructive Sleep Apnea
1502292|NCT02953015|Behavioral|Manipulative articulatory (ART) and myofascial techniques|Three manipulative articulatory (ART) and myofascial techniques will be performed to improve cervical and thoracic spine joint mobility and reducing soft tissue stiffness in the cervico-thoracic spine. ART technique is a low velocity to high amplitude technique where each joint is carried through its full motion to increase range of movement. The activating force is either a repetitive springing motion or repetitive concentric movement of the joint through the restrictive barrier. Myofascial technique is directed at the muscle and fascia treatment. It engages continual palpatory feedback to achieve release of myofascial tissues. During each treatment session, each technique will be carried out for 10 minutes including 2 minutes of resting.
1502293|NCT02953015|Device|Transcutaneous Electrical Nerve Stimulation|Transcutaneous Electrical Nerve Stimulation (TENS) of the upper trapezius muscle will be applied by a portable machine Master 932 (Elettronica Pagani SRL, Milan, Italy) that generates symmetric, bi-phasic rectangular pulses with 140μ sec duration. The current frequency will be set at 150 Hz and intensity will be increased up to patient's perception of paresthesia. The negative electrode will be placed on the active TrPs of the upper trapezius muscle and the positive one was on acromial tendon insertional site. The total duration of each application will be 20 minutes. Treatment frequency and duration will be the same of the EG treatment (1 session/week for 4 weeks). Each session will consist of 20 min of TENS and 10 min of resting in sitting position with the head lean on a pillow.
1502294|NCT02953015|Drug|OnabotulinumtoxinA (Prophylaxis therapy)|Prophylaxis therapy with OnabotulinumtoxinA according to the PREEMPT protocol (155U every three months into 31 injection site).
1502295|NCT02953002|Device|Calibrated Automated Thrombogram (CAT)|The Calibrated Automated Thrombogram (CAT). Thrombogram describes the concentration of thrombin in clotting plasma and is therefore a general physiologic function test of the thrombotic hemostatic system. The CAT measures thrombotic as well as bleeding tendency.
1502297|NCT02952976|Device|Abthera|ABThera group technique the dressing will be done according to the description and the manufacturer's instructions (Acelity, San Antonio, TX).
1502298|NCT02952976|Device|Barker|In Barker Group a fenestrated plastic will be used and that will be in contact with viscera followed by four pads with a suction drain and an adhesive finishing layer.
1502299|NCT02952963|Drug|Chenodeoxycholic Acid|
1502300|NCT02952963|Drug|Colesevelam|
1502301|NCT02952950|Other|Oralstimulation|The intervention group granted in total 1 hour instructions in a program of oral stimulation by one of two occupational therapists with experience in oral stimulation of preterm infants. The first guidance for parents has duration of approximately half an hour and then follow-up once or twice, depending on the needs of the family. To maintain consistent intervention over time is the program of oral stimulation written in a script, where the family also must record the following variables: date and time of oral stimulation. In occupational therapy the guidance and in the script examines the signs that the infant exhibits when it is ready / not ready for stimulation. The family also sees a movie where these signs and the program of oral stimulation review auditory and visual.
1502302|NCT02952937|Drug|GLA5PR GLARS-NF3 tablet 300mg|A new formulation(3rd.) of Pregabalin CR tablet
1502303|NCT02952937|Drug|GLA5PR GLARS-NF1 tablet 300mg|A new formulation(1st.) of Pregabalin CR tablet
1502304|NCT02952924|Drug|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO7049389 or matching placebo
1502305|NCT02952924|Other|Placebo|Placebo matching to RO7049389 will be administered as per schedule described in individual arm.
1502306|NCT02952924|Drug|RO7049389|RO7049389 will be administered as per schedule described in individual arm.
1502307|NCT02952911|Device|Smartphone and Smartwatch|Multiple sclerosis participants and healthy controls are required to wear the smartwatch; and to carry smartphone preferably in a median position in a belt bag, or alternatively in their pocket as they go about their daily routine.
1502308|NCT02952898|Drug|GDC 695|GDC 695 is a topical gel.
1502309|NCT02952898|Drug|Diclofenac Sodium Gel, 3%|Diclofenac sodium gel, 3% is an FDA-approved drug.
1502310|NCT02952898|Drug|Vehicle gel|Vehicle topical gel contains 0.0% of active drug and is color matched to the other two active test drugs.
1995834|NCT02641600|Device|Elastic stockings|Use of elastic stockings to alleviate patient symptoms
1502312|NCT02952872|Behavioral|Brief Tablet-based Intervention to Address Heavy Alcohol Use|The intervention will be be tablet-based and take approximately 20 minutes to complete. Content will focus on heavy alcohol use.
1502313|NCT02952859|Other|Irreversible electroporation|
1502314|NCT02952846|Other|Algorithm for tapering og analgosedation|Algorithm for tapering og analgosedation
1502315|NCT02952833|Drug|Saline|Sodium chloride solution.
1502316|NCT02952833|Biological|Zika Virus Purified Inactivated Vaccine (ZPIV)|Zika Virus Purified Inactivated Vaccine with aluminum hydroxide adjuvant.
1502317|NCT02952820|Drug|lemborexant|
1502318|NCT02952820|Drug|Placebo|
1995835|NCT02641600|Device|Placebo stockings|Placebo stocking with pressure applied to the legs
1995836|NCT02640703|Biological|Infanrix + Prevenar 13|Different time of application
1995837|NCT02641366|Device|Electromagnetic tracking|The electromagnetic tracking system will precisely measure the position of a patient's upper extremity in space during routine neurologic examination.
1502321|NCT02952794|Procedure|endoscopic submucosal dissection (ESD) and endoscopic mucosal band ligation (EMBL) for early cancer|
1502322|NCT02952781|Device|EKG Patch monitors (Zio and Carnation)|Each patient will be provided with both a Zio-XT Patch monitoring system and the CAM system and will be instructed to wear both simultaneously for 7 days.
1502323|NCT02952768|Behavioral|ultrasound training|Through the ultrasound-circulation-airway-breathing training curriculum to integrate the ultrasound into clinical practice.
1502324|NCT02952755|Drug|Co-administration of DWC20155/DWC20156|
1502325|NCT02952755|Drug|DWC20162|
1502326|NCT02952742|Drug|Black Cohosh|Vital Nutrients Black Cohosh Extract
1502327|NCT02952742|Other|Placebo|Inactive comparator resembling the Black Cohosh formulation in appearance. Ingredients include: cellulose; caramel color; powdered yellow dye; and powdered red dye.
1502328|NCT02952729|Drug|XMT-1522|one intravenous dose administered in-clinic every 21 days
1502329|NCT02952716|Biological|Human cord blood mononuclear cell|The patients were treated by human cord blood mononuclear cell through subarachnoid space
1502330|NCT02952716|Other|hyperbaric oxygen|The patients were treated by hyperbaric oxygen
1502331|NCT02952703|Behavioral|brief pre-delivery smoking cessation counseling|
1502332|NCT02952703|Behavioral|additional pre-delivery smoking cessation counseling|
1502333|NCT02952703|Behavioral|post- delivery smoking cessation counseling|
1502334|NCT02952703|Behavioral|incentives|
1502335|NCT02952690|Device|Glidescope® with tip manipulated stylet|The intubating style is curved in accordance with the curve of GVL blade and the distal tip of style is additionally bended to the left (15-20 degree)
1502336|NCT02952690|Device|Glidescope® with standard-curved tip|The style is curved in accordance with the curve of GVL blade
1502337|NCT02952677|Behavioral|Remind-to-move|Participants were required to wear sensory cueing wristwatch devices with vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
1502338|NCT02952677|Behavioral|Sham|Participants were required to wear sensory cueing wristwatch devices without vibration emitted on the affected arm for 3 consecutive hours daily, for a total of 4 weeks, at any time during the day, and received usual care as well.
1502339|NCT02952677|Other|Control|Participants received usual care
1502340|NCT02952664|Behavioral|PUMP Monitoring|A video camera will be placed in each subject room for recording the repositioning events to correlate the monitor signals with the actual subject repositioning captured by the video.
1502341|NCT02952651|Procedure|Pulse oximeter|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, POP waveforms are obtained from each index finger, which pulse oximeter sensor is applied by increasing contact force (from 0 to 1.4N, being increased by 0.2-0.3N). Then intravenous crystalloid 10 mL/kg is infused for 15 min.
1502342|NCT02952625|Other|Imaging|Single arm Imaging (PET/MR) study
1502343|NCT02952599|Drug|Edoxaban|Prescribed according to approved label
1502344|NCT02952586|Drug|Avelumab|Avelumab + SOC Chemoradiation
1502345|NCT02952586|Other|Chemoradiation|Cisplatin + Radiation Therapy
1502346|NCT02952573|Drug|JNJ-42756493|Once daily dosing
1502347|NCT02952573|Drug|Dexamethasone|Cycle 1 and 2: OD dosing on days 1-4, 9-12, and 17-20;Cycle 3: OD dosing on days 1, 8, 15, 22
1502348|NCT02952560|Other|Ultrasound scan|Ultrasound scanning examinations will be performed twice (pre-CT scan and post CT-scan). Each examination will be performed by two observers who are blinded to each other's measured values.Patients will be asked to place a small sip of water (20 mL)in their mouth and keep the mouth open during the imaging. A second ultrasound examination of each patient by the two observers will be performed after the CT-scan.
1502349|NCT02952547|Drug|Co-administration of DWC20155 and DWC20156|
1502350|NCT02952547|Drug|DWJ1366 Tab.|
1502351|NCT02952534|Drug|Rucaparib|Rucaparib will be administered daily
1502352|NCT02952521|Procedure|Blood Draw|
1502353|NCT02952521|Procedure|Tumor Tissue Biopsy|
1502355|NCT02952495|Behavioral|Online alcohol educational class|"Participants will be asked to review an online alcohol education class. This is a web-based patient educational program designed to prevent hazardous and harmful drinking in older adults. The project's specific objectives are to 1) provide reliable information on the extent to which A Toast to Health in Later Life! reduces alcohol-related risks and problems among older patients who drink and 2) evaluate the extent to which these reductions are associated with increases in health-related quality of life, patient knowledge and self-efficacy and decreases in the use of health services and the costs of care."
1502356|NCT02952482|Procedure|newborns testing for ALD|Routine newborn screening dried blood spots sample is used to test if elevation of C26:0-lyso-PC
1502357|NCT02952469|Drug|(68Ga)PSMA-HBED-CC|Experimental radiotracer for imaging prostate cancer
1502358|NCT02952456|Other|interview with a psychologist|interview with a psychologist in Bereaved families, Patients with épilepsy and relatives of patients with epilepsy Relatives (Parents / spouse/ Husband) of patients with epilepsy
1502359|NCT02952443|Behavioral|Exercise|Participants will be randomized, using a table of random numbers, to either an Exercise (EX) or a Control (CON) group. The EX group will participate in a 16-week multi-component training intervention (3x per week, 45 to 60 minutes/session, at moderate to vigorous intensity) that will include primarily resistance exercises, an aerobic warm-up and cool down, and include both flexibility and balance exercises throughout the session (Bray et al., 2016).
1502360|NCT02952443|Behavioral|Control|The CON group will be asked to maintain their normal daily living habits for the same duration (16 weeks). At the conclusion of the 16-weeks the exercise program will be made available to the CON group.
1502361|NCT02952430|Procedure|Emergency laparotomy|Patients already undergoing emergency laparotomy - groups divided pre-operatively into frail and not frail based on modified Rockwood score. Then outcomes observed.
1502362|NCT02952417|Other|Excess mortality|Relative survival was defined as the observed survival among patients with STEMI and NSTEMI divided by the expected survival in the age, sex and year matched populace of Sweden.
1502363|NCT02952404|Procedure|Educational workshop|The educational workshop for improved perineal support during vaginal delivery
1502444|NCT02951780|Drug|LY3185643|Administered SC
1502364|NCT02952391|Other|[18F] FEOBV PET scan|Cholinergic PET scan with the tracer [18F]Fluoroethoxybenzovesamicol
1502365|NCT02952378|Drug|Albumins|Infusion of 3ml/kg bodyweight of hyperoncotic albumin 20% during 30 minutes.
1502366|NCT02952365|Drug|Tissue sealant|Application of tissue sealant on eyes undergoing LASIK enhancement
1502367|NCT02952352|Behavioral|Diabetes Prevention Program|Culturally adapted diabetes prevention program
1502368|NCT02952339|Biological|RSV LID ΔM2-2 1030s vaccine|10^5.0 PFU; administered as nose drops
1502369|NCT02952339|Biological|Placebo|Administered as nose drops
1502370|NCT02952326|Procedure|XP Endo Finsher as final step of the irrigation protocol|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument. XP Endo finisher is used after the last instrument in preparation
1502371|NCT02952326|Procedure|Conventional needle irrigation only|The canals will be thoroughly irrigated using 3ml syringe of 2.5% Sodium hypochlorite between every subsequent instrument.
1502372|NCT02952313|Device|Nasal Implant|
1502373|NCT02952300|Procedure|neolix|single rotation file
1502374|NCT02952300|Procedure|wave one|single reciprocation file
1502375|NCT02952287|Device|4D PC MRI acquisition|Flow-sensitive 4D-MRI acquisitions will be synchronized to the heart rate and breathing using prospective ECG-gating and adaptive diaphragm navigator gating41. The MRI sequence will consist of a segmented k-space spoiled gradient echo sequence with interleaved 3D velocity encoding. Data will be acquired in a sagittal oblique 3D data volume individually adapted to include the heart and the thoracic and upper abdominal vessels of interest like ascending, transverse and descending aorta, main and branch pulmonary arteries, pulmonary veins, superior and inferior vena cava, celiac and superior mesenteric vessels. Velocity encoding (VENC) will be set at 150-500 cm/sec to encompass flow in various vessels.
1502376|NCT02952274|Device|mandibular overdenture retained with single midline implant using locator attachment|
1502377|NCT02952274|Device|mandibular overdenture retained with single midline implant using ball attachment|
1502378|NCT02952261|Device|3D printing device assisted localization|By the use of CT data, digital model was created through computer design and delivered to 3D printing machine. The device was printed according to the patient's CT which could fit the outline of the patient and indicate the puncture site. Thus the localization procedure was facilitated.
1502379|NCT02952261|Other|conventional localization|The patient received conventional localization procedure for small pulmonary procedure.
2002281|NCT02379416|Drug|Nilotinib + Paclitaxel|The BCR-Abl kinase inhibitor nilotinib demonstrated greater than additive activity in combination with the anti-tubulin agent paclitaxel in preclinical xenograft models, justifying the clinical evaluation of this combination for its antitumor activity
1502381|NCT02952235|Other|SPF50+|Sun protection
1502382|NCT02952235|Other|SPF100+|Sun protection
1502383|NCT02952222|Drug|Dexmedetomidine|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
1502384|NCT02952222|Drug|Propofol (Group P)|Patients in Group P will receive intravenous propofol in bolus increments (2.0 mg/kg bolus over one minute then 0.5 mg/kg bolus q 1 minute titrated to a BIS of 40-50). These patients will be maintained with a continuous intravenous infusion of propofol starting at 200 mcg/kg/min and will be titrated to an endpoint of maintaining a BIS level of 40-50.
1502385|NCT02952222|Drug|Propofol (Group DP)|Patients in Group DP will receive 0.5 mcg/kg DEX administered over 1 minute followed by an infusion of 0.15 mcg/kg/hr. Following the 0.5 mcg/kg DEX bolus, propofol will be administered with the identical protocol (with same endpoint of BIS 40-50) of the P Group. Propofol infusion will be started at 200 mcg/kg/min and will be titrated throughout the procedure to maintain a BIS 40-50. Propofol may be administered prn in 10-20 mg increments for any abrupt patient movement which may compromise the continuity of the procedure.
1502386|NCT02952209|Device|Xenograft|
2002282|NCT02375074|Behavioral|Supported Employment|Supported Employment (SE), focusing on competitive employment in real-life settings without long-lasting preceding training.
2002283|NCT02375074|Behavioral|Traditional Vocational Rehabilitation|Traditional Vocational Rehabilitation (TVR), offering training and preparation for the labor market in a sheltered environment
2002284|NCT02373813|Drug|etanercept pre-filled syringe sq injection|etanercept for injection in pre-filled syringes
1502390|NCT02952183|Device|PAMS I|"After general anesthesia, pressure sensor of PAMS I is placed into bladder, vagina and rectum. Then pressure change is monitored during performing pelvic autonomic nerve dissection.
Both PAMS I and IOM will be used for monitoring."
1502391|NCT02952170|Other|MRI|MRI to assess hepatic steatosis
1502392|NCT02952157|Drug|Lidocaine jelly application|
1502393|NCT02952157|Drug|Normal saline application|
1502394|NCT02952144|Device|Lixelle® treatment|The treatment will be performed with the Lixelle® column connected to upstream of the dialyzer in series on the routine HD circuit according to the description in the IFU. The dialyzer and the Kt/V urea in the conventional HD for each patient will be kept equal in Lixelle®-treatment. Since the maximum blood flow rate for Lixelle® is 250 ml/min, the dialysis time will be extended to achieve the target Kt/V urea. The study will not restrict the type of hemodialyzer and other conditions of HD as specified by the physician. However, any changes to the HD procedure should be recorded properly, and the Kt/V urea should be kept equal to that at the enrollment.
1502395|NCT02952131|Procedure|Lipoaspiration|Closed Syringe Harvesting Autologous Subdermal Fat
1502396|NCT02952131|Procedure|AD-cSVF|Use of Centricyte 1000 to isolate adipose stem/stromal cells via centrifugation
1502397|NCT02952131|Procedure|Normal Saline IV|Normal Saline IV containing AD-cSVF
1502398|NCT02952118|Device|Forrest Snoring device|
2002285|NCT02373813|Drug|Oral methotrexate|methotrexate capsules
1502401|NCT02952079|Device|Blephex|Lid margin exfoliation
1502402|NCT02952079|Device|MiboFlo|Lid warming treatment
1502403|NCT02952066|Procedure|Bronchial biopsy|
1502406|NCT02952040|Drug|ASP1517|Oral dose
1502407|NCT02952040|Drug|Lanthanum carbonate hydrate|Oral dose
1502408|NCT02952027|Behavioral|Use-recording, patient-reminder alarm for incentive spirometry|
1502409|NCT02952014|Dietary Supplement|C4 Extreme|Pre-Workout Dietary Supplement
1502410|NCT02952014|Dietary Supplement|C4 Extreme (without Advantra Z|Pre-Workout Dietary Supplement
1502411|NCT02952014|Dietary Supplement|Placebo|Pre-Workout Dietary Supplement
2002286|NCT02373813|Drug|Placebo for etanercept sq injection|etanercept placebo for injection in pre-filled syringes
2002287|NCT02373813|Drug|Placebo for methotrexate|methotrexate placebo capsules
1502414|NCT02951975|Drug|dexamethasone intravitreal implant|Dexamethasone intravitreal implant (OZURDEX®) as prescribed in clinical practice.
1502415|NCT02951962|Drug|Twynsta 80/5mg|Hypertension
1502416|NCT02951962|Drug|Crestor 20mg|Hyperlipidemia
1502417|NCT02951936|Device|NiCAS treated|"Measure each patient with the NiCAS once a day If Cardiac Index < 2.9 +Total Peripheral resistance Index >3000+Mean arterial pressure >70mmHG then add vasodilators.
If Heart Rate<60 consider to reduce beta blockers dose If Cardiac Index>4.2 and Mean arterial pressure 70-100mmHG and HR >100 then add Bata Blockers If patient have low Total Body Water then reduce diuretics If patient have High Total Body Water provide diuretics"
1502418|NCT02951936|Device|Non NiCAS treated|Measure each patient with the NiCAS once a day Do note use the NiCAS parameters to direct treatment For treatment we will use the standard care
1502419|NCT02951923|Dietary Supplement|Bovine Colostrum|Bovine colostrum vs. soy during rugby training
1502420|NCT02951923|Dietary Supplement|Soy|
1502421|NCT02951910|Device|Ophylosa tear supplement|Tear film dynamics is assessed by non-invasive tear film breakup time (NI-BUT) in parallel with continuous recordings of ocular sensations during forced blinking. Corneal sensitivity thresholds to selective stimulation of corneal mechanonociceptors, thermal receptors and chemical nociceptors are assessed using the Belmonte gas esthesiometer. All baseline measurements are repeated after one month of tear supplementation with zinc-hyaluronate (Ophylosa eye drop) 4x/day
1502422|NCT02951897|Procedure|lobectomy|
1502423|NCT02951897|Procedure|segmentecomy|
1502424|NCT02951897|Drug|chemotherapy（pemetrexed+CISPLATIN）|
1502425|NCT02951897|Procedure|Lymphadenectomy|Lymphadenectomy or lymph node dissection is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.
1502426|NCT02951897|Other|CanPatrolTM to detect CTCs|CanPatrol TM was used to detect CTCs, which is a newly established technology to detect CTCs, containing the following steps: (1) To remove erythrocytes by red blood cell lysis and deplete CD45+ leukocytes in 10ml blood sample using a magnetic bead separation method; (2) To enrich CTCs by 8-μm-diameter-pore calibrated membrane filters; and (3) To identify and characterize CTCs by using RNA-in situ hybridization (ISH), based on the branched DNA (bDNA) signal amplification technology, to detect EMT markers, e.g., cytokeratins(CK) 8, 18 and 19, epithelial cell adhesion molecule (EpCAM), vimentin and twist. The details of classification of CTCs by using CanPatrol TM was depicted in the recently published protocol. Finally, the CTCs were clustered into three subtypes, as per the EMT markers, i.e., epithelial (E-) CTCs, mesenchymal (M-) CTCs and epithelial- mesenchymal (E&M-) CTCs.
1502427|NCT02951884|Procedure|Aspiration Knee Joint|
1502428|NCT02951884|Drug|Bupivacaine|
1502429|NCT02951884|Drug|Epinephrine|
1502430|NCT02951858|Behavioral|Intervention Group|The medical staffs who received the training will use the manual of brief intervention to deliver BI and other materials about the harm of substance use.
1502431|NCT02951858|Behavioral|Control Group|The participants only receive the materials about the harm of substance use.
1502432|NCT02951845|Drug|JNJ-54416076 (Oral Suspension)|Participants will receive (25 mg) oral suspension of JNJ-54416076 in Part 1 and Part 2.
1502433|NCT02951845|Drug|JNJ-54416076 (Formulation 1: Direct Compression Tablets)|Participants will receive JNJ-54416076 Tablet formulation 1 (5*5 mg Tablets [25 mg total]) under fasted and fed condition in Part 1.
1502434|NCT02951845|Drug|JNJ-54416076 (Formulation 2: Fluid Bed Granulation Tablets)|Participants will receive JNJ-54416076 Tablet formulation 2 (5*5 mg Tablets [25 mg total]) under fasted and fed condition in Part 2.
2002288|NCT02371668|Biological|CR6261|50 mg/kg administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
2002289|NCT02371668|Biological|Placebo|Administered as a single 2-hour intravenous infusion on Day 1 (24 hours after virus administration).
2002290|NCT02368431|Drug|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
2002291|NCT02368431|Drug|Placebo|Placebo
1502439|NCT02951806|Drug|(R) Rapid spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 20 seconds then 10 mg hyperbaric bupivacaine.
1502440|NCT02951806|Drug|(S) Slow spinal fentanyl injection|Patients will receive 25 micrograms fentanyl ( after dilution with 2.5 ml CSF) in 90 seconds then 10 mg hyperbaric bupivacaine.
1502441|NCT02951793|Other|AUDIT-C|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including AUDIT-C about his/her alcohol behavior during last year and will be categorized into two groups: Those with AUDIT-C>4 versus AUDIT-C of 4 or below.
1502442|NCT02951793|Other|Smoking history|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including smoking history during last year and will be categorized into two groups: Current smoker versus ex- or never smoker (we also recorded smoking pack-years to distinguish heavy smokers)
1502443|NCT02951793|Other|Prior psychotropic medication use|Patients or their proxy/closest family member(s) undergo a comprehensive questionnaire including psychotropic medication use prior admission to ICU and will be categorized into two groups: Those who use psychotropic medication versus those who do not use psychotropic medication.
2002292|NCT02368509|Other|Perform sensory tests|
2002293|NCT02365662|Drug|ABBV-221|ABBV-221 will be given either every 3 weeks or 2 weeks on, 1 week off or weekly dosing by intravenous infusion approximately over 30 minutes to 3 hours. This is a dose escalation study, therefore the dose of ABBV-221 will change throughout the study.
2002294|NCT02365233|Drug|DPP4 inhibitor|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
1502445|NCT02951780|Drug|rGlucagon|Administered SC
1502446|NCT02951767|Drug|Atezolizumab|Atezolizumab 1200 mg will be given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria or unmanageable toxicity.
1502447|NCT02951754|Drug|Immediate-release Methylphenidate|Standard initial dose of 10 mg, twice or three times daily with doses increasing weekly until symptom control or occurrence of limiting adverse effects
2002295|NCT02365233|Drug|Pioglitazone|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
1502449|NCT02951728|Drug|Rituximab|
1502450|NCT02951728|Drug|Cyclophosphamide|
1502451|NCT02951728|Drug|Doxorubicin|
1502452|NCT02951728|Drug|Vincristine|
1502453|NCT02951728|Drug|Prednisone|
1502454|NCT02951728|Drug|Decitabine|
1502455|NCT02951715|Drug|zinc gluconate|2 months of treatment with zinc gluconate (Zinga 78 mg, 10 mg elemental zinc), two tablets twice per day (40 mg per day)
2002296|NCT02365233|Drug|Lantus insulin|Comparison between three common alternative therapeutic strategies to improve glycemic control in patients with type 2 diabetes who are not controlled with metformin alone.
2002297|NCT02364076|Drug|Pembrolizumab|Administration of 200 mg MK-3475 once every 3 weeks
2002298|NCT02364076|Drug|Epacadostat|100mg taken by mouth twice daily
1502461|NCT02951650|Device|Cyberonics VNS|Vagus nerve stimulation
1502462|NCT02951637|Drug|Pemetrexed plus carboplatin combined with gefitinib|Pemetrexed (500mg/m(2) d1) plus carboplatin (AUC5 d1) combined with gefitinib (250mg d4-28) and repeat every four weeks for up to six cycles and then continue to receive pemetrexed combined with gefitinib every four weeks.
1502463|NCT02951637|Drug|Gefitinib|Gefitinib (250mg daily)
1502464|NCT02951624|Behavioral|Control|Control intervention
1502465|NCT02951624|Behavioral|Breaker|Short breaks of physical activity
1502466|NCT02951624|Behavioral|Prolonger|longer breaks of physical activity
1502467|NCT02951624|Behavioral|Intermediate|Intermediate breaks of physical activity
1502468|NCT02951611|Procedure|Acupuncture stimulation|Transcutaneous electrical acupoint stimulation on SI3, SJ6, PC6 and LI4
1502469|NCT02951611|Procedure|Sham stimulation|Put electrodes on SI3, SJ6, PC6 and LI4 without stimulation
1502471|NCT02951585|Device|KARTILAGE CROSS|Intra-articular injection of Kartilage Cross
1502472|NCT02951585|Device|PLACEBO|Intra-articular injection of physiological serum (saline solution)
1502473|NCT02951572|Device|NIV|
1502474|NCT02951559|Device|Nasal Brushing|"Nasal brushing will be performed in non-sedated patients as follows. After administration of a local vasoconstrictor (1% epinephrine) with the use of a nasal tampon, inserted into the nasal cavity of the patient to locate the olfactory mucosa lining the nasal vault. A sterile, disposable brush (Copanflock, Copan, Brescia, Italy) will be inserted gently rolled on the mucosal surface, withdrawn,and immersed in 0.9% saline solution, UTM (Universal Transporter Medium) or 4% formaldehyde. Two swabs will be collected for each nostril."
1502475|NCT02951546|Dietary Supplement|Mediterranean diet|In the Mediterranean diet fat intake will be equal to 35% of the total energy intake minus carbohydrate and protein energy carbohydrate as 65% of total calorie intake, dietary cholesterol <300 mg/day, dietary fiber 25 g/day.
1502476|NCT02951546|Dietary Supplement|Low fat diet|In the hypocaloric low fat diet, fat will represent less than 25% of the total energy intake. Branched and essential amino acids will be administered taking into account the total protein intake.
1502477|NCT02951546|Other|Aerobic exercise|"A personalized program of aerobic exercise will be prescribed to the participants of both arms, following the FITT principles (frequency, intensity, time and type)."
1502478|NCT02951533|Drug|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution subcutaneously.
1502479|NCT02951533|Drug|Fumaric Acid Esters|Participants will receive Fumaderm initial/ Fumaderm tablets through self-administration.
1502480|NCT02951520|Procedure|new technique for lower limb nerve blocks using a single skin puncture (SOFT block)|The patients will be in supine position. The block needle will be inserted at the inguinal crease (medial to the femoral vein) and advanced towards the femoral nerve, then redirected towards the obturator nerve (deep to the pectineus muscle). Lastly, it will be redirected posteriorly towards the sciatic nerve (deep to the quadratus femoris muscle). A ropivacaine-lidocaine-epinephrine mixture will be used to block these nerves. The block success rate (painless surgery), performance time and patient discomfort will be recorded.
1502481|NCT02951507|Other|O T unilateral attachment|O T unilateral attachment system
1502482|NCT02951507|Other|New design of extracoronal attachment system|O T unilateral attachment
1502483|NCT02951494|Other|AlterG Anti-gravity treadmill|Participants in this group will complete a 12 week aerobic exercise training protocol with 40% lower body weight support on an AlterG Anti-gravity treadmill
1502484|NCT02951481|Behavioral|Systematic evaluation by an ID expert.|"Specific bundle of measures:
Systematic evaluation of all patients diagnosed with CDI by an Infectious Disease expert To ensure compliance with clinical practice guidelines about specific treatment for CDI, depending on the severity of the episode and the existence of previous episodes and to optimize concomitant antibiotic therapy (antimicrobial stewardship).
To ensure appropriate monitoring during the period of greatest risk of relapse in order to reduce as far as possible, the number of relapses. Personalized assistance by telephone or by email for early consultation in case of recurrence of symptoms or need for a new antibiotic course."
1502485|NCT02951468|Procedure|LCP plus iliac crest autograft|After exposure of the non- or malunion a complex multidimensional osteotomy of the clavicle with medial and lateral axial correction up to vital bone was performed [14]. Vital bone was verified by local blood extravasation resulting from drilling the previously osteotomized bone segments. The tricortical iliac crest bone graft was harvested according to the size assessed in the preoperative CT scan, consecutively adapted to the intraoperative measured size of the bony defect. After implantation of the bone graft the LCP was centered onto the clavicular shaft.
1502665|NCT02950285|Other|Baseline alert|PCP notification at baseline that patient has atrial fibrillation, high stroke risk, and is not anticoagulated.
1502486|NCT02951455|Behavioral|Critical Dialogue|Prompted by thematic images, aims to help participants develop a deeper understanding of how marginalizing processes (e.g., systematic stigma; feelings of rage as victims of discrimination) impact participants' lives and behavior.
1502487|NCT02951455|Behavioral|Capacity Building Project|Designed to create collaborative efforts to overcome and dismantle marginalizing processes by building positive social and organizational relationships and community capacity through the development and implementation of community projects aiming to address social determinants of health.
1502488|NCT02951455|Behavioral|Quality of Life Wheel|Aims to increase self-efficacy and help participants develop a vision for their future, breaking this vision down into small, feasible, measureable goals they can implement on a weekly basis (e.g. quitting smoking, improving relationships with family members, paying down debt).
1502489|NCT02951455|Behavioral|PF|Whether the intervention is delivered by a peer facilitator.
1502490|NCT02951455|Behavioral|LC|Whether the intervention is delivered by a licensed clinician.
1502491|NCT02951442|Biological|Biological sample|
1502492|NCT02951442|Procedure|Non invasive Arterial investigations|
1502493|NCT02951442|Procedure|Abdominal tomodensitometry|
1502494|NCT02951429|Drug|Pirfenidone|Pirfenidone will be given in the range of 1602 to 2403 milligram per day (mg/day), as 3 divided doses.
1502495|NCT02951429|Drug|Placebo|Placebo matched with sildenafil.
1502496|NCT02951429|Drug|Sildenafil|Sildenafil will be given as 20 mg, TID.
1502497|NCT02951416|Other|patient registry (observation and biomaterial sampling)|data are collected with patient questionnaires, additionally clinical data are collected at every routine visit and biomaterial is collected
1502498|NCT02951403|Procedure|Elbow arthroscopy|Arthroscopic debridement, osteophyte excision, loose body extirpation is carried on to patients.
1502499|NCT02951403|Other|Conservative treatment|Physiotherapy protocol is introduced to patients.
1502500|NCT02951390|Other|High-definition white-light endoscopy|The intervention is do not perform chromoendoscopy
1502501|NCT02951377|Other|Exercise (MDT approach)|Postural or movement exercises of the lower back that aim to centralise and reduce pain intensity.
1502502|NCT02951377|Drug|Transforaminal epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%)|An epidural steroid injection (20mg dexamethasone 0.5cc lidocaine 2%), under guidance of fluoroscopy is used to reduce inflammation at a lumbar spinal nerve root(s).
2002299|NCT02364037|Behavioral|CHOICE Project Structured Contraceptive Counseling|Women in both phases of the study will receive the structured contraceptive counseling developed by the Contraceptive CHOICE Project.
1502504|NCT02951351|Drug|Proparacaine Ophthalmic|Extra proparacaine will be applied to the conjunctival surface to determine its role in patient experience.
1502505|NCT02951351|Procedure|Conjunctival culture|Conjunctival cultures will be performed to ensure that the intervention does not interfere with antisepsis.
1502506|NCT02951338|Behavioral|PROPEL program|The PROPEL program involves both group aerobic exercise and group discussion aimed at enabling participation in exercise after discharge. Components of the PROPEL program were developed according to the Transtheoretical Model of health behaviour change and Social Cognitive Theory. In addition to group exercise participants will attend 1-hour small group discussion sessions once weekly to learn self-management skills for exercise in preparation for discharge from rehabilitation. These discussions include: identifying and solving problems around barriers to exercise; understanding personal and general benefits of exercise; exploring appropriate community resources for exercise; and finding individualized and realistic strategies for incorporating exercise in a regular routine. Participants will become comfortable with progressing their exercise and will set short- and long-term exercise goals.
1502507|NCT02951338|Other|Group aerobic exercise|"Supervised group exercise up to 3-times/week for 6 weeks. A typical exercise session will involve a 3-5 minute 'warm-up', 20-30 minutes of aerobic exercise at a target heart rate determined from a sub-maximal test, and a 3-5 minute 'cool-down' of low-intensity exercise. The choice of exercise modality for the submaximal test and for training (e.g., recumbent stepper, cycle ergometer, or treadmill) will be individually prescribed based on patients' sensori-motor recovery, postural control, functional abilities, and safety. Heart rate, blood pressure, rate of perceived exertion, workload, and duration of training will be documented for each session. These data will be reviewed by the physiotherapist with appropriate progression of the intensity and/or duration of exercise as necessary.
Participants may receive general advice to keep physically active after discharge, and may receive an individualized home exercise program, as is currently routine care at all sites."
1502508|NCT02951325|Radiation|Adjuvant RT|
1502509|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 25mg|25 μg oral inhalation via eFlow Nebulizer, once daily
1502510|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 75mg|75 μg oral inhalation via eFlow Nebulizer, once daily
1502511|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 200mg|200 μg oral inhalation via eFlow Nebulizer, once daily
1502512|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 200mg Jet|200 μg oral inhalation via inhalation via jet nebulizer, once daily
1502513|NCT02951312|Drug|Glycopyrrolate Inhalation Solution 500mg|500 μg oral inhalation via eFlow nebulizer, once daily
1502514|NCT02951312|Drug|Glycopyrrolate Inhalation Solution1000mg|1000 μg oral inhalation via eFlow nebulizer, once daily
1502515|NCT02951312|Drug|Placebo|Placebo 0.5 mL oral inhalation via jet nebulizer, once daily
1502516|NCT02951299|Drug|Pentoxifylline 400Mg Tablet|Investigators with AKI will received oral pentoxifylline (400 mg) three times a day for 14 days or no pentoxifylline according to their decision.
1502517|NCT02951286|Device|high pull headgear + OBA|a modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied in compination with a high pull headgear.
1502518|NCT02951286|Device|OBA (control group)|A modified version of the OBA (Open Bite Appliance),introduced by Erverdi and Usumez, will be applied alone (Control group)
2002300|NCT02364037|Behavioral|Clinic Provider Training|Clinicians at the recruitment sites will undergo a training session to discuss interuterine device and implant eligibility and same-day insertion considerations in an attempt to increase the number of patients who are receiving these methods, if desired.
1502666|NCT02950259|Drug|Cyclophosphamide|One dose of cyclophosphamide 300 mg/m2 IV infusion
2002301|NCT02364037|Device|Cost support for IUDs and implants|For women in phase II of the study, women who desire an IUD or implant and can receive one through the study at no cost. If women have insurance that covers the device, her insurance will be billed for the cost of the device.
1502520|NCT02951260|Drug|Metformin|17 days treatment with metformin
1502521|NCT02951260|Other|Placebo|17 days treatment with placebo
1502522|NCT02951247|Device|Hearing Aid|Successor of Phonak Virto V90-10 NW O
1502523|NCT02951234|Other|IVIG only|All patients will receive IVIG (2g/kg) in 10-12 hours alone, without high-dose aspirin.
1502524|NCT02951234|Other|IVIG and Aspirin|All patients will receive IVIG (2g/kg) in 10-12 hours plus high-dose aspirin (80-100mg/kg/day, divided into four doses) till fever subside.
1502525|NCT02951221|Drug|BIIB074 Treatment A|Lower dose RCF fasted
1502526|NCT02951221|Drug|BIIB074 Treatment B|Lower dose DCF fasted
1502527|NCT02951221|Drug|BIIB074 Treatment C|Higher dose DCF fasted
1502528|NCT02951221|Drug|BIIB074 Treatment D|Higher dose DCF fed
1502529|NCT02951208|Device|Active tDCS|Active anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
1502530|NCT02951208|Behavioral|Active VR Motivation Training|Active computerized treatment with a virtual reality-based motivation training program, administered for 60 minutes, three times per week for four weeks.
1502531|NCT02951208|Device|Sham tDCS|Sham anodal tDCS over the left DLPFC, administered for 30 minutes, three times per week for four weeks.
1502532|NCT02951208|Behavioral|Sham VR Motivation Training|Sham computerized training in a virtual reality-based environment, administered for 60 minutes, three times per week for four weeks.
1502533|NCT02951195|Drug|VX-152|
1502534|NCT02951195|Drug|Tezacaftor|
1502535|NCT02951195|Drug|Ivacaftor|
1502536|NCT02951195|Drug|Triple Placebo|
1502537|NCT02951195|Drug|Placebo for VX-152|
1502538|NCT02951182|Drug|Tezacaftor|
1502539|NCT02951182|Drug|Ivacaftor|
1502540|NCT02951182|Drug|VX-440|
1502541|NCT02951182|Drug|Matched Placebos|
1502542|NCT02951169|Other|No intervention|No intervention. Treatment are accordance with clinical practice.
1502550|NCT02951143|Drug|SPECTRUM cigarettes|Across six laboratory sessions, participants will consume 10 puffs of either their usual brand of cigarette (one session) or a SPECTRUM cigarette (five sessions) with a nicotine yield varying from 0.03 to 0.70 and either menthol (TPMF codes NRC 103, NRC 201, NRC 301, NRC 401, and NRC 501) or tobacco (TPMF codes NRC 102, NRC 200, NRC 300, NRC 400, and NRC 500) flavor, depending on preference. This will be followed by the collection of blood nicotine content and a cigarette purchase task.
1502551|NCT02951143|Drug|SPECTRUM cigarettes between|Participants will be assigned one of the nicotine concentrations of a SPECTRUM cigarette. They will complete a cigarette purchase task and make real purchases for the next week. Participants will return and make purchases again, repeating 4 times.
1502552|NCT02951130|Drug|Milrinone|The study intervention is an intravenous infusion of milrinone or placebo
1502553|NCT02951130|Drug|Placebo (5% Dextrose)|The study intervention is an intravenous infusion of milrinone or placebo
1502554|NCT02951117|Drug|Venetoclax|Tablet
1502555|NCT02951117|Drug|ABBV-838|Intravenous infusion
1502556|NCT02951117|Drug|Dexamethasone|Tablet or intravenous infusion
1502557|NCT02951104|Device|Noninvasive cardiac output monitor (NICOM)|
1502558|NCT02951091|Other|biomarker screening|immunohistochemistry and in situ hybridization
1502559|NCT02951078|Procedure|Thulium Laser en Bloc Resection of bladder tumor|
1502560|NCT02951078|Procedure|Electrical transurethral resection of bladder tumor|
1502561|NCT02951065|Other|Tooth brush without nylon bristles|Subjects will use a bristle-less tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
1502562|NCT02951065|Other|Tooth brush with soft nylon bristles|Subjects will use a soft bristled tooth brush. Subjects in both arms of the study will use the same waxed, mint-flavored floss; baking-soda based tooth paste; exams and professional tooth cleaning every 3-4 months; oral hygiene instruction every 3-4 months
2002302|NCT02363998|Drug|Lofexidine|All enrolled subjects will take lofexidine orally for 7 days, starting on Day 1 at a dose of 3.2 mg per day (0.8 mg QID), with lowering of the dose allowed to 2.4 mg daily (0.6 mg QID) if required for tolerability based on the subject's individual treatment goal and response per clinical judgment of the Principal Investigator.
2002303|NCT02363621|Drug|Ranibizumab 0.3 mg|Ranibizumab 0.3 mg Patient will receive intravitreal injection of Ranibizumab 0.3 mg
2002304|NCT02363621|Drug|Aflibercept 2.0 mg|Patient will receive intravitreal injection of Aflibercept 2.0 mg
1502667|NCT02950259|Drug|Indomethacin|Indomethacin 25 mg three times a day for 21 days
1502668|NCT02950259|Drug|Omeprazole|One tablet of omeprazole daily for 21 days
2002305|NCT02362438|Drug|Intrathecal Delivery of scAAV9/JeT-GAN|This is a non-randomized, phase I, single dose study to assess the safety of the gene transfer vector scAAV9/JeT-GAN through intrathecal delivery to the brain and spinal cord of patients with Giant Axonal Neuropathy (GAN, OMIM #256850).
1989785|NCT02377427|Drug|Mepolizumab|Mepolizumab is supplied as 100 mg lyophilised cake in sterile vials for subcutaneous administration in upper arm or thigh. The vial will be reconstituted with sterile water for injection prior to individual use.
2002306|NCT02362243|Other|Experimental Intervention|Participants will perform the back and core exercises that were tested in our previous firefighter study (Mayer, 2015), in addition to their usual physical fitness routine. All participants at a given fire station will receive the same intervention and all interventions will be completed at the fire station. Participants will perform 2 exercise sessions each week (each time they are on duty) throughout the study's 12-month duration. The back and core exercise program consists of 1 set of 5 exercises - 4 core exercises on a floor mat and 1 back extension exercise on a variable angle Roman chair - which will take approximately 10 minutes to complete for each session (Mayer, 2015).
1502568|NCT02951039|Drug|Edoxaban|Prescribed according to approved label
1502569|NCT02951026|Other|Not applicable (no therapy is administered as part of this study)|"No experimental therapy or placebo is being administered in this study. All subjects in this observational study received a single intra-articular injection of SM04690 or placebo in a prior parent study."
1502570|NCT02951013|Other|restrictive transfusion|Transfusion given when the hemoglobin concentration fell below 6.0 g/dL
1502571|NCT02951013|Other|liberal transfusion|
1502572|NCT02951000|Procedure|platysma suture|
1502573|NCT02951000|Procedure|no platysma suture|
1502574|NCT02950987|Device|Whole Body MRI|
1502575|NCT02950974|Drug|Sterofundin|Fluid loading
1502576|NCT02950974|Drug|NSS|Fluid loading
2002307|NCT02362243|Other|Placebo Comparator|Participants will receive a 45-60 minute, one-time educational session, which will be delivered to delivered by an exercise specialist in a 1-on-1 format while the participant is on-duty at the fire station, in addition to their usual physical fitness routine. Content for the educational session on evidence-based guidelines for exercise, physical fitness, and general physical activity will be derived from the American College of Sports Medicine (ACSM) Position Stand - Quantity and Quality of Exercise for Developing and Maintaining Cardiorespiratory, Musculoskeletal, and Neuromotor Fitness in Apparently Healthy Adults: Guidance for Prescribing Exercise (Garber, 2011).
1502578|NCT02950948|Drug|Progesterone|Progesterone will be administered subcutaneously once a day for 14 days/month, for 12 months.
1502579|NCT02950948|Drug|Placebo|A placebo solution will be administered subcutaneously once a day for 14 days/month, for 12 months.
1502580|NCT02950935|Drug|Progesterone|subcutaneous injection of progesterone solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
1502581|NCT02950935|Drug|Placebo|subcutaneous injection of placebo solution will be performed twice à day from onset of threatened abortion symptoms until week 12 of pregnancy.
1502582|NCT02950922|Drug|RVT-501 0.2% ointment|
1502583|NCT02950922|Drug|RVT-501 0.5% ointment|
1502584|NCT02950922|Other|Vehicle ointment|Placebo comparator
1502585|NCT02950909|Procedure|Static exercise for emphasized neck extensors|Emphasized activation of the deep neck extensors was searched for applying a localized resistance with the thumb and index finger at the level of the vertebral arch of C4 while pushing into flexion in a ventral-cranial direction, approximately parallel to the surface of the zygapophyseal joint, asking the patient to resist maximally during 6 seconds in sitting position
1502586|NCT02950909|Procedure|Dynamic exercise for emphasized neck extensors|The patient was asked to fix his gaze at an object lying between both elbows hoping to in order to emphasize extension in the lower cervical spine and consequently activation of the extensors in this region.
1502587|NCT02950909|Procedure|Static exercise for general neck extensors|Emphasized activation of all neck extensors was searched for applying the resistance with the therapist's hand or a wall respectively a towel at the occiput in sitting position
1502588|NCT02950909|Procedure|Dynamic exercise for general neck extensors|. The patient was asked to fix his gaze at an object lying between both hands. Extension consequently occurred in the entire cervical spine.
2002308|NCT02357173|Other|electronic cigarette|
2002309|NCT02357173|Other|cigarette group|
1502591|NCT02950870|Drug|Ombitasvir-Paritaprevir-Ritonavir|The patient will be treated daily with Ombitasvir-Paritaprevir-Ritonavir 25/150/100 mg total dose
1502592|NCT02950870|Drug|Dasabuvir|The patient will be treated daily with Dasubavir 500 mg total dose
1502593|NCT02950870|Drug|Ribavirin|Patients will be treated with ribavirin if necessary.
1502594|NCT02950857|Drug|EPEG (Pegylated erythropoeitin)|
1502595|NCT02950844|Other|Novel mapping algorithm|"Mapping and ablation of atrial fibrillation drivers identified by the STAR mapping algorithm.
In a sub-study a novel mapping system (CARTOFINDER, Biosense Webster, Inc, CA) was used in mapping drivers in AF."
2002310|NCT02356380|Other|Mobilization Type|"Group One: Mobilization Group: this group will receive grade 1,2,3,or 4 mobilization in prone based on the PT's clinical judgement. The treatment parameters will be recorded.
Group Two: Grade 3-4 mobilization group: this group will receive a grade 3-4 mobilization, for 30 seconds form the first through sixth thoracic vertebrae."
1502597|NCT02950818|Behavioral|Take Heart|Participants receive an evidence-based heart disease self management program consisting of a combination of four two-hour group sessions and telephone counseling offered by trained facilitators employed the Detroit Area Agency on Aging. The program is designed so that participants select an area to work on (e.g., diet, exercise, medication taking, communication with health care professionals) and receive support, information, and encouragement from group members and program facilitators.
1502598|NCT02950805|Drug|Placebo|Subjects will receive a placebo in either period 1 or period 2 by inhalation.
1502599|NCT02950805|Drug|AZD5634|Subjects will receive a single tentative dose of 625 μg of AZD5634 in either period 1 or period 2 by inhalation.
1502600|NCT02950792|Device|ViewRay MRI|ViewRay Magnetic Resonance Imaging
1502662|NCT02950324|Behavioral|Standard care|Patients in the 'standard care' arm of the study will not receive the study intervention. The patients will continue to be offered theatients in this arm of the study will not receive the study intervention. The patients will continue to be offered the standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care standard dietetic and psychological support as per the enhanced recovery pathway and current standard of care.
1502669|NCT02950259|Dietary Supplement|Multivitamin|Daily multivitamin containing 15-30 mg of zinc for 21 days.
2002311|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
1502601|NCT02950792|Radiation|Stereotactic Body Radiation Therapy Boost|In the (week 5), all patients will have a week 5 MRI and Four-dimensional computed tomography (4D CT) for purposes of planning Phase II boost. Gross tumors < 5 cm will receive a MR-based adaptive replanning Stereo boost of 80 Gy - 90 Gy (20 Gy-30 Gy in 5 fractions). Gross tumors < 5cm will receive an MR-based adaptive replan fractionated boost to 74 Gy at 2.4 Gy/day. Individualized radiation therapy prescription to primary tumor will maintain organs at risk (OAR) constraints to lung including mean lung dose (MLD) < 20 Gy with V20 < 37%. Simultaneously, MRI-based adaptive replanning boost of 12 Gy in 5 fractions (2.4 Gy/day) will be given to gross lymph nodes. Final doses prescribed will be limited by doses to all OARs.
1502602|NCT02950779|Other|Handgrip Strength Measurement|
1502603|NCT02950766|Drug|NeoVax|combination of Neoantigen peptides and poly-ICLC
1502604|NCT02950766|Drug|Ipilimumab|local administration of ipilimumab
1502605|NCT02950753|Drug|Lactated Ringer Solution|Fluid bolus of Lactated Ringer solution (30ml/kg).
1502606|NCT02950753|Drug|Normal Saline|Fluid bolus or Normal Saline (30ml/kg).
1502607|NCT02950727|Device|3 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the first group the osteotomy will be fixed using 3 bicortical screws
1502608|NCT02950727|Device|adjustable plate and 2 bicortical screws|after mandibular bilateral sagittal split ramus osteotomy surgery is performed in the second group the osteotomy will be fixed using adjustable plate and 2 bicortical screws
1502609|NCT02950714|Other|LIN_NOW|The Lupus interactive navigator (LIN) was developed to facilitate and support engagement and self-management for persons with lupus. It is a web-based program that provides access to relevant information, resources, support, and other tools to help them manage their illness. It is accessible by the Internet and compatible for use with computer, tablet, and mobile device. The content for the LIN was based on the results of focus group discussions and web-based surveys of persons with lupus and health care providers. Medical researchers, writers, designers and programmers worked with clinical experts affiliated with the Canadian Network for improved outcomes in Systemic Lupus Erythematosus (CaNIOS) and persons with lupus to provide the written content and interview videos.
1502610|NCT02950714|Other|LIN_WAIT|Usual care for three months prior to access to the LIN
1502611|NCT02950701|Device|Observational data collection.|
1502612|NCT02950688|Biological|Seasonal LAIV|10^7.0 fluorescent focus units (FFU); administered by intranasal spray
1502613|NCT02950688|Biological|Placebo|Administered by intranasal spray
1502614|NCT02950688|Biological|Wild-type A/California/2009-like Influenza Virus|Approximately 3.5 x 10^6 TCID50; administered intranasally
1502615|NCT02950662|Other|Overdenture|Active comparator will be metal housing and peek housing
1502616|NCT02950649|Device|invasive Hemodynamic monitoring via Clearsight/Nexfin Systems from Edwards Lifesciences|Experimental: Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed and its data will help guide (intervention) patient's management decisions (experimental).
1502617|NCT02950649|Device|No Hemodynamic Monitored Guided Assesment|Arm: Active Comparator: No Hemodynamic Monitored Guided Assesment This group will have the non-invasive hemodynamic monitoring device placed but its data will NOT be factored for intervention of the patient's management decisions.
1502618|NCT02950636|Other|Yoga|Restorative Yoga
1502619|NCT02950623|Other|titanium dioxide denture|patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles ) for 1 month in the initial phase then in the second phase after one month they will receive( rapid heat cured acrylic resin)denture according to the principle of crossover design
1502620|NCT02950623|Other|rapid heat denture|patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles ) according to the principle of crossover design
1502621|NCT02950610|Device|"Breath analysis - electronic signature Breath-print"|Patients and Healthy volunteers ( as defined in 3 cohorts) will breath into disposable, once-use only bacterial filter channeled into electronic device comprising on sensors capable to reacting to organic compounds. Breathing manoeuvre will be simple, non-exertional and relaxed. 2 breathing manoeuvres will be performed and sensor responses will be captured.
1502622|NCT02950597|Other|Observational Study to Evaluate Utility of Non-invasive Hemodynamic Monitoring|
1502623|NCT02950584|Other|Titanium dioxide denture|Patients will receive titanium dioxide denture (made from acrylic resin with titanium dioxide nanoparticles) for 1 month in the initial phase then in the second phase after one month they will receive (rapid heat cured acrylic resin)denture according to the principle of crossover design
1502624|NCT02950584|Other|Rapid heat denture|Patients will receive rapid heat denture for 1 month in the initial phase of the trial then in the later phase patients will receive titanium dioxide denture (made from conventional acrylic resin modified by titanium dioxide nanoparticles) according to the principle of crossover design
1502625|NCT02950571|Behavioral|Digital Picture Frame|The intervention is the provision of digital picture frames in long stay inpatient rooms in a ward at CAMH.
1502626|NCT02950571|Behavioral|Standard Care|High level of support from an interdisciplinary team.
1502627|NCT02950558|Drug|Ropivacaine|Single injection of ropivacaine immediately prior to surgery.
1502628|NCT02950558|Procedure|Nerve block|insertion of catheter to deliver continuous 7 day popliteal sciatic nerve block using a disposable ambulatory pain pump.
2002312|NCT02340975|Biological|MEDI4736|MEDI4736 will be administered by IV infusion.
2002313|NCT02340975|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion.
1502632|NCT02950532|Other|Retrospective radiological evaluation|Radiological evaluation will be performed in already existing imaging exams. Superior-inferior end plate angle (SIEA), vertebral body height (BH), local kyphosis (LK), inter-spinous distance (ISD) and inter-pedicular distance (IPD) will be measured in CT scans and radiographs (if available). PLC injury will be determinated with the gold standard method (MRI).
1502633|NCT02950519|Other|monitoring of cuff pressures|Cuff pressure will be checked per standard and additionally a minimum of every 8 hours.
1502663|NCT02950311|Drug|Intranasal xylitol spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
1502634|NCT02950506|Device|transcranial direct current stimulation|The anode will be placed over left DLPFC at F3, according to the 10-20 international system for EEG electrode placement. The cathode will be placed over the contralateral supraorbital area. They will be placed via two saline soaked electrode sponges (3 cm x 4.5 cm).After electrodes have been placed, the participants will be instructed to log into CRT software using a unique patient identifier. The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.)Active tDCS will be applied at a ramp-like fashion from 0 to 2mA over 10 seconds, and will be ramped down for the last 10 seconds of stimulation. Active tDCS will last 20 minutes each session. The sham procedure involves only 30 seconds of stimulation at 2mA.
1502635|NCT02950506|Other|Cognitive Remediation Therapy|The CRT software that will be used will be Cogmed working memory training program (Pearson Education, Inc.). Cogmed is a targeted computerized training program that has been shown to improve working memory and attention. (Spencer-Smith 2015).
1502636|NCT02950493|Other|perflutren lipid microsphere|Definity is tool for diagnosis used in echocardiography. Compare activated Definity with compressed Definity.
1502637|NCT02950480|Drug|zafirlukast|Patients will begin treatment with zafirlukast on post-operative day one following placement of tissue expander(s) once determined safe from a surgical recovery standpoint. They will be continued on the standard dosing (20mg PO twice per day) of zafirlukast through expander fill (6-12 weeks, up to 18 weeks for women receiving radiation). Treatment will be stopped 48 hours prior to expander-implant exchange, which is equivalent to five half-lives of the drug. Patients will be seen every 1 to 2 weeks for expander fill, and will be assessed clinically based on the Baker classification system of capsular contracture every two weeks.
1502638|NCT02950480|Other|Standard of Care (no intervention)|Standard of Care (no intervention)
1502639|NCT02950467|Drug|Psilocybin|One individual oral psilocybin treatment session
1502640|NCT02950467|Behavioral|Modified brief Supportive Expressive Group Therapy|Eight sessions of weekly manualized group therapy
2002314|NCT02340975|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab
2002315|NCT02340975|Biological|MEDI4736+tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab
1502643|NCT02950441|Dietary Supplement|Nicotinamide Riboside|
1502644|NCT02950441|Other|Placebo|
1502646|NCT02950415|Behavioral|virtual|Parent is present via an internet pad (iPad)
1502647|NCT02950415|Behavioral|coaching|Parent learns what to say verbally to soothe child
1502648|NCT02950415|Behavioral|physical|Parent is present in the operating room
1502649|NCT02950415|Behavioral|no coaching|Parent does not learn what to say verbally to soothe child
1502650|NCT02950402|Other|Two Dried Plums per day|Subjects will consume Two Dried Plums per day
1502651|NCT02950402|Other|Six Dried Plums per day|Subjects will consume Six Dried Plums per day
1502652|NCT02950389|Device|PMMA filter|
1502653|NCT02950389|Device|HFR17 filter|
1502654|NCT02950389|Device|F7 filter|
1502655|NCT02950376|Other|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the beginning of withdrawl、3 months later、 6 months later and 1 year later and record the information synchronously.
1502656|NCT02950376|Other|Virtual reality-based addiction assessment system|The healthy controls will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.The test will proceed at the baseline and 1 month later and record the information synchronously.
1502657|NCT02950376|Other|DSM-5 +Virtual reality-based addiction assessment system|The patients who used the amphetamine type stimulants will be diagnosed by the chief physician、associate chief physician or attending physician first to evaluate their addiction severity. And then the patients will finish the test in the virtual environment, at the same time their eye movement index and other physiological data will be recorded .Physiological data includes cardiac rate、galvanic skin response and electroencephalogram and so on.In this group which is designed to construct the norm of assessment system, the test will record the information synchronously and proceed after baseline assessment.
1502658|NCT02950337|Radiation|Group 1: Peripherally Located Tumors|Group 1: For peripherally located tumors patients will receive SBRT(Stereotactic Body Radiation Therapy) , 3 fractions of 18 Gy to a total dose of 54 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
1502659|NCT02950337|Radiation|Group 2: Peripherally Located Chest Wall Adjacent Tumors|Group 2: For chest wall adjacent tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 12 Gy to a total dose of 60 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
1502660|NCT02950337|Radiation|Group 3: Centrally Located Tumors|Group 3: For central tumors patients will receive SBRT (Stereotactic Body Radiation Therapy) , 5 fractions of 10 Gy to a total dose of 50 Gy, with a minimum of 40 hours between each treatment fraction is required. ( Gy = Gray and is the unit used to measure the total amount of radiation a patient is exposed to)
1502661|NCT02950324|Behavioral|Prehabilitation|Patients in the intervention, 'Prehabilitation', arm of the study will be enrolled into a multimodal programme that involves 15 weeks of exercise, nutritional support and psychological prehabilitation in the form of 'Medical Coaching'. This will take place during neo-adjuvant treatment prior to oesophagectomy or gastrectomy for cancer.
1502664|NCT02950311|Other|Intranasal saline spray|Two sprays into each nostril of intranasal xylitol spray will be administered to pediatric patients by parent(s)/caregiver(s) twice daily for 24 weeks.
1503484|NCT02943954|Procedure|Angiography guided PCI|
1502670|NCT02950246|Procedure|perineural catheterization implementation|Skin preparation (disinfection) with 10 ml of 2% alcoholic Chlorhexidine Perineural catheterization implementation Ultrasonography use
1502671|NCT02950246|Drug|2% alcoholic chlorhexidine|
1502672|NCT02950246|Drug|povidon iodine|
1502673|NCT02950233|Drug|NMDA active|NMDA active group will involve ketamine (0.5 mg/kg IV bolus pre-incision and 0.1 mg/kg/hr infusion postoperatively up to 24 hours) and oral memantine (5 mg BID [first week]; 10 mg BID [following three weeks]).
1502674|NCT02950233|Drug|Steroid active|Steroid active group will involve two doses of dexamethasone; 25 mg given prior to starting surgery and 25 mg given on the morning of second postoperative day.
1502675|NCT02950233|Drug|NMDA placebo|NMDA active group will involve normal saline (IV bolus pre-incision and infusion postoperatively up to 24 hours) and oral matching placebo to memantine (1 capsule BID [first week]; 1 capsule BID [following three weeks]).
1502676|NCT02950233|Drug|Steroid placebo|Steroid placebo group will involve two doses of normal saline; one dose given prior to starting surgery and one dose given on the morning of second postoperative day.
1502677|NCT02950220|Drug|Ibrutinib|Given PO
1502678|NCT02950220|Other|Laboratory Biomarker Analysis|Correlative studies
1502679|NCT02950220|Biological|Pembrolizumab|Given IV
1502680|NCT02950207|Genetic|miRNA|miRNA extraction
1502681|NCT02950194|Procedure|PPAWI|One-step procedure of a panniculectomy performed by a plastic surgeon together with a mesh augmentation of the abdominal wall by a general surgeon.
1502682|NCT02950181|Device|NIRS|Correlating the NIRS/Cerebral Oximetry readings to the various critical ill and injured pediatric patients, trends, interventions, and outcomes
2002316|NCT02341001|Other|Daily text message of support|
1502684|NCT02950155|Drug|Rituximab|A single infusion at a dose of 500 mg Mabthera/Rituximab.
1502685|NCT02950155|Drug|Sodium Chloride solution|A single infusion of Placebo/Sham.
1502686|NCT02950142|Other|CPOE with order sets for lab testing|CPOE including series of recommended tests ordered per indication
1502687|NCT02950142|Other|CPOE without order sets for lab testing|CPOE only
1502688|NCT02950129|Other|SIJ pain diagnostic tests|The subjects will undergo a specific physical exam of tests reported to be diagnostic of sacroiliac joint (SIJ) pain prior to receiving the routine injection in the SIJ; all tests will be repeated after the SIJ injection
1502689|NCT02950116|Device|Perform three multiple breath nitrogen washout tests (N2-MBW-test)|"Patient is sitting in upright position, nose clip in place and breathing through a mouth piece with filter (neither sitting forward with back bent, nor supporting arms such that shoulders are raised)
Patient's breathing pattern is stable for a minimum of 5 breaths
Start of washout by inhaling 100% oxygen (initiated by lab technician)
Continuous stable breathing pattern until end of washout test
End target = 1/40th of start N2 concentration
To ensure end of washout is achieved, patients should breathe 5 more breaths below the target concentration before the trial is terminated
Three N2-MBW-tests are performed consecutively. Time between each test is [duration of the previous test*1.5] (e.g. test duration = 6 min., time to next test = 6*1.5 = 9 min.)"
1502691|NCT02950090|Behavioral|MobilWise|see arm description for MobilWise above
1502692|NCT02950090|Behavioral|Fitbit Only|see arm description for Fitbit above
1502693|NCT02950077|Behavioral|mindfulness based stress reduction|The intervention will be delivered in a group setting and the group will meet for 2 hours once per week for 8 weeks. The intervention is based on new neuroscience of stress and resilient adaptive behaviors, mindfulness based stress reduction, therapeutic breath and synchronized yogic movement with a focus on the lower abdomen, integrated with cognitive and behavioral strategies for self-control and healthy decision making.
1502695|NCT02950051|Drug|Fludarabine|Fludarabine i.v.: cycles 1-6: 25 mg/m², d1-3, q28d
1502696|NCT02950051|Drug|Cyclophosphamide|Cyclophosphamide i.v.: cycles 1-6: 250 mg/m², d1-3, q28d
1502697|NCT02950051|Biological|Rituximab|Rituximab i.v. (before chemotherapy): cycle 1: 375 mg/m², d0; cycles 2-6: 500 mg/m², d1; q28d
1502698|NCT02950051|Drug|Bendamustine|Bendamustine i.v.: cycles 1-6: 90mg/m², d1-2, q28d
1502699|NCT02950051|Drug|Venetoclax|"Venetoclax p.o. (ramp-up: dose escalation until final dose is reached)
cycle 1: 20 mg (2 tabl. at 10 mg), d22-28, q28d
cycle 2: 50 mg (1 tabl. at 50 mg), d1-7; 100 mg (1 tabl. at 100 mg), d8-14; 200 mg (2 tabl. at 100 mg), d15-21; 400 mg (4 tabl. at 100 mg), d22-28, q28d
cycles 3-12: 400 mg (4 tabl. at 100 mg), d1-28, q28d"
1502700|NCT02950051|Biological|Obinutuzumab|"Obinutuzumab i.v.
cycle 1: 100 mg, d1; 900 mg, d1(2); 1000 mg, d8+15, q28d
cycles 2-6: 1000 mg, d1, q28d"
1502701|NCT02950051|Drug|Ibrutinib|"Ibrutinib p.o.
cycles 1-12: 420 mg, d1-28, q28d
cycles 13-36: 420 mg, d1-28, q28d"
1502702|NCT02950038|Drug|Ibrutinib|560 mg given by mouth daily in a 28 day cycle.
1502703|NCT02950038|Drug|Nivolumab|3 mg/kg by vein beginning with Cycle 2 on Days 1 and 15 of every 28 day cycle.
1502704|NCT02950025|Device|Online, adaptive MR-guided SBRT|Patients randomized to the online-adaptive treatment planning arm will have all tumor volumes and critical structures within 3 axial slices of the PTV re-contoured on the MR-localization image of the day. The estimated delivered dose should be calculated using the software on the console. An adapted radiation therapy plan should be generated
1502705|NCT02950025|Device|Online, non-adaptive MR-guided SBRT|Patients will not have online-adaptive treatment planning
1502706|NCT02950025|Other|European Organization for Research and Treatment of Cancer (EORTC) QLQ-30|"30 questions
28 questions about various health issues with answers ranging from 1=Not At All to 4 = Very Much
1 question asking about overall health with answers ranging from 1=very poor to 7 excellent
1 question asking about overall quality of life with answers ranging from 1=very poor to 7=excellent"
1502707|NCT02950012|Dietary Supplement|OPTI-BIOME™ Bacillus subtilis MB40|
1502708|NCT02950012|Other|Placebo|
1502709|NCT02949999|Drug|Voclosporin|
2002322|NCT02336451|Drug|LDK378|LDK378 (ceritinib) 750 mg once daily, orally administered
1502710|NCT02949986|Behavioral|Tablet-based Fall Prevention|The focus of the Otago Exercise Program is on improving strength and balance with a home-based balance exercise program. The program will be self-administered via tablet-based version of the Otago fall prevention program. Participants will complete 2 months of the home-based balance exercise program using the Health in Motion app. Participants will be asked to perform the exercises for 30 minutes 3x/week. Participants will be asked to perform the exercise program for 2 months.
1502711|NCT02949973|Drug|voclosporin|
1502712|NCT02949960|Drug|DMT210 Topical Gel|DMT210 Topical Aqueous Gel 5% applied twice daily
1502713|NCT02949960|Drug|Vehicle Control|Topical Vehicle Gel applied twice daily
1502714|NCT02949947|Drug|Ferric Carboxymaltose|15 mg/kg by vein (up to 750 mg) over 15 min infusion. Dose repeated 1 week later.
1502715|NCT02949947|Dietary Supplement|Iron Supplements|Participants take iron supplements by mouth every day for up to 3 months.
1502716|NCT02949947|Behavioral|Questionnaire|Health questionnaire completed at Baseline and at Weeks 4, 8, 12, and 24.
1502717|NCT02949934|Drug|Tolcapone|
1502718|NCT02949934|Drug|Placebo|
1502720|NCT02949908|Drug|Rebif (IFNβ-1b)|Subjects receiving Rebif in accordance with the licensed Summary of Product Characteristics label or currently approved specific country product information.
1502721|NCT02949895|Drug|BMS-986012|
1502722|NCT02949895|Drug|Cisplatin|
1502723|NCT02949895|Drug|Etoposide|
1502724|NCT02949882|Dietary Supplement|Yakult|Containing at least 6,5*10^9 colony forming units (cfu) of Lactobacillus casei Shirota (LcS)
1502725|NCT02949882|Dietary Supplement|Dairy Peach Drink (AH Basic)|Commercially available dairy drink with peach flavour.
1502726|NCT02949869|Other|Spinal Sonography|As described previously
1502727|NCT02949856|Device|Mallinckrodt, COVIDIEN|
1502728|NCT02949856|Device|Endotracheal tube, Unomedica|
1502729|NCT02949843|Drug|Chemotherapy|Receive other treatment
1502730|NCT02949843|Biological|Immunotherapy|Receive other treatment
1502731|NCT02949843|Other|Laboratory Biomarker Analysis|Correlative studies
1502732|NCT02949843|Biological|Nivolumab|Given IV
1502733|NCT02949843|Biological|Pembrolizumab|Given IV
1502734|NCT02949843|Drug|Targeted Molecular Therapy|Receive drug targeting secondary mutation
1502735|NCT02949843|Drug|Tyrosine Kinase Inhibitor|Given PO
1502736|NCT02949830|Drug|ALN-AS1|ALN-AS1 by subcutaneous (SC) injection
1502737|NCT02949817|Device|digital rehabilitation system with wearable multi-IMU(inertial measurement unit) sensors (Rapael kids)|The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with cerebral palsy. All 40 children will receive the conventional occupational therapy, but 20 of these children will receive the additional video-game based rehabilitation therapy. The additional video-game based training will be performed 30 minutes daily 6 times per week, for 4 weeks. The conventional occupation therapy will be performed 30 minutes daily 5 times per week, for 4 weeks.
1502738|NCT02949817|Other|conventional occupational therapy|The Rapael kids, a video-game based rehabilitation therapy system using IMU sensors as a game interface, newly-developed in Korea will be used on upper limb function of children with cerebral palsy. All 40 children will receive the conventional occupational therapy, but 20 of these children will receive the additional video-game based rehabilitation therapy. The additional video-game based training will be performed 30 minutes daily 6 times per week, for 4 weeks. The conventional occupation therapy will be performed 30 minutes daily 5 times per week, for 4 weeks.
1502739|NCT02949804|Behavioral|Comparison between two groups|Comparison will be made between smokers and non smokers regarding vasovagal tendency
1502740|NCT02949791|Procedure|Cytoreductive surgery|Maximal surgical effort to obtain a minimal residual disease of less than 2.5 mm
1502741|NCT02949791|Other|Low Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 8-12 mmHg
1502742|NCT02949791|Other|High Intra abdominal pressure HIPEC|Hyperthermic intraperitoneal chemotherapy using closed modality and intra abdominal pressure of 18-22 mmHg
1502743|NCT02949778|Procedure|QL-block|Bilateral quadratus lumborum block using either ropivacaine 3.75mg/ml or sodium chloride 0.9% is the intervention studied
1502744|NCT02949778|Drug|Ropivacaine|Ropivacaine 3.75mg/ml administered in QL-block as active treatment
1502745|NCT02949778|Drug|Sodium Chloride|Sodium chloride 9mg/mL administered in QL-Block as placebo
1502746|NCT02949765|Drug|Iron sulfate 105 mg|Daily supplementation with iron sulfate 105 mg 1 pill/day
1502747|NCT02949765|Dietary Supplement|Iron-rich diet|
1502748|NCT02949752|Drug|Aripiprazole|Aripiprazole 5 mg every morning will be prescribed for 12 weeks
1502749|NCT02949739|Behavioral|Intensive lifestyle modification|The intervention is delivered as 9 face-face and 13 telephone contact sessions over 12 months. Index cases are the focus for the intervention, but lifestyle modification encourages the whole family to adopt healthy living.
1502750|NCT02949726|Drug|Indocyanine Green (ICG)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
1502751|NCT02949726|Device|Near-infrared Fluorescence Lymphatic Imaging (NIRFLI)|"Near-infrared Fluorescence Lymphatic Imaging (NIRFLI) using Indocyanine Green (ICG) is used to visualize lymphatic vessel anatomy and function."
1502752|NCT02949713|Behavioral|Text messaging-motivational interviewing|Interactive weekly mobile phone text messaging plus prospective motivational interviews
1502754|NCT02949687|Procedure|ileal interposition with sleeve and sympathectomy|laparoscopic ileal interposition with sleeve and sympathectomy
1989788|NCT02374957|Drug|Cilostazol|100 mg twice daily for 90 days
1502757|NCT02949661|Procedure|Superficial cervical plexus block|Patients will receive bilateral superficial cervical plexus block
1989789|NCT02373280|Drug|10 day sequential therapy (Esomeprazole, amoxicillin, clarithromycin, metronidazole)|In this group, patients will receive the 10 day sequential regimen for eradication of H. pylori. 10 day sequential regimen is like follows; Esomeprazole 40 mg bid 10 days (D1-D10)+amoxicillin 1 g bid 5 days (D1-D5)+clarithromycin 500 mg bid 5 days (D6-D10)+metronidazole 500 mg tid 5 days (D6-D10).
1502758|NCT02949661|Procedure|Local wound infiltration|Patients will receive local wound infiltration
1502759|NCT02949648|Device|Electronic cigarette|Electronic cigarettes are devices that do not burn or use tobacco leaves but instead vaporize a solution the user then inhales. The device contains an electronic vaporization system, rechargeable batteries, electronic controls and cartridges of the liquid is vaporized.
1502760|NCT02949622|Behavioral|Multimodal intervention program|"The intervention is structured as follows:
Review of previous session (20 min) Agenda and goals (5 min) Presentation of the topic to be worked (15 min) Training (60 min) Summary and feedback (15 min)"
1502761|NCT02949622|Other|Lifestyle counseling|The group of lifestyle counseling will have basic guidelines, according to the recommendations of public health.
1502762|NCT02949609|Other|Mirror Therapy|Mirror therapy will consist in placing a large mirror in the sagittal plane of the subject so as to reflect his healthy arm while hiding the paretic one, and then asking him to perform movements of his healthy arm while looking at its reflection in the mirror.
1502763|NCT02949609|Other|Control Therapy|Performance of the same movements as the experimental group without the mirror or instructions as to where to look, 5 days/week, for 4 weeks.
1502764|NCT02949596|Behavioral|Quality of life and quality of sexual life questionnaires|
1502765|NCT02949583|Drug|Punica granatum Linn.|Mouthwash (6,25% of Punica granatum Linn) 10mL per day during 14 days
1502766|NCT02949583|Drug|chlorhexidine|standard anti-bacterial mouthwash Mouthwash (0,12% chlorhexidine) 10mL per day during 14 days
1502767|NCT02949570|Drug|Inecalcitol|Prospective open label, non-comparative, multicentre exploratory study. Divided in 2 parts Part1: Inecalcitol treatment will be added to imatinib for 12 months. Part 2: Follow-up after discontinuation of inecalcitol. Imatinib will be maintained for 2 years and then will be stopped for those still in MR4.5. These patients will then be followed for 2 additional years after discontinuation of imatinib.
1502769|NCT02949544|Other|water immersion|warm water immersion
1502770|NCT02949531|Drug|oxygen|
1502771|NCT02949518|Other|ERAS for Spine Pathway|The study team emphasizes that all components of the ERAS pathway are considered standard of care at this institution. The objective of this study is to ensure that the study patients assigned to the ERAS pathway will receive these standard of care components.
1502772|NCT02949505|Behavioral|Home prehabilitation program|12-week exercise therapy using daily step program (accelerometer), functional resistance exercise sessions and telephone/virtual clinic appointments
1502773|NCT02949492|Drug|IL-2 (interleukin 2)|Low-dose IL-2 will be initiated while study participants remain on a calcineurin inhibitor immunosuppressant. Following 4 weeks of treatment, participants showing at least a 2-fold increase in peripheral blood absolute Treg numbers, stable liver function and no adverse effects will undergo a liver biopsy to exclude sub-clinical graft damage, and subsequently will initiate immunosuppression withdrawal. Low-dose IL-2 will be maintained for a total of 6 months.
1502774|NCT02949479|Behavioral|Dissociation Investigation in Sex Offenders|prevalence of a clinical dissociative state during the offence; secondary : correlations of dissociation with childhood abuse or neglect, with significant lifetime dissociative experience, post traumatic stress disorder or dissociative disorder (DSM-5), violence and sexual estimated risk using actuarial and professional structured judgement tools
1502775|NCT02949466|Drug|Triamcinolone|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
1502776|NCT02949466|Device|Hyaluronic acid|compare the additional therapeutic effects of triamcinolone combined with hyaluronic acid injections to hyaluronic acid injections only to patients with knee osteoarthritis
1502777|NCT02949453|Behavioral|Semi-directed interview performed by a social sciences researcher|"Two semi-directed interviews performed by social sciences researcher:
first interview performed 6 weeks after the suicide attempt, in an suicide prevention unit, duration 1 to 1.5 hour
second interview performed 3 month after the suicide attempt, in a suicide prevention unit, duration 1 to 1.5 hour"
1502778|NCT02949440|Procedure|the caudal-to-cranial approach|Cutting the peritoneum along the line between the right mesocolon and retroperitoneum, enter the Toldt's space to dissect the posterior of Superior mesenteric vein and Superior mesenteric artery and their branches, and then finished the D3 dissection from caudal to cranial on both sides of the mesentery along the Superior mesenteric vein. In the end, cut the lateral ligament to mobilize the posterior space of ascending colon. This approach is called the caudal-to-cranial approach.
1502779|NCT02949440|Procedure|the medial-to-lateral approach|First, the pedicle of ileocolic vessels is identified and the mesocolon is dissected between the pedicle and the periphery of the Superior mesenteric vein to expose the second portion of the duodenum. The ileocolic vessels are then cut at their roots. The ascending mesocolon is separated from the retroperitoneal tissues, duodenum, and pancreatic head up to the hepatocolic ligament cranially. The important detail in this procedure is the wide separation between the pancreatic head and the transverse mesocolon.This approach is the medial-to-lateral(MtL) approach
1502780|NCT02949414|Procedure|Cadaveric decellularised tracheal scaffold seeded with autologous mesenchymal cells|The tracheal graft will be manufactured from cadaveric tracheal scaffold and bone marrow derived mesenchymal cells.
1502781|NCT02949388|Drug|Placebo|Two capsules (both containing Placebo enclosed) taken twice a day and approximately 12 hours apart
1502782|NCT02949388|Drug|400 mg (200 mg BID)|Two capsules (both containing two 50mg tablets enclosed) taken twice a day and approximately 12 hours apart
1502783|NCT02949388|Drug|300 mg (150 mg BID)|Two capsules (one containing 50mg tablet and one containing two 50 mg tablets) taken twice a day and approximately 12 hours apart
1502784|NCT02949375|Drug|Placebo Comparator|Placebo gel capsule to be taken daily for 28 days
1502785|NCT02949375|Drug|Active Comparator:4.5mg GRI-0621|4.5mg GRI-0621 gel capsule to be taken daily for 28 days
1502786|NCT02949375|Drug|Active Comparator: 6.0mg GRI-0621|6.0mg GRI-0621 gel capsule to be taken daily for 28 days
1502787|NCT02949362|Drug|Teduglutide|0.05mg/kg
1502788|NCT02949362|Other|SOC|Standard safety assessments and adjustments in nutritional support will be provided for all subjects throughout the study, including any teduglutide treatment periods
1502789|NCT02949349|Drug|Mycophenolate mofetil|Provided as 250mg/capsule, dose specific for each arm, orally twice a day, for 24 weeks.
1503485|NCT02943954|Device|Fractional Flow Reserve (FFR)|
1502790|NCT02949349|Drug|Azathioprine|Provided as 50mg/tablet, 1mg/kg, orally twice a day, for 24 weeks.
1502791|NCT02949349|Drug|Prednisolone|Daily dose not more than 10mg, orally, for 24 weeks.
1502792|NCT02949336|Radiation|Observational use of fluoroscopy|Minimal radiation exposure (0.17 mSv) for observational purpose
1502793|NCT02949323|Other|urinary stone|patients of group one have urinary stones
1502794|NCT02949310|Drug|Nefopam|
1502795|NCT02949310|Drug|Normal Saline|
1502796|NCT02949297|Device|Ovation Alto Abdominal Stent Graft System|Repair of Abdominal Aortic Aneurysm with Ovation Alto Abdominal Stent Graft System
1502797|NCT02949284|Drug|Abiraterone Acetate|Given PO
1502798|NCT02949284|Drug|Androgen Receptor Antagonist ARN-509|Given PO
1502799|NCT02949284|Biological|Gonadotropin-releasing Hormone Analog|Given SC
1502800|NCT02949284|Drug|Prednisone|Given PO
1502801|NCT02949284|Other|Quality-of-Life Assessment|Ancillary studies
1502802|NCT02949284|Other|Questionnaire Administration|Ancillary studies
1502803|NCT02949284|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
1502804|NCT02949271|Other|Programmed Intermittent Epidural Bolus|
1502805|NCT02949271|Other|Continuous Epidural Infusion|
1502806|NCT02949271|Drug|Ropivacaine|
1502807|NCT02949271|Drug|Fentanyl|
1502808|NCT02949258|Drug|oxaliplatin|oxaliplatin 150 mg will be administered from the celiac artery on day 1 of every cycle in all cases
1502809|NCT02949258|Drug|etoposide|etoposide 100 mg will be administered from the celiac artery on day 1 of every cycle in all cases
1502810|NCT02949258|Drug|epirubicin|epirubicin 30 mg will be administered from the celiac artery on day 1 of every cycle in all cases
1502811|NCT02949258|Drug|S1|Oral S-1 120 mg per day will be administered on days 1-14 of every cycle in all cases
1502812|NCT02949245|Procedure|Interventions|"Procedure/Surgery: Routinely performed surgical correction of spinal deformity
Routinely performed surgical correction of spinal deformity"
1502813|NCT02949232|Drug|Prednisolone|prednisolone will be will be initiated during the first week at 40mg/day for 3 days and 30mg/day for 4 days, followed by a decrease of 5mg/day per week during the remaining 5 weeks; in the second week, patients will use 25 mg/day, in the third week 20 mg/day is used etc. In the last week the patients will only take prednisolone on day 1-3 and day 5 and 7; a tapering scheme in line with the treatment guidelines for Inflammatory Bowel Diseases (2008).
1502814|NCT02949232|Drug|Placebo Oral Tablet|Dosing following the tapering scheme of the treatment of the treatment arm
1502815|NCT02949219|Other|Laboratory Biomarker Analysis|Correlative studies
1502816|NCT02949219|Biological|Pembrolizumab|Given IV
1502817|NCT02949206|Drug|JNJ-64179375|During part 1, participants will receive a single ascending Intravenous dose of JNJ-64179375 ranging from (0.03 mg/kg to 5.0 mg/kg). In Part 2, participants will receive a 2.5 mg/kg or highest tolerable dose if lower than 2.5 mg/kg of JNJ-64179375. In Part 3, participants will receive a Single Subcutaneous (SC) dose of 1.0 mg/kg or highest tolerable dose if less than 1.0 mg/kg of JNJ-64179375.
1502818|NCT02949206|Drug|Placebo|Participants will randomly receive matching placebo in all 3 Parts on day 1 administered via IV Route (for Part 1 and 2) and SC route (for Part 3).
1502819|NCT02949206|Drug|4 Factor Prothrombin Complex Concentrate (PCC)|Following a single dose of JNJ-64179375, participants will receive a single IV dose of 4 factor-PCC.
1502820|NCT02949193|Drug|evogliptin|evogliptin 5mg tablet qd + placebo tablet matching to sitagliptin 100mg
1502821|NCT02949193|Drug|Sitagliptin|sitagliptin 100 mg tablet qd + placebo tablet matching to evogliptin 5mg
1502822|NCT02949180|Device|Five minutes puls wave recording|iPhone will be positioned on the index finger for five minutes to record a pulse wave
1502823|NCT02949167|Behavioral|MyHealth|The MyHealth intervention is a nurse-led individually tailored symptom management program, focused on patient education and regularly collection of Patient Reported Outcomes (PRO) subsequently evaluated by specialist nurses and navigation to health care service. The nurse will meet with the patient on three-five planned appointments focused on adjustment of life after breast cancer treatment including information on symptoms of relapse or late effects and how to react on these. Close relatives are invited if patients accept. Patients will report PRO´s on symptoms of recurrence and late effects every three months during the first year and thereafter every six months.The appointments with the nurse are finalized within 3-6 month and patients will be followed with PRO for three years.
1502824|NCT02949141|Device|Lung Ultrasound|All patients will receive lung ultrasound, chest x-ray and computed tomography
1502825|NCT02949141|Device|Chest X-ray|All patients will receive chest x-ray as per usual care for evaluation for pneumonia
1502826|NCT02949141|Device|Chest Computed Tomography (CT)|All enrolled patients will receive a CT scan as the gold standard for diagnosing pneumonia
1502827|NCT02949128|Biological|ALXN1210|"Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
≥ 40 to <60 kg: 2400 mg loading, then 3000 mg every 8 weeks
≥ 60 to <100 kg: 2700 mg loading, then 3300 mg every 8 weeks
≥100 kg: 3000 mg loading, then 3600 mg every 8 weeks"
1502828|NCT02949115|Dietary Supplement|70 mL red beetroot juice|1x daily intake of 70 mL red beetroot juice
1502829|NCT02949115|Dietary Supplement|70 mL red beetroot juice without nitrate|1x daily intake of 70 mL red beetroot juice without nitrate
1502830|NCT02949115|Dietary Supplement|70 mL placebo drink plus potassium nitrate|1x daily intake of 70 mL placebo control drink plus 489 mg potassium nitrate (300 mg nitrate)
1502831|NCT02949115|Dietary Supplement|70 mL placebo drink|1x daily intake of 70 mL placebo control drink
1502832|NCT02949102|Dietary Supplement|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
1502833|NCT02949102|Dietary Supplement|Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
1502834|NCT02949089|Drug|ACH04|The subjects will receive the study medication in each group
1502835|NCT02949076|Behavioral|Exercise|Unilateral lower limb resistance exercise will be performed 3 times per week for 8 weeks in non-small cell lung cancer patients on only one leg, while the contralateral leg serves as a non-exercising control.
1502907|NCT02948439|Other|Aerobic exercise|Brisk walking 3-4 times per week for up to 40 minutes of activity.
1503634|NCT02942771|Drug|Cohort 1 - TT301/MW189|0.075 mg/kg IV twice daily on Days 1 through 5
1502836|NCT02949063|Behavioral|Comfortable Cafeteria Program|6-week program integrated into the cafeteria lunchtime to build capacity of supervisors and students to create a positive social and emotional atmosphere so that students can enjoy eating their lunch and socializing with peers.
2002324|NCT02322190|Procedure|Extracorporeal Photopheresis (ECP)|Twice weekly for 1 month or Twice every other week for 2 months or Twice during one week per month for 4 months for a total of up to 7 months of treatment
1502839|NCT02949037|Other|Mobile Health Care Environment (MHCE)|An integrated mobile health system modified to support type 2 diabetes self-care activities. Primary intervention includes visualization and trending of device outcomes AND tailored behavioral messages based on Patient Activation Measure scores.
1502840|NCT02949024|Drug|IVT aflibercept + SC CLS-TA|IVT aflibercept [2 mg (50 µL)] + SC CLS-TA [4 mg (100 µL)]
1502841|NCT02949024|Drug|SC CLS-TA|[4 mg (100 µL)]
1502842|NCT02949011|Drug|S-033188|2-4 X 20-mg tablets taken orally
1502843|NCT02949011|Drug|Placebo to S-033188|2-4 X 20-mg tablets taken orally
1502844|NCT02949011|Drug|Oseltamivir|75-mg capsules taken orally
1502845|NCT02949011|Drug|Placebo to Oseltamivir|Placebo capsules matching oseltamivir 75-mg capsules
1502846|NCT02948998|Drug|Spironolactone|The participants in this arm will be prescribed to take 20mg spironolactone orally and daily. Serum potassium concentration and creatinine and blood pressure will be monitored regularly to make the participants safe.
1502847|NCT02948985|Other|treated with FOLFIRI±cetuximab|Peripheral blood samples of 10 mL were collected from the patients for CTCs analysis and tumor marker in every cycle D0 and D8. Tumor response evaluation will be performed after four cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastatic organ, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.The correlation of the RAS status on CTCs and the mutant gene in ctDNA to the therapeutic response will be evaluated.
1502848|NCT02948972|Procedure|complete surgery|complete surgery of colorectal deep infiltrating endometriosis
1502849|NCT02948972|Procedure|In vitro fertilization without surgery|IVF without endometriosis surgery
2002325|NCT02322190|Drug|Methoxsalen|Used in conjuction with photopheresis procedure
2002326|NCT02323503|Device|CRT-D device replacement|
2002327|NCT02320123|Behavioral|Educational DVD|African American patients and their primary non-professional caregivers will watch a DVD created to introduce end-of-life care planning to African Americans receiving palliative care.
2002328|NCT02318771|Radiation|Radiation Therapy (RT)|Undergo RT
1502854|NCT02948946|Procedure|NETest|5 mL of blood will be drawn from participants for testing.
1502855|NCT02948920|Drug|Ephedrine|9 mg of ephedrine (3 ml)
1502856|NCT02948920|Drug|NSS|3 ml of normal saline
1502857|NCT02948907|Other|Procedure/Bronchoscopy|"Patients with enlarged hilar and/or mediastinal lymph nodes and indication for EBUS-TBNA undergo diagnostic bronchoscopy. For characterisation of the enlarged lymph nodes endobronchial ultrasound with elastography and Tissue Harmonic Imaging (THI) are used. Afterwards, EBUS-TBNA is performed. The results of elastography and THI are correlated with the cytological result obtained by EBUS-TBNA."
1502858|NCT02948894|Device|Mandibular advancement device|an oral appliance (a dental device) for obstructive sleep apnea
1502859|NCT02948881|Drug|ibandronate|
1502860|NCT02948868|Behavioral|Contingency Management|Administering of vouchers to methamphetamine users for negative urine samples
1502861|NCT02948842|Drug|Clostridium Histolyticum Collagenase|Dosing follows guidelines for XIAFLEX® approved treatment for Peyronie's disease
1502862|NCT02948842|Drug|Lidocaine|20 cc of 2% lidocaine jelly will be used for local anesthesia prior to study injection.
1502863|NCT02948829|Biological|Tetravalent Dengue Vaccine Candidate|TDV subcutaneous injection
2002329|NCT02318771|Drug|MK-3475|Given IV
2002330|NCT02318589|Drug|Irinotecan + Eribulin|Patients receive Oral Irinotecan on days 1-5 and IV Eribulin on days 1 and 8 of a 21 day cycle in the absence of disease progression or unacceptable toxicity.
2002331|NCT02318017|Drug|Methylphenidate|Before neurocognitive testing, Methylphenidate/Placebo will be given
1502867|NCT02948803|Behavioral|smartphone based intervention with Active Coach app|
1502868|NCT02948790|Device|Neuristim|Stimulation at high, medium and low intensity on apical, medial and basal Neuristim electrode
1502869|NCT02948790|Device|Cochlear implant|Stimulation at high, medium and low intensity on apical, medial and basal Cochlear implant electrode
1502870|NCT02948777|Drug|Evolocumab|Evolocumab 140 mg subcutaneous injection once every 2 weeks for 12 weeks
1502871|NCT02948764|Device|Vacuum-Assisted Biopsy|"A vacuum-assisted (7-9G), minimal invasive biopsy (VAB), either guided by ultrasound or by mammography (stereotaxis) will be performed once during the second trial visit (after NACT completion and before surgery).
VAB will be performed once, taking at least 5 biopsies (depending on the diameter of the VAB needle) in the (former) tumor region."
1502872|NCT02948738|Behavioral|Interactive Asthma Education|Active participation to develop asthma action plan and teach back cycles for asthma inhaler teaching/training
1502873|NCT02948738|Behavioral|Standard Asthma Education|Basic review of asthma action plan and inhaler use
1502874|NCT02948725|Other|Cross-education + standard rehabilitation|
1502875|NCT02948712|Behavioral|Distress Screening Thermometer|Screening took with an overall distress ranging from 0-10 and additional stress items in the areas of practical problems, family problems, emotional problems, spiritual or religious concerns, and physical problems
1502876|NCT02948712|Behavioral|NCCN Guidelines: Distress management|Based on the NCCN Guidelines Version 1.0.2016 which recommend brief screening, evaluation, and treatment of distress
1502877|NCT02948699|Dietary Supplement|Nutrison|Nutrison(400-600ml/d) will be given to Arm 1 patient between regular diet. When the daily ration was cut down to 50%,100ml/h Nutrison was added. When grade Ⅲ-Ⅳ oral mucositis appeared, total Nutrison was applied to patients by NG or PEG.
1503635|NCT02942771|Drug|Cohort 2- TT301MW189|0.15 mg/kg IV twice daily on Days 1 through 5
2002332|NCT02318017|Drug|Placebo|
2002333|NCT02316821|Drug|RTA 402|
2002334|NCT02316821|Drug|Placebo|
1502878|NCT02948686|Other|Self-Etching Application Strategy|In Group SET, the adhesive system Ambar Universal will be used in 55 teeth, according to the manufacturer's instructions, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
1502879|NCT02948686|Other|Enamel Etching Application Strategy|In Group SEE, 37% phosphoric acid will be applied during 15 seconds, only in enamel in 55 teeth. This acid will be removed using water, the cavity will be air-dried, and then, the adhesive system Ambar Universal will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores.
1502880|NCT02948686|Other|Self Etching with Extended time Application Strategy|In Group SETT, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 20 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 20 seconds, air-dried during 10 seconds and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
1502881|NCT02948686|Other|Self Etching with Extended layers number Strategy|In Group SETL, the adhesive system Ambar Universal will be used in 55 teeth, in the self-etching mode. The adhesive system will be brushed during 10 seconds in the cavity, will be air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, brushed again during 10 seconds, air-dried during 5 seconds, and activated during 10 seconds with LED light; After applying the adhesive, the restorations will be made with composite resin Opallis (FGM, Joinville, Brazil), and evaluated every 6 months for pain assessment, shape, staining or recurrent caries, using scores
1502882|NCT02948673|Dietary Supplement|Glutathione|4 oral GSH tablets/day (1000mg/day) for 4 weeks
1502883|NCT02948673|Other|Placebo|4 oral placebo tablets for 4 weeks
1502884|NCT02948660|Other|zolpidem tartrate|
1502885|NCT02948660|Other|melatonin|
1502886|NCT02948647|Other|Standard of care plus sugar-reduction education|This is a 12-week intervention where subjects will be educated on how to monitor their added sugar consumption. They will be asked to eliminate consumption of sweetened beverages for the 12-week period and will be receiving a weekly delivery of water bottles to their homes to displace the sweetened beverages in their home environment.
1502887|NCT02948634|Device|Sham Phoenix Laser Treatment|Sham treatment will be delivered via the same protocol in terms of time, application, and areas of treatment as stated above, except the laser unit will not discharge any photonic energy. Intervention will take place in the therapy room at the McDermott Center for Pain Management, which is appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
1502888|NCT02948634|Device|Active Phoenix Laser Treatment|The 30 min treatments will include multiple 60 sec applications to all tender points on the spine or extremities and a 10 minute application along the bilateral sympathetic ganglion in the paraspinous region. The treatment will be applied via a non-contact method, with the laser applicator held 12-18 inches above the participant's skin.
1502889|NCT02948621|Procedure|Endoscopic sleeve gastroplasty|Endoscopic sleeve gastroplasty is performed using a CE marked endoscopic suture device (Overstitch, Apollo Endosurgery, Austin, Tx. USA). Continuous stitches are placed to create a sleeve-shaped gastric path of 2 cm diameter to reduce stomach volume from the proximal antrum to the oeso-gastric junction.
1502890|NCT02948595|Other|Video feedback followed by structured verbal feedback|Video feedback followed by structured verbal feedback
1502891|NCT02948595|Other|Structured verbal feedback followed by video feedback|Structured verbal feedback followed by video feedback
1502892|NCT02948582|Drug|Glycopyrrolate Inhalation Solution12.5mg|Glycopyrrolate Inhalation Solution12.5mg via eFlow, once daily
1502893|NCT02948582|Drug|Glycopyrrolate Inhalation Solution 50mg|Glycopyrrolate Inhalation Solution 50mg via eFlow, once daily
1502894|NCT02948582|Drug|Glycopyrrolate Inhalation Solution 100mg|Glycopyrrolate Inhalation Solution 100mg via eFlow, once daily
1502895|NCT02948582|Drug|Glycopyrrolate Inhalation Solution 200mg|Glycopyrrolate Inhalation Solution 200mg via eFlow, once daily
1502896|NCT02948582|Drug|Glycopyrrolate Inhalation Solution 400mg|Glycopyrrolate Inhalation Solution 400mg via eFlow, once daily
1502897|NCT02948582|Drug|Placebo 0.5mL|Placebo 0.5mL via eFlow, once daily
1502898|NCT02948569|Drug|3-V Bioscience-2640|Subjects will take a singly daily dose of 3-V Bioscience-26400 before bedtime or 22:30, whichever comes first, for 10 days.
1502899|NCT02948543|Biological|Bacillus of Calmette-Guerin (BCG)|A strain of tubercle bacillus which modifies biologic response.
1502900|NCT02948543|Drug|Mitomycin C (MMC)|An antibiotic produced by a soil actinomycete which inhibits DNA synthesis.
1502901|NCT02948517|Other|Time restricted feeding|Time restricted feeding
1502902|NCT02948504|Procedure|Coiling or Clipping|All patients are treated under general anesthesia and systemic heparinization. A bolus of 50-75 IU/kg of heparin is given after femoral sheath placement, and intermittent boluses of 1250 IU per hour are given during the procedure. Activated clotting time is maintained at 2-3 times baseline level. Balloon-assisted coiling or stent-assisted coiling are considered in aneurysms with an unfavorable morphology (aneurysm neck≥ 4.0 mm or dome/neck ≤2.0). All anterior circulation aneurysms are clipped through a standard pterional or frontal temporal approach. The posterior circulation aneurysms are treated using far lateral approach depending on the aneurysm location.
1502903|NCT02948491|Other|Music therapy|Song that the mother sings to the child before birth, recording of the mother's voice.
1502904|NCT02948478|Other|Exposed|Precarious patients
1502905|NCT02948478|Other|Non exposed|Non precarious patients
1502906|NCT02948452|Other|fMRI|fMRI: reward task, anxiety provocation
2002335|NCT02316574|Behavioral|Cognitive Behavioral Coping Skills Therapy|"Cognitive Behavioral Coping Skills Therapy (CBCST) is an individual psychotherapy for alcohol dependence that helps individuals to reduce drinking by addressing the ability to regulate, or cope with alcohol cravings and other emotions that promote alcohol use."
1502909|NCT02948400|Behavioral|pedestrian safety training in pedestrian virtual environment|pedestrian safety training
1502910|NCT02948361|Other|QT Ultrasound Breast Scan|Subjects will be scanned on the QT Ultrasound Breast Scanner. For subjects that may have breast calcifications and/or mass(es) and/or other finding(s) on the QT scan image(s), standard imaging modalities (e.g., mammogram and HHUS) will be performed per American College of Radiology (ACR) recommendations.
1502911|NCT02948348|Drug|Nivolumab|Capecitabine:Dose of 1650mg/m2,14days, Radiation:45Gy/25 fractions, Nivolumab :240mg on day1 of each cycle, Surgical therapy:The resection (LAR), intersphincteric resection (ISR), or abdominoperineal resection (APR).
1502912|NCT02948322|Device|CMRI|Myocardial Imaging (CMRI) will be performed in patients (at baseline and 6 month after treatment) and healthy volunteers (baseline)
1502913|NCT02948322|Drug|Gadolinium|gadolinium injection will be performed during CMRI in patients and healthy volunteers.
1502914|NCT02948322|Procedure|OGTT|Growth Hormon (GH) secretion and metabolic status of the acromegalic will be evaluated by an measure of plasma glucose, insulin and GH (OGTT), and insulin-like growth factor-1 (IGF-I) will be measured in patients and healthy volunteers.
1502915|NCT02948309|Drug|Mistletoe extract (Iscador Qu)|1ml subcutaneous injection 3 times/week, dose escalation 0,01mg - 20mg
1502916|NCT02948309|Drug|Placebo|1ml subcutaneous injection 3 times/week
1502917|NCT02948296|Device|medial prefrontal cortex|neuroimaging and craving will be assessed after medial prefrontal cortex stimulation
1502918|NCT02948296|Device|dorsolateral prefrontal cortex|neuroimaging and craving will be assessed after dorsolateral prefrontal cortex stimulation
1502919|NCT02948296|Device|sham stimulation|neuroimaging and craving will be assessed after sham stimulation
1502920|NCT02948283|Other|Laboratory Biomarker Analysis|Correlative studies
1502921|NCT02948283|Drug|Metformin Hydrochloride|Given PO
1502922|NCT02948283|Other|Pharmacological Study|Correlative studies
1502923|NCT02948283|Drug|Ritonavir|Given PO
1502924|NCT02948283|Other|Quality-of-Life|Ancillary studies
1502925|NCT02948283|Other|Questionnaire|Ancillary studies
1502926|NCT02948257|Device|Cardiva Medical VASCADE VCS|At the end of peripheral endovascular interventional procedures performed via an antegrade femoral arterial approach, the femoral arterial access site is closed with the VASCADE VCS to achieve arterial hemostasis.
1502927|NCT02948244|Dietary Supplement|Creatine Monohydrate|Synthetically produced dietary supplement Creatine Monohydrate will be used in powder form reconstituted to a drink. The dosage will be 100mg/kg/day up to a maximum of 10 grams daily.
1502928|NCT02948244|Dietary Supplement|Placebo|Placebo
1502929|NCT02948231|Device|Mistral implantation|Mistral Implant is implanted in the Mitral valve
1502930|NCT02948218|Device|Acupuncture treatment|Acupuncture treatment will be the Traditional Chinese Medicine type. Acupuncture 3 times per week, 4 weeks is one treatment period. Every patient will be given 3 treatment period.
1502931|NCT02948205|Procedure|3D group|infertility patient get TU-LESS by 3D Laparoscopy
1502932|NCT02948205|Procedure|normal group|infertility patient get normal laparoscopic surgery
1502933|NCT02948192|Other|Survey, Sample collection|Survey is collected on the dietary intake of both cohorts. Sample collection is done from patients in both cohorts at multiple time points.
1502934|NCT02948179|Procedure|Preimplantation Genetic Diagnosis|Using Preimplantation genetic diagnosis, including multiple annealing and looping-based amplification cycles amplification technique, the investigators have had screened out healthy embryos by In Vitro Fertilization. Then the investigators transplanted embryos returned to the parent. Finally, participants will have healthy baby without pathogenic gene inheritance.
1502935|NCT02948166|Procedure|Angioplasty with stenting of the femoral artery|A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon expandable or self-expanding) of all the extension is mounted.
1502936|NCT02948166|Procedure|Open surgery|Performed open endarterectomy of the common, deep, initial of superficial femoral artery. Proximal plaque exfoliate as far as possible in the superficial femoral artery. After that, the translational and rotational motions loops under fluoroscopic guidance, continuing detachment of plaque in the antegrade direction to the distal end of plaque. Plastic of arteriotomy wounds performed patches of ksenoperikard treated with epoxy compounds. Control patency of the arterial vessel is performed intraoperatively by X-ray angiography. When rendering residual stenosis or intimal dissection, limiting blood flow, complemented by endovascular intervention plasticity.
1502937|NCT02948153|Other|clinical study|It is a comprehensive study in a large sample using multiple techniques to assess various aspects of the disease. All patients underwent the following : Induced Sputum, spirometry, fractional exhaled nitric oxide (FeNO), prick test, total IgE and blood albumin. Analysis of mucins and TLRs
1502938|NCT02948140|Procedure|MRI|
1502939|NCT02948140|Procedure|Abdominal scanner|
1502940|NCT02948127|Biological|RSV LID cp ΔM2-2 Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
1502941|NCT02948127|Biological|Placebo|Administered as nose drops
1502942|NCT02948114|Other|Control: Cow milk-based infant formula|
1502943|NCT02948114|Other|Experimental 1: Cow milk-based infant formula|Experimental 1: Cow milk-based infant formula with prebiotics
1502944|NCT02948114|Other|Experimental 2: Cow milk-based infant formula|Experimental 2: Cow milk-based infant formula with probiotics
1502945|NCT02948114|Other|Experimental 3: Cow milk-based infant formula|Experimental 3: Cow milk-based infant formula with prebiotics and probiotics
1502946|NCT02948101|Biological|PD 0360324|50 mg by vein on Days 1, 8, 15, and 22 of Cycle 1. Participants only receive 4 doses.
1503636|NCT02942771|Drug|Cohort 3 - TT301/MW189|0.30 mg/kg IV twice daily on Days 1 through 5
1502947|NCT02948101|Drug|Cyclophosphamide|Starting at Cycle 2, participants take 1 Cyclophosphamide 50 mg capsule by mouth at the same time every day in the morning until progression.
1502948|NCT02948075|Drug|Quisinostat|
1502949|NCT02948075|Drug|Paclitaxel|
1502950|NCT02948075|Drug|Carboplatin|
2002336|NCT02316028|Drug|Decitabine|"administration of decitabine by hepatic arterial infusion
Accrual of patients and dosing of decitabine will be guided by a traditional 3+3 design using an accelerated titration for the first three dose levels.
Proposed dose levels:
10 mg/m2 per course
15 mg/m2 per course
20 mg/m2 per course"
1502952|NCT02948023|Biological|Ex-vivo cultivated limbal stem cell pool|0.5 million stromal and epithelial cells will be incorporated in 0.05ml of commercially available fibrin glue and pasted over the corneal lesion after epithelial debridement.
1502953|NCT02948010|Device|Auto CPAP + comfort feature A|Auto CPAP + comfort feature A using Fisher & Paykel Healthcare CPAP Device
1502954|NCT02948010|Device|Auto CPAP with comfort feature B|Auto CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
1502955|NCT02948010|Device|Auto CPAP with no comfort feature|Auto CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
1502956|NCT02948010|Device|Auto CPAP with comfort feature A+B|Auto CPAP with comfort feature A+B using Fisher & Paykel Healthcare CPAP Device
1502957|NCT02948010|Device|CPAP with comfort feature A|CPAP with comfort feature A using Fisher & Paykel Healthcare CPAP Device
1502958|NCT02948010|Device|CPAP with comfort feature B|CPAP with comfort feature B using Fisher & Paykel Healthcare CPAP Device
1502959|NCT02948010|Device|CPAP with no comfort feature|CPAP with no comfort feature using Fisher & Paykel Healthcare CPAP Device
1502960|NCT02948010|Device|CPAP with comfort feature A + B|CPAP with comfort feature A + B using Fisher & Paykel Healthcare CPAP Device
1502961|NCT02948010|Device|CPAP at Sub therapeutic level|CPAP at Sub therapeutic level using Fisher & Paykel Healthcare CPAP Device
1502962|NCT02947997|Device|OFDI capsule|Imaging of esophagus using OFDI capsule and system
1502963|NCT02947984|Radiation|Standard Treatment|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
1502964|NCT02947984|Radiation|Higher Dose|55.8 CGE in 31 treatments of 1.8 CGE given once a day, for five days each week. Treatment based upon a treatment planning CT.
1502965|NCT02947971|Device|Experimental OFDI Imaging|Imaging of the esophagus with a compact OFDI system and distal scanning catheter
1502966|NCT02947958|Other|Teleconsultation|Teleconsultation - the teleconsultation usage in chronic diseases, such as benign hyperplasia, seems to be a promising scenario. Once the patient symptoms are evaluated and diagnosed as a stable disease he is able to keep his treatment annually. In a way to do not overload de tertiary system, such monitoring could be done under a teleconsultation with a urological supervision in the primary care.
1502967|NCT02947958|Other|Hospital (control)|The patient will keep his usual care at the tertiary care.
1502968|NCT02947945|Drug|Reslizumab|All subjects will receive Reslizumab
1502969|NCT02947932|Drug|Resveratrol|pre-ERCP intervention
1502970|NCT02947932|Drug|Indomethacin|post-ERCP intervention in high risk patients
1502971|NCT02947919|Behavioral|Music|A previously defined list of songs will be administered by headphones to these patients with an MP3 device with headphones.
1502972|NCT02947906|Other|No intervention|No intervention
1502973|NCT02947893|Drug|Placebo Capsule(s) Once a Day by Mouth|1 capsule of Placebo once a day for 6 months followed by 2 capsules of Placebo for another 6 months
1502974|NCT02947893|Drug|Nilotinib Capsule(s) Once a Day by Mouth|1 capsule of Nilotinib 150 mg once a day for 6 months followed by 2 capsules of Nilotinib (150 mg each capsule = 300 mb total) for the subsequent 6 months
1502975|NCT02947880|Drug|Bumetanide|For the patient of 25kg and more the bumetanide is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
1502976|NCT02947880|Drug|Placebo|For the patient of 25kg and more the placebo is used at the posology of 1mg in the morning and 1mg in the evening, for patient under 25kg the posology is 0.5mg in the morning and 0.5mg in the evening.
1502977|NCT02947867|Drug|aganirsen|aganirsen antisense oligonucleotide against Insulin Receptor Substrate (IRS-1)
1502978|NCT02947854|Drug|Fimaporfin (Photosensitizer)|
1502979|NCT02947854|Biological|Hiltonol (Poly-ICLC)|
1502980|NCT02947854|Biological|HPV E7 (Human Papilloma Virus E7) peptides|
1502981|NCT02947854|Biological|KLH (Keyhole Limpet Hemocyanin)|
1502984|NCT02947815|Drug|Clostridium Botulinum Toxin Type A|
1502985|NCT02947815|Drug|Clostridium Botulinum Toxin Type A|
1502986|NCT02947802|Other|Effectiveness of Labels in Reducing Purchasing of Sugar Sweetened Beverages|In one of our parallel assigned conditions participants will receive additional information (e.g., an intervention) of effectiveness information. These consumers will learn how effective these labels were in reducing the purchasing of sugar sweetened beverages in a recent study.
1502987|NCT02947802|Other|Control condition|In one of our parallel assigned conditions participants will receive no additional information and be asked to rate their support for the label.
1502988|NCT02947789|Procedure|Emergency surgery|Patients undergoing emergency surgery
1502989|NCT02947776|Behavioral|PEER|The experimental group will receive usual care + peer befriending. Peer befriending aims to utilise the skills and 'lived experience' of people with longer-term aphasia to offer support to others with aphasia, starting at a time of transition (discharge from hospital and withdrawal of intensive therapeutic input) and increased need. It aims to help people develop their own strategies for adjusting to life post-stroke. Peer-befrienders will visit participants 6 times over a period of 3 months (+2 times within the next 6 months). The schedule, nature of visits, and goals (e.g. discuss concerns; pursue activities) will be agreed between the pair. Visits may include: conversation, problem solving, trips out, joint activities.
2002339|NCT02315053|Other|Low dose FDG PET/CT 5 x.|Multiple FDG PET/CT studies will be added to the normal diagnostic procedures as a part of this study, with the number of scans depending on the study stage, to a maximum of 6 per patient.
1502990|NCT02947776|Behavioral|USUAL|The control group will receive usual care, i.e. all health, social care and voluntary services available to them in their borough. It is not known what exactly usual care comprises for people with aphasia who are discharged in the community with low levels of psychological problems, and this project will help to document this.
1502991|NCT02947763|Drug|mixture of metronidazole, ciprofloxacin, and minocycline|placement of intracanal medication
1502997|NCT02947737|Other|Amniotic membrane dressing|We will place an amniotic membrane dressing on the donor site
1502998|NCT02947737|Other|Gentamicin and xeroform dressing|We will place xeroform, gentamicin and telfa on the donor site
1502999|NCT02947724|Drug|SURGICEL®|Insertion of 4 pieces of SURGICEL® inside the cyst cavity. Insertion of 4 pieces of SURGICEL® inside the remaining ovarian tissues.
1503000|NCT02947711|Drug|E2027|2 x 50 mg capsules, once daily on Day 1 and Day 12
1503001|NCT02947711|Drug|Diltiazem ER|1 x 300 mg capsule, once daily on Days 7 through 24
1503002|NCT02947685|Drug|palbociclib|o Starting dose: 125 mg capsule taken orally once per day for 21 days followed by 7 days off to complete 28 day cycle. Dose reductions: 100 mg, 75 mg. allowed. Number of Cycles: until progression or unacceptable toxicity develops
1503003|NCT02947685|Drug|trastuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib. Trastuzumab dosing will be determined based on a loading dose of 8mg trastuzumab/kg body weight for Q3WK dosing schedules or a maintenance dose of 6mg/kg trastuzumab/kg dosing weight for Q3WK dosing schedules. Loading dose will be administered on Cycle 1, Day 1.
1503004|NCT02947685|Drug|pertuzumab|Patients must have received a minimum of 4 and maximum of 8 cycles of induction therapy prior to randomization to Arm A or B, at which point they will continue on antiHER2 therapy and endocrine therapy, with or without palbociclib.Pertuzumab will be administered at a loading dose of 840 mg infusion and then at a maintenance dose of 420 mg q3wks. If patient is within 5 weeks of receiving loading dose at Cycle 1, Day 1, patient may start with maintenance dose of 420 mg.
1503005|NCT02947685|Drug|letrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for letrozole oral therapy is 2.5 mg orally, once a day.
1503006|NCT02947685|Drug|Anastrozole|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for anastrozole is 1 mg orally, once a day.
1503007|NCT02947685|Drug|Exemestane|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for exemestane is 25 mg orally, once a day.
1503008|NCT02947685|Drug|Fulvestrant|There are several allowed endocrine treatment agents for Arm A and Arm B of this study. Administration is performed on an outpatient, self-administration basis according to local requirements and local standard practice. Endocrine treatment may have started before the patient enters the study. Agents will be administered at the discretion of principal investigator as well as according to standard institutional or regional practice. Recommended dosing regimen for Fulvestrant is 250 mg injections on Day 1 and Day 15 of Cycle 1, and q4weeks thereafter.
1503009|NCT02947672|Drug|Intravenous Dexamethasone|
1503010|NCT02947672|Drug|Intraperitoneal Dexamesathone|
1503011|NCT02947646|Device|BabyGentleStick™ ON|
1503012|NCT02947646|Device|BabyGentleStick™ OFF|
1503013|NCT02947633|Drug|Single-injection sciatic PNB|Single-injection sciatic PNB is a regional anesthetic technique employed to anesthetize the sciatic nerve with a single dose of local anesthetic. This technique offers pain control for a limited amount of time based on the volume and concentration of local anesthetic used.
1503093|NCT02947061|Drug|S1 plus Docetaxel|S1 80mg to 120 mg per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
1503094|NCT02947061|Drug|Capecitabine plus Docetaxel|Capecitabine 1,000 mg/m2 per day on Days 1-14, every 21 days; Docetaxel 75mg/m2 on Day 1
1503014|NCT02947633|Drug|Continuous sciatic PNB|"Continuous sciatic PNB entails placing a continuous perineural infusion (CPI) catheter so that local anesthetic may be released slowly but continuously adjacent to the sciatic nerve (perineural) for several days postoperatively. The continuous PNB has the ability to reliably provide analgesia on subsequent postoperative days.
Participants my be randomized to receive an additional experimental continuous pain ball during surgery which can provide up to 48 hours of pain relief."
1503015|NCT02947620|Drug|Metformin/Atorvastatin 1500mg/40mg, QD|
1503016|NCT02947620|Drug|Metformin 1500mg, QD|
1503017|NCT02947620|Drug|Atorvastatin 40mg, QD|
1503018|NCT02947607|Procedure|Colon biopsies|
1503019|NCT02947581|Drug|Albendazole and praziquantel|Intervention - PZQ (50 mg/k/d, up to 3600 mg/d, for 15 days), as an add-on to ABZ treatment (15 mg/k/d, up to 800 mg/d for days 1-20, up to 1200 mg/d for days 21-30). In order to maintain the double blind nature of the trial, ABZ placebo will be administered to individuals over 53 kg of weight until completing the equivalent doses in the comparison group.
1503020|NCT02947581|Drug|Albendazole and praziquantel placebo|PZQ placebo in similar doses, given during the initial 15 days of ABZ treatment at standard doses (15 mg/k/d up to 1200 mg/d for 30 days)
1503021|NCT02947568|Other|non-interventional study|
1503022|NCT02947555|Other|Non interventional|
1503023|NCT02947542|Device|One-catheter concept|Coronary angiography will be performed using the one-catheter concept.
1503024|NCT02947542|Device|Standard catheter|Coronary angiography will be performed using a standard catheter.
1503025|NCT02947529|Drug|Tranexamic Acid|
1503026|NCT02947529|Other|Placebo|
1503027|NCT02947516|Procedure|Endoscopic ultrasound-guided liver biopsy|Participants will undergo endoscopic ultrasound per standard technique, with liver biopsy performed at that time.
1503028|NCT02947516|Procedure|Percutaneous liver biopsy|Participants will undergo percutaneous liver biopsy per standard protocol.
1503029|NCT02947503|Drug|Metformin HCL 850 CF|At inclusion, patients (N=500) will be randomized 1:1 to metformin vs usual care (850 mg tablets, 3 times daily or, if tolerance is suboptimal, a lower maximally tolerated dose, 1-2 times daily), on top of diet and lifestyle, with an insulin rescue in both arms if needed.
1503030|NCT02947490|Other|Self BP measurement|BP home measurement by patient, results to GP and GP alters treatment as per usual practice
1503031|NCT02947490|Other|Standard Care|Self BP measurement and patient management of anti-hypertensive treatment altering their own medication under supervision depending on home BP measurements
1503032|NCT02947490|Other|Standard BP management|GP to measure BP and manage BP control
1503033|NCT02947490|Other|Treatment|Contacted by the study nurse and depending on BP levels recorded the patient will alter their medication to achieve target BP levels.
1503034|NCT02947477|Behavioral|EmoTrak|Ecological Momentary Assessment of Emotion through Iphone App
1503035|NCT02947464|Procedure|Standard clinical practice|
1503036|NCT02947464|Device|Standard clinical practice + Rapid Maxillary Expansion|
1503037|NCT02947451|Other|Manual Therapy|"In manual therapy group will be assigned a protocol with manual passive stretching for the quadriceps muscles, hamstrings, triceps surae, adductors and abductors of the hip; myofascial release peripatellar; joint mobilization grades 1 and 2 for tibiofemoral joint and femoro - patellar in the affected knee.
Stretching, myofascial release and mobilizations will be held for 30 seconds, with three repetitions of each. The intervention will be applied only once."
1503038|NCT02947451|Other|TENS|In TENS group will be applied to continuous current mode, frequency 100Hz and pulse width of 50μs for 40 minutes in a single application. The intensity will be defined by the patient, should the stimulus be considered intense, but pleasant to it.
1503039|NCT02947438|Drug|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.
Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
1503040|NCT02947438|Drug|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.
Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
1503041|NCT02947412|Other|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
1503042|NCT02947399|Radiation|Radioactive Iodine 124|After thyroid hormone withdrawal for 3-5 weeks, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
1503043|NCT02947386|Other|Laboratory Biomarker Analysis|Correlative studies
1503044|NCT02947386|Biological|Nimotuzumab|Given IV
1503045|NCT02947386|Biological|Nivolumab|Given IV
1503046|NCT02947373|Drug|Hyperpolarized Pyruvate|Hyperpolarized Pyruvate
1503047|NCT02947360|Other|Focused vascular ultrasound of the carotid arteries|Emergency physicians and a trained research sonographer will perform a focused vascular ultrasound of the carotids (FOVUS) in patients presenting to the emergency department with chest pain. The diagnostic test characteristics (sensitivity, sensitivity, negative predictive value, positive predictive value and likelihood ratios) for FOVUS carotid plaque height will be determined in relation to our primary outcome (30-day major adverse cardiac events)
2002340|NCT02312713|Behavioral|Internet Based Exercise Training|"Participants assigned to the PT arm will receive 3-8 individual visits with a physical therapist. The content of these visits will be semi-standardized, meaning that they will include some common core components (e.g., evaluation, prescription of home exercise program), but the therapists will have flexibility in terms of how many visits are appropriate and the details of the visit content."
1503053|NCT02947334|Biological|Bococizumab|Bococizumab PFS
1503054|NCT02947334|Drug|Placebo|Placebo
1503095|NCT02947048|Drug|L1-79|
1503096|NCT02947048|Drug|Placebo|
1503097|NCT02947035|Procedure|Thyroid lobectomy|Thyroid lobectomy is removal of only part of the thyroid
1503055|NCT02947321|Procedure|Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. 2 mL of 2% lidocaine will be injected into each of the three needles before the RFA probes are connected to the RFA generator and the generator is activated. The RFA is performed.
1503056|NCT02947321|Procedure|Sham Genicular Nerve RFA|Under fluoroscopic guidance, the target locations based on boney landmarks of the superior lateral (SL), superior medial (SM), and inferior medial (IL) branches of the genicular nerve will be determined. An empty syringe will be connected to each needle to mimic the action of injecting local anesthetic. The RFA probes for the control group will not be connected to the RFA generator (no neurotomy); however, the generator will still be activated to mimic the RFA group.
1503057|NCT02947321|Drug|Lidocaine|2 mL of 2% lidocaine prior to nerve ablation
1503058|NCT02947282|Other|Educational Workshop|They will attend a 2 hour class on pelvic floor health
2002341|NCT02312713|Behavioral|Physical Therapy|Participants assigned to the internet-based exercise training arm will be given access to a program that aims to tailor exercises based on individuals' functional levels. The program assigns specific exercises, progresses these exercises as appropriate over time, and shows individual video clips to demonstrate appropriate performance of exercises.
1503061|NCT02947256|Procedure|standard laparoscopic cholecystectomy|which included the classic dissection of Calot's triangle to achieve the CVS, with separate clipping and division of cystic duct and artery
1503062|NCT02947256|Procedure|RI approach|which included separation of the lower third of GB from its bed down to its pedicle (artery and duct) with mass ligation of both.
1503063|NCT02947243|Device|VR distraction via Oculus Rift|In addition to standard pharmacological treatment, Virtual reality distraction through the use of Oculus Rift® will be used as the experimental intervention. The Oculus Rift (Consumer version) is made of two Oled panels with a resolution of 1200p running at 90Hz. It has very effective 360 degree positional tracking and integrated 3D audio. These combine to produce a high level of immersion, with high photorealism while maintaining the low latency necessary to induce presence and prevent cybersickness. The child, depending on the burn site, will have the opportunity to interact with the game. Video games, approved by healthcare professionals with extensive experience in pediatrics, will be adapted for children and tailored to minimize cyber sickness.
1503064|NCT02947243|Drug|Morphine|As per unit's protocol
1503065|NCT02947230|Other|Tailored Knowledge Translation|Tailored knowledge translation strategies specific to maintaining and increasing physical mobility with age.
1503066|NCT02947217|Biological|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
1503067|NCT02947217|Other|Sterile Saline|0.5 mL of sterile Saline administered im
1503070|NCT02947191|Biological|Collagen membrane + HUC-MSCs|After separating bilateral nasal septum mucosas via septum reconstruction incision under endoscopy, the clinical grade HUC-MSCs combined with collagen membrane will be transplanted between the bilateral nasal septum mucosas and fixed. The patients will be treated with antibiotics for 1 week, and with naristillae menthae compositae, mucus promoting agent and other drugs for improving microcirculation for 1 month.
1503071|NCT02947178|Procedure|Fascial iliac regional soft tissue infiltration blockade|Fascial iliac regional soft tissue infiltration blockade: Pain relief procedure (offered to all patients undergoing hip arthroscopy)
1503072|NCT02947178|Behavioral|Pain Score Survey|Utilizing: Defense and Veterans Pain Rating Scale (DVPRS)
1503073|NCT02947178|Behavioral|Pill Count|Patient reported as needed (prn) pain medication usage
1503074|NCT02947178|Drug|Bupivacaine|
1503075|NCT02947178|Drug|Liposomal Bupivacaine|
1503076|NCT02947165|Drug|NIS793|Anti-TGF beta antibody
1503077|NCT02947165|Drug|PDR001|Anti-PD-1 antibody
1503078|NCT02947152|Drug|HKT288|Cadherin-6-targeting antibody-drug conjugate for intravenous administration
1503079|NCT02947139|Drug|Co-administration of DWC20155/DWC20156|
1503080|NCT02947139|Drug|DWC20161|
1503081|NCT02947126|Drug|Hypertonic Saline|Inhaled 7% Hypertonic saline
1503082|NCT02947126|Drug|Isotonic Saline|Inhaled 0.9% Isotonic saline
1503083|NCT02947126|Drug|Indium-DTPA|Inhaled Indium 111 DTPA
1503084|NCT02947126|Drug|Technetium Sulfur Colloid|Inhaled Technetium99m sulfur colloid
1503085|NCT02947113|Drug|Cisplatin|Cisplatin will be administrated in a 3-weekly scheme for 2 courses combined with pemetrexed (non-squamous cell lung cancer) or etoposide (squamous cell lung cancer)
1503086|NCT02947113|Radiation|hypofractionated radiotherapy|Hypofractionated radiotherapy of 24 x 2.75 Gy will be given combined with a 3-weekly scheme of cisplatin and pemetrexed/etoposide
1503087|NCT02947113|Drug|Pemetrexed|Pemetrexed will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for non-squamous cell lung cancer)
1503088|NCT02947113|Drug|Etoposide|etoposide will be administrated in a combination with cisplatin and hypofractionated radiotherapy (for squamous cell lung cancer)
1503089|NCT02947100|Drug|SCD-Omegatex™|"Subjects will receive SCD-Omegatex™ (Enteric Fish Oil 250 DHA/27 EPA Soft Gelatin Capsule, 450 mg) at one of two daily doses, orally, once a day for 6 months. The trial will follow a 3+3 design using two dose levels. In the phase I portion, subjects will be treated with a dose of 25 mg/kg/day DHA and EPA. If this is tolerated without dose limiting toxicity (DLT), a subsequent cohort of patients will be treated at a dose of 37.5 mg/kg/day with a maximum total daily dose of 4 grams. Once a maximum tolerated dose (MTD) is determined, subjects on the phase II portion of the study will be treated at that dose."
1503090|NCT02947087|Drug|Prolastin-C|Patients will receive Prolastin-C at 60mg/kg on day 0, 7, 14, and 21 days of transplantation
1503091|NCT02947087|Drug|Placebo|Patients will receive saline on day 0, 7, 14, and 21 days of transplantation
1503092|NCT02947074|Behavioral|Yoga Meditation|Briefly, subjects will be taught to progressively drive their attention to their inner-self, and keep a calm, nonjudgmental and observational approach towards their own thoughts for 30 minutes.
1503678|NCT02942524|Other|Questionnaire Administration|Ancillary studies
1503098|NCT02947035|Procedure|Total thyroidectomy with CCND|Total thyroidectomy with central compartment lymph node dissection is removal of the entire thyroid with the surrounding lymph nodes
1503099|NCT02947022|Drug|Calcium DTPA|"On Day 1, 2.5 mL of Ca-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Ca-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.
The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
1503100|NCT02947022|Drug|Zinc DTPA|"On Day 2, 2.5 mL of Zn-DTPA (1 g/5 mL) will be administered over a period of 1 minute. A solution of normal saline will then be administered at a rate of 300 mL/hr over 30 minutes. Patients will be seated with hands lowered to their sides to allow the chelator to dwell slightly in the soft tissues of the hands and feet. Patients will then be moved to a supine position and the infusion rate increased to 750 mL/hr over the next 60 minutes. At 90 minutes the remaining 2.5 mL of Zn-DTPA will administered IV over a period of 1 minute, and the normal saline will continue for the remaining 9 minutes. The IV line will then be removed. Patients will be instructed to drink plenty of fluids that evening.
The same treatment therapy will consist of 3 time-points, approximately 1 month apart."
1503101|NCT02947009|Behavioral|Diagnostic Study|Participants will undergo laryngoscopy at baseline and with exercise challenge and will rate severity of various symptoms related to the larynx (ex. shortness of breath, voice changes, cough).
1503102|NCT02946996|Drug|Metformin|
1503103|NCT02946996|Other|OPC|OPC is a derivative of grape seed extract
1503104|NCT02946983|Other|Fructose|Intragastric administration of fructose (25g dissolved in 250ml distilled water)
1503105|NCT02946983|Other|Control|Intragastric administration of distilled water
1503106|NCT02946970|Other|Quinine hydrochloride|Intragastric administration of a bitter tastant agonist (10 μmol/kg quinine-hydrochloride)
1503107|NCT02946970|Other|Control|Intragastric administration of distilled water
1503108|NCT02946957|Behavioral|Cognitive Behavior Therapy for Insomnia|Six telephone sessions that last 20-30 minutes presenting cognitive behavioral therapy for insomnia.
1503109|NCT02946957|Behavioral|Education Only Control|Six telephone sessions that last 20-30 minutes presenting sleep and osteoarthritis education.
1503110|NCT02946944|Drug|Sildenafil/apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups. Dual drug therapy is going to be administered to this group (experimental): sildenafil 30mg 3p \ g + 10 mg apixaban 2p \ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
1503111|NCT02946944|Drug|apixaban|After arrival to the emergency department, a series of surveys to determine the risk of death from pulmonary embolism are carried out. Then angiography, tensiometry of SBCC, catheter thrombus fragmentation are scheduled. Then puncture of the right jugular vein is performed. PigTail catheter is inserted via guidewire into the pulmonary artery . Angiography of the pulmonary arteries is performed. Miller index is calculated. Catheter thrombus fragmentation is performed by a PigTail catheter. RV, RA pressures are measured. In the ICU heparin is prescribed (of 1000 units per hour) under the control of PTT (50-75s). The next day patients are randomizaed to assign them into 2 groups.Mono drug therapy is going to be administered to this group (active comparator): apixaban 10 mg 2p \ d for 14 days. On the 7th day MSCT angiography of the pulmonary aretry with contrast and echocardiogram are performed. On the 14th day the controlechocardiogram is performed .
1503113|NCT02946918|Drug|Levothyroxine|Patients post-thyroidectomy will receive either levothyroxine in tablet form or in gelcaps
1503114|NCT02946892|Drug|Carvedilol|Carvedilol will be given for 12 weeks and then an exercise test will be performed
1503115|NCT02946892|Drug|Placebo|Placebo will be given for 12 weeks and then an exercise test will be performed
1503116|NCT02946879|Biological|AAV OPTIRPE65|comparison of different doses of AAV RPE65
1503117|NCT02946853|Procedure|Atrioventricular junctional (AVJ) ablation|RF energy delivery to AV node to create complete AV block
1503118|NCT02946853|Device|Cardiac resynchronization therapy - defibrillator|Insertion of device capable of providing biventricular pacing and cardiac defibrillation
1503119|NCT02946840|Device|FNA with 25 G Beacon needle|
1503120|NCT02946827|Dietary Supplement|Balanced low FODMAPs /gluten free diet|
1503121|NCT02946827|Dietary Supplement|Balanced gluten free diet|
1503122|NCT02946814|Drug|essential oils|
1503123|NCT02946814|Drug|essential oils without mouthwash|
1503124|NCT02946814|Drug|sterile water|
1503125|NCT02946801|Drug|Essential oils|
1503126|NCT02946801|Drug|Essential oils without alcohol|
1503127|NCT02946801|Drug|Sterile water|
1503128|NCT02946788|Drug|Minocycline|BPX-01 1 or 2% topical gel will be applied to face once daily
1503129|NCT02946762|Other|Test and treat|All incarcerated individuals found to have HIV infection will be offered universal voluntary HIV counseling and testing (HCV) through routine care provided at the correctional facility followed by referral to the study for immediate (routine, non-study prescribed) ART, regardless of CD4 cell count. The ART regimen prescribed will be the standard first-line, fixed-dose combination efavirenz plus lamivudine/emtricitabine and tenofovir per Zambian national guidelines.
1503130|NCT02946736|Behavioral|FSSB/Sleep Leadership Training|Supervisors will receive a training addressing family-supportive supervisor behaviors and sleep leadership.
1503131|NCT02946736|Behavioral|Actigraphy Feedback|Supervisors and employees will receive personalized feedback on their sleep and activity measurements.
1503132|NCT02946723|Procedure|ultrasound|Lead implantation surgery for SNM using ultrasound guided technique
1503133|NCT02946723|Procedure|X-ray|Lead implantation surgery for SNM using X-ray technique
1503134|NCT02946710|Biological|cerebrospinal fluid|Biological analysis on cerebrospinal fluid
1503135|NCT02946697|Behavioral|Social support intervention|The social support intervention is a 7-week program includes educational and peer mentoring support components. The education curriculum provides information on recognizing side effects of treatment and differentiating them from symptoms of cancer recurrence, physical therapy and alternative treatment, stress management, recognizing depression and managing emotional problems, communication with family members, and body image. The peer-support component assigns each participant with a mentor who is a breast cancer survivor. They share their own experience with participants and also make weekly phone calls to mentees during the intervention to provide support and address remaining concerns.
1503136|NCT02946684|Drug|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
1503137|NCT02946684|Drug|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
1503138|NCT02946671|Biological|Mogamulizumab|Mogamulizumab (0.1, 0.3 or 1.0 mg/kg) is administered.
1503139|NCT02946671|Biological|Nivolumab|Nivolumab (3.0 mg/kg) is administered.
1503140|NCT02946658|Procedure|lipoaspiration|Closed syringe harvesting subdermal fat
1503141|NCT02946658|Procedure|ADcSVF|Isolation of AD-cSVF
1503142|NCT02946658|Procedure|Normal Saline IV|Normal Saline IV containing AD-cSVF
1503143|NCT02946645|Device|Neuromuscular Bite (orthotic)|Orthotic is a device which simulates a set of properly positioned teeth
1503144|NCT02946645|Procedure|Mandibular Physiotherapy|"Mandibular Stabilisation Exercises
Place knuckle of index finger between top and bottom teeth.
Remove it, keeping the teeth separated one-knuckle apart.
Apply gentle pressure to the to the jaw using your index finger/thumb as demonstrated in the pictures above."
1503145|NCT02946645|Other|Placebo|No interventions.
1503146|NCT02946632|Drug|triple combination therapy|Xigduo (metformin 1000mg + dapagliflozin 10mg) saxagliptin 5mg
1503147|NCT02946632|Drug|Stepwise add-on therapy|metformin -> glimepirde -> sitagliptin
1503148|NCT02946619|Behavioral|Self-Regulation Condition|
1503149|NCT02946619|Behavioral|Enhanced self-Regulation Condition|
1503150|NCT02946606|Drug|GX-H9|Human growth hormone
1503151|NCT02946606|Drug|Genotropin|Human growth hormone
1503152|NCT02946593|Behavioral|Stroll Safe outdoor fall prevention program|The structure of the program will model the evidenced-based Lifestyle Re-Design program (Clark et al., 2012). Session 1, 2, 4 & 5 will include a brief didactic presentation about outdoor fall risks and strategy use from the group leader. This will be followed by group discussion/problem solving related to addressing risks. Identified strategies will be recorded on a wipe board and transcribed for group members in order to create handouts. Each 90 minute session will end with action planning, where participants will write down behavioral changes they will implement in the coming week. Session 3 and 6, also 90 minutes, will include outdoor mobility training and practice using strategies discussed in previous sessions. Training sessions will be led by the PI and an assistant. The final session will be a review of risks, strategy use, and reinforcement of behavioral changes in participant's action plans.
1503153|NCT02946593|Behavioral|Outdoor fall prevention brochure|The control group participants will be given a written brochure on tips for preventing outdoor falls.
1503154|NCT02946580|Drug|MOVANTIK™ (naloxegol)|
1503155|NCT02946580|Drug|Sugar Pill|
1503156|NCT02946567|Other|Noisy City information about hearing health care|Participants will play the game Noisy City, which contains information about hearing health care.
1503157|NCT02946567|Other|Generic Game|Participants will play a generic game without any particular information about hearing health care.
1503158|NCT02946554|Biological|HepaStem|
1503159|NCT02946541|Drug|evogliptin 5mg|evogliptin 5mg, QD
1503160|NCT02946541|Drug|Placebo|Placebo, QD
1503161|NCT02946528|Device|urgent-start peritoneal dialysis catheter|Patients initiated peritoneal dialysis as urgent-start dialysis modality with a peritoneal dialysis catheter.
1503162|NCT02946528|Device|central venous catheter|Patients initiated hemodialysis as urgent-start dialysis modality with a central venous catheter.
1503163|NCT02946515|Behavioral|Educational Intervention|The educational intervention will be the online simulation training program. Participants will be taught how to use the simulation during a 30 minute orientation session with a research staff person. We will use a mastery based approach rather than prescribing an absolute number of hours participants need to play. The criteria are as follows: 1) achieving a score of 90% or more on 2 out of the last 3 simulations played or 2) maximum of 8 hours of play, whichever comes first. After the orientation sessions, training sessions will be completed by participants on their own. The research team will confirm remote usage, and contact participants by email and phone to prompt usage as needed. The research team anticipates that the proposed method will accommodate for participant schedules while still ensuring intervention compliance.
1503164|NCT02946515|Behavioral|Wait List Control|Access to the online simulation training after the follow-up measurement visit is complete
1503165|NCT02946502|Procedure|Handheld dynamometry (handgrip strength)|Patients will perform handgrip strength dynamometry through holding the device in their dominant hand with the maximum strength, with standardized arm and body positions, as well as incentives
1503166|NCT02946489|Drug|CI-581a|CI-581a will be administered in wk2 and potentially in wk 3 or 4.
1503167|NCT02946476|Other|prognostic impact of non cardiac comorbidities|
1503168|NCT02946463|Biological|ALXN1210|"Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
≥ 40 to <60 kg: 2400 mg loading, then 3000 mg every 8 weeks
≥ 60 to <100 kg: 2700 mg loading, then 3300 mg every 8 weeks
≥100 kg: 3000 mg loading, then 3600 mg every 8 weeks"
1503169|NCT02946463|Biological|Eculizumab|Induction doses of 600 mg on Days 1, 8, 15, and 22, followed by regular maintenance dosing of 900 mg beginning on Day 29 and every 2 weeks thereafter
1503170|NCT02946450|Drug|Other: Not applicable-observational study|
1503171|NCT02946437|Drug|Sevoflurane|Postconditioning with sevoflurane (0.5-1.5vol%) for 4 hours after coiling or clipping of cerebral aneurysm in patients with severe SAH
1503238|NCT02945852|Drug|apatinib|apatinib 500mg/d until progressive Disease
1503637|NCT02942771|Other|Cohort 1 Placebo|Placebo twice daily on Days 1 through 5
1503172|NCT02946437|Drug|Propofol|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
1503173|NCT02946437|Drug|Midazolam|Before and after postconditioning with sevoflurane the patients will be sedated with intravenous sedatives (midazolam or propofol). The quality of sedation before the postconditioning (propofol or midazolam) will be compared to the sedation one hour after starting the postconditioning (sevoflurane) in the same patient.
1503174|NCT02946437|Device|MIRUS™System|The MIRUS™System is the normally used standard equipment for the administration of volatile anaesthetics to patients.
1503175|NCT02946424|Drug|Placebo Oral Capsule|12 month course of daily placebo
1503176|NCT02946424|Drug|Simvastatin|12 month course of daily simvastatin
1503177|NCT02946411|Procedure|Cardiac surgery|Glucose level will be measured after cardiac surgery.
1503178|NCT02946385|Biological|Meningococcal ABCWY Vaccine|Intramuscular injection of one booster dose at Day 1 to follow-on subjects primed with two or three doses of the study vaccine and two doses at Days 1 and 61 to Naive subjects.
1503179|NCT02946385|Biological|Meningococcal B Recombinant vaccine|Intramuscular injection of one booster dose of the rMenB+OMV vaccine to subjects primed with two doses of the vaccine and two doses to naive subjects.
1503180|NCT02946372|Procedure|internal limiting membrane transplantation (ILMT)|internal limiting membrane autologous transplantation (ILMT)
1503181|NCT02946359|Drug|Crizotinib, bevacizumab|Eligible patients with ALK translocation or ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID and bevacizumab at the dose of 7.5mg/kg every three weeks. The dose of crizotinib and bevacizumab may be adjusted depending on the type and severity of toxicity encountered
1503182|NCT02946346|Other|vaginal sampling|
1503183|NCT02946320|Device|Predilatation with non-compliant balloon|Coronary artery stenosis is dilated before BVS implantation with the use of non-compliant balloon (standard procedure). Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
1503184|NCT02946320|Device|Predilatation with scoring balloon (Scoroflex)|Coronary artery stenosis is dilated before BVS implantation with the use of scoring balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
1503185|NCT02946320|Device|Predilatation with cutting balloon (Flextome)|Coronary artery stenosis is dilated before BVS implantation with the use of cutting balloon. Size and dilatation pressure is done according to OCT measurement of the coronary artery (distal segment / balloon diameter = 1:1)
1503186|NCT02946307|Device|Restore DEB（dimeter>2.00 mm）|
1503187|NCT02946307|Device|Resolute DES|
1503188|NCT02946307|Device|Restore DEB（dimeter:2.00 mm）|
1503189|NCT02946294|Drug|Bupivacaine 0.25% with epinephrine|
1503190|NCT02946294|Drug|Bupivacaine 0.25% with epinephrine|
1503191|NCT02946281|Behavioral|Do CHANGE|The intervention aims to increase behavioral flexibility and change patients' (unhealthy) lifestyle. At the same time the intervention should increase patient self-management and improve the patient reported outcomes (e.g. quality of life, anxiety, depression).
1503192|NCT02946268|Drug|Ropivacaine|Change in administration of ropivacaine. Rate, Volume and Interval of bolus altered.
1503193|NCT02946255|Behavioral|Welcome Basket (WB)|"Peer Support Workers (PSWs) hold 1-2 meetings with clients (30-60 minutes) in the 2-week period before they are discharged from hospital. They describe the program and undertake an assessment. From this assessment the two core components of the intervention are initiated. First, a welcome basket is created for the client. The PSW also forms a plan with the client about tours of their neighbourhood to familiarize them with the local resources and support them in building confidence in accessing their local communities. These activities will take place through weekly visits (2 hours/visit) in the 4 weeks immediately following discharge. WB will be provided in combination with core Cognitive Adaptation Training (CAT) compensatory interventions e.g. setting up and placement of a calendar, basic organization of living space."
1503194|NCT02946255|Behavioral|Welcome Basket Brief (WBbr)|The brief version of the Welcome Basket (WBbr) was developed based upon the observation in feasibility testing that for some participants much of the benefit of this approach appeared to be centred upon the visits immediately prior and subsequent to discharge. In the WBbr the same core components will be present, albeit in an abbreviated form with one 30-60 minute visit in the week prior to discharge and a single, 3-hour visit in the week subsequent to discharge in which the welcome basket would be delivered, core CAT strategies discussed and implemented, and some basic orientation to community resources undertaken. This brief version of the intervention has not to date been studied.
1503195|NCT02946255|Behavioral|Treatment As Usual|Treatment as usual (TAU) involves the typical discharge procedures for clients from Unit 2, Forensic and EPU wards at CAMH. It includes referral to outpatient psychiatric services and relevant community supports with the transition facilitated by inpatient social work staff.
1503196|NCT02946242|Device|Ultrasound Exam|Subjects will be scheduled to attend up to up to five (5) ultrasound scans per day lasting up to 60 cumulative minutes each with approximately a 15 minute break before starting another study scan (limited to 15 cumulative minutes of scan time per eye, per day for ophthalmic scanning) as long as they remain eligible per the study inclusion and eligibility criteria.
1503198|NCT02946216|Genetic|ctDNA analysis|
1503199|NCT02946203|Other|Barium Sulfate|Barium Sulfate Oral Contrast-VoLumen
1503200|NCT02946203|Other|Flavored beverage Oral Contrast|Flavored beverage for neutral abdominal/pelvic imaging
1503201|NCT02946190|Biological|Pertagen® aP + Td-pur®|see arm/group descriptions
1503202|NCT02946190|Biological|Boostrix® dTpa|see arm/group descriptions
1503203|NCT02946177|Biological|Influenza Vaccine|Inactivated influenza vaccine indicated for immunization against disease caused by influenza virus subtype A and type B present in the vaccine. Approved for use in persons 5 years of age and older. Single Dose prefilled 0.5 ml syringe.
1503204|NCT02946177|Other|Sterile Saline|0.5 mL of sterile Saline administered im
2002346|NCT02308137|Drug|Domperidone|Simon-2-stage design for domperidone futility
1503206|NCT02946151|Device|Hypo-safe implantable EEG electrode and data storage device|The implantable EEG electrode will be implanted subcutaneously in the relevant temporal region by a certified neurosurgeon. The EEGgraphical data recorded will be transmitted transcutaneously to the data storage device via an inductive link.
1503207|NCT02946138|Radiation|carbon-ion radiotherapy|Hypofractionated carbon-ion radiotherapy was prescribed at a dose of 40Gy RBE in 5 fractions
1503208|NCT02946125|Drug|EYN-1601 Ophthalmic Solution|
1503209|NCT02946125|Drug|Phenylephrine Hydrochloride Ophthalmic Solution 2.5%|
1503210|NCT02946125|Drug|Phenylephrine Hydrochloride Ophthalmic Solution 10%|
1503211|NCT02946099|Procedure|Reciproc files in reciprocating motion|An endodontic file that works through a reciprocating motion
1503212|NCT02946099|Procedure|ProTaper Next files in continuous rotary motion|An endodontic file that works through a continuous rotary motion
1503213|NCT02946086|Behavioral|HABIT-ILE with prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation
1503214|NCT02946086|Behavioral|HABIT-ILE without prismatic adaptation|Bimanual and locomotor intensive intervention for 90h including 8 hours of prismatic adaptation wearing sham goggles.
1503215|NCT02946073|Drug|buprenorphine|
1503216|NCT02946073|Other|Placebo|
1503217|NCT02946060|Other|Audiobooks|iPods with audiobooks
1503218|NCT02946060|Other|Tempo-pace synchronized playlists|Playlists with or without RAS
1503219|NCT02946060|Other|Usual Care|iPods containing either a silent track or white noise
1503220|NCT02946047|Drug|Ixazomib|Patients Will be given oral Ixazomib on days 1, 8 and 15 of a 28 day cycle. Additional cycles, dosing days may be added and dose increased based on patient tolerability.
1503221|NCT02946034|Drug|Viekira Pak ± ribavirin|12 weeks treatment with AbbVie Viekira Pak ± ribavirin
2002347|NCT02308397|Other|Normal gluten containing bread|Group 1 will begin with Normal gluten containing bread(A) and then move to bread B,C and D
2002348|NCT02308397|Other|Bread with reduced gliadins content|Group 2 will begin with Bread with reduced gliadins content (B) and then move to bread A, C and D
1503224|NCT02946008|Radiation|Stereotactic Body Radiation Therapy|Delivered over 5 treatment sessions for approximately 1.5 weeks total.
1503225|NCT02946008|Procedure|Radical Prostatectomy|Open, laparoscopic, or robotic radical prostatectomy and pelvic lymph node dissection to remove the prostate, seminal vesicles, and pelvic lymph nodes.
1503226|NCT02945995|Procedure|hip arthroscopy|Follow up after hip arthroscopy in pt with previous PAO. Follow up by questionnaires send til the cohort
1503227|NCT02945982|Drug|Entecavir+Carvedilol+ Placebo|The subjects will be taking 1Carvedilol tablet per day at first week and 2 Carvedilol tablets per day from second week. At the same time,the subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 96 weeks.
1503228|NCT02945982|Drug|Entecavir+Carvedilol+ Fuzheng Huayu|The subjects will be taking 1Carvedilol tablet per day at first week and 2 Carvedilol tablets per day from second week. At the same time,the subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
1503229|NCT02945982|Drug|Entecavir+Carvedilol+ Fuzheng Huayu +TCM analysis|The subjects will be taking 1Carvedilol tablet per day at first week and 2 Carvedilol tablets per day from second week. At the same time,the subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.During this time,the subjects will be taking herbal medicine under TCM analysis.
1503230|NCT02945969|Behavioral|Low Sodium Diet|Once randomized to the Intervention program, study participants will be grouped into intervention cohorts of approximately 10 participants per group to facilitate group counseling sessions. Both the intensive intervention phase and the maintenance phase will include individual and group behavioral modification counseling designed to facilitate a reduction in dietary sodium intake. Success of the intervention will be assessed by comparing the urine sodium measurements from 24-hour urine collections performed at screening, 12 weeks and 24 weeks.
1503231|NCT02945956|Drug|Entecavir + Placebo|The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 96 weeks.
1503232|NCT02945956|Drug|Entecavir + Fuzheng Huayu|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 96 weeks.
1503233|NCT02945943|Other|High Velocity Low Amplitude mobilization|Mobilizations were performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
1503234|NCT02945943|Other|Exercise Protocol|This exercise regimen is a modified version of the balance training program described by McKeon et al.
1503235|NCT02945904|Procedure|adrenalectomy|Unilateral adrenalectomy for Conn's adenoma
1503236|NCT02945891|Device|HPV testing of Evalyn®Brush, FloqSwab and Colli-Pee specimens|Each woman use the self-sampling devices in an advised order the day before they go to the hospital. There will be change of sampling order with every patient so that 50% of women will use Evalyn®Brush (Rovers Medical Devices, Oss, The Netherlands) first and 50% a FloqSwab (Coban Flock Technologies, Italy) first. In addition women are asked to provide a first void urine sample using a Colli-PeeTM (Novosanis, Belgium) on the same morning as the hospital visit. At the hospital clinician will take an additional specimen for which the performance of different self-sampling devices will be compared to.
1503237|NCT02945865|Other|Pain assessment|Pain assessment with assessment tools
2002349|NCT02308397|Other|Bread with reduced ATIs content|Group 3 will begin with Bread with reduced ATIs content (C) and then move to bread A, B and D
2002350|NCT02308397|Other|Bread with reduced overall protein content|Group 4 will begin with Bread with reduced overall protein content (D) d then move to bread A, B and C
1503239|NCT02945839|Drug|Preventative Medication (PM)|Subjects in the PM group will be given acute migraine medication, preventive medication (topiramate), and the APP with the PMR component. The smartphone app and/or the electronic pill bottles will be used to monitor adherence.
1503240|NCT02945839|Behavioral|Enhanced Usual Care|General Education Class consisting of basic migraine information of basic migraine information such as evidence-based ways to treat migraines: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently.
1503241|NCT02945839|Behavioral|PMR (progressive muscle relaxation therapy)|Technique for learning to monitor and control the state of muscular tension
1503242|NCT02945826|Drug|One injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
1503243|NCT02945826|Device|PET/MRI|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/MRI of the brain
2002351|NCT02308332|Drug|Eviplera|switch from Atripla to emtricitabine/rilpivirine/tenofovir (Eviplera)
2002352|NCT02308163|Drug|peficitinib|oral
1503246|NCT02945800|Drug|nab-Paclitaxel|nab-Paclitaxel: 125 mg/m^2 intravenously (IV)
1503247|NCT02945800|Drug|Gemcitabine|Gemcitabine: 1000 mg/m^2 intravenously (IV)
1503248|NCT02945787|Behavioral|Spanish-Language Version of the Stop Smoking for Good|Participants in the first arm will receive the Spanish-language version of the Stop Smoking for Good (SS-SP) intervention distributed over 18 months.
1503249|NCT02945787|Behavioral|NCI-Produced Spanish-language Self-help Booklet|Participants in the second arm will receive a single, credible, NCI-produced Spanish-language self-help booklet. Outcomes will be assessed through 24 months.
1503250|NCT02945774|Radiation|(18F)-FEPPA|PET ligand that binds to activated microglia, a marker of neuroinflammation
1503251|NCT02945761|Procedure|High concentration of sugar solution|
1503252|NCT02945761|Procedure|conventional surgical dressing change|
1503253|NCT02945735|Behavioral|Attention Modification|Feedback according to participants' viewing patterns, in order to modify their attention.
1503254|NCT02945722|Drug|Decolonization|Decolonization schedule associate the use of mupirocin nasal ointment 3 times a day and chlorhexidine bath once a day for 5 days. Screening of persistent carriers will be done every 3 months
1503255|NCT02945722|Other|No decolonization|Screening of persistent carriers in this arm will be done every 3 months
1503256|NCT02945709|Behavioral|Personalized Attention control training (ACT)|In this intervention, participants will be trained with a personalized Dot-Probe task. Each participant will perform the task with the set of words that he or she ranked as the most threatening according to a Word Ranking Task.
1503257|NCT02945709|Behavioral|Non-personalized Attention control training (ACT)|"In this intervention, participants will be trained with the same Dot-Probe task as in the personalized condition, except that the word stimuli will be randomly fit for each participant. It should be noted that 25% out of the words in this condition will be high ranked words according to each patient's word ranking. The aim of this is to enhance similarity to a generic ACT intervention (see Badura-Brack et al., 2015), where there is some degree of exposure to what one may consider personalized stimuli (i.e., threat words that were randomly included by the researchers), although it is not deliberately set to idiosyncratic preferences."
1503258|NCT02945709|Behavioral|Control training.|In this intervention, participants will perform a computerized task, similar to the Dot-Probe task. In each trial, one neutral word will be presented at the center of the screen and participants will respond to a probe ('E' or 'f') presented following the removal of the words display. This version does not include the essential ingredients thought to reduce PTSD symptoms in the other dot-probe tasks: exposure to threat content and competition on attentional resources. Thus, this control version provides a control condition for the ACT interventions.
1503261|NCT02945683|Dietary Supplement|Reuterin D3|Lactobacillus reuteri DSM 17938 (10E8 CFU in 5 drops), Vitamin D3 (400 IU in 5 drops), sunflower oil, medium chain triglycerides, silicon dioxide
1503262|NCT02945683|Dietary Supplement|Placebo|sunflower oil, medium chain triglycerides, silicon dioxide
1503263|NCT02945670|Behavioral|Focus Group|
1503264|NCT02945657|Drug|MM36 topical ointment, 1%|Twice daily application for 28 consecutive days
1503265|NCT02945644|Drug|Trazodone|take at bedtime for 14 days
1503266|NCT02945644|Drug|Placebo|take at bedtime for 14 days
2002353|NCT02308163|Drug|Placebo|oral
2002354|NCT02308163|Biological|Etanercept|subcutaneous injection
1503269|NCT02945618|Device|Neurocryostimulation|"CRYOFOS will be applied on the ankle at the end of each of the 8 sessions (in accordance to the protocol established). The treatment time with the CRYOFOS will take between 1 and 2 minutes, and will be pain-free.
Both groups will also receive the same conventional program consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing."
1503270|NCT02945618|Other|Ice|The control group will receive the same conventional program (as the experimental group) consisting of: compression, bracing, early mobilization (including manual therapy), strengthening (isometric and isotonic using elastic bands) and proprioception (using proprioception boards) exercises, according to the grade of the sprain and the stage of biological ligament healing. Ice will be applied to the ankle for 15 minutes at the end of each of the 8 sessions.
1503343|NCT02945033|Procedure|Surgical resection of colonic adenocarcinoma stage III or II high risk|Surgical resection of colonic adenocarcinoma stage III or II high risk will be done in accordance with local guidelines
1503344|NCT02945033|Biological|Molecular analysis of exon 9 and 20 of PI3K|Molecular analysis of exon 9 and 20 of PI3K will be done using operative piece
1503345|NCT02945033|Biological|blood intake|Blood intake will be done every 6 months to evaluate patient compliance to treatment
1503271|NCT02945605|Other|Early Vestibular Rehabilitation|"Two visits/week for a maximum of 5 weeks will be provided with the approximate duration for each visit estimated at 50-60 minutes. Consistent with a previously validated framework for exercise prescription in patients with concussion, the exercises provided by the treating therapist can be classified into five main exercise categories:
Eye-Head coordination, gaze stability and convergence exercises
Sitting balance
Standing static balance (i.e. feet-in-place)
Dynamic balance (feet moving, but not walking)
Ambulation (gait exercises)
Other exercises: Sport specific exercises, Canalith repositioning maneuvers are recorded as others"
1503272|NCT02945605|Other|Standard of Care|Standard care as directed by a physician.
1503273|NCT02945592|Behavioral|Cueing|
1503274|NCT02945579|Procedure|Breast Biopsy|Participant undergoes an image-guided biopsy of the breast to test for evidence of disease at any point after completing chemotherapy and before beginning radiation therapy.
1503275|NCT02945579|Radiation|Radiation Therapy|Radiation therapy to the breast performed within 12 weeks after completion of chemotherapy. The dose amount and length of the radiation therapy period decided by treating physician.
1503276|NCT02945579|Behavioral|Questionnaire|Questionnaires about quality of life and symptoms completed at baseline and again at 6 months, 1, 3, and 5 years after post-chemotherapy biopsy.
1503277|NCT02945566|Procedure|Standard TME surgery|Total mesorectal excision
1503278|NCT02945566|Drug|Long course concurrent chemoradiation|Capecitabine 825 mg/m² orally, b.i.d., on radiotherapy days. Radiotherapy: A dose of 50 Gy, applied to the primary tumour and surrounding mesorectum, in 25 fractions of 2 Gy, 5 days a week.
1503279|NCT02945566|Radiation|Short course radiotherapy|A dose of 25Gy, applied, to the primary tumour and surrounding mesorectum in 5 fractions of 5 Gy, 5 days a week.
1503280|NCT02945553|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation (NMES) will be performed 5 times/week for one hour each day. NMES will start within 1 week of injury and continue till 3 weeks following surgery.
1503281|NCT02945553|Device|Microstimulation|Microstimulation will be performed 5 times/week for one hour each day. Microstimulation will start within 1 week of injury and continue till 3 weeks following surgery.
1503287|NCT02945488|Other|Exercise|Exercise intervention will entail 30 minutes of moderate intensity cardiovascular training 3 days/week and full body resistance training 2 days/week (supervised). Cardiovascular training will entail any weight-bearing activity that would achieve target heart rate, such as walking, jogging, stair climbing, dancing, etc. Resistance training will entail 2-3 sets of 8-12 repetitions of exercises targeting all major muscle groups with an external load applied, such as a dumbbell, barbell, medicine ball, etc.
1503288|NCT02945488|Other|Dietary plan|Mediterranean dietary plan, which contains foods, such as fish, vegetables, nuts, and oils, which are anti-inflammatory in nature.
1503289|NCT02945488|Other|Stretching|Stretching intervention will entail 30 minutes of flexibility training 3 days/week of stretches targeting all major muscle groups held for 20-30 seconds.
1503290|NCT02945462|Biological|autologous mesenchymal stem cells|Patients will be injected with autologous mesenchymal stem cells, intracavernously
1503291|NCT02945449|Biological|Wharton Jelly Mesenchymal stem cells|Intracavernous injection of Wharton Jelly Mesenchymal stem cells.
1503292|NCT02945436|Behavioral|Substance Use Brief Intervention|SUBI is a counseling intervention based on Motivational Interviewing techniques that focuses on the substance use and sexual health risks of participants.
1503293|NCT02945436|Behavioral|Standard of Care (SOC)|Standard of care is Counseling Testing and Referral (CTR). CTR is a standardized service in which counselors provide HIV testing, risk-related counseling and appropriate referrals (medical, social, prevention, and partner services) to clients.
1503299|NCT02945397|Behavioral|Group-based activity|Regular follow-up from welfare authority as well as a 3 month group activity with weekly gatherings, focusing on coping, goal-setting and relevant information regarding available public services.
1503300|NCT02945397|Behavioral|Individual activity|Regular follow-up from welfare authority as well as a 3 month membership card at a given gym.
1503301|NCT02945384|Behavioral|Creating Connections: Strong Families, Strong Brains|Dual-generation intervention
1503302|NCT02945371|Behavioral|Person-centered inhibitory control training|A brief, computer-based, multisession training aimed at increasing the connection between environmental risk cues (e.g., cigarettes) and engagement of the brain network for inhibitory control.
1503303|NCT02945371|Behavioral|Active behavioral response training|A brief computer-based, multisession training aimed at training behavioral responses to personalized environmental risk cues (e.g., cigarettes) that does not engage the inhibitory control network of the brain.
1503304|NCT02945358|Procedure|adult cardiac surgery with cardiopulmonary pump|Open-heart surgery both coronary artery bypass graft (CABG) and valve surgery
1503638|NCT02942771|Other|Cohort 2 Placebo|Placebo twice daily on Days 1 through 5
2002366|NCT02305849|Drug|peficitinib|oral
2002367|NCT02305849|Drug|Placebo|oral
2002368|NCT02303951|Drug|Vemurafenib + cobimetinib|
2002369|NCT02302092|Drug|Flomoxef|Flomoxef intravenous infusion
2002370|NCT02302092|Drug|Cefepime|Cefepime intravenous infusion
2002371|NCT02290782|Radiation|Intraoperative radiotherapy (IORT)|"The surgeon and radiation oncologist should choose the largest possible suitable applicator in order to ensure that the highest possible dose is delivered to the tumor bed tissue. A dose of 20 Gy at the surface of the applicator (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 20-50 minutes, depending on the size of the applicator.
To minimize radiation dependent side effects the skin-applicator surface distance should be more than 5 mm."
1503305|NCT02945332|Behavioral|Required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
1503306|NCT02945332|Behavioral|Non-required supervised walking|The intervention will include meeting at an agreed upon community center location and time convenient for both the participant and the researcher. During these meetings, the participants will engage in indoor walking under the supervision of the researcher. This is to ensure accurate walking distance recording and also to monitor the participants for any potential adverse events. The participants will have the option of walking as long or short as they please, so long that it is less than 20 miles per week. This is to protect the participants from exhaustion or overexertion. Overall activity of this group will be recorded using Fitbit Flexes, worn at all time for the duration of the study.
1503307|NCT02945332|Device|Fitbit Flex|
1503308|NCT02945306|Procedure|Adenotonsillectomy|
1503309|NCT02945306|Drug|Watchful waiting with supportive care|Use of widely prescribed medicines to treat associated conditions
1503310|NCT02945293|Other|Oxycodone|This study is interventional. Participants are given a single, one time administration of medication 10mg of oxycodone and observed
1503311|NCT02945280|Drug|apixaban|12 weeks of apixaban treatment to monitor for efficacy in the prevention of VTE-related mortality
1503312|NCT02945267|Drug|Nimotuzumab plus S1|Nimotuzumab Injection: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
1503313|NCT02945267|Drug|Placebo plus S1|Placebo: 400 mg/w, Intravenous infusion, Infusion time ≥ 60 min, d1, once every two weeks;S1: 40 mg (Body surface area<1.5 m2) or 60 mg (Body surface area>1.5 m2) ,oral,d1-d14, every three weeks for a cycle
1503314|NCT02945254|Device|NIghtingale (R) device for filtered white noise (Cambridge Sound Management, Waltham, MA)|
1503315|NCT02945241|Drug|Vancomycin|Intravenous
1503316|NCT02945241|Other|Cystatin C dosing algorithm|Expressed in milliliters per minute
1503317|NCT02945241|Other|Creatine clearance dosing algorithm|Vancomycin dosing algorithm based on creatinine clearance, expressed in milliliters per minute
1503318|NCT02945215|Drug|IBI301|IBI301 375mg/㎡
1503319|NCT02945215|Drug|Rituximab|Rituximab 375mg/㎡
1503320|NCT02945202|Device|Biometry|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
1503321|NCT02945202|Device|Refraction|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
1503322|NCT02945202|Device|Corneal Topography|All patients undergo all three examinations (biometry, refraction and corneal topography) 6 months after surgery
1503323|NCT02945176|Device|ARGOS-IO system|This study will enroll a minimum of 10 and a maximum of 15 patients. It is anticipated to be large enough to provide an initial estimate of common safety events and assessment of performance. Any adverse event (AE), serious adverse event (SAE), ADE (adverse device event) and SADE (serious adverse device event) will be listed. Incidence will be estimated with a 95% confidence interval (Pearson-Clopper, two-sided). The Bland-Altman method will be used to assess the limits of agreement between the IOP measurements ARGOS-IO and surgical manometry. When appropriate, two-sided 95% confidence intervals, for these limits will be calculated accounting for repeated measurements based on the method proposed by Zou (2011). Other secondary performance endpoints will be analyzed by descriptive and explorative statistical methods.
1503324|NCT02945163|Drug|Tenofovir|
1503325|NCT02945163|Drug|Lamivudine|
1503326|NCT02945163|Drug|Efavirenz|
1503327|NCT02945150|Drug|grazoprevir plus elbasvir (fixed dose combination)|HCV treatment for 12 to 16 weeks. Treatment length based upon presence of baseline resistance associated variant in the HCV virus
1503328|NCT02945124|Other|K tape|Applying K tape to children to the lower limb muscles during motor activities.
1503329|NCT02945111|Behavioral|Real-time view|
1503330|NCT02945111|Behavioral|No visual support|
1503331|NCT02945098|Other|Kinesio Taping|Kinesio Taping application with tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
1503332|NCT02945098|Other|Placebo Kinesio Taping|Kinesio Taping application without tension (Kinesio Tex Gold®, Japan) in the anterior region of the non-dominant arm.
1503333|NCT02945085|Other|Home Based Care Team|Clinical team will conduct comprehensive clinical assessments focused on cognitive impairment and depression, conduct comprehensive medication review and reconciliation, offer Problem Solving Therapy, and offer brief occupational therapy, physical therapy, nutrition, and social support services.
1503334|NCT02945085|Other|Telephone Based Care Team|Telephone contact will be made by nurses. Depending on level of need, follow up telephone and, in some cases, in home visits will be made by nurse or social worker from care management program.
1503335|NCT02945072|Procedure|TIVA|TIVA is use to anesthesia maintenance after anesthesia induction (Propofol 10mg/kg/h, Remifentanil 0.2mcg/kg/min, dose adaptation as required for sufficient anesthesia)
1503336|NCT02945072|Procedure|Sevoflurane|Sevoflurane is use to anesthesia maintenance after anesthesia induction (target et 2 Vol% in 50-70% N2O, dose adaptation as required)
1503337|NCT02945059|Procedure|Selective reversible portal vein embolization|Percutaneous access to the portal vein is achieved under general anesthesia with ultrasound or fluoroscopic control. After assessment of portal venous anatomy, embolization of selected portal vein segments is performed using the powdered form of an absorbable gelatin sponge.
1503338|NCT02945046|Drug|Fremanezumab - A|
1503339|NCT02945046|Drug|Fremanezumab - B|
1503340|NCT02945046|Drug|Placebo|Matching placebo
1503341|NCT02945033|Drug|aspirin intake|Patient with colonic adenocarcinoma stage III or II high risk will take aspirin 100 mg/day during 3 years
1503342|NCT02945033|Drug|placebo intake|Patient with colonic adenocarcinoma stage III or II high risk will take placebo of aspirin 100 mg/day during 3 years
1503346|NCT02945020|Drug|Dabigatran etexilate mesylate|Participants will receive dabigatran etexilate mesylate 75 mg, orally.
1503347|NCT02945020|Drug|Odalasvir (ODV)|Participants will receive ODV 25 mg, orally.
1503348|NCT02945020|Drug|Simeprevir (SMV)|Participants will receive SMV 75 mg, orally.
1503349|NCT02945007|Drug|JNJ-53718678|Participants will receive JNJ-53718678 under fed or fasted conditions.
1503350|NCT02944994|Other|Unified protocol|This is a transdiagnostic cognitive behavioral therapy
1503351|NCT02944994|Other|Routine Care|This arm will reflect typical care received in routine mental health care
1503352|NCT02944981|Drug|Gabapentin|Single oral dose
1503353|NCT02944981|Drug|Placebo|Single oral dose
1503354|NCT02944968|Device|THERMOCOOL SMARTTOUCH® SF-5D catheter|
1503355|NCT02944955|Drug|BLEX 404 Oral Liquid|"BLEX 404 Oral Liquid is orally administered twice daily in combination with azacitdine treatment cycles (2 cycles in Part I and 6 cycles in Part II).
Azacitidine treatment: SC or IV injections at 75 mg/m2, QD for 7 days each cycle. 28 days/cycle, and repeat cycles every 4 weeks."
1503356|NCT02944942|Procedure|General anesthesia|Patients undergoing general anesthesia
1503357|NCT02944929|Other|Self-rehabilitation program|The self-rehabilitation program will be based on muscle stretching, strengthening and task oriented exercises. For each patient, two exercises will be selected by the therapist for each of these 3 domains (total of 6 exercises) from a list of 50 exercises.
1503358|NCT02944916|Device|IryPump R Set|
1503359|NCT02944903|Other|Audit|Questionnair
1503360|NCT02944890|Device|Drug Eluting Balloon Catheters(RESTORE DEB）|
1503361|NCT02944890|Device|Drug Eluting Balloon Catheters(SeQuent® Please）|
1503362|NCT02944877|Behavioral|Harnessing Online Peer Education (HOPE) Social Media Intervention|
1503363|NCT02944864|Drug|TQ-B3395|TQ-B3395 p.o. qd
1503364|NCT02944838|Behavioral|Senior Change Makers Advocacy Program|see description
1503365|NCT02944838|Behavioral|Senior Change Makers Physical Activity Program|see description
2002372|NCT02291250|Dietary Supplement|Blackcurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.
The equivalent carbohydrate load will be standardised across the groups"
1503369|NCT02944812|Drug|Chidamide|Chidamide is given to the patients as described, and drug concentration is measured in patients' serum and CSF, also, parameters concerning efficacy and safety are also obtained.
1503370|NCT02944799|Drug|Placebo|Discontinuation of alendronate treatment
1503371|NCT02944799|Drug|Alendronate|
1503372|NCT02944799|Drug|Calcium|Daily dietary supplement of 800mg calcium
1503373|NCT02944799|Drug|Vitamin D|Daily dietary supplement of 38 micrograms vitamin D
1503374|NCT02944786|Behavioral|HOPE-model|There are four sessions of person-centered health dialogues. The sessions also include pain/stress management and education about stress and pain (the HOPE model that is an adolescent-centered school health prevention program when adolescents have chronic pain).
1503376|NCT02944760|Other|Low-Level Light Therapy|The application of laser therapy will take place 30 minutes before the start of dialysis. The application will take place with the Chattanooga device, with the laser diode cluster probe from the same manufacturer consisting of five diodes 850 nm and power output of 200 mW. It is irradiated 6 points in quadriceps and 4 points in gastrocnemius, bilaterally by 30 seconds. The patient will be supine on a stretcher to the implementation of the intervention.
1503377|NCT02944747|Behavioral|Education & paper based calendar|
1503378|NCT02944747|Behavioral|Education & cell-phone based SMS alert system|
1503379|NCT02944747|Behavioral|Education & smart-phone based application|
1503380|NCT02944734|Drug|Candesartan Cilexetil 8mg|Candesartan Cilexetil 8mg Daily oral administration for 8 weeks
1503381|NCT02944734|Drug|Candesartan Cilexetil 16mg|Candesartan Cilexetil 16mg Daily oral administration for 8 weeks
1503382|NCT02944734|Drug|Amlodipine 5mg|Amlodipine 5mg Daily oral administration for 8 weeks
1503383|NCT02944734|Drug|Amlodipine 10mg|Amlodipine 10mg Daily oral administration for 8 weeks
1503384|NCT02944721|Genetic|Genetical analyses|
1503385|NCT02944721|Other|Chronic pain identification questionnaires|
1503386|NCT02944721|Other|Neurophysiological and psychophysical evaluations|
1503387|NCT02944721|Other|Quality of life questionnaires|
1503388|NCT02944708|Drug|Conventional chemotherapy|
1503389|NCT02944708|Drug|Maintenance chemotherapy 1|
1503390|NCT02944708|Drug|Maintenance chemotherapy 2|
1503391|NCT02944695|Other|audit|Practice adherence to guidelines
1503393|NCT02944669|Device|ReWalk Personal Device|
1503394|NCT02944656|Drug|Gabapentin|Participants in this group will receive 600 mg of gabapentin given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion. Gabapentin is an FDA approved medication that is used to prevent seizures and to treat various forms of chronic and acute pain.
1503395|NCT02944656|Drug|Placebo|Participants in this group will receive 600 mg of gelatin capsules that are identical in appearance to gabapentin capsules. The placebo will be given 1-2 hours pre-operatively in conjunction with perioperative paracervical block for surgical abortion.
1503396|NCT02944643|Other|Mindfulness and Support Groups|
1503397|NCT02944630|Behavioral|Psychotherapy|Individual psychotherapy
1995838|NCT02641366|Procedure|Tremor kinetics after DBS|We will fit the patient with the electromagnetic sensors and then perform routine outpatient neurologic examinations with their DBS system in both the DBS on and the DBS off settings.
1503401|NCT02944604|Drug|PEG-rhG-CSF|
1995839|NCT02641366|Procedure|Tremor kinetics before and after DBS|We will perform two testing sessions: the first session will be performed during a routine preoperative visit, the second session will be performed during a routine postoperative DBS programming visit in both the DBS on and the DBS off settings.
1503402|NCT02944591|Device|COPD Co-Pilot|The COPD Co-PilotTM is a smartphone application for symptom reporting supported by a Call Center staffed with pulmonary nurses and Health Assistants who are trained to support patients with COPD. The call center staff are employees and subcontractors of the company that makes the COPD Co-PilotTM, HGE. It is located on the Campus of Temple University in Philadelphia Pennsylvania.
1503405|NCT02944565|Biological|Daratumumab|Given IV
1503406|NCT02944552|Drug|Bicyclol tablets|The trial drug: bicyclol, 25mg/ tablet. Low dose group: each oral bicyclol 25mg, three times daily for 4-8 weeks.
1503407|NCT02944552|Drug|polyene phosphatidylcholine capsules|polyene phosphatidylcholine capsules, 228mg/ particle. Control group: each oral polyene phosphatidylcholine 456mg, three times daily for 4-8 weeks.
1503408|NCT02944552|Drug|Bicyclol tablets|The trial drug: bicyclol, 25mg/ tablet. High dose group: each oral bicyclol 50mg, three times daily for 4-8 weeks.
1503409|NCT02944526|Drug|Ropivacaine Monohydrochloride|Suprascapular nerve block under ultrasound control: injection of 5ml Ropivacaine HCL 2mg /ml
1503410|NCT02944526|Drug|Placebo - Concentrate|Placebo suprascapular nerve block under ultrasound control: injection of 5ml physiological / isotonic saline
1503411|NCT02944513|Device|Quell|
1503412|NCT02944500|Drug|liraglutide|
1503413|NCT02944500|Other|Placebo|
1503414|NCT02944487|Drug|Lucerastat|Hard gelatin capsule for oral administration containing lucerastat
1503415|NCT02944487|Drug|Placebo|Matching placebo capsules
1503416|NCT02944474|Drug|Lucerastat|Capsule for oral administration containing lucerastat
1503417|NCT02944474|Drug|Placebo|Placebo capsules matching lucerastat capsules
1503418|NCT02944461|Drug|Dapsone 7.5 % gel|Dapsone gel 7.5% applied once daily to truncal acne
1503419|NCT02944448|Drug|CR845 tablet 1 mg|CR845 tablets will be provided as 1 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
1503420|NCT02944448|Drug|CR845 tablet 2.5 mg|CR845 tablets will be provided as 2.5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
1503421|NCT02944448|Drug|CR845 tablet 5 mg|CR845 tablets will be provided as 5 mg enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
1503422|NCT02944448|Drug|Placebo tablet|Placebo tablets will be provided as enteric-coated tablets. All tablets are white in color with no markings and are identical in appearance, regardless of dose and treatment.
1503423|NCT02944435|Drug|CB-839 Capsules|3 x 200 mg CB-839 Capsules (Reference Formulation)
1503424|NCT02944435|Drug|CB-839 Tablets|3 x 200 mg CB-839 Tablets (Test Formulation)
1503425|NCT02944409|Device|total knee prothesis VEGA System|total knee replacement
1503426|NCT02944396|Drug|veliparib|oral capsule; varying doses administered on Days -2 to 5 in a 21-day cycle
1503427|NCT02944396|Drug|nivolumab|intravenous; administered on Day 1 via infusion in a 21-day cycle
1503428|NCT02944396|Drug|carboplatin|intravenous; administered on Day 1 via infusion in a 21-day cycle
1503429|NCT02944396|Drug|pemetrexed|intravenous; administered on Day 1 via infusion in a 21-day cycle
1503430|NCT02944396|Drug|paclitaxel|intravenous; administered on Day 1 via infusion in a 21-day cycle
1503431|NCT02944383|Drug|Gemcabene|
1503432|NCT02944383|Drug|Placebo Oral Tablet|
1503433|NCT02944370|Behavioral|PlayFit - modified exercise games|Play modified games with other adults three times a week for 12 weeks. Complete a brief survey on the games played and program satisfaction.
1503434|NCT02944357|Drug|Cisplatin|Given IV
1503435|NCT02944357|Drug|Gemcitabine Hydrochloride|Given IV
1503436|NCT02944357|Procedure|Radical Cystectomy|Undergo cystectomy
1503437|NCT02944357|Biological|Tumor Cell-Derived Vaccine Therapy|Given AGS-003-BLD ID
1503438|NCT02944344|Behavioral|Four Conversations|The online Four Conversations program consists of tutorial videos, printable documents, and live sessions with a counselor to educate subjects on shared decision making and care planning for those with advanced disease.
1503439|NCT02944331|Procedure|Endovenous steam ablation|
1503440|NCT02944318|Behavioral|The Movement Program|The program duration will be one academic year (around ten months) in 2017. The intervention strategies will focus on: (1) teachers' training and activities on health in curriculum; (2) active opportunities in the school environment (facilities and materials for PA practice) and (3) health education (posters and folders to students and parents).
1503441|NCT02944305|Procedure|Endotracheal intubation|Endotracheal intubation under direct laryngoscopy using McIntosh blade
1503442|NCT02944292|Procedure|Deepening of sedation|Deepening of sedation will be achieved with a bolus and subsequent continuous infusion of propofol.
1503481|NCT02943980|Device|Macintosh Laryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the conventional Macintosh Laryngoscope
1503482|NCT02943967|Procedure|CXL + PRK group|Corneal cross-linking with subsequent photorefractive keratotomy after 6 months was performed in one eye
1503443|NCT02944292|Drug|Propofol|"Propofol will be dosed according to lean body weight (LBW) for bolus administration and according to total body weight (TBW) for continuous infusion.
All patients will receive a bolus of propofol 1 mg/kg LBW as a rapid infusion during one minute. Measurements will be made one minute after the ending of bolus infusion. Continuous infusion of propofol at a rate of 3 mg/kg/h will be started immediately following completion of measurements, not later than 5 minutes after bolus administration. The propofol infusion rate is decreased in case of hemodynamic instability by 1 mg/kg/h and until a minimum of 1 mg/kg/h, if needed. Maximum total dose of infusion of 5 mg/kg/h will not be exceeded (bolus not considered)."
1503444|NCT02944266|Other|Pre operative Focus assessed Transthoracic echocardiographic assessment.|
1503445|NCT02944253|Other|Low energy diet 70g carbohydrates|isocaloric (4128 kJ/day (1000 kcal/day) for women, 5021 kJ/day (1200 kcal/day) for men)low energy diet containing 70 gram carbohydrates
1503446|NCT02944253|Other|Low energy diet 100g carbohydrates|isocaloric (4128 kJ/day (1000 kcal/day) for women, 5021 kJ/day (1200 kcal/day) for men)low energy diet containing 100 gram carbohydrates
1503447|NCT02944253|Other|Low energy diet 130g carbohydrates|isocaloric (4128 kJ/day (1000 kcal/day) for women, 5021 kJ/day (1200 kcal/day) for men)low energy diet containing 130 gram carbohydrates
1503448|NCT02944227|Drug|Lucentis|Lucentis fixed-treatment arm
1503449|NCT02944214|Drug|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
1503450|NCT02944214|Drug|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
1503451|NCT02944201|Drug|Carvedilol|Carvedilol will give twice daily until prostatectomy
1503452|NCT02944188|Procedure|Laparoscopic right hemicolectomy plus ERAS|patients treated with Laparoscopic right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
1503453|NCT02944188|Procedure|Open right hemicolectomy plus ERAS|patients treated Open right hemicolectomy plus enhanced recovery after surgery (ERAS) programs
1503454|NCT02944175|Drug|Sugammadex|At the end of surgery and when 2 responses were achieved on the TOF stimulation, Sugammadex 2 mg·kg-1 was administered intravenously in Group S
1503455|NCT02944175|Drug|Neostigmine|At the end of surgery and when 2 responses were achieved on the TOF stimulation neostigmine 0.05 mg·kg-1 + atropine 0.02 mg·kg-1 was administered intravenously
1503456|NCT02944162|Biological|anti-CD33 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD33 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD33.
1503457|NCT02944149|Procedure|tubal ligation by minilaparotomy|Tubal ligation will be performed by minilaparotomy as per the Tanzanian government standards, with the standard family planning counseling and minilaparotomy surgical protocols used by the government being followed during the study.
1503460|NCT02944123|Drug|Clopidogrel 75 mg|Clopidogrel 600 mg as loading dose followed by 75 mg/day as maintenance dose.
1503461|NCT02944123|Drug|Prasugrel 5 mg|Loading / maintenance dose: prasugrel 60 mg / 10 mg/day; After 1-month treatment of conventional dose, followed half dose of 5 mg/day for chronic treatment.
1503462|NCT02944123|Drug|Ticagrelor 45 mg|Loading / maintenance dose: ticagrelor 180 mg / 90 mg/bid; After 1-month treatment of conventional dose, followed half dose of 45 mg/bid for chronic treatment.
1503463|NCT02944110|Drug|Glucagon receptor antagonist LY2409021|single oral dose of 300mg
1503464|NCT02944110|Drug|Placebo|Oral dose of placebo tablets
1503465|NCT02944097|Dietary Supplement|Vineatrol 30 native powder|
1503466|NCT02944097|Dietary Supplement|Vineatrol 30 micelles|
1503467|NCT02944084|Dietary Supplement|Rice bran extract|
1503468|NCT02944084|Dietary Supplement|Porridge in water|
1503469|NCT02944084|Dietary Supplement|Porridge in milk|
1503470|NCT02944071|Device|Boston Scientific Ranger™ and Ranger™ SL Paclitaxel-Coated PTA Balloon Catheter|
1503471|NCT02944058|Procedure|Multiloc nail|Intervention is surgery with Multiloc nail
1503472|NCT02944058|Procedure|Philos plate|Intervention is surgery with Philos plate
1503473|NCT02944045|Drug|Methylprednisolone|"Methylprednisolone intra veinous
Day 1 to 5 : 30mg twice per day
Day 6 to 10 : 30mg per day
Day 11 to 21 : 20mg per day"
1503474|NCT02944045|Drug|Placebo|saline serum
1503475|NCT02944032|Other|CogmedRM|Cogmed RM is a computer program that consists of twelve visually-engaging and interesting exercises that target skills involving visuo-spatial and verbal Working Memory. Difficulty of the tasks is automatically adjusted on a trial-by-trial basis throughout each training session to match a child's current working memory span, such that as the child becomes more proficient, the exercises become more difficult. During the intervention, children complete 25 training sessions. Children are asked to complete between 3 and 5 sessions per week, so the total treatment time to complete 25 sessions may range from 5 to 9 weeks. For children completing CogmedRM, sessions typically last between 25 and 45 minutes, depending on the child's working memory span.
1503476|NCT02944032|Other|Mobymax|"MobyMax's Reading Stories program is a program that focuses on reading comprehension skills. Participants will start their training with stories that are matched to their reading grade level. Each grade contains 30 lessons, with 3 stories in each lesson. Participants are given questions to answer at the conclusion of each story, and children advance or remain at that level depending on the progression of their reading skill. Participants randomized to this program will be asked to train 30-45 minutes per session for 25 training sessions over a 5 to 9 week period."
1503478|NCT02944006|Procedure|multi-parametric MRI|multiparametric MRI is performed in all patients, and the sequence includes dynamic contrast enhanced (DCE) MRI, diffusion weighted imaging (DWI), tissue maps, and MR cholangiography.
1503479|NCT02943993|Drug|Edoxaban|Prescribed according to approved label
1503480|NCT02943980|Device|CMAC Videolaryngoscope|In a randomised order we evaluate the quality of the IONM after securing the airway with the CMAC
1503483|NCT02943967|Procedure|PRK group|Photorefractive keratotomy alone was performed in contra lateral eyes
1503487|NCT02943928|Device|laryngoscope and chest CT image|First,the operator calculate the distance between the carina and the glottis by CT image and make s marker on the double lumen endotracheal tube. Then the operator when inserted into the double lumen tube under the visualof laryngoscope until see marker just at the glottis
1503488|NCT02943928|Device|traditional method by experience|Operator inserted the double lumen tube by experience
1503489|NCT02943915|Device|Ekso GT Rehabilitation Therapy|Walking Improvement for Spinal Cord Injuries with Exoskeleton
1503490|NCT02943915|Device|Body Weight Supported (BWS) Treadmill Training|Standard gait training using BWS PT and overground training
1503491|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 6 weeks|PCV10 1+1, 6 weeks & 9 months
1503492|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 1+1, 14 weeks|PCV10 1+1, 14 weeks & 9 months
1503493|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV10 ) 2+1|PCV10 2+1, 6&14 weeks & 9 months
1503494|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 6 weeks|PCV13 1+1, 6 weeks & 9 months
1503495|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 1+1, 14 weeks|PCV13 1+1, 14 weeks & 9 months
1503496|NCT02943902|Biological|Pneumococcal conjugate vaccine (PCV13 ) 2+1|PCV13 2+1, 6&14 weeks & 9 months
1503497|NCT02943889|Biological|Mesenchymal stem cell transplantation|Bone marrow aspiration by clinical pathologist. Isolation, propagation and differentiation of stem cells will be done in stem cell center. After confirmation of the trans-differentiation into hepatocytes at the laboratory level, it will be infused into the portal vein under ultrasound guidance.
1503498|NCT02943876|Other|personalized depression risk information|The personalized depression risk information is determined by sex-specific risk prediction algorithms based on one's family history of depression, current health status, childhood traumatic experience and ongoing life stressors. The information is in the form of probability of having a major depressive episode in the next 4 years.
1503499|NCT02943863|Device|HFNC followed by conventional nasal cannula|
1503500|NCT02943863|Device|Conventional nasal cannula followed by HFNC|
1503501|NCT02943850|Biological|Stem cell (HPC) implantation|All patients will received unilateral lumbar spinal cord injections of CNS10-NPC-GDNF cells.
1503502|NCT02943850|Device|Stereotactic surgical device|A newly developed stereotactic frame is being evaluated as a part of this trial
1503503|NCT02943837|Procedure|Device: 22G FNA needle|
1503504|NCT02943837|Procedure|Device: 20G FNB needle|
1503505|NCT02943824|Other|Machine Learning Planning|The intervention being tested is a novel approach to planning LDR treatment plans using a machine learning computer algorithm.
1503506|NCT02943824|Other|Radiation Therapist Planning|The intervention being compared to the experimental arm is conventional manual planning by a human expert LDR brachytherapy planner.
1503507|NCT02943811|Device|UTERINE MANIPULATOR|Patients were operated laparoscopically with the aid or not of an intrauterine probe to manipulate the uterus
1503508|NCT02943798|Drug|etoposide plus carboplatin|etoposide is administered by venus with a dose of 100mg/m2 from day 1 to3, and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
1503509|NCT02943798|Drug|Paclitaxel plus carboplatin|Paclitaxel is administered by venus with a dose of 175 mg/m2 from day 1 and carboplatin is administered by venus with a dose of AUC 5 on day 1 in a 21-day cycle.
1503510|NCT02943785|Drug|Edoxaban-based Regimen|15 mg, 30 mg and 60 mg film coated tablet for oral use (with anti-platelet therapy pre-declared at randomization if prescribed)
1503511|NCT02943785|Drug|VKA-based Regimen|Dosed at International Normalized Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in the country location (with anti-platelet therapy pre-declared at randomization if prescribed).
1503512|NCT02943772|Other|Local hypothermia|Cooled brick
1503513|NCT02943772|Other|Control|Control brick
1503514|NCT02943759|Drug|Neem leaf extract|A natural irrigant solution act as anti-inflammatory and anti bacterial
1503515|NCT02943759|Drug|Chlorhexidine gluconate|2%chlorhexidine gluconate , anti bacterial root canal irrigant solution
1503516|NCT02943746|Dietary Supplement|Standard Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.
1503517|NCT02943746|Dietary Supplement|High Protein Diet|Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.
1503518|NCT02943733|Drug|TAS-102|Anti-metabolite agent, taken orally.
1503519|NCT02943733|Drug|Temozolomide|Oral chemotherapy drug.
1503520|NCT02943720|Drug|AllerT|Bet v 1 contiguous overlapping peptides mixed with aluminium hydroxide solution
1503521|NCT02943720|Drug|placebo|placebo
1503522|NCT02943707|Procedure|Autologous bone marrow stem cells infusion|Autologous bone marrow stem cells are infused into proper hepatic artery
1503523|NCT02943707|Drug|drugs such as Ursodeoxycholic Acid tablets|Ursodeoxycholic Acid tablets(UDCA), each time 150 mg, three times a day orally
1503524|NCT02943694|Device|TaTME with CS-Compact (GelPoint pathway)|Standard TaTME with circular stapler (Short and straight, CS Compact), designed for extra-corporeal and endo-anal anastomosis procedures.
1503525|NCT02943681|Biological|Measles vaccine|
1503526|NCT02943668|Drug|Deferasirox|Given PO
1503527|NCT02943668|Other|Laboratory Biomarker Analysis|Correlative studies
1503528|NCT02943655|Drug|combined contraceptive pills (microcept)|oral combined contraceptive once daily
1503529|NCT02943655|Drug|medroxyprogesterone acetate (progest)|oral 5 mg medroxyprogesterone acetate daily
1503530|NCT02943655|Drug|mefenamic acid (ponstan forte)|oral 500 mg mefenamic acid three times per day
1503531|NCT02943642|Biological|A-dmDT390-bisFv(UCHT1)|anti-T cell immunotoxin (antibody targeting CD3 on T-cells tagged with diphtheria toxin without binding domain)
1503532|NCT02943642|Drug|Vorinostat|ZOLINZA is a histone deacetylase (HDAC) inhibitor indicated for the treatment of cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent or recurrent disease on or following two systemic therapies.
1503533|NCT02943629|Device|Apneic oxygenation: Eight minute|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
1503534|NCT02943629|Device|Without apneic oxygenation|A Pentax AWSTM video laryngoscope with attached P blade will be placed for eight minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
1503535|NCT02943629|Device|Apneic oxygenation: five minutes|A Pentax AWSTM video laryngoscope with attached P blade will be placed and then 10 l/minute flow of oxygen will be administered through the P blade (apneic oxygenation) for five minutes, or less if SpO2 falls to ≤ 95%. The trachea will then be intubated and the ventilation of the lungs will commence using 100% oxygen until SpO2 ≥ 98%.
1503536|NCT02943616|Device|Absorb BVS|"Commercially approved Absorb GT1 BVS, herein referred to as Absorb.
Scaffold diameters: 2.5, 3.0, and 3.5 mm
Scaffold lengths: 8, 12, 18, 23 and 28 mm
Absorb is a temporary scaffold that will fully resorb over time and is indicated for improving coronary luminal diameter in patients with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
1503537|NCT02943603|Drug|mFLOFOX6 + pembrolizumab|the combination of mFOLFOX6 + pembrolizumab is the single intervention even though the is dosed differently.
1503538|NCT02943590|Drug|Placebo|A pill taken once a day
1503539|NCT02943590|Drug|Atorvastatin|A pill taken once a day
1503544|NCT02943551|Other|Online Tutorial|For each group of practices, during the first month of intervention participation, study staff at Seattle Children's Research Institute will send each participating provider within a group/wedge, via email, a password to access the online tutorial. Participants will be asked to view the 40-minute tutorial at a time that is convenient for them but prior to the first webinar. Investigators will be able to track whether and how often participants access the online tutorial as a measure of engagement in the intervention. PROS will follow up, via email or phone, with providers who have not completed the tutorial within a three week timeframe.
1503545|NCT02943551|Other|Webinars|"The first webinar, focused on making appropriate antibiotic choices for bacterial ARTIs, will be held at the beginning of month 2 of intervention participation, and the second webinar, focused on recommended communication practices during visits for ARTIs, will be held at the beginning of month 3 of intervention participation. Due to webinar faculty time constraints, we will establish dates/times for the webinar prior to recruitment. Providers will be given information on webinar dates in both the randomization email, as well as include the dates in the study box letter.
The webinars will be recorded to facilitate attendance for those who are unable to make the scheduled date/time. Included in the recording will be the presentation and any questions and answers from participants."
1503546|NCT02943551|Other|Booster Sessions|"An online link to the first booster video vignette will be sent to practice participants via email at the beginning of month 5 of intervention participation for each group/wedge. The link will lead to a website in which the provider will need to create a user name and password to access the booster videos. Two additional booster vignettes will be made available for viewing at the beginning of months 7 and 9 of intervention participation.
For each of the three booster sessions, up to three reminders to complete viewing the video vignette will be sent over a 2-week period. The study team will be able to monitor whether participants access and complete the questions at the end of each vignette."
1503547|NCT02943551|Other|Feedback Reports|"During the intervention phase, providers will also receive 6 audit and feedback reports given by parents.
The first report will have two parts:
The first part will focus on the provider's overall antibiotic prescribing rates for all ARTIs (viral and bacterial) and rates of using second-line antibiotics for bacterial ARTIs.
The second part will report the rates at which the provider uses the targeted communication practices as well as their average satisfaction scores."
1503548|NCT02943551|Other|Parent Survey|Throughout the study, parents at participating practice sites will be offered the opportunity to complete a DART Parent Survey after their child's visit.
1503549|NCT02943538|Device|Telemedicine|Monitoring and control is performed through telematics platform integrated management of chronic NOMHAD, configurated to respond the patients specific needs.
1503550|NCT02943538|Device|Telephone|A telephone control of their state and evolution will be made through the nursing staff of the unit.
1503551|NCT02943538|Other|Conventional care|Conventional care provided in the unit to patients with IBD -high moderate complexity.
1503552|NCT02943525|Procedure|vaginal packing|Packing vagina with a Boric acid soaked gauze at the end of surgery
1503553|NCT02943512|Other|Discharge day of procedure|Subjects will be discharged the day of the procedure if safe
1503554|NCT02943499|Behavioral|App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
1503555|NCT02943499|Behavioral|App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
1503556|NCT02943499|Device|Smartphone|
1503557|NCT02943486|Other|dac-MSCs|Cell-free therapy
1503558|NCT02943486|Other|MSCs|Cell-based therapy
1503559|NCT02943486|Drug|Fitostimoline|Triticum vulgare
1503603|NCT02943109|Other|Low Touch|"Participants receives a visit from a patient navigator who helps to explain how to navigate the hospital system (active control)."
1503560|NCT02943473|Drug|Ibrutinib|"Ibrutinib is a type of drug called a kinase inhibitor. Kinases are proteins inside cells that help cells live and grow. Ibrutinib blocks a specific kinase protein in our bodies. This protein is thought to be very important in helping blood cancer cells live and grow. By blocking this kinase protein, ibrutinib stops cancer cells from growing."
1503561|NCT02943460|Drug|GS-9674|Tablet(s) administered orally once daily
1503562|NCT02943460|Drug|Placebo to match GS-9674|Tablet(s) administered orally once daily
1503563|NCT02943447|Drug|GS-9674|Tablet(s) administered orally once daily
1503564|NCT02943447|Drug|Placebo to match GS-9674|Tablet(s) administered orally once daily
1503565|NCT02943434|Other|Processed food|This is examining the effects of processed foods on diet-induced thermogenesis.
1503566|NCT02943421|Procedure|Transverse B-Lynch suture|
1503567|NCT02943408|Behavioral|person-centered mental health intervention|We anticipate that the PCMHI will be comprised of three, one-hour sessions offered over three to six weeks, scheduled at the participants' preference. Sessions will be one-on-one and the peer support specialist interventionist.
1503568|NCT02943408|Behavioral|health and wellness|The control condition will be an educational health and wellness intervention for stress related disorders that will match the experimental condition for time and attention. The control condition will be three, one hour, individual sessions covering the symptom cycle, managing stress, and identifying social supports.
1503569|NCT02943395|Other|E.Max CAD Laminate Veneers cemented with dual cure amine free adhesive resin cement|
1503570|NCT02943395|Other|E.Max CAD Laminate Veneers cemented with light cured adhesive resin cement|
1503571|NCT02943382|Other|Fingerprick autologous blood (FAB)|Pricking of cleaned finger using diabetic lancet and applying blood droplet to affected eye. Repeated with separate finger for other affected eye.
1503572|NCT02943369|Drug|Ticagrelor 180 mg loading dose|Ticagrelor 180 mg
1503573|NCT02943369|Drug|Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min|Intravenous Cangrelor 30 mcg/kg bolus + 4 mcg/kg/min for 2 hours
1503574|NCT02943356|Drug|Tadalafil|Patients will be treated with Tadalafil for 8 weeks
1503575|NCT02943343|Other|No intervention|
1503576|NCT02943330|Other|Questionnaire|Questionnaires such as Hospital Anxiety and Depression Scale (HADS) and Montgomery Asberg Depression Rating Scale (MADRS), Short-form Health-related Quality of Life (SF-36), as well as psychiatric diagnostic interview with the Mini-International Neuropsychiatric Interview (MINI) and the Family Interview for Genetic Study (FIGS).
1503577|NCT02943317|Drug|Part A - VS-6063|Part A - Oral VS-6063 (defactinib) twice-daily (BID) continuously starting on Day 1 of Cycle 1.
1503578|NCT02943317|Drug|Part A - Avelumab|Part A - avelumab IV treatment in 28-day cycles (10 mg/kg over approximately 1 hour on Days 1 and 15).
1503579|NCT02943304|Other|Symptomatic pregnant women with positive RT-PCR ZIKV in serum or urine, or a positive serologic test specific for ZIKV|
1503580|NCT02943291|Behavioral|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
1503581|NCT02943291|Behavioral|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes warm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
1503582|NCT02943278|Behavioral|Intensive Sleep Retraining|Participants in this group you will spend just over 1 day at our sleep lab, starting around their usual bedtime and ending the following day. Over a 20 hour period participants will complete a sleep retraining session, which involves an opportunity to fall asleep every 30 minutes; we will wake participants up after a few minutes if they fall asleep.
1503583|NCT02943278|Behavioral|Sleep Hygiene|Participants in this group will complete one session with a clinician focused on psychoeducation regarding sleep positive practices.
1503585|NCT02943252|Drug|Apatinib|apatinib 500 mg in tablet once daily
1503586|NCT02943252|Drug|S1|S-1 40-60mg bid, days 1-14 , every 3 weeks
1503587|NCT02943239|Drug|REGN1033|REGN1033
1503588|NCT02943239|Drug|REGN2477|REGN2477
1503589|NCT02943239|Other|Placebo|Placebo
1503590|NCT02943226|Device|Becton Dickinson Nexiva Diffusics System catheter|Becton Dickinson (BD Nexiva™ Diffusics™ System ) uses three laser-cut tear-drop holes located in the catheter tip to stabilize the catheter tip by reducing flow velocities while maintaining flow rates during intravenous contrast administration into the vein.
1503591|NCT02943226|Device|Standard intravenous catheter|The standard catheter has one hole at the tip for contrast infusion.
1503593|NCT02943187|Behavioral|Cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
1503594|NCT02943187|Dietary Supplement|Nutrition|Participants will be given dietary recommendations and nutritional supplements to optimize cognition.
1503595|NCT02943174|Behavioral|MIND programme for cancer patients|Psychotherapeutic programme based on Acceptance, Mindfulness and Compassion for cancer patients Other: Cancer Treatment as Usual
1503596|NCT02943174|Other|Treatment as Usual (TAU)|Standard personalized treatment of cancer
1503597|NCT02943161|Dietary Supplement|L-Citrulline|The purpose of this study is to see if citrulline supplementation will restore NO levels and lung function in subjects with asthma.
1503598|NCT02943148|Other|Davey score for striae gravidarum|
1503599|NCT02943135|Drug|lidocaine in-situ gel|
1503600|NCT02943135|Drug|placebo in-situ gel|
1503601|NCT02943122|Device|Ambulatory blood pressure monitor|
1503602|NCT02943109|Other|High Touch|"Participants receives an in person visit from an technology navigator who helps to explain the technology to the patient."
1503633|NCT02942810|Drug|WCK 5222|IV infusion over a period of 60 minutes
1503604|NCT02943109|Device|High Tech|Patient receives full-suite access to an inpatient patient portal with bi-directional communication enabled.
1503605|NCT02943109|Device|Low Tech|Patient receives a limited access version of the inpatient patient portal with bi-directional communication disabled.
1503606|NCT02943096|Dietary Supplement|CocoaVia|Flavanols represent a specific group of plant derived nutrients that are found in cocoa beans, grapes, tea, berries and various other fruits and vegetables. The specific flavanols investigated in this study come from cocoa.
1503607|NCT02943096|Other|Placebo|"The placebo looks like the other intervention pills, but does not contain any flavanols (it is sometimes called a sugar pill)."
1503608|NCT02943083|Behavioral|Relaxation Exercise|Groups receiving the intervention will be asked to engage in the relaxation protocol every day. Participants will be asked to continue practicing the relaxation protocol for the remainder of their pregnancy. Participants will be instructed to listen to the 7 minute guided muscle relaxation tape and engage in the 3 minute abdominal touch routine in the presence of the scent stick. Participants will be provided with a scent stick of their selected scent to take home. For the duration of the study, participants will be loaned standard headphones and an iPod Touch that contains only the guided progressive muscle relaxation audio recording to facilitate this at-home protocol.
1503609|NCT02943070|Device|Rezum System|"The Rezūm System treats patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death. The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
1503610|NCT02943057|Drug|2% guttae ganciclovir|2% guttae ganciclovir 5 times a day for 6 weeks
1503611|NCT02943044|Device|No intervention, this is an observational study|Non interventional, non-invasive measurements of tissue samples suspected of squamous cell carcinoma using an optical probe.
1503612|NCT02943031|Other|Individualized Precision Therapy Programs|After bile duct tumor samples were collected, whole genome sequencing, drug screening ( including Mini-PDX and PDX) will conduct. Suitable drugs will be decided according to the different genomics classification.OS and PFS will be recorded.
1503613|NCT02943018|Other|anovaginal distance variation|Kappa calculation
1503614|NCT02943005|Procedure|Rotator cuff repair|
1503615|NCT02942992|Behavioral|Resistance exercise|
1503616|NCT02942966|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
1503617|NCT02942953|Device|Diaphragmatic Pacer|The surgical procedure of DP implantation consists in placing four intramuscular electrodes, using a conventional abdominal laparoscopy with four ports. It consists in locating the optimum point for electrode insertion. The process involves mapping between 30 and 50 different points in each hemidiaphragm by applying an electric stimulus of 2-24 mA at 100 µsec pulse widths11. It results in both qualitative and quantitative assessment of diaphragmatic movement. Site of main electrode is identified as the location of each hemidiaphragm's change of maximum pressure and site of secondary electrode as replica of main site. Once the sites are identified intramuscular electrode placement phase is initiated. Finally the electrodes are tunneled out to the corresponding percutaneous exit site.
1503618|NCT02942940|Device|mobile app|The mobile app follow-up group will have no planned in-person follow-up, however these visits will be replaced with surgical site examination via submitted photos, Visual Analogue Scale (VAS), and Quality of Recovery - 9 questionnaire (QoR-9) and limb specific recovery monitoring. All information is submitted with the mobile app (QoC Health Inc, Toronto).
1503619|NCT02942940|Other|conventional in-person|Patients in the conventional follow-up group will have a planned clinic follow-up at 2 and 6 weeks post-operatively, which is the schedule currently used by our surgeons. At these scheduled follow-up visits, patients will be asked to complete the VAS to assess pain and the QoR-9 in addition to recovery questions about their operated extremity.
1503620|NCT02942927|Other|Medication reduction|Systematic approach to reduction in polypharmacy.
1503621|NCT02942914|Drug|LY3209590|Administered SC
1503622|NCT02942914|Drug|Placebo|Administered SC
1503623|NCT02942914|Drug|Insulin Glargine|Administered SC
1503624|NCT02942901|Procedure|PET-CT|
1503627|NCT02942875|Other|mirror therapy|"During MT, subjects will sit in front of a table on which a mirror will be placed vertically in the space ipsilateral to the paretic upper limb with its reflective surface facing the unaffected upper limb. The subjects are required to look at the mirror to observe the reflective image of the unaffected arm from shoulder to the hand, while it is performing certain designated movements. At the same time, the affected arm will be required to follow the unaffected arm to practice the same movements.
The upper limbs movements during the 30-min MT session are open and close of grasp; wrist flexion and extension; forearm supination and pronation; elbow flexion and extension; shoulder flexion and extension. A total of 120 repetitions for each action will be practiced."
1503628|NCT02942875|Other|control therapy|Control group subjects undergo the same bilateral upper limbs exercise protocol without mirror
1503629|NCT02942862|Drug|Orcein staining|Prognostic value of venous emboli detected by orcein staining
1503630|NCT02942849|Drug|r-hFSH|As per standard clinical practice
1503631|NCT02942836|Device|non-intrusive respiration monitor|Equivalence of CareTaker's respiration rate detection capability to that of predicate device
1503632|NCT02942823|Other|"The serious game KOP"|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
1503639|NCT02942771|Other|Cohort 3 Placebo|Placebo twice daily on Days 1 through 5
1503640|NCT02942758|Drug|low-dose Azacitidine|Azacitidine 75 mg/d s.c. for 7 days, repeated 28-day treatment cycle
1503641|NCT02942758|Drug|Pioglitazone|Pioglitazone 45 mg p.o. continuously from day 1
1503642|NCT02942758|Drug|ATRA|ATRA *45 mg/m² p.o. from day 1 to 28, 15 mg/m² from day 29 continuously; *this regimen will be chosen for the first dose to be evaluated.
1503643|NCT02942758|Drug|standard-dose AZA|Azacitidine 75 mg/m²/d s.c. for 7 days, repeated 28-day treatment cycle
1503644|NCT02942745|Behavioral|Betel Nut Cessation Social Support|The cessation sessions will be led by trained facilitators over 22-day period. Session 1 (Day 1) includes a discussion of health risks associated with betel nut chewing, and introduction to self-monitoring and triggers logs. Session 2 (Day 8) includes a review of their logs, and discussions of lifestyle changes to assist cessation of betel nut chewing. Session 3 (Day 15) will be the quit day for chewers. Coping mechanisms and plans to maximize social support will be discussed. Session 4 (Day 18) will focus on quitting experiences. Facilitators will also review the negative health effects when wanting to chew again. Discussion on quitting experiences will continue in Session 5 (Day 22). Facilitators will also address those who have experienced relapse, and how to manage relapse.
1503645|NCT02942745|Behavioral|Other Betel Nut Cessation Booklet|Betel Nut Cessation Booklet Group will serve as the control group. Participants will receive minimal intervention via a single booklet that contains all the information offered in the experimental group, minus the social support sessions. The participants will meet with study staff individually at a designated office in Guam or Saipan to receive the betel nut cessation booklet, complete three assessments (baseline, 22 days, 6 months), and provide saliva samples.
1503646|NCT02942732|Dietary Supplement|cholecalciferol (Euro-Pharm International, Canada)|All assigned patients received a supplement of 10,000 IU cholecalciferol (Euro-Pharm International, Canada) to be taken three times per week. The treatment was led for a period of 6 months.
1503647|NCT02942706|Drug|Cetuximab|anti-EGFR monoclonal antibody
1503648|NCT02942706|Drug|mFOLFOX6|Oxaliplatin+LV5FU2
1503649|NCT02942706|Drug|FOLFIRI|Irinotecan+LV5FU2
1503650|NCT02942693|Drug|Apatinib|Apatinib will be used as induction therapy in experimental arm.
1503651|NCT02942693|Radiation|Particle Therapy|Same total dose and fractionation will be used in both arms.
1503652|NCT02942680|Drug|acetylsalicylic acid started for 24 hours before surgery|
1503653|NCT02942680|Drug|acetylsalicylic acid stayed for 5 days before surgery|
1503654|NCT02942654|Drug|LY900014|Administered subcutaneously (SC)
1503655|NCT02942654|Drug|Insulin Lispro|Administered SC
1503656|NCT02942641|Procedure|Indwelling urethral catheterization (Foley)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.
Patients in this group received indwelling urethral catheter as the intervention."
1503657|NCT02942641|Procedure|Clean intermittent catheterization (CIC)|"Hospitalized patients who developed first-time AUR were randomly divided into two groups depending on the type of assigned intervention: CIC and indwelling urethral catheter groups.
Patients in this group received CIC as the intervention."
1503658|NCT02942641|Device|Foley|
1503659|NCT02942628|Other|Vegetarian diet followed by meat diet or vice versa|Half the patients will follow either a vegetarian diet for 6 weeks and the other half will adhere to or a meat-based diet for six weekd. This is followed by a 4 week period where patients eat their usual diet. Thereafter patients initially randomized to a vegetarian diet will follow a meat-based diet for six weeks while the patients initially randomized to meat will follow a vegetarian diet for six weeks.
2002373|NCT02291250|Dietary Supplement|Greencurrants with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.
The equivalent carbohydrate load will be standardised across the groups"
1503661|NCT02942602|Drug|Atorvastatin 20 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
1503662|NCT02942602|Drug|Cholestyramine 8 g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
1503663|NCT02942602|Drug|Omega-3 2g|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
1503664|NCT02942602|Drug|Concurrent with Atorvastatin 5 mg + Ezetimibe 10 mg|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
1503665|NCT02942602|Behavioral|Lifestyle modification|The patients who meet the 2013 American College of Cardiology/American Heart Association criteria for receiving lipid-lowering therapy will be randomized into 5 groups.
1503666|NCT02942589|Other|Meal portion size|
1503672|NCT02942563|Drug|FOLFOXIRI|"Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
Chemoradiation for patients who are not suitable to surgery:
Pelvic radiotherapy(45Grey/25Fraction and 5.4Grey/3Fraction boost to the tumor bed) combined with capecitabine(625mg/M^2, bid po, d1-5, qw), and additional four cycles of modified FOLFOX6 (mFOLFOX6) chemotherapy before TME.
All patients will receive 4-8 cycles of mFOLFOX6 as adjuvant chemotherapy after TME."
1503673|NCT02942550|Drug|Methylnaltrexone bromide (Relistor®).|
1503674|NCT02942550|Drug|Sodium Chloride 9mg/mL|
1503675|NCT02942537|Device|Microwave treatment, Emprint|Percutaneous application of microwave antenna with microwave treatment of fibroma
1503676|NCT02942537|Procedure|uterine artery embolization|Percutaneous applicaiton of a catheter into the femoral artery and embolization of uterine artery or branches thereof
1503677|NCT02942524|Other|Communication Intervention|Complete TEPID
1503679|NCT02942524|Other|Survey Administration|Ancillary studies
1503680|NCT02942498|Drug|Vitamin C 10mg/Kg Vitamin E 10 mg/Kg|
1503681|NCT02942498|Drug|Placebo|Placebo
1503682|NCT02942485|Drug|Metronidazole|P/r suppositories
1503683|NCT02942485|Drug|Tinidazole|P/o tablets
1503684|NCT02942459|Other|Music therapy|25 Weekly Hours of Music Therapy by an Educated Music therapist
1503685|NCT02942459|Other|Music Listening|25 weekly Hours of Being Together with and unknown Care Staff Member
1503686|NCT02942446|Device|Investigative Headgear with CPAP mask|Investigative Headgear with CPAP mask
1503687|NCT02942433|Behavioral|Behavior Change Communication|9-month weekly episode behavior change radio drama with interactive voice response (IVR)/short message service (SMS) listener engagement
1503688|NCT02942433|Behavioral|Community Mobilization|Listening and discussions groups, 2 male and 2 female groups per study site meet weekly for 39 weeks and will receive training on gender equity, intimate partner violence (IPV), life skills, community mobilization, non-violent conflict resolution for listening and discussion group (LDG) facilitators to support knowledge and skill set acquisition of LDG members. There will be a joint couple's session every month to foster mutual learning and understanding in addition to community mobilization incentives led by LDGs and encouragement of family members of LGD members to listen to the radio and attend LDG sessions once every 3 months. Participants will also receive awareness raising and street theater to engage families and community members.
1503689|NCT02942433|Behavioral|Advocacy|Training and 6-month follow up of religious/community leaders and religious leaders support community mobilization activity of local listening and discussion group (LGD).
1503690|NCT02942420|Drug|Bucillamine|Thiol donor which results in a cysteine-bucillamine complex for removing excess cysteine from the urine
1503691|NCT02942407|Drug|apixaban|oral anticoagulant
1503692|NCT02942407|Drug|warfarin|oral anticoagulant
1503693|NCT02942394|Device|sinus-Obliquus Stent System|
1503694|NCT02942381|Drug|Hydroxychloroquine Sulfate|200mg Bid (eGFR>60 ml/min/1.73m2 ), 100mg Tid(eGFR45-59 ml/min/1.73m2 ), 100mg Bid(eGFR 30-44 ml/min/1.73m2 )
1503695|NCT02942381|Drug|Placebo|
1503696|NCT02942368|Device|tDCS|Transcranial direct current stimulation with placement of the anode over the F3 region of the scalp and the cathode over the right supraorbital region.
2002374|NCT02291250|Dietary Supplement|Blackcurrants with glucose OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.
The equivalent carbohydrate load will be standardised across the groups"
2002375|NCT02291250|Dietary Supplement|Sugar matched water with polycal OGTT|"Sixteen overweight/obese volunteers from the Aberdeen area will be recruited into a randomised controlled study. Volunteers will be randomised into four groups matched for BMI and age and given 200 grams of blackcurrants (which contain anthocyanins) or greencurrants (which naturally contain no anthocyanins), followed by an OGTT.
The consumption of the currants will be followed by an oral glucose tolerance test (OGTT) with Polycal (complex carbohydrate) or glucose (simple carbohydrate) as the carbohydrate load.
The equivalent carbohydrate load will be standardised across the groups"
1503699|NCT02942342|Procedure|Computed Tomography (CT) Scan|CT Scans will be used as a diagnostic tool for asymptomatic CAD.
1503700|NCT02942329|Drug|apatinib|Apatinib was administered 500mg orally daily.
1503701|NCT02942329|Drug|SHR-1210|SHR-1210 was administered 3mg/kg (no more than 200mg) iv every 2 weeks.
1503702|NCT02942316|Device|Pupil dilation reflex measurement|"Pupillometry (PDR) at four standardized times perioperatively
after induction, before opioid administration
after opioid administration, steady state
surgical incision
end of procedure"
1503703|NCT02942303|Drug|Dysport|
1503704|NCT02942303|Procedure|lateral orbicularis injection|
1503705|NCT02942303|Procedure|Lateral orbicularis + corrugator injection|
1503706|NCT02942290|Drug|Venetoclax|Tablet; oral; Administered on Days 1-14 of 28 day cycle
1503707|NCT02942290|Drug|Azacitidine|Powder for injection; taken subcutaneously or intravenous (IV); Administered on Days 1-7 of 28 days cycle or Days 1-5 of Week 1 & Days 1-2 of Week 2 of 28 day cycle.
2002376|NCT02290808|Behavioral|Theory-based group|Workbooks and mini-counselling sessions will be provided to participants in this group.
2002377|NCT02288507|Drug|Sorafenib|Sorafenib 400mg PO BID for Cohort 1, if 2 or more patients with dose-limiting toxicity toxicity (DLT), Chort -1 is sorafenib 200mg PO BID, if 2 or more patients with DLT, sorafenib 200mg PO daily
2002378|NCT02288507|Radiation|yttrium-90 radioembolization|Yttrium-90 SIR-Spheres microspheres are instilled through a catheter into a branch of the hepatic artery
2002379|NCT02287909|Drug|Clopidogrel|Swiching from ticagrelor to clopidogrel
2002380|NCT02287909|Drug|Ticagrelor|Continue treatment with ticagrelor
1503826|NCT02941523|Drug|Carboplatin|Carboplatin administration
1503873|NCT02941094|Device|needle PLT-805AT|comparing success rate and complications using different needle to US probe angles.
2002381|NCT02287233|Drug|Venetoclax|Venetoclax will be taken orally once daily on Days 1 through 28 of each cycle. This is a dose escalation study, therefore the dose of venetoclax will change.
2002382|NCT02287233|Drug|Cytarabine|Cytarabine will be administered subcutaneously on Days 1 to 10 of each 28-day cycle.
2002383|NCT02285998|Biological|Flublok Quadrivalent Influenza Vaccine|Intramuscular injection of vaccine
2002384|NCT02285998|Biological|Inactivated Influenza Vaccine|Intramuscular injection of vaccine
2002385|NCT02285985|Drug|Saxagliptin|Tablets: 5 mg
2002386|NCT02285985|Drug|Placebo|Tablets: 5mg
2002387|NCT02279056|Behavioral|Self-help book for insomnia|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
2002388|NCT02279056|Behavioral|Sleep hygiene advice|RCT comparing efficacy of a self-help book for insomnia and sleep hygiene advice in patients with co-morbid OSA and insomnia.
2002389|NCT02272985|Other|[15O]H2O PET-CT scan|All participants will undergo 3 [15O]H2O PET-CT scans during the hemodialysis study session
2002390|NCT02272985|Other|NIRS (Invos)|All participants will undergo near infrared spectroscopy (NIRS) during the hemodialysis study session.
2002391|NCT02266875|Drug|hypertonic saline|
2002392|NCT02266875|Drug|standard saline|
2002393|NCT02267083|Drug|GPX-150 for Injection|GPX-150 at a starting dose of 265 mg/m2 every 21 days for 16 cycles or until death, disease progression, or unacceptable toxicity. The dose of GPX-150 may be reduced by 25% if any dose reduction criteria are met. Two reductions are allowed per subject during the course of the study.
1503717|NCT02942251|Other|Clinical features and medication|This group will be suggested to take optimize treatment according to Chinese treatment guidelines.
1503718|NCT02942251|Other|Psycho-social|This group will be suggested to add on psychotherapy on medical treatment.
1503719|NCT02942251|Other|immunology|This group will be suggested to add on Omega-3 polyunsaturated fatty acid(PUFAs) on medical treatment.
1503720|NCT02942251|Other|Laboratory abnormality|This group will be suggested to more safety antidepressants.
1503721|NCT02942251|Other|Comorbidity|This group will be suggested to treat their comorbidities as well as treat MDD.
1503722|NCT02942251|Other|Treatment as usual|Patients will accept routine treatments based on psychiatrist experience, not based on the relapse predict model.
1503723|NCT02942238|Procedure|CME|"the group underwent laparoscopic right hemicolectomy with CME. In CME group, in addition to D2 dissection, the whole mesocolon, from ascending colon to right half transverse colon, as well as the central lymph nodes should be entirely removed.
Intervention: Procedure: Complete mesocolic excision (CME)"
1503724|NCT02942238|Procedure|D3|"the group underwent laparoscopic right hemicolectomy with D3 lymph node dissection. In D3 group, the mesocolon should be removed and the dissection involves the paracolon and intermediate lymph nodes,including No.6 lymph node, which along the feeding vessels.
Intervention: Procedure: D3 radical operation"
2002394|NCT02264990|Drug|Veliparib|Oral Capsule
2002395|NCT02264990|Drug|Carboplatin|Intravenous infusion
2002396|NCT02264990|Drug|Paclitaxel|Intravenous infusion
2002397|NCT02264990|Drug|Cisplatin|Intravenous infection
2002398|NCT02264990|Drug|Pemetrexed|Intravenous infusion
2002399|NCT02263508|Drug|talimogene laherparepvec|Phase 1b: talimogene laherparepvec will be administered by intralesional injection at Day 1, Week -5; then every 2 weeks starting at Day 1, Week -2; Phase 3, Arm 1 talimogene laherparepvec will be administered by intralesional injection at Day 1 Week 0, 3, 5, 7 then every 3 weeks starting at Day 1 Week 9.
2002400|NCT02263508|Drug|pembrolizumab (MK-3475)|Phase 1b: pembrolizumab will be administered intravenously every 2 weeks starting at Day 1 Week 0; Phase 3, Arm 1 and Arm 2 pembrolizumab will be administered intravenously on Day 1 Week 0, then every 3 weeks starting at Day 1 Week 3.
1503732|NCT02942199|Other|MySafeRx|The MySafeRx platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser (i.e., MedicaSafe 3000), and a standardized protocol for supervising self-administration of medication via videoconferencing.
1503733|NCT02942173|Biological|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
2002401|NCT02263508|Drug|placebo|Phase 3, Arm 2 placebo will be administered by intralesional injection at Day 1 Week 0, 3, 5, 7 then every 3 weeks starting at Day 1 Week 9.
1503735|NCT02942147|Device|TENS|Group 2 patients were administered TENS therapy 30 minutes a day for 15 days at the outpatient physiotherapy unit of the Physiotherapy and Rehabilitation Department. The TENS therapy was applied in the form of conventional TENS subtype with 80-100 Hz frequency by placing four electrodes on the region where the pain was most intense.
1503736|NCT02942147|Procedure|Conventional or Pulse Radiofrequency|In the radiofrequency method applied to Group 1 and Group 3 patients, the targeted facet joints were marked while the fluoroscope was in antero-posterior position. During this marking, the fluoroscope was directed towards cephal or caudal so that at whatever level the median ramus block was to be involved the endplate of that vertebra would become a straight line. The connection point of the superior articular protrusion was marked on the fluoroscope using the transverse process and the intervention was applied with a 22G, 10-cm radiofrequency cannula with 0.5 cm active tip in a way that bone contact was established through the tunneled vision technique. The intervention was completed after the radiofrequency procedure was applied at four levels.
1503874|NCT02941094|Device|Ultrasound|Xario, Toshiba Tokyo Japan
2002402|NCT02262806|Drug|Metreleptin|A leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy.
2002403|NCT02257853|Other|Stress Reduction|Gentle chair yoga and breath work
2002404|NCT02252367|Drug|Tadalafil|Tadalafil 5 mg once daily for 12 weeks.
2002405|NCT02252367|Other|Placebo|Placebo tablet once daily for 12 weeks.
2002406|NCT02248649|Behavioral|Structured exercise|Walking instruction and encouragement
2002407|NCT02248649|Behavioral|Health education|"Provision of general information about a variety of health topics
Provision of general information about a variety of health"
2002408|NCT02240407|Genetic|Recombinant Adeno-Associated Virus Acid Alpha-Glucosidase|The dose for vector injections will be 5 x 10^9 vg per TA mg diluted in 1.5 ml saline.
2002409|NCT02240407|Drug|Rapamycin|Patients will receive Rapamycin (dose 0.6-2 mg/m^2/day, adjusted to maintain a trough serum sirolimus level of 2-4 ng/mL.) every day starting from 7 days before first injection of AAV9 until one month after second injection.
2002410|NCT02240407|Other|saline|Same volume as rAAV9-DES-hGAA injection will be used.
2002411|NCT02240407|Drug|Rituxan|Patients will receive Rituxan (dose: 750 mg/m^2 twice) 21 and 7 day prior first AAV9 injection. Rituxan will be repeated 7 days prior to the 2nd injection of the vector. The maintenance dose of Rituxan will be 750 mg/m^2 once.
2002412|NCT02240407|Drug|Diphenhydramine|25-50mg will be provided before each Rituximab dose.
2002413|NCT02240407|Drug|Acetaminophen|We will provide 650 mg of tylenol before each dose of Rituximab.
2002414|NCT02240407|Drug|Lidocaine|Lidocaine will be used based on standard of care: Percutaneous infiltration, concentration 0.5-1%, 1-10 mL, 5-300mg total dose.
1503737|NCT02942121|Other|LifeScience Technologies application|Application for mobile devices. The app enables users to review educational videos about a surgery and recovery from a surgery from home. It also enables the user to track different metrics specific to the user's health.
1503738|NCT02942108|Procedure|piezo surgery|
1503739|NCT02942108|Procedure|conventional surgery|
1503742|NCT02942082|Other|ACP oral care gel|a desensitizing agent will be applied on tooth before and/or after bleaching
1503743|NCT02942082|Other|glycrin|glycrin will be applied on tooth surface before and/or after bleaching
1503744|NCT02942069|Behavioral|Blood glucose measured using CGM during standardized physical activity|Standardized exercise on bicycle at 70% of the participants work capacity for ½ hour.
1503745|NCT02942056|Drug|Cinnamon|Cinnamon tablets to treat type 2 DM
1503746|NCT02942056|Drug|placebo|placebo
1503747|NCT02942043|Drug|Bevacizumab|"Group A (low dose group) Intrapleural injection of bevacizumab 2.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
Group B (medium dose group) Intrapleural injection of bevacizumab 5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard.
Group C (high dose group) Intrapleural injection of bevacizumab 7.5mg/kg/times, d1, d8; 21 days for a course of treatment. Subjects will received two courses of treatment if there is no termination of treatment listed in the standard."
1503748|NCT02942030|Other|Computerized assesment battery|All participants will do a computerized assessment battery to identify specific attentional profile
2002415|NCT02234843|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily or twice daily, as tablets
2002416|NCT02234843|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Age and body weight-adjusted dosing equivalent to 20 mg rivaroxaban in adults, once daily, twice daily or three times daily, as oral suspension
2002417|NCT02234843|Drug|Standard of Care|"LMWH (low molecular weight heparin) or fondaparinux or vitamin K antagonist (VKA) therapy.
dose : as per standard of care"
2002418|NCT02233868|Device|MRI|Functional Connectivity Magnetic Resonance Imaging (fcMRI) of connectivity in brain
1503753|NCT02941991|Biological|hESC-RPE|sub-retinal injection
1503754|NCT02941978|Behavioral|Motivational interview|
1503755|NCT02941978|Behavioral|Control|Patients assigned to the control group will be contacted via telephone for a pre-specified interview at 1 year after discharge
1503756|NCT02941965|Procedure|ICSI without PGS|Selection of embryos are based on morphology criteria on the 5th day of ICSI.
1503757|NCT02941965|Procedure|ICSI with PGS|PGS will be applied to selected embryos on the 5th day of ICSI.
1503758|NCT02941952|Device|Cardiac output and stroke ejection volume monitoring with both ClearSight® and PICCO® in major abdominal surgery.|
1503759|NCT02941939|Other|Hyperbaric chamber|
1503760|NCT02941939|Other|Ambient pressure|
2002419|NCT02233868|Drug|C-11PBR28|PET brain imaging of neuroinflammation using the radiotracer [11C]PBR28
2002420|NCT02233868|Drug|F-18FDG|PET brain imaging of neurofunction using the radiotracer F-18FDG
2002421|NCT02228174|Device|Intrauterine Ultrasound-Guided Radiofrequency Ablation System|The Sonata System combines intrauterine ultrasound (IUUS) with radiofrequency (RF) ablation in a single handpiece. Sonata is suitable in an inpatient or outpatient setting, and is intended to provide focal treatment of symptomatic fibroids responsible for heavy menstrual bleeding (HMB).
1503764|NCT02941913|Drug|palonosetron|receive a fix dose of 75 μg of palonosetron (group I - GI) and another forty patients will receive a bodyweight-adjusted dose of 1mcg/kg of palonosetron (group II - GII).
2002422|NCT02224846|Drug|Tadalafil|Administered orally
1503768|NCT02941887|Behavioral|Behavior Analysis|One examiner observed global behavior of patients during a dental care session, guided by a behavioral scale.
1503770|NCT02941861|Other|Recurrence Rate of HCC after surgery|Recurrence Rate of HCC after surgery
1503771|NCT02941861|Other|Recurrence Rate of CCA after surgery|Recurrence Rate of CCA after surgery
1503772|NCT02941848|Drug|HGP0816|
1503773|NCT02941848|Drug|HGP1404|
1503774|NCT02941848|Drug|HCP1306|
1503776|NCT02941822|Drug|Ambroxol|Details outlines in the intervention description.
1503777|NCT02941809|Behavioral|Placebo Dose Extension|"We are designating this as a behavioral intervention for two reasons: (1) the placebo pill is physiologically inert and is not classified under FDA regulations; and (2) other studies have demonstrated that the efficacy of the placebo pill is strongly dependent on the participants' anticipation of an effect. We are presenting the pill's efficacy in an open and transparent way to the participants, but using a positive frame. We are also using conservative qualifiers in our explanation, with terms such as if the PDE works, and asserting that we cannot guarantee that the PDE pill will work for addiction. We feel that this qualifies the placebo pill use as a behavioral intervention, in the same general category as exercise or relaxation. PDE pill formulation: magnesium stearate, D&C Red 7 Ca lake, and microcrystalline cellulose PH-102."
1503778|NCT02941796|Drug|HCP1105|
1503779|NCT02941796|Drug|HCP0918|
1503780|NCT02941796|Drug|HCP0816|
1503870|NCT02941133|Other|Standard Care|Ultrasound - Transcutaneous electrical nerve stimulation (TENS) - Massage therapy - Strengthening exercises
1503784|NCT02941757|Behavioral|Mediterranean diet Intervention|"Educational materials (online learning) will be provided via the study website; group educational sessions and written materials (brochure with Mediterranean Diet recommendations, shopping list recommendations and sample recipes, specific Mediterranean Diet Pyramid; videos; educational sessions; in-person chef-led, Mediterranean cooking demonstrations.
Peer-education and support
Discounted food access: The investigators have partnered with Kroger supermarkets, a large national chain with numerous stores in the Indianapolis area, to provide discounted access to key Mediterranean foods for both participating firefighters and their families.
Email or text message encouragement and reminders during the intervention."
1503785|NCT02941744|Drug|nivolumab|low fixed dose ipilimumab in combination with nivolumab
1503786|NCT02941744|Drug|ipilimumab|low fixed dose ipilimumab in combination with nivolumab
1503787|NCT02941731|Drug|HIP1403|Oseltamivir 6mg/mL
1503788|NCT02941731|Drug|HGP0919|Oseltamivir phosphate 6mg/mL
1503789|NCT02941718|Behavioral|Sleep Advancement Counseling|Participants will receive cognitive behavioral counseling on achieving adequate sleep duration.
1503790|NCT02941718|Behavioral|General Health Information|Participants will receive educational information on general health topics including diet, physical activity, skin protection, oral health and cancer screenings.
1503791|NCT02941705|Biological|Allogeneic Derived Cells|patients will have the CAP-1002 solution delivered through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
1503792|NCT02941705|Biological|Placebo/Control Arm|patients will receive the placebo through a coronary catheter inserted in the right and left coronary arteries using standard techniques in the cardiac catheterization laboratory. A right heart catheter will be used to obtain baseline (pre-infusion) hemodynamics.
1503793|NCT02941692|Drug|Oxytocin|
1503794|NCT02941692|Drug|Placebo|Placebo for Oxytocin
1503795|NCT02941679|Drug|HCP1202|Hanmi Pharmaceutical. Co., Ltd.
1503796|NCT02941679|Drug|HGP1011|Boehringer Ingelheim
1503797|NCT02941679|Drug|HCP0910|GlaxoSmithKline
1503798|NCT02941653|Device|Potassium nitrate 2% gel|"Teeth will be cleaned using rubber cups associated to pumice and water;
Relative isolation with roller cotton will be done;
Prior to each bleaching session, the patients will receive the potassium nitrate 2% desensitivity gel application on vestibular surface, for 10 minutes.
Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil)
A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
1503799|NCT02941653|Device|Potassium oxalate 5% gel|"Teeth will be cleaned using rubber cups associated to pumice and water
Relative isolation with roller cotton will be done;
Prior to each bleaching session, the patients will receive the potassium OXALATE 5%
Gingival dam will be performed using a fluid resin (Top Dam, FGM, Brazil) desensitivity gel application on vestibular surface, for 10 minutes.
A 35% hydrogen peroxide based bleaching agent will be mixed and applied on the vestibular surface of teeth, remaining for 40 minutes."
1503800|NCT02941640|Procedure|E group|The securing the base of appendix by endoloop.
1503801|NCT02941640|Procedure|S group|The securing the base of appendix by Stapler.
1503802|NCT02941640|Procedure|H group|The securing the base of appendix by Hem-o-lok clip.
1503803|NCT02941640|Procedure|DS group|The securing the base of appendix by DS clip.
1503804|NCT02941640|Device|Endoloop|
1503805|NCT02941640|Device|Stapler|
1503806|NCT02941640|Device|Hem-o-lok clip|
1503807|NCT02941640|Device|DS clip|
1503808|NCT02941627|Device|Neuro Cochlear Implant System|
1503810|NCT02941601|Drug|Necitumumab|Administered IV
1503811|NCT02941601|Drug|Gemcitabine|Administered IV
1503812|NCT02941601|Drug|Carboplatin|Administered IV
1503813|NCT02941588|Procedure|Non-cardiac surgery|Any surgery with general anesthesia except cardiac surgery
1503814|NCT02941575|Other|Crystal Ultra|Crystal Ultra: is a resin nano-ceramic material, that combines both advantages of ceramics and composites.
1503815|NCT02941575|Other|All ceramic|IPS Emax: is an all ceramic crown that has proven superior aesthetics and strength properties.
1503816|NCT02941562|Radiation|Short-course radiotherapy|Preoperative Radiation doses: 25 Gy in 5 fractions to the pelvis
1503817|NCT02941562|Drug|FOLFOX4 chemotherapy,preoperative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.
Repeat every 2 weeks"
1503818|NCT02941562|Radiation|Radiotherapy of neo-adjuvant therapy|Preoperative Radiation doses: 45 Gy in 25 fractions to the pelvis, 5.4 Gy in 3 fractions to the pelvis
1503819|NCT02941562|Drug|Concurrent chemotherapy of neo-adjuvant therapy|Capecitabine 825mg/m2 twice daily 5 days/week
1503820|NCT02941562|Procedure|Radical rectal cancer resection|Radical rectal cancer resection
1503821|NCT02941562|Drug|FOLFOX4 chemotherapy,post-operative|"FOLFOX4 chemotherapy：5-FU 400 mg/m2 i.v. bolus and Leucovorin 200 mg/m2 i.v. followed by 5-FU 600 mg/m2 i.v. 22 h-infusion day 1 + 2, oxaliplatin 85 mg/m2 day 1.
Repeat every 2 weeks"
1503822|NCT02941549|Other|Placebo capsules|
1503823|NCT02941549|Drug|DS102|
1503824|NCT02941536|Diagnostic Test|Circulating tumor cells evaluation|Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.
1503825|NCT02941523|Drug|NOX66|NOX66 administration
2002429|NCT02220985|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
1503827|NCT02941510|Drug|Budesonide|Budesonide is FDA approved for the treatment of asthma and Chronic Obstructive Pulmonary Disease (COPD). It works by reducing lung inflammation to increase oxygen uptake by the body. The researchers are examining if this medication can prevent altitude sickness.
1503828|NCT02941510|Other|Placebo|Subject(s) will participate in all study activities but will receive placebo.
1503829|NCT02941497|Behavioral|Social marketing and health promotion campaign|Students in the intensive intervention group developed a nine-month social marketing health campaign. The campaign included five costumed characters who interacted with students on campus in residence halls, dining halls, and other highly-trafficked public areas on campus. Photos and videos of interactions were put on social media. Student participants from the general population (the diffuse intervention group) were asked to set weekly healthy goals related to diet, physical activity, and stress management throughout the campaign and received email and text messages with goal-specific written and video health-promotion messages. Faculty partnered with the students throughout the intervention process to educate and give advice on the content of health promotion messages.
1503830|NCT02941484|Procedure|early oral intake|early oral intake is started within 24 hours after pancreaticoduodenectomies following to the ERAS guideline
1503831|NCT02941484|Procedure|jejunostomy tube feeding (JTF)|The jejunostomy tube was placed using the Flocare CH-10 tube with the longitudinal Witzel jejunostomy technique.nutrition is supplemented via JTF rather than early oral intake.Velocity is progressively increased by 20ml/hr until full nutritional goal (25Kcal/Kg)
2002430|NCT02220985|Drug|Cyclophosphamide|Given IV
2002431|NCT02220985|Drug|Fludarabine Phosphate|Given IV
1503834|NCT02941445|Drug|sitagliptin and metformin|
1503835|NCT02941445|Drug|Metformin|
1503836|NCT02941432|Other|Black tea compress treatment|Wet compresses with black tea applied 4-5 times daily to the face for 6 days
1503837|NCT02941419|Biological|Platelet lysate|Autologous intramuscular platelet lysate injection for patients with peripheral arterial disease
1503838|NCT02941393|Device|Intrauterine pressure catheter|
1503839|NCT02941393|Device|External tocodynamometry|
1503840|NCT02941367|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1503841|NCT02941367|Drug|Sulfonylurea|"Pharmaceutical form: tablet
Route of administration: oral"
1503842|NCT02941367|Drug|metformin|"Pharmaceutical form: tablet
Route of administration: oral"
1503843|NCT02941367|Drug|basal insulin|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1503844|NCT02941354|Drug|turoctocog alfa|Each subject will receive a single dose of turoctocog alfa as an intravenous (i.v.) bolus injection of 50 IU/kg.
1503845|NCT02941341|Drug|r-hFSH|As per standard practice
1503848|NCT02941315|Drug|etiologic treatment,anti-myocardial remodeling|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), participants were treated with drugs including etiologic treatment,anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
1503849|NCT02941315|Drug|anti-myocardial remodeling|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant without companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling according to guidelines for treatment of cardiomyopathy.
1503850|NCT02941315|Drug|anti-myocardial remodeling,anti-acute heart failure|When the etiology was not diagnosed clearly by cardiac magnetic resonance(CMR), in participant companioned with acute heart failure, participants were treated with drugs including anti-myocardial remodeling and anti- acute failure according to guidelines.
1503851|NCT02941315|Drug|Etiological, anti-remodeling and symptom treatment|When the etiology was diagnosed clearly by cardiac magnetic resonance(CMR), in participants were companioned with acute heart failure, the participant should be treated with drugs including etiologic treatment,anti-myocardial remodeling and anti-acute heart failure according to guidelines for treatment of cardiomyopathy.
1503852|NCT02941302|Procedure|Detecting of Biological Borders of Gliomas|Neural navigation combined with Intraoperative ultrasound detecting the borders of gliomas, In accordance with established plan to collect multiple targets undergo pathological examination and contrast with imaging boundary to determine the biological boundaries.
1503853|NCT02941289|Procedure|visual search performance of everyday objects in realistic scenes|
1503854|NCT02941276|Device|Active Electrostimulator device|Patients who will receive a fully functioning device
1503855|NCT02941276|Device|Sham Electrostimulator device|Patients who will receive a device that does not release electric stimuli (but provided mechanical/tactile stimulation)
1503856|NCT02941250|Device|ISSD emulator|induced tachy-arrhythmia to be terminated by ISSD emulator
1503857|NCT02941237|Device|Pulse oximeter|"Time taken to measure oxygen saturation.
Completion of usability questionnaire"
1503858|NCT02941224|Device|SELUTION DCB (sirolimus coated balloon)|
1503859|NCT02941211|Device|Aqueduct -100|
1503860|NCT02941198|Device|GyneFix|The fiber is fixed to the anchoring thread by means of a stainless steel clip 1 cm from the upper part of the anchoring knot. The anchoring knot is implanted into the myometrium of the uterus thus permanently securing the implant in the uterine cavity
1503861|NCT02941198|Device|Cu T380 A|An IUD is inserted into the uterus
1503862|NCT02941185|Drug|Devit-3 Oral Drop|
1503866|NCT02941159|Biological|SF2000SD|This is an intergrase inhibitor
1503867|NCT02941159|Biological|Placebo|
1503868|NCT02941146|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
1503869|NCT02941133|Other|Neural Mobilization|Neural mobilization techniques aimed at the lumbar root that is affected
2002432|NCT02220985|Other|Laboratory Biomarker Analysis|Correlative studies
1503875|NCT02941081|Dietary Supplement|IHAT|1 dose/day single IMP containing IHAT powder bioequivalent to 12.5 mg Fe (i.e. 20 mg Fe taking into account IHAT's relative bioavailability to FeSO4)
1503876|NCT02941081|Dietary Supplement|Ferrous Sulphate|1 dose/day single IMP containing FeSO4 powder equivalent to 12.5 mg Fe
1503877|NCT02941081|Other|Placebo|1 dose/day containing a placebo powder (no-iron, 'sugar' compound)
1503878|NCT02941068|Drug|fluconazole and caspofungin|
1503879|NCT02941055|Other|Fiber diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
1503880|NCT02941055|Other|Protein diet|Foods will be delivered with a home delivery chain once a week for 10 wks of each diet
2002433|NCT02220985|Drug|Methotrexate|Given IV
2002434|NCT02220985|Drug|Mycophenolate Mofetil|Given IV and PO
1503883|NCT02941029|Other|Plasma Blood collection|Plasma blood collection is collected at specific intervals prior to and during radiation treatment.
1503884|NCT02941016|Drug|Evolocumab or Alirocumab|All patients are treated with PCSK-9 inhibitors (Evolocumab or Alirocumab) to lower cholesterol
1503885|NCT02941003|Device|microscope|Detection of of histopathological characteristics of OCT treatment or OCT free samples from patients .
1503886|NCT02941003|Other|immunostaining|Detection of CD31/CD34, D2-40, Ki67 and p53 immunostaining of OCT treatment or OCT free samples from patients .
1503887|NCT02941003|Device|NGS|The investigators used the device to detect the gene mutations of OCT treatment or OCT free samples obtained from part of the patients.
1503888|NCT02940990|Radiation|SBRT concurrent with GM-CSF|SBRT and GM-CSF 125ug/m2 for 14 days
1503889|NCT02940990|Drug|two-drug chemotherapy containing platinum, including carboplatin/Cisplatin + pemetrexed/docetaxel/paclitaxel/etoposide/gemcitabine/vinorelbine/albumin-bound paclitaxel|two-drug regimen
1503890|NCT02940977|Other|Blood draws|Blood draws, from peripheral veins, each time 2 tubes, each 5 ml.
1503891|NCT02940964|Behavioral|Count on me Singapore (COMS) CPR|Using the song as a mental metronome to guide CPR.
1503892|NCT02940964|Behavioral|Standard CPR|"Standard CPR with one-and-two-and-three.... counting"
1503893|NCT02940951|Other|QPSS|Home care providers use an electronic tablet-based system (QPSS) that includes standardized instruments for assessing patient and family caregiver quality of life and satisfaction with care in routine care. In addition to instant calculation of scores, the QPSS allows for tracking scores over time and sharing them with other registered users from that home care service.
1503894|NCT02940951|Other|Usual care|Home healthcare services provided by nurses and, where applicable, multi-professional teams.
1503895|NCT02940938|Other|Applying pulse oximeter sensor|During general anesthesia, pulse oximeter sensor is applied with gradually increased contact force, from 0 to 1.5N (increase by about 0.2N), at an index finger and POP waveform is obtained for 60 seconds.
1503896|NCT02940925|Other|Drug: Taxol,cisplatin and capecitabine|Taxol, cisplatin and capecitabine as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
1503897|NCT02940925|Other|Drug: Cisplatin and 5-Fluorouracil|Cisplatin and 5-Fluorouracil as induction chemotherapy combined with cisplatin concurrent chemoradiotherapy with intensity modulated radiation therapy.
1503898|NCT02940912|Drug|Apomorphine|
1503899|NCT02940912|Drug|Placebo|
1503900|NCT02940899|Other|Intervention: Syracuse University Fir Families Program (SUFFP)|The SUFFP (Syracuse University Fit Families Program) is a randomized clinical trial, were 40 children with autism spectrum disorders ages 5-11 and at least one parent were randomly assigned to one of two group-based conditions; interventions or a control wait list group.
1503901|NCT02940886|Drug|Iron isomaltoside|
1503902|NCT02940886|Drug|Iron sucrose|
1503903|NCT02940873|Behavioral|HARPdoc courses|A six week group education package including hypoglycaemia-focussed cognitive behavioural therapy
1503904|NCT02940873|Behavioral|BGAT courses|A structured psycho-education programme focussing on better prediction and recognition of high and low blood glucose values
1503905|NCT02940860|Drug|Iron isomaltoside|
1503906|NCT02940860|Drug|Iron Sucrose|
1503907|NCT02940847|Procedure|medial brachial cutaneous nerve block and intercostobrachial nerve block with blind technique|It consists in performing a subcutaneous injection of the local anesthetic at the root of the arm, in the anterior-posterior direction.
1503908|NCT02940847|Procedure|medial brachial cutaneous nerve block and intercostobrachial nerve block with ultrasound-guided technique|Ultrasounds are used to visualize the anatomical variations, the good position of the needle and the good local anesthetic diffusion.
1503909|NCT02940821|Other|Toothbrushing|Mechanical plaque removal
1503910|NCT02940821|Other|Fluoridated Dentifrice (.15% sodium monofluorophosphate)|Fluoridated dentifrice application
1503911|NCT02940821|Other|Fluoridated Dentifrice Whitening System (.454% stannous fluoride with 2% hydrogen peroxide)|Application of Tooth Whitening Agent in Dentifrice
1503912|NCT02940821|Other|Whitening (4.5% hydrogen peroxide)|Application of Whitening Agent
1503913|NCT02940821|Other|Other Fluoridated Dentifrice (.454% stannous fluoride)|Fluoridated dentifrice application
1503914|NCT02940808|Dietary Supplement|Caffeine (200mg)|Oral consumption of capsule containing 200mg caffeine.
1503915|NCT02940808|Other|Placebo|Oral consumption of capsule containing a placebo substance.
1503916|NCT02940795|Other|Coke|Patients were given a 20 ounce bottle of Coke Cola.
1503917|NCT02940795|Other|Diet Rite|Patients were given a 12 ounce can of Diet Rite.
1503918|NCT02940782|Procedure|Reciproc single file system|A reciprocating Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
1503919|NCT02940782|Procedure|One Shape single file system|A rotary Nickel Titanium single file system used for instrumentation of root canals in endodontic treatment.
1503920|NCT02940782|Device|X-smart Plus, Dentsply Maillefer, Ballaigues, Switzerland|It is a micro-motor designed for performing root canal treatments with the reciprocating, single file technique or traditional continuous rotation file system.
2002435|NCT02220985|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with GCSF-mobilized CD34-enriched PBSC
2002436|NCT02220985|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSCT with CD45RA-depleted cells
1503956|NCT02940522|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
2002437|NCT02220985|Drug|Tacrolimus|Given IV or PO
2002438|NCT02220985|Drug|Thiotepa|Given IV
2002439|NCT02220985|Radiation|Total-Body Irradiation|Undergo TBI
1503926|NCT02940743|Behavioral|Education (Edu)|This intervention will take place during weeks 1-4 at the dialysis center. Each week, study staff will present participants with a brief educational video on: phosphorus binder adherence (week 1), meeting dietary protein needs (week 2), restricting dietary sources of phosphorus (week 3), and eliminating phosphorus-based food additives (week 4). These videos will be loaded onto tablet (Personal Computers) PCs so that participants can easily view them during regular dialysis treatment.
1503927|NCT02940743|Behavioral|SM intervention|During the first 12 weeks of the intervention, a study dietitian will review the participants' records, and provide individualized feedback via a password-protected NYULMC email address. Feedback will be provided twice per week during weeks 1-4, once per week during weeks 5-8, and once every two weeks during weeks 9-12. The email messages will focus on both the importance of self-monitoring and the behavioral targets of the intervention. Feedback will use standardized language rather than specific dietary examples to avoid providing individualized counseling to participants (which is not the purpose of the SM intervention).
1503928|NCT02940743|Behavioral|Social Cognitive Therapy (SCT)|This intervention will be delivered remotely online using the same tablet PCs provided for the SM intervention component of this treatment condition. The behavioral training program will focus on building a sense of self-efficacy with emphasis on mastery experiences that will include emphasizing past successes; setting incremental, easily achievable goals; self-monitoring to stay on track; identifying modifiable barriers to healthy behavior; positive feedback in goal achievement; and developing participant expertise in both the regimen and in problem solving around barriers to adherence.
1503929|NCT02940730|Drug|Dalbavancin via Intravenous Administration|Patients will undergo plasma fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
1503930|NCT02940730|Drug|Dalbavancin via Intraperitoneal Administration|Patients will undergo peritoneal fluid pharmacokinetic sampling for determination of dalbavancin concentrations at time zero, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours, at time of volume exchange.
1503931|NCT02940717|Other|Vita suprinity|New glass ceramic material
1503932|NCT02940717|Other|Emax CAD|standard etchable glass ceramic used for laminate venneers
1503933|NCT02940704|Procedure|Reciproc|"Canals will be instrumented using Reciproc reciprocating system set on an electric motor, with adjusted torque and speed according to the manufacturer's instructions.
There is no need for coronal preflaring with a Gates Glidden drill or an orifice opener since the design of the Reciproc instrument allows any obstructions in the coronal third to be removed, as claimed by the manufacturer.
Reciproc file selection: R40 (40/0.06) is to be used."
1503934|NCT02940704|Procedure|One Shape|"Coronal preflaring will be performed using Gates Glidden drill.
Canals will be instrumented using One Shape single-file (25/0.06) set on an electric motor with adjusted torque and speed according to the manufacturer's instructions.
For wide canals, One Shape Apical (30/0.06, 37/0.06) will be used."
1503935|NCT02940691|Drug|Grazoprevir/elbasvir|Grazoprevir/elbasvir (100mg/50mg) once daily for 12 weeks.
1503936|NCT02940678|Other|No intervention|
1503937|NCT02940665|Other|ERAS|Patients in the ERAS group received the ERAS protocol
1503938|NCT02940652|Radiation|Magnetic resonance imaging|No intervention - description of the position of the LMA obtained during routine elective MRI scanning of the brain and/or cervical spine
1503939|NCT02940639|Other|Non Interventional|
2002440|NCT02216617|Drug|Taxotere, Cisplatin, Afatinib|
2002441|NCT02211534|Device|Pulsed Electromagnetic Field Device (Provant)|The PEMF device delivers non-thermal, non-ionizing pulsed electromagnetic energy to the target tissue, using 27.12 megahertz pulses lasting 42 microseconds and delivered 1000 times per second. The system generates an electromagnetic field that is continuously monitored and regulated to ensure consistent dosing. The therapeutic electromagnetic field is delivered by means of an applicator pad that is placed against the treatment site. The active and sham devices will be identical in appearance and all other physical characteristics in order to maintain the masking of the treatment.
1503942|NCT02940613|Behavioral|Visual feedback of symptom frequency|Participants receive visual feedback of their symptom frequency over the first 4 weeks of active treatment, based on information they provide on a symptom checklist.
1503943|NCT02940600|Device|Normothermic machine perfusion|Patients undergoing liver transplant with the use of grafts preserved with normothermic perfusion machine
1503944|NCT02940600|Procedure|Static cold storage|Patients undergoing liver transplant using statically cold preserved grafts
1503945|NCT02940587|Device|Aurix|Aurix is a platelet-rich plasma gel used in the treatment of non-healing wounds. It will be administered twice weekly for 2 weeks then weekly.
1503946|NCT02940574|Drug|Syntocinon (Oxytocin)|Syntocinon nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
1503947|NCT02940574|Other|Placebo (Physiological water (solution of sodium chloride (NaCl) in water))|Placebo nasal spray. A single dose (24IU) of nasal spray (3 puffs of 4IU per nostril), followed by 4 weeks of a daily single dose (24IU; 3 puffs of 4IU per nostril) of nasal spray
1503948|NCT02940561|Drug|Methotrexate - Amneal|"Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate, USP and are round, biconvex, yellow tablets, scored in half on one side, engraved with A above the score and 1 below"
1503949|NCT02940561|Drug|Methotrexate - DAVA|Methotrexate Tablets, USP contain an amount of methotrexate sodium equivalent to 2.5 mg of methotrexate and are round, convex, yellow tablets, scored in half on one side, engraved with M above the score, and 1 below
1503950|NCT02940548|Drug|Nifedipine GITS|Nifedipine GITS 30~60mg/day for 8 weeks
1503951|NCT02940548|Drug|Amlodipine besylate|Amlodipine besylate 5~10mg/day for 8 weeks
1503952|NCT02940535|Drug|Diphereline (Triptorelin embonate)|
1503953|NCT02940535|Drug|Decapeptyl (Triptorelin)|
1503954|NCT02940535|Drug|human menopausal gonadotropin|
1503955|NCT02940535|Drug|human chorionic gonadotropin|
2002442|NCT02211534|Device|Sham Pulsed Electromagnetic Field Device|The Sham device will be identical in appearance, physical characteristics and operation to the Active device.
1503957|NCT02940522|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
1503958|NCT02940509|Drug|Ketamine plus Magnesium sulfate|"Patients will receive 2 IV infusions:
Ketamine (0.5mg/kg)
Magnesium sulfate (2g)"
1503959|NCT02940509|Drug|Placebo|Patients will receive 2 IV infusions, both of NaCl 0.9%, as placebos for Ketamine and magnesium sulfate
1503960|NCT02940496|Drug|Pembrolizumab|200 mg by vein every 3 weeks.
1503961|NCT02940483|Drug|5-Azacytidine|5-Azacytidine 10 mg into the fourth ventricle of the brain via the Ommaya reservoir 1 day a week for 12 weeks.
1503962|NCT02940470|Other|Calorie restricted diet plus exercise|Daily meals plus exercise providing 1000 kcal restriction per day for 12 weeks.
1503963|NCT02940470|Other|Weight management classes|Weekly 1-hour weight management classes for 12 weeks.
1503964|NCT02940457|Device|Verum tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 2 mA
1503965|NCT02940457|Device|Sham tDCS|Neuropsychological (working memory) training for 30 minutes, 6 sessions tDCS during training with 0 mA
1503966|NCT02940444|Drug|Heparin|
1503967|NCT02940431|Other|High Autonomy|Children will be given two active video games (AVGs) of their choice. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will be allowed to select their next game.
1503968|NCT02940431|Other|Low Autonomy|Children will be given their most-liked active video game (AVG) from the baseline relative reinforcing value assessment. After two weeks, a researcher will monitor progress and exchange the AVGs and sedentary games. At each exchange, children will receive a pre-determined game.
1503969|NCT02940418|Biological|Adipose mesenchymal cells with bone marrow mononuclear cells|Allogenic adipose-derived mesenchymal cells with autologous bone marrow mononuclear cells will be injected.
1503970|NCT02940405|Drug|Ketorolac Tromethamine|A 10 mg tablet of the medication will be given one hour before starting the root canal treatment
1503971|NCT02940405|Drug|Placebo|The placebo given as a tablet one hour before staring the root canal treatment
1503972|NCT02940392|Device|Rezum System|"The Rezūm System is designed to treat patients with bothersome urinary symptoms associated with benign prostatic hyperplasia (BPH). The Rezūm System utilizes radiofrequency current to generate wet thermal energy in the form of water vapor, which is then injected into the transition zone and/or median lobe of the prostate tissue in controlled 9-second doses. The vapor that is injected into the prostate tissue rapidly disperses through the interstitial space between the tissue cells. As the vapor cools, it condenses immediately on contact with tissue and the stored thermal energy is released, denaturing the cell membranes and causing cell death.
The denatured cells are absorbed by the body, which reduces the volume of prostate tissue adjacent to the urethra. The vapor condensation process also causes a rapid collapse of vasculature in the treatment zone, resulting in a bloodless procedure."
1503973|NCT02940379|Drug|sotagliflozin (SAR439954)|"Pharmaceutical form: tablet
Route of administration: oral"
1503974|NCT02940379|Drug|midazolam|"Pharmaceutical form: HCl syrup
Route of administration: oral"
1503975|NCT02940379|Drug|metoprolol|"Pharmaceutical form: tablet
Route of administration: oral"
1503976|NCT02940366|Drug|Pitavastatin 4 mg orally daily|Pitavastatin 4 mg orally daily for 24months
1503977|NCT02940366|Drug|Atorvastatin 20 mg orally daily|Atorvastatin 20 mg orally daily for 24months
1503978|NCT02940353|Device|TREFOIL concept|
1503979|NCT02940314|Drug|HIP1503|
1503980|NCT02940314|Drug|HGP1103|
1503981|NCT02940301|Drug|Ibrutinib|Given PO
1503982|NCT02940301|Other|Laboratory Biomarker Analysis|Correlative studies
1503983|NCT02940301|Biological|Nivolumab|Given IV
2002443|NCT02211755|Drug|Bortezomib plus Clofarabine|The proteasome inhibitor bortezomib and purine nucleoside metabolic inhibitor clofarabine demonstrated greater than additive activity in combination in preclinical xenograft models
2002444|NCT02207556|Drug|Doxycycline|"Doxycycline will be continued until one of the following criteria is met:
Patient has completed 1 year of doxycycline therapy
Patient develops any grade 3-4 toxicity related to doxycycline use."
1503986|NCT02940262|Device|Computed Tomography|Undergo PET/CT
1503987|NCT02940262|Radiation|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC|Given IV
1503988|NCT02940262|Other|Laboratory Biomarker Analysis|Correlative studies
1503989|NCT02940262|Device|Positron Emission Tomography|Undergo PET/CT
1503990|NCT02940249|Dietary Supplement|Apple polyphenols|Drinks will be delivered in random order at 4 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
1503991|NCT02940249|Dietary Supplement|Placebo|
1503992|NCT02940236|Other|Ultrasound|Before and after patient receives oral multimodal analgesia as per standard of care, two ultrasound scans will be performed (10 minutes apart for each time element).
1503993|NCT02940223|Drug|Regorafenib|Regorafenib started at a daily dose of 120 mg by mouth on Days 1-21 for the first cycle. Subsequent cycles dosed at a total daily dose of 160 mg on Days 1-21 unless dose modifications are made for toxicities.
1503994|NCT02940223|Dietary Supplement|Fish Oil|Participants take a fish oil supplement by mouth twice a day for 8 weeks.
1503995|NCT02940223|Other|Resistance Training|Participants perform resistance training 3 days/week for 8 weeks. Exercises include (but will not be limited to) squats, lunges, leg extensions, leg curls, and hip extensions.
1503996|NCT02940223|Other|Walking Program|Participants perform a walking program at home for 8 weeks. Participants will work toward the goal of 150 minutes of moderate intensity walking per week.
1503997|NCT02940223|Other|Placebo|Participants take placebo by mouth twice a day for 8 weeks.
1503998|NCT02940223|Behavioral|Symptom Questionnaire|Symptom questionnaire completed at Baseline and on Days 8, 21, 36, 50, and 57.
1503999|NCT02940223|Behavioral|Quality of Life Questionnaires|Quality of life questionnaires completed at Baseline and on Days 15, 29, 43, 57, and at end of study visit.
1504000|NCT02940223|Other|Walk Test|Walk Test performed at Baseline and on Days 29, 57, and at end of study visit. Participants are asked to walk as fast and as far as they can for six minutes, and the distance walked is measured.
1504049|NCT02939950|Device|PureVision contact lenses|contact lenses
1504373|NCT02937519|Drug|cisplatin chrono-chemotherapy|
1504001|NCT02940223|Other|Chair/Stand Test|On the start signal, participant rises to a full stand and then returns to a fully seated position. Participant completes as many full stands as possible within a 30 second period.
1504002|NCT02940223|Other|Stretching Exercises|Participants perform a control exercise program consisting of stretching exercises only. Participants in the control exercise intervention meet with exercise physiologist in the first week of the intervention in order to learn the stretches and receive written instructions on how they should be done.
1504003|NCT02940210|Device|Mediclore® (adhesion barrier)|
1504004|NCT02940197|Behavioral|MediterrAsian diet|no other description
1504005|NCT02940184|Drug|Tablet Sitagliptin 100mg (evening before and morning of experiments)|On one of two experiment days participants will have Dipeptidyl peptidase 4 activity inhibited using a DPP-4 inhibitor (Sitagliptin).
1504006|NCT02940184|Other|Intestinal Fructose administration|On both experimental days fructose (35g dissolved in water, total volume 100mL) will be administered via an intrajejunal tube
1504007|NCT02940171|Procedure|Early Excision of full thickness burn|first excision surgery of full -thickness burn performed within 48 hours from burn injury
1504008|NCT02940171|Procedure|Late Excision of full thickness burn|first excision surgery of full -thickness burn performed after 48 hours from burn injury
1504009|NCT02940158|Other|1/4 cup- Small red lentil|
1504010|NCT02940158|Other|1/4 cup- Small green lentil|
1504011|NCT02940158|Other|1/4 cup- corn|
1504012|NCT02940158|Other|1/4 cup- macaroni|
1504013|NCT02940158|Other|1/4 cup- white potato|
1504014|NCT02940158|Other|1/4 cup- white rice|
1504015|NCT02940158|Other|1/2 cup- small red lentil|
1504016|NCT02940158|Other|1/2 cup- small green lentil|
1504017|NCT02940158|Other|1/2 cup- corn|
1504018|NCT02940158|Other|1/2 cup- macaroni|
1504019|NCT02940158|Other|1/2 cup- white potato|
1504020|NCT02940158|Other|1/2 cup- white rice|
1504021|NCT02940145|Other|Resistance Training|The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
1504022|NCT02940132|Drug|SC10914|SC10914 will be administered orally.
1504023|NCT02940119|Device|Multi Radiance Medical®|Volunteers received all procedures of the study with active or placebo phototherapy (PBMT) in 9 sites of the neck and shoulders, twice a week. The PBMT was applied in all sessions.
2002445|NCT02203773|Drug|ABT-199|ABT-199 is taken orally once daily starting on Day 2 of cycle 1 and begin on day 1 of every other cycle thereafter. This is a dose escalation study, therefore the dose of ABT-199 will change.
1504026|NCT02940093|Other|Stem cell transplantation|Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
1504028|NCT02940067|Other|MedEx|A combination of dietary and exercise interventions over four weeks before scheduled pancreatic surgery
1504029|NCT02940054|Other|Red-flags questionnaire|A questionnaire composed by 8 items will be administered by GPs to those patients and they will be referred to a gastroenterologist with expertise in CD. All those patients will be evaluated, as per usual practice, to confirm or exclude Crohn's disease.
1504030|NCT02940041|Procedure|Pre-surgical diagnosis of uterine malignant tumors|All patientes who fit inclusion criteria will undergo a gynecologic sonography, pelvic MRI, determination of LDH, as in regular practice. No additional interventions will be done to any patient.
1504031|NCT02940028|Behavioral|Expressive writing|Brief expressive writing intervention
1504032|NCT02940028|Behavioral|Control writing|Brief fact-based writing exercise.
1504033|NCT02940002|Drug|BAY1003803|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
1504034|NCT02940002|Drug|Clobetasol propionate|Simultaneous application of 10μl on psoriasis plaque and on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
1504035|NCT02940002|Drug|Betamethasone/calcipotriene|Simultaneous application of 10μl on healthy skin for 4 weeks and evaluation of pharmacodynamic effect
1504039|NCT02939976|Device|Single Vessel Disease|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
1504040|NCT02939976|Procedure|Multi-vessel Disease, Culprit Vessel Only|Revascularization with Medtronic Resolute family of stents in infarct related artery; Possible use of Terumo Glidesheath Slender and Terumo TR Band Radial Compression Device
1504041|NCT02939976|Procedure|Multi-vessel Disease, Complete Revascularization|Complete revascularization of all diseased arteries
1504042|NCT02939976|Device|Medtronic Resolute family of stents|Revascularization with Medtronic Resolute family of stents in infarct related artery
1504043|NCT02939976|Device|Volcano based pressure wires Verrata, Verrata Plus and any subsequent marketed Volcano pressure wire technology|Complete revascularization of all diseased arteries
1504044|NCT02939976|Device|Terumo Glidesheath Slender|Possible use of Terumo Glidesheath Slender
1504045|NCT02939976|Device|Terumo TR Band Radial Compression Device|Possible use of Terumo TR Band Radial Compression Device
1504046|NCT02939963|Procedure|ATC then pressure support 7 cm H2O PEP 4 cm H2O|spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O during 30 minutes then 30 minutes of basal pressure support then 30 minutes with pressure support 7 cm H2O PEP 4 cm H2O
1504047|NCT02939963|Procedure|Pressure support 7 cm H2O PEP 4 cm H2O then ATC|30 minutes with pressure support 7 cm H2O PEP 4 cm H2O then 30 minutes of basal pressure support then 30 minutes with spontaneous breathing through endotracheal tube with no ventilator support except for ATC, the patient is connected to the ventilator with pressure support 0 cm H2O and PEP 4 cm H2O
1504048|NCT02939950|Device|samfilcon A soft contact lenses|soft contact lenses
1504050|NCT02939937|Drug|Phenytoin|100 mg phenytoin three time daily for three months, and phenytoin levels will be taken at one and three months later.
1504051|NCT02939937|Drug|placebo|100 mg placebo three time daily for three months, and phenytoin levels will be taken at one and three months later.
1504052|NCT02939924|Device|Kanshas DCB|The appropriate Kanshas DCB size is selected after review of the patient's baseline angiogram and determination of the reference vessel diameter and lesion length. The balloons is sized to ensure the full length of the lesion is treated. The initial inflation of the study device should be approximately 1 minute for optimal drug release. In order to optimize lesion dilatation, longer inflation times are possible at the discretion of the operator.
1504053|NCT02939911|Device|Residual neuromuscular blockade measurement|Just prior extubation in OR and at the arrival to PACU the residual neuromuscular blockade will be measured by accelerometry
1504054|NCT02939898|Drug|Placebo|Adjuvant therapy to recFSH during ovarian stimulation
1504055|NCT02939898|Drug|Letrozole|Adjuvant therapy to recFSH during ovarian stimulation
1504056|NCT02939872|Drug|aspirin and clopidogrel|at the discretion of investigator
1504057|NCT02939872|Drug|Clopidogrel only|at the discretion of investigator
1504058|NCT02939859|Procedure|Microcannula Harvest Adipose|Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells
1504059|NCT02939859|Device|Centricyte 1000|Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF
1504060|NCT02939859|Procedure|Sterile Normal Saline IV deployment AD-cSVF|Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
1504061|NCT02939846|Drug|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
1504062|NCT02939833|Procedure|Scalp Nerve Blocks With Ropivacaine|
1504063|NCT02939833|Procedure|Scalp Nerve Blocks With Saline|
1504064|NCT02939820|Drug|patisiran (ALN-TTR02)|patisiran (ALN-TTR02) administered by intravenous (IV) infusion
1504065|NCT02939807|Drug|ABC294640|"ABC294640 500 mg orally twice daily (approximately 12 hours apart) continuously.
ABC294640 will be dosed under fasting conditions (at least 1 hour before or 2 hours after eating). A cycle is defined as 28 days."
1504066|NCT02939794|Drug|Ferinject|1000 mg of a ferric carboxymaltose (Ferinject type) intravenously approximately 24 hours prior to surgery
1504067|NCT02939794|Drug|Placebo|Saline (normal saline, sodium chloride)
1504068|NCT02939781|Device|Indirect calorimetry|Indirect calorimetry measurement at baseline (stable state), at onset of fever and continued till fever dehiscence
1504069|NCT02939768|Other|High-intensity interval training (HIIT)|The HIIT sessions will be performed on cycle ergometers and will be consisted of 10 x 60-s cycling intervals interspersed with 60 s recovery. Individual workloads will be selected to elicit ~90% maximal heart rate attained in the cardiorespiratory fitness test (HRmax). A passive or active recovery will be given among high-intensity stimulus. Each training session will include 3-min warm-up and 2-min cool-down phase performed ~50% (HRmax), totalling 25 min. This intervention will last 10 weeks.
1504070|NCT02939768|Other|Strength training (ST)|ST protocol will consist of three sets performed at maximum weight that participants could move eight times with good technique in the following exercises: supine bench press (pectoralis major), leg press (quadriceps, biceps femoris, gluteus maximus), lat pulldown (latissimus dorsi), leg extension (quadriceps), shoulder press (deltoids), leg curl (biceps femoris) and abdominal crunch (abdominal muscles). It will be given 1-min rest between series, totalizing approximately 35 min of ST. This intervention will last 10 weeks.
1504071|NCT02939768|Other|ST combined with HIIT (ST+HIIT)|Participants in the ST+HIIT group will execute ST and HIIT (in this order) above described in the same training session, lasting approximately 60 min. This intervention will last 10 weeks.
1504072|NCT02939755|Behavioral|Stepped collaborative care intervention|Using website that was specifically designed for advanced cancer patient, collaborative with treatment from health professional
1504073|NCT02939755|Behavioral|Enhanced Usual Care|usual care from health providers
1504074|NCT02939742|Drug|Betamethasone|Betamethasone 12mg IM given every 24 hours for two doses
1504075|NCT02939742|Drug|Placebo|Sterile 0.9% normal saline solution given IM every 24 hours for two doses
1504076|NCT02939729|Other|Walking Programme|Walking programme measured by daily step count on pedometer provided to participant. Participants will be advised to increase daily step count from their baseline measure - realistic incremental rise according to individual ability and symptoms. Daily step count will be recorded in a participant study diary.
1504077|NCT02939729|Device|Incentive Spirometer|An incentive spirometer is a device used to measure lung tidal volumes. Participants will be asked to use the incentive spirometer to measure their tidal volume daily. Participants will record daily tidal volume measurement in the participant diary. A physiotherapist will teach participants how to use the incentive spirometer and provide an instruction sheet.
1504078|NCT02939729|Other|Deep Breathing Exercises|Participants will be taught deep breathing exercises - these are the same deep breathing exercises shown to all patients after cardiac surgery as part of chest physiotherapy treatment. Participants will be asked to carry out deep breathing exercises at home during the prehabilitation phase. An instruction sheet for the deep breathing exercises will be provided to participants.
1504079|NCT02939716|Other|Rhubarb|300gm rhubarb
1504080|NCT02939716|Other|Bread|2 slices bread
1504081|NCT02939716|Other|Lettuce|300g lettuce
1504082|NCT02939703|Other|Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance spectroscopy (MRS)|A DEXA scan for measurement of body fat and muscle content will be completed. The MRS will assess body fat distribution, liver fat, and organ size analysis.
1504083|NCT02939703|Other|23-hour Metabolic Calorimetry|The 23 hour Metabolic Calorimetry stay is in a specialized room that measures the amount of oxygen the subject uses and the amount of carbon dioxide they produce. Urine and fecal collection will take place during time spent in the Metabolic Chambers.
1504084|NCT02939703|Other|Whole Room Calorimetry|Continuous 23 hours a day in a specialized room that measures the amount of oxygen used, and the amount of carbon dioxide produced. A radiotransmitter pill (small silicone coated capsule) will be taken upon entering the whole room calorimeter. The pill will record core temperature, pressure, and PH level for the duration of the stay in the whole room calorimeter.
1504085|NCT02939703|Other|Polyethylene glycol (PEG)|to measure fecal energy and calculate diet energy extraction and digestion.
1504086|NCT02939690|Device|UVC|UVC insertion depth calculated by [(3× birth weight (Kg) + 9)/2+1)]
1504087|NCT02939690|Device|UVC|UVC insertion depth calculated by umbilicus to nipple distance-1
1504088|NCT02939690|Device|Ultrasound|
1504089|NCT02939677|Other|Targeted exercise|"12 weeks of targeted and supervised exercise intervention vs. care as usual (home based exercises)"
1504090|NCT02939664|Device|Banded (with polypropylene mesh) gastric bypass|The patient will be submitted to a Laparoscopic Roux-en-Y banded gastric bypass at the time of the operation, with a polypropylene mesh around the gastric pouch.
1504091|NCT02939664|Procedure|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
1504092|NCT02939651|Drug|Pembrolizumab|Pembrolizumab given intravenously at a fixed dose of 200mg every 3 weeks
2002446|NCT02203773|Drug|Decitabine|Decitabine will be administered by IV infusion over 1 hour beginning on Day 1 thru Day 5 of each Cycle for a minimum of 4 Cycles
2002447|NCT02203773|Drug|Azacitidine|Azacitidine will be administered by IV infusion over 10 to 40 minutes or subcutaneously based on the institutional guidelines, beginning on Day 1 through Day 7 of each Cycle, for a minimum of 4 Cycles.
2002448|NCT02203773|Drug|Posaconazole|Posaconazole will be administered twice a day on Cycle 1 Day 21 and once daily from Cycle 1 Day 22 to Cycle 1 Day 28.
1504098|NCT02939612|Behavioral|App for stress management|An app consisting of 10 modules that teaches stress management, cognitive behavioral coping skills and relaxation training.
1504099|NCT02939599|Drug|QCC374|0.015mg and 0.06mg
1504100|NCT02939586|Procedure|Haemodiafiltration post-dilution model|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HDF (2months) and switch to HD for 2 months, with 1 month washout period (using standard HD)
1504101|NCT02939586|Procedure|Haemodialysis|Participants will be randomly assigned into either HD or HDF group. The participants will received the assigned treatment for 2 months and cross-over to the other dialysis model- eg. HD (2months) and switch to HDF for 2 months, with 1 month washout period (using standard HD)
1504105|NCT02939560|Device|NeuroStar® TMS device (Neuronetics, Atlanta, GA)|Participants in this study arm will be evaluated before and after receiving rTMS. Outcome measures will include social skills rating scales, depression rating scales and cognitive tasks while undergoing functional magnetic resonance imaging (fMRI).
1504106|NCT02939547|Drug|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick Disease C1 ( NPC1)
1504107|NCT02939521|Procedure|Surgery|
1504108|NCT02939508|Other|Colon originated: Neostigmin, Colonoscopy decompression, Surgery|
1504109|NCT02939508|Other|Non-colon originated: Neostigmin, Colonoscopy decompression|
1504110|NCT02939495|Drug|Dapoxetine/Sildenafil 30/50 mg film coated tablet|1 tablet before sexual intercourse
1504111|NCT02939482|Drug|Triamcinolone Acetonide and normal saline solution|80 mg/2 ml Triamcinolone Acetonide and 18 ml normal saline solution
1504112|NCT02939469|Other|Physiologic maneuvers|"Subjects will perform
Valsalva maneuver Hand Grip Post exercise cuff occlusion Loud Noise and Skin pinch"
1504113|NCT02939456|Other|Magnetic Resonance Imaging|Double Inversion Recovery Magnetic Resonance Imaging (DIR-MRI) and Dynamic Contrast Enhanced Magnetic Imaging (DCE-MRI)
1504114|NCT02939443|Radiation|supine- and prone-position Computed Tomography|
1504115|NCT02939430|Drug|Sugammadex intravenous|Intravenous Injection of sugammadex (2 mg/kg) for reversal of rocuronium induced muscle relaxation
1504116|NCT02939430|Drug|Intravenous neostigmine and atropine|
1504117|NCT02939417|Other|Grape seed extract|Grape seed extract - collagen cross-linking agent
1504118|NCT02939391|Drug|KW-6356|Oral administration
1504119|NCT02939391|Drug|KW-6356|Oral administration
1504120|NCT02939391|Drug|Placebo|Oral administration
1504121|NCT02939378|Dietary Supplement|Ketogenic diet|Ketogenic diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
1504122|NCT02939378|Dietary Supplement|Standard diet|Standard diet adjuvant to salvage chemotherapy is given to recurrent glioblastomas.
1504123|NCT02939365|Drug|Belatacept|The transition to belatacept monotherapy and possibly to q 8 weeks administration can be safely done by applying personalized (i.e. precision) medicine. This includes phenotypic analysis of lymphocyte subsets, a quiescent molecular profiling of blood and urine prior to drug withdrawal and immune monitoring with KSORT after stepwise withdrawal of steroids and antiproliferatives. Furthermore, trough PK of belatacept will be measured for conversion to q 8 week therapy for discovering research purposes.
1504124|NCT02939352|Device|Real continuous Theta Burst Stimulation|Continuous Theta Burst stimulation delivered
1504125|NCT02939352|Device|Sham continuous Theta Burst Stimulation|active sham Continuous Theta Burst stimulation delivered
1504126|NCT02939339|Device|continuous theta burst stimulation (real)|a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
1504127|NCT02939339|Device|continuous theta burst stimulation (sham)|a sham version of a form of transcranial magnetic stimulation that noninvasively induces a depression in brain reactivity
1504128|NCT02939326|Drug|EB-001 injection|
1504129|NCT02939326|Drug|Placebo injection|
1504130|NCT02939313|Device|medial prefrontal cortex|a form of theta burst stimulation that noninvasively induces a depression in brain reactivity
1504131|NCT02939313|Device|dorsolateral prefrontal cortex|a form of transcranial magnetic stimulation that noninvasively induces an increase in brain reactivity
1504132|NCT02939313|Device|sham|sham stimulation
1504133|NCT02939300|Drug|Nivolumab|
1504134|NCT02939300|Drug|Ipilimumab|
1504135|NCT02939287|Drug|Aprepitant|Add aprepitant to anti-emetic regimen
1504136|NCT02939287|Drug|Olanzapine|add olanzapine to anti-emetic regimen
1504137|NCT02939274|Drug|Verteporfin|
1504138|NCT02939274|Device|Continuous Low-Irradiance Photodynamic Therapy (CLIPT)|
1504139|NCT02939261|Behavioral|Intervention - 4 Home Visits|4 home visits from a health educator, weekly e-mails, and monthly mailed behavioural supports.
1504140|NCT02939261|Behavioral|Control|monthly emails with general health information
1504141|NCT02939248|Drug|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
1504142|NCT02939248|Drug|Crushed ticagrelor, morphine,naloxone|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg intravenously and naloxone 1 mg orally
1504143|NCT02939235|Drug|Crushed ticagrelor followed by morphine|Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously
1504144|NCT02939235|Drug|Crushed ticagrelor, morphine,metoclopramide|Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously
1504145|NCT02939222|Device|Implant placement|Routine implant placement in the ideal three dimensional implant position
1504146|NCT02939209|Drug|Hydromorphone Hcl 2Mg Tab|Patients will be given 2 mg hydromorphone (immediate release formulation) in the post anesthetic care unit.
1504147|NCT02939209|Drug|Placebo|Patients may be randomized to placebo.
1504148|NCT02939196|Procedure|office hysteroscopy 3.7|office hysteroscopy with a 3.7 -mm outer sheath
1504149|NCT02939196|Procedure|office hysteroscopy 4|office hysteroscopy with a4-mm outer sheath
1995840|NCT02641080|Drug|Aspirin|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, this could lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
1504154|NCT02939170|Device|Delefilcon A Multifocal Contact Lenses with Molded Mark|
1504155|NCT02939170|Device|Delefilcon A Multifocal Contact Lenses|
1504156|NCT02939157|Other|Cardiac diagnostic ultrasound|Point-of-care ultrasound for diagnosing heart failure in primary care patients
1504157|NCT02939144|Dietary Supplement|Liquorice|Liquorice ingestion will mimic the inherited condition of 'Apparent mineralocorticoid excess (AME)by showing the effects of the reduced activity of 11ßHSD-2 (which leads to an accumulation of cortisol which binds MR and hence has the effect of aldosterone).
1504158|NCT02939131|Behavioral|Health and Wellness Combined Cognitive Behavioral Therapy and a Medication Management Algorithm|Behavioral therapy based on a manualized approach developed specifically for youth living with both HIV and depression, using problem-solving, motivational interviewing and cognitive-behavioral strategies to decrease adherence obstacles and increase wellness. The medication management algorithm includes guidance for clinicians on strategies and tactics to treat depression in this population, including factors to consider when deciding on treatments (i.e., drug-drug interactions, side effects).
1504159|NCT02939131|Behavioral|Enhanced Standard of Care|Ongoing psychopharmacological and psychosocial counseling and treatment for depression at HIV clinical treatment centers enhanced by providing clinicians with up-to-date information and didactic training on current principles for use of medication and psychotherapy in the treatment of depression.
1504160|NCT02939105|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
1504161|NCT02939092|Drug|Pomegranates peel extract|Pomegranate is antimicrobial
1504162|NCT02939092|Drug|Chlorhexidine|Chlorhexidine mouthwash is antiplaque agent
1504163|NCT02939079|Drug|Fingolimod|Produced by Osveh ® Pharm Company in Iran
1504164|NCT02939079|Dietary Supplement|Fish Oil|produced by Zahravi ® Pharm Company in Iran
1504165|NCT02939079|Drug|Placebo (for Fish Oil)|placebo capsules to mimic Fish Oil 1 g capsules
1504166|NCT02939040|Behavioral|Positive Activities|"The PPB intervention involves noting at least one positive event each day, writing it down on a slip of paper and then depositing this piece of paper in a piggy bank. This practice is to take place at the end of the day, every day over a circumscribed period of time. At the end of the deposit period the participant closes the account and makes a full withdrawal by taking all of the slips out of the piggy bank and reading each one the night before surgery."
1504167|NCT02939027|Device|Electronic Brachytherapy (6,1 Gy)|A total dose of 36.6 Gy is planned over 6 fractions of 6.1 Gy, given 2 days/week, during 3 weeks or lees, at least 2 days apart each fraction.
1504168|NCT02939027|Device|Electronic Brachytherapy (7 Gy)|A total a dose of 42 Gy is planned over 6 fractions of 7 Gy, given 2 days/week during 3 weeks or lees, at least 2 days apart each fraction.
1504169|NCT02939014|Drug|Brentuximab Vedotin|Brentuximab vedotin IV infusion.
1504170|NCT02939001|Device|iris recognition scanner|
1504171|NCT02938988|Procedure|Antimicrobial photodynamic therapy|Described in arm/group
1504172|NCT02938988|Procedure|Scaling and root planning|Described in arm/group
1504173|NCT02938988|Device|red laser|658nm; 0.1W; 2229J/cm², 10s per point
1504174|NCT02938988|Drug|methylene blue dye|
1504175|NCT02938975|Other|Ultra 30 Insect Repellent Lotion (30% Lipo DEET)|"One application of Lipo DEET protects for up to 12 hours and has a pleasant odour and non-greasy feel on the skin. DEET is a broad spectrum insect repellent and was selected this study because it has been extensively tested for safety and toxicity for human use and its efficacy against a broad variety of arthropod vectors. DEET was first registered in 1957 and has been conclusively proven to be safe for use on adults, children, pregnant and lactating mothers.
This Liposome-based repellent is the newest advancement in insect repellent technology. The Liposome envelops the active ingredient, DEET, and slowly time-releases it as needed, thereby extending the effectiveness of the repellent and reducing dermal absorption."
1504176|NCT02938975|Other|Permethrin Factory-Treated Army Combat Uniforms|Permethrin is the U.S., Australian and United Kingdom (UK) military's standard repellent for application to fabric and is considered the most effective clothing treatment available to prevent insect bites through fabric. The Army objective is to provide 90% bite protection for at least 50 launderings; an objective easily met through factory treatment of uniforms, which demonstrates 99-100% bite protection up to 50 launderings (the expected lifetime of the uniform).
1504177|NCT02938975|Other|Placebo lotion|A liposome lotion with no DEET
1504178|NCT02938975|Other|Army combat uniform|Army combat uniform with no permethrin
1504179|NCT02938962|Drug|Tranexamic Acid|
1504180|NCT02938949|Drug|alirocumab|
1504181|NCT02938949|Drug|placebo|
1504213|NCT02938624|Drug|Pembrolizumab 200 mg IV single dose|Pembrolizumab 200 mg IV single dose, 21 days later surgery
1504214|NCT02938624|Drug|Pembrolizumab 200 mg IV twice interval 21 days|Pembrolizumab 200 mg IV twice interval 21 days, 21 days later surgery
1504215|NCT02938624|Drug|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d|Pembrolizumab 200 mg IV Twice interval 21d,surgery after 10d
1504182|NCT02938936|Other|Pre-natal visit scheduling|This intervention will include a scheduled date and time for prenatal care follow-up visits. Women in the intervention group seeking care for their first ANC appointment will be offered several appointment slots on their return date by the nurse providing their first ANC visit. Women will be able select among the time options and will be provided an appointment card with their scheduled date and time. Staff will limit the number of scheduled women per hour by maintaining an appointment book. Clinic staff will be trained to differentiate between women returning for a scheduled visit from first prenatal visits, emergencies, and unscheduled return visits. First visits and emergencies will be seen during the first 2 hours after clinic opening and unscheduled women will be seen during a one-hour time slot midday. When women return on their date, they will be seen within one hour of their appointment time by clinic staff.
2002449|NCT02202499|Drug|Varenicline|All participants will take the following dose of varenicline: 0.5 mg once a day on days 1-3, 0.5 mg twice a day on days 4-7, and 1 mg twice a day through week 16 of the study. Arm descriptions show specific details for each group.
2002450|NCT02202499|Other|Counseling and Support Materials|Counseling and support materials (including a review and self-monitoring workbook tentatively titled, Winding Down: A Guide to Quitting Smoking using Varenicline) instructing participants to systematically utilize the FE techniques provided.
1504186|NCT02938910|Other|non interventional study|Non invasive imaging study without interventional procedures
1504187|NCT02938897|Behavioral|Registered Dietitian Nutritionist (RDN) Support|RDN provided individualized medical nutrition therapy via videoconference at weeks 1, 5, and 9 and telephonic nutrition coaching support at weeks 2-4, 6-8, and 10-12.
1504188|NCT02938897|Behavioral|Diet-related educational materials|Individualized caloric recommendations (500-750 kcal reduction) were made and food-based educational materials emphasizing general healthful eating patterns and increased intakes of nutrient-rich foods were provided.
1504189|NCT02938897|Behavioral|Self-monitoring tools|Self-monitoring tools including: weekly weight log, fruit and vegetable tracker, and a SMART (specific, measurable, achievable, relevant, and time bound) goal planner were provided.
1504191|NCT02938871|Dietary Supplement|Synbiotic|The patients of this group will receive 6 grams of synbiotic composition, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
1504192|NCT02938871|Dietary Supplement|Control|The patients of this group will receive 6 grams of maltodextrin, to be administered via feeding tube or orally, twice time a day, for 15 consecutive days.
1504193|NCT02938845|Behavioral|Spielberger's State-Trait Anxiety Inventory(STAI )|State anxiety (STAI-S) refers to a temporary emotional state related to a specific situation, whereas trait anxiety (STAI-T) represents anxiety as a relatively stable personality character. Each scale has values ranging from 20 to 80, with higher scores representing more severe anxiety. The STAI has no established categories, but a cutoff score of 40 has been used to identify patients with high/very high anxiety. The validity and reliability of the Turkish versions of these instruments have been validated.
1504194|NCT02938845|Procedure|total laparoscopic hysterectomy(TLH)|
1504195|NCT02938845|Procedure|total abdominal hysterectomy(TAH)|
1504196|NCT02938832|Behavioral|Advice on what food to choose and eat|Dietary advice
1504197|NCT02938819|Other|Goal-oriented upper-limb intervention|The Goal-oriented upper-limb intervention evaluated patients' expectations and the environmental factors influencing the performance of the specific task were identified for each of the three tasks. Patients were asked to perform the activity at home. After this, the observable target behavior corresponding to the target activity was determined. Then, an occupational and a physical therapist worked together with the patient to identify the assistance required to perform this activity such as human assistance, technical aids, assistive devices or verbal guidance.
1504198|NCT02938819|Other|Standard upper limb intervention|The standard upper limb intervention involved active upper limb range of motion, manual dexterity involving grasp and manipulation of small pieces such as marbles and stretching upper limb exercises.
1504199|NCT02938806|Other|No intervention|No intervention
1504200|NCT02938793|Drug|Durvalumab|intravenous administration
1504201|NCT02938793|Drug|Tremelimumab|intravenous administration
1504202|NCT02938780|Other|placebo text message|The subjects in the control group will receive placebo text messages which will be timed as the intervention group that are unrelated to the study or topics of exercise and nutrition.
1504203|NCT02938780|Other|nutrition physical activity text message|The subjects in the intervention group will receive text messages with nutrition and physical activity-related information throughout the study period on a daily basis, varying text message arrival over a 10 am to 7 pm time frame. The American Cancer Society recommends a set of exercise and nutrition behaviors for cancer survivors based upon developed expert evidence. These behaviors have been structured to achieve healthier lifestyles, improve quality of life and reduced mortality. The intervention will provide via text messaging exemplars and social norms designed to improve compliance with this advice.
1504204|NCT02938754|Behavioral|VR-based motor training|Subjects will perform 3 different training protocols in Virtual Reality that imply performing tasks of vertical and planar reaching and hitting spheres, or hockey pucks, spaced at different time, speed and color.
1504205|NCT02938754|Behavioral|Conventional Therapy|Subjects will perform conventional rehabilitation tasks for the upper-extremities that imply vertical and planar reaching movements.
1504206|NCT02938741|Drug|Anti－human Thymoglobulin|r-ATG 2.5MG/KG*4days were used in the conditioning
1504207|NCT02938741|Drug|Placebo|r-ATG 2.5MG/KG*4days were not used in the conditioning
1504208|NCT02938728|Other|Biopsies|
1504209|NCT02938715|Other|teledermatology feedback|subject provided feedback to continue or discontinue their cream (based on actinic keratoses grading and lesion counting)
1504210|NCT02938689|Other|Exercise|
1504211|NCT02938663|Behavioral|Questionnaires and Measurements|Participants completed anthropometric measurements and questionnaires assessing psychosocial stress, habitual dietary intake and physical activity as well as cultural identity, identity-based motivation and socioeconomic status. At home, participants recorded their habitual physical activity and food intake. Participants then returned to the laboratory to complete an assessment of identity-based motivation and received personalized information regarding their habitual physical activity and dietary patterns.
1504216|NCT02938624|Drug|Pembrolizumab 100 mg I.V single dose|Pembrolizumab 100 mg I.V single dose, surgery after 21 days.
1504217|NCT02938624|Procedure|Surgical resection of tumor|Surgical resection of tumor by any of the acceptable procedures
1504218|NCT02938598|Behavioral|Maternal Depression Education and Care-Seeking Motivation|Multicomponent behavioral and educational intervention. The investigators are only testing 3 components: Engagement, Problem-Solving, and Follow-Up Motivation
1504219|NCT02938585|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
1504220|NCT02938585|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
1504221|NCT02938572|Drug|NNC0143-0406|Administered subcutaneously (s.c. under the skin)
1504222|NCT02938572|Drug|Insulin Aspart|Administered subcutaneously (s.c. under the skin)
1504223|NCT02938559|Behavioral|Cognitive Therapy (CT) for depression|There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
1504224|NCT02938559|Behavioral|Cognitive Therapy (CT) for depression + Memory Support|The Memory Support Intervention will be delivered interwoven with CT. The Memory Support Intervention is designed to improve patient memory for treatment and involves a series of specific procedures that support the encoding and retrieval stages of episodic memory. It is comprised of eight memory promoting strategies: attention recruitment, categorization, evaluation, application, repetition, practice remembering, cued-based reminder and praise recall. These strategies are proactively, strategically and intensively integrated into treatment-as-usual to support encoding. Memory support is delivered alongside each 'treatment point', defined as a main idea, principle, or experience that the treatment provider wants the patient to remember or implement as part of the treatment.
1504225|NCT02938546|Radiation|18F-FDG|18FDG-PET scan was performed 4 weeks before the first administration of therapy or before the third cycle chemotherapy or before the 7th week of targeted therapy and after 3 days chemotherapy and targeted therapy. The lesions were analyzed by nuclear medicine physician and calculate the metabolism response. The size of percent changes was evaluated using the EORTC (European Organization for Research and Treatment of Cancer) PET criteria by oncologist who determine whether the scheme works and the scheme should continue or change. The seleted patients were double blinded to analyse the relationship between metabolism response and chemotherapy response.
2002451|NCT02202499|Other|Laboratory Assessments|The first laboratory assessment will consist of completion of questionnaires and a cue-reactivity test. The second laboratory assessment will be scheduled for the end of the week before the participant's quit date. It will involve completion of questionnaires and another cue reactivity test. A follow-up session conducted by research staff will occur one month after the target quit date to collect information about each participant's current smoking status, smoking rate, varenicline use, and opinion about the treatment. A second follow-up session will be conducted by telephone and will occur three months after the target quit date, at the end of varenicline use. At the end of the study, participants will be asked to complete a brief survey asking basic information, similar to the questions during the screening period.
2002452|NCT02200614|Drug|BAY1841788 (ODM-201)|BAY1841788 (ODM-201) tablets 2 x 300mg bid
2002453|NCT02200614|Drug|Placebo|Matching placebo tablets x 2 bid
1504233|NCT02938507|Drug|Formulation 1 solabegron|
1504234|NCT02938507|Drug|Formulation 2 solabegron|
1504235|NCT02938494|Drug|IDP-123 Lotion|Lotion
1504236|NCT02938494|Drug|Tazorac Cream|Cream
1504237|NCT02938494|Drug|Vehicle Lotion|Lotion
1504238|NCT02938494|Drug|Vehicle Cream|Cream
1504239|NCT02938468|Drug|Dexamethasone|
1504240|NCT02938468|Procedure|Any surgical intervention aim at treating chronic subdural hematoma|
1504241|NCT02938442|Biological|P10s-PADRE with MONTANIDE™ ISA 51 VG|Vaccination with standard chemotherapy
1504242|NCT02938442|Drug|Standard Chemotherapy|Standard chemotherapy only
1504243|NCT02938429|Other|Physical activity measures via Actigraph GT3X+ accelerometers for 7 consecutive days|
2002457|NCT02193425|Drug|F-18FDG|Participants will be tested with FDG-PET once to map glucose metabolism
2002458|NCT02193425|Device|MRI|To assess the short term test-retest reliability of the FC measures
2002463|NCT02186509|Radiation|Hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
2002464|NCT02186509|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
2002465|NCT02186509|Drug|Alisertib|Given PO
2002466|NCT02186509|Procedure|Quality-of-life assessment|Ancillary studies
2002467|NCT02186171|Drug|AMG 785|Subcutaneous injections of AMG 785 montly for 12 months.
2002468|NCT02186171|Drug|Placebo|Subcutaneous injections of placebo monthly for 12 months.
1504244|NCT02938416|Device|Isokinetic strengthening exercise|Isokinetic strengthening exercise provides muscle training throughout the range of motion of a joint at a pre-set constant speed of angular velocity. It can be performed in an eccentric or concentric way in a controlled manner, and is evidenced to be an effective and safe training method in patients with anterior cruciate ligament reconstruction, burn injury, ankle instability, osteoarthritic knee, and chronic stroke in the past literatures.
1504245|NCT02938416|Device|Isotonic strengthening exercise|Isotonic strengthening exercise keeps the tension remained unchanged during the muscle's length changing. As the muscle's force changes via the length-tension relationship during a contraction, an isotonic contraction will keep force constant while velocity changes. There are two types of isotonic contractions: (1) concentric and (2) eccentric. In a concentric contraction, the muscle tension rises to meet the resistance, then remains the same as the muscle shortens. In eccentric, the muscle lengthens due to the resistance being greater than the force the muscle is producing.
1504246|NCT02938403|Behavioral|In vivo counseling|Participants in the intervention group will receive 4 in session nicotine replacement therapy and counseling focused on their experience of using NRT, including positive experiences, side effects and smoking cessation expectancies. They will also received nicotine replacement therapy (nicotine lozenge and patch) to use for smoking cessation.
1504247|NCT02938403|Behavioral|Standard Smoking Cessation Counseling|Participants will receive 4 sessions of standard behavioral counseling to address their smoking. In addition, participants will received nicotine replacement therapy (Nicotine lozenge and patch) to use for smoking cessation.
1504248|NCT02938390|Procedure|Ultrasound for localizing intercostal perforating vessels|Use of an Intra-operative ultrasound during nipple sparing mastectomy to localize intercostal perforating vessels.
1504252|NCT02938364|Other|Earplugs|Plastic earplugs on both ears
1504253|NCT02938364|Other|Acupressure|Sea Bands put on the wrists of the participant to apply pressure on P6 points
1504254|NCT02938364|Other|Placebo|Non pressure bands put on the wrists of the participant
1995841|NCT02641080|Device|Portable Compression Device|If there is evidence that aspirin alone is equivocal to using both the pumps and aspirin, there could be lower health care cost and burden for patients undergoing total joint arthroplasty while establishing that the rate of DVT/PE does not increase with the absence of the compression device.
1504256|NCT02938338|Procedure|Bariatric surgery|Bariatric surgery, with an anticipated mean weight loss of 30 kg
1504257|NCT02938312|Behavioral|Weight Loss Only|Participants will attend in-person weekly sessions (about 1.5 hours each) for 6 months and then twice a month for 3 months and monthly for 3 months. Sessions focus on behavioral techniques supporting healthy diet (including calorie restriction for weight loss) and achieving recommended amounts of physical activity per week. During 1-year weight loss maintenance, participants receive monthly motivational phone calls.
1504258|NCT02938312|Behavioral|Weight Loss Plus|Participants attend in-person meetings as described above. This condition also includes community-wide strategies to increase access to healthy affordable food and safe opportunities for physical activity.
1504259|NCT02938299|Drug|L19IL2 + L19TNF|Mixture of L19IL2 and L19TNF once weekly
1504260|NCT02938299|Procedure|Surgery|Surgical resection of melanoma tumor lesions
1504261|NCT02938286|Device|Fractional CO2 laser, 2.5 mJ, 5% density|Pretreatment at 2.5 mJ/microbeam and 5% density. Pain stimulus at 50 mJ/microbeam and 5% density
1504262|NCT02938286|Device|Fractional CO2 laser, 2.5 mJ, 15% density|Pretreatment at 2.5 mJ/microbeam and 15% density. Pain stimulus at 50 mJ/microbeam and 5% density
1504263|NCT02938286|Device|Fractional Er:YAG laser, 9 mJ, 5% density|Pretreatment at 9 mJ and 5% density.
1504264|NCT02938286|Device|Fractional Er:YAG laser, 9 mJ, 15% density|Pretreatment at 9 mJ and 15% density.
1504265|NCT02938286|Device|Fractional CO2 laser, 50 mJ, 5% density|Pain stimulus at 50 mJ/microbeam and 5% density
1504266|NCT02938286|Drug|AHES|Topical application at test region I-IV under occlusion for 15 minutes
1504267|NCT02938273|Drug|avelumab|Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
1504268|NCT02938273|Radiation|radiotherapy|5 times a week, 7 weeks, total dose 70 Gy
1504269|NCT02938273|Drug|cetuximab|loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
1504270|NCT02938260|Drug|Metoprolol vs Diltiazem|
1504271|NCT02938247|Dietary Supplement|High caloric, high protein ONS|
1504272|NCT02938234|Dietary Supplement|High caloric, high protein ONS|
1504273|NCT02938221|Device|Telemedical video-oculography system|Telemedical video-oculography setup consisting of video goggles (EyeSeeCam, Interacoustics GmbH, Germany), a mobile telemedical workstation and an extended conferencing and remote control system (MEYTEC GmbH, Germany)
1504274|NCT02938208|Device|Jupiter Full Face Mask|Full Face Mask for the treatment of obstructive sleep apnea (OSA) using CPAP therapy.
1504275|NCT02938195|Radiation|radiotherapy|The clinical target volume of radiotherapy only includes the visible tumor and lymph nodes and the investigators wouldn't do any prophylactic radiation treatment.
1504276|NCT02938195|Procedure|Surgery|Surgery would be done 4-8 weeks after neoadjuvant chemoradiotherapy.
1504277|NCT02938182|Drug|clopidogrel|clopidogrel troche 75 mg daily for three months
1504278|NCT02938169|Behavioral|exercise|"stabilization exercise: Lumbar stabilization is a multi-component program and involves education/training, strength, flexibility, and endurance. It is generally used during all phases of a back pain episode and may be prescribed after a thorough evaluation of the patient's specific condition.
bracing exercise: patient is instructed as follows: Draw your navel up towards your head and in toward your spine without moving your pelvis. Continue to breathe normally as you do this.
walking exercise: treadmill gait with tolerable gait speed
flexibility exercise: stretching exercise(control)"
1504279|NCT02938143|Procedure|Exercise|The intervention treatment is a progressive 4-stage criteria-based exercise protocol within the limits of pain, consisting of progressive isometric, isotonic, plyometric, and sport-specific exercises.24 Progression criteria are individualized.
1504370|NCT02937519|Device|Routine intravenous drip|
1995842|NCT02640092|Drug|[18F]MNI-798|All enrolled subjects will undergo [18F]MNI-798 PET imaging visits. [18F]florbetapir PET imaging and 3T brain MRI will be obtained at screening for eligibility evaluation.
1995843|NCT02639702|Drug|Clozapine|Switching from twice-daily to once-daily clozapine dosing regimen
1504280|NCT02938143|Procedure|Exercise (usual care)|The control treatment is a painful heavy-load eccentric exercise program performed twice daily with 3 sets of 15 repetitions for 12 weeks on a 25° decline board. The downward component (eccentric component) will be performed with the symptomatic leg and the upward component (concentric phase) on the asymptomatic leg.
1504281|NCT02938130|Other|Wellness Programs|Wellness Programs delivered in the Community Partners and Community LIFE programs
1504282|NCT02938117|Other|cycling exercises|
1504283|NCT02938104|Dietary Supplement|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Posder (Immunocal) is provided.
Immunocal (1.5g/kg PO (by mouth) per day in daily doses"
1504284|NCT02938104|Behavioral|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
1504285|NCT02938104|Behavioral|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD
1504286|NCT02938091|Other|High-fat diet|Typical Western diet
1504287|NCT02938091|Other|Low-fat diet|Traditional Caribbean Hispanic diet
1504288|NCT02938078|Device|Avenova Lid Cleanser|Avenova lid cleanser is an FDA-cleared saline solution preserved with 0.01% pure hypochlorous acid.
1504289|NCT02938065|Procedure|Ultrasound|Baseline ultrasound is performed upon arrival. Ultrasound is performed when beverage is consumed and then every 30 minutes thereafter until stomach is empty.
1504290|NCT02938065|Other|2% milk|16 participants will drink 10 ounces of 2% milk
1504291|NCT02938065|Other|apple juice|16 participants will drink 10 ounces of apple juice
1504292|NCT02938065|Other|ensure clear|16 participants will drink 10 ounces of ensure clear
1504293|NCT02938052|Behavioral|PP-based health behavior intervention|The positive psychology exercises include 3 modules: Gratitude-based activities, Strength-based activities, and Meaning-based activities. The goal setting exercises include 3 modules: Physical activity, Heart-healthy diet, and Medication adherence.
1504294|NCT02938039|Device|Ambu LMA|Ambu Laryngeal Mask Airways
1504295|NCT02938039|Device|I-Gel LMA|I-Gel Laryngeal Mask Airways
1504296|NCT02938026|Procedure|Bariatric surgery|
1504297|NCT02938026|Behavioral|Telephone Intensive Lifestyle Counselling|
1504298|NCT02938013|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir [SOF/VEL/VOX]|antiviral therapy for HCV
1504299|NCT02938013|Drug|Sofosbuvir/Velpatasvir (SOF/VEL)|antiviral therapy for HCV
1504300|NCT02938000|Device|Theraband with exercise video|Theraband exercise band for resistance training
1504301|NCT02938000|Other|usual care with advice to exercise|advice to exercise
1504302|NCT02937974|Drug|Xuebijing|Xuebijing injection 50ml in 100ml of Normal Saline IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
1504303|NCT02937974|Drug|Placebo|Normal Saline 150ml IV, in 80mins, per 12 hours. administration of the agent for consecutive 5 days
1504304|NCT02937961|Biological|Early SLED|
1504305|NCT02937961|Biological|Late SLED|
1504306|NCT02937948|Other|Adaptative treatment plan|"Each patient will have 3 scanners before treatment initiation. One corresponding to an empty bladder, one to an intermediate one, one to a full bladder."
1504307|NCT02937948|Radiation|External radiotherapy|At the time of each fraction of external radiotherapy, the most appropriate plan (empty, intermediate, full bladder) covering the target and sparing the organs at risk is chosen.
1504308|NCT02937935|Biological|Protocol Guided Renal Replacement Therapy|
1504309|NCT02937935|Biological|On Demand Renal Replacement Therapy|
1504310|NCT02937922|Other|AEROBIC|The aerobic exercise session (AE) will consist of 40 minutes on an exercise bike in heart rate (HR) corresponding to 50-60% of heart rate reserve (moderate intensity) acquired by the formula of Karvonen: [(HR max - HR rest) x desired intensity] + HR rest; monitored through heart monitor brand Polar and perceived exertion rating (Borg scale of 6-20). It will be added to the exercise time 5-7 minutes to proper heating.
1504311|NCT02937922|Other|RESISTANCE|The resistance exercise session (RE) will last 40 minutes and will consist in carrying out 4 sets of 12 repetitions with interval of 60 to 90 seconds between sets and exercises. The weight will be adjusted to 60 to 70% of a maximum repetition (1-RM) (moderate intensity) in four exercise for the lower limbs: leg press, knee extension, bend knees and plantar flexion (calf). The cadence of each series will be controlled by electronic metronome and performed with 2 seconds in the concentric phase and 2 seconds in the eccentric phase. It will be added to the exercise time 5-7 minutes for the warming to be held in the leg press exercise (one set of 15 to 20 repetitions with 1/3 load set for the session).
1504312|NCT02937922|Other|COMBINED|The combined exercise session (resistance and aerobic) will last 40 minutes. The exercise resistance phase of the combined session will consist of 20 minutes, according to the resistance exercise described above. Immediately after resistance exercise, patients will perform aerobic exercise (AE) for 20 minutes. In order to keep the equivalent time among the three interventions (aerobic exercise, resistance and combined) will be performed two series (2 x 12 repetitions) in each resistance exercise.
1504313|NCT02937909|Other|Use of wound care products from a single manufacturer|The participating Healthcare Professionals will be asked to use BSN medical wound care products for the study duration
1504314|NCT02937896|Drug|Desmopressin|40 micrograms Nasal Desmopressin.
1504315|NCT02937896|Drug|Ketorolac|30mg intravenous Ketorolac.
1504316|NCT02937896|Drug|Normal Saline|1cc intravenous Normal Saline.
1504317|NCT02937896|Drug|Normal Saline|4 puffs nasal Normal Saline.
1504318|NCT02937883|Other|Empowerment intervention|Empowerment intervention for persons with young onset dementia
1504319|NCT02937870|Other|Test Product 1|Test adhesive 1 with a thin nozzle
1504320|NCT02937870|Other|Test Product 2|Test adhesive 2 with a thin nozzle
1504321|NCT02937870|Other|Reference Product|Adhesive Cream
1504322|NCT02937870|Other|Negative Control|No adhesive
1504323|NCT02937857|Drug|Standard treatment only|standard treatment， such as antiasthmatic,expectorant,antipyretic
1504324|NCT02937857|Drug|Standard treatment+Xiyanping injection|standard treatment+Xiyanping injection:standard treatment， such as antiasthmatic, expectorant and antipyretic plus Xiyanping injection,0.2-0.4mL/kg/day,qd for 5 days.
1504371|NCT02937519|Drug|induction Chrono-chemotherapy|
1504372|NCT02937519|Drug|induction Routine-chemotherapy|
1504325|NCT02937844|Biological|Anti-PD-L1 CSR T cells|Prescribed CSR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）.
1504326|NCT02937844|Drug|Cyclophosphamide|250 mg/m^2, d1-3
1504327|NCT02937844|Drug|Fludarabine|25mg/m^2, d1-3
2002469|NCT02184611|Drug|Umeclidinium bromide|Blended with lactose and magnesium stearate dry white powder of umeclidinium 62.5 mcg to be inhaled via a NDPI
2002470|NCT02184611|Drug|Placebo|Blended with lactose and magnesium stearate dry white powder to be inhaled via a NDPI
1504331|NCT02937805|Device|Moisturizing vaginal and vulvar sea buckthorn oil cream|
1504332|NCT02937805|Device|Moisturizing vaginal and vulvar cream|
1504333|NCT02937792|Drug|intrathecal 15 mg bupivacaine|spinal anesthesia with a large dose of bupivacaine 0.5% in elective caesarean section
1504336|NCT02937766|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
1504337|NCT02937766|Drug|Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL)|
1504339|NCT02937727|Device|3T MRI compatible and LFP recordable G106R of Beijing Pins medical.|
1504340|NCT02937714|Other|School Mental Health training|School based intervention (Teacher training intervention) is the teachers training program based on World Health Organization, Eastern Mediterranean Region (WHO-EMRO) School mental health manual draft (December 2014). Topics to be covered in training workshop include normal childhood development, behaviour management strategies for schools, life skills training, essential components for healthy schools, recognizing warning signs for common psychiatric and developmental disorders common to children and adolescents & school based interventions for various psychiatric problems
1504341|NCT02937701|Drug|ABP 710|Concentrate for solution, ABP 710 3 mg/kg infusion on day 1, at weeks 2 and 6, and every 8 weeks thereafter
1504342|NCT02937701|Drug|Infliximab|Concentrate for solution, Infliximab 3 mg/kg infusion on day 1, at weeks 2 and 6, and every 8 weeks thereafter
1504343|NCT02937688|Device|Medtronic DBS Therapy for Parkinson's disease|Bilateral Deep Brain Stimulation (DBS) of the Subthalamic Nucleus or Globus Pallidus interna.
1504344|NCT02937675|Drug|eFT508|
1504345|NCT02937662|Drug|Idarubicin|Idarubicin at a dose of 10 mg/㎡/d on days 1-3.
1504346|NCT02937662|Drug|Cytarabine|Cytarabine at a dose of 100mg/㎡/d on days 1-7.
1504347|NCT02937662|Drug|Cyclophosphamide|Cyclophosphamide at a dose of 350mg/㎡/d on the second day and the fifth day.
1504348|NCT02937662|Drug|Physician-Directed Regimens without Cyclophosphamide|Regimen without cyclophosphamide including FLA±G regimen, DA regimen, AAG regimen, decitabine with AA regimen.
1504349|NCT02937649|Procedure|Laparoscopic sleeve gastrectomy using 48-Fr bougie|After gastric mobilization, the 48-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient and surgeon are blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
1504350|NCT02937649|Procedure|Laparoscopic sleeve gastrectomy using 36-Fr bougie|After gastric mobilization, the 36-Fr bougie is inserted through the mouth by the anesthesiologist and positioned in the stomach. Patient and surgeon are blind to the type of bougie used. Gastrectomy is performed alongside the calibration bougie.
1995844|NCT02639494|Device|Self-Centering Guide Catheter|
1504353|NCT02937623|Device|Calcium sodium phosphosilicate|Experimental dissolvable polymer strip containing 15% weight by weight(w/w) calcium sodium phosphosilicate.
1504354|NCT02937610|Procedure|percutaneous endoscopic gastrostomy|PEG tube inserted with pull technique
1504355|NCT02937597|Behavioral|ePBP: eProficiency Based Progression|National e-learning programme plus Proficiency-based progression through 4 scenarios in an online learning course and facilitator when requested
1504356|NCT02937597|Behavioral|eS: eScenarios|National e-learning programme plus access to 4 scenarios in an online learning course and facilitator when requested
1504357|NCT02937597|Behavioral|HSE|National HSE e-learning programme only
1504358|NCT02937584|Drug|GP MDI (PT001) 14.4 μg|Glycopyrronium
1504359|NCT02937584|Drug|FF MDI (PT005) 9.6 μg|Formoterol Fumarate
1504360|NCT02937571|Drug|Carfilzomib|
1504361|NCT02937571|Drug|Lenalidomide|
1504362|NCT02937571|Drug|Dexamethasone|
1504365|NCT02937545|Other|Medication Therapy Management|Community pharmacists will provide medication therapy management in combination with pharmacogenetic testing
1504366|NCT02937545|Other|Pharmacogenetic testing|Community pharmacist will provide pharmacogenetic testing.
1504369|NCT02937519|Device|Chrono-chemotherapy pump:Melodie|
1995848|NCT02637856|Drug|Ocrelizumab|Participants will receive ocrelizumab as an initial dose of two 300-mg IV infusions (600 mg total) separated by 14 days (on Days 1 and 15) followed by one 600-mg IV infusion every 24 weeks for a maximum of 4 doses (up to 96 weeks).
1995849|NCT02637687|Drug|LOXO-101 (larotrectinib)|Capsules / Liquid Administration
1995850|NCT02637323|Drug|FX006|Sustained Release Steroid
1995851|NCT02637323|Drug|TCA IR|Immediate Release Steroid
1504374|NCT02937519|Drug|cisplatin routine-chemotherapy|
1504375|NCT02937519|Radiation|intensity-modulated radiation therapy|
1504376|NCT02937506|Drug|Propofol|The intervention is to use propofol as anesthesia during a colonoscopy.
1504377|NCT02937506|Drug|Fentanyl Plus Midazolam|The control is to use standard of care anesthesia, fentanyl and midazolam, during a colonoscopy.
1504378|NCT02937493|Behavioral|Lunar phases|Observation if lunar phases had an influence on occurrence of IPV
1504379|NCT02937480|Other|Task-specific training|The task-specific training will be composed by 30 minutes for upper limb and 30 minutes for lower limb tasks. Subjects will performed five minutes of exercise in each station of the circuit and only the last station will last 10 minutes and will involve a walking training with auditory stimulation. Individuals will be encouraged to work as hard as possible at each station and verbal feedback and instructions aimed at improving performance will be taken. Between each task, the participants will be allowed to rest for at least 1-2 minutes, and individual adjustments will be carried out for better adaptations to the training.
1504380|NCT02937480|Other|Global stretching, memory exercises, health care orientation|The control intervention will be composed by 40 minutes for global stretching, 20 minutes of memory exercises and health care orientation
1504381|NCT02937467|Device|SWE|a novel ultrasound-based elastographic method, a new real-time, quantitative, operator-independent, and reproducible technique
1504382|NCT02937454|Drug|ferric carboxymaltose|FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered
1504383|NCT02937454|Other|Normal saline 0.9%|Normal saline will be administered as a bolus injection.
1504384|NCT02937441|Other|Ultrasonic Measurement|"How we measure;
First measurement shall be taken in 4 hours.
Second measurement shall be taken at 12 hours in mild and 12-18 hours measurement shall be taken for severe diabetic ketoacidosis,
Third measurement shall be taken after fluid treatment.
Fourth measurement shall be taken at patients polyclinic control."
1504385|NCT02937428|Behavioral|Look away from the needle|Participant looks away from the needle during vaccination
1504386|NCT02937428|Behavioral|Look at the needle|Participant looks at the needle during vaccination
1504387|NCT02937415|Procedure|Breath carbon monoxide|Breath carbon monoxide measurement.
1504388|NCT02937415|Procedure|Pulmonary function tests.|Measurement of lung functions by blowing through a tube which measures flow and volumes of participant's lungs.
1504389|NCT02937415|Procedure|Oxidative stress and antioxidant status.|Measurement of parameters of oxidative stress and antioxidant status in blood samples.
1504390|NCT02937402|Procedure|Bronchoscopy with Bronchoalveolar Lavage|Undergo bronchoscopy with bronchoalveolar lavage
1504391|NCT02937402|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
1504392|NCT02937389|Procedure|Patients after esophagectomy|Endoscopic examinations are performed at 1, 8, and 15 postoperative days. Endoscopic examination is added when abnormal findings are demonstrated.
1504393|NCT02937376|Drug|N-acetyl cystein|A trial of exercise before and after 4 weeks of N-acetyl cystein (NAC) supplementation.
1504394|NCT02937376|Other|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
1504395|NCT02937363|Dietary Supplement|Alpha-lipoic acid|A trial of exercise before and after 4 weeks of alpha-lipoic acid supplementation.
1504396|NCT02937363|Other|Placebo|A trial of exercise before and after 4 weeks of placebo administration.
1504397|NCT02937350|Drug|D6-25-hydroxyvitamin D3|Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3
1504398|NCT02937337|Device|Laryngeal mask insertion with videostylet guided technique|
1504399|NCT02937337|Device|Laryngeal mask insertion with standard blind technique|
1504400|NCT02937324|Device|CloudUPDRS smartphone software assessment|Smartphone software consisting of a series of tapping and tremor-measurement tests designed to measure a subset of the UPDRS.
1504401|NCT02937324|Other|Clinical assessment|A clinician will assess the motor signs of the participant using the Unified Parkinson's Disease Rating Scale. The examination will be videoed and rated by 3 blinded examiners.
1504402|NCT02937311|Other|NMES|Participants received NMES using a portable, page-sized battery-powered stimulation device, which delivered current-regulated, charge-balanced, asymmetrical biphasic pulses. The implementation was done on the deltoid and supraspinatus muscles
1504403|NCT02937311|Other|Kinesiotape|The deltoid and supraspinatus muscles were taped in this study to align the shoulder in correct position to facilitate the function and achieve preferred body alignment. For supraspinatus application, Y strip tape was applied from the muscle insertion at the greater tuberosity of the humerus to its origin at the supraspinatus fossa of the scapula while the muscle was in an overstretched position. No tension was applied to the tape. For deltoid application, Y-shaped tape was used by placing the anchor acromion process. The front tail was implemented in the extended arm position, while the back tail was implemented in the horizontal abducted arm position. Both tails ended below the deltoid tubercule of the humerus. No tension was applied during application.
1504404|NCT02937311|Other|Standardized Physiotherapy|All participants received rehabilitation including Bobath neurophysiological approach. Bobath approach and other exercise programs were implemented early after the onset of the stroke to prevent immobility and soft tissue contracture and to alter the muscle tone to gain mobility. Through the exercise program and use of weight-bearing techniques, the therapist attempted to maintain and improve trunk and shoulder alignment to allow the functional use of the upper extremity.
2002481|NCT02170350|Procedure|Meditation therapy|Use brief mindful meditation practice
2002482|NCT02170350|Other|Quality-of-life assessment|Ancillary studies
2002483|NCT02170350|Other|Questionnaire administration|Ancillary studies
2002484|NCT02169869|Device|Mirena|A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.
2002485|NCT02169869|Device|Paragard|A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
1504411|NCT02937272|Drug|LY3200882|Administered orally
1504412|NCT02937272|Drug|LY3300054|Administered intravenously
1504413|NCT02937272|Drug|Gemcitabine|Administered intravenously
1504414|NCT02937272|Drug|nab-Paclitaxel|Administered intravenously
1504415|NCT02937272|Drug|Cisplatin|Administered intravenously
1504416|NCT02937272|Radiation|Intensity Modulated Radiotherapy|
1504417|NCT02937259|Other|Patient self-admission to inpatient treatment|Participants are given a contract whereby they are offered the possibility to admit themselves at will to the inpatient ward at the Stockholm Centre for Eating Disorders for a maximum of seven consecutive days at a time. They are also free to discharge themselves at any time. The participants may use this opportunity as often as they want to for a period of one year, or longer if the contract is renewed after one year.
1504418|NCT02937246|Device|SEMS(self-expandable metallic stent)|Find the obstruction site by ERCP(endoscopic retrograde cholangiopancreatography) and insertion the SEMS(self-expandable metallic stent) through duodenal endoscopy. Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
1504419|NCT02937246|Device|Stenting by ERCP (endoscopic retrograde cholangiopancreatography)|
1504420|NCT02937233|Biological|Zika Virus Purified Inactivated Vaccine|
1504421|NCT02937233|Other|Placebo|
1504422|NCT02937220|Procedure|monolithic zirconia crown|New crown material used as final restoration for dental implants
1504423|NCT02937220|Procedure|metal ceramic crown|Conventional crown material used as final restoration for dental implants
2002486|NCT02166463|Biological|Bleomycin Sulfate|Given IV or SC
2002487|NCT02166463|Drug|Brentuximab Vedotin|Given IV
2002488|NCT02166463|Drug|Cyclophosphamide|Given IV
2002489|NCT02166463|Drug|Doxorubicin Hydrochloride|Given IV
2002490|NCT02166463|Drug|Etoposide|Given IV
2002491|NCT02166463|Other|Laboratory Biomarker Analysis|Correlative studies
2002492|NCT02166463|Other|Pharmacological Study|Correlative studies
2002493|NCT02166463|Drug|Prednisone|Given PO
2002494|NCT02166463|Other|Quality-of-Life Assessment|Ancillary studies
2002495|NCT02166463|Other|Questionnaire Administration|Ancillary studies
2002496|NCT02166463|Drug|Vincristine Sulfate|Given IV
1504436|NCT02937194|Behavioral|Personal oral health instruction + pamphlets distribution|Personal oral health instruction (OHI) and oral health pamphlets distribution
1504437|NCT02937194|Behavioral|Pamphlets distribution|Oral health pamphlets distribution
1504438|NCT02937181|Drug|Ceftaroline|IV Ceftaroline will be given for 72 hours
1504439|NCT02937168|Drug|Reslizumab|Administered by IV infusion- single dose of reslizumab at 3 mg/kg at the baseline visit for the treatment period.
1504440|NCT02937168|Drug|Fludeoxyglucose F 18 (FDG)|Administered by IV infusion- Prior to each PET/CT scan, FDG.
1504441|NCT02937168|Drug|Placebo|Matching Placebo- single dose at the baseline visit for the treatment period.
1504442|NCT02937142|Behavioral|cognitive behavior group therapy|1,5 hours weekly session during 12 weeks, 8 participants, 2 therapists.
1504443|NCT02937142|Other|Treatment as usual|Education on ADHD, and ADHD medication if indicated
1504444|NCT02937116|Drug|IBI308|
1504445|NCT02937116|Drug|IBI308\Cisplatinum\Pemetrexed|
1504446|NCT02937103|Biological|Anti-CD123-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD123-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity,the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
1504447|NCT02937090|Other|Blood Draw|Blood sample will be drawn from participants at study entry.
1504448|NCT02937090|Other|Stool collection|Stool will be collected from participants at study entry.
1504449|NCT02937077|Device|Medtronic Reveal LINQ|
1504450|NCT02937051|Other|Tobacco product administration and assessment|two bouts of 10 puffs of a tobacco product with a 30-second interpuff interval separated by 60 minutes; preceded and followed by physiological, subjective and topography assessment
1504451|NCT02937025|Device|The Left Atrial Appendage Occulder of Shanghai Push Medical Device Technology CO.td|Implanting the Occluder to close the left atrial appendage
1504452|NCT02937012|Drug|Bezafibrate|Bezafibrate 200 mg manufactured in a pill/capsule presentation
1504453|NCT02937012|Drug|Ursodeoxycholic Acid|The patients will continue with the administration of ursodeoxycholic acid at a dose of 13 to 15 mg per Kg per day throughout the study
1504454|NCT02937012|Drug|Placebo (for Bezafibrate)|Starch pill/capsule manufactured to mimic bezafibrate 200 mg tablet
1504455|NCT02936999|Drug|Cholecalciferol|Cholecalciferol 100,000 IU followed by 4000 IU orally once daily for 30 days.
1504489|NCT02936687|Drug|NOS Inhibition|NOS inhibition: L - NMMA is a potent non-selective NOS inhibitor used to study vascular physiology. L-NMMA will be infused at 3 mg/kg body weight/hr bolus (over 10min ) followed by a maintenance infusion of 1 mg/kg/hr for the duration of the experiment. Systemic delivery of L - NMMA has been shown to elevate blood pressure ~8-15 mmHg that is within the range observed during exercise.
1504531|NCT02936388|Procedure|SIRT|catheter-based application of radioactive microspheres into the hepatic artery
1504456|NCT02936973|Device|Real catgut implantation at acupoints|"Absorbable surgical suture will be embedded in acupoints as below. Group A ：Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40). Each group will be used alternatively and treated once every 2 weeks.
lifestyle intervention :Experienced nutritionists calculated every participant's basal metabolic rate,then designed a proper diet and exercise treatment for them. During the treatment, a diet and exercise diary will be distributed to the patients, and detailed guidance concerning their diet and exercise will be provided according to the diary. The patients should be encouraged to maintain the diet and exercise diary for at least 4 days per week ."
1504457|NCT02936973|Device|sham catgut implantation at acupoints|"Empty needles without catgut will be pushed into the chosen position as below :Group A ：1 cun lateral from the Zhigou (TE 6), Tianshu (ST25), Weishu (BL21), Zhongwan (CV12) and Zusanli (ST36); Group B ：1 cun lateral from the Quchi (LI11), Huaroumen (ST24), Pishu (BL20), Shuifen (CV9), and Fenglong (ST40).Those two groups of acupoints will ultimately be selected for alternative treatment. Each group will be used alternatively and treated once every 2 weeks.
lifestyle intervention :It will be performed as the same as the real catgut implantation at acupoints group."
1504458|NCT02936947|Device|High Frequency Percussive Ventilation|High Frequency Percussive Ventilation
1504459|NCT02936947|Other|Free breathing|Free breathing
1504460|NCT02936947|Other|Active Breathing Control|Active Breathing Control
1504461|NCT02936934|Drug|Morphine|"Interventions pre-specified to be administered to participants:
Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery
Intravenous infusion:
200μg / kg of morphine + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration:24hours"
1504462|NCT02936934|Drug|Oxycodone|"Interventions pre-specified to be administered to participants:
Abdominal hysterectomy Block Anesthesia: bupivacaine 0.5% + 25 micrograms of fentanyl 10mg / kg metamizol sodium intravenously during surgery
Intravenous infusion:
150μg / kg of oxycodone + 3g metamizole sodium + 3mg / kg 2% lidocaine + 500mL saline solution. Time administration: 24hours."
1504463|NCT02936908|Other|Ventilatory support|Initiation of mechanical ventilatory support, invasive or non-invasive, Or modification of mechanical ventilatory support (modification of the parameters of the device, change of material, switch from non-invasive to invasive)
1504464|NCT02936895|Drug|Vitamin D3|vitamin D at a dose of 50,000 IU per day for 2 days
1504465|NCT02936895|Drug|Placebo|Placebo for 2 days
1504466|NCT02936882|Procedure|Preoperative gastric ultrasonography|Before surgical emergency procedure, a preoperative antral ultrasonography is performed to assess gastric content.
1504467|NCT02936869|Behavioral|Performance-based monetary incentives|
1504468|NCT02936856|Device|Hepatic Arteriography|
1504469|NCT02936843|Drug|Salsalate|1 gram, 3 times daily by mouth (total of 3 grams daily)
1504470|NCT02936843|Drug|PLACEBO|Placebo for Salsalate; 1 gram, 3 times daily by mouth (total of 3 grams daily)
1504471|NCT02936830|Drug|5% Sodium Fluoride Varnish|5% sodium fluoride varnish applied on the dentin by the dentist
1504472|NCT02936830|Drug|15% Nanohydroxyapetite paste|15% nanohydoxyapetite paste without potassium nitrate or fluoride applied on the dentin by the dentist
1504473|NCT02936830|Drug|Glycerol|Glycerol with water in a 1: 1 ratio
1504474|NCT02936817|Device|Aerobika® Device|For a period of 15 +/- 3 days subjects will use the Aerobika® device before administration of their stable standard of care treatment regimen (i.e. study patients should use the device before each inhalation medication administration, with a minimum use of the device of twice daily).
1504475|NCT02936817|Radiation|HRCT scans|A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, and visit 3. An upper airway (UA) scan will be taken on visit 1.
1504476|NCT02936804|Device|Low Dose Computed Tomography|LDCT was performed at baseline and 2 rounds of biennial repeated LDCT. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm. The management of abnormal nodules including precision diagnosis by endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), electromagnetic navigation bronchoscope (ENB) and peripheral biomarkers, and precision therapy by intraoperative frozen section guided lung resection and ENB radiofrequency ablation.
1504477|NCT02936765|Device|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
1504478|NCT02936765|Device|Anterior cervical discectomy with prosthetic disc replacement / Squale.|Anterior cervical discectomy, with the use of the Squale spacer (Manufacturer: OSD, Avignon, France) for the disc replacement.
1504479|NCT02936752|Drug|Entinostat|Given PO
1504480|NCT02936752|Other|Laboratory Biomarker Analysis|Correlative studies
1504481|NCT02936752|Biological|Pembrolizumab|Given IV
1504482|NCT02936739|Device|Anterior cervical discectomy with prosthetic disc replacement / ESP.|Anterior cervical discectomy, with the use of the ESP prosthesis (Manufacturer: FH orthopedics, Mulhouse, France) for the disc replacement.
1504483|NCT02936739|Device|Anterior cervical discectomy with prosthetic disc replacement / Rotaio.|Anterior cervical discectomy, with the use of the Rotaio prosthesis (Manufacturer: Signus Med, Alzenau, Germany) for the disc replacement.
1504484|NCT02936726|Behavioral|Exercise, Health Coaching and Meditation|Comparing Exercise, Health Coaching and Meditation In Combination
1504485|NCT02936726|Behavioral|Exercise and Health Coaching|Comparing Exercise and Health Coaching Alone
1504486|NCT02936713|Other|Fermented milk product with probiotics (FMPP)|2 pots of 125g FMPP / day
1504487|NCT02936700|Behavioral|Relaxation|relaxation program consists of 7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants.
1504488|NCT02936700|Behavioral|ACT therapy|"7 weekly, 2 hours sessions led by two therapist. Each group will consist of 7 participants. The ACT program aims at
decreasing the tendency to try to escape unpleasant mental experiences
increasing psychological flexibility
developing acceptance of psychological events and engagement in valued actions"
1504527|NCT02936427|Drug|Dexamethasone|perineural infiltration of dexamethasone
1504528|NCT02936414|Drug|Berberine|Berberine (300 mg/tid), as an adjuvant therapy will be used on the basis of the SGAs monotherapy.
1504529|NCT02936414|Drug|Placebo|Accept placebo(300 mg/tid)+SGAs monotherapy.
1504490|NCT02936687|Drug|ET-1 Inhibition|ET-1 inhibition: BQ 123 is an antagonist of the ETA receptor and has been used to research ET-1 signaling in diabetes, obesity, and hypertension. ETA receptors are the most likely to mediate excessive constriction in MetSyn patients. Infusion of BQ123 will take place at 0.51 mg/kg/hr for ~15 min bolus. Systemic delivery of BQ123 has been shown to decrease systolic blood pressure 4.5±10 mmHg and diastolic 3 ± 7.5 mmHg in hypertensives, and not alter mean arterial pressure in obesity.
1504491|NCT02936687|Drug|Placebo|Saline will be infused at the same rate and quantity as the corresponding drug visit.
1504492|NCT02936687|Device|3 Tesla MRI|A 3 Tesla MRI will be used to quantify cerebral blood flow and capture cerebral vessel structure at designated time points throughout the study visits (at baseline and during treatment conditions).
1504493|NCT02936687|Device|Intravenous Catheter|A blood sampling IV catheter will be used to draw up to 15 mL blood samples at specific time points throughout each study visit to measure concentrations of glucose and insulin as well as for markers of inflammation and oxidative stress.
1504494|NCT02936687|Other|Oral Glucose Tolerance Test|The subject will drink distilled deionized water (300ml) containing 75 grams glucose within 5 minutes.
1504495|NCT02936674|Device|Light - standard|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with standard spectral distribution
1504496|NCT02936674|Device|Light - alternate|Light will be given during the night to determine its effects on melatonin suppression. This light will be an LED with an altered spectral distribution (different color)
1504497|NCT02936661|Drug|Tranexamic Acid|
1504498|NCT02936661|Drug|Placebo|
1504500|NCT02936635|Drug|tirasemtiv|Oral
1504501|NCT02936622|Device|Zilver® Paclitaxel-Eluting Peripheral Stent|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
1504502|NCT02936622|Device|Zilver® Paclitaxel-Eluting Peripheral Stent with slower-dissolving polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
1504503|NCT02936622|Device|Zilver® Paclitaxel-Eluting Peripheral Stent with higher-dose polymer-free paclitaxel coating|Paclitaxel belongs to the Taxane drug class and coated on the stent at a much lower dose than when administered as a chemotherapy agent.
1504504|NCT02936609|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
1504505|NCT02936596|Drug|Ursodeoxycholic acid combination of immunosuppressive agents|Ursodeoxycholic acid combination of immunosuppressive agents(methylprednisolone with or without azathioprine)
1504506|NCT02936596|Drug|Ursodeoxycholic Acid|Ursodeoxycholic Acid
1504507|NCT02936583|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
(Formulation Code:Z09-067)"
1504508|NCT02936570|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
(Formulation Code:Z09-067)"
1504509|NCT02936557|Drug|BAY987521|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
(Formulation Code:Z09-054)"
2002500|NCT02161133|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy is a treatment approach that teaches patients strategies to address real-life problems.
1504511|NCT02936518|Procedure|Lingual frenotomy and/or maxillary labial frenectomy|
1504512|NCT02936505|Drug|Cyclosporine|"Cyclosporin A (Sandimmun Neoral® or similar):
Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.
Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; >12 months 100-150 ng/ml. Cyklosporine A will be administered twice daily."
1504513|NCT02936505|Drug|Mycophenolate mofetil (MMF)|"MMF target dose: 2000 mg/day (1gx2):
o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly."
1504514|NCT02936505|Drug|Rabbit Anti thymocyte globuline|Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globuline)(1.5 mg/kg given immediately postoperatively).
1504515|NCT02936505|Drug|Corticosteroids|"Corticosteroids:
Day 0 (day of lung transplantation); 500+500mg methylprednisolone iv. before reperfusion, i.e. restoration of blood flow into the transplanted allograft.
From day 1: Initiated at 0.2 mg/kg/day; tapered to 0.1 mg/kg 3-6 months; less than 0,1 mg/kg > 6 months."
1504516|NCT02936505|Drug|Tacrolimus|"Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.
Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, >12 months 6-8 ng/ml. Tacrolimus will be administered once daily."
1504517|NCT02936492|Drug|BAY1003803 0.01% lipophilic cream|Topical administration for 22 h per day
1504518|NCT02936492|Drug|BAY1003803 0.1% lipophilic cream|Topical administration for 22 h per day
1504519|NCT02936492|Drug|BAY1003803 0.01% ointment|Topical administration for 22 h per day
1504520|NCT02936492|Drug|BAY1003803 0.1% ointment|Topical administration for 22 h per day
1504521|NCT02936492|Drug|Lipophilic cream vehicle|Topical administration for 22 h per day
1504522|NCT02936492|Drug|Ointment vehicle|Topical administration for 22 h per day
1504523|NCT02936492|Drug|Clobetasol propionate|Topical administration for 22 h per day
1504524|NCT02936479|Drug|C1-INH (Berinert)|
1504525|NCT02936466|Behavioral|Bipolife® group|"The participant is proposed to play to the serious game Bipolife® with following instructions :
At least one connection per week during 4 weeks
Connection time is free On add on of usual treatment After the 4 weeks and the first visit (V1), the participant can continue to participate to the serious game as much as he wishes, without any specific instructions.
After connecting to the site www.bipolar.ubi.com, the participant is proposed to create his avatar and conduct him on his house. He realizes different kind of daily actions (like sleeping, sport activity, cooking) ; every action lead to win or to loose energy and mood points. The final aim is to stabilize the avatar's mood. Thanks to this experience, the participant can learn to distinguish positive and negative actions impacting on his condition."
1504526|NCT02936453|Procedure|Device implantation|"Implantation of Specify 5-6-5 lead in epidural space
Implantation of Activa RC neurostimulator"
1504532|NCT02936388|Procedure|DSM-TACE|catheter-based application of chemotherapy and degradable starch microspheres into the hepatic artery
1504533|NCT02936375|Drug|Iguratimod|
1504534|NCT02936375|Drug|Cyclophosphamide|
1504535|NCT02936375|Drug|Azathioprine|
1504536|NCT02936362|Other|Consumption of sourdough bread|Participants will be given sourdough bread to consume instead of other wheat products. 145g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
1504537|NCT02936362|Other|Consumption of white bread|Participants will be given white bread to consume instead of other wheat products. 110g will be consumed every morning in addition to ad libitum consumption throughout the day (matched between first and second intervention periods)
1504538|NCT02936349|Other|Transthoracic Contrast Echocardiogram|A transthoracic contrast echocardiogram (TTCE) is a still or moving image of the internal parts of the heart using ultrasound following the injection of microbubble contrast (agitated saline) into a vein in the arm, which then travels to the heart.
1504539|NCT02936336|Other|exercise|circuit exercise, aerobic dance and Tai Chi exercise
1504540|NCT02936323|Drug|PEN-221|Administration of PEN-221 once every three weeks
1504541|NCT02936310|Behavioral|Mindful Living With Stress|The proposed Mindful Living With Stress Intervention will be conducted weekly, 2 hours per session, 4-6 sessions, group based program in mindfulness.
1504542|NCT02936297|Dietary Supplement|High dose Gluten|
1504543|NCT02936297|Dietary Supplement|Low dose Gluten|
1504544|NCT02936297|Dietary Supplement|Lactose free placebo|
1504545|NCT02936284|Behavioral|Music Enhancement|
1504546|NCT02936284|Behavioral|Play Date|
1504547|NCT02936271|Other|Vasculera|"Vasculera is a specially formulated prescription medical food product. This study compares Vasculera to placebo at reducing post procedural pain, bruising and edema for patients requiring an intervention for lower extremity venous disease.
Patient will be randomized to receive Active Vasculera or Vasculera Placebo. The study product will be taken for two weeks prior to the patient's planned procedure and continued for four weeks after their procedure. If multiple procedures are required the patient will be instructed to use the product throughout treatment."
1504548|NCT02936271|Other|Placebo|
1504549|NCT02936258|Procedure|Standard of Care|Men in Arm B will undergo a 12-core systematic TRUS guided biopsy. All men in the study will be followed for two years or until they have had radical treatment (whichever comes first).
1504550|NCT02936258|Procedure|MRI|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
1504551|NCT02936258|Procedure|MRI Targeted Biopsy|Men will undergo a MRI followed by either a targeted biopsy of suspicious areas or will be followed for two years if there is no suspicious areas identified by MRI.
1504552|NCT02936245|Other|no specific intervention|We will not assign specific intervention in this research. We will record their baseline characteristics, received treatment, and assess the outcomes to analysis the predictors of outcome and natural history in patients with cervical spondylotic myelopathy.
2002501|NCT02161133|Behavioral|Health Education|Health Education provides didactic information about Gulf War Illness
2002502|NCT02153944|Drug|Propanolol|
1504555|NCT02936193|Procedure|Pylorus preservation|Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
1504556|NCT02936193|Procedure|Distal gastrectomy|Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
1504557|NCT02936180|Biological|HD-TIV|
1504558|NCT02936180|Biological|SD-QIV|
1504559|NCT02936167|Biological|Ringer Lactate|
1504560|NCT02936167|Biological|Plasmalyte|
2002503|NCT02153944|Drug|Methylphenidate|
2002504|NCT02149459|Radiation|Partial brain re-irradiation.|Partial brain re-irradiation to a dose of 30-35Gy delivered over 2 weeks (10 fractions).
1504563|NCT02936141|Behavioral|Group psychotherapy|Includes a group (up to 10 participants) weekly session with a duration of 90 minutes where it is stimulated communication, adaptative behaviour and social living
1504564|NCT02936128|Other|TruSkin|
1504565|NCT02936128|Other|Wound Cover|
1504566|NCT02936115|Other|TruSkin®|
1504567|NCT02936115|Other|Wound Cover|
1504568|NCT02936102|Drug|FAZ053|Anti-PD-L1 Antibody
1504569|NCT02936102|Drug|PDR001|Anti-PD-1 Antibody
1504570|NCT02936089|Drug|Ara-C|Ara-C was administered at 1-2 g/m2 q12 h ×6 cycles
1504571|NCT02936089|Other|autologous HSCT|
1504572|NCT02936089|Other|allogeneic HSCT|
1504573|NCT02936076|Other|Exercise intervention|
1504574|NCT02936076|Other|Delayed exercise intervention|
1504575|NCT02936063|Procedure|Surgical staples|Closure of surgical wound at skin level with surgical staples
1504576|NCT02936063|Procedure|Subcuticular sutures|Closure of surgical wound at skin level with subcuticular sutures
1504577|NCT02936050|Procedure|Diagnostic ultrasound|All participants will be examined by diagnostic ultrasound by nurses for the assessment of the Cardiac size and function, and for volumic state. Transmission of the ultrasound recordings by telemedicine and interpretation by specialist in echocardiography and heart failure. All participants will then be examined by reference imaging in specific ultrasound laboratories.
2002505|NCT02149459|Drug|Metformin|Different cohorts will receive no, low dose or higher dose metformin.
1504580|NCT02936024|Procedure|Two-Stage GSLO Technique|The patient will initially receive the first stage of the two-stage technique which involves the ligation of testicular vessels laparoscopically, or transection of these vessels using cautery. After the first stage is complete, the patient will be seen approximately 3-6 months later for the second stage. The second stage of the procedure involves free mobilization of the testis and placement/fixation of the testicle in the scrotum.
1504581|NCT02936024|Procedure|One-Stage GSLO Technique|The patient will receive only one surgical procedure during which ligation of testicular vessels is performed, as well as mobilization of the testis and placement/fixation of the testicle in the scrotum.
1504582|NCT02936011|Device|CTO PCI using Absorb Bioresorbable Vascular Scaffolds|CTO PCI
1504731|NCT02934958|Behavioral|Colon Cancer Screening Navigation|Patients with FIT Positive results that have been given the choice will be followed and navigated from referral to colonoscopy to assist in obtaining colonoscopy.
1504583|NCT02935998|Drug|Ziprasidone|During the study, at least 1 injection is needed per day. Whether the second, third or fourth one is needed according to patients' symptoms. If the BARS score>=5, clinicians are supposed to give 10mg or 20mg.If lower than 5, clinicians could choose to give 10mg or not according to patients' symptoms and doctor's experience. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day.It is not recommended to combine with other oral antipsychotic drugs. But if the patients' daily dose of injection has reached 40mg and agitation occurred 4 hours later after the last injection, with the BARS score higher than 5.The clinicians can determine whether or not to combine oral antipsychotic drug, and the dosage.
1504584|NCT02935985|Other|Point-of-care bio-markers (cTnI, hsCRP, D-Dimer) and biological parameters (CBC, glucose, cholesterol, LDL cholesterol, triglycerides, fibrinogen)|"Clinical evaluations will be performed, along with collecting venous blood samples for determining point-of-care bio-markers and biological parameters.
Participants will be assessed (clinically or by telephone) over a period of 180 days."
1504585|NCT02935972|Drug|Diazepam|received intravenous diazepam 5 mg slowly just before TRUS probe insertion
1504586|NCT02935972|Drug|Lidocaine 1%|received 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
1504587|NCT02935972|Drug|Diazepam and Lidocaine 1%|received intravenous diazepam 5 mg slowly just before probe insertion and 10 cc of 1% Lidocaine injected into the periprostatic nerve plexus bilaterally under ultrasound guidance
1504588|NCT02935959|Drug|nebulized ketamine|Drugs will be prepared in 3 mL of saline 0.9% before administration by a standard hospital jet nebulizer via a mouthpiece, with a continuous flow of 100% oxygen at 6 L/min for 10 to 15 minutes (30 minutes before GA). Treatment will be stopped when the nebulizer began to sputter.
1504589|NCT02935959|Drug|nebulized Dexmedetomidine|
1504590|NCT02935959|Drug|nebulized midazolam|
1504591|NCT02935946|Other|Cold Liquid Barium|Cold Liquid is defined as being between 4-9 °C. One liter bottles of Poland Spring Natural Spring Water will be kept in the radiology suite to remain at room temperature. As described by Fink and colleagues,(42) the bottled water will be used to mix the barium powder to create a thin liquid consistency, with 50% dilution, which is found to be most similar to human milk and infant formula. After the barium is prepared, 2oz will be poured into a bottle and placed in a refrigerator set to 36°F; this will allow the barium to cool to approximately 4-9°C. Before oral administration, the barium mixture will be measured with a thermometer (TP3001 Digital Thermometer from Red Lantern®) to document the exact temperature.
1504592|NCT02935933|Drug|bupivicaine|Paravertebral block
1504593|NCT02935933|Drug|morphine|
1504594|NCT02935933|Drug|Dexmedetomidine|
1504595|NCT02935920|Behavioral|Individualized, tailored follow-up program|Individualized follow-up in the context of shared decision making, with the use of PRO-data to evaluate the patient needs of consultations.
1504596|NCT02935907|Drug|APG-115|Multiple dose cohorts, PO, every other day of a 28 day cycle
2002506|NCT02149459|Behavioral|low carbohydrate diet|Under close supervision of a dietician, patients will receive a low carbohydrate diet, enriched as necessary with medium chain triglyceride (MCT) supplements.
2002507|NCT02144077|Drug|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
2002508|NCT02144077|Drug|methyl-aminolevulinate|topical treatment for photodynamic therapy combining drug application and subsequent illumination with a narrow spectrum light source (after 3 h of drug incubation)
1504600|NCT02935881|Device|Radio Frequency Ablation (RFA) (Stretta Procedure)|Radio Frequency Ablation (RFA) for the treatment of refractory gastroesophageal reflux disease.
1504601|NCT02935881|Procedure|Sham Procedure|Stretta device will be used but Radio Frequency Ablation (RFA) will not be generated.
1504602|NCT02935855|Drug|Dabigatran|
1504603|NCT02935855|Drug|Apixaban|
1504604|NCT02935855|Drug|Rivaroxaban|
1504605|NCT02935855|Drug|Edoxaban|
1504606|NCT02935855|Drug|Warfarin|
1504607|NCT02935855|Drug|Acenocumarole|
2002509|NCT02141035|Drug|Acetyl-l-carnitine|Those randomized to the treatment arm will receive the medication at 1 g tid for 60 days
1504610|NCT02935829|Other|Glucose as reference food|Ten subjects (male: 6, female: 4) consumed 25g glucose diluted in 250ml water, two times, in different weeks, within 5-10 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
1504611|NCT02935829|Other|White bread as reference food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from white bread along with 250ml water, two times, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
1504612|NCT02935829|Other|Carob snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from carob snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
1504613|NCT02935829|Other|Chocolate cookie snack as test food|Ten subjects (male: 6, female: 4) consumed 25g available carbohydrate from chocolate cookie snack along with 250ml water, one time, in different weeks, within 10-15 min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
1504614|NCT02935829|Other|Carob preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g carob snack). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
1504657|NCT02935569|Device|Compression HeadBand|"commercially available office rubber bands (Alliance® Sterling Rubber Bands, Size 105) OR commercially available medical non-latex bands (Allegience® 1 x 18 x .025) with Velcro adhesion
Plastics disks, hollow (3.5 cm diameter, by 1 cm height)
Two bands will be placed just behind the ears laterally, and over the occipital protuberance posteriorly. The plastic inserts will be placed in the temporal fossae bilaterally, under the band to provide adequate tension on the temporal artery."
1504615|NCT02935829|Other|Chocolate cookie preload|Fifty healthy subjects (male: 22, female: 28) consumed a standardized breakfast (bread and honey) and 2h after were offered a preload given as snack (40g chocolate cookie). Three hours after, subjects were given ad libitum access to a meal (lunch and dessert). The meal consisted of rice, roasted chicken breast and chocolate cake. Foods were weighed before serving and any leftovers were weighed again after meal. Fingertip capillary blood glucose samples were taken before breakfast, 120min after breakfast; before preload, 120minand 180minpost-preload consumption; before meal (lunch and dessert), 60minand 120min post-meal consumption. Subjective appetite ratings were assessed with 100mm VAS.
1504616|NCT02935816|Radiation|Whole body MRI|We have developed and assessed the feasibility of performing whole--‐body multi--‐parametric MRI for staging metastatic disease. We hypothesize that a whole body multi--‐parametric MRI will be more sensitive and specific than conventional imaging staging for detection of metastatic disease in patients with biochemical failure following local therapies. We therefore propose a comparative trial of conventional imaging verses whole--‐body multi--‐parametric MRI within this population of men
1504617|NCT02935803|Procedure|Trans-vaginal Mesh operation|Modified the transobturator TVM operation reported by Sergent et al. by inserting a stabilizing suture, which fixing the anterior edge of the mesh to the paraurethral tissues at the level of the mid-urethra with two non-resolvable anchoring stitches thereby promoting the proper elevation and closure of the urethra
1504618|NCT02935790|Drug|ACY-241|tablet
1504619|NCT02935790|Drug|nivolumab|infusion
1504620|NCT02935790|Drug|ipilimumab|infusion
1504621|NCT02935777|Dietary Supplement|Pomegranate Extract|The first computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, intervention capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
1504622|NCT02935777|Dietary Supplement|Placebo capsule|One computer cognitive testing session lasting approximately 45 minutes is undertaken by participants. After completion, placebo capsules are administered. After a 60 minute absorption period, the cognitive testing session is re-administered.
1504623|NCT02935764|Drug|Irinotecan|180 mg/m2 iv gtt, d1
1504624|NCT02935764|Drug|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
1504625|NCT02935764|Drug|Leucovorin|400mg/m2 iv gtt,d1
1504626|NCT02935751|Other|Lab tests for plasma levels of apixaban and anti-10a factor|All patients will have a blood draw at 48 hours prior to elective surgical procedure and then a second blood draw on the morning of the procedure to test apixaban plasma and anti-Xa levels.
1504627|NCT02935738|Drug|Prednisolone treatment|Infertile men were treated with prednisolone tablet, which is an intermediate acting corticosteroid, po, for 21 days of their wife's menstrual cycles. Briefly, the prednisolone regimen was started with a dose of 5mg, tid, for two weeks followed by 5mg bid for five days. This was further tapered to one tablet of 5mg/day for two days. Patients were then given one week of rest from the treatment, before this prednisolone regimen was repeated for another two cycles.
1504628|NCT02935725|Drug|Low dose AUT00206 800mg|
1504629|NCT02935725|Drug|High dose AUT00206 2000 mg|
1504630|NCT02935725|Drug|Placebo|
1504631|NCT02935725|Drug|Ketamine|
1504632|NCT02935725|Other|Saline|
1504633|NCT02935712|Drug|AZD8601+Placebo (SAD)|"Six subjects are randomized to receive one treatment of AZD8601 and one treatment of Placebo.
Single ascending dose (SAD) with a sequential cohort design and three dose levels of AZD8601 are planned to be investigated. Subjects will receive 0.004 mg per injection of AZD8601/placebo with a total proposed dose of 0.024 mg."
1504634|NCT02935712|Drug|AZD8601+Placebo|Subjects will receive dose with sufficient vascular endothelial growth factor (VEGF)-A protein production and a good safety profile as determined in Part A and the total dose per patient will not exceed the maximum dose given in Part A.
1504635|NCT02935712|Drug|Placebo+Placebo|Subjects are randomized to receive 2 placebo treatments.
1504636|NCT02935699|Drug|Test Drug (JDP-205)|JDP-205 Injection, 10 mg/mL, 1 mL
1504637|NCT02935699|Drug|Active Control (Diphenhydramine)|Diphenhydramine Injection, 50 mg/mL
2002510|NCT02141035|Drug|placebo|The control subjects will receive placebo tablets that are identical in appearance and taste to the active medication tid for 60 days
2002511|NCT02136004|Device|Closer VSS|At the end of a percutaneous endovascular procedure, the femoral arterial access site is closed with the Closer device to achieve arterial hemostasis.
2002512|NCT02128555|Procedure|Total Ankle Replacement|The joints are resurfaced with metal implants and a mobile plastic liner is placed between them as the gliding surface.
2002513|NCT02128555|Procedure|Arthrodesis|The remaining damaged cartilage is removed from the ends of the bone and the two bones are then held together in compression using screws, or plates until they join to become one (bone fusion), so that there is no longer any movement at that joint.
2002514|NCT02128126|Drug|ISA101/ISA101b|Four dose levels ISA101/ISA101b
1504644|NCT02935660|Device|enLighten Laser|Laser tattoo removal treatment
1504649|NCT02935621|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
1504650|NCT02935621|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
1504653|NCT02935595|Drug|Ketamine|Ketamine Hydrochloride Injection
1504654|NCT02935595|Other|Saline solution|Placebo - 0.9% saline solution
1504655|NCT02935582|Drug|Enstilar® aerosol foam|Treatment according to local labelling
1504656|NCT02935582|Drug|Other topical|Treatment according to local practise
1504658|NCT02935556|Other|no intervention|
1504732|NCT02934958|Behavioral|Standard of Care|Patients will be tracked to compare how effective are usual care methods
1504733|NCT02934945|Drug|budesonide 160μg/formoterol 4.5μg|SMART regimen
2002515|NCT02124564|Drug|Lacosamide|"Lacosamide (LCM) immediate-release, film-coated tablets at a strength of 50 mg orally administered twice daily in two equally divided doses.
4-week Titration Period: Starting on LCM 100 mg/day increased by 100 mg/day each week until 400 mg/day dose reached at the beginning of Week 4 .
The AED Withdrawal Period and Monotherapy Period (52- week Evaluation Period plus a Follow Up Period): During the AED Withdrawal and Monotherapy Period, the investigator may increase or decrease the dose of LCM to optimize tolerability and seizure control. The LCM dose may be decreased no lower than 200 mg/day or increased, no faster than 100 mg/day per week, up to 600 mg/day."
1504660|NCT02935530|Drug|s-LMWH|2125KU, subcutaneous injection of 5-10 days
1504661|NCT02935530|Drug|LMWH|4250KU, subcutaneous injection of 5-10 days
1504662|NCT02935530|Drug|Argatroban|20mg, injection for 5-10 days
2002516|NCT02122562|Drug|Ketamine|Treatment
1504664|NCT02935504|Behavioral|PRogram In Support of Moms (PRISM)|"PRISM Intervention Provider and staff training Webinar Delivered in person Engage providers - Registered Nurses (RN) and Patient Care Assistants (PCA) and ensure they attend:
Toolkit Care coordination Psychiatric consultation Implementation support
Engage clinic leaders and staff
Identify leadership group and prepare for change
Assess readiness to implement PRISM
Identify steps to achieve goals
Implement PRISM components into the clinic
Support, encourage and sustain change Office prompts Screening procedures Plus all MCPAP for Moms intervention"
1504665|NCT02935504|Behavioral|MCPAP for Moms|MCPAP for Moms Provider and staff training Delivered via web RN and PCA admin staff recommended to attend 30-60 minute presentation on perinatal depression Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns Access to one-time face-face evaluation with patient by a MCPAP for Moms psychiatrist for assessment and treatment recommendations for Ob/Gyn provider Access to Provider Toolkit which includes assessment and treatment protocols (available at www.mcpapformoms.org) Resource provision/referrals
1504666|NCT02935491|Device|Transcatheter Aortic Valve Implantation (TAVI)|"TAVI is a well-accepted method for aortic valve replacement without surgery. It is currently proposed to patients at high surgical risk or contraindicated to surgery. It consists of introducing a valve inserted inside a stent by the femoral artery in most cases.
Aortic calcifications will be determined by the analysis of the CT-scan performed systematically before the procedure. A semi-automated software (CreaTools) will be used"
2002517|NCT02122562|Other|Alcohol Infusion|Biomarker
1504668|NCT02935465|Behavioral|Mindfulness-Oriented Recovery Enhancement (MORE)|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
1504669|NCT02935465|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
1504670|NCT02935452|Behavioral|GENIE - social networking tool|GENIE is a way to help people think about the links they have with others to manage a health problem (local groups, friends, acquaintances, family members, professionals) and to reflect on their involvement in health and wellness activities and their ability to live an ordinary life with a long term condition. By using GENIE and thinking or talking through the GENIE mapping tool, individuals can visualize their network and can reflect on connections that provide value and resources for managing and where there are gaps in support- this might be social, practical or emotional as well as specifically related to a health condition.
1504671|NCT02935439|Other|Cell Phone|Participants responded to questions about their heart failure symptoms using a cell phone.
2002519|NCT02115607|Drug|Definity infusion|3 ml of Perflutren Lipid Microspheres (Definity) mixed in 50 ml of saline is infused at a rate of approximately 4ml/min
1504674|NCT02935413|Device|tDCS|Device: verum tDCS real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes Behavioral: VRT Vision restoration training, 10 sessions, 20 minutes
1504675|NCT02935413|Behavioral|Standard rehabilitation|Standard rehabilitation procedures involving PC-based training of saccades and visual exploration
1504676|NCT02935400|Drug|Hemin|Hemin will be administered under a separate protocol or for clinical treatment, and samples will be collected under this protocol before and after treatment.
1504677|NCT02935387|Other|Taper|Taper
1504681|NCT02935361|Drug|Atezolizumab|Given IV
1504682|NCT02935361|Drug|Guadecitabine|Given SC
1504683|NCT02935348|Radiation|Whole Body MRI|Routine whole body clinical MRI will be performed according to current clinical standard of care. Axial and coronal imaging from the maxilla to proximal femurs will be performed using a combination of T1 and T2 weighted sequences, with and without gadolinium administration.
2002520|NCT02114775|Drug|Growth Hormone|0.4 mg/day injected subcutaneously for one month then increased to 0.6 mg/day for two months during crossover phase. After crossover phase, 0.6 mg/day for six months
1504685|NCT02935322|Drug|0.12 % chlorhexidine + 0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.
In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
1504686|NCT02935322|Drug|0.2 % NaF mouthrinse|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.
In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
1508532|NCT02906566|Drug|Placebo|Placebo of Retinol
2002521|NCT02114775|Drug|Sildenafil|50 mg by mouth daily
2002522|NCT02114775|Drug|Placebo|Placebo either injected (GH group) or orally (sildenafil group) daily for three months during crossover phase of the study
1504687|NCT02935322|Drug|0.12% chlorhexidine|"In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.
In study II, subjects were asked to rinse with 10ml of the assigned test solution twice daily after tooth brushing during a 6-week period."
1504688|NCT02935322|Other|Placebo|"Contained all basic ingredients as the other three mouthrinses but no chlorhexidine and no NaF. In study I, subjects were asked to refrain from tooth brushing and interdental cleaning and rinse with 10 ml of the assigned test solution for one minute, twice daily (morning and evening) during 4 days.
In study II, subjects were asked to rinse with 10ml of the assigned solution twice daily after tooth brushing during a 6-week period."
1504692|NCT02935296|Behavioral|Integrated Intervention|systems navigation, psychosocial counseling
1504693|NCT02935283|Procedure|MRI|MRI, fMRI, 1H MRS, DTI
1504694|NCT02935283|Behavioral|Behavioral|Battery of executive function tasks
1504695|NCT02935257|Biological|CD19CAT-41BBZ CAR T-cells|Infusion with CD19CAT-41BBZ CAR T-cells
1504696|NCT02935231|Drug|Nicotine Replacement Therapy (NRT)|1-week free NRT (gum/patch) plus a card containing instruction and potential side effects.
1504697|NCT02935231|Behavioral|Minimal Cessation Advice (MCA)|Brief smoking cessation advice using AWARD model. AWARD: (1) Ask smoking habit; (2) Warn about smoking risk; (3) Advice to quit as soon as possible; (4) Refer to smoking cessation service; and (5) Do-it-again: if relapse/fail.
1504698|NCT02935231|Other|Health warning leaflet|An A4 double-side color leaflet containing shocking pictures of diseases associated with smoking.
1504699|NCT02935218|Behavioral|Parenting Skills for Mothers with BPD|The cognitive-behavioral Group Training for mothers with BPD consists of 12 weekly sessions promoting parenting skills including primary needs of children, stress and stress management, dealing with conflicts, mindfulness, emotion regulation, routine and flexibility, the role of the body in parenting, basic assumptions about parenting, and self-care.
1504702|NCT02935192|Biological|Seasonal Influenza Vaccine|Seasonal trivalent split, inactivated influenza vaccine (A/H1N1; A/H3N2 and B); 0.5 mL by IM injection
1504703|NCT02935192|Other|Phosphate Buffered Saline|Phosphate buffered saline, 0.5 mL by IM injection
1504705|NCT02935166|Other|Respiratory muscle training|General high-intensity training consists in maximum effort intervals of 30 seconds duration against an equivalent resistance 0.075 kg / kg of body mass followed by a recovery period of 4 minutes cycle ergometer; the total duration was 3 weeks. They were made in this regard, five weekly sessions of 30 minutes per session, Additionally, randomly, the patients were divided into one of 3 possible groups of respiratory training, which consisted of 5 sets of 10 full breaths (inspiration and expiration) in the morning and afternoon during 3 weeks.
1504706|NCT02935153|Biological|Anti-CD22-CAR-transduced T cells|The first 3 enrolled patients will receive autologous-derived CD22-targeted CAR-T cells on day 1, 2 and 3 with respective 10%, 30% and 60% of the total expected dosage after receiving lymphodepleting chemotherapy. If the 3 patients don't display severe toxicity, the next patients enrolled will get infused in 2 days with respective 40% and 60% total dosage.
1504707|NCT02935127|Procedure|Absorbable suture|Vascular anastomoses will be performed with absorbable materials
1504708|NCT02935127|Procedure|Non-Absorbable suture|Vascular anastomoses will be performed with non-absorbable materials
1504709|NCT02935114|Drug|37% Carbamide Peroxide|"no Gingival dam protection (as manufacturer´s instruction)
37% Carbamide Peroxide application (2 sessions of 45 minutes)
Tooth sensitivity (Verbal and visual scale) and color evaluation"
1504710|NCT02935114|Drug|35% hydrogen Peroxide|"Gingival dam protection (as manufacturer´s instruction)
35% Hydrogen Peroxide application (2 sessions of 45 minutes)
Tooth sensitivity (Verbal and visual scale) and color evaluation"
1504711|NCT02935101|Drug|Prednisolone|formulated for oral administration. encapsulated.
1504712|NCT02935101|Drug|Placebo (for Prednisolone)|Sugar pill manufactured to mimic Prednisolon 10mg capsules
1504713|NCT02935088|Device|Fractional Flow Reserve|Measurement of physiologic parameters
1504714|NCT02935075|Drug|Tenofovir disoproxil|
1504715|NCT02935075|Drug|Lamivudine|
1504716|NCT02935075|Drug|Efavirenz|
1504717|NCT02935062|Behavioral|Traditional Phonological Therapy|Phonological therapy based on generalizing the sounds presented by figures, repetition and naming words.
1504718|NCT02935062|Behavioral|Software Phonological Therapy- SIFALA|The phonological thearapy of this group will be based on software use with phonological model already developed, using naming and repetition of sounds.
1504719|NCT02935062|Behavioral|Placebo Therapy|No intervention to improve speech.
1504721|NCT02935036|Drug|ADPS topical product|topical product
1504722|NCT02935036|Drug|Placebo Control|topical product
1504723|NCT02935023|Radiation|CIRT with systemic therapy arm|carbon ion radiotherapy to the prostate(59.2GyE/16Fx to prostate and seminal vesicle) Systemic therapy:Hormonal therapy (LHRH agonist and/or antiandrogens) or chemotherapy
1504724|NCT02935010|Drug|Esomeprazole|proton pump inhibitor
1504725|NCT02935010|Drug|Bismuth Potassium Citrate|Gastric mucosal protective drug with anti-H. pylori effect
1504726|NCT02935010|Drug|Amoxicillin|antibiotic for H. pylori eradication
1504727|NCT02935010|Drug|Clarithromycin|antibiotic for H. pylori eradication
1504728|NCT02935010|Drug|Metronidazole|antibiotic for H. pylori eradication
1504729|NCT02935010|Drug|Levofloxacin|antibiotic for H. pylori eradication
1504730|NCT02934997|Other|Observational study|
1508533|NCT02906553|Drug|Glyceryl Trinitrate|
1504734|NCT02934932|Drug|Brexpiprazole|Comparison of brexpiprazole to placebo
1504735|NCT02934919|Drug|Nalmefene|30 patients with ICDs, will be treated with 18 mg per day of nalmefene during 3 months
1504736|NCT02934906|Procedure|Standard clinical treatment, including intravenous immunoglobulin and/or platelet transfusion|Observational study.
1504737|NCT02934893|Other|Medication Management Clinic|referral to medication management clinic from primary care
1504738|NCT02934893|Other|Diabetes+Me plus connected glucometer|Use of software and medication modeling tool as add on to medication management standard of care
1504739|NCT02934880|Other|immediate APA program|10 sessions of one hour APA in 5 weeks after patient randomization. 2 sessions per week will be organized
1504740|NCT02934880|Other|delayed APA program|10 sessions of one hour APA in 5 weeks 3 months after patient randomization. 2 sessions per week will be organized
1504741|NCT02934867|Other|Protocol phone advice|Protocol phone advice
1504742|NCT02934867|Other|Usual phone advice|Usual phone advice
1504743|NCT02934841|Drug|Conbercept|
1504744|NCT02934841|Drug|sham|
1504745|NCT02934828|Drug|Neoadjuvant Chemotherapy|Neoadjuvant Chemotherapy: TNBC:paclitaxel (PTX) 175mg/m2 d1, Carboplatin area under the curve（AUC4） d2, q14d*6. HER-2 Positive BC: PTX 175mg/m2 d1, Carboplatin AUC4 d2, q14d*6, and plus Herceptin 2mg/kg qw, 6mg/kg q3w after chemotherapy until 1 year.
1504746|NCT02934828|Drug|postoperative chemotherapy|postoperative chemotherapy: EC-P/D±H, paclitaxel and Carboplatin plus Herceptin(TCH）, EC/TC±H, and so on.
1504747|NCT02934815|Other|Supportive-expressive group therapy|The supportive-expressive group therapy (SEGT) is an intervention for women with BC that is designed to build bonds and to facilitate changes in emotional expression and regulation taking into account the role that emotions play in physiologic function, intimately related to the progression of the disease. It is based on seven main themes: building bonds, expressing feelings, detoxifying dying, reordering life priorities, improve support from and communication with family and friends, fortifying families, dealing with doctors, and control pain and anxiety. Although originally developed according to an existential perspective, recently the supportive-expressive group therapy has been used according to an attachment framework.
1504748|NCT02934802|Device|Total Knee prothesis e motion PS Pro|
1504749|NCT02934789|Procedure|Hysteroscopic myomectomy with Truclear|Hysteroscopic myomectomy with Truclear done on patients with abnormal uterine bleeding and submucosal fibroid(s).
1504750|NCT02934789|Drug|Medical therapy|Medical therapy for patients with abnormal uterine bleeding/ heavy menses and submucosal fibroids.
1504752|NCT02934763|Drug|Propranolol|propranolol iv by target controlled infusion, to achieve specific plasmatic concentration goals
1504753|NCT02934763|Drug|Saline|Saline as placebo
1504754|NCT02934750|Behavioral|Pursed lip breathing|"Pursed lip breathing will be taught to the participants following the chronic obstructive pulmonary disease (COPD) Foundation recommendations:
Breathe in through your nose (as if you are smelling something) for about 2 seconds.
Pucker your lips like you're getting ready to blow out candles on a birthday cake.
Breathe out very slowly through pursed-lips, two to three times as long as you breathed in.
Repeat."
1504755|NCT02934737|Other|Progression of diabetes|
1504756|NCT02934724|Procedure|Self sample from vagina|Self sample using The Rover's Evalyn Brush
1504757|NCT02934724|Procedure|Self sample from the oral cavity|Self sample using COPAN FloqSwab
1504758|NCT02934724|Other|Questionnaire|Questionnaire about vaccination status and sexual behaviour
1504759|NCT02934698|Drug|Ivacaftor|Subjects will be treated with ivacaftor for 6 months and followed for 7 months and will undergo assessments along the way to measure sweat chloride and sputum amounts.
1504760|NCT02934685|Radiation|hypofraction|70 Gy in 28 fractions over 5.6 weeks
1504761|NCT02934685|Radiation|convention|80Gy in 40 fractions over 8 weeks
1504762|NCT02934672|Other|Survey|Internet panelists, who self-reported that they or another adult in their household has osteoarthritis, were sent an email invitation to the survey site.
1504763|NCT02934659|Device|Atlas(TM) Knee System|The Atlas System is an extra-capsular knee implant designed to unload the medial knee.
1504764|NCT02934646|Device|Robotic treatment|Passive/active elbow mobilizzation provided by NEUROExos Elbow Module Robotic device
1504765|NCT02934633|Behavioral|Keeping Baby Safe 2-DVD package|Keeping Baby Safe is a 2-DVD package that teaches childhood injury prevention skills to parents of children from birth to 24 months of age. One DVD addresses automobile passenger safety and focuses on the correct choice and proper installation of child safety seat for the age of the parent's child. The second DVD covers a core set of home safety skills: (a) preventing falls, (b) preventing fires and burns, (c) preventing poisoning, (d) firearm safety, (e) preventing drowning, (f) preventing suffocation and choking, (e) play equipment safety, and (f) animal safety. Content in the home safety DVD is based on information the American Academy of Pediatrics (AAP) recommends that physicians provide to parents during well-baby visits.
1504766|NCT02934633|Behavioral|The Injury Prevention Program (TIPP) sheets|American Academy of Pediatrics The Injury Prevention Program (TIPP) sheets. Paper-based information sheets parents would typically receive from their pediatrician or general practitioner at well-baby visits.
1504767|NCT02934620|Device|CSD500 Condom|CSD500 is a commercial condom that complies fully with the requirements of ISO 4074, the international standard for male latex condoms. The product is designed to increase sexual pleasure.
1504768|NCT02934620|Device|Standard Condom|The standard condom is a standard condom in Vietnam at the time of the study. It is provided for pregnancy and disease prevention.
1504819|NCT02934256|Drug|Icotinib|Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.
1504820|NCT02934243|Device|laryngeal mask insertion|airway management with laryngeal mask
1508534|NCT02906553|Drug|Placebo|
1504769|NCT02934620|Behavioral|Condom Counseling|The intervention arm will receive counseling that briefly addresses condom's dual protection against pregnancy and HIV/STI but that otherwise emphasizes the potential for increased sexual pleasure with CSD500 use. Counseling to this arm also will include CSD500-specific instructions, such as the need to briefly massage the gel inside the condom teat onto the penis head after donning the condom and to not use multiple condoms within a 24-hour period. The control arm will receive standard counseling to use condoms for pregnancy and disease prevention without receiving any messages about the use of condoms for sexual pleasure.
1504770|NCT02934607|Drug|Symbicort pMDI with spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pressurized metered-dose inhaler (pMDI) with a spacer device (test)
1504771|NCT02934607|Drug|Symbicort pMDI without spacer device|Relative bioavailability of budesonide and formoterol delivered via Symbicort pMDI without a spacer device (reference)
1504772|NCT02934594|Other|Palliative Decompression|palliative decompression to MSCC patients: before motor deficit (Group A), within 48 hours after motor deficit (Group B1), 48 hours after motor deficit (Group B2)
1504773|NCT02934568|Drug|LEE011|Single agent LEE011 or in combination with other treatments
1504774|NCT02934555|Drug|Ubiquinol|300 mg Ubiquinol (3 mL liquid Ubiquinol).
1504775|NCT02934555|Dietary Supplement|Ensure|50 mL Ensure
1504776|NCT02934542|Device|AutoLap system|
1504777|NCT02934529|Drug|Irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min., day 1, q d15
1504778|NCT02934529|Drug|Folinic Acid|Folinic acid (racemic) 400 mg/m² iv, 120 min. day 1, q d15
1504779|NCT02934529|Drug|5-FU|5-FU 400 mg/m² bolus day 1, q d15
1504780|NCT02934529|Drug|5-FU|5-FU 2400 mg/m² iv over 46 h day 1-2, q d15
1504781|NCT02934529|Drug|Cetuximab|cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) day 1 + 8
1504782|NCT02934529|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg BW iv over 30 to 90 minutes: day 1
1504783|NCT02934529|Drug|Capecitabine|Capecitabine 1250 mg/m2 2 x day p.o. day 1-14, q d15
1504784|NCT02934529|Drug|regorafenib|160 mg per day (day 1-21) (repeated on day 28)
1504785|NCT02934529|Drug|Irinotecan 125mg|Irinotecan 125 mg/m² iv, 60 - 90 min. weekly (D1, D8, D15, D22)
1504786|NCT02934529|Drug|Cetuximab wkly|Cetuximab initially 400 mg/m² as a 120 min. infusion (≤ 5mg/min); subsequently 250 mg/m² iv respectively as a 60 min. infusion (≤ 10mg/min) weekly (D1, D8, D15, D22, D29, D36)
1504787|NCT02934516|Procedure|Cesarean section|"Abdominal disimpaction with lower uterine segment support: the edge of the lower uterine segment is grasped by 4-5 Allies forceps applied 1.5 to 2 cm apart from the other along the lower edge of the incision until it is completely supported. These forceps are handled by the assistant, and gentle traction is applied upward, perpendicular to the uterine surface and away from the fetal head without excessive force. Accordingly, the hand of the surgeon could be inserted into the uterine cavity, and adequate space for manipulations is available without applying pressure on the lower segment. The fetal head is eventually grasped and delivered.
Classic push method: delivering the head with assistance by pushing the fetal head vaginally"
1504788|NCT02934503|Biological|Pembrolizumab|
1504789|NCT02934503|Drug|Cisplatin|
1504790|NCT02934503|Drug|Carboplatin|
1504791|NCT02934503|Drug|Etoposide|
1504792|NCT02934503|Radiation|Radiation therapy|
1504793|NCT02934490|Device|Mesh|Meshes were made by Gynemech TM PS, (Johnson & Johnson Shanghai Medical Equipment Co. SFDA registration No. 3460365, size 10 × 15cm)
1504794|NCT02934477|Other|Hematopoietic Stem Cell Transplant|This observational study will compare outcomes of prospectively enrolled HCT recipients with outcomes of a cohort of age-matched non-HCT controls.
1504795|NCT02934464|Drug|RAMUCIRUMAB|
1504796|NCT02934464|Drug|Paclitaxel|
1504797|NCT02934464|Drug|FOLFOX 4|
1504798|NCT02934464|Drug|mFOLFOX 6|
1504799|NCT02934464|Drug|XELOX|
1504800|NCT02934438|Dietary Supplement|Neo40|
1504801|NCT02934438|Dietary Supplement|Placebo|
1504802|NCT02934425|Other|Refined carbohydrate-rich breakfast|Refined carbohydrate-rich breakfast containing approximately 8/66/26% kcal from protein/carbohydrate/fat, respectively
1504803|NCT02934425|Other|High pork protein breakfast|High pork protein breakfast containing approximately 35/39/26% kcal from protein/carbohydrate/fat, respectively
1504804|NCT02934412|Drug|SHR-1314|Single subcutaneous injection of SHR-1314 at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
1504805|NCT02934412|Drug|placebo|Single subcutaneous injection of placebo at 5 dose levels (20mg, 40mg, 80mg, 160mg, and 240mg) in healthy subjects.
1504806|NCT02934399|Other|27 hour subcutaneous fluid sampling|"One hour prior to the microdialysis catheter insertion the participants will be asked to receive a local anaesthetic on the injection site for the microdialysis catheter. Lignocaine 1% will be injected subcutaneously at a localised site on the abdomen covering a horizontal area of about 5cm after a brief acclimatisation period at the hospital.
A sterile linear catheter will be inserted using aseptic precautions at the anaesthetised site on the abdomen. The catheter is connected at one end to the microdialysis pump, and at the other end to the automated collection device. Subcutaneous tissue microdialysis samples will be collected regularly for the duration of the sampling period (27 hours)."
1504807|NCT02934386|Device|WinMedical WinPack device|
1504808|NCT02934373|Device|A New Sound Processor|
1504809|NCT02934360|Device|TR(ACE) Assay Testing|Serial plasma testing with TR(ACE) Assay
1504810|NCT02934347|Procedure|25 degree back-up position|To test whether a 25 degree back-up position improves laryngeal views and makes intubation easier compared to the standard horizontal position
2002540|NCT02108951|Drug|Nilotinib|Nilotinib 150mg hard gelatin capsules taken orally
2002541|NCT02106871|Drug|Sildenafil|50mg of Sildenafil daily for 4 weeks
1504814|NCT02934308|Device|Skin Conductance Monitor|
1504815|NCT02934295|Biological|Determination of Anti-Rubella Antibody, E1|
1504816|NCT02934282|Drug|HBOC-201|Hemoglobin Based Oxygen Carrier (HBOC)
1504817|NCT02934269|Drug|Placebo|
1504818|NCT02934269|Drug|CC-90006|
1504821|NCT02934230|Behavioral|Prehabilitation Program|"Strength training: This component consists of 1 set of 10 repetitions of each exercise: a. push-ups (modified to the individual's level of function as either wall push-ups, knee push-ups, or full push-ups); b. seated row (performed with an elastic resistance band); c. chest fly (performed with an elastic resistance band); d. deltoid lift (performed with an elastic resistance band); e. biceps curls (performed with an elastic resistance band); f. triceps extensions (performed with an elastic resistance band); g. chair squats; h. hamstring curls; i. standing calf raises; j. abdominal crunches (modified to be performed seated in a chair)
Aerobics: Walking for 20 minutes at moderate intensity.
Flexibility: Chest, arm, leg and truck stretches, with each stretch to be held for 20 seconds, done for 2 repetitions."
1504822|NCT02934217|Drug|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
1504823|NCT02934217|Drug|Placebo|One single intravenous bolus injection of Placebo
1504824|NCT02934217|Procedure|Echocardiography|3 years after AMI
1504825|NCT02934204|Drug|methotrexate|
1504826|NCT02934204|Drug|temozolomide|
1504831|NCT02934178|Biological|WRSS1|
1504832|NCT02934165|Behavioral|Family Safety 123|Theoretically-based injury prevention videos for families
1504833|NCT02934165|Behavioral|AAP TIPP sheets|American Academy of Pediatrics The Injury Prevent Program materials converted to web-based materials.
1504834|NCT02934152|Drug|H pylori eradication|H pylori eradication
1504835|NCT02934152|Other|H pylori eradication timing|Early or late eradication
1504836|NCT02934139|Drug|Cavosonstat|CFTR modulator that stabilizes CFTR
1504837|NCT02934139|Other|Placebo|Matched placebo
1504838|NCT02934126|Other|breast cancer patients|semi structured face to face interviews
1504839|NCT02934113|Behavioral|iOTA|The Individual Obesity Treatment Approach (iOTA) will assess individual behavior risks, collaborative goal-setting with a health coach, and the use of an interactive text system to provide ongoing support and self-monitoring of behavior change goals.
1504840|NCT02934113|Behavioral|HWPP|Work groups will participate in the Healthy Workplace Participatory Program (HWPP) to adapt and deploy interventions that change their work environments to support healthy eating and physical activity.
1504841|NCT02934100|Device|Shock Master 300|"Extracorporeal Shock Wave Therapy
In all treatments (from 1 to 10) applied number of pulses is 4500 and the frequency is based on the patients feelings (from 8 to 12 Hz). Variable is the pressure:
Treatment 1 - 2,5 Bar; Treatment 2 - 2,6 Bar; Treatment 3 - 2,7 Bar; Treatment 4 - 2,8 Bar; Treatment 5 - 3,0 Bar; Treatment 6 - 3,2 Bar; Treatment 7 - 3,4 Bar; Treatment 8 - 3,6 Bar; Treatment 9 - 3,8 Bar; Treatment 10 - 4,0 Bar.
Each patient will also receive kinesiotherapy treatment that will consist of:
eight-minute massage of posterior lower leg muscles
plantar aponeurosis stretching"
1504842|NCT02934100|Device|Skanlab 25 BODYWAVE|"Electric field diathermy therapy - Capacitive energy transfer system (CETS)
Time of each treatment (from 1 to 15) is eight minutes. Variable is the energy:
Treatment 1 - 3; Treatment 2 - 3; Treatment 3 - 4; Treatment 4 - 4; Treatment 5 - 5; Treatment 6 - 5; Treatment 7 - 6; Treatment 8 - 6; Treatment 9 - 7; Treatment 10 - 7; Treatment 11 - 7; Treatment 12 - 7; Treatment 13 - 7; Treatment 14 - 7; Treatment 15 - 7.
Each patient will also receive kinesiotherapy treatment that will consist of:
eight-minute massage of posterior lower leg muscles
plantar aponeurosis stretching"
1504843|NCT02934100|Device|EVO US13 CosmoGamma|"Ultrasound therapy
Doses applied as following:
Each treatment (from 1 to 15) is pulsed ultrasound (1MHz, pulsed 1:4). Variable is the time and intensity:
Treatment 1 - 4 minutes, 0,4 W/cm2; Treatment 2 - 5 minutes, 0,4 W/cm2; Treatment 3 - 5 minutes, 0,5 W/cm2; Treatment 4 - 6 minutes, 0,5 W/cm2; Treatment 5 - 6 minutes, 0,6 W/cm2; Treatment 6 - 6 minutes, 0,6 W/cm2; Treatment 7 - 6 minutes, 0,6 W/cm2; Treatment 8 - 6 minutes, 0,7 W/cm2; Treatment 9 - 7 minutes, 0,7 W/cm2; Treatment 10 - 7 minutes, 0,7 W/cm2; Treatment 11 - 7 minutes, 0,8 W/cm2; Treatment 12 - 8 minutes, 0,8 W/cm2; Treatment 13 - 8 minutes, 0,8 W/cm2; Treatment 14 - 8 minutes, 0,8 W/cm2; Treatment 15 - 8 minutes, 0,8 W/cm2.
Each patient will also receive kinesiotherapy treatment that will consist of:
eight-minute massage of posterior lower leg muscles
plantar aponeurosis stretching"
1504844|NCT02934100|Device|Sham LASER CTL1106MX|"Sham laser therapy Time of each treatment (from 1 to 15) is four to five minutes. Developed is 10 points, each point takes 15 seconds. Device is unplugged and it does not emit any radiation.The patient does not know that the procedure is not really executed.
Each patient will also receive kinesiotherapy treatment that will consist of:
eight-minute massage of posterior lower leg muscles
plantar aponeurosis stretching"
1504845|NCT02934087|Procedure|Endovascular Aneurysm Repair|Endovascular aneurysm repair (or endovascular aortic repair) (EVAR) is a type of endovascular surgery used to treat pathology of the aorta, most commonly an abdominal aortic aneurysm (AAA)
1504846|NCT02934074|Other|No intervention|
1504847|NCT02934061|Device|Tizaspray® administered intranasally|0,5 mg Tizaspray® administered intranasally
1504848|NCT02934061|Drug|Sirdalud® 2 mg tablets administered|Sirdalud® 2 mg tablets administered in patients with acute low back pain
1504849|NCT02934048|Other|7-day triple regimen guided by AST|Patients in this group will receive a 7-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
1504850|NCT02934048|Other|10-day triple regimen guided by AST|Patients in this group will receive a 10-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
1504851|NCT02934048|Other|14-day triple regimen guided by AST|Patients in this group will receive a 14-day triple regimen to eradicate H. pylori. The regimen is consist of a PPI and 2 susceptible antibiotics which are determined by AST. The susceptibility of amoxicillin, clarithromycin, metronidazole, tinidazole,levofloxacin, furazolidone and tetracycline will be evaluated.
1504852|NCT02934035|Drug|Antidepressant|
1504853|NCT02934022|Drug|Maraviroc|150 mg tablets, two or 4 tablets once daily (dependent upon concommitant medications)
1504854|NCT02934009|Device|Dermal nuclear magnetic resonance (NMR)-profile measurement|Nuclear magnetic resonance (NMR)-profile measurement of the dermis
1504855|NCT02933996|Device|Non TEAS|Patients allocated in the Non TEAS group recieve the electrode patch on the skin, connected electro-acupuncture device, with no current input.
1504856|NCT02933996|Device|TEAS|Patients allocated in the TEAS group receive standardised treatment at 2 acupuncture points (ST36 and BL23). The investigator put the electrode patch on the skin, connected electro-acupuncture device, and select the maximum current intensity patients can endure. The acupuncture treatment starts from 30min prior to operation to the end of surgery, and then four times within 48 hours post operation, 30 minutes for each time.
1504857|NCT02933983|Other|no intervention, compare URT microbiome healthy control group-chronic rhinosinusitis patients|
1504858|NCT02933970|Other|Telemedicine|Patients will be linked with the provider via two-way video-teleconferencing facilitated by an onsite OAT program staff member
1504859|NCT02933944|Biological|TG02-treatment|
1504860|NCT02933944|Drug|Pembrolizumab|
1504861|NCT02933918|Other|Probiotics|
1504862|NCT02933905|Drug|Intravitreal Ranibizumab injection|
1504863|NCT02933892|Procedure|Cardiac Catheterization|Cardiac catheterization is a diagnostic procedure used to treat and diagnose heart conditions.
1504864|NCT02933879|Drug|NVXT topical|topical treatment
1504865|NCT02933879|Drug|Placebo (Vehicle) Topical|topical treatment
1504866|NCT02933866|Drug|DSXS topical|topical treatment
1504867|NCT02933866|Drug|Vehicle topical|topical treatment
1504868|NCT02933853|Drug|Faster-acting insulin aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
1504869|NCT02933853|Drug|Insulin Aspart|A single dose administered subcutaneously (s.c., under the skin). The dose level will be 0.3 U/kg body weight.
1504870|NCT02933840|Device|AlertWatch|AlertWatch holds 510(k) FDA clearance K15335. It is a software program that takes data present in the medical record, including vital signs and laboratory results, and determines whether it meets predetermined thresholds for alerting a clinician. These thresholds are intended to correlate with signs of acute clinical deterioration in the patient being monitored.
1504872|NCT02933814|Drug|Liposomal Bupivicaine|Patients in Group 2 (Liposomal Bupivacaine + Plain Bupivacaine) will be treated intra-operatively with the initial injection of 0.25% bupivacaine 5 - 10 mL (12.5 - 25 mg) delivered to perform a field block of the soft tissue and subfascial plane at the initiation of the procedure.
1504873|NCT02933801|Drug|ODM-201|ODM-201 will be given at a dose of 600 mg BID orally on a continuous basis.
1504874|NCT02933801|Other|Placebo|Placebo will be given at a dose of 600 mg BID orally on a continuous basis.
1504875|NCT02933788|Drug|Cilostazol|Cilostazol sustained release capsule is new drugs developed by Otsuka Korea. This drugs have platelet aggregation inhibiting action, peripheral vasodilating action and endothelial function improving action.
1504876|NCT02933788|Drug|Acetylsalicylic acid|Aspirin may prevent coronary thrombosis in patients with cardiovascular event risk factors, such as ischemic heart disease family history, hypertension, diabetes mellitus, dyslipidemia and obesity.
1504877|NCT02933775|Genetic|CAR-CD19 T cells|Initial dose: A total of 1 - 10×10^7 CAR-CD19 T cells/kg will be administered by 1 - 3 infusions. Subsequent dose will be based on the subject's response to initial dose.
1504878|NCT02933775|Drug|Fludarabine|30 mg/m^2/day×4 days
1504879|NCT02933775|Drug|Cyclophosphamide|500 mg/m^2/day×2 days
1504880|NCT02933762|Drug|JNJ-54175446|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
1504881|NCT02933762|Drug|Placebo|Participants will receive a single oral dose of JNJ-54175446 suspension orally once on Day 1 of part 1 and Day 1 to Day 7 in part 2.
1504882|NCT02933749|Device|SctO2|The non invasive cerebral oxymetry (INVOS-Covidien) has been used to measure cerebral oxygen saturation.
1504883|NCT02933749|Device|BIS|Bispectral index
1504884|NCT02933736|Drug|Ribociclib|
1504885|NCT02933723|Procedure|Blood Draw|Sampling 3 blood draws Day 0 for humoral and CMI 30 ml prior to vaccination (up to 2 week prior to vaccination) Day 7 for CMI 20 ml (+/- 1 day) Day 28 for humoral 10 ml (+/- 3 days)
1504886|NCT02933697|Drug|Apixaban|Patients will be instructed to take one tablet of 2.5 mg twice daily: one tablet in the morning and one in the evening at approximately the same time every day (with about 12 hours gap) irrespective of the time of dialysis.
1504887|NCT02933697|Drug|Phenprocoumon|Subjects in phenprocoumon treatment group will receive phenprocoumon individually adjusted to an INR of 2.0-3.0 as recommended in the appropriate SmPC for AF patients.
1504888|NCT02933684|Drug|Seromycin|Seromycin (aka D-cycloserine) is an analogue of D-alanine and a partial agonist at the NMDA receptor, which facilitates the process of fear extinction.
1504889|NCT02933684|Behavioral|Virtual Reality Exposure Therapy|Allows for delivery of exposure therapy on an iPad. Participants read a speech to a virtual audience. Exposures become increasingly more difficult as the audience becomes more hostile and speeches increase in length and complexity.
1504890|NCT02933684|Drug|Placebo|Administered in pill form.
1504891|NCT02933671|Procedure|Suprainguinal fascia iliaca (SIFI) block|An ultrasound guided nerve block using a medication that numbs the nerve called ropivacaine.
1504892|NCT02933671|Procedure|Sham block|An ultrasound guided nerve block using a medication that does NOT numb the nerve called saline, or salt water.
1504893|NCT02933671|Drug|Ropivacaine|Local anesthetic (numbing drug)
1504894|NCT02933671|Drug|Saline|Salt water placebo
1504895|NCT02933658|Drug|Telmisartan|
1504896|NCT02933658|Drug|Amlodipine|
1504897|NCT02933658|Drug|Rosuvastatin|
1508728|NCT02905045|Drug|placebo|
1504898|NCT02933645|Drug|Insulin|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays or 160 IU of fast-acting human insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray.
1504899|NCT02933645|Drug|Placebo|Subjects administer 2 intranasal sprays into each nostril every minute for 4 minutes, a total of 16 sprays. Sprays contain Insulin Diluting Medium for Novorapid and Levemir (Novo Nordisk A/S, Bagsvaerd, Denmark). The glass spray flasks are produced by AeroPump GmBH, Germany and give 0,1 ml of fluid per spray. To account for the small amount of insulin absorbed into circulation after the insulin nasal sprays, on the placebo day subjects will be administered 2.5 mU/kg of additional intravenous insulin (Actrapid, Novo Nordisk A/S, Bagsvaerd, Denmark) over 15 minutes.
1504900|NCT02933645|Radiation|[18F]-FDG with PET-CT|All subjects will undergo two positron emission tomography (PET) studies. On both visits they are injected with 185 MBq [18F]-fluorodeoxyglucose and scanned with a combined PET and computed tomography scanner.
1504901|NCT02933645|Drug|Hyperinsulinemic euglycemic clamp|All subjects will undergo two hyperinsulinemic euglycemic clamp studies. The insulin infusion will be administered intravenously at a steady rate of 0.25 mU/kg/min for approximately 170 minutes. Glucose will be administered intravenously as a 200 mg/ml fluid to at varying rate to maintain euglycemia.
1504902|NCT02933632|Other|Physical Therapy-SAP|"Day 1) Patients started approach after discharged anesthesia. Patients received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;
Day 2) Patients repeated the exercises learned from day 1. Following the proposed activities patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this second day only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to the next day;
Day 3) Patients repeated the day 2. And the patient who had not started gait training in the day 2, began it on the day 3;
Day 4 and other days) Patients repeated the gait training until the discharge date."
1504903|NCT02933632|Other|Physical Therapy-ARP|"Day 1-1°approach) Patients started after discharged anesthesia. Received verbal orientation and demonstration of the physiotherapy exercises that would strengthen muscles (gluteal and thigh). They were oriented to the decubitus changes and how to leave bed. They practiced 3 repetitions of 12 complete movements for each exercise;
Day 1-2°approach) Patients repeated the exercises learned from day 1-1°approach. Following patients received verbal instructions on gait training and then starting gait training. Patients started gait training on this Day 1-2°approach only if they felt safe and claimed that their pain was controlled. Otherwise, training was postponed to next approach;
Day 1-3°approach) Patients repeat the day 1-2°approach. And the patient, who had not started gait training in the day 1 - second approach, began it in this third approach;
Day 2) Patients repeated three times the day 1-3°approach;
Day 3) Patients repeated three times the day 1-3°approach."
2002559|NCT02095509|Drug|Enoxaparin|Drug class: Low-molecular weight heparin
1504906|NCT02933593|Drug|Labetalol|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
1504907|NCT02933593|Drug|Hydralazine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
1504908|NCT02933593|Drug|nifedipine|To determine which protocol recommended by ACOG for severe hypertension in pregnancy decreases central arterial pressure the fastest, and the most efficaciously.
1504909|NCT02933580|Drug|JNJ-56136379|Participants will receive a single oral dose (tablets) of JNJ-56136379 on Day 1.
1504910|NCT02933580|Other|Placebo|Participants will receive matching placebo tablets on Day 1.
2002560|NCT02095106|Device|Waterproof Cast|
2002561|NCT02095106|Device|Traditional cast|
1504913|NCT02933528|Drug|DSXS Topical product|once daily for 28 days
1504914|NCT02933515|Other|yoga and occupational therapy|group OT addressed fall risk factors, such as risk factors inside and outside and how to best manage them. yoga was delivered in sitting, standing, and floor postures
1504915|NCT02933502|Drug|DSXS topical product|treatment daily for 28 days
2002562|NCT02091583|Dietary Supplement|Butter, sunflower and safflower oil|
2002563|NCT02091583|Dietary Supplement|High Oleic Canola Oil and DHA (HOCO-DHA)|
2002564|NCT02091583|Dietary Supplement|Barley beta-glucan|
2002565|NCT02091583|Dietary Supplement|HOCO-DHA and Barley beta-glucan|
1504920|NCT02933476|Device|Vibrotactile Stimulation|The tactile stimulator is being tested for an off-label use as treatment for Parkinson's disease. There are nodes embedded into the fingertips of gloves that gently vibrate in an alternating pattern. The sensation is similar to the feeling of a phone vibrating. This is a non-significant risk device.
1504921|NCT02933463|Other|Embrace Wetbond|not require an additional bonding agent hydrophilic, fluoride releasing
1504922|NCT02933463|Other|Clinpro sealant|
1504923|NCT02933450|Drug|Patiromer 25.2 g|Single dose of Patiromer 25.2 g
2002566|NCT02081417|Behavioral|Seeking Safety|SS is a present-focused clinical intervention designed to target trauma/PTSD and SUDs.
1504925|NCT02933424|Dietary Supplement|Protein Powder|
1504926|NCT02933411|Other|Genetic Analysis|Blood sample will be drawn to assess the number of participants enrolled that have sequence variation in the von willebrand factor gene and other genes affecting bleeding, clotting and blood vessel biology.
1509440|NCT02899156|Drug|Placebo|0.9% normal saline
2002567|NCT02079090|Drug|Ketofol|0.5 mg/kg Ketamine IV, and 2 minutes later receive 1 mg/kg Propofol (Diprivan).
2002568|NCT02079090|Drug|Fentofol|1 microgram/kg Fentanyl, and 2 minutes later receive 1 mg/kg Propofol (Diprivan)
2002569|NCT02077361|Genetic|rAAV2.REP1 vector|No additional details needed.
2002570|NCT02075047|Drug|placebo oral capsules|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
1504927|NCT02933411|Other|Medical Record Data Abstraction|"The subject's response to intranasal or intravenous desmopressin (DDAVP) challenge as performed as part of standard of care will be recorded. The desmopressin is a drug that increases the clotting factor in blood to prevent bleeding.
Medical and family history including and not limited to age, diagnoses, race/ethnicity, lab values, HMB and low VWF activity diagnoses, and treatment history and outcome will also be recorded."
1504928|NCT02933411|Other|Pictorial Blood Assessment Chart (PBAC) score|PBAC is a pictorial tool to assess menstrual blood loss. Study team will complete the PBAC assessment with each study participants evaluating and measure response to different treatments for menstrual blood loss in the clinic setting between those with VWD versus other bleeding disorders.
1504929|NCT02933411|Other|Complete Bleeding Symptom ISTH Bleeding Assessment Tool|Study participants will complete the ISTH BAT assessment. The ISTH BAT is a questionnaire to aid in the standardized evaluation of the presence and severity of bleeding symptoms.
1504930|NCT02933398|Procedure|Robotic Assisted Nephrectomy|
1504931|NCT02933398|Procedure|Laparoscopic Assisted Nephrectomy|
1504932|NCT02933385|Behavioral|Health Risks assessement|
1504933|NCT02933385|Behavioral|Web-based health discussions|
1504934|NCT02933385|Behavioral|SOS Kitchen website|
1504935|NCT02933385|Behavioral|Health screening|
1504936|NCT02933385|Behavioral|Sporting event|
1504937|NCT02933385|Behavioral|Coaching|
1504938|NCT02933385|Behavioral|Social media plateform|
1504939|NCT02933385|Behavioral|Accelerometer provided|
1504940|NCT02933372|Drug|Varenicline|In experiment 1, Patients will take Varenicline, 1 pill per day or 1 pill twice per day, for 10 days. In Experiment 2, patients will take either Varenicline or placebo initially for 3 weeks, then off for 3 weeks, then back on for 3 weeks.
1504941|NCT02933372|Radiation|PET Scan|"In Experiment 1, 2 different PET scanning sessions, radiotracers will be injected into the participant's vein through an IV (intravenous catheter or plastic tube inserted in an arm vein). A tracer refers to a small amount of a radioactive substance that does not alter body function.
Experiment 2 does not require any PET scans."
1504942|NCT02933372|Other|Evaluation by Investigator|In both arms, the patient will undergo a evaluation of of the participant's parkinsonism, mood, cognition, gait speed, and balance. This will be determined by cognitive testing and medical evaluation by investigator.
1504943|NCT02933333|Biological|GM-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF is a stimulator of the growth and differentiation of hematopoietic progenitor cells committed to neutrophils, monocytes or eosinophils.
1504944|NCT02933333|Biological|G-CSF|Granulocyte colony-stimulating factor (G-CSF) is a hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. G-CSF is a relatively specific stimulator of the growth and differentiation of hematopoietic progenitor cells committed to the neutrophil lineage.
1504945|NCT02933333|Biological|GM-CSF and G-CSF|Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are hematopoietic CSFs that decrease the duration and severity of neutropenia for patients receiving chemotherapy. GM-CSF and G-CSF share a number of biologic activities, GM-CSF seems to be more potent against fungi.
1504946|NCT02933320|Biological|BI-1206 single agent dose escalation phase|BI-1206 single agent dose escalation phase to determine the MTD or MAD and recommended Phase II dose (RP2D) for evaluation of BI-1206
1504947|NCT02933320|Biological|BI-1206 single agent expansion phase|BI-1206 single agent expansion phase at the Recommended Phase 2 Dose
1504948|NCT02933320|Biological|Combination of BI-1206 with Rituximab|An investigation of combination treatment of BI-1206 with Rituximab.
1504949|NCT02933307|Device|HealthPatch|The HealthPatch (Vital Connect) is a wireless patch and continuously measures single-lead ECG, heart rate, respiratory rate, stress, skin temperature, body posture and steps
1504950|NCT02933307|Device|ViSi Mobile|ViSi Mobile (Sotera Wireless) is wireless device that is able to continuously measure all important vital parameters: ECG, heart rate, oxygen saturation, blood pressure, respiratory rate and skin temperature.
1504951|NCT02933294|Procedure|Triportal pulmonary resection surgery|Uniportal video-assisted thoracoscopic surgery
1504952|NCT02933294|Procedure|Uniportal pulmonary resection surgery|Triportal video-assisted thoracoscopic surgery
1504953|NCT02933281|Biological|MTBVAC|Escalating dose levels (5 x 10^3 CFU, 5 x 10^4 CFU, 5 x 10^5 CFU, and 5 x 10^6 CFU
1504954|NCT02933281|Biological|BCG|BCG 5 x 10^5 CFU
1504955|NCT02933268|Dietary Supplement|High water intake|High water intake aimed at achieving an urine osmolality < 270mOsmo/kg. Individualised prescription for each participant based on the free water clearance formula calculation.
1504956|NCT02933268|Other|Ad libitum water intake|Water intake guided by thirst
2002571|NCT02075047|Drug|ziprasidone oral capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dosing design. Dosing is stratified based on weight, with subjects <45 kg having a target dose range of 60-80 mg/day and subjects >/= 45 kg having a target dose range of 120-180 mg/day.
1504959|NCT02933242|Radiation|Stereotactic Ablative Body Radiotherapy|The total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks
1504960|NCT02933229|Device|biopsy|patients enrolled in the study will receive gastroscopy and biopsies in order to evaluate status of pathology.
1504961|NCT02933229|Drug|H. pylori eradication|"H. pylori eradication therapy comprising esomeprazole, amoxicillin,clarithromycin and colloidal bismuth pectin.
If failed in eradicating H. pylori, a culture based antimicrobial susceptibility test will be used to guide H. pylori eradication."
1504962|NCT02933190|Procedure|transvaginal surgery；UAE and D&C|For cesarean scar pregnancy treatment
1504993|NCT02932930|Procedure|QLB bloc|
1504994|NCT02932930|Drug|0.2% Ropivacaine|0,2ml/kg of 0,2% ropivacaine
1504995|NCT02932930|Drug|0.9% normal saline|0,2ml/kg of 0.9% normal saline
1505156|NCT02931747|Dietary Supplement|Bacopa Monnieri 300 mg/day|Subjects are received Bacopa Monnieri at the dose of 300 mg/day once daily for 16 weeks.
1504963|NCT02933177|Behavioral|2 months control condition - 4 months chariot-flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.
The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):
Boards of known photographs to recall autobiographical memories
Newspapers to read, talk, associate memories around an article
Massage Oil, refreshing wipes, cream to reconnect with the body
Clay, cookie pieces, washable felt and paper to create shapes, draw.
Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .
Listening to music
Relaxation-Breathing
Cushion, foam balls to vent his energy on secure hardware.
Plush doll or to invest a vector object of affection and empathy
Sensory flash balls that the patient can squeeze, throw, roll.
Games with which the patient can play according to its possibilities."
1504964|NCT02933177|Behavioral|4 months control condition-2 months chariot flash|"The control condition is to propose the usual procedures for the management of productive symptoms during the emergence or increase of these symptoms.
The chariot-flash condition is a chariot with eleven drawers. Each drawer contains an activity (lasting about 15 minutes):
Boards of known photographs to recall autobiographical memories
Newspapers to read, talk, associate memories around an article
Massage Oil, refreshing wipes, cream to reconnect with the body
Clay, cookie pieces, washable felt and paper to create shapes, draw.
Walk with a person of the healthcare team the case of behavioral disorders in type of ambulation and untimely exit .
Listening to music
Relaxation-Breathing
Cushion, foam balls to vent his energy on secure hardware.
Plush doll or to invest a vector object of affection and empathy
Sensory flash balls that the patient can squeeze, throw, roll.
Games with which the patient can play according to its possibilities."
1504965|NCT02933164|Device|Continuous Glucose Monitoring System|Effectiveness and safety of a Continuous Glucose Monitoring System
1504966|NCT02933151|Dietary Supplement|Nutritional Supplement|Selection of which supplement to give to the patients will be left to the dialysis unit's governing body as this study is not interested in a specific supplement's effect on nutrient restoration and subsequent outcomes but rather on oral replacement of amino acids regardless of the agent used.
1504967|NCT02933125|Behavioral|Group psychotherapy|"Motivational enhancement psychotherapy (MEP) for Youths:
The participating youths have to attend one session a week for 10 weeks of a group program for relapse prevention based on motivational enhancement ideas and led by two experienced psychologists from the hospital.
Parenting skill training (PST) for Caregivers:
The PST program for the youths' caregivers also consist of 10 weekly, 120-minute sessions that were led by a senior consulting psychologist."
1504968|NCT02933125|Behavioral|Standard supervision|The standard supervision by the protection officers in Taiwan's Kaohsiung Juvenile and Family Court provide the adolescents with moral education, as well as counseling in their work or studies.
1504969|NCT02933112|Device|Auto-titrating mandibular positioner test|Participants will undergo a theragnostic test using the auto-titrating mandibular positioner to determine if they are eligible candidates to use oral appliance therapy for their obstructive sleep apnea. The device works by moving the lower jaw forward in response to respiratory events while the participant sleeps. All participants will undergo the same test.
1504970|NCT02933099|Drug|Aprepitant+palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus palonosetron 0.25 mg IV and dexamethasone (20 mg orally on day 1 and 8 mg orally on days 2 and 3)
1504971|NCT02933099|Drug|palonosetron+dexamethasone|Patients will receive the chemotherapy drugs as well as the following antiemetic drugs: palonosetron 0.25 mg IV and dexamethasone (12 mg orally on day 1 and 8 mg orally on days 2 and 3)
1504974|NCT02933073|Biological|OncoImmunome|The OncoImmunome will be a substance composed of a mixture of seven to ten peptides each containing 17-18 amino acids. Given that the vaccine will be tumor-specific based upon mutant peptide sequences identified in each tumor transcriptome, the vaccine for each patient will likely be a unique composition.
2002576|NCT02074761|Device|SImmetry|"The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.
The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
1504977|NCT02933047|Procedure|Outpatient LH|
1504978|NCT02933047|Other|Physical activity|In both arms physical activity will be measured by a pedometer before and after surgery.
1504979|NCT02933047|Other|Diary.|All participants will fill out a diary with a range of questions on anxiety, depression, well-being today, use of medication, pain records and how they sleep.
1504980|NCT02933047|Procedure|Inpatient LH|
1504981|NCT02933034|Drug|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|"EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT
CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)
CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI"
1504982|NCT02933021|Other|Blood sample taken|
1504983|NCT02933021|Other|Answering a lifestyle questionnaire|
1504984|NCT02933021|Other|Phone call from researcher|To enquire about status of participants monoclonal gammopathy of unknown significance, and whether there has been progression to multiple myeloma.
1504985|NCT02933008|Other|aNMT biofeedback|neuromuscular training intervention that incorporates biofeedback training
1504986|NCT02932969|Drug|BMS-986231|
1504987|NCT02932969|Drug|BMS-986231 Placebo|
1504988|NCT02932956|Genetic|GAP T cells|"Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule. The following dose levels will be evaluated:
DL1: 1x10^7/m2 DL2: 1x10^8/m2 DL3: 1x10^9/m2
The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
1504989|NCT02932956|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously.
1504990|NCT02932956|Drug|Fludara|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously.
1504996|NCT02932917|Device|MapMySmoke|Each patient in the study arm will download and install the MapMySmoke app to record all of their smoking and craving events. The app will generate a quantitative summary of their smoking behavior during a pre-quit phase, and will provide dynamic text support messages during the post-quit phase. The app will also capture spatial details of any relapse events during the post-quit phase.
1504997|NCT02932904|Drug|Vortioxetine|Vortioxentine Overencapsulated Tablet
1504998|NCT02932904|Drug|Paroxetine|Paroxetine Overencapsulated Tablets.
1504999|NCT02932904|Drug|Placebo|Vortioxetine Placebo-matching Capsules.
1505000|NCT02932891|Drug|DSXS topical|topical treatment
1505001|NCT02932878|Drug|DSXS topical|topical treatment
1505002|NCT02932852|Procedure|Lipoaspiration|The patient will have a liposuction surgery from which the autologous ADAS cell to transplant in the cornea will be obtained.
1505003|NCT02932852|Procedure|Transplantation|The ophthalmologist will carry out the transplantation of the ADAS cells with or without scaffold in the intrastromal cornea of the patient
1505004|NCT02932839|Device|NeuroPort micro-electrode array|Implantation of the Blackrock NeuroPort micro-electrode array for up to 29 days in patients who are undergoing evaluation with intracranial EEG electrodes
2002577|NCT02068586|Drug|Sunitinib|Given PO
2002578|NCT02068586|Drug|Valproic Acid|Given PO
2002579|NCT02065167|Biological|Cultured autologous Mesenchymal Cells|Cultured Mesenchymal Cells from bone marrow isolation, expanded under GMP protocol in associated facilities and introduced at the end of the appropriate forage up to the femoral head under fluoroscopic control.
1505008|NCT02932800|Procedure|"Fixation with ballerina technique and flip"|
1505009|NCT02932800|Procedure|Habitual Fixation|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture
1505010|NCT02932800|Other|Evaluation on the third and fift days, filogisticos and infectious signs, fixing loss, and culture|
1505011|NCT02932787|Device|Height-adjustable workstation|
1505012|NCT02932774|Drug|Cetirizine|Cetirizine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
1505013|NCT02932774|Drug|Loratadine|Loratadine HCl 10 mg (1 mg/ml) syrup once daily before 10:00 AM for 2 weeks
1505014|NCT02932774|Other|Placebo|Placebo syrup once daily before 10:00 AM for 2 weeks
1505015|NCT02932761|Drug|GnRHa|Two doses of GnRHa were administered by subcutaneous injection. The first dose was injected at the time of hysteroscopy examination, and the second dose was administered one day after the VR surgical procedure.
1505016|NCT02932761|Procedure|Vaginal repair of CSD|The procedure of vaginal repair of CSD was shown as following. The bladder was dissected away carefully from the uterus toward the abdominal cavity until the peritoneum was reached. The CSD tissue was cut to the normal healthy muscle after the abdominal cavity had been entered, and the lower uterine segments had been completely exposed. A double layer of 1-0 absorbable interrupted sutures was used to close the incisions.
1505017|NCT02932748|Dietary Supplement|Portion Controlled Meals (PCM)|Portion controlled meals provide conveniently packaged, low-energy, high-nutritional content food.
1505018|NCT02932748|Behavioral|Group Phone (GP)|Weight management program delivered via group conference call.
1505019|NCT02932748|Dietary Supplement|Conventional Diet|Conventional diet (CD) will consist of a nutritionally balanced, reduced energy, high volume, lower fat (fat= 20-30% energy) diet based on USDA's MyPlate recommendations.
1505020|NCT02932748|Behavioral|Individual Phone (IP)|Weight management program delivered via individual phone call.
1505021|NCT02932748|Behavioral|Enhanced Usual Care (EUC)|Weight management topics delivered face-to-face at clinic office every 6 months.
1505022|NCT02932722|Other|Control|Patients in the control groups do not receive any anesthetic during remote ischemic preconditioning.
1505023|NCT02932722|Drug|Propofol|Patients in the propofol group receive propofol anesthesia during remote ischemic preconditioning.
1505024|NCT02932722|Drug|Sevoflurane|Patients in the sevoflurane group receive sevoflurane anesthesia during remote ischemic preconditioning.
1505025|NCT02932709|Behavioral|suicide attempt|suicide attempt : We evaluated the effectiveness of telephone follow-up of patients who had referred to an emergency psychiatric unit for attempted suicide on any further attempt/s over the following year.
1505026|NCT02932696|Other|Cardiac training program|"This program takes place at the Cardiovascular Rehabilitation Department at the Nîmes University Hospital and includes a combination of various physical activities: treadmill, exercise bike, rower, aerobics, gymnastics, serious games, swimming. The program begins approximately 4 weeks after myocardial infarction and consists of 20 consecutive days of training. The main physical activity is aerobic interval training (AIT).
30-minute AIT sessions will occur 5x per week for 4 weeks.
1 AIT session includes a warm up for 8 minutes to reach a heart rate during exercise corresponding to 20 to 30% of maximum aerobic power determined during the initial effort test. Then interval training occurs with 4x2 min of high intensity effort (heart rate during exercise corresponding to 80% of maximum aerobic power) alternating with 2 min of active recovery at 20-30% of maximum aerobic power. Then recovery for 8 minutes."
1505027|NCT02932683|Device|MedNav|MedNav is a tablet based platform that uses auditory and visual cues to prompt people to perform the correct steps in neonatal resuscitation.
1505028|NCT02932670|Other|costoclavicular nerve block|ultrasound-guided costoclavicular nerve block
1505029|NCT02932657|Other|Non interventional study|First individual interviews will be set up with teenagers of Nantes University Hospital . Then, focus group will be conduct with patients and professionals in Nantes and Foch University Hospital.
1505030|NCT02932644|Other|Baseline serum vitamin D level below 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
1505031|NCT02932644|Other|Baseline serum vitamin D level at or above 50 nmol/l|There is no medical intervention. The two groups are simple allocated depending on serum levels of D-total at the time of diagnosis
2002580|NCT02064309|Device|Beta-Air device for encapsulation of transplanted human islets|
2002581|NCT02059876|Drug|carboplatin and paclitaxel and or without trastuzumab|dose-dense(biweekly) carboplatin and paclitaxel and or without trastuzumab as neoadjuvant treatment in early breast cancer
2002582|NCT02057952|Behavioral|Education and exercise|The active groups will meet twice a week for 75 minutes over six months. They will be followed for an addition six months to monitor maintenance.
1505032|NCT02932631|Other|THERAPY CONTROL AND MOVEMENT OF INDUCTION|"Volunteers conventional physiotherapy group will stretching, strengthening and / or mobilization and functional training of the affected muscles with 3 sets of 10 repetitions for 60 minutes.
The restriction therapy group and induction motion the volunteers will wear a brace on the top healthy member to be restricted in each session during the exercises for this group for a period of 60 minutes, encouraging tasks involving activities of daily living and / or daily. In group practice mental, the volunteers listen to a CD that in the first two minutes, will promote progressive relaxation where imaginary in a calm and quiet place followed by 13 minutes of listening to the restriction therapy exercise protocol and motion induction. The association group practices and mental restriction therapy, volunteer listens to the CD for 15 minutes following the same procedures mentioned in group practice mental, followed by exercises functional activities for 45 minutes in the paretic limb."
2002583|NCT02057211|Biological|autologous mesenchymal stem cell transplantation|
2002584|NCT02057211|Procedure|sham transplantation of mesenchymal stem cells|Placebo control for transplantation of mesenchymal stem cells
1505037|NCT02932592|Device|Continuous Glucose Monitoring System (i Pro 2 - Medtronic)|This device can register blood glucose values and excursions. This device consists of a needle (applied in subcutaneous way) and of a recording device.
1505043|NCT02932566|Drug|Pirfenidone|Pirfenidone is an orally bioavailable, small molecule antifibrotic agent.
1505044|NCT02932566|Drug|Placebo|Placebo capsule, manufactured with the exact components of the Pirfenidone capsules, without the active ingredient / investigational medicinal product
1505045|NCT02932553|Device|BVS+OMT|bioresorbable vascular scaffold implantation plus optimal medical treatment
1505046|NCT02932540|Other|change of head position|patient can be allocated to the transient change of the head position, persistent lying flat position in the first 24 hours of the hospital admission and persistent sitting up in the first 24 hours of the hospital admission
1505047|NCT02932527|Behavioral|Questionnaire about cannabis consumption|Questionnaire about cannabis consumption will be assessed to infertile male exposed to cannabis and infertile male not exposed to cannabis.
1505048|NCT02932527|Procedure|blood intake|blood intake is done for infertile male exposed and infertile male not exposed.
1505049|NCT02932527|Procedure|Semen samples collection|Semen samples are collected for infertile male exposed and infertile male not exposed.
1505050|NCT02932514|Device|Eversense (Senseonics) Continuous Glucose Monitoring System|"Evaluate accuracy of Eversense CGM System to SMBG Meter.
Compare performance between abdomen and arm insertion sites.
Determine the usability of the Eversense System in a home-use setting for 180 days."
1505051|NCT02932501|Procedure|Conservative treatment|Disinfectant mouth rinses, Antibiotic therapy, Antifungal therapy
1505052|NCT02932501|Procedure|Surgical treatment|Superficial debridement, Complete removal of necrotic bone, Complete bone resection, When applicable revision and soft tissue coverage
1505053|NCT02932501|Procedure|Adjuvant non-surgical treatment|Hyperbaric oxygen therapy Pentoxifylline and tocopherol Ozone therapy Low level laser therapy Pain relief Anti-inflammatory treatment Platelet rich plasma Parathyroid hormone and teriparatide Bone morphogenetic protein
1505054|NCT02932488|Drug|Sumatriptan|Sumatriptan is a 5-HT1B receptor agonist used for treatment of migraine attacks
1505055|NCT02932475|Drug|Metformin|1000 mg twice a day
1505056|NCT02932475|Drug|Placebo|Delivered to match active drug
1505057|NCT02932462|Drug|DSXS|topical product
1505058|NCT02932462|Drug|Placebo|topical product
1505059|NCT02932436|Drug|Empagliflozin|10 mg per os daily for 12 weeks
1505060|NCT02932436|Drug|Placebo|amount of Placebo corresponding to empagliflozin 10 mg per os daily for 12 weeks
1505061|NCT02932423|Other|Control product E|Plain water
1505062|NCT02932423|Other|Test product A|Beverage with no sugar but sweetener
1505063|NCT02932423|Other|Test product B|Beverage with 22 g/L sugar and sweetener
1505064|NCT02932423|Other|Test product C|Beverage with 33 g/L sugar and sweetener
1505065|NCT02932423|Other|Test product D|Beverage with 47 g/L sugar and sweetener
1505066|NCT02932423|Other|Comparative product F|Beverage with 98 g/L sugar
1505067|NCT02932410|Drug|Macitentan|Dispersible tablet; Oral use
1505068|NCT02932410|Other|Standard-of-care|Standard-of-care as per site's clinical practice which may comprise treatment with PAH non-specific treatment and/or up to two PAH-specific medications excluding macitentan and i.v./s.c. prostanoids.
1505069|NCT02932397|Drug|Intravenous dose of 0.5 mg/kg of propofol|
1505070|NCT02932397|Drug|Intravenous dose of 0.05 mL/kg of saline solution|
1505071|NCT02932384|Behavioral|Intervention-Passport and Peer Mentor|In addition to the passport and incentives described below for the control condition, participants assigned to the intervention will select a peer mentor trained in motivational interviewing. The mentor will help guide the participant to complete passport items and address priorities. Participants will also be incentivized for regular meetings with his peer mentor.
1505072|NCT02932384|Behavioral|Control-Passport Only|"A trained staff member will use a needs assessment and the participant's own priorities to develop a 'Passport to Wellness,' a personalized set of services whose access may encourage HIV prevention or address barriers to HIV testing.
Example passport items include: getting an HIV test, attending an informational session about PEP/PrEP, meeting with a PrEP provider, attending 12-step meetings, yoga classes, a massage or Reiki session, or reviewing specific HIV prevention information online. Participants will be incentivized for each passport item they complete."
1505073|NCT02932371|Device|ECOM™.|
1505074|NCT02932371|Device|Trans-esophageal echography|
1505075|NCT02932358|Other|Flexible Family Visitation Model (FFVM)|Visitation to ICU patients allowed during the period of 12 consecutive hours per day.
1505076|NCT02932358|Other|Restrictive Family Visitation Model (RFVM)|Visitation to ICU patients allowed during intermittent periods according local ICU regulation.
2002585|NCT02056236|Drug|Anti-epileptic drugs|"Recommendations for the treatment of status epilepticus are based on recent international guidelines for treatment of overt status epilepticus.
The objective of treatment with AED is to suppress all epileptiform activity. There is no clear proof that induction of a burst-suppression pattern is of additional value and induction of burst suppression is therefore not obligate. If the electroencephalographic status epilepticus returns after tapering sedative treatment at 24 hours, the procedure will be repeated. If the status returns after 2 x 24 hours, it will be considered refractory.
Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
1505081|NCT02932319|Device|Foley catheter|The Foley cathter will be inserted at term + 4 days for 24 hours.
1505082|NCT02932319|Other|expectative|expectative until the next day befor starting the induction
1505083|NCT02932306|Drug|IDP-121 Lotion|Lotion
1505084|NCT02932306|Drug|IDP-121 Vehicle Lotion|Vehicle
1505085|NCT02932293|Drug|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
1505087|NCT02932267|Drug|Adapalene 0.3% / BPO 2.5% gel|
1505088|NCT02932254|Drug|Magnesium Sulfate|After 90% of baseline T4 / T1, are injected intravenously magnesium sulfate 60 mg/kg over 10 minutes (100 mL solution).
1505089|NCT02932254|Drug|Saline|After 90% of baseline T4 / T1, are injected intravenously saline solution over 10 minutes (100 mL solution).
1505091|NCT02932228|Other|ImPACT|"The ImPACT team offers the following services:
An intensive intake process, including a home visit if deemed appropriate
Frequent contact (in-person, telephone, or secure messaging) tailored to a patient?s needs
After-hours access to on-call team member in order to avoid unnecessary emergency care
Optimization of chronic condition management using evidence-based protocols
Navigation of transitions between hospital and home
Coordination of specialty care, including contact with specialists when indicated
Rapid response to signs of health status deterioration or other stressful events
Assess patient goals, advance directives, Physician Orders for Life-Sustaining Treatment"
1505092|NCT02932215|Drug|lorcaserin|Open label
1505093|NCT02932215|Other|Fitbit Charge HR|This is actually not an intervention- it is a tool to measure activity and sleep; all participants will be receiving one to collect data
1505094|NCT02932202|Other|Longitudinal Nutritional Counseling|
1505095|NCT02932202|Other|Standard Care|
1505096|NCT02932189|Device|Inspiratory muscle training|For the inspiratory muscle training, an isokinetic device (K5 Power Breath, United Kingdom) will be attached to the artificial airway.
1505097|NCT02932176|Device|Non-invasive vascular testing|Results of clinically indicated non-invasive vascular testing will be used to develop a machine learning algorithm
1505098|NCT02932176|Device|machine-learning algorithm|
1505099|NCT02932150|Drug|TAF|25 mg tablet administered orally once daily
1505100|NCT02932150|Drug|Placebo|Tablet administered orally once daily
1505101|NCT02932137|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2）
1505102|NCT02932137|Drug|glucocorticoid|Patients receive high or low does glucocorticoids according to their disease activity.
1505103|NCT02932124|Device|mechanical chest compression device|
1505104|NCT02932111|Procedure|osteopathic session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
1505105|NCT02932111|Procedure|Placebo manipulative session|3 osteopathic manipulative sessions. An six-week double-blind treatment period lasting from week 2 (Visit V1) until week 6, Visit 3.
1505106|NCT02932098|Behavioral|Discharge instructions reminders|"Week 1, Day 1: Click through each discharge instruction; Week 1, Days 2-7: Click through single list of all discharge instructions.
Participants will receive a reminder of discharge instructions everyday for the first week post-discharge."
1505107|NCT02932098|Behavioral|Prompts to report symptoms via the web-enabled app|Group will receive reminders to enter new symptoms or changes in symptoms (based on a Likert scale or Y/N) on the following schedule: Week 1 (daily), Week 2 (every other day), Weeks 3-4 (once per week)
1505108|NCT02932098|Behavioral|Clinical Alerts|Alerts based on certain response thresholds are generated to inform the patient's care team of any concerning responses or trends that emerge from the patient reported outcomes. These alerts will inform providers of particular patient-related adverse events or symptoms requiring an intervention prior to the point that emergent medical care is needed. Information in the alert emails will include the participant's Medical Reference Number (MRN), initials, date of birth, and details about the symptom(s) that generated the alert. Pod nurses instructed to respond to any clinical alerts (sent via email) as soon as possible following standard of care.
1505109|NCT02932085|Device|Neurostar TMS Therapy System, NeuroStar XPLOR System|Repetitive transcranial magnetic stimulation
1505110|NCT02932059|Behavioral|Metamemory|Metamemory evaluation using a sentence construction strategy
1505111|NCT02932046|Dietary Supplement|Standardized noon meal|"The meal is treatment as usual in the specialized somatic stabilization ward for patients with severe anorexia nervosa."
1505112|NCT02932033|Procedure|Tack fixation of mesh|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) or spiral titanium tacks (active comparator) according to the result of randomization
1505113|NCT02932033|Procedure|Synthetic glue fixation|hernia mesh is fixed with synthetic glue (Histoacryl) (experimental) according to the result of randomization
1505114|NCT02932020|Drug|AlloGen-LI|interlaminar epidural injection of 2mL 0.5% marcaine and one 2-ml dose of AlloGen-LI
1505115|NCT02932020|Drug|depomedrol|interlaminar epidural injection of 2mL 0.5% marcaine and 1mL steroid (depomedrol 80mg/ml)
1505116|NCT02932020|Device|MRI|contrast enhanced MRI of the lumbar spine performed at Visit 1 and Visit 6 weeks (+7 days)
1505117|NCT02932020|Drug|0.5% marcaine|epidural injection of 2mL 0.5% marcaine
1505157|NCT02931747|Dietary Supplement|Bacopa Monnieri 600 mg/day|Subjects are received Bacopa Monnieri at the dose of 600 mg/day once daily for 16 weeks.
1505118|NCT02932007|Drug|Chloroquine Phosphate|Two tablets of study drug are to be taken on the day of study drug initiation and the next day, followed by one tablet each day for the next 12 days. Study drug to be orally administered and taken with food.
1505119|NCT02931994|Other|Knotted floss technique|The subjects use the knotted floss technique. In this modification of conventional flossing technique, a knot is tied in the floss at any distance in the middle third of the floss length. The floss is inserted past the interdental contact point by the conventional finger flossing technique in the non-knotted area and then during the 'to and fro movement' on the tooth surface cervical to contact point, the knotted area is engaged through the embrasure (Gomes et al 2016)
1505120|NCT02931981|Procedure|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
1505121|NCT02931968|Device|Monolithic zirconia prosthesis|Edentulous arch subjects treated with a monolithic zirconia implant supported fixed dental prosthesis.
1505122|NCT02931955|Other|Blood draw, stool collection.|Blood will be drawn by certified personnel according to local regulations. Stool will be collected by the patients after instructions on how to use a stool collection kit.
1505123|NCT02931942|Other|blood withdrawn|venous blood sampling
1505124|NCT02931929|Drug|68Ga-NeoBOMB1, 2-vial kit|intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)
1505125|NCT02931903|Other|Vita Enamic (hybrid dental ceramic)|Vita Enamic (hybrid dental ceramic) are provided as blocks to be milled using Computer aided design/Computer aided manufacturer (CAD/CAM) technology,
1505126|NCT02931903|Other|lithium disilicate glass-ceramic|All ceramic crowns (Lithium disilicate glass ceramic) milled by Computer aided design/Computer aided manufacturer (CAD/CAM) technology
1505127|NCT02931890|Drug|Docetaxel|3 weekly course of docetaxel i.v in arm 1 and 2
1505128|NCT02931890|Drug|Oxaliplatin|3 weekly course oxaliplatin as a 2 hr i.v. in arm 1 and 2
1505129|NCT02931890|Drug|Capecitabine|oral capecitabine in arm 1 and 2
1505130|NCT02931890|Procedure|gastrectomy|resection of gastric cancer after pre-operative chemotherapy for all arms
1505131|NCT02931890|Radiation|radiotherapy of gastric cancer|5 weeks of radiation, 5 times a week with a total of 45 Gy (in arm 2 and 3)
1505132|NCT02931890|Drug|Paclitaxel|5 weeks of paclitaxel i.v once a week (in arm 2 and 3)
1505133|NCT02931890|Drug|Carboplatin|5 weeks of carboplatin i.v once a week (in arm 2 and 3)
1505134|NCT02931877|Drug|sevoflurane|
1505135|NCT02931877|Drug|propofol|
1505136|NCT02931877|Other|control|
1505137|NCT02931864|Other|Online mindfulness training|5 weekly sessions of online self-administered mindfulness training programme in which they will receive audio-recorded and video-recorded instructions, pictorial or text-based instructions for various mindfulness exercises such as body scan meditation, mindful breathing and walking meditation.
1505138|NCT02931864|Other|Online symptom management|5 weekly online education module in which they will receive video-recorded, audio-recorded, pictorial or text-based instructions for various self-management strategies. Topics include fatigue, pain, numbness/tingling, lymphedema, anxiety/depression, and problems with sleeping.
1505143|NCT02931825|Behavioral|Reminder letter|"The letter will consist in several parts:
Reminder of : -the need of individual follow-up for high risk people for colorectal cancer AND - the general recommendations (one colonoscopy every 5 years)
Recommendation to consult their general practitioner or gastroenterologist if they haven't done their follow up
Request information if they've done their follow-up or if we have incorrect information
Indication that the letter is sent as part of a surveillance program specific for high risk people for colorectal Cancer"
1505144|NCT02931799|Behavioral|Nurse Follow-Up|Organized follow-up with an IBD advanced practice nurse at 24-48 hours, 7 days, and 30 days post-discharge; to monitor patients' health status with respect to their IBD.
1505145|NCT02931799|Other|Electronic Monitoring|"Patients will be provided access to a web-based application entitled: 'Health Promise'. The application will generate surveys every 3 days, where patients will self-report their IBD symptoms, quality of life and medication adherence on three separate scales:
PRO-2 Scale for patients with Crohn's Disease
6-Point Mayo Score for patients with Ulcerative Colitis
Morisky Medication Adherence Scale (MMAS-4)
The survey responses will be monitored by an IBD advanced practice nurse, to triage patients for outpatient follow-up."
1505146|NCT02931799|Other|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis; and Patient Satisfaction with the 'Health Promise' application.
1505147|NCT02931799|Other|Post-Discharge Questionnaire|Patients will complete a web-based questionnaire at 30 days post-discharge. The questionnaire will capture information related to: Demographics, Patient Satisfaction as measured by the CACHE questionnaire; IBD related quality of life as measured by the IBDQ questionnaire; Disease activity as measured by PRO-2 scale for Crohn's Disease or 6-Point Mayo Score for Ulcerative Colitis.
1505148|NCT02931799|Other|Standard of Care|Discharge summary detailing inpatient IBD admission; in addition to outpatient follow-up with a Gastroenterologist post-discharge
1505149|NCT02931786|Drug|propofol|propofol, midazolam and atropine administration via intravenous cannula.
1505150|NCT02931786|Drug|Ketamine propofol mixture|Administration of ketamine propofol mixture, midazolam and atropine via intravenous cannula
1505151|NCT02931786|Drug|midazolam and atropine|
1505152|NCT02931773|Device|Task Force® Monitor|A head up tilt test carried out with a Task Force monitoring system
1505153|NCT02931760|Device|subcutaneous pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
1505154|NCT02931760|Device|intramuscular pacemaker|During implant of a pacemaker the device is either implanted subcutaneously or intramuscular
1505155|NCT02931747|Dietary Supplement|Placebo|Subjects are received Placebo once daily for 16 weeks.
1505497|NCT02929199|Other|All ceramic crown|Pressed E-Max coping veneered with E-max veneering system
1505158|NCT02931734|Drug|Resin modified glass ionomer|Prophylaxis, washing and removing water excess , apply the Clinpro forming a uniform layer of 0.5mm, lightcure for 20 seconds
1505159|NCT02931734|Drug|Potassium Nitrate 2%|Prophylaxis, apply uniformly on the teeth, wait 10 minutes, remove the gel from the teeth with cotton and abundant water.
1505160|NCT02931734|Procedure|Low level laser therapy|Prophylaxis, applying infrared laser at low power in points: mesial, buccal, distal and in the apical point in the foyer of fornix with power of 110MW for 11 seconds at each point.
1505161|NCT02931721|Procedure|MRI|Pelvis MRI
1505162|NCT02931721|Procedure|MRI|MRI (pelvis)
1505163|NCT02931708|Other|Diaphragm functional electrical stimulation|Functional electrical stimulation: 80 Hz frequency, 0.4 ms pulse, rise 1s, 1s time on, decay 2s, 1s time off, intensity as patient tolerance
1505164|NCT02931695|Other|evaluation of QT interval duration|ECG to evaluation of QT interval duration
1505165|NCT02931695|Other|circulating sex hormones levels sample|Association between circulating sex hormones levels (progesterone, estradiol, testosterone, FSH) and QTcF duration (univariate and multivariate analysis).
2002586|NCT02056236|Other|No anti-epileptic drugs|"The non-intervention group will be treated conform standard guidelines of treatment of comatose patients after cardiac arrest, but without anti-epileptic drugs or EEG based deep sedation. Treatment to suppress clinical myoclonia or seizures with low dose propofol is left to the discretion of the treating physician.
Decisions regarding limitation or withdrawal of treatment will be done in accordance with the Dutch guideline postanoxic coma. Reasons for withdrawal of treatment will be documented."
1505167|NCT02931656|Other|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
1505168|NCT02931643|Other|High fat challenge breakfast|In this intervention, subjects are asked to consume high fat breakfast without mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
1505169|NCT02931643|Other|High fat challenge breakfast with mixed-spices|In this intervention, subjects are asked to consume high fat breakfast with mixed-spices. Standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
1505170|NCT02931630|Other|Whey protein powder|60 g of whey protein powder
1505171|NCT02931630|Other|Maltodextrin powder|60 g of Maltodextrin powder
1505172|NCT02931630|Other|High fiber bread|Wheat bread with high content of dietary fibers (approximately 30 g fibers/day)
1505173|NCT02931630|Other|Low fiber bread|Wheat bread with low content of dietary fibers (approximately 10 g fibers/day)
1505174|NCT02931617|Other|Chest Physiotherapy|
1505175|NCT02931617|Device|Post-therapy lung volume measurements|In both intervention groups.
1505176|NCT02931604|Device|SinuSafe Medical Device for Maxillary Sinus|Sinus lavage via the natural sinus ostium, without ostial dilation.
1505177|NCT02931591|Drug|Metformin|Metformin is administered as an oral solution
1505178|NCT02931591|Drug|Growth Hormone|Growth Hormone- no specific band
1505179|NCT02931591|Drug|Placebo|
1505180|NCT02931578|Other|Glucose100|
1505181|NCT02931578|Other|Glucose50|
1505182|NCT02931578|Other|Glucose42|
1505183|NCT02931578|Other|Oral Glucose Tolerance Test|For each OGTT, subjects will consume 50g of sweetener dissolved in water at a comfortable pace within 10 minutes. Blood samples for plasma glucose and insulin will be taken at -20, 0, 15, 30, 45, 60, 90 and 120 min after consuming the glucose drink. Plasma fructose will be tested at baseline, 30, 60, 90 and 120 minutes.
1505184|NCT02931565|Drug|IW-1701|
1505185|NCT02931565|Drug|Matching Placebo|
2002587|NCT02052596|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm at Visit Day 0 and Visit Month 2 for Co-Ad group and at Visit Month 2 and Visit Month 4 for Control group.
1505189|NCT02931526|Drug|Tigecycline|Patients who have the definitive diagnosis to treat with tigecycline for bacterial infection will be started on tigecycline with a loading dose 200mg IV followed by 100mg IV every 12h.
1505190|NCT02931513|Other|Blood samples|
1505191|NCT02931513|Device|Fibroscan|
1505192|NCT02931513|Other|Questionnaires|
1505193|NCT02931513|Biological|Liver biopsy|Liver biopsy will only be obtained if obtained as part of the diagnosis (will not be obtained for study purpose only)
1505194|NCT02931487|Behavioral|Attentional Bias Modification|Computerized
1505195|NCT02931487|Behavioral|Sham condition|Computerized
1505196|NCT02931474|Drug|Tesamorelin|Growth Hormone-Releasing
1505197|NCT02931474|Other|Placebo|
1505198|NCT02931461|Procedure|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration|
1505200|NCT02931435|Procedure|Nerve Block with Radiofrequency Ablation|Ablation of the genicular nerves of the knee by radiofrequency
1505201|NCT02931435|Procedure|Nerve Block with Sham Radiofrequency Ablation|Genicular radiofrequency of the knee without neurotomy
1505202|NCT02931422|Behavioral|Financial incentive|Conditional cash transfer upon HIV testing
1505203|NCT02931409|Procedure|Optimal PEEP|Optimal PEEP determined by Cstat during PEEP titration procedure.
1505204|NCT02931409|Procedure|Standard PEEP|Lung protective mechanical ventilation applying a PEEP value of 6 cmH2O
1505205|NCT02931396|Device|FES|
1505206|NCT02931383|Drug|Liraglutide 3 mg (Saxenda)|
1505207|NCT02931383|Drug|Liraglutide 3 mg placebo|
1505245|NCT02931058|Other|Four knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.
The knee-extension resistance training exercise is performed with an elastic exercise band."
1505498|NCT02929199|Other|Hybrid crown|pressed Bio HPP veneered with Visio-Lign Veneering system
1505208|NCT02931370|Dietary Supplement|Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
1505209|NCT02931357|Device|Hyaluronic Acid 0.54%|Administration: application of the gel on the gingival tissue, massage it in gently, five to six times a day
1505210|NCT02931357|Drug|Calgel®|Administration: application of the gel on the gingival tissue, massage it in gently, three/four times a day (away from meals). In any case the interval between gel applications must be at least 3 hours.
1505211|NCT02931344|Dietary Supplement|Dietary Supplement: Dietary Supplement: Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
1505212|NCT02931318|Behavioral|Nevsehir|The data of the study were collected with the questionnaire
1505213|NCT02931305|Drug|Epimedium Prenylflavonoids Extract|Each Epimedium Prenylflavonoids Extract capsule contains 370 mg of EPIMEDIUM EXTRACT
1505214|NCT02931305|Drug|Placebo|Use iron oxide (brown, black and yellow) to mimic Epimedium Prenylflavonoids Extract.
1505215|NCT02931292|Procedure|Laparoscopic sleeve gastrectomy|"Special care was given to the complete mobilization of the gastric fundus, with meticulous dissection of the posterior gastric wall from the left pillar. A 36-Fr calibration bougie was used. Resection started 2 to 6 cm from pylorus, and it was conducted upward to 1.5 cm from the angle of His, to avoid the critical area. A gastric remnant of 60-80 mL volume (measured by administering methylene blue saline solution via nasogastric tube) was obtained."
1505216|NCT02931279|Device|PASS OCT® Spinal System|Posterior osteosynthesis of the cervical and upper thoracic spine
1505217|NCT02931266|Device|PASS MIS®|Posterior mini-invasive osteosynthesis
1505218|NCT02931253|Drug|Metformin|Metformin will be started as one pill (500 mg metformin) once a day with a meal. If the subject has no side effects from this dose, the dose will be increased to two pills (1000 mg) twice a day to be taken with meals.
1505219|NCT02931240|Device|Revivent TC|Treatment of LV scar
1505220|NCT02931227|Procedure|temperature obtained by the non-invasive method of zero-heat flux|
1505221|NCT02931227|Procedure|esophageal temperature|
1505222|NCT02931227|Procedure|intracerebral temperature|
1505223|NCT02931227|Procedure|arterial temperature|
1505224|NCT02931214|Drug|GMI-1359|
1505225|NCT02931214|Drug|Placebo|
1505226|NCT02931201|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post-injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
1505227|NCT02931188|Drug|Anacetrapib|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
1505228|NCT02931188|Drug|Statin|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
1505229|NCT02931188|Drug|Placebo|No drug administration will occur on this sub-study. Participants will receive treatment on the main trial HPS3/TIMI 55: REVEAL (NCT01252953)
1505230|NCT02931175|Drug|ACTH gel|Starting at month 6, retreatment will be offered to study subjects who have demonstrated any level of response during the first 6 months and who meet any of these Retreatment Criteria listed below. Patients receiving retreatment will receive the dose that was assigned to them at randomization.
1505231|NCT02931162|Other|Herb-partitioned moxibustion|Patients receive herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
1505232|NCT02931162|Other|Sham herb-partitioned moxibustion|Patients receive sham herb-partition moxibustion 3 times a week, once a day for 30 minutes, for a total of 12 weeks.
1505233|NCT02931149|Drug|Platelet-rich plasma|Submucosal injection with PRP was performed prior to endoscopic resection
1505234|NCT02931136|Drug|Huperzine A|The participants will treatment by the Huperzine A 200 ug/day in 52 weeks.
1505235|NCT02931136|Drug|Placebo|
1505236|NCT02931123|Drug|lattulose and rifaximine|
1505237|NCT02931110|Drug|CBL0137|All dose are on Days 1 and 8 of every 22 day cycle. Number of Cycles: 2 or until progression or unacceptable toxicity develops
1505238|NCT02931097|Device|Deep brain stimulation|Stimulating deep brain electrodes and pulse generator
1505239|NCT02931097|Device|Sham stimulation|
1505240|NCT02931084|Other|Rehabilitation|In line with current treatment guidelines, patients will undergo rehabilitation for at least the first three months, before a decision regarding ACL reconstruction is taken
1505241|NCT02931084|Procedure|ACL reconstruction|Approximately half of the patients will have ACL-reconstruction after an initial time of rehabilitation
1505242|NCT02931071|Drug|filgrastim|G-CSF (12 μg/Kg/12 h) 8 days.
1505243|NCT02931071|Drug|plerixafor|Plerixafor 0,24 mg/kg/day after the fourth day of G-CSF, and until 5 cells CD34+/μL, max 4 doses of plerixafor
1505244|NCT02931058|Other|Two knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.
The knee-extension resistance training exercise is performed with an elastic exercise band."
1505395|NCT02929901|Dietary Supplement|placebo|placebo plus placebo
1505396|NCT02929888|Drug|Lysine Acetilsalicilate|
1505246|NCT02931058|Other|Six knee-extension exercise sessions per week.|"Each exercise session comprises a single strength training exercise; knee-extension, which is performed in 3 sets with 12 RM repetitions in each set.
The knee-extension resistance training exercise is performed with an elastic exercise band."
1505247|NCT02931045|Drug|Ticagrelor|Comparison of ticagrelor with another antiplatelet drug (clopidogrel)
1505248|NCT02931045|Drug|Clopidogrel|Comparison of clopidogrel with another antiplatelet drug (ticagrelor)
1505249|NCT02931032|Procedure|Sampling of dental plaque / infected dentine|A sample of dental plaque / infected dentine will be taken during routine dental treatment and cultivated in a lab. The headspace above the culture will be sampled and analyzed in GC-MS for the detection of unique volatile organic compounds emitted by the plaque components.
1505250|NCT02931019|Procedure|Intubation|
1505251|NCT02931006|Other|water|
1505252|NCT02931006|Other|bovine milk|
1505253|NCT02930993|Biological|anti-mesothelin CAR T cells|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, patients are intravenously infused with anti-mesothelin CAR T cells in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
1505254|NCT02930980|Device|Investigational Software loaded on Micra device|Subject will receive an investigational software loaded on subject's Micra device
1505255|NCT02930967|Biological|autologous CSR T|Patients will be received a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes. 1 to 4 days after lymphodepletion, a prescribed dose of CSR T cells will be intravenously infused to patient in a three-day split-dose regimen (day0,10%; day1, 30%; day2, 60%).
1505256|NCT02930954|Drug|Gefitinib|Patients received Gefitinib 250mg Qd orally until disease progression, intolerable toxicity or death.
1505257|NCT02930954|Drug|pemetrexed or gemcitabine plus carboplatin,|doublet chemotherapy with pemetrexed or gemcitabine plus carboplatin per 3 weeks
1505258|NCT02930954|Drug|bevacizumab|bevacizumab 7.5mg/kg intravenously per 3 weeks
1505259|NCT02930941|Drug|Tranexamic Acid|TXA (100 mg/1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
1505260|NCT02930941|Drug|0.9% Sodium Chloride|0.9% Sodium Chloride (1mL) in to the affected nostril(s) via intranasal atomization device. May repeat 2 doses in each affected nostril(s).
1505261|NCT02930928|Other|Accuracy of weight estimation|Computer based comparison
1505262|NCT02930915|Device|Hand-held laser scanner|The laser scanning is non-intrusive and the scan can be completed in approximately 15 minutes. The scanning process involves the patient sitting in a chair while a researcher performs the scan. As a precautionary measure we require the patient to wear an eye mask as although the scanner is CE marked and completely safe . The process can be completed in stages (e.g. 3 x 5 minutes) with a break of 2-3 minutes between each session. The laser scanner will then be moved around the patient to obtain a set of 3D points forming the surface of the patient's head. We believe the laser scanning to be the most accurate way to acquire the surface of the patient's face / head and we wish to compare the models we obtain with surfaces rendered from the patient's CT data set.
2002588|NCT02052596|Biological|Boostrix|1 dose administered intramuscularly (IM) in the deltoid region of the dominant arm at Visit Day 0 for both Co-Ad and Control groups.
1505268|NCT02930889|Device|Prostate Artery Embolization|Prostate Artery Embolization
1505269|NCT02930876|Behavioral|Resistance training|Set of muscle strengthening exercises of all major muscle groups, guided by physiotherapists.
1505270|NCT02930863|Other|pulse oximetry software|This pulse oximetry software will utilize automated verbal prompts that direct the patients to breathe when their pulse oximetry reading falls at or below 93%.
1505271|NCT02930863|Behavioral|Brief post-PACU stay survey.|Complete a brief post-PACU stay survey focused around their satisfaction and experience during their time in the PACU.
1505274|NCT02930811|Drug|Sildenafil 100 mg oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.
Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
1505275|NCT02930811|Drug|Placebo oral morning dose|"Measurement of maximal walking distance on a constant load treadmill test, SF-36 questionnaire, and Edimburg questionnaire at inclusion, 1 month, 3 month and 6 month.
Events occurence questionnaires, Tolerance and adverse events questionnaire, Welch questionnaire and walk recommendation at inclusion, 7 days, 14 days, 1-2-3-4-5-6 and 9 months"
1505276|NCT02930798|Drug|BAY987516|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
(Formulation Code:Z46-116)"
1505277|NCT02930785|Drug|BAY987517|"Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
(Formulation Code:Z46-104)"
1505279|NCT02930759|Drug|BAY987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-096)
1505280|NCT02930746|Drug|BAY987516|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z46-092)
1505281|NCT02930733|Drug|Bupivacaine|30 ml %0,25 bupivacaine bilaterally
1505282|NCT02930733|Drug|Saline|2 ml saline subcutaneously bilaterally
1505397|NCT02929888|Drug|Aspirin|
1505564|NCT02928679|Drug|Liraglutide 3 mg placebo|
2002596|NCT02044809|Drug|Cannabidiol|
2002597|NCT02044809|Drug|Placebo|
1505283|NCT02930707|Drug|Magnesium Sulfate|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine plus 2 mL magnesium sulfate 10% (200 mg), on each side of the abdominal wall.
1505284|NCT02930707|Drug|Bupivacaine|ultrasound guided TAP block with 20 mL of 0.25% bupivacaine on each side of the abdominal wall.
1505285|NCT02930694|Drug|JNJ-54175446 (capsule)|Participants will receive JNJ-54175446 capsule at a dose of 50 mg or 100 mg, orally.
1505286|NCT02930694|Drug|JNJ-54175446 (suspension)|Participants will receive JNJ-54175446 suspension at a dose of 50 mg or 100 mg, orally.
1505287|NCT02930681|Dietary Supplement|Glucosanol 500mg|
1505288|NCT02930681|Dietary Supplement|Placebo|
1505289|NCT02930668|Dietary Supplement|Glucosanol 350mg|
1505290|NCT02930668|Dietary Supplement|Glucosanol 500mg|
1505291|NCT02930668|Dietary Supplement|Placebo|
1505292|NCT02930655|Drug|Lucerastat|Hard gelatin capsules for oral administration formulated at a strength of 250 mg, and administered as 4 capsules in the morning and 4 capsules in the evening.
1505293|NCT02930655|Drug|Enzyme replacement therapy (ERT)|All the subjects received an ERT as background therapy for at least 24 months prior to the screening visit and they had to continue receiving this treatment during the conduct of the study.
1505294|NCT02930642|Behavioral|Mindful Eating|Mindful eating is a behavioral strategy in which food is eaten slowly, with deliberate and focused attention on the features of food, the process of eating, and physiological responses to eating. Objectivity is key.
1505295|NCT02930642|Other|Nutrition DVD|Participants watch a 50 minute video on nutrition to control for verbal aspects of food.
1505296|NCT02930629|Device|Train-of-Four (TOF) Watch|"For patients, on arriving in PACU after having had muscle relaxants during general anaesthesia
Two ECG electrodes will be placed 4 cm apart over the path of the ulnar nerve of the wrist after cleaning the skin with alcohol swabs.
The TOF force transducer will be placed on the volar aspect of the thumb.
The TOF Watch leads will be attached to the ECG electrodes.
A TOF stimulus will be applied: four twitches at 2Hz (every 0.5 seconds), each twitch lasting 0.2ms, and at a current of 50 mA. As far as possible, this will be done when patients are still slightly drowsy from the effects of anaesthesia.
Two TOF ratio will be elicited (two sets of four twitches 15 seconds apart), and an average of the two taken"
1505297|NCT02930616|Device|Patients in Group 1 will receive pCLE at first and WLE 2 months later|
1505298|NCT02930616|Device|patients in Group 2 will receive WLE at first and pCLE 2 months later.|
2002598|NCT02040805|Behavioral|Group Cognitive Behavioral Therapy|"Group therapy over approximately 20 weeks, based on a structured manual adapted from the individual CBT workbook for hoarding by Steketee and Frost (2006). Each session will be 2 hours in length and consists of weekly check-ins, psychoeducation about hoarding, developing understanding and awareness of one's hoarding symptoms and patterns, behavior modification, cognitive restructuring, goal-setting, motivational enhancement, in vivo and imaginal exposure for discarding and acquisition, executive skills training (organization, sorting, planning, decision-making, problem-solving, etc.), guidelines on establishing clutter buddies, and relapse prevention. Groups will be led by clinical postdoctoral psychology fellows in the Department of Psychiatry at UCSF."
1505302|NCT02930564|Other|CDED + milk fat and gluten|CDED phase 1- induction phase a milk fat /emulsifier challenge (one scoop of ice cream and one slice of yellow processed cheese every day in the evening over 7 days), or a gluten/emulsifier challenge ( 3-4 slices of bread)
1505305|NCT02930538|Other|Survey|Completing a survey on RedCap
1505306|NCT02930525|Other|High flow nasal cannula|Application of humidified heated ambient air with flow rates adapted to body weight of respective subject. Incremental increase of fraction of inspired oxygen as appropriate to maintain oxygenation (defined as transcutaneous pulse oximetry above 93%).
1505307|NCT02930512|Procedure|DXA scan|
1505308|NCT02930512|Procedure|pQCT scan|
1505309|NCT02930499|Device|Hyalomatrix extra-cellular matrix|An exta-cellular matrix made from hyaluronic acid
1505310|NCT02930499|Device|Mepilex wound dressing|A siliconized non-adhesive foam wound dressing
1505311|NCT02930486|Device|ZipTight suture endobutton|Zimmer Biomet ZipTight suture endobutton
1505312|NCT02930486|Device|Tricortical 3.5 mm syndesmotic screw|Depuy Synthes 3.5 mm screw
1505313|NCT02930473|Behavioral|NIC Psychotherapeutic Intervention(s) for Anxiety|Patients will be treated by NIC psychotherapeutic intervention(s) for anxiety (e.g. anxiety reduction) plus psychopharmaceuticals prescribed by their psychiatrist.
1505314|NCT02930473|Drug|Psychopharmaceuticals (any drugs prescribed by the psychiatrist)|Patients will be treated only by psychopharmaceuticals prescribed by their psychiatrist.
1505316|NCT02930434|Dietary Supplement|cholecalciferol|Administration of vitamin D3
1505317|NCT02930421|Other|Exercise training|30 min of exercise on a cycle ergometer at 80% of HRmax, 30 min of strength training of upper and lower limbs
1505318|NCT02930408|Procedure|electrocardiogram|
1505319|NCT02930408|Procedure|Echocardiography|
1505320|NCT02930395|Procedure|serum S100B assay|
1505321|NCT02930382|Other|Baroreflec assessment|
1505322|NCT02930369|Procedure|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with idiopathic macular hole (IMH)
1505323|NCT02930356|Other|NSPT|NSPT was done by ultrasonic scalers after administration of pre procedural mouth rinse in the test group (20 smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
1505324|NCT02930356|Other|Scaling and root planing|Scaling and root planing was done by ultrasonic scalers after administration of pre procedural mouth rinse in the control group (20 non smokers with chronic periodontitis).Clinical parameters (GI,PI) were assessed at baseline and at the end of 3 months.2 ml blood was drawn to assess the plasma hepatocyte growth factor levels at baseline and at the end of 3 months.
1505325|NCT02930343|Drug|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic diseases
1505326|NCT02930343|Drug|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
1505492|NCT02929212|Other|Solid Meal|Subjects will receive solid meals during meal study
1505327|NCT02930343|Drug|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
1505328|NCT02930343|Drug|Prednisolone|Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop)
1505329|NCT02930343|Drug|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
1505330|NCT02930343|Drug|Sulfasalazine|5-aminosalicylic acid (5-ASA) is the active component of sulfasalazine; the specific mechanism of action of 5-ASA is unknown; however, it is thought that it modulates local chemical mediators of the inflammatory response, especially leukotrienes, and is also postulated to be a free radical scavenger or an inhibitor of tumor necrosis factor (TNF)
1505331|NCT02930330|Behavioral|INT|"5 min warm-up (40% Pmax*)
30 min high intensity interval training (1 min 100% Pmax, 1 min 20% Pmax, in alternating sequence)
10 min cool-down (30% Pmax)
Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
1505332|NCT02930330|Behavioral|CONT|"5 min warm-up (40% Pmax*)
30 min moderate intensity continuous training (60% Pmax)
10 min cool-down (30% Pmax)
Pmax*: Maximal power output (Watt) achieved at the end of an incremental exercise test."
1505333|NCT02930317|Drug|Recombinant Factor VIII (50 IU/kg)|
1505334|NCT02930317|Drug|Recombinant Factor VIII (On-demand treatment)|
1505335|NCT02930304|Other|first physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions
1505336|NCT02930304|Other|second physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Kinesio taping will be applied two times per week total six times in addition to conventional physiotherapy
1505337|NCT02930304|Other|third physiotherapy|physiotherapy program consists of cold pack, Transcutaneous electrical nerve stimulation (TENS), and home exercise programme including stretching and eccentric strength exercises will be applied five times a week total 15 sessions. Extracorporeal shockwave therapy (ESWT) will be applied one times per week total three session.
1505338|NCT02930265|Drug|Liraglutide|Liraglutide intervention group will accept liraglutide (Novo Nordisk, specifications: 18mg / 3ml; 1.8mg subcutaneous injection of 1 / day)
1505339|NCT02930252|Device|Niti-S Biliary ComVi Stent|Endoscopic placement of biliary fully covered metal stents
1505340|NCT02930252|Device|Niti-S stent (D type)|Endoscopic placement of biliary uncovered metal stent
1505341|NCT02930239|Other|Gait rehabilitating with reduced bodyweight|Patients will perform 8 sessions of gait rehabilitation with reduced bodyweight using the anti gravity treadmill during week 2-5 post-surgery.
1505342|NCT02930239|Other|Standardized rehabilitation following an anterior cruciate ligament reconstruction at Linkoping University Hospital|Exercises for increased movement and circulation performed on a daily basis.
1505343|NCT02930226|Biological|Autologous Freeze Dried Plasma (FDP)|Safety of Ascending Doses of Autologous Freeze Dried Plasma (FDP) in Healthy Volunteers
1505344|NCT02930226|Biological|Fresh Frozen Plasma (FFP)|Controlled FFP in cohort 3 only
1505345|NCT02930200|Behavioral|Treatment as Usual|Tobacco Treatment Research Program (TTRP) or Treatment as Usual (TAU)
1505346|NCT02930200|Behavioral|QuitGuide|NCI QuitGuide Treatment App
1505347|NCT02930200|Behavioral|Smart-T|Smart-Treatment App
1505348|NCT02930174|Device|Respironics V-60|Continuous high flow, blower type of generator.
1505349|NCT02930174|Device|Drager V-500|Critical care ventilator that has a specific NPPV mode.
1505350|NCT02930161|Drug|Runihol|"Composition of Runihol®:
One tablet contains:
Active ingredients: succinic acid - 0.250 g; Riboxinum (inosine) - 0.100 g; taurine - 0.050 g; Methionine - 0.050 g Excipients - 0.184 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.
Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate."
1505351|NCT02930161|Other|Placebo|"The composition of the drug in one tablet:
Active substance: None. The tablet core - 0.634 g: potato starch, povidone, microcrystalline cellulose, calcium stearate, hypromellose, polysorbate-80.
Enteric coat - 0.061 g: methacrylic acid-ethyl acrylate copolymer, talc, titanium dioxide, triethyl citrate, colloidal silicon dioxide, sodium hydrogencarbonate, sodium lauryl sulfate.
Tablet weight enteric coated - 0.695 g"
1505352|NCT02930148|Other|PEGASO System (ICT based system/mHealth solution)|"Participants will be provided with a smart phone with the PEGASO system and will be asked to join the PEGASO community through the PEGASO Portal. Two smart garments, and two sensors will be provided at month 2 (to minimise the burden on the schools and participants allocating time and resources). The PEGASO System allows empowering the participants toward healthy habits, recording what he or she eats, monitor physical activity variables. The serious game is a central motivational component of PEGASO: it has an energy bar, used up by the player's actions, and replenished when achieving their behavioural goals, and it implements research mechanics that require the player to apply and develop their nutritional knowledge. The Bridge allows the connection between the PEGASO ecosystem and the personal health folder by creating a report to be shared with physicians"
1505353|NCT02930135|Procedure|Indirect pulp capping|Removal of superficial caries in young permanent molars that my expose tooth pulp if totally removed leaving deep carious layers to be sealed inside with two step bonding system and bulk fill composite as a final restoration
1505354|NCT02930122|Drug|Saline (0.9%) and anakinra (150mg)|i.a. administration
1505355|NCT02930122|Drug|anakinra (150mg) and Saline (0.9%)|i.a. administration
1505356|NCT02930122|Other|Saline intraarticularly|i.a. administration
1505357|NCT02930109|Drug|PTX-200|During the Phase I study, increasing dose levels of PTX-200 will be administered as an intravenous infusion on days 1, 8 and 15 of each cycle. Triciribine will be infused over 1 hour on days 1, 8, and 15 of each 21 day cycle. The initial dose level will be 25 mg/m2 and each dose level will be increased by 10 mg/m2 to a maximum dose of 55 mg/m2
1505358|NCT02930109|Drug|Cytarabine|Cytarabine will be given at a dose of 400mg/m2 as a continuous IV infusion on days 2-6 of each cycle.
1505493|NCT02929212|Other|Liquid Meal|Subjects will receive liquid meals, during meal study
1505494|NCT02929212|Drug|Acetaminophen|All subjects given acetaminophen to measure gastric emptying
1505359|NCT02930057|Drug|Celestone|all of the patients of the experimental Celestone group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of Celestone® Chronodose® around each dorsal root ganglion immediately after the radiofrequency treatment has been performed
1505360|NCT02930057|Procedure|pulsed radiofrequency treatment|all of the patients who will participate in the study will receive pulsed radiofrequency treatment adjacent to lumbosacral dorsal root ganglion(s).
1505361|NCT02930057|Drug|Control|all of the patients of the control group will receive transforaminal epidural injection of the solution of 1 cc of Lidocaine 1% with 1 cc of normal saline around each dorsal root ganglion immediately after the radiofrequency treatment will be performed.
1505362|NCT02930044|Other|Early administration of subcutaneous insulin glargine dose|DKA patients in the prospective intervention arm will receive subcutaneous glargine within two hours of starting their intravenous insulin infusion. The dose of glargine is 0.3 units/kg with a maximum dose of 30 units.
1505363|NCT02930044|Other|IV insulin infusion|All patients will receive the standard of care which is a protocol based continuous insulin infusion
1505364|NCT02930044|Drug|IV fluid repletion|0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.
1505365|NCT02930031|Dietary Supplement|n-acetylcysteine|20 mg//kg/day, orally, daily for eight days following exercise
1505366|NCT02930031|Dietary Supplement|Placebo|500 mL orally, daily for eight days following exercise
1505369|NCT02930005|Drug|Meclofenamic acid|
1505370|NCT02930005|Drug|Pentosan polysulfate sodium|
1505371|NCT02929992|Other|ART initiation in the home|Participants initiate ART use in the home without visiting a clinic
1505372|NCT02929992|Other|Mobile Van Refill and Monitoring|Participants will pick up their medication refills from the mobile van and have all clinical monitoring conducted in the mobile van.
1505373|NCT02929992|Other|Clinic ART Initiation|Participants are referred to the clinic to initiate ART use
1505374|NCT02929992|Other|Clinic ART Refill and Monitoring|Participants will return to the clinic for ART refill and clinical monitoring.
1505375|NCT02929979|Behavioral|Cognitive Training|Participants will complete 22.5 hours of cognitive training exercises over 6-weeks (training 5 times a week) using an app-based program, BrainHQ (BPI/Posit Science, San Francisco). BrainHQ is based on a previous neuroscience-based cognitive training program shown to improve cognition in several different randomized controlled studies with other clinical populations. The investigators will use a suite of BrainHQ exercises designed to target and ameliorate cognitive disruptions in 4 cognitive domains (see main outcome). The investigators will employ basic exercises that focus on increasing processing efficiency in the auditory and visual perceptual and working memory domains, as well as exercises that target impulsivity and cognitive biases. Exercises will be packaged into 4 modules (attention skills, memory skills, executive functioning skills, cognitive control skills) comprised of 4 exercises each. All participants will progress through the same fixed schedule of modules.
1505376|NCT02929979|Behavioral|Cognitive training placebo control|Participants will play a rotating set of commercial computer games at the same dose and frequency as the cognitive training. The investigators selected this control activity because it mirrors the game-like properties of the cognitive training and it will be used to control for contact with research personnel and for the non-specific effects of participant motivation and engagement with daily computerized activities. It also allows for a double blind study design. Games from the website Sporcle will be used and an online account can be created for each participant.
1505377|NCT02929966|Other|palliative care program|The program includes psychological support, spiritual care and respiratory therapist support
1505378|NCT02929966|Other|standard respiratory care|the usual standard pharmacological care plus oxygen therapy
1505379|NCT02929953|Other|chart review|data from charts and from registries will be compared
1505380|NCT02929940|Other|No intervention|No Intervention, observational
1505381|NCT02929927|Procedure|Rubber dam isolation|tooth was isolated using a rubber dam in order to avoid the outside microbe
1505382|NCT02929927|Device|PDT|Inject the photosensitizer (PS)to the parallel orifice of the canal,use the small file to stir the PS for 60s,then irradiation 120s.
1505383|NCT02929927|Drug|tooth disinfection|use 1% iodine to disinfect the crown of the teeth.in order to avoid the outside microbe
1505384|NCT02929927|Drug|1%NaOCl|use different concentration Naclo as irrigants
1505385|NCT02929927|Drug|2%NaOCl|use different concentration Naclo as irrigants
1505386|NCT02929914|Procedure|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
1505387|NCT02929914|Procedure|Tooth drying|The tooth was dried with air jet.
1505388|NCT02929914|Procedure|Dentin wash with sodium 0.9% saline|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a spoon (1#) was performed. The remaining dentin was washed with sodium 0.9% saline. After that a a new dentin collection was performed at another site of the cavity, and teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin(Z350,3M)
1505389|NCT02929914|Procedure|Antimicrobial Photodynamic Therapy|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a spoon (1#) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW（medium Wave） power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity.Then teeth were conventionally restored using the following materials: calcium hydroxide lining material and resin(Z350,3M)
1505390|NCT02929914|Drug|sodium 0.9% saline|Dentin is washed with sodium 0.9% saline.
1505391|NCT02929914|Device|DENFOTEX PADplus|Dentin is disinfected by using DENFOTEX PADplus.
1505392|NCT02929901|Dietary Supplement|caffeine and chlorogenic acid|caffeine plus chlorogenic acid
1505393|NCT02929901|Dietary Supplement|caffeine|caffeine plus placebo
1505394|NCT02929901|Dietary Supplement|chlorogenic acid|chlorogenic acid plus placebo
1505398|NCT02929875|Behavioral|Education based on TPB|Three Training sessions were given to the case group; each lasted for one hour, during a period of twenty days. During each one-hour training session a period of 45 minutes was dedicated to listening to lectures, having discussions, and discussing methods of using teaching aids such as pamphlets and manuals. The last 15 minutes was used to summarize issues and answer questions.
1505399|NCT02929862|Drug|LYC-55716|Increasing doses or oral 55716 given BID for a 28 day cycle.
1505400|NCT02929849|Dietary Supplement|300 mg SC|Salacia (T1) capsule given with breakfast (mixed meal tolerance test)
1505401|NCT02929849|Dietary Supplement|500 mg SC|Salacia (T2) capsule given with breakfast (mixed meal tolerance test)
1505402|NCT02929849|Dietary Supplement|Placebo|Placebo capsule given with breakfast (mixed meal tolerance test)
1505403|NCT02929836|Procedure|PVI|PVI was the complete isolation of all PVs, which was confirmed by entrance and/or exit block into or from the PV antra.
1505404|NCT02929836|Procedure|LA linear ablation|LA linear ablation include mitral isthmus ablation and roof line ablation. Mitral isthmus ablation (from the mitral annulus to the left inferior PV) was performed first, followed by roof line ablation (between the right and left superior PVs).
1505405|NCT02929836|Procedure|CFAE ablation|Ablation catheter was maintained in a stable position when the electrograms were being recorded for at least 5 s to avoid artifacts.The procedural endpoint of CFAEs was the complete elimination of fragmented atrial activity in local electrograms.
1505406|NCT02929836|Procedure|linear ablation|Right atrial CTI ablation was performed during SR.
1505407|NCT02929836|Device|CARTO|3 dimensional mapping system
1505408|NCT02929823|Drug|High Dose SJP-0035 Ophthalmic Solution|0.001% SJP-0035 Ophthalmic Solution
1505409|NCT02929823|Drug|Low Dose SJP-0035 Ophthalmic Solution|0.0002% SJP-0035 Ophthalmic Solution
1505410|NCT02929823|Drug|Vehicle of SJP-0035 Ophthalmic solution|0% SJP-0035 Ophthalmic Solution
1505411|NCT02929810|Behavioral|sleep extension|
1505412|NCT02929810|Behavioral|sleep maintenance|
1505413|NCT02929797|Biological|CD8+NKG2D+ AKT Cell|AKT: CD8+NKG2D+ AKT cell
1505414|NCT02929797|Drug|Gemcitabine|gemcitabine
1505415|NCT02929784|Device|Intervention|Device: neuroConn_CE_DC-STIMULATOR. Anodal stimulation to affected hemisphere.
1505416|NCT02929784|Device|Sham|no meaningful stimulation will be given.
1505417|NCT02929771|Device|Samsung GearVR|VR with head mounted display (HMD) and headphones. Treatment
1505418|NCT02929771|Device|iPad|iPad with headphones. Control
1505419|NCT02929758|Behavioral|Speed of processing training (SOPT)|This is a game-like program designed based on the UFOV. It consists of five activities (Sweep Seeker, Bird Safari, Jewel Diver, Master Gardener, and Road Tour). The duration of training will be 3 months. Participants will be encouraged to train at least three-times weekly for 1-hour blocks and must complete at least 20 training sessions over the course of the three months.
1505420|NCT02929745|Procedure|Skin biopsy|Four 4-5 mm punch biopsies of the skin
1505421|NCT02929745|Procedure|Blood draw|Blood will be drawn to test for HLA-cw6 status
1505422|NCT02929732|Other|Sympathetic nervous activity measurement|
1505423|NCT02929719|Drug|Test.|gel
1505424|NCT02929719|Drug|Aczone Gel 5%|gel
1505425|NCT02929719|Drug|Placebo|gel
1505426|NCT02929706|Genetic|test NUDT15 genotype and dose optimization according to the genotype|
1505427|NCT02929693|Drug|gefitinib|250 mg oral once a day until progression or unacceptable toxicity develops
1505428|NCT02929693|Drug|Yiqi-yangyin-jiedu decoction|Yiqi-yangyin-jiedu decoction is a traditional chinese herbal medicine formula,and should be taken one package, twice a day, until progression or unacceptable toxicity develops.
1505429|NCT02929693|Drug|placebo|Oral granules, which the taste and smell are similar to YYJD, has no therapeutic effect, Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, one package, twice a day, until progression or unacceptable toxicity develops.
1505430|NCT02929680|Device|FilmArray|Lower Respiratory specimens will be run on the BioFire FilmArray LRTI panel to evaluate its performance and collect data to support a proposal for the panel as an in vitro diagnostic device.
1505431|NCT02929667|Drug|Fluoxetine|Standard 6 weeks titration, starting 10 mg per day.
1505432|NCT02929667|Drug|Placebo|Standard 6 weeks titration.
1505433|NCT02929654|Device|OneTouch Verio®|Colour Enhanced Blood Glucose Meter.
1505434|NCT02929654|Device|OneTouch Verio® Flex|Colour Enhanced Blood Glucose Meter.
1505435|NCT02929654|Device|Subject's Own Blood Glucose Meter|Subject's Own Blood Glucose Meter
1505436|NCT02929641|Device|HDWL with magnification and OE with magnification|The polyps found will be observed carefully and recorded by HDWL with magnification and then OE with magnification.
1505437|NCT02929628|Device|Beijing PINS Programming|Using the programming control the Stimulator to change the parameter
1505438|NCT02929615|Other|Hematopoietic stem cell transplantation|
1505439|NCT02929589|Drug|Ibuprofen|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days
1505440|NCT02929589|Drug|Opioid Medication|1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
1505441|NCT02929589|Drug|Placebo|800 milligrams of a placebo pill (containing corn starch) to be taken by mouth every 8 hours as needed for pain
1505442|NCT02929589|Drug|Ibuprofen + Opioid medication|ibuprofen 800 milligrams by mouth every 8 hours as needed for pain for 5 days. 1 to 2 tablets of oxycodone/acetaminophen 5 milligrams/325 milligrams (Qty. 30) by mouth every 4 hours as needed for pain for 5 days
1505443|NCT02929576|Drug|Enzalutamide|Enzalutamide will be administered as four 40-mg capsules once daily (160 mg/day).
1505444|NCT02929576|Drug|Placebo|
1505445|NCT02929576|Drug|Paclitaxel|Paclitaxel (90 mg/m2) will be administered by constant-rate intravenous infusion of ≤ 1 hour once weekly for 16 weeks. Dose reductions or alterations to the schedule are allowed to maintain patient safety.
1505446|NCT02929563|Drug|Pantoprazole|
1505447|NCT02929563|Drug|Placebo (for pantoprazole)|
1505495|NCT02929212|Other|Single, 600 kcal meal|Subjects will receive a single, 600 kcal meal during meal study
1505496|NCT02929212|Other|Multiple, 200 kcal meals|Subjects will receive three, 200 kcal meals, during meal study
1505448|NCT02929524|Drug|Ketamine|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
1505449|NCT02929524|Drug|Placebo|As indicated the use of sedative and after authorization of the person responsible, the child receives the intranasal solution. Before administration of the solution 2 hour and 24 hours after the procedure, must be recorded vital signs of the patient. A person with the help of a clock will make the time count. The nurse and the patient's family must respond to the study protocol questions
1505450|NCT02929511|Procedure|Reciprocating single-file system|The device is moving in CW and CCW direction with different angles. It is a single-file endodontic file. The intervention is Reciproc Blue reciprocating single-file system.
1505451|NCT02929511|Procedure|Rotational single-file system.|The device is moving in continuous rotational. It is a single-fie endodontic file.
1505452|NCT02929498|Drug|GSK2879552|GSK2879552 will be administered orally as continuous daily dosing.
1505453|NCT02929498|Drug|Azacitidine|Azacitidine will be administered at 75 mg/m2 from Day 1 to Day 7 of each 28 day cycle by intravenous (iv) infusion or subcutaneous (sc) injection.
1505454|NCT02929485|Drug|Tolcapone|Tolcapone 200mg (single dose) administered at study visit
1505455|NCT02929485|Drug|Placebo|Placebo (200mg) administered at study visit
1505456|NCT02929485|Drug|Bromocriptine|Drug: Bromocriptine 1.25 mg (single dose) administered at study visit
1505457|NCT02929472|Behavioral|Physical exercise|The intervention group (INT, n = 17, 7 boys) who attended at least 75% of PA classes and met more than 50% of food goals.The exercise sessions took 90 minutes, in order to assure at least 60 minutes of physical exercise, during 12 weeks. The sessions were always taught by the same staff, and were composed of: 10 minutes of warm-up; 30 minutes of circuit training; 15-minute of pre-sports and recreational games;and 5 minutes resting activities.
1505458|NCT02929472|Behavioral|without physical exercise|The control one (CONT, n = 18, 6 boys), with a minimum or less than 49% attendance in PA classes, and were not involved in the nutrition education program.
1505459|NCT02929459|Dietary Supplement|Riboflavin Dose 1|
1505460|NCT02929459|Dietary Supplement|Riboflavin Dose 2|
1505461|NCT02929459|Other|Placebo|
1505462|NCT02929446|Procedure|Mobilisation|Mobilisation to sit in an armchair
1505463|NCT02929446|Procedure|Mobilisation and breathing exercises|Mobilisation to sit in an armchair and breathing exercises with PEP
1505464|NCT02929433|Other|Cycloergometer|Daily training of the RCT patients was provided by the use of a cycloergometer at home. Educational support once a month was guaranteed by a nurse of the telemedicine service
1505465|NCT02929420|Drug|Xiaoru Sanjie capsules|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
1505466|NCT02929420|Drug|Xiao Yao pills|Oral medication for a total of 90 days. According to the instructions, P.O., three times a day, each time three tablets, take a month as a treatment course, continuous use of 3 courses.
2002599|NCT02040805|Behavioral|Peer Facilitated Manualized Support Group|Sixteen sessions of peer facilitated, group support, over the course of 20 weeks, based on a structured manualized approach (Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding). Each session will be 2 hours in length. In this model, two trained peers, usually, but not necessarily, with personal lived experience of hoarding, will guide the group chapter by chapter through the Buried in Treasures manual.
2002600|NCT02037646|Other|Qualitative fecal immunochemical test|This test measures the amount of blood within the submitted stool specimen
1505470|NCT02929381|Device|Innovative colonoscopy (Olympus CF-HQ190L, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Kudo and NICE classifications.
1505471|NCT02929381|Device|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
1505472|NCT02929368|Device|PICC implantation under fluoroscopy|PICC Catheter implantation
1505473|NCT02929368|Device|PICC Implantation under Sherlock System|PICC Catheter implantation
1505474|NCT02929355|Other|carotid assesment by duplex ultrasonography|
1505475|NCT02929342|Drug|Pitolisant|
1505476|NCT02929342|Radiation|[14C]-Pitolisant|
1505479|NCT02929316|Drug|Vedolizumab|IV infusion week 0, 2 and 6
1505480|NCT02929303|Drug|Omegaven IV lipid emulsion|Therapy is started at a dose of 1 gm/kg/day over 12 hrs. Omegaven may be infused via a central or peripheral IV. If additional fat calories are needed they will be provided by the enteral route.
1505481|NCT02929290|Drug|BPI-9016M|
1505482|NCT02929277|Other|blood sampling, skin prick tests, assesment of atopic dermatitis, questionnaires|
1505483|NCT02929264|Drug|ABX-1431|Capsules, 40 mg, single dose
1505484|NCT02929264|Drug|Placebo|Capsules, single dose
1505485|NCT02929251|Drug|Anakinra|Anakinra (100 mg/day subcutaneously) (n=40) for 16 weeks
1505486|NCT02929251|Drug|Tocilizumab|Tocilizumab (162 mg/7 days subcutaneously) (n=40) for 16 weeks.
1505487|NCT02929251|Drug|Adalimumab|Adalimumab (40mg/14 days subcutaneously) (n=40) for 16 weeks
1505488|NCT02929238|Other|Polypropylene Suture Right Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
1505489|NCT02929238|Other|Polypropylene Suture Left Side|Suture Description: The suture used in this study will be a sterilized polypropylene suture and individually crossed in the base of the wound. Polypropylene is commonly used for commercially available implanted meshes. The polypropylene suture is intended for single use only and the individual suture will be packaged and purchased sterile.
1505490|NCT02929225|Drug|Bifid Triple Viable Capsules|BIFICO is prescribed as a dose of 4 capsules twice daily in half hours after meals. As reported by manufacturer, each capsule contained lyophilized bacteria (at least 10^7 Bifidobacterium, 10^7 Lactobacillus and 10^7enterococcus)
1505491|NCT02929225|Other|placebo|placebo is also prescribed as a dose of 4 capsules twice daily
2002601|NCT02037646|Other|Quantitative fecal immunochemical test|This test detects presence or absence of blood within a submitted stool specimen.
2002602|NCT02037646|Procedure|Colonoscopy|Patients with positive tests will be subjected to colonoscopy to determine presence or absence of advanced colorectal neoplasms.
1505501|NCT02929173|Other|Allceram|Pressed E-max coping veneered with E-max veneering system
1505502|NCT02929173|Other|hybrid crown|pressed Bio HPP coping veneered with visolign veneering system
1505503|NCT02929160|Procedure|Percutaneous nephrostomy|Percutaneous nephrostomy tube insertion under radiological guidance
1505504|NCT02929160|Procedure|Retrograde ureteric JJ stent|Retrograde ureteric JJ stent insertion using cystoscopy
1505505|NCT02929147|Drug|Morphine|In the Group 1 the PCA will set to administer a bolus dose of 1 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours. In the Group 2 the PCA set to administer a bolus dose of 0.5 mg morphine on demand with a lockout period of 10 minutes and maximum 20 mg for 4 hours.
1505506|NCT02929147|Drug|Dexketoprofen|The Group 3 will take 50 mg dexketoprofen in the recovery room. Intra venous injections of dexketoprofen will repeat every 8 hours.
1505507|NCT02929147|Drug|Placebo|In the Group 3 the PCA will contain placebo.
1505508|NCT02929134|Drug|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)
1505509|NCT02929134|Drug|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
1505510|NCT02929121|Drug|Doxycycline|Once daily tablet for 6 weeks: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)
1505511|NCT02929121|Drug|Placebo|Once daily tablet for 6 weeks: matching tablets containing no active ingredients
1505512|NCT02929108|Behavioral|Facebook|Participants will be enrolled in a Secret Facebook group for social support and education
1505513|NCT02929108|Behavioral|ACCESS|"Intervention will have two components.
Participants will be enrolled in a Secret Facebook group for social support and education
Participants will use web conferencing technology to participate in their interdisciplinary team meeting"
1505514|NCT02929095|Drug|dexmedetomidine|
1505515|NCT02929095|Drug|midazolam|
1505516|NCT02929095|Drug|remifentanil|- remifentanil will be administered to both dexmedetomidine and midazolam group as a routine part of procedure and it is no of interest of the protocol
1505517|NCT02929082|Radiation|IRM with a 5-minute- additional sequence to measure FRM|IRM with a 5-minute- additional sequence to measure FRM for patients in group 1,2 and 3
1505518|NCT02929069|Behavioral|ESTEEM|ESTEEM is a 10-session intervention based on the Unified Protocol, an individually-delivered CBT intervention with efficacy for reducing stress-sensitive mental health disorders (e.g., depression, anxiety) by enhancing emotion regulation skills; reducing avoidance patterns; and improving motivation and self-efficacy for behavior change.
1505519|NCT02929069|Behavioral|CMHT|CMHT is the current standard of care for LGB individuals who seek mental, behavioral, or sexual health care is LGB-affirmative therapy.The practice of LGB-affirmative therapy is outlined across 21 guidelines published by the American Psychological Association.
1505520|NCT02929069|Behavioral|VCT|Voluntary Counselling and Testing (VCT).
1505521|NCT02929056|Device|AmnioExCel dressing and compression therapy|Use of a dehydrated human amnion membrane as a biologic adjunct to the standard of care in patients with venous leg ulcers
1505522|NCT02929056|Device|SOC alginate dressing and compression therapy|Alginate dressing is an absorbent wound care product that contains sodium and calcium fibers to absorb fluids and promote healing
2002603|NCT02037646|Other|Cost analysis|Data on direct and indirect costs to patient and institution will be collected at each patient visit related to screening.
1505524|NCT02929030|Device|Nano|The stent system comprises of 2 components: stent steel platform, antiproliferative drug sirolimus, and stent balloon
1505525|NCT02929017|Other|SUPPORT|Members of this group will receive personal, enhanced printed materials, as well as face-to-face support, and digital information provided by the interventionist.
1505526|NCT02929017|Other|Currently Available Printed Material|Subjects will receive their usual standard of care, including currently available printed patient material.
2002604|NCT02037646|Other|Anxiety scores|Hospital Anxiety and Depression Scale (HADS) questionnaire
1505531|NCT02928978|Drug|Ruxolitinib|
1505532|NCT02928978|Drug|Placebo (for Ruxolitinib)|
1505533|NCT02928965|Drug|Minocycline|Capsules containing 100mg minocycline (modified release), administered orally by the patient, two per day for the first two weeks and then three per day for the reminder of the 12 month treatment period in addition to standard therapy.
1505534|NCT02928965|Drug|Placebo|Matching placebo with appearance of over - encapsulated minocycline
1505535|NCT02928952|Behavioral|Mind-STRIDE|Mindful Stress Reduction in Diabetes Education- mindfulness training with home practice will be introduced as part of diabetes education
2002605|NCT02037646|Other|Patient satisfaction scores|A 5-point patient satisfaction score will be documented at each patient visit related to screening.
1505537|NCT02928926|Other|intravenous thrombolysis|patients who are eligible with intravenous thrombolysis or admitted within the timeframe to receive thrombolysis but not eligible due to other reasons
2002606|NCT02037139|Other|Screening|Standard care screening
1509441|NCT02899143|Drug|Antibiotic|Targeted antimicrobial therapy
2002607|NCT02037139|Other|Brochure|Participants are given an illustrated educational brochure
1505539|NCT02928900|Behavioral|Clinician training intervention|This intervention is a clinician training using SP actors to improve communication and empathy skills of HIV care providers who serve HIV-positive adolescents and youth in Kenya.
1505540|NCT02928887|Other|Blue light|Exposure to high illuminance (1000 lux), blue spectrum (480 nm) light for a 24-hour photoperiod immediately before surgery and a 24-hour photoperiod immediately after surgery
1505541|NCT02928874|Behavioral|% COMPX (low ED vs. high ED preload)|
1505542|NCT02928874|Behavioral|EAH (low ED vs. high ED snacks)|
1505543|NCT02928861|Device|18F-FDG PET/CT|18F-FDG PET/CT will be conducted before, during and after chemotherapy. Patients were instructed to fast for at least 6 h before PET. The blood glucose level was measured to ensure that it was <200 mg/ dL. 18F-FDG was intravenously administered at a dose of 3.7 MBq/kg. Approximately 60 ± 10 min post- injection, a whole-body acquisition commenced in 6-8 bed positions (1 min/bed) using a hybrid system (PHILIPS Gemini TF) and covered from the base of the skull to the upper thigh, which was followed by CT in a non-contrast phase (modulated 100 mAs; 120 kV; slice thickness, 3 mm) for attenuation correction and anatomical localization purposes. The head acquisition was performed in one bed position (8-10 min/bed).
1505544|NCT02928848|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a type of noninvasive brain stimulation that modulates the resting excitability of neuronal populations, thereby altering patterns of brain activity in potentially behaviorally relevant ways. The stimulation involves 20 minutes of constant stimulation at 1.5 mA.
1505545|NCT02928835|Device|Knee flexion Dynasplint orthosis|Standardized rehabilitation procedures started at the first day after total knee arthroplasty. Both groups received the same standardized physical therapy intervention. The experimental group used the knee flexion Dynasplint orthosis (Dynasplint Systems, Inc. Canada, Woodbridge, ON) at night, while sleeping, over six continuous hours for one month, starting seven days after the total knee arthroplasty. The control group received only the standardized physical therapy intervention.
1505546|NCT02928822|Behavioral|VR-based sensorimotor aphasia therapy|VR-based sensorimotor aphasia therapy. 8 weeks, 1 session a week, 30min-1h per session of language and motor therapy using using VR rehabilitation gaming system. The patients will play in pairs.
1505547|NCT02928822|Behavioral|Control Group (conventional aphasia rehabilitation)|8 weeks, 1 session a week, 30min-1h per session of conventional aphasia rehabilitation training the same vocabulary as the experimental group.
1505548|NCT02928809|Device|low-level laser therapy|Three points will be irradiated over the masseter muscle (upper, middle and lower bundles) and one point will be irradiated over the anterior temporal muscle of each side of the face in the groups submitted to pre-fatigue laser. The following parameters will be employed: wavelength: 780 nm; energy density: 25 J/cm2; output power: 50 mW; power density: 1.25 W/cm2; and exposure time: 20 seconds per points, resulting in a total energy of 1 J per point. The laser will be applied punctually with a conventional tip in contact with the skin considering an area of 0.04 cm2.
1505549|NCT02928809|Other|Placebo comparator|The same equipment will be used in the placebo group, but with a pen that emits a red guide light and a warning sound, but without the emission of a laser beam.
1505550|NCT02928796|Behavioral|Cognitive Stimulus|Participants to pay attention to a supplementary display monitor and respond to specified stimulus images, all while performing the simulated cardiology-based procedure.
1505551|NCT02928783|Behavioral|Home-based cardiac rehabilitation|
1505552|NCT02928770|Device|Nastent|Use of the device while at home and in the sleep lab
1505553|NCT02928757|Other|Complex care clinic as part of the CCKO initiative|"The CCKO intervention involves intensive care coordination, defined as: deliberate organization of patient care activities between two or more participants (including the patient) involved in a patient's care to facilitate the appropriate delivery of health care services. Organizing care involves marshaling of personnel and other resources needed to carry out all required patient care activities and is often managed by the exchange of information among participants responsible for different aspects of care. Within CCKO, intensive care coordination will specifically include: 1) the tailored, family/health care provider co-creation and regular updating of care coordination plans for each child which will be 2) facilitated and accounted for by key workers partnering with families."
1505554|NCT02928744|Other|COPD|Plethysmography
1505555|NCT02928744|Other|COPD|Forced oscillations
1505556|NCT02928731|Other|Questionnaires set 1|Participants were asked to respond to the Chinese version of the Coping Behavior Checklist for Chinese Children, the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth, and the Pediatric Quality of life Inventory: cancer module.
1505557|NCT02928731|Other|Questionnaires set 2|Participants were asked to respond to the Chinese version of the Chinese University of Hong Kong: Physical Activity Rating for Children and Youth,and the Pediatric Quality of life Inventory: generic module
1505558|NCT02928718|Procedure|ERCP|Two expert endoscopists will perform ERCP. Patients will be sedated with midazolam(2-5mg) and pethidine(25-50mg) with careful monitoring. Duodenoscope (TJF-240 or TJF-260; Olympus Corp., Tokyo, Japan) will be used. Cholangiography or pancreatography will be gathered after selective bile duct or pancreatic duct cannulation. Therapy such as endoscopic sphincterotomy, stent insertion, and etc., will be done.
1505559|NCT02928705|Procedure|physician operated telemedical prehospital analgesia|Ambulances in the EMS of the city of Aachen are equipped with a portable telemedicine system. In emergencies requiring intravenous analgesia paramedics can use this system to contact the tele-EMS physician with an audio-connection. Vital parameters (e.g., ECG, pulse oximetry, non-invasive blood pressure) can be transferred in real-time. The transmission of still pictures - taken with an official smartphone - and video streaming from the inside of the ambulance are also possible. The tele-EMS physician supports the paramedics and can delegate the application of morphine and other analgesics based on two predefined algorithms for trauma and non-trauma cases that are displayed on a context-sensitive telemedical documentation system in the teleconsultation center.
1505560|NCT02928705|Procedure|prehospital analgesia by on-scene EMS physicians|This (control) group represents the conventional treatment in German emergency medical service (EMS). In addition to an ambulance manned with paramedics, a prehospital EMS physician is deployed to conduct analgesic treatment on-scene. Treatment data for this group are selected from the time period before implementing teleconsultation in routine and therefore represent a historical control group.
1505561|NCT02928692|Drug|Minocycline|
1505562|NCT02928692|Drug|Placebo|
1505563|NCT02928679|Drug|Liraglutide 3 mg (Saxenda)|
1505565|NCT02928666|Other|DSS for mitigating interactions between recommendations|DSS that detects and mitigates interactions between recommendations, proposing a set of non-conflicting guideline recommendations
1505566|NCT02928653|Dietary Supplement|Beverage|Participants will receive 1.25 - 1.75 L of sweetened beverage a day for 12 weeks
1505567|NCT02928640|Device|ClariCore System|Data collection to build the prostrate tissue classification algorithm.
2002608|NCT02037139|Behavioral|Education|Participants undergo a in-person educational intervention
1505569|NCT02928614|Drug|Liraglutide 3 mg (Saxenda)|
1505570|NCT02928614|Drug|Liraglutide 3 mg placebo|
1505571|NCT02928601|Drug|Ondansetron|After spinal anesthesia, half of the patients will be given intravenous 8 mg ondansetron.
1505572|NCT02928601|Drug|Saline|After spinal anesthesia, half of the patients will be given intravenous 2 mlt saline.
1505573|NCT02928575|Drug|Sunitinib|Before concurrent treatment, patients will receive sunitinib orally at a dose of 12.5 mg once daily for one week prior to radiation. Patients will then receive a concomitant treatment of sunitinib at a dose of 12.5 mg once daily along with temozolomide (75 mg/m2 daily) along with radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks.
1505574|NCT02928575|Drug|Temozolomide|Temozolomide (75 mg/m2 daily) will be administered along with sunitinib (12.5 mg once daily) and radiotherapy (60 Gy in 30 fractions) over a period of 6 weeks. This concurrent treatment of sunitinib, temozolomide and radiotherapy is followed by a 1 month break after which the adjuvant temozolomide treatment is administered at a dose of 150/200mg/m2 daily, for 5 of 28 days over a period of 6 months.
1505575|NCT02928575|Radiation|Radiation Therapy|Patients will receive a concomitant treatment of radiotherapy (60 Gy in 30 fractions), sunitinib (12.5 mg once daily) and temozolomide (75 mg/m2 daily) over a period of 6 weeks.
2002609|NCT02035384|Drug|turoctocog alfa|Patients will be treated with commercially available turoctocog alfa as prescribed by the treating physician in clinical daily practice and preferably according to the label for turoctocog alfa in the respective countries.
1505577|NCT02928549|Behavioral|semi-structured interviews|
1505578|NCT02928536|Other|no intervention|This is an observational study. No intervention is considered
1505579|NCT02928523|Drug|Autologous Fecal Microbiota Transplantation|
2002610|NCT02030119|Behavioral|Financial Incentives|
2002611|NCT02030119|Behavioral|Daily feedback|
2002612|NCT02027428|Drug|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
2002613|NCT02027428|Drug|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion
2002614|NCT02027428|Drug|Abraxane (Maintenance)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 of each 21-day cycle, administered as standard of care
2002615|NCT02027428|Other|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
2002616|NCT02027428|Drug|Abraxane (Induction)|100 mg/m2 IV infusion over 30 minutes on Days 1 and 8 and 15 of each 21-day cycle, administered as standard of care
2002617|NCT02027428|Drug|Carboplatin (Induction)|6 mg/min/mL IV on Day 1 of each 21-day cycle after completion of nab-paclitaxel infusion, administered as standard of care
1505588|NCT02928497|Device|WATCHMAN LAAC Implant|WATCHMAN LAAC Implant
1505589|NCT02928497|Drug|Single Antiplatelet Therapy of No Therapy|Single Antiplatelet Therapy or No Therapy at the discretion of the study physician.
1505590|NCT02928484|Dietary Supplement|Probiotic mix CBP-004019/C|One capsule per day of the probiotic mix CBP-004019/C during one month.
1505591|NCT02928484|Dietary Supplement|Placebo|One capsule per day of the placebo (maltodextrin) during one month.
1505592|NCT02928471|Dietary Supplement|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
1505595|NCT02928445|Drug|RVT-101 35 mg|once daily, oral, 35-mg tablets
1505596|NCT02928445|Drug|RVT-101 70 mg|once daily, oral, 35-mg tablets
1505597|NCT02928432|Drug|Steroids switch|Change of prednisone 5mg/12h to dexamethasone 0.5mg/24h
1505598|NCT02928419|Drug|Eltrombopag/Revolade|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral eltrombopag for a maximum of 36 months.
Starting dose will depend on PLT count determined on the day of first dose of eltrombopag. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts < 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
1505599|NCT02928419|Other|Placebo|"From day 1, patients presenting with PLT counts ≤ 100 Gi/L at any time will receive oral placebo for a maximum of 36 months.
Starting dose will depend on PLT count determined on the day of first dose of placebo. For patients experiencing PLT count 70 to 100 Gi/L, initial dosing is 50 mg/day. For subjects presenting with PLT counts < 70 Gi/L initial dosing is 100 mg/day. The dose of study medication must be increased sequentially by 50 mg every 7 days, up to a maximum dose of 300 mg/day until PLT ≥ 100 Gi/L. For East Asian subjects, a maximum dose of 150 mg is permitted."
1505600|NCT02928419|Drug|Lenalidomide|All patients will receive oral lenalidomide 10 mg/day for 21 days every 28 days. Patients will receive lenalidomide dosing according to the lenalidomide product information. Patients obtaining an erythroid response according to IWG 2006 criteria within the first 24 weeks will continue lenalidomide treatment until progression or other reasons for permanent discontinuation
1505601|NCT02928406|Drug|Atezolizumab|Participants will receive 1200 milligrams of atezolizumab by intravenous infusion every 3 weeks until investigator assessed loss of clinical benefit, unacceptable toxicity, investigator or participants decision to withdraw from therapy, or death (whichever occurs first).
2002618|NCT02027428|Other|Best Supportive Care (Maintenance)|The best palliative care per investigator (including but not limited to: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and/or focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis), excluding antineoplastic agents
1505606|NCT02928367|Other|rectal swab|rectal swab at baseline visit (2x) and at day 28 (2x) OR rectal swab at single timepoint (2x) (healthy volunteers)
1505607|NCT02928367|Other|nasopharyngeal swab|nasopharyngeal swab at baseline visit (1x) and at day 28 (1x) OR nasopharyngeal swab at single timepoint (2x) (healthy volunteers)
1505608|NCT02928367|Other|blood draw|blood draw at baseline visit (45ml) and at day 28 (45ml) (pneumonia patients) OR single blood draw (70ml) (healthy volunteers)
1505609|NCT02928354|Drug|Treatment A - AZD7594|Particle size Large as a single inhaled dose of 440 µg (nominal dose), administered via DPI
1505610|NCT02928354|Drug|Treatment B - AZD7594|Particle size Medium as a single inhaled dose of 440 µg (nominal dose), administered via DPI
1505611|NCT02928354|Drug|Treatment C - AZD7594|Particle size Small as a single inhaled dose of 440 µg (nominal dose), administered via DPI
1505612|NCT02928341|Other|Improved water supply|
1505613|NCT02928328|Drug|GABA oral solution|Oral mouth wash containing either GABA, lidocaine or distilled water will be used to decrease burning tongue pain produced by capsaicin
1505614|NCT02928328|Drug|Intramuscular GABA|The effect of intramuscular injection of GABA or lorazepam will be compared with buffered isotonic saline
1505615|NCT02928328|Drug|Pain modulation|The effect of GABA alone or in combination with lorazepam on muscle pain produced by intramuscular injection of glutamate will be assessed.
1505616|NCT02928315|Drug|Magnesium Sulfate|The patients in the study group will receive 10 mmol of magnesium sulphate (2.47 gm). Five ampoules of 500 mg of magnesium sulphate will be dissolved in 100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
1505617|NCT02928315|Other|control|100 ml of saline solution infused intravenously over 4 hours, once daily for 3 days starting when the patient is shifted to ICU.
1505618|NCT02928302|Other|TVU CL screening|
1505619|NCT02928289|Device|VISCO360 ab interno canaloplasty surgery|
1505620|NCT02928289|Device|Selective Laser Trabeculoplasty (SLT)|
2002619|NCT02020616|Drug|LY3053102|Administered SC
1505622|NCT02928263|Other|Non-Interventional|Other
1505623|NCT02928250|Dietary Supplement|Carnosine|Patients in intervention group received carnosine capsules orally daily
1505624|NCT02928250|Dietary Supplement|Placebo|Patients in placebo group received placebo that were similar in appearance to carnosine capsules and the administered dose was as the same schedule as carnosine.
1505625|NCT02928237|Device|transcranial direct current stimulation tDCS|A battery driven DC stimulator (neuroConn Gmbh,98693 llmenau, Germany)
2002620|NCT02020616|Drug|Exenatide extended release|Administered SC
2002621|NCT02020616|Drug|Placebo|Administered SC
2002622|NCT02012959|Drug|Tolvaptan|SAMSCA®
1505632|NCT02928211|Device|Sapphire II|A Class 1 laser device used in conjunction with the ointment to measure fluorescence emissions from the anterior segment (lens) of the eye.
1505633|NCT02928211|Drug|Aftobetin-HCl|The medical imaging agent (the ointment), Aftobetin-HCl is an amyloid binding ligand formulated into an ophthalmic ointment.
1505634|NCT02928211|Radiation|Positron Emission Tomography|Amyvid 370 MBq (10 mCi) is administered as a single bolus through a short intravenous catheter in a total volume of 10 mL.
1505635|NCT02928198|Device|ABSORB BVS|
1505636|NCT02928185|Behavioral|semi-structured interviews|
1505639|NCT02928159|Device|Mecta spectrum 5000Q device|LAP-ST and Right Unilateral (RUL) electrode placement.
1505640|NCT02928146|Procedure|Hernia Repair|
1505643|NCT02928094|Biological|Ad5FGF-4|Ad5FGF-4 administered via intracoronary infusion using standard balloon catheter, and under conditions of transient ischemia.
1505644|NCT02928094|Biological|Placebo|Placebo buffer administered via intracoronary infusion using standard balloon catheter, without transient ischemia.
1505645|NCT02928081|Procedure|Extended lymphadenectomy|Extended lymphadenectomy with nerve tissues around CHA and the SMA and nodes around the celiac trunk and SMA (No.16a2, 16b1)
1505646|NCT02928081|Procedure|Standard lymphadenectomy|Lymph node dissection includes(LN5, LN6),(LN8a, 8b),(LN12b1, 12b2, 12c),(LN13a, 13b),(LN14a, 14b),(LN17a, 17b)
1505647|NCT02928068|Behavioral|Occupational Performance Coaching (OPC)|OPC focuses on increasing positive child-caregiver interactions and child learning opportunities in everyday routines and contexts, which positions families for improved trajectories over time. OPC capitalizes on families' strengths, while supporting caregivers in using their own resources and ideas to advance child function. Caregivers identify goals, while therapists ask reflective questions and make reflective comments, affording caregivers an opportunity to gain a deeper understanding of their own current knowledge and the impact of their strategies on their children's adaptive behavior. Thus, families generate their own solutions and are ultimately responsible for carrying out the intervention and evaluating its effectiveness.
1505689|NCT02927860|Other|Fitbit|A FitBit HR monitor will be placed on patients when they arrive on the nursing unit after thoracic surgery. Sleep and activity will be monitored for the duration of the patient's hospitalization and the data from the Fitbit HR device will be downloaded by the study staff to a computer.
1505690|NCT02927847|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d) to wear for 1 month prior to the quit date. After the quit date, both groups will wear the nicotine patch for 8 weeks (21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks).
1506525|NCT02921789|Drug|Tacrolimus Capsules|Oral (po) or intravenous (iv) if medically indicated
1505648|NCT02928055|Device|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (daily dose is Group-dependent). Stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
1505649|NCT02928042|Other|Lactobacillus bacteria|Antimicrobial effects of Lactobacillus bacteria (LAB) on pathogen bacteria and commercial strains of the same bacteria's growth rate will be investigated.
1505654|NCT02928016|Other|Mixed meal 1|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives. The meal provided 794 kcal and contained approximately 500 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
1505655|NCT02928016|Other|Mixed meal 2|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables.The meal provided 399 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
1505656|NCT02928016|Other|Mixed meal 3|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20g kalamata olives. The meal provided 502 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
1505657|NCT02928016|Other|Mixed meal 4|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed a dish made with thick pasta, minced meat and béchamel sauce and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 893 kcal and contained approximately 600 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
1505658|NCT02928016|Other|Mixed meal 5|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed grilled chicken with vegetables and 11 ml extra virgin olive oil. The meal provided 497 kcal and contained approximately 300 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
1505659|NCT02928016|Other|Mixed meal 6|20 adults with type 1 diabetes (T1DM) on intensive insulin treatment consumed baked giant beans and 20 g kalamata olives and 11 ml extra virgin olive oil. The meal provided 601 kcal and contained approximately 400 kcal from protein and fat. Insulin requirements for the test meal were calculated based on the carbohydrate content of the dish according to the personalised carbohydrate to insulin ratio.
1505660|NCT02928003|Procedure|Lung surgery|Genetic analysis and questionnaires
1505661|NCT02927990|Other|Percutaneous Coronary Intervention|Percutaneous Coronary Intervention according to standard of care
1505662|NCT02927977|Other|control|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises and manual therapy. Participants will receive 4-6 treatments during 4 weeks.
1505663|NCT02927977|Other|dry needling|Individuals with neck pain will receive a multimodal rehabilitation program composed by pain education, exercises, manual therapy and dry needling in neck muscles. Participants will receive 4-6 treatments during 4 weeks.
1505664|NCT02927964|Drug|Ibrutinib|Given PO
1505665|NCT02927964|Other|Laboratory Biomarker Analysis|Correlatives studies
1505666|NCT02927964|Radiation|Radiation Therapy|Undergo radiation therapy
1505667|NCT02927964|Drug|TLR9 Agonist SD-101|Given IT
1505670|NCT02927938|Procedure|Allogeneic HCT|Allogeneic HCT
1505671|NCT02927938|Drug|Consolidation chemotherapy|Cytarabine-based consolidation chemotherapy
1505672|NCT02927925|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion.
1505673|NCT02927912|Radiation|Electron Beam Therapy|Undergo IOERT boost
1505674|NCT02927912|Procedure|Lumpectomy|Undergo lumpectomy
1505675|NCT02927912|Other|Quality-of-Life Assessment|Ancillary studies
1505676|NCT02927912|Other|Questionnaire Administration|Ancillary studies
1505677|NCT02927912|Radiation|Radiation Therapy|Undergo whole breast radiation therapy
1505678|NCT02927912|Procedure|Reconstructive Surgery|Undergo oncoplastic reconstruction
1505679|NCT02927899|Other|Survey Administration|Ancillary studies
1505680|NCT02927899|Dietary Supplement|Tomato-Soy Juice|Receive tomato-soy beverages with or without varying levels of arugula seed powder
1505681|NCT02927886|Procedure|Per-oral endoscopy pyloromyotomy|
1505682|NCT02927886|Procedure|Intrapyloric injection of Botulinum toxin|
1505691|NCT02927847|Drug|SPECTRUM Nicotine Research Cigarettes (.03 mg)|For 1 month prior to their quit date, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
1505692|NCT02927847|Behavioral|Behavioral Activation|Participants in the BA+VLNC group will undergo 7 60-minute behavioral sessions (5 pre-quit and 2 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of behavioral activation treatment. BA components will include activity monitoring, values assessment, activity scheduling, and social contracts.
1505693|NCT02927847|Behavioral|Supportive Counseling|Participants in the VLNC Only group will undergo 7 60-minute behavioral sessions (5 pre-quit and 2 post-quit) including 15 min of standard smoking cessation counseling and 45 minutes of supportive counseling. Supportive counseling will include empathic listening and brief relaxation exercises.
1505694|NCT02927834|Drug|6 day Prednisone|6 day prednisone burst
1505695|NCT02927834|Drug|Augmentin|Antibiotic augmentin for 3 weeks
1505696|NCT02927834|Drug|21 day Prednisone|21 day prednisone burst
1505698|NCT02927808|Behavioral|Motivational Interview|Informational leaflet about the risks of high LDL-C and the importance of adherence to lipid-lowering medication in patients with coronary artery disease. Follow-up motivational interviewing at 1 and 6 months after discharge.
1505699|NCT02927782|Procedure|Early Mobilization|early postoperative mobilisation (walking and sitting). Initial postoperative mobilisation is going to be under supervision of a qualified physiotherapist. The presence of a qualified physiotherapist at first mobilisation is solely for reasons of safety. No specific exercise or regimen is planned.
1505700|NCT02927782|Procedure|Bed Rest|48 hours of strict bed rest followed by postoperative mobilisation under supervision of a qualified physiotherapist. During the bed rest period elevation of the head is tolerated to a maximum of 30°.
2002648|NCT01994109|Drug|MYOBLOC|"MYOBLOC (rimabotulinumtoxinB) Injection, or botulinum toxin type B, is the B serotype of botulinum toxin. It is the only commercially available B serotype, and also the only available botulinum toxin that does not require reconstitution for use."
2002649|NCT01994109|Other|PLACEBO|
2002650|NCT01993719|Drug|Aldesleukin|Administered at a dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1hr)beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum 12 doses).
1505704|NCT02927743|Behavioral|evidence-based online feedback|GPs received during three months weekly mails about evidence-based practice and a small questionnaire to reflect about their practice and the new knowledge
1505705|NCT02927730|Other|no interventions|no interventions
1505706|NCT02927704|Other|Gingival crevicular fluid (GCF) sample|Single intervention has been performed for each subject. GCF samples were collected from four multi rooted teeth (premolar/molar) one of in each quadrant including two maxilla and two mandibula by single examiner in conjunction with clinical measurements in this intervention.
2002651|NCT01993719|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
2002652|NCT01993719|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mlD5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
1505709|NCT02927678|Other|white blood cell SPECT/CT (Single Photon Emission Computed Tomography/Computed Tomography) imaging|
1505710|NCT02927665|Device|Reshape Integrated Dual Balloon|
1505711|NCT02927652|Other|Questionnaires|"New patients at the Duke Clinic 1F and Duke Raleigh Otolaryngology will be asked to complete the Brief Symptom Inventory-18 (BSI-18), patient control scale, and CG-CAHPS.
If a patients answers a 1, 2, 3, or 4 to question #17 (Thoughts of ending your life) on the BSI-18, the nurse will immediately contact the investigator, who will refer for further assessment and/or treatment. The Duke Social Work office is available to provide support, and the Duke Emergency Department has certified social workers and a psychiatric team to do full evaluations if needed."
1505713|NCT02927626|Drug|Yang Yin Fu Zheng therapy|Yang Yin Fu Zheng is a Chinese herbal compound.
1505714|NCT02927626|Drug|Routine medical care|Routine medical care
1505715|NCT02927600|Other|Low GI Breakfast|Intake of low GI breakfast
1505716|NCT02927600|Other|High GI Breakfast|Intake of high GI breakfast
1505717|NCT02927600|Other|Low GI Dinner|Intake of Low GI dinner
1505718|NCT02927600|Other|High GI Dinner|Intake of high GI dinner
1505719|NCT02927587|Drug|The induction Cet of propofol|The induction Cet of propofol was targeted respectively at 1 and 2 ug/ml.
1505720|NCT02927574|Device|DCB|
1505721|NCT02927574|Device|POBA|
1505722|NCT02927561|Other|Diabetic Retinopathy screening|Diabetic Retinopathy screening
1505723|NCT02927535|Drug|TNF blockers monotherapy|
1505724|NCT02927522|Drug|Donepezil|An cholinesterase inhibitor
1505725|NCT02927522|Drug|Placebo|
1505726|NCT02927509|Drug|TNF alpha blockers|
1505727|NCT02927496|Drug|Doxycycline|"Once daily tablet for 6 weeks:
Active comparator: Doxycycline hyclate 200 mg per day x 6 weeks for patients >50 kg or 100 mg per day for patients <50 kg)"
1505728|NCT02927496|Drug|Placebo|Once daily tablet for 6 weeks. Placebo comparator: matching tablets containing no active ingredients
1505729|NCT02927483|Dietary Supplement|Endolex Forte®|Endolex Forte® oral capsules administered from Baseline Visit until Day 180, two capsules per day.
1505730|NCT02927483|Dietary Supplement|A combination of diosmin and hesperidin|A combination of diosmin and hesperidin is a combination of micronized diosmin (450 mg) and micronized hesperidin (50 mg) film-coated tablets administered from Baseline Visit until Day 180, two tablets per day.
1505731|NCT02927470|Device|Sham TMS condition|A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of sham TBS, the subject will perform the working memory task for 45 minutes.
1505773|NCT02927197|Behavioral|LearningRx cognitive training|A clinician will deliver forty 90-minute cognitive training sessions over 12-14 weeks for a total of 60 training hours. There are 23 different categories of training procedures sequenced in intensity and difficulty for a total of more than 1000 training tasks.
1505774|NCT02927184|Drug|VK2809|
1505775|NCT02927184|Drug|Placebo|
1505732|NCT02927470|Device|OffLine TMS Condition|A total of 200 trains will be delivered successively in 40 s, totaling 600 pulses. The pulses will be delivered at 80% of motor thresholds. A sham TMS coil will be used to measure baseline performance on the working memory task. The sham coil looks and sounds just like the real coil, but produces a negligible magnetic field. Following the 40 seconds of TBS, or sham TBS, the subject will perform the working memory task for 45 minutes.
1505733|NCT02927470|Device|Online TMS condition|A single train of pulses (3 pulses at 50Hz, duration 40ms) will be delivered once during a particular time epoch on each trial, followed by a minimum of 6 seconds of no stimulation. No more than 600 pulses will be applied in a single session. Similar to the offline TMS condition, a sham TMS coil will be used to measure baseline performance on the working memory task. In each session (frontal, sham) subjects will perform the working memory task for 45 minutes.
2002653|NCT01993719|Biological|Young Tumor Infiltrating Lymphocytes (Young TIL)|Cells (young TIL) will be infused intravenously (i.v.) on the Patient Care Unti via non-filtered tubing, gently agitating the bag during infusion to prevent clumping.
2002654|NCT01993719|Drug|Keytruda (pembrolizumab) - ONLY FOR RETREATMENT|ONLY FOR RETREATMENT Patients who do not respond or who experience a partial or complete response and subsequently progress and have received prior therapy with either pembrolizumab or nivolumab may receive a second treatment. Patients in the RETREATMENT ARM will receive 4 doses of Pembrolizumab at the NIH Clinical Center as follows: -DAY 0 (two to four days after the last dose of fludarabine), Pembrolizumab 2mg/kg IV approximately 4 hours prior to cell infusion given over approximately 30 minutes; -DAY 21 (+/- 2 days) following cell infusion, Pembrolizumab 2mg/kg IV given over approximately 30 minutes; -DAY 42 (+/- 2 days)following cell infusion, Pembrolizumab 2mg/kg IV given over approximately 30 minutes; -DAY 63 (+/- 2 days) following cell infusion, Pembrolizumab 2mg/kg IV given over approximately 30 minutes
1505736|NCT02927444|Biological|NBP606|A single intramuscular injection into the thigh
1505737|NCT02927444|Biological|Prevnar13|A single intramuscular injection into the thigh
1505738|NCT02927431|Drug|Danirixin 15 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion to provide a dose of 15 mg FBE.
1505739|NCT02927431|Drug|Danirixin 50 mg FBE|This intervention is available as a 50 mg FBE sterile lyophilized powder containing DNX (hydrobromide salt hemihydrate) equivalent to 50mg of free base along with Beta-cyclodextrin sulfobutylether, mannitol, citric acid and sodium hydroxide. The formulation is supplied as lyophilized powder/cake contained in a 30mL vial. Each vial is reconstituted with 9.5 mL water for injection and further diluted with saline for IV infusion.
1505740|NCT02927431|Drug|Placebo|No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
1505741|NCT02927431|Drug|Oseltamivir 75 mg|Oseltamivir (Tamiflu - manufactured by Roche) formulation is available as 75 mg Capsule and as powder for oral suspension. After constitution with 55 mL of water, each bottle delivers a usable volume of 60 mL of oral suspension equivalent to 360 mg oseltamivir base (6 mg/mL). No oseltamivir capsules or powder for oral suspension will be provided. Sites will source the OSV locally and it will be provided open-label.
1505742|NCT02927418|Behavioral|Strength & Conditioning|
1505743|NCT02927418|Behavioral|Control|
1505744|NCT02927405|Drug|Gabapentin|anticonvulsant drug that is used for neuropathic pain.
1505745|NCT02927405|Procedure|TAP Block|a procedure done anesthetize the anterior abdominal wall
1505746|NCT02927392|Drug|Leuprolide acetate|A subset of premenopausal women will receive GnRHAG (leuprolide acetate) 3.75 mg/mo by intramuscular injection every 4 weeks for 24 weeks (6 doses).
1505747|NCT02927379|Drug|Dexmedetomidine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus dexmetedomidine in two divided doses i.e. 20 ml is administered on each side of incision
1505748|NCT02927379|Drug|Ketamine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline plus ketamine in two divided doses i.e. 20 ml is administered on each side of incision
1505749|NCT02927379|Drug|Bupivacaine|local anesthetic wound infiltration with with 20 ml of bupivacaine 0.5 % diluted in 20 ml saline only in two divided doses i.e. 20 ml is administered on each side of incision
1505750|NCT02927366|Drug|QCC374|0.015 mg and 0.06 mg
1505751|NCT02927366|Drug|Placebo Matching|
1505752|NCT02927353|Drug|DMB-3113|subcutaneously injected in a single dose of 40 mg.
1505753|NCT02927353|Drug|Adalimumab|subcutaneously injected in a single dose of 40 mg.
1505754|NCT02927340|Drug|Lorlatinib|
2002655|NCT01993017|Other|Cognitive Behavioral Therapy (CBT)|"The main intervention is the impact of screening on quality of life and health care costs. CBT is provided only if depressive symptoms are detected and participant prefers this type of treatment.
CBT will be centrally telephone-administered by a trained CBT treatment specialist. The treatment specialist will work with local team members throughout a participant's involvement in the study, and will closely follow each participant until he or she has reached a requisite level of improvement ."
1505757|NCT02927314|Drug|CF102|orally q12h
1505758|NCT02927314|Drug|Placebo|orally q12h
1505760|NCT02927275|Behavioral|Experimental: Standing Modality|Cognitive performance when standing
1505761|NCT02927275|Behavioral|Experimental: Biking Modality|Cognitive performance when biking slowly
1505762|NCT02927275|Behavioral|Experimental: Walking Modality|Cognitive performance when walking at 1mph
1505763|NCT02927275|Behavioral|No Intervention: Seated Modality|Cognitive performance when sitting.
1505766|NCT02927249|Other|Placebo|Given PO
1505767|NCT02927249|Drug|Aspirin|Given PO
1505769|NCT02927223|Drug|Atropine|
1505770|NCT02927223|Procedure|Exercise treadmill test|
1505846|NCT02926677|Behavioral|Treatment as Usual|The control group. The standard treatment utilized at Stanford Youth Solutions
1505776|NCT02927171|Other|IntenSive Therapeutic Rehabilitation for Older Skilled Nursing Home Residents|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
1505777|NCT02927145|Biological|RH5.1/ ASO1|"The RH5.1 protein consists of the entire full-length ectodomain of the PfRH5 antigen (amino acids E26 - Q526) with the sequence based on the 3D7 clone of P. falciparum.
The AS01 adjuvant system has been developed and manufactured by GlaxoSmithKline (GSK) Biologicals and is presented as a liquid solution in a monodose glass vial. AS01 is a liposome-based Adjuvant System with a specific aim to improve cell-mediated immunity."
1505778|NCT02927132|Behavioral|Expressive Writing|Expressive writing is a brief intervention that has been linked to various health and social benefits. Expressing emotions through writing can lead to decreased levels of stress and negative affect, thereby serving as a coping mechanism. Furthermore, expressive writing allows participants to reconstruct their traumatic experiences and reorganize their memory of these events into a narrative. Expressive writing has been used to target drinking. Research has found that students have reduced drinking intentions after writing about a negative drinking event compared to control,suggesting that a narrative intervention may be effective in reducing drinking. Other research suggests that feelings of guilt were more strongly associated with intentions to reduce drinking after writing about a negative drinking event, and that this event-related guilt mediated intervention effects.
1505779|NCT02927132|Behavioral|Personalized Normative Feedback|"PNF approaches use information designed to correct normative misperceptions to reduce heavy drinking. Three pieces of information are necessary when providing personalized normative feedback: information about a student's own drinking, information about the student's perceptions of others' drinking, and information about others' actual drinking. The presentation of this information is designed to change students' perceptions of normal drinking by exposing their misperceptions of the norm as well as by comparing their behavior with normal behavior."
1505780|NCT02927119|Dietary Supplement|iodine|≥ 150 µg/day iodine supplementation (iodine containing pregnancy supplement) prior to enrollment
1505781|NCT02927106|Genetic|Genomics|AML cells will be examined by Next Generation Sequencing using an Illumina DNA sequencer.
1505782|NCT02927106|Diagnostic Test|Drug Sensitivity Assay|Ex vivo drug sensitivity testing will be performed on AML cells.
1505783|NCT02927106|Genetic|Proteomics|Biomarkers and genomic signatures will be identified in AML cells that correlate with disease response and adverse events.
2002656|NCT01993017|Drug|Antidepressant Medication|"The main intervention is the impact of screening on quality of life and health care costs. Antidepressant Medication is provided only if depressive symptoms are detected and patient prefers this type of treatment.
Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week, with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated."
2002657|NCT01993017|Other|Standard Care|Participants will receive standard care from either their primary care provider (PCP), or PCP-referred mental health provider in one of the arms, IF depressive symptoms are detected.
1505786|NCT02927067|Drug|Maribavir|200mg tablets
1505787|NCT02927067|Drug|Valganciclovir|450mg tablets
1505788|NCT02927067|Drug|Placebo|Placebo tablets with the same appearance and route of administration as either maribavir or valganciclovir
1505789|NCT02927054|Other|Sepsis Education|Education provided to hospital residents for the recognition and treatment of systemic inflammatory response syndrome (SIRS), sepsis and severe sepsis
1505790|NCT02927041|Device|transesophageal echocardiography (hTEE)|Hemodynamic interventions include volume resuscitation, vasopressors and positive inotropes. Anesthesiologist may or may not use the information provided by the transesophageal echocardiography.
1505791|NCT02927028|Other|Chewing|"On the first visit, the random nut treatments will include chewing walnuts, almonds and pistachios. The chewing conditions will include: 1) 5 g nuts alone, 2) 5 g nuts with 5 ml water, 3) 5 g nuts with 5 ml apple juice, 4) 5 g nuts with 5 g plain yogurt, 5) 5 g nuts with 5 g sweet yogurt.
On visits 2 and 3 the treatments of either 28 g of walnuts or walnut butter will be presented."
1505792|NCT02927015|Other|Purple Majesty potato chips|Purple Majesty potato chips
1505793|NCT02927015|Other|Mountain Rose potato chips|Mountain Rose potato chips
1505794|NCT02927015|Other|White potato chips|White potato chips
1505795|NCT02927015|Other|Crackers|Crackers
1505797|NCT02926989|Drug|Plasmalyte Glucos 50 mg/mL|Solution contains potassium chloride 5 mmol/L and sodium chloride 140 mmol/L.
1505798|NCT02926989|Drug|0.45% saline in 5% dextrose|Solution contains potassium chloride 20 mmol/L and sodium chloride 80 mmol/L.
1505799|NCT02926976|Drug|Risperidone with Clozapine|Risperidone may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
1505800|NCT02926976|Drug|Aripiprazole with Clozapine|Aripiprazole may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
1505801|NCT02926976|Drug|sodium valproate with Clozapine|sodium valproate may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
1505802|NCT02926976|Device|modified electroconvulsive therapy(MECT) with Clozapine|modified electroconvulsive therapy(MECT) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
1505803|NCT02926976|Device|Magnetic seizure therapy(MST) with Clozapine|Magnetic seizure therapy(MST) may be used as a synergistic agent of clozapine in the treatment of treatment-resistant schizophrenia
1505804|NCT02926963|Other|samples collection : hair and skin biopsy|
1505805|NCT02926950|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet
Route of administration: oral"
1505806|NCT02926950|Drug|Placebo|"Pharmaceutical form: tablet
Route of administration: oral"
1505807|NCT02926950|Drug|Metformin|"Pharmaceutical form: tablet
Route of administration: oral"
1505814|NCT02926898|Drug|ZX008 - 0.2 mg/kg/day|ZX008 - 0.2 mg/kg/day ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/ mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.
1506526|NCT02921789|Drug|Methylprednisone|Oral (po) or intravenous (iv)
1505815|NCT02926898|Drug|ZX008 - 0.4 mg/kg/day|ZX008 - 0.4 mg/kg/day ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/ mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.
1505816|NCT02926898|Drug|ZX008 - 20 mg/day maximum dose|ZX008 - 20 mg/day maximum dose ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and
1505817|NCT02926898|Drug|Matching Placebo|ZX008 Matching Placebo
1505818|NCT02926885|Device|CONVENTIONAL LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING CONVENTIONAL RETRACTOR DEVICE
1505819|NCT02926885|Device|FLEXIBLE LIVER RETRACTOR DEVICE|LIVER RETRACTION FOR THE EXPOSURE OF THE ESOPHAGOGASTRIC JUNCTION USING FLEXIBLE LIVER RETRACTOR DEVICE
1505820|NCT02926885|Procedure|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY|LAPAROSCOPIC ROUX-EN-Y GASTRIC BYPASS SURGERY
1505821|NCT02926872|Other|There is no intervention in the study|
1505822|NCT02926859|Drug|Cannabidiol as add-on|Cannabidiol capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
1505823|NCT02926859|Drug|Placebo as add-on|Placebo capsules 2x200 mg twice a day as add-on to individualized pharmacological treatment with either amisulpride, aripiprazole, olanzapine, quetiapine or risperidone over 26 weeks
1505824|NCT02926846|Drug|Intravenous vancomycin & gentamicin with adjunctive lavage|"Intravenous vancomycin and gentamicin are administered, together with adjunctive lavage performed by automated peritoneal dialysis machine over 48 to 72 hours.
(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
1505825|NCT02926846|Drug|Intraperitoneal vancomycin & gentamicin|"Intraperitoneal vancomycin and gentamicin are administered, with the usual continuous ambulatory peritoneal dialysis schedule maintained.
(choice of antibiotic is adjusted in accordance with the microbiology report when available)"
1505826|NCT02926833|Biological|KTE-C19|
1505827|NCT02926833|Drug|atezolizumab (anti-PD-L1)|
1505828|NCT02926820|Behavioral|Cogmed QM|The intervention consisted of 25 Cogmed sessions, typically completed over a five week period (i.e. 5 days per week), with each session lasting between 40-50 minutes per day. The program consists of 12 exercises that target visuo-spatial or verbal working memory. At each training session, participants completed 8 of the 12 exercises (order selected by the user), with 15 trials per exercise. Cogmed QM is an adaptive program, wherein task difficulty is adjusted to performance on each trial. The level of difficulty adjusts continuously and automatically, ensuring that each session provides an engaging, challenging level of WM capacity. Breaks were permitted, and encouraged, at the participants' discretion throughout the session.
1505829|NCT02926807|Other|FDG-PET Scan|a 18FDG-PET to quantify vascular inflammation
1505830|NCT02926807|Other|MDCT|a MDCT to calculate the Agatston score
1505831|NCT02926807|Other|biopsy and blood collection|biopsy and blood collection to assess biomarkers
1505832|NCT02926794|Behavioral|SA and II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
1505833|NCT02926794|Behavioral|SA and No II|Self affirmation intervention where participants rank 11 values, then write about why their top ranked value is important AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
1505834|NCT02926794|Behavioral|No SA and II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND Implementation intentions intervention where participants form two implementation intentions (If/then) statements regarding drinking behavior and write why these are important
1505835|NCT02926794|Behavioral|No SA and No II|Control writing intervention where participants rank 11 values, then write about why their 10th ranked value is important to someone else AND No implementation intentions intervention where participants write why selected health strategies are important (and do nothing else)
1505836|NCT02926781|Device|Dask Advanced Sinus kit|a kit of specially designed drills for closed sinus lift
1505837|NCT02926768|Drug|CK-101|"Phase 1: CK-101 will be administered in escalating dosages in a period of 21-day cycles
Phase 2: CK-101 will be administered daily"
1505838|NCT02926755|Procedure|Coronary Angiography|Coronary angiography which includes fractional flow reserve (FFR),that allows precise measurement of blood flow in the arteries to the heart; the Near Infra-Red Spectroscopy-Intravascular Ultrasound (NIRS IVUS) provides information about the amount of lipid and cholesterol in the plaque, and plaque volume;the Optical Coherence Tomography (OCT) allows physicians to assess tears in the surface of plaque and plaque thickness; and Coronary CT Angiography (CCTA) to evaluate plaque characteristics, and correlate with the invasive findings. The research portion of the study requires all imaging studies be performed (NIRS, IVUS, OCT, FFR) during coronary angiography, rather than just one or two of these imaging studies, and the CCTA.
1505839|NCT02926742|Device|EkoSonic Endovascular System|Ultrasound catheter-directed thrombolysis.
1505840|NCT02926729|Device|nonlinear microscopy imaging of excised surgical margins|Following standard lumpectomy excision, excised tissue will be imaged with NLM. If invasive cancer or ductal carcinoma in situ (DCIS) is detected on or close to the margin, additional excision may be performed. Following surgery, final margins will be evaluated using paraffin embedded histopathology as per standard procedure. Paraffin embedded histopathology will be used to make a final margin determination.
1505841|NCT02926729|Procedure|standard lumpectomy without nonlinear microscopy imaging|Lumpectomy with postoperative paraffin embedded histopathology to make a final margin determination.
1505842|NCT02926703|Other|Serum lactate and CK concentrations in blood samples|Serum lactate and CK concentrations in blood samples were measured routinely at admission
1505843|NCT02926690|Drug|OTS167PO|Single arm, no competitor
1505844|NCT02926677|Behavioral|Cue-Centered Treatment (CCT)|Identify stress reactions and develop coping skills to deal with them independently. Helps address ongoing traumatic stressors.
1505845|NCT02926677|Behavioral|Trauma-Focused CBT (TF-CBT)|Identifies negative cognitive/emotional patterns and helps re-frame them. Uses active support from guardians and focuses on emotional and cognitive conditioning. Focuses on discrete past incidents.
1506527|NCT02921789|Drug|Prednisone|Oral (po)
1505847|NCT02926677|Device|NIRScout|The device is a portable Functional Near-Infrared Spectroscopy (fNIRS) recording unit. NIRS technology uses specific wavelengths of light, introduced at the scalp to enable the non-invasive measurement of changes in the relative ratios of deoxygenated hemoglobin (deoxy-Hb) and oxygenated hemoglobin (oxy-Hb) in the capillary beds during brain activity.
2002658|NCT01993017|Other|Depressive symptom screener|8-item Patient Health Questionnaire, PHQ-8
1505849|NCT02926651|Drug|Conventional Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with three 250mg tablets of ascorbic acid (oral TXA placebo) given 6 hours postoperatively and a final 750mg ascorbic acid dose given the morning of postoperative day 1.
1505850|NCT02926651|Drug|Multi-Dose Oral TXA (Tranexamic Acid)|Three 650mg tablets of oral TXA 2 hours prior to incision with a second 1950mg oral TXA dose given 6 hours postoperatively and a final 1950mg oral TXA dose given the morning of postoperative day 1.
1505851|NCT02926638|Drug|Erlotinib Hydrochloride|Given PO
1505852|NCT02926638|Other|Laboratory Biomarker Analysis|Correlative studies
1505853|NCT02926638|Biological|Rilotumumab|Given IV
1505854|NCT02926625|Behavioral|Systematic follow-up|"Febrile children without a diagnosable illness and without danger signs do not need to return to the HEW unless they are still sick, as over 90% of fevers resolve by themselves.
HEW advice and procedures
Children with unclassified fever should come back for re-assessment after 2 days only if the child still has fever or is sick
Children who are getting worse should come back immediately or at any time for a re-assessment
All children who come back for re-assessment, regardless of when they come back, should have a full assessment of their condition again.
HEW should fill out a loose child assessment form
If child still has fever and a negative rapid diagnostic test for malaria (mRDT), the HEW should refer the child to the nearest health centre."
1505855|NCT02926625|Behavioral|Conditional follow-up|Health extension workers will be trained to counsel caregivers of children with unclassified fever that they should have a conditional follow-up visit, i.e. only to come back for re-assessment after 2 days if the child still has fever or is sick. This is in line with national IMNCI guidelines.
1505856|NCT02926612|Other|Next Generation Genomic Sequencing|DNA and RNA are extracted from biospecimens, amplified, sequenced, and then compared to known microbe databases, allowing for quantitative identification of non-host organisms
1505857|NCT02926599|Behavioral|Personal Optimization Training|
1505858|NCT02926586|Drug|Fludarabine|Fludarabine 50 mg/m2, IV (in the vein) in combination with cytarabine 1500mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
1505859|NCT02926586|Drug|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
1505860|NCT02926573|Drug|Gabapentin|
1505861|NCT02926573|Drug|Placebo|
1505862|NCT02926521|Device|2-octyl cyanoacrylate|Addition of 2-octyl cyanoacrylate liquid adhesive to nerve catheter dressing
1505863|NCT02926521|Device|Gum Mastic|Addition of gum mastic liquid adhesive to nerve catheter dressing
1505864|NCT02926508|Dietary Supplement|Bimuno (BGOS)|"The active supplement of the food supplement (Bimuno) used in this study is called galacto‐oliogosaccharides (Bimuno®, BGOS). BGOS is a compound metabolised by specific bifidobacteria, which are beneficial bacteria, in our colon. Bimuno (2.3 calories) is composed by the following ingredients per gram of Bimuno: 0.96g dry matter; <01g Fat; <0.06g Protein; 0.821g GOS; 0.119g Lactose; 0.0331g Glucose and 0.0029g Galactose. Bimuno is tasteless.
Bimuno will be supplied in coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink."
1505865|NCT02926508|Other|Maltodextrin|"Maltodextrin is a polysaccharide in powder form, which grows most bacteria in the gut, and not specifically the beneficial bifidobacteria.
The placebo will also be provided in daily coded sachets (3.5g) for dispensing by parents. Each participant will be required to consume 1 sachet daily during breakfast, by mixing it with food or in a drink.
This placebo has been used in previous studies, in which Bimuno was used as the active intervention. The placebo will be similar in taste and colour to the active intervention."
1505866|NCT02926495|Device|eCoin System|Median nerve neurostimulator.
1505867|NCT02926482|Behavioral|Physician Recruitment Bundle (PRB)|The Physician Recruitment Bundle (PRB) is a bundle of buprenorphine prescriber capacity building practices. The PRB to be implemented contains the following elements, a) candidate identification strategies, b) physician education forums, c) physician friendly buprenorphine delivery model, d) using academic detailing, e) telemedicine, and f) organizational leadership support.
1505868|NCT02926469|Device|Virtual Reality|Using Virtual Reality during labor
1505869|NCT02926443|Other|Upper Extremity Neuromuscular Training Program|Neuromuscular and strengthening shoulder exercises in a group setting.
1505870|NCT02926443|Other|Usual Physiotherapy Care|One-on-one physiotherapy care in a clinical setting.
2002659|NCT01993017|Other|No intervention|
2002660|NCT01988779|Drug|oral levofloxacin|
2002661|NCT01988779|Drug|nebulized levofloxacin|
1505874|NCT02926417|Procedure|High Density-Electroencephalogram|
1505875|NCT02926404|Device|UNiD Rods|Spinal osteosynthesis
1505876|NCT02926391|Device|UNiD 3D VBR|Corpectomy of one or several vertebral body(ies) followed by vertebral body(ies) replacement and fusion
2002662|NCT01985100|Other|hyperbaric oxygen chamber|
1505878|NCT02926365|Behavioral|ICBT|
1505879|NCT02926352|Behavioral|Extinction Training|Up to 40 min. of self-directed repeated exposure to a fear-provoking situation.
1505880|NCT02926352|Device|Low-Level Laser Therapy|1064nm light used to modulate a biological function and induce a therapeutic effect.
1505881|NCT02926352|Device|Sham Low-Level Laser Therapy|Placebo dose version of LLLT.
1505883|NCT02926326|Drug|BCT197|A single dose of BCT197
1505884|NCT02926326|Drug|Azithromycin|3 daily doses of Azithromycin
1505885|NCT02926313|Other|Individualized Seating provision|Seating system selected and adjusted to meet individual needs.
1505886|NCT02926300|Biological|stem cells|IV infusion
1506612|NCT02921061|Other|Laboratory Biomarker Analysis|Correlative studies
1505887|NCT02926287|Other|Ambulatory surgery|All patients who accepting participation to the study and operated for prolapse surgery, Patient eligible for Ambulatory surgery and return home on the same day if delivery criteria are satisfied ( Chung criteria+tsuccessful trial of void) Patient not eligible for Ambulatory surgery are included as control group
1505888|NCT02926261|Other|Bioelectrical impedance vector analysis|Evaluation of nutritional status with Bioelectrical impedance vector analysis, hand-grip strength and computed-tomography scan
1505889|NCT02926248|Drug|Colchicine|Colchicine is an anti-fibrotic and anti-inflammatory drug
1505890|NCT02926248|Other|Placebo|
1505891|NCT02926235|Drug|Amino Acid|Treatment arm
1505892|NCT02926235|Other|Placebo|
2002663|NCT01983228|Behavioral|Intervention Condition|Intervention participants will complete 6 sessions of telephone coaching over a 10-12 week period, using a patient workbook with visual aids (e.g., diagram of the pain/inactivity cycle) and worksheets that they will complete during the counseling sessions. Participants are expected to receive approximately 180 minutes of total therapist time during the study.
2002664|NCT01979536|Drug|Brentuximab Vedotin|Given IV
1505895|NCT02926209|Device|Aer-O-Scope (Colonoscopy)|"Patients in the Aer-O-Scope first arm will undergo a colonoscopy with the Aer-O-Scope, removing any polyps detected, followed by a colonoscopy using a conventional colonoscope, removing any polyps not previously detected with the Aer-O-Scope."
1505896|NCT02926209|Procedure|Colonoscopy (Conventional Colonoscope)|"Patients in the conventional colonoscope first arm will undergo a colonoscopy with a conventional colonoscope, removing any polyps detected, followed by a colonoscopy using the Aer-O-Scope, removing any polyps not previously detected with the conventional colonoscope"
1505897|NCT02926196|Drug|MSB0010718C|MSB0010718C-Avelumab is formulated as vials of 200 mg strength for IV administration
1505898|NCT02926183|Drug|Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel|Enrolled patients were administered a 30-min intravenous infusion of nab-paclitaxel at a dose of 125 mg/m2, followed by a 30-min intravenous infusion of gemcitabine at a dose of 1000 mg/m2, on day 1, 8, and 15 evey 4 weeks as one cycle of regimen.
1505899|NCT02926170|Drug|Rivaroxaban|Rivaroxaban will be started at 20 mg/day. Dose will be adjusted according to Cr Clearance. Cr Clearance 30-49 ml/min will receive 15 mg/day.
1505900|NCT02926170|Drug|acenocumarol|Doses will be adjusted according to INR
1505901|NCT02926157|Behavioral|Life Style and Sleep Intervention|
1505902|NCT02926144|Device|Laryngoscope with video|Intubation with video-laryngoscope McGrath with use of the video feature
1505903|NCT02926144|Device|Laryngoscope without video|Endotracheal intubation with video-laryngoscope McGrath without use of the video feature
1505904|NCT02926131|Other|Blood sampling|
2002665|NCT01979536|Drug|Crizotinib|Given PO
2002666|NCT01979536|Drug|Cyclophosphamide|Given IV
1505907|NCT02926105|Behavioral|T&E Home-based exercise programme|"T&E exercises programme consists of home-based individually tailored balance and functional strength tests and exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months."
1505908|NCT02926105|Behavioral|Otago|Otago exercises programme consists of home-based individually tailored balance, strength and walking exercises performed 3x a week over 12 months, accompanied by eight in-home visits of physiotherapists during the first six months.
1505909|NCT02926105|Behavioral|Helsana booklet|Helsana programme consists of a booklet with recommendations and 10 exercises performed 3x a week over 12 months.
1505910|NCT02926092|Diagnostic Test|Observation|Observation of progression of disease over time
2002667|NCT01979536|Drug|Cytarabine|Given IT and IV
1505912|NCT02926053|Procedure|Surgical removal of tumor tissue for T cell production|Surgical removal of > 1 cm3 tumor tissue chosen with regards to high rate of success and to minimize the general risks involved in a surgical procedure.
1505913|NCT02926053|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
1505914|NCT02926053|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1. Maximum dose of 50 mg per administration.
1505915|NCT02926053|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
1505916|NCT02926053|Drug|Interleukin-2|Interleukin-2 is administered as high-dose bolus infusions (600.000 IU/kg) over a 15 minute period every 8 hours and continuing for up to 5 days (maximum of 15 doses).
1505918|NCT02926027|Drug|Vascepa|Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
1505919|NCT02926027|Drug|placebo|placebo
1505920|NCT02926014|Device|Videolaryngoscopy|A rigid 70 degree laryngoscope is inserted into the subject's oropharynx, which allows to visualize the lingual tonsils. The size of the lingual tonsils is evaluated using DelGaudio and Friedman grading systems.
1505921|NCT02926014|Other|Reflux Symptom Index Questionnaire|A validated clinical tool for suspecting laryngopharyngeal reflux (LPR). The questionnaire was proposed by Belafsky et al. (2002) and consists of 9 most common gastroesophageal reflux disease (GERD) and LPR symptoms: hoarseness or a problem with your voice; clearing your throat; excess throat mucus or postnasal drip; difficulty swallowing food, liquids, or pills; coughing after you ate or after lying down; breathing difficulties or choking episodes; troublesome or annoying cough; sensation of something sticking in your throat or a lump in your throat; heartburn, chest pain, indigestion, or stomach acid coming up. Each symptom is evaluated on a scale from 0 to 5 (0 - no complaint, 5 - severe symptom). The sum of all symptom evaluations ranges from 0 to 45.
1505957|NCT02925715|Procedure|ultrasound guided central venous cannulation|ultrasound is a medical device which is frequently used for safe venous punctures as you can visualise the structures.so, device ''ultrasound'' will be used for intervention ''central line insertion'' in subclavian vein. ultrasound guided cannulation of the subclavian vein was done by supraclavicular or infraclavicular approach after randomization into either of the two groups.In the supraclavicular approach the puncture site is above the clavicle while in the infraclavicular group the puncture site is below the clavicle. Central venous cannulation is done after identifying the vein on ultrasound and using standard seldinger technique with full asepsis.
1505958|NCT02925702|Drug|Radium 223|Radium-223 55kBq/kg infusion IV every 3 weeks
2002668|NCT01979536|Drug|Dexamethasone|Given PO or IV
2002669|NCT01979536|Drug|Doxorubicin Hydrochloride|Given IV
1505922|NCT02926014|Other|Dysphagia Screening Questionnaire|"A validated questionnaire, proposed by Ohkuma et al. (2002). Lithuanian version of the questionnaire consists of 16 questions: choking during swallowing meals / liquids; difficulty eating solid foods; difficult swallowing; feeling of food getting stuck in the throat; longer than before eating time; feeling of food remaining in the mouth; feeling that food or liquid is going up into the throat from the stomach; feeling of food being stuck in the esophagus; weight loss; food getting stuck in the throat; food falling from the mouth; difficulty coughing during or after meals; occurrence of pneumonia; hoarseness; coughing during the night. Interpretation of dysphagia screening questionnaire:
Advanced symptom - 2 points; Moderate intensity symptom - 1 point; No symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points."
1505923|NCT02925988|Device|EEG monitoring|Neonates will receive their amplitude-integrated EEG monitoring as soon as the indication for monitoring is established, and conventional EEG electrodes will be applied in parallel.
1505924|NCT02925975|Drug|Carvedilol|Carvedilol starts from 6.25mg daily and increase to 12.5mg once daily in next week if being tolerated.
1505925|NCT02925975|Device|3D-vHPS|This 3D model of HPS is rebuilt by a software combining the anatomic information of vessels from CTA (computed tomographic angiography) and the blood stream speed of targeted vessel from Doppler Ultrasound.
1505926|NCT02925975|Procedure|Routine endoscopic procedures|These include esophageal band ligation and tissue glue injection in the fundus of stomach by upper GI endoscopy if there are visible varies in cirrhotic patients. There routine procedures are done to prevent potential varies associated bleeding.
1505927|NCT02925962|Other|Clinical Decision Support System (CDSS)|A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
1505928|NCT02925962|Other|Clinic Decision Sup System + Pharmacist|Includes everything in the CDSS intervention but adds a follow-up call from a pharmacist, who is part of the clinical team. The rationale for this third arm is based on the evidence that clinical pharmacists have been shown to be more effective than physicians alone at achieving BP control in other settings.
1505929|NCT02925949|Behavioral|DuoPACT|6 couple-based intervention sessions are administered weekly by a counselor.
1505930|NCT02925949|Behavioral|LifeSteps|3 individual-based intervention sessions are administered weekly by a counselor.
1505931|NCT02925936|Other|Thyroid facing the anode end of xray machine|Thyroid position: facing the anode end of xray machine
1505932|NCT02925936|Other|Thyroid facing the cathode end of xray machine|Thyroid position: facing the cathode end of xray machine
1505933|NCT02925923|Drug|Ticagrelor|After randomization, a blood sample will be obtained at baseline for platelet function study, the study drugs, ticagrelor and bivalirudin or heparin will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
1505934|NCT02925923|Drug|Eptifibatide|After randomization, a blood sample will be obtained at baseline for platelet function test, the study drugs, clopidogrel and eptifibatide bolus and heparin will be administered. Patients will undergo PCI using drug-eluting stents or bare-metal stents. Blood samples will be obtained at 30 mins, 2, 4, and 24 h after PCI for platelet function tests.
1505935|NCT02925923|Drug|Clopidogrel|
1505936|NCT02925910|Device|Shock absorbing wheelchair|2 randomised groups will try the softwheel wheelchair compare to regular one, but in different order.
1505937|NCT02925897|Behavioral|Behaviour change and motivational interviewing|nurses will help patients to identify health behaviours that they would like to change and to explore their motivation and strengths to achieve this.
1505938|NCT02925884|Device|Gunnar OTC Glasses Condition|Gunnar Over-The-Counter Computer Glasses have optical power of 0.5 diopter for reducing accommodation demands at typical computer-viewing distance. The lens also have a partially transmissive yellow tinting and anti-reflective coating for filtering part of the spectral peaks in typical fluorescent or incandescent light. The frame has a wrape-around design meant to reduce air flow in the vicinity of the eyes.
1505939|NCT02925858|Drug|Normal Saline Flush, 0.9% Injectable Solution_#1|Normal saline infusion mimicking infusion rate of ketamine for a given weight
1505940|NCT02925858|Drug|Ketamine Hydrochloride|Ketamine IV infusion (0.5mg/kg bolus prior to incision, 0.5mg/kg/hr until the end of surgery)
1505941|NCT02925845|Device|Neuromuscular electrostimulation|The device CompexTheta 400i provided with various developmental programs rehabilitation exercise with different phases, types and current is used. an adaptive program (heating, toning, muscular atrophy, strength-endurance) will be established for each patient during the study period. It shall apply at the level of the muscle bellies of the flexor and extensor muscles of the forearm dela upper extremity AV created. Electrodes are positioned at the anatomical reference positions. The intensity of the current will increase until a tolerable muscle contraction and painless by the patient.
1505942|NCT02925832|Procedure|Deep Topical Fornix Nerve block anesthesia|DTFNB would be performed using two sponges (2x3mm) soaked with either 0.5% bupivacaine or 0.75% ropivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with proparacaine local anaesthetic drops. The sponges are to be removed after 15 minutes.
1505943|NCT02925832|Drug|Ropivacaine|0.75% ropivacaine soaked sponges
1505944|NCT02925832|Drug|Bupivacaine|0.5% bupivacaine soaked sponges
1505945|NCT02925832|Drug|Proparacaine|For anaesthetising conjunctiva
1505946|NCT02925806|Other|Non-interventional study - retrospective database review|
1505947|NCT02925793|Drug|DS107|
1505948|NCT02925793|Other|Vehicle cream|
1505949|NCT02925780|Device|Resin Infiltration|
1505950|NCT02925780|Procedure|Microabrasion|
1505951|NCT02925767|Device|311-nm Ti:Sapphire laser|Pallas, LaserOptek, South Korea
1505952|NCT02925767|Device|308-nm excimer laser|XTRAC, PhotoMedex, US
2002670|NCT01979536|Drug|Etoposide|Given IV
2002671|NCT01979536|Drug|Ifosfamide|Given IV
1505955|NCT02925728|Other|Finger-Food|Finger-Food at lunch and having diner
1505956|NCT02925728|Other|Without Finger-Food|Without finger-food
1506613|NCT02921061|Drug|Mitoxantrone Hydrochloride|Given IV
2002672|NCT01979536|Other|Laboratory Biomarker Analysis|Correlative studies
1505960|NCT02925663|Behavioral|EFI-E|This is 10 web-based modules addressing foundational EF skills. Each online module will be accompanied by a videoconference with a therapist to review the skills and problem solve around adolescent-identified goals.
1505961|NCT02925650|Drug|Posiphen|oral solid dosage form capsule
1505962|NCT02925650|Drug|Placebo|oral solid dosage form capsule
1505963|NCT02925637|Other|FacoT|The intervention will include: functional activities, cognitive activities and strategies (pencil-pen treatment), and behavioural strategies
1505964|NCT02925624|Procedure|Pulmonary vein isolation|
1505965|NCT02925611|Drug|Isoflurane|
1505966|NCT02925611|Drug|Desflurane|
1505967|NCT02925598|Device|I-gel LMA insertion|'I-gel LMA insertion' was done following anesthesia induction.
1505968|NCT02925598|Device|AuraGain LMA insertion|'AuraGain LMA insertion' was done following anesthesia induction.
1505969|NCT02925598|Device|ETT insertion|'ETT insertion' was done following anesthesia induction.
1505970|NCT02925585|Other|Pre/post imaging|
1505971|NCT02925572|Other|Cycling exercises|All measurements are performed before and after the training program (12 weeks)
1505972|NCT02925559|Drug|Dapagliflozin|The active treatment will include a 10 mg dose of dapagliflozin orally once a day.
1505973|NCT02925559|Drug|Gliclazide MR|As comparator, gliclazide MR will be administered at a dose of 120 mg orally once a day.
1505974|NCT02925546|Drug|GSK2798745 Micronized API without SLS and hypermellose (Tablet A)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API; to be administered orally with 240 mL of water under fasted/fed conditions
1505975|NCT02925546|Drug|GSK2798745 Micronized API with SLS and hypermellose (Tablet B)|This is an immediate release tablet containing 2.4 mg of micronized GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions with 240 mL of water
1505976|NCT02925546|Drug|GSK2798745 milled API without SLS and hypermellose (Tablet C)|This is an immediate release tablet containing 2.4 mg of milled GSK2798745 API with SLS and hypermellose; to be administered orally in fasted/fed conditions, with 240 mL of water
1505977|NCT02925533|Drug|B-701|B-701 is a phage-derived, affinity-matured, human monoclonal antibody (mAb) specific for FGFR3. It is based on a human immunoglobulin G1 (IgG1) framework containing heavy chain VHIII and light chain VκI subgroup sequences.
1505978|NCT02925533|Drug|Pembrolizumab|Pembrolizumab is an mAb that binds to the programmed cell death protein 1 (PD-1) receptor and blocks its interaction with programmed death-ligand 1 (PD-L1) and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In syngeneic mouse tumor models, blocking PD-1 activity resulted in decreased tumor growth.
1505979|NCT02925520|Drug|Omegaven|"Therapy with Omegaven will be provided at a dose of 1 gm/kg/day infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Parenteral fat emulsion (Intralipid) will be administered only if necessary to administer adequate calories during Omegaven therapy. The same standards of care provided to all patients receiving parenteral nutrition solution will be followed.
Home Use of Omegaven:
The Omegaven dose for home use will be the same as that used while in the hospital: 1 gm/kg/day. As with the inpatient part of the protocol, this is a maximum dose and may be decreased at the discretion of the provider."
1505980|NCT02925507|Other|Swallowing Screen|Patient will be ask to undergo a swallowing screen by study staff
1505983|NCT02925481|Behavioral|Moderate Online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 150 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
1505984|NCT02925481|Behavioral|Stretching and toning|Phase 1: Developing 12 week prescription for online control videos Phase 2: Online streaming stretching and toning videos completed at home which consist of a warm-up, 1 balance, 2 core, 2-3 upper body and lower body exercises, 6 stretches, cool-down
1505985|NCT02925481|Behavioral|Low dose online yoga participation|Phase 1: Testing yoga videos for emotional regulation and self-compassion which will inform the selected videos for Phase 2 prescription Phase 2: 60 minutes of Online streaming yoga videos completed at home. Week 1/2 introductory videos that include short video clips breaking down each pose Weeks 3-12 increase in difficulty (all videos are appropriate for beginners)
1505986|NCT02925468|Device|Bite turbo|In this study the nature and speed of adaptation of the occlusal changes following insertion of an anterior bite plane (bite turbos) for the reduction of a deep overbite in growing patients will be investigated.
1505987|NCT02925455|Device|Contralaterally-controlled functional electrical stimulation|Contralaterally-controlled functional electrical stimulation (CCFES) is electrical stimulation of weak muscles of an impaired limb controlled via movement of the unimpaired contralateral limb.
1505988|NCT02925455|Device|Hand therapy video games|Hand therapy video games are designed to provide therapy to weak muscles of an impaired limb via goal-directed movements.
2002673|NCT01979536|Drug|Methotrexate|Given IT and IV
2002674|NCT01977651|Drug|Enzalutamide|Oral
2002675|NCT01975766|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
1505992|NCT02925416|Drug|oritavancin|
1505993|NCT02925416|Drug|placebo (D5W)|
1505994|NCT02925403|Biological|R21/Matrix-M1|
1505995|NCT02925403|Other|Saline|
1505996|NCT02925377|Behavioral|Neuromuscular warm-up|The intervention group replaced their regular warm-up routine with seven neuromuscular warm-up exercises performed for 15 minutes prior to each practice session (3x/week) over a period of eleven weeks.
1505997|NCT02925377|Behavioral|Standard warm-up|Athletes in the control group followed their regular 15 minutes warm-up routine provided by the team coaches.
1505998|NCT02925364|Radiation|magnetic resonance imaging (MRI)|all participants will undergo a functional MRI and an anatomical MRI in a single session
2002676|NCT01975766|Device|External beam radiation therapy|
1506002|NCT02925338|Other|QOL questionaire|Health assessment questionnaire disability index for rheumatoide polyarthritis questionnair
1506003|NCT02925325|Behavioral|Music therapy|Music therapy (MT) treatment focuses on the use of 2 techniques of intervention: receptive MT and active MT. The work of receptive application is described as the use of prerecorded music or executed by the music therapist with effect on the patient, without the latter's active involvement in the psychotherapeutic process of musical creation. While the active application, both the music therapist and patient are involved in musical creation, for example, the use of voice, body and musical instruments (Muñoz, 2008). Contemplate their psychotherapeutic possibilities in 3 different dimensions of patient: body, emotional and social work, as explained above. Treatment with MT, as in cognitive behavioral therapy, includes breathing exercises, stress-relaxation techniques, psychoeducation, and exercises for the management of irrational thoughts and erratic behavior patterns (Dobson and Dozois, 2010).
1506004|NCT02925325|Other|Usual Treatment|It is the usual medical treatment that patients with major depressive disorder in remission but with residual symptom receives at the sponsor institution in a monthly basis.
1506005|NCT02925312|Other|Diabetes Pathway|Medication algorithm, survival skills education, enhanced patient-provider communication
1506006|NCT02925299|Device|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:
Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 CGM and glucose suspend feature.
An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
1506007|NCT02925299|Device|Insulin pump therapy|Subjects will continue using their own insulin pump for 12 months.
1506008|NCT02925286|Other|Prevention program for gambling in the workplace|The intervention group will receive a gambling prevention program which includes generating and implementing policies and education on addiction and gambling. The full length of the program will be about 14 hours.
1506009|NCT02925273|Other|palmar grasp without dorsal stimulation|"The patient will then be asked to keep the arms at 90 degrees and the researcher will slightly stroke palm and fingers of both hands of the patient simultaneously. After completion of each technique, the presence or absence of the response will be noted. In addition, the prominence of the response on the rating scale will be obtained as explained below.
The scaling of the grasp response is as followed:
Flexion at the distal interphalangeal joint of the hand
Flexion at the proximal interphalangeal joint of the hand
Flexion at the metacarpal-phalangeal joint of the hand"
1506010|NCT02925273|Other|standard palmar grasp test with dorsal stimulation|The patient will be asked to put their arms at 90 degrees and the researcher will hold one hand at the wrist and dorsum of the palm and lightly stroke the palm and fingers. The patient will be instructed to relax hands and not hold on while doing the grasp and see if the response persists. The same technique will be repeated for the patient's other hand.
1506011|NCT02925260|Other|MRI with ileal pouch contrast and enema.|Pre enema 20mg IV or IM Hyoscine Butylbromide (Buscopan) Pre enema Small Field of View (SFOV) T2 sagittal series Pre enema SFOV T2 axial series Pre enema SFOV T1 sagittal series (fat suppressed) Pre enema SFOV T1 axial series (fat suppressed) Enema infiltration started During enema filling Dynamic T1 sagittal single image, fat suppressed, aligned on pouch-anal anastomosis During enema filling T1 sagittal series (fat suppressed) During enema filling T1 axial series (fat suppressed) Jelly infiltrated and held Evacuating series Oblique sagittal T2 evacuating series of the mid and distal pouch, aligned to the pouch-anal anastomosis
1506012|NCT02925247|Behavioral|Adherence to oral anticoagulant treatment|The adherence will be evaluated using the Morisky medication adherence scale. This patient self report scale has been previously validated for cardiovascular treatment adherence.
1506013|NCT02925234|Drug|Panitumumab|Panitumumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of panitumumab might be expected based on their molecular tumor profile.
1506014|NCT02925234|Drug|Olaparib|Olaparib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of olaparib might be expected based on their molecular tumor profile.
1506015|NCT02925234|Drug|Dabrafenib|Dabrafenib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of dabrafenib might be expected based on their molecular tumor profile.
1506016|NCT02925234|Drug|Nilotinib|Nilotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nilotinib might be expected based on their molecular tumor profile.
1506017|NCT02925234|Drug|Trametinib|Trametinib treatment for patients with an mutated advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trametinib might be expected based on their molecular tumor profile.
1506018|NCT02925234|Drug|Erlotinib|Erlotinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of erlotinib might be expected based on their molecular tumor profile.
1506019|NCT02925234|Drug|Trastuzumab and Pertuzumab (combination treatment)|Trastuzumab and Pertuzumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of trastuzumab + pertuzumab might be expected based on their molecular tumor profile.
1506020|NCT02925234|Drug|Vemurafenib and Cobimetinib (combination treatment)|Vemurafenib + Cobimetinib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of Vemurafenib + Cobimetinib might be expected based on their molecular tumor profile.
1506021|NCT02925234|Drug|Vismodegib|Vismodegib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
1506022|NCT02925234|Drug|Regorafenib|Regorafenib treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of vismodegib might be expected based on their molecular tumor profile.
1506023|NCT02925234|Drug|Nivolumab|Nivolumab treatment for patients with an advanced solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma, who are not eligible for on-label treatment but for whom anti-tumor activity of nivolumab might be expected based on their molecular tumor profile.
1506024|NCT02925208|Other|cochlear implant surgery|patients with severe to profound sensorineural hearing loss who underwent cochlear implant surgery
1506025|NCT02925195|Dietary Supplement|Vitamin D3|cholecalciferol (vitamin D3) 2000 IU capsules daily
1506026|NCT02925195|Drug|Placebo|
1506027|NCT02925182|Device|Er,Cr:YSGG Laser|
1506028|NCT02925169|Device|CT Scan|CT imaging
1506029|NCT02925143|Other|E-learning course in neuromuscular monitoring|An e-learning course designed to assess the challenges and common problems experienced by anesthetists when monitoring the neuromuscular blockade during general anesthesia.
1506030|NCT02925130|Drug|Salbutamol|Acute intake of Albuterol, a beta2-mimetic, either inhaled or oral.
1506031|NCT02925130|Drug|Placebo|Acute oral intake of a placebo drug
1506032|NCT02925117|Drug|ABT-494|Oral tablet
1506033|NCT02925117|Drug|Placebo|Oral tablet
1506034|NCT02925104|Drug|INC280|
1506035|NCT02925078|Device|Biohorizons Tapered Internal Implant, Laser-Lok, Resorbable Blast Textured (RBT)|Placement of implant in a subject with <2 mm mucosa thickness or a subject with ≥2 mm mucosa thickness.
1506036|NCT02925065|Other|Non-traditional group guitar instruction|A 6-week curriculum for non-traditional training in finger-style guitar has been developed with rhythmic and goal oriented upper extremity and finger movements. Guitar group intervention will be implemented at the Towson campus of the Peabody Preparatory. Intervention approaches will include rhythmic digital grip with finger isolation, goal directed rhythmic reach on the fret-board and rhythmic alternating tap-like digit and hand movements on the guitar. Participants will be provided with the instruments in the group setting without expectation of practice at home.
1506037|NCT02925052|Device|Gastric Tube Guide|
1506038|NCT02925052|Device|Conventional placement|
1506039|NCT02925039|Other|Rehab with computer feedback|Sit to stand training with addition of computerised feedback (speed, symmetry and trunk tilt)
1506040|NCT02925039|Other|Treatment as usual|Treatment as usual
1506041|NCT02925026|Dietary Supplement|Lactoferrin|
1506042|NCT02925026|Dietary Supplement|Lysozyme|
1506043|NCT02925026|Dietary Supplement|Placebo|
1506044|NCT02925013|Procedure|Blood sampling|
1506045|NCT02925013|Other|Dietary- Normal western diet|Normal western diet
1506046|NCT02925000|Drug|TLC178|TLC178
1506047|NCT02924987|Drug|Aflibercept Injection|Intravitreal injections of 0.05 mL (2mg) of Aflibercept will be injected. The intravitreal between the first 5 treatments sessions is 4 weeks, and the interval for the following treatment sessions up to week 52 is 8 weeks.
1506048|NCT02924974|Drug|Morphine|mixed with bupivacaine
1506049|NCT02924974|Drug|Lidocaine|sham procedure (s.c. lidocaïne)
1506050|NCT02924961|Device|Triathlon PS total knee system with mobile-bearing|
1506051|NCT02924961|Device|Triathlon PS total knee system with fixed-bearing|
1506052|NCT02924948|Procedure|Balloon inflation|EUS balloon inflation will be done before insertion through the subjects throat
1506053|NCT02924935|Dietary Supplement|Histidine|50mg/kg Histidine mixed in food or drink
1506054|NCT02924922|Procedure|Laparoscopic partial nephrectomy|The renal hilus is identified and both vein and artery are dissected. A laparoscopic ultrasound probe is introduced through a 12 mm port to define the tumor resection margins. A laparoscopic Satinsky clamp is used to induce total kidney ischemia, clamping both vein and artery. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Ischemia is interrupted once renorrhaphy is completed
1506055|NCT02924922|Procedure|Robot assisted partial nephrectomy|The renal hilus is carefully dissected, so that the arterial segmental branches are reached. Tumor resection margins are identified through ultrasound. Drop-in bulldog clamps are used to clamp segmental arterial branches and induce selective ischemia. Indocyanine green 0.2-0.3mg/KG is infused intravenously a few seconds after the selective ischemia is induced. The Firefly near infra-red fluorescence system is used to determine the extent of the ischemic area. The ischemic zone can now be tailored to the tumor by adding or removing bulldog clamps according to the vascular anatomical conditions. Athermal resection of the tumor is performed and titanium clips are used to close interlobar or arcuate arteries encountered during resection. The resection defect is closed with stitches secured by Hem-o-Lok clips and haemostatic glue. Selective ischemia will be interrupted once renorrhaphy is completed
1506056|NCT02924922|Device|Conventional laparoscopic instruments|Endoscope, Scissor, Needleholder, Forceps, Suction unit, Ports, Tissel, CO2, Sutures, Needles, Scalpel, Ultrasound-Probe, Monitors
1506057|NCT02924922|Device|Da- Vinci Robot and conventional laparoscopic instruments|Da Vinci Robot, Console, Ports and Instruments; Suction unit, Forceps, Tisseel, Ultrasound Probe, Monitors
1506058|NCT02924922|Drug|Mannitol|
1506059|NCT02924909|Drug|carboplatin paclitaxel|induction carboplatin paclitaxel for 2 cycles
1506060|NCT02924896|Dietary Supplement|Palm olein|60g of palm olein will be given in a milkshake at breakfast
1506061|NCT02924896|Dietary Supplement|Interesterified palm olein|60g of interesterified palm olein will be given in a milkshake at breakfast
1506062|NCT02924896|Dietary Supplement|Soybean oil|60g of soybean oil will be given in a milkshake at breakfast
1506063|NCT02924883|Drug|Atezolizumab|Atezolizumab 1200 mg IV infusion
1506064|NCT02924883|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion
1506065|NCT02924883|Other|Placebo|Placebo matched to atezolizumab
2002677|NCT01975389|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
2002678|NCT01975389|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
1506066|NCT02924870|Other|Health education program|"2 sessions, at 15 and 30 days after hospital discharge. The first session will consist of four stages:
Basic formation: basic lung anatomy and physiology, COPD concept, importance of tobacco, diagnostic tests for COPD, and how COPD is treated.
Care in COPD: diet, breathing exercises, physical exercise (walking, cycle, treadmill ...), lifestyle (clothing, hygiene, preening, exercise, rest, sexuality, social relations).
Management of conventional treatment: inhalers, oxygen therapy and smoking cessation.
Action Plan: the patient and the nurse will establish a target about the activities that the patient must perform as well as their frequency and duration, according to WHO guidelines.
Second session: changes from the previous session; compliance with the physical activity plan and the deviation causes; weaknesses of the patient; skills in the management of inhalers, oxygen, and breathing exercises; and a new physical activity plan."
1506067|NCT02924870|Other|Conventional management|Treatment and follow-up according to conventional clinical practice (GesEPOC guidelines), including recommendations on healthy habits and lifestyle.
1506068|NCT02924857|Device|Chocolate Touch|The Chocolate Touch™ Paclitaxel Coated Balloon Catheter is indicated for balloon dilatation, after appropriate vessel preparation as needed, of lesions in native superficial femoral or popliteal arteries up to 15 cm in length that are appropriate for angioplasty with balloon diameters from 3.5 mm to 6.0mm.
1506069|NCT02924857|Device|Lutonix Drug Coated Balloon|The Lutonix® 035 Drug Coated Balloon Catheter is indicated for improving luminal diameter for the treatment of obstructive de novo or non-stented restenotic lesions (≤ 15 cm in length) in native femoropopliteal arteries having reference vessel diameters of 4 mm to 6 mm.
1506070|NCT02924831|Other|Acupuncture|Stimulating acupoints by using stainless steel needles with manual manipulation.
1506071|NCT02924831|Other|moxibustion|Stimulating acupoints by using burned moxa
1506072|NCT02924831|Other|placebo|Stimulating acupoints by using stainless steel needles without manual manipulation.
2002679|NCT01975376|Drug|bococizumab (PF-04950615)|150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
2002680|NCT01975376|Drug|Placebo|Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
2002681|NCT01974765|Drug|Enzalutamide|All enrolled patients will be treated with enzalutamide 160mg by mouth QD. Study drugs will be self-administered by patients. A cycle is 28 days.
2002682|NCT01970865|Drug|PF-06463922|Oral, starting dose 10mg once a day, dose escalation in Phase 1 until recommended Phase 2 dose determined, continuous daily dosing, cycles lasting 21 days
2002683|NCT01970865|Drug|Crizotinib|Oral, starting dose of 250 mg BID continuous daily dosing every 21 days
2002684|NCT01969916|Drug|Regadenoson|Patients will be given a single dose of Lexiscan (0.4 mg, iv bolus)
1506080|NCT02924805|Other|Telemedical care|Telemedically guided care based on a standard operating procedure
1506081|NCT02924792|Device|Reinfusion - Sternal IO needle|
1506082|NCT02924792|Device|Reinfusion - Intravenous needle|
1506083|NCT02924779|Other|No intervention|Retrospective observational study
1506084|NCT02924766|Drug|Niraparib|Participants will start with niraparib 200 mg once daily.
1506085|NCT02924766|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4*60 mg) once daily orally.
1506086|NCT02924766|Drug|Abiraterone Acetate|Participants will receive 1000 mg (4*250mg) once daily.
1506087|NCT02924766|Drug|Prednisone|Participants will receive 10 mg (1*5 mg twice daily).
1506088|NCT02924753|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
1506089|NCT02924753|Drug|Fludarabine|Fludarabine 25mg/m2/day IV for 3 days (Day-5 to day-3).
1506090|NCT02924753|Biological|CART-19 cells|CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
1506091|NCT02924740|Behavioral|Pelvic Floor Muscle Training|Pelvic floor muscle training consist of fast (2 second) and slow contractions (5-s contraction, 10-s hold, 5-s relaxation, totally 20-s). One set of exercises includes ten fast and ten slow voluntary PFM contractions (VPFMCs). During week 1 and 2, participants will be instructed to perform two sets of exercises per day (20 fast and 20 slow contractions per day), which was progressively increased by two sets: four sets per day at week 3 and 4 (40 fast and 40 slow contractions per day); six sets per day at week 5 and 6 (60 fast and 60 slow contractions per day); eight sets per day at week 7 and 8 (80 fast and 80 slow contractions per day); ten sets per day from week 9 to week 12 (100 fast and 100 slow contractions per day).
1506092|NCT02924740|Behavioral|Vaginal Tampon Training|Vaginal tampon training will be applied for 5 days a week for 12 weeks. Exercises with tampons will be performed two days a week by physiotherapist (first author) and three days a week by patients. One set of tampon exercises consist 15 contractions. During vaginal tampon training, from week 1 to week 12, patients were instructed to perform two sets of exercises for five days a week (two days by physiotherapist, three days by themselves).
1506093|NCT02924727|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) tablet will be available in 24/26 mg, 49/51 mg and 97/103 mg, respectively
1506094|NCT02924727|Drug|Ramipril|Ramipril 1.25 mg, 2.5 mg, and 5 mg oral capsules
1506095|NCT02924727|Drug|Placebo of LCZ696|Matching placebo of LCZ696 tablets
1506096|NCT02924727|Drug|Placebo of ramipril|Matching placebo of ramipril capsule
1506097|NCT02924727|Drug|Valsartan|Valsartan (VAL489) 40 mg and 80 mg tablets, two doses for 1 day to patients who were previously treated with ACE inhibitors receiving the last dose of that agent during the last 36 hours prior to randomization
1506098|NCT02924727|Drug|Placebo of valsartan|matching placebo of valsartan for one day to patients who will be randomized to received ramipril
1506099|NCT02924714|Other|Discontinuation of imatinib|
1506100|NCT02924701|Other|Blood samples, fibroscan and questionaires|
1506270|NCT02923518|Other|Questionnaire|Observational study without any intervention described under intervention type
2002685|NCT01969851|Drug|Lacosamide|"Oral intake twice daily of tablet (100 mg or 50 mg) or syrup formulation (10 mg/ml).
Total daily dose will be titrated over a period of 6 weeks with starting dose of 100 mg/day or 2 mg/kg/day up to doses not exceeding 600 mg/day or 12 mg/kg/day tablet or syrup, respectively. Followed by a 12 week maintenance period with stable dosing of at least 200 mg/day or 4 mg/kg/day tablet or syrup, respectively."
2002686|NCT01968538|Radiation|Radiation Therapy|
2002687|NCT01965119|Drug|Ruxolitinib|20 mg orally twice a day for 4 weeks (One cycle) Treatment continued until documented disease progression or unacceptable toxicity.
2002688|NCT01964560|Drug|Lacosamide|"Pharmaceutical form: oral solution
Concentration: 1 mg/kg - 6 mg/kg BID (2 mg/kg/day - 12 mg/ kg/day)
Route of administration: oral use"
2002689|NCT01964560|Drug|Lacosamide|"Pharmaceutical form: tablet
Concentration: 50 mg - 300 mg BID (100 mg/day - 600 mg/day)
Route of administration: oral use"
2002690|NCT01962415|Drug|Hydroxyurea|Oral administration at 30 mg/kg/day.
1506112|NCT02924675|Drug|Pregabalin|150mg daily in three doses during three weeks
1506113|NCT02924675|Drug|Placebo|Three doses daily with lactose
2002691|NCT01962415|Drug|Alemtuzumab|"Intravenous (IV) administration. The first dose for each arm will be a test dose (0.2 mg/kg max 5 mg). The treatment doses of alemtuzumab will be based on the patients' assigned stratum as determined by their age, lymphocyte count and presence of infection.
Stratum 1: 1 mg/kg (max dose of 30 mg); Stratum 2: 0.5 mg/kg (max dose of 15 mg); Stratum 3: No treatment dose, test dose only."
1506115|NCT02924649|Procedure|Early Intensive mobilisation|The intervention will be performed using a tilt table with integrated stepping movements of the lower extremity (ERIGO, HOCOMA, Switzerland). The goal of the intervention session is that the patient stands upright for 20 minutes. If orthostatic intolerance or increase in intracranial pressure occurs the session will be paused. When the patient is stable mobilization is continued.
1506116|NCT02924636|Behavioral|ePPOP-ID program|This is a personalized and online program. The website will provide secure communication with dietician and lifestyle coaches.
1506117|NCT02924597|Procedure|zero ischemia robot-assisted laparoscopic RFA assisted TE|
1506118|NCT02924597|Procedure|zero ischemia robot-assisted laparoscopic partial nephrectomy|
1506119|NCT02924571|Procedure|Bone Marrow Aspirate Concentrate (BMAC)|Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest (BMAC+ ALLOGRAFT) or
1506120|NCT02924571|Procedure|Recombinant Human Bone Morphogenetic Protein-2 (BMP)|INFUSE rhBMP-2 Bone Graft (BMP). Using the standard technique for anterior lateral fusion, the bone graft from group 1 or 2 will be laid onto the decorticated transverse processes, lateral aspects of the facets, par interarticularis, and onto the facets.
1506121|NCT02924558|Other|Egg protein/unsaturated fatty acid|Study test foods (yogurt, muffins, waffles, and cookies) containing 8% higher protein energy (egg protein) and 8% higher fat energy (unsaturated fatty acids) than Control
1506122|NCT02924558|Other|Control|Study test foods (yogurt, muffins, waffles, and cookies) containing 16% higher carbohydrate energy than Egg protein/unsaturated fatty acid
1506123|NCT02924532|Biological|immediate post operative bioassay of Parathyroid Hormone|
1506124|NCT02924506|Device|Mobi-C prothesis|Mobi-C Prothesis, LDR Medical (company)
1506125|NCT02924506|Device|ProDisc-C prothesis|ProDisc-C prothesis, Vivo Depuy Synthes (company)
2002692|NCT01962415|Drug|Fludarabine|IV administration at 30 mg/m2/day or 1 mg/kg/dose, whichever is lower.
1506127|NCT02924480|Procedure|Cystectomy|
1506128|NCT02924480|Drug|Lidocaine|Patients will receive lidocaine infusion during surgery
1506129|NCT02924480|Drug|Saline|Patients will receive saline infusion during surgery
1506130|NCT02924467|Behavioral|1 Notice|1 Reminder notification via autodialer
1506131|NCT02924467|Behavioral|2 Notices|2 Reminder notifications via autodialer
1506132|NCT02924467|Behavioral|3 Notices|3 Reminder notifications via autodialer
1506133|NCT02924454|Drug|metoprolol|One hundred and twenty ml, 0.5 mg metoprolol/ml (as metoprolol tartrate) is administered as an intravenous bolus injection followed by a continuous infusion. Infusion is halted if heart rate drops below 35 bpm or systolic blood pressure drops below 80 mm Hg, or the participant experiences subjective side effects. Infusion stops at T=30 minutes.
1506134|NCT02924454|Drug|intravenous lipid emulsion|Intravenous lipid emulsion 20 % is administered as an intravenous bolus infusion (1.5 ml/kg) followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Lipid emulsion infusion is stopped at T = 30 minutes.
1506135|NCT02924454|Drug|Sodium chloride 0.9% solution - lipid emulsion dummy|Isotonic 0.9 % sodium chloride solution is administered as an intravenous bolus infusion (1.5 ml/kg), followed by continuous infusion (infusion rate: 0.25 ml/kg/min). Infusion is stopped at T = 30 minutes.
1506136|NCT02924454|Drug|Sodium chloride 0.9% solution - metoprolol dummy|Saline solution is administered as an intravenous bolus injection followed by a continuous infusion to T=30 minutes.
1506137|NCT02924441|Other|Lidocaine|Applied to breast skin
1506138|NCT02924441|Other|Calming Music|Played during mammography
1506139|NCT02924441|Other|No Music|No music played during mammography
1506140|NCT02924428|Device|Venus Versa|
1506141|NCT02924415|Behavioral|Tele-care support|Psychoeducation treatment based on telemedicine
1506142|NCT02924415|Other|Control group|Standard care
1506143|NCT02924402|Biological|XmAb13676|Biological
2002693|NCT01962415|Drug|Melphalan|IV administration at 70 mg/m2/dose.
2002694|NCT01962415|Drug|Thiotepa|IV administration at 200 mg/m2/dose
2002695|NCT01961297|Drug|Sodium oxybate|Sodium oxybate
1506147|NCT02924376|Drug|INCB054828|INCB054828 once daily
1506148|NCT02924363|Diagnostic Test|Cardiac MRI|MRI scans before and after the MitraClip clinical procedure
2002696|NCT01958281|Drug|SOF 100 mg|Sofosbuvir (SOF) 100 mg tablets administered orally once daily
2002697|NCT01958281|Drug|SOF 400 mg|SOF 400 mg tablet administered orally once daily
2002698|NCT01958281|Drug|RBV|Ribavirin (RBV) 200 mg tablet administered orally once daily
2002699|NCT01958281|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg fixed-dose combination (FDC) tablet administered orally once daily
2002700|NCT01957514|Other|Cytology Specimen Collection Procedure|Undergo tissue biopsy, blood, buccal mucosa, saliva, and urine collection
2002701|NCT01957514|Other|Laboratory Biomarker Analysis|Correlative studies
1506149|NCT02924363|Diagnostic Test|Blood sample|Blood samples collected to calculate Hematocrit for measurements of CMR extracellular matrix
1506150|NCT02924350|Other|Stannous fluoride|Experimental dentifrice containing 0.454% weight per weight (w/w) stannous fluoride (1100 parts per million [ppm] fluoride). Participants will directly apply (under supervision) a pea sized dose to each of the two qualifying teeth using their washed, clean finger by direct application and gently rubbing into the tooth's cervical margin for 60 Seconds. No rinsing will be permitted.
1506151|NCT02924350|Other|Monofluorophosphate|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride). Participants will directly apply (under supervision) a pea sized dose to each of the two qualifying teeth using their washed, clean finger by direct application and gently rubbing into the tooth's cervical margin for 60 Seconds. No rinsing will be permitted.
1506152|NCT02924337|Drug|Placebo|
1506153|NCT02924337|Drug|Imeglimin|
1506154|NCT02924337|Drug|Moxifloxacin|
1506155|NCT02924324|Device|propofol|
1506156|NCT02924324|Drug|ropivacaine|
1506157|NCT02924324|Behavioral|Wong-Baker FACES® Pain Rating Scale|Nurses will record patient-reported pain scores.
1506158|NCT02924324|Behavioral|Post-procedural quality of life (QOL)|
1506159|NCT02924311|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea 40 mg/mL - recommended dose of 2 mg - intravitreal injection monthly for five consecutive months, which constitutes the loading dose. The loading dose is followed by one injection every two months. After 12 months of treatment, the interval between two injections can be prolonged or adapted according to visual and anatomical results.
1506160|NCT02924298|Behavioral|SLIMM|Participants will perform 5 minutes of light activity for every 25 minutes spent seated for 12 weeks. Following the week 12 visit, participants will increase light activity to 10 minutes for every 20 minutes spent seated.
2002702|NCT01957514|Other|Quality-of-Life Assessment|Ancillary studies
2002703|NCT01957514|Other|Questionnaire Administration|Ancillary studies
1506163|NCT02924272|Drug|Ixazomib|Ixazomib Capsules
1506164|NCT02924259|Device|The GRID foam roll|Commercial rigid foam roll with an outer foam covering
1506165|NCT02924246|Biological|cholera vaccination|Oral cholera vaccination on day 0 and day 14
1506166|NCT02924246|Other|raw milk|raw milk
1506167|NCT02924246|Other|pasteurized milk|pasteurized milk
1506168|NCT02924246|Other|UHT milk|UHT milk
1506169|NCT02924233|Drug|Sym004|"Sym004 is a 1:1 mixture of two monoclonal antibodies (mAbs) which bind to two non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
Sym004 will be administered at different dose-levels via infusion Q2W"
1506170|NCT02924233|Drug|Nivolumab|Nivolumab is a humanized immunoglobulin G4 (IgG4) anti-PD-1 monoclonal antibody. Nivolumab will be administered via 60-minute infusion Q2W
1506171|NCT02924207|Other|PATH electronic decision support tool|PATH, a clinical decision support tool for Type 2 Diabetes, was developed based on patient impact of efficacy, cost, implementation difficulty, comorbidities, side effects, and evidence based pleiotropic benefit. Drug efficacy was estimated using published clinical data for agents, both in terms of placebo controlled trials and head-to-head studies. Additional information regarding interventions was added with regard to FDA package inserts as well as large post marketing studies. Cost impact of intervention was described in terms of patient's estimated copay drawn from insurance plan as well as average retail price.
1506172|NCT02924194|Device|stimulation ON|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
1506173|NCT02924194|Device|stimulation OFF|"The system used in the study includes the Model 37601 Activa PC stimulator, Model 3387 Lead and Model 37085 Extension, all manufactured and commercially available by Medtronic, Inc. Collectively, these devices will be referred to as the DBS System. The DBS System is commercially available in the United States and was approved by FDA on July 31, 1997 under PMA P960009. It is indicated for deep brain stimulation for the treatment of symptoms of Parkinson's disease and essential tremor."
1506174|NCT02924181|Device|SmartTouch Catheter|Pulmonary vein (PV) isolation guided by CF information
1506175|NCT02924168|Device|Active Radial Shockwave|Four weekly sessions of active radial shockwave treatment.
1506176|NCT02924168|Device|Sham Radial Shockwave|Four weekly sessions of sham radial shockwave treatment.
1506177|NCT02924155|Drug|SJP002|
1506178|NCT02924155|Drug|Placebo|
1506179|NCT02924142|Device|OT Cap attachment|The RHEIN 83 OT CAP attachment system is an extra-coronal castable attachment positioned on the distal of the abutment crowns as an extension allowing a lot of vertical space for optimal esthetics.
1506180|NCT02924129|Device|Evoke Spinal Cord Stimulator (SCS) System|Spinal Cord Stimulation that measures and records evoked compound action potentials (ECAPs).
1506181|NCT02924116|Device|Bioboosti|Subjects will place the device on the palm of their hand for 8 minutes. There is a light on the device that changes to indicate that the 8 minutes have passed. They will then place it on the palm of the other hand and keep it there for 8 minutes. Alternating 8-minute cycles between hands will be done up to 6 times.
1506182|NCT02924103|Device|Contamination free bacterial swab|"A comparison of the bacteriology in bacterial swabs (Eswab 481CE, Copan Diagnostics, Italy) from the middle meatus. On the RIGHT side using the Contamination free bacterial swab introduction device that facilitates the introduction of a bacterial swab into the nose without direct or indirect contact with the nasal vestibule."
1506183|NCT02924090|Drug|Etomidate|Etomidate will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.3 mg/kg
1506184|NCT02924090|Drug|Ketamine|Ketamine will be administered as a bolus intravenously to induce an adequate depth of anesthesia just prior to ECT at a dose of 0.5 to 1.0 mg/kg.
1506185|NCT02924090|Procedure|Hyperventilation|Hyperventilation will be performed in patients after full pre-oxygenation and induction of anesthesia, by administering 20 breaths in 30 seconds using a well-fitting face mask immediately before application of the ECT electrical stimulus.
2002704|NCT01952054|Drug|Denosumab|120 mg subcutaneously on Day 1 of every 28 day cycle.
1506186|NCT02924090|Procedure|Electroconvulsive therapy (ECT)|Bilateral, bitemporal electrode placement will be utilized to elicit a seizure via a SpECTrun 5000Q (MECTA Inc.). The electrical dose required will be determined in advance by the patient's attending psychiatrist.
1506187|NCT02924064|Drug|Teneligliptin 20mg|
1506188|NCT02924064|Drug|Placebo|
1506189|NCT02924064|Drug|Metformin ≥ 1000 mg|
2002705|NCT01946399|Drug|Ozurdex implant|Intravitreal injection of Dexamethasone implant
1506191|NCT02924038|Biological|IMA950|
1506192|NCT02924038|Biological|poly-ICLC|
1506193|NCT02924038|Biological|Varlilumab|
1506194|NCT02924025|Behavioral|Motivational interview|Motivational interview is an interview form based on the patients own thoughts of motivation. It will be conducted by a nurse who is specially trained in this interview type.
1506195|NCT02924012|Other|video game active|The session lasted 40 minutes. The participants held an active video game session. At the end they were monitored for 60 minutes at rest.
1506196|NCT02924012|Other|sedentary video game|The session lasted 40 minutes. The participants held an sedentary video game session, using the traditional joystick. At the end they were monitored for 60 minutes at rest.
1506197|NCT02924012|Other|walking|The session lasted 40 minutes. The participants held a walk using the treadmill. At the end they were monitored for 60 minutes at rest.
1506198|NCT02923999|Drug|P2G12 Dose Cohort 1|single dose of intravenous infusion: 0.125g of the P2G12 human monoclonal antibody
1506199|NCT02923999|Drug|P2G12 Dose Cohort 2|single dose of intravenous infusion: 0.25g of the P2G12 human monoclonal antibody
1506200|NCT02923999|Drug|P2G12 Dose Cohort 3|single dose of intravenous infusion: 0.5g of the P2G12 human monoclonal antibody
1506201|NCT02923986|Drug|BP1001 (varying dose)|BP1001 (varying dose)
1506202|NCT02923986|Drug|BP1001 (fixed dose)|BP1001 (fixed dose)
1506203|NCT02923986|Drug|Dasatinib|Dasatinib
1506204|NCT02923973|Other|Transvaginal ultrasound cervical length screening|Serial transvaginal ultrasound cervical length scan every week from 16 to 24 weeks
1506205|NCT02923960|Other|Standard ONS|One serving (237 ml) standard oral nutritional beverage
1506206|NCT02923960|Other|Diabetes specific ONS 1|One serving (237 ml) diabetes oral nutritional beverage
1506207|NCT02923960|Other|Diabetes specific ONS 2|One serving (296 ml) diabetes oral nutritional beverage
2002706|NCT01943539|Device|Neuro-typical controls and ADHD will receive EVO game play.|EVO mobile video application
1506209|NCT02923934|Drug|Ipilimumab|CTLA-4 (cytotoxic T-lymphocyte-associated protein 4) is a key regulator of T cell activity. Ipilimumab is a CTLA-4 immune checkpoint inhibitor that blocks T-cell inhibitory signals induced by the CTLA-4 pathway, increasing the number of tumor reactive T effector cells which mobilize to mount a direct T-cell immune attack against tumor cells. CTLA-4 blockade can also reduce T regulatory cell function, which may lead to an increase in anti-tumor immune response.
1506210|NCT02923934|Drug|Nivolumab|A fully human immunoglobulin (Ig) G4 monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death-1 (PD-1,PCD-1) with immune checkpoint inhibitory and antineoplastic activities. Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs (antigen presenting cells). This results in the activation of T-cells and cell-mediated immune responses against tumor cells or pathogens. Activated PD-1 negatively regulates T-cell activation and and plays a key role in in tumor evasion from host immunity.
2002707|NCT01943435|Drug|NSAIDs; adjunctive analgesics; adjunctive anti-depressants|Physician will administer these medications based upon the individual needs of each patient.
2002708|NCT01943435|Procedure|Lumbar epidural injection|The attending physician may refer subjects for epidural injections at a pain clinic that is affiliated with the University of Pittsburgh Medical Center. All epidural injections will be provided by licensed physicians who are board certified in physical medicine and rehabilitation or anesthesiology.
2002709|NCT01943435|Other|Joint Mobilizations (spine, sacroiliac, hip)|These joint mobilizations will be applied manually to the lumbar facet joints, sacroiliac joints, and/or hip joints by licensed physical therapists and chiropractors.
2002710|NCT01943435|Other|Individualized exercises: clinical setting|The treating physical therapist or chiropractor will work with each subject to develop a set of individualized exercises in the clinic setting. The goal is to have the subjects continue these exercises at home.
2002711|NCT01943435|Other|Group Exercise: community setting|The group exercise will take place at community centers that provide exercise classes for older adult. The exercises are taught by certified fitness instructors in a group setting at these community centers.
1506219|NCT02923882|Other|'$100Kitchen and improved cookstove'|
1506220|NCT02923869|Drug|Levobupivacaine|Children will receive 0.15 ml/kg of 0.2% Levobupivacaine through bilateral suprazygomatic MNB.
1506221|NCT02923869|Drug|Bupivacaine|Children will receive 0.15 ml/kg of 0.2% Bupivacaine through bilateral suprazygomatic MNB.
1506222|NCT02923856|Device|The results of clarithromycin susceptibility test of H. pylori isolates|According to the results of antibiotic susceptible testing, patients who were resistant to clarithromycin were belonged into clarithromycin resistance group.Patients who were sensitive to clarithromycin were belonged into the 7days/10days/14days treatment groups.
1506223|NCT02923856|Device|Computer generated random number, randomly assigned into groups|The patients with clarithromycin sensitive. Computer generated random number,randomly assigned into 7days/10days/14days treatment groups.
1506224|NCT02923856|Device|The result of 13C-urea breath test of patient in 7days/10days/14days treatment groups|The intervention focused on the results from the result of 13C-urea breath test at 8 weeks after treatment in patients. All patients were taking 75mg 13C-urea and analysis with a modified isotope ratio mass spectrometer to determine the 13CO2 content.The successful treatment groups were patients with negative in 13C-urea breath tests.The failed treatment of H. pylori groups were patients with positive in 13C-urea breath tests after the standardized triple therapy treatment.
1506271|NCT02923505|Procedure|polygraphy or polysomnography|
1506305|NCT02923297|Other|Blood sampling|blood sampling for determine and compare the expression patterns of GALIG gene
1506614|NCT02921061|Other|Quality-of-Life Assessment|Ancillary studies
1506225|NCT02923843|Other|Comprehensive Geriatric Assessment|The CGA is person-centered and unique for each patient, but is based on the core elements such as socio-demographic background, social network, health and medical history, medications, functional status, cognitive status, nutritional status, somatic status and psychosocial status including depression, providing a comprehensive assessment tailored for each person.
1506226|NCT02923830|Other|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
1506227|NCT02923830|Drug|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
1506228|NCT02923817|Biological|Transplantation of autologous bone marrow-derived mononuclear cells by lumbar injection|
1506229|NCT02923804|Dietary Supplement|Omega-3|3x 1g capsules taken daily for 6 months
1506230|NCT02923804|Dietary Supplement|Olive oil|3x 1g capsules taken daily for 6 months
1506231|NCT02923791|Biological|Filgrastim Hospira|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
1506232|NCT02923791|Biological|US-Approved Neupogen|5 consecutive daily doses (Days 1-5) in Period 1 and 1 dose (Day 1) in Period 2.
1506233|NCT02923778|Other|Laboratory Biomarker Analysis|Correlative studies
1506234|NCT02923778|Radiation|Radiation Therapy|Undergo radiation therapy
1506235|NCT02923778|Biological|Talimogene Laherparepvec|Given IT
1506236|NCT02923765|Other|Aerobic training by a stepper|Aerobic training by a stepper: 35 minutes/session, 5 sessions/week and 4-5 weeks in total
1506237|NCT02923752|Device|MRI|Contrast-enhanced MRI
1506238|NCT02923739|Drug|Paclitaxel|Paclitaxel 80 mg/m2 by vein on Days 1, 8, 15 and 22.
1506239|NCT02923739|Drug|Bevacizumab|Bevacizumab 10 mg/kg by vein on Days 1 and 15.
1506240|NCT02923739|Drug|Emactuzumab|Emactuzumab 1000 mg by vein on Days 1 and 15.
2002712|NCT01935609|Behavioral|Couples counseling|Intervention to promote couples' adjustment (TCI) - The TCI was developed based upon considerable clinical experience and research review. The TCI is a structured approach to helping couples after brain injury address issues related to relationship quality and emotional well-being. The TCI is implemented in five or six (optional parenting session) session. Each session is in-person and lasts for 120 minutes.
1506243|NCT02923700|Biological|Leukocyte-rich PRP intra-articular injections|
1506244|NCT02923700|Biological|Leukocyte-poor PRP intra-articular injections|
1506245|NCT02923687|Drug|Ketorolac Tromethamine|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, the experimental group will receive supplemental buccal infiltration of 30 mg/mL of Ketorolac Tromethamine.
1506246|NCT02923687|Drug|Placebo|All patients will receive standard inferior alveolar nerve block of 2% lidocaine with 1:800000 epinephrine and supplemental buccal infiltration of 0.9 mL 2% lidocaine with 1:800000 epinephrine. After five minutes, control group will receive buccal infiltration of normal saline.
1506247|NCT02923674|Behavioral|Weight loss|All participants will undergo a dietary WL intervention designed to elicit behavioral changes leading to decreased caloric intake sufficient to yield a ~10% loss of initial body mass. The WL intervention includes nutrition education, state-of-the-art behavioral methods for promoting WL, and strategies that optimize self-regulation.
1506248|NCT02923674|Behavioral|Exercise|Perform structured aerobic exercise (mostly treadmill walking) of moderate-intensity for 4-5 days/week, progressing to a duration of 200 min/week. Participants will attend center-based sessions for at least 3 days/week during the first intensive 6-month phase and at least one day/week during the second 3-month transition phase (months 7-9), with recording of home-based exercise for the other 2-4 days/week.
1506249|NCT02923674|Behavioral|Sitless|Encouraged and taught to reduce sedentary behavior (SB) during waking hours. The SitLess treatment targets increases in postural shifts and light, spontaneous physical activity (SPA) (MET level <3).
1506250|NCT02923661|Device|CM LOC|
1506251|NCT02923661|Device|ball attachment|
1506252|NCT02923635|Procedure|Standard wide local excision.|Excision of breast cancer without integration of plastic technique
1506253|NCT02923635|Procedure|oncoplastic breast surgery.|Integration of plastic techniques with oncological surgery for resection of breast cancer.
1506254|NCT02923622|Other|Traditional Chinese medicine herbals|TCM herbal treatment based on TCM syndrome differentiation，without any anti tumor therapy in Western Medicine
1506255|NCT02923622|Other|Integrated traditional Chinese and Western medicine|TCM herbal treatment combine with anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
1506256|NCT02923622|Other|Western medicine|Anti tumor therapy in Western Medicine ( including non recommended chemotherapy, radiotherapy and targeted therapy in clinical guidelines)
1506257|NCT02923609|Biological|Cell Therapy|Electro-anatomical mapping will be performed using the Biosense NOGA system (Biosense-Webster, Diamond Bar, California). Local diastolic function will be assessed by a novel algorhithm that allows for the measuring local ventricular relaxation times at each of the sampling points. Target areas for cell delivery will be defined as the myocardial segments with the evidence of local diastolic dysfunction and myocardial hibernation. Transendocardial delivery of cell suspension in the SC Group will be performed with MyoStar® (Biosense Webster) injection catheter. Each patient will receive 20 injections of 0.3 mL of stem cell suspension.
1506258|NCT02923609|Biological|Control Procedure|In the Control Group we will perform transendocardial injections using the same protocol as in the SC Group; stem cell suspension will be substituted with placebo (0.9% saline).
1506259|NCT02923596|Procedure|History of prior Surgery|History of prior Surgery will be reviewed
1506260|NCT02923596|Radiation|History of Radiation Therapy|History of prior radiation therapy will be reviewed
1506266|NCT02923557|Drug|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of nephroureterectomy.
1506267|NCT02923544|Procedure|YUMI manipulator|
1506268|NCT02923531|Drug|X4P-001|Continuous, oral, once daily dosing
1506269|NCT02923531|Drug|Nivolumab|240 mg I.V. every 2 weeks
1506272|NCT02923492|Behavioral|SafERteens|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
1506273|NCT02923479|Device|Specific ankle rehabilitation by ARBOT device|ARBOT is a programmable robotic device consisting in a two-degree-of-freedom electromechanical platform developed by Italian Institute of Technology - Advanced Robotics and Rehab Technologies. It is composed of a fixed base, a central strut, a moving platform supporting patient's foot and three actuated limbs with a universal-prismatic-spherical kinematic chain. A six-axis force/torque sensor mounted between the moving platform and the footplate senses the human-robot interaction force and torque. The device is interfaced to a standard all-in-one touch screen Personal Computer with graphic applications to give patients visual feedback in real time.
1506274|NCT02923479|Other|General Rehabilitation|All patients underwent general rehabilitation (gait training, aerobic conditioning), including - if necessary - an initial weight training phase before the functional full weight-bearing program.
1506275|NCT02923479|Other|Specific ankle rehabilitation performed by physiotherapist|Subjects in the control group underwent manually assisted range of motion exercises.
1506276|NCT02923479|Device|Specific ankle rehabilitation by Biodex System 3 dynamometer|Subjects in the control group performed non-robotic resistive training using a Biodex System 3 dynamometer
1506277|NCT02923479|Device|Specific ankle rehabilitation by ProKin PK254 platform|Subjects in the control group performed non-robotic proprioceptive training using a ProKin PK254 mobile electronic platform.
2002713|NCT01930409|Behavioral|Telephone Support and Coaching|"The participants will receive up to 5 telephone calls of 30-45 minutes each after hospital discharge to provide support and education for the transition from acute to community care. The first call will be made within 48-72 hours of hospital discharge and will have the following elements:
Health Status
Medication Management
Activity/Exercise Prescription and Goal-Setting
Falls Prevention
Clarification of Appointments
Coordination of Post-Discharge Home Services
What To Do If a Problem Arises"
1506279|NCT02923453|Dietary Supplement|CNT 2000 American ginseng extract|
1506280|NCT02923453|Dietary Supplement|Placebo|
1506281|NCT02923440|Biological|blood sample|
1506282|NCT02923427|Device|Laryngeal mask Supreme Evaluation|Evaluation of clinical performance in terms of Insertion, ventilation and complications
1506283|NCT02923427|Device|i-gel Evaluation|Evaluation of clinical performance in terms of Insertion,ventilation and complications
1506284|NCT02923414|Device|Standard escalating shocks|125 J, 150 J, 200 J
1506285|NCT02923414|Device|High energy shock protocol|360 J, 360 J, 360 J.
1506286|NCT02923401|Other|Exercise|"High-Intensity Interval Training (HIIT) Group: Participants walk uphill on a treadmill for a total of 33 minutes 3 times a week for 12 weeks.There is a 5-minute warm up, followed by four 4-minute intervals. Between each interval, participant walks for 3 minutes. There is a 3 minute cool down.
Moderate-Intensity Continuous Training (MICT) Group: Participants walk uphill on a treadmill or use a stationary bicycle continuously for 41 minutes 3 times a week for 12 weeks."
1506287|NCT02923401|Behavioral|Questionnaires|Participants complete questionnaires about their quality of life, exercise experience, and level of fatigue at baseline and at 12 weeks. These should take a total of about 15 minutes to complete.
1506288|NCT02923401|Behavioral|Motivational Session|One (1) time each month, participant attends a motivational session for 12 weeks.
1506289|NCT02923401|Behavioral|Phone Call|Participants called by a member of the study staff 1 time each week for 12 weeks and asked about any exercise they have done and their weight loss goals. Each phone call should take about 15 minutes.
1506290|NCT02923401|Other|Printed Materials|"High-Intensity Interval Training (HIIT) Group and Moderate-Intensity Continuous Training (MICT) Group: Participants receive written materials and instructions on how to perform their exercises.
Control Group: Participants receive written materials and counseling by an exercise physiologist."
1506291|NCT02923388|Drug|Injection Mecobalamin,|Injection Mecobalamin (500mcg) three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks.
1506292|NCT02923388|Drug|Tablet Pyridoxine hydrochloride|Tab. Pyridoxine hydrochloride (25 mg) 2 tablets thrice daily for 5 weeks
1506293|NCT02923388|Drug|Intravenous normal saline 1 ml|Normal saline 1 ml three times a week (day 1, 3 and 5 of vincristine chemotherapy) for 5 weeks
1506294|NCT02923388|Drug|Placebo pill|Placebo pill orally thrice daily for 5 weeks
2002714|NCT01930409|Behavioral|Education Only|An educational toolkit will be provided, with materials to self manage at home after hospital discharge following a fall related hip fracture
1506296|NCT02923362|Procedure|Laparoscopic Fundoplication|The gastric fundus of the stomach is wrapped or plicated around the lower end of the esophagus and and stitched in place reinforcing the closing function of the lower esophageal sphincter. The hiatus is also narrowed down with sutures or mesh to prevent or treat a concurrent hiatal hernia.
1506297|NCT02923362|Device|LINX Antireflux|The LINX is a flexible band of interlocked titanium beads with a magnetic core. The LINX is placed around the lower esophageal sphincter to help restore the function of the LES by preventing reflux into the esophagus.
1506298|NCT02923349|Drug|INCAGN01949|Initial cohort dose of INCAGN01949 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
1506299|NCT02923336|Drug|non selective beta blocker|"the patient is going to receive a device called smart pill before the beginning of treatment with propranolol, after the evaluation with the smart pill device, they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks,finally they will receive another smart pill to evaluate the second gastrointestinal transit time"
1506300|NCT02923323|Device|MRI including DTI , EEG, CGMS|Will be connected to continuous simultaneous systems
1506301|NCT02923323|Behavioral|Neurocognitive tests|Will perform multiple tests of neurocognitive functions after lunch
1506302|NCT02923310|Biological|Platelets Rich Plasma|
1506303|NCT02923310|Biological|Leucocyte - Platelets Rich Plasma|
1506304|NCT02923310|Drug|Hialuronic Acid|
1506306|NCT02923271|Device|CellControl|Technology that blocks incoming and outgoing calls and texts. CellControl Drive ID will monitor all cellphone use while driving (without blocking) for 3 weeks during baseline measurement period. During the intervention period (5 weeks) cellphone use will be monitored and blocking of incoming calls and texts will be active.
1506307|NCT02923258|Drug|Docetaxel|20mg/m2/w for 6 weeks
1506308|NCT02923258|Drug|Cisplatinum|40mg/m2/w for 6 weeks
1506309|NCT02923258|Radiation|IMRT|a total dose of 60Gy in 30 fractions over 6 weeks
1506310|NCT02923245|Other|point-of-care ultrasound|
1506311|NCT02923232|Device|Accommodative contact lens|Different downgaze angles will be experimented to determine whether the accommodative contact lens can alter its optical refraction at downgaze angles.
1506312|NCT02923219|Biological|Adipose-derived stem cells|The adipose-derived stem cells therapy involve injection of patient's own adipose-derived stem cells. Local anesthetic will be applied to the face prior to the injection. For adipose-derived stem cells preparation, proper volume of fat cells will be collected from each patient just before each procedure. The stem cells will be injected into each standardized injection point in a superficial manner. The injections points are along the inferior border of cheek and mid-cheek and temple, where will be followed by 10-15 minutes of icing.
1506313|NCT02923206|Device|TheraSorb sFlt-1 adsorber|Removal of excessive sFlt-1 from the plasma of subjects/ patients with therapeutic apheresis.
2002715|NCT01928849|Drug|Valproic Acid|"Intervention patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management and oral valproic acid 250mg preoperatively, then three times per day for either 6 days post-operatively or until discharge from the hospital."
2002716|NCT01928849|Other|Cherry Syrup|Intervention arm patients will receive standard regional anesthesia catheters (either peripheral nerve or epidural catheter), anesthetic management, and valproic acid 250mg preoperatively, and then three times per day for 6 days post-operatively.
1506316|NCT02923180|Drug|Enoblituzumab|
1506317|NCT02923167|Device|Amadeo® - Tyromotion|Training will be performed using the Amadeo®. The computer-controlled device maintains participants' forearm in a secure position using Velcro straps. Each training session will include 30 minutes of active movements that can be divided into up to 3 bouts of 10 minutes depending on participant fatigue. Training will take place up to 4 times per week for a total of 18 sessions over up to 7 weeks. Sessions will last approximately 60 minutes (including setup, training, and rest between each bout).
1506318|NCT02923154|Drug|MT-3995|
1506319|NCT02923154|Drug|Placebo|
1506320|NCT02923141|Behavioral|Neutral Writing|
1506321|NCT02923141|Behavioral|Expressive Writing|
1506322|NCT02923141|Behavioral|Contingency Management|
1506323|NCT02923128|Drug|Dexmedetomidine|Dexmedetomidine 150ug is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
1506324|NCT02923128|Drug|Sufentanyl|Sufentanyl(0.06ug.kg-1.h-1) is diluted to 150ml with 0.9% saline,continuous micro-pump infusion for 72 hours with 2ml/h speed.
1506325|NCT02923128|Drug|Saline|Saline is used to dilute other drugs
2002717|NCT01925014|Radiation|Diagnostic CT with low-dose radiation|Effective dose is aimed at approximately 2 millisievert in an average patient.
2002718|NCT01925014|Radiation|Diagnostic CT with standard-dose radiation|Effective dose is aimed at approximately 8 millisievert in an average patient.
1506328|NCT02923102|Dietary Supplement|Aloysia citriodora extract|2 capsules with 200mg - daily dosage 400mg
1506329|NCT02923102|Dietary Supplement|Maltodextrin|2 capsules with 200mg - daily dosage 400mg
1506330|NCT02923089|Other|Muffin: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
1506331|NCT02923089|Other|Muffin: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
1506332|NCT02923089|Other|Wheat muffin|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
1506333|NCT02923089|Other|Soup: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
1506334|NCT02923089|Other|Soup: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
1506335|NCT02923089|Other|Potato soup|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
1506336|NCT02923089|Other|Chili: 25g available carbohydrate from small green lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
1506337|NCT02923089|Other|Chili: 25g available carbohydrate from split red lentil|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
1506338|NCT02923089|Other|Rice chili|Comparison of postprandial blood glucose and insulin following consumption of food products with and without lentils.
1506339|NCT02923076|Other|CCR5 delta32/delta32 cord blood transplantation|
1506340|NCT02923063|Behavioral|Combined Aerobic and Resistance Exercise|
1506341|NCT02923050|Behavioral|Simple Suppers|Theory-based 10-week family meals program
1506342|NCT02923037|Procedure|Yoga|Complete guided and home yoga sessions
1506343|NCT02923037|Other|tape measurement of arm|Ancillary studies
1506344|NCT02923037|Other|Quality-of-Life Assessment|Ancillary studies
1506345|NCT02923037|Other|ldex measurement of arms|
1506346|NCT02923024|Behavioral|Patient Ping|The patient ping will be a fax sent from Oscar Health to physician that will include information on the physician's patient's trigger event and contact information for the physician to reach out to the member.
1506347|NCT02923011|Device|MRgFUS|Magnetic resonance-guided focused ultrasound ablation of osteoid osteoma
1506348|NCT02923011|Device|CTgRFA|Computed tomography-guided radiofrequency ablation of osteoid osteoma
2002719|NCT01924468|Drug|Oral methylphenidate and Oral haloperidol|
2002720|NCT01924286|Drug|Prednisone|
2002721|NCT01924286|Drug|Placebo|
2002722|NCT01918605|Device|Diluted spacer|
2002723|NCT01918605|Device|Non-diluted spacer|
2002724|NCT01911169|Drug|Cholecalciferol|5,000 International units versus 400 international units as an active comparator
1506353|NCT02922972|Device|Autologous Platelet Rich Plasma obtained with RegenKit®-BCT|After complete resection of the keloid scar, the first injection was administered before closure into the lesion resection bed and edges. Three additional injections were administered with a one-month interval.
1506354|NCT02922959|Behavioral|TTIP-PRO|TTIP-PRO includes: 1) a 30-minute computer-facilitated telephone intervention delivered by Peer Interventionists; and 2) a mailing which includes a report on the participant's risk factors for experiencing another opioid overdose.
1506355|NCT02922959|Drug|naloxone nasal spray kit|Naloxone nasal spray (NARCAN) is a potentially life-saving medication that can stop or reverse the effects of an opioid overdose. This nasal spray is approved by the FDA for reversing OODs and has a favorable side-effects profile. A take-home kit will be provided to the patient participants, which may be useful in the event of a future opioid overdose.
1506356|NCT02922959|Behavioral|information|Written information about opioid overdose and treatment for opioid use disorder.
1506357|NCT02922946|Drug|Entinostat|HDAC (histone deacetylase) inhibitor
1506358|NCT02922933|Drug|entinostat|HDAC (histone deacetylase inhibitor)
1506359|NCT02922933|Dietary Supplement|Omeprazole|Proton pump inhibitor
1506360|NCT02922933|Dietary Supplement|Famotidine|Histamine-2 blocker
1506361|NCT02922920|Other|Tart cherry juice|16 fl. oz of tart cherry juice
1506362|NCT02922920|Other|Placebo|16 fl. oz of placebo
1506363|NCT02922907|Dietary Supplement|arabinoxylan rice bran|a proprietary product derived from rice bran treated with extracts from three mushrooms
1506364|NCT02922907|Dietary Supplement|Placebo for arabinoxylan rice bran|inactive product
1506365|NCT02922894|Procedure|Acute episodic hypoxia|The subjects will undergo 30 minutes of baseline monitoring followed by 15 episodes of one minute of episodic hypoxia with supplemental CO2 to maintain isocapnia. This is followed by a 45 minute recovery period.
1506366|NCT02922894|Procedure|Supplemental oxygen|Supplemental oxygen therapy for 6 weeks
1506367|NCT02922894|Drug|Trazodone|100mg before bedtime
1506368|NCT02922894|Drug|Placebo|One placebo pill before-bedtime
1506369|NCT02922894|Procedure|Sham|Room air will be administered instead of episodic hypoxia or supplemental oxygen..
1506370|NCT02922881|Other|Ulcerative Colitis Diet (UCD)|
1506371|NCT02922868|Device|EndoSheath CST-5000 Scope|Cystoscopic procedures will be performed using the EndoSheath CST-5000 Scope.
1506372|NCT02922868|Device|Olympus Visera Elite OTV-S190 Scope|Cystoscopic procedures will be performed using the Olympus Visera Elite OTV-S190 Scope
1506373|NCT02922855|Behavioral|0 dollars group|Those assigned to the $0 group will not receive an incentive for visiting their PCP.
1506374|NCT02922855|Behavioral|50 dollars group|Those assigned to the $50 group will receive $50 if they visit their PCP within 6 months of study enrollment.
1506375|NCT02922855|Behavioral|25 dollars group|Those assigned to the $25 group will receive $25 if they visit their PCP within 6 months of study enrollment.
1506376|NCT02922842|Device|Transcutaneous Electrical Nerve Stimulation|
1506377|NCT02922816|Biological|Fecal Microbiota Transplant (FMT)|The Fecal Microbiota Transplant (FMT) using Allogeneic human stool in glycerol (10%) (AHSG) intervention will be administered via rectal retention enema and performed in either an inpatient or outpatient clinic.
1506378|NCT02922816|Procedure|Bowel preparation|Trial participants will undergo the bowel preparation by taking magnesium citrate the day before the cycle begins (Day -1).
1506379|NCT02922816|Procedure|Perirectal swab sampling|Perirectal swabs will be collected at screening (for eligibility determination) and Days 1, 2, 15, and 36 of each cycle.
1506380|NCT02922816|Other|Fasting|In Cycle 1 and Cycle 2, participants cannot consume food, alcohol, or other liquids on Day 1 prior to the intervention. Trial participants will not be fasting on Day 1 of Cycle 0.
1506381|NCT02922803|Drug|1 combination tablet of Vitamin D3/calcium per day|Combination tablet of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
1506382|NCT02922803|Drug|2 combination tablets of Vitamin D3/calcium per day|Combination tablets of Cholecalciferol (800 IU or 20 ug) and calcium carbonate (500 mg)
1506383|NCT02922790|Behavioral|standard health information|Subjects will review standard health information
1506384|NCT02922790|Behavioral|standard health information plus info. on DNA damage|Subjects will review standard health information and information on DNA damage
1506385|NCT02922790|Behavioral|Subjects will review standard health information and information on DNA damage, plus pictures of their DNA damage|Subjects will review standard health information and information on DNA damage, as well as review pictures of their cells' DNA damage
1506386|NCT02922777|Drug|BGB324|75 mg/m2 every 21 days
1506387|NCT02922777|Drug|Docetaxel|75 mg/m2 given IV every 21 days
1506388|NCT02922764|Drug|RGX-104|
1506389|NCT02922751|Other|Liver Stiffness Measurement (LSM)|LSM will be measured via transient elastography utilizing the non-invasive FibroScan™ ultrasound device. LSM will be measured at Baseline, Year 1 and Year 2 visits.
1506390|NCT02922738|Other|VisualDx|VisualDx is a computerized clinical information technology with medical image and text content in dermatology.
1506391|NCT02922725|Drug|5-hydroxytryptophan and Creatine|
1506392|NCT02922725|Other|Placebo control|
1506393|NCT02922712|Drug|NISE|Nise 200mg Max per day in 2 divided doses
1506394|NCT02922699|Drug|OMEZ 40|Omez 40 given to patients for 58days along with Amoxicilin and Clarithromycin
1506395|NCT02922699|Drug|OMEZ 80|Omez 80 patients for 58days along with Amoxicilin and Clarithromycin
1506396|NCT02922686|Drug|Flucloxacillin|One flucloxacillin capsule of 500mg strength taken four times daily for 7 days
1506397|NCT02922686|Drug|Phenoxymethylpenicillin|One capsule of phenoxymethylpenicillin of 500 mg strength taken four times daily for 7 days
1506445|NCT02922348|Drug|Hormone Replacement Therapy|Hormone replacement therapy as indicated in Arm 1
1506446|NCT02922348|Drug|Combined Oral Contraceptives|Combined oral contraceptives as indicated in Arm 2
1506398|NCT02922686|Drug|Placebo (for phenoxymethylpenicillin)|Over-encapsulation of phenoxymethylpenicillin will be performed by the manufacturer of the investigational medicinal products such that placebo and active phenoxymethylpenicillin are identical in size, shape, colour and smell, and are packaged in identical bottles
1506399|NCT02922673|Drug|Aspirin|
1506400|NCT02922673|Drug|Placebo|
1506401|NCT02922660|Drug|desflurane|method of anesthesia maintenance with desflurane ranged from 0.5~1.5 MAC during the procedure
1506402|NCT02922660|Procedure|total intravenous anesthesia|method of anesthesia in group TIVA is total intravenous anesthesia(TIVA) during the procedure
1506403|NCT02922660|Procedure|inhalation anesthesia|method of anesthesia in group DES is inhalation anesthesia with desflurane during the procedure
1506404|NCT02922660|Drug|Propofol|using propofol as sedative during the procedure of anesthesia and maintaining with propofol Cp 2—4 μg/ml in TCI
1506405|NCT02922660|Drug|Remifentanil|using remifentanil as analgesics during the procedure of anesthesia and maintaining with remifentanil 2—4 ng/ml in TCI
1506406|NCT02922647|Device|suprapubic catheterization|Experimental Arm: Suprapubic catheterization after rectal resection with low anastomosis for cancer in males
1506407|NCT02922647|Device|transurethral catheterization|Active comparator: Transurethral catheterization after rectal resection with low anastomosis for cancer in males
1506408|NCT02922634|Other|Mini Cog|short cognitive screen
1506409|NCT02922608|Other|simulation practice|simulation session
1506410|NCT02922595|Device|Intubation through ILMA®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.
Intubation will then be peformed"
1506411|NCT02922595|Device|Intubation through ILTS®|"It will be placed into patient's larynx through the mouth in accordance with manufacturer's recommendations by experienced airway providers.
Intubation will then be peformed"
1506414|NCT02922569|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Thirty minutes of training on computerized exercises that targets processing speed, memory and attention.
1506415|NCT02922569|Other|Commercially available computerized training|Thirty minutes of training on computerized, casual video games.
1506416|NCT02922569|Other|Mindfulness Training|Ten minutes of using an online training course that teaches skills to help overcome ongoing life stressors.
1506417|NCT02922569|Other|Veterans Affairs Information Session|Ten minutes of viewing Veterans Affairs related news, information, services, benefits and programs.
1506418|NCT02922556|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
1506419|NCT02922556|Other|Commercially available computerized training|
1506420|NCT02922530|Other|Computerized Plasticity-based Adaptive Cognitive Training|
1506421|NCT02922530|Other|Commercially available computerized training|
1506422|NCT02922504|Behavioral|Music intervention group|
1506423|NCT02922504|Behavioral|Controlled group|
1506424|NCT02922491|Dietary Supplement|vitamin E|daily intake of vitamin E
1506425|NCT02922491|Dietary Supplement|starch|daily intake of starch (control)
1506426|NCT02922478|Radiation|X-ray of the spine|Every participant will undergo X-ray of the spine so that vertebral fractures can be quantified using the Genant score.
1506427|NCT02922478|Procedure|Ambulatory blood pressure monitoring (ABPM)|ABPM will be performed using the brachial, oscillometric, automated self-measurement mobil-O-Graph device (I.E.M. GmbH, Stolberg, Germany) with integrated ARCSolver®-Software (Austrian Institute of Technology Wien).
1506428|NCT02922478|Radiation|Dual X-ray absorptiometry|Individual bone mineral density and T-Score will be determined by X-ray absorptiometry.
1506429|NCT02922478|Procedure|Non-invasive procedures|Other non-invasive study procedures include structured patient interview, sampling of blood, buffy coat and spot urine (including biobanking), electrocardiogram, pulse wave velocity and analysis, transthoracic echocardiography, 4-meter gait speed test, hand grip test, questionnaires
1506430|NCT02922465|Drug|K-877|
1506431|NCT02922465|Drug|Clopidogrel|
1506432|NCT02922452|Drug|BMS-986141|Single dose BMS-986141 and Multiple doses of Dilitazem
1506433|NCT02922452|Drug|Dilitazem|Single dose BMS-986141 and Multiple doses of Dilitazem
1506434|NCT02922439|Behavioral|Tailored Intervention|The intervention will focus on improving the health literacy of low literacy individuals by providing chronic disease self-management information tailored to cultural and linguistic characteristics of participants.
1506435|NCT02922439|Behavioral|Control Intervention|This intervention will provide information similar to that provided in the control condition, but will not utilize tailoring.
1506436|NCT02922426|Drug|ALKS 3831|Daily dosing for 21 consecutive days
1506437|NCT02922426|Drug|Olanzapine|Daily dosing for 21 consecutive days
1506438|NCT02922426|Drug|Placebo|Daily dosing for 21 consecutive days
1506439|NCT02922413|Biological|Hemin for injection|A single dose of Panhematin 4 mg/kg body weight reconstituted with 25% human albumin infused intravenously over at least 1 hour.
1506440|NCT02922413|Other|Placebo|Saline infusion
1506441|NCT02922400|Behavioral|Social Cognition Assessment and Training|The study includes an assessment and treatment phase: The assessment phase will test the efficacy and feasibility of a battery of measures evaluating social cognition and behavior. Functional magnetic resonance imaging (fMRI) will also be used to investigate functional differences in regions of the brain associated with social cognition and differences in cognitive progressing. The treatment phase will assess the efficacy and feasibility of a strategy-based social skills treatment using a virtual reality platform.
1506442|NCT02922387|Drug|Varenicline|Varenicline was given for 12 weeks to all patients in group A. The initial dose was 0.5 mg/day for days 1-3, and was then up-titrated to 0.5mg on days 4-7, and finally to 1 mg twice daily from day 8 until the end of treatment
1506443|NCT02922387|Behavioral|Behavioral support|An initial private consultation session and motivational interview while still in the hospital that lasted for at least 60 minutes. Follow-up phone calls with a minimum duration of 10 minutes were scheduled in weeks 1, 2, 4, and months 3,6 and 9 following smoking cessation.
1506444|NCT02922374|Drug|corticosteroids|Intravenous steroids were started with methylprednisolone 60 mg/d or hydrocortisone 400 mg/d for 3 days.
1506447|NCT02922335|Behavioral|Multisystemic Therapy for Emerging Adults|MST-EA is a home-based therapy in which therapists work closely with each young adult. Therapists often also work with the young person's family, as appropriate. MST-EA is designed to help young people work on their own behavior. This treatment also involves the use of coaches who help young people develop skills for young adulthood.
1506448|NCT02922335|Behavioral|Enhanced Treatment as Usual|Standard services that a young person would receive if they have been in trouble with the law and also have a mental illness.
1506449|NCT02922322|Other|Pilates Group|The Pilates group program (PG) was composed of 16 sessions, 2x per week, 60 minute session each for 8 weeks. The intervention was based on 20 out of the 34 original mat exercises proposed by the Pilates method, classified into basic, intermediate or advanced levels divided into 4 cycles of 5 exercises each. The exercises were performed during two series of 10 repetitions respecting the patients skills.
1506450|NCT02922309|Behavioral|Vocal Training Via Telepractice|Vocal Training Via Telepractice, delivered by integrated communication service
1506451|NCT02922309|Behavioral|Vocal Training Via face-to face practice|Vocal Training Via face-to face practice at medical facilities
1506452|NCT02922283|Device|IL2-PET scan|All patients in this study will undergo a IL2 PET scan at baseline and week 6 of treatment with immunotherapy.
1506453|NCT02922283|Procedure|Tumor biopsy|A procedure to acquire tissue of a predetermined melanoma metastasis will be performed in all patients that participate in phase 2 of this study.
1506454|NCT02922283|Device|CT scan|A CT scan of diagnostic quality will accompany all the PET scans and will additionally been made 12 and 16 weeks after start of immunotherapy to evaluate response to treatment.
1506455|NCT02922283|Procedure|Biopsy of non-target tissue|A biopsy of skin and colon non-target tissue involved in an immune-related side effect is optional in patients that participate in phase 2 of this study.
1506456|NCT02922270|Other|Peritoneal dialysis patients at the Istanbul Medical Faculty|The aims of this study were to evaluate patient and technique survival rates, investigate peritonitis rates and evaluate factors affecting mortality in peritoneal dialysis (PD) patients over a period of 20 years at Istanbul Faculty of Medicine Peritoneal Dialysis Unit.
1506457|NCT02922244|Other|Control|Apply moisture cream to the treatment skin everyday after radiation therapy
1506458|NCT02922244|Other|Cucumber cream|Apply cucumber cream to the treatment skin everyday after radiation therapy
1506459|NCT02922244|Other|Centella cream|Apply centella cream to the treatment skin everyday after radiation therapy
1506460|NCT02922244|Other|Thunbergia cream|Apply thunbergia cream to the treatment skin everyday after radiation therapy
1506462|NCT02922218|Drug|Enzalutamide|
1506463|NCT02922205|Device|Endoscopic Linear Cutter Stapler and reloads|
1506464|NCT02922192|Drug|TNF-α antagonists, non-TNFs, DMARD non-biologics|Exposure to TNF- α antagonists, non-TNF- α antagonists, oral DMARD, or non-biologic agents.
1506465|NCT02922179|Drug|Long- and intermediate- acting insulins|alone or in combination with metformin, short-acting insulin, or second-generation sulfonylurea
1506466|NCT02922166|Drug|SRX246|oral capsule
1506467|NCT02922166|Drug|Placebo|oral capsule
1506468|NCT02922153|Device|Cryoanalgesia|AtriCure® cryoICE cryo-ablation system
1506469|NCT02922153|Drug|Standard of Care|Institutional SOC for pain management will be followed.
1506470|NCT02922140|Behavioral|pharmaceutical care service|
1506471|NCT02922127|Drug|Ulipristal Acetate|Daily use of Ulipristal Acetate
1506472|NCT02922127|Drug|Combined Oral Contraceptive Pill|Daily use of Oral Contraceptive Pill
1506473|NCT02922114|Other|Ultrasonography|B-mode and power Doppler ultrasonography examination.Ultrasonography assessments includes wrists, metacarpophalangeal, proximal interphalangeal, elbows, shoulders, knees, ankles, metatarsophalangeal and twenty six tendons (wrist extensors, finger flectors and tendons of the ankles).
1506474|NCT02922101|Behavioral|Audit and Feedback|An online dashboard that provides insight into clinical performance on pain management quality indicators. It also incorporates an empty action plan, in which participating intensive care units can define potential bottlenecks in the care process and what actions they intend to undertake to improve.
1506475|NCT02922101|Behavioral|Toolbox|A quality improvement toolbox, incorporated within the action plan, that comprises for each pain management quality indicator (e.g., percentage of patients per shift whose pain is measured) a list of potential bottlenecks in the care process (e.g., staff is unaware of the prevailing guidelines for measuring pain every shift), associated recommendations for actions to solve mentioned bottlenecks (e.g., organize an educational training session), and supporting materials to facilitate implementation of the actions (e.g., a slide show presentation discussing the importance and relevance of measuring pain every shift).
1506476|NCT02922088|Device|DuraGraft|DuraGraft is a one-time intraoperative vascular graft treatment designed to prevent graft disease and failure and reduce the clinical complications associated with graft failure.
1506477|NCT02922075|Biological|Connective tissue graft|A 1.5 mm thick soft tissue graft removed from the palate with determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
1506478|NCT02922075|Biological|Collagen matrix graft|A 15x20 mm collagen matrix trimmed according to determined dimensions. The recipient site was prepared by performing laterally a delicate elevation of the facial tissue avoiding the mesial and distal papilla. The soft tissue graft length was equal to the horizontal distance between the two papillas and its length was set at 6 mm. Soft tissue grafts were placed at the level of the gingival margin and stabilized with simple interrupted sutures.
1506479|NCT02922075|Device|Immediate implant|A conical implant with a morse-taper connection with moderate roughness implant surface was properly installed in the ideal tridimensional position with its platform placed 4 mm below the facial gingival margin. After tooth extraction and dental implant installation with a torque > 32 Ncm patients were randomized into three groups (8 patients per group): 1- No soft tissue graft, Control group (CTL); 2- Collagen Matrix group (CM); 3- Connective tissue graft group (CTG).
1506524|NCT02921789|Drug|Mycophenolate Mofetil (MMF)|Oral (po) or intravenous (iv) two times a day (bid)
1506480|NCT02922075|Procedure|Tooth extraction|Compromised tooth was gently removed and the socket was debrided thoroughly, cleansed and inspected. The socket's palatal and apical bone was sequentially drilled. All surgeries were performed by the same surgeon and were individually planned according to the clinical and tomographic evaluation. Implant diameter was set as 3.5 mm and its length was selected according to the quantity of bone available apically to the fresh alveolar socket.
1506481|NCT02922075|Device|Immediate restoration|A titanium abutment was installed in the dental implant with manual torque and a prefabricated tooth shell was relined with resin material to fabricate cement or screw retained interim restoration. All interim restorations were installed in infra-occlusion matching the adjacent teeth color and form, with light proximal contacts and presented a subgingival concave contour.
1506482|NCT02922075|Biological|Bone regeneration|All sites received a non-cross linked collagen membrane and deproteinized bovine bone mineral containing 10% of porcine collagen.
1506483|NCT02922075|Drug|Post operative medication|Postoperative instructions were given, antibiotics were prescribed for 7 days (amoxicillin 500 mg t.i.d), analgesics to relieve from pain (Paracetamol 750 mg) and chlorhexidine 0.12% rinse twice a day for 15 days. Complementary, the patients were instructed to avoid chewing in the anterior region and to follow a soft diet.
1506484|NCT02922075|Device|Definitive prosthesis|Definitive implant-supported restorations were performed 6 months after dental implant placement.
1506485|NCT02922075|Other|No soft tissue graft|No soft tissue graft was used
1506486|NCT02922062|Other|Canola Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be canola oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
1506487|NCT02922062|Other|Palm Oil|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oil used in food preparation will be palm oil. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
1506488|NCT02922062|Other|Butter|Subjects will be provided with all their meals prepared in our metabolic kitchen in order to control their diets. The major cooking oils used in food preparation will be butter. The meals will be tailored to the caloric needs of each individual in order to maintain their body weight.
1506489|NCT02922049|Other|Biopsies with histopathology|All samples taken by biopsies will be correlated with the images taken by CLE.
1506490|NCT02922036|Device|WiSE System|The WiSE System is an implantable cardiac system to provide LV pacing stimulation in conjunction with a co-implanted system that provides right ventricular stimulation.
1506491|NCT02922023|Device|Ambulatory blood pressure monitor (ABPM)|"ABPM allows providers to obtain blood pressure readings over a 24 hour period, to assess blood pressure at night to determine dipping status, and to evaluate the efficacy of anti-hypertensive therapy."
1506492|NCT02922023|Other|Chronotherapy|Chronotherapy group will receive a shift in the timing of one of their antihypertensive medications to nighttime dosing without consulting their ABPM results.
1506493|NCT02921997|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
1506494|NCT02921997|Biological|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|Inactivated monovalent subvirion H3N2v vaccine containing hemagglutinin (HA) of A/Minnesota/11/2010 NYMC X-203 virus.
1506495|NCT02921997|Biological|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
1506496|NCT02921984|Drug|Docetaxel|Docetaxel only: 80 mg/m2 on day one, every 21 days if
1506497|NCT02921984|Radiation|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
1506498|NCT02921984|Drug|Pemetrexed|Pemetrexed only: 500 mg/m2 on day one, every 21 days
1506499|NCT02921984|Drug|Cisplatin|Cisplatin only: 70 mg/m2 on day one to day three, every 21 days
1506502|NCT02921958|Behavioral|occupational therapy|Family-centered occupational therapy services
1506503|NCT02921945|Biological|SCT800|recombinant human coagulation factor VIII
1506504|NCT02921932|Dietary Supplement|Ensure, Resource 2.0 and Glucerna|Preoperative nutritional supplement for undernourished patients
1506505|NCT02921932|Other|Cognitive Training, Memory Card Game|Preoperative memory card game
1506506|NCT02921932|Device|'Threshold' Inspiratory Muscle Trainer, Respironics of New Jersey Inc|Inspiratory muscle trainer protocol for strengthening respiratory muscles
1506508|NCT02921906|Other|High protein meal|Breakfast with high protein / low carbohydrate content
1506509|NCT02921906|Other|High carbohydrate meal|Breakfast with high carbohydrate / low protein content
1506510|NCT02921906|Drug|Paracetamol|Standard dose of paracetamol administered with each meal to allow measurement of rate of gastric emptying.
1506511|NCT02921906|Other|Fasting state - sulphonylurea only|People with diabetes take sulphonylurea medication in the absence of any food stimulus
1506512|NCT02921893|Drug|Dexamethasone|Given PO
1506513|NCT02921893|Drug|Ixazomib Citrate|Given PO
1506514|NCT02921893|Other|Laboratory Biomarker Analysis|Correlative studies
1506515|NCT02921893|Drug|Lenalidomide|Given PO
1506516|NCT02921893|Other|Questionnaire Administration|Ancillary studies
1506517|NCT02921880|Other|Cardiac Rehabilitation|
1506518|NCT02921867|Other|Simulation-based training|The simulation-based training will consist of nine modules that can be trained in random order and training periods within the eight weeks before clinical training starts.
1506519|NCT02921854|Other|Blood withdrawal|For each patient, 3 blood withdrawals of 25 ml each will take place during treatment
1506520|NCT02921841|Behavioral|D*STAR|
1506521|NCT02921841|Behavioral|D*HEALTH|Digital general health promotion intervention. Time and attention matched intervention that targets health behaviors relevant to youth including exercise, nutrition, sleep, and smoking. Basic information about HIV and sexuality is also included.
1506522|NCT02921789|Drug|Bleselumab|Intravenous infusion
1506523|NCT02921789|Drug|Basiliximab|Bolus injections
1511008|NCT02886481|Device|perioperative monitoring|
1506528|NCT02921776|Other|Aim 1 - VidaTalk - tasks|"Observation of task completion will be made while patients complete a series of messages using the VidaTalk app:
Tell me you are tired
Tell me you are having pain
Rate this pain
Tell me there is pain in your back
Tell me your pain is sharp
Ask to see the doctor
Write your favorite color by drawing with your finger
Type How are you? Patients will also complete a 1-item difficulty rating and a 3-item After-Scenario Questionnaire (ASQ) after each task.
Patients will also be asked to (a) comment on the customization of the app and make suggestions; (b) rate the extent to which they would use the device if they were an ICU patient and unable to speak.
Group 1 only:
Patients will be asked about their preferences for customizing the VidaTalk app."
1506529|NCT02921776|Other|Aim 2 - mechanical ventilation patients|Prior to implementing procedures for Aim 2, the company will have performed further iterative design assessments and engineered a Vidatalk tablet application prototype for a field-test for functionality (human-device interaction factors, feasibility, and usability) and acceptability. Data will be collected by a trained data collector as in Aim 1 with the addition of Ease of Communication and Frustration ratings before and after the testing sequence. To reduce burden, patients in this group will complete the 3-item ASQ one time after all tasks are completed. They will also complete a 13-item System Usability Scale (SUS).
1506530|NCT02921776|Other|Aim 3 - intervention with VidaTalk tablet|Patients in the intervention group will receive a protocolized instruction in the use of the VidaTalk application and mounting of the device including patient return demonstration of key features, customization of a personal message page if desired, and review/ testing to competence conducted by a trained interventionist. When available, a family member may be included in in customization of a message page if patient agrees. The interventionist will visit patients briefly (5-10 minutes) each day to check user needs and concerns and will review or retrain on message options if needed.
1506531|NCT02921776|Other|Aim 3 - attention-control with non-VidaTalk tablet|Patents randomized to the control group will receive a protocolized introduction to the bedside Android device without the VidaTalk app, focusing instead on a general health teaching application. Daily visits will be conducted with control group patients to query on use of the attention-control tablet.
1506532|NCT02921763|Drug|Dydrogesterone|
1506533|NCT02921750|Device|Exufiber|Gelling fibre dressing
1506534|NCT02921750|Device|Aquacel Extra|Gelling fibre dressing
1506535|NCT02921737|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally 2 times daily beginning the morning of Day 1 of each cycle and ending the evening of Day 5 of each cycle, as well as beginning the morning of Day 8 and ending the evening of Day 12 of each cycle. No TAS-102 will be given on Days 6-7 or Days 13-28 of each cycle.
1506536|NCT02921724|Device|TreC-Onco|"TreC-Onco is composed of two tools aimed at supporting patient self-care and health professional monitoring and intervention:
Mobile diary app. This is an Android app (for Android version 2.2 and higher) that allows patients to record parameters related to their health state (e.g. medications; blood pressure, weight, fever; side-effects or other symptoms) through a mobile device. Data are stored in a central database and are made available in real time to health professionals through a web dashboard on the TreC server or through a tablet app.
Web dashboard. Through this, oncologists can check patient data, monitoring their side-effects and adherence to prescriptions. The Dashboard is optimized for the Firefox browser in version 7 or higher."
1506537|NCT02921711|Device|LVIS®|Low-profile Visualized Intraluminal Support device
1506538|NCT02921698|Device|FRED®|Flow Re-Direction Endoluminal Device
1506539|NCT02921685|Drug|Monalizumab|Four dose levels will be tested.
1506540|NCT02921672|Other|Mediterranean Diet|Diet consisting of fruits, vegetables, grains, dairy, olive oils, seafood, and nuts. It is low in red meat and solid fats.
1506541|NCT02921659|Dietary Supplement|Niagen™|nicotinamide riboside chloride, 250mg capsules
1506542|NCT02921659|Dietary Supplement|Placebo|silicified microcrystalline cellulose, vegetarian capsule
1506543|NCT02921646|Other|Measure of resting energetic expenditure|
1506544|NCT02921633|Other|Intervention letter|
1506545|NCT02921620|Biological|PRX-102|Intravenous
1506546|NCT02921620|Other|Placebo|Intravenous
1506547|NCT02921607|Other|Observational group|Participants will be asked to complete a questionnaire prior to discharge and 3 months later to follow up
1506548|NCT02921594|Device|Total knee arthroplasty with Vanguard XP|
1506549|NCT02921594|Device|Total knee arthroplasty with Vanguard CR|
1506550|NCT02921581|Radiation|FDG-PET guided dose painting|
1506551|NCT02921568|Device|P200TE|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
1506552|NCT02921568|Device|Spectral OCT/SLO|Optical Coherence Tomography and Scanning Laser Ophthalmoscope device.
1506553|NCT02921555|Drug|Methylprednisolone|Intravenous bolus of methylprednisolone 0.5g/day for 3 consecutive days followed by a decreasing conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
1506554|NCT02921555|Drug|Prednisone|Conventional course of oral prednisone (week1; 60mg/d, w2; 50mg/d, w3;40mg/d, w4; 30mg/d, w5; 20mg/d, w6; 15mg/d, w7; 10mg/d, w8; 5 mg/d, w9; 0mg/d)
1506555|NCT02921542|Device|Laser Atherectomy|The Turbo-Power is laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
1506556|NCT02921529|Other|TEAS|Electric stimulation was given through electrode attached to specific acupoints
1506557|NCT02921529|Other|false stimulation|Electrodes were attached to specific acupoints without electric current
2002725|NCT01905683|Drug|IncobotulinumtoxinA (16-20 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total dose per injection cycle: up to 500 units; Mode of administration: intramuscular injection into spastic muscles.
1506561|NCT02921503|Other|mobile topical corticosteroid app|app used on mobile phones that takes the input of providers and suggests topical corticosteroids with specific information on the ingredient, vehicle, and amount
1506861|NCT02919345|Drug|Glibenclamide 5 mg|Glibenclamide 5 mg in addition to Metformin 1500 mg/day
1506562|NCT02921490|Device|FDG PET/MR examination.|All recruited patients will undergo an FDG PET examination focused on the lumbar spine.
1506563|NCT02921477|Drug|bosutinib|
1506564|NCT02921464|Other|none - registry clinic followup only|
1506565|NCT02921451|Device|Restorelle Smartmesh|Patients will have surgery using the device, Restorelle Smartmesh, for treatment of uterine prolapse.
1506566|NCT02921438|Device|VitalScan Magnetocardiograph|A passive, non-contact, mobile medical device that measures, displays, stores, and retrieves magnetic fluctuations caused by heart activity at a patient's bedside.
1506568|NCT02921412|Device|fanfilcon A|contact lens
1506569|NCT02921386|Drug|Oral Testosterone Undecanoate|
1506570|NCT02921373|Biological|19F Cell Sense-labeled PBMC|"Peripheral blood mononuclear cells (PBMC) will be isolated from patient whole blood samples and labeled in a GMP facility with GMP grade 19F Cell Sense imaging agent.
These cells will be re-administered to the patient prior to imaging."
1506571|NCT02921373|Device|MRI|Participants will undergo Magnetic Resonance Imaging (MRI) at 1 hour and 24 hours following PBMC administration
1506572|NCT02921360|Drug|acetylsalicylic acid|
1506573|NCT02921347|Procedure|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
1506574|NCT02921334|Procedure|switching between invasive and noninvasive ventilation|As defined criteria, patients are switched between invasive and noninvasive ventilation until the ventilator is successfully weaned.
1506575|NCT02921295|Device|Sidekick Stubbies|
1506576|NCT02921282|Genetic|Genotype dopamine|Laboratory investigations of nicotine reinforcement
1506577|NCT02921282|Genetic|Genotype cannabinoids|Laboratory investigations of nicotine reinforcement
2002731|NCT01882192|Behavioral|Family physical activity planning|"This material will include skill training content (workbook how to plan for family physical activity) and practical material to create a plan (i.e., a colourful dry erase wall calendar for family activities with fridge magnets). The skill training material for planning is based on several streams of prior work in the adult physical activity literature. Families were instructed to plan for when, where, how, and what physical activity will be performed commensurate with the creation of implementation intentions/action planning. The workbook, however, also focuses on problem solving barriers to physical activity which is more akin to coping planning and traditional goal setting."
2002732|NCT01877642|Drug|ADASUVE 10 mg|
2002733|NCT01877642|Drug|Lorazepam 2 mg IM|
2002734|NCT01877642|Drug|Staccato Placebo|Inhaler with no drug in it to mimic the ADASUVE inhaler
2002735|NCT01877642|Drug|Placebo IM|placebo IM solution to mimic lorazepam 2 mg IM
2002736|NCT01877382|Drug|DS-3032|DS-3032b will be administered as an oral capsule. It will be supplied in 5 mg, 20 mg, 80 mg, and 200 mg capsules individually packaged in desiccant-embedded aluminum blisters.
2002737|NCT01876446|Other|Laboratory Biomarker Analysis|Correlative studies
2002738|NCT01876446|Drug|Pegylated Irinotecan|Given IV
2002739|NCT01876446|Other|Pharmacological Study|Correlative studies
2002740|NCT01876212|Biological|DC vaccine|
1506589|NCT02921217|Dietary Supplement|Active Probiotic|Product 1: 200 mg maltodextrin and 100 mg of active Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) (1011 CFU/g),
1506590|NCT02921217|Dietary Supplement|Inactivated probiotic|Product 1: 200 mg maltodextrin and 100 mg of Bifidobacterium animalis subsp. lactis BPL1 (CECT 8145) inactivated by heat (1011 CFU/g),
1506591|NCT02921217|Dietary Supplement|Control|Placebo: 300 mg maltodextrin.
1506592|NCT02921204|Other|Vitamin D status|There is no intervention in this study
1506593|NCT02921191|Drug|filgrastim, TBO-filgrastim or pegfilgrastim|First cycle
1506594|NCT02921178|Other|Omalizumab|comparision of using Omalizumab and non-Omalizumab treatment
1506595|NCT02921165|Drug|analgesic mouth rinses (dissolved Aspirin)|Group 1 and Group 2 patients will be prescribed analgesic mouth rinses (dissolved Aspirin) twice daily along with the standard prescription of analgesics and antibiotics.
1506596|NCT02921165|Drug|Normal saline rinses.|Non Hypertensive patients will be prescribed normal saline rinses twice daily along with the standard prescription of analgesics and antibiotics.
1506597|NCT02921152|Procedure|bone marrow aspiration /trephine biopsy|
1506598|NCT02921139|Radiation|Stereotactic ablative radiotherapy (SABR)|Patients with HCC after incomplete TACE are randomized to stereotactic ablative radiotherapy (SABR). SABR will be delivered in 5 fractions.The preferred inter-fraction time interval is 48 hours. The entire treatment with 10 days is preferred.
1506599|NCT02921139|Procedure|Re-Transcatheter arterial chemoembolization (re-TACE)|Patients with HCC after incomplete TACE are randomized to further re-TACE.
1506600|NCT02921100|Procedure|cytology|The conventional cytology was interpreted independently by two cytopathologists, both of whom are blinded to the DIA results. The conventional cytologic diagnosis were classified as no abnormal cells, atypical cells, suspicious malignant cells and malignant cells.
1506601|NCT02921100|Procedure|DNA ploidy|DIA is a form of cytologic analysis that quantifies cellular constituents by using spectro photometric principles and a sister technique to flow cytometry.Quantification of DNA content, chromatin distribution, and nuclear morphology can be determined and suggest features of malignancy
1506602|NCT02921100|Procedure|EUS-FNA|All the enrolled participants underwent an operation of EUS-guided fine needle aspiration. Histological and cytological samples were obtained following this step.
1506603|NCT02921100|Device|EUS-guided fine needle|
2002741|NCT01876212|Drug|Dasatinib|
2002742|NCT01868269|Drug|Dexamethasone acetate|"First step:
immunosuppressive treatment with dexamethasone"
1506606|NCT02921074|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
1506607|NCT02921074|Other|Commercially available computerized training|
1506608|NCT02921061|Drug|Cladribine|Given IV
1506609|NCT02921061|Drug|Cytarabine|Given IV
1506610|NCT02921061|Drug|Decitabine|Given IV
1506611|NCT02921061|Biological|Filgrastim|Given SC
2002743|NCT01868269|Drug|dexamethasone and cyclophosphamide|second step (in case of insufficient response): immunosuppressive treatment with dexamethasone and cyclophosphamide
2002744|NCT01868269|Drug|dexamethasone and rituximab|third step (in case of insufficient response): immunosuppressive treatment with dexamethasone and rituximab
1506617|NCT02921022|Drug|Gemcitabine|
1506618|NCT02921022|Drug|Nab-paclitaxel|
1506619|NCT02921022|Drug|PEGPH20|
1506620|NCT02921009|Device|Crosslinking using UV light of two different fluence rates|The treatment of keratoconus involves the application of riboflavin followed by Ultraviolet light of differing intensities. This study will determine the effectiveness of a greater UV light fluence at a shorter treatment time than is currently utilized.
1506621|NCT02920996|Drug|Merestinib|Oral, predetermined dosage per protocol, once daily per 28 day treatment cycle
2002745|NCT01867710|Drug|Abiraterone Acetate|Type = exact number; unit = mg; number = 1000; form = tablet; route = oral; taken as four 250 mg tablets once daily at least 2 hours after eating and no food should be eaten for at least 1 hour after taking the tablets.
2002746|NCT01867710|Drug|Prednisone 5 mg twice daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
2002747|NCT01867710|Drug|Prednisone 5 mg once daily|type = exact number; unit = mg; number = 5; form = tablet; route = oral; taken once daily, in the morning after a meal
1506629|NCT02920944|Device|EUS-FNB with 20 gauge ProCore needle|EUS-FNB with 20-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
1506630|NCT02920944|Device|EUS-FNB with 22 gauge ProCore needle|EUS-FNB with 22-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)
1506631|NCT02920931|Drug|Tenofovir disoproxil|
1506632|NCT02920918|Drug|Canagliflozin|
1506633|NCT02920918|Drug|Sitagliptin|
1506634|NCT02920905|Drug|Lidocaine|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.
Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
1506635|NCT02920905|Drug|atracurium|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.
Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse and loss of pulse oximetry tracing in the ipsilateral index finger. The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
1506636|NCT02920905|Drug|Mg sulphate|"Two intravenous cannulae will be placed; one in a vein on the dorsum of the hand to be operated (22 gauge) and the other in the opposite hand. A double tourniquet will be positioned on the upper arm of the hand to be operated. Arm will be elevated for 2 min.
Circulatory isolation of arm will be confirmed by inspection of the color of the limb, absence of radial pulse . The upper (proximal) tourniquet will then be inflated to a pressure of 100 mmHg above the systolic blood pressure of the patient. The anesthetic solution will be prepared by an observer and will be given over a period of 90 seconds."
1506637|NCT02920892|Drug|AFQ056|Oral suspension (liquid)
1506638|NCT02920892|Other|Placebo|Oral suspension (liquid)
1506639|NCT02920892|Other|Language Intervention|The language intervention will be administered by a trained language specialist through a combination of in clinic visits and at home synchronous video conferencing sessions. The intervention will subsequently be delivered to the parent by a speech-language clinician through weekly clinician coaching, homework, and feedback sessions.
1506640|NCT02920879|Procedure|PEEP-level, driving pressure|Different levels of PEEP and different levels of driving pressures during mask-ventilation at anesthesia induction.
1506641|NCT02920866|Behavioral|Functional Strength Integration (FSI)|FSI intervention involves strengthening of the hip musculature combined with focused techniques emphasizing early initiation of hip muscle recruitment to stabilize the pelvis, integrating strength and movement pattern training to maximize functional recovery. The FSI program consists of therapeutic exercise in 3 domains: pelvic stability (PST) training, functional training (FT), and strength training (ST). PST includes early surgical-limb weight bearing and core muscle strengthening, progressively increasing in difficulty based on performance benchmarks and therapist monitoring. FT focuses on gait and stair climb exercise, progressing to higher level agility training. ST includes progressive, resistance exercise to improve lower extremity muscle strength. The ST exercises include use of weighted pulleys/weight-training machines. Therapists will determine an 8-rep max for muscle groups and weight will be increased by 10% every 2 weeks to maximize hypertrophy and strength gains.
1506642|NCT02920866|Behavioral|Control Group (CON)|Observed practice patterns from previous investigations and discussion with physical therapists indicate that patients receive rehabilitation services during the 2-3 day hospital stay after THA, but not routinely after hospital discharge. Yet, to control for attention and volume of rehabilitation for the FSI group, patients in the control group will attend outpatient physical therapy for 14 visits (40 minute sessions) over 8 weeks. This control program will mimic the typical postoperative experience for patients in our community, in which patients independently manage their activity. This program will focus on patient education, functional ADL training, and therapeutic exercise. However, the activities in the exercise domain will be limited to low load exercise such as isometric muscle exercise, range of motion (ROM), and flexibility activities. These activities are specifically designed to mirror usual care activity.
1506645|NCT02920840|Device|Intermittent theta-burst stimulation|see associated arm/group description
1506646|NCT02920840|Device|Negative-peak-triggered-TMS|see associated arm/group description
1506647|NCT02920840|Device|Open-loop replay TMS|see associated arm/group description
1506648|NCT02920827|Combination Product|Dapivirine Vaginal Ring|A platinum-catalysed silicone elastomer matrix vaginal ring containing 25mg of dapivirine used over 28 days
1506649|NCT02920827|Combination Product|Placebo vaginal ring|Placebo vaginal ring containing no dapivirine
1511009|NCT02886468|Other|skin ultrasound|
1506650|NCT02920814|Other|Cognitive Behavioural Therapy|Time intensive CBT over 8 weeks, including 6 weekly sessions and two intensive days of 4 hours each.
1506651|NCT02920801|Drug|saxagliptin|5mg per day for 12 weeks
1506652|NCT02920801|Drug|Metformin|1500mg per day for 12 weeks
1506653|NCT02920788|Behavioral|Goal-Oriented Attentional Self-Regulation (GOALS)|GOALS is a manualized, therapist-administered cognitive training program that targets executive control functions of applied mindfulness-based attention regulation and goal management strategies and links them to participant-defined real-life goals. In contrast to training via practice on isolated tasks, this training protocol involves application of attention regulation skills and strategies to participant-defined goals in real life, ecologically valid settings. One of main training aims is to improve self-regulatory control mechanisms as they contribute to goal attainment.
1506654|NCT02920788|Device|fMRI|Functional Magnetic Resonance Imaging of the Brain
1506655|NCT02920775|Other|Non-interventional study - retrospective database review|
1506656|NCT02920762|Other|on-interventional study - retrospective database review|
1506657|NCT02920749|Drug|Sevoflurane group A|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was adjusted for the same MAP range.
1506658|NCT02920749|Drug|Sevoflurane group B|In this group anaesthesia was maintained with sevoflurane. Initial and maintenance fresh gas flow was 4 and 1 l/min, respectively. Sevoflurane dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
1506659|NCT02920749|Drug|Propofol group C|In this group anaesthesia was maintained with propofol. Propofol was administered according to protocol. Propofol dosing was adjusted for the same MAP range.
1506660|NCT02920749|Drug|Propofol group D|In this group anaesthesia was maintained with propofol. Propofol dosing was set to maintain target BIS levels of 40 to 60 and MAP for controlled hypotension within 60-85 mmHg.
1506661|NCT02920723|Other|Training|
1506662|NCT02920723|Other|Control|
1506663|NCT02920710|Drug|Repository Corticotropin Injection|"Initial treatment with 80 units daily for ten days (induction phase)
Maintenance treatment with 80 units twice weekly (maintenance phase)"
1506664|NCT02920697|Drug|S 55746|S 55746, per os administration, from 50 to 1500 mg, once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
1506665|NCT02920684|Other|Passive legs mobilisation|A physiotherapist performs a passive leg movement
1506666|NCT02920684|Other|Passive cycloergometer|A motorised cycloergometer performs a passive cycling
1506667|NCT02920684|Other|Muscular electrical stimulation|A neuromuscular electrical stimulation device performs a quadriceps located stimulation
1506668|NCT02920684|Other|FES cycling|A motorised cycloergometer performs a passive cycling with quadriceps neuromuscular stimulation
1506669|NCT02920671|Other|Tracer-enhanced oral glucose tolerance test (OGTT*)|Oral glucose tolerance test with stable isotope tracers will be administered. Resting energy expenditure and respiratory quotient will be evaluated during this test using indirect calorimetry.
1506670|NCT02920671|Other|Muscle MRI|Non-invasive muscle MRI will be performed to evaluated metabolic capacity.
1506671|NCT02920671|Other|Dual energy x-ray absorptiometry (DXA)|DXA will be performed to evaluate body composition.
1506672|NCT02920671|Other|Questionnaires|Questionnaires will be used to evaluate participants' health and habits.
1506673|NCT02920658|Drug|NAVS Naphthalan|
1506674|NCT02920658|Drug|0.05% Betamethasone dipropionate|
1506675|NCT02920645|Other|AVM-related ICH|
1506676|NCT02920632|Behavioral|Online cognitive training 1|Eight-week online cognitive training program, three times a week for 45 minutes. The training contains several games of which the difficulty adjusts itself to participants' individual level. The games are designed to train executive functions, working memory, and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods.
1506677|NCT02920632|Behavioral|Online cognitive training 2|Eight-week online active comparator program, three times a week for 45 minutes. The training contains several games. The active comparator games focus on crystallized intelligence.
1506678|NCT02920619|Device|Ultrasound|Imaging of the rectus femoris, lower-trapezius, brachioradialis, tibialis anterior, middle deltoid, and pectoralis major will be conducted in Veteran participants during a single visit to the Washington D.C. Veterans Affairs Medical Center. Imaging will be conducted by investigators experienced with quantitative ultrasound using diagnostic musculoskeletal B-mode ultrasound with a 10 Mhz linear transducer.
1506679|NCT02920606|Procedure|Pulpotomy|
1506680|NCT02920606|Procedure|Endodontic treatment|
1506681|NCT02920593|Drug|Vitamin D3|Vitamin D prophylaxis
1506682|NCT02920580|Procedure|Tracheostomy|This is an insertion of tracheostomy. Tracheostomy must be done within 48 hours of randomization. If for any reason the patient does not receive a tracheostomy according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. We will remind the treating physician of the treatment assignment and ask them to reassess the patient for tracheostomy on a daily basis. If a patient is extubated instead of receiving a tracheostomy we will again record reasons for this, but the patient will be analysed in the tracheostomy group according to the intention-to-treat principle. In all participating centres, percutaneous tracheostomies are routinely performed in the ICU.
1506683|NCT02920580|Procedure|Extubation|This is an extubation by removal of endotracheal tube which must be done within 48 hours of randomization. Any decision to subsequently reintubate the patient will be left to the discretion of the clinical team. Similarly, if a tracheostomy is deemed necessary in a patient who fails the extubation attempt, this will be managed at the discretion of the treating team. If for any reason the patient is not extubated according to the randomized schedule, the reason(s) will be recorded on a protocol violation form and the site investigator will be notified. If a patient receives a tracheostomy instead of being extubated we will again record reasons for this, but the patient will be analysed in the extubation group according to the intention-to-treat principle.
1506723|NCT02920307|Procedure|TEP without fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
1506724|NCT02920307|Procedure|TEP with fixation|Standard totally extraperitoneal preperitoneal (TEP) inguinal hernia repair
1506684|NCT02920580|Procedure|Usual Care|Patients in this group will be treated according to usual care, which may include extubation (removal of endotracheal tube) or insertion of a tracheostomy, timed according to physicians' discretion. The inclusion of this arm will allow both intervention arms - prompt extubation and prompt tracheostomy - to be compared to usual practice, which often involves further observation and delayed decision-making due to clinician uncertainty about the optimal airway management strategy. Incorporation of usual care arms has been promoted as a design feature to improve the safety and interpretability of critical care clinical trials.
1506685|NCT02920567|Drug|Octreotide|After pancreatoduodenectomy, octreotide was injected to patients every 8 hours subcutaneously for 7 days
1506686|NCT02920567|Drug|Placebo|After pancreatoduodenectomy, normal saline was injected to patients every 8 hours subcutaneously for 7 days
1506687|NCT02920554|Procedure|wedge resection|The extent of hepatic resection is wedge resection of liver including gallbladder fossa
1506688|NCT02920554|Procedure|bisegmentectomy|The extent of hepatic resection is 4b/5 bisegmentectomy of liver
1506689|NCT02920541|Drug|S 055746|S 055746, per os administration, from 50 to 2000 mg once a day during a 21-day cycle. Participants will receive 21-day cycles of treatment until a discontinuation criterion is met.
1506690|NCT02920528|Drug|Ketamine|sub-dissociative ketamine
1506691|NCT02920528|Drug|Placebo|Normal Saline
1506692|NCT02920515|Drug|Triptorlin or Leuprorelin|Gonadotrophin releasing hormone agonists (GnRHa)
1506693|NCT02920515|Drug|Zhibo dihuang pills|Traditional Chinese Medicine
1506694|NCT02920515|Drug|Dabu ying pills|Traditional Chinese Medicine
1506695|NCT02920502|Dietary Supplement|Arm 2: cholecalciferol 50,000 IU|One time dose of cholecalciferol 50,000 IU
1506696|NCT02920502|Dietary Supplement|Arm 3: cholecalciferol 100,000 IU|One time dose of cholecalciferol 100,000 IU
1506697|NCT02920502|Dietary Supplement|Arm 4: cholecalciferol 200,000 IU|One time dose of cholecalciferol 200,000 IU
1506698|NCT02920502|Other|Arm 1: Placebo|One time dose of Placebo
1506699|NCT02920489|Drug|Individualized epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the numeric rating scale is 5 or higher. Analgesia will be terminated at the end of the third stage of labor.
1506700|NCT02920489|Drug|Routine epidural analgesia|Epidural analgesia will begin when asked by the parturients (during the first stage of labor) and the cervix is dilated to 1 cm or more. Analgesia will be terminated at the end of the third stage of labor.
1506701|NCT02920476|Drug|TAS-102|"Days 1 through 5: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 1 of each cycle and the last dose administered in the evening of Day 5. TAS-102 is to be taken within 1 hour of completion of morning and evening meals.
Days 6 through 7: Rest
Days 8 through 12: TAS-102 (35 mg/m2/dose) orally 2 times daily with the first dose administered in the morning of Day 8 of each cycle and the last dose administered in the evening of Day 12.
Days 13 through 28: Rest"
1506702|NCT02920450|Drug|Gedatolisib|"During the first phase, subjects will be sequentially enrolled to each increasing dose level, beginning with dose level 1 (110 mg) until the first dose limiting toxicity occurs, or safely accrued to dose level 3. PF-05212384 is intravenously infused over a thirty minute period.
Dose Level 1: 110 mg Dose Level 2: 150 mg Dose Level 3: 180 mg"
1506703|NCT02920450|Drug|Paclitaxel|Given as 200 mg/m2 infusion over a three hour period at every twenty-one days; the dose will not adjust as part of the study design.
1506704|NCT02920450|Drug|Carboplatin|The carboplatin dose (mg) = AUC x (CrCl + 25) where AUC = 6 depending on the dose level. carboplatin is intravenously infused over a thirty minute period following paclitaxel administration; the dose will not adjust as part of the study design.
1506705|NCT02920437|Behavioral|Four-week weekly intervention to reduce salt intake|The intervention group will receive a four-week weekly intervention, about 15 minutes each. Two sessions will be face-to-face and two sessions will be on the phone. The participants will be informed of their 24-hour urinary sodium excretion at each measurement time once available.
1506706|NCT02920437|Other|Usual government pamphlets|The control group will receive usual government pamphlets when they know their 24-hour urinary sodium excretion at baseline. However, they will not be informed of their follow-up urinary sodium excretion results immediately.
1506707|NCT02920424|Drug|JNJ-56022473|Subjects will be administered with JNJ-56022473 SC depending upon on the dose levels.
1506708|NCT02920424|Drug|Placebo|Subjects will receive matching placebo.
1506709|NCT02920411|Other|Pediatopic Treatment Cream|Applied twice a day minimum.
1506710|NCT02920411|Other|Pediatopic Body lotion|Applied at libitum.
1506711|NCT02920398|Drug|turoctocog alfa pegol|Administered as intravenous injections at a dose of 50 U/kg. Patients will receive each product in a randomised cross-over design for comparison of the pharmacokinetics between turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process.
1506712|NCT02920385|Drug|Semaglutide|Oral administration once daily alone or together with levothyroxine or Placebo
1506713|NCT02920385|Drug|SNAC|Oral administration once daily alone or together with levothyroxine or semaglutide
1506714|NCT02920385|Drug|Levothyroxine|Oral administration alone or together with SNAC or oral semaglutide
1506715|NCT02920385|Drug|Placebo|Oral administration once daily together with semaglutide
1506716|NCT02920372|Drug|EPOETIN ALFA|
1506717|NCT02920359|Drug|LEUPRORELIN ACETATE|
1506718|NCT02920333|Procedure|conventional rehab training|Conventional rehab training will be conducted daily for 10 days, after NIBS intervention.
1506719|NCT02920333|Device|tDCS|tDCS will be applied 10 days, followed by conventional rehab training. Stimulation will be conducted at the intensity of 2 mA and last for 20 minutes. anode will be placed over the affected primary motor cortex (M1) of cortical representation of the tibialis anterior muscle (TA), while the cathode will be used as reference electrode and placed over the forehead of the unaffected side.
1506720|NCT02920333|Device|rTMS|rTMS will be applied 10 days, followed by conventional rehab training. Subjects will receive 10 Hz rTMS, and a total of 1200 pulses will be delivered for one treatment session.
1506721|NCT02920333|Device|sham tDCS|The same stimulation parameters as tDCS treatment will be employed for the sham stimulation. However, the current will be applied for 30 seconds only, to give subjects the sensation of the stimulation.
1506725|NCT02920307|Procedure|TAPP without fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair without mesh fixation
1506726|NCT02920307|Procedure|TAPP with fixation|Standard transabdominal preperitoneal (TAPP) inguinal hernia repair
1506727|NCT02920294|Dietary Supplement|Probiotic 1|Fresh fermented dairy drink containing yoghurt ferments
1506728|NCT02920294|Dietary Supplement|Probiotic 2|Fresh fermented dairy drink containing probiotic strain
1506729|NCT02920294|Dietary Supplement|Placebo|Acidified dairy drink without ferments
1506730|NCT02920281|Other|Polysomnography|
1506731|NCT02920268|Other|Dance and yoga intervention|
1506732|NCT02920255|Other|Diagnostic|Measurement of spinal tilt
1506733|NCT02920242|Drug|Rifaximin (Sandoz GmbH) tablet|200 mg tablet administered orally.
1506734|NCT02920242|Drug|Rifaximin (Xifaxan)|200 mg tablet administered orally
1506735|NCT02920242|Drug|Placebo|Matching Placebo tablet administered orally
1506736|NCT02920229|Drug|68Ga- PSMA|100-200 MBq of 68Ga-PSMA will be injected intravenously prior to perform the PET/CT
2002748|NCT01867710|Drug|Prednisone 2.5 mg twice daily|type = exact number; unit = mg; number = 2.5; form = tablet; route = oral; taken twice daily, the first dose in the morning after a meal and the second dose after a minimum interval of 8 hours in the late afternoon or early evening, after a meal
1506738|NCT02920203|Genetic|Heart and spleen tissue|
1506739|NCT02920190|Drug|Liraglutide|Interventional, single-group, open label pilot study. The investigators will identify monoclonal gammopathy patients whose antibodies are lipid/VAT targeted (goal is 10 initially as a pilot) and who are overweight/obese (BMI > 27). Eligible patients will be started on Liraglutide up to 1.8 mg sc once daily, as adjunct weight loss treatment for 12 months.
1506740|NCT02920177|Drug|platelet-rich plasma injection|platelet-rich plasma injection
1506741|NCT02920177|Drug|corticosteroid injection|corticosteroid injection
1506742|NCT02920164|Device|Auricular acupuncture|Auricular acupuncture with indwelling permanent needles
1506743|NCT02920164|Device|Placebo acupuncture|Placebo acupuncture with placebo needles
1506744|NCT02920151|Other|balance exercises circuit|Thirteen workstations were organized in a circuit format on involved multidirectional gait in different bases of support, unstable surfaces, functional reach, exercise with balls, and single-leg stance
1506745|NCT02920125|Drug|SUVED|Ayurvedic formulation in ghana (concentrated) in capsules; 500 mg each
1506746|NCT02920125|Combination Product|REIMMUGEN|Whole Cow colostrum in powder put in capsules; 300mg each
1506747|NCT02920125|Other|Grain flour placebo|Grain flour in capsules. Jowari flour in dummy Reimmugen and Ragi flour in dummy Suved placebos
1506749|NCT02920099|Other|Nutrition Literacy Assessment Instrument (NLAI)|Assessment tool which combines elements of different nutrition literacy tools.
1506750|NCT02920086|Behavioral|Nutrition Education Program|"The OPTimal nutrition by Informing and Capacitating family members of best practices (OPTICS) intervention
Nutritional education will be provided to ICU patents' families by a dietitian
Tracking of nutritional information by family
Encouragement for families to advocate for two or more Oral Nutritional Supplements per day for the patients (approximately 400 kcal/day)"
1506751|NCT02920086|Other|Decision Support Program|"Families will be provided with a web-based decision support tool (My ICU Guide)
Families will meet with the ICU medical team early in ICU stay to review goals of care"
1506752|NCT02920060|Drug|Intravenous levetiracetam|intravenous levetiracetam(30mg/kg bolus followed by 20mg/kg/dose IV 12 hourly).
1506753|NCT02920060|Drug|Sodium valproate|intravenous sodium valproate(20mg/kg bolus followed by 10 mg/kg/dose IV 8hrly)
1506754|NCT02920047|Drug|Fimasartan/Amlodipine|Treatment B
1506755|NCT02920047|Drug|Fimasartan + Amlodipine|Treatment A
1506761|NCT02920008|Drug|guadecitabine|In Cycle 1, guadecitabine will be given for 10 days on Days 1-5 and Days 8-12. In Cycle 2, the guadecitabine dose will be 60 mg/m2 for either 10 days (Days 1-5 and 8-12) or 5 days (Days 1-5 only) based on assessment of disease response, and hematological recovery by Day ≥28.
1506762|NCT02920008|Drug|Treatment Choice (TC)|"High intensity: Intermediate or high dose cytarabine (HiDAC).
Low intensity:
LDAC.
Decitabine.
Azacitidine.
Best supportive care only: given according to standard and institutional practice."
1506763|NCT02919995|Drug|RPL554|RPL554 suspension administered using a nebuliser
1506764|NCT02919995|Drug|Placebo|Placebo solution administered using a nebuliser
1506765|NCT02919969|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered as a 30 minute IV infusion every 3 weeks.
1506766|NCT02919956|Other|Magnetic Resonance Imaging|An MRI scan takes pictures of the brain and heart using a magnet and radio waves. During scanning, measurements of oxygen delivery to the brain will be obtained (CMRO2) as well as evaluation of the heart as it relates to the brain. During the scan patients will be monitored for safety by ECG, blood pressure, television camera, pulse oximetry, and carbon dioxide measurements. Cardiac anesthesiologist and cardiologist will be present.
1506767|NCT02919956|Other|Neurodevelopmental Testing|Quantitative ND tests and standardized rating scales will be used in the areas of intellectual, adaptive, visual motor skills, academic achievement in math and reading, attention and executive functioning , motor skills, memory, language, social skills and behavior. Neurodevelopmental Testing will last approximately 3.5-4 hours. Testing will be done through the Neurobehavioral Core at CHOP. Breaks will be taken as needed and a one hour lunch break will be taken, if applicable. ND testing will be performed prior to MRI (if on the same day) or on a different day than the MRI to promote engagement and best performance.
1506768|NCT02919943|Procedure|Percutaneous Coronary Intervention|OCT-guided Percutaneous Coronary Intervention.
1506859|NCT02919358|Other|No music.|This is the control group.
1506769|NCT02919930|Device|Switch from oronasal to nasal mask during ASV treatment|One night of ASV treatment with oronasal mask followed by one night of ASV treatment with nasal mask.
1506770|NCT02919930|Device|Switch from nasal to oronasal mask during ASV treatment|One night of ASV treatment with nasal mask followed by one night of ASV treatment with oronasal mask.
1506771|NCT02919917|Drug|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
1506772|NCT02919917|Drug|Midodrine Hydrochloride|Level 1: Compression stockings, abdominal binder Level 2: Midodrine 5mg 2x/d Level 3: Midodrine 10mg 2x/d Level 4: Midodrine 15mg 2x/d Level 5: Midodrine 20mg 2x/d Level 6 Midodrine 20mg 2x/d and Fludrocortisone 0.1mg 2x/d Level 7 Midodrine 20mg 2x/d and Fludrocortisone 0.2mg 2x/d
1506773|NCT02919904|Device|ARESTM|"The ARESTM device is a commercial home sleep-testing device that can record the following parameters (for up to 7 continuous hours) when participants are asleep:
NREM and REM sleep frequency and duration
Duration and number of arousal
Blood oxygen saturation and pulse rate via a silicone-embedded optical sensor
Fluctuation in nasal airflow pressure via a nasal cannula and pressure transducer
Head movement actigraphy and flux in snoring as measures of sleep/wake patterns via two accelerometers and an acoustic microphone
Apnea/hypopnea index and respiratory disturbance index"
1506774|NCT02919891|Other|Questionnaire|Questionnaires
1506775|NCT02919878|Drug|Gemcitabine|Nucleoside analog- Chemotherapy
1506776|NCT02919878|Radiation|XRT|pre-operative radiotherapy given concurrently with Gemcitabine chemotherapy
1506777|NCT02919878|Drug|capecitabine|Capecitabine is given post operatively as adjuvant chemotherapy for 6 cycles. Each cycle consist of 2500 mg/m2 per day given orally from D1-14
1506778|NCT02919865|Device|MR perfusion imaging|"MR perfusion imaging will be performed in addition to the routine neuronavigational sequence obtained from re-operative/therapy planning.
Following MR examination, patient may undergo a surgical biopsy or excision as determined clinically by the neurosurgeon.
All patients, including those who do not go to surgery, will undergo clinical follow-up and imaging follow-up with perfusion imaging. This will allow for assessment of lesion progression over time, yielding valuable diagnostic information in differentiating radiation necrosis from tumour recurrence, particularly in those patients who do not undergo surgery."
1506779|NCT02919852|Procedure|laparoscopic retrovesical colpopectinopexia|Laparoscopic correction of pelvic organ prolapse using a mesh in retrovesical space with pectineal ligament fixation.
1506780|NCT02919839|Other|non-Interventional|
1506781|NCT02919826|Behavioral|Adapted Dialectical Behaviour Therapy|12 weekly sessions of DBT group therapy
1506782|NCT02919813|Behavioral|Mindfulness Based Group Cognitive BehaviorTherapy|Mindfulness Based Group Cognitive Behavior Therapy is a type of counseling that teaches women to have more control over their pain.
1506783|NCT02919813|Behavioral|Educational Seminars|Educational seminars teach women about the different aspects of PLV that affect emotional and physical health.
1506784|NCT02919800|Biological|MOD-5014|MOD-5014, a long-acting modified recombinant Factor VIIa
1506785|NCT02919800|Other|MOD-5014 Placebo|Placebo solution for SC injection containing the same inactive ingredients used in the active drug product at matching volumes
2002749|NCT01867710|Drug|Dexamethasone 0.5 mg once daily|type = exact number; unit = mg; number = 0.5; form = tablet; route = oral; taken once daily, in the morning after breakfast
2002750|NCT01865630|Drug|Etanercept|Lyophilized powder for reconstitution/ 25 mg/vial. 25 mg subcutaneously starting within 36 hours of SAH, and then receive doses 3.5 days and 7 days later for a total of 3 doses.
2002751|NCT01863186|Drug|Lofexidine HCl|Lofexidine HCl tablets will be available in 0.2 mg tablets. Lofexidine will be provided in total daily doses as indicated during the double blind portion of the study.
1506792|NCT02919774|Drug|POMA|"Pomaglumetad (POMA) is a mGluR 2/3 partial agonist"
1506793|NCT02919774|Drug|placebo|matching placebo tablets
1506794|NCT02919761|Drug|Acthar|
1506795|NCT02919761|Drug|Placebo|
1506796|NCT02919748|Other|Choral Singing|Weekly sessions at 1 hour of choral singing.
1506797|NCT02919748|Other|Health Education Program|Weekly session at 1 hour of health education talk and group activities
1506798|NCT02919735|Drug|CG 428 cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
1506799|NCT02919735|Drug|Placebo cutaneous solution|The patient will spray treatment 10 times directly to the scalp area, with the cannula, and then gently massage the whole scalp with fingertips, twice a day, spaced out by minimum 4 hours
1506801|NCT02919709|Biological|blood taking|
1506802|NCT02919696|Drug|Abemaciclib|Administered orally
1506803|NCT02919683|Drug|Nivolumab|
1506804|NCT02919683|Drug|Ipilimumab|
1506805|NCT02919683|Procedure|Standard of Care Surgery|
1506806|NCT02919670|Dietary Supplement|Enterade|
1506807|NCT02919670|Dietary Supplement|Placebo|
1506808|NCT02919670|Other|Standard Supportive Care|
1506809|NCT02919657|Dietary Supplement|Genepro Protein|weekly blood draws to measure blood protein levels
1506810|NCT02919657|Dietary Supplement|Whey Protein|weekly blood draws to measure blood protein levels
1506811|NCT02919644|Biological|autologous dendritic cells loaded with autologous tumour homogenate|Each vaccine dose consists of 10_7 autologous dendritic cells loaded with autologous tumor homogenate
1506812|NCT02919644|Drug|IL2|Each vaccine dose is followed, after two days, by IL-2 as adjuvant, at a dose of 3 MU daily for five consecutive days
1506813|NCT02919631|Drug|Triheptanoin|Anaplerotic dietary oil
1506814|NCT02919631|Drug|Placebo oil|Safflower oil
1506815|NCT02919618|Radiation|stereotactic body radiotherapy (SBRT)|(Cardiac ablative radiotherapy)
1506816|NCT02919605|Drug|Single dose of Pentacarinat®|The patients will come to the hospital to take a single dose of the Pentacarinat®.
1506817|NCT02919605|Drug|Two doses of Pentacarinat®|The patients will come to the hospital to take two doses of the Pentacarinat®, in interval of one week between them.
1506860|NCT02919345|Drug|Dapagliflozin 10 mg|Dapagliflozin 10 mg in addition to Metformin 1500 mg/day
1506818|NCT02919605|Drug|Three doses of Pentacarinat®|The patients will come to the hospital to take three doses of the Pentacarinat®, in interval of one week between them.
1506819|NCT02919592|Device|MemoryShape® Breast Implants|MENTOR® MemoryShape™ Breast Implants are devices with shells constructed from medical grade silicone elastomer. The shell is filled with Mentor's proprietary formulation of medical grade silicone gel. The textured shell is constructed of successive crosslinked layers of silicone elastomer, and includes raised orientation marks on the anterior and posterior of the implant intended to help the physician orient the implant and ensure proper placement during implantation. Each MENTOR® MemoryShape™ Breast Implant is provided sterile. MemoryShape Breast Implants are available in sizes ranging from 120 cc-775 cc and 5 styles with various projection and height options.
1506820|NCT02919592|Device|MemoryGel® Breast Implants|MENTOR® MemoryGel™ Breast Implants are round devices with shells constructed from medical grade silicone elastomer. The shell is filled with MemoryGel™, Mentor's proprietary formulation of medical grade silicone gel, and is constructed of successive cross-linked layers of silicone elastomer. There are two styles of shell: smooth and textured. Each MENTOR® MemoryGel™ Breast Implant is provided sterile. . MemoryShape Breast Implants are available in sizes ranging from 100 cc-800 cc and 4 styles with various projection and height options.
1506821|NCT02919592|Procedure|Other Aesthetic Surgery|Other aesthetic surgery procedures (for example, liposuction, rhinoplasty, brow lift, autoplasty, rhytidectomy, mentoplasty/genioplasty, otoplasty, or blepharoplasty; may not include silicone implants)
1506822|NCT02919579|Drug|Placebo (Intranasal)|Participants will receive intranasal placebo in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
1506823|NCT02919579|Drug|Esketamine|Participants will receive intranasal esketamine in Part A (as per the treatment sequence in period 1,2 and 3) and Part B.
1506824|NCT02919579|Other|Alcohol|Participants will receive oral alcohol in Part A (as per the treatment sequence in period 1,2 and 3).
1506825|NCT02919579|Drug|Placebo (Oral)|Participants will receive oral placebo in Part A (as per the treatment sequence in period 1,2 and 3).
1506826|NCT02919553|Procedure|modified wet-suction technique|Normal saline will be present in this needle, and once in the lesion of interest the suction will be re-established and the needle will be moved in a to-and-fro motion to collect the sample of interest. Then the sample will be collected.
1506827|NCT02919553|Procedure|"Capillary slow pull technique"|The needle will be introduced into the lesion of interest and using the to-and-fro motion, collect the sample. The needle will then be withdrawn and the sample will then be collected.
1506828|NCT02919540|Other|Kangaroo care approach|skin to skin contact between stable preterm infants and their naked mother's chest
1506829|NCT02919527|Other|Self-Myofascial-Release|Self-Myofascial-Release performed at the anterior thigh
1506830|NCT02919527|Other|Stretching|Static Stretching performed at the anterior thigh
1506831|NCT02919514|Other|Physical training on hard, sand and soft surfaces|
1506832|NCT02919501|Drug|Vortioxetine (IV)|17 mg, solution for infusion, administered, over 2 hours as single dose
1506833|NCT02919501|Other|Placebo (IV)|Saline: isotonic sodium chloride, administered, over 2 hours as single dose
1506834|NCT02919501|Drug|Vortioxetine (tablet)|10 mg, tablets, oral administration once daily for 15 days (open labelled)
1506835|NCT02919488|Other|Exercise Condition|A bout of exercise in the evening followed by high-sugar meal consumption the following morning
1506836|NCT02919488|Other|Control Condition|Rest in the evening followed by high-sugar meal consumption the following morning
1506837|NCT02919475|Drug|JTE-051|Active drug tablets containing JTE-051
1506838|NCT02919475|Drug|Placebo|Placebo tablets identical in appearance to the active drug tablets
1506839|NCT02919462|Drug|Oral vinorelbine|Oral vinorelbine 60-80 mg/m2 on days 1 and 8 (first cycle 60 mg/m2) every 3 weeks, for 4 cycles
1506840|NCT02919462|Drug|Cisplatin|Cisplatin 80 mg/m2 on day 1 every 3 weeks, for 4 cycles
1506841|NCT02919462|Drug|Maintenance with Metronomic Oral Vinorelbine|Maintenance with Metronomic Oral Vinorelbine 50 mg three times a week on Monday, Wednesday and Friday continuously until disease progression, patient refusal or excessive toxicity (1 cycle: 3 weeks).
1506842|NCT02919462|Drug|Pemetrexed|Pemetrexed, 500 mg/m2, day 1 every 3 weeks, for 4 cycles
1506843|NCT02919462|Drug|Cisplatin|Cisplatin 75 mg/m2, day 1 every 3 weeks, for 4 cycles
1506844|NCT02919462|Drug|Maintenance with Pemetrexed|Maintenance with Pemetrexed 500 mg/m2 day1 q 21 until disease progression (1 cycle: 3 weeks)
1506845|NCT02919449|Biological|MV-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of MV-NIS in combination with Atezolizumab in patients with metastatic NSCLC
1506846|NCT02919449|Biological|Atezolizumab|Atezolizumab will be administered every 3 weeks
1506847|NCT02919436|Drug|Tamsulosin|Active drug
1506848|NCT02919436|Drug|Placebo|Lactose-filled capsules identical to active drug
1506849|NCT02919423|Device|transcranial magenetic stimulation|
1506850|NCT02919410|Device|iodophor-impregnated adhesive drapes|
1506851|NCT02919410|Other|No adhesive drapes|
1506852|NCT02919397|Device|Wearable technology|Buddi wearable technology will record activity levels, participants will access activity data through smartphone application
1506853|NCT02919397|Behavioral|Diabetes Prevention Programme educational material|Educational material accessed through smartphone application
1506854|NCT02919397|Behavioral|Motivational messaging|Messages sent via smartphone application
1506855|NCT02919384|Other|2% oxygen concentration in the incubator|"At the time that embryos are changed from cleavage stage media to blastocyst stage media on day 3 of development, half of a given patient's embryos will randomly be placed in an incubator set at 2% oxygen concentration. The splitting of the embryos will be done under low magnification such that the embryologist will have no ability to bias allocation of embryos to 2% or 5% oxygen based on embryo morphology on day 3. The embryos will remain in this incubator until their developmental assessments on day 5 and 6."
1506858|NCT02919358|Other|Music|
2002752|NCT01863186|Drug|Placebo|Lofexidine-matching sugar pills will be provided as 4 tablets QID during the double-blind portion of the study to subjects randomized to placebo. One lofexidine-matching sugar pill will be taken with each dose for subjects assigned to the 2.4 mg treatment group to maintain the study blind.
1506865|NCT02919319|Drug|ACT-541468 (Formulation A)|Hard gelatin capsules for oral administration formulated at strengths of 5 mg, 25 mg and 100 mg
1506866|NCT02919319|Drug|ACT-541468 (Formulation B)|Soft gelatin capsules for oral administration formulated at the strength of 25 mg
1506867|NCT02919319|Drug|Placebo (Formulation A)|Hard capsules matching ACT-541468 Formulation A
1506868|NCT02919319|Drug|Placebo (Formulation B)|Soft capsules matching ACT-541468 Formulation B
1506869|NCT02919319|Drug|14C-labeled ACT-541468|Tracer at a nominal dose of 250 nCi (corresponding to 2.02 µg ACT-541468) administered either orally or intravenously
1506870|NCT02919319|Drug|Placebo tracer|Sterile NaCl 0.9% was used as placebo matching the tracer for oral and i.v. administration.
1506871|NCT02919306|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
1506872|NCT02919306|Biological|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
1506873|NCT02919306|Drug|Placebo|Participants will receive placebo intramuscularly Weeks 0, 12, 24 and 48.
1506874|NCT02919293|Biological|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine (adjuvant-free)|30μg /dose, Intramuscular
1506875|NCT02919293|Biological|Meningococcal Groups A and C and Haemophilus b Conjugate Vaccine(adjuvant)|0.5ml /dose, Intramuscular
1506876|NCT02919280|Other|Observational Study|The Dallas 2K is a 5-year natural history, longitudinal, prospective study of a cohort of 2,000 participants. There is no medication or non-medication treatment or intervention provided by this study.
1506879|NCT02919254|Dietary Supplement|Beet It Sport Shot|Commercially available concentrated beetroot juice supplement intended for athletes.
1506880|NCT02919254|Other|Placebo|Fruit juice cordial containing negligible nitrate
1506881|NCT02919241|Behavioral|Diagnostic interview|A profound interview to declare causes for negative thoughts, assumptions and beliefs towards dental care. Participants come from public and Private dental care.
1506882|NCT02919241|Behavioral|Combined interview and treatment.|Intervention for this group include both the diagnostic interview to declare causes for negative thoughts, assumptions and beliefs towards dental care and one session treatment. Participants come from the Institute of Dentistry.
1506883|NCT02919228|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
1506884|NCT02919215|Behavioral|Teacher Help Intervention|The intervention will be provided to collaborating psychologists and their teachers to access. Teachers will work through the intervention, and psychologists will act as the online support for teachers. Teachers will work with one student in their classroom with ADHD, ASD, or LD throughout the intervention phase. Each session in the program will provide factual information to teachers, strategies for implementation of best practices to address the specific mental health disorder in the classroom setting (i.e., ADHD, ASD, or LD), and access to additional help and advice.
1506885|NCT02919202|Procedure|Colgate Fluoride Varnish Suspension. 2.26% Sodium Fluoride.|Topical application to exposed dentine on one occasion.
1506886|NCT02919202|Procedure|Self-etching Dentine Bonding Agent|Topical application to exposed dentine on one occasion followed by light-curing procedure.
1506887|NCT02919189|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by fluorescent light lamps.
1506888|NCT02919176|Drug|Mirabegron|Mirabegron 50 mg/day
1506889|NCT02919176|Drug|Pioglitazone|Pioglitazone 30 mg/day
1506890|NCT02919176|Drug|Mirabegron and Pioglitazone|Mirabegron 50 mg/day and Pioglitazone 30 mg/day
1506891|NCT02919163|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by incandescent white light bulbs and color filters.
1506892|NCT02919137|Other|Visible light exposure|Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
1506893|NCT02919124|Device|Echoclip|An ultrasound transducer positioning device, the Echoclip device (Aalborg Hospital, Aalborg,Denmark), which can stabilize the involved part of the myocardium on the beating heart, keep the gel at place, and position the ultrasound transducer correctly for imaging will be used for visualising the coronary bypass anastomoses during surgery
1506894|NCT02919111|Drug|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
1506895|NCT02919098|Behavioral|Bystander, a game-based bystander intervention program|A game-based, high school age-appropriate program delivered by trained facilitators for sexual violence and harassment intervention
1506896|NCT02919098|Behavioral|Infection City, a game-based program about meningitis|A game-based, high school age-appropriate program delivered by trained facilitators to teach students about meningitis.
1506897|NCT02919085|Procedure|Early ambulation|Procedure to accelerate the ability of a patient to walk or move about by reducing the time to ambulation. It is characterized by a shorter period of hospitalization or recumbency than is normally practiced.
1506950|NCT02918760|Drug|Gabapentin|This group will include (32) women according to inclusion and exclusion criteria and will receive a card of Gabapentin which will be taken orally by the patient at home three times daily and maximum dose 2700mg per day by 300 mg increments each week until sufficient pain relief, or the occurrence of side effects such as dizziness, somnolence, edema and ataxia.
1508282|NCT02908607|Device|Thermal imaging|Examination of the cervix by thermal imaging camera
1506898|NCT02919072|Drug|Chloroprocaine|"5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 5 mL of the study anaesthetic solution will be administered epidurally.
Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch and then the remaining 10 mL of the study solution will be administered. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered."
1506899|NCT02919072|Drug|Ropivacaine|"5 mL of the study anaesthetic solution will be given epidurally and the block will be assessed after 2 minutes from the first injection using cold, pinprick and touch. Then intrathecal placement will be excluded and a further 5 mL of the study anaesthetic solution will be administered epidurally.
Two minutes after the start of the second injection, the sensory block will be re-assessed using cold, pinprick and touch and then the remaining 10 mL of the study solution will be administered. In case of pain or discomfort a 6 mL epidural top-up of the same anaesthetic will be administered."
1506900|NCT02919059|Drug|Dapagliflozin 10 mg|"Dagliflozin will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.
On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.
The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
1506901|NCT02919059|Drug|Glimepiride 4 mg|"Glimepiride will be administred once daily before the first meal of the day for the duration of the study or until early discontinuation. Subjects will take the first dose of study drug at the study centre on Day 1.
On the day of study visits when fasting blood samples are collected, subjects will be instructed to refrain from taking the study drug before the clinic visit. The subject will be instructed to take the dose of study drug before the subject´s next meal.
The study drug must be swallowed whole with liquid and not chewed, divided, dissolved or crushed. If the subject doesn´t take the study drug within 12 hours after the first meal of the day, the dose of the study drug should be skipped for that day and keep on taking the study drug on the following day before the first meal."
1506902|NCT02919046|Biological|GD2-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-GD2-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
1506903|NCT02919033|Other|Usual care|The hypertension care of this arm complies with the national guideline and includes designated follow-ups by PCPs once every 1-3 months for stage-1 (≥ 140/90 mm Hg) hypertension patients, once every 1 month for stage-2 (≥ 160/100 mm Hg) and once every 2 weeks for stage-3 (≥ 180/110 mm Hg) patients.
1506904|NCT02919033|Device|Self-management|"Usual care
Patients receive a BP telemedicine system developed by CareLinker Inc. (Shanghai, China) to facilitate BP self-management in addition to all the usual care components. The system consists of: 1) a BP tele-monitor with embedded GSM module that can upload BP readings; 2) a mobile App that allows patients to manually input healthcare data, display history BP measurements and lab test results, receive personalized lifestyle coaching contents and medication reminders, and communicate with PCPs through text-messaging.
All patients receive proficiency training in using the BP tele-monitor, and mobile App."
1506905|NCT02919033|Other|PCTM intervention|"Usual care
Self-management
PCPs and cardiologists use the secure CareLinker website to review patient data including BP measurements, lab test results and medications in use and comorbidities. The auto analytics tools of the website reveal BP average, BP trend, and risk score of each patient. Text alerts of abnormal BP variability will be pushed to PCPs' App when they occur and proactive interventions including phone consultation and medication dosage adjustment will be offered. A case review session will be set once every 1-2 months for PCPs and cardiologists to exam patients' disease progresses. The proprietary web-based analytic module also produces automated individualized medication recommendations to PCPs.
PCPs and cardiologists receive training of the CareLinker website."
1506906|NCT02919020|Other|Proprioceptive neuromuscular facilitation (PNF)|Proprioceptive neuromuscular facilitation, using the technique of rhythmic initiation and Combination of Isotonic on lower members
1506907|NCT02919020|Other|Resistance exercise|resistance exercise to strengthen lower limbs
1506908|NCT02919007|Device|Silk'h HST treatment|Intervention includes treatment with the Silk'n HST on the periorbital areas as instructed in the user's manual
1506909|NCT02918994|Behavioral|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
1506910|NCT02918981|Behavioral|Resistance Exercise|Participants will perform unilateral leg extension exercise immediately prior to ingestion of the experimental beverage
1506911|NCT02918981|Dietary Supplement|14 g Whey protein|
1506912|NCT02918981|Dietary Supplement|6.6 g Whey protein + 1.25 g leucine|
1506913|NCT02918981|Dietary Supplement|4 g Whey protein + 1.25 g leucine + 2.6 g Whey peptides|
1506914|NCT02918981|Dietary Supplement|6.6 g Whey protein + 1.25 g leucine + 0.8 g Citrulline|
1506915|NCT02918981|Other|Water control|
1506916|NCT02918968|Drug|Enzalutamide|Oral
1506917|NCT02918968|Drug|Flutamide|Oral
1506918|NCT02918968|Other|Androgen deprivation therapy|All subjects must undergo continuous Androgen deprivation therapy with GnRH agonist/antagonist or bilateral orchiectomy during the study period.
1506919|NCT02918955|Procedure|up-front neck dissection|
1506920|NCT02918955|Radiation|radiotherapy|70 Gy in 35 fractions to the macroscopic disease 50 Gy in 25 fractions (if sequential boost) or 56 Gy in 35 fractions (if simultaneous integrated boost) to the elective volumes 66 Gy in 35 fractions to the post-operative region with lymphatic extracapsular extension (Arm B only)
1506921|NCT02918955|Drug|Chemotherapy (Cisplatin)|"100 mg/m2 every three weeks during radiotherapy
In Arm B, chemotherapy can be omitted in case of a cT1-2 primary and a surgical downstaged pN0-1 neck without lymphatic extracapsular extension."
1507073|NCT02918071|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
1506922|NCT02918955|Procedure|Early Salvage Neck Dissection in case of less than cCR (Arm A only)|"Early salvage neck dissection in case of residual lymph node disease will be performed based on the response evaluation by MRI and PET/CT performed 3 and 4 months after the end of (chemo)radiotherapy, respectively (and additional diagnostic modalities if clinically indicated by the physician) and not more than 3 weeks after this post-radiotherapy evaluation.
In Arm A, a successful early salvage neck dissection without the operation of the primary tumor in case of less than clinical complete response (cCR) will be considered a component of the multimodality treatment and not as a failure."
1506923|NCT02918929|Drug|EDP 305|
1506924|NCT02918929|Drug|Placebo|placebo to match EDP 305
1506925|NCT02918916|Other|Phototherapy|The dosage applied will be 30 Joules per site (180 Joules per muscle). Parameters are described in the attached document.
1506926|NCT02918916|Other|Placebo|The same procedures as in the active phototherapy group will be applied to the placebo phototherapy group; however the emitter will be disabled.
1506927|NCT02918903|Procedure|Minimal caries removal|the experimental group will be treated by minimal caries removal where only caries at lateral walls of cavity will be removed then stainless steel crown will be placed as final restoration.
1506928|NCT02918903|Procedure|Complete caries removal|the control group will be treated by complete caries removal where all caries along lateral and pulpal walls of cavity will be removed, a base of resin modified glass ionomer will be placed then stainless steel crown will be placed as final restoration.
1506929|NCT02918890|Other|Constraint-induced Movement Therapy|
1506930|NCT02918890|Other|Hand-arm Bimanual Intensive Therapy|
1506931|NCT02918877|Drug|Sevoflurane|Volatile Anesthetic
1506932|NCT02918877|Drug|Propofol|Intravenous Anesthetic
1506933|NCT02918864|Drug|Oxytocin and social cognitive skills group|This is an integrated pharmacological-behavioral intervention targeting social cognitive skills for school-aged children with ASD. Four doses of intranasal oxytocin (24 IUs/dose) will be delivered each week before weekly homework and group therapy sessions. Social cognitive skills training utilize cognitive behavioral strategies such as problem identification, affective education, performance feedback, and weekly homework activities to target impairments in nonverbal synchrony, emotional expression, and interpretation of intent. The NETT curriculum is manualized and anchored in CBI strategies, such as problem identification, affective education, performance feedback, and weekly homework activities. Parent education sessions run concurrently with child groups to help facilitate generalization.
1506934|NCT02918864|Behavioral|Facilitated Play Therapy|The facilitated play therapy group is a manualized treatment designed to tailor play to the interests and abilities of group members. Therapists use general therapeutics strategies such as reflective functioning statements to foster communication with therapists as well as between peers. Standard educational practices for children with ASD such as visual supports, schedules, and short-directed statements are also used. The concurrent parent group is supportive in nature.
1506935|NCT02918851|Biological|Transfusion of 7-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 5 (7-day old) red blood cells.
1506936|NCT02918851|Biological|Transfusion of 28-day stored red blood cells|Subjects will donate blood at Week 2 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week 2 (28-day old) red blood cells.
1506937|NCT02918851|Biological|Transfusion of 42-day stored red blood cells|Subjects will donate blood at Week 0 and Week 5 of their participation and receive, at Week 6, back a transfusion of their Week0 (42-day old) red blood cells.
1506938|NCT02918838|Behavioral|Own Adherence Group|Participant chooses their adherence level to be reached at next clinic visit (at least 80%, but can be higher). If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
1506939|NCT02918838|Behavioral|Fixed Adherence Group|Participant is told to meet a pre-determined target of 90%. If they reach that percentage measured using the MEMS cap, they can participate in a lottery for an airtime reward of none, a small amount, and a larger amount. Participants also receive a weekly motivational message reminding them of their incentive to adhere. If they respond to the message they will receive airtime top-up.
1506940|NCT02918838|Behavioral|Control Group|
1506941|NCT02918825|Drug|Olanzapine|Olanzapine
1506942|NCT02918825|Drug|Paliperidone|Paliperidone
1506943|NCT02918812|Drug|Intracervical lidocaine|Intracervical lidocaine injected at four different points
1506944|NCT02918812|Drug|Intramuscular Diclofenac|Intramuscular Diclofenac 30 mins before HSG
1506945|NCT02918799|Behavioral|Mpowerment|MP is a multi-level intervention that reaches out to all YMSM in a community by mobilizing men to encourage their friends to reduce risk behavior and join the program (informal outreach), along with holding social activities that promote safe sex (formal outreach). MP provides YMSM with skills, support and confidence to find solutions within themselves for sexual health, and seeks to affirm the validity and rights of same-sex behavior and identities.
1506946|NCT02918786|Device|Nasal high-flow|After extubation, the patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set until maximal level of 60 LPM.
1506947|NCT02918786|Device|CPAP|After extubation, patients will receive CPAP at 5 cmH2O delivered by the variable generator WhisperFlow System. The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
1506948|NCT02918773|Device|Smartphone otoscope|A smartphone otoscope is a pocket size smartphone attachment that uses the technology and light source of a smartphone to capture reproducible images of the ear canal and tympanic membrane. The smartphone otoscope has the capability to capture still images and video, which can be referred to post-examination as well as be incorporated into an electronic medical record. Clinicians will use the smartphone otoscope for the duration of the 6-month study period.
1506949|NCT02918773|Device|Conventional otoscope|A conventional otoscope has a light and lenses to provide a view of the ear canal and tympanic membrane or eardrum. Clinicians will use the conventional otoscope for the duration of the 6-month study period.
1508440|NCT02907294|Drug|PBF-999 / 160 mg|2 capsule 80 mg x 8 days
1506951|NCT02918760|Other|Placebo|Group B (controls):This group will include (32) women according to inclusion and exclusion criteria and will receive a card of placebo.
1506952|NCT02918747|Drug|pegaspargase|2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: four.
1506953|NCT02918747|Drug|Gemcitabine|800mg/m2, ivd on day 1 and 5 of each 21 day cycle. Number of Cycles: four.
1506954|NCT02918747|Drug|Oxaliplatin|85 mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: four
1506955|NCT02918747|Drug|Dexamethasone|15 mg, Ivd on day 1 to day 5 of each 21 day cycle. Number of Cycles: four.
1506956|NCT02918747|Drug|Cyclophosphamide|750 mg/m2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
1506957|NCT02918747|Drug|Doxorubicin|50mg/m 2，ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
1506958|NCT02918747|Drug|Vincristine|1.4 mg/m 2(≤2mg），ivdrip day 1 of each 21 day cycle. Number of Cycles: four.
1506959|NCT02918747|Drug|Prednisone|60 mg/m 2 /day orally on days1- 5 of each 21 day cycle. Number of Cycles: four.
1506960|NCT02918747|Radiation|IMRT|After chemotherapy, if the patients get CR, PR or SD, IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 -56grays (Gy) in 25-28 fractions.
1506961|NCT02918734|Device|Endobutton CL BTB|ACL reconstruction with Endobutton CL BTB
1506962|NCT02918734|Device|Metal interference screw|ACL reconstruction with metal interference screw
1506963|NCT02918721|Device|Restylane Lidocaine|Intradermal injection
1506964|NCT02918721|Device|Restylane|Intradermal injection
1506965|NCT02918708|Biological|Synflorix|10-valent pneumococcal conjugate vaccine
1506966|NCT02918708|Biological|Prevenar13|13-valent pneumococcal conjugate vaccine
1506967|NCT02918682|Other|Exercise|
1506968|NCT02918669|Radiation|CT Scan|"Patients in the coflex IDE Study who presented at 24 months with a spinous process fracture that will undergo a CT Scan to evaluate the evidence or healing of fracture post-60 months.
There are no other interventions. It is just a onetime CT post 60 month time point."
1506969|NCT02918656|Other|Infographic presentation of health information|"The students in this group will read Cochrane systematic review summary in infographics format.
Infographics format is a form of visual presentation of results of systematic review, supported by pictures and graphs."
1506970|NCT02918656|Other|PLS presentation of health information|The students randomized in PLS group will read text format with simple explanation of the survey topic main findings which is intended for lay audience.
1506971|NCT02918656|Other|Scientific abstract presentation of health information|The students in scientific abstract group will read the the text written for the academic population and practitioners.
1506972|NCT02918643|Other|Use of an application to for mobile devices like decision-making support for prescription drugs to elderly patients|
1506973|NCT02918630|Drug|Nicotine Patch|Participants will receive nicotine patch (21 mg) starting study Week 1. Participants will be instructed to apply a new patch each morning.
1506974|NCT02918630|Drug|E-cigarette|The e-cigarette will consist of 1) a 3.3 V, 1000 mAh battery; and 2) a 1.5 Ohm, dual-coil cartomizer (SmokTech; Shenzhen, China). Study staff will load the cartomizer with 1 ml tobacco flavored 70% propylene glycol/30% vegetable glycerin liquid containing nicotine concentrations 36 mg/ml (AVAIL; Richmond, Virginia, USA).
1506975|NCT02918617|Drug|Control toothpaste containing Novamin® technology|
1506976|NCT02918617|Drug|Control toothpaste containing 1500 ppm fluoride as MFP|
1506977|NCT02918617|Drug|Test toothpaste with nano-HAP (high concentration)|
1506978|NCT02918617|Drug|Test toothpaste with nano-HAP (low concentration)|
1506979|NCT02918617|Drug|Test toothpaste with nano-HAP and KNO3|
1506980|NCT02918617|Drug|Control toothpaste without nano-HAP|
1506981|NCT02918617|Drug|Test toothpaste with nano-HAP (medium concentration)|
1506982|NCT02918617|Drug|Test cream with nano-HAP (higher concentration)|
1506983|NCT02918617|Drug|Control cream without nano-HAP|
1506984|NCT02918604|Device|infrared technology: Veinsite|peripheral vein access performed with Veinsite support by expert paediatric anaesthesiologists and intensivists
1506986|NCT02918578|Other|"Phone group"|"Participants in the phone group receive 12 individually tailored coaching sessions (15 - 20 min). The coaching calls are scheduled biweekly. Participants receive their tailored advice via interactive counseling."
1506987|NCT02918578|Other|"Phone and SMS group"|"The phone and SMS group receive the same coaching as the phone group. They additionally receive two tailored SMS per week over the course of six months."
1506988|NCT02918578|Other|"single writing group"|"The control intervention consists of a minimal credible physical activity PA promotion program. Participants in the control group receive a singular written advice and an activity plan but no counseling by phone."
1506989|NCT02918565|Behavioral|Drinking Cognition Feedback (DCF)|12 weeks of interactive text messaging focused on providing feedback related only to pre-weekend drinking cognitions (plans, desire to get drunk).
1506990|NCT02918565|Behavioral|Alcohol Risk Feedback (ARF)|12 weeks of interactive text messaging focused on providing feedback related only to post-weekend alcohol consumption (max drinks consumed on any occasion over the weekend).
1506991|NCT02918565|Behavioral|Adaptive Goal Support (AGS)|12 weeks of interactive text messaging focused on providing adaptive goal support (based on running average of max drinks consumed).
1506992|NCT02918565|Behavioral|COMBO|12 weeks of interactive text messaging incorporating features of DCF, ARF and AGS.
1506993|NCT02918552|Drug|sodium nitrite|Subjects to receive active study drug three times daily during treatment period and then post treatment testing period.
1506994|NCT02918552|Drug|Control|Subjects randomized to placebo to receive three times daily during treatment period and then post treatment testing period.
1506995|NCT02918539|Drug|florbetapir F 18 PET scan|For those patients who do not have an existing amyloid scan, each will receive an IV injection, 370 MBq (10 mCi), single dose of florbetapir F 18 followed by a Positron Emission Tomography (PET) Scan to determine amyloid status
1506996|NCT02918526|Device|airway management|airway management with Laryngeal Mask or Oro Tracheal Intubation
1506997|NCT02918513|Behavioral|Wellness Element 1 - Exercise|1. Daily wellness element focusing on Exercise; adherence documented online daily
1506998|NCT02918513|Behavioral|Wellness Element 2 - Mindfulness|2. Daily wellness element focusing on Mindfulness Meditation; adherence documented online daily
1506999|NCT02918513|Behavioral|Wellness Element 3 - Sleep Hygiene|3. Daily wellness element focusing on sleep hygiene; adherence documented online daily
1507000|NCT02918513|Behavioral|Wellness Element 4 - Social Connectedness|4. Daily wellness element focusing on Social Connectedness; adherence documented online daily
1507001|NCT02918513|Behavioral|Wellness Element 5 - Nutrition|5. Daily wellness element focusing on Nutrition; adherence documented online daily
1507002|NCT02918513|Behavioral|Wellness Element 6 - Wellness Exercises|6. Daily wellness workbook exercises focusing on improving mental wellness; adherence documented online daily
1507003|NCT02918513|Behavioral|Wellness Element 7 - Motivational Messages|7. Daily motivational emails offering information on one of the 5 wellness elements each day (Exercise, Mindfulness Meditation, Sleep, Social Connectedness, and Nutrition)
1507004|NCT02918500|Drug|Nicoderm Patch|Nicotine replacement therapy patch
1507005|NCT02918487|Drug|Polyherbal|Each capsule contains four herbs: Inula racemosa, Ocimum sanctum, Terminalia Belerica and Piperum longum
1507006|NCT02918487|Drug|Placebo|Inactive compound that is similar looking as the intervention
1507007|NCT02918474|Behavioral|Questionnaires|Participant with early stage breast cancer complete a brief questionnaire before and after her surgeon shows her the clinical tool. The questionnaires will take about 20 minutes to complete.
1507008|NCT02918474|Behavioral|Survey|After completing the clinical tool with 5 patients, each physician will complete a survey to determine whether the tool was useful, how the information was used, how patients reacted to the information provided, what impact the tool had on the patients' decision, and identify any problems in using the tool that can be addressed before it is made available to clinicians on a broader scale.
1507009|NCT02918461|Behavioral|Emerging from the Haze class|A 6-week class designed to combat chemotherapy-induced cognitive dysfunction. Patients will report symptoms at 6 months and 1 year after the end of their Haze class.
1507010|NCT02918448|Other|Training group|The investigation was carried out over a period of 18 weeks, with 12 weeks dedicated to the RT program and 6 weeks allocated for measurements. Anthropometric, one repetition maximum tests (1RM), body composition, blood pressure (BP), dietary intake and blood sample measurements were performed in weeks 1-3, and 16-18. A supervised progressive RT program was performed between weeks 4-15 by the training group.
2002753|NCT01863186|Drug|Open Label Lofexidine HCL|Lofexidine HCl tablets will are available in 0.2 mg tablets. During the optional open-label portion of the study, Lofexidine HCl can be prescribed at the discretion of the Investigator but total daily dose will not exceed 3.2 mg.
1507012|NCT02918422|Other|Nutritional and Dietary Manipulation|Participants will undertake a controlled feeding intervention. All food will be prepared and delivered to participants by research staff. Participants will be asked to exclusively eat what is provided to them in efforts to control any dietary effects.
1507013|NCT02918409|Drug|Colistin|
1507014|NCT02918409|Drug|Tobramycin|
1507015|NCT02918396|Device|Scar-Based Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and 3D-volumes of the atrial anatomy with superimposed dense LGE maps will be generated. Prior to the PVI, a dense voltage map of the left atrium will be performed (>1000 points) iin sinus rhythm. After PVI, low voltage areas (defined as <0.3 mV) which are superimposed on dense LGE on the MRI will be targeted by radio frequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
1507016|NCT02918396|Device|Rotor Anchors Radio-frequency Ablation|Left atrial (LA) myocardium will be manually segmented prior to the procedure and the LA shell, along with the LGE-MRI will be sent to the biomedical engineering team who will generate a 3D-model of the LA along with rotor anchor sites predicted by modeling. After the PVI, the 3D models will be displayed and the rotor anchor sites will be targeted by radiofrequency ablation with a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
1507017|NCT02918396|Device|Conventional PVI by Radio-frequency Ablation|Conventional wide area circumferential ablation (WACA) pulmonary vein isolation will be performed using a contact-force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
1507018|NCT02918383|Diagnostic Test|Indocyanin Green Dye (ICG)|
1507019|NCT02918370|Drug|Aripiprazole|Aripiprazole is an atypical antipsychotic drug that is used to treat mental/mood disorders. It works to restore the balance of neurotransmitters.
1507020|NCT02918370|Drug|Placebo|Inactive ingredient matching the active comparators in appearance.
1507021|NCT02918357|Drug|Ga-68 labeled PSMA-11 PET|Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
1507022|NCT02918344|Other|Hydroset|Calcium phosphate paste is used in mandibular lengthening surgery to avoid an unaesthetic notching at the lower border and to help stabilize the segments when osteosynthesis slippage is feared for.
1507023|NCT02918344|Procedure|Standard sagittal split osteotomy|The sagittal split osteotomy (SSO) is commonly used to correct dentofacial discrepancies.
1507024|NCT02918331|Drug|Daratumumab (16 mg/kg)|Daratumumab (16 mg/kg) will be administered by IV infusion to all participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity or study end.
1507025|NCT02918331|Drug|Lenalidomide|Participants will receive lenalidomide 25 mg orally on Days 1 through 21 of each 28 day cycle. Participants with creatinine clearance (CrCl) between 30 and 60 milliLitre (mL)/minute (min) will receive lenalidomide 10 mg every 24 hours.
1507026|NCT02918331|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg weekly, at day 1, 8, 15, 22 of each cycle.
1507027|NCT02918318|Drug|Placebo|Participant will receive 1 spray of placebo to each nostril at 0 minute, 5 minutes and 10 minutes.
1507028|NCT02918318|Drug|Intranasal esketamine (28 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute and placebo at 5 minutes and 10 minutes.
1507029|NCT02918318|Drug|Intranasal esketamine (56 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and placebo at 10 minutes.
1507030|NCT02918318|Drug|Intranasal esketamine (84 mg)|Participant will receive 1 spray of Esketamine to each nostril at 0 minute, 5 minutes and 10 minutes.
1507031|NCT02918305|Device|PRDS-001 Renal Denervation Ultrasound System|
1507032|NCT02918305|Procedure|Sham Procedure|
1507033|NCT02918292|Drug|Antithymocyte Globulin|Administration of ATG for the UCB arm should be over 8 hours IV daily for 4 days from Day -13 to Day -10. Administration of ATG for the haplo arm will be 0.5 mg/kg IV on Day -9 over 6 hours and 2 mg/kg IV on Days -8 and -7 over 4 hours.
1507034|NCT02918292|Drug|Fludarabine|Fludarabine dose will be 30 mg/m^2 IV daily for 5 days from Day -6 to Day -2 for both arms.
1507035|NCT02918292|Drug|Cyclophosphamide|Cyclophosphamide dose will be 50 mg/kg IV daily for 2 days on Day -3 and Day -2 for the UCB arm. Cyclophosphamide dose will be 14.5 mg/kg IV daily for 2 days (Day -6 to Day -5) prior to transplantation and 50 mg/kg IV daily for 2 days (Day +3 to Day +4) after transplantation for the haplo arm.
1507036|NCT02918292|Radiation|Total Body Irradiation (TBI)|TBI is to be delivered in a single dose of 200 cGy on Day -1 for both arms.
1507037|NCT02918292|Procedure|UCB HSCT|Eligible patients without a fully matched related or unrelated donor available will undergo unrelated umbilical cord blood hematopoietic stem cell transplant.
1507038|NCT02918292|Procedure|Haplo HSCT|Eligible patients without a fully matched related or unrelated donor available will undergo haploidentical bone marrow transplant.
1507039|NCT02918292|Drug|Tacrolimus|Tacrolimus should be started on Day -3 and administered to maintain a level of 10-15 ng/mL for the UCB arm. Tacrolimus should be started on Day +5 and administered to maintain a level of 10-15 ng/mL for the haplo arm.
1507040|NCT02918292|Drug|Mycophenolate mofetil (MMF)|MMF dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day -3 for the UCB arm. MMF dose will be 15 mg/kg PO three times a day (TID) up to 1 gm TID (or IV equivalent) starting on Day +5 for the haplo arm.
1507041|NCT02918292|Drug|G-CSF|G-CSF will be given IV or SQ starting on Day +1 at 5 mcg/kg/day until ANC is > 1500 for 3 days for the UCB arm. G-CSF will be given IV or SQ starting on Day +5 at 5 mcg/kg/day until ANC is > 1500 for 3 days for the haplo arm.
1507044|NCT02918266|Drug|Scopolamine|Scopolamine subcutaneous injection
1507045|NCT02918266|Drug|TAK-071|TAK-071 DIC
1507046|NCT02918266|Drug|Donepezil|Donepezil over-encapsulated tablet
1507047|NCT02918266|Drug|Scopolamine Placebo|Scopolamine placebo-matching subcutaneous injection
1507048|NCT02918266|Drug|TAK-071 Placebo|TAK-071 placebo-matching DIC
1507049|NCT02918266|Drug|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
1507050|NCT02918253|Radiation|targeted focal HDR brachytherapy|
1507051|NCT02918253|Radiation|Whole-gland HDR Brachytherapy|Control/Standard of Care
1507052|NCT02918240|Procedure|Appointment intervals|
1507053|NCT02918240|Device|fixed orthodontic braces|
1507054|NCT02918227|Procedure|Search retrograde ejaculation|Sperm count (spz) after orgasm achieved by masturbation will be measured, corresponding to the sum of spz collected in the ejaculate (E) and the first urine after orgasm (U). These measures will be made before surgery (E1 and U1) and after surgery (E2 and U2). The values E1, E2, U1 and U2 will be achieved by multiplying the concentration of spz per unit volume by the total volume of collection.
1507055|NCT02918201|Drug|Tranexamic Acid|To moisten the innermost wound dressing with diluted tranexamic acid 5 mg/ml.
1507056|NCT02918201|Drug|saline|To moisten the innermost wound dressing with saline (0.9% NaCl)
1507057|NCT02918188|Drug|Hydrogen|Patients will receive hydrogen-rich water orally (500mL three times one day, 0.6mM)
1507058|NCT02918175|Behavioral|mHealth|Personalized step count feedback and medication teaching tool.
1507059|NCT02918162|Drug|Pembrolizumab|Pembrolizumab dosed IV at 200mg every 21 days per cycle.
1507060|NCT02918162|Drug|Standard of care chemotherapy regimen|"Standard regimen containing at least a platinum and Fluorouracil (5-FU) agent (per National Comprehensive Cancer Network guidelines) - such as Doublet or Triplet chemotherapy with capecitabine, oxaliplatin, and epirubicin (optional) (21 day cycle). Epirubicin can be excluded at the discretion of the treating physician.
Example:
Oxaliplatin dosed IV at 130 mg/m2 every 21 days per cycle. Capecitabine dosed orally at 625mg/m2 twice a day daily."
1507061|NCT02918149|Other|Palpation Landmark Technique|"Clinician will follow routine palpation landmark technique procedure for LP, such as identification of anatomic landmarks by palpation (i.e., superior borders of the posterior iliac crest lies in parallel with L4 spinous process). Palpation will be followed by blind stick of the appropriate inter-spinous process space. The study member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
1507062|NCT02918149|Device|Ultrasound-Assisted Technique LP|"Clinician will use an ultrasound-assisted technique to perform the LP. The Phillips CX50 ultrasound machine is an FDA approved device and will be used in accordance with its approved labeling. Spinal ultrasound will be performed using a linear high-frequency transducer to locate and mark the termination of the conus medullaris, the narrowing of the spinal canal, and the midline to delineate a safe zone. The study team member will have 2 attempts to complete the LP. A successful attempt is obtaining cerebrospinal fluid."
1507063|NCT02918136|Device|Adipose-derived stem cell injection|
1507064|NCT02918136|Drug|cortisone injection|
1507065|NCT02918123|Biological|FURESTEM-CD Inj.|Patients will be treated FURESTEM-CD Inj. Subcutaneous injection
1507066|NCT02918110|Drug|Misoprostol|Women needed to be induced will get orally administrated solution of misoprostol (Cytotec®) or vaginal slow release misoprostol (Misodel®)
1507067|NCT02918097|Drug|Lithium Carbonate|
1507068|NCT02918097|Drug|Sertraline|
1507069|NCT02918097|Drug|Nortriptyline|
1507070|NCT02918097|Drug|Risperidone|
1507071|NCT02918084|Drug|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy → Anastrozole or Letrozole or Exemestane once a day for 5 years (sequential arm)
1507072|NCT02918084|Drug|Anastrozole or Letrozole or Exemestane|Adjuvant chemotherapy + Anastrozole or Letrozole or Exemestane once a day for 5 years (concurrent arm)
1507074|NCT02918058|Device|MedStopper|MedStopper is an electronic tool for the treating team (physician and pharmacists) to facilitate medication deprescription. MedStopper can identify potentially inappropriate medication use and the risk of adverse drug events.
1507075|NCT02918045|Device|HemCon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
1507076|NCT02918045|Device|Oxidized Cellulose Gauze|A common hemostatic measure after dental extractions placed into the extraction socket.
2002761|NCT01854359|Drug|Idebenone|
1507079|NCT02918006|Biological|VXA-A1.1|Enteric coated oral vaccine tablet
1507080|NCT02918006|Biological|Fluzone®|Fluzone Quadravalent (Fluzone®) influenza vaccine (QIV) suspension for intramuscular (IM) injection
1507081|NCT02918006|Other|Placebo Tablets|Placebo tablets similar in size, color and number to the active oral tablet vaccine drug product
1507082|NCT02918006|Other|Saline Solution for Placebo IM Injection|
1507083|NCT02917993|Drug|INCB039110|In Phase 1, INCB039110 at a protocol-defined starting dose, with subsequent dose escalation based on protocol-specific criteria. In Phase 2, INCB039110 at the recommended dose from Phase 1.
1507084|NCT02917993|Drug|Osimertinib|Osimertinib 80 mg once daily (QD)
1507085|NCT02917967|Drug|Botulinum toxin injection|"BoNT-A will be injected into two hamstring and/or gastrocnemius muscles under the guidance of ultrasonography or electrical stimulation.
Maximal total dose and dose regimen for each muscle would follow the recommendation of international consensus.
A. Semitendinosus 5 to 7.5 units/kg of body weight B. Semimembranosus 5 to 7.5 units/kg of body weight C. Gastrocnemius 10 units/kg of body weight D. Maximal total dose per patient : unilateral injection 500 units, bilateral injection 1,000 units E. The dosage of two hamstring muscles will depend on the severity of spasticity and gait abnormalities of children with CP"
1507086|NCT02917954|Device|ePRO Tool Intervention|The ePRO tool includes two features: 1) My Goal Tracker and 2) Health Journal. My Goal Tracker allows patients and providers to collaboratively create goal-oriented patient care-plans, and helps patients to track outcomes related to their goals using a mobile device. The Health Journal allows patients, their caregivers and primary care providers to monitor patients' symptoms and outcomes.
1507088|NCT02917928|Dietary Supplement|carnosine|Each participant will be given a daily oral dose 2 g of carnosine (4 tablets of 500mg each) for 14 weeks
1507089|NCT02917928|Drug|Placebo|Each participant will be given a daily oral dose 2 g of placebo (4 tablets of 500mg each) for 14 weeks
1507090|NCT02917915|Other|Canadian Standardized PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the New Canadian Standardized PR educational approach (experimental).
1507091|NCT02917915|Other|Traditional PR|Patients attend pulmonary rehabilitation (PR) 3 days per week for 6 weeks or 2 days per week for 8 weeks. Patients receive 2 hours of exercise training (aerobic and resistance) and 1 hour of education designed to promote self-management. In this intervention patients will receive the Traditional PR education approach (active comparator).
1507093|NCT02917889|Drug|Caffeine|Volunteers will consume 300 mg of caffeine in pills fifteen minutes before treadmill aerobic exercise.
1507094|NCT02917889|Drug|Placebo|Volunteers will consume 300 mg of placebo in pills fifteen minutes before treadmill aerobic exercise.
1507095|NCT02917889|Other|Cardiopulmonary test|assessment of the maximum oxygen consumption (VO2max) on a treadmill (Inbrasport / Millennium), using Buce protocol.
1507096|NCT02917889|Other|Treadmill aerobic exercise|30 mim of aerobic exercise (5 minutes at speed of 5.0 km/h for warming-up followed by 25 minutes at 60% of VO2max ).
1507097|NCT02917863|Drug|L-Thyroxine (tablet, per os)|
1507098|NCT02917863|Drug|L-Thyroxine (oral drops, solution)|
1507099|NCT02917850|Procedure|Isokinetic hip flexors strengthening|Isokinetic excentric strengthening of paretic hip flexors, 3/w during 6 weeks, in addition to conventional rehabilitation 7/w.
1507100|NCT02917850|Procedure|Conventional rehabilitation|Conventional rehabilitation 10/w during 6 weeks
1507101|NCT02917837|Other|Diagnostic imaging utilization for a prior six-month period|
1507102|NCT02917824|Other|Inspiratory muscle training|
1507104|NCT02917785|Device|Karman curettage|
1507105|NCT02917772|Biological|Nivolumab/Ipilimumab|"Induction: Mono-Therapy with Nivolumab (240 mg i.V. / Q2W x 8)
If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)
If SD/PD: Nivolumab/Ipilimumab Boost 1+2-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)
If CR/PR: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)
If SD/PD: Nivolumab/Ipilimumab Boost 3+4-Combination Therapy (Nivo 3 mg/kg i.V. and Ipi 1 mg/kg i.V. / Q3W x 2)
If CR/PR/SD: Nivolumab Maintenance Mono-Therapy (240 mg i.V. / Q2W)"
1507106|NCT02917746|Drug|Imiquimod|Patients in this group are treated with vaginal imiquimod cream during 16 weeks. A control colposcopy with diagnostic biopsies will be performed after 10 weeks to rule out disease progression. A final colposcopy with diagnostic biopsies will be performed after 20 weeks to evaluate disease efficacy.
1507107|NCT02917746|Procedure|Large Loop Excision of the Transformation Zone|Patients in this group are treated with LLETZ.
1507108|NCT02917733|Drug|LY3039478|Administered orally
1507109|NCT02917720|Other|TKI discontinuation|2nd TKI stop after pre-treatment with nilotinib.
1507110|NCT02917720|Drug|nilotinib|Pre-treatment with nilotinib 300 mg/bid for 2 years
1507111|NCT02917707|Other|normal colorectal tissues|The investigators will extract total protein, DNA and RNA from these groups.
1507112|NCT02917681|Other|Two intrathecal MSC injections|
1507113|NCT02917668|Other|FreeO2|Oxygen delivery automatically titrated by a closed-loop system that adjusts the oxygen flow based on the patient's real-time SpO2 and a programed SpO2 target of 90 %
1507114|NCT02917668|Other|Usual care|Oxygen delivery manually titrated by the nursing staff for a SpO2 target of > 95 %
1507115|NCT02917655|Behavioral|Womac|Answer WOMAC at baseline, 6, 12 and 24 months.
1507116|NCT02917655|Behavioral|Lequesne|Answer Lequesne at baseline, 6, 12 and 24 months.
1507117|NCT02917655|Behavioral|VAS|Answer VAS at baseline, 6, 12 and 24 months.
1507118|NCT02917655|Behavioral|IPAQ|Answer IPAQ at baseline, 6, 12 and 24 months.
1507119|NCT02917655|Behavioral|FTSST|Perform the FTSST at baseline, 6, 12 and 24 months.
1507120|NCT02917655|Behavioral|TUG|Perform the TUG at baseline, 6, 12 and 24 months.
1507121|NCT02917655|Behavioral|Six-minute Test|Perform the six-minute test at baseline, 6, 12 and 24 months.
1507122|NCT02917655|Behavioral|Two days of lectures|Participate in two days of classes about KOA, with the seven teams (orthopedics, psychology, physical therapy and fitness, occupational therapy, social workers and nutritionist).
1507123|NCT02917655|Behavioral|Session with the psychologists|Participate in a extra session group with the psychology team about their experiences with the program
1507124|NCT02917655|Behavioral|Sessions with the physical therapy team|Participate in a extra session group with the physical therapists
1507125|NCT02917655|Behavioral|Sessions with the physical educators team|Participate in a extra session group with the physical educators
1507126|NCT02917655|Behavioral|Nutritional habits to be improved|Attend 3 extra meetings about nutrition.
1507127|NCT02917655|Behavioral|Tampa Scale for Kinesiophobia (TSK)|Answer Tampa Scale for Kinesiophobia (TSK) at baseline, 6 months, 12 and 24 months.
1507128|NCT02917642|Device|Ultrasonic Irrigation|Passive Ultrasonic Irrigation is based on the transmission of acoustic energy through the irrigant by a stainless steel wire or endodontic file
1507129|NCT02917642|Device|Non-Ultrasonic Irrigation|Syringe and needle irrigation with no-ultrasonic activation
1507130|NCT02917629|Other|Laboratory Biomarker Analysis|Correlative studies
1507131|NCT02917629|Drug|Metformide Hydrochloride/Pioglitazone Hydrochloride Extended-Release Tablet|Given PO
1507132|NCT02917629|Other|Pharmacological Study|Correlative studies
1507133|NCT02917629|Other|Placebo|Given PO
1507134|NCT02917616|Other|Alkaline drinking-water|
1507135|NCT02917616|Other|Neutral drinking-water|
1507136|NCT02917603|Behavioral|Web Conferencing|Individuals will communicate with the nursing home team via web conferencing during quarterly care conference
1507137|NCT02917590|Other|Dual-task obstacle crossing training|Obstacle crossing simultaneously a color word stroop task training
1507138|NCT02917590|Other|Single-task obstacle crossing training|Obstacle crossing training
1507139|NCT02917577|Biological|Avaxim Pediatric®|2 doses (0.5 mL each) 6 months apart of Avaxim Pediatric® vaccine.
1507140|NCT02917577|Biological|Avaxim ® (adult)|2 doses (0.5 mL each) 6 months apart of Avaxim ® (adult) vaccine.
1507141|NCT02917564|Drug|Triamcinolone Acetonide 1 ml of 40 mg/mL suspension|After preparation, Triamcinolone Acetonide 1 ml of 40 mg/mL suspension is injected through the superotemporal conjunctival fornix using a 25 Gauge needle, 5/8 inch length on a 3 ml syringe, following the contour of the globe with the needle, external to sclera for the full length of the needle such that the needle tip is ultimately positioned immediately posterior to the macula with the bevel down.
1507142|NCT02917564|Drug|Prednisolone acetate 1%|Patients will be treated with topical prednisolone acetate 1% qid for as long as necessary until the choroidals have resolved
1507143|NCT02917551|Other|7 days of adequate antibiotic treatment|
1507144|NCT02917551|Other|14 days of adequate antibiotic treatment|
1507145|NCT02917538|Procedure|RFA|Both groups will receive radiofrequency ablation treatment
1507146|NCT02917525|Dietary Supplement|Vitamin K2|
1507147|NCT02917525|Other|Placebo|
1507148|NCT02917512|Drug|HU00701|Cyclosporine 0.01% + 3% trehalose
1507149|NCT02917512|Drug|HU007|Cyclosporine 0.02% + 3% trehalose
1507150|NCT02917512|Drug|Restasis|Cyclosporine 0.05%
1507151|NCT02917512|Drug|Placebo|Vehicle
1507153|NCT02917486|Other|blood sample|
1507154|NCT02917473|Behavioral|In-person counseling|"In-person counseling
Sun protection"
1507155|NCT02917473|Behavioral|Written advice|Written advice
1507156|NCT02917473|Behavioral|Medical skin screening|Medical skin screening
1507157|NCT02917460|Genetic|Genomic sequencing and molecular diagnostic results, if any|Samples will be stored in the pediatric genomic Biorepository. A subset of samples will undergo genetic/genomic analysis.
1507158|NCT02917447|Behavioral|DESTRESS-WV|"This is an online intervention for PTSD tailored for women Veterans. The intervention is based on cognitive behavioral therapy (CBT). The goal of CBT is to help people recognize and address their thoughts and behaviors in positive ways with the aim of improving their ability to function as well as possible in their lives.
Participants will be asked to log on to the website twice per week for about 30-60 minutes each time. On two occasions, participants will be asked to write about current stressors or hassles. Additionally, on two occasions participants will be asked to write about a traumatic experience and then rewrite it. Participants will be guided in using various coping skills taught in the program during this writing process. Homework assignments will include stress management skills that participants will be asked to practice and apply. A study coach will call each participant once a week for 8 weeks for about 15 minutes to review their progress with the prog"
1507159|NCT02917447|Behavioral|Phone Monitoring|A study coach will call participants once a week for 8 weeks for approximately 15 minutes. The coach will assess participants' PTSD symptoms and safety. She will encourage participants to use the time on the call to discuss any current life issues or problems that they would like. Active listening and rephrasing will be used, while teaching cognitive-behavioral strategies will be avoided.
1507160|NCT02917434|Dietary Supplement|Low Energy liquid Diet (LED)|Low Energy liquid Diet (LED), divided into 4 daily doses, gives any intake of 880 calories per day together with the recommended doses of vitamins and minerals. During an initial period of 12 weeks the patients only consume LED. After the strict period food is successively reintroduced during a period of 18 weeks.
1507271|NCT02916628|Behavioral|group counseling|Group counseling with positive psychology and motivational interviewing was undertaken once per week for 6 weeks.
1508441|NCT02907294|Drug|PBF-999 / 320 mg|4 capsule 80 mg x 8 days
1507161|NCT02917421|Radiation|Radiation|(Post-segmental Mastectomy, post-mastectomy and Post-mastectomy with expanders or final reconstruction): Prone whole breast or chest wall 3D-CRT or IMRT at 2.7 Gy X 15 fractions (40.50 Gy) with a concomitant boost of 0.50 Gy (7.5 Gy) to the original tumor bed in post-segmental mastectomy patients or mastectomy scar in post-mastectomy patients. Patients who have undergone reconstruction will not receive concomitant boost.
1507162|NCT02917395|Device|echocardiography|Tow echo examination, few hours apart, that includes strain rate will be done to each patient. The first, after taking the regular medical treatment excluding disopyramide and the last one after taking the disopyramide.
1507163|NCT02917369|Other|Normal lung tissue|The investigators will extract total protein, DNA and RNA from LCLC patients.
1507164|NCT02917356|Other|Spiritual laying on of hands (SP)|"The SP will be applied after physical therapy (kinesiotherapy). Spiritual healers from Spiritism will perform the SP. In order to produce a culturally acceptable environment, the Spiritist therapists will 'prepare' the environment by praying for 5 minutes. The Spiritist therapists will hold both hands 10-15 cm above the patients' head. Then, they will longitudinally lower their hands starting from the patients' head towards their legs, for four times. Subsequently, the therapists shall lay their hands on patients' head and on their knees. The therapists will remain silent during these procedures and try to 'heal' the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
1507165|NCT02917356|Other|Non-spiritual Laying on of Hands|"The non-spiritual laying on of hands will be applied after physical therapy (kinesiotherapy), for 5 minutes, without touching the patients and without 'preparing' the environment. They will hold their hands 10-15 cm above patient's head and will focus on healing the patients. They will visualize the following sentence: I want you to heal; without saying prayers or invocations. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
1507166|NCT02917356|Other|Control group|"The patients will be subjected to physical therapy (kinesiotherapy), only. However, they will be accompanied by people who will stay in the room and move slowly and randomly in order to sham the presence of someone performing the laying on of hands. However, they will not perform the laying on of hands. These people will not focus on healing the patients and they will be asked to mentally count 5 minutes while they are with the patients. The subjects will remain in a seated position, blindfolded with dark-blinded goggles, and will receive the following verbal command: Relax and calm your mind."
1507167|NCT02917343|Behavioral|mirror therapy and repetitive task training|
1507168|NCT02917330|Other|Stretching and progressive strength training|Intervention implemented by local physiotherapist.16 weeks, three treatment sessions each week. Minimum pause between two treatment sessions is one day. Week 1 and 2: To assure the correct dosage in each exercise and a satisfactory education of the session done at home, all three sessions will be implemented with the physiotherapist the first two weeks. From week 3: Two treatment/training sessions with the physiotherapist and one shorter training session at home.
1507169|NCT02917304|Biological|GC3110A vaccine|0.5mL, Intramuscular
1507170|NCT02917291|Drug|FAB117-HC|(Ph 1) Intramedullary administration. Open label dose escalation, 3 patients in cohort 1 (20 million cells) and 3 patients in cohort 2 (40 million cells)
1507171|NCT02917291|Other|Control group|(Ph 2) No treatment will be administered
1507172|NCT02917291|Drug|FAB117-HC|(Ph 2) Intramedullary administration of the maximum tolerated dose (20 or 40 million cells)
1507173|NCT02917278|Dietary Supplement|Meals|High Protein renal-specific meals
1507174|NCT02915471|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 45 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 1.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
1507175|NCT02915445|Biological|CAR-T cells recognizing EpCAM|Patients included will be infused the autologous T cells armed with CAR recognizing EpCAM. After infusion, cytokines and other medical test will be performed.
1507178|NCT02915419|Biological|PRP|platelet rich plasma
1507179|NCT02915419|Biological|PRF|PLATELET RICH FIBRIN
1507180|NCT02917252|Other|3-hydroxybuturate|Drink of ketone bodies
1507181|NCT02917252|Other|Placebo|Drink of saline
1507182|NCT02917226|Other|Clinical decision support and monitoring system|
1507183|NCT02917213|Other|Doppler echocardiogram exam|A complete echocardiographic study will be performed in the first 24 hours, and after a week and 6 months after enrollment. The echocardiographic images will be acquired as clinically recommended. The protocol will include the acquisition of 1) 2D images in parasternal axis long and short axis; 2) 2D and Doppler tissue images in the apical planes of 4, 2 and 3 chambers; 3) Pulsed, continuous and color Doppler M (DCMM) of transmitral LV flow and LV ejection; 4) 3-Chamber apical plane with and without color Doppler; and 5) 3D LV images. DCMM images will be obtained from the apical window using 4 and 5 chamber planes. Blood flow velocity will be obtained using Color and Gray mode in the 3 chamber view during 5-10 beats in apnea.
1507272|NCT02916628|Device|Auricular acupressure|Auricular acupressure using acupellets was performed for 6 weeks continuously
1507184|NCT02917213|Other|Carotid duplex ultrasound exam|A B-mode and Doppler ultrasound study will be performed using a linear probe 9L (9 MHz) for the evaluation of the common carotid artery bulb, the carotid bifurcation and the internal carotid during 24 h after enrollment. Intima-media thickness will be measured. Turbulent flow velocities in the area of stenosis will be measured by Doppler. The criteria used to grade the severity of carotid atherosclerotic disease will follow the Consensus Conference of the Society of Radiologist in Ultrasound 2003.
1507185|NCT02917213|Other|Cardiac MRI|"A cardiac MR will be acquired a week and 6 months after enrollment. The protocol includes the following sequences: cine mode of short axes from LV base to apex, 2-3-4 chambers and STIR +T2 sequence. Perfusion during the administration of a bolus of 0.05 mmol / kg Gadovist®. 3D sequence of late enhancement of inversion-recovery. Images will be acquired after 10 min of the administration of a total of 0.2 mmol / g of Gadovist®. Intraventricular thrombosis will be monitored. Phase contrast sequences in three orthogonal planes will be acquired. Morphological parameters of LV function (LVEF), contractility (Wall Motion Score ), sphericity index, infarct size, area at risk, edema, microvascular obstruction and first-pass perfusion will be obtained."
1507186|NCT02917213|Other|Brain MRI|A brain MR will be acquired a week and 6 months after enrollment. Axial, sagittal and coronal spin echo sequence in T1, axial images in diffusion sequences (DWI), enhanced spin echo T2 and FLAIR (fluid-attenuated inversion recovery) sequences shall be obtained. A cerebral infarction will be positive when finding the presence of a focal lesion of> 3 mm in diameter that meets one of these three characteristics: (1) high signal on isotropic DWI images and low signal on the apparent coefficient map Broadcast (ADC). (2) Cavitary lesion hyperintense on T2, with no signal (or low) in the FLAIR sequence. (3) Hyperintense lesion T2 / T1 hypointense with prior distribution defect known or new in a follow-up study.
1507187|NCT02917213|Procedure|Reveal LINQ insertable cardiac monitoring system|A Reveal LINQ insertable cardiac monitoring system will be implanted following 1:1 patient unblinded randomization (device:no device). The device will be interrogated at a week after implantation and at 6 months, or if symptoms (palpitations or syncope) have activated the device memory.
1507188|NCT02917213|Other|Coagulation blood test|5 ml of peripheral blood will be obtained for assessment of prothrombotic markers at enrollment, at one week and 6 months after enrollment.
1507189|NCT02917213|Other|Transcranial Doppler monitoring|A Transcranial Doppler monitoring will be performed in the first 24 hours after enrollment in order to detect High Intensity Transient Signals (HITs).
1507190|NCT02917200|Drug|Moxifloxacin|Oral route
1507191|NCT02917200|Device|DAV132|Oral route
1507192|NCT02917200|Other|Negative control|Oral route
2002762|NCT01852370|Biological|CD3/CD19 negative allogeneic hematopoietic stem cells|Negative selection for CD3/CD19 will be performed on a CliniMACS® depletion device within 36 hours of collection and given at time no less than 8 weeks post lung transplant.
1507195|NCT02917174|Behavioral|Mobile Asthma Management System|Patients in this group use a smartphone app in their asthma self-management.
1507196|NCT02917174|Behavioral|traditional Asthma Management System|Patients in this group use a printed asthma diary in their asthma self-management.
1507197|NCT02917161|Device|Prostatic Artery Embolization (PAE)|PAE is performed 6 weeks before radical prostatectomy
1507199|NCT02917135|Device|Angel® Catheter|"The Angel® Catheter is a retrievable inferior vena cava (IVC) filter attached to a multi-lumen central venous access (CVC) catheter. The device is designed to be placed at the bedside in the inferior vena cava, via the femoral vein, for the prevention of pulmonary embolism (PE) and for access to the central venous system.
The Angel® Catheter is intended for short-term (less than 30 days) vascular access via the femoral vein."
1507200|NCT02917122|Device|active tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
1507201|NCT02917122|Drug|Sertraline|Patients will take Sertraline.
1507202|NCT02917122|Device|sham tDCS|Patients will take 12 tDCS sessions (30min for each session): first 10 consecutive sessions for two weeks (Monday to Friday), and then 2 follow-up sessions scheduled 2 and 4 weeks after the consecutive treatment.
1507203|NCT02917109|Behavioral|LearningRx cognitive training|A clinician will deliver three 90-minute cognitive training sessions per week for 14 weeks. There are 16 different categories of leveled training procedures sequenced in intensity and difficulty for a total of 530 training tasks.
1507204|NCT02917096|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
1507205|NCT02917096|Drug|Fludarabine Phosphate|Given IV
1507206|NCT02917096|Other|Laboratory Biomarker Analysis|Correlative studies
1507207|NCT02917096|Drug|Melphalan|Given IV
1507208|NCT02917096|Other|Pharmacological Study|Correlative studies
1507209|NCT02917096|Drug|Ruxolitinib Phosphate|Given PO
1507210|NCT02917096|Drug|Sirolimus|Given PO
1507211|NCT02917096|Drug|Tacrolimus|Given IV and PO
1507212|NCT02917083|Genetic|CAR T Cells|"Three dose levels will be evaluated based on safety data from our current study of CD30 CAR T cells. Cohorts of three patients will be enrolled at each dose level. Each patient will receive one infusion of CAR modified T cells according to the following dosing schedule:
Dose Level One: 2x10^7 cells/m2. Dose Level Two: 1x10^8 cells/m2. Dose Level Three: 2x10^8 cells/m2."
1507213|NCT02917083|Drug|Cyclophosphamide|Patients who are not post autologous transplant will receive three daily doses of cyclophosphamide (Cy: 500mg/m2/day) finishing at least 48 hours before T cell infusion, but no later than 2 weeks prior to infusion of the cells.
1507214|NCT02917083|Drug|Fludarabine|Patients who are not post autologous transplant will receive fludarabine (Flu: 30mg/m2/day), finishing at least 48 hours before T cell infusion, but no later than 2 weeks prior to infusion of the cells.
1507215|NCT02917070|Other|Patients|In this study we aimed to investigate effect of family history and consanguineous marriage in the development of CKD in the adult Turkish population.
1507216|NCT02917057|Drug|exenatide once weekly|Exenatide treatment in customary clinical care in the USA
1507217|NCT02917057|Drug|basal insulin|basal insulin tretament in the customary clinical care in USA
1507218|NCT02917044|Procedure|Atrial Fibrillation Ablation|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by assessing electrograms circumferentially around the PV using the Orion catheter.
1511091|NCT02885753|Drug|Folinic Acid|400 mg/m² in intravenous
1507219|NCT02917044|Device|Catheters used to isolate pulmonary veins|Catheters transiently inserted into body via femoral veins in order to produce pulmonary vein isolation. These catheters are the same in each arm and comprise the Orion catheter (Boston Scientific) and the Tacticath (St Jude) which are used to produce pulmonary vein isolation and which are approved for use in standard EP procedures by the relevant authorities (CE marked). It is merely the protocol by which they are used that iffers in the two arms.
1507220|NCT02917044|Procedure|Atrial Fibrillation Ablation with HD mapping to isolate PVs|Procedure involving catheter ablation to produce pulmonary vein isolation. Pulmonary veins are isolated by use of electroanatomical mapping with the Orion catheter around the sites ablation in order to target points of breakthrough.
1507221|NCT02917044|Device|Rhythmia HD mapping|Mapping activation patterns using the Rhythmia system in conjunction with the Orion catheter
1507222|NCT02917031|Drug|Saxagliptin|5 mg or 2.5 mg, plain, yellow, biconvex, round, film-coated tablet
1507223|NCT02917031|Drug|Sitagliptin|50 mg or 100 mg, gray capsule
1507224|NCT02917031|Drug|Placebo to match saxagliptin|2.5 mg or 5 mg, plain, yellow, biconvex, round, film-coated tablet
1507225|NCT02917031|Drug|Placebo to match sitagliptin|50 mg or 100 mg, gray capsule
1507226|NCT02917018|Drug|Dexmedetomidine|Group I will receive 1 ug/kg, group II will receive 0.75 ug/kg and group III will receive 0.5 ug/kg) diluted to 50 ml NaCl 0.9% by syringe pump over 20 minutes before end of surgery.
1507227|NCT02917005|Drug|Palbociclib|CDK 4/6 inhibitor
1507228|NCT02917005|Drug|Exemestane|Aromatase inhibitor
1507229|NCT02917005|Drug|Goserelin|LHRH agonist
1507230|NCT02916992|Radiation|CT scan of the thorax|A low dose CT scan of the thorax (2mSv) wil be performed once.
1507231|NCT02916992|Genetic|blood sample for FLCN mutation analyses|A venous punction in order to withdraw 16ml blood is undertaken once.
1507232|NCT02916979|Drug|Fludarabine|Fludarabine: 30 mg/m2 daily for 5 days
1507233|NCT02916979|Drug|Busulfan|Busulfan: 100 mg/m2 daily for 4 days
1507234|NCT02916979|Biological|Rabbit ATG|"Rabbit ATG:
Related donors: 1.5 mg/kg daily x 2 days (on days -6 and -5) Unrelated donors: 1.5 mg/kg on day - 6 2 mg/kg on day -5 2.5 mg/kg on day -4"
1507235|NCT02916979|Drug|Methotrexate|"Methotrexate:
Related donors: 5 mg/m2 on days 1, 3 and 6 Unrelated donors: 5 mg/m2 on days 1, 3, 6 and 11"
1507236|NCT02916966|Other|Patient Registry|Patient Registry
1507237|NCT02916940|Drug|Diprophos|Single subcutaneous injection of Diprophos, in the acute phase.
1507238|NCT02916927|Drug|Ketamine IV Infusion|Ketamine 0.3 mg/kg in 100mL normal saline minibag administered over 15 min and placebo 10 mL normal saline syringe administered over 1 minute.
1507239|NCT02916927|Drug|Ketamine IV push|Ketamine 0.3 mg/kg in 10 mL normal saline syringe administered over 1 minute and placebo 100mL normal saline minibag administered over 15 min.
1507240|NCT02916914|Other|Q2 feeding|Infants are going to be fed every 2 hours
1507241|NCT02916901|Drug|CKD-519 200mg|
1507242|NCT02916901|Drug|Placebo|
1507243|NCT02916888|Other|Care provided by general pediatrician|Standard of care management of atopic dermatitis by a general pediatrician.
1507244|NCT02916888|Other|Care provided by pediatric dermatologist|Standard of care management of atopic dermatitis by a pediatric dermatologist.
1507245|NCT02916862|Dietary Supplement|Soluble Corn Fiber (SCF) without Calcium|Participants will consume a supplement with 12 g/day of SCF for 12 months
1507246|NCT02916862|Dietary Supplement|Soluble Corn Fiber (SCF) + Calcium|Participants will consume a supplement with 12 g/day of SCF + calcium carbonate (600 mg/day) for 12 months
1507247|NCT02916862|Dietary Supplement|Placebo|Participants will consume a supplement without SCF or calcium carbonate for 12 months
1507248|NCT02916849|Other|Safe Step|Strength and balance exercise-digital version
1507249|NCT02916849|Other|OEP|Strength and balance exercise -paper version
1507250|NCT02916836|Other|therapeutic drug conciliation sheet (TDC)|Use of therapeutic drug conciliation sheet (TDC)
1507251|NCT02916836|Other|No Use of therapeutic drug conciliation sheet (TDC)|
1507252|NCT02916810|Device|Active rTMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
1507253|NCT02916810|Device|Sham rTMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
1507254|NCT02916797|Other|Stepping training with feedback|Stepping training with the use of external feedback. The subjects will be instructed to shift/take their body-weight onto the affected leg until the green zone of the displayed section is lighting and a beep sound to alarm the subjects to step the non-affected leg forward and backward as much as they can.
2002763|NCT01841866|Other|LMA removal|
2002764|NCT01840241|Drug|sodium bicarbonate|BIVON group were received 0.5 mmol/kg of sodium bicarbonate for 1hours after induction of anesthesia and following 0.15 mmol/kg of sodium bicarbonate during the operation.
1507258|NCT02916758|Other|Let's Go Community Mobility Program|Four week multi-modal education and experiential program to improve community mobilty
1507261|NCT02916719|Device|MRI|MRI examination after the neo-adjuvant radiotherapy, but before the surgical treatment
1507262|NCT02916706|Drug|Teneligliptin 20mg|
1507263|NCT02916706|Drug|Placebo|
1507264|NCT02916693|Drug|Mirabegron|FDA-approved, beta 3 agonist for over active bladder
1507265|NCT02916680|Procedure|Pancreatic islet transplantation in the anterior chamber|Transplantation of allogeneic pancreatic islet cells into the anterior chamber of a severely visual impaired diabetic human eye
1507266|NCT02916667|Other|dietary guidelines|dietary guidelines will include chrono- nutrition diet plan
1507267|NCT02916654|Dietary Supplement|sucrosomial iron|administration of sucrosomial iron
1507268|NCT02916654|Drug|Sulphate iron|administration of sulphate iron
1507269|NCT02916641|Drug|Fuzhenghuayu|
1507270|NCT02916641|Drug|UDCA|
1507273|NCT02916628|Device|placebo acupressure|Placebo acupellets were prepared without metal projections, and placed on both sides in the same areas of the ear as the active condition.
1507274|NCT02916615|Other|High nitrate vegetables|vegetables naturally high in nitrate
1507275|NCT02916615|Dietary Supplement|Low nitrate vegetables + nitrate|pill containing KNO3
1507276|NCT02916615|Other|Low nitrate vegetables|vegetables naturally low in nitrate
1507277|NCT02916602|Drug|HCP1401|amlodipine, Losartan, Chlorthalidone FDC
1507278|NCT02916602|Drug|HCP0605|amlodipine, Losartan FDC
1507279|NCT02916589|Dietary Supplement|Diet|
1507280|NCT02916576|Device|Blood-Glucose Monitoring Systems for self-testing|"This is a user performance study, that is intended to show whether people with diabetes are able to obtain accurate measurement results with a blood glucose monitoring system (BGMS).
The subjects' measurement technique (e.g. applying blood onto the system reagent, reading the result) will be observed and documented by study personnel.
Immediately after the measurement by the subject, the study personnel will perform a measurement with the same test meter.
Measurement results obtained by the subjects with the BGMS will be compared to measurement results obtained with the comparison method.
Sample collection for the comparison measurement will be performed by study personnel within 5 min after the subject's measurement with the test meter.
The samples will be collected from the subjects' skin puncture (if possible), an additional skin puncture (if required) will be documented.
An additional skin puncture will be performed by study personnel with single-use lancing devices."
1507281|NCT02915406|Device|CliniMACs|
1507282|NCT02915380|Biological|Evaluation of pituitary endocrine function|"The basal thyroid hormone and test to perform will be: TSH, fT4, fT3.
When available, the following hormones will be tested:
FSH, LH, estradiol (in women), testosterone (in men), sex hormone-binding globulin (SHBG), ACTH, cortisol, prolactin, Na, K; serum levels of GH and IGF-1; and serum and urine osmolality.
Adrenal function will be evaluated through ACTH-stimulation testing . Adrenal or GH insufficiency will be evaluated by insulin tolerance testing (ITT)"
1507283|NCT02915380|Behavioral|Evaluation of clinical outcome|Patients' outcome will be assessed as modified Rankin Scale (mRS) at discharge from the hospital, at 3, 6 and 12 months.
1507284|NCT02915380|Behavioral|Evaluation of neuropsychological function|Neuropsychological examination will be conducted focusing on verbal comprehension (Token Test) and visual neglect. Verbal and visual short term and working memory visuospatial construction and figural memory will be performed through Rey Osterrieth Complex figure test, and psychomotor speed attention and concentration through Trail Making Test.
1507285|NCT02915367|Behavioral|SMS Reminders|Participants will receive daily reminders, with content and timing of their choosing, regarding their PrEP use. Participants will have the choice to later receive SMS reminders only when they forget to take their dose (as indicated by real-time adherence monitoring via WisePill).
1507286|NCT02915354|Drug|Etanercept|Etanercept must be discontinued. Cotherapy with disease modifying anti-rheumatic drugs or non-steroidal anti-inflammatory drugs could be continued if maintained at a stable dose for at least 4 weeks.
2002765|NCT01840241|Drug|normal saline|
1507288|NCT02916537|Drug|CTT1057|Single IV dose (370 MBq, or 10 mCi) of CTT1057 followed by combined PET/MR imaging (prostate + whole body).
1507289|NCT02916537|Procedure|Prostatectomy|Radical prostatectomy with lymph node dissection
1507290|NCT02916524|Behavioral|Semantic Feature Analysis (SFA)|SFA training entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, action associated with item). Treatment is applied to a set of items in the context of single-subject, multiple baseline designs so that replication of treatment effects could be evaluated within and across participants. Treatment will be administered two times per week until prescribed accuracy levels were met during treatment probes or a maximum number of treatment sessions was completed.
1507291|NCT02916511|Drug|Paclitaxel|paclitaxel 50mg/m2/d, ivgtt over 3 hours, d1, qw*5
1507292|NCT02916511|Drug|Carboplatin|carboplatin AUC=2, ivgtt, d1, qw*5
1507293|NCT02916511|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 25Fx
1507294|NCT02916498|Device|Boston Scientific's Precision SPECTRA™ Spinal Cord Stimulation System|Spinal cord stimulation for the management of chronic neuropathic pain
1507295|NCT02916485|Device|Bioresorbable scaffold|Percutaneous coronary intervention (PCI)
1507296|NCT02916472|Behavioral|CyberCycling|All exercise training will be performed under the supervision of a qualified exercise trainer certified in Advanced Cardiac Life Support. Patients in the exercise groups will be asked to perform aerobic exercise on a stationary bike ('cybercycle') 3 days per week for 12 weeks. Exercise intensity and duration will be based on a progressive program and adapted, as needed, based on the patient's tolerability. Heart rate will be monitored throughout the exercise session and Rating of Perceived Exertion (RPE) monitored at least every 10 minutes. The target heart rate (THR) zone will be determined using the Karvonen formula.
1507297|NCT02916472|Behavioral|Stretching|Patients randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Patients will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Patients will be instructed to start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all patients in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the patient by the exercise physiologist before the 12 week program begins.
1507336|NCT02916134|Procedure|Laparoscopic +/- Open Appendicectomy|Laparoscopic +/- open appendicectomy , with antibiotics at induction (intravenous co-amoxiclav 1.2g, or if penicillin allergic, cefuroxime 1.5g + metronidazole 500mg ), followed by 3 further intravenous doses of the same antibiotic. If a perforation is identified at the time of surgery, microbiology will be contacted regarding choice and duration of of antibiotic.
1508442|NCT02907294|Drug|Placebo|2 capsules of placebo x 8 days 4 capsules of placebo x 8 days
2002766|NCT01839669|Device|Foot Orthoses Only|patients wear foot orthoses as a treatment condition - no further therapy
1507298|NCT02916472|Behavioral|Resistance Bands|Patients randomized to the control condition will receive a progressive resistance training program with TheraBands™ and a stretching program to complete at home 2 days/week for 12 weeks. The resistance band program will include upper body and lower body exercises. Patients will be provided with two different colored resistance bands (one lighter colored for easier resistance; one darker colored for a harder resistance). Patients will be instructed to start by completing 1-2 sets, 2 days/week with the easier/lighter band for the first 4 weeks, progress to 2-3 sets, 2 days/week with the easier band for the next 4 weeks; and, then, progress to 1-2 sets with the darker/harder band for the last 4 weeks. In addition, all patients in the 'control' condition will be advised to conduct upper body and lower body stretches 2 days/week. All resistance band exercises and stretches will be demonstrated to the patient by the exercise physiologist before the 12 week program begins.
1507299|NCT02916459|Device|21G EBUS-TBNA needle|
1507300|NCT02916459|Device|Flexible 19G EBUS-TBNA needle|
1507301|NCT02916446|Biological|Viaskin Peanut 250 mcg|
1507302|NCT02916446|Biological|Placebo|
1507303|NCT02916433|Drug|Octreotide|
1507304|NCT02916420|Drug|Pomalidomide|4mg/day, d1-d21, 28 days per cycle
1507305|NCT02916420|Drug|Dexamethasone|≤70 years,40mg/day; >70 years,20mg/day, d1、d8、d15、d22, 28 days per cycle
1507306|NCT02916407|Drug|Sevoflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.
General anesthesia will maintained with sevoflurane 2-3 vol%."
1507307|NCT02916407|Drug|Desflurane|"Intravenous ketamine will administrate to the patients for decreasing of separation anxiety of children.
General anesthesia will maintained with desflurane 6-7vol%."
1507308|NCT02916394|Radiation|68Ga-NODAGA-ZIGF-1R:4：40|No Intervention
1507309|NCT02916381|Procedure|PEC block + General anaesthesia|Patients will receive an ultrasound-guided PEC block after the induction of general anaesthesia.
1507310|NCT02916381|Procedure|General anaesthesia|
1507311|NCT02916355|Drug|Anakinra|Subjects will receive Anakinra infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
1507312|NCT02916355|Drug|NaCl|subjects will receive NaCl infusion and afterwards they will be fed a very fat containing meal, and postprandial fatigue will be measured regularly until 3,5 hour after the meal.
1507313|NCT02916342|Procedure|Interscalene brachial plexus block|Patients will receive an ultrasound-guided interscalene brachial plexus block before general anaesthesia.
1507314|NCT02916342|Procedure|Supraclavicular-axillary nerve blocks|Patients will receive ultrasound-guided supraclavicular and axillary nerve blocks before general anaesthesia.
1507315|NCT02916329|Other|68Ga-NODAGA-Ac-Cys-ZEGFR:1907|68Ga-NODAGA-Ac-Cys-ZEGFR:1907 (Ac-Cys-ZEGFR:1907 : Ac-CVDNKFNKEMWAAWE EIRNLPNLN GWQMTAFIASLVDDPSQSANLLAEAKKLNDAQAPK-NH2)
1507316|NCT02916316|Drug|R-CHOP with doxorubicin|Chemoimmunotherapy every 21 days for 6 cycles. In unfavourable patients (stage II-IV) are allowed 2 additional cycles of rituximab at the end of the 6 cycles of R-CHOP.
1507317|NCT02916290|Drug|Fuzhenghuayu|
1507318|NCT02916290|Drug|UDCA|
1507319|NCT02916277|Biological|endocan|to look series Endocan level for 5 days in intubated patients
1507320|NCT02916264|Procedure|a scalp block|Bilateral blocks of six nerves: ie. supraorbital and supraorbital nerves (V1), zygomaticotemporal nerves (V2) , auriculotemporal nerves , greater occipital nerves, and lesser occipital nerves will be performed by a well trained anesthesiologist with 0.5% bupivacaine not exceeding 3 mg/kg
1507321|NCT02916251|Drug|ZP4207(dasiglucagon) glucagon analogue|Cross-over design with single s.c. administration in euglycemic and hypoglycemic T1D
1507322|NCT02916251|Drug|Glucagon (Native glucagon)|Cross-over design with single s.c. administration in euglycemic T1D
1507323|NCT02916238|Drug|Fluoxetine|Fluoxetine prescribed and dispensed beginning at 10 mg daily; side effects and symptoms monitored biweekly; dosage increased to 20 mg., then by 20 mg. increments according to protocol algorithm based on PHQ-9 score to a maximum dose of 60 mg.
1507324|NCT02916238|Behavioral|Enhanced Usual Care|Depression symptoms monitored at 3 month intervals; results from PHQ-9 available to ART clinic physicians.
1507325|NCT02916225|Behavioral|High Intensity Interval Training|The HIIT group will warm up for 10 minutes at 60% to 70% of peak heart rate(50% to 60% of V̇O2peak) before walking four 4-minute intervals at 85% to 95% of peak heart rate. Each interval will be separated by 3-minute active pauses, walking at 60% to 70% of peak heart rate. The training session will be terminated by a 3-minute cool-down at 60% to 70% of peak heart rate. Total exercise time will be 38 minutes for the HIIT group. Patients will perform 3 training sessions per week for 12 consecutive weeks.
1507326|NCT02916225|Behavioral|Moderate Continuous Training|The moderate continuous training (MCT) group will undergo treadmill walking continuously at 60% to 70% of peak heart rate for 47 minutes each session to make sure the training protocols will be isocaloric. Patients will perform 3 training sessions per week for 12 consecutive weeks.
1507327|NCT02916212|Other|Optimized alarm profiles|
1507328|NCT02916199|Device|cannulation of ampulla of Vater|Cannulation of ampulla of Vater is a procedure that a guide-wire is passed through ampulla using interventional devices
1507329|NCT02916186|Biological|Acellular Dermal Matrix|Puros Dermis is a collagenous membrane derived from solvent preserved,human dermis, works as biological scaffold for the new formation of vasculated connective tissue.
1507330|NCT02916186|Procedure|Tunnel technique with the subepithelial connective tissue graft|Tunnel prepared with the placement of subepithelial connective tissue graft harvested from the palate
1507331|NCT02916173|Drug|human chorionic gonadotrophin|5000 unit intramuscular
1507332|NCT02916173|Drug|human chorionic gonadotrophin + gonadotrophin releasing hormone agonist|2500 unit intramuscular + 1 mg subcutaneous
1507333|NCT02916160|Drug|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®)|SACUBITRIL - VALSARTAN (formerly LCZ696, ENTRESTO®) is a new treatment of HF recently indicated class I, level B in the recent ESC guidelines 2016 on HF. It combines inhibitory prodrug neprilysin and valsartan.
1507334|NCT02916147|Drug|Sevoflurane|
1507335|NCT02916147|Drug|Propofol|
1507459|NCT02915133|Procedure|macular buckling surgery|Participants with high myopia foveoschisis are scheduled to macular buckling (MB) surgery.
1508443|NCT02907281|Other|Observational|Observational
1507337|NCT02916134|Drug|Antibiotic treatment|"Intravenous co-amoxiclav 1.2g three times daily, then 625mg, orally three times daily. If penicillin allergic, intravenous cefuroxime 1.5g three times daily + metronidazole 500mg three times daily, then oral cefuroxime 500mg twice daily + oral metronidazole 400mg three times daily.
The patient will receive inpatient intravenous antibiotics until sufficient clinical improvement is noted by the surgical team, who will be assessing the patient twice daily. After discharge the patient will receive 5 further days of oral antibiotics."
1507338|NCT02916121|Dietary Supplement|folic acid 5 mg/cap|the intervention includes folic acid 5 mg/d and vitamin B12 500 ug/d
1507339|NCT02916121|Other|Placebo|placebo
1507340|NCT02916108|Other|Reading EEG|
1507341|NCT02916095|Drug|Kanitinib|Oral administration of Kanitinib tablets.
1507342|NCT02916082|Procedure|Cervical length measurement|Vaginal ultrasound to measure cervical length previous to use of prostaglandins.
1507343|NCT02916069|Device|Nearinfrared Spectroscopy (NIRS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
1507344|NCT02916069|Device|Transcranial Doppler (TCD)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
1507345|NCT02916069|Device|Bispectral index (BIS)|Patients will be monitored and interference will be done to optimize the medical condition based on such monitor
2002767|NCT01839669|Procedure|Foot Orthoses and Eccentric Exercise|patients wear foot orthoses and they perform an additional home-based eccentric training program for the M. tibialis posterior
1507347|NCT02916043|Procedure|Cardiovascular surgery with cardiopulmonary bypass|Patients who underwent cardiovascular surgery including valve replacement or thoracic aortic surgery with cardiopulmonary bypass
1507348|NCT02916030|Dietary Supplement|Vit D|It is to examine the relationship between serum 25 (OH) D levels and Stroke either ischemic or hemorrhagic types
1507349|NCT02916004|Device|Measurement of NFR and PDR|Feasibility testing of NFR and PDR in sedated, ventilated patients. Comparison of NFR and PDR with standard routine care of pain assessment
1507350|NCT02915978|Drug|Fentanyl|Fentanyl delivered via sublingual spray
1507351|NCT02915978|Drug|Placebo|Matching placebo delivered via sublingual spray
1507352|NCT02915965|Drug|DCX|docetaxel, cisplatin and capecitabine
1507353|NCT02915965|Procedure|surgery|Ivor Lewis Esophagectomy
1507354|NCT02915952|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure Device will be used for surgical wound closure in C-Section Surgery
1507355|NCT02915952|Other|Conventional Sutures|Conventional Sutures will be used for surgical wound closure in C-Section Surgery
1507356|NCT02915939|Behavioral|The Residential Care Transition Module|Residential Care Transition Module sessions focus on the experiences of the caregiver, the care recipient, and (potentially) other family members immediately following residential long-term care (RLTC) admission. The sessions are designed to establish a therapeutic rapport with the caregiver and the family; provide a safe environment to explore stressors; examine family relational dynamics as they relate to the RLTC placement decision itself as well as the roles different family members play in the life of the caregiver and relative in RLTC; identify new modes of communication to facilitate more effective interactions with other family members and care staff; and identify effective ways to advocate for improved quality of care for and quality of life of their relatives in RLTC.
1507357|NCT02915926|Behavioral|occupational performance coaching|
1507358|NCT02915926|Behavioral|standard OT|
1507359|NCT02915913|Behavioral|Experimental: High Intensity Interval|Walking on a treadmill 4min at 80-90% peak heart rate and recovery 4 min at 65% peak heart rate until expenditure of 500 kcal
1507360|NCT02915913|Behavioral|Resistance training|Completing a resistance circuit (including upper and lower muscle groups) as many times as needed according to subject weight until expenditure of 500 kcal
1507361|NCT02915913|Behavioral|Plus: High Intensity Interval + Resistance Training|Walking on a treadmill as intervention 1 until 50% the energy expenditure prescribed is reached, then completing a resistance circuit until 100% energy expenditure is reached
1507362|NCT02915913|Other|Non-exercise|This group will receive the usual clinical care according to the consensus recommendations of the national goals for cardiovascular health promotion and disease reduction of the American Heart Association and Colombian guidelines COLDEPORTES.
1507363|NCT02915900|Other|Gonadotropin removal test|Patient receives hormone dosage adjusted according to the results of the Gonadotropin removal test.
1507364|NCT02915900|Other|Routine IVF method|Patient receives hormone dosage according to the standard dosage regimen, without revealing the results of the Gonadotropin removal test to the clinician.
1507365|NCT02915887|Other|Cervical Taping|Kinesio®Tex Tape 23 was used in this study. Two strips of tape were applied. The first layer was a Y-shaped strip with 2 tails on 2 sides of the cervical vertebrae, placed over the posterior cervical extensor muscles and applied from the insertion to origin. The second strip was an I-shaped approximately 20cm long, transversally applied over the C5-C7 vertebra with a tension-on-base technique in a space correction technique.
1507366|NCT02915874|Behavioral|Acceptance and Commitment Therapy|
1507367|NCT02915861|Other|Non-invasive eschar samples + blood|
1507368|NCT02915861|Other|Non-invasive eschar samples+eschar biopsy+blood|
1507369|NCT02915861|Other|Non-invasive eschar samples+eschar biopsy+lymph node fine-needle aspiration biopsy+blood|
1507370|NCT02915861|Other|Blood+Skin sample|
2002768|NCT01839669|Device|Sham Foot Orthoses|patient wear sham foot orthoses (control condition)
1507372|NCT02915835|Drug|Riociguat|riociguat 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID; dose titration starting with 1.0 mg (planned up-titration every 2 weeks, with possibility of dose reduction for tolerability; 0.5 mg is the lowest dose and 2.5 mg is the highest dose to be administered)
1507373|NCT02915835|Drug|Placebo|Placebo 0.5 mg, 1 mg, 1.5 mg, 2 mg and 2.5 mg administered TID;
2002769|NCT01833169|Drug|BKM120|BKM120 100 mg (oral gelatine capsules) will be administered orally once daily starting from cycle 1 day 1 and will be dosed continuously every day for each 28- day cycle
2002770|NCT01828034|Drug|Gemcitabine|
1507376|NCT02915809|Biological|GC3110B vaccine|0.5mL, Intramuscular
1507377|NCT02915809|Biological|GCFLU Quadrivalent Inj. vaccine|0.5mL, Intramuscular
1507458|NCT02915146|Radiation|combined ultraviolet phototherapy (NB-UVB + UVA1) vs. NB-UVB monotherapy|NB-UVB combined with UVA1
1507378|NCT02915796|Biological|G-CSF + CD133(+) cells|Patients in the G-CSF + CD133(+) cells + PTA group, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize CD 133 cells from bone marrow to peripheral blood. After 72-120 hrs, 100 ml suspension of peripheral arterial blood were collected and send to Good Products Manufacturing (GPM) certified laboratory (Shanghai Chen Chuan Biological Material Co. Ltd.) within 24 hrs of obtaining sample to isolate CD 133(+) endothelial progenitor cells (EPC) using magnetic cell separator. Subjects in this group, after vascular PTA treatment, received transarterial infusion of 50 ml suspension of isolated autologous CD 133(+) cells over 30 min via catheter opened into popliteal artery. The infusion of CD 133 cells was repeated after 24 hours.
1507379|NCT02915796|Biological|G-CSF|Subjects in this group, after vascular PTA treatment, received 150 unit of recombinant human G-CSF intramuscular injection to mobilize EPCs from bone marrow to peripheral blood. But the C133 (+) cells were not isolated from the peripheral blood to infuse transarterially as in G-CSF + CD133(+) + PTA.
1507380|NCT02915796|Procedure|percutaneous transluminal angioplasty (PTA)|Subjects in this group only underwent below the knee percutaneous transluminal angioplasty .
1507381|NCT02915796|Biological|Placebo infusion|Neither G-CSF was injected nor CD133(+) cells. Instead, subjects received placebo infusion (50 ml of 0.9% sodium chloride injection ) over 30 min.
1507382|NCT02915783|Drug|lenvatinib|4 mg and 10 mg capsules
1507383|NCT02915783|Drug|everolimus|5 mg tablets
1507384|NCT02915770|Procedure|cholangiojejunostomy|Half of participants will receive hepatectomy, cholangiojejunostomy and T-tube Drainage,while the other half will receive hepatectomy and T-tube Drainage
1507385|NCT02915770|Procedure|hepatectomy|
1507386|NCT02915770|Device|T-tube|T-tube Drainage
1507387|NCT02915757|Device|EDOR test|"The ElectroDermal Orienting Reactivity (EDOR) specifically is optimized for the detection of electrodermal hyporeactivity.
The EDOR investigation last about 30 min. The EDOR Test Data is sent immediately after each EDOR Test for each Test Person to a Company named EMOTRA for blind analyses. The EDOR Test Report may change the basis for the assessment and a new risk assessment may be needed to be done.
Blood sample and clinical assessment"
1507396|NCT02915731|Dietary Supplement|Vitamin A supplement|200 000 IU vitamin A (once-off dose), given to participants as part of the national vitamin A supplementation program
1507397|NCT02915718|Procedure|protein A immunoadsorption|protein-A immunoadsorption for 5 days and i.v. IgG（0.5g/kg Body weight）substitution
1507398|NCT02915705|Biological|KRN23|KRN23 is a recombinant human immunoglobulin G isotype 1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).
1507399|NCT02915705|Drug|Oral Phosphate|
1507400|NCT02915705|Drug|Active Vitamin D|
1507401|NCT02915692|Device|ERASE Silver Coated Foley Catheter|Foley catheter from ERASE CAUTI Kit will be administered as required.
1507402|NCT02915692|Device|Comparator Silver Coated Catheter|Foley catheter coated with silver
1507403|NCT02915679|Other|Blood sample for genetic purpose, psychiatric assessment and pain investigation|"All the participant will performed the same evaluation and blood analysis:
A clinical assessment by psychiatrics assessing psychiatric disorder and suicidal behavior
Thermal stimulation for pain assessment
Computer game named Cyberball: test of social exclusion
Self report questionnaire for the assessment of reject sensitivity, relationship style, impulsivity, childhood trauma.
Routine blood sampling"
1507404|NCT02915666|Drug|Digoxin Combination|Digoxin 0.25 mg PO daily will be given for 8-week cycles
1507405|NCT02915666|Drug|Dabrafenib|dabrafenib 150mg PO twice daily for 8-week cycles
1507406|NCT02915666|Drug|Trametinib|trametinib 2 mg PO daily for 8-week cycles
1507407|NCT02915653|Other|Educational materials on a new diagnostic service|Educational materials on a new diagnostic service
1507408|NCT02915640|Other|Remote technology|Utilization of remote technology versus not using remote technology when triaging and managing pediatric patients in remote settings prior to pediatric specialized inter-facility transportation.
1507409|NCT02915627|Device|Application of Antishock garment|anti-shock garments are applied. Participants will then be examined for two 15 minute intervals with and without the anti-shock garments applied. During each 15 minute interval, echocardiograms will be performed.
1507410|NCT02915614|Procedure|Pulmonary rehabilitation|3-weeks of inpatient pulmonary Rehabilitation including exercise Training (daily endurance and strength Training)
1507411|NCT02915601|Drug|Sodium bicarbonate|
1507412|NCT02915601|Drug|Placebo|
1507413|NCT02915588|Other|early isometric loading after rotator cuff surgery|
1507414|NCT02915588|Other|passive motion after rotator cuff surgery|
2002771|NCT01828034|Drug|Cisplatin|
2002772|NCT01828034|Drug|MEK162|
1507417|NCT02915562|Other|exercise|
1507418|NCT02915549|Other|Progressive Feeding without MEF|This group will receive feeding volumes of 20-24ml/kg/d of day 1 of feeding followed by the study intervention of daily volume increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
1507419|NCT02915549|Other|Progressive Feeding with MEF|This group will receive minimal enteral feeds (MEF) with volumes of 20-24ml/kg/d for 4 days followed by daily increases in increments of 24-25ml/kg/d as tolerated until full enteral feeding is achieved.
1507420|NCT02915536|Other|Natural exposure of high iodine|Natural exposure of high iodine intake from drinking water
1507421|NCT02915523|Drug|entinostat|An orally available histone deacetylases inhibitor (HDACi).
1507422|NCT02915523|Drug|avelumab|A fully human antibody of the immunoglobulin (Ig) G1 isotype that targets and blocks Programmed death-ligand 1 (PD-L1), the ligand for Programmed cell death protein 1 (PD-1) receptor.
1507423|NCT02915523|Drug|Placebo|A pill containing no active drug ingredient.
2002773|NCT01826656|Procedure|tooth extraction|Patients from both groups will follow the extraction of an hopeless tooth
2002774|NCT01826656|Radiation|CBCT scan|A CBCT scan will be performed within 2 days from the tooth extraction at after 3 months (+/-2 days)
1507425|NCT02915497|Behavioral|Abbreviated Early Prolonged Exposure Therapy|Since many trauma patients are discharged within 4 weeks, AEPET with the same length (45 minutes - 1 hour) and number of sessions as PET, is given in a shorter time period (daily for 3 days as opposed to weekly over 3 weeks).
1507426|NCT02915484|Device|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
1507427|NCT02915328|Device|Filterwire EZ™|
1507428|NCT02915328|Device|MO.MA Ultra|
1507429|NCT02915328|Device|Stent Roadsaver®|
1507430|NCT02915328|Device|Carotid Wallstent|
1507431|NCT02915315|Dietary Supplement|salt|The protocol comprise a questionnaire survey and physical examination during a 3-day baseline observation period, a low-salt diet for 7 days (3g of salt per day) and a high-salt diet for 7 days (18g of salt per day). During the baseline period, each subject is given detailed dietary instructions to avoid table salt, cooking salt, and high-salt foods for the 17-day study duration. To ensure compliance of study participants with the intervention program, they are required to have their breakfast, lunch, and dinner at the study kitchen under supervision of the study staff during the entire study period. All foods are cooked without salt. Onsite study staff members add repackaged salt to the meals of individual subjects as indicated by the study protocol.
2002775|NCT01826656|Radiation|DXA scan|DXA scan will be performed at the hip and lumbar spine in all self-reported non-osteoporotic subjects who hasn't done one within 1 year, to confirm their normal bone mineral density. Osteoporotic subjects already have a DXA scanner.
2002776|NCT01826656|Radiation|Panoramic radiograph|As basic standard of care, a panoramic radiograph will be performed to both test and control subjects who haven't done one within the previous year, in order to give them a full-mouth dental diagnosis
1507434|NCT02915289|Procedure|Povidone Iodine|Vaginal preparation with 10% povidone iodine prior to non-emergent cesarean section.
1507435|NCT02915289|Procedure|Chlorhexidine gluconate|Vaginal preparation with 4% chlorhexidine gluconate prior to non-emergent cesarean section.
1507436|NCT02915276|Procedure|Blastocentisis|Removal of blastocoelic fluid from the blastocoelic cavity
1507437|NCT02915276|Procedure|Trophectoderm biopsy|Removal of trophectoderm cells from the blastocyst
1507438|NCT02915263|Drug|IGIV-C|Gamunex-C [immune globulin injection (human) 10% caprylate/chromatography purified] is a sterile solution of human immune globulin protein.
1507439|NCT02915263|Drug|0.9% Sodium Chloride|Sodium Chloride (also known as saline) is a solution of sodium chloride, or salt, and sterile water.
1507440|NCT02915250|Drug|BioChaperone® Combo|Injection of BioChaperone® Combo
1507441|NCT02915250|Drug|Humalog® Mix25|Injection of Humalog® Mix25
1507442|NCT02915250|Drug|Humalog®|Injection of Humalog®
1507443|NCT02915250|Drug|Lantus®|Injection of Lantus®
1507444|NCT02915250|Drug|Placebo|Injection of 0.9% NaCl
1507445|NCT02915237|Dietary Supplement|Concord grape juice|Daily dietary supplementation with a commercially available Concord grape juice.
1507446|NCT02915237|Dietary Supplement|Placebo Beverage|Daily dietary supplementation with a placebo beverage consisting of water, sugar, artificial flavoring and color that is formulated to look and taste like grape juice and have the same carbohydrate composition and energy load.
2002777|NCT01822496|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-D CRT
2002778|NCT01822496|Drug|Carboplatin|Given IV
1507449|NCT02915211|Dietary Supplement|Keyo|Keyo is a Food for Special Medical Purposes (FSMP) and is intended for use in the KD. It has a fat to protein and carbohydrate ratio of 3 to 1. This makes it appropriate for inclusion in all versions of the KD - classical, MCT, MAD and LGI. Keyo has been designed as a nutritionally complete, ready to use, pleasant tasting and versatile medical food for use in a KD.
2002779|NCT01822496|Drug|Cisplatin|Given IV
2002780|NCT01822496|Drug|Crizotinib|Given PO
1507452|NCT02915185|Procedure|strength training intervention|The strength training program will last 4 weeks (3 times/week, 60 minutes). Using dead weights, the 1RM (i.e. the maximal load that an individual can lift once) will be estimated by the 10RM in order to avoid tendino-muscular injuries and fatigue. The 10RM will be determined for the muscles playing a key role in the functional performance of the upper limb, which are the wrist extensors and the elbow and shoulder flexors. In addition, the grip muscles of the affected hand will be trained with a JAMAR® dynamometer. Participants' maximal grip force will be determined and used to dose the training of the hand muscles and its progression. The training will begin and end by a 5-minute warm-up and relaxation period comprising of active movements of the trained muscles.
1507453|NCT02915185|Device|tDCS|An anodal montage over the ipsilesional hemisphere will be used where the anode will be placed over the ipsilesional M1 area whereas the cathode will be placed on the contralateral supra-orbital region.For the tDCS real group, a direct current will be generated by a tDCS stimulator and gradually increased in a ramp-like fashion over the first 8 seconds until a maximum intensity of 2 mA is achieved. The tDCS will be applied for 20 minutes during each training session for a total of 12 sessions. For the group receiving sham tDCS, the protocol will be similar to the tDCS real group although the stimulation will be applied for the first 30 seconds only; a duration long enough to induce similar perceived sensation as real tDCS (tingling), to keep participants' blind to the tDCS type.
1507454|NCT02915172|Drug|Lenvatinib|"Phase 1 Dose Escalation: Starting dose of Lenvatinib 10 mg by mouth once daily of a 21 day cycle.
Phase 2 Dose Expansion: Starting dose of Lenvatinib is maximum tolerated dose from Phase 1."
1507455|NCT02915172|Drug|Capecitabine|Phase 1 Dose Escalation and Phase 2 Dose Expansion: Capecitabine 1000 mg/m2 twice daily by mouth on Days 1 - 14 of a 21 day cycle.
2002781|NCT01822496|Drug|Erlotinib Hydrochloride|Given PO
2002782|NCT01822496|Drug|Etoposide|Given IV
2002783|NCT01822496|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
2002784|NCT01822496|Other|Laboratory Biomarker Analysis|Correlative studies
2002785|NCT01822496|Drug|Paclitaxel|Given IV
2002786|NCT01810328|Other|Traumatized population|In the traumatized population (severe blunt traumatic injury), blood samples will be collected at admission, days 1, 4, 7, 14, 21 and 28, or until discharge from the ICU or death. A total of 5 mLs of blood will be collected at admission and day 1, 4 mLs of blood will be collected at each remaining time point.
1507460|NCT02915120|Procedure|Real Pulsed Radiofrequency|"Pulsed Radiofrequency uses radiofrequency current in short (20 ms), high-voltage bursts; the silent phase (480 ms) allows time for heat elimination, generally keeping the target tissue below 42° C. The Radiofrequency (RF) electrode will be inserted through the canula, and RF lesions will be generated by applying pulsed RF treatment to the inferomedial (IM), superomedial (SM), and superolateral (SL) GN branches for 8 minutes at 42°C."
1507461|NCT02915120|Procedure|Sham Pulsed Radiofrequency|Control patients will undergo the same procedure. The sensorial and motor stimulations will be applied too. The RF electrode will be then inserted through the cannula, and RF lesions will be simulated without applying pulsed RF treatment to the IM, SM and SL, GN branches for 8 minutes each GN branch and the temperature of the electrode tip was not raised.
1507462|NCT02915107|Device|BioFreedom|PCI with BioFreedom
1507463|NCT02915107|Device|Orsiro|PCI with BioFreedom
1507464|NCT02915094|Drug|Anakinra|
1507465|NCT02915081|Other|Blue light|"Illumination: High illumination lighting will be instituted with a Day*Light Classic Light (Uplift Technologies, Dartmouth, NS)
Blue wavelength: Each subject will be fitted with blue filtered goggles (Lee Filters, Burbank, CA). These goggles ensure the transmission of a bright (1700 lux) blue (peak 442 nm) spectrum light when the subject is within 12 inches.
Photoperiod: A 24-hour photoperiod will be used that commences at 0800 the morning prior to surgery and continues for 24 hours. To account for potential variability in the exposure of interest, each subject will complete a diary to catalogue duration and distance of light exposure. Postoperatively the same photoperiod will be instituted and continued for one 24 hour period."
1507466|NCT02915068|Behavioral|EHR-Physician Asthma Care Education Program|participants will receive EHR-PACE, an interactive 1.5 hour training module that teaches clinicians best practices for communicating with patients in the presence of computer systems in the exam room (specifically EHRs).
1507467|NCT02915055|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg to be taken every 8 hours (TID) as needed (PRN
1507468|NCT02915055|Drug|standard oxycodone/acetaminophen|
1507469|NCT02915042|Drug|Dexmedetomidine|Analgesic Efficacy
1507470|NCT02915042|Drug|Placebo|Saline placebo
1507471|NCT02915029|Other|Educational and lifestyle coaching|"Educational lifestyle and patient activation is a CHR lead home visits every other week to provide education on healthy lifestyles (diet, exercise, alcohol abuse and smoking) as patient preference; Education provided on management of diabetes, hypertension and hyperlipidemia POC testing for A1C and microalbuminuria conducted at patient homes. Lifestyle and diet related Motivational messaging carried out regularly. Patient will receive group session at the clinic every quarters.
Control arm will receive their usual care provided by IHS. The control group will receive a health evaluation at the initiation of the study and at the 6-month and 12-month."
1507472|NCT02915016|Biological|DNA-HIV-PT123 vaccine|Contains a mixture of three DNA plasmids in a 1:1:1 ratio, each at 1.33 mg: 1) clade C 96ZM651 gag, 2) clade C 96ZM651 gp140, and 3) clade C CN54 pol-nef, delivered at a total dose of 4 mg, administered by intramuscular (IM) injection to the left deltoid as a single 1 mL dose.
1507473|NCT02915016|Biological|Bivalent Subtype C gp120/MF59 vaccine|Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, each at a dose of 100 mcg, mixed with MF59 adjuvant, administered by IM injection to the right deltoid as a single 0.5 mL dose.
1507474|NCT02915016|Biological|Bivalent Subtype C gp120/AS01B vaccine|"Clade C TV1.C gp120 Env and clade C 1086.C gp120 Env, mixed with AS01B adjuvant, administered by IM injection to the right deltoid as a single 0.75 mL dose.
Groups 2 and 5 will receive a 100 mcg dose. Groups 3, 6, and 7 will receive a 20 mcg dose."
1507475|NCT02915016|Biological|Placebo|Sodium Chloride, 0.9%, administered by IM injection at volumes to match the active products.
1507476|NCT02915003|Behavioral|E-health website|e-Health website embedded with short, culturally and locally-tailored videos informed by behavior change principles that will teach patients/families about: the importance and benefits of health insurance, ACA coverage provisions and local insurance options available to them, the specifics of the new law and how it affects them, and how to navigate local systems and resources to obtain and maintain health insurance.
1507477|NCT02914990|Drug|BPI-15086|BPI-15086 is administered once daily with a starting dose of 25 mg in a 21-day cycle. When tolerated, increasing doses of BPI-15086 will be tested in subsequent cohorts, until a maximum tolerated dose is determined.
1507479|NCT02914964|Behavioral|Swank Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling to study participants to assist them in following the Swank Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
1507480|NCT02914964|Behavioral|Wahls Elimination Diet|A Registered Dietitian Nutritionist (RDN) skilled in motivational interviewing will provide nutrition counseling using to study participants to assist them in following the Wahls Elimination Diet at home. An in-person counseling session will occur at study visits 2 and 3. Five telephone counseling calls will occur between visits 2 and 3. The study participant may contact the RDN with questions at any time during the intervention.
1507481|NCT02914951|Behavioral|Cognitive-Behavioral Therapy|CBT is a behavioral intervention that consists of 12 60- to 90-minute-long weekly sessions. A modified, principles-based form of CBT will be used in this study to reduce complexity of activities during therapy sessions while retaining all key elements and principles of CBT.
1507482|NCT02914951|Other|Functional magnetic resonance imaging (fMRI)|Functional magnetic resonance imaging (fMRI). There will be two fMRI visits, 60 to 90 minute each, one before and the other after CBT. fMRI is a technique that uses magnetism to measure activity of the brain as participants perform simple tasks such as pressing the button in response to pictures. During this study, children will be asked to look at pictures of objects and press or not press the button in response to specific instruction. Participants will also look at pictures of faces and light-point displays depicted biological motion. fMRI is used as an outcome measure to explore if change in irritability is associated with change in brain responses to these tasks during fMRI.
1507483|NCT02914938|Drug|ME-401|
1507484|NCT02914925|Device|ArmeoSpring/CIT|Participating group will receive therapy with the Armeo®Spring Pediatric and CIT for 6 hours per day, 5 days per week for three weeks, totaling 90 hours
1507485|NCT02914899|Behavioral|focus groups|
1507486|NCT02914899|Behavioral|in-depth interviews|
1507487|NCT02914886|Drug|Apidra|Half of patients with lipoatrophy will be switched randomly to insulin Apidra for 12 months. Any site other than the lipoatrophic site would be used for delivering the insulin for the purpose of this study.
1507488|NCT02914886|Drug|current insulin|Half of patients with lipoatrophy will still use their current Insulin for 6 months. After 6 months the current insulin will be switched to insulin Apidra for the next 6 months.
1507489|NCT02914873|Procedure|Active surveillance|Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
1507490|NCT02914860|Device|Cardiac CT|"Cardiac CT - contract enhanced cardiac CT according to standard protocol
D-SPECT SUMO study - standard SUMO protocol (suggested reduction in mIBG dose and increase in scan time to minimize overall radiation burden)
Merge CT and D-SPECT image data to generate SUMO map."
1507491|NCT02914860|Procedure|Ablation Procedure|"CARTO-reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO.
High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline).
RF ablation only at points where there is an HFS positive response to SUMO DUA (in sinus rhythm if AF converts)
Target a region of 1.0 - 1.5 cm diameter around the SUMO mIBG DUA
Control HFS
At operator discretion, conventional PVI by circumferential antral ablation according to standard procedures.
Exit and entrance block confirmation
Attempt to induce sustained atrial tachycardia; optional mapping and ablation of post-ablation atrial tachycardia."
1507492|NCT02914860|Device|D-SPECT|
1507493|NCT02914847|Behavioral|Functional Imagery Training (FIT)|Functional Imagery Training comprises of three elements: a) formulation of idiosyncratic drivers of self-harming behaviour and reasons for change; b) motivational interviewing combined with mental imagery techniques that enhance motivation to change the self-harm dysfunctional habit; c) formulation of goals for change (i.e. the goal is a desired behaviour alternative to self-harm) and practice of functional imagery to support goal achievement.
1507494|NCT02914834|Other|Acupuncture|Standardized acupuncture treatment administered for 30 minutes each session
1507495|NCT02914834|Other|Non-pain related video health education|Attention control group will watch health education videos the equivalent of 10 hours from randomization up to study completion.
1507496|NCT02914821|Behavioral|Simulated tax via 3 cent per ounce price increase|For each of the 3 experimental conditions, investigators will increase the price of sugar-sweetened beverages by 3 cents per ounce. This price increase will be reflected in the price tag and described as a surcharge. In two of the arms (Pre-K and Childhood Healthy Eating), the beneficiary of the surcharge will be named.
1507497|NCT02914808|Other|Patients will undergo a lower limb MRI and blood tests|
1507498|NCT02914795|Other|diagnostic analysis of platelet function|analysis of platelet aggregation using optical measurements as well as the commercial VerifyNow technique
1507499|NCT02914782|Other|Observational Study|
1507500|NCT02914769|Drug|Ayahuasca|patients will receive a single dose of ayahuasca.
1507501|NCT02914769|Drug|placebo|patients will receive a single dose of a passive placebo.
1507502|NCT02914743|Behavioral|Motivational Interviewing|This intervention will involve a discussion intended to explore subjects' motivations to pursue dental care and empower them to visit a dentist upon release from the hospital.
1507503|NCT02914743|Procedure|Dental cleaning|This procedure will involve the removal of plaque and supragingival and subgingival calculus from the surfaces of the teeth.
1507504|NCT02914704|Device|MRI-HIFU|Treatment of uterine fibroids with MRI-HIFU
1507505|NCT02914691|Drug|Dapagliflozine 10 mg once daily tablet treatment|
1507506|NCT02914691|Drug|Placebo identical once daily tablet treatment|
2002787|NCT01810328|Other|Healthy Volunteers|The healthy volunteer participants will donate a one-time 5 mL blood sample which will undergo rapid leukocyte genomic screening. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
1507510|NCT02914652|Drug|Salbutamol|Ventoline(R), inhalation spray, 0,1 mg/dose, 9 doses administered as coherent single doses.
1507511|NCT02914652|Drug|Norflouran (Placebo Evohaler(R) )|Placebo Evohaler(R) MDI, inhalation spray, 60 mg/dose, 9 doses administered as coherent single doses.
1507512|NCT02914639|Drug|SF0166 Topical Ophthalmic Solution|
1507513|NCT02914626|Drug|Intravitreal ranibizumab|Intravitreal ranibizumab injection
1507514|NCT02914613|Drug|SF0166 Topical Ophthalmic Solution|
1507517|NCT02914587|Device|ARTAS System|
1507518|NCT02914587|Other|Manual Implantation|
1507519|NCT02914574|Other|PowersTM strap|The powers strap aims to decrease knee varus through supporting femoral abduction and external rotation. Participants will wear the Powers strap while performing functional tasks (running, squatting, single leg step down).
1507520|NCT02914561|Drug|Filgotinib|Tablet(s) administered orally once daily
1507521|NCT02914561|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
1507522|NCT02914548|Drug|OPA-15406|Subjects were treated with assigned 0.3% or 1% OPA-15406 ointment twice daily.
1507523|NCT02914548|Drug|Placebo|Subjects were treated with assigned 0% OPA-15406 ointment twice daily.
2002793|NCT01805869|Other|Third Molar Removal|Third Molar Removal
1507528|NCT02914509|Drug|Travoprost|
1507529|NCT02914509|Other|Placebo Vehicle|
1507530|NCT02914496|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT is a specific form of Cognitive behavior therapy (CBT) which will be given as a course consisting of seven sessions where each session is two hours long.
1507531|NCT02914483|Behavioral|Enhanced Usual Care|"Participants randomized into the EUC group will complete 8 weekly individual sessions by phone. Each weekly session consists of: brief check-in and review of AHA brochure- Women, Heart Disease and Stroke."
1507598|NCT02913950|Other|validation of pediatric stool scale|validation of pediatric stool scale
1507532|NCT02914483|Behavioral|Stress Management|Participants randomized into the stress management group will complete 8 weekly group sessions by phone. The intervention is a telephone adaptation of mindfulness-based cognitive therapy (MBCT) and focuses on building cognitive-behavioral and mindfulness skills to help manage and cope with stress. Each hour-long weekly session consists of: check-in, instruction, skill building, discussion, and home-based practice assignment.
1507533|NCT02914483|Device|Actigraph|The Actigraph (wGT3X-BT) will monitor sleep activity and will be worn by participants for 7 days, pre- and post stress based intervention.
1507534|NCT02914470|Drug|carbplatin, cyclophophamide, atezolizumab|
1507535|NCT02914457|Device|Standard biventricular pacing|Pacing will be performed on one LV electrode pair, (at different locations), and on the tip of the RV-lead.
1507536|NCT02914457|Device|MultiSpot simultaneous LV-ventricular pacing (MultiSpot-SYN)|Pacing will be performed on all electrodes on the LV wall and on the tip of the RV-lead simultaneously.
1507537|NCT02914457|Device|MultiSpot sequential LV-ventricular pacing (MultiSpot-SEQ)|Pacing will be performed on all electrodes on the LV wall sequentially. The RV-electrode will be paced simultaneously with last paced LV-electrode.
1507538|NCT02914431|Device|3D Printing Personalized Titanium Plate|The cutting guides were placed onto the planned position. The 11 screw holes were drilled using the predetermined screw holes on the guides. The osteotomy / ostectomy then start. Next, the 3D printing personalized maxillary fixation plates were adapted to reposition the Le Fort I segment to the planned position. The 11 screw holes on the bones defined by the cutting guides were used again as the bony reference. The personalized plate was first firmly installed on the maxilla above the osteotomy line by aligning the corresponding 5 screw holes on the plate to the bone. Afterwards, the osteotomized Le Fort I segment was moved and rotated till all the remaining corresponding 6 screw holes on bone and plate were aligned.
1507539|NCT02914418|Device|Transcranial Magnetic Stimulation using iTBS Paradigm|TMS is a non-invasive, painless method of stimulating the central and peripheral nervous system. ITBS is a form of TMS which is delivered for ~200sec and can promote changes in neural activity.
1507540|NCT02914405|Drug|Nivolumab|Nivolumab is a soluble protein consisting of 4 polypeptide chains, which include 2 identical heavy chains consisting of 440 amino acids and 2 identical light chains. Molecular weight is 146,221 daltons.
1507541|NCT02914405|Drug|Ch14.18/CHO|APN311 (ch14.18/CHO) is manufactured in a Good Manufacturing Practice (GMP) compliant facility of Polymun Scientific, Austria according to a state of the art aseptic manufacturing process based on a characterized and stable Chinese Hamster Ovary (CHO) cell line. After propagation of the working cell bank (WCB) in small volume vessels/bioreactors, manufacture is carried out in a 2500 L stirred tank reactor utilizing components which are free of material of animal or human origin.
1507542|NCT02914379|Drug|[¹⁴C]-LY3337641|Administered orally
1507543|NCT02914366|Drug|Ambroxol|
1507544|NCT02914366|Other|Placebo|
1507545|NCT02914353|Drug|EP=7041|Factor X!a Inhibitor
1507546|NCT02914353|Drug|Placebo|Normal Saline
2002794|NCT01801527|Behavioral|Telerehabilitation group|Interventions will be based on to provide cardiovascular, mobility, strength and stretching exercises through telerehabilitation system
1507548|NCT02914327|Drug|SNX-5422 plus ibrutinib|SNX-5422 capsule(s) dosed every other day for 21 days out of a 28-day treatment cycle to a total dose of 56 mg/m2 SNX-5422. Subjects will self-administer daily oral ibrutinib in the afternoon at least 8 hours apart from SNX-5422 for 28 days of each cycle.
2002795|NCT01776138|Other|Collect Blood and Survey Instruments|
1507550|NCT02914301|Device|Babyscripts Prenatal App|The use of a mobile digital app to facilitate certain aspects of standard prenatal care.
1507551|NCT02914301|Device|Placebo|No Mobile App, Usual care
1507552|NCT02914288|Other|High resolution magnetic resonance imaging for intracranial vessel walls|High resolution magnetic resonance imaging for intracranial vessel walls at initial (optional), 1 month, 3 month, 6 month (optional), and 12 month
1507553|NCT02914275|Biological|Seqirus Quadrivalent Inactivated Influenza Vaccine|The Seqirus study vaccine is a sterile, thimerosal-free suspension containing 60 mcg total hemagglutinin antigen per 0.5 mL (15 mcg each of the four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season). Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age, or the deltoid muscle of the non-dominant arm in children 36 months through 59 months of age.
1507554|NCT02914275|Biological|Comparator Quadrivalent Inactivated Influenza Vaccine|The comparator Quadrivalent Inactivated Influenza vaccine is a US-licensed product containing four recommended influenza strains for the Northern Hemisphere 2016/2017 influenza season. Subjects will receive one or two doses according to the recommendations of the Advisory Committee on Immunization Practices for the United States 2016-17 Influenza Season. Preferred sites for intramuscular injection are the anterolateral aspect of the thigh in infants 6 months through 11 months of age, the anterolateral aspect of the thigh (or the deltoid muscle of the arm if muscle mass is adequate) in children 12 months through 35 months of age, or the deltoid muscle of the non-dominant arm in children 36 months through 59 months of age.
1507555|NCT02914262|Drug|AKB-4924|Comparison of different dosages of AKB-4924
1507556|NCT02914262|Other|Placebo|Placebo comparator
1507557|NCT02914249|Other|Orange juice (500 mL/d)|Nutritionists prescribed a low-calorie diet that was estimated from total energy expenditure (TEE) for each individual minus 500 kcal per day (30% TEE). Both groups had the same diet plan based on individual weight. The dietary plan was composed of six meals/day: breakfast (fat-free milk and coffee; whole-grain bread with margarine, and an apple); snack 1 (250 mL OJ / banana and free-fat yogurt); lunch (brown rice, beans, grilled lean meat, salad, cooked vegetables); snack 2 (250 mL OJ / free-fat yogurt with oatmeal); dinner (brown rice, beans, grilled lean meat, cooked vegetables and salad); and snack 3 (salty crackers or oat cookies, tea without sugar). Body composition measurements were collected (monthly); blood samples and dietary questionnaires (every two weeks).
1507559|NCT02914223|Drug|Cenerimod|Oral formulation of cenerimod (2mg) containing 100 μCi (3.7 MBq) of 14C-radiolabeled cenerimod
1508808|NCT02904291|Drug|Patients are tested for their normal prescription medications|
1507560|NCT02914210|Device|Virtual physical therapy rehabilitation program|Virtual Exercise Rehabilitation Assistant (VERA), a virtual physical therapy delivery system installed in patient's home
1507561|NCT02914210|Other|No intervention|Traditional physical therapy delivered in clinic or via home-health visits
1507562|NCT02914197|Other|Full information|Patients will be randomized to receive full information or standard information at the study start. The second wave will follow the same randomization process 6 months following the study start.
1507565|NCT02914171|Biological|Autologous Bone Marrow-derived Mononuclear Cells|
1507566|NCT02914171|Device|Insertable cardiac monitor|Following surgical Ebstein repair a Medtronic Reveal LINQ Insertable Cardiac Monitor (ICM) will be placed subcutaneously in the anterior chest to continuously monitor the subject's heart rhythm and to record cardiac information through automatic detection of arrhythmias.
1507567|NCT02914158|Drug|Goserelin|
1507568|NCT02914158|Drug|Tamoxifen|
1507569|NCT02914158|Drug|Aromatase Inhibitors|
1507570|NCT02914145|Drug|Dihydroartemisinin-piperaquine|Mass drug administration
1507571|NCT02914132|Device|Seraph 100 Filter|Treatment of renal replacement therapy patients with bacteremia.
1507572|NCT02914119|Drug|Rocuronium|
1507573|NCT02914119|Drug|Succinylcholine|
1507574|NCT02914119|Drug|Cisatracurium|
1507575|NCT02914119|Drug|Mivacurium|
1507576|NCT02914119|Device|Objective neuromuscular monitoring (acceleromyography)|
1507577|NCT02914119|Drug|Sugammadex|
1507578|NCT02914119|Drug|Neostigmine|
1507579|NCT02914106|Other|Observational Study|Patients were diagnosed for AIS by a certified neurologist at the Emergency Room of the Central Military Hospital. Neurological, cognitive and functional status were determined by NIHSS score, Photo test, Pfeiffer mental status score and by modified Rankin score respectively. A sample of venous blood was withdrawn in the early morning (07 to 09 AM) after assessment of neurological and cognitive status.
1507580|NCT02914093|Other|IMT|Inspiratory muscle training for 6 weeks 2x30 breaths daily as a home based program
1507581|NCT02914067|Other|Neurocognitive testing|
1507582|NCT02914067|Device|rsfcMRI|The imaging protocols will be a combined version of a standard of care (SOC) protocol with a research portion. The SOC portion of the pre-surgical scans includes a 3D T2-weighted (T2w) scans and 3D pre- and post-contrast T1-weighted (T1w) images, both at high resolution (1.0 mm3) for use in the intraoperative navigation system. This scan also includes a DTI portion for definition of fiber bundles of interest. The SOC portion of the post-surgical scans includes transverse FLAIR and post-contrast T1w images in all 3 planes. The research portion of the scan will be identical at all 3 time points and include 15 min of rsfcMRI during which the non-sedated subjects will be asked to stay still and awake while looking at a fixation cross
1507583|NCT02914054|Drug|High dose Dexamethasone pulses|In HD-DXM arm, DXM was administered intravenously at 40 mg in 500cc normal saline (0.9% saline) during 1 hour for consecutive 4 days and then stopped. This cycle was repeated in 14 days interval to receive 3 cycles of treatment.
1507584|NCT02914054|Drug|Prednisone|Patients in PDN arm received PDN orally at 1.0 mg/kg body weight daily for 4 consecutive weeks. After achieving responses the medication tapered gradually to less than 15mg daily or terminated over 4-6 weeks aimed at maintaining platelet count over 30 ×109/L.
1507585|NCT02914028|Procedure|transversus abdominis plane block|A peripheric block needle is inserted entering the facia between musculus rectus abdominis and musculus transversus abdominis with ultrasonography and local anesthetics are injected in the facia.
1507586|NCT02914028|Drug|Tramadol and paracetamol|Tramadol 100 mg and paracetamol 1000 mg are applied to the patients at the end of the surgery
1507587|NCT02914015|Procedure|Continous QLB (quadratus lumborum block)|
1507588|NCT02914015|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
1507589|NCT02914015|Device|PAJUNK Contiplex S Catheter|
1507590|NCT02914015|Drug|Ropivacaine|"0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline given immediately after the correct position of the tip of the needle has been verified.
followed with 0.2% ropivacaine infusion at a rate of 0.125ml/kg/h given through the catheter inserted in between the quadratus lumborum muscle and psoas major muscle."
1507591|NCT02914015|Drug|Morphine given as IPCA|Bolus: 1-2mg, lock time: 10min, 1h limitation: 5-10mg. without background infusion.
1507592|NCT02914002|Behavioral|Psychoeducational intervention|A mobile kitchen visits the 16 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned as well as the importance of cooking at home and having family meals . A printed version of the recipe is given to every participant. Every session participants are encouraged to prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
1507593|NCT02913989|Other|Smoking habits characterization|
1507594|NCT02913976|Device|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
1507595|NCT02913976|Device|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
1507596|NCT02913963|Device|Kinesio Taping|Four Kinesio Taping strips will be placed with tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
1507597|NCT02913963|Device|Sham Kinesio Taping|Four Kinesio Taping strips will be placed without tension on skin forming an asterisk. The point of intersection of the four strips will be just above the myofascial trigger point. The subject will remain three days with the strips on his skin
1507599|NCT02913937|Device|Passive ultrasonic irrigation|Endodontic irrigation followed by passive ultrasonic agitation.
1507600|NCT02913937|Device|Endodontic needle|Endodontic irrigation
1507601|NCT02913924|Drug|Clonazepam|fixed-flexible daily dose to a maximum of 2 mg (1 mg twice per day) for the first 8 weeks of the trial
1507602|NCT02913924|Drug|Placebo|
1507603|NCT02913911|Other|feedback|Sit to stand training with external feedback
1507604|NCT02913898|Behavioral|IBLT|Information bias learning task-- a computer based task in which positive information is more useful when learning how best to complete it
1507605|NCT02913898|Behavioral|IBLT control|A control version of the IBLT task-- a computer based task in which both positive and negative information is useful when learning how to complete it
1507606|NCT02913885|Drug|Curodont Repair|composed of biomimetic regeneration scaffold self-assembling peptides (P11-4) used for remineralization
1507607|NCT02913885|Drug|fluoride varnish|fluoride inhibit the progression of white spot lesion
1507610|NCT02913846|Other|Nutritional evaluation|A first nutritional evaluation will be performed within 48h of patient admission. Weight and BMI will be measured once a week.
1507611|NCT02913846|Other|Muscular assessment|An assessment of muscular force will be performed once a week.
1507612|NCT02913846|Other|Pre-albumine dosage|Dosage performed once a month.
1507613|NCT02913833|Other|Pain evaluation|Pain will be assessed four times per day on a visual analogic scale.
1507614|NCT02913820|Other|snowfall > 5cm/day|the number of myocardial infarctions of every day analysed in this study will be correlated with the respective values of snowfall
1507615|NCT02913807|Procedure|Customized Jigs and Plates|The titanium locking reconstruction plates will be prefabricated based on the preoperative CT scans. Prior to procedure, customized planning for osteotomies will generate the prefabricated jigs.
1507616|NCT02913807|Procedure|Hand Contoured Osteotomies and Reconstruction Bars|This will be the traditional method of hand-conjuring the bar and bony sites.
1507617|NCT02913781|Procedure|polar body removal using zona drilling by laser then suction by injecting pipette|zona drilling with laser followed by polar body removal then ICSI procedure
1507618|NCT02913781|Procedure|Classic ICSI|Classic ICSI case was done be injecting sperm inside Oocyte while polar body is already existed at 6 or 12 O'clock position.
1507619|NCT02913768|Drug|Ondansetron|
1507620|NCT02913768|Drug|Normal saline|
1507622|NCT02913742|Procedure|monitoring by depth electrode|During laser interstitial thermal ablation (LITT) for mesial temporal lobe epilepsy, the study patients will receive invasive neurophysiologic intraoperative monitoring. In addition to the typical placement of LITT stereotactic laser ablation probe via occipital burr hole, the study patients will receive an 8-contact depth recording electrode placed through an adjacent burr hole. The recording electrode will be placed into the parahippocampal gyrus in parallel to the LITT device. The patient will be monitored for epileptic discharges for 10 minutes before and 10 minutes after the ablation process to record the change in discharges during the surgery. The monitoring will not be used to guide surgery. The probe will be removed with the LITT device at the end of the procedure.
1507623|NCT02913729|Radiation|partial breast irradiation|irradiation
1507624|NCT02913716|Drug|defactinib|Single oral dose of 400 mg [14C]-defactinib
1507625|NCT02913703|Drug|Ghrelin|Boluses of Ghrelin will be given over a 1 minute period at 3 ug/kg. Ensure (2 cans) will also be given.
1507626|NCT02913703|Other|Saline|Boluses of saline will be given over a 1 minute period. Ensure (2 cans) will also be given.
1507627|NCT02913690|Dietary Supplement|Placebo|2 x 150mg capsules daily
1507628|NCT02913690|Dietary Supplement|TRF|2 x 150mg capsules daily
1507629|NCT02913677|Dietary Supplement|nutrition|Feeding was started in the first 48 hours. Fed with 10-15 ml/kg/d MEN for 5 days and than feed volumes were advanced by 20-25 ml/kg/d until 150ml/kg/d feed volume was achieved.
1507630|NCT02913664|Drug|Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine)|"Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine) will be used to reduce SBP<130 mmHg; atorvastatin 80 mg daily will be administered to reduce blood lipid level. Additional antihypertensives may be used if needed.
Intensive Reduction of Vascular Risk Factors (IRVR)"
1507631|NCT02913664|Behavioral|Aerobic Exercise Training|Participants will take part in a supervised, moderate to vigorous aerobic exercise training program for approximately 24 months. This program consists of exercising 3 times per week for about 30 minutes per session at the beginning, and will increase to 4-5 times per week, 40-50 minutes per session over a period of 4-5 months. Exercise frequency, intensity and duration will be maintained at this level during the rest of the study period.
1507632|NCT02913664|Other|Usual Care|Participants will follow their regular doctor's recommendations for blood pressure and lipid control.
1507633|NCT02913664|Behavioral|Stretching Exercise|Participants will perform home-based stretching exercise 3 times per week, gradually increased to 4-5 times per week over a period of 4-5 months, and maintained at this level during the rest of the study period. They will be encouraged to attend monthly stretching exercise classes, which will be led by study staff or exercise trainers.
1507634|NCT02913664|Drug|Atorvastatin|
1507635|NCT02913651|Device|Polysomnography|The polysomnography, for both groups, was performed accordance with standard practice
1507636|NCT02913625|Other|Ultrasound guided retroclavicular block|Ultrasound guided retroclavicular block for forearm or hand surgery
1507637|NCT02913625|Other|Ultrasound guided infraclavicular block|Ultrasound guided infraclavicular block for forearm or hand surgery
1507638|NCT02913612|Drug|0.25% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.25% Timolol Maleate Gel Forming Solution
1507639|NCT02913612|Drug|0.5% Timolol Maleate Gel Forming Solution|50:50 Randomized 0.5% Timolol Maleate Gel Forming Solution
1507640|NCT02913573|Device|Ultrasound|Pectoral nerve block is a regional block administered under ultrasound guidance which blocks the nerves of the thorax and chest areas.
1507641|NCT02913573|Drug|0.25% bupivacaine|Pectoral nerve block is a regional block administered under ultrasound guidance where 15 mL of 0.25% bupivacaine is instilled between the pectoral major and pectoral minor muscles where the lateral and medial pectoralis nerves lie. In a similar manner, 20 mL of 0.25% bupivacaine will be deposited under ultrasound-guidance at the level of the third rib above the serratus anterior muscle.
1507642|NCT02913547|Device|Silk'n HST|Treatment with Silk'n HST on the periorbital area as instructed in the user's manual
1507643|NCT02913534|Radiation|whole brain radiotherapy|
1507644|NCT02913521|Drug|Diclofenac Sodium Gel 1%|
1507645|NCT02913521|Drug|Voltaren Gel|
1507646|NCT02913521|Drug|Placebo|
1507647|NCT02913508|Drug|Vedolizumab intravenous injection|Vedolizumab intravenous injection
1507648|NCT02913508|Drug|Vedolizumab subcutaneous injection|Vedolizumab subcutaneous injection
1507649|NCT02913495|Drug|Vaginal Progesterone|
1507650|NCT02913495|Drug|Intramuscular Progesterone|
1507652|NCT02913469|Drug|Morphine|The patients in group A would be administrated intravenous morphine 5mg
1507653|NCT02913469|Drug|metoclopramide|the patients in group C would be administrated intravenous metoclopramide 10mg
1507654|NCT02913469|Drug|saline|the patients in group D would be administrated intravenous 0.9%normal saline 2mland 0.9%normal saline 2ml.
1507655|NCT02913443|Drug|RO7051790|RO7051790 will be given orally. Treatment will be continued until disease progression/treatment failure, unacceptable toxicity, or study discontinuation.
1507656|NCT02913430|Drug|Fulvestrant|500mg IM Q28 days
1507657|NCT02913430|Drug|Tamoxifen|20mg PO Qdaily
1507658|NCT02913417|Device|SIR-Spheres® Yttrium 90|Patient treatment will consist of three parts: first, selective internal radiation with SIR-Spheres Yttrium-90 microspheres with dosage per package insert/institutional standards; second, concurrent ipilimumab 3mg/kg and nivolumab 1mg/kg every 3 weeks for 4 doses (immunotherapy part 1); then maintenance nivolumab at 3mg/kg every 2 weeks (immunotherapy part 2) until progression or 3 years
1507659|NCT02913417|Drug|ipilimumab|ipilimumab 3mg/kg every 3 weeks x 4
1507660|NCT02913417|Drug|nivolumab|nivolumab 1mg/kg every 3 weeks x 4 then 3mg/kg q 2 weeks
1507661|NCT02913404|Procedure|ACL Reconstruction|standard surgical procedure
1507662|NCT02913404|Procedure|ACL Recon. extra-articular-tenodesis|standard surgical procedure and extra-articular-tenodesis will be used for a randomized portion of participants
1507663|NCT02913404|Device|CT scan|a CT scan of bilateral knees will be taken in order to create 3D bone models
1507664|NCT02913404|Device|Vicon MX - markers|To track the general body movement -- the reflective markers placed throughout the body will be tracked using conventional optical motion tracking equipment
1507665|NCT02913404|Device|Novel's pedar system|To measure pressure distribution under the foot for each participant during the dynamic movement trials.
1507666|NCT02913404|Device|instrumented treadmill|This will collect ground reaction forces at 1000 Hz during each movement trial.
1507667|NCT02913391|Other|Recruitment|After extubation the patient who was randomized to the Recruitment Group will use noninvasive ventilation (NIV) with alveolar recruitment maneuver with PEEP 15 cm H2O and afterwards 20 cm H2O remaining 2 minutes in each, then being maintained in NIV for 30 minutes with pressure support for a tidal volume of 6 ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
1507668|NCT02913391|Other|Control|After extubation the patient who was randomized to the Control Group will use noninvasive ventilation (NIV) for 30 minutes with pressure support for a tidal volume of 6ml/Kg, PEEP 8 cm H2O, Fraction of inspired oxygen for a peripheral arterial Saturation of Oxygen ≥ 95%.
1507673|NCT02913339|Other|mHealth Risk Assessment|Using mobile phone application to calculate CVD risk and to schedule interviews at local government clinics.
1507678|NCT02913300|Drug|Lignocaine 1% concentration solution|
1507679|NCT02913300|Drug|Lignocaine 2% concentration solution|
1507680|NCT02913287|Dietary Supplement|Aquamin/Aquamin MG|Marine-based nutraceutical
1507681|NCT02913287|Other|Maltodextrin Placebo|Maltodextrin Placebo
1507682|NCT02913274|Device|Paclitaxel (Taxol) eluting angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation by a DEB of the same size for 2 minutes.
1507683|NCT02913274|Device|high-pressure angioplasty balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Then dilatation either by a shame balloon or by a DEB balloon of the same size for 2 minutes.
1507684|NCT02913274|Device|low-pressure balloon|Dilatation by a high-pressure conventional angioplasty balloon untill disappearance of the stenosis obstructive area and achievement of technical success. Thenn dilatation by a shame balloon i.e conventional low pression balloon of the same size for 2 minutes.
1507687|NCT02913248|Procedure|Conventional periodontal treatment|Non-surgical periodontal treatment including thorough instruction in self-performed oral hygiene
1507688|NCT02913235|Procedure|Oral hygiene discontinuation group|Discontinuation of regular oral hygiene for 10 days
1507689|NCT02913222|Other|Rehabilitation|Comparison of two rehabilitation approaches
1507690|NCT02913196|Drug|Apalutamide|"Orally available, small molecule, nonsteroidal potent and selective antagonist of the androgen receptor.
Cohort 1 dose: 120 mg QD Cohort 2 dose: 240 mg QD Cohort 3 dose: 180 mg QD"
1507691|NCT02913196|Drug|Abiraterone acetate|"Abiraterone acetate is the prodrug of the active drug abiraterone. Once absorbed after oral administration, abiraterone acetate is rapidly converted to the active form, abiraterone.
Dose: 1000 mg QD"
1507692|NCT02913196|Drug|Docetaxel|"Taxane cytotoxic chemotherapy with demonstrated survival benefit in those with advanced prostate cancer.
Dose: 75 mg/m2 Q3W"
1507693|NCT02913196|Drug|Prednisone|Dose: 5 mg BID
1507694|NCT02913183|Drug|young Fresh Frozen Plasma|Blood plasma from healthy male donors aged 18-30 years old.
1507695|NCT02913183|Drug|old Fresh Frozen Plasma|Blood plasma from healthy male donors aged 40-55 years old.
1507696|NCT02913170|Dietary Supplement|Nattokinase|
1507697|NCT02913170|Dietary Supplement|Placebo|
2002796|NCT01772004|Drug|Avelumab|Avelumab will be administered in study location using a protocol-defined dose escalation scheme until confirmed progression, unacceptable toxicity, or if any criterion for withdrawal from the trial or investigational medicinal product occurs. After determination of the dose and regimen for Expansion Phase, avelumab will be administered to subjects divided into 4 primary cohorts: Non-small cell lung cancer (NSCLC) post platinum doublet, NSCLC first-line, gastric/gastroesophageal junction (GEJ) cancer and metastatic breast cancer (MBC); 8 secondary cohorts: Colorectal cancer (CRC), castrate-resistant prostate cancer (CRPC), melanoma, ovarian cancer, adrenocortical carcinoma (ACC) mesothelioma, urothelial carcinoma, and renal cell carcinoma (RCC); and 4 efficacy expansion cohorts: gastric and GEJ cancer (third line), ovarian cancer (second-line only), urothelial carcinoma, and head and neck squamous cell carcinoma (HNSCC).
1507699|NCT02913131|Drug|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
1507700|NCT02913131|Device|MRI|MRI scan following the pyruvate (13c) injection
1507701|NCT02913118|Drug|Andrographolid Sulfonate Injection (AS Injection)|
1507702|NCT02913118|Drug|Cephalosporin|
1507703|NCT02913118|Drug|Azithromycin, Minocycline or Doxycycline|
1507704|NCT02913118|Drug|Amoxicillin-clavulantic acid|
1507705|NCT02913118|Drug|Fluoroquinolones|
1507706|NCT02913118|Drug|Placebo|
2002797|NCT01766206|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
2002798|NCT01760655|Drug|Fludarabine phosphate|Given IV
1507709|NCT02913092|Behavioral|Electronic sensor and OW education|MDI sensor-generated alerts will be relayed via app platform on participant's phone and responded to (e.g. outreach worker contacts the patient for a missed dose) in real-time to the intervention group. Outreach worker will also assess intervention group participants' need for further asthma education and provide education over the phone
2002799|NCT01760655|Drug|Thiotepa|Given IV
2002800|NCT01760655|Radiation|Total body irradiation|Undergo TBI
1507712|NCT02913066|Other|S-1 concurrent radiotherapy|Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~33 planning target volume times, 60~66 Gray/28~33 Gross tumor volume of primary tumor), synchronous chemotherapy S-1 70 mg/m2 5 to 1 per week, to the end of radiotherapy. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1, 70 mg/m2, 1~ 14 days, 21 days for a cycle.
1507713|NCT02913066|Other|S-1 plus Cisplatin concurrent radiotherapy|Radiotherapy 60~66 Gray/28~33 times (50.4~60 Gray /28~30 planning target volume times, Gross tumor volume of primary tumor60~66 Gray/28~33), synchronous chemotherapy S-1 70 mg/m2 1~ 14 days and 29 to 42 days, plus cisplatin 25mg/m2 1~ 4 days and 29 to 33 days. Two weeks after radiotherapy finish, two cycle adjuvant chemotherapy with S-1 70 mg/m2 1~ 14 days, plus cisplatin 25mg/m2 1~ 4 days, 21 days for a cycle.
1507714|NCT02913053|Behavioral|Aerobic exercise|Patients with mild cognitive impairment will undergo a one-year aerobic exercise program of 3 units of 45 min / week
1507715|NCT02913053|Behavioral|Non-aerobic exercise|Patients with mild cognitive impairment will undergo a one-year stretching and toning (non-aerobic) exercise program of 3 units of 45 min / week
1507716|NCT02913040|Other|High Flow Nasal Cannula|Oxygen delivery through Heated Humidified High Flow Nasal Cannula
1507717|NCT02913040|Other|Low Flow Nasal Prongs|Oxygen delivery through Low Flow Nasal Prongs
1507718|NCT02913027|Other|External Exam|"The pelvic exam will be completed in the following order: external, speculum, bimanual exam in the Standard group. In the Experimental group the pelvic exam will be done with external exam, bimanual exam, then speculum exam."
1507719|NCT02913027|Other|Bimanual Exam|
1507720|NCT02913027|Other|Speculum Exam|
1507721|NCT02913014|Other|No AAD post Ablation.|Subjects will not resume their pre-ablation anti-arrhythmic medications during the 90 following cryo ablation for Atrial Fibrillation
1507722|NCT02913001|Other|Low Glycemic Load Diet|Participants received a diet education on a low glycemic load diet.
1507723|NCT02913001|Other|Usual Eating Plan|Participants received a diet education to continue with their usual eating plan.
2002801|NCT01760655|Biological|Therapeutic allogeneic lymphocytes|Undergo donor lymphocyte infusion
2002802|NCT01760655|Drug|Cyclophosphamide|Given IV
2002803|NCT01760655|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo allogeneic PBSCT
1507728|NCT02912949|Drug|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
1507729|NCT02912936|Dietary Supplement|Ketogenic medium chain triglyceride drink (MCT drink)|10 days supplementation with the MCT drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
1507730|NCT02912936|Dietary Supplement|Placebo|10 days supplementation with the placebo drink. Participants in dose group 1 will be assigned to 10 g per day, those in dose group 2 will be assigned 20 g per day, those in dose group 3 will be assigned 30 g per day, those in dose group 4 will be assigned 40 g per day, and those in dose group 5 will be assigned 50 g per day. The drink will be taken in the morning and evening. Participants will be enrolled 8 per group in ascending order.
1507731|NCT02912923|Other|Visual + Force Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.
Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation."
1507732|NCT02912923|Other|Visual + Force + Game Scores Feedback|"Visual Feedback- Monitor displays two cursors that will represent the participant's hands, the cursors will fill with red ink as the user starts to compensate outside a normal error band. The amount of ink will increase proportionally to the magnitude of trunk compensation.
Force Feedback- Cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. The magnitude of the cue will be proportional to the magnitude of trunk compensation.
Game Scores- Numerical score displayed next to the cursors. The participant will be rewarded with more points when less compensation is exhibited, or with less points when an increased level of compensation is measured."
1507733|NCT02912910|Other|Nifedipine|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
1507734|NCT02912910|Other|Labetalol|patients will be assigned to antihypertensive medications by their physicians in the course of their routine care
1507735|NCT02912897|Other|Cellular therapy with EBV specific autologous CTL infusion|
1507736|NCT02912884|Drug|No cytoreductive vs cytoreductive drugs|No cytoreductive treatment vs cytoreductive drugs (hydroxycarbamide, alpha-interferon, ruxolitinib).
1507737|NCT02912871|Other|MRIgHIFU unilateral subthalamotomy|High Intensity focused ultrasound unilateral subthalamotomy: Unilateral thermolesion in the Subthalamic nucleus performed by High Intensity Focused ultrasound
1507738|NCT02912858|Device|geko plus R-2|"The gekoTM plus R-2 devices (acting on the common peroneal nerve) and IPC devices will be activated for 10mins prior to measuring blood flow.
The sequence of application of IPC and gekoTM plus R-2 devices will be randomly selected with 10 minutes recovery between active therapies."
1507739|NCT02912845|Drug|KamRAB - HRIG|
1507740|NCT02912832|Device|TBDx|The TBDx is an automated platform is based on an Olympus BX41 microscope with a 40 x objective lens, fitted with an Olympus XC 10 colour camera and a movable slide stage, with an attached computer that receives high-quality digital images acquired from the camera. The computer then operates detection algorithms that segment, evaluate, and classify objects of interest in these images which can be stored for subsequent review. The platform is able to integrate an optional 200-slide automated slide loader for high volume settings. The application can capture 100, 300 or more digital fields-of-view and can provide results for positive or negative smears in 5 minutes or less.
1507741|NCT02912819|Other|Open-lung approach|Increase and decrease in airway pressure to open the lung and keep them opened.
1507742|NCT02912806|Procedure|Total Knee Replacement|Primary total knee arthroplasty for knee osteoarthritis
1507743|NCT02912793|Drug|Hydroxypropyl-beta-cyclodextrin|Used in the treatment of Niemann-Pick C1
1507744|NCT02912767|Behavioral|questionnaire|A questionnaire that has been validated by investigators at the Mayo Clinic. The questionnaire has 13 items to assess the rate of patient-reported lymphedema. The questionnaire will be mailed and then followed up with a second mailing after month 1 and a phone call after month 2. Within 3 months of sending the questionnaire a patient will be either considered as a responder vs non-responder. The date of surgery and the date of when the questionnaire is filled out will be captured.
1507745|NCT02912754|Drug|ruxolitinib|ruxolitinib will be added to ibrutinib or 3 out of 5 weeks per cycle
1507746|NCT02912754|Drug|ibrutinib|patients will be taking ibrutinib for at least 6 months and will continue to take it at the same dose and schedule while taking ruxolitinib
1507747|NCT02912741|Drug|Vanish xt Extended Contact Varnish|resin modified glass- ionomer cement varnish applied as a thin layer coating and cured
1507748|NCT02912741|Drug|resin infiltration|low viscous light cure resin applied in layers and cured
1507749|NCT02912728|Behavioral|CGM + Family Behavioral Intervention|use of CGM combined with a CGM focused family behavioral intervention and to assess CGM adherence
1507750|NCT02912728|Device|Standard CGM|use of CGM alone to assess CGM adherence
1507751|NCT02912715|Device|Paclitaxel releasing angioplasty balloon|Paclitaxel releasing angioplasty balloon catheter is advanced through an introducer sheath and tracked over the wire until reaching the target lesion. The balloon can be precisely positioned by means of the radiopaque markers crimped on the inner shaft of the catheter. The catheter is dilated up to its intended diameter by inflating the balloon with a solution containing contrast media, causing a compression of the arterial plaque against the inner lining of the arterial wall and improving blood flow. After balloon inflation, the drug-carrier adheres to the arterial wall and facilitates the drug release to surrounding tissue. As there is no need for sustained release of Paclitaxel after the inflation, the drug carrier dissolves rapidly.
1507752|NCT02912702|Drug|Pegaspargase|2000U/m2 day5
1507753|NCT02912702|Drug|doxorubicin hydrochloride liposome injection|25 mg/m2 day 1
1507754|NCT02912702|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
1507755|NCT02912702|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
1507756|NCT02912702|Drug|Etoposide|150 mg/m2 twice weekly for 2 weeks and then weekly
1507757|NCT02912702|Drug|dexamethasone|initially 10 mg/m2 for 2 weeks followed by 5 mg/m2 for 2 weeks, 2.5 mg/m2 for 2 weeks, 1.25 mg/m2 for one week, and one week of tapering
1507758|NCT02912689|Device|Neurally Adjusted Ventilator Assist|NAVA during Non-invasive ventilation
1507759|NCT02912689|Device|Pressure support ventilation|PS during Non-invasive ventilation
1507760|NCT02912676|Drug|Thioguanine (oral)|Addition of incremental doses of oral Thioguanine to oral daily 6-mercaptopurine and oral weekly methotrexate maintenance therapy of Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma. 6-mercaptopurine is reduced by 33% two weeks before addition of 6-thioguanine, while dose of methotrexate is unchanged. Oral 6-thioguanine is then added at a starting dose of 2.5 mg/m.sq. with dose increments of 2.5 mg/m.sq. at two weeks intervals until a maximum dose of 12.5 mg/m.sq. of 6-thioguanine is given or dose-limiting toxicity occurs.
2002804|NCT01760655|Procedure|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
2002805|NCT01760655|Drug|Tacrolimus|Given IV
1507763|NCT02912650|Drug|Ibuprofen 250 mg / Acetaminophen 500 mg|2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
1507764|NCT02912650|Drug|Ibuprofen 250 mg|2 caplets of Ibuprofen 125 mg
1507765|NCT02912650|Drug|Acetaminophen 650 mg|2 tablets of Acetaminophen 325 mg
1507766|NCT02912650|Drug|Placebo|2 caplets of Placebo
1507767|NCT02912637|Other|Hyperpolarized Xenon MRI|MRI & MRS of lung using inhaled hyperpolarized Xenon as a contrast agent
1507768|NCT02912611|Procedure|Education and Protocol based management|
1507769|NCT02912598|Device|Mallinckrodt™ Endobronchial Tube|
1507770|NCT02912598|Device|Fuji Uniblocker™|
1507771|NCT02912598|Device|ETView VivaSight™-SL+EB|
1507772|NCT02912598|Device|COOK© Arndt Endobronchial Blocker|
1507773|NCT02912585|Biological|Oropharyngeal administration of own mother's colostrum|
1507774|NCT02912585|Other|Oropharyngeal administration of sterile water (placebo)|
1507775|NCT02912585|Biological|Oropharyngeal administration of donor human milk|
1507776|NCT02912572|Drug|Avelumab|Avelumab will be administered intravenously twice per cycle Each Cycle last 28 days Dosage is determine by physician Premedication Antihistamine and Paracetamol will be administered prior to treatment
2002806|NCT01760655|Drug|Mycophenolate mofetil|Given IV
1507783|NCT02912546|Procedure|MRI|A 1.5 Tesla MRI device with a large magnet bore (70 cm) allowing positions change will be used. Two measures will be performed, one in supine position and the other in head down position (-20°). A 3D FSE ASL sequence will be acquired and CBF maps reconstructed. Volume of interest (VOI) will be placed on cortical grey matter (frontal and posterior gyrus), on subcortical deep grey matter (caudate nuclei, thalami) and subcortical white matter (semi oval centers
1507784|NCT02912533|Drug|JR-131|
1507785|NCT02912520|Drug|Anti-Bacterial Agents|administration of any antibiotic substance(s) over the course of 2 weeks
1507786|NCT02912507|Device|Cutera enlighten laser|high-powered, Q-switched 670nm Picosecond laser system indicated for tattoo removal
1507787|NCT02912507|Device|CynoSure PicoSure 755nm laser|high-powered, Q-switched Alexandrite system that delivers laser energy in the 755 nm wavelength and has received FDA clearance (K133364) for tattoo and benign pigmented lesion removal.
1507788|NCT02912494|Drug|JR-131|
1507789|NCT02912494|Drug|Darbepoetin alfa|
1507790|NCT02912481|Procedure|posterior tibial artery|
1507791|NCT02912481|Procedure|radial artery|
1507792|NCT02912481|Procedure|dorsalis pedis artery|
1507796|NCT02912455|Drug|canagliflozin|encapsulated (gelatin capsule).
1507797|NCT02912455|Drug|Placebo (for canagliflozin)|encapsulated (gelatin capsule). The placebo capsule filler is called micro-crystalline cellulose.
1507798|NCT02912429|Device|Patellofemoral Arthroplasty|
1507799|NCT02912416|Dietary Supplement|Probiotics|
1507800|NCT02912416|Dietary Supplement|Placebo|
1507801|NCT02912390|Procedure|Cerclage|Macdonald cerclage placed in standard fashion
1507802|NCT02912390|Other|Expectant management|placed on activity restrictions: no heavy lifting, frequent reclining, and pelvic rest.
1507803|NCT02912377|Biological|Neulasta, B12019|GCSF, Growth Colony Stimulating Factor
1507804|NCT02912364|Drug|Eslicarbazepine|Healthy adults will be titrated onto Eslicarbazepine Acetate (800mg daily) . After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
1507805|NCT02912364|Drug|Carbamazepine|Healthy adults will be titrated onto Carbamazepine (400 mg bid). After four weeks maintenance they will be tapered off and enter washout period, then crossed over to 2nd drug.
1507806|NCT02912351|Other|Patient record review, Radiographs, and questionaires.|KSS-Objective Knee Scores, KSS Subsets, Radiographs and Patient Satisfaction
1507807|NCT02912338|Behavioral|Resistant Training|
1507808|NCT02912338|Other|Control Group|
1507809|NCT02912325|Dietary Supplement|Daily administration: 2 tablets FaseMETS a day|Treatment with FaseMETS for 6 consecutive months in lowering serum lipids and glucose in subjects with Metabolic Syndrome
1507810|NCT02912312|Radiation|Radiation Therapy|"Group 1 - Shorter Regional Nodal Irradiation (RNI): Participants receive 40 Gy in 15 fractions to the breast or chest wall and 37.5 Gy in 15 fractions to the undissected lymphatics. Radiation delivered 5 consecutive days a week. Participants also receive additional 'boost' dose to either the chest wall flaps (mastectomy patients) or tumor resection bed (segmental mastectomy patients) starting on day after RNI.
Group 2 - Standard Regional Nodal Irradiation (RNI): Participants receive 50 Gy in 25 fractions to the breast or chest wall and 45 Gy in 25 fractions to the undissected lymphatics. Radiation delivered 5 consecutive days a week. Participants also receive additional 'boost' dose to either the chest wall flaps (mastectomy patients) or tumor resection bed (segmental mastectomy patients) starting on day after RNI."
1507811|NCT02912312|Behavioral|Questionnaires|Questionnaires regarding general health and arm function completed at baseline, and at at months 3, 6, 12, 18, 24, 66, and 126 months after radiation therapy.
1507812|NCT02912299|Procedure|Skin biopsies|2 3mm skin biopsies will be taken
1507813|NCT02912299|Other|Blood and urine analysis|Measurement of sodium, potassium and kidneyfunction in blood and urine.
1507814|NCT02912299|Other|Blood collection for RNA-investigation|A blood sample that, in case of relevant differences between groups, could be used for RNA-profiling.
1507815|NCT02912286|Device|conventional needle irrigation|conventional side-vented syringe used to deliver irrigant in root canal treatment
1507816|NCT02912286|Device|passive ultrasonic irrigation|ultrasonic tip (IrriSafe) activate the irrigant after mechanical preparation in root canal treatment
1511125|NCT02885558|Drug|L-Type|8 weeks treatment with either nifedipine
1507817|NCT02912286|Device|sonic irrigation|vibringe system is a sonic device that deliver and agitate the irrigant
1507818|NCT02912273|Other|Baseline Participant Assessment|"Section 1 contains demographic questions
Section 2 contains daily activity questions with multiple choice answers, multiple physical function questions, and if the participants has fallen and how many falls have occurred in the last 6 months
Section 3 has the participant list all medication
Section 4 contains several questions about participant health (lists of illnesses and indicate if illness interferes with their activities)
Section 5 contains several questions about participant fall concerns with answers ranging from 1=Not at all to 4=Very
Section 6 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
1507819|NCT02912273|Other|Baseline Healthcare Provider Assessment|"Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)
Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.
Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
1507820|NCT02912273|Other|Follow-up Participant Assessment|"Section 1 contains multiple choice questions about daily actives and several physical function questions
Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions
Section 3 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
1507821|NCT02912273|Other|Follow-up Healthcare Provider Assessment|"Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.
Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
1507822|NCT02912273|Other|End-of-study Participant Assessment|"Section 1 contains multiple choice questions about daily actives and several physical function questions
Section 2 asks the participants how many medications they take on a daily basis, indicate any medication for depression, anxiety, nausea , and other stomach conditions
Section 3 contains multiple questions about the participant's concern about falling with answers ranging from 1=Not at all to 4=Very
Section 4 contains multiple questions asking about emotional distress/depression, fatigue, pain interference, pain intensity, and numbness and tingling"
1507823|NCT02912273|Other|End-of-study Healthcare Provider Assessment|"Cognition: Orientation-Memory-Concentration Test which contains 6 questions that the provider will ask the participant. Form items 1-3, the response is either correct (score 0) or incorrect (score 1). For items 4-6, subtract one point for each error. Total score of 11 or greater indicates cognitive impairment (maximum score =28)
Trail Making Test Part B - consists of 25 circles distributed over a sheet of paper. The circles include both numbers and letters; the participants draws lines to connect the circles in an ascending pattern, but with the added task of alternating between the numbers and letter. The test is timed.
Timed Up and Go - the provider measures the time in seconds it takes for the participant to stand up from a standard arm chair, walk a distance of 3 meters, turn, walk back to the chair, and sit down again."
1507824|NCT02912260|Drug|MGL-3196|
1507825|NCT02912260|Drug|Placebo|
1507826|NCT02912247|Drug|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection|human recombinant anti-tumor necrosis factor alpha monoclonal antibody injection, 40mg,subcutaneous injection,once
1507827|NCT02912247|Drug|adalimumab|adalimumab, 40mg,subcutaneous injection,once
1507828|NCT02912234|Drug|Apixaban|Multiple-dose clarithromycin and single-dose Apixaban
1507829|NCT02912234|Drug|Clarithromycin|Multiple-dose clarithromycin and single-dose Apixaban
1507830|NCT02912221|Other|Incentive|Both groups will receive fitbits to track their physical activity, however one arm of the study may receive additional incentives to achieve their step count goal.
1507831|NCT02912208|Drug|Eltrombopag/Revolade|Eltrombopag 50 mg once daily has been selected as the starting dose for this study. Thereafter, dependent on platelet response the dose of study medication can be increased by 50 mg every 2 weeks, up to a maximum dose of 300 mg once daily (150 mg in subjects of East Asian ethnicity).
1507832|NCT02912208|Other|Placebo|The administration is the same of eltrombopag
1507833|NCT02912195|Drug|Intravenous lidocaine|Intravenous lidocaine drip over 10 minutes followed by intravenous lidocaine drip over 50 minutes
1507834|NCT02912195|Drug|Intravenous morphine|Emergency department provider chooses appropriate dose of intravenous morphine
1507835|NCT02912182|Drug|Betamethasone|Betamethasone intravenous
1507836|NCT02912182|Drug|Placebo|Placebo intravenous NaCl intravenous administration Placebo tablets
1507837|NCT02912182|Drug|Prednisolone|Oral tablets
1507838|NCT02912169|Procedure|Liposuction under local anesthesia|Procedure will be performed via liposuction to harvest Adipose-derived stromal vascular fraction cells.
1507839|NCT02912169|Biological|Infusion of AD-SVF via IV and Intranasal|IV and Intranasal Infusion of isolated AD-SVF
1507840|NCT02912156|Drug|Vaway FC Tablets 200mg (Voriconazole)|
1507841|NCT02912156|Drug|VFEND FC Tablets 200mg (Voriconazole)|
1507842|NCT02912143|Other|documentation only|
1507843|NCT02912130|Dietary Supplement|Protein Supplementation|1.2-1.5g/kg/body weight per day
1507844|NCT02912130|Other|Aerobic Exercise|30-60 minutes per week of moderate intensity exercise
1507845|NCT02912130|Other|Resistance Exercise|60 minutes per week of progressive resistance training
1507846|NCT02912104|Biological|human amniotic epithelial cells (hAECs) transplantation|hAECs are prepared and cultured using GMP(Good Manufacturing Practice, GMP) rules, 2×107 hAEC in 5ml sample is separately injected into ovarian tissue by bilateral ovarian artery infusion.
1507847|NCT02912078|Other|Pocket-warming|Pocket-warming of epidural medication
1508981|NCT02902913|Other|D2i0.5|Oleocanthal provided in a 1:2 ratio compared to oleacein
1507848|NCT02912078|Other|Standard of Care Labor Epidural|Labor epidural medication administered per standard of care; no pocket warming.
1507849|NCT02912052|Drug|Peri-operative chemotherapy|Patients receive 2 cycles of chemotherapy before surgery,and contniue to receive another 4 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
1507850|NCT02912052|Drug|postoperative chemotherapy|Patients receive 6 cycles of chemotherapy 21-28 days later after surgery.The chemotherapy regime is XELOX(oxaliplatin130mg/m2 ivd d1 + Capecitabine1000mg/m2 po bid d1-14, 21d/cycle)
1507851|NCT02912039|Device|TetraGraph|A sequence of 3 sets of Train of four (TOF) stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
1507852|NCT02912039|Device|TOF Watch|A sequence of 3 sets of TOF stimuli delivered (every 20 sec) at the pre-determined current amplitude (for instance, 40 mA, then 30 mA, then 50 mA, then 20 mA).
1507853|NCT02912026|Drug|IV F901318|Metabolic profile AUC 0 to infinity
1507854|NCT02912026|Drug|Oral F901318|Metabolic profile AUC 0 to infinity
1507855|NCT02912013|Device|Me Mini|Home use hair removal device
1507856|NCT02912000|Behavioral|TEACH intervention|The TEACH intervention screens family for three modifiable behaviors ahead of the clinical encounter: parental tobacco use, children consumption of sugar-sweetened beverages and child dental health. The information from the screening is then shared with clinicians.
1507857|NCT02911987|Other|high intensity training (HIT) program|The participants are randomly divided through use of sealed envelopes into four groups that all follow high intensity training (HIT) programs. Each training group follows of a 12 week program (2x/week, 2h). All training will be conducted under the guidance of expert therapists.
1507858|NCT02911987|Other|moderate intensity training (MIT) exercise therapy|MIT exercise consisting of a combination of previous programs (cardiovascular fitness, muscular fitness and general training specific trunk muscles) (the 'MIT' group).
1507859|NCT02911974|Device|Acquire EUS Biopsy Device|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
1507860|NCT02911974|Device|Expect EUS Aspiration Needle|1. At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or Expect EUS Aspiration Needle.
1507861|NCT02911961|Drug|Acetaminophen|1 gram acetaminophen 4 times a day with at least 4 hour intervals between doses for the 3 days prior to the embolization procedure.
1507862|NCT02911948|Drug|Insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily
1507863|NCT02911948|Drug|Insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily
1507864|NCT02911935|Drug|Oral azithromycin|Oral azithromycin 10mg/kg/day for 7 days; then oral azithromycin 5mg/kg/day for 7 additional days
1507865|NCT02911935|Drug|Placebo|Placebo suspension
1507866|NCT02911922|Device|Endorectal Balloon|"Endorectal balloon (ERB): Immobilization device manually placed into the rectum prior to radiation treatment planning CT and daily treatment delivery, to immobilize the prostate and reduce prostate motion.
Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
1507867|NCT02911922|Device|Rectal Spacer|"Rectal spacer (RS): Biodegradable gel that is transperineally injected between the rectum and prostate under transrectal ultrasound guidance, to increase physical distance and thereby reduce radiation dose to the anterior rectal wall. The spacer begins to biodegrade in 2-3 months, and is fully absorbed within 6 months.
Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days."
1507868|NCT02911922|Radiation|Radiation therapy|Patients on each arm will receive 5 fractions of radiation, 7.25Gy per fraction, delivered 2-3 times a week (every other day excluding weekends), to total dose of 36.25 Gy. The total duration of treatment will be no shorter than 10 days.
2002810|NCT01742286|Drug|LDK378|LDK378 is a capsule taken by mouth, contents can be mixed with food for pediatric patients or mixed with water and given via NG/G tube
1507871|NCT02911883|Device|Optical Coherence Tomography Angiography|
1507872|NCT02911870|Drug|SNAC|Oral administration
1507873|NCT02911870|Drug|Placebo|Oral administration
1507874|NCT02911870|Drug|Moxifloxacin|Oral administration
1507876|NCT02911844|Drug|Fulvestrant|Fulvestrant 500 mg administered intramuscularly into the buttocks slowly as two 5 mL injections, one in each buttock, on days 0, 14, 28 and 56. Fulvestrant 250 mg (one 5 mL injection) will be used in patients with Child-Pugh Class B liver disease.
1507877|NCT02911831|Drug|Tranexamic Acid|
1507878|NCT02911831|Drug|Sodium Chloride|
1507879|NCT02911818|Behavioral|CMS-recommended lifestyle counseling|21 brief (15 minute) lifestyle counseling visits provided by a physician, nurse practitioner, or registered dietitian.
1507880|NCT02911818|Drug|Liraglutide 3.0mg|Liraglutide is a once-daily self-administered, subcutaneous (beneath the skin) injection.
1507881|NCT02911818|Other|Portion-Controlled Diet|A 1000-1200 kcal/day portion-controlled diet.
1507882|NCT02911805|Behavioral|Aerobic exercise|Stationary bicycle ergometer @ 50-80% of maximal heart rate reserve for 20 minutes to 45 minutes
1507883|NCT02911805|Behavioral|Balance exercise|Instructor-led exercises done in a group setting for strengthening, balance, flexibility
1507884|NCT02911792|Drug|Dapagliflozin|SGLT2 inhibitor
1507885|NCT02911792|Drug|Metformin|Oral diabetes medicine that helps control blood sugar levels.
1507886|NCT02911779|Procedure|change of medilateral angle line during crowning of the head|change of medilateral angle line during crowning of the head
2002811|NCT01732107|Drug|Dovitinib|Dovitinib will be administered 500mg orally in a 5 days on, 2 days off dosing schedule. Day 12 assessments are intended to be performed on the last dosing day of the 2nd week in cycle 1 and cycle 2 and day 26 assessments are intended to be performed on the last dosing day of the 4th week in cycle 1 and cycle 2.
2002812|NCT01716715|Drug|Cabozantinib S-malate|Given PO
2002813|NCT01716715|Other|Laboratory Biomarker Analysis|Correlative studies
1507894|NCT02911727|Procedure|Fast-track discharge|As described above
2002814|NCT01716715|Drug|Paclitaxel|Given IV
2002815|NCT01709539|Procedure|Diagnostiskt Centrum|Patients who are suspected of having cancer after investigation at the primary care center will be referred to Diagnostiskt Centrum. Each patient who is referred to Diagnostiskt Centrum will undergo the following: (1) clinical chemistry/microbiology tests; (2) medical history; (3) objective clinical examination; and (4) taking of blood samples for analysis of biomarkers. If necessary, patients will also undergo the following: (5) additional laboratory tests; (6) biopsy; (7) X-ray of painful joints; (8) CT scan of the neck, thorax, abdomen, and/or pelvis; (9) mammography and gynecological examination; (10); gastroscopy and/or colonoscopy; and (11) further investigation (e.g., PET-CT scan).
2002816|NCT01696474|Drug|Bortezomib|
1507900|NCT02911675|Device|EVD/IVC and the IPM/Camino|This is an interventional device study utilizing the EVD/IVC and the IPM/Camino to provide and evaluate data for optimized treatment for the control of elevated ICP and CCP in patients with severe TBI.
1507901|NCT02911662|Drug|Cephalexin|Cephalexin will be prescribed for women with a positive urine culture but no symptoms of urinary tract infection.
1507902|NCT02911662|Drug|Nitrofurantoin|Macrobid will be prescribed for women allergic to penicillin with a positive urine culture but no symptoms of urinary tract infection.
1507903|NCT02911649|Other|Wearable Technology - Garmin Vivosmart|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
1507904|NCT02911649|Other|Online Educational Group|A workshop leader will lead participants through an educational workshop and group discussion on topics related to reducing sedentary behaviour
1507905|NCT02911649|Other|Wearable Technology - FitBit Alta|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
1507906|NCT02911649|Other|Wearable Technology - Polar Loop 2|Wearable devices will be used to show participants their activity levels daily, as well as weekly overview of their activity levels.
1507907|NCT02911636|Radiation|Pelvic SABR with intra-prostatic SABR|described elsewhere
2002817|NCT01695239|Drug|Ixekizumab|Administered SC
1507909|NCT02911610|Device|arthroscopy + volar plate|surgery of wrist fractures with volar plate and added arthroscopy
1507910|NCT02911610|Device|Volar plate|surgery of wrist fractures with volar plate
1507911|NCT02911597|Drug|Naltrexone|adding naltrexone (or placebo) to a ketamine infusion to potentially block the effects of ketamine as an anti depressant.
1507912|NCT02911584|Procedure|Laparoscopic procedure|
1507913|NCT02911571|Device|MMprofiler SKY92 gene signature|"MMprofiler is a gene expression assay system for detection of the presence (or absence) of the SKY92 high-risk gene signature to aid in the determination of the Multiple Myeloma patient's prognosis"
1507914|NCT02911532|Procedure|Tissue engineering conjunctiva transplantation|During the operation,transplant the tissue engineering conjunctiva to the conjunctiva loss position
1507915|NCT02911519|Other|Brief Group Psychoeducation|First session: describe the clinical manifestations of schizophrenia, deny myths, and inform on the biological nature of the disorder. Second session: provide updated information regarding pharmacological treatment, their side effects and the importance of adherence to treatment. Third session: Achieving recognition of personal responsibility for the lifestyle, routine, physical care and the risk of addiction; awareness of the importance of self-monitoring of symptoms and the development of cognitive, behavioral and emotional strategies. Fourth Session: To recognize the role of family members in the treatment, the problem of expressed emotions and communication in times of crisis. Fifth Session: To know the rights and duties of patients and their families in the current health care system.
1507988|NCT02910843|Radiation|Radiotherapy|Monday through Friday for 5 weeks and 3 days (d1-38) starting on day 1 (daily fraction 1.8 Gy, final dose 50.4 Gy).
1507989|NCT02910843|Procedure|Surgery|6 weeks (± 1 week) after radio-chemotherapy (RCT) has been completed.
1507990|NCT02910817|Drug|Metformin|The metformin-treated group received metformin (1000 mg per day) with the start of controlled ovarian stimulation (COH) until the day of the pregnancy check.
2002818|NCT01695239|Drug|Placebo|Administered SC
2002819|NCT01695239|Drug|Adalimumab|Administered SC
1507916|NCT02911519|Other|Treatment as Usual|The patients in both arms of the intervention will receive this type of attention. The TAU is the psychiatric care that patients with schizophrenia usually receive in the clinic. This is done in consultation of 30 minutes, in which the psychiatrist evaluates the clinical condition of the patient and psychosocial factors that may be affecting, prescribes drugs according to protocols and clinical care and answers questions about the disorder. In the consultation a brochure with information is given about schizophrenia. The frequency of consultations varies depending on severity of symptoms usually split between one and six months.
1507917|NCT02911506|Other|Polysomnography|
1507918|NCT02911493|Behavioral|Reducing Sedentary Behavior|The experimental group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to reduce sedentary time.
1507919|NCT02911493|Behavioral|Reducing Sedentary Behavior|The intervention group will use the activPAL data to see how sedentary they have been throughout a week where as the control group will not see this data until the end of the study.
1507920|NCT02911493|Behavioral|Physical Activity Group|The Active Comparative group will wear an activPAL and have counseling sessions that use the Health Belief Model and Motivational Interviewing strategies to increase exercise time.
1507921|NCT02911480|Drug|Oxytocin|
1507922|NCT02911467|Drug|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
1507923|NCT02911467|Device|MRI|MRI scan following the Pyruvate injection
1507924|NCT02911454|Other|Infant formula|
1507925|NCT02911441|Behavioral|Cognitive Behavioral Therapy|
1507926|NCT02911428|Procedure|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
1507927|NCT02911415|Procedure|blood sampling collection|It is an observational study; no interventions are planned in the course of common clinical practices during the study period; investigated therapeutic agents or special methods of examination will not be used in the study, except the blood sampling procedure and clinical observation specified in this Protocol.
1507928|NCT02911402|Other|sea sickness questionnaires|
1507929|NCT02911389|Other|Home PT via web-based platform|
1507930|NCT02911389|Other|Home PT via paper manual|
1507931|NCT02911389|Other|outpatient PT|
1507932|NCT02911363|Device|Captivator cassette|The Captivator tissue cassette has an effect on the preservation of tissue histology.
1507933|NCT02911363|Other|Standard of Care|The specimen will be processed following the College of American Pathology Standards.
1507934|NCT02911350|Drug|Hormone Suppressors|
1507935|NCT02911350|Drug|Paclitaxel|
1507936|NCT02911350|Radiation|Radiation Therapy|
1507937|NCT02911337|Dietary Supplement|lifestyle modification|Subjects will be given meal replacements (shakes and bars) to be consumed twice per day for 8 weeks, and then once per day for an additional 3 weeks, and then transitioned to a structured diet.
1507938|NCT02911324|Drug|Nabilone|"Nabilone is a synthetic cannabinoid that is thought to be a Cannabinoid receptor type 1 (CB 1) agonist. It acts on the brain's endocannabinoid system, which has been hypothesized to play a role in OCD."
1507939|NCT02911324|Behavioral|Exposure and Response Prevention Therapy|Exposure and Response Prevention Therapy (EX/RP) is a type of Cognitive-Behavioral Therapy for OCD that involves intentionally confronting situations that trigger obsessional distress while refraining from doing compulsions.
2002820|NCT01676363|Drug|Diflunisal|Open-label diflunisal 500 mg twice daily for 4 weeks
2002821|NCT01663857|Drug|LY2228820|Administered Orally
1507942|NCT02911298|Drug|Metronidazole Benzoate gastro-resistant capsule with radio-labelled mucoadhesive formulation|
1507943|NCT02911298|Drug|Metronidazole Benzoate gastro-resistant capsule with radio-labelled non-mucoadhesive formulation|
1507944|NCT02911285|Drug|N-acetylcysteine|1200mg bid (2400mg/day)
1507945|NCT02911285|Drug|Placebo|Placebo pills bid
1507946|NCT02911285|Behavioral|Cognitive behavioral therapy|CBT for AUD/SUD, one hour/once a week
1507947|NCT02911272|Device|2-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 2-hour from the alert line
1507948|NCT02911272|Drug|Oxytocin|Oxytocin augmentation of slow labour progress at the respective action line location on the WHO modified partograph
1507949|NCT02911272|Procedure|Forewater amniotomy|Forewater amniotomy at the vaginal examination confirming active phase labour
1507950|NCT02911272|Device|4-hour action line on WHO modified partograph|observations and findings in a woman in labour are recorded on this device (WHO modified partograph) in a graphic format in which the action line is located 4-hour from the alert line
1507951|NCT02911259|Device|Suction is set to -2 cmH2O|Post-operative suction is set to -2 cmH2O (intervention).
1507952|NCT02911259|Device|Suction is set to -10 cmH2O|Post-operative suction is set to -10 cmH2O (standard treatment).
1507953|NCT02911233|Biological|Thromboelastograpgy|
1507954|NCT02911220|Genetic|demonstration of genetic mutations causing non-atopic asthma|recruitment of familial forms of non-atopic asthma (patients with non-atopic asthma and their relatives) to perform genetic analysis of exome sequencing
1507955|NCT02911207|Behavioral|patients choose one creative activity and one physical activity|taking part in 2 activities (a creative one and a physical one)
1507956|NCT02911194|Dietary Supplement|a2 milk|replace all milk with a2 milk
1507957|NCT02911194|Dietary Supplement|a1 containing milk|use a1 containing milk
1507958|NCT02911181|Other|BIVA measurement|
1507991|NCT02910804|Drug|68Ga-BBN-IRDye800CW|
1507992|NCT02910804|Device|PET/NIRF|
1507993|NCT02910804|Procedure|PET/NIR fluorescent imaging-guided surgery|
1507994|NCT02910791|Procedure|blood draw/skin biopsy|
1508032|NCT02910635|Drug|Moxifloxacin|Moxifloxacin Hydrochloride 400 mg tablet administered orally, Single Dose
2002822|NCT01663857|Drug|Carboplatin|Administered IV
2002823|NCT01663857|Drug|Placebo|Administered Orally
2002824|NCT01663857|Drug|Gemcitabine|Administered IV
1507959|NCT02911168|Procedure|Proximal Intercostal Block|After identifying the correct intercostal space, the ultrasound probe will be moved medially to identify the transverse processes, then again laterally from the transverse processes to rest over the ribs so as to obtain the best view of ribs and pleura. A 10cm, 21G needle will be inserted in-plane at the caudal border of the probe. An attempt will be made to keep the needle tip and the target injection position (just under the internal intercostal membrane (IIM)) in view. Correct needle tip placement will be demonstrated by depression of the pleura/endothoracic fascia upon local anesthetic injection and by lack of retrograde spread of LA over the muscles or the ribs. The LA will be injected in 4 cc aliquots after negative aspiration of air, CSF and blood.
1507960|NCT02911168|Procedure|Paravertebral Block|After identifying the correct intercostal space, the ultrasound probe will be placed between the adjacent transverse processes in a longitudinal/parasagittal plane measuring 2.5cm from the midline. The best possible view of the transverse processes, the superior costotransverse ligament and pleura will be obtained. An attempt will be made to keep the needle tip and the target injection position (immediately beneath the costotransverse ligament) in view. Correct placement of the needle tip will be demonstrated by depression of the pleura upon injection of local anesthetic and by lack of retrograde spread of LA over the muscles or transverse processes. The LA will be injected in 4 cc aliquots after confirming negative aspiration of air, CSF and blood.
2002825|NCT01657669|Drug|Intravitreal Aflibercept injection|Intravitreal Aflibercept injection 2.0 mg dosed every 4 weeks (monthly) for the first 3 months followed by 2.0 mg (0.05mL) via intravitreal injection once every 8 weeks (2 months). Dosing at monthly intervals is allowed if needed in the opinion of the investigator based on presence of fluid on OCT and/or a decrease in visual acuity of 5 letters or more from the best previous visit.
2002826|NCT01656538|Drug|Paclitaxel|
2002827|NCT01656538|Drug|Reolysin|
2002828|NCT01655836|Radiation|Brachytherapy|Undergo high dose rate brachytherapy
2002829|NCT01655836|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
2002830|NCT01655836|Procedure|Quality-of-life assessment|Ancillary studies
2002831|NCT01655836|Other|Questionnaire administration|Ancillary studies
1507970|NCT02911090|Other|Data Registry|Data Registry
1507971|NCT02911064|Behavioral|Questionnaires|Questionnaires completed before and after inpatient rehabilitation. Questionnaires ask about daily living activity performance, expectation of how well daily living activities will be performed after completion of inpatient rehabilitation, symptoms experienced in the past 24 hours, and physical, functional, social, and emotional well-being. These questionnaires should take about 15 minutes total to complete.
1507972|NCT02911051|Device|Actreen Hydrolite Cath|Depending of the use of the self catheterized patient could be 4 to 6 Actreen Hydrolite Cath per day
1507973|NCT02910986|Behavioral|Written educational brochure|Written educational brochure about breast density
1507974|NCT02910986|Behavioral|Promotora interaction|Promotora education about breast density
1507975|NCT02910973|Device|Vagus Nerve Stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch of the vagus nerve.
1507976|NCT02910973|Device|Sham Vagus Nerve Stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes. Blood will be withdrawn prior to stimulation and 1 hour following the stimulation. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
1507977|NCT02910960|Device|Acquire EUS Biopsy Device|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
1507978|NCT02910960|Device|SharkCore Biopsy System|At EUS, once the pancreatic mass is identified, patients will be randomized to undergo sampling using the 22G Acquire EUS Biopsy Device or SharkCore Biopsy System.
1507979|NCT02910947|Procedure|ultrasound guided quadratus lumborum or Transversus Abdominis plane block|The intervention consists of giving ultrasound guided local anaesthetic (0.125% bupivacaine ) in the quadratus lumborum plane or the transversus abdominis plane after randomization. These planes and technique for these procedures are well described in literature.
1507980|NCT02910934|Other|Actellic CS|Indoor residual spray with Actellic CS
1507981|NCT02910895|Other|tumor biopsy|biopsy
1507982|NCT02910882|Drug|PEGylated Recombinant Human Hyaluronidase (PEGPH20)|"PEGPH20 Dosing (Cohort I, Dose Escalation, First 3 patients): Administered as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute:
Dose level 1 - 1 mcg/kg; Dose level 2 - 1.6 mcg/kg; Dose level 3 - 3 mcg/kg.
PEGPH20 Dosing (Cohort II, Patients 4-10): Administered at a dose of 3 mcg/kg as an IV infusion over 10 minutes (+/- 2 Minutes), approximately 1mL/minute.
Dosing Schedule: Twice per week beginning Day #1 for 8 doses, then weekly until end of radiotherapy."
1507983|NCT02910882|Drug|Gemcitabine|"Gemcitabine Dosing: Administered at a dose of 600 mg/m2 as an IV infusion over 30 - 60 minutes with standard antiemetic pre-medication. If administered on PEGPH20 day, Gemcitabine will be infused 2-4 Hours after PEGPH20 infusion is completed.
Dosing Schedule: Weekly, beginning Day #2, per standard regimen."
1507984|NCT02910882|Radiation|Radiation|Radiotherapy, beginning Day #2, delivered at 1.8 Gy per fraction, 5 fractions per week (Monday - Friday), until a total dose of 50.4 to 54 Gy for up to 6 Weeks.
1507985|NCT02910869|Genetic|Pathway Genomics FIT test|
1507986|NCT02910843|Drug|Regorafenib|"Regorafenib dosel level 1-3: day 1 to 14 and day 22 to 35 (2 weeks on 1 week off, 2 weeks on, including Saturday and Sunday) at a daily dose according to the escalation table.
Regorafenib dosel level -1: day 1 to 5, day 8 to 12, day 22 to 26 and day 29 to 33 (5 days on and 2 days off during week 1, 2, 4 and 5; week 3 off) at a daily dose according to the escalation table."
1507987|NCT02910843|Drug|Capecitabine|• Capecitabine: day 1 to 38 (5 weeks and 3 days, including Saturday and Sunday) according to dose escalation table. The intake stops in the evening of the last day of RT.
1507995|NCT02910778|Drug|Atorvastatin|Subjects will receive 80 mg atorvastatin once daily for 14 days (until study day 15). On study day 15, 80 mg atorvastatin in combination with a loading dose of 180 mg ticagrelor will be administered.
1507996|NCT02910778|Drug|Placebo|Subjects will receive placebo once daily for 14 days (until study day 15). On study day 15, placebo in combination with a loading dose of 180 mg ticagrelor will be administered.
1507997|NCT02910778|Drug|Ticagrelor|
1507998|NCT02910765|Drug|methylene blue|
1507999|NCT02910765|Drug|ozone|
1508000|NCT02910765|Other|saline infusion|
1508001|NCT02910765|Other|oxygen|
1508002|NCT02910752|Drug|CLAM+PBSC|Cladribine 5mg/m2 + cytarabine 1.5g/m2 + mitoxantrone 10mg/m2 from D1 to D5
1508003|NCT02910739|Drug|MK-8931|MK-8931 40 mg
1508004|NCT02910726|Procedure|Sentinel Lymph Node Biopsy|
1508005|NCT02910726|Drug|indocyanine green (ICG)|
1508006|NCT02909946|Behavioral|Multi-modal Infection Control Program|"Standard precautions and hand hygiene for care of all residents. Enhanced barrier precautions including hand hygiene, glove use, and gown use for HCW when providing ADL assistance for residents at highest-risk (caregiver intervention).
Hand hygiene education to residents and families (resident-level intervention).
Standardized bathing practices including using chlorhexidine-based cloths to reduce resident MDRO colonization (resident-level intervention).
Standardized environmental protocol and education to reduce contamination on inanimate objects and surfaces (environmental intervention).
Feedback monthly of facility-level microbial data and new MDRO acquisition rates to infection control practitioners, HCWs, and facility leadership (facility intervention)."
1508007|NCT02909933|Drug|liraglutide|
1508008|NCT02909933|Drug|metformin and liraglutide|
1508009|NCT02909920|Other|Telerehabilitation|Initial Videoconference following telerehabilitation programs self-workout exercise with video support.
1508010|NCT02909920|Other|Traditional Physiotherapy|Traditional Physiotherapy receives assistance in a physiotherapy center with personalized therapy consisting of 1 to 1 with a physical therapist (Manual Therapy, home exercise programs and other physiotherapy techniques).
1508011|NCT02909907|Drug|Botulinum toxin|Botulinum injections into dominant upper extremity using protocol outlined above.
1508012|NCT02909907|Other|Placebo|Placebo injections in extensor carpi radialis (ECR) and extensor carpi ulnaris (ECU) per protocol outlined above
1508013|NCT02909894|Other|Prolonged Sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow investigators to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. Following this, a lunch meal will be provided and investigators will continue taking blood samples and blood pressure at 30, 60, 120 and 180 minutes after this lunch meal. In total, 10 blood samples will be taken over the 7 ½ hour testing period. There will also be a cognitive test in the morning and afternoon.
1508014|NCT02909894|Other|Light arm ergometry breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of light intensity arm ergometry on a desktop arm ergometer every 30 minutes following breakfast and lunch. In total they will do 12 five minute arm ergometry breaks throughout the 7 ½ hour test period (60 minutes of arm ergometry in total). In total 10 blood samples will be taken on the day.
1508015|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 0 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 0 g/min during a 150 min cycling exercise
1508016|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 1 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1 g/min during a 150 min cycling exercise
1508017|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 1.5 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 1.5 g/min during a 150 min cycling exercise
1508018|NCT02909881|Dietary Supplement|Use of PhytoSpherix at 2 g/min|PhytoSpherix (Sweet-corn derived sugar) will be fed at 2 g/min during a 150 min cycling exercise
1508019|NCT02909881|Behavioral|Cycling exercise|Male endurance athletes will complete a cycling exercise for 150 min at 50% of their respective maximum wattage
1508020|NCT02909868|Device|BackBeat-PHC|A conductance catheter will be used to obtain PV loops prior to a Moderato pacemaker implant procedure.
1508021|NCT02909855|Other|No intervention|Participants in this study will not receive any interventions as part of the study.
1508022|NCT02909842|Dietary Supplement|Drinking fermented milk|Drinking fermented milk containing Lactobacillus paracasei (IMULUS)
1508023|NCT02909842|Dietary Supplement|placebo|Acidified placebo milk with similar physical characteristics to the yoghurt drink
1508024|NCT02909842|Biological|Seasonal Influenza Vaccine (H1N1, H3N2, PhuB)|Intramuscular injection of a single shot of influenza vaccine
1508025|NCT02910700|Drug|Nivolumab|3 mg/kg by vein on Days 1 and 15 of a 28 day cycle.
1508026|NCT02910700|Drug|Dabrafenib|150 mg by mouth twice a day Days 1-28 of a 28 day cycle.
1508027|NCT02910700|Drug|Trametinib|2 mg by mouth on Days 1-28 of a 28 day cycles.
1508028|NCT02910687|Other|This is an observational study|
1508029|NCT02910661|Other|Focus Group|Concurrently at each site, an experienced facilitator, having no direct affiliation with the clinical team, will use standardized stakeholder-specific, semi-structured scripts (designed with patient and parent collaborators) to conduct the patient, parent, and HCP focus groups. The TAKE-IT intervention will be described, and Simplemed e-pillbox shown, to all focus groups. Questions posed to the patient and parent focus groups will focus on 2 themes: the intervention and electronic monitoring. Example stakeholder-specific scripts to guide the discussions are appended. Each focus group will last ~90 min. and be audio-recorded. An observer will take field notes.
1508030|NCT02910648|Behavioral|Modified Go/No-Go Task|Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
1508031|NCT02910635|Drug|Volanesorsen|ISIS 304801 is supplied as 200mg of volanesorsen with 1.0mL of solution per vial
1508033|NCT02910635|Drug|Placebo|
1508034|NCT02910622|Other|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
1508035|NCT02910609|Device|Echocardiography|Echocardiography is a kind of ultrasound test that shows the inner structure and functions of the heart in both groups.
1508036|NCT02910596|Drug|bethanechol chloride|bethanechol chloride(10) 2 tablets oral tid, ac. Start on3rd - 5th postoperative day
1508037|NCT02910596|Device|early bladder training|early bladder training start on 3rd - 5thpostoperative day
1508038|NCT02910596|Other|early bladder training and bethanechol chloride|bethanechol chloride 2 tablets oral tid, ac and early bladder training start on 3rd - 5th postoperative day
1508039|NCT02910596|Other|no early bladder training and no bethanechol chloride|no bethanechol chloride and no early bladder training
1508040|NCT02910583|Drug|ibrutinib|ibrutinib 420mg capsules administered orally once daily
1508041|NCT02910583|Drug|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally once daily
1508042|NCT02910583|Drug|venetoclax|venetoclax tablets orally will be administered at 400mg once daily
1508043|NCT02910570|Drug|Liraglutide 3 mg (Saxenda)|Dose escalation scheme: Initial dosage of 0.6 mg per day, escalated bi-weekly by 0.6 mg to 3 mg per day over a total of 8 weeks
1508044|NCT02910570|Drug|Liraglutide 3 mg placebo|Dose escalation scheme: Initial dosage of a 0.6 mg drug equivalent volume per day, escalated bi-weekly by an 0.6 mg drug equivalent volume per day to a 3 mg drug equivalent volume per day over a total of 8 weeks.
1508045|NCT02910544|Dietary Supplement|Intensive dietary intervention|Participants receive a hypo-caloric formula diet containing 800 to 1,000 kcal/day. The formula diet consists of ready-to-use meal bars and powders to mix with water to make shakes, soups, or porridge. The weight loss programme consists of an 8-week period with full meal replacement by a standard liquid energy intake protocol. To facilitate compliance with the programme, participants will be scheduled for weekly facility-based group sessions with 6-8 participants led by a dietician. The recommendations for daily nutrient intake will be met.
1508046|NCT02910531|Dietary Supplement|Alpha lipoic acid|Already mentioned in arm/group descriptions.
1508047|NCT02910531|Drug|Placebo|Already mentioned in arm/group descriptions.
1508048|NCT02910518|Drug|Insulin glulisine (U300)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1508049|NCT02910518|Drug|Insulin glulisine|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1508050|NCT02910518|Drug|Insulin aspart|"Pharmaceutical form: solution
Route of administration: intravenous/subcutaneous"
1508051|NCT02910518|Drug|NPH insulin|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1508052|NCT02910518|Drug|Glucagon|"Pharmaceutical form: Powder and solvent for solution for injection
Route of administration: subcutaneous"
1508053|NCT02910518|Drug|Glucose|"Pharmaceutical form: solution
Route of administration: intravenous"
1508054|NCT02910518|Drug|Heparin|"Pharmaceutical form: solution
Route of administration: intravenous"
1508055|NCT02910505|Device|enLighten Laser|Laser for tattoo removal
1508056|NCT02910492|Device|enLighten Laser|Nd:YAG dual-pulse duration laser for the treatment of skin rejuvenation
1508057|NCT02910479|Device|E-Celsius thermometer|comparison of temperature between e-celsius and thermometer, rectal thermometer, esophageal thermometer, vital sense capsule thermometer
1508058|NCT02910479|Device|Rectal thermometer|
1508059|NCT02910479|Device|Esophageal thermometer|
1508060|NCT02910479|Device|Vital sense capsule thermometer|
1508061|NCT02910466|Drug|rhPTH(1-84)|25, 50, 75, and 100 μg for once daily subcutaneous injection
1508062|NCT02910453|Procedure|Pulmonary lobectomy|
1508063|NCT02910440|Drug|DCL-101 vs Golytely|
1508064|NCT02910427|Other|Regular salt|Participants eat a regular salt diet.
1508065|NCT02910427|Other|Potassium-enriched salt|Participants eat a potassium-enriched salt diet.
1508066|NCT02910427|Other|Potassium and magnesium-enriched salt|Participants eat a potassium and magnesium-enriched salt diet.
1508067|NCT02910414|Drug|Dehydrated alcohol|Dehydrated Alcohol Injection, USP is used in the study.
1508068|NCT02910414|Device|Peregrine System Kit (Sham Procedure)|The Peregrine Catheter is delivered to the renal arteries, but the needles are not deployed and no alcohol is delivered to the perivascular space.
1508069|NCT02910401|Biological|Rhinovirus (GMP RV16 HRV-16)|300 tissue culture infectious dose (TCID)50 mg/ml intranasal one time only
1508070|NCT02910388|Device|LLETZ with colposcopy|Loop procedure using a colposcope in order to see and remove the abnormal cervical tissue
1508071|NCT02910388|Other|LLETZ without colposcopy|Loop procedure without using a colposcope
2002832|NCT01651117|Behavioral|Peer Mentoring|"Arm 2: Will receive peer mentoring from diabetic veterans who were once in poor control but are now in good control.
Arm 3: Will receive peer mentoring from former mentees"
2002833|NCT01650259|Drug|OAD|OAD except Trazenta tablets
1508074|NCT02910362|Device|Alcon phacoemulsification equipment|cataract surgery with Alcon phacoemulsification equipment.
1508075|NCT02910362|Device|AMO phacoemulsification equipment|cataract surgery with AMO phacoemulsification equipment.
1508076|NCT02910336|Other|Quantitative Sensory Testing|sensory testing profile
1508124|NCT02909803|Other|White Bread|Participants will consume white bread on at least two different test days
2002834|NCT01650259|Drug|Trazenta|Linagliptin
2002842|NCT01639443|Other|Predictive no-show overbooking|"During intervention period, every Veteran scheduled for an endoscopy will be offered fast-track offer, which gives them a chance to get their endoscopy procedure done earlier than usual scheduling by overbooking their appointment in a predictive no-show slot."
2002843|NCT01637558|Drug|8 hourly LPV/r during TB treatment|8 hourly LPV/r during TB treatment
2002844|NCT01637558|Drug|Nevirapine|
2002845|NCT01637558|Drug|Lopinavir/Ritonavir|
1508077|NCT02910310|Other|Uterine balloon tamponade|An intervention consisting of inserting a condom attached to a urinary catheter into the uterus and inflating it with fluid to stop postpartum bleeding
2002846|NCT01626755|Procedure|Sciatic name block|Ultrasound-guided sciatic nerve block.
1508079|NCT02910245|Drug|Mercaptopurine (Purinethol)|
1508080|NCT02910245|Drug|Placebo|
1508081|NCT02910245|Drug|Mesalamine|
1508082|NCT02910245|Drug|Prednisone|
1508083|NCT02910232|Device|bone void filler|Bone void filler device prepared from porous starch-hydroxyapatite composites for bone regeneration
1508084|NCT02910219|Drug|Crofelemer|Crofelemer 125 mg BID during cycles 1-2 of THP or TCHP
1508085|NCT02910206|Drug|Etomidate|etomidate is given intravenously
1508086|NCT02910206|Drug|propofol|propofol is given intravenously
1508087|NCT02910206|Drug|Sufentanil|sufentanil is given intravenously
1508088|NCT02910206|Drug|Cisatracurium|Cisatracurium is given intravenously
1508089|NCT02910167|Drug|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
1508090|NCT02910167|Drug|Paracetamol|Paracetamol 500 mg
1508091|NCT02910167|Drug|Hyoscine n-butylbromide|Hyoscine n-butylbromide 10 mg
1508092|NCT02910167|Drug|Paracetamol|Paracetamol 500 mg
1508093|NCT02910154|Dietary Supplement|Diet|Weight loss achieved by following an evidence-based low energy diet of 800-1200 kcal/day for 12 weeks (Cambridge Weight Plan). Hereafter follow 12 weeks of 'weight maintenance' with consumption of normal heart healthy diet. Goal: total weight loss of at least 10% without significant loss of muscle mass. Monitored and supervised by a dietician
1508094|NCT02910154|Behavioral|Training|Aerobic interval training and resistance exercise in group sessions twice weekly throughout the 24-week intervention. Training intensity individually adapted to the restricted calorie intake. Goal: Improved VO2 peak (at least 10%). Monitored by a physiotherapist.
1508095|NCT02910154|Drug|Medication (with statin and ACE-inhibition)|Medical treatment for hypertension and/or hypercholesterolemia if systolic blood pressure > 130 and/or low density lipoprotein (LDL) > 2.0.
1508096|NCT02910141|Device|Continuous subcutaneous insulin infusion|Infusion of short-acting insulin from a portable pump
1508097|NCT02910128|Behavioral|chiquichefs|A project based learning using healthy trough cooking as the core of the curriculum, so children learn the academic content through cooking workshop of mediterranean diet in their school.
1508098|NCT02910115|Other|Cold laparotomy sponges|Cold laparotomy sponges are lap sponges that are saturated in sterile, iced normal saline
1508099|NCT02910115|Drug|Pitocin|Pitocin is administered intravenously according to the usual protocol.
1508100|NCT02910102|Drug|RVT-101 35 mg|once daily, oral, 35-mg tablets
1508101|NCT02910102|Drug|Placebo|once daily, oral, matching tablets
1508102|NCT02910089|Behavioral|Shared Decision Making|This prospective study will include 700 beneficiaries of Horizon Blue Cross Blue Shield of New Jersey (BCBSNJ).
1508103|NCT02910076|Drug|Hydroxychloroquine|200 MG Plaquenil three times a day
1508106|NCT02910050|Drug|Bicalutamide|50mg once a day orally
1508107|NCT02910050|Drug|Aromatase Inhibitor|participants will receive any kind of aromatase inhibitor which has not been received before (steroidal AI change to nonsteroidal AI and vice versa), Letrozole 2.5mg once a day orally, Anastrozole 1mg once a day orally, Exemestane 25mg once a day orally
1508108|NCT02910024|Device|Magstim Super Rapid2 System, intermittent theta-burst-stimulation (iTBS) protocol|iTBS applied over ipsilesional M1
1508109|NCT02910024|Device|Magstim Super Rapid2 System, sham-stimulation (in iTBS)|iTBS applied with tilted coil over parieto-occipital vertex
1508110|NCT02910011|Drug|Nanodox 1% (doxycycline monohydrate hydrogel)|Subjects will be asked to apply NanoDOX® Hydrogel 1% once daily at bedtime for up to four weeks or until complete clearance whichever is sooner
1508111|NCT02909998|Other|Blood sample|Conservation at the end of the blood sample
1508112|NCT02909985|Other|Tungsten halogen light with narrow bandpass filters|As intensity in increased from 0 to 12 V, participants will say if/when they see a visual response to infrared light from a broad band tungsten halogen light source that passes through narrow bandpass filters ranging from 850 nm to 1400 nm. At the end of three trials per filter, the intensity will be turned up to 12 V, and participants will describe the color they see.
1508113|NCT02909985|Other|ERG|Participants will undergo electroretinography using both normal settings and infrared as the stimuli.
1508114|NCT02909985|Other|VEP|Participants will undergo visual evoke potential tests using both normal settings and infrared as the stimuli.
1508115|NCT02909972|Drug|ALRN-6924|Fixed dose of ALRN-6924 per cohort, administered IV, Days 1, 8, and 15 every 28 days.
1508116|NCT02909972|Drug|ALRN-6924 in combination with cytarabine|Cytarabine (100 or 200 mg/m2) will be administered as an IV infusion followed by ALRN-6924 on Days 1, 8, and 15 every 28 days.
1508117|NCT02909959|Drug|Sulforaphane|The investigational medicinal product is an uncoated tablet containing both glucoraphanin and myrosinase, the enzyme that converts glucoraphanin to sulforaphane in vivo. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
1508118|NCT02909959|Drug|Placebo|Placebo tablets are uncoated and matched in appearance to the investigational medicinal product, containing inert components. Participants in this arm will take 3-8 tablets by mouth once daily (dose depending upon weight) for 12 weeks.
1508119|NCT02909829|Other|Missed Bolus Intervention|"Participants will be admitted at the research facility around 8:30am. Each 9-hour intervention visit will include two standardized meals (9:00am, 1:00pm). Meals will be standardized between visits for the same participant.
At 9:00am, a mixed meal will be served. A prandial bolus will be administered as per standard practice, e.g. based on each participants' insulin-to-carbohydrate ratio (U per 10 g carbohydrates) or with their pump wizard.
At 1:00pm, a mixed meal will be served. No prandial bolus will be administered, mimicking a missed bolus scenario.
Glucose levels will be measured every 10 minutes by the real time sensor.
Participants will be discharged at 18:00."
1508120|NCT02909829|Device|Insulin infusion pump|
1508121|NCT02909829|Other|Meals|
1508122|NCT02909829|Drug|Human insulin|
1508123|NCT02909803|Other|Lentil Variety|Participants will consume 8 varieties of lentils that are cooked by boiling
1508125|NCT02909790|Device|Curve Low Level Laser Therapy|"Subjects assigned to the treatment group will be treated with 4 multi-paddle low-level diode laser consisting of 8 independent diode laser heads per treatment paddle, each emitting 630-680nm (red) laser light with each diode generating 40mW output (CURVE Laser - manufactured by YOLO Medical Inc.)."
1508126|NCT02909777|Drug|CUDC-907|
1508127|NCT02909764|Other|Low Sodium Group|Breakfast Cereal
1508128|NCT02909751|Drug|Epirubicin 90 mg/m2 iv|Max. 3 months
1508129|NCT02909751|Drug|Cyclophosphamide 600 mg/m2 iv|Max. 3 months
1508130|NCT02909751|Drug|Docetaxel 100 mg/m2 iv OR paclitaxel 80 mg/m2 iv|Max. 3 months
1508131|NCT02909751|Drug|Trastuzumab 8 mg/kg iv saturation, then 6 mg/kg iv (HER2 positive patients only)|Max. 3 months.
1508132|NCT02909751|Drug|Pertuzumab 840 mg iv saturation, then 420 mg iv (selected HER2 positive patients only)|Max. 3 months
1508133|NCT02909751|Dietary Supplement|Tocotrienol 300 mg x 3 daily|Max. 6 months
1508134|NCT02909738|Other|Volunteer to pedal a bicycle|
1508135|NCT02909725|Other|Limit accumulation of sedentary time|"Participants in this group receive a Fitbit Alta activity monitor, worn on the wrist for the entire intervention. The Alta is a fitness tracker designed to help individuals track their sedentary and physical activity behaviors when paired with an external device (e.g. iPhone, computer). The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to achieve a goal of 250 steps/hour. Using the reminder to move function, if a participant has not reached the hourly goal at 50 minutes, the Alta will vibrate, cueing the participant to walk."
1508136|NCT02909725|Other|Walk|"Participants in this group receive a Fitbit Charge activity monitor. There is no reminder to move function on this band. The Charge, worn on the wrist for the entire intervention is a fitness tracker designed to help individuals track their physical activity when paired with an external device. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
Each participant will have a Fitbit account set up with a Blossom Project username code to ensure privacy of the participant's identity. Participants will be asked to meet current pregnancy physical activity recommendations; walking 30 minutes, most days of the week (150 minutes/week). Participants can use the app to view their active minutes."
1508137|NCT02909725|Other|Normal daily routine; Usual Care|Participants in this group will not be provided with a Fitbit Charge activity monitor, as participants will be asked to simply continue on with their normal daily routine. The Sensewear armband and ActivPAL are not worn as part of the intervention; they are assessment tools used at the beginning and end of the study.
1508138|NCT02909712|Drug|sulfadoxine-pyrimethamine (SP)|"Women in Groups 1 and 2 will be provided the following SP regimen as directly observed therapy:
3 tablets total of 500 mg sulphadoxine and 25 mg pyrimethamine; 1 day of dosing."
1508139|NCT02909712|Drug|dihydroartemisinin-piperaquine (DHA-PQP)|Women in Groups 3 and 4 will be provided the following DHA-PQP regimen as directly observed therapy 3 tablets of 40 mg dihydroartemisinin and 320 mg piperaquine daily; 9 tablets total; 3 days of dosing.
1508140|NCT02909699|Other|Observation|In this trial, cardiovascular function will be measured without drug administration. The drug will be administered within the main trial.
1508141|NCT02909686|Dietary Supplement|Boswellia Serrata|
1508142|NCT02909686|Dietary Supplement|Curcumin|
1508143|NCT02909686|Dietary Supplement|Epimedium|
1508144|NCT02909686|Dietary Supplement|Fisetin|
1508145|NCT02909686|Dietary Supplement|Luteolin|
1508146|NCT02909686|Dietary Supplement|Nettle|
1508147|NCT02909686|Dietary Supplement|Pycnogenol|
1508148|NCT02909686|Dietary Supplement|Reishi Mushroom|
1508149|NCT02909686|Dietary Supplement|Resveratrol|
1508150|NCT02909686|Dietary Supplement|Placebo|
1508153|NCT02909660|Other|Cognitive-behavioural therapy|Empirically-supported psychological intervention for various mental health concerns including obsessive-compulsive disorder (OCD). Includes components to foster cognitive (i.e., thinking) and behavioural changes.
1508154|NCT02909647|Procedure|Preoperative planning|preoperative planning using 3D digital planning software or conventional template
1508155|NCT02909647|Procedure|Osteosynthesis|osteosynthesis using volar locking plate
1508156|NCT02909634|Other|AbStats and Ostom-I device|The surgeon will apply AbStats and Ostom-I devices upon completion of operation. Device recordings will continue until discharge, or until patient opts to remove the sensors as requested.
1508157|NCT02909621|Dietary Supplement|FLEXOFYTOL®|The product FLEXOFYTOL® is bio-optimized curcumin.
1508158|NCT02909621|Other|PLACEBO|
1508159|NCT02909608|Other|No interventions / observations only|This is an observational study only
1508160|NCT02909595|Device|Balloon catheter|Balloon stone extraction was carried out with a balloon catheter [Extractor Pro RX [M00547000, M00547010, or M00547020]; Boston Scientific,Shang hai,China). The Extractor Pro has multiple sizes (9-12, 12-15, and 15-18mm), the choice being made on the basis of the CBD diameter. It has a contrast-injection hole above the balloon for the performance of balloon occlusion cholangiography (BOC).
1508161|NCT02909595|Device|Basket catheter|Basket stone extraction was performed with a basket catheter (Flower Basket V [FG-V435P or FG-V425PR]; Olympus Corp., Shang hai,China).
1508162|NCT02909582|Procedure|Cohen Incision|This is a straight transverse incision through the skin, 3 cm below the level of the anterior superior iliac spines (higher than the Pfannenstiel incision). Should a pannus exist, the pannus should be left in the physiologic location (not retracted) to allow placement of the incision.
1508163|NCT02909569|Drug|INCB039110|All subjects will receive 400 mg PO QD for 12 weeks. If no clinical response after four weeks, dose will be increased to 600 mg PO QD. Total duration of subject participation will be six study visit over 20 weeks.
1508165|NCT02909543|Other|Observation and Interviwe|The research data will be conducted by using a semi structured interview of the participants in the study.
1508166|NCT02909530|Device|EUS-FNB with EZ Shot 3Plus first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
1508167|NCT02909530|Device|EUS-FNB with EZ Shot 2 19G first|Both needles (EZ Shot 3Plus 19G and EZ Shot 2 19G) will be used for endoscopic ultrasound-guided fine needle biopsy (EUS-FNB) in each patient following a predetermined random order which needle is used to pass through the tumor first.
1508168|NCT02909517|Other|cSLO imaging|
2002847|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
1508170|NCT02909478|Drug|Aprepitant+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin,leucovorin and 5-fluorouracil as well as the following antiemetic drugs:
aprepitant (125 mg orally on day 1 and 80 mg orally on days 2 and 3) plus Tropisetron (5mg IV of day1)"
1508171|NCT02909478|Drug|Dexamethasone+Tropisetron|"Patients will receive the chemotherapy drugs oxaliplatin, leucovorin and 5-fluorouracil as well as the following antiemetic drugs:
Dexamethasone (10 mg IV on day 1 and 5 mg IV days 2, 3) plus Tropisetron (5mg IV of day1)"
1508172|NCT02909465|Drug|Midazolam|Using Midazolam as a premedication for reducing ketamine-induced agitation
1508173|NCT02909465|Drug|Haloperidol|Using Haloperidol as a premedication for reducing ketamine-induced agitation
1508174|NCT02909465|Drug|placebo|distilled water
1508175|NCT02909465|Drug|Ketamine|Ketamine is routinely used for all procedural sedation in the patients.
1508176|NCT02909452|Drug|Entinostat|HDAC (histone deacetylase) inhibitor
1508177|NCT02909452|Drug|Pembrolizumab|A selective humanized monoclonal antibody (mAb)
1508178|NCT02909439|Drug|Sugammadex|Sugammadex will be given for reversal of neuromuscular blockade.
1508179|NCT02909439|Drug|Neostigmine|Neostigmine will be given for reversal of neuromuscular blockade.
2002848|NCT01623752|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
1508182|NCT02909413|Drug|Desﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Desﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, include 50％ O2 and 4～5％ Desflurane.
1508183|NCT02909413|Drug|sevoﬂurane|Anesthesia maintenance: After endotracheal intubation, half of the patients will be randomized into Sevoﬂurane Group. The gas flow rate of Desflurane group is 2 L/min, 50％O2 and 1.7-2.0% Sevoflurane.
1508184|NCT02909400|Drug|KH176|
1508185|NCT02909400|Drug|placebo|
1508186|NCT02909387|Behavioral|Project UPLIFT|UPLIFT is an 8-week distance-delivered mindfulness-based cognitive therapy intervention.
1508187|NCT02909374|Other|Balance training|The balance-training program was developed based on well-established principles of exercise and on the knowledge that balance control relies on the interaction of several physiological systems, as well as interaction with environmental factors and the performed task. It includes exercise with dual- and multi task performance. It is progressive as the exercises can be performed at different levels (basic, moderate, and advanced), making it progressively challenging for each individual throughout the whole program. The training is conducted as an individually tailored group program.
1508189|NCT02909348|Drug|Pembrolizumab|3mg/kg, intravenous and on day1 of each 21 day cycle until progression or unacceptable toxicity develops.
1508190|NCT02909335|Drug|Tacrolimus|"Tacrolimus is administered at an initial dose of 0.040 mg / kg twice a day on Day 5.
The doses are then adjusted to maintain trough levels :
between 6 and 10 ng / ml during the first 2 months,
between 5 and 8 ng / ml from the start of the end M3 and M6,
and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
1508191|NCT02909335|Drug|Everolimus|"Everolimus is administered at an initial dose of 1.5 mg twice a day on Day 5.
The doses are then adjusted to maintain trough levels:
between 6 and 10 ng / ml during the first 2 months,
between 5-8 ng / ml from the start of the end M3 and M6,
and between 4 and 6 ng / ml between the beginning and the end of M7 M12."
1508192|NCT02909335|Drug|Mycophenolate mofetil|mycophenolate mofetil is administered similarly in the two groups at the dose of 1.5 g for the first two months and then 1 g twice a day. The doses may be adjusted according to the tolerance of the product.
1508193|NCT02909335|Drug|Prednisolone, Prednisone or Methylprednisolone|Corticosteroid is similarly administered in both groups between baseline and the end of M6 and adjusted in case of acute rejection
1508194|NCT02909322|Procedure|Bupivacaine and Hydromorphone|Patients receive bupivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
1508195|NCT02909322|Procedure|Ropivacaine and Hydromorphone|Patients receive ropivacaine and hydromorphone infusion and bolus doses during surgery and 3 days after surgery.
1508196|NCT02909309|Device|JAWAC system + Capnoline + Spo2|
1508197|NCT02909296|Procedure|Endoscopic drainage|
1508198|NCT02909283|Procedure|Physical exams and blood analyzes|Blood samples collection (for DNA, plasma and cells analyzes) ; Hemorheologic analyzes ; ASL sequence on MRI ; Near Infra Red Spectroscopy (NIRS) and associated cardiofrequency analyze.
1508199|NCT02909270|Device|Mediclore|to apply mediclore fully around thyroid gland
1508200|NCT02909257|Drug|Same Bupivacaine Concentration|patient is exposed to the same concentration than previously successful one
1508201|NCT02909257|Drug|Lower Bupivacaine Concentration|patient is exposed to a lower concentration than previously successful one
1508202|NCT02909244|Biological|Biological sampling|Biological sampling
1508203|NCT02909218|Other|Early Access to ART for All|All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.
1508281|NCT02908620|Drug|Benzocaine only|Benzocaine 14% alone 200 uL (1 spray)
1508204|NCT02909205|Other|sensitization / educational program|the intervention program was built based on the results of the pre-intervention phase survey, about the knowledge of caregivers and parents of children with gastrostomy about gastrostomy management. It consists in booklets for caregivers and parents of children. This booklet is the support of a specific training of carers and parents of children who have recently benefitted from a gastrostomy
1508205|NCT02909205|Other|training / sensitization program|diffusion of gastrostomy in-hospital care protocols, and booklets for families. These tools have been prepared by a pilot group of professional of the investigating centers.
1508206|NCT02909192|Device|Light Therapy Device|
1508207|NCT02909179|Other|mCARE-II|mCARE-II is a package of interventions that provides guided client enumeration and follow-up support to community health workers, automated workflow scheduling, risk assessment, client prioritization and stratification and client-based demand generation messaging. These features are incorporated into a platform called OpenSRP, which integrates text message reminders, scheduling, and form submissions on the server side, and displays schedules and client lists on a tablet-based application for community health workers.
1508208|NCT02909166|Drug|aliskiren|
1508209|NCT02909153|Drug|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients on chronic peritoneal dialysis.
1508210|NCT02909140|Drug|Topical phenylephrine 2.5%|
1508211|NCT02909140|Drug|Topical cyclopentolate 1%|
1508212|NCT02909140|Drug|Intracameral Lidocaine 1%|
1508213|NCT02909140|Drug|Intracameral 0.2- 0.3ml of epinephrine 1:10,000|
1508214|NCT02909127|Other|SWALLOWING EVALUATION|Swallowing function of the CP patients will be imaged and recorded with Videofluoroscopic Swallowing Study (VFSS). The oral cavity, pharynx, larynx and just below the upper esophageal sphincter are visible. 3 trials of 3 ml of liquids will be used and the worst score will be considered for calculation. The Penetration-Aspiration Scale (PAS) will be used to assess dysphagia severity. The PAS is an ordinal scale consisting of eight scores. Scores are determined primarily by the depth to which material passes in the airway and by whether or not material entering the airway is expelled.
1508215|NCT02909127|Other|The Functional Independence Measure|The Functional Independence Measure for Children (Wee-FIM) will be used to assess the functional independence level of the CP children. The Wee-FIM is developed to emphasize habilitative and developmental aspects of children with special health care needs, genetic disorders, developmental disabilities, and acquired disabilities.
1508216|NCT02909127|Other|The PEDI-EAT-10|The PEDI-EAT-10 will also be administered.
1508217|NCT02909114|Radiation|Stereotactic body radiotherapy|"All patients will undergo planning CT simulation. 4-dimensional CT will be used for tumors in the lungs or liver. For all lesions, the gross tumor volume (GTV) will be defined as the visible tumor on CT and/or MRI imaging +/- PET. A Planning Target Volume (PTV) margin of 3-5 mm will be added depending on site of disease, immobilization, and institutional set-up accuracy.
The prescirbe dosage was as following: Lung lesion DT50-60 Gy/5 fractions; liver 50-60Gy/5-8 fractions; brain DT 40Gy/4-5fractions. All will be treated with SBRT"
1508218|NCT02909101|Device|Active Cognitive Training (ACT)|Cognitive training games
1508219|NCT02909101|Device|Control Training (CON)|Cognitive training games
1508220|NCT02909088|Drug|Ecopipam 50mg|
1508221|NCT02909088|Drug|Ecopipam 100mg|
1508222|NCT02909075|Device|PET/CT scans|
1508223|NCT02909075|Device|MRI|
1508224|NCT02909062|Device|Electronic Activity Monitoring (EAM)|All registered patients will receive a wearable EAM device that will measure their physical activity. Patients will wear this device around their wrist for the designated period of assessment. The EAM device has the potential to measure active minutes, number of steps, distance walked and number of floors climbed. For the purpose of this study the EAM data captured will focus on daily step count.
1508225|NCT02909062|Behavioral|Daily Questionnaire|Participants will be asked to complete this self-administered, paper-based questionnaire each day that they are expected to wear the EAM device. The questionnaire was designed specifically for the purpose of this study. It consists of 5 items that ask about the patient's perceived level of physical activity and fatigue in each 24 hour period that they have worn the EAM device. The daily questionnaires will be optional; however each participant will be encouraged to complete them.
1508226|NCT02909049|Drug|MIDAZOLAM|Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.
1508227|NCT02909049|Drug|MEPIVACAÍNE|Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.
1508228|NCT02909049|Drug|FENTANILE|Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.
1508229|NCT02909049|Drug|KETAMINE|Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.
1508230|NCT02909036|Device|Melphalan|
1508231|NCT02909036|Drug|Pegfilgrastim|
1508232|NCT02909036|Procedure|Autologous Hematopoietic Progenitor Cell Transplant|
1508233|NCT02909023|Biological|blood samples are performed to measure active T cellular immune response during a routine visit|"During the visit 1 (V1), after signing the informed consent, 40 mL blood sampling are carried out and analyzed with the test ELISPOT to check if the patient shows a T immune response against HBV.
The visit 2 will be performed 4-8 weeks (depending on the availability of the patient) following V1 visit, in case the patient shows an immune response against HBV positive T following the sample taken at V1. 150 ml blood sampling are carried out at this visit."
1508234|NCT02909010|Device|BIS™ Brain Monitoring System|The intervention group using BIS monitoring to adjust sedation in order to maintain values between 50-60
1508235|NCT02909010|Other|RASS|control group in which sedation was adjusted with the exclusive use of Richmond Agitation-Sedation Scale (RASS) to maintain RASS -2
1508236|NCT02908997|Other|MindMate|A dementia-specific mobile reminding application
1508237|NCT02908984|Behavioral|Specific neck rehabilitation|Guided craniocervical, axioscapular and proprioceptive training that includes education, postural exercises, as well as training of cervical and shoulder muscles, and of oculomotor function if indicated, and general exercises
1508238|NCT02908984|Other|Standard primary health care|The treatment includes individualized based pharmacological medication and physiotherapy or no active treatment
1508239|NCT02908971|Behavioral|soy based formula at infancy|The intervention is only past history of soy consumption
1508240|NCT02908958|Biological|PEG-somatropin|High dose group: PEG Somatropin 0.2 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
1508241|NCT02908958|Biological|PEG-somatropin|Low dose group: PEG Somatropin 0.14 mg/kg/w, subcutaneous use, inject once a week, the duration is for 26 weeks.
1508242|NCT02908945|Drug|Ketamine|Bolus dose before induction of anesthesia and infusion during maintenance of anesthesia.
1508243|NCT02908945|Device|NeuroSENSE monitor|NeuroSENSE monitors the brain using electroencephalography (EEG) and produces an index called the WAVCNS. WAVCNS is a measure of depth of hypnosis (DoH).
1508244|NCT02908932|Dietary Supplement|Phospholipid-bound omega-3 supplement|The dietary supplement is produced by Aker BioMarine. These krill oil capsules received a GRAS status approval from the U.S. Food and Drug Administration (FDA) in 2010. Aker BioMarine has a new pending application (2015) with the U.S. FDA for GRAS status for its new product on which this study capsule is based. Aker BioMarine markets a number of different krill-based omega-3 supplement products in the U.S. The US Food and Drug Administration (FDA) has determined that an Investigator New Drug (IND) Application is not required for this study. This phospholipid-bound omega-3 dietary supplement is provided in capsule form.
1508245|NCT02908932|Dietary Supplement|Placebo supplement|Placebo capsules that are identical in size and color to the experimental but contain an equal amount of macadamia nut oil.
1508246|NCT02908919|Procedure|Colonoscopy|The quality of bowel preparation, which is checked during colonoscopy
1508247|NCT02908906|Drug|JNJ-63723283|JNJ-63723283 administered by IV infusion.
1508248|NCT02908893|Behavioral|In-app and push notification mobile messages|Short messages (100-250 characters) are to be delivered to a mobile app both by push notification (i.e., appearing on the phone dashboard like a text message if the user has allowed notifications from the app) and in-app messages (visible in the news feed of the wellness program app when the app is opened). Messages contain a short title (30 characters) and 2-3 lines of text in the body (30 characters each).
1508249|NCT02908880|Device|MANTA vascular closure device|The appropriate size of MANTA closure device will be selected and used to for the closure of femoral arterial access sites following the use of 10-14F devices or sheaths or the use of 15-18F devices or sheaths.
1508250|NCT02908867|Other|Therapeutic Strategies|Using questionnaires (Erectile Function of International Index and American Impairment Scale) and search in public markets using semi structured form
2002849|NCT01624090|Drug|Mithramycin|30 mcg/kg IV over 6 h once daily for 7 days, to be repeated every 21 days (one cycle) until disease progression or unacceptable toxicity
1508252|NCT02908841|Device|Surgicel Snow|
1508253|NCT02908841|Other|Standard of Care|
1508254|NCT02908828|Dietary Supplement|Calanus oil|
1508255|NCT02908828|Dietary Supplement|placebo dietary oil|
1508256|NCT02908815|Device|rTMS active treatment|Repetitive Transcranial Magnetic Stimulation uses magnetic pulses to active neurons.
1508257|NCT02908815|Device|rTMS sham treatment|A fake treatment designed to mimic the sensations of rTMS
1508258|NCT02908802|Dietary Supplement|Probiotic|Probiotic
1508259|NCT02908802|Dietary Supplement|Placebo|Probiotics capsules without the active ingredient
1508260|NCT02908789|Radiation|Antimicrobial photodynamic therapy (aPDT)|Antimicrobial photodynamic therapy (aPDT) is an effective low potency laser that involves the activation of a photosensitizer( 0.01% methylene blue ) by a visible light source that creates chemical reactions, producing cytotoxic reactive oxygen species and causing oxidative stress and inactivation of pathogenic microorganisms.
1508261|NCT02908776|Dietary Supplement|Probiotic|Sachets with Streptococcus thermophilus DSM 32245: 70 billion, bifidobacteria (Bifidobacterium lactis DSM 32246, Bifidobacterium lactis DSM 32247) 40 billion, lactobacilli (Lactobacillus acidophilus DSM 32241, Lactobacillus helveticus DSM 29575, Lactobacillus paracasei DSM 32243, Lactobacillus plantarum DSM 32244, Lactobacillus brevis DSM 27961): 90 billion.
1508262|NCT02908776|Other|Placebo|Sachets of maltose, flavors and sylicium dioxide, indistinguishable from ecoviesel sachets.
1508263|NCT02908763|Drug|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
2002850|NCT01620567|Dietary Supplement|avocado or chickpeas/potatoes|1 avocado/day for 6 months or equivalent calories of chickpeas/potatoes for 6 months
2002851|NCT01619917|Device|Fractional Vascular Laser|laser energy will be applied to one of 2 sites (proximal or distal) depending on randomization result
1508266|NCT02908737|Device|Bass and Treble|Bass and Treble controls are clinician enabled and provide the recipient with access to the adjustment of low and high frequency sound balance, known as Bass and Treble respectively
1508267|NCT02908711|Drug|0.5% ropivacaine|Adductor canal block (ACB) performed as part of their analgesic regimen for primary total knee arthroplasty achieved with 20 cc of 0.5% ropivacaine under constant ultrasound visualization.
1508268|NCT02908698|Drug|Prednisone|"Total treatment duration: 15 days
Doses are as follows:
5 days daily treatment with 0.75 mg/kg of body weight 5 days daily treatment with 0.5 mg/kg of body weight 5 days daily treatment with 0.25 mg/kg of body weight"
1508269|NCT02908698|Drug|Placebo Control|Total treatment duration: 15 days. Doses will appear identical to prednisone arm.
2002852|NCT01618162|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
2002853|NCT01618162|Drug|placebo|Injected subcutaneously (under the skin) once daily.
2002854|NCT01606124|Drug|defined green tea catechin extract|Given PO
2002855|NCT01606124|Other|placebo|Given PO
2002856|NCT01606124|Other|questionnaire administration|Ancillary studies
2002857|NCT01606124|Other|laboratory biomarker analysis|Correlative studies
2002858|NCT01600274|Drug|Ethyinylestradiol Dienogest combination|"A: One tablet of Test B: One tablet of Reference
2 x 0.03 mg EE = 0.06 mg EE 2 x 2 mg DNG = 4 mg DNG"
1508277|NCT02908646|Procedure|microcoil localization|CT-guided localization by placing a microcoil into the lung parenchyma
1508278|NCT02908646|Procedure|hookwire localization|CT-guided localization by placing a hookwire into the lung parenchyma
1508279|NCT02908633|Procedure|canaloplasty and phacoemulsification|
1508280|NCT02908620|Drug|Benzocaine and Tetracaine|"A single application of either 1 or 2 sprays of a combination of benzocaine 14% and tetracaine 2% with a total dose of benzocaine 28 mg and tetracaine 2 mg per spray.
The control treatment is benzocaine 14% alone with a total dose of 28 mg."
2002859|NCT01598662|Device|Mirena (levonorgestrel-releasing intrauterine system)|The Mirena IUD is a levonorgestrel-releasing IUD which contains 52 mg levonorgestrel total and releases 20 mcg of hormone daily.
1508284|NCT02908581|Drug|Placebo|Administered orally once daily
1508285|NCT02908581|Drug|Iron 150 mg and Folic acid 0.5 mg|Iron will be administered with folic acid orally
1508286|NCT02908568|Device|Spring device|Brisk dilatation of fhe mouth.
1508287|NCT02908568|Device|Mandible stimulator|Stimulation of fhe mouth.
2002860|NCT01586858|Other|Observational|Observational study of subjects previously enrolled in the RAVE trial
1508289|NCT02908542|Genetic|genetic analysis with massively parallel sequencing|
1508290|NCT02908529|Drug|Combination of Atomoxetine and Oxybutynin|Combination of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
1508291|NCT02908529|Drug|Placebo, 2 tablets|Placebo 2 tablets 2 hours before sleep
1508292|NCT02908516|Drug|Tranexamic Acid|2 doses of 1.95 g TXA orally, once in the ED and another dose pre-operatively.
1508293|NCT02908516|Drug|Placebo|2 doses of 1.95 g cellulose orally, once in the ED and another dose pre-operatively.
1508294|NCT02908503|Other|Placebo Film|placebo vaginal films
1508295|NCT02908490|Drug|Sildenafil|Sildenafil 50 mg once daily
1508296|NCT02908490|Other|Placebo|Placebo once daily with same size, shape, color, and texture as Sildenafil 50 mg pill
1508297|NCT02908477|Radiation|Adjuvant Radiation Therapy|60 Gy / 2 Gy fractions (standard arm) 30 - 36 Gy / 1.5 - 1.8 Gy b.i.d. fractions (experimental arm)
1508298|NCT02908477|Drug|Docetaxel|15 mg/m2. Experimental arm only.
1508299|NCT02908477|Drug|Cisplatin|40 mg/m2. Standard arm only.
1508300|NCT02908464|Device|Lumosity|A neurocognitive training program designed to enhance cognitive abilities
1508301|NCT02908451|Biological|AbGn-107|Antibody Drug Conjugate
1508302|NCT02908438|Drug|Gonadotrophin releasing hormone agonist(GnRHa)|GnRHa group receive three injections of GnRHa(Decapeptyl) ,0.1 mg s.c. on the day of ET, and D3 and D6 after ET in addition to routine LPS.
1508303|NCT02908425|Other|Statin user|Subjects will be studied on 2 occasions with both being identical. One will be after 7 days or more of cholesterol lowering statin administration and the other occasion will be after at least 4 weeks of cholesterol lowering statin discontinuation. All study visits include (but are not limited to) blood draws, urine collection, and stable isotope infusions.
1508304|NCT02908412|Drug|Digital nerve block with bupivacaine|The aim of the study, the way it will be conducted, and the complications and possible risks are explained to them. written informed consent is obtained from them. Then, after induction of anaesthesia, an arterial line will be inserted in order to monitor blood pressure and to take blood samples. During the surgery, two rainbow adult ReSposable sensors will be attached to the third or fourth fingers of both hands, and each of sensors will be attached to a monitor. Patients will be randomly assigned to two groups: group A will receive DNB in left hand and group B will receive DNB in right hand. DNB will be performed by injecting 2 ml of 0.25% bupivacaine at the base of medial and lateral sides of the finger attached to the sensor (1 ml on each side of the base).
1508305|NCT02908399|Device|FLIR ONE|
1508306|NCT02908373|Other|Implementation of the coaching model|20 hours methodological help for each nursing home and an implementation kit
1508307|NCT02908360|Genetic|double positive T cells (CD4 + / CD8 +) to the specific peripheral blood of F prauznitzii analyse|
1508308|NCT02908347|Drug|MP1032|hard gelatine capsules containing 50mg MP1032 as active ingredient
1508309|NCT02908347|Drug|Placebo|hard gelatine capsules without active ingredient
1508310|NCT02908334|Drug|Sertraline|400 mg/day sertraline
1508311|NCT02908321|Behavioral|CBT|The group based manualised CBT intervention consists of The Cool Kids Anxiety Program: Autism Spectrum Disorder Adaptation (Cool Kids ASD).
1508312|NCT02908308|Procedure|Targeted temperature management to 33°C|Rapid cooling to below 33°C, followed by temperature control at 33°C for up to 28h.
1508313|NCT02908308|Procedure|Standard care with early treatment of fever|Normothermia and standard care - use of a device for temperature control if temperature is greater than or equal to 37.8°C
1508314|NCT02908295|Drug|Rectal Misoprostol|Rectal Misoprostol Misoprostol 400 mcg (200 mcg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
1508315|NCT02908295|Drug|Placebo|Rectal Vitamin B6 Vitamin B6 (Placebo) 200 mg (100 mg/tablet) or 2 tablets were given rectally at 15 - 30 minutes prior the operation
2002861|NCT01578720|Drug|EYLEA (Aflibercept) intravitreal injection|Intravitreal Injection once every 8 weeks with 3 initial monthly doses
1508318|NCT02908269|Biological|Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative|0.5 mL, Intramuscular
1508319|NCT02908269|Biological|Fluzone Quadrivalent vaccine, 2016 2017 formulation, No Preservative|0.5 mL, Intramuscular
1508320|NCT02908269|Biological|Fluzone High Dose, vaccine, 2016 2017 formulation|0.5 mL, Intramuscular
1508321|NCT02908256|Drug|Geloplasma (PVI)|In the PVI group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the PVI>15% during more than 5 minutes. The bolus will be repeated if the PVI remains over 15%.
1508322|NCT02908256|Drug|Geloplasma (delta PP)|In the delta PP group, a filling solution (geloplasma) will be given as a bolus of 250 ml administered in 10 minutes if the delta PP> 13% during more than 5 minutes. The bolus will be repeated if the delta PP remains over 13%.
1508323|NCT02908243|Other|collection of baseline data|collection of baseline data including ages, types, severity, inhibitors and comorbidities
1508324|NCT02908230|Behavioral|Enhanced Care|8-week (nutrition, physical activity, and mental health) summer curriculum/program
1508325|NCT02908230|Behavioral|Standard Care|8-week (nutrition and physical activity) summer curriculum/program
1508326|NCT02908230|Behavioral|Active Control|8-week (non-nutrition, physical activity or mental health) summer curriculum/program
1508982|NCT02902913|Other|D2i0|No oleocanthal and no oleacein
2002867|NCT01572493|Biological|rh IL-15|IL-15 IV for first 10 days of each cycle
2002868|NCT01572493|Biological|rh IL-15|rh IL-15 for first 5 days of each cycle
2002869|NCT01570491|Other|ultrasound guided placement spinal block|Anesthesiologist will use ultrasound as a guide for placement of spinal block.
1508329|NCT02908191|Drug|ABI-H0731|
1508330|NCT02908191|Drug|Placebo for ABI-H0731|
1508331|NCT02908191|Drug|Entecavir|
1508332|NCT02908191|Drug|Tenofovir disoproxil fumarate|
2002870|NCT01570491|Other|standard spinal anesthesia|Anesthesiologist will use standard technique for placement of spinal block.
1508334|NCT02908165|Drug|conventional TACE in combination with sorafenib, administered on a continuous schedule|Patients assigned to Group A will begin sorafenib on a continuous schedule starting at 400mg BID from Cycle 1 Day 1, one week prior to cTACE treatment on Cycle 1 Day 8. After week 6, cTACE will be provided on demand (as needed, up to 4 treatments total in the first 4 cycles) at week 2 in subsequent cycles, and sorafenib will continue to be administered. Patients will be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
1508335|NCT02908165|Drug|conventional TACE in combination with sorafenib, administered on a sequential schedule|Patients assigned to Group B will undergo cTACE up to 4 treatments within the first 4 cycles as needed prior to starting sorafenib. After it is determined that no further TACE treatment is necessary (via imaging and clinical assessment on follow-up), administration of sorafenib will begin on Day 1 of the following cycle. Dosing will begin at 400mg BID and maintained continuously provided no unmanageable toxicities develop, with follow-up assessments performed on week 6 of every 1-2 cycles as needed. Patients in Group B will also be allowed to undergo dose adjustments of sorafenib as long as it remains above the ¼ dose (400mg QOD).
1508336|NCT02908152|Dietary Supplement|curcumin|"1500 mg
1 capsule / day for 12 weeks"
1508337|NCT02908152|Dietary Supplement|placebo|"1500 mg
1 capsule / day for 12 weeks"
1508338|NCT02908139|Device|BR-102 plus PWA|Monitoring of Arterial Stiffness and Central Aortic Pressure
1508339|NCT02908139|Device|Tanita MC780 MA S|The device measured the size of total body water (TBW), Extra Cellular Water (ECW), Intra Cellular Water (ICW), fat mass (FM%), visceral fat%, fat free mass (FFM) and basal metabolic rate, (BMR) (kcal).
1508340|NCT02908126|Drug|Oxytocin|Oxytocin drug
2002871|NCT01569295|Drug|Idelalisib|Idelalisib 150 mg administered orally twice daily
2002872|NCT01569295|Drug|Rituximab|Rituximab 375 mg/m^2 on Day 1, then 500 mg/m^2 every 28 days administered intravenously for a maximum of 6 infusions
1508343|NCT02908100|Drug|GDC-0853 (high dose)|Participants will receive GDC-0853 twice daily, orally every 12 hours starting on Day 1 and ending at Week 48.
1508344|NCT02908100|Drug|GDC-0853 (low dose)|Participants will receive GDC-0853 once daily, and matching placebo twice daily, orally, starting on Day 1 and ending at Week 48.
1508345|NCT02908100|Drug|Placebo|Participants will receive matching placebo to GDC-0853 tablets twice daily, orally, every 12 hours starting on Day 1 and ending at Week 48.
2002873|NCT01569295|Drug|Bendamustine|Bendamustine 70 mg/mg^2/day on 2 consecutive days every 28 days administered intravenously for a maximum of 12 infusions
2002874|NCT01569295|Drug|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
1508348|NCT02908074|Drug|BGS649|Capsules will be taken weekly for a maximum of 24 weeks
1508349|NCT02908061|Procedure|Surgery Radical Cystectomy|
1508350|NCT02908061|Procedure|Ultrapro mesh|Surgery Mesh Placement
2002875|NCT01557543|Other|Cell Therapy|Intramyocardial Injection of BMSCs
2002876|NCT01553149|Drug|Lenalidomide|Given PO
2002877|NCT01553149|Other|Pharmacological Study|Correlative studies
1508354|NCT02908022|Device|Electroacupuncture Analgesia|Acupuncture needles will be inserted next to the cuff placed on the leg and will be connected to electrodes. Low-amplitude electrical current will be activated when a button is pressed via a handheld device, controlled by the acupuncturist, in order to reduce pain, acting as an analgesic.
1508355|NCT02908022|Device|Hokanson Rapid Cuff Inflator|The Hokanson Rapid Cuff Inflator will be placed on the lower right leg of the subject and utilized for pain testing purposes according to the protocol. Ascending pressures will be administered using the cuff to elicit different pain intensities.
1508357|NCT02907983|Drug|Stellate Ganglion Block Injection with Bupivicaine|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
1508358|NCT02907983|Drug|Saline injection|A computer-generated stratified randomization scheme by self-reported race and by etiology of menopause (natural versus surgical menopause) will be used to assign participants to receive either a SGB with bupivacaine or a sham injection with saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
1508359|NCT02907957|Device|FLIR ONE|Thermographic assessment of the lower extremities is obtained using the FLIR ONE smartphone camera and software.
1508360|NCT02907957|Procedure|Regional Anesthesia - Caudal Nerve Block|Nerve block placement as a pain management strategy indicated for certain urological and lower extremity surgeries.
2002878|NCT01544179|Drug|Gefitinib|Investigational Drug
2002879|NCT01544179|Drug|Placebo|Matching placebo as comparator
2002880|NCT01544179|Drug|Pemetrexed|Chemotherapy (concomitant therapy)
2002881|NCT01544179|Drug|Cisplatin|Chemotherapy (concomitant therapy)
2002882|NCT01543672|Radiation|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions within 10-14 days
2002883|NCT01543672|Radiation|Stereotactic Body Radiotherapy (SBRT)|3-5 fractions per tumor within one treatment session or sequential within one month
2002884|NCT01540565|Other|Laboratory Biomarker Analysis|Correlative studies
2002885|NCT01540565|Drug|Veliparib|Given PO
2002886|NCT01539291|Drug|Idelalisib|Idelalisib 150 mg tablet(s) administered orally twice daily
2002887|NCT01538654|Procedure|enteral protein tube feeding in obese|The intervention is represented by a new alternative to treat obese patients by means of a protein sparing modified fast administered by continous 24 h enteral feeding
1508361|NCT02907944|Behavioral|Implementation Facilitation|"Implementation Facilitation is an evidence-based strategy tailored to the specific needs of the clinic, designed to increase uptake of evidence based treatments for tobacco, alcohol and opioid use disorders. Will include provider education and academic detailing.
External Facilitator: Outside content expert who assists site
Local Champion: Site stakeholder who promotes change
Provider Education and Academic Detailing: Provision of unbiased peer education
Stakeholder Engagement: Aligning goals of implementation and those impacted
Tailor Program to Site: Addressing site specific needs based on Aim 1
Performance Monitoring and Feedback: Assess implementation of screening and treatment efforts and inform site of results
Formative Evaluation: Quant. and qual. determination of impact
Establish a Learning Collaborative: Shared learning opportunities tailored to stakeholders
Program Marketing: Increase attention to availability of on-site addiction treatment services"
1508362|NCT02907931|Other|Point of Care Ultrasound|
1508363|NCT02907918|Drug|Palbociclib|Palbociclib is an oral drug given at a dose of 125 mg daily on Days 1-21 of each 28-day cycle for a total of 4 cycles.
1508364|NCT02907918|Drug|Letrozole|Letrozole is an oral drug given at a dose of 2.5 mg orally once a day. It will be taken continuously (Days 1-28 of each cycle) until the day of definitive surgery.
1508365|NCT02907918|Biological|Trastuzumab|Trastuzumab will be administered on a weekly basis for 16 weeks (on Days 1, 8, 15, and 22 of each 28-day cycle for a total of 4 cycles). The first dose of trastuzumab on Cycle 1 Day 1 will be a loading dose of 4 mg/kg IVPB over 90 minutes. Subsequent doses of trastuzumab will be 2 mg/kg IVPB over 30 minutes. Weekly trastuzumab will continue after the completion of Cycle 4 of palbociclib until surgery.
1508366|NCT02907918|Drug|Goserelin|Goserelin is given subcutaneously at a dose of 3.6 mg on Day 1 of each cycle. Goserelin will be continued (once every 28-days) after the completion of Cycle 4 of palbociclib if required.
1508367|NCT02907918|Procedure|Breast surgery|Standard of care
1508368|NCT02907918|Procedure|Research tumor biopsy|Baseline, cycle 1 day 15, and surgery
1508369|NCT02907918|Procedure|Research bone marrow (OPTIONAL)|Baseline and surgery
1508370|NCT02907918|Procedure|Research blood sample|Baseline, cycle 1 day 15, surgery, and yearly post-surgery for 5 years
1508371|NCT02907918|Genetic|Research blood for germline DNA|Baseline
1508372|NCT02907918|Procedure|Blood for detection of circulating tumor cells|Baseline
1508373|NCT02907905|Biological|capillary sampling|"After elution in buffer (PBS-Tween azide and thiamol) eluate 200 microliter is processed on automated techniques (Siemens Centaur XL and Diasorin) after adjustment of the figures according to ISO 15189 scope B.
The results are qualitatively made and sent to the teams. The return of results, a proposal for appropriate care in the event of contact with virus (anti-HAV HCV HBV) through a rendering consultation results"
1508374|NCT02907892|Procedure|Glove change|Intra-operative changing of sterile surgical gloves immediately prior to abdominal closure during cesarean section
1508375|NCT02907866|Device|Ultrasound with EBUS scope and with linear ultrasound probe|All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
1508376|NCT02907853|Behavioral|Contingency Management|as described above
1508377|NCT02907840|Device|Swisstom BB2|Electrical impedance tomography lung monitoring uses a dedicated belt placed around patient's thorax to detect change in impedance due to change in aeration within the thorax
1508378|NCT02907827|Other|follow up DW MRI|Whole-body diffusion-weighted magnetic resonance imaging and cfDNA analysis
1508379|NCT02907814|Device|Optical Coherence Tomography (OCT)|The OCT scan is a brief, non-contact scan of the back of the eye using infrared light. Subjects will see a light and be asked to look forwards while the scan is completed.
1508380|NCT02907814|Other|Eye Exam|This is a brief, non-contact ocular exam.
1508381|NCT02907801|Behavioral|Perception-Action Approach|Environmental set-up, gentle manual guidance, and caregiver education
1508382|NCT02907775|Device|ShefStim|Electrode arrays will be worn over the affected arm with stimulation applied over the extensor aspect of the upper arm
1508383|NCT02907775|Device|Electrodes|electrodes placed over the radial nerve in radial grove
1508384|NCT02907762|Device|Endovascular aneurysm repair EVAR|
1508387|NCT02907723|Device|Sleep Recording|the device records movements during patients' sleep
1508388|NCT02907710|Drug|Endostar|intravenous infusion
1508389|NCT02907710|Drug|DDP|
1508390|NCT02907697|Behavioral|Life Steps-Drug Use|
1508391|NCT02907697|Behavioral|General Health Education|
1508392|NCT02907684|Dietary Supplement|Almonds|Participants to consume almonds as snacks to contribute to 20% of their energy requirements daily for 4 weeks
1508393|NCT02907684|Dietary Supplement|Muffins/Crackers|"Participants to consume muffins/crackers as snacks to contribute to 20% of their energy requirements daily for 4 weeks
NB all participants will have a run in period for 2 weeks whereby muffins are consumed, this is prior to randomisation."
1508394|NCT02907671|Procedure|carpal tunnel corticoanesthetic injection|Different Injection Sites (between the flexot tendons or around the median nerve with hydrodissection)
1508446|NCT02907255|Device|Oximetry monitor|Wireless respiratory monitoring system
1508447|NCT02907242|Other|Revealment|Cerebroplacental ratio revealment
1508448|NCT02907229|Device|NCVC-CS1|Intervention Description
1508451|NCT02907190|Other|Bean Type|1/2 cup of freshly boiled beans will be eaten by participants on separate study visits
1508983|NCT02902913|Drug|Ibuprofen|400 mg of Ibuprofen
1508395|NCT02907658|Behavioral|PROTECT intervention group|The indicated preventive intervention PROTECT consists of a cognitive-behavioral 4-session brief-protocol (90 minutes). It targets empirically identified risk factors of Internet Use Disorder (IUD), i.e. (1) boredom and motivational problems, (2) procrastination and performance anxiety, (3) social behavior and (4) emotion regulation. It addresses both risk-reduction and strength-promotion by cognitive behavioral (CB) interventions such as (1) psychoeducation, (2) cognitive restructuring (identification and modification of dysfunctional cognition), (3) behavior modification (improving problem solving skills, training of functional behavior and reinforcement) as well as (4) improving emotion regulation (training of sensory, imaginative and mindfulness based techniques).
1508396|NCT02907645|Behavioral|Local educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on local data
1508397|NCT02907645|Behavioral|National educational information|Adult patients in this arm receive educational information regarding influenza vaccination based on national data
1508398|NCT02907632|Drug|Metoclopramide|"Metoclopramide Solution 4 mg / ml; 30 ml canister (1 drop equals 0.2 mg). Dose: 0.2 mg / kg / dose (1 drop per kg) every 8 hours orally 15 minutes before lactation.
Duration: Until the child completes 40 weeks of post menstrual age."
1508399|NCT02907632|Drug|Placebo|Oral solution: 1 drop per kg of placebo 15 minutes before lactation with identical presentation appearance, taste and color than Metoclopramide. Duration: Until the child completes 40 weeks of post menstrual age.
2002888|NCT01516827|Behavioral|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT)|TF-CBT (see also HThttp://tfcbt.musc.eduTH) is a manualised intervention for traumatized children and adolescents 7 to 16 years old and their parent/caregiver. The primary components are summarized by the acronym PRACTICE: Parenting skills, Psychoeducation, Relaxation, Affect modulation, Cognitive processing, Trauma narrative, In vivo mastery of trauma reminders, Conjoint child-parent session, and Enhancing safety and future development. We will use the manual as provided by Cohen et al. and available in German. The treatment program will comprise 12 sessions with children and parents (partly separated, partly conjoined sessions) of 90 minutes each. The 12 sessions will be distributed over a duration of 16 weeks.
1508402|NCT02907580|Behavioral|Local educational information|Participants in this arm receive educational information regarding influenza vaccination based on local educational information.
1508403|NCT02907580|Behavioral|National educational information|Participants in this arm receive educational information regarding influenza vaccination based on national educational information.
1508404|NCT02907567|Drug|CT1812|Active study drug
1508405|NCT02907567|Drug|Placebo|non-active study drug
1508406|NCT02907554|Drug|cyclosporine A|
1508407|NCT02907554|Drug|Placebo|
1508408|NCT02907541|Other|QI4U learning|Learners will have access to 8 QI methods modules on QI4U
1508409|NCT02907541|Other|Facilitated learning|Learners will have access to quarterly learning events and bespoke training on QI methods through facilitated peer-to-peer learning workshops
1508410|NCT02907541|Other|QI4U and Facilitated learning|Learners will have access to the 8 QI modules on QI4U and attend quarterly learning events and bespoke training on QI methods through peer-to-peer learning workshops
1508411|NCT02907528|Biological|Bone|Furcation defect regenerated with bone graft material
1508412|NCT02907528|Biological|EMD|Furcation defect regenerated with EMD
1508413|NCT02907515|Device|cm-loc attachment|cm-loc is a new implant attachment mechanism with resin matrix housing to retain the overdenture
1508414|NCT02907515|Device|ball attachment|ball attachment is the gold slandered attachment mechanism with nylon cap and metal housing to retain the overdenture
1508415|NCT02907502|Dietary Supplement|Young-child formula with low protein content|Young-child formula with low protein content
1508416|NCT02907502|Dietary Supplement|Young-child formula with protein content similar to that of cow's milk|Young-child formula with protein content similar to that of cow's milk
1508417|NCT02907489|Other|triple antibiotic paste with an anti-inflammatory drug|Mixture of ciprofloxacin, metronidazole and minocycline.and diclofenac potassium 50 mg (Catafast)
1508418|NCT02907476|Behavioral|Iyengar Yoga|
1508419|NCT02907476|Behavioral|Walking|
1508420|NCT02907450|Device|TwiCare®.|
1508421|NCT02907437|Drug|Minocycline|Minocycline as an add-on drug (200 mg/day)
1508422|NCT02907437|Drug|Placebo|(200 mg/day)
1508423|NCT02907437|Other|Probiotics|(450 mg/day)
1508424|NCT02907424|Dietary Supplement|2 months of treatment|standard 2 months of treatment
1508425|NCT02907411|Other|Quadrivas Therapy|Quadrivas therapy will be applied to subjects. Quadrivas therapy is a intensive massage therapy for different tissues. Subjects will receive 12 treatments. The first lasting 2.5 hours and the remaining 11 lasting 1.5 hours.
1508426|NCT02907385|Device|LifeSeal™ Kit|LifeSeal™ Kit is applied as an additional protective layer over a stapled anastomosis
1508427|NCT02907372|Other|neuropsychologic evaluation|
1508428|NCT02907372|Other|oncogeriatric evaluation|
2002889|NCT01512693|Drug|MK-0822|A single oral dose (50 mg tablet) of MK 0822 will be administered on Day 1 after an overnight fast.
1508431|NCT02907346|Device|CGM|The intervention will reinforce patients for wearing CGM and for uploading it and reviewing its data.
1508433|NCT02907320|Drug|CYCLO 3 ® FORT|
1508434|NCT02907320|Drug|MPFF|
1508435|NCT02907320|Drug|placebo CYCLO 3 ® FORT|
1508436|NCT02907320|Drug|placebo MPFF|
1508437|NCT02907307|Device|LactiSal vaginal gel 1%|to be administered daily intravaginally for 6 days
1508438|NCT02907307|Device|LactiSal vaginal tablet 50mg|to be administered daily intravaginally for 6 days
1508439|NCT02907307|Drug|Clotrimazole vaginal tablet 100mg|to be administered daily intravaginally for 6 days
1508452|NCT02907190|Other|Starchy Foods|1/2 cup serving of one of 4 starchy foods will be eaten by participants on different study visit
2002890|NCT01510262|Behavioral|Tailored Socio-Contextual Intervention|"Develop strengths based case management intervention using input from interviews with repeat STI patients, consultants, & piloting.
Recruit/enroll in the intervention 500 subjects (50% women; African American focus).
After subjects receive STI diagnosis, treatment,& partner notification services, randomly assign subjects to:
A. The STI strengths-based prevention case management, or B. Standard care.
Assess participants' risk behavior, determinants of behavior & quality of life. Investigators will assess the incidence of new STI & test the efficacy of the intervention relative to control.
Conduct a qualitative evaluation. Investigators will sample repeaters and non-repeaters from the experimental group.
Conduct cost effectiveness analyses of intervention compared to the standard."
1508455|NCT02907164|Behavioral|Email invitation|Receive emails encouraging them to sign up
1508456|NCT02907164|Behavioral|Social norm|Receive information about how many people have signed up
1508457|NCT02907164|Behavioral|Intrinsic, health motive|Receive information about how the challenge helps people to stay fit in a fun way
1508458|NCT02907164|Behavioral|Extrinsic, reward motive|Receive information about how the challenge helps people to stay active and earn rewards
1508459|NCT02907151|Other|Survey|Complete a survey prior to the consultation and a questionnaire after
1508460|NCT02907138|Other|Medical Yoga|
1508461|NCT02907138|Other|Treatment as Usual (physical therapy)|
1508462|NCT02907125|Behavioral|SEHER Intervention delivered by TSM|"SEHER Intervention The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activitiesAwareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.
This intervention will be delivered in each school over the academic year."
1508463|NCT02907125|Behavioral|SEHER Intervention delivered by SM|"The SEHER intervention will be delivered by a lay health worker called as SEHER Mitra being trained to facilitate following activities: Awareness generation activities for all stakeholders in school; Wall-magazine, Speak-out box, Competitions, School Health Promotion Committee, School health policies, Peer groups of students of class IX and X students, Workshops and talks for all the students from standard IX, and for teachers, and Counselling and referral services for all the students in the school.
This intervention will be delivered in each school over the academic year."
1508464|NCT02907125|Behavioral|Tarang AEP|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
1508465|NCT02907112|Behavioral|Meat reduction|Advice, Motivational material and food products provided to participants
1508469|NCT02907086|Other|blood collection|
1508470|NCT02907073|Drug|BF4|Single IV dose of 9-11 mCi sodium [Fluorine-18] radiolabeled B4^F
1508471|NCT02907060|Device|Mechanical cervical ripening|"The mechanical cervical ripening is a double transcervical balloon. The device used in the study is the Cook® Cervical Ripening Balloon with CE marked (commercialized by the Cook® laboratory, ref JCRBS-184000). It is a silicone double balloon catheter. Maximum balloon inflation is 80 mL/balloon.
It will be used in accordance with user manual"
1508472|NCT02907060|Drug|Pharmacological cervical ripening|"The comparative pharmacological procedure is a vaginal slow releasing system of dinoprostone. The form used in the study is Propess (Ferring pharmaceuticals) containing 10mg of dinoprostone (prostaglandin E2).
It will be used in accordance with Summary of Product Characteristics"
1508473|NCT02907047|Other|tourniquet inflated|
1508474|NCT02907047|Other|tourniquet not inflated|
1508475|NCT02907034|Procedure|Virtual reality experimentation sequency (VR)|
1508476|NCT02907034|Procedure|Classical narrative approach (CN)|
1508477|NCT02907021|Drug|standard-of-care treatments for LV impairment|Treat patients with mild or moderate LV impairment by standard-of-care treatments for LV impairment using ACE-I and beta-blockers
1508478|NCT02907008|Other|Polysomnography|
1508479|NCT02906995|Drug|Sublingual tablet 4 mg versus Nicorette Lozenge 4mg|"One dose of study drug (sublingual tablet or Nicorette Lozenge) will be administered to each subject in the morning on Day 1.
The second administration of drug will occur at least 48 hours after the initial administration. Subjects will receive the other dosage form and be instructed according to whether they are receiving the sublingual tablet or the lozenge."
1508480|NCT02906982|Other|Gum health formulation in intra-oral device|The intervention is a gum health formulation for periodontal disease care and teeth whitening to be used within an accelerating intra-oral device.
1508481|NCT02906982|Other|Gum health formulation on toothbrush|The intervention is a gum health formulation for periodontal care and teeth whitening to be used on a toothbrush alongside standard toothpaste.
1508482|NCT02906969|Other|Colonoscopy Educational Video|Brief Video utilization to assess comprehension and evaluation bowel preparation quality
1508483|NCT02906969|Other|Placebo Educational Video|Brief Video utilization to provide placebo information and evaluation bowel preparation quality
1508484|NCT02906956|Behavioral|Preferred music playlist|Client will be instructed in a home program based on repetitive task practice principles and will complete this program with and without the use of a preferred music playlist during practice.
1508530|NCT02906579|Drug|IW-1973|
1508531|NCT02906566|Drug|Retinol|Retinol in the form of vitamin A lotion
1508490|NCT02906904|Other|Case Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, triggering of parasomniac episodes by auditory stimulations, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, parasomniac episodes, NREM stage 2 ans SWS
1508491|NCT02906904|Other|Control Intervention|24-hour sleep deprivation protocol, polysomnographic monitoring of the recovery sleep, thermoalgic stimulation (Modulator Sensory Analyzer Thermal Stimulator®) during wakefulness, NREM stage 2 ans SWS
1508492|NCT02906891|Device|Vigilant Diabetes Management Application|The Vigilant Diabetes Management Companion by InSpark Technologies was developed to assist in the prevention of hypoglycemia by providing the individual with an unobtrusive analysis of their blood glucose values and notifying them about periods of upcoming risk for low and high blood glucose; and in particular periods of risk for severe hypoglycemia. This allows the individual to take preventive corrective action. Subjects will download the Vigilant DiabetesManagement Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
1508493|NCT02906878|Procedure|Platelets transfusion|Prophylactic platelet transfusion in thrombocytopenic patients for the placement of a central venous catheter
1508494|NCT02906865|Other|Proximal hamstring tendons repair|Proximal hamstring tendons repair
1508495|NCT02906839|Other|Intervention group|Just after AF ablation, nocturnal polygraphy will be performed to diagnose SAS. If present and AHI >15/h, the SAS will be treated, based on type and severity of SAS and on patient tolerance to treatment.
1508496|NCT02906826|Device|Video game|Video game operated by performing therapy correctly
1508497|NCT02906813|Drug|TAK-935 tablets|Tablets
1508498|NCT02906813|Drug|TAK-935 Oral Solution|Oral solution
2002891|NCT01510262|Behavioral|Standard of Care|Currently, the total time spent in an STI exam w/men is 30 minutes & 60 w/women. More time is devoted to patients with sexual assault hx. Reason for the visit, symptoms, STI hx, contraception, condom use, number/gender of partners & number/type of sexual activities are assessed. The nurse takes a health hx and asks about typical HIV risks behavior. Due to time the risk assessment is 5 minutes. A risk reduction kit including condoms is issued. Information includes symptoms/treatment of STI, location of sexual health clinics, location of free condoms & testing/treatment resources. Referral information is provided when needed & more involved w/sexual assault survivors. Partner notification is conducted w/syphilis and HIV. This didactic process follows the medical model.
2002892|NCT01508572|Drug|bevacizumab-IRDye800CW|In this two stage, non-randomized, non-blinded, prospective, multicenter feasibility study, bevacizumab-IRDye800CW will be administered to a total of 20 patients with proven breast cancer.
2002893|NCT01488240|Procedure|pulsed dye laser|laser energy
1508502|NCT02906774|Biological|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation after antibiotic pretreatment
1508503|NCT02906761|Drug|Aspirin|Aspirin 600 mg (2 tablets of 300 mg) twice daily for 6 months
1508504|NCT02906761|Drug|Placebo|Placebo (2 tablets) twice daily for 6 months
2002894|NCT01482104|Drug|MAL-PDT re-treatment|a schedule of 1 single treatment of Metvix(R)-Photodynamic therapy with re-treatment of non-complete responders by 3 months
2002895|NCT01482104|Drug|usual MAL-PDT|schedule of 2 standard Metvix(R)- Photodynamic therapy treatment sessions 1 week apart.
1508507|NCT02906735|Procedure|Surgery|Implantation of knee joint prosthesis or deviation osteotomies of the knee
1508508|NCT02906722|Drug|Intravenous colimycin|administration once, twice or 3 times per day according to renal function
1508509|NCT02906722|Drug|Intravenous placebo|administration once, twice or 3 times per day according to renal function
1508510|NCT02906722|Drug|Nebulized colimycin|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
1508511|NCT02906722|Drug|Nebulized placebo|Nebulization is performed with a vibrating plate nebulizer (Aeroneb® Solo) every 8h
1508512|NCT02906709|Drug|Omarigliptin|Omarigliptin, 25 mg orally once weekly
1508513|NCT02906709|Drug|Placebo|Placebo to omarigliptin orally once weekly
1508514|NCT02906709|Biological|Insulin|Insulin will be administered subcutaneously during the trial as monotherapy; dosage and administration following each package insert.
1508515|NCT02906696|Drug|Bosutinib|Bosutinib dosed at 400 mg daily for the first 4 weeks. Participants who achieve CHR after 4 weeks continue on this dose. Those not achieving CHR can escalate to 500 mg, provided all prior Grade 3/4 events have resolved to Grade < or =2 prior to dose escalation. Participants receive daily Bosutinib until the end of the study, treatment failure, unacceptable toxicity, death, or withdrawal of consent.
1508516|NCT02906696|Behavioral|Phone Calls|Participant called by a member of the study staff every 12 weeks for up to 2 years and then every 24 weeks after that for the next 2 years. After that, participant called 4 times each year until the study ends or they withdraw from the study.
1508517|NCT02906696|Behavioral|Questionnaires|Participants complete symptom questionnaire and how they view their health on Day 28 of Cycles 12 and 24, and at end of study visit.
1508518|NCT02906683|Drug|TAS-303|Oral administration for 8 weeks, once daily.
1508519|NCT02906683|Drug|Placebo|Oral administration for 8 weeks, once daily.
1508520|NCT02906670|Drug|Sym013|Sym013 is a recombinant antibody mixture containing 6 humanized immunoglobulin G1 (IgG1) monoclonal antibodies (mAbs), which bind specifically to non-overlapping epitopes on the epidermal growth factor receptor (EGFR), and the human epidermal growth factor receptors (HER) HER2 and HER3.
1508521|NCT02906657|Other|Medication reconciliation|The medication reconciliation list will be compared to the drugs prescribed by the hospital physician at admission and discrepancies will be analyzed by discussion between the physician and the pharmacist
1508522|NCT02906644|Drug|lorcaserin|
1508523|NCT02906644|Drug|nicotine patch|
1508524|NCT02906644|Drug|placebo lorcaserin|
1508525|NCT02906618|Drug|LY3039478|Administered orally
1508526|NCT02906618|Drug|3C 15N 2H-LY3039478 IV|Administered IV
1508527|NCT02906605|Drug|JNJ-809|JNJ-809 (1*10^9) colony forming units (CFU) given as an infusion.
1508528|NCT02906605|Drug|Apalutamide|Apalutamide 240 mg orally daily.
1508529|NCT02906579|Drug|Matching Placebo|
2002896|NCT01468896|Biological|Cetuximab|Given IV
2002897|NCT01468896|Other|Laboratory Biomarker Analysis|Correlative studies
1508535|NCT02906540|Procedure|Transpubic symphysis reset therapy group|The patients in the treatment group will undergo daily transpubic symphysis reset therapy for 7 consecutive days.
1508536|NCT02906540|Procedure|Physiotherapy group|The patients in the control group will undergo physiotherapy and a sham treatment.
1508537|NCT02906527|Drug|Non-exposed group|Non-exposed group / Patients receiving VKA
1508538|NCT02906527|Drug|Exposed group|Exposed group / Patients receiving DOAC
1508539|NCT02906514|Drug|Non balanced Hydroxyethyl starch 130/0.4 (Voluven®, Fresenius)|1000mL used for cardiopulmonary bypass priming
1508540|NCT02906514|Drug|Sodium Chloride 0.9% (Fresenius)|1000mL used for cardiopulmonary bypass priming
1508541|NCT02906501|Procedure|The Penn Web-Based Computerized Neurocognitive Battery|The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
1508542|NCT02906501|Procedure|The Iowa Gambling Test (IGT)|The essential feature of this task is that it mimics real-life situations in the way it factors uncertainty, reward and punishment. The task involves four decks of cards, named A, B, C and D. The goal is to maximize profit on a loan of play money. Subjects are required to make a series of 100 card selections, but are not told ahead of time how many card selections they are going to be allowed to make. Cards can be selected one at a time, from any deck, and subjects are free to switch from any deck to another, at any time and as often as they wish. The decision to select from one deck or another is largely influenced by schedules of reward and punishment. These schedules are pre-programmed and known to the examiner, but not to the subject (Bechara et al., 1994, 1999a).
1508543|NCT02906475|Other|standardized skin care regimen|"Application of a standardized daily skin care regimen:
milk lotion once daily and
application of addendum for bathing as needed"
1508544|NCT02906462|Other|Early consideration of vulnerability|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
1508545|NCT02906462|Other|Usual practices|the centres applies their usual practices
1508546|NCT02906449|Behavioral|Meditation Technique|Alertness training or relaxation training
1508547|NCT02906436|Device|Xvivo Chamber|
1508548|NCT02906423|Other|PROMIS-10 questionnaire|Patient completed a PROMIS-10 questionnaire
1508549|NCT02906410|Other|Item-Level Calorie information|Information identifying the calorie content of individual items will be provided, as would be done on a restaurant menu board.
1508550|NCT02906410|Other|Meal-Level Calorie information|"Information from the calorie content of individual items that have been selected by the participant will be dynamically aggregated and presented as a Total Calories label on the menu screen."
1508551|NCT02906397|Drug|Galunisertib 150mg by mouth twice a day|on days 1-14 of 28 day cycles
1508552|NCT02906397|Radiation|Stereotactic Body Radiotherapy (SBRT)|18GY delivered in one fraction between C1D15 and C1D28
1508553|NCT02906384|Radiation|hippocampus avoidance|conformal avoidance of the hippocampal neural stem-cell compartment during prophylactic cranial irradiation
1508554|NCT02906371|Drug|Tocilizumab|Patients with ≥ 40% blasts in the bone marrow at pre-infusion will be enrolled in the early tocilizumab cohort and will follow early CRS treatment algorithm.
1508555|NCT02906371|Drug|Tocilizumab|Patients with ˂ 40% blasts in the bone marrow at pre-infusion (~ Day -5 to -1) will follow the standard CRS Rx algorithm
1508556|NCT02906371|Biological|CART 19|CART-19 cells transduced with a lentiviral vector to express either anti-CD19ζ scFv TCRζ:41BB, administered by i.v. injection using an intra-patient dose escalation approach: 10% on day 0, 30% on day 1 with a total dose goal of ~1.5 x107 - 5 x109 (~3x105 - 1x108/kg) T cells.
2002898|NCT01468896|Biological|Recombinant Interleukin-12|Given SC
2002899|NCT01446965|Device|wearable defibrillator|LifeVest wearable defibrillator
1508559|NCT02906345|Device|Therapeutic Plasma Exchange (TPE)|All treated patients should treated two (minimal) to five times by TPE, depending on the need of norephinephrine for the therapy. For each session 40 ml/kg body weight plasma should be exchange. Fluid resuscitation will be done with fresh frozen plasma.
1508560|NCT02906332|Drug|Pembrolizumab|Pembrolizumab 200 mg IV every 3 weeks x 2 cycles. This is followed by followed by pembrolizumab 200 mg IV every 3 weeks for 2 additional cycles.
1508561|NCT02906332|Drug|Lenalidomide|Lenalidomide 25 mg po daily x 14 days once weekly for a 21-day cycle x 2 cycles. This is followed by lenalidomide 25 mg po daily x 14 days for a 21-day cycle x 2 cycles for 2 additional cycles.
1508562|NCT02906332|Drug|Dexamethasone|Dexamethasone 40 mg po once weekly for a 21-day cycle x 2 cycles only.
1508563|NCT02906306|Behavioral|Individual Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
1508564|NCT02906306|Behavioral|Group Occupational Therapy|45 minutes 3 times per week 6 months in nursing homes (A and B)
1508565|NCT02906293|Other|Abdominal acoustic measurement|"On Day 1 participants will record their intestinal rate at baseline fasting, pre-small meal, and upon completion of the meal. On Day 2 participants will record their intestinal rate at baseline fasting, pre-large meal, and upon completion of meal."
1508566|NCT02906280|Device|EBUS-TBNA needle|tissue sampling
1508567|NCT02906267|Other|Diagnostic ultrasonography of gastric volume|Ultrasonic measurement of gastric insufflation during positive pressure ventilation (secondary endpoint) and final gastric volume after positive pressure ventilation (primary endpoint)
1508568|NCT02906254|Other|ECIL-4 guidelines group|Antibiotics were stopped when patients had been afebrile for more than 48 hours
1508569|NCT02906254|Other|Short-course antibiotic therapy|Antibiotics were stopped on day 5 in febrile or afebrile patients
1508570|NCT02906241|Behavioral|Patients: Questions to Ask Your Doctor: A Workbook for Patient-Doctor Teams|This booklet encourages patients to view themselves as members of the patient-doctor team and to participate actively during clinical interactions by asking questions and stating concerns.
1508571|NCT02906241|Behavioral|Physicians: Educational Module|Physicians will participate in an educational module and receive email prompts to encourage them to discuss trials with all patients who are eligible for a clinical trial, using patient-centered communication
1508572|NCT02906228|Radiation|Exposure within the given regulatory limits for non-ionizing electromagnetic fields according to ICNIRP guidelines and German law|
1508573|NCT02906215|Behavioral|Care Coordination Intervention|
1508574|NCT02906202|Genetic|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
1508575|NCT02906189|Radiation|MRI|
2002900|NCT01445392|Biological|Multicycle SS1P|Assigned dose level of SS1(dsFv)PE38 on days 1, 3 &amp; 5 of a 21 day cycle for 2 cycles
2002901|NCT01445392|Drug|Pemetrexed|500 mg/m2 on day 1 of each 21 day cycle until disease progression
1508578|NCT02906163|Drug|Thymalfasin (Thymosin alpha 1, Ta1)|In Phase I patients will be randomized to one of two different dosing regimens of Thymosin alpha 1 for a treatment duration of 4 months. At the completion of Phase I, data will be reviewed and a single dosing regimen will be carried forward into Phase II.
1508579|NCT02906163|Drug|SoC (tyrosine kinase inhibitor)|In Phase II patients will be randomized to SoC or Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 18 months.
1508580|NCT02906150|Drug|Thymalfasin (Thymosin alpha 1, Ta1)|Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
1508581|NCT02906150|Drug|SoC (chemotherapy and platinum agent)|Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
1508582|NCT02906137|Other|Peripheral blood and intestinal biopsies will be collected|Blood draw and intestinal biopsies
1508583|NCT02906111|Drug|estriol|"Study Group, treated with estriol
Control Group, no drug treatment
Both groups will undergo vaginal surgery for prolapse"
1508584|NCT02906111|Procedure|vaginal surgery|Control Group
1508585|NCT02906098|Behavioral|Patient centered oral health education|Procedure: The theorybased educational intervention follows a specific structure. The initial phase contain 3 treatment sessions (45-60 min each) during a period of 12 weeks (baseline, 2-3 weeks and 10-12 weeks). Follow up are performed at 6- and 18-months.
1508586|NCT02906098|Behavioral|Standard educational intervention|Procedure: The initial phase contain educational intervention in accordance with conventional routines (oral health information and oral hygiene instruction at one or several occasions). Follow up are performed at 6- and 18-months.
1508587|NCT02906085|Drug|Endothelin-1|
1508588|NCT02906085|Drug|Placebo|Isotonic saline
1508589|NCT02906072|Behavioral|Low fat plant-based diet|Conventional low fat plant-based meals three times daily. Plant-based meal replacements: Herbalife European Free From vanilla two times daily. Portion sizes and intake is unrestricted.
1508590|NCT02906072|Behavioral|Lectures on health effects of a low fat plant-based diet.|Participants attend the lectures on health effects of a low fat plant-based diet.
1508591|NCT02906059|Drug|AZD1775|
1508592|NCT02906059|Drug|Irinotecan|
1508593|NCT02906046|Device|Weight in Lower Limbs|
1508594|NCT02906033|Other|New perioperative practice model|The one and same anesthesia nurse takes care of the patient during the entire perioperative process and even pays the patient a visit to the ward the day after surgery.
2002902|NCT01445392|Drug|Cisplatin|75 mg/m2 on day 1 of each 21 day cycle until disease progression
1508597|NCT02906007|Drug|Bedaquiline|"100 mg oral tablets.
Doses will vary based on the participant's age and weight."
1508598|NCT02905994|Drug|Volasertib|Polo-Like Kinase Inhibitor
1508599|NCT02905994|Drug|Cytarabine|Standard chemotherapy at dosage and schedule for 7+3 induction
1508600|NCT02905994|Drug|Idarubicin|Standard chemotherapy at dosage and schedule for 7+3 induction
1508601|NCT02905994|Procedure|Bone Marrow Biopsy|Bone marrow biopsy assessments scheduled during induction to assess response
1508602|NCT02905981|Drug|Fer-In-Sol|Fer-In-Sol is an over-the-counter oral iron supplement. It will be administered during Period 1 at a dose of 3 mg/kg body weight.
1508603|NCT02905981|Drug|Shohl's solution|Shohl's solution will be supplied as 500-mL bottles containing citric acid USP 640 mg/5 mL and hydrous sodium citrate USP 490 mg/5 mL. It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
1508604|NCT02905981|Drug|Triferic|Triferic is an iron salt that is approved by the FDA for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis. It is experimental in this study because it has not yet been approved for patients with IRIDA. It will be administered during Period 1 at a dose of 3 mg/kg body weight. In Periods 2 and 3 the dose may be adjusted based on lab results.
1508605|NCT02905968|Device|transanual tube placement|Transanual tube placement after anastomosis in low anterior resection for rectal cancer.
1508606|NCT02905955|Device|Prevena, KCI, Acelity, NPWT|All patients will receive a Prevena NPWT (if inclusion criteria are met)
1508607|NCT02905942|Drug|PEG-rhG-CSF|PEG-rhG-CSF was given day +1 after autologous stem cell transplantation with a dose of 100μg/kg(bw).For patients more than 45kg, 6mg was suggested.
1508608|NCT02905942|Drug|rhG-CSF|rhG-CSF was given day +1 after transplantation with a dose of 5μg/kg once per day
1508609|NCT02905929|Device|ActivPAL inclinometer|Participants will wear a thigh-worn inclinometer for the first 3 weeks of the intervention, and at the mid-point of the intervention. The device will monitor their sitting and standing time.
1508610|NCT02905929|Behavioral|Phone counseling call: Breaking up sitting time|Participants will receive 5 counseling phone calls to check-in on goal setting, strategies, and tools.
1508611|NCT02905929|Behavioral|In-person counseling: Breaking up sitting time|Participants will receive 3 in-person health education sessions. At these sessions participants will receive feedback from the ActivPAL showing periods throughout the day where participants have been sitting. Participants will also develop action plans, check-in on goal setting, and use of tools at these sessions.
1508729|NCT02905032|Behavioral|Decision Aid|Observation of clinical encounter using the electronic decision aid to facilitate treatment option conversation between clinician and patient.
1508612|NCT02905929|Behavioral|Phone counseling call: Healthy living|Participants will receive a healthy living educational intervention over the phone, developed and tested by the investigators in previous studies. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
1508613|NCT02905929|Other|Tools to prompt standing|Investigators will provide standing desks to participants who spend time sitting at a computer. Additional tools to help prompt standing are mechanical and electronic timers set to interrupt long periods of sitting and cues in the environment such as standing during commercial breaks and phone calls.
1508614|NCT02905929|Behavioral|In-person counseling: Healthy living|Control subjects will receive one in-person counseling session about healthy living. Participants will not receive any information on diet, physical activity or sedentary behavior that may affect the outcomes.
1508615|NCT02905916|Drug|PEG-rhG-CSF|
1508616|NCT02905903|Drug|Tricholoacetic Acid (TCA)|We will be applying 4 concentrations of TCA (20%, 25%, 30%, 35%) to the buttocks to two spots each (total of 8 lesions) and following characteristics of these lesions and comparing them to acne induced PIH during the course of the study.
1508617|NCT02905890|Drug|Norethisterone enantate|
1508618|NCT02905890|Device|Condoms|
1508619|NCT02905877|Other|Behavioural study and functional MRI|reaching studies and other behavioural studies.
1508620|NCT02905864|Drug|Liraglutide 3 mg (Saxenda)|
1508621|NCT02905864|Drug|Liraglutide 3 mg placebo|
1508622|NCT02905851|Other|Feedback group|Monitoring ability to use teledermatology to modify antibiotic burden
1508623|NCT02905851|Other|Non Feedback group|To use as control to see if antibiotic burden has been reduced in the active feedback group
1508624|NCT02905838|Device|Anatomic e.max Abutment|Implant-supported single crown was fabricated using a prefabricated stock abutment made of yttrium oxide partially stabilized tetragonal zirconia polycrystalline (Y-TZP) (Anatomic IPS e.max Abutment, straight, color M1, Ivoclar, Liechtenstein) and pressed ceramic (fluorapatite glass-ceramic, IPS e.max ZirPress, Ivoclar, Liechtenstein) using the cut-back technique and hand veneered with a thin layer of fluorapatite veneering ceramic (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
1508625|NCT02905838|Device|CAD/CAM CARES Abutment|"Implant-supported single crown was fabricated using an individualized CAD/CAM abutment made of Y-TZP (CARES® Abutment, Institut Straumann AG, Basel, Switzerland) and hand build-up veneering ceramic technique (fluorapatite veneering ceramic, IPS e.max Ceram, Ivoclar, Liechtenstein).
All implant-supported crowns were fabricated in the same dental laboratory by the same dental technician (Dominique Vinci, Geneva, Switzerland). The implants were placed by experienced oral surgeons in a prosthetic ideal position."
1508626|NCT02905812|Other|RGI & Massage|A trained intervention nurse will administer a 15 min moderate pressure massage as well as guided imagery with music once daily for up to five consecutive days.
1508629|NCT02905786|Device|Cobas h232 (Roche Diagnostics)|NT-proBNP point-of-care test
1508630|NCT02905786|Other|Clinical audit and feedback|Clinical audit and feedback to detect previously unrecognized HF patients and inform GPs about their current quality of HF care
1508631|NCT02905786|Other|Assistance by a specialized HF nurse|Assistance by a specialized HF nurse in general practice for education of patients, advice in diagnosis and treatment, transition of care
1508632|NCT02905773|Other|root canal therapy|effect of devices ( ProTaper and Reciprocal Files)
1508633|NCT02905773|Other|root canal retreatment|effect of devices ( ProTaper and Reciprocal Files)
1508634|NCT02905760|Drug|Furosemide|"Furosemide: Special LASILIX (250 mg/25 ml) solution for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)"
1508635|NCT02905760|Drug|Placebo filling|Placebo filling: Glucose 5%, 500mL infused over 30 minutes.
1508636|NCT02905760|Drug|Placebo furosemide|"Placebo furosemide: glucose 5% for injection reconditioned glass bottle like penicillin of 80mg/8mL. Injection by slow intravenous (1 to 2 minutes per 80mg vial)."
1508637|NCT02905760|Drug|Vascular filling|Vascular filling: Sodium 0.9% 500mL infused over 30 minutes.
1508638|NCT02905747|Behavioral|Medical Exercise Therapy|physiotherapy intervention with Medical exercise therapy (MET) during 3 months
1508639|NCT02905734|Drug|Nicotine patch|Single administration of an active treatment (nicotine patch)
1508640|NCT02905734|Other|placebo patch|Single administration of a placebo treatment
1508641|NCT02905721|Procedure|Spectral cardiac CT scan|Cardiac CT scan : acquisition using the spectral mode imaging in order to identify inflammatory areas of the myocardium on the iodine map imaging.
1508642|NCT02905708|Device|Air-Activated heating packs|The subject disrobe and will dress in a jacket, pants, gloves and socks (ensemble) which will be removed from a vacuum pack. He will be assisted by the nurse in pre-operative area. The ensemble will remain in place until the subject is fully recovered from anesthesia.
1508643|NCT02905708|Device|Forced Air Warming Device|forced air-warming inflatable device applied according to standard hospital protocol.
1508644|NCT02905695|Drug|Chirocaine|
1508645|NCT02905695|Other|Placebo|
1508646|NCT02905682|Drug|Desmopressin|
1508647|NCT02905682|Drug|Placebo|
1508648|NCT02905669|Device|EndoFLIP|Esophago-gastric junction distensibility will be assessed in patients thanks to impedance planimetry using EndoFLIP device
1508649|NCT02905656|Behavioral|Brief Advice|Psychoeducation
1508650|NCT02905656|Behavioral|Motivational Interviewing|Guides participants toward choosing to make a change in their behavior with a collaborative conversation.
1508651|NCT02905656|Behavioral|Rate Reduction|Reducing the number of cigarettes consumed.
1508652|NCT02905656|Drug|Pharmacological|Nicotine Replacement Therapy in the form of gum.
1508653|NCT02905656|Behavioral|MI+RR|Combination of reducing the number of cigarettes consumed while guiding the participant to make a change in their behavior.
1508654|NCT02905643|Other|Study subjects|This study does not include an intervention it is only observational.
1508655|NCT02905630|Other|Exercise training|high intensity aerobic interval training
2002903|NCT01445392|Biological|Single cycle SS1P|Patients 1 - 3 of single cycle cohort. 45 mcg/kg of SS1(dsFv)PE38 on 4 or 5 days (depending on dose level) of cycle 1 only.
2002904|NCT01445509|Drug|Bevacizumab|Once the MTD of dasatinib with bevacizumab 5 mg/kg IV every two weeks is determined, one final dose level will be accrued with that MTD dose of dasatinib with bevacizumab at 10 mg/kg IV every two weeks in order to determine if we can safely escalate bevacizumab to full dose with dasatinib concurrently.
2002905|NCT01445509|Drug|Dasatinib|We will start dasatinib at 50 mg PO QD which is less than half the recommended Phase 2 dose as well as bevacizumab at 5 mg/kg IV every two weeks, which is half the single agent dose. If this is well-tolerated, study drugs will be escalated per schema to maximize the dose of dasatinib when given concurrently.
2002906|NCT01439373|Drug|GSK2336805|Active Investigational Drug
2002907|NCT01439373|Drug|Pegylated interferon alfa-2a|Standard of Care drug
2002908|NCT01439373|Drug|Ribavirin|Standard of Care drug
2002909|NCT01439373|Drug|GSK2336805 Matching Placebo|Placebo of Investigational Drug
1508665|NCT02905565|Drug|NBP Softgel Capsules|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing.
1508666|NCT02905565|Drug|Placebo|Take 4 capsules BID on an empty stomach at least 1 hour before food intake, and remain fasting at least 1 hour after dosing
1508667|NCT02905552|Other|No intervention|
1508668|NCT02905539|Drug|Iron Isomaltoside 1000|
1508669|NCT02905539|Drug|Ferric Carboxymaltose|
1508670|NCT02905526|Behavioral|Contraceptive instant messages|Contraceptive Instant messages
1508671|NCT02905526|Other|Mobile phone app|Mobile phone app
1508672|NCT02905513|Behavioral|Contraceptive app instant messages|
1508673|NCT02905513|Other|Mobile phone app|
1508674|NCT02905474|Other|Usual Care|Usual standard CKD care involves an outpatient clinic visit every 3 to 4 months (at minimum every 6 months) for a clinical assessment by their renal clinical care team.
1508675|NCT02905474|Device|Integrated mobile medication app|Use of mobile app to maintain, manage medication list on a smartphone device that allows for bidirectional transfer of medication information
1508676|NCT02905474|Device|Commercially available mobile medication app|Use of mobile app to manually record and maintain medication records with no integration to databases.
1508677|NCT02905461|Behavioral|Contraceptive text messages|
1508678|NCT02905461|Other|Text messages not about contraception|
1508679|NCT02905448|Other|Low fat plant-based nutrition|"Conventional low fat plant-based meals free from animal source foods three times daily.
Plant-based meal replacement with Herbalife European Free From Vanilla formula two times daily.
Herbal beverage two times daily. Food intake is taken ad libitum and no calorie counts or restrictions will be applied."
1508680|NCT02905435|Device|Biodegradable Temporizing Matrix|The Biodegradable Temporizing Matrix (BTM) (also known as BTM Dressing) comprises a completely synthetic, sterile, integrating dermal component (porous biodegradable polyurethane foam) and a temporary epidermal barrier component (a non-biodegradable polyurethane sealing membrane). These layers are adhered with a biodegradable polyurethane bonding layer. BTM will be implanted and fixed into position to close a debrided burn wound. After a period of integration, the sealing membrane is removed and a split skin graft is applied.
1508681|NCT02905422|Behavioral|H.E.A.L.T.H. II Intervention|12 month study with 6 month intervention phase and 6 month follow up phase. Participants will receive bi-weekly educational information pertaining to weight loss during the intervention phase. Participants will use online website to monitor weight, access meal plans, access weight loss information, and access fitness plans.
1508682|NCT02905409|Procedure|ILM peeling surgery|4PD or 2PD diameter of ILM peeling in surgery was given to patients with IMH (idiopathic macular hole)
1508683|NCT02905396|Device|Spinal cord stimulation|implantation of spinal cord stimulator
2002910|NCT01440010|Radiation|IORT with 50 kV x-rays, 20 Gy|Intraoperative radiotherapy with the INTRABEAM System with 20 Gy
1508730|NCT02905019|Biological|R21 with Matrix-M1|Vaccine
1508731|NCT02905019|Biological|ChAd63 ME-TRAP|Vaccine
1508732|NCT02905019|Biological|MVA ME-TRAP|Vaccine
1508733|NCT02905006|Drug|Bimekizumab|Subjects will be randomized to receive a combination of injections of Bimekizumab and Placebo (as appropriate) to maintain the blinding.
1508734|NCT02905006|Other|Placebo|Subjects randomized to the placebo group, will receive a combination of several injections of Placebo to maintain the blinding.
2002911|NCT01437098|Device|MDT-2111 CoreValve for TAVI|CoreValve Transcatheter Aortic Valve Implantation (TAVI) using the MDT-2111 system.
2002912|NCT01428388|Drug|Intravitreal injection of bevacizumab|1.25 mg per dose, delivered monthly by intravitreal injection for six months
2002913|NCT01428388|Drug|Intravitreal injection of ranibizumab (0.5 mg per dose)|0.5 mg per dose, delivered monthly by intravitreal injection for six months
2002914|NCT01420250|Drug|Cabazitaxel|"Administered weekly on the same day of radiation according to the following infusion levels:
Level 1 (Initial): 4 mg/m2; Level -1: 2 mg/m2; Level 2: 6 mg/m2; Level 3: 8 mg/m2; Level 4: 10 mg/2;"
2002915|NCT01420250|Radiation|Intensity Modulated Radiation Therapy (IMRT)|Starts 8 weeks after initiation of androgen deprivation therapy, given daily at 1.8 Gy for a total of 75.6 Gy
2002916|NCT01420250|Drug|Anti-Androgen Therapy: Bicalutamide|"Taken once daily by mouth starting between 2 weeks and 1 day before the first administration of Luteinizing Hormone-Releasing Hormone (LHRH)
Will continue once daily until the final day of IMRT"
2002917|NCT01420250|Genetic|Luteinizing Hormone-Releasing Hormone (LHRH) Agonist|"First administration will occur 1 day to 2 weeks after the start of Bicalutamide and 8 weeks prior to the start of IMRT (+/- 4 weeks)
Will continue for 24 months after IMRT
Total administered duration and agent used must be documented on the case report form"
2002918|NCT01419587|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
2002919|NCT01419483|Dietary Supplement|Ketogenic diet|A ketogenic diet matching the fat to carbohydrate + proteins in Keto-Cal(R) 4:1 by Nutricia North America.
1508685|NCT02905370|Behavioral|Progressive Multi-Component (PMC)|"Participants in the Progressive Multi-component intervention group will receive 1) high intensity physical therapy, 2) protein supplement, and 3) emphasis on functionally enhanced transitions of care following discharge from post-acute setting. High intensity physical therapy will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Functionally enhanced transitions of care protocol includes a personal health record with 5 domains that are addressed in an interdisciplinary manner with the patient. Participants will receive 12 intervention visits over 60 days. Participants will also receive a home exercise program."
1508686|NCT02905370|Behavioral|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 60 days. Participants will also receive a standardized home exercise program and standard nutritional education."
1508687|NCT02905357|Device|OCT|Optical Coherence Tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
1508688|NCT02905357|Other|CMR|Cardiac Magnetic Resonance Imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (swelling).
2002924|NCT01392573|Drug|insulin degludec/liraglutide|IDeg/Lira treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDegLira is injected subcutaneously (under the skin) once daily.
2002925|NCT01392573|Drug|insulin degludec|IDeg treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). IDeg is injected subcutaneously (under the skin) once daily.
1508692|NCT02905305|Device|Contour Advance electrode with controlled dose of dexamethasone base|The Combined Device consists of a standard cochlear implant receiver-stimulator coupled to a Contour Advance electrode loaded with a controlled dose of dexamethasone base.
1508693|NCT02905305|Device|Contour Advance electrode|Standard Contour Advance electrode
1508694|NCT02905292|Other|evaluation and treatment maneuver for BPPV|
1508695|NCT02905279|Behavioral|Biofeedback Relaxation Training|Participants will receive one-session biofeedback relaxation training (24 minutes) for anxiety reduction. Prior to biofeedback, participants will receive education about spiders and the development and maintenance of spider phobia.
1508696|NCT02905279|Behavioral|Exposure Therapy|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. Prior to exposure therapy, participants will receive education about spiders and the development and the development and maintenance of spider phobia.
1508697|NCT02905279|Behavioral|Exposure with Threat-Relevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure, participants will engage in actions opposite to the tendencies associated with threat avoidance. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
1508698|NCT02905279|Behavioral|Exposure with Threat-Irrelevant Opposite Actions|Participants will receive one-session exposure therapy (24 minutes) for fear of spiders. During exposure therapy, participants will engage in actions opposite of the action tendencies associated with the fear, but unrelated to the specific threats associated with spider phobia. Prior to exposure therapy, participants will receive education about spiders and the development and maintenance of spider phobia.
1508699|NCT02905266|Biological|Nivolumab|-Specified dose on specified days
1508700|NCT02905266|Biological|Ipilimumab|-Specified dose on specified days
1508701|NCT02905253|Drug|AC-084|Hard gelatin capsules for oral administration formulated in strengths of 1 mg, 10 mg, and 100 mg
1508702|NCT02905253|Drug|Placebo|Placebo capsules matching AC-084 capsules
1508705|NCT02905227|Drug|CVT-427 (zolmitriptan inhalation powder)|
1508706|NCT02905227|Other|Placebo|CVT-427 inhaler with placebo capsules for training.
1508707|NCT02905214|Device|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
1508708|NCT02905188|Genetic|GLYCAR T cells|"Three different dosing schedules will be evaluated. Two to four patients will be evaluated on each dosing schedule.
The following dose levels will be evaluated:
DL1: 1x10^7/m2
DL2: 1x10^8/m2
DL3: 1x10^9/m2
The doses are calculated according to the actual number of GPC3-CAR transduced T cells."
1508709|NCT02905188|Drug|Cytoxan|Cyclophosphamide will be given at a dose of 500 mg/m2/day for 3 days given intravenously
1508710|NCT02905188|Drug|Fludarabine|Fludarabine will be given at a dose of 30 mg/m2/day for 3 days given intravenously
1508711|NCT02905175|Procedure|blood sample|
1508712|NCT02905175|Procedure|synovial tissue|synoviocytes from synovial tissue
1508714|NCT02905149|Procedure|Serrato|Serratus plane block.
1508715|NCT02905149|Procedure|Control|Standard anesthesia
1508716|NCT02905136|Other|Fundamental research|
1508717|NCT02905123|Behavioral|Check Your Drinking|
1508718|NCT02905110|Drug|Methotrexate|Methotrexate 4 mg into fourth ventricle of the brain via the Ommaya Reservoir 2 days a week for 6 weeks. Each patient will have 12 infusions.
1508719|NCT02905110|Drug|Etoposide|Etoposide 1 mg into fourth ventricle of the brain via the Ommaya Reservoir 5 days a week for weeks 1, 3, and 5. Each patient will have 15 infusions.
1508720|NCT02905110|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
1508721|NCT02905097|Procedure|Knee Replacement|Surgical replacement of arthritic knee with an implant
1508722|NCT02905071|Other|filling of Serenat at baseline (T1)|Patients who consult occupational doctor complete the serenat questionnaire.The time taken to complete the serenat scale is about 5 minutes.
1508723|NCT02905071|Other|Serenat at baseline T1 and 3 others questionnaires|Subjects who consult occupational doctor complete the 4 questionnaires.The time taken to complete the 4 questionnaires is about 15 minutes.
1508724|NCT02905071|Other|filling of Serenat, HADS, STAY-Y and BDI at baseline T1|Patients who consult a psychiatrist in a stress anxiety unit complete the 4 questionnaires.
1508725|NCT02905058|Drug|Ketoprofen|oral non-steroidal antiinflammatory drug
1508726|NCT02905058|Drug|placebo|
1508727|NCT02905045|Drug|Ketoprofen|
1508735|NCT02904993|Other|L2 paravertebral block|nerve block group will receive preoperatively a L2 paravertebral block with indwelling catheter
1508736|NCT02904993|Other|periarticular injection group|periarticular injection group will receive the injection cocktail towards the end of the total hip replacement prior to skin closure.
1508737|NCT02904980|Behavioral|Technical Training|Children will watch an instructional video focused on movement related instructions regarding the throwing and catching task.
1508738|NCT02904980|Behavioral|Quiet Eye Training|Children will watch the same video as the TT group but will also receive instructions designed to optimise their quiet eye durations.
1508739|NCT02904967|Biological|Extra Blood Draw|
1508740|NCT02904954|Drug|Durvalumab|Intravenously
1508741|NCT02904954|Other|Durvalumab plus SBRT|Intravenously
1508742|NCT02904941|Biological|Amniotic Membrane Dressing|Amniotic membrane dressings will be made out of donated amniotic membranes from elective cesarean sections. Screening for relevant infectious diseases and irradiation will be performed from every included sample in order to minimise infectious risks. Dressings will be provided to attending surgeons during wound care at the operating theatre and removed every 72-96 hours.
1508743|NCT02904941|Device|Synthetic Dressing|Silicone dressings will used as an active comparator in this study. As with the amniotic membrane, dressings will be applied to wound care at the operating room and replaced every 72 to 96 hours.
1508744|NCT02904941|Procedure|Standard Wound Care|Every included participant will receive standard wound care regardless of treatment allocation. Contaminants such as clothes or other materials will be removed, and all burns will be cleaned using sterile saline solutions. Clorhexidine will also be used to clean the skin. Surgical debridement under general anesthesia or procedural sedation/analgesia will be performed to every included participant, in which nonviable tissues and blisters will be removed.
1508745|NCT02904915|Drug|Lidocaine|Intrauterine device (IUD) placement with paracervical block with 1% lidocaine.
1508746|NCT02904915|Other|No analgesia|IUD placement without analgesia.
1508747|NCT02904915|Device|Intrauterine device (IUD)|IUD placement with or without paracervical block with 1% lidocaine.
1508749|NCT02904889|Behavioral|Stay Active at Home|Stay Active at Home' aims to change the behaviour of community nurses and domestic support workers by offering them an intensive training programme. Subsequently, professionals are expected to deliver goal-oriented, holistic and person-centred services focusing on supporting older adults to maintain, gain or restore their competences to engage in physical and daily activities so that they can manage their everyday life as independently as possible.
1508750|NCT02904889|Other|Usual care|Homecare professionals will get no training and their clients will receive usual homecare.
1508751|NCT02904876|Radiation|Diffusion Magnetic Resonance Imaging at 6 months|
1508752|NCT02904863|Biological|Extra blood draw samples|
1508753|NCT02904850|Biological|group of patients|Plasma dosage of erlotinib and OSI-420 is made from the blood usually taken Further information are collected in the medical record of the patient during the CT scan reassessment after collection.
1508754|NCT02904837|Behavioral|Experimental training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.
Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
1508755|NCT02904837|Behavioral|Control training|"Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.
Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication."
1508756|NCT02904824|Biological|adipose derived regenerative cells|Stem cells from autologous adipose tissue in which autologous tissue is enriched or in suspension to fill the paralyzed vocal cord. The aim is to induce the overexpression and production of microvessels at local level. Route of administration: injection into the thickness of a paralyzed vocal cord.
1508757|NCT02904824|Biological|centrifuged autologous fat|centrifuged adipose tissue which is autologous tissue is used to fill the paralyzed vocal cord. The aim is to increase the volume of the vocal fold, to reduce the glottal gap.This effect is temporary. Route of administration: injection into the thickness of a paralyzed vocal cord.
1508758|NCT02904811|Other|Testing for Ct infection immediately|Self-taken vaginal samples will be immediately tested for Ct infection at the National Reference Centre (CNR) at University of Bordeaux, using a commercially available CE marketed real-time PCR assay.
1508759|NCT02904811|Other|Testing for Ct infection at the end of the study|Self-taken vaginal samples will be tested for Ct infection at the end of the study (M18).
1508760|NCT02904798|Drug|Polypodium Leucotomos|- PL 240mg to be taken by the patient for 28 days prior to irradiation with visible light
1508761|NCT02904785|Device|Extracorporeal Shock Waves|
1508762|NCT02904785|Device|Sham Extracorporeal Shock Waves|
1508763|NCT02904785|Other|Physical activities|Patients receive instructions for physical activities for strengthening of femoral quadriceps and stretching of hamstring muscles.
1508764|NCT02904772|Drug|alipogene tiparvovec|A dose of 1x10(*12) gc/kg alipogene tiparvovec (Glybera) of body weight administered as a single set of intramuscular injections at multiple sites in multiple muscles of both upper legs and if necessary, the lower legs.
1508765|NCT02904772|Drug|Prednisolone|IV bolus methylprednisolone 1mg/kg half hour prior to administration
1508766|NCT02904772|Drug|Cyclosporins|Immuno + group will receive cyclosporine (3 mg/kg/day) from three days prior to until 12 weeks following IMP administration
1508767|NCT02904772|Drug|Mycophenolate mofetil|Immuno + group will receive Mycophenolate mofetil (2x 1 g/day) from three days prior to until 12 weeks following IMP administration
1508768|NCT02904759|Drug|Desmopressin|
1508769|NCT02904759|Drug|Placebo|
1508770|NCT02904746|Behavioral|Make It!|The Make It! motivational enhancement intervention has been informed by Motivational Interviewing principles, a method that has widely demonstrated effectiveness in increasing a number of positive behavior changes, including appointment adherence. Make It! consists of a 10-15 minute intervention with 5 components: Common reactions to stressors that this exposure can lead to a range of reactions, pros and cons of attending the Information Class, visualization of the Information Class, expression of confidence that the client can progress towards change, and reiteration of main information.
1508771|NCT02904733|Other|mHealth platform|
1508772|NCT02904707|Procedure|Questionary EQ-5D|In addition to the pain questionary that is filled filled as usual, the EQ-5D questionary will be distributed at the beginning of hospitalization and completed by each patient, and will evaluate the impact of painful ulcers in their daily lives.
1508773|NCT02904707|Procedure|Numeric Evaluation NE of Pain|Pain assessment questionnaire by (NE (Numeric Evaluation) before and after the skin graft pellet, will be filled by a caregiver during an interview with each patient
1508774|NCT02904681|Other|No intervention. Observational and descriptive study|
1508775|NCT02904668|Other|self-administered program|One session was a session supervised by a physical therapist in the Faculty of Health Sciences. This session took place in groups of three or four people. All participants had to follow the physiotherapist instructions about the correct way to do the exercises with the foam roller or ball and nerve mobilizations of upper limbs.The other two weekly sessions were performed at home, following the instructions given by the physiotherapist in session.
1508776|NCT02904655|Other|healthy diet|Participants were provided meals and snacks for one month that represented a healthy diet that is high in unsaturated fats, approximating a Mediterranean diet
1508777|NCT02904642|Behavioral|SMS reminder|Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age
1508778|NCT02904642|Behavioral|Unconditional Incentive|A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
2002926|NCT01387282|Drug|Anamorelin HCl|Anamorelin HCL 100 mg will be orally administered daily at least 1 hour prior to meal
2002927|NCT01387282|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour prior to meal before the first meal of the day.
2002928|NCT01387269|Drug|Anamorelin HCl|Anamorelin HCl will be orally administered daily at least one hour before meal
2002929|NCT01387269|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
1508783|NCT02904564|Procedure|MMP with 5-FU|MMP with 5-FU using tattoo device
1508784|NCT02904564|Procedure|MMP with Saline infusion|MMP with saline infusion using tattoo device
1508785|NCT02904551|Procedure|Free gingival graft|After infiltration anesthesia, a recipient bed was prepared with a horizontal split-thickness incision made with a 15 stainless steel blade at the mucogingival junction (MGJ) on the facial side of the selected implants. An intermediate thickness (0.75 mm) graft was taken from the palate. The graft was sutured with 6-0 polypropylene suture at the recipient site. Co-Pak® was applied on the recipient site. Analgesics (over-the-counter Tylenol or Ibuprofen) were prescribed for 5-7 days. PeridexTM (3M, St. Paul, MN) was prescribed for 7-10 days. No antibiotics were prescribed in relation to the surgery.
1508786|NCT02904551|Procedure|Oral prophylaxis|Oral prophylaxis is a regular dental cleaning. Titanium periodontal curette and superfloss were used on implant sites. Stainless steel periodontal curettes and a piezo scaler were used for natural teeth.
1508787|NCT02904538|Drug|Dexamethasone|
1508788|NCT02904538|Drug|isotonic saline|
1508789|NCT02904525|Device|7 Tesla MRI, no contrast agent|Patients with newly diagnosed glioblastoma undergo a 7Tesla MRI
1508790|NCT02904512|Device|Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose|Testing Blood Glucose levels with Continuous glucose Monitoring (CGM) device and Point of Care (POC) blood glucose
1508791|NCT02904512|Other|Point of Care (POC) blood glucose|Testing Blood Glucose levels with Point of Care (POC) blood glucose
1508792|NCT02904499|Drug|Dabigatran|
1508793|NCT02904486|Behavioral|change behavior|Modified Health Belief Model Based Intervention to Reduce Body Mass Index for Age
1508794|NCT02904473|Other|GROWell|The GROWell intervention is a mobile health technology, including diet tracking, skills training and tailored feedback based on digital and human support strategies. Its message content is geared toward healthy diet change during pregnancy.
1508795|NCT02904447|Other|x-ray and pedobar foot pressure mapping|
1508796|NCT02904434|Other|Grapefruit Juice|On day 1 of the study, subjects will receive their standard voriconazole dose with no grapefruit juice. On day 2 of the study, subjects will receive approximately 240mL of reconstituted grapefruit juice by mouth or via nasogastric tube 30 minutes prior to receiving a scheduled dose of voriconazole. Blood samples will be collected during the 12 hours following voriconazole dosing on both days of the study.
1508797|NCT02904408|Behavioral|psychotherapy|Group psychotherapy
1508798|NCT02904395|Other|observational (no intervention)|
1508799|NCT02904369|Drug|Emtricitabine|
1508800|NCT02904369|Drug|Tenofovir alafenamide|
1508801|NCT02904369|Drug|Tenofovir disoproxil|
1508802|NCT02904356|Device|Repetitive transcranial magnetic stimulation|High-frequency, brainsway H-coil for repetitive transcranial magnetic stimulation will be administered to the medial prefrontal cortex for 3 weeks. The intensity of stimulation will be based on resting-motor threshold (RMT).
1508803|NCT02904343|Device|domestic hemodialysis machine|WEGO, DBB-27C
1508804|NCT02904343|Device|imported hemodialysis machine|Fresenius, 4008s
1508805|NCT02904330|Drug|K1-70 intramuscular|Each subject will receive one dose of K1-70 by IM injection on the morning of Day 1.
1508806|NCT02904304|Drug|Desloratadine+Phenylephrine+Ibuprofen|01 tablet, orally, every 12 hours.
1508807|NCT02904304|Drug|Placebo|01 tablet, orally, every 12 hours.
2002930|NCT01386385|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-conformal RT
2002931|NCT01386385|Drug|Carboplatin|Given IV
2002932|NCT01386385|Other|Laboratory Biomarker Analysis|Correlative studies
2002933|NCT01386385|Drug|Paclitaxel|Given IV
2002934|NCT01386385|Other|Placebo|Given PO
2002935|NCT01386385|Drug|Veliparib|Given PO
2002936|NCT01384513|Drug|Fludarabine|Given IV
2002937|NCT01384513|Drug|Busulfan|Given IV
1508811|NCT02904265|Drug|Diazepam|
1508812|NCT02904265|Drug|Acetazolamide|
1508813|NCT02904252|Other|Transient elastography|Transient elastography (TE) is an ultrasound-based device used for measuring the degree of liver stiffness. A transducer probe is used to create mild amplitude and low frequency vibrations (50 Hz) that transmitted through the liver tissue. This results in an elastic shear wave that propagates through the underlying liver tissue. The probe then utilizes pulse-echo ultrasound to follow the propagation of the shear wave and to measure its velocity. The velocity of the wave is directly related to tissue stiffness which correlates with fibrosis. The sensitivity and the specificity of TE is between 68%-88% and between 66%-100%, respectively for the detection of significant liver fibrosis (METAVIR score F>2).
1508814|NCT02904226|Drug|JTX-2011|JTX-2011 administered as a one hour IV infusion every 21 days
1508815|NCT02904226|Drug|nivolumab|Nivolumab 240 mg administered as a one hour IV infusion every 21 days
1508816|NCT02904213|Biological|ComBe Five (Liquid)|
1508817|NCT02904200|Device|Silicon adhesive dressing|Sterile soft silicon adhesive dressing
1508818|NCT02904200|Device|Acrylic adhesive dressing|Sterile acrylic adhesive dressing
1508819|NCT02904187|Other|Positron Emission Tomography (PET)|
1508820|NCT02904187|Other|Electroencephalogram (EEG)|
1508821|NCT02904174|Behavioral|Healthy Living Programme|A 6-week Healthy Living Program (HLP) was developed and implemented for all the participants. There was one 45 minutes weekly session over 6 week. Week 1 & 2 focused on healthy eating habits including food pyramid, balanced diet for the elderly, food labels, healthy snacks and healthy eating out. Week 3 & 4 were about fall prevention, which included risk factors and complications of fall among older adults, preventive measures, strengthening exercises and aerobic dance. Week 5 & 6 focused on drug management, such as knowledge on commonly used drugs, drug storage, use of analgesics and non-pharmacological pain relief strategies. Interactive activities such as games, puzzles and question & answer session were included in the group education.
1508822|NCT02904148|Procedure|Shoulder mobilisation|
1508823|NCT02904122|Other|teleconsultation|Determine the interest of teleconsultation in dentistry tool for the diagnosis of caries. Ie whether oral teleconsultations are of the same quality as conventional consultations for the diagnosis of caries ..
1508824|NCT02904109|Drug|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 8 days.
1508825|NCT02904109|Drug|Placebo|Once daily oral administration of placebo mannitol for 8 days.
2002938|NCT01384513|Radiation|Total Body Irradiation (TBI)|2 Gy administered as part of the conditioning regimen
1508827|NCT02904083|Behavioral|self assessment of adherence|
1508828|NCT02904070|Device|Vaginal swabbing|
1508829|NCT02904057|Device|Radiesse (+) Injectable Implant|Treated subjects will receive a maximum volume of 3.0 cc of Radiesse (+) per jawline.
1508830|NCT02904031|Drug|5-fluorouracil|
1508831|NCT02904031|Drug|oxaliplatin|
1508832|NCT02904031|Drug|l-leucovorin|
1508833|NCT02904031|Drug|panitumumab|
1508834|NCT02904018|Other|teleconsultation|Patients performing oral care required as a result of their diagnosis by teleconsultation in vulnerable populations (elderly, disabled adults).
1508835|NCT02904005|Other|Standardized assessment on depressed patients|"At inclusion, socio-demographic characteristics, main life events, psychopathology (comorbidity, personality dimensions, characterisation of SB) and biological sample will be performed by psychiatrist and nurse. Investigators will retrieve the results of biological assays routinely made as part of standard collect biological results routinely done for all depressed patient.
At follow-up (3 months, 6 months, 12 months), they will assess thymic state, occurrence of suicidal ideation and suicide attempt and environmental stressors. In case of non response, the general physician or the psychiatrist in charge of the patient will be contacted to assess the occurrence of SB during the year. In case of death or absence of clinical information, a request for cause of death certificate will be carried out through tne National Institute of Health and Medical research (INSERM) Unit 1018 / Epidemiological center on medical causes of death (CépiDc)."
1508836|NCT02903992|Radiation|Dual-energy X-ray absorptiometry (DXA)|Patients with at least one Fried criteria will have a Dual-energy X-ray absorptiometry (DXA) to measure lean muscle mass adjusted for body mass index. As part of the usual care in the Frailty Clinic patients will also have a clinical examination, a standard biological sample (requiring 15 ml of blood); an evaluation of the cognitive and functional performances, of their medico-economic situation and lifestyle.
1508837|NCT02903979|Other|HVGIC|In experimental group, the researches will be performed a restoration, after partial caries removal, with high viscosity glass ionomer cement in the teeth with deep caries lesion.
1508838|NCT02903979|Other|Indirect pulp capping|In control group, the researches will be performed a indirect pulp capping with calcium hydroxide cement and high viscosity glass ionomer cement in the teeth with deep caries lesion.
1508839|NCT02903966|Drug|GSK2982772|GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets in the morning and two tablets in the evening as directed.
1508840|NCT02903966|Drug|Placebo|Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets in the morning and two tablets in the evening as directed.
2002939|NCT01384513|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
1508842|NCT02903927|Device|Implantation of CT LUCIA IOL|
1508843|NCT02903927|Device|Implantation of Acrysof IQ SN60WF IOL|
1508844|NCT02903914|Drug|CB-1158|Arginase Inhibitor
1508845|NCT02903914|Drug|Nivolumab|PD-1 Inhibitor
1508846|NCT02903901|Drug|Melatonin|10 mg liquid Melatonin IR-SL at 7 pm for 1 week
1508847|NCT02903901|Drug|Placebo|10 mg liquid placebo at 7 pm for 1 week
2002940|NCT01384513|Drug|Cyclophosphamide (CY)|Given IV
2002941|NCT01384513|Drug|Tacrolimus|Given IV or PO
2002942|NCT01384513|Drug|Mycophenolate mofetil|Given IV
2002943|NCT01384513|Device|Allogeneic hematopoietic stem cell transplantation|Undergo CD34+ allogeneic PBSCT
2002944|NCT01384513|Procedure|Peripheral blood stem cell transplantation (PBSCT)|Undergo CD34+ allogeneic PBSCT
2002945|NCT01381718|Drug|modafinil|Given PO
2002946|NCT01381718|Other|placebo|Given PO
1508849|NCT02903875|Other|Patient therapeutic education (PTE) programme|
1508850|NCT02903862|Behavioral|Mindoula|The Mindoula intervention is a combination of case management and a messenger application. Case managers monitor how the participant is doing and any needs and provide 24/7 support & assistance, including care coordination, treatment adherence, and matching the participant with providers and community resources. Each participant will be given an intake questionnaire to establish goals and behavioral health history. Participants will use the app and work with the case manager for 12 weeks.
1508851|NCT02903862|Device|DANA|DANA is an FDA-cleared neurocognitive assessment software administered on a smartphone or tablet to measure changes in cognitive efficiency. DANA also includes Ecological Momentary Assessments to track mood, sleep, stress, and memory. Intervention participants will take DANA weekly. The Waitlist Control arm will take DANA weekly 12 weeks after enrollment.
1508852|NCT02903849|Behavioral|Drafting Motivational Messages|Write down three motivating messages
1508853|NCT02903849|Behavioral|Control Reminders|Receive standard reminders at three points during the challenge
1508854|NCT02903849|Behavioral|Treatment Reminders|Receive reminders containing the messages they leave themselves at three points during the challenge
1508855|NCT02903836|Drug|Nafithromycin 800 mg 3 days|
1508856|NCT02903836|Drug|Nafithromycin 800 mg 5 days|
1508857|NCT02903836|Drug|Moxifloxacin 400 mg|
1508858|NCT02903823|Drug|Baclofen bolus injection|A baclofen bolus injection (50 micrograms) will be administered daily after the patient returns from radiology to position catheter injection location. The injection may be given at C4, T4, T10 or L2 spinal locations depending on the catheter tip location.
1508859|NCT02903810|Biological|Mixed CAR-T Transfer|All subjects will be infused with αCD19-TCRz-41BB and αCD22-TCRz-41BB CAR-T cells in equal number
1508860|NCT02903784|Device|fMRI|Patient with grade 2 glioma and healthy volunteers use a brain imaging (fMRI)
1508861|NCT02903784|Procedure|tractography|Patient with grade 2 glioma and healthy volunteers use a brain imaging (tractography)
1508862|NCT02903784|Other|neuropsychological examination|Patient with grade 2 glioma and healthy volunteers use a neuropsychological examination
1508863|NCT02903771|Drug|Part A: Dose Escalation of Cantrixil|"Cantrixil will be administered via the intraperitoneal route only. The dose of study drug that each participant will receive will depend on how far the study has progressed when the participant enrols. There are 9 potential doses of Cantrixil, they are 0.06, 0.12, 0.24 (starting dose), 0.6, 1.25, 2.5, 5, 10, or 20 mg/kg. The dose each participant receives will remain the same during the study, unless it needs to be reduced for safety reasons. The dose will not be increased.
Each participant will receive the study drug once a week during the first two cycles; each cycle is 21-days (three weeks); the MTD will be determined during Cycle 1 only. If after two cycles of monotherapy, the patient tolerates Cantrixil adequately, they may continue to receive Cantrixil once a week and will also begin combination chemotherapy for another 6 cycles. Participants will receive no more than 8 cycles of study drug."
1508864|NCT02903771|Drug|Part B: Expansion Cohort of Cantrixil|Once the MTD has been established, an expansion cohort will be recruited at the MTD. An additional 12 patients will be recruited in this cohort on top of those recruited in Part A at the MTD. These patients will be subjected to the same intervention described in Part A with 2 cycles of monotherapy followed by up to 6 cycles of combination therapy.
1508865|NCT02903771|Drug|Part C: Twice weekly dosing of Cantrixil|Once Part B is complete, up to 6 patients may be enrolled in Part C. Part C will examine the tolerability of twice weekly doses of Cantrixil at the MTD-1 dose level Twice weekly doses will first be administered as a monotherapy during Cycles 1 and 2 on Days 1 and 4 of each week of the first two 3-week cycles. Patients who have not discontinued from the study at the end of Cycles 1 and 2 will proceed to twice weekly Cantrixil administration together with chemotherapy.
1508866|NCT02903758|Other|cross sectional|
1508867|NCT02903745|Other|observational|
1508868|NCT02903732|Other|observational|registry
1508869|NCT02903719|Drug|Ropivacaine|All included patients with a right sided shoulder pain score on a numeric rating scale (NRS) equal to or above 6 and without postoperative exclusion criteria will have two (1st and 2nd intervention) ultrasound guided phrenic nerve blocks performed.
1508870|NCT02903706|Other|Measure of Plasmodium prevalence (PCR)|
1508871|NCT02903693|Other|cross sectional|
2002947|NCT01371968|Drug|alfentanil|Alfentanil is administered intravenously at the end of surgery.
2002948|NCT01371981|Drug|Asparaginase|Given IM
1508874|NCT02903667|Device|Bone grafting|
1508875|NCT02903654|Other|observational|
1508876|NCT02903641|Behavioral|Personalized information|"During a prior study in June-July 2016, we collected anthropometric measures on the index children, including the children's height. Based on these data, for households assigned to the information treatment, enumerators provided personalized information to the children's primary caregiver about the index child's current height, during a baseline household visit. The enumerators carried a display card that visually showed where the child's height fell compared to healthy children of the same age and gender like those in East Africa. The enumerators emphasized to the caregivers that short stature is due to poor chronic malnutrition and is not just attributable to genetics or a recent illness. During this visit, the enumerators additionally pointed out that chronic malnutrition is not immediately life-threatening."
1508877|NCT02903641|Behavioral|Labeled cash transfer|Households received a cash transfer labeled for child food consumption and were told the money is designed to cover additional spending for food for the index child (and any other younger children in the household) over the next six weeks. Though it was given as a single, lump sum payment, the transfer was evenly split and handed to the household in six sealed envelopes, to help the households better allocate the money. To further encourage them not to spend the money all at once, each envelope was labeled with a number, the index child's name, and the dates for the week the money in the envelope should be spent. Enumerators clearly stated that this is a one-time money transfer.
1508878|NCT02903628|Behavioral|eye health education|give a lecture and issue knowledge manual for children and parents ,6 months once , 2.5 years
1508979|NCT02902926|Behavioral|Diet instruction|Answer the doubt and help the patient get the diet knowlege about the IBS.
2002949|NCT01371981|Drug|Bortezomib|Given IV
2002950|NCT01371981|Drug|Cytarabine|Given IT or IV
1508879|NCT02903615|Other|Novel diet|Novel diet to optimise glucose levels and minimise systemic inflammation: altered macronutrient composition: lower carbohydrate, Mediterranean-style, prebiotic fibre focus.
1508880|NCT02903615|Other|Standard diet|Standard diabetes diet recommendations
1508881|NCT02903602|Behavioral|Sharing Histories training method for CHW|Female Community Health Worker training participants were led through a guided process of recalling and sharing their autobiographical memories of their personal experiences in the first 1000 days of each of their children (pregnancy, childbirth, postpartum, newborn, breastfeeding, complementary feeding, infant diarrhea and hygiene, pneumonia). On the basis of memories, cultural beliefs and practices are identified and training content is built.
1508882|NCT02903602|Behavioral|Standard training method for CHW|Female Community Health Workers were trained with standard participatory teaching method with three phases: identify knowledge, provide new knowledge, evaluate learning.
1508883|NCT02903589|Other|observational|
1508884|NCT02903576|Procedure|injection of hESC-RPE in suspension|The first six patients will receive a sub retinal injection of hESC-RPE in solution after a complete pars plana vitrectomy to access safety of the cell implant alone.
1508885|NCT02903576|Procedure|injection hESC-RPE seeded in a substrate|Fifteen patients will receive a sub-retinal implantation of embryonic stem cell derived retinal pigmented epithelium seeded in a polymeric substrate to access safety of substrate seeded with RPE
1508886|NCT02903563|Other|observational|
1508887|NCT02903537|Drug|Autologous VitD3 tolerogenic monocyte-derived dendritic cells loaded with a pool of myelin peptides (tolDC-VitD3)|Intranodal administration
1508888|NCT02903537|Drug|Interferon-beta|Subcutaneous administration interferon-beta
1508889|NCT02903524|Drug|Doxorubicin Hydrochloride Liposome injection and cyclophosphamide|
1508890|NCT02903524|Drug|pirarubicin and cyclophosphamide|
1508891|NCT02903511|Drug|Metformin|Monitoring of safety and tolerability
1508892|NCT02903511|Drug|Placebo|Monitoring of safety and tolerability
1508893|NCT02903498|Drug|UFT|UFT 360mg/m2 qd po d1-14, q3w
1508894|NCT02903485|Other|nurses perform presurgical assessement and surveillance during surgery|
1508895|NCT02903485|Other|the anesthetic team performs presurgical assessement and surveillance during surgery|
1508896|NCT02903459|Other|Transversal Study so there is no intervention|
1508897|NCT02903446|Drug|Denosumab|Participants will be randomized (1:1) allocation to denosumab 60 mg administered subcutaneously (SC) every 6 months for a year + ULT standard of care OR ULT standard of care therapy
1508898|NCT02903433|Other|High-intake avocados|Families will receive 14 avocados on a weekly basis.
1508899|NCT02903433|Other|Low-intake avocados|Families will receive 3 avocados on a weekly basis.
1508900|NCT02903433|Behavioral|Diet tips|Diet tips will come from educational materials including culturally appropriate dietary and nutritional education materials, and personalized recommendations taken from http://www.choosemyplate.gov.
1508901|NCT02903433|Behavioral|Avocado consumption advice|Recipe book with healthy recipe suggestions that include avocado.
1508902|NCT02903420|Device|Transcatheter Aortic Valve Implantation (TAVI)|Implantation of Edwards SAPIEN 3 Transcatheter Heart Valve (Model: 9600TFX) via transfemoral, transapical or transaortic approach.
1508903|NCT02903407|Drug|Midazolam|IV midazolam will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
1508904|NCT02903407|Drug|Propofol|IV propofol will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
1508905|NCT02903407|Drug|Dexmedetomidine|IV dexmedetomidine will be administered as a continuous infusion to maintain set goal sedation level of RASS 0 to -2.
1508906|NCT02903394|Device|mLCI Device|imaging of cervical epithelium using mLCI device
2002951|NCT01371981|Drug|Daunorubicin Hydrochloride|Given IV
2002952|NCT01371981|Drug|Etoposide|Given IV
2002953|NCT01371981|Other|Laboratory Biomarker Analysis|Correlative studies
1508910|NCT02903368|Drug|Apalutamide|Apalutamide is administered orally once daily up
1508911|NCT02903368|Drug|Leuprolide|Leuprolide is administered via injection every 3 months.
1508912|NCT02903368|Drug|Prednisone|Prednisone is administered orally once daily.
1508913|NCT02903368|Drug|Abiraterone Acetate|Orally once daily predetermined dose
1508914|NCT02903368|Procedure|Radical Prostatectomy|Surgery
1508915|NCT02903368|Other|Observation-Post RP|No adjuvant therapy
1508916|NCT02903355|Drug|D-methionine|D-methionine, oral liquid suspension
1508917|NCT02903355|Drug|Placebo|Placebo contains sorbitol, orange flavor and purified water; is flavor and color matched to D-Met.
1508918|NCT02903342|Other|Leaflet|A leaflet designed from data obtained from previous qualitative and quantitative studies.
1508919|NCT02903329|Other|Detoxification|Two ways of composing the detoxification protocol
2002954|NCT01371981|Drug|Mitoxantrone Hydrochloride|Given IV
1508921|NCT02903303|Other|Hypnosis|"It will consist in 4 hypnosis sessions within 2 weeks mainly for analgesic purpose. The main themes are :
1st session : contact with the therapist, body scan, basic suggestions
2nd session : hypnosis induction followed by suggestions tu build a safe place
3rd session : it is the first complete hypnosis session (induction and specific suggestions against pain)
4th session : very similar to the previous session for the content, focused on auto-hypnosis learning."
1508922|NCT02903290|Other|Longitudinal Monitoring of Energy Expenditure, Dynamic Stability and Fatigue During Gait|
1508923|NCT02903290|Other|walking track GAITRite,manual dynamometer, and treadmill|
1508924|NCT02903264|Other|Gestational diabetes mellitus|
1508927|NCT02903238|Drug|Duloxetine|Duloxetine Delayed-Release Capsules: 30mg/day for 1 week ; 60mg/day for the remaining time
1508928|NCT02903238|Drug|Placebo Oral Tablet|Lactose capsule
1508980|NCT02902913|Other|D2i2|Oleocanthal provided in a 2:1 ratio compared to oleacein
2002955|NCT01371981|Other|Pharmacological Study|Correlative studies
1508929|NCT02903225|Behavioral|Cardiac Rehabilitation|All patients included in this group attended a supervised exercise training program. A cardiologist supervised the hole training sessions. Blood pressure, pulse rate, oxygen saturation, and body weight were measured in each session. The modified Borg scale was used to measure the perceived exercise intensity
1508930|NCT02903212|Biological|Autologous apoptotic cells injection|cells injection
1508931|NCT02903199|Dietary Supplement|Whey Protein|Whey protein (18 g) administered immediately prior to breakfast and lunch meals.
1508932|NCT02903199|Dietary Supplement|Hydrolysed Protein|Hydrolysed whey protein (19.1 g) administered immediately prior to breakfast and lunch meals.
1508933|NCT02903199|Dietary Supplement|Placebo|Placebo intervention administered immediately prior to breakfast and lunch meals.
1508934|NCT02903186|Behavioral|SMS|This is an intervention using short mobile messages (SMS)
2002956|NCT01371981|Other|Quality-of-Life Assessment|Ancillary studies
2002957|NCT01371981|Other|Questionnaire Administration|Ancillary studies
2002958|NCT01371981|Drug|Sorafenib Tosylate|Given PO
1508941|NCT02903147|Behavioral|Functional Meta-Cognitive Intervention|Functional-Meta-Cognitive Intervention Program was focused on raising awareness to safe driving risk factors identified at pre-screening, with reference to the difficulties that the driver raises and providing coping strategies. The intervention has been customized for each driver and included three sessions of two hours.
1508942|NCT02903147|Behavioral|The employer's training|
1508943|NCT02903121|Drug|Tamoxifen|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
1508944|NCT02903121|Drug|Placebo|Placebo orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the first 90 days of the study
1508945|NCT02903121|Drug|Tamoxifen (open label)|Tamoxifen 10 mg orally twice daily for 7 days. Treatment to be started after 3 consecutive days of bleeding and can be repeated every 30 days two more times in the second 90 days of the study
1508946|NCT02903108|Drug|SRP plus boric acid gel|SRP followed by 0.75% boric acid placement into intrabony defect
1508947|NCT02903108|Drug|SRP plus placebo gel|SRP followed by placebo gel placement into intrabony defect
1508948|NCT02903095|Drug|TD-1439|
1508949|NCT02903095|Drug|Placebo|
1508950|NCT02903082|Biological|Residue of blood further to NFS|
1508951|NCT02903082|Biological|Residue of blood further to preoperative workup|
1508952|NCT02903082|Biological|Bone marrow collected during a myelogram carried out for hematological pathology workup|
1508953|NCT02903082|Biological|Bone marrow collected during myelogram routinely performed during hospitalization in ICU|
1508954|NCT02903069|Drug|MRZ|"MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15, 29, and 36 during Concomitant Treatment.
MRZ dose ranges from 0.55 to 1.2 mg/m2 given IV over 10 minutes on Days 1, 8, 15 every 28 days during Adjuvant Treatment.
IV hydration will be given prior to the MRZ infusion."
1508955|NCT02903069|Drug|TMZ|"TMZ will be administered once daily, 7 days/week, for 6 weeks, starting on Day 1, at a dose of 75 mg/m2 during Concomitant Treatment.
TMZ will be administered once daily on Days 1-5 every cycle, dose range 150 to 200 mg/m2 during Adjuvant Treatment."
1508956|NCT02903069|Radiation|RT|Focal RT will be administered once daily, 5 days/week, for 30 doses over 6 weeks to a total dose of 60 Gy, starting on Day 1 during Concomitant Treatment.
1508957|NCT02903069|Device|Optune|Tumor Treating Fields Therapy device to be worn ≥ 18 hours per day.
1508958|NCT02903056|Other|Rett Syndrome|Diagnosis of Rett Syndrome
1508959|NCT02903030|Drug|Maltose (placebo)|Maltose with a trace amount of silicon dioxide
1508960|NCT02903030|Drug|Visbiome Extra Strength|It is a mix of 8 strains of beneficial bacteria that should improve gut flora, improving GI function and hopefully anxiety
1508961|NCT02903017|Drug|Tranexamic acid 5%|Via nasogastric tube, 100 mL
1508962|NCT02903017|Drug|Placebo|Via nasogastric tube, 100 mL
1508963|NCT02903004|Drug|Trabectedin|
1508964|NCT02903004|Drug|Pegylated Liposomal Doxorubicin|
1508965|NCT02903004|Drug|Topotecan|
1508966|NCT02903004|Drug|Gemcitabine|
1508967|NCT02903004|Drug|Weekly Paclitaxel|
1508968|NCT02903004|Drug|Carboplatin|
1508969|NCT02902978|Drug|E6130|
1508970|NCT02902978|Drug|Placebo|E6130 matched placebo
1508971|NCT02902965|Drug|Ibrutinib|Ibrutinib 840 mg orally, once daily continuously starting day 1 of cycle 1 until confirmed disease progression, unacceptable toxicity or other protocol specified reason for discontinuation
1508972|NCT02902965|Drug|Bortezomib|Cycles 1-8: (21-day cycle): Bortezomib 1.3 mg/m^2 sub-cutaneously on days 1, 4, 8, and 11 of each Cycle Cycles 9-12: (42-day cycle): Bortezomib 1.3 mg/m^2 sub-cutaneously on days 1, 8, 22 and 29 of each Cycle
1508973|NCT02902965|Drug|Dexamethasone|"Cycles 1-8: (21-day cycle): Dexamethasone 20 mg orally on days 1, 2, 4, 5, 8, 9, 11 and 12 of each cycle Cycles 9-12: (42-day cycle): Dexamethasone 20 mg orally on days 1, 2, 8, 9, 22, 23, 29 and 30 of each cycle Cycles 13+ (28-day cycle): Dexamethasone 40 mg orally once weekly
Dose adjustment of dexamethasone to 10 mg on days specified during cycles 1-12 and 20 mg weekly during cycles 13+ is recommended for subjects >75 years of age."
1508974|NCT02902952|Behavioral|Physical Exercise|An eight week physical exercise intervention
1508975|NCT02902952|Behavioral|Control Intervention|An eight week sedentary control intervention
1508976|NCT02902939|Device|minimal extracorporeal circulation (MEC)|We should use the modification of extracorporeal circulation to reduce the systemic inflammatory response due to excessive haemodilution, allogenic blood transfusion.
1508977|NCT02902939|Procedure|The cytokines modulations|We should use the modification of cytokines by CytoSorb devices and cytokines removal by PMMA membranes during extracorporeal circulation in patients with risk factors of complications (long duration of extracorporeal circulation, re-do procedures and other)
1508978|NCT02902926|Behavioral|Low FODMAPs Diet|Instruct to design and eat Low Fermentable，Oligo-，Di-，Mono-saccharides And Polyols(FODMAPs) Diet
1508984|NCT02902887|Device|Controlled Intermittent Alternate Occlusion (CIAO ) glasses|Monitored CIAO therapy glasses
1508985|NCT02902874|Other|Blood sample|
1508986|NCT02902861|Drug|Methotrexate|methotrexate 50 mg/ml in syringes for sub-cutaneous injection; Once weekly (every 7 days) s.c. administration of 17.5 mg MTX; If PASI50 is not reached after 8 weeks, the dosing will be increased to 22.5 mg
1508987|NCT02902861|Drug|Placebo ( for Methotrexate)|NaCl-Solution manufactured to mimic Methotrexate
1508988|NCT02902835|Behavioral|BUP_FAST|Peer mentorship including: buprenorphine education, identifying buprenorphine providers, accompaniment at appointments, and psychosocial support (via outreach phone calls)
1508989|NCT02902835|Behavioral|Referral to treatment|Participants will receive a pamphlet describing the buprenorphine treatment program at a Montefiore community health center.
1508990|NCT02902822|Procedure|Screening|"The screening visit consists in a general dermatological examination of the subject, with special focus on the onset of the following skin diseases during the follow-up period:
bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);
fungal skin infections (tinea corporis, cruris, pedis);
pigmented tumors (melanoma);
non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma)."
1508991|NCT02902822|Device|Tele-dermatology|"The system consists in a simple web-based/smartphone application through which subjects can send pictures of recently onset non-widespread skin lesions with special focus on the following diseases:
bacterial skin infections - pyoderma - or viral (erysipelas, impetigo, herpes zoster, molluscum contagiosum, viral warts);
fungal skin infections (tinea corporis, cruris, pedis);
pigmented tumors (melanoma);
non-melanocytic tumors (actinic keratoses, basal cell or squamous cell carcinoma).
A dermatology will judge online pictures based on a standard scale. Each subject who will use the system will be also seen by routine clinical visit to confirm the online diagnosis. Subjects who will not send any picture will be seen for a dermatological examination at the end of each year."
1508992|NCT02902809|Biological|Tralokinumab open-label|Subcutaneous injection; fixed dose; 300 mg
1508993|NCT02902796|Device|Spinal cord stimulator|Spinal cord stimulator will be programmed to deliver, according to the randomization status of the patient, burst, 1000 hertz, and standard stimulation during each treatment group.
1508994|NCT02902783|Other|Data Collection|Data collection relevant to this study will be obtained by observation and review of hospital charts. Limited data will be obtained through relevant organ donation organizations (ODOs).
1508995|NCT02902770|Drug|Lidocaine|1.5 mg/kg IV lidocaine drip (given over 10 minutes)
1508996|NCT02902770|Drug|Ketorolac Tromethamine|IV ketorolac 30mg push
1508997|NCT02902770|Drug|Normal Saline Drip|Normal Saline Drip Placebo given over 10 minutes
1508998|NCT02902770|Drug|Normal Saline Push|Normal Saline Push Placebo
1508999|NCT02902757|Procedure|Computed Tomography|Undergo FDG PET/CT
1509000|NCT02902757|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
1509001|NCT02902757|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
1509002|NCT02902744|Drug|ILUVIEN®|Patients will receive Iluvien as the standard of care treatment for diabetic macular edema.
1509003|NCT02902731|Drug|PLACEBO|
1509004|NCT02902731|Drug|ANAKINRA|
1509005|NCT02902718|Device|mē|The mē device will be used for self administered facial treatments that will be repeated up to 3 times every session. The duration of a treatment session is 5-10 minutes.
1509006|NCT02902705|Other|Biopsy of abdominal subcutaneous white adipose tissue (2-3 g)|The biopsies of abdominal subcutaneous white adipose tissue (2-3 g) will be performed during elective surgery (i.e. peritoneal dialysis catheter) for CDK patients or during elective urologic surgery (e.g. radical prostatectomy) for Non-CDK patients. 50-100 mg will fixed in osmium tetroxide for cellularity measurement and 1g of fresh adipose tissue were used from adipocyte isolation. The remnant part of the biopsies will be snap frozen in liquid nitrogen and stored at -80°C until use (gene expression).
1509007|NCT02902692|Other|Brief Mindfulness|15 minutes psycho-education about mindfulness and a small experiential exercise using a raisin. Following this, participants listen to a 30minute pre-recorded sitting meditation which encourages them to focus on their breath and the sounds around them. Participants will be randomly assigned to either receive the brief mindfulness intervention immediately or will be asked to wait one week before receiving the intervention.
1509008|NCT02902679|Drug|BMS-986177|
1509009|NCT02902666|Drug|Paracetamol 1000 mg/codeine phosphate hemihydrate 30 mg tablet|
1509010|NCT02902666|Drug|Paracetamol 500 mg/codeine phosphate hemihydrate 30 mg tablet|
1509011|NCT02902653|Drug|Oral misoprostol|hourly titrated misoprostol
1509012|NCT02902653|Drug|Vaginal misoprostol|Administration of 25 microgs every 6 hours, maximum 150 microgr
1509013|NCT02902653|Drug|Vaginal dinoprostone|Vaginal delivery system of 10mg of dinoprostone
1509014|NCT02902640|Drug|Guaifenesin|Guaifenesin will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
1509015|NCT02902640|Drug|Sulfamethoxazole|Sulfamethoxazole will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
1509016|NCT02902640|Drug|Trimethoprim|Trimethoprim will be administered as per treating physician's discretion, according to local labeling. The protocol does not specify any dose, frequency, and duration of treatment.
1509017|NCT02902627|Device|Non Invasive Monitoring Device (ANI)|Pain measure by ANI monitor and with visual analogical scale
1509018|NCT02902614|Procedure|Vegetal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
1509019|NCT02902614|Procedure|Animal Pole blastomer embryo|for day 3 embryo biopsy / cleavage stage
1509020|NCT02902601|Drug|JNJ-54175446, 600 mg|Participants will receive JNJ-54175446, 600 mg as an oral suspension.
1509021|NCT02902601|Drug|JNJ-54175446, 150 mg|Participants will receive JNJ-54175446, 150 mg as an oral suspension.
1509022|NCT02902601|Other|Placebo|Matching placebo to JNJ-54175446
1509023|NCT02902588|Other|ICG-PULSION|Intravenous administration of indocyanine green
1509024|NCT02902588|Device|LiMON, Pulsion Medical Systems|Application of near infrared light
1509025|NCT02902588|Other|Gadolinium (Gadovist, Bayer, Germany)|Injection of gadolinium
1509109|NCT02901899|Biological|Pembrolizumab|Given IV
1509026|NCT02902575|Procedure|Laparoscopic-assisted gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic-assisted gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
1509027|NCT02902562|Procedure|Contrast Enhanced Ultrasound (CEUS)|An intravenous line (IV) line will be inserted into a vein in your arm. You will be asked to lie on a table for the ultrasound imaging. First, a regular ultrasound (without contrast) will be performed and the images will be recorded. For the contrast enhanced ultrasound, the contrast agent will be injected into your IV line. We will perform another ultrasound and the images will be recorded
1509028|NCT02902562|Procedure|Magnetic Resonance Imaging (MRI)|For the contrast MRI, the contrast agent will be injected into your IV line The MRI scanner is a small, tunnel-like machine in which a patient will be required to lie still for a long period of time. There is little space inside the scanner, which causes anxiety and discomfort for patients who fear enclosed spaces. A technician will be present at all times during the examination to communicate with you about how you are feeling.
1509029|NCT02902536|Other|No interventions|
1509030|NCT02902523|Drug|Viread® tablet 300mg|Single dose administration(PO) in the fasted state
1509031|NCT02902523|Drug|HUG116 tablet 245mg|Single dose administration(PO) in the fasted state
1509032|NCT02902510|Other|Therapeutic yoga for people with Parkinson's Disease|Held for 8 weeks, individuals participated in therapeutic yoga 60 minutes 2x/week.
1509033|NCT02902484|Drug|Nintedanib|Nintedanib Monotherapy Followed by Combination Therapy of Nintedanib and Gemcitabine Plus nab-Paclitaxel
1509034|NCT02902471|Other|Forced oscillations measure|
1509035|NCT02902458|Other|Individual interview with a qualified psychologist|Individual, recorded interview with a qualified psychologist to discuss any and all subjects related to the ICD implantation, or any other topics deemed relevant by the patient.
1509036|NCT02902445|Biological|rotavirus rapid screen test|According to routine care
1509037|NCT02902445|Genetic|polymorphism exploration|from an oral swab collected after parents consent
1509038|NCT02902432|Drug|Endostar|The patients will be randomized to CRT arm and CRT+Endostar arm. All patients will receive one cycles of induction chemotherapy, intensity modulated radiation therapy (IMRT) with weekly cisplatin and 3 cycles of chemotherapy after IMRT.
1509039|NCT02902419|Other|Wound dressing removal.|
1509040|NCT02902393|Biological|Thromboelastography|
1509041|NCT02902380|Drug|dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to end of surgery
1509042|NCT02902380|Drug|control group|0.9% saline infusion
1509043|NCT02902367|Other|Outdoor walking and strength exercise|Exercise group: Participants are supposed to perform an outdoor walking exercise program and one strength exercise for 12 weeks. The first 2 weeks start with daily walks. The intensity and frequency of walks will progressively increase performed according to the Borg scale: 12-15, ie, moderate to strenuous. Participants will walk 5-7 days/week. Added to this is a strength exercise, i.e. chair-rising which also should be performed daily.
1509044|NCT02902367|Other|control group|Control-Group: Treatment as usual for 12 weeks, without restriction of being physically active.
1509045|NCT02902354|Other|Nifedipine for tocolysis|observational
1509046|NCT02902341|Dietary Supplement|Nutrition Therapy|Nutrition based on measured caloric needs.
1509047|NCT02902341|Dietary Supplement|Control|Standard protocol nutrition based on calculated caloric needs.
1509048|NCT02902315|Other|Cryotherapy|The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
1509049|NCT02902315|Other|Vitamins C and E|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection.
1509050|NCT02902315|Other|Vitamins C and E associated with cryotherapy|The session of resistance exercises with intervention will be based on the supplementation with vitamin C (1000 mg) and vitamin E (800 IU) by oral intake (100mL of water) 40 minutes before basal blood collection. The intervention will consist of the application of hypothermia by immersion of the lower limbs of water on individuals to 15ºC for a period of 10 minutes immediately after the exercise protocol.
1509051|NCT02902315|Other|Placebo|The volunteers from placebo exercise session will receive two pills (containing wheat flour) and the remaining procedures were conserved.
1509052|NCT02902302|Drug|Ibuprofen 400 mg/10 mL oral suspension|
1509053|NCT02902302|Drug|MOMENT 400 mg coated tablet|
1509054|NCT02902289|Drug|Ibuprofen 200 mg/5 mL oral suspension|
1509055|NCT02902289|Drug|MOMENT 200 mg coated tablet|
1509056|NCT02902276|Other|additional blood sample|Two blood samples will be taken at ICU admission
1509057|NCT02902250|Procedure|Decompression|vertebral body decompression in compression fracture
1509058|NCT02902250|Procedure|vertebroplasty|vertebroplasty in vertebral compression fracture
1509060|NCT02902224|Dietary Supplement|Tap water|300ml tap water via nasogastric tube
1509061|NCT02902224|Dietary Supplement|Glucose|300ml tap water with 75g glucose via nasogastric tube
1509062|NCT02902224|Dietary Supplement|Fructose|300ml tap water with 25g fructose via nasogastric tube
1509063|NCT02902211|Device|Ankle foot orthosis|Patients will wear an ankle foot orthosis at all times except when he/she is sleeping or bathing for three months.
1509064|NCT02902211|Other|Control/standard of care|Patients will carry out with typical activities suggested by their physician for three months.
1509065|NCT02902198|Dietary Supplement|Placebo|Tap water 200ml
1509066|NCT02902198|Dietary Supplement|Glucose|25g Glucose in 200ml tap water
1509067|NCT02902198|Dietary Supplement|Monosodium glutamate|1g monosodium glutamate in 200ml tap water
1509068|NCT02902198|Dietary Supplement|Quinine|17mg quinine in 200ml tap water
1509073|NCT02902159|Other|BWW Online Peer Support|Free access to BWW online peer support and other services offered by them (except live therapy), for 6 months.
1509074|NCT02902159|Other|NHS Moodzone Online Information|Directed to access to online information from NHS Moodzone
1509075|NCT02902146|Device|Bougie|
1509076|NCT02902146|Device|Endotracheal tube|
1509077|NCT02902133|Drug|Acetazolamide|Acetazolamide 500 mg twice per day for 5 days
1509078|NCT02902120|Drug|Pre-transplant Grazoprevir and Elbasvir|Treatment will be started in the pre-transplant patients on day 0 with the combination pill zepatier, containing grazoprevir 100mg/elbasvir 50mg by mouth once daily. The medications will be continued for a total of 12 weeks (16 weeks if resistance mutations, RAVs, are detected)
1509079|NCT02902120|Drug|Post-transplant Grazoprevir and Elbasvir|Treatment will be started in the post-transplant patients on day 0 with the combination pill zepatier, containing grazoprevir 100mg/elbasvir 50mg by mouth once daily. The medications will be continued for a total of 12 weeks (16 weeks if resistance mutations, RAVs, are detected)
1509080|NCT02902107|Device|CivaSheet|
1509081|NCT02902107|Radiation|Brachytherapy|
1509082|NCT02902107|Procedure|surgical resection|
1509083|NCT02902094|Device|Drug eluting balloons|
1509084|NCT02902094|Device|Non drug eluting balloons|
1509085|NCT02902081|Drug|Cannabidiol|
1509086|NCT02902081|Drug|Placebo|
1509087|NCT02902068|Device|NICaS Bio Impedance|"Hemodynamic monitoring will be carried out using non invasive NICaS cardiac impedance by the use of two electrodes stickers which are pasted on the wrists for about 6 minutes.
Monitoring will be done with women lying down or sitting up half an hour preoperatively (in the woman's surgery waiting room) intraoperatively, and postoperatively in the PACU.
Preoperative data will be compared to intraoperative and postoperative data, and will be analyzed in order to evaluate the dynamic cardiac output changes in women undergoing cesarean sections."
1509088|NCT02902055|Drug|Neuromuscular Blocking Agents|Neuromuscular blockae
1509089|NCT02902055|Drug|Isotonic saline|Placebo
1509090|NCT02902042|Drug|Encorafenib|Dose determined in phase I. Start dose: 450 mg qd
1509091|NCT02902042|Drug|Binimetinib|Dose determined in phase I. Start dose: 45 mg bid
1509092|NCT02902042|Drug|Pembrolizumab|Dose determined in phase I. Start dose: 200 mg q3w
1509093|NCT02902042|Drug|Pembrolizumab alone|200 mg q3w
1509094|NCT02902029|Drug|Vemurafenib|960 mg vemurafenib BID until progression or unacceptable toxicity develops
1509095|NCT02902029|Drug|Cobimetinib|60 mg cobimetinib QD, 21/7 until progression or unacceptable toxicity develops
1509096|NCT02902029|Drug|Atezolizumab|1200 mg atezolizumab administered intravenously on day 1 of each 21 day-cycle. Will be given until progression or unacceptable toxicity develops
1509097|NCT02902016|Drug|GED|Four duodenal biopsies will be collected. Two biopsies will stimulated with GED (PPARgamma modulator) ex vivo during 6 hours. Two biopsies will be unstimulated (control).
1509098|NCT02902003|Behavioral|Empowering Families|A program that integrates the healthy relationship curriculum, Family Wellness, into a comprehensive set of services that includes case management, employment services, and financial coaching. The program will have four core components: (1) 20 hours of core workshop sessions using the Family Wellness curriculum; (2) case management; (3) employment services; and (4) financial coaching. The core component of Empowering Families will be a 20-hour group workshop, organized into eight two-and-a-half-hour weekly sessions (Table 1). The main content of these sessions will be based on the Family Wellness relationship education curriculum which will be covered in six sessions. These six sessions will be led by two trained facilitators employed by The Parenting Center. The core workshops will be supplemented with two additional sessions on financial planning and employment topics that will designed to be useful to all participants, regardless of their level of financial and employment needs.
1509099|NCT02901977|Drug|Ramipril|Antihypertensive therapy
1509100|NCT02901977|Drug|Doxazosin|Antihypertensive therapy
1509101|NCT02901964|Other|Hip Abductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip abductors.
1509102|NCT02901964|Other|Hip Aductor Exercise|12 treatments sessions at 6 weeks: Heating, lower limb stretching, tibiofemoral and patellofemoral mobilization, strengthening the quadriceps, hamstrings, triceps sural and hip aductors.
1509103|NCT02901951|Biological|Engerix-B|Intramuscular administration of single challenge dose of Engerix-B to adults vaccinated 20 to 30 years ago with 3 or 4 doses of Engerix-B
1509104|NCT02901938|Procedure|cemented femoral stem|The patients assigned even numbers will undergo implantation of cemented femoral stem.
1509105|NCT02901938|Device|cannulated compression screws|The patients assigned even numbers will undergo percutaneous internal fixation with cannulated compression screws.
1509106|NCT02901925|Drug|ABY-029|Using a sample size of 6-12 patients, ABY-029 will be administered via single intravenous injection to subjects with recurrent glioma, approximately 1-3 hours prior to surgery. Microdose levels of ABY-029 have been selected to determine if a fluorescence signal can be detected by wide-field imaging technology with a signal-to-noise ratio of 10, which is considered necessary for subsequent assessment of diagnostic performance of ABY-029 as a tumor biomarker sufficient to guide surgical resection in the future. Administration of the study drug is not intended to alter the extent of planned brain tumor resection during the surgical procedure.
1509107|NCT02901899|Drug|Guadecitabine|Given SC
1509108|NCT02901899|Other|Laboratory Biomarker Analysis|Correlative studies
1509110|NCT02901886|Behavioral|Intensive smoking cessation intervention|The intervention includes 1) Individual motivational counseling (5 meetings within 6 weeks) in combination with 2) nicotine replacement therapy.
1509111|NCT02901873|Device|Electrical Impedance Spectroscopy|
1509112|NCT02901860|Other|Sleep, Dietary and Cardio-metabolic Measurements|"At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.
Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken."
1509113|NCT02901847|Other|PAD tailored care|PAD tailored care
1509114|NCT02901821|Genetic|salivary RNA collection|collection of saliva for microRNA (small noncoding RNA) processing
1509115|NCT02901782|Procedure|Personalized titanium plate|3D models of tumor-bearing bone segments were constructed by using computed tomography (CT) and magnetic resonance imaging (MRI). The 3D models were used to design the model of personalized titanium plates. The model of the plates was transferred into a numerical control machine for manufacturing the personalized titanium plates by 3D printing technology. The plates were then surgically implanted for reconstruction assistance following microwave-induced hyperthermia to remove the bone tumor. Implementation parameters and knee function were then evaluated.
1509116|NCT02901769|Other|fMRI|two fMRI paradigms, emotional prosody recognition and decision making
1509117|NCT02901756|Dietary Supplement|Antemig|Participants were instructed to take one tablet every morning for three months.
1509118|NCT02901743|Other|Scaling and Root planing|All the patients were asked to use a preprocedural mouthrinse and scaling and rootplaning was done using ultrasonic scalers.
1509119|NCT02901730|Procedure|532nm laser group|LPI with 532nm laser.
1509120|NCT02901730|Procedure|561nm laser group|LPI with 561nm laser.
1509121|NCT02901717|Drug|Standard of care with placebo lock (saline and heparin)|Standard of Care antibiotics appropriate for the infecting organism with a placebo lock solution of saline and heparin. The saline lock arm is reserved for coagulase-negative staphylococci, enterococci, or other organisms deemed to be of low virulence per the Investigator.
1509122|NCT02901717|Drug|Standard of care with Mino-Lok Therapy (MLT)|Standard of Care antibiotics appropriate for the infecting organism plus Mino-Lok therapy to disinfect and save the catheter.
1509123|NCT02901717|Drug|Standard of Care with an antibiotic lock|Standard of Care antibiotics appropriate for the infecting organism with an antibiotic lock solution using the same standard of care antibiotic delivered systemically. The antibiotic lock arm may include subjects with S. aureus, including methicillin-resistant S. aureus, vancomycin intermediate S. aureus, or vancomycin-resistant S. aureus; vancomycin resistant enterococci; Candida, Pseudomonas; other Gram negative organisms; or other organisms deemed to be of high virulence per the Investigator. The standard of care antibiotic will be determined by the investigator at the start of treatment.
1509124|NCT02901704|Device|Renal Denervation System (AngioCare)|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
1509125|NCT02901704|Procedure|Sham procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 10 minutes prior to introducer sheath removal.
1509126|NCT02901691|Other|musical rhythmic stimulation|
1509127|NCT02901678|Device|Intrusion by 400 g|using miniscrews and coil springs to apply the intrusive force on maxillary posterior segment intrusion.
1509128|NCT02901665|Other|FCC intervention|Communication to all NICU families that they should be in the NICU a minimum of 4 hours/day.
1509129|NCT02901652|Device|SLE; Specialised Laboratory Equipment|
1509130|NCT02901639|Other|counseling|
1509131|NCT02901626|Device|Pessary|"The Arabin cervical pessary is a soft, flexible silicone pessary and fits high around the cervix with no rigid metal framework or inflexible edges that put increase pressure on the vaginal wall. It is available in a variety of sizes however three sizes will be used in this study:
Pessary Size Upper diameter, lower diameter
Nulliparous 65 mm, 32 mm
Multiparous 70 mm, 32 mm
Alternative 70 mm, 35 mm"
1509132|NCT02901613|Device|Negative-pressure wound therapy|
1509133|NCT02901600|Other|Detection of the expression of DMTB1 by immunohistochemistry|
1509134|NCT02901587|Drug|Lu AF35700 (10 mg/day)|tablets for oral administration once daily
1509135|NCT02901587|Drug|Lu AF35700 (30 mg/day)|tablets for oral administration once daily
1509136|NCT02901587|Drug|Quetiapine (Seroquel XR® 800 mg/day)|tablets for oral administration once daily
1509137|NCT02901574|Device|Anodal or Cathodal tDCS|2 mA or Anodal or Cathodal tDCS stimulation is induced between 5cm X5 cm saline soaked sponges where one sponge (anode in group anode or cathode in group cathode) is placed on the right cerebellum. The stimulation will be delivered at an intensity of 2 mA in a ramp-like fashion for a maximum of 20 minutes.
1509138|NCT02901574|Device|Sham|2 mA of Anodal tDCS or Cathodal tDCS is induced between two 5cm X 5cn saline soaked sponges where one sponge (anode in group Anode and cathode in group Cathode) is placed on the right cerebellum. Ramping up of the current to 2 mA occurs over 15-30 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
1509139|NCT02901574|Behavioral|Computerized naming therapy|Computer delivered naming treatment requires matching (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red button if the word does not match the picture.
1509140|NCT02901561|Drug|misoprostol 200|
2002959|NCT01364597|Drug|Brivaracetam (BRV)|"Subjects must be able to tolerate at least 0.5 mg/kg of brivaracetam twice daily (bid). The maximum allowable brivaracetam dose is 5.0 mg/kg/day (2.5 mg/kg bid), not to exceed a dose of 200 mg/day for subjects with body weight >40 kg. Subjects <7 years of age will receive oral solution.
Subjects ≥7 years of age will receive tablets and should transition from the oral solution to the equivalent oral tablet dose. The maximum BRV tablet dose allowed in this study will be 200 mg/day (100 mg bid).
Subjects will continue to receive brivaracetam in this study for at least 3 years, or until approval for BRV has been obtained for pediatric subjects in their age range, or until the investigational product development is stopped by the Sponsor.
For subjects who prematurely discontinue the study, brivaracetam will be down titrated over a maximum of 4 weeks (Down-Titration Period)."
2002960|NCT01356628|Drug|PD-0332991|PD-0332991, 125mg, 3 cycles
1509144|NCT02901535|Other|Spirometry|Spirometry in baseline
1509145|NCT02901535|Other|telemonitoring|telemonitoring (phone call nurse - 45 and 90 days)
1509146|NCT02901535|Other|teleconsultation|teleconsultation (general practioner received phone call to respiratory care)
1509147|NCT02901535|Other|Spirometry - 20 weeks|Spirometry (20 weeks)
1509148|NCT02901522|Other|telemonitoring|Patients is evaluated by telemonitoring (phone call nurse - 45 and 90 days).
1509149|NCT02901522|Other|Spirometry (baseline)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
1509150|NCT02901522|Other|Spirometry (20 - 22weeks)|Patients is evaluated by Asthma Control Test and spirometry at baseline and after 20 weeks.
1509151|NCT02901522|Other|Teleconsultation|The general practioner received phone call to asthma care.
2002961|NCT01354444|Drug|Carvedilol|target dose of 25 mg daily which is half the maximum dose used in clinical practice
2002962|NCT01354444|Drug|Placebo|a pill that will look like the active drug but will not contain any carvedilol
2002963|NCT01352221|Drug|ST10|30 mg capsules to be taken orally twice a day for 12 weeks in double-blind phase
2002964|NCT01352221|Drug|Placebo oral capsule|Matching placebo capsules for ST10 to be taken orally twice a day for 12 weeks in double-blind phase
2002965|NCT01352312|Drug|Bendamustine|Bendamustine at the dose of 50 mg/m2 (or 70 or 90 or 40 mg/m2 depending on the dose level) daily on day 1 and 2.
1509157|NCT02901483|Drug|PEP503|PEP503 will be administered by intratumoral route as slow injection
1509158|NCT02901483|Drug|Cisplatin|The concurrent chemoradiotherapy. Weekly cisplatin 40 mg/m2 with a minimum of accumulated 200 mg/m2 during the 7~8 weeks' radiation period.
1509159|NCT02901483|Radiation|Radiotherapy|Patients will receive 70-72 Gy, 2-2.12 Gy/fraction over 7~8 weeks.
1509160|NCT02901457|Other|"The Healthy Body Image intervention"|Interactive workshops (3 x 90 minutes) include training techniques to increase media literacy, enhance self-esteem, positive body image, awareness of perfectionism, and include discussions related to truths and myths related to life style factors. Homework is an extension of each workshop that is simple and not time-consuming tasks to increase reflection and awareness of how all the mentioned factors are a part of their lives.
2002966|NCT01352312|Drug|Pentostatin|Pentostatin 4 mg/m2 on day 1 of each cycle. For patients with estimated or measured glomerular filtration rate (GFR) 30 to 60 ml/min/m2 pentostatin will be administered at the reduced dose of 2 mg/m2 on day 1 of each cycle.
2002967|NCT01352312|Drug|Ofatumumab|Ofatumumab 300 mg on day 2 of first cycle. Subsequently, from cycle 2 to 6, ofatumumab 1000 mg on day 2 will be administered.
1509163|NCT02901418|Biological|200 IU HBIG|additional 200 IU HBIG within 24 hours was used for the experimental group of newborns
1509164|NCT02901405|Device|Negative Pressure Wound Therapy (ActivVAC, KCI)|
1509165|NCT02901405|Device|Standard dressings|Current absorbent dressing is 'tegaderm with absorbent pad' (3M)
1509166|NCT02901392|Procedure|AMS-800|Artificial urianry sphincter
1509167|NCT02901392|Procedure|ADVANCE/ADVANCEXP|Male sling
1509168|NCT02901392|Procedure|VIRTUE|Male sling
1509169|NCT02901392|Procedure|INVANCE|Male sling
1509170|NCT02901379|Drug|Atorvastatin 80mg|Subject will be given atorvastatin 80mg for two weeks
1509171|NCT02901379|Drug|Atorvastatin 10mg|Subjects will be give atorvastatin 10mg as part of standard therapy in hospital
1509172|NCT02901366|Drug|14C-FYU-981|14C-FYU-981, (Oral single dosing)
1509173|NCT02901353|Device|Sirolimus Eluting Coronary Stent System|Patient with Angina Pectoris will be enrolled for the intervention
1509174|NCT02901340|Dietary Supplement|one to two liters of water daily|
1509175|NCT02901327|Procedure|Lumbar Stabilisation Exercise|"McGill protocol starting with:
'cat-camel' exercise exercise 10 repetitions with 7 seconds hold each
'curl-up' exercise 10 repetitions with 7 seconds hold each
'side-bridge' exercise 10 repetitions with 7 seconds hold each
'cat-camel' exercise 10 repetitions with 7 seconds hold each progression was based on subjects' tolerance and endurance."
1509176|NCT02901327|Procedure|treadmill walk exercise|"Bruce protocol
This include:
'5 minutes warm up' at zero degree inclination.
'20 minutes active exercise with increasing speed and inclination'
'5 minutes cool down'"
1509177|NCT02901314|Other|on-demand audio messages of heart failure education themes|
1509178|NCT02901301|Drug|Pembrolizumab|200mg, IV, q3weeks, Day 1
1509179|NCT02901301|Drug|Trastuzumab|6mg/kg (8mg loading dose), IV, q3weeks, Day 1
1509180|NCT02901301|Drug|Capecitabine|1000mg/m2, PO, BID, Day 1-14
1509181|NCT02901301|Drug|Cisplatin|80mg/m2 (level 1), IV, q3weeks, Day 1
1509182|NCT02901288|Drug|Isoniazid|Isoniazid is a widely used anti-tuberculosis medication. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique components of mycobacterial cell wall.
1509183|NCT02901288|Drug|Rifampicin|Rifampicin is a widely used anti-tuberculosis medication.
1509184|NCT02901288|Drug|Pyrazinamide|Pyrazinamide is a commonly used medication for tuberculosis, with bactericidal effect against intracellular mycobacterium tuberculosis.
1509185|NCT02901288|Drug|Ethambutol|Ethambutol is a widely used medicine in anti-TB regimens with bacteriostatic effect against M. tb.
1509186|NCT02901288|Drug|Levofloxacin|Levofloxacin is a commonly used antimicrobial for TB and other infections, which acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
2002968|NCT01351909|Drug|Cyclophosphamide|Given PO
2002969|NCT01351909|Other|Laboratory Biomarker Analysis|Correlative studies
1509187|NCT02901275|Drug|Within-subject test of blinded study medications|This is a double-blind within-subject Phase II trial. As such, study medications must remain blinded. Participants may receive a dose of medication from one or more of the following categories: prescription stimulants, prescription benzodiazepines, prescription opioids, prescription cannabinoids, over-the-counter medications, or placebo (sugar pill). This study will use a within-subject design, and all participants will serve as their own control. Study medication administration will be randomized within each participant.
1509188|NCT02901249|Drug|sertraline|
1509189|NCT02901249|Drug|Nortriptyline|
1509190|NCT02901249|Drug|Lithium Carbonate|
1509191|NCT02901236|Procedure|Standard Guarded Trabeculectomy|A fornix based conjunctival peritomy is performed. A partial thickness scleral flap is dissected. Then trabeculectomy is performed with a Kelly's punch. A surgical iridectomy is performed. The scleral flap is secured with two pre-placed 8-0 Vicryl sutures (Ethicon, Somerville, NJ). The anterior chamber (AC) is inflated with balanced salt solution and suture tension is adjusted. Finally, conjunctiva is closed with 10-0 running Nylon sutures (Ethicon, Somerville, NJ). Patients receive a subconjunctival injection of 0.4 ml dexamethasone (4 mg/ml) and of 0.4 ml gentamicin (40 mg/ml) at the end of the case. Adjuvant pharmacologic treatment to prevent episcleral fibrosis and failure of the procedure is applied according to treatment arm assignment.
1509192|NCT02901236|Drug|Mitomycin C|Sponges soaked in 0.02% mitomycin C (MMC) will be applied on bare sclera for 2 minutes. Subsequently, the area will be copiously irrigated with balanced salt solution.
1509193|NCT02901236|Drug|Bevacizumab|After conjunctival closure 1.25mg of bevacizumab will be injected into the anterior chamber through a paracentesis created earlier during the case.
1509194|NCT02901223|Procedure|Standard quadrantectomy|standard conservative surgery with no use of any plastic techniques
1509195|NCT02901223|Procedure|oncoplastic breast surgery|Integration of plastic techniques with oncological procedures
1509196|NCT02901210|Procedure|Modified delorme procedure|
2002970|NCT01351909|Drug|Veliparib|Given PO
2002971|NCT01346267|Procedure|Real Acupressure Band|Acupressure wristband
1509199|NCT02901184|Drug|Spironolactone|Treatment with Spironolactone tablets on top of standard care
1509200|NCT02901184|Other|Standard care|Standard care does not involve Spironolactone
1509201|NCT02901171|Behavioral|ACT group treatment combined with smartphone application|The Acceptance and Commitment Therapy (ACT) group treatment for smoking cessation will be delivered in six weekly 90-min sessions. Smoking cessation will be promoted in each session by targeting core processes of the ACT model including acceptance, cognitive defusion, mindfulness, flexible perspective taking, values clarification and committed action. In addition, participants will receive an ACT-based smartphone application for smoking cessation. The application will foster core processes of the ACT model through daily exercises, tips and tools.
1509202|NCT02901171|Behavioral|ACT group treatment|
1509203|NCT02901171|Behavioral|Group based Behavioural Support Programme|The Behavioural Support Programme will be facilitated by stop smoking experts and delivered in six weekly 90-min sessions in a group format. During the sessions, advice, support and information on smoking cessation will be given to participants and behavioural techniques will be reviewed.
1509204|NCT02901145|Drug|Nivolumab,low dose cyclophosphamide|treatment with IV Nivolumab 3mg/kg every 2 weeks . after a month-addition of low dose cyclophosphamide at a starting dose of 50 mg/kg/day x7 days every 14 days with dose adaptation based on level of Tregulatory cells on follow up immunophenotype.
1509205|NCT02901119|Dietary Supplement|Whey protein|Patients, maintaining their regular usual diet, are submitted to a protein supplementation, during 15 days. They recieve 20g packages of whey protein or casein, to take twice a day: 20g in the morning and 20g at night.
1509206|NCT02901106|Drug|Dimethyl fumarate|"Patient follow-up at 6, 12, 18, 36, and 60 months after the start of Dimethyl fumarate
Systematization of cerebral MRI examination at 18 month and 5 years from the beginning of treatment by Dimethyl fumarate"
1509207|NCT02901080|Device|Alpha Stim AID cranial electrotherapy stimulation|- 60 minutes of cranial electrotherapy stimulation via Alpha Stim AID once per day, for a minimum of 6 and maximum of 12 weeks.
1509208|NCT02901080|Behavioral|Pregnancy test|- Pregnancy test x 1 (day 1)
1509209|NCT02901080|Other|Anxiety questionnaire|- GAD-7 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
1509210|NCT02901080|Other|Quality of life questionnaire|- EQ-5D-5L questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
1509211|NCT02901080|Other|Work and social questionnaire|- WASA questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
1509212|NCT02901080|Other|Sleep questionnaire|- Athens questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
1509213|NCT02901080|Other|Depression questionnaire|- PHQ-9 questionnaire x 6 (day 1, week 4, week 6, week 8, week 12 and week 24)
1509214|NCT02901080|Other|Quality of life and financial questionnaire|- CSRI questionnaire x 3 (day 1, week 12 and week 24)
1509215|NCT02901067|Drug|Aspirin and Rosuvastatin|Patients assigned to the intervention arm will receive the standard of care anti-coagulation plus the combination experimental drugs (20mg of rosuvastatin daily and 325mg of aspirin) daily either orally or via feeding tube.
1509216|NCT02901067|Drug|Placebo (for Aspirin and Rosuvastatin)|Patients assigned to the control group will receive the standard of care anti-coagulation plus identical-looking placebos either orally or via feeding tube.
1509217|NCT02901054|Drug|Ondansetron|A single 15-min intravenous infusion of ondansetron
1509218|NCT02901041|Drug|Zonisamide|ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.
1509219|NCT02901041|Behavioral|Take Control|Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.
1509220|NCT02901041|Drug|Placebo (for Zonisamide)|Sugar pills manufactured to mimic Zonisamide capsules.
1509221|NCT02901028|Other|Laboratory testing|Subjects will visit the Human Performance Laboratory on two separate occasions to perform the testing procedures. testing consists of VO2, strength, biomechanics, dynavision, etc.
1509222|NCT02901028|Other|Blood and Urine Draws|subjects will have a blood draw and provide a urine sample
1509223|NCT02901015|Behavioral|Assessment battery A|"Social cognition tests version A are administered to the patients"
1509224|NCT02901015|Behavioral|Assessment battery B|"Social cognition tests version B are administered to the patients"
1509225|NCT02901002|Other|Sensory testing in the two hand|spontaneous sensations while watching a hand
1509226|NCT02901002|Other|Neuropsychological evaluation|Score to anxiety-depression scale
1509227|NCT02900989|Behavioral|Suicide screening|"Patients of the emergency unit usually do not pass this kind of questionnaire in the absence of warning signs. Then it could result in adverse effects on behavior and ideation.
The study had to be declared as an interventional study according to French law."
1509228|NCT02900976|Biological|Allogeneic LMP1/LMP2-Specific Cytotoxic T-Lymphocytes|Given IV
1509229|NCT02900976|Other|Laboratory Biomarker Analysis|Correlative studies
1509230|NCT02900976|Biological|Rituximab|Given IV
1509231|NCT02900963|Other|weekly assessment of patient's weight|Biological assessment to determine biological and inflammatory status Quality of life questionary
1509232|NCT02900950|Procedure|Multicolour inking specimens|
1509233|NCT02900950|Procedure|Monocolour inking specimens|
1509234|NCT02900937|Device|AmM MAGNITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
1509235|NCT02900924|Device|BioMimics 3D Stent|
1509236|NCT02900911|Other|Early rehabilitation|"Early swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting 2 weeks before radiotherapy
Expiratory/Inspiratory training: the training load is the maximum inspiratory/expiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), three times a day.
All sessions will be conducted under the supervision of an expert physiotherapist/swallowing therapist. The total duration of the training program is 6 months."
1509237|NCT02900911|Other|Late rehabilitation|Late swallowing exercises and respiratory muscle training: Standard swallow therapy and instructions for training submental muscles involved in swallowing function and expiratory strength starting after completing radiotherapy
1509238|NCT02900898|Other|Dynamic exercise and Mediterranean diet|DE, MD
1509239|NCT02900898|Other|Dynamic exercise|DE
1509240|NCT02900898|Other|Mediterranean diet|MD
1509241|NCT02900898|Other|Control|Control
2002972|NCT01346267|Procedure|Placebo Acupressure Band|Sham wristband
2002974|NCT01340872|Drug|ST10-021|30 mg capsules to be taken orally twice a day for 12 weeks
2002975|NCT01340872|Drug|Placebo Comparator|Matching sugar pill to be taken orally twice a day for 12 weeks
2002976|NCT01339559|Drug|Brivaracetam|"Tablet, Flexible dosing up to 200 mg/day, twice daily.
The study will continue until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures or until the Sponsor decides to close the study, or until the investigational product development is stopped by the Sponsor."
2002977|NCT01328587|Drug|Eltrombopag|
1509248|NCT02900768|Behavioral|Exercise|Combination of resistance and aerobic exercises for 100 days.
1509249|NCT02900755|Drug|Perampanel|The subjects will be administered oral perampanel for six months. Dose will be titrated according to the tolerance and be maintained at least 1 month before second EEG evaluation.
1509250|NCT02900742|Drug|YiQiFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable.
1509251|NCT02900742|Drug|YangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable.
1509252|NCT02900742|Drug|YiQiYangYinFang|Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe. YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable.
1509253|NCT02900742|Drug|Gemcitabine®|"Gemcitabinie®,Gemzar,1250 mg/㎡, ivgtt 30 min,days 1,8,every 21 days until progression or unacceptable toxicity develops."
1509254|NCT02900742|Drug|Pemetrexed®|"Pemetrexed®,Alimta,500 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity develops."
1509255|NCT02900742|Drug|Docetaxel®|"Docetaxel®,Taxotere,75 mg/㎡, ivgtt 30 min, day 1, every 21 days until progression or unacceptable toxicity."
1509256|NCT02900742|Drug|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
1509257|NCT02900729|Device|Radiofrequency ablation catheter|Subjects will be treated with the renal denervation procedure using WiseGo Catheter System after randomization.
1509258|NCT02900729|Drug|Amlodipine, losartan potassium and hydrochlorothiazide|Standardised triple anti-hypertensive medications of amlodipine 5 mg per day, losartan potassium 50 mg and hydrochlorothiazide 12.5 mg per day in the first 90 days after randomization. Subjects will be allowed to adjust baseline antihypertensive medications where clinically necessary in the second 90 days after randomization.
1509259|NCT02900716|Drug|DTRMWXHS-12|DTRMWXHS-12
1509260|NCT02900716|Drug|DTRM-505|DTRMWXHS-12 and everolimus
1509261|NCT02900716|Drug|DTRM-555|DTRMWXHS-12 and everolimus and pomalidomide
1509262|NCT02900703|Biological|stool samples|
2002978|NCT01316796|Drug|Sodium Nitrite Cream|
1509263|NCT02900677|Behavioral|Physical and nutrition program|6 education programs with physical enhancement and nutrition related information for 12 weeks
1509264|NCT02900664|Biological|PDR001|Powder for solution for infusion
1509265|NCT02900664|Biological|ACZ885|Solution for injection
1509266|NCT02900664|Biological|CJM112|Solution for infusion
1509267|NCT02900664|Drug|TMT212|Tablets
1509268|NCT02900664|Drug|EGF816|Tablets
1509269|NCT02900651|Drug|MAK683|Drug: MAK683
1509270|NCT02900638|Behavioral|Mentoring|Youth in the intervention group will participate in one-on-one mentoring sessions (between mentors and mentees) once per week after school. Mentoring sessions will focus on the development of a social bond between mentor and mentee.
1509271|NCT02900612|Other|Water aerobics training.|The WA group will be trained adopting the interval method, performing six blocks of five minutes each one, alternating four minutes at intensities corresponding to 90 to 100% of the heart rate corresponding to the second ventilatory threshold (HRVT2) and one minute at intensities between 80 and 90% HRVT2.
1509272|NCT02900612|Other|Water resistance training.|The WR group will perform four to eight sets of 20 to 10 seconds along the macrocycle, always at maximal speed execution of the exercises.
1509273|NCT02900612|Other|Control Group|The control group will perform relaxation classes, including meditation, balance exercises, coordination exercises.
1509274|NCT02900599|Other|Observationnal (no intervention)|
1509275|NCT02900560|Drug|CC-486|CC-486 Intervention will depend on cohort enrolled in. 100 mg tablet
1509276|NCT02900560|Biological|Pembrolizumab|Pembrolizumab 200 mg IV every 21 days
1509277|NCT02900547|Other|Patients with systolic heart failure|
1509278|NCT02900534|Other|Internet-based self-help|10 internet-based self-help sessions plus one supportive email a week with a cognitive-behavioural background
1509279|NCT02900508|Other|Exergaming training|
1509280|NCT02900508|Other|Physical therapy intervention|
1509281|NCT02900495|Device|transcutaneous electric nerve stimulation|electrodes placed per treatment arm, performed at bedtime, session time 20 min, frequency setting of 10 Hz, intensity setting to patient's tolerance, duration 30 days
1509282|NCT02900482|Other|Sampling saliva|
1509283|NCT02900469|Biological|denosumab|denosumab: 120 mg subcutaneous injection
1509284|NCT02900469|Procedure|Surgery|Surgery: approximately 2-4 weeks after dosing of denosumab
1509285|NCT02900443|Drug|Mycophenolate mofetil|
1509286|NCT02900443|Drug|Azathioprine|
1509287|NCT02900430|Other|Patients without antifungal prophylaxis|Epidemiology data: clinical and biological informations collecting
1509288|NCT02900430|Drug|Patients with antifungal prophylaxis|Hospitalized patients between 2012 and 2015 received Posaconazole prophylaxis during neutropenia period induced by induction or salvage chemotherapy.
1509289|NCT02900417|Drug|Sitagliptin|All the patients will receive sitagliptin 100mg daily
1509290|NCT02900404|Other|XAPPORT|A mobile device app based on different guidelines provides adequate guidance to physicians attending patients undergoing elective surgery, who have to interrupt treatment with rivaroxaban for surgery, in deciding how to approach the pre- and postoperative management of anticoagulation.
1509291|NCT02900404|Other|"Expert Panel (gold standard)"|A national panel of experts comprising anesthetists and surgeons from various disciplines advised in developing an algorithm supporting physicians how to approach the perioperative management of anticoagulation in patients receiving rivaroxaban and requiring elective surgery.
1509292|NCT02900378|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) will be avaialable in 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
1509293|NCT02900378|Drug|Placebo to LCZ696 (sacubitril/valsartan)|Placebo of LCZ696 (sacubitril/valsartan) will be available to match 24 mg/26 mg, 49 mg/51 and 97 mg/103 mg mg film-coated tablets
1509294|NCT02900378|Drug|Enalapril|enalapril will be available in 2.5 mg, 5 mg and 10 mg film-coated tablets
1509295|NCT02900378|Drug|Placebo to enalapril|Placebo of enalapril will be available to match 2.5 mg, 5 mg and 10 mg film-coated tablets
1509296|NCT02900365|Procedure|early cataract surgery & IOL implantation|first week cataract extraction and IOL implantation.
1509297|NCT02900365|Procedure|late cataract surgery & IOL implantation|first month cataract extraction and IOL implantation.
1509298|NCT02900352|Drug|Zonisamide|Titration of dose to 500mg oral, daily, over 8 weeks, then 7 weeks of treatment at that dose
1509299|NCT02900352|Drug|Placebo|Placebo
1509300|NCT02900339|Device|Magnetic Resonance Imaging|MRI of the Neurinfo platform is an MRI 3 Tesla Magnetom Verio model, Siemens (Siemens Healthcare, Erlangen, Germany). This imager is marked for European Conformity (CE), ensuring compliance with European Union safety standards.
1509301|NCT02900326|Other|Endurance exercise training|In each group, there will be a comparison of aerobic capacity, quality of life (with questionnaires), functional cerebral measurements (fRMI), and telomerase activity between before and after the 8 weeks program
1509302|NCT02900326|Other|Mindfulness-based-stress-reduction|
1509303|NCT02900326|Other|Both interventions together|
1509304|NCT02900326|Other|Vo2max measurements|
1509305|NCT02900326|Genetic|Telomerase activity on a blood sample|
1509306|NCT02900326|Other|Quality of life (questionnaires)|
1509307|NCT02900326|Other|Cerebral IRMf|
1509308|NCT02900313|Other|cardiac surgery|Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
1509309|NCT02900274|Device|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
1509310|NCT02900261|Other|No intervention|This study is observational and does not entail any intervention. Different methods to assess sodium and caffeine consumption will be compared.
1509311|NCT02900248|Other|Provider determined|Provider will treat patient as he/she feels best
1509312|NCT02900235|Drug|MT-3995|
1509361|NCT02899780|Device|Ultraviolet light emitting optical fiber|A ultraviolet light emitting optical fiber will be threaded through the existing catheter and withdrawn.
1509434|NCT02899182|Other|O2|the conventional group (C) will receive local anesthesia at the puncture site plus inhalation of 100% oxygen a face mask.
1509313|NCT02900222|Procedure|endoscopic choroid plexus coagulation|A burr hole will be made over the frontal lobe of the brain. An endoscope will be introduced into the ventricle of the brain and the choroid plexus coagulated with an electrocautery device. The septum pellucidum separating the right and left lateral ventricles will be opened, and the choroid plexus on the opposite side coagulated as well.
2002979|NCT01286012|Drug|Soluble Ferric Pyrophosphate in liquid bicarbonate|Subjects will receive hemodialysis containing SFP at 2 µM (11 µg iron/dL of dialysate) at every dialysis session, for a total duration of 36 weeks.
1509315|NCT02900196|Other|1 - Fermented dairy drink|1 - Fresh fermented dairy drink containing yoghurt ferments and probiotic strains consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
1509316|NCT02900196|Other|2 - Acidified dairy drink|2 - Acidified dairy drink without ferments consumed as follows: one bottle (100g) BID for 28 consecutive days (Day 0 to day 28)
1509317|NCT02900183|Drug|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
1509318|NCT02900157|Biological|MEDI9090|MEDI9090 will be administered by IV infusion
1509319|NCT02900157|Biological|Durvalumab|Durvalumab (MEDI4736) will be administered by IV infusion following MEDI9090
1509320|NCT02900144|Behavioral|Modified Comprehensive Behavioral Intervention for Tics|See information from arm/group description
1509321|NCT02900144|Behavioral|Comprehensive Behavioral Intervention for Tics|See information from arm/group description
1509322|NCT02900131|Drug|Jaungo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in trial group 2 will apply Jaungo to the lesion twice a day for three weeks.
1509323|NCT02900131|Drug|Placebo|Participants in trial group 1 will apply Jaungo and placebo to the lesion once a day for three weeks. Participants in control group will apply placebo to the lesion twice a day for three weeks.
1509324|NCT02900105|Drug|Letrozole|Letrozole 2.5mg (1 tablet) once a day for 4 months
2002980|NCT01286012|Drug|Placebo: Conventional liquid bicarbonate|Subjects will receive hemodialysis containing conventional liquid bicarbonate lacking SFP at every dialysis session, for a total duration of 36 weeks.
1509326|NCT02900079|Device|rapid diagnostic test for malaria antigen|rapid diagnostic test for malaria antigen to be used by travelers when febrile
1509327|NCT02900053|Device|tDCS|tDCS for transcranial Direct-Current Stimulation
1509328|NCT02900053|Device|Placebo tDCS|Placebo tDCS for transcranial Direct-Current Stimulation
1509329|NCT02900040|Other|kidney transplantation|
1509330|NCT02900027|Drug|APOC-III-L-Rx|Ascending single and multiple doses of IONIS-APOC-III-LRx by subcutaneous (SC) injection
1509331|NCT02900027|Drug|Placebo Comparator|Sterile Normal Saline (0.9% NaCl) calculated volume to match active comparator
1509332|NCT02900014|Procedure|sampling mesenchymal stem cells|nasal mesenchymental stem cells are collected in patients with cleft undergoing general anesthesia, during the initial surgical management of cleft
1509333|NCT02900001|Procedure|early coronary angiography|Routine coronary angiography and revascularization if appropriate within 24 hours
1509334|NCT02900001|Procedure|delayed coronary angiography|Routine coronary angiography and revascularization if appropriate after 72 hours
2002981|NCT01286012|Drug|Erythrocyte Stimulating Agent (ESA)|ESA was administered according to the recommendation of a blinded central anemia management center (CAMC) based on the weekly hemoglobin value and its rate of change.
2002982|NCT01286012|Drug|Intravenous (IV) Iron|Approved IV iron preparations were administered per a protocol driven algorithm when patients serum ferritin value decreased below 200 ug/L.
1509337|NCT02899975|Other|Validation|Validation of fitness and information software for elderly and caregivers. The participants use a Fitness Software for 2-3 months in their own homes. They should use it 3 times a week The aim of this Intervention is to find out if the regularly use of the Software maintains or improves your physical capabilities. The caregivers also use the games and get a lot of Information about supporting the elderly Person in their everyday life
1509338|NCT02899962|Drug|LEO 90100 aerosol foam|LEO 90100 aerosol foam twice weekly
1509339|NCT02899962|Drug|LEO 90100 aerosol foam vehicle|LEO 90100 aerosol foam vehicle twice weekly
1509342|NCT02899923|Other|Data collection|
1509343|NCT02899910|Behavioral|Health education|Education on lifestyle changes for treatment of metabolic syndrome
1509344|NCT02899910|Behavioral|Yoga|Training in the practice of yoga for treatment of metabolic syndrome
1509345|NCT02899897|Device|echocardiography in IV fluid therapy|
1509346|NCT02899884|Other|No Intervention|
1509347|NCT02899871|Other|diagnosis of joint|"The diagnosis of joint pain will be established by a rheumatologist and completed:
If necessary, by a clinically guided radiological assessment (plain x-rays, joint ultrasound, bone and joint MRI).
serum assays of the anti-TNF administered, as well as screening for associated antibodies."
1509348|NCT02899858|Other|Movement Assessment|Documentation of ASIA A (T2-8) status at Belmont Gait Lab
1509349|NCT02899858|Other|MRI Scan|Total MRI of spine to evaluate condition of spinal cord
1509350|NCT02899858|Procedure|IntraSpinal Micro-Stimulation|IntraSpinal Micro-Stimulation will be performed using a maximum of 16 electrodes inserted along each side of spinal cord that correlate with movements created across all 3 joints (hips, knees, and ankles)
1509351|NCT02899858|Other|Follow up clinical exam|All subjects will be expected to return for a follow-up visit with Drs. Konrad at 1, 3 and 6 month follow up visits.
1509352|NCT02899858|Other|Post Op MRI Scan|An MRI will be obtained at 3 months following the procedure to document the impact of the mapping procedure on spinal cord anatomy.
1509353|NCT02899858|Other|Follow up gait assessment|Follow-up assessment with the Belmont Gait Lab will be performed at the 6 month follow up visit
1509354|NCT02899845|Other|postural task|
1509355|NCT02899845|Other|walk task|
1509356|NCT02899832|Device|NIRS|Near Infra Red Spectroscopy
1509357|NCT02899819|Other|meconium|The meconium will be sampled in the first 2 days of life
1509358|NCT02899806|Other|Written Information|A written information on peridural anesthesia is delivered
1509359|NCT02899806|Other|Video Information|A link to a video explaining peridural anesthesia is delivered to the pregnant woman. The patient can watch the video several times.
1509435|NCT02899169|Drug|Realgar-Indigo naturalis formula|
1509364|NCT02899741|Drug|Omega-3|1000mg every day for 90 days
2002986|NCT01273155|Drug|Belinostat|Patients divided into 4 cohorts based on level of liver dysfunction. Belinostat administered IV over 30 minutes. On day -7 (Cycle 1 only), all patients receive a single dose of 400 mg/m2 belinostat. On days 1 5 of each cycle, patients receive belinostat at a dose dependent on the level of hepatic dysfunction (125-1000 mg/m2/day)
1509371|NCT02899702|Drug|PRIVIGEN (CSL Behring)|"Single administration of intravenous immunoglobulin solution Privigen® (CSL Behring AG, Bern, Switzerland) at a dose of 2g / kg. IGIV 2g/kg within 12 hours following PICU admission (or outbreak of first shock signs).
The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
1509372|NCT02899702|Drug|Albumin|"4%(LFB) ALBUMIN Single administration of human Albumin 4% diluted albumin (VIALEBEX® LFB), within 12 hours following PICU admission (or outbreak of first shock signs). Isovolume - so dose of 0.8 g/kg (4gG, 100 ML, Sodium chloride 0.61 G / 100ML Water for injections QSP 100 ML Sodium caprylate 0.3 G / 100ML) We chose as placebo albumin diluted to 4% because this solution has the advantage of having a comparable osmolality.
The treatment of toxic shock will be standardized. It consists of antibiotics: Amoxicillin-clavulanate and clindamycin (or Rifampicin, Rifadine® if allergic). Antibiotics are not considered as experimental treatments for this study. All treatments essential for the treatment of acute condition will be allowed and are not considered as experimental treatments for this study."
1509375|NCT02899676|Other|neuropsychological testing|
1509376|NCT02899676|Other|functional magnetic resonance imaging|
1509377|NCT02899676|Other|simple arithmetic operations|
1509379|NCT02899637|Device|Active high-frequency Transcranial Magnetic Stimulation|Active intervention, 5Hz on the lower limbs area of the motor cortex, during one week
1509380|NCT02899637|Device|Sham high-frequency Transcranial Magnetic Stimulation|Sham intervention, 5Hz on the lower limbs area of the motor cortex, during one week
1509381|NCT02899624|Biological|Extra blood draw samples|
1509382|NCT02899624|Biological|additional tissue samples|
1509383|NCT02899611|Drug|Valproate|ICV Valproate is a dilution of the commercially available Epilim product, which is a sterile intravenous (IV) formulation of Sodium Valproate.
1509384|NCT02899598|Biological|Extra blood draw samples|
1509385|NCT02899598|Biological|extra amniotic fluid samples|
1509386|NCT02899585|Other|Questionnaires|
1509387|NCT02899585|Other|Score|
1509388|NCT02899572|Procedure|Sexology consultation|a sexology consultation is planned in the 15 days after inclusion
1509390|NCT02899533|Drug|[18F] FES|[18F] FES PET/CT scan, imaging tracer
1509393|NCT02899507|Drug|Amoxicillin-Clavulanic acid|Patients without evidence of tracheobronchial aspiration were randomized to immediate prophylactic Amoxicillin-Clavulanic acid 1,2 gr/8h
1509394|NCT02899494|Other|Antenatal classes|
1509395|NCT02899494|Other|Physical and psychic preparation|
1509396|NCT02899481|Other|Transabdominal and transperineal ultrasound|Transabdominal ultrasound, for determining fetal head position, is performed with the pregnant women in supine position after bladder emptying, with the transducer placed transversely on the suprapubic region of the maternal abdomen. For the sonographic determination of the fetal descent we will perform a transperineal ultrasound achieved by placing the ultrasound transducer on the perineum in a mid sagittal position between the labia below the pubic symphysis.
1509397|NCT02899468|Device|BrightBrainer Virtual Reality (BBVR) Rehabilitation System|During the active treatment stage (3 sessions per week x 6 weeks), each BBVR therapy session will consist of a series of custom games targeting one or several cognitive domains of executive function, attention, short-term memory, working memory and language comprehension. In addition, the BBVR device incorporates uni- and bi-manual activities by having the subject manipulate hand-held devices, which are programmed to measure in real time the subject's 3D hand movement and index flexion/extension. Therefore, in addition to completing the cognitive tasks, subjects must manipulate virtual hands through a hand-held interface to also enhance visual-motor perception, hand-eye coordination, and upper limb function. In addition, wrist weights can be added to increase upper limb strength training.
1509432|NCT02899195|Drug|Maintenance Durvalumab|On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV over approximately 60 minutes.
1509433|NCT02899182|Drug|Nitrous Oxide NO|The NO group receive local anesthesia at the puncture site plus inhalation N2O-O2 mixture by self-demand valve
1509436|NCT02899169|Drug|all-trans retinoic acid|
1509403|NCT02899442|Other|collective prevention in workplace|From countermeasures referenced in guidelines, some tools were also created by the committee to standardize all preventive actions and to define measurable indicators. A specific monitoring for checking their applicability and for evaluating the duration of implementation is planned.Collective actions are classified in 7 categories:1)Standardized information of night work risk on health and countermeasure to prevent them, 2)Acknowledgement of the existence of the risk, thereby helping to raise general awareness, 3)Improvement of characteristics of night work (rhythm, rest, time to start and to end, schedule forecasted, duration of night work),4)Improvement of related conditions at night work (Job strain, monotonous or repetitive tasks, manager's help, collective co-operation; Light environment; Occupational physical activities, 5)Sleep improvements ,6)Improvement of dietetic intakes at work, 7)Improvement of leisure physical activity's practice within the work site
1509404|NCT02899403|Other|Rapid Visual Information Processing (RVIP) test|Rapid Visual Information Processing is a measure of sustained attention.
1509405|NCT02899390|Behavioral|Lifestyle Intervention|"Before implementation of the National Diabetes Prevention Program, adaptations will be made in order to be culturally acceptable in the community taking in consideration the type of food they eat and their activities in the population.
The lifestyle intervention will be implemented by group and individual sessions and is aimed at achieving a 7% loss weight from baseline and 150 minutes per week of physical activity. Sessions will be held weekly in a period of 6 months. Individual sessions consist in nutritional counseling according to energy needs and food preferences of each participant."
1509410|NCT02899364|Drug|Sodium thiosulfate|see description under experimental arm
1509411|NCT02899364|Drug|sodium chloride (NaCl)|see description under placebo arm
1509412|NCT02899364|Procedure|primary percutaneous coronary intervention|Primary treatment of the ischemia-related coronary artery is left to discretion of the operator and might consist of thrombus aspiration, balloon inflation and stent implantation. Additional balloon angioplasty or stenting of the culprit or other lesions will be performed when necessary.
1509413|NCT02899364|Other|cardiac magnetic resonance imaging|CMR-imaging will be used for assessment of left ventricular function, quantification of myocardial scar and diffuse myocardial fibrosis. CMR-imaging examinations will be performed on a 3 Tesla scanner using a phased array cardiac receiver coil at 4 months after randomization according to standard protocols{33}. The full study protocol lasts approximately 45 minutes and includes anatomy and function, LGE and T1-mapping.
1509414|NCT02899351|Device|Respiratory Volume Monitor|
1509415|NCT02899338|Drug|BI695501 Prefilled syringe|
1509416|NCT02899338|Drug|BI695501Autoinjector|
1509417|NCT02899325|Drug|Diagnostic PET/CT scans|These PET/CT scans will be performed for diagnostic purposes of hepatocellular carcinoma.
1509418|NCT02899312|Drug|PSMA PET/CT scan|"All participants will undergo the same procedures listed in Detailed Description in the protocol section."
2002994|NCT01256359|Drug|Docetaxel and AZD6244|Docetaxel 75mg/m2 IV and AZD6244 75mg bd daily. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but AZD6244 may be continued beyond this, until disease progression.
2002995|NCT01256359|Drug|Docetaxel and placebo|Docetaxel 75mg/m2 IV and placebo given bd. Docetaxel will be administered every 3 weeks for a maximum 6 cycles, but placebo may be continued beyond this, until disease progression.
2002996|NCT01251861|Drug|Akt Inhibitor MK2206|Given PO
2002997|NCT01251861|Drug|Bicalutamide|Given PO
1509424|NCT02899286|Biological|PEG-BCT-100|PEGylated recombinant human arginase
1509425|NCT02899260|Device|Peanut Exercise Ball|A Peanut shaped exercise ball.
1509426|NCT02899247|Procedure|Surface sealant|"Device:
Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.
Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.
Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)
7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA).
The composite surface and 1 mm external limit will be etched with a 37% acid phosphoric and after will be covered using a nanotechnology liquid polish system (Lasting Touch, Dentsply Caulk, Milford, DE, USA)."
1509427|NCT02899247|Procedure|No surface sealant|"Device:
Enamel and dentin etching with 37% phosphoric acid (Scotchbond Etchant; 3M/ESPE, St. Paul, MN, USA) for 30 s and 15 s.
Two coats of one-bottle adhesive (Adper TM Single Bond 2, 3M/ESPE, St. Paul, MN, USA) will be applied homogeneously to the surface with a disposable micro-brush.
Cavities will be restored with 2 mm increments of composite resin (Z350, 3M/ESPE, St. Paul, MN, USA)
7 Days after: Finishing and polishing will be performed with fine diamond and multilaminated burs, one step polishing system Pogo (Dentsply, Caulk, USA)."
1509428|NCT02899234|Other|E-cigarette|A third generation e-cigarette device will be used with pre-determined temperature, voltage and wattage settings.
2002998|NCT01251861|Other|Clinical Observation|Undergo clinical observation
2002999|NCT01251861|Other|Laboratory Biomarker Analysis|Correlative studies
1509431|NCT02899195|Drug|Concurrent Durvalumab|On Day 1 of each 21 day cycle: Durvalumab 1120 mg IV will be administered before pemetrexed and cisplatin chemotherapy over approximately 60 minutes. Approximately 30 minutes after the durvalumab infusion is complete, pemetrexed 500 mg/m² IV will be administered over 10 minutes. Cisplatin 75 mg/m² IV over 2 hours will begin approximately 30 minutes after the end of pemetrexed administration. If carboplatin is substituted for cisplatin, carboplatin Area Under the Concentration-Time Curve (AUC) 5 will be infused over 30 minutes beginning approximately 15-30 minutes after the end of the pemetrexed administration.
1509437|NCT02899169|Drug|Arsenic trioxide|
2003000|NCT01237041|Drug|Niacin|500 mg po four times on one of the inpatient days
2003001|NCT01237041|Drug|Placebo|
2003002|NCT01232556|Drug|Inotuzumab ozogamicin|1.8 mg/m2 on day 2 every 28 days by IV infusion, 3 to 6 cycles
2003003|NCT01232556|Drug|Rituximab|375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles
1509442|NCT02899130|Drug|Polyherbal|Each capsule contains 3 herbs. Phyllanthus niruri, Boerhaavia diffusa, picrorhiza kurroa
1509443|NCT02899130|Drug|Placebo|Inactive compound that is similar looking as the intervention
1509444|NCT02899117|Other|Yoga|There are 4 yoga sessions completed with a certified instructor during cancer treatment
1995855|NCT02636400|Other|controlled ovarian stimulation with gonadotropins + intrauterine insemination|
1509446|NCT02899091|Biological|CB-AC-02|"Stage1:
① Group1: CB-AC-02, 2.0 x 10^8 cells on day 0
② Group2: CB-AC-02, 2.0 x 10^8 cells, on day 0 and on week 4 (repeated injection)
Stage2
① Arm1: K-MMSE 20~26 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)
② Arm2: K-MMSE 10~19 CB-AC-02, 2.0 x 10^8 cells on day 0 and on week 4 (repeated injection)"
1509447|NCT02899091|Biological|Placebo|"Stage2:
Placebo on day 0 and on week 4 (repeated injection)"
1509448|NCT02899078|Drug|Ibrutinib|Given PO
1509449|NCT02899078|Drug|Nivolumab|Given IV
1509450|NCT02899065|Device|Cepheid GeneXpert Flu/RSV Assay|Patients receive a nasal swab that is then tested using the Cepheid GeneXpert Flu/RSV Assay. Results of this test are interpreted by the pharmacist, who provides direct education to the treating clinician.
1509451|NCT02899052|Drug|Venetoclax|Venetoclax tablet administered orally once daily during Cycles 1-18. Venetoclax dose level 1 (Ven1) 400 mg once daily, Ven2 800 mg once daily.
1509452|NCT02899052|Drug|Dexamethasone|Dexamethasone tablet administered orally during Cycles 1 - 18. Dexamethasone dose level 1 (Dex1) 40 mg once weekly, Dex2 40 mg once weekly, Dex3 20 mg twice weekly.
1509453|NCT02899052|Drug|Carfilzomib|"Carfilzomib lyophilized administered intravenously as a 10 to 30 minute infusion in Cycles 1 - 18 within 30 minutes to 4 hours after dexamethasone dosing.
Dose level 1 (K1) Cycle 1: 20 mg/m2 on Days 1 and 2, 27 mg/m2 on Days 8, 9, 15, and 16; Cycles 2 - 12: 27 mg/m2 on Days 1, 2, 8, 9, 15, and 16; Cycles 13 - 18: 27 mg/m2 on Days 1, 2, 15, and 16.
Dose Level K2: Cycle 1: 20 mg/m2 on Day 1; 70 mg/m2 on Days 8 and 15 Cycles 2 - 18: 70 mg/m2 on Days 1, 8, and 15. Dose Level K3: Cycle 1: 2 mg/m2 on Days 1 and 2; 56 mg/m2 on Days 8, 9, 15, and 16.
Cycles 2 - 18: 56 mg/m2 on Days 1, 2, 8, 9, 15, and 16."
1509454|NCT02899039|Biological|extra blood draw samples|
1509455|NCT02899026|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukumab, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
1509456|NCT02899026|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug
1509457|NCT02899026|Drug|Prednisone /Prednisone placebo|Prednisone will be provided as tablets with dosage level up to 20 mg/day. All subjects will receive 20 mg prednisone at Baseline (Randomization) and follow predefined taper regimen (6 weeks or 52 weeks) based on treatment assignment. Placebo to match prednisone will be provided as tablets
1509458|NCT02899013|Other|No intervention|Observational study to describe Perianal Lesions in a Cohort of Crohn's Disease Patients.
1509461|NCT02898974|Behavioral|Medical Marijuana|To investigate the effects of medical marijuana usage on physical function we will employ an observational case-control design
1509462|NCT02898961|Drug|30 mg/kg amikacin or 8 mg/kg gentamicin|"In order to improve the achievement of target peak concentrations, either 30 mg/kg amikacin or 8 mg/kg gentamicin was prescribed in ICU patients with severe sepsis.
In combination with broad-spectrum antibiotics, according to the suspected pathogens and local clinical practice, 30 mg/kg amikacin or 8 mg/kg gentamicin was given (30 min intravenous infusion; the dosage ampoule was systematically emptied with a 5 ml flush). The peak serum concentration sampling occurred 30 minutes after the end of the infusion."
1509463|NCT02898948|Biological|Procalcitonin (PCT) as a diagnostic marker of bacterial infection|
1995856|NCT02636283|Drug|Entresto|Oral pills
1509465|NCT02898909|Device|nuclear lens fragmentation in 8 pieces|
1509466|NCT02898909|Device|nuclear lens fragmentation in 16 pieces|
1509467|NCT02898896|Biological|blood test|Additional 21 ml of blood will be collected
1509468|NCT02898883|Behavioral|Building Resilience after Childhood Emergencies (BRACE)|See arm/group description for details regarding this intervention
1509469|NCT02898857|Other|biopsies|The biopsies of lung tumour samples will be analysed by immunochemistry (IHC), western blotting and qPolymerase Chain Reaction (PCR) approaches in Six with demonstrated down-staging of a KRAS mutant adenocarcinoma, Six with demonstrated no down-staging (persistent tumour cell involving lymph nodes in surgically resected specimens) of a KRAS mutant adenocarcinoma and Six with or without non-staging and triple negative adenocarcinoma
1509470|NCT02898844|Behavioral|Mixed Diet Condition|One roommate dieted and the other ate normally.
1509471|NCT02898844|Behavioral|Both Diet Condition|Both roommates dieted.
1509472|NCT02898831|Other|Cold Compress|Cold Compress placed on lower abdomen prior to and during IUD insertion.
1509473|NCT02898818|Other|vaginal and oral swab sample, questionnaire|vaginal and oral swab sample and questionnaire
1509474|NCT02898818|Other|papa smear|Papnicolaou Papa Smear test
1509475|NCT02898805|Other|Placebo|
1509476|NCT02898805|Other|Prescribed Diet|
1509477|NCT02898805|Dietary Supplement|LopiGLIK®|
1509478|NCT02898805|Dietary Supplement|Armolipid Plus|
1509479|NCT02898792|Drug|Targeted infusion of remifentanil|Remifentanil dosing will be calculated using ideal body weight and infused to achieve brain concentrations of 0.5, 1, 2, 3, and 4 ng/ml; approximately 10 minutes at each concentration.
1509507|NCT02898558|Behavioral|Magnification hand size|Participants will use magnifying lenses while completing a jigsaw puzzle for 30 min a day for 14 days.
1509508|NCT02898558|Device|magnifying lenses|
1509509|NCT02898545|Device|SEEQ monitor|An external cardiac rhythm monitor
1509666|NCT02897570|Device|EEG_pre|Electroencephalography (EEG) was performed prior each tolerance test to assess frontal P300-evoked potentials
1995857|NCT02636283|Drug|Placebo group|The placebo pills
1995858|NCT02635685|Other|Clinical Decision Support tool|Automatized support tool for identification of patients with a diagnosis of atrial fibrillation without appropriate anticoagulant therapy for stroke prevention.
1509480|NCT02898779|Drug|Primaquine, R-Primaquine, S-Primaquine, SR Primaquine|"Cohort 1: Eighteen individuals (6 per group) Cohort 2: Eighteen individuals (6 per group)
Group 1-15 mg of S-Primaquine followed by one-week washout, 15 mg of R-Primaquine followed by one week washout, and 30 mg of RS-Primaquine.
Group 2- 15 mg of R-Primaquine followed by one-week washout, 30 mg of RSPQ followed by one week washout, and 15 mg of SPQ.
Group 3- 30 mg of RS-Primaquine followed by one week washout,15 mg of SPQ followed by a one week washout, and 15 mg of RPQ."
1509481|NCT02898766|Other|Enteral Nutrition Formula|
2003004|NCT01232556|Drug|rituximab + gemcitabine|rituximab 375 mg/m2 on days 1, 8, 15, and 22 of cycle 1, and day 1 of cycles 2 to 6, every 28 days by IV infusion, 3 to 6 cycles; gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 28 days, 3 to 6 cycles
2003005|NCT01232556|Drug|rituximab +bendamustine|rituximab 375 mg/m2 on day 1 every 28 days by IV infusion, 3 to 6 cycles; bendamustine 120 mg/m2 on days 1 and 2 by IV infusion every 28 days, 3 to 6 cycles
2003006|NCT01228877|Other|exercise|Adduction, Abduction and Squat exercise three times a week for 16 weeks
2003007|NCT01217437|Biological|Bevacizumab|Given IV
2003008|NCT01217437|Drug|Irinotecan Hydrochloride|Given IV
2003009|NCT01217437|Drug|Temozolomide|Given PO
1509488|NCT02898727|Other|Local Therapy|"Neurosurgery: The decision whether or not to recommend neurosurgery will be made independently of this research study. The complexity and length of the surgery depends on the size and location of the tumour(s).
Stereotactic Radiosurgery: If the participant will be receiving stereotactic radiosurgery (either alone or in combination with neurosurgery), the Radiation Oncologist will organise for the participant to have a Radiotherapy planning. Single metastasis, smaller than or equal to 2cm, may require 1 fraction. Alternately, multiple metastasis, metastasis in the brain stem, or those bigger than 2cm will required multiple fractions to treat. The dose range for the study is 20Gy/1 fraction to 24Gy/3 fractions."
1509489|NCT02898701|Behavioral|Motor Practice of a Standing Serial Reaction Time Task|Subjects will perform a standing serial reaction time task on a step reaction mat. Subjects will step to a series of targets, based on a series of stimuli that are presented. One trial is composed of two 12-step sequences. One of the 12-step sequences is random, while the other is a repeated sequence; sequences are presented in random order. After each trial, the subject rests for 25 seconds. Six trials equal 1 block of practice, which is followed by a 4 minute rest break. After each block, feedback is provided about average response time (RT) on all steps included in the block. One complete day of practice consists of 6 blocks of practice in which each block consists of 6 trials.
1509490|NCT02898688|Behavioral|Control Site|Control sites will continue with their standard practice regarding discussing vaccines with their patients.
1509491|NCT02898688|Behavioral|Intervention Site|Intervention Sites will each assign a Vaccine Champion and will have Assessment, Feedback, Incentives, and eXchange (AFIX) visits. AFIX is a quality improvement program to raise immunization coverage levels, reduce missed opportunities to vaccinate, and improve standards of practices at the provider level. A Continuing Medical Education (CME) module will be given to all providers, covering the recommended maternal vaccinations and how to talk to patients about vaccines. Intervention sites will have access to written materials covering all recommended maternal and infant vaccinations, the diseases they prevent, potential adverse reactions and common patient questions with talking points and references for each topic.
1509492|NCT02898688|Behavioral|Patient-level Control Group|"Participants randomized the control arm will complete a computer-based questionnaire, on an iPad with a preloaded app. The questionnaire asks about vaccine knowledge, attitudes, and beliefs and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questionnaire includes questions requiring a yes or no response, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), questions to capture the vaccines participants plan to get for themselves and their children, and open-ended questions."
1509493|NCT02898688|Behavioral|Patient-level Intervention Group|"Participants randomized to the intervention arm will complete a computer-based questionnaire on an iPad with a preloaded app, prior to watching informational videos covering topics on maternal and childhood vaccines. The questionnaire asks about vaccine knowledge, attitudes, beliefs, and the participant's intent to receive vaccinations during pregnancy and to vaccinate their baby. The questions require yes or no responses, degree of agreement with vaccine-related statements (ranging from strongly agree to strongly disagree), and open-ended responses. After watching at least one informational video, the participant completes a questionnaire asking about the perceived usefulness of the app, degree of agreement with the vaccine information presented in the video, and ways to make the app more useful to participants."
1509494|NCT02898675|Device|Platelet rich fibrine|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
1509495|NCT02898675|Device|Open Flap Debridement|Only open flap debridement treatment the bone loss limitedly
1509496|NCT02898662|Drug|AZD1419|Inhaled AZD1419 administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
1509497|NCT02898662|Drug|Placebo|Inhaled Placebo administered at the clinic as once weekly inhalations with the I-neb® device. Start dose is Placebo 4 mg and dose adaptation is applied (downtitration to 1mg or uptitration to 8 mg or remain on 4 mg) based on appearance of flu like adverse events
1509498|NCT02898649|Device|Irreversible electroporation|IRE is operated to tumor under laparotomy or CT-guided percutaneous approach. Unipolar (19G) or bipolar (16G) electrode probe is inserted to around tumor. After insertion of probe, short duration (70-90㎲) of electric current (25~45A) is generated by IRE device (NanoKnife IRE device, AngioDynamics, Queens bury, New York). It is possible to obtain a three-dimensional ablation zone using multiple electrode. IRE can cause apoptosis of tumor cells, without adjacent tissue damage.
1509499|NCT02898636|Other|autopsy|At autopsy achieving adequate sampling of lesions and healthy skin
1509500|NCT02898623|Other|No intervention|Evaluation of performance of immunoassays based on the detection of antibodies directed against Mycobacterium tuberculosis antigen
1509501|NCT02898610|Drug|Colchicine|
1509502|NCT02898597|Behavioral|Cognitive Behavioral Therapy|Receive cognitive behavioral cessation counseling
1509504|NCT02898571|Dietary Supplement|Placebo|Placebo comparitor
1509505|NCT02898571|Dietary Supplement|Vitamin C|Active treatment
1509506|NCT02898571|Dietary Supplement|epicatechin|Active treatment
1509510|NCT02898532|Behavioral|Educational programmes|Children with ADHD or ADHD-like symptoms practicing target shooting sport in Danish Shooting Associations, during schooltime, for 6 months.
1509511|NCT02898519|Other|cohort|Blood sampling
1509514|NCT02898480|Procedure|Remote ischemic conditioning|Briefly reversible restricting of blood flow to upper limb in four cycles of 5 minutes of inflation at 200mm Hg followed by 5 minutes of deflation.
1509515|NCT02898467|Other|diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
1509516|NCT02898467|Other|non-diabetics|additional blood and urine collection during usual medical care endarterectomy samples during usual medical care
1995859|NCT02634749|Other|Systematic introduction of taste portions|A systematic introduction of plant foods from the Nordic diet
1995860|NCT02634749|Other|Protein reduced complementary foods|Specially prepared, protein-reduced, age-adjusted milk cereal drinks, baby cereals and baby milk, and commercially available baby foods in glass jars
1995861|NCT02634749|Other|Nordic diet|Taste portions, homemade and industry manufactured main meals with a predominance of Nordic ingredients
1509520|NCT02898441|Device|Low Dose Computed Tomography|LDCT were performed in screening arm. The abnormal nodules were defined as noncalcified nodules (NCN) larger than 4 mm.
1509521|NCT02898428|Device|Continuous glucose monitoring (CGM)|
1509522|NCT02898415|Procedure|Liver transplantation|
1509523|NCT02898402|Procedure|blood sample and questionnaire|In addition to normal blood sample performed at entry before delivery, an extra 5 ml blood sample will be taken to establish Q fever serodiagnosis and a short questionnaire will be filled in for clinical and epidemiological data.
1509527|NCT02898363|Other|Information campaign|During a two-year information program, physicians, mainly general practitioners, carers in and outside institutions, associations and families will be informed on cancer frequency, on cancer particularities and on cancer detection in persons with intellectual disabilities by means of documents, mails and e-mails, meetings and a website providing all available useful information on cancer in persons with intellectual disabilities.
1509528|NCT02898350|Device|Pulsed dye laser treatment|Scar minimization with Pulsed dye laser treatment on suture removal day
1509529|NCT02898350|Device|CO2 laser treatment|Scar minimization with CO2 laser treatment on suture removal day
1509530|NCT02898350|Device|Combined PDL and CO2 laser treatment|Scar minimization with Pulsed dye laser and CO2 laser treatment on suture removal day
1509531|NCT02898350|Device|Split PDL and CO2 Laser treatment|Split-scar with CO2 treatment after surgery and combined PDL and CO2 treatment on suture removal day
1509532|NCT02898337|Device|AliveCor handheld mobile ECG|"Specific Aim 1: independent risk factors for methadone-associated QTc interval prolongation will be determined through retrospective analysis of electronic medical records of methadone-treated patients in a narcotic treatment center. Patients will be asked to come to the Narcotic Treatment Center for one 12-lead ECG
Specific Aim 2: QTc intervals from ECGs generated by the AliveCor® heart monitor will be compared prospectively to simultaneous twelve lead ECGs for validation purposes in the methadone-treated patients in a narcotic treatment center."
1509533|NCT02898324|Other|KiVa program|KiVa program is an anti-bullying intervention developed in University of Turku, Finland. It is based on the participant role model, where bullying is seen as a group process focused on the bystanders' reactions to the bullying. This program includes universal and indicated actions. Universal actions include ten students lessons given by teachers where pupils learn the role of bystanders in the bullying process, how to increase empathy towards the victim, and safe strategies to supports victims. Indicated actions are delivered by a school team of three staff members, who handle acute cases of bullying.
1509534|NCT02898311|Device|immediate loading of posterior implants with chairside CAD-CAM composite crown|
1509536|NCT02898285|Behavioral|Team sports|Participants will choose from a list of 5 team sports and will be signed up with the team.
1509537|NCT02898285|Behavioral|Individual sport condition|Participants will choose from a list of 5 individual sports.
1509538|NCT02898285|Behavioral|Night out|Participants in this group will be asked to go out on a date such as dinner or a movie (only restrictions are they cannot go do a sport)
1509539|NCT02898259|Drug|Ixazomib|The prescribed administration of ixazomib doses in this study is 2.0, 3.0 or 4.0 mg ixazomib on days 1, 8 and 15 of each 28 day cycle.
1509540|NCT02898259|Drug|Lenalidomide|"Lenalidomide starting dose will be based on baseline calculated creatinine clearance as follows:
Starting lenalidomide Dose (20mg)
Calculated Creatinine Clearance: >=60ml/min receive 20 mg daily on Days 1 - 21 of each 28-day cycle
Calculated Creatinine Clearance: >= 30 and < 60 ml/min receive 10 mg daily on Days 1 - 21 of each 28-day cycle"
1509541|NCT02898259|Drug|Rituximab|Rituximab is administered intravenously at 375mg/m2 on days 1, 8, and 15 of cycle 1, day 1 of cycles 2-6 and day 1 of cycles 8, 10, and 12.
1509542|NCT02898233|Other|Deprexis|Deprexis is an experimental internet-based treatment program for depression created by Gaia (Hamburg, Germany).
1509543|NCT02898233|Device|Active low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Active LLLT includes 4 days, once per week for 4 weeks, during which LLLT is applied to two alternating positions on the participant's right forehead for 8 minutes total.
1509663|NCT02897570|Dietary Supplement|Milk & Cereals|A breakfast (B1) including a glass of milk (125ml) and 30 g-corn flakes was consumed. Prior and upon completion of each tolerance test, an EEG was performed
1509667|NCT02897570|Device|EEG_post|Electroencephalography (EEG) was performed upon completion of each tolerance test to assess frontal P300-evoked potentials
1995862|NCT02634736|Device|Exergame plus usual treatment|An individualised [i.e. frequency and duration will be set according to each participant's baseline levels] Exergame programme incorporated into participant's normal routines plus usual falls prevention treatment (prescribed by the physiotherapists).
1509544|NCT02898233|Device|Sham low-level light therapy|Administration of LLLT consists of applying light of a specific wavelength (1064 nanometers) that intersects with the absorption spectrum of cytochrome oxidase, using a laser diode, the high density laser (HD laser; Cell Gen Therapeutics, LLC). Sham LLLT includes 4 days, once per week for 4 weeks, during which sham LLLT (5 seconds active, 55 seconds sham) is applied to two alternating positions on the participant's right forehead for 8 minutes total.
2003021|NCT01189266|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
1509551|NCT02898168|Device|WA group|Conventional rehabilitation therapy and gait training with WAIntervention with WA is scheduled 40min/day, five times a week, for 8 weeks.
1509552|NCT02898168|Other|Control|Conventional rehabilitation therapy and gait training without WA.
1509553|NCT02898155|Other|measure of access to primary care and of the Interface Between Primary ans Secondary Care|
1509554|NCT02898142|Other|Postprandial test|Postprandial test : The preparation used for this test consists of a semi standardized liquid meal (400 ml energy drink Fresubin® 2 cal / ml, Fresenius Kabi, France), containing 800 kcal, 50% calories from carbohydrates, 15% in as protein, and 35% as lipid. The test meal will be performed in the morning during 6 hours (between 8:00 and 14:00) after 10 hours of fasting. This post prandial test is the same in the two study groups.
1509555|NCT02898129|Other|Questionnaire|
1509556|NCT02898129|Device|Lung function test|Basic lung function test performed with a micro-spirometer, without broncho dilatator
1509557|NCT02898116|Drug|Ensartinib|Ensartinib is taken orally, once per day. In this study, the starting dose for ensartinib will be 200 mg, which is considered an efficacious dose. Based on the results of the dose escalation phase, this dose may be escalated to the recommended ensartinib single agent dose of 225 mg or de-escalated to the minimum effective dose of 150 mg in the case of overlapping toxicities.
1509558|NCT02898116|Drug|Durvalumab|A durvalumab dose of 1500 mg will be administered as a 60-minute IV infusion every 4 weeks.
1509559|NCT02898103|Device|Ultrasound-guided percutaneous peripheral nerve stimulation|Using ultrasound guidance, the small electrical lead is inserted adjacent to a target peripheral nerve through a percutaneously introduced 20-gauge needle. Following needle withdrawal, the percutaneous lead is attached to a miniature stimulator half the size of a business card that is simply adhered to the skin. When activated, the (active) stimulator generates a small electrical current which passes through the insulated leads to the uninsulated lead tip, which activates nerve fibers (placebo stimulators do not generate current).
1509560|NCT02898077|Drug|Ramucirumab|Administered IV
1509561|NCT02898077|Drug|Paclitaxel|Administered IV
1509562|NCT02898077|Drug|Placebo|Administered IV
1509563|NCT02898064|Device|thoracolumbosacral orthosis or cervicothoracolumbar orthosis|"An off the shelf spinal brace which will be applied to the patients trunk. They will have straps and harnesses which the patient can fasten and remove if needed. The brace will need to be worn by the intervention group all the time for 3 months except when lying in bed. In the presence of lower thoracic (T8 downwards), thoraco-lumbar and lumbar (L1- L3) fractures, a thoracolumbosacral orthosis will be applied. For upper thoracic fractures (T1-T7) a cervico-thoracic or cervico-thoraco-lumbar orthosis will be used."
1509564|NCT02898064|Other|Standard care|Standard surgery, radiotherapy, chemotherapy, drug therapy as applicable and decided by the participants consultant as part of standard care
1509565|NCT02898038|Dietary Supplement|AYMES PARIS|AYMES PARIS is a powdered, high energy, oral nutritional supplement to be mixed with milk as a drink. It provides 320 kcal and 12.2 g protein per 139 ml serving. It is a Food for Special Medical Purposes (FSMP) and must, therefore, be used under medical supervision. It is not designed as a sole source of nutrition.
2003022|NCT01189266|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
2003023|NCT01189266|Other|Laboratory Biomarker Analysis|Correlative studies
2003024|NCT01189266|Drug|Vorinostat|Given PO
2003025|NCT01189643|Drug|irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator|Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
1509570|NCT02898012|Drug|Temozolomide|Temozolomide (TMZ) Temozolomide (TMZ) administered at 130-150 mg/m2 for 5 consecutive days every 4 weeks up to 12 cycles. IV or oral administration was allowed according to the clinical status. TMZ starts at 130 mgs/m2 and increase to 150 mgs/m2 during the second cycle in the absence of hematologic toxicity. In the case of grade 3 or 4 toxicity, the dose for the next cycle is decreased to 110 mg/m2. If the grade 3 or 4 toxicity persists at a dose of 110 mg/m2, treatment is discontinued.
1509571|NCT02898012|Drug|Bevacizumab|Bevacizumab (Bev) administered at a dose of 10 mgs/kg every 2 weeks. Bev was interrupted in cases of wound healing disturbances, gastrointestinal perforation, intestinal occlusion, fistula, uncontrolled hypertension, nephrotic syndrome, grade 4 or recurrent grade 3 thromboembolic events, arterial thrombosis, hemorrhage > grade 2, left ventricular failure, or posterior reversible leukoencephalopathy.
1509572|NCT02897999|Biological|QBKPN|QBKPN Site Specific Immunomodulators
1509573|NCT02897999|Other|Placebo|Placebo
1509574|NCT02897986|Drug|administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination|
1509575|NCT02897973|Other|Activity of daily living|walking, sitting-to-standing and standing-to-sitting, stairs ascending and descending
1509576|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Norway|
1509577|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Sweden|Surgery for neurogenic claudication due to lumbar spinal stenosis in Sweden
1509578|NCT02897947|Procedure|Surgery for lumbar spinal stenosis in Denmark|Surgery for neurogenic claudication due to lumbar spinal stenosis in Denmark
1509664|NCT02897570|Dietary Supplement|Milk, apple & snack|A breakfast (B2) including a glass of milk (220ml), an apple (200g), a cream chocolate filled sponge cake (30g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
1509580|NCT02897908|Procedure|vibration controlled transient elastography (VCTE)|Once on the examination table, the subject will be instructed to place the right arm under their head and to cross their right ankle over the left ankle. The subject will then be asked to slightly bend to the left side to open the intercostal space. Subsequently, a handheld probe is placed in the intercostal space overlaying the right hepatic lobe. The velocity of returning shear waves, measured at a depth of 25-65 mm, is converted into a liver stiffness measurement (LSM). The LSM obtained from a given VCTE exam is the median value of at least 10 successful measurements. This information, along with clinical data associated with the patient will be placed in a database for use in identifying potential subjects for future trials.
1509581|NCT02897895|Biological|levels of CNI in whole blood|
1509582|NCT02897895|Biological|Calcineurin activity (CN-a) in peripheral blood mononuclear cells (PBMCs)|
1509583|NCT02897882|Other|Lung transplant|Pain evaluation
1509584|NCT02897869|Drug|POL7080|7 doses of POL7080 alone over 2.5 days
1509585|NCT02897869|Drug|Amikacin|3 doses of Amikacin alone over 2.5 days
1509586|NCT02897869|Drug|POL7080 + Amikacin|7 doses of POL7080 and 3 doses of Amikacin over 2.5 days
1509587|NCT02897856|Drug|Buccal midazolam|Study subject will receive Buccal midazolam, Intramuscular placebo.
1509588|NCT02897856|Drug|Intramuscular midazolam|Study subject will receive Intramuscular midazolam,Buccal placebo
1509589|NCT02897843|Device|transcranial magnetic stimulation|tDCS stimulation will involve ten 20 minute stimulations daily, characterized by 2 milliamps (mA) anode over the left dorsolateral prefrontal cortex (DLPFC), with the cathode placed over the right suborbital region.
1509590|NCT02897843|Device|sham tDCS|sham tDCS
1509591|NCT02897830|Drug|Ixazomib|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.
Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).
Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21)."
1509592|NCT02897830|Drug|Lenalidomide|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.
Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week).
Late consolidation (consolidation part 2) will consist in 6 additional 28-day cycles of Ixazomib (4 mg on Days 1, 8 and 15) plus Lenalidomide (25 mg on Days 1 through 21).
Maintenance therapy will start within 28 days after the last dose of Lenalidomide in last cycle of Late Consolidation: Lenalidomide 10 mg/d taken on Days 1 through 21 for thirteen 28-day cycles"
1509593|NCT02897830|Drug|Dexamethasone|"induction therapy: comprising three 28-day cycles with Ixazomib (4 mg) on Days 1, 8 and 15 plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22.
Early consolidation : (consolidation part 1) will start 2 months (-/+ 14 days) after transplantation and will comprise 2 cycles of MLN - Rd (MLN R identical to induction therapy but low dose of Dexamethasone 20mg/d once a week)."
1509594|NCT02897804|Behavioral|Knowledge alone|Increase knowledge related STIs, STI risk, alcohol impairment, condom use skills, alcohol use behavior tracking skills, testing & treatment services.
1509595|NCT02897804|Behavioral|Self-efficacy alone|Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509596|NCT02897804|Behavioral|Perceived benefits alone|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
1509597|NCT02897804|Behavioral|Perceived benefits and self-efficacy|Increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509598|NCT02897804|Behavioral|Injunctive norms|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
1509599|NCT02897804|Behavioral|Injunctive norms and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509600|NCT02897804|Behavioral|Injunctive norms and perceived benefits|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509601|NCT02897804|Behavioral|Injunctive norms, perceived benefits, and self-efficacy|Correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509602|NCT02897804|Behavioral|Descriptive norms alone|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
1509603|NCT02897804|Behavioral|Descriptive norms and self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509604|NCT02897804|Behavioral|Descriptive norms and perceived benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
1509665|NCT02897570|Dietary Supplement|Milk, apple & bread w/ cream|A breakfast (B3) including a glass of milk (125ml), an apple (150g), bread (50g, hazelnut chocolate cream (15g) was consumed. Prior and upon completion of each meal tolerance test, an EEG was performed.
1509668|NCT02897557|Device|Insulet Artificial Pancreas (AP) System|
1509605|NCT02897804|Behavioral|Descriptive norms,perceived benefits,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509606|NCT02897804|Behavioral|Descriptive and injunctive norms|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
1509607|NCT02897804|Behavioral|Descriptive norms, injunctive norms,self-efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509608|NCT02897804|Behavioral|Descriptive and injunctive norms, benefits|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
1509609|NCT02897804|Behavioral|Descriptive and injunctive norms, benefits,efficacy|Correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and Increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509610|NCT02897804|Behavioral|Expectancies alone|Decrease the expectation that alcohol is needed to have good sexual encounter.
1509611|NCT02897804|Behavioral|Expectancies and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509612|NCT02897804|Behavioral|Expectancies and Perceived Benefits|Decrease the expectation that alcohol is needed to have good sexual encounter and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
1509613|NCT02897804|Behavioral|Expectancies, perceived benefits, self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509614|NCT02897804|Behavioral|Expectancies and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
1509615|NCT02897804|Behavioral|Expectancies, injunctive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509616|NCT02897804|Behavioral|Expectancies, injunctive norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
1509617|NCT02897804|Behavioral|Expectancies, injunctive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509618|NCT02897804|Behavioral|Expectancies and descriptive norms|Decrease the expectation that alcohol is needed to have good sexual encounter and correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors.
1509619|NCT02897804|Behavioral|Expectancies, descriptive norms, and self-efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509620|NCT02897804|Behavioral|Expectancies, descriptive norms, and benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
1509621|NCT02897804|Behavioral|Expectancies,descriptive norms, benefits, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509622|NCT02897804|Behavioral|Expectancies, descriptive and injunctive norms|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; and correct misperceptions regarding approval of alcohol misuse & sexual risk taking.
1509623|NCT02897804|Behavioral|Expectancies, descr& injun norms, efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509624|NCT02897804|Behavioral|Expectancies, desc & injun norms, benefits|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; and increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol.
1509625|NCT02897804|Behavioral|Expectancies,desc & injun norms,benefits,efficacy|Decrease the expectation that alcohol is needed to have good sexual encounter; correct misperceptions of prevalence of alcohol-induced sexual risk behaviors, alcohol use/misuse, and sexual risk behaviors; correct misperceptions regarding approval of alcohol misuse & sexual risk taking; increase perceived benefits to use protective behavioral strategies to reduce the negative consequences of engaging in sexual behaviors under the influence of alcohol; and increase self-efficacy to use protective behavioral strategies (e.g., condom negotiation skills) to reduce unprotected sex.
1509626|NCT02897791|Behavioral|written evaluations|answering questions about pictures and stories
1509627|NCT02897778|Drug|Entinostat|Single, supratherapeutic dose of entinostat given orally
1509628|NCT02897778|Other|Placebo|Single dose of Placebo containing inactive ingredients matching the appearance of the active product (entinostat).
1509629|NCT02897765|Biological|NEO-PV-01|Personalized cancer vaccine
1509630|NCT02897765|Biological|Nivolumab|monoclonal antibody against PD1
1509631|NCT02897765|Other|Adjuvant|immune adjuvant
1509632|NCT02897752|Device|gait training with WA|Thirty seven units (1 unit=20 minutes) of gait training with WA by a physical therapist for the WA group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
1509633|NCT02897752|Other|usual gait training|Thirty seven units of usual gait training by a physical therapist for the UT group for 4 weeks (+/- 1 week). Thirteen and 24 of the 37 units are training by a physical therapist and self-training, respectively.
2003026|NCT01180712|Dietary Supplement|Mirtoselect|"Male subjects (BMI > 30) with type 2 diabetes controlling their diabetes by diet alone or impaired glucose tolerance.
Volunteers will be given either a total daily dose of 1.4 grams of concentrated blaeberry extract (mirtoselect provided by Indena S.p.A. (http://www.mirtoselect.info/) in a hard gelatin capsules or control capsules containing lactose administered thrice a day for 21 days."
1509638|NCT02897726|Drug|NVP-1402|Oral
1509639|NCT02897726|Drug|NVP-1402R|Oral
1509640|NCT02897713|Other|intensive enteral nutrition|After recruitment, patients should be assessed for EN initiation during first 24 hours after ICU admission. 80% of energy target should be reached within 72 hours.
1509641|NCT02897713|Other|routine enteral nutrition|Attendings decide when and how EN should be administered according to guidelines from academic organizations, such as ESPEN or ASPEN.
1509642|NCT02897700|Drug|Single agent of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate|Procedure: Routine chemotherapeutic regimens using one out of cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as single agent was performed 30~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agent was given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
1509643|NCT02897700|Drug|cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM)|Procedure: Routine chemotherapeutic regimens using two agents from cyclophosphamide, doxorubicin, epirubicin, fluorouracil and methotrexate (CDEFM) as combinatorial treatment was performed 30~60 days before surgery：cyclophosphamide 100mg/M2, doxorubicin 60mg/M2, epirubicin 100mg/M2, fluorouracil 500mg/M2, or methotrexate 50mg/M2.The agents were given on a regular route of IV administration on the 1st and 8th day of each cycle, 28 days per cycle, totally 6 cycles. Subsequently, there was a 30-day interval between the last cycle and radical surgery.
1509644|NCT02897700|Drug|Placebo|Procedure: Routine placebo standardized in clinical oncology was provided to patients to replace any chemotherapeutic agent.
1509645|NCT02897687|Behavioral|Facebook Group|A closed, invite-only group within Facebook facilitated by an interprofessional team that not only reinforces skills, but also aims to promote bonds and a sense of community and connectedness between participants.
1509646|NCT02897687|Behavioral|Book Club Group|A topical book club group discussing Autism-related material conducted by a single healthcare professional.
1509647|NCT02897674|Dietary Supplement|Palm olein|two thirds of the 30% fat calories will come from palm olein
1509648|NCT02897674|Dietary Supplement|Interesterified palm olein|two thirds of the 30% fat calories will come from interesterified palm olein
1509649|NCT02897674|Dietary Supplement|soybean oil|two thirds of the 30% fat calories will come from soybean oil
1509650|NCT02897661|Procedure|FMT|fecal microbiota transplantation (FMT) via mid-GI
1509651|NCT02897661|Drug|Metronidazole|oral adminstration
1509652|NCT02897661|Dietary Supplement|EN|via nasal feeding tube
1509653|NCT02897648|Drug|Assessment of dermal administration of Beta-Lactams|Evaluation of Pharmacokinetic / Pharmacodynamic of dermal administration of Beta-Lactams
1509654|NCT02897635|Behavioral|Individualized Integrative Medicine Intervention|
1509655|NCT02897622|Other|Case management|Case management by Eira unit
1509656|NCT02897609|Other|No intervention. Observational study with a simple questionary filled by physician|
1509657|NCT02897596|Drug|Grazoprevir 100 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Grazoprevir (100 mg) during 8 weeks.
1509658|NCT02897596|Drug|Elbasvir 50 mg/d 8 weeks|Patients with 1b HCV genotype will be received treatment with Elbasvir (50mg) during 8 weeks.
1509659|NCT02897596|Drug|Grazoprevir 100 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Grazoprevir (100 mg) during 12 weeks.
1509660|NCT02897596|Drug|Elbasvir 50 mg/d 12 weeks|Patients with 1a or 4 HCV genotype will be received treatment with Elbasvir (50mg) during 12 weeks.
1509661|NCT02897583|Procedure|YAG vitreolysis|
1509662|NCT02897570|Dietary Supplement|Glucose|50g of glucose dissolved in 250 to 300ml of water was drunk. Prior and upon completion of each glucose tolerance test, an EEG was performed.
1509669|NCT02897544|Behavioral|Individualized Manualized Health Education Intervention|
1509670|NCT02897531|Procedure|ES anastomosis|The side wall of the transverse colon will be anastomosed to the end of the distal ileum with one circular stapler, and the blind end of the transverse colon will be closed with one linear stapler.
1509671|NCT02897531|Procedure|SS anastomosis|The side wall of the transverse colon will be anastomosed to the side wall of the distal ileum with two linear staplers.
1509672|NCT02897518|Device|Imago V-Balde|the endotracheal intubation will be performed with videolaryngoscopes (imago V-Blade) according to the user manual
1509673|NCT02897518|Device|Glidescope|the endotracheal intubation will be performed with videolaryngoscopes (Glidescope) according to the user manual
1509674|NCT02897505|Behavioral|Music Workshop|At each music workshop, the study staff will collect participants' pre- and post-session Physiological and Emotional Thermometer Surveys. The pre-session survey will be conducted prior to the start of the music workshop, and the post-session survey will be conducted within 15 minutes after the conclusion of the workshop.
1509675|NCT02897492|Other|Blood testing in a newly described method|"To exploit detection strategy termed Magnetic Modulation Biosensing, or MMB) to develop a novel, low-cost platform that can detect biomarkers, such as proteins and specific DNA sequences, rapidly and directly from real samples at very low concentrations."
1509676|NCT02897479|Drug|Savolitinib|Enrolled patients will be treated with Savolitinib 600mg once per day(QD), till disease progression, death or unacceptable toxicity, whichever comes first. A cycle of study treatment will be defined as 21 days of continuous dosing.
1509677|NCT02897466|Other|Direct Antimicrobial Susceptibility Testing|An antibiotic susceptibility testing will be performed directly on respiratory samples with Gram negative bacilli on direct smear examination of intensive care patients suspected of ventilator-associated pneumonia. The result of this test associated with GNB identification using mass spectrometry will be given to the physician in charge of the patient at Day 1, one day earlier than the conventional AST. This rapid method will allow a re-evaluation (adequation and/or de-escalation) of the antibiotic probabilist treatment one day earlier than the conventional method.
1509678|NCT02897453|Device|The Spinal Tethering System|An implant comprised of: vertebral body screws, vertebral body staples (washers), and a PET (polyethylene-terephthalate) cord.
1509679|NCT02897440|Procedure|Full Repairng of soft tissue surrounding the hip|Full repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
1509680|NCT02897440|Procedure|Partial Repairng of soft tissue surrounding the hip|Partial repairing soft tissue surrounding the hip damaged during the procedure of hip dislocation and prosthesis implanting.
1509681|NCT02897427|Procedure|Oropharyngeal Cancer Screening|Oropharyngeal exam performed at first study visit and then every 6 months for up to 5 years. Oropharyngeal exam performed using an imaging device that is passed through nose and shines a light on back of throat. Tonsils and back of tongue rubbed with a cotton swab to test for HPV.
1509682|NCT02897427|Procedure|Ultrasound Scans|Ultrasound scans of throat and the lymph nodes in neck to check for cancer and/or dysplasia at first study visit and then every 6 months for up to 5 years.
1509683|NCT02897427|Procedure|Anal Cancer Screening|Anal pap test to test for HPV performed at first study visit. Anal samples collected by gently swabbing the anal area with a cotton swab.
1509684|NCT02897427|Procedure|High-Resolution Anoscopy (HRA)|High-resolution anoscopy (HRA) performed at first study visit. Liquid solution of diluted acetic acid flushed into anal canal. Colposcope inserted into anus and used to take pictures of possible pre-cancerous areas.
1509685|NCT02897427|Procedure|Penile Cancer Screening|During first study visit penis rubbed with a cotton-like swab to test for HPV.
1509686|NCT02897427|Behavioral|Questionnaire|Participant completes a questionnaire about their cancer history, age, sex, race, income, smoking and alcohol drinking history, and sexual behavior. It should take around 15-20 minutes to complete.
1509687|NCT02897427|Other|Oral Rinse Samples|Participants swish with a small amount of mouthwash for 15 seconds, gargle for another 15 seconds, and then spit the mouthwash into a cup.
1509688|NCT02897427|Procedure|Blood Draw|Blood (about 2 teaspoons) drawn to test for HPV antibodies.
1509689|NCT02897427|Other|Follow Up|If participant is not selected to be part of the main study, the study staff will contact them 1 time each year for up to 5 years to check their health status and ask about any diagnosis of cancer or other HPV-related diseases. Participant may be contacted by phone, mail, or email. If called, it should last about 5 minutes.
1509690|NCT02897414|Other|Surveillance of state medical examiner databases|
1509691|NCT02897401|Biological|pregnancy test|Collection of 5 mL of urinary sample.The pregnancy test is done in each investigator center.
1509692|NCT02897401|Biological|urinary cotinine assesment|Collection of 10 mL of urinary sample for cotinine analysis. The analysis is maid during the study and is centralised at the hospital Paul Brousse.
1509693|NCT02897401|Biological|Urinary NNN assesement|Collection of 20 mL of urinary sample for NNN analysis. The analysis is maid at the end of the study and is centralised in a laboratory located at Strasbourg.
1509694|NCT02897401|Behavioral|Questionnaire (Fagerstrom test)|This questionnaire will permit to assess the smoking habits of the participants.
1509695|NCT02897401|Procedure|Measurement of carbon monoxide levels expired|This test will permit to determinate if the participant are axposed to passive smoking or not.
1509696|NCT02897388|Other|breast milk consume promotion|(1)Team building: organize a multidisciplinary breast milk consume improvement team；(2) Staff education: one nurse to train in Canada for 1 month as lactation coordinator, lactation consultant from Canada to teach NICU staff for 1 month; (3) Send breastmilk teaching materials for parents to teach mothers about breast milk feeding;(4) allocate an area in the NICU as a breast pumping room with breastfeeding pumps and chairs to support mothers pumping milk and feeding their babies; (5)purchase 10 breast pumps from Medela and establish a loaner program for mothers; (6)provide lactation counseling & promote consistent communication about the benefits of mothers' milk to encourage mothers to provide milk for their infants;(7)Coaching by lactation coordinator and nursing staff
1509697|NCT02897375|Drug|Carboplatin|Given IV
1509698|NCT02897375|Drug|Cisplatin|Given IV
1509699|NCT02897375|Drug|Palbociclib|Given PO
1509700|NCT02897349|Drug|placebo|
1509701|NCT02897349|Drug|linagliptin|
1509702|NCT02897349|Drug|background therapy|insulin with or without metformin
1509703|NCT02897336|Procedure|ultrasound-guided|ultrasound-guided caudal epidural corticosteroid injection
1509704|NCT02897336|Procedure|interlaminar|interlaminar epidural corticosteroid injection
1509705|NCT02897323|Other|description|
1509706|NCT02897284|Behavioral|Mindfulness 8 weeks|8 sessions of mindfulness
1509707|NCT02897284|Behavioral|Mindfulness 2 weeks|2 sessions of mindfulness
1509708|NCT02897245|Other|No intervention|
1509709|NCT02897232|Other|Survey|Clinical Faculty and community will be given a survey to define issues preventing HPV Vaccination
1509710|NCT02897219|Drug|ipragliflozin|Oral administration once daily
1509711|NCT02897219|Drug|Placebo|Oral administration once daily
1509712|NCT02897219|Other|Insulin Therapy|Continuous subcutaneous insulin infusion or multiple daily injections as standard of care
1509713|NCT02897206|Drug|Imipenem|A wide-spectre antibiotic from the carbapenem group
1509714|NCT02897206|Drug|Placebo|An imipenem-matching placebo
1509715|NCT02897193|Device|ICE dental implant 4.2 mm|ICE dental implant 4.2 mm diameter
1509716|NCT02897193|Device|NICE dental implant 3.2 mm|NICE dental implant 4.2 mm diameter
1509717|NCT02897193|Device|Alpha Bio's Graft Bovine bone|Alpha Bio's Graft Bovine Bone
1509718|NCT02897193|Device|Alpha Bio's Graft resorbable membrane|Alpha Bio's Graft resorbable collagen membrane
1509719|NCT02897180|Biological|Nyaditum resae(R)|Capsules containing Nyaditum resae(R)
1509720|NCT02897180|Biological|Placebo|Capsules containin Placebo
1509721|NCT02897167|Genetic|Retrospective study of frozen samples|Frozen samples of serum and peripheral blood mononuclear cell (PBMC) stored in the Biobank Valdecilla will be selected.
1509722|NCT02897167|Genetic|Prospective study of fresh samples|Samples of serum and cells will be drawn.
1509723|NCT02897141|Device|Health Management App with symptom strategies|The mVIP group will receive a Health Management App with symptom strategies. A mobile app which includes symptom strategies from the UCSF symptom management manual.
1509724|NCT02897141|Device|My Fitness Pal App|The attention control group will receive the My Fitness Pal App preloaded in their smartphones without symptoms strategies
1509725|NCT02897128|Other|Observational Only - Transcutaneous Oxygen Measurement|The transcutaneous oxygen at your surgical site will be measured at three time points prior to your surgery.
1509726|NCT02897115|Biological|Adalimumab|Administered subcutaneously for a maximum of 48 weeks, depending on participants' disease activity observed.
1509727|NCT02897115|Other|Standard of Care (SOC)|Treatment according to participants' physicians' routine practice (local SOC).
1509728|NCT02897102|Behavioral|Training|Training program based on abacus and other activities
1509729|NCT02897102|Other|Different group activities|ballroom dancing (5 participants), belly dancing (4 participants), chorus (16 participants), Spanish classes (8 participants) and chorus and Spanish classes (6 participants).
1509730|NCT02897089|Device|Adhesive agent|Agents used to bond the restorative materials to teeth structure.
1509731|NCT02897076|Drug|betamethasone 24 mg|
1509732|NCT02897076|Drug|12mg betamethasone +placebo|
1509733|NCT02897063|Drug|Droxidopa|Single oral dose 300 mg
1509734|NCT02897063|Drug|Midodrine|Single oral dose 10 mg
1509735|NCT02897063|Drug|Placebo|sugar pill
1509736|NCT02897050|Drug|Docetaxel|Docetaxel 75mg/m2, iv, d1 or 100mg/m2, iv, d1
1509737|NCT02897050|Drug|Capecitabine|Capecitabine 1200mg/m2/d, po, d1-d21
1509738|NCT02897050|Drug|Cyclophosphamide (tablet)|Cyclophosphamide 50 mg/d, po, d1-d21
1509739|NCT02897050|Drug|Fluorouracil|Fluorouracil 500mg/m2, iv, d1
1509740|NCT02897050|Drug|Epirubicin|Epirubicin 100mg/m2, iv, d1
1509741|NCT02897050|Drug|Cyclophosphamide (injection)|Cyclophosphamide 500mg/m2, iv, d1
1509742|NCT02897037|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
1509743|NCT02897037|Drug|heparin|heparin monotherapy
1509744|NCT02897024|Other|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
1509745|NCT02897011|Drug|Methotrexate|
1509746|NCT02896998|Procedure|Removal on demand of the syndesmotic screw|The syndesmotic screw will only be removed in case of a symptomatic implant (e.g. implant causing pain or restricted range of motion)
1509747|NCT02896998|Procedure|Routine removal of fhe syndesmotic screw|The syndesmotic screw will routinely be removed 8 - 12 weeks following placement of the screw
1509748|NCT02896972|Procedure|Vitrectomy|Vitrectomy with inverted ILM technique or ILM peeling
1509749|NCT02896959|Procedure|Arthroscopic rotator cuff repair|
1509750|NCT02896946|Radiation|Diffusion-weighted nuclear magnetic resonance imaging|All MRI examinations will be carried out using a Siemens Magnetom Avanto syngo MR B15 1.5 Tesla (Erlangen, Germany) or a Philips Intera 1.5 Tesla (Eindhoven, The Netherlands) and will include the following sequences: (i) T2 fat sat, with a FOV of 350 x 262, and a matrix of 384 x 207; slices, 30 per sequence, 6 mm thick; (ii) T1 in-phase and out-of-phase with a FOV of 380 x 262, and a matrix of 256 x 158; slices, 30 per sequence, 6 mm thick; (iii) T1 water excitation (= T1 ProSat), with a FOV of 300 x 300, and a matrix of 320 x 220; obtaining 20 slices of 4 mm; (iv) VIBE and THRIVE (dynamic T1 axial 3D EG after injection, during the arterial, portal venous, and late phases, in an axial plane, and optionally in a coronal plane during the portal venous phase), with a FOV of 400 x 312, a matrix of 384 x 192, and with fat suppression and breath-hold; slices 3 mm thick, with liver and pancreatic coverage. Contrast agent: gadobenate dimeglumine (MultiHance, Bracco Imaging, France).
2003027|NCT01174108|Device|Miltenyi CD34 Reagent System|
2003028|NCT01174108|Other|Donor derived G-CSF mobilized PBC|
2003029|NCT01156714|Behavioral|treadmill training|walk on treadmill for aerobic exercise
2003030|NCT01156714|Behavioral|computerized memory training|memory testing and training on computer program
1509787|NCT02896686|Procedure|Reinforcement with Light Polypropylene Mesh|Reinforcement with Light Polypropylene Mesh
1509989|NCT02895009|Device|experimental group|Participants allocated to the experimental group will receive a short term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 1st hour and completed at the 3rd hour, and the TR Band is removed at the 12th hour.
1509756|NCT02896894|Other|Big White Wall (BWW)|"The BWW is an internet-based intervention that incorporates several elements of mental health care that have been shown to be effective, in a virtual environment that provides anonymity (see www.bigwhitewall.com). The on-line portal gives users access to self-assessment tools to track symptoms for a wide range of conditions over time, educational materials, a social network that allows communication between people who may have similar problems, and access to on-line courses. The service is monitored at all times by Wall Guides to ensure that users are responded to and that the content posted is appropriate and safe."
1509757|NCT02896868|Drug|LY3041658|Administered IV.
1509758|NCT02896868|Drug|Placebo|Administered IV.
1509763|NCT02896842|Drug|Posology dose modification|
1509764|NCT02896842|Other|active comparator|
1509765|NCT02896829|Behavioral|Interruption of the treatment by Imatinib|
1509766|NCT02896816|Other|Surface EMG, MRI and PET Scan|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed. In addition, individuals with Parkinson's disease will undergo brain scans at Massachusetts General Hospital to examine whether there are any relationships between muscle activity and brain function.
1509767|NCT02896816|Other|Surface EMG|It will consist of two assessment sessions; one where muscle activity of the arms as well as movement characteristics will be assessed during a reaching task; and another where muscle activity of the legs and movement characteristics will be assessed while walking on a treadmill. Clinical evaluations will also be performed.
1509768|NCT02896803|Drug|mFLOX|5-fluorouracil 500 mg/m2 and folinic acid 20 mg/m2 infused both bolus weekly for 6 weeks (d1, 8,15, 22, 29 and 36) and oxaliplatin 85 mg / m2 infused over 2 hours at weeks 1,3 and 5 (d1,15 and 29). The scheme will be repeated every 8 weeks.
1509769|NCT02896790|Other|Interviews with 2 oncologists and 10 patients|
1509770|NCT02896790|Other|Interviews with 15 patients|
1509774|NCT02896764|Device|Cone-beam CT|
1509775|NCT02896751|Device|3D printed NIV mask|use of 3D printed mask
1995863|NCT02634684|Drug|Dextroamphetamine|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
1995864|NCT02634684|Drug|Placebo|Each participant receives a single pill of placebo or active drug (dextroamphetamine 10 mg) and completes approximately 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
1509778|NCT02896712|Behavioral|Acceptance and Commitment Therapy (ACT)|ACT will assist cocaine patients to notice internal cravings and triggers, abandon attempts to manage these triggers via active avoidance, suppression or other control-based strategies, and to make commitments to engage in behaviors consistent with chosen values or goals. ACT encourages clients to experience thoughts and feelings from an observer perspective, and helps clients not to believe distressing thoughts and feelings as if those thoughts and feelings are literally true and in need of action. ACT treatment will be based on the ACT therapy manual developed and tested previously.
1509779|NCT02896712|Behavioral|Drug Counseling (DC)|The investigators will use the manual-guided individual DC modeled after the NIDA Collaborative Cocaine Treatment Study and used as the active control therapy in previous studies. DC approximates clinical practice as it is considered the most common type of evidence-based treatment in the community for patients actively using cocaine.
1509780|NCT02896712|Behavioral|Contingency Management (CM)|The investigators will use the same high-magnitude CM schedule shown previously to be feasible and effective in facilitating initial cocaine abstinence. Subjects will earn vouchers for cocaine-negative urine samples collected at scheduled clinic visits each week. Under an escalating reinforcement schedule, voucher values will begin at $15 and increase by $10 for each consecutive negative urine. Bonus vouchers of $10 will be given for three consecutive negative urines. Provision of a cocaine-positive urine or failure to provide a scheduled sample will result in no vouchers earned and will reset the schedule to the initial value of $15.
1509781|NCT02896712|Drug|Placebo|The placebo capsule will be filled with corn starch and riboflavin.
1509782|NCT02896712|Drug|Modafinil|Modafinil capsules will start at 200 mg (day 1) and increase to the fixed dose of 300 mg (day 2) and will also contain riboflavin.
1509783|NCT02896699|Behavioral|PrEP Intervention Group|
1509784|NCT02896699|Other|Control Group|
1509785|NCT02896686|Radiation|Control CT|"At the end of the follow up (12 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the abdominal wall seen on the abdominal CT scan with the patient at rest.
The radiologist is blinded to the patient's history and the technique used for fascial closure."
1509786|NCT02896686|Other|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
1995865|NCT02632968|Procedure|Pinhole surgery with and without buttons|
1995867|NCT02633397|Drug|Riociguat|Riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
1509788|NCT02896673|Procedure|ventilatory conditions and measures with scanner and EIT|"Different ventilatory conditions are studied and measures are acquired with scanner and EIT
Time A: measure under basal conditions (TVbasal=6ml/kg of predicted weight), basal PEP, basal inspiratory time / total time = 30%)
Time B: different PEP are applied for 4 minutes: 5, 10, 15, 20 cm of H2O conserving the basal TV
Time C: different TV are applied for 4 minutes: 4, 7, 10 ml/kg of predicted weight conserving the basal PEP and the basal inspiratory time
Time D: recruitment in continuous positive airway pressure at 45 cm of H2O is performed for 30 seconds
Time E: return to adjustment period A"
1509789|NCT02896660|Device|ActiGraph Link|Subjects will be asked to wear the actigraph continuously for a 90-day period, and visit a clinician on day 30, 60, and 90 of the study for data collection.
1509790|NCT02896634|Biological|clinical biology analyzes spectrometry mass|clinical biology analyzes spectrometry mass
1509791|NCT02896621|Drug|Chlorthalidone plus amiloride|A capsule with chlorthalidone plus amiloride was taken once daily in the morning for eight weeks.
1509792|NCT02896621|Drug|Amlodipine|A capsule of amlodipine was taken once daily in the morning for eight weeks.
1509793|NCT02896608|Device|measure of neuronal excitability|
1509794|NCT02896595|Device|General Anesthesia with endotracheal tube|Patient randomized to this arm will have general anesthesia with endotracheal tube placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
1509795|NCT02896595|Device|General Anesthesia with laryngeal mask airway|Patients randomized to this arm will have general anesthesia with laryngeal mask airway placed and will be kept at an appropriate depth of anesthesia for patient comfort and procedure needs.
1509796|NCT02896582|Drug|Obinutuzumab|1000 mg D1, D8, D15 in GA-DHAP 1000 mg D-8 in GA-BEAM 1000 mg every 2 months for 3 years then every month if MRD+
1509797|NCT02896582|Drug|Dexamethasone|40 mg D1 to D4 in GA-DHAP
1509798|NCT02896582|Drug|Aracytine|2g/m² D1 & D2 in GA-DHAP 400 mg/m² D-6 to -3 in GA-BEAM
1509799|NCT02896582|Drug|Cisplatinum|100 mg/m² D1 in GA-DHAP
1509800|NCT02896582|Drug|Etoposide|400 mg/m² D-6 to D-3 in GA-BEAM
1509801|NCT02896582|Drug|Melphalan|140 mg/m² D-2 in GA-BEAM
1509802|NCT02896582|Drug|Carmustine|300 mg/m² D-7 in GA-BEAM
1509803|NCT02896569|Other|Topical combination therapy|
1509804|NCT02896556|Device|Resin infiltrate|A resin that used for micro-invasive treatment of enamel-restricted, non-cavitated caries or hypo/demineralized smooth enamel surfaces.
1509805|NCT02896543|Other|measurement|Blood is obtained into ethylene diamine tetraacetic acid（EDTA） tubes from all subjects via antecubital vein puncture to measure the number of dendritic cells(DCs) and the concentration of sP-selectin. The number of dendritic cells(DCs) and the concentration of sP-selectin are measured in all patients with STEMI at 0 and 5-7 days after admission. The number of dendritic cells(DCs) and the only once in control group after admission.
1509806|NCT02896530|Other|No intervention. Description study|
1509807|NCT02896504|Drug|Exposure: Adjuvant chemotherapy treatment|
1509808|NCT02896504|Drug|Exposure: Adjuvant hormonal therapy treatment|
1509809|NCT02896491|Radiation|Exposure with non-ionizing electromagnetic fields|In a cross-over design subjects will be exposed to sham (placebo), GSM 900 MHz (2W/kg) and TETRA (6W/kg)
1509810|NCT02896478|Other|No intervention. Only observational study|
1509811|NCT02896465|Other|Oral rehydration solution|
1509812|NCT02896465|Other|Zinc|
1509813|NCT02896465|Other|Human milk oligosaccharides|
1509814|NCT02896465|Other|Breastfeeding|
1509815|NCT02896439|Device|Neurophysiological MONITORING|"The neurophysiology team perform:
Implementation of the stimulation electrodes and collection (needle electrodes) SEP and EMG as described above.
Acquisition of data by the machine and the software Protektor® (Natus) in the following format:
A PES stimulation every 10 minutes consistently. Meanwhile, important surgical time and known to be at risk for neurological injury will be noted and their exact schedule specified:
Establishment of a spacer or forceps in the greater or lesser sciatic notch
Traction layout
For the ways of Kocher-Langenbeck, a collection of potential nerve sciatic trunk upstream of the critical region:
At the end of the incision
On the establishment of a spacer or forceps in the greater or lesser sciatic notch
When towing layout
At the end of the intervention"
1509816|NCT02896426|Behavioral|Collaborative Problem Solving|CPS is an approach for understanding and reducing challenging behavior in youth. Under CPS, caregivers are taught to understand and identify the specific neurocognitive skill deficits that underlie their child's challenging behavior. Then the caregivers are taught to interact with the child in a way that solves chronic behavior problems while building the lagging neurocognitive skills to avoid future problems.
1509817|NCT02896426|Behavioral|Positive Solutions For Families|Positive Solutions for Families groups provide information for families on how to promote children's social and emotional skills, understand their problem behavior, and use positive approaches to help children learn appropriate behavior.
1509818|NCT02896413|Drug|Dexmedetomidine group|dexmedetomidine infusion (0.4 mcg/kg/h) from immediately after anesthetic induction to 24 h after surgery
1509819|NCT02896413|Drug|Control group|0.9% saline infusion
1509820|NCT02896400|Behavioral|Brief Negotiated Interview (BNI)|Brief motivational interview on smoking behavior
1509821|NCT02896400|Drug|Nicotine replacement therapy (NRT)|6 weeks of nicotine replacement, patches and gum. First dose of each started in ED. Patches are 14mg or 21 mg. Gum is 2mg per piece.
1509822|NCT02896400|Other|CT Smokers Quitline (QL)|Faxed referral to the CT Smokers Quitline for the subject. QL will then call subject to offer phone based counseling.
1509823|NCT02896400|Other|SmokefreeText (Text)|Enrollment in a version of NCI's SmokefreeTxt, tailored for the study.
1509824|NCT02896374|Behavioral|Theory of mind without visual cues|Theory of mind stimulation without visual reinforcement while performing EEG recordings
1509825|NCT02896374|Behavioral|Theory of mind without visual cues|Theory of mind stimulation with visual reinforcement while performing EEG recordings
1509826|NCT02896361|Device|Reprogramming of spinal cord stimulator (Proclaim or Prodigy SJM internal pulse generator) parameters according to study protocol|Stimulation parameters are reprogrammed from original values to study defined ones
1509864|NCT02896010|Other|Sweetch App + DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
1509865|NCT02896010|Other|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
1509827|NCT02896348|Device|SynPhNe platform|SynPhNe is a non-invasive device. It consists of a piece worn around the forearm, a head component and it communicates wirelessly with the computer to provide feedback while performing motor tasks with the hemiparetic hand. The head cap records brain activity and gives feedback to help relaxing while exercising. The arm and the head component communicate wirelessly with the computer via Bluetooth. The head component reads brain signals while the arm gear senses your muscle signals when performing the exercises. The computer software adopts the appropriate difficulty level, speed and duration of the exercise depending on brain and muscle status to minimize fatigue.
1509828|NCT02896348|Other|Conventional therapy|Exercise program established with a therapist (6 sessions under therapist direct supervision and 12 sessions at home). Low functioning subjects will be given more proximal joint-muscle exercises and activities while higher functioning subjects will have a greater component of distal tasks and activities. The therapist will review the exercises therapy plan with the subject and re-adjust it.
1509829|NCT02896335|Drug|Palbociclib|
1509830|NCT02896322|Radiation|Partial breast irradiation with cyberknife|
1509831|NCT02896309|Dietary Supplement|Sodium bicarbonate|
1509832|NCT02896309|Dietary Supplement|Sodium chloride|
1509835|NCT02896283|Radiation|Low-level laser therapy|Low-level laser therapy with the following parameters: Wavelength:660 nanometer, power: 200 mW, continuous mode, tme of irradiation: 32 seconds
1509836|NCT02896283|Radiation|Turned-off laser|Laser device is turned-off. All parameters are like experimental group, however the laser in turned-off.
1509837|NCT02896270|Drug|Valproic Acid|The concomitant immunosuppressive regimen is to be reduced at the discretion of the investigators. It is suggested to lower immunosuppressive therapy only in valproic acid target trough levels have been attained.
1509838|NCT02896257|Other|Guideline treatment recommendations|Patient-tailored E-consult, orders and rationale to discontinue inhaled corticosteroids and discontinue or receive other COPD related care.
1995868|NCT02633397|Drug|Placebo|Matching placebo to riociguat 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg three times a day for 12 weeks
1509841|NCT02896218|Other|Pharmacists consultation|Pharmacists consultation of vancomycin individualized dosing strategy
1509842|NCT02896205|Drug|Mycophenolate mofetil|Subjects will be given oral Mycophenolate Mofetil starting at 500mg twice a day and increased gradually to a target dose of 2gram per day for 6 months
1509843|NCT02896205|Drug|Placebo|Subjects will be given matching placebo for 6 months
1509844|NCT02896192|Drug|Setmelanotide|RM-493 once daily subcutaneous injection
1509845|NCT02896192|Drug|Placebo|During the double blind placebo withdrawal period, patients will receive RM-493 or placebo at variable times over an 8 week period in order for patients to serve as their own control.
1509846|NCT02896179|Device|Robot-assisted gait training group+VR|The first group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GEO System plus Virtual Reality scenario. During each session, the patients will practice 15 to 20 min of simulated floor walking with simulating of a real walking trail. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
1509847|NCT02896179|Device|GEO|The second group will be subjected to Robot-assisted gait training (RAGT) for 6 weeks (2 sessions/ week) with a total of 12 sessions by mean of GE-O System. During each session, the patients will practice 15 to 20 min of simulated floor walking. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles
1509848|NCT02896166|Other|microwave ablation|eligible patients will be treated with microwave ablation in the primary tumor sites
1509849|NCT02896153|Other|Questionnaire|
1509850|NCT02896140|Other|Type 2 diabetes in WhyWAIT Program|The sum of servings per day of milk, cheese, yogurt, and other dairy foods.
1509851|NCT02896127|Drug|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
1509852|NCT02896127|Drug|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
1509853|NCT02896101|Drug|Pimecrolimus Cream, 1%|
1509854|NCT02896101|Drug|Elidel® (pimecrolimus) Cream|
1509855|NCT02896101|Drug|Placebo of Pimecrolimus Cream, 1%|
1509856|NCT02896088|Other|decayed tooth surfaces|The main variable is the number of new decayed tooth surfaces between the end and the beginning of the research. The caries experience will also be evaluated and expressed by the index 'dmfs' (accumulation of decayed tooth surfaces over those missing or filled due to caries). The secondary variable will be the expression of the retention of AS. The comparison of caries incidence between the two groups of teeth (with and without AS) will take into account the membership of the teeth to the same subject by means of the statistical test Chi-McNemar two. Regression models logistics and Poisson regression will be used to test the effect of independent variables on the appearance of new cavities. The Stata statistical software will be used.
1509859|NCT02896062|Behavioral|sleep-coaching|Sleep-coaching with elements of cognitive behavioral therapy for insomnia and general information about sleep
1509860|NCT02896049|Device|Hyperthermia|treatment with the Celsius42 Hyperthermia System additional to radiotherapy and/or chemotherapy
1509861|NCT02896036|Procedure|Veress needle entry with concomitant CO2|The Veress will be connected to the CO2 tubing, and a skin incision will be made with the scalpel, followed by starting the CO2 gas insufflation and insertion of the Veress needle.
1509862|NCT02896036|Procedure|Veress needle entry with subsequent CO2|A skin incision will be made with the scalpel. The Veress needle will be inserted until intraperitoneal location obtained. This will be followed by starting CO2 gas insufflation until the standard 15 mmHg.
1509863|NCT02896023|Drug|human menopausal gonadotropin|Induction of ovulation followed by ICSI
1995870|NCT02633293|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
1995872|NCT02631486|Other|Physiotherapy|Passive exercises, active exercises, strengthening, stretching
1995873|NCT02630719|Drug|Timolol eye drops|eye drops
2003031|NCT01141712|Procedure|Autologous transplant|Participants will receive the BEAM conditioning regimen followed by autologous HCT.
1509867|NCT02895984|Behavioral|Single-session alcohol intervention (BMI)|The intervention recipients will receive a 1-hour individual BMI. The BMI will follow the central principles of Motivational Interviewing (MI) and will include all the components determined to be efficacious in existing multi-component BMIs (e.g., personalized feedback on indicators of alcohol-related risk, including signs of alcohol dependence and family history of alcohol risk; normative comparisons of the participant's alcohol consumption with same-sex peers in his/her dorm and throughout campus, and protective behavioral strategies). Additional components will include reviewing the pros and cons of the participant's current pattern of alcohol use, providing estimates of the participant's recent Blood Alcohol Concentration (BAC), and providing information about risks of specific negative outcomes at different levels of drinking. Participants will identify goals for behavior change, and with the counselor will develop a plan to achieve the goals and to address barriers to success.
1509868|NCT02895958|Drug|Zepatier|Zepatier (elbasvir and grazoprevir +/- Ribavirin) will be administered in a community setting to HCV infected G1/4 treatment naïve patients on stable opiate substitution therapy with Cirrhotic and Non-cirrhotic liver disease
2003032|NCT01141712|Drug|BCNU|Participants will receive BCNU 300 mg/m^2 Day -6
1509870|NCT02895932|Radiation|PET imaging|Serotonin, Dopamine and Amyloid PET imaging
1509871|NCT02895919|Other|Culture|culture of ascitic fluid in standard culture media of blood culture bottles at bedside and fluid collected for culture in laboratory (study arm).
1509872|NCT02895906|Drug|NFC-1|Doses of NFC-1 will be administered as 50, 100, 200, or 400 mg twice daily as size 2, hard gelatin capsules for oral administration.
1509873|NCT02895893|Behavioral|PrEP Smart|Men who have sex with men and already prescribed and taking oral PrEP will use an application on their smart phone for 4 weeks.
1509874|NCT02895880|Behavioral|usual care|In order to characterize the content of and variation in usual care, the first 25 patients enrolled in the study will complete a post-visit questionnaire that asks what their doctor told them (if anything) about their risk of cardiovascular disease, risk reduction and statins specifically, and how this information was presented
1509875|NCT02895880|Behavioral|statin communication tool|The Statin Choice decision aid uses icon arrays to communicate the expected benefits of statins. This modified risk communication tool will maintain the components of the validated original. The adapted paper-based risk communication tool will describe modified risk profiles applicable to the survivors at increased risk for cardiac disease due to chest irradiation.
1509876|NCT02895867|Other|Full fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of full fat dairy products into their diet
1509877|NCT02895867|Other|Low fat dairy|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will be instructed to include at least ≥3 servings of low fat dairy products into their diet
1509878|NCT02895867|Other|Control|Participants will receive nutritional counseling aiming to maintain body weight from a registered dietician and will not be asked to include a specified amount or type of dairy products
1509879|NCT02895854|Radiation|Hypofractionated RT 5 x 7,25 Gy|
1509880|NCT02895854|Radiation|LDR-brachytherapy with I125 seeds|
1509881|NCT02895841|Device|SMART app wearable|"Patients will be given a wearable such as a Microsoft Band accelerometer to track movement, heart rate, galvanic skin response and sleep, which will be collected in combination with the data from the SMART visual dashboard. Data will be sent to the SMART dashboard as well as stored on the iPad/iPod touch via software from the manufacturer. Participants having a wearable device will receive the education intervention (such as haptic prompted texts that state 'try and walk today', 'have you had enough water today', 'make sure to take deep breaths')."
1509882|NCT02895828|Other|Core Stabilization Exercise|the participants asked to performed CSE program, 20 min/session, 2 session/week, 10 weeks
1509883|NCT02895828|Other|General Strengthening Exercise|the participants asked to performed GSE program, 20 min/session, 2 session/week, 10 weeks
1509884|NCT02895815|Combination Product|CNTO 2476 (6.0 * 10^4 cells)|Participants will receive a single subretinal administration of CNTO 2476 (6.0 * 10^4 cells) in 50 mcL given by subretinal delivery system (subretinal access kit [SRAK-02 kit] and third arm accessory).
1509885|NCT02895815|Combination Product|CNTO 2476 (3.0 * 10^5 cells)|Participants will receive a single subretinal administration of CNTO 2476 (3.0 * 10^5 cells) in 50 mcL given by subretinal delivery system (SRAK-02 kit and third arm accessory).
1509886|NCT02895802|Behavioral|Verbal instructions with picture diagram|verbal instructions and picture diagram
1509887|NCT02895802|Behavioral|Verbal instructions with video of ADSC|Verbal instructions and watching video depicting ADSC
1509888|NCT02895802|Behavioral|verbal instructions w. video of w/o DS|verbal instructions and watching video depicting person without DS washing her hands
1509889|NCT02895802|Behavioral|verbal instructions w. video w/DS|verbal instructions and watching video depicting person with DS washing his hands
1509890|NCT02895763|Other|Form administrations|
1509891|NCT02895750|Drug|Metformin|
1509892|NCT02895737|Device|TAVI: Edwards SAPIEN 3, Edwards Lifesciences|
1509893|NCT02895737|Device|TAVI: Edwards SAPIEN 3, Edwards Lifesciences; Claret Sentinel™ Cerebral Protection Systems|
1509894|NCT02895737|Device|TAVI: CoreValve® Evolut R™, CoreValve Medtronic|
1509895|NCT02895737|Device|TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Claret Sentinel™ Cerebral Protection Systems|
1509896|NCT02895724|Drug|Medical Oxygen|Hyperbaric oxygen therapy
1510026|NCT02894723|Dietary Supplement|syrup|The same bottle of the experimental group, but without l-arginine
2003033|NCT01141712|Drug|Etoposide|Participants will receive Etoposide 100 mg/m^2 BID Days -5 to -2
2003034|NCT01141712|Drug|Cytarabine|Participants will receive Cytarabine 100 mg/m^2 BID Days -5 to -2
2003035|NCT01141712|Drug|Melphalan|Participants will receive Melphalan 140 mg/m^2 Day -1
2003036|NCT01120782|Device|etafilcon A toric contact lens with new wetting agent|Investigational toric contact lens made of etafilcon A material with a new wetting agent.
2003037|NCT01120782|Device|etafilcon A toric contact lens|Marketed toric contact lens made of etafilcon A material.
1509897|NCT02895698|Device|Dry cupping|Dry cupping. First, the therapist identified the trigger point on calf muscle.After identification of the trigger point, the participant was in prone with the ankle outside the edge of the bed. Ultrasound gel was then placed over the trigger point as a lubricant to increase the suctioning of the plastic vacuum cup, after which the cup was placed. Air was withdrawn from the cup to create a suction force. The cup was maintained for 10 minutes, and the participant was asked to do active ankle dorsiflexion exercise after 5 minutes of placing the cup. The therapist held the cup in place while the participant performed exercise.
1509898|NCT02895698|Other|Stretching exercises|"The participant was in prone with the ankle outside the edge of the bed. The participant was asked to do active ankle dorsiflexion exercise after 5 minutes of lying on bed.
Standing self-stretching of the calf muscles.
Plantar fascia-specific self-stretching.The participant was instructed to start gently at first and then to work more aggressively as long as the pain is tolerable.
All stretches were done six times and the duration of each stretch is 30 seconds."
1509899|NCT02895685|Other|Dyad training|Participants will be paired in teams at the introduction. Participants will be instructed to train and supervise each other in pairs and will receive information on how to give constructive feedback. Participants will practice in pairs during on-site classes and encouraged to train in pairs during the self-regulated training at home. At the on-site classes, participants will be instructed to practice with their partner, during the expert-guided self-training and receive all feedback in pairs. Participants will train at the same table with space for two people. Outside the classroom, participants will decide themselves when and how often they will meet to practise. Participants are instructed to actively observe his or her partner while practising and are encouraged to discuss their performance and any difficulties they encounter. Testing will be done individually. With the training log, the investigators will measure whether the participants train in pairs at home as instructed.
1509900|NCT02895672|Drug|GLP-1 therapy|The investigators will assess the efficacy and safety of 12 months of GLP-1 therapy added to the therapeutic regimen of a group of T2DM patients who have received basal insulin therapy for a minimum of one year.
1509901|NCT02895659|Procedure|perioperative hemodynamic management with vasoactive medications (norepinephrine, adrenaline ect)|Perioperative hemodynamic management will be performed according to a specified treatment protocol.
1509902|NCT02895646|Other|Collection of blood sample|
1509903|NCT02895633|Other|Ecography|Standard Doppler ultrasound and perfusion imaging after injection of Sonovue
1509904|NCT02895633|Other|CT scan|With injection of Iomeron 400
1509905|NCT02895633|Other|MRI|With injection of gadolinium (Multihance)
1509906|NCT02895620|Biological|Xpert bladder Test|Xpert test positive or negative on urine samples of NMIBC patients treated by BCG
1509907|NCT02895607|Procedure|Ambulatory care among eligible patients|"The management of Anterior Cruciate Ligament (ACL) Reconstruction reconstruction in outpatient will be proposed in consultation with the surgeon.
After an explanation of the course of treatment a fact sheet on the protocol will be provided to the patient and his doctor to the patient to decide its support in CA (ambulatory surgery) or HC (conventional hospitalization)."
1509908|NCT02894606|Drug|Thymoglobulin Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
1509909|NCT02894606|Drug|Basiliximab Induction|The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.
1509910|NCT02894593|Other|alcohol free essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
1509911|NCT02894593|Other|alcohol essential oils mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
1509912|NCT02894593|Other|0.20% chlorhexidine mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
1509913|NCT02894593|Other|Placebo|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 15 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
1509914|NCT02894567|Device|Intraoperative test during a deep brain stimulation surgery|The spiderSTN lead is inserted in a selected track in the brain, and is connected to external neuro-recorder/stimulator . Once the intraoperative test phase is completed, the test devices are removed and the DBS surgery resumes.
1509915|NCT02894554|Drug|Telbivudine|
1509916|NCT02894554|Drug|Lamivudine|
1509917|NCT02894541|Drug|CKD-519 100mg|
1509918|NCT02894541|Drug|CKD-519 200mg|
1509919|NCT02894541|Drug|CKD-519 100mg|
1509920|NCT02894541|Drug|CKD-519 200mg|
1509921|NCT02895555|Procedure|i-FACTOR|Between 5-10 CC i-FACTOR putty mixed with local harvested autograft pr level spondylodesis compared to 30 grams of allograft pr level mixed with local harvested aulograft.
1509922|NCT02895555|Procedure|Allograft|Approx 50 g of allograft bone in the fused site
1509923|NCT02895529|Drug|Itraconazole|Participants will receive 200 milligram (mg) of itraconazole intravenously (IV) twice daily on Day 1 and Day 2, followed by 200 mg once daily through Day 14. From Day 15 to Day 28, participants will receive 200 mg (20 milliliters [mL]) of itraconazole oral solution orally twice daily. Participants, who are not suitable for oral administration of itraconazole based on the investigator's judgment, will receive 200 mg of itaconazole IV once daily from Day 15 to Day 28.
1509924|NCT02895529|Drug|Caspofungin|Participants will receive 70 mg of caspofungin IV once daily on Day 1 followed by 50 mg IV infusion once daily thereafter through Day 28.
1509925|NCT02895516|Device|Vibrating capsule|Patients will receive vibrating capsule for 6 weeks of treatment (2 capsules per week)
1509926|NCT02895503|Behavioral|Yoga|Participate in yoga
1509927|NCT02895503|Behavioral|Support Group Therapy|Participate in emotional support group therapy
1509928|NCT02895503|Other|FACT-L|This is a 44-item self-report instrument which measures multidimensional HRQOL. There are 5 sections dealing with physical, family, emotional, and functional well-being and their relationship with the doctor. There are nine questions in a sixth subscale that are specific to lung cancer (LSC), including shortness of breath, cough, etc. The TOI is the sum of the scores on the LCS and the physical well-being and functional well-being subscales of the FACT-L scale. The FACT-L has been shown to be reliable and valid and sensitive. (Cella, Bonomi, Lloyd, DS, Kaplan, & Bonomi, 1995). The instrument has been used with patients with lung cancer in the Massey Cancer Center.
1509929|NCT02895503|Other|Pulmonary function test|The pulmonary function test includes forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1) and peak expiratory flow rate (PEFR). Use of a digital spirometer provides an objective and reliable measure of the patient's vital capacity.
1509930|NCT02895490|Other|educational intervention|Receive a DVD containing educational information and communication skills
1509931|NCT02895490|Other|communication skills training|Receive a DVD containing educational information and communication skills
1509932|NCT02895490|Other|educational intervention|Receive information about the LINC group
1509933|NCT02895490|Other|questionnaire administration|Ancillary studies
1509934|NCT02895490|Other|quality-of-life assessment|Ancillary studies
1509935|NCT02895477|Device|hearing aid|
1509936|NCT02895464|Other|Exercise|The sessions will be led by a physiotherapist, in the older person's home. The sessions will consist of inspiratory muscle training with a resistance starting from 50% of their maximal capacity (30 breathes, 2 times/day). The training session will also consist of high-intensity individually adjusted functional strength and endurance training: chair-stand; stair climb/step up with weight belts, interval walking indoor and/or outdoor. This will be combined with functional task-exercises. The training will be conducted 2-3 times week, for at least two weeks or until they undergo surgery. During the remaining days, the participants will be instructed to follow the recommendation of 30 minutes of moderate physical activity per day, as well as to perform inspiratory muscle training.
1509937|NCT02895451|Behavioral|Extended behavioral intervention|The exercise goal is set in liaison between the patient and the physiotherapist, based on activities and target behaviors that the patient thinks is relevant and important. The patients are asked to self-monitor the defined exercise goal by completing an exercise diary. The exercise diary includes specification of the performed exercise dose (frequency, intensity and duration). The exercise diary is followed up by a physiotherapist every third week by a phone call or a personal meeting. Visual feed-back on the performed dose of exercise is given once by accelerometry. At end of intervention (16 weeks) the patient is offered a follow-up meeting with the physiotherapist to discuss a long-term exercise goal.
1509938|NCT02895438|Dietary Supplement|gluten|
1509939|NCT02895425|Other|Registry (No intervention)|
1509940|NCT02895412|Biological|Donor-derived WT1-CTL and P-CTL|"Donor-derived WT1-CTL and P-CTL.
P-CTL will be given prophylactically a minimum of 28 days after transplantation followed by administration of monthly infusions of WT1-CTL for up to four doses."
1509941|NCT02895399|Other|Cervico-Vaginal Smears analysis|Cervico-Vaginal Smears analysis
1509942|NCT02895386|Device|ROX Coupler|ROX Coupler will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
1509943|NCT02895386|Other|Sham procedure|Sham procedure + continuing current antihypertensive medications.
1509944|NCT02895373|Drug|Alprostadil|5ng/kg/min, continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
1509945|NCT02895373|Drug|0.9% sodium chloride solution|continuously, start within 24h of initiation of ECMO therapy and end at the end of ECMO therapy
1509946|NCT02895360|Drug|BAL101553|48-hour intravenous infusion at MTD. Oral capsule daily for one week during Cycle 2, dose calculated based on PK modeling
1509947|NCT02895347|Behavioral|Surgical Simulation Practice Modules|The surgical simulation practice modules simulate surgical settings for suturing.
1509948|NCT02895334|Behavioral|MyHeartBaby Program|Participating Caregivers will receive an electronic tablet loaded with a telemedicine intervention program (MyHeartBaby) to support caregivers remotely in the daily care and adjustment to having an infant with chronic medical needs with video-based telemedicine support services. There are a total of six sessions occurring at weeks 3, 6, 9, 12, and 15 of the study.
1509949|NCT02895321|Other|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
1509950|NCT02895321|Other|Colgate, Protection Caries|a fluorine-based toothpaste gels
1509951|NCT02895321|Other|Placebo gel|a glycerin and water gel
1509952|NCT02895308|Behavioral|Online psychoeducation|The online intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
1509953|NCT02895308|Behavioral|Face-to-face psychoeducation|The intervention consists of a psychoeducation component taken from affect focused psychotherapy. In this model, emotions are physiological patterns that are shaped mainly in the context of previous relations. By using the model, patients are helped to better understand their current emotions, behaviors and cognitions. The aim of the intervention used in this study is to provide information about the six basic affects and how they may influence everyday behaviors and well-being in recurring patterns.
1509954|NCT02895295|Behavioral|Expert Recommendation|Decision support tool that provides personalized information on the financial implications of enrolling in different plans and expert recommendations of particular plans.
1509955|NCT02895295|Behavioral|Individual Analysis|Decision support tool that provides personalized information on the financial implications of enrolling in different plans.
1509956|NCT02895295|Behavioral|Usual Care|Study subjects randomized to the control arm will receive information on how to download their prescription drug information from their electronic medical record and provided with a list of resources available in the community to help them choose a prescription drug plan.
1509957|NCT02895269|Behavioral|Collaborative shared care|Collaboration between complementary alternative health providers and primary health care providers in the care of persons with psychosis.
1509958|NCT02895256|Drug|Any treatment for cluster headache|
1509959|NCT02895243|Other|Prehabilitation|The study will use a generic prehabilitation program which will include the following components: Warm-up, cardiovascular training, strength training, flexibility training, and cool down. Prehabilitation will occur once per week and approximately 1 hour in duration. Participants will take part in prehabilitation until they receive a kidney transplant which by study design is approximately for 3-6 months.
1509960|NCT02895230|Other|Standard care|An extraction from French Health Reimbursement Agency database and French hospital discharge database will be performed using a simplified request based on inclusion criteria but the extraction will encompass a 4-year period to ensure sufficient follow-up.
1509961|NCT02895217|Other|ergocycle|
1509962|NCT02895204|Dietary Supplement|Fermented Maillard reacted whey protein (F-MRP)|6g of powder containing 4.2g fermented maillard reacted whey protein
1509963|NCT02895204|Dietary Supplement|Placebo|6g of maltodextrin
1509964|NCT02895191|Drug|ulinastatin|Patients will receive the study drugs for 7 to 14 days
1509965|NCT02895191|Drug|placebo|Patients will receive the placebo for 7 to 14 days
1509966|NCT02895178|Behavioral|Combined aerobic and strength exercise training|Subjects participate in supervised exercise sessions for 60 minutes thrice weekly and are encouraged to participate in a home-based exercise session over 30 minutes once weekly for 12 weeks.
1509967|NCT02895152|Behavioral|Feedback|Will receive feedback on the amount of activity that has been undertaken in the last week, will specialist advice on steps taken, active minutes each day, how much device has been worn and tailored advice on how to improve activity levels
1509968|NCT02895139|Device|Additive Manufactured Orthotic Device|The 3D foot scan data will be used to generate a 3D model of the foot orthotic which will then be adapted to be suitable for solid printing. The final model will be saved in .stl format for use in the printing software. The additive manufactured orthotic insoles and all features or additions will be produced in a single build from additive materials matched for hardness to medium density EVA. Post production the orthotic will be cleaned to remove support material and a top cover will be attached to the final additive manufactured orthotic insole.
1509969|NCT02895139|Device|Moulded orthotic|The foam impression box and prescription will be sent to an external company for production of the handmade moulded orthotics. Handmade moulded orthotics will be produced by heating and wrapping medium density Ethylene-vinyl acetate (EVA) around plaster casts of the impression boxes. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the moulded orthotic insole. A top cover will be attached to the final moulded orthotic insole.
1509970|NCT02895139|Device|Milled orthotic|The 3D foot scan data will be used to generate a 3D model of the foot orthotic. This will then be saved in .pan format for use in a CNC milling software. Orthotics and all features will be milled in a single mill from a block of medium density EVA. Post milling the orthotics will be cleaned. The orthotic insoles may be manually adapted to meet the requirements of the prescription, this could include cut out sections designed to offload regions of the foot or the addition of features such as metatarsal bars which provide varied support. Features and additions will be added in post manually by cutting and gluing onto the milled orthotic insole. A top cover will be attached to the final milled orthotic insole.
1509971|NCT02895126|Behavioral|"Appui Parental program"|
1509972|NCT02895126|Behavioral|Regular parental support|
1509973|NCT02895113|Drug|Aspirin|Patients suffering from type 2 diabetes will be randomized to receive 100 mg/day or placebo for one year
1509974|NCT02895113|Other|Placebo|Patients in this arm will be treated with placebo
1509975|NCT02895100|Drug|PTG-100|Daily dosing of PTG-100 by subject for a 12 week treatment period.
1509976|NCT02895100|Drug|Placebo group|Daily dosing of Placebo capsules by subject for a 12 week treatment period.
1509977|NCT02895087|Other|Diurnal Variation Group|This intervention occurs over one 24-hour period. Eligible participants will be required to be admitted into a supervised environment for 24-hours arriving no later than 0730. Blood draws will then be taken every 4 hours (0800, 1200, 1600, 2000, 2400 and 0400). Care will be taken to ensure the total blood draws (including the screening visit) stay within Red Cross Guidelines (less than 500 ml every 8 weeks).
1509978|NCT02895087|Other|External Stress Group|"2 visits will be required, each lasting approximately 2.5 hours in the afternoon.
At both visits participants will rest quietly for 15 minutes, then have 3 blood draws and 4 saliva samples over approximately one hour. Participants will also be required to complete short questionnaires about their mood and experience.
At the second visit, participants will also complete some thinking and talking tasks. In addition the autonomic nervous system of the participant's will be monitored throughout the visit."
1509979|NCT02895074|Procedure|Femtosecond laser-assisted cataract surgery|A femtosecond laser (Alcon-Lensx, Alcon-Lensx, Inc.) was used in this study. After pupil dilation and topical anesthesia, the laser was docked to the eye using a curved contact lens to applanate the cornea. With the integrated OCT imaging system, the locations of the cornea and the anterior and posterior surfaces of the crystalline lens were determined. A 5.0-mm-diameter capsulotomy was created by scanning a cylindrical pattern and followed by lens fragmentation. The laser was disconnected, and the remainder of the surgery was performed as phacoemulsification (Infiniti® Vision System; Alcon, USA). Folded intraocular lenses (IOLs) were implanted in the capsular bags.
1509980|NCT02895074|Procedure|Conventional phacoemulsification cataract surgery|Phacoemulsification was performed through a temporal 3.2-mm clear corneal incision with the same machine and followed by IOLs implantation.
1509981|NCT02895074|Drug|Tropicamide|After pupil dilation, 1 drop of tropicamide (0.5%) was applied every 15 minutes for 3 applications
1509982|NCT02895074|Drug|Proparacaine hydrochloride|topical anesthesia with proparacaine hydrochloride (0.5%) was applied.
1509983|NCT02895061|Drug|Alfacalcidol|Alfacalcidol 1 microgram/capsule
1509984|NCT02895035|Drug|Phenylephrine-ketorolac|Pehnylephrine-ketorolac is a combination of an alpha-one agonist (phenylephrine) and an NSAID (ketorolac). One 4-mL bottle of 1% phenylephrine/3% ketorolac is added to the irrigation solution during cataract surgery.
1509985|NCT02895035|Drug|Epinephrine|Epinephrine is a nonselective adrenergic agonist added to the irrigation solution during cataract surgery.
1509986|NCT02895022|Drug|Lidocaine 2% adrénalinée|
1509987|NCT02895022|Device|Epidural catheter|
1509988|NCT02895022|Procedure|Caesarean section|
1509990|NCT02895009|Device|control group|Participants allocated to the control group will receive a routine long term postoperative puncture site compression via TR Band. TR Band deflation is commenced at the 2nd hour and completed at the 6th hour, and the TR Band is removed at the 24th hour.
1509991|NCT02894996|Drug|fluid challenge|fluid challenge realized after induction of anesthesia at a steady state, to assess fluid responsiveness and correct hypovolemia. The usual fluid bolus of 15ml/kg in 10 minute will be fragmented in 2 fluid boluses (3ml/kg in 2 minutes followed by measurement of hemodynamic parameter after 1 minute of the end of the 1st fluid bolus and followed by 12 ml/kg in 8 minutes then followed by measurement of hemodynamic parameters after one minute after the end of the 2nd fluid fragmented fluid challenge. Total administered: 15 ml/kg in 11 minutes. end of the study at 12 minutes.
1509992|NCT02894983|Other|Flexion-ulnar cast|The group will be treated with closed reduction and flexion-ulnar deviation position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after weeks.
1509993|NCT02894983|Other|Functional cast|The group will be treated with closed reduction and functional position cast. This will take place under local anaesthesia by means of local infiltration commonly used in Finland. There is no preferable method for performing the reduction. Additional radiographs will be taken to verify the success of the reduction one week after the reduction and after two and five weeks of casting if treating health care professional it requires. The cast will be disposed after weeks.
1509994|NCT02894970|Device|Pulmonary PPG|Five minutes check with a lights source with two wave lengths of infrared and a detector.
1995874|NCT02630719|Drug|Artificial tears|Placebo drop
1509997|NCT02894931|Dietary Supplement|monosaccharides|The monosaccharides; Glucose, Fructose, Galactose and mannose, will be administrated after O.N fasting, 50gr, once.
1509998|NCT02894931|Dietary Supplement|Disaccharides|The Disaccharides; Lactose, Maltose and sucrose, will be administrated after O.N fasting, 50gr, once.
1509999|NCT02894931|Dietary Supplement|Amino acids|The Amino acids; Leucine, Isoleucine, and Valine, will be administrated after O.N fasting, 5g, once.
1510000|NCT02894931|Dietary Supplement|Artificial Sweeteners|The Artificial sweeteners: Saccharin, Aspartame, Sucralose and Steviol, will be administrated after O.N fasting, 300 mg, once.
1510001|NCT02894931|Other|Control- water|Chilled water flavored with lemon juice as control
1510002|NCT02894918|Drug|Peginterferon alfa-2a|180ug/0.5ml,hypodermic injection once a week
1510003|NCT02894905|Drug|AL-335|Participants with various degrees of impaired renal function (mild [Cohort 1], moderate [Cohort 2], severe [Cohort 3]) and normal renal function (Cohort 4) will receive a single oral dose of AL-335 800 mg (given as 2*400-mg tablets).
1510004|NCT02894892|Drug|(A)Bismuth|
1510005|NCT02894892|Drug|(B)Bismuth|
1510006|NCT02894892|Drug|(C)Bismuth|
1510007|NCT02894892|Drug|(D)Esomeprazole and Bismuth|
1510008|NCT02894892|Drug|(E)Esomeprazole and Bismuth|
1510009|NCT02894892|Drug|(F)Esomeprazole and Bismuth|
1510010|NCT02894892|Other|(G)Control|
1510011|NCT02894879|Device|BreatheMAX®|"Modify chest physical therapy
oscillated incentive spirometry (OIS) with inspiratory load of 5-8 cm H2O 30 times/set
oscillated positive expiratory pressure (OPEP) with expiratory load of 5-8 cm H2O 30 times/set
Coughing with splinting 3 times/set
Chest mobilization with overhead both arms rises 10 times/set total 5 set/day"
1510012|NCT02894879|Other|Routine treatment|"Routine chest physical therapy
Deep breathing exercise (upper and lower costal and diaphragmatic breathing exercise) as deep as possible for 10 times/set/level
Coughing with splinting 3 times/set
Chest mobilization with overhead both arms raised 10 times/set total 5 set/day"
1510013|NCT02894866|Device|hyperbaric oxygen|The hyperbaric oxygen treatment will be administered for 60 min in a baby hyperbaric oxygen chamber (YLC0.5/1A, WuHan, China) pressured with 100% oxygen to 1.5 to 1.8 atm absolute (ATA) and a constant oxygen flow was given to maintain the oxygen. concentration in the chamber at 80% or greater.The treatment will be administered once a day within 7 days after birth, 7 days is a course of treatment, at least for 4 courses.
1510014|NCT02894853|Genetic|Liquid (blood) biopsies and tumor biopsy (optional)|Liquid (blood) biopsies: 40 ml (maximal 10 times per patient) Tumor biopsy (optional)
1510015|NCT02894840|Biological|an inactivated influenza vaccine|The vaccine will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
1510016|NCT02894840|Other|Placebo|The placebo will be administered via the intramuscular route; the preferred injection site will be the deltoid of the non-dominant arm.
1510017|NCT02894827|Biological|Blood sample|
1510018|NCT02894827|Other|Flow cytometry|
1510019|NCT02894827|Other|western blot|
1510020|NCT02894814|Behavioral|One-Stop Dispensing|Use of own medication, review of the patient`s medication, partly or self-administration of medication during hospitalization under support from the health personnel to improve adherence, knowledge and feeling safe about the medication.
1510021|NCT02894814|Behavioral|One-Stop Dispensing and focused dialogue|Besides the elements of One-Stop Dispensing focused dialogue about the patient's medicine during hospitalization and at discharge to improve adherence, knowledge and feeling safe about the medication
1510022|NCT02894788|Other|ICU admission|
1510023|NCT02894749|Radiation|3D rotational angiography (3DRA)|3DRA allows CT-like reconstructions. It requires less X-rays and contrast medium than standard angioCT-scan. Furthermore, it can be performed in the operative room, during the procedure. Therefore, use of 3DRA should allow reduction of dose, contrast-medium and reintervention when compared to technical success assessment with angioCT-scan.
1510024|NCT02894736|Device|Soterix tDCS machine|Soterix tDCS machine - miniCT supervised neuromodulation system
1510025|NCT02894723|Dietary Supplement|L-arginine|30 ml arginoline contains 5 gr l-arginine
1511303|NCT02884050|Drug|Placebo|non-active placebo
1510027|NCT02894710|Drug|Lidocaine 20mg/ml|Patients in Lidocaine group received an intravenous bolus injection of 1,5 mg/kg lidocaine (0,075mL/kg of Lidocaine 20mg/mL) followed by a continuous lidocaine infusion of 2 mg/kg/hr during surgery (0,1mL/kg/hr of Lidocaine 20mg/mL) and 1 mg/kg/hr in recovery room (0,05mL/kg/hr of Lidocaine 20mg/mL).
1510028|NCT02894710|Drug|Glucose 5% (placebo)|Patients in control group received an intravenous bolus injection of 0,075mL/kg of placebo (Glucose 5%) by a continuous lidocaine infusion of 0,1mL/kg/hr of placebo (Glucose 5%) during surgery and 0,05mL/kg/hr of placebo (Glucose 5%) in recovery room.
1510029|NCT02894697|Device|Anigography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
1510030|NCT02894697|Device|Optical coherence tomography-guided PCI with BVS|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before stent implantation. After PCI, postprocedural OCT will be evaluated to find OCT-defined suboptimal results requiring additional PCI. If there is OCT-defined suboptimization, additional PCI will be performed including balloon angioplasty or additional stent or BVS implantation for scaffold optimization. Further postprocedural OCT will be also evaluated whether scaffold implantation is fully optimized or not.
1510031|NCT02894684|Drug|Aztreonam|14 days of AZLI: 75mg TDS PLUS IV Colistin
1510032|NCT02894684|Drug|Standard Care|14 days of IV Colistin plus one of Tazocin/Ceftazidime/Meropenem/Aztreonam/Fosfomycin
1510033|NCT02894671|Other|blood exams|in serum will be analyzed the level of IMA, iron, transferrin, ferritin, total albumin
2003038|NCT01119898|Drug|PENNSAID Gel|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
2003039|NCT01119898|Drug|Vehicle|2 mL applied to the front, back and sides of the knee twice a day (morning and night) for 4 weeks
1510036|NCT02894645|Drug|Prednisolone|Oral
1510037|NCT02894645|Drug|Dexamethasone|Oral
1510038|NCT02894645|Drug|L-Asparaginase|Intramuscular injection
1510039|NCT02894645|Drug|Vincristine|Intravenous
1510040|NCT02894645|Drug|Methotrexate|Intrathecal/ Intravenous/ Oral
1510041|NCT02894645|Drug|Daunorubicin|Intravenous
1510042|NCT02894645|Drug|Doxorubicin|Intravenous
1510043|NCT02894645|Drug|Cyclophosphamide|Intravenous
1510044|NCT02894645|Drug|Cytarabine|Intravenous/ Subcutaneous injection
1510045|NCT02894645|Drug|6-Mercaptopurine|Oral
1510046|NCT02894645|Drug|Thioguanine|Oral
1510047|NCT02894645|Drug|Fludarabine|Intravenous
1510048|NCT02894645|Drug|Imatinib|Oral (For BCR-ABL ALL only)
1510049|NCT02894632|Device|MRI compatible motion sensor (MARMOT)|MRI with motion control (several motion sensors placed on the volunteer's body)
1510050|NCT02894528|Drug|BioMend and ReproBone|Post-extraction sockets was filled by synthetic bone substitute ReproBone, and after the sockets were covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
1510051|NCT02894528|Drug|BioMend without ReproBone|Post-extraction the socket was filled only by clot and covered by a resorbable collagen membrane BioMend, which in turn was covered by a flap.
1510052|NCT02894515|Drug|Idalopirdine commercial tablet (test)|single dose, 10 mg, oral
1510053|NCT02894515|Drug|Idalopirdine clinical tablet (reference)|single dose, 10 mg, oral
1510054|NCT02894502|Behavioral|Motivational interviewing|The intervention will consist of a brief session of motivational interviewing (MI) performed by a trained nurse. During MI, the interventionist will address one or two aspects of self-care that the participants want to address. After this first intervention, the same interventionist will contact the participant by telephone to improve the first intervention and provide further support as needed. These telephone contact will be done three times at two week intervals following the first intervention (for a total of two months). Patients and caregivers that receive the intervention also will be given informational material on HF management that is consistent with international guidelines.
1510055|NCT02894489|Device|corneal lenses|wear corneal lenses on daily basis
1510056|NCT02894489|Device|large diameter lenses|
1510057|NCT02894463|Other|questionnaire|
1510058|NCT02894450|Other|blood test|bioassay xaban
1510059|NCT02894437|Other|qualitative interviews|semi-structured interviews as a conceptual frame work
2003040|NCT01116440|Drug|BGS649|0.1 mg capsules for oral administration. A total dose of 3 capsules of BGS649 0.1mg will be administered at randomization, week 4, and week 8 at the study site.
2003041|NCT01116440|Drug|Placebo|Placebo matching BGS649 will be provided by Novartis as capsules for oral administration. Three capsules of placebo will be administered at randomization, week 4, and week 8 at the study site.
2003042|NCT01116648|Drug|Cediranib Maleate|Given PO
2003043|NCT01116648|Other|Laboratory Biomarker Analysis|Correlative studies
2003044|NCT01116648|Drug|Olaparib|Given PO
1511385|NCT02883296|Other|Pelvis Magnetic resonance imaging|
2003045|NCT01116648|Other|Pharmacological Study|Correlative studies
2003046|NCT01111305|Drug|Reslizumab|
2003047|NCT01111305|Drug|Diethylcarbamazine|
2003048|NCT01111305|Other|Placebo|
2003049|NCT01073358|Procedure|Routine hilar lymphadenectomy|Hilar lymphadenectomy is performed before actual resection of the colorectal liver metastases
1510066|NCT02894372|Device|Oral spray 1|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
1510067|NCT02894372|Device|Oral spray 2|Research participants got topical oral spray immediately after surgery (hospital patients) and from the first doctor visit with pharyngeal disease (clinic outpatients).
1510068|NCT02894359|Device|cone beam imagery of cervical spine|
1510069|NCT02894346|Other|Teachers|Teachers are exposed to the WTMST survey that based on the theory of Self-Determination (SDT) will categorize them according to the elements of the SDT: Intrinsic, identified, introjected, external and a motivation.
1510070|NCT02894333|Behavioral|behavioral observation|
1510071|NCT02894320|Behavioral|Behavioral observation|
1510072|NCT02894307|Drug|Rivaroxaban|In patients with mechanical valves and unstable INR
1510073|NCT02894307|Drug|Apixaban 5 MG [Eliquis]|In patients with mechanical valves and unstable INR
1510074|NCT02894294|Other|implementation of seasonal malaria chemoprevention|administration of therapeutic doses of antimalarials (Sulfadoxine-pyrimethamine [SP] + Amodiaquine [AQ]) at monthly intervals during the high malaria transmission season in children 3-59 months of age.
1510075|NCT02894281|Device|pupillary light reflex|measure with infra-red cameras
1510076|NCT02894268|Drug|Doxycycline|Doxycycline 100g po bid
1510077|NCT02894268|Drug|Furazolidone|Furazolidone 100mg po bid
1510078|NCT02894268|Drug|Esomeprazole|Esomeprazole 20mg po bid
1510079|NCT02894268|Drug|Colloidal Bismuth Subcitrate|Bismuth 20mg po bid
1510080|NCT02894268|Drug|Sensitivity antibiotics|Two antibiotics based on antibiotic sensitivity of H.pylori culture, including amoxicillin, clarithromycin, metronidazole, levofloxacin, tetracycline and furazolidone.
1510081|NCT02894255|Device|Coronary artery bypass grafting|
1510082|NCT02894255|Procedure|Percutaneous coronary intervention|
1510083|NCT02894242|Device|F&P Deimos Nasal Pillows Mask|Investigative Nasal Pillows Mask to be used for OSA therapy
1510084|NCT02894229|Behavioral|Mindfulness Based Stress Reduction|A modified version of traditional MBSR. The current study's version of MBSR is shortened to 6-weeks.
1510085|NCT02894229|Behavioral|Cognitive-Behavioral Therapy (CBT) Group|A 6-week, 2-hour per group, skills group that focuses on various cognitive-behavioral skills for stress reduction (e.g., progressive muscle relaxation; cognitive restructuring).
1510086|NCT02894216|Procedure|radionuclide shuntography|the investigators retrospectively enrolled patient who received radionuclide shuntography
1510087|NCT02894203|Behavioral|Mindfulness|
1510088|NCT02894203|Behavioral|Yoga|
1510089|NCT02894177|Procedure|tcPCO2 measurement|tcPCO2 continuous monitoring during spontaneous breathing trials
1510090|NCT02894164|Other|No intervention|
1510091|NCT02894151|Drug|Depot medroxyprogesterone acetate|
1510092|NCT02894151|Device|LNG-IUS|
1510093|NCT02894138|Drug|alteplase|
1510094|NCT02894138|Drug|Placebo|
1510095|NCT02894125|Other|SPA Therapy|
1510096|NCT02894112|Dietary Supplement|non-fat milk|1 serving of non-fat fluid milk
1510097|NCT02894112|Dietary Supplement|carbohydrate control beverage|1 serving of carbohydrate control beverage (Carbohydrate powder + water)
1510098|NCT02894112|Dietary Supplement|caloric control beverage|1 serving of caloric control beverage (carbohydrate powder + protein powder + water)
1510099|NCT02894099|Other|Prolonged sitting time|Volunteers will be continuously sitting on a chair for 5 hours and should move the least possible. If the participant needs to stand from the chair, the stage will be invalidated.
1510100|NCT02894099|Other|PST+Light intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of low intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 50-60% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes) of light intensity physical activity.
1510101|NCT02894099|Other|PST+Moderate intensity Short bouts PA|Volunteers will have their time sitting interrupted every 20 minutes for 2 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (15 bouts of 2 minutes)of moderate intensity physical activity.
1510102|NCT02894099|Other|PST+Moderate intensity Long bouts PA|Volunteers will have their time sitting interrupted every 75 minutes for 10 minutes of physical activity of moderate intensity. In the active period, participants will be encouraged to walk in the hallway and reach a training heart rate between 65 a 75% HR max predicted for the age and measured by heart rate monitor. The Borg scale will be used at the beginning and the end of each active period in order to measure the subjective effort of the participants. In the end the volunteers will be sitting 5 hours and have 30 minutes (3 bouts of 10 minutes) of moderate intensity physical activity.
1510103|NCT02894086|Other|database.|
1510104|NCT02894073|Device|skin transilluminator|VeinViewer
1510105|NCT02894060|Other|blood tests|"Blood tests done by the nurse in the CRC (clinical research center). The quantity of blood taken wil be (3 5-mL tubes):
2 plain tubes and 1EDTA tube Arterial blood pressure will be measured at the CRC. Then, an X-ray of the profile of the abdomen will be taken without preparation to evaluate aortic calcification (in the radiology department of the Amiens hospital)"
1510106|NCT02894047|Biological|blood|measurement of CaSR expression levels on synovial fluid monocytes
1510107|NCT02894021|Procedure|classic closure|mastectomy with classic closure in 2 steps, drainage by negative pressure aspiration
1510108|NCT02894021|Procedure|padding|areas of padding and running sutures between subcutaneous tissue and pectoral muscle followed by closure in 2 steps, drainage by negative pressure aspiration for 48 h
1510109|NCT02894008|Drug|ChAd63-KH|ChAd63-KH in adults and adolescents with persistent PKDL.
1510110|NCT02893995|Drug|Slow Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
1510111|NCT02893995|Drug|Rapid Dose Titration Group of Subcutaneous Treprostinil|subcutaneous treprostinil
1510112|NCT02893982|Radiation|brachytherapy|image-guided navigation of catheter placement for high dose rate (HDR) brachytherapy treatment of patients with primary liver lesions
1510113|NCT02893969|Behavioral|Physical Activity|After 72 hours of full physical rest patients will gradually reintroduce physical activity into their daily routine.
1510114|NCT02893969|Behavioral|Rest|Complete physical rest until asymptomatic.
1510115|NCT02893956|Procedure|echocardiography with postural support|
1510116|NCT02893956|Procedure|echocardiography with standard condition (usual)|
1510117|NCT02893943|Dietary Supplement|Probiotics|
1510118|NCT02893943|Dietary Supplement|Placebo|
1510123|NCT02893904|Device|EEG monitoring under propofol|Steady state concentrations periods of Propofol for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
1510124|NCT02893904|Device|EEG monitoring under sevoflurane|Steady state concentrations periods of Sevoflurane for EEG data analyzes. Remifentanil was administrated at constant rate in all patients.
1510125|NCT02893891|Procedure|Laparoscopic sleeve gastrectomy|Sleeve gastrectomy involves removing most of the stomach, limiting the amount of food the patient can eat.
1510126|NCT02893891|Procedure|Laparoscopic gastric plication|Laparoscopic gastric plication involves sewing one or more large folds in the stomach. During the laparoscopic gastric plication, the stomach volume is reduced about 70%, which makes the stomach able to hold less and helps the patient eat less.
1510127|NCT02893891|Procedure|Intragastric balloon|The introduction of the balloon is non-invasive as it is inserted endoscopically (down the oesophagus). The balloon is then filled inside the stomach with a dyed physiological solution, which reduces the volume of the stomach.
1510128|NCT02893891|Device|Intragastric balloon implantation|Intragastric balloons (End-Ball, Medsil) will be implanted in the patients with morbid obesity.
1510129|NCT02893878|Other|Vaccine safety surveillance|Extraction of routinely collected primary care data from approximately 10 volunteer English general practices by using an improved card-based ADR reporting system to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
1510130|NCT02893865|Device|Continuous positive airway pressure|Continuous positive airway pressure treatment during three months with adherence recording
1510131|NCT02893865|Device|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
1510132|NCT02893852|Behavioral|Cognitive Orientation to daily Occupational Performance|The CO-OP protocol originally developed by Mandich and Polatajko (2004) comprises 12 sessions. It includes parental involvement acting as active participants at sessions of 60 minutes each, once or twice a week. The therapist teaches the participants a global cognitive strategy: GOAL - PLAN - DO - CHECK. The participants use the global strategy and cooperate to learn specific strategies to solve each task performance breakdown identified through Dynamic Performance Analyses (DPA). The therapist uses DPA at pre-intervention and throughout the sessions and mediational techniques to guide participants to use GOAL-PLAN-DO-CHECK to discover specific strategies to solve performance problems. Informative materials on DCD and CO-OP Approach for participants are available; home activities will be planned with participants to stimulate the use of cognitive strategies and to give support to generalization and transfer of skills.
1510133|NCT02893852|Behavioral|Cognitive Orientation to daily Occupational Performance with parents coaching groups|CO-OP Approach with parents coaching groups will include an addition of four extra coaching groups sessions for parents to provide additional information to supplement their knowledge on CO-OP (how to use GOAL-PLAN-DO-CHECK at home; how to use dynamic performance analysis to support their children's' performance solutions; to talk about their experiences with their children at home).
1510134|NCT02893839|Other|Prick to prick test|
1510135|NCT02893826|Drug|EG-1962 (nimodipine microparticles)|
1510136|NCT02893826|Drug|Enteral Nimodipine|
1510137|NCT02893800|Device|Locating system watch with GPS-technology|Patients using locating system watches with embedded global positioning system (GPS) technology and telephone function; Caregivers using a Smartphone with an installed application to see the current location of the patient and with the possibility to call the patient
1510138|NCT02893787|Other|Speckle Tracking Echocardiography|Echocardiography analyses
1510139|NCT02893774|Other|quality of life assessment|"All patients with breath cancer or melanoma will have quality of life assessment 1, 6, 12, 24, 48 and 60 months after the initial cancer diagnosis.
Those assessment will use standardized quality of life questionnaire :
QLQ-C30
SWLS (Satisfaction with Life Scale)
PTGI (Post-Traumatic Growth Inventory)
HADS (Hospital Anxiety and Depression Scale)
Brief COPE
MHLCS (Multidimensional Health Locus of Control Scale)"
1510140|NCT02893748|Device|HyGIeaCare Prep|Patients will receive the HyGIeaCare Prep, which is an open colon lavage system using warm water by gravity drip to evacuate the colon by stimulating peristalsis to cleanse the colon prior to colonoscopy.
1510141|NCT02893748|Procedure|Colonoscopy|Screening colonoscopy as per standard of care.
1510142|NCT02893748|Drug|polyethylene glycol (PEG)|PEG preparation to be delivered in two doses - 1/2 the night before and 1/2 the morning of the colonoscopy
1510143|NCT02893735|Other|Charisma-Diamond|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Charisma-Diamond in combination Gluma2 Bond etch&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
2003052|NCT01046929|Dietary Supplement|limonene|oral dosing at 2 gram QD
1510144|NCT02893735|Other|Filtek-Z550|The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Nano-hybrid resin composite system was used Filtek-Z550 in combination with Adper™ Single Bond 2 etch&rinse adhesive. The composite increments were carefully placed between the matrix strip and tooth by using a hand instrument. The composite resin restorations were light-cured (600 mW/cm²). Occlusion was checked with thin articulating papers. Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups whereas; proximal and labial surfaces were contoured and polished with finishing strips. The treatments were completed by instructing the patients about the oral hygiene measures for cleaning their restorations with toothbrush and dental floss.
1510145|NCT02893722|Drug|atosiban|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion in total dose of 37.5 mg is set in certain infusion rate, and complete the infusion in 3 hours.
1510146|NCT02893722|Drug|0.9% saline|give drugs 30 minutes before the start of the embryo transfer,and intravenous infusion is set in the same rate with experimental group, complete the infusion in 3 hours.
1510147|NCT02893709|Drug|Omeprazole|Oral administration of omeprazole at therapeutic dose (20 mg daily) for a duration of 7 days
1510149|NCT02893683|Other|Paris Visual Learning Test|
1510150|NCT02893670|Procedure|Radiologic (MRE) or endoscopic (sigmoidoscopy) evaluation|"All patients will be assessed for drug levels and metabolites. Patients diagnosed with ileal or ileo-colonic crohn's will undergo an MR Enterography (MRE). In crohn's patients, MRE was shown to have a higher impact on patient management than colonoscopy. Patients diagnosed with either UC, IBD-U or Crohn's colitis will undergo a flexible sigmoidoscopy.
Following re-evaluation each patient will undergo 2 transition meetings with pediatric and adult gastroenterologist as well as a meeting with IBD nurses and social worker."
1510151|NCT02893618|Drug|Diazoxide choline controlled-release tablet|QD tablet formulation of choline salt of diazoxide
1510152|NCT02893579|Behavioral|Early SR intervention|Self-directed stress reduction program delivered through a smart-phone application
1510153|NCT02893579|Behavioral|Delayed SR intervention|Activity tracking only for the first month
1510154|NCT02893566|Behavioral|Mi Band Step Challenge|
1510155|NCT02893553|Drug|Midodrine Hydrochloride|study 1 will be single blind. study 2 will be blinded randomized-control trial.
1510156|NCT02893553|Drug|Pyridostigmine Bromide|study 1 will be single blind. study 2 will be blinded randomized-control trial.
1510157|NCT02893553|Drug|Mirabegron|study 1 will be single blind. study 2 will be blinded randomized-control trial.
1510158|NCT02893553|Other|Placebo|placebo will only be used for study arm 2, the randomized blinded phase.
1510159|NCT02893540|Drug|Capecitabine|we are going to compare two maintenance treatment models with capecitabine in this study
1510160|NCT02893527|Behavioral|personalized coaching|personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
2003053|NCT01042535|Biological|adenovirus-p53 transduced dendritic cell (DC) vaccine|Given intradermally (ID)
2003054|NCT01042535|Drug|1-methyl-d-tryptophan|Given orally (PO)
1510163|NCT02893488|Drug|DTG/ABC/3TC FDC DISPERSIBLE TABLET|DTG/ABC/3TC FDC dispersible tablet
1510164|NCT02893488|Drug|EPZICOM (ABC/3TC)|"EPZICOM will be available as orange, film coated, modified capsule shaped tablets, debossed with GS FC2 on one side."
1510165|NCT02893488|Drug|TIVICAY (DTG)|TIVICAY will be available as white, round, biconvex tablets
1510166|NCT02893449|Behavioral|Social adaptation|"Questionnaire to fill-in.
The structured program of preoperative cognitive remediation is divided in 3 parts: one interview with the patient to do a building of the subjective theories (difficulties due to the disease, hope relative to the intervention), a study meeting of the cognitive remediation possibilities and a cognitive remediation meeting with the patient. The spouse will be included in the program."
1510167|NCT02893449|Behavioral|Intensive care management|In this group, the structured program of the SICRPPD group will be replaced by 3 unstructured psychiatric interviews during which patients will be assessed for their perception of the disease and the upcoming surgery. This group will allow to control for the intrinsic effect of the preoperative management independently of the remediation itself.
1510168|NCT02893449|Procedure|Deep brain stimulation|
1510169|NCT02893436|Procedure|Surgery with tracheal intubation curarisation|
1510170|NCT02893423|Drug|Ropivacaine|Using 2 Different Concentrations of Ropivacaine in Tap Block for Postoperative Analgesia for C-Section Patients
1510171|NCT02893397|Behavioral|Supervised Exercise Program|Assigned exercises with a physical therapist 3 - 5 times a week throughout chemotherapy (10-12 weeks), each exercise session lasting for 40 minutes
1510172|NCT02893384|Drug|Local Anesthetic Injection above the serratus anterior|This is a quantitative pilot study assessing whether a new technique of local anesthesia injection during mastectomy surgery gives better pain outcomes than the standard methods. Patients who meet inclusion criteria will be invited to partake and all patients will have the injection technique. These patients will then be monitored for pain outcomes up to 7 days following the surgery and the results compared with historical results from patients who have already had the surgery.
2003055|NCT01042535|Other|Laboratory biomarker analysis|Correlative studies
2003056|NCT01034787|Drug|CP-675,206|Patients will receive CP-675,206 at 15 mg/kg administered intravenously on day 1 of ever 90 cycle for up to 4 cycles or until progression or intolerance of toxicity. Tumor assessments will be done ever 3 months. Additional scans will be done if clinically indicated.
2003066|NCT01007526|Other|concomitant chemo-radiotherapy followed by VIDL chemotherapy with risk-based application of autologous stem cell transplantation|concomitant chemo-radiotherapy followed by VIDL (VP-16, Ifosfamide, Dexamethasone, L-asparaginase) chemotherapy with risk-based application of autologous stem cell transplantation
1510184|NCT02893358|Drug|Allisartan Isoproxil|Allisartan Isoproxil 80mg once daily taken in the morning during 8:00-9:00. To achieve the target blood pressure allisartan isoproxil may be doubled to 160mg once a day. If necessary, amlodipine 2.5mg may be combined with allisartan isoproxil. Duration: 12 months.
1510185|NCT02893358|Drug|Placebo|Corresponding placebo once daily taken in the morning during 8:00-9:00. Duration: 12 months.
1510186|NCT02893345|Behavioral|Safe@Home Intervention Group|For the 8 training visits, participants may select to work on skills in 2 of 5 activity modules: Improving mobility, balance and strength; Managing health and wellness; Staying On Your Own at Home; Maintaining the home; Getting out in the community. Participants may seek single service rehabilitation, medical, and psychological care as usual.
1510187|NCT02893345|Other|Usual Care Group|Persons can set goals and work on activities with or without a family member as they so choose. Participants may seek single service rehabilitation, medical, and psychological care as usual.
1510188|NCT02893332|Radiation|Radiation: SBRT|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL during a 1-week run-in period after which SBRT will be delivered to the all oligometastatic lesions concurrently with the TKI. The SBRT dose will be , ranging from at 25Gy (5 Gy per fraction) to 40 Gy (8 Gy per fraction).
1510189|NCT02893332|Drug|TKI (Gefitinib or Tarceva )|A first line TKI (Gefitinib 250mg po qd or Tarceva 150mg po qd ) will be administered according to the standard dosing of the drug for metastatic NSCL, no local therapy apply to oligo-metastatic sites.
1510190|NCT02893319|Behavioral|Feeding and growth differences, 5oz vs 8oz bottle|Group A: 5oz bottle Group B: 8oz bottle
1510191|NCT02893306|Biological|MSCs|origin: bone marrow of healthy donor; manipulation: ex vivo expanded; via: intravenous; vehicle: 5% human recombinant albumin in physiological serum; dose: 2-3 millions/Kg; dosage: single
1510194|NCT02893280|Drug|aspirin, clopidogrel, statin, enoxaparin, streptokinase|Acute coronary syndrome treatment
1510195|NCT02893267|Device|Peripheral Nerve Stimulation|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source but also serves as the anode. The 1-channel stimulator outputs a biphasic current waveform with current pulse parameter ranges suitable for PNS. The percutaneous lead is inserted using an introducer (like a hypodermic needle) which is withdrawn and the lead is retained in the muscle by a barb at its tip. After a 1-week stabilization period, stimulation is initiated (6 hrs/day). The duty cycle and daily dose remain constant, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period is 3 weeks after which the lead will be removed. Total time of electrode implantation is no more than 29 days.
1510196|NCT02893267|Other|Physical Therapy|Participants will receive 8 60-minute sessions of outpatient therapy over a 4 week period concurrent with PNS or sham-PNS treatment. Therapy may include: Proper Positioning and Handling, Therapeutic positioning and Strengthening Exercises, Mirror Therapy, Task-specific Therapy, Home Exercise Program, and a Mental Practice program.
1510197|NCT02893267|Other|Sham-PT|Participants randomized to sham-PT will receive 8 60-minute sessions with therapists with the goal of controlling for the effect of regular contact with a therapist and study staff in a therapeutic environment. Participants will undergo a hands-on evaluation and re-evaluation before and after treatment. Therapists will provide sham ultrasound therapy and light application of inert gel to the shoulder for 10 minutes, Pre-Gait Training or Gait training, Exercise therapy, and relaxation therapy.
1510198|NCT02893267|Device|Sham-PNS|The stimulation system includes an external stimulator, percutaneous lead and pad. The stimulator snaps onto the pad. The pad has an embedded power source.The stimulator will appear to function as normal though will not deliver electrical current to the electrode. The subjects will be prescribed 6 hours of sham-stimulation per day for 3 weeks.
1510199|NCT02893254|Drug|IBI303|12 cycles. IBI303: 40 mg, iH
1510200|NCT02893254|Drug|Adalimumab|12 cycles. Adalimumab: 40mg, iH
1510203|NCT02893228|Procedure|Saline|At the location chosen for interscalene block the needle tip will be positioned anterior to the anterior scalene muscle. At this point 10ml of 0.9% saline will be injected.
1510204|NCT02893228|Drug|Levobupivacaine|the needle tip will then be positioned between C5 and C6 nerve roots. At this location, 20 ml of 0.25% levobupivacaine will be injected in 5 ml increments with intermittent aspiration. The needle tip will not be repositioned unless the patient complaints of paraesthesia
1510205|NCT02893215|Other|Screening for silent AF with Zenicor thumb-ECG|Each patient has a device for 14 days, which monitorizes their heart rhythm. They send the ecg four times daily.
1510206|NCT02893202|Other|Therapeutic Horseback riding|An 8-week equine-assisted program designed to especially for veterans. The curriculum consists of eight 90-minute sessions designed to teach basic horse care and riding skills along with communication skills.
1510207|NCT02893189|Genetic|Infusion of modified CAR19 T-cells (4G7-CARD T-cells)|The original stem cells donor (or if not available the patient) will undergo unstimulated leucapheresis for generation of the Advanced Therapy Interventional Medicinal Product (ATIMP) 4G7-CARD T-cells. Escalating doses of the ATIMP will then be infused to the patient depending on outcome and any experienced side effects.
1510208|NCT02893176|Drug|macitentan|
1510209|NCT02893176|Drug|placebo (for macitentan)|
1510210|NCT02893163|Behavioral|CHANGE Intervention|Canadian Health Advanced by Nutrition and Graded Exercise Protocol
1510211|NCT02893163|Other|Usual Care|Usual Care by Family Doctor
1510242|NCT02892864|Other|Neuromuscular Retraining and Virtual therapy|Neuromuscular retraining is a problem solving approach to treatment using selective motor training to facilitate symmetrical movement and control undesired gross motor activity (synkinesis). Treatment consists to accomplish daily massages and facial exercises. Motivation on the part of the patient is a crucial element in the success of treatment
1510212|NCT02893150|Behavioral|TAU|"TAU (Treatment as Usual), individuals presenting with overweight (BMI of 25 kg/m ² to 29.9 kg/m ²), but without comorbidities, teams of primary care (PC) organized care plans to return to the track of normal BMI (BMI of 18.5 kg/m ² to 24.9 kg/m ²).
For those who have comorbidities such as hypertension and diabetes, in addition to including individuals in group activities, evaluates the need for individual dietary prescription by the nutritionist. This decision is discussed among the team of PC and Matrix support team"
1510213|NCT02893150|Behavioral|TAU+MBHP|"TAU (Treatment as Usual) + MBHP. We used a general (general vulnerability, not specific) mindfulness-based intervention (MBI) developed by our research group, an 8-week-group-based MBI called Mindfulness-Based Health Promotion (MBHP) program . It is based on the original model developed by Jon Kabat-Zinn and colleagues (MBSR), and subsequently adapted by our research group in order to fit it better into the context and needs of Primary Care (PC) and national and local Health Systems, which has been applied by the Center Mente Aberta in Brazil (www.mindfulnessbrasil.com), and by the University of Zaragoza, in Spain (www.webmindfulness.com). One of the sessions (the sixth one) is developed in silence, with the goal of deepening the mindfulness practice; more feasible to be implement in health services and facilities"
1510214|NCT02893150|Behavioral|TAU+MB-EAT|TAU (Treatment as Usual) + MB-EAT (mindfulness-based eating awareness training). Adapted from the MBSR, Mindfulness-based Eating Awareness Training (MB-EAT) or awareness training. This program was specially developed for the compulsive eating disorders and related problems[47]. In addition the four main techniques of meditation mentioned in the MBHP program includes modifications to these basic techniques, and include experimentation with different flavors, sweet and savory foods, etc. Has 10 weekly sessions of 2,5h
1510215|NCT02893137|Device|Optune|For further information see www.optune.com
1510216|NCT02893137|Procedure|Craniectomy|A small hole is placed in the skull between the tumor and the closest Optune electrode. The position and geometry of the craniotomy is determined by computersimulation of the electric field induced by Optune therapy. Craniotomy is a surgical procedure, which is carried out under general anaesthesia.
1510217|NCT02893124|Drug|peginterferon alfa|peginterferon alfa-2a 180 micrograms/week or peginterferon alfa-2b 80 micrograms/week, for at most 96 weeks.
1510218|NCT02893111|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 4 treatment cycles with 4 injections of 1 mg Bortezomib /m2 body surface per cycle
1510219|NCT02893098|Drug|Humia inj.|"Single injection of 3mL Humia inj.
Dummy: Single injection 2ml Normal Saline inj. given weekly for 2 weeks"
1510220|NCT02893098|Drug|High hyal Plus inj.|Single Injection of 2mL High hyal Plus inj. given weekly for 3 weeks
1510221|NCT02893085|Biological|bile sample analysis|tumor mutation profile tumor genotype
1510222|NCT02893085|Biological|biochemical markers, VEGF and MMPs, in bile samples|
1510224|NCT02893046|Other|No intervention|
1510225|NCT02893033|Device|repetitive transcranial magnetic stimulation|rTMS
1510226|NCT02893007|Other|Brief family-centered care (BFCC) program|The therapist provided the 4-session BFCC program twice a week for each dyad. The core principles treated family as a single unit and provided individually tailored interventions to improve family function through psychoeducation, social and emotional support, and actively raising questions to facilitate constructive awareness and changes. It was initially held to assess family function, then to provide information about BPD, to support and empower the dyads to change communication styles and resolve conflicts, and to sustain or improve family function in the cognitive, affective, and behavioral domains.
1510227|NCT02892994|Other|ultrasound|
1510228|NCT02892981|Other|cardiopulmonary exercise test,hypoxia and hypercapnia test|class I and IV Pulmonary hypertension patients in stable haemodynamic status and optimized medical therapy underwent cardiopulmonary test and hypoxia and hypercapnia tests to evaluate the chemoreceptor sensitivity
1510229|NCT02892968|Procedure|Fascia-Iliaca Block(FIB)|The target of the FIB is the potential space between the fascia iliaca and the iliacus muscle, at least 4 cm lateral to the Femoral artery. This is neither a drug nor a device.
1510230|NCT02892968|Procedure|Femoral Nerve Block(FNB)|The target of the FNB technique is the intersection of the fascia iliaca and the femoral nerve. This is neither a drug nor a device.
1510231|NCT02892955|Device|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate safety and clinical performance of the HM3 LVAS for the treatment of advanced, refractory, left ventricular heart failure following completion of enrollment in the the MOMENTUM 3 IDE Study.
1510232|NCT02892942|Drug|Gonal-F®|225 to 450 IU/d; from day 2 of menstrual cycle onward
1510233|NCT02892942|Drug|Cetrotide®|0.25 mg/day, starting on day 6 of Gonal-F®.
1510234|NCT02892942|Drug|Cetrotide®|1.5 mg/day (6 ampoules of 0.25 mg), starting on day 1 (S1) of Gonal-F® treatment until dhCG
1510235|NCT02892929|Behavioral|Motivational interviewing|"The approach combines the principles of patient-centered care with strategies to motivate the change.
Since the first appointment, Motivational Interviewing techniques will be used aiming to work the ambivalence that is to seek treatment and modify the unhealthy behavior. From the second encounter until the appointment of 120 days, the participants will be subjected to individual encounters in which the MI approach will be applied focusing on behavior change."
1510236|NCT02892929|Behavioral|Prescriptive Consultation|Prescriptive consultation is the Methodology usual consultation, in which the patient has little room to express themselves and the health professional who determines what and how the patient will hold the care of your health.
1510237|NCT02892916|Drug|Ketamine|A bolus of low intravenous dose (sub-anaesthetic) 0.5 mg/kg ketamine following induction of anaesthesia.
1510238|NCT02892916|Drug|Placebo|A bolus of an intravenous normal saline solution following induction of anaesthesia.
1510240|NCT02892890|Procedure|Muscle Magnetic Resonance Imaging (RMI) evaluation|
1510241|NCT02892890|Device|MRI|
1510286|NCT02892500|Drug|bupivacaine hydrochloride|5ml of bupivacaine hydrochloride into the tibiofibular ligament
1510380|NCT02891655|Other|immuno-histo-chemical analysis|in vitro immuno-histo-chemical analysis of corneal epithelium
1510669|NCT02889471|Procedure|ERCP alone|ERCP alone followed with standard laparoscopic cholecystectomy
1510243|NCT02892864|Other|Oro-myo-functional classical rehabilitation|"Patients taken care in external consultation who receive oro-myo-functional rehabilitation through a virtual rehabilitation program targeted at the smile, in their place of living in virtual conditions.
Patients taken care in consultation within the ENT service which provides oro-myo-functional classical rehabilitation."
1510244|NCT02892851|Device|Deep brain stimulation of the subthalamic nuclei (STN-DBS)|"3 phases :
Parameter setting
Cross-over double-bind (ON/OFF)
Open Phase (ON)"
1510245|NCT02892838|Device|mobile bearing knee system for total knee arthroplasty|
1510246|NCT02892838|Device|fixed bearing total knee prosthesis|
1510247|NCT02892825|Other|Music|headphones with music
1510248|NCT02892825|Other|No Music|headphones without music
1510249|NCT02892812|Biological|Pneumococcal conjugate vaccine|
1510250|NCT02892799|Other|CVP Diuresis protocol|Customized diuresis protocol based on central venous pressure
1510251|NCT02892799|Other|Echo diuresis protocol|Customized diuresis protocol based on echo-derived parameters
1510252|NCT02892799|Other|FACTT-LITE diuresis protocol|Diuresis protocol based on the FACTT-LITE trial
2003075|NCT01002742|Drug|Mycophenolate Mofetil|"Oral dosing should be delivered in 250 mg units. For those < 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.
Patients who weight > 60 kg should receive MMF 1 gm PO/IV every 8 hours.
Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.
Patients who weight <40 kg should receive 20 mg/kg IV or PO every 8 hours."
1510254|NCT02892773|Device|Incentive Spirometry|"A respiratory therapist will provide instruction on Incentive Spirometry (I.S.) procedure performance before supervised therapy and monitoring begins.
Study participants will be asked to take 10 deep breaths through the I.S.'s mouthpiece, followed by a 60 second pause.
The 10-breath cycle will be repeated 3 times per therapy session.
Each I.S. therapy session will last about 15 minutes, 3 times per day.
Lung monitoring and deep breathing measurements will occur during a scheduled I.S. sessions on day 1, 3, and 5 after surgery."
1510255|NCT02892773|Device|EzPAP® Positive Airway Pressure|"A respiratory therapist will provide instruction on EzPAP® procedure performance before supervised therapy and monitoring begins.
Study participants will be asked to breathe normally through the EzPAP® device's mouthpiece for 10 breaths, followed by a 60 second pause.
The 10-breath cycle will be repeated 3 times.
Each EzPAP® therapy sessions will last about 15 minutes, 3 times per day.
Lung monitoring will occur during a scheduled EzPAP® sessions on day 1, 3, and 5 after surgery."
1510256|NCT02892760|Device|C-Brace|C-Brace is a micro-computer controlled brace that is worn on the leg to assist with walking.
1510257|NCT02892747|Behavioral|Educational Program|
1510258|NCT02892734|Biological|Ipilimumab|Given IV
1510259|NCT02892734|Other|Laboratory Biomarker Analysis|Correlative studies
1510260|NCT02892734|Biological|Nivolumab|Given IV
1510261|NCT02892721|Other|Training with feedback|"One-day workshop of face to face training, comprising a mixture of theory and real-world CTC cases. Radiologists will complete four interpretation assessments lasting 2 to 3 hours: one set of 10 CTC cases immediately prior to training and a further test set of 10 immediately after, with tests repeated at 6 and 12 months (using different CTC cases for each set). Radiologists will be asked to identify colorectal cancer and polyps on the scans and complete an online answer form, including questions regarding diagnostic confidence, site of abnormality and management.
The intervention group will receive online, confidential, individualised feedback after each test, which will include a case by case breakdown of their performance with explanatory answers and learning points."
1510262|NCT02892708|Procedure|Surgery|partial or complete resection followed by radiotherapy
1510263|NCT02892708|Radiation|radiotherapy|radiotherapy after a brain biopsy
1510264|NCT02892695|Biological|anti-CD19 CAR-NK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD19 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD19.
1510265|NCT02892682|Other|BLOOD TEST|
1510266|NCT02892669|Other|non interventional study|non interventional study
1510267|NCT02892643|Procedure|Laparoscopic proximal gastrectomy|Laparoscopy proximal gastrectomy with esophago-jejunostomy, gastro-jejunostomy and jejuno-jejunostomy (double tract reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
1510268|NCT02892643|Procedure|Laparoscopic total gastrectomy|Laparoscopic total gastrectomy with esophago-jejunostomy and jejuno-jejunostomy (Roux-en-Y reconstruction). Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
1510270|NCT02892617|Other|Bacteriological analysis of disc|
1510271|NCT02892604|Device|insulin pump to inControl AP platform|Insulin from the pump is delivered according to the closed-loop algorithm fed by CGM data.
1510272|NCT02892591|Drug|Cannabis|vaporized plant material
1510273|NCT02892591|Drug|Oxycodone|oral capsule
1510274|NCT02892591|Drug|Placebo for Cannabis|vaporized placebo plant material
1510275|NCT02892591|Drug|Placebo for Oxycodone|oral placebo capsule
1510276|NCT02892578|Other|electrocardiogram|
1510277|NCT02892565|Other|Blood sample|
1510278|NCT02892552|Radiation|Cone Beam Computed Tomography (CBCT)|Patients had an additional Cone Beam Computed Tomography, after the usual MDCT
1510279|NCT02892552|Radiation|Multiple Detector Computed Tomography (MDCT)|Patients had a usual MDCT, before having an additional Cone Beam Computed Tomography
1510280|NCT02892539|Radiation|Coronary Angiography|
1510281|NCT02892526|Other|Abdominoplasty with exeresis of cutaneous tissue|
1510282|NCT02892526|Other|Collection of cutaneous tissue|
1510283|NCT02892513|Device|Percutaneous auricular neurostimulation|The Bridge device (manufactured by Key Electronics [Jeffersonville, IN, USA] and distributed by Innovative Health Solutions [Versailles, IN, USA]) provides continual neurostimulation for five days with alternating current.
1510284|NCT02892513|Device|Sham percutaneous auricular neurostimulation|Identical in appearance to active, device, but no stimulation will be given.
1510285|NCT02892500|Drug|bupivacaine hydrochloride and betamethasone sodium phosphate|5ml of 0.25% bupivacaine hydrochloride and 2 ml of 3mg/ml betamethasone sodium phosphate one injection into the inferior tibiofibular ligament
1510287|NCT02892487|Other|Swallowing therapy|Patients will undergo active swallowing therapy with a speech and language therapist (twice a week) combined to a detailed program of swallowing auto-exercises (twice a day) from start of radiotherapy to one month after the end.
1510288|NCT02892474|Procedure|Hybrid Coronary Revascularization (HCR)|Hybrid coronary revascularization (HCR) is a combination of surgery and catheter procedures to open up clogged heart arteries. HCR is the intentional combination of coronary artery bypass grafting (CABG) and percutaneous coronary intervention (PCI). The HCR strategy combines grafting of the left anterior descending artery (LAD) coronary artery using the left internal mammary artery (LIMA) with PCI of non-LAD coronary stenoses. Drug-eluting stents are substituted for saphenous vein grafts (SVG) for non-LAD coronary targets, and the surgical LIMA to LAD bypass is performed, ideally through a minimally invasive, limited access, sternal-sparing approach.
1510289|NCT02892474|Procedure|Coronary Artery Bypass Grafting (CABG)|Coronary artery bypass grafting (CABG) is a surgery to create a new path for blood flow to the heart. A healthy section of vein or artery from elsewhere in the patient's body will be attached to the coronary artery just above and below the area of concern, to create a way for blood to bypass the blocked part of the coronary artery.
1510290|NCT02892461|Procedure|Umbilical cord milking|As same as that in arm descriptions.
1510291|NCT02892448|Other|Cardiac magnetic resonance imaging (CMR)|Cardiac MRI is used to assess cardiac function in patients at risk of cardiotoxicity. In addition, Cardiac MRI enables imaging of inflammation, and fibrosis in the heart which may provide more specific information about the mechanism of injury in patients with high ion blood levels.
1510292|NCT02892435|Device|incisional negative pressure wound therapy|positioning incisional negative pressure therapy over closed wound.
1510293|NCT02892435|Device|conventional dressing|positioning conventional dressing
1510294|NCT02892422|Drug|Lu AF35700|"Flexible-dose of Lu AF35700, 10 or 20 mg/day, tablets, orally.
From Day 8, the daily dose can be increased to 20mg. Thereafter, the daily dose can be adjusted (decreased to 10mg or following a decrease, increased to 20mg/day)
Patients who completed the 16159A study, only, can be switched to a weekly 70 mg Lu AF35700 dosing regimen (tablets, orally, once weekly) after 8 weeks in this study"
1510295|NCT02892409|Drug|Clarithromycin|Clarithromycin tablets
1510296|NCT02892409|Drug|Amoxicillin|Amoxicillin capsules
1510297|NCT02892409|Drug|Tripotassium bismuth dicitrate|Tripotassium bismuth dicitrate tablets
1510298|NCT02892409|Drug|Lansoprazole|Lansoprazole capsules
1510299|NCT02892409|Drug|TAK-438|TAK-438 tablets
1510300|NCT02892370|Drug|SHR0302|SHR0302 tablets (10 mg)
1510301|NCT02892357|Drug|Jianpi Qinghua Recipe|patients in this group were administered the Jianpi Qinghua Recipe, 150ml/bag, 2 times/day, 10mg omeprazole once a day for 4 weeks.
1510302|NCT02892357|Drug|omeprazole|patients in this group were administered the Jianpi Qinghua Placebo, 150ml/bag, 2 times/day, 20mg omeprazole once a day for 4 weeks.
1510303|NCT02892344|Drug|QMF149 150/80 μg|QMF149 150/80 μg o.d via Concept1
1510304|NCT02892344|Drug|MF 200 μg|MF 200 μg o.d. via Twisthaler®
1510305|NCT02892331|Behavioral|Moderate intensity exercise training (MOD-INT)|Participants in the MOD-INT group will exercise at the heart rate associated with 45-55% VO2 max. The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)
1510306|NCT02892331|Behavioral|High Intensity exercise training (HI-INT)|Participants in the HI-INT group will exercise at the heart rate associated with 70-80% VO2 max (heart rate ranges will be updated at mid-intervention CRF assessment). The exercise volume will be 600 MET-minutes per week, which is consistent with current public health guidelines (500-1,000 MET-minutes)3
1510309|NCT02892279|Other|Diesel exhaust exposure|Evaluation of sympathetic nervous system activity as assessed by microneurography recording during an acute exposure to dilute diesel exhaust via mask.
1510310|NCT02892266|Other|Assessment of adherence, mental health, behavioral, quality of life and biological constructs|
1510311|NCT02892253|Device|Near Infrared Camera (NIR)|Surgical field is examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then open thyroidectomy is resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, are checked visually. NIR consists of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international standard IEC 60601-2-41). It is provided by the Fluobeam® camera, which is inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 2A device).
1510312|NCT02892240|Other|No intervention. Observational study|
1510313|NCT02892227|Procedure|Transmitral flow estimation|Estimation of the transmitral flow of the inferior vena cava and its variations
1510314|NCT02892214|Procedure|Pelvic floor physical therapy|
1510315|NCT02892214|Drug|estriol cream (ovestin)|
1510316|NCT02892214|Procedure|Low-level-laser therapy|
1510317|NCT02892201|Drug|Pembrolizumab|a constant dose of 200 mg every three weeks, for four cycles.
1510318|NCT02892175|Procedure|Advance Directives on End of Life|after information transmitted orally by the doctor (Dr P.Priollet) and agreement of the patient to participate, patients will be interviewed (Questionary) and data collected during visits to consultations City office of Dr. Priollet by Dr. Priollet assisted by Mrs. Helena Sanson (internal medicine), anonymized and handled within the vascular medicine department of Dr. Priollet to GHPSJ.
1510319|NCT02892162|Procedure|Additional LAAW linear ablation|Additional linear ablation on LAAW using ThermoCool SmartTouch ablation catheter.
1510320|NCT02892149|Drug|vadadustat|Oral tablet
1510321|NCT02892149|Drug|darbepoetin alfa|subcutaneous/intravenous
1510322|NCT02892123|Drug|ZW25, HER2 inhibitor|ZW25 administered IV once weekly or once every two weeks. Part 1: in multiple escalating doses; Part 2: ZW25 administered at MTD/OBD or RD from Part 1
1510323|NCT02892110|Drug|Varenicline|2 mg daily
1510324|NCT02892110|Drug|Placebo|2 mg daily
1510569|NCT02890173|Drug|Eplerenone|
1510670|NCT02889458|Other|Not Provided|
1510325|NCT02892097|Device|tDCS|tDCS is a form of noninvasive brain stimulation. Electrodes are placed on the scalp (parietal or primary motor cortex) and deliver a low level of direct current (2mA). tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
1510326|NCT02892097|Device|sham tDCS|Sham tDCS will be delivered for 30 minutes in conjunction with repetitive task-specific practice for the arm/hand.
1510327|NCT02892097|Behavioral|Repetitive task-specific practice (RTP)|Participants will practice using their paretic arm/hand to complete functional movements during each (3) 30 minute training session.
1510328|NCT02892084|Device|tDCS|Constant non-invasive, low intensity, direct electrical current utilized to stimulate specific areas of the brain. Evaluating immediate effects of anodal/cathodal stimulation during 20 minutes of treadmill walking.
1510329|NCT02892084|Device|Sham tDCS|"Per published protocols, tDCS will be administered for 30 secs allowing for sensory adaptation to occur and then turned off, so that the remaining sham stimulation will include zero current. Evaluating immediate effects during 20 minutes walking on a treadmill."
1510330|NCT02892071|Drug|22% TCA peel|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with one treatment with a 22% TCA Blue Peel, to achieve a level 2 frost (medium depth peel). Each treatment will take about 20 minutes. A 22% TCA concentration will be created by combining 5.5 mL of 30% TCA (from a purchased commercial bottle) with 2mL of blue dye (commercial), immediately before application.
1510331|NCT02892071|Device|CO2 laser|One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will receive one treatment with one pass of the fractionated ablative 10,600 nm CO2 (CO2RE Laser, Syneron) at Core 70 mJ, Ring 50mJ, 40% coverage, 1 pass, 8 mm square pattern. Each treatment will take about 20 minutes.
1510332|NCT02892071|Device|Qs-NdYag laser|Long pulsed Q-switched Nd:Yag laser. One of the three facial areas (based on random assignment- forehead, left cheek, right cheek) will be treated with Q-switched (Qs) 1064 Nd:YAG (Medlite C3; 6 mm spot size, collimated homogenous flat- top beam profile, energy fluence 2.0 J/cm2, 5Hz), with 5% coverage and 2 passes (or until mild erythema detected). Treatments will be performed at 2-week intervals for six sessions. Each treatment will take about 20 minutes.
1510333|NCT02892045|Device|MMG|neuromuscular monitoring device
1510334|NCT02892032|Behavioral|Attention Modification Training|Subjects are taught to disengage attention from a certain stimuli
1510335|NCT02892032|Behavioral|No Attention Modification Training|Subjects are exposed to two stimuli, but attention is not manipulated in any way
1510336|NCT02892019|Drug|Indacaterol acetate 75 μg|Indacaterol acetate 75 μg o.d. delivered via Concept1 inhaler
1510337|NCT02892019|Drug|Indacaterol acetate 150 μg|Indacaterol acetate 150 μg o.d. delivered via Concept1 inhaler
1510338|NCT02892006|Behavioral|Improvisational Comedy|6 week curriculum in improvisational comedy. Each class meets for 1.5 hours for 6 consecutive weeks.
1510339|NCT02891993|Other|IMPROVED|"The electronic symptom monitoring intervention, Improving Management of Patient-Reported Outcomes Via Electronic Data (IMPROVED), consists of patients self-reporting their symptoms each day using a tablet computer. At morning rounds each day, the clinical team will view reports detailing their patients' symptom burden."
1510340|NCT02891993|Other|Usual Care|Participants receiving usual care will also self-report their symptoms each day using tablet computers. However, these patients' clinicians will not receive their symptom reports. Patients randomized to usual care will report their symptoms to their clinicians as they usually would, at their own discretion.
1510341|NCT02891980|Biological|Ad26 Zaire Ebola Vaccine|A recombinant adenovirus vector comprising a polynucleotide encoding a filovirus antigenic protein, wherein the recombinant adenovirus vector comprises an adenovirus 26 capsid protein.
1510342|NCT02891980|Biological|MVA Multi-Filo Ebola Vaccine|A multivalent MVA-BN Filovirus vaccine, designed to protect against Ebola Zaire, Ebola Sudan and Marburg virus.
1510343|NCT02891967|Other|bulk fill composite|cavities will be incrementally layered with resin composite and each increment will be cured as directed by the manufacturer with the light curing unit (XL 3000; 3M/eSPe), with an energy higher than 450 mW/cm² (±50 mw/cm²)
1510344|NCT02891967|Other|Nano resin composite (K Z350 xt)|cavities will be restored by bulk fill composite (3M ESPE) as one increment then will be cured as directed by the manufacturer with the light curing unit.
1510345|NCT02891954|Drug|Canagliflozin|Healthy volunteers will receive canagliflozin (300 mg per day) in the morning for five days.
1510346|NCT02891928|Device|Rocker sole shoes|Measure of walk testing Measure of standing position
1510347|NCT02891928|Device|Normal shoes|Measure of walk testing Measure of standing position
1992841|NCT03288935|Behavioral|TICM|The TICM will be designed to include the seven domains of trauma-informed care articulated by SAMHSA (2014): 1) early screening and comprehensive assessment; 2) consumer driven care and services; 3) trauma-informed, responsive and educated workforce; 4) emerging and evidence-informed best practices; 5) safe and secure environments; 6) trauma-informed community partnerships; and 7) a performance monitoring system. The trained agency case managers and staff will provide the TICM to 50 newly resettled refugees during their regular R&P service period (i.e., 60 days).
1992842|NCT03288935|Behavioral|TICO|The community-based TICO will be based on the Im's CHW that comprises 8 sessions (2 hour per session), co-facilitated by trained refugee peer mentors and community service providers. The TICO sessions will include interactive sessions on healthy eating, healthy body and healthy mind, acculturation & resettlement stress, understanding trauma and stress, healthy coping, helping others, and community building.
1992843|NCT03288714|Device|Synchronized Transcranial Magnetic Stimulation (sTMS)|sTMS delivers brain stimulation via a continuous magnetic field created by the device and set to the individual patient's intrinsic alpha frequency (IAF).
1510352|NCT02891902|Other|hygienist response|The daily presence of a public health nurse in the intensive care unit would implement such a strategy for prevention of infections and reduce the incidence of bloodstream infections acquired in intensive care.
1510353|NCT02891863|Device|LEVER Acute Study System|The LEVER Acute Study System is an acute pacing and shock delivery system intended for investigational use only. The LEVER Acute Study System is intended for acute conversion testing of monomorphic ventricular tachycardia by one of three different VT conversion methods.
1510379|NCT02891668|Drug|Levothyroxine treatment|Eltroxin/Euthyrox is part of the normal treatment for hypothyroidism, and the patient is treated equally, whether he/she participates or not.
2003076|NCT01002742|Drug|Placebo|"Oral dosing should be delivered in 250 mg units blinded placebo. For those < 40 kg, IV dosing should be within ± 10% of the exact dose. Intravenous doses are infused over a two-hour period.
Patients who weight > 60 kg should receive placebo 1 gm PO/IV every 8 hours.
Patients who weight between 40-60 kg should receive 750 mg PO/IV every 8 hours.
Patients who weight <40 kg should receive 20 mg/kg IV or PO every 8 hours."
1510361|NCT02891811|Drug|Carfilzomib|Induction treatment: Cycle 1 day 1+2: 20 mg/m2; days 8,9, 15 and 16: 27 mg/m2; Cycle 2: 27 mg/m2 on days 1,2,8,9,15 and 16; Cycle 3-9: 56 mg/m2 on days 1, 8 and 15; IV duration: 30-60 minutes; Maintenance treatment with carfilzomib (last tolerated dose on day 1 and 15 (± 7 days) of each cycle)
1510362|NCT02891811|Drug|Thalidomide|100mg orally on days 1-28 in patients <75 years of age at Cycle 1; 50mg p.o. on days 1-28 in patients ≥ 75 years of age at Cycle 1
1510363|NCT02891811|Drug|Lenalidomide|25mg p.o. on days 1-21 of each cycle
1510364|NCT02891811|Drug|Dexamethasone|40mg p.o. on days 1, 8, 15,22 (± 1 day ) in patients <75 years of age at Cycle 1; 20mg p.o. on days 1, 8, 15, 22 (± 1 day) in patients ≥ 75 years of age at Cycle 1, given 4 hours-30 min prior to carfilzomib
1510365|NCT02891798|Drug|Bupivacaine + CBD|Nerve blocks before surgery of L2-L4 and L4-S3
1510366|NCT02891798|Drug|Bupivacaine Only (control arm)|Nerve blocks before surgery of L2-L4 and L4-S3
1510367|NCT02891785|Behavioral|ANtiPain|After the implementation of ANtiPain, patients will receive cancer pain self-management support by trained staff nurses who follow the ANtiPain protocol. ANtiPain is based on 3 key strategies: Provision of information, skill building and nurse coaching. It consists of an in-hospital one-to-one session before discharge and a telephone follow up according to a clinical algorithm based on pain intensity, patient satisfaction with pain management and patient adherence. Patients will be given a booklet with corresponding info. The implementation process will include training of designated staff nurses, coaching activities based on case discussions on the ward, as well as measures to ensure sustainability of the implementation (e.g., training of ward managers and clinical nurse specialists).
1510368|NCT02891772|Procedure|ultrasonographic measurement of corrected flow time(FTc) in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time). The blood pressure was taken before anesthetic induction and every two minutes after anesthetic induction till ten minutes after endotracheal intubation.
1510369|NCT02891759|Other|Alloderm RTU|-Most commonly used acellular dermal matrices
1510370|NCT02891759|Other|Cortiva 1mm Allograft Dermis|-Tutoplast processed dermis
1510371|NCT02891759|Procedure|Skin or nipple-sparing mastectomy|-Standard of care
1510372|NCT02891759|Other|Breast Q|"15 questions
10 questions in Part A asking how has the patient been feeling in past 24 hours, answers range from 0-10 with 0=none of the time and 10=all of the time
Part B has 5 questions asking patient if she has had any of the following in the last 24 hours, answers ranging from 0-10 with 0=none of the time and 10=all of the time"
1510373|NCT02891759|Procedure|Surgery|"To address the tissue expander
Standard of care"
1510374|NCT02891746|Other|non invasive sampling|
1510375|NCT02891720|Device|Proteus Sensor System|The Proteus Sensor System (PSS) intervention includes 12 weeks of daily FTC/TDF with a weekly text messages transmitted to participants with estimated HIV risk reduction based upon the DBS algorithm.
1510376|NCT02891707|Device|Rehabilitative Lower-limb Orthopedic Accommodating-feedback Device (ReLOAD)|"The study will use a novel piece of technology, the ReLOAD, which is a data collector system that uses instrumented insoles, custom, miniature (1x1) microcontroller with accelerometer, gyroscopes, and geomagnetic sensors connected to a Bluetooth transceiver to collect and transmit gait kinematic data to mobile devices, such as an iPad and iPod. When a person walks or performs a specific activity, the ReLOAD system captures the movement, which can then be stored locally within the mobile device and/or encrypted and sent to a secured central server. This allows the patient or provider to access clinically relevant biomechanical data to help guide rehabilitation."
1510377|NCT02891694|Other|in vitro immuno-histo-chemical analysis of corneal epithelium|
1510378|NCT02891681|Device|Optical Tomography Using Near Infrared Diffused Light Assisted with Ultrasound|
2003086|NCT00961792|Drug|Ethanol|Beverage containing 0.8 g/kg ethanol, 0.4 g/kg ethanol
2003087|NCT00961792|Drug|Placebo|Beverage containing 0.0 g/kg alcohol to act as placebo
2003088|NCT00961792|Drug|Diphenhydramine|Beverage containing dose equivalent to 1.5 standard doses of Diphenhydramine (Benadryl)
2003089|NCT00961792|Drug|Caffeine|Beverage containing the equivalent of 1.5 times the participant's daily caffeine intake
2003090|NCT00947141|Drug|ganciclovir (start when CMV PCR >200copies / ml x2)|"Group A: Start ganciclovir when CMV PCR >200copies / ml x 2) . Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.
Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
1510381|NCT02891642|Device|Immunomagnetic Detection|Immunomagnetic separation will be assessed through analysis of the percentage of positive samples identified compared to cytological techniques.
1510382|NCT02891629|Device|EyeControl device|Use of device features including control of gestures, use of menus, activation of pre- defined modes and writing full sentences
1510383|NCT02891616|Drug|fludeoxyglucose F 18|
1510384|NCT02891616|Device|Positron emission tomography-computed tomography|
1510385|NCT02891616|Drug|18F-fluorothymidine|
1510386|NCT02891616|Device|Positron emission tomography-magnetic resonance imaging|
1510387|NCT02891603|Drug|Pacritinib|Pacritinib Dose and Schedule: 200 mg twice a day (BID) orally from day 0 until day +100. PAC will be tapered to 50% of the total dose at day +70, then 25% of total dose at day +84, then stop at day +100 (+/- 7 days).
1510388|NCT02891603|Drug|Sirolimus|In addition to the study drug, pacritinib, sirolimus and tacrolimus (SIR/TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR/TAC taper. SIR/TAC levels will be monitored according to program standard operating procedures. Dose modifications of SIR/TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
1510389|NCT02891603|Drug|Tacrolimus|In addition to the study drug, pacritinib, sirolimus and tacrolimus (SIR/TAC) will be administered and dosed according to Moffitt Cancer Center, Department of Blood and Marrow Transplantation standard practice. Attending physician discretion is permitted with regard to timing, rapidity, and completion of SIR/TAC taper. SIR/TAC levels will be monitored according to program standard operating procedures. Dose modifications of SIR/TAC for concurrent use of CYP3A4 inhibitors or inducers will be based on program standard operating procedures.
1510390|NCT02891590|Drug|DTRMWXHS-12|
1510391|NCT02891577|Procedure|Ultrasonography|At the time of ICU admission, among critically ill patients with shock, the investigators will measure the diameter of the common femoral vein and that of the inferior vena cava by ultrasonography.
1510392|NCT02891564|Behavioral|Project:EVO|a mobile 3D video game that has been shown to reduce older adults' susceptibility to interference by augmenting sustained attention and working memory abilities (e.g. cognitive control) through targeted adaptive algorithms.
1510393|NCT02891538|Drug|Epigallocatechin gallate (EGCG)|Teavigo™ is a natural, caffeine-free, highly purified and refined green tea extract providing 94% epigallocatechin gallate (EGCG).*
1510394|NCT02891525|Dietary Supplement|50g glucose|
1510395|NCT02891525|Dietary Supplement|25g fructose|
1510396|NCT02891525|Dietary Supplement|220mg acesulfame-K|
1510397|NCT02891525|Dietary Supplement|250mL tap water|
1510398|NCT02891512|Other|ELF|Very low frequency magnetic fields (ELF) at intensity of 100 mT and a frequency of 1-80 Hz. Protocol (antiedema-antinflammatory): 12 sessions, 3 times a week for 4 consecutive weeks, each session lasted 30 minutes.
1510399|NCT02891512|Other|Xinepa®|2 tablets of Xinepa daily (morning and evening) for 1 month.
1510400|NCT02891512|Other|Placebo Xinepa®|2 tablets of Xinepa placebo daily (morning and evening) for 1 month.
2003091|NCT00947141|Other|Monitor (Treatment starts when CMV PCR >3,000 copies / ml)|"Group A: CMV viral load between 200-3,000 copies/ml (on 2 occasions). Participants are randomised to either Monitor or Treat. If monitored, treatment will only begin if viral load has increased > 3,000. If treated (and monitored) treat until <200 copies on 2 consecutive occasions.
Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
2003092|NCT00947141|Drug|Stop treatment when 2 levels CMV PCR <3,000 copies / ml|"Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.
Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
1510403|NCT02891486|Procedure|Spinal surgery|Elective spinal surgery performed
1510404|NCT02891473|Other|Mézières Method|10 sessions of rehabilitative treatment according to the Mézières Method, 2 sessions per week for 5 weeks, each lasting 1 hour.
1510405|NCT02891473|Other|Home based exercise program|1 single training session lasting 1 hour for the explication of the rehabilitation program that the patient has to perform independently at home followed by 2 sessions of home based exercises per week for 5 weeks, each lasting 1 hour.
1510406|NCT02891460|Device|40 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
1510407|NCT02891460|Device|80 mg MMC in 40 mL TC-3.|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature) for drug retention in the urinary bladder.
1510410|NCT02891434|Device|Acquisition on TouchScreen|Participants performed acquisition and retention on TouchScreen, transfer 1 on Kinect and transfer 2 on LeapMotion.
1510411|NCT02891434|Device|Acquisition on Kinect|Participants performed acquisition and retention on Kinect, transfer 1 on TouchScreen and transfer 2 on LeapMotion.
1510412|NCT02891434|Device|Acquisition on LeapMotion|Participants performed acquisition and retention on LeapMotion, transfer 1 on TouchScreen and transfer 2 on Kinect.
1510413|NCT02891421|Behavioral|Therapeutic Horseback Riding|Veterans were matched to a horse for best fit and the same horse was ridden each week. The warm-up exercises involved various repeated physical movements while the horse was walking or standing steady, such as head rotations, lifting arms, rotating ankles, flexing toes. The exercises began with riding at a walk during the early weeks, learning reining skills and riding positions, and progressed to light trotting. Veteran participants were able to build on skill sets related to grooming, tacking, mounting, and riding that were introduced in prior weeks. Skill progression was based on individual abilities and safety as determined by certified riding instructor and occupational therapist.
1510414|NCT02891421|Other|Standard Care|Standard Care: Participants received standard care
1510570|NCT02890160|Device|Firesorb|Sirolimus Target Eluting Bioresorbable Vascular Scaffold
1510416|NCT02891395|Drug|Imatinib Mesylate and Nilotinib|"For patients under Imatinib Mesylate: the total length of follow up period for those patients will be for 52 weeks following IM treatment, with a follow up at weeks IM4, IM8, IM12, IM26, IM38 and IM52.
For patients requiring a salvage phase: after the switch for nilotinib, the total length of follow up period for this phase will be for 52 weeks following nilotinib treatment, with a follow up at weeks nilo4, nilo8, nilo12, nilo26, nilo38 and nilo52."
1510417|NCT02891382|Behavioral|Diabetes education|Participants interact with a diabetes educator (DE), every two weeks.
1510418|NCT02891382|Behavioral|Goal setting|Goals for weight loss and change in levels of HbA1c
1510419|NCT02891382|Behavioral|Companion Support|Patient has a companion/team support partner to support achieving goals.
1510420|NCT02891382|Behavioral|Individual Reward|The cash reward is given to the patient with diabetes.
1510421|NCT02891382|Behavioral|Shared Reward|Patients with diabetes and their companion support will each receive 50% of the cash reward.
1510422|NCT02891369|Other|No intervention. Descriptive study|
1510423|NCT02891356|Device|DEXA|The Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
1510424|NCT02891343|Other|2-hour period of hypoxia|During this period, the FiO2 will be set on 21% (normoxia condition). A filter will be put between the mask and the tubes connecting it to the machine generating hypoxia (equipment reference = Altitrainer NP190). On that filter a gas analyser will monitor the FiO2 and a capnography monitor (Capnostream 20, ORIDION) will also be installed.
1510425|NCT02891330|Behavioral|Dietary and nutritional recommendations conducted by a nurse|Supplementary dietary and nutritional education
1510426|NCT02891304|Other|Quarterly Feedback|Learning curves received quarterly vs. annually
1510427|NCT02891278|Drug|Sertraline|"Sertraline is a selective serotonin reuptake inhibitor (SSRI) that is FDA approved to treat major depressive disorder, obsessive-compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder.
Sertraline will be administered orally twice a day starting on day -3. Sertraline will be administered at one of 4 pre-defined dose levels in the following dose-escalation: 50 mg daily, 50 mg twice a day, 50 mg QAM and 100 mg QPM, 100 mg twice a day. 100 mg QAM and 150 mg QPM."
1510428|NCT02891278|Drug|Cytosine arabinoside|"Cytarabine is a cytotoxic chemotherapy approved for use in acute myeloid leukemia, acute lymphoblastic leukemia, and chronic myelogenous leukemia. It is also approved to prevent and treat meningeal leukemia. Cytarabine kills cells in S-phase through inhibition of DNA polymerase, as well as by halting DNA synthesis after its incorporation into DNA.
Cytosine arabinoside (Ara-C) will be administered as a 72 hour intravenous continuous infusion (IVCI) beginning Day 1 of therapy and again beginning Day 10 of therapy. The total dose of ara-C for each 72 hour period is 2 gm/m2 (0.667 gm/m2/24 hours)."
1510429|NCT02891278|Procedure|allogeneic stem cell transplantation|Allogeneic stem cell transplantation involves transferring the stem cells from a healthy person (the donor) to a patient after high-intensity chemotherapy or radiation.
1510430|NCT02891265|Behavioral|Smoking cessation patch|To compare the smoking cessation outcome in patients with fractures with or without the help of smoking cessation patches.
1510431|NCT02891252|Procedure|outpatient procedure|
1510432|NCT02891239|Device|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wavelength of 785 nm that was added to the system
1510435|NCT02891200|Other|Peer support program|The Peer Support Program offers education and support to participants by especially trained 'peer mentors' with oversight from a social worker.
1510436|NCT02891200|Other|HCP support|Healthcare professional (HCP) support will be provided by a trained respiratory therapist who will provide COPD self-management education and support via an in-person session and written materials .
1510437|NCT02891187|Behavioral|Telephone follow-up|Patients will be called for postoperative care at 1-2 weeks, 6 weeks, and 3 months
1510438|NCT02891187|Behavioral|Outpatient Clinic Visits|Patients will return to the clinic at 1-2 weeks, 6 weeks, and 3 months
1510439|NCT02891174|Drug|Ibuprofen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with ibuprofen followed by acetaminophen.
1510440|NCT02891174|Drug|Acetaminophen|At the time of delivery, eligibility will be reviewed. If the participant remains eligible, she will be randomized by the study pharmacy to begin post-partum analgesic therapy with acetaminophen followed by ibuprofen.
1510441|NCT02891161|Drug|durvalumab|1500 mg Q4 weekly
1510442|NCT02891161|Radiation|Radiation Therapy|64.8 Gy, 36 daily fractions on weekdays over about 7 weeks
1510443|NCT02891148|Drug|BI 690517|
1510444|NCT02891135|Other|SLATE|Algorithm for collecting information required to determine if patient is eligible for immediate (same-day/same-visit) initiation of antiretroviral medications.
1510445|NCT02891109|Biological|Biological tests|From the blood: B and T cells extraction then co-culture B and T cells and characterization of lymphocytes by flow cytometry
1510446|NCT02891096|Procedure|inspiratory muscle strength|"Measurements:
in- and expiratory muscle strength (5min)
lung function (FVC, FEV1, PEF, PCF) (10 min)
Questionnaires:
ISCoS core data-set
ISCoS pulmonary function data sets
ISCoS quality of life questionnaire
questionnaire on individual respiratory muscle training, regular physical exercise and therapies
individual medication/vaccination and other medical complications will be assessed from patient's medical records
All measurements will be performed at each of the 4 measurement time-points (up to 4 times during inpatient rehabilitation) and last about 40 min per patient and measurement time-point in total (time with patient)."
1510447|NCT02891083|Drug|Adjuvant chemotherapy (Paclitaxel and Cisplatin)|Adjuvant chemotherapy group: three cycles: (Paclitaxel: 175mg/m2 ivgtt, 3h, d1 4week × 3 and cisplatin: 75mg/m2 ivgtt, d1 4 week × 3)
1510448|NCT02891083|Radiation|Adjuvant radiotherapy|"Target: the upper mediastinum and bilateral supraclavicular region (Upper bound: thyrocricoid, lower bound: carina of 3cm)
Dose: 50Gy
Technology: strong tone
Segmentation: conventional segmentation 2Gy/d"
1510449|NCT02891083|Other|Control group (Surgery alone)|
1510571|NCT02890160|Device|XIENCE|Everolimus Eluting Coronary Stent System
1510452|NCT02891057|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-036)
1510453|NCT02891044|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z44-040)
1510454|NCT02891031|Drug|Rhus (Somagh)|500 mg twice daily after meal for 6 weeks
1510455|NCT02891031|Drug|Placebo|500 mg twice daily after meal for 6 weeks
1510456|NCT02891018|Device|paclitaxel controlled release balloon catheter Vasoguard TM|
1510457|NCT02891018|Device|paclitaxel release coronary balloon catheter SeQuent Please|
1510458|NCT02891005|Device|paclitaxel controlled release balloon catheter (VasoguardTM)|paclitaxel controlled release balloon catheter implantation for small vessel lesion
1510459|NCT02891005|Device|common balloon catheter (Maverick2)|common balloon catheter implantation for small vessel lesion
2003093|NCT00947141|Other|Monitor (Treatment stops CMV PCR <200 copies / ml x2)|"Group B: Viral load > 3,000 copies/ml. Participants are randomised to treat until < 3,000 copies/ml on 2 occasions or treat until <200 copies/ml on 2 consecutive occasions.
Routine standard of care would include treatment of Valganciclovir 900mg Tablet BD (dose adjusted for renal impairment), Ganciclovir 5mg/kg BD IV, or Foscarnet 60mg/kg according to randomisation within Group A or Group B"
2003099|NCT00938912|Drug|Lacosamide|Lacosamide oral solution (syrup): Total daily dose between 2 mg/kg/day (1 mg/kg bid) to 12 mg/kg/day (6 mg/kg bid)
1510467|NCT02890979|Other|Cytology Specimen Collection Procedure|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
1510468|NCT02890979|Other|Laboratory Biomarker Analysis|Correlative studies
1510469|NCT02890979|Other|Quality-of-Life Assessment|Ancillary studies
1510470|NCT02890979|Device|Swallowable Sponge Cell Sampling Device|Undergo cytology specimen collection procedure using a swallowable sponge cell sampling device
1510471|NCT02890966|Drug|SHR4640|Day1~Day7:oral administration
1510472|NCT02890966|Drug|placebo|Day1~Day7:oral administration
1510473|NCT02890953|Drug|Pneumostem|direct intracerebroventricular injection of mesenchymal stem cells via ventricular tap
1510474|NCT02890953|Drug|Normal saline|direct intracerebroventricular injection of normal saline via ventricular tap
1510475|NCT02890940|Behavioral|Pet Therapy|"Patients will be asked to complete the standardized QLQ-C30/BN20 questionnaires. Following completion of the questionnaires, a trained pet therapy dog will be brought to the patients for approximately 10 minutes. After approximately 10 minutes, the dog will be removed and the patients will be asked to re-complete the standardized QLQ-C30/BN20 questionnaires. Patients will be photographed and videographed during this time.
Finally, patients will be asked to talk about how their perspectives on life have changed with their diagnosis. These responses will be captured for use in the art exhibit created from images collected during the study."
1510476|NCT02890927|Other|Cardio-geriatric co-management|"A comprehensive geriatric assessment on admission will stratify patients in groups:
Low risk patients are expected to do well and will not receive co-management.
Medium risk patients are expected to develop complications. A geriatric nurse will visit the cardiology wards daily to co-manage these patients aiming to prevent complications by coordinating interdisciplinary care, implementing protocols, perform assessments and bedside education. The geriatric nurse will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning.
High risk patients have an acute geriatric syndrome. The geriatric nurse with visit the cardiology wards (see above), and a geriatrician will co-manage the acute geriatric syndrome(s). The geriatrician will work collaboratively with the cardiology ward staff based on a shared decision making. Patients will receive early rehabilitation and discharge planning."
1510477|NCT02890914|Other|Transvaginal Ultrasound Educational DVD|"American Institute of Ultrasound in Medicine, Gynecology: Beginners Only®"
1510481|NCT02890849|Other|Liquid biopsy|
1510482|NCT02890836|Drug|Antihypertensiva, mainly Metyldopa|
1510483|NCT02890823|Drug|Cholecalciferol|
1510484|NCT02890810|Other|Real Acupuncture with Electrical Stimulation|Acupuncture is a therapy commonly used in East Asian countries, where the practitioner insert thin needles at specific body sites in order to relieve pain and illnesses. Recent studies found low frequency electricity applied through acupuncture needles can lead to profound pain relief by increasing endorphin levels in the central nervous system. Electroacupuncture will thus be used as the active intervention to treat chronic low back pain in this clinical study.
1510485|NCT02890810|Other|Simulated Acupuncture with Electrical Stimulation|This intervention serves as the placebo control of the active intervention. Sterile acupuncture needles and the ITO electrical stimulators will be used in this intervention. But special care will be taken to have this intervention mimic the real treatment yet remaining as physiologically inert as possible.
1510486|NCT02890797|Radiation|radiology|radiologic exam
1510487|NCT02890784|Drug|dasatinib (SPRYCEL®)|Treatment optimization for patients with chronic myeloid leukemia (CML)
1510488|NCT02890771|Procedure|Tooth Brushing with Dentifrice|Tooth Brushing with Dentifrice (Standard Tooth Brushing technique will be demonstrated by using same type of tooth brush and toothpaste).
1510489|NCT02890771|Procedure|Turmeric Massaging|:-Tooth Brushing with Dentifrice (with same type of tooth brush and toothpaste) and massaging with whole Turmeric Powder.
1510490|NCT02890771|Procedure|SRP with turmeric massaging|on one side of the arch only Scaling and Root Planing(SRP) to be done, while on the other side, after the Scaling and Root Planing massaging with whole Turmeric Powder shall be carried out by the patients/subjects
1510491|NCT02890758|Biological|Natural Killer (NK) Cells|dose escalation of Natural Killer (NK) Cells from two infusion of 10 x 10^6 cells/kg to 1000 x 10^6 cells/kg dependent on dose limited toxicity
1510492|NCT02890758|Biological|ALT803|given at 6mcg/kg weekly for four weeks
1510493|NCT02890745|Drug|Empagliflozin|
1510494|NCT02890745|Drug|Placebo|
1510495|NCT02890732|Device|Appet HEART|smartphone application prototype of personalized care of patients after hospitalization for coronary artery disease
1510496|NCT02890719|Drug|Grazoprevir 100 mg/day|Grazoprevir 100 mg/ day 12 weeks
1510497|NCT02890719|Drug|Elbasvir 50 mg/d|Elbasvir 50 mg/day 12 weeks
1510498|NCT02890719|Drug|Grazoprevir 100 mg/day|Grazoprevir 100 mg/day 16 weeks
1510499|NCT02890719|Drug|Elbasvir 50 mg/day|Elbasvir 50 mg/d 16 weeks
1510500|NCT02890719|Drug|Ribavirin 1200 mg/day|Ribavirin 1200 mg/day 16 weeks
1510501|NCT02890706|Device|Iodine Mapping using Subtraction in Pulmonary Embolism Computed Tomography versus Dual Energy Computed Tomography|Compare two techniques of the CT scanner
1510502|NCT02890693|Behavioral|interdisciplinary lifestyle and psychosocial intervention|The multidimensional interdisciplinary lifestyle and psychosocial intervention will be offered on top of usual care. It will consist of individual sessions (face-to-face or telephone contact) with different members of the interdisciplinary team (dietician, physiotherapist, clinical psychologist or coach) and two group sessions. It will take place during pregnancy and during the first year postpartum.
1510503|NCT02890680|Procedure|Platelet-rich fibrin|
1510504|NCT02890680|Procedure|Control group|
1510505|NCT02890667|Other|Incident cancer|The number of incident cancer cases
1510506|NCT02890654|Other|First time measure|"Initial Interview
Initial Survey,
Quality of life Scale
Kinesitherapy Review
Anxiety Scale"
1510507|NCT02890654|Other|Second time measure|"Kinesitherapy review
Second survey including numeric scale of pain
Anxiety scale
Scoliosis Research Society 22 quality of life scale"
1510508|NCT02890654|Other|Third time measure|"Scoliosis Research Society 22 quality of life Scale
Anxiety scale
Numeric scale of pain
Kinesitherapy review"
1510509|NCT02890641|Genetic|search for genetic abnormalities|
1510510|NCT02890615|Behavioral|Depression self-care|Toolkit and coaching
1510511|NCT02890602|Drug|Darbepoetin alfa|Darbepoietin alfa will be administered subcutaneously at a fixed dose of 360㎍. If it is impossible, administration by intravenous infusion is okay.
1510512|NCT02890602|Drug|R-CHOP|R-CHOP regimen is a practical procedure in patients with Diffuse Large B-cell Lymphoma. Darbepoietin alfa will be administered to these patients.
1510513|NCT02890589|Device|SYNERGY (Platinum chromium coronary stent)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.
Stent will be implanted according to manufacturer's and competent authority recommendations."
1510514|NCT02890589|Device|ABSORB (Everolimus-eluting Bioresorbable Vascular Scaffold)|"Coronary angiography will assess the presence of at least one eligible coronary lesion requiring stent implantation before revascularization by angioplasty.
Stent will be implanted according to manufacturer's and competent authority recommendations."
1510515|NCT02890576|Other|telemedicine|Monitoring of patients with cochlear implant with sessions of telemedicine
1510516|NCT02890563|Device|Class II Compression Stockings|
1510517|NCT02890537|Drug|Core decompression/PREOB® implantation|All subjects received a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
1510518|NCT02890537|Drug|Core decompression/BMC implantation|All subjects received a core decompression under general anesthesia combined with the implantation of BMC into the necrotic lesion (single administration).
1510519|NCT02890524|Device|night guard|60 days before and after intervention with the night guard
1510520|NCT02890524|Device|placebo night guard|60 days before and after intervention with the placebo night guard
1510521|NCT02890511|Drug|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed consent.
1510522|NCT02890485|Procedure|Dry Needling|Dry needling consists of small, monofilament needles that are administered directly into the tissue and manipulated to make the muscle relax for pain relief. This technique is used to treat dysfunctions in skeletal muscle and connective tissue to help diminish pain, reduce impairments of body structure and restore function. Dry needling will be performed in the gluteal or the quadriceps muscle groups depending upon group randomization.
1510523|NCT02890485|Procedure|Sham Dry Needling|"The same overall procedures will be used as in the true dry needling groups and applied to the same muscle groups (gluteal or quadriceps) depending upon ground randomization. Sham dry needling will be performed using a commercially available sham needling system commonly.This set-up utilizes a blunt tipped needle. When the sham needle is pressed downward, the barrel of the needle retracts into the handle, giving the appearance of insertion of the needle through the skin. This also creates pressure on the subject's skin, increasing the sensation of dry needling. Patients will not be allowed to observe the areas being needled or sham needled."
1510524|NCT02890485|Other|Physical Therapy|Physical Therapy and exercise as determined by the examining clinician based on the patients specific impairments and functional limitations. All subjects enrolled in this study will receive an initial physical therapy (PT) evaluation and then 2 additional PT sessions a week a part. Interventions and prescribed home exercises will be specific to the patients' primary individual impairments as determined during the initial PT evaluation. These interventions reflect current evidence, but will not be restrictive to specific exercises; prescribed exercises will be deemed appropriate based on the treating PTs' examination, evaluation, and identification of each patients' primary deficits, impairments, functional limitations, and current literature.
1510525|NCT02890459|Other|Prize incentive - Low|Low expected prize value.
1510526|NCT02890459|Other|Prize incentive - High|High expected prize value.
1510527|NCT02890459|Other|Escalating payment incentive|"The incentives will increase in value when participants are found to meet the pre-specified virologic suppression criteria at 6 weeks, 3 months and 6 months.
If the virologic threshold for an incentive is missed at the 6 week or 3 month time-point, the subsequent incentive for an undetectable HIV viral load will be reset to the initial incentive value."
1510528|NCT02890459|Other|Travel Voucher|Travel voucher to assist with linkage to care.
1510529|NCT02890459|Other|Standard care|Includes HIV viral load and treatment adherence counseling.
2003100|NCT00938912|Drug|Lacosamide|"Lacosamide tablets: Total daily dose between 100 mg (50mg bid) - 600mg (300 mg bid).
The maximum permissible dose of LCM will be 12 mg/kg/day or 600 mg/day."
1510671|NCT02889445|Drug|4-Demethyl-4-cholesteryloxycarbonylpenclomedine|IV administration as described
1510530|NCT02890459|Behavioral|Fixed Incentive - Prize|Men are informed that if they come for HIV testing, they will receive a specific prize (gain framing). The prize will be an item worth the same amount in US dollars as loss aversion and the expected value of a lottery prize. This gain-framed incentive resembles the form that incentives usually take in most studies and serves as a comparison to the lottery-based and loss-framed incentives.
1510531|NCT02890459|Behavioral|Loss Aversion - Prize|The prizes are worth approximately the same amount as the fixed incentive and expected value of a lottery prize. At the time of randomization, study staff will inform the participant that he has won a prize. Staff will ask the participant to choose a specific prize from several choices, and then provide an opportunity for the participant to see the prize. Study staff will then tell participants that they will lose the prize if they do not participate in HIV testing. In this way, the incentive is framed as a loss rather than a gain, thereby leveraging loss aversion while not requiring men in very low-income settings to experience an actual loss.
1510532|NCT02890459|Behavioral|Lottery - Prize|"Men are entered in a lottery that offers a chance to win high-value prizes after testing for HIV at a community health campaign. Staff will emphasize that only those who come for HIV testing will be entered into the lottery and that not everyone will win a prize. Participants were informed at enrollment about the list of prizes and corresponding probabilities of winning them, in terms that are understandable to men with low numeracy (e.g., 1 in 20 rather than 5%). The probabilities of winning prizes varied between 1-5%, with higher value prizes having lower probability."
1510533|NCT02890459|Behavioral|Fixed Incentive - Voucher|A standard gain-framed incentive arm in which participants will be offered a voucher for coming for a repeat HIV test in the future.
1510534|NCT02890459|Behavioral|Loss Aversion - Deposit|A loss-aversion framed incentive in which participants will be asked to voluntarily make a deposit that can be retrieved, with interest on the deposit, if they come for an HIV test in the future (i.e. for repeat testing)
2003101|NCT00933231|Drug|tacrolimus|Standard dose, Oral
1510536|NCT02890394|Other|Suboccipital inhibition technique|Suboccipital inhibition technique involves the placement of the hands of the physiotherapist under the patient's head so that fingers can feel the spinous processes of the cervical vertebrae. Then fingers slowly leads upward to contact the occipital condyles. At this point the investigator should gently move your fingers down, finding the space between the condyles and the spinous process of the axis. Remember that the atlas has no spinous process. Then, flexing the metacarpophalangeal joints at 90 degrees, slowly raises the skull
1510537|NCT02890381|Biological|RSV LID cp ΔM2-2 Vaccine|10^5 plaque-forming units (PFUs); administered as nose drops
1510538|NCT02890381|Biological|Placebo|Administered as nose drops
1510539|NCT02890368|Drug|TTI-621|"TTI-621 (SIRPαFc) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory do not eat (antiphagocytic) signal to macrophages."
2003102|NCT00933231|Drug|tacrolimus|Low dose, Oral
2003103|NCT00933231|Biological|Simulect|IV
2003104|NCT00933231|Drug|Cellcept|Oral
2003105|NCT00933231|Drug|Corticosteroids|IV and Oral
2003106|NCT00933231|Drug|Ramipril|Oral
2003107|NCT00933231|Drug|Irbesartan|Oral
1510546|NCT02890329|Drug|Decitabine|Given IV
1510547|NCT02890329|Biological|Ipilimumab|Given IV
1510548|NCT02890329|Other|Laboratory Biomarker Analysis|Correlative studies
1510549|NCT02890316|Other|Homeopathy remedy|Homeopathy remedy, prescribed by a physician and prepared by licensed pharmacy.
1510550|NCT02890316|Radiation|Radiation as adjuvant therapy for breast cancer|Daily radiation therapy.
2003108|NCT00924937|Behavioral|Mediterranean Diet|Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; <10% SAT).
1510552|NCT02890290|Dietary Supplement|Marine Protein hydrolysate|The participants will take the supplement in form of tablets and will be instructed to take three tablets twice a day, and in relation to meals, however, not the dinner meal. Each tablet contains 500 mg of marine protein hydrolysates (Nx6.25). The tablets are produced by Science in Nutrition/Pharmatech, and are added lemon flavor.
1510553|NCT02890290|Dietary Supplement|Placebo|Placebo tablets will be made based on maltodextrin. The tablets are produced by Science in Nutrition/Pharmatech, and are added lemon flavor.
1510554|NCT02890277|Device|the high intensity focused ultrasound (Mianyang Sonic electronic LLC)|
1510555|NCT02890277|Drug|Fu Tiankang disposable vaginal filling suppository, Albothyl (Policresulen Solution) , and the gynecologic medical antimicrobial dressing gel (chitosan gel).|
1510556|NCT02890238|Drug|Clomiphene citrate|50mg (clomid,) orally 2 times/day from 2nd- 7th day of the cycle
1510557|NCT02890238|Drug|sildenafil citrate|20mg tab from 7th-11th day of the same cycle orally 3times/day
1510558|NCT02890238|Drug|Placebo|tab from 7th-11th day of the same cycle orally 3times/day
1510559|NCT02890225|Procedure|EPVL performed in 3 days after RIRS|Patients in Group A undergo EPVL in 3 days after RIRS.
1510560|NCT02890225|Procedure|EPVL performed in 7 days after RIRS|Patients in Group B undergo EPVL in 7 days after RIRS.
1510561|NCT02890225|Procedure|EPVL performed in 14 days after RIRS|Patients in Group C undergo EPVL in 14 days after RIRS.
1510562|NCT02890212|Dietary Supplement|selenium supplementation|administration of selenium pills (400 micrograms) for randomized subjects
1510563|NCT02890212|Dietary Supplement|placebo|administration of placebo pills for randomized subjects
1510564|NCT02890199|Drug|Bupivacaine liposomal|
1510565|NCT02890199|Drug|Lidocaine|
1510566|NCT02890186|Device|Narcotrend|the investigator modified the effect-site target concentrations by NI.If NI fall down to 46 and keep 46 more than 30 seconds,propofol and remifentanil were infused as feedback automatically to achieve the target NI of 26-46.
1510567|NCT02890186|Other|experience|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
1510568|NCT02890173|Drug|CS-3150|
2003109|NCT00924937|Behavioral|Low Fat Diet|Low fat diet: <30% fat (12% MUFA; 6-8%PUFA; <10% SAT)
2003110|NCT00924326|Drug|Fludarabine|On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.
1510574|NCT02890095|Procedure|Breast cancer surgery|"First, 2 specific adipose tissue samples will be performed during the surgery :
1 sample near the tumor, to measure the contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)
1 remote sample of the tumor bed, superficial, at least 5 cm from the tumor, to be used to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC.
These withdrawals are made during surgery, during surgery, as part of the intervention and the remodeling of the mammary gland (standard care for patients). This is unused balance for diagnostic.
Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
1510575|NCT02890095|Procedure|plastic surgery|"The excision piece will follow the classical pathological circuit.
A specific charge of subcutaneous adipose tissue will be performed as part of research on the surgical specimen. This sample will be used:
measuring contaminants (dioxins, PCBs, organochlorine pesticides, polybrominated compounds)
to determine the level of expression of hormone receptors and to establish the expression profiles, after cutting and inclusion in paraffin blocks for marking IHC. These samples are all made during surgery, for usual care surgery these patients.
Before anaesthesia : specific blood samples (for the determination of circulating pollutants and for the analysis of gene polymorphism)"
1510576|NCT02890082|Drug|Tamoxifen stim in early follicular phase|"Day cycle of the patient when ovarian stimulation begin (early follicular phase) = D1 to D3
Stimulation with simultaneously: TAM (tamoxifen) 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve)
Monitoring (ultrasound + blood test E2, LH (luteinizing hormone) and P) every 2 to 3 days +/- dose adjustment of FSH
Ovulation by blocking the GnRH antagonist (gonadotropin-releasing hormone : CETROTIDE) introduced according to the usual criteria,
Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days
Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria
35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
1510577|NCT02890082|Drug|Tamoxifen stim in late follicular phase|"Day cycle of the patient when ovarian stimulation begin (late follicular phase) = D4 to D14
Monitoring (ultrasound + blood test E2, LH and P) until a follicle of 15 mm
Ovulation induction by OVITRELLE® 250μg.
Continued monitoring (ultrasound + blood test E2, LH and P) 4 days after OVITRELLE® to the proper stage for the beginning of stimulation.
Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE
Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH
Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria
35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia."
1510578|NCT02890082|Drug|Tamoxifen stim in luteal phase|"Day cycle of the patient when ovarian stimulation begin (luteal phase) = D15 to D28
1 or 2 Monitoring (ultrasound + blood test E2, LH and P) to check the validity of the post-ovulatory phase
Stimulation with simultaneously: TAM 60mg / day + FSH® 150 to 300 IU / day (following ovarian reserve) + CETROTIDE
Continued monitoring (ultrasound + blood test E2, LH and P) every 2 to 3 days +/- adaptation of FSH
Triggering ovulation by OVITRELLE ® 250μg according to the usual criteria
35 h after the onset, oocyte puncture transvaginally the gynecology unit under local or general anesthesia"
1510579|NCT02890069|Biological|PDR001|anti-PD1 antibody
1510580|NCT02890069|Drug|LCL161|
1510581|NCT02890069|Drug|Everolimus|
1510582|NCT02890069|Drug|Panobinostat|
1510583|NCT02890056|Behavioral|H2GO!|
1510584|NCT02890043|Procedure|robot-assisted spine surgery|robot-assisted spine surgery using Tirobot system
1510585|NCT02890043|Procedure|free-hand surgery|traditional free-hand surgery
1510586|NCT02890043|Device|TiRobot system|a robot-assisted spine surgery system
1510587|NCT02890030|Behavioral|Questionnaire|"Neurotoxicity
Medications of interest
General health
Family history"
1510588|NCT02890017|Other|postoperative hotel|"Outpatient surgery First night stay in a defined patient-hotel Patient come for consultation the next morning of surgery to remove the catheter and/or the compressive bandage. The absence of adverse events is checked, the discharge is confirmed and the evaluation questionnaire is given to the patient.
Postoperative consultation at 1 and 3 months."
1510589|NCT02890017|Other|conventional hospitalization|Hospitalization for surgery and first postoperative night stay. Postoperative consultation at 1 and 3 months
1510590|NCT02889991|Other|High Intensity Dry Needling|"This technique follows the criteria established by Dr Hong C-Z. This technique is known as fast in and fast out technique and uses repeated insertion of the acupuncture needle in the myofascial trigger point, with the aim to get multiple local twitch responses. The technique ends when the local twitch responses disappear."
1510591|NCT02889991|Other|Low intensity Dry Needling|Technique proposed by the main investigator and based on the studies of Professor Dr. Jay P. Shah and the mechanisms of neuromodulation that transmits us the acupuncture scientific evidence.
1510592|NCT02889991|Other|Fascial Mechanotransduction Dry Needling|"The Fascial Mechanotransduction Dry Needling Technique, strikes with the acupuncture needle until it reaches and pierces the myofascial trigger point. Then the acupuncture needle is rolled in the connective tissue, which causes an intense coupler that we define as needle grasp. Finally, the acupuncture needling is pulled-out twice.
The screwing and the two pull-out of the acupuncture needle is performed in the infraspinatus and supraspinatus muscles and we describe it as mechanotransduction cycle. Each cycle lasts 30 seconds and the whole technique lasts 3 minutes per session."
1510593|NCT02889991|Other|Technique Placebo of Dry Needling|"Technique with a total duration of 3 minutes per session:
To locate the myofascial trigger points of infraspinatus and supraspinatus muscles and put each bridle on them.
Monitor longitudinally taut band, with index and middle fingers.
Percuss with tube and needle placebo (Sham needle) on Infraspinatus.
Remove the tube and needle placebo from the device. Reintroducing the placebo needle into the tube and strike on the supraspinatus. Repeat this sequence without interruption for 3 minutes.
Remove the bridles and perform hemostasis with cotton.
We will give end to the technique placebo of dry needling."
1510627|NCT02889692|Drug|YiQiYangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.
YiQiYangYinFang: Patients with Qi and Yin deficiency syndrome are administered one package of each benefiting Qi and benefiting Yin and two packages of detoxication recipe, four packages, twice a day, until progression or unacceptable."
1510672|NCT02889432|Drug|Oral Melatonin 10mg|
1510673|NCT02889432|Drug|Placebo|
1510594|NCT02889952|Device|Near infrared camera (NIR)|"Surgical field was examined with NIR, during a few minutes (<5') with room lights switched off, to avoid parasite lights, then conventional open thyroidectomy was resumed conventionally. Real-time images, evocative of autofluorescent parathyroids, were checked visually.
NIR consisted of a 750 nm class 1 laser excitation, with a power <20mW/cm2 (5 times less than the limit of 100mw/cm2, fixed by the international norm IEC 60601-2-41). It was provided by the Fluobeam® camera, which was inserted into a sterile cover and hold at a 15-20 cm distance from the patient. The system has an FDA 510(k) authorization for clinical use in parathyroid surgery and a European Community certification (Class 1 device)."
1510595|NCT02889939|Other|Training + Enriched environment|A rehabilitation program consisting of high-intensity training in an enriched environment: The intervention takes take place at a rehabilitation facilities located in Spain. The program includes training of impaired function in the affected arm and hand, walking and balance training, as well as lectures designed to widen knowledge about stroke and its effects on the participants and related parties. The training is task-specific, goal-directed, intensive, including mass practice and gradually with increased difficulty. The environment at the rehabilitation facilities is physically challenging and participants are asked to challenge themselves physically.
1510596|NCT02889939|Other|Control|"Control subjects are evaluated before and after a three-week long period referred to as the control period. During this control period (taking place in participants' home environment) the control subjects are not offered any type of organized intervention but are allowed to continue with conventional treatment, that may not exceed 3 hours a week, while taking part in the trial. The control subjects are asked not to undertake any other rehabilitation during the control period, but only to continue ongoing training, if any according the above mentioned restrictions.
Directly after the control period, the participants will be crossing over and receive the intervention."
1510597|NCT02889926|Biological|a swab according to the method of Levine|A swab according to the method of Levine: choose the pathological area by pressing the swab over the area, with a rotation supported on at least 1 cm² for 5 seconds, to well up from the liquid.
1510598|NCT02889926|Biological|Bacteriological referred to biopsy|Bacteriological referred to biopsy: (This is the hole protocol) Choose the pathological area, debridement of the wound to the pad and a scalpel, cleaning with betadine followed by rinsing with saline, local anesthesia with xylocaine, 6 mm punch for drawing a carrot, put into a sterile container
1510599|NCT02889913|Other|No intervention only description|No intervention only description
1510600|NCT02889900|Drug|cediranib and olaparib|"Cediranib tablets oral dose 30 mg once daily; Olaparib(Lynparza) tablet 200 mg twice daily
Dose reduction for both products is allowed"
2003111|NCT00924326|Drug|Cyclophosphamide|On days -5 through -3, Cyclophosphamide 500mg/m2 IV will be infused over 60 minutes followed by fludarabine.
1510602|NCT02889861|Drug|IMCgp100|Bispecific soluble HLA-A2 restricted gp100-specific TCR fused to anti-CD3
1510603|NCT02889848|Other|Saline|Saline injection
1510604|NCT02889848|Drug|EN3835|Comparison of maximum marketed dose and multiple doses EN3835
1510605|NCT02889835|Device|Supreme Universal Restorative|
1510606|NCT02889835|Device|Supreme Flowable Restorative|
1510607|NCT02889835|Device|Bulk Fill Flowable Restorative|
1510608|NCT02889822|Drug|Alprostadil Liposomes for Injection|"Single-dose tolerance test:10ug/20ug/50ug/100ug/200ug/300ug/400ug of Alprostadil Liposome for Injection,ivgtt,qd
Multiple-dose tolerance test:100ug,ivgtt,qd,continuous administration for 7 days."
2003112|NCT00924326|Biological|Anti-CD19-CAR PBL|On day 0, cells will infused intravenously (IV) on the patient care unit over 20 - 30 minutes (2-4 days after the last dose of fludarabine).
2003113|NCT00920426|Drug|GSK1265744|Active drug
2003114|NCT00920426|Drug|Placebo|Placebo to match GSK1265744
2003115|NCT00912223|Biological|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
The conditioning regimen will consist of the following:
Rituxan 375 mg/m^2 on Day -13
Rituxan 1000 mg/m^2 on Days -6, +1, and +8
Fludarabine 30 mg/m^2 on Days -5 to -3
Cyclophosphamide 750 mg/m^2 on Days -5, -4, -3
Day 0 will be the day of the transplant.
The GVHD prophylaxis will consist of the following:
Tacrolimus .09 mg/kg/po (Day -2 thru Day +180). Doses will be adjusted to maintain blood levels of 5-15 ng/mL.
Methotrexate 5 mg/m^2 (Days +1, +3, and +6). Unrelated donor recipients will receive a fourth dose on Day +11."
2003116|NCT00910962|Drug|GW856553|7.5 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
1510618|NCT02889783|Other|record of urethral pain sensation during urodynamics study|Record of pain using a VAS scale during the first catheterizing of urodynamics study, at every centimeter
1510619|NCT02889770|Other|PEEP titration|Exposure to different PEEP levels
1510620|NCT02889757|Drug|Acteylcysteine|randomized into three arms
1510621|NCT02889744|Device|Arctic Sun|Targeted temperature management for 24 hours with core temperature 36℃ or 33℃
1510622|NCT02889718|Device|CONCERT-CL® station|"During cancer surgery (surgery > 1 hour), CONCERT-CL® station will be used in accordance with its CE marking to administer anesthetic agents:
Port B = open loop: Analgesic
Port A = closed loop: Hypnotic
Port C = closed loop: Curare"
1510623|NCT02889718|Other|Surgery|Regardless of the type of surgery the patient receives for his cancer, this surgery must be greater than 1 hour.
1510624|NCT02889705|Other|Ultrasonographic examination|
1510625|NCT02889692|Drug|YiQiFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.
YiQiFang: Patients with Qi deficiency syndrome are administered two packages of each benefiting Qi and detoxication recipe, four packages, twice a day, until progression or unacceptable."
1510626|NCT02889692|Drug|YangYinFang|"Prescriptions formulated into TCM granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi, benefiting Yin and detoxication recipe.
YangYinFang: Patients with Yin deficiency syndrome are administered two packages of each benefiting Yin and detoxication recipe, four packages, twice a day, until progression or unacceptable."
1510628|NCT02889692|Drug|placebo granules|Oral granules, which the taste and smell are similar to experimental TCM granules, has no therapeutic effect, four packages, twice a day, until progression or unacceptable.
1510629|NCT02889692|Drug|Erlotinib®|"Erlotinib®,tarceva, 150 mg oral once a day until progression or unacceptable toxicity develops."
1510630|NCT02889692|Drug|Gefitinib®|"Gefitinib®,Iressa, 250 mg oral once a day until progression or unacceptable toxicity develops."
1510631|NCT02889692|Drug|Icotinib®|"Icotinib®,Conmana 125 mg oral three times a day until progression or unacceptable toxicity develops."
1510632|NCT02889679|Procedure|Underwater resection|Underwater resection of eligible lesions will be performed with air exclusion (air will be suctioned and completely removed) without submucosal injection in a partially collapsed colon lumen filled with water. Water will be infused with the foot pedal to facilitate visualization during UR and there will be no limit to the amount of water infused. Hot and cold resection techniques will be utilized.
1510633|NCT02889679|Procedure|Conventional (gas distended colon) resection|Conventional polypectomy of eligible lesions will be performed in a gas distended colon. Hot and cold resection techniques will be utilized. Submucosal fluid injection with a solution containing hydroxyethyl starch, dilute epinephrine and a contrast agent may be used with conventional techniques for large (≥1cm) and/or flat lesions. There will be no limit to the amount of submucosal injection used.
1510634|NCT02889679|Procedure|Standard polypectomy|Standard polypectomy will be performed for diminutive (<6mm), pedunculated and semi-pedunculated lesions that do not fall under the inclusion criteria for the study. These lesions will be removed in a gas distended colon with a 9mm firm, thin wire cold snare or snare electrocautery for large (≥1cm) lesions.
1510635|NCT02889666|Drug|Cisplatin|Procedure: Preoperative chemotherapy using Cisplatin (60mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
1510636|NCT02889666|Drug|Carboplatin|Procedure: Preoperative chemotherapy using Carboplatin (400mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
1510637|NCT02889666|Drug|Docetaxel|Procedure: Preoperative chemotherapy using Docetaxel (120mg) as single agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
1510638|NCT02889666|Drug|Gemcitabine/Carboplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
1510639|NCT02889666|Drug|Gemcitabine/Cisplatin|Procedure: Preoperative chemotherapy using Gemcitabine (200mg) and Cisplatin (60mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
1510640|NCT02889666|Drug|Docetaxel/Oxaliplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Oxaliplatin (200mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
1510641|NCT02889666|Drug|Docetaxel/Carboplatin|Procedure: Preoperative chemotherapy using Docetaxel (120mg) and Carboplatin (400mg) as combinational therapy agent was performed 30 days before surgery through intravenous (IV) administration. IV administration once every 7 days, totally 4 cycles. There is a 2-day interval between the last dose and surgery.
1510642|NCT02889666|Drug|Placebo|Regular placebo in replacement of agent-specific chemotherapy was supplied to these patients.
1510643|NCT02889653|Drug|Any oral antithrombotics (antiplatelets or anticoagulants)|
1510644|NCT02889640|Other|SAGA Innovations|An intensive math tutoring program
1510645|NCT02889640|Other|Scale-up tutors|Tutors who have been selected for hire via the one-in-five randomization process
1510646|NCT02889640|Other|Standard Tutors|Tutors who have been selected for hire via SAGA's standard hiring process, which does not entail randomization
1510647|NCT02889627|Drug|Fecal Microbiota suspension|The prepared microbiota suspension was infused into mid-gut.
1510648|NCT02889627|Drug|Normal saline|The saline (placebo) was infused into mid-gut.
1510649|NCT02889614|Other|Hypobetalipoproteinemia diagnosis (LDL-C ≤ 50 mg/dL without hypolipidemic treatment)|LDL-C dosage.
1510650|NCT02889601|Other|Psycho-behavioural assessment|DAPHNE Scale
1510651|NCT02889562|Drug|Apixaban|Study arm that patient can be randomized to. Apixaban is a novel, orally active, potent, direct selective inhibitor of coagulation FXa that directly and reversibly binds to the active site of FXa and exerts anticoagulant and antithrombotic effects by diminishing the conversion of prothrombin to thrombin.
1510652|NCT02889562|Drug|Warfarin|Study arm that patient can be randomized to. Warfarin therapy has been the mainstay of therapy for patients with POAF. While the duration of therapy is usually short (3-4 weeks), complications of anticoagulation do occur. Additionally, warfarin therapy for POAF is associated with increased length of stay, need for monitoring, and bleeding complications.
1510653|NCT02889549|Drug|ticagrelor|Different doses of ticagrelor (22.5/45/90 mg, twice daily, oral) treatment for 1 month
1510654|NCT02889549|Drug|clopidogrel|Standard dose of clopidogrel (75 mg, once daily, oral) treatment for 1 month
1510655|NCT02889536|Other|Focus group interviews|Focus group interviews. Two groups with patients referred to repair of parastomal bulging and three groups with patients attending the outpatient stoma clinics
1510656|NCT02889523|Drug|Tazemetostat|Tablets 200 mg, to be administrated per os
1510657|NCT02889523|Drug|Rituximab|375 mg/m²/dose, D1
1510658|NCT02889523|Drug|Cyclophosphamide|750 mg/m²/dose, D1
1510659|NCT02889523|Drug|Vincristine|1.4 mg/m²/dose (max 2 mg), D1
1510660|NCT02889523|Drug|Doxorubicin|50 mg/m²/dose, D1
1510661|NCT02889523|Drug|Prednisolone|40 mg/m2 in the morning D1 to D5
1510662|NCT02889510|Drug|liraglutide|7-week subcutaneous liraglutide once daily
1510663|NCT02889510|Drug|placebo|7-week subcutaneous placebo once daily
1510664|NCT02889497|Biological|the first batch vaccine|
1510665|NCT02889497|Biological|the second batch vaccine|
1510666|NCT02889497|Biological|the third batch vaccine|
1510667|NCT02889484|Procedure|Lumbar disc hernia surgery|
1510668|NCT02889471|Procedure|ERCP with NB|ERCP with NB catheter for introperative tans-nasobiliary cholangiography
1510674|NCT02889419|Device|Evaluation of underwear Selfia®|Patients are evaluated for a week using their usual underwear for the realization of SC. At the end of the week, they receive Selfia ® adaptated underwear and they use it for one week for a new evaluation. Finally, underwear will be given to patients and during follow-up consultations in routine at 6 months and 1 year, he will be asked if they reused or bought underwear.
1510675|NCT02889406|Behavioral|Motivational intervention|motivational interviewing schema
1510676|NCT02889393|Drug|teduglutide|Daily subcutaneous injection of 0.05mg/kg teduglutide
1510677|NCT02889380|Drug|No Intervention|This study will retrospectively collect the data from the subjects who had been treated with 0.25 mg of Cetrotide injection daily in a fixed or flexible antagonist protocol with an available ART outcome.
1510678|NCT02889367|Drug|Odalasvir 100 mg|Participants will receive odalasvir 2*50 mg tablet, orally once on Day 1.
1510679|NCT02889367|Drug|Placebo|Participants will receive odalasvir matching placebo, tablet, orally once on Day 1.
1510680|NCT02889367|Drug|Odalasvir 500 mg|Participants will receive odalasvir 10*50 mg tablet, orally once on Day 1.
1510681|NCT02889367|Drug|Odalasvir (Up to maximum 1000 mg)|Participants will receive odalasvir to be decided up to maximum of 20*50 mg tablet, orally once on Day 1.
1510682|NCT02889354|Behavioral|Cognitive-behavioral therapy|
1510683|NCT02889341|Dietary Supplement|DHA|
1510684|NCT02889341|Other|Placebo|
1510685|NCT02889328|Drug|Regorafenib|Regorafenib 100mg continuous dosing arm
1510686|NCT02889302|Drug|KPS-0373|
1510687|NCT02889302|Drug|Placebo|
1510688|NCT02889289|Other|Xbox One Kinect Gaming|"The Veteran completed 15 sessions of supervised VR training. Each session lasted between 50 and 60 minutes in total. The intervention utilized 2 commercially available Xbox One Kinect games called Shape Up and Kinect Sports: Rivals to challenge both cardiovascular and balance systems. Each game is composed of mini-games (MG). Each MG lasted between 1:30 minutes to 4:00 minutes. Both games were played for approximately 25 minutes during each session. Rest breaks were allowed as the participant required them. Guarding by a therapist was provided dependent on the challenge of the game and the participant's abilities."
2003117|NCT00910962|Drug|GW856553|15 mg GW856553 starting dose, followed 12 hours later by 7.5mg BID
2003118|NCT00910962|Drug|Placebo|Placebo
1510691|NCT02889250|Device|Medtronic Activa SC DBS, Lead Model 3387|Deep Brain Stimulation
1510692|NCT02889237|Dietary Supplement|Calcium|Immediate administration of daily calcium supplementation for 12 weeks
1510693|NCT02889237|Dietary Supplement|Calcium + low dose vitamin D|Immediate administration of daily calcium and low dose vitamin D (1 sachet CaD 1000/880) supplementation for 12 weeks
1510694|NCT02889237|Dietary Supplement|Calcium + high dose vitamin D|Immediate administration of daily calcium and high dose vitamin D (2 sachets CaD 500/880) supplementation for 12 weeks
1510695|NCT02889224|Other|Obese|
1510696|NCT02889224|Procedure|Hypercortisolism|
1510697|NCT02889224|Other|Hydrocortisone|
1510698|NCT02889224|Other|Control|
1510699|NCT02889211|Behavioral|Gambling Task|
1510700|NCT02889198|Behavioral|Go NAP SACC|Go NAP SACC is a suite of online tools designed to help child care programs improve their nutrition environment. Tools include: self-assessment, goal setting, action planning, and tips and materials. In addition to these online tools, local technical assistance providers offer center directors an orientation on how to use Go NAP SACC and minimal ongoing technical assistance.
1510701|NCT02889185|Device|RTX1 IMAGIN EYE retinal camera|In addition to the routine examination including OCT, an imaging using RTX1 IMAGIN EYE retinal camera will be performed.
1510702|NCT02889172|Behavioral|Problem Solving Therapy|It will be apply a Brief Intervention (PST) for patients with Type II Diabetes Mellitus and Obesity who receive treatment in primary care centers from Mexico City to evaluate if PST improvement the depressive and anxiety symptoms and help to adhere to treatment and stabilize their metabolic variables
1510703|NCT02889159|Biological|Candida albicans antigen|0.1 milliliter (mL) injection into superficial dermis making small bleb at Baseline Visit.
1510704|NCT02889159|Biological|histamine phosphate|0.01 milliliter (mL) of histamine phosphate injected into the superficial dermis making a small bleb at Baseline Visit.
1510705|NCT02889159|Biological|imiquimod 5% cream|Pea sized amount of 5% cream to be applied to designated areas once daily for 4 days, beginning at Baseline Visit.
1510706|NCT02889159|Procedure|Tape Stripping|At Baseline Visit, adhesive tape firmly applied to designated area for 2 seconds, then removed. Procedure repeated between 20 and 50 times until skin is slightly red and tacky.
1510707|NCT02889146|Other|Conventional Physical Therapy|Control group will receive respiratory therapy according to the service routine and conventional physical therapy. Conventional physical therapy will be offered by the hospital physical therapists, according to their own criteria. Consists of passive, assisted and resisted mobilization, positioning in bed, transferring to bedside or chair, orthostatism and deambulation, however without a definition of a protocol. The physical therapist will be responsible for the choice of the techniques employed in each session. There will be no previous definition of the next sessions. No technology equipment will be used in this group, since they are not available in the routine care.
1510708|NCT02889146|Other|Early and progressive mobilization program|Protocol group will receive respiratory therapy according to the service routine and motor physical therapy according to the program of early and progressive mobilization. Patients will receive the program once daily during the intensive care unit stay, offered by a trained physical therapist, at the adequate level according to the level of consciousness and muscle strength. The program contains by techniques for muscle length and muscle strength maintenance or gain, aerobic exercises, exercises for gait rehabilitation and cognitive components. Patient will progress to the next level of the protocol completing the previous level. Technology equipment available: functional electrical stimulation device, dumbbells, cycle ergometer, fixed walker, ambulation assistive device and video game.
1510709|NCT02889146|Other|Respiratory therapy|Respiratory therapy according to the service routine.
1510710|NCT02889133|Drug|Iron-dextran|Approved for clinical use: 1-gram dose IV - diluted in 500 mL, one pint normal saline.
1510711|NCT02889133|Drug|Saline|Salt water IV - 500 mL, one pint normal saline.
2003119|NCT00908388|Device|GORE TAG® Thoracic Endoprosthesis|Endoprosthetic Implant
1510712|NCT02889133|Procedure|Blood Donation|Standard process of collecting and storing blood and blood components (approximately 450 mL, or a pint of blood). Following donation, the blood will be leukoreduced, packed, and stored in AS-3 solution.
1510713|NCT02889133|Procedure|24-hour PTR|"The way the FDA determines how good blood is for transfusion is called a radioactive 51-Chromium 24-hour post-transfusion red cell recovery study. The purpose is to measure how many of the transfused red cells are still in circulation (being pumped by the heart through blood vessels) 24 hours after transfusion. In order to measure the percent of red cells that are still in circulation, a small amount of the donated blood will be radioactively labeled. This will be infused in one arm and then blood will be collected from the other arm at different time points to measure how much of the transfused red cells are still in circulation."
1510714|NCT02889107|Other|personal frequency modulated systems|patients used personal frequency modulated systems for at least 4 hours daily for 10 weeks
1510715|NCT02889094|Other|Routine care|Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).
1510716|NCT02889081|Other|maternal biological folate level|supplementation status and serum level
1510717|NCT02889081|Other|maternal biological Vitamin D level|supplementation status and serum level
1510718|NCT02889068|Other|Blood sample|
1510719|NCT02889055|Device|patient requiring the MIRUS (mechanical ventilation)|
1510720|NCT02889042|Other|MRI and biological assessment|performing a MRI and a biological assessment
1510721|NCT02889029|Device|new 3D device|dedicated tailored stents wrought by 3D computer-assisted conception
1510722|NCT02889003|Drug|Pioglitazone + TKI|
1510723|NCT02888990|Drug|Dasatinib|
1510724|NCT02888964|Drug|Add-on therapy|Pioglitazone therapy
1510725|NCT02888938|Other|pelvic radiography|
1510726|NCT02888938|Other|pelvic MRI|
1510727|NCT02888938|Other|pelvic CT-scan|
1510728|NCT02888925|Other|Mooney test|
1510729|NCT02888925|Other|Benton Face Recognition test|
1510730|NCT02888925|Other|Face inversion effect test|
1510731|NCT02888925|Other|Face composite effect test|
1510732|NCT02888925|Other|Cambridge Face Memory Test|
1510733|NCT02888925|Other|Matching different view test|
1510734|NCT02888925|Other|Memorizing and recognition of new faces test|
1510735|NCT02888925|Other|Memorizing and recognition of new objects test|
1510736|NCT02888925|Other|Recognition of celebrities and access to semantic information test|
1510737|NCT02888925|Procedure|Lobectomy|In patients with anterior temporal epilepsy, at 6 to 12 months after inclusion, depending on surgery decision taken after pre-surgery conventional intercritical assessment
1510738|NCT02888912|Other|EQUIA|Placing glass ionomer restorations, the dentin and enamel of cavities were conditioned with 20% polyacrylic acid for 20 seconds, washed, and briefly dried. Equia Fil was injected into the cavity. Isolation was maintained using cotton rolls and a saliva ejector. After the setting time of 2.5 minutes, the restoration was polished wet using high-speed fine diamonds. When the restoration was briefly dried, Equia Coat was applied and photocured for 20 seconds using a photo-curing light.
1510739|NCT02888912|Other|Gradia Direct Posterior|The enamel and dentin were conditioned with G-Bond adhesive using a microtip applicator, left undisturbed for five to 10 seconds, and then dried thoroughly for five seconds with oil-free air under air pressure, Gradia Direct Posterior resin was applied with the incremental technique (2 mm thick layers) and light-cured for 20 seconds. Finally, the restoration was shaped with finishing diamonds and silicon instruments.
1510740|NCT02888899|Behavioral|Biofeedback|
1510741|NCT02888899|Drug|Loperamide|
1510742|NCT02888899|Drug|Stool bulking agent (sterculia or ispaghula husk)|
1510743|NCT02888899|Other|PTNS|
1510744|NCT02888886|Other|Questionnaires about food habits and tobacco|
1510745|NCT02888886|Other|Spirometry|
1510746|NCT02888886|Other|Carotid echography|
1510747|NCT02888886|Other|Blood sample|for genetic polymorphism analysis, CRP, homocysteine and cytokine tests, glycemia and dyslipidemia analyses
1510748|NCT02888873|Other|Charisma|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma was used in combination Gluma2 Bond etch&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.
Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
1510749|NCT02888873|Other|Charisma Classic|"The surfaces were etched using 35% phosphoric acid for 30 s. The etched surfaces were rinsed and dried. Charisma classic was used in combination Gluma2 Bond etch&rinse adhesive. The composite resin restorations were light-cured (600 milliwatt/cm²). Occlusion was checked with thin articulating papers.
Restoration surfaces were finished and polished with fine finishing diamond burs, stones and rubber cups."
1510750|NCT02888847|Device|Philips Zoom! White Speed whitening lamp|bleaching protocol with descending built in light intensities
1510751|NCT02888847|Device|Philips Zoom! Advanced power whitening lamp|bleaching protocol with high light intensity
1510752|NCT02888834|Other|Adverse drug reaction|
1510753|NCT02888821|Behavioral|CLS-FUERTE|The CLS-FUERTE program is an approximately 6-week program and includes school (behavioral consultation with teachers), caretaker (caretaker skills groups), and student (skills groups) components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
1510754|NCT02888808|Other|Gastroscopy|Upper gastrointestinal endoscopy procedure
1510755|NCT02888795|Drug|hypertonic dextrose prolotherapy|five intra-articular injection at 2-weeks intervals in weeks 0, 2, 4, 6, 8.
1510756|NCT02888782|Other|Pharmacist Consultation|
2003120|NCT00882050|Drug|Exenatide|Exenatide to be infused intravenously at 0.27 ng/kg/min (0.066 pmol/kg/min) for a duration of 3 to 6 hours.
1510788|NCT02888535|Other|Internal Medicine consultation|
1510789|NCT02888522|Biological|immunomodulation|Immunomodulation depending on chimerism
1510790|NCT02888496|Drug|tocilizumab|3 monthly IV infusions in PMR patients
1510791|NCT02888457|Other|Nasopharyngeal sampling with a swab|
1510792|NCT02888444|Drug|Varenicline|Two 0.5mg tablets taken twice daily
1510757|NCT02888769|Behavioral|Text Messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). Non-smokers will receive two general messages, two hypertension messages, one medication adherence message and one physical activity message per week. Smokers will receive one general message, two hypertension messages, one medication adherence message, one physical activity message and one smoking cessation message per week. Prior to study commencement, a bank of 280 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
1510758|NCT02888756|Biological|iHIVARNA-01|Therapeutic vaccination, followed by treatment interruption
1510759|NCT02888756|Biological|TriMix|Therapeutic vaccination, followed by treatment interruption
1510760|NCT02888756|Biological|Placebo|Therapeutic vaccination, followed by treatment interruption
2003121|NCT00882050|Drug|Exenatide|Exenatide to be infused intravenously 0.41 ng/kg/min (0.099 pmol/kg/min) for a duration of 3 to 6 hours
2003122|NCT00882050|Drug|Placebo|Intravenous Placebo of normal saline solution to be infused at same rate as drug comparator
1510765|NCT02888730|Drug|Tobramycin nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of tobramycin twice a dayAmpoules of tobramycin are filled by 5 ml containing 300 mg of tobramycin and 11.25 mg of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete.Antibiotic retained for the study, tobramycin is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. The study's product will be prepared with Base Tobramycin and excipients in accordance with TOBI's composition."
1510766|NCT02888730|Drug|Physiologic serum nebulized nasally|"Two sonic nebulizations per day will be realized by patients: morning and evening during 15 days. There should be a maximum of 12 hours between the 2 doses but shall not be less than 6 hours. The dosage should not be adjusted to body weight. All patients will receive one ampoule of placebo (Nacl 0.9%) twice a day.Ampoules of placebo are filled by 5 ml containing of sodium chloride. Bulb should be employed in nebulizer and administered by the inhalation route approximately 15 minutes to complete. Placebo for the study is manufactured by the Pharmacie à Usage Interne of the Henri Mondor Hospital. Patients in placebo arm will receive 5ml of sodium chloride with the same color (light yellow transparent) as tobramycin"
1510767|NCT02888717|Procedure|'OSNA stadification during surgery'|"The para-aortic dissection surgery is performed in the usual way. The lymph nodes are isolated from fat tissue during surgery, and cut into 4 slices sterile.
Slices A and C are sent OSNA analysis
Slices B and D are sent ultimately histological analysis (1 cup HES or 5 cup HES + IHC) The nodes of less than 5 mm will be sent in final histological analysis due to the inability to cut into 4.
After the analysis, the report indicates whether the node is:
Free (-): <250 copies
Micrometastatic (+): 250 ≤ - <5,000 copies,
Macrometastatic (++): ≥ 5000 copies."
1510768|NCT02888704|Drug|ADSTEM Inj. (Adult human mesenchymal stem cells)|Comparison of different dosages of the drug in the aspect of safety and efficacy.
1510769|NCT02888691|Other|Low carbohydrate diet|
1510770|NCT02888691|Other|High carbohydrate diet|
1510771|NCT02888678|Behavioral|Economic Strengthening (Impumelelo)|Economic Strengthening (Impumelelo): This intervention consists of 15 one-hour long sessions on financial education in combination with access to appropriate youth-friendly savings mechanisms.
1510772|NCT02888678|Behavioral|HIV Prevention Education (Vhutshilo 2.2)|HIV Prevention Education (Vhutshilo 2.2): This intervention consists of 15 one-hour long sessions that are interactive, skills focused, and cover such topics as expressing one's feelings; dealing with loss and grief; decision-making; coping; gender violence; understanding HIV and other sexually transmitted infections; healthy relationships and staying safe in sexual relationships; and contraception and risks associated with unplanned pregnancy.
1510773|NCT02888665|Drug|Doxorubicin Hydrochloride|Given IV
1510774|NCT02888665|Other|Laboratory Biomarker Analysis|Correlative studies
1510775|NCT02888665|Biological|Pembrolizumab|Given IV
1510776|NCT02888652|Drug|antiplatelet agents|Clinical physicians according to patients condition to give different antiplatelet agents.We only observe clinical curative effect.
1510777|NCT02888626|Device|Microlens Array|Treatment with Cutera Microlens Array Device used with the enlighten™ 532nm /1064nm/670nm laser
1510778|NCT02888613|Procedure|mini laparotomy|The patient will be positioned supine. After induction of general anesthesia, a median umbilical incision will be performed. The average length of the incision of the laparotomy will be 10 cm (8-12 cm). The small intestine will be then mobilized medially and held by an orthostatic retractor. Arterial dissection and control as well as bypasses will be performed according to the conventional technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft.
1510779|NCT02888613|Procedure|mini lumbotomy|"After induction of general anesthesia, the patient will be positioned in right lateral decubitus at 45° of the table plane. The incision will be performed from the tip of the eleventh rib with a slightly sloping path to the outer edge of the rectus muscle. The average length of the incision of the laparotomy will be 10 cm (8-12 cm).
Abdominal aorta will be approached retroperitoneally. Arterial dissection and control as well as bypasses will be performed according to the conventional retroperitoneal technique. In case of occlusive disease of the iliac arteries, femoral site will be selected to achieve the distal anastomoses of the bifurcated prosthetic graft."
1510780|NCT02888600|Behavioral|Mindfulness Training|Guided mindfulness meditation and stress management training
1510781|NCT02888600|Behavioral|Health Education|Guided health education and stress management training
1510782|NCT02888574|Drug|Intranasal Oxytocin|Intranasal oxytocin (Syntocinon; Novartis, Switzerland)
1510783|NCT02888574|Drug|Placebo|Placebo nasal spray
1510784|NCT02888561|Drug|Dobutamine|Dobutamine will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
1510785|NCT02888561|Drug|Nitrite|Nitrite will be infused at the time of coronary angiography while coronary and LV haemodynamics are measured using a Combowire (dual pressure and flow sensor tip guide wire) and left ventricular conductance catheter.
1510793|NCT02888444|Behavioral|Behavioural support|Consisting of the study-specific doctor delivering relapse prevention orientated behavioural support at the time of consultation, plus six 10-15 minute calls over the 12 weeks delivered by a research assistant.
1510794|NCT02888444|Drug|Placebo|Two 0.5mg tablets taken twice daily
1510795|NCT02888431|Device|bedside point-of-care device|A bedside point-of-care device is routinely used in the operating room to measure lactate, base deficit, and pH.
1510796|NCT02888418|Biological|Tetravalent recombinant human papilloma virus vaccine (6,11,16,18 type) (Hansenula polymorpha)|Injection vaccine produced by Beijing institute of biological products co., LTD, containing HPV antigen protein, 120μg/0.5ml/bottle
1510797|NCT02888418|Biological|placebo|
1510798|NCT02888405|Other|High-carbohydrate diet|
1510799|NCT02888405|Other|Low-carbohydrate diet|
1510800|NCT02888392|Other|Kiwifruit|2 green kiwifruit cultivar 'Hayward'
1510801|NCT02888392|Dietary Supplement|Psyllium|Pysllium seed husk; ispaghula, isabgol, or psyllium, are portions of the seeds of the plant Plantago ovata, (genus Plantago), a native of India, Bangladesh and Pakistan. They are hygroscopic, which allows them to expand and become mucilaginous. Psyllium is a faecal bulking agent used to treat constipation. It absorbs liquid in the intestines, swells and forms a bulky soft stool that is easy to pass
1510802|NCT02888379|Drug|TOP1288|
1510803|NCT02888379|Drug|Placebo (for TOP1288)|
1510804|NCT02888353|Device|Device: MRI|Perform MRI in patients with cardiac devices
1510805|NCT02888340|Other|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin. The needles do not go into the skin very far. Number of acupuncture sessions: one.
1510806|NCT02888327|Drug|AL-794|
1510807|NCT02888327|Drug|Oseltamivir|
1510808|NCT02888327|Drug|Digoxin|
1510809|NCT02888327|Drug|Midazolam|
1510810|NCT02888327|Drug|Pitavastatin|
1510811|NCT02888327|Drug|JNJ-63623872|
1510812|NCT02888301|Procedure|Computed Tomography|Undergo 18F-clofarabine PET/CT
1510813|NCT02888301|Radiation|Fluorine F 18 Clofarabine|Given IV
1510814|NCT02888301|Procedure|Positron Emission Tomography|Undergo 18F-clofarabine PET/CT
1510815|NCT02888288|Behavioral|Mental Health Intervention|Includes a standard format of greetings, review of last session content, homework discussion, new topic, assigning homework and ends with a fun activity, relaxation or game. First session is a joint session with youth and caregivers. Topics include common stresses and worries experienced by HIV+ youth; relaxation and coping techniques; cognitive behavioral triangle; story of finding out HIV status and if willing, to discuss this in an individual session, peer group session, and with caregiver; identify circles of support; discuss stigma and how to disclose HIV status to others; consider values, hopes and dreams for the future, and how to use this information to live positively with HIV. ART adherence is woven into case examples and discussions.
1510816|NCT02888288|Behavioral|Standard of Care|Standard of Care is enhanced with a 12 session HIV curriculum taught by youth leaders which is integrated into the HIV youth clinic. ART adherence is discussed in all sessions.
1510817|NCT02888275|Drug|Dexmedetomidine|
1510818|NCT02888275|Drug|normal saline|
1510819|NCT02888249|Other|Altered composition cigarette|This double-blind study will systematically determine the abuse liability of altered composition cigarettes using a behavioral economics abuse-liability approach. Altered composition cigarettes (e.g., cigarettes differing in casings, sugars, tar levels, moisture) may result in decreased intake and decreased dependence, although critical questions remain regarding the abuse-liability of altered composition cigarettes, whether exposure to these cigarettes reduces use, and whether altered composition cigarettes will substitute for standard cigarettes. The addictive effects and abuse liability of altered composition cigarettes, therefore, are not well understood, and will be tested in this study.
1510820|NCT02888236|Drug|LEO 32731|
1510821|NCT02888236|Drug|LEO 32731 Placebo|
1510822|NCT02888223|Biological|SCT800|
1510823|NCT02888223|Biological|Xyntha|
1510824|NCT02888210|Device|MD-15 Intraocular Lens|
1510825|NCT02888171|Drug|ferric citrate|Participants randomized to the ferric citrate arm will take 2 grams of ferric citrate three times a day with meals.
1510826|NCT02888171|Drug|ferrous sulfate|Participants randomized to the ferrous sulfate arm will take 325 mg of ferrous sulfate three times a day.
1510827|NCT02888158|Other|Robotic assistance|Robotic assistance will be implemented during Pelvic Trainer training sessions.
1510828|NCT02888158|Other|Pelvic Trainer|The standard Pelvic Trainer simulator for surgical training.
1510829|NCT02888132|Procedure|Echocardiography-guided transthoracic radio frequency ablation for HOCM ventricular septum|
1510830|NCT02888132|Procedure|Echocardiography-guided transthoracic laser ablation for HOCM ventricular septum|
1510831|NCT02888119|Device|PRISMA 3T MRI scanner (Siemens Medical Solutions)|A baseline MRI exam consisting of accelerated 3D-T1p, and T2, MRI will be performed. Longitudinal follow-up MRI exams (24 months) will be repeated on the same knee on all OA patients.
1510832|NCT02888106|Drug|Myrcludex B|
1510833|NCT02888106|Drug|PEG IFN alfa-2a|
1510834|NCT02888093|Device|Absorbent suture (polydioxanone) and Permanent suture (Gore-Tex CV2)|
1510835|NCT02888080|Drug|ACZ885|ACZ885 will be administered subcutaneously to assigned study subjects once monthly for 6 months.
1510836|NCT02888080|Drug|Placebo|Placebo will be administered subcutaneously to assigned study subjects once monthly for 6 months.
1510837|NCT02888067|Drug|Rocuronium bromide 0.5 mg/kg|Moderate neuromuscular blockade with rocuronium bromide
1510838|NCT02888067|Drug|Rocuronium bromide 1.0 mg/kg|Deep neuromuscular blockade with rocuronium bromide
1510839|NCT02888067|Drug|Sugammadex sodium 2 mg/kg|Reversal with sugammadex sodium
1510840|NCT02888067|Drug|Sugammadex sodium 4 mg/kg|Reversal with sugammadex sodium
1510841|NCT02888054|Drug|lesinurad/allopurinol 200/300 FDC tablet|
1510842|NCT02888054|Drug|lesinurad 200 mg|
1510843|NCT02888054|Drug|allopurinol 300 mg|
1510844|NCT02888041|Drug|Dinoprostone|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10 mg), patients receive a second Propess®, followed by Oxytocin 5U.I/ml (Syntocinon®) (if necessary) and epidural analgesia if desired by the patient.
1511699|NCT02880891|Procedure|prothetic procedure|splinted crown
1510845|NCT02888041|Drug|Oxytocine|In case of failure of cervical ripening after a first intravaginal delivery device of Dinoprostone (Propess® 10mg), patients receive directly Oxytocin 5U.I/ml (Syntocinon®) and epidural analgesia if desired by the patient.
1510846|NCT02888028|Procedure|ICD remote monitoring|ICD remote monitoring additionally to regular in-office visits
1510847|NCT02888028|Other|Control group|Regular in-office visits/FU 1,3,6 and 12 months post implantation of an ICD or post ICD replacement w/o remote FU
2003123|NCT00882492|Biological|GLP 1|This a continuous intravenous infusion of GLP-1 (7-36) amide infusion (1.5 pmol/kg/min)
1510849|NCT02888002|Behavioral|Guide to better alcohol habits|A 5-module therapeutic program wich includes self-help material in printed or web-based form with interactive exercises. The program includes instructions for the therapist.
1510850|NCT02887989|Device|Virtual Reality|A menu of VR experiences, lasting from 3-30 minutes each. For example, patients may watch a soothing virtual campfire, or fly over a scenic landscape, or play an interactive game.
1510851|NCT02887989|Device|Health and Wellness Channel|Relaxing content broadcast passively on the patient in-room television channel.
1510852|NCT02887976|Drug|SoluMatrix™ Abiraterone Acetate|SoluMatrix™ Abiraterone Acetate 500mg (4 x 125 mg qd) is an androgen synthesis inhibitor
1510853|NCT02887976|Drug|Methylprednisolone|Methylprednisolone (4mg bid) to maintain physiologic levels of corticosteroids which are reduced by SoluMatrix Abiraterone Acetate
1510854|NCT02887950|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician.
1510855|NCT02887950|Dietary Supplement|Equikilon-3 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 3 months and nutritional counseling.
Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
1510856|NCT02887950|Dietary Supplement|Equikilon-6 months|"The patient will receive 2 sachets per day of a dietary supplement containing resistant starch, epigallocatechin gallate and chlorogenic acid (Equikilon) for 6 months and nutritional counseling.
Nutritional counseling consists in: personalized dietary prescription associated with dietetic advise (on a monthly basis and upon patient's request) by a registered dietician."
1510857|NCT02887937|Drug|Definity|The contrast agent, Definity, 10 µL/kg, will be administered through an intravenous catheter placed in an antecubital vein. Definity is an FDA approved contrast agent for cardiac studies and will be an off-label use in this study. The agent will be injected as a single intravenous bolus followed by a 10 mL saline flush (0.9% NaCl). Images will be recorded with clip function for 90 seconds following the administration of contrast while the probe is stabilized and minimal pressure applied. During this time, qualitative evaluation of tumor enhancement will be observed, and the presence of contrast uptake within the tumor will be categorized.
1510858|NCT02887924|Device|Neopuff; Fisher and Paykel, Auckland, New Zealand|Following the oral and nasal aspirates, SLI at 25 cm H2O pressure will be applied for 15 seconds by using t-piece refreshing and binasal prongs and 5-cm nCPAP at H2O pressure will be applied.
1510859|NCT02887898|Device|Automated bolus calculator|
1510860|NCT02887898|Other|Education|
2003124|NCT00882492|Biological|normal saline solution placebo|This is a continuous intravenous infusion of normal saline solution as placebo (1.5 pmol/kg/min) during cardiac surgery
1510862|NCT02887872|Other|Electrical stimulation-dynamic hand orthosis|Each participant participated in the electrical stimulation-dynamic hand orthosis regimen. Repetitive grasp/release motions were performed for 30 minutes while wearing the dynamic hand orthosis. This was followed by 15 minutes of electrical stimulation applied to forearm extensor muscles. This regimen was performed daily, 5X/week for 6 weeks.
1510863|NCT02887859|Biological|Human Acellular Vessel (HAV)|Patients will be implanted with a Human Acellular Vessel (HAV) as a femoro-popliteal bypass conduit using standard vascular surgical techniques
1510864|NCT02887846|Device|Heated Humidified High-Flow Nasal Cannula|Patients requiring mechanical ventilation for at least 6 hours on the first 7 postnatal days will be included in the study.When patients were Fi O2 < 0,40, Pa CO2 < 65 mmHg, pH> 7.20, MAP (mean airway pressure) <7 cm H2O, they will be extubated if statistically stable.Oxygen-air mixture of 4-6 l / min flow rate will be set in HHHFNC group, and pressure will be set to 5-8 cm H2O in NCPAP group. When flow is 2 l / min, FiO2 is<0.30 at 24 hours and above, free oxygen will be introduced. In NCPAP group, when pressure is 5 cm H2O and FiO2 < 0.30 at 24 hours and above, free oxygen will be introduced.
2003125|NCT00864227|Biological|Hematopoietic Umbilical Cord Blood Stem Cell Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.
Fludarabine: 40 mg/m^2 intravenously (IV) on Days -6, -5, -4, -3, and -2
Cyclophosphamide: 50 mg/kg IV on Day -6
Total body irradiation: 200 centigray (cGy) on Day -1"
1510866|NCT02887820|Device|Thromboelastograph|A thromboelastograph flowchart will be followed in addition to traditional laboratory tests to manage blood transfusion and coagulation decisions
1510867|NCT02887807|Drug|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
1510868|NCT02887807|Drug|Single intravenous bolus of placebo at the onset of resuscitation|cardio-pulmonary resuscitation usual care of cardiac arrest
1510869|NCT02887794|Other|Clinical and psychoacoustic measures|Our study focuses on psychoacoustic tests, specialist care protocols (psychotherapy, neuromodulation ...) being made independently of our study, as part of medical activity of Cerletti care unit or differentiated protocols. Thus, our study shows no individual benefit for the patient. However, a better understanding of the neurophysiological mechanisms underlying auditory hallucinatory phenomenon could allow a better management of these patients in the near future
1510953|NCT02886962|Drug|Oral anticoagulation with vitamin K antagonists|"Vitamin K antagonist prescription with INR target between 2 and 3 as recommended in the guidelines.
Administration once daily or at the end of each dialysis session, according to the nephrologist choice.
INR monitoring at least once per week"
1510872|NCT02887755|Device|Near-Infrared Spectroscopy (NIRS) Sensor|These sensors utilize NIRS to evaluate oxygenated and deoxygenated hemoglobin, total oxygenation index and total blood flow. This is done by bouncing infrared light off of chromatophores (located within red blood cells), which is then refracted off of the cells in the capillary beds to the topical sensor.
1510875|NCT02887677|Drug|Dapagliflozin|Administration of dapagliflozin (film-coated tablet of 10mg, per os, q24h, 12 weeks)
1510876|NCT02887677|Drug|Placebo|Administration of placebo (film-coated tablet of same color and texture with dapagliflozin, 10mg, per os, q24h, 12 weeks).
1510877|NCT02887664|Procedure|Blood test|Blood will be drawn from mother's vein and from the cord to test for n-6:n-3 ratio and inflammatory markers: CRP, IL-6, TPO and TNF-alpha markers
1510878|NCT02887651|Radiation|Cavity boost radiation|Cavity boost radiation therapy with 10 x 3 Gy for patients suffering from complete resected cerebral metastases
1510879|NCT02887638|Other|Individual Profile Analysis (Physical therapy Intervention)|"The Individual Profile Analysis consists of the following components:
Analysis of the sitting-posture profile:
o cervical spine, thoracic spine, lumbar spine and pelvis during a longitudinal provoking task (working at a laptop).
Analysis of the dural profile before and after the provoking task:
o Determination of the dural sensitivity by the use of the slump-test
Analysis of the pain profile before and after the provoking task:
Determination of pressure pain sensitivity by the use of pressure algometry
Determination of the influence of pain on the quality of life by the use of the HIT-6 questionnaire"
1510880|NCT02887625|Drug|Pioglitazone plus exenatide|pioglitazone will be started at 30 mg/day and bydureon at 2 mg/week
1510881|NCT02887625|Drug|insulin glargine and insulin aspart|the dose will be escalated to maintain HbA1c <7.0%
1510882|NCT02887612|Other|ctDNA test|
1510883|NCT02887599|Procedure|Blood collection|1ml of blood specimen collection
1510884|NCT02887586|Other|auricular needling|Patients will be treated with auricular needling for 4 weeks. 4-8 specific auricular acupoints are selected unilaterally at a time, and alternate to another side every 2-3 days, treatment will last for 4 consecutive weeks. The following 4 ear acupoints points will be selected for every patient: Ear Shenmen, Stoma, Spleen, and Subcortex. Other ear acupoints including Triple Energizer, Liver, Sympathetic Nerve and Smallintestine will be selected based on the condition of patients. Treatment will be performed by a registered Chinese medicine practitioner.
1510885|NCT02887573|Drug|Free-residue nutrients|This trial evaluated the efficiency of free-residue nutrients for the bowel prepartion of CCE.
1510886|NCT02887573|Drug|Low fiber diet|Low fiber diet often used in the bowel prepartion of CCE. In this study, it is the control group.
1510887|NCT02887573|Procedure|Colon capsule endoscopy|In the study,all patients should undergo two colonoscopies.The first is for examinations and the second for therapy.
1510888|NCT02887573|Drug|2L PEG|2L PEG are laxatives for experiment group.
1510889|NCT02887573|Drug|4L PEG|4L PEG are laxatives in the control group.
1510890|NCT02887573|Drug|PEG|These PEG are for boosters. All patients will take 0.75L and 0.5L PEG for two boosters.
1510891|NCT02887573|Drug|Mosapride citrate|5mg mosapride citrate are used to promote gastric motivity.
1510892|NCT02887560|Procedure|transoesophageal echocardiography|
1510894|NCT02887534|Drug|SPARC1401-low dose|SPARC1401- low dose
1510895|NCT02887534|Drug|SPARC1401-mid dose|SPARC1401- mid dose
1510896|NCT02887534|Drug|SPARC1401-high dose|SPARC1401-high dose
1510897|NCT02887534|Drug|Reference1401 (Tizanidine)|Reference1401 (Tizanidine) three times a day
1510898|NCT02887534|Drug|Placebo1401|Placebo
1510899|NCT02887521|Other|education|pulmonary rehabilitation participant manual
1510900|NCT02887521|Procedure|rehabilitation|pulmonary rehabilitation
1510901|NCT02887521|Device|pedometer|receive a pedometer
1510902|NCT02887521|Other|education|receive a pamphlet with exercises plus the standard course of care
1510903|NCT02887521|Procedure|surgery|patients undergo surgery
1510904|NCT02887508|Behavioral|HINTS Intervention|HINTS is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on sexual risk reduction.
1510905|NCT02887508|Behavioral|Healthy Living Control|The Healthy Living Control is a four-session, group-based behavioral intervention delivered exclusively online and developed using the IMB model of health behavior change focused on non-sexual health topics.
1510906|NCT02887482|Biological|GLS-5700|GLS 5700 at 2 mg DNA/dose
1510907|NCT02887482|Biological|Placebo|
1510908|NCT02887469|Drug|3% hypertonic saline|The same as above
1510909|NCT02887456|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
1510910|NCT02887456|Drug|Endodontic treatment using MTA paste|Endodontic treatment using MTA paste
1510911|NCT02887443|Drug|Raxone (idebenone 150 mg)|Raxone (idebenone 300 mg t.i.d.) on days 3 and days 5 to 10
1510912|NCT02887443|Drug|Midazolam 2,5 mg|Midazolam (2,5 mg single oral dose) on days 1, 3 and 10
1510913|NCT02887430|Other|foot reflexology therapy|standard care and foot reflexology
1510916|NCT02887391|Other|No intervention - observational study|No intervention - observational study
1510917|NCT02887378|Device|hot clamps|reusable hot biopsy forceps
1510918|NCT02887378|Device|normal clamps|
1510919|NCT02887365|Drug|tegafur-uracil|
1510920|NCT02887352|Other|assessment of problem-solving ability|
1510921|NCT02887339|Other|Training Website|Additional training website can be found at gtextraing.org
1510922|NCT02887339|Other|Control|Standard training given by OPOs and GTEx staff
1510923|NCT02887313|Drug|mFOLFOX6 with radiation|Patients receive mFOLFOX6 for 4 cycles during neoadjuvant radiotherapy, and after CRT, another 4-6 cycles of mFOLFOX6 would be given before surgery.
1510924|NCT02887300|Behavioral|Mantra Meditation|"Week 1:
20 minute meditation session. Prescribed text discussion. Encouraging a daily practice; the log, daily readings, timer etc.
Week 2:
Review of the practice followed by a 20 minute meditation period. Challenges to learning meditation. Second 20 minute meditation. Discussion of prescribed text.
Week 3:
20 minute meditation. Review of Atul Gawande's lecture. Second 20 minute period of meditation. Discussion of prescribed text.
Week 4:
20 minute meditation session. Discussion of prescribed text. A second 20 minute meditation. End of programme review."
1510925|NCT02887287|Drug|EEN|
1510926|NCT02887261|Device|"BardPowerPort sip Implantable Port"|capable for power injection for contrast media.
1510927|NCT02887261|Device|Conventional Port|not for power injection for contrast media.
1510928|NCT02887248|Drug|nab-paclitaxel|"Induction: 125 mg/m² by intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles to be given with Gemcitabine.
Maintenance: single agent nab-paclitaxel (260 mg/m²) by IV infusion every 21 days) until disease progression, intolerable toxicity or patient decision to discontinue treatment."
1510929|NCT02887248|Drug|Gemcitabine|Induction: 1000 mg/m²) by IV infusion on Days 1 and 8 of each 21-day cycle for 3 to 6 cycles.
1510930|NCT02887235|Other|Home Delivered, Medically Tailored Meals (HDTM)|
1510931|NCT02887222|Drug|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
2003126|NCT00864227|Biological|GVHD prophylaxis|"GVHD prophylaxis regimen will consist of:
Cyclosporine: beginning on Day -3 with the dose adjusted to maintain a level of 200-400 mg/mL
MMF: 1 gram IV three times a day (TID) if greater than 50 kg, or 15 mg/kg IV TID if less than 50 kg beginning on Day -3; continued until Day 30 or 7 days after engraftment, whichever day is later
Day 0 is the day of the infusion of the umbilical cord blood graft units, which will be obtained from partially HLA-matched unrelated donors.
Beginning on Day 1, participants will receive G-CSF 5 mcg/kg/day until absolute neutrophil count (ANC) is greater than or equal to 2,000/mm^3 for three consecutive measurements, each on different days."
1510933|NCT02887183|Drug|LCZ696 (sacubitril/valsartan)|LCZ696 (sacubitril/valsartan) is supplied as unscored, ovaloid, film-coated oral tablets in the strengths of 24/26 mg, 49/51 mg, 97/103 mg twice daily (bid)
1510934|NCT02887157|Device|Swept Source OCT|The swept source optical coherence tomography device was developed at Duke University as the result of collaboration between the Departments of Ophthalmology and Biomedical Engineering. The SSOCT system has a 100kHz repetition rate, 1050nm-centered swept-source light source (Axsun Technologies). This swept-source system allows near real-time OCT imaging during movement while imaging and it provides better OCT imaging of the choroid. The SSOCT system is a non-contact device and therefore does not touch the eye.
1510935|NCT02887157|Other|Magnetic Resonance Imaging|Non-sedated research brain MRI: Magnetic resonance imaging (MRI) is a minimal risk procedure that uses a magnet and radio waves to make diagnostic medical images of the body. There have been no ill effects reported from exposure to the magnetism or radio waves used in this test. However, it is possible that harmful effects could be recognized in the future. A known risk is that the magnet could attract certain kinds of metal. Therefore, we will carefully ask about metal within the body. If there is any question about potentially hazardous metal within the body, MRI imaging will not be performed. We will also keep the examining room locked so that no one carrying metal objects can enter while the child is in the scanner.
1510936|NCT02887157|Other|Scavenged blood collection|Serum/plasma (residual in the laboratory) collected as part of clinically indicated care will be shipped to the University of Florida for neuroinflammatory biomarker testing to identify central nervous system cellular injury.
1510937|NCT02887144|Device|SenSura|SenSura is a Commercial and CE-marked ostomy product (1pc) manufactured by Coloplast A/S
1510938|NCT02887144|Device|SenSura test product|SenSura test product is a CE-marked ostomy product (1pc) manufactured by Coloplast A/S
1510939|NCT02887131|Other|Dynamic CT of the ankle|during inversion and eversion mouvement, with Aquilion One Toshiba scanner
1510940|NCT02887105|Other|Standard neuropsychological assessment|
1510941|NCT02887105|Other|Brain MRI|
1510942|NCT02887053|Device|MRI|
1510943|NCT02887040|Radiation|Radiation|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive radiation.
1510944|NCT02887040|Drug|Atengenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
1510945|NCT02887040|Drug|Astugenal|Subjects ≥ 3 years of age with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
1510946|NCT02887027|Behavioral|Exercise4Mood Intervention|The Exercise4Mood Intervention was designed based on principles from the Exercise for Mood and Anxiety protocol (Smits et al., 2009) and consists primarily of a mobile application called Exercise4Mood. It will be supported by text-messages, delivered through SymTrend, reminding participants about their scheduled exercise sessions and prompting them to engage with the app. Its core features include: motivational tips to encourage exercise, reminders about scheduled exercise, tracking of exercise behavior, tracking of mood before, during, and after exercise, and post-exercise positive reinforcement statements.
1510947|NCT02887014|Procedure|SPECIFIC VERBAL INSTRUCTIONS|Participants will be randomized either to get detailed instructions verbally by the medico-paramedical staff of the participating centers (physicians or nurses) before starting bowel preparation (Group A) or to get ordinary instructions as usual in each of the participating centers (Group B). Instructions provided to Group A will include details about the procedure of bowel preparation, its potential side effects and the importance of the adequate preparation (Appendix)
1510948|NCT02887001|Other|Pharmacist consultation|
1510949|NCT02886988|Drug|Botulinum toxin type A|50 units of botulinum toxin diluted in 1 ml of normal saline will be administered. 0.1mlof BTA will be injected with a 30G needle.
1510950|NCT02886988|Drug|normal saline|0.1mlof normal saline will be injected with a 30G needle.
2003127|NCT00859040|Drug|SOM230C|Injection in the buttocks every 28 days
1510952|NCT02886962|Biological|No oral anticoagulation|No oral anticoagulation, and no monitoring of the INR.
1511004|NCT02886507|Dietary Supplement|NSK-SD (nattokinase)|Nattokinase is a fibrinolytic enzyme from the fermented soy product natto. Encapsulated 100mg/capsule, excipient include microcrystalline cellulose.
2003128|NCT00853580|Drug|Lovastatin ™|Lovastatin starting at 20mg for 2 weeks, increasing to 40mg for 14 weeks. Total duration of trial is 16 weeks.
1510954|NCT02886936|Device|iFIT Transtibial Prosthesis|Transtibial amputee volunteers will be fit with the iFIT device and instructed on its use. Patient will wear the iFIT device for a two week time period according to a provided wear schedule. At the end of this time patient will rate it for comfort, stability and ease of use.
1510955|NCT02886910|Other|Clinical observation|Antibiotics will be started only if sepsis-related signs or symptoms are present.Clinical observation consists in a standardized physical examination protocol according to which newborns are observed by the nurses at 1, 2, 4, 8, 12, 16, 20, 24 hours of life and then every 6 hours up to 48 hours of life. The following signs and symptoms are checked: skin colour (pink/pale/cyanotic/mottled), respiratory rate (lower or higher than 60 breaths/minute) and presence or absence of respiratory distress.
1510956|NCT02886910|Other|Standard management|Antibiotics will be started at birth. Clinical observation will be carried out with the same timing and protocol
1510957|NCT02886897|Biological|D-CIK and anti-PD-1 antibody|Autologous dendritic and cytokine-induced killer cells (D-CIK)(1.0-1.5*10^10 cells)were incubated with anti-PD-1 antibody and infused into participants.
1510958|NCT02886884|Drug|20 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
1510959|NCT02886884|Drug|100 million Allogeneic Mesenchymal Human Stem Cells|1 single intravenous infusion
1510960|NCT02886871|Behavioral|Step Goal Delivery by Smartphone|
1510961|NCT02886858|Device|Device : Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
1510962|NCT02886858|Device|Device : sham Transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
1510963|NCT02886845|Genetic|rs183489969,rs185670819|compare the frequency of two germline mutations in breast cancers and controls
1510964|NCT02886832|Dietary Supplement|Prostate Health formulation|
1510965|NCT02886819|Other|vibration|Whole body vibration
1510966|NCT02886806|Other|BIS XP, Covidien, Ireland|Closed loop for propofol and remifentanil using BIS XP TM, Covidien, Ireland
1510967|NCT02886806|Other|EV-1000 TM, Edwards Lifesciences, Irvine, California, USA|Closed loop for fluid perfusion using EV-1000 TM, Edwards Lifesciences, Irvine, CA, USA
1510968|NCT02886793|Drug|fludeoxyglucose|
1510969|NCT02886780|Behavioral|Concentrated exposure treatment (cET)|Psychological cognitive behavioral treatment
1510970|NCT02886780|Behavioral|Self-help|
2003129|NCT00853580|Device|placebo|Starting at 20mg for 2 weeks, then increasing to 40mg for 14 additional weeks for a total duration of treatment of 16 weeks.
1510972|NCT02886754|Behavioral|Proficiency-based progression|Use of validated metrics and performance benchmarks to simulation training
1510973|NCT02886754|Behavioral|National e-learning programme only|National e-learning programme (COMPASS)
1510974|NCT02886754|Behavioral|Standard simulation|Paper based simulation cases
1510975|NCT02886741|Other|Quality Improvement Campaign|"How To Guide addressed development of a QI plan; small-scale tests of change- (PDSA cycles) to refine implementation approaches through iterative learning; and reliance on multi-disciplinary implementation teams. IHI recruited relevant professional organizations to identify faculty."
2003133|NCT00843193|Drug|INTRAVENOUS GSK679586|GSK679586 will be provided as a clear or colorless to pale yellow liquid with the unit dose strength of 10mg/kg and will be infused over an hour. The infusion will be delivered by a programmable infusion pump
1510980|NCT02886715|Drug|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to cover the entire face once daily for 84 consecutive days.
1510981|NCT02886715|Drug|Tazorac®|Tazorac® applied to cover the entire face once daily for 84 consecutive days.
1510982|NCT02886715|Drug|Placebo|Placebo (vehicle of the test product) applied to cover the entire face once daily for 84 consecutive days.
1510983|NCT02886702|Drug|Tazarotene Cream 0.05%|Tazarotene Cream 0.05% to cover only the lesions with a thin film.
1510984|NCT02886702|Drug|TAZORAC® (tazarotene) Cream 0.05%|TAZORAC® (tazarotene) Cream 0.05% to cover only the lesions with a thin film.
1510985|NCT02886702|Drug|Placebo|Placebo (vehicle of the test product) to cover only the lesions with a thin film.
1510986|NCT02886689|Drug|TNF-alpha antagonist and other biotherapy|
1510987|NCT02886676|Drug|Spirulina capsules|Spirulina capsules 2gm daily for 1 month
1510988|NCT02886663|Other|stimulation of the blind visual field|
1510989|NCT02886650|Procedure|Thermocoagulation|Thermocoagulation During pre-surgical Invasive EEG Monitoring
1510990|NCT02886637|Other|None intervention|
1510991|NCT02886624|Drug|Grazoprevir/Elbasvir|Once-daily, oral grazoprevir/elbasvir combination therapy at fixed-dose (100mg/50mg) for 8 weeks
2003134|NCT00843193|Drug|INTRAVENOUS PLACEBO|Clear or colorless 0.9% sodium chloride saline solution will be infused over an hour. The infusion will be delivered by a programmable infusion pump
1510993|NCT02886585|Drug|Pembrolizumab|
1510994|NCT02886585|Radiation|MRI|
1510995|NCT02886585|Radiation|PET/CT|
1510996|NCT02886585|Procedure|Stereotactic Radiosurgery|
1510998|NCT02886559|Drug|Chidamide plus DCAG regimen|chidamide, decitabine, aclarubicin, cytarabine and G-CSF
1510999|NCT02886546|Procedure|pneumoperitoneum|
1511000|NCT02886546|Device|oesophageal Doppler monitor|
1511001|NCT02886533|Other|Antithrombotic|Collection of clinical, biological data
1511002|NCT02886520|Device|PVDF transobturator tape|
1511003|NCT02886520|Device|Polypropylene transobturator tape|
1511005|NCT02886507|Dietary Supplement|Placebo|The placebo capsules contain microcrystalline cellulose.
1511006|NCT02886494|Drug|BAC|
1511010|NCT02886455|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
1511011|NCT02886455|Other|New adhesive strip|This a newly developed adhesive strip.
1511012|NCT02886442|Other|Standard adhesive strip|This is a standard adhesive strip (hydrocolloid)
1511013|NCT02886442|Other|New adhesive strip|This is a newly developed adhesive strip
1511014|NCT02886429|Drug|Bupivacaine|Ultrasound guided paravertebral block with bupivacaine
1511015|NCT02886429|Drug|Dexmedetomidine|Ultrasound guided paravertebral block with dexmedetomidine
1511016|NCT02886416|Other|Non interventional study|
1511017|NCT02886403|Other|Standard adhesive strip|A standard adhesive strip (hydrocolloid)
1511018|NCT02886403|Other|New adhesive strip|A newly developed adhesive strip
1511019|NCT02886390|Device|ischemic conditioning|In this study, the remote ischemic conditioning treatment was composed of five cycles of bilateral upper limb ischemia intervened by reperfusion, which was induced by two cuff placed around the upper arms respectively and inflated to 200 mm Hg for 5 minutes followed by 5 minutes of reperfusion by cuff deflation.
1511020|NCT02886377|Biological|blood test of anti-AQP4 antibody|Patients were sub-divided into an AQP4 seropositive group and an AQP4 seronegative group, according to blood test of the AQP4-Ab.
1511021|NCT02886364|Behavioral|Adapted Safe Childbirth Checklist|The World Health Organization has created and endorsed the WHO Safe Childbirth Checklist as a tool for improving quality of care around childbirth. This tool has been modified to the context in Mexico by another group of investigators at the National Institute of Public Health. Our team expanded the Mexican version of the WHO Safe Childbirth Checklist to include indicators around respectful maternity care.
1511022|NCT02886351|Drug|Nitrous Oxide|Nitrous Oxide at 60%-70% concentration administrated by mask, to achieve cooperation in Pediatric dentisry
1511023|NCT02886338|Device|capsule endoscopy|The magnetic navigated CE would enable detailed investigations of the whole upper gastrointestinal tract, including the esophagus, stomach and duodenum. Using this remote magnetic manipulation, capsule endoscope might improve diagnostic accuracy and extend the examination of specific area of interest in the gastrointestinal tract.
1511024|NCT02886325|Behavioral|Cancer Clear and Simple|This is a 2.5 hour educational program about cancer knowledge, cancer risk factors and preventative cancer screenings.
1511025|NCT02886325|Behavioral|Nutrition Education|This is a 2.5 hour educational program about nutrition and making healthy choices.
1511026|NCT02886312|Device|Supplemental Oxygen Delivery System|
1511027|NCT02886299|Drug|Fenofibrate|
1511028|NCT02886299|Drug|Simvastatin|
1511031|NCT02886273|Other|Group 1|Observation
1511032|NCT02886273|Other|Group 2|Observation
1511033|NCT02886273|Other|Group 3|Observation
1511034|NCT02886273|Other|Group 4|Observation
1511035|NCT02886234|Behavioral|Mindfulness Training (MT)|Participants assigned to the MT condition will receive a phone-delivered 30-minute mindfulness training once a week for 8 weeks. ). In addition to the weekly training session, participants will be instructed to practice mindfulness techniques for 15 minutes daily using a standardized audio recording to guide the participant through the techniques learned with the instructor.
1511036|NCT02886234|Behavioral|Health Coaching (HC)|The HC condition will consist of educational modules designed to control for the contact time and attention received in the MT condition. To match the time MT participants will spend doing mindfulness exercises at home, HC participants will be assigned a 15-minute daily activity that is aligned with the HC topics
1511037|NCT02886221|Procedure|Reverdin-Isham Osteotomy|Incision on the medial part of the foot, a Shannon Isham burr was introduced at the junction of metaphysis and epiphysis. It was applied to the flat bone surface achieved previously at approximately 45°, keeping the articular cartilage surface of the first metatarsal head as reference point on the superior cortex. In this position, under fluoroscopic control, the osteotomy was started following a distal-dorsal and proximal-plantar direction. At this point, the burr was slightly withdrawn in order to preserve a few millimetres of the lateral cortex, and the osteotomy of the plantar cortex was performed completely. Then, a Wedge burr was used to create a wedge with a medially oriented base. At the point of closing the wedge, osteoclasis of the preserved lateral cortex was achieved, modifying the orientation of the articular surface, normalizing the DMAA value, and adding an intrinsic stability to the osteotomy by producing contact of the trabecular bone.
1511038|NCT02886208|Behavioral|Measurement|The intervention consists of diabetes prevention education sessions focusing on increasing physical activity and decreasing the intake of sugared drinks while increasing intake of fruits and vegetables. The 2-hr sessions occur weekly for 6 weeks. Height and weight is measured for each consenting participant at baseline and after 6 weeks. Participants are also asked to complete a short questionnaire to collect demographic and knowledge data. Outcome measures include: BMI, knowledge of physical activity and dietary habits conducive to diabetes prevention, and feelings of food insecurity.
1511039|NCT02886195|Drug|pemetrexed|500mg/m2 ivgtt d1, per three weeks
1511040|NCT02886195|Drug|cisplatin|80mg/m2 ivgtt d1, per three weeks
1511041|NCT02886195|Drug|Erlotinib|150mg po. every day
1511042|NCT02886169|Other|High fat meal with Sacha Inchi|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) added with 15ml of Sacha Inchi oil and 125ml of coffee with 10g of sugar
1511043|NCT02886169|Other|high saturated fat meal|Participants will receive 100 g of bread with 70 g of butter (high saturated fat meal) and 125ml of coffee with 10g of sugar
1511044|NCT02886156|Device|CPAP|CPAP plus BSC group Participants in the CPAP plus BSC group will receive CPAP treatment plus the aforementioned BSC intervention. CPAP treatment (LOTUS AUTO; Curative Medical Technology Inc., Beijing, China) will be initiated using standard clinical practice at each center. Participants in both groups will be asked to continue their usual medical care during the trial.
1511045|NCT02886156|Dietary Supplement|BSC|BSC only group Participants in the BSC only group will receive advice regarding lifestyle modification, sleep hygiene, naps, exercise, caffeine, and diet, and avoiding alcohol consumption, but no specific weight loss program, diet, or salt restriction will be suggested.
1511090|NCT02885753|Drug|5 Fu|5 fluorouracil : 400 mg/m² in bolus of 10 minutes (intravenous) following by 2400 mg/m² during 46 hours in intravenous
1511046|NCT02886143|Procedure|Active Voiding Trial|"Nursing protocol:
Instill 250-400 cc of STERILE SALINE via the lumen of the Foley catheter into the bladder via gravity drainage or slow push
Clamp the Foley
Deflate the catheter balloon and remove the catheter from the bladder.
Record the amount of saline that was instilled into the bladder.
Immediately assist the patient to void. Report the amount instilled and the amount voided to the physician within one hour a. Unless the patient reports extreme bladder fullness or pain, give the patient one hour to urinate
7. If the patient fails the voiding trial, the physician will decide to do in and out catheterization or place a new Foley catheter"
1511047|NCT02886143|Procedure|Passive Voiding Trial|"Nursing protocol:
Deflate the catheter balloon and remove the catheter from the bladder.
Record the time that the catheter was removed and the time the patient is due to void (approximately 6 hours).
5. If the patient has not voided within 5 hours, assist the patient to try to void.
6. If the patient is unable to void, is only voiding in small amounts, or reports fullness or abdominal pain, perform a bladder scan.
7. If the patient has not voided after 6 hours, report this to the physician along with the results of the bladder scan 8. The physician will decide to do in and out catheterization or place a new Foley catheter"
1511048|NCT02886130|Dietary Supplement|Placebo|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
1511049|NCT02886130|Dietary Supplement|Experimental|Monitoring of supplementation (e.g., compliance, subject blindness), diet (to control dietary choline ingestion), training volume and adverse effects will be performed on a weekly basis to ensure maximal control of confounding factors as well as the safety of volunteers during the study.
1511050|NCT02886104|Procedure|CRLM resection group|Simultaneous resection of both primary and secondary tumors in synchronous CRLM or resection of metachronous CRLM.
1511051|NCT02886104|Device|CRLM ablation group|Microwave ablation of CRLM with a 2.15-gigahertz(GHz) microwave generator and a 14 gauge diameter transcutaneous antenna within 30 days after resection of primary tumor in synchronous CRLM or ablation of metachronous CRLM.
1511052|NCT02886078|Procedure|Dorsal approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the dorsal approach.
1511053|NCT02886078|Procedure|Volar approach CapFlex arthroplasty|Arthroplasty of the PIP joint with the CapFlex implant. Surgery will be done with the volar approach.
1511058|NCT02886052|Behavioral|Therapist guided Internet-CBT for insomnia|
1511059|NCT02886052|Other|Active control|
1511060|NCT02886039|Other|Electroencephalogram|Prognostic evaluation of electroencephalogram score created with a retrospective cohort Creation of composite score to predict neurologic outcome in cardiorespiratory arrest
1511063|NCT02885987|Device|AmplifEYE|AmplifEYE will be attached to the tip of the colonoscope prior to start of procedure.
1511064|NCT02885974|Drug|Celecoxib|Celecoxib (100 mg daily)
1511065|NCT02885974|Drug|Gemcitabine|1,000 mg/m2 (IV), on Days 1 and 8 of each 21-day cycle. Up to 4 cycles.
1511066|NCT02885974|Drug|Cisplatin|70 mg/m2 (IV), on Day 1 of each 21-day cycle. Up to 4 cycles.
1511067|NCT02885961|Drug|Dabigatran|Anti-coagulant
1511068|NCT02885961|Radiation|FDG PET scan|Scan using PET combined with a high resolution CT scan (HRCT)
1511069|NCT02885948|Drug|Naloxone|used to block the effects of opioids, especially in overdose
1511070|NCT02885948|Drug|Placebo|Placebo, ineffective control arm
1511071|NCT02885935|Other|Recommended protein intake|Recommended protein intake diet contained 10% protein, 55% carbohydrate,and 35 % fat.
1511072|NCT02885935|Other|Elevated protein intake|Recommended protein intake diet contained 20% protein, 45% carbohydrate,and 35 % fat.
1511073|NCT02885922|Drug|anti-diabetic drug|Add-on anti-diabetic drug in type 2 diabetic patients
1511074|NCT02885909|Device|CONTINUE GLUCOSE MONITOR|Continue glucose monitor
1511075|NCT02885909|Procedure|Insulin protocal|Using insulin protocal based on glucose monitor
1511076|NCT02885883|Device|MRI 3T|
1511077|NCT02885870|Procedure|Combination of multiparametric MRI and electrophysiology|MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis
1511078|NCT02885857|Drug|Shenyan Kangfu Tablet|Observation period: 24 weeks. The dosage regimen: each piece weighs 0.48 g. 5 / time, 3 times daily, orally after dinner.
1511079|NCT02885844|Procedure|INVERTED VISION|The tasks will be performed either with normal or inverted vision (upside down) using commercial off-the-shelf inverting prism goggles
1511080|NCT02885844|Procedure|NORMAL VISON|subject's field of view will be restricted by goggles without lenses in order to be equivalent to the inverted vision one.
1511081|NCT02885831|Device|Abduction splintage|Treatment by abduction splintage 24 hours a day and 7 days a week, for 2 months.
1511082|NCT02885805|Drug|BAY987516|2.00 mg/cm2 ± 0.04 mg/cm2
1511083|NCT02885805|Drug|SPF 15 Control|2.00 mg/cm2 ± 0.04 mg/cm2
1511084|NCT02885792|Other|Illness history|Existing psychiatric and somatic diagnosis and treatment. Charlson co-morbidity Index.
1511085|NCT02885792|Other|Measure of social conditions|A self-report questionnaire measuring social isolation, including relations to family and friends.
1511086|NCT02885792|Other|Measure of psychiatric condition|This method measures symptom severity, therapeutic response and general improvement, suicidal ideation, cognitive insight and awareness of illness and need for treatment and the ability to relabel symptoms.
1511087|NCT02885792|Procedure|Cardiovascular measurement|This procedure is used to detect early identification of cardiovascular disease progression.
1511088|NCT02885766|Drug|PF-114|
1511089|NCT02885753|Drug|Oxaliplatin intravenous|85 mg/m² in intravenous. 1 cycle each 15 days
1511092|NCT02885753|Drug|Oxaliplatin intra-arteriel|85 mg/m² in intra-arterial. 1 cycle each 15 days
1511093|NCT02885753|Drug|Panitumumab|Only for patient RAS wild: 6 mg/Kg at each cycle in intravenous
1511094|NCT02885753|Drug|Bevacizumab|Only for patient RAS mutated : 5 mg/m² at each cycle in intravenous
1511095|NCT02885740|Other|Quantification assay of adenosine and methionine cycle metabolites|
1511096|NCT02885740|Genetic|Polymorphism analysis of genes related to adenosine metabolism and methionine cycle|
1511097|NCT02885740|Other|Quantitative and qualitative nutritional evaluation|Questionnaire on consumption of 208 foods and drinks
1511098|NCT02885740|Biological|Blood sample|
1511099|NCT02885727|Drug|Durvalumab|Evaluate if the combination of RT and durvalumab can improve median PFS compared to chemotherapy historical control data in metastatic pancreas cancer patients who have progressed through first-line chemotherapy
1511100|NCT02885727|Radiation|Radiation Therapy|The primary intent of RT in this study is to augment a pancreatic cancer-specific immune response when given with durvalumab.
2003135|NCT00843193|Drug|FLUTICASONE PROPIONATE|Subjects will be supplied fluticasone propionate at Screening, Run-in and when needed during the study. Subjects will be up-titrated to 1000 μg/day and those who were already taking greater than equal to 1000 μg/day fluticasone propionate or equivalent prior to the study will remain on their pre-study dose.
2003136|NCT00816114|Other|Chart Review|Investigator review of MDACC CML patient charts.
1511103|NCT02885701|Other|No Splint|The no splint group received a soft dressing consisting of an occlusive petroleum gauze strip (Xeroform, Mansfield, MA) over the wound, one folded 4x4 gauze, and a single wrap of roll gauze around the hand, and the wrist was placed and secured by a Coban wrap (3M, St. Paul, MN). The dressing permitted wrist and finger motion. Patients were further instructed to remove the dressing at five days and place an adhesive bandage (Band-Aid, Johnson & Johnson, New Brunswick, NJ) over the incision.
1511104|NCT02885701|Other|Removable Splint|The removable splint group received a V-strap Wrist support (Medical Specialties, Inc., Charlotte, NC) placed over the identical soft dressing that was placed on the no splint group. The cock-up wrist splint was designed to keep the wrist fixed in a 20 degree extended wrist position. Patients were instructed to wear the splint for comfort as needed during day and night. While the patient was wearing the cock-up splint, only finger motion was permitted. Wrist motion was permitted when the cock-up splint was removed.
1511105|NCT02885701|Other|Non-removable Splint|The plaster non-removable splint group received an occlusive petroleum gauze strip placed over the wound, followed by a 4X4 gauze, and a Webril cotton roll wrap (Covidien, Inc., Covidien, Ireland). A 4- inch, 15-layer thick plaster splint was placed across the volar wrist and molded to keep the wrist in approximately 20 degrees of extension allowing full digital range of motion (ROM). The splint was to be kept dry and not removed by the patient.
1511106|NCT02885688|Dietary Supplement|Liquid Nutrition|Participants receive liquid nutrition by vein non-stop for up to 7 days.
1511107|NCT02885688|Procedure|Insulin Drip|"Insulin drip by vein to keep serum glucose level between 140 and 180 mg/dL as per ICU protocol.
The interventions required in the current standard management of patients with septic shock is based on the MD Anderson Evidence-Based Protocol (EBP) for management of Severe Sepsis initiated on admission to the ICU."
1511108|NCT02885675|Other|blood sampling|sample no more than 3ml
1511109|NCT02885662|Drug|CS-3150|CS-3150 2.5 to 5.0 mg , orally.
1511110|NCT02885649|Drug|Enzalutamide|Given PO
1511111|NCT02885649|Other|Laboratory Biomarker Analysis|Correlative studies
1511112|NCT02885649|Procedure|Nephrectomy|Undergo partial or radical nephrectomy
1511113|NCT02885636|Drug|Albuterol|": Experimental: Inhaled albuterol
2.5 mg inhaled albuterol through a high efficiency nebulizer as a single dose"
1511114|NCT02885636|Other|Saline placebo|Saline inhaled through a nebulizer as a single dose
1511115|NCT02885610|Biological|Placebo plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
1511116|NCT02885610|Biological|RC18 80 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
1511117|NCT02885610|Biological|RC18 160 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator herapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
1511118|NCT02885610|Biological|RC18 240 mg plus standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive and immunomodulator therapy(i.e.,azathioprine,mycophenolate ,cyclophosphamide,methotrexate,leflunomide, Tacrolimus ,ciclosporin )
1511119|NCT02885597|Drug|Juanbi pill|4g, twice a day, 3month, oral
1511120|NCT02885597|Drug|Juanbi pill placebo|4g, twice a day, 3month, oral
1511121|NCT02885597|Drug|Methotrexate|5mg, once a week, 3 month, oral
1511122|NCT02885584|Device|High frequency percussive ventilation|
1511123|NCT02885571|Device|SomnoDent Flex with DentiTrac|
1511124|NCT02885558|Drug|L + T-type|8 weeks treatment with either efonidipine
2003137|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 0% of MF59.
2003138|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 25% of MF59.
2003139|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 50% of MF59.
2003140|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 3.75_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 3.75 µg Subunit Influenza Vaccine containing 100% of MF59.
1511126|NCT02885545|Device|Watchman|If the patient is randomized to the Intervention Arm of the study the Watchman device will be implanted into the left atrial appendage of the heart
1511127|NCT02885545|Drug|Continued therapy with the prescribed oral anticoagulant|If the patient is randomized to the control arm of the study, they will continue taking the oral anticoagulant that has been prescribed (vitamin K antagonist, Apixiban 2.5mg bid or Rivaroxaban 15mg od)
1511128|NCT02885532|Other|University of California, San Diego Brief Assessment of Capacity to Consent Tool|Non-pregnant, English speaking patients older than 18 with evidence of acute alcohol intoxication were considered eligible for participation. Patients were asked to complete the 10 question tool on arrival to the emergency department. Patie
1511129|NCT02885519|Behavioral|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.
Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists and medical doctors) with the treatment modalities:
Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment"
1511130|NCT02885519|Behavioral|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).
Mental health care is provided according to a stepped care model with the following treatment modalities:
Psychoeducation Bibliotherapy Stress-coaching Mindfulness-based stress reduction Monitoring and re-assessment
Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
1511131|NCT02885506|Drug|Oral administration of P218 capsules|Oral administration of P218 capsules. The number of capsules is determined by the dose level of the cohort.
1511132|NCT02885506|Drug|Oral administration of P218 matching placebo.|Oral administration of P218 matching placebo. The number of capsules is identical to the corresponding number of P218 capsules administered to the volunteers on the investigational drug.
2003141|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 0% of MF59.
1511134|NCT02885480|Behavioral|questionnaires|
1511135|NCT02885467|Procedure|Total knee arthroplasty with Saphenous nerve burial|
1511136|NCT02885467|Procedure|Standard total knee arthroplasty|
1511137|NCT02885454|Drug|Drospirenone/ethinylestradiol|Each tablet contains 3 mg drospirenone and 0.02 mg ethinylestradiol to be taken orally on Days 1, 6, 25, and 32.
1511138|NCT02885454|Drug|AL-335|AL-335 (800 mg) tablet once daily on Days 5-7 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
1511139|NCT02885454|Drug|Odalasvir (ODV)|ODV 25 mg tablet once daily on Days 12-25 and then on Days 26-32 (as a component of 3-DAA combination) to be taken orally.
1511140|NCT02885454|Drug|Simeprevir (SMV)|SMV 75 mg capsule as a component of 3-DAA combination to be taken orally on Days 26-32.
2003142|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 25% of MF59.
1511143|NCT02885428|Device|echography|
1511144|NCT02885415|Procedure|Gastrointestinal surgery|Major resectional gastrointestinal surgery (define as resection of part of gastrointestinal tract during esophageal, Gastric or colorectal surgeries)
1511145|NCT02885402|Other|MRI Sodium ( 23Na )|
1511146|NCT02885376|Device|Dentoxol|Mouthrinse
1511147|NCT02885376|Device|Placebo|Mouthrinse
1511148|NCT02885363|Other|Clinical examination|
1511149|NCT02885363|Other|Blood sample|
1511150|NCT02885363|Procedure|Echocardiography|
1511151|NCT02885350|Drug|Spinal analgesia for labour pain|Intrathecal dose of either fentanyl or sufentanil delivered by combined spinal-epidural technique
1511152|NCT02885350|Drug|Epidural analgesia for labour pain|Epidural dose of either fentanyl or sufentanil delivered through an epidural catheter.
1511153|NCT02885337|Other|Multi-Modal Frailty Intervention|"Exercise: A Kinesiologist will develop an individualized exercise program and schedule appointments with the patient at home including goal setting discussion. Participants will be offered free YMCA membership.
Cognitive-behavioural Change Strategy(CBCS) and education: CBCS may be an effective way to facilitate coaching strategies to increase participant exercise levels. Throughout the intervention, CBC and education about exercise, hip arthroplasty and osteoarthritis will be administered.
Protein Supplement: Participants will be provided with twice-daily supplements (containing 20 gram protein, 1.5 g β-Hydroxy β-Methylbutyrate /serving) to be taken with a meal or on activity days within 3-hours of exercise.
Vitamin D: All participants in the intervention arm will be provided with a supply of Vitamin D3 (1000 IU/day tablets) for the duration of the intervention period.
Medication Review: A geriatrician will review the medications for patients in the intervention arm."
1511154|NCT02885337|Other|Usual Care|"Patients in the control arm will receive usual care which may include the recommendation to attend fitness classes before surgery, however these patients will not receive the more intensive assessment/intervention of the Kinesiologist and other intervention components. Control participants will be asked pre-operatively and post-operatively to indicate whether or not they exercise, take protein or vitamin supplements.
For participants in intervention and control groups will, 1) we will monitor the YMCA attendance and 2) participants will be instructed on the completion a dietary intake log (including days of the week and weekend days) that indicate the type of food and amount over a four-day period in order to calculate energy and micronutrient consumption."
1511155|NCT02885324|Drug|Cabozantinib|Subjects will receive Cabozantinib
1511156|NCT02885311|Behavioral|Motivation Enhancement Therapy|Motivation Enhancement Therapy (MET) similarly allows for goal choice in treatment, and has been shown to be effective in treating a broad spectrum of drinking problems in both abstinent and non-abstinent goal conditions. The unique goals of MET (enhancing intrinsic motivation for change and facilitating development of a self-generated change plan).
1511157|NCT02885311|Behavioral|Modified Behavioral Self-Control Therapy|Motivational Interviewing was developed to increase self-efficacy and motivation for drinking, and Cognitive Behavioral Therapy allows for individuals to develop strategies for drinking reduction. Both are evidence-based interventions that have been combined in previous studies for drinking reduction in problem drinkers.
1511778|NCT02880228|Drug|Lenalidomide|Given PO
1511158|NCT02885311|Drug|Naltrexone|Participants, who choose medication treatment, will be offered naltrexone (50 mg per day), which is an FDA-Approved medication for alcohol use disorder. According to the package insert for NTX, the medication has been associated with liver toxicity at very high doses (up to 300 mg/day); however, a number of clinical trials and published studies suggest there are few serious adverse effects, including minimal hepatotoxicity, associated with daily dose of 50 mg of naltrexone. Its most common side effects in opioid-free individuals are nausea, vomiting, anxiety, headache, abdominal discomfort, difficulty sleeping, fatigue, irritability, and decreased appetite. A rare serious adverse effect may include minimal liver toxicity, but is more likely to occur at very high doses (300 mg/day).
1511159|NCT02885311|Behavioral|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
1511160|NCT02885311|Other|Referral to specialty substance use disorder treatment|Participants who present with complex drinking concerns will be referred to specialty substance use disorder treatment. This treatment will be provided in a separate treatment facility that focuses on substance use disorders and will potentially provide a combination of medication management and individual/group behavioral treatment for substance use disorders.
1511161|NCT02885298|Procedure|Upright intubation|Upright Intubation procedure performed with patient elevated above the supine position. Defined as upright greater to or equal to 45 degrees or inclined 10-44 degrees
1511162|NCT02885285|Behavioral|Spinning Class|Spinning Class twice a week for six weeks.
1511163|NCT02885285|Behavioral|Yoga Class|Yoga Class twice a week for six weeks.
1511164|NCT02885285|Behavioral|Dance Class|Dance Class twice a week for six weeks.
1511165|NCT02885285|Other|No Exercise Class|No exercise class. Subject will continue regular activities for six weeks.
1511166|NCT02885272|Drug|FDG|10 mCi (370 MBq) of FDG administered by vein prior to imaging.
1511167|NCT02885272|Procedure|PET/CT|"At one-hour post FDG administration, participant moved to the PET/CT system and a brain + whole body scan (standard of care) acquired.
Participant has 2 more FDG PET-CT scans at 4 - 5 hours and at 7 - 8 hours after receiving the contrast drug."
1511168|NCT02885272|Procedure|MRI|Standard of care MRI of brain performed after FDG administration and brain and whole body scan done.
1511169|NCT02885259|Drug|rHuPH20|human immunoglobulin and one vial of recombinant human hyaluronidase
1511171|NCT02885233|Behavioral|Free From Falls Online|Subjects in the active group will participate in the Free From Falls Online Program consisting of 8 weekly 30 minute webinars providing education about risk factors for falls and fall prevention strategies; self-assessment exercises to evaluate understanding of the material; video-based exercise program targeting balance, posture, strength and flexibility to be performed at least 3 times per week; supplementary, downloadable printed material for both education and exercise; and a social forum to allow participants to interact with each other.
1511172|NCT02885233|Behavioral|Waitlist Control|"Subjects in the waitlist control condition will receive an educational brochure developed by the National Multiple Sclerosis Society called Minimizing Your Risk of Falls: A Guide for People with MS, which includes information on identifying risk factors for falling and fall risk management approaches with no exercise component; will inform their provider that they have fallen at least twice in the previous 2 months and discuss subsequent falls over the course of the 5-month study; and will be invited to participate in the Free From Falls Online Program at study completion."
1511173|NCT02885220|Other|Conventional Program|No scheduled intermediate weight loss goals provided to patient
1511174|NCT02885220|Other|Goal-directed Program|Scheduled program with intermediate weight loss targets reinforced to patients during follow up.
1511175|NCT02885207|Biological|Focal epilepsy of unknown cause|"Male or female 18-65 years presenting focal epilepsy on the following arguments:
Crisis with clinical symptoms indicating focal seizure
& / Or crisis or critical focal inter-recorded EEG interpreted by a neurologist with expertise in the field of epilepsy.
From unknown cause:
No evidence of injury (excluding temporal or hyperintensity of hippocampal sclerosis) on brain MRI with focus on regions of interest cuts.
No discharge or generalized photosensitivity recorded over an extended interpreted by a neurologist with expertise in the field of epilepsy video-EEG.
No argument for metabolic or neurodegenerative genetic epilepsy.
Normal neurological examination. Epilepsy that started within a maximum period of 2 years prior to inclusion in the study (including vegetative symptoms of temporal focal seizures).
Without treatment by benzodiazepines or anti-epileptics first-line monotherapy (excluding benzodiazepines)."
1511176|NCT02885194|Other|Laser-Evoked potential|Laser-Evoked potential can document lesions of spinothalamic tract and lateral brainstem and of thalamo-cortical projections conducting nociceptive signals. The rapid heating of skin by infrared laser pulses stimulate small fibers sensory pathways. The main cortical laser evoked potential is a complex of components N2-P2. Evaluation of the registered potentials includes shape, latency and amplitude.
1511177|NCT02885181|Drug|GS-9876|Tablets administered orally once daily
1511178|NCT02885181|Drug|Filgotinib|Tablets administered orally once daily
1511179|NCT02885181|Drug|GS-9876 placebo|Tablet administered orally once daily
1511180|NCT02885181|Drug|Filgotinib placebo|2 tablets administered orally once daily
1511181|NCT02885181|Drug|Methotrexate|Background therapy with methotrexate administered orally or parenterally once weekly
1511182|NCT02885168|Drug|Recombinant Activated Protein C|24 μg/kg/h during 96 hours - intravenous injection
1511183|NCT02885168|Device|Near-infrared spectroscopy (NIRS)|After baseline measurement, cuff is blown up to obtain a muscular saturation at 40% and then deflated. Reactive hyperthermia is measured. It is considered as an index for endothelial function.
1511184|NCT02885168|Drug|Phenylephrine|"Continuous administration of phenylephrine with electric syringe with increasing dosing levels: 0.0; 0.02; 0.05; 0.1; 0.2; 0.5; 0.75; 1.00; 1.50; 3.00; 4.50; 6.00; 9.00 et 12 µg/kg/min. Each level is maintained for 5 minutes. Administration of phenylephrine is stopped progressively with the same schema.
Arterial tension through an invasive approach is measured during the test."
1511304|NCT02884037|Drug|Rifaximin group 1|Rifaximin: 1100mg/day, 550 mg tablets 1 × 2 before meals
1511185|NCT02885168|Biological|Blood sample|Analysis of inflammation and cellular adhesion markers and free radicals
1511186|NCT02885155|Other|Echocardiography|planned at regular intervals
1511187|NCT02885155|Other|Hemodynamic examinations (right cardiac catheterization)|planned at regular intervals
1511188|NCT02885142|Procedure|Local excision for early rectal cancer|
1511189|NCT02885116|Device|Nasal high flow (NHF) supplementation|use of NHF for 20 min/ 35 l/min, at the end of this period right heart catheterization
1511190|NCT02885116|Device|oxygen supplementation|hypoxemic patients will use their normal oxygen supplementation durch right heart catheterization
1511191|NCT02885103|Device|Nasal high flow (NHF)|NHF will be combinated with a nebulizer. Inhalation will be done on nasal cavity.
1511192|NCT02885103|Device|Nebulizer|Inhalation will be done will Nebulizer and via mouth
1511193|NCT02885090|Procedure|Blood sampling|In children: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml and 2 PAXgene tubes of 2.5 ml (max 0.8-0.9 ml blood/kg) In parents: 2 EDTA tubes of 7 ml, 1 Heparin Li tube of 5 ml.
1511194|NCT02885077|Device|High-intensity IMT + combined exercise|
1511195|NCT02885051|Procedure|Recording of skin conductance and heart rate variability.|When a procedure of care will be prescribed, installation of the electrodes of measure of the cutaneous conductance on the foot and connection of the NIPE monitor to the cardio-respiratory monitor of the child used in routine. At this stage, beginning of the video recording.
1511196|NCT02885038|Other|Platelet concentrate transfusion|
1511197|NCT02885025|Dietary Supplement|Broccoli Sprout Extract|Broccoli Sprout Extract contains the antioxidant Sulforaphane which is the active ingredient being studies.
1511198|NCT02885025|Drug|fluticasone nasal|fluticasone is a nasal steroid that is currently approved for treatment of allergic rhinitis.
1511199|NCT02885025|Dietary Supplement|brocooli sprout extract placebo|a tablet similar to the actual broccoli sprout extract though without BSE.
1511200|NCT02885025|Drug|normal saline nasal spray|normal saline to replace nasal fluticasone in specific arms of the study
1511201|NCT02885012|Drug|Ambrisentan|At entry to the study following the screen visits, patients will be switched from bosentan to ambrisentan to complete a 24 week trial. The only study intervention will be ambrisentan.
1511202|NCT02884986|Drug|Etoricoxib|120mg of oral etoricoxib under the brand name Arcoxia® (Merck Sharp & Dohme) one hour prior to spinal anaesthesia induction
1511203|NCT02884986|Drug|Placebo|120mg of placebo
1511204|NCT02884960|Procedure|Uterine Fibroid Embolization|This procedure involves the administration of the study device into the uterine arteries to block the flow of blood in these vessels. This deprives fibroid tumors within the uterus of their blood flow, which can cause the tumors to die. This in turn can lead to the relief of symptoms associated with fibroids.
1511205|NCT02884921|Drug|Paracetamol|Paracetamol
1511206|NCT02884921|Drug|Paracetamol|Paracetamol
1511207|NCT02884921|Drug|Placebo|Placebo
1511208|NCT02884908|Drug|Pregabalin plus BBCET|Medication; BBCET = Brief Behavioral Compliance Enhancement Treatment
1511209|NCT02884908|Other|Placebo plus BBCET|Placebo; BBCET = Brief Behavioral Compliance Enhancement Treatment
1511210|NCT02884895|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction Disposable
1511211|NCT02884895|Device|Direct Laryngoscopy|Direct Laryngoscopy
2003143|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 50% of MF59.
1511213|NCT02884869|Device|Intubating Laryngeal Mask|Direct laryngoscopy
1511214|NCT02884843|Device|Intubation laryngeal Tube Suction|Intubation laryngeal Tube Suction
1511215|NCT02884843|Device|AuraGain Laryngeal Mask|AuraGain Laryngeal Mask
1511216|NCT02884830|Device|continuous positive airway pressure|positive airway pressure given by a medical device through a nasal mask
1511217|NCT02884817|Drug|Experimental: essential oils and ELA|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the Experimental solution, Listerine Gum Therapy. This oral hygiene routine was repeated for 21d.
1511218|NCT02884817|Other|Placebo|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the 21.6% hydroalcoholic solution. This oral hygiene routine was repeated for 21d.
1511219|NCT02884817|Other|Water|The participants were instructed to insert the tooth guard in Q1 every time they brushed their teeth and to perform a mechanical oral hygiene routine twice a day in the three other quadrants. After brushing properly, they were instructed to rinse for 30s with water before removing the tooth guard. And then rinse again for 30s with water without the mouth guard. Following this procedure the participants rinsed, as instructed, with the sterile water, sham comparator. This oral hygiene routine was repeated for 21d.
1511220|NCT02884791|Dietary Supplement|oral carbohydrate challenge|Participants will fast for 8 hours and then drink a beverage containing fructose.
1511221|NCT02884778|Device|Device PMD200TM offering intraoperative NoL Index|We will evaluate the changes of the NoL index absolute values after different types of stimulations such as intubation, surgical incision and electrical tetanic stimulation of the forearm (applied with the standard muscle relaxation monitor) in a patient under general anesthesia + epidural anesthesia for abdominal surgery
1511222|NCT02884765|Procedure|Non-surgical|Non-surgical treatment in both condylar fractures
1511223|NCT02884765|Procedure|Non-surgical / Surgical|Non-surgical treatment in one condylar fracture and surgical treatment of the contralateral fracture
1511224|NCT02884765|Procedure|Surgical|Surgical treatment in both condylar fractures
1511225|NCT02884739|Other|Data collection|
1511779|NCT02880228|Biological|Pembrolizumab|Given IV
1511227|NCT02884713|Drug|Levofloxacin|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
1511228|NCT02884713|Drug|Doxycycline|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
1511229|NCT02884713|Drug|Esomeprazole|The primary objective was to evaluate the efficacy of the 10-day course of levofloxacin, doxycycline and esomeprazole in non-responders to first-line therapies for H. pylori eradication in Saudi Arabia. Secondary objectives included; symptoms response to treatment, factors associated with eradication of H. pylori and adverse events associated with the treatment
1511230|NCT02884700|Biological|Real-time PCR testing of lower respiratory tract samples|qPCR and high-throughput DNA sequencing testing of lower respiratory tract samples collected routinely in patients with severe legionellosis
1511231|NCT02884674|Device|Active Repetitive Transcranial Magnetic Stimulation|modulation of the electrical activity of the right inferior frontal gyrus cortex in order to reduce Obsessive Compulsive Disorders symptoms by Active Transcranial Magnetic Stimulation (TMS) targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using theta burst stimulation and using a TMS neuronavigated robot
1511232|NCT02884674|Device|Placebo Repetitive Transcranial Magnetic Stimulation|Sham rTMS will be delivered using non active magnetic coil, targeting the right frontal inferior gyrus, 2 sessions per day, each session 5min30 day, during 10 consecutive days, using TMS neuronavigated robot. A subjective sensation will be obtained via frontal dermic electrical stimulation.
1511233|NCT02884648|Drug|Bevacizumab|15 mg/kg by vein on Day 1 of every 21-day study cycle.
2003144|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 7.5_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 7.5 µg Subunit Influenza Vaccine containing 100% of MF59.
2003145|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_0%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 0% of MF59.
1511236|NCT02884622|Other|nasal epithelial|CF patients with the same procedures as in the usual management of routine care, only the sampling nasal epithelial cells will be added
1511237|NCT02884622|Other|Blood sampling|CF patients with the same procedures as in the usual management of routine care, only the sampling 5ml additional blood will be taken
1511238|NCT02884596|Drug|selective serotonin reuptake inhibitor|Taking any type of SSRI medicaments
1511239|NCT02884583|Other|Pulmonary function test|Patients hospitalized for OFC realise a Resting pulmonary function tests (PFT) which include the assessment of ventilatory capacity: spirometry (forced expiratory flows and mobilisable volumes) and static volume assessment, by using body plethysmography, were realized before, during and after the OFC. An exhaled fraction of NO (FeNO) is also realized to characterize asthma.
1511240|NCT02884570|Other|Auto-Questionnaires|Consents and questionnaires will be sent to the parental home or filled in an interview with an investigator (or telephone consultation).
1511241|NCT02884557|Other|collection of gut biopsies collection of blood samples|Four to eight colon biopsies will be sampled during endoscopy. Thirty milliliters of blood will be sampled.
1511242|NCT02884544|Drug|HLD100|Treatment
1511245|NCT02884518|Device|PET|Subjects in the patient group will receive a reduced intake of antipsychotics by 25% after each week of the four-week period in which they and healthy controls will also undergo PET imaging at the baseline, 7 week, and 8 week marks to detect the correlation between the capacity of presynaptic dopamine and relapse in the patients discontinuing treatment.
1511246|NCT02884518|Behavioral|clinical scale|Healthy controls should complete clinical scales at baseline. Patient group should complete clinical scales at 0, 2, 4, 6, and 8 week.
1511247|NCT02884505|Device|Pupillometry|Measures pupillary dynamics in darkness and light conditions
1511248|NCT02884505|Behavioral|Psychomotor Vigilance Task|Response time task measuring neurobehavioral alertness
1511249|NCT02884505|Other|Auditory Evoked Potential|Measure of electroencephalographic response to standardized auditory tones
1511250|NCT02884505|Behavioral|Hypersomnia Severity Index|Self-report measure of hypersomnolence
1511251|NCT02884492|Drug|18F-THK- 5351|18F-THK-5351 is a PET radioligand that binds abnormal tangles made of the protein tau. These tau tangles develop in the brain in people with Alzheimer's disease.
1511252|NCT02884492|Procedure|Lumbar Puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of Alzheimer's disease biomarkers in cerebrospinal fluid.
1511253|NCT02884479|Drug|PT-112|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
1511254|NCT02884479|Drug|Docetaxel|Increasing doses of intravenously administered PT-112 in combination with 60 mg/m2 docetaxel every 3 weeks (Q3W) in subjects with advanced solid tumor of any histological type.
1511255|NCT02884466|Behavioral|Multidisciplinary rehabilitation intervention|Both groups will receive examination and medicine adjustment from a rheumatologist, and treatment from physiotherapist, occupational therapist and nursing staff, respectively. The multidisciplinary rehabilitation intervention in both groups will be based on the biopsychosocial model of illness. The inpatient stays of 8-10 hours per day will consist of 1) group tuition, 2) group and individual treatment and 3) unassisted training sessions.
1511256|NCT02884453|Drug|ibrutinib|Ibrutinib (PCI-32765) is a first-in-class, potent, orally-administered, covalently-binding small molecule inhibitor of Bruton's tyrosine kinase (BTK) currently under development for the treatment of B-cell malignancies. Ibrutinib is being co-developed by Janssen Research & Development, LLC and Pharmacyclics Inc.
1511257|NCT02884440|Drug|TAP block ropivacaine|
1511258|NCT02884440|Drug|TAP block placebo|
1511259|NCT02884440|Drug|General anesthesia|Induction PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml CISATRACURIUM 2mg/ml if necessary DEXAMETHASONE 8 mg KETAMINE 0,15mg/kg Maintenance PROPOFOL 10mg/ml REMIFENTANIL 50 μg/ml
1511305|NCT02884024|Other|no intervention|there is no intervention in this study
1511260|NCT02884427|Device|Cathode stimulation|Electrical stimulation through the cathode or negative pole, in which a peripheral nerve will be subject to the passage of a direct current seeking increased excitability and conductivity during the passage of current.
1511261|NCT02884427|Device|Anode stimulation|Electrical stimulation through the anode or positive pole, in which a peripheral rib will be subjected to the passage of a direct current seeking to reduce excitability and conductivity during the passage of current.
1511262|NCT02884427|Device|Placebo|Current application without the actual electric conduction to the person occurs. This will be achieved by adjusting parameters while installing another channel and not one that is working.
1511263|NCT02884414|Device|Cutaneous stimulation|A non-invasive external device that will be placed on the leg of the subject. The device consists of a sensing module to determine specific points in the gait cycle, a processor to analyze signal from the sensor, and a stimulus module to provide feedback to the subject.
1511264|NCT02884401|Device|Dental implant placement (Straumann® Bone Level Tapered, BLT, Roxolid® SLActive®)|A tapered bone level implant (Straumann® BLT Roxolid® SLActive®, Basel, Switzerland) will be placed according to the manufactures guidelines trying to achieve primary stability in the correct prosthetic position
1511265|NCT02884388|Procedure|combined nerve block|Patients in this group were assigned to receive lower lumbar plexus block, sciatic nerve block, and paraspinal nerve L1-2 block.
1511266|NCT02884388|Procedure|general anesthesia|Patients in this group were assigned to receive general anesthesia.
1511267|NCT02884375|Other|Extensive GA|"GA includes an evaluation of nine domains according to international recommendations :
functional status (six-item Activities of Daily Living (ADL) score, Instrumental Activities of Daily Living (IADL))
mobility (timed get-up-and-go test, one-leg standing balance test, history of fall)
nutritional status (French National Authority of Health guidelines, weight loss body mass index (BMI), Mini Nutritional Assessment, albumin )
cognitive status (Mini-Mental State Examination (MMSE), history of dementia, confusion)
mood (Mini-Geriatric Depression Scale (Mini-GDS), symptoms of anxiety, depression (DSM V))
comorbidities (CIRS G)
polypharmacy (number of medications)
social environment (primary caregiver, support at home, friends , family, living alone)
urinary and/or fecal incontinence"
1511268|NCT02884362|Other|clinical biological data collection on melanoma|collection and centralization of clinical and biological data of patients with melanoma
1511269|NCT02884349|Procedure|RoM assessment|This group will have a CT scan at three months post-operatively instead of the two radiographs, an anterior/posterior pelvis view and a lateral hip view, which are standard care. They will also have a RoM assessment session in the movement analysis laboratory in the hospital at the same time point lasting about one hour, which is additional to standard care.
1511270|NCT02884336|Other|No intervention|
1511271|NCT02884323|Device|geko™ device|The geko™ (T-2 and R-2) devices are small disposable, internally powered, neuromuscular stimulators that are applied externally to the leg.
1511272|NCT02884310|Drug|Remifentanil adapted to SPI|
1511273|NCT02884310|Drug|Remifentanil fixed|
1511274|NCT02884297|Drug|Contrast agent: SonoVue®.|SonoVue® Injection: will be done through the peripheral venous way already set up by the anesthetist for its injection. None venous dedicated way will be established. The injection will take place when the woman will be under general anesthesia, ventilated and under constant cardio-respiratory monitoring.
1511275|NCT02884284|Other|clinical biological database collection|
1511276|NCT02884271|Procedure|cardiopulmonary resuscitation|start cardiopulmonary resuscitation
1511277|NCT02884245|Drug|Estrogens|The estrogens pretreatment will began between the day 20 and the day 24 of an ovarian cycle and should be continued until Wednesday beyond the onset of menses
1511278|NCT02884232|Procedure|Nasofibroscopy|
1511279|NCT02884219|Drug|Ibuprofen|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
1511280|NCT02884219|Other|Expectative Management|Expectative PDA management is characterized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
1511281|NCT02884219|Drug|Indomethacin|In the medical treatment (COXi) arm the intention is to close the ductus arteriosus.
1511286|NCT02884193|Procedure|Brief Cooling|Brief Application of cold, for a period of up to 30 seconds on a body surface which seeks to promote the activation of the nervous system to produce increased excitability.
1511287|NCT02884193|Procedure|Prolonged Cold|Prolonged application of cold, for at least 5 minutes or more, on a body surface that aims to reduce nervous system activation by reducing the NCV.
1511288|NCT02884193|Procedure|Sham Ice Bag|"Placebo application through an ice bag empty."
1511289|NCT02884180|Drug|Dexamethasone|A dose of 24 mg dexamethasone given after start of anaesthesia
1511290|NCT02884180|Drug|Saline isotonic|A dose of 6 ml of isotonic saline given after start of anaesthesia
1511291|NCT02884154|Device|Echotip ProCoreⓇ HD Ultrasound Biopsy Needle|
1511292|NCT02884128|Drug|PEP02|PEP02 was administered on Day 1. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
1511293|NCT02884128|Drug|5-FU|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
1511294|NCT02884128|Drug|LV|5-FU/LV were started after the end of PEP02 infusion on Day 1 and also on Day 8. Treatment repeated every 3 weeks and it was regarded as one cycle of treatment.
1511295|NCT02884115|Drug|benzathine penicillin|
1511296|NCT02884102|Genetic|genetic sequencing|
1511301|NCT02884063|Procedure|NGS reading for Media Free DNA|NGS reading for Media Free DNA instead of blstomer biopsy
1511302|NCT02884050|Drug|Topiramate|antiepilepsy drug
1511306|NCT02883998|Other|Outpatient Physical Therapy|traditional outpatient physical therapy which occurs at a physical therapy office
1511307|NCT02883998|Other|Home Base Physical Therapy|Patients will be provided a packet of exercises via a website which allows access to instructional physical therapy videos specifically designated for UKA patients and equipment to perform the home based physical therapy
1511308|NCT02883985|Radiation|6 Gy/ fraction|"All patients will be treated with 6 Gy (measure of radiation dose) /fraction (each radiation session) delivered in 5 fractions over a 2 week period for a total dose of 30 Gy.
In addition to routine care, patients may receive antihormonal drugs as part of your base line treatment."
1511309|NCT02883972|Other|Intervention letter|Behavioural-insight informed letter template
1511310|NCT02883972|Other|Control letter|Invitation letter used by local area last year (updated as required)
1511311|NCT02883972|Other|Reminder|Behavioural-insight informed SMS/email reminder message to return consent form
1511312|NCT02883959|Other|music therapy|Music therapy will be delivered through headphones during nursing procedures (toilet and/or surgical dressings): from initiation up to 30 minutes after the end of procedure.
1511313|NCT02883946|Other|Data collection|
1511314|NCT02883933|Other|Data collection|
1511315|NCT02883920|Other|Allergy and respiratory functional tests|
1511316|NCT02883894|Other|Blood sample for dosages of cytokines (IL-17 and IL-23) and of the protease MMP-9|
1511317|NCT02883842|Behavioral|Text messaging|Patients will receive regular semi-personalized text messages for 6 months. Each participants will receive 6 text messages per week, which will be sent at random times of the day (9.00am, 12noon, 4.00pm). They will receive one general messages, one hypertension message, one glucose control message, one lifestyle message, one medication adherence message and one physical activity message per week. Prior to study commencement, a bank of 270 messages have been developed based on guidelines and behavior change theory (BCT), and have underwent multidisciplinary expert review and qualitative review process.
1511318|NCT02883829|Behavioral|Peer-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a peer-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
1511319|NCT02883829|Behavioral|Provider-Based Web-Based Health Information|The intervention will be a brief vignette to present educational content about alcohol use risks for Type 1 Diabetes; framed and delivered from a provider-based source. The content for the intervention will be drawn on existing theories of behavior change, including the concepts of 'consciousness raising', 'self-reevaluation' and 'helping relationships'. The intervention will comprise of PowerPoint slides for final implementation as a narrated video that can be posted to a website for participant viewing.
1511320|NCT02883816|Other|assessment of lung function|measurement of lung volumes and flow rates of bronchial
1511321|NCT02883803|Biological|Injection of mesenchymal stem cells|
1511322|NCT02883803|Biological|Injection of albumin alone|
1511323|NCT02883790|Dietary Supplement|Somnage|Melatonin 1mg, Zinc, Magnesium
1511324|NCT02883790|Other|Placebo|Placebo
1511325|NCT02883777|Behavioral|High Protein and Low Glycemic Index Diet|It will be evaluated a type of high protein diet with 1,3g/kg/day in kidney transplant recipients over 1 year after transplantation.
1511326|NCT02883777|Behavioral|Conventional Diet|Conventional diet over 1 year after transplantation.
1511327|NCT02883751|Radiation|LED|A device with 36, rectangular, red LEDs, registered with the Brazilian National Health Surveillance Agency (ANVISA authorization nº 8.04554.6), λ = (650 ± 20) nm, with an output power of 324 mW and an output area of 2.54 cm2 (Cosmedical, Brazil), will be enveloped with sterile, disposable, plastic wrap (transparent in the red wavelength) to permit contact with the skin for ten minutes during each session. The plastic wrap will be changed after each use. The amount of energy delivered will be 194.4 J.
1511328|NCT02883751|Procedure|Control group|Conventional ulcer treatment with rayon® (Polar Fix, Polar Fix, Mauá, SP, Brazil) and essential fatty acids (Dersani®, Saniplan, Daudt, São Paulo, SP, Brazil) (composition: decanoic acid, caprylic acid, hexanoic acid, lauric acid, linoleic acid, lecithin, retinyl palmitate, tocopheryl acetate and alpha-tocopheryl).
1511329|NCT02883738|Other|tremor|evaluation of the intensity of the tremor
1511330|NCT02883725|Other|data collection|
1511335|NCT02883686|Behavioral|Peer-BA for Pregnant Women|Individual behavioral activation therapy sessions as delivered by trained peers
1511336|NCT02883686|Behavioral|Care as Usual|Routine care plus ongoing screening, feedback, and referral to behavioral health services as indicated
1511337|NCT02883673|Device|InPress Device|It is a teardrop-shaped, soft silicone ring that is placed into the uterus, where gentle suction is applied to cause the uterus to contract and shrink in size, compressing the blood vessels so the bleeding stops.
1511338|NCT02883660|Genetic|Genocept Assay|battery of pharmacogenetic tests relevant to psychiatry
1511339|NCT02883647|Drug|Entecavir or Tenofovir|Patients in retreatment group receive nucleos(t)ide analogs therapy (Entecavir 0.5mg/d or Tenofovir 300mg/d) again
1511340|NCT02883634|Other|Specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation according to the physical examination performed prior to the treatment allocation.
1511341|NCT02883634|Other|Non-specific manipulation|Patients allocated to the specific manipulation group will receive spinal manipulation on the upper thoracic spine that will be not related to the physical examination performed prior to the treatment allocation.
1511342|NCT02883621|Procedure|cap assisted upper endoscopy|A soft plastic cap is attached to the tip of the scope to allow pressing of the folds and thus enhance the visualization.
1511343|NCT02883621|Procedure|standard upper endoscopy|standard examination without using a cap
1511344|NCT02883608|Procedure|cap assisted forward-viewing endoscope|a cap fitted to the to top of the forward-viewing endoscope
1511345|NCT02883595|Drug|thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
1511346|NCT02883595|Other|Placebo|Subcutaneous injections of placebo (saline) twice per day for seven days
1511347|NCT02883582|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
1511348|NCT02883582|Device|oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
1511349|NCT02883569|Procedure|open or endoscopic discectomy|FDA approved surgical procedures
1511350|NCT02883569|Procedure|epidural block|epidural block
1511351|NCT02883569|Other|exercise|educated exercise
1511352|NCT02883569|Drug|ibuprofen, naxoprofen, Cox-2 inhibitor, aceclofenac|FDA approved medication such as ibuprofen, naxoprofen etc.
1511353|NCT02883569|Procedure|decompression|FDA approved surgical procedure such as lamiectom and, laminotomy
1511354|NCT02883569|Procedure|instrumentation and fusion|FDA approved surgical procedure such as PLIF, ALIF, DLIF, OLI and TLIF
1511355|NCT02883569|Drug|codeine, oxycontine, IRcodone, Tramadol|FDA approved opioid drug such as codeine, oxycontin, IRcodon
1511356|NCT02883569|Procedure|epidural adhesiolysis|FDA approved epidural adhesiolysis with catheter or endoscope
1992844|NCT03288714|Device|Sham Stimulation|Sham stimulation is designed to look, sound and feel like the investigational device, but does not deliver magnetic stimulation to the brain.
1511358|NCT02883543|Drug|icotinib|Icotinib is orally administered three times per day.
1511359|NCT02883543|Drug|Chemotherapy|"Chemotherapy is given by intravenous administration. Three regimens are available in this study.
Regimen 1: etoposide 75mg/m2 d1-5 + cisplatin 75 mg/m2 day1/ day1-2.
Regimen 2: docetaxel 75mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2.
Regimen 3: pemetrexed 500mg/m2 d1 + cisplatin 75 mg/m2 day1/ day1-2"
1511360|NCT02883543|Radiation|Radiotherapy|5Gy/75.00Gy, 10f/2w for peripheral lung cancer, and 2.4Gy/59.52Gy, 20f/4w for central lung cancer.
2003146|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_25%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 25% of MF59.
1511362|NCT02883517|Genetic|Cytogenetic and molecular studies|Detect cell-free circulating tumoral DNA in a blood sample, with correlations with clinical characteristics and metastatic outcome.
1511363|NCT02883504|Procedure|Echo-Doppler examination and left heart catheterization|
1511364|NCT02883478|Device|UV-X 1000 (3 mW/cm²)|Ultraviolet-A (UVA) irradiation for 30 minutes at 3 milliwatt/cm² (mW/cm²).
1511365|NCT02883478|Procedure|UV-X 2000 (9 mW/cm²)|Ultraviolet-A (UVA) irradiation for 10 minutes at 9 mW/cm².
1511366|NCT02883478|Drug|riboflavin with hydroxypropyl methylcellulose|Drops of riboflavin with hydroxypropyl methylcellulose will be applied in the eye for 20 minutes before ultraviolet-A(UVA) irradiation and every 2 minutes during UVA irradiation
1511367|NCT02883465|Procedure|Diaphragmatic ultrasound|"All patients will have a diaphragmatic ultrasound in the 4 hours before the extubation.
a record of the right and left diaphragmatic cupolas run, with a chest approach and using a 4-5 MHz (megahertz) cardiac or abdominal sensor. 3 acquisitions for each side
a record of the diaphragm thickening at the right and left apposition zones with a 10-12 MHz (megahertz) vascular sensor. 3 acquisitions for each side"
1511368|NCT02883452|Biological|Infliximab|
1511369|NCT02883439|Drug|MP29-02|local nasal application
1511370|NCT02883439|Drug|Fluticasone propionate|local nasal application
1511371|NCT02883426|Biological|H3N2v MN 2010/AA ca live attenuated influenza vaccine (LAIV)|Approximately 10^7.0 Fluorescent Focus Units (FFU) per 0.2 mL dose; administered intranasally
1511372|NCT02883426|Biological|H3N2v inactivated subvirion influenza vaccine|15 μg; administered intramuscularly
1511373|NCT02883426|Biological|Placebo|Administered by nasal spray
1511374|NCT02883413|Behavioral|CRT + Teach the Parent|CRT sessions will occur for 45-60 minutes every day (excluding weekends) for 6-8 days while adolescents are in hospital. Adolescents will be given homework and asked to practice tasks each day.
1511375|NCT02883413|Behavioral|CRT + Contact Control|Adolescents will be asked to spend 3-4 sessions with their parents engaging in fun activities (games, coloring, trivia). Adolescents will be able to choose 2 tasks from a list and be asked to engage in those tasks with their parents.
1511376|NCT02883400|Drug|Spironolactone|spironolactone 25 mg up to 50 mg
1511379|NCT02883374|Drug|Chidamide|
1511380|NCT02883361|Behavioral|Motivational enhancement therapy|
1511381|NCT02883361|Behavioral|Attention Control|
1511382|NCT02883335|Other|Observational registry|
1511383|NCT02883322|Other|Cross cultural adaptation of patient reported outcomes (PRO)|Process used to adapt a questionnaire from one cultural setting to another
1511384|NCT02883309|Other|intradialytic physical training program|Nine patients participated in the experimental group in a combined training program, which lasted 12 weeks with a frequency of 3 times a week, the training sessions were carried out within each dialysis session during the first 2 hours of the dialysis treatment, the working session involved a warm up period, aerobic exercise with pedals, or strength exercises based on free weight depending on the training stage. The Borg scale and the heart rate reserve were used to control the training intensity. The disability level was evaluated at the beginning and the end of the study through the World Health Organization Disability Assessment Schedule II, the aerobic capacity was evaluated through the six minute walk and the limbs strength was evaluated through a dynamometer.
2003147|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_50%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 50% of MF59.
2003148|NCT00812019|Biological|Cell Culture-Derived H5N1 Subunit Influenza Vaccine, 15_100%MF59|Two vaccinations of Cell Culture-Derived H5N1 15 µg Subunit Influenza Vaccine containing 100% of MF59.
1511386|NCT02883283|Procedure|Epidural loading dose|Labor epidural analgesia loading dose
1511387|NCT02883283|Device|Epidural catheter|Epidural loading dose via epidural catheter
1511388|NCT02883283|Device|Epidural needle|Epidural loading dose via epidural needle
1511389|NCT02883270|Device|Robot-assisted Gait Training|Robot-assisted Gait Training is an effective alternative to treadmill therapy with partial body weight in intense gait rehabilitation and provided to the feet and the patient actively controls the knee and hip joints.
1511390|NCT02883270|Other|conventional rehabilitation|The participants of controls receive 60 min conventional rehabilitation daily for 8 weeks. Interventions included physiotherapy for muscle strengthening, endurance and gait training; occupational therapy to improve activity of daily living (domestic, community tasks).
1511391|NCT02883257|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy will include core mandatory modules of key effective components (e.g., behavioural activation, cognitive restructuring) and optional elements to address individual maintaining factors (e.g., coping and social skills training, perfectionism and self-criticism).
1511392|NCT02883244|Device|Soft-Picks Advanced|Soft-picks Advanced will be used once a day to clean interdental sites at home.
1511393|NCT02883244|Device|Floss|Floss will be used once a day to clean interdental sites at home.
1511394|NCT02883231|Other|taking peripheral blood|taking peripheral blood of no more than 3ml
1511395|NCT02883192|Drug|Ondansetron|Zofran 4 mg.
1511396|NCT02883192|Drug|Placebo|Placebo
1511397|NCT02883179|Drug|lidocaine injection|anhydrous solution
1511398|NCT02883179|Drug|lidocaine-prilocaine cream|topical cream
1511399|NCT02883166|Drug|abiraterone|integested with a continental breakfast
1511400|NCT02883153|Drug|Zirconium-89 girentuximab PET/CT|Thirty patients (suspected of ccRCC) will be included in whom conventional diagnostics are inconclusive. During a multidisciplinary team (MDT) the hypothetical next step in the clinical process will be noted. Subsequently, in these patients a Zirconium-89-girentuximab PET/CT will be performed 4-5 days after single intravenous injection of 5 mg Zirconium-89-girentuximab (37 MBq). The results of the PET/CT will be discussed during the MDT and will be used to decide what the next step in the clinical process will be. This step will be compared with the hypothetical next step from the MDT before the scan. Whether or not the PET/CT scan had impact on clinical decision making will be assessed for each individual patient.
1511401|NCT02883140|Other|Three-dimensional sialography CBCT and MRI sialography|"MRI sialography: Achieved on a 3 Tesla MRI (INGENA 3T Philips Medical Systems). Patient supine positioned. Sialo-MR sequences (3D T2 DRIVE, TSE, SENSE and SPIR) and conventional sequences (T2 turbo spin echo).
3D CBCT sialography: Achieved same day as the MRI sialography, after acute episode subsided. 0.5ml of high concentration, water-soluble, iodinated contrast product (HEXABRIX 320®, 320g /L, Guerbet, France) is injected in the symptomatic salivary gland and maintained in the gland. Image acquisition performed on a wide-field CBCT device (NewTom VGi, QR, Verona, Italy). Front and profile scout views achieved. mA and exposure time modulated according to scout views. Reconstruction in Maximal Intensity Projection, 3-dimensional and MultiPlanar Reconstructions sections"
1511402|NCT02883127|Behavioral|Motivational interviewing|"The aim is to provide a one-to-one contact every second week of approximately 10 minutes duration. An action plan for improving dietary behavior will be made during the first session and evaluated in subsequent sessions. The following dietary objectives will be set for each participant to achieve or to maintain:
Watch portion size - to be conscious about the amount of carbohydrates in each meal.
Eat mainly carbohydrates of low glycaemic index.
Reduce the intake of carbohydrate of high glycaemic index.
Watch daily weight changes - aim for the recommended weekly changes.
In addition to the motivational intervention the women are given unchanged routine care."
1511403|NCT02883114|Drug|PF-06648671|Subjects will receive a single dose of PF-06648671 25 mg oral suspension on day 1 in period 1 and a single dose on Day 4 in period 2.
1511404|NCT02883114|Drug|Itraconazole|Subjects will receive itraconazole 200 mg oral solution once a day for 14 days in period 2
1511405|NCT02883101|Behavioral|Pulmonary Rehabilitation|"The Rehabilitation Programme will include the following :
i. Patient education ii. Exercise training iii. Ventilator and breathing exercises"
1511406|NCT02883088|Procedure|Frequency Domain - Optical Coherence Tomography (FD-OCT)|FD-OCT assessment of the native proximal-mid left descending artery during clinically indicated coronary angiography
1511407|NCT02883075|Procedure|Position after placement of spinal anesthetic|
1511408|NCT02883062|Drug|Atezolizumab|Given IV
1511409|NCT02883062|Drug|Carboplatin|Given IV
1511410|NCT02883062|Other|Laboratory Biomarker Analysis|Correlative studies
1511411|NCT02883062|Procedure|Lumpectomy|Undergo lumpectomy
1511412|NCT02883062|Procedure|Mastectomy|Undergo mastectomy
1511413|NCT02883062|Drug|Paclitaxel|Given IV
2003149|NCT00804466|Device|CareHPV|Low-cost HPV DNA Screening test
2003150|NCT00798265|Biological|Gardisil|.5 mL dose injected IM at 0 2 and 6 months
2003151|NCT00798265|Behavioral|Survey|Administration of on-line risk behavior and knowledge survey
2003155|NCT00753441|Procedure|Surgical bypass|Surgical bypass (choledochojejunostomy, in combination with gastroenterostomy if necessary)
2003156|NCT00753441|Procedure|Endoscopic stenting|Placement of a biliary metal stent (in combination with a duodenal metal stent in case of gastric outlet obstruction if necessary)
2003157|NCT00713492|Drug|Alcohol|
2003158|NCT00713492|Procedure|Self-Administration|
1511431|NCT02883036|Other|blood sampling|sampling after diagnosis and the mononuclear cells will be given tigecycline stimulation in vitro
1511432|NCT02883036|Other|blood sampling|sampling after register and the mononuclear cells will be given tigecycline stimulation in vitro
1511433|NCT02883023|Other|Electrosclerotherapy|Combination of intralesional bleomycin sclerotherapy and electroporation
1511434|NCT02883023|Drug|Intralesional bleomycin injection|Local intralesional injections with bleomycin
1511435|NCT02883010|Device|PICO Softport V1.6|PICO is a Single-Use Negative Pressure Wound Therapy (NPWT) System consisting of a small portable pump, 2 lithium batteries, 2 dressings and fixation strips. The system is capable of delivering up to 80 mm Hg negative pressure to a wound or surgical incision site and managing low to moderate levels of exudate or fluid generated by the wound or incision. The therapy may be administered for up to 2 weeks.
1511436|NCT02883010|Other|Standard Care|Care path normally used by the hospital
1511437|NCT02882997|Behavioral|an interactive computer game|Duck Duck Punch is an interactive computer game designed to elicit repetitive practice of paretic arm movements in stroke patients.
1511438|NCT02882997|Behavioral|standard activities|For community dwelling stroke survivors this is a hard copy, written/illustrated home exercise program for the paretic arm. For inpatient stroke patients this is standard recreational activities organized by the facility during non therapy hours (evenings and weekends).
1511439|NCT02882984|Drug|Gefitinib 250mg po qd or Tarceva 150mg po qd or Icotinib 125mg po tid Other Name: Gefitinib/Tarceva/Icotinib|radiation given along with one of kind TKI
1511440|NCT02882984|Radiation|WBRT|3750 cGy in 15 fractions given within 3 weeks time.
1511441|NCT02882984|Radiation|HFSRS|All HFSRS given in 5 fractions. dose per fraction ranges from 5 to 8 Gy depending on the target volume and organs at risk tolerance.
1511442|NCT02882971|Behavioral|Pain Assessment|To create an objective observational pain scoring system and validate.
1511443|NCT02882945|Other|Group A|150 healthy blood donors without a family history of diabetes mellitus were enrolled in the study.
1511444|NCT02882945|Other|Group B|200 cases of type 2 DM without complications were enrolled in the study.
1511445|NCT02882945|Other|Group C|120 cases of type 2 DM with macroangiopathy complication were enrolled in the study.. Among the group C subjects, 65 individuals had CHD; 55 patients had cerebrovascular disease (CVD); and 30 subjects had a combination of peripheral vascular diseases (PVD) and CHD.
1511446|NCT02882932|Procedure|Super Oxidized Solution in group I|Two groups were made as group I and group II. Peritoneal Lavage was given with SOS and normal saline in group I. in group II only normal saline wash was given.
1511447|NCT02882919|Behavioral|Check Yourself v2.0|In the intervention group, adolescents complete Check Yourself which delivers personalized, motivational feedback on their health behaviors prior to their primary care appointment. Key components of Check Yourself include the provision of age normative feedback, goal setting strategies, and strategies to increase motivation for healthy behaviors. Primary care providers will receive a summary report of health risk behaviors prior to their adolescent patient's primary care appointment.
1511448|NCT02882893|Drug|Clostridium Botulinum A Toxin|
1511449|NCT02882893|Drug|Clostridium Botulinum A Toxin|
1511450|NCT02882880|Device|The Luco Hybrid OSA Appliance|Group 1, initial treatment with the device, reassessed at 14 and 60 days, Group 2, removal of the treatment for 48 hours, to determine if relapse occurs, retested at 60 days with the device (recovery from intervention).
1511451|NCT02882867|Other|Injuries in Swedish Youth Athletics. The KLUB-study.|
1511452|NCT02882854|Drug|Guanfacine|Patients will receive 1 mg of guanfacine to take orally.
1511453|NCT02882854|Drug|Placebo|Patients will receive a placebo containing no drug that appears similarly to guanfacine to take orally.
1511454|NCT02882841|Other|Biopsies, stool and blood collection|
1511455|NCT02882828|Drug|switched from Prograf® to Envarsus®|
1511456|NCT02882815|Device|IrisFIT PFO Occluder|
1511457|NCT02882802|Behavioral|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) is a group-based intervention in which participants are taught different mindfulness meditation practices, including body scan (focusing attention to different areas of the body in sequence), sitting meditation (focusing attention to one's breathing), and Hatha yoga postures (focusing attention to different body sensations during gentle stretching). Participants also are taught how to practice mindfulness while engaging in ordinary activities including walking, standing, and eating. MBSR consists of 8, two-hour weekly sessions and will be delivered in group format.
1511458|NCT02882802|Behavioral|Trauma Recovery Education Class|Trauma Recovery Education Class (TREC): TREC is a group based treatment that focuses on providing information on PTSD and traumatic reactions. TREC provides psycho-education to Veterans on PTSD, including common reactions to trauma and the role of avoidance, common problems associated with PTSD, as well as common barriers to care (e.g., stigma, maladaptive beliefs, fear). Additional content focuses on problem identification and goal setting, discussion of current problems and life issues, and treatment planning. TREC consists of 8, one-hour weekly sessions.
1511459|NCT02882789|Drug|LCB01-0371|Cohort1 & 3: Placebo-controlled, Single ascending dose administration
1511460|NCT02882789|Drug|LCB01-0371 400mg|Cohort 2: Crossover designed administration
1511461|NCT02882776|Dietary Supplement|Ginger drink|Ginger powder dissolved in water
1511462|NCT02882763|Other|Parents As Teachers (PAT)|A trained PAT parent educator (pediatric nurses in this study) visits families at their homes, approximately two times a month (individual frequencies may vary depending on specific risk factors) until the children are three years old. PAT is an educational home visitation program that aims to a) help parents to understand child developmental aspects and improve their parenting skills, b) detect developmental shortcomings, c) prevent child abuse and neglect, and d) enhance school preparedness. Additionally, the project offers monthly group meetings.
1511463|NCT02882750|Other|EORTC QLQ-C30 (version 3.0).|Quality of Life Questionnaire
1511464|NCT02882750|Other|PS Q18|Patients Satisfaction Questionnaire
1511465|NCT02882750|Other|Decision Self-Efficacy Scale|Questionnaire
1511466|NCT02882737|Drug|Glucagon before exercise|
1511467|NCT02882737|Drug|Glucagon after exercise|
1511468|NCT02882737|Drug|Glucagon after resting|
1511469|NCT02882724|Behavioral|Exercise|8-week aquatic exercise training program
1511470|NCT02882724|Behavioral|Control|Control group did not do the exercise training.
1511471|NCT02882711|Drug|Ketamine|Ketamine will be infused (slow IV infusions of ketamine (0.5 mg/kg) over 40 minutes) twice weekly over a period of 4 weeks and weekly for the following 4 weeks of the study treatment period (8 weeks total).
1511472|NCT02882698|Behavioral|Down Syndrome Group 1|Acquisition and retention phase on maze A, transfer on maze B and C.
1511473|NCT02882698|Behavioral|Down Syndrome Group 2|Acquisition and retention phase on maze C, transfer on maze A and B.
1511474|NCT02882698|Behavioral|Typical Development Group 1|Control group. Acquisition and retention phase on maze A, transfer on maze B and C.
1511475|NCT02882698|Behavioral|Typical Development Group 2|Control group. Acquisition and retention phase on maze C, transfer on maze A and B.
1511476|NCT02882685|Procedure|Roux-en-y gastric bypass|
1511477|NCT02882685|Procedure|Single anastomosis gastric bypass|
1511478|NCT02882672|Other|Experimental|Doing exercise at 60-85% of maximal heart rate, lasted 45-60 minutes and included a 10-minute warm-up, 40 minutes of aerobic exercises, consisting of stationary cycling, walking and/or jogging
1511479|NCT02882672|Other|Control|They did not do ant exercise training during 8 weeks.
1511480|NCT02882659|Biological|Dendritic Killer Cell (DKC)|DKC is a hybrid cell type capable of dual functionality, i.e. cytotoxicity and antigen presentation, similar to NK cells and DCs, respectively.
1511481|NCT02882646|Device|Bi-ADLER|Subjects will be asked to use the Bi-ADLER for 60 minutes. All subjects will be seated on the Bi-ADLER and asked to perform a battery of bimanual evaluation tasks (creating ovals, standard ADL tasks like pouring, reaching, drinking etc).
1511483|NCT02882620|Behavioral|High Intensity (Group 1)|The high intensity intervention includes: navigated outreach, with four in-depth education outreach sessions; mailed FIT; education material; and follow-up mailed reminders (Group 1). The navigated outreach includes one-on-one information dissemination about CRC, importance of adhering to CRC screening guidelines, identification and solutions to screening barriers, motivation, self-efficacy and comprehension on how to complete the FIT kit, and gathering (if requested) and return of the completed FIT to the laboratory. The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
1511484|NCT02882620|Behavioral|Medium Intensity (Group 2)|The medium intensity intervention includes: mailed FIT; education material; and follow-up mailed reminders (Group 2). The educational material (brochure) is specially developed and culturally tailored for the six Tribes recruited for this study. The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
1511485|NCT02882620|Behavioral|Reference Group (Group 3)|The reference group (Group 3), per IHS guidelines and current standard of care at participating IHS facilities, receives usual care (ie, screening recommendation and a FIT kit at a clinic visit). The FIT kit used is the Polymedco OC FIT-CHECK® OC-Light test, which is a single collection test that meets USPSTF's guidelines.
1511486|NCT02882607|Behavioral|Mzanga Samala Moyo Wako ([Mzanga] Peer Groups|8 small group sessions led by community young women, focused on reproductive health, including HIV, STI and unintended pregnancy prevention; includes skill-building for self-efficacy
1511487|NCT02882594|Behavioral|Observing patient behaviors for anesthesia induction compliance|Observing patient behaviors for anesthesia induction compliance so to test reliability and validity of the CIBA Tool
1511488|NCT02882581|Radiation|11C-metformin|400MBq of 11C-metformin is injected in the cubital vein. The participant is then scanned for 120 min using Position Emission Tomography.
1511489|NCT02882568|Biological|blood analysis|Pilot study, single center, interventional including 15 obese subjects with acute sepsis. Inflammatory and immunological tests during acute phase and one month later after a presumed return parameters at baseline
1511490|NCT02882555|Behavioral|Exercise|6 min running on a motor-driven tredmill in a climate room (18-20°C, humidity <10 mg/l). Tredmill speed and slope are adjusted to increase heart rate to about 80 % of maximum value predicted for age (= 210 - age in years) during the first 2-3 min and pursued until the end of exercise (3-4 min). Heart rate is measured during the whole exercise.
1511491|NCT02882555|Drug|Capsaicin|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
1511492|NCT02882555|Drug|Normal saline|A compressed air-driven nebuliser is controlled by a dosimeter and a valve is used to deliver similar inspiratory flows for 400 msec in children and 1200 msec in adults.
1511493|NCT02882542|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
1511494|NCT02882529|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
1511495|NCT02882516|Other|Visible light exposure|Subjects will be exposed to visible colored light for 15 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.
1511496|NCT02882503|Device|endoscopic ultrasound - radiofrequency ablation (EUS-RFA)|Radiofrequency ablation will be applied with an innovative monopolar radiofrequency probe (1.2 mm Habib EUS-RFA catheter) placed through a 19 or 22 gauge fine needle aspiration (FNA) needle in patients with a tumor in the head of the pancreas.
1511497|NCT02882490|Behavioral|Parent Training|
1511498|NCT02882490|Other|Supportive Therapy|
1511499|NCT02882477|Drug|Deferiprone|
1511500|NCT02882477|Drug|Acetylcysteine|
1511501|NCT02882477|Drug|Sitagliptin and Metformin|
1511502|NCT02882464|Device|PC-02 Centrifuge device,2PRF+CAF|In 2PRF+CAF group two layers of stacked PRF membranes were positioned over the recession area at the level of cemento-enamel junction(CEJ). In CAF+2PRF group,two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ
1511503|NCT02882464|Device|PC-02 Centrifuge device, 4 PRF+CAF|Following this, in test groups, a horizontal sulcular incision was designed at the buccal side of recession area at the level of CEJ. The incision was extended in the interdental area to be connecting CEJ. A split thickness flap was raised without vertical incision.18 The papillae were disepithelialized. The root was planned and hard accumulations were removed but no chemical root treatment was performed. In test group-1, two layers of stacked PRF membranes were positioned over the recession area at the level of CEJ. In test group-2, four layers of stacked PRF membranes were positioned over the recession area at the level of CEJ (Figure 2). Membranes were sutured to the recipient bed by a resorbable suture (polyglycolic acid 6/0, Doğsan, Turkey) at the level of CEJ.
1511630|NCT02881320|Drug|B/F/TAF|Tablet administered orally once daily without regard to food
1511633|NCT02881307|Behavioral|Dietary recommendations|recommendations for one meal per day including lean protein and vegetables
1511504|NCT02882464|Procedure|CTG+CAF|The connective tissue graft was sutured to the recipient bed by resorbable suture at the level of CEJ. Split thickness flap was coronally advanced and sutured by resorbable suture. Finally, periodontal dressing was fixed on the recipient surgical area.
1511505|NCT02882451|Dietary Supplement|pinaverium bromide|
1511506|NCT02882451|Dietary Supplement|Vitamin C|
1511507|NCT02882438|Drug|infected group|Ginkgo Biloba in different dosage forms
1511508|NCT02882438|Drug|control group|placebo without Ginkgo Biloba
1511509|NCT02882425|Drug|Selexipag for intravenous use|Selexipag was reconstituted in sterile 0.9% w/v NaCl before infusion via an infusion pump at a rate of 2.5 µg/min.
1511510|NCT02882425|Drug|Selexipag for oral use|Tablet containing 200 µg of selexipag
1511511|NCT02882412|Other|observational|
1511512|NCT02882399|Other|Shortystrap|
1511513|NCT02882386|Other|Strength Training|
1511514|NCT02882386|Dietary Supplement|Milk 1%|
1511515|NCT02882386|Dietary Supplement|Whey protein concentrate 80 (WPC-80)|
1511516|NCT02882386|Dietary Supplement|Microparticulated whey|
1511517|NCT02882386|Dietary Supplement|Hydrolyzed whey|
1511518|NCT02882386|Dietary Supplement|Native whey|
1511519|NCT02882373|Drug|L-Arginine|Starting dose: 200 mg/kg/day given as oral supplementation in the form of liquid preparation.
1511520|NCT02882373|Other|Placebo|Starting amount of placebo/liquid is an amount equivalent to the dose in group 1 in 4 divided doses.
1511521|NCT02882373|Behavioral|Phone Call|One (1) month after participant stops taking part in the study, they will be called by the study staff. This call should last about 5 minutes.
1511522|NCT02882360|Device|Kerlix-AMD|Application of PHMB impregnated gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
1511523|NCT02882360|Other|placebo--normal gauze|Application of gauze pre-operatively (for booked C-sections) and post-operatively for all patients with LSCS. Gauze to be changed daily or more frequently if damp/blood-tinged
1511524|NCT02882347|Drug|Somatostatin|
1511525|NCT02882334|Device|Finger Force Manipulandum|
1511526|NCT02882334|Other|Conventional physiotherapy|
1511527|NCT02882321|Drug|IACS-010759|"Dose Escalation Phase Starting Dose: 0.5 mg by mouth daily on a 21-day schedule.
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
1511528|NCT02882321|Behavioral|Phone Call Follow Up|If participant's disease appears to be responding to study drug, member of the study staff calls every 3-6 months for up to 5 years.
1992845|NCT03287466|Drug|Oxygen|targeted oxygen therapy
1992846|NCT03287921|Drug|mono bronchodilatation|within indication according to current GOLD recommendation
1511532|NCT02882295|Other|Validation of a handwriting scale|
1511534|NCT02882269|Drug|Postoperative chemotherapy|Locally advanced colon cancer patients will receive surgery first, followed by 6 months of chemotherapy. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
1511535|NCT02882269|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy will be given to locally advanced colon cancer patients for 3-4 cycles. Surgery will be performed between 3 to 4 weeks subsequent to the last cycle of chemotherapy. After surgery, additional chemotherapy will be given. Preoperative and postoperative chemotherapy will be given for a total of 6 months. The recommended chemotherapy regimes includes FOLFOX, CapeOX, FOLFIRI, Capecitabine monotherapy.
1511536|NCT02882256|Other|Video discharge instructions|Discharge instructions provided in video form
1511537|NCT02882243|Device|FLXfit Cage for fusion|Evaluating patient outcomes and radiographic outcomes
1511538|NCT02882230|Drug|prescription of at least one of the following drugs: rilpivirine, elvitegravir, dolutegravir|
1511539|NCT02882217|Drug|XC8 (histamine glutarimide)|
1511540|NCT02882217|Drug|Placebo|
1511541|NCT02882191|Drug|LevoCept|placement of LevoCept IUD
1511542|NCT02882165|Other|Medical review|"A personalised, medical review will be conducted by a respiratory-trained Clinical Fellow. The Clinical Fellow will address any changes needed to optimise their lung health, any comorbidities and social situation. Education will be provided with regards to the COPD diagnosis, identifying and treating exacerbations, inhaler technique, smoking cessation and nutrition. The review will ensure any secondary prevention needs have been addressed and suggest onward referral to other services in primary or secondary care as the patient requires.
A follow up appointment will be booked during the initial appointment; to take place four to eight weeks later to identify and act upon any new clinical issues relevant to the patient's COPD and to follow up any clinical issues previously identified"
1511543|NCT02882152|Procedure|femoral nerve blockade|"femoral nerve blockade followed by a catheter placement for continuous infusion and a single shot block of the sciatic nerve at the end of the surgery"
1511544|NCT02882152|Procedure|morphine|Intrathecal morphine injection
1511545|NCT02882126|Drug|Subcutaneous Treprostinil|Remodulin (1.0, 2.5, 5 and 10 mg/ml formulations as available) will be administered by continuous subcutaneous infusion via a subcutaneous cannula using a microbore infusion tubing set and a micro infusion pump.
1511546|NCT02882113|Drug|Advagraf|same dose as Tacrolimus bid der day in 24 weeks
1511547|NCT02882100|Biological|adjuvanted trivalent influenza vaccine|Nursing home residents over 65 years are allocated to receive adjuvanted trivalent vaccine. Residents under 65 years are provided standard trivalent vaccine (TIV-Fluvirin).
1511548|NCT02882100|Biological|trivalent influenza vaccine|Nursing home residents are allocated to receive standard trivalent vaccine (TIV).
1511549|NCT02882087|Drug|Placebo plus MTX|All patients had a foundation MTX therapy.The researchers evaluated the efficacy of the patient in 12 week.study investigator evaluate the patients of curative effect . The researchers evaluated the efficacy of the patient in 12 week.Evaluation of efficacy in patients if not get the ACR20 response, adjust the treatment plan given the test drug.Test group continue to the test drug,placebo group switch to the test drug.
1511550|NCT02882087|Drug|RC18 160 mg plus MTX|
1511551|NCT02882074|Drug|Human albumin|human albumin 5% during surgery
1511552|NCT02882074|Drug|Hydroxyethyl starch|6% Hydroxyethyl starch 130/0.4 during surgery
1511553|NCT02882061|Procedure|Thoracic spinal manipulation|The most hypomobile (stiff) and/or painful segment between T1-T4 will be determined , and this is the segment to which the examiner will apply the thrust. The manipulation will be performed with subjects lying supine. The examiner will use a 'pistol grip' to apply pressure on the articular pillars of the thoracic segment bilaterally in order to block the inferior vertebrae of the hypomobile segment. The subject will cross their arms over their chest to the point where the elbows are aligned. This will allow the examiner to apply pressure through both elbows in an anterior-to-posterior direction. The examiner will assure the direction of force is felt into his/her stabilizing hand. The subject will be asked to take a deep breath in and then exhale completely. A grade V (HVLA) thrust will be applied at the end of the subject's exhalation. If a cavitation is not heard or felt by either the subject or examiner, a second thrust will be performed.
1511554|NCT02882048|Procedure|NADA Protocol|NADA Protocol is a standardized acupuncture technique in which five designated points in the ear are needled.
1511555|NCT02882048|Other|Medication management|Standard of care medication management defined by an opioid weaning protocol with specific, symptomatic medication regimens.
1511556|NCT02882035|Other|OFA|
1511557|NCT02882022|Device|Continuous positive airway pressure|A CPAP machine will be used to deliver positive pressure at various levels after which middle ear pressure and ear drums will be evaluated for changes.
1511558|NCT02882009|Drug|Gantenerumab|Gantenerumab as a HCLF will be administered via SC injection according to assigned treatment sequence.
1511559|NCT02882009|Drug|Placebo|Gantenerumab Placebo solution will be administered via SC injection according to assigned treatment sequence.
1511560|NCT02881996|Drug|IV tylenol|IV tylenol given scheduled in addition to standard PCA
1511561|NCT02881996|Drug|No IV tylenol|No additional IV Tylenol given
1511562|NCT02881996|Drug|Ketorolac|both groups receive as part of our standard postop pain protocol after all operations
1511563|NCT02881983|Other|the presentation of pictures (static stimuli) or videos (dynamic stimuli)|
1511564|NCT02881970|Drug|autologous cord blood stem cell|
1511565|NCT02881957|Drug|Cholecalciferol|
1511566|NCT02881957|Other|Placebo|Oral syrup placebo
1511567|NCT02881944|Behavioral|Low FODMAP Diet|Diet low in foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
1511568|NCT02881944|Behavioral|High FODMAP Diet|Typical diet of foods containing Fermentable Oligo-, Di-, and Mono-saccharides and Polyols
1511569|NCT02881931|Behavioral|FuRST 2.0|Cognitive Pre-testing of new Functional Rating Scale
1511570|NCT02881918|Other|Blood sample|Blood sample with 6 tube of blood (40 mL), after diagnosis and before any specific anticancer treatment
1511571|NCT02881905|Device|ball attachment|it is attachment part that connects the overdenture to the implant
1511572|NCT02881905|Device|cm loc attachment|It is a new attachment made of peek material
1511573|NCT02881892|Other|Measure plasma and dialysate level of IL-6, procalcitonin and VEGF|correlation between plasma levels, dialysate appearance rate of VEGF, inflammatory cytokines (IL- 6, procalcitonin) and PSTR, dialysis adequacy in CAPD patients.
2003159|NCT00694551|Biological|Peptide Vaccine|Peptide vaccine (PSMA and TARP peptide vaccine with Poly IC-LC adjuvant). Pilot study using three treatment arms of increasing peptide dose levels (100 mcg, 300 mcg, and 1 mg) with a fixed dose of Poly IC-LC as an adjuvant. Patients were randomly assigned to one of the 3 arms upon enrollment.
1511575|NCT02881866|Drug|Furosemide|
1511576|NCT02881866|Drug|Saline|
1511577|NCT02881853|Drug|XmAb7195|
1511578|NCT02881853|Drug|Placebo|
1511579|NCT02881840|Drug|14C-APD421|
1511580|NCT02881827|Radiation|Low level laser therapy|Supported by the physical phenomenon of stimulated emission postulated by Albert Einstein in 1916 the laser (light amplification by Stimulated Emission of Radiation) is a device consisting of solid source materials, liquid or gas that produces beams of light when excited by a source of energy. This bright feature is a particular type of electromagnetic radiation, which differs from that emitted by conventional incandescent sources. These are the effects attributable to LLLT analgesic, anti-inflammatory and biostimulates and has been widely used due to low power densities and wavelengths with a penetration capacity in tissues without the generation of photothermal effects, which makes its feasible use multiple applications in Health area.
1511581|NCT02881827|Other|Placebo|Simulation of treatment with the device switched off
1511582|NCT02881827|Other|Control|"A scientific control group allows the experimental study of a variable at a time, and is a vital part of the scientific method. In a controlled experiment, two identical experiments are conducted. In one, the treatment - tested factor - is applied. In another - control - the tested factor is not applied.
For example, when testing a drug, it is important to carefully check the suspected drug effects are produced by the drug. Doctors can it with a double-blind study in a clinical trial: two (statistically) identical groups of patients are compared, one gets the drug and the other receives a placebo. Neither subjects nor investigators know which group receives the actual drug, which serves to prevent bias and isolating effects of such drugs."
1511583|NCT02881814|Diagnostic Test|Lung and diaphragm ultrasound|The ultrasound physiotherapist/operator performs a lung and diaphragm ultrasound. He is blinded to the patient's status and clinical physiotherapist examination. He/she is not involved in patient management or patient clinical decision-making. The ultrasound findings are recorded in the LUS report. The LUS report is reported to the clinical physiotherapist and to the intensivist. The ultrasound diagnosis(es) is recorded.
2003160|NCT00694551|Drug|Poly IC-LC|Administered subcutaneously, one 2 mg/ml vial,(divided into two equal portions for each injection site).
1511586|NCT02881762|Drug|Maraviroc|Participants will receive 4 weeks of maraviroc (dosing based on concomitant HIV antiretroviral regimen). Serial measurements of HCV viral load will be obtained before, during, and after maraviroc exposure. Study duration will be approximately 12 to 16 weeks.
1511587|NCT02881749|Radiation|Total skin electron beam therapy (TSEBT)|"TSEBT will be given in 6 fractions at 2 Gy per fraction every Monday, Wednesday, and Friday over the course of 2 weeks (total TSEBT dosage is 12 Gy). Supplements up to 8 Gy will routinely be applied to the perineum and soles as well as any other shadowed sites involved by disease, such as the inframammary regions, scalp, etc. Discrete tumors may receive additional boost up to 8 Gy."
1511631|NCT02881307|Dietary Supplement|Whey Protein&Prebiotic Supplement|Dietary supplement (protein drink) commercially available protein shakes
1511588|NCT02881749|Drug|mechlorethamine gel 0.016%|The maintenance period for this study includes one year of weekly mechlorethamine gel 0.016%. This period will not begin until the observation period (30 days) has been completed. During the first week of the maintenance period, patients will apply mechlorethamine gel to the entire body surface daily. After the first week, patients will apply mechlorethamine gel to entire body surface one time per week for the rest of the maintenance period.
1511589|NCT02881736|Other|electroencephalographic,magnetic resonance imaging|
1511590|NCT02881723|Procedure|Surgery|
1511591|NCT02881723|Radiation|Radio- chemotherapy|
1511592|NCT02881710|Other|contrast product used to assess biomarkers variations|
1511593|NCT02881697|Other|Adipose tissue sampling|
1511594|NCT02881684|Device|Aspiration Therapy (AspireAssist®)|Use of the AspireAssist device in aspiration therapy
1511595|NCT02881684|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
1511596|NCT02881671|Genetic|genetic blood analysis|patients will undergo a blood sample (15 ml) to analyse their genetic profile
1511597|NCT02881658|Dietary Supplement|Plant sterols-enriched soya beverage provided by Vitasoy|the study product is a 2g plant sterols-enriched in 250ml soya beverage
1511598|NCT02881658|Dietary Supplement|Soya beverage provided by Vitasoy|the placebo product is a 250 ml soya beverage
1511599|NCT02881645|Behavioral|Best practices|Nurses in intensive care units will be trained to the best practices protocol for a period of two-month preceding the trial
1511600|NCT02881632|Device|Structured Light Plethysmography (SLP) - Pneumscan|Both healthy infants and bronchiolitis infants will have their chest movements monitored using Structured Light Plethysmography (SLP) performed by a device (Thora-3 Di) using a projector and two cameras. A light pattern of black and white squares is projected on the child's chest and the cameras record how the shape of this pattern changes with breathing. A computer converts this information to show how the child's chest moves during breathing.
1511601|NCT02881619|Drug|Etodolac|The patient will receive a single-dose of Etodolac (400 mg) one hour before the bleaching procedure.
1511602|NCT02881619|Drug|Placebo|The patient will receive a single-dose of placebo one hour before the bleaching procedure.
1511603|NCT02881606|Device|Naso-alveolar molding (NAM)|
1511604|NCT02881606|Device|Computer aided design NAM (CAD/NAM)|
1511605|NCT02881580|Other|No intervention : descriptive study|
1511607|NCT02881554|Procedure|Computed Tomography|Undergo SC SPECT/CT
1511608|NCT02881554|Procedure|Single Photon Emission Computed Tomography|Undergo SC SPECT/CT
1511609|NCT02881554|Drug|Technetium Tc-99m Sulfur Colloid|Given IV
1511610|NCT02881541|Procedure|Enhanced support|
1511611|NCT02881541|Procedure|Usual care|
1511612|NCT02881528|Drug|Metformin Hydrochloride|Liquid formula metformin administered by oral syringe in a dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
1511613|NCT02881528|Drug|Placebo|Liquid formula of placebo administered by oral syringe in an equivalent volume to a metformin dose of 10mg/kg body weight once daily for 2 weeks, then to 10mg/Kg twice daily (maximum 500mg twice daily) for a further two weeks during the first month, increasing to 20mg/kg body weight twice daily (maximum 1000mg twice daily) thereafter.
1511614|NCT02881515|Other|Low Sodium Diet|Ten days of low sodium diet
1511615|NCT02881515|Other|Medium Sodium Diet|Ten days of a medium sodium diet
1511616|NCT02881515|Other|High Sodium Diet|Ten days of a high sodium diet
1511617|NCT02881502|Other|severe asthma group|No intervention
1511618|NCT02881489|Other|Biological: Cell-based therapy|Human autologous bone marrow-derived mesenchymal stem cell transplantation in ALS patients.
1511619|NCT02881476|Other|Biological: Cell-based therapy|Human allogeneic Wharton's jelly-derived mesenchymal stem cell transplantation in ALS patients.
1511620|NCT02881463|Other|therapeutical exercises|Participants of experimental group performs daily an 8-week home therapeutical exercise program. Exercises are periodized by weeks (1-8 weeks). The aim of program is the leg muscle strengthening using an elastic band (Thera-Band, System of Progressive Exercise, USA), body balance training, and leg muscle stretching.
1511621|NCT02881437|Drug|IgHy10|Sub Cutaneous IgHy10 administration
1511622|NCT02881411|Other|Self-soft tissue therapy|Manual therapy for the muscles in the upper or lower limbs.
1511623|NCT02881411|Other|Fibromyalgia coping skills programme|Exercise, education programme
1511624|NCT02881398|Device|mHealth|After randomization and at the time of the initial encounter, study subjects are assessed at the point-of-care with mHealth devices that measure symptoms, functional status, and for structural abnormalities. These devices include activity monitoring for an assessment of a 6-minute walk test, smartphone connected blood pressure, oxymetry and ECG for functional assessments, and structural assessments with handheld-echocardiography and point-of-care BNP. Treatment decisions for an intervention with percutaneous valvuloplasty or valve replacement were performed based on the aggregate of these mHealth findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
1511625|NCT02881398|Other|Standard-Care|After randomization and at the time of the initial encounter, study subjects randomized to standard-care underwent a physical examination, 12-lead ECG, radiographic and laboratory tests as warranted and clinically required. Treatment decisions for percutaneous valvuloplasty or valve replacement were based on the aggregate of the standard-care findings. Confirmation of the severity of structural heart disease on transthoracic echocardiography was performed on all participants.
1511626|NCT02881372|Other|Oral food desensitization|The child's specific food antigen will be diluted in a 50% glycerin/water solution containing ascorbic acid (Vitamin C). This oral spray solution will need to be administered twice a day, every day for a total of 4 months
1511627|NCT02881359|Device|LifeSeal® Kit|used as an adjunct to suture or staple line during standard surgical repair of the GI tract (anastomosis or linear) to provide re-inforcement and help reduce leaks.
1511628|NCT02881346|Drug|Enstilar®|Once daily application of cutaneous foam to plaques on body and/or extremities
1511629|NCT02881333|Genetic|Blood samples|
1511632|NCT02881307|Behavioral|Dietary Counseling|Dietary Counseling
1511635|NCT02881281|Other|educational program for Development of problem-solving skills|
1511636|NCT02881281|Other|no education program|no education program
1511637|NCT02881268|Other|blood sample|
1511638|NCT02881255|Device|Implantable Cardioverter Defibrillator|Patients will be randomized to receive either a subcutaneous or transvenous ICD.
1511639|NCT02881242|Other|Laboratory Biomarker Analysis|Correlative studies
1511640|NCT02881242|Other|Quality-of-Life Assessment|Ancillary studies
1511641|NCT02881242|Drug|Trametinib|Given PO
1511642|NCT02881216|Device|Synergy Stent|Patients with narrowed coronary artery disease qualifying for PCI were treated with Synergy stent implantation.
1511643|NCT02881216|Device|Currently common drug-eluting stent (DES)|Patients with narrowed coronary artery disease qualifying for PCI were treated with DES implantation (Xience Prime, Resolute Integrity, Promus Element Plus)
1511644|NCT02881203|Device|Breathe Well|Breathe Well is an audiovisual biofeedback device used to assist patients to regulate their breathing whilst undergoing radiation treatment.
1511645|NCT02881203|Device|RPM|Varian Real-time Position Management (RPM) system
1511646|NCT02881190|Drug|RC48-ADC|
1511647|NCT02881177|Drug|Oxytocin|40 IU
1511648|NCT02881177|Drug|Placebo|40 IU
1511649|NCT02881164|Other|Low glycemic index|Subjects intake a low glycemic index breakfast
1511650|NCT02881164|Other|High glycemic index|Subjects intake a high glycemic index breakfast
1992847|NCT03287921|Drug|dual bronchodilatation|within indication according to current GOLD recommendation
1511652|NCT02881138|Drug|RC48-ADC|
1511655|NCT02881112|Device|Provant Therapy System|Treatment with the Provant Therapy System
1511656|NCT02881086|Drug|Rituximab|
1511657|NCT02881086|Drug|Nelarabine|
1511658|NCT02881086|Drug|PEG-Asparaginase|
1511659|NCT02881086|Procedure|Cranial irradiation|
1511660|NCT02881086|Drug|Imatinib|
1511661|NCT02881086|Drug|Idarubicin|
1511662|NCT02881086|Drug|Dexamethasone|
1511663|NCT02881086|Drug|Cyclophosphamide|
1511664|NCT02881086|Drug|Fludarabine|
1511665|NCT02881086|Drug|Vincristine|
1511666|NCT02881086|Drug|Mercaptopurine|
1511667|NCT02881086|Drug|VP16|
1511668|NCT02881086|Drug|Daunorubicin (DNR)|
1511669|NCT02881086|Drug|Methotrexate|
1511670|NCT02881086|Procedure|Stem cell transplantation|
1511671|NCT02881086|Drug|Cytarabine|
1511672|NCT02881086|Drug|Vindesine|
1511673|NCT02881086|Drug|Adriamycin|
1511674|NCT02881086|Drug|Prednisolone|
1511675|NCT02881073|Other|Maternal plasma PlGF quantification|A point of care test performed on maternal plasma, to quantify the level of the protein PlGF (placental growth factor) in the serum of the pregnant woman with suspected pre eclampsia to help the clinician in stratifying the level of further care for her in her pregnancy
1511676|NCT02881060|Dietary Supplement|Alcohol|
1511677|NCT02881060|Dietary Supplement|Placebo|
1511678|NCT02881047|Device|ablative fractional laser|
1511679|NCT02881047|Other|Biospecimen Collection|
1511680|NCT02881034|Drug|Triple therapy|
1511681|NCT02881021|Other|Rehabilitation program|Standardized conventional evidence-based physiotherapy for treating rotator cuff tendinopathy.
1511682|NCT02881021|Device|Kinesiotaping|Combined Kinesiotaping techniques (3 strips) for rotator cuff tendinopathy, following the principles of Kenzo Kase et al. (2003).
1511683|NCT02881008|Drug|Myrcludex B|
1511684|NCT02881008|Drug|Entecavir|
1511685|NCT02880995|Device|PET scan|The patient group and the healthy control group will undergo PET scan at the baseline. the investigators are going to measure striatal dopamine synthesis capacity using [18 fluorine(F)]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a >30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
1511686|NCT02880995|Behavioral|clinical scale|Patient group should complete clinical scales at baseline and 6 week.
1511687|NCT02880995|Drug|6 weeks of treatment with amisulpride|The investigators are going to measure striatal dopamine synthesis capacity using [18 fluorine(F)]DOPA positron emission tomography in drug-naïve first episode psychosis and determine treatment response after 6 weeks of treatment with amisulpride. Response will be defined as a >30% reduction in symptom ratings on the Positive and Negative Syndrome Scale.
1511688|NCT02880982|Dietary Supplement|Cholecalciferol|Weekly oral softgel capsule containing 10,000 IU (250 micrograms) cholecalciferol (vitamin D3)
1511689|NCT02880982|Other|Placebo|Weekly oral placebo softgel capsule
1511690|NCT02880969|Behavioral|answering questionnaires|
1511691|NCT02880956|Drug|ABBV-8E12|ABBV-8E12 (20 mg/mL) solution for IV infusion
1511692|NCT02880956|Drug|placebo for ABBV-8E12|placebo solution for IV infusion
1511693|NCT02880943|Drug|XOFIGO|"XOFIGO® will be administered intravenously as a bolus injection every 4 weeks with a maximum of 6 administrations per patient.
Four dose levels are available for evaluation : 27.5 kBq/kg, 55 kBq/kg, 88 kBq/kg and 110 kBq/kg.
Starting dose for phase I will be 55 kBq/kg."
1511694|NCT02880930|Dietary Supplement|Fultium-D3 drops (Internis)|Oral daily doses of vitamin D3 (400 IU for 3 months; and 1,000 IU for an additional 3 months)
1511695|NCT02880917|Device|tDCS-Sham|Sham tDCS will involve an identical electrode montage, with stimulation ceasing after a 30-second ramp-up period to provide equivalent scalp sensation.
1511696|NCT02880917|Device|tDCS-Active|tDCS was delivered using the anode electrode positioned over the left dorsolateral prefrontal cortex (DLPFE) and the cathode electrode at supra orbital right region. The electrodes were placed into a 25-35 cm2 square sponge immersed in saline solution for better current conductivity. Current density used was 2 mA and electrodes attached to the scalp were sustained by rubber band.
1511697|NCT02880917|Other|Cognitive training|. The cognitive training consisted of an online application of a Dual N-Back task .The Training will last for 8 days.
1992848|NCT03287778|Dietary Supplement|Pyridoxine|Max dose of 400 mg QD PO
1992849|NCT03287778|Dietary Supplement|Placebo|Matching placebos will be administered.
1511700|NCT02880878|Procedure|Early Surgical Hematoma Evacuation|Early Minimally Invasive Parafascicular Surgery (MIPS)
1511701|NCT02880865|Biological|CD-JEV|Single 0.5 mL dose of World Health Organization prequalified live, attenuated SA 14-14-2 JE vaccine manufactured by Chengdu Institute of Biological Products, Chengdu, China, administered by subcutaneous injection
1511702|NCT02880865|Biological|MMR|Single 0.5 mL dose of live, attenuated measles-mumps-rubella vaccine (Schwarz measles virus, RIT 4385 mumps strain, and Wistar RA 27/3 rubella virus) manufactured by GlaxoSmithKline, Inc., administered by subcutaneous injection.
2003161|NCT00692939|Biological|autologous CD34-selected peripheral blood stem cells transplant|high-dose immunotherapy followed by infusion of autologous CD34-selected peripheral blood stem cells (PBSC)
1511704|NCT02880839|Device|Partial cervical lamina excision group|Patients with cervical fracture were assigned to undergo partial cervical lamina excision and cervical pedicle screw internal fixation.
1511705|NCT02880839|Device|Pipeline-dredge discharge group|Patients with cervical fracture were assigned to undergo pipeline-dredge discharge and cervical pedicle screw internal fixation.
1511706|NCT02880839|Device|Digital navigation group|Patients with cervical fracture were assigned to undergo digital navigation assisted cervical pedicle screw placement.
1511707|NCT02880826|Behavioral|Measure the culture of safety in the reanimation units|
1511708|NCT02880813|Other|Infusion|infusion of nutrients
1511709|NCT02880800|Drug|Morphine as IVPCA|"Morphine as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of morphine as below:
Morphine bolus 1mg with a lockout interval of 5 minutes, no background infusion and maximum 30 mg in 4 hours"
1511710|NCT02880800|Drug|Hydromorphone as IVPCA|"Hydromorphone as IVPCA: Patients will be given a patient controlled analgesia (PCA) pump containing a standard solution of Hydromorphone as below:
Hydromorphone bolus 0.2 mg with a lockout interval of 5 minutes and a maximum dose of 6 mg in 4 hours."
1511711|NCT02880800|Drug|Morphine|IV opioids: Morphine 2 to 5 mg every 1h PRN (max. 20 mg/4h)
1511712|NCT02880800|Drug|Hydromorphone|Hydromorphone 0.5 - 1 mg every 1h PRN (max. 4 mg/4h)
1511713|NCT02880787|Drug|Rocuronium|Anesthesia induction with Propofol and maintaining with desflurane. For adult patients, the curare is rocuronium (0.6 mg/kg) For pediatric patients, the curare can be rocuronium (0.6 mg/kg), cisatracurium (0.1 mg/kg) or atracurium (0.5 mg/kg)
1511714|NCT02880787|Device|Neuromuscular monitoring with TOFScan® and TOF-Watch SX®|Each monitor on one arm
1511715|NCT02880774|Other|mandibular nonspecific mobilization|The mobilization will be held with the individual in supine position, by a trained and experienced therapist, where using disposable gloves, will position the first finger on the last molar, performing intermittently mobilization during 1 minute, will be held five repetitions. Going on a break during the repetition, in that the individual will carry out 15 times language exercises on the palate. With regard to mobilizing joint side, this will be previously set by means of the RDC/TMD and may be unilateral or bilateral basis, depending on the diagnosis. The therapist will remain in orthostatic in opposite side the mobilization to prevent any pressure on the jaw. The treatment will last for 4 weeks, 3 times a week, for a total of 12 sessions.
1511716|NCT02880774|Other|Ultrasound detuned,|Will be held the identical positioning to group A with the individual supine on the stretcher, used ultrasound equipment detuned on the region of the face with the presence of TMD. The procedures of this group will have a duration of 4 weeks, 3 times a week, for a total of 12 sessions.
1511717|NCT02880761|Procedure|Assessment guiding surgery and puncture for AVF|Assessment guiding surgery and puncture for AVF. Assessing the parameters of vascular vessels during following-up and making suggestions on surgery and puncture of AVF
1511718|NCT02880748|Other|Water exchange (WE) method|Water exchange (WE) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
1511719|NCT02880748|Other|Air insufflation (AI) method.|Air insufflation (AI) method was used for insertion to the cecum. And air was insufflated to distend the lumen for inspection and biopsy or polypectomy during withdrawal procedure.
1511720|NCT02880735|Device|Non Invasive Ventilation.|Non Invasive Mechanical Ventilation through oronasal mask. Mode: Bilevel with rate backup (spontaneous/time). Inspiratory Pressure: 30-10, Expiratory Pressure : 4-15, Backup Rate;14-25 rpm. Use Time: During Sleep.
1511721|NCT02880709|Dietary Supplement|Special diet|Tate and energy content adjusted with spices to obtain maximal intake
1511722|NCT02880696|Behavioral|Regular stimulation sequence|Vibrotactile stimulation of the right hand with regular intervals and random omissions
1511723|NCT02880696|Behavioral|Random stimulation sequence|Vibrotactile stimulation of the right hand with random intervals and random omissions
1511724|NCT02880696|Device|DCS|Near-infrared imaging of the neurovascular response in the left somatosensory cortex
1511725|NCT02880683|Device|NeuroTronik CANS Therapy System|
1511726|NCT02880670|Drug|BMS-986142|
1511727|NCT02880657|Dietary Supplement|SODB®|Subjects are supplemented with SODB®, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
1511728|NCT02880657|Dietary Supplement|Placebo|Subjects are supplemented with Placebo, daily over 10 weeks. Each volunteer was seen for the 4 visits: - visit of pre-inclusion V1, - visit V2, so-called inclusion visit, - visit V3 after 4 weeks of physical training and - visit V3 after 8 weeks of physical training
1511729|NCT02880631|Device|Barostim Neo™ System|
1511730|NCT02880618|Device|Barostim Neo™ System|
2003162|NCT00683644|Dietary Supplement|Zinc sulfate|Zinc sulfate taken once daily
2003163|NCT00678301|Biological|GSK Biologicals' Synflorix™|3 IM doses.
1511733|NCT02880566|Procedure|Scalp block|Full scalp block
1511734|NCT02880540|Drug|Fentanyl|
1511735|NCT02880540|Drug|Morphine|
1511736|NCT02880540|Drug|Dexmedetomidine|
1511780|NCT02880215|Behavioral|Attention Bias Modification|Behavioral intervention designed to decrease negative attention bias.
1511781|NCT02880215|Behavioral|Cognitive Control Training|Behavioral intervention designed to improve sustained attention.
2003164|NCT00678301|Biological|GSK Biologicals' Polio Sabin™|3 oral doses
2003165|NCT00678301|Biological|GSK Biologicals' Zilbrix™ Hib|3 IM doses.
1511737|NCT02880527|Other|Patients with polymyositis / dermatomyositis|"recruitment of patients with polymyositis / dermatomyositis using :
medical specialists , hospital and liberals who support patients with polymyositis / dermatomyositis ( internists , dermatologists, neurologists, pulmonologists , rheumatologists ) ;
general practitioners
the PMSI data for public and private hospitals ; 4 ) data boxes regional health insurance (primary health insurance fund , MSA Normandy , Social Scheme for Self )
5) Norman patients, members of an association of patients with polymyositis / dermatomyositis : the French Muscular Dystrophy Association"
1511738|NCT02880514|Device|Propel Mini Sinus Implant|
1511739|NCT02880514|Procedure|In-office Sinus Dilation|
1511740|NCT02880501|Device|proximal femoral nail antirotation|Twenty patients with intertrochanteric femoral fracture scheduled to undergo proximal femoral nail antirotation (PFNA) implantation.
1511741|NCT02880475|Drug|OXN PR tablet|Orally administered OXN PR tablet 5/2.5 mg or OXN PR tablet 20/10 mg
1511742|NCT02880462|Dietary Supplement|sulforaphane|Sulforaphane is a compound that can be extracted from broccoli, Brussel sprouts, cabbage, and other cruciferous plants.
1511743|NCT02880462|Other|placebo|Placebo is made of starch
1511744|NCT02880449|Behavioral|Intervention|A PA promoting intervention which provides education, social support and information about local opportunities for PA to pre-existing groups of older women living in socio-economically disadvantaged areas
1511745|NCT02880436|Other|air pollution|impact of various pollution agents above threshold and their correlation with acute myocardial infarctions are analyzed
1511746|NCT02880423|Procedure|tubal ligation group II|"Every woman , who is eligible to enter the study in terms of the above criteria , will receive a detailed explanation of the study and will review the consent form , and then be asked whether she agrees to participate in . If so , the participant will stamped on the informed consent form .
The control group will be women who undergo tubal ligation method BTL during cesarean section . All women will be invited to follow up about three months after surgery. The women will answer questionnaire to quantify the symptoms of menopause by NAMS , blood test for AMH and sonar and Doppler examination of both the ovaries"
1511747|NCT02880423|Procedure|salpingectomy group I|women who agreed to participate in the study and assigned randomly to this group will have salpingectomy during cesarean section for sterilization.
1511748|NCT02880410|Device|NeuroBlate System|Laser Interstitial Thermal Therapy
1511749|NCT02880410|Drug|Radiation therapy and temozolomide|Radiation therapy and temozolomide
1511750|NCT02880397|Drug|Garcinia mangostana|The properties of mangostana includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
1511751|NCT02880397|Drug|Placebo gel|The properties of placebo includes antibacterial, antifungal, anti-inflammatory, anti-microbial, antioxidant, anticancer, anti-proliferative, pro-apoptotic, aromatase inhibitory properties
1511752|NCT02880384|Other|FilmArray LRTI v.2.0 IUO Panel|Patients will provide sputum or sputum equivalent to be probed with FilmArray LRTI v.2.0 IUO Panelpanel.
1511753|NCT02880371|Drug|ARRY-382|ARRAY-382 will be taken by mouth once daily at a fixed dose.
1511754|NCT02880371|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously over 30 minutes every 3 weeks.
1511755|NCT02880345|Drug|PEMBROLIZUMAB|
1511756|NCT02880345|Radiation|hypofractionated radiation|
1511757|NCT02880332|Other|Usual care|During usual care therapy, children and their parents will receive a +/- 1 h session containing bio-medical directed education and information about the gastro-intestinal system and its function. This knowledge will be brought to bear with a hypnotic journey through their body, guided by a nurse with specific expertise in pediatric abdominal pain. Furthermore, the influence of stress on the gastro-intestinal system will be explained, combined with exercises to practise abdominal respiration.
1511758|NCT02880332|Other|Pain Neuroscience education|"This therapy will consist out of a +/- 1 h one-on-one educational session about neurophysiology of pain, adjusted to the child's comprehension status. The content of the education sessions and pictures will be based on the book Explain Pain by Butler and Moseley and will include explanation and reassurance about the cause of pain, a brief summary of relevant pain mechanisms and the integral role of psychosocial and physical factors in precipitating and maintaining pain. Metaphors, leaflets, books and audio-visual media will be used in a supportive function to consolidate verbally transmitted information. Parents will participate in the PNE session as well."
1511759|NCT02880332|Other|Extra care|During this therapy session, all the patient's/ parents questions that arose from the previous session (Usual care) will be answered. Afterwards, the educated content from this previous session will be revised. Nothing new will be taught. At the end of the session, the participant will be asked to demonstrate the previously learned exercises on abdominal respiration. If the exercises are not well performed, the therapist will correct them.
1511760|NCT02880319|Drug|Stereotactic Body Radiation Therapy (SBRT)|
1511761|NCT02880319|Device|Stereotactic Linear Accelerator|
1511762|NCT02880306|Other|RA|RA was diagnosed based on the 1987 American College of Rheumatology diagnostic criteria
2003166|NCT00662402|Other|Extensive Consultations|receives 15 free hours of multidisciplinary consultations towards the preparation of their career development grant.
2003167|NCT00656019|Drug|Vitamin D|2000, 4000, and 6000 IU, oral
2003168|NCT00608062|Drug|GnRHant - Ganirelix acetate|1 subcutaneous injection at 0.5 mg then daily injections of 0.25 mg for 6 days (total of 7 days of injections); testing will occur on injection day 4 and day 7
2003169|NCT00608062|Drug|Transdermal estradiol patch|0.075mg/d starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
1511771|NCT02880280|Drug|Human Menopausal Gonadotropin|Human Menopausal Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
1511772|NCT02880280|Drug|Human Chorionic Gonadotropin|Human Chorionic Gonadotropin injection treating congenital hypogonadotropic hypogonadism in teenagers
1511773|NCT02880254|Device|Kurbo|health/weight loss app designed for children and adolescents to help them track intake, output and understand healthy eating habits
1511774|NCT02880254|Device|Personal Health Coach|weekly health coach via facetime or Skype to motivate and counsel subjects during the weight loss process
1511775|NCT02880241|Drug|MMV390048|Tablets of 20mg each
1511776|NCT02880228|Drug|Dexamethasone|Given PO
1511777|NCT02880228|Other|Laboratory Biomarker Analysis|Correlative studies
1511782|NCT02880202|Other|Massage Therapy|The massage therapy is provided by certified massage therapists and delivered in the home setting. Techniques and duration of massage therapy is customized based on input from the patient and/or caregiver at the start of the session regarding nature and location of discomfort and other symptoms, and based on other factors such as contra-indications/complicating factors, medical issues, and additional diagnoses. The number of massage therapy interventions range from 2-3, 1 week apart, with each session lasting between 20-45 minutes in duration.
1511783|NCT02880189|Device|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
1511784|NCT02880189|Procedure|Endoscopic Ultrasound Guided Core Liver Biopsy|
1511785|NCT02880176|Other|Financial Incentive to Increase Ambulation|Financial Incentive and possibility for financial lottery entry in addition to education on the benefits of post-surgery ambulation
1511786|NCT02880163|Device|ResQFoam|Hemostatic device for the treatment of emergent, exsanguinating, Class III or IV intraabdominal hemorrhagic shock in subjects due to trauma
1511787|NCT02880150|Other|Stress test|
1511788|NCT02880137|Drug|Perflutren Lipid Microsphere|Definity (injectible suspension ultrasound contrast agent) will be diluted with saline for both Pediatric and Adult subjects. For pediatric subjects under 60kg (kilogram), the dose will be 20MicroL/kg (MicroLiter/kilogram) diluted to the same concentration used in the adult dosing. Hand Injections will be performed at baseline, Pre-peak, and peak perfusion stages.
1511789|NCT02880137|Procedure|RTMPE|Utilizes intravenous administration of biologically-inert microbubbles to assess myocardial perfusion and has demonstrated utility for identifying small vessel coronary artery disease.
1511790|NCT02880124|Dietary Supplement|Solution ingestion|Subjects will be required to ingest 2 litres of the experimental solution, spread over the 2 hours of exercise. A first ingestion of 572 mL of solution will be made at rest, 30 minutes before starting exercise, and 286 mL will be ingested immediately before the start of exercise and every 30 minutes during the exercise period.
1511791|NCT02880124|Behavioral|Constant load cycling|Subjects will be required to perform 2 hours of cycling exercise at a power output eliciting 60% of VO2max.
1511792|NCT02880124|Procedure|Expired gas sampling|Subjects will be asked, twice, to provide a forced expiration into a 10 mL plastic tube in order to collect a sample expired gases. This procedure will be done immediately before blood sampling and ingestion of the solution, every 30 minutes.
1511793|NCT02880124|Procedure|Indirect respiratory calorimetry|A mouthpiece and nose plug will be placed on the subject and expired gases will be analyzed by a metabolic cart during 3 minutes. This procedure will be done immediately before expired gas collection, blood sampling and ingestion of the solution, every 30 minutes.
1511794|NCT02880124|Other|Palatability|Subjects will be asked to fill out a short form on the palatability of the solution ingestion, after ingesting the first solution and at the end of exercise, after ingestion the last solution.
1511795|NCT02880124|Other|Gastrointestinal|At the end of the time trial, subjects will be asked to fill out a short form on gastrointestinal issues they might have had during experimentation.
1511796|NCT02880124|Procedure|Blood sampling|A catheter will be inserted in an antecubital vein and a saline solution will be continuously perfused to maintain the vessel open. 15 mL of blood will be collected every 30 minutes, immediately before ingesting the solution.
1511797|NCT02880124|Behavioral|Time trial|Subjects will be required to complete a simulated 20-km time trial on the cycle ergometer set in linear mode (where resistance is proportional to pedalling cadence), starting at 70% of the peak power output for the cadence spontaneously adopted by the subject during 2 hours of exercise.
1511798|NCT02880098|Biological|Troponin T blood level|assess Troponin T blood level for every child born from the same sample of blood (after clamping the umbilical cord) used for assessment of pH and lactate.
1511799|NCT02880085|Drug|Local anesthetic|local injection
1511800|NCT02880072|Dietary Supplement|phosphate orally|4 different preparations of phosphate
1511802|NCT02880033|Drug|deferiprone|to test the action of deferiprone on lymphocytes from patients and controls ex vivo
1511803|NCT02880033|Drug|placebo|to control the action of placebo on lymphocytes from patients and controls ex vivo
1511804|NCT02880020|Biological|Ipilimumab|Given IV
1511805|NCT02880020|Other|Laboratory Biomarker Analysis|Correlative studies
1511806|NCT02880020|Biological|Nivolumab|Given IV
1511807|NCT02880007|Radiation|External Beam Radiation Therapy|45 Gy pelvis / 25 fr
1511808|NCT02880007|Radiation|PDR Brachytherapy|1 puls/hour ; 12 Gy / day
1511809|NCT02880007|Drug|Cisplatin|increase in dose to the target volume at high risk (85 to 90 Gy over 90% of its volume) and the intermediate target volume (60 Gy to 90 % of its volume) in 3D Pulsed Dose Rate Brachytherapy
1511810|NCT02879994|Other|Laboratory Biomarker Analysis|Correlative studies
1511811|NCT02879994|Biological|Pembrolizumab|Given IV
1511812|NCT02879981|Drug|Guaifenesin|Administration of treatment will be according to physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
1511813|NCT02879981|Drug|Sulfamethoxazole|Administration of treatment will be according to physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
1511814|NCT02879981|Drug|Trimethoprim|Administration of treatment will be according to physician's recommendation under local labeling. The study protocol does not specify any treatment regimen.
1511815|NCT02879968|Other|Non-interventional study|
1511816|NCT02879955|Other|Glucose + Fructose|Ingestion of the separate monosaccharides glucose (25 g) and fructose (25 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
1511817|NCT02879955|Other|Sucrose|Ingestion of the disaccharide sucrose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
1511818|NCT02879955|Other|Isomaltulose|Ingestion of the slowly digestable disaccharide isomaltulose (47.5 g) dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
1512226|NCT02876900|Drug|Placebo|The study will evaluate Asenapine maleate patches against a placebo patch.
1512227|NCT02876887|Drug|Cocoa|
1511819|NCT02879955|Other|Sucrose + Acarbose|Ingestion of the disaccharide sucrose (47.5 g) and the alpha glucosidase inhibitor acarbose dissolved in 200 mL of water. The load provides 0.1385 mol glucose and 0.1385 mol fructose.
1511820|NCT02879942|Other|Ultrasound study of the placenta|The placenta will be scanned to measure the placental volume, chorionic plate, basal plate and thickness.
1511821|NCT02879942|Other|Measurement of angiogenic and anti-angiogenic factors (sFlt-1 and PlGF) in the first trimestre blood test|
1511822|NCT02879916|Drug|Levobupivacaine|Inject 3ml of levobupavacaine into the stellate ganglion area
1511823|NCT02879916|Drug|NaCl 0.9%|Inject 3ml of NaCl 0.9% into the stellate ganglion area
1511824|NCT02879903|Procedure|Periodontal treatment|"An experienced periodontist will be performed clinical periodontal parameters, including Plaque Index, Bleeding On Probe, Pocket Probing Depth, Gingival Recession, Clinical Attachment Level using a periodontal probe, at six sites per tooth at all teeth, excluding third molars.
Quadrant scaling and root planning will be weekly performed on each patient under local anesthesia using periodontal curettes and ultrasonic scalers. The maintenance therapy will be included professional plaque control and Scaling and root planing in recurrent periodontal pockets."
1511825|NCT02879903|Procedure|Microbiological collect|Biofilm will be collected with the paper point to analyse presence of Porphyromonas gingivalis fimbrial subunit gene type I, II, III, IV and V.
1511826|NCT02879903|Procedure|Questionnaire|Age will be expressed in years Sex -female and male, will be expressed in percentage. Time of cigarette consumption - will be expressed in years
1511827|NCT02879877|Drug|UCB7858|
1511828|NCT02879877|Drug|Placebo|
1511829|NCT02879864|Device|light therapy|
1511830|NCT02879864|Procedure|Usual care|usual care in oncology: The patient will be taken care of according to local chemotherapy in routine care and the recommendations. A set of questionnaires evaluation of fatigue and quality of life will be given to the patient at baseline and at weeks 12 and 24. They will complete the same day or the day before, and / or chemotherapy before . A follow-up visit will be performed 1 month after the last visit (week 28). A set of questionnaires evaluation of fatigue and quality of life will be given to the patient and will complete the same day or the day before
1511831|NCT02879838|Other|Blood sample|Biobank. Analysis of cytokines and DNA polymorphisms
1511832|NCT02879825|Device|Cardiac MRI|"Group-A patients, with mitral valve prolapse but no mitral regurgitation, will undergo specifically for research purposes a cardiac MRI, 24-hour external loop recording and exercise ECG on top of regular echocardiography evaluation.
Realization of these examinations will be performed according to recommendations for patients with mitral regurgitation (groups B, C and D)"
1511833|NCT02879812|Other|Performance Feedback Reports|Medical directors will be provided performance feedback reports that are a summary of clinical performance of transplant and racial disparity performance over a period of time aimed at providing information to allow them to assess and adjust their transplant performance. The report will emphasize tailored facility-specific information on the mean time on dialysis for patients in that facility and transplant access performance measures, such as wait listing and transplantation, including the magnitude of racial disparity, detailing when a facility is performing below the national or regional average.
1511834|NCT02879812|Other|Educational Video for Staff|Dialysis facility staff will watch a ~10 minute educational video that describes the role of dialysis staff in improving transplant access, the new kidney allocation policy, and how the new policy impacts minority patients and those on dialysis for a substantial period of time.
1511835|NCT02879812|Other|Educational Video for Patients|Dialysis facilities will receive a ~10 minute educational video targeted to dialysis patients to explain the transplant process and allocation policy.
1511836|NCT02879812|Other|Educational Webinar|Education for medical directors and facility staff about the kidney allocation policy will be discussed in a webinar and information will be hosted on a website for participants to access. The seminar will be roughly 45 minutes, and CME will be offered.
1511837|NCT02879812|Other|Standard Care|Dialysis facilities will conduct standard or usual care and education regarding transplantation.
1511838|NCT02879812|Other|United Network for Organ Sharing (UNOS) Pamphlet|Dialysis facility staff will be provided an educational pamphlet detailing the changes in the new kidney allocation policy .
2003170|NCT00608062|Drug|Transdermal placebo patch|Starting on day 4 of the injections following testing time point two; continue for 3 days and retest (day 7)
1511840|NCT02879786|Other|Posturographic tests|
1511841|NCT02879786|Other|Questionnaire of motion sickness susceptibility|
1511842|NCT02879773|Radiation|CTPVe|Non contrast computed tomography (CTPVe) scan during end inspiration and end expiration in supine position
1511843|NCT02879760|Biological|Ad-MAGEA3|Intramuscular injection
1511844|NCT02879760|Biological|MG1-MAGEA3|Intravenous infusion
1511845|NCT02879760|Biological|Pembrolizumab|Intravenous infusion
1511846|NCT02879747|Drug|Genotropin|Children were randomized to either decreased dose by 50% or unchanged dose after 2-3 years of Catch-up growth
1511847|NCT02879734|Other|Prophylactic laparoscopic omentopexy|Fixation of omentum with sutures to anterior abdominal wall during laparoscopic surgery
1511848|NCT02879721|Drug|Candesartan|Angiotensin II, type 1 receptor inhibitor, (candesartan) 8 mg once daily for
1511849|NCT02879721|Drug|Enalapril|Angiotensin-converting enzyme (ACE) inhibitor (enalapril) 5 mg once daily
2003171|NCT00607620|Behavioral|Brief Intervention|Training in brief interventions for alcohol use disorders, with a focus on motivational interviewing
2003172|NCT00604201|Other|Umbilical Cord Blood|
2003173|NCT00604201|Other|Haploidentical Stem Cells|
1512228|NCT02876887|Drug|Placebo|
2003174|NCT00604201|Device|Miltenvi CliniMACs CD34 Reagent System|
2003175|NCT00598286|Drug|[18F]FMPEP-d2|
2003176|NCT00594061|Device|Iowa/Nucleus 10/10 mm and Freedom Cochlear Implantation|Participants will receive one standard Nucleus Freedom electrode array and an Iowa/Nucleus 10/10 mm electrode array on the contralateral side.
2003183|NCT00581308|Device|GORE® HELEX® Septal Occluder|Percutaneous transcatheter closure of ostium secundum atrial septal defects (ASDs)
2003184|NCT00574951|Drug|motesanib diphosphate|
1511856|NCT02879682|Procedure|nTMS data available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will be available for the surgeon
1511857|NCT02879682|Procedure|nTMS data not available for the surgeon|the preoperatively acquired map of the motor cortex by nTMS will not be available for the surgeon
1511861|NCT02879656|Procedure|non-operative treatment|conservative treatment with 5 weeks cast immobilization
1511862|NCT02879656|Procedure|operative treatment|surgery with volar locking plate with modified Henry's volar approach
1511863|NCT02879643|Drug|Marqibo in combination with UK ALL R3|The first six subjects treated on this protocol will be treated at Marqibo® Dose Level 1 (1.5 mg/m2/dose (no dose cap). Once safety is established at this dose, a dose escalation will be performed to Dose Level 2 (2.0 mg/m2/dose, no dose cap). There will be no intrapatient dose escalation or de-escalation. Only 1 course of treatment will be permitted.
1511864|NCT02879617|Drug|durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
1511865|NCT02879604|Other|Compensatory cognitive training|In addition to the usual care, method of compensatory cognitive remediation
1511866|NCT02879604|Other|Usual|Usual care
1511867|NCT02879591|Other|Social Skills training with Avatar therapist|
1511868|NCT02879578|Drug|NBI-98854|
1511869|NCT02879565|Other|Semi structured interviews + EEG exams|
1511870|NCT02879552|Procedure|Traditional upper blepharoplasty|The skin incisions were marked using a skin marking pen. Preseptal orbicularis skin and muscle were removed using a size-15 scalpel blade and scissors. Hemostasis was achieved with conservative electrocuatery. The skin was closed with a running 6-0 nylon suture.
1511871|NCT02879552|Procedure|Brassiere suture with blepharoplasty|"Prior to skin closure as above, three 6-0 polyglactin sutures are passed along the lateral fourth of the orbital rim. The sutures attach the inferior orbicularis oculi edge to the arcus marginalis of lateral ROOF. Sutures are placed until there is a visible plumping of the sub-brow tissues."
1511872|NCT02879539|Device|MP3000 sound coding strategy or ACE strategy with lower stimulation|
1511873|NCT02879526|Drug|C-CPT|Chidamide 30mg ，twice a week Prednisone 20mg qd Cyclophosphamide 50mg qd Thalidomide 100mg qd
1511874|NCT02879513|Drug|Paclitaxel|
1511875|NCT02879513|Drug|Cisplatin|
1511876|NCT02879513|Drug|Epirubicin|
1511877|NCT02879513|Drug|Cyclophosphamide|
1511878|NCT02879513|Drug|5-fluoruracil|
1511879|NCT02879500|Other|Diet beverages|
1511880|NCT02879487|Device|Monopolar needle electrode|Colpotomy during total laparoscopic hysterectomy
1511881|NCT02879474|Behavioral|Melanoma scale questionnair|
1511882|NCT02879461|Procedure|LUMBAR DESCOMPRESSION|ATRODESIS AND DESCOMPRESSIO OFF VERTEBRAL CANAL
1511883|NCT02879448|Device|Amulet Left Atrial Appendage Occluder|Transcatheter left atrial appendage closure
1511884|NCT02879448|Device|WATCHMAN Left Atrial Appendage Closure|Transcatheter left atrial appendage closure
1511885|NCT02879435|Drug|Bupivacaine|pre-operative wound infiltration with 10 ml of numbing medicine
1511886|NCT02879435|Other|Placebo|pre-operative wound infiltration with 10 ml of sterile water
1511888|NCT02879409|Drug|Metformin|Initial: 500 mg once daily; dosage may be increased by 500 mg weekly; maximum dose: 2,000 mg once daily
1511889|NCT02879409|Drug|Gliclazide|"There is no fixed-dosage regimen for the management of diabetes mellitus with gliclazide. Dose will be individualized based on frequent determinations of blood glucose during dose titration and throughout maintenance. The 30 mg modified-release tablet equals the 80 mg immediate-release tablet.
Immediate-release tablet: Initial: 80 mg twice daily; titrate based on blood glucose levels. Usual dosage range: 80 to 320 mg/day (maximum dose: 320 mg/day); dosage of ≥160 mg should be divided into 2 equal parts for twice-daily administration.
Modified-release tablet: Initial: 30 mg once daily; titrate in 30 mg increments every 2 weeks based on blood glucose levels. Maximum dose: 120 mg once daily"
1511890|NCT02879409|Drug|Sitagliptin|Oral: 100 mg once daily
1511891|NCT02879409|Drug|Liraglutide|SubQ: Initial: 0.6 mg once daily for 1 week; then increase to 1.2 mg once daily; may increase further to 1.8 mg once daily if optimal glycemic response not achieved with 1.2 mg daily.
1511892|NCT02879409|Drug|Pioglitazone|"Oral, Monotherapy or combination therapy: 15-30 mg once daily
Patients with heart failure (NYHA Class I or II): Monotherapy or combination therapy: 15 mg once daily"
1511893|NCT02879409|Drug|Dapagliflozin|5mg once daily increasing to 10mg once daily as required
1511894|NCT02879409|Drug|human insulin|insulin dosage and administration according to physician
1511895|NCT02879396|Behavioral|PA4LE Program|"Medication self-management including medication reconciliation, therapy recommendations, and education by pharmacist (chronic conditions and medications including Beers Criteria)
Use of a patient-centered health record that helps guide patients through the care process (portable, health and medication record for elders)
Primary care provider and specialist follow-up (patient awareness of discharge action plan and follow-up)
Patient understanding of red flag indicators of worsening condition and appropriate next steps
Behavioral interventions - Adherence, Lifestyle modifications, Mindfulness & Lovingkindness meditations to combat anxiety, insomnia and other behavioral symptoms"
1511963|NCT02878850|Other|Augmented Blood Pressure|
1511964|NCT02878837|Drug|Dexmedetomidine|
2003192|NCT00564564|Drug|Quetiapine|Quetiapine once a day at maximum dosage of 200mg per day asociated to a SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
2003193|NCT00564564|Drug|Clomipramine|Clomipramine once a day at maximum dosage of 75mg per day plus SSRI (maximum dosage of 40mg per day for fluoxetine; 200mg per day for sertraline and 60mg per day for citalopram)
2003194|NCT00554515|Drug|HD IL2|
1511896|NCT02879383|Procedure|DMR Procedure|The Fractyl DMR procedure using the Revita System utilizes an over the wire endoscopic approach to ablate the duodenum. The procedure may be completed in an endoscopic suite or in an operating room depending on the facilities and support at each investigative site. All subjects are monitored and anesthetized by conscious sedation per each facility's standard protocol. A full DMR procedure is defined as 5 complete ablations or 9 axial centimeters of circumferentially ablated tissue in the duodenum. Subjects who do not receive any ablations during the DMR procedure will be followed for safety through the 4 week visit and then discontinued from the study.
1511897|NCT02879383|Procedure|Sham Procedure|The sham procedure will consist of placing the Revita Catheter as described above into the duodenum and leaving it in place for a minimum of 45 minutes and then removing it from the patient.
2003195|NCT00530218|Drug|ganciclovir|
1511899|NCT02879357|Behavioral|Training|"Clinician training
System for patient selection
System of triggering and tracking conversations
Training on how to use the Serious Illness Care Guide, a guide for patients about initiating conversations with family members about end-of-life goals and values
Longitudinal Medical Record (LMR) documentation module to serve as a Single source of truth about advance care preferences in the LMR."
1511900|NCT02879344|Other|Blood draw|
1511901|NCT02879331|Procedure|10 coils in upper lobes|
1511902|NCT02879331|Procedure|15 coils in upper and lower lobes|
1511903|NCT02879331|Procedure|cycloergometry|
2003196|NCT00530218|Other|pharmacological study|
2003197|NCT00530218|Procedure|allogeneic hematopoietic stem cell transplantation|
2003198|NCT00516399|Drug|povidone-iodine 1.25% ophthalmic solution|
2003199|NCT00516399|Drug|natamycin ophthalmic suspension, USP 5%|
1511908|NCT02879305|Drug|Daprodustat|Daprodustat dose is based on prior ESA dose, the dose is adjusted thereafter in order to achieve the target range.
1511909|NCT02879305|Drug|rhEPO|The initial ESA dose is based on converting the prior ESA dose to the nearest available study rhEPO dose and is administered IV. The dose is adjusted thereafter in order to achieve the target range.
1511910|NCT02879305|Drug|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
1511911|NCT02879305|Drug|Iron therapy|Participants will receive supplemental iron therapy if ferritin is <=100 ng/mL or TSAT is <=20%. The investigator will choose the route of administration and dose of iron.
1511912|NCT02879292|Other|Spinal anesthesia|Spinal Anesthesia
1511913|NCT02879279|Device|Amadeo, Pablo, Diego and Motore.|In the robotic rehabilitation group, patients will be treated with the following systems: Amadeo, Pablo and Diego (Tyromotion GmbH, Austria), and Motore (Humanware, Italy). A ratio of one therapist to every 3 or 4 patients will be used, depending on the patient's severity. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
1511914|NCT02879279|Other|Conventional rehabilitation|In the conventional rehabilitation group, patients will undergo a conventional treatment with a ratio of one therapist to one patient. The rehabilitation treatment will be performed daily for 45 minutes, for 5 days per week, for 6 weeks. A total of 30 sessions will be performed.
1511915|NCT02879266|Biological|TetraVax-DV TV005|Contains 10^3 plaque-forming units (PFUs) of rDEN1Δ30, 10^4 PFUs of rDEN2/4Δ30(ME), 10^3 PFUs of rDEN3Δ30/31-7164, and 10^3 PFUs of rDEN4Δ30; administered by subcutaneous injection in the deltoid region of the upper arm
1511916|NCT02879266|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
1511917|NCT02879240|Other|Animated Cartoon|An animated cartoon chosen by the parents is displayed on a smartphone attached on the spacer of the child.
1511918|NCT02879240|Other|Black screen|A video displaying a black screen is used as control, and displayed on a smartphone attached on the spacer of the child.
1511919|NCT02879227|Drug|Cisplatin|Arm cisplatin : 75mg/m2, day n*1 and day n*22, And radiotherapy 50 Gy, 2Gy/f
1511920|NCT02879227|Drug|Oxaliplatin|85 mg/m2 every 2 weeks, 6 times And radiotherapy 50 Gy, 2Gy/f
1511921|NCT02879214|Radiation|Simultaneous boost along with chemo|Prior studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3), the studies often use single drug. This study treatment plan will use dose intensify in both chemotherapy and radiation. The chemotherapy have two drugs regimens of mitomycin with cisplatin or taxol with cisplatin along of radiation dose escalate, the RT dose escalation to biological GTV defined by PET scan to dose of 57.50 Gy in 25 fx while the elective volumes are held constant at 45 Gy.
1511922|NCT02879201|Procedure|Slow efficiency dialysis|Slow dialysis 4 times weekly 8 hours CVVHDF predilution mode
1511923|NCT02879188|Other|Physical Therapy|Patients will initiate inpatient physical therapy on the day of their surgery including attempted ambulation with an assistive device that is supervised by a physical therapist.
1511924|NCT02879188|Other|Standing|Patients will initiate inpatient physical therapy on postoperative day 1. On the day of their surgery they will dangle their feet over the edge of the bed with supervision of nursing.
1511925|NCT02879162|Drug|Durvalumab|
1511926|NCT02879162|Drug|Tremelimumab|
1511927|NCT02879149|Device|AUGMENT® Bone Graft|AUGMENT® Bone Graft
1511928|NCT02879149|Procedure|Standard of Care|Autologous Bone Graft
1511929|NCT02879136|Drug|Methylphenidate|Patient will be randomized to Methylphenidate
1511930|NCT02879136|Other|Physical Therapy|All Patients will have standard of care PT used for PD patients
1511931|NCT02879136|Drug|Atomoxetine|Patient will be randomized to Atomoxetine
1511965|NCT02878837|Drug|Midazolam|
1512231|NCT02876861|Procedure|Distal ureterectomy|Distal ureterectomy.
2003200|NCT00489125|Other|physiologic testing|physical testing of range of motion, grip strength etc.
2003201|NCT00483496|Drug|Titanium dioxide (Ti02) microfine 12.15% alone (formula RV3131A-MV1209)|
2003202|NCT00483496|Drug|Ti02 pigmentary 3% alone (formula RV3131A-MV1211)|
2003203|NCT00483496|Drug|bisoctrizole 10% alone (formula RV3131A-MV1237)|
2003204|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% (formula RV3131A-MV1213)|
2003205|NCT00483496|Drug|Ti02 microfine 12.15% + bisoctrizole 10% (formula RV3131A-MV1329)|
2003206|NCT00483496|Drug|Ti02 pigmentary 3% + bisoctrizole 10% (formula RV3131A-MV1212)|
1511934|NCT02879097|Biological|CBT124|Induction Phase: CBT124 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
1511935|NCT02879097|Biological|EU-sourced Avastin®|Induction Phase: EU-sourced Avastin® 15 mg/kg IV infusion-Day 1 of each 3-week Cycle for 6 cycles; Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles; Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles. Maintenance Phase: All the subjects who complete the induction phase and are alive at Week 19 without progression of the disease can be included in the maintenance phase and receive CBT124 (bevacizumab, 15 mg/kg, intravenous infusion on Day 1 of each 3-week Cycle) up to disease progression or unacceptable toxicity (that precludes further treatment with bevacizumab) or death.
1511936|NCT02879097|Drug|Carboplatin|Induction Phase: Carboplatin AUC 6 mgXmin/mL (calculation-Calvert formula recommended) on Day 1 of each 3-week Cycle for 6 cycles.
1511937|NCT02879097|Drug|Paclitaxel|Induction Phase: Paclitaxel 200 mg/m2 on Day 1 of each 3-week Cycle for 6 cycles.
1511938|NCT02879058|Procedure|Intraoperative contact ultrasonography|In patients randomized to myomectomy with contact ultrasonography, the laparoscopic or robotic ultrasound probe will be advanced through an existing port site into the pelvis after traditional myomectomy has been performed. The face of the ultrasound transducer will be guided over the uterus (including open hysterotomy sites) in systematic strokes, taking special care to note locations of myomas that may have been missed by the preceding excision. Additional hysterotomy sites will be made as necessary in order to remove persistent myomas. Any number of additional ultrasound passes and excisions may be performed in order to achieve the most comprehensive removal of myomas.
1511939|NCT02879045|Other|Elasticity Belly® oil|We will enroll about 50 Nulliparous women randomly, who are in their second trimester of pregnancy. We divide each of the volunteer's abdomen skin into two parts through medioventral line, one of the abdomen skin will receive the elasticity Belly® oil to prevent striae gravidarum, and the other side will use the Clarins® oil. Volunteers apply these two kinds of oil daily until birth. We'll take abdomen pictures before and after interventions, and the occurrence of striae on abdominal skin and its severity will be evaluated as our primary end point of the study.
1511940|NCT02879019|Other|Stretching exercise group|In each stretching class, approximately 20 exercises will be performed. The total duration of the session will be approximately 30 minutes.
1511941|NCT02879019|Other|Walking training group|Patients will perform two walking session per week, each consisting of 15*2-min walking bouts, with 2-min of rest in between. The intensity will be set at heart rate corresponding to the pain threshold.
1511942|NCT02879006|Drug|Chinese Herbal Medication|Capsules, 26 month course, starting 2 months pre-OIT
1511943|NCT02879006|Drug|Placebo|Placebo capsules that look identical to E-B-FAHF-2, 26 month course, starting 2 months pre-OIT
1511944|NCT02879006|Drug|Omalizumab|4 months course, starting 2 months pre-OIT through the 2 month build-up phase
1511945|NCT02879006|Drug|Multi OIT|24 months of multi OIT (maintenance dose of 1gm each food allergen)
1511946|NCT02878993|Device|Recording of diaphragm EMG|Recording of diaphragm EMG prior to extubation using surface diaphragm electromyography
1511947|NCT02878980|Behavioral|Exercise Intervention|Undergo supervised 1-on-1 exercise sessions
1511948|NCT02878980|Other|Laboratory Biomarker Analysis|Correlative studies
1511949|NCT02878980|Other|Quality-of-Life Assessment|Ancillary studies
1511950|NCT02878980|Other|Questionnaire Administration|Ancillary studies
1511951|NCT02878954|Other|No intervention (Observational study)|"160 patients will be recruited to:
Fill in questionnaires related to demographic characteristics, severity of disease and physical activity.
Perform a six-minute walk test Comparison between men and women will be performed."
1511952|NCT02878954|Other|Control session|"Out of the 160 participants of the observational study, at least 40 (20 men and 20 women) will be recruited.
In the control session participants will be seated in resting position for 15 minutes."
1511953|NCT02878954|Other|Exercise session|40 patients will perform a single maximal exercise test on a treadmill. Speed will be maintained at 3.2 km/h and the grade will be increased with 2% every 2 min following Gardner's protocol.
1511955|NCT02878928|Genetic|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
1511956|NCT02878915|Device|Ultrasound guided femoral puncture|
1511957|NCT02878902|Other|Post implementation|Patient group whose care course was organized by the nurse coordinator of chronic renal failure
1511958|NCT02878889|Drug|S-1|
1511959|NCT02878876|Dietary Supplement|Oral consumption of milk with sequence A1-A2|Oral consumption of 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
1511960|NCT02878876|Dietary Supplement|Oral consumption of milk with sequence A2-A1|Oral consumption of 300 ml of milk containing only A2 type beta casein at 8:00 a.m. on Visit 1 (after 12-hour fasting) and 300 ml of milk containing both A1 and A2 type beta casein at 8:00 a.m. on Visit 2 (after 12-hour fasting).
1511961|NCT02878863|Drug|Paeoniflorin + phosphatidylcholine or silymarin|
1511962|NCT02878863|Drug|Phosphatidylcholine or silymarin|
1511966|NCT02878824|Other|Ethnicity|"As mentioned by Goldberger and Veroff (1995) the concept of ethnicity is also associated with culture and is often used interchangeably with culture as well as with race. Ethnic differences are not necessarily inherited, but they are learned through constant exposure; however have strong genetic influences that explain consequent behavioural differences between different ethnic groups (Chudek & Henrich, 2011). An individual's genetic makeup greatly affects their behaviours (Klahr & Burt, 2014).
In this study, we look at exposure to different ethnicity as exemplified by comparison between two groups of typically-developing children from different ethnicity (Chinese children in Hong Kong and Filipino Children in Hong Kong)."
1511967|NCT02878824|Other|Environment|The living environment has been implicated to have an effect on a person's psychological functioning (Rutter, Picker, Murray & Eaves, 2001) and eventually how behaviour is manifested. The proposed disparity or effects between urban and rural dwelling is built on research that looks at the restorative and calming features of the natural environment, as well as the chaotic organization of the living spaces in urban settings.
1511968|NCT02878811|Other|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
1511969|NCT02878798|Drug|topiramate|Oral topiramate at a target dose of 50mg twice daily.
1511970|NCT02878798|Other|Placebo|overencapsulated placebo of identical color, shape and packaging to topiramate
1511971|NCT02878785|Drug|Decitabine|DNA methyltransferase inhibitor
1511972|NCT02878785|Drug|talazoparib|poly ADP ribose polymerase (PARP) inhibitor
1511973|NCT02878772|Drug|vinpocetine|30 mg of the drug by intravenous infusion once daily, for fourteen consecutive days, beginning within one hour after the baseline MRI and no later than 48 hours after the onset of symptoms.
1511974|NCT02878772|Drug|Aspirin|100mg, once daily, oral medication
1511975|NCT02878759|Device|Wristbot|The proposed technology comprises a hardware device with four motors that can apply torques to the human wrist about its three degrees of freedom (i.e. axes of rotation: wrist flexion/extension,abduction/adduction and forearm pronation/supination). This allows for guided and controlled movements of the wrist by delivering assistive, resistive, perturbation or no forces (patient actively moves the wrist). It contains a set of specialized software modules that a) allow for the objective, psychophysical assessment of sensory dysfunction in patients, and b) provide specialized training modules designed to improve sensory and motor functions of the wrist.
1511976|NCT02878746|Device|Robotic mirror therapy|2-dimensional
1511977|NCT02878746|Device|Conventional mirror therapy|2- and 3-dimensional
1511978|NCT02878733|Drug|Albumin|patients that had either received any volume of 5% albumin in addition to at least 500mL of any crystalloid (0.9% saline, buffered salt solutions such as Plasma-Lyte, Lactated Ringers etc.)
1511979|NCT02878720|Device|Transcutaneous vagal nerve stimulation|"The stimulation of the auricular branch of the vagus nerve will be performed through an electric stimulator and two Ag-AgCl electrodes placed in the left external acoustic meatus at the inner side of the tragus. For sham stimulation, electrodes will be attached to the left ear lobe. tVNS will be delivered as trains lasting 30 s and composed by 600 pulses (intra-train pulse frequency = 20 Hz; pulse duration = 0.3 ms) repeated every 5 min for 60 min. The intensity of stimulation will individually adjusted to a level ranging above the detection threshold and below the pain threshold. In this range, when possible, the investigators will chose an intensity of 8 mA.
Each day, for 10 consecutive working days, each patient will receive a session of robotic therapy following the real or sham tVNS stimulation"
1511980|NCT02878707|Drug|Dexmedetomidine|
1511981|NCT02878694|Biological|Myoblast autologous graft|30 million autologous myoblasts in 6 intramuscular injections No treatment in the second eye
1511982|NCT02878681|Drug|Ranibizumab|0.5 mg intravitreal injections
1511983|NCT02878681|Drug|Aflibercept|2 mg intravitreal injections
1511984|NCT02878668|Procedure|hepatopancreatobiliary surgery|hepatopancreatobiliary surgery
1511985|NCT02878629|Device|Mandibular Advancement Devices|
1511986|NCT02878616|Drug|LFG316|LFG316 single dose
1511987|NCT02878616|Drug|IVIG|IVIG single dose
1511988|NCT02878603|Biological|caplacizumab|
1511989|NCT02878590|Device|BONGO DEVICE|A device to be used for the treatment of mild to moderate obstructive sleep apnea
1511990|NCT02878577|Device|fMRI|fMRI scans, mapping brain connectivity using EEG in combination with eye-tracking technology (Brain Network Activation (BNA) technology developed by ELMINDA), characterizing of cortical layers using magnetic resonance (the CoLI technology developed by Tel-Aviv University), and Diffusion Tensor Imaging (DTI) imaging (imaging of brain tracks).
1511991|NCT02878564|Drug|Praziquantel|40 mg/kg, PO (orally administered tablets)
1511992|NCT02878551|Other|Prehabilitation program|multimodal prehabilitation intervention composed of exercise, nutritional supplement and psychological well-being
1511993|NCT02878538|Drug|Deferiprone|Subjects will then begin an experimental No1 design: placebo-deferiprone-placebo. Study drug will be administered in three 3 month blocks. All subjects will receive 30 days of active study drug. The placebo-deferiprone contrast compares placebo to active drug initiation. The deferiprone-placebo contrast tests active drug withdrawal. All will be given placebo in months 1-3, and 6-12. This will allow the investigators to examine active drug exposure on d score up to one year and prospective time to MCI conversion. Dosing: Participants will be treated 25 mg/kg po tid (75mg /kg /d total) The dose will be rounded by the prescriber to the nearest 250 mg (half-tablet).
1511994|NCT02878538|Other|Placebo phase|Placebo tablets with inactive substance will be provided to subjects for two, 3 month blocks during the study.
1511995|NCT02878525|Procedure|Laparoscopic internal gastric banding|Laparoscopic internal gastric banding
1511996|NCT02878525|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
1511997|NCT02878512|Procedure|PCNL under General Anesthesia|Patients undergoing percutaneous Nephrolithotomy received General anesthesia.
1511998|NCT02878512|Procedure|Segmental Epidural Anesthesia|Patients undergoing PCNL surgery received Segmental epidural anesthesia with 0.5% bupivacaine.
1511999|NCT02878499|Other|polysomnography|
2003207|NCT00483496|Drug|Ti02 microfine 12.15% + Ti02 pigmentary 3% + bisoctrizole 10% [V0096 CR (formula RV3131A-MV1166)]|
2003208|NCT00483496|Drug|V0096 CR vehicle (formula RV3131A-MV1197)|
1512191|NCT02877160|Drug|AL-794 suspension|
1512192|NCT02877160|Drug|AL-794 tablet|
2003209|NCT00482053|Procedure|Total lymphoid irradiation (TLI)|
2003210|NCT00482053|Drug|Anti-thymocyte globulin (ATG)|
2003211|NCT00482053|Procedure|Allogeneic hematopoietic cell transplantation|
1512004|NCT02878460|Other|ORI with alarm|If ORI is equal to 0.00, the FiO2 is not changed. if ORI is equal or above to 0.01 --> ORI alarm sounds --> the nurse will decrease the FiO2 of 10%.
1512005|NCT02878460|Other|SpO2|If SpO2 is below to 100%, the FiO2 is not changed. If SpO2 is equal or above to 100% --> the nurse must reduce FiO2 of 10% every 10 minutes until a SpO2 less than 100% , with FiO2≥25 %.
2003212|NCT00482053|Procedure|Autologous hematopoietic cell transplantation (AHCT)|
1512007|NCT02878421|Device|electronic cigarette + 16mg nicotine & flavor|comparison of different strengths of nicotine
1512008|NCT02878421|Other|electronic cigarette + 0mg nicotine & flavor|comparison of different strengths of nicotine
1512009|NCT02878421|Other|Tobacco cigarette|Participant to remain on traditional cigarettes for 28 days
1512010|NCT02878408|Genetic|Blood sampling|supplementary blood sampling for analysis of: immuno-genetic, inflammatory process, retro-viruses activity, Questionaries about environment risk factors
1512011|NCT02878395|Procedure|Ileocolic resection|
1512012|NCT02878382|Other|Conventional MAL-PDT|Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
1512013|NCT02878382|Other|Calcipotriol assisted MAL-PDT|Calcipotriol 50 mcg/g for 15 days prior to PDT. Curettage of lesions and application of MAl cream 16% for 90 minutes under occlusion followed by LED 635 nm illumination at 37 J/cm2 total dose
1512014|NCT02878369|Procedure|Doppler measurement of blood flow in the outflow tract of the left ventricle and the femoral artery,Reading blood pressures displayed on the monitor.|
1512015|NCT02878356|Behavioral|Regular MI-training|Regular training (n= 59) the Motivational Interviewing (MI) -training methods used in the Swedish county councils and municipalities
1512016|NCT02878356|Behavioral|Regular MI-training + supervision half|Regular MI-training followed by six individual MI-supervision sessions at monthly intervals based on only the behavior counts component of MITI (n= 58)
1512017|NCT02878356|Behavioral|Regular MI-training + supervision full|Regular MI-training followed by MI-supervision based on both the behavior counts and the five global dimensions of MITI (n= 58)
1512018|NCT02878343|Behavioral|Incentives|Daily lottery type incentives tied to achievement of weight loss goals
1512019|NCT02878343|Behavioral|Environmental strategies|Individually tailored environmental strategies around food intake and physical activity; automated text/emails sent from study website platform
1512020|NCT02878330|Drug|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life
1512021|NCT02878330|Drug|Placebo|Commercially available 0.9% (w/v) saline.
1512022|NCT02878317|Other|Low AGE diet|The low AGE diet will focus in reducing the AGE content in food by changing cooking techniques and by choosing foods low in AGEs according to a food choice list.
1512023|NCT02878291|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 1:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 10 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
1512024|NCT02878291|Biological|Meningococcal ACYW135 Polysaccharide Conjugate Vaccine|Group 2:3/2/1 dose(s) according to age of subjects. Single intramuscular dose contains 5 µg each of Serogroup A, C, Y, and W135 polysaccharide conjugated to Tetanus Toxoids.
1512025|NCT02878278|Drug|Chidamide BIW|Chidamide is given 30mg, twice a week
1512026|NCT02878278|Drug|Chidamide QD|Chidamide is given 10mg,QD
1512027|NCT02878265|Dietary Supplement|Vitamin A|Vitamin A supplements
1512028|NCT02878265|Dietary Supplement|Vitamin A and ZInc|Combination of vitamin A and zinc supplements
1512029|NCT02878265|Dietary Supplement|Vitamin A , Zinc and Multivitamin|Combination of vitamin A, zinc and multivitamins
1512030|NCT02878239|Other|Steps 1|Kinematic characteristics are obtained by the portal gait analysis system in the patients. Kellgren-Lawrence Scores are obtained according to their radiography.
1512031|NCT02878239|Other|Steps 2|Kinematic characteristics are obtained by the portal gait analysis system in the subjects.Physical examinations are taken to avoid other diseases.
1512032|NCT02878226|Procedure|repair of rupture|
1512033|NCT02878213|Device|D700 System|Atrial Fibrillation Ablation Procedure
1512034|NCT02878200|Biological|dihydroartemisinin-piperaquine|A treatment course of DHAP consists of three doses taken daily. Treatment doses for household members will be prepared based on measured weight
1512035|NCT02878187|Device|Doppler|"Color Doppler ultrasound will be used to demonstrate the main ascending branches of left and right uterine arteries as they cross over the hypogastric vessels just before they enter the uterus at the uterine-cervical junction. The high pass filter was set at 125 Hz and the uterine artery will be obtained immediately after the crossing of the hypogastric artery. The sample volume will be placed on the artery with an angle of about 0°. After detection of blood flow and visu¬alization of the waveform of the uterine artery, five blood flow indices will be automatically cal¬culated:
The pulsatility index The resistance index The peak systolic velocity ; The end-diastolic velocity The time-averaged maximum"
1512036|NCT02878174|Procedure|internal jugular vein catheterization|internal jugular vein catheterization using ultrasound (US) or US-based prelocation techniques
1512037|NCT02878161|Drug|methotrexate(necessary)|Methotrexate will be received orally with dosage of 10mg/ week for every patient and MTX dose must be stable for at least 4 weeks.
1512038|NCT02878161|Biological|infliximab|infliximab :intravenous injection 200mg,every times,0,2,6,14week ,4 times)
1512039|NCT02878161|Biological|etanercept|Etanercept :hypodermic injection,25mg/twice a week
1512040|NCT02878161|Biological|adalimumab|Adalimumab:hypodermic injection,40mg/twice a week
1512041|NCT02878161|Drug|leflunomide (permitted, not necessary)|LEF will be permitted if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
1512042|NCT02878161|Drug|NSAIDs (permitted,not necessary)|NSAIDs will be allowed if patient had received for 1 month before enrollment and will not be changed for 14 weeks.
1512043|NCT02878161|Drug|Glucocorticoids (permitted,not necessary)|Glucocorticoids (prednisone less than 10mg/day, or equal dosage of other similar drugs) will be permitted if the patient had received for 1 month before enrollment and the dosage will not be changed during the period.
1512044|NCT02878148|Device|Diagnostic imaging modalities for suspected renal colic|"All patients included will undergo ultrasonography in addition to unenhanced CT of pelvis and abdomen and plain X-ray of the abdomen.
Imaging examination will be performed according to current guidelines.
Ultrasonography study and colour doppler will include the kidney, ureterovesical joint and ureters. Unenhanced CT will be performed using a dedicated low-dose protocol."
1512045|NCT02878135|Procedure|fast application|
1512046|NCT02878135|Procedure|slow application|
1512047|NCT02878122|Procedure|Cancer treatment|Chemotherapy and laparoscopic surgery
1512048|NCT02878109|Device|All patients enrolled|4D-THRIVE and 4D-FLOW using magnetic resonance imaging (MRI)
1512049|NCT02878096|Drug|[14C]-SK-1404|In Part 1, each subject will receive a single PO dose of SK-1404 followed by an IV microtracer dose of [14C]-SK-1404.
1512050|NCT02878083|Drug|VEDOLIZUMAB|Infusion at week 0 week 2 week 6 week 14 for all patients Infusion at week 22 for responder patient only
1512051|NCT02878083|Drug|ADALIMUMAB|For nonresponder patients only : Injection at week 22 week 24 week 26 and week 28
1512052|NCT02878070|Behavioral|Calls from a Peer Health Coach for 6 months|Weekly calls for 2 months, bi-weekly calls for 2 months, monthly calls for 2 months.
1512053|NCT02878057|Drug|Apatinib|Dosing regimen: apatinib tablets: 500 mg, Po, QD; 4 weeks as a cycle, continuous treatment until disease progression, death or intolerable toxicity (giving endocrine therapy simultaneously if hormone receptor positive)
1512055|NCT02878031|Drug|Oral amoxicillin for CI pneumonia|"CHW management of chest indrawing (CI) pneumonia in children 2-59 months old using oral amoxicillin, given in the following age specific dosage:
2 months ≤ children age <12 months (4 - <10kg): one (1) tablet 250mg dispersible amoxicillin twice daily (morning and evening) for 5 days.
12 months≥ children age <3 years (10 kg - <14 kg): two (2) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days.
≥ 3 years of age children <5 years (14kg - 19kg): three (3) tablets 250mg dispersible amoxycillin taken twice daily (morning and evening) for 5 days."
1512056|NCT02878018|Drug|Qi ji shen kang lotion;Zhubai lotion;More Kidney lotion|Qijishenkang lotion(Xiao Ji15-25g,Lao Tou cao10-20g,Bai hua she she cao10-20g,Chong Lou10-15g,Xian He cao10-15g,Dan Pi10-15g,Dan Shen15-20g,Huang Qi15-25g) Zhubai lotion(Tu Fu ling10-20g,Cang Zhu5-10g,Huang Bai10-15g,Lao Tou cao10-15 g,Xiao Ji10-20g,Mao Gen10-20g,Sheng Di yu10-15 g,Pu Huang tan5-10g,Sheng Di5-10g,Dang Gui5-10g) More Kidney lotion(Huang Qi15-25g,Tai Zi shen10-15g,Xiao Ji10-20g,Bai Mao gen10-20g,Bai hua she she cao10-20g,Dan Shen10-20g,Sheng Di10-20g,Zi Cao10-20g,Yi Mu cao10-20g,Ji Guan hua10-15g,Qian Shi10-20g,Dan Pi10-15g,Gan Cao5-15g) 5—10years：lotion,150ml/d,3 times a day;11—14years：lotion,240ml/d,3 times a day;15—18years：lotion,300ml/d,3 times a day
1512057|NCT02878018|Drug|Angiotensin-converting enzyme inhibitor orangiotensin II receptor blocker ;Tripterygium Glycosides;Adrenocorticotropic hormone ;Other Immunosuppressant|ACEI or ARB:Captopril or Losartan and so on; Tripterygium Glycosides:1 mg/(kg·d),3 times oral,3-6months; ACTH:1-1.5mg/Kg.d,3-6months; Other Immunosuppressant:Cyclophosphamide,CYA,MMF and so on
1512058|NCT02878005|Device|Intubating Laryngeal Tube Suction|Intubating Laryngeal Tube Suction
1512059|NCT02878005|Device|Ambu AuraGain Laryngeal Mask|Ambu AuraGain Laryngeal Mask
1512060|NCT02877992|Procedure|Ovarian puncture|Donors and patients are subjected to ovarian puncture as part of their donation procedure or IVF treatment. Oocyte are retrieved in this procedure along with granulosa and cumulus cells. Donors and patients sign an informed consent in order to donate their granulosa and cumulus cells for the study.
1512061|NCT02877979|Drug|DS003 vaginal tablet|The trial will be conducted in three cohorts of 12 women each. In each cohort, participants will be randomised in a 3:1 ratio to receive either DS003 or placebo on Day 0 and Day 17. In each cohort, therefore, 9 participants will receive DS003 vaginal tablets and 3 participants will receive placebo vaginal tablets.
1512062|NCT02877979|Drug|Placebo|
1512063|NCT02877966|Dietary Supplement|Amixea|Amixea is a mixture of amino acids. It consists mainly of essential amino acids (EAA) that cannot be synthesized de novo by the organism, and therefore must be supplied in its diet.
1512064|NCT02877966|Other|Placebo|
1512065|NCT02877953|Behavioral|the prevention of complications post-TIPS|Continuous nursing through telephone follow-up, family visits, and WeChat guided patients to prevent gastrointestinal bleeding, infection and constipation ,intake quality low-protein diet, recognize minimal encephalopathy, monitor blood ammonia, return visit regularly, deal with adverse drug reactions of anticoagulant.
2003216|NCT00464386|Device|Continuous Glucose Monitoring|measure glucose levels on burn patients
2003217|NCT00326417|Drug|Fludarabine|Doses of 30 mg/m^2 IV will be given for no less than 30 minutes daily for 4 days (Days -5 to -2)
2003218|NCT00326417|Drug|Cyclophosphamide 150mg|A total dose of 150 mg/kg will be given as 50 mg/kg per day for 3 days (Days -4, -3, -2)
1512069|NCT02877927|Drug|Omadacycline|po tablets
1512070|NCT02877927|Drug|Linezolid|po tablets
1512071|NCT02877914|Other|Observational study|This is a non-interventional study, patients receive their usual treatment as determined by the physician.
1512072|NCT02877901|Drug|long acting tolterodine 4 mg|receive one tablet at bed time for 4 weeks
1512073|NCT02877901|Drug|placebo|one tablet at bed time
1512074|NCT02877888|Drug|fluoride varnish 22600ppm|topical application on teeth every 6months
1512075|NCT02877875|Behavioral|Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, and Conduct Problems|MATCH-ADTC (Chorpita & Weisz, 2009) is designed for children aged 6-15. Unlike most evidence-based treatments (EBTs), which focus on single disorder categories (e.g., anxiety only), MATCH is designed for multiple disorders and problems encompassing anxiety, depression, post-traumatic stress, and disruptive conduct, including the conduct problems associated with ADHD. MATCH is composed of 33 modules—i.e., specific treatment procedures derived from decades of research on EBTs. The various modules can be organized and sequenced flexibly to tailor treatment to each child's characteristics and needs.
1512229|NCT02876874|Drug|indocyanine green(ICG)|ICG will be injected into the dorsal of hand/foot
1512076|NCT02877875|Other|Monitoring and Feedback System|For each child, the web-based MFS system provides weekly monitoring of the MATCH modules used and the child's treatment response, in two forms (a) changes on the Behavior and Emotions Survey and (b) changes in severity of the top treatment concerns identified by youths and caregivers. At the end of treatment, the MFS provides a complete record of modules used, and child treatment response, across all the weeks of treatment.
1512077|NCT02877875|Behavioral|Treatment as usual|Treatment in the UC condition will use the procedures therapists and their supervisors consider appropriate and believe to be effective.
1512078|NCT02877862|Behavioral|mAGIC app|7-day app to encourage uptake of genetic counseling
2003219|NCT00326417|Drug|Cyclophosphamide 100mg|A total dose of 100 mg/kg will be given as 50 mg/kg per day for 2 days (Days -3, -2)
1512080|NCT02877836|Other|magnetic resonance imaging (fMRI)|To identify movement-related fMRI activation pattern in dystonic patients in comparison to healthy controls Assessment of white matter integrity in the corticospinal tract in a group og dystonic patients compared with the healthy control group
2003220|NCT00326417|Drug|Cyclophosphamide 50mg|A total dose of 50 mg/kg will be given once at 50 mg/kg per day on Day -2
1512083|NCT02877810|Other|Telemedicine|Telemedicine is a live, interactive, audiovisual teleconferencing system.
1512084|NCT02877810|Other|Telephone|Consultations will be given over telephone.
1512085|NCT02877797|Device|Cap|cap assisted esophagogastroduodenoscopy
1512086|NCT02877784|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
1512087|NCT02877784|Drug|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
1512088|NCT02877784|Device|Electrical Impedance Myography (EIM)|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
1512089|NCT02877784|Procedure|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
1512090|NCT02877784|Other|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
1512091|NCT02877784|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
1512092|NCT02877784|Other|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
1512093|NCT02877784|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
1512094|NCT02877784|Other|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
1512095|NCT02877784|Other|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
1512096|NCT02877771|Device|t:slim insulin pump with predictive low glucose suspend|To assess the functionality of a predictive low glucose suspend (PLGS) system that uses Continuous Glucose Monitoring (CGM) values to suspend basal insulin delivery when hypoglycemia is predicted as well as resume basal insulin delivery once Continuous Glucose Monitoring (CGM) values begin to increase.
1512097|NCT02877758|Other|Tomorrowlabs cosmeceutical formulation|
1512098|NCT02877758|Other|Sham cosmeceutical formulation|
1512099|NCT02877745|Other|Stratification, no intervention|
1512100|NCT02877732|Device|EYE-SYNC eye-tracking|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
1512101|NCT02877732|Other|SCAT-3 subtests|Following subtests of SCAT-3 will be administered to the participant: Symptom, Balance, Orientation and Immediate memory
1512102|NCT02877732|Other|DEM|Participant will be asked to read list of numbers out loud from a card
1512103|NCT02877732|Other|Simple Reaction Time subtest of ANAM-SRT|Participants will perform Simple Reaction Time sub-test of ANAM-SRT test. They will be asked to click the mouse button every time they see an asterisk on the screen. Participants will perform ANAM-SRT 1 and ANAM-SRT 2 in this study.
1512104|NCT02877732|Other|Level of Alertnesss|Participants will answer questions. This assessment is to assess their alertness level.
1512105|NCT02877719|Other|Questionnaires|Participants were asked to respond to the Chinese version of the Center for Epidemiologic Studies Depression Scale for Children, the Rosenberg self-esteem scale, and the Pediatric Quality of Life Inventory.
1512106|NCT02877706|Other|no specific intervention|
1512107|NCT02877693|Radiation|Thoracic MRI Scan|is to demonstrate the MRI scan will not adversely affect the functionality of the ICD system. To do so, the ICD system will be exposed to MRI scan of thoracic region, where the radiofrequency (RF) component of the scan is maximized.
1512108|NCT02877680|Behavioral|T1Doing Well|Strengths-based mobile health (mHealth) app for parents of adolescents with type 1 diabetes, which will prompt parents to recognize and reinforce their adolescents' diabetes-related strength behaviors
1512109|NCT02877667|Device|planar acoustic wave device|accessory to laser treatment
1512224|NCT02876900|Drug|Low Dose Asenapine maleate, transdermal patch|The study will evaluate low dose Asenapine maleate transdermal patches versus placebo transdermal patches.
1512230|NCT02876861|Procedure|Radical nephroureterectomy|Radical nephroureterectomy (RNU) with an ipsilateral bladder cuff
1512110|NCT02877654|Procedure|colonoscopy with biopsies in the left colon to assess intestinal permeability|"Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin; occludin and ZO-1.
One blood sample is taken to assess plasmatic zonulin (ELISA kit)."
1512111|NCT02877641|Dietary Supplement|Cholecalciferol|Given PO
1512112|NCT02877641|Other|Laboratory Biomarker Analysis|Correlative studies
1512113|NCT02877641|Dietary Supplement|Multivitamin|Given PO
1512114|NCT02877641|Other|Placebo|Given PO
1512115|NCT02877641|Other|Questionnaire Administration|Ancillary studies
1512116|NCT02877628|Other|Pharmacokinetic-pharmacodynamic model in liver transplantation|Biological: tacrolimus and calcineurin dosage, donor and recipient CYP3A5 and ABCB1 genotypes determination
1512117|NCT02877615|Drug|S 44819 150 mg twice a day|One sachet of S 44819 150 mg and one sachet of placebo twice a day
1512118|NCT02877615|Drug|S 44819 300 mg twice a day|Two sachets of S 44819 150 mg twice a day
1512119|NCT02877615|Drug|Placebo|Two sachets of placebo twice a day
1512120|NCT02877602|Device|MRI|
1512121|NCT02877602|Device|Transient Elastography|
1512122|NCT02877589|Other|hepatitis B virus (HBV) and hepatitis C virus (HCV) serologies and a screening questionnaire to detect risk factors of hepatitis B virus (HBV) and hepatitis C virus (HCV)|
1512123|NCT02877576|Procedure|Implantation of mixed intracerebral electrodes|"5 macro electrodes with micro electrodes are implanted in internal temporal structures (amygdala, anterior and posterior hippocampus, rhinal cortex, posterior para-hippocampal gyrus).
Each electrode has 8 microcontacts, each recording the activity of 0 to 3 neurons (activity of 0 to 120 neurons/patient)."
1512124|NCT02877576|Behavioral|Face detection|Visualization of images of 60 unknown faces and 60 objects that are not faces (object, house, scene, animal, plant, word, letter…). Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
1512125|NCT02877576|Behavioral|Face individualization|"Visualization of images of celebrities (persons known by patient), showed randomly. Each image is showed for 500 ms and separated from following image by black screen of 1500 ms. In order to keep patient attention on image, patient will be asked to push a button at color change of fixation cross in the centre of image.
Several celebrities are showed, with for each the presentation of 60 images different from that celebrity. 1 to 3 celebrities are showed (60 to 180 total images)."
1512126|NCT02877563|Other|Contrast ultrasound perfusion imaging of the limb|Contrast enhanced ultrasound imaging at rest and during contractile exercise will be performed prior to revascularization and 3-4 weeks after revascularization.
1512127|NCT02877550|Drug|Obinutuzumab|Obinutuzumab: 1000 mg, i.v. infusion; d1, 8, 15 C1 and d1 C2-6
1512128|NCT02877550|Drug|Venetoclax|p.o. once daily according to dose level (DL) or MTD
1512129|NCT02877537|Drug|Salbutamol|bronchodilation obtained with 2 inhalations of salbutamol (100 µg per dose) with inhalation chamber
1512130|NCT02877537|Procedure|Forced oscillation technique|before and after bronchodilation
1512131|NCT02877537|Procedure|Plethysmography|
1512132|NCT02877524|Other|Adaptive support ventilation|ASV during NIV
1512133|NCT02877524|Other|Pressure support ventilation|PSV during NIV
1512134|NCT02877511|Drug|BAY987517|Applied liberally to the skin (Formulation: Y73-161
1512135|NCT02877511|Drug|Sunscreen Lotion (Y65-110)|Applied liberally to the skin
1512136|NCT02877498|Other|Adaptive support ventilation|Adaptive support ventilation during invasive mechanical ventilation
1512137|NCT02877498|Other|Volume controlled ventilation|Volume controlled ventilation during invasive mechanical ventilation
1512138|NCT02877485|Drug|Triamcinolone Acetonide|2 sprays sprayed to both nostrils daily for 42 days.
1512139|NCT02877485|Drug|Ayr saline nasal mist|110mcg (2 sprays) sprayed to both nostrils daily for 42 days.
1512140|NCT02877472|Device|porous tantalum rod|Patients with avascular necrosis of the femoral head after femoral head fracture surgery receive treatment of core decompression and porous tantalum rod implantation
1512141|NCT02877472|Procedure|core decompression|Patients with avascular necrosis of the femoral head after femoral head fracture surgery will undergo core decompression.
1512142|NCT02877459|Device|AeriSeal System|Subjects will undergo two bronchoscopy procedures two months apart and will be treated with AeriSeal foam unilaterally, in two sub-segments during each bronchoscopy (4 segments treated in total).
1512143|NCT02877433|Device|Roxolid short implant, 4 mm length (4)|Placement of a combination of four short implants (in positions 35/45, 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
1512144|NCT02877433|Device|Roxolid short implant, 4 mm length (2)|Placement of a combination of two short implants (in positions 36/46) as distal support and two implants of conventional length (in positions 33/43) in the interforaminal region, in order to support a cross-arch fixed screw-retained prosthesis.
1512145|NCT02877420|Other|Non-Technical Skills Training Curriculum|
1512146|NCT02877420|Other|Conventional Simulation Training Group|
1512147|NCT02877407|Procedure|patient who undergo laparoscopic/robotic-assisted hysteropexy|
1512148|NCT02877407|Procedure|patient who undergo vaginal hysterectomy|
1512149|NCT02877394|Device|Squatting Assist Device|The Squatty Potty is a 7 inch tall stool to assist subjects in maintaining a squatting position while using a toilet. While sitting on the toilet, the subject supports her feet on the Squatty Potty.
1512150|NCT02877394|Device|Sham Squatting Assist Device|This stool will be 2 inches tall and be similar in appearance to the Squatty Potty. While sitting on the toilet, the subject supports her feet on the 2 inch high stool.
1512151|NCT02877381|Procedure|Revision Total Knee Arthroplasty (TKA)|Femoral component exchange, tibial component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision TKA, randomization will be done to ensure equivalent numbers of each type of revision TKA between the treatment groups.
1512225|NCT02876900|Drug|High Dose Asenapine maleate, transdermal patch|The study will evaluate high dose Asenapine maleate transdermal patches versus placebo transdermal patches.
1512152|NCT02877381|Procedure|Revision Total Hip Arthroplasty (THA)|Femoral component exchange, acetabulum component exchange, both component exchange, explant of both components and placement of antibiotic cement spacer, or a second stage re-implantation procedure. Given the variability in blood loss between types of revision THA, randomization will be done to ensure equivalent numbers of each type of revision THA between the treatment groups.
1512153|NCT02877368|Other|Computed tomography|
1512155|NCT02877342|Other|Pre-hospital notification|Pre-hospital notification smartphone/tablet application in the form of an Android program that will be used by ambulance clinicians to notify emergency departments of selected hospitals of an impending arrival of a patient.
1512156|NCT02877329|Behavioral|Internet-delivered ACT|Therapist-guided Internet-delivered ACT (acceptance and commitment therapy) for 8 weeks
1512157|NCT02877316|Other|MYPLAN-safety plan as an application for smart phones|MYPLAN app as a integral part of the standard treatment
1512158|NCT02877316|Other|safety plan on paper|Standard treatment with safety plan on paper
1512159|NCT02877303|Drug|Cyclophosphamide|Cycles 1 + 3: 300 mg/m2 by vein over 3 hours every 12 hours for 6 doses Days 1,2,3 (total dose 1800 mg/m2).
1512160|NCT02877303|Drug|MESNA|Cycles 1 + 3: 600 mg/m2/d by vein continuous infusion daily for 24 hrs, starting approximately 1 hour prior to Cyclophosphamide and completing by approximately 12 hrs after the last dose of Cyclophosphamide.
1512161|NCT02877303|Drug|Dexamethasone|Cycles 1 + 3: 40 mg by vein or by mouth daily on Days 1-4 and Days and Days 11-14.
1512162|NCT02877303|Drug|Ofatumumab|"Cycles 1 + 3: 2000 mg by vein on Day 1 and 11 for patients with positive cluster of differentiation antigen 20 (CD20) expression (regardless of level of expression). (Ofatumumab given at the dose of 300 mg on Day 1 of cycle 1. Subsequent infusions given at the dose of 2000 mg).
Cycles 2 + 4: 2000 mg by vein on Day 1 and 8 for patients with positive CD20 expression (regardless of level of expression)."
1512163|NCT02877303|Drug|Methotrexate|"Cycles 1 + 3: 12 mg intrathecally (6 mg via Ommaya reservoir) on Day 2.
Cycles 2 + 4: 200 mg/m2 by vein over 2 hrs followed by 800 mg/m2 over 22 hrs on Day 1.
Maintenance Therapy: Methotrexate 20 mg/m2 (rounded) by mouth weekly."
1512164|NCT02877303|Drug|Doxorubicin|Cycles 1 + 3: 50 mg/m2 by vein over 24 hrs via central venous catheter on Day 4 after last dose of Cyclophosphamide.
1512165|NCT02877303|Drug|Vincristine|"Cycles 1 + 3: 2 mg by vein on Day 4 and Day 11.
Maintenance Therapy: Vincristine 2 mg by vein approximately every 28 days."
1512166|NCT02877303|Drug|Cytarabine|"Cycles 1 + 3: 100 mg intrathecally on Day 7.
Cycles 2 + 4: 3 g/m2 by vein over 2 hrs every 12 hrs for 4 doses on Days 2 and 3.
CNS prophylaxis: Cytarabine 100 mg intrathecally Day 7."
1512167|NCT02877303|Drug|Rituximab|"Cycles 1 + 3: 375 mg/m2 by vein Days 1 and 11. Replaces Ofatumumab if insurance does not approve Ofatumumab and if CD20 expression is ≥10%.
Cycles 2 + 4: 375 mg/m2 by vein on Days 2 and 8. Replaces Ofatumumab if insurance does not approve Ofatumumab and if CD20 expression is ≥10%."
1512168|NCT02877303|Drug|Pegfilgrastim|Cycles 1 + 3: 6 mg as a one-time dose at the end of every cycle until post-nadir granulocytes > 1.0 x 109/L.
1512169|NCT02877303|Drug|G-CSF|Cycles 1 + 3: G-CSF 10 mcg /kg (rounded) subcutaneously daily (or 5 mcg /kg twice daily) until post-nadir granulocytes > 1.0 x 109/L.
1512170|NCT02877303|Drug|Leucovorin|Cycles 2 + 4: Leucovorin rescue 50 mg by vein followed by 15 mg by vein every 6 hours for 8 doses beginning 12 hrs +/- 2 hrs post Methotrexate.
1512171|NCT02877303|Drug|Blinatumomab|Blinatumomab administered as continuous intravenous infusion at a dose of 28 μg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle for 4 cycles. In the first cycle, the initial dose of Blinatumomab is 9 μg/day for the first 7 days of treatment (to mitigate for potential cytokine release syndrome (CRS) and central nervous system (CNS) events associated with introduction to blinatumomab, then escalated to 28 μg/day starting on Day 8 (Week 2) through Day 29 (Week 4). For all subsequent cycles, 28 μg/day is the dose for all 4 weeks of continuous treatment every 6 weeks.
1512172|NCT02877303|Drug|6-Mercaptopurine|Maintenance Therapy: 6-mercaptopurine 50 mg by mouth three times daily.
1512173|NCT02877303|Drug|Prednisone|Maintenance Therapy: Prednisone 200 mg by mouth daily Days 1 to 5 approximately every 28 days, starting with Vincristine (if given).
1512174|NCT02877303|Behavioral|Phone Calls|Participant called by the study staff and asked about their health 1 time each month for up to 24 months after all participants have been enrolled in the study. These calls should last about 5-10 minutes each.
1512175|NCT02877290|Device|non-invasive ventilation (NIV)|
1512176|NCT02877277|Dietary Supplement|Vitamin C|Oral intake of vitamin C tablet (500 mg) daily for 56 days
1512177|NCT02877277|Dietary Supplement|Placebo|Oral intake of placebo tablet daily for 56 days
1512178|NCT02877264|Drug|vapendavir 132 mg capsule|
1512179|NCT02877264|Drug|vapendavir 264 mg tablet|
1512180|NCT02877264|Drug|vapendavir 24 mg/mL oral suspension|
1512181|NCT02877238|Drug|Sevoflurane plus remote ischemic preconditioning|Inhalational anesthesia (Sevoflurane) in addition to remote ischemic preconditioning
1512182|NCT02877238|Drug|Total intravenous anesthesia plus remote ischemic preconditioning|Total intravenous anesthesia (propofol plus fentanyl) in addition to remote ischemic preconditioning
1512183|NCT02877225|Drug|Ibrutinib|Ibrutinib (test treatment) 140 milligram (mg), tablet.
1512184|NCT02877225|Drug|IMBRUVICA|IMBRUVICA (reference treatment), 140-mg capsule
1512185|NCT02877212|Drug|Eltrombopag|Eltrombopag will be given to steroid refractory ITP patients and ITP patients treated with standard Immunosuppressive therapy (IST) will be taken as control.
1512186|NCT02877199|Other|Triple therapy|Cohort of patients who received triple therapy combining pegylated-interferon/ribavirin + first generation protease inhibitor boceprevir or telaprevir as part of routine clinical practice
1512187|NCT02877186|Other|commercially-available diet soda|Subjects are asked to consume diet soda three times daily for one week.
1512188|NCT02877186|Other|carbonated water (control)|Subjects are asked to consume carbonated water three times daily for one week.
1512189|NCT02877173|Drug|Alprostadil Liposomes for Injection|3 doses of Alprostadil Liposomes for Injection are 20ug/q.d,40ug/q.d,60ug/q.d.All groups will be continuous administration for 3 weeks.
1512190|NCT02877173|Drug|Alprostadil Injection|Alprostadil Injection(the positive control group):10ug/q.d,continuous administration for 3 weeks.
1512193|NCT02877147|Other|SEBTC|SEBTC benefits were issued on EBT cards using either the existing EBT delivery systems for the Supplemental Nutrition Assistance Program (SNAP) or Supplemental Nutrition Assistance Program for Women Infants and Children (WIC). Sites selected only one of the two EBT systems to be used to implement SEBTC prior to random assignment; households were not randomized to a specific delivery system.
1512194|NCT02877134|Drug|JNJ-64304500|Participants will receive JNJ-64304500 Subcutaneously.
1512195|NCT02877134|Drug|Placebo|Participants will receive placebo Subcutaneously.
1512196|NCT02877134|Drug|Ustekinumab|Participants will receive ustekinumab as per the dosing regimen.
1512197|NCT02877095|Drug|Furosemide|subcutaneous furosemide delivered via subcutaneous pump
1512198|NCT02877082|Biological|Thymoglobulin|Given IV
1512199|NCT02877082|Drug|Bortezomib|Given IV
1512200|NCT02877082|Drug|Tacrolimus|Given IV and PO
1512201|NCT02877069|Device|VYC-12 HA injectable gel|VYC-12 Hyaluronic Acid (HA) injectable gel administered as an intradermal injection.
1512202|NCT02877056|Procedure|Endoscopy|Tissue samples taken from tumor and normal colorectal tissue during standard endoscopy before therapy.
1512203|NCT02877043|Procedure|resection pulmonaire|
1512204|NCT02877030|Other|Video game|The protocol sensorimotor exercises consist of a virtual game that attaches to the Nintendo Wii and using arrows that are thrown from above, players must perform weight-shifting movements in the Nintendo platform to the target be directed to the trajectory the arrows. The goal is to catch as many arrows.
1512205|NCT02877017|Behavioral|Family safety reporting bundle|family safety reporting intervention for families and providers
1512206|NCT02877004|Device|3 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatment - at a frequency of 3 times per week for 4 weeks
1512207|NCT02877004|Device|2 Low-Level Laser Therapy Treatments Weekly|Receives 12 LLLT treatments - at a frequency of 2 times per week for 6 weeks
1512208|NCT02877004|Device|1 Low-Level Laser Therapy Treatment Weekly|Receive 12 LLLT treatments - at a frequency of once per week for 12 weeks
1512209|NCT02876991|Procedure|Sodium fluoride PET|"Sodium fluoride Pet is realized maximum after 4 weeks from choline PET (inclusion).
Injection of 4MBq 18F-FNa/kg of body weight is followed after 60 min (± 5 min) by acquisition of images on Biograph 6 PET/CT scanner (SIEMENS).
Data from sodium fluoride PET are interpreted independently and blind from other data by 3 medical doctors (2 at hospital of Nancy and 1 at hospital of Strasbourg) (for inter-judge reproducibility); a second interpretation of data is consensually realized by 2 of 3 readers, limited to discordant analyses (metastatic status or not, and/or number of lesions); results from this second interpretation are final results."
1512210|NCT02876978|Genetic|CAR-GPC3 T Cells|Intravenous infusion of CAR-GPC3 T cells is conducted 1 - 2 days following lymphodepletion.
1512211|NCT02876978|Drug|Fludarabine|30 mg/m^2/day x 4 days
1512212|NCT02876978|Drug|Cyclophosphamide|500 mg/m^2/day x 2 days
1512213|NCT02876965|Procedure|Muscle Stretching|Once the program of aerobic physical exercise of moderate intensity is completed, subjects will perform a program of stretching on the main muscle groups of the body
1512214|NCT02876965|Procedure|Physical Exercise|Aerobic physical exercise program of moderate intensity
1512215|NCT02876952|Other|HIGH VOLUME (HV) Supervised exercise|"Supervised exercise two nonconsecutive days per week (day 1-on the treadmill, day 2-on the bike) for 16 weeks. High-intensity interval training (HIIT) protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. 1-4 min cool-down at moderate-intensity.
HIIT protocol on the bike: 5 to 10-min warm-up at moderate intensity. After that, 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 16 repetitions in HV-HIIT week by week. 5-10 min cool-down at moderate-intensity"
1512216|NCT02876952|Other|Mediterranean Diet Recommendations|"Participants will be interviewed regarding their usual eating habits. They will receive practical information about which are the Mediterranean Diet (DMed) foods according to the model proposed in the PREDIMED trial. Medical doctors or nurses will give this information.
Before starting the program of intervention, participants will assist to an informative talk in which benefits for the health of the DMed will be exposed and general information about food composition, frequencies of consumption, etc. will be explained.
Nutritional management: Diet reviews and body mass control will be performed every two weeks to assess the body composition and adherence to treatment. In the event of poor compliance strategies will be addressed for its correction."
1512217|NCT02876952|Other|Physical Activity Recommendations|Participants will be advised to perform, without supervision, moderate to high-intensity dynamic aerobic exercise (walking, jogging, cycling or swimming) 3-5 days per week, following an adequate warm-up of 5-15 min, at moderate to high intensity (below the ischemic threshold) for a period of 20 to 40 min (not including warm-up and cool-down) followed by a cool-down period of 5-10min. Participants will receive information related to heart rate values regarding moderate and high exercise intensity domains for the self monitoring of exercise intensity.
1512218|NCT02876952|Other|LOW VOLUME (LW) Supervised exercise|Supervised exercise two nonconsecutive days per week (one day on the treadmill, and the second one on the bike) for 16 weeks. HIIT protocol on the treadmill: 5-min warm-up at a moderate-intensity, before walking 2 intervals of 4 min at high-intensity interspersed with intervals of 3 min of walking at moderate-intensity. The training session will end with a 1-4 min cool-down period at moderate-intensity. Total exercise time of 20min HIIT protocol on the bike: 10-min warm-up at moderate intensity. After that, participants will cycle for 4 repetitions (1rep = 30 s high-intensity followed by 60 s moderate-intensity) and gradually increased to 8 repetitions in LV-HIIT week by week. The training session will end with a 5-10 min cool-down period at moderate-intensity.
1512219|NCT02876939|Other|kinesiology tape around the hip, knee and ankle joints|We will also demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
1512220|NCT02876939|Other|No kinesiology tape around the hip, knee and ankle joints|Investigators will demonstrate that taping the skin increases the central representation of cutaneous afferent input in HSAN III.
1512221|NCT02876926|Behavioral|"Smart home-based test for HIV"|A standard home-based HIV test kit, fit with a Bluetooth low energy beacon to allow remote monitoring.
1512222|NCT02876926|Behavioral|Home-based testing only|A standard home-based HIV test kit.
1512223|NCT02876926|Behavioral|Reminder letters for clinic-based testing|Letters reminding patients to get tested at a free clinic location
1512232|NCT02876861|Drug|Neoadjuvant Chemotherapy|Gemcitabine, 1250mg/m2, d1 d8, Cisplatin, 75mg/m2, d1-d3, 21d, 2-4 cycles.
1512233|NCT02876848|Other|OPTIMUM e-health tool|"If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to:
Contact you over the phone or in person to provide medical advice on how to better take your pills,
Contact your pharmacist(s) and other doctors about your anti-cancer treatment."
2003221|NCT00317772|Drug|Topotecan|"Phase I Starting Dose: 2 mg/m^2 by vein Weekly Over 30 Minutes on Days 1, 8, and 15.
Phase II: MTD dose from Phase I by vein weekly on Days 1, 8, and 15."
2003222|NCT00317772|Drug|Gefitinib|"Phase I: 250 mg by mouth daily for 28 Days.
Phase II: 250 mg by mouth daily for 28 Days."
1512238|NCT02876822|Drug|Vitamin D|
1512239|NCT02876796|Drug|GS-0976|Capsule(s) administered orally
1512240|NCT02876796|Drug|Placebo|Capsule(s) administered orally
1512241|NCT02876796|Other|1-13C acetate|10 g ± 0.25 g in 1000 mL 0.45% saline solution administered intravenously for 19 hours
1512242|NCT02876796|Other|Fructose solution|Fructose solution administered orally under fasted conditions immediately after study drug and every 30 minutes for a total of 20 doses
1512243|NCT02876783|Other|Observational - No intervention|
1512244|NCT02876770|Dietary Supplement|Experimental: Melatonin|Our protocol was composed of three experimental sessions. During each testing session, participants were requested to attend the laboratory at 20:00h where they ingested a standardized light meal. Melatonin (5 mg or 8 mg) or placebo were ingested in capsule in the evening at 21:00h in a double-blind randomized design
1512245|NCT02876770|Dietary Supplement|Placebo|In a double-blind randomized design, participants have taken placebo supplementation in one of the three experimental sessions
1992850|NCT03286855|Device|Vibrating Mesh Nebuliser|The Aerogen Ultra vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
1512247|NCT02876744|Other|ophthalmologic examination|ophthalmologic examination including optical coherent tomography with angiography module
1512248|NCT02876731|Device|PET-CT|NaF PET-CT
1512249|NCT02876731|Device|MRI|DWMRI
1992851|NCT03286855|Device|Standard Hospital Care|"The standard hospital care refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications. This is the Hudson micromist small volume nebuliser."
1512251|NCT02876705|Other|Exercise|Completion of this study will took a total of three sessions, separated by one-week intervals. At week one, participants will complete a baseline incremental cycling and running tests to determine the workload and velocity values corresponding to their RPE (6-20 Borg's scale) = 15 (i.e., heavy). Participants also will be familiarized with the use of body maps and reporting procedures. At week two and three, participants will complete the constant-power cycling and constant velocity running tasks. The constant-power cycling and running will last up to volitional exhaustion. The end will be set when participants won't be able to cycle longer at the fixed cadence.
1512252|NCT02876692|Device|Machine perfusion|Deceased donor kidneys were preserved by hypothermic machine perfusion
1512253|NCT02876679|Drug|Cyclophosphamide|GVHD prophylaxis: All patients will receive post-transplant 50mg/Kg/day cyclophosphamide (day +3 and +4) AND cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil in case of an HLA-matched unrelated donor
1512254|NCT02876679|Drug|Anti-Thymocyte Globulin|GVHD prophylaxis: 2.5 mg/Kg/day ATG (Thymoglobuline®) for 2 consecutive days (day -2 and -1) All patients will receive cyclosporine-A alone in case of an HLA-sibling donor, or cyclosporine-A and mycophenolate-mofetil (MMF) in case of an HLA-matched unrelated donor.
1512255|NCT02876679|Drug|Conditioning regimen|30 mg/m2/day fludarabine for 5 days (day-6 to day-2) 130 mg/m2/day IV busulfan once daily for 2 days (day -4 and -3)
1512256|NCT02876666|Behavioral|SCI Virtual Coach|Participants are given a computer with the SCI Virtual Coach program and are asked to interact with the Coach daily for 2 months.
1512257|NCT02876653|Other|Polysomnography , blood collection, bone densitometry and Functional respiratory explorations|"Blood collection, Bone densitometry and Functional respiratory explorations are a specific interventions of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  healthy volunteers "
1512258|NCT02876640|Other|Laboratory Biomarker Analysis|Correlative studies
1512259|NCT02876640|Drug|Retinoid 9cUAB30|Given PO
1512260|NCT02876640|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection surgery
1512261|NCT02876627|Behavioral|Exercise training|twelve-week aerobic exercise training program consisted of three sessions per week, each session lasting 30 to 60 minutes 50 to 75 percent of their maximum heart rate reserve
1512262|NCT02876601|Drug|Defibrotide|6.25mg/kg bodyweight over 2h infusion
1512263|NCT02876601|Drug|Placebo (0.9% sodium chloride)|(0.9% sodium chloride) infusion over 2h infusion
1512264|NCT02876601|Drug|Lipopolysaccharide|bolus infusion of 2ng/kg bodyweight lps
1512265|NCT02876588|Other|Unrestricted|Users may open up to 4 patient records at a time.
1512266|NCT02876588|Other|Restricted|Users are restricted to open 1 patient record at a time.
1512267|NCT02876575|Device|A bipolar instrument for tonsillectomies|A bipolar electrosurgical device that employs RF energy and pressure to ligate vessels interposed between its jaws which can then be transected using the built in knife deployed by the device trigger.
1512268|NCT02876562|Procedure|root coverage with collagen matrix|the material used is a porcine derived native collagen matrix which serves an alternative to connective tissue graft. the material is 1.5 mm in thickness with a specific tissue surface to allow for cell migration and a fibrous outer layer. it has a resorption time of 6 months.
1512269|NCT02876549|Drug|Chloroquine|10 mg/kg on day 0 & 1 and 5mg/kg on day 2, (Afghanistan NMLCP guidelines)
1512270|NCT02876549|Drug|Primaquine 0.25 mg/kg/day|0.25 mg/kg/day for 14 days
1992852|NCT03287687|Device|Carbon dioxide gas for insufflation|Carbon dioxide gas use for insufflation during endoscopy instead of air
1992853|NCT03287687|Device|Air|Air is the standard of practice and will be used in the control arm
1512271|NCT02876549|Drug|Primaquine 0.75 mg/kg weekly|0.75 mg/kg weekly for eight weeks
1512272|NCT02876536|Device|TENS|The effect of TENS device will be compared in case and control groups.
1512273|NCT02876510|Drug|Fludarabine|Fludarabine infusion
1512274|NCT02876510|Drug|Cyclophosphamide|Cyclophosphamide infusion
1512275|NCT02876510|Biological|IMA101 T-cell product|i.v. infusion of IMA101 product(s).
1512276|NCT02876510|Biological|Recombinant human interleukin-2|Low dose IL-2 Infusion for two weeks
1512277|NCT02876510|Diagnostic Test|IMA101_Detect|IMA101_Detect is a laboratory test that is part of screening used to determine the mRNA expression of ACTolog target source genes in tumor biopsies from solid tumors. IMA101_Detect is intended for investigational use only.
1512278|NCT02876497|Other|Define macrophages migration mode|Archival tumor samples analysis and blood sample testing
1512279|NCT02876484|Drug|Colesevelam|
1512280|NCT02876484|Drug|Chenodeoxycholic Acid|
1512281|NCT02876484|Other|Water|
1512282|NCT02876471|Other|CPAP|OSA complicated with hypertension：In order to avoid the effects of drugs on this study, we calculated the time to stop based on the half-life of patients taking oral drugs and last time administration time. The subject who withdrawal time was less than three days was enrolled in our study. These patients were hospitalized and close monitoring of blood pressure, for blood pressure three times greater than 180/110mmHg or appearing dizziness, headache and other clinical syndrome, we give a timely clinical intervention and get rid of our study. Screening of 40 newly diagnosed patients with hypertension and subjects with poor blood control,the investigators would give one-night CPAP
1512283|NCT02876458|Other|Immediate coronary angiogram|An immediate coronary angiogram will be performed
1512284|NCT02876458|Other|Delayed coronary angiogram|A delayed coronary angiogram (between 48 to 72 hours) will be performed
1512285|NCT02876445|Other|ZARIT Burden Interview|ZARIT Burden Interview completed Day 0 and 1 year
1512286|NCT02876432|Device|Electroacupuncture|"The acupuncture points selected were ST36, BL25, GB30, BL40, GB34 the needles were inserted into acupoints and the depth of needle insertion depended of the acupoints selected to achieve Deqi sensation, which is characterized as a numb, heavy, sore and/or distending sensation.
Electrical stimulation was delivered at 4 Hz. The stimulator (ITO EST-160) was then switched on, and the intensity was gradually increased to reach a strong but comfortable level the sensation of EA which is characterized for numbness, tingling and a light muscle cramp. For 15 minutes"
1512287|NCT02876432|Drug|Diclofenac sodium|100 mg Diclofenac sodium was administrated orally every 12 hours for 5 days.
1512288|NCT02876432|Other|Sham electroacupuncture|The investigators use 1.0 cm outside point of the real electroacupuncture, the depth of needle insertion was superficial to avoid Deqi sensation, the cables wasn't connected to the electro stimulator and was then switched on for 15 minutes. The participants were threaded separately to avoid sharing experiences about the electroacupuncture sessions
1512289|NCT02876354|Drug|Menaquinone|Patients on hemodialysis will be supplemented by 360 μg /d of menaquinone for 4 weeks. At baseline they will have a lateral abdominal X-Ray and dosage of dp-ucMGP. At the end of the study patients will have a second measurement of dp-ucMGP levels.
1512290|NCT02876328|Biological|Ad26.ZEBOV|0.5 mL at a dose of 5x10^10 vp administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
1512291|NCT02876328|Biological|MVA-BN-Filo|0.5 mL at a dose of 1x10^8 InfU administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
1512292|NCT02876328|Biological|rVSVΔG-ZEBOV-GP|1 mL at a dose of 2x10^7 pfu/ml administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
1512293|NCT02876328|Biological|Placebo|0.5 mL or 1 mL (depending upon the arm) sterile normal saline administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
1512294|NCT02876328|Biological|rVSV boost|1 mL at a dose of 2x10^7 pfu/ml administered by intramuscular (IM) injection into the upper arm for adults or the thigh for children
1512295|NCT02876315|Dietary Supplement|Redoxon VI|"Each tablet contains:
Vitamin C (500mg) Vitamin A (1167IU) Vitamin B6 (3.3mg) Vitamin B12 4.8µg) Vitamin D (200IU) Vitamin E (22.5mg) Folic Acid (200µg) Zinc (5mg) Selenium (55µg) Copper (450µg) Iron (2.5mg)
Other ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc"
1512296|NCT02876315|Dietary Supplement|placebo|Ingredients: Microcrystalline cellulose, magnesium stearate, hydroxypropylmethylcellulose, hydroxypropylcellulose hypromellose, titanium dioxide, microcrystalline cellulose, iron oxide yellow, sodium croscarmellose, and talc
1512297|NCT02876302|Drug|Ruxolitinib|15 or 20 mg, twice daily by mouth. The run-in part of ruxolitinib lasts 7 days; The treatment of ruxolitinib part lasts 12 weeks.
1512298|NCT02876302|Drug|Paclitaxel|80 mg/m2, IV (in the vein) weekly for 12 weeks.
1512299|NCT02876302|Drug|Doxorubicin|60 mg/m2, IV (in the vein) every 14 days for 4 doses.
1512300|NCT02876302|Drug|Cyclophosphamide|600 mg/m2, IV (in the vein) every 14 days for 4 doses.
1512301|NCT02876289|Drug|Perampanel|
1512303|NCT02876250|Drug|Cyclosporine A|a pharmacological postconditioned group with IV administration of 2.5 mg/kg of CsA prior to first graft reperfusion
1512304|NCT02876250|Drug|Placebo|a control group with IV administration of 2.5 mg/kg of placebo prior to first graft reperfusion
1512305|NCT02876237|Other|geriatric assessment and quality of life|"Included patient must have a geriatric assessment before radiotherapy and 6 months later. This standardized geriatric assessment will collect social information, functional, sensory, cognitive, emotional, motor, nutritional, and medical related to comorbidities .
Patient must complete quality of life questionnaire before radiotherapy then 2 and 6 months later."
1512306|NCT02876237|Radiation|Radiotherapy|standard radiotherapy
1512307|NCT02876224|Drug|Atezolizumab|Atezolizumab 840 mg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
1512308|NCT02876224|Drug|Bevacizumab|Bevacizumab 5 mg/kg will be administered by IV infusion on Days 1 and 15 of each 28-day cycle.
1512309|NCT02876224|Drug|Cobimetinib|Cobimetinib 60 mg or at dose determined during safety run-in phase will be administered orally once daily for 21 days of each 28-day cycle as specified in the arm descriptions.
1512310|NCT02876211|Drug|Paricalcitol|Paricalcitol 2 capsules/three times per week
1512311|NCT02876211|Drug|Epoetin beta|epoetin 1-3 times per week
1512312|NCT02876211|Drug|Placebo|Placebo 2 capsules/three times per week
1512313|NCT02876198|Device|Gonioscopy|Study of the trabecular structure by gonioscopy
1512314|NCT02876185|Other|Monitoring by an orthoptist then by an ophthalmologist|At each visit, the usual monitoring tests will be collected and viewed by the orthoptist then by the ophthalmologist concerning the necessity of an anticipated ophthalmological consultation
1512317|NCT02876159|Biological|2016-2017 Influenza Vaccine|Quadrivalent influenza A/H1N1, A/H3N2, B, B virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension administered as a single 0.5 mL intramuscular dose.
1512319|NCT02876133|Device|narrow band imaging withdrawal|colonoscope withdrawal and mucosal inspection performed under narrow band imaging
1512320|NCT02876133|Device|white light withdrawal|colonoscope withdrawal and mucosal inspection performed under white light imaging
1512321|NCT02876120|Other|Implementation|Multifaceted implementation strategy to implement evidence based international osteoarthritis treatment recommendations among GPs and PTs in private practice, template for PT discharge reports to GP, patient osteoarthritis education programs, and facilitate multidisciplinary collaboration between the PTs and GPs.
2003230|NCT00302731|Drug|Prempro, premarin, provera conjugated estrogens, medroxyprogesterone acetate|Prempro, premarin .45mg, provera 1.5mg conjugated estrogens, medroxyprogesterone acetate
2003231|NCT00302731|Drug|Estradiol , estriol , progesterone|Estradiol .5mg, estriol 210mg, progesterone 100mg
2003232|NCT00302731|Drug|estradiol,progesterone|estradiol,progesterone
2003233|NCT00302731|Drug|estriol, progesterone|estriol 2.5mg, progesterone 100mg
2003234|NCT00290693|Drug|Capecitabine|Orally, 1600mg/m2/day given as (800mg/m2 BID), Days 1 through 14 of 21-day cycle
2003235|NCT00290693|Drug|Docetaxel|30 mg/m2, IV, days 1 and 8 every 3 weeks
2003236|NCT00265941|Biological|cetuximab|Given IV
2003237|NCT00265941|Drug|cisplatin|Given IV
2003238|NCT00249431|Drug|Sertraline|Patients will be started on 25mg/day of Sertraline, and their dose will be increased to 50 mg/day by week two, and then weekly by 50mg/day based on clinical response and emergence of side effects. The maximum dose will be 200mg/day
1512331|NCT02876094|Drug|celecoxib|dose-response
1512332|NCT02876081|Drug|Afatinib|to evaluate the efficacy of afatinib, an EGFR TKI, on lung adenocarcinomas, EGFR wild-type, bearing the NTS/NTSR1 complex with a high level of expression
1512333|NCT02876055|Drug|Single shot interscalene nerve block|Peripheral regional anesthesia nerve block - Single shot interscalene nerve block
1512334|NCT02876055|Drug|Continuous interscalene nerve block|Peripheral regional anesthesia nerve block - continuous catheter interscalene nerve block
1512335|NCT02876055|Drug|Local Infiltration Analgesia (LIA)|Injection of local anesthetic into the peri-articular tissues and intra-articular capsule in a systematic approach for orthopedic surgery
1512336|NCT02876042|Device|BAROSTIM NEO™ System|
1512337|NCT02876029|Other|Reference|the reference product used
1512338|NCT02876029|Other|Test product|The test Product used
1512339|NCT02876016|Device|functional MRI|locate the cerebral bases in functional imaging
1512340|NCT02876003|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
1512341|NCT02875990|Biological|Blood sample|
1512342|NCT02875977|Other|Educational video|A 4 minute educational video describing PFPT
1512343|NCT02875964|Device|electroencephalogram|Implanting electrode to measure brain activity
1512344|NCT02875964|Device|magnetoencephalogram|Implanting electrode to measure brain activity
1512345|NCT02875938|Behavioral|Simultaneous music and reading lyrics|music with sung lyrics simultaneously with silent reading of the lyrics.
1512346|NCT02875938|Behavioral|Priming with music|priming with music and sung lyrics followed by reading of the lyrics.
1512347|NCT02875938|Behavioral|Control|control condition using reading materials without music.
1512348|NCT02875925|Other|MTM|Medication management is a process that ensures each patient's medications are assessed to determine the appropriateness, effectiveness, safety, and convenience of each medication for the patient. Medication management is fully integrated with the care team. Pharmacists provide this service to identify, prevent, and resolve drug therapy problems improve outcomes.
1512349|NCT02875912|Behavioral|Family Care Rituals|"Family members being enrolled are given a pamphlet outlining the Family Care Rituals. They are informed of the opportunity to perform these rituals, but that they are in no way obligated to do so.
Family members are then surveyed at enrollment, and 90 days post ICU discharge for symptoms of PTSD, as well as depression, and anxiety.
Family members, day-time nursing, and attending physicians are surveyed for concordance of care at enrollment and ICU day 5.
Demographic information is also collected on the patient and the family members at enrollment Nursing completes surveys while the patient is in the ICU noting what care rituals, if any, are being performed. Additionally, they are asked to complete a survey indicating their opinion of the impact on the care they deliver"
1512350|NCT02875886|Drug|Amiloride|Combined with hydrochlorothiazide
1512351|NCT02875886|Drug|Hydrochlorothiazide|Combined with amiloride
1512352|NCT02875886|Other|Low-sodium diet|
1512353|NCT02875873|Drug|Plasma-Lyte|Plasma-Lyte will be used for fluid expansion and maintenance
1512354|NCT02875873|Drug|Saline 0.9%|Saline 0.9% will be used for fluid expansion and maintenance
1512355|NCT02875873|Other|Slow infusion speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 333 mL/h. NOTE: This intervention will not be blinded.
2003239|NCT00249431|Behavioral|Relapse Prevention Therapy|Patients will have a weekly one-hour session for medication evaluation, relapse prevention therapy and answer questionnaires.
1512356|NCT02875873|Other|Fast Infusion Speed|Whenever fluid expansion is deemed necessary by the attending physician, infusion speed will be set at 999 mL/h. NOTE: This intervention will not be blinded.
1512357|NCT02875860|Device|GoldBal2 detachable balloon|Placement of the balloon using the plug/unplug method.
1512358|NCT02875860|Device|Baltaccidbpe100 Delivery Catheter|The catheter assists with implanting the balloon in the plug/unplug method.
1512359|NCT02875847|Dietary Supplement|HMO1|
1512360|NCT02875847|Dietary Supplement|HMO2|
1512361|NCT02875847|Dietary Supplement|Dextropur|
2003245|NCT00217594|Drug|Alemtuzumab (Campath)|
2003246|NCT00195624|Drug|Alemtuzumab (Campath )|
1512366|NCT02875821|Drug|Ipragliflozin|Patients treated with ipragliflozin (50 mg/day) as add on therapy to metformin and pioglitazone dual therapy (triple therapy) for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Experimental Group)
1512367|NCT02875821|Drug|metformin with pioglitazone|Patients maintain metformin and pioglitazone dual therapy for 6 months. During whole periods of study, subjects are educated for nutrition and exercise. (Control group)
1512368|NCT02875795|Procedure|automatic speech processing tool|
1512369|NCT02875782|Behavioral|Smoking cessation and DM specific component intervention|A brief stage-matched smoking cessation intervention plus a DM-specific leaflet on smoking cessation
1512370|NCT02875782|Behavioral|Control group|A simple, brief advice and a self-help general leaflet on smoking cessation
1512371|NCT02875769|Procedure|Dental prophylaxis|Full mouth dental prophylaxis (FMDP) was conducted in one appointment lasting 10 minute, using an ultrasonic scaler at a frequency of 25 kHz (Cavitron Select SPC, Dentsply professional, York, PA, USA) at less than 50% power. The FMDP performed without anesthesia and in order to eliminate supragingival plaque, calculus and stainings.
1512372|NCT02875769|Drug|Mouthwash CPC+Zn+F|The volunteer rinsed with pre-procedural mouthwash containing 0.075% cetylpyridinium chloride, 0.28% zinc lactate and 0.05% sodium fluoride in an Alcohol-free base for one minute, 20 ml of solution and then expectorated all remaining liquid.
1512373|NCT02875769|Drug|Mouthwash CHX|The volunteer rinsed with pre-procedural mouthwash containing 0.12% CHX with 10% alcohol for one minute, 20 ml of solution and then expectorated all remaining liquid.
1512374|NCT02875769|Other|No rinsing|The volunteer did not rinse with any pre-procedural mothwash.
1512375|NCT02875769|Other|Water|The volunteer rinsed with pre-procedural mouthwash containing water from a three-way syringe for one minute, 20 ml of water and then expectorated all remaining liquid.
1512376|NCT02875756|Procedure|10 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 10 times
1512377|NCT02875756|Procedure|20 revolutions|The 22G needle (Vizishot, Olympus) will be used to obtain specimens from the enlarged lymph nodes during EBUS. Once inside the lymph node, needle will be passed to and fro 20 times
1512378|NCT02875743|Drug|Posaconazole|
1512379|NCT02875730|Procedure|Pulse Sequence|Cylindrical Navigator Preparatory Pulse Sequence
1512380|NCT02875730|Procedure|CMRI|Cardiac Magnetic Resonance Imaging
1512381|NCT02875717|Drug|Acetylsalicylic acid|
1512382|NCT02875717|Drug|low molecular weight heparin|
1512383|NCT02875704|Other|Anterior Chamber (AC) Tap|Aqueous Samples will be collected for measurement of biomarkers
1512384|NCT02875691|Dietary Supplement|green tea extract|Patients are given daily dose of 1000mg aqueous green tea extract (of 6 grams of dried green tea leaf) in the form of 2 capsules( 500 mg) for three months.
1512385|NCT02875691|Dietary Supplement|placebo|Patients in placebo group receive daily dose of 1000 mg cellulose in the form of 2 capsules (500 mg) for three months
1512386|NCT02875678|Drug|ABX-1431|Single-dose ABX-1431
1512387|NCT02875678|Drug|Placebo|Single-dose matching placebo
1512388|NCT02875665|Device|geko(TM) device|The geko(TM) device will be used to electrically stimulate the posterior tibial nerve
1512389|NCT02875652|Biological|Blood sampling|3 vials of 7,5 ml of peripherical blood will be collected at each blood sample.
1512390|NCT02875639|Drug|Yiqi prescription|
1512391|NCT02875639|Drug|Huoxue prescription|
1512392|NCT02875639|Drug|Buyang huanwu decoction|
1512393|NCT02875639|Drug|QISHEN YIQI DRIPPING PILLS|
1512394|NCT02875639|Drug|Placebo 1|Placebo 1：a drug which imitated QISHEN YIQI DRIPPING PILLS,but do not have active ingredient,just have the excipient.
1512395|NCT02875639|Drug|Placebo 2|Placebo 2：a drug which imitated Buyang huanwu decoction,but do not have active ingredient,just have the excipient.
1512396|NCT02875626|Drug|Infracyanine|In the beginning of the intervention, a periareolar injection of the Infracyanine will be carried out (Infracyanine®, 2ml to 2.5mg/ml whether 3.2nM).
1512397|NCT02875613|Drug|Avelumab|Avelumab 10mg/kg IV on days 1 and 15 of each 28-day cycle. Treatment will be given until disease progression, unacceptable toxicity, investigator decision or patient withdrawal.
1512398|NCT02875600|Other|Nutri Drink|To determine the difference in baseline MR flow measurements and post prandial MR flow measurements between patients diagnosed with CGI and patients not diagnosed with CGI
1512399|NCT02875587|Drug|Cabergoline|Cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5 mg is administered orally at bed time for 8 days starting on the day of HCG administration
1512400|NCT02875587|Drug|Calcium gluconate|Intravenous 10% calcium gluconate, 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1, day 2, and day 3 after ovum pickup. Intravenous infusion will be performed within 30 minutes.
1512401|NCT02875574|Drug|Any treatment regimen|Treatment regimen used to treat patient once isoniazid resistance known (exposure of interest for cohort study)
2003247|NCT00185731|Drug|Atorvastatin|80 mg orally once daily
2003248|NCT00175825|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 7-week Treatment Period
2003249|NCT00175825|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 5 mg/day in a double-blinded way for the 7-week Treatment period
1512402|NCT02875574|Other|Bacterial mutation|Resistance, compensatory or other mutation in the infecting strain of Mycobacterium tuberculosis (exposure of interest for nested case-control study)
1512403|NCT02875561|Device|Sonopet Ultrasonic Aspirator|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
1512404|NCT02875561|Device|CO2 Laser Ablation|To evaluate the incident of recurrence of VIN dysplasia events in women treated for VIN with the sonopet ultrasonic aspirator compared to CO2 Laser Ablation
1512405|NCT02875548|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
1512406|NCT02875535|Behavioral|RLAS|"The implementation model for this intervention will increase school-based supports and safety for gender and sexual minorities and broader student bodies, and be applicable to addressing other priority child and adolescent health and mental health issues within schools. The investigators refer to the model as RLAS (Implementing School Nursing Strategies to Reduce LGBTQ Adolescent Suicide)."
1512407|NCT02875522|Other|Individualized, non-linear aerobic exercise training|Aerobic exercise performed on lower body stationary ergometer and an upper extremity arm crank. Intensity (50-95% workload maximum) and durations (20-45 min) are fluctuated daily to optimize training stress and adaptation
1512408|NCT02875483|Other|Expedited Scheduling|Patients are scheduled for tubal ligation surgery prior to discharge from the post-partum hospital service, with target date 4-8 weeks post-partum.
1512409|NCT02875483|Other|Standard Scheduling|Scheduling of tubal surgery occurs after completion of post-partum office visit
1512410|NCT02875470|Device|Intensiv Perio Set|Diamond burs for root planing
1512411|NCT02875470|Device|Gracey curette|
1512412|NCT02875457|Drug|apatinib;etoposide and cisplatin|
1512413|NCT02875457|Drug|placebo;etoposide and cisplatin|
1512414|NCT02875444|Other|Angio-CT|
1512415|NCT02875431|Procedure|Patients undergo ACDF or cervical vertebral body replacement|
1512416|NCT02875418|Device|EUM|"STUDY DESIGN
Explanation regarding the study and assessing eligibility criteria.
Signing an informed consent.
Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
1512417|NCT02875418|Device|Tocodynamometry|"STUDY DESIGN
Explanation regarding the study and assessing eligibility criteria.
Signing an informed consent.
Recording of uterine contractions by both EUM and tocodynamometry. A correlation between EUM and tocodynamometry will be calculated. For the purpose of this study, a positive EUM or tocodynamometry will be defined as 3 at least 3 contractions in 30 minutes."
1512418|NCT02875405|Procedure|Posterior left pericardiotomy|Patient will receive a posterior left sided pericardiotomy. The incision will be made posterior to the phrenic nerve and run from the inferior left pulmonary vein to the diaphragm.
1512419|NCT02875392|Other|275mg Oligo Fucoidan + 275mg HS Fucoxanthin|Fucoidan is a water-soluble dietary fiber which is extracted from brown seaweed. Slimy surface of brown seaweed has unique ingredients and different kind of brown seaweed has slightly different effectiveness.The subject of this study focus on assessing the impact on the metabolism of fatty liver and liver fibrosis after taking oral FucoHiQ capsules.
1512420|NCT02875392|Other|placebo pills|taking placebo pills as if patients are under treatment.
1512421|NCT02875379|Procedure|Measurements|Measurements of respiratory mechanics and parameters, arterial blood gases and comfort
1512422|NCT02875366|Drug|LUM/IVA|
1512423|NCT02875366|Drug|Placebo|
1512424|NCT02875353|Device|Doppler Endoscopic Probe|A colon length catheter (probe).
1512425|NCT02875340|Drug|VAL401|Risperidone formulated into a liquid lipid filled capsule
1512426|NCT02875314|Drug|Induction|vincristine, cisplatin, cyclophosphamide, etoposide, high-dose methotrexate
1512427|NCT02875314|Drug|Single Cycle Intensive Chemotherapy|Carboplatin, thiotepa, etoposide
1512428|NCT02875314|Drug|Tandem 3 Cycle Intensive Chemotherapy|Carboplatin, thiotepa
1512429|NCT02875301|Behavioral|150 Minutes Week|This group will walk 150 minutes per week. Participants will have 3 supervised exercise sessions per week. A walking duration of 30 minutes will be achieved by the third week of the program and be maintained for the duration of the intervention. Heart rate will be monitored to ensure proper intensity levels. Participants will also be instructed to exercise at home for 30 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone.
1512430|NCT02875301|Behavioral|225 Minutes Week|This group will walk 225 minutes per week. Participants will have 3 supervised exercise sessions per week. A walking duration of 45 minutes will be achieved by the sixth week of the program. This will be maintained for the duration of the intervention and heart rate will be monitored to ensure proper intensity levels. Participants will be instructed to exercise at home for 45 minutes for two other days of the week at a similar intensity. The prescribed intensity will be 50-60% of the maximum heart rate reserve for weeks one to six and 60-75% for the remainder of the program. Participants in the walking conditions will wear heart rate monitors and be encouraged to walk within their target heart rate zone.
1512431|NCT02875301|Behavioral|Stretch and Tone|The control condition will focus on improving balance, flexibility, and strength. This group will meet for supervised sessions 3 times per week for 12 months. Resistance bands, balance disks, yoga blocks, and exercise mats will be used to engage in non-cardiorespiratory activities. These are progressive in nature and include modifications to accommodate injuries, physical difficulties, etc. A new set of similar, yet slightly more challenging activities will be introduced every four weeks. During the first two weeks, participants are introduced to the new activities, and, during the second two weeks, they are encouraged to increase intensity by using more weight or more repetitions.
1512432|NCT02875288|Drug|liposomal bupivicaine|"The intervention that is being tested and who will perform the procedures; Two general surgeons will perform the procedure with either liposomal or plain bupivacaine.
The treatment procedures or regimens; The treatment procedure is direct, surgical site infiltration with either liposomal or plain bupivacaine.
Dosage level and justification; Liposomal Bupivacaine: 266 mg/20 mL liposomal bupivacaine diluted to 30 mL Plain Bupivacaine: 30 mL of 0.5% plain bupivacaine
Route of drug administration; Surgical site infiltration"
1512433|NCT02875275|Other|Glucose with grass jelly solution|50 g glucose and 3.12 g grass jelly dissolve in water (top up to 200g)
1512434|NCT02875275|Other|Glucose with grass jelly (solid)|50 g glucose and 3.12 g grass jelly and 3.12g starch dissolve in hot water (top up to 200g)
1512435|NCT02875275|Other|Porridge and juice with coconut oil|Add instant porridge with hot water with oil. Consume with commercially available orange juice
1512436|NCT02875275|Other|Porridge and juice with coconut oil gel|Add instant porridge with hot water with oleogel. Consume with commercially available orange juice
1512437|NCT02875262|Drug|Deferoxamine|Patients will be given deferoxamine 32 mg/kg/day (max iv rate 15 mg/kg/hr), patients with ferritin levels between 2,000 and 3,000 ng/ml will receive 32 mg/kg/day and patients with serum ferritin levels below 2,000 ng/ml wil receive 25 mg/kg/day.during 3 days
1512438|NCT02875262|Other|placebo|placebo (NaCl 0.9%) in equal dose to treatment
1512439|NCT02875249|Other|patients stool collection|patients stool collection
1512440|NCT02875236|Drug|OctaplasLG®|"OctaplasLG is an donor plasma product pooled from approximately 1000 single donor units. It possesses unique features when compared to standard fresh frozen plasma, such as having standardized concentrations of natural pro- and anti-coagulation factors, a standardized volume as well as being pathogen free. The manufacturing method of OctaplasLG removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation by immune neutralization. OctaplasLG should reduce the inflammatory hit on the endothelium, including the glycocalyx, by having standardized levels of coagulation proteins, which can give more sustainable support to the endothelial regeneration as compared to standard fresh frozen plasma."
1512441|NCT02875236|Drug|Ringer-acetat|Crystalloid used as standard of care.
1512442|NCT02875223|Drug|CC-90011|
1512443|NCT02875210|Procedure|Laximeter measurement|
1512444|NCT02875197|Other|Running on a treadmill at 6 different speeds|All subjects will be required to run at 6 prescribed speeds (2.5, 3.0, 3.5, 4.0, 5.0, and 6.0 m/sec) on a treadmill completing at least 10 consecutive strides, or running for 30 seconds.
1512445|NCT02875171|Drug|Anthracycline administration|Patients suffering from lymphoma or acute leukemia and requiring anthracycline administration were included
1512446|NCT02875158|Procedure|Cyclophotocoagulation protocol|"Intravenous route is installed
Retrobulbar anaesthesia : 50% Xylocaïne (2%) + 50% Bupivicaïne
Parameters set for laser treatment (1250mW-4seconds or 2000mW-2 seconds depending on the assigned group)
Pars plana measurement using transillumination (if needed)
Laser treatment applied approximately 1mm post to limbus
Dexamethasone 0,5 mg subconjunctival injection
Post-op regimen: Prednisolone 1% qid x 4 weeks, Atropine 1% bid x 2 weeks + Erythromycin ointment + patch x 6h"
1512447|NCT02875158|Procedure|Conventional cyclophotocoagulation|1250 mW for 4 seconds.
1512448|NCT02875158|Procedure|Modified cyclophotocoagulation|2000 mW for 2 seconds.
1512449|NCT02875145|Procedure|Cataract surgery|
2003250|NCT00175825|Drug|Brivaracetam 20 mg/day|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg/day in a double-blinded way for the 7-week Treatment period
2003251|NCT00175825|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 7-week Treatment period
2003252|NCT00160667|Drug|Placebo|Daily oral dose of two equal intakes, morning and evening of placebo in a double-blinded way for the 4-week treatment period
2003253|NCT00160667|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening of Brivaracetam 200 mg/day in a double-blinded way for the 4-week treatment period
2003254|NCT00160667|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening of Brivaracetam 400 mg/day in a double-blinded way for the 4-week treatment period
2003255|NCT00125762|Device|FibroScan|
2003256|NCT00089570|Drug|terlipressin|
2003257|NCT00089570|Drug|Placebo|
1512458|NCT02875093|Drug|ADI-PEG 20|Investigational Medicine
1512459|NCT02875093|Drug|Cytarabine|
1512460|NCT02875080|Drug|OPC-34712|
1512461|NCT02875067|Biological|Pembrolizumab|
1512462|NCT02875067|Drug|Lenalidomide|
1512463|NCT02875054|Behavioral|Constraint induced movement therapy (CIMT)|Involves forcing use of ones affected upper extremity (UE) by physically restraining the less affected upper extremity
1512464|NCT02875054|Behavioral|Hand-arm bimanual intensive training (HABIT)|Facilitates the translation of gains to improve goal-directed bimanual performance.
1512465|NCT02875041|Device|Transcranial Magnetic Stimulation (TMS)|
1512466|NCT02875041|Device|MAGSTIM Rapid2|
1512467|NCT02875028|Drug|Vorapaxar|10mg-20mg vorapaxar to achieve >80% thrombin-receptor activated peptide-6 (TRAP) induced platelet inhibition
1512468|NCT02875028|Drug|Placebo|
1512469|NCT02875028|Other|LPS|2ng/kg Lipopolysaccharide as a bolus infusion
2003258|NCT00076843|Drug|Hu MiK-Beta-1|
2003259|NCT00001464|Procedure|Oxygen therapy|
2010620|NCT02915432|Biological|3 mg/kg humanized anti-PD-1 mAb|"This study is planned to conduct the 3 mg/kg dose group study at first. After enrollment, the subjects will be administered every 2 weeks (Q2W) with 4 weeks as a cycle, until absence of further benefits, acceptable toxicity, investigator decision, consent withdrawal or death.
If patient experiences 1st onset of disease progression and investigator judges that patient will obtain clinical benefit from the study treatment, patient can continue the study treatment after the discussion between investigator and medical monitor from sponsor or authorized CRO and approval is obtained afterwards. If the subject develops 2nd disease progression after 1st disease progression, he/she should permanently withdraw from the study treatment."
1512473|NCT02875002|Drug|volasertib|Volasertib (BI6727) is a small molecule inhibitor of the polo-like kinase 1 (PLK1) protein. Infusion for 60 minutes. Dosing will start at 25 mg/m^2, is schedule to increase to 100mg/m^2, and be administered on days 1 and 8 of each 28-day cycle.
1512474|NCT02875002|Drug|belinostat|Belinostat is a histone deacetylase inhibitor. Infusion will take 30 minutes. Dosing will start at 600 mg/m^2 , is scheduled to increase to 1000 mg/m^2, and will be administered on days 1,2,3 and 8,9,10 of each 28-day cycle.
2010621|NCT02915432|Biological|10 mg/kg humanized anti-PD-1 mAb|If under the dose of 3 mg/kg, a certain indication cannot reach the predefined study endpoints, subjects inclusion of this indication under the dose of 10 mg/kg will be initiated with the number same as the above.
1512476|NCT02874976|Device|Active and Active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
1512477|NCT02874976|Device|Active and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
1512478|NCT02874976|Device|Placebo and active Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
1512479|NCT02874976|Device|Placebo and Placebo Phototherapy|Participants performed a aerobic training. Ninety-six subjects practice a regular aerobic exercise program on a treadmill was applied 3 times a week for 12 weeks,each session lasting 30 minutes, ranging between 70-80 % of maximum heart rate intensity and the evaluations are done monthly through a maximum progressive exercise protocol. Phototherapy, active or placebo, were applied in 9 different points of quadriceps,6 points in the posterior thigh and two points in the gastrocnemius muscle, depending the group randomized, before and after each training session.
1512480|NCT02874963|Procedure|Surgical Periodontal Treatment|In the patient's with periodontal disease at least one tooth extraction will be performed.
1512481|NCT02874963|Device|Non Surgical Periodontal Treatment includes scaling root planing with UDS-J Ultrasonic Scaler.|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included: full-mouth scaling and root planing (FM-SRP) with ultrasonic device (UDS-J Ultrasonic Scaler, Guilin Woodpecker Medical Instrument) and periodontal curets for mechanical debridement of the supra- and sub-gingival plaque and calculus.
1512482|NCT02874963|Drug|Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)|Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
1512483|NCT02874950|Other|office exercise training|The exercise group, did 6 months office exercise training.
1512484|NCT02874950|Other|ergonomic modification|The ergonomic modification group, followed 6 months modified office ergonomic modification.
1512485|NCT02874950|Other|Exercise and ergonomic|The mixture group, did 6 months exercise training and also followed 6 months modified office ergonomic modification.
1512486|NCT02874950|Other|Control|Control group did not do any exercise and did not follow any ergonomic modification.
1512487|NCT02874937|Drug|Atomoxetine|norepinephrine transporter inhibitor
1512488|NCT02874937|Drug|Matching Placebo|matching placebo identical in appearance.
2010622|NCT02914977|Drug|Daunorubicin|"Agent: Daunorubicin
Dose: 6.75 mg/m2/day
Route: IV
Schedule: Days 1-5
Duration: One cycle"
1512491|NCT02874911|Other|General training|Advanced spinocerebellar disease receive 12 weeks of coordinative training based on commercially available videogames (Product names: Nintendo Wii ®, Microsoft XBOX Kinect®).
1512492|NCT02874898|Behavioral|Brief Imaginal Exposure|Psychoeducation and imaginal exposure components of full prolonged exposure, in which patients relive the trauma vividly and process thoughts and feelings related to it
1512493|NCT02874885|Procedure|Blood Draws|"Healthy Participants: Blood (about 2 tablespoons) drawn at 1 time point.
Rectal Cancer Participants: Blood (about 2 tablespoons) drawn 1 time before participant starts treatment.
Blood also drawn:
Just before tumor surgery 1-8 weeks after surgery, or before chemotherapy begins 1-12 weeks after last dose of chemotherapy
year after surgery, OR 1 year after completion of treatment if no surgery
years after surgery, OR 2 years after completion of treatment if no surgery If the disease gets worse during treatment, OR If disease comes back within 6 years after treatment, OR at end of 6 years follow-up."
1512494|NCT02874872|Behavioral|OASIS Collaborative|OASIS (Optimizing Antibiotic Stewardship in Skilled Nursing Facilities) is a system redesign of skilled nursing facility work systems
1512495|NCT02874846|Drug|Netarsudil ophthalmic solution|Ophthalmic solution once daily
1512496|NCT02874846|Drug|Placebo comparator|Ophthalmic solution (placebo) once daily
1512497|NCT02874833|Other|Exercise|After performance diagnostics, participants will complete an 8-week supervised, individualized exercise program. Training will include up to 3 aerobic training sessions and up to two resistance training units per week.
1512498|NCT02874820|Radiation|[11C]BU99008|Baseline and blocked scans
1512499|NCT02874820|Drug|Idazoxan|Idazoxan dose up to 80mg
1512500|NCT02874807|Drug|Empagliflozin|
1512501|NCT02874807|Other|Placebo|
1512502|NCT02874794|Drug|LCZ696 (sacubitril/valsartan)|24/26mg, 49/51mg and 97/103mg oral, tablets.
1512503|NCT02874794|Drug|Enalapril|2.5mg, 5mg, and 10mg, oral, tablets
1512504|NCT02874794|Drug|Placebo of Enalapril|matching placebo (2.5mg, 5mg and 10mg) oral, tablets
1512505|NCT02874794|Drug|Placebo of LCZ696|matching placebo (24/26mg, 49/51mg and 97/103mg) oral, tablets
1512506|NCT02874768|Drug|Dexmedetomidine|Patient receives continuous intravenous infusion of dexmedetomidine (infusion dosage range: 0.1 ~ 0.7 mcg/kg/h)
1512507|NCT02874768|Drug|Propofol|Patient receives continuous intravenous infusion of propofol (infusion dosage range: 0.3 ~ 1.6 mg/kg/h)
1512970|NCT02871466|Drug|stem cells infusion|
1512508|NCT02874755|Other|Tuberculosis Program|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free digital chest X-ray, free sputum microscopy, free or subsidized drug-susceptibility testing, free first-line anti-TB treatment) within the PPIA network, and (2) training or certified medical education (CME) sessions for the providers from the PPIA. Meanwhile, program marketing, CMEs, and other advocacy efforts are aimed to raise awareness in the communities.
1512513|NCT02874729|Procedure|Venesection|Blood will be removed from the circulatory system through a cut (incision) or puncture for the purpose of analysis by qualified staff. Serum or plasma will be separated from the cellular fraction and stored for analyses.
1512514|NCT02874729|Procedure|Urine collection|Urine will be collected in appropriate sterile holders provided.
1512515|NCT02874729|Procedure|Sputum collection|Saliva will be collected in appropriate sterile holders provided.
1512516|NCT02874729|Procedure|Bronchoalveolar lavage|Bronchoscopy will be performed. Briefly, clinical care team will collect liquid after an instrument (bronchoscope) is passed through the nose or mouth into the lungs, and saline solution is squirted into a small part of the lung, then collected for analyses.
1512517|NCT02874716|Other|Tuberculosis Program (PPIA)|The intervention includes a variety of (1) non-financial incentives that are intended to reduce clinical and financial costs for presumptive TB patients and TB cases for diagnostic testing and treatment (free sputum microscopy, free digital chest X-ray, free or subsidized drug-susceptibility testing (DST), free first line anti-TB treatment), (2) training or certified medical education sessions for the providers from the PPIA, and (3) financial incentives to engaged providers for patient registration, diagnostic testing, treatment initiation, and treatment adherence. Meanwhile, health camps, advertising, and other advocacy efforts are aimed to raise awareness in the communities.
1512518|NCT02874703|Other|Cardiac MRI/MRS|
1512519|NCT02874690|Drug|Methylphenidate|
1512520|NCT02874690|Drug|Placebo|Identical to methylphenidate dispensing with placebo drug
1512521|NCT02874677|Other|Effort reeducation program|personalized reeducation program at a load level preceding hyperventilation
1512523|NCT02874651|Drug|Apatinib|Patients will take oral apatinib. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
1512524|NCT02874651|Drug|Placebo|Patients will take oral placebo. The initial dose is 500 mg once daily. 28 days as one cycle. After 1 cycle, the dose will be escalated to 750 mg once daily in patients with good tolerance. Dose interruption or reduction is permitted in case of adverse events per protocol.
1512525|NCT02874638|Dietary Supplement|BASE egg protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
1512526|NCT02874638|Dietary Supplement|BCAA-enriched egg protein|BCAA-enriched egg protein provided as crystalline amino acid.
1512527|NCT02874638|Dietary Supplement|small amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of essential amino acid in BASE egg protein
1512528|NCT02874638|Dietary Supplement|large amount of essential amino acids|essential amino acids modeled after egg protein, provided as crystalline amino acid, which is equivalent to the amount of amino acid in BCAA-enriched egg protein
1512529|NCT02874625|Procedure|Dental restoration|
1512530|NCT02874612|Other|Psychosocial Survey Questionnaires|Young adults with Type 1 Diabetes Mellitus will be invited to participate in a observational study in which they complete psychosocial measures immediately after completing a readiness transition survey and then again 1 year later.
1512531|NCT02874599|Procedure|Dental restoration|
1512532|NCT02874586|Other|Plasma exchange combination of immunosuppressive regimens|
1512533|NCT02874573|Drug|Tocilizumab|Investigational agent
1512534|NCT02874573|Drug|Normal saline|Placebo
1512536|NCT02874534|Behavioral|Behavioral Activation|Treatment will consist of 15 weekly 45-minute sessions.
1512537|NCT02874534|Behavioral|Mindfulness Treatment|Treatment will consist of 15 weekly 45-minute sessions.
1512538|NCT02874521|Other|Intra-dialytic LF-EMS|Electrical muscle stimulation during haemodialysis
1512539|NCT02874521|Other|Intra-dialytic cycle training|Cycle training during haemodialysis
1512540|NCT02874495|Behavioral|Psychological tests|Related to affective and cognitive dimensions of pain.
1512575|NCT02874235|Behavioral|Receptive music therapy|16 sessions of a length of one hour comprising of receptive music psychotherapy with 5 - 15 minutes of music listening included
1512792|NCT02872636|Device|Spinal catheter insertion with extracorporeal filtration of CSF|Extracorporeal filtration of CSF
1512541|NCT02874495|Device|Magnetic Resonance Imaging|"With a certain or uncertain anticipation phase of distension (warning light) followed or not by a rectal distension at the pain threshold previously determined, and then a retrospective quotation of pain during distension and the fear of pain induced by anticipation. Structural MRI and rest of functional connectivity measure MRI.
With measure of heart rate variability."
1512542|NCT02874495|Behavioral|Heart Rate Variability|During MRI session, from the electrocardiographic signal. (measure of variations on R-R interval in milliseconds ms).
1512543|NCT02874469|Other|Diary|"The diary was specifically created for the purpose of the present study by personal working at ICU at CHRU of Lille (France).
All relatives, doctors and paramedics close to the patient during his hospital stay are allowed to write some comments inside the diary when he is comatose.
The diary will be implemented during the second period of the study within the first 8 hours after admission.
It will be given to the patients themselves at discharge or to their relatives in case of in-hospital death. An anonymous copy will be kept by investigators."
1512545|NCT02874443|Other|Knowledge Translation of labor management guidelines|
1512546|NCT02874430|Drug|Metformin Hydrochloride|Given orally
1512547|NCT02874430|Drug|Doxycycline|Given orally
1512548|NCT02874417|Behavioral|CAST psychoeducation|
1512549|NCT02874417|Behavioral|PHET|
1512550|NCT02874404|Drug|Ibrutinib|Given PO
1512551|NCT02874404|Other|Laboratory Biomarker Analysis|Correlative markers
1512552|NCT02874404|Drug|PI3K-delta Inhibitor TGR-1202|Given PO
1512553|NCT02874378|Drug|Dexmedetomidine|
1512554|NCT02874378|Drug|0.9%NaCl solution|
1512555|NCT02874365|Procedure|Endoscopic biopsies|intestinal biopsies
1512556|NCT02874352|Device|high resolution impedance manometry with Automated Impedance Manometry analysis|
1512557|NCT02874339|Device|High flow nasal oxygen therapy|In the optiflow group, oxygen will be administered through a heated humidifier (Airvo 2, Fisher and Paykel healthcare) and applied through large bore binasal prongs. Initial gas flow rate will be set at of 60 l/min and adjusted to 40-50 l/min based on patient's tolerance. FiO2 will be adjusted to maintain an SpO2 ≥ 92%. Initial temperature will be set at 37° and reduced according to patient's tolerance.
1512558|NCT02874339|Device|Non invasive ventilation|In the NIV group, NIV will be delivered through a face mask connected to a ventilator with pressure support applied in a noninvasive ventilation mode. The Pressure-support level will be adjusted to obtain an expired tidal volume of 6-8 ml/kg of predicted body weight and a respiratory rate of 25-30 b/min. PEEP (range 5-10 cm of water) and FiO2 will be adjusted to maintain an SpO2 ≥92% and to patient's comfort.
1512559|NCT02874326|Drug|Octreotide LAR|
1512560|NCT02874313|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
1512561|NCT02874313|Drug|Pharmacological treatment|Conventional pharmacological treatment with oral antidiabetic drugs or insulin
1512562|NCT02874313|Other|Conventional anti-diabetic diet recommendations|
1512563|NCT02874300|Other|High intensity supervision arm|The higher-intensity supervision arm will comprise 6 occupational therapist (OT) home visits and 5 physiotherapist visits (1,1,2,2,6,12,18,24,30,36 and 52) plus supervised support from a rehabilitation support worker (RSW) twice a week for 3 months, once a week for 3 months, once a fortnight for 3 months and once a month for 3 months. Initially, and at review and progression points, the RSW will visit jointly with the therapists.
1512564|NCT02874300|Other|Moderate intensity supervision arm|The moderate-intensity supervision arm will be based on an ongoing Australian trial (83, 112). There will be 6 OT home visits and 5 physiotherapist visits (weeks 1,1,2,3,4,5,6,7,8,10,12) and three OT telephone calls (weeks 9,10,11). Participants will be expected to exercise independently in-between supervised sessions.
1512565|NCT02874287|Drug|Hydroxychloroquine Sulfate Tablets|Subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 16 weeks. After that, there is a 23-week washout period. And then subjects are treated with oral placebo tablets 200mg twice daily for 16 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
1512566|NCT02874287|Drug|Placebo Tablets|Subjects are treated with oral placebo tablets 200mg twice daily for 16 weeks. After that, there is a 23-week washout period. And then subjects are treated with oral hydroxychloroquine sulfate tablets 200mg twice daily for 16 weeks. All the interventions are built on the guideline-based secondary prevention of coronary heart disease medications.
1512567|NCT02874274|Behavioral|Standard of Care|
1512568|NCT02874274|Behavioral|Home Visit Program (HVP)|The study team will also contact the subject by phone within one week of each vaccination visit to assess for any adverse effects related to vaccination, included but not limited to: injection site pain, tenderness, swelling, pruritus, induration, or erythema; systemic symptoms such as fatigue, chills, headache, anorexia, malaise, myalgias, or anaphylaxis. Subjects will be contacted 90 days (+ 14 days) following Visit 3 to inquire about any additional symptoms and healthcare utilization.
1512569|NCT02874261|Device|Whole Body Periodic Acceleration|oscillating bed that the subject will lie on 3 days a week for 45 minutes at 140 cycles per minute.
1512570|NCT02874248|Drug|15 mg E4/3 mg DRSP|a single oral dose of 15 mg E4/3 mg DRSP (n=10) followed, after a washout of at least 14 days, by multiple oral doses of 15 mg E4/3 mg DRSP (n=10) once daily for 14 days
1512571|NCT02874248|Drug|30 mg E4/6 mg DRSP|a single oral dose of 30 mg E4/6 mg DRSP, followed, after a washout of at least 14 days, by multiple oral doses of 30 mg E4/6 mg DRSP once daily for 14 days
1512572|NCT02874248|Drug|60 mg E4/12 mg DRSP|a single oral dose of 60 mg E4/12 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 60 mg E4/12 mg DRSP once daily for 14 days
1512573|NCT02874248|Drug|Visually matching placebo|a single oral dose of a placebo which visually matches the active medication, followed, after a washout of at least 14 days, by multiple oral doses of matching placebo once daily for 14 days
1512574|NCT02874248|Drug|75 mg E4/15 mg DRSP|a single oral dose of 75 mg E4/15 mg DRSP, followed, after a washout of at least 14 days, by oral doses of 75 mg E4/15 mg DRSP once daily for 14 days
1512793|NCT02872623|Radiation|Enterography-MRI without enteroclysis|
1512576|NCT02874235|Behavioral|Psychological treatment|16 sessions of a length of one hour comprising of verbal based psychotherapy based on principles from Narrative Exposure Therapy or Cognitive Behavioral Therapies
1512577|NCT02874222|Other|surveys completed by subject|Cohort study designed to validate previously identified associations between 10 specific SNPs and discontinuation of treatment with AIs due to the development of MSS among women with breast cancer.
1512578|NCT02874209|Other|sodium MRI|
1512579|NCT02874196|Procedure|Standard arthrography|
1512580|NCT02874196|Procedure|Dual energy arthrography|
1512581|NCT02874196|Procedure|Arthro-tomosynthesis|
1512582|NCT02874196|Procedure|Arthro-tomography|
1512583|NCT02874196|Procedure|Surgery on painful prosthesis|Possibly performed during 6 months from arthrography
1512584|NCT02874183|Behavioral|Pharmacist intervention|Pharmacist counseling and follow-up phone calls
1512585|NCT02874170|Other|Spectroscopy magnetic resonance of phosphorus 31|
1512586|NCT02874157|Biological|blood draw|
1512587|NCT02874144|Drug|AZ compound|40 mg three times daily po for 12 weeks
1512588|NCT02874144|Other|Collection of Biological Specimens|collection of biomarkers for analysis of nasal disease
1512589|NCT02874144|Drug|Intranasal corticosteroid|QD Nasal Spray
1512590|NCT02874131|Behavioral|Behavioral Activation|Behavioral activation
1512591|NCT02874131|Behavioral|Cognitive Processing Therapy|Cognitive processing therapy
1512592|NCT02874118|Behavioral|Fried scale for frailty assessement|
1512595|NCT02874092|Drug|Ticagrelor|
1512596|NCT02874092|Drug|MTX therapy|
1512597|NCT02874079|Other|Blood sample and cotton skin swabs|
1512598|NCT02874066|Drug|PTV/r/OBV/DSV|Viekirax/Exviera for 12 weeks
1512599|NCT02874040|Procedure|Endoresection|Endoresection of the tumor scar
1512600|NCT02874040|Procedure|Laser diode|Transpupillary thermotherapy by laser diode on the tumor scar
1512601|NCT02874027|Other|The TBI patients with depression|The study is to investigate whether exist the relationship between depression and circadian rhythm of patients with TBI or not.
1512603|NCT02873988|Other|bronchial epithelial cell culture|
1512604|NCT02873975|Drug|LY2606368|
1512605|NCT02873962|Drug|Bevacizumab|"Bevacizumab will be given intravenously at a pre-determine dosage
One dose reduction will be allowed for Bevacizumab"
1512606|NCT02873962|Drug|Nivolumab|"Nivolumab injection is to be administered as an IV infusion at a pre-determine dosage.
No dose reductions or escalations will be allowed for Nivolumab"
1512607|NCT02873949|Biological|Crevicular samples (1-10µl)|"In periodontitis patients: from 2 sites affected by periodontitis and 1 healthy site, 2 samples/site, before and after treatment
In non-periodontitis individuals: 2 samples from 1 site"
1512608|NCT02873949|Biological|Saliva samples (1ml)|
1512609|NCT02873949|Other|Etiologic treatment|education on oral hygiene, scaling and root planing
1512610|NCT02873949|Other|Psychometric tests|Spielberger State-Trait Anxiety Inventory and Cohen Perceived Stress Scale
2010623|NCT02914535|Drug|Filgotinib|Tablet(s) administered orally once daily
2010624|NCT02914535|Drug|Placebo|Tablet(s) administered orally once daily
2010625|NCT02913378|Procedure|Osteosynthesis with locking plate|Open reduction and osteosynthesis with locking plate
1512614|NCT02873923|Other|No intervention|No intervention : meta analysis from patients in old clinical trials, but no specific inclusion for this project
1512615|NCT02873910|Dietary Supplement|IQP-AS-119|
1512616|NCT02873910|Dietary Supplement|Placebo|
1512617|NCT02873897|Dietary Supplement|Session A: Experimental products (selected enriched products)|
1512618|NCT02873897|Dietary Supplement|Experimental session: to select enriched products|
1512619|NCT02873897|Dietary Supplement|Session B: Control (standard products without enrichment)|
1512620|NCT02873897|Dietary Supplement|Control session|
1512621|NCT02873884|Behavioral|Case-management|
1512622|NCT02873871|Device|Standardized compressive dressing|Standardized compressive dressing
1512623|NCT02873871|Device|Hemostasis with TerumoBand®|Hemostasis with TerumoBand®
1512624|NCT02873858|Other|smell and taste tests|
1512625|NCT02873845|Other|Preliminary validation of the COBQoL questionnaire|
1512626|NCT02873832|Biological|Blood sample|
1512627|NCT02873832|Other|Flow cytometry|
1512628|NCT02873832|Other|western blot|
1512629|NCT02873819|Drug|GL-0817|GL-0817, IV at the dose 1.5 mg will be administered 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
1512630|NCT02873819|Drug|Hiltonol|Hiltonol will be administered intramuscularly at the dose of 1.4 mg as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
1512631|NCT02873819|Drug|Sargramostim|Sargramostim will be administered intramuscularly at the dose of 100 μg/m2, as adjuvant to GL0817, 3 times at 3-week intervals followed by 7 doses at 3-month intervals beginning at the Week 18 visit
1512632|NCT02873819|Drug|cyclophosphamide|cyclophosphamide will be administered IV at a dose of 200 mg/m2 (maximum dose 400 mg) one day prior to first three vaccinations of GL0817 with adjuvants
1512633|NCT02873819|Drug|Placebo|Placebo (normal saline) will be administered as per the schedule of cyclophosphamide and GL0817/adjuvants administration
1512634|NCT02873806|Procedure|Implantation of two iStent inject micro-bypass stents|- Implantation of two trabecular micro-bypass stents (iStent inject) in a standalone procedure (i.e., without cataract surgery).
1512635|NCT02873806|Drug|Topical travoprost|- Topical travoprost (0.004%, 1 drop each evening in study eye) started on postoperative Day 1.
1512636|NCT02873806|Device|Two iStent inject micro-bypass stents|- Two trabecular micro-bypass stents (iStent inject) implanted in a standalone procedure.
1512794|NCT02872623|Radiation|enteroCT with enteroclysis|
2010626|NCT02913378|Procedure|Sling|Conservative treatment with sling and rehabilitation
2010627|NCT02913352|Procedure|Latarjet procedure|Open anterior glenoid bone graft from coracoid process
2010628|NCT02913352|Procedure|Modified Eden-Hybinette|Open anterior glenoid bone graft from iliac bone crest, with capsular suture and screw fixation
2010629|NCT02913326|Drug|Dabigatran etexilate|
1512637|NCT02873806|Drug|Tobramycin|"Topical antibiotic (tobramycin):
1 drop four (4) times per day in the study eye for one week (in cases of allergy or contraindication, Polytrim (polymyxin B sulfate + trimethoprim sulfate ophthalmic solution, USP, or equivalent) may be used as an alternative medication) ."
1512638|NCT02873806|Drug|Dexamethasone|"Topical anti-inflammatory medication (dexamethasone ophthalmic suspension 0.1%):
Week 1: 1 drop four (4) times per day in the study eye
Week 2: 1 drop three (3) times per day in the study eye
Week 3: 1 drop two (2) times per day in the study eye
Week 4: 1 drop one (1) time per day in the study eye"
1512639|NCT02873793|Genetic|Extraction of total RNA from healthy and tumour tissues|
1512640|NCT02873767|Drug|PR1|"Active substance: UCB4019
Route of Administration: subcutaneously"
1512641|NCT02873767|Other|PL1|"Active substance: Placebo
Concentration: 0.9 % saline
Route of Administration: subcutaneously"
1512642|NCT02873754|Behavioral|Cognitive Behavioral Counseling|Participants will receive five cognitive-behavioral counseling sessions designed to improve rates of smoking cessation, enhance relapse prevention, and increase physical activity.
1512643|NCT02873754|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. They will also be asked to wear a fitness tracker to monitor physical activity (i.e., steps walked). Participants are provided monetary reward for videos that suggest smoking abstinence, and for fitness tracker readings that suggest increased physical activity.
1512644|NCT02873754|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 6-month follow-up.
1512645|NCT02873754|Drug|Transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
1512646|NCT02873754|Drug|Nicotine polacrilex|Nicotine gum will be initiated at smoking quit date; 4 mg dose administered as needed
1512647|NCT02873754|Drug|Nicotine lozenge|Nicotine lozenge will be initiated at smoking quit date; 4 mg dose administered as needed
1512648|NCT02873741|Procedure|Perianal and Digital Anorectal Exam|The physician will inspect the outside of the anus and use a gloved finger to feel the anus for any masses.
1512649|NCT02873741|Procedure|Cervical Swabs|A speculum will be inserted into the vagina to visualize the cervix. The sample for research tests will be collected with one ThinPrep cytobroom inserted into the cervix. Collection will be same for the sample to be paced in the RNA storage solution for future biomarker studies.
1512650|NCT02873741|Procedure|Anal Swabs|The anal cytology specimen will be collected by inserting a saline moistened cotton-tipped swab into the anus, rotating it clock-wise for 20 seconds, and placed in SurePath. The first twenty participants will have anal cells collected in two different ways for validation/optimization: 1) saline moistened Dacron swab placed directly in ThinPrep medium and 2) Medscand Cytobrush Plus, a special brush, placed directly into ThinPrep medium. After validation/optimization is complete for up to 20 participants, the best collection method will be selected and will be used for all future enrolled participants.
1512651|NCT02873741|Procedure|High Resolution Anoscopy (HRA)|High Resolution Anoscopy is a procedure that allows for examination and evaluation of the anal canal. Using a small thin round tube called an anoscope, the anal canal is examined with a high resolution magnifying instrument called a colposcope. Application of a mild acidic liquid (acetic acid or diluted vinegar) or a brown iodine-based solution (Lugol's) onto the anal canal facilitates evaluation of abnormal tissue such as anal dysplasia. If abnormal staining is seen using acetic acid (dense white lesion) or Lugol's solution (bright yellow lesion) a biopsy of that area will be obtained.
1512652|NCT02873728|Procedure|Remote Ischemic Conditioning|Creation of Brief 5 min Ischemia to upper limb using a Blood pressure cuff
1512653|NCT02873728|Other|Control|Puting blood pressure cuff on upper limb and inflating to 10mmhg for 5 min
1512656|NCT02873702|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules
1512657|NCT02873702|Drug|Lansoprazole|Lansoprazole capsules
1512658|NCT02873702|Drug|Placebo|Dexlansoprazole placebo-matching capsules
1512659|NCT02873689|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsule
1512660|NCT02873689|Drug|Placebo|Dexlansoprazole placebo-matching capsules
1512661|NCT02873676|Behavioral|nutritional intervention|The intervention is made up of nutrition supplements and dietary pattern modification, which includes whey 30g/d(plus three times every week),vitamin D 1000IU, omega-3 fatty acid (DHA1200mg and EPA 800mg)
1512662|NCT02873676|Behavioral|resistance training program|The training program involve warm-up exercise, muscle strength training and relaxing
1512663|NCT02873676|Behavioral|lifestyle modification project|Lifestyle modification project is made up of multi-dimensional intensive nutritional intervention and resistance training
1512664|NCT02873676|Behavioral|control|The intervention involve dietary pattern modification and protein intake standardization
1512665|NCT02873663|Procedure|Plasma and head hair collection|Plasma and head hair collection
1512667|NCT02873637|Device|under sartorial catheter|
1512668|NCT02873637|Device|femoral catheter|
1512669|NCT02873624|Procedure|Laparoscopic cholecystectomy|
1512670|NCT02873611|Device|MRI|patients will undergo an additional MRI testing of apprx. 0.5-1 hour.
1512671|NCT02873611|Procedure|genicular ablation procedure|
1512827|NCT02872363|Other|Intervention B - Priority|"SMS reminder with 'Priority' message:
'Is your breast screening appointment on your priority list? Apt at (time), (date) at (site). Call 02033136644 to rearrange.'"
1512674|NCT02873585|Device|Stationary intraoral tomosynthesis|Bitewing radiographs using a stationary intraoral tomosynthesis unit
1512675|NCT02873585|Device|Standard conventional bitewing radiography|Bitewing radiographs using a stationary intraoral tomosynthesis unit will be performed after standard bitewing radiography
1512676|NCT02873572|Behavioral|step 1: online assessment|Anonymous psychiatric and behavioral assessments to evaluate in particular addiction or pathological gambling/gaming and behavioral profile of gamblers/gamers. Once questionnaire completed, if the subjects want to continue to participate, they sent their email to investigators.
1512677|NCT02873572|Behavioral|step2: biomarkers of gamblers/gamers|"For each arm, subjects were divided into 2 groups: dependant or not dependant gamblers/gamers. Investigators focused on decision-making biomarkers following the following flow-chart:
psychiatric assesment and
registration of brain activity during a decision-making task in conditions of uncertainty (IGT) with its version for HR-EEG validated by investigators (Giustiniani, 2015)."
1512678|NCT02873559|Drug|testosterone|Testosterone supplemented in 5 months
1512679|NCT02873559|Other|Progressive muscle training|Progressive muscle training during 4 months
1512681|NCT02873533|Other|geriatric care and longitudinal follow up|geriatric care and longitudinal follow up
1512682|NCT02873520|Drug|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
1512683|NCT02873520|Biological|Precision Cell Immunotherapy|DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
1512684|NCT02873507|Other|MRI of donor liver prior to transplant|MRI of the on ice donor liver within the transport cooler on its way to the operating room
1512685|NCT02873494|Device|PHYSIOFLOW - PF05 Lab1TM|
1512687|NCT02873468|Drug|EMS Fluticasone 1|The patient will take 4,5mL, oral, BID.
1512688|NCT02873468|Drug|EMS Fluticasone 2|The patient will take 7mL, oral, BID.
1512689|NCT02873468|Drug|EMS Fluticasone 3|The patient will take 9mL, oral, BID.
1512690|NCT02873468|Other|EMS Placebo Fluticasone|The patient will take 5mL, oral, BID.
1512691|NCT02873455|Other|Short video clip including the circumstance of operation theater, and surgeon's interview|
1512692|NCT02873442|Procedure|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～ 40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
1512693|NCT02873442|Biological|Precision Cells|"DC cell suspension (1×107 DC+ physiological saline
+ 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PMAT/PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
1512694|NCT02873416|Drug|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/ m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
1512695|NCT02873416|Biological|Precision Cells|Precision Cells DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision Cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
1512696|NCT02873403|Device|KNEEMO knee brace|Bespoke knee brace made by additive manufacturing
1512697|NCT02873403|Device|Popular knee brace|Customized knee brace used in the management of medial knee ostearthritis
1512698|NCT02873390|Biological|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
1512699|NCT02873377|Drug|Nicorette Gum|GlaxoSmithKline Nicorette Gum (nicotine replacement therapy)
1512700|NCT02873377|Drug|Nicoderm CQ|GlaxoSmithKline Nicoderm CQ (nicotine replacement therapy)
1512701|NCT02873377|Other|Smoking Quitline Referral|Fax referral to the State smoking Quitline
1512702|NCT02873377|Behavioral|Behavioral Smoking Cessation Counseling|One time face-to-face smoking cessation counseling and follow-up phone call
1512703|NCT02873364|Drug|Vitamin D3 (High dose)|Daily 4000 unites vitamin D
1512704|NCT02873364|Drug|Vitamin D3 (Low dose)|Daily 600 unites vitamin D
1512705|NCT02873351|Drug|carbidopa-levodopa 25-100 mg|included in arm description
1512706|NCT02873351|Drug|placebo for carbidopa-levodopa 25-100 mg|included in arm description
1512707|NCT02873338|Drug|CX-01|4 mg/kg IV bolus followed by doses of 0.125, 0.25, or 0.325 mg/kg/hr given on days 1 through 7 with standard induction therapy, on days 1 through 5 or 7 with standard re-induction therapy, and on days 1, 3 and 5 with standard consolidation therapy
1512708|NCT02873338|Drug|Idarubicin|12 mg/m2/day by slow (10 to 15 minutes) IV injection daily on days 1, 2 and 3 of induction therapy, and on days 1 and 2 of re-induction therapy
1512709|NCT02873338|Drug|Cytarabine|"100 mg/m2/day by continuous IV infusion on days 1 through 7 of induction therapy, and on days 1 through 5 of re-induction therapy
1.0 g/m2 IV infusion given over 3 hours every 12 hours on days 1, 3, and 5 of consolidation therapy"
1512710|NCT02873325|Other|antiviral therapies for CMV and/or ADV|salvage antiviral treatments for ADV and/or CMV
2010630|NCT02913326|Drug|Warfarin|
2010631|NCT02913261|Drug|Ruxolitinib|Tablet for oral use
2010632|NCT02913261|Drug|Best Available Therapy (BAT)|Best Available Therapy
2010633|NCT02912988|Drug|Letrozole|Daily 150-300 IU human menopausal gonadotrophin (HMG) / Follicle stimulating hormone (FSH) from cycle day 2-4 (at least 5 days after stopping the oral contraceptive pill) and co-treatment with letrozole 2.5 mg daily from stimulation day 5 until the day before hCG administration. GnRH antagonist (cetrotide or orgalutran) 0.25 mg daily from stimulation day 5 until the day of hCG administration.
2010634|NCT02912559|Drug|Atezolizumab|Given IV
2010635|NCT02912559|Drug|Fluorouracil|Given IV
2010636|NCT02912559|Other|Laboratory Biomarker Analysis|Correlative studies
2010637|NCT02912559|Drug|Leucovorin Calcium|Given IV
1512711|NCT02873312|Device|StimRouter|"The StimRouter System is a neuromodulation system consisting of the following components and accessories:
An implantable multi-electrode lead with integrated receiver in loader and surgical tools for implantation of the implantable lead.
An external programming system with a clinician programmer, a clinician programmer cradle and charger, an external pulse transmitter tester and accessories.
A patient-operated system with an external pulse transmitter (StimRouter EPT), a disposable StimRouter Electrode, an external patient programmer and charger, and accessories."
1512712|NCT02873299|Other|10 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 10 Hz rTMS of the right dorsolateral prefrontal cortex
1512713|NCT02873299|Other|20 Hz rTMS of the right dorsolateral prefrontal cortex|Ten sessions of 20 Hz rTMS of the right dorsolateral prefrontal cortex
1512714|NCT02873286|Biological|MVA-BN-RSV|MVA-mBN294B
1512715|NCT02873286|Other|Placebo|Tris Buffered Saline, sterile
1512717|NCT02873260|Biological|TetraVax-DV-TV005|TetraVax-DV-TV005 contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^4.3 PFU/mL of rDEN2/4Δ30(ME), 10^3.3 PFU/mL of rDEN3Δ30/31-7164, and 10^3.3 PFU/mL of rDEN4Δ30. The vaccine is administered in 0.5 mL containing 10^3.0 PFU of each component with the exception of rDEN2/4Δ30 that is given at a dose of 10^4 PFU. TetraVax-DV-TV005 is administered by subcutaneous injection in the deltoid region of the upper arm.
1512718|NCT02873260|Biological|rDEN3Δ30|Administered at a dose of 10^4 PFU by subcutaneous injection in the deltoid region of the upper arm.
1512719|NCT02873260|Biological|Placebo|Administered at a volume of 0.5 mL by subcutaneous injection in the deltoid region of the upper arm.
1512720|NCT02873234|Drug|Traditional Chinese Medicine|Participants are treated with TCM twice per day according to syndrome differentiation. For example, the syndrome of one participant with depression is kidney deficiency. He will take Zishui Qinggan Yin twice per day before the breakfast and dinner.
1512721|NCT02873234|Drug|Antidepressants|Participants are treated with different antidepressants. The dosage, frequency and duration are determined according to guideline.
1512722|NCT02873221|Drug|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
1512723|NCT02873221|Drug|Placebo-matching Ubrogepant|Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
1512724|NCT02873221|Drug|Usual Care|Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.
1512725|NCT02873208|Drug|ALKS 3831|Coated bilayer tablet containing 10 mg, 15 mg or 20 mg olanzapine and 10 mg samidorphan
2010638|NCT02912559|Drug|Oxaliplatin|Given IV
2010639|NCT02912559|Other|Quality-of-Life Assessment|Ancillary studies
2010640|NCT02913482|Drug|RO7034067|RO7034067 will be administered orally.
1512731|NCT02873182|Device|Autonomic nervous system monitoring|Two intracorporal electrode needles will be inserted beneath the skin of the genitalia. After insertion, the electrodes will be secured and connected by leads to two standard neurophysiological devices for differential amplification, display, and storage. Smooth muscle free-running (continuous) and stimulated EMG will be recorded.
2010641|NCT02911701|Drug|Acetaminophen|
1512733|NCT02873156|Drug|E2027|Participants will receive E2027 capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 will be administered orally with 240 milliliter (mL) (8 fluid ounces) of water.
1512734|NCT02873156|Drug|E2027 matched placebo|Participants will receive E2027 matched placebo capsules, orally once daily (QD) on Days 1 to 14 after an overnight fast of at least 10 hours. E2027 matched placebo will be administered orally with 240 mL (8 fluid ounces) of water.
1512735|NCT02873143|Other|No intervention|No intervention
1512736|NCT02873130|Behavioral|Telepractice Global Voice Prevention Model|
1512737|NCT02873130|Behavioral|In-person Global Voice Prevention Model|
1512738|NCT02873130|Behavioral|Telepractice, Vocal Hygiene and Vocal Education|
1512739|NCT02873117|Other|Prostate biopsy, prostatectomy or prostate resection|Collection of prostate examination
2010642|NCT02911701|Drug|Ibuprofen|
1512741|NCT02873091|Procedure|Epidural analgesia|
1512742|NCT02873091|Procedure|Continuous epidural infusion|
1512743|NCT02873091|Procedure|Intermittent epidural bolus|
1512744|NCT02873091|Drug|ropivacaine|
1512745|NCT02873091|Drug|sufentanil|
1512746|NCT02873078|Behavioral|Internet-delivered Cognitive behavior therapy|The treatment is delivered via an online platform and is based on interventions for adults, adolescents and children tested in previous trials. Therapists are CBT-psychologists och students in clinical psychology under supervision.
1512747|NCT02873065|Drug|Ilaprazole|
1512748|NCT02873065|Drug|Esoprazole|
1512749|NCT02873052|Device|MyoVista|The clinical set up of MyoVista™ is identical to that of a traditional 12-lead ECG but it obtains and processes signal information in a way that permits much greater resolution of the electrical activity associated with the myocardium MyoVista.
1512750|NCT02873026|Drug|Triamcinolone Acetonide|Following the repair of the open globe eye trauma, the use of Triamcinolone Acetonide will be investigated
1512751|NCT02873000|Behavioral|Incentive Spirometry|Incentive Spirometer is a tool that allows for deep breathing in a controlled setting while providing the user with visual feedback demonstrating the inspiratory volume of each breath.
2010643|NCT02911116|Drug|Ustekinumab|
1512753|NCT02872948|Genetic|Diagnostic|
1512788|NCT02872675|Dietary Supplement|HOST-DM059|"Experimental Supplement: HOST-DM059.
Participants will be asked to orally consume one powdered sachet each day, at the same time in the morning, reconstituted in tea/coffee/fruit juice, or sprinkled over cereal etc. Whichever method of consumption is chosen, this must be kept consistent across both supplementation phases."
1512789|NCT02872675|Dietary Supplement|Maltodextrin|Placebo Comparator: Maltodextrin.
2010644|NCT02911753|Other|Mediterranean Lemonade|All participants will be advised to consume all of the beverage assigned (mediterranean lemonade) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
1512756|NCT02872922|Other|Low intensity therapeutic ultrasound|The ultrasound equipment (Sonopulse III, 1 MHz, IBRAMED, Brazil) was calibrated with the radiation force method. In study, the head of the transducer will be positioned and applied for 5 min over the brachial artery at the same point that will be evaluated the endothelium function (Cruz et al., 2016). Continuous waveforms of ultrasound therapy (CWUT) are applied in the stationary mode for 5 minutes at a spatial averaged temporal intensity (SATA) of 0.4 W/cm2 using a transducer 1-MHz. A pulsed waveform of ultrasound therapy (PWUT) are applied (5 minutes) with a 20% duty cycle (2 ms on, 8 ms off), which represents a constant intensity of 0.08 W/cm2 SATA. In the placebo intervention, all of the procedures above are repeated, but with the ultrasound equipment powered off (Cruz et al., 2016).
1512757|NCT02872909|Device|Ambulight (Ambicare Health)|"battery-operated low irradiance red light LED (skin cancer plaster)"
1512758|NCT02872896|Procedure|Orthopedic, urologic or general surgery|Patients having orthopedic, urologic or general surgery may have the ClearSight device; patients having orthopedic, urologic or general surgery may have the non-ClearSight device to monitor subject blood pressure during surgery
1512759|NCT02872883|Procedure|Expectant management|
1512760|NCT02872883|Procedure|Minimal Vaginal examinations (only when necessary)|
1512761|NCT02872883|Procedure|Active management|
1512762|NCT02872883|Procedure|Routine vaginal examinations|
1512763|NCT02872870|Behavioral|auditory lexical decision task|
1512764|NCT02872870|Device|electroencephalogram|
1512765|NCT02872857|Drug|Placebo|Placebo will match drug capsules.
1512766|NCT02872857|Drug|8mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
1512767|NCT02872857|Drug|12mg galantamine twice daily|Drug will be administered within 36 hours of hospitalization and continued for 90 days.
1512768|NCT02872831|Device|22G SharkCore™ needle|The 2 dedicated passes from the SharkCore™ needle will be placed in a jar with formaldehyde-based fixative and sent for routine histopathology evaluation. The cassette will be processed, embedded in paraffin, and then prepared in hematoxylin and eosin to be evaluated by one pathologist, who was blinded to the randomization sequence, for the presence of a histologic tissue. If adequate histologic tissue is present, the specimen will be graded as optimal or suboptimal.
1512769|NCT02872831|Device|22G BNX EUS-FNA Needle|Aspirates will be placed onto glass slides and preserved with Diff-Quik stain (American Scientific Products, McGraw Park, Illinois, USA). In addition, a smear will also be placed in alcohol for Papanicolaou staining. Any additional material was sprayed into Hanks's solution and sent for cell block processing. The cytology technician or cytopathologist on site will verify adequacy of specimens. At least two passes will be obtained from the lesion unless the technician established the presence of malignant appearing cells.
1512770|NCT02872818|Drug|17β estradiol hemihydrate|4mg/kg/day for 20 days
1512771|NCT02872818|Drug|Metformin|50 mg/kg/day last 10 days
1512772|NCT02872818|Drug|medroxyprogesterone acetate|1mg/kg/day last 10 days
1512773|NCT02872805|Behavioral|Educational Intervention (EI)|Prior to the initiation of the intervention an individualized transition plan will be developed to address patient needs identified in the readiness for transition assessment. The educational intervention will include handouts and other educational materials and other pertinent information needed for the transition process. The EI will be present to explain information to participants and their parents but they will not accompany participants to appointments in the adult setting.
1512774|NCT02872805|Behavioral|Peer Transition Advocate (PTA)|The PTAs will be present during patient clinic appointments to mentor and support participants in the development of independent health care behaviors. They will engage patients in role-plays to simulate appointments in adult practices. The PTAs will accompany patients during the transition process to the adult providers, to inform, support, and facilitate their successful transition to adult care. PTA duties, performed in the clinic and in the community, will include psychosocial support; facilitation of disclosure; adherence counseling, monitoring, and support; screening of patients for significant signs of illness and referral for care; and tracking and defaulter tracing of patients. PTA will support counseling and testing services for adolescents within the facilities. For those perinatally-infected, important care and support services include disclosure and stigma issues.
1512775|NCT02872792|Device|Early mobilisation with cyclo ergometer|Early mobilisation with cyclo ergometer is done daily during hospitalization for sepsis in an Intensive Care Unit
1512776|NCT02872792|Other|Standard physiotherapy|Standard physiotherapy included passive and active manual mobilization, sitting on bed, sitting in chair, walking
1512777|NCT02872779|Procedure|Blood sampling for free mutant DNA analysis|Blood sampling for Patients Treated for Metastatic Colorectal cancer
1512779|NCT02872753|Biological|ACP|Autologous Conditioned Plasma will be obtained directly in the operatory room from the peripheral venous blood of the patient, and injected intra-articularly at the end of arthroscopic meniscectomy
1512780|NCT02872753|Other|Standard Meniscectomy|Patients will receive standard arthroscopic meniscectomy
1512781|NCT02872740|Procedure|Embolization of Left Gastric Artery|Left gastric artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
1512782|NCT02872740|Procedure|Embolization of Gastroepiploic Artery|Gastroepiploic artery will be embolized to stasis with 150-250 micron polyvinyl alcohol particles
1512783|NCT02872727|Other|Respiratoy health, biological investigations|Once the subjects have agreed to participate, self-surveys on their lifestyle habits will be filled and EACand urine samplings will be taken during one same consultation, in addition to exhaled CO and No measurements. This consultation will also include a spirometry test. The employees' workstation data (and their evolution since the first study) will be collected. Therefore, the volunteers' participation is limited to one single visit including non-invasive examinations and self-surveys.
1512784|NCT02872714|Drug|INCB054828|INCB054828 once daily on a 2-weeks-on-therapy and 1-week-off-therapy schedule
1512785|NCT02872701|Drug|OTL38 for Injection|Folate analog ligand conjugated with an indole cyanine-like green dye as a solution in vials containing 3 mL at 2 mg/mL
1512786|NCT02872701|Device|Near infrared camera imaging system|Near infrared camera imaging system
1512787|NCT02872688|Other|GanedenBC30|
1512790|NCT02872649|Drug|Dabigatran|
1512795|NCT02872610|Behavioral|Self-help Online|"The internet-based self-help program consist of 6 modules that each take a week to complete. Every module consists of a theoretical section, a compulsory exercise, and several optional exercises: Participants are encouraged to spend a minimum of 30 minutes every day with the self-help program. On the website, the participants in the intervention condition may also access an Acute Help page where information on help options are listed and a My Profile page where changes to login and contact details may be made, also, the informed consent form is found here. Participants may furthermore access a message system where they can write questions to the trial manager."
1512800|NCT02872584|Drug|Prednisone|prednisone treatment as required by dermatological condition (pemphigus/pemphigoid)
1512801|NCT02872571|Drug|Intramuscular Islet Autograft|Intramuscular Islet Autograft After Extensive Pancreatectomy
1512802|NCT02872558|Other|Acute Otitis Media Choice Decision Aid|Decision Aid
1512803|NCT02872558|Other|Usual Care|Usual Care
1512804|NCT02872545|Procedure|Rest tomoscintigraphy in forward tilted|Rest tomoscintigraphy in forward tilted position
1512805|NCT02872545|Procedure|Rest tomoscintigraphy in semi sitting position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
1512806|NCT02872545|Procedure|Rest tomoscintigraphy in dorsal decubitus position|Rest tomoscintigraphy in forward tilted position, followed by a second rest tomoscintigraphy in semi sitting position, after max 30 min
1512807|NCT02872532|Procedure|Testicular tissue cryopreservation|Testicular tissue will be removed
1512808|NCT02872519|Radiation|(S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG)|
1512809|NCT02872519|Procedure|Positron Emission Tomography|
1512810|NCT02872519|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis
1512811|NCT02872506|Drug|Anti TNF|Patients are admitted to day hospital with blood test less than 7 days. In the absence of contraindications, hydrocortisone infusion 200 mg will be conducted for 15 minutes followed by anti-TNF treatment infusion over 2 hours for the first three sessions. The following infusions of anti-TNF therapy will be on the same terms without hydrocortisone, every 4 to 8 weeks, in doses of 5-10mg/kg. Adverse effect most frequently reported was URTI. The most serious adverse reactions, were a reactivation of hepatitis B, congestive heart failure, serious infection, serum hypersensitivity reactions, blood diseases, systemic lupus erythematosus / lupus-like syndrome, demyelinating disorders, hepatobiliary metabolism disorders. The QOL will be assessed by IBDQ score at the inclusion visit before the first infusion and at 6 months.
1512812|NCT02872506|Procedure|ileocecal resection|The operation is performed by laparoscopy or laparotomy. Hospital stay is on average 6 days. Preparation for the intervention is sometimes required 3 weeks to 1 month before the procedure to avoid risk situations.The main risk of the intervention is the anastomotic fistula. This risk of anastomotic leakage mainly concerns malnourished patients operated within the context of abdominal sepsis (abscess). An assessment protocol of post-operative pain, every 3 hours, is now well codified in routine surgery. The QOL will be assessed by the IBDQ score before surgery and at 6 months.
1512813|NCT02872493|Procedure|Small bowel length measurement|The total length of the small bowel with be measured at the time of the bariatric surgical operation.
1512814|NCT02872480|Other|ACTIVE Training|Participants will be asked to complete aerobic exercise on a stationary bike during 30-minute sessions. Intensity will progress under a standard procedure for healthy participants (60-80% of VO2max) and as tolerated by concussed participants (starting at 60% of symptom exacerbation).
1512815|NCT02872467|Drug|Syntocinon treatment|24 IU twice daily (A single dose will be delivered consisting of 6 intranasal insufflations (3 in each nostril) which is equivalent to a total of 24 international units (IU) of oxytocin twice daily).
1512816|NCT02872467|Other|Placebo|Placebo nasal spray vials will contain the same ingredients in the nasal preparation, but without oxytocin.
1512817|NCT02872454|Behavioral|Text Messaging|Each week, enrolled participants will receive daily text messages from one of three randomly assigned psychotherapeutic modalities—cognitive restructuring, behavioral activation, and techniques based on Acceptance and Commitment Therapy (ACT)—for a total of 12 weeks. The messages were developed, reviewed, and refined by a multidisciplinary team of experienced therapists, including social workers, psychologists, and psychiatrists.
1512818|NCT02872441|Biological|blood sample|One blood sample of 50 milliliter 24 hours after the inclusion
1512819|NCT02872428|Drug|Valproic Acid|By infusion over 1 hour
1512820|NCT02872428|Drug|Isotonic saline solution|By infusion over 1 hour
1512821|NCT02872415|Biological|Blood puncture site|
1512822|NCT02872402|Behavioral|Lifestyle intervention|Women who are still breastfeeding at the first postpartum visit will be encouraged to pursue. References to local breastfeeding supporting groups will be done, if needed. The intervention will be conducted in order to reach recommendations for food servings and nutrient needs. Particular attention will be paid to increase fruits, vegetables, fish and whole grains intake, and decrease added sugars and high fat meat/dairy products. Women will be strongly encouraged to be active at least 150 min/week. They will be provided with targeted strategies for exercising, types of exercises and tips for including physical activity into the daily routine as well as fun exercises for the whole family.
1512823|NCT02872402|Behavioral|Active control lifestyle intervention|Participants in the control group will receive standard lifestyle recommendations in the form of written information at each visit.
1512824|NCT02872389|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
1512825|NCT02872389|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic knee surgery under general anesthesia. End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period.
1512826|NCT02872363|Other|Intervention A - Behavioural Regulation|"SMS reminder with 'Behavioural Regulation' message:
'Don't forget to make a diary note of your screening mammogram apt at (time)(date) at (site). Call 02033136644 to rearrange'"
1512828|NCT02872350|Device|Abdominal ultrasound|Techniques and predictive characteristics of the combination abdominal ultrasound abdomen and shot in the prognostic assessment of ECUN in premature under 33SA.
1512829|NCT02872337|Behavioral|Preoperative Physical Therapy Session|This was a one-on-one preoperative physical therapy session on preoperative education. These patients were also given access to a surgery specific web-based microsite
1512830|NCT02872337|Behavioral|Group Preoperative Education Session (per the standard of care)|
1512831|NCT02872324|Other|Procurement questionnaires|
1512832|NCT02872311|Biological|High Dose Influenza vaccine|Licensed and FDA approved Fluzone HD vaccine to be administered to study participants
1512833|NCT02872311|Biological|Adjuvanted Influenza vaccine|Licensed and FDA approved FluAd vaccine to be administered to study participants
1512834|NCT02872311|Biological|Standard Dose Influenza vaccine|Licensed and FDA approved Fluvirin vaccine to be administered to study participants
1512835|NCT02872311|Biological|Recombinant Influenza vaccine|Licensed and FDA approved FluBlok vaccine to be administered to study participants
1512836|NCT02872298|Device|Targeted Lung Denervation|The Holaira Lung Denervation System, manufactured by Holaira, Inc., is intended to deliver TLD Therapy using predetermined radiofrequency (RF) energy over a predetermined period of time to ablate airway nerve trunks which are located on the outside of the main bronchi.
1512837|NCT02872298|Biological|Inflammatory Biomarker Collection|Inflammatory biomarkers will be collected in a sub-set of patients. These biomarkers will be collected at two intervals (once during the treatment procedure and once during the airway inspection at 90 days post-treatment).
1512838|NCT02872298|Drug|Glucocorticoids|Subject will be required to take a glucocorticoid for 4 week run-in period at baseline (in addition to a long-acting beta agonist (LABA)).
1512839|NCT02872298|Drug|Long-acting Beta Agonist (LABA)|Subject will be required to take a long-acting beta agonist (LABA) for 4 week run-in period at baseline (in addition to a glucocorticoid).
1512840|NCT02872298|Drug|Tiotropium|Subject will be required to take tiotropium for 7 day run-in period at baseline.
1512841|NCT02872298|Drug|Prednisone|Subject will be required to take prednisone 3 days prior to scheduled treatment and 5 days following the treatment procedure.
1512842|NCT02872298|Drug|Azithromycin|Subject will be required to take azithromycin for 3 days following the treatment procedure.
1512843|NCT02872285|Drug|Drug: LYC-30937-EC|
1512844|NCT02872285|Drug|Placebo|
1512845|NCT02872272|Drug|Treatment with Amikacin|Aminoglycosides. Blood sampling for pharmacokinetic evaluation
1512846|NCT02872259|Drug|BGB324+pembrolizumab|Combination
1512847|NCT02872259|Drug|BGB324+dabrafenib and trametinib|Combination
1512848|NCT02872259|Drug|pembrolizumab|Monotherapy
1512849|NCT02872259|Drug|dabrafenib and trametinib|Combination
1512850|NCT02872246|Drug|BAY 987516|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
1512851|NCT02872246|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
1512852|NCT02872233|Drug|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
1512853|NCT02872233|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
1512854|NCT02872220|Drug|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
1512855|NCT02872220|Drug|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
1512856|NCT02872220|Drug|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
1512857|NCT02872220|Drug|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride [NaCl]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
1512858|NCT02872207|Drug|BAY 987516 (Y65-122)|5 µL in one eye
1512859|NCT02872207|Drug|BAY 987516 (Y65-118)|5 µL in one eye
1512860|NCT02872207|Drug|Control|5 uL in other eye
1512861|NCT02872194|Drug|BAY987516, Y55-170|10 uL in one eye
1512862|NCT02872194|Drug|BAY987516, X72-151|10 uL in one eye
1512863|NCT02872194|Drug|BAY987516, Y49-034|10 uL in one eye
1512864|NCT02872194|Drug|Standard shampoo mixture (control)|10 uL in one eye
1512865|NCT02872181|Procedure|Supine|Placed in Supine position
1512866|NCT02872181|Procedure|Left uterine displacement|Placed in 15 degrees left uterine displacement
1512867|NCT02872168|Other|Not intervention|None. there is no modification in the treatment of patients. A urine collection is carry out in patients during the day of their enrolment.
1512868|NCT02872155|Other|Oral hydratation|500 mL of water two hours before computed tomography and 2000 milliliters 24 hours after performing computed tomography
1512869|NCT02872155|Drug|Bicarbonate endovenous hydratation|Intravenous hydration: sodium (1.6 molar) Bicarbonate 3 mL / kg / h starting one hour before the computed tomography and sodium bicarbonate (1/6 M) 1 mL / kg / h during the hour after computed tomography.
1512870|NCT02872155|Drug|Saline endovenous hydratation|If there is contraindication for administration of bicarbonate the pattern of intravenous hydration is performed with saline solution: 3 ml / kg / h for 1 hour before the procedure and normal saline 1 mL / kg / hour for hour after computed tomography.
1512871|NCT02872142|Biological|Albutein 5%|Plasma exchange will be performed using Albutein 5% as the replacement solution. Albutein is manufactured from human plasma. The dose of Albutein 5% for replacement following plasma removal will be calculated based on gender, weight, and the hematocrit of the subject.
1512878|NCT02872103|Drug|F-627|F-627 subcutaneous injection on Day 2 of TA chemotherapy cycles. TA chemotherapy treatments are part of standard-of-care and not the study
1512879|NCT02872103|Drug|Placebo|Placebo subcutaneous injection on Day 2 of the first TA chemotherapy cycle. TA chemotherapy treatments are part of standard-of-care and not the study.
1512880|NCT02872090|Drug|Indacaterol|inhalation
1512881|NCT02872090|Drug|Glycopyrronium|inhalation
1512882|NCT02872090|Drug|Tiotropium|inhalation
1512883|NCT02872090|Drug|Placebo|
1512884|NCT02872090|Procedure|photoplethysmography|inhalation
1512885|NCT02872077|Other|Auricular acupuncture|
1512886|NCT02872064|Drug|Verteporfin|Verteporfin (which is marketed under the brand name Visudyne) is the photosensitizer. Verteporfin is a benzoporphyrin derivative which is clinically active when formulated with liposomes. By itself the clinically recommended dose of Verteporfin is not cytotoxic. It produces cytotoxic agents only when activated by light in the presence of oxygen. When energy absorbed by the porphyrin is transferred to oxygen, highly reactive short lived singlet oxygen is generated. Singlet oxygen causes damage to biological structures, leading to local vascular occlusion, cell damage and cell death.
1512887|NCT02872051|Behavioral|IBBIS mental health care and standard vocational rehabilitation|"Standard vocational rehabilitation.
Stepped mental health care provided by the IBBIS mental health care team (e.g. nurses, psychologists, and medical doctors) with the treatment modalities:
Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment"
1512888|NCT02872051|Other|Integrated mental health care and vocational rehabilitation|"Integrated mental health care and vocational rehabilitation provided by the IBBIS team. The IBBIS team is composed by employment specialists from the municipal job centers and health care professionals from the mental health services (e.g. nurses, psychologists, and medical doctors).
Mental health care is provided according to a stepped care model with the following treatment modalities:
Psychoeducation Bibliotherapy Cognitive-behavior Therapy Monitoring and reassessment
Vocational rehabilitation is inspired by Individual Placement and Support and is a workplace-oriented intervention with problem-solving conversations as a core element"
1512892|NCT02871999|Device|Acupuncture therapy|
1512893|NCT02871999|Procedure|Laparoscopic Surgery|
1512894|NCT02871986|Drug|Routine transdermal oestrogen patch|Transdermal oestrogen patch will be used with an incremental dose increase at 4 months
1512895|NCT02871973|Behavioral|Sit Down and Play|Sit Down and Play (SDP) is designed to be a brief, low-cost intervention that incorporates key theoretical constructs to elicit positive parenting behaviors. It is intended to be delivered by existing clinical staff, nonprofessionals, or volunteers during each of the eight well-child visits between 2-24 months of age while a family waits to be seen by their pediatrician in the examination room.
1512896|NCT02871973|Behavioral|Handout|Handouts developed by Center for Disease Control and Prevention (CDC) to provide information regarding age-specific early childhood milestones
1512897|NCT02871960|Procedure|Robotic and Laparoscopic Colectomy|
1512898|NCT02871934|Genetic|SLCO1B1 Genotype|Polymerase chain reaction (PCR) assay for SLCO1B1 rs4149056, with possible results T/T, T/C, or C/C.
1512899|NCT02871921|Behavioral|Conversational Engagement|Examine whether increasing social interaction through face-to-face conversations could improve cognitive functions, targeting seniors aged 80 and older who are socially isolated
1512900|NCT02871908|Drug|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 twice daily 2 x 10^8
1512901|NCT02871908|Drug|Placebo|Placebo
1512902|NCT02871882|Radiation|Gastric Emptying test|participants eat a standardized meal labeled with radioactive markers (99mTc DTPA [diethylenetriaminepentaacetic acid] and In111 Chloride). They have scans taken at specific times after the meal to document the rate of gastric emptying.
1512903|NCT02871882|Other|Mixed Oral Glucose Tolerance test|Participants eat a meal containing 63g glucose in 240mL (milliliters) of skim milk, 2 scrambled eggs, 50g Canadian bacon and one slice of bread. Blood samples are taken prior to and for 6 hours after the meal at specific time points.
1512904|NCT02871882|Drug|Conjugated bile acids sodium|500 mg tablets taken orally twice daily for 28 (+/- 4) days
1512905|NCT02871882|Other|Placebo|Placebo tablets taken orally twice daily for 28 (+/- 4) days
1512906|NCT02871869|Drug|vindesine|3 mg/㎡ (maximum dosage: <4mg), d1, 21 d as a cycle, for 4～6 cycles
1512907|NCT02871869|Drug|cyclophosphamide|750 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
1512908|NCT02871869|Drug|Epirubicin|60 mg/㎡, d1, 21 d as a cycle, for 4～6 cycles
1512909|NCT02871869|Drug|prednisone tablets|100 mg, d1～5, 21 d as a cycle, for 4～6 cycles
1512910|NCT02871869|Drug|Cinobufacini Tablets|0.3 g per tablet, 3 tablets per time, tid., p.o., until progressive disease or intolerable drug toxicities
1512911|NCT02871869|Drug|Rituximab|375mg/㎡,one day before CHOP protocol
1512912|NCT02871856|Radiation|Low dose CT|
1512913|NCT02871843|Drug|RRx-001 dose escalation with TMZ + RT|Dose escalation of RRx-001. Dose levels of 0.5, 1.0, 2.0 and 4.0 mg, once weekly.
1512914|NCT02871843|Radiation|Radiation|Conformal or intensity-modulated radiotherapy (60 Gy in 2 Gy fractions) given 5 days a week for 30 fractions (about 6 weeks)
1512915|NCT02871843|Drug|Fixed dose Temozolomide (75 mg/m2)|Oral temozolomide 75 mg/m2 daily for 6 weeks
1512916|NCT02871843|Drug|TMZ Maintenance|TMZ maintenance at 150-200 mg/m2
1512917|NCT02871830|Behavioral|Physical Activity|15 mins physical activity per day within the school setting.
1512918|NCT02871817|Other|Paxos Checkup Study Mobile Medical Application|The Digisight Paxos Checkup TM is mobile vision assessment system which consists of an application installed on a mobile device with an Internet connection, an Internet Cloud-based vision care network and a web site. The Paxos Checkup app contains a set of quantitative near vision tests, which a patient can take at home or elsewhere using an Internet capable mobile device.
1512919|NCT02871804|Procedure|combined resection of the splenic vein|combined resection of the splenic vein with the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
1512920|NCT02871804|Procedure|separated resection of the splenic vein|separated resection of the splenic vein from the pancreatic parenchyma before ligation and division during distal pancreatectomy using mechanical staplers.
1512921|NCT02871791|Drug|Palbociclib|
1512922|NCT02871791|Drug|Everolimus|
1512923|NCT02871791|Drug|Exemestane|
1512928|NCT02871765|Other|Patient education related Warfarin|Patient education related Warfarin: each subject in the experimental group was taught individually according to investigator's brochure in the outpatient department (OPD) by researchers. Three months later, participants received a follow-up phone call in order to clarify any questions related to the brochure. The contents of the brochure consisted of: the purpose of taking Warfarin, side effects, adjustments to daily diet, and precautions (i.e. how to take medication safely, interaction between foods and medicine, prevention and checking of signs and symptoms of bleeding). The control group received the brochure after pretest and routine care only in the OPD. All participants completed posttest at 6-month follow-up.
1512929|NCT02871752|Behavioral|MBSR|mindfulness-based stress reduction
1512930|NCT02871739|Behavioral|Webinar|1 hour online, interactive webinar that covers shared decision making skills in clinical encounters.
1512931|NCT02871739|Behavioral|DA viewing|Participants will receive 3 decisions aids to review.
1512932|NCT02871739|Behavioral|SPI feedback|Rating of shared decision making skills and opportunities for improvement based on transcript of a standardized patient interaction
1512933|NCT02871726|Device|TRUS-Robot|A robotic device used to hold and manipulate the ultrasound probe during a transrectal prostate biopsy
1512934|NCT02871713|Other|Bilateral Quadratus lumborum block with 0.5% ropivacaine|Bilateral Quadratus lumborum block with 0.5% ropivacaine
1512935|NCT02871713|Other|Intrathecal Morphine with 100 mcg morphine|Intrathecal Morphine with 100 mcg morphine
1512936|NCT02871700|Behavioral|Action observation therapy|The patients were asked to observe everyday life actions of which they had motor experience or the actions belong to the motor repertoire of observers', they had better performance. The common categories of motor actions and tasks for stroke patients are selected in this study: (a) active range of motion (AROM) exercises, (b) reaching movement or object manipulation, and (c) upper-extremity (UE) functional tasks practice.
1512937|NCT02871700|Behavioral|Mirror therapy|The MT group will receive 60 minutes of upper-limb training in a mirror box. MT treatment activities will include AROM exercises (10 to 15 minutes), reaching movement or object manipulation (15 to 20 minutes), and functional tasks practice (30 minutes) in a mirror box.
1512938|NCT02871700|Behavioral|Customary bilateral UE training|The participants in this group will receive dose-matched customary bilateral UE training programs for 1 hour per session. The treatment protocol of control group will also include: (a) AROM exercises (10 to 15 minutes), (b) reaching movement or object manipulation (15 to 20 minutes), and (3) functional tasks practice (30 minutes).
1512939|NCT02871687|Drug|Simvastatin|Simvastatin 40 mg daily
1512940|NCT02871687|Drug|Pravastatin|Pravastatin 80 mg daily
1512941|NCT02871687|Other|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
1512942|NCT02871674|Behavioral|Good Night Project|The behavioural interventions have been designed on the basis of three sources. Firstly, a systematic review conducted by the research team that examined the best evidence in the field in different countries. Secondly, a Delphi study, which aimed to identify behavioural interventions that can be used to manage sleep difficulties in Saudi Arabia in accordance with professionals' views and primary caregivers' needs, and which was also conducted by the research team. Thirdly, evidence-based practice resources that help in understanding and managing sleep difficulties will be translated into Arabic.
1512943|NCT02871661|Drug|Amitriptyline|Volunteers will take 25 milligrams of this medication every day from their enrollment until completing eight weeks long.
1512944|NCT02871661|Other|Kinesiotherapy|Volunteers will be taught to contract their pelvic floor muscles right before stretching it, following a home protocol, every day for eight weeks long.
1512945|NCT02871661|Device|IC (Quark)|Volunteers will visit physical therapy clinic once a week to receive twenty minutes of electrical stimulation with Interferential Current (Duapex 961 of Quark Medical manufacturer) in their perineal area, for eight weeks long.
1512946|NCT02871648|Drug|Placebo|Placebo prepared by Investigation Drug Services at Brigham and Women's Hospital
1512947|NCT02871648|Drug|Fludrocortisone|Fludrocortisone 0.1 mg
1512948|NCT02871648|Drug|Eplerenone|Epleronone 100 mg
1512951|NCT02871622|Device|BioMatrix AlphaTM|Cobalt Chromium BA9 TM drug-eluting stent
1512952|NCT02871609|Other|Stent examination, urinary analysis, USSQ questionnaire|
1512953|NCT02871596|Other|Placebo|A combination of maltodextrins and red and blue food colors.
1512954|NCT02871596|Dietary Supplement|Flavonoids|A combination of blueberry extract, black current extract, and black rice extract.
1512955|NCT02871596|Dietary Supplement|Flavonoids+Prebiotics|A combination of blueberry extract, black current extract, black rice extract, inulin, and fructooligosaccharide.
1512956|NCT02871583|Procedure|lichtenstein|tension free mesh hernioplasty (lichtenstein) procedure will be applied for inguinal hernia repair
1512957|NCT02871583|Procedure|Kugel|preperitoneal mesh hernioplasty (Kugel) procedure will be applied for inguinal hernia repair
1512958|NCT02871570|Drug|Rivipansel|A single dose of IV Rivipansel over 20 minutes
1512959|NCT02871544|Other|BNP and NGAL|
1512960|NCT02871531|Procedure|Pneumatic retinopexy|
1512961|NCT02871531|Procedure|Vitrectomy|
1512962|NCT02871518|Drug|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22) combine with IMRT
1512963|NCT02871518|Drug|Cisplatin combine with IMRT|Concurrent cisplatin (100mg/m2，D1,D22 and D43) combine with IMRT
1512964|NCT02871505|Drug|Benzathine Penicillin G|
1512971|NCT02871453|Device|Scalp Acupuncture Treatment|The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.
1512972|NCT02871453|Other|Rehabilitation treatment|The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
1512973|NCT02871440|Drug|Omega 3|
1512974|NCT02871440|Drug|Optive Advanced|
1512975|NCT02871440|Drug|Optive|
1512976|NCT02871427|Drug|Nelotanserin|Once Daily, Oral, at 20, 40, 60, or 80 mg dose
1512977|NCT02871414|Behavioral|REST - Early Group|Intervention - 7 weeks of sleep skills education provided in group and one-on-one format
1512978|NCT02871414|Behavioral|REST - Late Group|Control for REST - Early Group, then provided group and one-on-one sleep education and sleep skills intervention
1512981|NCT02871388|Behavioral|CONECT|1 monthly in person + 1 monthly telephone + 4 monthly email contact for behavior modification. Focus on motivation, self efficacy and information provision.
1512984|NCT02871362|Dietary Supplement|IQP-AS-118|
1512985|NCT02871362|Dietary Supplement|Placebo|
1512986|NCT02871349|Drug|Propranolol|Propanolol will be given on a titration schedule in which participants will begin with small doses (single capsules) of the drug and increase to a larger dosage (divided over 3 capsules) over the course of three weeks. Participants aged 15-24 years will undergo an MRI.
1512987|NCT02871349|Drug|Placebo|Placebo will be given in the form preferred by the participant and on the same schedule as the propanolol regime. Participants aged 15-24 years will undergo an MRI.
1512988|NCT02871349|Device|Magnetic Resonance Imaging (MRI)|An MRI will be performed on participants aged 15-24 years.
1512989|NCT02871336|Other|Data collection|
1512990|NCT02871323|Biological|Durvalumab|Given IV
1512991|NCT02871323|Other|Laboratory Biomarker Analysis|Correlative studies
1512992|NCT02871310|Dietary Supplement|IQP-AS-118|
1512993|NCT02871310|Dietary Supplement|Placebo|
1512996|NCT02871271|Dietary Supplement|IQP-AS-121|
1512998|NCT02871245|Procedure|Laparoscopic Surgery|
1512999|NCT02871245|Device|Acupuncture treatment|
1513000|NCT02871232|Other|Researched Abuse, Diversion and Addiction-Related Surveillance (RADARS) System of post-marketing surveillance of prescription medication abuse, misuse, and diversion|
1513003|NCT02871206|Biological|Fluad|
1513004|NCT02871206|Biological|Fluzone|
1513005|NCT02871193|Drug|Ropivacaine|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml
1513006|NCT02871193|Drug|Dexamethasone|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.5% ropivacaine 20ml and dexamethasone 5 mg
1513007|NCT02871193|Other|saline|ultrasound-guided thoracic paravertebral nerve block (TPVB) with 0.9% saline 20ml
1513008|NCT02871180|Dietary Supplement|Late night snack|The late night snack was one slice of whole meal rye bread containing approximately 20 g of carbohydrate.
1513009|NCT02871180|Other|No late night snack|Patient consumed no nutrients at late night.
1513010|NCT02871167|Procedure|Controlled ovarian hyperstimulation (COH)|"After information and consent, patients are addressed to a reproductive medicine center.
The COH will be performed according to a standardized protocol between surgery and the start of adjuvant chemotherapy. Follicular growth will be achieved with an antagonist protocol and by using high dose recombinant FSH (r-FSH). The triggering of the final follicular and oocyte maturation will be obtained by a GnRH (Gonadotropin Releasing Hormone) agonist injection in order to minimize the risk of ovarian hyper-stimulation."
1513011|NCT02871167|Procedure|Oocyte/embryo freezing|Egg or embryo freezing will be performed according to a standardized protocol: slow-freezing process for embryo; vitrification technique for oocytes. Cryopreserved oocytes and embryos will be stored in the biological bank of each reproductive medicine center (min. 10 years).
1513012|NCT02871154|Other|Delaying oocyte pick up beyond 39 hours post hCG|Unlike the traditional less-than 39 hours interval from hCG injection to oocyte pick up, we will extend the interval up to 47 hours
1513013|NCT02871141|Procedure|electroconvulsive therapy|electroconvulsive therapy
1513014|NCT02871141|Drug|Antidepressant|Antidepressant
1513015|NCT02871128|Dietary Supplement|Natureheme-iron|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
1513016|NCT02871128|Dietary Supplement|Placebo|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 2 capsules per day containing either 1000 mg starch placebo of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
1513017|NCT02871128|Drug|supplement|An 12 week double-blinded randomized parallel study with 4 week follow-up period was performed in mild anemia subjects. Consenting eligible subjects were receive 1 capsule per day containing either 100 mg Fe of similar appearance for 12 weeks. The subjects were required to visit at baseline, every 6 weeks during the intervention period (6 weeks), and at follow-up 4 weeks after treatment had ended. During each study visit, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
1513018|NCT02871115|Other|Pharmacy Intervention|Patients randomized to the pharmacy intervention (PRIME) will undergo evaluation with a clinical pharmacist at their second or third chemotherapy infusion who will: (1) perform detailed medication reconciliation and obtain allergy and vaccination history; (2) evaluate and document polypharmacy, potentially inappropriate medications, lack of appropriate medications; and (3) document their findings in the medical record and discuss their recommendations the oncology team.
1513019|NCT02871115|Other|Usual Care|Participants receiving usual oncology care will not meet with the pharmacist unless indicated as part of their routine clinical care. Study staff will obtain all patient-reported measures from the patient.
1513020|NCT02871102|Procedure|Recruitment Maneuver with PEEP and Tidal Volume Optimization|A staircase recruitment maneuver will be performed on pressure control ventilation followed by a decremental PEEP trial. During the decremental PEEP trial inspiratory tidal volumes will be varied at each step between 3 ml/kg and 10 ml/kg predicted body weight while recording the continuous pressure and flow tracings from the mechanical ventilator. With each PEEP and tidal volume combination, end expiratory and end-inspiratory plateau pressure and stress index will be assessed. At the completion of the decremental PEEP trial, the patient will be returned to ARDSnet-recommended ventilator settings.
1513021|NCT02871089|Device|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:
Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.
An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device.
Rapid acting insulin analogue will be used (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue)."
1513022|NCT02871089|Other|Multiple Daily Injections|"Rapid acting insulin analogue and long acting insulin analogue will be subcutaneously administered using CE-marked insulin pen devices in accordance with the manufacturer's instructions for their intended purposes.
Participants will be given long acting analogue (insulin glargine, insulin detemir or similar) once or twice daily according to their needs and boluses of rapid acting analogue (insulin aspart, insulin lispro, insulin glulisine or similar or ultra-rapid insulin analogue) when carbohydrates are consumed."
1513023|NCT02871076|Device|Acupuncture|Patients will be randomized to either treatment arm, verum acupuncture or sham placebo acupuncture.
1513024|NCT02871050|Other|Sample Collection|Excess blood sample tubes and/or buccal swabs or saliva will have DNA and RNA extracted and serum and plasma separated out to be stored for future research purposes based on the results of this preliminary research.
1513025|NCT02871037|Drug|PF-05221304|Single or repeated, escalating dose of PF-05221304
1513026|NCT02871037|Other|Placebo|single or repeated dose of placebo
1513027|NCT02871024|Device|Toraymyxin|Toraymyxin is an extracorporeal hemoperfusion device designed to reduce blood endotoxin levels in sepsis
1513028|NCT02871011|Drug|Nitric Oxide|Delivered as a footbath
1513029|NCT02871011|Drug|Water|Delivered as a footbath
1513030|NCT02870998|Other|Active learning|1-day continuing education activity consisting of a lecture on patient education.
1513031|NCT02870998|Other|Passive learning|1-day continuing education activity consisting of a brief lecture on patient education and workshops.
1513032|NCT02870985|Device|Coronary Stent|
1513035|NCT02870946|Procedure|Simultaneous RRT|The patients in the simultaneous RRT arm will receive RRT when ECMO is commenced. (see Study Description)
1513036|NCT02870946|Procedure|Standard care|The patients in the standard care arm will not receive RRT when ECMO is commenced. Only when a patient demonstrates AKI and fulfills any one of the criteria of the conventional RRT indication, RRT would be delivered.
1513037|NCT02870933|Biological|Transepicardial with Transseptal CD 133+ Implantation|Transepicardial with Transseptal CD 133+ Implantation
1513038|NCT02870920|Drug|Tremelimumab|
1513039|NCT02870920|Drug|Durvalumab|
1513040|NCT02870920|Other|Best Supportive Care|
1513059|NCT02870868|Behavioral|Slow breathing|Slow breathing techniques from yoga
1513061|NCT02870842|Device|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
1513062|NCT02870842|Other|Respiratory management|Appropriate respiratory managements depending on the lung ultrasound findings
1513063|NCT02870829|Drug|menaquinone-7|Oral supplement given post dialysis 3x/week
1513064|NCT02870816|Procedure|Tissue Engineered Skin Substitute|Application of skin substitute and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
1513065|NCT02870816|Device|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
1513066|NCT02870816|Procedure|Amnionic Membrane Graft|Application of amnion membrane graft and non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
1513067|NCT02870790|Drug|TDF/FTC|one pill daily
1513069|NCT02870764|Drug|Dan-shen extract|A kind of injection made from a kind of Chinese herb: salvia miltiorrhiza
1513070|NCT02870764|Drug|Placebo|200mg glugose added into 250ml 0.9% saline injection by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
1513071|NCT02870764|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
1513073|NCT02870738|Procedure|Pelvic Floor Physical Therapy|Internal and/or external myofascial release of the pelvic floor muscles
1513074|NCT02870738|Drug|Bladder Instillations|A solution of heparin sulphate 40,000 IU (4 cc of 10,000 units/cc), lidocaine 2% 16 ml, Sodium bicarbonate 8.4% 4 ml and Kenalog 40 mg (1cc) to reach a total fluid volume of 25 ml will be instilled into the bladder with a urinary catheter
1513075|NCT02870725|Behavioral|CBT Individual Psychotherapy|The 4-session CBT treatment will include receipt of a manualized cognitive behavioral intervention, delivered individually, to treat the depression symptoms (e.g. cognitive restructuring, behavioral activation) and teach adaptive coping strategies to manage their depression. Ideally, the intervention will also positively affect their chronic headaches (i.e. reduction of headache frequency, severity and level of disability). Each session is approximately 60 minutes with specific, reflective and guided activities related to a specific module within the intervention.
1513076|NCT02870712|Procedure|suture or non suture of first degree perineum|
1513079|NCT02870686|Procedure|ERCP without the use of fluoroscopy|ERCP removal of stone technique without the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with catheter aspiration of bile, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket- number of stones removed should compare number detected on EUS, (5) confirmation of complete stone clearance with radiocontrast.
1513080|NCT02870686|Procedure|ERCP with the use of fluoroscopy|ERCP removal of stone technique with the use of fluoroscopy involves: (1) catheter with wire achieve bile duct, (2) confirmation of bile duct achievement with fluoroscopy images, (3) performance of endoscopic biliary sphinctertome, (4) stone removal with balloon or basket, (5) confirmation of complete stone clearance with radiocontrast.
1513081|NCT02870673|Drug|SHINCORT|triamcinolone Acetonide (10mg/ml) 0.5 ml
1513082|NCT02870673|Drug|XYLOCAINE|xylocaine(20mg/ml) 0.5 ml
1513083|NCT02870673|Device|sham electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
1513084|NCT02870673|Device|electroacupuncture|1.5 inches 32 gauze stainless steel needles Transcutaneous electrical nerve stimulation machine (MODEL-05B(6))
1513085|NCT02870660|Other|Registry|
1513086|NCT02870647|Other|Echocardiographic, polygraphy, electrocardiography measurements and sleep questionnaire|each patient is asked to undergo an echocardiographic, polygraphy, electrocardiography measurements, and respond to 2 sleep questionnaires, both at inclusion and after 6 months
1513087|NCT02870634|Drug|Cu(II)ATSM|copper-containing synthetic small molecule
1513088|NCT02870608|Other|lung and liver elastography measurement of fetus|
1513127|NCT02870309|Biological|Alpha-1 MP|Alpha-1 MP is a stable, sterile, lyophilized preparation of human alpha1-PI, also known as α1-antitrypsin
1513089|NCT02870595|Device|Microvibratory Stimulator|Informed consent will be obtained from patients undergoing finger local anesthesia digit blocks. Subjects will be randomly assigned (using GraphPAD Randomization Software Tool) to receive the first of their two digit block injections with either the traditional technique (control) or while using the DVICS/ Microvibratory Stimulator. All injections will utilize a 27-gauge needle. The subjects will be given a standard dose of 2mls of 1% lidocaine without epinephrine delivered over 30 seconds. Injections will be timed and performed by a single clinician to avoid large variations in technique and expertise.
1513090|NCT02870595|Device|Microvibratory Stimulator'|As above, Microvibratory Stimulator will be used as a sham device in parallel group.
1513095|NCT02870556|Device|cervical epidural analgesia|
1513096|NCT02870543|Drug|Phytolacca decandra|Treatment of bruxism
1513097|NCT02870543|Drug|Melissa officinalis|Treatment of bruxism
1513098|NCT02870543|Drug|Phyt.decandra + Melissa offic.|Treatment of bruxism
1513099|NCT02870530|Procedure|division-less gastric bypass|in division-less gastric bypass, the investigators will do the gastric bypass without division of the stomach into 2 part (pouch part and the rest of the stomach that still connected to the duodenum) but the pouch which will anatomised with the small intestine is excluded from within, in comparison to standard mini-gastric bypass so that we try to decrease the cost of stapler and its complication
1513100|NCT02870530|Procedure|mini-gastric bypass|classic laparoscopic mini-gastric bypass as described by Rutledge
1513101|NCT02870517|Other|Relaxing Music|Relaxing music, will be played through noise-cancelling headphones during induction of anesthesia. All of the songs used in this study will have <60 BPM, be instrumental rather than lyrical, and utilize predictable chord progressions. Music will be divided into several themed playlists which will be focused on the type of instruments involved including guitar, steel drum, and piano. The patient will listen to the music through noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
1513102|NCT02870517|Other|No Music|The patient will wear noise-cancelling headphones beginning fifteen minutes prior to induction and ending one minute after intubation.
1513103|NCT02870504|Procedure|Corneoscleral limbus group|Laser spot locates on the corneoscleral limbus
1513104|NCT02870504|Procedure|one spot group|Laser spot locates on one spot away from the corneoscleral limbus
1513105|NCT02870504|Procedure|two spots group|Laser spot locates on two spots away from the corneoscleral limbus
1513109|NCT02870465|Procedure|Closed Reduction Internal Fixation|K-wires placed percutaneously through the skin to achieve fixation of a hand after reduction of the fracture in a closed manner.
1513112|NCT02870439|Other|Blood drawn|
1513113|NCT02870426|Other|No intervention is proposed|No intervention is proposed
1513114|NCT02870413|Behavioral|Telelactation services|Mothers will get unlimited access (for a three month period) to video calls with lactation consultants who are available 24/7. Mothers can use the service as demanded.
1513115|NCT02870400|Drug|REGN2477|Participants will receive ascending doses of REGN2477
1513116|NCT02870400|Drug|Placebo|Participants will receive matching placebo
1513117|NCT02870387|Other|Comprehensive Care with Inpatient consultation|Comprehensive care with Inpatient Consultation: HRCC patients randomized to the comprehensive care with inpatient consultation group that are admitted to CMHH will receive inpatient consultation by HRCC providers during their stay with input and recommendations conveyed to the hospital inpatient team on admission and at discharge at a minimum (in person consultations on weekdays and phone consultations on the weekends). The HRCC providers will review the inpatient care plan and will make treatment and discharge recommendations with a focus on coordination and integration of inpatient and outpatient care. Ideally, the inpatient consultations are face-to-face meetings with the hospital inpatient team but could also be a phone call or a consult note written in the medical record.
1513118|NCT02870387|Other|Usual Inpatient Care|High-Risk Children's Clinic (HRCC) patients randomized to the usual inpatient care group who are admitted to Children's Memorial Hermann Hospital (CMHH) will receive usual inpatient care from the primary hospital admitting team (residents and fellows supervised by pediatric faculty physicians) with usual occasional communication with the patient's assigned HRCC provider. HRCC patients admitted to CMHH in this treatment group will receive usual inpatient care that is not modified by the study protocol.
1513119|NCT02870374|Behavioral|Answering specific quality of life questionnaire in kidneys transplantation population|
1513120|NCT02870361|Drug|intranasal insulin|
1513121|NCT02870361|Drug|Placebo|
1513122|NCT02870348|Biological|Alpha-1 MP|Weekly intravenous infusions of 60 mg/kg Alpha-1 MP
1513123|NCT02870335|Other|Manual Therapy|The patient remained lying on the gurney and the treatment was performed in the order set forth below and included: overall bilateral manipulation of L5-S1-Sacroiliac, subsequently decompression hip joint, the tibiofemoral decompression, stretching rotators hip flexion or hip and knee mobilization technique downing head and base of the fibula, tibiofibular-talus tali posteriorización decompression and with the help of a wedge to facilitate technical.
1513124|NCT02870335|Other|Proprioceptive neuromuscular facilitation|Stretching were conducted in the hamstrings, psoas, adductors, pyramidal, quadriceps and right above.
1513607|NCT02866838|Drug|Saline 0.9%|intravenous
1513128|NCT02870296|Other|Enhanced Assessment and Education|Patients in the Intervention Group will: 1) have an in-home pharmacist medication assessment; 2) receive enhanced medication instructions (including pictograms); 3) receive an additional individualized assessment and educational session with a clinician provider related to the medication management for their disease (VTE).
1513129|NCT02870283|Drug|Lithium|
1513130|NCT02870283|Drug|Valproic Acid|
1513131|NCT02870283|Drug|Carbamazepine|
1513132|NCT02870270|Other|Cancer treatment|Patients undergoing treatment for cancer in the head and neck region
2010645|NCT02911753|Other|Green Tea|All participants will be advised to consume all of the beverage assigned (green tea) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
1513135|NCT02870244|Biological|Escalating Doses|"Subjects will receive a single infusion of autologous bulk TIL 13831 TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 13831 TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4 + and CD8+ T Cells expressing the TIL 13831 TCR.
Subjects in Cohort 1 will receive 7.5 x 10^6/kg TIL 1383I TCR transduced T cells.
Subjects in Cohort 2 will receive 2.5 x 10^7/kg TIL 1383I TCR transduced T cells.
Subjects in Cohort 3 will receive 7.5 x 10^7/kg TIL 1383I TCR transduced T cells."
1513136|NCT02870231|Drug|NNC9204-0530|Once-daily subcutaneous (s.c., under the skin) administration.
1513137|NCT02870231|Drug|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration.
1513138|NCT02870231|Drug|placebo|Once-daily subcutaneous (s.c., under the skin) administration
1513139|NCT02870218|Drug|Smoking research cigarettes with e-cigarette|Smoking research cigarettes with varying levels of nicotine with unlimited access to 15 mg/ml nicotine-containing e-cigarettes.
1513140|NCT02870205|Drug|GSP 301 NS|2 spray in each nostril twice daily for 14 days
1513141|NCT02870205|Drug|GOM-NS|2 spray in each nostril twice daily for 14 days
1513142|NCT02870205|Drug|GMM-2 NS|2 spray in each nostril twice daily for 14 days
1513143|NCT02870205|Drug|GSP 301 placebo NS|2 spray in each nostril twice daily for 14 days
1513144|NCT02870192|Procedure|Laparoscopic ventral mesh rectopexy|Laparoscopic opening of the Daglous pouch, dissection till reach the levator ani muscle, mesh implementation and fixation, closure of the daglous. The mesh implemented may be synthetic or biological mesh.
1513145|NCT02870179|Device|Pulse Oximeter|Measurement of physiological parameters
1513146|NCT02870166|Other|blood sample|
1513147|NCT02870153|Drug|SOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
1513148|NCT02870153|Drug|XELOX|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
1513149|NCT02870140|Device|SUPRAFLEX|Percutaneous Coronary Intervention
1513150|NCT02870140|Device|XIENCE|Percutaneous Coronary Intervention
1513151|NCT02870127|Other|blood sample|
1513152|NCT02870101|Device|NAAT 1 to Detect Rectal and Pharyngeal NG and CT|Nucleic acid amplification assay test 1 to estimate the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis in the rectum and pharynx.
1513153|NCT02870101|Device|NAAT 2 to Detect Rectal and Pharyngeal NG and CT|Nucleic acid amplification assay test 2 to estimate the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis in the rectum and pharynx.
1513154|NCT02870101|Device|NAAT 3 to Detect Rectal and Pharyngeal NG and CT|Nucleic acid amplification assay test 3 to estimate the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae and Chlamydia trachomatis in the pharynx and rectum.
1513155|NCT02870101|Device|NAAT 4 to Detect Rectal and Pharyngeal NG|Nucleic acid amplification assay test 4 to estimate the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Neisseria gonorrhoeae in the rectum and pharynx. Test 4 will be used as a tiebreaker assay in case of disagreement between the reference NAAT results.
1513156|NCT02870101|Device|NAAT 4 to Detect Rectal and Pharyngeal CT|Nucleic acid amplification assay test 4 to estimate the positive percent agreement (PPA) and negative percent agreement (NPA) for detecting Chlamydia trachomatis in the rectum and pharynx. Test 4 will be used as a tiebreaker assay in case of disagreement between the reference NAAT results.
1513157|NCT02870088|Behavioral|Prolonged Sitting|After consuming 1st meal, participants sat on a chair for 180 min. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants sat on a chair for another 120 min.
1513158|NCT02870088|Behavioral|Breaking Sitting|After consuming 1st meal, participants walked 2 min on a treadmill every 20 minutes for the following 180 min. For the remainder of the time participants sat on the chair. After 180 min, the 2nd meal was provided. After finishing the 2nd meal, participants continued 2 min of walking every 20 min for the following 120 min.
1513159|NCT02870075|Behavioral|Fed exercise|Participants consumed a meal (Fed) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
1513160|NCT02870075|Behavioral|Fasted exercise|Participants remained fasting (Fasted) 2 h prior to 1 h moderate intensity exercise at 60% VO2max.
1513161|NCT02870062|Other|Daily baths with chlorhexidine wipes, oral spray and standard shampoo|Description already mentioned in arm/group descriptions.
1513162|NCT02870062|Other|Daily baths with placebo wipes, oral spray and shampoo|Description already mentioned in arm/group descriptions.
1513167|NCT02870036|Drug|Simmitecan|
1513168|NCT02870036|Drug|5-fluorouracil and Leucovorin Calcium|
1513169|NCT02870036|Drug|Thalidomide|
1513170|NCT02870023|Other|Balance training|
1513171|NCT02870023|Other|Strength training|
1513172|NCT02870010|Biological|blood samples (5 ml) will be taken|blood samples (5 ml) will be taken
1513173|NCT02870010|Radiation|Chemoembolization|Chemoembolization will take place in the Interventional Radiology room: the syringe, prepared at the pharmacy, will contain microspheres loaded with a defined dose of idarubicin. Then five millilitres of Visipaque® will be added to visualize the injection
1513174|NCT02869997|Device|Aspect BIS XP (A-2000) Bispectral Index Patient Monitor|
1513175|NCT02869984|Drug|Ramosetron|
1513176|NCT02869971|Device|Embosphere® (Prostatic Arteries Embolization)|Prostatic Arteries Embolization with 300-500 µm trisacryl microspheres
1513177|NCT02869971|Drug|Drug therapy|Combodart (dutasteride 0.5 mg/tamsulosin 0.4 mg)
1513178|NCT02869958|Other|Digital action plan for asthma exacerbations + Written action plan|Digital action plan for asthma exacerbation available through an AppWeb and requiring a connected device such as a Smartphone or a tablet computer. The patient must connect and describe the situation to obtain the names, doses and dosing of the treatment his/her physician has recommended for him/her according to the level of severity of the exacerbation
1513179|NCT02869958|Other|Written action plan|
1513180|NCT02869945|Genetic|Identification of COMT HH, COMT HL or COMT LL genes|COMT HH, COMT HL or COMT LL genes identification
1513181|NCT02869945|Other|Brain MRI with resting state scan|MRI scan with resting state study to be performed to assess the compensation mechanisms at the networks level.
1513182|NCT02869945|Other|Brain MPET|Monophotonic emission tomography with I-123-Ioflupane to assess the level of dopaminergic denervation.
1513183|NCT02869932|Radiation|Lung CT scan|Lung CT scan without injection
1513184|NCT02869919|Other|AKI|Vitamin D levels
1513185|NCT02869906|Other|FFR and iFR|The investigators aimed to assess the reliability of the instantaneous wave-free ratio (iFR) and fractional flow reserve (FFR) measurements in non-culprit coronary lesions during the acute and subacute phase of ST-segment elevation myocardial infarction (STEMI).
1513186|NCT02869893|Drug|Secretin|
1513187|NCT02869880|Other|Enhanced Pre-Consent Discussion|The enhanced pre-consent discussion intervention is a tool that includes both textual and graphical information regarding the trial and an interactive component designed to initiate and facilitate conversations between all parties in the decision—parent, patient, healthcare provider and research staff.
1513188|NCT02869880|Other|Standard Pre-consent Discussion|Standard pre-consent discussion for a clinical trial
1513189|NCT02869867|Other|refrigerated cushion|refrigerated cushion
1513192|NCT02869841|Drug|Levobupivacaine continuous infusion|Levobupivacaine continuous infusion to rectus sheath catheters
1513193|NCT02869841|Drug|levobupivacaine bolus dosing|Levobupivacaine bolus dosing to rectus sheath catheters
1513194|NCT02869841|Drug|single bolus of levobupivacaine|Levobupivacaine single dose to rectus sheath catheters
1513195|NCT02869841|Other|Placebo|No rectus sheath analgesia
1513196|NCT02869828|Device|Monitoring by arterial catheter and Spot-on|
1513197|NCT02869828|Device|Monitoring by oesophagal probe and Spot-on|
1513198|NCT02869815|Procedure|ICG+Methylene Blue|"ICG+Methylene Blue Arm:
One ml of methylene blue (1%) would be in injected sub-areolarly 5 minutes before surgery, and 1ml of ICG (0.125%) in the same site 3 minutes later. Massage of the breast would be applied to facilitate the movement of the tracers. A small incision would be made in the axilla, and a special device would be used to search the light nodes. During the sampling, blue nodes would also be resected . After the completion of SLNB, complete axillary dissection would be carried out."
1513199|NCT02869802|Procedure|Tumour Biopsy|If there is the presence of a tumour lesion amenable to core needle biopsy as judged by a staff interventional radiologist, a minimum of 3 tumour cores will be obtained under CT or US guidance.
1513200|NCT02869802|Other|Serial Collection of Plasma, Serum and Urine Samples|Participants will undergo serial collection of plasma, serum and urine samples at baseline and every 4 weeks until radiological disease progression is confirmed using RECIST 1.1.
1513201|NCT02869789|Drug|Nivolumab in combination with Ipilimumab|Specified dose on specified days
1513202|NCT02869776|Behavioral|Questionnaire|Behavioral questionnaires
1513203|NCT02869776|Procedure|Rapid finger stick|HIV and HCV testing through rapid finger stick
1513204|NCT02869776|Procedure|Venipuncture|HIV and HCV testing through venipuncture
1513205|NCT02869763|Dietary Supplement|10 g ethanol|"31 mL of Vodka Absolut® diluted in 369 mL of lemon flavored-water (LFW) Fontvella®.
A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
1513206|NCT02869763|Dietary Supplement|20 g ethanol|"63 mL of Vodka Absolut® diluted in 337 mL of lemon flavored-water (LFW) Fontvella®.
A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. Administration of ethanol beverage will be controlled: participants will have 5 minutes to drink each glass."
1513207|NCT02869763|Dietary Supplement|Water|400 mL of lemon flavored-water Fontvella®. A total volume of 400 mL of the drink will be administered, distributed in three 133 mL cool glasses. The administration will be controlled: participants will have 5 minutes to drink each glass.
1513208|NCT02869737|Device|Coagucheck, Roche, France|Capillary puncture for POC INR measurement
1513209|NCT02869724|Other|Weekly divided delivery|
1513210|NCT02869724|Other|Monthly divided delivery|
1513211|NCT02869711|Other|Health care quality management|
1513215|NCT02869685|Radiation|radiotherapy|
1513216|NCT02869672|Biological|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine|Tiantan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
1513217|NCT02869672|Biological|Hualan Biology ACYW135 meningococcal polysaccharide vaccine|Hualan Biology ACYW135 meningococcal polysaccharide vaccine, intramuscular injection, 0.5 ml
1513270|NCT02869308|Device|E-CAM Camera|Acquisition of images of angioscintigraphy with E-CAM camera, after injection of Angiocis and Technetium-99m
1513218|NCT02869659|Behavioral|Weight Loss Group|All participants will follow the Medifast Achieve TM 4 & 2 & 1 Plan® which includes the 4 MR products per day, with the addition of 2 Lean and Green™ Meals and 1 Healthy Snack
1513219|NCT02869659|Behavioral|Delayed Weight Loss|18 weekly, group dietary and exercise sessions led by the study staff in which participants will follow a modified Diabetes Prevention Program
1513220|NCT02869646|Procedure|Procedure: Acupuncture|Acupuncture is a general term indicating the insertion and stimulation of needles at one or more prescribed points in order to effect the biology of the individual.
1513221|NCT02869646|Procedure|Procedure: Sham acupuncture|Sham acupuncture is a general term indicating the use of needles, whether inserted or not, at points on the body that are not expected to have a clinically significant biological effect.
1513222|NCT02869633|Drug|Ibrutinib|Given by mouth
1513223|NCT02869633|Other|Laboratory Biomarker Analysis|Correlative studies
1513224|NCT02869620|Other|Data collection|
1513225|NCT02869607|Other|Data collection|
1513226|NCT02869594|Other|Data collection|
1513227|NCT02869581|Other|Data collection|
1513228|NCT02869568|Other|Data collection|
1513229|NCT02869555|Other|Data collection|
1513230|NCT02869542|Other|Data collection|
1513231|NCT02869529|Other|Data collection|
1513232|NCT02869516|Other|Clinical data collection|
1513233|NCT02869503|Other|Data collection|
1513234|NCT02869490|Other|Data collection|
1513235|NCT02869477|Other|Data collection|
1513236|NCT02869464|Other|Imaging-Ultrasound|Abdominal Ultrasound
1513237|NCT02869464|Other|Imaging-MRA|Non-contrast Enhanced Magnetic Resonance Angiogram
1513238|NCT02869464|Genetic|DNA, RNA testing|To test for the co-prevalence of shared genetic markers in afflicted populations.
1513239|NCT02869451|Drug|bupropion|Prescribed one week prior to quit and continued until the 6 month follow-up visit.
1513240|NCT02869451|Drug|transdermal nicotine patch|Initiated at smoking quit date; 7 mg to 21 mg patch depending on amount smoked by participant
1513241|NCT02869451|Drug|Nicotine polacrilex|Initiated at smoking quit date.
1513242|NCT02869451|Drug|nicotine lozenge|Initiated at smoking quit date.
1513243|NCT02869451|Behavioral|counseling for marijuana and smoking cessation|5 sessions of cognitive-behavioral counseling designed to facilitate marijuana and smoking cessation and promote relapse prevention
1513244|NCT02869451|Behavioral|mobile contingency management|treatment that provides money rewards for abstinence from smoking and marijuana
2010646|NCT02911753|Other|Flavored Water|All participants will be advised to consume all of the beverage assigned (flavored water) on a daily basis (rather than save up and consume large amounts on fewer days). The beverages will be prepared in advance by study personnel, refrigerated, and distributed to study participants on a weekly basis. Participants will be provided a daily 32-ounce beverage container for beverage consumption and instructed to clean the container nightly. Participants will also be asked to keep a log of completion of beverage on a daily basis and instructions regarding intake of other beverages will be provided.
2010647|NCT02909673|Behavioral|Fourth R|Fourth R integrates the promotion of healthy relationship skills and prevention of teen dating violence into existing school curricula so that students receive regular course credit in health. Fourth R is grounded in social cognitive theory in which youth learn to formulate and choose behavior strategies, which translate into knowledge and practice in decision-making, non-aggressive conflict resolution skills, and self-efficacy..
1513247|NCT02869425|Drug|arbaclofen ER Tablets|arbaclofen ER tablets, 10 mg, 15 mg, or 20 mg
1513248|NCT02869425|Drug|Placebo for arbaclofen ER tablets|matching placebo tablets to arbaclofen ER tablets 10 mg, 15 mg or 20 mg
2010648|NCT02909556|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via transfemoral access
2010649|NCT02907996|Drug|Sofosbuvir|400 mg tablet administered orally once daily
1513253|NCT02869399|Dietary Supplement|dietary intervention in addition to standard recommendations|"The diet of the intervention group will be based on the AICR/WCRF recommendations for cancer prevention and for the prevention of recurrences (www.dietandcancerreport.org):
avoid or limit alcoholic drinks (2 drinks men, 1 drink women)
increase consumption of a variety of non-starchy vegetables, fruits (at least 400g per day) and dietary fibers (at least 25g per day)
eat mostly food of plant origin
eat lean meat, limit intake of red meat and avoid processed meat
increase consumption of anti-inflammatory foods, such as fish and whole grain cereals, f.e. brown rice and barley creams
avoid high glycaemic and high insulinemic foods, such as refined flours, white breads, and pastries"
1513254|NCT02869386|Procedure|STEMO|STEMO, the intervention, includes prehospital neurological emergency assessment with the option to perform CT and CT-angiography, start specialized treatment at the door-step of the patient's house, including thrombolysis with tissue Plasminogen Activator and blood pressure Management (choice of drug at discretion of treating physician), use telemedicine for further expertise as well as results of point-of-care laboratory, prenotification (e.g. for endovascular treatment), triage and transport.
1513255|NCT02869386|Procedure|Regular care|A regular ambulance, the comparator intervention, not equipped with advanced point-of-care laboratory or CT scanner, without telemedicine and not staffed with a neurologist.
1513256|NCT02869373|Behavioral|spinal stabilizaton exercise|In Exercise group, spinal stabilization exercise program was carried out 3 days a week for 8 weeks.
1513257|NCT02869347|Drug|Conestat alfa|Two intravenous injections (over 5 minutes) of Conestat alfa immediately pre-procedure (elective coronary angiography) and 4 hours later; for patients less than 84kg at a dose of 50 U/kg, and for patients of 84kg body weight or greater at a dose of 4200 U.
1513258|NCT02869347|Drug|Sodium chloride 0.9%|Two intravenous injections of sodium chloride 0.9% (maximum 28 ml, matching the respective amount of the Conestat alfa arm) immediately pre-procedure (elective coronary angiography) and 4 hours later.
1513263|NCT02869321|Drug|Fentanyl|
1513264|NCT02869321|Drug|Morphine Sulfate|
1513265|NCT02869321|Drug|Fentanyl placebo|
1513266|NCT02869321|Drug|Morphine Sulfate placebo|
1513267|NCT02869321|Procedure|Gastrostomy|
1513268|NCT02869308|Drug|stannous pyrophosphate|Injection of 1ml Angiocis
1513269|NCT02869308|Drug|Technetium-99m|Injection of 900 MBq Technetium-99m, 30 min after Angiocis injection
1513411|NCT02868203|Device|eLuting stent|
1513271|NCT02869308|Device|CZT Semiconductor Camera (D-SPECT)|Acquisition of images of angioscintigraphy with D-SPECT camera
1513273|NCT02869282|Other|Blood samples|Additional blood samples at baseline, 6, 12, 18 and 24 months.
1513274|NCT02869282|Other|Urine samples|Additional urine samples at baseline, 6, 12, 18 and 24 months.
1513275|NCT02869269|Device|Early stage|patients who classed as clinical stage 1 and 2
1513276|NCT02869269|Device|Late stage|patients who classed as clinical stage 3 and 4
1513277|NCT02869256|Other|Practices evaluation|Practices evaluation
1513278|NCT02869243|Drug|hrBMP4|"Patients will undergo a resection or biopsy of the tumour, confirmation of viable malignant glioma tumour cells and intratumour/interstitial placement under neuronavigational guidance of 2 or 3 catheters.
Catheters will be placed during a second procedure a few days later based upon the patient's condition.
Patients will receive intra-tumour and interstitial CED of increasing amounts of hrBMP4 solutions (starting dose of 0.5 mg) and 1:70 gadolinium-diethylenetriamine pentaacetic acid (Gd-DTPA) in a total of 44-66ml over up to 4-6 days. Gd-DTPA will be co-infused with BMP4 to determine the extent of intra-tumour and interstitial drug delivery. HrBMP4 will be delivered as a continuous infusion via the intracranial catheters."
1513279|NCT02869230|Procedure|ROLL|The ROLL technique (radioguided occult lesion localization) is characterized by the injection of a radiotracer in the center of the lesion
1513280|NCT02869230|Procedure|wire-guided lesion localization|wire-guided lesion localization, including better lesion centricity in relation to margins,decreased marking time, reduced surgery time, and better aesthetic outcomes
1513281|NCT02869217|Drug|Cyclophosphamide|
1513282|NCT02869217|Biological|TBI-1301|
1513283|NCT02869204|Other|Leucocyte - Platelet rich Plasma|Autologous L-PRP are studied regarding it's accelerating effect on tissue repair.
1513284|NCT02869204|Dietary Supplement|Vitamin C|A daily dietary supplement of 500 mg Vitamin C. Provided from POD2-3 until POD30
1513285|NCT02869204|Dietary Supplement|Zinc|A daily dietary supplement of 44 mg Zinc. Provided from POD2-3 until POD30
1513286|NCT02869204|Dietary Supplement|L-Arginine|A daily dietary supplement of 5 g L-Arginine. Provided from POD2-3 until POD30
1513287|NCT02869165|Drug|Premarin vaginal cream|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
1513288|NCT02869165|Drug|Apricot kernel oil|Comparison of the bacterial communities in the vagina and urine of postmenopausal women who use Premarin vaginal cream versus apricot kernel oil and to themselves before and after use.
1513289|NCT02869152|Other|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for SLN mapping with gamma probe
1513290|NCT02869152|Other|Endoscopic injection of ICG|Dye injection around the rectal tumor for SLN mapping with NIR imaging.
1513291|NCT02869152|Other|Endoscopic injection of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
1513292|NCT02869152|Procedure|Flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dyes.
1513293|NCT02869152|Procedure|Endoscopic NIR imaging and gamma probe|Endoscopic near infrared (NIR) imaging of ICG and detection of radiotracer with gamma probe after standard removal of rectal neoplasm.
1513294|NCT02869152|Procedure|Dissection of sentinel lymph node(s)|Surgical removal of identified lymph nodes in the rectum.
1513295|NCT02869139|Other|Mentholated lip moisturizer and ice popsicle|Mentholated package of measures
1513296|NCT02869139|Other|Non-mentholated lip moisturizer and ice popsicle|Non-mentholated package of measures
1513297|NCT02869126|Procedure|Tomoscintigraphy with D.SPECT camera (SPECTRUM Dynamics®, Israel)|"During stress test, intravenous injection of 99mTc-Sestamibi (between 80 and 150 MBq according to weight) in patient
Stress conventional acquisition with D.SPECT camera 20 min after injection
60 min after 99mTc-Sestamibi injection, rest injection of thallium-201 (50% activity of stress 99mTc-Sestamibi)
double isotope acquisition 5 min after thallium-201 injection
injection of 99mTc-Sestamibi at rest (activity 3 times higher), after 2 hours from first 99mTc-Sestamibi injection
rest conventional acquisition 20 min later"
1513298|NCT02869126|Drug|99mTc-Sestamibi|"First intravenous injection between 80 and 150 MBq according to patient weight and second injection with 3-time-higher activity, 2 hours after the first
For tomoscintigraphy"
1513299|NCT02869126|Drug|Thallium-201|"Injection of thallium-201 (50% activity of first 99mTc-Sestamibi injection)
For tomoscintigraphy"
1513300|NCT02869113|Drug|BAY98751 (Y65-110)|10 µL in one eye
1513301|NCT02869113|Drug|BAY 98751 (Y65-102)|10 µL in one eye
1513302|NCT02869113|Drug|BAY 98751 (Y65-106)|10 µL in one eye
1513303|NCT02869113|Drug|Standard shampoo mixture (Control)|10 µL in other eye
1513304|NCT02869100|Other|Blood sample|
1513305|NCT02869100|Procedure|Sodium fluoride Positron Emission Tomography|
1513306|NCT02869100|Other|Magnetic Resonance Imaging|
1513307|NCT02869100|Other|Radiography|
1513308|NCT02869087|Device|Akesys Prava Scaffold|Implantation of the Akesys Prava Sirolimus Eluting Bioresorbable Peripheral Scaffold System
1513309|NCT02869074|Genetic|VWF gene analysis|52 exons adjacent intronic regions and promotor of VWF will be analyzed
1513310|NCT02869061|Procedure|Liposuction|
1513311|NCT02869061|Procedure|Transurethral bladder neck resection.|
1513312|NCT02869061|Biological|ADRC|Injection of ADRC suspension will be performed endoscopically into the bladder neck close to the site of resection.
1513313|NCT02869061|Other|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in up to 9.5 ml of normal saline.
1513314|NCT02869035|Drug|Escitalopram|Patients will be treated with an antidepressant drug (escitalopram) at flexible standard doses for 12 weeks. If no response after 4 weeks; shift to duloxetine arm.
1513315|NCT02869035|Drug|Duloxetine|Patients who at 4 weeks of escitalopram have not responded will be shifted to duloxetine at flexible standard dosages.
1513316|NCT02869022|Drug|Custodiol-N|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
1513608|NCT02866825|Biological|IFX-1|
1513317|NCT02869022|Drug|Custodiol|comparison of two Solutions, Custodiol-N versus Custodiol, for organ Perfusion in heart transplantation
1513318|NCT02869022|Procedure|organ perfusion for heart transplantation|
1513319|NCT02869009|Drug|clopidogrel|
1513320|NCT02869009|Drug|Aspirin|
1513321|NCT02868996|Drug|Recombinant human tissue kallikrein|Intravenous DM199
2010650|NCT02907359|Drug|Guadecitabine|Guadecitabine regimen is 60 mg/m2 given SC daily on Days 1-5 in 28-day cycles (delayed as needed to allow blood count recovery). Treatment should be given for at least 6 total cycles in absence of unacceptable toxicity or disease progression requiring alternative therapy.
1513323|NCT02868970|Biological|Meningococcal B|Bexsero is indicated for active immunisation of individuals from 2 months of age and older against invasive meningococcal disease caused by Neisseria meningitidis group B.
1513324|NCT02868970|Biological|High-Dose TIV|Fluzone High-Dose is an injectable influenza vaccine made to protect against the flu strains most likely to cause illness for that particular flu season.
1513325|NCT02868970|Biological|Tdap (tetanus-diphtheria-acellular pertussis)|Tdap is a combination vaccine that protects against three potentially life-threatening bacterial diseases: tetanus, diphtheria, and pertussis (whooping cough).
1513326|NCT02868957|Other|impression data from reference scanner|To create a reference images for the assessment of the trueness, the impressions of the upper and lower arch of the oral cavities of four patients were taken using a polyether impression material (3M ESPE Soft Monophase; Minnesota Mining and Manufacturing Co.), and the intaglio scanning was performed on the impression body using a desktop scanner. Scanned images were transformed to the Standard Tessellation Language (STL) file format, and used as reference images.
1513327|NCT02868957|Device|iTero|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of iTero intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner.
1513328|NCT02868957|Device|Trios|The participants visited the dental clinic and performed scanning for 4 days. In order to investigate the difference in the precision and trueness of Trios intraoral scanners, the participants scanned the dental arch of a single patient 10 times using an assigned digital intraoral scanner. .
1513329|NCT02868944|Drug|experimental group : sequential combined spinal epidural with local anesthetic injection (chirocaine) associated with morphine (sufentanil).|
1513330|NCT02868944|Drug|control group : sequential combined spinal epidural with local anesthetic injection (chirocaine) alone.|
1513331|NCT02868931|Behavioral|INPUT|"Treatment and education program based on the self-management theory of behavioral medicine.
The program is delivered by certified and specially trained diabetes educators."
1513332|NCT02868918|Other|biodentine|tricalcium silicate cement used to replace the carious dentin
1513333|NCT02868918|Other|glass ionomer cement|high viscosity glass ionomer used as a base material
1513334|NCT02868905|Procedure|Blood sample|
1513335|NCT02868892|Drug|Pemetrexed|Pemetrexed 500 mg/m2
1513336|NCT02868879|Other|Quantitative multiparametric and functional MRI|"Structural connectivity assessed in the cortex and the white matter using multimodal quantitative parametric imaging (R1, R2, R2*, DTI, susceptibility, macromolecular proton fraction, cortical thickness, VBM).
Functional connectivity assessed using simple BOLD and combined ASL-BOLD sequences during multiple tasks including motor, language and working memory tasks."
1513337|NCT02868866|Behavioral|Immediate Intervention|Committees from 40 churches will be trained in the Faith, Activity, and Nutrition program by Community Health Advisors. The training focuses on helping churches create healthier church environments for physical activity and healthy eating using Cohen's structural model of health behavior as a guide. Each church committee participates in a full-day training and submits a program plan and budget. Churches receive materials to support implementation of the program. After the full-day training, trained churches receive 12 monthly technical assistance calls to help them implement their program plan. The church coordinator receives 8 calls and the pastor receives 4 calls over the 12 months. In Phase 2, the intervention is open to any church in the SC Conference of the United Methodist Church.
1513338|NCT02868853|Behavioral|Photo App|Use of a mobile photo app that takes pictures of foods consumed and allows users to share these pictures with other members of the study in order to receive feedback.
1513339|NCT02868853|Behavioral|Diet App|Use of a mobile diet app that allows users to track all foods and beverages consumed in order to calculate the calories consumed each day.
1513340|NCT02868853|Behavioral|Podcasts|Listen to 2 podcasts per week about healthy eating and exercise.
1513341|NCT02868840|Behavioral|Tai Chi exercise|exercise twice a week each for one hour
1513342|NCT02868840|Behavioral|symptom management|sending text message weekly to manage symptoms related to stroke
1513343|NCT02868827|Drug|Cholecalciferol|400000 international Units of cholecalciferol will be dissolved in 45 ml of fresh milk (Nestle) and it will be given to interventional group patients through enteral route within 24 hours of ICU admission as a single dose.
1513344|NCT02868827|Other|Milk (Nestle)|45 ml of Nestle milk will given to patients assigned as placebo
1513345|NCT02868814|Drug|Pregabalin Release Tablets|
1513346|NCT02868814|Drug|Pregabalin Release Tablets|
1513347|NCT02868814|Drug|Placebo|
1513348|NCT02868801|Drug|Placebo|same intervention as the experimental group
1513349|NCT02868801|Drug|Pregabalin SR tablet 165mg/day|According to the efficacy and safety in titration
1513350|NCT02868801|Drug|Pregabalin SR tablet 330mg/day|According to the efficacy and safety in titration
1513351|NCT02868801|Drug|Pregabalin SR tablet 660mg/day|According to the efficacy and safety in titration.
1513352|NCT02868788|Dietary Supplement|dietary fiber|
1513353|NCT02868775|Procedure|cystoscopy, bladder hydrodistention and bladder biopsy|
1513354|NCT02868749|Device|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in one side of the abdomen or one breast, 3 weeks to 4 months before the surgery.
1513355|NCT02868749|Device|Hyaluronic Acid filler|Linear retrograde, subcutaneous injection of 0,5 ml of hyaluronic acid gel in other side of the abdomen or other breast, 5 to 9 days before the surgery.
1513356|NCT02868736|Device|Synovasure PJI Lateral Flow test and Synovasure PJI ELISA Test|
1513603|NCT02866864|Other|Animal allergy +|Allergic symptom occurs when subject contact animal
1513357|NCT02868723|Other|Aggressive Management|With the aid of the nurse and pharmacist, the individuals in the interventional group will receive additional management of stroke by change is diet plan, increased exercise
1513358|NCT02868710|Other|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: individualized (i.e. ventilatory threshold) and standardized (i.e. heart rate reserve)
1513359|NCT02868697|Drug|TauroLock U 25000|taurolidine citrate, 4% citrate /25000 IU unit urokinase (TauroLock U25000
1513360|NCT02868697|Drug|(TauroLock Hep500)|1.35% taurolidine citrate (2H-1,2,4-thiadiazine-4,4`-methylenebis[tetrahydro-1,1,1`,1`-tetraoxide], 4% citrate and 500 IU/ml heparin (TauroLock Hep500) (TauroPharmGmbH
1513361|NCT02868671|Other|acupuncture|
1513362|NCT02868671|Other|sham acupuncture|
1513363|NCT02868658|Biological|Blood sampling|
1513364|NCT02868658|Other|Nasal swab|
1513365|NCT02868645|Biological|Blood sampling|Patients with bone fibrous dysplasia will have blood sampling to assess periostin rate in serum
1513366|NCT02868632|Drug|MEDI4736|anti-PD-L1 human monoclonal antibody
1513367|NCT02868632|Drug|Tremelimumab|anti-CTLA4 human monoclonal antibody
1513368|NCT02868632|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy (SBRT) will be administered at the standard dose of 6 Gy daily for 5 days.
1513369|NCT02868619|Other|Functional MRI|functional MRI assessed on all the volunteers in condition of hunger and in Condition of satiety
1513370|NCT02868619|Other|ADO-BEDS scale|Evaluate the severity of BED according to Marcus and Kalarchian temporary diagnosis criteria
1513371|NCT02868619|Other|R-CMAS scale|Evaluate the anxiety
1513374|NCT02868593|Other|Pharyngeal swab|
1513375|NCT02868580|Drug|Triumeq|Triumeq, a combination of dolutegravir, abacavir and lamivudine is an anti-retroviral therapy indicated for people with HIV-1 infection.
1513376|NCT02868567|Drug|dalfampridine|Pill open label
1513377|NCT02868554|Device|AcceleDent Aura|Patients receiving vibration therapy will be instructed to bite down on the AcceleDent mouthpiece, which vibrates at a .25 Newtons (25 grams) force level with a 30 Hertz frequency for 20 minutes per day.
1513378|NCT02868554|Device|Accelerated Invisalign therapy|Patients receiving accelerated Invisalign therapy will be instructed to wear each aligner 24 hours day. Patients will be permitted to progress to the subsequent aligner after 4 days of compliant aligner wear.
1513379|NCT02868541|Other|Naso pharyngeal swab|
1513380|NCT02868528|Genetic|chromosome screening with NGS technology|
1513381|NCT02868515|Other|Hot cereal contain 3 g dietary fiber|Intervention involves consumption of a hot cereal over 14 day period
1513382|NCT02868502|Device|Goldmann tonometer|IOP measurement in the sitting position and lateral decubitus
1513383|NCT02868502|Device|Pneumatonometer|IOP measurement in the sitting position and lateral decubitus
1513384|NCT02868502|Device|Tonopen XL|IOP measurement in the sitting position and lateral decubitus
1513385|NCT02868502|Device|ICare rebound tonometer|IOP measurement in the sitting position and lateral decubitus
1513386|NCT02868489|Dietary Supplement|LactoWise®|blend of bacillus coagulans and galactomannans
1513387|NCT02868489|Other|Placebo|Placebo to be selected is calcium carbonate (since participant routine standard of care already includes intake of calcium carbonate)
1513388|NCT02868450|Biological|Blood Sample|
1513389|NCT02868437|Device|intrauterine self-cross-linked hyaluronic acid gel|intrauterine self-cross-linked hyaluronic acid gel will apply after curettage for retained product after second trimester abortion
1513390|NCT02868424|Drug|fRPE cells|fRPE cells transplantation directly into the subretinal space of one eye (experimental eye) in a single transplant procedure
1513391|NCT02868411|Other|Rectal Swab|
1513394|NCT02868372|Drug|Povidone iodine|After closure of the anterior wall of the rectus sheath, the subcutaneous tissues of the cesarean section wound will be swabbed with 10% undiluted Povidone iodine without mobbing.
1513396|NCT02868346|Other|Anal swab|
1513397|NCT02868320|Other|SMS messages|"Daily educational messages addressing the following categories: diet, exercise, complications, medications, foot care, blood sugar testing, and hypo- and hyperglycemia.
Weekly reminder messages of blood glucose testing."
1513398|NCT02868320|Other|Instruction booklet|General detailed instructions addressing the same SMS categories.
1513399|NCT02868307|Behavioral|Answering questionnaire|
1513400|NCT02868294|Device|Fassier-Duval Nail|Implementation of a telescopic system intramedullary
1513401|NCT02868281|Drug|ACT guided Routine Treatment|The ACT is a validated, short, easy to use, and self-administered instrument used to assess asthma control. Subjects in this group received routine treatment as per ACT score.
1513402|NCT02868281|Drug|Routine Treatment|Subjects in the controlled treatment group will receive usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
1513403|NCT02868268|Other|Gene panel sequencing of tumor specimens|Archival or biopsied tumor specimens will undergo gene panel sequencing to identify subgroups with targetable genetic (ALK, MAPK pathway, Metabolic-related genes) and/or immunologic (tumor associated macrophage infiltration, PD-L1 expression) biomarkers in neuroblastoma. A clinical report will be provided to subjects/subject physician detailing observed mutations and identified NBL subgroups and information on clinical trials that best match them. Subjects will be followed and data collected on treatments administered for one year after receipt of clinical report.
1513404|NCT02868255|Procedure|Collection of human samples|Several types of samples will be used to test the effect of the drug candidate
1513407|NCT02868229|Drug|COR-001|
1513408|NCT02868229|Other|Placebo|
1513409|NCT02868216|Behavioral|Anger control therapy|
1513410|NCT02868203|Device|OCT|OCT after stent implantation
1513412|NCT02868190|Device|Two trabecular micro-bypass stents (iStent inject)|Standalone implantation of two trabecular micro-bypass stents (iStent inject)
1513415|NCT02868164|Drug|Fecal Microbiota Transplantation|
1513416|NCT02868164|Drug|Standard Treatment|
1513417|NCT02868164|Other|Weight Reduction|
1513418|NCT02868151|Drug|Ascorbic Acid|Ascorbic acid oral supplementation 1g four times daily for the entire treatment period and 30 days after treatment by tapering the dose of the drug to half. The drug has to be started 2 days prior to initiation of treatment of cancer.
1513419|NCT02868151|Drug|Multivitamin supplements other than vitamin c|Multivitamin supplements other than Vitamin C, such as methylcobalamin 1500mcg, folic acid 1.5mg, thiamine hydrochloride 10mg, pyridoxine hydrocloride 3mg, alpha lipoic acid 100 mg to be initiated 2 days prior treatment of cancer by radiotherapy and continued for entire period of therapy. The dose is reduced to half after the cessation of treatment of cancer and continued for 30 more days and stopped
1513420|NCT02868125|Radiation|X ray radiography|All studied patients will undergo an x-ray radiography of the operated hip. This protocol is a part of the investigators' common practice policy regardless of the study.
1513421|NCT02868112|Other|Usual Oncology Care|Participants receiving usual oncology care will not meet routinely with geriatric clinicians, though they may receive a geriatrics consult at their request or at the discretion of their treating team.
1513422|NCT02868112|Other|Transdisciplinary Intervention|Patients randomized to the transdisciplinary intervention will undergo evaluation with a board-certified geriatric clinician, who will tailor their care based on the results of a brief geriatric screening tool, completed prior to their visit. We will test a two-visit transdisciplinary intervention with the first visit occurring within four weeks of enrollment and the second visit four weeks after the initial visit.
1513423|NCT02868099|Drug|Romiplostim|
1513424|NCT02868099|Drug|Placebo|
1513425|NCT02868086|Device|OCT B-scans|
1513426|NCT02868086|Device|OCT angiography|
1513427|NCT02868073|Drug|VXA-G1.1-NN Oral Vaccine|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose
1513428|NCT02868073|Drug|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
1513430|NCT02868047|Procedure|Endoscopic Ultrasound|Patients will undergo elective upper endoscopic ultrasound to evaluate the pancreas in patients both with and without chronic pancreatitis
1513431|NCT02868034|Behavioral|SMT|"All patients receive 2 SMT sessions in the first week. The subject is supine. The clinician stands opposite the side to be manipulated and side-bends the subject away from the side to manipulate. The side to be manipulated is the more painful. If the subject cannot identify a more painful side the clinician selects a side. The clinician rotates the subject, and delivers a high-velocity, low-amplitude (HVLA) thrust to the pelvis in a posterior/inferior direction. The clinician notes if a cavitation (ie, a pop) occurred. If it does, SMT treatment is complete. If no cavitation occurs, the subject is repositioned and SMT is performed again. If no cavitation occurs on the second attempt, the clinician manipulates the opposite side. A maximum of 2 attempts per side is permitted. If no cavitation is noted by that time, SMT treatment is complete. Substitution with a side-posture HVLA technique is allowed if the preferred technique is not possible due to subject preference or comfort."
1513432|NCT02868034|Behavioral|Mobilizing Exercises|Mobilizing exercises will include a program of repeated movements progressing into end-ranges of spinal flexion and/or extension shown in past studies to improve ROM and reduce spinal stiffness. Patients will be instructed in mid-range exercises and will be further assessed for a directional preference. A directional preference is present if movement in a particular direction decreases LBP intensity or causes symptoms to centralize towards the midline. If a subject has a directional preference he or she will be prescribed exercises specifically in that direction along with mid-range exercise. Otherwise the subject will be assigned exercises moving into either flexion or extension based on the clinician's discretion. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
1513433|NCT02868034|Behavioral|Activation Exercises|Activation exercises are designed to facilitate use of the lumbar multifidus muscle. Exercises will begin with isometric multifidus contractions in different positions with clinician feedback and exercises to isometrically co-contract the multifidus and deep abdominal muscles. Subjects will also perform lumbar extensor strengthening exercises shown to produce 20%-50% of multifidus maximum voluntary contraction. Subjects will continue to perform isometric exercises throughout treatment. Subjects will perform their prescribed exercises at treatment sessions and will be instructed to perform the exercises daily on other days.
1513434|NCT02868034|Behavioral|SMT extended|This treatment involves 6 additional SMT sessions. Each SMT session is conducted as described previously.
1513435|NCT02868021|Device|Strength testing|Test the strength of subject's lower extremity muscles on the dynamometer system
1513436|NCT02868021|Behavioral|Short Physical Performance Battery (SPPB)|The SPPB is a timed short distance walk, repeated chair stands, and balance test that measures lower extremity function.
1513437|NCT02868021|Behavioral|Six-minute walk (SMW)|Subjects walk back and forth along a 100-ft hallway for six minutes after instructions to complete as many laps as possible.
1513438|NCT02868021|Behavioral|Numerical pain scale|Measure pain using an 11-point numerical pain scale.
1513439|NCT02868021|Behavioral|Self-assessed function|Using the Late Life Function and Disability Instrument.
1513440|NCT02868021|Procedure|Muscle biopsies|During the course of the surgery two small muscle biopsies from the quadriceps muscle of the operative leg will be collected.
1513604|NCT02866864|Other|Animal allergy -|Allergic symptom does not occur when subject contact animal
1513609|NCT02866825|Biological|Placebo|
1513441|NCT02868021|Device|Determination of 1 Repetition Maximum (1-RM)|Following the warm-up, subjects will attempt to complete one repetition of the leg press exercise at progressively greater resistance until a full repetition can no longer be performed. The weight of the last complete unassisted repetition will be recorded as the 1-RM.
1513442|NCT02868021|Device|Blood flow restriction exercise|Perform lower-extremity exercises (leg press, leg extension, leg curl, and calf extension) at an intensity of 30% of 1-RM with external compression applied to the proximal thigh of each leg.
1513443|NCT02868021|Behavioral|Borg CR10 scale|Following each exercise session, participants will provide a rating of perceived exertion (RPE) for the session according to the Borg CR10 scale.
1513444|NCT02868008|Procedure|Microsurgical resection of brain AVMs|fMRI guided microsurgical resection of brain AVMs
1513446|NCT02867982|Procedure|Subcrestal implant placement|Dental implants placed 2 mm below the alveolar ridge
1513447|NCT02867982|Procedure|Paracrestal implant placement|Dental implants placed flush to the alveolar ridge
1513448|NCT02867982|Drug|prophylactic antibiotics|amoxicillin was used before and after implant surgery for prophylactic reasons
1513449|NCT02867982|Device|dental implant|dental implants (Ankylos® system,Dentsply Implants Manufacturing GmbH, Mannheim, Germany) were surgically placed into the edentulous alveolar ridge
1513450|NCT02867982|Radiation|x-ray examination|radiographies were taken before treatment and at different time point during the follow-up period
1513451|NCT02867969|Other|Motor training|The motor training will comprise of demanding coordinative exercises based on commercially available developed by Microsoft Game Console (XBOX Kinect™) exergames that specifically target ataxia dysfunctions.
1513455|NCT02867930|Drug|Dexmedetomidine|drug for moderate sedation in trans-esophageal echocardiography
1513456|NCT02867930|Drug|Ketofol(ketamine+propofol)|drug for moderate sedation in trans-esophageal echocardiography
1513457|NCT02867917|Drug|Volcolon sugar free|1 sachet contains 4 g powder 980mg/g psyllium fibers x 4 g per sachet = 3.92 g psyllium fibers/sachet
1513458|NCT02867917|Drug|Metamucil Orange|1 sachet contains 3.4 g psyllium fibers So 25 ml contains 0.425 g psyllium fibers
1513459|NCT02867917|Drug|Psyllium Orange|1 sachet contains 3.25 g psyllium fibers So 25 ml contains 0.406 g psyllium fibers
1513460|NCT02867904|Drug|Methylprednisolone (40 mg depomedrol, 1ml, injection)|Experimental Drug
1513461|NCT02867904|Drug|Marcaine (4ml 0.5%, injection)|Control
1513462|NCT02867878|Drug|Adenosine|
1513463|NCT02867878|Drug|Saline solution|
1513464|NCT02867865|Drug|Gemcitabine|Those randomized to systemic chemotherapy alone will proceed to receive Chemotherapy Gemcitabine gemcitabine 1000 mg/m2delivered day 1 and 8 every 3 weeks for 4 cycles
1513465|NCT02867865|Drug|Cisplatin|Inj. cisplatin 25 mg/m2 delivered. day 1 and 8 every 3 weeks for 4 cycles
1513466|NCT02867865|Radiation|Chemoradiation|Radiotherapy will be for 5 weeks and will be given only in the study arm. The radiation dose will be 50-55 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2).
1513467|NCT02867865|Procedure|PETCECT|All the patients will undergo PETCECT to rule out metastatic disease
1513468|NCT02867865|Procedure|Laparoscopy|Patients will be subjected to staging laparoscopy with 16b1 lymph node biopsy to rule out metastatic disease.
1513469|NCT02867852|Drug|Abiraterone acetate|Abiraterone acetate is a prodrug of abiraterone, an irreversible inhibitor of 17α hydroxylase/C17, 20-lyase (cytochrome P450c17 [CYP17]), a key enzyme required for testosterone synthesis. This enzyme is found in the testes, adrenals, prostate tumors
1513470|NCT02867839|Drug|Oxaliplatin plus S-1|8 cycles of adjuvant chemotherapy with Oxaliplatin plus S-1
1513471|NCT02867839|Drug|S-1 only|16 cycles of adjuvant chemotherapy with S-1 only
1513472|NCT02867826|Device|Cap|Cap-assisted endoscopy
1513473|NCT02867813|Biological|Evolocumab|subjects will receive evolocumab 140 mg every 2 weeks (Q2W) or 420 mg monthly (QM), according to the subject's preference.
1513474|NCT02867800|Drug|Diphenhydramine|"(Standard of Care) Premedication
Diphenhydramine: 1 mg/kg IV or PO q 8 hours (maximum=50 mg)"
1513475|NCT02867800|Drug|Acetaminophen|"(Standard of Care) Premedication
Acetaminophen: 10-15 mg/kg PO q 6 hours (maximum=1000 mg)"
1513476|NCT02867800|Drug|Methylprednisolone|"(Standard of Care) Premedication
Methylprednisolone: 0.25-0.5 mg/kg IV q 6 hours"
1513477|NCT02867800|Drug|Meperidine|"(Standard of Care) Premedication
Use as needed (PRN) Meperidine: 0.5 mg/kg IV q 4-6 hours (for rigors)"
1513478|NCT02867800|Drug|Alemtuzumab|"(Standard of Care) Immunosuppression
Alemtuzumab:
A test dose of alemtuzumab, 3 mg, should be administered IV over 2 hours the first day. If the test dose is tolerated, administration of three treatment doses should begin within 24 hours. The three treatment doses should be administered on consecutive days. 10 mg/m2 should be given the first day, 15 mg/m2 the second and 20 mg/m2 the third."
1513479|NCT02867800|Drug|Thymoglobulin|"(Standard of Care) Immunosuppression
Thymoglobulin: A 4 mg/kg dose of anti-thymocyte globulin should be administered in place of each alemtuzumab dose not completed."
1513480|NCT02867800|Drug|Fludarabine|"(Standard Conditioning Regimen)
Fludarabine should be administered 30 mg/m2 IV daily for five days. It should be infused over 30 to 60 minutes."
1513481|NCT02867800|Drug|Melphalan|"(Standard Conditioning Regimen)
Melphalan should be administered 140 mg/m2 IV 3 days before marrow infusion. It should be infused within 60 minutes of preparation and over a maximum of 30 minutes. It should be infused immediately after the fludarabine infusion is complete."
1513482|NCT02867800|Drug|Thiotepa|"(Standard Conditioning Regimen)
Thiotepa should be administered 8 mg/kg IV 3 days before marrow infusion. It should be infused immediately after the fludarabine infusion is complete. The thiotepa should be infused over one hour."
1513483|NCT02867800|Drug|Cyclosporine|"(Standard GVHD Prophylaxis) Calcineurin inhibitor
Cyclosporine: Administration will commence no later than at least 36 hours before marrow infusion; Cyclosporine doses will be adjusted to maintain a level of 150-300 ng/ml."
1513484|NCT02867800|Drug|Tacrolimus|"(Standard GVHD Prophylaxis) Calcineurin inhibitor
Tacrolimus: Administration will commence no later than at least 36 hours before marrow infusion; Tacrolimus doses will be adjusted to maintain a level of 8-15 ng/ml."
1513485|NCT02867800|Drug|Methotrexate|"(Standard GVHD Prophylaxis)
Methotrexate will be given at a dose of 15 mg/m2 IV on day 1 and a dose of 10 mg/m2 IV on days 3, 6 and 11. Dosing shall be based on actual weight."
1513486|NCT02867800|Drug|Abatacept|"(Investigational)
Abatacept will be administered intravenously at a dose of 10 mg/kg based on actual weight with a maximum of 750 mg. In cases where the calculated dose is less than or equal to 110% of a simple multiple of a 250 mg vial: 250 mg (275mg), 500 mg (550 mg) or 750 mg (825 mg), the dose may be rounded down to the nearest multiple. No rounding up of the abatacept dose is permitted."
1513487|NCT02867800|Procedure|Marrow infusion|"(Standard)
A procedure that infuses healthy cells, called stem cells, into your body to replace damaged or diseased bone marrow. A bone marrow transplant may also be used to treat certain types of cancer"
1513488|NCT02867787|Drug|Botox arm|
1513489|NCT02867774|Behavioral|Physical Activity|"8 week exercise program specifically designed for patients with chronic pain at Transitions Training Studio, a rehab-focused, medically-based fitness center based at the University of Michigan.
The program is designed to gradually increase intensity and duration. If causes pain exacerbation, patients will go back to earlier level of intensity. It favors short, frequent activity episodes as this is often better tolerated than longer, infrequent episodes. The program begins with 30 minutes sessions 3 times per week with goal of increasing duration over course of the program.
The program incorporates elements of flexibility, strength and cardio. Program design includes common elements but allows for a personalized program based on a subject's baseline fitness, interest and tolerance to activity. The program design emphasizes activities that patients can incorporate into their daily routine."
1513490|NCT02867761|Drug|Indacaterol/Glycopyrrolate|27.5/15.6 mcg active indacaterol/glycopyrrolate
1513491|NCT02867761|Drug|Placebo|27.5/15.6 mcg placebo
1513492|NCT02867748|Procedure|TVT-Abbrevo|
1513493|NCT02867748|Procedure|Serasis|
1513494|NCT02867735|Drug|LKA651|Interventional
1513495|NCT02867735|Other|Sham Comparator|
1513496|NCT02867722|Drug|aminolevulinic acid HCl|Drug will be administered to consented patients
1513497|NCT02867709|Drug|Ubrogepant|Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
1513498|NCT02867709|Drug|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
1513499|NCT02867696|Other|Standard Care|Subjects in this arm will receive the standard care that is provided by their bariatric surgical team following bariatric surgery.
1513500|NCT02867696|Behavioral|Technology-based Intervention (TECH)|"Dietary recommendations: based on the subjects' baseline body weight, with calorie goals ranging from 1200-2100 kcal/day.
The physical activity component: unsupervised home-based exercise program. Intensity/Mode: aerobic physical activity recommended at a moderate intensity. Prescription: progress to 250 min/wk by 13th week of the intervention.
Self-monitoring: Jawbone UP3 System includes a wearable device to monitor physical activity and energy expenditure that will transmit real-time feedback on calories expended and physical activity directly to a smart phone. An integrated digital smart scale will also be provided.
Contact: scheduled intervention telephone call: Month 1: One call per week for the first 4 weeks of the study; Months 2-6: One call per month."
1513501|NCT02867683|Other|Vibrotactile Feedback|Balance training Vibrotactile feedback applied to the trunk
1513502|NCT02867670|Device|Transcranial Magnetic Stimulation|TMS is a form of non-invasive brain stimulation which uses magnetic pulses to stimulate regions of the brain from outside the head, on the scalp. Specifically, TMS is performed with a copper-and-plastic coil that emits a magnetic field, which can affect brain cells in specific locations. In this study, researchers will also use a form of TMS called theta-burst stimulation (TBS), where TMS pulses are delivered rapidly over time.
1513503|NCT02867657|Behavioral|Mindfulness|Five days MBSR curriculum with meditation and yoga
1513506|NCT02867631|Behavioral|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes|6 week challenge with 1 year of home visits: health texting, in home exercise supports, social support, healthy eating and feeding classes
1513507|NCT02867618|Drug|Carfilzomib|Carfilzomib given intravenously twice a week for 3 consecutive weeks, on days 1, 2, 8, 9, 15, and 16 on the 28-day cycle. This will be in combination with the oral TGR-1202
1513508|NCT02867618|Drug|TGR-1202|Oral TGR-1202 will be given PO once daily on Days 1-28 . This will be given in combination with the intravenous Carfilzomib
1513509|NCT02867605|Dietary Supplement|Hyaluronan|
1513514|NCT02867566|Drug|IBI301 plus CHOP|Six cycles. IBI301: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
1513515|NCT02867566|Drug|Rituximab plus CHOP|Six cycles. Rituximab: 375 mg/m2, IV, day 1 of each cycle; Cyclophosphamide: 750 mg/m2, IV, day 2 of each cycle; Doxorubicin: 50 mg/m2, IV, day 2 of each cycle; Vindesine: 4 mg, IV, day 2 of each cycle; Prednisone: 100 mg, po, day 2 to day 6 of each cycle.
1513516|NCT02867553|Drug|rituximab|
1513517|NCT02867553|Radiation|Multi-fields radiotherapy|
1513518|NCT02867540|Other|MRI enterography|
1513605|NCT02866851|Other|Monitoring by Web-application|Patients have to log in a web-application every day (from D5) to indicate their temperature and the presence of gravity sign in case of fever.
1513606|NCT02866838|Drug|Tranexamic acid|intravenous
1513519|NCT02867514|Device|transcranial Direct Current Stimulation (tDCS)|After locating the stimulation areas, treatment will be delivered during 30-minute session. Treatment will be occur 1 session per day during 10 days (5 days per week during 2 successive weeks). Subjects will be monitored during tDCS for any side effects or adverse events.
1513520|NCT02867488|Other|Soybean oil in salad dressing|
1513521|NCT02867475|Other|Physical activity motivation|Physical activity motivation
1513522|NCT02867462|Other|Standard care|standard care
1513523|NCT02867462|Other|manipulator consultation radiotherapy added to standard care|
1513524|NCT02867449|Behavioral|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
1513525|NCT02867449|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
1513526|NCT02867436|Other|Gluten-free diet|
1513527|NCT02867423|Device|CK Boost radiation|single dose of 8 Grays is issued by the CK to the 6th week after conventional radiation
1513528|NCT02867410|Other|No intervention|
1513529|NCT02867397|Drug|Teysuno (S1) in combination with epirubicin and oxaliplatin|
1513530|NCT02867384|Drug|Obinutuzumab|B cell depletion
1513531|NCT02867384|Drug|Placebo|
1513532|NCT02867371|Device|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
1513533|NCT02867358|Drug|KT07 Capsule|
1513534|NCT02867358|Other|Placebo|
1513535|NCT02867345|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
1513536|NCT02867345|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
1513537|NCT02867345|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
1513538|NCT02867332|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
1513539|NCT02867332|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
1513540|NCT02867332|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/ day (if tolerant).
1513541|NCT02867319|Biological|A dose of ACYW135 meningococcal polysaccharide vaccine|A dose of ACYW135 meningococcal polysaccharide vaccine will be given in certain arm.
1513542|NCT02867306|Drug|ASP1707|Oral
1513543|NCT02867306|Drug|methotrexate (MTX)|Oral
1513544|NCT02867293|Procedure|ultrasound guided ascitic fluid drainage|
1513545|NCT02867293|Procedure|operative drainage of ascites through small skin incision after induction of anesthesia|
1513546|NCT02867293|Device|ultrasound|
1513547|NCT02867280|Drug|Sorafenib|red round tablet
1513548|NCT02867267|Drug|Thymosin alpha 1|Subcutaneous injections of 1.6 mg thymosin alpha 1 twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
1513549|NCT02867267|Other|Placebo|Subcutaneous injections of 1.6 mg twice per day for seven days, prior to administration, the lyophilized powder is to be reconstituted with 1 ml of the provided diluent.
1513552|NCT02867228|Other|changes in ventilator settings|Ventilator settings will be adjusted (vent mode, pressure support/control level, cycling, inspiratory time, mandatory rate).
1513553|NCT02867215|Other|Barley bread|120g barley bread per day for 3 weeks.
1513554|NCT02867215|Other|Wheat bread|120g wheat bread per day for 3 weeks.
1513555|NCT02867202|Device|Intrauterine balloon|After the completion of hysteroscopic adhesiolysis, intrauterine balloon was inserted and inflated with 3-5 mL normal saline which was removed after 1 week.
1513556|NCT02867202|Device|Intrauterine contraceptive device|After the completion of hysteroscopic adhesiolysis, copper IUD was inserted into the uterine cavity and removed after at the second time of hysteroscopy.
1513557|NCT02867189|Other|atlas of micro-instrument|Nurses after training can improve the instrument cleaning quality, reduce the reaction after cataract surgery
1513558|NCT02867176|Drug|Gabapentin|The gabapentin (Neurontin, Pfizer, Mexico) group was instructed to take one 300-mg capsule the night before surgery and 1 capsule every 8 hours on the day of surgery and for the first 3 postoperative days.
1513559|NCT02867176|Drug|Ketorolac|The ketorolac group (Dolac, Siegfried Rhein, Mexico) was instructed to take their 10-mg tablets every 8 hours on the day of surgery and for the first 3 postoperative days.
1513560|NCT02867163|Drug|Tranexamic Acid|Intravenous or local administration of TXA, in any dosage
1513561|NCT02867150|Device|Ward Photonics Photonica Professional|"Active Device: Ward Photonics, Photonica Professional Red light therapy system
UltraSlim Cold Light® is the name of a patented treatment regimen using the Photonica Professional device for fat removal using LED red light therapy."
1513563|NCT02867124|Drug|XR-NTX|Vivitrol
1513564|NCT02867124|Other|place of residence|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at place of residence
1513565|NCT02867124|Other|opioid treatment program|One injection of XR-NTX in prison, followed by 6 monthly injections post-release at a community opioid treatment program
1513569|NCT02867098|Drug|XmAb5871|
1513570|NCT02867085|Other|Observational|The BoHemE study does not provide any recommendations for treatment. Guidelines for osteoporosis treatment and standardized instructions for MDS patients are available, however the choice of treatment is up to the treating physician and should be reported as such.
1513571|NCT02867072|Procedure|Open appendectomy|
1513572|NCT02867072|Procedure|Laparoscopic appendectomy|
1513573|NCT02867059|Drug|(+)-SJ000557733|(+)-SJ000557733 (SJ733), in short SJ733, will be the second PfATP4 inhibitor to enter clinical development after KAE609 (Novartis) which is currently in Phase 2 stage. KAE609 (cipargamin; previously known as NITD609) is a spirotetrahydro-β-carbolines (spiroindolone). KAE609 inhibits QP15C20_SJ733_Challenge Protocol_v2.0_26July2016 Page 28 of 110 PfATP4, which results in a disruption of parasite sodium homeostasis. Compared to KAE609, SJ733 has the potential to be a very fast acting, antimalarial drug for human therapeutic application and may have a different safety profile in human participants. Finally, SJ733 blocks parasite transmission in vivo at potencies close to those where it is efficacious in blood stages, indicating its potential for transmission blockade in humans.
1513574|NCT02867046|Drug|S1 transforaminal epidural steroid(dexamethasone) injection|"medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy
lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen"
1513585|NCT02867007|Drug|KHK2455|oral dosing
1513586|NCT02867007|Drug|Mogamulizumab|i.v. administration
1513587|NCT02866994|Behavioral|Project Connect Online|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family
1513588|NCT02866994|Behavioral|PCO PLUS|Three-hour workshop to complete personal website regarding breast cancer experience to share with friends and family, as well as other women diagnosed with breast cancer
1513589|NCT02866981|Other|Observation|
1513590|NCT02866968|Procedure|FLAPS|Surgical procedures will involve 1) excision of pterygium tissue from cornea and conjunctiva, 2) resection of residual Tenon and coagulation to stop any bleeding 3) preparation of a 8x8 mm conjunctiva autograft in the superior bulbar conjunctiva with the femtosecond laser (12 o´clock position) and 4) fixation of the graft with fibrin glue to the resection site.
1513591|NCT02866955|Drug|Estramustine|140mg/4 caps/day
1513592|NCT02866955|Drug|Tamoxifen|20mg/day
1513593|NCT02866942|Drug|Administration of Live attenuated influenza vaccine (LAIV)|
1513594|NCT02866929|Procedure|Decortication|Under local anesthesia, vertical and inter-radicular gingival incisions will be performed on the vestibular of the maxillary and mandibular arch, starting 2-3 mm below the interdental papilla and with sufficient depth to the periosteum to allow the scalpel to reach the alveolar bone. These incisions will be kept as small as possible; then, through them, using a piezoelectric scalpel (piezotome), several bone cuts will be performed. These cuts will have sufficient depth for drilling the cortical alveoli.
1513595|NCT02866929|Device|Orthodontics|Self-ligation brackets in upper and lower teeth
1513596|NCT02866929|Drug|Mucograft|Porcine naturally cross-linked collagen matrix
1513597|NCT02866916|Drug|SXL01|
1513598|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|Intraperitoneal (IP) OXAliplatin (OXA) in association with systemic FOLFIRI bevacizumab chemotherapy Intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI (Irinotecan IV + 5-FU IV) bevacizumab chemotherapy in escalation dose (every 14 days) starting with the level 1
1513599|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|systemic FOLFIRI chemotherapy
1513600|NCT02866903|Drug|intraperitoneal (IP) OXAliplatin (OXA) + systemic FOLFIRI bevacizumab chemotherapy|bevacizumab
1513601|NCT02866890|Device|Laryngeal Tube Suction|Laryngeal Tube Suction Measurement of leak pressure
1513602|NCT02866877|Other|Pharmacokinetic modeling|Timed blood draws and urine collections to model drug clearance
1513611|NCT02866799|Other|Multi-PAP|Complex intervention based on the ARIADNE principles with two main components: 1) Training of general practitioners and 2) Patient centered clinical interview.
1513612|NCT02866799|Other|Usual care|Patients will receive the usual clinical care based on current clinical practice guidelines.
1513613|NCT02866786|Drug|Metformin|
1513614|NCT02866786|Drug|ethinyl estradiol and cyproterone acetate|Oral Contraceptive Pill
1513615|NCT02866773|Behavioral|PA1: Education sessions, Reminders, Whataps group|"The intervention includes three components:
Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior
Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise
Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
1513616|NCT02866773|Behavioral|PA2: Education sessions, Reminders|"The intervention includes two components:
Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior
Physical activity Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of performing regular exercise"
1513617|NCT02866773|Behavioral|PA3: Education sessions, Whataps group|"The intervention includes two components:
Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior.
Physical activity ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on performing regular physical activity and program implementation."
1513618|NCT02866773|Behavioral|PA4: Education sessions|"The intervention includes one component only:
- Physical activity knowledge enhancement session: one core session and one booster session on increasing physical activity and reducing sedentary behavior"
1513619|NCT02866773|Behavioral|HD1: Education sessions, Reminders, Whataps group|"The intervention includes two components:
- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.
Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake.
- Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
1513620|NCT02866773|Behavioral|HD2: Education sessions, Reminders|"The intervention includes two components:
Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.
Healthy diet Anti-inertia Reminder: souvenirs and electronic healthy messages are sent to participants in this group to promote the awareness of reducing sugary intake."
1513621|NCT02866773|Behavioral|HD3:Education sessions, Whataps group|"The intervention includes two components:
Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake.
Healthy diet ambassadors' electronic communication group: the community leaders and ambassadors' formed an electronic communication group to share their experience on reducing sugary intake and program implementation."
1513622|NCT02866773|Behavioral|HD4: Education sessions|"The intervention includes one component only:
- Healthy diet knowledge enhancement session: one core session and one booster session on increasing reducing sugary intake."
1513623|NCT02866747|Radiation|Hypofractionated stereotactic radiation therapy|
1513624|NCT02866747|Drug|Durvalumab|
1513628|NCT02866721|Biological|Mesenchymal Stem Cells|"A single dose, one time infusion (in the vein) of one of the following doses of hMSCs: 1 x 10^6, 3 x 10^6 or 5 x 10^6 hMSCs/kg body weight during Visit 2. A traditional 3+3 design will be utilized.
Allogeneic MSCs will be derived from bone marrow aspirates from a healthy donor whose serum tests negative for cytomegalovirus (CMV) antibodies. Healthy donors will undergo tests for infectious disease and screening for 41 common CFTR mutations. In addition, the MSCs will be validated for in vitro and in vivo efficacy and potency using the in vivo murine pre-clinical model of CF lung infection and inflammation."
1513629|NCT02866708|Device|Intermittent negative pressure device|This intervention study will be designed as a randomized cross-over study.
1513631|NCT02866682|Drug|Prograf|Brand Drug for the duration of the study.
1513632|NCT02866682|Drug|Prograf followed by Tacrolimus|Brand followed by Generic Drug
1513633|NCT02866682|Drug|Tacrolimus|Generic
1513634|NCT02866682|Drug|Multiple Tacrolimus|Multiple Generic
1513635|NCT02866669|Behavioral|Practice Facilitation|ractices that are randomized to the practice facilitation arm will work with a practice facilitator that will help practice staff for 15 months to make practice level changes to improve hypertension control. Practice facilitation is a highly customized, staged approach to helping a practice to implement process and structural changes to enhance the quality of care and improve patient and staff satisfaction
1513636|NCT02866669|Behavioral|Peer Coach|Participants enrolled from practices that are randomized to the peer coach arm will be matched with peer advisors who will work with the participants for 12 months.
1513637|NCT02866669|Behavioral|Enhanced usual care|Practices in the usual enhanced care arm will receive a blood pressure medication algorithm developed using national guidelines and content experts on our study team. Practices will be provided the Joint National Committee (JNC) recommended protocol to measuring blood pressures. Practices will receive a laptop workstation that has access to the Patient Activated Learning System - an online education video system.
1513638|NCT02866656|Other|Conventional conservative treatment|Treatment last for 4 weeks, three times a week,
1513639|NCT02866656|Device|therapeutic ultrasound|Treatment last for 4 weeks, three times a week, stimulation was given 8 minutes every time, location of treatment were lower limb ischemia area and its surrounding tissues；
1513640|NCT02866643|Drug|Etonogestrel-Immediate|The investigational intervention will be to insert the contraceptive implant immediately postpartum in the delivery room insertion (0-2 hours following delivery).
1513641|NCT02866643|Drug|Etonogestrel-Delayed|The investigational intervention will be to insert the contraceptive implant 24-48 hours following delivery.
1513643|NCT02866617|Device|Vacuum Formed Thermoplastic Retainers Constructed On 3D Reconstructed Orthodontic Study Model|
1513644|NCT02866604|Procedure|Sterofundin|
1513645|NCT02866604|Procedure|0.9% saline|
1513649|NCT02866578|Procedure|Open lung protective ventilation strategy|
1513650|NCT02866565|Drug|adipose-derived regenerative cells (ADRCs)|
1513651|NCT02866552|Drug|Stromal Vascular fraction|
1513652|NCT02866552|Drug|Ringer lactate|
1513653|NCT02866539|Drug|Polyherbal capsule coccinia, bougainvillea, catharanthus|A unique combination of 3 herbs that lower blood sugars
1513654|NCT02866539|Drug|Placebo|Similar looking inactive powder
1513655|NCT02866526|Other|Patient questionnaire|quantitative and qualitative data collection will be proposed.
1513656|NCT02866513|Other|evaluate the variations of transpulmonary pressure during the use of APRV by clinicians.|
1513657|NCT02866500|Behavioral|Quality of life survey/ dental statement|Assessment of oral state and patients quality of life before radiotherapy and along treatment for oral cancer
1513659|NCT02866474|Dietary Supplement|population living at home with meals on wheels|
1513660|NCT02866474|Dietary Supplement|population living in an EHPAD|
1513661|NCT02866461|Other|No treatment|Observation
1513662|NCT02866448|Drug|Vehicle control|Described in arm
1513663|NCT02866448|Drug|Isoquercetin|Described in arm
1513664|NCT02866448|Drug|Aspirin|Described in arm
1513665|NCT02866448|Drug|Isoquercetin plus Aspirin|Described in arm
1513666|NCT02866435|Drug|Insulin|In each clamp, a small intravenous catheter is placed in participant's arm for infusion of insulin together with potassium phosphate and glucose. Insulin is a hormone that body makes naturally and it causes blood sugar to decrease. Insulin (and glucose) will be infused in calculated doses to maintain blood sugar level in the target range of 95 mg/dl or 50 mg/dl depending on the clamp.
1513667|NCT02866435|Drug|Glucose|Glucose is administered together with insulin and potassium phosphate during each clamp via the intravenous catheter. Glucose is a sugar and it is used to carefully regulate blood sugar level.
1513668|NCT02866435|Drug|Potassium phosphate|Potassium phosphate is administered together with glucose and insulin during each clamp via the intravenous catheter. Potassium is a salt-like substance that is present in the blood.
1513669|NCT02866422|Other|No Intervention|Observational Study: No intervention
1513670|NCT02866409|Procedure|scalp block|"In this group following nerves were blocked-
Supra-orbital nerve
Supra-trochlear nerve
Zygomatico-temporal nerve
Auriculo-temporal nerve
Posterior auricular branches of the greater auricular Nerve
The greater, lesser, and third occipital nerves"
1513671|NCT02866409|Procedure|infiltration|The incision site was infiltrated with drug. {1/3rd in the muscle and 2/3rd in the subcutaneous tissue}.
1513672|NCT02866409|Drug|Dexmedetomidine|Dexmedetomidine was administered as a dose of 1 µg/kg in 20 ml 0.25% bupivacaine for scalp block or infiltration.
1513673|NCT02866409|Drug|Bupivacaine|20 ml of Bupivacaine 0.25% was administered to the patients either in the form of scalp block or infiltration
1513674|NCT02866396|Drug|Pregabalin|Pregabalin continued at the same preoperative dose 1h before surgery associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
1513675|NCT02866396|Other|Naive patient|Pregabalin 150mg PO initiated 1h before surgery Associated to paracetamol 1g PO and ketoprofen 100mg PO Intraoperative: nefopam 20mg IV + ketamine 0.3mg/kg IV + dexamethasone 8mg IV Postoperative: morphine titration in PACU (NRS > 3) + paracetamol 1g/6h PO + ketoprofen 100mg/12h PO systematically, oxycodone 5-10mg/12h PO if NRS>3
1513676|NCT02866383|Drug|Nivolumab|3 mg/kg is given over 60 minutes I.V. on day 1 just after radiation and then every 2 weeks (q2w)
1513677|NCT02866383|Drug|Ipilimumab|1 mg/kg is given over 90 minutes I.V. on day 1 30 minutes after the completion of nivolumab infusion and then every 6 weeks IV (q6w)
1513678|NCT02866383|Radiation|Radiotherapy|15 Gy x 1 fraction given on day 1
1513679|NCT02866370|Drug|Nintedanib|Nintedanib (BIBF1120) 200mg twice daily PO, continuously, until progression or withdrawal from the treatment.
1513680|NCT02866370|Drug|Paclitaxel|"Ovarian Cancer Patients Paclitaxel (80mg/m2) IV Day 1, 8, 15 every 28 days* Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days*
* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
1513681|NCT02866370|Drug|Pegylated Liposomal Doxorubicin (PLD)|"Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days*
* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
1513682|NCT02866370|Drug|Topotecan|"Ovarian Cancer Patients Topotecan 4mg/m2 IV Day 1, 8, 15 every 28 days*
* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
1513765|NCT02865811|Drug|Pembrolizumab|"Please see Arms for description."
1513766|NCT02865811|Drug|Pegylated Liposomal Doxorubicin (PLD)|"Please see Arms for description."
1513683|NCT02866370|Drug|Carboplatin|"Endometrial Cancer Patients Carboplatin (AUC 5) and Paclitaxel (175mg/m2) IV every 21 days*
* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity."
1513684|NCT02866370|Drug|Doxorubicin|"Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days*
* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2."
1513685|NCT02866357|Other|No intervention|Just collection of nasopharyngeal aspirate for assessment
1513686|NCT02866344|Device|Microwave ablation|Laparoscopic or robot-assisted laparoscopic microwave ablation of cancerous lesions with a 2.45-GHz microwave generator and a 1.8-mm-diameter transcutaneous antenna.
1513687|NCT02866344|Procedure|Hepatic resection|Laparoscopic or robot-assisted laparoscopic surgical resection of cancerous lesions.
1513688|NCT02866331|Drug|G-CSF (Leucostim)|
1513689|NCT02866331|Biological|CB (autologous cord blood)|
1513690|NCT02866331|Drug|Placebo (Normal saline)|
1513691|NCT02866318|Device|Echocardiography|
1513692|NCT02866305|Procedure|VATS bullectomy and mechanical pleuradesis.|Thoracoscopic bullectomy is performed on all visible bullae, alternatively is no visible bullae, the apex is resected. Then mechanical pleuradesis is performed.
1513693|NCT02866305|Procedure|Chest tube insertion|Conventional chest tube insertion.
1513694|NCT02866305|Drug|Epidural|All surgical participants received an epidural prior to the procedure.The epidural was removed simultaneous with the the chest tube.
1513695|NCT02866305|Radiation|High-resolution Computer Tomography|All participants included in this study had a HRCT performed.
1513696|NCT02866292|Other|Pelvic floor muscle and sexual function evaluation|"PFM evaluation was performed by vaginal palpation and vaginal squeeze pressure. During vaginal palpation the physiotherapist introduced the index and middle fingers about 4cm inside the vagina, and requested to hold the maximum contraction of the PFM. Muscle function was classified by the Oxford Scale Modified.
The vaginal squeeze pressure was measured through Perineometer.To obtain the measurements, the subjects remained positioning and vaginal sensor was introduced into the vaginal cavity. The women were oriented and motivated verbally to perform three voluntary maximal contractions sustained for five seconds and one minute interval between them.
Sexual function was evaluated by the Female Sexual Function Index (FSFI) questionnaire. The questionnaire consists of 19 multiple-choice questions, which involves six sexual response domains: desire, arousal, lubrication, orgasm, satisfaction and pain."
1513697|NCT02866279|Device|Etonogestrel Contraceptive Implant|Women will be randomized to the TIMING of implant placement
1513698|NCT02866266|Other|Retrospective database review|
1513699|NCT02866253|Drug|DHEA|Interventional patients should take DHEA 25mg tid 12weeks before enter the IVF cycle.
1513700|NCT02866240|Device|Cathodal Transcranial Direct Current Stimulation (tDCS).|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered to the brain area of interest via electrodes on the scalp.
1513701|NCT02866227|Drug|TOL-463|TOL-463 vaginal gel
1513702|NCT02866227|Drug|TOL-463|TOL-463 vaginal insert
1513703|NCT02866214|Drug|Febuxostat|Film Coated Tablets of Donifoxate (Eva Pharma company ) 40mg administered thrice weekly post hemodialysis session
1513704|NCT02866214|Drug|Placebo|"Film Coated Tablets (Placebo) to be administered thrice weekly post hemodialysis session.
same color, taste , size . Same all ingredients except Febuxostat (Active ingredient) ."
1513705|NCT02866201|Other|Rectal swab|
1513706|NCT02866188|Device|Check pulse with Smart watch on 3 parts of patient's body surface|Check pulse with smart watch on wrist, carotid artery, and eye of patients in shock or cardiac arrest state.
1513711|NCT02866162|Genetic|High-throughput exome sequencing|
1513712|NCT02866149|Biological|Blood sampling|Up to 5 blood samplings can be performed at different time points
1513713|NCT02866149|Procedure|Tumor sampling|One tumor sampling can be performed, if applicable
1513714|NCT02866149|Other|Stool sampling|Up to 5 blood samplings can be performed at different time points
1513715|NCT02866136|Drug|VP16, carboplatin|Systemic treatment : Intravenous injections, 2 cycles (21 days)
1513716|NCT02866136|Drug|Melphalan|intraarterial injections, 3 to 6 cycles (1 month)
1513717|NCT02866136|Drug|VP16, carboplatin, vincristin|Systemic treatment : Intravenous injections, 6 cycles (21 days)
1513718|NCT02866136|Drug|Carboplatin + laser day 1 (chemothermotherapy)|Chemothermotherapy : Intravenous injection by carboplatin and Laser at day 1
1513719|NCT02866136|Device|Laser (local treatment)|
1513720|NCT02866136|Device|cryoapplication (local treatment)|
1513721|NCT02866136|Radiation|I125 radioactive plaques (local treatment)|
1513722|NCT02866136|Drug|intravitreal Melphalan (local treatment)|
1513723|NCT02866123|Other|ultrasonography|
1513724|NCT02866123|Radiation|pulmonary radiography|
1513725|NCT02866110|Behavioral|Neurofeedback|The Blood Oxygenation Level Dependent (BOLD) signal from the amygdala, recorded with functional magnetic resonance imaging, is utilized as a feedback signal to patients.
1513726|NCT02866110|Device|MRI|Echo-planar Imaging of brain BOLD signal
1513727|NCT02866097|Other|mHealth inventory management|Improved stock management of iCCM commodities using the DHIS2 mHealth platform
1513728|NCT02866097|Other|Supportive supervision|Strengthening of supportive supervision using DHIS2
1513729|NCT02866097|Other|ICCM current standard of care|ICCM implementation as per current practice without mHealth interventions
1513767|NCT02865785|Drug|Intralipid 20%|intralipid D4-9 of induction ovulation to be repeated within 7 days of positive pregnancy test.
1513768|NCT02865785|Drug|Placebo|saline infusion D4-9 of induction of ovulation to be repeated within 7 days of positive pregnancy test.
1513730|NCT02866084|Device|Device|"The following parameters will be set for active treatments using the CVS Device:
A standardized CVS time-varying waveform lasting approximately 19 minutes will be used. Treatments will be administered up to twice daily. The two daily treatments should ideally be separated by at least one hour.
The waveform schedule will consist of a warm sawtooth delivered to one ear and a cold sawtooth delivered to the other ear. The warm sawtooth will go from body temperature to 42 °C, and the cold sawtooth will go from body temperature to 17 °C. The two waveforms will be delivered simultaneously, but will have different oscillation frequencies."
1513733|NCT02866058|Procedure|Cesarean Section|
1513734|NCT02866045|Procedure|EUS-guided fine needle biopsy|EUS-FNB is performed using a 22 or 25 G core biopsy needle (SharkCore FNB, Medtronic, Fridley, MN) by standard linear EUS-guided technique. The needle tip has six cutting edge surfaces and an opposing bevel to catch tissue as it is sheared off, enabling cohesive units of tissue acquisition with minimal tissue fracturing. 3 separate passes will be done into the lesion. Additional passes may be made if clinically necessary. No suction will be applied on the first pass. If the FNB sample obtained is deemed to be inadequate, negative pressure (using the standard suction syringe) will be applied to the needle on additional passes. The histology and cytology specimens will be processed as per standard clinical care.
1513735|NCT02866045|Procedure|Single incision needle knife biopsy|For patients allocated to the SINK group, after EUS confirmation, the esophagogastroduodenoscopy (EGD) will be repeated to perform the SINK biopsy. Under direct endoscopic visualization, a 10 mm linear incision will be made to the surface of the SEL using a conventional needle-knife sphincterotome with standard blended electrocautery (Endocut mode - ERBE system USA, Marietta, GA). A conventional biopsy forceps will then be introduced through the incision deep into the mass to obtain at least 3 samples. The incision will then be closed using 1 to 3 endoclips for prophylaxis against subsequent bleeding. The biopsies will be placed in formalin as per standard surgical pathology protocol.
1513736|NCT02866032|Drug|MOB015B|
1513737|NCT02866032|Drug|Ciclopirox 80 mg/g|
1513738|NCT02866019|Device|CLS2702C/CLS2702D|CLS2702C (cell sheet) will be transplanted to the wound site using CLS2702D (transplantation device) (screening period, 1 month [4 weeks]; cell sheet culture period, 0.5 month [16 days]; transplantation period, assessment/follow-up period, 6 months [24 weeks])
1513739|NCT02866006|Drug|BVAC-C|BVAC-C IV injection at 0, 4, 8th weeks.
1513740|NCT02865993|Other|betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with low molecular weight povidone-iodine solution ('Betadine LMW') (PVP-I LMW) diluted 50:50 with normal saline.
1513741|NCT02865993|Other|no betadine group|Patients intra-operatively received intraperitoneal irrigation prior to abdominal closure with only normal saline solution.
1513742|NCT02865980|Other|clove extract|in intervention group, first will be washed the Catheter with Betadine after 2 minutes will be used of the clove extract with 2 ml of scrub for 15 seconds. The incidence of inflammation of vascular access will be assessed in patients on hemodialysis for each patient before starting the process over a period of 2 weeks is equivalent to 6 sessions of hemodialysis.
1513743|NCT02865980|Other|Betadine|in control group, will be washed the Catheter with Betadine
1513744|NCT02865967|Other|Usual care + a-GPS|Clinicians will be provided a-GPS data on a regular basis for intervention group, but not control group such as their risk factors for asthma, quality of care, and asthma outcomes.
1513745|NCT02865967|Other|Usual care|The subjects will be treat for their asthma by their physicians according to usual care.
1513746|NCT02865954|Device|iball (mhealth application)|mhealth application and associated device to support activation of the pelvic floor muscles.
1513747|NCT02865941|Dietary Supplement|Fortification with modular protein|Modular product supplementation is based on most recent breast analysis done for the participant.
1513748|NCT02865941|Dietary Supplement|Fortification with modular carbohydrate|Modular product supplementation is based on most recent breast analysis done for the participant.
1513749|NCT02865941|Dietary Supplement|Fortification with modular fat|Modular product supplementation is based on most recent breast analysis done for the participant.
1513750|NCT02865928|Drug|Bupivicaine HCl|Ultrasound guided serratus plane block with bupivicaine
1513751|NCT02865928|Drug|Normal Saline|Same injection technique as intervention arm with normal saline
1513752|NCT02865915|Drug|MLE4901 40mg|
1513753|NCT02865915|Drug|Placebo|Placebo to match active drug
1513754|NCT02865902|Device|Low-Level Laser Therapy by Ezlase; Biolase®|comparision of the effects of low-level-laser therapy on wound healing of palatal donor site
1513755|NCT02865889|Procedure|Laparoscopy in Gynecologic Oncologic Indications|
1513756|NCT02865889|Procedure|Conventional surgery (abdominal radical surgery)|
1513757|NCT02865876|Procedure|Accelerated Corneal Cross-linking|All participants in this group receiving conventional therapy (moxifloxacin 0,5% for bacterial keratitis or natamycin for mycotic keratitis) plus accelerated cross-linking (Avedro Inc., Waltham, USA) under topical anesthesia using 0.1% riboflavin (Vibex, Avedro Inc, Waltham, USA) for 10 minutes and irradiation 30 mW/cm2 during 3 minutes.
1513758|NCT02865863|Dietary Supplement|Eurycomalongifoliawater extract (Physta®) +Multivitamin|
1513759|NCT02865863|Dietary Supplement|Placebo|
1513760|NCT02865850|Drug|vadadustat|oral tablet
1513761|NCT02865850|Drug|Darbepoetin alfa|subcutaneous/intravenous
1513763|NCT02865824|Drug|Continue thienopyridine|Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy
1513764|NCT02865824|Drug|Discontinue thienopyridine|Patients who are taking dual antiplatelet therapies stop thienopyridine one week before they undergo colonoscopy
1513769|NCT02865759|Behavioral|Mindfetalness|The pregnant woman is motivated to practice Mindfetalness verbally, by a brochure and at a website.
1513770|NCT02865746|Drug|Bethametasone|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
1513771|NCT02865746|Drug|Placebo|The injections were performed with the aid of syringes fitted with ultrafine needles (BD ultrafine U-100, 0.3 x 8 mm), in the buccal mucosa, submucosally near the tooth's periapex of the periapical region of the tooth involved, by using the submucosal infiltration technique.
1513772|NCT02865733|Drug|Remodulin|After Fontan operation, the mean pulmonary arterial pressure (mPAP)evaluated by CVP or transpulmonary pressure gradient(TPG) evaluated by Echo will be measured firstly, if the data met the criteria, and the patients were enrolled in the experimental group, the patients would be administrated intravenously of Remodulin® with the beginning of 5ng/kg/min, with the rate of 10ng/kg/min every 30 minutes up to 80ng/kg/min.
1513773|NCT02865733|Drug|distilled water|After Fontan operation, the mPAP (evaluated by CVP) or TPG (evaluated by Echo) will be measured firstly, if the data met the criteria, and the patients were enrolled in placebo group, then the patients would be administrated intravenously of distilled water with the beginning of 0.15ml/hr, with the rate of 0.3ml/hr every 30 minutes up to 2.45ml/hr.
1513774|NCT02865720|Drug|CINRYZE 500 U|IV infusion administered twice weekly
1513775|NCT02865720|Drug|CINRYZE 1000 U|IV infusion administered twice weekly
1513776|NCT02865707|Dietary Supplement|Synergy-1|Synergy-1 is chicory-derived β-fructans inulin plus FOS (1:1).
1513777|NCT02865707|Dietary Supplement|Maltodextrin|Maltodextrin is carbohydrate adsorbed in the small bowel.
1513778|NCT02865694|Other|Cascade|
1513779|NCT02865681|Drug|Menopur|Nasal versus injectable
1513780|NCT02865681|Drug|Synarel|nasal
1513781|NCT02865681|Drug|HCG trigger|injectable
1513782|NCT02865681|Drug|Clomiphene citrate|oral
1513783|NCT02865681|Drug|Letrozole|Oral
1513784|NCT02865668|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 500 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
1513785|NCT02865668|Drug|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
1513786|NCT02865668|Drug|Metformin Extended Release (XR)|Participants will receive 1 metformin XR tablet of 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
1513787|NCT02865655|Procedure|Hysteroscopic|
1513790|NCT02865629|Drug|N-acetyl cysteine|N-acetylcysteine will be initiated at 600 mg PO daily for week 1, then increased to 600 mg PO twice a day for Week 2, then increased to 600 mg PO morning and 900 mg PO evening for Week 3, then increased to 1200 mg PO twice a day for Week 4-8. Doses might be decreased anytime if clinically indicated. Following the study, all patients will be referred to treatment as usual. Adherence will be assessed in weekly visits in the first month and then bi-weekly in the second month. Adherence will be assessed by subject interview, pill counts during each study visit, and by legal guardian interview (if minor).
1513791|NCT02865616|Drug|MET-2|Microbial Ecosystem Therapeutics (MET) is a new treatment approach for debilitating recurrent Clostridium difficile infection that has been developed as an alternative to fecal transplantation.
1513792|NCT02865616|Drug|Vancomycin|Patients will be on vancomycin to control symptoms up until the time of the treatment. Patient must hold their p.o. vancomycin for 24 hours prior to receiving the first dose.
1513793|NCT02865603|Behavioral|PAX Good Behavior Game|PAX GBG includes evidence-based kernels and a classroom game where students are reinforced for their mutual success in withholding inappropriate behavior.
1513794|NCT02865590|Device|sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)|
1513795|NCT02865590|Device|Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)|
1513796|NCT02865564|Dietary Supplement|Lactobacillus reuteri DSM 17938|
1513797|NCT02865564|Dietary Supplement|Placebo|
1513798|NCT02865564|Drug|ampicillin and gentamicin|
1513799|NCT02865551|Device|Foley catheter|Extended bladder catheterization after epidural anesthesia.
1513800|NCT02865551|Device|Short term catheter|Intermittent catheterization every 4 hours after epidural anesthesia.
1513801|NCT02865551|Drug|Epidural anesthesia|Performance of epidural anesthesia by a certified anesthesiologist.
1513802|NCT02865538|Drug|NT-814|
1513803|NCT02865538|Drug|Placebo (for NT-814)|
1513804|NCT02865512|Procedure|thoracic epidural catheterization|thoracic epidural catheterization for the management of postoperative pain
1513806|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 2.
1513807|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 3.
1513808|NCT02865486|Dietary Supplement|Lipid emulsion|1 of 4 isovolumetric (200 ml) and isocaloric (380 kcal) lipid emulsions with different acid and shear stability will be ingested on visit 4.
1513809|NCT02865473|Drug|Pilocarpine|topical instillation into the study eye
1513810|NCT02865460|Drug|Ubiquinol|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
1513811|NCT02865460|Drug|Placebo|Take oral tablets as directed (2x200 mg for 2 months; 1x200 mg for 4 months) with food each morning- upon waking
1513812|NCT02865447|Device|total hip arthroplasty implant|PROFEMUR PRESERVE total hip arthroplasty femoral stem
1513813|NCT02865434|Drug|Tc99m-tilmanocept|Tilmanocept is a radiotracer that accumulates in macrophages by binding to a mannose binding receptor that resides on the surface.
1513814|NCT02865434|Procedure|SPECT Imaging (60 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 60 Minutes post-injection.
1513815|NCT02865434|Procedure|SPECT Imaging (180 Minutes post-injection)|Subjects enrolled in Groups 1-9 will receive whole body planar SPECT imaging with 3D SPECT or SPECT/CT for targeted joints of interest 180 Minutes post-injection.
1513816|NCT02865434|Procedure|Whole body planar SPECT imaging (15 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 15 minutes post-injection for dosimetry.
1513817|NCT02865434|Procedure|Whole body planar SPECT imaging (60 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 60 minutes post-injection for dosimetry.
1513818|NCT02865434|Procedure|Whole body planar SPECT imaging (180 Minutes post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 180 minutes post-injection for dosimetry.
1513819|NCT02865434|Procedure|Whole body planar SPECT imaging (18-20 Hours post-injection)|Subjects enrolled in Groups 10-11 will receive a whole body planar SPECT scan performed 18-20 Hours post-injection for dosimetry.
1513820|NCT02865434|Procedure|Blood Collection for PK Testing (15 Mins Before Injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis within 15 minutes prior to administration of Tc 99m tilmanocept
1513821|NCT02865434|Procedure|Blood Collection for PK Testing (after injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis immediately following administration of Tc 99m tilmanocept (00:00)
1513822|NCT02865434|Procedure|Blood Collection for PK Testing (15 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 15 ± 5 minutes post injection of Tc 99m tilmanocept
1513823|NCT02865434|Procedure|Blood Collection for PK Testing (60 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 60 ± 15 minutes post injection of Tc 99m tilmanocept
1513824|NCT02865434|Procedure|Blood Collection for PK Testing (180 minutes post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 180 ± 15 minutes post injection of Tc 99m tilmanocept
1513825|NCT02865434|Procedure|Blood Collection for PK Testing (18-20 hours post injection)|Blood will be collected for subjects enrolled in Groups 10-11 for the purpose of PK analysis at 18-20 hours post injection of Tc 99m tilmanocept
1513826|NCT02865421|Drug|stem cells|adipose tissue derived mesenchymal stem cells
1513827|NCT02865421|Drug|platelet rich plasma|
1513828|NCT02865408|Dietary Supplement|Peptamen 1.5% via enteral|Study patients in this group will be prescribed 1.0 g/kg/d of protein using standard enteral Peptamen 1.5%. Based on current compliance or tolerance statistics, investigators expect patients to only receive 50-60% of these prescribed doses; effective protein intake will therefore be approximately 0.5-0.6 g/kg/d.
1513829|NCT02865408|Dietary Supplement|Prosol 20% IV to 1.75g/kg/day|Patients in group 2 will receive Peptamen 1.5% but in addition, will receive sufficient intravenous amino acid supplements (Prosol 20%) to achieve an effective fixed dose of 1.75 g/kg/day.
1513830|NCT02865408|Dietary Supplement|Prosol 20% IV to 2.5g/kg/day|Patients in this group will receive intravenous amino acids, Prosol 20% in addition to standard enteral Peptamen 1.5% to achieve an effective protein intake of 2.5 g/kg/d.
1513831|NCT02865395|Drug|Belladonna and Opium Suppository|
1513832|NCT02865395|Procedure|Rectal Exam|
1513833|NCT02865382|Procedure|white light was used for colonoscopy withdrawal|
1513834|NCT02865382|Procedure|OE mode was used for colonoscopy withdrawal|
1513835|NCT02865369|Drug|Daclatasvir and Asunaprevir|Daclatasvir and Asunaprevir combined treatment will not be assigned to the enrolled patients, but the patients who are treated with Daclatasvir and Asunaprevir will be included in this observational study.
1513836|NCT02865356|Drug|Cyclosporine 5% solution|topical solution
1513837|NCT02865356|Drug|Placebo|topical vehicle solution
1513838|NCT02865343|Device|Non-invasive Ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a minimal pressure of 12 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
1513839|NCT02865343|Device|Sham Non-invasive ventilation(NIV)|The ventilator will be set in spontaneous mode with a ramp to reach a maximal pressure of 5 centimeters of water (cmH2O) during inspiration and 3 cmH2O during expiration.
1513840|NCT02865330|Other|Registry|National Registry of patients with prostate cancer as monitored through active surveillance, with the intention of testing the hypothesis that cancer-specific mortality in very low-risk and low-risk patients is less than 5% at 15 years.
1513841|NCT02865304|Drug|endostar|
1513842|NCT02865291|Device|ForConti device|
1513843|NCT02865278|Other|Standard meal|The participants consume the drink, experimental or placebo drink. After 3 hours they consume a standard meal (905 kcal, 15% protein, 46% fat, 39% CHO). Blood samples are taken at fasting, over 3 hours after drink consumption and over 5 hours after the test meal to evaluate metabolic response. Fasting and 48h-urine are collected to evaluate bioavailability of polyphenol.
1513844|NCT02865265|Procedure|Pecs II and parasternal blocks|"Pecs II block was performed at the level of the fourth rib in the fascial plane between the minor pectoral and serratus anterior muscles, and 20 ml of 0.5% levobupivacaine solution were injected.
An ultrasound-guided ipsilateral parasternal block was performed via two separate injections of 4 ml of 0.375% levobupivacaine at the level of the 2nd and 4th intercostal space underneath the external intercostal membrane between the major pectoral and intercostal muscles close to the surface of the 2nd and 4th rib."
1513845|NCT02865252|Other|MWM Treatment|
1513846|NCT02865252|Other|MWM Sham|
1513848|NCT02865226|Other|paravertebral block by the anesthetist before incision (paravertebral block guided by ultrasound)|
1513849|NCT02865226|Other|paravertebral block by the thoracic surgeon at chest closure (paravertebral block visual).|
1513850|NCT02865213|Device|OBA|"The intrusion of posterior teeth using removable appliance OBA."
1513851|NCT02865213|Device|Miniplates|"The intrusion of posterior teeth using temporary anchorage Miniplates."
1513852|NCT02865213|Device|Miniscrews|"The intrusion of posterior teeth using temporary anchorage Miniscrews."
1513853|NCT02865200|Other|Dry Needling Application|Dry needling was performed on active and/or latent TPs at Gluteus Medius, Quadratus Lumborum, Multifidus, Erector Spinae muscles of the subjects in the study groups without applying any local anesthetic substance. The needles were applied with a 90º angle for Multifidus, Quadratus Lumborum and Gluteus Medius muscles; while they were applied with a 45º angle for Erector Spinae muscles. Thin stainless steel needles of 0.25x0.40 mm and 0.30x0.60 mm were applied in infiltration form on the TP through many points in conformity with the injection technique.
1513854|NCT02865200|Other|Classic Physiotherapy Program|"Hot-pack was applied for 20 minutes. Burst TENS was applied on the lumbar regions of the cases of the control group paravertebrally with 4-electrode reusable silicone rubber. The dimensions of electrode is 5x5cm. Pulse width was set for 100 µsn, pulse frequency was set for 2 Hz, cycle time is set for 0.5 seconds and the amplitude was increased until visible muscle contraction was reached. If the muscle contraction is lost during the session, the amplitude was increased again.
Ultrasound was paravertebrally applied to the lower back regions of the subjects. The treatment was applied with 1 MHz frequency, 1.5 W/cm2 power, for 6 minutes a day, for 10 sessions in total with direct contact with the patient's skin."
1513855|NCT02865187|Dietary Supplement|Vitamin D|Vitamin D 600IU/day
1513856|NCT02865187|Drug|Hormonal contraception|Hormonal contraceptives
1513857|NCT02865174|Drug|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 100 ml normal saline into knee joint after closure of the joint capsule
1513858|NCT02865174|Drug|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
1513859|NCT02865174|Drug|Enoxaparin|Enoxaparin will be administrated sc 40mg each day postoperatively as venous thromboembolism prophylaxis in the duration of hospital stay
1513860|NCT02865161|Drug|NISELAT|NISELAT 600MG BD
1513861|NCT02865148|Behavioral|Cognitive behavioral therapy|CBT-based protocol tailored to advanced breast cancer patients with a focus on managing a broad array of symptoms including psychological distress, pain, and fatigue. Important features of the protocol are: 1) a unique motivational interviewing component in the first session that will focus on patients' motivation for engaging in the protocol, confidence (i.e., self-efficacy) to learn new strategies, and potential barriers to adopting recommendations for lifestyle change; and 2) protocol that targets multiple symptoms, and 3) adapted to meet the unique needs of advanced breast cancer patients.
1513862|NCT02865135|Drug|DPX-E7 vaccine|Therapeutic vaccine for the treatment of incurable HPV16-related oropharyngeal, cervical and anal cancer in HLA-A*02 positive patients.
1513863|NCT02865135|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating drug indicated for treatment of multiple malignant diseases. In this study a low dose is being given in combination with the DPX-E7 vaccine.
1513864|NCT02865122|Drug|NTRA-9620|Oral daily dose
1513865|NCT02865122|Drug|Placebo|Oral daily dose
1513867|NCT02865083|Device|Traxi Pannus Retractor|traxi® Panniculus Retractor is a retraction device used for retraction of the panniculus during surgical procedures. traxi retracts and holds the panniculus for the duration of the operation, freeing the surgeons hands and those of the staff to better care for the patient.
1513868|NCT02865070|Device|Skin Sensor|Wireless vitals monitor
1513869|NCT02865057|Procedure|Vaginal assessment|Vaginal assessment of position prior to delivery
1513870|NCT02865044|Other|Wax Ester Marine Oil|Wax ester marine oil (Calanus oil; 4 g providing 260 mg EPA and 156 mg DHA; 8 capsules) consumed once, in clinic, at t=0.
1513871|NCT02865044|Other|Ethyl Ester Marine Oil|Ethyl ester (EE) marine oil (Lovaza OM3 EE; 1 g providing 465 mg EPA and 375 mg DHA; 1 capsule), consumed once, in clinic, at t=0
1513872|NCT02865031|Drug|Decorin|Intravitreal Injection following ocular trauma to prevent scar tissue formation.
1513873|NCT02865018|Drug|cetirizine|
1513874|NCT02865005|Drug|Dapsone 5.0% Gel (SEEGPharm)|Topical Gel
1513875|NCT02865005|Other|Placebo|Topical Gel
1513876|NCT02865005|Drug|Dapsone 5.0% Gel (Allergan)|Topical Gel
1513878|NCT02864966|Device|Condom|This study involves testing a condom, however the device will not be used as intended. The device will be destroyed to make the test patches required for this safety study.
1513879|NCT02864953|Drug|CIRARA (glyburide for injection)|
1513880|NCT02864953|Drug|Placebo (for CIRARA)|
1513881|NCT02864940|Device|Lumosity|A web-based cognitive training platform that includes games designed with the purpose of improving the user's cognitive abilities
1513882|NCT02864940|Device|Crossword puzzle|This game offers a choice between three puzzle sizes, three levels of complexity, and varying font sizes. It also includes optional help features such as filling in an unknown letter or word.
1513883|NCT02864927|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
1513884|NCT02864927|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
1513885|NCT02864914|Drug|Empagliflozin|drug
1513886|NCT02864914|Drug|Sulfonylurea|drug
1513887|NCT02864914|Drug|DPP-4 inhibitors|drug
1513890|NCT02864888|Radiation|Radiation|Children with a diffuse, intrinsic brain stem glioma will receive radiation.
1513891|NCT02864888|Drug|Atengenal|Children with a diffuse, intrinsic brain stem glioma will receive Atengenal in combination with Astugenal (Antineoplaston therapy) and radiation
1513936|NCT02864602|Drug|IV dexamethasone|An infusion of IV dexamethasone
1513892|NCT02864888|Drug|Astugenal|Children with a diffuse, intrinsic brain stem glioma will receive Astugenal in combination with Atengenal (Antineoplaston therapy) and radiation
1513893|NCT02864875|Drug|Fibrinogen concentrate|Drug: Fibrinogen concentrate 50mg/kg after hospital arrival.
1513894|NCT02864862|Device|Immediate implant|
1513895|NCT02864862|Biological|SCTG|
1513896|NCT02864862|Biological|ADM|
1513897|NCT02864849|Drug|Oxaliplatin|
1513898|NCT02864849|Drug|Capecitabine|
1513899|NCT02864849|Radiation|Intensity modulated radiotherapy|
1513900|NCT02864849|Procedure|Total mesorectal excision|
1513901|NCT02864836|Procedure|Samples collection|5 samples collected for each patient (tumor biopsy, healthy tissue around the tumor, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins 4 samples for each patient (healthy tissue, blood, urine and saliva), quantification of isotopes, measure of mRNA expression of proteins
1513902|NCT02864823|Procedure|Perichondrium Autografts|Perichondrium tissue was harvested from the patient's ear cartilage and transplanted to reconstruct the scleral defect.
1513903|NCT02864810|Drug|[18F]GP1|[18F]GP1 PET/CT imaging for detecting thromboembolism
1513905|NCT02864784|Drug|Amorphous calcium carbonate|Subjects in this arm of the study will receive standard treatment with ZA or Denosumab (4 mg once every 4 weeks for ZA and 120mg (1.7ml injection) every 4 weeks for Denosumab) as well as AMOR-1 tablets, containing 200 mg elemental calcium per tablet, individually titrated up to the maximum level which does not induce grade 2 hypercalcemia.
1513906|NCT02864784|Other|Placebo|
1513910|NCT02864745|Device|functional electrical stimulation-assisted cycle ergometry|Early intensive rehabilitation protocol, which includes the use of functional electrical stimulation-assisted cycle ergometry
1513911|NCT02864745|Other|standard rehabilitation|This group will receive standard rehabilitation, which will be monitored, but not protocolised.
1513914|NCT02864719|Other|Energy Conservation+Problem Solving Therapy|The intervention was delivered by telephone. Each EC+PST intervention session was planned to last approximately 45 minutes and occur twice a week for up to 4 weeks. Sessions terminated when the participants identified and solved two fatigue-related problems of their choice or had participated in the intervention for eight sessions. A Participant Workbook was used throughout the intervention. During eight intervention sessions, participants identified two fatigue-related problems and solutions for them, implemented the solution plans, and reviewed the implementations.
1513915|NCT02864706|Drug|Everolimus|All patients, independent of their initial randomization in the core study, are now followed up as in one single group
1513916|NCT02864693|Device|Kinnex|The Kinnex is a microprocessor controlled hydraulic ankle foot device (Freedom Innovations, Irvine, CA).
1513917|NCT02864693|Device|Pacifica LP|The Pacifica LP is a carbon-fiber ankle foot device (Freedom Innovations, Irvine, CA)
1513918|NCT02864680|Other|Electroretinography|
1513919|NCT02864680|Other|Contrast sensitivity test during Electroencephalography|Stimuli are black and white grids, having different range of spatial frequencies, presented with different contrasts on a grey background thanks to a computer monitor, in a dark room. Participants are requested to maintain central fixation. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
1513920|NCT02864680|Other|Visual simultaneity test during Electroencephalography|Two vertical bars are showed on a monitor, on the link and right of point of central fixation. Bars appear simultaneously or with a 10 to 200 ms asynchrony. Participants must determine whether stimuli are simultaneous or asynchronous and answer pressing the link button for simultaneity or right button for asynchrony. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
1513921|NCT02864680|Other|Face perception test during Electroencephalography|Faces filtered in different spatial frequence ranges are showed randomly on a monitor, in a dark room. Participants must maintain a central fixation thank to a fixation cross. During the test patients stay sit, head hold by chin strap. A pause can be asked by participant and done at every moment. This test lasts approximately 30 minutes.
1513922|NCT02864680|Other|CAST (cannabis abuse screening test)|
1513923|NCT02864680|Other|PANSS (Positive And Negative Symptoms Scale) test|
1513924|NCT02864680|Other|Delayed Matching to Sample (DMS) test|
1513925|NCT02864680|Other|Spatial Working Memory (SWM) test|
1513926|NCT02864680|Other|Rapid Visual Information Processing (RVP) test|
1513927|NCT02864680|Other|Test for attentional performance (TAP) / Divided Attention|
1513928|NCT02864680|Other|Collection of saliva sample|In case of specific consent of participant to ancillary study, for ancillary study
1513929|NCT02864654|Procedure|ADRC injection|10 mL of autologous ADRC suspension will be injected intramuscularly
1513930|NCT02864654|Other|ADRC isolation|ADRC will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 10 ml of normal saline.
1513931|NCT02864654|Procedure|Liposuction|
1513932|NCT02864641|Behavioral|Planet K|Planet K is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' chronic kidney disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
1513933|NCT02864628|Biological|MVA-BN-RSV|MVA-mBN294B
1513934|NCT02864628|Other|Placebo|Tris Buffered Saline
1513937|NCT02864589|Behavioral|Internet-delivered habit reversal training|The I-HRT group will receive a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on habit reversal training (i.e. Woods, D.W. (2008). Managing Tourette syndrome: A behavioral intervention for children and adults therapist guide. OUP, USA.) with added interactive features as videos and illustrations. In short, the participants practice to become more aware of their tics and inhibit them by performing competing responses (movements). The treatment is therapist guided: the participants have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
1513938|NCT02864589|Behavioral|Internet-delivered exposure and response prevention|The I-ERP group receives a 10-week therapist-guided, parent-assisted, Internet-delivered behavioural treatment. The treatment is based on existing literature on exposure and response prevention (i.e. Verdellen, C. et al. (2011). Tics: Therapist manual & workbook for children. Boom, Amsterd.) with added interactive features as videos and illustrations. In short, the participants practice to suppress their tics for longer and longer times, at the same time as premonitory urges are intentionally provoked. The treatment is therapist-guided: the children and parents have regular (up to 5 days a week) contact with a personally assigned therapist via written text in the platform and occasionally via the telephone. The children and parents have separate logins and access partly different content.
1513939|NCT02864576|Behavioral|Cognitive Remediation_Aerobic Exercise|"Cognitive Remediation:
The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.
Aerobic Exercise:
12 weeks of systematic aerobic exercise program. Patients will walk with a moderate intensity 10 minutes the first week and will increase gradually up to 30 minutes-walk with a moderate intensity. Patients will also perform 5 minutes of warm-up and stretching."
1513940|NCT02864576|Behavioral|Cognitive Remediation_Health Promotion|"Cognitive Remediation:
The REHACOP program consists of: Attention unit training sustained, selective, alternant and divided attention; Memory unit focusing on visual and verbal learning, recall and recognizing memory; Language unit including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit training cognitive planning, proverbs, analogies; and Social cognition unit exercising theory of mind, social reasoning and moral dilemmas.
Health Promotion:
12 weeks of health promotion sessions. These sessions will be carried out by a specialized/trained nurse."
1513941|NCT02864563|Procedure|Blood sampling|"Blood sample at diagnosis to evaluate MYCN amplification in plasma.
In case of NB with a MYCN amplification, blood samples are also collected during treatment and follow-up."
1513942|NCT02864550|Drug|Doxycycline|
1513943|NCT02864550|Other|Placebo|
1513944|NCT02864537|Other|Training|Patients were trained to measure INR and dose warfarin
1513945|NCT02864524|Other|Manipulative and Massage Therapy|
1513946|NCT02864524|Other|Exercise Program|
1513947|NCT02864511|Procedure|Nefertiti lift|
1513948|NCT02864498|Drug|DS107|
1513949|NCT02864498|Drug|Placebo|
1513951|NCT02864472|Procedure|PDT|PDT and ranibizumab
1513952|NCT02864472|Drug|Ranibizumab|Ranibizumab
1513953|NCT02864472|Drug|ranibizumab PRN|ranibizumab PRN
1513954|NCT02864459|Other|Muscular ultrasound|Muscular ultrasound is done before extubation
1513955|NCT02864420|Other|Home hospitalization|
1513956|NCT02864420|Other|Inpatient Hospitalization|
1513958|NCT02864394|Biological|pembrolizumab 2 mg/kg|IV infusion
1513959|NCT02864394|Drug|Docetaxel 75 mg/m^2|IV infusion
1513960|NCT02864381|Drug|Andecaliximab|800 mg administered via intravenous (IV) infusion every 2 weeks
1513961|NCT02864381|Drug|Nivolumab|3 mg/kg administered via intravenous (IV) infusion every 2 weeks
1513962|NCT02864368|Drug|5-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of 150-200 mg/m^2/day on days 1-5 of each 28 day cycle
1513963|NCT02864368|Drug|21-day TMZ|Chemotherapy agent FDA approved to treat newly-diagnosed glioblastoma given as cycles of dose-intensified TMZ (75-100 mg/m2/day on days 1-21 of each 28 day cycle)
1513964|NCT02864368|Biological|PEP-CMV|500 µg of PEP-CMV Component A (a synthetic long peptide) mixed with Montanide ISA-51 intradermally administered in the right groin and 500 µg of PEP-CMV Component B (a neutralizing antibody epitope from human CMV glycoprotein B conjugated to Keyhole Limpet Hemocyanin) mixed in 150 µg of GM-CSF intradermally administered in the left groin
1513965|NCT02864368|Drug|Tetanus-Diphtheria booster|At time of enrollment, after signing consent and undergoing immune monitoring blood work, patients will receive Tetanus-diphtheria booster vaccination with 0.5 mL of Td (tetanus, diphtheria toxoid, absorbed)
1513966|NCT02864368|Drug|Tetanus Pre-Conditioning|All patients will receive a tetanus pre-conditioning injection in the right groin intradermally on day 22 (±1 day) of the first post-radiation cycle of TMZ
1513967|NCT02864355|Device|Goal Directed Therapy|Participants in this group will have a FloTrac monitor attached to their arterial line and the Goal Directed Therapy algorithm will be followed to manage blood pressures.
1514038|NCT02863783|Device|EUS with Fiducial|EUS will be used to place fiducial into pancreas tumor at time of biopsy
1514080|NCT02863380|Device|Classical tDCS (transcranial direct current stimulation)|
1513970|NCT02864316|Drug|Nivolumab|
1513971|NCT02864303|Other|Saliva samples|saliva specimens were collected using a neutral or citric acid impregnated Salivette cotton swabs on Alzheimer patients to quantify the level of amyloid peptides
1513972|NCT02864290|Drug|AGS62P1|intravenous (IV) infusion
1513973|NCT02864277|Procedure|No Intervention Conventional Strategy|"The Conventional Strategy Group description encompasses over 4 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.
Preoperative Management Interoperative Management Postoperative Management Post discharge"
1513974|NCT02864277|Procedure|ERAS|"The ERAS Group description encompasses over 3 pages of concise directions on how to take care of the participant. This cannot be reduced to less than 1000 characters.
Preoperative Management Interoperative Management Postoperative Management Post discharge"
1513982|NCT02864238|Other|electronic milestone pathway|an electronic based, clinical milestone driven pathway developed to guide the care of cardiac valve surgery patients.
1513983|NCT02864225|Device|Scalp electrode,|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
1513984|NCT02864225|Device|Fetal doppler|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
1513985|NCT02864225|Device|EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler
1513986|NCT02864199|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered for 12 to 48 weeks. The dose will range from 135 mcg (Group C) to 180 mcg (Groups A, B, and D) once weekly via SC route.
1513987|NCT02864199|Drug|Ribavirin|Ribavirin will be administered for 12 to 48 weeks. The total daily dosage will range from 200 mg (Group C) to 1200 mg (Group D), depending upon CrCl and participant-specific factors.
1513988|NCT02864186|Device|control|Women wont use support bra 24 hours a days for six months
1513989|NCT02864186|Device|surgical support bra|Women will use surgical support bra 24 hours a day for six months
1513990|NCT02864186|Device|common support bra|Women will use common support bra 24 hours a day for six months
1513991|NCT02864173|Genetic|Whole genome small nucleotide polymorphism genotyping|
1513992|NCT02864160|Behavioral|Health Coaching|Life style coaching in 3 in-person meetings and 14 phone calls; written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
1513993|NCT02864160|Behavioral|Comparison Group|Written educational materials; self-management tools (stretch band, a glucometer, and a diabetes cookbook in Spanish).
1513996|NCT02864121|Other|all patients included in IDAHO study|
1513997|NCT02864095|Drug|Tranexamic acid (TXA)|IV and topical administration
1513998|NCT02864095|Drug|Epinephrine|
1513999|NCT02864082|Drug|PAT-001, 0.1%|PAT-001 is a topical ointment. PAT-001, 0.1% contains 0.1% of active drug.
1514000|NCT02864082|Drug|PAT-001, 0.2%|PAT-001 is a topical ointment. PAT-001, 0.2% contains 0.2% of active drug.
1514001|NCT02864082|Drug|Vehicle|Vehicle topical ointment contains 0.0% of active drug and is color matched to the active test article, PAT-001.
1514039|NCT02863770|Other|EUS enhanced with contrast to evaluate pancreas|Patients will receive intravenous contrast during EUS to assess whether it increases diagnostic yield of the examination
1514081|NCT02863367|Drug|Apatinib|Apatinib：500 mg，po，qd, d1-14, every 3 week
1514082|NCT02863367|Drug|Gemcitabine|Gemcitabine：1000mg/m²，vein input 30-40，d1，d8，every 3 week
1514083|NCT02863354|Drug|Aflibercept|Intravitreal injection
1514084|NCT02863341|Other|Team-care deprescribing with deprescribing guide|Beers criteria 2015, STOPP criteria 2014, drug interaction
1514002|NCT02864069|Behavioral|Walking Intervention|The walking intervention will begin following baseline assessments and will be continued for 12 weeks. Participants will be given a pedometer to use daily and log their daily steps, with an identified goal of increasing step counts by 3000 steps a day over the course of the intervention. After obtaining a week long baseline step count, individuals in the intervention group will progressively increase their step counts by 100 steps daily each week for the first three weeks, by 200 steps daily for weeks four through six, by 300 steps daily for weeks seven through nine, and by 400 steps daily for weeks ten through twelve. Mean baseline step counts for sedentary older adults in our pilot work were 4150 per day; therefore, most participants will almost double their daily activity by the end of the intervention.
1514003|NCT02864069|Behavioral|Cognitive Training Intervention|In the CT condition, participants will use Brain HQ, a computer cognitive training program (Posit Science Corporation, San Francisco, CA), shown to be well tolerated by older adults with positive short- and long-term cognitive outcomes. Participants will use the program 60 minutes/day, 5 days/week for 12 weeks. If participants do not have a home computer/internet access, they can complete the modules at another location such as a public library, senior center, or at the MARC, but training will still be self-directed.
1514004|NCT02864069|Behavioral|Combined Intervention|The combined condition will concurrently follow both the walking and the CT programs as described above.
1514005|NCT02864056|Other|Tai Chi|Ancient Chinese form of mind/body gentle exercise; this will be done while standing to improve postural balance.
1514006|NCT02864043|Device|NvisionVLE with Real Time Targeting|Physician will complete a VLE scan of the esophagus and target areas of interest using the VLE optical marking probe
1514007|NCT02864030|Drug|ERIBULIN MESYLATE|"Eribulin mesylate will be administered according to the European Medicines Agency (EMA) and Italian Medicines Agency (AIFA) approved indications and schedule consists in 1.23 mg/m2 on day 1 and on day 8 of each cycle. Cycles will be repeated every 21 days until progression of disease, unacceptable toxicity, patient refusal or medical decision.
The decision to treat patients with Eribulin is independent from the trial. Patients will be treated and managed according to clinical practice. The physician can choose any further line of treatment after disease progression with Eribulin."
1514008|NCT02864017|Procedure|Enteral nutrition|
1514009|NCT02864017|Dietary Supplement|L-Citrulline|
1514010|NCT02864017|Dietary Supplement|Placebo|
1514011|NCT02864004|Drug|Apomorphine|Apomorphine (5 mg/ml) is supplied as solution for infusion in a 10 ml glass ampoule Hourly flow rate is adjusted during the whole duration of the study to doses of minimum 3 mg/hour up to a maximum of 10 mg/hour
1514012|NCT02864004|Other|Best Medical Treatment|Most efficient single treatment of Parkinson's disease symptoms or their combinations, in concordance with the guidelines of the European Federation of Neurological Societies
1514013|NCT02863991|Drug|ONC201|ONC201
1514014|NCT02863978|Other|Multimodal signal acquisitions|"Cardiac and respiratory signals are collected from the clinical monitoring routinely gathered in hospital neonatal units.
Movement quantification and baby's sounds are extracted thanks to a dedicated system which will collect images and sound with microphones and cameras."
1514015|NCT02863952|Other|Single photon emission computed tomography myocardial perfusion imaging|
1514016|NCT02863952|Device|novel cadmium-zinc-telluride (CZT) SPECT cameras|
1514017|NCT02863939|Device|Single photon emission computed tomography myocardial perfusion imaging|a novel cadmium-zinc-telluride (CZT) SPECT camera
1514018|NCT02863939|Other|exercise|
1514019|NCT02863926|Device|Injection of cBMA aspirate into the index leg|Injection of cBMA into the anterior tibialis muscle and upper index leg of subjects scheduled for semi-elective BKA 7-21 days before surgery
1514020|NCT02863913|Biological|PD-1 Knockout T Cells|PD-1 Knockout T Cells and PD-1 wild-type T Cells will be made by Cell Biotech Co., Ltd. 2x107/kg T cells will be used for test group and comparable group separately.
1514021|NCT02863913|Drug|Cyclophosphamide|"Cyclophosphamide at 20mg/kg single dose will be administered 3 days i.v. before cell infusion.
Interleukin-2 (IL-2) will be given in the following 5 days, 720000 international unit（IU）/Kg/day (if tolerant)."
1514022|NCT02863913|Drug|IL-2|Interleukin-2 (IL-2) will be given in the following 5 days after cell infusion, 720000 international unit（IU）/Kg/day (if tolerant).
1514023|NCT02863900|Other|cohort of BC of each subtypes|
1514024|NCT02863887|Behavioral|Weight loss intervention|The intervention will involve utilizing trained community health coaches to deliver the weight loss intervention. There will be 10 group based sessions conducted at each church over 6 months. Session frequency will be 4 weekly sessions (4) for the first month, bimonthly sessions for 2 months (4) and monthly sessions for 2 months (2). The study is based upon weight loss strategies that have been utilized in the Diabetes Prevention Program. The group sessions will be augmented by utilizing text messages. The text messages will be delivered weekly and three types of messages will be delivered: 1) lesson content, 2) motivational, 3) behavioral prompts.
1514025|NCT02863874|Device|VicrylPlus®|Suture
1514026|NCT02863874|Device|Vicryl®|Suture
1514027|NCT02863861|Drug|Dexmedetomidine-ketamine|
1514028|NCT02863861|Drug|propofol-ketamine|
1514029|NCT02863848|Dietary Supplement|OraftiR inulin‐type fructans|
1514030|NCT02863848|Dietary Supplement|Placebo|maltodextrin
1514031|NCT02863835|Other|EIT|All participants will have continuous monitoring of EIT whilst self venting
1514032|NCT02863835|Other|Salbutamol nebulisation and with CPAP|All participants will have continuous monitoring - salbutamol nebulisation will be given during 15 minutes using 5mg of salbutamol. Assessments on CPAP will be performed at 3 different level of pressure during this time.
1514033|NCT02863822|Behavioral|Low FODMAP Diet|Subjects in the experimental arm, will be educated in the low fermentable oligo-di-monosaccharides and polyols (FODMAP) diet.
1514034|NCT02863822|Behavioral|Choose My Plate Diet|Subjects in the active comparator arm will be educated in the ChooseMyPlate.gov Diet.
1514035|NCT02863809|Drug|Riboflavin|Riboflavin, a water soluble vitamin, is an essential nutrient and a natural component of many foods.
1514036|NCT02863809|Drug|Dextran|Dextran is used to increase the viscosity of the solution.
1514037|NCT02863809|Device|UVA Light Source|Avedro's KXL® System is a UVA irradiation system that uses a light emitting diode (LED) to deliver a dose of UVA light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.
1514040|NCT02863744|Procedure|coronally advanced flap with subepithelial connective tissue graft|"Under local anesthesia 2% lignocaine hydrochloride using a No. 15 BP (Bard Parker) blade full thickness flap will be elevated till the MGJ (mucogingival junction) using a small periosteal elevator and a partial-thickness flap will be raised beyond the mucogingival junction to allow a passive coronal displacement of the flap completely covering the CEJ without tension.
The donor site consisting of 2 mm thick palatal connective tissue graft will be harvested from the premolar to the first molar area using the 'trap door' technique.14 The connective tissue graft will be secured in position with 4-0 absorbable sutures in recipient sites.
The flaps will be stabilized with sling suture in a coronal position, followed by interrupted suture on releasing incisions in an apico-coronal direction using 4-0 absorbable sutures."
1514041|NCT02863731|Other|Alternating working postures, first day|On the first day of measurement participants execute five test battery trials in alternating postures (sit/stand/sit/stand/sit). On the second day of measurement participants execute the test battery in a sitting posture (sit/sit/sit/sit/sit).
1514042|NCT02863731|Other|Alternating working postures, second day|On the first day of measurement participants execute five test battery trials in a sitting posture (sit/sit/sit/sit/sit). On the second day of measurement participants execute the test battery in alternating postures (sit/stand/sit/stand/sit).
1514043|NCT02863718|Drug|Ibrutinib|Bruton's tyrosine kinase Inhibitor Ibrutinib 420mg daily
1514044|NCT02863718|Drug|Placebo|Placebo 420mg daily
1514045|NCT02863705|Drug|brimonidine tartrate/timolol malate Ophthalmic Solution|One drop of brimonidine tartrate/timolol malate (COMBIGAN®) Ophthalmic Solution in the affected eye, administered twice daily for 12 months
1514046|NCT02863705|Drug|bimatoprost ophthalmic solution 0.01%|Bimatoprost ophthalmic solution 0.01% (LUMIGAN®) administered once daily in the evening 5 minutes after COMBIGAN® instillation if additional lowering IOP is needed
1514048|NCT02863653|Other|observational study|application of several standard instruments in patients with rheumatoid arthritis
1514049|NCT02863640|Device|Color retinography|
1514050|NCT02863640|Device|Optical coherence tomography|
1514051|NCT02863640|Device|Fundus autofluorescence imaging|
1514052|NCT02863627|Other|Newborn Care Pathway|consultation with the pediatric emergency, two telephone interviews to complete Questionnaires with the parents after the emergency department visit
1514053|NCT02863614|Drug|Ibuprofen 600 mg|
1514054|NCT02863614|Drug|Lorazepam 1 mg|
1514055|NCT02863614|Drug|Placebo|
1514056|NCT02863588|Biological|seropositive for Toxoplasma gondii|blood sample
1514060|NCT02863562|Other|Kinesio taping|Kinesio taping technique was used on both ankles on the first day of training with the aim of functional and mechanical correction, following the method described by Duenas et al. It was removed on the second day of training. This procedure was repeated each week for one month.
1514061|NCT02863562|Other|Proprioceptive exercises|Proprioceptive exercises were performed twice a week for one month. They were incorporated into their normal training routine (twice per week), and included 20 min of standardised proprioceptive exercises: single leg balancing on stable surfaces, on bosu/togu balls, and hopping activities, all repeated with eyes open/closed.
1514062|NCT02863562|Other|Placebo Kinesio taping|
1514063|NCT02863549|Device|MitraClip in tricuspid valve|MitraClip in tricuspid valve
1514064|NCT02863536|Device|Polybactum®|3 cycles treatment one per month.. Duration of one cycle: 1 week; administration for each cycle: 1 ovule at Day 1, 1 ovule at Day 4; 1 ovule at Day 7.In the two following cycles, the same treatment will be repeated immediately after the end of the first and second menstrual bleeding.
1514065|NCT02863523|Behavioral|Integrated Behavioral Care|Patients receive intensive behavioral counseling that may include elements of cognitive behavioral therapy, problem solving therapy, and small changes lifestyle counseling in addition to medical care.
1514066|NCT02863510|Device|Renal Sympathetic Denervation|Renal sympathetic denervation is a minimally invasive, endovascular catheter-based procedure using radiofrequency ablation of sympathetic nerves located in the walls of renal arteries, aimed at treating treatment-resistant hypertension.
1514067|NCT02863497|Behavioral|Mindfulness-based Sex Therapy|These group sessions will include education about sexuality, and the practice of mindfulness skills (including paying attention to the present moment, and to body sensations). Each group will include 7-8 women, plus the group facilitators. The group facilitators for the study will include Dr. Laurel Paterson (who has extensive experience in administering Mindfulness-based sex therapy in other populations of women), and occasionally one of the research team members.
1514068|NCT02863484|Other|surgery|pealing of the outer layer of the cavernous sinus
1514070|NCT02863445|Drug|Levonorgestrel-based emergency contraception 1.5 mg|Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
1514071|NCT02863445|Drug|Levonorgestrel-based emergency contraception 3.0mg|Evaluating pharmacodynamic outcomes in obese women using 1.5mg versus 3.0mg of LNG-based EC
1514075|NCT02863406|Other|Bronchoalveolar lavage|Bronchoalveolar lavage in order to determine rate of dust
1514076|NCT02863393|Other|Diaphragmatic breathing exercise|Through diaphragmatic breathing exercise to verify the impact of this item interventions on patients' metabolism indicators.
1514077|NCT02863380|Procedure|Functional magnetic resonance imaging used to individualize rTMS protocol|Procedure consisting in personalizing the rTMS targets and stimulation pattern based on functional magnetic resonance imaging
1514078|NCT02863380|Device|Individualized rTMS (transcranial magnetic stimulation)|
1514079|NCT02863380|Device|Classical rTMS (transcranial magnetic stimulation)|
1514087|NCT02863315|Device|tsDCS|"Both groups use the same DC-Stimulator Plus (NeuroConn GmbH, Ilmenaus, Germany).
In the tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 20 min, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system)
In sham tsDCS group, anode electrode is placed over tenth thoracic vertebra to target spinal cord with 2mA for 30s, and the cathode (reference) electrode on the head vertex (in the Cz location according to the 10-20 EEG system). The current was discontinued after 30 s while the power indicator remained on."
1514088|NCT02863302|Other|Reflexology treatment|All patients will receive reflexology (a specialized foot therapy) from a certified reflexologist twice weekly from the beginning of chemotherapy treatment.
1514089|NCT02863276|Procedure|Intensified insulin therapy|
1514090|NCT02863263|Device|Foam Dressing|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device on its own. Subjects are randomised to one of 2 arms.
1514091|NCT02863263|Device|Foam Dressing with Povidone Iodine|The purpose of the study is not to compare between the 2 devices, but to determine the efficacy of each type of device own. Subjects are randomised to one of 2 arms.
1514092|NCT02863198|Device|endometrial injury|Endometrial injury was done only for patient of the study group. It was done on day 5, under complete aseptic conditions, no anesthesia, was given in most of cases. Endometrial local injury was performed on the posterior wall, midline, and 10-15 mm from the fundus using pipelle endometrial sampling (Pipelle).
1514093|NCT02863185|Drug|Pitavastatin|
1514094|NCT02863185|Drug|Atorvastatin|
1514095|NCT02863172|Behavioral|Questionnaires|"Consenting Proband Group: Participants fill out questionnaires about work, family history, medical history, and health habits at baseline. It should take about 20 minutes to complete the questionnaires. Participants also complete a health and lifestyle questionnaire, which contains 20 questions for men and 22 questions for women. Questionnaire should take about 10 minutes to complete. Follow-up questionnaire at least 1 time in 5 years to update medical, cancer, and family history.
Family Members (MDA Registered Patients) Group and Family Members (Not MDA Registered Patients) Group: Participants complete a health questionnaire, which collects information about their personal medical history, demographics (age, race, sex, and so on), and questions about their alcohol and tobacco use at baseline. Questionnaire should take about 20 minutes to complete. Participants complete follow-up questionnaire at least 1 time in 5 years to update their medical, cancer, and family history."
1514096|NCT02863172|Procedure|Blood Draw/Saliva Sample|About 2-3 tablespoons blood drawn. Participants may give a saliva sample instead.
1514097|NCT02863159|Device|Tecnis Multifocal 1-Piece IOL|+2.75D (ZKB00), +3.25D (ZKB00), +4.00D (ZMB00)
1514098|NCT02863133|Device|Liquid Embolic|The Easyx liquid embolic, manufactured by Antia AG, is intended to occlude hypervascular lesions in the brain such as tumors, arteriovenous malformations (a tangle of abnormal and poorly formed blood vessels) and dural arteriovenous fistulas (abnormal connection of blood vessels).
1514103|NCT02863107|Behavioral|Questionnaires|Participants complete questionnaires about work, family history, medical history, and health habits. Questions are about quality of life, well-being, concerns they may have, as well as the types of health care and follow-up care they are receiving.
1514104|NCT02863107|Procedure|Blood Draw|About 2 tablespoons blood collected 1 time.
1514106|NCT02863081|Other|Survey|Administered to healthcare providers
1514107|NCT02863081|Other|interview|Administered to patients and LAR (i.e., interviews)
1514108|NCT02863068|Drug|Topical Sodium Nitrite|"Subjects will have 0.1 cm of 2% sodium nitrite cream applied per 1 cm2 of the total ulcerated area. Areas will be rounded to the nearest 1 cm2. If a subject has more than one ulcer, all of them will be treated with either study cream in this intervention."
1514109|NCT02863068|Other|Placebo|Subjects will have Placebo applied to total ulcerated area. If a subject has more than one ulcer, all of them will be treated with placebo in this intervention.
1514110|NCT02863055|Drug|Nintedanib|Nintedanib 200 mg administered twice daily
1514111|NCT02863055|Drug|Placebo|Matching placebo administered twice daily
1514112|NCT02863042|Procedure|Repair Deltoid Tendon|
1514113|NCT02863042|Other|Ankle Fracture Without Deltoid Tendon Repair|Standard of care
1514114|NCT02863029|Procedure|Flexible Sigmoidoscopy|A sigmoidoscopy is the minimally invasive medical examination of the large intestine from the rectum through the last part of the colon, using a flexible endoscope.
1514115|NCT02863016|Device|SelectBag One|Each patient will be subjected to two stages of each month, where it will be treated with online HDF postdilution with two kind of concentrates: acetic acid (Ac-HDF) and acetate-free citrate containing one (HDF-Cit ). For each of the sessions will be used online HDF postdilution with TMP biofeedback (UltraControl) and Filter high permeability.
1514116|NCT02862977|Drug|ketoprofen and cyclobenzaprine association with caffeine|The patient will take 2 tablets (combination of ketoprofen and cyclobenzaprine and caffeine), oral, per day, each 12h
1514117|NCT02862977|Drug|Cyclobenzaprine with caffeine|The patient will take 2 tablets (combination of cyclobenzaprine and caffeine), oral, per day, each 12h
1514118|NCT02862964|Other|identify L4/L5|"For each participant, a provider will first attempt to identify the L4/L5 space using the traditional technique of palpating the iliac crests to estimate spinal level. The provider will mark this space on the person's back with a single dot from a marking pen. The provider will then use the Accuro to again attempt to identify the L4/L5 interspace and mark this point with two dots.
The participant will then be taken into the fluoroscopy suite for their scheduled procedure a metal instrument will be laid on the skin at the interspace or interspaces that were marked using the palpation and Accuro techniques. Metal instruments show up on fluoroscopy, but the skin markers will not.
The anesthesiology attending in the fluoroscopy suite will then confirm the true interspace position of these marks under fluoroscopy performed for the standard of care procedure"
1514157|NCT02862613|Procedure|TACE|Lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg.According to tumor area of maximum diameter,0.1～0.2ml/cm2 Hepatic arterial infusion.
1514119|NCT02862938|Drug|NT-501 ECT implant|NT-501 ECT implant will be placed into the vitreous and out of the visual axis of the study eye. The surgical procedure involves making a small incision through the sclera (white part of the eye), inserting the implant and securing it with a suture.
1514120|NCT02862938|Other|Sham|Sham surgery
1514121|NCT02862925|Procedure|Fetal Scalp Stimulation|"During a routine vaginal exam, if there is concern for fetal distress based on local definitions, the midwife will gently stroke the fetal head with her finger. She will then observe for a rise in the fetal heart rate as observed by the Doppler monitor. A rise to above 15 beats per minute above the baseline is termed an acceleration and NEGATIVE test. Absence of an acceleration is a POSITIVE test and reason for intervention."
1514122|NCT02862912|Drug|Chloroprocaine|Administered as a single injection or continuously through an indwelling catheter - 50 mg
1514123|NCT02862912|Drug|Bupivacaine|A dextrose Solution is usually given as an injection - 9 mg (1.4 ml)
1514124|NCT02862912|Drug|Fentanyl|15 mcg Fentanyl will be included int he spinal anesthetic in both groups
1514125|NCT02862912|Drug|Saline|Preservative free normal saline (0.3 ml) to bring the volume to ~ 2 ml
1514126|NCT02862899|Device|Thermowire|
1514127|NCT02862886|Other|myometrium biopsy|
1514128|NCT02862873|Procedure|Spinal anaesthesia|
1514129|NCT02862873|Drug|Ondansetron|
1514130|NCT02862873|Other|saline solution|
1514131|NCT02862860|Biological|blood sample|
1514132|NCT02862860|Biological|urine sample|
1514133|NCT02862860|Device|installation of Holter|
1514134|NCT02862847|Other|stool samples|
1514135|NCT02862834|Genetic|High-throughput exome sequencing|
1514136|NCT02862821|Other|HR-EEG|
1514137|NCT02862795|Procedure|HPV detection in anal canal samples|Additional anal taking during the colonoscopy with cytobrush
1514138|NCT02862782|Drug|hCG (Ovitrelle 250 mcg mcg - Merck Serono)|
1514139|NCT02862782|Drug|hCG (Ovitrelle 250 mcg mcg - Merck Serono) + GnRH agonist (Decapeptyl 0.2mg - Ferring Gmgh)|
1514140|NCT02862769|Drug|Lidocaine|. Perioperatively, when lidocaine is administered as a continuous infusion at clinically relevant doses (1-2 mg/kg/hr) results in plasma concentration below 5µg.mL-1. At this plasma level, it is adequate to attenuate sympathetic responses , decrease pain and demonstrate a significant opioid sparing effect.
1514141|NCT02862769|Drug|Saline|The second group will include those who receive a intraoperative placebo infusion(saline infusion) (Induction bolus dose of 1.5 mg/kg body weight followed by a continous saline infusion 1.5 mg/kg/hr.
1514144|NCT02862730|Device|Artificial Pancreas Controller in Dual Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
1514145|NCT02862730|Device|Subject's insulin pump|Subject will continue on their subcutaneous delivery of insulin on his/her own insulin pump using their own basal rates and carb ratios for meal boluses, managing their blood sugar as they normally would.
1514146|NCT02862730|Device|Artificial Pancreas Controller in Single Hormone Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
1514147|NCT02862730|Device|Artificial Pancreas Controller in Predictive Low Glucose Suspend Mode|The artificial pancreas controller contains an algorithm for managing blood glucose in people with type 1 diabetes which includes an exercise detection component. The new algorithm will have 3 modes: a single hormone closed-loop insulin only mode, a dual-hormone closed-loop insulin and glucagon mode and an insulin only mode with predictive low glucose suspend. Closed-loop Artificial Pancreas Controller includes insulin delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to one Tandem t:slim insulin pumps filled with insulin.
1514148|NCT02862704|Biological|MG7-CART|Ultrasound-guided intra-tumor injection as the route of T cell delivery, so that more T cells gathered at the tumor site, less migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And MG7-CART is a 2nd CAR, with MG7 as the target protein, 4-1BB as co- stimulator
1514149|NCT02862691|Drug|Acetaminophen/Oxycodone (Oral analgesic)|2 oral tablets of acetaminophen 325 mg plus oxycodone 5 mg given once
1514150|NCT02862691|Drug|Bupivicaine (Injectable local anesthetic)|local injection of bupivicaine 0.5% at root of maxillary tooth or nerve block for mandibular tooth
1514151|NCT02862678|Other|diffusion-weighted MRI|Two diffusion-weighted MRI will be performed (one 8 days before chemoradiotherapy treatment and one 3 months after the end of chemoradiotherapy treatment).
1514152|NCT02862665|Drug|iron isomaltoside 1000 (Monofer®)|The patients will receive iron isomaltoside 1000 (Monofer®) as an i.v. infusion of 1000 mg (diluted with normal saline, 10 mg/ml) twice; 3 days before surgery and 3 days after surgery. They will receive iron isomaltoside 1000 (Monofer®) 1000 mg over 15 min.
1514153|NCT02862665|Drug|normal saline 100 ml|The patients will receive normal saline 100 ml as an i.v. infusion twice; 3 days before surgery and 3 days after surgery. They will receive normal saline 100 ml over 15 min.
1514154|NCT02862652|Other|Blood sample|Blood sample to quantify microparticles and to study expression and activity of the tissue factor on their surface
1514155|NCT02862639|Device|Experimental group|patient receive intra articular injection (hip joint) of viscosupplementation in combination with corticosteroid
1514156|NCT02862639|Device|control group|patient receive intra articular injection (hip joint) of corticosteroid alone
1514158|NCT02862613|Biological|Precision Cells|DC cell suspension (1×107 DC+ physiological saline + 0.25% human bloodalbumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
1514159|NCT02862600|Drug|Perhexiline|Period 1 (Weeks 1-8) and Period 2 (Weeks 9-16): dose titrated to two different plasma levels of perhexiline
1514160|NCT02862600|Device|Use of bioanalytical assay to monitor plasma levels of perhexiline|The bioanalytical assay is the device under investigation. It will be used to monitor plasma levels of perhexiline. The data obtained from this analysis will be used to guide dose adjustments of perhexiline.
1514161|NCT02862587|Drug|Chemotherapy|Cisplatin：60mg/m2，Gemcitabine：1g/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
1514162|NCT02862587|Biological|precision cells|precision cells DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PNAT/PMAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
1514163|NCT02862574|Drug|Andecaliximab|Administered via subcutaneous injection once weekly
1514164|NCT02862574|Drug|Placebo|Administered via subcutaneous injection once weekly
1514165|NCT02862574|Drug|Methotrexate|Administered orally weekly as part of the participant's current treatment regimen
1514166|NCT02862574|Drug|TNF Inhibitor|An approved stable subcutaneous formulation of one of the following TNF inhibitors may include adalimumab, certolizumab, entanercept, or golimumab.
1514167|NCT02862561|Drug|Chemotherapy|Cisplatin：60mg/m2，5-FU：500mg/m2,Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
1514168|NCT02862561|Biological|Precision Cells|DC cell suspension (1×10*7 DC+physiological saline + 0.25% human bloodalbumin)1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. Precision cells suspension (1-6×109 Precision cells + physiological saline + 0.25% human bloodalbumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63.
1514169|NCT02862548|Drug|TAF|25 mg tablet administered orally once daily
1514170|NCT02862548|Drug|TDF|300 mg tablet administered orally once daily
1514171|NCT02862535|Drug|Andecaliximab|Administered via intravenous (IV) infusion every 3 weeks
1514172|NCT02862535|Drug|S-1|Administered orally twice daily for the first 14 days of the 21 day cycle
1514173|NCT02862535|Drug|Cisplatin|Administered via IV infusion on Day 8 of every 5 weeks
1514174|NCT02862535|Drug|Oxaliplatin|Administered via IV infusion on Day 1 of each 21-day cycle
1514175|NCT02862535|Drug|Nivolumab|Administered via IV infusion every 2 weeks
1514176|NCT02862522|Other|Questionnaire of overall health|The standardized questionnaire was used to assess occurrence of major adverse cardiovascular events including stroke, re-hospitalization, myocardial infarction or death. Responses were verified by medical record review conducted by an investigator blinded to the results of the standardized questionnaire.
1514177|NCT02862509|Drug|Budesonide nasal instillation|
1514178|NCT02862509|Drug|Normal saline nasal instillation|
1514179|NCT02862483|Drug|Tamsulosin 0.2mg|
1514180|NCT02862483|Drug|Tadalafil 5mg|
1514181|NCT02862483|Drug|Placebo for Tamsulosin|
1514182|NCT02862457|Drug|INCB024360 25 mg|25 mg tablet administered orally, twice a day (BID) on Days 1-5 and Days 8-28 of Cycle 1 (28-day Cycle) and Days 1-21 of Cycles 2 through 35 (21-day Cycles) for INCB024360 Cohort and on Days 1-21 of Cycles 1 through 35 (21-day Cycles) for INCB024360 + MK-3475 Cohort.
1514183|NCT02862457|Drug|INCB024360 100 mg|100 mg tablet administered orally, twice a day (BID) on Days 1-5 and Days 8-28 of Cycle 1 (28-day Cycle) and Days 1-21 of Cycles 2 through 35 (21-day Cycles) for INCB024360 Cohort and on Days 1-21 of Cycles 1 through 35 (21-day Cycles) for INCB024360 + MK-3475 Cohort.
1514184|NCT02862457|Drug|INCB024360 300 mg|300 mg tablet administered orally, twice a day (BID) on Days 1-5 and Days 8-28 of Cycle 1 (28-day Cycle) and Days 1-21 of Cycles 2 through 35 (21-day Cycles) for INCB024360 Cohort and on Days 1-21 of Cycles 1 through 35 (21-day Cycles) for INCB024360 + MK-3475 Cohort.
1514185|NCT02862457|Biological|pembrolizumab 200 mg|Administered as an intravenous (IV) infusion on Day 8 of Cycle 1 (28 days) and Day 1 of Cycles 2 through 35 (21-day Cycles) for INCB024360 Cohort and on Day 1 of Cycles 1 through 35 (21-day Cycles) for INCB024360 + MK-3475 Cohort .
1514186|NCT02862444|Other|Culturally Appropriate Intervention|Women in the intervention arm will receive a culturally appropriate intervention that will be provided to them according to the five strategies of culturally appropriate interventions of Kreuter et al. (2003).
1514187|NCT02862431|Drug|JNJ-64565111|Participants will receive JNJ-64565111 subcutaneously in the abdomen on Days 1, 8, 15 and 22.
1514188|NCT02862431|Drug|Placebo|Participants will receive Placebo subcutaneously in the abdomen on Days 1, 8, 15 and 22.
1514189|NCT02862418|Other|UTE MRI|One MRI with UTE settings will be acquired.
1514190|NCT02862405|Other|vision tests|
1514193|NCT02862379|Behavioral|home-based program|The objective of the rehabilitation program is to reduce the risk of falls after management of the risk factors identified. This intervention is a home-based program combining exercises, home modifications and education on fall risk factors
1514194|NCT02862366|Other|Blood sampling|Blood sampling every 6 month following the routine calendar of visit
1514196|NCT02862340|Genetic|Genetic test|
1514197|NCT02862327|Drug|intravenous dexamethasone|intravenous injection of dexamethasone
1514198|NCT02862327|Drug|intravenous placebo|intravenous injection of placebo
1514199|NCT02862327|Drug|perineural ropivacaine|brachial plexus block with perineural injection of Ropivacaine in the axillary fossa
1514200|NCT02862327|Other|ultrasound guidance|ultrasound guidance for brachial plexus block in the axillary fossa
1514201|NCT02862314|Biological|Blood sample|
1514203|NCT02862288|Device|Microwave ablation with Acculis Accu2i pMTA Applicator|
1514204|NCT02862275|Drug|Atezolizumab|Given IV
1514205|NCT02862275|Other|Laboratory Biomarker Analysis|Correlative studies
1514206|NCT02862262|Device|ARIES Bordetella Assay|
1514207|NCT02862249|Biological|Faecal microbiota transplantation|The FMT (200mls) will be administered following preparation of the bowel with MoviPrep®, into the duodenum via a gastroscope derived from 50g of fresh donated stool from a healthy donor. The gastroscopy will be performed as per the King's College Hospital Gastroenterology Protocol.
1514208|NCT02862249|Biological|Placebo|An identical appearing placebo solution (200mls 0.9% normal saline and 12.5% glycerol) will be administered into the duodenum via a gastroscope in a single blinded fashion following preparation of the bowel with MoviPrep®.
1514209|NCT02862236|Drug|Hypericum perforatum extract|250 or 500 mg Remotiv capsules of hypericum perforatum extract, p.o.
1514210|NCT02862236|Drug|Alprazolam|0.25 mg Xanagis capsules of Alprazolam, p.o.
1514211|NCT02862223|Dietary Supplement|Neoprinol|
1514212|NCT02862210|Drug|Lithium Carbonate|Lithium will be prescribed starting at 150 mg/day, with subsequent dose titration to 300, 450, and 600 mg/day as tolerated according to side effects and blood lithium level.
1514213|NCT02862210|Drug|Placebo|Placebo will be prescribed starting at 1 pill per day, with subsequent dose titration to 2,3, and 4 pills per day as tolerated by sham blood lithium levels.
1514214|NCT02862171|Drug|Dapivirine Vaginal Ring-004|To assess the safety profile of the 25 mg Dapivirine Vaginal Ring-004, when inserted at monthly intervals, in an open-label trial
1514215|NCT02862158|Device|FDT visual field|
1514216|NCT02862158|Device|Standard HVF|
1514217|NCT02862145|Drug|MRX34|Treatment of melanoma with pharmacodynamics biopsy of tissue and blood
1514218|NCT02862145|Drug|Dexamethasone|Premedication during the week of treatment
1514219|NCT02862132|Drug|Vedolizumab|
1514220|NCT02862119|Procedure|FFR Treatment Arm|Fractional Flow Reserve-guided PCI of non-culprit lesions during index hospital admission
1514221|NCT02862119|Other|Conservative Treatment Arm|Initial Conservative management of non-culprit lesions during index hospital admission
1514222|NCT02862106|Biological|εPA-44|subcutaneously injection of εPA-44 900μg at week 83,86,89,92,95,98,101,104,108,112,116,120,124,128
1514223|NCT02862093|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation of the dorsolateral prefrontal cortex
1514224|NCT02862067|Other|Assessment of cardiorespiratory fitness|Assessment of cardiorespiratory fitness
1514225|NCT02862054|Procedure|splenectomy|
1514226|NCT02862041|Device|Echogenic needle - Pajunk sonoplex echogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
1514227|NCT02862041|Device|Non Echogenic needle - Stimuplex Braun Nonechogenic needle|Ultrasound guided infraclavicular brachial plexus block for upper extremity surgeries
1514228|NCT02862028|Biological|HerinCAR-PD1 cells|herinCAR-PD1 cells transfusion: (1-5×107/kg herinCAR-PD1 + physiological saline + 0.25% human alloalbumin) 300ml for each infusion. IV (in the vein) for each infusion, 2 cycles, each cycle received one infusions on day 21, 43.
1514231|NCT02862002|Other|"therapeutic education of type caratif"|"study the effects of a therapeutic education program type caratif, based on a communication pedagogy, with the patient receiving opioid therapy in medical oncology"
1514232|NCT02862002|Other|Standard care|patients receiving standard care of cancer pain.
1514233|NCT02861989|Other|qualitative study|
1514234|NCT02861976|Other|Opioid risk screen development & implementation|Development of a screening tool for the risk of opioid misuse in patients with traumatic injury.
1514235|NCT02861963|Procedure|Experimental: RVOT reconstruction by femoral allogenic vein valve conduit|Right ventricular outflow tract reconstruction using femoral allogenic vein valve conduit under CPB and induced ventricular fibrillation
1514236|NCT02861963|Procedure|Modified Blalock-Taussig shunt|"Shunt formed between the right subclavian and pulmonary arteries or the left subclavian and pulmonary arteries of the type end to side."
1514237|NCT02861950|Drug|Caudal block with ropivacaine|Patients in this arm will receive a caudal block with ropivacaine
1514238|NCT02861950|Drug|penile nerve block with bupivacaine|Patients in this arm will receive a penile block with bupivacaine
1514240|NCT02861924|Other|microcirculatory responses|"The effect of the duration and intensity of the pressure; reproducibility and correlation with ischemic hyperemia post.
measurements are made with the Imager SPECKLE imager (LSCI) give the microvascular perfusion data in arbitrary units called perfusion units (UP)."
1514241|NCT02861911|Other|Current flow between sensory and motor threshold|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
1514242|NCT02861911|Device|Current intensity upper of motor threshold by Kneehab XP technology|Artificial strength training by means of neuromuscular electrical stimulation (NMES)
1514243|NCT02861898|Drug|Intra-arterial Cetuximab|
1514244|NCT02861898|Drug|Intra-arterial Mannitol|
1514245|NCT02861885|Other|Chromoendoscopy|Colonoscopy will run in accordance with standard procedure, including air insufflation throughout the endoscope rise. The endoscope will be a Olympus NBI videoscope (180 series and latest). First, progression will run until caecum without systematic terminal ileum intubation. Polyps will be searched out during descent phase. The patient will be eligible as soon as the operator suspects an ascendant colon SSL with white light. The operator will have to initiate the WLI colonoscopy. If a SSL is suspected in the colon, the operator will run at the same time, a NBI colon examination, then an indigo carmine chromoendoscopy colon examination. Each lesion will be pictured before and after mucus clean-up. Lesions biopsy or resection will be ran in accordance with standard procedure.
1514246|NCT02861859|Drug|Olanzapine|Olanzapine 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
1514247|NCT02861859|Drug|Olanzapine Placebo|Olanzapine Placebo 5 mg (2 x 2.5 mg) PO OD (once a day) on days 1-4.
1514248|NCT02861846|Biological|profile of CSF biomarkers of AD|dosage of biomarker of AD
1514249|NCT02861833|Other|nursing support|Determining the Variability of adaptation strategies and correlations with specific nursing management, individual and contextual characteristics of patients with cancerous wounds
1514250|NCT02861820|Device|MRI: Brain Imaging Data Collection|This study has no intervention, it is observational. The investigator will collect brain imaging data and behavioral assessments.
1514251|NCT02861807|Device|Brain stimulation with mindfulness-based relapse prevention|Participants will participate in weekly or twice weekly group mindfulness based relapse prevention (MBRP) + transcranial direct current stimulation (tDCS) intervention sessions for up to eight weeks. All participants will receive 8 two hour sessions of MBRP + tDCS, regardless of the group schedule. Subjects will receive 30 minutes of either active or sham tDCS stimulation, depending on their group assignment. After tDCS, sessions will include discussions of mindfulness as a means of coping with craving, cognitions, and emotions, role play exercises, and mindfulness practice.
1514252|NCT02861794|Procedure|GMK Sphere|Total Knee Replacement
1514253|NCT02861781|Other|Collection of blood samples and tissues|Collection of blood samples and tissues during bariatric surgery and blood samples during followup visits
1514254|NCT02861768|Biological|Pharyngeal swab|
1514255|NCT02861755|Behavioral|Positive Affect Skills Training|Blend of enhancements may include: 5-minutes of facilitator contact, an online discussion board, or gamification via virtual flower badges.
1514256|NCT02861755|Behavioral|5-week Emotion Reporting|
1514257|NCT02861742|Other|Delivery of questionnaires|After patient and partner information, clinical research associate or clinical research nurse will give to the couple 2 booklets containing 5 questionnaires, respectively T1, T2, T3, T4 and T5.
1514258|NCT02861742|Behavioral|Questionnaire T1 to fill|T1 is to fill before chemotherapy.
1514259|NCT02861742|Behavioral|Questionnaire T2 to fill|T2 is to fill after the 6th cycle of chemotherapy.
1514260|NCT02861742|Behavioral|Questionnaire T3 to fill|T3 is to fill at the end of radiotherapy.
1514261|NCT02861742|Behavioral|Questionnaire T4 to fill|T4 is to fill 4 month after beginning of hormonotherapy or surveillance if no hormonotherapy.
1514262|NCT02861742|Behavioral|Questionnaire T5 to fill|T5 is to fill 1 year after the beginning of hormonotherapy or surveillance if no hormonotherapy.
1514263|NCT02861729|Other|Vita Suprinity|zirconia reinforced lithium silicate partial coverage restorations
1514264|NCT02861729|Other|IPS e.max|lithium disilicate partial coverage restorations
1514265|NCT02861716|Drug|Bupivacaine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.
After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight in 2ml volume and it will be injected slowly over 20 seconds."
1514266|NCT02861716|Drug|Fentanyl|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.
After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus fentanyl 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
1514267|NCT02861716|Drug|Dexmedetomidine|"premedication with Ondansetron (Zofran®) 0.1 mg/kg and Diazepam ( 0.01 mg/kg ), then general anesthesia will be induced with inhalation of sevoflurane 8% in oxygen via face mask. After that intravenous cannula will be placed, and fluid therapy will be standardized during and after surgery.
After securing the tube in place, the patients will be placed in the lateral decubitus position and a single dose of intrathecal anesthesia will be performed using a 25 gauge needle (Brown ®, Germany) and free flow of CSF technique. Then children will receive intrathecal bupivacaine (0.5%) 0.4mg/kg body weight plus dexmedetomidine 0.2 μg/kg in 2ml volume and it will be injected slowly over 20 seconds."
1514268|NCT02861703|Behavioral|Face-to-face lifestyle intervention|In-person, group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
1514269|NCT02861703|Behavioral|Online lifestyle intervention|Online, computer-mediated interactive group-based lifestyle intervention addressing thoughts, feelings, behaviours related to eating, physical activity, and other psychosocial issues related to breast cancer survivorship (e.g., mood, body image, existential issues, social support).
1514270|NCT02861690|Drug|Liposomal Paclitaxel|Patients received Liposomal Paclitaxel 175mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
1514271|NCT02861690|Drug|Nedaplatin|Patients received Nedaplatin80mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.
1514272|NCT02861677|Other|pharmaceutical care|
1514273|NCT02861664|Other|Stannous fluoride|Dentifrice containing 0.454% weight by weight (w/w) stannous fluoride and 0.072% w/w sodium fluoride
1514274|NCT02861664|Other|Sodium monofluorophosphate|Dentifrice containing 1400 parts per million (ppm) fluoride as sodium monofluorophosphate
1514275|NCT02861651|Other|DNA sequencing|
1514276|NCT02861638|Device|Experimental group|Video of the exercises
1514277|NCT02861638|Device|Control group|video of nature scenes
1514278|NCT02861638|Device|Conventional physiotherapy|Mobilization, exercises and transfer practice.
1514279|NCT02861625|Behavioral|Letter of condolence and post-death medical consultation|Process of sending a letter of condolence with consultation proposition.
1514280|NCT02861612|Procedure|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
1514281|NCT02861599|Other|proprioceptive therapy|
1514282|NCT02861599|Other|speech therapy|
1514287|NCT02861573|Biological|Pembrolizumab 200 mg|IV Q3W
1514288|NCT02861573|Drug|Olaparib 400 mg|Eight 50-mg capsules PO BID
1514289|NCT02861573|Drug|Docetaxel 75 mg/m^2|IV Q3W
1514290|NCT02861573|Drug|Prednisone 5 mg|One 5-mg tablet PO BID
1514291|NCT02861573|Drug|Enzalutamide 160 mg|Four 40-mg capsules PO QD
1514292|NCT02861573|Other|Dexamethasone 8 mg|Premedication for Cohort B given PO at 12, 3, and 1 hours prior to docetaxel infusion Q3W
1514293|NCT02861560|Other|dHACM|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA)
1514294|NCT02861547|Other|death|
1514297|NCT02861521|Device|Shoe lift|Subjects will be given a shoe lift post-knee replacement to correct leg length discrepancy
1514298|NCT02861521|Device|Sham|Sham shoe modification
1514299|NCT02861508|Other|Point-of-care ultrasound|
1514300|NCT02861508|Other|Usual care|
1514301|NCT02861495|Device|Humeral Compression/Distraction (CD) Nail|Surgical fixation of humeral shaft fractures with Humeral Compression/Distraction (CD) Nail implant
1514302|NCT02861482|Device|Bakri Balloon|Gradually increase the liquid volume inside Bakri Balloon to 250-500ml until bleeding is decreased or stopped
1514303|NCT02861482|Drug|Oxytocin|using oxytocin(usage:20IU oxytocin in 500ml lactated Ringer's, ivgtt to a maximum of 60IU) for the first step when dealing with PPH before laying Bakri Balloon
1514304|NCT02861482|Drug|Hemabate|using Hemabate (usage:250-500ug im) for the first step when dealing with PPH before laying Bakri Balloon
1514305|NCT02861482|Drug|Duratocin|using Duratocin (usage:100ug iv) for the first step when dealing with PPH before laying Bakri Balloon
1514306|NCT02861482|Procedure|Uterine Massage|continuous uterine massage for the first step when dealing with PPH before laying Bakri Balloon
1514307|NCT02861482|Procedure|B-lynch Suture|One of conservative surgical procedures if Bakri Balloon didn't work
1514308|NCT02861482|Procedure|Uterine Artery Embolization using sponges|One of conservative surgical procedures if Bakri Balloon didn't work
1514309|NCT02861482|Procedure|Cervical cerclage|One of conservative surgical procedures if Bakri Balloon didn't work
1514310|NCT02861482|Procedure|Hysterectomy|Hysterectomy with all the above measures not working
1514311|NCT02861482|Drug|Blood Product|transfusion of blood product if necessary no matter which surgical procedure has been taken
1514312|NCT02861469|Other|Semi-structured interviews|individual semi-structured interviews with general practitioners and family members
1514313|NCT02861456|Other|Standard Model of Care|
1514314|NCT02861456|Other|Alternative Model of Care|
1514315|NCT02861443|Behavioral|practice of colonic irrigation|
1514316|NCT02861430|Procedure|Immunochemistry and molecular biology on sentinel lymph node specimen|
1514326|NCT02861404|Genetic|skin flakes collection|viral status assessment of skin flakes
1514327|NCT02861391|Device|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
1514328|NCT02861378|Drug|Phentolamine mesylate|Injection of 1ml at lidocaine injection site
1514329|NCT02861378|Drug|Water|Injection of 1ml of physiologic saline water at injection site
1514330|NCT02861352|Other|Diet zinc|4 mg zinc, as zinc sulfate, was added to a controlled diet; 25 mg supplemental zinc was given during the final recovery period when an ad lib diet was consumed
1514331|NCT02861339|Device|Opthalmologic measure with DM OPD scan III (Nidek)|Bilateral measure of corneal refractometry, pachymetry, topography and aberrometry
1514332|NCT02861326|Device|Gracey Curettes|
1514333|NCT02861313|Device|CM LOC attachment|CM LOC attachment
1514334|NCT02861313|Device|ball attachment|Ball attachment
1514335|NCT02861300|Drug|CB-839|Patients will receive CB-839 orally twice daily during each cycle. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
1514336|NCT02861300|Drug|Capecitabine|capecitabine will be given orally twice daily for 14-21 days of cycles. Each cycle will be 21 days long. Disease assessment will occur after cycle 3.
1514337|NCT02861287|Other|Economic evaluation|
1514338|NCT02861274|Device|pacemaker|
1514339|NCT02861261|Drug|1. Berberine hydrochloride tablets ; 2. ProMetS probiotics powder|"0.6g (6 pills) of Berberine tablets administered twice a day orally before meal ;
4g (2 strips) of ProMetS probiotics powder administered orally every night"
1514340|NCT02861261|Drug|1. Berberine placebo tablets ; 2. ProMetS probiotics powder|"6 pills of Berberine placebo tablets administered twice a day orally before meal;
4g (2 strips) of ProMetS probiotics powder administered orally every night"
1514341|NCT02861261|Drug|1. Berberine hydrochloride tablets; 2. Probiotics placebo powder|"0.6g (6 pills) of Berberine tablets administered twice a day orally before meal;
2 strips of probiotics placebo powder administered orally every night"
1514342|NCT02861261|Drug|1. Berberine placebo tablets; 2. Probiotics placebo powder|"6 pills of Berberine placebo tablets administered twice a day orally before meal;
2 strips of probiotics placebo powder administered orally every night"
1514343|NCT02861248|Procedure|Fractional micro-plasma radiofrequency treatment|After the patient's scars were subjected to a mild cleanser and 70% alcohol, a topical cream of 5% lidocaine hydrochloric acid (Beijing Ziguang Medication Manufacture Corporation Ltd, Beijing, China) was applied to the entire scar surface under occlusion for 60−90 min before treatment to achieve local anesthesia. Fractional micro-plasma radiofrequency treatment (Pixel RF, Accent XL; Alma Lasers, Caesarea, Israel) was applied using a roller tip at 50−80 watts. Three or four passes were made in different directions over each affected area. A high rolling speed of roughly 5 cm/s was manually controlled. This treatment was accompanied by an air cooler (Cryo 5; Zimmer, Warsaw, IN, USA) for pain control. All patients attended three to five treatment sessions at intervals of 8−16 weeks.
1514344|NCT02861235|Other|Stress thallium-201 tomoscintigraphy, followed by a second rest tomoscintigraphy if necessary|with gamma-camera and D.SPECT camera
1514345|NCT02861235|Other|Rest technetium-99m tomoscintigraphy followed by stress technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Toulouse centre
1514346|NCT02861235|Other|Stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy on the same day|with gamma-camera and D.SPECT camera, in Nancy centre
1514347|NCT02861235|Other|stress technetium-99m tomoscintigraphy followed by rest technetium-99m tomoscintigraphy in two different days|with gamma-camera and D.SPECT camera, in Paris centre
1514348|NCT02861235|Other|Rest thallium-201 tomoscintigraphy with gamma-camera and D.SPECT camera|rest thallium-201 tomoscintigraphy for myocardial viability assessment
1514349|NCT02861235|Other|Rest technetium-99m tomoscintigraphy with gamma-camera and D.SPECT camera|rest technetium-99m tomoscintigraphy for myocardial viability assessment
1514350|NCT02861222|Drug|Doxorubicin|
1514351|NCT02861209|Other|Implementation of a care pathway|The care pathway will consist of procedures of care in the hospital (e.g. consultations with doctors, contact moments with nurses, ...) that describe the initiation of an oral anticancer therapy and the further follow up. The care pathway should describe how care can efficiently be organised.
1514352|NCT02861196|Procedure|Intensity modulated radiation therapy, Radical cystectomy|Postoperative Intensity modulated radiation therapy(IMRT) will be applied to effective team.Radical cystectomy will be applied to ineffective team.
1514353|NCT02861183|Device|OVT (Sodium Hyaluronate)|A Peri-osteotendinous injection of OVT will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
1514354|NCT02861183|Device|Saline|A Peri-osteotendinous injection of sterile saline will be administered into the soft tissue 1 cm from the lateral epicondyle at the point of greatest pain in two planes using a fanning technique. Two injections will be performed with a 22-25 gauge needle and spaced one week apart.
1514355|NCT02861170|Behavioral|Brief Mindfulness-Based Intervention|In addition to the educational materials that will be provided to all participants, the participants in the intervention group will also receive a 10-minute mindfulness-based intervention called a body scan. The body scan is a guided meditation exercise where participants are lead through focusing their attention on their body while maintaining awareness and acceptance of their sensations, emotions, and thoughts without trying to control or change them. The goal of the intervention is to increase mindfulness (i.e., moment-to-moment, non-judgmental and non-reactive awareness of sensations, emotions and thoughts), to provide self-regulation strategies, and to promote healthy and adaptive responses to stress.
1514356|NCT02861157|Behavioral|Planet T1D|Planet T1D is a mobile and web-based technology infrastructure specifically designed to (a) enhance youths' type 1 diabetes disease- and treatment-related knowledge through interactive and game-based educational materials; (b) support adherence to the treatment regimen through customized task prompts via mobile and web-based delivery; and (c) promote patient-provider communication through real-world data collection and feedback loops.
1514357|NCT02861144|Other|Ma ka hana ka ̒ike|Ma ka hana ka ̒ike is a self-management program for diabetic patients which includes 5 interactive group sessions lasting 1-1/2 hours in length delivered by community peer educators once a month for 6 months.
1514358|NCT02861144|Other|Hanapū Provider Toolbox|Hanapū Provider Toolbox is an educational tools that will aid the health care providers in guiding their patients to optimal glycemic control.
1514359|NCT02861131|Drug|Sugammadex|At the end of the surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Sugammadex will be dosed once at 2 mg/kg through an intravenous line with brisk flow
1514406|NCT02860754|Other|Six-minute walk test to perform before surgery|During the outpatient preoperative assessment, eligible patients will perform the six-minute walk test.
1514498|NCT02860039|Biological|Trivalent Influenza Vaccine|High dose Trivalent Influenza Vaccine given intramuscular
1514360|NCT02861131|Drug|Neostigmine|At the end of surgical procedure at a depth of neuromuscular blockade after the reappearance of T2 on the train-of-four, Neostigmine will be dosed once at 0.07 mg/kg to a maximum of 5 mg through an intravenous line with brisk flow. Glycopyrrolate will be administered with Neostigmine at a dose between 0.1 to 0.2 mg of Glycopyrrolate per 1.0 mg of Neostigmine administered.
1514361|NCT02861118|Other|No Intervention|
1514362|NCT02861105|Drug|LMWH|LMWH will be given on daily basis subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
1514363|NCT02861105|Other|0.9% saline solution|0.9% saline solution will be given subcutaneously every 24 hours starting one day after ovum pick up till documentation of fetal life by ultrasound at 7 weeks.
1514364|NCT02861079|Device|Foley catheter|An 18-F Foley catheter will insert into the endocervical canal and the balloon will fill with 30 mL of saline solution.
1514365|NCT02861079|Drug|PGE2|10 mg PGE2 vaginal ovul (Propess,Ferring®) will place high into the posterior vaginal fornix.
1514366|NCT02861066|Behavioral|Mindfulness-based Intervention|MBI will be delivered in group format, 120 minutes per week, for 6 consecutive weeks with 10-20 participants per group.
1514367|NCT02861053|Other|regular and moderate physical activity|regular and moderate physical activity will be done 3 times per week more than usual
1514368|NCT02861053|Other|No regular and moderate physical activity more than usual|regular and moderate physical activity will be done as usual
1514369|NCT02861040|Other|Laboratory Biomarker Analysis|Correlative studies
1514370|NCT02861040|Other|Pharmacological Study|Correlative studies
1514371|NCT02861040|Drug|Vincristine Sulfate Liposome|Given IV
1514372|NCT02861040|Drug|Volasertib|Given IV
1514373|NCT02861027|Procedure|PPTHA|The control group will receive Protocol Physiotherapeutic Total Hip Arthroplasty (PPTHA), consisting of guidelines on the care and post THA. The PPTHA, is held once a day, for 60 minutes, accompanied by a physiotherapist and has the following composition: 1 day) oral guidance and exercise to strengthen the gluteal muscles and muscles of the thigh, with recommendation for 3 repetitions of 12 movements, for each financial year. Patients are encouraged to sit outside the bed, after the exercises; Day 2) patients perform exercises the first day and begin the March training, with the aid of a Walker or crutches Canadians for the room; Day 3) patients perform exercises and are encouraged to walk in the hallway of the hospital wing. Day 4) reassessment and discharge.
1514374|NCT02861027|Procedure|FES and PPTHA|The PPTHA associated with FES. The stimulation protocol of FES is performed with the patient positioned in supine position in bed. After cleaning the skin, two electrodes are positioned in the posterolateral region of the thigh in motor point of the medium gluteus muscle. The total time for application of the apparatus 30 min per day totaling more 1 min per day as suggested in specialized references. The intensity is adjusted according to the tolerance of the patient. The apparatus used is wavelength Ibramed Neurodyn Compact.
1514376|NCT02861001|Device|conventional bronchoscopy|optical guidance of percutaneous tracheotomy is done by conventional bronchoscopy
1514377|NCT02861001|Device|VivaSight-SL tube|optical guidance of percutaneous tracheotomy is done by the VivaSight-SL tube
1514378|NCT02860988|Behavioral|MCCC treatment|Participants receive newly supported grant services to enhance fatherhood and parenting among individuals with substance use issues.
1514379|NCT02860975|Drug|Inhaled Nitrogen|"To create the correct gas mixture, nitrogen tanks or membrane technology nitrogen generators will be utilized.
Humidified, high flow, hypoxic gas by nasal cannula will allow the participant to walk short distances, eat, execute basic personal needs (e.g., use of toilette, washing, bathing etc.), or take breaks from wearing the mask."
1514380|NCT02860962|Drug|Dextromethorphan Hydrobromide|Dose as a single capsule preparation formulated by the Investigational Drug Service of MUSC specifically for the purposes of this trial.
1514381|NCT02860949|Drug|0.5% bupivacaine 100 mg, morphine sulfate 5 mg, 0.1% epinephrine 0.6 mg, and ketorolac 30 mg mixed NSS up to 100 mL|
1514382|NCT02860949|Procedure|Drug injection at Anterior soft tissue (25 mL)+Medial gutter area (25 mL)+Lateral gutter area (25 mL)+Posterior capsular infiltration (25 mL)|
1514383|NCT02860949|Procedure|Drug injection at Anterior soft tissue (34 mL)+Medial gutter area (33 mL)+Lateral gutter area (33 mL|
1514384|NCT02860936|Drug|Lenvatinib|Lenvatinib will be self orally administered at 24 mg daily, on a continuous basis in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Study drug should be taken at approximately the same time each morning.
1514385|NCT02860923|Drug|Exenatide|
1514386|NCT02860923|Drug|Placebo|
1514387|NCT02860910|Behavioral|Cognitive Behavioral Group Therapy|
1514388|NCT02860897|Drug|Premarin|Vaginal estrogen cream
1514389|NCT02860897|Drug|Vagifem|Vaginal estrogen tablet
1514390|NCT02860884|Procedure|liver biopsy|
1514391|NCT02860884|Other|infrared spectroscopy|
1514392|NCT02860871|Other|infrared spectroscopy|
1514393|NCT02860858|Biological|Intravitreous aflibercept injection|
1514394|NCT02860845|Device|Boric acid and probiotics|Vaginal capsules administered once a day during 7 days.
1514395|NCT02860845|Drug|Antibiotic (Clindamycin)|Vaginal capsules containing a reference antibiotic (when bacterial vaginosis is suspected) administered once a day during 3 days.
1514396|NCT02860845|Drug|Antifungal (Clotrimazole)|Vaginal capsules containing a reference anti-fungal (when candidiasis is suspected) administered once a day during 6 days.
1514397|NCT02860819|Drug|Veliparib|Veliparib 250mg BID, continuously
1514398|NCT02860819|Drug|Gemcitabine|Gemcitabine 800mg/m2, day 1 and 8
1514399|NCT02860819|Drug|Carboplatin|Carboplatin AUC = 4, day 1
1514400|NCT02860806|Drug|JNJ-63623872|3 mg/mL solution as intravenous (IV) infusion or a single oral 600 mg dose (2 tablets of 300 mg) under fasted conditions will be administered.
1514401|NCT02860806|Drug|Placebo|Intravenous infusion of matching placebo.
1514402|NCT02860793|Other|Bone marrow aspiration|
1514403|NCT02860793|Other|Blood sampling|
1514404|NCT02860780|Drug|prexasertib|Administered IV
1514405|NCT02860780|Drug|ralimetinib|Administered orally
1514407|NCT02860741|Behavioral|REJOICE|Small groups led by lay leaders undergo an 8-session faith-based behavioral activation protocol that provides individuals with education about: identifying depressive symptoms, identifying pleasurable activities, scheduling pleasurable activities, and identifying and addressing avoidant behaviors that act as barriers to completing pleasurable activities
1514408|NCT02860741|Other|Control|Churches in the control arm will receive an educational materials about identifying depressive symptoms and self-management options for addressing depressive symptoms.
1514409|NCT02860728|Behavioral|Individualized Resistance Training|Lower body resistance exercises will be prescribed in various combinations over multiple days and individually modified and progressed to achieve advances in both movement pattern, intensity, and exercise volume.
1514414|NCT02860689|Other|using questionnaires - International Index Erectile Function|using questionnaires
1514415|NCT02860676|Drug|cirmtuzumab|cirmtuzumab, dose based on ongoing phase 1 trial, q14days x 4 doses, then q28 days x 4 doses, until disease progression.
1514416|NCT02860663|Dietary Supplement|Vitamin D3|10 ug/d of vitamin D3 for 6 weeks
1514417|NCT02860663|Dietary Supplement|Vitamin D2|10 ug/d of vitamin D3 for 6 weeks
1514418|NCT02860663|Dietary Supplement|25OHD|10 ug/d of vitamin D3 for 6 weeks
1514424|NCT02860637|Other|Questionnaires|Sexual function was assessed by the International Index of Erectile Function (IIEF) and level and degree of injury were determined following the guidelines of the International Standards for Neurological and Functional Examination Classification of Spinal Cord Injury.
1514425|NCT02860624|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) being taken orally each morning on an empty stomach for 8 weeks
1514426|NCT02860624|Drug|40mg esomeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) being taken orally each morning on an empty stomach for 8 weeks
1514427|NCT02860572|Other|follow-up without intervention|
1514428|NCT02860572|Other|fluid bolus|
1514432|NCT02860533|Device|cuff device|Measurement of blood pressure during stress testing with cuff device
1514433|NCT02860533|Device|iphone|Measurement of blood pressure during stress testing with iPhone
1514434|NCT02860507|Drug|sugammadex|
1514435|NCT02860507|Drug|Neostigmine|
1514436|NCT02860507|Drug|Glycopyrrolate|
1514437|NCT02860494|Drug|Everolimus|Everolimus topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months. Dose regimens will be identical, regardless of the dose-strength of the topical formulation. The topical formulation will be applied onto areas of the face affected by FA by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
1514438|NCT02860494|Drug|Placebo|Placebo topical formulation will be applied to the affected areas, once daily, in the evening, for 6 months, by the patient or the patient's parents/legal guardians, while observing standardised precautions (avoiding the eyes, washing the hands after application, etc.).
1514439|NCT02860481|Procedure|blood sample for FSHR analysis|
1514440|NCT02860481|Procedure|blood sample for FSHR analysis|
1514443|NCT02860455|Device|RAD57 measurement (SpCO)|"SpCO measurement (Experimental)
Non invasive pulse CO-oximetry will be carried out by prehospital emergency nursing staff trained in the use of the Rad-57 pulse CO-oximeter (Masimo, Inc., Irvine, CA, USA), using the adult sized sensor (Sensor, Rev. B) placed on the 3rd or 4th digit, according to manufacturer recommendations. Nail polish will be removed if necessary. SpCO was expressed in total percentage of hemoglobin."
1514444|NCT02860455|Device|CO-oximeter|"COHb measurement (Active Comparator)
Venous blood will be collected into EDTA treated tubes (Beckton Dickinson) prehospitally and sent to the toxicology laboratory for further carboxyhemoglobin testing. Blood carboxyhemoglobin will be analyzed by derivative spectrophotometry using an automated CO-oximeter (IL 682, Instrumentation Laboratory SpA V.le Monza 338-20128 Milan, Italy). Blood carboxyhemoglobin will be detected within a range of 0-100% and accuracy of 0.5% and reported as percentage of total haemoglobin."
1514490|NCT02860078|Device|Ultrasound|Location and function of sacral epidural space with ultrasound
1514491|NCT02860078|Device|Radioscopy|Location and puncture of the sacral epidural space only with fluoroscopy
1514492|NCT02860065|Drug|CPC-201|solifenacin and donepezil
1514493|NCT02860065|Other|Positron emission tomography (PET)|measure activity of cerebral acetylcholinesterase
1514494|NCT02860052|Drug|SB208 2%|SB208 2% once daily
1514495|NCT02860052|Drug|SB208 4%|SB208 4% once daily
1514496|NCT02860052|Drug|SB208 16%|SB208 16% once daily
1514497|NCT02860052|Drug|Vehicle Gel|Vehicle Gel once daily
1514445|NCT02860442|Behavioral|Smartphone brief intervention (SP-BI)|"Participants in the SP-BI group will receive a 20-30 minute intervention through an app program based on the FRAMES format: providing personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-efficacy regarding making changes. The intervention is designed to address the target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan."
1514446|NCT02860442|Other|Enhanced Usual Care (EUC)|Those assigned to EUC will receive an informational brochure with resources available to members of the military related to mental health and alcohol use. They will be contacted to complete 3-, 6-, and 12-month follow-up assessments.
1514447|NCT02860429|Drug|Cinobufacini injection|cinobufacini injection 20ml mixed with 5% Glucose injection 500ml started at the first day of chemotherapy until seven days once a day.
1514448|NCT02860429|Drug|chemotherapy|Chemotherapy is the oxaliplatin combination with fluorouracil regimen.
1514449|NCT02860403|Procedure|motor imagery|Intervention consisted of supervised MI during which the participants were trained to imagine performing a single-joint wrist extension movement and a multiple-joint reach-to-grasp movement using tenodesis. The two movements were practiced in separate blocks and each 45 minute MI session consisted of six to eight blocks. Within a given block patients; i) performed the movement once, ii) imagined it using visual imagery (between five and ten repetitions), iii) performed the movement again, and iv) imagined it using kinesthetic imagery (between five and ten repetitions). All movements (performed and imagined) were timed by the experimenter to ensure that the durations of both imagined and physically practiced movements were similar. Imagery vividness was controlled with self-rated assessments using a visual analogic scale (from 0, the image or feeling was absent, to 10 when it was as clear or intense as physical practice).
1514450|NCT02860390|Other|Denver Health Asthma Management Program|text message (SMS) support including educational, motivational, and resource content.
1514451|NCT02860390|Other|Person of Support|Subjects in the adolescent cohort will designate a support person (e.g. parent) to receive messages from the Denver Health Asthma Management Program
1514452|NCT02860377|Procedure|recorded maternal voice|"A voice recording will be performed before the operation. At a preoperative visit or preoperative clinic, informed consent was obtained before the recording. On a calm environment, the mother was asked to speak following sentences.OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. 
At the end of surgery, the recorded maternal voice was delivered to the child every 15 seconds until he/she wakes up."
1514453|NCT02860377|Procedure|recorded stranger's voice|"A voice recording will be performed before the operation. On a calm environment, a blinded female investigator was asked to speak following sentences.OO (first name of child), wake up~. Let's go home with mommy. OO, wake up~. Open your eyes. Take a deep breath. "
1514454|NCT02860364|Procedure|Hypothermic circulatory arrest|During cardiac surgery requiring circulatory arrest, the patient's body temperature is lowered significantly to reduce the cellular metabolic rate and reduce ischemic injury.
1514455|NCT02860325|Device|NIV-NAVA|Non-invasive ventilatory support by means of neurally adjusted ventilatory assist (SERVO-n, Maquet, Solna, Sweden)
1514456|NCT02860325|Device|Conventional|Non-invasive ventilatory support by means of nCPAP or non-synchronized nIPPV (Infant Flow, CareFusion)
1514457|NCT02860312|Behavioral|Intradialytic exercise on stationary bicycles|Patients are exercising for 30-60 min during dialysis on an Rated Perceived Exertion (RPE) Scale between 12 and 14
1514458|NCT02860312|Behavioral|Non-exercising group|Patients are having their usual physical activity
1514459|NCT02860299|Drug|citrate 4%|
1514460|NCT02860299|Drug|unfractionated heparin|
1514461|NCT02860299|Biological|blood sample|
1514462|NCT02860286|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
1514463|NCT02860273|Device|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen at 21% in COPD patients involved in a Pulmonary Rehabilitation program.
1514464|NCT02860273|Device|Treadmill|Exercise capacity testing in COPD patients involved in a Pulmonary Rehabilitation Program.
1514465|NCT02860260|Biological|Blood samples|
1514466|NCT02860260|Other|Cerebral MRI|
1514467|NCT02860234|Drug|Oxaliplatin|
1514468|NCT02860234|Drug|Capecitabine|
1514469|NCT02860234|Radiation|intensity modulated radiotherapy|
1514470|NCT02860234|Procedure|DRE-Endoscopy-MRI-CEA|
1514471|NCT02860234|Procedure|Nonoperative Management|
1514472|NCT02860234|Procedure|Local Excision|
1514473|NCT02860234|Procedure|Total Mesorectal Excision|
1514474|NCT02860234|Behavioral|Quality of Life Questionnaires|
1514475|NCT02860221|Drug|Tranexamic acid (TXA)|IV and topical administration
1514476|NCT02860221|Drug|Epinephrine|
1514477|NCT02860208|Procedure|3 years follow-up|Examination 3 years after surgical treatment of peri-implantitis
1514478|NCT02860195|Other|oral dose of alcohol|
1514479|NCT02860195|Device|alcotest|
1514480|NCT02860195|Biological|blood samples|
1514481|NCT02860195|Device|Transdermal monitor|
1514482|NCT02860182|Other|measure the elastic properties of aortic wall|
1514486|NCT02860117|Drug|Ketamine continuous infusion|Ketamine 0.1% 250mL continuous infusion (0,2ml/kg/h)
1514487|NCT02860117|Drug|Placebo|Placebo continuous infusion (0,2 ml/kg/h)
1514488|NCT02860104|Device|microwave ablation|ultrasound guided percutaneous microwave ablation for breast lesions
1514489|NCT02860091|Drug|Ropivacaine infusion|Delivered via paravertebral nerve block catheter.
1514499|NCT02860039|Biological|Quadrivalent Influenza Vaccine|Standard dose Quadrivalent Influenza Vaccine given intramuscular
1514500|NCT02860039|Other|Laboratory Biomarker Analysis|Correlative studies
1514501|NCT02860026|Other|Marketed cow's milk-based infant formula|
1514502|NCT02860026|Other|Cow's milk-based infant formula with added nutrients|
1514503|NCT02860013|Device|Telemedicine|
1514504|NCT02860000|Drug|Alisertib|Given PO
1514505|NCT02860000|Drug|Fulvestrant|Given IM
1514506|NCT02860000|Other|Laboratory Biomarker Analysis|Correlative studies
1514507|NCT02859987|Procedure|PICC Placement by Landmark Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
1514508|NCT02859987|Procedure|PICC Placement by Ultrasound-guided Technique|Comparison of two different techniques for PICC Placement (Landmark versus Ultrasound-guided)
1514509|NCT02859987|Device|Ultrasound Scan|Initially the nurses use ultrasound for explore venous anatomy and then they use real-time ultrasound imaging during needle placement
1514510|NCT02859974|Behavioral|Respiratory retraining for PVFMD|"Patients serve as their own controls. During a three week baseline, participants will complete the Dyspnea Index (DI), and have their heart rate, Resp. minute volume and ETCO2 on days 1 and 21 (or on the day treatment commences). Participants will complete a daily log reporting their daily symptoms. This will serve as the baseline prephase.
Post 1 phase will include five individual therapy sessions teaching the respiratory retraining techniques over an estimated three week period.
Post2 phase will comprise of a six week home practice phase. There will be four measuring points per participant: pre1/pre2 measurements on day 1 and 21 (or on the day therapy begins), post1 upon completing five therapy sessions and post 2 upon completion of the home practice phase."
1514511|NCT02859961|Drug|PRO 140|PRO 140 350 mg (175 mg/mL) SC injection per week
1514512|NCT02859948|Drug|SKLB1028|SKLB1028 capsules in six doses beginning at 20 mg and rising to 200 mg.
1514513|NCT02859935|Behavioral|Screening and feedback|Screening via questionnaires on mental health problems and feedback on the questionnaires
1514514|NCT02859922|Device|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
1514515|NCT02859922|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
1514516|NCT02859909|Biological|BT595|
1514520|NCT02859870|Device|FUSE-TM colonoscope|Colonoscopy in conditions of normal security including patient clinical examination before leaving the hospital. Data collection by each operator.
1514521|NCT02859857|Drug|BXQ-350|BXQ-350 is a novel anti-neoplastic therapeutic agent configured from two components: Saposin C (SapC), an expressed (human) lysosomal protein, and the phospholipid dioleoylphosphatidyl-serine (DOPS), a phospholipid located on cell membranes. When both the components are assembled together stable SapC-DOPS nanovesicles are formed(clinical formulation BXQ-350).
1514522|NCT02859844|Device|Transcutaneous Tibial Nerve Stimulation (TTNS)|
1514523|NCT02859831|Other|water samples|
1514524|NCT02859818|Other|therapeutic education program|
1514525|NCT02859805|Other|validation of a diagnostic tool severity of non-motor symptoms in Parkinson patients|
1514529|NCT02859779|Behavioral|education programs|
1514530|NCT02859766|Drug|Abicipar pegol|Abicipar pegol 2 mg administered to the study eye by intravitreal injection.
1514531|NCT02859753|Other|Percutaneous Radiofrequency Ablation|
1514532|NCT02859753|Other|Percutaneous Microwave Ablation|
1514533|NCT02859740|Other|SIGAM Questionnaire|
1514534|NCT02859727|Drug|CDZ173|140 mg/day
1514535|NCT02859714|Other|screening data|
1514536|NCT02859701|Drug|AK002|IV AK002
1514537|NCT02859701|Other|Placebo|
1514538|NCT02859688|Genetic|pyrosequencing|
1514539|NCT02859688|Genetic|Methylome|
1514540|NCT02859675|Other|triangular test|
1514541|NCT02859662|Procedure|ruptured aortic aneurysm|All patients with ruptured abdominal aortic aneurysm may be included in this study, whatever the surgical treatment.
1514542|NCT02859649|Behavioral|neuropsychological test|neuropsychological test
1514543|NCT02859610|Other|research on interactions between portal hypertension and microparticles|
1514544|NCT02859597|Device|High flow nasal cannula|High flow nasal cannula at 50 liters per minute and 50% oxygen will initially be used for oxygenation.
1514545|NCT02859584|Biological|Measure OF SERUM TOTAL CORTISOL, SERUM FREE AND SALIVARY CORTISOL|
1514546|NCT02859571|Drug|Oxytocin|
1514547|NCT02859558|Drug|elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or other medically-appropriate FDA-approved antiretroviral therapy|Participants will receive one tablet of elvitegravir 150mg/cobicistat 150mg/emtricitabine 200mg/tenofovir alafenamide 10mg by mouth daily with food.
1514548|NCT02859545|Behavioral|Emotional Validation Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to validate the individual with chronic pain's pain-related distress and given education about validation. This involves an approximately 45-minute brief, interactive training.
1514549|NCT02859545|Behavioral|Chronic Pain Education Training for Romantic Partners|In this intervention, romantic partners of individuals with chronic pain are trained individually by a research assistant. The romantic partner is trained on how to ask health professionals questions about treatment options and given health education about chronic pain. This involves an approximately 45-minute brief, interactive training.
1514550|NCT02859532|Radiation|elastography SWIRE|
1514551|NCT02859519|Drug|MOB015B|
1514552|NCT02859519|Drug|MOB015B Vehicle|
1514553|NCT02859506|Other|Respiratory quotient|
1514554|NCT02859506|Other|Olfactory liking|
1514555|NCT02859493|Device|Saccharomyces cerevisiae|
1514556|NCT02859493|Device|Placebo|
1514557|NCT02859480|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg tablet, q.d., for 30 months
1514558|NCT02859480|Drug|Rosuvastatin 20mg|Rosuvastatin 5mg tablet, q.d., for 30 months
1514565|NCT02859402|Drug|Busulfan|intravenous, 3.2 mg/kg + 5% DW (the diluent quantity should be 10 times the volume of Busulfan, so that the final concentration of busulfan becomes approximately 0.5 mg/mL), once daily for 3 hours for 3 days (days -7 to -5)
1514566|NCT02859402|Drug|Fludarabine|intravenous, 30 mg/m2 + 5% DW 100㎖, over 1 hour once daily for 6 days (days -8 to -3)
1514567|NCT02859376|Dietary Supplement|sucrose 24%|Premature neonates undergoing blood samples through skin breaking procedures, meeting inclusion criteria, will be randomized as soon as the doctor decision to drown the blood is made, to either sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE the skin breaking procedure or sucrose 24% 0,3 mL if < 1000 g or 0,5 mL if > 1000 g two minutes BEFORE and DURING the skin breaking procedure, according to a computer generated randomization list.
1514568|NCT02859363|Genetic|26 common Fabry mutation types in Taiwan|Historical DNA samples from projects 103-3254C (98-3889A3) and 100-4008C (97-0470B) will perform specific genetic testing.
1514569|NCT02859350|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
1514570|NCT02859350|Biological|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
1514571|NCT02859350|Other|Normal Saline|0.9% Sodium chloride
1514572|NCT02859350|Biological|PfSPZ Challenge (for PfSPZ-CVac)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge)
1514573|NCT02859337|Drug|UPA-ECx1|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 30mg of UPA-based EC
1514574|NCT02859337|Drug|UPA-ECx2|Evaluating the pharmacodynamic and pharmacokinetic outcomes in obese women using 60mg of UPA-based EC
1514575|NCT02859324|Drug|CC-122|
1514576|NCT02859324|Drug|Nivolumab|
1514577|NCT02859311|Drug|Withdrawal of therapy|Withdrawal of heart failure therapies (angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, mineralocorticoid receptor antagonists and loop diuretics)
1514578|NCT02859298|Device|Uterine Cervix Polarimetric Imaging|Polarimetric imaging is a promising optical technique that can provide information in large field and potentially in vivo about the abundance and 3D structure of collagen. Images will be taken with a polarimetric colposcope. As the imaging is realized with visible light from classical sources (lamps or LEDs, neither lasers or other high intensity sources, nor any ionizing UV radiation) and without any chemicals, it is totally innocuous, just like the intensity imaging used in conventional colposcopy.
1514579|NCT02859285|Other|Placebo vulvar cream|
1514580|NCT02859285|Other|Estradiol vulvar cream|
1514581|NCT02859259|Drug|BMS-663068 (1 tablet at 600 mg)|BMS-663068 (1 tablet at 600 mg). A single dose of BMS-663068 administered orally as specified.
1514582|NCT02859259|Drug|BMS-663068 (4 tablets at 150 mg each tablet)|BMS-663068 (4 tablets at 150 mg each tablet). A single dose (4 tablets) of BMS-663068 administered orally as specified.
1514583|NCT02859246|Drug|Mucinex®|Mucinex®
1514584|NCT02859233|Other|Lack of hyperhydration|
1514585|NCT02859220|Other|Determination of PTH following|"Determination of PTH following:
in group 1: intact PTH Elecsys Roche"
1514586|NCT02859220|Other|Determination of PTH following:|"PTH 1-84 complete (PAC) report and CAP / CIP, the package Duo PTH IRMA Scantibodies. The CIP is obtained by calculating the difference between total intact PTH and PTH 1-84 in the kit used."
1514587|NCT02859207|Drug|E2609|Participants will receive a single 50-mg dose (1× 50-mg E2609 tablet).
1514588|NCT02859194|Procedure|Veno-veno-arterial ECMO|
1514592|NCT02859155|Procedure|Multivisceral en bloc resection surgery|Multivisceral en bloc resection for colorectal cancer in advance patients (T4)
1514596|NCT02859129|Drug|rosuvastatin 40 mg tablet|Single oral dose of 40 mg (1 x 40 mg tablet) rosuvastatin (Crestor®) (Day 1).
1514597|NCT02859129|Drug|Epanova™ QD (2 x 1 g capsules)|Multiple oral doses of 2 g (2 x 1 g capsules) Epanova™ QD for 10 consecutive days (Days 4 to 13)
1514598|NCT02859129|Drug|Multiple doses of 4 g Epanova™ with single of rosuvastatin 40 mg dose|Multiple oral doses of 4 g Epanova™ QD for 13 consecutive days with coadministration of single 40 mg oral dose of rosuvastatin (Crestor®) with the 11th dose of Epanova™ on Day 24
1514599|NCT02859129|Drug|Multiple (20) oral doses of 2 g Vascepa® every 12 hours|Multiple oral doses of 2 g (2 x 1 g capsules) Vascepa® every 12 hours for 20 consecutive days (Days 1 to 20).
1514600|NCT02859116|Procedure|Collection of digestive tissues|The surgeon will resect a sample (approximately 1-5 cm x 1-5 cm) of healthy tissue from the distal margins of the segment and at least 4 cm from the diseased area. The specimen for research will be obtained from the tissue that would ordinarily be removed during surgery.The tissue collected for our research purposes will be only remnant tissue which is discarded by the surgeon during the surgical intervention and has no diagnostic clinical value.
1514601|NCT02859103|Drug|Desvenlafaxine|Patients will be provided 50mg dose of desvenlafaxine for 1 week titrated up to 100mg dose of desvenlafaxine for 7 weeks.
1514602|NCT02859090|Procedure|tonsillectomy|
1514603|NCT02859090|Biological|blood sample|
1514604|NCT02859077|Drug|EGFR-TKI|EGFR-TKI (gefitinib)
1514605|NCT02859077|Drug|Chemotherapy（pemetrexed/gemcitabine）|Chemotherapy (pemetrexed/gemcitabine)
1514606|NCT02859077|Drug|Chemotherapy（carboplatin）|Chemotherapy（carboplatin）
1514607|NCT02859064|Drug|Lanreotide|Administered every 28 days irrespective of when SIR-Spheres is administered. No waiting or adjusting of schedule is required. Lanreotide treatment may continue monthly until disease progression or unacceptable toxicity occurs.
1514608|NCT02859064|Device|Y-90 microspheres|To be administered by injection through a trans-femoral catheter into the hepatic artery.
1514609|NCT02859051|Device|Humanoid Robot MEDi|Humanoid robot programmed with cognitive-behavioral interventions such as role modeling, teaching coping strategies, positive reinforcement, parent encouragement
1514610|NCT02859038|Procedure|Upfront cytoreductive surgery|Upfront cytoreductive surgery with a maximum cytoreduction, then followed by 6 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5
1514611|NCT02859038|Procedure|Interval debulking surgery|3 cycles of Paclitaxel 175mg/m2 or Docetaxel 60-75 mg/m2 plus Carboplatin AUC (area under the curve) 5, Interval debulking surgery with a maximal cytoreduction of complete gross resection, then followed by another 3 cycles of chemotherapy
1514612|NCT02859025|Biological|anterior iliac crest graft|Anterior iliac crest spongy bone filled the defects followed by coverage with collagen membrane.
1514613|NCT02859025|Biological|lateral ramus cortical bone+BFPSC+NBBM|ramus cortical bone cage created a protected healing space and BFPSCs cultured over NBBM were put over the graft.
1514614|NCT02859025|Biological|anterior iliac crest graft+BFPSC+NBBM|Anterior iliac crest spongy bone filled the defects and BFPSCs cultured over NBBM were put over the spongy bone.
1514615|NCT02859012|Drug|Axitinib|Dosing schedule: 5mg twice per day orally (4 weeks is considered as 1 cycle)
1514616|NCT02859012|Other|Observation|this group is observational ones.
1514617|NCT02858999|Drug|PAD-VCD|12 weeks of induction chemotherapy by liposomal Bortezomib-Dexamethasone-Doxorubicin (PAD) alternating with Bortezomib-Dexamethasone-Cyclophosphamide (VCD) for a total of 4 cycles
1514618|NCT02858986|Procedure|3D laparoscopy|
1514619|NCT02858986|Procedure|4K laparoscopy|
1514622|NCT02858960|Device|High Flow Nasal Cannula Oxygen|Exercise capacity testing according to High Flow Nasal Cannula Oxygen in COPD patients involved in a Pulmonary Rehabilitation program.
1514623|NCT02858960|Device|The Venturi Mask|Exercise capacity testing according to the oxygen Mask Venturi in COPD patients involved in a Pulmonary Rehabilitation program.
1514624|NCT02858947|Procedure|Aelite Flo|Microhybrid flowable composite
1514625|NCT02858947|Procedure|x-tra base|Bulk-fill flowable composite
1514626|NCT02858934|Radiation|Tomotherapy|"Dose prescription:
Whole breast irradiation: 25 Gy in 5 daily fractions of 5 Gy Boost: 30 Gy in 5 daily fractions of 6 Gy The boost will be delivered as a simultaneous integrated boost (SIB).
Target volumes:
Clinical target volume (CTV) breast: defined by the soft tissue of the breast down to the pectoralis fascia, but excluding the skin and the underlying muscle, ribs, lung and heart.
Gross tumor volume (GTV) boost: includes all gross tumor volume, as visible on computer tomography, mammography and/or magnetic resonance imaging (MRI). MRI imaging is preferentially performed in treatment position.
CTV boost: includes the primary tumor, with a margin of 1.0 cm in all directions to encompass potential microscopic disease extension. The CTV boost excludes the skin, pectoralis muscle, ribs, lung and heart.
Planning target volume (PTV): CTV plus a margin of 5 mm in all directions, but limited at 5 mm below the skin surface."
1514627|NCT02858921|Drug|Dabrafenib|Dabrafenib, a 4-(3-aminosulfonylphenyl)-5-(pyrimidine-3-yl) thiazole, is a potent and selective inhibitor of B-RAF kinase activity with a mode of action consistent with adenosine triphosphate (ATP)-competitive inhibition, and is approved as monotherapy in BRAF V600E-mutant advanced/metastatic melanoma.
1514628|NCT02858921|Drug|Trametinib|Trametinib, a pyrido - pyrimidine derivative, is a potent and highly selective allosteric non-competitive inhibitor of MEK1/MEK2 activation and kinase activity has been approved as monotherapy in BRAF (V600E)-mutant and BRAF (V600K)-mutant melanoma.
1514629|NCT02858921|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
1514631|NCT02858895|Drug|MDNA55|
1514632|NCT02858882|Other|Screening|Screening of elite swimmers
1514633|NCT02858869|Biological|Pembrolizumab|Given IV
1514634|NCT02858869|Radiation|Stereotactic Radiosurgery|Undergo SRS
1514635|NCT02858856|Drug|Sipjeondaebo-tang|Herbal medicine which is a compound of 10 herbs.
1514636|NCT02858843|Drug|lumacaftor-ivacaftor|Drug given for cystic fibrosis
1514637|NCT02858830|Other|High fat mixed meal|
1514638|NCT02858817|Drug|atovaquone/proguanil 250mg/100mg (A/P)|Combination drug for chemo-prophylaxis or treatment of malaria
1514639|NCT02858817|Biological|PfSPZ Challenge (NF54)|cryo-preserved Plasmodium falciparum sporozoites injected by venous inoculation
1514640|NCT02858817|Other|NaCl 0,9%|0.9% NaCl solution for injection
1514641|NCT02858804|Drug|Etoposide|50 mg/m2, IV d1-4
1514642|NCT02858804|Drug|Doxorubicin|10 mg/m2, IV, d1-4
1514643|NCT02858804|Drug|Dexamethasone|30 mg/d, d1-5
1514644|NCT02858804|Drug|Vincristine|0.4 mg/m2, IV, d1-4
1514645|NCT02858804|Drug|Cyclophosphamide|750 mg/m2 ,d5
1514646|NCT02858804|Drug|Cytarabine|2g/m2, q12h, d1
1514647|NCT02858804|Drug|Cisplatin|100mg/ m2,IV, d1
1514648|NCT02858804|Drug|Rituximab|375 mg/m2 IV, d1
1514649|NCT02858804|Drug|Thalidomide|50-150mg/d, po, d1-28
1514650|NCT02858804|Drug|Prednisone|0.5mg/Kg, po, qod
1514651|NCT02858778|Other|Early order of palliative care consultation|
1514652|NCT02858765|Other|Application of white polychromatic light for 2h30 at different times of day|
1514653|NCT02858752|Other|Experience 1 : Auditory and Visual Discrimination|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
1514654|NCT02858752|Other|Experience 2 : Passive and Active Auditory Perception|Neuropsychological tests consist in listening to sounds under 2 conditions, an active or a passive one, during which different auditory stimuli will be presented: frequent stimuli (standard) and rare stimuli (deviants). These two stimuli differ in some of their feature (height, duration, …). A third, very rare (novel) stimulus will also be used (the subject's first name). Responses will be provided using a response-button and feedback will be given at each response. EEG will be recorded all along to measure Neurophysiological signals.
1514655|NCT02858752|Other|Experience 3 : Visual Attention Training|This experience aims at training visual attention through serious games. Children will play against an artificial intelligence and will focus their attention on one out of many possible targets (checkers, cards, boxes) presented on screen. Responses will be provided using a response-button, sometimes completed by an eye-tracking measure. Feedback will be given to the child after his response. EEG will be recorded all along to measure Neurophysiological signals.
1514656|NCT02858752|Other|Experience 4 : Attention and Distractibility|Neuropsychological tests consist in listening to sounds preceded by a visual cue indicating (or not) in which ear the sounds will be played. The subject Child should detect the target sound (e.g. a dog barking). In some trials, a distracting distraction will be introduced between the visual cue and the target sound. Responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
1514657|NCT02858752|Other|Experience 5 : Sustained Visual Attention|Neuropsychological tests consist in watching visual stimuli presented in 3 blocks of 3 minutes each, with a break of one minute between each block. The child has to detect the presence of a red letter in a pattern made of four letters (the three other letters are black). Behavioral responses will be provided using a response-button. EEG will be recorded all along to measure Neurophysiological signals.
1514658|NCT02858739|Device|BIOFREEDOM STENT|
1514659|NCT02858726|Drug|CR845 0.5 mcg/kg|IV medication delivered three times/week
1514660|NCT02858726|Drug|CR845 1 mcg/kg|IV medication delivered three times/week
1514661|NCT02858726|Drug|CR845 1.5mcg/kg|IV medication delivered three times/week
1514662|NCT02858726|Drug|Placebo|IV medication delivered three times/week
1514663|NCT02858713|Drug|Enstilar 0.005%-0.064% Topical Foam|
1514664|NCT02858700|Biological|dosage of the umbilical cord blood Procalcitonin for diagnosing of IBNP|
1514665|NCT02858687|Other|Nasopharyngeal swab|
1514666|NCT02858674|Other|Pop Up Interruption Alert|Traditional Pop Up Alert used in Epic
1514667|NCT02858674|Other|Side Bar Non Interruptive Provider Checklist|Noninterruptive alert that sits in the checklist
1514668|NCT02858661|Other|Nasopharyngeal swab|
1514669|NCT02858648|Behavioral|Behavior intervention with smart phone based self-monitoring|Use two smartphone applications for self-monitoring of diet, physical activity, weight, and blood glucose (connected via a blue-tooth enabled glucometer), plus 11 group session and 1 individual session focused on behavioral strategies
1514670|NCT02858648|Behavioral|Behavior intervention with paper diary based self-monitoring|Use paper diaries along with a calorie counter booklet, weight scale, food scale, and pedometer for self-monitoring of diet, physical activity, weight, and blood glucose, plus 11 group session and 1 individual session focused on behavioral strategies
1514671|NCT02858635|Other|Clinical and neuropsychological assessment, Blood and saliva samples|Clinical and neuropsychological assessment: impulsivity, aggressiveness, psychological pain, angor with specific scales and smartphone.
1514672|NCT02858622|Drug|bupivacaine|bupivacaine 0.25% at a dose 2 mg/kg in the transversus abdominis plane
1514673|NCT02858622|Drug|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
1514674|NCT02858622|Drug|perfalgan|intravenous paracetamol
1514675|NCT02858622|Drug|fentanyl|
1514676|NCT02858609|Other|Nasopharyngeal Swab|
1514677|NCT02858596|Dietary Supplement|Semi-solid feed (Terumo PG soft)|
1514678|NCT02858596|Dietary Supplement|Liquid feed (Meibalance)|
1514681|NCT02858570|Biological|MenCC-BIO Vaccine|The Bio-MenCC vaccine is composed of serogroup C meningococcal polysaccharide conjugated to tetanus toxoid as the carrier protein, with 10 microgram of capsular polysaccharide of group C, 10-20 microgram of tetanus toxoid per dose and aluminum hydroxide at a concentration of 1 milligram dose (0.35 milligram Al3 +) with phosphate buffered saline as diluent. The vaccine is lyophilized and must be reconstituted with diluent and homogenized at the time of application. The lyophilised vaccine is presented as a white powder and the sterile diluent is translucent. Both are presented in vial of colorless neutral glass.
1514682|NCT02858570|Biological|Combined - CRM197|The comparison is against meningococcal C vaccine produced by the Foundation Ezequiel Dias (FUNED), licensed by ANVISA and currently provided by the National Immunization Program in the child's immunization schedule. This vaccine containing 10 microgram of meningococcal C oligosaccharide conjugate 12,5-25microgram of CRM197 protein of Corynebacterium diphtheriae, and presents aluminum hydroxide (0.3 to 0.4 milligram Al3 +) in its formulation. It is also a lyophilized product must be reconstituted and homogenized before use. The meningococcal C vaccine adsorbed (combined - CRM197) comprises two frascos- ampoule, containing a white or off-white lyophilized powder and another vial containing a white opalescent suspension (diluent).
1514683|NCT02858557|Behavioral|Mediterranean diet|The Mediterranean diet is rich in complex carbohydrates and fibers and low in animal proteins and fats.
1514684|NCT02858557|Behavioral|Specific Carbohydrate Diet|The specific carbohydrate diet is a dietary program popular among patients with IBD. The diet allows carbohydrate foods consisting of mono-saccharides only, and excludes di-saccharides and most polysaccharides.
1514685|NCT02858544|Other|The Concussion Identification Index|Patient completion of the Concussion Identification Index, a report of crash characteristics, injuries sustained, and post-accident neurological signs and symptoms
1514686|NCT02858544|Other|ImPACT|Patient- completed computerized neurocognitive test battery
1514687|NCT02858531|Other|data retrieval|data retrieval with the Hospital Information System
1514688|NCT02858518|Other|questionnaires|scales : HEMORR2HAGES (hepatics diseases, alcoholism, cancer, thrombocytopenia, anemia and antecedent...), HAS-Bled (arterial hypertension, renal function, liver function, cerebrovascular accident...), ATRIA (anemia, serious kidney diseases, hypertension, antecedent...), Shireman (gender, age, hemorrhage, diabetes, anemia...), Charlson (age, cardiovascular disease, lung disease, neurological disease, endocrinal disease, nephrology, liver disease, gastroenterology, cancer) and standardised geriatric assessment (comorbidities, cognition, mobility, pain, nutrition, living environment...)
1514689|NCT02858505|Drug|27 mg elemental iron|
1514690|NCT02858505|Drug|54 mg elemental iron|
1514693|NCT02858479|Other|stimulation on painful area (area allodynic)|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.
stimulations for 6 seconds"
1514694|NCT02858479|Other|same stimulation on non-painful area|"these stimulations will be performed either with a brush, with a cold block or with forced air (cold air or air to ambient temp) : calibrated to induce pain bearable.
stimulations for 6 seconds"
1514695|NCT02858479|Radiation|MRI scan|"2 sessions for 10 minutes :
11 controls stimulations for 6 s each spaced 20 s without stimulation.
11 allodynic stimulations for 6 s each spaced 20 s without stimulation."
1514696|NCT02858466|Radiation|MRI scan|
1514700|NCT02858440|Biological|Infanrix® -IPV/Hib|Subjects will receive (Infanrix® -IPV/Hib) three-dose primary vaccination course at 3, 4.5 and 6 months of age and as a booster dose at 18 months of age. The vaccine will be administered intramuscularly, at a 90-degree angle into the upper side of the thigh on the right side. The vaccine should not be administered in the buttock
1514705|NCT02858414|Other|additional blood sample|
1514706|NCT02858401|Drug|Vesatolimod|Tablet(s) administered orally once every 2 weeks
1514707|NCT02858401|Drug|Placebo|Tablet(s) administered orally once every 2 weeks
1514708|NCT02858401|Drug|ARV regimen|Participants' current ARV regimen must be used in accordance with their prescribing information and may include the following: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), raltegravir, dolutegravir, rilpivirine, and maraviroc.
1514711|NCT02858362|Drug|ezutromid|oral suspension
1514712|NCT02858349|Behavioral|No intervention|No intervention
1514713|NCT02858349|Behavioral|High-intensity interval training|High-intensity walking exercise using bursts of concentrated effort alternated with recovery periods
1514882|NCT02857062|Device|E45 Eczema Repair Emollient|E45 Eczema Repair Emollient
1514721|NCT02858297|Drug|Glucosamine sulfate|Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect
1514722|NCT02858297|Drug|triamcinolone acetonide|Topical corticosteroid
1514723|NCT02858284|Device|TUG|Therapeutic Ultrasound for Glaucoma
1514724|NCT02858284|Device|Sham|
1514725|NCT02858271|Drug|AKB-9778 subcutaneous injection|
1514726|NCT02858258|Drug|R-CHOP/R-DHAP|Drug: R-CHOP/DHAP Alternating 3x R-CHOP (Rituximab , Cyclophosphamide ,Doxorubicine ,Vincristine , Prednisone) / 3x R-DHAP (Rituximab , Dexamethasone, Ara-C, Cisplatine, G-CSF)
1514727|NCT02858258|Drug|Ibrutinib (Induction)|Ibrutinib: only in cycle 1,3,5 on Day 1-19
1514728|NCT02858258|Drug|ASCT conditioning|"ASCT conditioning THAM or BEAM, stratified per site before trial activation at site
THAM (TBI (total body irradiation), Ara-C, Melphalan) or
BEAM (BCNU, Etoposide, Cytarabine, Melphalan)"
1514729|NCT02858258|Drug|Ibrutinib (Maintenance)|Ibrutinib (Maintenance), daily 560 mg for 2 years;
1514730|NCT02858245|Other|No intervention - registry|
1514731|NCT02858232|Biological|MASCT-I|Dendritic cells(DC) loaded with antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
1514740|NCT02858193|Drug|1.35 g SCMC- lys powder|1.35 g SCMC- lys powder for oral solution
1514741|NCT02858193|Drug|Fluifort® syrup|SCMC-lys Syrup 90 mg/ml
1514742|NCT02858180|Drug|Sofosbuvir/ledipasvir fixed dose combination(SOF/LDV FDC)|1 pill once daily of SOF/LDV FDC
1514743|NCT02858167|Device|FDG-PET|FDG injection followed by cerebral examination with X ray spiral CT after 40 minutes and FDG-PET after 60 minutes
1514744|NCT02858154|Other|HFNC|All subjects will have a 3-4 hour intervention of HFNC to test effectiveness and safety for treating OSA
1514745|NCT02858154|Other|Oxygen by Cannula|All subjects will have a 6 to 8 hours intervention during the clinically scheduled PSG of titration of oxygen by nasal cannula (standard of care) to control sleep apnea and desaturations
1514746|NCT02858141|Other|Data collection|
1514747|NCT02858128|Other|IMAGING STUDY|Choline-PET/CT versus NMRscan comparative study
1514748|NCT02858115|Other|Fluid challenge|100 ml of crystalloid was infused over 1-min
1514749|NCT02858115|Other|Trans-oesophageal echography|an echocardiographic assessment at 1-min,
1514750|NCT02858102|Behavioral|Physical activity program|The intensity of physical activity will be adapted to the possibilities of the participants making individualized proposals to encourage participants to acquire active lifestyle habits to improve their health. All sessions end with a routine of relaxation and passive stretching. Simultaneously self-employment is controlled outside the guided sessions.
1514751|NCT02858076|Drug|2-mg Intravitreous Aflibercept Injection|Soluble decoy receptor fusion protein that has a high binding affinity to all isoforms of VEGF as well as to placental growth factor.
1514752|NCT02858076|Procedure|Prompt Vitrectomy Plus Panretinal Photocoagulation|Surgical removal of the vitreous gel and associated hemorrhage, concurrent delivery of panretinal endolaser
1514753|NCT02858050|Device|Portal-724 MEMs Cap|
1514754|NCT02858037|Combination Product|Dapivirine Vaginal Ring|Dapivirine Vaginal Ring, 25 ring given monthly for at least one year.
1514755|NCT02858024|Drug|Dapivirine Vaginal Ring-004 and no tampons|Dapivirine Vaginal Ring-004 for 28 days, with menses, no tampon use (Treatment A),
1514756|NCT02858024|Drug|Dapivirine Vaginal Ring-004 with tampons|followed by Dapivirine Vaginal Ring-004 for 28 days, with menses, with tampon use (Treatment B)
1514757|NCT02858024|Drug|Dapivirine Vaginal Ring-004 with no menses|Dapivirine Vaginal Ring-004 for 28 days, with no menses occurring (Treatment E; treatment period 3).
1514758|NCT02858024|Drug|Dapivirine Vaginal Ring-004 and same ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and the same ring re-inserted five days later (estimated completion of menses) (Treatment C)
1514759|NCT02858024|Drug|Dapivirine Vaginal Ring-004 and new ring inserted after menses|Dapivirine Vaginal Ring-004 used continuously until the start of menses, at which time the ring will be removed, and a new ring inserted five days later (estimated completion of menses) (Treatment D)
1514883|NCT02857049|Other|Oral nutritional supplements (ONS) degustation|
1514760|NCT02858011|Other|Cash distribution during 36 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
1514761|NCT02858011|Behavioral|Accompanying information sessions on health, child nutrition, household economics and education during 36 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
1514762|NCT02858011|Dietary Supplement|PNP|Fortified flour supplements for children and pregnant/lactating mothers.
1514763|NCT02858011|Other|Cash distribution during the last 12 months|Three-monthly distribution of Cash (30,000 FCFA/trimester) to households that are beneficiary of the Jigisemejiri program.
1514764|NCT02858011|Behavioral|Accompanying information sessions on health, child nutrition, household economics and education during the last 12 months|Large group gatherings of cash beneficiaries are organized in parallel to the cash distributions. During these meetings, local NGOs present and discuss a topic related to health, child nutrition, household economics or education.
1514765|NCT02857998|Drug|HMPL-523|Oral administration, once daily
1514766|NCT02857985|Device|3D RA|3D RA is realised just after angioplasty.
1514767|NCT02857985|Device|MRI|MRI is realised between 24h and 96h post angioplasty.
1514768|NCT02857972|Device|Wondaleaf®|Use of Wondaleaf® during menstruation every night in one menstrual cycle.
1514769|NCT02857959|Drug|Benzathine Penicillin G|
1514770|NCT02857946|Drug|Prevaglip (linagliptin)|1 tablet contains 5 mg linagliptin
1514771|NCT02857946|Drug|Trajenta (linagliptin)|1 tablet contains 5 mg linagliptin
1514772|NCT02857933|Other|Physical Therapy|One-on-one physical therapy sessions (one therapist and one patient). Principles of motor learning used include repetition, task-specificity, active practice, generalization of skills, errors, structured practice, and developmentally appropriate feedback with sufficient time to practice.
1514773|NCT02857920|Drug|Bevacizumab|7.5 mg/kg IV every 3 weeks (continuous)
1514774|NCT02857920|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfusion in 3 times, i.v.
1514775|NCT02857907|Other|Blood sample|A blood sample is performed one year after kidney transplantation.
1514776|NCT02857881|Procedure|De-epithelization and therapeutic photokeratectomy|
1514777|NCT02857868|Drug|ABL001|
1514778|NCT02857855|Procedure|80% fraction of inspired oxygen for 6 postoperative hours|80% fraction of inspired oxygen delivered for 6 postoperative hours, either by a nonrebreathing facemask with a reservoir or by a respirator
1514779|NCT02857855|Procedure|28% fraction of inspired oxygen for 6 postoperative hours|28% fraction of inspired oxygen delivered for 6 postoperative hours, either by a Venturi facemask or by a respirator
1514780|NCT02857842|Drug|Prednisolone|
1514781|NCT02857829|Dietary Supplement|SPRINT|SPRINT will be a blend consisting of caffeine (100 mg), L-theanine (200 mg), vinpocetine (40 mg), L-tyrosine (300 mg), pyridoxine (0.06 mg), and cobalamin (20 mg).
1514782|NCT02857829|Dietary Supplement|Caffeine-alone|Caffeine (100 mg)
1514783|NCT02857829|Other|Placebo|Rice flour
1514785|NCT02857803|Procedure|Virtual Reality|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
1514786|NCT02857803|Procedure|Paper and Pencil|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
1514787|NCT02857803|Procedure|Conventional Therapy|Intervention of 30 minutes, 3 times a week until reaching 12 sessions.
1514788|NCT02857777|Drug|Esketamine|Subjects will self-administer intranasal esketamine as per the treatment regimen.
1514789|NCT02857751|Behavioral|Surf therapy|The NMCSD surf therapy program is approximately 6 weeks in duration. Each surf therapy session lasts 2-3 hours and occurs in a group setting that can accommodate up to 20 service members per session. Each service member is paired with a surf instructor who works with him or her each week for the 6-week session. Goals are individually-tailored to the service member (based on participant's level of comfort in the water, experience with surfing, etc.) and can incorporate both physical and psychological objectives.
1514790|NCT02857738|Drug|BAY 987519|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
1514791|NCT02857738|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
1514792|NCT02857725|Drug|BAY 987517|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
1514793|NCT02857725|Drug|SPF 15 Control|Single dose application of two (2) mg/cm² of test product. Each 50 cm² test site area requires 100 mg of a product to obtain a standard 2 mg/cm² test application.
1514794|NCT02857712|Drug|Axitinib|Axitinib will be self orally administered at 5 mg twice daily approximately every 12 hours, on a continuous basis (each morning and evening), in 4 week cycles until tumour progression, unacceptable toxicity or other criteria for discontinuation is met. Patients who tolerate axitinib with no adverse events axitinib-related should have a dose increased until to 10 mg twice.
1514795|NCT02857686|Procedure|intravenous regional anaesthesia|tourniquet over the arm and intravenous lidocaine with a dose of 4 mg/kg
1514796|NCT02857686|Procedure|forearm IVRA|tourniquet over the forearm and lidocaine with a dose of 1.5 mg/ kg
1514797|NCT02857673|Behavioral|Child Abuse Prevention Problem Solving|The CAPPS intervention includes problem solving, motivational interviewing, and referral to existing services. Intervention providers will conduct three core problem solving sessions and three sessions tailored to the common problems experienced by parents of CSHCN: caregiver burden, difficulties navigating complex medical services, and social isolation. Intervention providers will use their motivational interviewing skills during regular, ongoing interactions with their clients to enhance willingness to participate meaningfully in CAPPS sessions. Referral to existing services in the medical home and in the community will occur as needs arise during CAPPS sessions.
1514884|NCT02857036|Other|rhythmic parameter recording|the following rhythmic parameters are recording during 48 hours: temperature, heart rate and actimetry
1515038|NCT02855710|Other|Rhythm workers training sensorimotor timing|Sensorimotor timing training
1514798|NCT02857673|Behavioral|Active Control Condition|Parents in both study groups will receive the standard medical and social work services offered in the patient-centered medical homes where their children receive care. In addition, to account for potential surveillance bias, families in the control group will be contacted by a member of the study team six times over 12 weeks, approximating the frequency of contact that the intervention group receives from the CAPPS providers.
1514799|NCT02857660|Other|Whole body Electromyostimulation (exercise)|1.5 x 20 min/week (e.g. each Tuesday and every second Friday) with bipolar current, 85 Hz, 360 µs, rectangular mode, intermittent with 4 sec of current and 4 s of rest.
1514800|NCT02857660|Dietary Supplement|Protein|up to 1.5-1.7 g/kg bodymass/d of protein (whey protein)
1514801|NCT02857647|Behavioral|An information video|Participants who will assigned to the experimental group will be asked to watch a 30 minutes videotaped lecture 1-2 weeks prior to the surgery date. Topics includes: types of surgeries, preparation to the hospitalization process and to the surgery (e.g. what to expect, personal equipment needs, description of the surgery admission process, etc.), dietary guidelines pre- and post-surgery (e.g. low carb diet 2-3 week prior to the surgery, post-surgery diet progression, techniques of eating and drinking, recommended dietary supplements), recommendation and tips for long term surgery success (e.g. definition of weight loss expectations, physiological, nutritional and life-style strategies for long-term weight loss).
1514802|NCT02857634|Device|Cellvizio dual band|Using fluorescence cytoscopy, lesions in the bladder will be resected. The samples will be immediately observed in order to keep the fluorescein effect under confocal microscopy (Cellvizio dual band). After confocal microscopy samples will be fixed in formalin and prepare for the pathologist that will confirm the diagnosis. The Cellvizio system can be used to observe a resected sample ex vivo, offering a cellular-level view of internal tissue. This technique allows the visualization of the microstructure of the tissue in real-time which may improve targeted sampling, provide earlier disease detection and help patient management. The Cellvizio system includes miniaturized optics, optical fiber bundles, high-speed scanning and advanced image processing components.
1514803|NCT02857608|Drug|Lymphoseek|
1514804|NCT02857595|Behavioral|Online Behavioral Weight Loss program|
1514805|NCT02857595|Behavioral|Weight Loss Nomogram|
1514806|NCT02857595|Behavioral|Bite Counter|
1514807|NCT02857582|Biological|Cultured human intestinal microbiota|Secondary treatment for C diff in replacement for regular vancomycin.
1514808|NCT02857582|Drug|Vancomycin|Active comparator to treatment with ACHIM
1514809|NCT02857582|Drug|Metronidazole|Primary treatment for C diff in all treatment arms
1514810|NCT02857569|Drug|Ipilimumab IT|
1514811|NCT02857569|Drug|Ipilimumab IV|
1514812|NCT02857569|Drug|Nivolumab IV|
1514813|NCT02857556|Biological|Blood sample|
1514814|NCT02857556|Other|Retinal photography:|
1514815|NCT02857556|Other|dialyse|
1514816|NCT02857543|Other|Plant-Based Diet|
1514817|NCT02857543|Other|American Heart Association Diet|
1514818|NCT02857543|Other|Mediterranean Diet|
1514819|NCT02857530|Drug|rhTPO|rhTPO
1514820|NCT02857530|Drug|placebo|without rhTPO
1514821|NCT02857517|Drug|conbercept|0.05ml conbercept
1514827|NCT02857478|Drug|BAY 987519, SPF 50, Y51-002|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
1514828|NCT02857478|Drug|BAY 987519, SPF 50, P04-147|Sufficient amount to cover all exposed skin liberally two times - approximately 240 min.
1514829|NCT02857465|Drug|Dexamethasone|single epidural injection of dexamethasone (8 mg) in addition to local anesthetics used for epidural analgesia
1514830|NCT02857465|Drug|Placebo|single epidural injection of sodium chloride 0.9% (2 mL) in addition to local anesthetics used for epidural analgesia
1514831|NCT02857465|Drug|Ropivacaine|NAROPEINE 7.5 mg/mL is diluted at the concentration of 1 mg/mL prior to the epidural use. The perfused dose depends on the efficacy of analgesia in reducing the delivery labor pain.
1514832|NCT02857465|Drug|Sufentanil|Sufentanil 0.5 mg/L is used as solution for injection for epidural analgesia and used in combination with ropivacaine. The administered dose is bolus of 15 to 20 micrograms diluted into 10 mL.
1514833|NCT02857452|Other|SLA Questionnaire|
1514834|NCT02857452|Other|Lupus Qol Questionnaire|
1514835|NCT02857439|Other|Standard diagnostic item list|All consecutive patients are assessed by both examiners, according to a standardized physical examination item list.
1514837|NCT02857400|Other|current standard of care|connection documentation faxed to GP (General practitioner) on the day of patient's discharge
1514838|NCT02857400|Other|CREDO standard of care|"organized consultation return home between patient, GP DESC (diploma of complementary specialized study) and patient's referent GP"
1514840|NCT02857374|Procedure|Diagnostic Microscopy|Undergo intravital microscopy
1514841|NCT02857374|Drug|Fluorescein Sodium Injection|Given IV
1514842|NCT02857374|Other|Laboratory Biomarker Analysis|Correlative studies
1514843|NCT02857374|Procedure|Sentinel Lymph Node Biopsy|Undergo standard of care sentinel node biopsy
1514844|NCT02857361|Drug|Sublingual ketamine wafers|Two sublingual ketamine 25 mg wafers
1515122|NCT02855060|Device|Pelvic Binder|
1514845|NCT02857348|Behavioral|Night Shift|Night Shift is an adventure video game with the transformational goal of teaching physicians key characteristics of patients with non-representative severe injuries - injuries classified by the American College of Surgeons as life-threatening or critical but that do not fit the archetype of injuries typically requiring treatment at a trauma center. Players take on the persona of Andy Jordan, a young emergency physician who moves home after the disappearance of his estranged grandfather (Robert Jordan) and takes up a job in the local Emergency Department (ED). In the preamble, players learn they have two explicit objectives. First, they must diagnose and treat patients who present to their ED. Second they must solve the mystery of Robert's disappearance: was he murdered or has he simply chosen to disappear?
1514846|NCT02857348|Behavioral|Educational Module|The educational module consists of two separate apps, both commercially available. myATLS includes a review of each chapter of the Advanced Trauma Life Support (ATLS) textbook, a series of videos demonstrating common trauma procedures, and clinical resources including checklists for use at the bedside. Trauma Life Support MCQ Review includes 550 multiple-choice questions with correct answers and explanations. The investigators will ask physicians to review the myATLS app and then complete questions in the Trauma Life Support MCQ Review, spending at least 1 hour on the combined tasks.
1514847|NCT02857335|Behavioral|neurocognitive tests|Subjects will undergoe a battery of neurocognitive testing which will test memory, flexible thought process, problem, attention span
1514848|NCT02857322|Other|Accompanying patient's specific perioperative|
1514849|NCT02857309|Device|OPTIMIZER|The OPTIMIZER System delivers non-excitatory cardiac contractility modulation (CCM) signals to the heart that are intended to influence myocardial properties in patients with chronic heart failure. The system has no pacemaker or implantable cardioverter-defibrillator (ICD) functions.
1514850|NCT02857309|Drug|Optimal medical therapy|OMT using standard heart failure (HF) drugs
1514851|NCT02857296|Other|interview and observation|
1514852|NCT02857283|Other|Ozone|Subject will be exposed to a concentration of ozone for 6.5 hours
1514853|NCT02857283|Other|Filtered Air|Subject will be exposed to filtered clean air
1514854|NCT02857270|Drug|LY3214996|Administered orally
1514855|NCT02857270|Drug|Midazolam|Administered orally
1514856|NCT02857270|Drug|Abemaciclib|Administered orally
1514857|NCT02857270|Drug|Nab-paclitaxel|Administered IV
1514858|NCT02857270|Drug|Gemcitabine|Administered IV
1514859|NCT02857257|Biological|ACHIM|After an observation period of 4 weeks patients with IBS-D will be treated with ACHIM
1514860|NCT02857244|Drug|Duloxetine|Patients will first receive Duloxetine for 4 weeks starting at 30mg, 60mg, 90mg then 120mg (if tolerated). Increases in dosage amounts will occur every week.
1514861|NCT02857244|Drug|Donepezil|Patients will receive Donepezil after 4 weeks of dosing with Duloxetine. Patients will receive Donepezil in combination with the highest dose of Duloxetine that was tolerated. Patients will remain on this for 2 weeks with increasing doses at each week. One week of 5mg, one week of 10mg.
1514862|NCT02857244|Drug|Modafinil|Patients will receive Modafinil after a 4 week washout period (after dosing with donepezil & duloxetine in combination). Patients will receive Modafinil for two weeks with increasing doses at each week. One week at 100mg, one week at 200mg.
1514863|NCT02857218|Drug|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
1514864|NCT02857218|Procedure|Magnetic Resonance Imaging|Undergo ferumoxytol-enhanced MRI
1514865|NCT02857218|Device|Magnetic Resonance Imaging|
1514866|NCT02857218|Device|PET/CT|
1514867|NCT02857205|Other|Fecal samples|High throughput sequencing methods and analysis for microbiome analysis on fecal samples from a multicenter cohort of patients at various ages.
1514868|NCT02857192|Biological|Blood samples|
1514869|NCT02857179|Procedure|bariatric surgery|gastric bypass Or gastric banding Or Biliopancreatic diversion with duodenal switch Or sleeve gastrectomy Or endoscopic procedure (Endobarrier,…)
1514870|NCT02857166|Biological|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
1514871|NCT02857153|Drug|Urapidil|If necessary, intravenous urapidil 0.2-0.5 mg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
1514872|NCT02857153|Drug|Phenylephrine|If necessary, intravenous phenylephrine 4-6 μg/kg when mean arterial pressure exceeded 10 mmHg of the target value, rather than more anesthesia, may be used in situations wherein sympathetic stimulation was high; yet a sufficient amount of anesthesia was being administered and bispectral index showed an adequate depth of hypnosis. Sedation was provided by a propofol infusion targeted to a BIS number of approximately 50 during general anesthesia.
1514873|NCT02857153|Procedure|Low-level MAP|MAP is regulated to the goal level (60-70 mmHg) during general anesthesia.
1514874|NCT02857153|Procedure|High-level MAP|MAP is regulated to the goal level (90-100 mmHg) during general anesthesia.
1514875|NCT02857127|Behavioral|Walking program|To encourage people to exercise more through a behavioural and educational intervention during six months and other six months of follow up.
1514876|NCT02857114|Other|massage|
1514877|NCT02857101|Other|dosage of calprotectin|
1514878|NCT02857088|Behavioral|olfactory assessment|determination of olfactory sensitivity through olfactory threshold assessment (butanol) determination of hedonicity and intensity of 16 usual odors
1514879|NCT02857088|Behavioral|image visualization|20 images (from the IAPS-international affective picture systems) are presented to the subject. He has to determine the hedonicity of each picture.
1514880|NCT02857088|Behavioral|psychophysiological assessment|during the olfaction assessment and the image visualization, skin conductance reactivity (SCR) is recorded to assess unconscious emotional reactivity
1514881|NCT02857075|Other|Blood donation|Red cell concentrates derived from healthy blood donating people. In France, all blood donation is realized by the Etablissement Français du Sang, so all the study samples are from this center.
1514885|NCT02857036|Behavioral|psychiatric assessment|different psychometric scales are filled in: Montgomery and Asberg depression rating scale (MADRS), Quick inventory depression scale (QIDS-C16) and Beck depression inventory (BDI)
1514887|NCT02857010|Biological|Allogenic mesenchymal stem cells|Cell therapy
1514888|NCT02857010|Other|Placebo|Serum without stem cells
1514889|NCT02856997|Drug|Chidamide with ICE regimen|Chidamide and ICE regimen, dosage described in arm description
1514890|NCT02856958|Procedure|Nerve decompression|
1514891|NCT02856958|Other|Non-operative|Physical therapy
1514892|NCT02856932|Other|Conventional high viscosity glass ionomer|Dental restorative material
1514893|NCT02856932|Other|Glass ionomer with glass hybrid technology|Dental restorative material
1514894|NCT02856919|Drug|brimonidine tartrate|Mirvaso® gel (5 mg/g brimonidine tartrate)
1514895|NCT02856906|Other|occlusal adjustment|
1514896|NCT02856893|Drug|Osimertinib|
1514897|NCT02856893|Drug|Gefitinib|
1514898|NCT02856880|Other|Test zinc-IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride and 0.1% w/w IPMP and 1426ppm fluoride as sodium fluoride.
1514899|NCT02856880|Other|Test zinc non- IPMP toothpaste|Test toothpaste containing 0.6% w/w zinc chloride, 0% w/w IPMP and 1426ppm fluoride as sodium fluoride.
1514900|NCT02856880|Other|Positive control|Positive control toothpaste containing 0.454% w/w stannous fluoride (Fluoride Toothpaste (1100ppm Fluoride as stannous fluoride)).
1514901|NCT02856880|Other|SLS negative control|Negative control toothpaste containing 2.0% SLS, 0.65% Tegobetain and 1150 ppm fluoride as sodium fluoride
1514902|NCT02856880|Other|non-SLS negative control|Negative control toothpaste containing 1426 ppm fluoride as sodium fluoride
1514903|NCT02856867|Drug|Nintedanib|
1514904|NCT02856867|Drug|Fluorouracil|
1514905|NCT02856867|Drug|Leucovorin|
1514906|NCT02856867|Drug|Oxaliplatin|
1514907|NCT02856867|Drug|Placebo|
1514908|NCT02856854|Drug|EMB-001|EMB-001 is a combination of metyrapone (720mg per dose in this study) and oxazepam (24mg per dose in this study)
1514909|NCT02856854|Drug|Placebo|EMB-001 matched placebo
1514910|NCT02856854|Drug|Cocaine IV|Cocaine administered at doses of 20 and 40mg
1514911|NCT02856854|Drug|Saline IV|Cocaine matched placebo
1514912|NCT02856828|Device|DIE|digital image enhancement
1514913|NCT02856815|Biological|Immuncell-LC|Activated T lymphocyte : intravenous dripping of 200ml (1 x 10^9 ~ 2 x 10^10 lymphocytes / 60kg adult) for 1 hour
1514916|NCT02856789|Other|Routine hemostasis tests|Prothrombin Time (PT),Thrombin Time (TT), Activated Partial Thromboplastin Time (APTT), Fibrinogen, D-Dimers
1514917|NCT02856789|Other|Fibrin structure (FS)|FS will be determined on STA-R® prototype at Percy and at Stago
1514918|NCT02856789|Other|Thromboelastography (TEG)|Thromboelastography will be processed on TEG® at Percy
1514919|NCT02856789|Other|Specialized hemostasis tests|Coagulation factors
1514920|NCT02856776|Dietary Supplement|Vitamin D3|Vitamin D provided in capsule form
1514921|NCT02856750|Drug|Gabapentin|Gabapentin 300 mg three times daily x30 days
1514922|NCT02856737|Other|eye masks and earplugs|Materials similar to those offered on long commercial flights
1514923|NCT02856724|Drug|PGE2|10 mg PGE2 vaginal ovul(Propess)
1514924|NCT02856711|Behavioral|Trauma-informed group|"The two interventions will be: 1) A viewing of All Babies Cry and a discussion of what it's like to be a new parent, 2) A Planning to Parent stress activity where parents discuss when they have felt overwhelmed, the coping mechanisms they used, and what can be done to manage those emotions in the future. The goal of this project is to gain insight from current participants in CenteringPregnancy group care around the ways that these interventions can better prepare parents to deal with the common stresses of parenthood."
1514925|NCT02856698|Drug|Midazolam|
1514926|NCT02856698|Drug|Morphine|
1514927|NCT02856685|Drug|Mitoxantrone Hydrochloride Liposome|Mitoxantrone Hydrochloride Liposome will be administered via IV infusion over 60 minutes once at the beginning (Day 1) of each 28-day cycle
1514930|NCT02856633|Device|Vitaliti|
1514931|NCT02856620|Other|Observational only|Observational only
1514932|NCT02856607|Other|determine the prognosis of threated patients according to the clinical care pathway.|
1514935|NCT02856581|Drug|Varenicline|Given PO
1514936|NCT02856581|Drug|Placebo|Given PO
1514937|NCT02856581|Other|Tobacco Cessation Counseling|Complete counseling session
1514938|NCT02856568|Drug|Cisplatin|Given IV
1514939|NCT02856568|Drug|Gemcitabine Hydrochloride|Given IV
1514940|NCT02856568|Other|Laboratory Biomarker Analysis|Correlative studies
1514941|NCT02856568|Other|Pharmacological Study|Correlative studies
1514942|NCT02856568|Drug|Ricolinostat|Given PO
1514943|NCT02856555|Drug|GS-0976|Capsule(s) administered orally once daily
1514944|NCT02856555|Drug|Placebo|Capsule(s) administered orally once daily
1514946|NCT02856529|Other|Training|The Basic Infection Control Skills License program (BICSL) includes meningitis and influenza vaccination as well as fit test to verify the correctly fitting of the respirator. Also, the license program includes training on hand hygiene and the use of personal protective equipment (PPE). To get the license, each participants must get the vaccination and attend one to one training session with a program trainer 34.
1515036|NCT02855723|Other|Surgery: Classic strategy|systematic lymphadenectomy
1514947|NCT02856529|Other|General session|A general session about the basic of infection control was conducted for this group. The lecture performed in the same way of the regular training fulfill.
1514948|NCT02856516|Other|Boost Glucose Control (A)|Oral nutrition supplement
1514949|NCT02856516|Other|Boost Glucose Control (B)|Oral nutrition supplement
1514950|NCT02856516|Other|Boost Original|Oral nutrition supplement
1514951|NCT02856503|Drug|Vitamin D3|Weekly oral dose of Vitamin D3 per protocol.
1514952|NCT02856477|Biological|urine analysis|a sample of urine is collected during 8 hours.
1514953|NCT02856464|Other|DLI will be administered to all patients at Month 4 (+/- 20 days) after stem cell transplant regardless of peripheral blood CD3 chimerism (including if they have full donor chimerism)|
1514954|NCT02856464|Other|DLI will be administered from Month 6 (+/- 20 days) after stem cell transplant according to institutional practice|
1514955|NCT02856451|Biological|Nivolumab|Specified dose on specified days
1514959|NCT02856425|Drug|Nintedanib|Nintedanib oral tablets. An angiokinase inhibitor targeting VEGFR 1-3, FGFR 1-3, and PDGFR α/β as well as RET. Refer to current IB for product details
1514960|NCT02856425|Drug|Pembrolizumab|Pembrolizumab, Intravenous. An IgG4 anti-PD-1 blocking monoclonal antibody. Refer to current IB for product details
1514961|NCT02856412|Other|Veterans Group Exercise (VGX)|Integrative Exercise incorporates elements of strength training, flexibility, cardiovascular training, and controlled breathing exercises.
1514962|NCT02856412|Other|Illness Management and Recovery|Illness Management and Recovery is an educational program focused on helping individuals more effectively manage their illnesses to pursue their personal recovery goals. The classes include the following topic areas which have been adapted for use in PTSD: recovery, practical facts about PTSD, stress-vulnerability, building social support, medications for PTSD, drug and alcohol use, reducing relapse, coping with stress, coping with persistent symptoms, getting needs met in the VA healthcare system, and living a healthy lifestyle.
1514963|NCT02856386|Dietary Supplement|polyphenol supplement|8 mL once daily
1514964|NCT02856373|Procedure|RNS and RDN|The patients will undergo electrical renal nerve stimulation and subsequently renal nerve denervation
1514965|NCT02856360|Other|Moderate Stiffness Footwear|Standard moderately stiff footwear for typical high school football players will be randomly allocated to each group
1514966|NCT02856360|Other|High Stiffness Footwear|Standard highly stiff footwear for typical high school football players will be randomly allocated to each group
1514967|NCT02856347|Other|18F-DOPA|Injection of 18F-DOPA and PET / CT-scan assessment
1514968|NCT02856308|Device|Hairstetics hair implant device|
1514969|NCT02856295|Drug|clexane (LMWH)|to compare tow doses of clexane for preventing VTE in postpartum women
1514970|NCT02856282|Drug|Pirinase Hayfever Relief for Adults 0.05% Nasal Spray|Aqueous suspension of 0.05% micronised fluticasone propionate.Each actuation contains 50 micrograms of fluticasone propionate
1514971|NCT02856269|Dietary Supplement|Zinc gluconate|Participants will take a daily dose of zinc gluconate.
1514972|NCT02856256|Dietary Supplement|RedBull® energy drink|Subjects consume 25 mL of RedBull® energy drink
1514973|NCT02856243|Drug|new antiviral therapy|
1514974|NCT02856230|Device|Ranger SL DEB|BTK angioplasty using Ranger SL DEB
1514975|NCT02856217|Procedure|Peritoneal tunneling or non-tunneling during minimal invasive abdominal sacrocolpopexy|Placement of mesh between vaginal apex and sacrum is retroperitoneally (creating a tunnel between vaginal apex and sacrum under peritoneum without disturbing the integrity of the peritoneum) or placement of mesh between vaginal apex and sacrum is retroperitoneally (incised and sutured peritoneum between vaginal apex and sacrum).
1514976|NCT02856204|Other|Cytology Specimen Collection Procedure|Undergo collection of blood
1514977|NCT02856204|Other|Laboratory Biomarker Analysis|Correlative studies
1514978|NCT02856191|Other|Holter|
1514979|NCT02856178|Drug|F901318|F901318 treatment starting after completion of chemotherapy. Max. 14 days of intravenous F901318 b.i.d. treatment, followed by one oral dose of F901318. Loading doses 4 mg/kg b.i.d. , maintenance doses 2 mg/kg b.i.d.
1514980|NCT02856178|Drug|Caspofungin|Intravenous Caspofungin treatment starting during chemotherapy for concomitant prophylaxis of fungal infection. Loading dose 70 mg q.d., maintenance doses 50 mg q.d.
1514981|NCT02856165|Device|High-flow nasal canula oxygen therapy|High-flow nasal canula oxygen therapy (HNF) using Optiflow junior system and AIRVO2 turbine (F&P, NZ) at initial flow to 3l/kg/min (up to a maximum of 20l/min), FiO2 adjusted for SpO2 > 94%.
1514982|NCT02856165|Device|Low-flow oxygen therapy with standard nasal canula|flow adjusted to SpO2 > 94% (up to a maximum of 2l/min).
1514983|NCT02856152|Drug|GDC-0276 capsule|Three 90 milligram [mg] capsules of GDC-0276 administered orally.
1514984|NCT02856152|Drug|GDC-0276 tablets|Three 90 mg GDC-0276 tablets administered orally.
1514989|NCT02856113|Drug|Alogliptin Benzoate|Alogliptin benzoate tablets
1514990|NCT02856113|Drug|Placebo|Alogliptin benzoate placebo-matching tablets
1514991|NCT02856100|Drug|18F DCFPyL- Radiopharmaceutical|
1514992|NCT02856087|Drug|High dose Remifentanil|remifentanil infusion at 4ng/ml of Ce
1514993|NCT02856087|Drug|Naloxone|naloxone infusion
1514994|NCT02856087|Drug|Low dose remifentanil|remifentanil infusion at 1ng/ml of Ce
1514995|NCT02856087|Drug|Normal Saline|normal saline infusion
1515037|NCT02855710|Other|Rhythm workers training Perceptive timing|Perceptive timing training
1514998|NCT02856061|Behavioral|Pivotal Response Treatment|Pivotal response treatment (PRT) is an empirically validated behavioral treatment for individuals with ASD that has its foundation in principles of Applied Behavioral Analysis. It was designed to improve social communication skills by addressing core deficits in social motivation or pivotal responses. By working specifically with each child's natural motivations, PRT focuses on naturalistic, functional skills, as opposed to rote skills. In this study, participants randomized to the PRT group will receive 6 hours of direct PRT, across three sessions per week, provided by Dr. Ventola's clinical team. Parents will have an additional one-hour session per week focused on PRT parent training using a practice-with-feedback model. Specific intervention goals in our target population include: Speech to respond to inquiries, Speech to inquire, Speech to comment, Reciprocal conversation, Monitor nonverbal information, and Perspective taking.
1514999|NCT02856048|Drug|Triptorelin (GnRHa) + Chemotherapy|During her chemotherapy, the patient in the experimental arm will have regular injections of Triptorelin (DECAPEPTYL LP 3 mg, IPSEN) in order to preserve her fertility
1515000|NCT02856035|Other|Neural feedback plus FES and motor training|Neural feedback involves sequential rtfMRI (phase I) and rtfNIRS (phase II) training; Neurally-triggered, peripherally-directed FES-assist practice of wrist and finger extension will be combined with rtfNIRS training in Phase II; 46 additional motor learning sessions without brain neural feedback will be provided in Phase III.
1515001|NCT02856022|Device|Electrical ilioinguinal nerve stimulation|"Four abdominal points are selected. The upper two points are located 2.5 cun bilateral to Guanyuan (Ren 4). The lower two points are located 1.5 cun bilateral to Zhongji (Ren 3). Four long needles are punctured obliquely 1~2 cun in depth (depending on the fat layer thickness of the patient) to the four points to make the needling sensation reaching the urethra or vulva.
After the needling sensation reach the above regions, each of two pairs of electrodes from a device are connected with the two ipsilaterally inserted needles. The parameters are continuous waves, a frequency of 2.5 Hz and intensity that the patient feels comfortable for 60 min, three times a week for at least four weeks."
1515002|NCT02856022|Procedure|Intravesical Irrigation|The patient was asked to lie on a couch in a lithotomy position after urination. A catheter was passed through the urethra into the bladder and any residual urine drained. The Cystistat 50mL 40mg (sodium hyaluronate, Bioniche Teoranta, Ireland) solution is instilled through the catheter into the bladder. The catheter is then withdrawn leaving the Cystistat inside the bladder coating the lining. It was recommended the solution was retained for as long as possible, ideally at least 30 minutes. The instillation is once weekly for at least four weeks.
1515004|NCT02855996|Other|Fathers in Action/Padres Activos (FA/PA) program|The program focuses on increasing the father's role in the child's education, nurturing and bonding with the child, loving and respecting the child's mother, coaching the child, and serving as a role model. The program also includes employment coaching.
1515005|NCT02855983|Procedure|Fat Grafting|Grafting of autologous fat tissue is a minimally invasive surgical technique that starts with the harvest of fat tissue from the abdomen or thighs using liposuction through incisions less than 2mm in length. The lipoaspirate is then processed to concentrate the adipose fraction and reinjected into the graft site. This surgical procedure involves the immediate transplantation of a patient's own tissue in a single operative procedure.
1515006|NCT02855970|Other|completion of a quality of life questionnaire|
1515007|NCT02855957|Other|Free α-Hb pool analysis|
1515008|NCT02855944|Drug|Chemotherapy|Chemotherapy will be administered per local standard of care and regulations. Specific comparator will depend on platinum status and investigator decision.
1515009|NCT02855944|Drug|Rucaparib|Tablets of rucaparib, at a dose of 600 mg, will be taken orally twice daily
1515011|NCT02855918|Other|Blood sample for genetic purpose|"All the participants will performed the same evaluations and blood analysis :
A clinical assessment by psychiatrist
Self report questionnaires for the assessment of a potential mood disorder and history of SB, moral/physical pain, personality traits…
A neuropsychological assessment for the evaluations of cognitive performances
A routine blood sampling to the realization of a standard blood test
A specific blood sampling (PAXgene® tubes) to extract total RNA of blood cells and measure the expression of ADARS RNA and editing of the PDE8A transcript."
1515013|NCT02855892|Other|Placebo|
1515014|NCT02855892|Drug|GV1001|
1515015|NCT02855879|Other|Collection of biological data|
1515016|NCT02855879|Other|Collection of clinical data|
1515017|NCT02855866|Procedure|thyroidectomy|
1515018|NCT02855866|Other|cryotherapy|
1515019|NCT02855866|Drug|cortisone aerosol|
1515020|NCT02855866|Drug|Dexamethasone acetate|
1515021|NCT02855866|Drug|paracetamol|
1515022|NCT02855853|Other|serious game et virtual reality|
1515023|NCT02855853|Other|Nintendo Wii|
1515026|NCT02855801|Other|constant exercise|
1515027|NCT02855801|Other|cryotherapy|
1515028|NCT02855801|Other|intermittent exercise|
1515029|NCT02855788|Drug|Paclitaxel 60mg/m2, Oxaliplatin 50mg/m2, Leucovorin 20mg/m2, and 5-FU 425mg/m2 IV weekly|metronomic chemotherapy
1515030|NCT02855775|Other|additional blood sample|blood sample every 3 weeks
1515031|NCT02855762|Other|High polyunsaturated fatty acid diet.|The investigators hypothesize the diet will improve gut health and psychiatric clinical outcomes.
1515032|NCT02855749|Procedure|ultrasound-guided percutaneous tracheostomy|to compare the reliability of the traditional landmark method, ultrasound-guided long axis in plane applications and ultrasound-guided short-axis out of plane application in the implementation process percutaneous tracheostomy
1515033|NCT02855736|Behavioral|Positive Psychology|"Gratitude Journal (Emmons and Stern, 2013)
Every evening, patients have to write down the things they feel grateful about."
1515034|NCT02855736|Behavioral|Placebo (food journal)|"Food journal (i.e. alimentary list):
Patients have to write down the list of foods eaten during the day."
1515035|NCT02855723|Other|Surgery: GS strategy|sentinel node biopsy
1515039|NCT02855710|Other|No Rhythm workers training|No training
1515046|NCT02855671|Device|Infrared thermal imaging|Patients in all groups will undergo infrared thermal imaging of the face and anterior leg (centered on the knee)
1515047|NCT02855658|Drug|SS-1|The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12 weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12 weeks SS-1 treatment. SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day.
1515048|NCT02855658|Drug|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
1515049|NCT02855645|Drug|Trichosanthes root|Trichosanthes root at a rate of 1.5 g two times per day for 84 days.
1515050|NCT02855645|Drug|Placebo|Trichosanthes root at a rate of 0.15g (10%) two times per day for 84 days.
1515051|NCT02855632|Drug|G-CSF|7 days after first hysteroscopic adhesiolysis, G-CSF will be injected into the uterine cavity after balloon removing.
1515052|NCT02855632|Drug|Normal saline|7 days after first hysteroscopic adhesiolysis, normal saline will be injected into the uterine cavity after balloon removing.
1515053|NCT02855632|Drug|hormone therapy|In all cases hormone therapy was commenced shortly after the operation, consisting of oestradiol valerate at a dose of 6 mg per day for 21-28 days with the addition of medroxyprogesterone acetate at a dose of 6 mg per day for the last 7-10 days of the oestrogen therapy. Following the withdrawal bleed, the hormone therapy was repeated for another cycle.
1515054|NCT02855632|Other|Cook balloon|At the end of the procedure, the Cook balloon were placed in the uterine cavity of each patient.the device was removed after 7 days.
1515055|NCT02855619|Procedure|Martin|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to the higher resistance tolerated by the patient in a set of 6 breaths. Participant repeats 4 sets of 6-10 breaths with 2 minutes of resting with mechanical ventilation between each set.
This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
1515056|NCT02855619|Procedure|Cader|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance to 30% of the Maximal Inspiratory Pressure initially recorded the day of the inclusion. Participant breaths against this resistance during 5 minutes. The resistance is daily increased of 10 % to the higher tolerated.
This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
1515057|NCT02855619|Procedure|EDRIC|"The physiotherapist perform the IMT using the threshold IMT inspiratory muscle trainer, connected to the intubation tube. He manage the resistance at 30% of the Maximal Inspiratory Pressure of the day for the first set of 20 breaths with a resistance 's increasment of 10% at each set. Participant repeats 4 sets of 20 breaths with 2 minutes of resting with mechanical ventilation between each set.
This treatment is made twice a day, 7days per week from inclusion to extubation exept if Glasgow score is under 8, hyperthermia more than 39°c, haemodynamic's instability, or hypoxemia( PaO2/FiO2<150)."
1515058|NCT02855567|Device|Acupuncture needles|Acupuncture needles (29 and 30 gauge) used to perform the acupuncture
1515059|NCT02855554|Other|Cardiac Magnetic Resonance (CMR) imaging techniques|Evaluation of clinical potential of fast quantitative myocardial tissue characterization using recently emerged CMRI techniques to aid the diagnosis, treatment, and follow up of patients with myocardial diseases.
1515061|NCT02855528|Device|Tin Filter|
1515062|NCT02855515|Procedure|Short-time diagnostic anaesthesia|Patients will undergo a short-time general anaesthesia in order to diagnose Obstructive Sleep Apnoea when relaxed.
1515063|NCT02855502|Drug|Prednisolone|
1515064|NCT02855502|Drug|Placebo|
1515065|NCT02855489|Behavioral|Attitudes Only|
1515066|NCT02855489|Behavioral|Norms Only|
1515067|NCT02855489|Behavioral|Perceived Behavioral Control Only|
1515068|NCT02855489|Behavioral|Intentions Only|
1515069|NCT02855489|Behavioral|Three Constructs|
1515070|NCT02855489|Behavioral|Four Constructs|
1515071|NCT02855450|Drug|rhNGF|Recombinant Human Nerve Growth Factor 180μg/ml (one 35 μl drop equals to 6.30 μg of rhNGF) reconstituted solution
1515072|NCT02855450|Drug|Vehicle|Ophthalmic Placebo solution of the same composition as the test product with the exception of rhNGF reconstituted solution
1515073|NCT02855437|Device|IVR (Phone call)|IVR will auto dial participants at a schedule time. Participants complete questions using their phone keypad. Participants can also call the IVR to complete surveys if they experience a flare. The IVR will be programmed to call the patient weekly for 26 weeks to complete a weekly Gout Flare Survey and Patient Reported Outcomes Survey. Consistent with the published gout flare self-report definition, gout flare ascertainment questions will include whether the recent flare is similar to past flares, the number of swollen joints and the number of warm joints. Pain at rest during the attack will be assessed on a 0-9 scale. Further questions will include peak pain, timing of attack and duration of attack if completed. We will capture patient reported outcome measures (e.g. pain, fatigue, sleep) using instruments from NIH PROMIS. In addition at months 1 , 3, and 6 will assess IVR ease of use, burden of use, and disruption to daily activities.
1515074|NCT02855437|Device|RheumPro (Smartphone application)|"RheumPRO will be programmed to notify participants weekly for 26 weeks via a scheduled pop-up to complete Gout Flare and Patient Reported Outcomes Surveys. Participants self-navigate through the survey questions using their smartphone. If participants do not complete the Gout Flare or Patient Reported Outcomes surveys RheumPro will generate 2 more pop-ups at the same time over the proceeding 2 days (eg. Tuesday 4 PM, Wednesday 4 PM). Participants can also open the RheumPro application on their smartphone and complete surveys or if they experience a flare on a day they are not scheduled to complete a survey. In addition RheumPro questionnaires at months 1 , 3, and 6 will assess RheumPro ease of use, burden of use, willingness to continue use and disruption to daily activities."
1515075|NCT02855424|Other|the low-intensity exercise group|Totally 20-time training, frequency 2-6 time/week, total 20 times.
1515076|NCT02855424|Other|the moderate-intensity exercise group|Totally 20-time training, frequency 2-6 time/week,total 20 times.
1515077|NCT02855411|Drug|PF-04958242|0.15 mg or 0.5 mg, twice daily (BID) for 12 weeks, capsule
1515078|NCT02855411|Drug|placebo|placebo, twice daily (BID) for 12 weeks, capsule
1515079|NCT02855372|Procedure|Lung transplantation|
1515086|NCT02855346|Combination Product|200 mg of DPV + 320 mg LNG|DPV VR, containing 200 mg DPV
1515087|NCT02855346|Combination Product|200 mg of DPV|DPV-LNG VR, containing 200 mg of DPV + 320 mg LNG
1515088|NCT02855333|Other|EORTC and QLQ-C30 / QLQ-OES24 questionnaire|EORTC and QLQ-C30 / QLQ-OES24 questionnaire was sent to patients to asses QoL after MER or CON procedure
1515089|NCT02855320|Other|Nurse-led self-management education intervention|A nurse education consultation at M 0 and M3 in addition to the usual care by the rheumatologist. The nurse will assess the patients' health beliefs and educational needs, focusing on safety skills, self-injections and motivation. The control group will have usual care by the rheumatologist.
1515090|NCT02855307|Other|60-minute exercise|Patients will be admitted at the research clinical facility at 6:30. The artificial pancreas intervention will start at 7:00. A standardized breakfast will be served at 8:00. At 9:30, patients will performed a 60-minute exercise on the ergocycle at 60% of VO2 max. At 11:30, patients will be switched to standard insulin pump therapy and a lunch will be served. Patients will be discharged after lunch consumption.
1515091|NCT02855307|Device|Insulin pump|Patient's insulin pump will be used to infuse insulin. An Accu-Chek Combo (Roche) will be used to infuse glucagon.
1515092|NCT02855307|Device|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
1515093|NCT02855307|Drug|Insulin|Patient's usual fast-acting insulin analog will be used.
1515094|NCT02855307|Other|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Patient's usual fast acting insulin analog (Lispro, Aspart or Guilisine) will be infused using the patient's pump. The glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom Inc.) will be entered manually into the computer every 10 minutes. The pump's infusion rate will then be changed manually based on the computer generated recommendation infusion rates.
1515095|NCT02855294|Drug|COC containing 30 μg of EE and 3mg of drospirenone|treatment for 6 consecutive cycles. Each treatment cycle consisted of 3 weeks of pill treatment followed by a 1-week pill-free period.
1515098|NCT02855255|Behavioral|NHS 1-1 smoking cessation programme.|Smoking cessation using cognitive behavioural therapy/motivational interviewing
1515099|NCT02855255|Behavioral|Group smoking cessation programme|Smoking cessation using Allen Carr's Easyway method being delivered in a spoken form.
1515100|NCT02855242|Behavioral|Lifestyle Counseling|Participation in weekly group sessions over a period of 10 weeks, with information on healthy nutrition and exercises promoting weight loss
1515101|NCT02855242|Other|Controls Group|Subjects not participating in any lifestyle counseling
1515102|NCT02855216|Other|Manual technique of sub-occipital inhibition|
1515103|NCT02855216|Other|Self-treatment by way of Occipivot®|
1515104|NCT02855203|Radiation|Stereotactic Ablative Body Radiosurgery (SABR)|
1515105|NCT02855203|Drug|Pembrolizumab|
1515106|NCT02855190|Other|68Ga-citrate and 18F-FDG PET scans|68Ga-citrate and 18F-FDG PET/CT or PET/MR scans before operations
1515107|NCT02855177|Drug|Placebo|Placebo as suspension administered every 8 hours, with food
1515108|NCT02855177|Drug|PF-06427878|500 mg suspension administered every 8 hours, with food
1515109|NCT02855164|Drug|LJN452|Comparison of different doses of drug
1515110|NCT02855164|Drug|Placebo|Comparator
1515111|NCT02855138|Drug|oral isotretinoin|
1515112|NCT02855125|Drug|TAS-114|TAS-114 is a modulator of 5-fluorouracil (5-FU).
1515113|NCT02855125|Drug|S-1|S-1 was designed to provide oral delivery of 5-FU and to reduce the rate of degradation of 5-FU in vivo.
1515114|NCT02855112|Biological|Adipose derived mesenchymal stem cell|Allogeneic Adipose derived Mesenchymal Stem cell transplant
1515115|NCT02855099|Other|Rehabilitation|The duration on the rehabilitation will be 3 month and will be a multidisciplinary program that includes supervised physical activity
1515116|NCT02855086|Biological|Cetuximab|Given IV
1515117|NCT02855086|Drug|Cetuximab-IRDye 800CW|Given IV
1515118|NCT02855086|Procedure|Conventional Surgery|Undergo tumor resection
1515119|NCT02855086|Other|Laboratory Biomarker Analysis|Correlative studies
1515120|NCT02855073|Biological|ReJoinTM|adipose derived mesenchymal progeinitor cells
1515121|NCT02855073|Drug|Sodium Hyaluronate|Sodium Hyaluronate Injection
1515123|NCT02855034|Other|Blood samples|Blood samples for dosage: copeptine and protein S100B
1515124|NCT02855021|Other|Explorations|"Imaging tests and neuropsychological assessment are carried out within 60 days following patient enrollment.
Neuropsychological assessment lasts 1:30 to 2:00 hours and is conducted by a psychologist in an interview during which patient will pass several tests on memory, language, attention or orientation in space.
These tests do not require discontinuation of Parkinson's disease treatment."
1515125|NCT02855008|Behavioral|STEPS|Nine agencies will be randomly ordered for participation. Within each agency, six group homes (3 male; 3 female) will be identified and randomly assigned to either experimental or active comparator condition. Individuals with ID and staff in the group homes will be recruited after randomization to simplify the process of explaining the study. Residential staff will be consented first and informed about the study, its risks, and assured that participation is voluntary; if fewer than two consent, that group home will be ineligible and the third group home serving the same gender will be approached. Individuals with ID (or guardians if they have one; if so assent will be obtained) will be informed of the study, its risks and that participation is voluntary. 18 homes will participate in STEPS.
1515126|NCT02855008|Behavioral|Food for Life|Nine agencies will be randomly ordered for participation. Within each agency, six group homes (3 male; 3 female) will be identified and randomly assigned to experimental or active comparator conditions. Individuals with ID and staff in the group homes will be recruited after randomization to simplify the process of explaining the study. Residential staff will be consented first and informed about the study, its risks, and assured that participation is voluntary; if fewer than two consent, that group home will be ineligible and the third group home serving the same gender will be approached. Individuals with ID (or guardians if they have one; if so assent will be obtained) will be informed of the study, its risks and that participation is voluntary. 18 homes will be in Food for Life.
1515129|NCT02854982|Procedure|therapeutic management of the prostate Cancer as usual|
1515130|NCT02854969|Behavioral|Device: Anapphylaxis|
1515131|NCT02854956|Behavioral|Neuropsychological, cognitive and behavioral assessment|"The assessment includes mainly :
The Raven's Progressives matrices test which allow to assess the non-verbal reasoning mental age of the patient
The Wechsler scale or Brunet Lézine scale which allow to assess The Intellectual Quotient
The Peabody Picture Vocabulary Test Revised which allow to determine the Vocabulary age (receptive language).
The Vineland adaptive behavioral scale which allow to assess the adaptive behavior
The Nisonger child behavior rating form which allow to assess the behavior disorders
Analogical visual reasoning task (eye-tracking assessment and behavior assessment) which allow to identify the strategy used to solve the task and provides an objective and quantitative assessment of visual analogical reasoning and cognitive inhibition.
Kinematic analysis of a grasping movement which allow to study the effect of the orientation and the type of pinch on the movement duration and both the transport component and the grasp component."
1515132|NCT02854930|Other|questioning|
1515133|NCT02854904|Drug|Dexmedetomidine intervention|Immune effect of alpha-2 agonist to arthrodesis. Dexmedetomidine as a immune control anesthesic in patients undergoing to arthrodesis. Alpha-2 agonist to general anaesthesia.
1515134|NCT02854904|Drug|Placebo|Placebo controlled
1515135|NCT02854891|Other|autorefractometer, A-scan ultrasound|A measurement of refraction will be made by the Autorefractometer. A measurement of the eyes' biometer data will be made by A-scan ultrasound.
1515136|NCT02854878|Device|The Lucy ultrasonic comb models A and B combined with the LucyGel|
1515138|NCT02854839|Biological|MG4101|MG4101 is ex vivo-expanded, allogeneic natural killer cells. MG4101 were manufactured from normal healthy donor who underwent lymphopheresis under good manufacturing practice (GMP) conditions.
1515139|NCT02854826|Other|SAFE Care model of care|"SAFE Care Model Site Intervention:
Endorse best practices for frail patients;
Identify frail patients promptly using multi-dimensional screening and assessments;
Employ interprofessional unit-based care team approach to frailty risk reduction during inpatient stay and create post-acute care transitions (PACT) plan recommendations;
Develop electronic health record templates for patient-centered interprofessional frailty notes;
Communicate PACT plans to primary care providers to promote safe transitions to the ambulatory setting and across the continuum of care.
Increase awareness, improve management of frailty, and improve overall health and well-being for adults who are frail or at risk of becoming frail."
1515140|NCT02854800|Drug|varenicline|Participants will follow the schedule of dosing that is specified on the label: 0.5 mg once daily (Days 1-3), 0.5 mg twice daily (Days 4-7), and 1 mg twice daily (Days 8-84).
1515143|NCT02854774|Behavioral|Muscle activation exercises|
1515144|NCT02854761|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
1515145|NCT02854748|Drug|Empagliflozin 25mg|Empagliflozin 25 mg QD for 5 days
1515146|NCT02854748|Drug|Lobeglitazone 0.5mg|Lobeglitazone 0.5mg QD for 5 days
1515147|NCT02854748|Drug|Empagliflozin 25mg/Lobeglitazone 0.5mg|Empagliflozin 25 mg + Lobeglitazone 0.5mg QD for 5 days
1515646|NCT02850575|Device|Mpact Double Mobility cup|
1515148|NCT02854735|Other|Imaging by CT and densitometry|Imaging by CT and densitometry, no intervention involved
1515149|NCT02854722|Drug|Deferasirox and calcium-vitamin D3|"deferasirox and calcium-vitamin D3 Deferasirox is an orodispersible tablet and should be taken daily 30 minutes before breakfast, with a dose of 10 mg/Kg/day ± 5 mg/Kg/day during 12 month.
Calcium 500 mg and vitamin D3 800 IU should also be taken daily as a basic therapy."
1515150|NCT02854722|Drug|Calcium-vitamin D3|Calcium 500 mg and vitamin D3 800 IU are taken daily as a basic therapy.
1515151|NCT02854709|Behavioral|Sleep extension|Sleep extension by 1 hour for 2 weeks
1515152|NCT02854696|Procedure|Islet graft|Patients will be transplanted with pancreatic islet cells
1515153|NCT02854696|Drug|best medical care|Patients will continue their insulin treatment
1515154|NCT02854683|Drug|Normal Saline|1 liter of intravenous saline will be delivered over 1 hour
1515155|NCT02854683|Dietary Supplement|Oral Rehydration Solution|1 liter of ORS solution given by mouth
1515156|NCT02854670|Drug|Capsaicin patch|After a pre-medication with paracetamol, patches are applied and removed after 20 minutes. Patients remain under observation for 2 hours after removal.
1515157|NCT02854657|Behavioral|Skin Self- examination structured training|A PowerPoint presentation will be provided as a PDF file. The file will be available in English and Spanish. This is the same skin self-examination structured training intervention used in the original RCT (MoleScore)
1515158|NCT02854644|Other|additional blood sample|
1515163|NCT02854605|Drug|GS-9674|Tablet administered orally once daily
1515164|NCT02854605|Drug|Placebo to match GS-9674|Tablet(s) administered orally once daily
1515165|NCT02854592|Drug|rtPA|intravenous thrombolysis with rtPa
1515166|NCT02854592|Drug|urokinase|intravenous thrombolysis with urokinase
1515167|NCT02854579|Biological|neural progenitor cell|Neural progenitor cells are derived from the same aborted human fetal forebrain.
1515168|NCT02854579|Biological|Paracrine factors|The factors obtained from cultured human mesenchymal stem cells were concentrated 50 times
1515169|NCT02854579|Biological|progenitor cell and paracrine factors|Neural progenitor cells will be received after paracrine factors therapy
1515170|NCT02854566|Device|osteosynthesis|Fracture reduction and fixation with screws/plates/cables (standard of care)
1515171|NCT02854553|Procedure|Transversus abdominis plane block|ultra sound guides Transversus abdominis plane block
1515172|NCT02854553|Procedure|rectus sheath block|ultrasound guided rectus sheath block
1515173|NCT02854540|Device|Hydrogel electrode-based iontophoresis|During the 12 day treatment period, participants will be asked to treat one hand with the hydrogel electrode-based iontophoresis device on a daily basis. Participants will also be asked to leave the other hand untreated.
1515182|NCT02854514|Procedure|Aspiration of endometrial secretion|intra uterine flushing of the endometrial cavity by five millilitre of saline through embryo transfer catheter then aspirated then centrifuged then analyzed for detection of concentration of tumor necrosis factor a and interleukin 1 b
1515183|NCT02854488|Drug|Yervoy|
1515184|NCT02854475|Procedure|Venous blood collection|weekly within two weeks
1515185|NCT02854475|Procedure|Raman spectroscopy|weekly within two weeks, on the volar forearm, using a RiverDiagnostics gen2-SCA Skin Composition Analyzer
1515186|NCT02854462|Behavioral|Language comprehension intervention|
1515187|NCT02854462|Behavioral|Counting intervention|
1515188|NCT02854436|Drug|Niraparib|Participants will receive 300 mg niraparib (3 capsules*100 mg) orally once daily.
1515189|NCT02854423|Device|percutaneous coronary interventions|Consecutive diabetic patients undergoing percutaneous coronary interventions with Biodegradable polymer Biolimus Eluting Stent or durable polymer Everolimus Eluting Stent implantation
1515190|NCT02854410|Dietary Supplement|Sodium nitrate|Dietary intake:Sodium nitrate 0.5mmol/kgbodyweight,bid
1515191|NCT02854410|Dietary Supplement|sodium chloride|Dietary intake:sodium chloride 0.5mmol/kgbodyweight,bid
1515192|NCT02854397|Other|blood sample|
1515193|NCT02854371|Drug|gadoxetic acid enhanced liver MRI|"Gadoxetic acid enhanced liver MRI is performed and the standard dose of contrast media (0.025mmol/kg) is administered intravenously at a rate of 1mL/sec. Before and after contrast media injection, T1 map sequence is performed to calculate hepatocyte fraction.
Routine MR sequences (T2WI, T1WI, dual-echo sequence, DWI, MR elastography) are performed according to clinical protocol in the institution."
1515194|NCT02854371|Drug|ICG R15|ICG R15 (Indocyanine green retention test) is performed within 3 days after gadoxetic acid liver MRI, according to clinical standard protocol.
1515195|NCT02854358|Drug|mixed powder of A. digitata and M. sylvestris|
1515196|NCT02854358|Drug|Hypozalix spray (artificial saliva)|Hypozalix spray (artificial saliva)
1515197|NCT02854345|Device|Tomoscintigraphic parathyroid imaging on a CZT camera|
1515198|NCT02854332|Device|tDCS session|Direct current transcranial magnetic stimulation
1515199|NCT02854332|Device|rTMS session|Repetitive transcranial magnetic stimulation.
1515200|NCT02854319|Device|LOTUS Edge Valve System|Transcatheter Aortic Valve Implantation (TAVI) with the LOTUS Edge™ Valve System when used with the Lotus™ or iSleeve™ Introducer Set
1515201|NCT02854306|Procedure|Bariatric surgery|With mindfulness programm
1515202|NCT02854306|Procedure|Bariatric surgery|Without mindfulness programm
1515203|NCT02854293|Other|Booklet-Question List|"Booklet-Question List (BQL) proposed in palliative cares, divided into 8 chapters, given to the patient before the first palliative care consultation.
Providing a list of questions to patients and their families without any obligations allows individual adaptation of information; patients or families who are afraid of asking these questions can take advantage of this opportunity, while respecting the need to avoid these subjects for other patients"
1515204|NCT02854280|Biological|Pedalling exercise on a cycle ergometer|At 80% of the maximal aerobic power, until exhaustion
1515205|NCT02854280|Biological|Isolated contractions of the quadriceps|Until exhaustion
1515206|NCT02854254|Device|peripherally inserted central catheter|peripherally inserted central catheter
1515207|NCT02854254|Device|peripherally venous access|standard over-the-needle intravenous catheter
1515208|NCT02854241|Procedure|Biannual ultrasonography|Biannual ultrasonography for HCC surveillance, performed by board-certified radiologists.
1515209|NCT02854241|Procedure|Annual noncontrast liver MRI|"Annual noncontrast liver MRI consisted of T2WI, precontrast T1WI, dual-echo image, DWI (single shot, multishot) and T2 map.
DWI using multishot and T2 map are not included for initial MR reading."
1515210|NCT02854241|Procedure|Contrast enhanced liver CT|In patients without report of HCC during surveillance period, contrast CT is performed 6 months after the last MR scan.
1515212|NCT02854202|Other|Arm1: Whey protein|Arm1: Whey protein:The participants will consume 42 g protein, namely from Whey protein in the breakfast
1515213|NCT02854202|Other|Arm 2 Breakfast- other proteins|Arm 2 Breakfast- other proteins: The participants will be assigned to 42 g protein of other protein sources at breakfast
1515214|NCT02854202|Other|Arm 3 Breakfast- low protein|Arm 3: Low protein' :The participants will consume 22 g protein at breakfast
1515215|NCT02854189|Device|Oxford unicompartmental knee arthroplasty|The Oxford unicompartmental knee arthroplasty was applied in all patients with medial osteoarthritis knee.The Oxford unicompartmental knee arthroplasty is mobile bearing unicompartmental knee arthroplasty.
1515216|NCT02854176|Procedure|Somatosensory electrical stimulation|
1515217|NCT02854176|Procedure|Control|
1515218|NCT02854163|Drug|Secukinumab|All eligible patients registered into the study will receive four 150 - 300 mg subcutaneous injections at weekly intervals, followed by regular injections 150mg once a month thereafter for a total of 12 months
1515219|NCT02854150|Genetic|characterization of variants in new genes using high throughput sequencing either on a panel of targeted genes or on exome in families.|
1515220|NCT02854137|Drug|BAY987521|10 micro L of the appropriate test product is place into the lower conjunctival sac of the designated eye (Formulation code: Y49-103).
1515221|NCT02854137|Drug|Control|10 micro L of the appropriate controlled product is place into the lower conjunctival sac of the designated eye.
1515222|NCT02854124|Procedure|Melanoma and peritumoral skin excision|Surgical retrieval of the primary tumor and safety retrieval of the surrounding normal peritumoral skin and sentinel lymph node
1515225|NCT02854085|Behavioral|Art Therapy|The Art Therapy will consist of creating art pieces, narrating thoughts and inner experiences in relation to the pieces produced (2 sessions a month) and guided visits to the art gallery (one session a month) and art museum (one session a month); there will be 12 sessions weekly for 12 weeks. For the next 6 months, sessions will be fortnightly and consist of creating an art piece once a month alternating with a visit to either the art museum or gallery, once a month; there will be 12 sessions in 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead.
1515226|NCT02854085|Behavioral|Music Reminiscence Activity|Music Reminiscence activity will be held weekly for 12 weeks and fortnightly for 6 months. Each session will last 45 minutes and will begin with 5 minutes of mindful relaxation to help participants focus on the task ahead. Session will entail listening and watching music videos and discussing activities, events and experiences related to the music; additional prompts such as photographs may be used to facilitate therapy.
1515227|NCT02854072|Drug|GV1001|At week 1, GV1001 will be administered intradermally on day 1, day 3 and day 5. This will be followed by a once weekly schedule for weeks 2, 3, 4 and 6. After that, GV1001 will be administered once monthly until withdrawal from trial treatment due to patient choice, intolerable toxicity or disease progression. GM-CSF will be used as an adjuvant, given 10-15 minutes prior to each administration of GV1001.
1515228|NCT02854072|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 will be intravenously administered on day 1,8 and 15 followed by 7 days' rest.
1515229|NCT02854072|Drug|Capecitabine|Capecitabine 830 mg/m^2 will be orally given in the morning and evening (total dose of 1660 mg/m^2) for 21 days followed by 7 days' rest.
1515230|NCT02854059|Biological|HMed-IdeS|One dose of 0.25 mg/kg BW HMed-IdeS on study day 0. Following and evaluation of efficacy and safety in the first three patients the dose may be increased to 0.5 mg/kg BW.
1515231|NCT02854046|Other|Calcific Uremic Arteriolopathy|
1515232|NCT02854007|Device|Coronary angioplasty with implant of bioresorbable device|Percutaneous coronary intervention
1515233|NCT02853981|Device|Harmonic scalpel|a method for liver parenchymal transection
1515234|NCT02853981|Device|Kelly clamp crush technique|a method for liver parenchymal transection
1515235|NCT02853968|Procedure|Blood draw/buccal swab|The research project will need a blood sample of no more than 50mL per two month period. The research project may also request a buccal swab from patients if needed.
1516778|NCT02841878|Genetic|Analysis on colorectal biopsy|
1515236|NCT02853955|Device|Percutaneous edge-to-edge repair of the mitral valve|MitraClip in patients with recurrent MI after surgical mitral valve repair.
1515237|NCT02853942|Biological|Autologous adipose stem cell therapy|
1515238|NCT02853942|Drug|Mecobalamin|
1515243|NCT02853903|Biological|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfusion in 3 times, i.v.
1515244|NCT02853890|Other|Questionnaires during hospitalization for delivery|Questionnaires during hospitalization for delivery (one questionnaire completed by doctors about different technic of analgesia and anesthesia and one questionnaire completed by women about pain, and feeling about the different techniques of analgesia and anesthesia used during delivery, eventually caesarean section or uterine revision)
1515245|NCT02853877|Behavioral|Weekly Incentive|The tailored incentives intervention aims to assess the impact of tailored messaging and financial incentives on weight loss among obese employees.
1515246|NCT02853864|Drug|0.0 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0 ng/ml
1515247|NCT02853864|Drug|0.4 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4 ng/ml
1515248|NCT02853864|Drug|0.6 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6 ng/ml
1515249|NCT02853864|Drug|0.8 ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8 ng/ml
1515250|NCT02853864|Drug|Propofol|The propofol infusion was started to provide an effect-site concentration of 1.0 ug/ml, and increased by 0.2 ug/ml until loss of consciousness
1515251|NCT02853851|Other|interviews|Each subject will be asked to participate in an individual semidirective interview lasting about 40 minutes on the theme of the stress factors encountered in intensive care. All of the interviews will be audio-taped, transcribed and anonymized. The participants will also have to answer a socio-demographic questionnaire (sex, age, socio-professional category, speciality in intensive care, working hours, family situation, training, diplomas, length of time in the service).
1515252|NCT02853838|Other|Prolonged slow expiration+provoked coughing|"Five cycles of prolonged slow expiration and provoked coughing, which will be repeated five times.
During the prolonged slow expiration, the infant will be in supine while the therapist applies pressure at the same time on the rib cage and abdomen during spontaneous expiration. The pressure is applied slowly during two o three respiratory cycles, only during the final phase of expiration."
1515253|NCT02853838|Other|Manual chest wall vibration|"Five cycles of manual chest wall vibrations during 20 seconds each, being repeated five times.
The manual chest wall vibrations are oscillatory maneuvers applied on the thorax to improve mucociliary clearance of bronchial mucus and ease its removal."
1515254|NCT02853838|Other|Standard Therapy|Standard therapy (ST): nasopharyngeal suction, oxygen therapy, fluids administration, 0.5% adrenaline nebulization, and chest physiotherapy.
1515255|NCT02853825|Behavioral|Relationship Skill Enhancement|Receive relationship classes with access to parenting, employment services, and financial services.
1515256|NCT02853812|Other|Functional brain MRI|Sound evoked functional MRI assessment on patients with single sided tinnitus
1515257|NCT02853799|Other|Comparison of the Effects of Intermittent and Continuous Enteral Feeding on Glucose-Insulin Dynamics in Critically Ill Medical Patients|"Placement of feeding tube stomach (oral- or naso-gastric tube)
Randomized to receive either continuous feeding or intermittent feeding for 24 hours and then be crossed over to receive the other feeding for an additional 12 hours .
Placement of continuous glucose can be monitored (Dexcom G4).
During the study who will have 10 blood sugar checks.
If two blood sugars are above 180 mg/dl then you will be placed on regular insulin drip"
1515258|NCT02853799|Dietary Supplement|Osmolite 1.2 cal/ml Enteral Feeds|Osmolite 1.2 cal/ml Enteral Feeds via feeding tube (oral- or naso-gastric tube)
1515259|NCT02853786|Behavioral|LENA and advice|Language recording with the LENA device, with the LENA results, we will advise the parents how to improve the language environment to help their children with CIs for their language development
1515260|NCT02853786|Other|LENA without advice|Language recording with the LENA device. Regular speech therapy follow blindly the results of LENA
1515264|NCT02853760|Behavioral|walking|
1515265|NCT02853760|Device|Treadmill|
1515266|NCT02853734|Other|SEVERE PERIODONTITIS|Patients exhibiting moderate to severe periodontitis
1515267|NCT02853734|Other|NO PERIODONTITIS|Patients without existing periodontitis or exhibiting mild periodontitis
1515268|NCT02853721|Other|iPTH|iPTH assay six hours after surgery
1515269|NCT02853721|Other|no dosage of iPTH|Ca and P on postoperative day 1 and 2
1515270|NCT02853682|Biological|plasma|assesment of glycocalyx protein
1515271|NCT02853669|Procedure|Ultrasound-guided Lumber Plexus Block|(30 cc of 0.25% of bupivacaine, via a 22-gauge 2-inch Stimuplex A needle) with nerve stimulator confirmation. The type of motor response (e.g., quadriceps, patellar) and the minimum current needed were recorded. Ultrasound pictures (preinjection and postinjection) were obtained to verify proper local anesthetic placement.
1515272|NCT02853669|Procedure|adductor canal block|ultrasound-guided Adductor Canal Block (15 cc of 0.5% of bupivacaine)
1515273|NCT02853643|Drug|ASN002|Single dose study with food effect
1515274|NCT02853630|Drug|Metformin|Participant will be instructed to take Metformin tablets as per instructions given by the physician.
1515275|NCT02853630|Drug|Vildagliptin|Participant will be instructed to take one tablet of Vildagliptin 50mg per day, 30 minutes after breakfast in the morning and second tablet at night, 30 minutes after dinner
1515276|NCT02853617|Biological|AV0328 - Cohort 1|Cohort 1 will receive 15 µg to be given as an IM injection
1516779|NCT02841839|Drug|Stannous Fluoride|
1515277|NCT02853617|Biological|AV0328 - Cohort 2|Cohort 2 will receive 30 µg to be given as an IM injection
1515278|NCT02853617|Biological|AV0328 - Cohort 3|Cohort 3 will receive 75 µg to be given as an IM injection
1515279|NCT02853617|Biological|AV0328 - Cohort 4|Cohort 4 will receive 150 µg to be given as an IM injection
1515280|NCT02853604|Drug|ADXS11-001|
1515281|NCT02853604|Drug|Placebo|
1515282|NCT02853591|Procedure|Pneumoinsufflator mode and setting|Patients undergoing total laparoscopic hysterectomy will be randomized to pneumoperitoneum creation by one of two modes (standard or pressure-barrier) at one of two set pressures (15mmHg or 9mmHg) for a four-armed factorial designed study.
1515283|NCT02853578|Drug|Busonid (budesonide 200mcg and 400mcg)|"cartridge containing 60 tablets of 200 mcg or 400 mcg and an inhaler;
1 application (inhalation) of 200mcg every 12 noon (400 mcg / day). During the visits of monitoring (V1 and V2) the doctor in charge assess the need to increase the dose of PSI 400mcg for every 12 hours (800mcg / day); treatment for 12 weeks."
1515284|NCT02853565|Drug|CAN008|The dose escalation in the phase I study including 200mg in the first cohort and 400mg in the second cohort to Recommended for Phase 2 Dose (RP2D)
1515285|NCT02853552|Drug|Misoprostol|800mcg misoprostol taken sublingually
1515286|NCT02853539|Drug|Denosumab|Subcutaneous injection of Denosumab
1515287|NCT02853526|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach (p-TIPS). Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal for the prevention of shunt dysfunction.
1515288|NCT02853526|Drug|Propranolol|Propranolol is a kind of non-selective beta blockers, and is used for reducing the portal pressure.
1515289|NCT02853526|Procedure|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation and sclerotherapy.
1515290|NCT02853526|Drug|Warfarin|Oral warfarin was used for six months to one year prescribed at dosages to achieve an international normalized ratio (INR) of up to two times the upper limit of normal.
1515291|NCT02853500|Device|Surefire|Surefire is a modified microcatheter with an expandable cone at its tip to prevent retrograde reflux of flow and change flow dynamics downstream.
1515292|NCT02853500|Device|Traditional Delivery|Low profile tubing microcatheter for easier access to more peripheral/distal vascular branches for precise targeted delivery of medications.
1515293|NCT02853500|Drug|Doxorubicin|Medication used in cancer chemotherapy, including intraarterial delivery for liver malignancies.
1515294|NCT02853487|Device|Actigraphy|An actigraph from Philips
1515295|NCT02853487|Other|Diary|Questions on sleep times and awakenings and attacks in the morning and evening for 2 weeks.
1515296|NCT02853474|Behavioral|Early Palliative Care visit|"A PC visit is a visit done by a PC physician. Any kind of visits done by other professionals IS NOT a PC visit.
Five PC visits are scheduled in this arm."
1515297|NCT02853474|Other|EORTC-QLQ-C30 questionnaire|The Quality of Life is assessed with the QLQ-C30 questionnaire at baseline, 12 and 24 weeks after inclusion, as well as every 8 weeks thereafter.
1515298|NCT02853474|Other|HADS score|The depression is assessed with the HADS scale (Hospital Anxiety and Depression Scale) at baseline, and then 12 and 24 weeks after inclusion.
1515299|NCT02853461|Other|Sonication|Ultrasound bath (40 kHz, 1 W/cm2, 1 min) of bearing components of the prosthesis in sterile conditions.
1515300|NCT02853461|Other|Microbiological analysis|Plating the sonicates on agar plates.
1515301|NCT02853448|Device|Novel Blood Drawing Apparatus|
1515305|NCT02853396|Other|Cognitive Behaviour Therapy|
1515306|NCT02853396|Other|Psychoeducation|
1515307|NCT02853370|Drug|Bendamustine and Rituximab|
1515308|NCT02853357|Other|Manipulation|"Middle Thoracic: Participants are placed in the supine position with their arms over their chest. The clinician rolls the participant to their side and places the fulcrum at the desired thoracic segment and the participant is rolled back onto the clinician's hand. The participant is instructed to take a deep breath. As the participant is exhaling, the clinician uses his body to push through the participant's arms to perform a high velocity thrust in an anterior to posterior directed force. Lower Thoracic: With the patient in a prone position, the clinician achieves a skin lock with both pisiforms over the transverse processes of the target vertebra. The clinician then uses his body to push down through his arms to perform a high-velocity, low-amplitude posterior to anterior thrust."
1515309|NCT02853357|Other|Sham Manipulation|The participants are positioned in prone and the clinician's hands are placed with the pisiforms of each hand over the transverse processes of the target vertebra. The clinician will only apply minimal pressure and slide the hands across the skin to mimic the manipulative thrust. This sham procedure has been shown to be an adequate sham comparator for spinal manipulative therapy (SMT) with similar expectations and believability as SMT active treatment
1515375|NCT02852798|Drug|Apatinib Combined With Docetaxel|Docetaxel 75 mg/ (m2.d)IV gtt 1h d1 q3w Apatinib Mesylate Tablets : 500 mg qd, 4 weeks as one cycle for continuous drug administration
1515310|NCT02853357|Other|Core Strengthening Exercises|Both groups will receive the following exercises at each visit. The core strengthening (core strengthening) exercises are a standard protocol used by Richardson et al and Franca et al which are proposed to target muscles responsible for segmental stabilization, specifically the transverse abdominis (TrA) and the lumbar multifidi (LM). Exercises will include: TrA exercises in 4 point kneeling and in supine with flexed knee, LM exercises in prone, and co-contraction of TrA and LM in upright position. Three sets of 15 repetitions will be done for each exercise.
1515311|NCT02853344|Biological|Pembrolizumab|IV infusion
1515312|NCT02853331|Biological|Pembrolizumab|Intravenous infusion
1515313|NCT02853331|Drug|Axitinib|Oral tablet
1515314|NCT02853331|Drug|Sunitinib|Oral capsule
1515315|NCT02853318|Biological|Bevacizumab|Given IV
1515316|NCT02853318|Drug|Cyclophosphamide|Given PO
1515317|NCT02853318|Other|Laboratory Biomarker Analysis|Correlative studies
1515318|NCT02853318|Biological|Pembrolizumab|Given IV
1515324|NCT02853279|Behavioral|Interval exercise training|"Interval exercise sessions (INT) involving work:recovery ratios of 40 s at 70% delta work-rate followed by 80 s active recovery at 20 W. 70% delta (∆) is 70% of the difference between work rate peak (WRpeak) and work rate at the lactate threshold (WRLT) calculated as:
70%∆ =0.7(〖WR〗_peak- 〖WR〗_LT )+ 〖WR〗_LT
Where WR is work rate, LT is lactate threshold)
Each session was for 30 min and this was undertaken twice per week for 12 weeks. One home based exercise session was incorporated per week."
1515325|NCT02853279|Behavioral|Continuous exercise training (CON)|Exercise sessions involved cycling at 20%∆ work-rate peak for the duration of the session. This work-rate was chosen so that all participants in the group would be exercising in the heavy-intensity domain. To enable participants in the CON exercise group to complete the same amount of work (kJ) as the participants in the INT exercise group, the amount of work that would be completed if the CON participants completed an INT exercise session was calculated. Participants exercised for 26 min (varying to match interval group) twice per week for 12 weeks.
1515326|NCT02853266|Other|laboratory biomarker analysis|Archived serum samples are analysed for measurement of biomarker NCRA
1515327|NCT02853253|Dietary Supplement|SMOFlipid®|"SMOFlipid® (FreseniusKabi France, Sèvres, France). It is a 3rd generation LE containing a physical mixture of soybean oil (30%), MCT (30%), olive oil (25%) and fish oil (15%). Its ratio omega6/omega 3 is 2,5/1. SMOF will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day; daily increase: 0.5 to 1 g/kg/day ; target: 3 to 4 g/kg/day.
All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
1515328|NCT02853253|Dietary Supplement|Medialipide®|"Medialipide® 20% (B Braun Medical, Boulogne, France). It is a second generation LE containing soybean oil (50%) and MCT (50%). Its ratio omega6/omega 3 is 7/4. Medialipide will be initiated within the 1st day of life of neonates and will be prescribed daily by the attending physician following these guidelines: initiation rate: 1 g/kg/day ; daily increase: 0.5 to 1 g/kg/day; target: 3 to 4 g/kg/day.
All included preterms will receive nutritional support according to a single protocol based on the ESPGHAN recommendations: parenteral glucose and amino acids (Primene 10%, Clintec Parenteral, Maurepas, France) soon after birth (in their 1st day of life). Initiation rate of parenteral glucose and amino acids will be 6 to 8 g/kg/day and 2 g/kg/day respectively. The daily increase of parenteral glucose and amino acids will be 1 to 2 g/kg/day and 0.5 g/kg/day respectively, for a target rate of 14 to 17 g/kg/day and 3.5 g/kg/day respectively."
1515329|NCT02853240|Procedure|Muscle biopsy|A biopsy (specifically done for the study) of a muscle that has already been injected with botulinum toxin before inclusion of the patient in the study will be performed, taken during a planned surgery (for tendon transfer or muscle lengthening). A biopsy of a muscle that has never been injected with botulinum toxin may be performed during surgery. No biopsy will be made on a member that would not require surgery. Thus sampling will be conducted on a muscle requiring a surgery: 2 to 3 millimeters will be taken on 10 mm muscle before transfer or lengthening.
1515330|NCT02853227|Other|digital photography|Photographies with digital cameras were taken postoperatively for the documentation, anonymised and used for evaluation of cosmetic results after surgery.
1515331|NCT02853214|Genetic|Genetic analysis of peripheral blood samples|M.D investigators report the identified families with all the information: description of the familial area (for example: 2 cases father and son), last medical report for the case with the type of dysglobulinemia, monoclonal component isotype, medical background and contact information for one of the patients or cases with Name/surname/Date of Birth/address and phone. They contact the patient to explain the study and establish the family pedigree. They collect the information on all the family members and send to the patient a mail: an information note on the study, a prescription for the blood sample and the informed consents. They proceed in the same way for the relatives with the additional prescription: EIP. They organize the logistic in the medical lab or hospital chosen by the person. They receive 4 Heparin and 1 serum tubes for each and with this, they obtain a large amount of biological material for the genetic analysis thanks to the establishment of lymphoblastoid cell lines
1515332|NCT02853188|Other|venous thromboembolism|
1515380|NCT02852772|Behavioral|Cognitive function tests|
1516780|NCT02841826|Other|IUD|
1515334|NCT02853149|Behavioral|Spinal Cord Injury (SCI)|"The SCI Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
1515335|NCT02853149|Behavioral|Caregiver Intervention(CCC)|"The Caregiver Intervention group will undergo intense exercise, a defined nutrition program, and an educational program taught by the study investigators. The exercise will require them to undergo supervised activity 3 times weekly for 6 months. They will also participate in a series of educational sessions that examine their lifestyle, and modify exercise/nutritional habits. After 6 months they will advance to another 6 months or extension phase in which the investigators expect them to continue to exercise up to 3 times per week at our center or at home by using elastic exercise bands (Thera-band) and handles that the Investigators will provide and teach how to use. They will also be expected to continue the modified nutritional program."
1515336|NCT02853149|Behavioral|Caregiver Control (CC)|The Caregiver Control group will also discuss ways in which health and fitness can be improved through exercise and nutrition and will also be offered a fully paid membership to the an exercise fitness center to encourage them to exercise and consume a healthy diet. Unlike the Caregiver Intervention group(CCC) the lifestyle recommendations will be provided by internet authorities such as Web Medical(WebMD), the US Department of Agriculture, and the US Department of Human Health Services, which are dependable websites that promote healthy ways of living.
1515337|NCT02853136|Drug|Fluvoxamine|single dose
1515338|NCT02853136|Drug|BI 409306|low single dose
1515339|NCT02853136|Drug|BI 409306|medium or high dose
1515340|NCT02853123|Drug|Tiotropium|fixed dose combination once daily
1515341|NCT02853123|Drug|Olodaterol|fixed dose combination once daily
1515342|NCT02853123|Drug|Tiotropium|
1515344|NCT02853097|Other|Cytology Specimen Collection Procedure|Undergo blood collection
1515345|NCT02853097|Other|Laboratory Biomarker Analysis|Correlative studies
1515346|NCT02853084|Drug|HL2351|The dose will be adjusted based on disease activities
1515347|NCT02853071|Drug|Estramustine|
1515348|NCT02853071|Drug|standard practice|standard practice
1515349|NCT02853058|Radiation|normal PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
1515350|NCT02853058|Radiation|pathological PI|measurement of the PI in the uterine artery for pregnant women during labor, expressed in MoM
1515351|NCT02853045|Drug|period with drug (trade name) then period with generic|"The list of drugs is detailed in the study description"
1515352|NCT02853045|Drug|period with generic then period with drug (trade name)|"The list of drugs is detailed in the study description"
1515353|NCT02853032|Device|Active repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver active repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
1515354|NCT02853032|Device|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
1515355|NCT02853032|Device|Sham repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver placebo repetitive electromagnetic pulses in this research study's treatment of post-traumatic stress disorder.
1515356|NCT02853019|Other|Electroencephalogram|
1515357|NCT02853019|Behavioral|Cognitive tasks|
1515358|NCT02853019|Behavioral|subjective evaluation scales|
1515359|NCT02853006|Biological|Blood and respiratory fluids sampling|In order to extract RNA (LungCancerTest) and DNA (mutation, reassortment).
1515360|NCT02853006|Procedure|Biopsy|
1515361|NCT02853006|Procedure|Excised tissues|
1515362|NCT02852980|Other|gestational diabetes women|No intervention.
1515363|NCT02852967|Drug|KD025|
1515364|NCT02852967|Drug|Placebo tablet|
1515365|NCT02852941|Device|CardioScreen 1000|Haemodynamic Measurement System, Medis Impedance cardiography (ICG)
1515366|NCT02852941|Device|Tanita 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
1515367|NCT02852915|Procedure|Laparoscopic surgery|Laparoscopic surgery for T4 cancer
1515368|NCT02852876|Drug|ASP2151|Oral
1515369|NCT02852876|Drug|Placebo|Oral
1515370|NCT02852863|Other|Gum|Subjects will fast for a minimum of 8 hours. A baseline ultrasound assesment will be performed to evaluate gastric content. Next, subjects will chew sugarless gum for one hour with changes of gum every 20 minutes (a total of 3 gums will be chewed per subject). Once the last gum is chewed, the gum will be disposed in the trashcan. Three more ultrasound assessments will take place: immediately after one hour of chewing gum, and at the first and second hour after chewing gum has stopped. The content will be classified as empty, with fluids, or with solid. In case of fluids, volume will be measured.
1515371|NCT02852837|Drug|Daratumumab|Intravenous (IV) infusion of 8 mg/kg or 16 mg/kg daratumumab.
1515372|NCT02852824|Drug|BI 655130|
1515373|NCT02852824|Drug|Placebo|
1515374|NCT02852811|Other|Group education|Intervention involving two education session with topics common in menopause transition.
1515381|NCT02852759|Procedure|Selective Cold treatment|The volunteers will undergo cold treatment to neck, supraclavicular interscapular regions for 2 hours daily for 8 weeks. The temperature is below 10 degree celsius achieved by ice pads or refrigerated vest and electroacupuncture is conducted by commercially available device. Insulin sensitivity will be determined by hyperinsulinemic euglycemic clamp at 0 week and 8 week of treatment. Glucose tolerance will be measured by oral glucose tolerance test (OGTT) at 0, 4, 8 week of treatment. Blood will be drawn at 0, 4, 8 week to measure related parameters. In vivo brown fat activation will be assessed by PET-CT scan at 0 and 8 week. Fat biopsy will be taken from the treated area at 0 and 8 week. The participants will be instructed to maintain their normal behavior and calorie intake.
1515382|NCT02852759|Device|Electroacupuncture|Electroacupuncture (EA) is an add-on treatment and it is applied when starting the cold treatment at the cold treated region.The device is Huatuo SDZ-II model made by Suzhou Medical Appliance Factory, China.
1515383|NCT02852759|Device|PET-CT scan|PET-CT scan will be conducted at 0 and 8 weeks to assess brown fat activities.
1515385|NCT02852733|Other|end-of-life emergencies' management|
1515386|NCT02852720|Drug|Levobupivacaine|After the block procedure, 2 ml blood samples will be taken in defined times to determine the plasma blood levels of levobupivacaine.
1515387|NCT02852720|Procedure|Spinal anesthesia|Spinal anesthesia in the L3-L4 or L4-L5 interspace with hyperbaric bupivacaine 0,75% 1,4 ml plus 20 ug fentanyl to achieve a bilateral anesthetic level of T4 determined by pinprick.
1515388|NCT02852720|Procedure|Peripheral vein canulation|An intravenous (18-gauge) catheter will be placed under local anesthesia for co hydration and a second IV catheter for venous sampling
1515389|NCT02852720|Procedure|Ultrasonography|TAP blocks will be performed using a ultrasound Sonosite M-Turbo US machine (Sonosite Inc, Washington) with an L38x 10-5 megahertz (MHz), 38-mm broadband linear array probe.
1515390|NCT02852720|Device|Holter|A portable 12-lead Holter (NorthEast Monitoring®, Boston, USA) will record continuously the electrocardiogram (ECG) after the TAP block, for 24 hrs.
1515394|NCT02852694|Drug|Methotrexate|Subcutaneous methotrexate once weekly 15mg/m2 body surface area (19, 30), with a maximal dose of 25mg/week. Odansetron (Zofran) premedication (4-8mg 1Hour prior to injection) is recommended, folate acid substitution (15mg po, 3 days after Methotrexate injection, for children <20kg: 1x 5mg) is recommended.
1515395|NCT02852694|Drug|Adalimumab|Subcutaneous Adalimumab started at a dose of 160mg followed by 80mg 2 weeks later and then 40mg every 2 weeks in patients over 40kg. In patients < 40kg sc doses of Adalimumab are as follows: induction 160mg/1,73m2 BSA (max 160mg), followed by 80mg/1,73m2 Body surface area (max 80mg) 2 weeks later and maintenance of 40mg/1,73m2 Body surface area (max 40mg) every 2 weeks, all doses rounded up to the nearest 5 multiplications.
1515396|NCT02852694|Drug|Azathioprine / 6 Mercaptopurine|Oral Azathioprine /6mercaptopurine at a dose of 2.5 mg/kg once daily rounded to the nearest multiplication of 12.5mg or oral 6mercaptopurine at a dose of 1.5mg/kg once daily rounded to the nearest multiplication of 12.5mg.
1515397|NCT02852681|Drug|15 mg E4/3 mg DRSP|All subjects received both Treatment A and Treatment B either at the first treatment period (Period 1) or the second treatment period (Period 2). Approximately half of the subjects was randomized to receive either Treatment A followed by Treatment B (Sequence AB), or Treatment B followed by Treatment A (Sequence BA)
1515398|NCT02852668|Other|Power Training|This experimental groups underwent an intervention period of power training
1515399|NCT02852668|Other|Strength Training|This experimental groups underwent an intervention period of strength training
1515400|NCT02852655|Drug|MK-3475|
1515401|NCT02852642|Other|Exercise|Plyometric training
1515402|NCT02852629|Other|observational study|
1515403|NCT02852616|Behavioral|Narrative Exposure Therapy|8 - 15 sessions: 1 lifeline session, 5 - 12 sessions narrative exposure, 1-2 sessions of future-oriented counselling
1515404|NCT02852577|Drug|Clonazepam|Administration of clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 36 months. If no remission after 8 weeks augmentation with paroxetine once a day, flexible dose (10 - 40 mg/day), for 34 months.
1515405|NCT02852577|Drug|Paroxetine|Administration of paroxetine once a day, flexible dose (10 - 40 mg/day), for 36 months. If no remission after 8 weeks augmentation with clonazepam once a day, flexible dose (0.5 - 2 mg/day), for 34 months.
1515406|NCT02852564|Drug|Ethacrynic Acid|One oral dose at 50 mg prior to bladder tumor removal surgery
1515410|NCT02852525|Device|Confocal laser endomicroscopy (pCLE)|Patients agreeing to participate in the research study will receive an additional intravenous injection during endoscopy. This dose of 2.5 mg of IV fluorescein will be administered during their EGD. Probe-based microscopy will be used to evaluate the mucosa of the esophagus and GE junction
1515490|NCT02851849|Drug|LGD-6972-15 mg|15 mg LGD-6972 QD
1515491|NCT02851849|Other|Placebo|Placebo QD
1515492|NCT02851836|Behavioral|image visualization and quotation|"two sets of 60 pictures are shown to the adolescents. we ask them to quote for their valence, hedonicity, arousal and to characterize the emotion elicited in each picture.
This evaluation takes approximately 1hour."
1515411|NCT02852512|Procedure|sacrocolpopexy|Peritoneal incision from the sacral promontory to the Pouch of Douglas. After careful dissection of the inter-rectovaginal space, a two-piece Y-shaped polypropylene mesh was fixed posteriorly to the levator ani muscles using a absorbable suture. The midpoint of the mesh is anchored to the posterior wall of the vagina. The anterior portion of mesh was then introduced and fixed within the intervesico- vaginal space to the anterior/apical vaginal wall with a running suture. The tails of both meshes were fixed to the sacral promontory with a strong non-absorbable polypropylene suture. The peritoneal incision was re- approximated with a running absorbable suture
1515412|NCT02852499|Other|Urine sampling|
1515413|NCT02852499|Other|Carry a GPS and BET|
1515414|NCT02852499|Other|Carry pollution sensor|
1515415|NCT02852499|Other|Sampling at the maternity|
1515416|NCT02852499|Other|Self-questionnaires|
1515417|NCT02852499|Other|Sampling in partum period|Meconium and a strand of hair.
1515418|NCT02852486|Drug|Pioglitazone|30 mg/day, orally, for 3 months, before imatinib discontinuation
1515419|NCT02852486|Other|imatinib discontinuation|imatinib discontinuation after 3 months of pioglitazone
1515420|NCT02852473|Other|Continuous Positive Airway Pressure|CPAP requires subjects to wear a plastic pressurized mask/apparatus, which is connected via a filter and hose to a pump capable of supplying variable pressure (typically on the range of 4-20 cm H2O). The investigators plan to use a full-face mask to prevent subjects from reducing pressure by opening their mouths. If this cannot be tolerated or properly fitted, or is not compatible with the CPAP ventilator, subjects would use a nasal mask only and be asked to keep their mouths closed.
1515421|NCT02852460|Other|rapid recovery|
1515422|NCT02852434|Drug|Lidocaine Gel (2%)|
1515423|NCT02852434|Drug|Lidocaine Paracervical Block (1%)|
1515424|NCT02852421|Procedure|Single injection paravertebral block|"The patients in single injection group will receive single injection paravertebral block at T3-T4 level with 25 ml of 0.5% ropivacaine and four subcutaneous sham injections"
1515425|NCT02852421|Procedure|Multiple injection paravertebral blocks|"Patients in the multiple injection group will receive five injections of paravertebral blocks from T1 to T5 level. 5 ml of 0.5% ropivacaine was injected at each level."
1515426|NCT02852408|Procedure|Laparoscopic cholecystectomy|
1515427|NCT02852395|Drug|JNJ-48816274|Oral dose; dose range of 5 mg up to 250 mg
1515428|NCT02852395|Drug|Placebo|Oral dose; appearance matched to JNJ-48816274
1515429|NCT02852382|Drug|Bupivacaine|In the scalp block and local infiltration arms; bupivacaine %0,5 will be used.
1515430|NCT02852382|Drug|morphine patient controlled analgesia|End of the surgery all of the patients in 3 groups will receive morphine patient controlled analgesia (PCA) including 1mg/ml morphine. The PCA was set to administer a bolus dose of 1 mg on demand with a lockout period of 10 minutes and maximum 25 mg for 4 hours.
1515431|NCT02852369|Behavioral|Task Oriented Treatment|"The intervention administered during each of the training sessions was modeled after the protocol outlined in Winstein et al. (2013) however implementation was in the participant's home setting and involved tasks in the participant's real world.
The manual entitled, Upper-Extremity Task-Specific Training After Stroke or Disability by Lang and Birkenmeier (2014) was also utilized to give a general overview of task specific training for the upper extremity and to help guide each activity the participant chose to work on."
1515432|NCT02852356|Device|MIRI-TL Incubator|MIRI-TL Timelapse incubator
1515433|NCT02852330|Device|SA16 research software|Software for measurement of voltage tomography intraoperatively.
1515434|NCT02852330|Device|CS19 (1.6.2)|Software for measurement of voltage tomography post-operatively.
1515437|NCT02852278|Other|Web-based Survey|This is a prospective 12-month study of patients with motor neuron disease enrolled in CReATe Connect, an RDCRN Contact Registry.
1515438|NCT02852265|Drug|Etonogestrel contraceptive implant|Place nexplanon
1515439|NCT02852252|Drug|OTL38|Patients will be given imaging agent 2-3 hours before surgery to assist in imaging.
1515440|NCT02852252|Drug|ICG|Patients will be given imaging agent 24 hours before surgery to assist in imaging.
1515442|NCT02852226|Drug|Pre Exposure Prophylaxis|Uptake will be measured as the proportion of female patients at the LifeLong clinic who are approached that start PrEP after being offered PrEP, the numbers and rate of PrEP discontinuation, the reasons given for PrEP discontinuation (side effects, no longer at risk, fear of stigma, inability to adhere), and drug concentrations. Drug concentrations are monitored using dried blood spots, which have a large dynamic range capable of detecting use of a few pills every month up through daily use. The main measure of PrEP utilization is the proportion of time that PrEP is used effectively among those attempting to use PrEP.
1515443|NCT02852226|Behavioral|Characteristics of women who enroll|The investigators are interested in characterizing the women who decide to take PrEP through this project. Demographic and psychosocial variables will be used to describe the population who enroll. Sexual and behavioral risk profiles of those who decide to initiate PrEP will also be described as part of this study. Demographics of women who uptake PrEP through community partners will also be compared to the demographics of Alameda County women who have incident HIV infection. In addition to demographics and risk behavior, the investigators will also describe the contraceptive use and intentions of women on PrEP towards future pregnancies as these may be important factors driving interest in PrEP among women.
1515444|NCT02852226|Behavioral|referral sources of women who enroll|Process data will capture the outreach efforts made to recruit participants for this study. At the time of baseline visit, the investigators will capture the source of referral for each woman screened, as well as the primary reason for joining the study. Enrollment progress will be carefully tracked against outreach activities to monitor the relationship between outreach efforts and demand generation. This will help to inform future implementation of PrEP among women.
1515495|NCT02851810|Behavioral|oculomotor parameter recording|visual scanning behavior is assessed during visualization of emotional pictures
1515496|NCT02851810|Behavioral|attachment scale interview (ASI)|ASI is used to determine the attachment style of each participant
1515447|NCT02852187|Device|SIGNUS MOBIS PEEK Cage|Lumbar Interbody Fusion
1515448|NCT02852187|Device|SIGNUS MOBIS II ST Cage|Lumbar Interbody Fusion
1515449|NCT02852174|Behavioral|Mindfulness meditation training|Mindfulness meditation training
1515450|NCT02852161|Device|Magnet assissted capsule endoscopy|Patients due to have a clinically indicated gastroscopy will be asked to have a MACE procedure on the same day
1515451|NCT02852148|Device|ACTICOAT|ACTICOAT is a silver coated antimicrobial barrier dressing. ACTICOAT dressings consist of three layers: an absorbent inner core of polyester and rayon sandwiched between outer layers of silver coated, low adherent, high density polyethylene mesh.
1515452|NCT02852135|Device|LMA Proseal|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium,LMA Proseal was inserted and cuff inflated in each group.
1515453|NCT02852135|Device|LMA Supreme|After preoxygenation, anaesthesia was induced with propofol, fentanyl and cisatracurium ，LMA Supreme was inserted and cuff inflated in each group.
1515454|NCT02852122|Drug|C-11 choline|This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA > 20 ng/mL, or Gleason score 8-10, or clinical stage >T2c) would be included.
1515455|NCT02852096|Other|Dual or Multiple Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With Dual or Multiple Tumor Tissue Paraffin Blocks
1515456|NCT02852096|Other|One Paraffin Blocks|Assessing Her2/Neu Expression in Gastric Cancer With One Tumor Tissue Paraffin Blocks
1515457|NCT02852083|Drug|Pioglitazone|Pioglitazone 25 mg once daily, p.o.
1515458|NCT02852083|Drug|nivolumab|3 mg per kilogram of body weight every 2 weeks, p.o. (standard treatment)
1515459|NCT02852083|Drug|Treosulfan|Treosulfan 250 mg twice daily, p.o.
1515460|NCT02852083|Drug|Clarithromycin|Clarithromycin 250 mg twice daily p.o.
1515461|NCT02852070|Procedure|bronchoalveolar lavage 120ml|120mL sterile saline solution instilled into the distal bronchial tree in 3 times
1515462|NCT02852070|Procedure|bronchoalveolar lavage 60ml|60mL sterile saline solution instilled into the distal bronchial tree in 3 times
1515463|NCT02852057|Drug|timolol maleate and dorzolamide hydrochloride|Timolol maleate and dorzolamide hydrochloride loaded contact lenses
1515464|NCT02852044|Behavioral|Rest|Allowed to watch television or read for one hour prior to oral glucose tolerance test
1515465|NCT02852044|Behavioral|Exercise|One hour of cycling at 50% of maximal power output
1515466|NCT02852044|Other|Dorsal Hand Vein Cannulation (heated hand technique)|
1515467|NCT02852044|Other|Venous Cannulation|
1515468|NCT02852031|Other|Collaborative Learning Network|
1515469|NCT02852018|Genetic|Identification of genetic polymorphisms|
1515470|NCT02852005|Biological|MVA/HIV62B vaccine|1×10^8 TCID50 dose to be administered as a 1 mL intramuscular (IM) injection in the deltoid
1515471|NCT02852005|Biological|AIDSVAX B/E vaccine|600 mcg/mL dose to be administered as a 1 mL IM injection in the deltoid
1515472|NCT02852005|Biological|Placebo|Sodium Chloride for Injection USP, 0.9% to be administered as a 1 mL IM injection in the deltoid
1515473|NCT02851992|Device|GTS cementless stem|Total Hip Arthroplasty
1515474|NCT02851979|Other|Olfactory stimulations|"Odors are disseminated using a portable fragrance device, a prototype developed by a research unit, CNRS UMR5292. The device is outside the incubator, the only part inside is a disposable Teflon tube. The odor flux stimulates distally the NBs' nostrils. Odoriferous compounds are placed in glass tubes. This allows the olfactometer to deliver three distinct odors (to avoid habituation) in a random scheme: spearmint odor, vanilla odor, and grapefruit odor (chemicals registered by Chemical Abstracts Service), while controlling for intensity (amount of compound), duration, and odor sequence. For the vehicle period, the glass tubes remain empty.
Stimulations occur every 5 minutes, for 5 seconds, they are mixed in medical gas to avoid infection. There are three 24-hour periods, and two 24-hour wash out periods, followed by a maximum of 3 days of surveillance."
1515475|NCT02851966|Procedure|mTESE|mTESE time may be postponed or advanced.
1515476|NCT02851953|Device|Aqueduct-100|
1515477|NCT02851940|Procedure|Rubber Band Ligation|Anoscopic rubber band ligation by bedside with patient in the jack-knife position (equipment: anoscope, rubber band applicator)
1515478|NCT02851940|Procedure|Hypertonic Saline Infusion|Endoscopic retroflexed 3 ml injection of 20% hypertonic saline 1cm above the dentate line (equipment: Flex sig, injection needle, 20% saline)
1515479|NCT02851927|Procedure|Mini Thoracoscopy|Pleural biopsy using rigid mini thoracoscope
1515480|NCT02851927|Procedure|SemiRigid Thoracoscopy|Pleural biopsy using semirigid thoracoscope
1515481|NCT02851914|Drug|"Tricyclic Antidepressants (TCA)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
1515482|NCT02851914|Drug|"Selective Serotonin Uptake Inhibitors (SSRI)"|if patient shows signs of depression they will be placed on one of these medications and seen by a psychiatrist.
1515483|NCT02851901|Drug|Varenicline|
1515484|NCT02851888|Drug|Bupivacaine|Iliac fascia block was performed in the experimental group with a single shot of bupivicaine.
1515485|NCT02851888|Other|Normal Saline Sham Injection|Sham block using normal saline instead of iliac fascia block but otherwise employing the equivalent technique.
1515486|NCT02851888|Procedure|General Anesthesia|Patients were induced and maintained in a fashion consistent with standard practices.
1515487|NCT02851875|Other|Registry|
1515488|NCT02851849|Drug|LGD-6972-5 mg|5 mg LGD-6972 QD
1515489|NCT02851849|Drug|LGD-6972-10 mg|10 mg LGD-6972 QD
1515497|NCT02851810|Behavioral|psychophysiological recording|this consists of the measurement of the skin conductance reactivity (SCR) during the picture visualization
1515498|NCT02851810|Behavioral|psychometric assessment|self administered questionnaires are used to assess anxiety, depression and alexithymia.
1515499|NCT02851810|Behavioral|parent interview|an interview of the adolescent parent is performed in order to assess the confusion of the parent-child role and the interaction between the child and its parent.
1515502|NCT02851784|Biological|adoptive immunotherapy|HCC (D ≤5 cm, fewer than three tumors) patients were treated with radical MWA and 4-6 courses of immunotherapy with CIK every year.The immunotherapy were started at 2 weeks, 4 weeks, 6 weeks, 10 weeks, 14 weeks, 18 weeks and then every 12 weeks after MWA. Peripheral blood mononuclear cells were differentiated into phenotypically confirmed DCs and effector cells. DC-CIK and CTL were injected into the abdominal cavity. CIK was infused intravenously.
1515503|NCT02851784|Procedure|MWA|ALL the HCC patients will be treated only by microwave ablation and then enter the follow-up
1515504|NCT02851771|Other|Nasopharyngeal Swab|
1515506|NCT02851745|Drug|Linagliptin|
1515507|NCT02851745|Drug|Placebo|
1515508|NCT02851732|Behavioral|Educational multifaceted intervention|To assess the impact of and educational multifaceted intervention in adherence to evidence based thearapies prescription (according to local guidelines) for cardiovascular prevention in high risk patients for (lipid lowering agents, antiplatelets and ACE Inhibitors) in 12 months.
1515509|NCT02851719|Other|PFMT with biofeedback + Home PFMT|24 outpatient sessions PFMT with biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
1515510|NCT02851719|Other|PFMT without biofeedback + Home PFMT|24 outpatient sessions PFMT without biofeedback (twice a week). Simultaneously, it was prescribed a home exercise daily program during three months (supervised treatment).
1515513|NCT02851680|Biological|blood samples|
1515514|NCT02851667|Behavioral|Resident training programs|A total of 24 resident training programs such as talks, day camp and thematic activities were delivered in the intervention estate by CFSC from June to November 2011. Each program included an introduction to the concepts of Learning Family and family 3Hs as well as how to promote family 3Hs through learning and communicating with family, delivered by interactive games and workshops.
1515515|NCT02851654|Device|Infrared oculography|The infrared oculography provides binocular recordings and allows simultaneous measurement of horizontal and vertical eye movements.
1515516|NCT02851641|Procedure|"pushed mono-canaliculonasal intubation"|
1515517|NCT02851628|Device|Alternative sizing model based trial mask|A trial full face mask to be used for this trial for the treatment of obstructive sleep apnea using CPAP therapy.
1515518|NCT02851628|Device|Prototype Full Face Mask|A prototype full face mask with previous clinical trial experience used for the treatment of obstructive sleep apnea using CPAP therapy.
1515519|NCT02851615|Behavioral|SCThrive Intervention for Adolescents with SCD|Chronic Disease Self-Management Program
1515520|NCT02851602|Biological|Blood sample|
1515521|NCT02851589|Biological|PCAR-019 (anti-CD19 CAR-T cells)|
1515522|NCT02851576|Other|Infusion of ADV specific T cells|Cell engineering
1515523|NCT02851537|Other|an advanced technique as magnetic resonance spectroscopy (MRS)|subjects who had an advanced technique as magnetic resonance spectroscopy (MRS) It is based on the detection of cerebral metabolites, and the variations of their concentration to characterize different pathologies.
1515524|NCT02851524|Other|posturography|
1515529|NCT02851498|Other|Food product: high-protein pasta and cereal|
1515530|NCT02851485|Drug|GLPG1972 600 mg oral solution fasted|dosing after overnight fasting
1515531|NCT02851485|Drug|GLPG1972 600 mg oral tablet fasted|dosing after overnight fasting
1515532|NCT02851485|Drug|GLPG1972 600 mg oral tablet fed|dosing after high-fat high-calorie breakfast
1515533|NCT02851472|Drug|Inhaled Nitric Oxide|Nitric oxide gas will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems.
1515534|NCT02851472|Drug|Placebo|Placebo gas (nitrogen) will be added to the inhaled gas mixture that the patient was already receiving at baseline, using standard of care gas delivery systems.
1515535|NCT02851459|Behavioral|Baseline Survey|The baseline survey contains questions regarding level of existing vaccine hesitancy (Parent Attitudes about Childhood Vaccines (PACV) short scale and HealthStyles questions), demographic information, and intent to vaccinate their children. All study surveys will be completed on an electronic device.
1515578|NCT02851134|Genetic|genetic analysis|genetic (Whole Exome Sequencing )
1515536|NCT02851459|Behavioral|Pre-intervention Survey|Participants will be contacted two weeks after completing the baseline survey to answer questions about their moral beliefs. The survey will include questions form the Moral Foundations Questionnaire as well as additional questions. An algorithm will calculate the participant's moral matrix based on answers to these questions.
1515537|NCT02851459|Behavioral|Morally Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations. The fourth summarizes the contents of the prior paragraphs.
Participants randomized to the morally congruent arm will receive a vaccine-related message developed to appeal to their three most-emphasized moral foundations. The first paragraph focuses on the most emphasized foundation, the second on the third-most emphasized, and the third on the second-most emphasized."
1515538|NCT02851459|Behavioral|Morally Non-Congruent Message|"Intervention messages consist of four short paragraphs. The first three focus on how getting vaccinated helps uphold specific moral foundations.
Participants randomized to the morally non-congruent arm will receive a vaccine-related message developed to appeal to their three least-emphasized moral foundations. The first paragraph focuses on the least emphasized foundation, the second on the third-least emphasized, and the third on the second-least emphasized."
1515539|NCT02851459|Behavioral|Control Message|Participants randomized to the control arm will be provided with a short passage about the costs and benefits of bird feeding.
1515540|NCT02851459|Behavioral|Post-Intervention Survey|Immediately after reading the randomly assigned message participants will complete a follow-up survey assessing level of existing vaccine hesitancy (PACV short scale and HealthStyles questions) and intent to vaccinate their children.
1515541|NCT02851446|Other|measure dyspnoea> Borg 7|
1998520|NCT01285037|Drug|Ramucirumab|Ramucirumab given via IV infusion every 2 weeks in a 28-day treatment cycle. Treatment with ramucirumab may continue until excessive toxicity or evidence of disease progression. In the absence of disease progression, treatment with LY2801653 may continue even if ramucirumab is discontinued provided no dose limiting toxicity related to LY2801653 is present. In the event that LY2801653 is discontinued, treatment with ramucirumab may be continued if there is no dose limiting toxicity related to ramucirumab.
1515545|NCT02851407|Drug|Defibrotide|
1515546|NCT02851407|Other|Best Supportive Care|
1515550|NCT02851381|Drug|FG-3019|"The FG-3019 treatment will be administered over a 28-day cycle:
Dose: 35 mg/kg
Route: IV over one hour following completion of gemcitabine infusion
Schedule:
Days 1, 8, and 15
Please note that Day 8 infusion will on be completed during the first treatment cycle"
1515551|NCT02851368|Device|near infrared fluorescence imaging (NIFI)|The NIFI system will be evaluated for its ability to 1) visualize nodules and their margins 2) differentiate between benign and malignant nodules and 3) identify additional undiagnosed nodules after receiving an injection of indocyanine green 1 day prior to planned surgery.
1515552|NCT02851368|Drug|Indocyanine Green|Indocyanine Green will be administered intravenously 1 day prior to NIFI.
1515553|NCT02851316|Other|Whole Body Vibration|Participants will stand in a squatted position on a platform that provides a brief vibratory stimuli.
1515554|NCT02851303|Drug|Morphine|Morphine wean protocol as described in arm description
1515555|NCT02851303|Drug|Methadone|Methadone wean protocol as described in arm description
1515556|NCT02851290|Procedure|Caudal block anesthesia|After induction of general anesthesia, a caudal block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
1515557|NCT02851290|Procedure|Dorsal penile nerve block anesthesia|After induction of general anesthesia, a dorsal penile nerve block will be performed using 0.75-1 mL/kg of 0.2% ropivacaine without epinephrine
1515562|NCT02851238|Other|Driving Pressure Limited Ventilation|Positive end expiratory pressure is adjusted to minimize driving pressure, plateau pressure minus end expiratory pressure from 2 to 10 cmH2O during one-lung ventilation
1515564|NCT02851212|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 1000 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
1515565|NCT02851212|Drug|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablets) under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
1515566|NCT02851212|Drug|Canagliflozin|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
1515567|NCT02851212|Drug|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
1515568|NCT02851199|Device|Electroencephalography|Electroencephalograph recording following hyperventilation in different participant's body postures
1515571|NCT02851173|Device|LLLT|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA).
1515572|NCT02851173|Device|Placebo|The treatment will consist of applying light of a specific wavelength (1064 nm) using a laser diode supplied by Cell Gen Therapeutics, LLC (CG-5000 laser, HD Laser Center, Dallas, TX, USA). However, the placebo group will receive approximately 1/12th of the cumulative energy density as the treatment group.
1515573|NCT02851160|Other|semi-structured interview conducted by a clinical psychologist|semi-structured interview conducted by a clinical psychologist
1515574|NCT02851160|Other|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology|semi-structured interview conducted by a psychiatrist specialized in psycho-oncology
1515575|NCT02851147|Device|SL-D301|Slit Lamp
1515576|NCT02851147|Device|DC-4|Digital Camera Attachment
1515577|NCT02851147|Device|SL-3G|Slit Lamp
1516781|NCT02841826|Other|Uterine sounding|
1515579|NCT02851134|Biological|blood and stools samples|biological collection
1515580|NCT02851121|Other|Sensorial stimulations|
1515581|NCT02851121|Other|Experimental protocols|
1515582|NCT02851121|Behavioral|Emotional protocols|
1515583|NCT02851121|Other|Protocol with a spatial dimension|
1515584|NCT02851108|Drug|Methylene Blue|50 patients will receive methylene blue
1515585|NCT02851108|Drug|Primaquine|50 patients will receive primaquine
1515586|NCT02851095|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 50 mg and metformin 1000 mg orally under fed (Treatment B) or fasted (Treatment D) condition in a given treatment period as per treatment sequence.
1515587|NCT02851095|Drug|Canagliflozin|Participants will receive canagliflozin 50 mg oral tablet) under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
1515588|NCT02851095|Drug|Metformin Extended Release (XR)|Participants will receive 2 metformin XR tablets of each 500 mg orally under fed (part of treatment A) or fasted (part of treatment C) condition in a given treatment period as per treatment sequence.
1515589|NCT02851082|Other|Endurance training program|"Exercise intensity will be fixed to the corresponding powers for ventilatory thresholds, if applicable for pain tolerance. The endurance interval training workout is known to induce metabolic and physiological adaptations. For intermittent workout training protocol, recovery periods at moderate intensity between periods at high intensity help to sustain repeated high intensity periods of exercise. If pain disturbs exercise tolerance, power will be lowered as necessary.
A set of 3 training sessions per week of 45 minutes each for 6 consecutive weeks will be proposed (one session every two days). This scheme is usually encouraged for patients suffering from chronic diseases."
1515594|NCT02851043|Device|pneuRIP (breathing with resistance)|subjects are given a resistance element to breath through
1515595|NCT02851043|Device|Respitrace system (Carefusion) (breathing without resistance)|subjects are asked to breath normally
1515596|NCT02851030|Behavioral|Move, Play, Learn!|Participants will attend a 4 hour workshop at the beginning of the intervention and the midpoint, covering project information, physical activity for young children, and distribution of project materials. Teachers will focus on one area of their child care day for 2 weeks each: indoor structured PA, outdoor structured PA, transitions between activities, and circle time. Participants will receive an email newsletter introducing the topic and will implement short (10 minutes) classroom activities. Teachers will also be educated about teacher PA practices, focusing on 1 behavior during each segment. Research staff will contact the teachers weekly to provide technical assistance, help teachers troubleshoot any issues that participants have with the activities, and provide encouragement.
1515597|NCT02851017|Other|Exercise|This study is designed to examine and comparing there intervention program on postural control, flow and technology acceptance in young healthy adults.
1515598|NCT02851004|Drug|BBI608(Napabucasin)|"1 cycle is 21days.
BBI608: Oral administration at a dose of 240mg or 480 mg twice daily (BID), every day
The therapy will be repeated until meeting the discontinuation criteria."
1515599|NCT02851004|Drug|Pembrolizumab|"1 cycle is 21days.
Pembrolizumab: Administration at a dose of 200 mg/body on Day 1 of each cycle
The therapy will be repeated until meeting the discontinuation criteria."
1515600|NCT02850991|Radiation|High-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
1515601|NCT02850991|Radiation|Standard-dose|Drug: concurrent chemotherapy with radiation paclitaxel plus carboplatin are used weekly in both arms
1515603|NCT02850965|Drug|BI 695501|
1515604|NCT02850965|Drug|Humira|
1515605|NCT02850952|Other|Rehab MATRIX|Rehab MATRIX is a patient assignment tool that objectively categorizes patients undergoing inpatient rehabilitation based on nurse identified acuity variables.
1515606|NCT02850939|Behavioral|Mobile phone app + patient navigation|The intervention group will receive two components: 1) a culturally sensitive, personalized and easy to use smartphone app; and 2) support from a patient navigator. The intervention is based in Social Cognitive Theory and principles of motivational interviewing - and will feature basic components of individual empowerment, motivation and engagement, including knowledge, attitudes, skills, peer modeling, social support/reinforcement and self-efficacy beliefs and expectations
1515607|NCT02850926|Other|Soccer head gear|Each head gear model consists of lightweight materials with a cross strap design that is fully adjustable or a single elastic headband. All models meet or exceed the American Society for Testing and Materials (ASTM) testing standards for soccer headgear and are approved by the National Federation of High Schools and The Fédération Internationale de Football Association (FIFA) for use by interscholastic soccer players. Players will be allowed to choose the brand of head gear to use and wear it for each practice and game during the soccer season.
1515608|NCT02850913|Drug|Doxycycline|"115 participants will be randomized to either oral Doxycycline 100 mg daily for six weeks.
Treatment will be initiated in hospital but will be continued at home.
Scheduled study clinic visits will be made by the participants at 6, 12 and 24 months.
Each participant will be visited at home at 2, 4 and 6 weeks for adherence monitoring and assessment of safety"
1515609|NCT02850913|Other|Placebo|- Placebo (matching capsules containing no active ingredients)
1515610|NCT02850900|Behavioral|Internet Survey|Weekly survey will be emailed, subjects should complete them
1515611|NCT02850887|Other|general endotracheal anesthesia|sedation with the use of endotracheal intubation
1515612|NCT02850887|Other|deep sedation without endotracheal intubation|deep sedation without endotracheal airway management.
1515613|NCT02850874|Procedure|Hyperthermic intraperitoneal chemotherapy|HIPEC in this study involves the washing of the peritoneal cavity with a heated (40-48°C), (1000 mg/m sq) solution of gemcitabine in 1.5% dextrose for 90 min. Compared with systemic delivery of chemotherapy, intraperitoneal delivery can increase site-specific concentration of chemotherapeutic agents and decrease duration of perfusion, vascular complications, and systemic toxicity. The use of heated chemotherapeutic agents, compared to conventional protocols, has been shown to increase direct cytotoxicity to malignant cells and augment penetration into tumors.
1515614|NCT02850874|Procedure|Open pancreaticoduodenectomy|"Tumors of the pancreatic head will be surgically removed by open PD (standard and pylorus-preserving approaches) with the aim of achieving en bloc R0 tumor resection (no macroscopic residual cancer remaining). In all patients, a lymphadenectomy will be performed along the hepatoduodenal ligament, common hepatic artery, vena cava, and the interaortocaval and right side of the superior mesenteric artery. In cases with portal vein involvement, a venous resection will be performed to achieve R0 resection. Patients with arterial infiltration by the tumor will be deemed locally nonresectable and will be excluded from analysis.
Established, routine surgical and ERAS protocols will be followed for pre-, intra-, and postoperative care of patients. Patients will be discharged after postoperative day 5 if tolerating oral intake and showing no signs or symptoms of complications."
1515615|NCT02850874|Drug|Gemcitabine|Neoadjuvant and adjuvant systemic chemotherapy will be administered to all PDAC patients with the aim of diminishing the tumor burden and maximizing the chance of complete surgical resection. Gemcitabine (GEMZAR®) will be administered for 6 months (including period of neoadjuvant therapy) according to established institutional guidelines for dosing, frequency, duration, administration route, and setting.
1515616|NCT02850861|Device|Condylar reductor|A new surgical instrument was designed to assist the surgeons to perform condylar fracture reduction.
1515617|NCT02850848|Drug|Entigin Film Coated Tablet 0.5mg|
1515618|NCT02850848|Drug|(Baraclude 0.5mg Tablets|
1515619|NCT02850835|Other|Video Decision Aid|A video decision aid was developed inform patients about pelvic organ prolapse, to include female anatomy, and treatment options.
1515623|NCT02850796|Behavioral|Kg-Free|Cognitive-behavioral intervention based on promoting acceptance, mindfulness and self-compassion abilities
1515624|NCT02850796|Other|Treatment as Usual|Standard nutritional treatment that involves dietary and physical activity support provided by the medical units Standard
1515625|NCT02850783|Procedure|89Zr-nanocoll and Indocyanine Green|
1515626|NCT02850770|Behavioral|Pedometers and Walking Logs|Participants were recommended to use the pedometer and walking log to self-monitor how many steps participants walked each day. Participants were recommended to gradually increase daily steps over the course of 12 weeks until reaching 10,000 steps per day. Participants were also recommended to walk at a brisk pace for 3000 of these steps, which roughly translates to 30 minutes per day.
1515627|NCT02850770|Behavioral|Phone Messaging|Participants received short text or voice messages (depending on participant preference) as reminders to review daily step goals and to self-monitor; explaining the benefits of regular physical activity, importance of regular physical activity to daily life, and ways to overcome commonly identified barriers to physical activity; asking participants to report on their physical activity performance; providing feedback based on responses.
1515628|NCT02850770|Behavioral|Family/Friend Support|Participants identified a family member or close friend (FF) to receive short text or voice messages (depending on FF preference) with suggested behaviors that are perceived as supportive by individuals making physical activity behavior changes.
1515629|NCT02850757|Device|U shaped Guedl's airway|To use U shaped Guedl's airway for assisting fiberoptic bronchoscope during endotracheal intubation
1515630|NCT02850757|Device|Modified William's airway|Use Modified William's airway for assisting fiberoptic bronchoscope dduring endo tracheal intubation
1515631|NCT02850744|Drug|PQR309|80mg capsules p.o. once daily and possibly Standard Treatment with temozolomide
1515632|NCT02850731|Device|plate-forme Hu360®|the innovative technology (plate-forme Hu360®) will be used in the experimental arm
1515633|NCT02850718|Drug|Sublingual Sildenafil|50 mg sildenafil sublingual wafer.
1515634|NCT02850718|Drug|Oral Sildenafil|50 mg oral sildenafil (Viagra)
1515635|NCT02850692|Other|measure of endothelial function|
1515636|NCT02850666|Behavioral|Interdisciplinary process drama|Process drama program (5 days/week, 1 week, 25-3 hour sessions) of movement-based activities combining music, art, and drama. Activities have been planned by a collaborative team of drama teachers, occupational therapists, and speech language pathologists.
1515637|NCT02850653|Biological|PCR : 16S ribosomal DNA and real-time targeted PCR|
1515638|NCT02850653|Biological|Sampling of aqueous humour|
1515639|NCT02850627|Drug|Tongguan capsule|eligible participants were randomized to receive Tongguan capsule ( 1.5 g/day for six months immediately after PCI)
1515640|NCT02850627|Drug|placebo capsule|eligible participants were randomized to receive placebo capsule ( 1.5 g/day for six months immediately after PCI)
1515643|NCT02850601|Drug|Dexamethasone|Dexamethasone solution 0.5 mg/mL, rinse for 5 minutes and expectorate
1515644|NCT02850588|Procedure|Transcarotid artery revascularization|Direct implantation of a stent into the carotid artery via a surgical incision in the neck combined with blood flow reversal in the carotid artery during stent placement
1515645|NCT02850588|Procedure|Carotid endarterectomy|Removal of carotid atherosclerotic plaque (endarterectomy) via a surgical incision in the neck
1515647|NCT02850562|Behavioral|Walking|The Walking Arm will walk 5 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point.
1515648|NCT02850562|Behavioral|Walking + Exercise|The Walking + Exercise Arm will walk 2 times per week for at least 10 minutes/day at the start of the study and build to 30 minutes/day by the 3-month time point and in addition, complete exercises to improve strength and balance on 3 days each week.
1515649|NCT02850549|Other|Procedure: physical therapy and Neck Pain Classification|Physical therapists treated patients in phase one as they usually do and in phase two were trained to follow a neck classification and matched intervention system.
1515650|NCT02850536|Biological|anti-CEA CAR-T cells|Gene modified patient T cells
1515651|NCT02850523|Other|Cognitive Behavioural Therapy for Perinatal Anxiety|The treatment consists of cognitive and behavioural strategies for treating anxiety, tailored specifically to a perinatal/postpartum population.
1515652|NCT02850510|Behavioral|Brief Incredible Years parent training|The IY parent training programme (3-8 years) developed by Webster-Stratton at the Parenting Clinic, University of Washington, is a manualised and video-based training programme for parents of young children with conduct problems (Webster-Stratton and Reid, 2003a). Parents assigned to the short IY Basic (S-IY) condition were divided into groups of 10-12 parents. The S-IY was led by two experienced group leaders and parents met weekly for two-hour sessions at a public health care center in the community. The group leaders led discussions regarding central aspects of parenting on the basis of the video vignettes, role play and homework.
1515653|NCT02850497|Device|optical coherence tomography at 6 months|6-month evaluation of malapposition and endothelization with the use of intracoronary optical coherence tomography
1515654|NCT02850484|Drug|Budesonide|Inhaled corticosteroid
1515655|NCT02850484|Drug|Formoterol|Long Acting Beta Agonist (LABA)
1515656|NCT02850471|Device|electroacupuncture|Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
1515657|NCT02850458|Device|implant-retained overdentures|patients treated with an implant-retained overdenture in the mandible
1515658|NCT02850445|Drug|Olanzapine|All patients with schizophrenia were under medication treatment at the baseline. Individualized plan of antipsychotic medication for the patients were determined by psychiatrist who were blind to the group allocation. Medications could be changed at any time during the course of the study if the change was clinically warranted, the drug can also be any other antipsychotic medication.
1515659|NCT02850445|Other|Cognitive behavior therapy|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Cognitive behavioral therapy.
1515660|NCT02850445|Other|Rehabilitation treatment|Rehabilitation treatment include three modules: medication management, symptom management, and social kill training. Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Rehabilitation treatment therapy.
1515661|NCT02850445|Other|Case management|Patients with schizophrenia allocated to the Integrated Treatment(IT) group received Case management.
1515662|NCT02850432|Procedure|Invasive treatment|Endovascular therapy or surgery with medical therapy according to Trans-Atlantic Inter-Society Consensus II scoring system (TASC II)) as described in the main study protocol
1515663|NCT02850432|Other|Conservative treatment|rehabilitation with medical therapy
1515667|NCT02850406|Drug|GBT440|GBT440 will be administered as oral capsules
1515668|NCT02850393|Other|Functional magnetic resonance imaging|
1515669|NCT02850393|Behavioral|behavioral measures|
1515670|NCT02850393|Other|physiological measurements|
1515671|NCT02850380|Other|"FLIP SWITCHES DOWN IN WEIGHTLESSNESS"|"The circular instrument panel that subjects will see into the cylindrical mask consists of one switch surrounded by a luminous ring (left part of the figure below). The switch can be flipped into any direction within the full 360° range. The switch provides no visual cues about down, but the experimenter can add such cues by means of visually polarized labelling displayed on a circular black screen at the center of the panel (right part the figure below)."
1515672|NCT02850367|Dietary Supplement|Nitrate|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
1515673|NCT02850367|Dietary Supplement|Nitrate and L-Arginine|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
1515674|NCT02850367|Dietary Supplement|Nitrate and L-Citrulline|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with NO precursors.
1515675|NCT02850367|Dietary Supplement|Placebo|Subjects will be supplemented orally either acutely or chronically (4-8 weeks) with a placebo.
1515676|NCT02850367|Biological|Evaluation of post-ischemic vascular reactivity|After the intake of the supplement. Concentration of hemoglobin (g/mL) in the quadriceps with the device : NIRS system Oxymon, ARTINIS.
1515677|NCT02850367|Biological|Neuromuscular evaluations|After the intake of the supplement. Measure the stretching force in the ankle (N)
1515678|NCT02850354|Other|anti-g maneuvers|investigate the effects of anti-g maneuvers on cardiovascular and respiratory tolerance to the push-pull-effect.
1515679|NCT02850341|Device|Pedometer|Patients receive a pedometer with instructions how to raise their number of daily steps
1515680|NCT02850328|Other|examination of muscle function and MVC in weightlessness|"MVC tested during three different tasks: (1) leg press, (2) plantarflexion and (3) grip strength.
parameters of muscle function that can be easily implemented in parabolic flight:
Rate of force development
Electromyographic activity
Ultrasound measure: fascicle length and pennation angle of the gastrocnemius medialis muscle
Superimposed twitch torque (M-waves at rest and V-waves in MVC conditions)
Maximum voluntary activation capacity (%VA): %VA = (1-[torque superimposed twitch/torque resting twitch])*100%."
1515681|NCT02850315|Device|optimal coherence tomography|
1516782|NCT02841826|Radiation|Transvaginal ultrasound|
1515682|NCT02850302|Other|PET with FDG|A PET with FDG will be performed before the treatment is started and after 6 cycles of chemotherapy.
1515683|NCT02850302|Other|Tumor exome analysis|A biopsy of the tumor will be performed before the treatment is started and after 6 cycles of chemotherapy. Tumor exome analysis will be performed before treatment is started and after 6 cycles of chemotherapy.
1515684|NCT02850289|Drug|Pegylated interferon (PEG-INF) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a will be administered as per investigator's discretion and will be in line with the current product monograph.
1515685|NCT02850289|Drug|Ribavirin|Ribavirin will be administered as per investigator's discretion and will be in line with the current product monograph.
1515686|NCT02850276|Drug|Pyridostigmine|
1515691|NCT02850224|Behavioral|Motivational interviewing to elicit PCO in pediatrics|A motivational interviewing style webinar. Physicians watch the webinar, incorporate communication techniques.
1515692|NCT02850211|Drug|Celecoxib|1 capsule of 200mg Celebrex PO(per oral) twice a day for 14 days
1515693|NCT02850211|Drug|Ibuprofen|1 tablet of 385mg Ibuprofen PO(per oral) twice a day for 14 days
1515694|NCT02850211|Drug|Tramadol|1 tablet of 50mg Tramadol PO(per oral) twice a day for 14 days
1515695|NCT02850198|Device|scalp electroacupuncture|
1515696|NCT02850198|Device|sham scalp electroacupuncture|
1515697|NCT02850185|Device|oxyhydrogen|Hydrogen/oxygen mixed gas inhaled(proportion 2:1),3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
1515698|NCT02850185|Device|Oxygen|oxygen inhaled,3 L/min . 1 hour each time,twice a day(BID).Test Duration is three months.
1515699|NCT02850185|Drug|Conventional treatment|Bronchodilator (LABA,LAMA) with or without ICS.Conventional treatment is invariable with which was given to COPD patients in 3 months before the study.
1515700|NCT02850172|Behavioral|Walk, Eat, & Breathe|"Walking exercise: 3 times per week, 20~30 mins per section
Eat: nutritional assessment and advice weekly
Inspiratory muscle training: twice every day, 7 days a week, 6~8 weeks before surgery"
1515701|NCT02850159|Device|rTMS and tDCS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
1515702|NCT02850159|Device|rTMS|Patients underwent five consecutive daily sessions of dual-mode NIBS with high-frequency repetitive transcranial magnetic stimulation (rTMS) over the primary motor cortex of the lower leg and sham anodal transcranial direct current stimulation (tDCS) over the left dorsolateral prefrontal cortex simultaneously
1515703|NCT02850146|Drug|18F-AV-1451|
1515704|NCT02850133|Other|aerobic exercise training|aerobic exercise training for 36 sessions within 12-16 weeks
1515705|NCT02850120|Procedure|Tension-free vaginal tape (TVT)|Surgical insertion of Tension-free vaginal tape (TVT) polypropylene mesh in the treatment of stress urinary incontinence.
1515706|NCT02850120|Procedure|Trans-obturator tape (TOT)|Surgical insertion of Trans-obturator tape (TOT) polypropylene mesh in the treatment of stress urinary incontinence.
1515707|NCT02850120|Procedure|Suprapubic sling (SS)|Surgical insertion of Suprapubic sling (SS) polypropylene mesh in the treatment of stress urinary incontinence.
1515708|NCT02850107|Device|Medtronic HawkOne® or TurboHawk™|Use of FDA Cleared Directional Atherectomy (DA) Devices. Medtronic HawkOne® Directional Atherectomy System or TurboHawk™ Plaque Excision System. DA followed by DCB will be performed in all enrolled subjects.
1515709|NCT02850107|Device|Medtronic IN.PACT® Admiral® DCB|FDA Approved Drug Coated Balloon (DCB) Technology. Medtronic IN.PACT® Admiral® DCB will be used after DA.
1515710|NCT02850107|Device|Medtronic Spider™ Distal Protection Device (DPD)|It is recommended that the Medtronic Spider™ Distal protection device (DPD) be paired with DA when used in complex, calcified lesions (TurboHawk™ IFU).
1515711|NCT02850107|Device|"Volcano Visions® PV .014 IVUS catheter"|"Lesion IVUS assessment using the Volcano Visions® PV .014 IVUS catheter will be required in all cases."
1515712|NCT02850107|Device|Nitinol Stent Placement|Only FDA approved nitinol stents can be used if provisional stenting is required.
1515713|NCT02850094|Behavioral|Financial Bonuses|Each participant is eligible to receive $10 per week for increasing their minutes of moderate to vigorous physical activity by 10% from the previous week, or for meeting CDC guidelines of 150 minutes/week. Participants who meet their target minutes of PA every week for one month, three months, or six months receive $15, $25, or $50 bonuses respectively. If all members of a team meet their individual PA goals, each participant's reward is doubled. In total, participants can earn up to $860 if they meet all their goals.
1515714|NCT02850081|Drug|Statin|"Standard of care treatment (one of four):
Simvastatin (to 40mg without amlodipine)
Simvastatin (to 20 mg if currently on amlodipine)
Atorvastatin (to 80mg)
Rosuvastatin (to 20mg)"
1515715|NCT02850081|Drug|Atorvastatin|"A lipid-lowering agent and for prevention of events associated with cardiovascular disease.
10 mg or 80 mg capsules"
1515716|NCT02850081|Other|Placebo|A placebo pill will be used for patients that are to maintain their current dose of statins prior to their CEA.
1515786|NCT02849483|Drug|Ramosetron|Administer 2 ml of normal saline iv before induction. Inject ramosetron 0.3 mg iv at the end of surgery. Add ramosetron 0.6 mg to the iv PCA.
1515717|NCT02850068|Device|Geniculate Artery Embolization|Geniculate artery embolization (GAE) is a new procedure that is being used to reduce pain and disability (resulting from pain, stiffness and difficulty performing daily activities) caused by knee osteoarthritis (OA). Embolization is a procedure where physicians intentionally block the blood vessels to specific areas of the body to prevent blood flow to that region. By doing this, the decrease in blood flow will decrease the size of the area of interest. In this case, the goal is to decrease the size of inflammatory tissue around the knee, resulting in improvement of pain, stiffness and difficulty performing daily activities from OA.
1515718|NCT02850055|Other|Conventional Physiotherapy|"Leaflet care and health habits of the temporomandibular joint.
Program of cranio-cervical and temporomandibular exercises.
Massage of the cervical muscles and self care document for home."
1515719|NCT02850055|Other|Specific Manual Therapy|"Leaflet care and health habits of the temporomandibular joint.
Program of cranio-cervical and temporomandibular exercises.
Massage of the cervical muscles and self care document for home.
Specific manual therapy techniques focusing on the temporomandibular joint and temporomandibular muscles."
1515720|NCT02850042|Behavioral|Occupation-based practice (OBP)|
1515721|NCT02850042|Behavioral|Modified-constraint induced therapy (m-CIT)|
1515722|NCT02850029|Other|Observational study, no intervention|
1515723|NCT02850016|Drug|3BNC117|Intravenous Infusion of 3BNC117
1515724|NCT02850016|Drug|Romidepsin|Intravenous Infusion of Romidepsin
1515725|NCT02850003|Drug|IDP-120 Gel|Gel
1515726|NCT02849990|Drug|Abiraterone Acetate|Given PO
1515727|NCT02849990|Drug|Apalutamide|Given PO
1515728|NCT02849990|Drug|Degarelix|Given SC
1515729|NCT02849990|Drug|Indomethacin|Given PO
1515730|NCT02849990|Other|Laboratory Biomarker Analysis|Correlative study
1515731|NCT02849990|Drug|Prednisone|Given PO
1515732|NCT02849951|Drug|LT-02|12-weeks of 1.6 g BID delayed-release phosphatidylcholine (LT-02)
1515733|NCT02849951|Drug|LT-02 Placebo|12-weeks of 0 g BID delayed-release phosphatidylcholine (LT-02) placebo
1515734|NCT02849938|Device|TytoCare Device|Tyto is a handheld, mobile device designed for capture and transmission of ear/throat/skin images and lung/heart auscultations. It may be used to perform non-invasive, medical examinations, either on a patient (by another person, most commonly a family member, or by a medical professional) or self-performed by the patient, for remote review by a medical practitioner. It is suitable for use on patients in both clinical and home environment.
1515736|NCT02849912|Other|questionnaire|
1515737|NCT02849899|Drug|Vildagliptin|"Galvus is prescribed as recommended by the marketing authorization. In adults, the recommended dose of Galvus is 100 mg per day (one tablet in the morning and another in the evening).
In patients with moderate or severe kidney problems, the recommended dose is 50 mg once daily (one tablet in the morning).
Patients with creatinine clearance greater than 50 ml/min the vildalgliptin dose will be 100 mg/day. For those whose clearance is less than 50 ml/min, the daily dose is 50 mg. The creatinine clearance will be measured each week.
The treatment duration will be 3 months, divided into 2 months of complete treatment and one month of cessation treatment with half dose of vildagliptin."
1515738|NCT02849899|Drug|Placebo|The placebo is the same as Galvus (packaging, shape, color, registration) but will contain only excipient. The given dose will also be identical.
1515741|NCT02849873|Drug|IDP-123 Lotion|Lotion
1515742|NCT02849873|Drug|Tazorac Cream|Cream
1515743|NCT02849860|Drug|IDP-121 Lotion|Lotion
1515744|NCT02849834|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|20Hz and Theta Burst stimulation, both at 80% of motor threshold in contralateral intrinsic hand muscles. Five consecutive days of each mode of stimulation, separated by a minimum of 4 weeks. Daily self-monitoring of pain, sleep quality and fatigue by mans of a 10-item questionnaire
1515745|NCT02849821|Other|hypobaric pressure chamber|hypobaric chamber: ascent within 10 minutes, 3 hour exposure to hypoxic conditions simulating an altitude of 4,000 m.a.s.l., afterwards controlled descent under continuous pulsoximetric control
1515746|NCT02849821|Other|Sigmoidoscopy|To retrieve biopsies from the colon during the course of the study 3 sigmoidoscopies were performed. The first sigmoidoscopy was performed 1 day before the stay in the hypobaric chamber. The second sigmoidoscopy was performed directly after the hypobaric chamber and the third sigmoidoscopy was performed 1 week after the hypobaric chamber. During each sigmoidoscopy 6 biopsies were taken with standard size forceps (2.4 mm). One biopsy was analysed by real-time quantitative polymerase chain reaction (PCR), one biopsy was analysed by Western blotting and another biopsy was analysed for gene gene-expression by in situ hybridisation. Two biopsies were analysed by immunohistochemistry (IHC) and one biopsy was stained with hematoxylin and eosin (H&E).
1515747|NCT02849795|Other|bone densitometry|
1515748|NCT02849795|Other|questionnaires|
1515749|NCT02849795|Other|biological analyses|
1515750|NCT02849782|Drug|Fampridine|Oral intake of 10 mg twice daily
1515751|NCT02849756|Other|older in intensive care unit|It is an observational study with no intervention.
1515752|NCT02849743|Drug|Syntocinon|The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.
1515753|NCT02849743|Drug|Placebo (for Syntocinon)|The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.
1515754|NCT02849730|Device|Fentanyl/ropivacaine based Epi-PCA|Fentanyl and ropivacaine was diluted and administered to the patients according to the clinician's determination. The clinician decided dose, infusion rate, bolus dose, lockout time and total amount of drug mixed in the Epi-PCA.
1515755|NCT02849717|Behavioral|Exercise for Cancer Patients|a standardized, daily, home-based, progressive exercise program
1515832|NCT02849171|Radiation|18F-Fluorocholine (18F-FCH)|
1515756|NCT02849704|Drug|Creon36™|Creon36™ delayed-release capsules, a pancreatic enzyme preparation, is an FDA approved medication. Subjects with chronic pancreatitis (CP) will take Creon36™ for nine days, at a daily dose of 72,000 lipase units per meal (two capsules) and 36,000 units per snack (one capsule), with each capsule containing 36,000 lipase units. Subjects will take Creon36™ for three days prior to Visit 2, the day of Visit 2 and then for five days after the visit until they have completed stool collections.
1515757|NCT02849678|Drug|Ropivacaine|0.5% Ropivacaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision. It is the local anesthetic used as the standard drug in paravertebral nerve blocks at our institution. It is also used in other nerve block infusions at our hospital and institutions across the country. It will be used as the standard drug to which lidocaine is compared.
1515758|NCT02849678|Drug|Lidocaine|"Lidocaine will be infused through a catheter placed in the thoracic paravertebral space to block the transmission of pain signals at the level of the spinal nerves from the abdominal incision.
At a concentration of 0.5%, Lidocaine has been deemed safe to use for peripheral nerve blocks and analgesia. There are several studies to support this as listed in the references. Compared to ropivacaine, lidocaine is shorter-acting, less cardiotoxic, and safer to use."
1515759|NCT02849665|Other|Kangaroo Position|
1515760|NCT02849652|Behavioral|ATTOC Intervention|ATTOC is implemented in a systematic 3-phase process with 10 steps to guide sites through cultural change and implementation of evidence-based practice.
1515761|NCT02849652|Behavioral|UC Intervention|Sites randomized to UC will not receive an organizational intervention to address TUD treatment. To ensure standardization across UC sites, study personnel will provide a 1-day training seminar that will include written materials describing recommended treatments for TUD to UC personnel consistent with established treatment guidelines.
1515762|NCT02849639|Other|Placebo|Participants will receive educational materials, but will not receive MTM.
1515763|NCT02849639|Other|Medication Therapy Management (MTM)|Participants will receive MTM in addition to the educational materials.
1515764|NCT02849639|Drug|Scopolamine patch|At the beginning and end of the study, participants will be asked to use a scopolamine patch. This patch is not being used to prevent motion sickness (as approved by the FDA), but instead is being used to challenge the participant's memory and thinking abilities and determine cognitive reserve.
1515765|NCT02849626|Drug|Perampanel|E2007
1515766|NCT02849613|Other|Adipose Derived Stem Cells|
1515767|NCT02849613|Other|Vehicle media|
1515768|NCT02849587|Drug|cannabis|Participants will smoke a cannabis cigarette ad libitum as per their usual routine
1515769|NCT02849561|Other|Therapeutic hypothermia|With a mattress at 4°C to reach a central temperature at 33,5°C.
1515770|NCT02849561|Device|Synchronized Intermittent Mandatory Ventilation|Constant volume 6 ml/kg
1515771|NCT02849561|Other|Electroencephalography|
1515772|NCT02849561|Device|Pupillary light reflex surveillance|With Neurolight® device.
1515773|NCT02849561|Device|Transcranial Doppler|Monitoring tool for brain hemodynamic evaluation. With Philips HD15 Ultrasound system®.
1515774|NCT02849548|Drug|suvorexant|First in class orexin antagonist approved by the FDA for the treatment of insomnia
1515775|NCT02849548|Other|placebo|Pill with inactive ingredients
1515776|NCT02849535|Behavioral|PRISM care program|PRISM care is a multidisciplinary program that includes sessions with a hospital pharmacist about the oral chemotherapy: information is given to the patient on adverse events occurrence and management, optimizing drug dosage plan, including drug-drug interactions. Physical sessions will be planned at the beginning of month 1, month 2 and month 3 after the inclusion, then telephone interviews of physical sessions will be planned at month 4, month 5 and month 6. During all these sessions and during the final physical session at the end of month 6, data will be recorded for outcomes assessment.
1515777|NCT02849522|Procedure|Prostatic Artery Embolisation|"The aim of PAE for LUTS (due to BPH) is to reduce the blood supply of the prostate gland, causing some of it to undergo necrosis with subsequent shrinkage.
The procedure is usually performed with the patient under local anaesthetic and sedation. Using a percutaneous transfemoral approach, super-selective catheterisation of small prostatic arteries is carried out using microcatheters. Embolisation involves the introduction of microparticles to block these small prostatic arteries. Embolisation agents include polyvinyl alcohol (PVA), gelatine sponge and other synthetic biocompatible materials.
NICE published Interventional Procedures Guidance (IPG453) in April 2013. The evidence at the time of assessment was deemed inadequate in quantity and quality. Therefore, the procedure was given a 'Research-only' recommendation."
1515778|NCT02849522|Procedure|TURP|Transurethral resection of the prostate. A cystoscope is passed up the urethra to the prostate, where the surrounding prostate tissue is excised. This is a common operation for benign prostatic hyperplasia (BPH), with around 15,000 procedures performed in the UK per year (NHS Choices). The conventional TURP method of tissue removal utilizes a wire loop with electrical current flowing in one direction (monopolar) through the resectoscope to cut the tissue. Bipolar TURP allows saline irrigation and eliminates the need for an ESU grounding pad thus preventing TUR syndrome and reducing other complications.
1515779|NCT02849522|Procedure|Open prostatectomy|In an open prostatectomy the prostate is accessed through an incision that allows manual manipulation and open visualization through the incision. The most common types of open prostatectomy are retropubic prostatectomy (RP) or transvesical prostatectomy (TVP).
1515780|NCT02849522|Procedure|Laser prostate surgery|"This surgical method (HoLEP or KTP/Greenlight) utilizes laser energy to remove tissue. With laser prostate surgery a laser fibre inserted via an endoscope is used to transmit laser energy to enucleate (HoLEP) or vaporise (KTP) the tissue. The specific advantages of utilizing laser energy rather than a traditional electrosurgical TURP is a decrease in the relative blood loss, elimination of the risk of TUR syndrome, the ability to treat larger glands, as well as treating patients who are actively being treated with anti-coagulation therapy for unrelated diagnoses."
1515781|NCT02849509|Drug|Pradaxa (dabigatran)|Pradaxa (dabigatran etexilate)110mg or 150mg
1515782|NCT02849509|Drug|Vitamin K antagonist|Vitamin K antagonist or Pradaxa
1515833|NCT02849158|Other|Biopsy|Rectoscopy with biopsy
1515787|NCT02849483|Drug|Normal saline|Administer dexamethasone 10 mg iv before induction. Inject 2 ml of normal saline iv at the end of surgery. Add 4 ml of normal saline to the iv PCA.
1515788|NCT02849470|Procedure|Intradermal Injection in hair loss|Comparative Injection of Control (PRP & Acel) in hair loss; 2) Intradermal Injection in hair loss
1515789|NCT02849470|Procedure|Platelet Rich Plasma|Growth factors and cytokines to promote healing and vascular supply
1515790|NCT02849470|Procedure|Adipose Derived Stem/Stromal Cells|Harvesting Adipose Lipoaspirate with Microcannula System
1515791|NCT02849470|Procedure|Stem/Stromal Cellular Isolation (Digestive)|Cell isolation and concentration add back to AD-stem/stromal cells utilizing Centricyte 1000 Protocol
1515792|NCT02849470|Procedure|MatriStem Matrix (ACell) - Current Standard of Care|
1515793|NCT02849470|Procedure|HD-PRP (High Density Platelet Rich Plasma)|
1515794|NCT02849470|Procedure|Emulsified AD-tSVF|
1515795|NCT02849470|Procedure|Emulsified AD-cSVF|Stem/Stromal Cellular Isolate Added Back to Emulsified AD-tSVF
1515796|NCT02849457|Drug|Vigabatrin|Subjects randomized to vigabatrin in Arm A will be treated with vigabatrin 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study (Arm B) and continue to be followed until 36 months of age.
1515797|NCT02849457|Drug|Placebo|Subjects randomized to placebo in Arm A will be treated with matching placebo at 100mg/kg/day until 24 months of age or until they show evidence of clinical seizures or electrographic seizures on video EEG. If electrographic or clinical seizures occur while on study drug, they will transition into the Open label phase of the study (Arm B) and continue to be followed until 36 months of age.
1515798|NCT02849444|Other|Anti-myeloma treatment at physician discretion|non Interventional Study
1515799|NCT02849431|Behavioral|Mindfulness-based intervention|A version of mindfulness-based cognitive therapy that has been adapted for people with a diagnosis of borderline personality disorder. This comprises eight weekly session, each lasting ninety minutes.
1515802|NCT02849405|Device|MHRC: Metabolic Hyperspectral Retinal Camera|Comparison of hyperspectral signature of retinal arterioles between subjects suffering from arteriosclerosis and healthy control subjects.
1515803|NCT02849392|Other|Pistachio added 20% of kcals to diet|Pistachio added 20% of kcals to diet
1515804|NCT02849379|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
1515805|NCT02849379|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
1515806|NCT02849366|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
1515807|NCT02849366|Biological|NK immunotherapy|Each treatment: 8-10 billion cells in all, transfuion in 3 times, i.v.
1515808|NCT02849353|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
1515809|NCT02849353|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
1515810|NCT02849340|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
1515811|NCT02849340|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
1515812|NCT02849327|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
1515813|NCT02849327|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
1515814|NCT02849314|Device|Cryosurgery|Percutaneous ablation under CT or ultrasound guidance
1515815|NCT02849314|Biological|NK immunotherapy|Each treatment: 8~10 billion cells in all, transfuion in 3 times, i.v.
1515816|NCT02849301|Device|Arabin cervical pessary|
1515817|NCT02849288|Device|Bigfoot Biomedical Type 1 Diabetes Management System (T1DMS)|Automated Insulin Delivery System
1515818|NCT02849275|Other|Lactose Free 1% Milk|isocaloric study treatment containing lactose free 1% milk consumed once daily over 4-5 weeks as a control.
1515819|NCT02849275|Other|Fermented Milk (Probiotic) Treatment|isocaloric fermented milk (probiotic) treatment, consumed once daily, over 4-5 weeks.
1515820|NCT02849262|Drug|Omiganan (CLS001) topical gel|
1515821|NCT02849262|Drug|Vehicle topical gel|
1515822|NCT02849249|Biological|allergovac polimerized (100/100)|Patients will recieve a initiation phase plus a mantenaince phase for 3 months of an allergy vaccine.
1515823|NCT02849236|Drug|Ropivacaine (PECS bloc)|"Ropivacaine 3.75mg/mL
Injection of a local anesthetic between pectoral major and pectoral minor muscles"
1515824|NCT02849236|Drug|Placebo|20 mL saline 0.9%
1515825|NCT02849223|Device|Anodal Transcranial Direct Current Stimulation|2 milliamps (mA) of anodal stimulation will be applied to the left dorsal lateral cortex for 20 minutes concurrent with working memory training.
1515826|NCT02849223|Device|Sham stimulation|30 seconds of anodal TDCS stimulation will be applied to the left dorsal lateral cortex concurrent with working memory training
1515828|NCT02849197|Procedure|surgery for pilonidal sinus disease|surgical treatment of pilonidal sinus disease via primary closure, Limberg flap0 technique and Modified Limberg flap technique.
1515829|NCT02849184|Drug|suvorexant|Suvorexant (20mg for 64 years or younger; 15mg for 65 years or older) once daily before bedtime.
1515830|NCT02849184|Other|Placebo|Placebo once daily before bedtime.
1515831|NCT02849171|Device|PET scan|
1515834|NCT02849145|Biological|Blood sampling|7,5 ml of patient peripherical blood will be collected at each blood sample.
1515835|NCT02849132|Drug|Entecavir|oral entecavir 0.5mg daily for 5 years
1515836|NCT02849119|Procedure|Laparoscopic or robotic partial nephrectomy|Laparoscopic or robotic partial nephrectomy of a small renal masses (T1a) through transperitoneal or retroperitoneal approach
1515837|NCT02849106|Procedure|biopsy to obtain a chemogram|All patients enrolled will have biopsies (on primary tumor or on a metastasis) before treatment in order to obtain a chemogram by ex vivo 3D culture cells
1515838|NCT02849093|Other|Non-invasive OCT imaging|Optical Coherence Tomography (OCT) to capture high resolution cross-sectional images of tissue microstructures using infra-red radiation.
1515839|NCT02849080|Drug|semaglutide|Oral administration once-daily.
1515840|NCT02849080|Drug|sitagliptin|Oral administration once-daily.
1515841|NCT02849067|Other|Group Treatment|Patients in this group will watch a comedy show that will will not exceed 30 minutes. This group will have until five patients.
1515842|NCT02849067|Other|Group Control|patients in this group will watch a documentary that will not exceed 30 minutes. This will have until five patients
1515843|NCT02849054|Device|Measurement of PTPdi|Insertion of pressure transducer catheter to measure gastic and oesophadgeal pressures for calculation of PTPdi
1515844|NCT02849054|Device|TTV at 4ml/kg|Provision of targetted tidal volume of 4ml/kg
1515845|NCT02849054|Device|TTV at 5ml/kg|Provision of targetted tidal volume of 5ml/kg
1515846|NCT02849054|Device|TTV at 6ml/kg|Provision of targetted tidal volume of 6ml/kg
1515847|NCT02849041|Device|medical imaging|Low-dose CT-scanner
1515848|NCT02849041|Biological|Identification of Circulating Tumor Cells|Research of circulating tumor cells in blood
1515849|NCT02849041|Procedure|Psychological Questionnaires|"The procedure of screening test could be stressful. False positive results can cause anxiety and lead to additional costs, as well as increased exposure to radiation and invasive medical examination. Although this is based on some objective results, there is a high probability of adverse psychological effects in case of false positives; so there is cause for concern in the short term anxiety associated with positive results and the use of additional tests during the intervals between screening phases. There is no data related to psychological distress potentially caused by the discovery of circulating tumor cells."
1515850|NCT02849028|Behavioral|sleep disorder|The study is to investigate whether exist the relationship between sleep disorder and circadian rhythm of patients with TBI or not.
1515851|NCT02849015|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
1515852|NCT02849015|Biological|NK immunotherapy|Natural killer cell(each treatment: about 10 billion cells transfusion in 3 times, i.v.)
1515854|NCT02848989|Other|Qigong Mind-Body Exercise|An exercise program that involves gentle movements combined with breathing/relaxation techniques
1515855|NCT02848976|Other|Re-training to effort (RE)|The RE program includes three weekly sessions, supervised individually by a teacher in adapted physical activity, during 1:30, for four weeks, for a total of 12 sessions
1515856|NCT02848963|Drug|Ketamine-propofol mixture|Ratio of Ketamine-propofol mixture will be compare for every groups.
1515857|NCT02848950|Drug|Metformin|Supplementation of the study group with Metformin till the day of pregnancy confirmation
1515858|NCT02848937|Device|Bath with citrate|bath with citrate which allows the equivalence of mass balance (Ca_eq) compared to the concentrate with 3 mM acetate and 1.5 mM of calcium
1515859|NCT02848937|Device|Bath with citrate and Ca_eq|bath with citrate and Ca_eq of concentrate with 3 mM acetate and 1.5 mM of calcium
1515860|NCT02848924|Other|No intervention|
1515861|NCT02848911|Drug|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks
1515862|NCT02848898|Device|Equistasi|
1515863|NCT02848898|Other|Placebo|
1515866|NCT02848859|Behavioral|Go! to Sleep|This is an online interactive program that delivers cognitive behavioral therapy for insomnia via the internet.
1515867|NCT02848859|Behavioral|General Sleep Education|Providing patients information on healthy sleep and habits to promote healthy sleep.
1515868|NCT02848846|Device|Robotic Hand|"The patients will use the robotic hand for a period of one year that will be divided in 3 different phases. The first phase is the intensive phase where the patient will use the robotic hand from Monday to Friday all days. This phase will last 6 weeks. The second phase is the semi-intensive where the patient will use the robotic hand only two days per week. This phase will last 6 weeks. The third phase is the monitoring where the patient will use the robotic hand only one day per week until the end of the trial.
During this phases the patient will perform different task requiring the use of the robotic hand."
1515871|NCT02848820|Drug|Augmentin + Gentamicin|Amoxicillin/clavulanic acid (Augmentin) 25/2.5mg 6-hourly (total 100/10 mg/kg daily; maximum 6000/600mg a day) intravenously for 48 hours Oral amoxicillin/clavulanic acid 50/12.5 mg/kg 8-hourly (max 1500/375mg a day) for in total 7 days Gentamicin 7mg/kg once daily for 48 hours
1515872|NCT02848820|Procedure|Appendectomy|Pre-, peri- and postoperative care according to local protocol. No routine postoperative antibiotics
1515873|NCT02848807|Dietary Supplement|NUTRIDRINK Compact Protein|high-energy, high-protein, oral liquid nutritional supplement; dosage: 2x125 ml per day, 7 days per week for 12 weeks (3 months)
1515874|NCT02848794|Drug|Apatinib and Irinotecan|Patients were administered at apatinib (850mg po qd) and irinotecan(125mg/m2 d1,8) intravenously every three weeks for up to 6 cycles.Maintenance apatinib (500mg po qd) was administered until disease progression or unacceptable toxicity.
1515956|NCT02848261|Behavioral|Remote Monitoring|Education and training on the use of remote monitoring
1516783|NCT02841813|Other|No intervention|No intervention
1515875|NCT02848781|Device|Implantable Cardioverter Defibrillator (ICD)|An ICD is a battery-powered device placed under the skin that keeps track of heart rate. Thin wires connect the ICD to the heart. If an abnormal heart rhythm is detected, the device will deliver an electric shock to restore a normal heartbeat.
1515876|NCT02848781|Procedure|Catheter Ablation|Catheter ablation is a procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats. Destroying this tissue helps restore the heart's regular rhythm.
1515877|NCT02848768|Drug|Sunitinib|
1515878|NCT02848755|Device|Cranial ultrasonography|
1515881|NCT02847637|Drug|Emicizumab|Participants will receive emicizumab prophylaxis at the specified dose subcutaneously until the end of the study (maximum up to 2 years).
1515882|NCT02847624|Drug|tolvaptan|
1515883|NCT02847611|Device|Dynamometer LABIN|LABIN is a prototype of dynamometer containing a handle of metal strength, connected with a sensor of pressure registering(recording) the applied strength and transmitting the data in a computer showing an IT curve of the strength according to time.
1515884|NCT02847598|Drug|BIIB059|Administered as specified in the treatment arm.
1515885|NCT02847598|Drug|Placebo|Administered as specified in the treatment arm.
1515886|NCT02847585|Dietary Supplement|Water-soluble Ubiquinol|10 mg/kg BW/d, by oral drops
1515887|NCT02847572|Procedure|Cataract Surgery|All patients wil be having intraocular lens surgery
1515888|NCT02847559|Biological|Bevacizumab|Given IV
1515889|NCT02847559|Procedure|Electric Field Therapy|Undergo electric field therapy using Optune device
1515890|NCT02847559|Device|NovoTTF-100A Device|Undergo electric field therapy using Optune device
1515891|NCT02847559|Procedure|Quality-of-Life Assessment|Ancillary studies
1515892|NCT02847546|Device|True™ Flow Valvuloplasty Perfusion Catheter|Balloon Aortic Valvuloplasty as preparation step in implantation of a Tanscatheter Aortic Valve Implantation (TAVI).
1515893|NCT02847533|Procedure|blood sample|blood sample for concentration levels of inflammatory markers
1515894|NCT02847533|Behavioral|psychometric scales|Mini international interview MADRS, C-SSRS, QIDS-SR, BIS-10, BDHI, BART, ERD
1515895|NCT02847520|Behavioral|Canadian Index Excessive Game|self-administered questionnaire Canadian Index Excessive Game
1515896|NCT02847494|Drug|metoclopramide|metoclopramide 10mg intravenous infusion over 15 minutes
1515897|NCT02847494|Drug|Dexamethasone|dexamethasone 10mg intramuscular injection
1515898|NCT02847494|Drug|methylprednisolone acetate|methylprednislone acetate 160mg intramuscular injection
1515899|NCT02848729|Drug|Acetaminophen (APAP) tablets|
1515900|NCT02848729|Drug|IV acetaminophen (APAP)|
1515901|NCT02848729|Drug|IV morphine|
1515902|NCT02848716|Procedure|Surgery followed with chemoradiation|"Patients with negative paraaortic lymph nodes will be managed with external beam radiotherapy to the pelvis (as defined by the surgical clips applied at the lower limit of the paraaortic node dissection) at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy (High Dose Rate (DR), Low DR or Pulse DR) with intent to cure.
Patients with metastatic disease to paraaortic lymph nodes will receive extended-field external beam radiotherapy followed by intracavitary brachytherapy with intent to cure. Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.
Concurrent platinum-based chemotherapy (in the 2 sub groups above) will be given with definitive radiation therapy."
1515903|NCT02848716|Radiation|Standard chemoradiation|"patients with negative paraaortic lymph nodes on PET imaging will be managed with external beam radiotherapy to the pelvis at a usual dose of 45 Gy. Limited boosts will be indicated individually on clinically involved parametria or pelvic nodes. The external beam radiation therapy will be followed by intracavitary brachytherapy with intent to cure (HDR, LDR or PDR). Patients who complete both external beam radiation and intracavitary radiotherapy will receive a total dose of 80-90 Gy low-dose equivalent to Point A.
Concurrent platinum-based chemotherapy will be given with definitive radiation therapy."
1515904|NCT02848716|Radiation|chemoradiation|
1515908|NCT02848690|Behavioral|Educational Intervention|The educational intervention sessions will be conducted face-to-face, one hour-long and with the aim to encourage and motivate the low-sodium diet adherence. The dietitian's approaches will provide individual skills to achieve the goals (sodium restriction), developing changes in behavior and monitoring the progress towards the skills needed to reduce patient's barriers and difficulties for sodium restricted diet adherence.
1515909|NCT02848690|Other|Usual Care Intervention Group|Participants assigned to the control group will have a dietitian consultation receiving general recommendations for hypertension, such as increasing the consumption of fruits and vegetables, reducing salt intake, avoiding processed and high-sodium foods, reducing body weight if BMI> 25Kg/m2 and limiting consumption of alcoholic beverages. They will be provided with an explanatory folder about hypertension. During six months, participants assigned to the control group will be monitored in monthly visits to the dietitian without modifying their usual care
1515910|NCT02848677|Behavioral|Nutritional counseling|Nutritional counseling implemented by a dietitian for a low sodium diet rich in fruits, vegetables, low fat dairy foods, and low in processed foods.
1515911|NCT02848677|Behavioral|usual care|usual care of hypertensive patients.
1515912|NCT02848664|Device|Passy Muir Swallowing Self Trainer|External vibratory stimulation to the larynx to trigger swallow reflex in patients with dysphagia
1515914|NCT02848625|Other|Yoga|Yoga and breathing exercises designed for patients with IPF. Sessions will be two times per week for 12 weeks
1515915|NCT02848612|Drug|anticoagulation by unfractionated heparin|anticoagulation by unfractionated heparin
1515916|NCT02848599|Drug|morphine|
1515917|NCT02848599|Drug|levobupivacaine|
1516034|NCT02847689|Behavioral|Control Treatment|Standard of Care
1515918|NCT02848586|Other|ECIGS|15 subjects will receive ECIGs and 5 control subjects will continue to smoke their chosen usual brand of combustible cigarettes (UB). Each group will receive either ECIG or UB for a total of 4 weeks and undergo pulmonary and behavioral assessments during this period. A mobile contingency management (mCM) procedure will be used to provide monetary reinforcement for biochemically verified abstinence from combustible cigarettes. Participants in the UB group will also undergo mCM procedures, but contingencies will differ. After 4 weeks, the ECIG group will be allowed to transition back to their chosen combustible cigarette product for an additional 2 weeks with additional pulmonary and behavioral assessments. All subjects will undergo three respiratory assessments in the DCRU.
1515919|NCT02848586|Behavioral|mobile contingency management (mCM)|"mCM procedures are a novel smoking cessation tool previously used in the field by our colleagues in the Beckham research group. This equipment is part of a procedure called mobile contingency management or mCM. The participant will use a study smartphone to record his/her CO levels and moods at random times of the day and to verify his/her cigarette usage. The mCM program will reward the participant for each CO level and data transmitted to the study team. The study team will provide detailed information and training to allow them to participate in this part of the study."
1515920|NCT02848586|Other|Usual brand|"The usual brand of cigarettes is the control group in this study. 5 participants will be allowed to continue using their usual brand of combustible cigarette in this arm of the study."
1515921|NCT02848560|Drug|Hyperpolarized Xenon|Inhaled contrast for MRI occurring at each of 4 visits.
1515922|NCT02848547|Behavioral|Text Messaging via Short Message Service|
1515923|NCT02848534|Biological|neutrophil to lymphocyte ratio|value of the neutrophil to lymphocyte ratio in the diagnosis of bacterial infections
1515924|NCT02848508|Drug|Metformin|
1515925|NCT02848495|Genetic|Non-Interventional|
1515926|NCT02848482|Device|Photodynamic therapy|Photodynamic therapy (HELBO Photodynaimc Systems GmbH, Wels, Austria)
1515927|NCT02848482|Procedure|Mechanical debridement|Plastic scalers (Have implantrecallset, Kerr, Italy) will be used to curette the contaminated sites.
1515928|NCT02848482|Drug|Irrigation|0.2% chlorhexidine digluconate solution (Bioworld, Madision, US) will be irrigated at contaminated sites for 1 minute.
1515929|NCT02848469|Dietary Supplement|1000mg of eicosapentaenoic acid and 1000mg docosahexaenoic acid|
1515930|NCT02848456|Procedure|Spinal Manipulation|Manual, side-posture, high-velocity low-amplitude spinal manipulation targeting the lower lumbar spine and sacroiliac joints
1515931|NCT02848456|Procedure|Max Voluntary Isometric Contraction|A 10 second plantar flexion maximal voluntary isometric contraction
1515932|NCT02848456|Procedure|SM+MVIC|The spinal manipulation immediately preceding the maximal voluntary isometric contraction
1515933|NCT02848443|Drug|Trifluridine/tipiracil hydrochloride (S 95005)|Film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, given orally at the dose of 25 or 30 or 35 mg/m2/dose, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
1515934|NCT02848443|Drug|Oxaliplatin|Concentrate for solution for infusion containing 5mg/ml of oxaliplatin, administered intravenously at the dose of 65 to 85 mg/m2, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
1515935|NCT02848443|Drug|Bevacizumab|Concentrate for solution for infusion containing 25mg/ml of bevacizumab, administered intravenously at the dose of 5 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
1515936|NCT02848443|Drug|Nivolumab|Concentrate for solution for infusion containing 10mg/ml of nivolumab, administered intravenously at the dose of 3 mg/kg, until unacceptable toxicity according to the investigator, disease progression or patient withdrawal.
1515937|NCT02848430|Dietary Supplement|Humulus lupulus|Extract of spent hops standardized to xanthohumol, isoxanthohumol, 6-prenylnaringenin, and 8-prenylnaringenin
1515938|NCT02848417|Drug|Curcumin|Perform a randomized phase I/II study comparing curcumin (increased bioavailable form, body cell mass-85, 400 mg twice a day) to glutathione (liposomal bioavailable form 630 mg bid), with a 3 month intervention and assessment of safety, efficacy and biomarker response to therapy.
1515939|NCT02848417|Drug|Glutathione|Perform dynamic modeling studies before and after 3 months of therapy, repeating the method used previously in order to compare the response to exercise across groups and better quantify the degree of recovery in treated subjects using an exercise challenge and 9 point in time blood and saliva collections over 24 hours with genomic, cytokine, neuropeptide and cell population studies.
1515940|NCT02848417|Other|Placebo|"Placebo liquid 120 ml per/ bottle
Placebo capsules 60 capsules per bottle 400 mg /cap
With the addition of a Partner PI, redox/methylation expert Dr. Richard Deth, perform studies of antioxidant and methylation-related metabolic status prior to, during and after acute exercise in GWI subjects before and after interventions."
1515941|NCT02848404|Device|Categorical Language Fluency Smartphone Application|4 weeks' training
1515942|NCT02848391|Other|Environmental|hypobaric flight simulation
1515943|NCT02848365|Device|Endotracheal intubation|Endotracheal intubation will be done with any of these equipments
1515944|NCT02848352|Other|Placebo nasal spray|
1515945|NCT02848352|Other|Film Sequence|
1515946|NCT02848339|Drug|aspirin|aspirin desensitization
1515947|NCT02848326|Drug|AGN-241689|AGN-241689 capsule.
1515948|NCT02848326|Drug|Placebo-matching AGN-241689|Placebo-matching AGN-241689 capsule.
1515949|NCT02848313|Drug|Elamipretide|40 mg dose of elamipretide administered once daily as a 1.0mL SC injection.
1515950|NCT02848300|Drug|Bimatoprost 1% Formulation A|Bimatoprost 1% Formulation A solution applied to the scalp and trunk once daily for 14 days.
1515951|NCT02848300|Drug|Bimatoprost 1% Formulation B|Bimatoprost 1% Formulation B solution applied to the scalp and trunk once daily for 14 days.
1515952|NCT02848287|Drug|normal saline|1*2 gauze is soaked with 5 cc of 0.9 % normal saline, applied in tonsillar fossae for 3 min, then removed.
1515953|NCT02848287|Drug|ropivacaine|1*2 gauze is soaked with 5 cc of 0.75% ropivacaine, applied in tonsillar fossae for 3 min, then removed.
1515954|NCT02848261|Behavioral|Developmental Demands|Education and training related to use of CGM in this age group
1515955|NCT02848261|Behavioral|Distress Reduction|Education and training on reducing distress
1515957|NCT02848261|Behavioral|Fear of Hypoglycemia|Education and training on reducing fear of hypoglycemia
1515958|NCT02848261|Behavioral|No intervention|No intervention - serves as the control group
1515960|NCT02848235|Other|Standard of Care + EMMA|Mother Mentors will provide enhanced care, above that of the standard of care, to include clinic visit exit discussions, visit reminder messages, and patient follow-up in the event that a clinic visit is missed.
1515963|NCT02848209|Procedure|TCA 20% Peeling|TCA peel at a concentration of 20% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
1515964|NCT02848209|Procedure|Phenol/croton oil Peeling|Phenol/croton oil is applied on subcutaneous undermined skin samples and occluded with silicone tape for 24 hours and not neutralized.
1515965|NCT02848209|Procedure|TCA 40% Peeling|TCA peel at a concentration of 40% is applied on subcutaneous undermined skin samples for 2 to 4 minutes until even frosting and neutralized at the even frosting Point.
1515966|NCT02848196|Radiation|Stereotactic Body Radiation Therapy|The schedule will be 3 fractions of 15 Gy up to a total dose of 45 Gy delivered every day with VMAT and Flattening filter-free (FFF) beams. Image-guided systems, including CBCT, will be used for all patients.
1515967|NCT02848183|Drug|Cytarabine|
1515968|NCT02848183|Drug|Idarubicin|
1515969|NCT02848183|Drug|Mitoxantrone|
1515970|NCT02848183|Drug|Etoposide|
1515971|NCT02848183|Procedure|Hematopoietic stem cell transplantation|
1515972|NCT02848170|Drug|CS-3150|CS-3150 2.5mg, oral
1515973|NCT02848170|Drug|olmesartan medoxomil|olmesartan medoxomil 10 mg, oral
1515974|NCT02848157|Drug|Dexmedetomidine|Patients are put in lithotomy position. Two separate injection points are marked at 3 and 9 o'clock, about 2 to 2.5 cm from the center of anus. After aseptic preparation, a nerve stimulator needle advanced 1.5 to 3.5 cm perpendicular to the skin, and stimulation current is 2.5 to 5 mA. The unilateral contraction of anal sphincter means the inferior anal nerve stimulation. After reducing the current to 0.5 mA, the needle is then moved deeper until an up-and-down penile movement is observed. This is stimulation of the perineal branch of the pudendal nerve. Prepared drug (0.25% ropivacaine and 0.3 mcg/kg dexmedetomidine in the experimental group, and equivalent doses of ropivacaine and normal saline in the control group) is injected in half and half bilaterally.
1515975|NCT02848157|Drug|plain ropivacaine|ropivacaine and normal saline equivalent doses of dexmedetomidine
1515976|NCT02848157|Drug|Ropivacaine|
1515977|NCT02848144|Other|blood samples|
1515978|NCT02848144|Other|Collection of nosocomial infections|
1515981|NCT02848118|Device|A nasal-oral cannula of capnography|After propofol infusion, the complete induction is defined when capnography shows hypoventilation and bronchoscope is then introduced to patients.
1515982|NCT02848118|Other|Observer Assessment of Alertness and Sedation scale|After propofol infusion, the complete induction is defined when OAAS is 3 to 2 (conscious sedation) and bronchoscope is then introduced to patients.
1515983|NCT02848105|Drug|VPA|Valproic acid with 1000mg loading dose with 500mg q12 4 hours later to maintain a trough level above 75ug/ml
1515984|NCT02848092|Behavioral|FOCAL+|Weekly for 5 weeks, teens complete a computer training program designed to train teens to limit the length of glances away from the roadway. On a computer, the top portion of the screen plays a simulated video drive while the bottom half of the screen contains a map. Teens complete tasks that require switching between the 2 halves of the screen. While doing so, they receive feedback regarding how long they are looking away from the driving portion of the screen. After each session of computerized FOCAL training, teens will complete two 5-minute simulated drives. During the drives, teens will be cued to a complete a visual search task which will require them to divert their gaze from the road. Eye tracking goggles will monitor eye glances and provide real time auditory feedback when a visual glance away from the roadway exceeds 2 secs.
1515985|NCT02848092|Other|Rules of The road|Weekly for 5 weeks, teens will perform computer-based training regarding traffic codes, laws, and rules of the road. After each computerized training, teens will complete two 5-minute drives. This time in the driving simulator will be contextualized as a time for them to practice the rules of the road they learned during training. Importantly, teens in the sham intervention group will complete the same distraction tasks but will NOT receive any feedback regarding their eye gaze during simulated driving.
1515986|NCT02848079|Drug|combined TAS-102 and TAS-OX|Combination treatment with TAS-102 and oxaliplatin. TAS-102 is an oral medication; oxaliplatin (TAS-OX) is given by infusion.
1515987|NCT02848066|Procedure|Blood sample(10cc) collection|In both groups, serum haptoglobins to be collected and analyzed
1515988|NCT02848053|Other|no intervention|
1515989|NCT02848040|Other|IDK Bile Acids|colourimetric in-vitro laboratory diagnostic test
1515990|NCT02848027|Biological|Regenexx SD® procedure|Correlate patient outcomes 6 months after receiving the Regenexx SD procedure with measurements of synovial fluid collected before and after procedure.
1515991|NCT02848014|Behavioral|Writing task|
1515992|NCT02848001|Drug|CC-90009|
1515993|NCT02847988|Device|Neuromuscular electrical Stimulation (NMES)|Electrical stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo). The intensity of stimulation will be titrated based on maximal tolerable muscle contraction
1515994|NCT02847988|Device|Sham Stimulation|Sham stimulation of lower extremities will be applied using an electrotherapy stimulator device (Vectra® Neo).
1515995|NCT02847975|Dietary Supplement|Sodium nitrate|Sodium nitrate will be ingested orally
1515996|NCT02847962|Other|Corn Soy Blend Plus (CSB+)|
1515997|NCT02847962|Other|Corn Soy Blend 14 (CSB14)|
1515998|NCT02847962|Other|White Sorghum Cowpea Blend Variety 1|
1515999|NCT02847962|Other|White Sorghum Cowpea Blend Variety 2|
1516000|NCT02847962|Other|Red Sorghum Cowpea Blend|
1516001|NCT02847962|Other|White Sorghum Soy Blend|
1516003|NCT02847936|Procedure|vicryl plus suture|episiotomy with triclosan-coated sutures
1516004|NCT02847936|Procedure|vicryl suture|episiotomy with non antibacterial coated suture
1516005|NCT02847923|Other|Presentation of alternative communication application|At this stage the purpose of the application is submitted, what its purpose and its features in a brief and clear manner.
1516006|NCT02847923|Other|Familiarization with the software interface|At this stage, the volunteer will be asked to use the application by himself for a short time so that he can get acquainted and learn to use it
1516007|NCT02847923|Other|Test of the software|"Then, the volunteer is instructed to use the application following a script task that will expose a simple and fast way all the application features. These tasks have easy actions to be executed, for example: The user must communicate through the application the phrase I want to drink water, so that he will be instructed to perform the actions to select the option and then drink the water option."
1516008|NCT02847923|Other|Answer the questionnaire|After performing all the tasks the user replies to a questionnaire to evaluate the usability of the application after you use.
1516009|NCT02847910|Procedure|the disposable tissue suction set|Induced abortion is a main backstop for terminating unwanted pregnancies, however, traditional hard metal instruments has lots of insufficiencies such as easily tissue damage, and repeatedly sterilization increases the incidence of cross infection in the hospital what leads to more complications of pelvic inflammation, infertility and so on. Therefore disposable non-metallic instruments are desperately needed as a way to decrease the complications and provide better medical services to patients. So, the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
1516010|NCT02847910|Procedure|traditional metal instruments of abortion|Induced abortion is a main backstop for terminating unwanted pregnancies. In Chinese hospital, traditional metal instruments are always used during the surgery. So the investigators want to explore the clinical effect of disposable tissue suction tube set and make comparison with traditional metal instruments.
1516011|NCT02847897|Device|CO2 AcuPulse Laser|Each subject will receive 3 treatments 4 weeks apart and 3 Follow Up visits, at 1, 3, and 6 months following the last treatment.
1516012|NCT02847884|Biological|Infliximab|Patients will be prescribed Infliximab as a standard of care regardless of study participation.
1516013|NCT02847871|Behavioral|PRISME-3P program|"PRISM-3P program will consist on a visit in the geriatric centre:
Consultation with the geriatrician to rule a condition associated with loss of mobility and not known until now.
Perform a nutritional assessment by a dietician followed by appropriate care management.
Educational activity based on exercises and physical activity and balance: MAPA teaches exercises to develop strength and balance; gives tips to increase time spent on non-sedentary activities and enhance endurance followed by a monthly phone coaching.
At 3 months, in case of no improvement of the SPPB score of 1 point, a training of 10 weeks with two sessions per week will be perform by the MAPA individually or in small patients groups;
Implementation of a information exchange processing (mail, phone and book binding) between the various stakeholders."
1516014|NCT02847858|Behavioral|Health-E You: a computer-based intervention to improve the use of effective contraception among Hispanic adolescents|School-based health centers which were randomized into the intervention arm will use the Health-E You App (n=7 clinics).
1516015|NCT02847845|Dietary Supplement|red ginseng powder capsule|usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
1516016|NCT02847845|Dietary Supplement|Placebo|Control (Placebo) : red ginseng powder capsule(placebo) usage : 3C bid ac 30min dose : total 3g for 1day drug administration : oral administration administration session : 6weeks
1516017|NCT02847832|Other|Standardized transvaginal ultrasound examination|
1516018|NCT02847819|Device|airway ultrasound for vocal cords movement assessment.|Glottic aperture will be scanned using 7.5 megahertz (MHz) linear transducer portable ultrasound machine. after getting the best acoustic window, true, false vocal cords arytenoid movements will be visualized. Individual cord will be focused and doppler velocity will be measured for both the cords.
1516019|NCT02847806|Biological|Estradiol (Insulin sensitivity)|
1516020|NCT02847806|Biological|Testosterone (Insulin sensitivity)|
1516021|NCT02847793|Behavioral|Gaze training|Participants are required to maintain their gaze in a given picture (e.g., a happy face), for a given time (i.e., 750ms vs 1500 ms) to advance to the next trial. (A total of 576 trials will be distributed in a 2-day intervention).
1516022|NCT02847793|Behavioral|Placebo intervention|Participants are exposed to the same amount of time to the experimental stimuli used in the experimental group but there is no contingency between participants' gaze patterns and the end of each of the 576 trials.
1516023|NCT02847780|Device|Active Comparator :C-Mac Videolaryngoscope|Real time assessment of Glottic aperture at the time of extubation by videolaryngoscope
1516024|NCT02847780|Device|Experimental: Airway ultrasound,|Airway ultrasound using portable ultrasound machine to assess vocal cords movement.
1516025|NCT02847767|Procedure|Perfusion Imaging|IV contrast perfusion CT will be performed at baseline and at 1 week after completing treatment. Perfusion imaging is similar to a diagnostic CT except a smaller region is serially imaged post contrast injection with multiple data acquisitions and high temporal resolution
1516026|NCT02847754|Other|Isometric resistance training|"Exercises in the all-fours position Exercises in the swimming Position Exercises in the forearm support Position Exercises with elastic rubber band"
1516027|NCT02847741|Other|patient's routine care|Interview by psychiatrists, questionnaires, blood analysis
1516029|NCT02847702|Drug|VM902A 200-mg Capsules|Taken orally with food twice daily
1516030|NCT02847702|Drug|VM902A 400-mg Capsules|Taken orally with food twice daily
1516031|NCT02847702|Drug|Naproxen 500-mg Capsules|Taken orally with food twice daily
1516032|NCT02847702|Drug|Placebo|Capsules to match VM902A and/or naproxen taken orally with food twice daily
1516033|NCT02847689|Behavioral|Language Treatment|Recording of a mother's voice reading a children's storybook.
1516035|NCT02847676|Procedure|Tissue sample donation|Patients undergo planned gynaecological surgery. Tissue samples, which are routinely taken, are donated.
1516036|NCT02847663|Device|Kryosauna Space Cabin|The whole body cryotherapy device is able to generatue temperatures up to -195°C for 3 minutes. In this study, we generate temperatures of -135°C for 2 minutes as proposed in the manual. The participant will enter the cabin in cold-resistant shoes and will remain in standing position during the whole procedure. The cold temperature is generated by vaporization of liquid nitrogen.
1516037|NCT02847663|Other|cold water tub|The tub will be filled with cold water up to the sternal level of the participants. Adding ice will ensure a constant temperature. The participant will sit inside the tub during the whole procedure.
1516038|NCT02847481|Procedure|fecal microbiota transplantation|fecal microbiota transplantation
1516039|NCT02847481|Drug|placebo fecal microbiota transplantation|placebo fecal microbiota transplantation
1516040|NCT02847481|Procedure|FMT with antibiotic pre-treatment (v1)|FMT with antibiotic pre-treatment (v1)
1516041|NCT02847481|Procedure|FMT with antibiotic pre-treatment (v2)|FMT with antibiotic pre-treatment (v2)
1516042|NCT02847468|Other|FDG Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FDG) before treatment with Sorafenib is started and 1 month after treatment started.
1516043|NCT02847468|Other|FCH Positron Emission Tomography|Subject will performed Positrons Emission tomography (PET) with 18F-Fluorocholine (FCH) before treatment with Sorafenib is started and 1 month after treatment started.
1516044|NCT02847455|Drug|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each
1516045|NCT02847455|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
1516046|NCT02847455|Drug|10 mg Rabeprazole|one 10-mg Rabeprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
1516047|NCT02847442|Drug|BIA 9-1067|Opicapone (BIA 9-1067) 50 mg hard capsules. Oral administration, once daily at bedtime, at least one hour before or after the last daily dose of L-dopa/DDCI.
1516048|NCT02847442|Drug|levodopa/dopa decarboxylase inhibitor|OPC enhances the effects of L-dopa. Hence, it may be necessary to reduce the subject's L-dopa/DDCI dose within the first days or weeks of OPC treatment by extending the dosing intervals and/or reducing the amount of L-dopa/DDCI per dose
1516049|NCT02847429|Drug|Crenolanib|
1516050|NCT02847429|Drug|Placebo|
1516051|NCT02847416|Device|BreatheMAX breathing device|
1516052|NCT02847403|Drug|Exenatide|Patients will be injected subcutaneously 2 mg long-acting exenatide once-weekly. No dose titration is foreseen.
1516053|NCT02847403|Other|placebo|patients will be seen at the Center for Cognitive Disorders and Dementia according to their usual schedule.
1516054|NCT02847390|Other|Education intervention|The investigators will develop and deliver a diabetes physician and nursing inpatient diabetes superuser educational curriculum focused on delivering safe, evidence-based diabetes care in the hospital setting. The physician educational curriculum will consist of 10 case-based modules taught to internal medicine residents at two academic hospitals and taught to hospitalists at two academic hospitals and one community hospital. The nursing educational curriculum will consistent of 12 case-based modules taught to unit-based nurses at two academic hospitals and one community hospital. These educational interventions will be delivered over a 6-month time frame from August 2016-April 2017.
1516055|NCT02847377|Other|Injection of [18F]-ODS2004436 radiotracer|
1516056|NCT02847364|Dietary Supplement|chewing gum|The patient will chew one piece (1.45g) of regular chewing gum starting morning of post-operative day 1 for 30 minutes each time, three times per day, till the first bowel movement.
1516057|NCT02847351|Dietary Supplement|Arabinoxylan Diet|"19 free-living subjects (16 F/ 3M) attending from one year the Outpatient Obesity Clinic Policlinico S. Matteo were enrolled. All subjects were already reached weight loss and were in a sort of weight steady state. Based on 7-day food diary, a nutritionist composed 19 isocaloric diets, replacing all consumed carbohydrates with normal or AX crackers. The mean carbohydrates intake was 189.5g, with total fiber 20.6g. In AX diet total fiber was 25.3g/day (20.6 plus 4.68g of AX).
Height, weight, waist circumference were obtained at time 0, at week 4 and 8. At every time were collected blood samples for glucose, insulin, total cholesterol, HDL-chol., tryglicerides, plasma acyl and des-acyl ghrelin. Glucose and insulin were , also collected 2 h after a 75 g oral glucose tolerance test (OGTT)."
1516058|NCT02847338|Drug|Amlodipine|Amlodipine 5mg and Amlodipine 10mg will be one of the treatments in which patients will receive on the monotherapy arm and on the dual therapy arm.
1516059|NCT02847338|Drug|Lisinopril|"Lisinopril 10mg and Lisinopril 20mg will be one of the treatments in which patients will receive on the monotherapy arm.
Lisinopril 20mg will be one of the treatments in which patients will receive on the dual therapy arm."
1516060|NCT02847338|Drug|Amiloride|Amiloride 10mg will be one of the treatments in which patients will receive on the dual therapy arm.
1516061|NCT02847338|Drug|Chlortalidone|Chlortalidone 25mg will be one of the treatments in which patients will receive on the dual therapy arm and monotherapy arm.
1516062|NCT02847325|Drug|AC0058TA|50 mg AC0058TA 100 mg AC0058TA 200 mg AC0058TA 400 mg AC0058TA
1516063|NCT02847325|Drug|Placebo capsules|Placebo capsules
1516064|NCT02847312|Other|High avenanthramide, phenolic acid|High avenanthramide and high phenolic acid, matched with energy and insoluable fibre.
1516065|NCT02847312|Other|Low avenanthramide, medium phenolic acid|Low avenanthramide and moderate phenolic acid, matched with energy and insoluable fibre.
1516066|NCT02847312|Other|Control|Control are matched with energy and insoluable fibre.
1516067|NCT02847299|Device|"increase of cough peak flow (Astral ventilator)"|instrumental increase of cough peak flow with a ventilator by hyper-insufflation and with air stacking method
1516068|NCT02847286|Drug|Dapivirine Ring-004|Treatment A: Dapivirine Ring-004 for 28 days
1516069|NCT02847286|Drug|Dapivirine Ring-004 for 28 days along with clotrimazole|Treatment B: Dapivirine Ring-004 for 28 days along with clotrimazole, 5 g per day for 7 days
1516070|NCT02847286|Drug|Clotrimazole|Treatment C: Clotrimazole, 5 g per day for 7 days
1516131|NCT02846831|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
1516072|NCT02847247|Drug|CCRE|Endotoxin challenge: Subjects will undergo inhalation of 20,000 EU CCRE. The CCRE will be inhaled by subjects as a nebulized preparation using an ultrasonic nebulizer until the challenge solution is completely spent (generally 10 minutes).
1516073|NCT02847208|Other|self-report written questionnaire|The questionnaire was filled-in by the patients in presence of a clinical nurse. The gynaecological healthcare options and contraceptive choices were recorded. All following questions were closed-ended (answer yes/no): use of contraception; use of contraceptive pill; use of contraceptive implant; use of intrauterine device; use of tubal sterilization; use of mechanical contraception; use of other type of contraception; previous delivery (term pregnancy); gynaecological follow-up; previous Pap smear. In case of a positive answer to one of these questions, more details were requested (depending on the situation: name of the contraception, date of delivery, frequency of the gynaecological follow-up, date of the last pap smear). An internal validation of the questionnaire was performed on a subgroup of patients.
1516074|NCT02847195|Device|pupillometry|This is a safe and painless examination (the device is simply placed on the orbit of the eye). The optical pupillometer is cleaned by doctors before and after each use, using cleaning wipes containing antibacterial, antiviral and antifungal drugs; such wipes are already in use in the service for cleaning equipment.
1516075|NCT02847182|Biological|Cord Blood Infusion|
1516076|NCT02847182|Biological|Placebo|
1516077|NCT02847169|Device|filcon IV1 toric lens|toric contact lens
1516078|NCT02847169|Device|ocufilcon D toric lens|toric contact lens
1516079|NCT02847156|Other|Physical assessment|1 year follow-up in CF infants with clinical, microbiological and therapeutic assessments
1516080|NCT02847143|Drug|nasal oxytocin or placebo|nasal administration of oxytocin or palcebo 45 min befor fMRI session
1516081|NCT02847143|Device|fMRI|FMRI during emotional image visualization
1516082|NCT02847143|Behavioral|Attachement scale interview (ASI)|this scale is used to determine the attachement style of each participant
1516083|NCT02847143|Behavioral|psychometric scales|self adminstrated questionnaires which asses the level of anxiety (Spielberger State-trait anxiety interview-STAI), depression (Beck depression inventory-BDI) and alexithymia (Toronta Alexuthymia scale-TAS 20)
1516084|NCT02847130|Other|Informational Intervention|Participate in focus group
1516085|NCT02847130|Other|Interview|Undergo one-on-one interviews
1516086|NCT02847130|Other|Medical Chart Review|Review of medical chart
1516087|NCT02847117|Other|Mastiha|The volunteers will follow a low-phytochemical diet for five days, meaning that they will exclude fruits, vegetables, legumes, coffee, tea, alcoholic beverages and chocolate. On the day of the experiment and after overnight fasting, the volunteers will consume 10g of natural Mastiha and blood samples will be obtained on timepoints 0h, 30min, 1h, 2h, 4h, 6h and 24h after Mastiha intake. Until timepoint 6h, will be allowed to consume only water. Urine samples will also be collected on timepoints 0h, 4h, 8h and 24h.
1516088|NCT02847104|Other|dynamic insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and dynamic insulin protocol
1516089|NCT02847104|Other|static insulin protocol|Adaptation of insulin infusion rate according to hourly capillary blood glucose and static insulin protocol
1516091|NCT02847078|Device|smart phone app|App for this study is provided with real time updating educational materials, reminder, and consultation for improving secondary prevention, and the related information is pushed to a patient in chronological order after his or her PCI operation.
1516092|NCT02847078|Device|A guideline booklet|A guideline booklet with general advice on secondary prevention of coronary artery disease.
1516093|NCT02847052|Other|Non interventional study|
1516094|NCT02847039|Genetic|Blood samples|Blood samples at baseline.
1516095|NCT02847026|Biological|IPV at 14 and 22 weeks of age, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
1516096|NCT02847026|Biological|IPV at 14 and 22 weeks of age, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a full dose IPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
1516097|NCT02847026|Biological|IPV at 14 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
1516098|NCT02847026|Biological|IPV at 14 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 14 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
1516099|NCT02847026|Biological|IPV at 6 and fIPV at 22 weeks, Rotarix|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
1516100|NCT02847026|Biological|IPV at 6 and fIPV at 22 weeks, RotaTeq|Participants in this arm will receive a full dose of inactivated poliovirus vaccine (IPV) at 6 weeks of age and a fractional dose IPV (fIPV) booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
1516101|NCT02847026|Biological|fIPV at 6-14-22 weeks of age, Rotarix|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, Rotarix, at 6 and 10 weeks of age.
1516102|NCT02847026|Biological|fIPV at 6-14-22 weeks of age, RotaTeq|Participants in this arm will receive a fractional doses of inactivated poliovirus vaccine (fIPV) at 6 and 14 weeks of age and a fIPV booster at 22 weeks of age. They will also receive the rotavirus vaccine, RotaTeq, at 6, 10, and 14 weeks of age.
1516103|NCT02847013|Drug|TAP block with Liposomal bupivacaine|
1516104|NCT02847013|Procedure|TAP block with normal saline|
1516105|NCT02847000|Drug|Tetrahydrouridine|"Starting dose is by weight:
THU is supplied as 250 mg/capsule Weight 40-60kg = 2 capsules of Tetrahydrouridine. Weight 61-80kg = 3 capsules of THU. Weight 81-100kg or higher = 4 capsules of THU.
Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
1516106|NCT02847000|Drug|Decitabine|"Starting dose is by weight:
DEC is supplied as 5 mg/capsule. Weight 40-60kg = 2 capsules of Decitabine. DEC capsules are ingested ~60 minutes after THU capsules. Weight 61-80kg = 3 capsules of DEC. DEC capsules are ingested ~60 minutes after THU capsules. Weight 81-100kg or higher = 4 capsules of DEC. DEC capsules are ingested ~60 minutes after THU capsules.
Timing between THU and Dec, Frequency of administration: Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days. Treatment on protocol monitoring continues for 52 weeks, however, subjects will have the option to continue beyond this period if it judged to be in their interests."
1516107|NCT02846987|Drug|Abemaciclib|
1516108|NCT02846974|Device|Pulse oximeter|A pulse oximeter will be used for calibration
1516109|NCT02846948|Other|Focused assessed echocardiography|Focused assessed transthoracic echocardiography is non-invasive, painless procedure. The transducer is placed on the chest at certain locations and angles to get the required information on patient's condition.
1516110|NCT02846935|Drug|Decitabine|2-4 capsules depending on the weight of participant. Dec capsules are ingested ~60 minutes after THU capsules.
1516111|NCT02846935|Drug|Tetrahydrouridine|2-4 capsules depending on the weight of participant. Oral THU capsules followed 60 minutes later by oral Dec capsules are ingested 2X/week on consecutive days.
1516112|NCT02846909|Drug|Progesterone|
1516113|NCT02846883|Biological|MSC's|Intravenous infusion of 1 million allogeneic MSCs/kg.
1516114|NCT02846883|Biological|MSC's|Intravenous infusion of 3 million allogeneic MSCs/kg
1516115|NCT02846883|Drug|Placebo|Intravenous infusion of Plasmalyte A (placebo)
1516118|NCT02846857|Other|15-week intervention with sensor-augmented pump|A sensor will be inserted on the day before the start of the intervention by the participant. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have been previously shown how to use the study insulin pump.
1516119|NCT02846857|Other|15-week intervention with single-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks.
1516120|NCT02846857|Other|15-week intervention with dual-hormone closed-loop|A sensor will be inserted on the day before the start of the intervention by the participant. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 15 weeks. Participants will have to reconstitute glucagon everyday.
1516121|NCT02846857|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
1516122|NCT02846857|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
1516123|NCT02846857|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
1516124|NCT02846857|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
1516125|NCT02846831|Other|2-week intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day before the start of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 2 weeks.
Participants will have been previously shown how to use the study insulin pump."
1516126|NCT02846831|Other|2-week intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.
Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 2 weeks."
1516127|NCT02846831|Other|2-week intervention with dual-hormone closed-loop strategy|"A sensor will be inserted on the day before the start of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.
Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 2 weeks. Participants will have to reconstitute glucagon everyday."
1516128|NCT02846831|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
1516129|NCT02846831|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
1516130|NCT02846831|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
1516132|NCT02846818|Procedure|Microdialysis|Extracerebral MD catheters were positioned in a retrograde direction in the internal jugular vein.
1516133|NCT02846805|Procedure|implant-retained overdentures|subjects will receive two-implant-retained overdentures in the mandible,and they continue wearing their complete denture in the maxilla.
1516134|NCT02846792|Other|Laboratory Biomarker Analysis|Correlative studies
1516135|NCT02846792|Biological|Nivolumab|Given IV
1516136|NCT02846792|Drug|Plinabulin|Given IV
1516137|NCT02846779|Other|Low intensity|Low intensity telepharmacy outreach
1516138|NCT02846779|Other|Moderate intensity|Moderate intensity telepharmacy outreach
1516139|NCT02846779|Other|High intensity|High intensity telepharmacy outreach
1516140|NCT02846766|Drug|Lenvatinib|Lenvatinib is administered orally at a starting dose of 24 mg per day. Lenvatinib is administered in cycles of 28 days.
1516141|NCT02846753|Procedure|trans catheter heart valve replacement|trans catheter heart valve replacement
1516142|NCT02846740|Device|Alpha-Stim®.|cranial electrical stimulation
1516143|NCT02846740|Behavioral|Montgomery-Åsberg Depression Rating Scale, Hamilton Anxiety Rating Scale, The Pittsburgh Sleep Quality Index and agitated behavior Scale|A summed global score from rating scales measuring the Modifiable suicide risk factors (MSRF's).
1516144|NCT02846727|Device|skin perfusion image|Upon enrollment following written, informed consent, the patient will receive an injection of 7.5 mg of Indocyanine Green (ICG) intravenously (Dilute 25 mg of Indocyanine Green (ICG) with 10 cc of solvent to achieve a 2.5 mg/cc concentration.) Following injection, Novadaq's LUNA™ fluorescence angiography system will be utilized to map a standard skin perfusion image (SPI) over the upper extremities and anterior chest wall.
1516146|NCT02846701|Drug|duloxetine|The concentration of duloxetine is measured by liquid chromatography coupled to tandem mass spectrometry on blood sample
1516147|NCT02846675|Biological|autologous SVF|SVF will be obtained from lipoaspirates of subjects which will contain more than 5 millions nucleated cells.
1516148|NCT02846675|Biological|Placebo|a Placebo treatment without SVF cells
1516149|NCT02846662|Behavioral|CONEMO|The study intervention has two components: the smartphone application CONEMO and primary care nurses monitoring patients' adherence to the intervention. CONEMO is a 6-week low-intensity behavior activation program delivered in 18 sessions that include messages related to the treatment goals, motivating them to do certain activities, helping to select and plan activities and messages related to psychological skills that facilitate the incorporation of activities in everyday life and to tackle obstacles that hinder patients to be more active. Primary care nurses are responsible for training participants to use the CONEMO app, monitoring patients' adherence to CONEMO, calling patients when they are non-adherent, and giving technical support when necessary.
1516150|NCT02846649|Behavioral|PIER|Daily text message queries with tailored support
1516153|NCT02846597|Procedure|Sustained lung inflation in preterms (SLI).|Providing a positive pulmonary ventilation with an opening lung pressure for the first breath of preterm infant for a sustained period of time
1516154|NCT02846584|Biological|CD19 or CD20 CAR T cells briging HSCT|Patients will receive a one-week regimen of chemotherapy consisting of fluid arabise and cyclophosphamide aimed to deplete the lymphocytes. One week later, patients are intravenously infused autologous anti-CD19 or anti-CD20 CAR T cells.
1516155|NCT02846571|Biological|Human Pancreatic Islet Transplantation|Human Pancreatic Islet Transplantation in the Eye Anterior Chamber of legally blind Diabetic Patients with Stable Kidney Transplantation
1516156|NCT02846558|Other|Frequent Patient Interaction|Weekly informational and supportive text messages will be sent to patients, encouraging adherence to the calorie restriction diet.
1516157|NCT02846558|Behavioral|Timing Restriction|Patients continue to follow their normal diet, but limit food intake to an 8-hour period during the day.
1516158|NCT02846558|Device|LoseIt! Smartphone Application|Patients will be trained by study staff to download the LoseIt! application, and use it to log all food intake throughout the study duration. Data collected from the application will be the primary measure of adherence to dietary changes.
1516159|NCT02846545|Biological|Golimumab|Participants will receive subcutaneous golimumab intermittently for 52 weeks, where doses will be based on weight and/or body surface area.
1516160|NCT02846545|Biological|Placebo|Matching Placebo to golimumab
1516165|NCT02846506|Drug|Canagliflozin and Metformin Extended Release (XR) Fixed Dose Combination [FDC]|Participants will receive 1 XR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed (Treatment B)or fasted condition (Treatment D) in a given treatment period as per treatment sequence.
1516166|NCT02846506|Drug|Canagliflozin 50 mg|Participants will receive canagliflozin 50 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
1516167|NCT02846506|Drug|Canagliflozin 100 mg|Participants will receive canagliflozin 100 mg oral tablet under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
1516168|NCT02846506|Drug|Metformin Extended Release (XR)|Participants will receive metformin XR 500 mg tablet orally under fed (part of Treatment A) or fasted condition (part of Treatment C) in a given treatment period as per treatment sequence.
1516169|NCT02846493|Drug|bromocriptine|Patients in this group will receive rectal bromocriptine at a daily dose of 2.5 mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT), Vascular Endothelial Growth Factor(VEGF),drink intake (Intake) and urine volume.
1516170|NCT02846493|Drug|dexamethasone|Patients in this group will take oral dexamethasone at a daily dose of 3mg for 7 days,from the day of oocyte pickup.At oocyte retrieval and at the 3rd d and 5th d of treatment, all the patients received the measurements of body mass index (BMI), abdominal circumference (AC), maximum depth of ascites in ultrasonic (D),hepatorenal function, coagulation function ,white blood cell count (WBC), hematocrit (HCT),Vascular Endothelial Growth Factor(VEGF), drink intake (Intake) and urine volume.
1516171|NCT02846480|Other|physical therapy|"Pre-surgical Physical Therapy: physical therapy aimed to correct the posture, to the awareness and the strengthening of the pelvic floor muscles.
Post-surgical Physical Therapy: checking the correct contraction of the pelvic floor muscles and hypopressive exercises."
1516172|NCT02846480|Other|surgical treatment|Surgical correction of POP.
1516173|NCT02846480|Other|behavior therapy|At hospital discharge, patients will receive a fact sheet on the sanitary and behavioral measures recommended for the prevention of POP and urinary incontinence (proper weight, prevent constipation, avoid weight bearing and cough and high impact exercise).
1516174|NCT02846467|Other|Informed consent trough a portable video media|Information provided to patients using the mobile application (iURO app)
1516175|NCT02846467|Other|Written informed consent|Information provided to patient trough the traditional informed consent (written IC) for transurethral resection of bladder or prostate.
1516176|NCT02846454|Other|inulin|Investigate the satiating effects of consuming 4g/d inulin in 2 daily doses of 2g
1516177|NCT02846454|Other|arabinoxylan|Investigate the satiating effects of consuming 4g/d arabinoxylan in 2 daily doses of 2g
1516178|NCT02846441|Procedure|hepatobiliary scintigraphy|99mTc-mebrofenin hepatobiliary scintigraphy with single photon emission computed tomography (SPECT)
1516179|NCT02846428|Drug|5-Fluorouracil|5-FU will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle during neoadjuvant treatment period for 4 cycles.
1516180|NCT02846428|Drug|Capecitabine|Capecitabine will be administered at 900 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
1516181|NCT02846428|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 500 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
1516182|NCT02846428|Drug|Docetaxel|Docetaxel will be administered at 100 mg/m^2 by IV infusion on Day 1 of each 21-day cycle for 4 cycles during adjuvant treatment period.
1516183|NCT02846428|Drug|Epirubicin|Epirubicin will be administered at 100 mg/m^2 by short IV infusion on Day 1 of each 21-day cycle for 4 cycles during neoadjuvant treatment period.
1516184|NCT02846415|Behavioral|Play Intervention for Dementia|"12 weekly session, 45-75 minutes each
Play with toys
Sessions will be facilitated by a play specialist, trained play assistants, and centre staff."
1516185|NCT02846402|Other|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
1516186|NCT02846389|Other|Moderate Exercise|Aerobic training utilizing the portable stationary pedal exerciser (Pedlar) which contains two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. Participants are required to perform 15 minutes/day of aerobic exercise using the Pedlar device on radiation treatment days; during a standard radiation course, this will typically yield 75 minutes/week of aerobic time.
1516187|NCT02846376|Drug|Nivolumab|Nivolumab is a fully humanized immunoglobulin 4 (IgG4) monoclonal antibody (mAb) which binds to PD-1 (CD279) with nanomolar affinity and shows a high degree of specificity for PD-1; blocking binding of PD-1 to PD-L1 and PD-L2. Nivolumab binds selectively to human PD-1 and does not bind to other members of the cluster of differentiation protein 28 (CD28) family.
1516188|NCT02846376|Drug|Ipilimumab|Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
1516189|NCT02846363|Other|public awareness campaign|"The public awareness campaign was based on improving knowledge and skills of public to recognize stroke symptoms. The campaign materials were:
3 posters presenting the three main symptoms of stroke and the need to call the EMS immediately
A leaflet on stroke will be created
3 participatory movies: These films will be posted on YouTube and broadcast on the website and the Facebook campaign page
Actions on social networks: A Facebook group will be created (AVC: votre appel peut sauver des vie).
A website developed with ICAP - UCBL Lyon1 (http://avc.univ-lyon1.fr/)
On the occasion of World Stroke Day, held annually on 29 October, will be organized an event in Lyon in order to educate and inform the general public about stroke: the main symptoms and reflexes to adopt in case of stroke: call the EMS urgently"
1516190|NCT02846350|Behavioral|Motivational Interviewing|"The training will include MI skills and elements identified as most effective, MI spirit (collaboration, evoking patient motivation, honoring patient autonomy, recognizing and reinforcing change talk, and rolling with (not fighting) resistance. Physicians utilizing MI will learn to engage with patients in an empathic, nonjudgmental manner and to pose simple but strategic questions to motivate change; when patients resist change, the physician learns to ''roll'' with resistance instead of confronting it. If and when the patient is ready to initiate a change, the physician will be prepared to support their decision"
1516232|NCT02845999|Drug|interleukin-2|day -1 : addition of 1000 UI/ml of interleukin 2 to NK cells and overnight culture at 37°C, 5%CO2 ; day 0, hour +12 : 10 MUI of interleukin 2 injection, 2 times a week during 3 weeks.
1516233|NCT02845986|Procedure|Laparoscopic Spleen-Preserving No.10 Lymph Node Dissections|After exclusion of T4b, bulky lymph nodes, or distant metastasis case et al. Laparoscopic spleen-preserving No.10 lymph node dissections will be performed with curative treated intent in patients with locally advanced upper third gastric adenocarcinoma.
1516273|NCT02845674|Drug|OTX-101 0.09%|0.09% cyclosporine nanomicellar solution
1516191|NCT02846337|Procedure|ULTRAFILTRATION|"Peritoneal dialysis: at least one daily contact, 5 days a week minimum, with a hypertonic solution. Le number of contact et the stasis duration will be decided by the practitioner.
Hemodialysis: at least one hemodialysis per week, one hemofiltration and/or hemodiafiltration per week, and at least 2 liter of ultrafiltrate extraction per week. In case of serious interdialytic weight gain, and/or hemodynamic unsteadiness, sessions can be up to 6 per weeks. Sessions duration will be adjusted to the needful ultrafiltrate and hemodynamic tolerance.
Isolated ultrafiltration: at least once a week, and includes an extraction of minimum 2 liter ultrafiltrate in less than 4 hours. It could be done, according to routines and department capacity, on a hemodialysis generator, plasmatic exchange generator, or mobile ultrafiltration device."
1516192|NCT02846337|Procedure|ENHANCED MEDICAL TREATMENT|"Close cardiologic and nephrologic follow-up, minimum 4 times a year, This incidence matches the heart failure, and chronic kidney failure care guidance for our sample
Medical care adjustment in order to apply European and American guidance for chronic heart failure care
Hydric, caloric, peptic and sodium input evaluation by a dietician, and adjustment if needed
Physical rehabilitation suggestions by a physiologist
Evaluation of an interventional approach requirement, and implementation if needed (pacemaker, defibrillator, cardiac resynchronization, diagnosis and therapeutic coronary angiography, ventricular stimulator) according to European and American guidance."
1516193|NCT02846324|Drug|GBT440|Capsules which contain GBT440 drug substance in Swedish orange
1516194|NCT02846324|Drug|Placebo|Placebo capsules
1516195|NCT02846311|Device|Flu Test|
1516196|NCT02846298|Biological|Drug Monitoring|Evaluation of Pharmacokinetic / Pharmacodynamic Data and Interest Individualized Therapeutic Drug Monitoring Glycopeptides and β-lactam-aminoglycoside ICU
1516197|NCT02846285|Other|No intervention|
1516198|NCT02846272|Procedure|Observation|Observation of MRI changes in subjects
1516199|NCT02846246|Other|Person-centred and health-promoting home care service|Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.
1516200|NCT02846246|Other|Care as usual|The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
1516201|NCT02846233|Drug|GLP1 receptor agonist|"Albiglutide or Dulaglutide will be added to a basal insulin."
1516202|NCT02846233|Drug|basal insulin|The participant will continue with the basal insulin.
1516203|NCT02846233|Drug|SGLT2 inhibitor|"Empagliflozin will be added to a basal insulin."
1516204|NCT02846233|Drug|Metformin|The participant will continue with metformin.
1516205|NCT02846220|Behavioral|Overcoming Immunity to Change health coaching|
1516206|NCT02846207|Drug|Yiqi huoxue|Buyang Huanwu demolition, which includes: Astragalus 60g, Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
1516207|NCT02846207|Drug|Yiqi group|Astragalus 60g.Oral administration, twice one day, for 12weeks.
1516208|NCT02846207|Drug|Huoxue group|Radix Paeoniae Rubra 15g, ligusticum wallichii 12g, angelica sinensis 20g, earthworm 12g, flos carthami 12g and peach seed 12g. Oral administration, twice one day, for 12weeks.
1516209|NCT02846207|Drug|placebo|Dextrin,oral administration, twice one day, for 12weeks.
1516210|NCT02846194|Behavioral|brief guided imagery|
1516211|NCT02846181|Drug|[14C]-SK-1405|
1516212|NCT02846155|Other|clear water|the patients just drink common clear water before Magnetic-controlled Capsule Endoscopy examination
1516213|NCT02846155|Drug|simethicone|the patients drink clear water and simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion) before Magnetic-controlled Capsule Endoscopy examination
1516214|NCT02846155|Drug|simethicone combined with pronase|the patients drink simethicone (Espumisan; Berlin-Chemie, Germany, containing 40 mg simethicone in 1 mL emulsion)，pronase granules（Deyou；Beijing Tide Pharmaceutical Co，China,containing 20,000iu pronase），and clear water before Magnetic-controlled Capsule Endoscopy examination
1516215|NCT02846142|Drug|PTI-428|
1516216|NCT02846142|Other|Placebo|
1516217|NCT02846142|Drug|ethinyl estradiol and levonorgestrel|
1516218|NCT02846116|Other|Prosthetic crown|
1516219|NCT02846103|Other|Biological samples|blood and tumor tissue samples
1516220|NCT02846090|Drug|Dexmedetomidine to reduce the IOP|Dexmedetomidine 50 micrograms group (D50) in which peribulbar block was given using 10 ml of a mixture of local anesthetics. The mixture was composed of 5 ml of 0.5% bupivacaine +4.5 ml of 2% lidocaine +0.5ml of 50 micrograms of Dexmedetomidine with 150 IU hyaluronidase.
1516222|NCT02846064|Procedure|Autograft of cryopreserved ovarian tissue|Orthotopic transplantation
1516227|NCT02846012|Other|CSCM2|
1516228|NCT02845999|Biological|allogenic immunotherapy based on Natural Killer cells adoptive transfer|day -1 : donor NK cell purification ; day 0 : adoptive transfer (according to a dose escalation) ; Dose escalation protocol : 3.10^6 ; 8.10^6 and 12.10^6 cells/kg of recipient body weight
1516229|NCT02845999|Biological|cetuximab|day -8 : cetuximab 400 mg/m2 ; day -1 and every week (for 7 weeks) : cetuximab 250 mg/m2
1516230|NCT02845999|Drug|Cyclophosphamide|day -6 : cyclophosphamide 60 mg/Kg
1516231|NCT02845999|Drug|fludarabine|day -6 to day -2 : fludarabine 25 mg/m2
1516234|NCT02845986|Drug|oxaliplatin|oxaliplatin or platinum-based chemotherapy is used when the patients undergo adjuvant chemotherapy after the surgery.
1516235|NCT02845973|Biological|gut microbiota|
1516236|NCT02845960|Behavioral|rapid recovery|rapid recovery
1516237|NCT02845947|Behavioral|Music Therapy|The music therapy intervention offered during the time of the patient's extubation readiness trial (ERT) will consist of live music using a multitude of instruments and patient-preferred and improvised music. The music therapy interventions will always include the use of live music, including guitar, keyboard, voice, ocean drum, reverie harp, and/or various percussive instruments. The music therapist will use a tablet to understand how to play patient-preferred songs. To ensure patient safety, the music therapist will adhere to the infection control policies set forth by the institution. The following are the intended goals of the Music therapy intervention: facilitating relaxation, alleviation of anxiety, and successful utilization of new coping skills.
1516239|NCT02845921|Other|leg elevation|A stand making an angle of 30 degree to the horizontal is used to elevate both the legs
1516240|NCT02845921|Other|leg wrapping|Esmarch bandage is used to wrap each lower limb
1516241|NCT02845921|Other|control|no intervention has been done
1516242|NCT02845908|Drug|POF|Paclitaxel plus Oxaliplatin plus Leucovorin plus 5-FU
1516243|NCT02845908|Drug|FOLFOX|Oxaliplatin plus Leucovorin plus 5-FU
1516244|NCT02845908|Drug|FOLFOX plus PAC(ip)|FOLFOX plus intraperitoneally PAC
1516245|NCT02845895|Other|Caregiver dedicated|Organization of nutrition screening with the help of a caregiver
1516246|NCT02845895|Other|Classic strategy|Classic organization with the training of the department team
1516247|NCT02845882|Drug|Prednisone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine|Prednisone 60 mg/m2 per day,d1-28, then taper over 9 days; Vincristine 1.5 mg/m2 per day (max 2 mg),d1,8, 15, 22; Daunorubicin 30 mg/m2 per dose,d5,12,19; Pegylated-asparaginase 2000 IU/m2 per dose,d16,36,57; Cyclophosphamide 1000 mg/m2 per dose, d36, 57; Cytarabine 75 mg/m2 /d, d36-42,d 57-63; 6-Mercaptopurine 60 mg/m2 per day, d36-42, 57-63; Triple it, d8,29,36,57 1,8, 15, 22
1516248|NCT02845882|Drug|6-mercaptopurine,Methotrexate|6-Mercaptopurine 25 mg/m2 per day, d1-56; Methotrexate 5g/m2 per dose, d1, 15, 29, 43; Triple it, d1, 15, 29, 43;
1516249|NCT02845882|Drug|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Doxorubicin, 6-mercaptopurine|Dexamethasone 10 mg/m2 per day, d1-7, d15-21; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 8, 15; Doxorubicin 30 mg/m2 per dose, d1, 8, 15; Pegylated-asparaginase 2,000 IU/m2 per dose, d3, 24; Cyclophosphamide 1000 mg/m2 per dose, d29; Cytarabine 75 mg/m2 /d, d29-35; 6-Mercaptopurine 60 mg/m2 per day, d29-35; Triple it, d1, 29;
1516250|NCT02845882|Drug|Dexamethasone,Vincristine, Pegylated-asparaginase, Cytarabine, Cyclophosphamide, Methotrexate|Dexamethasone 20mg/m2/day, d1-5; Vincristine 1.5 mg/m2 per day (max 2 mg), d1, 6; Methotrexate 5000mg/m2, d1; Cyclophosphamide 200mg/m2/dose, q12h×5, d2-4; Cytarabine 2000mg/m2/dose, ，q12h×2, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
1516251|NCT02845882|Drug|Dexamethasone, Vindesine, Methotrexate, Ifosfamide, Daunorubicin, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Vindesine 3mg/m2（MAX 5mg）, d1, 6; Methotrexate 5000mg/m2, d1; Ifosfamide 800mg/m2/dose, q12h×5,d2-4; Daunorubicin 25mg/m2/dose, d5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d1;
1516252|NCT02845882|Drug|Dexamethasone, Cytarabine, Etoposide, Pegylated-asparaginase|Dexamethasone 20mg/m2/day, d1-5; Cytarabine 2000mg/m2/dose，q12h× 4, d1, 2; Etoposide 100mg/m2/dose，q12h×5, d3,4,5; Pegylated-asparaginase 2,000 IU/m2 per dose, d6; Triple it, d5;
1516253|NCT02845882|Drug|Methotrexate, 6-mercaptopurine|6-mercaptopurine 50 mg/m2 per day, Daily; Methotrexate 20 mg/m2 per dose, Once a week; Triple it, Once every 4 weeks for 12 times;
1516254|NCT02845869|Device|THOR laser LX2 system|Treatment session will take up to 25 minutes and will include stimulation of local lymph nodes and soft tissue, de-activation of trigger points, and eliciting analgesia.
1516255|NCT02845869|Device|Sham|The therapeutic light will be turned off but the system will produce similar noises and mild heat.
1516256|NCT02845856|Drug|Cetuximab|400 mg/m2 IV over 120 minutes on day 1 of cycle 1 only, and 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations
1516257|NCT02845856|Biological|NK immunotherapy|For each procedure, 10 billion cells will be infused in 4 times
1516258|NCT02845843|Drug|Combination of Lopinavir /Ritonavir and Interferon beta-1b|Lopinavir /Ritonavir 400mg +100 mg / ml twice daily for 14 days and Interferon beta-1b 0.25 mg subcutaneous every alternate day for 14 days
1516259|NCT02845843|Drug|Placebo|Same characteristics as Lopinavir /Ritonavir and Interferon beta-1b to maintain blinding
1516260|NCT02845817|Other|Qualitative research|Semi-structured interviews
1516261|NCT02845804|Device|Alpine|
1516262|NCT02845791|Behavioral|Interactive Lifestyle programme workshop|Participants will attend eight 90 minute sessions of an interactive lifestyle programme along with their parent(s)/guardian(s).
1516263|NCT02845778|Drug|Melatonin|Each sachet contains 0.5 g
1516266|NCT02845752|Drug|Stiolto Respimat|Oral inhalation spray
1516267|NCT02845752|Drug|Placebo Respimat|Oral inhalation spray
1516269|NCT02845726|Other|Stent examination, urinary analysis, USSQ questionnaire|
1516270|NCT02845713|Drug|Ivermectin, Diethylcarbamazine Albendazole (IDA)|To evaluate the safety and tolerability of triple drug therapy (a single dose of ALB, IVM and DEC)
1516274|NCT02845661|Drug|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 1 was started from 0.9 µg/kg
1516275|NCT02845661|Drug|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 2 was started from 1.0 µg/kg
1516276|NCT02845661|Drug|Dexmedetomidine|a bolus of dexmedetomidine was administered intravenously 15 min after spinal anesthesia,and the initial dose in group 3 was started from 1.1 µg/kg
1516277|NCT02845648|Drug|anticholinergic|Initial anticholinergic therapy to all patients
1516278|NCT02845635|Other|Personal history of multiple sclerosis|Participants will be stratified into one of four cohorts based on their experience (or lack of experience) with the three major forms of multiple sclerosis.
1516279|NCT02845622|Dietary Supplement|Hazelnut|This dietary supplement contains 30 g of hazelnut.
1516280|NCT02845622|Dietary Supplement|Cocoa|This dietary supplement contains 2.5 g of cocoa powder.
1516281|NCT02845622|Dietary Supplement|No hazelnuts / No cocoa|This dietary supplement does not contain hazelnut nor cocoa powder.
1516282|NCT02845622|Dietary Supplement|Cream|This dietary supplement is just a cream obtained by grinding hazelnuts.
1516283|NCT02845622|Dietary Supplement|Snack|This dietary supplement is a commercial snack containing either hazelnut or cocoa or both.
1516284|NCT02845609|Drug|Sialic Acid-Extended Release|Oral drug of Sialic acid
1516294|NCT02845570|Other|68Ga-DOTANOC PET/MRI|
1516295|NCT02845570|Other|18F-FDG PET/MRI|
1516296|NCT02845557|Other|OGTT and IVGTT tests|
1516297|NCT02845544|Other|Pilates-based exercises|
1516298|NCT02845531|Device|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator and Optimal Medical Therapy
1516299|NCT02845531|Drug|Optimal Medical Therapy|
1516300|NCT02845518|Procedure|Cardiac magnetic resonance imaging|"RV contouring and indexed aortic flow measurement from cMRI will be performed locally with the dedicated software used in clinical practice by the physicians of each centre. Cardiac index and RVEF will be derived from these measures. MRI interpretation will be performed blind with respect of clinical and RHC data.
Right atrial pressure, pulmonary artery pressures and cardiac index will be measured with RHC as currently recommended, therefore performing RHC will not be considered as an intervention but as a routine practice"
1516301|NCT02845505|Other|Intravascular Ultrasound, coronary computed tomography angiography|
1516302|NCT02845492|Other|Qigong|Qigong is a mind-body exercise based around gentle exercise and the cultivation of a meditative focus on bodily sensations
1516303|NCT02845492|Other|Complete Health Improvement Program (CHIP)|The CHIP program is a validated weekly wellness and exercise program designed to promote health and wellbeing.
1516304|NCT02845479|Other|Integrative Care|Standardized supplemental/natural health product, physical, nutritional and mental/emotional recommendations based on the phases of standard care (neo-adjuvant, perioperative, adjuvant and long-term maintenance).
1516305|NCT02845466|Biological|Becaplermin|0.25 cm of 100 µg/g Becaplermin gel topically per 1cm² of ulcer area applied 3 times per week for 6 weeks.
1516306|NCT02845466|Device|Promagran Dressing|44% oxidized regenerated cellulose (ORC), 55% collagen and 1% silver-ORC wound dressing applied 3 times per week for 4 weeks.
1516307|NCT02845466|Device|Placebo Dressing|Inactive wound dressing.
1516308|NCT02845453|Drug|Quetiapine|
1516309|NCT02845453|Drug|Placebo|
1516310|NCT02845440|Other|Academic Detailing|Academic detailing (AD) is a targeted continuing medical education (CME) strategy that adapts social marketing techniques, using mixed interactive and didactic formats in individual and group settings integrated into the practice setting to promote beneficial changes in medical care. AD helps clinicians understand and adopt targeted evidence-based practices and is one of the few Continuing Medical Education (CME) interventions that has consistently demonstrated improved alignment of physician prescribing behavior with evidence-based practice.
1516311|NCT02845440|Other|Community Health Worker|Community Health Worker (CHW) The CHW will offer to support patients and prescribers in health promotion and preventive care in general and specifically to support communication between the primary care provider and patient regarding smoking status, smoking cessation, and to aid implementation of any smoking cessation treatments recommended by prescribers. CHWs will complete the standard CHW certificate training program in general preventive medicine, available through the Boston Public Health Commission. CHWs will then receive the additional specialized training.
1516312|NCT02845440|Other|Treatment as Usual (TAU)|Usual care (TAU) for adults with SMI in Massachusetts consists of rehabilitation services publicly funded by the state and traditional fee for service outpatient medical and psychiatric care. Importantly, medical care is not programmatically integrated with the psychiatric rehabilitation services.
1516313|NCT02845427|Device|closed suction drain|using closed suction drain system postoperative
1516314|NCT02845427|Procedure|no suction drain|the surgical wound will be closed with no suction drain
1516315|NCT02845414|Drug|CD133KDEL|
1516316|NCT02845401|Other|Stop NA therapy|Cases will stop antiviral therapy
1516317|NCT02845388|Drug|Sildenafil citrate|
1516318|NCT02845388|Drug|estradiol valerate|
1516319|NCT02845375|Drug|Sugammadex|Sugammadex will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
1516320|NCT02845375|Drug|Neostigmine|Neostigmine will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
1516448|NCT02844426|Drug|bifid triple viable capsule and pectin|
1516321|NCT02845375|Drug|Placebo|Placebo will be administered following a period of muscle relaxation after wich respiratory measurements will be obtained.
1516322|NCT02845362|Other|Sydney Swallow Questionnaire|The Sydney Swallow Questionnaire (SSQ) is a validated self-report symptom questionnaire, it contains 17 items recorded as visual analogue scales and is a tool specifically designed for evaluation of swallowing difficulties.
1516323|NCT02845349|Drug|Vortioxetine|The study drug, vortioxetine received approval from the U.S. Food and Drug Administration (FDA) to treat adults with major depressive disorder. This study is being done to determine its effectiveness in a specialized population, i.e. those who have developed major depression after a traumatic brain injury. As patients who have sustained a TBI are medically fragile and sensitive to side-effects of medications, it is important to test the effectiveness and safety of vortioxetine in this population.
1516324|NCT02845349|Drug|Placebo|A placebo comparator will be used in one subset of patients.
1516325|NCT02845336|Drug|Celecoxib|celecoxib 100mg PO twice per day for 3 months
1516326|NCT02845336|Drug|artificial tears|Standard care for mild thyroid eye disease is lubrication with artificial tears (over the counter), avoidance of cigarette smoke.
1516327|NCT02845323|Drug|Nivolumab in combination with Urelumab|Two cycles of Nivolumab Two cycles of Urelumab
1516328|NCT02845323|Drug|Nivolumab monotherapy|Two cycles of Nivolumab alone
1516329|NCT02845310|Procedure|Restricted fluid therapy group|Patients will receive restricted fluid management (2ml/Kg/h) with concomitant SVV monitoring using ICON cardiometry device. GDT protocol will be used to fulfil the two targets (SVV < 10% - MAP >65 mmHg). A fluid bolus of 200 ml Lactated ringer will be infused if SVV is more than 10% for 5 minutes, the dose will be repeated every 10 minutes if SVV is still above 10%. If the total fluid boluses reached 20 ml/Kg in a patient with MAP > 65 mmHg, no fluid boluses will be infused unless there is evident blood loss or hypotension. If MAP was achieved (>65mmHg) at any time, the first three steps in the protocol will be bypassed. If MAP was not achieved after reaching 20 ml/Kg , norepinephrine (inotropes) will be given as shown in fig. 1 with dose of 0.01ug/kg/min.
1516330|NCT02845310|Procedure|Standard fluid management|Patients will receive standard fluid management of 6 ml/Kg/h plus rescue fluid boluses of 200 ml lactated ringer if Mean arterial pressure (MAP) decreased less than 65 mmHg and central venous pressure less than 8 mmH2o.
1516331|NCT02845297|Drug|pembrolizumab|Intravenous pembrolizumab
1516332|NCT02845297|Drug|Azacitadine|Intravenous or subcutaneous
1516333|NCT02845284|Behavioral|enhanced group support|Routine Care plus enhanced group support, and peer education beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
1516334|NCT02845284|Behavioral|enhanced individual support|Routine Care plus individual peer education and support beginning every 4 weeks post enrollment to delivery and at 6 and 10 weeks, 3, 6 and 9 months post delivery.
1516335|NCT02845271|Drug|placebo|"Pharmaceutical form:solvent for parenteral use
Route of administration: intraarticular"
1516336|NCT02845271|Drug|GZ389988|"Pharmaceutical form:suspension for injection
Route of administration: intraarticular"
1516337|NCT02845271|Drug|acetaminophen or paracetamol|"Pharmaceutical form: tablet
Route of administration: oral"
1516338|NCT02845271|Drug|fixed combination of paracetamol + codeine|"Pharmaceutical form: capsule
Route of administration: oral"
1516339|NCT02845271|Drug|fixed combination of paracetamol + tramadol hydrochloride|"Pharmaceutical form: tablet
Route of administration: oral"
1516340|NCT02845258|Procedure|Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS)|"Pancreatic pseudocyst drainage with a plastic or self-expandable metallic stent (SEMS):
This procedure is to be regarded as a clinical routine procedure since a couple of years back. The type of stent (material? length? thickness?), the cyst appearance (large? infected? cyst wall thickness?) and the type of access (transgastric? transduodenal?) may however vary from patient to patient.
In this study we perform EUS-drainage using different types of equipment on a wide range of pancreatic pseudocysts of different appearance and character. All procedures are performed as recommended. The very aim of the study is to investigate which technique and Equipment is to be preferred in different scenarios."
1516341|NCT02845245|Other|3D printed plastic model prototype|
1516342|NCT02845245|Other|3D CT scan|
1516343|NCT02845245|Other|Plain film radiographs|
1516344|NCT02845232|Other|Transfusion|The number and type of blood products administered were registered from the time of diagnosis to the time of death corresponding for all patients to the time of last follow-up. Transfusion of a single unit of packed red blood cell (PRBC) or one whole blood-derived platelet concentrate (PC) or fresh frozen plasma (FFP) was considered a transfusion event and considered for statistical analysis.
1516345|NCT02845219|Drug|semaglutide|Oral administration once daily alone or together with oral contraceptive.
1516346|NCT02845219|Drug|SNAC|Oral administration once daily together with oral contraceptive.
1516347|NCT02845219|Drug|Microgynon®|Oral administration once daily alone or together with oral semaglutide or SNAC.
1516348|NCT02845206|Procedure|Patient specific cutting blocks|'MyKnee' Instrumentation
1516349|NCT02845206|Procedure|Conventional cutting blocks|Standard Instrumentation
1516350|NCT02845193|Device|Modified Nasoalveolar molding|Infants will receive this appliance which is a maxillary plate with nasal stent in addition to taping on the upper lip (taping is routine step in Grayson's nasoalveolar molding technique).
1516351|NCT02845193|Device|Taping|Infants will receive a tape only on the upper lip segments to mold it to touch each other.
1516352|NCT02845193|Device|CAD/NAM|computer aided design NAM
1516353|NCT02845180|Procedure|Adipose Allograft Extracellular Matrix (AAM) Injection|Injection followed by surgery
1516354|NCT02845167|Other|Preoperative exercise|Patients will perform 3 consecutive days of 60 min submaximal cycling exercise at a moderate exercise intensity. During the 60 min of exercise, patients will be provided with three equally spaced 3min rest periods
1516355|NCT02845154|Other|bolus purge|complete and uninterrupted purge
1516356|NCT02845154|Other|Intermittent purge|intermittent portal purge
1516357|NCT02845141|Procedure|Actifuse|bone tunnel filled with Actifuse
1516358|NCT02845141|Procedure|bone graft|bone graft to fill bone tunnel
1516449|NCT02844426|Drug|maltodextrin|
1516622|NCT02843022|Behavioral|standardized electronic messages|supportive and educational short messages
1516359|NCT02845128|Other|predicting failure of HFNC treatment using ROX index|Using ROX index to predict the need for mechanical ventilation in patients admitted to ICU with ARF receiving treatment with high-flow nasal cannula
1516360|NCT02845115|Device|Conventional implantation|"Usual implantation technique of a middle ear implant. The principle of the ossicular stimulator middle ear transducer MET 7000 (Middle Ear Transducer, METTM) is to directly transmit sounds on the ossicles bypassing the outer ear. Their constraint is the surgical placement of the implant.
MET 7000 system (OTOLOGICS LLC, USA) is the implant that the investigators will use for their patients. The stimulator is usually placed against the body of the anvil by simple contact in the case of sensorineural hearing loss. In the case of mixed hearing loss, the stimulator will come in contact with the bracket using a titanium clip (ossicular prosthesis used in otologic surgery for ossiculoplasties). The optimized version corresponds to the use of the conventionally used in mixed deafness and applied to neurosensory deafness art. It is screwed onto the mastoid bone, the motor is suspended in the mastoid cavity and transmits vibrations to the body of the anvil by simple contact of the transducer."
1516361|NCT02845115|Device|optimized implantation with laser velocimetry|
1516362|NCT02845102|Other|Pre-Post Feasibility|The feasibility testing phase will include 25 subjects. Total duration of pre-post feasibility testing will be 6 weeks upon retrieval of the RA-CBT tablet and follow up questionnaires, quantitative exit interview, and/or an optional extended qualitative exit interview. The extended exit interview is a qualitative semi-formal interview focusing on gathering participant experiences working with the intervention, the barriers and facilitators encountered, as well as overall feedback for the pre-post feasibility study and the relational agent.
1516363|NCT02845076|Other|Protocol for weaning of noninvasive ventilation|3 protocols for weaning of noninvasive ventilation will be compared
1516364|NCT02845063|Behavioral|concentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of concentric type contractions on a softrobotic device.
1516365|NCT02845063|Behavioral|eccentric cardiovascular training|Subjects will carry out 8 weeks of cardiovascular training by an interval type of protocol that includes a high repetition number of eccentric type contractions on a softrobotic device.
1516366|NCT02845063|Genetic|ACE genotyping|Subjects will be genotyped for the ACE-I/D gene polymorphism.
1516367|NCT02845050|Drug|Vinflunine|"One cycle is defined as a period of 3 weeks of treatment:
Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion
Cisplatin (70 mg/m²) on Day 2, every 21 days
4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
1516368|NCT02845050|Drug|Cisplatin|"One cycle is defined as a period of 3 weeks of treatment:
Vinflunine (280 mg/m²) on Day 1, every 21 days as a 20 minute IV infusion
Cisplatin (70 mg/m²) on Day 2, every 21 days
4 cycles of neo-adjuvant chemotherapy prior to radical cystectomy"
1516369|NCT02845050|Procedure|Radical cystectomy|max. 4 weeks after 4 cycles of neo-adjuvant treatment radical cystectomy will be performed
1516370|NCT02845037|Drug|BIA 5-453|BIA 5-453 Gelatine capsule for oral administration (1, 10 or 20 mg). Single oral doses of BIA 4-543 2 mg, 10 mg, 20 mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg and 1200 mg were administered to subjects in fasting conditions.
1516371|NCT02845037|Drug|Placebo|Placebo Gelatine capsule for oral administration. The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient (API).
1516372|NCT02845024|Drug|Doxycycline Group|Oral doxycycline 100mg was taken within 15 days
1516373|NCT02845024|Drug|placebo Group|Oral placebo was taken within 15 days
1516374|NCT02845011|Device|Cardio First Angle|"Patients in the intervention group will be received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel TM (InotechGruppe, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates to a sternum compression depth of 50-60 mm, is followed by an audible click sound to alert the rescuer to cease compression. The click sound is also audible upon spring decompression alerting the rescuer to resume compression. When used properly rescuers may deliver approximately 100-120 compressions per minute. The device functions purely mechanically and does not require electrical power supply."
1516375|NCT02844998|Behavioral|physical activity|patients will do moderate running which make them breathe somewhat harder than normal for at least 30 minutes for 5 days in a week
1516376|NCT02844998|Drug|dapoxetine 30 mg on demand|Dapoxetine, a short-acting selective serotonin reuptake inhibitors, has been utilized for the treatment of premature ejaculation in various countries
1516377|NCT02844985|Other|No Intervention|
1516378|NCT02844946|Behavioral|Acceptance and Commitment Therapy|Contextually focused form of cognitive behavioral psychotherapy that uses MINDFULNESS and behavioral activation to increase patients' psychological flexibility in areas such as ability to engage in values-based, positive behaviors while experiencing difficult thoughts, emotions, or sensations.
1516379|NCT02844933|Drug|Cannabidiol|Oral solution
1516380|NCT02844933|Drug|Placebo|Matching oral solution
1516381|NCT02844920|Device|Intrauterine ultrasound guided radio-frequency ablation|Radiofrequency ablation for the treatment of uterine fibroids
1516382|NCT02844907|Drug|Exendin (9-39)|Upon establishing a hyperglycemic clamp (target blood glucose at basal +3 mM) Exendin (9-39) will be infused.
1516383|NCT02844907|Drug|Dexamethasone|Between Visit-2 and Visit-3, Dexamethasone (4 mg tablet) once daily for 5-7 days.
1516384|NCT02844907|Other|Hyperglycemic Clamp|A variable infusion of 20% dextrose will begin to clamp the blood glucose at basal +3 mM.
1516385|NCT02844894|Drug|Dexmedetomidine|
1516386|NCT02844894|Drug|Esmolol|
1516387|NCT02844894|Drug|Placebo|normal saline
1516388|NCT02844881|Drug|Apatinib|Apatinib 850 mg p.o. qd every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
1516389|NCT02844881|Biological|MASCT|Dendritic cells(DC) loaded with 17 antigens ih day 8, cytotoxic T lymphocytes ( CTL) induced by DC IV day 21-28, every 28 days until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends
1516390|NCT02844868|Device|Active tDCS|During the first 20 min of training program, patient will have active tCDS : the patient received a 2 mA anodal tDCS over the lower limb ipsilesional motor area. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
1516391|NCT02844868|Device|Sham tDCS|During the first 20 min of training program, patient will have sham tCDS : the patient received a 2 mA anodal tDCS (only during the first and the last 30 seconds of the stimulation) and then, patient will have sham tDCS. The anodal electrode was positioned on the hotspot previously identified with TMS. The cathode was placed above the contralesional orbit.
1516392|NCT02844855|Behavioral|Cognitive tests|MMSE, (Folstein et al., 1975), HAD (Hospital Anxiety and Depression Scale; Zigmond & Snaith, 1983), a cognitive assessment (the 5 words test, Dubois et al., 2002; Trail Making test, Godefroy et al., 2008; BREF, Dubois et Pillon, 2000; Assessment of apraxia, Mahieux-Laurent, 2009) + the experimental task (verbal learning and action learning).
1516394|NCT02844829|Other|Prostate MRI|MRI of the prostate prior to prostate biobsy
1516397|NCT02844803|Drug|Combination of Metformin + S. Baicalensis|the combination therapy for 8 weeks
1516398|NCT02844803|Drug|Combination of Metformin + Placebo|the metformin single therapy for 8 weeks
1516399|NCT02844790|Drug|insulin degludec/insulin aspart|A single dose of IDegAsp will be administered subcutaneously (s.c., under the skin).
1516400|NCT02844777|Drug|Placebo|200 mg applied once-daily for 28 days
1516401|NCT02844777|Drug|5% VDA-1102|200 mg applied once-daily for 28 days
1516402|NCT02844777|Drug|10% VDA-1102|200 mg applied once-daily for 28 days
1516403|NCT02844764|Biological|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit (AUCRU) and Platelet Rich Plasma (PRP) processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated with direct injections to the joint with Platelet Rich Plasma processed by RegenLab (RegenKit BCT-3) PRP product. Day 0 [StroMed + platelet rich plasma (PRP)], Day 7, 14 and 30 [PRP]
1516404|NCT02844751|Biological|[StroMed + platelet rich plasma (PRP)]|[Day 0] - Because no enzymes or drugs are added with this mechanical process, the resulting cell concentrate still contains the extra-cellular matrix. In addition, the cells have not been altered by manipulation with enzymes or culturing. This autologous, cell concentrate is of minimal risk to the patient with no artificial ingredients added. Also Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint.
1516405|NCT02844751|Biological|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 7,14 and 30
1516406|NCT02844751|Biological|[PRP] platelet rich plasma|Additional treatments with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product and by direct injection to the affected joint. Days 30 and 60
1516407|NCT02844738|Biological|[StroMed + platelet rich plasma (PRP)]|Patients will be treated with autologous StroMed obtained by the Adipose Ultrasonic Cell Recovery Unit and Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product each as direct injections to the affected joints at the time of initial treatment. Thereafter the affected joints will be treated as direct injections to the joint with Platelet Rich Plasma processed by the RegenLab (RegenKit BCT-3) PRP product. Day 0 [StroMed + platelet rich plasma (PRP)], Days 7 and 14 [PRP]
1516410|NCT02844712|Other|Evaluation of reexposure to a negatively tested betalactam|
1516411|NCT02844699|Drug|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
1516412|NCT02844699|Drug|Placebo|5% infusion solution of dextrose (glucose)
1516413|NCT02844686|Other|Cardiac SPECT|3-D dynamic acquisition of cardiac SPECT at rest and after pharmacological stress
1516414|NCT02844673|Drug|Hydroxyurea|Patients will receive fixed dose Hydroxyurea therapy (15 mg/Kg/day) with standard monitoring
1516415|NCT02844673|Device|Mobile Directly Observed Therapy|Mobile DOT will consist of a web based medication adherence monitoring system that includes direct video confirmation of adherence using the patient's personal cellular telephone. Patients will receive alerts on their cell phone at pre-arranged times to remind them to take their medications.
1516418|NCT02844647|Other|Hyperpolarized Pyruvate (13C)|MRI contrast agent
1516419|NCT02844634|Drug|Doxycycline 100mg PO daily x 12 months|Immediate use of daily doxycycline (12 months duration, to start immediately)
1516420|NCT02844634|Drug|Tenofovir/emtricitabine 200/300mg PO daily|Daily use of tenofovir/emtricitabine
1516421|NCT02844634|Drug|Doxycycline 100mg PO daily x 6 months|Deferred use of doxycycline (6 months duration, to start 6 months post-randomization)
1516422|NCT02844621|Drug|Omeprazole|20mg orally once daily
1516486|NCT02844101|Device|GT3X Actigraph accelerometer.|
1516487|NCT02844088|Other|Meningococcus C conjugate vaccine|
1516784|NCT02841800|Device|'Intra-luminal radiofrequency ablation (Habib EndoHPB)|endobiliary radiofrequency ablation device
1516428|NCT02844569|Device|Xenograft bone substitute|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket will be treated with xenograft bone substitute. At 6 months post-extraction a dental implant will be placed at the extraction site.
1516429|NCT02844569|Device|Collagen dressing|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a collagen dressing to cover the surgical site.
1516430|NCT02844569|Device|3D-collagen matrix|Subjects requiring tooth extraction will have the hopeless tooth extracted. The extraction socket treated with xenograft bone substitute will receive a 3D collagen matrix to cover the surgical site.
1516431|NCT02844556|Procedure|SMILE surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
1516432|NCT02844556|Other|FS-LASIK surgery|SMILE surgery and FS-LASIK surgery are both effective method for the correction of myopia and myopic astigmatism. They have been proved to offer many advantages in terms of visual acuity, corneal sensitivity and corneal biomechanics compared with traditional refractive surgeries.
1516433|NCT02844543|Device|EYE-SYNC eye-tracking device|The EYE-SYNC® portable eye-tracking system. The eye tracker is a handheld isolated display environment with embedded eye tracking sensors. The eye tracker is connected to a high-performance Windows tablet though a customized docking station. Included accessories with EYE-SYNC are a U.S. tablet power supply adapter and disposable sanitary masks. Participants are asked to follow a dot with their eyes, as the dot moves on the screen of the EYE-SYNC device.
1516434|NCT02844543|Other|SCAT-3 Symptom subtest|The Symptom subtest of SCAT-3 test will be administered to participant.
1516435|NCT02844543|Device|Desktop Eye-Tracker (Eyelink CR, SR Research)|Eye movements are recorded with an eye tracking system with up to 1000 Hz temporal resolution. The target stimulus is presented on a computer screen approximately 50 cm from the participant. Participants are asked to follow a dot with their eyes, as the dot moves on the monitor screen of the desk-top eye-tracking device.
1516436|NCT02844530|Drug|90Y-epratuzumab tetraxetan|"The Primary objective is to compare the complete response rate (CR + CRp) after 2 injections of 370 MBq/m² of 90Y-epratuzumab tetraxetan RIT at day 1 and day 8 versus standard of care salvage chemotherapy regimens in adult CD22+ relapsed/refractory B-ALL.
A second RIT cycle (consolidation) will be allowed in the experimental group in case of response (CR or CRp).
From an ethical point of view, it will be also permitted to propose the RIT experimental treatment in the control group in case of treatment failure or relapse during the 6 months following inclusion. Follow-up will be also 12 months from the RIT for these patients"
1516437|NCT02844530|Drug|chemotherapy/ immunotherapy|
1516438|NCT02844517|Device|Artificial Pancreas|Subjects will be provided the Artificial Pancreas (AP) system which includes the inControl Diabetes Management Platform, a study insulin pump and continuous glucose monitor. This AP system is designed to help control blood sugar in people living with type 1 diabetes.
1516439|NCT02844504|Behavioral|Low Intensity Exercise Training 1|Subjects will perform handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
1516440|NCT02844504|Behavioral|Low Intensity Exercise Training 2|Subjects will perform a different handgrip exercise training at low intensity (20% maximal force) 5 times a week for 6 weeks (more details not provided to keep study blinded)
1516441|NCT02844491|Other|additional biological samples|blood and tissue samples
1516442|NCT02844478|Behavioral|SBP English|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks.
1516443|NCT02844478|Behavioral|SBP SPANISH|The SBP caregiver intervention has been successfully delivered and disseminated in the US. It is currently offered in 9 states and 16 Texas counties . The SBP is designed to a) improve the QoL of family caregivers who provide care for people with ADRD and b) help caregivers manage their stress and cope better with their lives. The SBP is implemented using a Master Trainer/Group Facilitator (lay leader) model. The SBP is a multi-component intervention that meets for 90 minutes once a week for 9 consecutive weeks. The Spanish translation and cultural adaptation of the SBP has been completed under the direction of the PI.
1516445|NCT02844452|Device|Acupuncture|Acupuncture is a form of alternative medicine and a key component of traditional Korean medicine (TKM) involving thin needles inserted into the body at acupuncture points. It can be associated with the application of heat, pressure, or laser light to these same points. Acupuncture is commonly used for pain relief, though it is also used for a wide range of other conditions. Clinical practice varies depending on the country.
1516446|NCT02844452|Device|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders. In an ideal controlled study, subjects would not know whether they were getting true or sham acupuncture. We are going to use Park Sham Acupuncture, which is composed of sham acupuncture needle not penetrating the skin of subjects and Park sham acupuncture device attacted on the subject's skin in order to block the seeing whether the acupuncture needle penetrates skin or not.
1516447|NCT02844439|Drug|Tesevatinib|
1516450|NCT02844413|Other|aerobic interval training|In the first group (G1), aerobic interval training (AIT) was undertaken for 5 months (40 professional AIT sessions performed two times per week in 50 minute sessions) and followed a specially developed program. The second control group (G2), did not attend any training sessions but received medical advice on how to maintain physical activity as outlined by JNC hypertension guidelines
1516451|NCT02844400|Device|Biometric Devices|Patients will wear two devices: HealthPatch Sensor and Phillips Actiwatch. Health data (e.g. average steps per day, resting heart rate) will be collected and monitored over the course of a cycle of cytotoxic chemotherapy.
1516452|NCT02844400|Other|Physical Performance Testing|Patients will complete a CPET and 6 minute walk test within one week of starting an upcoming chemotherapy cycle and they will undergo a second CPET upon completion of said chemotherapy cycle.
1516453|NCT02844387|Dietary Supplement|L-arginine hydrochloride solution|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive either oral arginine supplementation one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
1516454|NCT02844387|Other|Placebo|Patients with unresectable brain metastases from solid tumors that are candidates from twice-daily fractionated radiation therapy will be randomized to receive oral placebo one-hour prior to each fraction of radiation. Radiation therapy consist in whole-brain treated by two lateral fields to a total dose of 32 Gy in 20 fractions of 1.6 Gy each two times a day with a 6 hours interval between treatments (10 days), followed by a 22.4 Gy boost over the evident lesions with the same fractionation schedule (7 days). The spinal cord dose will be limited to 40 Gy
1516455|NCT02844374|Other|Functional stereotaxic exploration|Visual analysis : in order to define the level of cortical resections. Epileptogenic maps : calculated for each crisis and for all crisis in general. Connectivity maps : calculated for each site stimulated at low-frequency. Post-operative evaluation : in order to assess the extent of resection.
1516456|NCT02844361|Other|autologous stem cell transplantation|Patients in this group will receive BEAC(BCNU+VP-16+CTX+Ara-c) as conditioning regimen and then with autologous stem cells feedback
1516457|NCT02844361|Other|conventional chemotherapy|Patients in this group will receive previously effective chemotherapeutic regimen as consolidation therapy
1516458|NCT02844348|Other|Hypnosis session|
1516459|NCT02844335|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
1516460|NCT02844335|Biological|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
1516461|NCT02844322|Drug|Bortezomib|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
1516462|NCT02844322|Drug|Rituximab|compare the efficiency of bortezomib and rituximab in Waldenström macroglobulinemia
1516463|NCT02844309|Drug|Thalidomide|thalidomide 50-150 mg per night
1516464|NCT02844296|Behavioral|Video about exercise|Video about short-bout exercise will be played for the participants.
1516465|NCT02844296|Behavioral|App about exercise|A smartphone App about exercise will be installed in participants' mobile phone.
1516466|NCT02844296|Behavioral|Leaflet about exercise|A leaflet about exercise will be provided for the participants.
1516467|NCT02844296|Behavioral|Video about diet|Video about healthy diet will be played for the participants.
1516468|NCT02844296|Behavioral|App about diet|A smartphone App about healthy diet will be installed in participants' mobile phone.
1516469|NCT02844296|Behavioral|Leaflet about diet|A leaflet about healthy diet will be provided for the participants.
1516470|NCT02844283|Drug|Ad-HGF|
1516471|NCT02844283|Other|0.9% NaCl|
1516472|NCT02844270|Device|Rapamycin Drug-Eluting Bioresorbable Coronary Stent System|Implantation of the Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
1516473|NCT02844244|Behavioral|training group|The training workshop included two two-hour sessions. It focused on the enhancement of knowledge, attitude, and practice of peer health promoters on implementing community activities for the residents.
1516474|NCT02844231|Other|Single-photon emission computed tomography|
1516475|NCT02844218|Other|Age of patient|"Historical Comparison Between Patients Aged 60 to 69 and Patients Aged ≥ 70 Years Treated With Intensive Chemotherapy.
Comparison between Intensive Chemotherapy and Low-Intensity Treatments in Patients Aged ≥70 Years.
Improvement of Treatments Over Time
Overall Survival (OS) of patients aged ≥ 70 Years during3 study periods. Period 1, from 1985 to 1999, during which all patients with acute Myeloid Leukemia received an intensive chemotherapy regimen at the University Hospital. Period 2, from 2000 to 2006, during which all patients received an Intensive Chemotherapy regimen, Improved Supportive Care and follow-Up protocol at the University Hospital. Period 3, From 2007 to 2014, during Which patients received Improved Supportive Care and follow-up protocol at the University Hospital and Personalized Therapy (Intensive Chemotherapy or Low-Dose Intensity Treatment)"
1516476|NCT02844205|Other|quotation of the newborn behavioral observation scale|quotation of the newborn behavioral observation scale by 12 experimented nurses. Patient will be filmed during an usual care and nurses will quote the scale thanks to the video.
1516477|NCT02844179|Drug|HTBZ|
1516478|NCT02844166|Other|viscoelastic surface support|Patients will be placed in an ICU bed with viscoelastic surface support
1516479|NCT02844166|Other|pyramidal foam surface support|Patients will be placed in an ICU bed with pyramidal foam surface support
1516480|NCT02844153|Other|modalities of metformin prescription|Metformin prescription or not, in each CKD stage
1516481|NCT02844140|Procedure|DE-CT's and SE-CT|Patients included in the trial will receive 3 extra DE-CT's and 3 extra SE-CT's
1516482|NCT02844127|Procedure|Implantable Cardioverter Defibrillator (ICD)|Patients will receive an Implantable Cardioverter Defibrillator (ICD), with the leads implanted in either the apex or the septum as the first location. After defibrillation threshold is determined, the leads position will be changed to the second location and DFT will be determined again.
1516483|NCT02844114|Drug|Ganoderma lucidum spore|G 300mg, 5 tablets by mouth
1516484|NCT02844114|Drug|Placebo|Sugar pill manufactured to mimic tramadol 1500mg tablet
1516485|NCT02844114|Drug|Chemotherapy|iv.30 minutes
1516488|NCT02844075|Drug|MK-3475(pembrolizumab)|"Neo-adjuvant chemoradiation period:The treatment consisted of taxol, carboplatin, pembrolizumab and radiation. The radiation treatment comprises 44.1Gy (2.1Gy/Fr, total 21Fr) and that will be about 5 weeks. Intensity modulated RT (IMRT) or 3D CRT (three-dimensional conformal radiotherapy) will be allowed.
Surgery:Before surgery, abdomen/chest CT scan, endoscopic ultrasound (EUS), and gastroscopy with biopsy will be done. Surgery should be done within 12 weeks after last neo-adjuvant treatment.
Adjuvant period:Adjuvant treatment with pembrolizumab 200mg every 2week (maximum 2 years) should be performed within 8 weeks after surgery (recommended period : 3-6 weeks after surgery). Gastroscopy and abdomen/chest CT scan will be performed at 6 month after surgery."
1516489|NCT02844062|Biological|anti-EGFRvIII CAR T cells|CAR T cells are infused intravenously to patients in a three-day split-dose regimen（day0,10%; day1, 30%; day2, 60%）with a total targeted dose.
1516490|NCT02844062|Drug|cyclophosphamide|250 mg/m^2 d1-3
1516491|NCT02844062|Drug|Fludarabine|25mg/m^2 d1-3
1516492|NCT02844049|Device|Deep Brain Stimulation|surgical procedure
1516501|NCT02844023|Behavioral|Clinical evaluation|With questionnaire.
1516502|NCT02844023|Other|Paraclinical evaluation|Symptom inflammatory, biomarkers.
1516503|NCT02844023|Device|Imaging|Thoraco-abdominal scanner injected or PET scanner if contraindication for scanner.
1516504|NCT02844023|Other|Ophthalmologic examination|
1516505|NCT02844023|Biological|Dosage of biomarkers|Control patients.
1516506|NCT02844010|Other|weighing|
1516507|NCT02843997|Genetic|Endophenotype and sequencing|Draw an endophenotype and genetic study
1516508|NCT02843984|Drug|Lactoferrin|
1516509|NCT02843971|Device|Intraocular pressure measurement with the Sensimed triggerfish Device|
1516510|NCT02843958|Device|HEMOPTIC|
1516511|NCT02843945|Device|LDR Planar Directional Brachytherapy Source|The FDA Cleared CivaSheet Directional Pd103 Brachytherapy Source is a planar radiaiton source which utilizes gold shielding in its construction. This device is radioactive on one side only, and is capable of safely delivering high doses of radiation to target areas even when placed directly adjacent to sensitive, healthy tissue or critical structures.
1516512|NCT02843932|Other|functional brain MRI|functional imagery during motor-perception tasks
1516513|NCT02843919|Other|Electroencephalography and Electrocardiography|
1516514|NCT02843906|Procedure|Lombar Punction|cerebrospinal fluid testing at screening and M36
1516515|NCT02843906|Radiation|Magnetic Resonance Imaging (MRI)|MRI done at screening and M36
1516516|NCT02843906|Radiation|Positron-Emission Tomography (TEP) /(FDG)|TEP/FDG done at screening and M36
1516517|NCT02843906|Other|Psychiatric tests|
1516518|NCT02843906|Other|Neuropsychological Tests|done at screening, M12, M24 and M36
1516519|NCT02843906|Genetic|Apolipoprotein (ApoE) detection|ApoE detection done at screening
1516520|NCT02843893|Device|Measure the minimum intensity of a painful stimulation|With Neurolight device.
1516521|NCT02843867|Other|blood sample|36 ml of blood sample at D0 and 1 year after transplantation
1516522|NCT02843841|Other|Blood and fecal sample.|Blood (28 ml) and fecal sample at day 0, 4 days, 3 months and one year after transplantation
1516525|NCT02843815|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
1516526|NCT02843815|Biological|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
1516527|NCT02843802|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
1516528|NCT02843802|Biological|NK Immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
1516529|NCT02843789|Drug|Tocilizumab|
1516530|NCT02843776|Other|Questionnaires completion|
1516531|NCT02843763|Other|Blood sample|Blood sample (28 ml)
1516532|NCT02843750|Behavioral|Inspiratory Muscle Training-Rehabilitation|"The training will include the following components:
Breathing Awareness
Upper and Lower Extremity Exercise.
Instructions for Inspiratory Muscle Training (IMT) performed using the PFlex valve
Practice at home"
1516533|NCT02843750|Other|Questionnaires|Patient quality of life will be measured using patient-reported outcomes measurement information system (PROMIS) global items. Patients will also complete the Chronic Respiratory Questionnaire (CRQ) and the Medical Research Council Dyspnea Scale (MCR).
1516534|NCT02843737|Other|Polysomnography under spontaneous breathing|Patient will come to the sleep laboratory to perform the polysomnography under spontaneous breathing prescribed by the clinician
1516535|NCT02843724|Other|Naturopathic Care|Naturopathic diabetes care will be selected from a pre-approved menu. Participants' other health concerns will be addressed at naturopathic doctors' discretion
1516536|NCT02843724|Other|Usual (Conventional) Care|2016 Canadian Diabetes Clinical Practice Guidelines (self-management, blood-glucose-lowering, vascular protection, pharmacotherapy) will be implemented
1516537|NCT02843711|Genetic|Sequencing|Tumour samples are coming from routine histopathological procedure. They are used with consent of the patients. Genomic DNA extraction is performed from paraffin-embedded formalin-fixed (FFPE) tumour samples of lung adenocarcinoma. The genomic DNA mutations are identified by mass spectrometry array (Sequenom) using the LungCarta Panel. This panel could identify 214 mutations among 26 oncogenes.
1516621|NCT02843035|Drug|GZ402671|
1516538|NCT02843698|Drug|Dexmedetomidine|Dexmedetomidine infusion was previously reported to improve oxygenation and lung dynamics in patients with obstructive lung diseases. In our study we are going to investigate its effect on oxygenation and lung dynamics in restrictive lung disease
1516539|NCT02843698|Drug|Normal saline|Normal saline
1516540|NCT02843685|Drug|Drotrecogin alfa activated|
1516541|NCT02843672|Procedure|Triple Weil´s Osteotomy|"A 10mm longitudinal incision is made with a No.15 blade in the second intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. An intra-articular osteotomy in the metatarsal head is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. A second osteotomy is performed perpendicular to the metatarsal shaft,.The osteotomy is fastened with a 2.0mm snap-off screw.
Once all the osteotomies are completed, the incisions are closed with a 2/0 monofilament suture."
1516542|NCT02843672|Procedure|Distal metatarsal minimally invasive osteotomy|A 5mm longitudinal incision is made with a MIS blade No.64 in the intermetatarsal space immediately behind the dorsal interdigital fold, parallel to the extensor tendon. Under fluoroscopy vision, an extra-articular osteotomy in the metatarsal neck is performed angled 45º relative to the long axis of the metatarsal and in a dorsal-distal to proximal-plantar direction. The osteotomies scheduled preoperatively are performed, repeating the same procedure for each ray needing an osteotomy. Once all are completed, the incisions are closed with a 4/0 monofilament suture.
1516543|NCT02843659|Drug|BMS-931699|Specified dose on specified days
1516544|NCT02843659|Drug|BMS-986142|Specified dose on specified days
1516545|NCT02843659|Drug|Placebo|Specified dose on specified days
1516546|NCT02843646|Device|Walk Aide training|
1516547|NCT02843633|Device|BioFreedom™ Drug Coated Coronary Stent System|a non-surgical procedure that uses a catheter to place a stent to open up coronary arteries that have been narrowed by atherosclerosis
1516548|NCT02843633|Drug|Dual Antiplatelet Therapy|a combination of aspirin and a P2Y12 platelet receptor inhibitor
1516549|NCT02843620|Dietary Supplement|b-2Cool|b-2Cool® is native type II collagen extracted from chicken sternums
1516550|NCT02843620|Other|Placebo|Excipients only
1516551|NCT02843607|Device|Cryosurgery|Argon-helium cryosurgical system (percutaneous ablation under CT or ultrasound guidance)
1516552|NCT02843607|Biological|NK immunotherapy|Natural killer cell (each treatment: about 10 billion cells transfusion in 3 times, i.v.)
1516553|NCT02843594|Procedure|LEEP intervention|Low Energy Endosafe Phaco (LEEP) with micro-interventional lens fragmentation
1516554|NCT02843594|Procedure|Standard Phaco Control|
1516555|NCT02843581|Device|Cryosurgery|Argon-helium cryosurgical system
1516556|NCT02843581|Biological|NK immunotherapy|Nutral killer cell immunotherapy for more than 6 times
1516561|NCT02843542|Device|PET-MR|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo 18FCH PET/MRI for detecting adenomas and their location.
1516562|NCT02843542|Device|PET-CT|Patients with Hyperthyroidism and surgery indication will be recruited and directed to imagine exams. In addition to the conservative 99mTc-MIBI and US, patients will also undergo PET-CT for detecting adenomas and their location.
1516563|NCT02843529|Other|Altoida: neuropsychological, EEG and CSF biomarkers|"Data collection at baseline: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both aMCI and Nold subjects. Only in aMCI subjects, APOE genotyping. The local clinical Unit should document the positivity at the baseline session of at least one of the biomarkers of AD mentioned above.
Data collection at 6 and 12 months of follow up: clinical (neurological, activity of the daily life, instrumental activity of the daily life, depression scale), standard neuropsychological exam, ALTOIDA and neurophysiology (EEG/ERPs) in both aMCI and Nold subjects."
1516564|NCT02843516|Other|No intervention|No intervention
1516565|NCT02843503|Device|Arterialized-venous reference (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. The samples will be arterialized using a heated-hand-box (arterialized-venous reference (YSI). Blood will be drawn for the determination of glucose concentrations using arterialized-venous sampling techniques per YSI.
1516566|NCT02843503|Device|Venous reference measurement (YSI)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive an iv-catheter to sample venous blood. Blood will be drawn for the determination of glucose concentrations using venous sampling techniques measured per YSI.
1516567|NCT02843503|Device|Capillary reference (SMBG)|All patients will be fitted with the a CGM system, Dexcom G5 Mobile, patients receive vingerstick measurements to sample capillary blood measured per Self Monitoring of Blood Glucose (SMBG) device.
1516568|NCT02843490|Drug|Ranibizumab|Three injections (o.5 mg Ranibizumab) within the first three months is followed by an individual therapy interval based on the clinical progress (PRN)
1516569|NCT02843477|Device|ultrasonographic measurement of corrected flow time in carotid artery|Corrected carotid artery flow time is measured using 10-5 MHz linear probe on a portable ultrasound machine. On the two-dimensional image, the optimal image of the long-axis view is obtained at the left common carotid artery. The sample volume is placed on the center of the lumen, 2 cm proximal to the bulb, and a pulsed wave Doppler examination was performed while the Doppler beams were adjusted to ensure < 60° of angle for the best signal. Then, cardiac cycle time and carotid flow time is measured. Carotid flow time is measured between the upstroke of the flow tracing and the dicrotic notch, and it is corrected for pulse rate by dividing flow time by the square root of the cardiac cycle time to calculate corrected carotid artery flow time (flow time/√cycle time).
1516900|NCT02840786|Device|Stent|
1516570|NCT02843464|Other|reported remote ischemic preconditioning (RIPC)|Three five-minute cycles of upper limb ischaemia and three five-minute pauses using a blood pressure cuff inflated to 200 mmHg.
1516573|NCT02843438|Other|Fluorescein angiography|
1516574|NCT02843438|Other|Dilated fundus examination|
1516575|NCT02843438|Biological|Toxoplasmosis serology|
1516576|NCT02843438|Drug|Anti-toxoplasmosis treatment|
1516577|NCT02843438|Drug|Anti-inflammatory treatments|
1516578|NCT02843438|Other|Puncture in anterior chamber|
1516579|NCT02843425|Other|Regular Diet|Participants follow their normal diet (not including beans for 8 weeks)
1516580|NCT02843425|Other|Navy Beans (Canned)|Participants add 1/2 cup of canned beans per day to their diets for the first 2 weeks. This is increased to 1 cup per day for the following 6 weeks of the study.
1516581|NCT02843412|Procedure|choose two tumor tissue paraffin blocks|
1516582|NCT02843386|Drug|Adjuvant chemotherapy by Fotemustin|"Fotemustin is given for 6 cycles :
One Induction cycle: Fotemustin 100 mg/m², 1 hour IV infusion, D1D8D15, 5 week rest period, restart on D50.
Five Maintenance cycles: Fotemustin 100 mg/m², 1 hour IV infusion, D1-D21."
1516583|NCT02843386|Other|Intensive surveillance|"Intensive surveillance
Total duration: 3 years.
liver functional tests/3 months, - liver MRI or CT-scan/6 months, - whole body CT-scan/12 months."
1516584|NCT02843373|Device|TMS|
1516585|NCT02843347|Procedure|Blood draw|Three tubes of blood (28.5 mL in total) will be obtained at the Baseline Visit. The sample will be stored for future research.
1516586|NCT02843334|Biological|Dried blood spot (DBS) sampling|DBS be collected during a hemodialysis session and deposited on an anonymized blotting paper. Laboratory ARCHIMED Life Science GmbH, based in Austria will perform all the biological analysis. For the diagnosis, men will have a measure of the alpha-galactosidase activity level, whereas screening in women will be established on the association of alpha-galactosidase activity and lyso-GB3 analyses. If results are compatible, genetic mutation will be searches in order to confirm the diagnosis for women.
1516587|NCT02843321|Biological|T-cell infusion, influenza vaccination|Donor derived infection-specific T-cells (with activity against CMV,adenovirus, EBV, VZV, Influenza, BKV and Aspergillus) and vaccination (with Fluvax)
1516588|NCT02843308|Behavioral|Facilitated group therapy with behavioral practice; 18 weeks|Facilitated group therapy for hoarding disorder with behavioral practice
1516589|NCT02843295|Other|blood samples|
1516590|NCT02843282|Behavioral|Advanced Reasoning Training|This is a strategy-based intervention to enhance frontal lobe function. Strategies equip participants to improve their strategic attention, integrated reasoning, and innovation abilities.
1516591|NCT02843269|Behavioral|Multi-component lifestyle intervention|The exact same intervention was given to the three Stepped-wedge groups - but each of the three groups were started up three months apart. The waiting groups served as control groups. Thus, the intervention were for all three groups a multi-component intervention consisting of Intelligent Physical Exercise training (IPET), Dietary Advice and Weight loss (DAW) and Cognitive Behavioral Therapy (CBT)
1516592|NCT02843256|Device|Isomark Canary|The Isomark Canary will analyze the exhaled air and generate a breath delta value.
1516593|NCT02843230|Radiation|Avastin|
1516594|NCT02843230|Radiation|Lomustine|
1516595|NCT02843230|Radiation|Temozolomide|
1516596|NCT02843230|Device|MRI|
1516597|NCT02843230|Device|MRS|
1516598|NCT02843230|Device|DSC|
1516599|NCT02843217|Behavioral|Lifestyle, screening|
1516600|NCT02843204|Drug|Nivolumab|Nivolumab solution for Injection 3 mg/kg Intravenous every 2 weeks until disease progression, discontinuation due to unacceptable toxicity, withdrawal of consent or study closure
1516601|NCT02843204|Biological|NK immunotherapy|Each treatment: about 10 billion cells in all, infusion in 3 times, i.v.
1516602|NCT02843191|Drug|Chemotherapy|5-FU, Leucovorine, and Oxaliplatin (FOLFOX regimen)
1516603|NCT02843178|Behavioral|Vouchers|A voucher is given that can be used at the cashier of participating grocery stores, corner stores, and farmer's markets, enabling a participant to have the voucher's value subtracted from their grocery bill.
1516604|NCT02843165|Drug|CBI|Approved CBIs (including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
1516605|NCT02843165|Radiation|CBI plus SBRT|SBRT at 28.5 Gy (9.5 Gy x3 fractions) will be delivered within 1 - 21 days of the start of Cycle 1 of the CBI plus CBI (approved CBIs including anti-CTLA-4 and anti-PD-1/PD-L1 antibodies)
1516606|NCT02843126|Drug|Trastuzumab|Pre-dose (0 hours) on Day 1 of Cycles 1 to 8 (cycle length of 21 days)
1516607|NCT02843126|Biological|NK immunotherapy|For each procedure, 10 billion cells will be infused for 4 times
1516608|NCT02843113|Behavioral|4 Your Child Program|Integrates the provision of responsible parenting, economic stability, and relationship education services to fathers at risk for paternal disengagement.
1516609|NCT02843100|Other|Modified Exclusive Enteral Nutrition|Two weeks of Exclusive Enteral Nutrition with Modulen
1516610|NCT02843100|Other|Crohn's Disease Exclusion Diet|a limited whole food diet
1516611|NCT02843100|Other|Partial Enteral Nutrition|25-50% of Energy from formula
1516612|NCT02843100|Other|Standard Exclusive Enteral Nutrition|8 weeks of Exclusive Enteral Nutrition
1516613|NCT02843074|Drug|elotuzumab|Given intravenously (IV)
1516614|NCT02843074|Drug|Lenalidomide|Given by IV
1516615|NCT02843074|Drug|Dexamethasone|Given orally (PO) or by IV
1516616|NCT02843074|Procedure|autologous stem cell transplantation|
1516617|NCT02843061|Drug|Rituximab|
1516618|NCT02843061|Biological|NK immunotherapy|Each time 10 billion cells, 4 times in all,i.v.
1516623|NCT02843022|Behavioral|nurse phone call if requested|"If participant responds yes to an offer for a phone call, a nurse calls them within a week of this response"
1516624|NCT02843022|Behavioral|Staff nurse phone follow-up|Usual care: hospital nurse or lactation consultant calls patient within 2-3 weeks prior to discharge. Message left if patient is not reached.
1516625|NCT02843009|Behavioral|Resistance Exercise Training|Resistance exercise will involve 2 sessions per week for 18 weeks. Each session will involve participants carrying out the following exercises: calf press, leg press, leg extension and leg curl
1516626|NCT02843009|Dietary Supplement|Supplementation|Participants randomised to either 3g/day of fish oil or safflower oil for 18 weeks
1516627|NCT02842983|Drug|Esmolol|conventional management plus esmolol infusion
1516629|NCT02842944|Device|open loop weaning group (Beacon)|
1516630|NCT02842944|Other|Routine care|
1516631|NCT02842931|Drug|R-DA-EPOCH-21|R-DA-EPOCH-21 treatment without auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
1516632|NCT02842931|Drug|R-DA-EPOCH-21 + auto-SCT|R-DA-EPOCH-21 treatment with auto-SCT for DLBCL patients younger than 60 years with intermediate and high risk for IPI
1516633|NCT02842931|Drug|R-mNHL-BFM-90|R-mNHL-BFM-90 without auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
1516634|NCT02842931|Drug|R-mNHL-BFM-90 + auto-SCT|R-mNHL-BFM-90 with auto-SCT in patients with DLBCL under the age of 60 years with intermediate and high risk for IPI
1516635|NCT02842918|Procedure|Spinal Manual Therapy|
1516636|NCT02842918|Procedure|Spinal Range of Motion|
1516637|NCT02842905|Other|Physician counselling and assessment|Phase II of the COSI (Client Orient Scale of Improvement) process completed in a scheduled visit with the referring physician
1516638|NCT02842905|Other|Audiologist counselling and assessment|Phase II of the COSI (Client Orient Scale of Improvement) process completed in a scheduled visit with the initial audiologist involved with fitting the hearing aid
1516639|NCT02842892|Other|Tissue stiffness|
1516640|NCT02842879|Other|Outpatient Foley cervix priming|Outpatient setting for cervix priming with Foley catheter
1516641|NCT02842866|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
1516642|NCT02842866|Biological|Meningococcal Polysaccharide Vaccine, Groups A, C, Y, and W 135 Combined|0.5 mL, Intramuscular
1516643|NCT02842853|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (Lot 1)
1516644|NCT02842853|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (Lot 2)
1516645|NCT02842853|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (Lot 3)
1516646|NCT02842853|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
1516647|NCT02842840|Behavioral|Patient-based intervention|
1516648|NCT02842840|Behavioral|Family based intervention|
1516649|NCT02842840|Other|Routine counseling|
1516650|NCT02842827|Drug|IMG-7289|LSD1 inhibitor
1516651|NCT02842827|Drug|All-trans retinoic acid|Derivative of Vitamin A, differentiating agent.
1516652|NCT02842814|Other|Drug free|Both Glucocorticoid(GC) and hydroxychloroquine(HCQ) treatment are stopped in stable SLE patients.
1516653|NCT02842814|Drug|HCQ|Glucocorticoid(GC) treatment is stopped in stable SLE patients. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d
1516654|NCT02842814|Drug|GC+HCQ|Glucocorticoid(GC) is kept no more than 7.5mg/d. Hydroxychloroquine (HCQ) is kept as 0.2-0.4g/d.
1516656|NCT02842788|Procedure|Prone positioning|Turning the patient face down for several consecutive hours
1516657|NCT02842775|Other|balance perturbation training|perturbation training on the split-belt balance perturbance treadmill,
1516658|NCT02842762|Device|Right ventricular epicardial pacing|The patient's own heart rate at that moment will be the starting point for the study. Right ventricle pacing will be instituted by selecting a rate that is 5 beats above the patient's own heart rate. We will use a stepwise approach where we increase the pacermaker's rate with steps of 5 beats until we have 100% capture of the pacemaker beats. After waiting for at least one minute of pacing we will obtain a set of measurements.
1516659|NCT02842762|Procedure|cardiac surgery|Elective cardiac surgery, with use of cardiopulmonary bypass.
1516660|NCT02842762|Device|3D TEE|Intraoperatively, all patients will be monitored by means of TEE
1516661|NCT02842762|Device|Pacemaker lead|All patients will have a epicardial pacemaker lead in situ.
1516662|NCT02842749|Drug|everolimus|Everolimus is taken at a starting dose of 10 mg orally once daily.Patients will be provided with adequate supply of study treatment for self-administration at home until at least their next scheduled study visit.All patients will be followed for adverse events and serious adverse events for 30 days following the last dose of study drug. Beyond these 30 days, any serious adverse events that are suspected to be related to the study drug will also be collected
1516663|NCT02842736|Device|Cerene(TM) Cryotherapy Device|
1516664|NCT02842723|Radiation|Protontherapy|59,5 Gy (1,7 Gy daily, 5 fractions per week).
1516665|NCT02842710|Device|GeneXpert®|Detection is carried out after a sample within the patient's nasal cavity. The swab containing the sample is placed in the PLC GeneXpert® Cepheid . The analysis takes one hour . The results leave automatically.
1516666|NCT02842697|Procedure|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter
1516667|NCT02842697|Procedure|CTA|Three-dimensional hepatic vein-portal vein model constructed with CTA images
1516668|NCT02842697|Procedure|Doppler ultrasound|Portal vein velocity measured by Doppler ultrasound
1516776|NCT02841891|Device|Sylys Surgical Sealant|Standard Colorectal or Illeorectal Anastomosis Surgical Procedure with the addition of Sylys Surgical Sealant
1516669|NCT02842684|Device|TraumaCad software|restitution of anatomical- radiological parameters after total hip arthroplasty with TraumaCad , conventional planning systems and without planning.
1516670|NCT02842671|Other|Assigned Ambassador|If assigned to the intervention group, participants will be contacted by the assigned medical student ambassador at least 1 day prior to the procedure. A brief discussion will take place to review the child's history and survey results. The family will be met by the Ambassador at the hospital and stay with the family until the patient is in the post anesthesia recovery unit. The ambassador is expected to make accommodations for the child as determined by the accommodations survey results. The family will be required to allow the Ambassador to stay through check-in and the procedure.
1516671|NCT02842658|Other|A high-intensity interval exercise group|To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
1516672|NCT02842658|Other|An Attention-Control Group|Patients will be contacted weekly to access physical activity. To avoid or reduce muscle soreness or cramps, adequate warm-up is suggested
1516675|NCT02842619|Biological|BonoFill-II|"Sinus augmentation - Surgery will be performed by either open or close sinus augmentation as per investigator discretion and as per common medical practice. After the elevation, BonoFill-II will be transplanted on the residual sub-antral bone.
Bone grafting after removal of cysts from jaws - Treatment will be performed according to the size of the cyst: in relatively small cyst total enucleation will be performed. In large cysts, a process of marsupialization will be performed. The entire cyst will be removed, including the epithelium layer, and the BonoFill-II product will be used for filling."
1516676|NCT02842606|Other|Test meal|The two test meals are designed to have the same energy and macronutrient composition. They differ only in the carbohydrate source: fiber-enriched pasta or control pasta. Blood samples are taken at fasting and every 30 minutes over 4 hours. Fasting and postprandial intestinal fermentation is evaluated by breath test.
1516677|NCT02842593|Behavioral|Lower-repetition, heavier-load|8-12 reps/set at ~80% 1 repetition maximum
1516678|NCT02842593|Behavioral|Higher-repetition, lighter-load|20-25 reps/set at ~30% 1 repetition maximum
1516679|NCT02842580|Drug|5 FLUOROURACYL|"Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as a 2 hr infusion.
The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).
The cycles will last 14 days. For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days."
1516680|NCT02842580|Drug|acide folinique|200 mg/m² if Elvorine
1516681|NCT02842580|Drug|irinotecan|"Irinotecan is administered IV at a dose of 180 mg/m² over 90 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with irinotecan.
The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).
The cycles will last 14 days."
1516682|NCT02842580|Drug|Oxaliplatin|"Oxaliplatin is administered IV at a dose of 85 mg/m² over 120 minutes. Folinic acid is administered IV at a dose of 400 mg/m² (or 200 mg/m² if Elvorine) as an infusion over 2 hours, to be given in Y along with oxaliplatin.
The 5FU bolus is administered in less than 10 minutes at 400 mg/m² (on D1). The continuous 5FU is administered IV at a dose of 2400 mg/m² over 46 hr (D1 and D2).
The cycles will last 14 days."
1516683|NCT02842580|Drug|capécitabine|For this 1st line chemotherapy, the investigator has the choice of using capecitabine instead of LV5FU2; in this case the cycle lasts 21 days.
1516684|NCT02842580|Drug|bevacizumab|Bevacizumab is administered IV at a dose of 5 mg/kg over 90 min at cycle 1, then 60 min at cycle 2 and 30 min in subsequent cycles. Bevacizumab is administered every 2 weeks before the start of chemotherapy
1516685|NCT02842567|Drug|Hydroxytyrosol plus Vitamin E|This group will treated with 2 pills daily, each containing 3.75 mg of hydroxytyrosol plus 5 mg of Vitamin E, given orally for 16 weeks
1516686|NCT02842567|Drug|Placebo|This group will treated with 2 identical placebo pills daily given orally for 16 weeks.
1516687|NCT02842554|Other|EPT|
1516688|NCT02842554|Drug|Drug Placebo Administration|
1516689|NCT02842554|Other|C|No Intervention
1516690|NCT02842541|Drug|EBI-031|
1516691|NCT02842528|Behavioral|Diagnostic Interview for Genetic Studies|
1516692|NCT02842528|Behavioral|Family Informant Schedule and Criteria|
1516693|NCT02842528|Behavioral|Temperament and Character Inventory|
1516694|NCT02842528|Behavioral|Barratt Impulsiveness Scale|
1516695|NCT02842528|Behavioral|Wisconsin Card Sorting Test|
1516696|NCT02842528|Genetic|blood sample withdrawn|
1516697|NCT02842515|Other|teeth avulsion|
1516698|NCT02842502|Procedure|Collection of supernumerary biopsies during skin graft pellet procedure|
1516699|NCT02842489|Procedure|left lateral tilt-down position|patients will be positioned on their left side and at an angle of 20 degree
1516700|NCT02842489|Procedure|left lateral horizontal position|patients will be horizontally positioned on their left side
1516701|NCT02842476|Device|Disposable Sensor|Two adhesive based Pulse Oximeter Probes, S0136J-L were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
1516702|NCT02842476|Device|Reusable Sensor|Two soft reusable Pulse Oximeter Probes, Model S0080D-S were connected to the Cadwell Pulse Oximetry and then placed on each subject to evaluate the SpO2 accuracy performance during steady state non-motion conditions.
1516703|NCT02842476|Device|Control Pulse Oximetry|A Clinimark Control Pulse Oximetry system was also placed on the subject to evaluate the stability of the draws.
1516705|NCT02842450|Device|Photos + definitions|A broad group of experts (19 proctology and a dermatologist) will be contacted to choose two typical images of LAP (superficial ulceration, deep ulceration ...). 12 photos lesion initially selected by experts.
1516706|NCT02842450|Other|definitions only|
1516707|NCT02842437|Drug|dexmedetomidine|receive a loading infusion of dexmedetomidine (1ug/kg) for 10min follow by a maintenance infusion (0.5ug/kg·h) continued until the end of the surgery
1516708|NCT02842437|Other|normal saline|receive matching placebo (equal volume of normal saline)
1516709|NCT02842424|Drug|Ramipril|Ramipril therapy will start at 2.5mg/day for 1 week. Then 5mg/day for 1 week and will be increased to 10mg/day by the third week. The patients will stay on Ramipril 10mg/day for 22 weeks.
1516710|NCT02842398|Behavioral|Balance Master|
1516711|NCT02842398|Behavioral|Customary Care|
1516712|NCT02842385|Other|Implant|One or two stages of implants within thin and thick gingiva were monitored 1.5 year after placement
1516713|NCT02842359|Drug|Irbesartan/atorvastatin fixed dose combination|Pharmaceutical form:Tablet Route of administration: Oral
1516714|NCT02842359|Drug|Irbesartan SR47436|Pharmaceutical form:Tablet Route of administration: Oral
1516715|NCT02842359|Drug|Atorvastatin|Pharmaceutical form:Tablet Route of administration: Oral
1516716|NCT02842346|Other|ultrasonography|
1516717|NCT02842333|Other|Additional biological samples|Blood samples
1516719|NCT02842307|Procedure|Manual acupuncture implemented by senior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Senior acupuncturists have to have more than 15 years of acupuncture clinical practice experience.
1516720|NCT02842307|Procedure|Manual acupuncture implemented by junior acupuncturists|Manual acupuncture once per day. No limitation on points, manipulations and time per session. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
1516721|NCT02842307|Procedure|Manual acupuncture on P6 point|Manual acupuncture implemented by junior acupuncturists once per day. P6 point, bilaterally, should achieve deqi sensation by even manipulations. Junior acupuncturists have to have less than 5 years of acupuncture clinical practice experience.
1516722|NCT02842294|Drug|Bevacizumab|
1516723|NCT02842281|Other|Fructan|Short-chain oligosaccharide primarily composed of fructose polymers
1516724|NCT02842281|Other|Maltodextrin|Polysaccharide produced from starch
1516725|NCT02842268|Drug|BAY987517|Test product dried for at least 15 minutes.Subjects to ride for 30 minutes on a stationary bicycle.(Formulation Number :Y73-161)
1516726|NCT02842255|Device|Calibrate the oximeter ALTITRAINER200®|During normoxic condition and four situations of hypoxia.
1516727|NCT02842242|Drug|MYK-461|
1516728|NCT02842190|Device|NIPPV|after ekstubation
1516729|NCT02842177|Procedure|Classic group|The speculum was placed into the vagina and the cervix was cleansed with povidone iodine. After placement of single toothed vulsellum on the anterior lip of the cervix, for traction and fixation of the uterus, the uterine sound was inserted for determination of uterine length and uterine position followed by Cu-IUD insertion. The duration of IUD insertion were reported.
1516730|NCT02842177|Procedure|Uterine sounding sparing group|after bimanual examination, the same sonographer (Level II experience) performed transvaginal /US using a SonoAce X6 machine (Medison, Korea) with transvaginal probe (4-8 MHz frequency, using an average 6.5 MHz). Firstly, he evaluated the uterine position. Then, he measured the endometrial and cervical stripe lengths in the sagittal view of the uterus and summed to have the actual length of the uterus; by which the IUD tube was adjusted before insertion.The same speculum and vulsellum were used and the IUD was inserted directly into the uterine cavity.
1516731|NCT02842177|Radiation|Transvaginal ultrasound|
1516732|NCT02842177|Device|Cu-IUD|
1516733|NCT02842164|Other|Tension group|
1516734|NCT02842164|Other|No tension group|
1516735|NCT02842164|Other|Foley catheter Balloon|
1516736|NCT02842151|Procedure|Manifest refraction|Manifest refraction performed by autorefraction (automated) and manual procedures (standard)
1516737|NCT02842151|Device|ACRYSOF® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
1516738|NCT02842151|Device|Topcon® KR-1W Wave-Front Analyzer|Wavefront and topography system used to obtain autorefraction data
1516739|NCT02842138|Biological|autologous anti-CD19 CAR T cells|Patients will receive a three-day regimen of chemotherapy consisting of fludarabine and cyclophosphamide aimed to deplete the lymphocytes. Four days after lymphodepletion, patients are intravenously infused autologous anti-CD19 CAR T cells. A prescribed CAR T cell dose will be intravenously infused to patient in a three-day split-dose regimen (day0,30%; day1, 30%; day2, 40%).
1516740|NCT02842125|Drug|Ad-P53|Adenoviral Investigational Product Ad-P53 to treat metastases using an intra-arterial catheter, with oral metronomic Xeloda
1516741|NCT02842125|Drug|Xeloda|Oral metronomic chemotherapeutic agent
1516742|NCT02842112|Other|PBSC mobilization and leukapheresis|"Mobilization and harvest of autologous PBSCs was scheduled during the recovery phase after the consolidation course. Granulocyte colony stimulating factor (G-CSF) (150 µg/m2/day) was given by daily subcutaneous injection from day 20 of the chemotherapy course until completion of the blood stem cell collections. PBSC collections were performed on 1 - 5 consecutive days during the hematopoietic recovery phase, as soon as the leukocyte count exceeded 2x 109/L.
Collections were performed after induction or after consolidation. In cases in which the minimum number of CD34+ cells was not collected, an additional mobilization was performed in steady state.
Harvesting was performed using continuous flow blood cell separators. Cells were stored in liquid nitrogen until use, according to standard techniques."
1516743|NCT02842099|Drug|TA or TAC|Taxol, Epirubincin, with or without Cyclophosphamide
1516744|NCT02842099|Drug|X|Capecitabine
1516745|NCT02842086|Drug|F/TAF|200/25 mg tablet administered orally once daily
1516746|NCT02842086|Drug|F/TDF|200/300 mg tablet administered orally once daily
1516747|NCT02842086|Drug|F/TAF Placebo|Tablet administered orally once daily
1516748|NCT02842086|Drug|F/TDF Placebo|Tablet administered orally once daily
1516777|NCT02841891|Procedure|Anastomosis Surgical Procedure|Standard Colorectal or Illeorectal Anastomosis Surgical Procedure without the addition of Sylys Surgical Sealant
1516751|NCT02842060|Behavioral|myDEx|myDEx will consist of a 6-session online program. Cognizant of challenges maintaining users' attention in a web application and to facilitate delivery through a smartphone, the investigators will design each session to be no more than 20 minutes in length. In the course of these 6 sessions, participants will have a total of 120 minutes of intervention exposure. Across sessions, the investigators will emphasize the importance of sexual decision-making across different partner types, help men consider what type of relationship(s) they want, and align these relationship desires with safer sex practices.
1516752|NCT02842060|Behavioral|NTHP|The investigators will create a 6-session attention-control comparison to match the intervention in time and attention yet have non-tailored and non-interactive content (NTHP). NTHP will include HIV/STI information currently available on sex education websites. The attention-control condition allows the investigators to avoid confounding due to content and ensures that all participants receive some HIV prevention content given their high vulnerability to HIV. Further, this comparison will help critically examine the extent to which tailoring increases the acceptability to the program, above and beyond having a non-tailored, non-interactive intervention.
1516753|NCT02842047|Behavioral|Stop, Breathe & Think™|online daily meditations delivered using smart phone or other computer based application
1516754|NCT02842047|Behavioral|End of Life Planning Videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though key aspects of end of life planning.
1516755|NCT02842047|Behavioral|Caregiver wellness videos|Three videos, each 10 minutes in length which will be viewed over the study period. The videos will walk participants though general caregiver wellness.
1516756|NCT02842034|Device|Repetitive Transcranial Magnetic Stimulation|Stimulate the dorsomedial prefrontal cortex for 4 weeks.
1516757|NCT02842021|Drug|S2G6T-1|Twice a day topical cream
1516758|NCT02842021|Drug|S2G6T-2|Twice a day topical cream
1516759|NCT02842021|Drug|S2G6T-3|Twice a day topical cream
1516760|NCT02842021|Drug|S2G6T-4|Twice a day topical cream
1516761|NCT02842008|Behavioral|Exercise group|This group will receive a home exercise program of shoulder based on mobility, strength and strengthening exercises, lasting 10 weeks, 3 times per weeks. The target dose use for mobility consisted in 8 repetitions for each 4 movements, for strengthening using resistive bands, 3 sets (including 5 exercises) of 10 repetitions with a 45 second rest between sets and 5 repetitions for each 5 strength with a 30 second rest and general protocol of postural hygiene. The instructional of the program is 30 minutes each day during the time of the study (10 weeks) with a screening about the exercise program and the daily activities performed every 4 weeks. Physiotherapist provided support to subjects through email along 10 weeks.
1516762|NCT02841995|Drug|KD025|
1516763|NCT02841982|Procedure|single-injection QLB(quadratus lumborum block)|Inject local anesthetics in between quadratus lumborum and psoas major without continuous local infusion
1516764|NCT02841982|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scan
1516765|NCT02841982|Device|PAJUNK StimuLong|
1516766|NCT02841982|Drug|single dose ropivacaine|"0.6ml/kg 0.5% ropivacaine with 1:200,000 adrenaline.
given immediately after the correct position of the tip of the needle has been verified."
1516767|NCT02841982|Drug|Morphine given as IPCA(intravenous patient controlled analgesia)|bolus: 1.5~2mg, lock time: 10min, 1h limitation: 6~8mg
1516768|NCT02841969|Other|Electrolysed water|Irrigation of wound using electrolysed water
1516769|NCT02841969|Other|Prontosan|Irrigation of wound using Prontosan
1516770|NCT02841956|Other|Electronic Screen + Education (Phase 1)|PHASE 1 Electronic Screening Arm + Targeted Education: Referral sources will receive the same standard targeted education as active comparator. In addition, the PQ-B (a 21 item screening questionnaire) will be administered to all patients at their first visit to the referral sites (e.g. intake) via an android tablet provided to the site for ease of administration and scoring. The investigators will provide multiple tablets per site so that the screening is available for more than one individual simultaneously and can be completed in any appropriate location. The investigators will allow paper-and-pencil administration for situations where it is more appropriate (e.g. emergency room).
1516771|NCT02841956|Other|Targeted Provider Education (Phase 1)|PHASE 1 Targeted Education Intervention: EDAPT standard targeted provider education1 focuses on increasing awareness about the signs of early psychosis & building collaborative relationships with community members so community members see EDAPT as a rapid, effective source of help. It consists of a 2-hour workshop describing: 1) how to identify specific early symptoms & changes associated with the onset of psychotic illness, 2) the benefits of early intervention on treatment outcomes in psychosis, 3) the structure, philosophy & treatment model of the EDAPT Clinic, and 4) procedures for expeditious referral to our program. Case-based vignettes are reviewed to ensure understanding of the key symptoms.
1516772|NCT02841956|Other|Community Mobile Engagement (Phase 2)|PHASE 2 Community-based Mobile Engagement: Clinical assessment appointments will take place at the EDAPT clinic or within the community, wherever the individual would prefer. With patients deemed eligible for EDAPT services, the EDAPT clinician will obtain vitals and contact the EDAPT psychiatrist with a telemedicine-enabled laptop to complete the psychiatric evaluation remotely. The psychiatrist will prescribe medications and order labs, as indicated. The EDAPT clinician will follow up with the individual within 5 days to determine if the prescribed medication regimen has started.
1516773|NCT02841956|Other|Clinic based Engagement (Phase 2)|PHASE 2 Clinic-based Engagement: The clinical assessment appointment will be completed within the EDAPT clinic. If deemed eligible for EDAPT services, the individual will be scheduled for a clinic-based appointment with the EDAPT psychiatrist within 5 days, who will prescribe medications and order labs as indicated. The EDAPT clinician will follow up with the individual within 5 days of the psychiatric evaluation (by phone or in the clinic) to determine if the prescribed medication regimen has started.
1516774|NCT02841930|Other|ActionHealth NYC|care coordination, covered preventive services, and standardized costs for ambulatory care
1516775|NCT02841904|Device|Confocal LASER Endomicroscopy|
1516786|NCT02841774|Drug|Pravastatin|40mg daily (Weeks 2 - 14)
1516787|NCT02841774|Drug|Rosuvastatin|20mg daily (Weeks 2 - 14); at Week 6, if AST, AST, and CK <+1.5 x ULN, and LDL-c is >60 and decreased by less than 25% compared with week 2, then dose will be increased to rosuvastatin 40mg daily
1516788|NCT02841761|Drug|Midalozam|Syrup for oral use
1516789|NCT02841761|Drug|ACT-132577|Capsules for oral use
1516790|NCT02841748|Drug|Pembrolizumab|200mg, every three weeks, iv, x 1 year
1516791|NCT02841748|Drug|Placebo|iv, every three weeks, x 1 year
1516792|NCT02841735|Device|Smartphone breathalyzer device/app use|Participants randomized to this condition will be able to blow into the smartphone breathalyzer after consuming each alcoholic drink, which produces an accurate breath alcohol reading on the app. These breath alcohol readings may inform participants' subsequent decisions regarding drinking.
1516793|NCT02841735|Device|BAC estimator app use|Participants randomized to this condition will be able to make an entry into the BAC estimator app after consuming each alcoholic drink, which produces an estimated blood alcohol concentration based on the individual's sex, weight, number of alcoholic drinks and time spent drinking alcohol. These estimated blood alcohol concentrations may inform participants' subsequent decisions regarding drinking.
1516794|NCT02841735|Device|Text messaging procedure|Participants randomized to this condition will be instructed to send a text to a smartphone they will use for the study after each alcoholic drink. A consideration of the number of texts sent may inform participants' subsequent decisions regarding drinking.
1516795|NCT02841722|Procedure|ERIBULIN + G-CSF (Granulocyte-Colony Stimulating Factor)|8 additional blood samples
1516796|NCT02841709|Drug|ACT-541468|Capsules for oral administration containing ACT-541468 at a strength of 5 mg, 10 mg or 25 mg
1516797|NCT02841709|Drug|Placebo|Capsules for oral administration matching the ACT-541468 capsules
1516798|NCT02841696|Device|Cardiac echography|The exam is in the left lateral decubitus position. 4 electrodes are applied to the patient's chest for a synchronization with the Electrocardiogram (ECG). The examination is conducted as standard with acquisition loops of records in parasternal long axis parasternal short axis, apical 4-cavities, 2-cavities and aorta 2 cavities.
1516799|NCT02841683|Behavioral|Tabac Info Service|A smoking cessation E-intervention, Tabac Info Service (TIS), by website and mobile application
1516800|NCT02841670|Device|InFo - Instant Focus (c) lens implantation|
1516801|NCT02841631|Genetic|HPV status and typing of tissue|HPV status and typing of tissue
1516802|NCT02841618|Other|High Linoleic Acid Healthy Cookies|
1516803|NCT02841618|Other|High Oleic Acid Healthy Cookies|
1516804|NCT02841605|Procedure|Rectosigmoidoscopy with colonic biopsies|Rectosigmoidoscopy with colonic biopsies performed for Alzheimer patient and both control groups Parkinson and PSP
1516805|NCT02841605|Procedure|Colonoscopy with colonic biopsies|Colonoscopy with colonic biopsies performed only in patient at risk of colic cancer
1516806|NCT02841592|Other|Flush rate oxygen|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes.
1516807|NCT02841592|Other|Flush rate oxygen with assist|Using a standard flowmeter (Precision Medical, 8MFA), the flow of oxygen will be fully opened and oxygen will be administered for three minutes. Positive pressure breaths to match the subject's inspiration will be provided during the three minute period.
1516808|NCT02841579|Drug|Osimertinib|The patients will be treated with 1 tablet of osimertinib (AZD9291) 80 mg per os (p.o.) daily up to 78 weeks from the time of the first administered dose.
1516809|NCT02841566|Other|questionnaire|
1516810|NCT02841540|Drug|H3B-8800|H3B-8800 capsules will be administered at assigned dose regimen (at the maximum tolerated dose [MTD] or recommended Phase 2 dose [RP2D] identified in the Dose Escalation part of the study) once daily by mouth in an open-label fashion in a 5 day on/9 day off schedule in one full cycle of 28 days. Treatment will continue until intolerability, withdrawal of consent, or progression.
1516811|NCT02841527|Procedure|Gastric Band|Surgical intervention in which a band is inserted around the top of the stomach to reduce its size.
1516812|NCT02841527|Procedure|Gastric Bypass|Surgical intervention where a small pouch is made in the top of the stomach and a loop of bowel connected to this pouch to bypass the rest of the stomach.
1516813|NCT02841527|Procedure|Sleeve Gastrectomy|Surgical intervention which reduces the size of the stomach by about 75%, creating a narrow tube. It is done by stapling down the stomach and removing the remainder of the stomach.
1516814|NCT02841514|Device|The Y10 Tooth Whitening system including the Y10 toothpaste and the Y10 device|
1516815|NCT02841514|Other|OTC toothpaste and an unoperated Y10 device|
1516816|NCT02841501|Genetic|Analysis of genetic polymorphisms|An analysis of the SNPs (single nucleotide polymorphism) of 25 candidate genes will be performed. This analysis will be completed by a genome wide association study.
1516817|NCT02841488|Procedure|Continuous peripheral sciatic nerve block|Continuous infusion of local anesthetics through perineural sciatic nerve catheter
1516818|NCT02841488|Drug|Fentanyl|Use of patient controlled analgesia device with intravenous fentanyl
1516819|NCT02841488|Drug|Ropivacaine|
1516820|NCT02841488|Device|Perineural catheter|
1516821|NCT02841475|Other|Charlson comorbidity index|Charlson comorbidity index
1516822|NCT02841462|Device|Intra-bursal thermal ablation|A single 3-minute intra-bursal perfusion of a physiological saline solution at increasing temperatures using the Ablaflex device.
1516823|NCT02841449|Behavioral|Hypohydrated|Participants remain hypohydrated after the heat tent procedure
1516824|NCT02841449|Behavioral|Rehydrated|Participants rehydrate after the heat tent procedure
1516825|NCT02841436|Device|Irreversible Electroporation (IRE) System|
1516826|NCT02841423|Procedure|neuropsychological test battery|
1516827|NCT02841410|Other|Magnetic Resonance Imaging|
1516828|NCT02840279|Drug|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
1516829|NCT02840279|Drug|Placebo|
1516830|NCT02840253|Device|NIRS|
1516901|NCT02840773|Other|Peri-implanter sulcus fluid sampling|PISF sampling was made twice
1516831|NCT02840240|Drug|Gabapentin enacarbil|600 mg BID 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg BID 3 days post-operative
1516832|NCT02840240|Drug|Placebo|600 mg BID taken 1 day pre-op and 2 hours before surgery, 6 hours after surgery, 600 mg 3 days post-operative
1516833|NCT02841384|Other|taping patellar McConnell|Taping patellar McConnell: Lateralization correction of the patella with self-adhesive rigid bandage Johnson® positioned lateral border of the patella to the medial condyle of the femur, allowing the lifting of the medial border of the patella and stretching of the knee lateral structures.
1516834|NCT02841384|Other|Placebo taping|Placebo taping through vertical application of patellar rigid taping, with the knee in flexion without medialization of the patella.
1516835|NCT02841371|Radiation|99mTc-DTPA|a 99mTc-DTPA renal dynamic imaging measurement as the reference glomerular filtration rate (rGFR).
1516836|NCT02841358|Biological|Blood sampling|
1516837|NCT02841358|Biological|Biopsy|
1516838|NCT02841345|Other|behavioral and fMRI|"The experience will include 3 sessions. Each session will consist of the presentation of a pseudo-random sequence of 24 black and white images of negative emotional natural scenes, 24 positive emotional situations and 24 neutral emotional situations.
In the first session, participants will carry out an emotional assessment task: it will show at the end of each test his emotional feeling - pleasant, unpleasant or nothing - using a joystick.
In a second session, the participant will perform a motor task decision: it will show at the end of each test the tendency to action he would handle the situation actually using 3 buttons également- approach withdrawal or neither one nor the other.
In the third session, the participant will perform a simple visual perception task. To be comparable to the engine plane with the other sessions, a non-categorical motor task will be requested from participants."
1516839|NCT02841332|Drug|F-MISO|"The fluoro-misonidazole is a positron emission tomography tracer (labeled with Fluorine-18)-specific hypoxia. This compound penetrates into cells where it is reduced by a nitroreductase enzyme. It is rapidly regenerated by reoxidation when the cell is properly oxygenated. This metabolite can accumulate in viable hypoxic cells (necrotic cells that can provide initial reduction reaction of F-MISO).
Moreover, the fixing of this tracer appears to be independent of blood flow. The advantage of this technique is to provide a direct image of hypoxic cells by directly targeting under stress hypoxic."
1516840|NCT02841332|Other|Cerebral magnetic resonance imagery|"During the pre-therapeutic imagery session :
Morphological magnetic resonance imagery ( axial T1 sequence axial T1 post contrast , Flair Axial )
magnetic resonance imagery spectroscopy sequence
Perfusion magnetic resonance imagery sequence
Diffusion magnetic resonance imagery sequence"
1516841|NCT02841332|Drug|Bevacizumab|Administration of bevacizumab during 7 cycles of treatment (J1, J15, J30, J45, J60, J120 and J180)
1516842|NCT02841332|Other|Clinical examination|"During the examination, the following parameters will be checked :
Neurological examination
Corticotherapy prescribed
General status of patient (world health organization score)
Weight and height
Control of arterial pressure
Chirurgical and medical history
Concomitant treatment"
1516843|NCT02841319|Other|Virtual Reality Exercises using Hand Tutor|Virtual reality technology is rapidly becoming a popular application for physical rehabilitation and motor control research. The prototype, which includes a built-in movement sensor, allows the user to do controlled exercises as part of a rehabilitation program. The supervised intervention program consists of a forty-minute exercise session three times a week for 8 weeks. In addition, these patients will receive a home exercise program. The patients in the control group will receive only a home exercise program for 8 weeks. The home exercise program consists of different games and exercises such as range of motion, stretch, and strengthening exercises for hand.
1516844|NCT02841306|Drug|Ursodeoxycholic Acid|
1516845|NCT02841293|Other|Utility Cost evaluation|Medical consequences in terms of quality-adjusted life year and costs within the first year. quality-adjusted life year will be estimated using EQ-5D-3L scale
1516846|NCT02841293|Other|Clinical and medical parameters|"Cumulative dose and time duration of pain medication
Pain evaluation
Time to complete healing
Duration of nursing requirements after discharge
Perineal hernia symptomatic or not"
1516847|NCT02841280|Drug|Chlorthalidone|This is a forced-titration study and the study drug or placebo will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
1516848|NCT02841280|Drug|Placebo|This is a forced-titration study and the study drug or placebo will be increased if goal BP is not achieved (dosage of chlorthalidone not to exceed 50 mg)
1516849|NCT02841267|Drug|PF 06252616|
1516850|NCT02841254|Other|Non interventional study|
1516851|NCT02841241|Drug|Esmolol|Esmolol infusion
1516852|NCT02841228|Radiation|IMRT + SIB + Chemotherapy|For all patients, the dose to the PTV will be kept constant at 60 Gy in 30 fractions at 2.0 Gy per fraction , SIBV will be kept constant at 72 Gy in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks. All patients will receive standard concurrent chemotherapy.
1516853|NCT02841215|Drug|Ivermectin 200 µg/kg|Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)
1516854|NCT02841215|Drug|Ivermectin 400 µg/kg|Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)
1516855|NCT02841202|Drug|oral contraceptive pills|
1516856|NCT02841189|Device|King Vision video Laryngoscope|The King Vision video laryngoscope (Ambu) will be used for tracheal intubation.
1516857|NCT02841176|Other|Thermography|Thermographic imaging of arthritic joints will be performed at baseline and within 5 days after the participant's 2nd and 4th doses of monthly Golimumab
1516858|NCT02841176|Biological|Golimumab|Participants will start monthly Golimumab after their baseline visit
1516859|NCT02841163|Drug|Herbal medicine|Herbal medicine was administered 2-3 times daily in water-based decoction (120ml) and dried powder (2g) form (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes japonica, Psoralea corylifolia, Saposhnikovia divaricata, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, Glycine max, Atractylodes japonica).
1516860|NCT02841163|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly proximal acupuncture points and Ah-shi points.
1516861|NCT02841163|Procedure|Pharmacopuncture|Select herbal ingredients (Eucommia ulmoides cortex, Acanthopanax sessiliflorum cortex, Achyranthis bidentata radix, Saposhnikovia divaricata radix, Cibotium barometz rhizoma, Paeonia albiflora radix alba, Ostericum koreanum radix, Angelica pubescens radix, and Scolopendra subspinipes corpus (Paeonia albiflora twice the proportion of that of other ingredients)) were freeze dried into powder form after decoction, then diluted in water-for-injection and adjusted for acidity and pH. Pharmacopuncture was administered once daily at Hyeopcheok (Huatuo Jiaji, EX B2), Ah-shi points and local acupuncture points using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
1516862|NCT02841163|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was administered only after confirming a negative response to hypersensitivity skin tests. Diluted bee venom (saline:bee venom ratio, 10,000:1) filtered for allergens was injected at 4-5 acupoints proximal to the painful site at the physician's discretion. Each acupuncture point was injected to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
1516863|NCT02841163|Procedure|Chuna manipulation|Chuna is a Korean version of spinal manipulation that incorporates spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement. Chuna manipulation was administered 3-5 times a week to pelvic, lumbar, thoracic, and cervical vertebrae at the physician's discretion.
1516864|NCT02841150|Drug|IMBRUVICA (Treatment A)|IMBRUVICA (reference treatment), 4*140 milligram (mg), capsules.
1516865|NCT02841150|Drug|Ibrutinib (Treatment B)|Ibrutinib (test treatment), 1*560 mg, tablet.
1516866|NCT02841137|Drug|Progesterone|comparison of different dosages of drug towards the active comparator
1516867|NCT02841124|Other|interviews|face-to-face interviews with the referent oncologist (or hematologist) and his patient (conducted by a physician and a psychologist respectively) as well as interviews with other partners involved in the situation (care staff and relatives)
1516868|NCT02841098|Other|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT)|Carotid endarterectomy (CEA) combined with optimal medical therapy (OMT) (Surgery and Drug)
1516869|NCT02841098|Drug|Optimal medical therapy alone|Optimal medical therapy alone
1516870|NCT02841085|Genetic|Genetic sample|Blood sample or saliva collection
1516871|NCT02841059|Procedure|LSH|laparoscopic subtotal hysterectomy: LSH
1516872|NCT02841059|Procedure|CLSH|laparoscopic cervical ligament sparing hysterectomy: CLSH
1516873|NCT02841059|Procedure|LAVH|laparoscopic assisted vaginal hysterectomy: LAVH
1516874|NCT02841046|Device|cardiac index|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group cardiac index with CI as the primary judgment.
1516875|NCT02841046|Device|Stroke Volume Variation|group cardiac index（CI） and group Stroke Volume Variation（SVV） are different treatment schemes of goal-directed fluid therapy guided by SVV and CI,group Stroke Volume Variation with the combination of SVV and CI as the primary judgment.
1516876|NCT02841033|Drug|daratumumab|Daratumumab by IV infusion once weekly for two months, then every 2 weeks for four months, then once each month until progression or inability to tolerate.
1516877|NCT02841020|Procedure|Additional biopsy|
1516878|NCT02841007|Device|geko neuromuscular electrostimulation device|
1516879|NCT02840994|Biological|CV301|
1516880|NCT02840994|Biological|Pembrolizumab|
1516881|NCT02840955|Device|Staphefekt SA.100|
1516882|NCT02840955|Other|Placebo|
1516883|NCT02840942|Behavioral|Coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to teach coping skills."
1516884|NCT02840942|Behavioral|Non-coping Robot|"Socially assistive robot MAKI will interact with children via tablet game designed to be distraction only."
1516887|NCT02840916|Procedure|laser acupuncture|Subjects were treated at acupoints including the Stomach and Hunger points of the ear, ST25, ST28, ST40, SP15, CV9, and SP6 by using laser acupuncture (GaAlAs laser, maximal power, 150 milliwatt; wavelength, 810 nm; area of probe, 0.03 cm2; power density, 5 W/cm2; pulsed wave; 5.625 J/ cm2) over 5 sessions per week, 12 treatment sessions in total.
1516888|NCT02840916|Procedure|sham laser acupuncture|Subjects underwent sham laser acupuncture treatment without any laser output. The acupuncture points, application duration, and total number of treatments were similar to those in verum laser acupuncture group.
1516890|NCT02840890|Procedure|osteopathic technique|Osteopathe will perform continuous pressure on the middle ribs in order to reduce the mechanical stress of the anatomical elements related to liver
1516891|NCT02840890|Procedure|Placebo|patients will have a relaxing osteopathic technique. A non therapeutic abdominal technique
1516892|NCT02840877|Behavioral|DOTS Adherence Monitoring|Study participants will meet with a study-employed DOTS worker daily during weekdays throughout the course of their TB treatment
1516893|NCT02840864|Device|Sonography assisted breast surgery|
1516896|NCT02840812|Drug|Nemonoxacin|Nemonoxacin Malate Capsules 500mg single dose oral
1516897|NCT02840799|Drug|Potassium Nitrate (KNO3)|The effect of potassium nitrate (KNO3) supplementation on exercise capacity and peak oxygen consumption in HFpEF will be assessed.
1516898|NCT02840799|Drug|Potassium Chloride (KCl)|Potassium Chloride (KCl) is the matching placebo control drug in this trial.
1516899|NCT02840786|Device|plaque excision system|
1516902|NCT02840773|Other|Probing depth|The change of probing depth between baseline and 12 month after prosthetic loading. Probing depth was measured with a plastic periodontal probe (mm)
1516903|NCT02840773|Other|Crestal bone loss|Crestal bone loss was measured on digital radiographs at baseline and after 1 year of prosthetic loading with a Java program me (Image-J 3.0 NIH, Bethesda, USA)
1516904|NCT02840773|Other|Presence of bleeding on probing|The change bleeding on probing of between baseline and 12 month after prosthetic loading. Presence of bleeding on probing were performed at four sites of implants.
1516905|NCT02840773|Other|Plaque index levels|The change of plaque index level between baseline and 12 month after prosthetic loading. Presence of plaque index was performed at four sites of implants.
1516906|NCT02840760|Device|Repetitive Transcranial Magnetic Stimulation|Stimulate the primary motor cortex for 2 weeks.
1516907|NCT02840734|Other|Kinesio taping|This study was conducted in a randomized crossover double-blind design. Each subject was tested for muscular power, strength, endurance, and fatigue of the lower extremities under three conditions: 1) NT (no taping), 2) PT (placebo taping, 3M tape) and 3) KT (Kinesio taping). For allocation of treatment sequence, the participants drew straws for which treatment first (each treatment indicated different numbers).
1516909|NCT02840708|Drug|Sargramostim|
1516911|NCT02840669|Procedure|Cardiac magnetic resonance imaging (CMR)|
1516912|NCT02840669|Procedure|Exercise-stress test|
1516913|NCT02840669|Procedure|Echocardiography (ECHO)|
1516914|NCT02840669|Procedure|Cardiac-related blood studies|
1516915|NCT02840656|Other|oropharyngeal swabbing|microbiological sampling will be performed on buccal mucosa with standard swab. only one sample will be done
1516916|NCT02840656|Other|rectal swabbing|same process as oropharyngeal swabbing will be used to collect rectal microbiological sample
1516917|NCT02840643|Behavioral|Bimanual hand therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive bimanual hand therapy, which involves actively using both hands in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
1516918|NCT02840643|Behavioral|Constraint therapy|Children will receive 90 hours (6 hrs/day, 5 days/week, 3 weeks) of intensive constraint therapy, which involves actively using the impaired hand in play-based activities, games, arts and crafts, and activities of daily living. The different arms of the study will receive blocks of unimanual (constraint) therapy and bimanual therapy, in different orders.
1516920|NCT02840617|Drug|Indocyanine Green (ICG)|
1516921|NCT02840591|Drug|Ramelteon|
1516922|NCT02840591|Drug|Citicoline|
1516923|NCT02840565|Drug|BIA 5-453|Presented as blue hard gelatine capsules (size 2) of 1 mg, 10 mg and 50 mg for oral administration
1516924|NCT02840565|Drug|Placebo|The composition of the placebo is qualitatively the same but without BIA 5-453 pharmaceutical active ingredient.
1516925|NCT02840552|Drug|18F-Fluoromethylcholine (18F-FCH)|FCH PET/CT
1516927|NCT02840526|Procedure|Paravertebral blockade (PVB)|preoperative ThPVB performed unilaterally at Th10 level
1516928|NCT02840526|Drug|Sopodorm|midazolam 0,1 mgkg-1 intravenously (anesthesia induction)
1516929|NCT02840526|Drug|Propofol WZF|propofol 2 mgkg-1intravenously (anesthesia induction)
1516930|NCT02840526|Drug|Nimbex|cis-atracurium 0,15 mgkg-1 intravenously (anesthesia induction)
1516931|NCT02840526|Drug|Fentanyl WZF|fentanyl 1,5 µgkg-1 intravenously (anesthesia induction)
1516932|NCT02840526|Drug|Sevorane|sevoflurane in 1 MAC (Minimal Alveolar Concentration) - anesthesia maintenance
1516933|NCT02840526|Device|Intubation|Intratracheal intubation with a single lumen endotracheal tube
1516934|NCT02840526|Drug|Oxynorm|1 mgml-1 concentration oxycodone solution intravenously
1516935|NCT02840526|Drug|Paracetamol Kabi|1g paracetamol intravenously every 6 hours
1516936|NCT02840526|Drug|Ketonal|100 mg ketoprofen intravenously every 12 hours
1516937|NCT02840526|Drug|Bupivacaine WZF|0,3 ml kg-1 0,5% plain bupivacaine (regional anesthesia - paravertebral blockade)
1516938|NCT02840513|Other|Smartphone app and carbon monoxide self-monitoring|
1516942|NCT02840461|Drug|Ivermectin Cream, 1%|
1516943|NCT02840461|Drug|Placebo/Vehicle cream|
1517014|NCT02839837|Device|Paired Associative Stimulation|After aerobic exercise participants will receive a paired associative stimulation (PAS) paradigm. PAS consists of paired brain and peripheral nerve stimuli. Participants will receive 200 paired stimuli. Peripheral nerve stimulation will be delivered to the median nerve at the level of the wrist via electrical stimulation at 300% perceptual threshold. Brain stimulation will be delivered via transcranial magnetic stimulation (TMS) over the hand knob of the motor cortex at an intensity that elicits a 1mV response in the contralateral abductor pollicis brevis muscle. During each paired stimulation, peripheral nerve stimulation will precede the TMS stimulation by 25ms.
1517015|NCT02839824|Procedure|Bowel preparation|Bowel preparation for bowel cleansing in a real clinical practice
1516944|NCT02840435|Behavioral|Sit to Quit|Sit to Quit(STQ) is a smoking cessation program adapted from Mindfulness Training for Smokers (MTS) with core content available on the STQ video. STQ contains many elements found in traditional interventions (e.g. instruction on planning and structuring a quit day, garnering support from others, assessment of prior relapse occasions, development of strategies to avoid triggers). In addition, STQ provides instruction in various mindfulness practices and in how to apply mindfulness skills to manage common causes of relapse. Exercises are provided, and it is recommended to learn the skill experientially. STQ requests that participants practice guided meditation each day using an audio recording and employ other mindfulness practices targeted to manage relapse challenges. Participants will also receive the STQ Participant Manual, which provides all the instruction found in the STQ Video, but provides additional discussion of topics for smokers who desire additional material.
1516945|NCT02840435|Behavioral|Quit for Life|"Quit for Life integrates telephone counseling, written materials, NRT, and an online program called Web Coach. Web Coach is an interactive internet-based support system that provides health information on smoking cessation, assistance in the development of quit strategies, and an interactive blog to interact with other smokers. Web Coach is used by approximately 70% of AWI callers. Web Coach is not a complete program, but instead is designed to supplement AWI phone-based therapy. In addition, Quit for Life also provides the Quit Guide, which is a smoking cessation manual with written instructions on the use of medications, planning a quit day, and cessation-related cognitive skills."
1516946|NCT02840422|Device|ARTHRUM H 2%|ARTHRUM H 2%
1516947|NCT02840409|Drug|Vinblastine|
1516948|NCT02840409|Drug|Bevacizumab|
1516951|NCT02840383|Other|Delayed Intervention|Schools not receiving intervention until two years after implementation.
1516952|NCT02840383|Other|Intervention|intervention at the beginning of study.
1516957|NCT02840344|Behavioral|Couples MBSR|Both members of the couple will be asked to participate in the weekly video sessions and activities.
1516958|NCT02840344|Behavioral|Individual MBSR|Only the young breast cancer survivor will participate in the weekly video sessions and activities.
1516961|NCT02840318|Other|Compassion Intervention|See arm description
1516962|NCT02840305|Other|Evaluation of visual function|
1516963|NCT02840305|Other|Magnetic Resonance Imaging|
1516964|NCT02840227|Procedure|General anesthesia with opioid analgesia|General anesthesia with routine drugs and intravenous patient controlled opioid analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs.
1516965|NCT02840227|Procedure|Combined general/epidural anesthesia|Combined general/epidural anesthesia and analgesia. General anesthesia may include propofol, isoflurane, sevoflurane, and other drugs. Epidural anesthesia will include bupivacaine and other local anesthetics.
1516966|NCT02840214|Device|transcranial direct current stimulation|Soterix tDCS RCT device given over left DLPFC for 20 minutes at 2mA.
1516967|NCT02840214|Device|sham tDCS|Soterix tDCS RCT device given over left DLPFC with 30 second ramp on and off of current
1516968|NCT02840188|Other|Radius tilt angle|Fracture classification in children. Tilt angle measurement of the distal radius growth plate.
1516969|NCT02840175|Drug|etanercept|will be tapered from every week to every 2 weeks for 12 weeks then to every 3 weeks for 12 weeks
1516970|NCT02840175|Drug|adalimumab|will be tapered from every 2 weeks to every 3 weeks for 12 weeks and to every 4 weeks for 12 weeks
1516971|NCT02840175|Drug|Abatacept|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
1516972|NCT02840175|Drug|Tocilizumab|will be tapered from every 4 weeks to every 6 weeks for 24 weeks
1516973|NCT02840162|Drug|Celecoxib|Selective inhibition of COX-2 without significant cyclooxygenase-1 (COX-1) inhibition
1516974|NCT02840162|Drug|Placebo|
1516975|NCT02840149|Drug|68Ga-DOTATATE PET/CT|68Ga-DOTATATE PET/CT scan
1516976|NCT02840136|Drug|Piperacillin-tazobactam combination product|
1516977|NCT02840136|Drug|Meropenem|
1516978|NCT02840136|Drug|Ceftazidime|
1516979|NCT02840123|Biological|Autologous dendritic cells|
1516980|NCT02840110|Other|ACTR087|
1516981|NCT02840097|Drug|Tranexamic Acid|Active drug is provided to participants as described based on the TXA arm they are randomized to.
1516982|NCT02840097|Drug|Placebo|Normal saline is provided to participants if randomized to this treatment arm.
1517016|NCT02839811|Procedure|Immediate hypersensitivity to BLC|immediate hypersensitivity to BLC by In vitro diagnosis
1517017|NCT02839798|Device|NEST (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Bipolar Depression.
1517018|NCT02839785|Drug|Ibuprofen|
1517019|NCT02839785|Drug|Placebo|
1517020|NCT02839772|Other|Current skin care regimen plus 2% glycerine added to soaking water|
1517021|NCT02839772|Other|Current skin care regimen|
1516983|NCT02840084|Device|Aspen(TM) Ultrasound System|"Two transducers per breast are applied. There will be 10 30 minute sessions, with 2 sessions per week for five weeks. The transducers will be placed on the medial and lateral positions of the affected breast, and then rotated to the superior and inferior aspects, and finally directly over the nipple-areolar complex. Following treatment, the affected breast will be massaged and bandaged per the Aspen Rehabilitation protocol, and the patient will be provided with home exercises as part of the Aspen Rehabilitation Technique.
The treated breast(s) will be examined both prior to and immediately following each treatment session. To evaluate safety, any adverse events such as swelling, redness, or pain will be assessed. To determine efficacy, any change in the Baker Grade level will be assessed by physical examination. The breasts will be photographed prior to treatment at each visit to assist in evaluation of any visible change in the breasts."
1516984|NCT02840071|Other|Psychological therapy|Acceptance and commitment therapy is a third-wave cognitive behavioural therapy. The aim of ACT intervention is to increase a person's psychological flexibility by enabling them to change their relationship with distressing cognitions (acceptance) and doing things that are personally meaningful to them (commitment). The ACT model does not focus on distress reduction, although this is a secondary consequence of acceptance and commitment. This is targeted through the six core processes: present moment awareness, cognitive defusion, acceptance, self-as-context, values and committed action which means taking effective action, guided by the identified values. The intervention will involve six 1.5 hourly individual sessions.
1516985|NCT02840058|Other|Biological samples|blood and tumor tissue samples
1516986|NCT02840058|Drug|Anti PD1/PDL1 treatment|
1516987|NCT02840045|Device|high-density electroencephalography|Musical stimulation during electroencephalography recording
1516988|NCT02840019|Device|Investigational MRI coil designed for pregnant women|The investigational MRI receiver coil designed specifically for pregnant women will be used during the 60 minute full research MRI scan. An MRI receiver coil is part of the MRI machine that is placed over the body part being imaged during every MRI scan. A coil is required to obtain MR images, yet there isn't one designed for pregnant women. This investigational MRI receiver coil for pregnant women will be tested to see if it helps improve image quality and take images faster.
1516989|NCT02840019|Procedure|MRI Scan|All participants will participate in an MRI scan. The add-on MRI scan will be 15 minutes. The full MRI scan will be 60 minutes.
1516990|NCT02840006|Procedure|General anesthesia only|Induction drugs: Citrate of fentanyl, atracurium, etomidate
1516991|NCT02840006|Procedure|General anesthesia and Spinal anesthesia|Induction drugs: Citrate of fentanyl, atracurium, etomidate Spinal anesthesia: Bupivacaine hyperbaric, Morphine
1516992|NCT02839993|Device|tDCS|
1516993|NCT02839993|Behavioral|training|
1516994|NCT02839967|Other|Phototherapy|Intraoral phototherapy is applied in the temporal, medial and lateral pterygoid, bilateral, totaling 4 points of application of phototherapy. The researcher who will perform the treatments will receive the equipment with the stylus activates and pre-programmed dose, an eye protection (glasses, opaque) will be used by the participants, to protect the eyes, because the same does not cause any sensation to volunteer. The technique is used, contact an area. The individual is positioned supine on a stretcher, with the legs supported on a foam roller 20 cm in diameter, the head supported on a pillow, to accommodate her comfortably in a resting posture, prompted the opening of the mouth and placing the tip of phototherapy in sections as described below, with 2 minutes interval between one application and another for rest with the mouth closed.
1516995|NCT02839967|Other|Phototherapy placebo|The volunteers will be subjected to the same Group intervention, Phototherapy and the researcher will receive the equipment unaware if the pen that will apply the phototherapy is active or placebo, only the research coordinator will have this knowledge, and for this group the researcher will receive placebo pen. Fits the caveat that, when the voluntary participation, will be held with the active pen treatment.
1516996|NCT02839954|Biological|anti-MUC1 CAR-pNK cells|
1516997|NCT02839941|Drug|Iguratimod|Subjects will receive iguratimod orally, twice a day, for consecutive 52 weeks
1516998|NCT02839941|Drug|Mycophenolate mofetil|All subjects will receive mycophenolate mofetil for consecutive 52 weeks
1516999|NCT02839941|Drug|Tacrolimus|All subjects will receive tacrolimus for consecutive 52 weeks
1517000|NCT02839941|Drug|Glucocorticoids|All subjects will receive glucocorticoids for consecutive 52 weeks
1517001|NCT02839928|Drug|Intranasal ketamine|The experimental arm consists of an single intranasal administration of Ketamine (Ketalar).
1517002|NCT02839928|Device|Intranasal atomizer|Ketamine will be applied to each nare via intranasal atomizer
1517003|NCT02839928|Drug|EMLA|
1517004|NCT02839915|Drug|Folinic Acid|Capsule form, taken twice a day with a max dose of 50 mg
1517005|NCT02839915|Other|Placebo|Inactive placebo comparator
1517008|NCT02839889|Drug|Naloxegol|Naloxegol 25mg tablets for two weeks, followed by a two week open-label period
1517009|NCT02839889|Drug|Placebo|Placebo once daily for two weeks, followed by two week open-label period
1517010|NCT02839876|Drug|Intravenous acetaminophen|Subject receives 1 g acetaminophen by the intravenous route every 6 hours for 4 doses beginning in the preoperative holding area.
1517011|NCT02839876|Drug|Oral acetaminophen|Subject receives 1 g acetaminophen by the oral route every 6 hours for 4 doses beginning in the preoperative holding area.
1517012|NCT02839850|Device|Cementless Total Knee Arthroplasty|Patients will undergo a primary total knee replacement using one of the two configurations of the ATTUNE Cementless knee (CR RP or PS RP)
1517013|NCT02839837|Behavioral|Aerobic Exercise|Aerobic exercise will be performed on a stationary cycle ergometer for 15 minutes at an intensity of 35% heart rate reserve or 70% heart rate reserve. During the control condition the participant will remain seated on the stationary cycle for 15 minutes and will not perform exercise.
1517022|NCT02839759|Other|TELLYHealth|Educational videos and vehicle for Q&As on hearing aid use and issues.
1517023|NCT02839720|Other|Laboratory Biomarker Analysis|Correlative studies
1517024|NCT02839720|Drug|Selumetinib|Given PO
1517030|NCT02839694|Drug|decitabine (DAC)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
1517031|NCT02839694|Drug|Tetrahydrouridine (THU)|Administered IV at increasing frequency or dose from 3-5 times per week for 8-12 weeks
1517032|NCT02839694|Drug|Celecoxib|400 mg orally twice a day every day for while on DAC-THU therapy
1517034|NCT02839668|Drug|Lidocaine|Continuous infusion of lidocaine
1517035|NCT02839668|Drug|Sevoflurane|maintenance of hypnosis during anaesthesia with sevoflurane
1517036|NCT02839668|Drug|TIVA-TCI|maintenance of hypnosis during anaesthesia with sevoflurane
1517037|NCT02839668|Drug|Acetaminophen|administration of 1 g acetaminophen for postoperative analgesia
1517038|NCT02839668|Drug|Tramadol|administration of tramadol for postoperative analgesia
1517039|NCT02839668|Drug|Neostigmine|A 0.05 mg/kg dose of neostigmine will be administered to antagonize the neuromuscular block at the end of surgery.
1517040|NCT02839668|Drug|Atropine|A 0.2 mg/kg dose of atropine will be administered at the end of surgery to attenuate the parasymatomimetic effects of neostigmine
1517041|NCT02839668|Device|BIS|For the groups receveing TIVA-TCI anesthesia the bispectral index will be monitored
1517042|NCT02839655|Device|Da Vinci Xi|
1517043|NCT02839642|Drug|Rivastigmine|
1517044|NCT02839642|Drug|Placebo|
1517045|NCT02839629|Other|Non-Interventional|
1517046|NCT02839616|Procedure|orthotopic liver transplantation|
1517047|NCT02839590|Device|HiFU|Ciliary Ablation Treatment ( HiFu ultrasound treatment)
1517048|NCT02839590|Device|Baerveldt implant|External (sub-conjunctival) Drainage Surgery (Baerveldt implant)
1517049|NCT02839590|Device|Ahmed implant|External (sub-conjunctival) Drainage Surgery (Ahmed Implant)
1517050|NCT02839590|Device|STARflo|Suprachoroidal Shunt Surgery (STARflo)
1517051|NCT02839590|Device|Hydrus Microstent implant|Trans-trabecular meshwork implants (Hydrus Microstent implant).
1517052|NCT02839590|Device|iStent implant|Trans-trabecular meshwork implants (iStent implant).
1517053|NCT02839590|Device|Kahook Dual Blade|It removes part of the trabecular meshwork
1517054|NCT02839577|Drug|High Volume injection without corticosteroid|"Injection with 10 mls 0.5% bupivacaine hydrochloride and
• 40 ml saline around the tendon."
1517055|NCT02839577|Drug|High Volume injection with corticosteroid|Injection with 10 mls 0.5% bupivacaine hydrochloride, 20 mg Depomedrol and 40 ml saline around the tendon.
1517056|NCT02839564|Procedure|Laparoscopic adhesiolysis|After diagnostic laparoscopy to confirm adhesions and exclude other pathology laparoscopic adhesiolysis was performed
1517057|NCT02839564|Procedure|Diagnostic laparoscopy|After diagnostic laparoscopy to confirm adhesions and exclude other pathology treatment was stopped.
1517058|NCT02839551|Procedure|simplified drug provocation test|Assessment of the Hypersensitivity to betalactams by simplified drug provocation test
1517059|NCT02839538|Procedure|Local Infiltration|Injection at perianal region with ropivacaine 0.75%(20ml)
1517060|NCT02839538|Procedure|Subarachnoidal block|Injection at subarachnoidal space with bupivacaine 0.5% ( 2ml)
1517061|NCT02839525|Dietary Supplement|Omega 3|3000mg of n-3 oil (2000mg EPA e 1000mg DHA)
1517062|NCT02839525|Dietary Supplement|Isolate whey protein|23g of protein of whey protein
1517063|NCT02839525|Dietary Supplement|Omega 3 and Isolate whey protein|3000mg of n-3 oil (2000mg EPA e 1000mg DHA) and 23g of protein of whey protein
1517064|NCT02839525|Other|Eccentric exercise|100 maximal eccentric contractions of knee extensors, divided into 10 sets of 10 repetitions at intervals of 60 seconds between the series
1517065|NCT02839512|Device|Jejunal to Ileal Diversion|The Jejunal to Ileal Diversion procedure will be performed using colonoscopes to place magnets to create a side to side compression anastomosis. The colonoscope delivered magnet creates the proximal end of the anastomosis approximately 100 cm distal from the ligament of Treitz. The colonoscope delivered magnets creates the distal end of the anastomosis approximately 100 cm proximal from the ileocecal junction.
1517066|NCT02839499|Device|RU sleeping®|Each patient included in the study has a test by RU-sleeping. The diagnosis of obstructive sleep apnea syndrome will be asked for an index of respiratory events estimated as greater than or equal to 10.
1517067|NCT02839499|Other|autonomy scale (ADL and AGGIR)|autonomy data
1517068|NCT02839499|Other|various activity scale (IADL)|activity of life data
1517069|NCT02839486|Other|vancomycin pharmacokinetics|vancomycin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
1517070|NCT02839486|Other|cefoxitin pharmacokinetics|cefoxitin serial plasmatic and ultrafiltrate samples in order to assess plasmatic and ultrafiltrate drug concentrations
1517071|NCT02839473|Device|Castalie water spray|
1517072|NCT02839473|Device|Hydrogel Hydrosorb®|
1517073|NCT02839460|Procedure|Outpatient Muscle Biopsy|Outpatient Muscle Biopsy involving skeletal muscle sample collected from the vastus lateralis muscle
1517074|NCT02839447|Other|no intervention|
1517075|NCT02839434|Procedure|Blood sample|This blood sample does not require specific puncture because it is made on the occasion of a sample justified by the patient monitoring.
1517076|NCT02839421|Drug|Scaling and Root Planing combined with moxifloxacin|Scaling and Root Planing combined with systemically administered moxifloxacin (MOX) 400 mg, once daily for 7 days
1517077|NCT02839408|Dietary Supplement|Lactobacillus rhamnosus SP1|Sachet containing Lactobacillus rhamnosus SP1
1517078|NCT02839408|Drug|Azithromycin|Tablet containing 500mg Azithromicyn
1517079|NCT02839408|Other|Talc powder|Sachet containing talc powder and tablet containing talc powder
1517080|NCT02839408|Procedure|Periodontal treatment Scaling and root planning|
1517081|NCT02839395|Other|No intervention- base line|the subject will sited in a dim light room. No screen light illumination.
1517082|NCT02839395|Other|Acute|The subject will be sited in front of computer screen light illumination for 2 hours.
1517083|NCT02839395|Other|Chronic|The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
1517225|NCT02838264|Drug|Itraconazole|200 mg oral dose of itraconazole on Days 1 to 11 during Period 2
1517087|NCT02839369|Other|walking under varies conditions|The children were asked to walk an electronic mat, three cycles for each one of the different trials as comfortable regular speed, walking as fast and as slow as possible, walking on straight line etc
1517088|NCT02839369|Other|walking under varies conditions|walking on electronic walkway under different conditions
1517089|NCT02839356|Drug|epinephrine|20-mL irrigation with epinephrine diluted to 0.02% in saline over the entire papilla
1517090|NCT02839356|Drug|normal saline|20-mL irrigation with physiological saline over the entire papilla
1517091|NCT02839343|Radiation|radiation therapy|
1517092|NCT02839343|Procedure|surgery|
1517093|NCT02839343|Drug|mFOLFIRINOX|oxaliplatin IV, irinotecan IV, leucovorin IV and 5-FU IV
1517094|NCT02839343|Drug|FOLFOX|oxaliplatin IV, leucovorin IV and 5-FU IV
1517097|NCT02839317|Biological|Biological|comparison of microbiota, genetic profile between pediatric- and elderly-onset CD
1517098|NCT02839304|Device|PolarStar System|Pulmonary Vein Isolation
1517099|NCT02839291|Other|quality of life questionaries|
1517100|NCT02839291|Drug|intravenous or oral bone antiresorptive treatments|
1517101|NCT02839278|Biological|Blood sample|
1517102|NCT02839265|Drug|FLT3 Ligand Therapy (CDX-301)|See Arm 1 descriptions
1517103|NCT02839265|Radiation|Stereotactic Body Radiotherapy (SBRT)|See Arm 1 descriptions
1517104|NCT02839252|Behavioral|Iggy and the Inhalers Asthma Education for Kids|It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
1517105|NCT02839239|Dietary Supplement|Drops with lactobacilli and vitamin D3|Oil suspension with lactobacilli and vitamin D3
1517106|NCT02839239|Dietary Supplement|Drops with vitamin D3|Oil suspension with vitamin D3
1517107|NCT02839226|Drug|AR/101|
1517108|NCT02839226|Drug|Placebo|
1517109|NCT02839213|Drug|Hyoscine Butyl bromide|
1517110|NCT02839213|Drug|Saline|
1517111|NCT02839200|Drug|ACT-541468 5 mg|Capsule for oral administration containing ACT-541468 at a strength of 5 mg
1517112|NCT02839200|Drug|ACT-541468 10 mg|Capsule for oral administration containing ACT-541468 at a strength of 10 mg
1517113|NCT02839200|Drug|ACT-541468 25 mg|Capsule for oral administration containing ACT-541468 at a strength of 25 mg
1517114|NCT02839200|Drug|Zolpidem|Over-encapsulated zolpidem tablet at a strength of 10 mg
1517115|NCT02839200|Drug|Placebo 1|Placebo capsules matching ACT-541468 capsules
1517116|NCT02839200|Drug|Placebo 2|Placebo capsules matching over-encapsulated zolpidem
1517117|NCT02839187|Radiation|Neuroimaging|AV45-positron emission tomography
1517118|NCT02839161|Biological|Na-GST-1/Alhydrogel|
1517119|NCT02839161|Biological|Na-APR-1 (M74)/Alhydrogel|
1517120|NCT02839161|Biological|Hepatitis B Vaccine|
1517121|NCT02839148|Dietary Supplement|Food supplementation|"Arm 1 will be given food supplementation (FS), psychosocial stimulation (PS) and routine clinical care will be given and arm will be provided only with routine clinical care.
The control children will receive routine clinical care but no FS or PS."
1517122|NCT02839135|Drug|Reformulated scopolamine patch|Reformulated scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with deliver approximately 1.0 mg over 72 hours
1517123|NCT02839135|Drug|Marketed scopolamine patch|Marketed scopolamine patch of 1.5 mg (+/- 0.3 mg) /system of 2.5 cm2 surface area with delivery of approximately 1.0 mg over 72 hours.
1517124|NCT02839122|Drug|Tadalafil|
1517125|NCT02839122|Drug|Dutasteride|
1517126|NCT02839096|Drug|Placebo|Cellulose placebo that will be used in place of a second dose of ferrous sulfate in the subjects randomized to once daily dosing of ferrous sulfate
1517127|NCT02839096|Drug|Ferrous Sulfate|Subjects will receive once or twice daily dosing of ferrous sulfate. This will be provided by our hospital pharmacy and be identical in appearance to the placebo.
1517128|NCT02839083|Other|Thoracic Paravertebral group|Thoracic paravertebral block is performed using bupivacaine 0.25% in a total volume of 30 ml
1517129|NCT02839083|Other|Pecs II group|Ultrasound guided ipsilateral Pecs II block is performed using bupivacaine 0.25% in a total volume of 30 ml
1517130|NCT02839070|Other|Sleep/Wake Schedule|Timing of sleep and wake
1517131|NCT02839057|Procedure|Non-surgical treatment|Cervical collar immobilisation for 12 weeks.
1517132|NCT02839057|Procedure|Surgical treatment|Stabilisation of C2-fracture by posterior fusion C1-C2, posterior fusion C2-C3, anterior fusion C2-C3 (no postoperative collar) or anterior screw osteosynthesis C2 (postoperative collar for 6 weeks).
1517135|NCT02839031|Behavioral|"CBT (Cognitive-Behavioral Therapy)"|
1517136|NCT02839031|Behavioral|Control (telephonic support without CBT content)|
1517137|NCT02839005|Other|Continuous suture with polyglecaprone 25|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyglecaprone 25
1517138|NCT02839005|Other|Continuous suture with polyamide (nylon)|At the end of surgical procedemento of cesarean delivery , for skin closure continuous suture was performed with polyamide (nylon)
1517139|NCT02838992|Drug|Rabbit ATG, (Genzyme)|ATG is an infusion of rabbit-derived antibodies against human T cells, which is used in the prevention and treatment of acute rejection in organ transplantation and therapy of aplastic anemia
1517140|NCT02838992|Drug|Cy|Cyclophosphamide is a medication mainly used in chemotherapy. It is an alkylating agent of the nitrogen mustard type
1517141|NCT02838992|Drug|CsA|CsA is an immunosuppressant drug widely used in organ transplantation to prevent rejection. It reduces the activity of the immune system by interfering with the activity and growth of T cells
1517142|NCT02838992|Biological|Cord blood|Cord blood is blood that remains in the placenta and in the attached umbilical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and genetic disorders
1517143|NCT02838979|Dietary Supplement|L-glutamine|Oral Glutamine for 2 weeks at dose of 0.4mg/kg/day in three divided daily doses
1517144|NCT02838979|Dietary Supplement|Maltodextrin|Oral maltodextrin as described for the active agent: 2 weeks at dose of 0.4mg/kg/day in three divided daily doses.
1517145|NCT02838966|Dietary Supplement|Nestle IMPACT Advanced Recovery|
1517146|NCT02838966|Dietary Supplement|Nestle Boost High Protein Drink|
1517147|NCT02838953|Behavioral|Pulmonary Rehabilitation|Comprehensive intervention based on a thorough patient assessment followed by patient- tailored therapies that include, but are not limited to, exercise training, education, and behavior change, designed to improve the physical and psychological condition of people with chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.
1517148|NCT02838940|Procedure|Blood samples.|"At the beginning of the first incision in the skin, first blood sample will be taken for levels of antibiotics in serum test.
Second blood sample for drug levels in serum test, will be taken while closing the surgical incision in the skin at the end of the operation."
1517149|NCT02838940|Drug|Cefazolin|According to the ward protocol prior to the anesthesia by an anesthesiologist, the women will receive one dose of 1 g Cefazolin the usual loading dose. Women with a BMI over 30 will receive Cefazolin of about 2 grams.
1517150|NCT02838927|Other|No intervention|No intervention
1517151|NCT02838914|Procedure|radiofrequency ablation (RFCA)|Patients undergo radiofrequency ablation (RFCA)
1517154|NCT02838888|Device|Automatic polyp detection software|A computer program for the detection of colonic polyps will be used during colonoscopy
1517155|NCT02838875|Procedure|Blood samples|After birth - taking blood sample from the umbilical cord (arterial and venous) + blood sample from the patient.
1517156|NCT02838849|Dietary Supplement|Fiber|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men), keeping the usual liquid intake
1517157|NCT02838849|Dietary Supplement|Fiber and Water|Fiber composed of wheat bran, pectin and green banana flour (total daily amount of 13 g for women and 20 g for men) plus 2 liter of water/day
1517158|NCT02838836|Procedure|Study sample collection|Blood draws, urine and tissue asservation, and bone marrow aspiration will be done during surgery
1517160|NCT02838810|Drug|peginterferon alfa|peginterferon alfa-2b or peginterferon alfa-2a
1517161|NCT02838810|Drug|Nucleoside analogues|Nucleoside analogues
1517162|NCT02838797|Drug|RQ-00000010|orally administered serotonin 4 receptor partial agonist
1517163|NCT02838797|Drug|Placebo|oral acetate buffer
1517166|NCT02838771|Other|Water drinking test|Patient takes a sip of water about 60-70 ml. We assess: coughing, choking, voice changes.
1517167|NCT02838771|Other|Dysphagia screening questionnaire|Lithuanian version of the questionnaire consists of 16 questions. Interpretation of dysphagia screening questionnaire: advanced symptom - 2 points, moderate intensity symptom - 1 point, no symptom - 0 point. At least one advanced symptom means - dysphagia. Higher score represents stronger dysphagia intensity. The maximum score is 32 points.
1517173|NCT02838732|Dietary Supplement|L-carnitine|
1517174|NCT02838719|Drug|Perineural Dexamethasone acetate|
1517175|NCT02838719|Drug|Intravenous dexamethasone acetate|
1517176|NCT02838706|Procedure|Surgery for hip fracture|
1517177|NCT02838693|Procedure|Not applicable. This is an observational study.|Not applicable. This is an observational study.
1517178|NCT02838680|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
1517179|NCT02838667|Procedure|Standard of Care plus Nephrology Care|
1517180|NCT02838654|Procedure|cervical epidural injection|sensitivity, specificity, positive predictive value, negative predictive value
1517181|NCT02838641|Device|GeneXpert|Real time integrated and automated nucleic acid amplification test for detection of TB
1517182|NCT02838628|Drug|KX2-391|KX2-391 Ointment will be applied once daily for X consecutive days
1517183|NCT02838615|Procedure|epidural steroid (dexamethasone) injection|spinal injections performed in epidural space to relieve chronic low back pain or leg pain
1517184|NCT02838602|Radiation|Carbon ions therapy|External radiotherapy by accelerated carbon nucleus in a specialized hadrontherapy center
1517226|NCT02838251|Other|No intervention|
1517227|NCT02838238|Drug|Capecitabine|
1517228|NCT02838238|Drug|Placebo|
1517185|NCT02838602|Radiation|Advanced external radiotherapy by Xrays or protons|Radiotherapy by any appropriate advance procedure of photontherapy (IMRT, Volumetric Modulated Arc Therapy (VMAT), Tomo, etc.) or when possible by protontherapy or even a combination of both types of radiotherapy
1517186|NCT02838589|Drug|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
1517187|NCT02838589|Drug|Isotonic saline|Single dose of subcutaneous injection of 20 μL isotonic saline (placebo).
1517188|NCT02838576|Drug|Conjugated Equine Estrogen|Use of conjugated equine estrogen for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
1517189|NCT02838576|Drug|Placebo|Use of placebo for 12 weeks. Adherence will be monitored during periodical hospital visits in order to receive pills.
1517190|NCT02838563|Other|SIWA|To investigate the scale reliability over time, SIWA are assessed twice, ten minutes apart. To investigate the validity of the tool, SIWA is correlated with another quality of life questionnaire (QoL-AD), a quality of health scale including an analog portion (EQ 5D), and a behavioral disorder scale (Neuropsychiatric Inventory, NPI).
1517191|NCT02838550|Behavioral|Motivational Online Intervention|"The self-administered Motivational Online Intervention developed by the authors was based on the Transtheoretical Model of Change. It attempts to facilitate the decisional balance, the increase of the self-efficacy, and the use of experiential and behavioral processes of change (e.g., consciousness raising, counterconditioning, reinforcement management, stimulus control). The main objective is to deliver information to increase the motivation to practice physical activity and to set individualized goals. It has a total length of 45 minutes, and it is delivered in a web platform at the beginning of the intervention."
1517192|NCT02838550|Behavioral|Pedometer|Wearing a pedometer of new generation that provides motivational messages from time to time to motivate the user to increase the physical activity, as well as information in the screen regarding all-day activity: steps taken, calories burned, distance travelled, floors climbed and active minutes.
1517193|NCT02838537|Drug|Exposure to Triptan|
1517194|NCT02838537|Drug|Exposure to Ergot|
1517195|NCT02838511|Other|Modified Frailty Index (MFI)|non-cardiac surgical patients will have frailty evaluated
1517196|NCT02838511|Other|Hopkins Frailty Score (HFS)|non-cardiac surgical patients will have frailty evaluated
1517197|NCT02838498|Device|ERCP Mechanical Simulator (EMS)|Hands on EMS training
1517198|NCT02838485|Other|Mirror|The healthy hand will be mirrored and the amputated hand unseen by the subject while performing hand movements.
1517199|NCT02838485|Other|Imagery|The subject will be asked to imagine performing hand movements.
1517200|NCT02838472|Drug|Ascorbic Acid|Ascorbic acid administration at a doses of 75-80% of the upper limit of allowance according to IOM
1517201|NCT02838446|Procedure|Cognitive Therapy|"Graded Motor Imagery has three stages:
Lateralisation (2 or 3 weeks) Motor Imagery (2 or 3 weeks) Mirror Therapy (2 or 3 weeks)"
1517202|NCT02838433|Other|biological samples|blood and tissue samples
1517205|NCT02838407|Other|BAL fluid sampling|Following routine BAL procedures at the hospital, collection of BAL fluid samples: at least 2 mL, at Day 0.
1517206|NCT02838407|Other|Nasopharyngeal swab sampling|1 swab, Day 0
1517207|NCT02838394|Procedure|Dry needling|Acupuncture filiform needles are inserted into myofascial trigger points
1517208|NCT02838394|Other|Sham dry needling|Blunted needles will be pressed against the skin, but no actual penetration will occur
1517209|NCT02838381|Other|Additional biological samples|blood and tissue samples
1517210|NCT02838355|Device|Respiratory Depression Monitoring with End Tidal Carbon Dioxide Nasal Cannula (ETCO2- NC)|The ETCO2-NC is a non-invasive device that monitors the amount of carbon dioxide that is exhaled with every breath.
1517211|NCT02838355|Other|Standard Non-invasive Respiratory Depression Monitoring|Standard non-invasive respiration monitoring includes telemetry of heart rate and rhythm, respiratory rate, blood pressure, CF-LVAD flow, and oxygen saturation (SpO2) via pulse oximetry.
1517212|NCT02838342|Drug|Metronomic cyclophosphamide|50 mg oral tablet, one tablet per day, every day for 6 months; abort if progression or intolerance
1517213|NCT02838342|Drug|Interferon-alpha|3 months of treatment from the 4th cycle metronomic cyclophosphamide : subcutaneous injection, initial dose of 3 MIU three times a week. The dose may be adjusted as tolerated to achieve a T cell counts greater than 500 / mm3
1517214|NCT02838329|Other|warming of ropivacaine for BT|
1517215|NCT02838329|Drug|Ropivicaine|
1517216|NCT02838316|Drug|Autologous Muscle Derived Cells for Gastro-Intestinal Repair (AMDC-GIR)|Autologous muscle derived stem cells
1517217|NCT02838303|Other|Organophosphate|Chlorpyrifos 50% plus cypermethrin 5%, WHO Class II: Moderately hazardous
1517218|NCT02838303|Other|Placebo|Multineem, WHO Class U: Unlikely to present acute hazard in normal use
1517219|NCT02838290|Other|Induction|Participants will be randomly assigned (computer generated straight away after clicking the link to the research) to one of 4 experimental conditions: stress at work, dealing with a patient's death, managing stress at work or all topics together. Each module includes brief reflection parts and quizzes. Participants will be asked to fill in an online survey just before the induction and a week after. The survey is about current occupational distress and organizational factors.
1517220|NCT02838290|Other|Control group|Participants in the control group will be asked to fill in an online survey, but will not have any task at time-1. However, participants in the control group will be invited to complete induction programme after time-2 (a week time after time-1) in ensure the same expectations in both, experimental and control, groups.
1517221|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 50 mg on Day 1 of Period 1 and Day 5 of Period 2
1517222|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 75 mg on Day 1 of Period 1 and Day 5 of Period 2
1517223|NCT02838264|Drug|PF-06463922|Single oral dose of PF-06463922 100 mg on Day 1 of Period 1 and Day 5 of Period 2
1517224|NCT02838264|Drug|PF-06463922|Highest safe single oral dose (mg) of PF-06463922 identified in the previous cohorts will be administered on Day 1 of Period 1 and Day 5 of Period 2
1517229|NCT02838225|Drug|Docetaxel, Doxorubicin|
1517230|NCT02838225|Drug|Docetaxel, Doxorubicin, Cyclophosphamide|
1517231|NCT02838212|Drug|adverse drug reaction|drug-related death
1517232|NCT02838199|Device|SAPIEN 3|
1517233|NCT02838199|Procedure|SAVR|
1517234|NCT02838186|Procedure|retroflexion|examination of the right colon with scope retroflexion
1517235|NCT02838186|Procedure|forward view|examination of the right colon in forward view
1517236|NCT02838173|Procedure|serratus plane bloc : Ropivacaine 2mg/ml (0,3ml/kg)|
1517237|NCT02838173|Procedure|tissue infiltration : Ropivacaine 2mg/ml (0,3ml/kg)|
1517238|NCT02838173|Procedure|serratus plane bloc : placebo|
1517239|NCT02838173|Procedure|tissue infiltration : placebo|
1517240|NCT02838160|Behavioral|Routine Care|After baseline measurement, Group 1 did not receive any intervention or education.
1517241|NCT02838160|Behavioral|Routine care Plus the designed booklet|Group 2 received only the designed booklet without any participation in the oral presentation.
1517242|NCT02838160|Behavioral|Routine care Plus the designed booklet Plus participation in oral presentations|Group 3 participated in oral presentations 14 days after completing self-study booklet. Interactive, standardized and mandatory oral presentations were held five times to ensure maximum attendance of the three nursing shifts.
1517243|NCT02838160|Behavioral|Routine care Plus the designed booklet Plus participation in oral presentations Plus clinical teaching in bedside|The Group 4 received clinical teaching in bedside after completing self-study booklet and a series of interactive, standardized and mandatory 90-120-minute oral presentations.
1517244|NCT02838147|Device|FreeStyle sensors.|Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.
1517245|NCT02838147|Device|Glucometer|Patients with pathological OGTT - 1 abnormal value Patients with pathological OGTT - 2 abnormal value
1517246|NCT02838134|Other|Rocuronium|A bolus of 0.7 mg/kg rocuronium is administered just after tracheal intubation and then an infusion of rocuronium (0.3 to 0.4 mg/kg) is started when PTC is more than 0 and titrated towards PTC 1-2.
1517247|NCT02838134|Other|No additional Rocuronium|No additional rocuronium is administered after tracheal intubation.
1517248|NCT02838121|Drug|Aclasta|Aclasta once annually for 2 years
1517249|NCT02838121|Drug|Placebo|No IV aclasta
1517250|NCT02838095|Behavioral|Nap|A 1-hour daytime nap opportunity
1517251|NCT02838082|Behavioral|Sleep Hygiene Protocol|Sleep Hygiene Protocol involving 1) Improved sleep environment 2) Enhanced Circadian Stimuli 3) Increased Daytime Activation (blue light therapy, daytime light exposure and daytime sleep restriction) 4) Adjusted morning ADL routines and 5) Restricted Caffeine intake
1517252|NCT02838082|Behavioral|Standard of Care|All standard of care procedures in a specialized traumatic brain injury inpatient rehabilitation unit
1517253|NCT02838069|Biological|Injection (2x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (2x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
1517254|NCT02838069|Biological|Injection (10x106 ASC/5ml).|Injection of Autologous adipose derived stem cells (10x106 ASC/5ml). The patient of this group will receive one single administration of the cells and will be followed for 12 months. A final follow up visit will occur at Month 24.
1517255|NCT02838069|Other|Placebo|Injection of placebo 0.5% glucose in saline with 4.5% alb/5ml The patient of this group will receive one single administration and will be followed for 12 months. A final follow up visit will occur at Month 24.
1517256|NCT02838056|Drug|epidural injection|drug combination: 2% lidocaine 17 ml + 2 ml alfentanil (544 mcg x 2 = 1088 mcg) + 7% sodium bicarbonate 2.3 ml (1.9 mEq) + 0.1mg epinephrine (1:200000)
1517257|NCT02838043|Dietary Supplement|Probio'Stick|A combination of the probiotic strains Lactobacillus helveticus and Bifidobacterium longum
1517258|NCT02838030|Drug|L-arginine|
1517259|NCT02838030|Drug|Placebo (for L-arginine)|
1517260|NCT02838030|Drug|acetylsalicylic acid|
1517261|NCT02838017|Device|Dermabond|
1517262|NCT02838017|Device|Steri-Strips|
1517263|NCT02838004|Device|IOL MINI WELL READY|IOL MINI WELL READY implant
1517264|NCT02837991|Drug|CDX-014|
1517265|NCT02837978|Drug|Tacrolimus|Tacrolimus capsule: 0.5mg to 1mg, po, twice per day (Bid) until the endpoint or unacceptable toxicity develops.
1517266|NCT02837978|Drug|MTX|MTX： 7.5mg to 15mg, po, once per week (Qw) until the endpoint or unacceptable toxicity develops.
1517267|NCT02837965|Drug|treatment with topical superpotent corticosteroid therapy|
1517268|NCT02837965|Drug|treatment with systemic therapy (methotrexate)|
1517269|NCT02837965|Drug|treatment systemic therapy (prednisone)|
1517270|NCT02837965|Drug|treatment with systemic therapy (prednisone)|
1517271|NCT02837965|Drug|treatment with systemic therapy (doxycycline)|
1517272|NCT02837952|Drug|FDC IBU/APAP 250 mg/500 mg|FDC IBU/APAP 250 mg/500 mg
1517273|NCT02837952|Drug|Placebo|Placebo
1517274|NCT02837939|Drug|Human derived Transfer factor|"One dose (the content of one amp.) of lyophilised drug contains:
Leucocyte dialysatum 200 x 10 to the power of 6 (Lyophilized dialysate from 200 million leukocytes) pH = 7.8 to 9 after reconstitution (dissolving) of drug
To be administered subcutaneously as follows:
12 doses TF in total:
3 x TF in first week: day 1,3,5
2 x TF in week 2: day 8 , 11
1 xTF in week 3 and 4 : day 15, 22
1 x TF once a month up to 6 month"
1517275|NCT02837939|Drug|Aqua pro injectione 4ml ampules for subcutaneous injection|"12 doses in total:
3 doses in first week: day 1,3,5
2 doses in week 2: day 8 , 11
1 dose in week 3 and 4 : day 15, 22
1 dose once a month up to 6 month"
1517276|NCT02837926|Other|questionnaire|
1517277|NCT02837926|Biological|Gardasil vaccine|
1517278|NCT02837926|Biological|Cervarix®|
1517279|NCT02837913|Device|VitaHeat underbody heating mattress|Use of VitaHeat underbody heating mattress will be used for the intervention arm to reduce hypothermia post operatively
1517280|NCT02837900|Drug|TPX-100 200 mg 4 times weekly for 4 weeks|Ea. subject will received active TPX-100 200mg in the Left knee
1517281|NCT02837900|Drug|TPX-100 200 mg 4 times weekly for 4 weeks|TPX-100 100mg Right
1517282|NCT02837887|Behavioral|Computerized Cognitive Behavior Therapy|Undergo computerized cognitive behavior therapy
1517283|NCT02837874|Procedure|Isoperistaltic|Same direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the distal part of remnant stomach
1517284|NCT02837874|Procedure|Antiperistaltic|Reverse direction of peristalsis between stomach and jejunum, efferent loop of jejunum is located on the proximal part of remnant stomach
1517285|NCT02837861|Drug|Routine Nutritional Support plus supplemental IV amino acids|Enteral nutrition as tolerated Plus supplemental IV AA infusion to meet the target of 1.5-2.0gm protein/kg/day total starting within 24 hours of injury for 5 days.
1517286|NCT02837861|Other|Routine Nutritional Support|Enteral nutrition as tolerated.
1517289|NCT02837835|Drug|ceftazidime|20 mg/kg of body weight followed by 60 mg/kg/day
1517290|NCT02837835|Drug|ceftazidime|20 mg/kg over 30 min every 8 h
1517291|NCT02837822|Device|Spinal cord stimulator|Spinal cord stimulator is a reversible and minimally invasive neuromodulation device used for the treatment of various diseases related to chronic pain, including CRPS and FBSS. Briefly, this technology uses electrical pulses to generate action potentials in nerve cells that induce paresthesias (buzzing or tingling sensations) in the affected limb and can relieve pain.
1517292|NCT02837822|Procedure|Implantation of a spinal cord stimulator|The electrical pulses are induced by one or more electrodes surgically implanted into the epidural space. These electrodes are usually placed under the skin in the abdomen or upper buttock.
1517293|NCT02837809|Radiation|Low dose CT|annual CT vs biennial CT
1517294|NCT02837796|Procedure|transobturator tape|
1517295|NCT02837783|Drug|Linaclotide|Oral, once daily
1517296|NCT02837783|Drug|Placebo|Oral, one daily
1517297|NCT02837770|Drug|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
1517298|NCT02837770|Drug|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
1517299|NCT02837770|Drug|Oral Diclofenac|One Diclofenac Sodium sustained-release 75mg tablet administered per os 4 hours prior to the IVI.
1517300|NCT02837770|Drug|Diclofenac Eye Drops|One drop of Diclofenac 0.1% will be instilled 45' prior to the IVI.
1517301|NCT02837770|Drug|Pacebo pill|Pacebo pill will be administered 4 hours before the IVI.
1517302|NCT02837770|Drug|Artificial Tears|One drop Artificial Tears will be instilled 45' prior to the IVI.
1517303|NCT02837757|Other|Biological samples|blood and tumor tissue samples
1517306|NCT02837731|Device|Treatment Starling SV monitor|A dynamic assessment of fluid responsiveness will be performed at every clinical decision point for the first 72 hours of study enrollment. Fluid responsiveness will be assessed using a passive leg raise (PLR) and Starling SV hemodynamic monitor to guide corresponding treatment.
1517307|NCT02837718|Other|successful blockage|
1517308|NCT02837718|Other|unseccessful blockage|
1517309|NCT02837705|Other|blood draw|
1517314|NCT02837679|Other|Geriatric Follow up|
1517315|NCT02837666|Dietary Supplement|Supplementation with Spirulina maxima|Supplementation with Spirulina maxima (4.5 g/d) in capsules during 6 weeks.
1517316|NCT02837666|Other|Washout|2 weeks washout period to each study subject to avoid any possible carryover effect.
1517317|NCT02837666|Other|Supplementation with placebo|Supplementation with placebo (4.5 g/d) in capsules during 6 weeks.
1517318|NCT02837666|Other|Isoenergetic diet|All participants will have a personal isoenergetic diet according to their height, weight, body composition and daily physical activity during 14 weeks
1517319|NCT02837666|Other|Exercise program|Participants are going to exercise five days a week with the following protocol: Between 5 and 10 min of heating exercise, Between 20-30 min anaerobic exercise and 20-30 min of aerobic exercise (cardiovascular exercise): walking, jogging, running and/or cycling, Three days a week aerobic intensities will be between 60% and 80% and two days between 70% and 90% of the maximum heart rate reserve, and five final minutes of stretching.
1517320|NCT02837653|Behavioral|Physical Activity Counselling|
1517321|NCT02837653|Other|Therapeutic Exercise for LBP|
1517322|NCT02837653|Other|Superficial Thermotherapy|
1517323|NCT02837640|Drug|levodopa-carbidopa|sinemet 200/50 1/2 tablet b.i.d. for 2 days and then t.i.d for 6 months
1517324|NCT02837627|Other|Tube feeding|During the study period, enteral feeds will be administered according to different tube feeding modalities: bolus feeding followed by the removal of the feeding tube; bolus tube feeding with permanence of the feeding tube for the whole post-prandial period; continuous feeding over a 3-hour period.
1517325|NCT02837614|Drug|dexamethasone acetate|1 milliliter of dexamethasone (4milligram) administered in the deltoid muscle before commencement of surgical procedure
1517383|NCT02837081|Other|Prospective audit strategy of antimicrobial stewardship|applying prospective audit as a different strategy of antimicrobial stewardship
1517384|NCT02837081|Other|preauthorization strategy of antimicrobial stewardship|applying preauthorization as one strategy of antimicrobial stewardship
1517326|NCT02837614|Drug|submucosal dexamethasone injection|Local anesthesia was achieved using 2% lignocaine hydrochloride and 1:100 000 adrenaline and a standard technique was followed to block Inferior alveolar, lingual and long buccal nerve in all patients. In Group B patients, 1 ml of dexamethasone was administered in submucosa. Investigators divided 1 ml Dexamethasone is into 0.4 milliliter, 0.3 milliliter and 0.3 milliliter parts. Following the local anesthesia, each part of dexamethasone was injected submucosally in the buccal, lingual and retromolar region around the tooth to be extracted. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation and tooth elevated. The flap was sutured using three simple interrupted 3-0 black braided silk suture. All patients were given amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively.
1517327|NCT02837614|Procedure|Third molar surgery|Surgical access was gained through standard Terrence Ward's incision to raise a full thickness mucoperiosteal flap. Bone removal done around the tooth using a round bur under copious 0.9% normal saline irrigation. The tooth sectioned at cemento-enamel junction whenever required and a Coupland elevator is used to elevate tooth or fragmented tooth out of socket. The socket examined for any debris and sharp bony margins smoothened. The empty socket was irrigated copiously and flap was sutured using three simple interrupted 3-0 black braided silk suture.
1517328|NCT02837614|Drug|Amoxicillin and paracetamol|Amoxicillin 500 milligram every 8 hours orally for 5 days, and 500 milligram of paracetamol postoperatively (every 6 hours 1 tablet for 2 days).
1517329|NCT02837601|Device|AirSeal® Insufflation System (AIS)|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® iFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal. Specifically, the AirSeal® System creates a pressure barrier within the proximal housing of the cannula which acts as an invisible seal to maintain pneumoperitoneum during the course of surgery. It utilizes a re-circulation and filtration control unit (AirSeal® iFS) designed specifically for the AirSeal® Access Port to create and maintain the pressure barrier.
1517330|NCT02837588|Device|Hyperthermy treatment with MJS electrode|30 patients who are diagnosed Pelvic pain with myofascial syndrome by gyneacologist or urologist goes to Pelvic Floor Physiotherapist for 4 session with hyperthermy treatment with MJS electrode at pelvic floor trigger points
1517331|NCT02837575|Biological|VCL-HB01|Investigational Product
1517332|NCT02837575|Other|Phosphate-buffered saline|Placebo
1517333|NCT02837562|Other|Slit lamp eye examination|All participants in the trial will undergo a slit lamp eye examination
1517335|NCT02837536|Other|Horizontal iCare|IOP of the right eye will be measured using the iCare tonometer held in the horizontal position first and then in the vertical position.
1517336|NCT02837536|Other|Vertical iCare|IOP of the right eye will be measured using the iCare tonometer held in the vertical position first and then in the horizontal position.
1517337|NCT02837510|Behavioral|Standard smoking cessation counseling|Participants will discuss reasons for quitting, the model of smoking as a learned habit, triggers for smoking, and trigger management; receive brief training in how to manage withdrawal symptoms and relapse prevention counseling and receive the NCI Clearing the Air self-help smoking cessation booklet. The target quit date (TQD) session will be scheduled to occur up to 2 weeks following the pre-quit session. Participants will then meet with a smoking cessation counselor for a 15 minute booster counseling session. During the first week following TQD there will be two monitoring visits to closely monitor abstinence. Weekly thereafter for four weeks, participants will attend a brief booster counseling session.
1517338|NCT02837497|Other|ICU-RESUS CPR Improvement Bundle|"Point-of-care CPR training
Post-cardiac arrest educational debriefings"
1517339|NCT02837484|Other|NuTech Affinity™ Membrane|NuTech Affinity™ Membrane is an aseptically produced hypothermically stored amniotic membrane patch.
1517340|NCT02837471|Device|PiezoRx medical grade pedometer|"Participants will be asked to freely use the PiezoRx medical grade pedometer for 12 weeks.
Participants have access to a personal account created online and can record the daily steps count and physical activity.
Participants will receive the standard care by the FrancoForme Cardiovascular rehabilitation and prevention program"
1517341|NCT02837458|Device|High-Frequency|high-Frequency electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1517342|NCT02837458|Device|Sham Stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1517343|NCT02837445|Device|BackBeat-PHC ON|Eligible patients randomized after optimization phase to PHC ON for 3 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator
1517344|NCT02837445|Device|BackBeat-PHC OFF|Eligible patients randomized after optimization phase to PHC OFF for 3 months. Patients continue standard or modified anti-hypertension medical regime at discretion of the investigator.
1517345|NCT02837432|Drug|Hydrocortisone acetate|
1517346|NCT02837432|Drug|Placebo|
1517347|NCT02837419|Behavioral|Health related Quality of life EQ-5D|
1517348|NCT02837393|Procedure|Ureteral catheterization|During ureteral catheterization, urine samples will be obtain from each kidney
1517349|NCT02837380|Drug|FF|FF is a dry white powder blended with lactose. It is the first strip of DPI. Per blister contains 100 mcg of dose
1517350|NCT02837380|Drug|VI/UMEC|VI and UMEC bromide combination is a dry white powder blended with lactose and magnesium stearate. It is the second strip of DPI. Per blister contains 25 mcg/62.5 mcg of VI/UMEC dose
1517351|NCT02837367|Genetic|Genetic modeling|
1517352|NCT02837367|Dietary Supplement|Administration of supplements containing methyl-donors|
1517353|NCT02837354|Other|No intervention|
1517354|NCT02837341|Device|Philips®Vital Sign Device - Camera-based system (Prototype)|"Respiratory rates monitored via camera-based system and capnography simultaneously The Philips Vital Sign Device will record chest movements by camera. The program will use an algorithm to convert the chest movements into the respiratory rate"
1517357|NCT02837315|Behavioral|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; a marijuana use decisional balance exercise; personalized marijuana-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students use marijuana and actual student norms, (b) a comparison of the student's marijuana use vs. norms, (c) drug-related problems experienced, (e) money spent on marijuana, and (f) alcohol norms and consequences if participants indicated they also drink alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if she or she indicates interest.
1517358|NCT02837315|Behavioral|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how marijuana use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
1517359|NCT02837315|Behavioral|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, students are asked about their reaction to the relaxation techniques and are provided with relaxation training handouts.
1517360|NCT02837302|Drug|Livact|Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.
1517361|NCT02837289|Other|Therapy taping|Therapy taping follows an anatomical pattern from the femur until tibia for correction of dynamic valgus with therapy taping.
1517362|NCT02837289|Other|Placebo taping|Placebo taping follows a different anatomical path without tension, eliminating all therapeutic process elements
1517363|NCT02837263|Radiation|Stereotactic body radiotherapy (SBRT)|"SBRT treatment will consist of 40-60 Gy delivered in five fractions prescribed to the planning target volume (PVT). Image guidance with MRI, megavoltage CT or cone beam CT scans would be required.
SBRT will be initiated on Day 0. This should be initiated within 4 weeks of signing informed consent. An additional 2 weeks will be allowed if necessary due to SBRT treatment planning."
1517364|NCT02837263|Drug|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. KeytrudaTM (pembrolizumab) has recently been approved in the United Stated for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilumumab and, if BRAF V600 mutation positive, a BRAF inhibitor.
1517365|NCT02837250|Behavioral|Pos4Health|This is a personalized, interactive, patient-centered Internet intervention targeting nonadherence to ART among substance users living with HIV.
1517366|NCT02837250|Behavioral|Patient Education|This is a patient education website with content about nonadherence to ART pertinent to substance users living with HIV.
1517367|NCT02837237|Drug|KBP-5074|"In Part 1 of the study, non-HD patients with severe CKD in Cohort 1 will receive a single oral capsule dose of KBP-5074 on Day 1 following a fast between 2 and 4 hours.
In Part 2 of the study, HD patients with severe CKD will receive a single oral capsule dose of KBP-5074 following a fast between 2 and 4 hours. The dose of KBP 5074 will be administered on Day 1 immediately following a dialysis session."
1517368|NCT02837224|Device|The Situate Detection System|The Situate Detection System for locating surgical sponges
1517369|NCT02837211|Behavioral|Tapered Low Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Tapered Diet Arm will undergo the following 24 week feeding study intervention.
The difference between a participant's run-in period energy intake and low-calorie prescribed energy intake (1000 kcal for women; 1200kcal for men) will be divided by six. At weekly intervals from weeks 1-6, daily caloric intake will be decreased by this fixed amount, reaching the final daily caloric goal (1000 kcals for women and 1200 kcals for men) by the end of the 6th week. Participants will present twice per week during weeks 1-6 to receive food that sums to that week's prescribed calorie level.
From weeks 7-24, these participants will then follow a traditional low-calorie diet, still presenting for food pickups twice per week at a stable caloric level during this period."
1517370|NCT02837211|Behavioral|Traditional Low-Calorie Diet|"All participants will start with a 3 week run-in period during which they are fed a diet at 1.4 x their resting metabolic rate (kcal). Participants who are weight stable at the end of run in and are randomized to the Traditional Diet Arm will undergo the following 24 week feeding study intervention.
Immediately following run-in, these participants will start a low-calorie diet (1000 kcal per day for women; 1200kcal for men) Participants will present twice per week during weeks 1-24 to receive food that sums to that week's prescribed calorie level."
1517371|NCT02837198|Drug|FYU-981|
1517372|NCT02837198|Drug|Topiroxostat|
1517373|NCT02837185|Procedure|Botulinum Toxin injection|Botulinum toxin injection for cervical dystonia subjects (as part of clinical care)
1517374|NCT02837185|Other|Physiological measures|These include TMS and EMG measurements
1517375|NCT02837172|Other|Diffusion Weighted Imaging (DWI)|"MDS-UPDRS,Montreal Cognitive Assessment, PDQ-39, DTI imaging (MRI), and neurological examination.
Expert evaluation: Record review, PD Medical History and PD Family History Form, the Montreal Cognitive Assessment, PDQ-39. standard, full, neurological examination, and MDS-UPDRS"
1517376|NCT02837159|Other|mHealth application|Dietary and physical activity recommendations trough a mobile application
1517377|NCT02837146|Biological|Tocilizumab (TCZ)|Induction phase: TCZ subcutaneously (162 mg weekly) from baseline to week 24
1517378|NCT02837146|Drug|Methotrexate (MTX)|Induction and maintenance phase: Methotrexate 15-20 mg/week from baseline to week 54
1517379|NCT02837133|Behavioral|integrated yoga program|the program as a one-time session for 3 hours as a component of a Stress Management Education program
1517380|NCT02837107|Dietary Supplement|Mind Master|80ml Mind Master / day for 8 weeks
1517381|NCT02837107|Dietary Supplement|Placebo|80ml a look-alike Placebo / day for 8 weeks
1517382|NCT02837094|Drug|C19-A3 GNP|
1517385|NCT02837068|Device|Wheelchair handrail compensator|Patients were treated by wheelchair handrail compensator for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks. The handrail compensator would help the paralysis upper limb kept the shoulder joint stretch forward, the elbow joint extend, the forearm in pronation, the wrist in flection and the fingers extend.
1517386|NCT02837068|Device|Ordinary wheelchair|Patients were treated by ordinary wheelchair for six times per week during the four-weeks treatment, with each treatment lasting at least 60 minutes, and follow up by eight weeks.The ordinary handrail could prevent the disable arm from sinking, but could not help the upper limp keep a normal position.
1517387|NCT02837055|Device|VivaSight intubation|patients are intubated with an endotracheal tube with an integrated camera
1517388|NCT02837055|Device|conventional intubation|patients are intubated with a conventional endotracheal tube
1517390|NCT02837029|Other|Laboratory Biomarker Analysis|Correlative studies
1517391|NCT02837029|Biological|Nivolumab|Given IV
1517392|NCT02837029|Radiation|Yttrium Y 90 Glass Microspheres|Given IA
1517395|NCT02837003|Drug|Aspirin|Discontinuation of aspirin at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
1517396|NCT02837003|Drug|Thienopyridine|Discontinuation of thienopyridine at 3 months after the Ultimaster sirolimus-eluting stent implantation by the physician's discretion.
1517397|NCT02836990|Device|Prevena Incision Management System|A negative pressure system which holds incision edges together and removes exudate and debris from site to prevent surgical wound infections
1517398|NCT02836990|Device|Dermabond|A surgical skin adhesive used to prevent surgical wound infections
1517399|NCT02836977|Drug|tegafur-uracil|Eligible patients will receive tegafur-uracil orally at a dose of 400mg/day (100mg/Cap., 2 capsules each time, twice a day) and folinic acid 30mg/day (15mg/Tab., 1 tablet each time, twice a day) for one year.
1517400|NCT02836964|Device|Dental Implant|Dental implant
1517401|NCT02836951|Other|Withdrawal of blood and CSF|Withdrawal of blood and CSF
1517402|NCT02836938|Other|Collection of exhaled breath volatile organic compounds|
1517403|NCT02836925|Drug|Sofosbuvir+Ledipasvir|"Patients with genotype 1 or genotype 4 Sofosbuvir 400 mg + Ledipasvir 90 mg
12 weeks in previously untreated infected patients
24 weeks for previously treated patients with uncertain subsequent retreatment options"
1517404|NCT02836925|Drug|Sofosbuvir+Ribavirin|"Patients with genotype 2 Sofosbuvir 400 mg + Ribavirin 1000 mg <75Kg / 1200 mg ≥75kg
· 12 weeks of treatment"
1517405|NCT02836925|Drug|Sofosbuvir+Ledipasvir+Ribavirin|"Patients with genotype 3 Sofosbuvir 400mg + Ledipasvir 90 mg + Ribavirin 1000mg <75Kg / 1200 mg ≥75kg
· 24 weeks of treatment"
1517406|NCT02836912|Other|Exercise|Besides the same information for the education group, exercise of upper extremity without loading, exercise of lower extremity, and training of respiratory muscles are used for the exercise group
1517407|NCT02836899|Drug|Nitric Oxide|Inhaled nitric oxide will be administered in a final concentration of 80 ppm. The treatment will begin at the onset of the cardiopulmonary bypass until to 24h after Intensive Care Unit (ICU) admission, including 2-4 hours of weaning from nitric oxide and careful hemodynamics monitoring.
1517408|NCT02836899|Other|Placebo|This is the placebo group. Nitrogen will be added instead of nitric oxide.
1517409|NCT02836873|Drug|Bexagliflozin|Bexagliflozin tablet, 20 mg
1517410|NCT02836873|Drug|Placebo|Placebo (inactive) tablet to match the active comparator
1517412|NCT02836847|Procedure|biological test|mutation and signal pathway activation status analysis
1517413|NCT02836847|Drug|GEMOX|Conventional chemotherapy:gemcitabine and oxaliplatin
1517414|NCT02836847|Drug|Cetuximab|
1517415|NCT02836847|Drug|Trastuzumab|
1517416|NCT02836847|Drug|Gefitinib|
1517417|NCT02836847|Drug|Lapatinib|
1517418|NCT02836847|Drug|Everolimus|
1517419|NCT02836847|Drug|Sorafenib|
1517420|NCT02836847|Drug|Crizotinib|
1517421|NCT02836834|Biological|JS-001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS-001.Each of the 3 dose levels will use 2 dose schedules: single dose, and repeated doses every 2 weeks. Subjects will be assigned to a dose schedule in the order of study entry.
1517422|NCT02836821|Drug|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
1517423|NCT02836821|Drug|Rifampicin Capsules|rifampicin was administered in the morning 2 hours after breakfast
1517424|NCT02836808|Behavioral|CAIPaDi|Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.
1517425|NCT02836795|Biological|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
1517426|NCT02836782|Procedure|Blood sample withdrawal|Blood withdrawal for HIV-DNA or HCV resistance test
1517427|NCT02836769|Behavioral|Rehabilitation Consult (RC)|The RC was designed to foster key contributors to self management in the participants. The RC is administered by a rehabilitation professional and consists of an initial one-hour face-to-face consult and follow-up appointment(s) 2-12 weeks later, either telephone or face-to-face. The initial consult consists of orientation, consultation, goal-setting, teaching cognitive strategies, introduction to online resources/action planning/planning coping responses, review/implementation intentions/scheduling follow-up. The follow-up consists of a reminder, reorientation, checking of progress on goals and plans, re-planning as necessary, and discharge or scheduling of further follow-up as necessary.
1517428|NCT02836743|Drug|Circadin|Slow-release melatonin
1517430|NCT02836730|Procedure|Low back pain surgery|
1517431|NCT02836717|Device|sacral nerve modulation|electric stimulation of the sacral nerve using an implanted electrode and stimulator
1517432|NCT02836704|Drug|INSULIN GLARGINE|"Pharmaceutical form: solution
Route of administration: subcutaneous injection"
1517433|NCT02836704|Drug|metformin|"Pharmaceutical form: table or capsule
Route of administration: oral administration"
1517434|NCT02836704|Drug|acarbose|"Pharmaceutical form: table or capsule
Route of administration: oral administration"
1517435|NCT02836691|Device|EKG (electrocardiogram)|Analysis of the heart rate variability with an electrocardiogram with a commercial device adapted to asthmatic patients using 12 leads, a respiratory band and a pulseoximeter.
1517436|NCT02836678|Biological|Ridge splitting, immediate implant, Nanobone with PRF.|"Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).
Alloplast bone graft material (Nanobone)
PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
1517437|NCT02836678|Biological|Ridge splitting, immediate implantand PRF.|"Dental implant (is a surgical component that interfaces with the bone of the jaw or skull to support a dental prosthesis).
PRF platelet rich fibrin. (second-generation Platelet rich plasma where autologous platelets and leucocytes are present in a complex fibrin matrix to accelerate the healing of soft and hard tissue)."
1517438|NCT02836665|Procedure|Telemedicine for dermatological emergency patients|"Study-related photographs of the skin lesion made by a tablet and anamnesis data are uploaded to the hospital information system medico. Those data can directly be processed by the dermatological investigator in charge who enters his diagnosis and his therapy proposal without being on site."
1517439|NCT02836652|Device|HeartMate II (HMII)|Left Ventricular Assist Device
1517440|NCT02836652|Drug|Warfarin|(INR Target 2.0-2.5, median 2.25, per standard of patient care)
1517441|NCT02836652|Drug|acetylsalicylic acid (ASA) therapy|(81mg/day)
1517442|NCT02836639|Drug|Busulfan|Busulfan 0.8 mg/kg four times per day from day -7 to day -5
1517443|NCT02836639|Drug|Etoposide|Etoposide 400 mg/m2 from day -5 to day -4
1517444|NCT02836639|Drug|Bendamustine|Bendamustine 200 mg/m2 starting dose on day -3 and -2
1517445|NCT02836626|Procedure|deep fascial mobilization|Pelvic and abdominal myofascial release techniques as described by Barnes will be performed to facilitate independent mobility between tissue layers as needed following the direction of palpated fascial tension. Following this, direct scar mobilization techniques as described by Manheim will be done, applying a stretch in the direction of palpated restriction . This involves applying deep pressure whose force and direction is dictated by the tightness the therapist palpates and the subject reports. These are each held until a release is felt (defined as a sudden relaxation of tissue tension), usually 60-120 seconds. Total treatment time will last 25 minutes. Treatments will include all the above techniques but the therapist will tailor each treatment to address palpated restrictions. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
1517446|NCT02836626|Procedure|superficial fascial mobilization|This group will undergo four 25-minute sessions of gentle superficial effleurage to the abdomen and posterior trunk followed by superficial skin rolling to the scar. Each treatment session will be terminated a) after 25 minutes or 2) when the patient asks to stop due to discomfort. Reasons for termination will be documented. Subjects will be instructed to carry on their normal routines between sessions and will not be given any home interventions. Treatment sessions will total four to occur within a three week time period.
1517447|NCT02836613|Biological|Galcanezumab|Administered SC
1517449|NCT02836587|Behavioral|Balance training|The interventional program will last 8 weeks with the intensity of two 60-minutes lectures a week. Training sessions will be delivered by a physiotherapist to small groups of patients (3-5). Participants will receive individualized exercises which will be focused on main 4 types - stance exercises, gait and transition exercises and strength exercises especially focused on muscle strength of the lower extremities. The difficulty level will be increased progressively after participant's ability to complete each exercise independently (e.g. eyes closed, exercises on balance equipment - wobble board, foam etc., addition of a secondary cognitive task). The training session will consist of a ten-minute warm-up followed by five-minute stretching, 30 minutes of balance training and 15 minutes of stretching and relaxation.
1517450|NCT02836574|Biological|Neo-Kidney Augment (NKA)|Autologous selected renal cells (SRC).
1517451|NCT02836561|Other|Telephone message|A pre-visit telephone intervention describing availability of long-acting reversible contraceptives at time of uterine evacuation
1517452|NCT02836548|Drug|Vorinostat|vorinostat 360 milligram once daily
1517453|NCT02836535|Behavioral|qualitative interviews|
1517454|NCT02836522|Behavioral|Assessment of Health-Related Quality|Demographic Questionnaire, ANCHOR HRSI, FACT-G, MDASI, Patient ECOG PS, PGIC
1517455|NCT02836509|Drug|Paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes.
1517456|NCT02836509|Drug|Ibuprofen|800 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
1517545|NCT02835846|Drug|Estrogen Cream|Participants are provided a vaginal estrogen cream (i.e., Premarin Cream® 0.625 mg conjugated estrogen/gram) and instructed to use 0.5 grams with an applicator twice weekly for 12 weeks.
1517546|NCT02835833|Drug|Nintedanib|Nintedanib will be given twice daily at either 150 mg or 200 mg.
1517461|NCT02836483|Drug|LCB01-0371 800mg, QD|Oral administration
1517462|NCT02836483|Drug|LCB01-0371 400mg, BID|Oral administration
1517463|NCT02836483|Drug|LCB01-0371 800mg, BID|Oral administration
1517464|NCT02836483|Drug|Tubes 3~5Tablet, QD|Oral administration
1517465|NCT02836483|Drug|Zyvox 600mg, BID|Oral administration
1517466|NCT02836470|Drug|LB1148|A total of 700 mL of drug product will be administered orally as a split dose before surgery.
1517467|NCT02836470|Drug|Placebo|A total of 700 mL of placebo will be administered orally as a split dose before surgery.
1517469|NCT02836431|Drug|Dexmedetomidine 1mcg/kg Intranasal|DEX 1 mcg/kg Intranasal
1517470|NCT02836431|Drug|Dexmedetomidine 2mcg/kg Intranasal|DEX 2 mcg/kg Intranasal
1517471|NCT02836431|Drug|Dexmedetomidine 1mcg Intravenous|DEX 1 mcg/kg Intravenously
1517472|NCT02836418|Drug|ATYR1940|ATYR1940 at a dose no greater than 3.0 mg/kg administered via IV infusion over 90 minutes once weekly.
1517473|NCT02836405|Device|Transcranial Magnetic Stimulation|Single pulses of TMS as well as continuous theta burst stimulation (cTBS) will be applied to the motor cortex.
1517474|NCT02836392|Behavioral|Questionnaire|
1517476|NCT02836353|Drug|Somatostatin|Single dose of short acting Somatostatin (100mcg) pre Oral glucose tolerance test
1517477|NCT02836353|Drug|Rifaximin|1 week course of 400mg three times daily (TDS) pre Oral glucose tolerance test
1517478|NCT02836340|Drug|2-Iminobiotin|The Investigational Medicinal Product (IMP) under study is 2-IB, which is a biotin (Vitamin H or B7) analogue and a selective inhibitor of neuronal and inducible nitric oxide synthase (NOS).
1517479|NCT02836327|Other|Magnetic Resonance Imaging|Magnetic Resonance Imaging
1517480|NCT02836314|Other|Anorganic Bovine Bone Mineral (ABBM)|In the control group, periodontal intrabony defects were treated with ABBM alone.
1517481|NCT02836314|Other|Anorganic Bovine Bone Mineral and Platelet Rich Fibrin (PRF)|In the test group, periodontal intrabony defects were treated with ABBM and PRF combination.
1517482|NCT02836301|Behavioral|Control ending - Uplifting|The control ending is emotionally uplifting. In this video, the decedent previously registered as an organ donor through online registration and discussed his decision with family. The scene cuts to the family affirming the deceased's wish. In the next scene, the donor family and recipient meet for the first time, ending with a plea from both parties for viewers to register for donation.
1517483|NCT02836301|Behavioral|Negative Consequences Ending|A sad ending where the decedent did not register or discuss their position with family; family is asked to consider donation as an option, but they do not agree. The patient with kidney failure misses the window of opportunity, and the final scene is of both families grieving at their respective family members' grave plots…a missed opportunity.
1517484|NCT02836301|Behavioral|Unresolved Ending|In this ending, the team checks for registration status, and while searching, the scene cuts to physicians discussing the death with family and whether they might consider preservation and organ donation. The video then cuts to the potential recipient and family hoping for a kidney transplant before it is too late. The story ends without resolution, leaving viewers to contemplate how they might respond in the same situation
1517485|NCT02836288|Drug|Ketamine|Ketamine 1.0 mg/kg mixed with syrup will be given by mouth once a day for 12 weeks.
1517486|NCT02836288|Other|Placebo|Placebo syrup will be given by mouth once a day for 12 weeks.
1517487|NCT02836275|Other|Diffusion/Perfusion-weighted Magnetic Resonance Imaging|
1517488|NCT02836262|Device|HIT Hip Replacement System|HIT Hip Replacement System
1517489|NCT02836249|Drug|TAF|TAF 25 mg tablet administered orally once daily
1517490|NCT02836249|Drug|TDF|TDF 300 mg tablet administered orally once daily
1517491|NCT02836249|Drug|TAF Placebo|TAF placebo tablet administered orally once daily
1517492|NCT02836249|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
1517493|NCT02836236|Drug|TAF|TAF 25 mg tablet administered orally once daily
1517494|NCT02836236|Drug|TDF|TDF 300 mg tablet administered orally once daily
1517495|NCT02836236|Drug|TAF Placebo|TAF placebo tablet administered orally once daily
1517496|NCT02836236|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
1517497|NCT02836223|Device|Interdental cleaning device|Water Flosser
1517498|NCT02836223|Device|Manual Tooth brush|Control
1517499|NCT02836210|Device|27-gauge vitrectomy wound construction|Conventional, 3-port pars plana vitrectomy with membrane peeling is performed for epiretinal membrane indication. Angled and straight trocar entry will be directly compared.
1517500|NCT02836197|Behavioral|Communication skills training|The general aim of the communication skills training program is to help physicians learn effective communication skills in contexts of high uncertainty. The training will last 30 hours, will be spread over 4 months. The training will be conducted by group of 3 subjects. The training will include mainly role-plays, theoretical information and modeling techniques. A training manual has been developed to increase content standardization and reduce potential group or trainee biases. The role-plays will be based on clinical cases brought up by the participants.
1517501|NCT02836184|Drug|Nicotinic Acids|Nicotinic acids is administered at an initial dosage of 50mg four times daily in the first week. If no significant side effects detected, the dosage will be titrated to 100mg five times daily within the second week and last to the end of study.
1517502|NCT02836184|Drug|Calcium Carbonate|Calcium Carbonate 500mg per oral, twice a day
1517503|NCT02836171|Drug|Apatinib Mesylate Tablets|apatinib was administered in the morning after an overnight fast of at least 10 h
1517504|NCT02836171|Drug|Itraconazole Capsules|rifampicin was administered in the morning 0.5 hours after breakfast
1517547|NCT02835833|Drug|Bevacizumab|Bevacizumab will be given at 15 mg/kg
1517505|NCT02836158|Drug|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2); methotrexate 1.5 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 20mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
1517506|NCT02836145|Other|Differentiation of hiPSCs to skeletal muscle progenitors|
1517507|NCT02836132|Behavioral|Weight Watchers Online|
1517508|NCT02836132|Behavioral|Experience Success Virtual Reality Platform|
1517509|NCT02836106|Other|Butter|Butter with jam and three slices of bread
1517510|NCT02836106|Other|Cheese|Cheese with jam and three slices of bread
1517511|NCT02836106|Other|Whipped cream|Whipped cream with jam and three slices of bread
1517512|NCT02836106|Other|Sour cream|Sour cream with jam and three slices of bread
1517513|NCT02836093|Behavioral|FACIT-Fatigue 52-point questionnaire|
1517514|NCT02836080|Behavioral|Integrated Collaborative Care Team (ICCT)|An integrated, collaborative pathway of needs-based services. ICCTs will offer a wide variety of services, including Solution-Focused Brief Therapy (SFBT) on a scheduled and walk-in basis, care navigators, various clinician-guided interventions, psychiatry, nurse practitioner services, access to primary care, and peer support, all co-located in youth-friendly, community-based clinics. For each intervention, standardized intervention protocols will be used.
1517515|NCT02836080|Other|Treatment as Usual (TAU)|Standard out-patient treatment provided at each participating hospital site. This typically entails referral to a psychiatrist at the participating hospital, who will provide assessment and treatment, with referral to appropriate services, guided by local treatment protocols.
1517516|NCT02836067|Behavioral|Counseling|Smoking cessation counseling
1517517|NCT02836067|Drug|Smoking Cessation drugs|Medication to aid smoking cessation
1517518|NCT02836067|Procedure|Bronchoscopy|Bronchoscopy
1517519|NCT02836067|Procedure|Blood Draw|Screening and research blood draws
1517520|NCT02836067|Behavioral|Questionnaires|Behavioral questionnaires
1517521|NCT02836054|Procedure|lumbar puncture (LP)|
1517522|NCT02836054|Procedure|brain MRI|
1517523|NCT02836041|Behavioral|questionnaires|"Pre-hospital sleep questionnaire completed (Brief Infant Sleep Questionnaire (BISQ)7 in children 0-3 years old; Children's Sleep Habits Questionnaire (CSHQ)8 in children 4 years and older). Subsequent Day(s):
In-hospital sleep questionnaire completed between one and three times per subject (Sleep at MSK questionnaire (SAM), adapted from Sleep in a Children's Hospital (SinCH)9 by Dr. Lisa Meltzer). (Patients will be observed for up to 3 consecutive nights in total)."
1517524|NCT02836041|Device|actigraph|This device reliably measures sleep by monitoring the child's motion.
1517525|NCT02836028|Drug|Talazoparib|Talazoparib monotherapy 1mg/day orally
1517526|NCT02836028|Drug|Temozolomide|temozolomide 37.5 mg/m2 on days 1-5 of each cycle
1517528|NCT02836002|Drug|Sulfadoxine-pyrimethamine (low dose)|- subcurative regimen (500mg/25mg)
1517529|NCT02836002|Drug|Piperaquine (low dose)|- subcurative regimen (480 mg)
1517530|NCT02836002|Drug|Sulfadoxine-pyrimethamine (high dose)|- curative regimen (1000mg/50mg)
1517531|NCT02836002|Drug|Piperaquine (high dose)|- curative regimen (960 mg)
1517532|NCT02836002|Biological|malaria challenge infection, P. falciparum 3D7|malaria challenge infection by P. falciparum 3D7-infected mosquito bites
1517533|NCT02836002|Drug|Atovaquone-proguanil|- curative regimen: 1000/400 mg, for 3 days
1517534|NCT02835989|Other|CP@Home|Community paramedics (CPs) will be assigned to visiting the participants for a first time the week following the initial EMS call. Participants will complete the informed consent process with a CP on their first visit. This visit will also include a full assessment and risk analysis that will take approximately 90 minutes and will be located in the participant's home. As a result of the initial visit, the CP will make all relevant clinical referrals and decisions based on predetermined @Home algorithms. A second visit will be made to the participant 2-4 weeks following the initial call for a streamlined follow-up and reassessment during a 30 minute period. A final visit will be made 6-8 weeks following the initial call for a final evaluation of their situation. It is anticipated the patient will be discharged from the CP@Home program at this point. If the patient calls EMS following the third visit, if they meet the inclusion criteria, they will be re-entered into the CP@Home program.
1517535|NCT02835976|Drug|Olesoxime|Olesoxime will be given orally on Day 1 as a 600-mg liquid suspension within 30 minutes after starting a standardized high-fat breakfast.
1517536|NCT02835963|Other|Data collection|Usual data collection
1517537|NCT02835950|Device|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.
Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
1517538|NCT02835937|Other|No-Transfuse|Patients will not receive an otherwise-indicated red blood cell transfusion
1517539|NCT02835924|Drug|Regorafenib|
1517540|NCT02835898|Other|Conventional periodontal treatment|Conventional routine periodontal treatment will be done for patients in test group
1517541|NCT02835885|Device|Digitmer High Voltage Stimulator model DS7A TENS unit|
1517542|NCT02835872|Other|dietary fiber|Fiber containing drink mixes and crackers to be consumed with meals (1g fiber/serving) three times per day for a total of 3 g fiber.
1517548|NCT02835820|Dietary Supplement|Ketogenic Diet|12 week delivery of all meals/snacks (eucaloric) prepared by a registered dietician.
1517549|NCT02835807|Behavioral|Health Chat including Indoor Tanning|Participants in the intervention join a private Facebook group to participate in the Health Chat program. The group is not viewable to the public, including other Facebook users. The content of Health Chat is designed primarily for mothers, the participants in the group. Posts will occur twice daily for 12 months for a total of 720 posts. Each group will be hosted by a moderator who is responsible for managing the intervention goals and mothers' engagement. Mothers likely will not continuously engage with a social media campaign that is limited only to indoor tanning. To engage mothers in the Health Chat program, content addressing several major health and wellness topics relevant to adolescent girls and their mothers will be posted.
1517550|NCT02835807|Behavioral|Health Chat excluding Indoor Tanning|In the comparison condition, 25% of the posts will be about prescription drug abuse and misuse. Prescription drug abuse was selected as control content because it is a) completely unrelated to tanning, and b) an emerging issue of great interest and relevance to young adults in east Tennessee. This 25% segment of posts is the only difference between the intervention and comparison conditions.
1517551|NCT02835794|Drug|Omacetaxine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
1517552|NCT02835794|Drug|Azacitidine|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
1517553|NCT02835794|Drug|G-CSF|Comparison of different doses of omacetaxine in combination with azacitidine and G-CSF
1517554|NCT02835781|Other|Acellular dermal matrix implantation|Acellular dermal matrix obtained from Central tissue bank, University Hospital Bratislava, will be used for acellular dermal matrix implantation.
1517555|NCT02835768|Other|Internet-based injury prevention program|"An injury prevention website serves as the Internet-based intervention providing two key topics: 1) Types of domestic injury, and 2) how to prevent different types of domestic injury. The domestic injury prevention information Home Safety Tips is divided into four subgroups according to various safety issues relevant to infants/children's age groups. Apart from a knowledge hub, the website incorporates additional functions of feedback counselling, video demonstration, online consultation, games, safety checklist and discussion forum."
1517556|NCT02835755|Other|Educational Intervention|Receive standard HPV and HPV vaccine information
1517557|NCT02835755|Other|Educational Intervention|Receive mHealth HPV vaccine intervention
1517558|NCT02835755|Other|Survey Administration|Ancillary studies
1517559|NCT02835742|Drug|Sargramostim|
1517560|NCT02835742|Drug|Placebo|
1517561|NCT02835729|Drug|Idarubicin|Chemotherapy
1517562|NCT02835729|Drug|Cytarabine|Chemotherapy
1517563|NCT02835729|Drug|Indoximod|IDO pathway inhibitor
1517564|NCT02835729|Other|Placebo|Placebo
1517565|NCT02835716|Drug|roflumilast|DALIRESP is used in adults with severe chronic obstructive pulmonary disease (COPD) to decrease the number of flare-ups or the worsening of COPD symptoms (exacerbations
1517566|NCT02835716|Biological|ustekinumab|STELARA is approved to treat adults 18 years and older with moderate or severe plaque psoriasis that involves large areas or many areas of their body
1517567|NCT02835703|Procedure|Surgical repair of coarctation of aorta|Surgical repair of coarctation of aorta with aortic arch hypoplasia under CPB
1517568|NCT02835690|Biological|Pembrolizumab|IV infusion
1517569|NCT02835677|Behavioral|Behavioral|Education and skills building, including problem solving, cognitive restructuring, and stress management
1517570|NCT02835664|Dietary Supplement|Nicotinamide Riboside (Niagen)|
1517571|NCT02835664|Dietary Supplement|Placebo|
1517572|NCT02835651|Dietary Supplement|Palmitic acid|Experimental products are enriched with C16:0
1517573|NCT02835651|Dietary Supplement|Stearic acid|Experimental products are enriched with C18:0
1517575|NCT02835625|Radiation|Synthetic Mammography + Digital Breast Tomosynthesis|Two-view tomosynthesis performed with GE Senoclaire 3D Breast Tomosynthesis.
1517576|NCT02835625|Radiation|Digital mammography|Two-view digital mammography performed with GE Senoclaire 3D Breast Tomosynthesis.
1517577|NCT02835612|Other|Early stimulation|Intervention Group: skin-to skin care by mother ( kangaroo care ) plus massage therapy by mothers. They will receive the tactile-kinesthetic stimulation by mothers from randomization until hospital discharge. Intervention performed exclusively by the mothers was based on studies regarding the application of skin stimulations and passive exercises in preterm infants
1517578|NCT02835612|Other|Conventional care|skin-to skin care by mother, kangaroo care. Standard care, according to the routine care of the NICU.
1517579|NCT02835586|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery and/or popliteal artery after stenting. Dosing will be based on the lesion surface area and will be calculated using the following formula : 22/7 x diameter (mm) x length (mm) x 3 µg/mm3
1517580|NCT02835560|Drug|Ilaprazole antisecretory drug of each quadruple therapy the Ilaprazole -based quadruple therapy|Ilaprazole -based quadruple therapy for 14 days: Ilaprazole 5mg bid, Bismuth Potassium Citrate 220mg bid, amoxicillin 1000mg bid, clarithromycin 500mg bid
1517581|NCT02835560|Drug|Esoprazole antisecretory drug of each quadruple therapy Esoprazole-based quadruple therapy|Esoprazole -based quadruple therapy for 14 days: Esoprazole 20mg bid, Bismuth Potassium Citrate 220mg bid, Amoxicillin 1000mg bid, Clarithromycin 500mg bid
1517582|NCT02835547|Other|Data collection|Risk factors will be collected retrospectively (5 years) and cardiovascular events prospectively (2 years)
1517583|NCT02835534|Drug|rhTNK-tPA|Dose:16mg; Mode of admin: Single bolus Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
1517584|NCT02835534|Drug|alteplase|Dose:50mg; Mode of admin: administered as an 8-mg initial IV bolus followed by an infusion of 42 mg over the next 90 minutes Enoxaparin or unfractionated heparin for anticoagulant therapy, clopidogrel and aspirin for antiplatelet therapy before fibrinolytic therapy.
1517585|NCT02835521|Procedure|Reception|
1517586|NCT02835521|Drug|Joint injection with triamcinolone hexacetonide|joint injection with corticosteroids
1517587|NCT02835508|Drug|JNJ-56021927 60 Milligram|JNJ-56021927 60 mg oral tablet.
1517588|NCT02835508|Drug|JNJ-56021927 120 Milligram|JNJ-56021927 120 mg as 2 tablets of 60 mg.
1517589|NCT02835508|Drug|JNJ-56021927 240 Milligram|JNJ-56021927 240 mg as 4 tablets of 60 mg.
1517592|NCT02835482|Procedure|Femtolaser surgery|
1517593|NCT02835482|Procedure|Phacoemulsification|
1517598|NCT02835430|Procedure|Coronally advanced flap and PRF with DFDBA|• For Test site: i. Following pre-suturing of coronally advanced flap, DFDBA (Rocky Mountain Particulate Allograft) was placed over the exposed root and adjacent bone surface and subsequently covered by PRF membrane.
1517599|NCT02835430|Procedure|Coronally advanced flap and PRF without DFDBA|. For Control site: i. Following pre-suturing of coronally avanced flap, exposed root and adjacent bone surface was covered by PRF membrane.
1517600|NCT02835404|Drug|Nedaplatin|Chemotherapy: Nedaplatin(NDP) 30-40mg/m2 iv., on day1, 4weeks as one cycle
1517601|NCT02835404|Radiation|Pelvic External Radiotherapy|patients received 20 Gy2.0/f, for 25-27f (SSD)with 8mv-X rays (SSD)
1517602|NCT02835404|Radiation|252-Cf Neutron Intracavitary Brachytherapy|total dose of reference point A was 4400cGy, in four times Transvaginal implant sessions during Pelvic External Radiations
1517603|NCT02835391|Device|PerClot|Haemostatic device for the control of bleeding from capillary, venous or arteriolar vessels by pressure, ligature or other conventional means is either ineffective or impractical.
1517604|NCT02835391|Device|Floseal, Surgicel, Surgiflo, Arista|Haemostatic device for the control of bleeding
1517605|NCT02835391|Procedure|Electrocautery/Diatermy|Procedure for the control of bleeding
1517606|NCT02835378|Other|No intervention|
1517607|NCT02835352|Other|Essential oils massages|
1517608|NCT02835352|Other|Oil massages|
1517609|NCT02835339|Drug|Magnesium sulfate 4g loading dose, 1g/hr infusion|
1517610|NCT02835339|Drug|Magnesium sulfate 6g loading dose, 2g/hr infusion|
1517611|NCT02835326|Behavioral|Exercise and Dietary Weight Loss|The EX+DWL intervention consists of group and individual exercise sessions, as well as, nutritional and dietary counseling. Bimonthly phone calls are made in the final year of the study to aid in maintenance of the program.
1517612|NCT02835326|Behavioral|Walk with Ease|The WWE 6 week program consists of health education lectures on arthritis self-management, a walking exercise portion, and at- home strength exercises. Participants will complete two consecutive WWE programs. Monthly and bimonthly phone calls are made to participants in months 4-12 and 12-24, respectively, to aid in maintenance of the program.
1517613|NCT02835313|Behavioral|FAST|Subjects participate in fast walking training 3x/week for 12 weeks.
1517614|NCT02835313|Behavioral|FAST+SAM|Subjects participate in fast walking training plus a step activity monitoring program 3x/week for 12 weeks
1517615|NCT02835313|Behavioral|SAM|Subjects participate in a step activity monitoring program 3x/week for 12 weeks
1517616|NCT02835300|Behavioral|CampAir|CampAir is a dynamic e-learning intervention to help adolescents with uncontrolled asthma to manage their illness and to improve their asthma control. CampAir consists of seven online modules with one module being completed each week over seven weeks. Each module provides a brief introduction to the topics and strategies focused on in that module followed by a set of interactive exercises and games for practice and personalized feedback.
1517617|NCT02835300|Behavioral|Information and Referral|The information and referral comparator condition will provide access to existing generic asthma education websites. They will also be referred to their medical providers for asthma. After the completion of the trial, all participants will have access to CampAir.
1517618|NCT02835287|Other|Protocol-based integrated care|The protocol-based integrated care, which will provide a standardized, combined, multi-component intervention according to clinical guideline treatment algorithms for diabetes and comorbidities in community clinics, will be delivered by trained primary care physicians, health managers, and nurses supported by diabetes specialists.
1517619|NCT02835274|Device|Deep Brain Stimulation (DBS) Boston Scientific VerciseTM PC System with Directional Lead|
1517620|NCT02835261|Other|Sleep Restriction|Mild sleep restriction (-1.5 h/night) over a period of 6 weeks
1517621|NCT02835248|Other|Fall Detection|All participants will wear a device configured to detect falls.
1517622|NCT02835235|Drug|NNC9204-0530|Administered daily subcutaneously (s.c., under the skin)
1517623|NCT02835235|Drug|placebo|Administered daily subcutaneously (s.c., under the skin)
1517624|NCT02835222|Drug|Cytarabine|Given IV
1517625|NCT02835222|Drug|Daunorubicin Hydrochloride|Given IV
1517626|NCT02835222|Drug|Selinexor|Given PO
1517627|NCT02835209|Other|Work of breathing during SBT|Pulmonary function tests and work of breathing indices will be collected during the spontaneous breathing test.
1517628|NCT02834104|Device|RMI|
1517629|NCT02834104|Other|myocardial biopsy|
1517630|NCT02834104|Biological|blood sample|
1517631|NCT02834091|Procedure|Hypnoanalgesia|
1517632|NCT02835183|Device|iDECIDE|The iDECIDE app will be installed in study participant's smartphone. The app requests from study participants input on food consumed (included food's carbohydrate content), alcohol consumed (included alcohol's carbohydrate content) and exercise plans (including duration and intensity). Based on that input the app suggests insulin bolus dosing.
1517633|NCT02835183|Device|Insulin pump|Study participants will use during the study their own insulin pump and continuous glucose sensor. As inclusion criteria, investigators expect study participants to have been using their insulin pump and continuous glucose sensor for at least one year.
1517636|NCT02835157|Drug|Balanced salt solution|Balanced salt solutions as boluses of 20 ml/kg would be administered.
1517637|NCT02835157|Drug|Normal saline|Normal saline as boluses of 20 ml/kg would be administered
1517638|NCT02835144|Other|TIQAAM_therapy|The treatment program consists of TIQAAM therapy blocks to three priority areas: promoting change and motivation, relapse prevention and relapse management, and promote resource and euthymic activities to increase the abstinence motivation. The TIQAAM is based on behavioral approaches as well as motivational interviewing of Miller and Rollnick.
1517639|NCT02835144|Other|Psychoeducation|This intervention is a psychoeducation module pertaining to substance use disorders.
1517640|NCT02835131|Drug|Pasireotide|
1517641|NCT02835118|Drug|Surotomycin|Two oral doses of surotomycin in hard gelatin capsules totaling either 0.5, 1 or 2 g per day, for 14 days
1517642|NCT02835118|Drug|Placebo|Two oral doses of placebo for surotomycin in hard gelatin capsules per day, for 14 days
1517643|NCT02835105|Drug|Surotomycin|A single oral dose of either 0.5, 1, 2 or 4 g surotomycin in hard gelatin capsules
1517644|NCT02835105|Drug|Placebo|A single oral dose of placebo for surotomycin in hard gelatin capsules
1517645|NCT02835092|Other|Take Shape For Life Program|The Take Shape For Life (TSFL) Program group will be assigned to the Optimal Weight 5 & 1 Plan™ for weight loss. This group will have scheduled coaching sessions with a TSFL coach for the duration of the study.
1517646|NCT02835092|Other|Medifast Direct Program|The Medifast Direct Program (MEDD) group will be assigned to the Medifast Achieve™ Plan (4 & 2 & 1 Plan®) for weight loss. MEDD participants will have access to the services of the Medifast Nutrition Support Team.
1517647|NCT02835092|Other|Self-directed Control|The Self-directed Control Group will be assigned to a food-based, reduced calorie diet consistent with the 2015 Dietary Guidelines for Americans.
1517648|NCT02835079|Drug|Tamoxifen|
1517649|NCT02835066|Other|Integrated Fitness Assessment|Undergo function/fitness assessment
1517650|NCT02835066|Procedure|Psychosocial Assessment and Care|Undergo psychosocial health assessments
1517651|NCT02835066|Procedure|Quality-of-Life Assessment|Complete EORTC QLQ-C30 and QLQ-LC13 questionnaires
1517653|NCT02835040|Other|New model of service delivery|Introduction of a new CAP disease specific clinical team to ensure systematic implementation of standardized treatment protocols (similar to a clinical pathway) for interventions supported by Level-1 evidence.
1517654|NCT02835040|Other|Current practice|Interventions as determined by the treating General Medical team consistent with current usual practice.
1517655|NCT02835027|Procedure|Open versus endovascular surgery|Treatment for acute ischemia
1517659|NCT02835001|Procedure|Bronchoscopy|Two sequences of 30 minutes are necessary by patient
1517660|NCT02835001|Device|Lung Volume Reduction Coil (HEAT-LVRC)|
1517661|NCT02834988|Procedure|Sentinel Lymph Node Dissection|Sentinel Lymph Node Dissection (SLND) in Surgical Staging
1517662|NCT02834975|Drug|Pembrolizumab|Pembrolizumab at 200mg (IV) on Day 1, every 21 days per protocol.
1517663|NCT02834975|Drug|Paclitaxel|Paclitaxel 175mg/m2 (IV) on Day 1, every 21 days per protocol.
1517664|NCT02834975|Drug|Carboplatin|Carboplatin AUC 6 on Day 1, every 21 days per protocol.
1517665|NCT02834962|Procedure|single bundle ACL reconstruction|anterior cruciate ligament reconstruction using single bundle technique
1517666|NCT02834962|Procedure|double bundle ACL reconstruction|anterior cruciate ligament reconstruction using double bundle technique
1517670|NCT02834936|Drug|pyrotinib|
1517671|NCT02834923|Behavioral|Enhanced Engagement Protocol for CTH (EE-CTH)|EE-CTH integrates CTH with an efficacious, structured, motivational interview (MI)-informed protocol.
1517672|NCT02834923|Behavioral|Connection to Health (CTH)|CTH is a comprehensive SMS program that focuses on behavior change.
1517673|NCT02834910|Other|collection of bacterial sample|
1517674|NCT02834897|Radiation|EOS and CT Exam|EOS and CT Examen for pregnant women in the 8th month of pregnancy
1517676|NCT02834871|Device|Electromyogram|
1517677|NCT02834858|Biological|Umbilical Cord Mesenchymal Stem Cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using umbilical cord mesenchymal stem cells
1517678|NCT02834858|Biological|saline|
1517679|NCT02834845|Drug|Sevoflurane|Sevoflurane %2-3 for general anesthesia maintenance
1517680|NCT02834845|Drug|Desflurane|Desflurane %6-8 for general anesthesia maintenance
1517682|NCT02834819|Drug|3% Nebulized Hypertonic Saline|
1517683|NCT02834806|Device|BioNIR Ridaforolimus Eluting Coronary Stent System|BioNIR Ridaforolimus eluting coronary stent system with modified delivery system
1517684|NCT02834793|Drug|Perampanel|
1517685|NCT02834793|Drug|Placebo|
1517686|NCT02834780|Drug|H3B-6527|H3B-6527, a Fibroblast growth factor receptor 4 (FGFR4) inhibitor, will be supplied as capsules and will be administered orally once daily, continuously in 21-day cycles with sequential escalating dose cohorts in the Dose Escalation part (Part 1). In the Expansion part (Part 2), participants will receive the recommended Phase 2 dose (RP2D) established during Part 1 of the study. In the Extension Phase, participants will continue to receive the same treatment and dose they received during the Treatment Phase, provided termination criteria are not met.
1517687|NCT02834767|Device|Genioglossis Strength Trainer|The genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. The device can be set to a specific pressure resistance ranging from 10 to 40 Newtons. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
1517688|NCT02834767|Device|Placebo Genioglossis Strength Trainer|The placebo genioglossis strength trainer is a handheld device, manufactured in house, consisting of an outer tube, inner piston, and pressure loaded spring. Whereas the pressure loaded spring in the active trainer can be set to a wide range of pressures, the placebo trainer has a maximum resistance of 5 Newtons. The device is set to a specific pressure resistance of 5 Newtons at all times. Users press against the inner piston with their tongues until the piston moves approximately 1/2 centimeter (and the inner pressure loaded spring depresses approximately 1/2 centimeter).
1517691|NCT02834741|Drug|NYX-2925|NYX-2925 is a small molecule that acts as an N-methyl-D-aspartate receptor (NMDAR) functional glycine-site partial agonist.
1517692|NCT02834728|Behavioral|telephone interview|
1517693|NCT02834715|Dietary Supplement|Stevia rebaudiana liquid extract|Sweetener made of liquid stevia self administered daily for 30 days
1517694|NCT02834702|Device|Sinew acupuncture|The subject is asked to be on sitting posture. The skin around the needling points is disinfected with a 75% alcohol swap. A tube-guided, sterilized, disposal needle is then inserted (at a small angle to the skin) into the acupoint at 0.5-1 cun (depending on point location and body size of the subject). No needle sensation (deqi sensation) is required. A piece of surgical adhesive tape will be applied to the needle immediately after insertion.
1517695|NCT02834702|Device|Sham acupuncture|The procedure in the sham acupuncture group will be as similar to that of the acupuncture group as possible. In the sham acupuncture group, however, a mock plastic needle guiding tube is tapped on the surface of each acupoint (Ashi point and traditional acupoints) to produce some discernible sensation. A piece of adhesive tape is immediately applied to fix the needle on the dermal surface tapped, without needle insertion. In addition, a plastic tube-guided needle is superficially inserted at the sham point at less than 5mm in depth.
1517698|NCT02834676|Drug|Gelified Ethanol|Pain relief with chemonucleolysis by using gelified ethanol regard to age, sex, ASA score, and complications.
1517699|NCT02834663|Drug|Lucentis|
1517700|NCT02834650|Other|Cardiac MRI with contrast|Cardiac MRI
1517701|NCT02834650|Other|Cardiac MRI without contrast|Cardiac MRI
1517702|NCT02834650|Other|Blood Test|Hematocrit, Creatinine, Troponin, BNP
1517703|NCT02834650|Other|Heart Rate|Holter Monitor
1517704|NCT02834650|Other|Pulmonary Function Test|Pulmonary Function Test
1517705|NCT02834650|Other|Genetic Testing|Genetic Testing
1517706|NCT02834650|Other|Repeat MRI scan|Repeat MRI scan
1517707|NCT02834637|Drug|bivalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
1517708|NCT02834637|Drug|nonavalent HPV vaccine|head to head comparisons of different dose schedules and HPV vaccine types
1517709|NCT02834624|Drug|Poractant alfa|Randomized to receive Curosurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist.
1517710|NCT02834624|Drug|calfactant|Randomized to receive Infasurf as the surfactant to treat respiratory distress syndrome. Doses 3ml/kg. to be repeated as needed by determination of attending neonatologist
1517711|NCT02834611|Drug|Ceramide NanoLiposome|Intravenous administration of Ceramide NanoLiposome
1517712|NCT02834598|Device|high-density electroencephalography|Cerebral measurements from high-density electroencephalography while standard and deviant sounds are presented to the participant.
1517713|NCT02834585|Other|Ultrasound|
1517714|NCT02834572|Behavioral|All About Me|Assessment and algorithm to determine recommended HIV testing approach
1517715|NCT02834572|Behavioral|Control|HIV testing information
1517716|NCT02834559|Drug|5-fluorouracil and low molecular weight heparin|Intraoperative adjuvant application of 5-fluorouracil (5-FU) and low molecular weight heparin (LMWH) via intraocular infusion during routine pars plana vitrectomy (PPV).
1517717|NCT02834559|Drug|Placebo|Routinely used intraocular infusion with balanced salt solution (BSS) during routine pars plana vitrectomy (PPV).
1517718|NCT02834546|Biological|Sorafenib plasma concentration 4 weeks after treatment initiation|
1517719|NCT02834533|Device|Lokomat|Lokomat (Hocoma Inc., Zurich, Switzerland)includes a treadmill, a BWSS and two powered gait orthosis robotic actuators with integrated computer-controlled linear actuators at each hip and knee joint . As compared to Lokomat-Nanos, the Pro device offers a VR through an Augmented Feedback Module, which provides instructive, stimulating, interactive, and direct feedbacks to enhance the patient's motivation by projecting his/her avatar while walking on a screen.
1517720|NCT02834507|Drug|Placebo|Matching placebo capsules
1517721|NCT02834507|Drug|BIA 3-202|Capsules containing nebicapone 75 mg or 150 mg
1517722|NCT02834507|Drug|Comtan®|Capsules containing entacapone 200 mg
1517723|NCT02834507|Drug|Sinemet®|levodopa/carbidopa (Sinemet®) dose patient used to take
1517724|NCT02834494|Procedure|3D Shear Wave Elastography (SWE)|Ultrasound imaging with Elastography will be performed at the inclusion (T0), after course 1 and course 2 respectively with anthracyclines, at the end of anthracycline treatment and at the end of taxane treatment.
1517725|NCT02834494|Biological|Biopsy|Optional biopsy of breast tumor under neoadjuvant chemotherapy after the course 2 of anthracycline.
1517726|NCT02834481|Device|ANI/NIPE|ANI/NIPE monitors is a continuous noninvasive measurement of the parasympathetic tone, as a component of the autonomous nervous system. It uses the tiny variations of heart rate induced by each respiratory cycle (natural or induced) to quantify parasympathetic tone (respiratory sinus arrhythmia).
1517727|NCT02834468|Drug|DEX Combined With RTX, CSA and IVIG|The investigators are undertaking a multicenter trial of 100 primary ITP adult patients from 5 medical centers in China. All participants receive dexamethasone (given orally at a dose of 40 mg per day for 4 days), rituximab (given intravenously at a dose of 500mg once), cyclosporin (given orally at a dose of 2.5-3 mg/kg per day for 28 days) and intravenous immunoglobulin (given intravenously at a dose of 5g per month for 6 months) for the treatment of adults newly diagnosed ITP patients.
1517728|NCT02834455|Device|Contrast-enhanced CT|50% of patients with unilateral pleural effusion will have performed a CE-CT
1517729|NCT02834455|Device|PET-CT|50% of patients with unilateral pleural effusion will have performed a PET-CT
1517730|NCT02834442|Drug|MT-7117|
1517731|NCT02834442|Drug|Placebo|
1517734|NCT02834403|Drug|L-NMMA|Nitric oxide synthase inhibitor
1517735|NCT02834403|Drug|Docetaxel|Mitotic inhibitor, cytotoxic
1517736|NCT02834403|Drug|Amlodipine|Long-acting calcium channel blocker
1517737|NCT02834403|Drug|Pegfilgrastim|Colony-stimulating factor
1517738|NCT02834390|Drug|quizartinib|[Induction period] Once-daily repeated oral administration day 8 to day 21. [Consolidation period] Once-daily repeated oral administration day 6 to day 19.
1517739|NCT02834390|Drug|Cytarabine|"[Induction period] Once-daily intravenous injection of 100 mg/m2 cytarabine on day 1 to 7.
[Consolidation period] Twice-daily intravenous injection of 3.0 g/m2 cytarabine at 12-hour intervals on day 1, 3, and 5."
1517740|NCT02834390|Drug|Idarubicin|Either Idarubicin or Daunorubicin will be used [Induction period] Once-daily intravenous injection of 12 mg/m2 idarubicin on day 1 to 3.
1517741|NCT02834390|Drug|Daunorubicin|Either Idarubicin or Daunorubicin will be used [Induction period] Once-daily intravenous injection of 60mg/m2 daunorubicin on day 1 to 3.
1517742|NCT02834377|Other|Treatment algorithm targeting individual cardiac output|
1517743|NCT02834364|Drug|Encorafenib|450 mg p.o. once daily. One cycle is defined as 28 days
1517744|NCT02834364|Drug|Binimetinib|45 mg p.o. twice daily. One cycle is defined as 28 days
1517745|NCT02834351|Other|Muscle Biopsy|"A distal and proximal biopsy of the sartorius muscles ( 0.5 cm3 each) will be performed during surgery for saphenous vein withdrawal (cardiac group) or arterial bypass (PAD group) The samples are then treated with neurovascular and mitochondrial biology laboratory.
the activity of the complex 1 is analyzed and compared between the 2 groups."
1517796|NCT02833974|Drug|GSK2245035 Nasal Spray Solution|GSK2245035 Nasal Spray Solution 0.2 microgram (mcg)/mL delivering 10 ng GSK2245035 per actuation. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate.
1517797|NCT02833974|Drug|Placebo Nasal Spray Solution|Nasal Spray Solution as for GSK2245035 without active ingredient.
1517798|NCT02833961|Device|Magnetic resonance imaging|
1517799|NCT02833948|Drug|Acetylicsalicylic acid|"Drug: Acetylsalicylic acid:
75 - 100 mg OD (for first 90 days only in arm 1)"
1517747|NCT02834325|Procedure|mechanical ventilation|
1517750|NCT02834299|Behavioral|DBT Guided Self-Help|DBT self-help manual plus six 30-minute therapy sessions for 12 weeks
1517751|NCT02834299|Behavioral|DBT Unguided Self-Help|DBT self-help manual without any therapy sessions for 12 weeks
1517752|NCT02834299|Behavioral|Self-Esteem-Focused Unguided Self-Help|Self-esteem focused self-help manual without any therapy sessions for 12 weeks
1517753|NCT02834286|Drug|Rituximab|Rituximab 100 mg weekly days 1, 7, 14, 21
1517754|NCT02834286|Drug|Eltrombopag|Eltrombopag 50 mg PO days 1-28
1517755|NCT02834286|Drug|Dexamethasone|Dexamethasone 40 mg IV/PO days 1-4
1517756|NCT02834273|Behavioral|stroke education workshops|
1517757|NCT02834260|Drug|Dexamethasone implant OZURDEX|
1517758|NCT02834247|Drug|TAK-659|TAK-659 Tablets
1517759|NCT02834247|Drug|Nivolumab|Nivolumab intravenous infusion
1517760|NCT02834234|Genetic|comparative genomic analysis|DNA and RNA extraction will be performed in Lyon University hospital (genomic platform) using commercially available kit. Percentage of tumors cells will be controlled by stained section before extraction. The CGH arrays will be realized on frozen samples in Lille (genomic platform). Pangenomic Agilent array will be used. Micro-array include 180000 probes. Analysis will be performed in Lille (genomic platform / department of BioInformatics) with Marie Brevet. Data will be processed from the log2 transformed data into normalization with the WACA method. Then copy number variation will then be identified with Circular Binary Segmentation. Copy number variations will be called as gain or deletion according to the log2 ratio distribution and the percent of tumoral cells. Using matched tumoral and normal DNA will eliminate Copy Number Polymorphisms. We will construct non supervised hierarchical analyses to study the classification of peritoneal mesothelioma based on copy number variation
1517761|NCT02834221|Device|Real-time ultrasound-guided puncture|A 7 megahertz ultrasound linear probe will be used.
1517762|NCT02834221|Other|Anatomical landmark guided puncture|Anatomical landmark puncture
1517763|NCT02834208|Other|MRI (Magnetic resonance imaging)|
1517764|NCT02834208|Genetic|Polymorphism (SNP in DNA)|
1517765|NCT02834208|Genetic|quantitative measures of mRNA|
1517766|NCT02834208|Other|Neuropsychological assessment|
1517767|NCT02834182|Behavioral|IRMf|
1517768|NCT02834182|Behavioral|Mini International Neuropsychiatric Interview|
1517769|NCT02834182|Behavioral|Positive And Negative Syndrom Scale|
1517770|NCT02834182|Behavioral|Young Mania Rating Scale|
1517771|NCT02834182|Behavioral|Hamilton Depression Scale|
1517772|NCT02834169|Other|Non interventional|Data collection
1517773|NCT02834156|Other|LP in a seated position then LP in a lying position|
1517774|NCT02834156|Other|LP in a lying position then LP in a seated position|
1517775|NCT02834143|Other|No intervention|The is no intervention. This study is a descriptive one
1517776|NCT02834130|Behavioral|Evaluation of psychological and psychopathological|
1517777|NCT02834117|Other|natural cycle|Ovulation is not induced by drugs
1517778|NCT02834117|Drug|moderate ovarian stimulation|Ovulation is induced by recombinant follitropin alpha and recombinant choriogonadotropin
1517779|NCT02834078|Dietary Supplement|BGG|
1517780|NCT02834078|Other|Placebo|
1517781|NCT02834065|Device|Cardiopulmonary bypass machine|Routinely used cardiopulmonary bypass machine (standard of care) will be used to initiate circulatory arrest
1517782|NCT02834052|Drug|pembrolizumab|200mg pembrolizumab will be given intravenously on Day 1 of each 3-week cycle
1517783|NCT02834052|Drug|Poly-ICLC|"The maximum tolerated dose of Poly ICLC will be given twice weekly, in each 3-week cycle:
Week 1, Days 1 and 4
Week 2, Days 8 and 11
Week 3, Days 15 and 18"
1517784|NCT02834039|Procedure|Tidal volume 6 ml/kgBW|Tidal volume 6ml/kgBW was given to subjects after endotracheal tube was inserted properly.
1517785|NCT02834039|Procedure|Tidal volume 10 ml/kgBW|Tidal volume 10 ml/kgBW was given to subjects after endotracheal tube was inserted properly.
1517786|NCT02834026|Other|Cicloergometry training|
1517787|NCT02834026|Other|No Cicloergometry training|
1517791|NCT02834000|Device|LiDCO rapid™ CNAP monitoring|LiDCO rapid™ CNAP monitoring allows through analysis of the arterial blood pressure trace to acquire information about CO, HR variability, SVR, SV and BIS during general anaesthesia.
1517792|NCT02833987|Drug|Apixaban (ATC B01AF02)|Exposure to apixaban (ATC B01AF02) will be defined as a new prescription for apixaban in the 30 days following the date of an incident VTE diagnosis.
1517793|NCT02833987|Drug|Dabigatran (ATC B01AE07)|Exposure to dabigatran (ATC B01AE07) will be defined as a new prescription for dabigatran in the 30 days following the date of an incident VTE diagnosis.
1517794|NCT02833987|Drug|Rivaroxaban (ATC B01AF01)|Exposure to rivaroxaban (ATC B01AF01) will be defined as a new prescription for rivaroxaban in the 30 days following the date of an incident VTE diagnosis.
1517795|NCT02833987|Drug|Warfarin (ATC B01AA03)|Exposure to warfarin (ATC B01AA03) will be defined as a new prescription for warfarin in the 30 days following the date of an incident VTE diagnosis.
1517800|NCT02833948|Drug|Clopidogrel|Drug: Clopidogrel 75 mg OD for first 90 days
1517801|NCT02833948|Drug|Rivaroxaban|"Drug: Rivaroxaban (Xarelto):
10 mg OD (once-daily)"
1517802|NCT02833935|Behavioral|Physical Activity Intervention|"The PA intervention will be delivered in a virtual face-to-face format using the secure and confidential Remote Education, Augmented Communication, Training and Supervision online video-based software. Intervention participants will receive 8 PA sessions over 2 months (1/week), following collaborator specific telephone-based PA counselling protocol. The counsellor will individually tailor her approach to each participant by understanding the participant's past and current PA experiences, motives to be physically active, salient concerns and barriers regarding PA, and physical home environment. Throughout the intervention, the PA counsellor and participants will co-construct and collaboratively adapt the intervention with the participants."
1517804|NCT02833909|Other|surgery|
1517805|NCT02833896|Genetic|surgery|
1517806|NCT02833883|Drug|Enzalutamide|
1517807|NCT02833883|Drug|CC-115|
1517808|NCT02833870|Behavioral|Musical intervention|
1517809|NCT02833870|Behavioral|Non-musical (cooking) intervention|
1517810|NCT02833870|Behavioral|Control with no intervention|
1517811|NCT02833857|Drug|Study Drug|AMG 416
1517815|NCT02833831|Drug|ALS-008176|Participants will receive a single dose of ALS-008176 orally.
1517816|NCT02833831|Drug|Placebo|Matching Placebo will be administered.
1517817|NCT02833831|Drug|Moxifloxacin|Participants will receive a single dose of moxifloxacin 400 mg.
1517818|NCT02833818|Dietary Supplement|CAKE-intervention|Increased protein and energy supplementation and conversations
1517819|NCT02833818|Dietary Supplement|CAKE-control|nutrition according to established procedures
1517820|NCT02833805|Drug|Thymoglobulin|Day -9: 0.5 mg/kg Days -8 and -7: 2 mg/kg daily
1517821|NCT02833805|Drug|Fludarabine|Days -6 through -2: 30 mg/m^2 IV daily
1517822|NCT02833805|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
1517823|NCT02833805|Radiation|Total body irradiation|Day -1: 200 centigray (cGy) in a single fraction
1517824|NCT02833805|Drug|Tacrolimus|Start on Day 5 through Day 365
1517825|NCT02833805|Drug|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
1517826|NCT02833792|Drug|Human Mesenchymal Stem Cells and Lactated Riunger's Solution|Intravenous administration
1517827|NCT02833792|Other|Placebo|Intravenous administration
1517828|NCT02833779|Other|Individual exercises|
1517829|NCT02833779|Other|Group exercises|
1517831|NCT02833753|Drug|Oxaliplatin|"Intraperitoneal oxaliplatin will be given along with standard chemotherapy FOLFIRI.
Level 1: Oxaliplatin 25mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 2: Oxaliplatin 55mg/m2 IP every 2 weeks on day #1 of chemotherapy Level 3: Oxaliplatin 85mg/m2 IP every 2 weeks on day #1 of chemotherapy"
1517832|NCT02833740|Device|Click-MUAC prototype & regular MUAC tape|Screening of children using Click-MUAC and regular MUAC tape
1517833|NCT02833727|Other|Smoking|Smoking equal or greater than 10 pack/years; never smokers: lifelong history without smoking.
1517834|NCT02833701|Dietary Supplement|Ascorbic Acid|Given IV
1517835|NCT02833701|Biological|Bevacizumab|Given intravenously (IV)
1517836|NCT02833701|Other|Laboratory Biomarker Analysis|Correlative studies
1517837|NCT02833701|Other|Quality-of-Life Assessment|Ancillary studies
1517838|NCT02833688|Drug|dexmedetomidine|dexmedetomidine 2mg is diluted in 0.9% sodium chloride with the concentration of 4 ug ml-1 is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
1517839|NCT02833688|Drug|0.9% sodium chloride|0.9% sodium chloride is administered with an loading dose of 0.5ug kg-1 of 10 min, and maintained with infusion rate of 0.5 ug kg-1 h-1. The infusion is ceased after the resection of the hepatic issues.
1517840|NCT02833662|Other|Measure of ODI and heart rhythm|Record nocturnal respiratory and cardiac parameters before and after surgery.
1517841|NCT02833649|Device|Toric Implantable collamer Lens|The toric implantable collamer lens (TICL) is conventionally indicated for the Correcting the refractive error in keratoconus using the TICL is an off label use of the lens.
1517842|NCT02833636|Procedure|ACEF score|
1517843|NCT02833623|Behavioral|Short-message-based Re-education|
1517844|NCT02833623|Behavioral|conventional education|
1517845|NCT02833610|Drug|Denosumab Q4W|
1517846|NCT02833584|Drug|Paracetamol|Paracetamol 500 mg x 1 tablets according to patient's body weight
1517847|NCT02833584|Drug|Placebo|Placebo 500 mg x 1 tablets according to patient's body weight
1517848|NCT02833558|Device|PuraStat®|PuraStat® gel is applied through a safe catheter delivery system (via endoscope) over the bleeding point
1517849|NCT02833558|Procedure|Electrocautery|Electrocautery (coagulation current) to stop bleeding during ESD
1517850|NCT02833545|Device|Ozone gas|Injection of ozone gas intra articularly
1517851|NCT02833532|Device|Volus/Powerfill|Maximum: 22ml
1517852|NCT02833519|Behavioral|group exercise|"Group training supervised by Physiotherapists from Copenhagen University Hospital, Rigshospitalet. 70 minutes sessions twice a week for 12 weeks.
The training consists of 10 minutes of warm up (Borg scale 7-10), 20 minutes of fitness training on exercise bike, tread mill or cross-trainer (Borg scale 11-15), 25 minutes of muscle training and 15 minutes stretching/relaxation, (Borg scale 6).
The intensity of the training follows national recommendations on physical activity for pregnant women, which recommends moderate physical activity or more depending on the pregnant woman's fitness level prior to pregnancy.
The pregnant women´s general practitioners are informed about the intervention and who is participating in the project.
A weekly supportive email."
1517856|NCT02833480|Drug|Fluticasone group|
1517857|NCT02833480|Drug|Budesonide group|
1517858|NCT02833480|Drug|Formoterol group|
1517859|NCT02833454|Procedure|direct insertion anterior cruciate ligament reconstruction|ACL reconstruction based on direct insertion of ACL.
1517860|NCT02833454|Procedure|single bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using single bundle technique
1517861|NCT02833454|Procedure|double bundle anterior cruciate ligament reconstruction|anterior cruciate ligament reconstruction using double bundle technique
1517862|NCT02833441|Behavioral|Peer Support|
1517863|NCT02833428|Device|Biomedical equipment (Eclipse Nim, Medtronic®)|"It is the principal investigator (coordinator investigator moving on the website of the Pitié-Salpêtrière) that will install bedside biomedical equipment for the project (Eclipse Nim, Medtronic®) The term of monitoring will depend of length of stay in the PACU (the post anesthesia care unit) Gaston Cordier and will not exceed 72 hours.
• Patients will be reviewed at 6 and 12 months for conventional control with establishing a ASIA score (American Spinal Cord Injury Association). Of SEP (Somatosensory evoked potentials) and MEP(Motor Engine Potentials) will be performed in the laboratory at 6 and 12 months (electrophysiology laboratory Pitié-Salpêtrière). They are part of the traditional support in the context of spinal cord trauma."
1517864|NCT02833415|Drug|[U-13C3] glycerol|Ingestion of [U-13C3] glycerol based on human's body weight such as (50 mg/kg body weight).
1517865|NCT02833415|Drug|Empagliflozin|Active drug
1517866|NCT02833415|Drug|Placebo (for Empagliflozin)|Placebo tablet manufactured to mimic EMPA 10 mg tablet.
1517867|NCT02833402|Device|InterStim Therapy|Sacral Neuromodulation, delivered by the InterStim® System, offers long-term control of bladder control and bowel control symptoms through modulation of the nerves that help control the pelvic floor and lower urinary tract.
1517868|NCT02833389|Drug|Placebo|UTTR1147A matching placebo will be administered SC.
1517869|NCT02833389|Drug|UTTR1147A|UTTR1147A will be administered SC.
1517870|NCT02833376|Other|alcohol antisepsis|
1517871|NCT02833376|Other|chlorhexidine antisepsis|
1517872|NCT02833350|Drug|GDC-0853|Participants will receive GDC-0853 at low, mid, or high doses, orally once or twice daily for 12 weeks in Cohort 1 or 2.
1517873|NCT02833350|Drug|Adalimumab|Participants will receive adalimumab, subcutaneously Q2W starting on Day 1 for 12 weeks.
1517874|NCT02833350|Drug|Folic Acid|Participants will receive stable background therapy of folic acid of at least 5 mg total dose weekly (or equivalent) as per investigator's discretion.
1517875|NCT02833350|Drug|MTX|Participants will receive stable background therapy of MTX 15-25 mg/week (oral or parenteral; for participants entering the trial on MTX doses 15 mg/week, doses as low as 7.5 mg/week are allowed only if there is clear documentation in the medical record that higher doses were not tolerated or that the dose of MTX is the highest acceptable dose based on local clinical practice guidelines).
1517876|NCT02833350|Drug|Placebo|Participants will receive placebo matched to adalimumab, subcutaneously Q2W and/or placebo matched to GDC-0853, orally once or twice daily for 12 weeks in Cohort 1 or 2.
1517881|NCT02833311|Behavioral|Computer Tablet Group|Participants will first meet once with a trained health education specialist. During this meeting the health education specialist will work with the participant in setting constructive and manageable goals and how to achieve them safely. Participants will then receive weekly follow-up phone calls to discuss progression and/or possible trouble-shooting strategies. Participants will be asked to set goals related to increasing self managing health behaviors. Participants will be encouraged to self-monitor goals, behaviors and symptoms using a computer tablet.
1517882|NCT02833311|Behavioral|Paper and Pencil Group|Participants will first meet once with a trained health education specialist. During this meeting the health education specialist will work with the participant in setting constructive and manageable goals and how to achieve them safely. Participants will then receive weekly follow-up phone calls to discuss progression and/or possible trouble-shooting strategies. Participants will be asked to set goals related to increasing self managing health behaviors. Participants will be encouraged to self-monitor goals, behaviors and symptoms using a paper-pencil diary.
1517883|NCT02833311|Behavioral|Standard Treatment Control Group|Participants will first meet once with a health education specialist. During this meeting the health education specialist will provide general information about engaging in healthy behaviors. Information will primarily focus on the benefits of engaging in healthy behaviors and safety precautions. Participants will then receive weekly follow-up phone calls to discuss various health topics.
1517886|NCT02833272|Behavioral|EMPOWER Educational Brochure|The EMPOWER educational brochure explains the risk of benzodiazepine and non-benzodiazepine sedative use to patients with a current prescription. The brochure also provides a tapering schedule if the patient chooses to discontinue taking the drug.
1517887|NCT02833246|Other|SMS/MMS text messaging|text messaging reminders on oral chemotherapy medication adherence
1517888|NCT02833246|Other|usual care|
1517889|NCT02833233|Procedure|Cryoablation|
1517890|NCT02833233|Drug|Ipilimumab|
1517891|NCT02833233|Drug|Nivolumab|
1517892|NCT02833220|Device|transcranial magnetic stimulation|
1517895|NCT02833181|Device|BIS monitor|Monitoring circadian variation of EEG
1517896|NCT02833168|Other|patient-filled questionnaires|All patients answer selected questionnaires on sleep-related symptoms, sleep quality, daytime performance, and health-related quality of life.
1517897|NCT02833168|Device|spiromanometry|Measurement of forced vital capacity, maximum inspiratory pressure and maximum expiratory pressure
1517898|NCT02833155|Drug|Entinostat|Given PO
1517899|NCT02833155|Drug|Exemestane|Given PO
1517900|NCT02833142|Drug|BIIB033 (opicinumab)|
1517901|NCT02833116|Drug|Betamethasone|
1517902|NCT02833116|Drug|Dexamethasone|
1517903|NCT02833103|Drug|Danshu Capsules|Danshu Capsules (0.9g potid/day) for three months by oral
1517904|NCT02833103|Drug|Pinaverium Bromide|Pinaverium Bromide (100mg potid/day) for three months by oral
1517905|NCT02833090|Procedure|biomarkers|transthoracic echocardiography, radial, and aortic arterial blood sampling
1517906|NCT02832154|Other|Internet-Based Intervention|Complete online PA program
1517907|NCT02832154|Procedure|Quality-of-Life Assessment|Ancillary studies
1517908|NCT02832154|Other|Questionnaire Administration|Ancillary studies
1517909|NCT02832154|Behavioral|Telephone-Based Intervention|Participate in daily reporting via text message
1517910|NCT02832141|Procedure|Mobilization anterior|Participant in prone position. Central thoracic mobilization from posterior-to-anterior.
1517911|NCT02832141|Procedure|Mobilization posterior|Participant in sitting position. Central thoracic mobilization from anteriors-to-posterior.
1517912|NCT02832128|Drug|AUT00063|4 capsules of 200 mg AUT00063, to take orally with food for 4 weeks
1517913|NCT02832128|Drug|Placebo|4 capsules of placebo, to take orally with food for 4 weeks
1517914|NCT02832115|Drug|Topical Nitroglycerine|Topical nitroglycerine is applied to wrist prior to transradial cardiac catheterization to dilate radial artery and reduce spasm in study arm patients
1517915|NCT02832115|Drug|Topical Lidocaine|Topical Lidocaine is applied to wrist prior to transradial cardiac catheterization in both study and control arms
1517916|NCT02832102|Procedure|Standard treatment of SCCHN patients|The interventions may include surgery, radiotherapy, chemotherapy or combined therapies, as recommended by best practice and international guidelines.
1517917|NCT02832089|Drug|oral carvedilol|oral carvedilol in escalating doses for reducing ventricular rate in AF patients
1517918|NCT02832076|Procedure|Subcutaneous negative suction drain for 10 days|
1517919|NCT02832076|Procedure|No subcutaneous drain|
1517920|NCT02833064|Radiation|Non-contrast magnetic resonance imaging|
1517921|NCT02833064|Other|Biological sampling|Blood, urine, stool and breath sampling and analysis
1517922|NCT02833038|Drug|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
1517923|NCT02833038|Drug|Normal saline|the same bolus and infusion volumes of normal saline
1517924|NCT02833025|Device|Thrombin generation and Platelet Function Testing|Point-of-care testing of thrombin generation, platelet function, and rotational thromboelastometry
1517925|NCT02833012|Drug|Caprylic Triglyceride Oil|10 g Caprylic Triglyceride Oil (10.5 mL) at Hour 0 on Day 1
1517926|NCT02833012|Drug|AC-1202|60 g AC-1202 (shaken in 180 mL of water) at Hour 0 on Day 1
1517927|NCT02833012|Drug|Axona|40 g Axona (shaken in 120 mL of water) at Hour 0 on Day 1
1517928|NCT02833012|Drug|AC-1204|40 g AC-1204 (shaken in 120 mL of water) at Hour 0 on Day 1
1517929|NCT02832999|Drug|sub cutaneous liraglutide|
1517930|NCT02832999|Drug|Oral Vildagliptin|
1517931|NCT02832986|Other|Medical Questionary|"The medical questionary will contain :
Date of initial infection by Herpes zoster
Localisation
Severity
Presence of postherpetic pain
Postherpetic pain Intensity
Postherpetic pain duration
Antiviral treatment
History of chronic pathologies
Concomitant treatment"
1517932|NCT02832973|Drug|Spironolactone|Spironolactone 25 mg
1517933|NCT02832973|Drug|Furosemide,|Furosemide 20-40 mg
1517934|NCT02832973|Drug|Amiloride|Amiloride 5 mg
1517935|NCT02832973|Drug|Ramipril|Ramipril 5-10 mg
1517936|NCT02832973|Drug|Bisoprolol|Bisoprolol 5-10 mg
1517937|NCT02832960|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
1517938|NCT02832960|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
1518055|NCT02831946|Device|MODIFIED VICRYL PLUS|closing the intra-cuticular layer with MODIFIED VICRYL PLUS suture
1517939|NCT02832947|Drug|Rivaroxaban 10 mg|At study month 7 (+/-1 month), patients receive at 8 a.m. a single dose of 10 mg rivaroxaban. Study specific blood tubes are sampled the same day at the indicated time points from T -1h to T 12h.
1517940|NCT02832934|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
1517941|NCT02832934|Drug|Placebo|Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug. Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg.
1517942|NCT02832921|Behavioral|cognitive training by virtual reality|
1517943|NCT02832921|Behavioral|watching a tv series about the brain|
1517944|NCT02832921|Device|treadmill|"VR cognitive training will be augmented by walking on a treadmill, since it is well established that dual tasking—i.e. performing the VR-based cognitive effort together with a motor task, even as simple as walking on a treadmill—places greater demand on cognitive resources than a single task."
1517945|NCT02832908|Other|Change from semi-seated position to supine|from semi-seated position (30°) to lying position
1517946|NCT02832895|Other|Transcranial doppler examination|Assessment of frontal bone window for transcranial doppler
1517947|NCT02832882|Procedure|No-touch RFA|No-touch RFA indicates RFA without tumor puncture. In this study, no-touch RFA is performed using Octopus electrodes.
1517948|NCT02832882|Procedure|Conventional tumor puncture RFA|Conventional tumor puncture RFA indicates routine procedure of RFA in our institution. In this study, RFA procedure is performed using Octopus electrodes.
1517949|NCT02832869|Other|short message service based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
1517950|NCT02832869|Other|Wechat based re-education|The patients will receive standard written instructions on preparing for a colonoscopy plus intervention such as Wechat based re-education by one investigator on the day before colonoscopy.
1517951|NCT02832856|Behavioral|Healthy Relationship Education|RS+ is a widely-implemented healthy relationship education curriculum that aligns with the Georgia Department of Education performance standards in health education. The full curriculum features 12 lessons covering such topics as healthy relationships, dating violence prevention, communication skills, conflict management, and decision making.
1517952|NCT02832856|Behavioral|Job Readiness Curriculum|"Beginning to Work it Out (BWIO) assists youth who are preparing for first-time employment. Topics include recognizing how personal beliefs and behaviors may be perceived in the workplace, as well as soft skills such as emotional self-management and problem-solving skills."
1517953|NCT02832830|Radiation|IMRT|Intensity modulated Raiotherapy (IMRT) of the involved spinal bone metastasis
1517954|NCT02832830|Radiation|fractionated RT|external beam Radiotherapy of the involved spinal bone metastasis
1517955|NCT02832817|Device|Pulse oximeter|For each monitoring of Arterial Oxygen Saturation, measures of Arterial Pulsed Oxygen Saturation will be made for each pulse oximeter.
1517956|NCT02832804|Device|transcranial Direct Current Stimulation|Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
1517957|NCT02832791|Procedure|QUADRICEPS TENDON|Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. We will make an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line (about 2 cm of the medial edge of the patel) that is used as an instrumentation portal. Then,, a high anteromedial portal, is made higher than the previous to see the femoral footprint. Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft. A 4 cm vertical incision is made starting at the proximal pole of the patella and directed proximally and centered in line with the quadriceps tendon. The subcutaneous tissue is dissected and a 70-80 mm long ,10 mm wide and 7mm depth graft is obtained with the use of a n21 scalpel 2cm of both limbs of the graft are sutured
1517958|NCT02832791|Procedure|HAMSTRING TENDON|"Once the limb is prepped and draped,it is exsanguinated, and the tourniquet is raised to 250 mm Hg. The procedure begins with an arthroscopic examination through an anterolateral viewing portal to corroborate the ACL injury as well as the determination of possible associated lesions. The accessory medial portal is stablished slightly above the joint line, at about 2 cm of the medial edge of the patellar tendon. This portal is used as an instrumentation portal. A third portal, a high anteromedial portal, is made higher than the previous, this portal will allow visualization of the femoral footprint.
Once the associated meniscal or cartilaginous lesions are addressed attention turns to the harvesting of the graft.
A 4cm oblique incision is made starting 2 cm medial to the tibial tubercle and directed proximally and medially. After dissecting the subcutaneous tissue the Sartorius fascia is incised and both tendons are identified and harvested with the use of a tendon stripper"
1517959|NCT02832778|Drug|Efavirenz|Efavirenz 400mg
1517960|NCT02832778|Drug|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
1517961|NCT02832778|Drug|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
1517962|NCT02832778|Drug|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
1517963|NCT02832778|Drug|Rifinah or local generics|Rifampicin 600 mg and isoniazid 300 mg if ≥50kg or rifampicin 450 mg and isoniazid 300 mg if <50kg.)
1517964|NCT02832765|Radiation|A|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions of the involved spinal bone metastases
1517965|NCT02832765|Radiation|B|Intensity modulated radiotherapy (IMRT) 30Gy in 10 fractions with an SIB with 40 Gy in 10 fractions to the metastasis of the involved spinal bone metastases
1517966|NCT02832765|Radiation|C|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions of the involved spinal bone metastases
1517967|NCT02832765|Radiation|D|Intensity modulated radiotherapy (IMRT) 20Gy in 5 fractions with an SIB with 30 Gy in 5 fractions to the metastasis of the involved spinal bone metastases
1517968|NCT02832752|Procedure|ECPR Protocol|The regional protocol is activated for eligible patients who remain pulseless after 3 cycles of resuscitation, and intubation. The hospital team is activated at this time, which includes the emergency department team, a perfusionist, and a cardiovascular surgeon. A mechanical CPR device (Lucas chest compression device) is applied at this time and the patient is transported to hospital. The goal times from first professional CPR to ECMO flows is < 60 minutes, and from emergency department (ED) arrival to ECMO flows < 30 minutes.
1517969|NCT02832739|Device|SENACA - ICT based self-management support system|SENACA - ICT based self-management support system is a structured self-management support system with several interacting components, combining tele-monitoring devices and a solution for personalised health plans. ==> www.senaca.ch
1517970|NCT02832726|Dietary Supplement|Vitamin B12|
1517971|NCT02832713|Drug|Botulinum toxin A ( BoNT-A)|Intra-articular injection of BoNT-A
1517972|NCT02832713|Device|Hyaluronic acid (HA)|Intra-articular injection of Hyaluronic acid
1517973|NCT02832700|Dietary Supplement|Casein glycomacropeptide|
1517974|NCT02832700|Dietary Supplement|Placebo|
1517975|NCT02832687|Drug|Acetaminophen|patients 50kg or more receive1000mg in 100milliliters of normal saline every 4 hours to a maximum dose 4000mg/24 hours. <50kg receive 12.5mg/kg to a maximum of 75mg/kg/24 hours.
1517976|NCT02832687|Drug|normal saline|100mL of normal saline every 4 hours to a maximum administration of 400mL
1517977|NCT02832674|Device|Percutaneous Radiofrequency single treatment|Percutaneous Radiofrequency single treatment' under controlled temperature conditions based on pre-defined amounts of energy as controlled by the device internal algorithm, and investigator expertise. Additionally, Hunsted solution will be infused in the treatment area to eliminate the electrode/fiber to touch inner layers of the skin. External temperatures (skin surface) will be monitored using a temperature reading camera to ensure the external temperature stays within acceptable levels during the procedure Ice packs will also be used as needed to cool the treatment area based on the Thermal Camera Reading where the . heat delivery may be exceeding the threshold.
1517978|NCT02832648|Dietary Supplement|selenase (selenium)|Selenase (Biosyn, Germany) Sodium selenite pentahydrate
1517979|NCT02832635|Drug|TMZ|TMZ 75mg/m2/d from the 1st day to the last day of radiotherapy
1517980|NCT02832635|Radiation|WBRT with avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT (Intensity Modulation Radiated Therapy), with or without boost. The maximum dose of hippocampus should be no more than 18Gy.
1517981|NCT02832635|Radiation|WBRT without avoidance of hippocampus|Whole brain radiotherapy of 30Gy/10f by IMRT, with or without boost. The dose of hippocampus is not considered.
1517982|NCT02832622|Device|MPP|MPP ON within 1 month post implant and then continuously programmed ON until 12 months (i.e., MPP ON for months 1-12 continuously)
1517983|NCT02832622|Device|BiV/MPP|MPP ON at the 12-month study visit and for at least 3 continuous months prior to 12-month assessment (i.e., BiV pacing ON at some point in months 1-9 and MPP ON for months 10-12)
1517984|NCT02832622|Device|BiV|MPP OFF at the 12-month study visit and for at least three continuous months prior to 12-month assessment (i.e., BiV pacing ON for months 10-12)
1517985|NCT02832622|Device|Other Pacing|Other pacing schemes not covered above (Retrospective categorization implemented based on the usage of MPP or BiV pacing for 12 months)
1517986|NCT02832609|Other|Supine|measurements after 30 minutes in complete supine position
1517987|NCT02832596|Drug|Norepinephrine|Ordinary anaesthesia and maintained preanesthetic blood pressure by norepinephrine infusion
1517988|NCT02832596|Procedure|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
1517989|NCT02832583|Device|Regenkit BCT-HA Cellular Matrix|To assess the efficacy of PRP-HA on skin rejuvenation, thirty one patients with chronological aging including wrinkles, dull and dry skin with loss of elasticity and firmness. The patients received three PRP-AH injection sessions 4 weeks apart into the cheeks.
1517992|NCT02832557|Other|Salivary collection|Collection of saliva via swab for miRNA processing
1517993|NCT02832557|Other|Vineland Adaptive Behavior Scale-II Assessment|
1517994|NCT02832557|Other|Medical history questionaire|
1517995|NCT02832557|Other|Autism Diagnostic Observation Schedule -2nd edition (ADOS-2)|
1517996|NCT02832544|Drug|Rivaroxaban (20 mg)|Rivaroxaban is non-inferior to VKAs for the prevention of stroke or systemic embolism in patients with AF/flutter and RVHD and potentially superior to VKAs.
1517997|NCT02832544|Drug|Vitamin K antagonists (VKA)|
1517998|NCT02832531|Drug|Rivaroxaban (15 mg)|"Rivaroxaban is superior to aspirin for the prevention of the composite of stroke or systemic embolism in patients with RVHD with AF or flutter who are unsuitable for VKA therapy, or in patients with RVHD without AF or Flutter with at least one of the following:
Left atrial enlargement ≥ 5.5 cm, OR
Left atrial spontaneous echo contrast OR
Left atrial thrombus OR
Frequent ectopic atrial activity (>1000/24 hours) on Holter ECG."
1517999|NCT02832531|Drug|Aspirin|
1518000|NCT02832505|Other|No intervention but only observational|This study is a cross-sectional and observational MRI study with three cohorts of patients, and no interventions will be applied.
1518001|NCT02832492|Behavioral|pupil near response|
1518002|NCT02832466|Other|Functional Test|Observation of physical function in hemodialysis patients during a period of 6 months
1518003|NCT02832453|Behavioral|Lifestyle|The counselling program consists of 6 group meetings of 1 hour and 3 individual consultations of at least 15 minutes each. Sessions will be set up with the aim to enhance knowledge and empowerment related to physical activity, sedentary conducts, dietary habits, as well as strategies for behaviour change will be given. Individual consultations will focus on establishing realistic objectives and to involve the participants in taking decisions.
1518056|NCT02831946|Device|DERMABOND GLUE|closing the intra-cuticular layer with Dermabond glue
1518057|NCT02831933|Biological|ADV/HSV-tk|Replication-defective recombinant adenovirus vector
1518004|NCT02832453|Behavioral|Aerobic interval training|The supervised aerobic interval training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of 4 series of 4 minutes of cycling at a heart rate of 80% of the VO2peak interspersed with active pauses of 2 minutes at 60% of the VO2peak .
1518005|NCT02832453|Behavioral|Traditional continous training|The supervised traditional continous training will consist of 16 supervised group training lessons lasting 60 minutes and 32 individual nonsupervised training lessons that would be self-administered by each participant. The main part of the training lessons will consist of activities such as walking, cycling, or tonification exercises always at an intensity of 60% of the VO2peak.
1518006|NCT02832440|Other|Exercise programmes|
1518007|NCT02832414|Behavioral|Intensive weight loss program|behavioral and dietary supplement
1518008|NCT02832401|Drug|Caffeine|
1518009|NCT02832401|Drug|Placebo|
1518010|NCT02832375|Drug|stannous fluoride|0.454% w/w stannous fluoride containing 1100ppm of fluoride
1518011|NCT02832375|Drug|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
1518012|NCT02832362|Drug|Carbomer 980|Test product containing 0.5% carbomer 980 gel
1518013|NCT02832362|Other|Placebo|Reference product containing vehicle without 0.5% carbomer 980 gel
1518014|NCT02832349|Other|Educational Actions|Individual educational session and 3 group educational sessions (5-6 patients per group) built around the epileptic disease, its treatment and daily life, will constitute the program of EA group.
1518015|NCT02832336|Drug|Vivarin|Adenosine is an endogenous sleep-promoting substance with neuronal inhibitory effects. Adenosine has been proposed to be a sleep-inducing substance accumulating in the brain during prolonged wakefulness. Caffeine is an adenosine receptor antagonist. It inhibits a part of the sleep cycle and, in turn, promotes the wakeup state. Caffeine results in the release of norepinephrine, dopamine and serotonin in the brain and the increase of circulating catecholamines, consistent with reversal of the inhibitory effect of adenosine.Vivarin Drug class :Central nervous system (CNS) stimulants.
1518016|NCT02832336|Drug|Fiber|Fiber will be used as placebo.
1518018|NCT02832310|Procedure|valsalva maneuver|the effects of valsalva maneuver on arterial pressure
1518019|NCT02832297|Other|Vectra DA|
1518020|NCT02832297|Other|Usual Care|
1518021|NCT02832271|Drug|SUNPHENON EGCg|SUNPHENON EGCg Oral, 400mg, twice per day
1518022|NCT02832271|Drug|Placebo|Placebo
1518023|NCT02832232|Other|translational dorsal glide mobilization technique grade III|"Translational dorsal glide mobilization technique grade III of the atlanto-occipital joint, it is a mobilization technique of Orthopedic Manual therapy according to Kaltenborn-Evjenth concept. The aim is to produce a dorsal glide of the occipital on the atlas, which will be held back by the therapist's hand, producing a stretch component of the suboccipital muscles.
And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
1518024|NCT02832232|Other|pressure maintained suboccipital Inhibition technique|"Pressure maintained suboccipital Inhibition technique is aimed to inhibit the tone of the suboccipital muscles. Although some dorsal occipital glide is produced by the weight of the head itself, the main effect is on the muscles due to dorsally pressure is not added to the occipital.
And Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education."
1518025|NCT02832232|Other|Control Group|Protocolized physiotherapeutic treatment: Three weeks of daily sessions (five a week) of stretching exercises, thermotherapy and postural education.
1518026|NCT02832219|Dietary Supplement|Molecular hydrogen|
1518027|NCT02832219|Dietary Supplement|Placebo|
1518028|NCT02832206|Procedure|hybrid ablation|Surgical thoracoscopic epicardial ablation (box-lesion) and left atrial appendage occlusion , followed (after 2-3months) by electrophysiological examination, and catheter ablation (completion of the box-lesion, cavotricuspid isthmus ablation and other ablation if indicated)
1518029|NCT02832180|Drug|OC containing EE and NET|
1518030|NCT02832180|Drug|BMS-986142|
1518032|NCT02832063|Biological|B244|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
1518033|NCT02832063|Biological|Placebo|4 pumps of spray to saturate the entire face applied BID. Applications should occur in the morning and at night for 12 weeks.
1518034|NCT02832050|Behavioral|Play therapy|See previous description of play therapy intervention arm.
1518035|NCT02832050|Behavioral|Standard of care|See previous description of comparator arm.
1518036|NCT02832037|Drug|BI 425809 dose 1|
1518037|NCT02832037|Drug|BI 425809 dose 2|
1518038|NCT02832037|Drug|BI 425809 dose 3|
1518039|NCT02832037|Drug|BI 425809 dose 4|
1518040|NCT02832037|Drug|Placebo|
1518041|NCT02832024|Device|plaque excision system|
1518042|NCT02832024|Device|stent|
1518043|NCT02832024|Device|Balloon|
1518044|NCT02832011|Dietary Supplement|olive oil|The infants fed with olive oil will have received same amount of calorie with infants who will receive eoprotin-fortified breast milk.
1518045|NCT02832011|Dietary Supplement|Eoprotin|Low birth weight infants are premature infants that born with birth weight less than 1500 g. Because these infants have low birth weight, weight gain can be increased by fortifying breast milk after post-natal 7 with eoprotin.
1518046|NCT02831998|Drug|ZP|Apply topically.
1518047|NCT02831998|Drug|ChloraPrep|Apply topically.
1518048|NCT02831998|Drug|ZP Vehicle|Apply topically.
1518049|NCT02831985|Procedure|general practice follow-up|Post-surgery follow-up by general practitioner
1518050|NCT02831985|Procedure|ear-nose-throat (ENT) specialist follow-up|Post-surgery follow-up by ear-nose-throat (ENT) specialist
1518051|NCT02831972|Drug|AG120|
1518052|NCT02831972|Drug|Itraconazole|
1518058|NCT02831933|Drug|Valacyclovir|Prodrug of the antiviral drug acyclovir
1518059|NCT02831933|Radiation|SBRT|Low-dose SBRT
1518060|NCT02831933|Drug|nivolumab|Fully human immunoglobulin (Ig) G4 anti-PD-1 monoclonal antibody
1518061|NCT02831920|Other|CEUS and targeted biopsies|
1518062|NCT02831920|Other|MRI and targeted biopsies|
1518063|NCT02831907|Procedure|Cardiac surgery|All cardiac surgery procedures with the use of cardiopulmonary bypass
1518064|NCT02831894|Drug|0% Hypnotic Medication Taper|Participants will not have their soporific hypnotic medication dosage changed during a 20 week blinded tapering period
1518065|NCT02831894|Drug|25% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 25% every two weeks during a 20 week blinded tapering period.
1518066|NCT02831894|Drug|10% Hypnotic Medication Taper|Participants will have their soporific hypnotic medication dosage reduced by 10% every two weeks during a 20 week blinded tapering period.
1518067|NCT02831868|Device|HAVAI|
1518074|NCT02831829|Other|water-based exercise training|Water-based training will be performed in upright position, in waist to xyphoid process deep thermo-neutral water at temperature of 32,8 C. The immersed exercise will include two session of aerobic and calisthenic exercise per day, six days of a week, both lasting 30 minutes
1518075|NCT02831829|Other|land-based exercise training|Land-based training will include two aerobic and calisthenic exercise session per day, six days of a week, both lasting 30 minutes
1518076|NCT02831816|Drug|ZP|Apply topically.
1518077|NCT02831816|Drug|ChloraPrep|Apply topically.
1518078|NCT02831816|Drug|ZP Vehicle|Apply topically.
1518079|NCT02831803|Dietary Supplement|Walnuts|28 gm/day in single-serve package
1518080|NCT02831803|Dietary Supplement|Extra Virgin Olive Oil|32 gm/day provided in 3, 34 ounce bottles
1518081|NCT02831790|Other|Fontan Education Videos|"The intervention will consist of three brief (~5 minute) professionally-developed whiteboard videos, available online. The videos will feature lay language at a grade 7 level or below and will be engaging. Topics are based on key findings of the Family Resilience Study, namely:
Stress reactions in children and parents post Fontan. This video will be supplemented with existing resources on the topic.
Anticoagulation
Prolonged pleural drainage"
1518082|NCT02831777|Device|non-invasive blood pressure monitor|Equivalence of CareTaker blood pressure to classical sphygmomanometry
1518086|NCT02831751|Biological|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
1518087|NCT02831751|Biological|60 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
1518088|NCT02831751|Biological|FluLaval® Tetra (15 µg/strain)|Single dose of a licensed quadrivalent vaccine
1518089|NCT02831751|Biological|Fluzone® High-Dose (60 µg/strain)|Single dose of a licensed trivalent vaccine
1518090|NCT02831738|Dietary Supplement|Polydextrose|Polydextrose 12 g
1518091|NCT02831738|Dietary Supplement|Control Treatment|no polydextrose
1518092|NCT02831712|Dietary Supplement|Ferrous Fumarate|One tablet of a commercial iron supplement (Ferrous Fumarate 200 mg, from Drug House of Australia) will be provided to participants after overnight fast. The intervention is only one time.
1518093|NCT02831686|Drug|Selinexor|
1518100|NCT02831647|Dietary Supplement|AYMES PRAGUE|AYMES PRAGUE is a ready to drink, high energy, low volume oral nutritional supplement drink. It provides 300 kcal and 12g protein per 125ml serving. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision. It is not designed as a sole source of nutrition.
1518101|NCT02831634|Procedure|Blood sampling|After inclusion in the protocol, a blood sample (50 mL in EDTA tubes) will be withdrawn during pre-operative consultation.
1518102|NCT02831621|Behavioral|lifestyle intervention (diet OR diet+exercise)|diet or diet+fitness training
1518103|NCT02831608|Biological|Influenza vaccine|
1518104|NCT02831608|Biological|Placebo|
1518105|NCT02831595|Device|GKS Prime Flex Bioloy by Permedica, a TiNbN coated fixed-bearing cruciate-retaining total knee prosthesis|
1518106|NCT02831582|Dietary Supplement|Omega-3 Fatty Acid|Given PO.
1518107|NCT02831582|Other|Placebo|Given PO.
1518110|NCT02831543|Drug|Motireb 5/100 mg|
1518111|NCT02831543|Drug|Mosapride citrate|
1518112|NCT02831543|Drug|Placebo|
1518113|NCT02831530|Drug|Abemaciclib|
1518114|NCT02831517|Drug|BIIB074|Administered as specified in the treatment arm
1518115|NCT02831517|Drug|Placebo|Matched Placebo
1518116|NCT02831491|Drug|Ramucirumab|Administered IV
1518117|NCT02831491|Drug|Docetaxel|Administered IV
1518118|NCT02831478|Drug|BAY987517|Applied liberally to the skin (Formulation: RB# Z16-071)
1518119|NCT02831478|Drug|Sunscreen Lotion (RB# T78-190B)|Applied liberally to the skin
1518120|NCT02831465|Behavioral|Healthy Subjects|Subjects with normal lung function performed MVV at increasing breathing frequencies and maximal tidal volume, from 10 to 100 cycles per minute. Inspiratory capacity (IC) was measured at rest and after each 12 seconds of MVV in order to detect DH. From the moment DH appeared at a given frequency, only one additional MVV at a higher breathing frequency was conducted to confirm DH.
1518121|NCT02831452|Other|pelvic floor muscle strength evaluation|
1518122|NCT02831439|Behavioral|Basic public reporting|The basic intervention will comprise public reporting through the WCHQ website. Individual-level, claims data submitted for billing to third party payers by participating healthsystems will be used to (i) identify cohorts of women with incident breast cancer at the practice-level and (ii) construct the metrics for public reporting and individual benchmarking information. These data are consistent with Medicare and Marketscan claims in both format and content thereby ensuring seamless application of the validated algorithm as well as construction of outcome variables as proposed in Aims 1 and 2 of the study.
1518123|NCT02831439|Behavioral|Enhanced intervention|The enhanced intervention adds an app comprising a decision tool, patient education and communication information that will be delivering concise, readily accessible information about the main components of the intervention. Specifically, physicians in participating practices will be provided a smartphone-based, point-of-care application that will include i) a list of the unproven/ineffective interventions with statements about a) scientifically proven appropriate use; b) proven or suspected downsides to inappropriate use; ii) clinical calculators that allow physician to input individual patients' clinical/tumor characteristics for each test; iii) practice-specific summary of publicly reported results; and iv) printable patient information adapted from the ASCO Choosing Wisely website.
1518124|NCT02831439|Behavioral|Control group - observational|"Comparison states will be used to evaluate the interventions in light of possible secular trends in the region and the nation. The design strategy will enable estimates of the effectiveness of the basic intervention (Aim 1) by comparing (i) the pre-intervention rates to post-intervention rates as well as by comparing (ii) changes between the pre- and post-intervention periods for the treatment state (WI) relative to comparison states, neighboring states and others. A similar approach will be used in Part II to provide estimates of the enhanced intervention's impact relative to the basic intervention and contemporary usual care provided in control states, thereby enabling the cost-savings analyses proposed as part of Aim 3."
1518153|NCT02831283|Drug|18F-Florbetaben|18F-Florbetaben (Neuraceq) has FDA approval for human use in evaluation of Alzheimer's disease. 18F-Florbetaben will be administered at activity up to 8.1 mCi per injection.
1518154|NCT02831283|Procedure|Lumbar puncture (optional)|Subjects have the option to have lumbar puncture performed for the measurement of inflammatory markers in cerebrospinal fluid.
1518155|NCT02831270|Procedure|Acute normovolemic hemodilution (ANH)|
1518156|NCT02831270|Drug|hydroxyethyl starch (HES 130/0.6)|
1518157|NCT02831257|Drug|AZD2014|
1518125|NCT02831426|Device|Two-stage with Acellular Dermal Matrix (CELLIS® Breast)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by an ADM (CELLIS® Breast, MECCELLIS BIOTECH, 40 rue Chef de Baie, 17000, La Rochelle FRANCE) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
1518126|NCT02831426|Device|Two-stage with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After mastectomy, an immediate reconstruction will be performed by means of a tissue expander, of any shape and type available, positioned in a subcutaneous, pre-pectoral, position. The tissue expander will be held in place by a Titanium Coated Polypropylene Mesh (TiLOOOP® Bra, pfm medical, ag Wankelstraße 60 ,50996 Köln GERMANY) either completely wrapped around it or just covering its anterior surface. After at least 6 months a TE/implant exchange procedure will be performed with a synchronous fat grafting procedure to ameliorate the skin flap thickness and softness over the medial border and upper pole. Fat grafting will be performed with the wash and filter principle technique of handling the harvested fat tissue.
1518127|NCT02831413|Behavioral|RS+|The curriculum's 12 sessions will be delivered over a period of about 12 weeks during the winter quarter, with an average of one session taught per week. The lessons cover topics such as personal values, the principals of smart relationships, communication and conflict management, and sexual decision making.
1518128|NCT02831413|Behavioral|Codeacademy|a computer programming curriculum, Codeacademy, that teaches students how to use HTML.
1518129|NCT02831400|Behavioral|Walking test|Walking test to increase cardiac output, maximum 12 minutes
1518130|NCT02831400|Behavioral|Standard Meal|After the walking test, volunteers eat a standard warm meal
1518131|NCT02831387|Drug|P-321 Ophthalmic Solution|P-321 Ophthalmic Solution 0.017%
1518132|NCT02831387|Drug|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
1518133|NCT02831374|Drug|Local anesthesia|The surgical extraction under local anesthesia (2% Lignocaine and 1:100000 Adrenaline) procedure was the same in all patients.
1518134|NCT02831374|Procedure|surgical extraction of impacted third molar|After achieving Local anesthesia using 2% lignocaine hydrochloride with 1:100,000 epinephrine, standard Terrence Ward's incision was placed to raise a full thickness mucoperiosteal flap. Disto-buccal bone was carefully exposed and bone surrounding the buccal aspect of impacted tooth was performed using surgical bur under copious irrigation with 0.9% saline. Tooth was elevated using Coupland elevator and if required situations tooth was sectioned with surgical bur to facilitate its removal. The socket was checked for any tooth or bony debris. The bony margins smoothened using a file and irrigated with 0.9% saline.
1518135|NCT02831374|Biological|Preparation of PRP gel|Before surgery, 10 milliliter of venous blood was collected from the anticubital fossa of the patients forearm and stored into sterile tubes containing anticoagulant (0.5 milliliter citrate phosphate dextrose) from each patient in the experimental group using routine venipuncture procedure. The whole blood is then centrifuged at 1,200 rotations per minute for ten minutes. The supernatant layer obtained was platelet poor plasma and buffy coat was collected in a new sterile tube and centrifuged again at 1,000 rotations per minute for 10 min. The upper half of the supernatant is removed and the lower half is mixed carefully to get platelet rich plasma. Five drops of mixture of 10 % CaCl2 and 1000 Units bovine thrombin to 2 milliliter Platelet rich plasma to obtain the gel form.
1518136|NCT02831374|Procedure|Placing platelet Rich plasma and suturing|Subsequently, platelet rich plasma gel was placed into the extraction sockets of patients in the group A and wound closure was done using simple interrupted 3.0 black silk sutures.
1518137|NCT02831374|Procedure|Suturing|Wound closure was done using simple interrupted 3.0 black silk sutures.
1518138|NCT02831374|Drug|Postoperative medication|Patients were advised regular post extraction and prescribed 500 milligram of paracetemol postoperatively (1 tablet every 6 hours for 2 days).
1518139|NCT02831361|Drug|Gemigliptin|
1518140|NCT02831361|Drug|Gemigliptin placebo|
1518141|NCT02831361|Drug|Metformin|For patients who have been taking metformin, the patients who had taken at least 1000 mg of metformin daily and continue the same dosage and administration as before participant in the study
1518142|NCT02831361|Procedure|Diet/exercise questionnaire|"doing exercise with about intermediate intensity(50~70%) for ≥150minutes in total over at least 3 times(every other day) weekly should be recommended and regualr diet without greater changes in life style as much as possible during the whole study period.
the questionnaire regarding diet/exercise will be collected at -week2, week 1 week 7, week 13, week 19, week 25"
1518143|NCT02831335|Other|MRI|Perform MRI studies
1518144|NCT02831335|Other|MRI|Perform MRI studies
1518145|NCT02831335|Other|MRI|Perform MRI studies
1518146|NCT02831335|Other|Group 4|Perform MRI studies
1518147|NCT02831322|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention was a nonsurgical technique for treating obstructive coronary artery disease
1518148|NCT02831309|Behavioral|Light-Intensity Condition|The light-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, light--intensity activity breaks performed at 25% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
1518149|NCT02831309|Behavioral|Moderate-Intensity Condition|The moderate-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, moderate-intensity activity breaks performed at 50% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
1518150|NCT02831309|Behavioral|High-Intensity Condition|The high-intensity condition consisted of 8 hours of sitting interrupted with 2--minute, vigorous-intensity activity breaks performed at 75% of heart rate reserve (HRR) every 18 minutes. Standardized meals were provided.
1518151|NCT02831309|Behavioral|Sedentary Condition|The sedentary condition consisted of 8 hours of sitting interrupted with 2-minutes of screen time every 18 minutes. Standardized meals were provided.
1518152|NCT02831283|Drug|11C-PBR28|11C-PBR28 is a PET radioligand that binds to the 18 kDa translocator protein (TSPO), a marker of inflammation. 11C-PBR28 has previously been administered in humans. 11C-PBR28 will be administered at activity of up to 20 mCi per injection.
1518158|NCT02831244|Device|Agili-CTM|Consenting individuals will be selected from the population of patients with osteoarthritis of the great toe examined by a participating investigator. Following signing an informed consent, candidates will be evaluated by an adjudication committee for possible inclusion in the trial based on medical history and Standing Foot X-ray. Candidates that are approved or conditionally approved by the adjudication committee will undergo Agili-CTM implantation procedure
1518159|NCT02831231|Drug|xanomeline tartrate|xanomeline tartrate, 75 mg capsule, TID
1518160|NCT02831231|Drug|Trospium chloride|trospium chloride, over encapsulated 20 mg tablet, BID
1518161|NCT02831218|Procedure|QCA and Aspirin|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
1518162|NCT02831218|Procedure|QCA and Clopidogrel|QCA(quantitative coronary angiography) guided BVS implantation and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
1518163|NCT02831218|Procedure|Imaging guided and Aspirin|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
1518164|NCT02831218|Procedure|Imaging guided and Clopidogrel|BVS size and length were selected by on-line IVUS(intravascular ultrasound) or OCT(optical coherence tomography) measurements and all patients are treated with dual antiplatelet therapy (aspirin 100mg/day and clopidogrel 75mg per day[or ticagrelor 90mg po bid]) for 12 months after BVS implantation, and randomized to either aspirin alone (aspirin 100mg/day) or clopidogrel alone (clopidogrel 75mg /day) for the next 4 years.
1518165|NCT02831205|Device|everolimus-eluting bioresorbable vascular (Absorb) scaffold|
1518166|NCT02831205|Device|everolimus-eluting cobalt-chromium (Xience) stent|
1518167|NCT02831192|Biological|microtransplantation|HLA mismatched donor mobilized prepheral stem cell infusion
1518168|NCT02831179|Drug|Capecitabine|Given PO
1518169|NCT02831179|Drug|Temozolomide|Given PI
1518170|NCT02831179|Drug|Veliparib|given PO
1518171|NCT02831179|Other|Pharmacological Study|Correlative studies
1518172|NCT02831179|Other|Laboratory Biomarker Analysis|Correlative studies
1518175|NCT02831153|Procedure|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
1518176|NCT02831140|Behavioral|Early exercises|"In postoperative phase:
Early exercises: within the first hour ;setting a half bed position, deep breathing and coughing . In the second hour, curbing vagal malaise and performing relaxation movements. In the third hour, walking about 20 to 30 minutes."
1518177|NCT02831140|Behavioral|Removing urinary probe and all catheters.|In postoperative phase : Removing urinary probe and all catheters.
1518178|NCT02831140|Behavioral|Early alimentation|In postoperative phase :Early alimentation: in the first hour to the second hour .
1518179|NCT02831140|Behavioral|commun interventions|"In preoperative phase: stopping smoking at least 2 weeks, hospitalization and balanced alimentation one day before the surgery.
In peroperative phase : no use of benzodiazepines in the anesthesia , selective intubation , maintaining vital parameters as normal and using a mini invasive surgical approach ( video thoracoscopy , video assisted thoracoscopy , thoracotomy with preservation of the posterior muscles of the chest wall
, preservation of Serratus anterior and the front part of Latissimus Dorsi ).
In postoperative phase : Immediate extubation ( less than 30 minutes from the surgery end) , peridural or paravertebral or intercostal block analgesia , no use of abusive antibiotic , all analgesic drugs are permitted if there are no contraindications and physiotherapy from the 6th hour."
1518180|NCT02831127|Other|short message service group|Each month after stent implantation, the investigator sent a text message by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date to come back to the hospital for stent management. Patients were requested to respond by SMS and were encouraged to contact the investigator if they had any questions about stent management. Besides, patients received conventional reminder:After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
1518218|NCT02830880|Drug|FACBC PET-CT|Anti-3-[18F]FACBC is an investigational positron emission tomography (PET) radiotracer being studied given intravenously prior to PET scan.
1518181|NCT02831127|Other|conventional group|After stent implantation, all patients received oral and written instructions about further management. If single or multiple plastic stents were inserted, patients were informed to come back to the hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed to come back to the hospital at 6 months after ERCP.
1518182|NCT02831114|Other|Acupuncture|Acupuncture uses tiny needles to promote blood flow, nervous system signaling, and brings the body back into homeostasis which the state of optimum functioning. Treatment for taxane induced peripheral neuropathy will consist of traditional acupuncture and will use points located in the foot (SP 3, ST 41, LR 3, K 3, GB 41), knee (SP 9, ST 36, K 10, GB 34), and arm (LI 11). Participants will continue to take their conventional therapy. Each acupuncture treatment will take place at Oriental Medicine Associates with trained acupuncturist, William Hendry. Each session should last about 30 minutes.
1518185|NCT02831088|Drug|Neu2000KWL High-does group|1st infusion of 750mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 500 mg at intervals of 12 hours
1518186|NCT02831088|Drug|Neu2000KWL Low-does group|1st infusion of 500mg in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of 250 mg at intervals of 12 hours
1518187|NCT02831088|Drug|Placebo|1st infusion of the same volume of saline in patients receiving endovascular therapy within 8 hours following ischemic stroke onset followed by 9 consecutive infusions of same volume of saline at intervals of 12 hours
1518188|NCT02831075|Biological|Adipose-derived stem cell|stem cell acquisition, processing and reinfection, to evaluate the efficacy of adipose-derived stem cell.
1518189|NCT02831075|Biological|saline|
1518190|NCT02831062|Other|low protein diet + ketosteril|Patients will follow a diet containing 0.6 g protein/kg per day, phosphorus 5-10 mg/kg/day, Ketosteril 1 capsule per 5 kg body weight/day divided over three doses (max 8 capsules per dose).
1518194|NCT02831036|Other|training program|subjects in the trial group will follow a training program which includes 3 times a week running on a treadmill.
1518195|NCT02831036|Other|VO2max test|each subject will perform 4 times VO2max test according to BRUCE protocol in order to evaluate his aerobic fitness.
1518196|NCT02831036|Other|spatial orientation test|each subject will undergo 4 spatial orientation tests during the trial (month between 2 tests), each test is composed of 5 following days in which the subject will wear virtual reality glasses (Oculus Rift DK2) and attempt to arrive different destinations in a virtual maze tasks (using xbox one controller). each day will be given 3 attempts, the duration of each attempt is 2 min.
1518197|NCT02831023|Drug|Sulphadoxine-pyrimethamine|Each Fansidar tablet is scored containing 500mg sulphadoxine and 25 mg pyrimethamine. Doses will be administered by weight.
1518198|NCT02831023|Drug|0.25 mg/kg primaquine|Primaquine will be administered in an aqueous solution according to weight-based dosing.
1518199|NCT02831023|Drug|Dihydroartemisinin-piperaquine|160mg/20mg or 320mg/40mg of dihydroartemisinin/piperaquine tablets will be used to administer weight-based doses.
1518200|NCT02831023|Drug|Methylene blue|Methylene blue will be given as minitablets in prepackaged sachets according to weight groups.
1518201|NCT02831023|Drug|Amodiaquine|Amodiaquine will be administered once daily for 3 days, following weight-based dosing of 150 mg tablets.
1518202|NCT02830997|Device|Stereotactic guidance system|
1518203|NCT02830984|Procedure|EST+LBD+ENBD|Nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
1518204|NCT02830984|Procedure|EST+LBD|Without nasobiliary drainage after endoscopic sphincterotomy plus large-balloon dilation in treating of large bile duct stones
1518205|NCT02830971|Procedure|Doing Different ICU techniques and skills|
1518206|NCT02830958|Device|Kinesiotaping|The Kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting. Latex-free and wearable for days at a time, Kinesio® Tex Tape is safe for populations ranging from pediatric to geriatric, and successfully treats a variety of orthopedic, neuromuscular, neurological and other medical conditions.
1518207|NCT02830958|Other|No intervention|No intervention. Uses of an ordinary tape
1518208|NCT02830945|Behavioral|Motivational Interviewing Intervention Arm|
1518209|NCT02830945|Other|Control Brochure Arm|
1518210|NCT02830932|Drug|VXA-RSV-f Oral Vaccine|The drug product will be provided as small white enteric-coated tablets. Multiple tablets may be administered to delivered the high dose.
1518211|NCT02830932|Drug|VXA Placebo Tablets|The placebo will be provided as small white enteric-coated tablets that are similar in size and number to the active drug product tablets.
1518212|NCT02830919|Drug|Glucosamine and chondroitin sulfate combination (Eurofarma)|
1518213|NCT02830919|Drug|Glucosamine and chondroitin sulfate combination (Zodic)|
1518214|NCT02830906|Drug|ramosetron|intravenous ramosetron 0.3 mg before spinal anesthesia and intrathecal morphine
1518215|NCT02830906|Drug|Ondansetron|intravenous ondansetron 8 mg before spinal anesthesia and intrathecal morphine
1518216|NCT02830893|Device|LARA|Study participants will use LARA to propel themselves and to play computer games with the impaired upper extremity for 30 min/day in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
1518217|NCT02830893|Behavioral|Standard|Study participants will receive no exposure to LARA, will use a standard wheelchair, and will be asked to perform a program of conventional arm exercises for 30 min/day, also in addition to standard of care rehabilitation therapy for 3 weeks or the duration of their stay.
1518219|NCT02830880|Other|MRI, CT, or Bone Scan|Conventional imaging such as a MRI, CT, or Bone scan will be performed to correlate imaging findings.
1518220|NCT02830854|Other|Molecular Hydrogen|
1518221|NCT02830841|Device|remote ischemic preconditioning(RIPC)|After anesthesia induction, donors or recipients will be treated with automated blood pressure cuffs on their upper arms to receive RIPC by cuff inflation (to 15mmHg above systolic pressure) for 5 minutes and left inflated for 5 minutes. The cuff will then be deflated to 0 mm Hg and left uninflated for 5 minutes. This cycle will be performed 3 times in total.
1518222|NCT02830841|Device|Sham RIPC|Only blood pressure cuff will be placed to the patient, but no inflation or deflation will be performed.
1518223|NCT02830828|Other|Investigation of precision pinch grip control|
1518224|NCT02830802|Other|Dr. Hauschka Med Mundspüllösung Salbei / cosmetics|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.
For an application fill the closure cap with the mouthwash. Rinse the mouth vigorously for 30 seconds, for easier timekeeping use the hourglass. Then spit out the mouthwash, do not rinse."
1518225|NCT02830802|Other|Placebo|"Supervised use over 6 weeks 1x/day additional to habitual oral hygiene protocol.
For an application fill the closure cap with the mouthwash."
1518226|NCT02830789|Dietary Supplement|Calcium Carbonate|
1518227|NCT02830789|Dietary Supplement|Calcium Citrate|
1518228|NCT02830789|Dietary Supplement|Placebo|Tablet manufactured to mimic a calcium carbonate tablet
1518229|NCT02830789|Procedure|Roux-en-Y gastric bypass|Roux-en-Y gastric bypass surgery at least 12 months before study inclusion
1518230|NCT02830776|Drug|bimatoprost 0.03% ophthalmic solution|Latisse (bimatoprost 0.03% ophthalmic solution) applied to the eyelid margin for dermatochalasis (upper eyelid drooping)
1518231|NCT02830763|Dietary Supplement|CNT-02|Each subject will take 2.0g of the investigational product orally 3 times a day after every meal. Unless an apparent worsening of symptoms or unacceptable adverse event occurs, the subject will continue to take the investigational product for up to 6 months.
1518232|NCT02830750|Procedure|Ablation|
1518233|NCT02830737|Procedure|Traditional RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the lesion center
1518234|NCT02830737|Procedure|No-touch RFA|Radio frequency ablation via an ultrasound-guided electrode needle penetrating into the tumor-free zone (within 5mm along the edge of the tumor)
1518239|NCT02830711|Other|Positive and Negative Affect Scale for Children|A 36-item instrument, including the Mood and Anxiety Symptom Questionnaire (MASQ)16 developed by Chang and Yeh and the Positive and Negative Affect Scale for Children developed by Watson and Clark
1518240|NCT02830685|Device|DTI with Acellular Dermal Matrix (CELLIS® Breast)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using an ADM (CELLIS® Breast), either completely covering the implant or simply covering the anterior surface of it. The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
1518241|NCT02830685|Device|DTI with Titanium Coated Polypropylene Mesh (TiLOOOP® Bra)|After conservative mastectomy, a pre-pectoral subcutaneous reconstruction with definitive implant will be performed using a TCPM (TiLOOOP® Bra), either completely covering the implant or simply covering the anterior surface of it.The implant could be of any shape, material and texture available with no restriction. After at least 6 months, a fat grafting procedure, using a wash and filter principle for fat handling, will be performed over the implant.
1518242|NCT02830672|Procedure|Surgical release A1 pulley for Trigger finger of the hand|
1518243|NCT02830646|Other|DFG mesure|Measure the effect of gastric bypass on the report DFG / VEC.
1518244|NCT02830633|Procedure|LNTME|Patients in this group received laparoscopy-assisted nerve-preserved TME for treatment of rectal cancer
1518245|NCT02830633|Procedure|OTME|Patients in this group received traditional open TME for treatment of rectal cancer
1518246|NCT02830620|Other|Dosage of chimiokines|
1518247|NCT02830607|Device|Xiaomi Mi Band|participants will wear Xiaomi Mi Band as assessment tool for recovery after epidural steroid injection for treatment of low back pain
1518248|NCT02830594|Radiation|External Beam Radiation Therapy|Undergo palliative external beam radiation therapy
1518249|NCT02830594|Other|Laboratory Biomarker Analysis|Correlative studies
1518250|NCT02830594|Biological|Pembrolizumab|Given IV
1518251|NCT02830568|Procedure|open donor nephrectomy|open donor nephrectomy
1518252|NCT02830568|Procedure|standard and hand-assisted laparoscopic donor nephrectomy|standard and hand-assisted laparoscopic donor nephrectomy
1518253|NCT02830568|Procedure|laparoscopic robotic-assisted nephrectomy|laparoscopic robotic-assisted nephrectomy
1518254|NCT02830542|Drug|SER-262|SER-262 is a rationally designed, multi-strain Ecobiotic® microbiome therapeutic produced synthetically by in vitro fermentation. It is a consortium of anaerobic, commensal bacteria in spore form, encapsulated for oral administration.
1518255|NCT02830542|Drug|Placebo|Placebo will be identical to the investigational product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
1518256|NCT02830529|Behavioral|MAD DASH|Participants were taught mindfulness meditation including body scan, loving kindness meditation and breathing exercises. The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
1518373|NCT02829424|Drug|Methotrexate Placebo|Use of placebo- MTX in psoriasis patients receiving anti TNF alpha agent according to the approved indication
1518257|NCT02830529|Behavioral|DASH diet education|The diet education component included lecture on reading labels, low cost healthy meal preparation, and dietary consultation regarding personal strengths and self-identified areas of improvement.
1518258|NCT02830516|Other|Measurement of lung elastance by two methods|Measurement of tidal variations in esophageal pressure followed in the same patient by performing a PEEP-step while simultaneously measuring the change in lung volume
1518259|NCT02830503|Procedure|Feeding tube daily replacement|Feeding tubes replaced once a day in the first week of life.
1518260|NCT02830490|Other|functional tests|Test-retest reliability of physical function in hemodialysis patients
1518262|NCT02830438|Device|Shear wave elastography|Ultrasound technique of the kidneys to assess wave elastography.
1518263|NCT02830425|Other|No intervention|
1518264|NCT02830412|Other|Postoperative nausea and vomiting (PONV) reminder|The postoperative nausea and vomiting (PONV) electronic reminder will be programmed to assess the patient risk for PONV according to the risk factors identified by Apfel and Koivuranta. The PONV risk assessment and current guidelines will be displayed electronically for patients randomized to receive the reminder.
1518265|NCT02830399|Device|active rTMS-ECT|5 High Frequency (20Hz) rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
1518266|NCT02830399|Device|sham rTMS-ECT|5 sham rTMS (applicated on the left prefrontal dorsolateral cortex) before 5 bilateral ECT
1518267|NCT02830386|Device|LVIS stent|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
1518268|NCT02830373|Device|LVIS stents|Patients who meet the inclusion criteria will be treated with a low profile visualized intraluminal support (LVIS) stent with coils.
1518269|NCT02830360|Drug|Antiarrythmic Drug Therapy|Patients will be prescribed antiarrhythmic drugs (either amiodarone or sotalol based on specific clinical presentation, including medical history, functional class, ejection fraction, and renal function.)
1518270|NCT02830360|Procedure|Catheter ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
1518273|NCT02830321|Other|helicopacter pylori stool antigen test (CER TEST BIOTEC)|Stool samples were tested by using one step H.pylori stool antigen test (CER TEST BIOTEC)for the detection of H. pylori antigen in pregnant women with hyperemesis gravidarum
1518274|NCT02830295|Other|Basic Body Awareness Therapy|Basic body awareness therapy is a health oriented and person-centred approach with focus on the patient's resources. This is a method in physiotherapy, where we search to promote movement quality in daily life through self-exploration and self-experience.BBAT conceives the person from the biomechanical, physiological, bio-psycho-social and existential aspects, using the movement quality as a witness of the link in between all these perspectives.It can be done individually or in groups, through different daily life movements: lying, sitting, standing, walking, pair movements, use of voice and massages. BBAT has validated and reliable assesment tools, as BARS and BAS-I
1518275|NCT02830282|Other|Blood Collection|
1518277|NCT02830256|Other|NCS-I (Nociception Coma Scale adapted intubated patients)|Every included patient will be assessed by the 3 methods 3 times (before, during, after the procedure fo care) in 3 conditions. There will be 2 painful conditions usually performed in ICU (Nursing and bronchoaspiration) and a painless condition (RASS assessment).
1518278|NCT02830243|Drug|Sevoflurane|End-tidal concentration of sevoflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
1518279|NCT02830243|Drug|Desflurane|End-tidal concentration of desflurane was maintained at age-corrected 1 minimum alveolar concentration throughout the study period. The remifentanil infusion rate was adjusted using TCI pump to achieve surgical pleth index between 20 and 50.
1518280|NCT02830230|Drug|Tab cefixime,Tab Azithromycin|The women with clinical cervicitis will receive treatment for cervicitis.
1518281|NCT02830204|Device|Mitral Valve Replacement with Sapien3|subjects with surgical MVR with Sapien3
1518282|NCT02830165|Other|Laboratory Biomarker Analysis|Correlative studies
1518283|NCT02830165|Other|Quality-of-Life Assessment|Ancillary studies
1518284|NCT02830165|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1518285|NCT02830152|Device|LAAO|The left atrial appendage is occluded with the AMPLATZER™ Amulet™ device, which offers a conformable disc and lobe designed for complete occlusion of the left atrial appendage.
1518286|NCT02830152|Drug|Medical Therapy|Available options included in Medical therapy are: anticoagulation with OAC or NOAC, antiplatelet therapy (including monotherapy and dual antiplatelet therapy) and no pharmacological antithrombotic therapy.
1518287|NCT02830139|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Cisplatin 60mg/m2, 5-Fu 1500mg/m2, 43°C, 60min, During surgery and 7 days after surgery.
1518288|NCT02830139|Procedure|Radical colorectal resection|radical colorectal resection with lymphadenectomy
1518289|NCT02830139|Drug|Oxaliplatin , Capecitabine|XELOX postoperative chemotherapy Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
1518290|NCT02830139|Drug|Normal saline , Cisplatin , 5-Fu|
1518291|NCT02830126|Other|Anesthesiology Control Tower Feedback|Clinicians in the Anesthesiology Control Tower will provide extra support for the anesthesiology team in the operating room.
1518292|NCT02830113|Procedure|non-surgical periodontal treatment|One session of complete scaling, polishing, root planning, and the irrigation of periodontal pockets with a 10% povidone iodine solution
1518293|NCT02830100|Other|Healthy volunteers|Magnetic Resonance Imaging during intern speech, listening, talking, thinking.
1518294|NCT02830100|Device|MRI|
1518374|NCT02829411|Behavioral|Workforce Readiness Program|job readiness workshops, organized into ten daily sessions over two weeks.
1518295|NCT02830087|Procedure|Tourniquet Cuff Pressure|Tourniquet cuff pressure is how hard the tourniquet cuff, which is placed around the patient's thigh, presses on the thigh in order to cut off blood supply to the lower leg during total knee surgery.
1518296|NCT02830074|Behavioral|Best practices PAP + patient Education +ongoing Support and Training|"This is a combined sleep and PAP adherence program, called the BEST program (Best practices PAP + Education + ongoing Support/Training"
1518297|NCT02830074|Behavioral|Sleep Education|This program includes non-directive sleep education plus standard treatment of SDB.
1518299|NCT02830048|Drug|Glibenclamide|
1518300|NCT02830035|Procedure|Real-time Ultrasound-guided|Real-time ultrasound guided paramedian spinal anesthesia
1518301|NCT02830035|Procedure|Anatomical Landmark Technique|Conventional anatomical landmark technique for paramedian spinal anesthesia
1518302|NCT02830022|Other|physiological explorations|
1518303|NCT02830009|Other|Urines samples|24-hour urines will be collected
1518304|NCT02830009|Other|Blood sample|
1518305|NCT02829996|Drug|trabodenoson 6.0% / latanoprost 0.005% QD|Trabodenoson 6.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
1518306|NCT02829996|Drug|trabodenoson 3.0% / latanoprost 0.005% QD|Trabodenoson 3.0% / latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
1518307|NCT02829996|Drug|trabodenoson 6.0% / latanoprost 0.0025% QD|Trabodenoson 6.0% / latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
1518308|NCT02829996|Drug|latanoprost 0.005% QD|Latanoprost 0.005% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
1518309|NCT02829996|Drug|latanoprost 0.0025% QD|Latanoprost 0.0025% administered once per day in both eyes and placebo administered once per day in both eyes, for 8 weeks.
1518315|NCT02829957|Drug|Apixaban|10mg BID for 7 days, then 5mg BID for three months
1518316|NCT02829957|Drug|Rivaroxaban|15mg BID for 7 days, then 20mg daily for three months
1518317|NCT02829944|Drug|Ropivacaine|
1518318|NCT02829944|Drug|Ketorolac|
1518319|NCT02829944|Drug|Placebo|
1518320|NCT02829931|Radiation|Hypofractionated Stereotactic Irradiation|Hypofractionated Stereotactic Irradiation (HFSRT) prior to nivolumab.
1518321|NCT02829931|Drug|Nivolumab|Nivolumab intravenously (IV): 240 mg every (q) 2 weeks x 4 months followed by 480 mg q 4 weeks.
1518322|NCT02829918|Drug|Nivolumab|Participants will receive nivolumab at a dose of 240 mg intravenously (IV) every 2 weeks (Q 2W) for 16 weeks (16W) and then 480 mg Q4W from 17 weeks to end of study.
1518323|NCT02829892|Device|Light therapy|14-days exposure with an innovative ambient light
1518324|NCT02829879|Drug|8% arginine/1450ppm sodium monofluorophosphate dentifrice|
1518325|NCT02829879|Drug|5% potassium nitrate/2500ppm sodium fluoride dentifrice|
1518326|NCT02829866|Device|AMIStem-H|
1518327|NCT02829853|Genetic|Genetic analysis by SANGER and WHOLE EXOME NEXT GENERATION SEQUENCING|Patients with sarcoidosis patients are monitored in the regular follow-up in one of 28 GSF clinical centers. Blood sampling was performed in two 5ml classical heparinized tube, as used for red/white/platelets blood cells analysis. The patients receive complete information on the SARCFAM protocol and sign an informed consent stating that the genetic study will be conducted on the BTNL2 gene and genes related to immunity, including loci other than BTNL2.DNA was extracted from a 1-5 ml sample of blood and stored in frozen conditions until analysis. Genomic DNA is captured using Agilent in-solution enrichment methodology (Human Clinical Research Exome, Agilent) with their biotinylated oligonucleotides probes library, followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 400. For each genomic position, the exomic frequencies (Homo & HTZ) are determined from all the exomes already sequenced and/or the exome results provided by 1000G, EVS, HapMap database.
1518328|NCT02829840|Drug|Ponatinib|"Part 1: Ponatinib at starting dose of 30 mg by mouth every day for one 28 day cycle.
Part 2 Phase I Dose Escalation: Ponatinib at starting dose of 30 mg by mouth every day of a 28 day cycle.
Part 2 Phase II Dose Expansion: Ponatinib at maximum tolerated dose from Phase I by mouth every day of a 28 day cycle."
1518329|NCT02829840|Drug|5-azacytidine|"Part 2 Phase I Dose Escalation: 5-azacytidine at dose of 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) for on Days 1-7 of every 28 day cycle.
Part 2 Phase II Dose Expansion: 5-azacytidine 75 mg/m2/d administered subcutaneously (SQ) or intravenously (IV) on Days 1-7 of every 28 day cycle."
1518330|NCT02829840|Behavioral|Phone Calls|"About 30 days after end-of-study visit, study staff calls participant and asks if they have had any side effects and/or started any new treatment(s).
If disease appears to be responding to study drugs, study staff calls participant every 3-6 months for up to 5 years and asks how they are doing and about any side effects they may be having."
1518332|NCT02829814|Drug|TNX-102 SL Tablet, 2.8 mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
1518333|NCT02829814|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
1518371|NCT02829437|Other|Treatment for EST|Surgery and/or Chemotherapy and or/radiotherapy for EST treatment according to disease guidelines: no specific treatment is imposed by protocol (observational study)
1518372|NCT02829424|Drug|Methotrexate|Use of low dose methotrexate (MTX) in psoriasis patients receiving an anti TNF alpha agent
1518334|NCT02829801|Behavioral|AAT and cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with a 15 minute introductory activity allowing the establishment of the relationship with the dog and between the participants. Activities with the dog will be offered: games, caresses, brushing.
Then, a 40 minute cognitive stimulation will be offered. Finally, 5 minutes will be devoted to the closing of the session and to say goodbye to participants and the dog (pet him, play with him ...)."
1518335|NCT02829801|Behavioral|Cognitive stimulation and rehabilitation of social tie.|"There are 8 workshops, one workshop per week. The workshops will begin with an introductory activity of 15 minutes that will establish the relationship between the participants. Different topics will be proposed to foster communication and exchange.
Then, the same cognitive stimulation in the AAT arm will be offered."
1518336|NCT02829788|Other|Non interventional|Peroperative data collection
1518337|NCT02829775|Drug|Pegylated Interferon Alfa-2a|Participants will maintain the same dose they were receiving in the parent protocol.
1518338|NCT02829775|Drug|Recombinant Interferon Alfa 2a|Participants will maintain the same dose they were receiving in the parent protocol.
1518339|NCT02829762|Other|Program of geriatric and Social intervention associated techniques of Domotic and Remote assistance|Implementation of social aids, a monthly social monitoring and home improvement with domotic techniques and remote assistance
1518340|NCT02829749|Device|NeoChord beating heart mitral valve implantation|The NeoChord DS1000 procedure is performed in five steps: (1) Device Preparation; (2) Left Ventricular Access; (3) Leaflet Capture and Verification; (4) Suture Deployment and (5) Suture Closure. The sutures are placed via a ventriculotomy 2-4 cm postero-lateral from the apex of the left ventricle via thoracotomy. The procedure is performed on a beating heart through a 2 to 3 inch right antero-lateral thoracotomy, then one to five Goretex neochordae are introduced with a transcatheter delivery system through the apex of the heart, into the left ventricle, and fixed on the free edge of the prolapsed leaflet. This is performed with transesophageal echocardiographic guidance.
1518341|NCT02829749|Procedure|Control|traditional mitral valve repair performed under cardiac arrest
1518342|NCT02829736|Procedure|Intraoperative sealing test|A standard 28 Fr chest tube is inserted through the anterior port hole and all port holes are closed. With the tip of the chest tube below water, the pleura is emptied from air during continuous ventilation of the lungs. An air leak after 5 minutes of ventilation indicates a negative sealing test, whereas a cessation of air leak within 5 minutes indicates a positive sealing test.
1518343|NCT02829736|Procedure|Standard post-operative chest tube|A regular chest tube is left in the pleura.
1518344|NCT02829736|Procedure|Intraoperative chest tube removal|Chest tube is removed intraoperatively.
1518345|NCT02829723|Drug|BLZ945|
1518346|NCT02829723|Drug|PDR001|
1518347|NCT02829710|Behavioral|Nurse-driven sedation protocol|The nurse-driven sedation protocol included the COMFORT-B scale. Initial doses were chosen by the physicians then all changes were made by the nurses with the aim of attaining an optimal range of analgesia and sedation, which was defined as values from 11 to 17 on the COMFORT-B score.
1518348|NCT02829697|Drug|Ropivacaine|Perineural injection.
1518349|NCT02829684|Other|Data collection|This register will follow the evolution of the clinical practices and their consequences in the health of the patients, in all regions of France in order to have a national register. for Children and adults.
1518350|NCT02829671|Other|Clinical and biological assessment|Blood sample, clinical assessment with quetsionnaires
1518351|NCT02829658|Behavioral|Psychologic test|Assessment by a psychologist including the Structured Interview for Diagnostic and Statistical Manual (DSM)-IV Personality Disorders (SIDP-IV) was given straight to those who had a score above 28. This questionnaire allowed us to distinguish one group of subjects with BPD and a group with other PD (without BPD). Clinical evaluation included Axis I (MINI), Axis II (SIDP-IV), psychopathological features (YSQ-I, Defense Style Questionnaire (DSQ-40), demographic variables and therapeutic alliance (Haq-II).
1518352|NCT02829658|Other|No intervention|No intervention
1518353|NCT02829645|Other|Clinical assessment|Clinical assessment with questionnaires
1518354|NCT02829632|Behavioral|Group Sessions|Participants will receive a 3-session behavioral lifestyle program for a healthful lifestyle and weight loss.
1518355|NCT02829632|Behavioral|Feedback|Participants will receive up to 4 daily feedback messages based on progress in attaining target behavior. The feedback messages will be delivered on a variable ratio schedule and tailored to data in subjects' dietary recordings.
1518356|NCT02829632|Behavioral|Self-monitoring|Participants will receive an one-time how to self-monitor using the smartphone session.
1518357|NCT02829606|Other|small scotoma using Head Mounted Display No re-mapping|re-mapping software turned off
1518358|NCT02829606|Other|Large scotoma using Head Mounted Display PLUS re-mapping|re-mapping software turned on
1518359|NCT02829593|Other|hypoglycemia (low blood sugar) and MRI|hypoglycemia (low blood sugar) and MRI
1518360|NCT02829580|Procedure|Echocardiography|Measures by Doppler and study of endothelial function
1518361|NCT02829567|Behavioral|Motivational interviewing|
1518362|NCT02829541|Drug|BIIB068|Administered as specified in the treatment arm.
1518363|NCT02829541|Drug|Placebo|Administered as specified in the treatment arm
1518364|NCT02829528|Behavioral|Little Flower Yoga For Kids|Little Flower Yoga for Kids is a promising yoga and mindfulness program for children developed by Jennifer Cohen Harper, MA, E-RCYT, which incorporates five elements (connect, breathe, move, focus, relax) to improve the child's ability to sustain attention and regulate emotions.
1518365|NCT02829515|Procedure|tonsil surgery with or without concomitant adenoidectomy|tonsillectomy, tonsillectomy with adenoidectomy, tonsillotomy, tonsillectomy with adenoidectomy
1518366|NCT02829502|Drug|Byetta|Single dose of subcutaneous injection of 5 μg exenatide (Byetta).
1518367|NCT02829502|Drug|Normosaline|Single dose of subcutaneous injection of 20 μL normosaline (placebo).
1518368|NCT02829476|Biological|Osteoblast sample|culture osteoblasts obtained from vertebrae fragments from 30 patients with AIS and from 10 control patients with secondary scoliosis
1518369|NCT02829463|Radiation|Magnetic resonance imaging|3.0 T Magnetic resonance imaging of knee joints. It does not harm the subjects.
1518370|NCT02829450|Other|peritoneal ultrafiltration|Peritoneal fluids should be inserted intraperitoneally for several hours dwell
1518375|NCT02829411|Behavioral|Relationship education|"25-hours of Within My Reach curriculum and relationship skills education sessions"
1518376|NCT02829398|Procedure|CerebroSpinal fluid and plasma samples|CerebroSpinal fluid and plasma samples for biological markers
1518377|NCT02829385|Drug|Apatinib and XELOX combined treatment group|"Apatinib Mesylate Tablets 500 mg P.O.d1-21 and XELOX (oxaliplatin 130mg/㎡ i.v. d1, capecitabine 1000mg P.O. d1-d14)
Every 3-week time is a cycle until PD or intolerance of drug toxicity occurs."
1518378|NCT02829372|Drug|CD3/HER2 bispecific monoclonal antibody|Increasing doses, IV on day 1 and 15 of each 28 day cycle
1518379|NCT02829359|Drug|Entecavir therapy|Patients in the antiviral group received entecavir begin in the first 3 days before surgery for at lest 1 month.
1518380|NCT02829346|Drug|Peri-articular tranexamic acid|750 mg of peri-articular TXA, prior to deflating the tourniquet and wound closure
1518381|NCT02829346|Drug|Intravenous tranexamic acid|750 mg of IV TXA, prior to deflating the tourniquet and wound closure
1518382|NCT02829333|Other|general anesthesia and patient controlled intravenous analgesia|Patients receive general anesthesia intraoperative period and continuous intravenous analgesia postoperation
1518383|NCT02829333|Other|spinal anesthesia and continuous postoperative epidural analgesia|Patients receive spinal anesthesia intraoperative period and continuous epidural analgesia postoperation
1518384|NCT02829320|Drug|GSK1278863|GSK1278863 will be provided as round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, 4 mg or 6 mg of GSK1278863 as active ingredient.
1518385|NCT02829320|Drug|Iron|Subjects will receive supplemental iron therapy if ferritin is <=100 ng/mL and TSAT is <=20%. The investigator (or subinvestigator) will choose the route of administration and dose of prescription iron.
1518386|NCT02829307|Drug|89Zr-GSK3128349 1 mg|89Zr-GSK3128349 is a mixture of unlabelled and zirconium-labelled GSK3128349, in the form of solution for IV administration, and is associated with about 15 MBq of radioactivity.
1518387|NCT02829294|Device|E002 - cerumen removal aid|topical treatment
1518388|NCT02829281|Drug|Botulinum Toxin Type A|Joint injection of Botulinum Toxin Type A
1518389|NCT02829281|Drug|Triamcinolone hexacetonide|Joint injection of triamcinolone hexacetonide
1518390|NCT02829281|Drug|Saline|Joint injection of Saline
1518391|NCT02829268|Drug|dantrolene sodium|"The purpose of this study is to assess the safety and tolerability of dantrolene sodium in patients with Wolfram syndrome. In addition, we will assess the efficacy of dantrolene sodium on the cardinal manifestations of Wolfram syndrome, including visual acuity, remaining beta cell functions, and neurological functions.
There is a screening period up to 56 days, a 24-week treatment period, and a 4-week safety follow-up period. Study assessments include medical & medication history, physical exams, neurological exams, eye exams, endocrine exams, vital signs, height, weight, electrocardiograms, blood and urine tests, pregnancy test if applicable, and questionnaires."
1518392|NCT02829255|Other|altitude exposure|altitude exposure
1518393|NCT02829242|Device|NIRS Monitoring (SenSmart Monitor)|
1518394|NCT02829229|Behavioral|Community-based obesity treatment (PP)|Participants in the treatment (PP) arm will receive a 5-component intervention: 1)Behavior change goals; 2)Self-monitoring; 3)Tailored skills training; 4)Video testimonials & 5)Interpersonal counseling. Both treatment and usual care arms will receive the current standard of care offered to postpartum mothers at WIC.
1518395|NCT02829190|Device|Magnetic Resonance Imaging (MRI),|Magnetic Resonance Imaging (MRI) of flow using phase contrast (PC) methods
1518396|NCT02829177|Drug|Allopurinol|
1518397|NCT02829177|Drug|Placebo|
1518398|NCT02829151|Drug|Triple antiplatelet therapy (aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) )|Combination antiplatelet therapy using aspirin (100 mg), clopidogrel (75 mg), and cilostazol (200 mg) after the index angioplasty
1518399|NCT02829151|Drug|Dual antiplatelet therapy (aspirin (100 mg) and clopidogrel (75 mg)) using aspirin and clopidogrel|Combination antiplatelet therapy using aspirin (100 mg) and clopidogrel (75 mg) after the index angioplasty
1518400|NCT02829151|Drug|Dual antiplatelet therapy (aspirin (100 mg) and cilostazol (200 mg)) using aspirin and cilostazol|Combination antiplatelet therapy using aspirin (100 mg) and cilostazol (200 mg) after the index angioplasty
1518401|NCT02829138|Genetic|Genetic information and Omega-3 fat intake|Only the Genetic group will receive their personal genetic information prior to beginning the 3-month study.
1518402|NCT02829138|Behavioral|General Nutrition related to Omega-3 fats|Both the Genetic and Non-Genetic groups will receive general nutrition information about omega-3 fats.
1518407|NCT02829073|Device|Neuromonics Tinnitus Treatment Program|The Neuromonics Oasis™ treatment device will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
1518408|NCT02829073|Device|Placebo Device|A placebo device, identical to the Neuromonics Oasis™ device with altered firmware will be fit to individuals reporting significant tinnitus. Assessment of primary and secondary measures will be made at 0 and 6 months following fitting.
1518409|NCT02829060|Drug|Nitrofurantoin 100 MG, 7d|7 day course, 100 mg twice daily, PO
1518410|NCT02829060|Drug|Gentamicin, 5mg/kg|Peri-operative dose: 5 mg/kg of ideal body weight, IV
1518411|NCT02829060|Drug|Ampicillin 2g|Peri-operative dose: 2 grams, IV
1518412|NCT02829060|Drug|Nitrofurantoin 100 mg, 48 hrs|48 hour course, 100 mg twice daily, PO
1518413|NCT02829060|Drug|Gentamicin, 80 mg, 7d|7 day course, 80 mg daily, IM or IV
1518414|NCT02829060|Drug|Gentamicin, 80 mg, 48hr|48 hour course, 80 mg daily, IM or IV
1518415|NCT02829047|Device|Vibrating Capsule|Patients will receive vibrating capsule for 6 weeks of treatment (14 capsules in 3 weeks)
1518416|NCT02829034|Drug|Ranolazine|Ranolazine 500mg by mouth twice per day and after two weeks increases to 1000mg by mouth twice per day and continue for a total of 26 weeks.
1518417|NCT02829034|Drug|Placebo|Placebo by mouth twice per day for a total of 26 weeks
1518418|NCT02829021|Device|FLIR ThermaCAM P-65|Women recalled for assessment after positive screening mammography were offered dynamic infrared thermography before clinical mammography and further tests.
1518419|NCT02829008|Drug|low-dose-bevacizumab/pemetrexed|Bevacizumab is administrated at a dose of 2 mg/kg once weekly by intravenous transfusion, which is on day 1, 8 and 15, and pemetrexed is given at a dose of 500mg/m2 once on the first day by intravenous transfusion, and repeated every three weeks, too.
1518420|NCT02829008|Drug|Treatment of physician's choice|The clinicians can select any drug or regimen that has been approved in metastatic cancer at present, including monotherapy, combination therapy, target therapy and palliative therapy. Specific agents include taxanes, capecitabine, gemcitabine, vinorelbine, cisplatin,carboplatin, nutrient solutions, and so on. These agents can be administered as monotherapy or in combination.
1518421|NCT02828995|Other|Comprehensive Diabetes Stigma Survey|"The surveys to be administered in the ENDSTIGMA study are as follows:
The Adherence to Refills and Medications for Diabetes survey is a validated, diabetes-specific survey measure utilizing patient self-report to assess diabetes medication adherence.
The Demographics survey will be used to assess participant baseline characteristics, including body mass index (BMI). The questions contained in this survey have been validated by Dr. Kerri Cavanaugh's research group.
Comprehensive Diabetes Stigma Survey is a novel survey being developed and validated in the ENDSTIGMA study. The ENDSTIGMA study will also compare the results from this survey with the medication adherence results, to determine if there is an association between diabetes stigma and medication adherence."
1518422|NCT02828982|Device|Powered ankle prosthesis|This device is a commercially available powered ankle prosthesis, (BioM, Bionx, Bedford, MA) which was given FDA device exempt status.
1518423|NCT02828982|Device|Dynamic Response Foot|This condition is a sham condition as the participant will wear the prosthesis they were clinically prescribed and usually wear.
1518424|NCT02828969|Other|Phone call or physical consultation|
1518425|NCT02828943|Behavioral|IMT with High Resistance EMT|
1518426|NCT02828943|Behavioral|IMT with Low Resistance EMT|
1518427|NCT02828930|Drug|Idasanutlin|Idasanutlin 300 mg tablet orally on Day 1; 400 mg tablet orally on Day 11 and Day 19. Participants, who are eligible to enter in optional treatment extension phase, will continue treatment with idasanutlin 200 mg tablet orally once daily for 5 days of 28-day cycle.
1518428|NCT02828930|Drug|Placebo|Placebo matching to idasanutlin aqueous dispersion will be administered orally on Day 11.
1518429|NCT02828930|Drug|[13C]-radiolabeled Idasanutlin|[13C]-radiolabeled idasanutlin 100 mcg will be administered as IV infusion over 15-minute on Day 1.
1518430|NCT02828930|Drug|[14C]-radiolabeled Idasanutlin|[14C]-radiolabeled idasanutlin 100 mg capsule (2, 50 mg capsules containing approximately 100 microcurie of radioactivity) will be administered orally on Day 1.
1518431|NCT02828917|Device|MedJ-01 Ridaforolimus Eluting Coronary Stent System|
1518432|NCT02828891|Device|Two-Dimensional Transcranial Doppler|Transcranial Doppler will be used to measure CSF pressure.
1518433|NCT02828878|Biological|Allogeneic MPBC transplantation from matched related donor|
1518434|NCT02828865|Device|Irreversible Electroporation (IRE) System|
1518435|NCT02828852|Other|Blood sample|"In washed platelets and whole blood, study shall determine the percentage of aggregation after activation by different agonists and the amount of certain membrane markers of platelet activation. Furthermore, an assay of estradiol plasma will be made.
In whole blood, study will evaluate the percentage of platelet adhesion to collagen matrix or fibrinogen and the volume of thrombies formed."
1518436|NCT02828839|Procedure|Access needle|The primary purpose of the single-use disposable access needle is to guide the use of a biopsy gun to obtain a tissue sample from the patient's prostate gland through a percutaneous puncture of the perineum. The primary purpose of the disposable needle guide is to stabilize the needle biopsy and better approximate the most direct path to the prostate.
1518437|NCT02828826|Other|telephone coaching|
1518438|NCT02828800|Other|Cartography of allodynic and hypoasthetic territories|The cartography of allodynic and hypoasthetic territories will be performed by applying a tactile stimulation of an application force of 15g (for allodynia) or 0.7g (for hypoesthesia). Tracings will be plotted on tracing paper layer that will then be evaluated by the VISITRAK® tool (Smith & Nephew), validated method reproducible and standardized, enabling accurate measurement of the area concerned .
1518439|NCT02828787|Other|MRI|"The study will take place in two phases. The first phase consists of a meeting of inclusion. During this phase, the principal investigator of the study will verify the inclusion criteria for patients using a questionnaire and an interview. Then, the effects of video on each person will be tested to verify that they well induce itch and measure it using visual analogue scales. This phase will also test the benefit of the relief by scraping and cold.
The second phase will be carried out only if the mental induction of pruritus has been possible in the first session. It involves acquiring the corresponding physiological signals fMRI. It will also be achieved during this phase an anatomical image of the brain of each participant and an image in DTI.
The phases will be carried out in this order in each participant. They will be separated at least one night."
1518440|NCT02828774|Other|there will be no intervention.|this study is observational, procedure are done in vitro and on animal models.
1518441|NCT02828761|Procedure|Coronary Calcium Scoring|Scan with 64-detector row or better CT scanners with quantification by the Agatston method.
1518442|NCT02828761|Procedure|Standard Care|Routine clinical monitoring of chest pain patients. Any of a number of non-invasive cardiac tests such as coronary CT angiography, stress echocardiography and stress radionuclide myocardial perfusion imaging may be performed.
1518443|NCT02828748|Other|no intervention in patients treatment, only biopsy taken|
1518444|NCT02828735|Device|respiration assessment|Respiration Breathing Exercise
1518507|NCT02828345|Other|Specimen Collection|
1518445|NCT02828722|Other|Controlled light and noise|"Purpose: The day-night ratio of the environmental illumination (limit 8 lux) and that of the noise level (limit 20 dBA) must correspond to the necessary value required by a healthy human body as defined by the National Sleep Foundation (USA).
Implementation: Simulation of the daytime period is performed with blue predominant artificial light with colour temperature between 5500 and 8000 K with lux values of 1000-1200 measured at the head of the patient. Simulation of the nighttime period is performed with a sleeping mask and earplugs."
1518446|NCT02828722|Other|Controlled nutrition|"In compliance with the standard daily nutrition protocol, nutrition is carried out only during daytime both in case of enteral and parenteral feeding in accordance with European Society for Clinical Nutrition and Metabolism 2016 guidelines.
Nutritional regimen should be stopped for 8 hours/24 at night (non-nutritional period may be depending on the work schedule of the actual ICU) , even if the daily energy/protein target is not reached."
1518447|NCT02828709|Device|Irreversible Electroporation|Guided by CT and accompanied by an external spacer for fixation, needle electrodes will be placed. The amount of probes and probe placement will be attuned for specific tumour size and location, granting 15mm between the electrodes with an active tip length of 15mm. IRE pulses with pulse intensity of 1500 V/cm will be delivered in 90 consecutive pulses of 90µs.
1518448|NCT02828696|Device|"No prep treatment of worn dentition with CAD-CAM composite"|Realization of minimally invasive prostheses in PICN (CAD-CAM composite)for worn dentition. Tooth tissues are preserved: no preparation is performed and ultra-thin restorations are CAD-CAM milled.
1518449|NCT02828683|Device|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST segment elevation myocardial infarction (STEMI)
1518450|NCT02828683|Device|PCI in patients with ST-elevation myocardial infarction|Percutaneous coronary intervention in patients with ST-segment elevatio myocardial infarction
1518452|NCT02828644|Device|EVO|videogame-like digital therapy
1518453|NCT02828631|Device|Macintosh laryngoscope|
1518454|NCT02828631|Device|McGrath videolaryngoscope|
1518455|NCT02828631|Device|Pentax videolaryngoscope|
1518461|NCT02828605|Device|Virtual Interactive Platform (VIP) Transplant|
1518462|NCT02828592|Drug|Fludarabine|30 mg/m2 IV QD x 5 days (Days -6 to -2)
1518463|NCT02828592|Drug|Cyclophosphamide|14.5 mg/kg/day IV x 2 doses (Days -6 & -5)
1518464|NCT02828592|Radiation|Total Body Irradiation|300 cGy x1 dose (Day -1)
1518465|NCT02828592|Drug|Rabbit ATG|1.5 mg/kg/day x 3 days (Days -3 to -1)
1518466|NCT02828592|Drug|Cyclophosphamide|Post-transplant: 50 mg/kg IV QD (Day +3 to +4)
1518467|NCT02828579|Procedure|Bariatric surgery|Laparoscopic Sleeve Gastrectomy (LSG) Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
1518468|NCT02828566|Drug|IN ketamine|Intranasal ketamine 100 mg/mL solution (10 mg/kg, maximum 800 mg)
1518469|NCT02828566|Drug|IV ketamine|Intravenous ketamine 50 mg/mL solution (1 to 1.5 mg/kg, maximum 120 mg)
1518470|NCT02828566|Drug|IN saline 0.9%|Intranasal 0.9% normal saline
1518471|NCT02828566|Drug|IV saline 0.9%|Intravenous 0.9% normal saline
1518472|NCT02828553|Other|Aggressive planned ambulation with a mobility aide|A trained mobility aide will provide aggressive ambulation at least 3X per day for all patients on the heart failure unit
1518473|NCT02828540|Drug|HT047 High-dose group|HT047 2250mg, three times a day dosing schedule, 3 tablets per dose
1518474|NCT02828540|Drug|HT047 Low-dose group|HT047 1500mg, three times a day dosing schedule, 3 tablets per dose
1518475|NCT02828540|Drug|Placebo|placebo having the same appearance as HT047 Tab. 250mg
1518476|NCT02828527|Other|Observational|
1518477|NCT02828501|Procedure|Spinal Manipulation|A spinal manipulation is a high velocity, low amplitude thrust through a physiological barrier in order to elicit a cavitation.
1518478|NCT02828488|Other|No intervention|It is a descriptive study. No intervention
1518479|NCT02828475|Other|CALYPSO|Software platform of machine-learning based predictive models of surgical complication.
1518480|NCT02828475|Behavioral|Standard Care|Previous standard of care based on surgeon judgement alone.
1518481|NCT02828462|Other|CAPRI|
1518482|NCT02828449|Behavioral|therapeutic education program|
1518483|NCT02828436|Device|Precision Spectra System|Spinal Cord Stimulation
1518484|NCT02828423|Procedure|EMD|Regenerative surgery with EMD
1518485|NCT02828423|Procedure|BC|Regenerative surgery with BC
1518486|NCT02828410|Dietary Supplement|SBI|Serum bovine immunoglobulin protein isolate 10 g twice per day
1518487|NCT02828397|Drug|REGN2222|
1518488|NCT02828384|Other|low fodmap diet|dietary teaching
1518489|NCT02828384|Dietary Supplement|Psyllium|7.1g of psyllium daily
1518490|NCT02828371|Device|stepping verticalization|After patient positioning, the slope of the tilt table was gradually increased from 0° to 20°, 40° and then 60° in a time span of nine minutes. The stepping frequency was set at 20 steps/min for the entire treatment. Cardiovascular and respiratory parameters were continuously monitored. The net time of the session was 30 minutes
1518491|NCT02828371|Other|conventional mobilization|in-bed physiotherapy (mobilization exercises in supine and sitting position on bed, without out-of-bed mobilization nor verticalization)
1518508|NCT02828332|Other|Vineland II (VABS -II)|semi-structured interview with a psychologist; Measure 4 areas: Communication, skills of daily living, socialization and skills Motrices
1518509|NCT02828332|Other|Quality of life|Evaluation of the quality of life and comorbidities
1518510|NCT02828319|Drug|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
1518512|NCT02828293|Other|Dynamic videofluoroscopic analysis|Patients bearing 3 different prosthesis (3 groups) will be prospactively assessed with videofluoroscopy.
1518513|NCT02828280|Device|NuMask|The NuMask is a relatively new mask ventilation device that has been registered with the FDA and used in the United States since 2006.
1518514|NCT02828280|Device|Traditional mask|A traditional air inflated facemark used to ventilate patients
1518515|NCT02828267|Behavioral|Brief Negotiational Intervention|This is a 5-10 minute conversation using the principles of motivational interviewing between the healthcare practioner and the patient to motivate the patient to identify at risk alcohol use and through self-empowerment create a plan to decrease alcohol use.
1518516|NCT02828254|Drug|PRI-724|
1518517|NCT02828241|Drug|DFD-04 Ointment|
1518518|NCT02828241|Other|Placebo Ointment|
1518519|NCT02828228|Drug|Vitamin D 1200 IU|Vitamin D 1200 IU once a day for 26 weeks
1518520|NCT02828228|Drug|Placebo|placebo once a day for 26 weeks
1518521|NCT02828215|Device|Swept-source optical coherence tomography (SS-OCT)|"The SD-OCT provides faster images and the ability to scan more of the central retina (macula). SD-OCT simultaneously measures multiple wavelengths of reflected light across a spectrum generating up to 40,000 A-Scans (axially sample points) per second. This allows the generation of 3 dimensional faster based volumetric images of the retina. The Spectralis OCT utilises real-time hardware eye tracking to resample lines scan enhancing the signal to noise ratio by improving the image quality.
The swept-source OCT (SS-OCT) uses a tuneable laser light source with a longer wavelength of light (typically 1040-1050 nm) that the light source seen in more conventional SD-OCT devices. The tissue penetration and resolution is greater with fast acquisition speeds and longer line scan lengths."
1518522|NCT02828202|Other|Biological|DNA from peripheral blood mononuclear cells, RNA, plasma, serum sampled at inclusion, every 6 months and before each new systemic therapy.
1518523|NCT02828202|Other|Tissular|Primary melanoma (mostly paraffin embedded), metastatic sample (s)(paraffin embedded and frozen) from at least 1 site at inclusion and during evolution, particularly before treatment modification if clinically required.
1518524|NCT02828202|Other|Quality of life|Specific questionnaires (FACT-M, EUROQUOL, MMAS8) at inclusion, every 3 months and before each new systemic therapy.
1518525|NCT02828189|Other|Physical Exercise|The patients were instructed to perform autonomous physical exercise program based preferences (progressive march on flat ground, dancing, cycling, etc.). They will receive written information. The program is 6 weeks with a frequency of 3 days per week and sessions about 50 minutes long.
1518526|NCT02828189|Behavioral|Therapeutic Education|Individual Therapeutic Education about healthy habits and exercise on breast cancer.
1518527|NCT02828189|Other|Therapeutic exercise-Physiotherapy|"15 minutes of exercise in step with moderate intensity (80% of maximum heart rate).
Force-resistance exercises of principals muscle groups of the lower limbs, upper limbs and trunk. The exercises included in the program as resistance will own body weight and exercised by the partners. In the exercises with your own body weight, intensity depend on the perception of effort that has the performer herself, and on that basis the number of repetitions will be established. In resisted exercises in pairs, you will be prompted to assistant exercising adequate strength so that the performer can perform the number of repetitions without problems.
Stretches corresponding muscle groups involved (upper limbs, lower limbs and trunk)."
1518528|NCT02828176|Procedure|electric cardiometry|"The following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance.
these parameters are measured on arrival to operating room before subarachnoid block in three different angles of lateral uterine tilt ( 0, 15 and 30 degrees )"
1518529|NCT02828176|Procedure|IV line insertion|two Iv lines are inserted and 500cc crystalloid is administered to parturient .
1518530|NCT02828176|Procedure|spinal anesthesia ( subarachnoid block )|Subarachnoid block (SAB) was performed in sitting position under complete asepsis using 25 g spinal needle. SAB was achieved by intrathecal injection of 10 mg hyperbaric bupivacaine plus 25ug fentanyl. Success of SAB was tested within five minutes after drug injection. SAB was considered successful if adequate block reached T4 dermatome.
1518531|NCT02828176|Procedure|electric cardiometry|after SAB the following measured variables were recorded using electric cardiometry heart rate, stroke volume, cardiac output, systemic vascular resistance at three different angles of left uterine lilt (0,15,30 degrees)
1518532|NCT02828163|Other|Autologous Platelet rich plasma|Intralesional injection of 1 milliliter of autologous Platelet rich plasma in the oral erosions every 2 weeks for 3 months.
1518533|NCT02828163|Drug|Triamcinolone Acetonide|10mg/ml of Triamcinolone acetonide will be injected in one side of the oral mucosa of pemphigus vulgaris patients every 2 weeks for 3 months.
1518534|NCT02828150|Dietary Supplement|Parenteral nutrition|Patients will receive a tailored nutritional support (parenteral nutrition) to cover estimated protein-calorie requirements. Energy: resting energy expenditure [Harris-Benedict] multiplied by a factor of 1.5. Protein: 1.5 g/kg/day. In obese patients (BMI >30 kg/m2) support will be calculated on ideal body weight (BMI=23 kg/m2)
1518537|NCT02828111|Drug|patidegib gel 2% - cohort 1|patidegib gel 2% applied once daily
1518538|NCT02828111|Drug|patidegib gel 4% - cohort 2|patidegib gel 4% applied once daily
1518539|NCT02828111|Drug|Vehicle - cohort 1|Vehicle applied once daily
1518540|NCT02828111|Drug|patidegib gel 2% - cohort 3|patidegib gel 2% applied once daily
1518541|NCT02828111|Drug|patidegib gel 4% - cohort 4|patidegib gel 4% applied twice daily
1518542|NCT02828111|Drug|vehicle - cohort 2|Vehicle applied once daily
1518543|NCT02828111|Drug|Vehicle - cohort 3|Vehicle applied twice daily
1518544|NCT02828111|Drug|Vehicle - cohort 4|Vehicle applied twice daily
1518545|NCT02828098|Drug|BO-112|Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).
1518546|NCT02828085|Biological|Nasal swab|Nasal swab will be performed in addition to the routine diagnosis visit in order to determine the diagnosis of infective pericardite with a more specific technique: PCR
1518547|NCT02828072|Other|SKY therapy|slow breathing
1518548|NCT02828072|Drug|usual drug therapy|
1518549|NCT02828059|Drug|Ropivacaine|Surgical wound Infiltration over 48 hours
1518550|NCT02828046|Biological|M281|
1518551|NCT02828046|Other|Placebo|
1518552|NCT02828033|Drug|Rilonacept|All patients will receive rilonacept with an initial loading dose of 320 mg delivered as two, 2-mL, subcutaneous injections of 160 mg each given on the same day at two different sites. The initial dose will be administered at the study site by study personnel. Dosing will then be a once-weekly injection of 160 mg administered as a single, 2-mL, subcutaneous injection by the patient at home. Patients will be dosed for 24 weeks.
1518553|NCT02828020|Drug|Ubrogepant|50 mg ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
1518554|NCT02828020|Drug|Placebo-matching Ubrogepant|Placebo-matching ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
1518555|NCT02828007|Device|NIV Group|Each patient will be using Non Invasive Ventilation (NIV) and will use it on each possible ventilation mode in a random order with a 10 minutes washout period between modes.
1518556|NCT02827994|Other|neurophysiology of pain education and exercises|"Pain neurophysiology education covered the neurophysiology of pain, transition from acute to chronic pain and the nervous system ability to modulate the pain experience. It was delivered in small groups (4 to 7 participants). A total of 4 sessions were delivered over 4 weeks (1 session per week). Each session took between 45 minutes and 1 hour.
Exercises were aimed at increasing the endurance and strength of the deep neck flexor and extensor muscles and of the scapular muscles delivered over 3 sessions (the first session covered pain neurophysiology education only). Each exercise was performed in 3 series of 10 repetitions. The number of exercises targeting the same group of muscles increased from one in the 2nd session to 2/3 in the 4th session."
1518557|NCT02827968|Drug|KN035|KN035 is a monoclonal antibody drug which is formulated for subcutaneous injection in a single-use vial (brown neutral borosilicate) containing a total of 300 mg antibody in 1.5 ml of solution.
1518558|NCT02827955|Device|Gamma Knife® radiosurgery bilateral|
1518559|NCT02827942|Drug|vonoprazan 20 mg bid|Vonoprazan is potent acid inhibitor. Vonoprazan 20 mg is dosed twice daily for 1 week.
1518560|NCT02827942|Drug|Amoxicillin 500 mg tid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. Then, 500 mg of amoxicillin is dosed three times daily for 1 week.
1518561|NCT02827942|Drug|Amoxicillin 750 mg bid|Amoxicillin is antibiotics. Its bactericidal effect is time-dependent. However, the standard regimen in Japan, 750 mg of amoxicillin is dosed twice daily with clarithromycin or metronidazole for 1 week. Then, 750 mg of amoxicillin is dosed twice daily.
1518562|NCT02827942|Drug|Clarithromycin 200 mg bid|Clarithromycin is antibiotics. It is involved in the standard first line regimen in Japan. Then, 200 mg of clarithromycin is dosed twice daily for 1 week.
1518563|NCT02827942|Drug|Metronidazole 250 mg bid|Metronidazole is antimicrobial agent. It is involved in the standard second line regimen in Japan. Then, 250 mg of metronidazole is dosed twice daily for 1 week.
1518564|NCT02827929|Behavioral|Education|3 times systemic education program will be provided to patients were diagnosed as asthma or COPD by their physicians.
1518565|NCT02827916|Device|Assessment of neuropathic pain with theThermotest device|Measure of painful neuropathy with thermotest
1518566|NCT02827916|Device|Assessment of neuropathic pain with SUDOSCAN device|Measure of painful neuropathy with sudoscan Devices
1518567|NCT02827916|Device|Assessment of neuropathic pain with the Neuropathic Pain Symptom Inventory.|Measure of painful neuropathy with Neuropathic Pain Symptom Inventory.
1518568|NCT02827903|Drug|Metformin + Rosuvastatin|Group I: Metformin + Rosuvastatin,
1518569|NCT02827903|Drug|Metformin + placebo|Group II: Metformin + placebo,
1518570|NCT02827903|Drug|placebo + Rosuvastatin|Group III: placebo + Rosuvastatin
1518571|NCT02827890|Drug|Januvia Tab. 100mg|Januvia Tab. 100mg*1T/day for 5days, QD, PO
1518572|NCT02827890|Drug|Januvia Tab. 100mg + Duvie Tab. 0.5mg|Januvia Tab.100mg + Duvie Tab. 0.5mg*1T/day for 5 dyas, QD, PO
1518579|NCT02827864|Behavioral|sequentially apply tDCS and MT|The participants in the SEQ group will first receive a-tDCS applied over M1lesioned without any active arm practice for 20 minutes. For the following 20 minutes, the participants will receive the MT, while the electrodes will be remained on the scalp without stimulation (sham tDCS). Then the electrodes will be removed from the scalp, and the participants will continue another 20 minutes of MT without tDCS. The treatment session will be ended with 30 minutes of functional task practice.
1518580|NCT02827864|Behavioral|apply tDCS concurrently|Sham tDCS will be first applied for 20 minutes without active arm practice. Twenty minutes of a-tDCS will then be applied concurrently with MT followed by another 20 minutes of MT without tDCS. The participants will also practice functional tasks for 30 minutes after MT.
1518581|NCT02827864|Behavioral|MT with sham tDCS|The training procedure will be the same as the above 2 groups except that sham tDCS will be provided in the first 40 minutes.
1518582|NCT02827851|Procedure|Liposuction|
1518583|NCT02827851|Other|SVF isolation|SVF will be isolated according to patent pending technology based on enzymatic digestion, washing and concentration of cell pellet in 5 ml of Hartmann's solution.
1518584|NCT02827851|Other|Intraarticular administration of autologous SVF|
1518585|NCT02827838|Biological|Durvalumab|Given IV
1518586|NCT02827838|Other|Laboratory Biomarker Analysis|Correlative studies
1518587|NCT02827838|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1518588|NCT02827825|Other|No intervention|No intervention. It's a study on retrospective Data
1518589|NCT02827812|Other|Comprehensive evaluation|At baseline (T0) and after 3-months (T1) all patients will be evaluated with Scales and questionnaire.
1518590|NCT02827812|Other|Physical Intervention at home|A traditional custom-tailored rehabilitative exercise program. The exercises will include functional strengthening, stretching, postural changes and balance activities; - An aerobic training on a cycle ergometer 3 days /week for three months.
1518591|NCT02827812|Other|Home-Based telemedicine program|"A nurse-tutor will follow patients through structured telephone appointments, collecting information about disease status and symptoms, offering advice regarding diet, lifestyle and medications and suggesting changes in therapy, according with the neurologist. The patient's clinical data and any suggestions made will be filled in a personal health electronic record.
A physiotherapist-tutor will supervise the patient's home-based individualized rehabilitation program, through scheduled videoconferences."
1518592|NCT02827799|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|This behavioral intervention includes training on managing the sleep environment (stimulus control), managing dysfunctional beliefs and attitudes about sleep (cognitive therapy), relaxation (progressive muscle relaxation), changing sleep behaviors (sleep hygiene), and managing sleep duration and continuity (sleep restriction).
1518593|NCT02827799|Behavioral|Heart Failure Self-Management Education|This intervention includes learning about how to manage one's heart failure. This includes understanding when to seek treatment, monitoring oneself for daily signs and symptoms, daily weight, dietary changes, physical activity, and adherence to medication taking.
1518594|NCT02827786|Device|Electromagnetic Acoustic Imaging|Electromagnetic Acoustic imaging (EMA) is a novel experimental platform utilizing the combination of electromagnetic radio frequency (RF) and acoustic waves to enhance ultrasound images. The resultant imaging allows (based on early experimental models) tissue differentiation based on its mechanical and electrical properties. Combined with conventional US scanning, this technology potentially allows high spatial resolution imaging of a target tissue with superimposed high contrast functional information. This is a proof-of-concept pilot study in humans.
1518595|NCT02827773|Other|Talking Pill Bottle|Made by Talking Rx
1518598|NCT02827747|Other|Antioxidants (Vitamins A,C,E) plus GSH|Study medication would contain 500 milligrams of vitamin C, 400 International Units of vitamin E, and 15 milligrams of beta-carotene (the equivalent to 25,000 International Units of vitamin A).The study medication would also contain 1000mg of Glutathione (GSH).
1518599|NCT02827747|Other|Placebo|Placebo pill
1518600|NCT02827747|Dietary Supplement|Centrum|Centrum
1518601|NCT02827747|Combination Product|Dietary Sources|From dietary sources of vitamins.
1518602|NCT02827734|Device|multiple breath washout tests|
1518603|NCT02827734|Device|impulse oscillometry|
1518604|NCT02827734|Device|body plethysmography|
1518605|NCT02827721|Device|impulse oscillometry|
1518606|NCT02827721|Device|multiple breath washout test|
1518607|NCT02827721|Device|body plethysmography|
1518610|NCT02827695|Behavioral|SMASK|Medication adherence and BP monitoring
1518611|NCT02827695|Behavioral|EnhancedSC|Standard care without med reminder functions with healthy lifestyle texts
1518612|NCT02827682|Device|Angel-6000D Multiparameter Anesthesia Monitor (IoC)|The Angel-6000D Multiparameter Anesthesia Monitor, Shenzhen Weihaokang Medical Technology Co., Ltd, Guangdong, China
1518613|NCT02827682|Device|BIS VISTA Monitor (BIS)|BIS VISTA Monitor, Covidien, Changchun city shi jia trade co., Ltd, Changchun, China
1518614|NCT02827669|Behavioral|One Drop Experts Program|
1518615|NCT02827669|Behavioral|One Drop Experts Program + Apple Watch|
1518616|NCT02827656|Drug|Decapeptyl|luteal support as described and vaginal progesterone 200 mg 3 times a day
1518617|NCT02827656|Drug|hCG luteal support|luteal support as described and vaginal progesterone 200 mg 3 times a day
1518618|NCT02827643|Drug|TDF/3TC or FTC/EFV plus Calcium and vitamin D supplement|Once daily calcium carbonate 1,250 mg that equal to elemental calcium 600 mg and weekly vitamin D2 20,000international units are given in intervention arms for duration of 24 weeks the subjects in this arm continue previous ART before enrollment to the study
1518619|NCT02827643|Other|TDF/3TC or FTC/EFV|arm continue previous ART before enrollment to study without any intervention with standard for HIV-infected patient.
1518620|NCT02827630|Other|Proteus Discover|FDA cleared Wearable Sensor with Ingestible Sensor and Mobile Device Application
1518621|NCT02827630|Other|Usual Care|Routine medical care including medication titration, adherence counseling, and lifestyle coaching.
1518622|NCT02827617|Drug|Ibrutinib|Treatment with ibrutinib 420 mg quaque die in the clinical practice
1518623|NCT02827578|Drug|Tamsulosin|Tamsulosin
1518624|NCT02827578|Drug|Solifenacin|Solifenacin
1518625|NCT02827578|Drug|Solifenacin placebo|Solifenacin placebo
1518628|NCT02827539|Device|LessRay|A software device has been developed that combines the benefits of reduced radiation associated with low-dose and/or pulse settings while preserving and possibly offering enhanced resolution. LessRay is a software device that is viewed on a separate monitor next to the fluro screen of the C-arm.
1518629|NCT02827539|Device|Standard Fluoroscopy|For control arm, patients will receive the standard fluoroscopy for imaging.
1518630|NCT02827526|Drug|Ketamine|
1518631|NCT02827526|Drug|Control|
1518632|NCT02827513|Drug|CTN SR1|
1518633|NCT02827513|Drug|CTN XR1|
1518634|NCT02827513|Drug|CTN XR2|
1518635|NCT02827513|Drug|CTN XR3|
1518636|NCT02827500|Drug|ivabradine|Active Comparator: ivabradine
1518637|NCT02827500|Other|Usual Care|Placebo Comparator: usual care
1518638|NCT02827487|Drug|Tramadol|Women will receive Tramadol 100mg (Trama®, Global Napi, Giza, Egypt) orally 2 hours before IUD insertion.
1518639|NCT02827487|Drug|Celecoxib|Women will receive Celecoxib 200mg (Celebrex® 200, Pfizer, USA) orally 2 hours before IUD insertion.
1518640|NCT02827487|Drug|Placebo 1|Women will receive a placebo similar to Tramadol orally 2 hours before IUD insertion.
1518641|NCT02827487|Drug|Placebo 2|Women will receive a placebo similar to Celecoxib orally 2 hours before IUD insertion.
1518642|NCT02827487|Procedure|IUD|IUD insertion
1518643|NCT02827474|Other|Patient Interview|Patient intervention includes a 30 minute interview prior to their abortion procedure and a follow up phone-interview that will be 10-minutes and held 24-72 hours from the procedure.
1518644|NCT02827474|Other|Provider Interview|For physician participants, providers will be interviewed after completion of the patient's visit and this will be 10-15 minutes.
1518645|NCT02827435|Drug|Rocuronium bromide|Pharmacokinetic-pharmacodynamic modeling blood sampling and Rocuronium bromide concentration measure muscle relaxation evaluation
1518646|NCT02827422|Other|not provided|
1518647|NCT02827409|Procedure|Short Delay Cord Clamping|Delay cord clamping will occur for up to 1 minute. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the radiant warmer for resuscitation.
1518648|NCT02827409|Procedure|Extended Delay Cord Clamping|Extended delay cord clamping will occur for at least 5 minutes and will continue until the subjects begins breathing and/or the cord stops pulsating. Subject will be placed on mother's abdomen for warmth and stimulation. If the subject is depressed they will be transferred to the LifeStart bed for resuscitation adjacent to the mother's bedside.
1518649|NCT02827396|Behavioral|Psychosocial intervention|"This training is aimed at Mothers/Fathers/Caregivers/Grandparents of children with intellectual disabilities.
Individual (for severe mental health problems) or group counseling for similar psychological issues should be a vital ingredient of this program. The package runs for 40 hours. It will run for five days continuously. It's important to promote participatory rather than deductive approach allow a lot of time for questions and discussions."
1518650|NCT02827383|Behavioral|Stair Climbing Frequency|Includes 1 sedentary day prior to completing crossover phases.
1518651|NCT02827370|Behavioral|Behavioral Dietary Intervention|Receive dietary counseling
1518652|NCT02827357|Other|No specific intervention|Clinical, drug and data collection : characteristics of patients (age, sex and histology), non HER 2-directed treatments including response and duration of response
1518653|NCT02827344|Biological|blood sample collection for CTC and MDSC analysis|"Isolation of circulating tumor cells from 2 tubes by ISET filtration module. Peripheral blood samples will be collected for CTC analysis within 7 days before commencing treatment (defined as baseline) and following four cycles of immunotherapy,
Analysis of PD-L1 and PD-L2 expression by immunocytochemistry on CTC
Analysis of the expression of PD-L1, PD-L2 , CTLA4 on the histological specimen by immunohistochemistry"
1518654|NCT02827331|Other|Exposition to hypnotics or anxiolytics benzodiazepines|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :
Benzodiazepine derivatives (N05BA)
Benzodiazepine derivatives (N05CD)
Benzodiazepine related drugs (N05CF)"
1518655|NCT02827331|Other|Exposition to non benzodiazepines antidepressants, hypnotics or anxiolytics|"Exposition to at least one drug belonging to the following classes during the last 12 months before index date :
Antipsychotics (N05A)
Antiepileptics with the exception of clonazepam (N03)
Drugs used for alcohol dependance (N07BB)
Drugs used for opioids dependance (N07BC)"
1518656|NCT02827331|Other|Medical consultation without prescription|Medical consultation without prescription of any drugs of interest
1518657|NCT02827331|Other|Administrative and medical data|"Gender
Birthdate
Department of residence
City of residence
Vital status (month and date of death)
Affiliation to Universal Health Coverage
Number of chronic long-term illness, medical diagnostic or pathology (CIM 10 code), onset and end dates
Drugs reimbursements (Date of care onset, drugs identification code, number of box delivered)
Data collected from medicalisation program of information system and private and public home care structures
Medical consultations, medical acts ( Common Classification of Medical Acts nomenclature)"
1518658|NCT02827318|Dietary Supplement|Isomaltulose|75g Isomaltulose (low glycaemic load intervention)
1518659|NCT02827318|Dietary Supplement|Glucose|75g Glucose (high glycaemic load intervention)
1518660|NCT02827318|Dietary Supplement|Sweetened water|Sweetened water will be used as a control
1518661|NCT02827305|Drug|Gotukola|10 ml of mouthwash to be rinsed for duration of 60 seconds
1518662|NCT02827305|Procedure|Scaling|Ultrasonic scaling was performed in one visit on both upper and lower arches.
1518663|NCT02827292|Other|music|"A standard music with a standard volume as per the protocol will be played with headphones during the entire duration of the surgery starting from the point of induction to the time of extubation.
A proper silent operative room environment will be maintained."
1518664|NCT02827292|Other|No music|Silent Headphones (Without music) will be applied to the patient from the point of induction of anaesthesia to the time of extubation.
1518665|NCT02827292|Procedure|Laparoscopic Surgery|Patients will undergo Laparoscopic Surgery as per the set protocol
1518666|NCT02827279|Other|emotional induction|The eye-tracking mesure the reaction at emotional induction using of sound stimuli in a group of children with or without ASD, in a context of
1518667|NCT02827266|Drug|Epoetin beta|Participants will receive epoetin beta as a weekly subcutaneous (SC) injection over an 8-week correction phase with 60 international units per kilograms (IU/kg) as starting dose. Baseline weight will be used to determine the dose and adjustments in the dose will be implemented based on the participant's blood hemoglobin levels. Participants with a response to correction treatment will then enter a 4-week extension phase to receive the SC injection every 2 weeks, and those without response will continue at the same weekly dose for a 4-week continuation phase.
1518668|NCT02827253|Device|MRI|MRI will be performed during interdialysis period in the haemodialysis group. MRI will be performed at the beginning of the study in predialysis group.
1518669|NCT02827240|Other|Oral HIV Self-Testing|The Oral HIV Self-Test is an in-home test that uses an oral swab to collect samples of oral mucosa that is used to detect the presence of HIV antibodies. The test is read after 20 minutes by the user. The test can be done by an individual at any time and place of the user's choosing. The test is read visually.
1518865|NCT02825719|Drug|Ferrous sulphate|Ferrous sulphate 300mg three times a day will be prescribed if haemoglobin level is less than 10g/dL.
1518670|NCT02827227|Biological|lymphocytes immunophenotyping|"The lymphocytes immunophenotyping were performed from fresh EDTA-anticoagulated blood harvested during a routine follow-up of patients in HIV Lyon centers.
HIV patients with a known history of PHI and a minimum of 2 years of effective cART (< 200 copies/mL) without interruption or virological failure were included in 2 centers in Lyon (Croix-Rousse and Edouard Herriot hospital).
Baseline factors at the time of PHI, delay, type and duration of first and duration of total cART, CMV status, nadir CD4 cells count and level of activation markers on CD4 and CD8 cells (CD38 and HLA-DR) at the time of the study were assessed.
Patients with hepatitis C or B virus co-infection or with a history of neoplasia or immunosuppressive therapy after the date of PIH were excluded."
1518671|NCT02827201|Drug|FOLFIRI.3|For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)
1518672|NCT02827201|Drug|nab-paclitaxel+ gemcitabine|For each cycle : 3 weeks out of 4 - injection at Day 1, 8 and 15 Nab-paclitaxel : 125 mg/m² of nab-paclitaxel in perfusion over 30 mn. Gemcitabine 1000 mg/m² in perfusion over 30 mn immediately after Nab paclitaxel administration is over.
1518673|NCT02827188|Other|Mega Team-videogame|Subjects randomly assigned to the treatment group will be instructed to practice Mega Team for 30-35 minutes a day, approximately 5 days a week for a minimum of 21 days and a maximum of 25 days.
1518674|NCT02827175|Other|blood sample|
1518675|NCT02827136|Drug|Lidocaine patch and hypafix|Appliance of Lidocaine patch and hypafix on both shoulder tip after anesthetic induction
1518676|NCT02827136|Drug|hypafix|Appliance of hypafix on both shoulder tip after anesthetic induction
1518677|NCT02827123|Device|McGrath MAC videolaryngoscopy|Orotracheal intubation with McGrath MAC videolaryngoscopy after anesthetic induction
1518678|NCT02827123|Drug|Macintosh Laryngoscopy|Orotracheal intubation with Macintosh Laryngoscopy after anesthetic induction
1518679|NCT02827110|Device|fiberoptic bronchoscope|Tracheal intubation using fiberoptic bronchoscope
1518680|NCT02827110|Device|pentax-airway scope|Tracheal intubation using pentax-AWS
1518681|NCT02827110|Procedure|semi-rigid collar|semi-rigid collar immobilization of the cervical spine
1518682|NCT02827097|Drug|denogan and rectus sheath block|administration of denogan and rectus sheath block with 0.375% ropivacaine
1518683|NCT02827097|Drug|denogan|administration of denogan
1518684|NCT02827084|Device|Kinesio Taping|Application of the Kinesio Taping with tension in the vatus mediallis muscle.
1518685|NCT02827084|Device|Placebo|Application of the Kinesio Taping without tension in the vatus mediallis muscle.
1518686|NCT02827058|Device|G25 pencil point needle|
1518687|NCT02827058|Device|G27 pencil point needle|
1518688|NCT02827045|Device|Vestibular test|
1518689|NCT02827032|Device|MobiusHD™|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
1518690|NCT02827019|Other|questionnaire|a questionnaire made puerperium the 2nd day of life during the interview with the parents on the basis of a semi-structured interview about the progress of the birth and the immediate postpartum period using the memories of parents
1518691|NCT02827006|Procedure|corrective osteotomy distal radius|Opening wedge corrective osteotomy on dorsal malunions of the distal radius. Distraction and correction of deformity.
1518692|NCT02826993|Device|CCE in incomplete Colonoscopies|When the initial colonoscopy has failed, participants are invited to ingest a CCE on the day prior to their subsequent CT colonography. Thus, the CCE and CT will be compared within subjects for their ability to identify and estimate sizes of polyps
1518693|NCT02826980|Other|questionnaire|Patients consultant in gynecology in the service of Doctor Sauvanet, for whom a diagnosis of endometriosis has been established (clinical history and imaging tests confirming the diagnosis) will be offered to fill a self-administered questionnaire during their consultation
1518694|NCT02826967|Procedure|Colonic Irrigation|
1518695|NCT02826954|Other|Upper airway assessment, including nasal biopsy|
1518696|NCT02826941|Other|hypothermia|Systemic hypothermia by Cincinnati Sub-Zero Blanketrol II®, servo-controlled to 33.0 degrees C rectal temperature, started within 6hours of hypoxic ischemic birth, and continued for 48hours
1518697|NCT02826941|Other|normothermia|Rectal temperatures in neonates receiving normothermia were maintained at 37.0+or -0.5 degrees C, using overhead warmer or Cincinnati Sub-Zero Blanketrol II®, servo-controlled to rectal temperature of 37.0 degrees C.
1518699|NCT02826915|Device|Near Infra Red Spectroscopy (NIRS)|
1518700|NCT02826915|Device|Electroencephalogram (EEG)|
1518701|NCT02826902|Drug|propofol and remifentanil|Anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil
1518702|NCT02826902|Drug|desflurane and remifentanil|Anesthesia is induced and maintained with desflurane and remifentanil
1518703|NCT02826889|Device|Philips Intelivue MP70 monitor|Philips Intelivue MP70 monitor (Intellivue MP70, Philips medical Systems, Suresnes, France) -a radial arterial cannula is inserted and arterial pressure waveforms are monitored through Philips Intelivue MP70 monitor. In the monitor, PPVauto is displayed in real-time. It is based on automatic detection algorithms, kernel smoothing, and rank-order filters.
1518704|NCT02826889|Device|Pleth Variability Index (PVI)|PVI is the measure of the dynamic changes in the Perfusion Index (PI) that occur during one or more complete respiratory cycles. A rainbow Pulse CO-Oximetry sensor is attached to the patient's finger and the PVI is displayed in real-time on the Root monitor.
1518705|NCT02826876|Drug|Topical use|Topical use of Ropivacaine in laparoscopic surgery
1518706|NCT02826876|Other|laparoscopic repair of inguinal hernia|intra-operative treatment with ropivacaine Vs placebo in laparoscopic repair of inguinal hernia
1518707|NCT02826876|Other|laparoscopic bariatric surgery|intra-operative treatment with ropivacaine Vs placebo in laparoscopic bariatric surgery
1518708|NCT02826863|Drug|ZX008 - 0.8 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.
1518709|NCT02826863|Drug|ZX008 - 0.2 mg/kg/day|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5 and provided in concentrations of 1.25 mg/mL, 2.5 mg/mL, and 5 mg/mL. The product is sugar free and is intended to be compatible with KD.
1518710|NCT02826863|Drug|Placebo|Placebo will be administered twice a day (BID) in equally divided doses with food.
1518711|NCT02826850|Procedure|Saphenous Nerve|Saphenous nerve neurotomy by radiofrequency, guided by ultrasound.
1518712|NCT02826850|Procedure|Genicular nerves|Genicular nerves neurotomy by radiofrequency, guided by fluoroscopy
1518713|NCT02826837|Drug|LEAC-102 500mg capsule and FOLFOX + Bevacizumab/Cetuximab|"The subjects will be administered FOLFOX + Bevacizumab/Cetuximab by intravenous infusion.
Cycles repeat every 2 weeks. Dose and schedule modifications may be made at the treating physician's discretion.
A standard 3+3 trial design will be used for LEAC-102 dose escalation cohorts.The dosing of LEAC-102 will be divided into 3 cohorts, the subjects will receive LEAC-102 every day
Cohort 1: LEAC-102 500 mg capsule, 3 capsules, three times per day for 24 weeks (oral), Cohort 2: LEAC-102 500 mg capsule, 4 capsules, three times per day for 24 weeks (oral), Cohort 3: LEAC-102 500 mg capsule, 5 capsules, three times per day for 24 weeks (oral)"
1518714|NCT02826798|Drug|VBI-1501A|VBI-1501A: 0.5 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
1518715|NCT02826798|Drug|VBI-1501A|VBI-1501A: 1.0 μg with alum with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
1518716|NCT02826798|Drug|VBI-1501A|VBI-1501A: 2.0 μg with alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
1518717|NCT02826798|Drug|VBI-1501|VBI-1501: 1.0 μg without alum-administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168
1518718|NCT02826798|Drug|Placebo|buffer/sucrose used for VBI-1501 suspension- administered as a 0.5 mL intramuscular injection on Days 0, 56, and 168.
1518719|NCT02826785|Behavioral|Cognitive strategy training|The intervention teaches strategies in a way that promotes generalization and enhances daily function . It includes four core elements known to enhance learning transfer: (1) self-generation of broadly applicable strategies, (2) practice across multiple contexts and activities, (3) emphasis on metacognition, and (4) use of meaningful everyday activities.
1518720|NCT02826772|Drug|GT0918|anti-tumor activity
1518721|NCT02826759|Other|diabetes|the exposure of interests are obesity, diabetes and insulin-resistance
1518722|NCT02826746|Drug|Magnesium Sulfate|adminstration of intravenous magnesium as bolus of 50 mg/kg, followed by continuous infusion at rate of 10 mg/kg/h
1518723|NCT02826746|Drug|Normal saline|the same bolus and infusion volumes of normal saline
1518724|NCT02826733|Device|Electroencephalogram (EEG)|
1518725|NCT02826733|Device|Near Infra Red Spectroscopy (NIRS)|
1518726|NCT02826733|Device|magnetic resonance imaging (MRI)|
1518727|NCT02826720|Other|No intervention was applied|No intervention was applied
1518728|NCT02826707|Behavioral|SPPAC intervention|A peer coach will deliver a physical activity counselling intervention using a Smartphone. Individualized programs will be based on participants physical activity/wheelchair mobility goals.
1518729|NCT02826694|Genetic|Well infant, whole exome sequencing|Whole exome sequencing will be performed in children with diagnosed conditions. Investigators will analyze results that are associated with their condition.
1518730|NCT02826694|Genetic|Diagnosed, whole exome sequencing|In addition to returning results of conditions associated with a child's phenotype, investigators will also analyze genes that are associated with conditions that have childhood onset and are medically actionable.
1518731|NCT02826681|Drug|Injectafer® (Ferric Carboxymaltose - FCM)|Intravenous Iron
1518732|NCT02826681|Drug|Placebo (Normal Saline)|Normal Saline Solution
1518734|NCT02826655|Device|WF-AO-OCT|WF-AO-OCT allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. This unit is being conducted under an abbreviated IDE.
1518735|NCT02826642|Drug|IDH305|
1518741|NCT02826616|Drug|Trimetazidine|Trimetazidine 60 mg 30min before PCI and 20 mg for 12 months after surgery
1518744|NCT02826590|Other|Neck passive mobilizations|Passive mobilizations performed to the neck of the participant by a Physiotherapist
1518745|NCT02826590|Other|Manual contact|Manual contact applied to the neck of the participant by a Physiotherapist
1518746|NCT02826577|Drug|Pregnenolone 175mg|Single Dose 175mg
1518747|NCT02826577|Drug|Pregnenolone 400mg|Single Dose 400mg
1518748|NCT02826577|Drug|Placebo|Single Dose
1518749|NCT02826564|Drug|pembrolizumab|
1518754|NCT02826538|Device|fracture fixation with patient specific guides|Using the preoperative computed tomography scan, a 3D planning of the fracture Fixation is made and patient-specific guides for fracure fixation are produced using a 3D Printer. These Patient-specific guides are used for fracture fixation
1518755|NCT02826538|Device|standard procedure of fracture fixation|the standard procedure of fracure fixation for each fracture localisation is used as a standard of reference
1518756|NCT02826525|Drug|AZD4076|Investigational product
1518757|NCT02826525|Drug|Placebo|Control
1518758|NCT02826512|Drug|Niraparib|niraparib 300 mg QD continuously
1518759|NCT02826499|Device|Pediguard|It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
1518760|NCT02826499|Other|Fluoroscopy|The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
1518761|NCT02826486|Drug|BL-8040|BL-8040 1.25 mg/kg subcutaneous(SC) injections
1518762|NCT02826486|Drug|BL-8040 plus pembrolizumab|pembrolizumab will be given as a 30-minute IV infusion
1518763|NCT02826473|Other|BRAINCHECK|Subjects of the Intervention-Group will undergo a brief cognitive assessment, using the BRAINCHECK, during hospital admission assessments. Subjects with positive results will then be referred to a Memory Clinic undergoing subsequent interdisciplinary comprehensive diagnostic examinations. Patients with established diagnosis will be invited to counselling services of the Alzheimer Association (providing social counselling).
1518764|NCT02826434|Biological|PVX-410|This is a Vaccine that will be injected intramuscularly as a mixture with an adjuvant.
1518765|NCT02826434|Biological|Durvalumab|This is an intravenous infusion of a monoclonal antibody.
1518766|NCT02826434|Drug|Hiltonol|This is an intramuscular injection of an adjuvant to enhance the immune response to vaccine.
1518767|NCT02826421|Device|UltraSert Preloaded Delivery System|Includes AcrySof IQ monofocal posterior chamber IOL Model AU00T0, intended for long term use over the lifetime of the subject
1518768|NCT02826421|Device|iTec Preloaded Delivery System|Includes TECNIS 1-piece monofocal IOL, intended for long term use over the lifetime of the subject
1518769|NCT02826421|Device|iSert Preloaded Delivery System|Includes Model 251 or Model 250 posterior chamber IOL, as selected by the Investigator, intended for long term use over the lifetime of the subject
1518770|NCT02826421|Device|Monarch III D Manual IOL Delivery System|Includes AcrySof IQ monofocal IOL posterior chamber IOL Model SN60WF, intended for long term use over the lifetime of the subject
1518771|NCT02826408|Drug|Rabeprazole sodium|WIll study effect of the medication on palpittions
1518772|NCT02826408|Drug|Pacebo|Placebo comparison to active treatment
1518773|NCT02826395|Drug|Carbon-11 Sodium Acetate|PET/CT Scans will be performed with or without oral and IV contrast. All investigational scans will be read by at least one board-certified nuclear medicine physician with established expertise in PET/CT of at least 5 years' experience. Fifteen minutes after injection of 11C-Sodium Acetate, we will acquire a scan Emission images will be acquired for 3-5min/bed position. Intravenous and oral contrast will be given for the CT portion of the study.
1518774|NCT02826382|Drug|[68Ga]P15-041|Imaging by Positron Emission Tomography after injection of [68Ga]P15-041
1518779|NCT02826330|Other|biomarkers|fecal microbiota analysis antibodies in serum and saliva DNA polymorphisms
1518780|NCT02826317|Procedure|preoperative and postoperative setting|Preoperative assessment will consist on collecting demographic data as well as the presence preoperative chronic pain and its localization, preoperative opioid, gabapentin or pregabalin consumption. In postoperative, we will collect the following data: type of anesthesia, intra operative ketamine administration, type and total dose of opioid administered during surgery. Pain will be evaluated at least 2 hours after the surgery within the same day (D0) and then at day 2 (D2), 1 (M1) and 2 months (M2) after the surgery. Pain will be assessed using a 10-point NPS. If NPS >0, neuropathic pain will be diagnosed on the basis of DN4 questionnaire. NCPSP is defined by NPS >0 and positive DN4 (DN4 ≥ 4 /10) (11). APSNP and CPSNP are defined by D0/D2 DN4≥ 4/10 and M1/M2 DN4≥ 4/10, respectively.
1518781|NCT02826304|Procedure|Vaginal hysterectomy|"All the cases were performed by the same surgical team
Incision is made at the anterior cervical lip below the bladder reflection
Anterior peritoneal entry .
Douglas pouch entry.
The uterosacral ligaments and the cardinal ligaments are clamped, divided and ligated .
Uterine artery clamping division and ligation
After securing the uterine A., debulking procedures was performed in the form of bisection, coring or myomectomy
Utero-ovarian and round clamping-division and ligation ( in cases where oophorectomy was performed this part was done at the level of the infundibulo-pelvic ligament).
Hemostasis
The vaginal vault is closed after insertion of intraperitoneal drain and"
1518866|NCT02825719|Drug|Tranexamic Acid|Tranexamic Acid 500mg four times a day on request basis will be prescribed if patient complained of menorrhagia.
1518782|NCT02826304|Procedure|Laparoscopic assisted vaginal hysterectomy|"Uterine manipulator was inserted through the cervix to mobilize the uterus
Veress needle was inserted through the base of the umbilicus
creation of pneumoperitoneum
Insertion of 4 trocars one at the base of umbilicus for the camera and 3 lateral trocars
The round and the utero-ovarian ligament are coagulated and divided.
Dissection through the vesico-uterine space to displace bladder away from the cervix.
Uterine artery was coagulated and divided laparoscopically
anterior colpotomy over the cup of the uterine elevator.
Vaginal part starts with opening of douglas pouch and clamping , division and ligation of uterosacral and cardinal ligaments followed by removal of the uterus and closure of the vault. reinflation to ensure proper hemostasis."
1518783|NCT02826291|Device|RD-100i, OSNA|quantitative reverse transcription polymerase chain reaction (qRT-PCR) cytokeratin-19 detection in specimen (sentinel lymph node)
1518784|NCT02826278|Other|External genitalia measurements in female newborns|
1518785|NCT02826265|Device|multiple breath washout test (MBW)|
1518786|NCT02826265|Device|impulse oscillometry (IOS)|
1518787|NCT02826265|Device|body plethysmography (BP)|
1518788|NCT02826265|Device|quantitative computed tomography (qCT)|ultra-low-dose qCT
1518789|NCT02826252|Drug|Iloprost,(Ventavis, BAYQ6256)|Ventavis (Iloprost) nebulizer solution for inhalation as 10 μg/mL (V10) and 20 μg/mL (V20).
1518790|NCT02826252|Device|I-Neb AAD system|Nebulizer, allows digital recording of inhalation data such as doses, inhalations per day and duration of inhalation (per day) etc.
1518791|NCT02826239|Device|multiple breath washout test (MBW)|measured in upright and supine position
1518792|NCT02826226|Device|multiple-breath-washout test|
1518793|NCT02826226|Drug|Bronchodilator Agents|
1518796|NCT02826200|Drug|Acenocoumarol|Standard of care plus oral anticoagulant therapy (acenocoumarol)
1518797|NCT02826200|Other|Standard of care|Standard of care
1518798|NCT02826187|Other|Early complications data|"Early complications of interest are :
New arthroplasty for any reason
Related to the implant :
Wrong position of the implant
Early displacement of the implant
Related to the intervention :
Hematoma
Dislocation (or not causing the resumption of joint replacement)
Deep vein thrombosis
Pulmonary embolism
Acute Infection"
1518799|NCT02826187|Other|Late stage complications data|"Late complications taken into account are:
New arthroplasty for any reason
Aseptic loosening
Delayed hypersensitivity reaction type IV
Solid Tumors
Recurrent dislocation (causing or not the resumption of joint replacement)
Allergic reactions of any kind
Chronic infection"
1518800|NCT02826187|Other|Patient Satisfaction|Patient satisfaction evaluated by Womac reduced Score
1518801|NCT02826187|Other|Efficacity|Efficacity as evaluated by Harris HIP score
1518802|NCT02826187|Other|Radiographic evaluation|Bone reaction visible in radiography
1518803|NCT02826174|Procedure|closed PKP under topical anesthesia|a closed corneal transplantation under topical anesthesia with the anterior chamber maintained
1518804|NCT02826174|Procedure|open-sky PKP under retrobulbar anesthesia|an open-sky corneal transplantation under retrobulbar anesthesia
1518805|NCT02826174|Drug|Anti-Rejection Agents|Anti-Rejection Agents for both groups
1518806|NCT02826174|Drug|Anti-Inflammatory Agents|Anti-Inflammatory Agents for both groups
1518807|NCT02826161|Drug|Napabucasin|Napabucasin will be administered in continuous 28-day cycles. The starting dose of napabucasin is 240 mg twice daily (480 mg total daily dose) with approximately 12 hours between each dose. Napabucasin should be taken with fluids either 1 hour prior to a meal or 2 hours after a meal.
1518808|NCT02826161|Drug|Paclitaxel|Paclitaxel will be administered intravenously, once weekly, via one-hour infusion at a starting dose-level of 80 mg/m^2 body surface area. The weekly paclitaxel infusion will be given during 3 out of every 4 weeks, on days 1, 8, and 15 of each 28-day study cycle.
1518809|NCT02826148|Other|RAADS-R scale|This scale is a self-administered questionnaire completed by the person himself assisted by a clinician
1518810|NCT02826135|Procedure|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension in pediatric patients with single ventricle, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
1518811|NCT02826122|Device|Pai APP|Prescription: Target 100 PAI Points per week
1518812|NCT02826122|Device|FitBit APP|Prescription: Target daily 10.000 steps
1518813|NCT02826109|Device|PeriAcryl®90 HV|
1518814|NCT02826096|Behavioral|Biofeedback therapy|The brief version of biofeedback therapy is conducted by psychologists following the structure way. Biofeedback therapy is six session treatment once a week.
1518815|NCT02826083|Dietary Supplement|XXS|
1518816|NCT02826083|Dietary Supplement|non-XXS|
1518817|NCT02826070|Drug|Telbivudine|Telbivudine, 600mg, oral, daily
1518818|NCT02826070|Drug|Adefovir dipivoxil|Adefovir dipivoxil 10mg, oral, daily
1518819|NCT02826070|Other|off-treatment follow-up|
1518820|NCT02826057|Other|Targeted temperature management (33 degree Celsius)|
1518821|NCT02826044|Drug|SP2086|The study has 3 doses groups and the 30 subjects were administrated SP2086 50mg,100mg,200mg respectively.
1518822|NCT02826031|Drug|Sodium Hyaluronate Injection|
1518823|NCT02826031|Drug|DICL-SR|
1518824|NCT02826018|Drug|ALN-HBV|Ascending doses of ALN-HBV by subcutaneous (sc) injection
1518825|NCT02826018|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
1518826|NCT02826005|Device|MRI|
1518828|NCT02825979|Procedure|Cryoballoon-based PVI|Patients randomized to first-line cryoballoon (CB) ablation will have the pulmonary vein isolation procedure performed according to standard clinical practice using the Arctic Front Cryoballoon ablation catheter. No anti-arrhythmic drugs will be prescribed in this arm.
1518958|NCT02824939|Other|Quadratus Lumborum (QL) Block|0.4 ml/kg of 0.25 % Bupivacaine deposited in the anterolateral aspect of the quadratus lumborum muscle under ultrasound guidance postoperatively
1518829|NCT02825979|Drug|Anti-Arrhythmic Drug Therapy|Antiarrhythmic drug therapy (Class I - flecainide, propafenone; Class III - sotalol, dronedarone) will prescribed and monitored based on local clinical practice, and according to guideline-suggested drug management for symptomatic patients with paroxysmal AF.
1518831|NCT02825953|Drug|surfactant|the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant
1518832|NCT02825953|Device|nasal continuous positive airway pressure|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
1518833|NCT02825953|Device|non-invasive intermittent positive-pressure ventilation|each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
1518834|NCT02825953|Device|Neopuff|Fisher and Paykel, Auckland, New Zealand
1518835|NCT02825953|Device|neonatal ventilator|GE Healthcare, Madison, USA
1518839|NCT02825927|Other|Oral screen|The oral screen is used for 30 seconds, three times a day, before meals and implies new possibilities for training of the orofacial muscles.
1518840|NCT02825914|Dietary Supplement|Casein glycomacropeptide (CGMP)|
1518841|NCT02825914|Dietary Supplement|Placebo|
1518842|NCT02825901|Dietary Supplement|Placebo|
1518843|NCT02825901|Dietary Supplement|Djulis-Buckwheat|
1518844|NCT02825901|Dietary Supplement|Buckwheat|
1518845|NCT02825875|Drug|18F DCFPyL- Radiopharmaceutica|
1518846|NCT02825862|Behavioral|Question-behaviour effect (for affective attitudes)|Investigators propose to investigate the Question-behaviour effect (omit affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on affective attitudes will substituted for non-affective items (e.g. on political parties).
1518847|NCT02825862|Behavioral|Question-behaviour effect (negatively-worded attitudes)|Behavioral: Question-behaviour effect (for negatively-worded attitudes) Investigators propose to investigate the Question-behaviour effect (omit negatively-worded affective attitudes). Investigators will conduct an experimental manipulation by omitting certain items from a questionnaire assessing attitudes to organ donation. Specifically, investigators will omit questions on negatively-worded affective attitudes. This group will complete a similar questionnaire to the comparison group, with the same number of items, but items on negatively-worded affective attitudes will substituted for non-affective items (e.g. on political parties).
1518848|NCT02825849|Biological|Intrauterine infusion of platelet rich plasma|Patients randomized to study group will have 30cc of blood drawn with isolation of platelet rich plasma (PRP) per standard manufacturer's protocol, with subsequent intrauterine infusion of this autologous PRP.
1518853|NCT02825810|Behavioral|Cervical motor control|Intervention will consist in a tailored exercise training following a previous published motor control protocol
1518854|NCT02825797|Drug|3BNC117|Intravenous infusion of 3BNC117
1518855|NCT02825797|Drug|10-1074|Intravenous infusion of 10-1074
1518856|NCT02825797|Other|Analytical treatment interruption|Analytical treatment interruption
1518857|NCT02825797|Drug|Placebo|Intravenous infusion of placebo (sterile saline)
1518858|NCT02825784|Dietary Supplement|Renastart|Renastart: specially formulated to meet the unique nutritional needs of children from birth to 10 years with chronic kidney disease (CKD).
1518859|NCT02825771|Behavioral|Caring Contacts via Text Message|Text messages expressing care and support are sent following initial meeting on the following schedule: one day, one week, months 1, 2, 3, 4, 6, 8, 10, 12 plus the participants' birthday. (This schedule may change as a result of cultural adaptation in Year 1)
1518860|NCT02825771|Behavioral|Usual Care|Usual care consists of services available to the participant in their community to reduce their suicide risk and improve their behavioral health
1518861|NCT02825758|Dietary Supplement|ZestiVits|"The study product is a low-carbohydrate, orange flavour, vitamin, mineral and trace element (micronutrient) supplement for use in ketogenic and restricted therapeutic diets, for children aged from 11 years of age and adults.
The recommended dosage of the study product for each subject will be determined and prescribed by a dietitian. This will be based on individual requirements for micronutrient supplementation."
1518862|NCT02825745|Dietary Supplement|Betashot|Betashot is a Food for Special Medical Purposes (FSMP). Suitable for use from 3 years of age.
1518863|NCT02825719|Drug|Ulipristal acetate|Ulipristal acetate 5mg daily will be prescribed
1518864|NCT02825719|Other|Placebo pills|Placebo pills will be prescribed
1518959|NCT02824926|Drug|Dapaconazole|
1518868|NCT02825693|Procedure|Conventional cataract surgery (phacoemulsification)|
1518869|NCT02825693|Procedure|Femtosecond laser assisted cataract surgery|
1518870|NCT02825680|Other|Enhanced NCP Support|NCP is a central policy office that provides support to MOVE! program teams through monthly phone calls and technical assistance. Facilities will also have access to the audit and feedback process and barrier buster tool
1518871|NCT02825680|Other|LEAP|The Learn. Engage. Act. Process (LEAP) intervention relies on virtual (phone and online) coaching based on the IHI Model of Change, an online learning platform for clinician teams to share ideas and progress, an audit and feedback process, and a barrier buster tool
1518872|NCT02825667|Other|Physiotherapy sessions|Physiotherapy by techniques myofascial therapy, in patients with ankle hemophilic arthropathy
1518873|NCT02825641|Drug|Oxytocin|"Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:
Induction of labor on presentation at the delivery room.
Induction of labor after 24 hours of rupture of membranes."
1518874|NCT02825641|Drug|Dinoprostone|"Labor induction and cervical ripening by dinoprostone in women with premature rupture of membranes in 2 types of women:
Induction of labor on presentation at the delivery room.
Induction of labor after 24 hours of rupture of membranes."
1518875|NCT02825628|Drug|Osteodex|formulation: solution for infusion route of administration: intravenous infusion
1518876|NCT02825615|Procedure|Radial artery cannulation|Radial artery cannulation done with conventional and ultrasound guidance in two respective groups of patients and their first pass success and ultimate success rates compared in different hemodynamic subsets of the patients.
1518877|NCT02825589|Device|BIA|BIA or bioelectrical impedance analysis using electric current through body tissues to estimate body composition particularly body fat and total body water calculating to target body weight.
1518878|NCT02825576|Drug|Sugammadex|
1518879|NCT02825576|Drug|Neostigmine/Glycopyrrolate|
1518880|NCT02825563|Drug|Anlotinib|in the fasting state
1518881|NCT02825563|Drug|Anlotinib|in the high fat diet
1518883|NCT02825537|Device|Compression stocking|A class III (20 to 36 mm Hg) elastic compression stocking according to the french classification
1518884|NCT02825537|Other|No use of compression stocking|No use of compression stocking
1518885|NCT02825524|Device|Habib™ EndoHBP|During an endoscopic retrograde cholangiography, endobiliary application of radiofrequency through a dedicated probe named Habib.
1518886|NCT02825498|Device|Contact force guided RFA|Contact force guided RFA during Atrial Flutter ablation procedure.
1518887|NCT02825485|Procedure|Voiding cystourethrogram|
1518888|NCT02825472|Behavioral|exercise training|3 times per week 30 minutes of exercise training in the target heart rate zone
1518889|NCT02825459|Behavioral|Abstinence from e-cigarettes|Abrupt cessation for 6 days
1518890|NCT02825446|Procedure|angioplasty tibial arteries|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion.
Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
1518891|NCT02825446|Procedure|"angioplasty tibial arteries augmented radio frequency denervation popliteal artery by the useVessix Renal Denervation System Balloon"|"Under local anesthesia using the standard endovascular access and renders the affected arterial segment. Are stenosis or occlusion of the artery, the hydrophilic guide. Occlusion or subintimal perform transluminal recanalization of the artery. Then do balloon angioplastic stenosis or occlusion. Then in 3 portion of the popliteal artery starts ablation by the use Vessix Renal Denervation System Balloon performed radiofrequency denervation. After removal of the balloon, control angiography is performed.
Drug therapy includes the administration of aspirin before the procedure (160-300 mg/day) starting at least one day, and heparin during the procedure (5000 IU intravenously). After the procedure, all patients are administered aspirin (100 mg daily) for a long time."
1518892|NCT02825433|Other|No intervention, only ventilation monitoring|
1518893|NCT02825420|Drug|trabectedin|
1518894|NCT02825407|Dietary Supplement|Oral physiology|
1518897|NCT02825368|Biological|MMR|0.5 mL, subcutaneous
1518898|NCT02825368|Biological|Tdap|0.5 mL, intramuscular
1518899|NCT02825368|Other|Diphtherinum®|
1518900|NCT02825368|Other|Pertussinum®|
1518901|NCT02825368|Other|Tetanotxicum®|
1518902|NCT02825368|Other|Morbilinum®|
1518903|NCT02825368|Other|Ourlianum®|
1518904|NCT02825368|Other|Sterile saline|0.5 mL, intramuscular
1518905|NCT02825368|Other|Sugar pellets|
1518906|NCT02825355|Procedure|Sentinel lymph node mapping|Patients in intervention group will receive sentinel lymph node mapping.
1518907|NCT02825342|Drug|Citalopram|
1518908|NCT02825329|Device|TORAYMYXIN PMX-20R|Two (2) PMX cartridges will be administered approximately 24 hours apart. PMX Cartridge is an extracorporeal hemoperfusion device. Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
1518909|NCT02825316|Behavioral|Mediterranean diet|Eight weeks course of Mediterranean diet (rich in plant-based food and low in animal protein and fat).
1518910|NCT02825316|Behavioral|Low residue diet|Eight weeks course of low residue diet (minimal consumption of foods that add residue to the stool, such as raw fruits, vegetables and seeds, as well as nuts, legumes and whole grains).
1518960|NCT02824926|Drug|Ketoconazole|
1518961|NCT02824913|Drug|P-321 Ophthalmic Solution|
1518911|NCT02825303|Other|Workplace consisting of two height-adjustable desks|Desk arrangements: self-determined by the participants Desk equipment: depending on pre-intervention condition - 1 or 2 screens per desk Build-up: one day prior to the intervention period at the location of the workplace Adjustment: together with the study leader
1518912|NCT02825290|Drug|Choriogonadotropin alfa|
1518913|NCT02825290|Drug|Triptorelin acetate|
1518914|NCT02825277|Device|Doppler|acquisition of 3D power Doppler of uteroplacental vascularization unit in 72h before delivery and morphological analysis for placenta
1518918|NCT02825238|Other|Supervised exercise program|
1518919|NCT02825225|Other|20 core-biopsy fragments|Using the extended sextant fashion prostate biopsy, this randomized group was submitted to a 20-fragments core-biopsy to evaluate the diagnostic power, pain perception and complications comparative to institution's standard 12 cores.
1518920|NCT02825225|Procedure|Base and apex local anesthesia|Using the institution's standard local anesthesia protocol (base injection) as active comparator group, this randomized group was submitted to base and apex local anesthetic application to evaluate tolerability of the procedure, pain perception (with use of previous validated analogue pain scale) and complications.
1518921|NCT02825212|Drug|Harvoni|12 weeks for naïve subjects or non-cirrhotic treatment experienced subjects; or 24 weeks for treatment experienced subjects with cirrhosis
1518922|NCT02825199|Dietary Supplement|Caffeine|capsule: 300mg caffeine
1518923|NCT02825199|Dietary Supplement|Non caffeine|capsule: placebo (maize starch)
1518924|NCT02825186|Drug|Loteprendol etabonate 0.5%|Steroid eye drops used after strabismus surgery.
1518925|NCT02825186|Drug|Dexamethasone 0.1%|
1518926|NCT02825173|Device|Seal-G|"Intervention:
Device: Seal-G Seal-G is applied adjunctively to cover standard closure techniques"
1518928|NCT02825147|Drug|Pegaspargase|
1518929|NCT02825147|Drug|Methotrexate|
1518930|NCT02825147|Drug|Dexamethasone|
1518931|NCT02825147|Drug|Etoposide|
1518932|NCT02825147|Radiation|radiotherapy|
1518933|NCT02825134|Device|Transcatheter aortic valve replacement|Retrograde transfemoral transcatheter aortic valve replacement with any CE mark approved aortic bioprosthesis with or without concomitant percutaneous coronary intervention.
1518934|NCT02825134|Device|Surgical aortic valve replacement|Conventional surgical aortic valve replacement with a bioprosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest with or without concomitant coronary artery bypass graft surgery.
1518935|NCT02825121|Device|Monitoring Neuromuscular Blockade the Flexor Hallucis|
1518936|NCT02825121|Device|Monitoring Neuromuscular Blockade adductor of the thumb.|
1518937|NCT02825108|Drug|Intra uterine injection of tissue culture medium containing HCG+ET|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
1518938|NCT02825108|Drug|Intra uterine injection of tissue culture medium +ET|) only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
1518939|NCT02825108|Procedure|ET|the embryo transfer ( ET) is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
1518940|NCT02825095|Procedure|Talc Pleurodesis|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
1518941|NCT02825095|Procedure|Indwelling Pleural Catheter|Indwelling Pleural Catheter type PLEURAX will be inserted to the pleural space. the patients will be discharged with the pleural catheter.
1518942|NCT02825095|Procedure|chest ultrasound|All insertion of a chest drain will be guided by ultrasound
1518943|NCT02825095|Drug|Local anesthesia|Inserting a chest drain will be after local anesthesia with 10-20 mL of Lidocaine hydrochloride 20MG/ML - Esracain injection 2%
1518944|NCT02825095|Procedure|Chest Tube|chest tube type PIGTAIL 10 - 14 Fr will be inserted to the pleural space. In case of fluid discharges less than 250 cc/24, talc pleurodesis will be performed
1518945|NCT02825082|Procedure|Abdominal emergency surgery|all abdominal emergency surgery procedures
1518949|NCT02825043|Device|High-Flow Nasal Cannula|This is a humidified oxygen delivery system.
1518950|NCT02825030|Drug|Coppertone (BAY 987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation-SR15-78_Y73-167).
1518951|NCT02825017|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2mg/cm*2 test application.(Formulation-SR15-79_Y73-161)
1518952|NCT02825004|Behavioral|Psychological Intervention|
1518953|NCT02824991|Procedure|detection of local twitch response intensities during dry needling|
1518954|NCT02824965|Drug|Pembrolizumab|Pembrolizumab is a selective monoclonal antibody that blocks the interaction between PD1 and its ligands PDL1 and PDL2, resulting in infiltration of tumour specific CD8+ T-cells and ultimately leads to tumour rejection.
1518955|NCT02824965|Biological|CVA21|CAVATAK is an oncolytic Coxsackie virus that specifically infects and kills ICAM overexpressing tumour cells
1518956|NCT02824952|Drug|Tagrisso|taking orally everyday for 6 or 12 weeks.
1518957|NCT02824939|Other|Transversus Abdominis Plane (TAP) Block|0.4 ml/kg of 0.25 % Bupivacaine deposited in the transversus abdominis plane under ultrasound guidance postoperatively
1518962|NCT02824913|Drug|P-321 Ophthalmic Solution placebo|
1518966|NCT02824887|Other|Electro-acupuncture|Electro acupuncture deep needling protrusion of lumbar intervertebral disc the five acupoints
1518967|NCT02824887|Other|Conventional treatment of Western Medicine|Routine non operative treatment of Western Medicine
1518968|NCT02824874|Drug|Duvie Tab. 0.5mg|Duvie Tab. 0.5mg*1T/day for 5days, QD, PO
1518969|NCT02824874|Drug|Duvie Tab. 0.5mg + Januvia Tab. 100mg|Duvie Tab. 0.5mg + Januvia Tab.100mg*1T/day for 5 dyas, QD, PO
1518970|NCT02824861|Behavioral|Bemobile|
1518971|NCT02824848|Behavioral|Passive Stretching|Passive stretching and associated strengthening activities to change head/neck and body alignment
1518972|NCT02824848|Behavioral|Perception-Action Approach|Environmental set-up and gentle manual guidance to promote spontaneous exploration of alternative head/neck and body alignment possibilities
1518973|NCT02824835|Procedure|biopsy during colonoscopy|sampling the lesion with forcept biopter
1518974|NCT02824796|Behavioral|Schema Parent Behavioral Training|A novel protocol for parent whose children suffer from ADHD and comorbidities. The protocol combines elements from Schema Focus Therapy (SFT) and Parent Behavioral Training (PBT)
1518975|NCT02824796|Behavioral|Parent Behavioral Training|A state of the art Parent Behavioral Treatment (PBT) for Children who suffer from ADHD symptoms
1518980|NCT02824744|Device|treatment by 2l/min/kg in High Flow Nasal cannula (HFNC)|
1518981|NCT02824744|Device|treatment by 3l/min/kg in High Flow Nasal cannula (HFNC)|
1518982|NCT02824731|Radiation|Radiation with protons|
1518983|NCT02824731|Radiation|Radiation with photons|
1518984|NCT02824718|Drug|Teriparatide|human recombinant parathormone
1518985|NCT02824718|Drug|Thiazide|Diuretic
1518986|NCT02824718|Drug|Potassium sparing diuretic|Diuretic
1518987|NCT02824718|Drug|Alfacalcidol|Belongs to the class of vitamin D and analogues
1518988|NCT02824705|Procedure|Congenital Heart Disease Surgery|Stool sample collected prior to surgical intervention for congenital heart disease; stool and blood samples then collected in days following cardiac intervention.
1518989|NCT02824692|Device|heart lungs and abdomen ultrasound|
1518990|NCT02824679|Drug|hyoscine butylbromide|20 - 40 mg of hyoscine butylbromide is given intravenously during the first stage of labor
1518991|NCT02824679|Drug|saline|0.9%normal saline
1518992|NCT02824666|Drug|ATI-9242|"Formulated ATI-9242 will be administered as an IV bolus injection (2mg/mL of ATI-9242 in 40% solution of propylene glycol).
Two doses will be tested: single IV bolus injection of 0.5mg/kg and single IV bolus injection 1.0 mg/kg. In the event that a third cohort is needed the IV bolus injection would be 2.0 mg/kg"
1518993|NCT02824666|Radiation|[18F]Fallypride Imaging|Subjects will be injected with approximately 250 MBq or 6.75 mCi of [18F]Fallypride [5-6 mCi being the typical range of injected dose].
1518994|NCT02824653|Biological|Mesenchymal Stem Cells|Allogenic Human Bone Marrow Mesenchymal Stem Cells (ex-vivo expanded in pooled human platelet lysate)
1518995|NCT02824640|Behavioral|Patient Navigation|The study will follow a PN model (Check Hep C) developed by NYCDOH in collaboration with Montefiore and the community. HCV PNs will provide the following interventions to those randomized to the PN arm: coordination of HCV treatment; health promotion; assisting patients to overcome barriers; and psychosocial support.
1518996|NCT02824640|Behavioral|modified Directly Observed Therapy|Subjects will be observed taking medications, a minimum of 5 times a week for those enrolled in the OAT setting, and a minimum of 3 times a week for those enrolled in the community health clinic setting.
1518997|NCT02824627|Drug|Oxytocin|A growing body of data shows that intra-nasal administration of oxytocin has promise for treating a host of psychiatric disorders. Considerable data indicates that oxytocin reduces amygdala response to negative stimuli in patients with generalized anxiety disorder, borderline personality disorder, and post-traumatic stress disorder. Given that one of the potential underlying neurobiological mechanisms of irritability and emotional dysregulation in pediatric population with disruptive behavior and mood disorder is the hyperactivity of amygdala to negative emotional stimuli, and that oxytocin reduces this, it is critical to determine the extent to which this intervention improves irritability and emotional dysregulation in children and adolescents with disruptive behavior and mood disorders.
1518998|NCT02824627|Drug|Placebo|Inactive substance administered in volume equivalent to volume administered in active treatment arm.
1518999|NCT02824614|Dietary Supplement|E967-Xylitol|
1519000|NCT02824614|Dietary Supplement|E968-Erythritol|
1519001|NCT02824601|Device|Laser|1-visit-treatment (n=12): Chemomechanical preparation (CMP) - CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after CMP
1519002|NCT02824601|Drug|Calcium hydroxide|2-visit-treatment (n=12): Chemomechanical preparation (CMP) + Ca(OH)2 + SSL medication for 14-days + PDT. CMP was performed by using the single-file reciprocating technique + 2.5% NaOCL and 17% EDTA. Methylene blue was applied to root canals for 60 seconds and submitted to laser with a potency of 60 mW and energy density of 129 J/cm2 for 120 seconds after 14-days of intracanal medication
1519003|NCT02824588|Behavioral|Working Memory Training|Training mental flexibility
1519004|NCT02824588|Behavioral|Internet use|Used as control for time spent on computer
1519005|NCT02824575|Drug|Rebastinib|50 mg or 100 mg po BID continuously. Cycle duration: 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
1519006|NCT02824575|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly. Cycle duration = 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
1519007|NCT02824575|Drug|Eribulin Mesylate|Eribulin 1.4 mg/m2 day 1 & 8. Cycle duration : 21 days. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
1519009|NCT02824549|Device|FreeStyle Libre Flash Glucose Monitoring|
1519010|NCT02824536|Drug|3BNC117|Intravenous Infusion of 3BNC117
1519011|NCT02824536|Drug|10-1074|Intravenous Infusion of 10-1074
1519012|NCT02824536|Drug|Placebo|Intravenous Infusion of Sterile Saline (NaCl 0.9%)
1519013|NCT02824523|Drug|aspirin|
1519014|NCT02824510|Other|Algorithmic changes in insulin therapy.|Based on SG evolution in first treadmill test, algorithms will evaluate the modifications in insulin therapy required to normalize SG during the second treadmill test.
1519015|NCT02824510|Other|Treadmill exercises|25 min treadmill exercise at 60% of maximal heart rate estimated for age
1519016|NCT02824510|Drug|Insulin aspart, glargine and detemir|
1519017|NCT02824497|Other|No intervention. It's a description study|
1519018|NCT02824484|Behavioral|GWDP|"In each writing session participants are asked to:
Describe memories concerning cancer illness in a chronological order, with an objective and detached attitude
Describe: (a) thoughts and emotions perceived during the illness experience; (b) the impact of illness on their daily lives, and how it has changed their attitudes toward life.
Focus on their actual situation, think about the entire illness experience, and report on the following aspects: -Their present thoughts and feelings, and how those differ from the ones felt during the illness experience. -To what extent they have come to terms with, understand and appreciate themselves to have dealt successfully with the illness."
1519019|NCT02824484|Behavioral|Control|Participants are requested to write about events of their daily routine happened during the past week; they are also asked to focus on facts, with an objective and detached attitude.
1519020|NCT02824471|Other|SCD Group|No Intervention. Use of discard blood/tissue
1519021|NCT02824458|Drug|Apatinib|Patients will be treated with Apatinib, 250/500/750 mg(dose determined from Part A of study) p.o., daily
1519022|NCT02824458|Drug|Gefitinib|Patients will be treated with Gefitinib, 250 mg p.o., daily
1519023|NCT02824458|Drug|Placebo|
1519024|NCT02824445|Device|individualized Transcranial Magnetic Stimulation|
1519026|NCT02824419|Drug|Methionine|Subject undergoes imaging studies with FDG and with methionine.
1519027|NCT02824419|Drug|DOTANOC|Subject undergoes imaging studies with FDG and with DOTANOC.
1519028|NCT02824406|Drug|Acetazolamide|Acetazolamide is administered to all participants to induce vasodilation, in order to assess the physiologic response on cerebral blood flow.
1519029|NCT02824393|Biological|Autologous mesenchymal stem cell|Intravenous infusion of ex vivo cultured adipose tissue derived autologous mesenchymal stem cells, twice at two week intervals in total 1x10/6 cells/kg.
1519030|NCT02824380|Drug|DA-4001 H|5% minoxidil / high dose of finasteride
1519031|NCT02824380|Drug|DA-4001 L|5% minoxidil / low dose of finasteride
1519032|NCT02824367|Behavioral|Completion of scales evaluation|Patient complete scores to perfectionism scales (Frost Multidimensional Perfectionism Scales (FMPS), Hewitt Multidimensional Perfectionism Scale (HMPS), scores to depression scale (Beck Depression Inventory (BDI)) and anxiety scale (State Trait Anxiety Inventory (STAI))
1519033|NCT02824354|Drug|Nalmefene (Selincro®) 18 mg tablet|
1519034|NCT02824354|Drug|placebo|
1519035|NCT02824341|Device|fMRI|
1519036|NCT02824315|Drug|AL-335|AL--335 800 mg once daily on Days 1--3, 24--26 and 34--36.
1519037|NCT02824315|Drug|Odalasvir (ODV)|ODV 150 mg on Day 14 and 50 mg once daily on Days 15--23, 24--26, 27--33 and 34--36.
1519038|NCT02824315|Drug|Simeprevir (SMV)|Simeprevir 75 mg once daily on Days 4-13, 27--33 and 34--36.
1519039|NCT02824302|Other|Survey|Patients coming for induction of labor will be handed a survey regarding their expectation of their coming labor pain. And then will be followed up after 24 hours of their delivery.
1519040|NCT02824289|Behavioral|Sun Safe Workplaces Program|The intervention began by sending a Program Announcement Packet and requesting the first face-to-face meeting. At the first meeting, intervention staff covered: 1) Introduction to SSW; 2) Sun Safety Practices in the Workplace; 3) Sun Safety Policy for Outdoor Workers; 4) Sun Safety Policy Adoption; 5) Sun Safety Policy Reinforcement and Maintenance. They presented the SSW Website and a Sun Safety Tool Box. Following the first meeting, the manager scheduled Sun Safety Training by intervention staff with various employee groups. Workplace Sun Safety Materials were sent in four sets (twice a year over two years) for distribution to employees. Research staff made monthly Follow-up Contacts with managers.
1519041|NCT02824289|Behavioral|Attention Control|Research staff sent printed materials on occupational sun safety to local government organizations twice. These included posters with personal protection messages and skin cancer rates, risk assessment brochures, worksite guides, total skin self-examination CD-Rom, the American Academy of Dermatology SPOT bookmark, and a sun safety tip card from the Occupational Safety and Health Administration (OSHA). Staff made presentations on general sun safety topics (not policy) at state professional conferences.
1519042|NCT02824276|Drug|Oxycodone or morphine sulfate immediate release (MSIR)|Oxycodone or morphine sulfate immediate release (MSIR)
1519043|NCT02824276|Drug|Placebo Treatment|Lactose (Appearance and Weight-matched placebo capsules)
1519044|NCT02824263|Device|CPAP withdrawal|CPAP is discontinued for 3 nights.
1519045|NCT02824250|Behavioral|MBSR|Mindfulness-Based Stress Reduction (MBSR) is an 8-week classroom based program of mindfulness meditation and gentle yoga.
1519046|NCT02824237|Device|Improved cook stove|The investigators will conduct a pre-post intervention study to evaluate effectiveness of improved stoves and compare outcomes after two years
1519047|NCT02824224|Drug|Tamoxifen|10mg PO (by mouth) twice daily for 7 days starting on day 21 after IUD insertion for one course
1519048|NCT02824224|Drug|Placebo (for Tamoxifen)|Sugar pill manufactured to mimic the tamoxifen 10mg tablet
1519049|NCT02824211|Device|Right Dose System|Automated titration of oxygen system during exertion
1519050|NCT02824198|Biological|CYD Dengue Vaccine (5 dose formulation)|0.5 mL, Subcutaneous
1519051|NCT02824198|Biological|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
1519142|NCT02823548|Drug|Droglican|Chondroitin Sulfate 1,200mg + Glucosamine Hydrochloride 1,500mg
1519143|NCT02823548|Drug|Placebo|Placebo
1519052|NCT02824185|Device|PET/MRI system (SIEMENS AG, Munich, Germany; distributed in France by SIEMENS S.A.S, Saint-Denis, France)|A PET/MRI examination will be performed once for all included patients, using injected fluorocholine, with a dose of 3MBq/kg, up to 2 months before HCC treatment.
1519053|NCT02824172|Other|cast immobilization group|Patients in this group will have their knee locked with a resin going from the ankle to the top of the thigh for 4 weeks, followed by 4 weeks without cast but with rehabilitation through physiotherapy.
1519054|NCT02824172|Other|complete sport rest.|Patients included in this group will follow the current standard procedure for this disease that is to say complete sport rest during 8 weeks including rehabilitation through physiotherapy, following the exact same technic as the experimental group .
1519055|NCT02824159|Other|Blood samples for pharmacokinetics exploration|6 blood sample at regular intervals
1519056|NCT02824159|Other|Imagery|Efficacity will be assessed with 3 sessions of resonance magnetic imaging or positron emission tomography scan
1519057|NCT02824159|Other|Quality of life scale|Quality of life will be evaluated with questionaries 5 times during the study
1519058|NCT02824159|Other|Detection of adverse events|The detection will be assessed using the AMA (assistance des malades ambulatoires) system
1519059|NCT02824159|Genetic|Saliva samples|Saliva samples will be collected to explore genetic characteristics of germinal DNA (genes involved in drug pharmacokinetic)
1519060|NCT02824159|Genetic|Blood sample|A unique blood sample will be performed in order to determine characteristics of tumoral DNA (resistance to treatment mutation)
1519061|NCT02824159|Other|Biological statement|"The following parameters will be assessed :
Complete blood count
Hemoglobin
Hepatic enzymes
Creatinine clearance
Lactate dehydrogenase rate
Total bilirubin rate
Cluster of differentiation 4 T lymphocytes rate
Total gamma-globulins rate"
1519062|NCT02824159|Other|Clinical examination|"The clinical examination are composed by :
Weigh, Height and body mass index measurement
Clinical state of patient during examination
Stage of the disease (OMS grade, binet classification, Ahn Arbor classification)
Presence of B symptomatology
Prognostic factors (Genetic, Mantle Cell Lymphoma International Prognostic Index, Follicular Lymphoma International Prognostic Index, presence of lymph nodes, other target organs ...)"
1519063|NCT02824146|Other|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (15 cmH2O of PEEP + 15 cmH2O of driving pressure) for 10 breaths.
1519064|NCT02824133|Drug|AZD4547|80 mg bd (per os)
1519065|NCT02824120|Other|Comedy|patients will watch comedy film
1519066|NCT02824120|Other|Documentary|patients will watch a documentary film
1519069|NCT02824094|Drug|crizotinib|Crizotinib, 250 mg BID, will be administered orally on a continuous daily dosing schedule
1519070|NCT02824081|Biological|Blood sample|Blood sample in order to study inflammatory biomarkers and genetics purpose
1519071|NCT02824068|Drug|glucosidase alfa|Long-term use in an observational study of licenced drug
1519072|NCT02824055|Drug|Placebo|Participants will receive placebo matched to RO5545965 capsules orally daily in any of the three intervention period.
1519073|NCT02824055|Drug|RO5545965|Participants will receive RO5545965 5 mg capsules or RO5545965 15 mg capsules (5 mg for 3 days, 10 mg for 3 days and 15 mg for 15 days) orally daily in any of the three intervention period.
1519076|NCT02824029|Drug|Ibrutinib|Given PO
1519077|NCT02824029|Other|Laboratory Biomarker Analysis|Correlative studies
1519078|NCT02824029|Other|Pharmacological Study|Correlative studies
1519079|NCT02824016|Biological|biological sample|T4, thyrotropic-stimulating hormone (TSH) and Thyroglobulin antibody were systematically measured
1519080|NCT02824016|Radiation|supraclavicular irradiation|Irradiation of the homolateral supraclavicular area delivering 46 Gy in 23 fractions
1519081|NCT02824003|Drug|ISIS-GCGRRx|once weekly dosing for 13 weeks
1519082|NCT02824003|Drug|Placebo|once weekly dosing for 13 weeks
1519083|NCT02823990|Biological|TG4010|Given SC
1519084|NCT02823990|Biological|Nivolumab|Given IV
1519085|NCT02823977|Drug|Ketamine|Blinded study drug administered to experimental arm
1519086|NCT02823977|Drug|Dexmedetomidine|Open-label study drug administered to both arms
1519087|NCT02823977|Drug|Normal saline|Blinded comparator administered to control arm
1519088|NCT02823964|Drug|Liprotamase|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
1519089|NCT02823951|Drug|Rebif|
1519090|NCT02823951|Drug|Tecfidera|
1519091|NCT02823938|Other|existing database on data collection.|This is an observational study on an existing database.
1519092|NCT02823925|Drug|Pamidronate or Zoledronate|
1519093|NCT02823912|Drug|Capsaicin|
1519094|NCT02823912|Drug|Magnesia calcinada|
1519095|NCT02823899|Biological|HL-OCV|Pharmaceutical company in Bangladesh is now producing HL-OCV, with technological support from MSD wellcome trust Hilleman pt. ltd, which meets international Good manufacturing practice( GMP) standards and WHO production guidelines.
1519096|NCT02823899|Biological|Shanchol|The vaccine is manufactured by Shantha Biotechnics in hyderabad, India and is prequalified by the WHO. Shanchol is available in a single dose. This vaccine is used as two dose regimen.
1519097|NCT02823886|Other|MRI at D7|The infarct size measured on MRI at 7 days.
1519098|NCT02823886|Biological|Blood samples|Blood samples at H0; H4; H12; H24, H48, D7 and 1 month post MI
1519099|NCT02823873|Device|Pulsewave oscillometric wrist cuff blood pressure monitor|Blood pressure monitor utilizing wrist cuff administered and measured using mobile technology.
1519242|NCT02822846|Other|lung ultrasound|
1519100|NCT02823860|Other|Collection of biospecimens and Quality of Life (QoL) assessment|Serum, plasma, buffy coat and formalin-fixed-paraffin-embedded (FFPE). Biospecimens are collected at various stages of diagnostic and therapeutic care.All patients fill out questionnaires of Health related quality of life (QLQ-C30 + QLQ-CR29/STO22, Hospital Anxiety and Depression scale - HAD) and social-demographic survey (Medical Outcome Studies - Social Support Survey- MOS-SSS).
1519101|NCT02823847|Behavioral|Screening Interview|Participants asked about demographic information, and questions about history of tobacco, alcohol, and mouthwash use. Interview lasts about 7 minutes.
1519102|NCT02823847|Device|Carbon Monoxide Test|Carbon monoxide testing given to participants at baseline. Participants blow into a device that measures the amount of carbon monoxide in the lungs.
1519103|NCT02823847|Behavioral|Self-Help Materials|"Participants who want to stop smoking are given referral information for a tobacco cessation program at baseline.
Participants with premalignant and malignant oral lesions [PMOL]) given printed materials and web-based programs for tobacco and alcohol cessation."
1519104|NCT02823847|Procedure|Visual Oral Screening Examination|Intraoral exam performed under incandescent (white light) conditions at baseline, and again two weeks later.
1519105|NCT02823847|Procedure|Direct Fluorescent Oral Visualization Examination|Intraoral exam performed under reduced room lighting with a handheld autofluorescence imaging device at baseline, and again two weeks later.
1519106|NCT02823847|Procedure|Oral Biopsy|Premalignant and malignant oral lesions [PMOL]) still present 2 weeks after oral exam are biopsied.
1519107|NCT02823834|Device|PROFEMUR® Gladiator Plasma Femoral Stems|THA using PROFEMUR® Gladiator Plasma stems and PROCOTYL® L Beaded Acetabular Components
1519108|NCT02823821|Other|Default dialysate sodium concentration of 137mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
1519109|NCT02823821|Other|Default dialysate sodium concentration of 140mmol/l|Default defined here as use of allocated dialysate sodium concentration for at least 90% of delivered dialysis sessions.
1519110|NCT02823808|Drug|NESINA ACT TAB. 25/15mg|Alogliptin/Pioglitazone 25/15mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
1519111|NCT02823808|Drug|AMARYL-M TAB. 2/500mg|Glymepiride/Metformin 2/500mg will be administered to the group once a day in a fixed dose on a fixed schedule for 104 week.
1519112|NCT02823795|Behavioral|Motivational Interviewing|Patients will get motivational interviewing sessions by a patient activation coach (medical social workers and/or nurses trained in motivational interviewing and in the intervention) in five post hospital discharge sessions (whereof one face-to-face, four by phone) aiming to increase patient motivation to become active in self-management (medication management, care plan/follow-up, symptoms/signs of worsening condition, contacts with health care provider).
1519113|NCT02823782|Other|MRI|MRI and neuropsychological assessment planned for the study for patient and volunteers
1519114|NCT02823782|Other|neuropsychological assessment|
1519115|NCT02823769|Device|SI-R21204 resin composite|Primary caries of posterior teeth will be restored using SI-R21204 resin composite. Procedures will be done under local anesthesia if necessary. The preperation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
1519116|NCT02823769|Device|Nanohybrid resin composite|One of the cavities will be restored with a nanohybrid resin composite (Clearfil Majesty) as a control restoration wth ordinary restorative techniques.
1519117|NCT02823756|Procedure|Physical Therapy|Exercise, education, spinal manipulation
1519118|NCT02823743|Drug|Aspirin|Daily medication
1519119|NCT02823743|Drug|Placebo|Daily intake
1519120|NCT02823730|Other|PCI with Synergy Stent|500 patients who have received the Synergy stent. Data will be mined from the DES registry database for the identified Synergy patients at the following time points, in-hospital and then at 1 year, 2 years, 3 years, and 4 years after percutaneous coronary intervention (PCI).
1519121|NCT02823691|Drug|Lanreotide and Metformin|Lanreotide and Metformin
1519122|NCT02823678|Procedure|Pancreatectomy|Patients will undergo pancreatectomy as part of routine care for their pancreatic neoplasms.
1519130|NCT02823639|Procedure|Transcranial direct current stimulation|
1519131|NCT02823626|Drug|Spironolactone and patiromer|High dose spironolactone with or without patiromer based on the patient's baseline potassium
1519134|NCT02823600|Device|RetinaVue 100 camera|Images of the subject's eye will be obtained using the RetinaVue 100 camera and uploaded to a secure network. The study doctor, a board-certified ophthalmologist, will interpret the patient images and return a diagnosis and management plan to the dialysis unit.
1519135|NCT02823587|Other|Pulmonary Rehabilitation|The exercise program will consist of an individual exercise prescription on the treadmill or bike, the initial intensity of 85% VO2max and active exercises or active-resistance for upper and lower limbs according to the capacity of each volunteer.
1519136|NCT02823587|Other|Control|No supervised exercise session, only will be informed at the beginning of the study to perform thirty minutes of physical activity of moderate intensity several days a week is associated with health benefits
1519137|NCT02823574|Biological|Nivolumab|
1519138|NCT02823574|Biological|Ipilimumab|
1519139|NCT02823574|Other|Placebo|
1519140|NCT02823561|Dietary Supplement|Garcinia mangostana|
1519141|NCT02823561|Behavioral|Control group|
1519144|NCT02823535|Behavioral|Iwin: Individual Well-Being Navigator|Immediately following the baseline assessment, the Intervention Group will receive a secure link to download the IWin app. The app provides three types of integrated interventions: 1) stage-matched feedback on the participant's risk behaviors as determined via the assessments; 2) up to two in app messages a day determined by a series of algorithms that control the timing, content, and cadence of the messages; and 3) up to two prompts a week to complete stage-matched activities that foster behavior change (e.g., quizzes, calculators, guided visualizations, info-graphics, testimonials, and more).
1519145|NCT02823522|Other|Patients recruitment|Between July and November 2016, the patients included in the previous retrospective study were contacted by phone, mail and e-mail and invited to come back to the respective clinics where they had been initially diagnosed as NCWS patients: the Department of Internal Medicine of the University Hospital of Palermo and the Department of Internal Medicine of the Hospital of Sciacca (province of Agrigento).
1519146|NCT02823509|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation-SR15-68_R84-089)
1519147|NCT02823496|Other|Sunscreen Lotion , BAY 987521|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. Formulation A: Y49-103, Formulation B: Y71-150.
1519148|NCT02823496|Other|Untreated skin|One site is patched without treatment as control
1519149|NCT02823483|Other|Sunscreen Lotion (BAY987521)|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.Formulation A: Y49-103, Formulation B: Y71-150.
1519150|NCT02823483|Other|Untreated Skin|This site is patched without treatment as irradiated control
1519151|NCT02823470|Drug|LUM/IVA|LUM 400 mg q12h/IVA 250 mg q12h through Week 48.
1519152|NCT02823470|Device|activated smart device|
1519153|NCT02823470|Device|de-activated smart device|
1519154|NCT02823457|Behavioral|VBMI|12 week values based motivational interviewing intervention with a licensed psychologist
1519158|NCT02823418|Procedure|No neuraxial labor analgesia|Neuraxial analgesia will not be performed. Analgesics will be prescribed by the obstetricians according to routine practice.
1519159|NCT02823418|Procedure|Neuraxial labor analgesia|Epidural or combined spinal-epidural labor analgesia will be performed when the cervix is dilated to 1 cm or more and continued until the cervix is fully dilated to 10 cm.
1519160|NCT02823405|Drug|X4P-001|X4P-001 100 mg capsules, administered orally, continuous daily dosing
1519161|NCT02823405|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg, administered by IV infusion every 3 weeks
1519162|NCT02823392|Other|DBMV|the occurrence of at least two following events which were requiring application of CPAP with opening airway maneuvers, requiring oropharyngeal airway, requiring two-person bag mask ventilation, unable to perform bag mask ventilation or presence of desaturation (SpO2 < 95%).
1519163|NCT02823379|Behavioral|Physical Activity|A Smartphone delivered physical activity program
1519164|NCT02823379|Behavioral|Wellness|A Smartphone delivered wellness intervention focused on topics other than physical activity (e.g., skin care, oral health, and breast exams).
1519165|NCT02823366|Drug|Fenofibrate|
1519166|NCT02823366|Drug|UDCA|
1519167|NCT02823353|Drug|Fenofibrate|
1519168|NCT02823353|Drug|UDCA|
1519169|NCT02823340|Device|Fractional microneedle RF(United, Peninsula Medical, China)|
1519170|NCT02823327|Genetic|Laboratory Biomarker Analysis|Correlative studies
1519171|NCT02823327|Other|Medical Chart Review|Medical chart review is performed
1519172|NCT02823314|Device|Cure Tape™ covering T 7 and T 8 dermatomes|The intervention group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 20 x 5 cm and they will have to be placed on the T7-T8 dermatome area.
1519173|NCT02823314|Device|Cure Tape™ away from dermatomes T 7 and T 8|The control group will have to apply two strips of special hypoallergenic tape called Cure Tape™ that will have a size of 5 x 4 cm and they will have to be placed near the greater trochanter area.
1519210|NCT02823041|Behavioral|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
1519211|NCT02823041|Behavioral|Individual Placement and Support|An job/school specialist will use the Individual Placement and Support model to help participants return to school or work and provide ongoing outreach support.
1519425|NCT02821468|Drug|Droglican|Combined Chondroitin Sulfate 1200 mg + Glucosamine Hydrochloride 1500 mg
1519176|NCT02823275|Other|Functional mobilisation|functional mobilisation
1519177|NCT02823275|Other|Short term plaster cast fixation|2 weeks cast immobilisation
1519178|NCT02823262|Other|Breast Cancer Treatment Decision Aid for women 70+|We developed a decision aid on breast cancer treatment for women 70 years or older newly diagnosed with estrogen receptor positive (ER+), clinically lymph node negative (LN-), HER2 negative (HER2-), breast cancers that are 3 centimeters or less. The DA was written using low literacy principles and provides information on the benefits and risks of mastectomy vs. breast conserving surgery (BCS), radiotherapy after BCS, and of hormonal therapies (e.g., anastrozole). It also considers the impact of competing health issues on older women's treatment choices.
1519179|NCT02823262|Other|Usual Care|
1519180|NCT02823249|Dietary Supplement|1.56 g L-Tryptophan|
1519181|NCT02823249|Dietary Supplement|1.56 g L-Leucine|
1519182|NCT02823249|Dietary Supplement|50 g Xylitol|
1519183|NCT02823249|Dietary Supplement|75 g Erythritol|
1519184|NCT02823249|Dietary Supplement|75 g Glucose|
1519185|NCT02823249|Dietary Supplement|Tap water|
1519186|NCT02823249|Dietary Supplement|Mixed liquid meal (Ensure Plus®; 17% protein, 29% fat and 54% carbohydrate)|
1519187|NCT02823249|Device|Nasogastric Tube|
1519188|NCT02823236|Drug|Topical Pirfenidone|Pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
1519189|NCT02823236|Drug|Triamcinolone + Pirfenidone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months. And pirfenidone 8% gel will be applied three times per day during 6 months in the surface of the keloid scar.
1519190|NCT02823236|Drug|Intralesional Triamcinolone|Triamcinolone will be injected in the keloid scar 4 mg/cm2 every 4 weeks for 6 months.
1519191|NCT02823223|Device|Zephyr endobronchial valve placement|Patients will have ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve inserted into the target lobe of the lung with the aim of complete lobar exclusion.
1519192|NCT02823197|Other|Active transport lesson|
1519193|NCT02823197|Other|Active transport lesson and Facebook group|
1519194|NCT02823184|Biological|RNA sample of total leukocytes before start of treatment|RNA sample of total leukocytes before start of treatment
1519195|NCT02823171|Drug|Treatment A: 400 mg Pacritinib P3CT|400-mg oral dose of pacritinib P3CT (reference) formulation capsules
1519196|NCT02823171|Drug|Treatment B: 400 mg of pacritinib FMI|400-mg oral dose of pacritinib FMI (test) formulation capsules
1519197|NCT02823158|Procedure|Deep brain stimulation (DBS) of Globus Pallidus internus (GPi) and Best medical treatment (BMT)|"Patients in the GPi group will be implanted with DBS-electrodes within 6 weeks after randomisation. The stimulation parameters and the medical treatment are adjusted for optimal control of motor and non-motor signs and symptoms according to published guidelines using a specified algorithm. The stimulation parameters are recorded at the beginning and at the end of each post-surgical assessment.
Best medical treatment is applied in combination with GPi-DBS."
1519198|NCT02823158|Procedure|Best medical treatment|Patients will receive optimized medical treatment according to published evidence based guidelines.
1519199|NCT02823145|Drug|ZX008 (Fenfluramine Hydrochloride)|
1519200|NCT02823132|Biological|blood sample|
1519201|NCT02823119|Device|Mini-hysteroscopy|Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.7-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 3.3 mm. All of the procedures will be diagnostic.
1519202|NCT02823119|Device|Conventional Office Hysteroscopy|. Hysteroscopy will be performed with the use of the non-touch technique (vaginoscopic approach). The investigators will use a rigid 2.9-mm hysteroscope with a 30° forward oblique lens and an outer sheath diameter of 5 mm. All of the procedures will be diagnostic.
1519203|NCT02823106|Drug|Verapamil and Citicoline|Single dosing strategy will be used.
1519204|NCT02823106|Other|Placebo|Single matching dosing strategy will be used.
1519205|NCT02823080|Drug|Cetrorelix|study group received 3-day Cetrorelix Acetate sc injection (0.25 mg/day) started on Day-0. Serum E2, pain scores and MOD were checked daily. Hematocrit value (Ht%), total leucocytic count (TLC), gastrointestinal (GI) manifestations and ascites control (24 patients) did not receive Cetrorelix Acetate. Grading were re-evaluated on Day-3, 6 and 8.
1519206|NCT02823067|Other|Blood sample|One extra blood sample of 10 ml will be taken during a routine venapunction for immunoserology testing.
1519207|NCT02823054|Device|EZ-Blocker|the Blocker group, the EZ-Blocker will be set up after anesthesia induction and standard orotracheal intubation to allow lung exclusion during homolateral internal thoracic artery sampling, and thus a one-lung ventilation. This material will be removed at the end of surgical surgery.
1519208|NCT02823041|Behavioral|Cognitive Training|24 weeks of systematic computerized cognitive training, 4 hours per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The 2nd 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group is designed to aid generalization of training to everyday life situations.
1519209|NCT02823041|Behavioral|Aerobic Exercise|Aerobic exercise occurs as two 45-minute sessions at the clinic and two 30-minute sessions at home weekly. Exercise involves an adaptation of interval training, including a variety of calisthenics that can be done without specialized equipment. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
1519212|NCT02823028|Drug|NRT|8-weeks of study provided NRT patch, and 6-weeks of study provided NRT gum of varying strengths or 6-weeks of study provided NRT lozenges, depending on patient level of nicotine dependence.
1519213|NCT02823028|Behavioral|Web Guide|"A website that will provide participants with access to an evidence-based set of base treatment materials in one central location. The site will include information on the proper use of nicotine patches, gum, lozenges, and it will have a direct link for participants to access the NCI's Smokefree.gov Quit Guide. The website will remind participants about quit dates and send alerts via email to participants to complete the appropriate NCI Quit Guide modules."
1519214|NCT02823028|Behavioral|Tweet2Quit|"A fully automated, 90-day quit smoking intervention that provides an online, peer-to-peer support group for quitting and uses twice-daily automessages to encourage and direct the peer-to-peer exchanges. Each group will consist of 12 buddy pairs (matched on key demographics) that will be introduced via automated texts. The program will generate twice-daily programmed contacts (e.g., what benefits do you hope to get from quitting smoking?). Automated pattern detection software will identify and address any problematic low tweeting within a group."
1519215|NCT02823002|Procedure|Slow, Room Temperature Injection|The room temperature local anesthetic agent will be administered by slow infiltration.
1519216|NCT02823002|Procedure|Rapid, Room Temperature Injection|The room temperature local anesthetic agent will be administered by rapid infiltration.
1519217|NCT02823002|Procedure|Slow, Warm Temperature Injection|The warmed local anesthetic agent will be administered by slow infiltration.
1519218|NCT02823002|Procedure|Rapid, Warm Temperature Injection|The warmed local anesthetic agent will be administered by rapid infiltration.
1519219|NCT02823002|Procedure|Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
1519220|NCT02823002|Procedure|Non-Buffered Injection|One side of the body will be randomized to receive an injection of the buffered agent, while the contralateral side will be assigned to receive an injection of the unbuffered anesthetic agent.
1519221|NCT02823002|Drug|Lidocaine|Injectable lidocaine solution (Lidocaine Hydrochloride and Epinephrine)
1519222|NCT02823002|Drug|Buffer|Sodium Bicarbonate
1519225|NCT02822950|Drug|Ceftazidime/avibactam|Ceftazadime/avibactam dosing in ICU patients
1519226|NCT02822937|Drug|Methylphenidate|Methylphenidate is a central nervous system stimulant. It affects chemicals in the brain and nerves that contribute to hyperactivity and impulse control. Methylphenidate is used to treat attention deficit disorder (ADD), attention deficit hyperactivity disorder (ADHD), and narcolepsy.
1519227|NCT02822937|Drug|Triazolam|Triazolam is a benzodiazepine similar to Valium. Triazolam affects chemicals in the brain that may become unbalanced and cause sleep problems (insomnia). Triazolam is used to treat insomnia (trouble falling or staying asleep).
1519228|NCT02822937|Other|Project: EVO|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
1519229|NCT02822937|Drug|Placebo|Sugar pill
1519230|NCT02822924|Procedure|Prostate artery embolization (PAE)|Right femoral arterial puncture is performed under local anesthesia. The blood supply to the prostate is mapped by angiography of the iliac vessels and the prostate arteries. Microcatheters are used for super-selective catheterization of the right and left inferior vesicle arteries. Embolization is performed with a microcatheter to deliver microspheres of 300 micron diameter. The microsphere mixture is slowly injected under fluoroscopic guidance. The endpoint of embolization is flow stasis in the prostatic vessels with prostatic gland opacification, without reflux of the mixture to undesired arteries.
1519231|NCT02822911|Behavioral|Alcohol Used Disorders Identification Test (AUDIT C)|"The Audit-C questionnaire is a three item alcohol screen that can help identify persons who are hazardous drinkers or have active alcohol abuse disorders (including alcohol abuse or dependence). The AUDIT-C is a modified version of the 10 question AUDIT instrument.
Score from 0 to 12. Each Audit-C question has a 5 answer choice, allotted points are from 0 to 4 points. In men, a score of 4 is considered as positive, optimal for identifying hazardous users or active alcohol abuse disorders. The same for 3 points in women."
1519232|NCT02822911|Procedure|Carbohydrate deficient transferrin|Blood sample to collect carbohydrate deficient transferrin (CDT) only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
1519233|NCT02822911|Procedure|Gamma glutamyl transpeptidase|Results of Gamma glutamyl transpeptidase (GGT) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reaches at least 1 point.
1519234|NCT02822911|Procedure|Mean Corpuscular Volume|Results of Mean Corpuscular Volume (MCV) performed as routine practice collected only if the Alcohol Used Disorders Identification Test (AUDIT C) reports at least 1 point.
1519235|NCT02822898|Drug|NaCl 0.9% in Glucose 5% with 40mEq Potassium|NaCl 0.9% in Glucose 5% with 40mEq Potassium, administered at 25 mL/kg IBW/h for 48h
1519236|NCT02822898|Drug|Glucion 5%|Glucion 5% (premixed solution containing 54 mmol/L sodium and 26 mmol/L potassium amongst others), administered at 25 mL/kg IBW/h for 48h
1519237|NCT02822885|Radiation|Ultrasonography|Ultrasonographic assessment of the thickness of the endometrium of the uterus and transvaginal color Doppler ultrasonography for measurements of Pulsatility index and resistance indices of uterine arteries and spiral arteries
1519243|NCT02822833|Procedure|Sentinel lymph node mapping|Before laparoscopic hysterectomy and lymphadenectomy procedure for endometrial cancer, Indocyanine green solution will be injected through cervix. Then the surgeon will look for sentinel lymph nodes under fluorescence visualization.
1519244|NCT02822820|Device|Ligasure-Covidien|Vessel sealing device Ligasure-Covidien used during laparoscopic hysterectomy and pelvic lymphadenectomy
1519245|NCT02822820|Device|RoBi forceps-Karl Storz|Vessel sealing device RoBi forceps-Karl Storz used during laparoscopic hysterectomy and pelvic lymphadenectomy
1519246|NCT02822807|Biological|Blood sampling|
1519247|NCT02822794|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
1519248|NCT02822794|Drug|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
1519249|NCT02822781|Other|No intervention|There is no intervention. The patients will receive common questionnaire usually used by doctors (SNOT 22). Some Data to describe the population are collected then.
1519252|NCT02822755|Other|Home Exercise Program and Adherence Logs|Both groups will receive physical therapy prescribed home exercises and be asked to record adherence to their program on an exercise log.
1519253|NCT02822742|Drug|DE-117 ophthalmic solution|
1519254|NCT02822742|Drug|Latanoprost ophthalmic solution 0.005%|
1519255|NCT02822729|Drug|DE-117 ophthalmic solution|
1519256|NCT02822729|Drug|Timolol ophthalmic solution|
1519257|NCT02822716|Procedure|IRE treatment|The treatment procedure is carried out percutaneously under ultrasound or CT guidance, or using laparoscopic or laparotomy approach when the lesion is close to hollow viscera or abdominal wall, with the patient under general anaesthesia. Insulated needle electrodes, will be placed in the treatment areas under ultrasound or CT guidance. The tumor lesion is identified, measured, and located by ultrasound or CT. Electrical current is administered in pulses with electrocardiographic synchronization to reduce the risk of cardiac arrhythmia.
1519258|NCT02822716|Device|Ultrasound|
1519259|NCT02822703|Device|rTMS Active 20Hz|Active stimulation will be delivered with 70mm Double Air Film Coils. Participants will attend eight 20Hz sessions within two weeks of the scheduled quit date. Participants will receive 20Hz at 110% of the MT for 1 second, less than the limits indicated in the guidelines. These stimulation parameters have been utilized with no serious adverse events in previous studies to decrease delay discounting among smokers and non-smokers. These parameters are similar to or less intense than those utilized in other smoking cessation studies. All participants will receive rTMS over the same area of the DLPFC (6cm anterior to the MT area) while reading relapse prevention booklets supervised by the study coordinator.
1519260|NCT02822703|Device|rTMS Sham|The sham stimulation uses a similar 70mm Double Air Film Coil to look and sound like the active coil, but the magnetic field produced by the sham coil is markedly attenuated (only 5% of stimulator output setting: that is 2.25% of the maximum stimulator output (5% of 45% = 2.25%) and biologically inactive. Participants in this condition will attend eight sham sessions within two weeks of their scheduled quit date. During these sessions, they will also read relapse prevention booklets supervised by the study coordinator. The sham coil is not intended to and does not produce a stimulation effect so there is no proposed biologic mechanism of action.
1519261|NCT02822690|Other|Hospice care at UMCG|introduction of hospice care facilities on the wards at the UMCG
1519262|NCT02822664|Behavioral|Pedophiles patients|cerebral MRI and/or cerebral PET imaging
1519263|NCT02822664|Behavioral|Healthy subjects|cerebral MRI and/or cerebral PET imaging
1519264|NCT02822664|Device|PET/MRI|
1519265|NCT02822651|Biological|Blood sampling|Patients will have a blood sampling at inclusion to measure vitamin D blood concentration.
1519266|NCT02822651|Other|self-administered questionnaire|Patients will fill a self-administered questionnaire the day of inclusion
1519267|NCT02822638|Other|STEMI PATIENT Cohort|PCI
1519272|NCT02822599|Drug|RiaStAP|To decrease post-operative bleeding volume.
1519273|NCT02822599|Drug|Saline|Placebo consisting of normal saline 0.9%
1519274|NCT02822586|Radiation|TSEB Therapy|TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.
1519275|NCT02822586|Drug|Brentuximab vedotin|An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.
1519276|NCT02822573|Drug|Donepezil 5 mg|Participants will be asked to take one 5 mg tablet of donepezil daily for 6 weeks followed by two 5mg tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
1519277|NCT02822573|Drug|Placebo|Participants will be asked to take one tablet of matching placebo daily for 6 weeks followed by two tablets daily for 18 weeks. After 24 weeks, participants will begin a 12 week wash-out period.
1519278|NCT02822560|Device|pEVAR|percutaneous femoral access using a suture-mediated closure device
1519279|NCT02822560|Procedure|open femoral access|cutdown to femoral artery and surgical closure
1519280|NCT02822547|Drug|Peginterferon alfa-2a|Patients will receive Peginterferon alfa-2a according to the standard medical practice
1519281|NCT02822534|Drug|SP2086|the study has 3 doses groups and the 24 subjects were administrated SP2086 50mg,100mg,200mg respectively.
1519282|NCT02822521|Other|Mobile Application|A mobile health application that asks daily questions about participants' pain, function, and disease activity.
1519426|NCT02821468|Drug|Paracetamol or oral NSAIDs excluding COX2 inhibitors|
1519628|NCT02819804|Other|Laboratory Biomarker Analysis|Correlative studies
1519283|NCT02822521|Other|Population Management System|Study staff will act as care managers behind a web-based dashboard to monitor participants' responses to the daily questions on the mobile application and connect them with their HCPs.
1519284|NCT02822508|Drug|BLI801 Laxative|BLI801 oral laxative
1519285|NCT02822508|Drug|BLI801 Placebo|BLI801 oral laxative placebo
1519286|NCT02822495|Biological|Epstein-Barr Virus Cytotoxic T Lymphocytes (EBV-CTLs)|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
1519287|NCT02822482|Drug|Copanlisib|Copanlisib will be given at Day 1, Day 8 and Day 15 (1 cycle = 28 days), administered intravenously over 60 minutes, in association with Cetuximab.
1519288|NCT02822482|Drug|Cetuximab|Cetuximab will be given weekly at Day 1, Day 8, Day 15 and Day 22 (1 cycle = 28 days), administered intravenously over 120 minutes (Cycle 1 Day 1) or 60 minutes (subsequent infusions), in association with Copanlisib.
1519289|NCT02822469|Other|Manual Therapy Treatment|"Treatment starts with 10 deep breathing movements for global relaxation. The anterior and posterior neck muscles, shoulder girdle and subdiaphragmatic will be addressed with myofascial techniques repeated 10 times in each stroke. The cervical spine will be pulled in the longitudinal direction. The draw will be held 1 time, lasting 1 minute. The thoracic region will receive mobilization technique in the anteroposterior direction,10 repeated movements involving all thoracic segment.
The treatment will be applied previously trained therapists, 4 weeks, 2 times a week, totaling eight sessions. The treatment time per session is about 25 minutes."
1519290|NCT02822469|Device|Placebo Ultrasound|A detuned pulsed ultrasound will be applied to regions of the muscles around the shoulder girdle and anterior posterior cervical, for 25 minutes (2.5 minutes in each zone ). The device will be used with the internal cables disconnected for the placebo effect . However, you can handle it and adjust the doses and alarms as it is connected in order to simulate clinical practice and increase the credibility of the use of this device in the voluntary . The placebo treatment will be applied by previously trained therapists. Treatment will have 4 weeks, 2 times a week, totaling eight sessions.
1519291|NCT02822456|Procedure|VFSS|VFSS using assignment of tube type among the interventions such as individual 3D printed guiding tube, traditional IOE tube, levin tube
1519294|NCT02822430|Other|Pain scales|"Visual analogic scale of pain
Pain behaviour scale
Short-FormHealth Survey (SF-36)
Clinical Global impression
Mini International Neuropsychiatric Interview (MINI)"
1519295|NCT02822404|Dietary Supplement|Urinary and blood sample for Cystaine dosage|Urinary and blood cystatin C are sampled in patient with nephrotoxic risks before the treatment beginning, after the first course of chemotherapy, in the middle and at the end of the treatment. A follow up assessment is also required at 2 and 5 years. The cystatin C measurements are compared to traditional nephrology markers. Their sampling requires additional blood and urinary collection but involve minimal risks for patient.
1519296|NCT02822391|Other|observation|
1519297|NCT02822378|Dietary Supplement|Dried Plum|Participants randomized to the 50g dried plum group will consume 6 dried plums per day for the duration of the 52 week intervention. Participants randomized to the 100g dried plum group will consume 12 dried plums per day for the duration of the 52 week intervention.
1519298|NCT02822378|Dietary Supplement|Calcium supplement|All participants will consume calcium supplements for the duration of baseline and intervention.
1519299|NCT02822378|Dietary Supplement|Vitamin D supplement|All participants will consume vitamin D supplements for the duration of baseline and intervention.
1519300|NCT02822365|Procedure|Computed Tomography|Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
1519301|NCT02822365|Device|Imaging Phantoms|Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
1519302|NCT02822365|Procedure|Positron Emission Tomography|Undergo PET/CT scan as clinically indicated.
1519303|NCT02822352|Other|Chromoendoscopy|High definition virtual chromoendoscopy
1519304|NCT02822339|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z12-030)
1519305|NCT02822326|Biological|CD19-CAR-T2 Cells|
1519306|NCT02822313|Drug|Coppertone (BAY987518)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-76_V27-006)
1519307|NCT02822300|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-74_R84-086)
1519308|NCT02822287|Drug|Acetylcystine|Clear oral solution containing 2% acetylcysteine (g/mL) in a 100 mL amber glass bottle.
1519309|NCT02822274|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-70_R84-064)
1519310|NCT02822261|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-66_R84-088)
1519311|NCT02822248|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: SR15-64-R84-070)
1519312|NCT02822235|Other|No Intervention|
1519313|NCT02822222|Drug|RMJH-111b|Four (4) RMJH-111b (magnesium citrate, tribasic anhydrous) soft gelatin capsules (110 mg elemental magnesium/capsule) orally bid for 7 days
1519314|NCT02822222|Drug|Placebo|Four (4) placebo soft gelatin capsules (0 mg elemental magnesium/capsule) orally bid for 7 days
1519315|NCT02822209|Behavioral|EORTC QLQ-C30|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
1519316|NCT02822209|Behavioral|Satisfaction questionnaire - patient|The patient will fill in a satisfaction questionnaire three times : around the third, the sixth and the twelfth month after they started an anti-cancer therapy.
1519317|NCT02822209|Behavioral|Satisfaction questionnaire - general practitioner or home nurse|The general practitioner or the nurse in charge of the patient at home will fill in a satisfaction questionnaire six months after the patient started an anti-cancer therapy.
1519318|NCT02822209|Behavioral|EORTC QLQ-LC13|Questionnaire submitted at the beginning of the study. Then three more times : 3, 6 and 12 months after the start of anti-cancer therapy. The questionnaire can also be completed before the 12th month: when the care program is about to end
1519319|NCT02822196|Drug|Lidocaine|Local Anesthesia using 1% Lidocaine
1519320|NCT02822196|Drug|Bupivacaine|Local Anesthesia using 0.25% Bupivacaine
1519321|NCT02822183|Other|Online Survey|
1519323|NCT02822157|Drug|Olaparib|
1519324|NCT02822157|Drug|carboplatin + gemcitabine or carboplatin + paclitaxel or carboplatin + liposomal doxorubicin or liposomal doxorubicin 4-weekly or topotecan or paclitaxel weekly|physician's choice chemotherapy
1519325|NCT02822144|Drug|Etomidate|
1519326|NCT02822144|Drug|Succinylcholine|
1519327|NCT02822144|Drug|Propofol|
1519328|NCT02822144|Drug|Remifentanil|
1519329|NCT02822144|Drug|Lidocaine|
1519330|NCT02822131|Dietary Supplement|sodium phosphate|
1519331|NCT02822131|Drug|sevelamer, sodium bicarbonate, sodium chloride|
1519332|NCT02822118|Drug|Chang'an I Recipe|Patients in this group were administered the Chang'an I Recipe, 150ml/bag, 3 times/day for 8 weeks.
1519333|NCT02822118|Drug|Placebo|Patients in this group were administered the placebo, 150ml/bag, times/day for 8 weeks.
1519334|NCT02822105|Biological|the H3N2 M2SR monovalent influenza vaccine|The H3N2 Bris10 M2SR influenza vaccine candidate (Bris10 M2SR) is formulated to contain different levels of an M2-deleted non-replicating influenza virus expressing the HA and NA genes of influenza strain A/Brisbane/10/2007.
1519335|NCT02822105|Other|Placebo|saline
1519336|NCT02822092|Drug|Risperidone (patients only)|Inpatients deemed eligible for the study, we be put on open-label risperidone
1519337|NCT02822066|Procedure|Electroporation|Effectivity and safety of irreversible electroporation for refractory neoplasms in liver and pancreas
1519338|NCT02822053|Procedure|US-guided laser ablation for refractory neoplasms|
1519339|NCT02822040|Other|Intraoral Scan|All patients will have an intraoral scan performed for measurements to be taken on.
1519340|NCT02822027|Drug|human gamma globulin|human gamma globulin for preterm infants with encephalopathy of prematurities
1519341|NCT02822027|Drug|non-human gamma globulin|Non-human gamma globulin for preterm infants with encephalopathy of prematurities
1519342|NCT02822014|Other|FDG-PET/CT|We performed baseline FDG-PET/CT, another FDG-PET/CT after 2 months of TB treatment and a PET/CT at the end of treatment in 18 HIV/TB patients.
1519347|NCT02821988|Device|External fetal monitor for Nonstress test|
1519348|NCT02821988|Device|Ultrasonography for Biophysical profile|
1519349|NCT02821975|Other|Cognitive computer training|COGNIFIT is cognitive computer training. Its purpose is to improve cognitive function and is designed to accommodate each individual's cognitive strengths and weaknesses. The cognitive computer training last three months and must be done three times a week, in session lasting 10-20 minutes.
1519350|NCT02821962|Behavioral|Sedentary prompts from a VTAP device|
1519351|NCT02821949|Biological|PCT dosage|When connecting chemotherapy products, a PCT dosage will be made. The results of dosage won't be communicated to the clinician responsible for the patient. Patient's care will then be identical to any other chemotherapy treated patient
1519352|NCT02821936|Procedure|Parametric Imaging|2 parametric PET (one at the inclusion and one at 42 gray of the beginning of radiotherapy)
1519353|NCT02821923|Dietary Supplement|E967-Xylitol|24g xylitol/d
1519354|NCT02821923|Dietary Supplement|E968-Erythritol|36g erythritol/d
1519355|NCT02821910|Drug|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
1519356|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
1519357|NCT02821910|Drug|High dose FDC Empagliflozin/Linagliptin/Metformin XR, fasted|High dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
1519358|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
1519544|NCT02820493|Drug|vedolizumab|
1519629|NCT02819804|Biological|Nivolumab|Given IV
1519359|NCT02821910|Drug|Low dose FDC Empagliflozin/Linagliptin/Metformin XR, fed|Low dose Empagliflozin/Linagliptin/Metformin extended release (XR) fixed dose combination (FDC) tablet
1519360|NCT02821910|Drug|1 tab Empagliflozin +1 tab Linagliptin +2 tabs Metformin XR|1x Empagliflozin + 1x Linagliptin + 2x Metformin extended release (XR) tablets
1519361|NCT02821897|Procedure|Target-controlled intravenous anaesthesia|
1519362|NCT02821897|Procedure|Total anaesthesia|
1519363|NCT02821884|Device|Combination of tDCS and NMES|Both tDCS and NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. The NMES electrodes are placed over the following muscle: extensor digitorum communis, extensor carpi radialis to produce wrist and hand extension. The settings for the NMES is frequency at 50 Hz, pulse width of 200μs,duty cycle of 10 seconds on and 10 seconds off,current amplitude is adjusted to patients comfort (10-20mA).
1519364|NCT02821884|Device|Combination of tDCS and sham NMES|Both tDCS and sham NMES conduct simultaneously for 30 minutes. The anodal electrode of tDCS is placed on the scalp site corresponding to primary motor cortex (M1) of the hemisphere affected by stroke. The cathodal electrode of tDCS is placed on the scalp site corresponding to unaffected primary motor cortex. The current is initially increased in a ramp-like fashion over 30 seconds until reaching 2 mA and is decreased ramp-like fashion over 30 seconds until reaching 0 mA. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
1519365|NCT02821884|Device|Combination of sham tDCS and sham NMES|Both sham tDCS and sham NMES conduct simultaneously for 30 minutes. Sham tDCS electrodes are placed in the same position on patients receiving the sham stimulation. Just like during real tDCS, stimulation is started in a ramp-like fashion but fade out slowly after 30 seconds. Sham NMES electrodes are placed away from all extensor digitorum communis, extensor carpi radialis motor points, and the patients receive cutaneous stimulation just above the sensory threshold without motor activation(wrist extension).
1519366|NCT02821871|Drug|SP2086|
1519367|NCT02821871|Dietary Supplement|high fat diet|
1519368|NCT02821858|Drug|Odalasvir (ODV)|ODV 50 mg (1 tablet) in Treatment A, 100 mg (2 tablets of 50 mg) in Treatment B and 300 mg (6 tablets of 50 mg) in Treatment C.
1519369|NCT02821858|Drug|AL-335|AL-335 400 mg (1 tablet) in Treatment D, 800 mg (2 tablets of 400 mg) in Treatment E and 1200 mg (3 tablets of 400 mg) in Treatment F.
1519370|NCT02821858|Drug|Placebo|Matching placebo will be administered.
1519371|NCT02821845|Behavioral|Trained SCI Hip|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of hip control, members of this group will be trained at slow gait speeds,
1519375|NCT02821819|Other|Random start ovarian stimulation|Egg-donors will start ovarian stimulation randomly at different moments throughout the menstrual cycle.
1519376|NCT02821819|Drug|Gonadotrophins|Urinary FSH 150-225 IU/d
1519377|NCT02821819|Drug|GnRH antagonist|Cetrorelix acetate 0,25 mg/d starting five days after ovarian stimulation
1519378|NCT02821819|Drug|GnRH agonist|GnRH agonist triggering with triptorelin 0,2 mg for final follicular maturation.
1519379|NCT02821793|Other|Consultation, evaluation questionnaire|Consultation, evaluation questionnaire
1519380|NCT02821793|Other|Geriatric consultation, evaluation questionnaire|Geriatric consultation, evaluation questionnaire
1519386|NCT02821728|Dietary Supplement|Dietary intervention|Participants in this group will consume three portions of broccoli and stilton soup per week for a minimum of four weeks before their scheduled template prostate biopsy. The soup will be made with a specially cultivated broccoli known as Beneforte, which contains an enhanced dose of a substance called glucoraphanin.
1519387|NCT02821728|Other|Normal diet|Participants in this group will continue with their normal diet up until the day of their scheduled template prostate biopsy.
1519388|NCT02821715|Drug|THN102 300/3|
1519389|NCT02821715|Drug|THN102 300/27|
1519390|NCT02821715|Drug|Modafinil 300|
1519391|NCT02821702|Device|Vaginal ultrasound|
1519392|NCT02821702|Biological|Blood sample|
1519393|NCT02821689|Drug|Pirfenidone|Pirfenidone was administered in three divided doses (200mg tid), and increased to the manufacturer's instructed target dose (600mg tid) over a 2-week period. The maximum dose was maintained throughout the study in patients who tolerated it.
1519394|NCT02821676|Procedure|PECI/SPB Block with Active Anesthetic + Placebo Multilevel Intercostal Nerve Block followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of 0.5% Ropivacaine with 1:200,000 epinephrine preoperatively via an ultrasound guided PECI/SPB regional block and 5mL of Normal Saline intraoperatively as an intercostal nerve block to each of the T2-T7 nerve segments
1519395|NCT02821676|Procedure|Placebo PEC/SPB Block + Multilevel Intercostal Nerve Block with Active Anesthetic followed by Latissimus Dorsi Flap Breast Reconstruction|30mL of Normal Saline via an ultrasound guided PECI/SPB block and 5mL of 0.5% Ropivacaine with 1:200,000 epinephrine as an Intercostal nerve block to each of the T2-T7 nerve segments
1519396|NCT02821663|Behavioral|vocal intervention|10 x 60 min. sessions of vocal intervention
1519397|NCT02821650|Other|TEJ (Traditional stove to Efficient stove in Jhuggi)|TEJ (means 'Bright' in Hindi) is an improved cook stove, locally designed and manufactured, aimed at reducing the indoor air emissions and improving health outcomes. 'Jhuggi' is a Hindi word which stands for a 'slum dwelling'
1519398|NCT02821637|Other|Eurofit Tests of Physical Fitness (Eurofit)|Eurofit tests are a physical skills assessment. For the study, tests performed on the 1st and the 13th session of the program, then 3 more times : 2 months, 6 months and 12 months after the 13th weekly session.
1519399|NCT02821637|Behavioral|Child Health Questionnaire (CHQ)|The CHQ is a questionnaire about quality of life. The CHQ children form (CHQ-CF87) and the CHQ parent form (CHQ-PF50) are completed each time the Eurofit tests are performed : at the 1st and 13th weekly session then 2 months, 6 months and 12 months later.
1519400|NCT02821637|Other|Effort rehabilitation program|Part of the routine practice of the Pediatric Obesity and Pediatric Diabetes Organization of Mulhouse, the program consists in 13 sessions of 1hour30 of adapted physical activity. The physical activity in this program use cycles of games where rules are adapted to the overweight or obese children. The activities are performed in a playful atmosphere, for example using creative games like tchoukball or peteca, with each session aiming a specific objective each time.
1519401|NCT02821624|Drug|G1T38 (CDK 4/6 Inhibitor)|CDK 4/6 Inhibitor
1519402|NCT02821624|Drug|Placebo|Placebo
1519403|NCT02821611|Behavioral|Meditation Group|twice daily 20 minute mantra-based meditation practice for 8 weeks
1519404|NCT02821598|Other|Upper Limb pattern with flexion - abduction - external rotation|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
1519405|NCT02821598|Other|Lower Limb pattern with flexion - adduction - external rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
1519406|NCT02821598|Other|Lower Limb pattern with flexion - abduction - internal rotation with knee flexion|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
1519407|NCT02821598|Other|Lifting to the right|"The PNF pattern will be applied three times. Participants will be in supine position under a stretcher, with arms folded and lower limbs in neutral position. In order to induce irradiation for the contralateral lower limb, the left foot sole will be kept in contact with the wall. For EMG recording, the participant will be positioned at the end of the PNF pattern and then the isometric contraction will be solicited. The command used was: do not let me move you."
1519408|NCT02821598|Other|Sit to Stand|"Subjects will be sitting on a chair without armrests with ankles positioned at approximately 10 degrees of dorsiflexion. Knees will be kept at approximately 100 degrees of flexion. During the task, the participant will be instructed to stand from the sitting position while keeping their arms crossed over the chest. The examiner will give the command ready - set - go. The task will be performed three times."
1519409|NCT02821585|Behavioral|Nutritional Counseling|Carbohydrate counting will be reviewed, as well as hypoglycemia management. The 9 following visits will focus on different aspects of each diets: types of fats, meat and alternatives, grain products, milk and alternatives, fruits and vegetables, salt intake, energy density and restaurants.
1519412|NCT02821559|Drug|TOMOX|
1519413|NCT02821559|Drug|Bevacizumab|Bevacizumab was allowed and used at 7,5 mg/kg or 5 mg/kg every 2 weeks.
1519414|NCT02821546|Drug|Lactated Ringer's solution|Standard fluid hydration with Lactated Ringer's solution is calculated based on Holiday Segar's equation Aggressive hydration with Lactated Ringer's solution is defined as administration of 150 ml/hour of fluid
1519415|NCT02821533|Procedure|TACE|TACE is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.
1519416|NCT02821533|Drug|Cisplatin|Cisplatin will be mixed with a mixture of Lipiodol and ethanol (LEM), which consists of 33% ethanol by volume in Lipiodol, in a ratio of 2mg cisplatin per mL of LEM, and delivered through catheters or microcatheters to the tumors until there is flow reduction at the tumor feeders. The total dose of cisplatin given in each treatment session is limited to 100mg (50mL LEM) in each treatment session. The usual volume of LEM delivered will be 20 - 30 mL.
1519417|NCT02821520|Drug|conbercept|At baseline conbercept injection is administered.And thereafter is administered based on re-treatment criteria from month 1 to 11.The PRN conbercept re-injection should be monthly.
1519418|NCT02821520|Procedure|Initial PDT|At baseline PDT with verteporfin is administered initially.And thereafter PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
1519419|NCT02821520|Procedure|Delayed PDT|PDT is administered based on re-treatment criteria from month 3 to 11.The PRN PDT retreatment intervals should be no less than 3 months.
1519420|NCT02821507|Drug|sirolimus and cyclophosphamide|
1519421|NCT02821494|Biological|Hespecta|A dose escalation of Amplivant® conjugated peptide
1519422|NCT02821481|Dietary Supplement|Beta-alanine|
1519423|NCT02821481|Dietary Supplement|Placebo|
1519424|NCT02821481|Behavioral|Muscular endurance exercise|
1519428|NCT02821442|Device|Acupuncture|Acupuncture points selected on the arms and legs using both acupuncture and electroacupuncture to assess effectiveness in alleviating neuropathic pain caused by chemotherapy in breast cancer patients
1519429|NCT02821442|Device|Sham Acupuncture|Placebo needles appear to penetrate but do not actually penetrate the skin
1519430|NCT02821429|Other|Combined Thoracic Echography Record|This examination will be done to do the longitudinal follow-up of the patient
1519433|NCT02821403|Device|clear lens with regular coating|
1519434|NCT02821403|Device|regular coating lens with yellow tint|
1519435|NCT02821403|Device|clear lens with blue-light blocking coating|
1519436|NCT02821390|Drug|Nepafenac Eye Drops|One drop instilled to the eye's cul de sac prior to the intravitreal injection.
1519437|NCT02821390|Drug|Placebo (Artificial Tears)|One drop instilled to the eye's cul de sac prior to the intravitreal injection
1519438|NCT02821377|Drug|intravenous furosemide|treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) plus small volumes of HSS (150mL 1.4-4.6% NaCl), from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
1519439|NCT02821377|Drug|Hypertonic saline solutions|Intravenous small volumes of HSS (150mL 1.4-4.6% NaCl), plus treatment with intravenous infusion of furosemide (doses 125-250mg⁄ bid) from the first day after admission until 3 days before discharge, with water restriction and a normal sodium diet.
1519440|NCT02821377|Procedure|Seriated paracentesis|repeated paracentesis from the first day after admission until 3 days before discharge
1519442|NCT02821351|Device|Radio frequency (RF) Cardiac ablation|Catheter based RF cardiac ablation to treat Paroxysmal Atrial Fibrillation
1519443|NCT02821338|Drug|Lamotrigine Extended Release|Lamotrigine Extended Release (generic) and Lamictal XR (brand).
1519445|NCT02821312|Drug|DA-8010|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 8 subject for DA-8010.
Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 8 subject for DA-8010."
1519446|NCT02821312|Drug|Placebo|"Part A will comprise a single-dose, sequential-group study incorporating a food effect evaluation. Total 70 subjects will be studied in 7 groups (Groups A1 to A7); 60 male and 10 female. Each group will consist of 10 subjects of the same sex and 2 subject for DA-8010.
Part B will comprise a multiple-dose, sequential-group study. Total forty subjects (30 male and 10 female) will be studied in 4 groups (Groups B1 to B4), with each group consisting of 10 subjects of the same sex and 2 subject for DA-8010."
1519447|NCT02821299|Other|Laryngeal transplantation|
1519449|NCT02821273|Other|Modified INSURE technique|modified INSURE means intubation-surfactant-X-ray relieved-extubation. Extubation and noninvasive ventilation is used after the X-ray relieving.
1519450|NCT02821273|Other|INSURE technique|INSURE means intubation-surfactant-extubation. Extubation and noninvasive ventilation is used after surfactant administration.
1519452|NCT02821234|Other|MRI|
1519453|NCT02821182|Radiation|stereotactic body radiotherapy|"In patients with metastatic melanoma, anti-PD-1 treatment will be combined with stereotactic body radiotherapy (SBRT).
A total dose of 24 Gy SBRT will be delivered in 3 fractions to one measurable lesion and fractions will be separated >48h and <96h."
1519454|NCT02821169|Drug|ropivacaine|injection of 4mL of ropivacaine in the sphenopalatine area through an endoscopic approach
1519455|NCT02821169|Drug|saline solution 0.9%|injection of 4 mL of saline solution in the sphenopalatine area through an endoscopic approach
1519458|NCT02821117|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days followed by 8 weeks unmasked wear.
During the 2 weeks of masked device wear participants will use the BG strip port for self-monitoring of blood glucose (SMBG). Scanning the sensor at least every 8 hours during this phase.
Followed by 8 weeks of unmasked device wear when participants will use the device (Sensor glucose and SMBG) according to labelling for their day to day management."
1519459|NCT02821091|Other|Interactive Dynamic Balance Training|
1519460|NCT02821078|Other|4D flow imaging sequence|
1519461|NCT02821065|Device|Telus Health Remote Patient Monitoring|
1519462|NCT02821052|Drug|insulin degludec/insulin aspart|Enrolled patients will be treated with Ryzodeg® under routine clinical practice.
1519619|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x1|200 mg SPI-1005 bid po x21d
1519463|NCT02821026|Procedure|Omental Islet transplant|The intervention is transplanting the islets into an omental pouch instead of into the liver. The omentum is a large apron-like fold of membrane inside the abdomen that drapes over the intestines. This study will test to see if omental islet transplantation is safe and effective. Standard immunosuppressive medicines (anti-thymocyte globulin, tacrolimus, mycophenolic acid, sirolimus, etanercept) will be used in this study to prevent rejection of the islets.
1519464|NCT02821026|Drug|Anti-Thymocyte Globulin|
1519465|NCT02821026|Drug|Mycophenolate mofetil|
1519466|NCT02821026|Drug|Tacrolimus|
1519467|NCT02821026|Drug|Etanercept|
1519468|NCT02821026|Drug|Sirolimus|Sirolimus will be used in case of tacrolimus or/and mycophenolate mofetil intolerance.
1519469|NCT02821013|Other|Intermittent PD-1 inhibitor therapy|
1519470|NCT02821013|Other|Continuous PD-1 inhibitor therapy|
1519471|NCT02821000|Biological|Pembrolizumab|Intravenous infusion
1519472|NCT02820987|Drug|MEROPENEM|Administration of MEROPENEM according to a protocol of extended infusion defining dose and duration of infusion.
1519473|NCT02820987|Drug|PIPERACILLIN-TAZOBACTAM|Administration of PIPERACILLIN-TAZOBACTAM according to a protocol of continuous infusion defining dose and duration of infusion.
1519474|NCT02820987|Drug|CEFEPIME|Administration of CEFEPIME according to a protocol of continuous infusion defining dose and duration of infusion.
1519475|NCT02820961|Drug|entinostat|An orally available histone deacetylases inhibitor (HDAC)
1519476|NCT02820961|Drug|exemestane|Aromatase inhibitor
1519477|NCT02820948|Drug|Vitamin E ointment application|Before the skin stapling and after the subcutaneous irrigation with normal saline, sterile Vitamin E acetate ointment was applied in the subcutaneous tissue; 2 ml were applied in the suprapubic incision and 0.5 ml in the rest of port sites.
1519478|NCT02820935|Drug|CC-220|
1519479|NCT02820935|Drug|Rifampin|
1519480|NCT02820935|Drug|Itraconazole|
1519481|NCT02820922|Procedure|Orthopedic|anesthesia techniques with regard to age, sex, ASA score, anaesthesia technique, comorbidities, surgery diagnosis, length of surgery, complications and admission to intensive care unit after surgery
1519482|NCT02820909|Procedure|venous and arterial catheter set-up using ultrasound guidance|The insertion of the venous and arterial catheter will be done using ultrasound guidance. Vein and artery will be identified in cross section. In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than > 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit.
1519483|NCT02820909|Procedure|Anatomical guidance.|"In the anatomical group, catheter will be inserted using, as it is currently done in intensive care unit, anatomic landmarks. If catheterization according to the anatomic method is considered too difficult (> 3 punctures), a conversion to ultrasound guidance will be done.
In case of anatomical difficulties, complications of puncture with anatomical landmarks, or if installation time is greater than > 5 minutes, an intra-osseous catheter will be put in place to avoid delaying of treatment according to the current practice of the intensive care unit."
1519484|NCT02820896|Drug|Placebo|Participants will receive single or multiple doses of RO7105705 matching placebo IV.
1519485|NCT02820896|Drug|RO7105705|Participants will receive single or multiple doses of RO7105705 IV or SC.
1519486|NCT02820883|Biological|Staphylococcus aureus vaccine (60µg/per protein)|two doses of 60µg/0.6ml per dose
1519487|NCT02820883|Biological|Staphylococcus aureus vaccine (30µg/per protein)|two doses of 30µg/0.6ml per dose
1519488|NCT02820883|Biological|Staphylococcus aureus vaccine (15µg/per protein)|two doses of 15µg/0.6ml per dose
1519489|NCT02820870|Behavioral|Statin Decision Support Intervention|"The investigators have developed a mock medical record decision support tool for this project. Each week the investigators will pull a list of patients scheduled for a primary care visit at the Ann Arbor VAMC then calculate each patient's risk based on the clinical guidelines algorithm and compare the statin recommendation against their current prescriptions. For each patient whose current medication therapy is not consistent with the new guidelines (i.e., are guideline discordant), a brief recommendation will be generated. Each day the research assistant will deliver a hardcopy of these patient specific recommendations to the providers for their use. In addition, providers will receive monthly audit and feedback reports on the percentage of their patients meeting the guideline."
1519490|NCT02820857|Drug|Folfiri-bevacizumab|Patient treated with a combination Folfiri-bevacizumab. Treatment every 2 weeks (D1 = D15)
1519491|NCT02820857|Drug|Folfiri|Patient treated with Folfiri only. Treatment every 2 weeks (D1 = D15)
1519499|NCT02820805|Other|Meal Skipping|No meal
1519500|NCT02820805|Other|French fries|50g of available carbohydrates meal
1519501|NCT02820805|Other|Mashed potatoes|50g of available carbohydrates meal
1519502|NCT02820805|Other|Hash browns|50g of available carbohydrates meal
1519503|NCT02820805|Other|Rice|50g of available carbohydrates meal
1519504|NCT02820805|Other|Beans|50g of available carbohydrates meal
1519505|NCT02820792|Procedure|function tests|function tests: ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
1519506|NCT02820792|Device|LMA ProtectorTM|
1519507|NCT02820792|Device|Ambu AuraGainTM|
1519508|NCT02820779|Device|WILLIS|WILLIS® intracranial stent graft system is composed of the stent, delivery system, cobalt-based alloy stent and PTFE graft. It can effectively shunt the blood flow and keep it off of the aneurysm wall.
1519509|NCT02820753|Behavioral|EHR + Text|Text reminders to promote adherence
1519510|NCT02820753|Behavioral|EHR + Portal|Engage portal to promote adherence and medication knowledge.
1519511|NCT02820753|Behavioral|EHR + Text + Portal|See if texting and portal use promote adherence more than each element alone.
1519512|NCT02820740|Device|NeuroBlate System|Laser Interstitial Thermal Therapy
1519513|NCT02820714|Drug|BLI801 Laxative|BLI801 Laxative
1519514|NCT02820701|Procedure|OMT|Osteopathic Manipulative Treatment to low back region
1519515|NCT02820688|Drug|Bupivacaine 0.25%|
1519516|NCT02820688|Drug|Prilocaine 1%|
1519517|NCT02820688|Procedure|Infraclavicular Nerve Block|Ultrasound guided infraclavicular nerve block
1519518|NCT02820688|Drug|Bupivacaine 0.167%|
1519519|NCT02820688|Drug|Bupivacaine 0.125%|
1519520|NCT02820688|Drug|Prilocaine 0.66%|
1519521|NCT02820688|Drug|Prilocaine 0.5%|
1519522|NCT02820688|Device|Ultrasound|All nerve blocks will be performed with ultrasound guidance
1519523|NCT02820675|Other|structured case analysis|implementation of a structured analysis of cases coded as sepsis, severe sepsis, or septic shock after risk adjustment for low-risk-fatalities, high-risk-survivors, and coding errors for preventable deaths, best practice, quality improvement and improvement in coding precision.
1519524|NCT02820675|Other|"strucured screening every patient, every shift"|implementation of a strutured screening and rescue algorithm on regular wards, emergency departements, and intermediate and intensive care units by checking every patient in every shifts for clinical signs of deterioration and apllying a rescue algorithm including consiliary help and/or the help of outreach teams
1519525|NCT02820662|Other|RETCAM|
1519526|NCT02820662|Biological|Blood samples|
1519527|NCT02820649|Other|Sleep deprivation|40 hours of continuous wakefullness
1519528|NCT02820636|Behavioral|S-CBT|The SCBT-SB protocol has 3 phases. Phase I, which is fixed (core sessions), includes 7 sessions (1 family, 4 individual & 2 caretakers sessions). Topics include: understanding the suicidal crisis, getting to know the participants, chain analysis, communication skills, the power of thought and decision making, parenting skills, and family communication. Phase II is flexible and consists of coping skills modules (thoughts, affect regulation, peer relationships, activities, substance abuse & family communication). The treatment plan is adjusted to adolescents' needs. A trauma session is also included as necessary. Phase III consists of closing family and primary caretaker sessions, that are flexible, depending on the caregivers' needs. Participants have received an adequate course of treatment if they complete the core sessions, a basic coping skills module, and the closing sessions. This protocol should take 3-6 months. Once the active phase ends, booster sessions are recommended.
1519529|NCT02820636|Behavioral|Treatment as Usual|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents
1519530|NCT02820623|Behavioral|Self-report|
1519531|NCT02820623|Behavioral|Chart-Stimulated Recall|
1519532|NCT02820623|Behavioral|Behavioral Rehearsal|
1519533|NCT02820610|Drug|Dexmedetomidine|1 ug/kg of dexamedetomidine will instilled into the peritoneal cavity
1519534|NCT02820610|Drug|Magnesium Sulfate|mg/kg of magnesium sulfate will instilled into the peritoneal cavity
1519535|NCT02820610|Drug|Control group|normal saline will instilled into the peritoneal cavity
1519536|NCT02820597|Device|ClariFix Device|
1519537|NCT02820584|Biological|GSC-loaded autologous dendritic cells|
1519538|NCT02820558|Drug|Substance P|
1519539|NCT02820545|Other|Sociological interview|A sociological interview will be performed with each patient by a sociologist, during their hospital stay
1519540|NCT02820545|Other|Self-administrated questionnaire|Self-administrated questionnaire will be performed by patients themselves at the end of hospital stay and one week after they left hospital
1519541|NCT02820532|Device|Protura Treatment table|The treatment couch will be moved according to the respiratory motion of the patient. As a reference first the respiration will be measured without couch motion, than the couch will be switched on and we will evaluate if the respiration changes due to the motion of the couch. This procedure will be repeated once.
1519542|NCT02820519|Drug|Loxapine|Loxapine dose escalation according to tolerability and analgesic efficacy
1519543|NCT02820506|Procedure|SLN mapping and removal of PET-positive lymph nodes|Sentinel node mapping will be performed, followed by systematic removal og PET/CT positive lymph nodes
1519545|NCT02820480|Device|Rehab in a Crate System|"The therapy gym is Rehab in a Crate with 4 stations for upper and lower limb assessment/therapy. Each station will allow adaptive game-based therapy.
Note: The device is not being used at this moment for diagnostic or evaluation. Users will be asked to explore the device, try the systems, and provide feedback about use."
1519546|NCT02820467|Device|fluorescence angiography|Injection of indocyanine grey in an antecubital vein at the posology of 0.05 mg/kg
1519547|NCT02820454|Drug|AGuIX|A single intravenous injection on day 1. Dose level 1: 15mg/kg; Dose level 2: 30mg/kg, Dose level 3: 50mg/kg; Dose level 4: 75mg/kg; Dose level 5: 100mg/kg
1519548|NCT02820454|Radiation|whole brain radiation therapy|30Gy in 10 sessions of 3Gy (5 days a week in weeks 1-2); first session 4 hours after AGuIX injection.
1519549|NCT02820441|Drug|Zopiclone|
1519550|NCT02820441|Drug|Placebo|
1519551|NCT02820428|Other|Healthy participants|Semi-structured interview
1519552|NCT02820415|Other|chromosomal status of blastocysts from fresh and vitrified/warmed oocytes|
1519553|NCT02820389|Procedure|Optical colonoscopy|Patients with suspected colorectal cancer in this group will undergo Optical Colonoscopy as the initial imaging modality.
1519554|NCT02820389|Procedure|CTC|Patients with suspected colorectal cancer in this group will undergo Computed Tomography Colonography (CTC) as the initial imaging modality. Subsequent imaging might be required based on the findings from the CTC scan, i.e. patients with medium to large polyps or colorectal cancer will undergo Optical Colonoscopy as the second imaging test.
1519555|NCT02820376|Other|Differential renal function assessment by 4D CT|Low dose 4D (perfusion) renal acquisition after injection of iodinated contrast medium (ICM) (13 passes every 3 seconds, 3 passes every 10 seconds); estimated additional DLP 400 mGy.cm No additional contrast medium
1519556|NCT02820363|Device|"CERAMENT|G"|"Surgical repair of tibia fracture, CERAMENT™|G applied to bony voids."
1519557|NCT02820363|Procedure|SOC treatment|surgical repair of tibial fracture
1519558|NCT02820350|Device|SCD-F40|CRRT with SCD
1519559|NCT02820324|Drug|Oliceridine|
1519560|NCT02820324|Drug|Placebo|
1519561|NCT02820324|Drug|Morphine|
1519562|NCT02820311|Drug|TD-4208 175 mcg|via nebulizer
1519563|NCT02820311|Drug|TD-4208 700 mcg|via nebulizer
1519564|NCT02820311|Drug|Placebo for TD-4208|via nebulizer
1519565|NCT02820311|Drug|Moxifloxacin 400 mg|oral
1519566|NCT02820298|Drug|Bexagliflozin|Bexagliflozin tablet, 20 mg
1519567|NCT02820285|Other|Evaluation of the staging of fibrosis liver|The investigators will determine the severity of steatosis, inflammation and fibrosis by histological study of liver biopsies
1519568|NCT02820285|Other|Determine the expression level of semaphorin|The investigators will determine the expression level (gene and protein) of immune semaphorin and their (s) receptor (s) in the liver and subcutaneous and visceral adipose tissue by RT-PCR,
1519569|NCT02820285|Other|Determination of the composition of immunity cells|"The investigators determine the composition of immunity cells by immunohistochemical and biochemical analyses (Western Blotting
)"
1519570|NCT02820272|Procedure|NPWT with cold water|Each of dressing change would be treated with NPWT and injection of cold sterile water kept in 4°C temperature into sponge 10 minutes before dressing change
1519571|NCT02820272|Procedure|NPWT with normal saline room temp|Each of dressing change would be treated with NPWT and injection of room temperature sterile water kept in room temperature into sponge 10 minutes before dressing change
1519572|NCT02820272|Procedure|NPWT without other intervention|Each of dressing change would be treated with NPWT without injection of any liquids into sponge before dressing change
1519573|NCT02820259|Drug|Tacrolimus|
1519574|NCT02820246|Other|nutrition|type and amount of food eaten or type of oral nutritional supplements as well as enteral or parenteral nutrition
1519575|NCT02820194|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation is a therapy for delivering a conformal high dose of radiation to the tumor and a minimal dose to surrounding critical tissues, with a hypofractionation schedule
1519576|NCT02820194|Procedure|Microwave Ablation|Microwave ablation (MWA) is a newer technology that utilizes high-frequency electromagnetic radiation to create thermal damage and coagulation necrosis
1519577|NCT02820181|Device|novel tracheostomy bi-ties|The investigators designed a novel tracheostomy bi-tie to ensure the safety and conveniences during exchanging and cleaning them, the primary feature of which is double belts and easy to operate.
1519578|NCT02820181|Device|traditional Tracheostomy ties|Traditionally, the tracheostomy tube is fixed using ordinary tracheostomy ties made of medical bandage or long strands.
1519579|NCT02820155|Drug|RGN1016|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
1519580|NCT02820155|Drug|Placebo|Stage I: single oral dose Stage II: multiple oral dose (QD, 7days)
1519581|NCT02820129|Device|Medication Wallet Card|A medication wallet card will be given to the intervention group. This will be personalized for each patient and will include the patient's medications, dosages, and medical conditions. It will be personally given to a patient after a medical appointment with their family physician.
1519582|NCT02820129|Device|Reminder Card|"A reminder card will be given to this group. The card will not be personal and will be mailed to patients. It will state, Remember to keep an up-to-date listing of your medications and bring your medications to your doctor's appointments."
1519583|NCT02820116|Drug|Icotinib|In the neoadjuvant treatment phase, eligible patients will receive 125mg of Icotinib three times per day for 8 weeks (56 days). In the post-surgery phase, Icotinib 125mg/three tims/day taken orally for 2 years or till disease progression or unacceptable toxicity.
1519620|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x2|400 mg SPI-1005 bid po x 21d
1519621|NCT02819856|Drug|SPI-1005 Ebselen 200mg Capsule x3|600 mg SPI-1005 bid po x 21d
1519624|NCT02819830|Behavioral|Exercise Intervention|Combined strength and aerobic exercise
1519625|NCT02819817|Drug|Aloe Vera Gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
1519626|NCT02819817|Other|Ultrasound gel|The participant will be asked to place the allocated substance onto the wound twice daily and cover with a supplied dressing on each occasion for 1 week.
1519584|NCT02820103|Behavioral|Text+Visual BCT-based intervention|Participants in the visual intervention group will receive usual care specified below plus a specifically developed Text + Visual BCT-based intervention, comprising 12 BCTs identified from SR and expert consensus study. An animated video, just under 8 minutes in length is hosted online in the Intervention Modelling Experiment. The animation contains 9 of the 12 BCTs and tells the 'delay stories' of three different characters. It was not possible to deliver all of the 12 BCTs comprehensively in the relatively passive media of the animation as some techniques require active participation from participants (e.g. action planning). Thus, n=7 BCTs (1 2 Problem-solving; 1 4 Action planning; 5 2 Salience of consequences; 7 1 Prompts/cues; 9 3 Comparative imagining of future outcomes; 15 2 Mental rehearsal of successful performance) are also delivered via short web-based exercises which follow the animation.
1519585|NCT02820103|Behavioral|Text-only BCT intervention|Participants in the text-only BCT-based intervention group will receive the usual care specified above plus a text-only BCT-based intervention. This was developed in the same way as the text + visual BCT-based intervention but does not include the visual elements (i.e. animation). Instead, the voiceover from the animated film is displayed in text on screen and narrated in audio. The BCTs which require active engagement are delivered via identical web-based exercises as the text + visual BCT-based intervention.
1519586|NCT02820103|Behavioral|Leaflet information (control)|Participants in the control group will receive information that is currently used routinely in the NHS site to inform patients with ACS what to do if they experience symptoms after discharge.
1519587|NCT02820077|Device|Hemospray (Endoscopic treatment with hemostatic powder)|Malignant bleeding lesions will be treated with endoscopic powder and patients will receive optical clinical management afterwards
1519588|NCT02820064|Procedure|duodenal biopsy during gastroduodenal endoscopy|Patients for who and esophagogastroduodenoscopy in order to diagnose is performed. 8 duodenal biopsy specimens will be removed.
1519594|NCT02820038|Behavioral|Medication Guides|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
1519595|NCT02820038|Behavioral|SMART Program|The investigators will determine if the effectiveness of written medication information can be increased by Gist Reasoning Training, delivered via the SMART Program, which is designed to enhance patients' ability to extract meaningful gist from complex information.
1519596|NCT02820038|Behavioral|Drug Facts Boxes|The investigators will compare the effectiveness of two types of written prescription drug information targeted for patients: (1) Medication Guides mandated by the Food and Drug Administration, and (2) Drug Facts Boxes, developed by Woloshin and Schwartz.
1519597|NCT02820025|Drug|doxapram|
1519598|NCT02820025|Other|saline|
1519599|NCT02820012|Other|Scoliosis|Questionnaires, radiography
1519600|NCT02819999|Drug|Rovalpituzumab Tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
1519601|NCT02819999|Drug|Cisplatin|
1519602|NCT02819999|Drug|Etoposide|
1519603|NCT02819986|Behavioral|Progressive Goal Attainment Program|Behavioural intervention that consists of 10 one hour weekly therapy sessions that focus on goal setting, challenging thoughts about return to work, problem solving, behavioural activation, and resuming occupational roles.
1519604|NCT02819973|Other|Educational Video1|
1519605|NCT02819973|Other|Educational Video 2|
1519606|NCT02819973|Other|Usual Care 3|
1519607|NCT02819960|Drug|PROBIO-FIX INUM®|Each capsule contents: 2 lyophilized probiotic strains, total amount of minimum 7x10 9 CFU/cps, ratio LGG®: BB-12® = 50% : 50% (Culture percentages are based on cell concentration and are approximate) Lactobacillus rhamnosus GG® (ATCC 53103) Bifidobacterium animalis subsp. lactis BB-12® (DSM 15954) Additives: maltodextrin, microcrystalline cellulose, silicium dioxide, magnesium stearate
1519608|NCT02819960|Drug|Placebo|Maltodextrin
1519609|NCT02819947|Other|This is an observational prospective study.|Investigators will get clinical information including gender, date of birth, height, weight, family history for systemic sclerosis, education, and symptoms of organ involvement of skin, lung, heart, gastrointestinal tract, kidney, musculoskeletal system and laboratory data. Investigators will evaluate nailbed capillary microscope, hand x-ray, 6 minute walk test, echocardiography, computed tomography of chest, pulmonary function test (FVC%, DLCO%), and electrocardiogram as baseline. Investigators permit replacement of previous results within one year from baseline. Participants in the cohort will be followed up annually and investigators will treat SSc patients according to their routine practice in the best interest of patents. Medications for other comorbid conditions are allowed.
1519610|NCT02819934|Drug|KD101|after 10 min KD101 administered, 14C KD101 3.52ug/1ml administrated. both of them will be administrate for oral
1519611|NCT02819921|Drug|Desvenlafaxine succinate|Pristiq
1519612|NCT02819921|Drug|Placebo|Placebo
1519613|NCT02819908|Drug|Imprimis Dropless|Tri-Moxi-Vanc transzonular intravitreal injection
1519614|NCT02819908|Drug|Imprimis Less Drops|Pred-Moxi-Ketorolac and Pred-Ketorolac topical instillation qd postoperatively
1519615|NCT02819895|Other|A customized windows® software application|A customized windows® software application with the ability to send automated voice call, SMS and email reminder about due dates for childhood routine immunizations.
1519616|NCT02819882|Other|No intervention|
1519617|NCT02819869|Drug|Statin and Metformin use|
1519618|NCT02819856|Drug|Placebo|0 mg SPI-1005 bid po x 21d
1519630|NCT02819804|Other|Pharmacological Study|Correlative studies
1519631|NCT02819791|Other|Optimized conventional therapy alone|Patients will benefit from a traditional follow-up as provided for this type of patients at 3 months and 1 year
1519632|NCT02819791|Behavioral|Optimized conventional therapy with therapeutic education|"The objectives of this therapeutic education program involve:
learning objectives and acquisition of knowledge and self-care skills making the patient more autonomous and facilitating its adherence.
the objectives of acquiring coping skills ( self-confidence , stress management , setting projects ) to improve their quality of life .
the development objectives respects the relevant criteria of quality , realism and principle of educational progress."
1519633|NCT02819778|Procedure|usual care|
1519634|NCT02819778|Procedure|S100B|
1519635|NCT02819752|Drug|Pembrolizumab|
1519636|NCT02819752|Radiation|Radiotherapy|Radiotherapy - Standard Treatment
1519637|NCT02819752|Drug|Chemotherapy|Chemotherapy - Standard Treatment
1519638|NCT02819739|Drug|medical oxygen|
1519639|NCT02819726|Biological|SAIT101|1,000 mg i.v. of SAIT101 on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
1519640|NCT02819726|Biological|MabThera|1,000 mg i.v. of MabThera® on Day 1 and 15. 1,000 mg i.v. of MabThera® on week 24 and 26 for eligible patients.
1519641|NCT02819726|Biological|Rituxan|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of Rituxan® on week 24 and 26 for eligible patients.
1519642|NCT02819726|Biological|Rituxan/SAIT101|1,000 mg i.v. of Rituxan® on Day 1 and 15. 1,000 mg i.v. of SAIT101 on week 24 and 26 for eligible patients.
1519643|NCT02819713|Other|ultrasound gel|
1519644|NCT02819713|Other|Instillagel|
1519645|NCT02819700|Behavioral|prevalence of behavioural dysexecutive syndrome|Behavioural Dysexecutive Syndrome Inventory (ISDC)
1519646|NCT02819687|Drug|RDX5791|
1519647|NCT02819687|Drug|Placebo|
1519648|NCT02819661|Device|SOMNOTOUCH RESP|Ventilatory effort recorder
1519649|NCT02819661|Procedure|Caesarean section|Cesarean delivery is defined as the delivery of a fetus through surgical incisions made through the abdominal wall (laparotomy) and the uterine wall (hysterotomy).
1519650|NCT02819661|Drug|Spinal anesthesia with intrathecal morphine|is a form of regional anaesthesia involving injection of a local anaesthetic into the subarachnoid space
1519651|NCT02819648|Drug|Prednisolone|40 mg prednisolone (two tablets Prednisolone 20 mg, Aventis Intercontinental, Paris, France)
1519652|NCT02819648|Other|Control|Milk Tablet
1519655|NCT02819609|Procedure|myomectomy|Myomectomy as part of routine clinical care
1519656|NCT02819609|Procedure|endometrial ablation|Endometrial ablation as part of routine clinical care
1519657|NCT02819609|Procedure|uterine artery embolization|Uterine artery embolization as part of routine clinical care
1519658|NCT02819609|Procedure|MRI-guided focused ultrasound ablation|MRI-guided focused ultrasound ablation as part of routine clinical care
1519659|NCT02819596|Drug|Savolitinib|
1519660|NCT02819596|Drug|MEDI4736|
1519661|NCT02819596|Drug|Tremelimumab|
1519662|NCT02819583|Biological|PCAR-019 (anti-CD19 CAR-T cells)|
1519663|NCT02819570|Drug|I.V cefuroxime 750 mg*3/d for 2 days|
1519664|NCT02819570|Drug|I.V ampicillin 2 gram x4/d for 2 days|
1519665|NCT02819570|Drug|P.O cefuroxime 500 mgx2/d for 5 days|
1519666|NCT02819570|Drug|P.O roxithromycin 150 mg*2/d for 7 days|
1519667|NCT02819570|Drug|P.O moxypen 500 mgx3/d for 5 days|
1519668|NCT02819557|Drug|Ataluren|Ataluren
1519669|NCT02819544|Drug|Sodium chloride administration|Sodium chloride administration
1519670|NCT02819544|Drug|Ropivacaine administration|Ropivacaine administration
1519671|NCT02819531|Device|Rotational atherectomy|Pre-stenting lesion modification using the rotational atherectomy device using standard technique under intravenous infusion of heparin. Burr size will be selected by the operator according to vessel size. IVUS images will be obtained before lesion modification and after stenting.
1519672|NCT02819531|Device|Orbital atherectomy|Pre-stenting lesion modification using the orbital atherectomy device according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
1519673|NCT02819531|Device|Scoring balloon system|Pre-stenting lesion modification using the scoring balloon system according the manufacturer's guidelines. IVUS images will be obtained before lesion modification and after stenting.
1519680|NCT02819505|Dietary Supplement|beta-alanine|
1519681|NCT02819505|Dietary Supplement|Placebo|
1519684|NCT02819466|Device|3D echography|ultrasound visualization of the stomach in fasting patients.
1519685|NCT02819453|Drug|Dexamethasone|Patients with acute respiratory distress syndrome treated with dexamethasone for three to five days.
1519686|NCT02819440|Drug|Tadalafil|Tadalafil is an FDA approved, clinically-available drug that inhibits the enzyme phosphodiesterase type 5A (PDE5). Subjects who are randomized to this arm will be provided with 20mg of Tadalafil to take every day for 12 weeks, beginning at their baseline visit.
1519687|NCT02819440|Drug|Placebo|100 patients will be randomized to receive a placebo pill. Subjects in this arm will be provided with 20mg Placebo to take every day for 12 weeks, beginning at their baseline visit.
1519688|NCT02819427|Device|Near Infra Red Spectroscopy (NIRS)|
1519832|NCT02818322|Device|telemedical monitoring ( T)|
1519689|NCT02819427|Device|Electroencephalography (EEG)|Electroencephalography (EEG) in a simultaneous High-Resolution (HR) recording.
1519690|NCT02819414|Drug|Paracetamol drops|15 mg/kg/dose x 4/day diluted 1:15 yielding dose of 2.25 ml/kg/dose to be given for three days
1519691|NCT02819414|Other|Placebo|2.25 ml/kg/dose x 4/day of sterile water to be given for three days
1519692|NCT02819401|Other|pediatric formula|high-fiber enteral formula
1519693|NCT02819388|Behavioral|Contraceptive counseling|A culturally adapted counselling session lasting up to 45 minutes at the community setting. The interview is based in WHO guidelines and communication tools, in social cognitive theory and in motivational interviewing. Along the interview, topics follow easy to read leaflets prepared to discuss the main benefits of contraception from the view of the immigrant communities, with guided discussions on family planning in the life course, the amount of time required to care children, the economic resources that newborn and children need, and an assessment of the knowledge on the contraceptive methods, and of their current use. Contraceptive methods, abortion and emergency contraception are discussed. Primary health care centre and sexual and reproductive health clinic access is reinforced.
1519694|NCT02819375|Drug|Propofol|1 mg/kg propofol
1519695|NCT02819375|Drug|Propofol+Remifentanil|0.5 mg/kg propofol+0.5 mg/kg remifentanil
1519696|NCT02819375|Drug|Propofol+Ketamine|0.5 mg/kg propofol and 0.5 mg/kg ketamine
1519697|NCT02819362|Device|MRI|The magnetic resonance imaging (MRI) will be performed before the two-step surgery: a ductal-MRI sequence (highly weighted sagittal T2) - followed by sequence with axial plane, T2, T1, injection in dynamic sequences, subtractions.
1519698|NCT02819349|Behavioral|Texting for Relapse Prevention (T4RP)|T4RP is a relapse prevention mHealth program text messaging to people who have schizophrenia/SAD. Content is guided by components of the Assertive Community Treatment (ACT) and focuses on facilitating improved patient-provider communication, promoting medication adherence, helping people self-monitor their early warning signs, and promoting self-management of symptoms.
1519699|NCT02819336|Device|Electroacupuncture (EA)|"The EA group will receive the verum therapies using the following procedures.
Let the patient lie down on lateral decubitus.
The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, CV6 and bilateral points of SP11 and SP6.
The verum acupunctures are inserted on each acupoint inside the installed guide-tube. (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Republic of Korea)
After de qi response is elicited, the electrical stimulation is presented for 20 minutes by middle frequency (30 Hz). (STN-111, Stratek, Republic of Korea)
The practitioner should have at least 1-year clinical experiences.
The procedure will be repeated 10 times (once a session) within 21 days."
1519700|NCT02819336|Device|Sham electroacupuncture|"Let the patient lie down on lateral decubitus.
The practitioners install the same guide-tubes as Park sham needle on CV2, CV3, CV4, and CV6 unilaterally & SP11 and SP6 bilaterally.
The non-penetrating sham acupunctures are implemented on each acupoint inside the installed guide-tube.
The electrical stimulation is presented for 20 minutes by middle frequency (30 Hz), (STN-111, Stratek, Republic of Korea) even though the electrical stimulation is not delivered through the skin because the needles are not penetrated through the skin.
The practitioner should have at least 1-year clinical experiences.
The procedure will be repeated 10 times (once a session) within 21 days."
1519701|NCT02819323|Drug|PEG-ELS|polyethylene glycol based bowel preparation
1519702|NCT02819323|Drug|BLI800|BLI800 bowel preparation
1519703|NCT02819310|Drug|BLI400 Laxative|oral laxative
1519704|NCT02819297|Drug|BLI400 Laxative|Oral laxative
1519705|NCT02819297|Drug|BLI400 Placebo|BLI400 Placebo
1519706|NCT02819284|Drug|KPI-121 0.25% Ophthalmic Suspension|
1519707|NCT02819284|Drug|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
1519708|NCT02819271|Drug|CXL-1427 Ascending Dose|
1519709|NCT02819271|Other|Placebo|
1519710|NCT02819271|Drug|CXL-1427 Descending Dose|
1519711|NCT02819258|Other|Endodontic treatment|
1519712|NCT02819245|Procedure|posterior correction and fusion|
1519713|NCT02819232|Other|Blood sampling|Detection of bacteria will be performed on a blood sample
1519714|NCT02819219|Dietary Supplement|Supplemental|participants were provided with either placebo, placebo + ElevATP, or placebo + ElevATP + Caffeine + Vitamins.
1519715|NCT02819219|Other|Exercise Intervention|Concurrent with the supplemental intervention, all subjects participated in a resistance exercise intervention.
1519716|NCT02819206|Other|Blood sampling|Detection of bacteria will be performed on a blood sample
1519717|NCT02819193|Other|raw mother's own milk|Infants receive mother's own milk before day 7.
1519718|NCT02819180|Biological|Butantan Influenza Trivalent, Fragmented and Inactivated vaccine|
1519719|NCT02819167|Other|neurologic and neuropsychological evaluation|cognitive prognosis, cognitive reserve, brain volume will be studied on patients with scale, questionnaire, magnetic resonance imaging
1519720|NCT02819154|Behavioral|phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay|"phone call to evaluate the social changes, emotional, professional a cohort of patients following ICU stay. Investigators will use :
Questionnaire SF 36: Only the first two questions of the SF-36 are used exploring the felt quality of life at the time of the telephone call and in comparison with the period before hospitalization in intensive care.
Stress Assessment Questionnaire posttraumatic (Revised Impact of Event Scale, IES-R)
ADL: Assessment of independence in activities of daily life"
1519721|NCT02819141|Drug|Dexmedetomidine|Patient will receive a maintenance intravenous infusion of medication (Dexmedetomidine) and have access to self-controlled sedation medication (Dexmedetomidine) for anxiety.
1519722|NCT02819128|Other|Swabs skin, pharyngeal, and blood sample|Collection of one blood sample with a volume of 10 mL (2 tubes of blood 5 mL ) and 2 swabs ( throat and skin ).
1519723|NCT02819128|Other|Collection of body lice|For the subjects infested with body lice , if they want, their underwear will be recovered and sent to the laboratory to measure the resistance to permethrin.
1519724|NCT02819115|Biological|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Butantan Fragmented Inactivated Trivalent Influenza Vaccine
1519725|NCT02819102|Drug|BCX7353 and probes|
1519726|NCT02819089|Drug|Dexmedetomidine|Demedetomidine infusion (2mcg/ml); loading 0.5 mcg/kg for 30 min (BW/2 ml/h for 30 min), then 0.5 mcg/kg (BW/4 ml/h) until 30 minutes before finish the operation.
1519727|NCT02819089|Other|NSS|NSS infusion; loading BW/2 ml/h for 30 min, then BW/4 ml/h until 30 minutes before finish the operation.
1519728|NCT02819076|Other|pain scale|
1519730|NCT02819037|Procedure|gas chromatography|
1519731|NCT02819037|Procedure|Stool analysis for detection of malabsorption|
1519732|NCT02819024|Drug|Dexamethasone|Given PO BID
1519733|NCT02819024|Device|Device for PET|Undergo 18F-FLT PET scan
1519734|NCT02819024|Other|Laboratory Biomarker Analysis|Correlative studies
1519735|NCT02819024|Procedure|Positron Emission Tomography|Undergo 18F-FLT PET scan
1519736|NCT02819011|Device|AFO|Subjects will be provided with a pair of orthopedic shoes plus a custom made AFO
1519737|NCT02819011|Other|Control|Subjects will be provided with a pair of orthopedic shoes
1519739|NCT02818985|Drug|Dexamethasone|patients will receive intra-articular 8 mg dexamethasone added to 18 mL 0.25% bupivacaine into the knee joint.
1519740|NCT02818985|Drug|Dexmedetomidine|patients will receive intra-articular 1ug/kg dexmedetomidine added to 18 mL 0.25% bupivacaine into the knee joint.
1519741|NCT02818985|Drug|Saline|patients will receive intra-articular 18 mL 0.25% bupivacaine and 2mL isotonic saline into the knee joint.
1519742|NCT02818972|Device|Relay PRO|Endovascular treatment with investigational device.
1519743|NCT02818959|Device|JenaValve Pericardial TAVR System|The JenaValve Pericardial TAVI system is intended for use in subjects with symptomatic severe aortic stenosis who are at high risk for surgical aortic valve replacement.
1519744|NCT02818946|Device|MRI|Detection of cancer by MRI for pathologic nipple discharge
1519745|NCT02818920|Drug|Pembrolizumab|"Pembrolizumab (prior to surgery) 200 mg IV over 30 min, days 1 & 22, two cycles; followed by surgery; followed by standard adjuvant chemotherapy (per med. oncologist) +/- radiation therapy per institutional standard of care; followed by adjuvant pembrolizumab 200 mg IV over 30 min every 21 days for 4 cycles
-Note: Standard radiation therapy in selected patients for standard clinical indications"
1519746|NCT02818907|Other|Additional biological samples|blood and tumor tissue samples
1519747|NCT02818894|Drug|Lidocaine|Spinal anesthesia administered prior to participant's THA
1519748|NCT02818894|Drug|Bupivacaine|Spinal anesthesia administered prior to participant's THA
1519749|NCT02818881|Other|High-speed yoga|
1519750|NCT02818881|Other|Low-speed yoga|
1519751|NCT02818868|Drug|apixisaban|
1519752|NCT02818855|Procedure|Coronally advanced flap (CAF)|"The test group will be treated by means of the association of Collagen Matrix + Coronally Advanced Flap. As treatment, the control group will receive the association of a subepithelial Conjunctive Tissue Graft + Coronally Advanced Flap.
The aim of both procedures will be to obtain root coverage. All these procedures will be performed in a standardized manner."
1519753|NCT02818855|Drug|Collagen Matrix|A new collagen membrane
1519754|NCT02818855|Procedure|Subepithelial connective tissue graft|Connective tissue graft
1519755|NCT02818842|Other|Primary Health Insurance Fund data|"Data collected are:
First and last name of mother
Age
Mother's date of birth
Theorical date of beginning of pregnancy
Childbirth date"
1519756|NCT02818842|Other|Prenatal Diagnostic Center of Toulouse University Hospital data|"Data collected are :
First and last name of the mother
Mother's birth date
Mother Obstetric history
Course of pregnancy
Drug exposure (name, decision period)
Medical termination of pregnancy (date, cause ...)
Malformations (description, test results, gender of the child,
Weight, height and head circumference, American Pediatric Gross Assessment Record, neonatal pathology)."
1519757|NCT02818842|Other|Mother and child protection data collection|"Date collected are :
Name and surname of Mother
Date of birth of the mother
Obstetric history of the mother (the first certificate to 8 days)
Course of pregnancy (1st certificate to 8 days)
Birth data (1 certificate to 8 days)
Child gender,
Age of the child at the time of the review,
Weight, height and head circumference of the child
American Pediatric Gross Assessment Record (1 certificate to 8 days)
Neonatal diseases (1 certificate to 8 days)
Birth defects (1 certificate to 8 days)
Death (age at death)
History (certificates at 9 and 24 months)
Current diseases (certificates at 9 and 24 months)
Psychomotor development (certificates at 9 and 24 months).
Date of drugs issue
Amount of drug issued
Type of feeding (1 certificate to 8 days)"
1519758|NCT02818842|Other|Medicalisation Program of Information Systems data|"Data collected are :
First and last name of the mother
Mother's birth date
History of abortions (date and cause)"
1519759|NCT02818829|Other|Collection of biological samples|Collection of biological samples including whole blood, serum, plasma, saliva, DNA and RNA from tumor cells, tissue from tumor biopsies, tissue from tumor and adjacent tissue of pancreas
1519760|NCT02818816|Drug|brimonidine tartrate 0.2%|Alpha adrenergic receptor agonist
1519761|NCT02818816|Other|Carboxymethylcellulose Eye Drops|Ocular lubricants
1519762|NCT02818803|Other|Propolis|
1519763|NCT02818803|Drug|Miconazole|
1519764|NCT02818790|Behavioral|Intervention 1|Bodyguard + Precious App. Short onsite training session on how to use the system.
1519765|NCT02818790|Behavioral|Intervention 2|Bodyguard + Precious App + Motivational Interviewing. Face to face counseling session followed by a short onsite training session on how to use the system.
1519766|NCT02818777|Drug|cannabidiol|"Purified CBD, is a strawberry flavored liquid, in sesame oil, provided as 100 mg/ml, extracted from high CBD plant material.
A component of cannabis that has evidence suggesting it is relatively safe and perhaps neuroprotective, reduces tremor, anxiety and psychosis and is well tolerated in PD. Besides limiting the psychoactive effect of THC, studies support that CBD has anti-inflammatory, anticonvulsant, anti-oxidant, anxiolytic and antipsychotic properties."
1519767|NCT02818777|Drug|placebo|
1519773|NCT02818738|Drug|Levamisole Hydrochloride|Dosage : 5, 10, 25 et 50 mg. Dosage form : oral tablets, coated and non dividable for taste-masking Posology : 2.5 mg/kg on alternate days maximum 150mg. Treatment duration : 6 months
1519774|NCT02818738|Other|Placebo|matching verum
1519775|NCT02818725|Drug|Chemotherapy|METHOTREXATE 30 mg/m2 on day 1 VINBLASTINE 3 mg/m2 on day 2 DOXORUBICIN 30 mg/m2 on day 2 CISPLATIN 70 mg/m2 on day 2
1519776|NCT02818725|Drug|panitumumab|PANITUMUMAB 6 mg/kg on day 2
1519777|NCT02818699|Dietary Supplement|Placebo|280mg placebo capsule containing only maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
1519778|NCT02818699|Dietary Supplement|EMIQ|280mg placebo capsule containing 180 mg EMIQ and 100mg maltodextrin, twice daily, one with breakfast, one with dinner, for 12 weeks
1519779|NCT02818686|Drug|TD-1473|
1519780|NCT02818686|Drug|Placebo|
1519781|NCT02818673|Radiation|labelled human serumalbumin (125-I, Séralb®CisBio)|Intra-veinous injection of 0,015 MBq/Kg ; 0,5 to 2 mL injected over less than a minute
1519782|NCT02818673|Radiation|labelled albumin (99m-Tc, Vasculocis®, Cisbio)|intra-peritoneal injection of 200 MBq of labelled albumin (99m-Tc, Vasculocis®, Cisbio) ; 5 ml injected over less than a minute
1519783|NCT02818660|Drug|Synachten|To stimulate the adrenals to increase the cortisol Production as much as possible
1519784|NCT02818647|Procedure|Tonsillectomy|Tonsillectomy is the name of the surgery where tonsils are removed via capsullary dissection. There are various techniques and its basically removing the tonsil from its tonsillary fossa and conducting hemostasis with various equipments.
1519785|NCT02818634|Procedure|Harvesting rib cartilage|
1519786|NCT02818621|Drug|Group Dex (dexmedetomidine)|1mcg/kg loading dose followed by 0.5mcg/kg/hr infusion of dexmedetomidine which was administered at induction of anesthesia through skin closure
1519787|NCT02818608|Device|Transcranial direct brain stimulation (tDCS)|Transcranial direct brain stimulation (tDCS) + Sham Functional Electrical Stimulation (FES)
1519788|NCT02818608|Device|Functional Electrical Stimulation (FES)|Functional Electrical Stimulation (FES) + Sham Transcranial direct brain stimulation (tDCS)
1519789|NCT02818608|Device|Combination of tDCS and FES|Real Functional Electrical Stimulation (FES) + Real Transcranial direct brain stimulation (tDCS)
1519790|NCT02818595|Device|electroencephalogram (HR-EEG)|
1519791|NCT02818595|Device|Near Infra Red Spectroscopy (NIRS)|
1519794|NCT02818569|Drug|Dexmedetomidine|Oral form
1519795|NCT02818569|Other|Saline Placebo|Saline Placebo
1519796|NCT02818556|Drug|Restalyne Silk|
1519797|NCT02818556|Drug|Belotero Balance|
1519798|NCT02818543|Drug|LYC-30937|
1519799|NCT02818530|Device|IOP by tonometer|Electronic tonometer will be used as gold standard for intraocular pressure measurement in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
1519800|NCT02818530|Device|Anterior chamber depth measurement by ultrasound|Anterior chamber depth will be measured by ultrasound in supine position after induction of anaesthesia and every 2 hours intraoperatively and at end of surgery.
1519801|NCT02818517|Other|ACE inhibitors|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
1519802|NCT02818517|Other|beta blockers|Evaluating the cardio toxicity effect of chemotherapy and radiation and estimating the effect of ACE inhibitors and beta blockers in the prevention of heart failure.
1519803|NCT02818504|Other|Wize Mirror|Interactive mirror which integrates contactless sensors and a touch screen interface to derive a semeiotic model of the face with reference to cardiometabolic risk in healthy subjects
1519804|NCT02818491|Drug|Placebo|Normal saline 0.9% in 2 mls
1519805|NCT02818491|Drug|Dexamethasone 1 mg|Dexamethasone 1 mg in 2 mls
1519806|NCT02818491|Drug|Dexamethasone 2 mg|Dexamethasone 2 mg in 2 mls
1519807|NCT02818491|Drug|Dexamethasone 3 mg|Dexamethasone 3 mg in 2 mls
1519808|NCT02818491|Drug|Dexamethasone 4 mg|Dexamethasone 4 mg in 2 mls
1519809|NCT02818491|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% 15 mls
1519810|NCT02818478|Other|Reporting of patient reported outcome measures|Electronic reporting of patient reported outcome measures from home, compared to reporting of patient reported outcome measures at the outpatient clinic
1519811|NCT02818465|Other|Vascular calcifications by Xray|
1519812|NCT02818465|Other|Vascular calcifications by tomodentimetry|
1519813|NCT02818465|Biological|Blood sample withdrawn|
1519814|NCT02818452|Other|Oatmeal + OatWell28XF|Intervention involves consumption of one cereal in the beginning of each visit of the crossover sequence
1519815|NCT02818452|Other|Oatmeal|
1519816|NCT02818452|Other|Hot cereal|
1519818|NCT02818426|Drug|UCPVax|
1519819|NCT02818413|Other|Biospecimen collection and questionnaires|Biospecimen collection and questionnaires
1519820|NCT02818400|Procedure|composite tissue allotransplantation|
1519821|NCT02818387|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
1519822|NCT02818387|Drug|Remifentanil|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration.
1519823|NCT02818387|Drug|Midazolam|Remifentanil 0.125 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.015 mg/kg administration 1 min after remifentanil infusion start.
1519824|NCT02818374|Device|oral accessibility spatula (SAB)|
1519825|NCT02818361|Drug|Topical tripterygium gel|
1519826|NCT02818361|Drug|Placebo gel|
1519827|NCT02818348|Drug|darunavir/cobicistat|800/150 mg, once daily during 35 days + etravirine 400 mg, once daily during 14 days
1519828|NCT02818348|Drug|etravirine|400 mg, once daily during 28 days + darunavir/cobicistat 800/150 mg, once daily during 7 days
1519829|NCT02818335|Drug|LY3023414 Reference Fasted|Administered Orally
1519830|NCT02818335|Drug|LY3023414 Test Fasted|Administered Orally
1519831|NCT02818335|Drug|LY3023414 Test Fed|Administered Orally
1519833|NCT02818322|Device|classic monitoring|
1519834|NCT02818309|Drug|Lesogaberan|120 mg bid
1519835|NCT02818309|Drug|Placebo|Placebo
1519836|NCT02818296|Behavioral|Active IU CBM-I|
1519837|NCT02818296|Behavioral|Control CBM-I|
1519838|NCT02818283|Other|Soy Pretzel|Each packet (5oz.) of soy pretzel contains high gluten wheat flour, soy flour, soymilk, vegetable shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides ~280 calories (16% fat, 54% total carbohydrates, and 30% protein).
1519839|NCT02818283|Other|Wheat Pretzel|Each packet (5oz.) of wheat pretzel contains high gluten wheat flour, vital wheat gluten, shortening, sugar, yeast, salt, and ascorbic acid. Each packet provides ~290 calories (16% fat, 54% total carbohydrates, and 30% protein).
1519840|NCT02818270|Drug|Salbutamol|Salbutamol (albuterol ) was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
1519841|NCT02818270|Drug|Acetylcysteine|Acetylcystine was delivered by a jet nebulizer with a 50 pis oxygen flow at 6 L/min.
1519842|NCT02818257|Other|Strip A|Adhesive strip A
1519843|NCT02818257|Other|Strip B|Adhesive strip B
1519844|NCT02818257|Other|Strip C|Adhesive strip C
1519845|NCT02818244|Device|Fit Bit Blaze Heart Rate Monitoring Device|
1519846|NCT02818244|Device|Garmin Forerunner 235 Heart Rate Monitoring Device|
1519847|NCT02818244|Device|Tom Tom Spark Cardio Heart Rate Monitoring Device|
1519848|NCT02818244|Device|Apple Watch Heart Rate Monitoring Device|
1519849|NCT02818244|Device|Scosche Rhythm + Heart Rate Monitor|
1519850|NCT02818231|Other|Brushing of the olfactory cleft|Non invasive sampling of olfactory cleft cells, by brushing under local anesthesia during fiberendoscopy Form: survey of acceptability
1519851|NCT02818218|Procedure|Liver Transplant|liver transplant recipient surgery
1519852|NCT02818205|Other|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
1519853|NCT02818179|Radiation|THERMOGRAPHY IMAGING|
1519854|NCT02818166|Procedure|Mitral valve surgery|Right mini-thoracotomy mitral valve replacement/repair.
1519855|NCT02818153|Other|Self questionnaire for allergic rhinitis control|
1519856|NCT02818140|Procedure|Ropivacaine TQL block|Unilateral ultrasound-guided TQL block with 30 mL ropivacaine 0.75% 30 min prior to the surgical procedure
1519857|NCT02818140|Procedure|Saline TQL block|Unilateral ultrasound-guided TQL block with 30 mL of saline 0,9% 30 min prior to the surgical procedure
1519858|NCT02818140|Drug|Ropivacaine|
1519859|NCT02818140|Drug|Saline|
1519860|NCT02818140|Device|Ultrasound|
1519861|NCT02818127|Procedure|coronary angiography|Coronary angiography will be performed by transfemoral or transradial approach in all patients. In order to evaluate each coronary artery, at least four views from the left and two views from the right system will be taken.
1519863|NCT02818101|Behavioral|Hypnosis session|
1519864|NCT02818088|Behavioral|n-Back (Cognitive Training)|
1519865|NCT02818075|Other|Mobile Phone Based Peer Support|Adolescents allocated to the experimental group will have access to all standard prenatal and postpartum community supports. In addition, mobile phone-based peer support (MPPS), which consists of support provided by a peer mentor via mobile phone (with both voice calling and Short Message Service text message capabilities) will be provided during pregnancy and for 12 weeks postpartum. Peer support is defined as a specific type of social support (informational, appraisal, and emotional support) that is provided by a peer mentor who possesses experiential knowledge of adolescent motherhood and is of similar age to the participant.
1519866|NCT02818075|Other|Usual Care|Participants allocated to the usual care group will not receive the peer support intervention but will have access to all standard community prenatal and postpartum support services such as 1) the Canada Prenatal Nutrition Program; 2) postpartum home visits / telephone support from a public health nurse; 3) postpartum appointments with midwives, obstetrician, family physician, and / or pediatricians, and 4) prenatal and postpartum support as needed from psychiatrists, psychologists, social workers, breastfeeding clinics, and community resources.
1519867|NCT02818062|Biological|Cytokines dosage in Aqueous humor|Specify details not covered in associated Arm Description.
1519868|NCT02818049|Procedure|Bronchoalveolar Lavage|BAL was performed in accordance with current practice. Patients are oxygenated with FiO2=1 at least 5 min before the start and 4 h after the procedure. Blood pressure, central venous pressure, heart rate and breathing are monitored by a monitor. O2 saturation (SpO2) is monitored continuously by pulse oximetry.
1519869|NCT02818036|Drug|Naltrexone|
1519870|NCT02818036|Drug|Placebo|
1519871|NCT02818023|Drug|Pembrolizumab|"Pembrolizumab will be given at a dose of 200 mg q3 weeks (this is the standard dosage, ). Treatment with pembrolizumab and vemurafenib will commence on the same day.
One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
1519872|NCT02818023|Drug|Vemurafenib|"Vemurafenib will be given at 480 mg twice daily, 720 mg twice daily, or 960 mg twice daily. Treatment with pembrolizumab and vemurafenib will commence on the same day.
One cycle of treatment will be defined as one dose of pembrolizumab and 3 weeks of vemurafenib."
1519873|NCT02818010|Other|Global Physical Activity Questionnaire|The practice of physical activity is measured by the GPAQ 2 questionnaire (Global Physical Activity Questionnaire) developed by the World Health Organization.
1519875|NCT02817971|Behavioral|Enhanced feedback|Hospital level feedback delivered every month through paediatrician on the level of adherence to revised pneumonia treatment recommendations.
1519876|NCT02817971|Behavioral|Standard feedback|Hospital level feedback delivered every two months through paediatrician on the performance of multiple paediatric care indicators for managing severely ill children.
1520026|NCT02816879|Other|Laboratory Biomarker Analysis|Correlative studies
1519878|NCT02817945|Drug|68Ga-NOTA-3PTATE-RGD|68Ga-NOTA-3PTATE-RGD were injected into the patients before the PET/CT scans
1519879|NCT02817932|Drug|Ranolazine|
1519880|NCT02817906|Drug|ITI-007|
1519881|NCT02817906|Drug|Placebo|
1519885|NCT02817867|Device|tDCS|Transcranial direct current stimulation (tDCS)
1519886|NCT02817867|Device|TMS|Transcranial magnetic stimulation
1519887|NCT02817867|Device|tDCS + TMS|Association between tDCS and TMS.
1519888|NCT02817854|Procedure|Measure PCT, CRP and WBC at admission|Measure PCT, CRP and WBC at admission after diagnosis of acute diverticulitis with CT scan has been done
1519889|NCT02817854|Procedure|Measure PCT, CRP and WBC 1 day after admission|Measure PCT, CRP and WBC at one day after admission for acute diverticulitis
1519890|NCT02817854|Procedure|Measure PCT, CRP and WBC 2 days after admission|Measure PCT, CRP and WBC at 2 days after admission for acute diverticulitis
1519892|NCT02817828|Drug|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
1519893|NCT02817815|Device|Electrocardiogram (ECG)|
1519894|NCT02817815|Biological|Blood sampling from the cephalic vein|
1519895|NCT02817815|Biological|Blood sampling from the femoral vein|Blood sampling will be done during radiofrequency ablation of AF procedure, after the introduction of catheter
1519896|NCT02817815|Biological|First blood sampling from left atrium|Blood sampling will be done during radiofrequency ablation of AF procedure, after transeptal punction
1519897|NCT02817815|Procedure|Atrial stimulation|Patients will receive atrial stimulation with the catheter positioned in the coronary sinus to induce AF
1519898|NCT02817815|Biological|Second blood sampling from left atrium|After 20min of continuous AF, a blood sampling from left atrium will be done
1519899|NCT02817802|Device|Magmaris|PCI (Magmaris)
1519900|NCT02817789|Drug|Ticagrelor alone|180 mg loading dose before intervention and 90 mg twice daily during 30 days after the procedure
1519901|NCT02817789|Drug|Combination lysine acetylsalicylate - clopidogrel|75 mg before and 75 mg daily after the procedure of lysine acetylsalicylate and 300mg loading dose before and 75 mg of clopidogrel daily after the procedure
1519903|NCT02817763|Procedure|Connective tissue graft (CTG)|Periodontal surgical technique to treat gingival recessions
1519904|NCT02817763|Procedure|CTG plus resin composite restoration|Periodontal surgical technique to treat gingival recessions Procedure/Surgery: Resin composite restoration Restorative procedure do treat tooth structure loss
1519905|NCT02817763|Drug|sodium dipyrone|sodium dipyrone was recommended for all participants after the surgical procedures.
1519906|NCT02817750|Drug|zolpidem hemitartarate tablet 3.5 mg (fasting + post-prandial)|zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting and zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial
1519907|NCT02817750|Drug|zolpidem hemitartarate tablet 3.5 mg (post-prandial + fasting)|zolpidem hemitartarate orodispersible tablet 3.5 mg postprandial and zolpidem hemitartarate orodispersible tablet 3.5 mg in fasting
1519910|NCT02817698|Drug|cannabis|All cannabis dependent subjects will use cannabis cigarettes to induce elevated dopamine and beta endorphin levels in the brain.
1519911|NCT02817685|Other|3 months|
1519912|NCT02817685|Other|6 months|
1519913|NCT02817685|Other|3 month ultrasound(US)+3 month CT/MRI+3 month US+3 month CT/MRI|
1519914|NCT02817672|Behavioral|PRIME 1.0|Mobile application designed to improve psychosocial functioning and motivational deficits (sans NLP-powered dashboard).
1519915|NCT02817672|Behavioral|PRIME 2.0|Mobile application designed to improve psychosocial functioning and motivational deficits (with NLP-powered dashboard).
1519916|NCT02817659|Drug|Glucagon|Glucagon infusion
1519917|NCT02817646|Other|Computed tomography scan made for clinical reasons|Patients were included if a computed tomography scan of the abdomen or thorax was made early during intensive care admission (1 day before up to 4 days after admission)
1519918|NCT02817646|Dietary Supplement|Nutrition as per hospital protocol|Patients received enteral and/or parenteral nutrition as per usual hospital protocol
1519921|NCT02817620|Dietary Supplement|Spirulysat®|
1519922|NCT02817620|Dietary Supplement|Placebo|
1519923|NCT02817607|Procedure|Sensory testing and Biopsy|"Semmes-Weinstein testing: Each breast will be subdivided into 5 regions. This will include the upper 1/3rd, the middle 1/3rd medial and lateral to the nipple areola complex, the lower 1/3rd and the nipple areola-complex. These regions are consistent with the dermatomes described for the breast innervation.
A cutaneous nerve/skin biopsy is a simple procedure commonly performed on an outpatient setting. The total procedure is expected to take 20 minutes and may be done at the time of surgery as well as 2 and 6 months post operatively either during a revision or at a follow up visit."
1519924|NCT02817568|Other|Drawing Blood|Drawing Blood for genetic analysis
1519953|NCT02817399|Procedure|Active exercises|Subjects will receive training exercise according to ACL reconstruction protocol
1519954|NCT02817386|Other|interview|Trained clinical research assistants interviewed the patients on the first and second day post surgery. The interview included the Confusion Assessment Method (CAM) and MDAS. CAM is a diagnostic algorithm used to determine the presence or absence of delirium.
1519925|NCT02817555|Drug|Epoetin Alfa|"The investigator will adjust epoetin doses as per the study algorithm during the run-in (every two weeks) and active phases (every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.
All epoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.
It is not anticipated that a subject will require a dose of epoetin > 30 000 units weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.
Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
1519926|NCT02817555|Drug|Darbepoetin alfa|"The investigator will adjust darbepoetin doses as per the study algorithm during the run-in (every two weeks) and active phases(every four weeks). This will continue until the 12 month active phase is complete or the patient is withdrawn from the study.
All darbepoetin will be administered intravenously through a hemodialysis machine port using a manufacturer-provided pre-filled syringe.
It is not anticipated that a subject will require a dose of darbepoetin >150µg weekly. If this occurs the dose will not be escalated any higher. Such a patient would likely meet the criteria for study withdrawal.
Intravenous iron will be given as per the study algorithm and only one formulation of iron is used, sodium ferric gluconate."
1519927|NCT02817542|Device|percutaneous coronary intervention|Percutaneous coronary intervention. Procedures include: Implantation of stents The thrombus aspiration (TA) will be started before crossing the coronary atherosclerosis lesion. A minimum of two syringes (40 mL) of aspirate will be recommended. The guide catheter will be engaged with the coronary ostia when removing the thrombectomy catheter. The guide catheter will be aspirated after thrombectomy to avoid embolisation of air or thrombus. PCI procedure will be done without thrombectomy as per the investigator. Direct stenting will not be mandated in either treatment group. Bailout thrombectomy will be allowed after a failure of the initial PCI alone strategy. The decision about bailout thrombectomy will be made by the interventional cardiologist performing the initial PCI.
1519930|NCT02817516|Drug|TAK-828|TAK-828 solution.
1519931|NCT02817516|Drug|Placebo|TAK-828 placebo-matching solution.
1519932|NCT02817503|Drug|Standard BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
1519933|NCT02817503|Drug|Moderate BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
1519934|NCT02817503|Drug|Intensive BP control|Enalapril-folic acid will be used as an initial therapy. Other drugs, including CCB (amlodipine preferred), diuretics (hydrochlorothiazide preferred), and β-blockers, are allowed, in order to achieve the SBP target.
1519935|NCT02817490|Other|patient education program|"The PREDUSED patient education program aims to make the patient actor of his pathology by providing him a box of therapeutic tools in order to: improve his knowledge of the disease, improve the management of pain, fatigue and episodes of instability; learn to communicate about the disease; set realistic goals.
The program includes theoretical information, practical cases, and discussions between participants and professionals.
It is the first patient education program in France for the patients with hypermobility type Ehlers-Danlos Syndrome. It is proposed two times a year. Six patients can participate at each session."
1519936|NCT02817477|Drug|Ketamine Hydrochloride|Delivered intranasally using an atomizer
1519937|NCT02817477|Drug|Morphine|Delivered either as an IM injection or a slow IV bolus
1519938|NCT02817464|Drug|TV-46046 - 400 mg/mL|A single subcutaneous injection in the abdomen of TV-46046 - 400 mg/mL
1519939|NCT02817464|Drug|TV-46046 - 200 mg/mL|A single subcutaneous injection in the abdomen of TV-46046 - 200 mg/mL
1519940|NCT02817464|Drug|TV-46046 - 300 mg/mL (if warranted)|A single subcutaneous injection in the abdomen of TV-46046 - 300 mg/mL (if warranted)
1519941|NCT02817451|Biological|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
1519942|NCT02817451|Biological|Hexaxim®: DTaP-IPV-HB-PRP-T Combined Vaccine|0.5 mL, Intramuscular at 6, 10, and 14 weeks of age + a booster at age 15 to 18 months
1519943|NCT02817438|Behavioral|Good Days Ahead|Good Days Ahead is a web-based program based on the principles of Cognitive Behavioral Therapy (CBT). It can be used to supplement traditional psychotherapy, or as a stand-alone intervention. There are 9 lessons that address Thinking Skills, Behavioral Skills, Schemas, and Coping Tools. Lessons include videos from expert therapists and a Practice Section in which patients complete forms for self-monitoring symptoms and challenging negative thoughts.
1519944|NCT02817425|Drug|SOX Sequential S-1|8 cycles SOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1.Every 21 days as a cycle.
1519945|NCT02817425|Drug|SOX|S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. Every 21 days as a cycle
1519946|NCT02817425|Drug|TEGAFOX Sequential S-1.|6 cycles TEGAFOX followed by S-1 monotherapy until disease progression. S-1: 40 mg/m2 bid,po, day 1 ~14 (S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid) Oxaliplatin: 130 mg/m2 iv 2h,day 1. TF 1000 mg/m2 with calcium folinate 300 mg/m2 IV infusion from Day 1 to Day 5 Every 28 days as a cycle.
1519947|NCT02817412|Behavioral|Go/No-Training|
1519948|NCT02817412|Behavioral|Stop-Signal Training|
1519949|NCT02817412|Behavioral|Dot-Probe Paradigm|
1519950|NCT02817412|Behavioral|Generic Response Training|
1519951|NCT02817399|Device|Functional electrical stimulation|Electrical stimulation that cause muscle contraction while walking
1519952|NCT02817399|Device|Neuro-muscular electrical stimulation|Electrical stimulation that cause muscle contraction in a stationary position
1519955|NCT02817373|Other|Ultrasound scan performed through a vaginal probe|5-8 minute scan recording : endometrial thickness, endometrial pattern, endometrial -myometrial junction appearance, subendometrial wave contractions (presence and number), endometrial surface area
1519956|NCT02817360|Drug|RAS-antagonist and beta-blocker up-to maximal dosages|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Patients receive a prescription and/or up-titration to maximum recommended or tolerated dose of RAS-antagonist and beta-blockers within three months of study entry. The Number of titration visits is up to the treating physician, but one visit should be performed at least at the end of titration.
1519957|NCT02817360|Other|RAS-antagonist and beta-blocker none or at stable dose|All patients have to be stable on their glucose lowering, lipid lowering and blood pressure lowering therapy at least for 3 months. RAS-antagonist and beta-blocker therapy at entrance is allowed. Changes in RAS-antagonist or beta-blocker therapy are not allowed in the control group during the study phase. If there is a vital indication for changes, this has to be argued and documented.
1519958|NCT02817347|Drug|piperacillin 4% + tazobactam 0.5% + dexamethasone 0.1%|
1519959|NCT02817347|Drug|piperacillin 8% + tazobactam 1.0% + dexamethasone 0.1%|
1519960|NCT02817347|Drug|piperacillin 2% + tazobactam 0.25%|
1519961|NCT02817347|Drug|piperacillin 4% + tazobactam 0.5%|
1519962|NCT02817347|Drug|piperacillin 8% + tazobactam 1.0%|
1519963|NCT02817334|Drug|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
1519964|NCT02817321|Procedure|single-injection TPVB|Inject local anesthetics in the T8 paravertebral space without continuous local infusion
1519965|NCT02817321|Procedure|single-injection TPVB + continuous TPVB|Inject local anesthetics in the T8 paravertebral space followed with catheter insertion and continuous local infusion.
1519966|NCT02817321|Device|Philip CX50 Ultrasound Scanner|The curved (C1-5) probe of Philip CX 50 Ultrasound Scanner is used for scanning
1519967|NCT02817321|Device|PAJUNK Contiplex S Catheter|
1519968|NCT02817321|Device|PAJUNK StimuLong|
1519969|NCT02817321|Drug|single dose ropivacaine|"0.2mg/kg ropivacaine in saline with 1:200,000 adrenaline, 25ml in total
given immediately after the correct position of the tip of the needle has been confirmed"
1519970|NCT02817321|Drug|continuously infusion of ropivacaine|"0.2% ropivacaine, infusion rate 0.125ml/kg/h
given through the catheter inserted in the T8 paravertebral space following the single dose"
1519971|NCT02817321|Drug|Morphine given as IPCA|bolus: 2mg, lock time: 10min, 1h limitation: 8mg
1519972|NCT02817308|Other|samples of blood, saliva and urine|Spot samples of Blood, urine and saliva
1519973|NCT02817295|Other|clinical measurements|follow up on the number of complications, revisions, hospitalization and co-morbidities
1519974|NCT02817282|Other|Hand hygiene implementation strategy|Implementation strategy: Individual oriented activities. Education based on the different determinants influencing HCWs' behavior. Reminders for supporting the actual performance of HH; by distributing posters. Performance feedback for awareness. Goal setting will be encouraged and the feedback will be used to help HCWs evaluate their success and determine how they could best adapt their behavior in order to reach their goal. Organisational oriented activities. Products and facilities: The physical environment will be adapted by improving the availability of hand based hand rub. Team-oriented activities; The social environment will be adapted by training at a group and individual level, to improve social and descriptive norms. Positive role models will be stimulated through this training.
1519975|NCT02817269|Other|Manual palpation|The manual palpation level will kept constant by applying enough digital pressure to cause the finger nail bed to blanch. When the nail will be turn pale, the amount of pressure will be measured at approximately 3 4kg/cm2 and will be maintained for 5-10 seconds to evoke referred pain. A manual palpation referred pain will be present if the pain radiated far enough for the patient to feel more than just a local pain.
1519976|NCT02817269|Other|Deep dry needling|Intramuscular needling will be carried out via deep dry needling into myofascial trigger point (MTrP) area without the introduction any substances. The aim is to elicit a local twitch response upon inserting the needle into the MTrP area and perform a neurological stimulation (by rotating the needle 360 degrees) to more easily evoke referred pain, holding for 10 seconds and then extracting the needle gently. The procedure will be followed by one minute of haemostatic compression.
1519977|NCT02817256|Dietary Supplement|Vitamins and Minerals|Multivitamins and Minerals supplementation
1519978|NCT02817243|Drug|SP2086|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
1519979|NCT02817243|Drug|Simvastatin|SP2086 will be administered orally (by mouth) as 100 mg on Days 4, 5, 6, 7, and 8 and Simvastatin will be administered orally as two 20mg tablets on Days 1 and 8. Both SP2086 and Simvastatin tablets will be taken with 8 ounces (240 mL) of water.
1519980|NCT02817230|Drug|Statin|
1519981|NCT02817217|Drug|SP2086|SP2086 will be administered orally (by mouth) as 100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
1519982|NCT02817217|Drug|Valsartan|SP2086 will be administered orally (by mouth) as100mg on Days 4, 5, 6, 7, and 8 and Valsartan will be administered orally as two 80mg tablets on Days 1 and 8. Both SP2086 and Valsartan tablets will be taken with 8 ounces (240 mL) of water.
1519983|NCT02817204|Behavioral|Aerobic Exercise|Cycle ergometer exercise for 3 sessions a day (3 minutes Warm up,45 minutes Resistance Exercise at 75% of HRmax;10 minutes Recovery). 5 days a week(about 2000kcal) and continues 12 weeks
1519984|NCT02817204|Behavioral|Health Education|Lower salt,fat and calorie diet,Recommendation of regular exercise,No smoking and alcohol
1519985|NCT02817191|Drug|Hylo-Comod eye drop|The patients were administrated Hylo-Comod eye drop four times a day after Phaco+IOL
1519986|NCT02817191|Drug|Tears Naturale Forte eye drop|The patients were administrated Tears Naturale Forte eye drop four times a day after Phaco+IOL
1519987|NCT02817178|Other|Additional biological samples|blood and tumor tissue samples
1519988|NCT02817165|Dietary Supplement|Probiotic (BioK+)|Probiotic (BioK+) with 3 stains of Lactobacillus
1520025|NCT02816879|Procedure|Cytology Specimen Collection Procedure|Undergo anal cytology collection
1519989|NCT02817165|Other|Placebo|Strawberry flavored tub of milk, identical (taste, color, odor) to the active Bio-K+ treatment.
1519992|NCT02817139|Device|TDCS|
1519993|NCT02817126|Procedure|Robot-assisted resection|Arm I: Robot-assisted resection using da vinci system.
1519994|NCT02817126|Procedure|Laparoscopic resection|Arm II: Traditional laparoscopic resection.
1519995|NCT02817113|Drug|NC-6004|One cycle of treatment lasts for 3 weeks. NC-6004 will be administered over 1 hour on Day 1 (after the cetuximab infusion) every 3 weeks
1519996|NCT02817113|Drug|Cetuximab|One cycle of treatment lasts for 3 weeks. For each cycle, cetuximab will be administered at least 1 hour before the start of chemotherapy at a loading dose of 400 mg/m2 given over 2 hours initially (ie, on the first day of treatment), followed by a subsequent weekly doses of 250 mg/m2 over 1 hour.
1519997|NCT02817113|Drug|5-FU|One cycle of treatment lasts for 3 weeks. 5-FU will be administered at a dose of 1,000 mg/m2/day on Day 1- Day 4 as continuous infusion every 3 weeks.
1519998|NCT02817100|Drug|BAY1817080|Study part 1: Escalating doses of BAY1817080; single dose administration; solid dosage form (redosing of BAY1817080 at dose group 1 and 2 together with itraconazole; redosing of BAY1817080 at dose group 4 together with food [American breakfast]) Study part 2: Escalating doses of BAY1817080; single dose administration together with an American breakfast; solid dosage form (redosing of BAY1817080 at dose group 1, 2 and 4 together with food [Continental breakfast])
1519999|NCT02817100|Drug|Placebo|Study part 1: Escalating doses of respective placebos; single dose administration; solid dosage form (redosing of placebo at dose group 1 and 2 together with itraconazole; redosing of placebo at dose group 4 together with food [American breakfast]) Study part 2: Escalating doses of respective placebos; single dose administration together with an American breakfast; solid dosage form (redosing of placebo at dose group 1, 2 and together with food [Continental breakfast])
1520000|NCT02817100|Drug|Itraconazole|Redosing of BAY1817080/placebo at dose group 1 and 2 together with itraconazole (study part 1)
1520001|NCT02817087|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation delivered through scalp
1520002|NCT02817074|Behavioral|MIND Diet|3-year dietary counseling to adhere to the MIND diet and for mild weight loss
1520003|NCT02817074|Behavioral|Mild Weight Loss|3-year dietary counseling to reduce calorie intake by 250 kcal/day for mild weight loss
1520004|NCT02817061|Device|Omnilux|The Omnilux LED array sources can be changed to emit different wavelength.
1520005|NCT02817048|Device|chest tube|
1520006|NCT02817048|Procedure|VATS without chest tube placement|Patient received Video-Assisted Thoracic Surgery (VATS) wedge resection for peripheral lung nodule without chest tube placement (Tubeless)
1520007|NCT02817048|Procedure|VATS with chest tube placement|
1520008|NCT02817035|Device|noninvasive mechanical ventilation|To examined the physiological signals of patients and healthy subjects during spontaneous breathing and noninvasive mechanical ventilation.
1520009|NCT02817022|Other|developmentally supportive care|DSC components will be strictly emphasized on protected sleep, pain and stress assessment and management, activities of daily living (positioning, feeding and skin care), the healing environment
1520010|NCT02817009|Behavioral|Social Support|The social worker for the parent support group addresses culturally specific questions and adopts culturally acceptable strategies for setting limits and promoting healthy behaviors, engaging the group as a whole and building peer support.
1520011|NCT02817009|Behavioral|Nutrition Session|Nutrition sessions will focus on how to make traditional Latin American foods healthier, including the sharing of recipes and learning what foods to buy in local supermarkets. Home visits by the nutritionist assists with family-centric strategies for healthier eating in their urban Latino households, including those with large extended families.
1520012|NCT02817009|Behavioral|Physical Activity Session|45 minutes physical activity session to promote healthy behaviors
1520013|NCT02816996|Procedure|Hand-holding|Subject will have their hand held.
1520014|NCT02816996|Procedure|Stress Ball|Subject will be given a stress ball to hold.
1520015|NCT02816983|Radiation|SBRT|
1520016|NCT02816970|Drug|Vildagliptin|1 tablet contains 50 mg vildagliptin
1520017|NCT02816970|Drug|Vildagliptin|1 tablet contains 50 mg vildagliptin
1520018|NCT02816957|Drug|nigella sativ|nigella sativa powder (2 gm/day) for 3 consecutive months.
1520019|NCT02816944|Procedure|EUS-guided laser ablation for refractory neoplasms|
1520022|NCT02816905|Drug|0.1 % Dexamethasone|20 eyes are randomized to receive topical 0.1% Dexamethasone four times per day for 2 weeks.
1520023|NCT02816905|Drug|0.1% Fluorometholone|20 eyes are randomized to receive topical 0.1% Fluorometholone four times per day for 2 weeks.
1520024|NCT02816905|Drug|1% Rimexolone|40 eyes are randomized to receive topical 1% Rimexolone four times per day for 2 weeks. 20 of these eyes were the contralateral eyes of the patients who received 0.1% Dexamethasone in their first eye. The other 20 eyes were the contralateral eyes of the patients who received 0.1% Fluorometholone in their first eye
1520027|NCT02816866|Other|empowered primary care model|mode of survivorship care
1520028|NCT02816866|Other|specialty survivor clinic|mode of survivorship care
1520029|NCT02816853|Drug|Domperidone|Domperidone 10 mg or 20 mg tablets will be administered.
1520030|NCT02816853|Drug|Placebo|Matching placebo will be administered.
1520031|NCT02816853|Drug|Moxifloxacin|Moxifloxacin 400 mg tablet will be administered.
1520032|NCT02816840|Radiation|PET-CT|Patients in this arm take radiotherapy positioning with PET-CT.
1520033|NCT02816840|Radiation|PET-MRI|Patients in this arm take radiotherapy positioning with PET-MRI.
1520034|NCT02816827|Dietary Supplement|AG-01|Product to increase mental alertness
1520035|NCT02816827|Dietary Supplement|AG-05|Product to increase mental alertness
1520036|NCT02816827|Dietary Supplement|AG-06|Product to increase mental alertness
1520037|NCT02816827|Dietary Supplement|AG-07|Product to increase mental alertness
1520038|NCT02816814|Other|Diet rich in omega-3 fatty acids|A diet rich in omega-3 fatty acids (7g/die) will be administered for 4 months to overwieght women in menopause
1520039|NCT02816814|Other|Diet with extra virgin olive oil|A diet rich in EVO (25-30g/die) will be administered for 4 months to overwieght women in menopause
1520040|NCT02816801|Other|Butler-Program 2.0|Internet based intervention for elderly, in which they learn how to use e-mail, video conferencing and a blog, in addition to virtual relaxation exercises.
1520041|NCT02816788|Behavioral|Equine Assisted Therapy (EAT)|Psychotherapy incorporating use of equines (Equine Assisted Therapy; EAT) to facilitate therapy to improve the social, emotional and psychological well-being of participants and alleviate PTSD symptoms.
1520042|NCT02816775|Device|Macintosh Laryngoscope|After induction of anesthesia, tracheal intubation will made by Macintosh Laryngoscope
1520043|NCT02816775|Device|McGRATH Videolaryngoscope|After induction of anesthesia, tracheal intubation will made by McGRATH Videolaryngoscope
1520044|NCT02816762|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure by a nasal mask. CPAP pressure will be automatically titrated using a AutoSet device (ResMed).
1520045|NCT02816762|Drug|Pharmacological treatment|Conventional pharmacological treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor antagonists or anti-aldosterone agents.
1520046|NCT02816762|Other|Diet|Conventional anti-diabetic diet recommendations
1520047|NCT02816749|Procedure|Maggot debridement therapy|Participant will receive bio-bags treatment every 3 days until the wound heal completely, when wounds assessed.
1520048|NCT02816749|Procedure|Conventional Dressing Therapy|Participant will be disinfected by iodophor and dressed by gauze 3 days until the wound heal completely, when wounds assessed.
1520049|NCT02816736|Drug|LCZ696|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR < 30 mL/min/1.73m²: starting dose of LCZ696 = 50 mg po BID.
Subjects taking an ARB at greater than low dose: starting dose of LCZ696 = 100 mg po BID.
Subjects taking an ACEI at greater than low dose: starting dose of LCZ696 = 100 mg po BID.
Dose adjustments will be performed every 2 weeks by doubling the dose of LCZ696 up to the target max dose of 200 mg po BID as tolerated.
The doses of LCZ696 are 50mg (one low-dose (50mg) tablet), 100mg (one high-dose (100mg) tablet), and 200mg (two high-dose (100mg) tablets.) These doses are equivalent to 24/26 mg, 49/51 mg, and 97/103 mg commercial Entresto™, respectively."
1520050|NCT02816736|Drug|valsartan|"Subjects previously taking no or low-dose ACEI or ARB, or who have an eGFR < 30 mL/min/1.73m²: the starting dose of valsartan = 40 mg po BID.
Subjects taking an ARB at greater than low dose: starting dose of valsartan = 80 mg po BID.
Subjects taking an ACEI at greater than low dose: starting dose of valsartan = 80 mg po BID.
Dose adjustments will be performed every 2 weeks by doubling the dose of valsartan up to the target maximum dose of 160 mg po BID, as tolerated.
The doses of valsartan are 40mg (one low-dose (40mg) tablet), 80mg (one high-dose (80mg) tablet), and 160mg (two high-dose (80mg) tablets)."
1520051|NCT02816736|Drug|LCZ696 placebo|LCZ696 placebo tablets will be supplied to match the low-dose (50mg) and high-dose (100mg) active LCZ696 tablets. Dosing for LCZ696 placebo will mirror dosing for active valsartan (the same number of low or high-dose tablets will be given.)
1520052|NCT02816736|Drug|valsartan placebo|Valsartan placebo tablets will be supplied to match the low-dose (40mg) and high-dose (80mg) active valsartan tablets. Dosing for valsartan placebo will mirror dosing for active LCZ696 (the same number of low or high-dose tablets will be given.)
1520053|NCT02816723|Behavioral|Mindfulness-based Stress Reduction|mindfulness/meditation/movement training
1520054|NCT02816723|Behavioral|Brain Health|Brain Health Education
1520055|NCT02816710|Drug|Conbercept|
1520056|NCT02816697|Other|CEASE|"Clinical and Community Effort Against Secondhand Smoke Exposure (CEASE)
CEASE is a system-level intervention that integrates tobacco-use screening, cessation assistance, and referral to outside services into routine visits"
1520057|NCT02816697|Other|Usual Care Tobacco Treatment Services|
1520058|NCT02816684|Behavioral|Pegasys-VR|Pegasys-VR uses artificially intelligent avatars and serious game technology to assist children in the acquisition and use of social skills.
1520059|NCT02816684|Behavioral|Social Effectiveness Therapy for Children|Group social skills training, peer generalization sessions, individual exposure therapy
1520060|NCT02816671|Device|Surgical Stapler|Patients in whom the MicroCutter stapler was used during a thoracic surgical procedure.
1520061|NCT02816658|Other|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
1520062|NCT02816658|Other|Robotic Inguinal Hernia Repair|Robotic Inguinal Hernia Repair
1520063|NCT02816645|Procedure|Magnetic Resonance Imaging (MRI)|
1520064|NCT02816632|Other|mRI|Neural bases of feedbacks' influence on decision making processes
1520109|NCT02816255|Device|Full Face Mask with same CPAP Pressure|Full Face Mask with same CPAP Pressure
1520110|NCT02816255|Device|Full Face Mask with new Pressure|New cpap pressure derived from our formula for the final two weeks.
1520111|NCT02816242|Other|concept map teaching|teaching anatomy using concept map to improve critical thinking
1520112|NCT02816242|Other|traditional teaching|teaching anatomy using lecture
1520203|NCT02815488|Drug|Placebo (Part 1 - SAD)|Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
1520065|NCT02816632|Other|Effect of Galvanic Vestibular Stimulation on decision making processes|Galvanic Vestibular Stimulation (GVS) stimulates the vestibular system through low intensity electric currents applied at the basis of the VIII cranial nerve, upon the mastoid processes. In the Right-Anodal condition the positive electric charge is applied through electrodes placed upon the right mastoid and it mainly activates structures within the left brain hemisphere. In the Left-Anodal condition the positive electric charge is applied through electrodes placed upon the left mastoid and it mainly activates structures within the right brain hemisphere. In the SHAM condition, low intensity electric currents are applied 5 cm below the mastoid processes. This condition does not activate the vestibular system and serves as a control condition to account for unspecific activating effects of all electric stimulations (e.g., arousal, discomfort). The three conditions will be applied in three different sessions (i.e. days) in randomized order.
1520066|NCT02816619|Behavioral|Personalized Physical Activity coaching program|
1520067|NCT02816619|Behavioral|Free practice of physical activity|
1520068|NCT02816606|Procedure|Flexible reamers|These reamers allow creation of the femoral tunnel to be made in reduced knee flexion and potentially maximise tunnel length
1520069|NCT02816606|Procedure|70-degree arthroscope|Using this arthroscope (rather than the more traditional 30-degree) gives improved visualisation of the femoral and tibial footprints. This may translate into better positioning of the tunnel within these regions
1520070|NCT02816593|Drug|hydrogen peroxide 6%|Office; hydrogen peroxide 6%, 3 sessions of 20 minutes of application
1520071|NCT02816593|Drug|hydrogen peroxide 15%|Office; hydrogen peroxide 15%, 3 sessions of 20 minutes of application
1520072|NCT02816593|Drug|Carbamide Peroxide 10%|Homemade; Carbamide Peroxide 10%, 2 hours per day for 21 days
1520073|NCT02816580|Other|Blood collection|
1520074|NCT02816567|Drug|propofol|
1520075|NCT02816567|Drug|NMBA - cisatracurium|
1520076|NCT02816567|Drug|placebo - isotonic saline serum|
1520077|NCT02816567|Drug|sufentanil|
1520078|NCT02816567|Procedure|laparoscopic surgery|
1520079|NCT02816554|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 10-12 days interval
1520080|NCT02816554|Biological|JECEVAX-1|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 1 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
1520081|NCT02816554|Biological|JECEVAX-0.8|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.8 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
1520082|NCT02816554|Biological|JECEVAX-0.5|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 10-12 days
1520083|NCT02816541|Other|Pelvis Retroverted|Pilates-based therapeutic exercises with the pelvis retroverted - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
1520084|NCT02816541|Other|Pelvis in Neutral Position|Pilates-based therapeutic exercises with the pelvis in neutral position - Exercises executed with the retroverted pelvis, including the Footwork (toes, arched, heels, tendon stretch), Hundred, Coordination, Frog, Leg Circles (performed at the Universal Reformer apparatus ); Double Leg Stretch (performed at the Mat apparatus); Arm Spring Series (Performed at the Cadillac apparatus); The Wall Series (Performed at the Wall).
1520085|NCT02816541|Other|Aerobic exercise|Aerobic exercises (walking) performed on a treadmill.
1520086|NCT02816528|Behavioral|Training program|Physicians will be given informations regarding antibiotic consumptions and bacterial resistance in their activity area every 3 months during 12 months.
1520087|NCT02816502|Behavioral|Stress Management Skill Building Program A|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
1520088|NCT02816502|Behavioral|Stress Management Skill Building Program B|Subject will meet with the instructor and other students in the group once a week and complete homework and track amount of practice during the week.
1520089|NCT02816489|Device|Clarity SL MBT brackets; 3M Unitek, Monrovia, CA, USA|(passive self-ligating ceramic orthodontic brackets with stainless steel archwire slot liner)
1520090|NCT02816489|Device|Gemini MBT brackets; 3M Unitek, Monrovia, CA, USA|(conventional stainless steel orthodontic brackets ligated with elastomeric ligature)
1520091|NCT02816476|Drug|Daratumumab|
1520092|NCT02816463|Device|Ambu AuraGain|
1520093|NCT02816463|Device|LMA Supreme|
1520094|NCT02816450|Behavioral|Water Intake|
1520095|NCT02816437|Biological|OpenBiome Fecal Microbiota Transplantation retention enema|Keep enema frozen until ready for administration. A single transfer of all 250mL of fecal material using universal precautions to a standard retention enema bag over 1 hour with material retained for at least 1 hour.
1520096|NCT02816424|Behavioral|Teens Exploring and Managing Prevention Options (TEMPO)|
1520097|NCT02816411|Dietary Supplement|Milk protein isolate|"Milk protein isolate in a powder form consisted of 80% casein and 20% whey protein. 20g were diluted into 500 ml water.
Placebo consisted of 365 ml water, 125 ml sugar-free cordial and 2g of low-calorie glucose/dextrose powder."
1520098|NCT02816411|Dietary Supplement|Placebo|500 mL drink that contained water (375 mL), sugar-free cordial (125 mL) and 2 g of low-calorie glucose/dextrose powder.
1520099|NCT02816398|Device|Percutaneous creation of an arteriovenous fistula|Use of catheter system for percutaneous creation of an arteriovenous fistula
1520100|NCT02816385|Procedure|Antegrade cardioplegia|Injection of the cardioplegia in the coronary arteries
1520101|NCT02816385|Procedure|Retrograde cardioplegia|Injection of the cardioplegia in the venous system
1520102|NCT02816372|Other|Tidal volume reduction to 4 ml/kg Predicted Body Weight (PBW)|Tidal volume reduction to 4 ml/kg predicted body weight from inclusion to weaning PEEP trial
1520103|NCT02816359|Other|head-bed position|Head-bed position at 0° for 30 minutes then head-bed position at 30° for 30 minutes
1520104|NCT02816346|Biological|Shigella sonnei 53G|
1520105|NCT02816320|Other|Hospitalization|Patients who were hospitalized in acute care
1520106|NCT02816307|Other|blood samples|
1520107|NCT02816294|Behavioral|Housing Prescription|
1520108|NCT02816268|Other|Pulmonary vein isolation|
1520114|NCT02816216|Behavioral|CampAir|An empirically-based dynamic e-health intervention (based on the evidence-based ASMA) to assist adolescents with uncontrolled asthma to learn how to manage their illness and improve their asthma control.
1520115|NCT02816203|Device|Hemostatic Intra-Uterine suction cup|The hemostatic intra-uterine suction cup is introduced to the uterine cavity and a negative pressure is applied into the device.
1520116|NCT02816190|Procedure|prone position|
1520117|NCT02816177|Other|Telemedicine|
1520118|NCT02816177|Other|Usual Care|
1520119|NCT02816164|Drug|Neupogen|Subcutaneous injections
1520120|NCT02816151|Drug|full dose at 16 UI/kg for Dysport or 6,5 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
1520121|NCT02816151|Drug|half dose at 8 UI/kg for Dysport or 3,25 UA/kg for Botox|Intradetrusor injection under general anesthesia. Injection done through 25 points of 1cc each.
1520123|NCT02816125|Dietary Supplement|omega-3 fatty acid|SEE YOURSELF WELLTM OMEGA-3 Dietary Supplement: See Yourself Well Inc., Leamington, Ontario) containinged 200 mg of EPA and 100 mg of DHA for a total of 1.2 g n-3/day.
1520124|NCT02816112|Drug|Ciprofloxacin|Antibiotic
1520125|NCT02816112|Drug|Neupogen|Granulocyte-colony stimulating factor
1520126|NCT02816099|Biological|Prise de sang|
1520128|NCT02816073|Device|Pan-retinal photocoagulation using pattern scanning laser|Patients receive the designated number of laser shots of pan-retinal photocoagulation with pattern scanning laser in a single session
1520129|NCT02816060|Procedure|manual therapy|manual therapy with neural exercise will be applied on patients with neck pain
1520130|NCT02816047|Other|Registry|Observational study to describe WCD indications, event rates, inappropriate shock rates and follow up (including ICD rate, shock rate, morbidity and mortality) in all Austrian WCD patients
1520131|NCT02816034|Behavioral|Visuo-motor rotation|Participant moves a cursor on a screen by sliding a pen over a digital tablet. Participants perform a center-out movement, aiming to a target that appears over one of a set of eight markers radially distributed. In several block of trials, the mapping of the pen position to the cursor is rotated.
1520132|NCT02816034|Behavioral|Explicit strategy|Participant is provided with an explicit instruction as to how counteract the effects of the visuo-motor rotation via aiming to a marker adjacent target
1520133|NCT02816021|Drug|Azacitidine|300 mg by mouth daily for 15 days (Days 1-15) of every cycle.
1520134|NCT02816021|Drug|Pembrolizumab|200 mg by vein every 3 weeks and after the oral dose of Azacitidine on concurrent treatment days.
1520135|NCT02816008|Behavioral|Cognitive rehabilitation training with RGS in the clinic|Daily cognitive training with the Rehabilitation Gaming System (RGS) in the clinic during 6 weeks (5 days per week a 30 minutes).
1520136|NCT02816008|Behavioral|Passive/conventional cognitive training at home.|Daily conventional cognitive rehabilitation at home as recommended by the neurologist during 6 weeks (5 days per week a 30 minutes).
1520141|NCT02815969|Other|vena punction|vena punction and urine collection
1520144|NCT02815943|Procedure|biliopancreatic diversion with duodenal switch|
1520145|NCT02815943|Procedure|sleeve gastrectomy|
1520146|NCT02815943|Other|liquid meal|will be consumed over 30 minutes with [U-13C]-palmitate (0.2 g mixed in the liquid meal) and H2-glucose
1520147|NCT02815943|Radiation|PET/scan|a dynamic and whole body PET acquisition will be performed on a thoraco-abdominal segment, 150 minutes after an oral administration of 18FTHA
1520148|NCT02815943|Other|[7,7,8,8-2H]-palmitate|i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to 360 min.
1520149|NCT02815943|Device|indirect calorimetry|will be performed every hour throughout the protocol along with exhaled breath collection
1520150|NCT02815930|Other|HCU Status|Total healthcare expenditures in the top 5% of Ontarians
1520151|NCT02815917|Drug|[18F]FTP PET/CT|All PET/CT imaging sessions will include an injection of [18F]FTP. Pilot data will be collected to evaluate preliminary information on brain uptake of [18F]FTP in healthy volunteers and cocaine-dependent volunteers.
1520152|NCT02815904|Other|Yakson touch|Yakson is a Korean therapeutic touch given to neonates and infants by caressing their abdomen with one hand while the other hand is placed on the back of the neonate\infant to relieve their pain or to calm them down.
1520153|NCT02815904|Other|Conventional handling|Positioning of preterm infants for optimal physiological development
1520154|NCT02815904|Other|Kinesthetic stimulation|For kinesthetic stimulation, all the limbs were given six passive flexion and extension movements
1520155|NCT02815904|Other|Kangaroo Mother Care|Providing skin to skin human touch
1520156|NCT02815878|Behavioral|Enhance Wellness|A 6-month health promotion intervention which pairs participants with a wellness coach to identify and pursue a health-related goal of their choosing.
1520157|NCT02815865|Device|Foley catheter and pitocin|Foley catheter will be inserted through the cervix and inflated with 80 ml saline, pitocin will be initiated 1 hour later in the delivery room
1520158|NCT02815865|Device|Foley catheter and Dinoprostone|Foley catheter will be inserted through the cervix and inflated with 80 ml saline Dinoprostone 3 mg will be inserted 1 hour later to the posterior fornix
1520159|NCT02815865|Drug|Dinoprostone|Dinoprostone 3 mg will be inserted to the posterior fornix
1520160|NCT02815852|Other|Women under 40 years old with histological diagnosis of breast cancer|Evaluation of imaging characteristics (ultrasound, mammography and mammary MRI if available) of breast cancer with the corresponding histological reports and assess whether in women <40 years the typical imaging presentation pattern of malignancies observed in women> 40 years are confirmed.
1520161|NCT02815839|Drug|SHR4640|
1520162|NCT02815839|Drug|Placebo|
1520163|NCT02815826|Other|Barefoot training|During 16 weeks, habitual shod runners kept their normal running training routine (wearing shoes), while they were introduced progressively to BF condition. Three training sessions were performed per week. Barefoot training started with 5% and ended with 20% of their WTV being performed without shoes. Soft surfaces (i.e. sand and grass) were adopted in the beginning of training (week 1 to 8). From week 9 to 16, participants mixed soft with harder surfaces, as treadmill and asphalt, to accomplish the training.
1520164|NCT02815826|Other|Shod training|Running training planned individually to each runner, according to their physical fitness, and performed with shoes.
1520165|NCT02815813|Behavioral|PeerFIT|The PeerFIT intervention involves: (a) once weekly group weight management sessions led by a lifestyle coach; (b) an optional weekly peer-led physical activity session; and (c) Facebook and mHealth technology (i.e., Fitbits, text messaging support) to increase motivation and facilitate self-monitoring and peer social support for health behavior change.
1520166|NCT02815813|Behavioral|BEAT|Participants in BEAT receive materials with tips and strategies for healthy eating and physical activity. They are also given a wearable activity tracker (i.e., Fitbit Zip) to use throughout the study with instructions for using the device and connecting it with a personal smartphone, tablet, or computer. Following an initial educational session, participants in BEAT have access to once monthly technical assistance meetings with a lifestyle coach who can make sure the Fitbit is working properly, answer any questions about the device, and show participants how to check progress by synching the Fitbit to a personal computer or smartphone.
1520167|NCT02815800|Dietary Supplement|ETHNODYNE VISIO|
1520168|NCT02815787|Drug|SP2086|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
1520169|NCT02815787|Drug|Glyburide|In the A sequence Glyburide was taken at 5mg qd dose on Days1,4,5,6,7 and 8; SP2086 will be administered orally (by mouth) as 200mg on Days 8.In the B sequence was that SP2086 was taken at 200mg qd dose on Days1,4,5,6,7 and 8;Glyburide will be administered orally (by mouth) as 200mg on Days 8.
1520170|NCT02815774|Drug|SP2086|all subjects were given SP2086 50mg only one time.
1520172|NCT02815748|Drug|SP2086|SP2086 was taken only one time at 100mg dose in health volunteers
1520173|NCT02815735|Device|comfilcon A|contact lens
1520174|NCT02815735|Device|lotrafilcon B|contact lens
1520175|NCT02815722|Drug|SP2086|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
1520176|NCT02815722|Drug|Simvastatin|The A sequence was that SP2086 was taken at 200mg qd on Days1-Day10; Simvastatin will be administered orally (by mouth) as 40mg on Days 6-Day10.The B sequence was that Simvastatin was taken at 40mg qd dose on Days 6-Day10.
1520177|NCT02815709|Drug|Oliceridine|
1520178|NCT02815709|Drug|Placebo|
1520179|NCT02815709|Drug|Morphine|
1520180|NCT02815696|Device|Magnetic Resonance Imaging|Specific MRI sequences (delayed gadolinium-enhanced magnetic resonance imaging of cartilage -dGEMRIC) performed before the surgery, 6 months and 1 year after surgery will allow to measure the following parameters: disc height, total lumbar spine lenght, GAGs concentration.
1520181|NCT02815670|Drug|Idarucizumab|
1520182|NCT02815657|Drug|SP2086|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
1520183|NCT02815657|Drug|Valsartan|The A sequence was that Valsartan was taken at 160mg qd on Days1-Day12; SP2086 will be administered orally (by mouth) as 200mg on Days 8-Day12.The B sequence was that SP2086 was taken at 200mg qd dose on Days 8-Day12
1520185|NCT02815631|Device|Cardiogoniometry (CGM)|
1520186|NCT02815631|Device|Fractional Flow Reserve (FFR)|
1520187|NCT02815618|Device|BabyLux Neuro-monitor|Measurement of cerebral blood flow index (CBFi) and tissue oxygen saturation (StO2).
1520194|NCT02815566|Drug|tenofovir-alafenamide-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
1520195|NCT02815566|Drug|tenofovir-emtricitabine|comparison of tenofovir-emtricitabine and tenofovir-alafenamide-emtricitabine on bone mineral density
1520196|NCT02815553|Procedure|Direct Transthoracic Cardiac Tumor Radio Frequency Ablation Therapy|
1520197|NCT02815553|Procedure|Direct Transthoracic Cardiac Tumor Laser Ablation Therapy|
1520198|NCT02815540|Procedure|15-Lead ECG|Subjects will be monitored while on cannabadiol with a 15-Lead ECG and/or Holter monitoring
1520199|NCT02815540|Drug|Cannabadiol|Subjects who are planning to take state dispensed medical cannabadiol, or are already taking state dispensed medical cannabadiol.
1520200|NCT02815527|Other|Fresubin intensive|Enteral nutrition containing a high protein concentration
1520201|NCT02815501|Biological|blood samples|for the determination of thyroid hormones (TSH, FT3, FT4 ) and antibodies against the thyroid (anti TPO antibodies and anti thyroglobulin)
1520202|NCT02815488|Drug|CHF6297 (Part 1 - SAD)|Single doses of CHF6297 at each period (for up to 3 periods per subject)
1520204|NCT02815488|Drug|CHF6297 (Part 2 - MAD)|Twice daily doses of CHF6297 for 7 days
1520205|NCT02815488|Drug|Placebo (Part 2 - MAD)|Twice daily doses of placebo matching CHF6297 for 7 days
1520206|NCT02815488|Drug|CHF6297 (Part 3)|Twice daily doses of CHF6297 for 14 days
1520207|NCT02815488|Drug|Placebo (Part 3)|Twice daily doses of placebo matching CHF6297 for 14 days
1520208|NCT02815488|Drug|CHF6297 (Part 4)|Twice daily doses of CHF6297 for 7 days
1520209|NCT02815488|Drug|Placebo (Part 4)|Twice daily doses of placebo matching CHF6297 for 7 days
1520210|NCT02815475|Dietary Supplement|Placebo comparator|
1520211|NCT02815475|Dietary Supplement|Curcumin|
1520212|NCT02815475|Dietary Supplement|Turmeric powder|
1520213|NCT02815462|Other|FAMFACESG|- PNs will receive the FAM-FACE-SG FA risk scores for frequent admitters admitted to their ward.
1520214|NCT02815462|Other|Control|- Usual hospital Care
1520215|NCT02815462|Other|FAMFACESG|- PNs will be instructed to prioritize intervention of frequent admitters for intervention based on the FA risk score.
1520216|NCT02815462|Other|FAMFACESG|"For high and moderate risk patients who do not require transitional home care (THC), PN will do the case management and follow up.
For high and moderate risk patients & have complex nursing and / or high functional needs, PNs will refer these patients for THC.
For mild risk patients, PNs will refer them to care coordinator."
1520217|NCT02815462|Other|FAMFACESG|- For low risk patients, PNs will continue usual hospital care.
1520218|NCT02815449|Other|Meals prepared with iron fortified cube with Low stabilizer level|Meals prepared with iron fortified cube with Low stabilizer level
1520219|NCT02815449|Other|Meals prepared with iron fortified cube with Medium stabilizer level|Meals prepared with iron fortified cube with Medium stabilizer level
1520220|NCT02815449|Other|Meals prepared with iron fortified cube with High stabilizer level|Meals prepared with iron fortified cube with High stabilizer level
1520221|NCT02815436|Other|Telephone reminder|a personal, interactive telephone reminder by a centre colleague to remind return to the centre for taking faecal tubes for screening
1520222|NCT02815436|Other|SMS reminder|a one-way, SMS message sent from the centre to the screening participant's mobile phone
1520223|NCT02815423|Biological|UCMSCs|Transplatation of umbilical cord mesenchymal stem cells
1520224|NCT02815423|Biological|Percutaneous|Percutaneous injection
1520225|NCT02815410|Drug|levetiracetam|Patients in this group are with newly diagnosed glioblastoma patients who are supposed to be treated with concurrent chemoradiotherapy (CCRT) and adjuvant chemotherapy with temozolomide (TMZ). Patients ( intervention Group) will be given levetiracetam (LEV) from the beginning of treatment till after the adjuvant chemotherapy with TMZ is over.
1520227|NCT02815371|Procedure|Needle Acupuncture|See above
1520228|NCT02815371|Procedure|Laser Acupuncture|See above
1520229|NCT02815371|Procedure|Sham Laser Acupuncture|See above
1520230|NCT02815358|Other|Segmental Stabilization Exercises|The stabilization program focuses on the reestablishment of motor control and coordination between deep and superficial trunk muscles. The exercise program is based on the following criteria progression: 1) Precise contraction of the transverse abdominal and multifidus muscles, keeping the lumbar spine in a neutral position (as the middle way between maximum flexion and extension, repeated three times); 2) Keep the neutral position for 10 repetitions of 10 seconds; 3) Perform exercises with lower limbs in different postures.
1520231|NCT02815358|Other|Home Exercises|Home exercises include passive stretching and active mobilization of the spine.
1520232|NCT02815345|Device|Rhinometry|An acoustic rhinometry device will be used to evaluate the area and the volume of the nasal cavities. Both nasal cavities will be measured except for patients with nasogastric tube.
1520233|NCT02815332|Drug|BPX-01 1% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
1520234|NCT02815332|Drug|BPX-01 2% Minocycline Topical Gel|Approximately 1 gram applied once daily for 12 weeks
1520235|NCT02815332|Drug|BPX-01 Vehicle Topical Gel|Approximately 1 gram applied once daily for 12 weeks
1520236|NCT02815319|Drug|Dexamethasone|Steroid prophylaxis
1520237|NCT02815306|Device|Polyaxial brace|The Polyaxial brace were made by a technician trained by the China National Disabled Persons Federation. For all patients, gypsum models were prepared first, and then braces were fabricated according to the models. The detailed technique was fully in accordance with the Ponseti method.
1520238|NCT02815293|Drug|AGN-195263|1 drop of AGN-195263 will be instilled in each eye twice daily.
1520239|NCT02815293|Drug|Vehicle|1 drop of AGN-195263 vehicle (placebo) will be instilled in each eye twice daily.
1520240|NCT02815280|Drug|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
1520241|NCT02815280|Drug|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
1520242|NCT02815267|Drug|FMX-101, 4% minocycline foam|FMX-101, 4% minocycline foam applied topically once daily for 12 weeks
1520243|NCT02815267|Drug|Vehicle Foam|Vehicle foam applied topically once daily for 12 weeks
1520244|NCT02815254|Other|High intensity functional exercise|
1520245|NCT02815254|Other|Low intensity functional exercise|
1520246|NCT02815241|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-046)
1520247|NCT02815228|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z43-034)
1520248|NCT02815215|Procedure|Minimally Invasive Carroll's Technique|Patient will be treated with minimally invasive Carroll's technique by 3 small incisions in the heel, in the medial side of the foot and in the planta pedis, respectively. Long-leg plaster cast fixation was applied for 6-8 weeks
1520249|NCT02815215|Procedure|Ponseti method|As a control, Patient will be treated with classical Ponseti method, including multiple steps: manipulative correction, continuous plaster, achilles tendon cutting, fixation.
1520250|NCT02815202|Drug|BAY987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code: Z12-034)
1520289|NCT02814864|Other|Mesenchymal Stromal Cell (MSC) injections|12 patients suffering of PRD (LENT-SOMA scale>2) will receive Mesenchymal Stromal Cell (MSC) injections
1520362|NCT02814331|Device|multimodal high-resolution EEG-NIRS|
1520251|NCT02815189|Procedure|Ibuprofen for post operative pain|All treatment sessions were approximately 50 minutes in length to allow for acceptable time for completion of treatment and retreatment in one or two visits. All the clinical procedures were performed by the author. Following local anesthesia with 2% lidocaine with 1:100,000 epinephrine (Septodont Saint-Maur des Fossés, France) and rubber dam isolation the tooth was disinfected with 5.25% NaOCl (Ultra bleach, Bentonville, AR, USA).
1520252|NCT02815189|Drug|Acetaminophen 325 mg for Flare up|Each patient will be evaluated a week after completion the clinical procedures.
1520253|NCT02815176|Other|Blood sampling|Sampling the blood including DNA to investigate the thrombotic profile
1520254|NCT02815163|Other|Empowerment education|"admission (1 hour)
▪partnership
2 ds after THR (30-45min)
listening
dialogue
reflection
action
feedback
2 WKs after THR (30 min)
listening
dialogue
reflection
action
feedback
6 WKs after THR (30 min)
listening
dialogue
reflection
action
feedback
10 WKs after THR (30 min)
listening
dialogue
reflection
action
feedback"
1520255|NCT02815150|Dietary Supplement|preoperative oral carbohydrate drink|5% glucose solution 250ml 2-3 hours before surgery
1520256|NCT02815137|Other|Digital Polymerase Chain Reaction|Determination of mutation of XPO1 E571K by digital PCR in blod sample of patient with classical hodgkin lymphoma
1520257|NCT02815124|Other|Standard of Care|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Standard of Care
1520258|NCT02815124|Other|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, subject will receive activation/programming of their implant using Image-Guided Cochlear Implant Programming
1520259|NCT02815111|Drug|Ketamine|Receive an analgesic regimen that involves Ketamine infusions
1520260|NCT02815111|Drug|Lidocaine|Receive an analgesic regimen that involves Lidocaine infusions
1520261|NCT02815111|Drug|Acetaminophen|May be administered Acetaminophen rectally, by mouth, or intravenously in patients not suitable for either of the other methods of administration
1520262|NCT02815111|Drug|Neurontin|May be given Neurontin by mouth as an approved medication for pain control
1520263|NCT02815085|Other|RecoverLINK technology|HF patients will receive the RecoverLINK app upon study enrollment for 30-days. The Mount Sinai HF care team will interact with patients via the RecoverLINK cloud-based system during this period
1520264|NCT02815072|Other|Skin biopsy|A sample of skin (approximately 0.5cm x 0.5cm) from inner thigh area. The skin biopsy will be conducted and completed with a single stitch to close the wound under local anaesthesia to minimise any discomfort. The skin biopsy will be taken by the medical doctor trained in biopsy collection. The tissue sample will be processed and cells will be grown out of them under appropriate conditions. These cells will only be used for laboratory experiments that include experimental transplantation models and laboratory bench-top research.
1520265|NCT02815059|Drug|Ibrutinib|Ibrutinib 420mg PO daily (dose level 0) or 560mg PO daily (dose level +1) administered Day 15 through day 90.
1520266|NCT02815059|Drug|Dasatinib|Dasatinib 100mg PO daily (Day 1 through Day 90). Dasatinib dose will be increased to 140mg daily in patients tolerating dasatinib 100mg who have not achieved a complete bone marrow response (less than 5% blasts) by Day 22 or who have not achieved major molecular response by Day 43.
1520267|NCT02815059|Drug|Prednisone|Prednisone 60mg/m2 PO daily (Day 1 through Day 32)
1520268|NCT02815046|Drug|Botulinum toxin type A|Intravesical injections of Botulinum toxin A (Botox) into the bladder wall.
1520269|NCT02815046|Device|Polyacrylamide hydrogel|Midurethral injections of the bulking Agent Bulkamid into the submucosal tissues of the urethra.
1520270|NCT02815033|Drug|Enzalutamide|
1520271|NCT02815033|Procedure|11C or 18F-Choline PET/CT|
1520272|NCT02815033|Procedure|Whole body MRI|
1520273|NCT02815033|Procedure|Bone scan|
1520274|NCT02815020|Other|Boot Camp Translation - community-participatory process|Series of meetings and conference calls with expert presentation on patient self-management support, facilitated discussion, and creation of product to bring to community to improve patient self-management support
1520275|NCT02815007|Drug|Chidamide with EGFR-TKI|Chidamide and EGFR-TKI, dosage described in arm description.
1520276|NCT02814994|Behavioral|tidal volume guided by respiratory system compliance|ventilated with tidal volume guided by respiratory system compliance
1520277|NCT02814994|Behavioral|low tidal volume|ventilation ventilated with low tidal volume
1520278|NCT02814968|Drug|Enzalutamide|
1520279|NCT02814968|Device|18-FDG PET/CT|
1520280|NCT02814968|Device|Whole body MRI|
1520281|NCT02814968|Device|Bone scan|
1520282|NCT02814942|Device|Cardiac Resynchronization Therapy|Cardiac resynchronization therapy with or without ICD
1520283|NCT02814916|Drug|Dalbavancin single dose|"Dalbavancin, weight-adjusted dose, up to 1500mg. Intravenous (IV) administration.
Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used."
1520284|NCT02814916|Drug|Dalbavancin two dose|"Dalbavancin, weight-adjusted dose, up to 1000mg. Intravenous (IV) administration, with second dalbavancin weight-adjusted dose, up to 500mg.
Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used."
1520285|NCT02814916|Drug|Comparator|"Course of either vancomycin not to exceed a total daily dose of 4000 mg;or oxacillin; or flucloxacillin not to exceed a total daily dose of 2000 mg. Intravenous (IV) administration. Possible oral switch after at least 72 hours from oxacillin or flucloxacillin to oral cefadroxil, or from IV vancomycin to oral clindamycin (for MRSA).
Aztreonam may be administered at randomization for presumed co-infection with a Gram-negative pathogen and could be discontinued if a Gram-negative pathogen is not documented by culture. For suspected anaerobic pathogens, metronidazole oral/IV may be used.
Additional comparator drugs may be used, if an alternate comparator regimen is indicated by local susceptibility patterns."
1520288|NCT02814877|Other|promotion of appropriate use of antibiotics in hospital|promotion of appropriate use of antibiotics in hospital by visiting physicians
1520290|NCT02814851|Device|Transesophageal echocardiogram|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann. A transesophageal echocardiogram (TEE) will be performed and the TEE probe will stay continuously during the entire procedure, to allow all necessary measurements.
1520291|NCT02814851|Device|Thermistor-tipped catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a thermistor-tipped catheter (model 93A-131-7F, Edwards, Santa Ana, CA) will be inserted into the pulmonary artery to measure right atrial pressure (Pra), pulmonary arterial pressure (Ppa), Ppao and thermodilution cardiac output. Ringer's lactate will be infused to maintain an occluded pulmonary arterial pressure (Ppao) of 8-10 mmHg.
1520292|NCT02814851|Device|Pressure/volume catheter|All patients will undergo a standard surgical procedure by the surgical team of CHU Brugmann.During the procedure, a pressure/volume catheter (CD Leicom, Zoetermeer, Netherland) will be placed in the left ventricle through a left superior pulmonary vein purse string, in order to measure alternatively LV pressure/volume loops and LA pressure.
1520293|NCT02814851|Device|Transthoracic echocardiography|"A complete transthoracic echocardiography will be performed the day before the surgical procedure. It will establish the presence of the inclusion and exclusion criteria, as stipulated above. This will be done using a Philips IE33 echocardiograph (Koninklijke Philips Electronics N.V., Netherlands).
During the surgical procedure, a transesophageal echocardiogram will be performed, using an Acuson Sequoia system (Siemens AG, Germany)."
1520294|NCT02814838|Drug|Ladarixin|Ladarixin oral capsule
1520295|NCT02814838|Drug|Placebo|Placebo oral capsule
1520296|NCT02814825|Other|ViviGen|ViviGen Cellular Bone Matrix is a formulation of cryopreserved viable cortical cancellous bone matrix and demineralized bone. ViviGen is a Human Cells, Tissues, and Cellular and Tissue-based Product (HCT/P) as defined by the U.S. Food and Drug Administration in 21 CFR 127 1.3(d).
1520297|NCT02814812|Procedure|CT scan|
1520298|NCT02814799|Other|bone removal|
1520299|NCT02814786|Radiation|MRI scanner|"This examination is divided in 2 parts:
Passive movement: after placing the ankle joint in the fixture, each child will be asked to relax the lower limb musculature and then the fixture will be cyclically moved by a technician at a speed which does not trigger spasticity.
Active movement: no technician will be present and children will be asked to perform voluntary plantar-dorsiflexion between the extreme positions on the beat of the metronome."
1520300|NCT02814786|Other|Gait analysis|For gait evaluation, each child will undergo a lower limb gait analysis in a motion analysis laboratory equipped with Camera system and 4 AMTI force plates Sixteen reflective markers will be placed on the lower limbs. Each child will walk bare foot and gait will be recorded during each of five 10-meter trials. A velocity of 1 m/s (+/- 10%) will be imposed using a stop watch in order to eliminate the influence of velocity on gait kinematics and kinematics while comparing across subjects. Each child will be allowed to walk for 5 minutes after attaching the reflective markers and before recording the gait data. In addition to the joint kinematics, joint powers and moments will be computed using an inverse dynamics method.
1520301|NCT02814773|Other|questionnaires|
1520302|NCT02814760|Other|training of emergency professionals to acute stroke management|"The training program aiming at improving the timeliness of care of acute stroke patients in ED was designed for triage ED nurses and ED physicians and it was based on 3 sub-objectives:
Improving knowledge and skills of triage nurses to recognize patients with stroke symptoms
Improving knowledge and skills of ED physicians to recognize stroke symptoms, to realize a good quality neurological examination and be able to measure the NIHSS (National Institute of Health Stroke Score), to have a better understanding of the physiopathology of ischemic stroke and thrombolysis, and to have a better understanding of the consequences of wasted time for patients Developing, together with other hospital professionals involved in acute stroke management, a clinical pathway adapted to the local characteristics an organization (ED organization optimization, management steps, connections between ED, radiology unit and stroke unit, thrombolysis organization)."
1520303|NCT02814747|Other|quantitive study: 500 patients likely to be candidates for HTS|
1520304|NCT02814747|Other|qualitative study: 30 patients who have benefited from HTS|
1520305|NCT02814721|Device|Sonic Window ultrasound device|
1520306|NCT02814708|Biological|rTSST-1v|Each subject of a total of seven groups will receive three injections (first injection day 0; second injection 3 months ± 4 weeks after the first, third injection 6 months ± 4 weeks after the second) of one of two different doses of Vaccine or Adjuvant, each group comprising 20 subjects. Subjects will be controlled 24 h post vaccination. Follow‐up will last 18 months on the average, with visits every three months (± 2 weeks). Response to treatment is defined by seroconversion from a TSST‐1 binding Ab titer of < 20 to > 40 or a 4‐fold increase in TSST‐1 binding Ab titer .
1520307|NCT02814695|Dietary Supplement|Vit E 1|
1520308|NCT02814695|Dietary Supplement|Vit E 2|
1520309|NCT02814695|Dietary Supplement|Vit E 3|
1520310|NCT02814695|Dietary Supplement|YE 1|
1520311|NCT02814695|Dietary Supplement|YE 2|
1520312|NCT02814695|Dietary Supplement|YE 3|
1520313|NCT02814695|Dietary Supplement|Vit C 1|
1520314|NCT02814695|Dietary Supplement|Vit C 2|
1520315|NCT02814695|Dietary Supplement|Vit C 3|
1520318|NCT02814656|Drug|AZD8871|Multiple inhaled doses of AZD8871 will be administered via single dose dry powder inhaler (DPI). Each subject will receive a single inhaled dose of AZD8871 on Day 1 and then single once daily inhalations of AZD8871 will be administered for 12 days from Day 5 until Day 16.
1520319|NCT02814656|Drug|Placebo|Multiple inhaled doses of placebo powder will be administered via single dose DPI. Each subject will receive a single inhaled dose of placebo on Day 1 and then single once daily inhalations of placebo will be administered for 12 days from Day 5 until Day 16.
1520320|NCT02814643|Drug|Benralizumab|Benralizumab SC administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
1520321|NCT02814643|Drug|Benralizumab Placebo|Placebo administered every 4 weeks for 3 doses (Weeks 0, 4, and 8).
1520361|NCT02814344|Device|Electrohysterography|
1520322|NCT02814643|Drug|Seasonal influenza virus vaccine|Patients will receive 1 dose of seasonal influenza virus vaccine Intramuscular (IM) at Week 8.
1520323|NCT02814630|Biological|Xolair|The patients will receive one subcutaneous injection of Xolair® (omalizumab) at a dose of 300 mg on Days 1, 30, and 60. This dose is based on the results of the international, multicenter, randomized, double-blind, placebo-controlled study which demonstrated that omalizumab significantly decreased clinical symptoms and signs of chronic idiopathic urticaria in patients who had remained symptomatic despite the use of H1-antihistamines (Maurer et al., 2013)
1520324|NCT02814617|Dietary Supplement|Cordyceps sinensis mycelium culture extract 1.68 g|Cordyceps sinensis mycelium culture extract 1.68 g
1520325|NCT02814617|Dietary Supplement|Placebo|
1520326|NCT02814604|Other|Nutrition Rating Systems|Behavioural: Nutrition Rating Systems (shown on a mobile app) provide consumers with an interpretation of the healthfulness of a food or beverage product.
1520327|NCT02814591|Device|spatially offset Raman spectrometer (SORS)|Raman spectra will be collected non-invasively from patients using a lower power 830 nm laser. A probe is brought into gentle contact with the patients skin and measurements taken. The laser power has a pre-defined safe threshold of 30 mW into a 3.5 mm diameter aperture. Built in device safety features prevent this threshold from being exceeded. The probe that comes into patient contact is suitable for disinfecting.
1520328|NCT02814578|Other|Optical coherent tomography|
1520329|NCT02814578|Other|IntraVascular UltraSound|
1520330|NCT02814565|Drug|Cyclobenzaprine HCl|Cyclobenzaprine HCl extended-release capsules
1520331|NCT02814565|Drug|Placebo|Cyclobenzaprine HCl extended release placebo-matching capsules
1520332|NCT02814552|Other|HTN PRA App|The HTN PRA App will be used to adjust standard of care medication dosages for high blood pressure drugs which may include: thiazide diuretic (water pill), usually called hydrochlorothiazide (HCTZ) or chlorthalidone, and an ACE inhibitor or an angiotensin receptor blocker.
1520333|NCT02814552|Other|Blood Sample|Blood sample for plasma renin activity activity will be obtained at least once (at baseline) and if BP is not controlled after 1-3 months, an additional blood sample may be obtained.
1520334|NCT02814526|Behavioral|Aerobic exercise|Moderate/high intensity aerobic exercise will involve training at 70-80% heart rate reserve for 30 min, with an additional 10 minutes for warm-up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA .
1520335|NCT02814526|Behavioral|Stretching/balance/range of motion exercise|The stretching/balance/range of motion program will involve exercise at or below 35% heart rate reserve for 30 min, with an additional 10 minutes for warm up and 5 minutes for cool-down, 4 times per week, for 12 months while supervised twice per week by a study-certified trainer at a participating YMCA.
1520336|NCT02814513|Device|ANDAGO|Feasibility: the researchers will examine technical features as well as patient-related aspects, safety and operability of the device during static (standing) and dynamic (walking) tasks.
1520337|NCT02814513|Device|ANDAGO|Differences in static and dynamic tasks when standing/walking in the ANDAGO or when being supervised by a therapist/walking with regular walking aids.
1520338|NCT02814513|Device|ANDAGO|Investigate the handling of the ANDAGO. Patients will have time to practice with the device and the researchers will evaluate improvements in static/dynamic task performance with the ANDAGO.
1520339|NCT02814513|Device|ANDAGO|Determine which patients (characterized by demographics and neurological, cognitive and functional status) can improve their handling with the ANDAGO (i.e. whether patients can improve relatively quickly (i.e. 30 minutes of practice time) in dynamic tasks).
1520340|NCT02814513|Device|ANDAGO|To investigate how well healthy age- and gender matched children can perform the dynamic tasks (obstacle and precision course) and compare these results to those obtained in patients.
1520341|NCT02814500|Drug|DP-R212|Investigational product is prescribed to all of randomized subjects
1520342|NCT02814500|Drug|Amlodipine|Investigational product is prescribed to all of randomized subjects
1520343|NCT02814500|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
1520344|NCT02814474|Other|Na-3-hydroxybutyrate|Infusion of Na-3-hydroxybutyrate (0.18 g/kg/hour) for 390 minutes
1520345|NCT02814474|Other|Saline|Infusion of 0.9 % saline
1520346|NCT02814461|Drug|Axitinib|Axitinib (dose escalation): for total 8 weeks during and after RT, with starting dose of 1mg BID. According to the rule of traditional 3 + 3 design, 3-level axitinib dose escalation will be conducted: 1mg BID (level - I), 2mg BID (level - II) and 3mg BID (level - III).
1520347|NCT02814461|Radiation|Radiation|Radiotherapy (RT) dose (fixed strength for normal liver): 37.5 to 67.5 Gy in 15 fractions (2.5 to 4.5 Gy per fraction) to liver tumor(s) (e.g. portal vein thrombosis, tumors with size ≥3 cm, or recurrent/refractory tumors). The final prescribed dose is based on an upper limit of mean liver dose of 18 Gy for all plans. (Daily Entecavir 0.5-1mg or Telbivudine 600mg is recommended for patients with positive hepatitis B during and 3 months after RT.)
1520348|NCT02814448|Device|CryoPen|Provides a means of freezing tissue without the use of gases or liquids
1520349|NCT02814448|Device|CO2 standard cryotherapy|Standard therapy using carbon dioxide for freezing of tissue
1520350|NCT02814448|Device|Thermocoagulator|The use of heat produced by high-frequency electric current to bring about local destruction of tissues
1520353|NCT02814409|Drug|Intravenous recombinant tissue plasminogen activator (rtPA) Alteplase|
1520354|NCT02814409|Drug|Intravenous Tenecteplase|
1520355|NCT02814383|Other|Brain Monitoring Platform|This study is being done to evaluate the changes in brain perfusion measured by the DCM using a comprehensive and innovative brain monitoring platform that encompasses direct and continuous measures of cerebral blood flow (CBF), cerebral oximetry, cerebral autoregulation, partial pressure of carbon dioxide (PCO2), and arterial blood pressure (ABP).
1520356|NCT02814357|Other|Control (market standard)|
1520357|NCT02814357|Other|wheat flour|
1520358|NCT02814357|Other|chickpea flour|
1520359|NCT02814357|Other|guar gum|
1520360|NCT02814357|Other|barley|
1520364|NCT02814305|Behavioral|Financial|Patient receives information on a program that may offer a financial benefit for disposing of unused opioid analgesics at a pharmacy
1520365|NCT02814305|Behavioral|Educational|Patient watches a video featuring narrative vignettes of patients who developed opioid dependence or abuse after using opioids postoperatively
1520366|NCT02814279|Procedure|CAF plus connective tissue graft|Periodontal surgery for root coverage by the trapezoidal flap associated with connective tissue graft.
1520367|NCT02814279|Procedure|Tunnel plus connective tissue graft|Periodontal surgery for root coverage by the tunnel flap associated with connective tissue graft.
1520368|NCT02814279|Drug|Sodium dipyrone|All participants were instructed to take 500 mg sodium dipyrone just in case of pain.
1520369|NCT02814279|Drug|chlorhexidine rinse|All participants were instructed to perform 0.12% chlorhexidine rinse after the surgical procedures.
1520370|NCT02814266|Other|difficult intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
1520371|NCT02814266|Other|easy intubation|Goniomastoid Distance: The distance between gonion and mastoid while the neck is fully extension and the mouth maximally open. Thyrogonial Distance: The distance between thyroidea and gonion while the neck is fully extension and the mouth maximally open.
1520372|NCT02814240|Other|NMR|
1520373|NCT02814240|Biological|Blood samples|
1520374|NCT02814240|Other|fibroscan|
1520375|NCT02814227|Device|Zansors® sleep screening device|Intervention is the validation of a sleep apnea screening device against the gold-standard assessment of in-laboratory polysomnography
1520376|NCT02814214|Device|ECG+IEGM|Cardiac Resynchronization Therapy programming adjustments
1520377|NCT02814201|Behavioral|SRT|"simple reaction time ( SRT) defined as the fastest response time to a target stimulus ( phase worst -off at the Parkinson's patient )"
1520378|NCT02814188|Other|Carbohydrate Beverage|750 ml of a 13.5% carbohydrate (sucrose) beverage
1520379|NCT02814188|Other|Placebo Beverage|750 ml of an artificially-sweetened beverage
1520382|NCT02814149|Procedure|Type 1 implant placement|Implant is placed immediately following tooth extraction in one surgical procedure
1520383|NCT02814149|Procedure|Type 3 implant placement|Implant is placed in the site which is left to heal for 3 months following tooth extraction
1520384|NCT02814136|Procedure|Ablation|
1520385|NCT02814123|Other|24-hour inpatient intervention|Subjects will be admitted at the research facility at 7:30. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. Each 24-hour intervention visit includes 3 standardized meals (8:00, 12:00, and 17:00), an evening snack (21:00) and an overnight stay. The glucose level as measured by the real time sensor will be entered manually into the computer every 10 minutes. The insulin and pramlintide pumps' infusion rates will then be changed manually based on the computer generated recommendation, while still maintaining the ratio. The computer generated recommendations are based on a predictive algorithm.
1520386|NCT02814110|Drug|Granulocyte colony-stimulating factor (Filgrastim)|Drug administration
1520387|NCT02814097|Drug|elamipretide|Subcutaneous injection of 40 mg elamipretide once daily for 28 consecutive days
1520388|NCT02814097|Drug|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
1520389|NCT02814084|Device|Bilateral Internal Mammary Artery grafts|Sternal Wound Edge Oxygenation in patients undergoing Coronary Artery bypass surgery with Bilateral Internal Mammary Artery grafts
1520390|NCT02814084|Device|Prevena|The Prevena wound management system applies negative pressure to the closed wound for up to 7 days and is associated with lower rates of surgical site infection.
1520392|NCT02814058|Drug|zolpidem hemitartarate 1.75 mg - Sequency 1|zolpidem hemitartarate 1.75 mg in fasting (period 1) and zolpidem hemitartarate 1.75 mg postprandial (period 2)
1520393|NCT02814058|Drug|zolpidem hemitartarate 1.75 mg - Sequency 2|zolpidem hemitartarate 1.75 mg postprandial (period 1) and zolpidem hemitartarate 1.75 mg in fasting (period 2)
1520394|NCT02814019|Drug|Idebenone 150 mg film-coated tablets|
1520395|NCT02814019|Drug|placebo|
1520396|NCT02814006|Other|health educational video|visualization of health educational video
1520397|NCT02813993|Other|Health educational video|
1520398|NCT02813980|Other|There are no interventions. This is a prospective observational study.|
1520399|NCT02813967|Radiation|Radiotherapy 54 Gy|Radiotherapy was administered in 1.8 Gy fractions 5 times weekly to a total dose of 54 Gy.
1520400|NCT02813967|Radiation|Radiotherapy 60 Gy|Radiotherapy was administered in 2 Gy fractions 5 times weekly to a total dose of 60Gy.
1520401|NCT02813967|Drug|S-1|S-1 70mg/m2 was administered on days 1-14 and 29-42.
1520402|NCT02813954|Device|Blood Gas Sampling|analyzing amniotic fluid by blood gas device
1520403|NCT02813941|Other|Current GRADE SoF table|The current GRADE SoF table will be the common comparator for the other two SoF tables
1520404|NCT02813941|Other|Alternative GRADE SoF table|The alternative GRADE SoF table format will be developed from a user-testing survey.
1520405|NCT02813941|Other|EPC SoF table|For the EPC SoF table, the investigators will use one of their format which was recently published
1520406|NCT02813928|Genetic|ccfDNA analysis|The level of circulating ccfDNA, defined as extra cellular DNA, increases in CRC patients. The Inplex® method could validate the use of ccfDNA as a cancer biomarker in terms of prognosis and surveillance
1520408|NCT02813902|Drug|Heliocare with Fernblock PLE technology|240 mg taken orally daily over the course of 1 year
1520409|NCT02813902|Other|Sugar Pill|
1520481|NCT02813421|Device|CGM Informed|
1520536|NCT02813122|Device|x-ray|x-ray for the detection of leaks and bleeding
1520410|NCT02813889|Device|SmarToyGym|"We aim to develop a SmarToyGym where sensitized, wireless toys are strategically hung and placed within reach of infants to elicit toy-oriented body and arm/hand movements. Each toy will be equipped with sensors capable of measuring the infant's grasping actions such as squeezing, pinching, tilting, etc.
A low-cost 3D motion capture system will be used to collect video data and the infants' reaching and body kinematics in response to the toys. A pressure mat will be used to measure postural changes to detect weight shifts, rolling, crawling and other movements away from the initial posture."
1520411|NCT02813876|Other|Enhanced recovery protocol|
1520412|NCT02813863|Drug|SP2086|
1520413|NCT02813863|Drug|Metformin|
1520414|NCT02813850|Device|oxygen therapy|Oxygen therapy early in the night (2L/min) during 4hours per days
1520415|NCT02813837|Biological|CD19CART|Patients will be given infusions of CD19CART cells into the vein over a period of 1 to 3 days. The target dose range administered in this study is 1x10e5-1x10e7 CD19CART cells/kg. Patients will be monitored for a response, toxic effects, and the expansion and persistence of circulating CD19CART cells.
1520421|NCT02813785|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
1520422|NCT02813785|Drug|Docetaxel|Docetaxel will be administered as 75 milligrams per square meter (mg/m^2) via IV infusion on Day 1 of each 21-day cycle.
1520423|NCT02813772|Dietary Supplement|Milk formula NAN Sensitive, Nestle|Infants randomized to group 1 will receive the milk formula NAN Sensitive, Nestle for a period of 4 weeks.
1520424|NCT02813772|Dietary Supplement|Milk formula Optipro, Nestle|Infants randomized to group 1 will receive the milk formula NAN Optipro, Nestle for a period of 4 weeks.
1520425|NCT02813759|Other|Sucralose|Subjects drank 200 mL of water with 14 mg sucralose, followed by a standard breakfast.
1520426|NCT02813759|Other|Placebo|Subjects drank 200 mL of water alone (placebo), followed by a standard breakfast.
1520427|NCT02813746|Dietary Supplement|Fitness program|
1520428|NCT02813746|Behavioral|Stop smoking|
1520429|NCT02813746|Procedure|Endometrial fluid collection|
1520430|NCT02813733|Procedure|Thyroid surgery|Thyroidectomies performed by all surgeons in 5 academic hospitals in France.
1520431|NCT02813720|Radiation|HR-pQCT High resolution peripheral quantitative CT-scan|"HR-pQCT is a powerful device providing low dose irradiation already used in bone field.
It is a high resolution tool (voxel size=82µm) that the investigators adapted to look after the distal joint involved by onycholysis. An anteroposterior scout view is used to define the region of interest (ROI), which spanned from the top of the distal phalange to the distal part of the intermediate phalange in order to contain the distal joint of the target finger. Images are then analysed for erosions, osteophytes and volumetric bone mineral density."
1520432|NCT02813707|Other|QoL questionnaire regarding the long term complication|Micronutrients evaluation
1520433|NCT02813694|Drug|lefamulin|antibacterial agent
1520434|NCT02813694|Drug|Moxifloxacin|antibacterial agent
1520435|NCT02813681|Procedure|US-epidural SVD|participants who received US examination prior to epidural placement. The purpose of this group is to determine if US derived landmarks reduce pressure sensitivity.
1520436|NCT02813681|Procedure|US sham- epidural SVD|participants who received US examination process but with the monitor turned off. The purpose of this group is to determine if the standard of care epidural placement technique will increase pressure sensitivity at the insertion site. The purpose of this group will also be to reduce the placebo effect from the US exam and to maintain blinding of the patient to their group status (US epidural or US sham epidural).
1520437|NCT02813681|Procedure|US-epidural CS|Same as group 1 except subject delivers by cesarean section (CS)
1520438|NCT02813681|Procedure|US sham - epidural CS|Same as group 2 except subject delivers by spontaneous vaginal delivery (SVD).v
1520439|NCT02813681|Procedure|Spontaneous vaginal delivery without an Epidural|Spontaneous vaginal delivery without an Epidural The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after spontaneous vaginal delivery. Participant must meet the inclusion requirements and not meet any of the exclusion requirements
1520440|NCT02813681|Procedure|Cesarean section without an Epidural|Cesarean section without an Epidural. The purpose of the control group is to serve as a baseline (or a measure of normal). The control participant's measurement will be compared to those that did receive treatments (either epidural alone or ultrasound and epidural). This information will tell the investigator how many women have back pain after cesarean section. Participant must meet the inclusion requirements and not meet any of the exclusion requirements.
1520441|NCT02813681|Device|Algometer|Wagner FPX series manual algometer will be used to assess pain pressure threshold.
1520442|NCT02813668|Behavioral|Lifestyle Intervention Training Program|Participants will be placed into a peer-led classes of 10 to 12 people. The curriculum contains sixteen core sessions that occur weekly for four months followed by an eight month maintenance period. During lifestyle classes, participants will learn strategies for eating a healthy diet, increasing physical activity, overcoming barriers, building social support, reaching and maintaining a healthy wait, and maintaining healthy blood glucose levels. Participants will also be assigned goals to achieve; increasing physical activity and losing 7% of their baseline body weight. During maintenance, participants will receive biweekly SMS text messages providing lifestyle advice tips and encouragement.
1520482|NCT02813395|Device|Low Level Laser Therapy|"Low Level Laser Therapy was applied at four points to the dominant upper limb of the volunteers on the muscle belly of the biceps. Delineation was done using a measuring tape from the elbow joint line to the acromion marked at points corresponding to 20%, 30%, 40% and 50% of this distance, focusing the application on the muscle belly region, thereby excluding the tendinous region.
An 808 nm equipment was used for applying laser therapy, with a power of 100 mW and total energy of 20 J."
1520443|NCT02813655|Drug|Tetracosactide (Synacthène®)|"Tetracosactide, manufactured by Sigma-Tau® laboratories and marketed under the name of Synacthène®.
All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 1 mg of Synacthène® intravenously during 20 minutes. Four vials of 1 ml of Synacthène® will be added to a bag of 100 ml of physiological saline. The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
1520444|NCT02813655|Drug|placebo saline (0.9% NaCl)|"placebo saline manufactured by the laboratory Aguettant: 10ml vial, 4 mL will be collected and added to a bag of 100 ml of saline.
All women who received epidural or combined spinal-epidural labour analgesia and presenting post-partum post dural puncture headache were randomized. The patient will receive 4 ml of placebo saline added to a bag of 100 ml of physiological saline ( 104 ml of physiological saline). The injection of study treatment must be done within 6 hours after the inclusion. Monitoring of the patient is carried out throughout the duration of administration of the drug, then between H2 and H6, D1, D2, D3 and D15."
1520445|NCT02813642|Biological|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
1520446|NCT02813642|Biological|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
1520447|NCT02813642|Procedure|Vascular calcification score|measurement of vascular calcification score by X-ray of the lateral abdominal aorta
1520448|NCT02813629|Device|tDCS plus PES|"transcranial direct current stimulation (tDCS) uses a pair of electrodes and sponges soaked in saline solution placed over specific regions of the head to polarize neurons and produce changes in resting membrane potentials. This changes may increase or decrease neuronal excitability and produce diverse clinical effects, including analgesia.
PES uses also a pair of electrodes over specific regions of the body to promote neuronal action potentials in peripheral nerves. PES over motor threshold increases cortical excitability, and at the sensory threshold decreases excitability."
1520449|NCT02813603|Procedure|EBUS|19G and 22G EBUS needles are compared in a randomized prospective way in lung cancer patients with enlarged mediastinal lymph nodes.
1520450|NCT02813590|Other|Ascitic fluid puncture|
1520451|NCT02813590|Other|Skin swaps from puncture side|
1520452|NCT02813590|Other|Stool samples|
1520453|NCT02813577|Procedure|Lutonix035 Drug Coated Balloon PTA Catheter|Female subjects will receive the Lutonix 035 Drug Coated Balloon PTA Catheter.
1520454|NCT02813564|Behavioral|Cognitive Assessment & Video-game INtervention Solutions (CAVINS)|"This is a computerized video-game like intervention. The participants will exercise/strengthen the cognitive (mental) deficits that may be responsible for symptom profiles such as socialization impairments, academic disabilities, and repetitive behaviour for several weeks. This program will stimulate communication between brain regions that make up an information processing neural network in order to promote proper network development."
1520455|NCT02813551|Drug|Torsemide|
1520456|NCT02813551|Drug|Placebo|
1520457|NCT02813538|Drug|Indocyanine green clearance|To evaluate liver function by injection of indocyanine green by a peripheral vein and measure its clearance
1520458|NCT02813538|Other|Thromboelastometry|To evaluate blood coagulation impairment by obtaining blood sample from a peripheral vein and measure anticoagulant proteins levels plus obtaining thromboelastometry
1520459|NCT02813525|Other|ISI index on Doppler systolic flow in the aortic isthmus|Measure of the ISI index on Doppler systolic flow in the aortic isthmus in the follow-up by ultrasound of the fetus
1520460|NCT02813512|Drug|ADSCs|Autologous ADSCs
1520462|NCT02813486|Biological|Biological: GC3111 vaccine|0.5mL, Intramuscular
1520463|NCT02813486|Biological|Biological: Boostrix® vaccine|0.5mL, Intramuscular
1520464|NCT02813473|Radiation|Coronary Angiography|Coronary angiography is an X-ray test to diagnose diseases of the arteries that supply blood to the heart. Coronary angiography can detect weakened blood vessel walls and narrowed or blocked vessels. X-rays are taken after a special dye has been injected into the bloodstream, making the vessels and blood flow through the vessels visible on X-rays.
1520465|NCT02813473|Radiation|Computed Tomography (CT) scan|A CT scan is an X-ray imaging technique that uses a computer to produce cross-sectional images. It can be used to examine the heart and blood vessels for problems
1520466|NCT02813460|Drug|Formulation A (ALS-008176)|Reference formulation, 60 mg/mL ALS-008176 oral suspension without sweetener/flavor.
1520467|NCT02813460|Drug|Formulation B (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 12 mg/mL sucralose.
1520468|NCT02813460|Drug|Formulation C (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and strawberry flavor.
1520469|NCT02813460|Drug|Formulation D (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and strawberry flavor.
1520470|NCT02813460|Drug|Formulation E (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and masking flavor and cream vanille flavor.
1520471|NCT02813460|Drug|Formulation F (ALS-008176)|60 mg/mL ALS-008176 oral suspension containing 4 mg/mL sucralose and fantasy fruit flavor.
1520472|NCT02813460|Drug|Formulation G1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
1520473|NCT02813460|Drug|Formulation G2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
1520474|NCT02813460|Drug|Formulation G3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 1 from session 1.
1520475|NCT02813460|Drug|Formulation H1 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 1 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
1520476|NCT02813460|Drug|Formulation H2 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 2 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
1520477|NCT02813460|Drug|Formulation H3 (ALS-008176)|60 mg/mL ALS-008176 oral suspension with concentration 3 of sucralose (maximum 12 mg/mL) and best flavor 2 from session 1.
1520478|NCT02813447|Drug|Sertraline|
1520479|NCT02813447|Drug|Placebo|
1520480|NCT02813434|Radiation|florbetapir|18F-AV-45 or 18F-Florbetapir
1520483|NCT02813395|Device|Placebo Laser|Laser application simulation with a second pen of the laser device, which was disconnected and did not effectively irradiate energy.
1520484|NCT02813382|Drug|Bupivacaine|Spinal anesthesia was performed using 10.5mg bupivacaine with added sufentanil (2µg).
1520485|NCT02813382|Drug|Prilocaine|Spinal anesthesia was performed using 60mg prilocaïne with added sufentanil (2µg).
1520486|NCT02813382|Drug|Chloroprocaine|Spinal anesthesia was performed using 40mg hyperbaric 2-chloroprocaïne with added sufentanil (2µg).
1520487|NCT02813369|Drug|naloxegol|non-interventional study where patients are exposed to naloxegol during normal clinical practice
1520488|NCT02813369|Drug|non-PAMORA laxative|non-interventional study where patients are exposed to non-peripherally acting mu-opioid receptor antagonist (PAMORA) laxative
1520491|NCT02813343|Device|BlueStar app|BlueStar is a smart-phone enabled application that is designed to serve as a virtual coach for patients. The app sends daily evidence-based, real-time messages as well as longitudinal feedback on how to improve diabetes management. The Bluestar app has been shown to be effective at teaching patients about dietary impacts on their blood glucose levels, encouraging patients to generate higher-quality blood glucose data for enhanced self-monitoring, and to improve overall management of diabetes as represented by reductions in levels of HgbA1c. Benefits have been demonstrated in time periods as brief as three months. One US based study showed a decrease in hospitalizations and emergency department visits among participants who use the application.
1520492|NCT02813330|Other|Subcutaneous sterile water injection|sterile water injection in two points of low back pain
1520493|NCT02813330|Other|saline injection|Saline injection in two points of low back pain
1520494|NCT02813304|Behavioral|Gradual reloading|Participants will be asked to perform isometric strengthening exercises in lateral rotation and abduction. Participants will place their affected arm by the side with the elbow gently tucked in close to the body, elbow flexed at 90°, and the thumb pointing upwards. The opposite hand will resist the lateral rotation and abduction. They will be asked to push against the uninvolved hand, building up to sub-maximal pressure (approximately 50% to 75% of the maximum possible force) over five seconds. Then the contraction will be slowly released. A maximum pain level of 5/10 will be accepted when performing the contraction. Elevation movements will also be performed 3 times a day in the frontal, sagittal and scapular plane.
1520495|NCT02813304|Behavioral|Rest and cryotherapy|Participants will be asked to apply ice wrap on their painful shoulder 3 times a day over the area of pain for 15 minutes. They will be asked to place the ice wrap inside a damp towel cloth (minimise the risk of an ice burn) and secure around the shoulder with a towel. After the 15 minutes, they will be asked to perform gentle, slow, pain free shoulder movements that do not provoke pain. All participants will be provided with a commercial ice wrap. They will also be asked to avoid painful movements, working above shoulder level, repeated or sustained elevation movements and lifting weights.
1520496|NCT02813291|Device|tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:
- Subjects of the Stimulation groups (Young Stim and Elderly Stim) will receive in parallel an anodal tDCS of the primary motor cortex."
1520497|NCT02813291|Device|sham tDCS|"All subjects will mentally repeat a complex finger sequence with the left hand, for 13 min:
- Subjects of the Sham groups (Young Sham and Elderly Sham) will receive in parallel a sham tDCS of the primary motor cortex."
1520498|NCT02813278|Dietary Supplement|simo decoction|Participants allocated to SMD and acupuncture were asked to take oral SMD decoction (Hansen Co., Ltd., Yiyang, Hunan province, China, 10 mL/dose) three times per day beginning on the first day after colorectal resection. They also received bilateral injections of vitamin B1 (50 mg x 2) at the tsusanli acupoint one time per day. This intervention was performed for a total of 5 consecutive days or until flatus.
1520499|NCT02813278|Other|gum chewing|Participants allocated to chewing gum were instructed to chew commercially available sugar-free gum (Extra & Reg, Wm. Wrigley Jr. Co., Ltd., Shanghai, China) three times daily starting on the first postoperative morning. They were instructed to chew the piece of gum for at least 10 min. This intervention was performed for 5 consecutive days or until flatus.
1520500|NCT02813265|Drug|KPI-121 0.25% Ophthalmic Suspension|
1520501|NCT02813265|Drug|Vehicle of KPI-121 0.25% Ophthalmic Suspension|
1520503|NCT02813239|Other|hCG|Oocyte maturation with hCG
1520504|NCT02813239|Other|hCG + GnRH agonist|Oocyte maturation with hCG + GnRH agonist
1520505|NCT02813226|Other|Molecular Imaging|Baseline and follow-up FDG PET-CT and DCFPyL PET-CT
1520506|NCT02813213|Procedure|Skin micro Grafts|0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)
1520507|NCT02813213|Procedure|Standard skin graft|Standard split thickness (0.3-0.5mm) skin graft
1520508|NCT02813200|Drug|Seretide® Diskus® 500/550 μg|Every day during 7 days
1520509|NCT02813200|Drug|Ultibro® Breezhaler® 110/50 μg|Every day during 7 days
1520510|NCT02813200|Drug|Spiriva® Respimat® 2,5 μg|Every day during 7 days
1520511|NCT02813187|Biological|cellular and tissue based therapy|
1520512|NCT02813187|Procedure|debridement|
1520513|NCT02813187|Procedure|advanced wound therapy|
1520514|NCT02813187|Dietary Supplement|Nutritional screening|
1520515|NCT02813174|Behavioral|Compassionate Mind Training from Compassion-Focused Therapy|
1520516|NCT02813161|Biological|cellular and tissue based therapy|
1520517|NCT02813161|Device|negative pressure wound therapy|
1520518|NCT02813161|Procedure|debridement|
1520519|NCT02813161|Procedure|advanced wound therapy|
1520520|NCT02813161|Dietary Supplement|Nutritional screening|
1520521|NCT02813161|Device|off-loading|
1520522|NCT02813161|Device|Hyperbaric oxygen Therapy|
1520523|NCT02813148|Drug|Naloxegol|Non-interventional study of drug utilization
1520524|NCT02813135|Drug|Ribociclib|
1520537|NCT02813096|Drug|folfox4 chemotherapy regimen|"Folfox regimen:Oxaliplatin 85 mg/m2 in 250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1;leucovorin 200 mg/m2 in 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 400 mg/m2 5-FU in 20mL 0.9% NaCl solution, IV(administered as follow leucovorin); then 600 mg/m2 5-FU in 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.
Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
1520538|NCT02813096|Other|Placebo|"Placebo regimen:250 mL 5% glucose solution, IVD (administered as 2-hour infusion) on day 1; 100 mL 0.9% NaCl solution, IVD (administered as 2-hour infusion) on days 1 and 2; 20mL 0.9% NaCl solution, IV; then 100 mL 0.9% NaCl solution (administered as 22-hour continuous infusion) on days 1 and 2 of each 14 days cycle.
Number of cycles: 4 cycles, or until progression or unacceptable toxicity develops."
1520539|NCT02813083|Other|No intervention (observational)|No intervention (observational)
1520540|NCT02813070|Drug|[18F] Flutemetamol|PET brain imaging and Magnetic resonance brain imaging
1520541|NCT02813057|Procedure|Stoppa inguinal hernia repair|Stoppa inguinal hernia repair
1520542|NCT02813057|Procedure|Total extraperitoneal inguinal hernia repair|Total extraperitoneal inguinal hernia repair
1520543|NCT02813044|Drug|total intravenous anesthesia (TIVA)|In the TIVA group,anesthesia is induced and maintained by effect-site target controlled infusion of propofol and remifentanil.
1520544|NCT02813044|Drug|inhalation anesthesia group|In the inhalation anesthesia group, anesthesia is induced by pentothal sodium 4-6mg/kg and remifentanil 1 μg/kg, and then maintained with end-tidal sevoflurane concentration of 0.8 to 1 MAC and continuous infusion of remifentanil at 0.1-0.3μg/kg/min.
1520545|NCT02813031|Other|Functional meat products|
1520546|NCT02813031|Other|Traditional meat products|
1520547|NCT02813018|Procedure|0.2 ml/kg of 0.2% ropivacaine|In the preemptive group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of 0.2% ropivacaine, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
1520548|NCT02813018|Procedure|0.2mg/kg of Normal Saline|In the saline group, 5 minutes before skin incision, the epidural catheter is dosed with 0.2 ml/kg of normal saline, followed by continuous infusion of 5 minutes before skin incision at 0.2 ml/kg/h.
1520549|NCT02813005|Procedure|Jet ventilation group|MONSOON III™ (Acutronic Medical System AG®, SEBAC) with Double lumen catheter 12CH (Acutronic Medical System AG®, SEBAC)
1520550|NCT02813005|Procedure|Standard ventilation group|apnea made by the anesthesiologist to the request of the radiologist
1520551|NCT02812992|Drug|Nab-paclitaxel|
1520552|NCT02812992|Drug|Gemcitabine|
1520553|NCT02812992|Other|Best Supportive Care|
1520554|NCT02812979|Device|Airvo2 with Aerogen Solo|Nebulization of salbutamol with Airvo 2 and Aerogen solo
1520555|NCT02812979|Device|Mask|Usual nebulization of salbutamol with mask
1520556|NCT02812979|Device|arm control Airvo2 without nebulization of salbutamol|Airvo2 with Aerogen Solo. No nebulization of salbutamol
1520557|NCT02812966|Device|Lutonix|Drug Coated Balloons
1520558|NCT02812966|Device|IN.PACT|Drug Coated Balloons
1520559|NCT02812940|Drug|Everolimus|GvHD prophylaxis
1520560|NCT02812927|Device|Edelvaiss Multiline-8|Optimised infusion line
1520561|NCT02812927|Device|Standard infusion line|
1520565|NCT02812901|Procedure|cardiac surgery scheduled in the morning|cardiac surgery scheduled in the morning
1520566|NCT02812901|Procedure|cardiac surgery scheduled in the afternoon|cardiac surgery scheduled in the afternoon
1520567|NCT02812888|Drug|thionamide treatment for 3 months|Hyperthyroid patients would received thionamide treatment (methimazole, propylthiouracil, or propranolol) for 3 months, and euthyroidism would be obtained.
1520568|NCT02812875|Drug|CA-170|"Dose escalation stage (Phase 1a) accelerated titration and standard 3+3 dose escalation in patients with advanced solid tumor or lymphoma.
Dose expansion stage (Phase 1b) in patients with tumors that are shown to be responsive to anti-PD-1 or anti-PD-L1 checkpoint inhibitors and/or in tumor types known to express PD-L1 or VISTA, including but not limited to: melanoma, non-small cell lung cancer, renal cell carcinoma, Hodgkin lymphoma, triple negative breast cancer, head and neck cancer, colorectal cancer, gastric cancer, bladder cancer, and ovarian cancer."
1520569|NCT02812862|Drug|Ultibro/ Breezhaler|LABA/ LAMA combination therapy a combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent
1520570|NCT02812849|Drug|Cu-64 DOTATATE|
1520571|NCT02812836|Device|Manometry|Each patient will be investigated first by anorectal manometry, standard protocol of conventional parameters will be recorded such as: resting pressure, squeeze pressure, bear down manoeuver, thresholds of sensation and threshold of recto anal inhibitory reflex. 3D picture of anal canal will be recorded. After that balloon with 50 ml of water will be inserted into the rectum and patient will be asked to expel the device within 1 min in privacy.
1520572|NCT02812823|Device|High-resolution anorectal manometry|Recording of conventional manometric parameters after insertion of the catheters.
1520573|NCT02812810|Device|active rTMS|
1520574|NCT02812810|Device|sham rTMS|
1520575|NCT02812784|Device|Nephrocheck TM|
1520576|NCT02812771|Drug|Efinaconazole|Solution
1520577|NCT02812758|Device|transthoracic echocardiography|recording of data on cardiac output measured non-invasively by transthoracic echocardiography, including the SVV
1520578|NCT02812745|Device|recording of cardiac output|
1520579|NCT02812745|Device|other parameters|BIS (bispectral index ), PI (perfusion index ), etCO2 (end-tidal carbon dioxide ), and brain NIRS (near-infrared spectroscopy)
1520580|NCT02812732|Behavioral|DOSE HPV|"The primary goals of the DOSE HPV intervention are to 1) change clinician HPV vaccine recommendations and responses to hesitant parents, and 2) support systems changes to improve the vaccination process. The first four sessions follow a standardized curriculum, while the last three sessions include development and implementation of tailored activities designed to meet individual practice needs.
Sessions 1 and 2 generate motivation for the project through feedback of vaccination rates (Session 1) and education on HPV disease (Session 2). Brief Negotiated Interview (BNI) skills are taught in Sessions 3&4. Action Plans are developed in Session 5. Sessions 6&7, which follow a standard quality improvement format: plan-do-study-act (PDSA) cycles."
1520581|NCT02812719|Drug|Glycolic acid peel alone|"One of two sides of the face will be randomly treated with glycolic acid peel 35% alone.
This treatment will be administered at visit 1 (but to entire face) and 3 subsequent visits (to one randomly selected side of the face), for a total of 4 treatments at 2 week intervals"
1520582|NCT02812719|Drug|Glycolic and salicylic acid peel|"The other randomly chosen side of the face will be treated with glycolic acid peel 35% followed by salicylic acid peel 20%, as a combination treatment.
This treatment will be administered at visits 2, 3 and 4 (to one randomly selected side of the face), for a total of 3 treatments at 2 week intervals."
1520584|NCT02812693|Drug|Imatinib Mesylate|Given PO
1520585|NCT02812693|Other|Laboratory Biomarker Analysis|Correlative studies
1520586|NCT02812693|Biological|Pembrolizumab|Given IV
1520587|NCT02812680|Other|Blood Draw|Blood draw to assess the use of circulating microRNA (miRNA) and circulating tumour cells (CTC) as biomarkers of cancer and predictive markers for neoadjuvant therapy.
1520588|NCT02812667|Drug|Nivolumab + Plinabulin|
1520589|NCT02812654|Drug|Doxorubicin|Doxorubicin 75mg/m2 (cycle 1,2 and 3)
1520590|NCT02812654|Drug|Ifosfamide|Ifosfamide 9 g/m2 (cycle 1 and 3)
1520591|NCT02812654|Radiation|radiotherapy|radiotherapy: 25 Gy / 5 x 500 cGy/day
1520592|NCT02812641|Drug|BPF-CCRT (run-in)|Six patients will be enrolled in run-in phase. If <= 1 patient developed dose-limiting toxicity, the trial will be continued to randomized phase. If > 1 patients developed dose-limiting toxicities, the protocol will be discontinued.
1520593|NCT02812641|Drug|BPF-CCRT (randomized)|Twenty-two patients will be planned to assign to the experimental arm
1520594|NCT02812641|Drug|PF-CCRT (randomized)|Twenty-two patients will be planned to assign to the active control arm
1520595|NCT02812628|Procedure|LAPR|Patients undergoing conventional LAPR, the common surgical procedure to treat low rectal cancer ≤5m from anal verge.
1520596|NCT02812628|Procedure|LAPR-TILT|Patients undergoing LAPR-TILT, a modified APR procedure that is supposed to be safer and less invasive as compared to the LAPR.
1520597|NCT02812615|Dietary Supplement|Egg|After enrollment, participants will receive one large egg 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
1520598|NCT02812615|Dietary Supplement|Milk|After enrollment, participants will receive 150ml of milk 6 days a week for 3, 2 and 2 months for stunted children, children at risk of stunting, and malnourished adults, respectively.
1520599|NCT02812615|Drug|Albendazole/Pyrantel Pamoate|As per the national guidelines, treatment will be provided based with 200 mg of Albendazole or 10mg/kg Pyrantel Pamoate single dose if the participants have not been treated for helminths in the preceding three months.
1520600|NCT02812615|Behavioral|Nutritional counselling|Parents/caregivers will be given nutritional counselling
1520601|NCT02812615|Dietary Supplement|Micronutrient sprinkles|For the child cohort, one sachet of multiple micro-nutrient sprinkles per day to be administered with the mid-day meal for two months
1520602|NCT02812602|Drug|Lidocaine patch|Lidocain patch will be applied around the surgical wound about 20 minutes before removal of staples.
1520603|NCT02812602|Drug|placebo|Placebo patch will be applied around the surgical wound about 20 minutes before removal of staples.
1520604|NCT02812589|Other|Diffusion tensor imaging (DTI) in Breast MRI|
1520605|NCT02812563|Other|genetic|Galilee exam - Corn analysis with Optiwave Refractive Analysis
1520606|NCT02812550|Procedure|colonoscopy procedure|endoscopy performed with a standard forward view colonoscopy or with full-spectrum endoscopy
1520607|NCT02812537|Other|patients with conduct disorders|
1520608|NCT02812524|Drug|Intratumoral Ipilimumab|Patients with a planned resection of SCCHN will have a biopsy procedure 7-10 days prior to surgery and receive an injection of ipilimumab directly into a tumor.
1520609|NCT02812511|Procedure|Biopsy|Skin biopsy is performed at the arm with a punch of 3 mm in diameter or a scalpel under local anesthesia, and then preserved in low glucose DMEM at room temperature.
1520610|NCT02812498|Other|Teleconsultation|The patients in the consultation group arranged their bookings on a website, where they could also access to web educational courses or to nutritional and psychological counselling
1520611|NCT02812498|Other|Standard|Group of patients followed in a traditional way
1520612|NCT02812472|Other|Treadmill training with functional electrical stimulation|
1520613|NCT02812472|Other|Treadmill training without functional electrical stimulation|
1520614|NCT02812459|Other|Kinesio taping|Kinesio taping is a new taping modality which act diminishing pain.
1520615|NCT02812459|Other|Electrical Stimulation|Electrical stimulation therapy is a electrical current that allow patients diminish pain.
1520616|NCT02812446|Other|IAI infection|
1520617|NCT02812446|Other|Staphylococcus aureus nasal carriage infection|
1520618|NCT02812433|Drug|Sildenafil|sildenafil 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
1520619|NCT02812433|Drug|Ora-Blend|Ora-Blend, 2 mg/kg/dose per os twice a day for seven consecutive days (from day 2 of life to day 9 of life) if brain injury on day 2 of life
1520620|NCT02812420|Drug|Durvalumab|1500 mg by vein on Day 1 of Weeks 1 and 5.
1520621|NCT02812420|Drug|Tremelimumab|75 mg by vein on Day 1 of Weeks 1 and 5.
1520622|NCT02812420|Procedure|Cystectomy|Surgery (cystectomy with pelvic lymph node dissection) performed 4-6 weeks after the last infusion of Durvalumab and Tremelimumab.
1520623|NCT02812420|Behavioral|Phone Calls|Every 3 months for a total of 1 year from the start on the study, participants called and asked how they are doing.
1520624|NCT02812407|Device|Mucosal Impedance|"During the clinical endoscopy, the 2.13 mm catheter will be passed through the channel of the standard endoscope this is called an Intraluminal Impedance. The Intraluminal impedance (made by Sandhill Scientific) has not been approved by the Food and Drug Administration (FDA) but it is considered to be minimal risk related to using it. The catheter gives the investigators a reading at each level.
The catheter will be placed on the esophageal mucosa 5 cm above the gastroesophageal junction (where the stomach and esophagus meet) for 5 second
At 10 cm above the gastroesophageal junction the catheter will be placed for 5 seconds
And at 20 cm"
1520625|NCT02812394|Drug|CVT-301 (Dose Level 1)|All subjects will receive a single dose of low-dose CVT-301 with a 1-day washout between the doses.
1520626|NCT02812394|Drug|CVT-301 (Dose Level 2)|All subjects will receive a single dose of high-dose CVT-301 with a 1-day washout between the doses.
1520627|NCT02812394|Drug|Sinemet®|All subjects will receive carbidopa/levodopa tablets administered every 8 hours.
1520628|NCT02812381|Procedure|KT|to aplicate neuromuscular bandage technique(KT)
1520629|NCT02812381|Procedure|SCS|To aplicate strain-counterstrain above trigger point
1520630|NCT02812368|Drug|Clonidine|
1520631|NCT02812368|Drug|Placebo (for clonidine)|Placebo pill manufactured to mimic clonidine
1520632|NCT02812355|Drug|Heparin|
1520633|NCT02812342|Drug|Tofacitinib ointment|Patients with AA (with at least 2 patches of alopecia involving the scalp), AT or AU will be treated with tofacitinib ointment for a maximum of 6 months. During treatment, patients will be evaluated every 4 weeks and effectiveness of the medication will be measured by changes in hair growth.
1520634|NCT02812329|Behavioral|HIV prevention videogame|Assess acceptability and efficacy of a HIV prevention videogame
1520635|NCT02812316|Device|HI-BRITE Large Diameter Rigid Gas Permeable Contact Lens|Approximately At least one hundred and forty (140) subjects (280 eyes) will be enrolled in this study at approximately two (2) clinical sites in Taiwan. All subjects will be fitted for and dispensed study lenses by each Investigator.
1520636|NCT02812303|Other|Centralized support for population health management activities|
1520637|NCT02812264|Behavioral|API App|Mobile application that uses API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale
1520638|NCT02812264|Behavioral|Non-API App|Mobile application that does not use API technology to deliver evidence-based weight loss intervention. Includes syncing with wearable fitness tracker and scale.
1520639|NCT02812264|Behavioral|fitness tracker|fitness tracker to monitor physical activity and sleep patterns that is connected to transfer data to app
1520640|NCT02812264|Behavioral|scale|Connected scale that will transfer weight information to app
1520641|NCT02812251|Drug|JNJ-61393215|JNJ-61393215 (projected dose levels as described above for Part 1) will be administered as an oral suspension.
1520642|NCT02812251|Drug|Placebo|Matching placebo will be administered.
1520645|NCT02812225|Device|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
1520646|NCT02812212|Device|ultrasonography|bilateral ultrasonography to measure the antero-posterior renal pelvic diameter (APRPD) in both positions.
1520647|NCT02812212|Device|diuretic renography|diuretic renography to measure the cortical transit time.
1520648|NCT02812199|Device|Composite Removable Sinus Stent|Post-FESS bilateral implantation of sinus stent into middle meatus. Nasal tampon will be placed to stop bleeding. Stent will be removed after 14 - 28-day implantation, during self-crimp procedure induced by cold saline flush and safely pulled out. During implantation period patients will be examined endoscopically for inflammation, adhesions and middle turbinate position.
1520649|NCT02812199|Drug|adrenaline-lidocaine|adrenaline - lidocaine administration to minimize bleeding prior to stent removal (group 1 and group 2)
1520650|NCT02812199|Procedure|cold saline wash|nasal wash with cold saline prior to stent removal, to induce stent self-crimping.
1520651|NCT02812186|Procedure|deep neuromuscular blockade|"After induction and intubation, the patient will be maintained in a deep (post-tetanic count, one or two twitches) neuromuscular block (NMB), obtained with an intubating dose of rocuronium of 0.6 mg/kg followed by a continuous infusion. The initial infusion rate will be set at 0.6 mg/kg/h. To minimize any type of carry-over effects, after the completion of the deep NMB 20 minute period, a transition period of approximately 10-15 minutes will begin. During this transition period the rocuronium infusion will be paused and the Train of Four (TOF) monitor will be set to every 1-2 min. Once the patient has achieved a moderate NMB state (one to two twitches), the infusion of the muscle relaxant will be resumed at a low dose to maintain the patient at this level of blockade."
1520652|NCT02812186|Procedure|moderate neuromuscular blockade|"After induction and intubation, the patient will be maintained in a deep (post-tetanic count, one or two twitches) neuromuscular block (NMB), obtained with an intubating dose of rocuronium of 0.6 mg/kg followed by a continuous infusion. The initial infusion rate will be set at 0.6 mg/kg/h. To minimize any type of carry-over effects, after completion of the moderate NMB 20 minute period, a transition period of approximately 10-15 min will begin. During this transition period the rocuronium infusion will be increased in increments of 0.1-0.2 mg/kg/hr. and the TOF monitor will be set to every 1-2 min. Once the patient has no twitches and a PTC of 0-1 (deep NMB) the infusion will be adjusted to maintain the patient at this level of NMB."
1520653|NCT02812186|Drug|Rocuronium|
1520654|NCT02812173|Device|suprapubic tube ex 2 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the second day after the surgery
1520655|NCT02812173|Device|suprapubic tube ex 5 day|balloon catheter for suprapubic bladder-drainage, suprapubic tube removal on the fifth day after the surgery
1520656|NCT02812173|Device|transurethral catheter ex 5 day|transurethral catheter withdrawal removal on the fifth day after the surgery
1520657|NCT02812147|Drug|L-DOPS|Added as described in the Arm/Group Descriptions.
1520658|NCT02812147|Drug|Placebo|Added as described in the Arm/Group Descriptions.dded as described in the Arm/Group Descriptions.
1520659|NCT02812121|Drug|umbilical cord blood mesenchymal stem cells|
1520660|NCT02812108|Device|intracranial stent, flow diverter and coils|
1520662|NCT02812082|Other|web-based patient education|
1520663|NCT02812082|Behavioral|questionnaire|
1520664|NCT02812069|Device|ThermaZone® Device|The device will be used to intraoperatively warm patients having minor-to moderate surgical procedures
1520665|NCT02812056|Drug|Alisertib|"Dose Escalation Phase:
Starting dose of Alisertib: 30 mg by mouth 2 times a day on Days 1 - 7 each 21 day cycle.
Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
1520666|NCT02812056|Drug|TAK-228|"Dose Escalation Phase:
Starting dose of TAK-228: 1 mg by mouth daily Days 3 - 18, with the exception of 2 mg daily Days 3 - 7 and 10 - 14 schedule in a 21 day cycle.
Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
1520667|NCT02812043|Device|1,064nm Long-pulsed Nd:YAG|Long-pulsed 1,064nm will be used for the treatment of onychomycosis which wll use 35-45 J/cm2 spot size 4, frequency 1 Hz for 2 passes on the infected nails
1520668|NCT02812043|Drug|Amorolfine|Amorolfine nail lacquer will be applied by the patient once a week on the infected nails
1520669|NCT02812030|Other|National Eye Institute Visual Functioning Questionnaire|Routine treatment plus visual functioning questionnaires
1520670|NCT02812017|Behavioral|Thirty Million Words- Well Baby|Through evidence-based strategies, the TMW-WB curriculum teaches parents how to harness the power of their words to build their child's brain and impact their child's learning trajectory.
1520671|NCT02812017|Other|Safety Starts at Home|A portion of the Safety Stars at Home set is shown. Demonstrating proven childproofing techniques and accident-prevention strategies, which unifies safety guidelines and shows caregivers how to take proactive measures at home. Many no- or low-cost safety alternatives are offered.
1520672|NCT02812004|Device|Ultra Q Reflex YAG laser (Ellex)|"Group 1 receives up to 2 sessions of vitreolysis performed with the Ultra Q Reflex YAG laser (Ellex). There is no cut off for total energy per treatment session.
For the sham treatment in group 2, the physician quickly manipulates the light switch of the laser's slit lamp to create light flashes and simulate laser pulses."
1520673|NCT02811991|Drug|Paracetamol injection|325mg(32.5mL) or 500mg(50mL) iv q6h,4 doses in 24h.Infushion time≥15min.
1520674|NCT02811991|Drug|Normal Saline injection|32.5mL or 50mL iv q6h,4 doses in 24h.Infushion time≥15min.
1520675|NCT02811991|Drug|Morhpine PCA|Morphine PCA will be connected upon the first dose of study drug(roughly 30min prior to the completion of would suture). Morphine PCA is set as follows:1mg bolus every 5min with background infusion of 0.25mg/h and maximal dose<25mg/4h.
1520676|NCT02811978|Drug|Bortezomib|Participants will receive 1.3 mg/m^2 bortezomib on Days 1, 4, 8, and 11 of a 3 week cycle.
1520677|NCT02811978|Drug|Dexamethasone|Participants will receive Dexamethasone at a dose of 20 mg PO on the day of and the day after bortezomib dosing (Days 1, 2, 4, 5, 8, 9, 11, and 12 of each cycle).
1520678|NCT02811965|Other|Control|No heel offloading is applied to the heel
1520679|NCT02811965|Other|Pillow Condition 1|The heel is offloaded by placing the heel on a standard hospital pillow.
1520680|NCT02811965|Other|Pillow Condition 2|The heel is offloaded by placing a standard hospital pillow under the calf suspending the heel above the hospital bed mattress.
1520681|NCT02811965|Device|Heel Foam Pillow|An economy heel offloading device constructed of egg shell foam.
1520682|NCT02811965|Device|Offloading Device A|Heel offloading device that utilizes open cell foam to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate.
1520683|NCT02811965|Device|Offloading Device B|Heel offloading device that utilizes pressure absorbing filling to offload the heel. Device has a published clinical study demonstrating effectiveness at reducing heel ulceration rate
1520684|NCT02811965|Device|Offloading Device C|Heel offloading device that utilizes a similar pressure absorbing filling to Offloading Device B; however this device does not have published clinical literature demonstrating effectiveness at reducing heel ulceration in the clinic.
1520685|NCT02811952|Other|without intervention|without intervention
1520686|NCT02811939|Drug|Active Dronabinol|20 mg capsule of Dronabinol will be administered orally
1520687|NCT02811939|Drug|Active Pregnenolone|1.79 mg/kg of Pregnenolone will be administered sublingually (under the tongue)
1520688|NCT02811939|Drug|Placebo Dronabinol|Control: Placebo pill (no active cannabinoids) administered orally
1520689|NCT02811939|Drug|Placebo Pregnenolone|Control: Placebo given sublingually (under the tongue)
1520690|NCT02811913|Other|repetitive transcranial magnetic stimulation (rTMS)|"3 types of interventions on different sessions
session 1 - High frequency rTMS targeting contralesional sensory cortex
session 2 - Low frequency rTMS
session 3 - sham rTMS"
1520691|NCT02811900|Procedure|Roux en Y gastric bypass|Laparoscopic RYGB is performed as following: a gastric pouch of approximately 30mL was obtained using successive firings of the Endo GIATM linear stapler, followed by the creation of an antecolic alimentary limb of 150cm and of a biliopancreatic limb of 75cm. A gastrojejunal anastomosis was fashioned with the PCEEA™ 28 circular stapler until 2012, and using the Endo GIA™ linear stapler afterwards. The mesenteric defect and Petersen's defect were closed using a non-absorbable running suture.
1520692|NCT02811900|Procedure|Sleeve gastrectomy|Laparoscopic SG is performed as following: after greater curvature mobilization, the gastric tube was calibrated over a 36F bougie and transection started approximately 5-6 cm from the pylorus toward the left diaphragmatic crus, using successive firings of 3.5- or 4.8-mm-high staples, depending on gastric thickness.
1520693|NCT02811900|Procedure|Gastric banding|Laparoscopic gastric banding is performed as following: a perigastric tunel is performed by blunt dissection and the banding is calibrated over the stomach.
1520694|NCT02811900|Procedure|Intragastric balloon|Flexible endoscopy is used to place intragastric balloon for a maximum interval of six months.
1520695|NCT02811887|Behavioral|Supervised exercise|A 12 week supervised and facility-based exercise training program. The program is facility based and supervised by a physiotherapist. The program runs 3 times weekly for 12 weeks. The exercise is group-based. The exercise program lasts approximately 1 hour and consists of a brief warm-up phase (bicycle ergometer at moderate intensity) followed by a circuit training program focusing on strength and endurance exercises of the large muscle groups (e.g. quadriceps).
1520743|NCT02811497|Drug|Azacitidine|
1520744|NCT02811497|Drug|Durvalumab|
1520696|NCT02811887|Other|Usual Care|Participants allocated to usual care will receive instructions related to healthy living, alcohol absenteeism, and benefits of increased physical activity. The instructions will be provided by a physical therapist and/or a nurse, and will be given according to recommendations and local and national guidance. The participants are offered continued regular visits at the rehabilitation clinic, but no supervised physical exercise.
1520697|NCT02811887|Behavioral|SMS-messages|"Participants allocated to SMS-messages will receive the same intervention as usual care (see above) AND regular text messages via SMS over a 12-week period.
The text messages will be unidirectional and will serve as motivational information but will not allow two-way communication with a researcher or health professional about clinical management. The messages will provide information, motivation, and support to adhere to a healthy lifestyle, alcohol absenteeism, and physical activity and will reinforce the information and instructions received at the face-to-face information (usual care)."
1520698|NCT02811874|Behavioral|diabetes education|Diabetes education program includes: 4 theoretical sessions, 60 minutes long, taught once a week for 4 weeks, developed in the form of group classes, and given by one of the authors. The educational program content comprises (1) definition of diabetes, and identification of modifiable risk factors for type 2 diabetes, (2) non-pharmacological treatment, with emphasis on diet and exercise, (3) pharmacological therapy, including mechanism of action and side effects of anti-diabetic medications provided by the Brazilian public health system and (4) an overview of chronic diabetes complications.
1520699|NCT02811874|Behavioral|education in other areas|Four theoretical sessions related to education in other health areas, not related to diabetes, administered during 4 weeks
1520700|NCT02811861|Drug|lenvatinib|
1520701|NCT02811861|Drug|everolimus|
1520702|NCT02811861|Drug|pembrolizumab|
1520703|NCT02811861|Drug|Sunitinib|
1520704|NCT02811822|Drug|GMI-1271|
1520705|NCT02811809|Drug|Apalutamide|Apalutamide 240 mg (4 60mg tablets) daily
1520706|NCT02811809|Drug|IHT|Leuprolide 3-month depot 22.5 intramuscular dose
1520707|NCT02811796|Other|angio-based FFR estimation|The investigators will acquire specific angiograms to permit angio-based FFR (QFR) calculation. An independent corelab will estimate the QFR value. This value will be related to prognosis to verify if it is able to discriminate those at higher risk of adverse events.
1520710|NCT02811770|Other|kidney biopsy|
1520711|NCT02811757|Procedure|tenotomy|
1520712|NCT02811757|Procedure|tenodesis|
1520713|NCT02811744|Drug|11C-acetate|Participants will receive injection of radioactive tracer 11C-acetate and complete a PET/CT scan.
1520714|NCT02811731|Drug|CKD-330 16/5mg - B|
1520715|NCT02811731|Drug|Candesartan 16mg and Amlodipine 5mg|
1520716|NCT02811718|Behavioral|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
1520717|NCT02811718|Behavioral|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
1520718|NCT02811705|Other|Quality of life|Quality of life
1520720|NCT02811679|Drug|Blinatumomab|Blinatumomab is a bispecific t cell engaging antibody targeting CD19 and CD3 approved for B cell acute lymphoblastic leukemia
1520721|NCT02811666|Device|Assessment of sarcopenia by CT-Scan|
1520722|NCT02811666|Device|hand gauge|
1520723|NCT02811653|Device|Brain MRI|
1520724|NCT02811653|Other|neuropsychological evaluation|
1520725|NCT02811653|Biological|Blood|
1520726|NCT02811640|Other|Study Participants|IAP will be observed and measured with a hand held Stryker Pressure Monitor during laparoscopic surgery and compared to the standard IAP measurements obtained with the insufflator at the time of PD catheter insertion
1520727|NCT02811627|Drug|Memantine|Namenda (pill and the liquid) will be started at 5 mg/day doses to be titrated up 20 mg/day based on response and tolerability, as per the package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks. Namenda XR will be started at 7 mg/day to be titrated up to 28mg/day based on response and tolerability, as per package insert instructions and based upon clinical titration in other clinical trials for a period of 12 weeks.
1520728|NCT02811627|Device|Magnetic Resonance Imaging|The subjects will undergo an MRI assessment after baseline behavioral assessment. The session will involve a structural MRI scan, single voxel spectroscopy scans and resting state functional MRI. The subjects will be started on memantine post the imaging session. The imaging will be carried out on a research dedicated 3 Tesla (3T) Siemens Trio Scanner at the University of Missouri Brain Imaging Center by trained personnel.
1520729|NCT02811614|Procedure|Endoscopic Evacuation|Endoscopic surgery for treatment of supratentorial hypertensive intracerebral hemorrhage.
1520730|NCT02811614|Procedure|Stereotactic Aspiration|Using image guidance to aspirate hematoma.
1520731|NCT02811614|Procedure|Craniotomy|Craniotomy with a big bone flap to evacuate intracerebral hematoma.
1520732|NCT02811601|Procedure|PEAL surgery|Patients will undergo percutaneous externally-assembled laparoscopic surgery where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
1520733|NCT02811588|Device|Non-invasive ventilation|
1520735|NCT02811562|Device|manikin|
1520736|NCT02811562|Device|fiberoptic bronchoscope|
1520737|NCT02811562|Device|pentax-airwayscope|
1520738|NCT02811549|Device|HiResolution Bionic Cochlear Implant|HiRes 90K™ Advantage implant with HiFocus™ 1J electrode, HiRes 90K™ Advantage implant with the HiFocus Helix™ electrode or the HiRes 90K™ Advantage implant with the HiFocus™ Mid-Scala electrode will be implanted in adults with eligible hearing profile.
1520739|NCT02811536|Device|optical coherence tomography angiography|Imaging with optical coherence tomography angiography
1520740|NCT02811523|Drug|Doxorubicin|Doxorubicin by In Vivo Lung Perfusion
1520741|NCT02811510|Drug|Placebo|Placebo pill (no active cannabinoids)
1520742|NCT02811510|Drug|Dronabinol|10 mg capsule of Dronabinol will be administered orally.
1520745|NCT02811484|Drug|Exenatide-LAR plus Dapagliflozin placebo|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin placebo x 52 weeks and behavioral therapy.
1520746|NCT02811484|Drug|Exenatide-LAR plus Dapagliflozin|Exenatide-LAR 2 mg every week x 24 weeks plus Dapagliflozin 5 mg x 2 weeks, then 10 mg for 22 weeks and behavioral therapy.
1520747|NCT02811484|Drug|Insulin Titration|Basal insulin titration up to 12 weeks followed by basal-bolus regimen in those with HbA1c>8%
1520748|NCT02811484|Behavioral|Behavioral Therapy|Subjects will be seen by a registered dietitian and receive nutritional and lifestyle counseling according to a web-based weight management program.
1520749|NCT02811458|Behavioral|Transdiagnostic Cognitive-Behavioral Therapy|Treatment in the Transdiagnostic CBT condition will consist of 12 weekly 2-hour sessions following the manualized treatment protocol including psychoeducation, cognitive restructuring, exposure and relapse prevention.
1520750|NCT02811432|Other|Kangaroo mother care|
1520751|NCT02811432|Other|Incubator care|
1520752|NCT02811419|Device|i-scan|examination will be performed with i-scan digital enhancement
1520753|NCT02811419|Device|standard high-definition white light|examination will be performed with high-definition white light
1520754|NCT02811406|Procedure|Receives IV albumin infusion|"IV albumin 20% 50 mL for every 1L of ascitic fluid drained. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.
If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP < 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
1520755|NCT02811406|Biological|Do not receive IV albumin infusion|"No IV albumin infusion. Blood pressure and heart rate are recorded every four hours in both groups in the first 48 hours.
If hypotension occurs (defined as fall in systolic blood pressure of > 20 mmHg from baseline) during drainage, drain is clamped and the patient will be clinically evaluated for cause of hypotension. If no other causes of hypotension are found and patient remains asymptomatic, repeat blood pressure measurement in 30 minutes. If blood pressure maintains > 90/50 mmHg after 30 minutes and patient is asymptomatic, continue drainage and patient stays in the study. If patient remains hypotensive (BP < 90/50) or develops symptomatic hypotension, then the patient will be taken off study and the hypotension managed as clinically indicated."
1520756|NCT02811393|Other|Assess muscle function|Assess muscle function with hand grip test and sit and stand test
1520757|NCT02811380|Device|BIP CVC|BIP CVC catheterization to minimize risk of infections for venous access during and after elective large surgery
1520758|NCT02811380|Device|Uncoated Standard CVC|Standard CVC catheterization for venous access during and after elective large surgery
1520759|NCT02811367|Device|HPV test|Women will perform the HPV self-test and will also undergo a physician-performed HPV test.
1520760|NCT02811354|Drug|AZD9291|oral administration as a single daily dose of 80 mg
1520761|NCT02811341|Drug|Scopolamine Hydrobromide|
1520762|NCT02811341|Drug|normal saline|
1520763|NCT02811315|Other|Observational. Non interventional study|Observational. Non interventional study
1520764|NCT02811302|Device|Capnostream Monitor|Capnography and pulse oximetry monitoring data will be collected for up to 48 hours while patients are on the hospital ward. In addition, a 1-month follow up will be completed.
1520765|NCT02811289|Drug|Mirbetriq (Mirabegron)|50mg of Mirabegron will be administered orally at time 0 in protocol A.
1520766|NCT02811289|Other|cold exposure|Acute cold exposure protocol using a water-conditioned cooling suit will be applied from time 120 to 300 min in protocol B
1520767|NCT02811289|Radiation|injection of 18FDG|I.v. injection of 18-fluorodeoxyglucose (18FDG) will be performed at time 270 min, followed by 30 min dynamic PET/CT scanning
1520768|NCT02811289|Radiation|injection of 11C-acetate|i.v. injection of 11C-acetate will be performed, followed by 20 min dynamic PET/CT scanning
1520769|NCT02811289|Radiation|[3-3H]-glucose|i.v. administration of 1.5 uCi/min of [3-3H]-glucose
1520770|NCT02811289|Other|[U-13C]-palmitate|i.v. administration of 0.08 umol/kg/min of [U-13C]-palmitate
1520771|NCT02811289|Other|2H-Glycerol|i.v. administration of 0.05 µmol/kg/min of 2H-glycerol
1520772|NCT02811276|Other|Diet|The High-Protein Diet Group will receive a eucaloric diet composed of 35% of carbohydrate, 40% of protein, and 25% of lipid constructed around a soy protein-based meal replacement (Almased®) for one and a half day. Participants will consume 1 gram ± 0.1 of Almased® per kg of body weight mixed with linseed oil and skim milk in their breakfast, lunch and dinner. Two snacks (afternoon and evening) composed of 1 gram ± 0.1 of Almased® per kg of body weight mixed with vegetable juice and linseed oil will also be provided.
1520773|NCT02811263|Drug|Normal saline placebo|Equal volume of normal saline to be used as placebo
1520774|NCT02811263|Drug|Erythropoietin|Epogen drawn from commercially available single dose 4000U/mL vials
1520775|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 8 Gy|
1520776|NCT02811250|Radiation|Stereotactic radiotherapy 5 x 8 Gy|
1520777|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 10 Gy|
1520778|NCT02811250|Radiation|Stereotactic radiotherapy 4 x 12 Gy|
1520781|NCT02811198|Other|No intervention|
1520782|NCT02811185|Drug|[F-18]-Fludeoxyglucose|Radiopharmaceutical imaging agent
1520783|NCT02811172|Other|BEhavior of biomarkers during pregnanCy and lactatiOn|
1520784|NCT02811159|Drug|Proellex 12 mg|
1520785|NCT02811146|Device|Bilevel Positive Pressure Airway|Heart rehabilitation with noninvasive ventilation, for 12 weeks, 3 times a week
1520786|NCT02811146|Other|Heart rehabilitation|Heart rehabilitation, for 12 weeks, 3 times a week
1520787|NCT02811133|Drug|Inositol|Subjects will receive inositol
1520789|NCT02811107|Other|Questionnaires|Completion of questionnaires on tablet computers in the preoperative area by 6 nurse anesthetists, 1 hospital physician and 1 resident physician.
1520790|NCT02811094|Other|polymerase chain reaction (PCR) technique of blood transcriptome analysis|this study (LUMIER2 study) is to test the hypothesis that a test score or prognostic transcriptomic allows to discriminate clinically quiescent or patients who will not present a push of Systemic Lupus Erythematosus
1520791|NCT02811081|Procedure|Passive Deflation|In the control group, residual carbon dioxide gas was evacuated by the routine method using passive exsufflation through the port site at the end of surgery.
1520792|NCT02811081|Procedure|Normal Saline Instillation|In the normal saline instillation group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), isotonic normal saline (20 ml/kg of body weight) was infused in the sub-diaphragmatic region at the end of surgery.
1520793|NCT02811081|Procedure|Normal Saline Instillation + Pulmonary Recruitment|In the combined intervention group, in addition to the routine method, the patients were placed in the Trendelenburg position (30°), and a pulmonary recruitment maneuver was performed after instillation of isotonic normal saline (20 ml/kg of body weight) in the sub-diaphragmatic region at the end of surgery.
1520795|NCT02811055|Biological|Blood sampling|Blood sampling for Plasma aldosterone, Plasma cortisol, plasma renin, plasma electrolytes after before and after administration of Aprepitant 80 mg once per day during 14 days or Administration of placebo once per day during 14 days
1520796|NCT02811055|Procedure|Blood Pressure Measurement|Blood Pressure Measurement before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
1520797|NCT02811055|Device|electrocardiogram|Electrocardiogram before and after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
1520798|NCT02811055|Procedure|orthostatic test|Orthostatic test after Administration of Aprepitant 80 mg once per day during 14 days or administration of placebo once per day during 14 days
1520799|NCT02811055|Drug|Administration of Aprepitant|Administration of Aprepitant 80 mg once per day during 14 days
1520800|NCT02811055|Drug|Administration of placebo|Administration of placebo once per day during 14 days
1520801|NCT02811042|Device|Ambu AuraOnce|Oropharyngeal leak pressure was determined by closing the expiratory valve of the anaesthesia breathing system and a fixed gas flow of 3 l minute-1. The airway pressure at which an equilibrium was reached was noted (maximum allowed 40 cm H2O).
1520802|NCT02811042|Device|Ambu AuraGain|The airway tube view was scored using an established scoring system (4=only vocal cords visible; 3=vocal cords plus posterior epiglottis; 2=vocal cords plus anterior epiglottis; 1=vocal cords not seen)
1520803|NCT02811029|Behavioral|measurement of phonology|measurement of phonology will be assess using BILO-3, EDA, VS and VL tests
1520804|NCT02811016|Drug|Budesonide 200|200 µg inhaled at 7:00 a.m. and 7 p.m.
1520805|NCT02811016|Drug|Budesonide 800|800 µg inhaled at 7:00 a.m. and 7 p.m.
1520806|NCT02811016|Drug|Placebo|Placebo Inhalation at 7:00 a.m. and 7 p.m.
1520808|NCT02810990|Drug|Bosutinib|"Bosutinib is given orally accordingly with this scheme:
A. 200 mg OD: starting dose (wash-in period) at week 1 and week 2 B. 300 mg OD: from week 3 to the end of week 16
At the end of week 12 evaluation of molecular response (BCR-ABL1 level by RT-Q-PCR).
Bosutinib dose is then managed as follows :
C1. if BCR-ABL1 ≤1% at week 12: 300 mg OD from week 17 to week 52 C2. if BCR-ABL1 > 1% at week 12: 400 mg OD from week 17 to week 52
All the responsive patients who are still on Bosutinib at the end of week 52, will continue Bosutinib at the same dose (300 mg OD or 400 mg OD) for the next two years ( if tolerated and in absence of safety concerns)."
1520809|NCT02810977|Device|Ultrasound|Ultrasound assessment of gastric content and volume
1520810|NCT02810964|Drug|Sulforaphane Nutraceutical|Sulforaphane Nutraceutical 6 tablets by mouth daily
1520811|NCT02810964|Drug|Identical-appearing Placebo|Identical-appearing Placebo 6 tablets by mouth daily
1520812|NCT02810951|Genetic|FCX-007|FCX-007 is a genetically modified cell product obtained from the subject's own skin cells (Autologous fibroblasts). The cells are expanded and genetically modified to produce functional collogen VII. After expansion, the cells are frozen and when ready for use are thawed and prepared for injection. FCX-007 cell suspension is injected intradermally.
1520813|NCT02810951|Drug|Sterile Saline|In Phase II (subjects 7 through 12), FCX-007 treated wounds will be compared to wounds administered sterile saline
1520814|NCT02810938|Device|Ablation of atrial flutter|Ablation of atrial flutter using IntellaTip Mifi 8 mm technology in combination with Maximum voltage-guided ablation approach
1520815|NCT02810925|Procedure|PENS T6|Patients undergo percutaneous electrical stimulation of dermatome T6, weekly, during 12 weeks.
1520816|NCT02810925|Procedure|TENS T11/T12|Patients undergo transcutaneous electrical stimulation of dermatomes T11-T12, weekly, during 12 weeks.
1520817|NCT02810925|Dietary Supplement|Hypocaloric 1200 Kcal/day diet|Patients follow a Hypocaloric 1200 Kcal/day diet during 12 weeks.
1520818|NCT02810925|Dietary Supplement|Normocaloric 2000 Kcal/day diet|Patients follow a Normocaloric 2000 Kcal/day diet during 12 weeks.
1520819|NCT02810912|Other|the effect of surgical position|Investigators do not have intervention in the observation study. Investigators only use the MII-pH catheter to observe the episodes of gastric regurgitation in patients receiving supraglottic airway device under general anesthesia. Thus, investigators are going to observe the effect of surgical position change, body weight, surgical time. And investigators will have a control group, which patients undergo elective surgeries without surgical position change, no longer surgical time, and normal range of body weight.
1520820|NCT02810899|Drug|dexmedetomidine|A loading dose dexmedetomidine (0.5 ug/kg IV infused in 15 minutes) will be administered after anesthesia induction, followed by a continuous infusion at a rate of 0.5 ug/kg/h until the closure of the brain duramater at the end of surgery.
1520821|NCT02810899|Drug|normal saline|Normal saline will be administered in the same rate, volume and duration as that in the dexmedetomidine group
1520822|NCT02810886|Drug|68Ga-(HBED-CC)-PSMA|68Ga-PSMA-ligand intravenous administration duration is around one minute. Once the patient is injected, the tracer needs 60 minutes to be evenly distributed through the body. PET/CT images will then be performed.
1520827|NCT02810860|Procedure|Laparoscopic cholecystectomy|Administration of a disease-specific and generic PROMs survey to patients undergoing Laparoscopic Cholecystectomy
1520828|NCT02810847|Device|I-Bit plus|The study will treat amblyopia (lazy eye) using 3-D computer technology and active shutter glasses. Computer games and DVD's are viewed through the active shutter glasses and are specially prepared to preferentially stimulate the lazy eye; the child can only play the game accurately if they are using their lazy eye.
1520829|NCT02810834|Behavioral|Walking/Running program|"Participants will receive a behavioral intervention that consists of a school-based, walking/running/jogging program. Participants work to accumulate miles towards a goal of at least 100 miles, over the course of the school year. Program will be implemented through a champion in the school and structured/scheduled according to the schools resources (before, during, or after school). Miles are tracked at the school level, and incentives are provided for participants' completion of set milestones (25, 50, 75, and 100 miles).
The intervention will run over two school years (approximately 16 months)"
1520830|NCT02810834|Behavioral|Classroom physical activity break program|"Participants will receive a behavioral intervention that consists of a classroom-based, physical activity break program. Classroom teachers, paraprofessionals, and other school staff will lead short (5-15 minute) activity breaks that include both higher intensity (ex. jumping jacks, squats) and low-intensity (ex. stretching, yoga) activities. Classrooms will be encouraged to integrate at least one short break per day. Activities are connected to national Common Core academic standards so that breaks can be integrated with academics.
The intervention will run over two school years (approximately 16 months)"
1520831|NCT02810808|Procedure|1+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the injection of the same does at the first month.
1520832|NCT02810808|Procedure|3+PRN|PRN intravitreal injections of Ranibizumab 0.5mg guided by BCVA stabilization after the first three monthly intravitreal injections of the same does.
1520833|NCT02810808|Drug|Ranibizumab|Ranibizumab — a recombinant, humanized monoclonal antibody Fab that neutralizes all active forms of VEGF-A was recently approved by the Food and Drug Administration for the treatment of all angiographic subtypes of subfoveal neovascular age-related macular degeneration
1520834|NCT02810795|Other|Diagnostic detection of coronary artery disease|Myocardial perfusion defect on dynamic CT perfusion imaging, and diagnostic accuracy as compared invasive FFR.
1520835|NCT02810782|Drug|Phenobarbital|Phenobarbital per os
1520836|NCT02810782|Drug|Chlorpromazine|Chlorpromazine per os
1520837|NCT02810782|Drug|Morphine|Morphine per os
1520838|NCT02810769|Dietary Supplement|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
1520839|NCT02810769|Dietary Supplement|Control|Sugar matched control containing berry flavouring and no phytochemicals
1520840|NCT02810769|Dietary Supplement|Powdered berry drink|Berry drink made from a powder concentrate standardised to contain 500mg of polyphenols
1520841|NCT02810756|Drug|New Pazopanib formulation|
1520842|NCT02810743|Drug|ddAC-CP-Olaparib|ddAC-CP-Olaparib
1520843|NCT02810743|Drug|ddAC-mini CTC|ddAC - mini CTC
1520844|NCT02810730|Procedure|Pancreatic MRI|Pancreatic MRI in the 6 months following the first consultation
1520845|NCT02810717|Device|theta-burst stimulation using a MagPro X1000|TBS over left and right dorsolateral prefrontal cortex for a period of three weeks. iTBS over left DLPFC: 3-pulse 50 Hz bursts will be given every 200ms (at 5 Hz) in 2-second trains with an inter-train interval of 8 seconds. Trains will be repeated 20 to reach a total number of 600 pulses per session. cTBS over right DLPFC: cTBS will comprise uninterrupted bursts to reach a total number of 600 pulses per session. Two sessions per day, separated by 60 minutes; 30 Sessions in total over 3 weeks.
1520846|NCT02810717|Device|sham stimulation using a MagPro X1000|Sham TBS with the coil set at 45° against the skull will be performed over left and right dorsolateral prefrontal cortex for a period of three weeks
1520847|NCT02810704|Drug|Enteric Coated Aspirin|
1520848|NCT02810704|Drug|Warfarin|
1520849|NCT02810704|Drug|Rivaroxaban|
1520850|NCT02810691|Dietary Supplement|Soluble fiber supplementation|Two different doses of psyllium powder will be diluted in 250 ml of orange-flavored water and drink in 5 minutes before breakfast.
1520851|NCT02810691|Dietary Supplement|Placebo (for fiber supplementation)|Placebo will consist of 250 ml of orange-flavored water to be drink in 5 minutes before breakfast.
1520852|NCT02810678|Other|Latent Tuberculosis Infection program evaluation & diagnosis|
1520853|NCT02810665|Behavioral|Visual acuity measurement by ETDRS chart|All participants must complete VA measurement of the study eye using 3 charts including the original ETDRS alphabet, ETDRS Landolt C, and ETDRS numeric charts for 2 times, at least 30 minutes apart.
1520854|NCT02810652|Other|Usual Care|Usual Care participants will not meet with a geriatric clinician perioperatively, though they may receive a geriatric consult at their request or at the discretion of their treating cancer team.
1520855|NCT02810652|Other|Perioperative Geriatrics Intervention|Patients randomized to the perioperative geriatrics intervention will undergo evaluation with a board-certified Massachusetts General Hospital (MGH) geriatric clinician, both pre- and post-operatively. The geriatric clinician visits will focus on the following issues: comorbidity, polypharmacy, nutrition, physical and mental function, and social support.
1520892|NCT02810314|Other|resting state functional magnetic resonance image (rs-fMRI)|rs-fMRI
1521095|NCT02808975|Drug|Adalimumab|Weekly subcutaneous injection
1521096|NCT02808975|Drug|Placebo|Weekly subcutaneous injection
1520856|NCT02810626|Device|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.
BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.
BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
1520857|NCT02810600|Other|Gallium-68 DOTA TATE PET scan|One PET/CT scan using Gallium-68 DOTA TATE
1520858|NCT02810587|Drug|Topical antibiotics following injection|Either receive or not receive topical antibiotics following intravitreous injection
1520859|NCT02810574|Behavioral|Cognitive training|
1520860|NCT02810574|Device|Noninvasive brain stimulation (active)|Neuroconn DC-STIMULATOR PLUS
1520861|NCT02810574|Device|Noninvasive brain stimulation (sham)|Neuroconn DC-STIMULATOR PLUS
1520862|NCT02810561|Other|No Intervention|No intervention was completed with this study.
1520863|NCT02810548|Procedure|OFD alone|Periodontal surgical cleaning procedure
1520864|NCT02810548|Drug|Platelet rich Fibrin|Natural platelet concentrate rich in growth factors
1520865|NCT02810548|Drug|Nanohydroxyapatite|Synthetic bone graft
1520866|NCT02810535|Other|Observation|"Visit 1:
Physical examination (inspection of nasopharynx, auscultation of heart and lungs)
Completion of a Health Questionnaire
Lung function testing with spirometry
Skin prick test
Visit 2:
Physical examination (inspection of nasopharynx, auscultation of heart and lungs)
Measurement of nitric oxide in expired air (FeNO)
Taking nasal secretion samples with a cotton carrier for 15 min
Nasal provocation test with dust mite
Blood sample collection to define blood count, IgE and specific IgE"
1520867|NCT02810522|Device|OneTouch Select® Plus Glucose Test Strips|
1520868|NCT02810496|Genetic|blood collection for mutation characterization|
1520869|NCT02810483|Drug|Topiramate|"Increase phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.
Dose of study:
200mg for 5 weeks.
Decrease phase:
The 9th week, 100mg for 4 days then 50mg for 3 days."
1520870|NCT02810483|Drug|Placebo Comparator|"ncrease phase. The starting dose is 50 mg / day with gradual increase in dose to 50 mg / week until the end of the 3rd week.
Dose of study:
200mg for 5 weeks.
Decrease phase:
The 9th week, 100mg for 4 days then 50mg for 3 days."
1520871|NCT02810470|Dietary Supplement|Fortimel Compact Protein|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
1520872|NCT02810470|Dietary Supplement|Fortimel Cream|Each product will be tested by all patients spread over 2 days. A first half of volunteers will start the testing process with the beverages at day 1 and continue with the creams at day 2. The second half of volunteers will process inversely (day 1 = creams, day 2 = beverages). The test order of flavors will be randomly allocated to the volunteers among the list of all possible combinations.
1520873|NCT02810457|Drug|FKB238 (bevacizumab)|
1520874|NCT02810457|Drug|Avastin (bevacizumab)|
1520875|NCT02810457|Drug|Paclitaxel|
1520876|NCT02810457|Drug|Carboplatin|
1520877|NCT02810444|Biological|BT595|
1520880|NCT02810392|Drug|Intranasal Insulin|Delivery is with the Vianase device, 20 IU twice daily for 3 weeks.
1520881|NCT02810392|Drug|Intranasal saline|Delivery is with the Vianase device, 0.5 cc of normal saline
1520882|NCT02810379|Procedure|written informed consent|
1520883|NCT02810379|Procedure|video+written informed consent|
1520884|NCT02810366|Other|Physician versus Computer Coded Verbal Autopsy|Comparing the performance of computer coded verbal autopsies (CCVA) to physician coded verbal autopsies (PCVA) at the population level.
1520885|NCT02810353|Device|Differential rapid maxillary expansion|Twenty-five patients will be submitted to rapid maxillary expansion using the expander with differential opening. Appliance anchorage will be provided by bands adapted either on the maxillary first permanent molars or on the second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. If the maxillary second deciduous molars will be banded, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars. Both anterior and posterior screws will be activated with a complete turn a day during 6 days. Then, only the anterior screw will be additionally activated for 4 more days. After the active period of RME, the screws will be fixed with acrylic resin and the appliance will be kept as a retainer for 6 months.
1520886|NCT02810353|Device|Conventional rapid maxillary expansion|Twenty-five patients will undergo rapid maxillary expansion using conventional Hyrax expander. Bands will be adapted either on the maxillary first permanent molars or on second deciduous molars and circumferential clamps will be bonded to the maxillary deciduous canines. Similarly to the experimental group, a lingual extension wire will be placed in the partially erupted maxillary first permanent molars if the maxillary second deciduous molars will be banded. The expander screw will be activated with a complete turn a day during 6 days. After the expansion active phase, the screw will be fixed with acrylic resin and the appliance will be kept in the dental arch as a retainer for 6 months.
1520887|NCT02810340|Biological|MCV-5 with adjuvant|
1520888|NCT02810340|Biological|MCV-5 without adjuvant|
1520889|NCT02810340|Biological|Menactra|
1520890|NCT02810327|Genetic|Genetic Sequencing|Sequencing of the SERPINA1 gene
1520891|NCT02810314|Behavioral|neuropsychological battery|neuropsychological battery including cognitive and behavioural tests
1520893|NCT02810301|Other|Probiotic ES1|B. longum ES1 is formulated for oral use as Glutagest. Each capsule contains 1 billion CFU of B. longum. The capsules are off-white in color and cylindrical in shape with approximate dimensions of 19 mm x 6.63 mm and a weight of 500 mg. Non-medicinal ingredients consist of the common excipients filler rice maltodextrin, lubricant stearic acid, and encapsulating agent vegetable cellulose.
1520894|NCT02810301|Other|Placebo|The placebo is composed of the same non-medicinal ingredients as the investigational product (IP) (i.e. rice maltodextrin, stearic acid, and vegetable cellulose) but it does not contain the active ingredient B. longum ES1. The placebo is designed to resemble the IP in terms of physical appearance.
1520895|NCT02810288|Behavioral|Voluntarily response all items in the questionnaire.|"The study type is a cross-sectional study, by means of electronic self-administered survey as online questionnaire sent by e-mail.
The questionnaire for the survey was developed with reference to previously published guidelines on the design of questionnaire surveys. The content validity of the questionnaire was verified by review of clinicians not participating into the project and by a statistician."
1520896|NCT02810275|Drug|Folinic Acid|Folinic acid 5 mg, taking in the morning, daily, during four weeks
1520897|NCT02810275|Drug|Placebo|Placebo capsule received 1 tablet, taking in the morning, during four weeks
1520898|NCT02810262|Other|Bone metastases biopsy|The vast majority of bone biopsy are performed under CT-scan. In some rare cases, the histology will be performed during surgery (either biopsy of the bone metastasis or surgical piece when treating a fracture).
1520899|NCT02810249|Other|No intervention used|
1520900|NCT02810236|Procedure|Ultrasound|Ultrasound will be performed.
1520901|NCT02810236|Behavioral|Discussion|Radiologist will discuss with the patient the findings on mammogram.
1520902|NCT02810223|Biological|CART-19|2 to 5 x 10(6) autologous CART-19 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
1520903|NCT02810210|Other|fundus examination|"In cohort 3, a fundus examination will be carried in addition to the current medical practice.
This exam is part of current medical practice for other groups."
1520904|NCT02810210|Other|Head ultrasound|"In cohort 3, a head ultrasound will be carried in addition to the current medical practice.
This exam is part of current medical practice for other groups."
1520905|NCT02810197|Behavioral|Psychopathological assessment|
1520906|NCT02810197|Behavioral|Neuropsychological assessment|
1520907|NCT02810197|Device|Functional magnetic resonance imaging (fMRI)|
1520908|NCT02810184|Radiation|cone-beam computed tomography (CBCT)|additional CBCT scan at 24 and 36 months, for analysis of evolution of bone volume
1520909|NCT02810171|Behavioral|Cognitive Behavioral Therapy|A therapy which teaches patients coping skills to manage anxiety and gradually yet repeatedly exposes patients to anxiety-provoking thoughts and situations until the anxiety habituates/diminishes.
1520910|NCT02810171|Behavioral|Relaxation Therapy|An active control therapy with minimal effects on anxiety symptoms. If randomized to this therapy, participants will have the option to cross-over to CBT once the relaxation therapy arms has been completed.
1520911|NCT02810132|Drug|Metformin|
1520912|NCT02810132|Drug|Placebo|
1520915|NCT02810093|Other|retrospective medical records analyze|Ten thousand medical records (between years 2000 and 2016) will be analyzed
1520916|NCT02810067|Procedure|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
1520917|NCT02810067|Procedure|Tunnel + NovaDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (NovaDerm®).
1520918|NCT02810054|Procedure|Minimally Invasive Surgical Techniques (MIST)|Using minimally invasive surgical techniques.
1520919|NCT02810054|Procedure|Enamel Matrix Derivative (EMD)|Use of enamel matrix derivative for the treatment of intrabony periodontal defects.
1520920|NCT02810041|Dietary Supplement|yoghurts enriched with XXS|
1520921|NCT02810041|Dietary Supplement|yoghurts non enriched with XXS|
1520923|NCT02810015|Drug|Botulinum Toxin Type A|BTX-A will be reconstituted as directed by the manufacturer. 2.5 mL of diluent (0.9% Saline) per 100 U vial will be used to reconstitute the solution while swirling. This creates a solution with a concentration of 4 U/0.1 mL. Patients will be seated and all usual precautions of sterility and skin preparation will be completed (i.e. alcohol wipes) Injections will be administered unilateral and/or bilaterally in accordance with the topography of the corresponding muscles (temporalis and masseter) into areas of maximal tenderness and pain. Plastic single use insulin syringes with 30 gauge needles will be used to inject 30 U intramuscularly into each masseter, divided evenly into 5 sites and 20 U will be injected into each temporalis, divided evenly over 5 sites. Injections will be completed by the principal investigator and supervisors who will be trained in botulinum toxin injections.
1520924|NCT02810002|Device|Experimental infantry boot - DEFINITE-REGULATOR|Training: infantry basic training in the experimental boots
1520925|NCT02810002|Device|Control infantry boot|Training: infantry basic training in the control boots
1520927|NCT02809976|Drug|Ruxolitinib 1.5% Phosphate Cream|twice daily topical application of Ruxolitinib 1.5% Phosphate Cream beginning at baseline and ending at week 20
1520928|NCT02809963|Drug|Eplerenone|50 mg tablets, oral use.
1520929|NCT02809963|Drug|Placebo|50 mg tablets, oral use
1521132|NCT02808572|Biological|Plasma fibroblast growth factor 23 level|dosage of plasma fibroblast growth factor 23
1521180|NCT02808143|Biological|Pembrolizumab|Given intravesically
1520930|NCT02809950|Other|oral carbohydrate beverage|oral carbohydrate beverage (12.8% carbohydrates, 50 kcal/100ml, 290 mOsm/kg, NO-NPO®, Daesang WelLife Co., Ltd., Korea) 400ml in the evening of the day before surgery and at 6 am on the day of surgery, respectively
1520931|NCT02809950|Other|control group|NPO from midnight of the day before surgery
1520932|NCT02809937|Drug|dexmedetomidine|low-dose dexmedetomidine infusion
1520933|NCT02809937|Drug|placebo|normal saline infusion
1520934|NCT02809924|Other|Simulation-based just-in-time training|Video and low fidelity simulation (Laerdal® Neonatal Intubation Trainer, Laerdal Medical, Toronto, Canada)
1520935|NCT02809924|Other|Video training|Video describing endotracheal intubation
1520936|NCT02809911|Device|Provant|
1520937|NCT02809898|Procedure|surgery or biopsy|Do radical surgery or biopsy to obtain a pathological result
1520938|NCT02809885|Biological|Hepatitis E serology|
1520939|NCT02809872|Other|Diagnostic Thoracic Ultrasound|
1520940|NCT02808754|Procedure|Remote Ischemic Preconditioning|Those randomized to RIPC will undergo a standard protocol of 4 cycles of 5 minutes of forearm ischemia with 5 minutes of reperfusion requiring 35 minutes for an application. Forearm ischemia will be induced by a blood pressure cuff inflated to 200mmHg or at least 15mmHg higher than the systolic pressure if systolic > 185mmHg or until the radial pulse is obliterated. This can occur during anesthesia induction and incision/dissection prior to manipulation or clamping of the carotid.
1520941|NCT02808741|Drug|F901318 SDD|Pharmacokinetics area under curve
1520942|NCT02808741|Drug|F901318 IR|Pharmacokinetics area under curve
1520943|NCT02808741|Drug|F901318 IR Fasting|Pharmacokinetics area under curve
1520944|NCT02808741|Drug|F901318 IR Fed|Pharmacokinetics area under curve
1520945|NCT02808728|Drug|Pain Cocktail with Exparel|pain cocktail: bupivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 80cc preparation as well as an injection of Exparel (bupivacaine liposome injectable suspension), 20cc of 1.3% Exparel, to total 100cc.
1520946|NCT02808728|Drug|Pain Cocktail with Ropivacaine|pain cocktail: ropivacaine, ketorolac, morphine, and epinephrine mixed with saline into a 100cc preparation.
1520947|NCT02808715|Other|Blood Sample Collection|Blood draw #1 Site of blood draw: IMU Volume of blood: 20mL Purpose of blood draw: Isolation of genomic DNA Site of storage: NHRIS biobank Coding: Specimens will be identified using a research ID that will be affixed to samples using bar-coding. After the blood is collected, stored the blood at 4 degree Celsius and contact the NHCS biobank coordinator to collect the blood samples. The blood samples must be collected within 1 hour of collection.
1520948|NCT02808702|Behavioral|Cognitive-behavioral therapy|Twelve weekly sessions of individual cognitive-behavioral therapy
1520949|NCT02808689|Behavioral|Lifestyle Factors|Will look at nutrition and exercise that influence long-term health and chronic diseases.
1520950|NCT02808689|Other|Customized use of Dietary Supplements|Reduce ongoing biologic imbalances from deficiencies in dietary oxidants/ antioxidants via vitamin supplementation. Approach is customized based on results for laboratory testing.
1520951|NCT02808689|Other|Currently Accepted Asthma Care Guidelines|Use of asthma care guidelines set forth by the National Institutes of Health/National Heart, Lung and Blood Institute (NIH/NHLBI) and Global Initiative for Asthma
1520952|NCT02808676|Dietary Supplement|Vitamin D3|Dose: 10000 IU, three times per week, orally.
1520953|NCT02808676|Other|Exercises (E)|All participants will complete three (3) group training sessions per week (total 20 weeks), under the supervision of trainers. Each exercise session will last approximately 60 minutes and will happen after the cognitive training/control (CT cCT) session. The exercise session will be a combined aerobic and progressive strengthening exercise. Within each small group of four to eight individuals, participants follow the program tailored to their individual functioning level, with constant monitoring by the trainers. Participants are expected to attend all training sessions and research staff will strongly encourage them to do so.
1520954|NCT02808676|Other|Cognitive Training (CT)|CT intervention will involve computer-based multimodal and multi-domain dual-task training with memory load. A custom-written program, developed for neuro-rehabilitation and used in previous research trials for cognitive and mobility outcomes will be used. Training sessions will take place in groups of four to eight participants before each of the fitness-training session for duration of 30 min max. Participants will perform a concurrent visuo-motor task (dual-task combination) composed of different sets of visual stimuli that have to be identified by tapping designated figures on an digital tablet (IOS or Android system). Participants will perform discrimination tasks involving sets of items (e.g. letters, numbers, animals, vehicles, fruits, celestial bodies).
1520955|NCT02808676|Other|placebo D3|matching placebo for Vitamin D3
1520956|NCT02808676|Other|control cognitive training|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 30 min computer skills training.
1520957|NCT02808676|Other|Placebo exercise|As a control activity to ensure the same time exposure as in the interventions arms, participant in the control arm will receive a 60 min of a tone exercise regimen
1520958|NCT02808663|Biological|fecal calprotectin concentration|
1520959|NCT02808663|Biological|blood collection|
1520960|NCT02808650|Other|Laboratory Biomarker Analysis|Correlative studies
1520961|NCT02808650|Other|Pharmacological Study|Correlative studies
1520962|NCT02808650|Drug|Prexasertib|Given IV
1520963|NCT02809846|Device|Quell|
1520964|NCT02809846|Device|Sham Quell|
1520965|NCT02809833|Drug|Tocilizumab|Tocilizumab must be selected by the treating physician in advance of the study and will be not provided by the Sponsor. The dose/regimen are at the discretion of the prescriber. However, tocilizumab in the SmPC is specified as 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion at 4-week intervals.
1520966|NCT02809820|Drug|Carvedilol|Patients randomized to this group will receive carvedilol at the highest dose tolerated
1520967|NCT02809820|Drug|Metoprolol|Patients randomized to this group will receive metoprolol at the highest dose tolerated
1521084|NCT02809040|Other|Portable digital auscultation|"Traditional Stethoscope :An acoustic medical device for auscultation, or listening to internal sounds of human body.
Digital Stethoscope :Electronic stethoscope is a passive heart sound recording device. The heart sound listening and recording will be performed by trained personnel in a way very similar to that of using conventional cardiac auscultation"
1521085|NCT02809027|Drug|Ginger|
1520968|NCT02809807|Other|measurement of the work of breathing|We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Comfort has also been assessed. FreeO2 System has been used and pre-programmed in accordance with the patient SpO2 target zone for potential correction of the hypoxemia occurrences. Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
1520969|NCT02809807|Device|Gas Mask|Differences among randomized conditions are one without gas mask as for the baseline and two with gas masks but different canisters.
1520970|NCT02809794|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
1520971|NCT02809781|Biological|Intravenous infusion of MSCs|Intravenous infusion of MSCs:Human bone marrow-derived MSCs 1.0E+6 MSC/kg, IV drop
1520972|NCT02809781|Drug|Etanercept|50mg,hypodermic injection,once per week, for 12 weeks
1520973|NCT02809768|Drug|Avatrombopag|
1520974|NCT02809768|Drug|Fluconazole|
1520975|NCT02809768|Drug|Itraconazole|
1520976|NCT02809768|Drug|Rifampin|
1520977|NCT02809755|Drug|4% Lidocaine|
1520978|NCT02809755|Other|Saline|
1520979|NCT02809742|Drug|Ropivacaine|Epidural : automatic intermittent boluses associated with patient controlled bolus using ropivacaine
1520984|NCT02809716|Other|Biomarker Analysis|Correlative studies
1520985|NCT02809716|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue samples
1520987|NCT02809690|Device|CAT|Undergo 18F-FMAU PET/CT
1520988|NCT02809690|Drug|18F-FMAU|Patients receive radiotracer F 18 d-FMAU IV over 1 minute and then undergo 18F-FMAU PET/CT
1520989|NCT02809690|Other|Laboratory Biomarker Analysis|Correlative studies
1520990|NCT02809690|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo mpMRI
1520991|NCT02809690|Device|Positron Emission Tomography|Undergo 18F-FMAU PET/CT
1520992|NCT02809690|Device|Ultrasound|Undergo TRUS-guided biopsy
1520993|NCT02809677|Drug|Escitalopram|Escitalopram (ESC) for the Major Depressive Disorder (MDD). Dose titration schedule: begin at Week 1 at 5mg PO QD for 4 weeks. Increase to 10mg PO QD at Week 4 (if needed). Increase to 20mg PO QD at Week 8 (if needed).
1520994|NCT02809677|Drug|Venlafaxine XR|Venlafaxine Extended Release (VEN XR) for the Major Depressive Disorder (MDD). Dose titration schedule: begin at Week 1 at 75mg PO QD for 4 weeks. Increase at Week 4 to 150mg PO QD (if needed). Increase at Week 8 to 300mg PO QD (if needed).
1520995|NCT02809677|Drug|Bupropion XR|Bupropion Extended Release (BUP XR) for the Major Depressive Disorder (MDD). Dose titration schedule: begin at Week 1 at 150mg PO QD for 4 weeks. Increase at Week 4 to 300mg PO QD (if needed). Increase at Week 8 to 450mg PO QD (if needed).
1520996|NCT02809677|Drug|Sertraline|Sertraline (SERT) for the Major Depressive Disorder (MDD). Dose titration schedule: begin at Week 1 at 50mg PO QD for 4 weeks. Increase at Week 4 to 100mg PO QD (if needed). Increase at Week 8 to 200mg PO QD (if needed).
1520997|NCT02809677|Drug|Mirtazapine|Mirtazapine (MIRT) for the Major Depressive Disorder (MDD). Dose titration schedule: begin at Week 1 at 15mg PO qHS for 4 weeks. Increase at Week 4 to 30mg PO qHS (if needed). Increase at Week 8 to 45mg PO qHS (if needed).
1520998|NCT02809677|Drug|Buspirone|"Buspirone (BUSP) as an augmenting agent for the Major Depressive Disorder (MDD).
Dose titration schedule: begin at Week 24 of the study (if needed) at 10mg PO QD for 3 days, then 10mg PO BID for 4 weeks. Increase at Week 28 (if needed) to 15mg PO BID. Increase at Week 32 (if needed) to 20mg PO BID."
1520999|NCT02809677|Drug|Quetiapine|"Quetiapine (QUET) as an augmenting agent for the Major Depressive Disorder (MDD).
Dose titration schedule: begin at Week 24 of the study (if needed) at 25mg PO qHS for 4 weeks. Increase at Week 28 (if needed) to 50mg PO qHS. Increase at Week 32 (if needed) to 100mg PO qHS."
1521000|NCT02809677|Drug|Aripiprazole|Aripiprazole as an augmenting agent for the Major Depressive Disorder (MDD) for non-response patients at Week 48 of study. Dose titration schedule: begin at Week 48 (if needed) at 2mg PO QD for 4 weeks.
1521001|NCT02809677|Drug|Lithium|Lithium as an augmenting agent for the Major Depressive Disorder (MDD) for non-response patients at Week 48 of study. Dose titration schedule: begin at Week 48 (if needed) at 300mg PO qHS for 4 weeks.
1521002|NCT02809651|Device|Infrascanner|bilateral measurement cerebral blood flow with near infrared spectroscopy using the Infrascanner on the frontal, temporal, parietal and occipital region of the head.
1521003|NCT02809638|Other|ultrasound elastography|
1521004|NCT02809612|Behavioral|Internet-based platform|Internet-based platform with information and training modules based on acceptance and commitment therapy for vulvodynia patients
1521086|NCT02809027|Drug|Placebo|
1521087|NCT02809014|Other|Dentifrice F-Complex|Use of few of dentifrice on brushing for one week, twice day.
1521088|NCT02809014|Other|Dentifrice F-Complex + NaF|Use of few of dentifrice on brushing for one week, twice day.
1521089|NCT02809014|Other|Dentifrice standard|Use of few of dentifrice on brushing for one week, twice day. It's for the positive control of fluoride
1521090|NCT02809014|Other|Dentifrice with tara gum|Use of few of dentifrice on brushing for one week, twice day. It's for analysis of negative control of fluoride and action only of tara gum.
1521005|NCT02809599|Behavioral|DIZZTINCT|The intervention, DIZZTINCT, is a multi-faceted educational and care-process based intervention designed to improve the guideline-concordant care of patients with BPPV in the emergency department. The intervention includes six main components: the recruitment and training of local champions who will serve as colleague experts in the community; interactive hands-on educational sessions that address BPPV mechanisms, evidence and practice; a high-yield decision-aid web application for self study and point of care use; development of a referral network for follow up care; follow-up educational sessions to review successes and barriers amongst the intervention group; and other resources developed locally in partnership with the community medical providers.
1521006|NCT02809586|Behavioral|SMI + I|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. Participants will earn incentives for interaction during the intervention (8 weeks).
1521007|NCT02809586|Behavioral|SMI|This 8-week social media based intervention consists of e-coaches delivering positive content to facilitate peer interaction. This group will NOT receive incentives for their participation in the secret group.
1521008|NCT02809573|Drug|Chidamide|In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.
1521009|NCT02809573|Drug|cyclophosphamide|On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m^2 in 5 minutes after chidamide administration
1521010|NCT02809573|Drug|adriacin|On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m^2 soon after cyclophosphamide administration.
1521011|NCT02809573|Drug|vincristine|On Day 1, vincristine is given in IV infusion at 1.4 mg/m^2 after adriacin administration.
1521012|NCT02809573|Drug|prednisone|On Day 1 to 5, prednisone is given orally at 100 mg once a day
1521013|NCT02809560|Procedure|Induced sputum method using hypertonic serum|Collection of expectoration in sterile vial, conserved in ice all along the examination
1521014|NCT02809547|Device|Dried Blood Spot device|
1521015|NCT02809534|Drug|Anlotinib|Anlotinib p.o. qd
1521016|NCT02809521|Other|Activity Liking|
1521017|NCT02809508|Dietary Supplement|Oily fish|A selection of oily fish, including salmon, herring and mackerel, provided for dinner and lunch
1521018|NCT02809508|Dietary Supplement|Poultry|A selection of poultry, mainly chicken, provided for dinner and lunch
1521019|NCT02809495|Other|use of app in smartphone|
1521020|NCT02809482|Other|Eucaloric feeding|3 days of a diet designed to maintain energy balance
1521021|NCT02809482|Other|Overfeeding|3 days of a diet designed to induce a 40% positive energy balance
1521022|NCT02809469|Drug|apixaban dose reduction|Participants taking apixaban 5mg BID will have their dose reduced to 2.5mg BID, and those taking 2.5mg BID will have their dose reduced to 2.5mg once daily (in the morning).
1521023|NCT02809456|Drug|Nicorandil|oral intake
1521024|NCT02809443|Biological|GLS-5700|GLS-5700 contains a single plasmid containing DNA encoding for pre-membrane and envelope (prME) proteins of the Zika virus
1521025|NCT02809430|Device|Continuous Positive Airway Pressure|Auto-titrating Continuous Positive Airway Pressure (APAP) among patients admitted to a rehabilitation unit after ischemic or hemorrhagic stroke for 3 month treatment period.
1521027|NCT02809391|Device|Orthotics alone|The sole thin sport orthotic will be heat moulded to participants footwear. A top cover will be used of similar cushioning thickness and durometer properties as the orthotics+texture intervention.
1521028|NCT02809391|Device|Orthotics+textured top cover|The sole thin sport orthotic will be heat moulded to participants footwear. A textured material will be used as the orthotic top cover in this intervention.
1521029|NCT02809378|Drug|Palonosetron|newly developed 5-HT3 antagonists with long half life (48 hrs) intravenous administration prior to anesthesia induction
1521030|NCT02809378|Drug|sevoflurane|Inhalational anesthetics Halogenated.
1521031|NCT02809378|Drug|remifentanil|ultra-short acting opioid anesthetics
1521032|NCT02809378|Drug|pentothal sodium|intra-venous anesthetics for anesthesia induction
1521033|NCT02809378|Drug|propofol|intra-venous anesthetics for anesthesia induction and maintenance
1521034|NCT02809365|Device|FreeStyle Libre|Addition of FreeStyle Libre system for 10 weeks to the treatment of uncontrolled Type 2 diabetic patients currently on multiple daily injections
1521035|NCT02809365|Device|personal glucometer|Subjects in the Control Group will measure blood glucose levels by personal glucometer (SMBG = self monitoring blood glucose)
1521036|NCT02809352|Biological|Human papillomavirus genotyping|
1521037|NCT02809339|Other|Questionnaires|
1521091|NCT02809001|Procedure|Fat grafting|In the experimental group, liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin.
1521092|NCT02808988|Procedure|periodontal phase 1 therapy|periodontal phase 1 therapy consisted of scaling and root planning with ultrasonic and hand instruments under local anesthesia and gingival crevicular fluid collection by the same investigator.
1521041|NCT02809313|Dietary Supplement|Treatment Gingivitis with Probiotic|gingivitis treatment (scaling and coronary polish) and one sachet containing Lactobacillus rhamnosus SP1 per day during 3 months
1521042|NCT02809313|Other|Treatment Gingivitis conventional|gingivitis treatment (scaling and coronary polish) and one sachet containing Placebo (talc powder) per day during 3 months
1521043|NCT02809300|Biological|blood collection|
1521044|NCT02809287|Procedure|Jackknife posture|patients with left lateral position plus jackknife position when perform laparoscopic hepatectomy
1521045|NCT02809274|Other|questionnaires|• Influence of iron parameters on Patient-reported symptoms as assessed by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS) for assessment of the severity of symptoms, Quality of life evaluation by The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30) and fatigue assessment by PROMIS Fatigue Scale: Short Form
1521046|NCT02809261|Procedure|Ultrasound-guided perineural injection with 5% dextrose|Ultrasound-guided perineural injection with 5% dextrose (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
1521047|NCT02809261|Procedure|Ultrasound-guided perineural injection with normal saline|Ultrasound-guided perineural injection with normal saline (3cc) between proximal carpal tunnel and surrounding median nerve with hydrodissection.
1521048|NCT02809261|Drug|Normal Saline|Normal saline is safe for perineural injection.
1521049|NCT02809261|Drug|5% Dextrose|5% Dextrose could decrease the release of CGRP and substance P to reduce the nerve inflamation.
1521050|NCT02809248|Device|ZES|stent implantation (zotarolimus eluting stent)
1521051|NCT02809248|Device|BMS|stent implantation (bare metal stent)
1521052|NCT02809235|Dietary Supplement|coconut oil|3 tablespoons per day of supplemental coconut oil
1521055|NCT02809196|Behavioral|1: Tailored SMS program implicating friend and mother|
1521056|NCT02809196|Behavioral|2: Standardized SMS program implicating friend and mother|
1521057|NCT02809196|Behavioral|3: Tailored SMS program implicating friend, not mother|
1521058|NCT02809196|Behavioral|4: Standardized SMS program implicating friend, not mother|
1521059|NCT02809196|Behavioral|5: Tailored SMS program implicating mother, not friend|
1521060|NCT02809196|Behavioral|6: Standardized SMS program implicating mother, not friend|
1521061|NCT02809196|Behavioral|7: Tailored SMS program not implicating mother or friend|
1521062|NCT02809196|Behavioral|8: Standardized SMS program not implicating mother or friend|
1521063|NCT02809196|Behavioral|9: No SMS program|
1521064|NCT02809183|Drug|Placebo|oral suspension
1521065|NCT02809183|Drug|TRC101|oral suspension
1521068|NCT02809144|Procedure|Nerve block|Nerve block: 31 ml ropivacaine 7.5 mg/ml (Lateral sagittal infraclavicular brachial plexus block) + 4 ml ropivacaine 5 mg/ml (suprascapular nerve block) + 5 ml ropivacaine 5 mg/ml (superficial cervical plexus block)
1521069|NCT02809131|Drug|polymixin/bacitracin|Antibacterial irrigation
1521070|NCT02809131|Drug|cephalexin, or levofloxacin, or clindamycin|Post operative oral antibiotics
1521071|NCT02809131|Drug|Saline|Saline irrigation
1521072|NCT02809118|Drug|AM-111 0.4 mg/ml|AM-111 0.4 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
1521073|NCT02809118|Drug|AM-111 0.8 mg/ml|AM-111 0.8 mg/mL gel is administered with a single dose into the affected ear after topical anesthesia
1521074|NCT02809118|Other|Placebo|Placebo gel is administered with a single dose into the affected ear after topical anesthesia
1521077|NCT02809092|Biological|NK Cells + Chemotherapy Starting|"Drug: G-CSF G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.
Other Names:
Filgrastim Neupogen Drug: Fludarabine monophosphate 30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.
Other Names:
Fludarabine Phosphate Fludara Drug: Cytarabine 2 g/m^2 by vein on Days -6, -5, -4, -3, and -2.
Other Names:
Ara-C Cytosar DepoCyt Cytosine arabinosine hydrochloride Procedure: Natural Killer (NK) Cell Infusion NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema."
1521078|NCT02809079|Drug|Mycophenolate mofetil|Mycophenolate mofetil 500mg Bid
1521079|NCT02809079|Drug|Prednisone|prednisone 10mg Qd
1521080|NCT02809066|Other|Sufficient dietary calcium intake in premenstrual syndrome|"Intervention group was ensured to take at least 1000 mg calcium from foods, 700-800 mg of it from dairy and dairy products, according to Recommended Dietary Allowances (RDA), for two months. These foods were;
50 gr kashkaval cheese,
400 ml milk and
150 gr yogurt for each day."
1521081|NCT02809053|Biological|SAIT101|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
1521082|NCT02809053|Biological|MabThera®|Dose of 375mg/m2 body surface area (BSA) i.v. on Days 1, 8, 15, and 22
1521083|NCT02809040|Other|Electrocardiogram/Echocardiography|"Electrocardiogram (ECG) is a non-invasive (does not require an incision into the body) test that records the electrical activity of the heart.
Echocardiography is a non-invasive scanning of heart images using standard two-dimensional, three-dimensional, and Doppler ultrasound to create images of the heart."
1521093|NCT02808988|Procedure|gingival crevicular fluid collection|gingival crevicular fluid collection by periopapers
1521094|NCT02808988|Other|zoledronic acid|5 mg/year zoledronic acid (i.v.)
1521097|NCT02808962|Procedure|Cooled RFA of sacral lateral branches|A single target will be identified at the junction of the sacral ala and S1 superior articular process, corresponding to the location of the L5 dorsal ramus. Then, utilizing a stainless steel Epsilon Ruler (Kimberly Clark, Irving, TX, USA), three targets will be localized 8-10 mm lateral to the S1 and S2 posterior sacral foramen at the 2:30, 4:00, and 5:30 positions. Two targets will be localized at the S3 level. Local infiltration with 1% lidocaine and minimal sedation with IV midazolam will be utilized. Once suitable sensory and motor stimulation are verified and impedance is acceptable, each target will be anesthetized with 1 mL of 1% lidocaine prior to each lesion being created at 60 degrees centigrade for 2 minutes and 30 seconds.
1521098|NCT02808949|Drug|Dapivirine|Participants will receive a silicone elastomer vaginal matrix ring containing 25 mg of dapivirine to wear for approximately 14 continuous days. Participants age 18 and over, at least 6 weeks postpartum, able to produce and express breast milk for 14 consecutive days.
1521099|NCT02808936|Procedure|Remote ischemic preconditioning|three cycles of ischemia (5 min) / reperfusion (5 min) of available upper or lower limb with an automated machine using blood pressure cuff
1521100|NCT02808936|Procedure|Sham control|The patients had the same pneumatic cuff around the upper arm and similar maneuvers were performed, but pressure was not applied to the cuff.
1521101|NCT02808923|Other|Foam Rolling|"Participants will perform unilateral hamstring rolling for 2 repetitions of 1 minute with 15 second rest breaks on each leg with a 6x 36 foam roller."
1521102|NCT02808923|Other|Static Stretching|Participants will perform supine static hamstring stretch on a wall for 2 repetitions of 1 minute with 15 second rest breaks on each leg. When the position no longer causes a moderate stretching sensation to the hamstring, subjects will move their bodies closer to the wall to intensify the stretch.
1521103|NCT02808910|Behavioral|Nudged to eat less added salt and more other seasonings|
1521104|NCT02808910|Behavioral|Nudged to avoid foods high in salt content, and to choose foods low in salt content|
1521105|NCT02808910|Behavioral|Nudged to eat more vegetables|
1521106|NCT02808910|Behavioral|Nudged to eat smaller portions|
1521107|NCT02808910|Behavioral|Nudged to eat less calorie-dense food|
1521108|NCT02808897|Device|Standard drainage|One (1) chest tube must be placed in the anterior mediastinum. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 French (FR) to 32 FR shall be used for the single anterior mediastinal chest tube.
1521109|NCT02808897|Device|Active Clearance Technology drainage|One (1) PleuraFlow chest tube must be placed in the anterior mediastinum with one (1) standard chest tube. The other chest tube(s) may be placed at the discretion of the operator. Chest tubes with internal diameter 28 FR to 32 FR shall be used for the single anterior mediastinal chest tube.
1521110|NCT02808884|Genetic|Circulating tumor DNA assay|Blood samples will be separated into plasma and cellular fraction including erythrocytes and buffy coat.The plasma fraction will be placed in a separate tube and frozen for subsequent analysis. Frozen plasma samples, de-identified, will be delivered to Pathway Genomics where DNA content will be analyzed with a circulating tumor DNA assay employing the UBC/Boreal Genomics enrichment technology. All of the participants' plasma will be sent to Pathway, where it will be used up in the assay. Circulating tumor DNA assay results (raw sequencing data) from Pathway Genomics will be returned to UBC and analyzed for the presence of cancer mutations. Any samples showing activating mutations above the assay's technical Limit of Detection (LOD) will be called positive. One exception will be made for TP53 mutations that are known to exist in some normal individuals at low levels. For these mutations, a level of 0.1% will be set, above which the sample will be called positive.
1521111|NCT02808871|Drug|Pirfenidone|Pirfenidone three times daily (2403 mg) for 52 weeks
1521112|NCT02808871|Drug|Placebo|Placebo three times daily for 52 weeks
1521113|NCT02808845|Other|microalbuminuria|
1521114|NCT02808832|Behavioral|Educational materials|5-minute video and information sheet with a list of suggested questions to ask the provider
1521115|NCT02808819|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
1521116|NCT02808819|Biological|Benralizumab|Benralizumab administered subcutaneously every 8 weeks
1521117|NCT02808806|Other|real-time audio-visual feedback|real-time audio-visual feedback to caregivers on TSD (i.e. displaying time, a colour code which will provide an easy-view visualization on whether or not pre-set median time delays between locations are exceeded, and auditory signals indicating the elapsed time), displayed through handhelds and on pre-mounted tablets through the whole trajectory of acute stroke care
1521118|NCT02808793|Drug|AK002|
1521119|NCT02808767|Drug|Prasugrel|Prasugrel 60 mg loading dose and 10mg/5mg once daily maintenance dose
1521120|NCT02808767|Drug|Ticagrelor|Ticagrelor 180 mg loading dose and 90 mg twice daily maintenance dose
1521121|NCT02808637|Other|Manual Pressure|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered in accordance with the conventional injection technique.
1521122|NCT02808637|Other|Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using rapid injection without aspiration technique.
1521123|NCT02808637|Other|Manual Pressure + Rapid Injection without Aspiration|First, the infants were seated on their mothers' knees. Next, 10-second manual pressure was applied on the vaccine injection site. Then DTaP/IPV/Hib was administered by using the rapid injection without aspiration technique.
1521124|NCT02808637|Other|Control|First, the infants were seated on their mothers' knees. Then DTaP/IPV/Hib was administered by using the conventional injection technique.
1521125|NCT02808624|Drug|L-CARNOSINE|L-CARNOSINE is a supplement given with chemotherapy to prevent peripheral neuropathy.
1521126|NCT02808611|Drug|propranolol|Reduction of the ANS response
1521127|NCT02808611|Drug|Placebo|
1521128|NCT02808598|Behavioral|Breast Cancer Clinical Trials Education Program|The purpose of this study is to test a program designed to increase African American and Hispanic American women's scientific literacy, knowledge of clinical trials, and to facilitate breast cancer clinical trial participation.
1521129|NCT02808585|Drug|PB1046 Injection|Four weekly subcutaneous injections of PB1046.
1521130|NCT02808585|Drug|Placebo Injection|Four weekly subcutaneous injections of placebo.
1521131|NCT02808572|Biological|Plasma osteoprotegerin level|dosage of plasma osteoprotegerin
1521133|NCT02808572|Procedure|Vascular calcification score|measurement of vascular calcification score by multidetection computerized tomography
1521134|NCT02808559|Device|Bodystudio ATBM (Automatic Total Body Mapping)|The mapping of the entire body is automatically done using a high-resolution apparatus (20 photographs of the patient in 8 positions (face, back, lateral left and right, specific extremities) The photographs will be done with a standardized procedure established by FotoFinder. Every lesion is completely evaluated and the PASI score can be calculated.
1521135|NCT02808533|Drug|Topiramate|Topiramate capsules starting with 25 mg b.i.d with an incremental increase of 25 mg b.i.d weekly upto a maximum of 100 mg b.i.d.
1521136|NCT02808533|Other|Placebo|Placebo capsules visually identical to those containing topiramate will be administered.
1521137|NCT02808507|Other|Active TB case finding|Active TB case finding (ACF) refers to any number of strategies used to identify individuals with active TB disease, outside of passive case finding. In passive case finding, individuals with symptoms present at health centers for diagnosis. In active case finding, the health system makes an effort to identify TB cases before they present passively.
1521138|NCT02808468|Behavioral|Brief Cognitive Therapy|Cognitive strategies to help achieve balanced thinking around sexual assault and alcohol use
1521139|NCT02808455|Drug|Pacritinib 400 mg Capsule (Treatment A)|Four 100-mg capsules of pacritinib administered as a single oral dose
1521140|NCT02808455|Drug|Pacritinib 80 mg Solution (Treatment B)|A single 80-mg oral solution dose of pacritinib
1521141|NCT02808442|Genetic|UCART19|
1521142|NCT02808429|Drug|Atacicept 25 mg|Subject will receive Atacicept 25 milligram (mg) once weekly as a subcutaneous (SC) injection for 72 weeks.
1521143|NCT02808429|Drug|Atacicept 75 mg|Subject will receive Atacicept 75 mg once weekly as an SC injection for 72 weeks.
1521144|NCT02808429|Drug|Placebo|Subject will receive matching Placebo to atacicept once weekly as an SC injection for 72 weeks.
1521145|NCT02808429|Drug|Atacicept 25 mg|Subject will receive Atacicept 25 mg once weekly as an SC injection for 156 weeks.
1521146|NCT02808429|Drug|Atacicept 75 mg|Subject will receive Atacicept 75 mg once weekly as an SC injection for 156 weeks
1521147|NCT02808429|Drug|Atacicept 150 mg|Subject will receive Atacicept 150 mg once weekly as an SC injection for 156 weeks.
1521148|NCT02808429|Drug|Placebo|Subject will receive matching Placebo to atacicept once weekly as an SC injection for 156 weeks.
1521149|NCT02808416|Biological|Personalized cellular vaccine|"Cancer patients with brain metastases will undergo tumor resection or biopsy, and receive tumor antigen pulsed cellular vaccines.
Other Names:
• Tumor antigen pulsed DC and PBMC, autologous tumor vaccine"
1521150|NCT02808403|Other|No intervention|No intervention; observation of routine medical care
1521151|NCT02808390|Drug|GED-0507-34-Levo 80 mg|GED-0507-34-Levo 80 mg BID for 8 Weeks
1521152|NCT02808390|Drug|GED-0507-34-Levo 160 mg|GED-0507-34-Levo 160 mg BID for 8 Weeks
1521153|NCT02808390|Drug|Placebo|Placebo BID for 8 Weeks
1521154|NCT02808377|Other|Surgical Pelvic Organ Pessary|In participants randomized to intervention, the SPOP will be placed at the completion of surgery, following routine placement of IDC and prior to placement of vaginal pack. The SPOP is available in 4 sizes and the surgeon will select the appropriate size so that the SPOP rests snugly without undue tension inside the hymeneal remnant. The SPOP is sutured in place with 2/0 Vicryl to prevent dislodgement at the level of the hymen.
1521155|NCT02808364|Biological|Personalized cellular vaccine|Patients with recurrent glioblastoma will undergo tumor resection and receive tumor antigen pulsed cellular vaccines.
1521156|NCT02808351|Drug|Berberine|
1521157|NCT02808325|Drug|Gelaspan 4%|Gelaspan 4% combined with Sterofundin ISO
1521158|NCT02808325|Drug|Gelofusine 4%|Gelofusine 4% combined with Sodium Chloride
1521160|NCT02808299|Other|HBV infection history|HBV infection history or HBV carriers
1521161|NCT02808286|Behavioral|Hybrid|The hybrid emotion-focused treatment integrates procedures from exposure and dialectical behavior therapy (DBT) with a clear uniting conceptualization focused on targeting underlying processes that maintain co-occurring chronic pain and emotional problems.
1521162|NCT02808286|Behavioral|internet Cognitive Behavior Therapy (iCBT)|A state-of-the-art CBT pain treatment, delivered via the internet.
1521163|NCT02808273|Drug|Bemiparine|
1521166|NCT02808234|Procedure|One or two level lumbar interbody fusion surgery|One or two level lumbar interbody fusion surgery with allograft derived from human amnion and amniotic fluid.
1521167|NCT02808234|Other|Nucel|Allograft derived from human amnion and amniotic fluid
1521168|NCT02808208|Biological|Adipose Derived Mesenchymal Stem Cells (AMSC)|This group will receive Autologous stem cells derived from own fat biopsy.
1521169|NCT02808195|Other|Constraint-induced therapy|
1521170|NCT02808195|Other|kinect-based unilateral upper limb motor rehabilitation program|
1521171|NCT02808182|Drug|Nicotinic acid|oral administration of nicotinic acid (100mg at 0, 30, 60, 90, 120, 180, 240 and 300 min) to minimize WAT intracellular lipolysis
1521172|NCT02808182|Other|[7,7,8,8-2H]-palmitate|using i.v. administration of [7,7,8,8-2H]-palmitate (in 25% human albumin) from time -60 to +360 min
1521173|NCT02808182|Other|[U-13C]-palmitate|oral administration of [U-13C]-palmitate (0.2 g mixed into the liquid meal) at time 0 min
1521174|NCT02808182|Procedure|Biopsy|A subcutaneous abdominal 0.5-g adipose tissue biopsy will be performed at the end of protocols A0 and A1
1521175|NCT02808182|Other|liquid meal|At time 0, a standard liquid meal (400 mL, 906 kcal, 33g-fat/34g-protein/101g-carbohydrates i.e. 33%/17%/50% calories) will be drunk over 20 minutes
1521176|NCT02808156|Other|unilateral upper limbs intensive training|
1521177|NCT02808156|Other|bilateral upper limbs intensive training|
1521178|NCT02808143|Biological|BCG Solution|Given intravesically
1521179|NCT02808143|Other|Laboratory Biomarker Analysis|Correlative studies
1521181|NCT02808143|Other|Pharmacological Study|Correlative studies
1521182|NCT02808130|Other|hyperlipidemia, periodontitis, gingivitis|GCF samples were collected using periopaper strips. Prior to sample collection, each site was gently air-dried, all supragingival plaque was removed, and the area was carefully isolated to prevent samples from being contaminated by saliva
1521183|NCT02808117|Dietary Supplement|MNP|"Program that delivered MNP and implemented by an MFI in Haiti during 2011-2012.
One form of micronutrient supplementation proven to effectively combat micronutrient deficiency."
1521184|NCT02808104|Drug|mazindol|
1521185|NCT02808091|Drug|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for 4 cycles
1521186|NCT02808091|Drug|GIFOX-Bortezomib|GIFOX-Bortezomib will be given every 21 days for a total of 6 cycles.
1521187|NCT02808091|Radiation|IMRT|a minimum of 50 Gy of IMRT to tumor bed and neck (5 weeks)
1521188|NCT02808078|Device|Gait training with augmented reality|20 sessions (30 min. duration) over 4 weeks of gait training with augmented reality.
1521189|NCT02808078|Device|Standard training|20 sessions (30 min. duration) over 4 weeks of gait training without augmented reality.
1521190|NCT02808065|Drug|Tacrolimus|Administered dose were individualized according to their own prescription
1521191|NCT02808065|Drug|Mycophenolate mofetil|Administered dose were individualized according to their own prescription
1521192|NCT02808052|Drug|Minocin (minocycline) for Injection|200mg IV Minocin given over 1 hour
1521193|NCT02808039|Other|Platelet reactivity testing|assessment of platelet aggregation using the VerifyNow purinergic receptor P2Y, G-protein coupled, 12 (P2Y12) platelet function assay (Accumetrics, San Diego, California)
1521194|NCT02808026|Drug|CS-3150|CS-3150 2.5 to 5mg, orally, once daily after breakfast
1521195|NCT02808013|Drug|NDS-446|
1521196|NCT02808013|Drug|Placebo|
1521197|NCT02808000|Device|BIP Foley (latex) or BIP Foley -silicone|
1521198|NCT02808000|Device|Standard catheter|
1521199|NCT02807987|Drug|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
1521200|NCT02807974|Drug|CS-3150|CS-3150 1.25 to 2.5, 5mg, orally
1521201|NCT02807961|Drug|ELX-02|Synthetic aminoglycoside
1521202|NCT02807961|Drug|Placebo|Placebo comparator
1521203|NCT02807948|Device|Pacemaker, ICD, or CRT device|MRI Scans on SJM device implanted subjects for clinical purpose
1521204|NCT02807935|Device|Optical coherence tomography imaging|
1521205|NCT02807922|Drug|Zopiclone|
1521206|NCT02807922|Drug|Placebo|
1521207|NCT02807909|Drug|BMS-986177|
1521208|NCT02807909|Drug|Itraconazole|
1521209|NCT02807909|Drug|Diltiazem ER|
1521210|NCT02807883|Drug|Blinatumomab|Participants receive Blinatumomab as continuous intravenous infusion at a dose of 28 µg/24 hours over 4 weeks followed by a treatment-free period of 2 weeks, defined as one 6-week treatment cycle. In the first induction cycle, the initial dose of Blinatumomab is 9 µg/day for the first 7 days of treatment which then will be escalated (dose step) to 28 µg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 µg/day is the dose for all 4 weeks of continuous treatment. Participants receive 4 cycles of blinatumomab at 3, 6, 9, and 12 months following hematopoietic cell transplantation (HCT).
1521211|NCT02807883|Procedure|Hematopoietic Cell Transplantation|Hematopoietic progenitor cell infusion
1521212|NCT02807870|Drug|Methylphenidate|Methylphenidate treatment with a initial dosage of 0,3 mg/kg per day (weekly dosage adjustments).
1521213|NCT02807870|Behavioral|Parental training|Weekly parental training conducted by behavioral psychologists.
1521214|NCT02807870|Other|Psychoeducational groups for parents|Weekly psychoeducational groups conducted by educators.
1521215|NCT02807870|Drug|Placebo pill|Placebo pill during 8 weeks.
1521216|NCT02807857|Procedure|Standard care|Patients will receive the treatment that their primary care physician has decided to prescribe for their disease
1521217|NCT02807844|Drug|MCS110|
1521218|NCT02807844|Drug|PDR001|
1521219|NCT02807831|Behavioral|Executive functions training|Daily training of executive functions via activities to develop auto-regulation, attention and memory.
1521220|NCT02807831|Behavioral|Language skills training|Daily training of language skills via activities to develop phonological awareness and vocabulary.
1521221|NCT02807831|Other|Regular school curriculum|Ministry of Education national school curriculum.
1521223|NCT02807805|Drug|Abiraterone Acetate|Given PO
1521224|NCT02807805|Drug|Niclosamide|Given PO
1521225|NCT02807805|Drug|Prednisone|Given PO
1521226|NCT02807792|Device|Perianal access device|Perianal access device
1521227|NCT02807779|Drug|Dexamethasone infusion|Patients will receive dexamethasone infusion following plain balloon angioplasty
1521228|NCT02807779|Device|Drug coated balloon|Patients will receive angioplasty with a drug-coated balloon following plain balloon angioplasty
1521229|NCT02807766|Behavioral|Behavior modification|Each group has 30 subjects and experiences six months' training.
1521230|NCT02807766|Behavioral|Behavior modification and sensory integration training|Each group has 30 subjects and experiences six months' training.
1521231|NCT02807766|Behavioral|Behavior modification and applied behavioral analysis|Each group has 30 subjects and experiences six months' training.
1521232|NCT02807766|Behavioral|Behavior modification and TEACCH|Each group has 30 subjects and experiences six months' training.
1521233|NCT02807753|Other|Ankle and Knee Ultrasound Joint Assessment|Ultrasound Examination of the ankles and knees
1521234|NCT02807753|Other|Ankle and Knee Magnetic Resonance Imaging|Ankle and Knee Magnetic Resonance Imaging
1521235|NCT02807740|Other|Virtual reality|Each session will consist of multiple exercises. These ones are already described, each exercise will be performed by the patient for 4 minutes followed by a 1 minute of rest.
1521236|NCT02807740|Other|Conventional rehabilitation program|In each C rehabilitation session, patients underwent 3 phases: 1) Warm-up phase: passive mobilization of main joints and muscular strengthen of lower limbs; 2) Active phase (both standing than seated): exercises of motor coordination with upper and lower limbs, balance training, start and stop exercises, deambulation training; 3) cool-down phase (with seated patient): manipulation exercises, mobilization exercises, respiratory exercises.
1521237|NCT02807727|Drug|Intralipid 20%|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
1521238|NCT02807727|Drug|Modified Ringers Lactate|Single intravenous bolus dose of 1.5 ml/kg over 3 minutes
1521239|NCT02807701|Procedure|Laparoscopic pancreaticoduodenectomy|"Laparoscopic pancreaticoduodenectomy
dissection
reconstruction"
1521240|NCT02807701|Procedure|Open pancreaticoduodenectomy|Open pancreaticoduodenectomy
1521241|NCT02807688|Behavioral|Health Promotion Intervention|"The intervention package consists of the following elements:
i. educational sessions on the importance of diet and fitness; ii. motivational interviews to maintain participants in the program, to discuss participants' physical conditions, habits and opinions as to diet and fitness; iii. monitoring the participation in the program and health behaviour, specifically for diet and fitness, and adherence to the intervention on diet and fitness; iv. regular physical exercise under the guide and supervision of an expert trainer."
1521242|NCT02807675|Drug|CVT-301, LIP|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
1521243|NCT02807675|Other|Placebo|All subjects will receive 1 dose of CVT-301 and 1 dose of placebo inhalation powder, to be taken concomitantly with their standard oral medication in 2 dosing periods. The order of treatment will be randomized, with subjects assigned to 1 of 2 sequences CVT-301 (A) administered first, followed by placebo (B), or the reverse order (BA)
1521244|NCT02807662|Behavioral|Adapted Seeking Safety Intervention|Intervention participants received Seeking Safety psychosocial education Intervention adapted for prenatal care setting.
1521245|NCT02807649|Dietary Supplement|Experimental: Nutrilite® Low dose|Two tablets consume daily with meal.
1521246|NCT02807649|Dietary Supplement|Experimental: Nutrilite® High dose|Two tablets consume daily with meal.
1521247|NCT02807649|Dietary Supplement|Placebo Comparator: Placebo|Two tablets consume daily with meal.
1521248|NCT02807636|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
1521249|NCT02807636|Drug|Carboplatin|Carboplatin will be administered at doses to achieve area under the concentration-time curve (AUC) of 4.5 milligram per milliliter into minute (mg/mL*min) by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
1521250|NCT02807636|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 milligrams per square meter (mg/m^2) by IV infusion on Day 1 and Day 8 of each 21-day cycle, until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
1521251|NCT02807636|Other|Placebo|Placebo matched to atezolizumab will be administered by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1. In specific circumstances treatment may continue beyond disease progression.
1521252|NCT02807636|Drug|Cisplatin|Cisplatin will be administered at a dose of 70 mg/m^2 by IV infusion on Day 1 of each 21-day cycle until investigator-assessed disease progression per RECIST v1.1 or unacceptable toxicity.
1521253|NCT02807623|Drug|Ibuprofen|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
1521254|NCT02807623|Behavioral|Compound Exercise of Pushups|The participants will perform an exercise intervention of pushups as immediately as possible but no more than 15 minutes after influenza vaccine receipt. The number of pushups performed will be at least 80% of the participants last Army Physical Fitness Test (APFT) score in one session. The number of pushups will be recorded. A baseline lactate fingerstick blood specimen will be collected with either the serology sample (if possible) or from the hand opposite the vaccine receipt arm prior to performing pushups and a second finger stick sample within 3-8 minutes, but no more than 15 minutes after vaccine receipt.
1521255|NCT02807623|Drug|oral placebo|The participants will take their first dose of the study drug immediately after influenza vaccine receipt. The medication will be blinded and dispensed by a research pharmacist. The participants will receive instructions on the dosing, frequency and a recommendation to take with food or milk and will be provided a snack with their first dose.
1521256|NCT02807610|Drug|Inj Etomidate|Induction of anesthesia using IV Etomidate 0.3mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0`.2mg kg-1 and IV Fentanyl 2ug kg-1.
1521257|NCT02807610|Drug|Injection Propofol|Induction of anesthesia using IV Propofol 2mg kg-1 as a single dose in patients undergoing day care procedure, after premedication with IV midazolam 0.2mg kg-1 and IV Fentanyl 2ug kg-1
1521258|NCT02807610|Drug|Placebo for Propofol|After premedication with IV midazolam 0.2mg/kg and IV Fentanyl 2ug/kg Placebo was given.
1521259|NCT02807597|Other|LS301|-LS301 is a small molecule consisting of a NIR fluorescent dye and an octapeptide that is cyclized through a disulfide bond.
1521260|NCT02807597|Device|Cancer Vision Goggles|-Surgeon will wear during surgery
1521261|NCT02807597|Procedure|Surgery|-Standard of care
1521262|NCT02807584|Device|ELECT|
1521263|NCT02807571|Procedure|Wide Awake Local Anesthesia No Tourniquet|Wide Awake Local Anesthesia No Tourniquet for office based hand surgery.
1521266|NCT02807545|Behavioral|Scoliosis Specific Exercises|
1521267|NCT02807532|Other|atrial fibrillation|In the case-control trial, patients with atrial fibrillation 7 days after surgery will be assigned to an atrial fibrillation group.
1521268|NCT02807532|Other|non-atrial fibrillation|In the case-control trial, patients without atrial fibrillation 7 days after surgery will be assigned to a non-atrial fibrillation group.
1521311|NCT02807207|Drug|C: 400 mg moxifloxacin|Treatment C
1521312|NCT02807194|Other|spinal anesthesia|
1521313|NCT02807194|Other|general anesthesia|
1521314|NCT02807194|Procedure|lumbar disc herniation|
1521269|NCT02807519|Genetic|collection of salivary cytokines|Collection of the saliva will be done following this procedure: The collection will be done prior to any other dental manipulation. The test person is sitting with its head tilted slightly forward. Initially, any saliva present in the mouth must be swallowed or spit out completely. Then, a paraffin gum is given to the test person. This paraffin gum must be chewed for minimally 2 and maximally up to 5 minutes. During the time period that the test person is chewing the paraffin gum, the saliva must be spitted into a cup repeatedly, or the saliva can also be let run passively into the cup. The amount of saliva is then weighted (1g equivalent to 1 ml) and a saliva flow rate (ml/min) is calculated and noted.
1521270|NCT02807506|Device|Mobile Service Robot|The goal is to build a low-cost mobile service robot with an arm that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
1521273|NCT02807480|Behavioral|Exposure-based therapy|Exposure-based therapy
1521274|NCT02807480|Behavioral|Behavioral Activation therapy|Behavioral Activation therapy
1521275|NCT02807480|Behavioral|Computer-based behavioral assessment|Computer-based tasks during which participants respond to images on the screen, including abstract images, emotional faces, and pleasant and unpleasant images.
1521276|NCT02807480|Behavioral|Surveys and Interviews|Surveys and interviews in which participants will be asked to answer questions related to their mental and physical health history and current symptoms.
1521277|NCT02807480|Device|Magnetic resonance imaging (MRI)|Magnetic resonance imaging (MRI) will be used to obtain information concerning the structure of the brain, as well as to assess changes associated with blood flow in the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
1521278|NCT02807480|Device|Electroencephalography (EEG)|Electroencephalography (EEG) will be used to assess changes in the electrical activity of the brain while participants are completing behavioral tasks (see description of computer-based behavioral assessment intervention).
1521279|NCT02807467|Drug|Dexmedetomidine|Continuous infusion of dexmedetomidine between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
1521280|NCT02807467|Drug|Propofol|Continuous infusion of propofol between 8pm and 6am after diagnosis of hyperactive or mixed delirium. The infusion might have to be repeated several times to achieve resolution of delirium.
1521281|NCT02807454|Drug|Daratumumab|
1521282|NCT02807454|Drug|Durvalumab|
1521283|NCT02807454|Drug|Pomalidomide|
1521284|NCT02807454|Drug|Dexamethasone|
1521285|NCT02807441|Drug|Acetylsalicylic acid|Patients will receive different doses of aspirin perioperatively to assess bleeding association.
1521286|NCT02807428|Drug|AYX1 Injection 660 mg/6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
1521287|NCT02807428|Other|Placebo Injection 6 mL|6 mL solution for intrathecal injection; vehicle formulation designed to mimic AYX1 Injection (with no active drug)
1521288|NCT02807415|Drug|Lumacaftor plus Ivacaftor|Oral treatment with lumacaftor/ivacaftor tablets according to the prescribing information
1521289|NCT02807389|Drug|MSC Fistula Plug|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cell.
1521290|NCT02807376|Device|Surgeon's 'standard of care' stapler|
1521291|NCT02807376|Device|Ethicon Powered Vascular Stapler|
1521292|NCT02807363|Drug|Leuprolide Oral Tablet QD|4-mg oral tablet once daily for 28 consecutive days.
1521293|NCT02807363|Drug|Leuprolide Oral Tablet BID|4-mg oral tablet twice daily for 28 consecutive days.
1521294|NCT02807363|Drug|Leuprolide Depot|3.75 mg intramuscular depot injection
1521297|NCT02807337|Drug|Caphosol|
1521298|NCT02807337|Drug|0,9% NaCl|
1521299|NCT02807324|Other|Venapunction|The only invasive procedure is a venapunction where 75 ml blood will be extracted. The only unfavourable side effect can be a small hematoma (rare).
1521300|NCT02807298|Drug|4%articaine|intraligamentary injections of 0.9 ml of 4%articaine and 1:100,000 epinephrine
1521301|NCT02807298|Drug|2% Lignocaine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
1521302|NCT02807298|Drug|Epinephrine|Intraligamentary injections of 1.8 ml of lidocaine and 1:100,000 epinephrine
1521303|NCT02807285|Drug|Ocrelizumab|Participants will receive 600 mg ocrelizumab as two 300 mg infusions separated by 14 days, every 24 weeks.
1521305|NCT02807259|Behavioral|Multi-level intervention|At the individual level, the intervention will focus on: (i) structured reflection groups for FSWs to enhance self-esteem, encourage critical reflection around gender norms and violence, and build individual and collective efficacy; (ii) separate sessions for intimate partners to discuss issues around violence and condom use as well as gender, equity, respect and responsibility; (iii) skills building around female condoms (iv) access to individual and couples-based counselling. At the community level, the intervention will focus on: (i) strengthening the supportive crisis management systems so that they are able to address 'domestic' as well as 'work-place' violence among FSWs and (ii) building an environment that encourages action against violence from intimate partners by training male champions and developing folk media troops to generate discussion around gender, masculinity, violence and HIV risk behaviours.
1521306|NCT02807246|Biological|Maflor®, Mamsel Pharmaceuticals, Turkey|"Dietary Supplement: Probiotics probiotics at a dose of 1x109 CFU/day. (Maflor®, Lactobacillus rhamnosus GG 109 CFU, Mamsel Pharmaceuticals, Turkey)
Other Name: Maflor®"
1521307|NCT02807246|Other|drops of saline|Dietary Supplement: Breast milk +drops of saline
1521308|NCT02807220|Drug|Imuneks 10mg|Two capsules of the study drug every morning approximately two hours after breakfast for six weeks
1521309|NCT02807207|Drug|A: 400 mg pacritinib|Treatment A
1521310|NCT02807207|Other|B: Placebo|Treatment B
1521317|NCT02807168|Other|NT-proBNP (Cardiac Biomarkers)|
1521318|NCT02807155|Behavioral|Transition Empowerment Program|Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
1521319|NCT02807155|Behavioral|Transition Empowerment Program + Diabetes Wellness Council|Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
1521320|NCT02807155|Behavioral|Online Transition Empowement Program Access|Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
1521321|NCT02807142|Biological|NC 1 cell therapy|All patients will be treated with NC1
1521322|NCT02807129|Biological|blood withdrawn|
1521323|NCT02807129|Biological|urine collection|
1521324|NCT02807116|Drug|Pacritinib|Subjects received a single oral 400-mg dose of pacritinib
1521325|NCT02807116|Drug|Rifampin|Subjects received 600-mg oral doses of rifampin; administered QD following a 7-day washout period
1521326|NCT02807116|Drug|Pacritinib and Rifampin|On Day 17, a single oral 400-mg dose of pacritinib was co-administered with the final 600-mg dose of rifampin.
1521327|NCT02807103|Drug|Rituximab|1 g intravenous pulse at day1 and day15
1521328|NCT02807103|Drug|Placebo-rituximab|intravenous pulses at day1 and day15
1521329|NCT02807103|Drug|Cyclophosphamide|intravenous 9 pulses : 600 mg/m2 at days 1, 15 and 29, and then 500 mg-fixed dose at days 50, 71, 92, 113, 134 and 155.
1521330|NCT02807103|Drug|Placebo-cyclophosphamide|intravenous 7 pulses : at days 29, 50, 71, 92, 113, 134 and 155.
1521331|NCT02807090|Other|Lumbar Stabilization Exercise|There will be 16 sessions, twice a week, with 40-60 minutes each session. In this arm the participants will learn basic notions about anatomy and biomechanics and the lumbar stabilization technique. They will be evaluated by a pressure biofeedback in the first day that will be used in the training. The lumbar stabilization technique consists of three stages: cognitive, associated and automatic. The biofeedback is used in the first stage and it helps patients to do the best contraction of stabilization muscles in different levels of pressure. Then, in stage two the patients do the contraction without the use of biofeedback and in the last phase different exercises are associated with the contraction of stabilization muscles.
1521332|NCT02807090|Other|Circular dance|There will be 16 sessions, twice a week, with 60 minutes each session. In this arm the participants will do the exercises in a group of 20 subjects. In every meeting there will be the follow stages: reception, reflection, warming/stretching, explanation about circular dance, choreography orientation, practice and finishing.
1521333|NCT02807077|Drug|Pacritinib|Group 1, 2, 3, and 5 will be administered single oral 400-mg dose of pacritinib. Subjects in the Group 4 received a single 400-mg dose of pacritinib during two different treatment periods: Dialysis and Inter-Dialysis
1521334|NCT02807064|Drug|Bifidobacteria|0.5 ml per os all days for 2 months
1521335|NCT02807064|Drug|placebo|0,5 ml per os all days for 2 months
1521336|NCT02807051|Drug|Pacritinib|Single 400-mg dose (four 100-mg capsules) administered in the morning on Days 1 and 12
1521337|NCT02807051|Drug|Clarithromycin|Twice-daily, 500-mg dose (one 500-mg tablet) administered every 8 to 12 hours on Day 8 through the morning of Day 12
1521338|NCT02807051|Drug|Pacritinib and Clarithromycin|On Day 12, a single oral 400-mg dose of pacritinib was co-administered with the final 500-mg dose of clarithromycin
1521339|NCT02807038|Procedure|Lung function test|Pregnant woman use the individual passive sampler 15 days before the spirometry test at each trimester
1521340|NCT02807012|Other|Nursing educational intervention|"The nursing educational intervention by home visits will consist in three home visits by nurses until 14, 21 and 30 days after discharge to the intervention group. The nurses will give verbal information to family caregiver related to the care of elderly with stroke based on protocol with orientation related: information about stroke; emotional support; how to access health services; nutrition; airway; hygiene; positioning and transferring; prevent falls; dress/undress; medications; physiological eliminations; skin care. Furthermore, nurses will give some printed materials that contain orientations related to the care.
The control group could have ou not the usual care guidelines provide by health services that have access."
1521341|NCT02806999|Drug|Berberine; Insulin|Participants will receive 500mg Berberine twice a day for 8 days; Meanwhile，participants will also continue to receive intensive insulin therapy.
1521342|NCT02806999|Drug|Insulin|Participants will continue to receive intensive insulin therapy; Meanwhile, Participants will also receive a placebo twice a day for 8 days.
1521343|NCT02806986|Biological|IGSC 20%|Weekly administration of IGSC 20% via intravenous infusion
1521344|NCT02806973|Drug|LY900018|LY900018 administered intranasally
1521345|NCT02806960|Drug|LY900018|Administered intranasally.
1521346|NCT02806947|Drug|Sirolimus|Sirolimus will be administered with a starting dose of 6 mg for patients older than 12 years, or 5 mg/m^2 for patients ≤ 12 years. Trough levels will be routinely measured and sirolimus will be kept at maintenance dosing for target therapeutic levels for minimum duration through Day 56 post-randomization.
1521347|NCT02806947|Drug|Prednisone|Prednisone will be administered at 2mg/kg/day x 3 days, and then tapered according to individual treating clinician judgment.
1521348|NCT02806934|Procedure|biological and ultrasound test|biological and ultrasound test 20 days after implantation in order to see the implantation rate
1521349|NCT02806921|Device|ZenLens|The ZenLens™ semi-scleral lenses are manufactured by Alden Optic Laboratories Inc., Lancaster, NY. They will be made in Boston XO material.
1521350|NCT02806908|Drug|JZP-110|
1521351|NCT02806908|Drug|Placebo|
1521352|NCT02806895|Drug|JZP-110|
1521353|NCT02806895|Drug|Placebo|
1521354|NCT02806882|Drug|Ceftaroline fosamil|600mg IV infusion
1521359|NCT02806843|Device|Rehab InterCap system and 3D Kinect|The therapist will conduct a therapy session which will consist of various activities of daily living. During the session, the motion of the therapist and patients will be collected with a custom motion capture system (Rehab InterCap) and 3D visual mapping may take place using the Kinect device, audio will be recorded, and basic measurements of length (i.e. the distance from a participant's shoulder to elbow) will be taken. Patients and therapists will wear the sensors to capture their arm movements. 3D video motion capture may be completed with some subjects. This will involve subjects wearing reflective markers on their upper arms in addition to the intercap sensors.
1521360|NCT02806830|Drug|Optive|Optive eye drops will be prescribed to each included patients after their second intravitreal injection; patients will received 1 drop in the affected eye 2 times a day during 3 days
1521361|NCT02806817|Drug|ME-344|ME-344 is a synthetic small molecule mitochondrial inhibitor based on the isoflavan ring structure. ME-344 is a chiral compound, and is manufactured predominantly as a single stereoisomer that is dextrorotatory. As a stereoisomeric drug with two chiral centers, ME-344 is one of four potential stereoisomers. The current manufacturing process produces a racemic mixture of two of those stereoisomers, which are enantiomers, and ME-344 is separated from the levorotatory enantiomer by chromatography in the final step.
1521362|NCT02806817|Drug|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
1521363|NCT02806817|Other|Normal saline|Use saline as placebo
1521364|NCT02806804|Biological|one dose test vaccine|
1521365|NCT02806804|Biological|one dose commercially available trivalent influenza vaccine|
1521366|NCT02806804|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
1521367|NCT02806791|Drug|FILGRASTIM|
1521368|NCT02806778|Other|BIS Monitor-guided sedation|The patients enrolled in the study will undergo BIS Monitor-guided sedation. Standard BIS Monitor will be used for the procedure to monitor the depth of sedation.
1521369|NCT02806778|Other|Jugular bulb catheter|Jugular bulb catheter will be implanted in the patients enrolled in the study.
1521370|NCT02806765|Dietary Supplement|(1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol|25 micrograms of (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol every day for 6 months
1521371|NCT02806765|Other|Control|Placebo in Softgel form
1521372|NCT02806752|Drug|Triamcinolone Acetonide|Intravitreal inject 0.5mg of Ranibizumab and 2mg of Triamcinolone Acetonide.
1521373|NCT02806752|Drug|Ranibizumab|Intravitreal inject 0.5mg of Ranibizumab.
1521374|NCT02806739|Dietary Supplement|Soy Group (Soy Protein + Isoflavones)|Women in the intervention group are asked to eat a combination of soy foods that contain about 25 grams of protein and 60-75 milligrams of isoflavones per day, from the 16th gestational week to birth. A registered dietitian will instruct them to incorporate the soy foods into their daily diet.
1521375|NCT02806739|Dietary Supplement|Control Group (Minimize Soy Intake)|Women in the control group will be instructed by the dietitian how to avoid soy supplements and minimize soy intake.
1521376|NCT02806713|Drug|Phenazopyridine|
1521377|NCT02806713|Other|no intervention|Because the obvious effects on the urine coloration of pyridium no placebo or dummy are provided
1521378|NCT02806700|Behavioral|Twitter Diabetes Intervention|This group will be asked to use twitter for heart health ( e.g. tweeting, following, receiving tweets)
1521379|NCT02806687|Drug|Gene Therapy product CYL-02|"Gene Therapy product CYL 02 = = plasmid DNA encoding SST2 + DCK::UMK genes pre-complexed to linear polyethylenimine.
Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumoral injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every week. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume, 30 days after the first administration followed by three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose. Patients have infusion of Gemcitabine 3 weeks/month during 6 months (or until progression)."
1521380|NCT02806687|Drug|Gemcitabine|Gemcitabine alone 3 weeks/month during 6 months (or until progression).
1521383|NCT02806661|Procedure|Vagus nerve-preserving Robot-assisted Gastrectomy|
1521384|NCT02806661|Procedure|Conventional Robot-assisted Gastrectomy|
1521385|NCT02806648|Drug|Palbociclib|Palbociclib
1521386|NCT02806635|Behavioral|OurRelationship|
1521387|NCT02806635|Behavioral|PREP Online|
1521388|NCT02806609|Other|Cold water immersion, with 10 degrees, for 10 minutes|cold water immersion
1521389|NCT02806609|Other|immersion in water at room temperature|immersion in water at room temperature
1521390|NCT02806609|Other|active recovery - running|active recovery
1521391|NCT02806609|Other|rest in the chair|rest in the chair
1521392|NCT02806596|Drug|Sevoflurane|After at least 4 minutes of stable inspired sevoflurane concentration, that concentration will be titrated to obtain a targeted bispectral index (BIS) level required for perform laryngoscopy. This level was initially set at 40, based on a preliminary study showing that such level of BIS was obtained at the laryngoscopy after common general anesthesia induction. For the next patients, BIS target was set according to a sequential allocation method (up and down).
1521394|NCT02804841|Dietary Supplement|Cholecalciferol -Vitamin D3|
1521395|NCT02804841|Other|Placebo -gel capsule containing no vitamin D.|
1521396|NCT02804828|Dietary Supplement|Individualized mitochondrial cocktail|
1521397|NCT02804828|Dietary Supplement|Arctic cod liver oil capsules|
1521398|NCT02804828|Dietary Supplement|Placebo|
1521399|NCT02804815|Drug|Aspirin 100mg|Aspirin 100mg
1521400|NCT02804815|Drug|Aspirin 300mg|Aspirin 300mg
1521401|NCT02804815|Drug|Placebo 100mg|Placebo 100mg
1521402|NCT02804815|Drug|Placebo 300mg|Placebo 300mg
1521403|NCT02804802|Other|questionnaire|dietary habits and physical activity questionnaire
1521404|NCT02804776|Drug|Gefitinib|250mg oral daily for 4 weeks
1521407|NCT02804750|Drug|CORT125134|
1521408|NCT02804737|Device|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
1521409|NCT02806557|Device|Home finger-prick capillary blood count monitoring|A nurse will visit the participant's home according to the test schedule (up to a maximum frequency of 21 visits in a 21-day cycle) and perform the finger-prick capillary blood test and measure the neutrophil count using the Hemocue® WBC DIFF device.
1521410|NCT02806544|Drug|Tamoxifen|Tamoxifen 20mg by mouth daily
1521411|NCT02806531|Biological|two doses enterovirus 71 vaccine|Two doses of enterovirus 71 vaccine will be given in children aged 6-35 months old, 28 days interval.
1521412|NCT02806518|Procedure|DIRT|An infrared camera is used to capture video sequences of thermal images before, during and after exposure of the lower abdomen to a cold challenge.
1521413|NCT02806505|Drug|Peginterferon alfa-2a|Chronic Hepatitis C participants with end-stage renal disease undergoing hemodialysis will receive Peginterferon alfa-2a either 135 or 90 mcg SC once weekly up to Week 48.
1521414|NCT02806492|Other|50-100ug phenylephrine before CPB|In this intervention we will administer 50-100 μg phenylephrine to the patient before CPB is started. This intervention will take place when the patient shows hypotension (MAP <60mmHg, according to protocol22). Because of the increase in PVR there will be a baroreceptor-reflex-mediated decrease in CO. On-line, we will quantify the percentage decrease in systemic blood flow (i.e. CO) by using the Modelflow algoritm incorporated in a non-invasive beat-to-beat finger blood pressure monitor. This will allow us to obtain a reference for the decrease in CO to use in the next interventions. Our hypothesis is that CO will decrease because of the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
1521415|NCT02806492|Other|50-100ug phenylephrine during CPB|In this intervention we will induce only 1 component of the changes at intervention (1), being the increase in MAP of approximately 20 mmHg by administrating 50-100 μg phenylephrine. The CPB enables us to maintain a constant CO and thus eliminating the baroreceptor-reflex. During this intervention NIRS and TCD MCA will be recorded.
1521416|NCT02806492|Other|decreasing CPB flow|With this intervention we will only create a change in CO, which enables us to eliminate the effect of blood pressure. We will modify CPB flow to achieve the CO decrease (in %) measured at intervention (1) meaning: pre-CPB after the bolus of 50-100 μg phenylephrine. In the case of unexpected increase (in %) of CO measured at intervention (1), we will still decrease CPB flow so we will be able to analyse decrease as well as increase in CPB flow. During this intervention NIRS and TCD MCA will be recorded.
1521417|NCT02806492|Other|Decreasing CPB flow AND 50-100ug phenylephrine|In this intervention we will simulate the 'normal' physiological state when administering phenylephrine. We will modify CPB flow to achieve the percentage change CO as observed during intervention (1) as well as administrate 50-100 μg phenylephrine. We expect to see similar outcomes as in intervention (1). During this intervention NIRS and TCD MCA will be recorded.
1521418|NCT02806492|Other|Increasing CPB flow|In this last intervention we will create an increase in MAP without using phenylephrine but only by increasing CO. This enables us to eliminate a possible direct α1-adrenergic effect on the cerebral vasculature. MAP will be raised approximately 20 mmHg by increasing CPB flow 20%. During this intervention NIRS and TCD MCA will be recorded.
1521419|NCT02806479|Other|Observational: Arrhythmogenic Substrate|
1521420|NCT02806466|Procedure|Fiberoptic bronchoscopy|
1521421|NCT02806453|Dietary Supplement|thickened formula|
1521422|NCT02806453|Dietary Supplement|Mg alginate|
1521423|NCT02806453|Behavioral|reassurance with lifestyle changes|
1521424|NCT02806440|Drug|Low dose naltrexone|Active comparator
1521425|NCT02806440|Drug|Placebo|Placebo comparator
1521426|NCT02806427|Other|Enteral Formula|
1521427|NCT02806414|Drug|Ivermectin|
1521428|NCT02806401|Device|landmark|
1521429|NCT02806401|Device|US_Ax|
1521430|NCT02806375|Procedure|Allogeneic hematopoietic stem cell transplantation|Day 0: Infusion of unmanipulated graft
1521431|NCT02806375|Drug|Busulfan|Days -5 through -3: Busulfan 1 mg/kg po qid №10
1521432|NCT02806375|Drug|Fludarabine monophosphate|Days -7 through -2: 30 mg/m2/day iv qd x 6 days
1521433|NCT02806375|Drug|Cyclophosphamide|Day +3 and +4: 50 mg/kg/day iv qd
1521434|NCT02806375|Drug|Ruxolitinib|Days -8 through -2 15 mg tid
1521435|NCT02806375|Drug|Ruxolitinib|Days +5 through +100: 7.5 mg bid
1521436|NCT02806362|Drug|Ombitasvir/paritaprevir/ritonavir|Tablet
1521437|NCT02806349|Dietary Supplement|American Ginseng|herb
1521438|NCT02806349|Dietary Supplement|Konjac-glucomannan fiber blend|Blend of 2 viscous fibers: konjac mannan and xanthan
1521439|NCT02806349|Dietary Supplement|Control|Fiber matched control for intervention (corn starch and wheat bran)
1521440|NCT02806336|Behavioral|Multi Modal Balance Training|Group balance class, obstacle course, strengthening exercises
1521441|NCT02806336|Behavioral|Weight Loss|Nutritional counseling to achieve 500 kcal standard hypocaloric diet
1521442|NCT02806323|Other|Yoga practice|
1521443|NCT02806310|Other|Blood draw|blood sampling for biomarker levels
1521444|NCT02806297|Procedure|Early cholecystectomy with IOC|The intervention will be laparoscopic cholecystectomy with intraoperative cholangiogram (IOC) on admission within 24 hours of presentation regardless of whether pain or tenderness are present or laboratory values are elevated.
1521476|NCT02806089|Device|Electrical bioimpedance analysis|Evaluation of lean body mass
1521445|NCT02806297|Procedure|Late cholecystectomy with IOC|The control will be laparoscopic cholecystectomy with IOC once the patient has met the following criteria: (a) a score of less than 2 on the Visual Analogue Pain Scale, (b) no tenderness on physical exam, and (c) decreased lipase to either less than half of the peak value or within normal range (73-393 U/L).
1521446|NCT02806284|Biological|PPSV23, Act-HIB|"described in Arm description"
1521447|NCT02806271|Behavioral|Worry Postponement|"In worry postponement, participants are instructed to learn to notice naturally occurring episodes of worry. When they notice they are worrying they are instructed to disengage from their worry and postpone it to a designated 30 minute worry period to be carried out at the same time and place daily during the two week intervention. Participants are to use their worry time to worry about problems that have come up during the day and to problem solve where appropriate."
1521448|NCT02806271|Behavioral|Worry Monitoring|For two weeks participants are instructed to monitor their worry using a smartphone based application. Participants are instructed to make a record each time they have a worry episode by briefly describing the content of their worry. Participants also complete two brief daily questionnaires about the duration of their worry, the intensity of their worry, their ability to disengage from their worry, and the occurrence of nighttime episodes of worry.
1521449|NCT02806258|Radiation|Accelerated partial breast irradiation|To date, there is no report on external beam APBI associated with CT in the neoadjuvant setting.In the NeoAPBI 01 trial, the objective is to demonstrate the efficacy of combined APBI and CT administered sequentially in patients with intermediate ad high risk BC. The hypothesis is that combined PST-sequential APBI may increase the rate of pCR, breast conservation and survival without additional toxicity, as seen with WBI.
1521450|NCT02806258|Drug|Chemotherapy|minimum of six cycles of PST using anthracycline and/or taxane based regimens
1521455|NCT02806219|Device|Prefilled syringe (PFS)|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By prefilled syringe (PFS)
1521456|NCT02806219|Device|e-Device|Active substance: Certolizumab Pegol Pharmaceutical form: Solution for injection Administration: By e-Device
1521457|NCT02806206|Drug|Prucalopride|A single 2 mg oral dose of prucalopride will be given to each study participant just before the ingestion of the capsule endoscopy pill.
1521458|NCT02806206|Drug|Placebo|A single dose of a placebo pill will be given to each study participant just before the ingestion of the capsule endoscopy pill.
1521459|NCT02806193|Procedure|Cardiovascular Magnetic Resonance Imaging|"Cardiac magnetic resonance imaging (CMR) has emerged as both a remarkably powerful diagnostic and prognostic tool for the assessment of cardiovascular disease. The high spatial resolution of CMR and the ability to characterize soft tissue provides the opportunity for unique diagnostic assessment of a myriad of cardiac pathology, including ischemic heart disease (IHD), preoperative assessment, intra- cardiac mass and thrombus, pericardial disease, valvular heart disease, and cardiomyopathy evaluation.
Between individual CMR programs, GCMR will offer information useful in assessing the differences in protocol, performance, and clinical adaptation by varying geographic regions, institutional environments, and expertise. Such an assessment is critical for uncovering possible reasons for disparities in performance and obtaining opportunities for advancement."
1521460|NCT02806180|Procedure|Dual Operator Ultrasound Guided IV placement|Second operator holds ultrasound probe.
1521461|NCT02806180|Procedure|Single Operator Ultrasound Guided IV placement|Single operator holds ultrasound probe and places IV.
1521462|NCT02806167|Other|Clinical algorithm|Patients presenting with suspected acute CES will be assessed in accordance with the algorithm previously outlined.
1521464|NCT02806141|Drug|Aerosolized plus intravenous colistin|Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
1521465|NCT02806141|Drug|Intravenous colistin|Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
1521466|NCT02806128|Drug|Human Urinary Kallidinogenase for Injection|Patients need to complete laboratory tests within a specified time and to complete the experimental requirements of medication time
1521467|NCT02806115|Procedure|acetic acid-enhanced endoscopy|Acetic acid-enhanced endoscopy combines conventional endoscopy with the instillation of acetic acid.
1521468|NCT02806115|Drug|Acetic Acid|The concentration of acetic acid used in this study is 1.5%.
1521469|NCT02806115|Device|endoscope|This study using an EG-29-i10 endoscope (Pentax, Tokyo, Japan) and an EPK-i7010 processor (Pentax, Tokyo, Japan).
1521470|NCT02806102|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
1521471|NCT02806102|Drug|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
1521472|NCT02806102|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention
1521473|NCT02806102|Drug|Dual-antiplatelet therapy|Dual AntiPlatelet Therapy
1521474|NCT02806089|Device|Handheld dynamometer|Evaluation of muscle strength
1521475|NCT02806089|Biological|Creatinine index|Evaluation of muscle mass using plasma creatinine level
1521477|NCT02806089|Other|"Voorrips score questionnaire"|Evaluation of physical activity
1521478|NCT02806089|Biological|Inflammatory and nutritional status|Evaluation of C reactive protein and albumin
1521479|NCT02806076|Procedure|No-touch RFA arm|No-touch RFA arm indicates RFA procedure without direct tumor puncture. In this study, RFA is done by using dual cooled electrode.
1521480|NCT02806076|Procedure|Conventional tumor puncture RFA arm|"Conventional tumor puncture RFA arm indicates RFA procedure using conventional tumor puncture technique. In this study, RFA is done by using dual cooled electrode."
1521481|NCT02806063|Procedure|intraoperative samples|
1521482|NCT02806050|Drug|Palbociclib|all patients will be treated with palbociclib, on a 3 weeks on, 1 week off cycle until progression
1521483|NCT02806050|Device|FES PET|all patients will have a FES PET at baseline
1521484|NCT02806050|Drug|Letrozole|all patients will be treated with Letrozole daily until progression
1521485|NCT02806024|Drug|Tranexamic Acid|
1521486|NCT02806024|Drug|Placebo Drug|50 cc Normal Saline IV
1521487|NCT02806011|Biological|Livercellgram|
1521488|NCT02805998|Behavioral|Web-based CBT-I|
1521489|NCT02805998|Other|Treatment as Usual|
1521490|NCT02805985|Device|FLXfit™ TLIF Interbody Fusion Device|The FLXfit™ is an expandable, articulated interbody fusion device (IBFD) used in conjunction with supplemental fixation to provide structural stability in skeletally mature individuals following total or partial discectomy.
1521493|NCT02805959|Device|MTS2|
1521494|NCT02805946|Drug|posaconazole|iv versus oral
1521495|NCT02805920|Drug|Bupivacaine|comparison of different volumes-dosages of 0.25% Bupivacaine
1521496|NCT02805907|Drug|Calcifediol|
1521497|NCT02805907|Drug|Placebo|
1521498|NCT02805894|Drug|NBTXR3 activated by IMRT only|Single local administration of NBTXR3 by injection into the prostate gland prior to the IMRT treatment
1521499|NCT02805894|Drug|NBTXR3 activated by Brachytherapy & IMRT|Single local administration of NBTXR3 by injection into the prostate gland prior to the Brachytherapy & IMRT treatment
1521500|NCT02805881|Device|Neurolief system|Non-invasive cephalic neurostimulation device
1521501|NCT02805868|Procedure|Bone Marrow Aspiration and Biopsy|Undergo bone marrow aspiration and biopsy
1521502|NCT02805868|Other|Laboratory Biomarker Analysis|Correlative studies
1521503|NCT02805868|Biological|Siltuximab|Given IV
1521504|NCT02805855|Drug|Autologous Adipose-Derived Mesenchymal Stromal Cells|Human, autologous, culture expanded, adipose derived, mesenchymal stromal cells (AMSCs) produced on site in the Mayo Clinic Human Cellular Therapy Laboratory using current good manufacturing practices (cGMPs).
1521505|NCT02805842|Drug|Tacrolimus BID|Administration of Tacrolimus BID
1521506|NCT02805842|Drug|Advagraf QD|administration of Advagraf QD
1521507|NCT02805829|Drug|Trastuzumab + NK cells|NK cellular therapy conduct 2 cycles per year. Herceptin initial dose of 8 mg/kg over 90 minutes IV infusion, followed by 6 mg/kg over 30 to 90 minutes IV infusion every 3 weeks till to disease progress.
1521508|NCT02805803|Other|Quality of life questionary|Patients will be asked to fill out the questionaries before treatment initiation and at 3, 6 , 12 and 24 months after antibiotherapy initiation.
1521509|NCT02805790|Drug|Elamipretide|40 mg elamipretide administered once daily subcutaneously
1521510|NCT02805790|Drug|Placebo|4 weeks of treatment with placebo administered once daily subcutaneously
1521511|NCT02804724|Other|No intervention|
1521516|NCT02804698|Behavioral|Education intervention|13-week educational and physical activity intervention
1521517|NCT02804685|Other|exercise protocol|The multi-intervention exercise protocol consists in a performance of agility, strength and balance exercises. It has to be fulfilled during 6 weeks (twice a week) before the regular training performance. The exercises should be done for almost 15 minutes approx. There will be 6 exercises in total: squat with toe raise, one-leg squats, single-leg balance (throwing a ball with a partner), vertical jumps, hamstring exercise, quick forwards and backwards sprints.
1521518|NCT02804659|Other|microRNA|Extraction of the microRNA using the mirVana miRNA isolation kit and quantification using real-time PCRs
1521519|NCT02804646|Drug|recombinant human endostatin|endostar was continuous intravenous transfusion for 7 days，with the dose of 15mg/m2 for one day
1521520|NCT02804646|Drug|pemetrexed plus cisplatin or carboplatin|the dose of pemetrexed was 500mg/m2 on day 1 of every 21 days,plus cisplatin or carboplatin.
1521521|NCT02804633|Drug|IV Acetaminophen|1 gram every 6 hours
1521522|NCT02804633|Drug|Placebo|100 ml of normal saline every 6 hours
1521523|NCT02804620|Behavioral|Peer-led, Empowerment-based Approach to Self-management efforts in Diabetes|The investigators will train patients with type 2 diabetes who are well-controlled and pair them up with participants. Peer leaders will help the participants overcome their problems and teach them how to make changes by 5 step goal setting strategy. The peer leaders never give advice on any medical condition. All the medical questions will be referred to the research team.
1521524|NCT02804607|Other|questionnaire|
1521525|NCT02805751|Device|Early loading on a training pedal|The patients will perform early loading by using a special training pedal for 5 weeks, starting 2 weeks after the rupture. The patients will remove the walker and train twice a day on this pedal.
1521526|NCT02805751|Other|Tendon strain exercises|The patients will perform tendon strain exercises 3 times each day from 2 weeks after the rupture.
1521527|NCT02805751|Other|Early weight bearing|The patients are allowed to bear weight as much as tolerated in the walker from day 1.
1521528|NCT02805738|Drug|CKD-390|CKD-390 1 Tablet (48 weeks)
1521529|NCT02805738|Drug|viread|viread1 Tablet (24 weeks), CKD-390 1 Tablet (from 24 weeks to 48 weeks)
1521993|NCT02801890|Biological|Intravenous injection|Intravenous injection of stem cell or placebo to the patients with The patients with ultra filtration failure (UFF) .
1521530|NCT02805725|Drug|Phase 1: Trabectedin|"A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.)
Patients will be allocated 4 doses of Trabectedin following a 3 + 3 design:"
1521531|NCT02805725|Drug|Phase 2: Trabectedin|All patients will be treated at the RP2D of trabectedin defined in the preliminary phase I trial with the same schedule as in the phase I trial.
1521532|NCT02805725|Drug|Phase 1: Cyclophosphamide|A treatment cycle consists of 4 weeks. Treatment may continue until disease progression or study discontinuation (withdrawal of consent, intercurrent illness, unacceptable adverse event or any other changes unacceptable for further treatment, etc.) Cyclophosphamide will be administered bi-daily (50 mg x 2), and given on a week on/week off schedule.
1521533|NCT02805725|Drug|Phase 2: Cyclophosphamide|All patients will be treated with metronomic cyclophosphamide with the same schedule as in the phase I trial.
1521534|NCT02805712|Other|Verbal Information and Discussion|Intervention patient will receive a outpatient session with a palliative care social worker in the heart failure clinic two weeks post discharge consent focusing on goals of care.
1521535|NCT02805712|Other|Control|The control group will receive usual written care material and a palliative care consult if ordered by physician.
1521536|NCT02805699|Drug|Baofeikang Granule|To observe the efficacy and safety of Baofeikang granules on Combined Pulmonary Fibrosis and Emphysema Treatment.Baofeikang Granules consist of（Codonopsis 30g, Cordyceps fungi powder 12g, ophiopogon root 10g, Schisandra 10g, angelica 15g, Bulbus Fritillariae thunbergii 10g, Sophora flavescens 10g,Forsythia suspensa 12g，Pinellia 10g, saponins thorn 10g, Radix Peucedani 10g）.1 bags,P.O（Oral）twice of each 3 months cycle.
1521537|NCT02805699|Drug|Placebo|On the basis of comprehensive treatment of spasmolysis antiasthmatic and anti-inflammatory, expectorant, cough ， give Chinese medicine placebo,1 bags,P.O（Oral）twice of each 3 months cycle.
1521538|NCT02805686|Device|spectral domain optical coherence tomography|
1521539|NCT02805686|Device|multifocal electroretinogram|
1521540|NCT02805673|Procedure|Osteopathy|
1521541|NCT02805660|Drug|mocetinostat|Mocetinostat oral capsule, administered three times weekly in combination with durvalumab
1521542|NCT02805660|Drug|durvalumab|Durvalumab 1500mg intravenously administered in 28 day cycles in combination with mocetinostat
1521543|NCT02805634|Other|Nine Hole Test|The Nine Hole Pegs technique is a simple manual dexterity test, commonly used in ergotherapy. The participant tries to place 9 pegs in a 9 holes perforated plate, and then tries to remove them as quickly as possible. The hand must stay in a depression within the plate, thereby insuring a constant distance between the hand and the pegs.
1521544|NCT02805634|Device|Triple Stimulation Technique|TST (Triple stimulation technique) combines two techniques used in neurologic diagnosis: magnetic stimulation and electroneuromyography. It is based on the principle of two collisions between the descending central stimulation (magnetic stimulation) and the ascending peripheric stimulation. TST allows to better quantify central nervous system diseases. The abnormal amplitude registered by TST is proportional to the intensity of conduction disorders. The evaluation of these disorders is more precise than with the magnetic stimulation technique alone.
1521545|NCT02805608|Drug|Injection of 68Ga-NOTA-AE105|One injection intravenously of 68Ga-NOTA-AE105
1521546|NCT02805608|Drug|Injection of 18F-FDG|One injection intravenously of 18F-FDG
1521547|NCT02805608|Device|Positron Emission Tomography and CT|Following of injection of 68Ga-NOTA-AE105 the patients will be PET/CT scanned starting 20 minutes post injection
1521548|NCT02805608|Device|Positron Emission Tomography and MRI|Following injection of 18F-FDG the patients will be PET/MRI scanned starting 60 minutes post injection
1521549|NCT02805595|Drug|23.4% Hypertonic saline|
1521550|NCT02805595|Drug|Saline|
1521551|NCT02805582|Drug|10ml ropivacain 0.5%|Ultrasound guided nerve block
1521552|NCT02805569|Device|articulating stylet|patient who intubated with articulating stylet
1521553|NCT02805569|Device|conventional stylet|patient who intubated with conventional stylet
1521554|NCT02805556|Drug|BMS-663068|Single oral dose of BMS-663068
1521555|NCT02805556|Drug|BMS-626529|Single intravenous dose of [13C]BMS 626529
1521556|NCT02805543|Device|Color doppler imaging|
1521557|NCT02805530|Other|First line systemic treatment|Epidermal growth factor receptor (EGFR)-mutated with tyrosine kinase inhibitors (afatinib, erlotinib or gefitinib). Patients without driver mutation duplet of chemotherapy based on platin taking account histologic subtype (Carboplatin or Cisplatin plus pemetrexed for adenocarcinomas, gemcitabine for epidermoid or paclitaxel for both) at discretion of the treating physician.
1521558|NCT02805530|Other|Radical treatment|to the primary and to the metastases will be with surgery, radiotherapy, chemoradiotherapy, stereotactic radiosurgery or radiofrequency ablation.
1521559|NCT02805530|Radiation|radiation therapy|Patients will receive dose and fraction regimen according to the metastatic site.
1521560|NCT02805530|Other|Chemoradiotherapy|Chemoradiotherapy with duplet based on platins (Carboplatin or cisplatin plus pemetrexed or paclitaxel or etoposide or vinorelbine) or monotherapy with carboplatin.
1521561|NCT02805517|Device|Percuvance™ Percutaneous Surgical System|Patients will undergo percutaneous externally-assembled laparoscopic donor nephrectomy where one or more 3 mm instruments are added or substituted for conventional 5 or 10 mm trocars.
1521562|NCT02805504|Drug|Exparel|This group will receive intraoperative local Liposomal Bupivacaine injection at the surgical site.
1521563|NCT02805504|Drug|Marcaine|This group will receive intraoperative Bupivacaine HCl injection at the surgical site.
1521564|NCT02805491|Other|meconium|to evaluate internal exposure to pesticide
1521565|NCT02805491|Other|self questionnaires to parents|to evaluate external exposure to pesticide
1521566|NCT02805478|Other|There is no intervention|This is a prospective observational cohort study without any intervention
1521567|NCT02805465|Device|CRT Device and Bi-ventricular pacing|Bi-ventricular pacing by a CRT device
1521568|NCT02805465|Device|CRT Device and His-bundle Pacing|His-bundle pacing by a CRT device through the pacing lead at His-bundle region
1521569|NCT02805452|Drug|Succinate of Solifenacin|
1521570|NCT02805452|Drug|Placebo of Succinate of Solifenacin|
1521994|NCT02801877|Behavioral|IntelliCare|
1521995|NCT02801877|Behavioral|Hub App with the Recommender System|
1521574|NCT02805426|Drug|Tranexamic Acid|
1521575|NCT02805426|Drug|Placebo|
1521576|NCT02805426|Drug|Misoprostol|
1521577|NCT02805413|Other|Détermination and comparison of blood pressure|Rebreathings will be performed every parabola (2, 4, 6, 8, 10…). Ultrasound measurements will be performed during the remaining parabolas (1, 3, 5, 7, 9…). The procedure consists of a fixed breathing frequency of 20 breaths per minute and an exact triggered start point for the measurements. . Central blood pressure measurements, finger blood pressure measurements, impedance cardiography, carotid plethysmography and phonocardiography will be performed continuously during the flights. The breaks between parabolas 10 and 11 and 20 and 21 will be used to change subjects, which takes approximately 5 minutes.
1521578|NCT02805400|Other|determination of cortical activity|"Cortical activity will be determined under changing gravity level by electroencephalography (EEG/LORETA). Brain hemodynamics change will be evaluated by NIRS. Heart rate and respiratory evaluation will be indicators of cardio-vascular and central nervous arousal and stress. Cognitive performance will be evaluated by computerized tests.
For these methods only commercially available CE marked devices will be used."
1521579|NCT02805387|Dietary Supplement|Treatment|Bicarbonate was ingested
1521580|NCT02805374|Drug|ASP1517|Oral
1521581|NCT02805348|Drug|Bixalomer|Oral
1521582|NCT02805335|Device|KTFIX PLUS|
1521583|NCT02805322|Device|ARC InstaTemp MD|Measurement of Body Temperature using an Infrared Non-Touch Thermometer - Experimental arm.
1521584|NCT02805322|Device|Covidien Genius 2 Tympanic Thermometer|Measurement of Tympanic Temperature using a standard approved method - Control arm.
1521585|NCT02805322|Device|Welch Allen SureTemp Plus Sublingual Thermometer|Measurement of Sublingual Temperature using a standard approved method - Control arm.
1521586|NCT02805309|Behavioral|Exercise|Exercises will target balance, flexibility, strength, and endurance (source: https://go4life.nia.nih.gov/). Home visits will take place twice a week for week 1 and 2; once a week for week 3 and 4; every other week for week for week 5 through week 8. Participants are instructed to do prescribed exercises for 30 minutes daily. The duration of this intervention is about 40 mins.
1521587|NCT02805309|Behavioral|Cognitive behavioral interventions|The following cognitive-behavioral strategies will be employed: 1) enhance positive beliefs about exercise through discussion of benefits of exercise; 2) discussion of barriers to exercise; 3) individualized goal setting and self-monitoring progress using exercise calendar; 4) develop a detailed exercise plan on how, what, when, and where to conduct exercise; 5) $10 rewards for exercising ≥30 mins per day for ≥5 of 7 days. The duration of this intervention is about 20 mins.
1521588|NCT02805309|Behavioral|Attention control education program|A health care professional will call the participant weekly for a period of 8 weeks to teach general tips about exercise and diet (source: https://go4life.nia.nih.gov/). No recommendations for a specific exercise program will be made, except for walking 30 minutes daily or as tolerated. Each telephone session will cover 4 exercise tips and 4 healthy eating tips. The duration of the intervention is about 30 minutes.
1521589|NCT02805296|Other|Light irradiance|Comparison of double vs. single phototherapy
1521590|NCT02805270|Other|medication reconciliation intervention|medication reconciliation intervention comprises medication reconciliation on admission and discharge, bedside medication counseling and take-home medication list
1521591|NCT02805257|Drug|Mitomycin-C|Intraoperative and postoperative injections of mitomycin-c/Mitosol
1521592|NCT02805257|Other|Balanced Salt Solution|Intraoperative and postoperative injections of BSS
1521593|NCT02805244|Drug|JTZ-951, 14C-JTZ-951|
1521594|NCT02805231|Other|Vitamin D receptor polymorphic analysis|
1521595|NCT02805218|Drug|PEG-rhG-CSF|
1521596|NCT02805205|Drug|PEG-rhG-CSF|
1521597|NCT02805192|Device|Size Measurement by a Smart phone App|
1521598|NCT02805179|Radiation|High Dose Radiation|Radiation will be delivered once daily for a total of 30 fractions, five days per week.
1521599|NCT02805179|Drug|Temozolomide|Patients will receive concurrent temozolomide (75 mg/m^2 daily for 6 weeks). Adjuvant temozolomide will be given at 150-200 mg/m^2, D1-5 every 28 days for a minimum of six cycles and will be started approximately four weeks following completion of radiotherapy.
1521600|NCT02805166|Drug|PEG-rhG-CSF|
1521601|NCT02805153|Drug|PEG-rhG-CSF|
1521602|NCT02805153|Drug|rhG-CSF|
1521603|NCT02805140|Behavioral|Virtual exercise|Using videoconferencing, mothers assigned to intervention arm will participate in daily (weekdays) virtual exercise sessions for 6 weeks with other mothers.
1521604|NCT02805140|Behavioral|Mobile apps|During virtual exercise sessions, mothers assigned to intervention arm will follow exercise routines using mobile exercise apps that are recommended by study staff.
1521605|NCT02805140|Behavioral|Exercise resources and information|For all mothers, the investigators will provide standard information on the benefits of exercise and link to existing public health resources on how to start and stay active.
1521606|NCT02805101|Drug|Biodentine|Biodentine is going to be used as the sealing agent for the perforation.
1521607|NCT02805101|Drug|MTA|MTA is going to be used as the sealing agent for the perforation.
1521608|NCT02805088|Other|Electroencephalographic recordings|
1521609|NCT02805088|Other|neuropsychological evaluation|
1521610|NCT02805088|Other|clinical evaluation of symptoms|
1521611|NCT02805075|Other|Fructooligosaccharide|Given PO
1521612|NCT02805075|Other|Laboratory Biomarker Analysis|Correlative studies
1521613|NCT02805062|Procedure|Digital Pleural Manometry|Measurement of intra-pleural pressure and the removal of pleural fluid.
1521614|NCT02805062|Procedure|Magnetic Resonance Imaging|Subject lies a long tunnel shaped scanner and images are recorded.
1521615|NCT02805049|Drug|Echinocandins|The patients included in this protocol require routine treatment with caspofungin or micafungin. Though this intervention is under study, it is not modified by this protocol.
1521616|NCT02805036|Device|echocardiography|• Prospective, simultaneous recording of the cardiac output (measured non-invasively via transthoracic echocardiography) and a number of parameters commonly monitored in the surgical intensive care unit (CVP, SBP/DBP/MBP).
1521617|NCT02805036|Device|Arterial oximetry|measured by co-oximetry of a blood sample taken via the arterial catheter implemented for critical care
1521618|NCT02805023|Biological|BGC101 (autologous EnEPC preparation)|Intramuscular injections - single treatment session
1521619|NCT02805023|Biological|Control medium|Intramuscular injections - single treatment session
1521620|NCT02805010|Drug|Abatacept|On Day 1, subjects will receive a single SC dose of abatacept 125mg
1521621|NCT02805010|Other|Placebo|On Day 1, subjects will receive a single SC dose of placebo
1521622|NCT02804984|Genetic|ICUS|
1521623|NCT02804958|Procedure|STEMI treated with primary PCI|Primary percutaneous coronary intervention was performed according to the current standard guidelines. Coronary angiography was performed using standard techniques. The use of thrombectomy devices, intravascular ultrasound, intra-aortic balloon pump, and percutaneous cardiopulmonary support was up to the operator.
1521624|NCT02804945|Biological|Mesenchymal Stem Cells (MSCs)|Participants receive a maximum dose of 3 x 10^6 cell/Kg by vein one time on Day 1.
1521625|NCT02804945|Other|Standard of Care Treatment|Physician to decide on Standard of Care treatment.
1521626|NCT02804932|Dietary Supplement|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
1521627|NCT02804932|Other|Placebo|Microcrystalline cellulose (daily) for 8 weeks
1521628|NCT02804919|Device|Fisher & Paykel Healthcare CPAP Device|Fisher & Paykel Healthcare CPAP Device
1521629|NCT02804906|Behavioral|Home-based physical therapy|"Participants will be visited by a physical therapist 3 times a week for approximately 1 hour each day, for a duration of 4 weeks. These visits will serve to encourage adherence to the intervention, reinforce activities recommended at discharge, monitor safety under direct supervision, and adjust the exercise prescription if/as needed (e.g. advance recommended activity level) if necessary. Patients will also be provided with a tablet computer device installed with software, Moving Analytics, that will reinforce the cardiac rehabilitation program through daily reminders and easily accessible visual activity plans. This program will be updated by the physical therapist during home visits as the program advances. Daily patient-reported health status (Your Activities of Daily Living) 26 will be ascertained on the same tablet device by participants three times per week using open source software designed."
1521630|NCT02804906|Behavioral|Usual Care|"Participants in the control arm will be provided with a 30-minute counseling session on risk factor modification prior to discharge. Participants will be provided with a tablet computer device to complete patient-reported health status (Your Activities of Daily Living) 26 three times per week using open source software designed. Participants will be visited by the Research Coordinator or member of the study team at one month post-hospital discharge to perform a follow-up assessment that will include ADLs, IADLs, SF-12 PCS, frailty measures, and questions on healthcare utilization (hospital readmissions)."
1521631|NCT02804893|Procedure|VATS vs.RATS|
1521639|NCT02804867|Procedure|Online questionnaire and self-administered blood spot|
1521640|NCT02804854|Drug|Neutrophil Activation Probe (NAP)|Delivery of NAP by direct pulmonary administration followed by fibreoptic confocal microendoscopy. A total of 240 mcg (±25%) in three divided doses of 80 mcg (±25%).
1521643|NCT02804581|Dietary Supplement|Gum Arabic|Oral intake of GA in powder from30 grams per day
1521644|NCT02804568|Drug|ALKS 3831|Oral capsule, daily administration
1521645|NCT02804555|Other|Oxygen|Oxygen administration
1521646|NCT02804542|Other|Observational|
1521647|NCT02804542|Other|Retrospective review|
1521648|NCT02804529|Device|Veress needle|
1521649|NCT02804516|Behavioral|the nurse did early mobilization|the nurses know and do what is the early mobilization in ICU
1521650|NCT02804516|Behavioral|the nurse do not do early mobilization|the nurses do not know and do what is the early mobilization in ICU
1521651|NCT02804503|Behavioral|Calorie Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
1521652|NCT02804503|Behavioral|Exercise Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
1521653|NCT02804503|Behavioral|No Labels|Participants were asked to order food from the assigned menu as if they were having lunch in a fast food restaurant.
1521996|NCT02801877|Behavioral|Coaching|
1522211|NCT02800070|Biological|Lentivirus Alpha-gal A transduced stem cells|
1521654|NCT02804490|Dietary Supplement|Conventional white maize|Women and their infants will receive 2 meals/day prepared with conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
1521655|NCT02804490|Dietary Supplement|Provitamin A carotenoid biofortified maize|Women and their infants will receive 2 meals/day prepared with provitamin A carotenoid biofortified orange maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
1521656|NCT02804490|Dietary Supplement|Preformed vitamin A fortified maize|Women and their infants will receive 2 meals/day prepared with preformed vitamin A fortified, conventional white maize flour (287 g dry weight/d for women; 50 g dry weight/d for infants), 6 days/week for 15 weeks
1521657|NCT02804451|Device|Macintosh laryngoscope|intubation with standard macintosh larygoscope; gold standard
1521658|NCT02804451|Device|TruView EVO2 laryngoscope|A TruView EVO2 laryngoscope with blade size 3 (EVO2; Truphatek Holdings, Ltd., Netanya, Israel),
1521659|NCT02804451|Device|TruView EVO2 PCD laryngoscope|A TruView EVO2 PCD laryngoscope with blade size 3 (PCD; Truphatek Interbational Ltd., Netanya, Israel),
1521660|NCT02804451|Device|ETView SL|An ETView SL (ETView; ETViewLtd, Misgav, Israel) ednotracheal tube
1521661|NCT02804425|Other|actor-spectator|"actor-spectator group : actor at least once during the simulation session"
1521662|NCT02804412|Other|Control group|This is the control group with 14 h treatment over 10 workdays.
1521663|NCT02804412|Other|CIAT-group|Examine the efficacy of CIAT (30 h over 10 workdays) versus Control-group and communication treatment group.
1521664|NCT02804412|Other|communication treatment group (CTG)|Examine the efficacy of CTG (30h over 10 wokrdays) versus CIAT-group and control group
1521668|NCT02804373|Drug|Oxytocin continuous|Administration of 24 IU of oxytocin daily during 28 days
1521669|NCT02804373|Drug|Placebo|Placebo daily during 28 days
1521670|NCT02804373|Drug|Placebo continuous|Placebo administration the following 2 days after each OXT administration, during 28 days.
1521671|NCT02804373|Drug|Oxytocin|Administration of 24 IU of oxytocin every 3 days during 28 days.
1521672|NCT02804360|Device|dexamethasone injection|intravitreal dexamethasone in retinitis pigmentosa cystoid macular edema
1521673|NCT02804347|Device|Cognitive Function Imaging and Battery|Individuals will be placed in the fMRI scanner and complete the NBACK Cognitive Task
1521674|NCT02804347|Device|Sniffin Sticks|Using Sniffin Sticks, olfactory functioning will be assessed using three tests: identification, discrimination, and threshold.
1521675|NCT02804347|Other|Cognitive Batteries|Participants will conduct the following cognitive batteries: DSST, TMT A & B, RAVLT
1521676|NCT02804334|Procedure|Psychiatric Questionnaires|
1521677|NCT02804334|Procedure|Blood draw|
1521678|NCT02804308|Behavioral|Combined Training|
1521679|NCT02804295|Other|Collaborative Care Intervention|All eligible subjects that meet the eligibility requirements for approach and consent and have a positive screen for PDM will complete a baseline survey and will be enrolled into the intervention condition. This is an open trial and thus all consenting eligible subjects will receive the intervention.
1521681|NCT02804269|Other|Cardiovascular Magnetic Resonance|For the evaluation of heart function and structure of the cardiovascular system.
1521682|NCT02804269|Other|Fatmass measurement|It utilizes a scale machine to measure the body fat and skeletal muscle percentage
1521683|NCT02804256|Other|Blood Sample Collection|10 patients with ICCs to provide a second blood sample (20mls - 2 tablespoons) on top of the samples that will be collected for the biorepository.
1521684|NCT02804243|Device|nasal high flow therapy|The nasal high flow therapy has enabled high flow oxygen to be derived through nasal cannula. This mode not only allows constant FiO2 during peak inspiratory flow but also confers benefits including a low level of continuous positive airway pressure with increased end-expiratory lung volume and reduced work of breathing, partly through intrinsic positive end-expiration pressure compensation and dead space washout. The inspired gases are warmed and humidified, improving comfort and possibly reducing airway inflammation, leading to improved drainage of respiratory secretions.
1521685|NCT02804230|Device|MRgFUS Ablation of Epileptic Foci|MR-Guided Focused Ultrasound
1521686|NCT02804217|Other|Genetic: mutation profile|
1521687|NCT02804204|Drug|Anti-TNF|
1521688|NCT02804191|Drug|LO2A|eye drop solution.
1521689|NCT02804191|Drug|Saline|Placebo
1521690|NCT02804178|Drug|ATR-101|
1521691|NCT02804165|Genetic|Enterovirus vaccination|Enterovirus vaccination in genetically predisposed subjects having a high risk to develop type 1 diabetes.
1521692|NCT02804152|Behavioral|CBT for Chronic Pain in Pregnancy|"The content will be included in 8 weekly sessions, i.e., sessions 1-3 (Education on chronic pain, Theories of pain and diaphragmatic breathing and Progressive muscle relaxation and visual imagery), sessions 4 and 5 (Automatic thoughts and pain and Cognitive restructuring), sessions 7, 8 and 10 (Pleasant activity scheduling, Time-based pacing and Sleep hygiene), sessions 6 and 9 (Stress management and Anger management). Following this content, 1-2 sessions will be dedicated to review and reinforcement of key concepts or addressing any stuck points as well as cover content in session 11 (Relapse Prevention). The last session of therapy would include a review of achievements and commitment to continued application of CBT for chronic pain in participants daily lives."
1521693|NCT02804139|Other|Standard care plus physical therapy|Subjects attend 1 to 2 physical therapy sessions per week for 6 weeks beginning 8-10 weeks post-C section. The physical therapy program includes scar management, core retraining, and lumbar and pelvic joint mobilization.
1521694|NCT02804139|Other|Standard Care|Standard Care after C-section with no additional physical therapy.
1521821|NCT02803060|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formaulation number- SR15-62 -Z15-038).
1521695|NCT02804126|Procedure|TAP (transversus abdominis plane block)|ultrasound-guided regional block between abdominal wall muscles to treat acute postoperative pain. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
1521696|NCT02804126|Procedure|QL (quadratus lumborum block)|ultrasound-guided regional block between abdominal wall muscles to treat acute pain, similar to transversus abdominis plane block, but with distribution of local anesthetic towards paravertebral space. Stimuplex Ultra 360 needle will be used and 0.25% bupivacaine administered (0.2 mL/kg).
1521697|NCT02804126|Drug|Bupivacaine|In both groups (TAP&QL) 0.25% bupivacaine will be given (0.2 mL/kg)
1521698|NCT02804126|Device|Needle|Ultrasound-guided, Stimuplex ultra 360 needle will be used in the study
1521699|NCT02804126|Drug|Paracetamol|Intravenous paracetamol will be used (1.0 gram), up to 4 grams per day
1521700|NCT02804126|Drug|Metamizol|Intravenous metamizol will be used (1.0 gram), up to 4 grams per day
1521701|NCT02804126|Drug|Ketoprofen|Intravenous ketoprofen will be used (0.1 gram), up to 200 milligrams per day
1521702|NCT02804126|Drug|Morphine|Intravenous morphine (5 mg) will be given when pain exceeds 40 mm in VAS (maximum 2 doses per day)
1521703|NCT02804113|Device|Supera Peripheral Stent System|
1521704|NCT02804087|Device|MobiusHD|The MobiusHD device is a self-expanding nitinol implant that is delivered intravascularly to the internal carotid sinus via the delivery catheter.
1521705|NCT02804087|Other|Sham Implantation|
1521706|NCT02804074|Other|Optimization of antihypertensive treatment based on office BP|Optimization of antihypertensive treatment based on office BP
1521707|NCT02804074|Other|Optimization of antihypertensive treatment based on 24-hour ABPM|Optimization of antihypertensive treatment based on 24-hour ABPM
1521708|NCT02804061|Behavioral|NELIP|
1521709|NCT02804048|Other|superficial heat pelvic floor muscle|Superficial heat application in the pelvic floor muscle
1521710|NCT02804048|Other|superficial heat low back|Superficial heat application in the low back
1521711|NCT02804048|Other|Pelvic Floor Muscle Training|Pelvic floor muscle training exercises
1521712|NCT02804048|Other|Manual therapy in iliopsoas, diaphragm and piriformis|Manual therapy in iliopsoas, diaphragm and piriformis for 10 minutes
1521713|NCT02804048|Other|Intra Vaginal Manual therapy|Intra Vaginal Manual therapy in the pelvic floor muscles
1521714|NCT02804048|Other|Electromyographic biofeedback|Electromyographic biofeedback in the pelvic floor muscles
1521716|NCT02804022|Device|VPIA analgesia|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line with an anti-reflux valve to ensure precise drug administration and no backflow.
1521717|NCT02804022|Drug|Morphine|Recruited subjects will be given a VPIA device containing 1mcg/ml of morphine. Morphine will be administered via an intravenous infusion line.
1521718|NCT02803996|Drug|Aramchol|Part A: Aramchol oral tablets at 400 mg or 600 mg single dose Part B: Aramchol oral tablets at 400 mg or 600 mg multiple dose for 10 consecutive days.
1521719|NCT02803996|Drug|Placebo|Part A: Placebo oral tablets single dose Part B: Placebo oral tablets multiple dose for 10 consecutive days.
1521720|NCT02803983|Procedure|Pediatric hip plate|Children were treated with pediatric hip plate.
1521721|NCT02803983|Procedure|Cannulated screw|Children were treated with cannulated screw.
1521722|NCT02803957|Device|NeoChord DS1000|Trans-apical, beating heart repair of degenerative mitral valve insufficiency with artificial chordae implanted with the NeoChord DS1000
1521723|NCT02803957|Device|Surgical Mitral Valve Repair|Surgical repair of degenerative mitral valve insufficiency with cardiopulmonary bypass, and annuloplasty ring and some form of leaflet repair or artificial chordae.
1521724|NCT02803944|Drug|Azithromycin|
1521725|NCT02803931|Device|Cardiogoniometry|Cardiogoniometry cardiologic explorer, Enverdis GmbH medical solutions, Germany
1521726|NCT02803931|Device|12-lead ECG|
1521731|NCT02803905|Biological|Biological: Islet transplantation|This is a single procedure protocol. Only a single islet transplant will be performed in the patient. Islets can be isolated from more than one pancreas donor. The final islet product is a sterile suspension of ≥70% viable, ≥30% pure, allogeneic islets. A minimum of 5000 IEQ/KG will be transplanted. Although this study is a single dose protocol, islet transplant recipients with partial islet graft function will be considered for a second islet transplant (intra-hepatic administration) if they do not achieve primary efficacy endpoint criteria at 1 year
1521732|NCT02803892|Drug|rapamycin|Rapamycin will be administered at an initial dose 0.2 mg/kg on day 0, followed by 0.1 mg/kg/die. The daily dose will be adjusted to the whole blood 24-hr trough to target, as tolerated, 8-10 ng/mL
1521733|NCT02803892|Drug|Vildagliptin|Vildagliptin will be administered at a dose of 50 mg x2/die starting from day 0.
1521734|NCT02803892|Drug|Placebo 1|Placebo 1 will be titrated according to a random schedule alternating plausible doses of placebo. After 4 weeks of treatment patients will discontinue placebo 1
1521735|NCT02803892|Drug|Placebo 2|Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
1521736|NCT02803879|Device|Cardiogoniometry|
1521737|NCT02803866|Behavioral|Training program CAP-PREM|1ºAfter recruitment parents will fill the PMP S-E tool and the psychological tests evaluating their stress and depression . 2º parents will receive the training program during 4 weeks. 3º: before hospital discharge parents will fill again the PMP S-E tool and the psychological test evaluating their depression and anxiety
1521782|NCT02803424|Other|Volume controlled ventilation|During anesthesia and surgical procedure, volume-controlled ventilation will be applied with an inspiration:expiration ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg) without ventilatory mode change.
1522587|NCT02797236|Biological|SF2a-TT15 vaccine|
1521738|NCT02803853|Behavioral|Intervention|Intervention components will occur at the policy level (working with tribal leaders makers to sustain intervention components; food retail outlet level (working with grocery stores and owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with worksites and schools to deliver nutrition intervention sessions to youth and adults in intervention neighborhoods); household level (providing a social media program that provides parents and caregivers tips for healthier eating).
1521739|NCT02803840|Radiation|Low-dose radiotherapy|2 x 2 Gy on symptomatic sites only
1521740|NCT02803827|Other|Rapid diagnostics|Participants will have enteric specimens obtained using a flocked rectal swab, which will be transported in 2 mL Cary Blair medium. These will be tested using the BioMerieux BioFire FilmArray GI panel.
1521741|NCT02803827|Biological|Probiotic|The probiotic given will be Lactobacillus reuteri DSM 17938, 5x10e8 cfu/mL x 60 days, suspended in vegetable oil.
1521742|NCT02803827|Other|Placebo|The placebo will be the vegetable oil vehicle and look identical to the probiotic.
1521743|NCT02803814|Procedure|Superior mesenteric artery approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the superior mesenteric artery approach
1521744|NCT02803814|Procedure|Classic approach for pancreatoduodenectomy|Pancreaticoduodenectomy in tumors of the head of the pancreas and peripancreatic area using the classical approach
1521747|NCT02803775|Device|CRT Algorithm|
1521748|NCT02803762|Drug|Pacritinib|400 mg [14C]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose following at least a 10-hour fast (not including water) on Day 1
1521749|NCT02803749|Drug|Buspirone|
1521750|NCT02803749|Drug|Placebo|
1521751|NCT02803736|Device|acupuncture|Acupuncture involves the insertion of extremely thin needles through skin at strategic points on human body. Many Western practitioners view the acupuncture as a device to stimulate nerves, muscles and connective tissue, and believe that it can increases blood flow.
1521752|NCT02803723|Procedure|Holding-cuddling|"The Holding-cuddling is started 5 minutes before veinipuncture."
1521753|NCT02803723|Procedure|Sucrose|The sucrose adminstration is started 2 minutes before veinipuncture.
1521754|NCT02803710|Other|Microbiological study|
1521755|NCT02803697|Other|Patients|
1521756|NCT02803684|Other|MRI examination with tensor diffusion protocol acquisition. No injection needed.|standard MRI examination
1521757|NCT02803671|Device|TFU-NIRS|
1521758|NCT02803671|Device|NIRS|
1521759|NCT02803671|Device|EEG|
1521760|NCT02803658|Behavioral|smoking behavior|
1521761|NCT02803658|Biological|Sperm collection|
1521762|NCT02803645|Biological|blood sample|
1521763|NCT02803632|Behavioral|questionnaires|
1521764|NCT02803632|Device|actigraphic recording|
1521765|NCT02803593|Behavioral|Technology-based information and coaching/support program|The TICAA has three components in four languages (English, Mandarin Chinese, Korean, and Japanese): (a) social media sites; (b) interactive online educational sessions; and (c) online resources. The social media sites provide a mechanism by which participants can receive coaching/support from culturally matched peers and health care providers. The educational sessions provide information about general and sub-ethnic- specific topics related to breast cancer survivorship. The online resources include 35 Web links to resources related to breast cancer survivorship from scientific authorities and from general and sub-ethnic-specific health organizations/institutes.
1521766|NCT02803567|Behavioral|Brief psycho-educational intervention|Participants in the intervention arm will receive a computerized brief intervention composed of tailored feedback and psycho-education specific to their chronic condition.
1521769|NCT02803528|Drug|Biodentine|Biodentine is going to be used as the direct pulp capping material
1521770|NCT02803528|Drug|MTA|MTA is going to be used as the direct pulp capping material in the second group
1521771|NCT02803515|Biological|peripheral venous blood samples|peripheral venous blood samples measured preoperatively and postoperatively HIPEC (Day 1, day 3 and day 5 postoperative)
1521772|NCT02803502|Device|Chronometric method|Chronometric method of FVIII dosage on STA-R PLC automate (reactive Cephascreen STAGO, Unicalibrateur STAGO, plasma deficient Cryopep, Controls STAGO)
1521773|NCT02803502|Device|Chromogenic method|"Chromogenic FVIII assay method ( BIOPHEN FVIII: C and BIOPHEN Factor IX of the firm Hyphen BioMed)"
1521774|NCT02803502|Device|Thrombin generation test (TGT)|"Briefly: the measurement of thrombin generation is performed by the technique of calibrated and automated Thrombinography (CAT) developed by Hemker HC. This technique allows the simultaneous analysis of multiple samples using a fluorometer (Fluoroscan Ascent, ThermoLabsystems OY, Helsinki, Finland) and a Thrombinoscope® software that converts the fluorescence intensity obtained by concentration of active thrombin. The reagent PPP-reagent Low respectively containing 1pm FT and 4μM phospholipid (PL) as a final concentration will be used."
1521775|NCT02803489|Device|medical device intervention|
1521776|NCT02803463|Procedure|open appendectomy with peritoneal closure|open appendectomy with peritoneal closure under general anesthesia for acute appendicitis
1521777|NCT02803463|Procedure|open appendectomy without peritoneal closure|open appendectomy without peritoneal closure under general anesthesia for acute appendicitis
1521778|NCT02803450|Procedure|Epidural needle|Medication administration via epidural needle.
1521779|NCT02803450|Procedure|Catheter Administration|Medication administration via epidural catheter.
1521780|NCT02803450|Procedure|Standard of Care Epidural Administration|Medication administered at higher concentration, lower volume via epidural catheter.
1521852|NCT02802852|Drug|Filgrastim|Administration of Filgrastim 10 mcg/kg every 3rd day for 30 days
1521853|NCT02802839|Device|Virtual Reality|
1521783|NCT02803424|Other|Autoflow-volume controlled ventilation|After tracheal intubation, volume-controlled ventilation will be initiated with an I:E ratio of 1:2 and a tidal volume of 8 mL per ideal body weight (kg). Immediately after CO2 pneumoperitoneum with steep Trendelenburg positioning, Autoflow-volume controlled ventilation will be applied instead of volume-controlled ventilation. Immediately after CO2 desufflation and supine positioning, volume-controlled ventilation will be applied again.
1521784|NCT02803398|Other|Compression bandages application and interface pressure measurements|Bandages, which are applied in a spiral pattern on the leg, are composed of Biflex 16 (Thuasne) and/or Rosidal K (Lohmann & Rauscher).
1521785|NCT02803385|Other|Continous Epidural Analgesia|continuous epidural infusion at rate of 5-8 ml /hr based on maximum allowable safe dose as per body weight. The pump settings will be set at 0.1 ml per bolus with lockout interval of 20 minutes. Cross over to other group will occur after 36hours.
1521786|NCT02803385|Other|Patient Controlled Epidural Analgesia|patient controlled epidural analgesia in form of Patient Controlled Analgesia pumps with continuous rate of 5-8ml/hour & demand dose of 2-3 ml p.r.n with a lock out interval of 20 minutes based on maximum allowable safe dose as per body weight .The group will have a cross over at 36 hours postop.
1521787|NCT02803372|Other|Goal-directed circulatory management|In addition to routine monitoring, invasive LiDCOrapid is used to monitor MAP, SVV and CI. Intraoperative circulatory management is performed according to the goal-directed principal, i.e., to maintain MAP > 95 mmHg, SVV < 6%, and CI 3.0-4.0 L/min/m2, started from renal artery clamping and maintained until the end of surgery. Crystalloid solution is firstly infused to maintain SVV at the target level, dobutamine and/or noradrenaline are then infused to maintain MAP and CI at the target levels.
1521788|NCT02803372|Other|Routine circulatory management|Routine monitoring is performed, which include invasive blood pressure and urine output. Intraoperative circulatory management is performed according to routine practice, i.e., to maintain blood pressure within 20% from baseline level and urine output > 0.5 ml/kg/h by infusing crystalloid solution and administering vasoactive drugs when considered necessary.
1521789|NCT02803359|Procedure|Placement of a needle electrode through the thyrohyoid membrane into the submucosal space within the false vocal fold|
1521790|NCT02803346|Other|Circulating blood (leukocytes)|mHLA-DR measurement (in vitro)
1521791|NCT02803333|Other|No Intervention|
1521792|NCT02803320|Drug|SPF 50 Y65 110 (BAY 987516)|Subjects applied the assigned products to all sun-exposed areas of their face and body liberally and evenly, in accordance with instructions. Sun exposure was divided into two periods. Each period consisted of direct sun exposure (out of water; Cycle A) and water exposure (Cycle B). Cycles A and B were repeated two times before study closeout.
1521793|NCT02803307|Drug|TLC599|Single dose via intra-articular injection
1521794|NCT02803294|Procedure|transcatheter aortic valve replacement|
1521795|NCT02803281|Other|Frailty Assessment|Various physiologic and frailty assessment tests
1521796|NCT02803268|Drug|MT-8554 low dose|
1521797|NCT02803268|Drug|MT-8554 middle dose|
1521798|NCT02803268|Drug|MT-8554 high dose|
1521799|NCT02803268|Drug|Placebo|
1521800|NCT02803255|Device|MAHI Exo-II|
1521801|NCT02803242|Other|Patient Reported Outcomes|
1521802|NCT02803229|Drug|Adderall-XR|
1521803|NCT02803229|Drug|Matched placebo|matched placebo provided for placebo arm
1521804|NCT02803216|Drug|standard triple region|ten days of standard triple region (20mg omeprazole 20mg, 1.0 amoxicillin, 0.5 clarithromycin, Bid).
1521805|NCT02803216|Drug|2-week Xiang-sha-liu-jun decoction|2-week Xiang-sha-liu-jun decoction, bid.
1521806|NCT02803216|Drug|4-week Xiang-sha-liu-jun decoction|4-week Xiang-sha-liu-jun decoction, bid.
1521807|NCT02803203|Drug|osimertinib|
1521808|NCT02803203|Drug|Bevacizumab|
1521809|NCT02803190|Behavioral|ICG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program with focus on central muscle groups. ICG subjects received once weekly group exercise.
1521810|NCT02803190|Behavioral|MTG|All participants received a CD-ROM and one hour education on osteoporosis, sarcopenia, frailty, fall prevention, nutrition, low back pain, good posture, and coping strategy and another hour of professional led exercise program on central muscle groups. MTG subjects received twice weekly machine-based resistance training on major and central muscle groups.
1521811|NCT02803177|Biological|BMC2012|
1521812|NCT02803177|Device|beta-TCP Chronos® Synthes|
1521813|NCT02803164|Device|Wound Vacuum-assisted dressing|Management of chronic open chest wounds with V-AD assisted dressing.
1521814|NCT02803151|Radiation|Stereotactic ablative radiotherapy|SABR with 36 to 45 Gy in six fractions to the defined target volume with met organ-at-risk constraint criteria using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given once per day, 2-3 fractions per week with no more than 2 consecutive daily fractions, over 2 to 2.5 weeks.
1521815|NCT02803125|Behavioral|Psychosocial intervention|This intervention is to be developed during the study. It will likely include modules that provide anger management strategies, communication skills, and education about interpersonal relationships and social support. In addition, psychoeducation about behavioral activation and stress management will likely be included
1521816|NCT02803125|Behavioral|Support group control|The support groups will be process-oriented in nature with core elements manualized to facilitate consistency of the intervention. In particular, group leaders will facilitate a check-in with the group, and the agenda will be open to topics brought in by group members
1521817|NCT02803112|Procedure|Emergent craniotomy for traumatic brain injury|Emergent craniotomy for traumatic brain injury (either for removal of an epidural hematoma, subdural hematoma, intraparenchymal hematoma or decompressive craniectomy).
1521818|NCT02803099|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number-SR15-63-Z13-084).
1521819|NCT02803073|Drug|Testosterone|Testosterone Cypionate Intramuscular injections will be administered weekly
1521820|NCT02803073|Drug|Normal Saline|Normal Saline Intramuscular injections will be administered weekly
1521895|NCT02802566|Dietary Supplement|Standard prenatal vitamin|Standard prenatal vitamin
1521822|NCT02803047|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation number - SR15-61-Z15-034).
1521823|NCT02803034|Drug|Coppertone (BAY987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number- SR15-60-Z15-030).
1521824|NCT02803021|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation Number - SR15-47-Z13-076)
1521825|NCT02803008|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation number - SR15-46-Z13-072)
1521827|NCT02802969|Procedure|Surgery|"The operative approach and operating time will be performed according to neurosurgical practices (for head and neck) or surgical orthopaedic team (for sacrum) depending on the location, the extension and the relationship of the lesion to critical structures.
The surgery can be macroscopically complete or incomplete."
1521828|NCT02802969|Radiation|Protontherapy|Radiotherapy will be done with the Cyclotron, for a total dose of 78 Gray Relative Biological Effective (Gy RBE) - 70 Gy RBE to the tumor bed and macroscopic volume and 8 Gy RBE to the the hypoxic component volume, delivered in 39 fractions spread over 67 days.
1521829|NCT02802969|Drug|18F FAZA|FAZA PET/CT, in order to target the hypoxic zones
1521830|NCT02802956|Other|Daily Life Promotion Program|Daily Life Promotion Program
1521831|NCT02802956|Other|general rehabilitation treatment|general rehabilitation treatment
1521832|NCT02802943|Biological|Peptide Vaccine|Individualized multi-peptide cocktail consisting of 257µg each of 5 HLA class I and 5 HLA class II restricted peptides. The peptides for each individual patient will be selected from a warehouse consisting of 40 different peptides restricted by the 7 most common HLA class I allotypes (A*01, A*02, A*03, A*24, B*07, B*08, B*44) and 5 HLA class II peptides. HLA class I peptides to be applied in each CLL patient will be selected in a personalized manner guided by the mass spectrometric analysis of the patient-individual HLA ligandome. Peptides will be administered subcutaneously. Vaccination will take place on d1, d4, d8, d15, d22 followed by vaccinations every 4 weeks for 1 year. The peptide warehouse is selected based on our data on the non-mutant HLA-presented antigenome of CLL identified as frequently presented CLL-associated T cell epitopes with a high potential for broad clinical application.
1521833|NCT02802943|Drug|Lenalidomide|MRD-positive patients will receive 2.5 mg lenalidomide (Revlimid®) p.o. daily. Low dose lenalidomide will be administered as an immunomodulatory adjuvant. 8-10 weeks after completion of first-line treatment MRD-positive patients will start immunomodulatory therapy at day 5 with 2.5 mg of lenalidomide p.o. daily.
1521834|NCT02802943|Drug|Imiquimod|All patients will receive imiquimod (Aldara®) as local adjuvant, applied topically at the side of vaccination 18h to 24h prior to the vaccination.
1521835|NCT02802930|Drug|SPF 50 Y65 110 (BAY987519)|Application of 200 µL in an occlusive patch of Webril (0.150 ± 0.010 mg) compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
1521836|NCT02802930|Drug|SPF 50 Y51 002 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
1521837|NCT02802930|Drug|SPF 15 V27 104 (BAY987519)|Application of 200 µL in an occlusive patch of Webril compared to that of a negative control (0.9% sodium chloride, NaCl) and followed by irradiation with UV A and UVB.
1521838|NCT02802930|Drug|Sodium chloride [NaCl]|Negative control (200 µL, 0.9% sodium chloride [NaCl]) after a single 24 h application of test materials followed by irradiation with ultraviolet A (UVA) and ultraviolet B (UVB).
1521839|NCT02802917|Drug|SPF 50 Y49 091 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
1521840|NCT02802917|Drug|SPF 50 X15 158 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
1521841|NCT02802917|Drug|SPF 50 X15 160 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
1521842|NCT02802917|Drug|SPF 50 X57 162 (BAY 987516)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
1521843|NCT02802917|Other|J & J baby shampoo, X46 046 (control)|5 μL of the appropriate test or control article were instilled into the lower conjunctival sac of the eye.
1521844|NCT02802904|Other|Diet: Palm olein IV64|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat Palm Olein IV64 which was incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
1521845|NCT02802904|Other|Diet: Cocoa butter|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat cocoa butter which was incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
1521846|NCT02802904|Other|Diet: Virgin olive oil|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment test fat virgin olive oil which incorporated into daily snacks (~50g of test fats, brownies (~15g test fat each) for breakfast and 4 pieces cookies (~5g test fat each) with low fat palm olein based background diet daily.
1521847|NCT02802878|Device|Electrodes (Sekisui Plastics Co.) and Joint Motion Sensors (Mutoh Engineering, Inc.)|"Electrodes (Sekisui Plastics Co., Tokyo, Japan) will be placed on the anterior thigh over the motor points of the bilateral vastus medialis and lateralis, and on the posterior thigh over the motor points of the medial and lateral hamstrings. Electrical stimulation intensity will be set to approximately 40% of 1 repetition maximum (RM).
A joint motion sensor (Mutoh Engineering Inc., Tokyo, Japan) will trigger stimulation of the antagonist once it senses the initiation of volitional contraction of the agonist muscle group."
1521848|NCT02802878|Device|Isokinetic Training with Computer Sports Medicine Inc. (CSMi) HUMAC NORM|Low intensity exercises completed using CSMi HUMAC NORM in isokinetic mode at approximately 40%1 RM.
1521849|NCT02802865|Drug|Clomiphene|
1521850|NCT02802865|Drug|Letrozole|
1521851|NCT02802852|Device|Pneumatic calf compression|Application of a pneumatic calf compression device for two hours per day, every day for 30 days.
1521854|NCT02802826|Behavioral|Tailored Exercise Prescription|The intervention is a walking- based exercise prescription with the aim of a graduated increase in exercise to achieve national guidelines (i.e. Over 150mins of moderate intensity exercise over a week).
1521855|NCT02802813|Drug|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ)|
1521856|NCT02802813|Drug|Dihydroartemisinin-piperaquine (DP) + Primaquine (PQ) placebo|
1521857|NCT02802800|Other|Plyometric training|Plyometric exercises
1521858|NCT02802787|Other|Camp Discovery|Activities will include physical, social, emotional, sensory and spiritual activities.
1521859|NCT02802774|Other|Plaster Splint|The custom plaster splint is the historical standard. The surgical incision is dressed with non-stick gauze, 4x4 gauze pads, cotton padding, a plaster splint applied to the palmar surface of the palm and forearm, and then a cloth wrap to keep it all in place. Patients will wear the plaster splint for 2 weeks post-op.
1521860|NCT02802774|Other|Velcro Brace|The Velcro wrist brace is a commercially available over-the-counter splint which will initially be fitted over a thin layer of non-stick gauze, 4x4 gauze, and cotton padding. Patients will be asked to wear the brace as much as possible for the first 2 weeks post-op.
1521861|NCT02802774|Other|Soft Dressing|Patients in the soft dressing group will have non-stick gauze, 4X4 gauze, cotton padding, and a cloth wrap. It will be the same dressing as the custom splint without the plaster slab. Patients wear the soft dressing for the first three days post-op.
1521862|NCT02802748|Drug|Oral Vinorelbine|Metronomic Schedule of Vinorelbine administered orally in a schedule monday-wednesday-friday, tuesday-thursday-saturday, etc
1521863|NCT02802748|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg QD for 3 weeks.
1521864|NCT02802735|Drug|Apremilast|
1521865|NCT02802735|Drug|Placebo|
1521866|NCT02802722|Dietary Supplement|Vitamin D3 supplementation|Capsules to be dispensed using an electronic dispenser to allow real time logging of adherence.
1521867|NCT02802722|Biological|Peripheral blood and induced sputum sampling|To attain samples for immunological testing
1521868|NCT02802722|Radiation|Chest computerised tomography (CT) scans|For volumetric quantification of lung abnormalities
1521869|NCT02802722|Other|Symptom questionnaire|Symptom questionnaire for recent symptom history
1521870|NCT02802722|Other|Placebo|To be dispensed using an electronic dispenser to allow real time logging of adherence.
1521871|NCT02802709|Device|SB-061|delivered via intra-articular injection
1521872|NCT02802709|Other|Placebo|Placebo
1521873|NCT02802696|Drug|Furosemide|A bolus dose of 20mg furosemide (20mg/2mL) will be given intravenously by slow intravenous push within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
1521874|NCT02802696|Drug|Normal Saline|A single bolus dose of 2 mL normal saline will be given intravenously immediately within 60 minutes prior to the start of the red blood cell transfusion; infusion via minibag is also acceptable.
1521875|NCT02802683|Drug|Bupivacaine|spinal anesthesia with hyperbaric bupivacaine
1521876|NCT02802683|Drug|Levobupivacaine|spinal anesthesia with isobaric levobupivacaine
1521877|NCT02802683|Drug|Phenylephrine|continous infusion of phenylephrine
1521878|NCT02802683|Drug|normal saline|continous infusion of normal saline
1521879|NCT02802670|Drug|[14C]-GDC-0810|Participants will receive a single 300-mg dose of GDC-0810 containing approximately 100 microcuries of [14C]-labeled GDC-0810 on Day 1.
1521880|NCT02802657|Procedure|Treat-and-Extend regimen|For the T&E regimen,we recorded patients' data after retreatment by 3 monthly intravitreal injections of Conbercept. Patients were examined 6 weeks after the third injection, with ETDRS visual acuity testing, fundus ophthalmoscopy and photography, and OCT, and treated on the same day. The interval between treatments was extended by 2-week (12-week was a maximum) provided that OCT and fundus examination did not show either exudative manifestations or new macular hemorrhage or active CNV or reduced by 2 weeks (4-week was minimum) in case of such manifestations or hemorrhage. The persistence of pigment epithelium detachment was not considered a condition that justified shortening the interval between injections.
1521881|NCT02802657|Procedure|Pro Re Nata|For the PRN group, we recorded patients'data after retreatment by 3 monthly intravitreal injections of Conbercept.Subsequent reinjections were given as needed according to the changes in patients'visual acuity and/or the exudation shown by OCT. Four to five weeks after the third and last injection, all patients in the PRN group underwent an examination, including ETDRS visual acuity, fundus photography,and OCT. In case of persistent subfoveal or perifoveal fluid, macular intraretinal edema, visual loss of >5 letters, or the occurrence of a new hemorrhage, patients were retreated. The persistence of hemorrhage without evidence of fluid was not considered a criterion for retreatment. In the absence of retreatment criteria, no further injections were given and another examination was proposed usually 4 weeks later.
1521882|NCT02802657|Drug|Conbercept|
1521883|NCT02802644|Drug|Sitagliptin|Sitagliptin is indicated to control hyperglycemia in type 2 diabetic patients.
1521884|NCT02802644|Drug|Non DPP-4 Inhibitor|This group patients is permitted to take any other oral anti-hyperglycemic agents except sitagliptin.
1521887|NCT02802618|Other|Interactive 3D visualization technique|The pulmonary rehabilitation consists of exercise training during two times/week for 10 weeks and a theoretic part presented with 3D visualization technique.
1521888|NCT02802605|Drug|Bemiparin|Bemiparin subcutaneus administration
1521889|NCT02802592|Drug|Epogen|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
1521890|NCT02802592|Drug|Normal Saline|1:1 randomization to either the Epogen arm or Placebo(Normal Saline) arm
1521891|NCT02802579|Radiation|standard protocol|tube voltage: 120 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
1521892|NCT02802579|Radiation|enhanced protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 90° (with two detectors in a 90° angle)
1521893|NCT02802579|Radiation|enhanced obesity protocol|tube voltage: 140 kV current time product: 350 mAs/rotation rotation: 180° (with two detectors in a 90° angle)
1521894|NCT02802566|Dietary Supplement|BMI-based prenatal vitamin|The intervention group receives additional antioxidant micronutrients that we have found to be decreased in obese pregnant women.
1521896|NCT02802553|Device|SmartGoggle|SmartGoggle is a novel stereoscopic wearable multimodal intraoperative imaging and display systems entitled Integrated Imaging Goggles for assessment of SLNs. The prototype system offers real time stereoscopic fluorescence imaging along with in vivo handheld microscopy. The investigators have found that the system can detect fluorescent targets with as low as 1.2 picomoles ICG (60 nM concentration). The hand-held microscopy module has a resolution of 25 micron. The prototype system has 2 complementary metal-oxide-semiconductor (CMOS) imaging sensors housed on a printed circuit board (PCB) with imaging lenses and emission filters optimized for ICG dye. The light source provides concurrent excitation centered at 780 nm and white light illumination with OD6 level cut-off. The SmartGoggles is a non-invasive imaging system that does not require contact with patients.
1521897|NCT02802553|Other|Cardio-Green|Indocyanine Green for Injection USP is a sterile, lyophilized green powder containing 25 mg of indocyanine green with no more than 5% sodium iodide. Indocyanine Green for Injection USP is dissolved using Sterile Water for Injection, and is to be administered intravenously.
1521898|NCT02802553|Device|SPY Elite|Previously validated fluorescence detection system. Will be used to look at the same regions as the SmartGoggles to confirm sensitivity
1521899|NCT02802553|Device|gamma probe|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
1521900|NCT02802553|Other|Blue Dyes|Gold standard for fluorescence detection. The gamma probe and blue dyes will be used in conjunction to confirm presence of Sentinel Lymph Nodes (SLNs). The gamma probe provides non-imaging sensing data and the blue dyes provide visual signs for detection of SLNs.
1521901|NCT02802540|Drug|Nabilone|Patients going to take 0.5 mg capsules of nabilone (CESAMET) the first 2 weeks and then increased to 1 mg to complete 8 weeks.
1521902|NCT02802540|Drug|Placebo|Patients going to take capsules of placebo until complete 8 weeks.
1521903|NCT02802527|Procedure|Percutaneous Tracheostomy|
1521908|NCT02802501|Drug|Tafenoquine|This intervention is provided as tablet containing 150 mg of tafenoquine. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
1521909|NCT02802501|Drug|Matched-Placebo for Tafenoquine|This intervention contains tafenoquine matched-placebo. Two tablets of this formulation will be administered orally with water as a single dose after a meal. Dose will be taken at least 3 hours after DHA-PQP.
1521910|NCT02802501|Drug|Primaquine|This intervention is provided as over-encapsulated tablet containing 15 mg of primaquine. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
1521911|NCT02802501|Drug|Matched-Placebo for Primaquine|This intervention contains primaquine matched-placebo. One capsule of this formulation will be administered orally with water as a single dose after a meal for 14 days. Dose will be taken at least 3 hours after DHA-PQP (Days 1, 2 and 3).
1521912|NCT02802501|Drug|Dihydroartemisinin-piperaquine (DHA-PQP)|This formulation is provided as tablet containing 320 mg of piperaquine tetrasphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). This tablet will be administered orally as single dose for 3 days. For subjects weighing <75 kg, 3 tablets will be administered per day. For subjects weighing >=75 kg, 4 tablets will be administered per day. Dose will be taken at least 3 hours after last food intake. No food will be allowed for at least 3 hours after dosing.
1521913|NCT02802501|Drug|ACT plus PQ (Rescue medication)|Subjects with relapse during the 180 day follow up period will be given an ACT plus PQ 0.5 mg/kg for 14 days as rescue medication.
1521914|NCT02802501|Drug|PQ (End of study treatment)|Subjects who do not relapse during the study will receive PQ 0.5mg/kg for 14 days at the end of the study.
1521915|NCT02802488|Procedure|Blood sampling|"A blood sampling will be performed in patients diagnosed with atrial fibrillation in order to test if having a D-dimers value superior or equal to the patient's age is predictive of a thrombus.
Thombus will be diagnosed according to the standard of care."
1521916|NCT02802475|Biological|vena punction|
1521917|NCT02802462|Behavioral|HIT|3-minute intervals at 40% and 80%VO 2max
1521918|NCT02802462|Behavioral|MCT|sustained 60%VO 2max
1521919|NCT02802449|Drug|25 Hydroxy- Vitamin D3 [25 (OH) D3]|Two 50,000 IU tablets of oral Vitamin D3 [also known as cholecalciferol or 25 hydroxy-Vitamin D3 or 25 (OH) D3] will be given at baseline and 2 weeks after the baseline visit under direct observation by the nurse or research coordinator.
1521920|NCT02802449|Drug|Placebo|
1521921|NCT02802436|Procedure|Extraction with socket graft|Extraction will be done as usual standard of care to preserve socket walls. Sockets will be measured at all 4 line angles for depth with the same periodontal probe, Buccal-Lingual dimension will be measured prior to graft placement. Graft material (mineralized cortical/cancellous Bone Powder 250-1000µ) will be used for both sites. Volume of graft used will be recorded. Both sites will be filled slightly below marginal bone level (1mm). Test site will be injected with Bioactive Agent. At 3 levels apical 1/3rd, middle 1/3rd and coronal 1/3rd. Control site will be injected with saline (or vehicle) at same levels. Occlusal orifice will be closed with Collagen plug adjusted for depth to meet free gingival margins and then sutured with 4-0 PGA (Vicryl)
1521922|NCT02802423|Drug|BLEX 404 Oral Liquid|BLEX 404 Oral Liquid is administered twice daily during the Docetaxel monotherapy period. The dose of Docetaxel is 75 mg/m2 IV, 21 days a cycle.
1521923|NCT02802410|Device|IQ-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
1521924|NCT02802410|Device|Kinesiotape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
1521925|NCT02802410|Other|No-Tape|RMS-values of leg muscles at pre-activation (50ms) before ground-contact and post-activation 0-30ms and 30 - 150ms after ground-contact during drop-jump, running and stair climbing.
1521926|NCT02802397|Other|Self-administered questionnaire and blood and urine samples|Self-administered questionnaire and blood and urine samples
1521927|NCT02802371|Behavioral|Psychosocial intervention|Caregivers included in this group will benefit from a multi-component intervention with three collective sessions and individual interview in face-to-face or by phone according to the follow-up time.
1521928|NCT02802371|Other|Pharmaceutical care and psychosocial support|"Caregivers included in this group will benefit from the same multi-component intervention that group psychosocial intervention with the integration of pharmaceutical care by a clinical pharmacist. The clinical pharmacist will intervene in: 1) the pharmaceutical need assessment of the caregivers considering their medication management and the medication management of their relatives at the inclusion; 2) a collective session on medication management; and 3) personalized interviews to consider needs, medication problems and difficulties in the therapeutic optimization process."
1521929|NCT02802358|Procedure|Surgery or non-invasive procedure (reduction of the fracture, immobilization, stabilization)|
1521933|NCT02802332|Behavioral|Footlength Card|The footlength card has an image of a baby's foot. The card is to be held up against the baby's foot after birth; if a baby's foot is smaller than the image, or if the woman/family member is concerned about the health of their baby, they can call the number printed on the card and hear a pre-recorded message about basic care for newborn babies
1521934|NCT02802319|Device|Porcine Xenograft (Zcore)|Ridge preservation bone grafting after tooth extraction
1521935|NCT02802319|Device|Bovine Xenograft (Bio-Oss)|Ridge preservation bone grafting after tooth extraction
1521936|NCT02802306|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System
1521939|NCT02802280|Other|Cardiovascular risk in HCV patients|"Cardiovascular risk assessement (through Flow-mediated vasodilatation FMV, measurement of endothelial function biomarkers, carotid ultrasound, etc.)
This is a prospective study. The only intervention planned will consist of performing different tests that define the individual cardiovascular risk. These tests will be carried out on a single group cohort at different times.
Notwithstanding, the investigators will record the exposure to DAA to assess any change in CVR.
Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)
(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
1521940|NCT02802267|Drug|Inecalcitol|vitamin D receptor agonist
1521941|NCT02802267|Drug|Placebo Oral Tablet|placebo
1521942|NCT02802254|Behavioral|Patient-targeted individual physical-activity-feedback|At cardiac consultation receive an individual feedback on their personal physical activity level.
1521943|NCT02802254|Device|Pedometer|Patients receive a pedometer two weeks prior to cardiac consultation.
1521944|NCT02802241|Drug|placebo|
1521945|NCT02802241|Dietary Supplement|peppermint oil|
1521946|NCT02802228|Drug|Ifetroban|thromboxane prostanoid receptor antagonist delivered as infusion and oral capsule
1521947|NCT02802228|Drug|Placebo|matched placebo delivered as infusion and oral capsule
1521948|NCT02802215|Drug|metformin|Metformin group will receive 1500 mg of metformin per day orally ( 500 mg every 8hrs in the middle of meal) starting from 12th week of gestation till delivery.
1521949|NCT02802215|Drug|placebo (folic acid )|500 micro gram of folic acid every 8 hrs
1521950|NCT02802189|Other|Exercise programme|"Endurance and Resistant training exercise program (Duration: 45 minutes)
Muscle retraining of longus colli and endurance training of the deep cervical flexors.
Resistant exercises for the muscles involved in neck flexion, extension, side bending and rotation of the neck region. Isometric contractions exercises (20-70% of MVC) and resistant exercises (12-15RM).
Active ROM exercises for the neck muscles
Upper limbs exercises with resistant bands
Stretching exercises for the neck and upper limbs muscles"
1521951|NCT02802189|Other|Integrated Neuromuscular Inhibition Technique application.|"Integrated Neuromuscular Inhibition Technique application.
(Duration: 15min)
The protocol was applied to the following muscles:
Upper border of the trapezius muscle
sternocleidomastoid
levator scapulae muscle
splenius capitis muscle
Integrated Neuromuscular Inhibition Technique includes the combination of the following technique:
Ischemic compression
Muscle energy technique
Strain-counterstrain technique"
1521954|NCT02802163|Drug|Panobinostat|"Induction Phase: Panobinostat (dose escalation beginning at 10 mg) will be administered 3 times a week (TIW) by mouth every other week starting on day 1 of each cycle.
Maintenance Phase: Panobinostat will be administered TIW by mouth every other week starting on day 1 of each cycle. The dose of panobinostat during maintenance phase will be the same dose taken during cyce 8 of induction phase."
1521955|NCT02802163|Drug|Carfilzomib|Induction Phase: Carfilzomib will be administered at 20 mg/m^2 on Cycle 1 Day 1. Beginning on Cycle 1 Day 2 the carfilzomib dose will be according to the assigned level of 27 mg/m^2 or 36 mg/m^2. Carfilzomib will be administered twice weekly IV on Days 1,2, 8,9,15, and 16.
1521992|NCT02801903|Drug|SB204 4%|Topically Once Daily (AM)
1522290|NCT02799472|Drug|MTX|Capsule, tablet or liquid administered orally or as SC injection.
1521956|NCT02802163|Drug|Lenalidomide|"Induction Phase: Lenalidomide (25 mg) will be administered once-daily by mouth on Days 1-21, 25.
Maintenance Phase: Lenalidomide (10 mg) will be administered once-daily by mouth on days 1-21."
1521957|NCT02802163|Drug|Dexamethasone|Induction Phase: Dexamethasone (20 mg) will be administered twice weekly by mouth or by IV on Days 1,2, 8, 9, 15, and 16.
1521958|NCT02802150|Dietary Supplement|Zanthoxylum Schinifolium Seed Oil(4g/day)|parallel design
1521959|NCT02802150|Dietary Supplement|Soy Bean Oil;placebo(4g/day)|parallel design
1521960|NCT02802137|Drug|tafluprost|
1521961|NCT02802137|Drug|tafluprost and dorzolamide/timolol|
1521962|NCT02802124|Radiation|carbon-ion radiotherapy alone|
1521963|NCT02802124|Radiation|proton plus carbon-ion radiotherapy|
1521964|NCT02802111|Drug|Albuterol|Patient receives albuterol 5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention.
1521965|NCT02802111|Drug|Levalbuterol|Patient receives levalbuterol 2.5 mg aerosolized. Oxygen consumption and vital signs are measured for 1 hour after intervention
1521966|NCT02802098|Drug|Durvalumab|Durvalumab is an investigational human monoclonal antibody directed against programmed death ligand-1 (PD-L1). PD-L1 can be expressed by tumours to evade detection by the immune system through binding to PD-1 on cytotoxic T lymphocytes. Durvalumab blocks the PD-L1 interaction with PD-1, countering the tumour's immune-evading tactics.
1521967|NCT02802098|Drug|Bevacizumab|Bevacizumab is a recombinant humanized monoclonal antibody that blocks angiogenesis by inhibiting vascular endothelial growth factor A (VEGF-A)
1521968|NCT02802085|Device|VEGA Knee|TKA
1521969|NCT02802072|Device|Enterprise stent implantation|Enterprise stent system (Johnson & Johnson (Shanghai) Medical Equipment Co.,Ltd., China) is a closed loop self-expanding stent system that is made of Ni-Ti alloy. It consists of a self-expanding stent and a delivery system.
1521970|NCT02802072|Drug|Only aspirin medication|Only aspirin medication will be conducted, initial dose is 300 mg/d, 200 mg/d 6 months later, and 100 mg/d 1 year later.
1521973|NCT02802046|Radiation|Computed tomographic angiography of coronary artery|
1521976|NCT02801994|Device|PAV, Puritan Bennett 980 ventilator|The PAV mode will be delivered by Puritan Bennett 980 ventilator (Covidien, Boulder, USA). Levels of PEEP and FiO2 will be kept constant. The level of assistance in PAV, named %-assistance will be set in order to keep the patient in a respiratory effort zone corresponding to a respiratory muscles pressure time product (PTPmus) between 50 and 150 cm H2O • s / min. As it is not possible to calculate directly the PTPmus at bedside, the investigators will use as a substitute its main component, the pressure peak muscle of the airways according to the previous report from Carteaux et al. This setting has been described extensively and its use has been the subject of a feasibility study in 50 patients. After a 20-minutes stabilization period, a 30-minutes recording will be performed.
1521977|NCT02801981|Drug|GSK2230672|It will be supplied as white to slightly colored, round, film coated tablet for oral administration containing 10 mg or 45 mg of GSK2330672.
1521978|NCT02801981|Drug|Placebo|It will be supplied as placebo tablets (with no GSK2230672) visually matching to GSK2230672
1521979|NCT02801968|Procedure|Tap block|
1521980|NCT02801968|Other|intravenous analgesia|
1521981|NCT02801955|Procedure|gastrectomy|radical total/subtotal gastrectomy with D2 lymph node dissection
1521982|NCT02801955|Procedure|sampling of peritoneal washing aspirate|After thoroughly examination of the peritoneal cavity revealing the absence of peritoneal dissemination, the peritoneal cavity was washed with 200 ml of saline, and at least one third was aspirated from several regions of the peritoneal cavity, including near the primary tumor, the left and right subphrenic areas and the pouch of Douglas with suction tubes to a clean bottle and designated as the peritoneal sample for determination of peritoneal levels of CEA and CA 19-9.
1521987|NCT02801929|Drug|Coppertone (BAY987518)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number - SR15-72_V27-010).
1521988|NCT02801916|Other|0 grams oat bran|200 milliliters water plus 0 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
1521989|NCT02801916|Other|4.5 grams oat bran|200 milliliters water plus 4.5 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
1521990|NCT02801916|Other|13.6 grams oat bran|200 milliliters water plus 13.6 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
1521991|NCT02801916|Other|27.3 grams oat bran|200 milliliters water plus 27.3 grams OatWell22, a commercial oat bran product containing 22% oat beta-glucan, followed by 119 grams white bread
1521997|NCT02801864|Device|Real tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
1521998|NCT02801864|Device|Sham tDCS|Participants will receive tDCS at 1mA for 20min of the total three hours of intensive speech therapy time at the beginning of each session. Stimulation will be provided via an electrode using a Starstim device.
1521999|NCT02801864|Other|Intensive Speech Therapy|Participants will receive one hour of group therapy and two hours of individual therapy that will follow VNeST format. The purpose of therapy will be to have the client generate verbs and nouns in written and verbal form.
1522000|NCT02801851|Behavioral|SCREEN-ED|SCREEN-ED will have 4 key components: systematic screening for delirium using the CAM; informing providers of the screening result; a checklist protocol for initial delirium management based on clinical guidelines tailored to the ED, which includes identification of cause, risk factor modification, and behavioral interventions; documentation in the Electronic Health Record (EHR) and communication with inpatient providers of delirium screening results.
1522001|NCT02801838|Drug|Morphine|If the physician in charge of the patients judges it necessary, after the optimization of the ventilators settings, if the patient remains uncomfortable, a second therapeutic intervention using a maximum of 10mg morphine titration may be performed. After this second therapeutic intervention, a third non-verbal measure of respiratory discomfort will be performed with the IC-RDOS. Concomitantly, EEG and EMG will be again recorded over a of 15-minutes period.
1522004|NCT02801812|Device|nailfold capillaroscopy|Detection by nailfold capillaroscopy of capillary abnormalities in patients with Systemic Lupus Erythematosus and comparison with healthy controls at enrolment
1522005|NCT02801799|Drug|Varying infusion rates of Ropivacaine 0.2%|"Participants will receive one nerve catheter adjacent to the common peroneal nerve (trial day 1) and adjacent to the sciatic nerve (trial day 2). Each catheter will be randomly allocated to one of five infusion groups. All peroneal nerve catheters will receive the same volume of ropivacaine 0.2%. All the sciatic nerve catheters will receive the same volume of ropivacaine 0.2%.
The only inter-group variable will be the infusion rate. The fixed volume of ropivacaine will be determined in a separate study ('The Volume Study'), which is also part of the project: 'A novel technique for reliable, precise and safe postoperative management'.
The largest volumes tested in The Volume Study are 30 mL for the sciatic nerve and 20 mL for the common peroneal nerve. Therefore the highest volume for the two intervention days cannot exceed 30 mL (150 mg of ropivacaine).
We will ensure constant infusion rate and precise delivery of LA by using an electronic infusion pump and a nerve catheter."
1522006|NCT02801786|Drug|Placebo|The arm will be composed of 03 women who used placebo capsules and gel.
1522007|NCT02801786|Drug|Lidocaine|The arm 2 will consist of women who used the placebo capsules for 5 days and 4% lidocaine gel 15 minutes before the test.
1522008|NCT02801786|Drug|Tamoxifen|The arm 01 is composed of patients who use tamoxifen 20mg one capsule per day for 05 days before the test and placebo gel 15 minutes before the exam.
1522009|NCT02801773|Dietary Supplement|Treatment Gingivitis with Probiotic|Gingivitis Treatment (scaling and coronary polish) and one lozenge containing Lactobacillus reuteri per day during 3 months
1522010|NCT02801773|Other|Treatment Gingivitis conventional|gingivis treatment (scaling and coronary polish) and and one lozenge containing Placebo (mint lozenge) per day during 3 months
1522011|NCT02801747|Behavioral|Heart to Heart2 (HTH2)|The present study uses a fractional factorial design to evaluate the efficacy of five distinct culturally appropriate intervention components on the primary outcome, HIV viral suppression.
1522012|NCT02801734|Other|EQUIP|Patients in the EQUIP intervention group will receive four face-to-face sessions. The focus of these sessions is to equip patients with the skills and strategies needed to cope with common symptoms experienced by lung cancer patients.
1522013|NCT02801721|Other|psycho social stimulation|The psychosocial intervention lasted for 9 months and included play demonstrations at home by a play leader (PL) who was trained to visit homes and teach the mothers about child development and care practices. They also showed the mothers how to play with children using toys in a way to promote good child development. In the original study all anemic children in early childhood received 30 mg ferrous sulphate daily based on recommendations from both the WHO (2003) and IOM reports (2001) for 6 months.
1522014|NCT02801695|Drug|Citrulline|Citrulline supplementation
1522015|NCT02801695|Drug|Placebo|Placebo
1522022|NCT02801630|Device|PainShield SAW Patch Device|The PainShield is a self contained Surface Acoustic Wave device, where the waves are delivered locally through a trasnducer embedded into a patch that sits on the affected area.
1522023|NCT02801617|Drug|PRO-067|1 drop QD during 30 days is a sterile ophthalmic solution formulated by Laboratorios Sophia S.A. de C.V.
1522024|NCT02801617|Drug|GAAP Ofteno®|1 drop QD during 30 days Active comparator, reference medication.
1522025|NCT02801591|Procedure|Conventional ovarian stimulation proctol without rhGH|
1522026|NCT02801578|Drug|Ibrutinib|Cycle 1 daily dose of ibrutinib is 420 mg (3 capsules), in the second cycle 280 mg (2 capsules), and in the third cycle 140 mg (1 capsule).
1522027|NCT02801565|Drug|Conventional controlled ovarian stimulation proctol|Conventional controlled ovarian stimulation proctol without rhGH.
1522028|NCT02801552|Device|PRF|Regenerative Endodontic Procedure with PRF: autologous PRF will be used instead of blood clot in the second vist.
1522029|NCT02801539|Device|RMT therapy using modified RMT device|The exercises provided by the RMT device is intended to strengthen breathing muscles.
1522291|NCT02799472|Drug|Folic (or folinic) acid|Capsule, tablet or liquid and will be administered orally.
1522030|NCT02801539|Device|Sham-RMT therapy using modified RMT device|The exercises provided by the Sham-RMT modified device is not intended to strengthen breathing muscles.
1522031|NCT02801526|Drug|CKD-330 16/5mg - A|
1522032|NCT02801526|Drug|Candesartan 16mg and Amlodipine 5mg|
1522033|NCT02801513|Behavioral|Brief Mindfulness Training|Brief mindfulness training comprising of three weekly individual sessions and daily guided meditation home practice
1522034|NCT02801513|Behavioral|Resting Control Training|Brief resting control training comprising of three weekly individual sessions and daily home practice consisting of resting periods
1522035|NCT02801500|Device|Magnetic Compressive Anastomosis|The magnetic compressive anastomosis device will be used to complete the anastomosis during bilioenteric anastomosis.
1522036|NCT02801500|Procedure|Manual Anastomosis|A handsewn technique will be used to complete the anastomosis during bilioenteric anastomosis.
1522037|NCT02801487|Radiation|CIRT with concurrent chemo arm|Five dose levels (52.5GyE, 55GyE, 57.5GyE, 60GyE, 62.5GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 62.5 GyE are safely delivered, the recommended dose (or 62.5 GyE) will be the prescribed dose in the Phase II part of the study. Ninety-five percent (95%) of the isodose line should cover the GTV+3~5mm. Cisplatin (40mg/m^2) monotherapy will be given weekly along with radiotherapy.
1522038|NCT02801474|Procedure|direct fracture reduction and fixation|In the DR group, the posterior malleolar fracture was reduced and fixed in a direct way via a posterolateral approach with the patients in prone position.
1522039|NCT02801474|Procedure|indirect fracture reduction and fixation|In the IR group, the posterior malleolus was reduced through ligamentotaxis following open reduction and internal fixation of lateral and medial malleolar fractures. Percutaneous cannulated screws were used to fix the posterior malleolar in anterior-to-posterior direction.
1522041|NCT02801448|Drug|sulforaphane|sulforaphane-containing broccoli sprout extracts
1522042|NCT02801448|Drug|Placebo|Maltodextrine-based placebo without sulforaphane
1522043|NCT02801435|Drug|0.5% Icotinib hydrochloride cream|Topical administration for twice daily
1522044|NCT02801435|Drug|1.0% Icotinib hydrochloride cream|Topical administration for twice daily
1522045|NCT02801435|Drug|2.0% Icotinib hydrochloride cream|Topical administration for twice daily
1522046|NCT02801435|Drug|4.0% Icotinib hydrochloride cream|Topical administration for twice daily
1522047|NCT02801435|Drug|Placebo|Topical administration for twice daily
1522049|NCT02801409|Drug|Combined Epi-GA|Thoracic epidural catheterization will be performed according the surgical incision site. General anesthesia will be induced and maintained as in the control group, combined with epidural anesthesia which will be maintained with 0.5% ropivacaine during surgery.
1522050|NCT02801409|Drug|PCEA|Patient-controlled epidural analgesia (0.12% ropivacaine and 0.5 ug/ml sufentanil) will be provided after surgery.
1522051|NCT02801409|Drug|GA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with intravenous (propofol), inhalational (sevoflurane), or combined intravenous-inhalational anesthetics. Opioids and muscle relaxants will be administered when considered necessary.
1522052|NCT02801409|Drug|PCIA|Patient-controlled intravenous analgesia (0.5 mg/ml morphine) will be provided after surgery.
1522053|NCT02801396|Device|Etafilcon A Design 1 (Test 1)|
1522054|NCT02801396|Device|Etafilcon A Design 2 (Test 2)|
1522055|NCT02801396|Device|Etafilcon A (Control)|
1522056|NCT02801383|Drug|Yallaferon®， the recombinant human interferon α-2b gel|
1522057|NCT02801383|Other|gel without active ingredient|
1522058|NCT02801370|Drug|12 mg ciprofloxacin|Single administration of OTO-201
1522059|NCT02801370|Drug|Sham Control|Simulated, single adminstration
1522065|NCT02801331|Device|Stochastic Vibrotactile Stimulation (SVS)|The infants isolette mattress will be replaced with a specially constructed mattress (non-commercially available) to provide gentle vibrations and sounds during mattress stimulations.
1522066|NCT02801318|Procedure|Polysomnography|
1522067|NCT02801305|Drug|Diltiazem Gel 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
1522068|NCT02801305|Drug|Nitroglycerin Ointment 2%|This a topical agent which will be applied on digital ulcers by scleroderma patients.
1522069|NCT02801305|Drug|Vaseline|This is used as the topical placebo agent.
1522070|NCT02801292|Drug|Ketamine|Single bolus of Ketamine .25 milligrams per kilogram of weight.
1522071|NCT02801279|Other|Conventional bilateral arm training|
1522072|NCT02801279|Other|Kinect-based bilateral arm training|
1522073|NCT02801266|Behavioral|Evidence informed birth control counseling|Counselors underwent training on the use of 10 best practices for contraceptive counseling.
1522074|NCT02801240|Other|Nutrition support product|Nutrition support product contains macronutrients, micronutrients, phytonutrients, prebiotics, and glutamine. Product is in powder form and is mixed with water or juice before consumption. Taken orally as a nutritional shake twice per day.
1522075|NCT02801227|Drug|Oxytocin|Intravenous oxytocin: 2.5 mIU per minute with increments of 2.5 mIU every 20 minutes until achieving 4-5 contractions during 10 minutes or 20 mIU. Then after continuous infusion without increasing oxytocin dose will be continued. In case of lack of painful contraction/active labor after 24 hours with oxytocin a trial with PGE2 will be initiated (as described for PGE2)
1522076|NCT02801227|Drug|Prostaglandin E2|PGE2 2 mg wil be inserted to the posterior fornix, this will be repeated every 6 hours until achieving painful contractions or up to 4 doses (24 hours). In case of lack of painful contraction/active labor after the fourth dose of PGE2 a trial with oxytocin will be initiated (as described for Oxytocin).
1522077|NCT02801214|Other|fMRI|
1522078|NCT02801201|Drug|Midazolam|
1522079|NCT02801201|Drug|Bupivacaine|
1522080|NCT02801188|Drug|Bupivacaine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5% and water soluble radio-opaque dye.
1522081|NCT02801188|Drug|Mixture of bupivacaine and dexmedetomidine|Paravertebral blockade will be performed using combined mixture of bupivacaine 0.5%, water soluble radio-opaque dye, and1 ug/kg of dexmedetomidine
1522082|NCT02801175|Procedure|Pulmonary vein isolation|
1522083|NCT02801162|Device|conventional ABG analyser|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
1522084|NCT02801162|Device|Proxima 3®|pO2 mmHg, pH, pCO2 mmHg, Base excess, Hct %
1522085|NCT02801149|Procedure|Wrist Magnetic Resonance Imaging (MRI)|Patients that enter this group are randomised to receive non-standard care with a 3-sequence MRI scan of the scaphoid following the initial conventional radiography.
1522086|NCT02801136|Behavioral|CBT for PNES|
1522087|NCT02801136|Behavioral|Supportive Therapy|
1522088|NCT02801123|Behavioral|Mindfulness Based Cancer Recovery (MBCR)|Mindfulness-Based Cancer Recovery (MBCR) is a standardized group program which focuses primarily on the challenges faced by people living with cancer. It is an 8-week program consisting of weekly group meetings of 1.5 to 2 hours. Home practice of 45 minutes per day (15 min yoga; 30 min meditation) is prescribed. As the weeks progress, different forms of meditation are introduced, beginning with a body scan sensory awareness experience, progressing to sitting and walking meditations. Gentle Hatha yoga is incorporated throughout, as a form of moving meditation. Didactic instruction as well as group discussion and reflection, problem solving and skillful inquiry are commonly applied teaching tools.
1522089|NCT02801123|Behavioral|Tai Chi/Qigong (TCQ) for Cancer Patients|"TCQ involves a series of slow specific movements or forms done in a meditative fashion. It is purported that focusing the mind solely on the movements of the form helps to bring about a state of mental calm and clarity. The practice itself has been separated from its martial arts roots and is widely taught as a health behavior practice and exercise. Qigong exercises generally have three components: a posture (whether moving or stationary), breathing techniques, and mental focus on guiding qi through the body. Our program, developed specifically for a cancer patient population, incorporates simple Tai Chi elements within a healing framework stemming from Qigong principles."
1522090|NCT02801097|Drug|RRx-001|
1522091|NCT02801097|Drug|Irinotecan|
1522093|NCT02801071|Drug|15g L-citrulline daily p.o.|
1522094|NCT02801071|Drug|Placebo|
1522095|NCT02801058|Other|Osteopathic manipulative treatment|Osteopathic manipulative techniques on thoracic diaphragm
1522096|NCT02801045|Behavioral|art therapy|"Patient's creativity is stimulated by visual arts materials and various art therapy techniques including punctual use of music, poetry and body expression. The intervention, based on the investigators previous experience, is founded on:
humanistic phenomenological focus
transpersonal therapeutic bound
transdisciplinarity in the artistic approach
integrative-relational specialized counseling of the grief, loss and trauma aspects."
1522097|NCT02801032|Drug|Tadalafil|"Single dose, 20 mg capsule p.o. minimum one week apart from placebo.
MRI of cerebrum before the first trial day.
Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.
Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.
EndoPAT2000 to estimate endothelial function before and after intervention.
Endothelial biomarkers in blood samples before and after intervention."
1522098|NCT02801032|Drug|Placebo|"Single dose, matching capsule p.o. minimum one week apart from active treatment.
MRI of cerebrum before the first trial day.
Transcranial Doppler to measure blood flow velocity in MCA bilaterally before and after intervention.
Near-infrared spectroscopy (NIRS) to measure cortical brain oxygenation before and after intervention.
EndoPAT2000 to estimate endothelial function before and after intervention.
Endothelial biomarkers in blood samples before and after intervention."
1522099|NCT02801019|Other|E-poly|comparison of two different polyethylene plastic 0,04 mm at 3 months 0,06 at 2 years
1522100|NCT02801019|Other|ArComXL|comparison of two different polyethylene plastic 0,03 mm at 3 months 0,10 mm at 2 years
1522101|NCT02800980|Procedure|Drainage and sclerotherapy.|Lymphocele percutaneous / transvaginal drainage with a use of a vascular catheter followed by sclerotherapy.
1522102|NCT02800980|Procedure|Drainage alone.|Lymphocele percutaneous / transvaginal drainage with a vascular catheter alone (without sclerotherapy).
1522103|NCT02800967|Dietary Supplement|Pure Aronia juice|Pure Aronia juice with appx. polyphenols content of 1000 mg gallic acid equivalents/100ml
1522104|NCT02800967|Dietary Supplement|Aronia juice-based beverage|Aronia juice-based beverage with appx. polyphenols content of 250 mg gallic acid equivalents/100ml, obtained as a blend of ¼ vol. of pure Aronia juice and ¾ vol. of placebo beverage.
1522105|NCT02800967|Dietary Supplement|Placebo beverage|A polyphenol-free formulation with matched nutrient composition (sugars, vitamins, minerals) and similar sensory characteristics to active interventions
1522106|NCT02800954|Biological|blood samples|
1522107|NCT02800954|Biological|Bone marow samples|
1522109|NCT02800928|Drug|CERC-501|CERC-501
1522110|NCT02800928|Drug|Placebo|Placebo
1522112|NCT02800902|Drug|placebo|Oral prophylaxis followed by placement of placebo gel
1522113|NCT02800902|Drug|Rosuvastatin|Oral prophylaxis followed by placement of rosuvastatin gel
1522114|NCT02800902|Drug|Atorvastatin|Oral prophylaxis followed by placement of atorvastatin gel
1522115|NCT02800889|Drug|Pixantrone|
1522116|NCT02800876|Other|CT-acquisition|
1522117|NCT02800863|Device|Dorsal Root Ganglion (DRG) Stimulation (Axium™ Neurostimulator System)|Electrical stimulation of the DRG using the Axium™ Neurostimulator System
1522118|NCT02800850|Behavioral|Bright Light|
1522119|NCT02800850|Behavioral|Placebo Light|
1522120|NCT02800824|Drug|Budesonide|
1522121|NCT02800824|Drug|Uceris|
1522122|NCT02800811|Drug|FR104|GMP FR104 is provided to the site in extractable volume vials containing FR104. Appropriate Dilutions in Ringer's lactate solution is made on site.
1522123|NCT02800811|Drug|Placebo|The placebo injection contains the vehicle. For placebo dosing, vehicle is administered in accordance with the volume of study drug administered.
1522124|NCT02800798|Other|Preeclampsia positive|
1522125|NCT02800785|Drug|Cefoxitin, Ertapenem, Moxifloxacin, Tigecycline, Ticarcillin-Clavulanic Acid; Metronidazole plus Cefazolin, Cefuroxime, Ceftriaxone, Cefotaxime, Ciprofloxacin, or Levofloxacin|Patients will be offered a treatment regimen of antibiotics based on guidelines published jointly by the Surgical Infection Society and the Infectious Disease Society of America. After IV antibiotics are administered for a period of at least 24 hours, a regimen of oral antibiotics will be continued for a total treatment length of 10 days. Preferred oral antibiotic regimens include Moxifloxacin alone, and combinations such as Metronidazole or Clindamycin, for anaerobic bacteria coverage, plus Ciprofloxacin or Levofloxacin, or an oral Cephalosporin for aerobic Gram-negative bacteria coverage.
1522126|NCT02800785|Procedure|Appendectomy|Appendectomy will be performed by an open or laparoscopic approach, depending on patient and surgeon preference.
1522127|NCT02800772|Dietary Supplement|acetic acid|
1522128|NCT02800772|Dietary Supplement|saline|
1522129|NCT02800759|Dietary Supplement|JOINTRUS®|100% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
1522130|NCT02800759|Dietary Supplement|80% dose of JOINTRUS®|80% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
1522131|NCT02800759|Dietary Supplement|62.4% dose of JOINTRUS®|62.4% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
1522132|NCT02800759|Dietary Supplement|Starch 100%|0% Fatty acid compound with 12.5% Cis-9-cetylmyristoleate
1522133|NCT02800746|Drug|Ferric carboxymaltose|Ferric carboxymaltose 15 mg/kg mg is intravenously administered on 7-10 day before surgery.
1522134|NCT02800746|Drug|Placebo|normal saline 100 ml is intravenously administered on 7-10 day before surgery
1522135|NCT02800733|Dietary Supplement|Saffron|20 patients with mild to moderate GAD, diagnosed by Diagnostic and Statistical Manual of Mental Disorders-IѴ (DSM-IѴ) who receive sertraline will randomly receive saffron (450 mg) as an add-on therapy on daily bases for 6 weeks. Hamilton Anxiety Rating Scale (HAM-A) will use to assess the effect of treatment.
1522136|NCT02800733|Dietary Supplement|placebo|20 patients with mild to moderate GAD who receive sertraline will receive placebo too
1522137|NCT02800720|Behavioral|Meditation Awareness Training|8 Week Meditation Intervention
1522138|NCT02800720|Behavioral|Cognitive Behavioral Therapy for Groups|8 week intervention based on Cognitive Behavioral Theory
1522139|NCT02800707|Other|Sucralose|Sweetner
1522140|NCT02800707|Other|Stevia|Sweetner
1522141|NCT02800694|Drug|"bupivacainediluted with 1 ml of normal saline and 25 μg fentanyl "|The intrathecal medication included 1ml of 0.5% heavy bupivacaine (5 mg) diluted with 1 ml of normal saline and 25 μg fentanyl. Then, the parturients were placed in the supine position with left lateral displacement produced by placing a wedge under the right hip to prevent aortocaval compression and hypotension. Supplemental oxygen was applied using nasal cannula (2-4 L/min). Routine monitoring included maternal vital signs, uterine contractions and fetal heart rate tracing. The cardiotocogram was recorded continuously throughout the study period
1522142|NCT02800681|Other|Expert panel evaluation|"From the medical records, described social and psychiatric history and observed psychiatric symptoms will be summarized and presented to two senior psychiatric consultants. The panels evaluation ensures the identification of subjects with typical symptoms, according to a best estimate clinical consensus.
The panel divides the participants into 4 groups: 'participant with symptoms typical of AS', 'participant with symptoms typical of SD', 'participant with inconclusive/non typical symptoms' and 'non eligible participant'."
1522143|NCT02800681|Other|Semi-structured psychopathological interviews|Included participants are asked for a detailed social and developmental history and interviewed with 3 semi-structured interviews: 1. Schedules for Assessment in Neuropsychiatry (SCAN); Covering psychopathology and behaviour associated with the major psychiatric disorders. 2. Autism Diagnostic Observation Schedule (ADOS), module 4; An assessment to identify symptoms within the autism spectrum. 3. Examination of anomalous self-experience (EASE); A checklist for exploration of experiential anomalies. The Ph.D.-student will obtain social and developmental history and carry out SCAN and EASE interviews. ADOS will be carried out by a consultant psychologist at The Danish Autism Centre.
1522144|NCT02800681|Other|Self-administered rating scales|1.The Autism Quotient (AQ), a 50 question scale, for the assessment of autistic traits, 2. The Schizotypal Personality Questionnaire (SPQ), a 74 item scale, for the assessment of schizotypal personality, 3. The WHO-5 Well-Being Index (WHO-5), a 5 item scale, for the assessment of subjective psychological well-being.
1522145|NCT02800681|Other|Other general interviewer ratings|1. Global Assessment of Functioning (GAF), a numeric scale (1 through 100) for assessing social, occupational, and psychological functioning, 2. The Clinical Global Impressions scale (CGI-Severity), an assessment of the clinician's global view of the patient's severity of psychopathology on a 7 point scale.
1522146|NCT02800668|Device|DJBL (Duodenal jejunal bypass liner, EndoBarrier)|Implantation of EndoBarrier after medical and patient's decision, Duration of treatment 12 months in maximum, follow up for 4 weeks after Explantation, follow up during treatment by physical examination, ECG control, sampling and analysis of blood parameters, mixed meal tolerance tests only for diagnostic purposes to assess gut hormonal changes and metabolic parameters
1522147|NCT02800655|Device|Digital Health Feedback System|"This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their ARV medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their ARV medications.
Other Names:
DHFS"
1522149|NCT02800629|Dietary Supplement|Modified Citrus Pectin|MCP versus placebo
1522150|NCT02800629|Dietary Supplement|Placebo|
1522151|NCT02800616|Other|The Healthy Primary School of the Future|In two out of four intervention schools, a whole-school approach named 'The Healthy Primary School of the Future', is implemented with the aim of improving physical activity and dietary behaviour. For this intervention, pupils are offered an extended curriculum, including a healthy lunch, more physical exercises, and social and educational activities, next to the regular school curriculum.
1522152|NCT02800616|Behavioral|The Physical Activity School|In the two other intervention schools, a physical-activity school approach called 'The Physical Activity School', is implemented, which is essentially similar to the other intervention, except that no lunch is provided.
1522153|NCT02800603|Behavioral|Family Check Up|"The FCU is an ecologically sensitive, evidence-based, targeted intervention that aims to reduce child EBP. Features of the FCU: 1) Assessment-driven: a multi-method, multi-informant assessment in which the consultant reviews strengths and difficulties across domains of contextual risk, family functioning and child health. A tailored intervention plan is then created based on results 2) Motivational interviewing: Caregivers engage in self-assessment about motivation and barriers to addressing factors that may perpetuate risk. The consultant and caregiver work to establish a menu of services 3) The family may be offered up to 6 sessions of the Everyday Parenting curriculum. The FCU has demonstrated effectiveness and cultural sensitivity across multiple US settings."
1522154|NCT02800590|Drug|ABP-700|
1522155|NCT02800577|Device|General Practitioner Emotional Test Battery (GP-ETB)|The GP-ETB (Class I Medical Device) comprises three computer tasks. In the first task, the 'Emotional Categorisation Task' patients are given forty words that might be used to describe them and indicate whether they would 'like' or 'dislike' to be described by a particular word. In the 'Facial Expression Recognition Task' patients are asked to judge whether a briefly displayed face is expressing one of six emotions. In the final task, the 'Emotional Recall Task', the patient should recall as many words as they can from the series of words that were presented in the first task. The patients perform these tasks once before antidepressant treatment and again seven days after treatment begins.
1522156|NCT02800564|Behavioral|Active mass media approach|Communities will be exposed to twice weekly radio programming for up to 18 months. Interactive voice response systems (IVRS) will be promoted where listeners can chose to receive pre-recorded audio/voice messages or text messages on mobile phones. Messages will be consistent with the weekly radio program. The topic of the radio program will be discussed in monthly open community meetings. Each individual may choose to participate or not to listen to the radio program, receive the IVRS system, and attend monthly meetings.
1522157|NCT02800564|Behavioral|Passive mass media approach|These communities will be exposed to twice weekly radio programming for up to 18 months only.
1522158|NCT02800551|Radiation|dose-intensified image-guided SBRT using simultaneous integrated boost|
1522159|NCT02800551|Radiation|External 3-dimensional conformal radiotherapy (3D-CRT)|
1522160|NCT02800538|Dietary Supplement|intragastric infusion of nutrient|Intragastric infusion of nutrient that can be widely found in daily food or placebo.
1522161|NCT02800525|Device|Picosecond laser|Picosecond 532 and 1064 nm laser Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesions.
1522162|NCT02800525|Device|Q-switched Nd:YAG laser|Q-switched Nd-YAG 532 and 1064 nm laser. Treatment of facial pigmented lesions. The energy using depends on the endpoint of immediate whitening of the lesions. The wavelength using depends on the depth of lesion.
1522163|NCT02800512|Procedure|Robotic sacrocolpopexy|Sacrocolpopexy is a procedure to surgically correct vaginal vault prolapse where mesh is used to hold the vagina in the correct anatomical position. Robotic assistance is a minimally invasive method to perform this abdominal procedure.
1522164|NCT02800512|Procedure|high uterosacral ligament suspension|Utilizing uterosacral ligaments to support the vaginal cuff can be performed vaginally—by passing sutures bilaterally through the uterosacral ligaments. near the level of the ischial spine. HUSLS is a vaginal minimally invasive procedure for POP.
1522165|NCT02800486|Drug|Intra-arterial Cetuximab|
1522166|NCT02800486|Drug|Intra-arterial Mannitol|
1522167|NCT02800486|Radiation|Hypofractionated re-irradiation|
1522170|NCT02800460|Procedure|fMRI-3T|fMRI-3T will be performed during the visit 1: day of anesthesia consultation (this fMRI-3T will last approximately one hour)
1522171|NCT02800447|Drug|Natulan|Each baseline BEACOPP regimen lasts 21 days, and each cycle consists of： Cyclophosphamide injection: 650mg/m2, IV infusion, day 1； Doxorubicin hydrochloride injection: 25mg/m2, IV infusion, day 1； Etoposide injection: 100mg/m2, IV infusion, day 1~3; Natulan (procarbazine hydrochloride capsule): 100mg/m2，po, day 1~7; Bleomycin hydrochloride injection: 10mg/m2, IV or IM, day 8; Vincristine: 1.4mg/m2 (single maximum dose is 2mg), IV infusion, day 8; Prednisone tablet: 40mg/m2, po, day 1~14
1522172|NCT02800447|Drug|ABVD|Each ABVD cycle lasts 28 days1 cycle of the ABVD regimen consists of： Doxorubicin hydrochloride injection：25mg/m2，IV infusion，day 1 and 15; Dacarbazine injection：375mg/m2，IV infusion，day 1 and 15； Bleomycin injection：10mg/m2，IV or IM，day 1 and 15； Vincristine injection：1.4mg/m2 (single maximum dose is 2mg), IV infusion，day 1 and 15;
1522173|NCT02800434|Procedure|hand allograft|
1522209|NCT02800083|Drug|Pitolisant (BF2.649)|
1522210|NCT02800083|Drug|Placebo|
1522174|NCT02800408|Other|Whole grain high-BCX maize|The whole grain orange maize will be milled and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
1522175|NCT02800408|Other|Refined grain high-BCX maize|The refined grain orange maize will be degermed, milled, and prepared into muffins to be consumed daily. Muffins will contain a target of 500 µg beta-cryptoxanthin per day.
1522176|NCT02800408|Other|Whole grain white maize|The whole grain white maize will be milled and prepared into muffins to be consumed daily. Muffins will contain minimal beta-cryptoxanthin, matched for dry maize weight.
1522177|NCT02800395|Procedure|Malnutrition screening and perioperative nutritional support|"Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines
Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)
Implementation of an adapted nutritional support based on ESPEN Guidelines"
1522178|NCT02800382|Other|Take samples|Fiberoptic bronchoscopy was performed under local anaesthesia and sedation for taking Bronchoalveolar Lavage Liq for Paraoxanase activity. Blood samples were taken too.
1522179|NCT02800369|Biological|ZFN-603 and ZFN-758|Each suppository contain 500 µg of ZFN-603 or ZFN-758
1522181|NCT02800343|Procedure|routine administration of 0.9% sodium chloride|0.9% sodium chloride is used as the wash and suspension solution for red blood cells during the Intraoperative red blood cell salvage (ICS) procedure.
1522182|NCT02800330|Drug|Esomeprazole 40mg concomitantly|During phase B the patients will use esomeprazole 40mg concomitantly with regorafenib for 5 days.
1522183|NCT02800330|Drug|Esomeprazole 40mg before|During phase C the patients will use esomeprazole 40mg 3 hours before regorafenib for 5 days.
1522184|NCT02800330|Drug|Regorafenib 160mg or 120mg|Patients will use regorafenib 160mg or 120mg during all phases (A, B, C)
1522185|NCT02800317|Procedure|RISAS|RISAS procedure contains Radioactive Iodine Seed localisation in the Axilla in axillary node positive breast cancer combined with a Sentinel node procedure.
1522186|NCT02800278|Other|observational|describe bone status and outcome of odontoid fracture
1522187|NCT02800265|Dietary Supplement|Avmacol|Avmacol is an over-the-counter mixture of broccoli seed and sprout extracts in tablet form to promote detoxification. These tablets contain natural substances that stimulate the body's own defense mechanisms against toxic substances commonly encountered in the environment, such as air pollution and tobacco smoke.
1522188|NCT02800252|Drug|Placebo|One-stage full-mouth periodontal ultrasonic debridement plus placebo intervention
1522189|NCT02800252|Drug|3g omega-3 plus 100mg aspirin daily for 60 days|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days after periodontal therapy
1522190|NCT02800252|Drug|omega-3 plus aspirin before periodontal therapy|Full-mouth periodontal debridement, 3g omega-3 plus 100mg aspirin daily for 60 days before periodontal therapy
1522191|NCT02800239|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
1522192|NCT02800226|Device|10Hz|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
1522193|NCT02800226|Device|iTBS|Magventure Cool B70 Coil with X100 Stimulator and ANT Neuronavigation System
1522196|NCT02800200|Procedure|Platelet rich plasma|Sono-guided injection with 3 cc Platelet rich plasma were performed in both groups.
1522197|NCT02800200|Device|shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
1522199|NCT02800174|Device|Smart nitinol stent implantation|Before intervention, clopidogrel (75 mg/d), aspirin (100 mg/d) and atorvastatin (40 mg/d) were prescribed. One week later, aortic arch and aortocranial angiography were performed under general anesthesia to determine the site, range and extent of the lesion and the status of the cerebral microcirculation, and consequently to inform the treatment strategy and the selection of the correct size of self-expanding nitinol stent system.
1522200|NCT02800174|Drug|antiplatelet drug|Patients with carotid artery stenosis treated conservatively were commenced on an indefinite course of one or more oral antiplatelet drugs. The antiplatelet regimes comprised 100 mg or 300 mg aspirin before sleep with clopidogrel 125 mg or 250 mg daily; or 75 mg clopidogrel before sleep daily.
1522201|NCT02800161|Drug|Trehalose|Trehalose 70g/die
1522202|NCT02800161|Drug|Maltose|Maltose 70g/die
1522203|NCT02800148|Drug|Azelaic acid foam|
1522204|NCT02800148|Drug|Azelaic acid foam|
1522205|NCT02800148|Drug|Azelaic acid foam - Placebo|
1522206|NCT02800135|Drug|Furosemide|1.0 mg/kg of intravenous furosemide. In order to minimize the risk of hypovolemia, urine output will be replaced ml for ml with either Ringers lactate or normal saline for six hours after the furosemide stress test.
1522212|NCT02800044|Device|Wearing a non-invasive glucose sensor|Glucose readings will be obtained from both a glucometer (fingerstick readings) and from the non-invasive glucose sensor at the following four timepoints: fasting, 1.5 to 2 hours after consuming a meal, and before and after 15-30 minutes of moderate exercise on a stationary bicycle.
1522213|NCT02800031|Device|Transvaginal ultrasonography|
1522214|NCT02800018|Other|risk factors|investigators will analyze if certain risk factors will influence the progression of the encephalopathy
1522215|NCT02800005|Device|AFA group (successive patients)|The abdominal fat area at the umbilical level was measured using a CT scanner(sango Mount Monitor Wireless Panel; Siemens , Munich, Germany) while the examinee was in a supine position and estimated using a Volume software (fat Pointer; Siemens , Munich, Germany). The imaging conditions were 120 kilovolt and 50 milliampere, using a 5-mm-thick slice.The areas covered by visceral fat software calculated from pixels with densities ranging from-190 to -30 hounsfield unit . No contrast agent is needed.
1522216|NCT02800005|Other|BMI group (successive patients)|The formula for BMI is weight in kilograms divided by height in meters squared (kg/m2). the normal range is usually considered to be 18.5 to 24.9, with less than 18.5 considered underweight, more than 25.0 considered overweight and above 30.0 obese.
1522217|NCT02799992|Procedure|689 nm Laser Treatment of the Macula|
1522218|NCT02799992|Procedure|Half Dose Photodynamic Therapy|
1522219|NCT02799979|Device|3D right ventricular imaging echocardiographic|Echocardiographic data (3D right ventricular imaging echocardiographic) will be collected at baseline and after 6months.
1522220|NCT02799966|Device|Myndmove|
1522222|NCT02799927|Procedure|Indirect Pulp Treatment with Bioactive Dentin Substitute|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Biodentine and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
1522223|NCT02799927|Procedure|Indirect Pulp treatment with Calcium hydroxide|The indirect pulp treatment (IPT), with Biodentine is a vital pulp procedure for dep cariously primary teeth without carious exposure, involving the removal of the softened, humid and infected dentin layer, leaving intact intentionally the deepest layer of the dentin-pulp complex, followed by the placement of Ultra-Blend plus, and a hermetic restoration to provide a seal against microleakage, without the necessity to reenter for removing the residual caries.
1522224|NCT02799914|Device|Sinus-Venous stent (Optimed GmbH)|Stent implantation
1522225|NCT02799901|Biological|Nivolumab|Injection of nivolumab
1522226|NCT02799901|Radiation|hypofractionned radiotherapy|radiation
1522227|NCT02799888|Drug|Maraviroc|Maraviroc will be administered 300mg twice daily and start on day -2 end on day +30 after stem cell transplant for 33 days.
1522228|NCT02799888|Drug|Cyclosporine (in HLA-Unrelated Donor Transplantation)|Cyclosporine will be given intravenously at a dose of 2-3 mg/kg starting Day -1. Subsequent dosing will be based on blood levels. Patients were advanced to oral cyclosporine once they could tolerate. The dose should be adjusted accordingly to maintain a suggested target serum level of 150-250 ng/mL. In the absence of aGVHD, the oral cyclosporine dose was reduced by approximately 5% weekly, beginning on or near day 100, and therapy was usually discontinued by Day 180 after transplantation or relapse.
1522229|NCT02799888|Drug|Tacrolimus (in HLA-Mismatched Related Donor Transplantation)|Tacrolimus will be given orally at a dose of 0.05 mg/kg twince a day or intravenously at a dose of 0.03 mg/kg starting Day -3. Subsequent dosing should be adjusted accordingly to maintain a suggested target serum level of 5-10 ng/mL. Tacrolimus taper can be initiated at a minimum of 100 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
1522230|NCT02799888|Drug|Methotrexate|Methotrexate will be administered intravenously at a dose of 15 mg/m^2 on day +1, and 10 mg/m^2 on day +3, +6 and +11 after HSC transplantation.at the doses of 15 mg/m^2 IV bolus on Day +1, and 10 mg/m^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +11 dose of methotrexate will be not given to those patients who fail to reach white blood cell count (WBC) of more than 1.0×10^9/L.
1522231|NCT02799875|Other|Higher permissive hypercapnia|"pCO2 ≥ 60mmHg with an upper limit ≤ 75mmHg;
pH ≥ 7.20 from a capillary or arterial blood sample;"
1522232|NCT02799875|Other|Lower Permissive Hypercapnia|"pCO2 ≥ 40mmHg with an upper limit ≤ 55mmHg;
pH ≥ 7.25 from a capillary or arterial blood sample;"
1522233|NCT02799862|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered in accordance with the SmPC of Nab-Paclitaxel.
1522234|NCT02799862|Drug|Carboplatin|Carboplatin will be administered as combination partner of Nab-Paclitaxel in accordance with SmPC of Nab-Paclitaxel.
1522235|NCT02799849|Other|Sleep and metabolism assessment|
1522236|NCT02799836|Device|Blindfold|Study subjects will be blindfolded to create an environment of complete light deprivation which will be worn for 48 hours.
1522237|NCT02799823|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with HLT Transcatheter Aortic Valve System
1522238|NCT02799797|Procedure|ultrasound guided long axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed parallel to the long axis of the adductor canal while scanning, and the catheter is placed along the long axis of the canal using an in-plane approach
1522239|NCT02799797|Procedure|ultrasound guided short axis placement of adductor canal catheter|The long axis of the ultrasound probe is placed vertical to the long axis of the adductor canal while scanning, and the catheter is placed along the short axis of the canal using an in-plane approach
1522240|NCT02799797|Device|Philip CX 50 Ultrasound Scanner|The linear (C5-12) probe of Philip CX 50 Ultrasound Scanner is used for scanning
1522241|NCT02799797|Device|PAJUNK Contiplex S Catheter|
1522242|NCT02799797|Drug|Ropivocaine|0.2% ropivacaine 10ml is given as loading dose. Following that, 0.2% ropivacaine 5ml/h is given as maintenance dose.
1522243|NCT02799784|Drug|UMEC/VI|ELLIPTA dry powder inhaler (DPI) will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5 mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
1522244|NCT02799784|Drug|TIO/OLO|TIO/OLO inhalation spray will be supplied as an inhalation spray delivered using a RESPIMAT inhaler. Each actuation from the RESPIMAT inhaler delivers 3.124 mcg tiotropium bromide monohydrate (equivalent to 2.5 mcg tiotropium) and 2.736 mcg olodaterol hydrochloride (equivalent to 2.5 mcg olodaterol)
1522245|NCT02799784|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be supplied as an inhalation spray via metered dose inhaler and will be issued for reversibility testing at Visit 1. Albuterol/salbutamol will be permitted throughout the study for use as-needed
1522246|NCT02799758|Drug|NK-104-CR|NK-104-CR 8 mg for 52 weeks
1522247|NCT02799758|Drug|Livalo® IR|Livalo® IR 4 mg daily for 52 weeks
1522248|NCT02799758|Drug|Placebo (for NK-104-CR)|NK-104-CR 8 mg placebo for 52 weeks
1522249|NCT02799758|Drug|Placebo (for Livalo® IR)|Livalo® IR 4 mg placebo for 52 weeks
1522252|NCT02799706|Drug|Degarelix|a GnRH antagonist will be given for a predefined duration of 18, 24, or 36 months as per institution policy
1522253|NCT02799706|Drug|approved GnRH agonist|A non-steroidal anti-androgen (e. g. flutamide, bicalutamide) will be given orally one week before the first injection of the GnRH agonist and will be continued for no longer than 8 weeks to protect against flare.Dose may vary due to availability of different brand names and pharmaceutical forms The start of antiandrogen must be registered as day 1 of treatment in the GnRH agonist arm.
1522254|NCT02799706|Radiation|Radiotherapy|.As the study investigates the effect of two drugs given concomitantly to radiotherapy, all patients will be treated with the same treatment technique and target dose. The preferred treatment technique is intensity modulated radiotherapy (IMRT)
1522255|NCT02799680|Biological|allogeneic CART-33|allogeneic CD33-directed chimeric antigen receptor-modified T cells (CART-33)
1522256|NCT02799667|Device|Standard Dressing|Patients are randomized to the standard dressing at the time of fascial closure.
1522257|NCT02799667|Device|Negative Pressure Wound Therapy Dressing|Patients are randomized to the NPWT at the time of fascial closure.
1522262|NCT02799628|Behavioral|intervention|intervention with recommendation and therapist introduction
1522263|NCT02799628|Other|placebo|low back pain education, and physical therapy 3 times per week
1522264|NCT02799615|Drug|Infliximab|No standard dosing regimen will be used and the dose of infliximab will be determined by the treating physician
1522269|NCT02799589|Drug|Remifentanil|1mcg/kg over 1 min followed by an infusion (0.05-0.5 mcg/kg/min)
1522270|NCT02799589|Drug|Dexmedetomidine|1mcg/kg over 10 mins followed by and infusion (0.2-0.7 mcg/kg/hr)
1522271|NCT02799589|Drug|Ropivacaine|Caudal anesthesia block with Ropivicaine 0.2% 1ml/kg injected into the caudal space
1522273|NCT02799563|Other|Coach, Preselected number of cases|
1522274|NCT02799563|Other|Coach, Self-selected number of cases|
1522275|NCT02799563|Other|No coach, Preselected number of cases|
1522276|NCT02799563|Other|No coach, Self-selected number of cases|
1522277|NCT02799550|Biological|allogeneic CART-19|allogeneic CD19-directed chimeric antigen receptor-modified T cells (CART-19)
1522278|NCT02799537|Other|Randomized clinical study|Participants will be randomly assigned to one of two advance directives and we will assess which they prefer. This is not a human health intervention
1522279|NCT02799524|Other|comparison of screening scales|Concordance degrees Assessment of each of 2 scales ( HADS and GDS ) from the DSM- V , for diagnostic confirmation of major depressive episodes in elderly patients with cancer or haematological malignancies
1522280|NCT02799511|Biological|protein expression|Differential protein expression between the period of acute cerebral ischemia and the control period
1522281|NCT02799498|Device|Auto-injector device|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
1522282|NCT02799498|Other|Etanercept (ENBREL®) via Manual injection|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
1522283|NCT02799498|Drug|Etanercept (ENBREL®)|Single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
1522288|NCT02799472|Drug|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
1522289|NCT02799472|Drug|Placebo|0.9% weight by volume (w/v) sodium chloride solution administered as SC injection.
1522292|NCT02799459|Procedure|General anaesthesia|the patient will receive a general anaesthesia do proceed at her conization
1522293|NCT02799459|Procedure|Hypnosis in conization|this is the experimental treatment which is allocated to the experimental group
1522294|NCT02799446|Drug|Reslizumab|Reslizumab 3mg/kg intravenous (IV)
1522295|NCT02799446|Drug|Placebo|Matching Placebo intravenous (IV)
1522296|NCT02799433|Behavioral|Usual services + HAP|The HAP process includes child care center providers completing a self-assessment(s), setting improvement goals, receiving technical assistance materials, attending topic-specific workshops, improving best practices, re-self-assessment and qualification for a HAP award.
1522297|NCT02799433|Behavioral|Usual services|Control condition
1522300|NCT02799407|Other|ResearchKit Consent|Multi-tiered consent form using the Apple ResearchKit Platform.
1522301|NCT02799394|Other|Activity modification, exercises and gradual return to sport|
1522302|NCT02799381|Drug|ABT-SLV187|Dose levels will be individually optimized.
1522303|NCT02799381|Drug|optimized antiparkinsonian treatment|Dose levels of prescribed antiparkinsonian medications will be individually optimized to their maximum therapeutic effect.
1522306|NCT02799355|Drug|Sofosbuvir, Ribavirin, With or Without Pegylated Interferon|Retrospective will carried out to find percentage of patients with sustained virologic response at 12 weeks after the end of treatment
1522307|NCT02799316|Other|HBV core antibodies testing. • Real time PCR testing.|"HBV core antibodies testing in HBV surface antigen negative patients.
Real time PCR testing for those having positive HBc antibodies."
1522308|NCT02799303|Device|Multi-parametric MRI|Non contrast magnetic resonance imaging using T1/T2 weighting, DWI and ADC will be performed. MRI images will be reviewed by a single uro-radiologist and assessed using the PiRADs standards.
1522309|NCT02799303|Other|PSA testing|Serum prostate specific antigen (PSA) testing will be performed using a standardized laboratory assay.
1522312|NCT02799277|Drug|Testosterone|Effect of testosterone on moral decision making
1522313|NCT02799277|Drug|Placebo|
1522314|NCT02799264|Drug|Cabotegravir 30 mg|Cabotegravir (GSK1265744B ) is available as white to almost white, oval shaped, film coated tablet, of weight 515 mg. The tablet contains micronized cabotegravir, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, and magnesium stearate. Each tablet is equivalent to 30 mg cabotegravir and needs to be taken orally with 240 mL of water. Cabotegravir tablet will be administered to subjects either in fasting condition or following a high fat meal.
1522315|NCT02799251|Other|Collection of plasma cell rate|Lymphocytes counts are obtained from patients undergoing pulmonary or digestive cancer surgery. The rates are assessed before surgery (day 0) and at days 1, 3, 5 and 8 after surgery. Anesthetic and surgical procedures are collected as well as risk factors for postoperative infections recognized in the literature. Clinical and biological signs of infection are collected.
1522316|NCT02799238|Biological|ALECSAT|3 doses of ALECSAT/4 weeks followed by ALECSAT/3 months
1522317|NCT02799238|Radiation|radiotherapy|Radiotherapy 5 days/week for 6 weeks
1522318|NCT02799238|Drug|Temozolomide|Temozolomide daily for 6 weeks followed by 6 cycles 5days/4weeks
1522319|NCT02799212|Drug|somatostatin infusion|postoperative somatostatin infusion during 5 days at 6mg/day, followed by one day at 3mg/day.
1522320|NCT02799212|Drug|placebo infusion|Placebo infusion (50ml of 0.9% NaCl/day) during 6 days.
1522321|NCT02799186|Procedure|blood sample for genetic analysis|
1522322|NCT02799173|Biological|RANKL/OPG ratio|
1522323|NCT02799173|Device|bone densitometry|
1522324|NCT02799173|Device|fan beam CT scan|
1522325|NCT02799173|Device|Doppler ultrasound|
1522326|NCT02799147|Procedure|Allogeneic stem cell transplantation|
1522327|NCT02799147|Drug|Fludarabine monophosphate|
1522328|NCT02799147|Drug|Busulfan|
1522329|NCT02799147|Drug|Bendamustine|
1522330|NCT02799134|Drug|Dexamethasone|
1522331|NCT02799134|Drug|Vitamin C|
1522332|NCT02799121|Device|ReGenerCell™ Autologous Cell Harvesting Device|
1522333|NCT02799108|Device|NIRS|High-resolution EEG-fNIRS recording lasting a maximum of 30 minutes by using expressive and receptive language paradigms
1522334|NCT02799108|Device|fMRI|fMRI acquisition under the same stimulation conditions
1522335|NCT02799095|Drug|ALKS 4230|Intravenous infusion over 30 minutes given daily for 5 consecutive days followed by an off-treatment period
1522336|NCT02799082|Drug|Vehicle|topical treatment for photodynamic therapy combining vehicle application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
1522337|NCT02799082|Drug|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and subsequent illumination with broad or narrow spectrum light sources (after 3 h of drug incubation).
1522338|NCT02799069|Drug|BF-200 ALA|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
1522375|NCT02798770|Other|No Intervention Foreseen|
1522339|NCT02799069|Drug|MAL Cream|topical treatment for photodynamic therapy combining drug application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
1522340|NCT02799069|Drug|Vehicle|topical treatment for photodynamic therapy combining vehicle application and after a 3 h incubation subsequent illumination with a broad or narrow spectrum light source.
1522341|NCT02799056|Device|Thoracic ultrasound|The ultrasound will be performed using the ultrasound system GE Logiq XP equipped with a linear probe of 10 MHz. The diaphragm is visualized as two parallel echogenic lines (diaphragmatic pleura and peritoneal membrane) at the eighth or ninth intercostal space in the mid-axillary line (diaphragmatic apposition site). The images will be captured during the inspiratory and expiratory tidal volume to and during maximum inspiration and expiration. Each image will be frozen in B mode and the diaphragm thickness will be measured from the center line pleural half the peritoneal line. The fraction of diaphragmatic thickening it is calculated by the formula: diaphragmatic thickness at the end of inspiration - thickness to diaphragmatic at the end of exhalation / diaphragmatic thickness at the end of exhalation x 100. The number of areas with lines B also will be measured.
1522342|NCT02799043|Procedure|Standard PVI|Standard PVI procedure without FIRMap.
1522343|NCT02799043|Procedure|FIRM-Guided Procedure and PVI|
1522344|NCT02799030|Drug|BF-200 ALA 1%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
1522345|NCT02799030|Drug|BF-200 ALA 3%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
1522346|NCT02799030|Drug|BF-200 ALA 10%|topical treatment for photodynamic therapy combining drug application and after 3 h of drug incubation subsequent illumination with a broad spectrum light source .
1522347|NCT02799017|Other|Intensive Phonology Treatment|Phonology based reading, writing, and naming therapy.
1522348|NCT02799017|Other|Intensive SFA Treatment|Semantic based reading, writing, and naming therapy.
1522349|NCT02798991|Drug|GSK3179106|It is uncoated round or oblong tablet with 3 strengths viz;. 5, 25 and 100 mg. It is White to slightly colored tablet and will be administered orally
1522350|NCT02798991|Drug|Matched Placebo|It is uncoated round or oblong placebo tablet prepared to match actives across all strengths. It is White to slightly colored tablet and will be administered orally
1522351|NCT02798978|Drug|GSK1795091|GSK1795091 will be supplied as solution for injection vial. Each 5 mL vial contains 0.001 milligram/mL (mg/mL; 1000 ng/mL) or 0.0001 mg/mL (100 ng/mL)of GSK1795091 and will be administered as IV bolus over 2-5 minutes (min) followed by a IV bolus of 10 mL normal saline.
1522352|NCT02798978|Drug|Placebo|Matching placebo will be supplied as a solution for injection vial and will be administered as IV bolus over 2-5 min followed by a IV bolus of 10 mL normal saline
1522353|NCT02798965|Biological|serodiagnosis|
1522354|NCT02798952|Biological|Engerix™-B Kinder|Subjects previously primed and boosted with 4 doses of Infanrix hexa vaccine in the first 2 years of life received a single dose of Engerix-B Kinder vaccine as an intramuscular (IM) injection into the deltoid region of the non-dominant arm at 14-15 years of age.
1522355|NCT02798926|Device|polyethylene bag|The infant will be wrapped in a polyethylene bag 15 min before starting central venous catheter placement
1522356|NCT02798913|Drug|Short DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 3 months
1522357|NCT02798913|Drug|Long DAPT|acetylsalicylic acid 100 mg/day life-long + clopidogrel 75 mg/day for 12 months
1522358|NCT02798900|Other|Functional task-training|The functional task-training program includes warming up followed by a functional circuit with muscle strengthening exercises for the major groups of hip oriented to daily life activities and ends with stretching.
1522359|NCT02798900|Device|Therapeutic Ultrasound|Therapeutic pulsed ultrasound will be applied prior to functional task-training with an intensity of 2.2 W/cm2, frequency of 1 MHz and application time of 4 minutes on the anterior, medial and lateral hip area.
1522360|NCT02798887|Procedure|Ridge preservation|Ridge preservation comparing the clinical and histologic healing with or without a barrier membrane
1522361|NCT02798874|Drug|Ticagrelor|ticagrelor 180 mg 30 min before PCI and 90 mg for 12 months after surgery
1522362|NCT02798874|Drug|Clopidogrel|Clopidogrel 600 mg 30 min before PCI and 75 mg for 12 months after surgery
1522363|NCT02798861|Device|Fibroscan 402/530|Fibroscan 402/530 obtained before procurement in the donor and at 3 to 6 months post-transplant in the liver recipient.
1522364|NCT02798848|Device|Tablet computer|iPad
1522365|NCT02798835|Drug|Adductor canal block|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal in PACU.
1522366|NCT02798835|Drug|Adductor canal block with dexamethasone|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine in the adductor canal along with 8mg dexamethasone IV in PACU.
1522367|NCT02798835|Drug|Adductor canal catheter|Spinal anesthesia with 2-3 ml 0.5% bupivacaine and 0-20mcg of fentanyl. At the end of the case, the surgeon will infiltrate 30ml 0.5% ropivacaine peri-articularly. 20ml 0.5% ropivacaine and a catheter placed in PACU, with a continuous infusion of 0.2% ropivacaine started.
1522368|NCT02798835|Drug|Bupivacaine|Used in spinal anesthetic
1522369|NCT02798835|Drug|Fentanyl|May or may not be used in spinal anesthetic
1522370|NCT02798835|Drug|Ropivacaine 0.5% Injectable Solution|Local anesthetic to be used by surgeon as local infiltration and by anesthesiologist in adductor canal block.
1522371|NCT02798835|Drug|Dexamethasone|To be given intravenously at time of nerve block to one of the study arms.
1522372|NCT02798822|Procedure|Rapid maxillary expansion|When rapid maxillary expander was in-situ, patients waited 7 days before starting the screw activation of one quarter turn a day (0.22 mm) until overcorrection. Expansion was considered adequate when the occlusal surface of the first maxillary palatal cusp contacted the occlusal surface of the mandibular first molar facial cusp. When was achieved, rapid maxillary expander stayed in place for 10 months.
1522373|NCT02798809|Other|Clinical dental examination|Clinical dental examination and a questionnaire that was filled out by the parents before each clinical examination.
1522374|NCT02798796|Device|MRI|All patients will be submitted to MRI
1522377|NCT02798744|Drug|Empagliflozin|25mg once daily to be taken orally for the duration of the study (24 weeks)
1522378|NCT02798744|Behavioral|Diet|Daily energy restriction diet to be followed for the duration of the study (24 weeks)
1522379|NCT02798744|Drug|Placebo|Placebo once daily for the duration of the study (24 weeks)
1522380|NCT02798718|Dietary Supplement|full-fat milk|intake 250ml full-fat milk per day, do not intake any other dairy products
1522381|NCT02798692|Biological|Low dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
1522382|NCT02798692|Biological|Medium dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
1522383|NCT02798692|Biological|High dose HB-101|Three intra muscular administrations at Day 0, Month 1 and Month 3
1522384|NCT02798692|Biological|Placebo|Three intra muscular administrations at Day 0, Month 1 and Month 3. The diluent is used as placebo.
1522385|NCT02798666|Other|High intensity exercise training|Exercise training using sprint interval exercise
1522386|NCT02798666|Other|Continuous exercise training|Exercise training using continuous exercise at constant heart rate
1522387|NCT02798653|Drug|Choriomon® injection|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the embryos transfer (ET) day, as well as 4 days after the embryos transfer for luteal support
1522388|NCT02798653|Drug|Choriomon® injection+Endometrin ®|Intramuscular injection of 1,500 IU of hCG (Choriomon®; IBSA) on the ET day, as well as 3 and 6 days after the transfer along with Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
1522389|NCT02798653|Drug|Endometrin ® vaginal tablets|Endometrin ® vaginal tablets (Ferring Pharmaceuticals Ltd., Germany) 100 mg twice daily for luteal support from the day of oocyte pickup to the day of the pregnancy test.
1522390|NCT02798640|Device|Celliant|100% Celliant garment
1522391|NCT02798640|Device|Control|Control Garment
1522392|NCT02798627|Drug|NS2359|NS2359 is a small molecule which inhibits the reuptake of dopamine, norepinephrine and serotonin with equal affinity.
1522393|NCT02798627|Drug|placebo|Placebo pills identical in appearance to the NS2359 will be provided
1522394|NCT02798614|Device|10-day cast|Removal of plaster cast fixation 10 days after reduction
1522395|NCT02798601|Other|Hypernatremia|Serum Sodium goal: 150 - 155 milliequivalent/L.
1522396|NCT02798588|Radiation|PET-MRI|18Fluoro-Desoxy-Glucose's infusion for PET (glucose neural metabolism assessment, with quantitative information permitted by radioactivity monitoring through arterial catheter ; dosage = 1,5 MBq/Kg + 18,5 MBq as loading dose 5 min= Outside the scanner, Installation and movement management: Curare+/- sedative injection with standardized routine care protocol 10 min= Outside the scanner, Starting PET continuous acquisitionT= 0, Morphological MRI sequences- 3DT1, 3DFlair, T2SE, T2 HR on brainstem, Susceptibility and simple Diffusion Weighted Imaging-Specifically dedicated MR sequences based upon clinical issues 25 min, MRI in Resting state N°1 (global short-term functional connectivity)13 min, MRI DTI acquisition, 64 directions, sensitive to white matter injury 8 min, IRM in 2D-Arterial Spin Labelling:Quantitative Cerebral blood flow information (no Gadolinium)->8 min, IRM in Resting state 2 (repeated occurrence to assess stationarity) 13 min, End of PET continuous acquisition
1522397|NCT02798575|Device|Astral 150 ventilator|Patients indicative for invasive ventilation will receive the Astral 150 ventilator at the weaning station of the hospital. The ventilator will be set by the physician. Afterwards patients will be transferred into home care.
1522398|NCT02798562|Device|Native and dynamic contrast-enhanced CT|
1522399|NCT02798549|Other|blood draw|blood draw of 150ml, twice
1522404|NCT02798510|Radiation|Concurrent Chemoradiotherapy|
1522405|NCT02798510|Drug|capecitabine|
1522406|NCT02798510|Drug|gemcitabine|
1522407|NCT02798497|Other|Serum and Blood samples|
1522408|NCT02798484|Device|Diffusion-weighted Nuclear Magnetic Resonance Imaging (MRI)|MRI examinations performed on two devices: Ingernia 3 Testla (Philips) on the Horta site of the CHU Brugmann hospital, and Area 1,5 Tesla (Siemens) on the Brien site of the CHU Brugmann hospital. Diffusion sequences last 6 minutes and are already performed in the standard of care. Compared to the standard of care, one additional MRI will be performed one month after the start of the neo-adjuvant treatment, with diffusion analysis.The post-processing of the examinations will be realized with the Syngo Onco Care application of Siemens.
1522411|NCT02798458|Device|Smartpill|The SmartPill Test is approved by the U.S. Food and Drug Administration (FDA) to measure transit time in the GI tract. This procedure uses the SmartPill capsule, a receiver, and computer software.
1522497|NCT02797873|Other|Motivation rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
1522588|NCT02797236|Biological|SF2a-TT15 vaccine + adjuvant|
1522412|NCT02798458|Procedure|Endoscopic Mucosal Resection and Sigmoidoscopy|a Sigmoidoscopy is an exam used to evaluate the lower part of the large intestine) during which an Endoscopic Mucosal Resection (removal of a small amount of tissue from the outermost layer of gut wall) will be completed.
1522413|NCT02798445|Other|TAPIRS|Terminal Axial Perforator Interruption Reflux Source plus Adjustable compression system
1522414|NCT02798445|Other|CONTROL|Multilayer bandages and wound care
1522415|NCT02798432|Procedure|Total knee arthroplasty|Use of an uncemented femoral component or a cemented femoral component randomly assigned.
1522416|NCT02798432|Device|NEXGEN LPS total knee arthroplasty|Hybrid (non cemented femoral component, cemented tibial component) NEXGEN LPS total knee arthroplasty versus Cemented NEXGEN LPS total knee arthroplasty (both components are cemented).
1522417|NCT02798419|Drug|DFD05 Cream|
1522418|NCT02798419|Drug|Active01 Cream|
1522419|NCT02798406|Biological|DNX-2401|On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.
1522420|NCT02798406|Biological|pembrolizumab|Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401
1522421|NCT02798393|Other|Infrared Phototherapy|Subjects will wear a cuff on their extremities for a set period of time at set intervals over a period of several weeks. The cuff will emit the Infrared Phototherapy treatment (or sham if randomized to the non-treat group).
1522422|NCT02798393|Other|Sham|
1522423|NCT02798380|Drug|HTS-519 Insert|Maximum feasible dose of HTS-519 Insert per diseased nail
1522424|NCT02798367|Behavioral|CBT-I|Behavioral techniques of Sleep Hygiene and Stimulus Control standardized in clinical protocol.
1522425|NCT02798367|Drug|Melatonin 3 mg|01 tablet, orally, always at night one hour before bedtime, for 21(±2) days.
1522426|NCT02798367|Drug|Melatonin 5 mg|01 tablet, orally, always at night one hour before bedtime, for 21(±2) days.
1522427|NCT02798354|Behavioral|Quality Improvement Collaborative|1)Every 8 month 1-2 day interactive webinar learning sessions 2)Monthly webinars sharing best practices 3)Monthly team interactions with dedicated QI coach 4)Monthly data submission on both process and outcome measures 5)Monthly data feedback both at aggregate level with full inter-team transparency as well as at institutional level 6)Monthly mini root cause analyses performed on 1 error at each site 7)Multidisciplinary teams consisting of at least a physician, nurse, and office practice associate 8)Instruction on best practices from content area experts in QI, diagnostic errors, hypertension, mental health, leadership, behavior change, Model for Understanding Success in Quality (MUSIQ) and EHRs 9)Ongoing sharing of best ideas and barriers/issues among institutional teams
1522428|NCT02798341|Other|Biospecimen Collection|
1522429|NCT02798328|Device|TEG6s DOAC Cartridge|Testing subjects for presence of DOAC
1522430|NCT02798302|Other|Flush rate oxygen using a standard flowmeter (Precision Medical, 8MFA). See description for details. This is specific.|A standard oxygen flowmeter will be fully opened and oxygen will be administered for three minutes.
1522432|NCT02798276|Procedure|AGTP-treatment|Patients with a myocardial necrosis candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered with the adipose graft and the revascularizable area will be treated with the normal procedure (by-pass).
1522433|NCT02798276|Other|Control|Patients with a myocardial necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
1522434|NCT02798263|Other|Kinesiotherapy|Compare the standard treatment of pain, by kinesiotherapy versus acupuncture and Stiper.Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
1522435|NCT02798263|Other|Acupuncture|30 minutes of classical acupuncture using predefined points.
1522436|NCT02798263|Other|Stiper|They will be used the same acupuncture points of the group II, but using the needles in place Stiper.
1522437|NCT02798250|Other|Dual-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, closed-loop will be initiated. At 9:00, a standardized breakfast (45g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will be allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions. The intervention day will end at 13:00.
1522438|NCT02798250|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra).
1522439|NCT02798250|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
1522440|NCT02798250|Device|Dexcom G4 Platinum glucose sensor|
1522441|NCT02798250|Device|Accu Chek Combo insulin pump|
1522442|NCT02798237|Other|Aerobic treadmill training|"Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of aerobic treadmill training at 60-80% of heart rate reserve). The training intensity progression will be individualized.
Before and after the training, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously during training. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program. Device: treadmill."
1522443|NCT02798237|Other|Control (overground walking)|Participants will receive three sessions per week over 12 weeks, in groups of 2-4 participants, by a trained physiotherapist. The duration of the sessions will be 40 minutes (5-10 minutes of warm-up/cool-down and 30 minutes of comfortable walking below 40% of heart rate reserve). Before and after the exercise, participants will remain at rest for 10-15 minutes to measure heart rate, blood pressure and peripheral oxygen saturation (SpO2). The heart rate will be measured continuously. Participants will be asked to report any discomfort and to not volunteer to participate in other exercise program
1522498|NCT02797873|Behavioral|FEFA2|Assessing ability to recognise emotional face, performed at a computer at first visit. See Detailed Study Description.
1522444|NCT02798224|Behavioral|e-assist: Colon Health|Online e-assist program uses educational messages and workflow tools. The intent is to reduce mental workload in terms of how to proceed by filtering and presenting information in a usable manner at a time of peaked situational awareness. The program will prompt patients to indicate their decision stage based on the Precaution Adoption Process Model. e-assist users are then prompted to view additional information and logistical assistance personalized for their decision stage.
1522445|NCT02798224|Behavioral|Healthwise Educational Program|Online access to fact sheets that provide basic information about colorectal cancer and screening.
1522446|NCT02798211|Drug|Secukinumab|300 mg
1522447|NCT02798211|Drug|Secukinumab|150 mg
1522448|NCT02798211|Other|Placebo|Placebo
1522449|NCT02798198|Other|T2DM|T2DM without DKD
1522450|NCT02798172|Drug|Alogliptin and Metformin|The patients in the control group were given metformin (1,000 mg, bid po) and the patients in the intervention group were given metformin (500 mg, bid po) combined with alogliptin (25 mg, qd po)
1522451|NCT02798159|Drug|TD0025|
1522452|NCT02798159|Drug|Sildenafil Citrate 50mg|
1522453|NCT02798146|Other|blood collection|Blood samples are collected on the following days after human chorionic gonadotropin (hCG) injection: Day 0, Day 1, Day 2, Day 3, Day 4, Day 5, Day 6
1522454|NCT02798133|Procedure|OLA|PEEP titration trial for best Cdyn after the alveolar recruitment maneuver
1522455|NCT02798133|Procedure|RM-5|Fixed standard PEEP after the alveolar recruitment maneuver
1522456|NCT02798120|Drug|SB204 4%|Open label, topical SB204 4%
1522457|NCT02798107|Drug|idarucizumab|drug
1522458|NCT02798081|Behavioral|Single arm study|In Step 1 the elderly will participate of eight conventional computer classes which they were spontaneously enrolled. In Step 2, 10 minutes of the next eight classes will be used to practice serious games using virtual reality, using physical interface (keyboard or mouse).
1522459|NCT02798068|Drug|Solu-medrol or placebo administration|patients will receive 500mg of methylprednisolone in 100ml NaCl 0,9% or placebo (100ml NaCl 0,9%) at anesthesia induction
1522460|NCT02798055|Drug|Bosentan group|
1522461|NCT02798042|Other|Urine Sample|We plan to collect a urine sample during the pre-surgical visit.
1522462|NCT02798029|Radiation|Frameless Fractionated Stereotactic Radiation Therapy (FFSRT)|"Participants receive FFSRT to the brain daily for 3-5 days (weekdays only), based on what the doctor thinks is needed.
Dose prescription to the planning target volume (PTV) based on maximum diameter of each individual brain lesion:
< 3.0 cm: 27 Gy/3 fractions
3.0 - 3.9 cm: 30 Gy/5 fractions
4.0- 5.0 cm: 25 Gy/5 fractions"
1522463|NCT02798016|Procedure|Platelet-Rich Plasma|This Platelet-Rich Plasma will be taken from each patient and is going to be used in the treatment of atrophic acne scars
1522464|NCT02798016|Procedure|Micro-needling|Micro-needling will be applied on the acne scars in one side of the face.
1522465|NCT02798003|Other|Functional magnetic resonance imaging (fMRI)|The food-cue elicited response in the reward-circuitry of the brain will be assessed by using fMRI. This technique is based on different magnetic properties of oxygenated and deoxygenated blood. Increased neuronal activity causes an increase in blood flow. Thereby, neuronal activity is indirectly reflected by changes in blood oxygenation level-dependent (BOLD) contrast.
1522466|NCT02797977|Drug|SRA737, gemcitabine, cisplatin|
1522467|NCT02797977|Drug|SRA737, gemcitabine|
1522469|NCT02797951|Drug|Galcanezumab|Administered SQ
1522470|NCT02797938|Device|Taper guard tube|Taper guard tube was intubated
1522471|NCT02797938|Device|Cylindrical tube|Cylindrical tube was intubated
1522472|NCT02797925|Other|Training|Long slow strength training of the tendon for 3 months to improve function
1522473|NCT02797912|Other|No intervention|
1522474|NCT02797899|Device|Platelet Rich Fibrin|Native growth factors
1522475|NCT02797886|Other|FES + VOL|Electrical stimulation is applied in concert with the subject's volitional movement.
1522476|NCT02797886|Other|FES|Electrical stimulation is applied to the subject while they are asked to do nothing.
1522477|NCT02797886|Other|VOL|The subject initiates and completes the movement without electrical stimulation.
1522478|NCT02797873|Other|fMRI - Stroop task|2 x 10 minutes Stroop task (2 x 5 minutes emotional blocks, 2 x 5 minutes non-emotional blocks, order balanced across participants) performed during fMRI scan. See Detailed Study Description.
1522479|NCT02797873|Other|fMRI - MID task|2 x 10 minutes MID task performed during fMRI scan. See Detailed Study Description.
1522480|NCT02797873|Behavioral|Stop Signal Task|Performed at a computer at first visit, 10 minutes divided into 3 blocks. See Detailed Study Description.
1522481|NCT02797873|Other|SCID-II|See Detailed Study Description.
1522482|NCT02797873|Other|SDQ|See Detailed Study Description.
1522483|NCT02797873|Other|ASRS|See Detailed Study Description.
1522484|NCT02797873|Other|AQ|See Detailed Study Description.
1522485|NCT02797873|Other|TAS-20|See Detailed Study Description.
1522486|NCT02797873|Other|Raven's SPM|See Detailed Study Description.
1522487|NCT02797873|Other|Reading ability|See Detailed Study Description.
1522488|NCT02797873|Other|Ishihara's tests for colour deficiency|See Detailed Study Description.
1522489|NCT02797873|Other|Additional questionnaire|including questions about somatic disease, current medication, BMI, smoking habits, first menstruation, last menstruation's first day, days without active oral contraceptive pill during last month, claustrophobia, vision impairment.
1522490|NCT02797873|Other|Brown-ADD|See Detailed Study Description.
1522491|NCT02797873|Other|MFQ|See Detailed Study Description.
1522492|NCT02797873|Other|STAI-T|See Detailed Study Description.
1522493|NCT02797873|Other|BIS|See Detailed Study Description.
1522494|NCT02797873|Other|DAWBA|See Detailed Study Description.
1522495|NCT02797873|Other|STAI-S|See Detailed Study Description.
1522496|NCT02797873|Other|Sleepiness rating|Acquired 6 times while in MRI-scanner. See Detailed Study Description.
1522499|NCT02797873|Other|Structural T1 MRI scan|See Detailed Study Description and Outcome Measures.
1522500|NCT02797873|Other|Structural T2 MRI scan|See Detailed Study Description.
1522501|NCT02797873|Other|DTI MRI scan|See Detailed Study Description and Outcome Measures.
1522502|NCT02797873|Other|Resting state MRI scan|See Detailed Study Description and Outcome Measures.
1522503|NCT02797860|Drug|Rocuronium|comparison of onset time and duration of rocuronium using Train of Four watch
1522504|NCT02797847|Drug|ALN-TTRSC02|Ascending doses of ALN-TTRSC02 by subcutaneous (SC) injection
1522505|NCT02797847|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
1522506|NCT02797834|Procedure|Endometrial fluid collection|
1522507|NCT02797821|Drug|Asfotase alfa|
1522508|NCT02797808|Drug|Sertraline|Impact of sertraline on functional brain connectivity
1522509|NCT02797808|Other|No Intervention|Healthy control non-intervention
1522510|NCT02797795|Drug|NEV801|Dose Escalation
1522511|NCT02797782|Other|Detection of anti HBs antibody titer|All samples will be analyzed for anti HBs antibody titer using ELISA kits.
1522512|NCT02797769|Drug|Other Biologics|Exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. There are no protocol-specified biologic agents, although the analyses will be stratified by TNFi and non-TNFi targeted therapies. The drug selection and regimen are at the discretion of the prescribing physician.
1522513|NCT02797769|Drug|Tocilizumab|Tocilizumab exposure data will be gathered from claims databases, and no medicine will be administered in this non-interventional study. The regimen is at the discretion of the prescribing physician.
1522514|NCT02797756|Procedure|Esophago-gastro-duodenoscopy (EGD) with biopsy|
1522515|NCT02797756|Procedure|Esophageal Impedance Monitoring (EIM)|
1522516|NCT02797743|Other|Whole blood|"Adults ≥18 yrs of age: up to 50 mL (5 tubes)
Adolescents 12-17 yrs of age: up to 30 mL (3 tubes)
Children 0-11 yrs of age: single tube (1 tube, 10 mL)"
1522517|NCT02797730|Behavioral|art-therapy sessions|
1522518|NCT02797717|Radiation|Radiotherapy:|"All patients will have 2 OPEAcycles(chemotherapy cycle:Vincristine,Etoposide,Prednisone,doxorubicin) ,After assignment ( by randomization) to one of the arms the patient will be treated accordingly . response assessment will be done after OPEA cycles (ERA) and after cycles of copdac 28 or DECOPDAC 21(LRA).according to the assessments results patients will have radiotherapy or not."
1522519|NCT02797717|Drug|Vincristine|ARM A and ARM B
1522520|NCT02797717|Drug|Etoposide|ARM B , 100mg/m2/day
1522521|NCT02797717|Drug|Prednisone|ARM A and ARM B , 40mg/m2/day p.o
1522522|NCT02797717|Drug|Doxorubicin|ARM B , 25mg/m2
1522523|NCT02797717|Drug|Dacarbazine|ARM A and ARM B , 250mg/m2 i.v
1522524|NCT02797717|Drug|Cyclophosphamide|ARM A and ARM B , 625mg/m2 i.v
1522525|NCT02797704|Drug|Aflibercept|
1522526|NCT02797691|Other|CaCBT|Culturally Adapted Cognitive Behaviour Therapy
1522527|NCT02797691|Other|Medication/ Psychotherapy|Medication/ Psychotherapy used as usual
1522528|NCT02797665|Drug|corticosteroids|prednisone 0.6mg/kg/d
1522529|NCT02797665|Procedure|biliary stent|placement of biliary stent during endoscopic retrograde cholangiopancreatography (ERCP)
1522530|NCT02797652|Procedure|Neoadjuvant chemotherapy before surgery|The operable breast cancer patients takes neoadjuvant chemotherapy before surgery.
1522531|NCT02797652|Procedure|Surgery followed by adjuvant chemotherapy|The operable breast cancer patients takes surgery followed by adjuvant chemotherapy.
1522532|NCT02797639|Other|Co-PID|"The program was carried out by the school occupational therapist and homeroom teachers. The Co-PID had two phases. The first phase was a 1.5 hour in-service meeting that focused on the concept of Participation.
In the second phase of the Co-PID intervention, a collaborative consultation model was used. It included eight 45-minute consultation meetings, which took place every other week over a 3-months period. The meetings took place between the occupational therapist and each teacher, with the purpose of brainstorming; thinking of activities that the teacher could implement during the lessons for enhancing participation among the students."
1522533|NCT02797639|Other|IS|IS group included three meetings, a 1.5 hour in-service meeting focusing on the concept of participation, and two more workshop meetings aimed at sharing teachers' experience.
1522534|NCT02797626|Procedure|Primary retroperitoneal lymph-node dissection (pRPLND)|Open or laparoscopic robotic-assisted nerve-sparing retroperitoneal lymph node dissection (modified template RPLND, if possible ipsilateral nerve-sparing)
1522535|NCT02797613|Behavioral|Restricted Reporting|An abbreviated version of the microbiology report indicating that growth is present and the physician should call the lab for further details if clinically important
1522536|NCT02797600|Behavioral|Questionnaires|Questionnaires will be used to obtain self-reported demographic, behavioral, social, family and medical history, and quality of life data. The questions are standardized and taken from either nationally recognized surveys, CARE I surveys, or represent validated survey items.
1522537|NCT02797600|Other|Biological Samples|All biological samples will be collected at the time of the clinical Pap smear for the controls, and will be collected for the Arm 2 (newly diagnosed) during a scheduled clinic visit. For those individuals in Arm 1, biological samples will be collected during a scheduled visit with the research staff.
1522538|NCT02797587|Drug|Varenicline|1 week starter kit followed by 1mg twice daily for 12 weeks.
1522539|NCT02797587|Drug|Cytisine|Multi-daily dosing, range 3-9 mg daily for 25 days.
1522540|NCT02797587|Drug|Nicotine Replacement Therapy|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
1522541|NCT02797587|Drug|Varenicline Placebo|1 week starter kit followed by 1 pill twice daily for 12 weeks.
1522542|NCT02797587|Drug|Cytisine Placebo|Multi-daily dosing for 25 days.
1522543|NCT02797587|Drug|Nicotine Replacement Therapy Placebo|Mouth spray dosing based on standard recommendations tapered over 8 weeks.
1522544|NCT02797574|Procedure|Punch Biopsy at a Lesional Site|
1522545|NCT02797574|Procedure|Punch Biopsy at a Non- Lesional site|
1522546|NCT02797561|Other|5 year Follow-up|
1522547|NCT02797548|Drug|Aspirin only|Aspirin only during surgery
1522548|NCT02797548|Drug|No antiplatelet therapy|No antiplatelet therapy will be during surgery
1522589|NCT02797236|Biological|Placebo|
1522549|NCT02797535|Procedure|Endoscopy procedures|GI fluids samples will be collected from: (i) fluids suctioned during standard endoscopy procedures / pouchoscopy, (ii) from ileostomy/colostomy bags removed for bag replacement and (iii) from stool samples collected by patients after pouch surgery.
1522550|NCT02797522|Drug|ARC-521 Injection|
1522551|NCT02797522|Other|Placebo|0.9% normal saline
1522552|NCT02797509|Behavioral|Psychosocial Skills-Based Intervention|Subjects will attend group skills-based sessions once weekly (either in-person or via Vidyo) for 6 weeks and learn skills to cope and manage stroke-related stressors.
1522553|NCT02797496|Other|Asymmetric Motor Strengthening|"In the Asymmetric Motor Strengthening program, the principle is to concomitantly reinforce the body openers and stretch the body closers. One alternates two types of practice during a session. Active exercises consist of fatiguing series of rapid alternating movements against light weights working on movements of extension/abduction/external rotation/supination. Stretch postures consists of short 1-2 minutes bouts of flexor/internal rotator/adductor/pronator stretch. The duration of rehabilitation program is 8 weeks."
1522554|NCT02797496|Other|Conventional therapy|Conventional therapy will include general stretch, strengthening and balance exercises, respiratory exercises and relaxation methods.
1522555|NCT02797483|Other|Test Fat Blue|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Blue which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
1522556|NCT02797483|Other|Test Fat Green|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Green which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
1522557|NCT02797483|Other|Test Fat Red|Each subject received a palm olein-based run in diet for 2 weeks, followed by random assignment Test Fat Red which incorporated into daily snacks (~50g of test fats, 2 experimental cupcakes (~15g test fat each) for breakfast and 4 pieces experimental cookies (~5g test fat each) for afternoon tea together with a palm olein-based background diet for 16 weeks.
1522558|NCT02797470|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
1522559|NCT02797470|Drug|Carmustine|
1522560|NCT02797470|Drug|Cytarabine|
1522561|NCT02797470|Drug|Etoposide|
1522562|NCT02797470|Other|Laboratory Biomarker Analysis|Correlative studies
1522563|NCT02797470|Biological|Lentivirus Vector CCR5 shRNA/TRIM5alpha/TAR Decoy-transduced Autologous CD34-positive Hematopoietic Progenitor Cells|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
1522564|NCT02797470|Drug|Melphalan|
1522565|NCT02797470|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo infusion of lentivirus vector CCR5 shRNA/TRIM5alpha/TAR decoy-transduced autologous CD34-positive hematopoietic progenitor cells
1522566|NCT02797457|Procedure|Bilateral allograft of the hands and forearms.|Bilateral allograft of the hands and forearms.
1522567|NCT02797457|Procedure|Prosthetic forehands|Prosthetic forehands
1522568|NCT02797444|Other|semi-structured interviews|
1522571|NCT02797418|Behavioral|Cognitive remediation program|"Comparison between a cognitive remediation program (Cognitus and Me) (groupe 1) and a training group of fine motor skills (group 2)"
1522572|NCT02797405|Radiation|Standard treatment|Sarcoma patients will undergo radiotherapy followed by surgery Rectum cancer patients will undergo radio-chemotherapy followed by surgery Esophagus cancer patients will undergo radio-chemotherapy followed by surgery
1522573|NCT02797392|Behavioral|Lifestyle intervention|1) Systematic collection of information on lifestyle risk factors using questionnaire 2) Risk estimation and stratification into risk groups based on questionnaire data and information from the electronic patient record (EPR) using validated risk estimation models, 3) An individual electronic health profile with personalized advise on lifestyle change and 4) targeted preventive services incl. lifestyle counseling at the GP or the municipality for citizens at increased risk of lifestyle disease and citizens with risk behavior, respectively.
1522574|NCT02797379|Other|Psychoeducation|The intervention is focused on psychoeducation. Four psychoeducation guides will be available: parent/caregiver, adult with ASD, adolescent with ASD, and child with ASD. The guides introduce the concept of anxiety and how it presents in individuals with ASD, different anxiety triggers, strategies that can be used to manage anxiety, and an introduction to specific anxiety disorders. Level of detail, language and presentation of content will vary across the guides to be appropriate for the functioning level of the readers.
1522575|NCT02797366|Radiation|Proton radiotherapy|
1522576|NCT02797353|Other|Maternal Neonatal and Child Health Interventions|Antenatal care, postnatal care, skilled birth attendance, recognition and referral of complicated cases, immunization
1522577|NCT02797340|Other|Blood draws and urine samples for metformin concentration measurements|
1522578|NCT02797340|Drug|Metformin|
1522579|NCT02797314|Other|Bone biopsies|Bone biopsies
1522580|NCT02797301|Other|synthetic test|The children performed the synthetic test with no time restriction.
1522581|NCT02797301|Other|computerised test|The children performed the computerised test with no time restriction.
1522582|NCT02797275|Drug|Albuterol|
1522583|NCT02797275|Drug|Placebo|
1522584|NCT02797262|Other|Proteus digital health feedback (PDHF) system|Building on the available Proteus devices, the investigators will design and create a PDHF system to transmit the adherence data using mobile technology to allow treatment monitoring that is, direct confirmation of the type, dose, date and time of oral pharmaceutical ingestion using wirelessly observed therapy (WOT).
1522585|NCT02797249|Drug|Aspirin|Low dose aspirin（100mg）per day starting between 12+ and 20 weeks of pregnancy until 34 weeks of pregnancy,taking at night.
1522586|NCT02797249|Other|Blank|Routine examination during pregnancy.
1522590|NCT02797236|Biological|Placebo + adjuvant|
1522591|NCT02797223|Behavioral|Semi-structured interviews|Qualitative phenomenological study. Data collection will be done through semi-structured interviews. Each interview will last between 60 and 90 minutes. It will be the same researcher who interviewed and analyze them.
1522592|NCT02797210|Device|Continuous theta-burst stimulation|
1522593|NCT02797197|Procedure|handgrip strength test|
1522594|NCT02797197|Drug|chemotherapy|
1522595|NCT02797184|Drug|KNO3, potassium nitrate|KNO3, potassium nitrate will be given orally in a gelcap, which will be compounded by the Barnes-Jewish Hospital Pharmacy. The doses are described in the arm/group descriptions.
1522596|NCT02797184|Dietary Supplement|Beetroot juice|"2 shots of beetroot juice - one Sport Shot and one organic shot ~ 2/3 Cup total containing ~11.2 mmol Nitrate."
1522597|NCT02797184|Other|placebo|a placebo pill will be given orally in a gelcap, which will be compounded by the Barnes-Jewish Hospital Pharmacy
1522600|NCT02797158|Procedure|TAVI procedure|Targeted and selected revascularization guided on myocardial ischemia detection after the TAVI procedure by using single photon emission computed tomography (SPECT) myocardial perfusion imaging.
1522601|NCT02797145|Drug|Digoxin dose-adjusted|Serum digoxin concentration : 0.5 to 0.9 nanogram/mL
1522602|NCT02797145|Drug|Standard dose|the dose of digoxin will be determined at the physician's discretion using traditional dosing methods.
1522603|NCT02797132|Drug|lumacaftor/ ivacaftor|
1522604|NCT02797119|Drug|tranexamic acid 1 g (TA1)|1 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
1522605|NCT02797119|Drug|tranexamic acid 0.5 g (TA1/2)|0.5 g standard dose tranexamic acid, intravenous unique bolus over 1 minute
1522606|NCT02797119|Drug|Saline Solution (TA0)|
1522607|NCT02797106|Other|Practice survey of health professionals|Survey of the practices and opinions of health care professionals to describe care pathways, assessment and treatment of drooling in children with cerebral palsy
1522608|NCT02797080|Drug|interferon γ-1b|ACTIMMUNE® will be administered three times per week by subcutaneous injection. The initial dose will be individualized for each participant and will be determined by the investigator, provided that the initial dose does not exceed the maximum tolerated dose in HZNP-ACT-302 (NCT02593773). The investigator may subsequently adjust the dose for any participant if deemed clinically appropriate, provided that the dose does not exceed 100 μg/m2.
1522609|NCT02797067|Drug|indomethacin suppository|100mg rectal indomethacin 30min before ESWL
1522610|NCT02797067|Drug|glycerin suppository|30min before ESWL
1522611|NCT02797054|Behavioral|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
1522612|NCT02797054|Behavioral|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
1522613|NCT02797054|Behavioral|Usual care|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
1522614|NCT02797041|Drug|Bortezomib|Re-challenge with bortezomib as second line therapy in myeloma patients relapsed after a previous bortezomib-based treatment
1522615|NCT02797028|Dietary Supplement|Anthocyanidins capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
1522616|NCT02797028|Dietary Supplement|Placebo capsule|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
1522617|NCT02797028|Drug|Allopurinol|Continuous intervention for 1 years, detect the indicators in the intervention of 0,6,12 months
1522618|NCT02797015|Drug|RPC1063|Oral capsule daily
1522620|NCT02796989|Dietary Supplement|Wheat bran|20 g each day
1522621|NCT02796989|Dietary Supplement|Placebo|20 g each day
1522622|NCT02796976|Other|Training or control condition|Participants get a 12 week high intensity and walking-based interval training which is adapted to their individual physical fitness level or a general recommendation on physical activity according to European Guidelines.
1522623|NCT02796963|Behavioral|Crowdsourced intervention|The crowdsourced intervention is composed of three phases that cumulatively draw on crowd wisdom to engage the community: (1) a crowdsourcing contest to solicit optimal images/concepts/taglines; (2) a designathon to formulate optimal HIV testing campaigns; (3) a process of localization unique to each of the eight cities.
1522624|NCT02796963|Behavioral|Traditional intervention campaign|The pre-intervention period will include conventional HIV testing campaigns organized by local CDC, CBO, and partners. These are typically designed by experts and social marketing companies.
1522625|NCT02796950|Drug|Acipimox|P.o. administration of 250 mg acipimox
1522626|NCT02796937|Biological|Alpha-1 MP|Alpha-1 MP 60 mg/kg/week for up to 104 weeks
1522627|NCT02796924|Device|MagStim Rapid2 Transcranial Magnetic Simulation|A non-invasive method of brain stimulation
1522628|NCT02796911|Drug|Xenograft|group II will be treated with CAOT combined with bovine derived xenograft (Biogen, Biotecksrl Fermi, Arcugraro VI, Italy);
1522629|NCT02796911|Drug|Bioactive glass|group III will be treated with CAOT combined with bioactive glass (Bio-Glass, Excellence Pharm Inc., Egypt).
1522630|NCT02796898|Drug|SM88 (Cohort 1)|"Tyrosine Isomers - 230 mg qd
Phenytoin - 50 mg qd.
Methoxsalen - 10 mg qd
Sirolimus - 0.5 mg qd"
1522631|NCT02796898|Drug|SM88 (Cohort 2)|"Tyrosine Isomers - 460 mg (230 mg bid)
Phenytoin - 50 mg qd
Methoxsalen - 10 mg qd
Sirolimus - 0.5 mg qd"
1522632|NCT02796885|Other|no intervention - observational study|
1522633|NCT02796872|Dietary Supplement|GOS|GOS resource (β-galactosidase from Bacillus circulans) Commercial infant formula containing 4% w/w FOS:GOS (1:3)
1522845|NCT02795286|Device|Artis Haemodialysis Machine w/o ASIST Software|
1522634|NCT02796872|Dietary Supplement|B-GOS 3%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 3% w/w FOS:B -GOS (1:2)
1522635|NCT02796872|Dietary Supplement|B-GOS 2%|Bimuno-GOS (B-GOS) resource (β-galactosidase from Bifidobacteriumbifidum) Commercial infant formula containing 4% w/w FOS:B -GOS (1:3)
1522636|NCT02796872|Dietary Supplement|Mother's breast milk|exclusively breastfed infants for at least 7 days prior to enrollment
1522637|NCT02796859|Drug|Siltuximab|Investigational agent
1522638|NCT02796859|Drug|normal saline|Placebo
1522639|NCT02796833|Drug|SMOFlipid20%|
1522640|NCT02796820|Drug|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
1522641|NCT02796807|Drug|68Ga-HBED-CC-PSMA (DKFZ-11) PET/CT|
1522642|NCT02796794|Dietary Supplement|Genistein|Total 30 patients will be included into the study They will be divided into two groups each containing 15 patients. Intervention group will receive supplemental genistein (60 mg/day) to enteral nutrition
1522643|NCT02796794|Other|enteral nutrition only|These are the patients receiving enteral nutrition
1522645|NCT02796768|Other|3D US Scanning|3D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
1522646|NCT02796768|Other|2D US Scanning|2D ultrasound will be used by both clinicians to scan both the right and left hips of the infant.
1522647|NCT02796755|Drug|Riluzole|Study participants randomized to this arm will take 100 mg/day of riluzole for 8 weeks.
1522648|NCT02796755|Drug|Placebo|Study participants randomized to this arm will take a placebo, that matches the appearance of 100 mg tablets of riluzole, daily for 8 weeks.
1522649|NCT02796742|Other|Collecting samples from all patients presenting with SSTIs requiring drainage|The study will be conducted by microbiology laboratories. Before the start of the study, each participating laboratory will send an information letter to its corresponding emergency departments to increase vigilance of clinicians in collecting samples from all patients presenting with SSTIs; this will improve the level of inclusion. Each participating lab will also insure connection to local representation of the project for ethical clearance, collection of clinical data and SSTI specimen.
1522650|NCT02796729|Procedure|Magnetic resonance imaging|MRI offers excellent images of the brain and is an important tool for diagnosing metastatic brain tumors. MRI scans are often used to plan treatments such as surgery and radiotherapy. When imaging participants with metastatic brain tumors, a contrast agent is often injected intravenously to highlight the relatively small tumours in the MRI. The standard metal-based MRI contrast agent is Health Canada approved and contains a material called gadolinium. MRI studies that use gadolinium-based contrast agents are called gadolinium enhanced MRI.
1522651|NCT02796729|Drug|Gadovist (Gadobutrol)|Gadobutrol (INN) (Gd-DO3A-butrol) is a gadolinium-based MRI contrast agent (GBCA).
1522652|NCT02796729|Drug|50% dextrose solution|50% Dextrose Injection, USP is a sterile, nonpyrogenic, hypertonic solution of dextrose in water for intravenous injection.
1522653|NCT02796716|Device|Testing on new technology called Accelerate ID/AST system|
1522654|NCT02796703|Dietary Supplement|Heat Inactivated probiotics|Biotikid, a probiotic mixture, will be heated to 100 degrees Centigrade for 10 minutes to inactivate and then 1 tsp will be diluted in milk and give with feeds to treatment group
1522655|NCT02796703|Dietary Supplement|Placebo|2 cc of milk will be given to control group
1522656|NCT02796690|Other|nasal swabs will be collected|After formal consent, nasal swabs are collected for each participant. SA nasal carriage and its susceptibility to methicillin is determined using a rapid PCR technique (GenExpert, Cepheid). Each participant is asked to complete a short questionnaire regarding some demographic variables, smoking habits, long-term medication, sector of activity, and direct manipulation of the pathogen.
1522657|NCT02796677|Drug|Aclidinium bromide 400 μg/Formoterol Fumarate 12 μg (AB/FF 400/12 μg)|Inhalation powder
1522658|NCT02796677|Drug|Aclidinium bromide 400 μg (AB 400 μg)|Inhalation powder
1522659|NCT02796677|Drug|Formoterol fumarate 12 μg (FF 12 μg)|Inhalation powder
1522660|NCT02796677|Drug|Placebo to AB/FF 400/12 μg, AB 400 μg and FF 12 μg|Inhalation powder
1522661|NCT02796677|Drug|Tiotropium 18 μg (TIO 18 μg)|Powder in capsules for oral inhalation
1522662|NCT02796677|Drug|Placebo to TIO 18 μg|Powder in capsules for oral inhalation
1522663|NCT02796664|Dietary Supplement|Ginseng|2grams twice per day (0.5gram/capsule, 2capsuels twice a day) for 12months
1522664|NCT02796664|Dietary Supplement|Placebo|2grams twice per day (0.5gram/capsule, 2capsuels twice a day) for 12months
1522665|NCT02796651|Drug|Formoterol fumarate (6 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
1522666|NCT02796651|Drug|Formoterol furmarate (20 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
1522667|NCT02796651|Drug|Placebo for formoterol fumarate|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
1522668|NCT02796651|Drug|Formoterol fumarate (12 μg)|Oral Inhalation (by Pressair® Dry Powder Inhaler, DPI)
1522669|NCT02796651|Drug|Formoterol fumarate (40 μg)|Oral Inhalation (via a standard jet nebulizer connected to an air compressor.
1522670|NCT02796638|Device|Adaptive Servo-Ventilation|A positive pressure airway device that increases and decreases inspiration pressure in concordance with the patient's natural breathing cycles.
1522672|NCT02796612|Other|no intervention|Patients do not receive any interventions but are treated according to current standard of care.
1522673|NCT02796612|Behavioral|delivery of a take-home brochure|Content of brochure is dealing with symptoms, as well as mammographic and ultrasound findings, which need further investigation, will be addressed. The procedure of the breast biopsy itself will be explained in detail. The time in which the histological diagnosis can be expected will be indicated and follow up in case of a benign histology and the necessary therapy in case of breast cancer will be addressed.
1522674|NCT02796612|Behavioral|patient care by a psychologically trained physician|The physicians who perform the biopsies will be instructed by means of a psychological training how to give structured and standardized information in order not only to inform comprehensively, but also to meet the patients' emotional needs.
1522846|NCT02795273|Drug|Grass-SPIRE|
1522676|NCT02796586|Other|Counseling|Participants will be randomly assigned to group versus individual contraceptive counseling
1522678|NCT02796560|Drug|Brand name travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
1522679|NCT02796560|Drug|Generic travoprost|Depending on the arm, either brand name or generic Travoprost will be administered by the patient. After 3 weeks, the intraocular pressure will be measured and a crossover will happen. Patients having taken brand name Travoprost will be switched to generic Travoprost and vice versa. At 6 weeks, the intraocular pressure will be measured. Questionnaires on the comfort and intolerances of the drops will be administered at the visits of 3 and 6 weeks.
1522680|NCT02796547|Drug|Levobupivacaine|Infiltration of the banks of the episiotomy done with Levobupivacaine
1522681|NCT02796547|Other|Physiological serum|Infiltration of the banks of the episiotomy done with physiological serum
1522682|NCT02796534|Other|Diagnosis of sleep apnea by oxymetry|
1522683|NCT02796521|Other|dietary counseling|Patients received individualized nutritional counseling encouraging them for enrichment
1522684|NCT02796521|Other|nutritional workshop with enrichment during a meal|Patients received in group nutritional informations for enrichment and are encouraged to try enrichment together during a meal.
1522687|NCT02796495|Device|Operation of hand prosthesis with direct nerve stimulation|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of the amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.
The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.
The use of the prosthesis during different tasks will be considered the intervention."
1522688|NCT02796482|Dietary Supplement|EnergieShake 1.5kcal Complete|Participants will be given EnergieShake 1.5 kcal Complete drink twice daily. i.e. 2 bottles of ONS per day during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days, followed by 8 day intervention on EnergieShake 1.5 kcal Complete drink.
1522689|NCT02796469|Drug|Pentoxifylline|
1522690|NCT02796469|Drug|Corticosteroid|
1522691|NCT02796469|Drug|Placebo|
1522692|NCT02796456|Other|blood sample|
1522693|NCT02796443|Procedure|Laparoscopic cholecystectomy (LC)|Removal of the gallbladder via a minimally invasive approach
1522694|NCT02796430|Other|Time needed to start indirect calorimetry measurement|Comparison of the time needed to start EE measurements by the new calorimeter and the currently used calorimeter, including the time needed for calibration, patient data input, connection to the ventilator circuit.
1522695|NCT02796430|Other|Indirect calorimetry measurement|Comparison of EE measurements by the new calorimeter and the currently used calorimeter when using different mechanical ventilators, different ventilation modes, different patient conditions and severity
1522696|NCT02796417|Behavioral|REHACOP|REHACOP group consists of 90-minute-long sessions 3 days per week. Specifically, REHACOP group remediation consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas
1522697|NCT02796417|Behavioral|Occupational activities|Occupational group activities conducted included drawing, gardening, reading the daily news and constructing using different materials (such as paper or wood).
1522698|NCT02796404|Device|Homebased cardiac rehabilitation program|homebased cardiac rehabilitation program with monitoring vest Nuubo
1522699|NCT02796404|Other|Traditional cardiac rehabilitation program|multidisciplinary intervention in cardiac rehabilitation gym
1522701|NCT02796378|Drug|Training+Simvastatin+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10-placebo.
1522702|NCT02796378|Drug|Training+Simvastatin-placebo+Q10-placebo|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin-placebo and Q10-placebo.
1522703|NCT02796378|Drug|Training+Simvastatin+Q10|8 weeks of exercise training on a bycycle ergometer 3 times/week combined with Simvastatin 40 mg/day and Q10 400 mg/day.
1522704|NCT02796365|Other|Exercise|Intervention will include 10 weeks of a standard cardiac rehabilitation program consisting of thrice a week aerobic exercise and 1-2 days per week resistance exercises.
1522705|NCT02796352|Drug|High dose bolus interleukin-2 (HD IL2)|"Each course consists of 2 cycles of HD IL2 as follows: high-dose IL2 at 600,000 IU/kg is given intravenously (IV) every 8 hours for up to 14 doses (one cycle), followed by a rest period of 1-2 weeks and readmission for a second HD IL2 cycle for up to 14 doses (second cycle).
The planned treatment consists of 3 courses (6 cycles) of HD IL-2."
1522709|NCT02796313|Behavioral|DASH Groceries + Dietitian Sessions|Intervention group participants will receive 1 hour of in-person nutritional counseling and a personalized prescription for the low-salt DASH diet based on estimated calorie needs at baseline, followed by weekly 20-minute phone calls in weeks 1-8 to provide extra support.
1522710|NCT02796313|Behavioral|Groceries + Brochure|Control group participants will receive a printed brochure about the health benefits of a low-salt diet. They will place an unrestricted $30 grocery order for 8 weeks.
1522711|NCT02796300|Device|Bioflo Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
1522712|NCT02796300|Device|Palindrome Dialysis Catheter|The catheter placement procedure will be performed in the interventional radiology suite. The catheter will be inserted subcutaneously through incision in the chest through the tract.
1522713|NCT02796287|Procedure|achieving a neuropsychological examination in the acute amnesic phase|achieving a neuropsychological examination in the acute phase in addition to the normal protocole
1522714|NCT02796287|Procedure|Neurological consultation with neuropsychological evaluation|Neurological consultation with neuropsychological evaluation one year after the acute amnesic phase
1522715|NCT02796287|Radiation|MRI|Brain MRI with the same protocol or an acquisition time of 15 minutes without gadolinium, one year after the acute amesic phase
1522718|NCT02796248|Other|cross-sectional survey|This is an observation study. Participants will complete a survey at one occasion. Participants are also invited to do a A1c mail-in capillary test.
1522719|NCT02796235|Other|Venous Doppler ultrasound of the lower limbs|Venous Doppler ultrasound of the lower limbs at 6, 9 and 12 months of the initial injury
1522720|NCT02796209|Drug|Atomexetine|Upon completion of the 4-week treatment period (period 1), the investigator or research nurse will instruct the subject to discontinue the study medication for 1 week (wash-out period). After this period, the subject will complete the second 4-week treatment period (period 2).
1522721|NCT02796209|Drug|Placebo|Upon completion of the 4-week treatment period (period 1), the investigator or research nurse will instruct the subject to discontinue the study medication for 1 week (wash-out period). After this period, the subject will complete the second 4-week treatment period (period 2).
1522722|NCT02796196|Other|Medical Chart Review|Review of medical chart
1522723|NCT02796196|Device|Monitoring Device|Wearable physical activity monitoring device
1522724|NCT02796196|Procedure|Physical Therapy|Undergo primarily self-directed physical therapy
1522725|NCT02796183|Drug|Subconjunctival bevacizumab (Altuzan)|Subconjunctival injections of Altuzan 3.75mg were applied in order to eliminate the macular edema.
1522726|NCT02796170|Drug|Dapagliflozin|5mg pill taken once daily
1522727|NCT02796170|Drug|Sulfonylurea|Subjects may take any of the sulfonlyurea medications, titration will be done per standard of care.
1522728|NCT02796170|Drug|Placebo|5mg pill taken once daily- placebo of Dapagliflozin
1522729|NCT02796157|Device|PCI with Absorb everolimus-eluting bioresorbable vascular scaffold|Patients allocated to this arm will undergone PCI with Absorb everolimus-eluting bioresorbable vascular scaffold. It will be allowed to used multiple stents for a long coronary lesion.
1522730|NCT02796157|Device|PCI with Xience everolimus-eluting metallic stent|Patients allocated to this arm will undergone PCI with Xience everolimus-eluting metallic stent. It will be allowed to used multiple stents for a long coronary lesion.
1522731|NCT02796144|Drug|Lorcaserin|Max dose of 10 mg BID
1522732|NCT02796144|Drug|Metformin|Max dose of 1,000 mg BID
1522733|NCT02796144|Drug|Placebo|Matching placebos will be administered for each drug.
1522734|NCT02796131|Drug|RDX5791|
1522735|NCT02796131|Drug|Placebo|Placebo
1522736|NCT02796118|Drug|ASP2151|Oral
1522737|NCT02796118|Drug|Placebo|Oral
1522738|NCT02796105|Drug|Progevera|
1522739|NCT02796105|Drug|Orgalutran|
1522740|NCT02796092|Device|Fibered platinum coils|
1522741|NCT02796092|Device|Vascular plugs|
1522742|NCT02796079|Biological|mesenchymal stem cells|stem cell acquisition, processing and reinfection, to evaluate the efficacy by using autologous bone marrow stem cell
1522743|NCT02796079|Biological|saline|saline injections
1522744|NCT02796066|Drug|Vehicle|Applied once a day
1522745|NCT02796066|Drug|TSN2898|Applied once a day
1522746|NCT02796066|Drug|TSN2898|Applied once a day
1522747|NCT02796066|Drug|TSN2898|Applied once a day
1522748|NCT02796053|Drug|TAB08|The TAB08 will be administered intravenously, by infusion.
1522749|NCT02796053|Other|Placebo|The Placebo to TAB08 will be administered intravenously, by infusion.
1522750|NCT02796040|Device|MRI|
1522751|NCT02796027|Other|BRIDGE|"BRIDGE, enhanced HIV service integration package, has three components:
peer driven recruitment using a Social Network Strategy (SNS) -- which has been designated as a high impact and highly effective strategy by the CDC for reaching out and engaging PWID in HIV testing
HCT using CTR with Rapid Testing
ARTAS -- a CDC case management strategy for linking HIV-positive PWID to HIV care that addresses specific barriers and gaps in HIV service delivery in NSPs"
1522753|NCT02795988|Biological|IMU-131|IMU-131 vaccine is a P467-CRM197 peptide antigen in PBS buffer and Montanide ISA 51 Sterile adjuvant
1522754|NCT02795988|Drug|Cisplatin and either Fluorouracil (5-FU) or Capecitabine|Chemotherapy to include the following: cisplatin, IV (80 mg/m2 on Day 14, then every 21 days) and either 5-FU, 4000 mg/m2 CIV (administered as 1000 mg/m2/day as continuous infusion for 96 hours on days 14 to 17, then every 21 days) or capecitabine for 14 days at 2000 mg/m2/day, orally (administered as 1000 mg/m2 twice daily morning and evening for a total of 2000 mg/m2/day on days 14 to 27, then every 21 days).
1522755|NCT02795962|Other|Direct transfer to an Endovascular Center|Cluster randomized controlled study: allocation to active or no intervention arm will be performed accordingly to a pre-established temporal sequence
1522756|NCT02795949|Drug|Antipseudomonal beta-lactam antibiotic|Pharmaceutical form: solution for infusion
1522847|NCT02795273|Drug|Placebo|
1522757|NCT02795949|Drug|De-escalation(short-spectrum antibiotic)|Pharmaceutical form: solution for infusion
1522758|NCT02795936|Procedure|Cardiac rehabilitation|Perform exercise prescription for 12 weeks
1522759|NCT02795910|Behavioral|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
1522760|NCT02795910|Behavioral|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
1522761|NCT02795884|Drug|intercalation therapy using pemetrexed, cisplatin and erlotinib|During the intercalation phase of the initial 12-week period, erlotinib is to be orally administered at the dose of 150 mg daily from Day 8 to Day 21 at every cycle of 21 days. During the maintenance phase after 12 weeks, it is orally administered at the cycle of 28 days without a wash-out period at the dose of 150 mg daily for one year. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1. Pemetrexed 500 mg/m2 will be diluted in 100 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 minutes. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes. The combination of pemetrexed and cisplatin will be administered for 4 cycles in total by each cycle of 21 days, and it is to be administered by intravenous (IV) infusion on every Day 1.
1522762|NCT02795884|Drug|Vinorelbine, cisplatin|Vinorelbine 25mg/m2 will be diluted in 50 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 6 to 10 minutes and then wash the catheter using 100 ml of 0.9% saline solution. Cisplatin 75 mg/m2 will be diluted in 150 ml of 0.9% saline solution and will be administered by intravenous (IV) infusion for 10 to 15 minutes.
1522763|NCT02795871|Behavioral|Neuropsychological and cognitive assessment|
1522764|NCT02795858|Drug|Ramucirumab|
1522765|NCT02795858|Drug|Somatostatin Analog|
1522766|NCT02795845|Dietary Supplement|Probiotic Capsule containing L. acidophilus, L. Paracasei, L. Rhamnosus, streptococcus thermophilus and Bifidobacterium bifidum|Probiotic
1522767|NCT02795845|Other|Placebo|capsule without active ingredient
1522768|NCT02795832|Drug|ZPL-5212372 1% w/w Ointment BID|
1522769|NCT02795832|Drug|Placebo OIntment BID|
1522770|NCT02795819|Drug|AR-42|AR-42 tablets will be taken orally once per day on 3 non-consecutive days during the first 3 weeks of each 4-week cycle. If treatment must be interrupted during the cycle, the cycle may be extended.
1522771|NCT02795819|Drug|Pazopanib|Pazopanib tablets will be taken orally once daily continuously during each 4-week treatment cycle. There are no scheduled breaks in pazopanib therapy.
1522772|NCT02795793|Drug|Non-operative management group (NOM)|With intravenous Piperacillin with Tazobactam (Tazocin)
1522773|NCT02795793|Procedure|Appendectomy group (Operative management, OM)|
1522776|NCT02795754|Drug|GSK2838232 PIB|GSK2838232 will be available as oral suspension for reconstitution, will be administered as 50, 100 and 200 mg in Part A and as 20, 50, 100 or 200 mg in Part B.
1522777|NCT02795754|Drug|GSK2838232 IR1|GSK2838232 will be available as film-coated tablet for oral use
1522778|NCT02795754|Drug|GSK2838232 IR2|GSK2838232 will be available as film-coated tablet for oral use
1522779|NCT02795754|Drug|Placebo PIB|Oral suspension of hydromellulose acetate succinate will be supplied as powder-in-bottle for reconstitution.
1522780|NCT02795754|Drug|Ritonavir|It is to be purchased by site. It will be white film-coated ovaloid tablets for oral administration.
1522781|NCT02795741|Device|Cooling Bolero|a vest filled with a new material (not ice or a gel) that provides controlled cooling by absorbing heat
1522782|NCT02795728|Other|Application of the GIC based sealant|Application of the GIC based sealant was carried out according to the manufacturer's instructions.
1522783|NCT02795728|Other|Resin based sealant|Application of the resin based sealant on the occlusal surfaces was carried out as per the manufacturer s recommendations.
1522784|NCT02795715|Device|tDCS|
1522785|NCT02795715|Behavioral|training|
1522786|NCT02795702|Device|tDCS|
1522787|NCT02795702|Behavioral|training|
1522788|NCT02795676|Biological|PRX-102 (pegunigalsidase alfa)|PRX-102 1 mg/kg every 2 weeks
1522789|NCT02795676|Biological|agalsidase beta|agalsidase beta 1 mg/kg every 2 weeks
1522790|NCT02795663|Device|NIRS EEG HR recording|NIRS EEG HR recording
1522791|NCT02795650|Drug|Personalised treatment|Personalised treatments include chemotherapy, targeted therapy, immunotherapy or others based on the previous test results, chosen from a database that include more than 2000 different drugs.
1522792|NCT02795650|Drug|Treatment chosen per investigator´s judge|Investigators are allowed to chose what they consider the best standard treatment option for their patients.
1522793|NCT02795637|Drug|dasotraline|dasotraline 8mg capsule/day
1522794|NCT02795624|Procedure|Spirometry|Test is done to assess how well the lungs work by measuring how much air is inhaled, how much is exhaled, and how quickly it is exhaled.
1522795|NCT02795624|Procedure|Pulse Wave Analysis|It is a non-invasive assessment of the pulse character
1522796|NCT02795624|Procedure|Peripheral arterial tonometry|It is a non-invasive method to measure endothelial dysfunction.
1522797|NCT02795611|Behavioral|Family-centered occupational therapy|Caregivers will be equipped with the skills of guiding children with ASD in play and participation in their daily life.
1522798|NCT02795611|Behavioral|regular occupational therapy|regular occupational therapy
1522799|NCT02795611|Other|intervention done outside our hospital|intervention done outside our hospital
1522841|NCT02795299|Drug|Folic Acid|Acid folic (folate) 1mg to be administered once daily during the treatment period.
1522842|NCT02795299|Drug|Placebo|10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
1522843|NCT02795286|Device|Artis Haemodialysis Machine w/ ASIST Software - Isonatremic|
1522844|NCT02795286|Device|Artis Haemodialysis Machine w/ ASIST Software - Isotonic|
1522800|NCT02795598|Procedure|Single injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.
30 milliliters of mepivacaine 1.5% will be injected incrementally in 5ml boluses at this location looking for spread of local anesthetic under and medial to the subclavian artery. The needle may be slightly repositioned to improve the distribution of the injectate at the discretion of the attending anesthesiologist."
1522801|NCT02795598|Procedure|Double injection supraclavicular nerve block|"The ultrasound probe will be applied in a sterile fashion in the supraclavicular fossa to obtain a short-axis view of the subclavian artery. A 22G, 50mm Echogenic Stimuplex needle will be advanced in-plane with respect to the image, and the needle tip will be advanced to the junction of the first rib and subclavian artery. Ultrasound cineloops will be kept of all nerve block procedures.
15 milliliters of mepivacaine 1.5% will be injected incrementally at the same, above-mentioned location. The needle will then be redirected to the superolateral aspect of the brachial plexus, and an additional 15ml will be injected here. Again, the needle may slightly repositioned at the discretion of the attending anesthesiologist in order to obtain adequate spread."
1522802|NCT02795585|Other|QFR (observational)|QFR assessment by Medis Suite, Medis medical imaging B.V., The Netherlands
1522803|NCT02795572|Dietary Supplement|Vitamin D|Vitamin D 2000 IU oral once daily
1522804|NCT02795572|Dietary Supplement|Vitamin B6|Vitamin B6 100 mg oral once daily
1522805|NCT02795572|Dietary Supplement|Vitamin B12|Vitamin B12 100 mcg oral once daily
1522806|NCT02795572|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids 900 mg oral three times a day (600 mg EPA, 300 mg DHA)
1522807|NCT02795559|Other|Glucose|75g glucose dissolved in 300ml water
1522808|NCT02795559|Other|Inulin|75g glucose plus 24g inulin dissolved in 300ml water
1522809|NCT02795559|Other|Resistant starch|75g glucose plus 28g resistant starch in 300ml water
1522810|NCT02795546|Drug|Alendronate sodium|400µg of alendronate sodium is combined with beta-tricalcium phosphate bone graft and implanted in periodontal intra-osseous defects as a single, local dose.
1522811|NCT02795546|Biological|beta-tricalcium phosphate bone substitute|beta-tricalcium phosphate bone graft is implanted in periodontal intra-osseous defects.
1522812|NCT02795533|Behavioral|Clinical follow-up|"All included patients will have a clinical follow-up consisting of:
A medical examination
Quality of life questionnaires
Neuropsychological test
All instruments have been translated into Norwegian and validated and tested in clinical practice."
1522813|NCT02795520|Drug|OTS167IV|
1522814|NCT02795507|Device|Rehabit-Tec System|Device with visual and kinesthetic feedback
1522815|NCT02795507|Device|Rehabit-Tec System|Device without visual and kinesthetic feedback
1522816|NCT02795507|Behavioral|conventional exercises|
1522817|NCT02795494|Behavioral|WOMAC questionnaire at baseline|Patient-reported pain, stiffness and physical function outcome score
1522818|NCT02795494|Behavioral|ASK-P questionnaire at baseline|Patient-reported activity level score
1522819|NCT02795494|Behavioral|WOMAC questionnaire at 2 weeks|Patient-reported pain, stiffness and physical function outcome score
1522820|NCT02795468|Procedure|Radial arterial cannulation|Radial arterial cannulation using usual palpation method or ultrasound guided technique according to the group
1522824|NCT02795442|Other|Even protein|5 day intake of even protein 3 day rotating menu.
1522825|NCT02795442|Other|Skewed protein|5 day intake of skewed protein 3 day rotating menu.
1522826|NCT02795429|Drug|PDR001|PDR001 will be administered intravenously
1522827|NCT02795429|Drug|INC280|INC280 will be administered orally
1522828|NCT02795416|Drug|"Secukinumab Cosentyx TM"|"Secukinumab Cosentyx TM 150 mg PFS (pre-filled syringe) containing for solution for s.c. injection will be applied as 2 units (300 mg dosage) per patient at each visit.
First month: 300 mg injections/week, 4 weeks Starting from 4th week until Week 16, one injection/month"
1522829|NCT02795403|Other|blood draw of 150ml, twice|
1522830|NCT02795390|Drug|Chinese herbal medicine|
1522831|NCT02795390|Drug|Placebo|
1522832|NCT02795364|Procedure|Structural Image Guidance|Resecting the tumor in accordance with the margin on MRI T1W-enhanced delineation
1522833|NCT02795364|Procedure|Metabolic Image Guidance|Aggressive resecting of the tumor in accordance with the margin on MRS CNI delineation
1522834|NCT02795351|Drug|Sildenafil|Single oral administration of active or placebo one week apart
1522835|NCT02795351|Drug|Placebo|
1522836|NCT02795338|Procedure|brain mapping|pre-operative and intra-operative brain mapping to identify eloquent areas
1522837|NCT02795325|Drug|DCR-PH1|IV infusion of DCR-PH1
1522838|NCT02795312|Behavioral|Smoking Cessation Program|Participants will take part in a 9-week Smoking Cessation Program
1522839|NCT02795299|Drug|Gerilimzumab|Either Gerilimzumab 5 mg followed by 2 mg, or Gerilimzumab 10 mg followed by 5 mg or Gerilimzumab 20 mg followed by 10 mg are to be administered once every 8 weeks during the treatment period of the study.
1522840|NCT02795299|Drug|Methotrexate|Methotrexate (MTX) to be administered once a week every week during the treatment period.
1522848|NCT02795260|Biological|Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of BCG .
1522849|NCT02795260|Biological|placebo of Bacillus Calmette - Guerin|The participants are injection intradermally with 0.1ml ESAT6-CFP10(EC) in the right OR left arm and TB-PPD in the other arm(right OR left) after 12 weeks immunization of placebo of BCG .
1522850|NCT02795247|Procedure|Anterior Cruciate Ligament Reconstruction|
1522851|NCT02795234|Other|Blood samples|
1522852|NCT02795208|Procedure|Lung recruitment maneuver|The lung recruitment maneuver consists in a brief and controlled increment in airways pressure (20 cmH2O of PEEP + 20 cmH2O of driving pressure) for 10 breaths.
1522853|NCT02795195|Radiation|CIRT arm (3GyE per fraction)|Four dose levels (54GyE, 57GyE, 60GyE, 63GyE) are planned within the Phase I part. Daily fraction of 3 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 63 GyE are safely delivered, the recommended dose (or 63 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3~5mm.
1522854|NCT02795182|Drug|BGB-3111|
1522855|NCT02795182|Drug|BGB-A317|
1522856|NCT02795156|Drug|afatinib|40 mg orally (p.o.) once daily for each 28-day cycle
1522857|NCT02795156|Drug|regorafenib|160 mg p.o. once daily for the first 21-days of each 28-day
1522858|NCT02795143|Drug|Isotretinoin|
1522859|NCT02795143|Other|Placebo|
1522860|NCT02795130|Procedure|Sclerotomy closure|Comparison between two suture materials: 1) 8-0 polyglactin 910, 2) 6-0 plain gut
1522861|NCT02795117|Drug|Ivermectin|
1522862|NCT02795117|Drug|Ivermectin (reference)|
1522863|NCT02795117|Drug|Placebo|
1522864|NCT02795104|Behavioral|Educational Intervention via brochure|"Educational Intervention via brochure:
In this arm of the educational intervention the participant receives brochures"
1522865|NCT02795104|Behavioral|Educational Intervention via DVD|Educational Intervention via DVD: In this arm of the educational intervention the participant receive a tailored interactive DVD to watch
1522866|NCT02795104|Behavioral|Educational Intervention-DVD & Telephone Based Navigation|Educational Intervention via Telephone-Based Navigation: In this arm of the educational intervention the participant receives a tailored interactive DVD to watch and telephone calls from a patient navigator
1522867|NCT02795091|Other|manual cleaning|manual clean the rag and floor towel
1522868|NCT02795091|Device|machine clean|machine clean the rag and floor towel
1522869|NCT02795078|Drug|conservative treatment|
1522870|NCT02795078|Procedure|Aneurysms clipping|
1522871|NCT02795078|Procedure|Interventional embolization forAneurysms|
1522872|NCT02795078|Procedure|stenting for stenosis|
1522873|NCT02795065|Drug|Enoxaparin|Use of enoxaparin 40 mg subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
1522874|NCT02795065|Drug|Bemiparin|Use of bemiparin 3500 IU subcutaneous once daily in high risk intensive care patients as a prophylaxis against venous thromboembolism
1522875|NCT02795052|Procedure|Intravenous BMSC|Autologous Bone Marrow Derived Stem Cells provided intravenous.
1522876|NCT02795052|Procedure|Intranasal BMSC|Autologous Bone Marrow Derived Stem Cells provided intranasal (lower 1/3 of nasal passages).
1522877|NCT02795039|Drug|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Fulvestrant into the right buttock (upper outer quadrant)
1522878|NCT02795039|Drug|Fulvestrant|Single 5 mL intramuscular injection (slowly over 1-2 minutes) of Faslodex® (Fulvestrant) into the right buttock (upper outer quadrant)
1522879|NCT02795026|Procedure|Manual therapy|Myofascial trigger point release technique is a technique used to help ease tight muscles. This technique involves palpating the tight muscle for the 'knot'/trigger point and gently applying pressure for 30-60 seconds to help ease out the trigger point.
1522880|NCT02795026|Procedure|Trigger point dry needling|Trigger point dry needling is a treatment technique involving the use of a single, disposable, fine filament acupuncture needle. Here the tight muscle is palpated and the acupuncture needle is directed towards the trigger point. The insertion of the needle is not felt, however the twitch reflex elicited to ease off the trigger point can be felt . This can be sore, but lasts only for a few seconds. Trans-perineal trigger point dry needling is an effective dry needling technique for the pelvic floor muscles done externally, targeting the trigger points in the pelvic floor muscles.
1522881|NCT02794987|Device|SpyGlass® choledoscopy|Stage 1: patients included were evaluated using a standard duodenoscope and both SpyGlass® cholangioscopes: First generation, SpyGlass® Direct Visualization System and Second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA) Procedures were performed by one experienced endoscopists with more than 300 ERCP/year (C.R.M). Biopsies were taken in order to correlate to histopathology. Stage 2: patients will be evaluated using a standard duodenoscope and second generation, Digital SpyGlass® DS System (Boston Scientific, Marlborough, Massachusetts, USA). Procedures will be performed by two experienced endoscopists with more than 300 ERCP/year (C.R.M and M.S.A). Biopsies will be taken in order to correlate to histopathology.
1522882|NCT02794974|Other|cervical plexus block|ultrasound-guided application of 20ml ropivacaine 0.75%
1522883|NCT02794974|Other|facial nerve block|ultrasound-guided application of 5ml prilocaine 1%
1522884|NCT02794974|Other|perivascular block|ultrasound-guided application of 5ml prilocaine 1%
1522885|NCT02794961|Biological|CD22 CAR-T|Autologous CAR-T cells with average 1*10^6 cells/kg body weight
1522886|NCT02794948|Other|Chinese medicine granules (HuYang Yang Kun Formula)|Take Chinese medicine granules (HuYang Yang Kun Formula), 1 sack every time,twice a day Take DHEA(dehydroepiandrosterone) placebo,1 capsule every time ,once a day. Treatment for 3 months Both Chinese Medicine formula granules and DHEA placebo were produced by Jiangyin Medical &pharmaceutical limited company in Jiangsu province
1522887|NCT02794948|Dietary Supplement|dehydroepiandrosterone|The DHEA( dehydroepiandrosterone)25mg,1 capsule every time once a day. Take Chinese medicine granules placebo , 1 sack every time,twice a day Treatment is 3 months. DHEA were produced by General Nutrition Center(GNC)company in America and The placebo granules of Chinese Medicine were produced by Jiangyin Medical &pharmaceutical limited company in Jiangsu province.
1523343|NCT02791516|Drug|Romosozumab|Subcutaneous injections of Romosozumab monthly for 6 months.
1522888|NCT02794935|Other|Inspiratory muscle training (IMT)|Participants will be submitted to a linear pressure resistance (PowerBreathe) with an inspiratory load of 30% of maximal inspiratory pressure (adjusted weekly), seven days a week, session duration of 30 minutes for 12 weeks. During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 30% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 30% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
1522889|NCT02794935|Other|Sham IMT|Participants will be submitted to inspiratory muscle training with the same equipment as the intervention group, but without a load generating resistance. Sham IMT Participants will receive IMT for 30 min, 7 times per week for 12 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center
1522890|NCT02794922|Drug|Neurovit Forte|
1522891|NCT02794922|Drug|Corn Starch|
1522892|NCT02794909|Device|Cardiopulmonary ultrasound exam|The cardiopulmonary ultrasound exam consists of a point-of-care ultrasound scan of the heart, lungs, peritoneal cavity, aorta, and femoral veins.
1522893|NCT02794896|Drug|High dose propofol, fentanyl and sevoflurane|Deep Anesthesia
1522894|NCT02794896|Drug|Low dose propofol, fentanyl and sevoflurane|Shallow Anesthesia
1522895|NCT02794883|Biological|Durvalumab|Given IV
1522896|NCT02794883|Other|Laboratory Biomarker Analysis|Correlative Studies
1522897|NCT02794883|Procedure|Surgical Procedure|Undergo surgical tumor resection
1522898|NCT02794883|Biological|Tremelimumab|Given IV
1522899|NCT02794870|Biological|RSV LID ΔM2-2 1030s vaccine|10^5.0 PFU; administered as nose drops
1522900|NCT02794870|Biological|Placebo|Administered as nose drops
1522901|NCT02794857|Drug|NP001|
1522902|NCT02794857|Drug|Placebo|
1522903|NCT02794844|Genetic|Genotype Guided Dosing|Dosing of PPIs such as Prevacid and Nexium will be recommended based on CYP2C19 genotype information.
1522904|NCT02794818|Behavioral|Produce boxes with nutritional education|"CSA produce boxes prescribed to study participants with free online nutritional education included"
1522905|NCT02794805|Device|¹³C-Octanoate Breath Test|Octanoate Breath Test to be performed on subjects with suspected HCC
1522906|NCT02794792|Drug|Ipragliflozin L-proline|Oral
1522907|NCT02794792|Drug|Metformin|Oral
1522908|NCT02794792|Drug|Placebo|Oral
1522909|NCT02794779|Drug|Oxytocin|Intravenous bolus infusion of oxytocin 3UI followed by re-asessment of uterine tone by obstetrician after 3 minutes. Infusion stops when uterine tone is adequate and is repeated if inadequate to the maximum of 9UI (3 bolus infusions). If uretine tone is inadequate after 9UI then other methods for preventing bleeding will be used.
1522910|NCT02794766|Drug|Inulin+SS|Experimental treatment: A gum of inulin 1g plus Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
1522911|NCT02794766|Drug|S salivarius|Active comparator: A gum of Streptococcus salivarius 1 billion CFU per oral each 12 hours for 10 days
1522912|NCT02794766|Drug|Placebo|Placebo 1 gum each 12 hours for 10 days
1522913|NCT02794753|Behavioral|Working memory training|
1522914|NCT02794753|Behavioral|Game|
1522915|NCT02794740|Drug|Ibuprofenamine Hydrochloride spray|External Spray
1522916|NCT02794740|Drug|Placebo|External Spray
1522917|NCT02794727|Device|Blinded Fitbit|Subjects will wear a blinded Fitbit to monitor activity while in the workplace for 12 weeks.
1522918|NCT02794727|Device|Unblinded Fitbit|Subjects will be unblinded to the Fitbit display for 12 weeks with set activity goals.
1522919|NCT02794714|Drug|Deep neuromuscular blockade|Deep neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction of anesthesia with intermittent boluses of 0.15 - 0.2 mg/kg to maintain a Post Tetanic Count (PTC) of 1-2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 4mg/kg.
1522920|NCT02794714|Drug|Moderate neuromuscular blockade|Moderate neuromuscular blockade attained during surgery using Rocuronium 0.6mg/kg at induction with intermittent boluses of 0.15 - 0.2 mg/kg to maintain Train of Four Count (TOFC) of 2 throughout surgery. Neuromuscular blockade reversed at the end of surgery with Sugammadex 2mg/kg.
1522921|NCT02794701|Other|People with silicosis|
1522922|NCT02794688|Procedure|Ductal lavage therapy|"Patient lies in supine position, with routine sterilizing and draping procedure.
Local anesthesia with 5-10ml lidocaine (1%) around the nipple.
Identification of 4-5 openings of the lactiferous ducts from the nipple.
Insertion of all infusion cannula (21-23G ) into the identified openings of the lactiferous ducts.
Start the infusion pump with 10ml irrigation solution (2% Lidocaine 5ml, Triamcinolone acetonide 40mg，0.9% saline 10ml and ceftriaxone 1.0g). If the patients had elevated white blood cell count and fever (>38 celsius degree), oral intake or infusion of antibiotics were allowed, when necessary.
The patient returns to the clinic the next day, with the irrigation solution staying in the lactiferous ducts overnight, and receives breast massage.
Repeat step 1-6 every other day for 2 weeks.
Fine needle aspiration is allowed. Oral intake of corticosteroids, excisional drainage or surgery are not allowed."
1522923|NCT02794675|Drug|Cesium 131|The number sources and activity will be based on the target volume to deliver total radiation dose, this will vary per patient.
1522924|NCT02794662|Procedure|Oxygen Environment|FiO2 delivered by servo-controlled incubator
1522925|NCT02794662|Procedure|Nasal Cannula Oxygen|FiO2 delivered by nasal cannula
1522926|NCT02794623|Device|Tinnitus masking|Tinnitus masking via CI system
1522927|NCT02794610|Drug|Tacrolimus|Topical tacrolimus 0.05% eye drops will be instilled into the eyes of patients every minute for 5 minutes. After 15 minutes, at the time of cataract surgery, aqueous samples will be collected and will be subjected to detection of presence and level of tacrolimus.
1522928|NCT02794597|Behavioral|Intervention|a brief peer-led behavioral intervention focused on contraceptives, reproductive needs, and motivational interviewing.
1522929|NCT02794584|Drug|sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
1522930|NCT02794584|Procedure|Hybrid closure|Hybrid closure of ventricular septal defects through the delivery system without cardiopulmonary bypass by transthoracic minimally invasive small incision.
1522931|NCT02794584|Procedure|Control|Surgical closure of ventricular septal defects with cardiopulmonary bypass by routine open thoracotomy.
1522934|NCT02794558|Device|ExAblate MRgFUS|"MR images of the breast will be obtained for lesion localization purposes. The breast surgeon or the radiologist will make a treatment plan or map. Sonication at therapeutic power level will be performed on multiple overlapping points successively until sonication of the target volume has been completed.
Follow-up evaluation will be made within 14 to 21 days after the MRgFUS treatment."
1522935|NCT02794545|Procedure|cART course|The investigators would start regular cART course immediately for early infection patients to achieve functional cure.
1522936|NCT02794532|Procedure|High-flow nasal cannula|Oxygenation will be done via a high-flow nasal cannula
1522937|NCT02794519|Drug|Sirukumab|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
1522938|NCT02794519|Drug|Placebo|This intervention will be provided in a 1.0 mL pre-filled syringe (PFS) fitted with spring-powered, disposable autoinjector device for single SC use that is permanently assembled on the syringe. The sirukumab PFS is aseptically filled to deliver a dose of 50 mg/1.0 mL of sirukumab.
1522939|NCT02794519|Drug|Rescue medication|Rescue medication (salbutamol/albuterol) shall be supplied to subjects at Screening for use when needed during the study.
1522940|NCT02794506|Drug|Propolis|Propolis capsules was taken by the experimental group for 6 months after receiving scaling and root planing (SRP).
1522941|NCT02794506|Drug|Placebo|Placebo capsules was taken by the control group for 6 months after receiving scaling and root planing (SRP).
1522942|NCT02794493|Drug|Traditional Chinese Medicine Formula LC09|
1522943|NCT02794493|Other|Placebo|
1996477|NCT02469389|Behavioral|Health & Wellness (H&W)|"Health & Wellness (H&W) will focus on health and wellness issues and education on ways to better manage health-related
concerns following a basic structure that includes: review of the previous session's material, new educational content, and discussion/application.
Topics will include: 1) Overview, 2) Physical Activity (3 sessions), 3) Nutrition/Healthy Eating (3 sessions), 4) Managing
Fatigue/Sleep (3 sessions), 5) Relaxation (3 sessions), 6) Tobacco cessation (3 sessions), 7) Substance Use (3 sessions),
8) Medication/Side Effects (3 sessions), 9) Review (1 session), and Closing (1sessi"
1996478|NCT02469233|Behavioral|Transdiagnostic Intervention for Sleep and Circadian Dysfunction|The intervention is a modular treatment composed of core modules that are given to all participants and modules that are delivered based on the need/s of the participants. The interventions are all cognitive behavioral.
1996479|NCT02468284|Drug|degarelix|
1522947|NCT02794467|Drug|Epelsiban|Epelsiban will be supplied as modified capsule shaped, white coated, oral tablet with a unit dose strength of 25 or 150 mg; to be taken with food or immediately after a meal, without chewing
1522948|NCT02794467|Drug|Placebo|A matching placebo will be supplied as modified capsule shaped, white coated, oral tablet; to be taken with food or immediately after a meal, without chewing.
1522949|NCT02794454|Other|HeezOn Ultra-1|
1522950|NCT02794454|Other|HeezOn Ultra-2|
1522951|NCT02794454|Other|Placebo|
1522952|NCT02794441|Drug|Dexamethasone|Dexamethasone 0.6mg/kg (maximum 15mg) PO x 1 dose
1522953|NCT02794441|Other|Placebo|Matched oral solution
1522954|NCT02794428|Drug|Eflornithine|Eflornithine*, 2 tablets, Oral, Daily for 18 months
1522955|NCT02794428|Other|Eflornithine placebo|Eflornithine placebo, 2 tablets, Oral, Daily for 18 months
1522956|NCT02794415|Other|Community-based exercise|"Intervention Phase (6 months): The HIV Community-Based Exercise (CBE) intervention is a 6-month exercise program at the Central Toronto YMCA. Participants will meet the fitness instructor to establish an individualized exercise program that will include a combination of aerobic, resistive, neuromotor and flexibility training. Participants will attend exercise sessions for ~1.5 hour, 3 times per week for 24 weeks. Sessions will be supervised weekly by a fitness instructor.
Post-Intervention Phase (8 months): At the end of the 24 week intervention, participants will be encouraged to continue to engage in unsupervised exercise 3 times per week. As per usual practice at the YMCA, a fitness instructor will be available to monitor participants monthly."
1522957|NCT02794402|Drug|Exenatide|Bydureon (Exenatide once weekly) injections s.c.
1522958|NCT02794402|Behavioral|Placebo|Placebo once weekly injections sc
1522959|NCT02794389|Drug|N-acetyl cysteine|
1522960|NCT02794389|Drug|Placebo|
1522963|NCT02794363|Biological|Autologous platelet rich plasma|5cc of autologous platelet rich plasma derived from 50cc of whole blood will be injected into vulvar skin.
1522964|NCT02794350|Device|Cochlear implant|
1522965|NCT02794337|Radiation|SBRT|Intervention involves administering high precision radiation to the tumour in 6-8 fractions over 2-2.5 weeks
1522966|NCT02794337|Procedure|TACE|Involves catheterization of the tumour feeding vessels and injecting 100 mg of doxorubicin drug eluting beads. Maximum 3 TACE procedures are done
1522967|NCT02794337|Drug|Sorafenib|Sorafenib will be initiated 2 weeks before 1st TACE at a dose considered appropriate by the treating clinician. Though 400 mg bid is the recommended dose a lower dose may be used as per the judgement of treating clinician. It will be omitted on the days of TACE and SBRT. Sorafenib will be reinitiated 4 weeks after SBRT completion and will continue to be administered till progression or 12 months whichever is earlier. Sorafenib can however be stopped in patients who fail to tolerate sorafenib even after dose modifications.
1523094|NCT02793401|Device|Hotpack|All patients had the same physical therapy (PT) protocol including hot pack (HP) for 20 min/session,
1523344|NCT02791516|Drug|Placebo|Subcutaneous injections of placebo monthly for 6 months.
1996480|NCT02468232|Drug|LCZ696|LCZ696 50 mg, 100 mg, 200 mg film-coated tablets
1996481|NCT02468232|Drug|Enalapril|Enalapril 2.5 mg, 5 mg, 10 mg film-coated tablets
1996482|NCT02468232|Drug|Placebo to LCZ696|Placebo to match LCZ696 50 mg, 100 mg and 200 mg film-coated tablets
1522968|NCT02794324|Procedure|Voluntary deep-inspiratory breath hold|Patients undergoing scanning in v_DIBH will be positioned supine with arms extended on a MedTec breast board. They will be monitored visually on screen and will be given a buzzer to press when they have taken a breath. CT images will be obtained during DIBH. If the patient needs to release their breath, they will be asked to press the buzzer a second time. Patients will be closely monitored by radiographers via CCTV.
1522969|NCT02794324|Procedure|Active-breathing-controlled deep-inspiratory breathhold|Patients undergoing scanning in ABC_DIBH will be positioned supine with arms extended on a MedTec breast board to which an activated-breathing control device (Elekta, Crawley, UK) has been attached. They will breathe through the device. During ABC_DIBH, CT images will be obtained.
1522970|NCT02794324|Procedure|Prone treatment|Patients undergoing scanning in a prone position will lie on a customised prone treatment platform. CT images will be acquired under free-breathing conditions.
1522971|NCT02794324|Device|Active-breathing-controlled deep-inspiratory breathhold|The ABC unit allows for temporary and reproducible immobilization of internal thoracic structures by monitoring the patient's breathing cycle and implementing a breath hold at a predefined lung volume level. The device consists of a mouthpiece connected to a pneumotachometer via a bidirectional valve and tubing. The air flow across the pneumotachometer is integrated and displayed on a computer monitor. The computer also controls a scissor valve which, when enabled, restricts air flow through the system, enabling the breath hold phase. The mouthpiece and air filter are patient specific, as is a nose clip that is used to ensure that patients are breathing through the device.
1522972|NCT02794311|Other|Alcoolpredict|psychological (personality), neuropsychological (executive functions, memory), genetic (snp polymorphisms) and neuro-anatomical (fMRI)
1522973|NCT02794298|Device|Transcranial direct current stimulation (tDCS)|
1522974|NCT02794298|Device|sham-tDCS|
1522975|NCT02794285|Biological|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
1522976|NCT02794285|Drug|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 152 for a total of 39 doses
1522977|NCT02794272|Device|tDCS|
1522978|NCT02794272|Device|sham-tDCS|
1522979|NCT02794259|Device|tDCS|
1522980|NCT02794259|Device|sham-tDCS|
1522981|NCT02794246|Biological|CART-19 cells|
1522982|NCT02794233|Other|Impedance measurements|Refer to study description
1996483|NCT02468232|Drug|Placebo to Enalapril|Placebo to match enalapril 2.5 mg, 5 mg and 10 mg film-coated tablets
1522987|NCT02794194|Other|Proprioceptive training on a whole body vibration platform|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on a Fitvibe Excel Pro vibration platform (Fitvibe, Bilzen, Belgium).
1522988|NCT02794194|Other|Proprioceptive training with the BOSU® on the floor|The Training programme consisted of three series of 4 exercises of 45 seconds with 45 seconds rest between exercises. In this intervention participants trained with the BOSU® on the floor.
1522993|NCT02794142|Procedure|renal transplantation|
1522994|NCT02794129|Other|Functional Magnetic Resonance Imaging|
1522995|NCT02794116|Procedure|Conventional Sealants|It is a preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
1522996|NCT02794116|Procedure|Resin Sealants|It is a resin sealants to preventive treatment for caries lesions. The procedure following operative sequence: prophylaxis; absolute isolation; application of 37.5% phosphoric acid for 30 s in enamel; extensive washing; drying with cotton and air jet for 5 s; sealing with resin sealant application (Fluroshield, NY, USA), according to manufacturer guidelines; removal absolute isolation; examination of occlusal contact and final polishing.
1522997|NCT02794103|Device|Virtual Reality Distraction|VR prototype developed by the SAT will be used as the experimental intervention. It has a wide screen installed at the end of the hydrotherapy tank offering a 150-degree field view, on which appears a game allowing the child to have the immersive entertainment experience without the need to wear a helmet or 3D glasses. The child or a proxy, depending on age and burn site, will have the opportunity to interact with the game. The interactive component is not mandatory for the immersive and distractive experiences provided by the prototype. Video games tailored to the child's age and injury, different from the commercially available ones, will be adapted to each age-group of children recruited with control over the speed of movement to avoid motion sickness.
1522998|NCT02794090|Behavioral|Usual care, individual visits|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
1522999|NCT02794090|Behavioral|Telephone coaching|Randomized controlled study of two types of delivering behavioral treatment to Children suffering from obesity.
1523000|NCT02794077|Drug|Cyclophosphamide|Patient receive oral cyclophosphamide 50 to 150mg daily continuously in the absence of disease progressive or unacceptable toxicity.
1523001|NCT02794064|Device|Tri-modal imaging|This tri-modal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified
1523002|NCT02794051|Behavioral|Group Therapy|Participating children and their caregivers will attend 90-minute weekly group therapy sessions for 10 consecutive weeks.
1523499|NCT02790502|Device|Food Photography Application©|Group testing RFPM as method of recording plate waste
1523005|NCT02794025|Drug|Esmolol|"patients in the esmolol group received continuous infusion of esmolol via a micro-pump through a catheter placed in the superior vena cava. The initial dose was 0.05 mg/kg/min and was adjusted based on heart rate (HR) (target HR: 70 bpm < HR < 100 bpm within 72 hours).
Control group also received natural saline via a micro pump, in the same way the esmolol group received esmolol."
1523006|NCT02794025|Drug|natural saline|Control group also received natural saline via a micro pump,
1523007|NCT02793999|Device|Near-Infrared Spectroscopy (NIRS)|
1523008|NCT02793986|Drug|propofol|For patients in Group P, the sedation was achieved with a target-controlled infusion (TCI) of propofol, and the effect site concentration was set to 0.8-1.0μg/ml.
1523009|NCT02793986|Drug|dexmedetomidine|For patients in Group D, the sedation was achieved with a bolus of dexmedetomidine at 1.0 μg/kg (over a period of 15 to 20 min) and followed by an infusion of dexmedetomidine at 0.2-0.7 μg/kg/h. The depth of sedation was considered enough when patient was unresponsive to voice.
1523010|NCT02793973|Device|shoe lifts|
1523011|NCT02793960|Drug|topical BPM31510 3.0% Cream|Application of drug to lesions of epidermolysis bullosa
1523012|NCT02793947|Drug|Ropivacaine|400 mg of 0.75% ropivacaine (53.33 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
1523013|NCT02793947|Drug|Epinephrine|0.6 mg of 1 mg/mL epinephrine (0.6 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
1523014|NCT02793947|Drug|Morphine|5 mg of 0.5 mg/mL morphine sulfate (10 mL) will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
1523015|NCT02793947|Drug|0.9% sodium chloride solution|36.07 mL 0.9% sodium chloride solution will be included in the multimodal analgesic cocktail that will be injected intra-operatively into the superficial and deep peri-incisional tissues after completion of femur fracture fixation/instrumentation.
1523016|NCT02793934|Other|Scales|"For stroke patients there are used scales:
Modified Rankin Scale, NIH Stroke Scale , Glasgow Coma Scale, Dysphagia Severity, Rating Scale Speech or Language Impairment Severity Rating Scale, Modified Rivermead Mobility Index, Berg Balance Scale, Modified Ashworth Scale, Medical Research Council Scale, Frenchay Arm Test, Montreal Cognitive Assessment Scale, Spielberger Scale, Beck's Depression Inventory, Visual Analogue Scale, Functional Independence Measure For patients after AMI: Rankin scale, GRACE scale, MoCA, VAS, Hospital scale of anxiety and depression, Canadian classification if stenocardia
For patients after THR:
The pain of the operated joint on VAS scores The Harris scale (the total amount), Scale Lequesne (total), Hospital scale of anxiety"
1523017|NCT02793934|Other|New model of rehabilitation|
1523018|NCT02793934|Other|Old model of rehabilitation|
1523019|NCT02793934|Other|ICF reader|
1523020|NCT02793921|Behavioral|Moderate-Intensity Aerobic Exercise Intervention|The intervention is moderate-intensity aerobic exercise, monitored on-site. Walking on a motorized treadmill will be the encouraged mode of exercise; however participants may use other equipment. Participants will begin by exercising 10-15 minutes for 3 days/week during the first 2 weeks and gradually increase the duration for the following 4 weeks until they reach 40-50 minutes per session/3 days per week. This level is then maintained for the remainder of the 6 months. The rate of increase will be tailored based on baseline cardiorespiratory fitness and response to exercise. All sessions start and end with a vital sign check and 5-10 minutes warm-up/cool-down. Trained exercise physiologists will supervise all exercise sessions and closely monitor adherence, intensity, and safety.
1523021|NCT02793908|Drug|Pleyris|Luteal phase will be supplemented starting by the ovulation day for 14 days
1523022|NCT02793908|Drug|Crinone8|Luteal phase will be supplemented starting by the ovulation day for 14 days
1523023|NCT02793895|Device|Medtronic SEEQ™ mobile cardiac telemetry system|The SEEQ™ system consists of a wearable sensor which is a single-lead, low-profile, peel-and-stick device applied over the anterior left chest wall of the subject. The wearable patch is designed for one-time use only and cannot be re-applied if removed. Each sensor provides up to 7.5 days of monitoring. Subjects randomized to the intervention group will undergo 30 days of continuous cardiac rhythm monitoring with the SEEQ™ device at the time of randomization. At 6+/-1 months, subjects randomized to the intervention group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
1523024|NCT02793895|Other|Usual Care|For subjects randomized to the usual care group, no protocol-mandated cardiac rhythm monitoring will be performed. However, subjects in the control group may undergo rhythm monitoring during the study period if their treating physicians deem that there is a clinical indication to so do. At 6+/-1 months, subjects randomized to the usual care group will undergo 14 days of continuous cardiac rhythm monitoring with the SEEQ™ device.
1523025|NCT02793882|Drug|18F-Fluorocholine PET/CT|
1523026|NCT02793856|Drug|Cyclophosphamide|To deplete Tregs before collecting peripheral blood
1523027|NCT02793856|Other|PD-1 Knockout T Cells|Autologous lymphocytes are collected and PDCD1 gene is knocked out in the laboratory. Cells are selected and expanded ex vivo. Cells are infused back to the patients for treatment
1523028|NCT02793856|Drug|Interleukin-2|Given in the following 5 days at 720,000 international unit（IU）/Kg/day
1523029|NCT02793843|Drug|Ondansetron (Zofran)|Intravenous administration of 4 mg ondansetron 15 minutes before spinal anesthesia
1523030|NCT02793843|Drug|Dexamethasone (Decadron)|Intravenous administration of 8 mg dexamethasone 15 minutes before spinal anesthesia
1523031|NCT02793843|Other|Spinal anesthesia|Intrathecal anesthesia by 10 mg hyperbaric marcain, 5 mcg sufentanyl and 150 mcg morphine using 27 G spinal needle (27 G Quincke needle)
1523032|NCT02793830|Other|Daily reminders of taking medications|Reminders. Participants will receive medication-taking reminders from the researcher. These reminders are sent through the mobile application—BB Reminder on an unencrypted external device (a phone borrowed from Duke University School of Nursing and is used specifically for this study by the researcher). BB Reminder has the function that after inputting a patient's phone number and prescriptions, participants can receive reminders through text messages of the name, dosage, function, and administration route for every dose of his/her medications. The daily reminders will be sent to participants 15 minutes before every dose of their medications.
1523033|NCT02793830|Other|Educational materials|Educational materials. Participants will receive educational materials from the researcher. These educational materials will be sent through the mobile application-WeChat. The educational materials include short articles (< 500 words) and/or pictures. They will be retrieved from the Chinese Cardiovascular Disease-Prevention Information Website (www.healthyheart-china.com), which is governed by the Chinese Ministry of Health. The validity of information from it is guaranteed. The retrieved educational materials will be screened by the cardiologist, the head nurse, and the researcher, before sending to participants. The educational materials will be sent to participants every other day at any time during 8 am and 10 pm.
1523034|NCT02793817|Drug|KPI-121 1% Ophthalmic Suspension dosed BID|
1523035|NCT02793817|Drug|Vehicle of KPI-121 Ophthalmic Suspension dosed BID|
1523036|NCT02793804|Device|Oraquick (made in Thailand)|
1523037|NCT02793791|Procedure|minimally invasive ablation therapies|Including RFA (radiofrequency ablation);MWA (microwave ablation); PEI (percutaneous ethanol injection),etc.
1523042|NCT02793752|Other|Age|Maternal Age
1523043|NCT02793739|Procedure|Hyaluronic acid filler injection|Hyaluronic acid filler will be injected into the dorsal fingers at day 0 and at day 14 if a touch-up is necessary.
1523044|NCT02793726|Procedure|NMR|
1523045|NCT02793713|Procedure|Endobronchial Ultrasound|Patients undergoing EBUS with TransBronchial Needle Aspiration will be invited to enroll on the day of their procedure. Once informed consent is obtained, the surgeon will assess the sonographic criteria, take pictures, and biopsy every lymph node of interest. All three elements of this assessment will need to be completed for a specimen to be included in the study. After the procedure, the operating surgeon will fill the Lymph Node Assessment questionnaire, assign an aggregate score to every lymph node specimen, and attach the pictures to the form. Pictures from every specimen will stored electronically to be reviewed and secondarily rated by a second blinded surgeon. Patient involvement in the study ends at the completion of the planned procedure.
1523046|NCT02793687|Drug|MEXIDOL® (ethylmethylhydroxypyridine succinate)|
1523047|NCT02793687|Other|Placebo|
1523048|NCT02793674|Device|high flow nasal cannula|Measurements of effort of breathing will be obtained at flow rates of 0.5, 1.0, 1.5, and 2.0 L/kg/min. Adequate time will be allowed at each flow rate for stabilization of EOB and flow levels will be trialed in a random order, each being trialed for approximately 5 minutes.
1523049|NCT02793661|Device|RenalGuard|Replacement of urine output by infusion of a matched volume of sterile replacement solution to maintain a patient's intravascular fluid volume. Diuretic is administered to reach an optimum urine flow and protect efficiently the patients' kidneys.
1523050|NCT02793661|Other|Control|Hydration protocol following ESC Guidelines 2014
1523051|NCT02793648|Drug|Ascorbic Acid|Two daily oral doses of 200mg of encapsulated vitamin C twice a day, administered at breakfast and dinner
1523052|NCT02793648|Drug|Alpha tocopherol|Two daily oral doses of 200mg of encapsulated vitamin E twice a day, administered at breakfast and dinner
1523053|NCT02793648|Drug|PLACEBO|Two daily oral doses of 200mg of encapsulated placebo, administered at breakfast and dinner
1523054|NCT02793635|Device|Indego Powered Exoskeleton|Subjects who have Spinal Cord Injury will wear the Indego device which will include being trained and evaluated for fifteen (15) sessions.
1523055|NCT02793622|Drug|Monthly Sulfadoxine-Pyrimethamine (SP) During Pregnancy|
1523056|NCT02793622|Drug|Monthly Dihydroartemisinin-Piperaquine (DP) During Pregnancy|
1523057|NCT02793609|Other|Intervention is to let patient to go home.|Intervention is to let patient to go home.
1523058|NCT02793609|Other|Intervention is to observe women in the ward.|Intervention is to observe women in the ward.
1523059|NCT02793596|Other|Obstetrical patients|Epidural waveform analysis as a confirmation of loss of Resistance
1523060|NCT02793583|Drug|TGR-1202 + Ublituximab|
1523061|NCT02793583|Drug|TGR-1202|
1523062|NCT02793583|Drug|TGR-1202 + Ublituximab + Bendamustine|
1523063|NCT02793570|Other|observational|
1523064|NCT02793557|Drug|FOL-005|Intradermal injection of 50 μl solution
1523065|NCT02793557|Other|Placebo|
1523066|NCT02793544|Drug|Fludarabine|"Fludarabine 30 mg/m2/day (adjusted for renal function) is administered over a 30-60 minute IV infusion on Days -6 through -2 (maximum cumulative dose, 150 mg/m2).
The body surface area (BSA) for fludarabine dosing is based on adjusted ideal body weight (IBW) (Appendix K).
creatinine clearance may change during the days fludarabine is given. Adjustment in fludarabine dose due to creatinine changes during conditioning is permitted."
1523067|NCT02793544|Drug|Cyclophosphamide 14.5 mg/kg/day IV on Days -6, -5|"Cy 14.5 mg/kg/day is administered as a 1-2 hour IV infusion on Days -6 and -5 after hydration.
Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
Hydration prior to Cy may be given according to institutional guideline.
Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
1523068|NCT02793544|Radiation|Total Body Irradiation (TBI) 200cGy on Day -1|"200 cGy TBI is administered in a single fraction on Day -1.
Radiation sources, dose rates, and shielding follow institutional practice."
1523069|NCT02793544|Procedure|Infusion of non-T-cell depleted bone marrow on Day 0|"On Day 0, the harvested bone marrow is infused.
Donor bone marrow will be harvested with a target yield of 4 x 108 nucleated cells/kg recipient weight.
The lowest acceptable nucleated cells yield is 1.5 x 108 cells/kg recipient weight."
1523070|NCT02793544|Drug|Busulfan|"Busulfan ≥ 9mg/kg total dose (IV or PO) on Days -6, -5, -4, -3 (PK monitoring required to achieve a daily area under the curve (AUC) target of 4800-5300 μM*min (Perkins et al., 2012))
Busulfan dosing is based on adjusted IBW (Appendix K)"
1523095|NCT02793401|Device|Transcutaneous electrical nerve stimulation|All patients had the same physical therapy (PT) protocol includingTENS (Fizyotens 4000, Fizyomed Medical Devices Ltd,Turkey) (50-100 Hz) for 20 min/session,
1523071|NCT02793544|Drug|Cyclophosphamide 50mg/kg/day IV on Days -2,-1|"Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -2 and -1 after hydration.
Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
Hydration prior to Cy may be given according to institutional guideline.
Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
1523072|NCT02793544|Drug|Cyclophosphamide 50mg/kg/day IV on Days -5,-4|"Cy 50mg/kg/day is administered as a 1-2 hour IV infusion on Days -5 and -4 after hydration.
Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
Hydration prior to Cy may be given according to institutional guideline.
Cy and mesna are dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual weight."
1523073|NCT02793544|Radiation|Total Body Irradiation (TBI) 200cGy twice a day on Days -3, -2, -1|"200cGy TBI is administered in twice daily on Days -3, -2, and -1.
Radiation sources, dose rates, and shielding follow institutional practice."
1523074|NCT02793544|Drug|Post-HCT Cyclophosphamide 50mg/kg IV on Day+3, +4|"Cy 50mg/kg IV, over 1-2 hours (depending on volume), is given on Day+3 (ideally between 60 and 72 hours after bone marrow infusion) and on Day+4 (approximately 24 hours after Day+3 Cy).
Hydration with Cy, management of volume status, and monitoring for hemorrhagic cystitis will follow institutional standards.
Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
Cy is dosed according to IBW, unless the subject weighs less than IBW, in which case these drugs will be dosed according to actual body weight."
1523075|NCT02793544|Drug|Sirolimus|"Sirolimus dosing is based on adjusted IBW (Appendix K).
Sirolimus prophylaxis is discontinued after the last dose on Day+180, or may be continued if there is GVHD.
For subjects ≥ 18 years old:
A one-time sirolimus loading dose, 6 mg PO, is given on Day+5, at least 24 hours after Cy completion.
Sirolimus is then continued at a maintenance dose (starting dose 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by high performance liquid chromatography (HPLC) or immunoassay.
For subjects < 18 years old:
A one-time sirolimus loading dose, 3 mg/m2 PO with the dose not to exceed 6 mg, is given on Day+5, at least 24 hours after Cy completion.
Sirolimus is then continued at a maintenance dose (starting dose 1 mg/m2 PO QD, maximum 2 mg PO QD), with dose adjustments to maintain a trough of 5 - 15 ng/mL as measured by HPLC or immunoassay."
1523076|NCT02793544|Drug|Mycophenolate mofetil|"MMF begins on Day+5, at least 24 hours after completion of PTCy. MMF dose is 15 mg/kg PO TID (adjusted IBW (Appendix K)) with total daily dose not to exceed 3 grams (i.e. maximum 1 g PO TID).
An equivalent IV dose (1:1 conversion) may instead be given. MMF prophylaxis is discontinued after the last dose on Day+35, or may be continued if there is GVHD."
1523077|NCT02793544|Drug|G-CSF|"Granulocyte-colony stimulating factor (G-CSF): filgrastim or a biosimilar begins on Day+5 at a dose of 5 mcg/kg/day (actual body weight) IV or subcutaneously (SC) (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is ≥ 1,000/mm3 over the course of 3 consecutive days.
Additional G-CSF may be administered as warranted."
1523078|NCT02793544|Drug|Pre-HCT Mesna on Days -6 and -5|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
1523079|NCT02793544|Drug|Pre-HCT Mesna on Days -2 and -1|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
1523080|NCT02793544|Drug|Pre-HCT Mesna on Days -5 and -4|"Use of Mesna and dosing will be done according to institutional standards. A recommended approach is as follows: Mesna IV dose of ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy.
Mesna is dosed according to adjusted IBW (Appendix K), unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual weight."
1523081|NCT02793544|Drug|Post-HCT Mesna|"Mesna is required. Mesna IV dose must be ≥ 80% of the total daily dose of Cy and given in divided doses 30 minutes before and at 3, 6, and 8-9 hours after completion of Cy on Day+3 and Day+4.
Mesna is dosed according to IBW, unless the subject weighs less than IBW, in which case Mesna will be dosed according to actual body weight."
1523082|NCT02793531|Other|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
1523083|NCT02793518|Behavioral|psychological tests|
1523084|NCT02793505|Drug|metformin|This is not an intervention but an observed exposure.
1523085|NCT02793505|Drug|any drug not known as a major teratogen or major fetotoxicant|This is not an intervention but an observed exposure.
1523087|NCT02793466|Drug|Durvalumab; MEDI4736|IV Infusion every 2 weeks for a maximum of 26
1523088|NCT02793453|Other|periodontal smears|
1523089|NCT02793440|Other|cortivazol treatment|
1523090|NCT02793440|Other|lumbar traction|
1523091|NCT02793427|Biological|blood sample collection|
1523092|NCT02793401|Device|Hıgh İntensity Laser (HILT)|HILT was performed using a BTL-6000 High Intensity Laser, 12 W(watt), 1064 nm device was a hot laser with Nd: YAG LASER source. In HILT group, the investigators applied the device on the shoulder area in two phases: phase I - analgesia, and phase II - biostimulation.
1523093|NCT02793401|Device|Ultrasound|BTL 4710 US device was applied at 3 MHz frequency, and 1.5watt/cm2 intensity over 25 cm2 surface area. Headpiece area of the device was 5 cm2, and the application was performed as the head of device was positioned at 90º (perpendicular) at full contact for 5 minutes by using gel, and performing continuous circular motions.
1523500|NCT02790489|Dietary Supplement|Valedia|
1523096|NCT02793401|Other|Therapeutic exercises|All patients had the same physical therapy (PT) protocol including therapeutic exercises for shoulder muscles
1523097|NCT02793401|Other|Balneotherapy|All patients had the same physical therapy (PT) protocol including balneotherapy in 38-40 °C thermomineralized water for 20 minutes.
1523098|NCT02793388|Drug|Supervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided supervised every other day.
1523099|NCT02793388|Drug|Unsupervised primaquine treatment|Following schizontocidal treatment malaria patients (P. falciparum and P. vivax) will receive 14days primaquine treatment if found to be G6PD normal. Primaquine treatment is provided unsupervised.
1523100|NCT02793375|Drug|Montelukast|Age appropriate dose of Montelukast given to patients prior to undergoing adenotonsillectomy, with pain scores and amount of opioid pain medication required measured postoperatively.
1523101|NCT02793375|Drug|Placebo|Age appropriate dose of placebo given to patients prior to undergoing adenotonsillectomy, with pain scores and amount of opioid pain medication required measured postoperatively.
1523102|NCT02793349|Device|Absorb Bioresorbable Vascular Scaffold|Absorb Bioresorbable Vascular Scaffold
1523103|NCT02793323|Other|Superficial cervical nerve block|A nerve stimulator is used to guide superficial cervical blockade to relieve shoulder pain.
1523104|NCT02793323|Other|NSAID|100 mg (100 ml) intravenous NSAIDs (Profenid)
1523105|NCT02793323|Other|General anesthesia|General anesthesia is induced with 1 μg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg/kg nimbex. Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 μg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen
1523106|NCT02793323|Other|IV placebo|100 ml IV saline
1523107|NCT02793323|Other|Placebo superficial cervical nerve block|Superficial cervical nerve block containing 5 ml saline
1523108|NCT02793310|Procedure|DMEK|The intervention group will receive cornea transplantation by DMEK
1523109|NCT02793310|Procedure|DSAEK|The usual care / control group will receive cornea transplantation by DSAEK
1523110|NCT02793297|Other|refined wheat crisp bread|Refined wheat crisp bread (52 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
1523111|NCT02793297|Other|sourdough fermented rye crisp bread|Sourdough fermented rye crisp bread (59.4 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
1523112|NCT02793297|Other|unfermented rye crisp bread|Unfermented rye crisp bread (59.8 g) was served as part of a regular breakfast together with margarine (15 g), cheese (20 mg), coffee/tea (150 mL), and juice (150 mL). The amount of crisp bread was adjusted so that all arms provided a similar amount of available carbohydrate (35 g).
1523113|NCT02793284|Radiation|18F-DCFPyL PET/CT scan|PET/CT scan using the radioactive agent 18F-DCFPyL
1523114|NCT02793271|Behavioral|RESHAPE|Mental health services users and primary care workers who have previously completed the training are trained using PhotoVoice and other techniques to participate as co-facilitators. They participate in introductions to the intervention, myth busting, recovery stories, psychosocial communication role plays, and collaborative activities addressing challenges and barriers to task sharing/ task shifting mental health services in primary care.
1523115|NCT02793271|Behavioral|PRIME/mhGAP|"Primary care workers are trained using the mental health Global Action Programme (mhGAP) to identify and treat mental disorders in primary care. Primary care prescribers (those who can administer psychotropic medication) are trained to treat disorders including depression, alcohol use disorder, psychosis / schizophrenia, and epilepsy. Non-prescribers (primary care workers not authorized to dispense medications) are trained to deliver psychosocial and psychological interventions."
1523116|NCT02793258|Device|transcranial direct current stimulation|"Subjects will receive 10 30-minutes sessions of two milliamps transcranial direct current stimulation , twice a day for 5 consecutive day.
Facial emotion recognition task and attentional task with measurement of eye-tracking, heartrate, respiratory frequency and skin conductance will be conducted before and after the first session, and after the last session."
1523117|NCT02793245|Other|Questionnaire|Questionnaire on their main characteristics : age, gender, height, weight, smoking
1523118|NCT02793245|Other|Simplified pulmonary function test|
1523119|NCT02793232|Drug|PF-06751979 single dose|PF-06751979 administered as a single dose suspension in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF 06751979). The planned dose levels are 200 mg, 400 mg, 700 mg, 200 mg fed (these doses are subject to change based on emerging data).
1523120|NCT02793232|Drug|Placebo single dose|Matched Placebo suspension administered as single dose
1523121|NCT02793232|Drug|PF-06751979 multiple ascending dose|PF-06751979 suspension administered daily for 14 consecutive days to parallel cohorts. The planned dose levels are mg, 100 mg, 200 mg, 340 mg (these are subject to change based on emerging data).
1523122|NCT02793232|Drug|Placebo multiple ascending dose|Matched placebo suspension administered daily for 14 consecutive days.
1523123|NCT02793232|Drug|PF-06751979 multiple dose|PF-06751979 suspension administered daily for 14 consecutive days. The planned dose level is 340 mg (this is subject to change based on emerging data).
1523124|NCT02793232|Drug|Placebo multiple elderly dose|Multiple dose administration to Healthy Elderly Subjects (Placebo)
1523127|NCT02793206|Device|Imaging|
1523128|NCT02793193|Dietary Supplement|Probiotic|Probiotic B.longum 1714 will be donated by Alimentary Health Ltd. (Cork, Ireland) and each sachet contains 10 billion CFU
1523129|NCT02793193|Dietary Supplement|Placebo for antibiotic|The placebo supplementation is identical-looking to the antibiotic Xifaxan ®
1523130|NCT02793193|Drug|Antibiotic|Antibiotic Xifaxan ® will be 200mg per tablet
1523131|NCT02793193|Dietary Supplement|Placebo for probiotic|The placebo identical-looking to the probiotic B.longum 1714
1523132|NCT02793167|Device|AKI alert|
1523133|NCT02793154|Drug|Exenatide|Supplied as SC injection containing 250 mcg/mL of exenatide, provided in the following dose regimens: Part A: 10 mcg taken twice daily for 5 days; Part B: 5 mcg twice daily taken for 4 weeks followed by uptitration to 10 mcg for 4 weeks In both parts, it will be administered within 60-minute period before morning and evening meals (or before 2 meals with approximate >=6 hours apart)
1523134|NCT02793154|Drug|Albiglutide|Part B: Albiglutide will be supplied as follows:30 mg SC injection pen containing 40.3 mg lyophilized albiglutide and 0.65 mL; 50 mg SC injection pen contains 67 mg lyophilized albiglutide and 0.65 mL water; Starting dose will be 30 mg weekly for 4 weeks and then uptitrated to 50 mg weekly for 4 weeks; Administered as a single SC injection once a week in the morning
1523137|NCT02793115|Behavioral|Disclosure Letter-RISKS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
1523138|NCT02793115|Behavioral|Disclosure Letter-BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
1523139|NCT02793115|Behavioral|Disclosure Letter-RISKS AND BENEFITS|This disclosure letter will provide information on the physicians' financial relationships with industry, and will also provide a standardized statement regarding the potential RISKS AND BENEFITS of physicians' conflicts of interest with for-profit industry. This letter also includes a standard statement reminding the patient about the appointment and the location of the appointment.
1523140|NCT02793115|Behavioral|Disclosure Letter-NO RISKS OR BENEFITS|This letter includes a standard statement reminding the patient about the appointment and the location of the appointment.and DOES NOT provide any information on the physicians' financial relationships with industry nor information regarding the potential risks and benefits of physicians' conflicts of interest with for-profit industry.
1523141|NCT02793115|Behavioral|Letter-APPOINTMENT REMINDER|This letter only includes a standard statement reminding the patient about the appointment and the location of the appointment.
1523142|NCT02793102|Other|Olfactory workshop|Twenty odorants are selected: 10 evoke a food (including 5 pleasant and unpleasant 5) and 10 suggest a non-food source
1523143|NCT02793102|Other|Somesthesia workshop|Kinesthetic time or time for moving the body (30 min), and kinesthetic sensations (duration 10 min), and Talk Time
1523144|NCT02793102|Other|Auditory workshop|Twenty extracts of music tracks (30 seconds each) are built in the same fashion as those used during the workshops, but are different.
1523145|NCT02793089|Other|Analysis of Ectopic Pregnancy incidence|Collect retrospectively data. Analysis of Ectopic Pregnancy incidence through Estradiol (E2) and progesterone (P4) levels on hCG day and seven days later (hCG+7)
1523146|NCT02793076|Other|Bollywood Dance|8 week Bollywood Dance Program
1523147|NCT02793063|Other|Web-based Survey|This study will occur online. Participants will be asked to complete multiple surveys one time. Participants may receive study reminder emails to complete surveys. Participants will be able to complete the surveys all at once or in multiple sessions. Participants will have approximately 3 months to complete the surveys after consenting.
1523148|NCT02793050|Drug|Trabectedin|Collection of data on the clinical use of Trabectedin
1523150|NCT02793024|Behavioral|Intervention|Adolescents in the intervention arm will receive 3 face to face session about making smart shopping choices. The following 9 weeks will consist of utilizing social media to improve shopping choices.
1523151|NCT02793011|Drug|Dexamethasone|Oral dexamethasone elixir (0.5mg/ml or 4 mg/ml) mixed with Ora-sweet or simple syrup to mask the taste. Or 1 mg or 4 mg dexamethasone capsules if age appropriate
1523152|NCT02793011|Drug|Placebo|Placebo liquid (Ora-sweet or simple syrup) or Placebo capsule
1523153|NCT02792998|Drug|IW-1701|IW-1701 Tablet
1523154|NCT02792998|Drug|Placebo|Matching Placebo Tablet
1523155|NCT02792985|Behavioral|Multisensory stimulation protocol|"Participation in occupation-based multisensory stimulation (e.g. personal care with aromatic soaps, varying water temperatures and textured sponges, drink preparation of different flavoured beverages) with a variety of different sensory stimuli (e.g. strong smells, different shapes and weights). The participant will receive two individual 30-minute therapy sessions with an Occupational Therapist.
An enriched environment will be set up in the participant´s bedroom. It will include items that provide a range of meaningful sensory stimuli (e.g. familiar personal objects, projection of photos and known places, familiar music). The participant is encouraged to follow a timetable including regular rest breaks through out the day in their room."
1523156|NCT02792985|Behavioral|Control protocol|"Retraining of basic activities of daily living or participation in table top tasks and games in an individual 30 minute session or a one hour small group session with an Occupational Therapist.
Minimal changes are made to the participant´s room (e.g. orientation board, photos of family and friends)."
1523157|NCT02792972|Other|A. oleracea|The plant extract A. oleracea manipulated with Transcutol® were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
1523158|NCT02792972|Other|70% alcohol|70% alcohol were used in the volunteers before the venipuncture procedure as allocation in study groups. Held collection of skin microbiota by the swab technique and the end of the venipuncture procedure was applied to the volunteer, the visual numeric scale (VNS) standard to determine the degree of pain.
1523159|NCT02792959|Device|Functional Imaging previous the second course|Functional Imaging before and after 1 cycle of chemotherapy treatment, in the previous 4 days before the second course: PET1 and MRI1
1523993|NCT02786719|Drug|Etoposide|Cycle 3+5 (given daily for 3 days)
1523160|NCT02792959|Device|Functional Imaging previous the surgery|Functional Imaging after 4 cycles of chemotherapy treatment, in the 3 weeks after the chemotherapy, before the interval surgery: PET4 and MRI4 The RECIST evaluation will be done, usually, by scanner to 4 courses of chemotherapy before the surgery interval
1523161|NCT02792946|Drug|Acebrophylline|
1523162|NCT02792933|Procedure|air in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be then withdrawn and the low resistance syringe filled with 3-5mL of air will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
1523163|NCT02792933|Procedure|saline in epidural space|The epidural puncture will be performed in the L3-L4 or L4-L5 interspinous space in a seated position. A local anaesthesia with 2-5 mL of 2% lidocaine will be applied subcutaneously using a 25Gm 25mm needle. The epidural space will be localized using a Perifix® set by inserting the Tuohy needle in the ligamentum flavum or the interspinous space. The obturator will be withdrawn and the low resistance syringe filled with 3-5mL of saline solution will be connected. After localizing the epidural space, the catheter will be inserted 3-5 cm. An aspiration test will be performed through the catheter in a decline position with a 2 mL syringe, and a 3mL test dose with bupivacaine 0,25% plus epinephrine 1/200.000 will be administered to exclude an intradural or an intravascular position of the catheter.
1523164|NCT02792920|Device|CoCr-EES|
1523165|NCT02792907|Device|Compressive stocking|"After hindfoot and middlefoot surgery the patients from the Intervention Group will be treated with compressive stockings the removal of the suture. That means from the end of week 2 until the end of week 6 after surgery.
Additionally the patients wearing behaviour is monitored by a electronic sensor, which is implanted in the patient´s stocking."
1523166|NCT02792894|Behavioral|Family networks program|Intervention, Family networks Program (FaNs), is administered once weekly over 9-10 weeks in a group format over 3 hours per sessions. Family networks Program (FaNs) is based on WHO mhGAP module for developmental disorders and incorporates WHO parent skills training program for children with developmental disorders and delays. Parents Skills Training Program includes modules on communication, play, daily living skills, managing challenging behavior, coping with stress. Intervention is provided by the family volunteers (members of community, mostly women, who have a child affected in their families).
1523167|NCT02792881|Procedure|Laparoscopic total gastrectomy with D2 lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy will be performed with curative treated intent.For carcinomas arising in the remnant stomach with a gastrojejunostomy, jejunal lymph nodes adjacent to the anastomosis are included as regional lymph nodes. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
1523168|NCT02792868|Other|24 h urines analyses|patient collects urines during 24h
1523169|NCT02792855|Device|snifﬁng Position(place a 7-cm cushion under head )|Awake fiberoptic bronchoscope(FOB) orotracheal under snifﬁng position.The snifﬁng position was obtained by placement of a 7-cm cushion under the head of the patient. When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
1523170|NCT02792855|Device|Simple Head Extension(without cushion)|Awake fiberoptic bronchoscope(FOB) orotracheal under Head Extension position.The Head Extension position was obtained by simple head extension.When the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
1523171|NCT02792842|Drug|ART-123 (High Frequency)|intravenous drip infusion
1523172|NCT02792842|Drug|ART-123 (Low Frequency)|intravenous drip infusion
1523173|NCT02792842|Drug|Placebo|intravenous drip infusion
1523174|NCT02792829|Drug|Lenvatinib|All participants will receive one single dose in each of the 2 treatment periods (total of 2 doses). The total duration of the treatment periods is 12 days (6 days per period) in healthy adult volunteers.
1523175|NCT02792816|Drug|First line antimalarial in Myanmar (artemether-lumefrantrine, dihydroartemisinin-piperaquine, and artesunate-mefloquine)|Being a observational cohort study, one of the ACT was selected in each study site to assess the efficacy and safety.
1523176|NCT02792803|Drug|Xalatan|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
1523177|NCT02792803|Drug|Apo-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
1523178|NCT02792803|Drug|Co-Latanoprost|A prostaglandin analogue used to reduce intraocular pressure in patients diagnosed with glaucoma.
1523179|NCT02792777|Other|Interviews|Patients will be engaged in open-ended, semi-structured qualitative interviews, which will be performed one-on-one either in person or over the phone (depending on the healthcare setting that they are recruited from). Qualitative interviews will be audio recorded, with the patient's permission, transcribed, de-identified and entered into NVivo 10.0 software for coding and analysis.
1523180|NCT02792777|Other|Concept Mapping (CM)|"The CM process consists of 3 steps that take place over 3 sessions:
Step 1: Generation of Ideas- Participants brainstorm and generate responses to the focus statement. Once the group agrees that no new statements are being generated, the list of statements is reviewed within the group.
Step 2: Structuring of Statements- Each participant is given a set of sort cards and asked to sort the statements into piles. Participants then rate each idea regarding importance. Research staff enters this information into the CM software.
Concept Systems Global Software generates point maps using a technique that detects underlying similarities/differences between statements. The CM software then uses hierarchical cluster analysis to draw boundaries around the point map to create conceptual clusters.
Step 3: Interpretation- The CM group revises the concept map. Participants review the cluster names suggested by the software and decide upon final naming of each cluster as a group."
1523760|NCT02788448|Device|VIVASURE CLOSURE DEVICE|Large hole closure device
1523181|NCT02792751|Device|Bispectral Index Monitorisation (BIS)|Standard monitoring was performed with electrocardiography, pulse oximetry and non invasive blood pressure. Additionally, Bispectral index (Aspect Medical Systems, Natica, MA) electrodes were connected to Group B patients
1523182|NCT02792751|Other|Ramsey Sedation Scale|Propofol administration was done to keep the Ramsey Sedation scale of 3 or 4
1523183|NCT02792738|Behavioral|hypnosis|
1523185|NCT02792712|Drug|Ticagrelor|Ticagrelor 180 mg LD，then 90 mg BID
1523186|NCT02792712|Drug|Clopidogrel|Clopidogrel 300 mg LD，then 75 mg QD
1523189|NCT02792686|Drug|ABX464|Single Administration
1523190|NCT02792673|Other|embryos will be transferred using a medium of 0.5 mg/mL of Hyaluronan-enriched medium (EmbryoGlue®, Vitrolife, Sweden)|
1523191|NCT02792673|Other|embryos will be transferred using a medium of 30% Protein-supplemented Culture Medium (Global total®, Life Global group, Canada)|
1523192|NCT02792673|Other|a novel technique in which embryos will be transferred using a medium of autologous Follicular Fluid|
1523193|NCT02792673|Device|Labotect embryo transfer catheter|
1523194|NCT02792660|Device|Injeq IQ-Needle|Injeq IQ-Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
1523195|NCT02792647|Drug|Placebo|Administered orally
1523196|NCT02792647|Drug|IX-01|Administered orally
1523197|NCT02792634|Procedure|Sleeve-Gastrectomy, Roux en Y gastric bypass|
1523198|NCT02792621|Dietary Supplement|Acipimox|Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
1523199|NCT02792621|Dietary Supplement|placebo|The placebo supplement will contain only cellulose microcrystalline. This is an inert substance widely used in many pill and tablet formulations. It is an insoluble fibre and is not absorbed into the blood stream therefore is unlikely to cause toxicity when taken orally.
1523200|NCT02792608|Behavioral|Mindfulness-based Therapy|MBT will be delivered in group format, 135 minutes per week, for 5 consecutive weeks with 10-20 participants per group.
1523201|NCT02792595|Other|Negative Control|Untreated area
1523202|NCT02792595|Other|Positive Control|High SPF Standard P3/SPF 15
1523203|NCT02792595|Other|Test Product A|Yosemite Falls (Forte Day SPF upgrade) Variant A
1523204|NCT02792595|Other|Test Product B|Yosemite Falls (Forte Day SPF upgrade) Variant B
1523205|NCT02792595|Other|Test Product C|Yosemite Falls (Forte Day SPF upgrade) Variant C
1523206|NCT02792595|Other|Test Product D|Yosemite Falls (Forte Day SPF upgrade) Variant D
1523207|NCT02792595|Other|Test Product E|Yosemite Falls (Forte Day SPF upgrade) Variant E
1523208|NCT02792595|Other|Test Product F|Yosemite Falls (Forte Day SPF upgrade) Variant F
1523209|NCT02792595|Other|Test Product G|Yosemite Falls (Forte Day SPF upgrade) Variant G
1523210|NCT02792595|Other|Test Product H|Yosemite Falls (Forte Day SPF upgrade) Variant H
1523211|NCT02792582|Radiation|Proton Therapy|The protocol-specific radiation dose will be prescribed to a target defined by the use of computerized tomography (CT) and magnetic resonance imaging (MRI). The target will encompass the residual tumor and/or tumor bed and will include a margin mean to treat subclinical microscopic disease. There is no time limit for the interval from surgery or study enrollment to when proton therapy commences. The time course of administration of proton therapy will be 1 treatment/day, 5 days/week, for a period 6 weeks.
1523212|NCT02792582|Procedure|Surgery|When possible, tumors will be removed surgically prior to proton therapy. If no tumor remains following surgery, no proton therapy will be given, and participants will be followed for 5 years to collect outcome data for comparison between groups.
1523213|NCT02792569|Procedure|Biopsy of ovarian cortical tissue|Biopsies will be taken from either right or left side. The cortical tissue will be isolated and fragmented in 1x1 mm2 pieces, followed by auto-transplantation to a peritoneal pocket.
1523214|NCT02792556|Device|Urine pregnancy test|Urine pregnancy test Check Top after transvaginal ultrasound
1523215|NCT02792543|Device|Entéromate™|Chyme reinfusion (the experimental treatment) consists of continuously reinfusing the chyme collected from the proximal small bowel segment via the enterostomy, and into the diverted distal small bowel segment. It implies the use of the Entéromate™ pump.
1523216|NCT02792543|Drug|parenteral nutrition|Parenteral nutrition (the gold standard treatment) consists of electrolyte supplementation, hydration, and nutrition through a central venous catheter.
1523217|NCT02792530|Other|Dietary consultation|Dietary consultation for sodium restriction to decrease dietary intake to 2 grams/day less than the patients consume currently
1523218|NCT02792517|Drug|AMG 334|A single dose of AMG 334 will be administered in the abdomen.
1523219|NCT02792517|Drug|Estrogen/Progestin|An oral contraceptive will be taken daily for three cycles
1523220|NCT02792491|Drug|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone|Reduced dose of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone
1523221|NCT02792465|Drug|CFI-402257|
1523222|NCT02792426|Drug|Research ENDS S-TA-U001|
1523223|NCT02792426|Drug|Nicotrol Inhaler|
1523224|NCT02792413|Drug|Denosumab|
1523225|NCT02792413|Drug|NaCl (placebo)|
1523226|NCT02792400|Drug|LY2403021|Glucagon receptor antagonist
1523227|NCT02792400|Drug|LY2403021 placebo|
1523228|NCT02792400|Procedure|Standardised liquid meal|
1523229|NCT02792400|Drug|Linagliptin|DPP-4-inhibitor
1523230|NCT02792400|Drug|Linagliptin placebo|
1523231|NCT02792400|Drug|Empagliflozin|SGLT2-inhibitor
1523232|NCT02792400|Drug|Empagliflozin placebo|
1523984|NCT02786745|Drug|Dapsone gel|Dapsone gel applied to face once daily for 12 weeks
1523234|NCT02792374|Other|Psychological Measurement|Measurement of psychological status in three levels: discrete symptom level, dimensional level, global level as measured by the scale
1523235|NCT02792361|Procedure|Standard Suction Drain|The intervention of the experimental group will be a standard suction drain placed at the surgical site following a Pterional Craniotomy.
1523236|NCT02792348|Other|Laboratory biomarker analysis on urine sample|Archived urine samples are analyzed for specific metabolite patterns by nuclear magnetic resonance
1523237|NCT02792335|Drug|apixaban|
1523238|NCT02792335|Drug|dabigatran|
1523239|NCT02792335|Drug|rivaroxaban|
1523240|NCT02792335|Drug|warfarin|
1523241|NCT02792322|Device|Transoral Robotic Surgery (TORS) with the daVinci Robotic Surgical System device|Patient's will be having TORS surgery in a seated position
1523242|NCT02792309|Behavioral|MotherWise Program|Healthy Marriage or Relationship Education services for pregnant women.
1523243|NCT02792296|Other|Project: EVO Monitor|Project: EVO Monitor was designed to incorporate a proprietary multi-tasking assessment into a state-of-the-art mobile video game-like platform, which deploys modern videogame graphics, engaging reward loops, and real-time adaptive mechanics to dynamically personalize difficulty in order to assess the user's ability.
1523245|NCT02792270|Other|Caloric Restriction Diet|"A nutritional supplement called Scandishake (Nutridrinks, Perivale, UK) will be used for 3 days before surgery.
- Scandishake will be mixed with 8 oz of whole fat cow milk, whole fat lactaid milk, almond milk or soy milk. The proposed macronutrient profile for the 3 days of caloric restriction (CR) is: 45% fat, 46% carbohydrate, and 8% protein."
1523256|NCT02792205|Other|Non interventional study|
1523260|NCT02792166|Procedure|BPD-DS|Biliopancreatic Diversion with Duodenal Switch
1523261|NCT02792166|Procedure|SADI-S|Single Anastomosis Duodeno-ileal Bypass with Sleeve Gastrectomy
1523262|NCT02792153|Drug|Estradiol|AN participants will be prescribed 28 days of transdermal estradiol 0.1 mg/d (Days 1-28) plus 10 days (days 21-31) oral medroxyprogesterone 2.5 mg/d.
1523263|NCT02792140|Drug|Naltrexone|one week
1523264|NCT02792140|Other|Placebo|one week
1523265|NCT02792127|Behavioral|Online Program for Social Anxiety|This program will be completed from participants' homes using their own computers. This online format is based on a Cognitive Behaviour Therapy framework (CBT) and involves seven modules that ask participants to engage in a variety of thinking exercises and activities.
1523266|NCT02792114|Drug|Cyclophosphamide|
1523267|NCT02792114|Biological|Mesothelin-targeted T cells|
1523268|NCT02792114|Drug|AP1903|
1523269|NCT02792088|Drug|Besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
1523270|NCT02792088|Drug|Tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
1523271|NCT02792075|Other|2year Follow-up|
1523273|NCT02792049|Device|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with integrated internal handle
1523274|NCT02792049|Device|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
1523275|NCT02792036|Drug|Carboplatin|"Carboplatin will be given intravitreally. Participants are eligible to receive up to 8 injections per eye (once approximately every 14 days) based on lack of toxicity and evidence of tumor response. An injection of consolidation will be given once a complete response is observed. If further regression of stable seeds is noted, additional injections (up to 8 maximum per eye) will be provided at the discretion of the treating team. Injections could be repeated if vitreous recurrence occurs from another source (and patient has not reached 8 max limit per eye)."
1523276|NCT02792036|Drug|Maxitrol®|Maxitrol® contains neomycin and polymyxin B sulfates and dexamethasone ophthalmic suspension and is for topical ophthalmic use only. It will be given for continued use for five days following the carboplatin injection to prevent infection.
1523994|NCT02786719|Drug|Vincristine|Cycle 4+6 (given daily for 3 days)
1523277|NCT02792036|Procedure|Focal Therapy|Simultaneously with intravitreal carboplatin, focal therapy will be applied as needed to eradicate the retinal source of the seeding as well as all epiretinal and subretinal active tumors at the discretion of the treating ocular oncologist.
1523278|NCT02792036|Procedure|Plaque Radiotherapy|Participants who have developed progressive disease despite focal (non-irradiative) therapy will receive brachytherapy determined by consensus between the treating ophthalmologist and radiation oncologist.
1523279|NCT02792023|Other|Immunochemical fecal occult blood test|Participants will be provided with a single immunochemical fecal occult blood test. Participants will introduce a small sample of feces inside and bring the test to the hospital
1523280|NCT02792023|Device|Colonoscopy|A colonoscopy (procedure performed using a scope design to examine the large bowel) will be offered to the participants
1523281|NCT02792023|Device|Upper endoscopy|An upper endoscopy (procedure performed using a scope to examine the upper digestive tract) will be offered to the participants
1523282|NCT02792010|Device|Hip cartilage MRI|Hip cartilage MRI
1523283|NCT02791997|Other|Neuropsychological tests|Neuropsychological tests consist in listening to sounds in various contexts and providing behavioral responses with response-buttons.
1523284|NCT02791997|Other|Neurophysiological tests|Neurophysiological tests consist in the recording of EEG and/or MEG signals while realizing the neuropsychological tests, as well as MRI scanning to characterize the patients' brain lesions and reconstruct the brain sources of surface EEG/MEG signals.
1523285|NCT02791984|Device|Fluid challenge with 250 ml of Ringer Lactate|"Fluid challenge with 250 ml of Ringer Lactate over less than 2 minutes, intra-venous, help by a syringe of 50 ml.
Measure of peak velocity before and after the fluid challenge"
1523286|NCT02791971|Behavioral|SpeakOut|"SpeakOut aims to increase social communication about IUDs and implants between adolescent IUD and implant users and their peers. SpeakOut has four components:
Coaching session. Research staff will deliver a script to encourage recipients to share information about their contraceptive method with peers.
Printed materials for recipients to keep and/or share with friends.
Websites with information and resources. Staff will refer recipients to a website, either SpeakOutIUD.org or SpeakOutImplant.org, which contain information about their method.
Text messages with information about recipients' method and about how to share their experience. Recipients will be given the opportunity to sign up for text messages that will be sent for 8 weeks following receipt of SpeakOut in clinic."
1523287|NCT02791971|Behavioral|Alcohol Control Intervention|The active comparator intervention is an alcohol assessment and education intervention using an SBIRT (Screening, Brief Intervention, and Referral to Treatment) framework. SBIRT is an evidence-based practice model aimed at preventing problematic use and identifying potential abuse and dependency issues. Research staff will ask two screening questions developed by the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the American Academy of Pediatrics to screen for adolescents potentially at risk. Using a script based on tenets of motivational interviewing to assess alcohol related consequences, the research staff will guide teens in identifying personally relevant motivators for healthier behaviors, assess readiness to change, and offer educational materials and referrals.
1523288|NCT02791958|Drug|Cardiovascular Fixed Dose Combination Pill AAR|A once daily oral dose of the Cardiovascular Fixed Dose Combination Pill AAR (acetylsalicylic acid 100 mg, atorvastatin 40 mg and ramipril 10 mg) for 4 weeks.
1523289|NCT02791958|Drug|Atorvastatin 40 mg|A once daily oral dose of atorvastatin 40 mg (Lipitor®) for 4 weeks
1523290|NCT02791958|Drug|Ramipril 10 mg|A once daily oral dose of ramipril 10 mg (Altace®) for 4 weeks
1523294|NCT02791932|Behavioral|Exercise|See description above.
1523295|NCT02791919|Drug|Cytarabine|Given IV or IT
1523296|NCT02791919|Biological|Filgrastim|Given IV or SC
1523297|NCT02791919|Drug|Fludarabine Phosphate|Given IV
1523298|NCT02791919|Other|Laboratory Biomarker Analysis|Correlative studies
1523299|NCT02791919|Other|Pharmacological Study|Correlative studies
1523300|NCT02791919|Drug|WEE1 Inhibitor AZD1775|Given PO
1523301|NCT02791906|Drug|ISMN|
1523302|NCT02791906|Dietary Supplement|Vitamin C|
1523305|NCT02791880|Procedure|Transcatheter Aortic Valve Replacement|The investigators will collect blood and urine samples from patients with aortic stenosis who are undergoing transcatheter aortic valve replacement.
1523306|NCT02791867|Drug|AphoelineBrake|The study is proposed as a placebo controlled randomized controlled trial with an intervention (AphoelineBrake) in addition to their standard treatment in comparison to a standard treatment control arm receiving an identical placebo. Prior to the commencement of any study procedures, participants will document informed consent and acknowledgement of privacy rights. Participants will be seen for initial consenting procedures, initial study procedures, and follow-up procedures at the Dasman Diabetes Institute clinic.Scheduled study visits will occur at Day 0, Day 7, Months: 1, 3, 6, 9, and 12 months in accordance with standards of medical care.
1523307|NCT02791841|Behavioral|Rhythmic Reading Training|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed.
1523337|NCT02791581|Other|Data Collection|Nurse assessment, MRI exam, laboratory tests, questionnaires, disability measures, exercise tests.
1523338|NCT02791581|Other|Assessments|Nurse assessment, MRI exam, laboratory tests, questionnaires, disability measures, exercise tests.
1523339|NCT02791568|Procedure|Ultrasound Scan|The research exam is expected to take 30 minutes for blood flow assessments
1523340|NCT02791568|Procedure|MRI Scan|MR imaging will take approximately 30 minutes.
1523341|NCT02791529|Procedure|Electrocautery|Skin incision performed by electrocautery
1523342|NCT02791529|Procedure|Scalpel|Skin incision performed by scalpel
1524654|NCT02781766|Other|Thrombin generation measurement.|
1523308|NCT02791841|Behavioral|Visual Hemispheric-Specific Stimulation + Action Video Games|"This training combines Visual Hemisphere-Specific Stimulation (VHSS) according to Bakker's Balance Model, and Action Video-Games (AVG). Hemispheric-specific stimulation is carried out by tachistoscopic presentation of words to a visual hemifield in order to selectively stimulate right-hemisphere perceptual analysis or left-hemisphere linguistic anticipation. A computerized program is used, in which the word is flashed and presented for less than 350 ms only if the child clicks on the mouse at the exact moment a dot is crossing a central target (control of eye position and fixation).
AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used."
1523309|NCT02791841|Behavioral|Action Video Games|AVG training involves dyslexic participants in a video-game training, specifically aimed at improving visuo-spatial attentional abilities. A commercial WiiTM video game from UbisoftTM (suitable for children age 7 and older by the Pan European Game Information) called 'Rayman Raving Rabbids' is used.
1523310|NCT02791815|Drug|Midazolam|Single oral dose of 7.5 mg midazolam (tablet)
1523311|NCT02791815|Drug|Selexipag|Oral administration of selexipag (200 µg film-coated tablet) for 12 consecutive days (with a titration scheme from 400 to 1600 μg b.i.d. )
1523312|NCT02791789|Other|Autism Spectrum Disorder|Training to the serious game sematic, clinical exam, speech and language therapy and neuropsychological evaluations
1523313|NCT02791776|Other|Scoliosis|"self-administered questionnaire (SRS 30) to assess the state of health and disability of patients.
Collection of patient's radiographic and clinical parameters"
1523314|NCT02791763|Drug|1 to 4 mg tablets of GSK1278863|7.0 millimeters(mm) round, standard biconvex, white film coated tablets containing 1 mg, 2 mg, or 4 mg of GSK1278863 as active ingredient, to be orally administered once daily
1523315|NCT02791763|Drug|6 mg GSK1278863 tablet|9.0 mm round, standard biconvex, white film coated tablets containing 6 mg of GSK1278863 as active ingredient, to be orally administered once daily.
1523316|NCT02791763|Drug|Epoetin beta pegol|An injectable formulation containing 25 mcg, 50 mcg, 75 mcg, 100 mcg, 150 mcg, 200 mcg, or 250 mcg of epoetin beta pegol per syringe (0.3 mL), supplied as a glass syringe prefilled with epoetin beta pegol solution (clear colorless to pale yellow). Epoetin beta pegol will be subcutaneously administered once every 2 or 4 weeks
1523318|NCT02791737|Behavioral|Exercise Intervention|Complete individualized exercise program
1523319|NCT02791737|Other|Laboratory Biomarker Analysis|Correlative studies
1523320|NCT02791737|Procedure|Physical Therapy|Complete individualized exercise program
1523321|NCT02791737|Other|Quality-of-Life Assessment|Ancillary studies
1523322|NCT02791737|Other|Questionnaire Administration|Ancillary studies
1523323|NCT02791724|Behavioral|Desiconnect|Desiconnect is an Internet intervention for persons with epilepsy and elevated depression. Content is continuously adapted to patients' concerns and needs. Techniques to overcome depression (e.g., cognitive restructuring, behavioral activation) and to cope with anxiety symptoms (e.g., exposure, role of avoidance, mindfulness exercises) are conveyed in interactive sequences that are accompanied by audio recordings, illustrations, and worksheets. Topics covered also include coping with epilepsy symptoms, identifying and coping with seizure auras and triggers, and the role of nutrition and exercise. Patients are also prompted to regularly complete brief symptom severity self-monitoring questionnaires. Optional daily text messages with motivational content accompany the program. The program can be accessed for 180 days after registration.
1523324|NCT02791724|Other|CAU|Care as Usual
1523325|NCT02791711|Other|High Flow Nasal Cannula|Evaluation of the use of High Flow Nasal Cannula by biological marqers, questionnary of quality of use of HFNC by the physician, questionnary of evaluation of adverse events with HFNC
1523326|NCT02791685|Behavioral|MULTIFIT Cardiac Rehabilitation|MULTIFIT is a cardiac rehabilitation program delivered by the Movn smartphone application that will provide risk factor modification, prescribed exercises, education and counseling. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
1523327|NCT02791685|Behavioral|Movn Pulmonary Rehabilitation|Movn pulmonary rehabilitation is a program delivered by the Movn smartphone application that includes targeted educational content and prescribed exercises with mild resistance training in addition to walking and other cardiovascular exercises. The application will track activity using a built-in accelerometer or through connected devices such as a Fitbit for daily physical activity and management. Weight and blood pressure (BP) will be tracked by manual input or through wireless scales and BP monitors. The program will last for 12 weeks.
1523328|NCT02791685|Behavioral|Standard of Care Cardiac Rehabilitation|Standard cardiac rehabilitation involves a facility's standard rehabilitation practices. Participants will be seen at baseline and during a 12 and 24 week follow-up visit.
1523329|NCT02791672|Behavioral|Discharge within 24 hours|If both the physician and patient have no concerns within 24 hours of a Latissimus Dorsi Flap breast reconstruction the patient will be discharged home and enrolled in the cohort group.
1523330|NCT02791659|Radiation|Automatic beam adjustment function|The fluoroscopy system has an automatic beam adjustment function to maintain a good quality of image output.
1523331|NCT02791646|Behavioral|Pain Coping Skills Training Full|Pain Coping Skills Training Full(PCST-Full) will consist of a 5-session intervention delivered to participants at the medical center by their therapist.
1523332|NCT02791646|Behavioral|Pain Coping Skills Brief|Pain coping skills training brief (PCST-Brief) will consist of a 60 minute, in-person session followed by 4-weeks of daily text messaging
1523333|NCT02791633|Other|Questionnaire|Quality of recovery and quality of recovery follow up questionnaires
1523334|NCT02791620|Device|a nanofractional radiofrequency device|A nanofractional radiofrequency device. noninvasive fractional radiofrequency device that provides ability to control and adjust the ratio of ablation and coagulation effect. Venus Viva, licensed by Health Canada, is cleared by the FDA for ablation and resurfacing dermatological procedures.
1523335|NCT02791594|Drug|Pembrolizumab|
1523336|NCT02791581|Other|Observational|Nurse assessment, MRI exam, laboratory tests, questionnaires, disability measures, exercise tests.
1523345|NCT02791503|Procedure|Irreversible electroporation (IRE)|IRE is based on permeabilization of the cell membrane through electrical pulses leading to apoptosis. Theoretically, IRE only affects viable tumor tissue, leaving surrounding vital structures relatively intact. It is therefore considered to cause less morbidity than thermal ablative strategies.
1523346|NCT02791503|Procedure|Stereotactic ablative radiotherapy (SABR)|Stereotactic ablative radiotherapy (SABR) is a form of external beam radiation that has important advantages over conventional radiotherapy such as a more precise and greater biological dose delivery and hence less toxicity and presumably better outcome.
1523347|NCT02791490|Drug|Sitagliptin|Oral tablet, 100 mg, once daily at approximately the same time each day
1523348|NCT02791490|Drug|Placebo|Oral tablet, once daily at approximately the same time each day
1523349|NCT02791490|Drug|Metformin IR|All participants will take immediate-release metformin (Met-IR) as background medication. Initially, they will take 1 x 500 mg tablet Met-IR twice daily (1000 mg/day). After randomization, all participants will be titrated to 2 x 500 mg tablets of Met-IR twice daily (2000 mg/day).
1523350|NCT02791477|Device|Attune FB PS knee arthroplasty|
1523351|NCT02791464|Behavioral|Transcendental Meditation program|a mental technique using a mantra or 'soothing sound' that refines the thought process enabling the mind to 'transcend' its own thinking process and experience a state of pure consciousness. Subjects practice this technique twice a day for 20 minutes sitting in chair with eyes closed.
1523352|NCT02791451|Device|telemonitoring|To predict exacerbation of COPD with wireless telemonitoring
1523353|NCT02791438|Drug|TAK-536 2.5 mg|TAK-536 2.5 mg granules + TAK-536 5, 10, 20 mg tablets
1523354|NCT02791438|Drug|TAK-536 5 mg|TAK-536 5, 10, 20, 40 mg tablets
1523355|NCT02791425|Device|Brain Computer Interface (BCI) device|A BCI system to facilitate communication in intubated patients. Patients use the device in the ICU for communication for 2 hours a day for 3 consecutive days.
1523356|NCT02791425|Other|Communication picture board|The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
1523357|NCT02791412|Procedure|percutaneous coronary intervention or coronary-artery bypass graft|
1523358|NCT02791399|Behavioral|ISOP Intervention with the Nurse Care Manager|A Nurse Care Manager (NCM) will maintain a registry of enrolled patients, track opioid medication-related events from the medical record, and provide decision support to Primary Care Providers for issues related to prescription opioid safety. The NCM will also meet individually with enrolled participants in the intervention group to discuss strategies for preventing/reducing opioid side effects, preventing diversion, and providing rationale for screening for prescription opioid misuse.
1523359|NCT02791373|Drug|Vinorelbine|Mobilisation Chemotherapy
1523360|NCT02791373|Drug|Gemcitabine|Mobilisation Chemotherapy
1523361|NCT02791360|Other|Brain MRI|
1523362|NCT02791347|Other|Nutrition Intervention|
1523363|NCT02791334|Drug|LY3300054|Administered IV
1523364|NCT02791334|Drug|Ramucirumab|Administered IV
1523365|NCT02791334|Drug|Abemaciclib|Administered orally
1523366|NCT02791334|Drug|Merestinib|Administered orally
1523367|NCT02791321|Other|ADS severity|Evaluation of the ADS severity with the CARS scale
1523368|NCT02791321|Other|Adaptative and intellectual functioning|Evaluation with IQ and Vineland II scale
1523369|NCT02791321|Other|Psychiatric and somatic comorbidities|Evaluation with the Reiss, DSQIID and CIRS Scales
1523370|NCT02791308|Drug|Pimecrolimus Cream 1% (Valeant)|
1523371|NCT02791308|Drug|Vehicle cream|
1523372|NCT02791308|Drug|Pimecrolimus Cream, 1%|
1523373|NCT02791295|Other|Diet and physical activity program|A personalized intervention focused on improving diet and increasing physical activity will be implemented at-home with a monthly support by a registered dietician and physical activity educator during 6 months
1523374|NCT02791282|Other|Index test: functional dynamic contrast enhanced (DCE)-MRI|Index test: functional dynamic contrast enhanced (DCE)-MRI Reference test: Ventilation-perfusion (VQ) single-photon emission computed tomography (SPECT) Follow-up per patient: clinical assessment after 6-12 months
1523375|NCT02791269|Drug|Peginterferon alfa-2a|180 mcg SC injection QW for 48 weeks.
1523376|NCT02791256|Drug|Ribavirin|
1523377|NCT02791256|Drug|peginterferon alfa-2a|
1523378|NCT02791243|Drug|Finasteride 0.25%|Cutaneous solution of finasteride 0.25%
1523379|NCT02791243|Drug|Placebo for Finasteride 0.25%|vehicle cutaneous solution of P-3074
1523380|NCT02791243|Drug|Negative Control|0.9% aqueous NaCl
1523386|NCT02791178|Procedure|Optical coherence tomography (OCT)|Special camera to study part of your heart that was affected
1523387|NCT02791178|Procedure|Index of microcirculatory resistance (IMR)|Special wire to study part of your heart that was affected
1523388|NCT02791178|Other|Cardiac MRI|Special scanner if the heart to assess the damage of your heart
1523389|NCT02791139|Other|Cardiovascular Magnetic Resonance Imaging (MRI)|Cardiovascular MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create heart images.
1523390|NCT02791139|Other|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
1523391|NCT02791139|Other|Tonometry|Tonometry is a noninvasive method to obtain arterial pressure waveform
1523985|NCT02786745|Drug|Placebo|Placebo applied to face once daily for 12 weeks
1523392|NCT02791139|Other|Genetic Testing (Blood)|The blood will be stored for genetic tests and development of cell lines to study genetic risks for aging related diseases and cardiovascular disease.
1523393|NCT02791139|Other|Hand-Grip Strength Measurement|We will measure your hand grip strength using a standard hand dynamometer which is a portable meter that you will use your hands to press on.
1523394|NCT02791139|Other|Body Fat Mass Analysis|Body composition will be analysed by a body composition analyser machine onto which you will have to stand on.
1523395|NCT02791126|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
1523396|NCT02791126|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
1523397|NCT02791113|Other|Fractional Flow Reserve (FFR) Measurement|FFR is defined as the distal pressure to coronary lesion divided by the proximal coronary pressure. FFR is measured through a standard diagnostic catheter during coronary angiogram. FFR is used to guide whether to perform angioplasty or stenting or not in patients with coronary stenosis.
1523398|NCT02791100|Behavioral|Promotion of chicken eggs|Community is provided with chickens and young children are to receive 2 eggs a day plus egg shell
1523399|NCT02791087|Other|Computed Tomography Angiography|The CTA is non-invasive and is used commonly for patients who have chest pain to assess the coronary artery disease, prior to the more invasive coronary angiogram.
1523400|NCT02791087|Other|Intra-operative graft flow rate measurement|This procedure involves the insertion of a Medistim Ultrasound Transit Time Flow Probe into the graft vessel to measure its flow rate. This technique is commonly used for evaluating graft opening during CABG surgery.
1523401|NCT02791074|Other|NTproBNP|To assess its level in the blood, as a marker of heart failure presence and severity.
1523402|NCT02791074|Other|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
1523403|NCT02791074|Other|Arterial tonometry|A noninvasive method to obtain arterial pressure waveform.
1523404|NCT02791061|Other|Cardiovascular Magnetic Resonance Imagine (MRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images.
1523405|NCT02791061|Other|Cardiopulmonary exercise testing (CPET)|Cardiopulmonary exercise testing (CPET) is non-invasive simultaneous measurement of the cardiovascular and respiratory system during exercise to assess a patient's exercise capacity.
1523406|NCT02791061|Other|Echocardiography|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help us understand the type and severity of heart failure.
1523407|NCT02791048|Behavioral|Music therapy|"Music therapy is a clinical intervention conducted by qualified therapists who use shared music-making and improvisation to engage and interact with the client (s) in order to work towards specific therapeutic objectives.
This is the aim of sessions, rather than the teaching or utilising of any musical skills, and clients do not have to have any prior musical training or experience whatsoever in order to participate in and benefit from music therapy. The intervention is client-led and the therapist will guide the patient in a range of strategies and activities appropriate to the therapeutic aims in place. Sessions can be individual, or family members can also be involved if appropriate and desired."
1523408|NCT02791035|Drug|Oral administration of Ipragliflozin|
1523409|NCT02791022|Device|SPYDER ECG sensor|
1523410|NCT02791009|Other|Cardiovascular Magnetic Resonance Imaging (CMRI)|CMRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
1523411|NCT02791009|Other|Electrocardiogram (ECG)|ECG is a non-invasive test used to detect any underlying heart conditions by measuring the electrical activity of the heart.
1523412|NCT02791009|Other|Blood Sample Collection|Blood will be drawn for circulating biomarkers, which are measurable indicators of the severity or presence of the heart failure condition.
1523413|NCT02791009|Other|Clinical Assessment|Check health status, blood pressure, heart rate, height and weight measured. In addition, subject will undergo a heart examination.
1523414|NCT02791009|Other|Cardiovascular Ultrasound (CVUS)|To measure heart chamber size, heart function, blood vessel size and blood vessel function. These measurements will help the investigators understand the type and severity of heart failure.
1523415|NCT02791009|Other|Cognitive Test|To relate the presence and severity of cognitive impairment (CI) with simultaneously acquired advanced cardiovascular imaging characteristics and circulating biomarkers of cardiovascular function, inflammation and coagulation.
1523416|NCT02790996|Drug|Vancomycin|
1523417|NCT02790970|Device|PReDicT Test|PReDicT Test, when completed 7-9 days after starting antidepressant treatment, is able to predict a patient's subsequent response to that antidepressant treatment 4-6 weeks later
1523418|NCT02790970|Other|Treatment as Usual|Patients treated by the clinician conventionally using signs and symptoms to determine treatment changes or medication changes.
1523419|NCT02790957|Drug|Plerixafor|Single injection of 0.24 mg/kg Plerixafor
1523420|NCT02790957|Drug|Placebo|Single injection of an equal volume of NaCl solution
1523421|NCT02790944|Genetic|Multi-gene Next Generation Sequencing Panel|Participants will have genetic testing
1523422|NCT02790931|Other|Intervention Group|Patients will receive a physical therapy intervention in groups twice/wk, and using a software twice/ wk for 3 months, for foot and ankle strengthening, stretching and functional training. They must continue to exercise at home twice a week with the software supervision for one year.
1523423|NCT02790918|Other|6MWT|Each patient will also receive 6MWT at cardiovascular rehabilitation and preventive cardiology laboratory. Besides the distance covered in meters or converted measure (such as feet) over 6 minutes, a portable metabolic system is used to measure oxygen uptake during exercise (VO2 testing) for each patient.
1523424|NCT02790918|Other|Cardiovascular Magnetic Resonance Imaging (CMRI)|MRI uses interaction of the magnetic properties of body tissues with strong magnetic fields to create images; for about 1 hour. Several sets of images are needed. No injection of drug or dye will be used for this procedure.
1523986|NCT02786732|Biological|210mg Brodalumab|Brodalumab 210mg administered subcutaneously
1523426|NCT02790879|Other|Transition pediatric - adult|
1523427|NCT02790866|Behavioral|LuCaS Decision Aid|Web-based Lung Cancer Screening Decision Aid
1523428|NCT02790866|Behavioral|NCI Website|NCI Website on Lung Cancer Screening
1523429|NCT02790853|Procedure|White Light (WL) Clinical Examination|Participant's oral cavity inspected using a standard white light headlamp.
1523430|NCT02790853|Device|PS2.1/PS3 Imaging|Participant's oral cavity examined with wide-field auto-fluorescence imaging device PS2.1/PS3. Clinical images recorded from a normal area and from any other suspicious or unusual areas.
1523431|NCT02790853|Other|Proflavine Hemisulfate|A cotton-tip applicator soaked in 0.01% proflavine hemisulfate placed on the oral mucosa around the involved area before re-imaging with high-resolution optical system (HRME).
1523432|NCT02790853|Device|High-Resolution Optical System (HRME)|After proflavine hemisulfate applied, oral mucosa re-imaged with high-resolution optical system (HRME). Clinical images recorded.
1523433|NCT02790853|Procedure|Brush Biopsy|Soft oral cell sampler biopsy brush pressed against the lesion and rotated 5-10 times or more depending on the thickness of the lesion.
1523434|NCT02790853|Procedure|Tissue Biopsy|Oral areas requiring pathologic assessment biopsied. After local anesthesia, a 4 or 5 mm punch biopsy instrument used to remove the oral tissue.
1523435|NCT02790840|Drug|Omeprazole|20 mg oral capsules administered once daily for 10 days
1523436|NCT02790840|Drug|Omeprazole|40 mg oral capsules administered twice daily for 10 days
1523437|NCT02790840|Drug|Gefapixant|Gefapixant oral tablets (15 mg administered as two 7.5 mg tablets) administered twice daily for 15 days
1523438|NCT02790840|Drug|Gefapixant|Gefapixant oral tablets (30 mg administered as four 7.5 mg tablets) administered twice daily for 15 days
1523439|NCT02790827|Behavioral|CETA|CETA first focuses on: 1) awareness of alcohol problems, violence, and the link between them; 2) gender norms. Skills taught include: changing drinking behaviors, coping with cravings, family dynamics that contribute and result from alcohol use, the role gender plays, and community norms around problem drinking, and cognitive/emotional/behavioral patterns connected with inter-personal violence. The intervention then addresses: 1) positive parenting, 2) positive family relationships, conflict management, and communication skills, 3) attitudes and beliefs about violence, 4) mental health problems and 5) reducing (further) traumatic experiences. The cognitive behavioral therapy (CBT) principles of CETA overlap with the CBT skills for alcohol reduction.
1523440|NCT02790827|Behavioral|Treatment as usual|The control condition is defined as 'treatment as usual'. In Zambia, there are no formal services or standard of care for alcohol use problems or domestic violence. There are, however, organizations (such as non-governmental organizations) operating in Lusaka that provide intermittent services for these types of problems. Some families receive informal counseling from parish priests or other leaders in their communities. In this study we are therefore defining these types of informal services as 'treatment-as-usual.' We will closely track the type, number, and degree of these kinds of services that all participants receive and access. Following the conclusion of the study, we will offer the CETA intervention to control families if it has been found to be safe and effective.
1523441|NCT02790814|Device|Moyo strap-on|Continous measurements
1523442|NCT02790814|Device|Hand-held fetoscope|Intermittent measurements
1523443|NCT02790801|Other|observation|observation
1523444|NCT02790788|Drug|Methylprednisolone; hydrocortisone|Methylprednisolone 40 mg during resuscitation and stress-dose hydrocortisone for postresuscitation shock
1523445|NCT02790788|Drug|Saline Placebo|Saline placebo during resuscitation and during the postresuscitation phase.
1523446|NCT02790775|Drug|Anti-VEGF in quadrant 1|
1523447|NCT02790775|Drug|Anti-VEGF in quadrant 2|
1523448|NCT02790775|Drug|Anti-VEGF in quadrant 3|
1523449|NCT02790775|Drug|Anti-VEGF in quadrant 4|
1523450|NCT02790762|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion, and repeated every week for four times.
1523451|NCT02790749|Procedure|Adjunctive hip arthroscopy to accompany PAO|This is the experimental group: those patients who undergo adjunctive hip arthroscopy in addition to periacetabular osteotomy (PAO).
1523452|NCT02790749|Procedure|PAO without adjunctive hip arthroscopy|This is the control group: those patients who undergo periacetabular osteotomy (PAO) alone, without adjunctive hip arthroscopy.
1523453|NCT02790736|Drug|propranolol|active treatment
1523454|NCT02790736|Drug|placebo|inactive pill
1523456|NCT02790710|Drug|Propanolol|Active treatment
1523457|NCT02790710|Drug|Placebo|Inactive pill
1523458|NCT02790697|Other|Indirect calorimetry|Indirect calorimetry will be conducted using the new calorimeter and mixing chamber method using the mass spectrometer.
1523459|NCT02790684|Drug|DS-8500a|
1523460|NCT02790671|Drug|DS-8500a|DS-8500a 25mg tablet
1523461|NCT02790671|Drug|Itraconazole|200mg itraconazole
1523462|NCT02790658|Dietary Supplement|Intake of grumixama juice|In the morning of experimental day after 10 h fasting, the volunteers have been collect the first urine in the morning and it was collected the blood before the intake of grumixama juice, after they drink the juice (0 min), it was collected blood at the times: 15 min, 30 min, 60 min,120 min, 240 min and 24 h; and it was also collected urine at the period: 0 -1h, 1 - 2h, 2 - 4h, 4 - 6 h, 6 - 12 h, 12 - 14 h, the first urine in the morning in the second day (24 h). During the period in the first 4 h of experiment the volunteers only intake the juice.
1523463|NCT02790645|Other|Group 2a. Telemedicine program|CSII (Accu-Chek Spirit®) and medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
1523464|NCT02790645|Other|Group 1a. Control|Treatment with CSII (Accu-Chek Spirit®) and follow-face doctor visits (conventional treatment -SMC-) (6 months).
1523465|NCT02790645|Other|Group 1b.Telemedicine program|After a washout period of 3 months and the crossing, Group 1 begins with medical monitoring via telematics application (Emminens Conecta® System, Roche Diagnostics SL) (TM) (6 months).
1523466|NCT02790645|Other|Group 2b. Control|After a washout period of 3 months and the crossing, Group 2 begins with face doctor visits (conventional treatment -SMC-) (6 months) .
1523467|NCT02790632|Drug|EG-1962 (nimodipine microparticles)|Single intraventricular administration of EG-1962 via EVD and placebo capsules or tablets administered for up to 21 days
1523468|NCT02790632|Drug|Enteral Nimodipine|Enteral Nimodipine capsules or tablets administered for up to 21 days and single intraventricular administration of saline via EVD
1523469|NCT02790619|Device|tDCS via Chattanooga Ionto Iontophoresis System-Phoresor|Small electrical current delivered non-invasively to the scalp. 1mA electrical current to Meditation and Active Stimulation 1 condition. 2mA to Meditation and Active 2 Stimulation condition.
1523470|NCT02790619|Device|Sham tDCS Chattanooga Ionto Iontophoresis System-Phoresor|Blinds participants to meditation condition by applying 30 seconds of real stimulation and then turning the device off.
1523471|NCT02790593|Device|Juxta-Cures™|Juxta-CURES™ is an adjustable compression device, which may be used as a secondary dressing for the treatment of open venous stasis ulcers. It is an inelastic wrap around device with a Built-In-Pressure System™, which allows patients to easily and accurately apply pressure to their own leg and adjust it throughout the day.
1523472|NCT02790593|Device|Standard Compression|Compression bandaging
1523473|NCT02790593|Device|PicoPress®|Pressure monitoring to be done at time of bandage application and removal for both arms of the study.
1523474|NCT02790593|Device|Silhoutte® 3D wound imaging system|Photographic imaging system to measure wound surface area and depth. Picture to be taken at each appointment. This intervention is for both arms of the study.
1523475|NCT02790580|Drug|Dose-dense doxorubicin/cyclophosphamide + sunitinib|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide Oral sunitinib 12.5mg daily for 7 days prior to cycle 1 ddAC (days -7 to 0) Oral sunitinib 12.5mg daily for 5 days prior to cycle 2, 3, 4 ddAC (days 10-14 of preceding cycle)
Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
1523476|NCT02790580|Drug|Dose-dense doxorubicin/cyclophosphamide|"Doxorubicin 60mg/m2 day 1, every 2 weeks x 4 cycles Cyclophosphamide 600mg/m2 day1, every 2 weeks x 4 cycles Subcutaneous pegfilgrastim 6mg, 24-36 hours after each cycle of doxorubicin/cyclophosphamide
Lumpectomy or mastectomy with sentinel lymph node biopsy or axillary lymph node clearance as appropriate should be considered after completing four cycles of chemotherapy for curative intent in non-metastatic patients and for local control for patients with metastatic disease."
1523477|NCT02790567|Other|HEP score|"The HEP score is a clinicobiological score evaluating the probability of the HIT diagnosis.
The HEP score is based on the blood platelet count, the timing of the platelet decrease, the existence of clinical manifestations of HIT (thrombosis, haemorrhage, skin necrosis) and the existence of an other cause of thrombocytopenia."
1523478|NCT02790567|Other|4Ts score|The 4Ts score is a clinicobiological score evaluating the probability of the HIT diagnosis. The 4Ts score is based on the change in blood platelet count during heparin therapy, the timing of platelet decrease, the existence of a thrombosis, and the existence of an other cause of thrombocytopenia.
1523479|NCT02790567|Other|ID-PaGIA test|The ID-PaGIA test is a particle gel immunoassay that detects immunoglobulins (Ig) G, A and M specific to the heparin/PF4 complexes.
1523480|NCT02790567|Other|HIT-Ab(PF4-H) test|The HIT-Ab(PF4-H) test consist in the incubation of plasma samples with latex beads coated PF4/polyvinylsulfate complexes. After binding of the plasma antibodies a monoclonal antibody recognizing PF4/heparin complexes is added. In the presence of human anti-PF4/heparin antibodies, binding of the monoclonal antibody and subsequent agglutination of latex beads is inhibited. Inhibition of agglutination is quantified and reported in arbitrary units (U/ml). A value equal or higher than 1.0 u/ml may indicate the presence of HIT antibodies.
1523483|NCT02790541|Device|Hyperbaric Oxygen Therapy|60 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 3 months.
1523484|NCT02790528|Drug|Atorvastatin|20mg QD
1523485|NCT02790528|Drug|Placebo|Placebo drug will be administered.
1523486|NCT02790515|Drug|Anti-thymocyte globulin (rabbit)|Given intravenous (IV) prior to transplant on Days -14, -13, -12.
1523487|NCT02790515|Drug|Blinatumomab|Given by continuous IV infusion at least 2 weeks post-engraftment. Blinatumomab will be given only to patients with CD19+ malignancies.
1523488|NCT02790515|Drug|Cyclophosphamide|Given by IV infusion prior to transplant on Day -9.
1523489|NCT02790515|Drug|Fludarabine|Given IV prior to transplant on Days -8, -7, -6, -5, and -4.
1523490|NCT02790515|Drug|G-CSF|Given IV or subcutaneous (SQ) following transplant on Days 6 and 7.
1523491|NCT02790515|Drug|Melphalan|Given IV prior to transplant on Days -2 and -1.
1523492|NCT02790515|Drug|Mesna|Given IV prior to cyclophosphamide administration and at approximately 3, 6, and 9 hours after cyclophosphamide infusion.
1523493|NCT02790515|Drug|Rituximab|Given IV prior to transplant on Day -1.
1523494|NCT02790515|Drug|Tacrolimus|Given oral (PO) or IV beginning prior to transplant on Day -2. The dose will begin to taper at approximately day +60 after transplant in the absence of GVHD. Tacrolimus was used for the first 5 participants enrolled on study. Subsequent participants receive sirolimus.
1523495|NCT02790515|Drug|Thiotepa|Given IV prior to transplant on Day -3.
1523496|NCT02790515|Biological|HPC,A Infusion|Hematopoietic Progenitor Cell, Apheresis (HPC,A) infusion of TCRɑβ+ depleted cells on day of transplant (Day 0) and HPC,A infusion of CD45RA+ depleted cells on Day +1 following transplant.
1523497|NCT02790515|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
1523498|NCT02790515|Drug|Sirolimus|Given orally (PO) prior to transplant on Day -2. The dose will begin to taper at approximately day +100 after transplant in the absence of GVHD.
1524699|NCT02781363|Other|Thoracic ultrasound|
1523501|NCT02790476|Other|Letters|"The letters will be factual and nonjudgmental, signed by the County Medical Examiner, and would state that a patient they had treated with controlled substances died of an opioid poisoning. The letter will encourage judicious prescribing, and will provide information developed by an advisory group: how to identify and taper unsafe regimens (high dose, polypharmacy, or use of multiple prescribers); how to identify addiction and compassionately refer patients for medication-assisted treatment; and recommendations to avoid bad outcomes (e.g. do not fire your patient for signs of addiction.) The letter would also encourage use of the CURES system before prescribing, as well as co-prescribing of naloxone."
1523503|NCT02790450|Drug|Benzbromarone|1x200mg Benzbromarone will be applied after baseline measurements during right heart catheterization. The effects of the drug on the pulmonary hemodynamics will be assessed after 2 hours.
1523504|NCT02790437|Drug|IdeS|One dose of 0.25 mg/kg BW IdeS on study day 0. If negative crossmatch is not achieved, a second dose can be given within 2 days of the first infusion.
1523505|NCT02790424|Device|Imaging devices|technological adjustment tests
1523506|NCT02790411|Device|Imaging devices|technological adjustment tests
1523507|NCT02790411|Device|New Non Invasive Devices|Tests with REX BIONICS Exoskeleton
1523508|NCT02790398|Behavioral|Transdiagnostic treatment protocol|Transdiagnostic treatment protocol for emotional disorders whose aims are to learn and practice adaptive ways to regulate emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention. These components are organized in twelve modules.
1523509|NCT02790398|Behavioral|Transdiagnostic treatment protocol + PA regulation component|Transdiagnostic treatment protocol for emotional disorders + PA regulation components has the purpose of learning and practicing adaptive ways to regulate emotions from a transdiagnostic perspective. This protocol includes the same components but it also includes 4 additional modules focused specifically on the regulation of positive affectivity.
1523510|NCT02790385|Device|Negative Pressure Wound Therapy|
1523511|NCT02790385|Other|Standard Gauze Treatment|
1523512|NCT02790372|Other|Case conferencing|Intervention nursing homes carries out regularly case conferencing based on comprehensive geriatric assessments. Case conferencing is carried out each month for nursing home patients included in the study
1523513|NCT02790359|Other|Air|Group of patients who would receive air insufflation
1523514|NCT02790359|Other|Carbon dioxide|Group of patients who would receive carbon dioxide insufflation
1523515|NCT02790346|Procedure|arthrodesis talonavicular|
1523516|NCT02790346|Procedure|tendon gestures|
1523517|NCT02790333|Procedure|traditional reloads|Blue cartridge with3.0mm height staple was used for pancreatic stump
1523518|NCT02790333|Procedure|Tri-Staple reloads|Purple cartridge with2.0-2.5-3.0mm varied-height staples was used for pancreatic stump
1523519|NCT02790307|Device|The Geko|transcutaneous tibial nerve stimulation (stick on patch)
1523520|NCT02790294|Device|Magnetic Resonance Imaging|The routine spine MRI protocol will be utilized, which includes the following sequences: haste localizer, sagittal T1, T2, and short-T1 Inversion Recovery (STIR), axial T2 for lumbar spine or axial gradient echo for cervical and thoracic spine, axial T1, post contrast sagittal and axial T1. All scans will be obtained using a 1.5 Tesla magnet.
1523521|NCT02790281|Procedure|Blood sampling|Blood sample collected at a single visit
1523522|NCT02790268|Procedure|Lens Subluxation Surgery|Surgical Intervention to include Cionni Ring implantation and in-the-bag IOL implantation
1523523|NCT02790255|Other|Cold air|
1523524|NCT02790255|Other|Cold water|
1523525|NCT02790229|Other|anti-gravity treadmill (alter G®)|Patients in the experimental arm will be treated with manual lymphatic drainage, cryotherapy and a fixed protocol of training in an anti-gravity treadmill (alter G®). The protocol is designed parallel to standard physiotherapy with a frequency of two to three times a week with duration of about 20 minutes for six weeks.
1523526|NCT02790229|Other|standardized physiotherapy|Patients in the control arm will be treated with manual lymphatic drainage, cryotherapy and 20 minutes of physiotherapy two to three times a week for six weeks. Physiotherapy will be done according to a standardized protocol.
1523527|NCT02790216|Procedure|Brachytherapy|Biopsies will be obtained after intraoperative plan to rule out significant cancer outside a high risk planning target volume
1523528|NCT02790203|Drug|Celecoxib|NSAIDS
1523529|NCT02790203|Drug|Placebo|Placebo
1523530|NCT02790190|Other|Radiotherapy dose|
1523531|NCT02790177|Drug|Hyaluronic Acid|
1523532|NCT02790177|Drug|NORMAL SALINE|
1523533|NCT02790164|Drug|Esmeron|Neuromuscular Blockade
1523534|NCT02790164|Drug|Saline|Normal Saline
1523535|NCT02790151|Behavioral|Standard Therapy|Learning and practicing Memory strategies
1523536|NCT02790151|Behavioral|Experimental Intervention|Computerbased Working Memory Training in Combination with a Recollection Training
1523540|NCT02790125|Drug|BMS-986166|
1523541|NCT02790125|Drug|Placebo matching BMS-986166|
1523542|NCT02790112|Other|GnRHas|"Influence of early adiposity rebound, genetic polymorphisms and GnRHa treatment on long-term outcome of treated and untreated girls with idiopathic central precocious compared to a control group.
puberty."
1523543|NCT02790099|Drug|Bupivacaine|Surgical rectus sheath block will be performed by injection of 40ml bupivacaine (2.5mg/ml) before closure of rectus sheath during the operation.
1523544|NCT02790099|Drug|Morphine|0.1mg preservative free morphine will be injected intrathecally by anaesthesiologist at the time of spinal anaesthesia.
1523545|NCT02790073|Drug|SNF472|SNF472 for calciphylaxis
1523546|NCT02790047|Device|A non-re-breathing face mask with conical-PEP device|Participant will use a non-re-breathing face mask with conical-PEP device during an interval endurance spot marching exercise.
1523547|NCT02790047|Other|A home-base exercise program|"Duration of the program is 8 weeks A frequency of exercise session is 3 to 5 sessions per week A content of each exercise session includes
Stretching exercise (shoulder, trunk and leg muscles) to warm up for 5 to 10 minutes
Interval endurance exercise using a spot marching movement for 30 to 40 minutes. In each phase of spot marching exercise, patients will perform the exercise from 0 to 3 or 4 score of 10 score of a modified dyspnea Borg scale, they will record exercise the exercise duration time. Then, they will be required to rest until a modified dyspnea Borg scale < 1 score. Next, they will perform the next interval of spot marching exercise with the same protocol.
Stretching exercise (shoulder, trunk and leg muscles) to cool down for 5 to 10 minutes"
1523548|NCT02790047|Other|Health education|"Health education include
Knowledge of COPD disease
Smoking status and smoking cessation
Medication correctly
Self dyspnea management
Basic nutrition for COPD"
1523549|NCT02790047|Other|ฺBreathing strategies for self secretion clearance|"Using a modified active cycle breathing technique (mACBT) include
Control breathing
Pursed lip breathing (PLB)
Slow inhale with sustain thoracic expansion for 3 sec and exhale with PLB technique
Force expiratory technique (FET) with low to medium lung volume
Huffing or coughing"
1523550|NCT02790047|Drug|The medication following the COPD GOLD guidelines (2015)|"Patients will receive medications following the COPD GOLD guidelines (2015). The medication names were listed below
Bata 2 agonist (short acting); Salbutamol (oral or inhaler), Terbutaline (oral)
Bata 2 agonist (long acting); Bambuterol (oral), Procaterol (oral), Salmeterol (inhaler), Formoterol (inhaler)
Xanthine derivative (sustained release theophylline)
Anticholinergic; Tiotropium(inhaler), Ipratropium bromide (inhaler)
Corticosteroids; Beclomethasone (inhaler), Budesonide(inhaler), Fluticasone(inhaler)
Combined anticholinergic+ Beta 2-agonist; Ipratropium+fenoterol (inhaler), Ipratropium+salbutamol (inhaler)
Combined Beta 2-agonist+ corticosteroids; Formoterol+ Budesonide(inhaler), Salmeterol+ Fluticasone(inhaler)"
1996490|NCT02466724|Device|Aiddly (Web Site)|A website designed to better educate patients on how to prepare for their colonoscopies
1523553|NCT02790021|Procedure|Lymphaticovenous anastomosis (LVA)|LVA is a minimally invasive procedure that can be performed under local anesthesia. Indocyanine green (ICG) lymphography is used to visualize the (obstructed) lymphatic vessels. When using the images as a guide, the lymphatic pathways and the sites for incisions for lymphaticovenous anastomoses are marked with a pen. The patient's limb is then prepared for surgery. Under a surgical microscope the lymphatic vessels are identified and viable lymphatic vessels are anastomosed to similarly sized adjacent recipient venules in the subdermal plane.
1523554|NCT02789995|Procedure|Human biological samples|Blood sample - Muscle biopsy - Bone marrow sample (mesenchymal stem cells)
1523555|NCT02789982|Drug|β-adrenergic blocker propranolol|
1523556|NCT02789982|Behavioral|Treatment as usual|
1523557|NCT02789969|Drug|Hydromorphone|Hydromorphone 15mcg/kg IV
1523558|NCT02789969|Drug|Fentanyl|Fentanyl 1.5mcg/kg IV
1523559|NCT02789956|Device|Internal vs. external cad cam co/cr framework|
1523560|NCT02789943|Procedure|Cardiac Bypass Surgery|elective cardiac bypass surgery during which a sample of right atrial appendage and/ or aortic button can be removed
1523561|NCT02789930|Other|"Device: Accuracy of a program and the anesthesia tape (Anästhesie-Lineal)"|Computer based comparison of the two devices based on collected patient data
1523562|NCT02789917|Other|Dual Therapy|Combination of Apixaban 5mg/dl (or in reduced dosing of 2.5 mg/d depending on age, renal function and body weight) in combination with Clopidogrel 75 mg/d for 6 months.
1523563|NCT02789917|Other|Triple Therapy|"HAS-BLED-Score <3:
Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 6 months.
HAS-BLED-Score ≥ 3:
Combination of Phrenprocoumon (INR 2.0-2.5), Clopidogrel (75mg/d) and ASA (100 mg/d) for 1 month followed by Phrenprocoumon (INR 2.0-3.0) and Clopidogrel (75mg/d) for 5 months."
1523564|NCT02789904|Other|blood taking|Blood taking will be done for chest pain patients presenting with chest pain at 0, 1 and 2 hour
1523565|NCT02789891|Procedure|D2 lymphadenectomy including No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal with D2 lymphadenectomy including No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
1523566|NCT02789891|Procedure|lymphadenectomy excluding No. 14v|After exclusion of T4b, or distant metastasis case by diagnostic laparoscopy, Laparoscopic distal gastrectomy with D2 lymphadenectomy excluding No. 14v Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience
1523567|NCT02789878|Drug|Goserelin|Androgen Deprivation Therapy
1523568|NCT02789878|Drug|Prednisone|Corticosteroid
1523569|NCT02789878|Drug|Abiraterone|CYP17 inhibitor
1523570|NCT02789878|Drug|Apalutamide|Androgen-receptor antagonist
1523571|NCT02789865|Drug|Ertapenem, Levofloxacin and Metronidazole|The patients will be treated with intravenous broad-spectrum antibiotics (Ertapenem 1g/d) for 3 days and oral antibiotics (Levofloxacin 500mg once daily and Metronidazole 500mg 3 times per day) for 7 days. If patients in the antibiotic group deteriorate during the hospital stay (suspicious perforation or any symptoms of peritonitis) patients will be operated.
1523572|NCT02789865|Procedure|Endoscopic retrograde appendicitis therapy (ERAT)|The procedures of ERAT will be performed as below：1.Cannulation of the appendiceal lumen. 2.Endoscopic retrograde appendicography (ERA). 3.Irrigation and appendicolith removal. 4.Stenting for drainage.
1523573|NCT02789865|Procedure|Appendectomy|The patients will receive laparoscopic appendectomy according to standard routines.
1523574|NCT02789852|Device|Orthosis|use orthosis
1523575|NCT02789839|Procedure|Blood test|Blood test of 30mL
1523576|NCT02789839|Procedure|Medullar test|Medullar test for 2-5mL and a smear
1523577|NCT02789826|Procedure|Laparoscopic gastrectomy|Patients allocated to the 'laparoscopic gastrectomy' arm will receive gastrectomy via laparoscopy.
1523578|NCT02789826|Procedure|Open gastrectomy|patients allocated to the 'Open gastrectomy' group will receive gastrectomy via laparotomy
1996491|NCT02466269|Procedure|The supratemporalis approach|The supratemporalis approach was applied in treatment of diacapitular condylar fractures
1523583|NCT02789800|Behavioral|DIMAC02|Integrated Approach For Chronic Diseases (DIMAC02) is an integrated approach for chronic disease prevention and management services that aims to improve and coordinate different regional initiatives in 11 Family Medicine Groups related to : Self-management, Case management, Patient-centred care for persons with multimorbidity, Motivational approach, Interprofessional collaboration. DIMAC 02 specific objectives are: 1) To make available, in FMG's, an interdisciplinary educational intervention for prevention and management of chronic diseases for patients with low and high risk for complication. 2) To Increase the flow of communications between FMG and hospital facilities to improve continuity of care.
1523584|NCT02789787|Procedure|Maxillary Protraction|"Maxillary protraction is an alternative non-surgical approach to correct the Cl III malocclusion. At ages 11- 14, the maxillary sutures have not fused and can be mobilized by alternating weekly expansion and constriction with a rapid palatal expander (RPE), thereby allowing the maxilla to be protracted in order to correct the underbite. This treatment is offered to the patients, age 11-14, who have the Cl III malocclusion with or without cleft lip and palate."
1523585|NCT02789787|Procedure|Orthognathic Surgery|The orthognathic surgery is the current standard of care for treating the Cl III malocclusion after pubertal growth. This treatment is offered to the patients, after pubertal growth, who have the Cl III malocclusion with or without cleft lip and palate.
1523588|NCT02789761|Dietary Supplement|High-flavanol milk choocolate|
1523589|NCT02789761|Dietary Supplement|Low-flavanol milk chocolate|
1523590|NCT02789748|Device|Kinesthetic stimulation|Activation of mechanoreceptors by vibration bursts
1523591|NCT02789735|Device|Active laser therapy|Laser therapy at predetermined sites
1523592|NCT02789735|Device|Sham laser therapy|Sham therapy at predetermined sites
1523593|NCT02789722|Other|Yerba Mate Extract|Yerba Mate extract capsules 750 mg
1523594|NCT02789722|Other|Placebo|Take 3 capsules, 3 times daily for 28 days.
1523595|NCT02789709|Procedure|Surgery|Segmental resection for colon cancer and anterior resection in patients with rectal cancer
1523596|NCT02789696|Other|Diagnosis of acromegaly|Biological analysis of IGF-1
1523597|NCT02789683|Other|Fine emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
1523598|NCT02789683|Other|Coarse emulsion|Emulsion is made up of distilled water, olive oil and emulsifier. Emulsion will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
1523599|NCT02789683|Other|Control|Beverage is made up of distilled water and olive oil. Beverage will be flavored, sweetened (sucralose) and served in a portion of 300ml and approximately 3 slices of white bread (50g of available carbohydrate). Additional glass of plain water will be provided with every treatment.
1523600|NCT02789670|Other|Blood sample collection|Peripheral blood will be collected in patients at the different time of the study to analyze phenotypic and functional properties of B cells in MS patients and control group
1523601|NCT02789657|Drug|paclitaxel|80 mg/m2 (or nab-paclitaxel 80-100 mg/m2) weekly
1523602|NCT02789657|Drug|Trastuzumab|Either every 3 weeks (8 mg/kg cycle 1 then 6 mg/kg cycles 2-4) or weekly (4 mg/kg week 1 then 2 mg/kg weeks 2-12)
1523603|NCT02789657|Drug|Pertuzumab|every 3 weeks (840 mg cycle 1 then 420 mg cycles 2-4) or weeks 1 and 2 cycle 1 (420 mg each dose) during the first 3-6 weeks of treatment, then 420 mg day 1 of cycles 2-4.
1523604|NCT02789657|Drug|Carboplatin|AUC 2 administered weekly with no planned treatment breaks
1523605|NCT02789657|Procedure|Breast surgery|breast conserving or mastectomy
1523606|NCT02789657|Drug|AC|"doxorubicin and cyclophosphamide (AC) every 2 or 3 weeks for 4 cycles
Dose-dense AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 every 2 weeks x 4 cycles
Standard AC: Doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2 IV day 1 r every 3 weeks x 4 cycles"
1523607|NCT02789644|Drug|Ursodeoxycholic Acid|Day 1: Ursodeoxycholic acid 400mg or 800mg qd Day 2 to 15: Ursodeoxycholic acid 200mg bid
1523608|NCT02789631|Other|assessment|
1523609|NCT02789618|Other|A01|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The gel will be applied in the evening of three consecutive days during the study time period
1523610|NCT02789618|Other|B99|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days. The bonding agent will be professional applied immediately prior to the clinical assessments.
1523611|NCT02789618|Other|M89|Subjects will brush their teeth twice a day using their assigned toothpaste for 56 days.
1523612|NCT02789605|Drug|Bacilor|Patient receiving Lactobacillus rhamnosus Lcr35®, orally taken, 4 times a day, during 3 months. Then all patients will be then followed up for 3 additional months without treatment.
1523613|NCT02789605|Drug|Placebo|Patients of group B will took the placebo similarly at the Lactobacillus rhamnosus Lcr35® orally . All patients will be then followed up for 3 additional months without treatment.
1523614|NCT02789592|Drug|Melatonin PR|For experimental treatment of RBD
1523615|NCT02789592|Drug|Clonazepam|For experimental treatment of RBD
1523616|NCT02789592|Drug|Melatonin PR placebo|Placebo pill manufactured to mask melatonin PR 2mg tablet
1523617|NCT02789592|Drug|Clonazepam placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
1523618|NCT02789579|Drug|levofloxacin|There are 50 patients in the group,each patient receives levofloxacin 0.5g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
1523619|NCT02789579|Drug|Nitrofurantoin|There are 50 patients in the group,each patient receives nitrofurantoin 0.1g, qd, po 7 days before Minimally invasive upper tract lithotomy.All patients in all groups, 30 minutes before surgery, are given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
1523620|NCT02789579|Drug|cefuroxime|There are 150 patients in the group, 30 minutes before surgery, each patient is given preventive medication cefuroxime 1.5g ivgtt, and continue using 1.5g q12h ivgtt until postoperative 48 hours.
1523621|NCT02789566|Drug|Primaquine|Primaquine 30 mg taken after meal in the morning.
1523624|NCT02789527|Drug|Phenotyping|finger-tip blood drop : enzymatic activities assessed by specific single point concentration ratios after oral intake of the Geneva micrococktail made of : CYP1A2: paraxanthine/caffeine CYP2B6: 4-hydroxybupropion/bupropion CYP2C9: 4-hydroxyflurbiprofen/flurbiprofen CYP2C19: 5-hydroxyomeprazole/omeprazole CYP2D6: dextrorphan/dextromethorphan CYP3A4: 1-hydroxymidazolam/midazolam
1523625|NCT02789527|Genetic|Genotyping|DNA sampling from a saliva sample
1523626|NCT02789501|Device|4% citrate lock solution regimen|(CitraFlow™ 4%, MedXL, Montreal, Canada) will be injected in each of the 2 lumens of the tunneled catheters after each dialysis session (2ml/lumen, 3x/week).
1523627|NCT02789501|Device|TauroLock lock solution regimen|After the first two dialysis sessions of the week (before the short intervals) 2 ml of TauroLock™-Hep500 containing 1% (cyclo)-taurolidine, 4% citrate and 500 IU/mL heparin will be injected into each of the two lumens of the tunneled catheter. After the third dialysis of the week, thus before the long interval, 2 ml of TauroLock™-U25.000 which contains 1% (cyclo)-taurolidine, 4% citrate and 25.000 IU urokinase will be applied into each lumen.
1523628|NCT02789488|Dietary Supplement|Fenugreek seeds extract 500 mg|Furocyst one caps BID
1523629|NCT02789475|Drug|Amlodipine|Amlodipine administration
1523630|NCT02789475|Drug|Rosuvastatin|Rosuvastatin administration
1523631|NCT02789462|Procedure|Laser-assisted percutaneous coronary interventions|Chart review and data collection of patients undergoing laser-assisted percutaneous coronary interventions
1523632|NCT02789449|Other|assessment of DLNO and DLCO|
1523633|NCT02789436|Drug|L. reuteri Prodentis® lozenges|Twice daily, for 28 days
1523634|NCT02789436|Other|Placebo lozenges|Twice daily, for 28 days
1523635|NCT02789423|Procedure|Direct Pulp Capping using Dycal and Biodentine|The operative procedure performed as follows: i)Administration of L.A and rubber dam isolation. ii)High-speed carious enamel removal. iii)Dentine mechanical curettage. iv)Manual final dentine curettage using a spoon excavator. v)Hemorrhage control by cotton pellet moistened with 2.5% sodium hypochlorite placed over the exposure for 1-2min. vi)The exposure site would then be dried with sterile cotton pellet.The operator shall apply the pulp capping agent(dycal/Biodentine)according to the manufacturer's instructions.And then another cover of glass ionomer is applied.This would be followed by permanent restoration.
1523636|NCT02789410|Drug|Morphine|Morphine is administered as part of spinal anesthesia for post-operative pain relief.
1523637|NCT02789410|Drug|Hydromorphone|Hydromorphone is administered as part of spinal anesthesia for post-operative pain relief.
1523638|NCT02789397|Drug|Rituximab (RTX) and Azathioprine (AZA)|Rituximab 375 mg/m2/dose IV over 4 hours first dose, IV over 2-3 hours each subsequent dose weekly for 4 weeks at enrollment and again at months 6 and 12 for the active comparator arm Rituximab (RTX) and Azathioprine (AZA).
1523639|NCT02789397|Drug|Placebo Administration|IV placebo will be administered on the same schedule as Rituximab and oral placebo will be administered by mouth daily for 18 months.
1523640|NCT02789384|Other|Procedure/Surgery|"Procedure/Surgery: Newly obtained biopsy if applicable and Blood samples collection.
For each patient:
Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling
Blood samples will be obtained for genetic profiling and assessment of markers.
The classification as CINSARC will be performed for each patient. Patients should be treated by neoadjuvant anthracycline-based chemotherapy. Chemotherapy regimen must contain at least doxorubicin (dose range: 60 -75 mg/m²) and ifosfamide (dose range: 2.5-3g/m²) to be delivered on a 21-days cycle basis up to 6 cycles prior surgery. After neoadjuvant chemotherapy completion, patients will be treated by surgery followed or not by radiotherapy.
All patients should be managed according to the usual medical practices."
1523641|NCT02789371|Procedure|the first pass is made with 5ml suction technique|the first pass is made with 5ml suction technique, then modified wet suction technique / 5ml suction technique/ modified wet suction technique is operated successively.
1523642|NCT02789371|Procedure|the first pass is made with modified wet suction technique|the first pass is made with modified wet suction technique, then 5ml suction technique/ modified wet suction technique/ 5ml suction technique is operated successively.
1523643|NCT02789358|Other|Conventional cryotherapy dosage|Cryotherapy dosage: 180 seconds applications until block of the pulmonary vein plus 1 bonus freezing of 180 seconds
1523644|NCT02789358|Other|Experimental cryotherapy dosage|"cryotherapy dosage: applications time to block of the vein plus 60 seconds long until block of the vein plus 1 bonus freezing of 120 seconds"
1523645|NCT02789358|Device|Arctic Front Advance ST Cryoenergy Balloon Catheter|Electrical isolation of pulmonary veins with Arctic Front Advance cryoballoon
1523646|NCT02789358|Drug|Adenosine triphosphate|12 mg of adenosine triphosphate are administrated intravenously to test dormant conduction in pulmonary veins apparently disconnected
1523647|NCT02789358|Device|nECG platform Nuubo®|30 days electrocardiographic monitoring system to detect atrial fibrillation episodes after ablation
1523651|NCT02789332|Drug|PwO|paclitaxel 80 mg/m² iv weekly in combination with olaparib tablets 100 mg twice daily for 12 weeks (PwO) (65 patients)
1523652|NCT02789332|Drug|PwCb|paclitaxel 80 mg/m² iv weekly in combination with carboplatin AUC 2 iv weekly for 12 weeks (PwCb) (37 patients)
1523653|NCT02789332|Drug|EC|both Arms followed by 4 cycles of epirubicin 90 mg/m² and cyclophosphamide 600 mg/m² (EC) either every 3 or every 2 weeks followed by surgery.
1524700|NCT02781363|Other|CXR|
1523654|NCT02789332|Procedure|Surgery after neoadjuvant Therapy|In both study arms, treatment will be given until surgery, disease progression, unacceptable toxicity, or withdrawal of consent of the patients.
1523655|NCT02789332|Other|Stratification|Hormone-receptor status (HR+ vs HR-) Age < 40 years vs >= 40 years
1523656|NCT02789319|Device|Blood Glucose Meter Systems|
1523657|NCT02789306|Procedure|Epidemiological study on the incidence of peri-implantitis|Clinical and radiographic examination in the routine based protocol
1523658|NCT02789293|Device|EyeOP1 device|Ultrasound Ciliary Plasty (UCP procedure) using Focused Ultrasound
1523659|NCT02789280|Behavioral|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
1523660|NCT02789280|Other|Wait list|will receive the behavioral activation condition after one week of completing baseline assessment.
1523661|NCT02789267|Other|Regular dietary support|Systematic and regular dietary support after radiotherapy
1523662|NCT02789254|Biological|FLYSYN|"Cohort 1:
Patient 1-3: FLYSYN 0.5 mg/m² body surface area (BSA) day 1
Cohort 2:
Patient 4-6: FLYSYN 0.5 mg/m² body surface area (BSA) day 1 FLYSYN 1.0 mg/m² BSA day 2
Cohort 3:
Patient 7-9: FLYSYN 0.5 mg/m² body surface area (BSA) day 1, FLYSYN 4.5 mg/m² BSA day 2
Cohort 4:
Patient 10-12 and 13-28*: FLYSYN 0.5 mg/m² body surface area (BSA) day 1, FLYSYN 14.5** mg/m² BSA day 2 * If the maximum tolerated dose (MTD) is reached in Cohorts 1-3, the respective cohort will be expanded by additional 16 patients for assessment of efficacy.
** The maximum upper limit for calculation of antibody dose is fixed at a body surface of 2.0 m², even if the calculated body surface exceeds this. In this study DLT are defined as the following treatment-related adverse events or laboratory abnormalities, graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03."
1523663|NCT02789241|Biological|Endotoxin|Reference Endotoxin is a purified LPS prepared from Escherichia coli O:113 (US Standard Reference Endotoxin); Clinical Center Reference Endotoxin (CCRE) Lot #94332B1 manufactured and vialed under GMP guidelines by List Biological Labs, Inc., 540 Division St., Campbell, CA 95008, for the Pharmacy Development Service, Clinical Center, National Institutes of Health, Bethesda, MD, USA. The material has been approved by the FDA (Food and Drug Administration) for 'Investigational Use Only'. This specific Lot from List Biological Labs specified for use in this study contains 1 mcg/vial.
1523664|NCT02789241|Other|Placebo|Normal saline will be administered as the control to evaluate the effects on the biomarkers over time and to compare the responses following LPS to those following the control injection of normal saline.
1523666|NCT02789215|Behavioral|Proposed Meal Changes for CACFP: Impact on Child Food Intake and Costs|
1523667|NCT02789202|Other|Silver diamine fluoride|Treatment of initial dental caries lesion in occlusal surface using the silver diamine fluoride.
1523668|NCT02789202|Other|Fluoride Varnish|Treatment of initial dental caries lesion in occlusal surface using the fluoride varnish
1523669|NCT02789189|Drug|nedaplatin and gemcitabine|
1523670|NCT02789176|Other|Surveys|Regarding development, epilepsy, and family impact
1523671|NCT02789176|Other|EEG|
1523672|NCT02789163|Device|Ultrasound|breast ultrasound; hand held and automated volume breast scanner
1523673|NCT02789150|Drug|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 65-70
1523674|NCT02789150|Drug|Norepinephrine (Levophed)|Titrate norepinephrine to MAP 85 or greater
1523675|NCT02789124|Other|Carotid Doppler Measurement in response to passive leg raise|The investigators will measure Carotid Flow time in the semi-recumbent position, then lay the patient flat and do a passive leg raise. The investigators will then meausre Carotid Flow Time at 1 minute, 2 minutes, and 3 minutes. Patients who have 10 % increase in stroke volume on the Flotrac / Vigileo monitor will be considered fluid responders. The investigators will try to identify an optimum % increase of Carotid Flow Time that can predict fluid responsiveness.
1523676|NCT02789111|Drug|Alvimopan|Alviimopan 12 mg twice daily up to 15 doses
1523677|NCT02789111|Drug|Placebo|Placebo twice daily up to 15 doses
1523678|NCT02789098|Other|(15)-O water positron emission tomography and Biomarkers|Coronary endothelial function is assessed using (15)-O water positron emission tomography and cold pressor test . The response to the test is defined by the percentage increase myocardial blood flow . Assessment of fibrosis, inflammation an endothelial function is performed using biomarkers.
1523679|NCT02789085|Device|ULF TENS stimulation|
1523680|NCT02789072|Other|central aortic pressure (measured in mmHg).|"Blood pressure will only be measured during the 0g (microgravity) phase. Seven 5 ml blood sample will be drawn in the aircraft: before the first parabola (1) and after each block of 5 parabola (6).
On ground after flight, a 9th 5 ml blood sample will be drawn and then the mobil-o-graph, the SOMNOtouch NIBP and the intravenous cannula will be removed."
1523681|NCT02789059|Other|muscle oxygenation|Subjects will be invited to perform an isokinetic effort of the knee extensors against an isokinetic dynamometer. During this effort, muscle oxygenation and oxygen consumption will be assessed with a near infrared spectroscopy device and a gas exchange measurement device. Patients affected by Becker muscular dystrophy and healthy controls will be invited to have a muscle biopsy of the vastus lateralis.
1523682|NCT02789046|Procedure|peripheral intravenous catheterization|success or failure intravenous placement on first attempt and factors associated with failed intravenous catheterization
1523683|NCT02789033|Drug|Chitosan|Chitosan chemically is a high-molecular-weight linear polycationic heteropolysaccharide comprising copolymers of 1,4-linked D-glucosamine and N-acetyl-D-glucosamine
1523684|NCT02789033|Drug|Isosorbide dinitrate|Isosorbide dinitrate (ISDN), is an organic nitrate, is a vasodilator with effects on both arteries and veins. The chemical name of ISDN is 1,4:3,6-dianhydro-D-glucitol 2,5-dinitrate
1523685|NCT02789033|Drug|Placebo|placebo
1523686|NCT02789020|Drug|Rasagiline|Rasagiline will be taken for one year at the dose of 1mg a day. and subjects will undergo functional and structural brain imaging to determine if rasagiline is slowing the progression of Parkinson's Disease in the brain.
1523687|NCT02789020|Other|Placebo|A placebo tablet will be taken for one year, once a day, and at the same dose of 1mg. subjects will undergo functional and structural brain imaging to be compared with the group taking the rasagiline intervention.
1523688|NCT02789020|Device|Magnetic Resonance Imaging|This test will be performed at baseline and one year.
1523689|NCT02789020|Device|functional Magnetic Resonance Imaging|This test will be performed at baseline and one year.
1523690|NCT02789020|Other|Physical Function Performance Test|This test will be performed at baseline and one year.
1523691|NCT02789007|Other|Assess the impact of parabolic flight|"MRI testing will be performed using a 3T MRI facility in Bordeaux close to Novespace (CHU Pellegrin).
Spatial cognition will be assessed using a battery of in-house virtual paradigms General cognitive performance testing will include a wide range of cognitive functions, and particularly executive control using the Cognition Battery Mental status will be assessed on a tablet computer using a visual analogue scale Vigilant attention will be determined using the 3-min Psychomotor Vigilance Test (PVT) Blood samples (5 mL per collection) will be collected prior to neuroimaging by venepuncture"
1523692|NCT02788994|Device|Endovis BA2 nail|"The EBA2 intramedullary nailing system is designed for the treatment of lateral proximal femoral fractures, and consists of a standard or medium length nail implantable with the same set of instruments.
The system has been designed to allow:
stable fracture synthesis for fast rehabilitation and early mobilization
an efficient set of instruments (only 11) for a swift, reproducible operating technique (just 7 surgical steps)"
1523693|NCT02788994|Device|Dynamic Hip Screw (DHS)|"The DHS is designed to provide strong and stable internal fixation of a variety of intertrochanteric, subtrochanteric and basilar neck fractures, with minimal soft tissue irritation.
This Dynamic Hip Screw method is currently used and is a one off surgical fixation."
1523694|NCT02788981|Drug|Mifepristone|Patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
1523695|NCT02788981|Other|Placebo|Patients will receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle).
1523696|NCT02788981|Drug|Nab-Paclitaxel|Patients will either receive placebo and nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle) or patients will receive mifepristone 300 mg daily on the day prior to and day of each dose of nab-paclitaxel (100 mg/m2 on days 1, 8 and 15 of each 28 day cycle). Patients will receive mifepristone and nab-paclitaxel, or placebo and nab-paclitaxel. Not all three.
1523697|NCT02788968|Other|MRI|"Conventional reasoning tasks in both  with and without cognitive conflict and realized during an MRI"
1523698|NCT02788955|Behavioral|Dietary counselling|
1523699|NCT02788955|Other|Dietary Protein|
1523700|NCT02788942|Procedure|Removing from Epigastric port|The cholecystectomy material will be removed from epigastric port. This will be experimental group. Port site infection rates will be measured
1523701|NCT02788929|Device|Fitbit Charge HR|Patients randomized to the FitBit group will receive Fitbit Charge HR, a simple, user-friendly, wrist-worn, commercially available device which provides feedback on exercise goal adherence, in combination with the Fitbit mobile platform application.
1523702|NCT02788916|Other|No Intervention|
1523703|NCT02788903|Other|Weight Counseling|This is a natural experiment which will observe the impact of weight counseling by primary care physicians on patient outcomes.
1523707|NCT02788877|Drug|aflibercept|Aflibercept 2mg is injected into the vitreous cavity through the pars plana using 30 gauge needle-attached syringe.
1523708|NCT02788864|Drug|Arterakine (DHA/piperaquine)|"Stage 1: Parasite Clearance
Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days
Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days
Stage 2: Forest trip
• Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
1523709|NCT02788864|Drug|Placebo|"Stage 1: Parasite Clearance
Arterakine (DHA/piperaquine), one tablet contains 40 mg of dihydroartemisinine and 320 mg piperaquine. Weight based regimen: 7 mg/kg dihydroartemisinine; 55 mg/kg piperaquine phosphate) for 3 days
Primaquine (One tablet contains 13.2mg primaquine disphosphate/7.5mg base. Weight based regimen: 0.25mg base/kg) for 14 days
Stage 2: Forest trip
• Placebo (visually matched to Arterakine (DHA/piperaquine) for 3 days prior to forest visit (day -2, -1 and day 0 prior forest visit)"
1523710|NCT02788851|Drug|Methylphenidate compounds and /or Amphetamine compounds and/or Strattera or Guanfacine|Medication is titrated over a 4-week period with stepwise increments each week. Participants and their significant others will complete ADHD symptom scales at baseline and before each medication visit. Participants also complete a side effects scale at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participant will remain on this dose for the remainder of the study. Additionally, once the optimal dose is reached participants will attend 8 weekly educational sessions about ADHD in adulthood.
1523711|NCT02788851|Behavioral|Aerobic Exercise|Participants will attend a structured aerobic exercise class twice a week for 8 weeks. Each class will last 60 minutes.
1523712|NCT02788825|Procedure|Targeted biopsies using Magnetic Resonance Imaging guiding|Prostate biopsies targeted by findings on MRI where findings are classified according to PI-RADS v2.
1523713|NCT02788812|Procedure|Open modified Lichtenstein repair|Open Lichtenstein Hernioplasty
1523714|NCT02788812|Procedure|Laparoscopic TAPP inguinal hernia repair|Laparoscopic TAPP Hernioplasty
1523987|NCT02786732|Biological|140mg Brodalumab|Brodalumab 140mg administered subcutaneously
1523715|NCT02788799|Other|Standard 12-Lead ECG|Conventional record of Standard 12-lead ECG in every patient with suspect of acute coronary syndrome.
1523716|NCT02788799|Other|Posterior ECG Leads|Recording posterior ECG leads (V7, V8 and V9) in addition to standard 12-lead ECG for identifying STEMI involving left cirumflex coronary artery.
1523717|NCT02788786|Drug|Chlorhexidine|non-alcoholic chlorhexidine gluconate antiseptic mouth rinse
1523718|NCT02788786|Drug|Cetylpyridinium chloride|non-alcoholic cetylpyridinium chloride antiseptic mouth rinse
1523719|NCT02788786|Drug|Salt and Water|salt and water mix oral rinse
1523720|NCT02788773|Drug|Durvalumab|
1523721|NCT02788773|Drug|Tremelimumab|
1523722|NCT02788760|Device|Cervical collar (Miami J collar - Össur)|The two groups of patients will similar in every way and will be treated with the same type of cervical collar - the only difference will be the length of treatment
1523723|NCT02788747|Drug|4 mg elamipretide|Subcutaneous injection of 4 mg elamipretide administered once daily for 28 consecutive days
1523724|NCT02788747|Drug|40 mg elamipretide|Subcutaneous injection of 40 mg elamipretide administered once daily for 28 consecutive days
1523725|NCT02788747|Drug|Placebo|Subcutaneous injection of placebo administered once daily for 28 consecutive days
1523726|NCT02788734|Other|Web-based survey|This study protocol consists of one anonymous survey. Each participant can complete only one survey. The survey will take approximately 25 minutes to complete. The survey is designed to identify items that best reflect the symptom severity and functional status in patients with CTS and CMT. A unique link to the survey will be included in an email invitation distributed to all adult CMT or HNPP patients self-registered in the RDCRN INC Contact Registry. Upon clicking the link, the participant will be directed to the IRB-approved online consent form. Upon providing consent, the participant will be directed to the online survey.
1523727|NCT02788721|Drug|GLPG2451 single dose|GLPG2451 oral suspension, single ascending doses, daily
1523728|NCT02788721|Drug|Placebo|Placebo, oral suspension, daily
1523729|NCT02788708|Drug|Lenvatinib Mesylate|Given PO
1523730|NCT02788708|Drug|Paclitaxel|Given IV
1523731|NCT02788708|Other|Pharmacological Study|Correlative studies
1523732|NCT02788682|Genetic|WT+ Diplotype|3 or 4 vitamin D binding protein major alleles
1523733|NCT02788656|Device|Implantable Hemodynamic Monitor|The CardioMEMS device is an implantable pulmonary artery pressure monitor that is FDA-approved for use in patients with symptomatic heart failure and previous heart failure hospitalization. Patients eligible for this study are those with an already implanted CardioMEMS device.
1523734|NCT02788656|Drug|Angiotensin-Converting Enzyme Inhibitor|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction
1523735|NCT02788656|Drug|Angiotensin II Type 1 Receptor Blocker|Conventional, guideline-directed therapy for heart failure and reduced ejection fraction in ACE-inhibitor intolerant patients
1523736|NCT02788656|Drug|sacubitril/valsartan|Angiotensin-neprilysin inhibitor that is now FDA-approved and guideline-directed therapy for patients with symptomatic heart failure and reduced ejection fraction despite treatment with an ACE-inhibitor/Angiotensin-Receptor Blocker
1523737|NCT02788643|Biological|biological fluids (serum, bronchoalveolar lavage and pulmonary aspiration) and bronchial biopsies collection|
1523738|NCT02788630|Behavioral|Sleep hygiene counseling|The mothers of the eligible infants will be visited at home and will be invited to participate at the study. To those who sign the Consent Form (CF) a following visit will be scheduled to within 5 days. Between CF signature and the 5-day visit, the enrolled children will use an actigraph-device in the leg and the mothers will fill out a sleep diary registering the times of the day the child is asleep, awake, napping, and feeding. At the 5-day visit the child allocation in the trial (intervention or control group) will be uncovered and the sleep recommendations will be delivered to mothers in the intervention group. Phone calls on days 6 and 7 and a home visit on day 8 will be paid to support mothers for possible difficulties in implementing the recommendations.
1523739|NCT02788617|Device|Diafert|The Diafert output, the G-CSF concentration in FF, will be recorded but will not be used in patient management.
1523742|NCT02788591|Drug|Proton Pump Inhibitor (PPI) Therapy|Subject will take a proton pump inhibitor (PPI) of their choice (Omeprazole, Esomeprazole, Pantoprazole, or Lansoprazole) 2 times a day for 8 weeks.
1523743|NCT02788591|Drug|Sucralfate|Subject will take Sucralfate 4 times a day for 8 weeks.
1523744|NCT02788552|Drug|Thiamine Hydrochloride|Administered Intravenously in 100ml bag of normal saline (0.9%) infused over 30 mins.
1523745|NCT02788539|Behavioral|Our Whole Lives Website|OWL is a nine-session, web accessible, self-paced curriculum that has interactive components of self-monitoring and social support (online community).
1523746|NCT02788526|Procedure|Adjuvant TACE|1~2 cycles TACE were performed as adjuvant therapy after radical hepatectomy
1523747|NCT02788526|Procedure|Follow-up|Patients received just follow-up to monitor the recurrence of HCC
1523748|NCT02788513|Drug|BI 425809 dose 1|
1523749|NCT02788513|Drug|BI 425809 dose 2|
1523750|NCT02788513|Drug|BI 425809 dose 3|
1523751|NCT02788513|Drug|BI 425809 dose 4|
1523752|NCT02788513|Drug|Placebo|
1523753|NCT02788500|Other|Incidence of sports-related injuries and illnesses|The SRIIP-study is an epidemiological cohort study aimed to prospectively collect self-report data on sports-related injuries and illnesses incidence and risk exposure during training and competition for approximately one year among Swedish para-athletes.
1523756|NCT02788474|Drug|nintedanib|
1523757|NCT02788474|Drug|placebo|
1523758|NCT02788461|Radiation|Chemoradiotherapy|Patients will receive radiotherapy of 60Gy in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
1523759|NCT02788461|Radiation|Chemoradiotherapy with Integrated Boost Dose|Patients will receive an RT integrated boost to tumor subvolumes (max boost dose of 85Gy) in 30 fractions (5x per week) with concurrent cisplatin and etoposide chemotherapy.
1523761|NCT02788435|Behavioral|Absolute Voice Rest|Patients will be instructed to not use their voice and minimize any voice-use activities such as coughing or throat-clearing for a period of 7 days following surgery.
1523762|NCT02788422|Other|Video discharge instructions|Online video containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
1523763|NCT02788422|Other|Standard of Care|One page paper handout containing information on how to manage symptoms of acute otitis media and when to return to a health care professional.
1523764|NCT02788409|Other|Not applicable for study|Provide external perspective on background second primary cancer incidence rates for REASSURE study.
1523765|NCT02788370|Device|a conical positive expiratory pressure device|The CPEP device will be connected to respiratory transducer for generating positive expiratory pressure with therapeutic rang (5 to 20 cm H2O).
1523766|NCT02788370|Other|Constant work load cycling test|"Participants will per form constant work load cycling test until symptom limit with 50 to 60 rpm. The termination criteria include
sever breathlessness (>5 /10 score of modified Borg scale)
leg fatigue (can not maintain speed between 50 to 60 rpm)
Hear rate (HR) >80 % age-predicted maximum HR
Exercise time up to 10 minutes
Other symptom that stated by American thoracic Society(2002)"
1523767|NCT02788357|Drug|Atomoxetine|Subjects will receive a single daily oral dose of 40 mg of atomoxetine. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
1523768|NCT02788357|Drug|Placebo|Subjects will receive a single daily oral dose of placebo. We will administer 2 hours/daily of motor training sixty minutes after drug intake.
1523769|NCT02788344|Other|Daily practice care for patients with suspected of STEMI|N/A: Practice care evaluation in real-life setting
1523770|NCT02788331|Other|No intervention|
1523771|NCT02788318|Other|Brain samples|Collected in patients died
1523772|NCT02788318|Other|Skin samples|Collected in patients died
1523774|NCT02788292|Drug|Acetylcysteine|See arm description
1523775|NCT02788279|Drug|Atezolizumab (MPDL3280A), an Engineered Anti-PDL1 Antibody|Participants will receive atezolizumab IV at 840 mg on Day 1 and Day 15 in a 28-day cycle as a combination therapy or at 1200 mg on Day 1 in a 21-day cycle as a monotherapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
1523776|NCT02788279|Drug|Cobimetinib|Participants will receive cobimetinib 60 mg orally on Days 1 to 21 in a 28-day cycle as a combination therapy until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
1523777|NCT02788279|Drug|Regorafenib|Participants will receive regorafenib 160 mg orally on Days 1 to 21 in a 28-day cycle until disease progression according to RECIST Version 1.1, unacceptable toxicity, death, participant's or physician decision to withdraw, or pregnancy, whichever occurs first.
1523778|NCT02788266|Procedure|connective tissue graft+composite resin|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus composite resin
1523779|NCT02788266|Procedure|connective tissue graft+ glass ionomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus resin modified glass ionomer cement
1523780|NCT02788266|Procedure|connective tissue graft+giomer|treatment of gingival recession associated with cervical lesions with sub epithelial connective tissue graft plus giomer
1523781|NCT02788240|Drug|Peg GCSF|
1523782|NCT02788240|Biological|20% Albumin|
1523783|NCT02788240|Dietary Supplement|Nutrition|
1523784|NCT02788240|Other|Bowel wash|
1523785|NCT02788240|Drug|Terlipressin 1- 4mg,if indicated|
1523786|NCT02788240|Drug|Meropenem or Imepenem, if indicated|
1523787|NCT02788240|Drug|Placebo|
1523788|NCT02788227|Drug|rVSVdeltaG-ZEBOV GP (2X 107 pfu/mL)|The vaccine uses a live replicating vesicular stomatitis virus (VSV) replacing the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Zaire strain of Ebola (rVSVdeltaG-ZEBOV GP also known asV920).
1523794|NCT02788162|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation Number - X71-144)
1523795|NCT02788149|Device|Ultrasound Exam|Ultrasound of Neck will be used to assess the Lateral parapharyngeal wall thickness. Ultrasound of neck with Submental approach will be used to assess tongue base thickness, subcutaneous fat thickness, retropalatal diameter, retroglossal diameter and upper airway length during normal tidal expiration, forced inspiration and muller's maneuver
1523796|NCT02788149|Device|Polysomnography|"Full-night PSG will be performed in the sleep laboratory according to protocol of sleep medicine department after US assessment. Apnea will be defined as the absence of airflow ≥10 sec and hypopnea will be defined as >50% decrease in airflow ≥10 sec associated with reduced arterial oxygen saturation by 4%, or an arousal. These two parameters are collectively defined as apnea-hypopnea index (AHI). An arousal will be recorded if there is a 3-second or longer abrupt shift in electroencephalogram frequency to alpha or theta or above 16 Hz, following at least 10 seconds of sleep, and, if arising in rapid eye movement sleep, there should be a rise in electromyographic tone. An independent technician blinded to the US results will analyze the sleep studies.
Episodes of AHI per hour will be used to diagnose and grade the severity of OSA:
Non-OSA : < 5/hr mild OSA : 5- 14/hr moderate OSA :15-29/hr and severe OSA : ≥30/hr."
1523797|NCT02788136|Drug|human chorionic gonadotropin|At 08 AM of day 0, all subjects underwent to a single intramuscular injection of hCG of 5000 IU
1523798|NCT02788123|Drug|bismuth tripotassium dicitrate|oral
1523799|NCT02788123|Drug|pantoprazole|oral
1523800|NCT02788110|Other|Noninvasive neurally adjusted ventilatory assist (NIV NAVA)|Neurally adjusted ventilatory assist (NAVA) is a mode of ventilation that uses a functional naso/orogastric tube with embedded electrodes which detect diaphragmatic contractions (called the Edi signal). NAVA uses this Edi signal to synchronize ventilator support to the patient's own respiratory efforts and to support these efforts as needed.
1523801|NCT02788110|Other|Nasal intermittent positive pressure ventilation (NIPPV)|"Nasal intermittent positive pressure ventilation (NIPPV) or noninvasive pressure control ventilation (NIV PC) is a mode of ventilation delivering unsynchronized puffs of air or breaths to a baby through nasal cannulae."
1523802|NCT02788097|Procedure|Progesterone supplementation|artificial frozen embryo transfers
1523803|NCT02788071|Dietary Supplement|FMT capsules|25 capsules per day for 12 days
1523804|NCT02788071|Dietary Supplement|FMT placebo|25 capsules per day for 12 days
1523805|NCT02788058|Drug|EGFR-TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
1523806|NCT02788058|Radiation|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
1523811|NCT02788032|Other|EnergieShake oral supplement|The participants will be given EnergieShake® powdered nutritional supplement twice daily during the study period in place of their usual ONS. Participants will take their usual ONS for 2 days followed by an 8 day intervention on EnergieShake®
1523812|NCT02788019|Drug|Ropivacaine|Ropivacaine is routinely used to perform localized blockade prior to surgery to improve management of postoperative pain.
1523813|NCT02788006|Drug|Regorafenib 160 mg|
1523814|NCT02787993|Behavioral|Cognitive Behavioral Mult-Symptom management(CBT)|Learn to manage distress, fatigue, and/or pain via Cognitive Behavioral Multi-Symptom Management(CBT). Four sessions will be conducted each session is approximately one hour.
1523815|NCT02787980|Biological|Additional taking blood|Additional blood collection of 1 ml during the biological workup usually done.
1523816|NCT02787967|Drug|CHF 1535 35/4µg NEXThaler®|4 (four) inhalations (total dose: BDP/FF 140/16 µg)
1523817|NCT02787967|Drug|free comb. beclomethasone DPI and formoterol DPI|2 (two) inhalations BDP 100 µg DPI + 4 (four) inhalations FF 6 µg DPI (total dose: BDP 200 µg + FF 24 µg
1523818|NCT02787954|Procedure|TACE|Procedure for giving chemotherapy directly to tumor cells.
1523819|NCT02787954|Procedure|Y-90|Using a combination of radiation and chemotherapy directly on the tumor cells to cause cell death.
1523820|NCT02787954|Procedure|MWA|Using heat to kill tumor cells.
1523821|NCT02787954|Procedure|IRE|Using energy to disrupt tumor cell activity, thereby causing cellular death.
1523822|NCT02787941|Behavioral|Pharmacist-delivered multifaceted intervention|"First counselling: A pharmacist performs a 30-minute in-person counselling within 1 week before discharge including: (1) assessment and giving advice on basic knowledge of acute coronary syndrome: definition, risk factors, possible cardiac events, and prevention; (2) assessment of past experiences of using medications, encouragement and tailored advice; (3) providing support with pill organiser and drug information leaflet; (4) teaching back and correcting misunderstanding.
Second counselling: A pharmacist performs a 30-minute telephone counselling within 1 week after discharge including: (1) assessment of general and medication-related issues patients concerning; (2) encouragement and tailored advice; (3) teaching back and correcting misunderstanding."
1523823|NCT02787928|Drug|Intrathecal hydromorphone|Intrathecal hydromorphone will be administered in an up/down dosage fashion. A successful dose will be defined as a patient not requiring additional narcotic pain medication outside of the standard VCU order set, which includes PRN oxycodone 5 and 10 mg every 4 hours and a one time PRN 1 mg hydromorphone IV. Failure of a dose will be if patient requires additional narcotic pain medication outside of these parameters
1523824|NCT02787915|Biological|DC1-CTL|Autologous cytotoxic of T lymphocytes (CTL) were induced by type-1 polarized dendritic cells (DC1) loaded with MAGE-3/MAGE-4/survivin/ her2 /COX-2 CTL epitope peptides .
1523825|NCT02787902|Behavioral|Communication|Behavioral weight management program adapted for mother-daughter dyads with communication skills training
1523826|NCT02787902|Behavioral|Standard|Behavioral weight management program adapted for mother-daughter dyads without communication skills training
1523827|NCT02787889|Other|Uneven Protein intake pattern|Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)] on net protein synthesis over 8 weeks.
1523828|NCT02787889|Other|Even Protein Intake Pattern|Each participant will consume 33% of total protein consumed each meal
1523829|NCT02787876|Drug|Pegteograstim|
1523830|NCT02787863|Biological|Prevenar 13|Conjugate 13 serotype pneumococcal vaccine
1523831|NCT02787863|Biological|Immunovac|Vaccine against Staphylococcus aureus, Klebsiella pneumoniae, Proteus vulgaris, Escherichia coli.
1523832|NCT02787863|Drug|Polioxidonium|Polioxidonium. Immunomodulatory drug. Increases the body's resistance against local and generalized infections. The basis of the mechanism of immunomodulating effect of Polyoxidonium is a direct impact on faguoqitirute cells and natural killer cells, and stimulation of antibody production. Active ingredient: anoxemia bromide (polyoxidonium).
1523833|NCT02787863|Biological|Pneumo-23|Polysaccharide 23-valent pneumococcal vaccine.
1523834|NCT02787850|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
1523835|NCT02787837|Drug|Abiraterone|Treatment with Abiraterone 250 mg/d oral
1523836|NCT02787824|Drug|Iron Sucrose Supplement|
1523837|NCT02787811|Device|Intrauterine insemenation|Semen preparation processing hen intrauterine transfer after 24 hours of HCG triggering of ovulation
1523842|NCT02787772|Procedure|Elective Hernia repair|abdominal wall hernia repair using onlay mesh.
1523843|NCT02787759|Other|Hands-Free Walking|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything
1523844|NCT02787759|Other|Challenge Based plus Hands-Free'|Walking on a treadmill at 60-80% maximum heart rate without holding onto anything under 9 different challenging conditions
1523845|NCT02787746|Drug|Donepezil|Patients is treated with Aricept® 5 mg/day for 4 weeks, and then titrated to 10 mg/day for the remaining 20 weeks of study period. Aricept® should be taken in the evening, just prior to retiring. If patients cannot endure 10mg/d，reduce to 5mg/d or stop for 2 weeks then increase again to 10mg/d. Those cannot endure the titration of 2nd time should be regarded as to abandon research.
1523846|NCT02787733|Dietary Supplement|Citrus flavonoid|Daily dose of 500mg divided over two capsules
1523847|NCT02787733|Dietary Supplement|Placebo|Daily dose of 500mg divided over two capsules
1523848|NCT02787720|Other|Family centered empowerment model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Perceived threat, Problem solving, Educational partnership, and Evaluation
1523849|NCT02787720|Other|Continuous care model|The intervention was conducting Family-Centered Empowerment Model. The intervention package had three steps including pre intervention, during intervention and post intervention. The model has four stages including Orientation, Sensitization, Control, and Evaluation
1523852|NCT02787694|Other|Factor Targeted Walking Training|Individuals walk on a treadmill for 30 minutes while exposed to either endurance, balance, challenge, strength, or speed focused approaches
1523853|NCT02787694|Device|treadmill|
1523854|NCT02787681|Device|NEMO Gauge|Measurement and adjustment of endotracheal tube position by stylet.
1523855|NCT02787668|Other|Carbohydrate-restricted diet|Participants will be randomized (20 per group) to the carbohydrate restricted diet (i.e., CHO <10%; fat >65%, protein 25%) or a low fat diet (CHO 55%; fat 20%; protein 25%) for 8 weeks. Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
1523856|NCT02787668|Other|Control, low-fat diet|Individual counseling with the study physician and registered dietitian (RD) will be provided at baseline for initial assessment and diet instruction. Participants will meet with a RD for an individual counselling session at week 2, 4, and 6 of the diet intervention to ensure adherence to the diet prescription. Participants will be encouraged to keep track of dietary intake by using electronic food diaries (weeks 1-8) to review with the RD during individual counseling at week 2, week 4 and week 6.
1523859|NCT02787642|Drug|Olaparib|Olaparib will be administered per os bidaily, as appropriate assigned dose level, during 7.5 weeks (D1 to D52). Olaparib should be started one week before the start of radiotherapy and will be continued until the last day of radiotherapy. Beyond this period, Olaparib could be continued at the investigator's discretion and after sponsor authorization, until progression.
1523860|NCT02787642|Radiation|Concomitant Radiotherapy|Radiotherapy consists of fractionated focal irradiation at a dose of 1.8 Grays (Gy) per fraction given once daily five days per week (Monday through Friday) over a period of 6.5 weeks, for a total dose of 59.4 Gy. Radiotherapy starts at D8.
1523861|NCT02787629|Procedure|Simultaneous Intubation|Intubation with GlideScope and ETT inserted simultaneously
1523862|NCT02787629|Procedure|Standard Intubation|Intubation with GlideScope inserted first and ETT insertion after the GlideScope view is obtained
1523863|NCT02787616|Genetic|buccal swab|cheek swab for DNA sampling
1523988|NCT02786732|Biological|Ustekinumab|Ustekinumab 45mg or 90mg adminstered subcutaneously
1523989|NCT02786732|Biological|Placebo|Placebo administered subcutaneously
1523864|NCT02787603|Other|Interruption of antibiotic treatment due to PCT measurement|In group A at day 5, if the patient shows no clinical signs of infection and PCT levels < 0,25ng/mL OR PCT > 0,25 ng/mL AND 80% reduction in comparison with day 0 PCT levels, antibiotic will be interrupted. If there is a constant level or decrease less than 80% when compared day 0 or 5, there is no change in antibiotic treatment.
1523867|NCT02787577|Behavioral|Sleep Lengthening|Behaviour change techniques targeting sleep hygiene
1523878|NCT02787538|Behavioral|US-ANSWER-2 decision aid|US-ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
1523879|NCT02787538|Behavioral|Control group (Online medication guide)|Standard online medication guide.
1523880|NCT02787525|Other|Questionnaire|"A clinical sweep follow up will be performed in all patients of both groups and results will be analyzed. It will be in form of a standardized questionnaire and if necessary telephone interviews asking about thrombo-embolic events, stroke, death, any bleeding but also on their current medication, comorbidities (i.e. arterial hypertension, diabetes mellitus, renal impairment and liver disease), any hospitalizations and their quality of life. For all events, the source documents will be gathered from general physicians, cardiologists, hospitals or registry offices.
The questionnaire will be sent by mail to the patients. If information is missing or unclear, patients and if necessary their treating physician will be contacted by phone."
1523881|NCT02787512|Device|Stent|Endoscopic biliary stent insertion
1523882|NCT02787499|Procedure|HIV-1 RNA Resistance Testing|Perform drug resistance on enrollment to guide management of virologic failure
1523883|NCT02787486|Other|Blood sampling for Laboratory Developed Test (LDT) analysis|Each enrolled subject, either in the first or second trimester, will donate up to 50 mL (just over 3 tablespoons) of whole blood for development of the LDT
1523884|NCT02787473|Drug|pemetrexed|Pemetrexed 500mg/m2 IV on day 1 every 4 weeks for 2 cycles
1523885|NCT02787473|Drug|cisplatin|Cisplatin 25mg/m2 IV on day 1-3 every 4 weeks for 2 cycles
1523886|NCT02787473|Radiation|thoracic radiation therapy|Chemoradiotherapy, radiation 60Gy with 2 cycles of pemetrexed+ carboplatin/cisplatin
1523887|NCT02787473|Drug|docetaxel|Docetaxel 60 mg/m2 IV on day 57 every 3 weeks for 2 cycles
1523888|NCT02787460|Behavioral|Behavioral Text Messages|
1523889|NCT02787447|Drug|TKI|Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
1523890|NCT02787447|Radiation|Thoracic Hypofractionated Radiotherapy|40-45 Gy/5-15f
1523891|NCT02787447|Drug|Thymosin Alpha 1|Initiating thymosin alpha 1 therapy(1.6mg, qd, d1-d14;1.6mg, biw, d15-d90) at the second week of radiotherapy.
1523892|NCT02787434|Other|Prostate Cancer Screening Decision Aid|All patients recruited to the study will receive the PCSPrep decision aid. There is only 'study arm.' The Clinical Research Coordinator (CRC) will provide the patient with an iPad to complete the pre-test, PCSPrep and post-test. Individuals will see the survey questions on screen and will hear accompanying audio through headsets. Participants will: (1) be introduced to PCSPrep and the menu of activities/topics; (2) enter information about themselves for personal tailoring (e.g., risk factors); (3) participate in a values-clarification exercise to rate the personal importance of varied courses of action (i.e., pros/cons of PCS); (4) receive a printout with an individualized plan for discussing PCS with their primary care provider.
1523893|NCT02787421|Device|Breathe-Rite Nasal Dilator Strip|During the pre-operative clinic visit, participants will be given a Breathe-Rite Nasal Dilator Strip
1523894|NCT02787408|Device|EW Tricuspid Transcatheter Repair System|Treatment with the EW Tricuspid Transcatheter Repair System
1523895|NCT02787395|Procedure|shoulder dislocation self reduction|shoulder dislocation self reduction using one of three methods in the study
1523896|NCT02787382|Device|echocardiographic examination|"Patients will undergo echocardiography (us) starting at the time of the first referral and every 3-4 weeks until delivery and at the 2-7th day birth. Cardiac scans of fifty pregnant women the healthy women from the group will serve as controls at the 2-7th day birth. Cardiac scans of fifty pregnant women and the healthy women from the group will serve as controls
EXPECTED RESULTS Subtle myocardial deformation abnormalities are expected to be commonly found in fetuses and infants with CMV infection."
1523897|NCT02787369|Drug|ACY-1215|
1523898|NCT02787369|Drug|Ibrutinib|
1523899|NCT02787369|Drug|Idelalisib|
1523990|NCT02786719|Drug|Topotecan|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
1523991|NCT02786719|Drug|Cyclophosphamide|CYCLE 1+2 (given by intravenous catheter daily for 5 days)
1523904|NCT02787317|Drug|bivalirudin|Bivalirudin is an alternative to heparin in patients undergoing percutaneous coronary intervention.
1523905|NCT02787317|Drug|Heparin|Heparin is used in patients undergoing percutaneous coronary intervention.
1523906|NCT02787304|Drug|SHP626|5 mg, 10 mg, and 20 mg of SHP626 capsule by orally once daily in a double-blinded fashion
1523907|NCT02787304|Drug|Placebo|Matching placebo
1523908|NCT02787291|Device|Ellipse VR ICD and Durata/Optisure lead|Non-diagnostic MRI Scan sequence of head and chest
1523909|NCT02787278|Drug|SP-8203 High dose|High-dose group: 160mg will be intravenously administered as 80mg/dose twice daily (intervals of 12 hours).
1523910|NCT02787278|Drug|SP-8203 Low dose|Low dose group: 80mg will be intravenously administered as 40mg/dose twice daily (intervals of 12 hours).
1523911|NCT02787278|Drug|Placebo|Same dosage of SP8203. Placebo will be intravenously administered twice daily (intervals of 12 hours)
1523913|NCT02787252|Device|Implant procedure, Freedom Spinal Cord Stimulation System|A needle is carefully inserted near the spinal cord. The stimulator is then slide through the needle to lay close to the spinal cord. The end of the stimulator is then sutured underneath the skin of the back.
1523914|NCT02787239|Drug|HLX01|
1523915|NCT02787239|Drug|Rituximab|
1523916|NCT02787239|Drug|CHOP|
1523917|NCT02787226|Drug|Liposomal Bupivacaine Infiltration|Surgical wound infiltration of 266 mg of 1.3% liposomal bupivacaine suspension.
1523918|NCT02787226|Drug|Continuous Perineural Ropivicaine Infusion|Indwelling interscalene catheter with a continuous infusion of 6ml per hour of 0.2% ropivacaine.
1523921|NCT02787174|Other|Asthma Medication Adherence Education|
1523922|NCT02787161|Device|Hemodiafiltration|High volume online HDF
1523923|NCT02787161|Device|Hemodialysis|High-flux HD
1523924|NCT02787148|Behavioral|Cognitive behavioral therapy|
1523925|NCT02787135|Behavioral|emotion-oriented Cognitive Behavior Therapy|Emotion-oriented Cognitive Behavior Therapy with a focus on delusions: Aim of the intervention is to change factors that are involved in the formation and maintenance of delusions: emotional stability and regulation of negative emotions, sleep quality and self-esteem.
1523926|NCT02787122|Behavioral|CBT-E|Patients receive 25 sessions of individual emotion-focused Cognitive Behavior Therapy based on a manual. Interventions aim on patients' mood by implementing positive activities in their daily routine. Further, patients train to reduce worrying behavior. Social contacts are fostered as well. Later, patients are informed on emotions and train emotion regulation strategies. Finally, the focus of CBT-E is on self-acceptance.Patients receive psychoeducation on self-acceptance and learn strategies in order to reduce negative self-schema and foster positive self-schema.
1523927|NCT02787122|Behavioral|Treatment as Usual|Patients receive standardized treatment. After a waiting period of six month, patients receive CBT-E
1523928|NCT02787109|Biological|CTH522-CAF01|CTH522 chlamydia antigen adjuvanted with CAF01 for IM administration
1523929|NCT02787109|Biological|CTH522-Al(OH)3|CTH522 chlamydia antigen adjuvanted with aluminium hydroxide, Al(OH)3 , for IM administration
1523930|NCT02787109|Biological|Placebo|Saline
1523931|NCT02787096|Device|LaxIRM|Dynamic knee laxity measurement coupled to MRI for the diagnosis of ACL tear
1523932|NCT02787083|Drug|Mirabegron|
1523933|NCT02787083|Drug|Placebo|
1523934|NCT02787070|Drug|PQ supervised|
1523935|NCT02787070|Drug|PQ unsupervised|
1523936|NCT02787057|Drug|vancomycin|IP vancomycin 1g every 5 days
1523937|NCT02787057|Drug|moxifloxacin|oral moxifloxacin 400mg QD
1523938|NCT02787057|Drug|ceftazidime|IP ceftazidime 1g QD
1523939|NCT02787044|Biological|High Dose Trivalent Influenza Vaccine|High Dose Trivalent Influenza Vaccine
1523940|NCT02787044|Biological|Standard Dose Quadrivalent Influenza Vaccine|Standard Dose Quadrivalent Influenza Vaccine
1523941|NCT02787031|Procedure|Neuraxial anesthesia|
1523942|NCT02787031|Procedure|General anesthesia|
1523943|NCT02787018|Drug|Ropivacaine and Normal saline|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 1 ml normal saline
1523944|NCT02787018|Drug|Ropivacaine and Dexamethasone|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 4mg (1ml) dexamethasone
1523945|NCT02787018|Drug|Ropivacaine and Dexmedetomidine|Supraclavicular brachial plexus block will be given with 0.5% ropivacaine with 50 mcg (1ml) dexmedetomidine
1523948|NCT02786992|Drug|Misoprostol|
1523949|NCT02786992|Drug|Oxytocin|
1523950|NCT02786992|Drug|Carbetocin|
1523951|NCT02786992|Drug|Placebo|
1523952|NCT02786979|Drug|Beraprost|Oral
1523953|NCT02786979|Drug|Aspirin|Oral
1523954|NCT02786966|Other|Canadian C-Spine Rule|Paramedic assessment for potential cervical spine injuries using the Canadian C-Spine Rule
1523956|NCT02786940|Device|Cardiophone|Remote live monitoring for 15 days for detection or exclusion of arrhythmias
1523992|NCT02786719|Drug|Cisplatin|Cycle 3+5 (given daily x 4 days)
1523961|NCT02786901|Drug|LE Gel dosed TID|Gel
1523962|NCT02786901|Drug|LE Gel dosed BID|Gel
1523963|NCT02786901|Drug|Vehicle Gel dosed TID|Gel
1523964|NCT02786901|Drug|Vehicle Gel dosed BID|Gel
1523971|NCT02786862|Other|independent ventilation|comparison conventional and independent 1:1 ventilation
1523972|NCT02786849|Other|neuromuscular electrical stimulation of high frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.
Will be applied using portable stimulators with 4 channels. The parameters are: frequency of 50 Hz, pulse width 400ms, rise time and 2s descent, stimulus mode on-off starting with a ratio of 1: 2 in the first week (stimulus time of 10 seconds and rest time of 20s, aiming at adaptation and mitigation of the effects of muscle fatigue), evolving from the second week to a ratio of 1:1 (stimulation time of 10 seconds and rest time of 10s).
The current intensity is adjusted individually for the first application and gradually increased as the tolerance of patients.
In each session there will be a warm-up period, training and slowdown. The intensity will be the maximum tolerated by the patient in order increments every session, this being monitored for further evolutionary calculating."
1523973|NCT02786849|Other|neuromuscular electrical stimulation of low frequency and intensity|"Training with neuromuscular electrical stimulation isometric form in lateral and medial bilaterally vast, three times a week, lasting an hour, the first two hours of dialysis.
Will be applied using portable stimulators with 4 channels. The parameters are: 5 Hz frequency, time on: off 1: 3 with a pulse duration of 100ms.
The current intensity is adjusted individually for the first application and it was the least noticeable by the patient.
In each session there will be a warm-up period, training and slowdown."
1523974|NCT02786836|Drug|13C-methacetin|"The test substrate in this study, ¹³C-methacetanilide solution for single-use oral administration (75 mg in 150 ml purified water), is administered orally or via feeding tube, rapidly absorbed, exclusively metabolized by hepatic mixed function oxidase via O-demethylation, mainly by cytochrome P450 enzyme, subtype 1A2, into acetaminophen and formaldehyde. The formaldehyde is then transformed through two successive oxidative steps to ¹³carbon dioxide, the quantity of which is measured in exhaled breath as a ratio of 13C to 12C.
The nasal breath sampling ID circuit continuously transports the breath sample from the patient to the BreathID® MCS device before and following administration of the 13C-methylacetanilide test substrate."
1523975|NCT02786823|Dietary Supplement|Folic acid|tab. Folic acid 5 mg
1523976|NCT02786823|Dietary Supplement|Vitamin B12|tab. Vitamin B12 500 mcg
1523977|NCT02786823|Drug|Oral hypoglycemic agents [Metformin +/- Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents
Sulfonylurea
Metformin
Metformin plus Sulfonylurea"
1523981|NCT02786784|Other|6 week exercise treatment|This six-week exercise programme was developed based on the current recommendations, consisting of four exercises to strengthen gluteus medius and maximus muscle, as well as the quadriceps muscle. In addition, two exercises to stretch the hamstrings muscles and to increase the ankle dorsi range of motion were included.
1523982|NCT02786771|Device|Spire|
1523983|NCT02786771|Device|Muse headband|
1996522|NCT02464163|Biological|Panblok|Intramuscular injection
1996523|NCT02464163|Biological|rHA adjuvant|Intramuscular injection
1996524|NCT02464059|Drug|Vitamin D3|The design of the study to complete this aim will be in the format of a baseline and repeat bronchoscopy after oral supplementation with 50,000 IU vitamin D3 weekly for eight weeks in individuals with reduced vitamin D levels.
1996525|NCT02463981|Device|real-time fMRI neurofeedback training running on Turbo Brain voyager (TBV) 3.2 (Brain Innovation, Maastricht, The Netherlands)|
1996526|NCT02462720|Drug|Varithena®|Varithena® treatment in accordance with full prescribing information and instructions for use
1996527|NCT02462720|Device|Radiofrequency ablation|Radiofrequency ablation conducted per physicians' standard of care.
1523995|NCT02786719|Drug|Cyclophosphamide|Cycle 4+6 (given daily for 2 days)
1523996|NCT02786719|Drug|Doxorubicin|Cycle 4+6 (given daily for 3 days)
1523997|NCT02786719|Drug|Sargramostim|Granulocyte macrophage colony stimulating factor (rhu GM-CSF, rGM-CSF, GM-CSF)
1523998|NCT02786706|Device|Optic nerve ultrasound|All patients will undergo Optic Nerve Ultrasound (ONUS), with measurement of Optic Nerve Sheath Diameter (ONSD) by both an expert investigator as well as by the automated image analysis algorithm.
1523999|NCT02786680|Behavioral|stroop test in condition DBS off|Patients were evaluated in DBS Off
1524000|NCT02786680|Behavioral|stroop test in condition DBS on|Patients were evaluated in DBS On
1524003|NCT02786641|Drug|Docetaxel|Docetaxel 65mg/m2 in induction chemotherapy
1524004|NCT02786641|Drug|Cisplatin 1|Cisplatin 75mg/m2 in induction chemotherapy
1524005|NCT02786641|Drug|Xeloda|Xeloda 2000mg/m2 D1-14 in induction chemotherapy
1524006|NCT02786641|Radiation|IMRT|IMRT for all patients
1524007|NCT02786641|Drug|Cisplatin 2|Cisplatin 100mg/m2 in concurrent chemotherapy
1524008|NCT02786628|Other|Physical performance testing and patient-generated health data|All patients will complete cardiopulmonary exercise testing and 6 minute walk distance performance testing prior to a cycle of chemotherapy (or transplant) and wear a Fitbit Charge HR for the duration of one cycle of chemotherapy.
1524009|NCT02786615|Behavioral|Peer Unity|A 4-session, group-delivered intervention focusing on peer/social network-based recruitment and referral program to receive HIV prevention and treatment services in the community.
1524010|NCT02786602|Genetic|pyrosequencing|
1524011|NCT02786589|Biological|Blood-stage infection of P. vivax|Plasmodium immunotherapy: Each patient will be vaccinated with 5-10 mL of P. vivax-infected red blood cells containing approximately 1 × 10^8 Plasmodium parasites. And successful infection will be indicated by microscopic observation of parasitemia in peripheral blood samples. The treatment will last at least 28 days from the day of finding the Plasmodium from peripheral blood and will be terminated by DUO-COTECXIN or chloroquine phosphate plus primaquine phosphate.
1524012|NCT02786550|Drug|Botulinum Toxin|A total of 7.5U per side of botulinum toxin will be injected to the lateral part of obicularis oculis muscle (3 injections of 2.5 U).
1524013|NCT02786550|Other|Normal Saline|The same amount (3 cc) of Normal saline will be injected to the lateral part of obicularis oculis muscle
1524014|NCT02786537|Drug|sofosbuvir/ledipasvir|Sofosbuvir/Ledipasvir (400/90 mg) for approximately 12 to 24 weeks (treatment duration and use of ribavirin is per discretion of HCV provider)
1524015|NCT02786537|Drug|ombitasvir/paritaprevir/ritonavir (Phase 1 only)|(Phase 1 only) Ombitasvir/paritaprevir/ritonavir (12.5/75/50mg) for 12 to 24 weeks (treatment duration and use of ribavirin as per HCV provider)
1524016|NCT02786537|Drug|elbasvir/grazoprevir|Elbasvir/grazoprevir (50/100mg) tablet once daily with or without food with or without RBV for 12 to 16 weeks with or without RBV
1524017|NCT02786537|Drug|Dasabuvir|250 mg daily for 12 to 24 weeks
1524018|NCT02786524|Behavioral|Specialized Symptom Management and Supportive Care|Based on Patients who score 5 or higher on the Baseline Patient Palliative Care Survey that will identify patients that will most benefit from specialty palliative care
1524019|NCT02786511|Drug|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term implications of autologous transplant
1524020|NCT02786498|Drug|Vitamin D3|
1524021|NCT02786498|Other|Placebo|
1524024|NCT02786472|Behavioral|Online Bystander Training|Large groups of 120-150 students will complete Haven training via computer; training lasts duration of the online program.
1524025|NCT02786472|Behavioral|Online Substance Abuse Training|Large groups of 120-150 students will complete EverFi training via computer; training lasts duration of the online program.
1524026|NCT02786472|Behavioral|In-Person Bystander Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
1524027|NCT02786472|Behavioral|In-Person Combination Training|In-person training of large groups of 120-150 students; training lasts 3-4 hours
1524028|NCT02786459|Device|ProxiScan|ProxiScan probe will be coupled with ProstaScint (a radioactive tracer) and used to perform imaging to detect small lesions in the pelvis that will otherwise be hard to detect with conventional imaging modalities.
1524029|NCT02786459|Device|Magnetic Resonance Imaging|Used as a comparative to ProxiScan.
1524030|NCT02786459|Device|SPECT-CT|Used as a comparative to ProxiScan.
1524031|NCT02786446|Drug|Lidocaine gel,|2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
1524032|NCT02786446|Drug|Naproxen Sodium|Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
1524033|NCT02786446|Drug|Lidocaine gel and Naproxen Sodium|Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
1524034|NCT02786433|Other|conventional physiotherapy|
1524035|NCT02786433|Other|Virtual Reality with X- Box Kinect®|
1524036|NCT02786407|Drug|Botulinum Toxin Type A for Injection|In these studies,patients received a minimum intramuscular(IM) dose of 100U of Botulinum Toxin Type A administered to 20 injection sites
1524037|NCT02786407|Drug|Placebo|In these studies,patients received placebo administered to 20 injection sites
1524038|NCT02786394|Behavioral|REACH|REACH is a lifestyle intervention program which aims to reduce sedentary behaviour, increase physical activity, and increase strength and balance. The REACH program is comprised of six sessions which include evidence-based education, behaviour change theory, and activity instruction. REACH also teaches goal setting techniques, mindfulness, and encourages active community engagement. In this study we are running the REACH program for women aged 55 and older alongside a supplementary optional walking program run by SportMedBC.
1524039|NCT02786368|Behavioral|Control group|A comparison group; no intervention for year 1, EHFP after 1 year of program implementation.
1524040|NCT02786368|Behavioral|EHFP group|Intervention group: training; inputs cost-sharing for EHFP activities.
1524042|NCT02786342|Procedure|blood sample collection|
1524043|NCT02786329|Drug|TIVA+lidocaine|Patients will be subjected to total intravenous anesthesia with propofol-fentanyl+i.v. lidocaine infusion for the first 48 h postoperatively
1524044|NCT02786329|Drug|Sevoflurane+lidocaine|Patients will be subjected to anesthesia with sevoflurane- fentanyl + lidocaine infusion for the first 48 h postoperatively.
1524045|NCT02786329|Drug|TIVA+placebo|Patients will be subjected to TIVA with propofol-fentanyl + saline infusion for the first 48 h postoperatively
1524046|NCT02786329|Drug|Sevoflurane+placebo|Patients will be subjected to anesthesia with sevoflurane-fentanyl + saline infusion for the first 48 h postoperatively
1524047|NCT02786316|Other|HIT program|HIT program for the rehabilitation of persons with NSCLBP
1524048|NCT02786316|Other|conventional rehabilitation program|a conventional rehabilitation program in persons with NSCLBP
1524049|NCT02786303|Device|Whole-body diffusion- weighted MRI|
1524050|NCT02786290|Device|Zenflow Spring System|The Zenflow Spring is a nitinol urethral implant for the treatment of Lower Urinary Tract Symptoms (LUTS) that arise due to bladder outlet obstruction (BOO), secondary to the presence of Benign Prostatic Hypertrophy (BPH). The device is intended to be a permanent implant however it may be removed if necessary.
1524051|NCT02786277|Other|Alert|An alert informing the provider of the presence of acute kidney injury will be fired.
1524052|NCT02786264|Drug|Dexmedetomidine|A dexmedetomidine- dominant anesthetic will be defined as an anesthetic that included a continuous infusion of dexmedetomidine within 15 minutes of anesthesia start.
1524053|NCT02786264|Drug|Propofol|A propofol-dominant anesthetic will be defined as an anesthetic that included a continuous infusion of propofol within 15 minutes of anesthesia start.
1524054|NCT02786264|Drug|Fentanyl and/or Midazolam|A fentanyl / midazolam dominant anesthetic will be defined as monitored anesthesia care in the presence of fentanyl or midazolam and in the absence of a propofol or dexmedetomidine infusion.
1524055|NCT02786251|Other|Cold exposure|During cold exposure intervention, we will use an individualized cold exposure protocol above the individual shivering threshold of each participant using liquid condition garments and a temperature controlled room.
1524056|NCT02786251|Other|Exposure to thermoneutral conditions|For the thermoneutral conditions intervention, subjects will be exposed to thermoneutral conditions (~26-28oC).
1524057|NCT02786238|Behavioral|Standard Behavioral Treatment (SBT)|See description of treatment arm.
1524058|NCT02786238|Behavioral|Acceptance-Based Treatment (ABT)|See description of treatment arm. **Cherokee Nation members receive only the ABT intervention as they are in an open, feasibility trial and are not randomized.**
1524059|NCT02786225|Behavioral|Collaborative Care|Intervention Group: Women (n=118) will be seen one time, simultaneously by a VUMC perinatologist and a VUSN nurse-midwife (the CARE visit). During the CARE visit, the nurse-midwife and perinatologist will complete the CARE checklist The checklist will be signed by the woman and providers and scanned into the medical record. Following the CARE visit, women will return to midwifery care or be referred to perinatology depending on their needs, remaining in the study. Women returning to the midwifery practice will see a primary midwife for the remainder of care.
1524060|NCT02786225|Behavioral|Comparison Care- Usual Care + primary midwife|Comparison Group: Usual care enhanced with primary midwife. Women in the comparison group (n=118) will receive the standard individual consult visit with a perinatologist and then, if they return to midwifery care, have one consistent midwife (primary midwife) for the majority of remaining prenatal care.
1524061|NCT02786212|Drug|Dexmedetomidine|
1524062|NCT02786212|Drug|Normal Saline|
1524063|NCT02786160|Dietary Supplement|HMO|
1524064|NCT02786160|Dietary Supplement|Dextropur|
1524069|NCT02786134|Radiation|PET scan|A cardiac PET scan will be performed at baseline (main CIRT trial randomization) and at 12-months.
1524070|NCT02786134|Radiation|Echocardiogram|An echocardiogram will be performed at baseline (main CIRT trial randomization) and at 12-months.
1524071|NCT02786108|Procedure|left gastric artery embolization|
1524072|NCT02786108|Behavioral|healthy diet and exercise|
1524073|NCT02786082|Drug|20mg Azilsartan Tablets|Strength: 20mg, oral administration 1 tablet/ day
1524074|NCT02786082|Drug|40mg Azilsartan Tablets|Strength: 40mg, oral administration 1 tablet/ day
1524075|NCT02786069|Drug|Propionyl L-carnitine Hydrochloride|500mg/ tablet; for oral administration, 1 dosage form is set for this trial: 1g, 2g and 4g.
1524076|NCT02786056|Other|Lung MRI examination|Lung MRI examination is performed for approximately 30 min on a 3T machine (Achieva 3T, Philips) using UTE sequences, both during free breathing with image synchronisation using an echo-navigator, and during an end-inspiratory and end-expiratory pauses. In the 10 first subjects, the MR protocol is optimized in order to maximize MRI parenchymal signal intensity, signal-to-noise ratio and contrast-to-noise ratio. The final image acquisition parameters will be applied in the following 30 subjects in order to assess the outcomes of the study.
1524077|NCT02786043|Drug|Propionyl-L-Carnitine Hydrochloride|1g twice a day on first 4 days and 1g/ day on day 5 during Phase III
1524078|NCT02786030|Behavioral|Outreach education training|Printed copies of the patient management tool (PMT) and outreach education training
1524079|NCT02786030|Behavioral|No outreach education training|Printed copies of the patient management tool (PMT) without outreach education training
1524080|NCT02786017|Biological|Conventional therapy|Patients will receive the conventional therapy.
1524081|NCT02786017|Biological|Injectable Collagen Scaffold + HUC-MSCs|Injectable collagen scaffold combined with HUC-MSCs was injected into left lateral segment, left medial segment, right anterior segment, right posterior segment and caudate lobe under B-mode ultrasound supervision, respectively. The total amount of HUC-MSCs was 5*10^8.
1524082|NCT02786004|Device|Full Field Digital Mammography|
1524083|NCT02786004|Device|Digital Breast Tomosynthesis|
1524084|NCT02785991|Procedure|Balloon cryoablation|pulmonary vein cryoablation for atrial fibrillation
1524090|NCT02785965|Device|electroacupuncture|Disposable, single-use, sterilized stainless-steel needles (Yunlong, Beijing, China; length 40/100 mm, diameter 0.30 mm) are inserted into waist, bilaterally. All of the six points are located in the Dai Meridian route corresponding to the ovaries. Four needles, 0.25mm in diameter and 25mm in length, are also placed in distal acupuncture points which are located in the feet and lower arms to enhance local points' effects. Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into GB26(Daimai) with a depth of 25-65mm by an angle of 15°, following the path of Dai Meridian (towards medial and downside). The other needles are inserted vertically into the acupoints with a depth of 10-30mm, depending on the thickness of muscles. Electro-acupuncture is applied to both sides of GB26 and ST25(Tianshu): cathode is connected to GB26; anode to ST25. Needles are stimulated electrically with low frequency (2 Hz) for 20 min.
1524091|NCT02785965|Behavioral|lifestyle modification|The diet restricts patients to 1400 calories a day for 12 weeks.The exercise included 12 weeks of aerobic exercise in moderate level (60 to 70% of maximum heart rate), for 3 sessions a week, each session for 60 min. The exercises included: Warning up: 10 min, main phase (aerobic exercise): 40 min and cooling down: 10 min. Polar Pulse measuring device from China was used to control the intensity of the exercises.
1524092|NCT02785952|Biological|Ipilimumab|Given IV
1524093|NCT02785952|Other|Laboratory Biomarker Analysis|Correlative studies
1524094|NCT02785952|Biological|Nivolumab|Given IV
1524095|NCT02785939|Other|Laboratory Biomarker Analysis|Correlative studies
1524096|NCT02785939|Drug|Palbociclib|Given PO
1524097|NCT02785913|Other|Laboratory Biomarker Analysis|Correlative studies
1524098|NCT02785913|Drug|Taselisib|Given PO
1524099|NCT02785900|Drug|33A|33A, 10 mcg/kg, every 4 weeks via intravenous (IV) push
1524100|NCT02785900|Drug|placebo|Volume equivalent to 10 mcg/kg, every 4 weeks via IV push
1524101|NCT02785900|Drug|azacitidine|75 mg/m2 given subcutaneously (SC) or IV x 7 days, every 4 weeks
1524102|NCT02785900|Drug|decitabine|20 mg/m2 given IV x 5 days, every 4 weeks
1524103|NCT02785887|Other|Geriatrician review|In addition to routine oncological care, patients will be reviewed by a geriatrician and may receive intervention if CGA deficits are found
1524104|NCT02785874|Drug|Statin|Divide HCC patients into two groups under randomization, one is with Statin and the other is without Statin to verify whether Statin could prolong disease-free survival
1524105|NCT02785861|Behavioral|supervision of physical activity|
1524106|NCT02785861|Behavioral|distance supervised physical activity|
1524107|NCT02785848|Other|Interviews and Surveys|The investigators will perform semi-structured interviews and surveys on this cohort
1524108|NCT02785822|Drug|hMG-HP|Ovarian stimulation with hMG-HP (150 IU / day)
1524109|NCT02785822|Drug|hFSH-HP|Ovarian stimulation with hFSH-HP (150 IU / day)
1524110|NCT02785809|Other|Pausing oral contraceptive|
1524111|NCT02785796|Other|CV4|
1524112|NCT02785796|Other|SHAM TECHNIQUE|
1524113|NCT02785783|Device|Standard colonoscopy|
1524114|NCT02785783|Device|EndoRings™|Colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
1524885|NCT02780115|Drug|AGN-199201 Vehicle|Vehicle to AGN-199201
1524118|NCT02785757|Other|Thrombin Generation Assay|
1524119|NCT02785744|Other|Gaucher disease DNA mutation analysis|
1524120|NCT02785731|Procedure|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
1524121|NCT02785731|Procedure|Blood draw|Within 60 days prior to, or on the day of the pelvic mass surgery, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
1524122|NCT02785731|Procedure|laparotomy or laparoscopy|A laparotomy or laparoscopic procedure will be performed by a qualified individual for excision of the pelvic mass. Representative tissue samples will be taken from the excised pelvic mass and evaluated in pathology departments within each institution according to institutional guidelines. Results from the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
1524123|NCT02785718|Other|Global Haemostasis assays|
1524124|NCT02785705|Biological|poliovirus vaccine|Different vaccination schedules with bOPV, tOPV and cIPV would be provided for 6 arms respectively.
1524125|NCT02785692|Radiation|Radiation|preoperative Radiotherapy/ IMRT
1524126|NCT02785679|Dietary Supplement|cow's milk formula|addition of cow's milk formula in two different dosage - one only 20ml per day and one group a full meal per day
1524129|NCT02785653|Drug|Sevoflurane|Patients were ventilated with 2 % inspired concentration of sevoflurane in a fresh gas flow of 5 litres containing 66.6% nitrous oxide and 33.3% percent of oxygen
1524130|NCT02785653|Drug|Rocuronium|rocuronium 0.6mg per kg body weight was given intravenously after induction of anaesthesia
1524131|NCT02785640|Behavioral|Hourly prompts to stand delivered by Microsoft Outlook|Prompt group
1524132|NCT02785627|Other|Comprehensive bone health assessment|Blood sample taken for biomarkers of bone turnover, anthropometric measurements, assessments of physical function, DXA scan, HR CT T12 vertebra, Xtreme pQCT radius
1524133|NCT02785614|Drug|trazodone hydrochloride prolonged-release tablet|150 mg, oral administration, 1 per day
1524134|NCT02785614|Drug|trazodone hydrochloride tablet|50mg, oral administration 3 times per day
1524135|NCT02785601|Drug|Trazodone Hydrochloride prolonged-release tablets|strength 75mg, 150 mg. Oral administration with 200ml water
1524136|NCT02785588|Device|3.0 T Neonatal MRI scanner|eligible subjects will undergo neonatal MRI scan procedure
1524137|NCT02785575|Other|HeProCalc algorithm|Heparin and protamine dosage calculated by the algorithm HeProCalc
1524138|NCT02785562|Other|Assessment of PDL1 expression|Intervention : 2 biopsy slides will be analyzed in central laboratory.
1524139|NCT02785549|Drug|Ibuprofen|600 mg/8hours
1524140|NCT02785549|Drug|Acetaminophen|1 g/8 hours
1524141|NCT02785549|Drug|Amoxicillin/clavulanic acid|875mg/125mg/8 hours
1524142|NCT02785536|Behavioral|RITCh Treatment|"The RITCh treatment increased the emphasis on stress management, negative affect management and utilized language and activities to foster an internal locus of control. Activities were added to address impulsive decision-making, develop home smoking policies, increase the positive valance of treatment, and address barriers to use of the nicotine patches. The treatment materials were also tailored with numerous examples relevant to lower SES groups and African Americans. For example: stress management components specifically address financial stress, discrimination, and micro-aggressions; treatment utilization components include reinforcing the value of individual contributions to the group, structured positive feedback among group members at every session, sending missed you post cards signed by all group members to participants who miss a treatment session, specifically addressing myths about nicotine patch use, and practicing the application of nicotine patches together."
1524143|NCT02785536|Behavioral|Standard Treatment|The components of the standard treatment include education and activities in which participants gain an understanding of the biopsychosocial underpinnings of tobacco dependence and the cue-urge-response cycle of smoking. Interventions include self-monitoring, guided scheduled rate reduction, treatment goal setting, medication education, stress management, cognitive and behavioral strategies for managing cravings and cues, problem-solving, conflict management, enhancing social support, relapse prevention, and cigarette refusal training. A participant workbook was provided that corresponded to the activities in the treatment sessions.
1524144|NCT02785523|Drug|Ganoderma Spore Lipids|
1524145|NCT02785523|Drug|Placebo|
1524146|NCT02785523|Drug|Chemotherapy|
1524147|NCT02785497|Other|Control group|will be turn on the equipment, positioning the patient but no put intensity
1524148|NCT02785497|Other|Treatment group|This group will receive electrostimulation
1524149|NCT02785484|Other|Label with constituent disclosure message|Labels with constituent disclosure messages that include text about chemicals in cigarette smoke and health effects of the chemicals will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 disclosures selected at random; at the week 3 visit, they will get one of the 2 remaining disclosures selected at random, and at the week 4 visit they will get the remaining disclosure. Study investigators developed the text and design of these labels.
1524150|NCT02785484|Other|Label with litter message|Labels with litter messages that include text about littering cigarette butts will be applied to participants' cigarette packs on the right side (the Surgeon General's warning is on the left side). At the week 2 visit, participants' packs will be labeled with 1 of 3 litter messages selected at random; at the week 3 visit, they will get one of the 2 remaining litter message selected at random, and at the week 4 visit they will get the remaining litter message. Study investigators developed the text and design of these labels.
1524151|NCT02785471|Behavioral|Screening for Mental Health only|Participants in the Screening for Mental Health (SMH)-only group will complete the online depression and suicide screening and receive immediate feedback and referrals.
1524152|NCT02785471|Behavioral|Screening for Mental Health & Man Therapy|"Participants assigned to Screening for Mental Health, plus Man Therapy (SMH+MT) group will be offered the Man Therapy program in conjunction with Screening for Mental Health. MT provides online early intervention services designed specifically for men who are at risk for suicide and are less likely to engage in help-seeking behavior. MT takes an innovative and humorous approach to mental health education and help seeking through a fictional therapist named Dr. Rich Mahogany, who is a no-nonsense man's man who informs men about the importance of honest talk about life's challenges in addressing their problems. The web portal allows review manly mental health information, facts and tips, explore man therapies, and view videos of men with lived experience."
1524153|NCT02785458|Behavioral|EMC2 Strategy|The intervention includes 1) distribution of simplified one-page medication guide summaries, 2) an automated follow-up call to assess medication safety and problematic side effects and 3) summary reports of call to providers with any concerns flagged for clinic follow-up.
1524154|NCT02785445|Device|Dip.io Home Based Dipstick Analyzer|"First intervention (assigned to the All participants arm)."
1524155|NCT02785445|Device|ACON U500 Mission® U500 Urine Analyzer|"Second intervention (assigned to the All participants arm)."
1524156|NCT02785432|Device|Pre program low level laser|Phase 1 is an intervention only phase (LLLT or Sham) with no additional elements of the pain program (PT, counseling). Intervention will be completed at the Outpatient Physical Therapy Clinic in the School of Health Professions. Intervention will take place in the rooms that are appropriately equipped for laser administration. Application of therapeutic laser will be completed by licensed physical therapists who have completed safety training for therapeutic laser application including appropriate use of safety eyewear, room access, laser signage for laser use, and patient monitoring.
1524157|NCT02785432|Device|Program low level laser|"Laser intervention (LLLT): Clinician will apply 10 minutes of low level laser therapy at a dosage of 15-25 watts for a total of 9,000-15,000 joules based on body surface area treated. Application will be with light to moderate contact pressure based on patient tolerance (should be no additional discomfort from laser). Area for administration will include 6 minutes of application along spine (C2-S1), and 4 minutes of application either to bilateral upper extremity or bilateral lower extremity based on areas of primary pain complaint.
Sham laser intervention (Sham): same protocol in time, application, and areas of treatment as stated above except laser unit will not discharge any photonic energy."
1524158|NCT02785419|Behavioral|Arm Training with Action Selection|Treatment occurs in 1.5 hour sessions, 5 times a week for 3 weeks. In each treatment session, you will practice functional tasks with your weaker arm and hand. Additionally, you will be given cues on a computer screen that dictate your movement response (action selection). Practice will be scaled to match your current level of function and progressed over time as able.
1524159|NCT02785406|Drug|suvorexant|Subjects will receive suvorexant capsules (10 mg week 1, 20 mg week 2), once daily at 10 PM.
1524160|NCT02785406|Drug|Placebo (for suvorexant)|Subjects will receive placebo capsules once daily at 10 PM.
1524161|NCT02785393|Drug|Sugar Pill|The administration of a sugar pill
1524162|NCT02785393|Drug|Doxazosin|The administration of the Doxazosin medication
1524163|NCT02785380|Procedure|laparoscopic surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
1524164|NCT02785380|Procedure|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
1524165|NCT02785367|Procedure|Cord blood samples|"After delivery, 8 cord blood samples will be taken from the umbilical cord in 8 syringes of about 3 ml, washed with Heparin (Designated syringes exist in the delivery room). 4 syringes will be stored in room temperature. Thermometer will be attached to any sample, and temperature values will be indicated before any measurement.
The samples will be measured in a gas measurement device, in 4 time points: at the birth, after 15 minutes, after 30 minutes and after 60 minutes from the birth."
1524166|NCT02785341|Other|questionnaires every 6 weeks (T0, T1, T2, T3 and T4)|Questionnaire MFI 20 Questionnaire life satisfaction Scale of measurement of the positive and negative affects Questionnaire QLQ-C30 (EORTC) Questionnaire on the personal goals
1524167|NCT02785341|Other|6-minute walk test) every 6 weeks (T0, T1, T2, T3 and T4)|
1524168|NCT02785341|Other|leptin level with a blood test every 12 weeks (T0, T2 and T4)|blood sample
1524169|NCT02785328|Other|memory evaluation at V1 and V2 (with treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance. The children receive drug treatment (BECTS and Narcolepsy) or surgical (OSA) as part of their routine care.
1524170|NCT02785328|Other|memory evaluation at V1 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
1524171|NCT02785328|Other|memory evaluation at V1 and V2 (without treatment)|Overnight episodic and procedural memory consolidation performance will be assessed at V1 and V2. The performance will be correlated with sleep data, diurnal neuropsychological assessment and academic performance.
1524172|NCT02785315|Behavioral|rehabilitation & remediation approach|The rehabilitation & remediation approach group will receive 12 weekly 90-minute combined cognition interventions in a group. The first half of each session will be cognitive training which focus on teaching various cognitive strategies to enhance the attention, memory, processing speed, and executive functions. The second half of the session will apply rehabilitation intervention by discussing everyday situations with memory problem and specific strategies related to real-life situations. Investigators will also include one individual session in the 12 group sessions.
1524173|NCT02785315|Behavioral|remediation approach|The remediation approach will receive 12 weekly 90-minute cognitive training which focus on teaching various cognitive strategies and their applications to enhance the attention, memory, processing speed, and executive functions.
1524174|NCT02785289|Device|Vaginal swab|Vaginal cell collection will be performed with the two types of indicated swab.
1524175|NCT02785276|Device|AutoFuser Pain Pump|Closed loop local anaesthetic infusion system
1524176|NCT02785276|Drug|Ropivacaine|Commonly used local anaesthetic drug
1524177|NCT02785276|Other|Normal Saline (0.9%)|Normal saline is a sterile, non-pyrogenic solution for fluid and electrolyte replenishment for intravenous administration. This will be the solution used for the intraperitoneal infusion in the placebo/control group.
1524178|NCT02785263|Radiation|2.15 gray and 1.8 gray. Max. 6 weeks.|
1524179|NCT02785263|Radiation|2.15 gray and 1.8 gray. Max. 5 weeks.|
1524180|NCT02785250|Biological|DPX-Survivac|SubQ injection
1524181|NCT02785250|Drug|Cyclophosphamide|PO BID
1524182|NCT02785250|Drug|Epacadostat (INCB024360)|PO BID
1524183|NCT02785237|Device|Coroflex® ISAR Drug-eluting stent|Coroflex® ISAR Drug-eluting stent and an Ultimaster® Drug-eluting stent in the second lesion.
1524184|NCT02785237|Device|Ultimaster® Drug-eluting stent|Ultimaster® Drug-eluting stent and a Coroflex® ISAR Drug-eluting stent in the second lesion.
1524185|NCT02785224|Drug|Vasopressin Steroids Epinephrine|Vasopressin Steroids Epinephrine: Vasopressin (up to 5 doses of 20 IU) and methylprednisolone (single dose - 40 mg) in addition to epinephrine during cardiopulmonary resuscitation, and stress dose hydrocortisone (300 mg/day for 7 days maximum followed by gradual taper) for postresuscitation shock.
1524186|NCT02785211|Behavioral|Behavioral Activation Treatment|The modified model will be provided weekly to four groups for intervention, each group including about 10 participants with 1 facilitator for a period of 8 weeks after the baseline survey and general introduction. Each of the 8-week sessions will last for 2 hours. Groups 1 to 4 will have sessions on Mondays, Tuesdays, Wednesdays, and Thursdays respectively; four groups will meet on the same day of the week for all 8 weeks. The scheduling and timing of intervention provide consistency of scheduling for participants.
1524187|NCT02785198|Device|Passive knee extensor machine|The passive training machine, moves both legs from flexion to extension and back, 60 times per minute in 1 hour, 3 times per week. ROM is 60 degrees
1524188|NCT02785185|Drug|IDP-122 Vehicle Lotion|Vehicle
1524189|NCT02785185|Drug|IDP-122 Vehicle Cream|Vehicle
1524190|NCT02785185|Drug|IDP-122 Lotion|Lotion
1524191|NCT02785185|Drug|Ultravate Cream|Cream
1524192|NCT02785172|Drug|IDP-118 Vehicle Lotion|Vehicle
1524193|NCT02785172|Drug|IDP-118 Vehicle Cream|Vehicle
1524194|NCT02785172|Drug|IDP-118 Lotion|Lotion
1524195|NCT02785172|Drug|Ultravate Cream|Cream
1524196|NCT02785159|Drug|IDP-118 Lotion|Lotion
1524197|NCT02785159|Drug|Tazorac Cream|Cream
1524198|NCT02785159|Drug|IDP-118 Vehicle Lotion|Lotion
1524199|NCT02785159|Drug|IDP-118 Vehicle Cream|Cream
1524200|NCT02785146|Drug|Huaier Granule|Huaier Granule is continuously taken three times per day, 20g per time.
1524201|NCT02785146|Drug|Oxaliplatin|85 mg/m², ivdrip, D1
1524202|NCT02785146|Drug|Calcium folinate|Calcium folinate 400 mg/m², ivdrip, D1; or calcium levofolinate, 200 mg/m², ivdrip, D1
1524203|NCT02785146|Drug|5-fluorouracil|400 mg/m², iv, D1; and 2400mg/m², civ, 48h
1524204|NCT02785133|Device|UVL1000 Treatment Station|"Non-coherent light source administered 365 nm, 630 nm, and 530 nm at an output intensity of 0.1 mW directly into an existing intravascular 20 gauge 1.0 catheter"
1524205|NCT02785133|Drug|Normal Saline Solution|150 ml of 0.9% Sodium Chloride Solution
1524206|NCT02785133|Device|Peripheral Catheterization|"20-gauge 1.0 catheter"
1524207|NCT02785120|Drug|TF0023|TF0023 is a new Investigational drug as a topical spray as an anti thrombosis drug, indicated for relief of the signs and symptoms and functional improvement of patients with ischemic strokes.
1524208|NCT02785107|Behavioral|M-PAC Group|Participants attended a workshop, completed a worksheet and received a booster phone call follow-up at week four.
1524209|NCT02785094|Behavioral|Observation|Observation of Participants' behaviour
1524210|NCT02785068|Drug|MM-151|Oligoclonal antibody
1524211|NCT02785068|Drug|nal-IRI|Nanoliposomal irinotecan
1524212|NCT02785068|Drug|Leucovorin|folinic acid
1524213|NCT02785068|Drug|5-FU|Chemotherapy
1524217|NCT02785042|Device|Heidelberg Spectralis OCT|
1524218|NCT02785029|Device|OCT|
1524313|NCT02784340|Device|25G spinal needles|
1524314|NCT02784327|Drug|PRF110|
1524315|NCT02784314|Procedure|Robotic-Assisted Radical Prostatectomy|
1524224|NCT02784990|Biological|Lipase, amylase and CRP (C-reactive protein) dosages|
1524225|NCT02784977|Device|Positive Airway Pressure (PAP)|Treatment of OSA with PAP
1524226|NCT02784977|Device|Intraoral device (IOD)|Treatment of OSA with IOD
1524227|NCT02784977|Procedure|Uvuloplasty|Uvuloplasty
1524228|NCT02784977|Other|Conservative treatment|No active intervention
1524229|NCT02784964|Drug|Elixcyte|Elixcyte 8mL, ADSC 6.4*10^7 cells, allogeneic injection
1524230|NCT02784964|Drug|Hya Joint Plus|Hya Joint Plus synovial fluid supplement 3mL, SciVision Biotech Inc.
1524231|NCT02784951|Drug|Red blood cells (0Rh D-neg)|Fresh produced RBC
1524232|NCT02784951|Drug|Whole blood (O Rh D-neg K-neg)|Fresh produced WB
1524233|NCT02784951|Drug|Freeze dried plasma (LyoPlas)|(LyoPlas N-w (German Red Cross)
1524234|NCT02784938|Behavioral|Vocational Empowerment Photovoice (VEP)|The VEP program is a 10-week manualized, structured, peer-led intervention delivered in 2-hour group sessions. The VEP manual includes a Workbook for the clients and a corresponding Leader's Guide for the group peer-leaders. The VEP program integrates Photovoice methodology, Rehabilitation Readiness technology and elements of the Anti-Stigma Photovoice (ASP) curriculum previously developed and tested by the Boston University Center for Psychiatric Rehabilitation (BU CPR). VEP group sessions combine didactic information, Photovoice exercises, and group discussions to empower participants in pursuing employment services and opportunities, all refined with input from individuals with a lived experience.
1524235|NCT02784925|Device|Ultrasound (US) B mode image|"Ultrasound (US) B mode image is an alternative method to measure tissue structure
and has proven to be an accurate technique to measure subcutaneous fat thickness."
1524236|NCT02784899|Drug|iloprost|"20μg(2ml) of inhaled iloprost (Ventavis®)
When anesthesia induction finishes, change patients' position from supine to lateral position and measure arterial blood gas analysis (ABGA), venous blood gas analysis (VBGA) while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
1524237|NCT02784899|Drug|normal saline|"20μg(2ml) of inhaled normal saline
When anesthesia induction finishes, change patients' position from supine to lateral position and measure ABGA, VBGA while two lung is ventilated. After 20 minutes of applying one lung ventilation, measure ABGA. Apply iloprost or normal saline inhalation for each iloprost and control group and measure ABGA at the time of 20 min and 40 min after iloprost (or normal saline) inhalation has finished."
1524238|NCT02784886|Biological|Women at high risk of MAP|Blood sample
1524240|NCT02784860|Drug|Lidocaine|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the lidocaine group, lidocaine 2% is administered as a bolus followed by a continuous intravenous infusion after loss of consciousness
1524241|NCT02784860|Drug|normal saline|Propofol (0.5 mg/kg or more) is titrated to provide loss of consciousness. Then in the placebo group, the same volume of normal saline is administered after loss of consciousness
1524242|NCT02784847|Drug|Triheptanoin|Triheptanoin oil administered three times per day during meals at a total dose 1mg/kg/day for 3 months
1524243|NCT02784834|Drug|dimethyl fumarate|
1524244|NCT02784821|Drug|Antibiotic|Babies that are assigned to antibiotics receive therapy based on the clinical team's discretion.
1524245|NCT02784821|Other|Gastric fluid|Microbiome, metabolome, and inflammatory mediators will be evaluated using gastric aspirate.
1524246|NCT02784821|Other|Breast milk|Microbiome, metabolome, and inflammatory mediators will be evaluated using mother's breast milk.
1524247|NCT02784821|Other|Stool samples|Microbiome, metabolome, and inflammatory mediators will be evaluated using infant's stool.
1524248|NCT02784821|Drug|Antibiotics - pre-emptive|Babies that are randomized to antibiotics receive therapy based on the clinical team's discretion.
1524249|NCT02784808|Drug|Biological DMARDs|Participants will receive biologic DMARDs as per standard of CARE. The choice of specific biologic DMARD will be at the descretion of treating physician.
1524250|NCT02784808|Drug|Non-Biologic DMARDs|Participants will receive non-biologic DMARDs as per standard of care. The choice of specific non-biologic DMARD will be at the descretion of treating physician.
1524258|NCT02784782|Device|Orthesis|
1524259|NCT02784782|Behavioral|No orthesis|
1524260|NCT02784769|Other|measurement of skin autofluorescence|
1524261|NCT02784769|Other|skin biopsy collection|
1524263|NCT02784743|Drug|''albendazole'' and ''ivermectin''|annual single dose administration of albendazole 400mg and ivermectin 150ug/kg of weight (according to the height)
1524264|NCT02784730|Procedure|Iterative PICC placement|Intervention is the catheterisation strategy (not the device)
1524265|NCT02784730|Procedure|Long term PAC placement|Intervention is the catheterisation strategy (not the device)
1524267|NCT02784704|Drug|Eravacycline|
1524268|NCT02784704|Drug|Meropenem|
1524269|NCT02784704|Drug|Placebo|
1524270|NCT02784691|Device|Feeligreen patch|
1524316|NCT02784314|Procedure|Laparoscopic Radical Prostatectomy|
1524655|NCT02781753|Biological|Human Serum Albumin/interferon alpha2b|Human Serum Albumin/interferon alpha2b fusion protein 300-1200 μg single dose S.C. at Day0
1524271|NCT02784678|Procedure|closed reduction group|Patients in the experimental group will undergo C-arm fluoroscopy-assisted minimally invasive closed reduction and internal fixation with fully threaded headless cannulated compression screws. In the experimental group, fractures will be reduced and internally fixed with fully threaded headless cannulated compression screws of appropriate lengths (Acutrak plus; Acumed Inc., Beaverton, OR, USA) under C-arm fluoroscopic guidance to restore the radial inclination and ulnar deviation of the distal radius.
1524272|NCT02784678|Device|open reduction group|Patients in the control group will undergo open reduction and internal fixation with a titanium plate (Ningbo Cibei Medical Treatment Appliance Co., Ltd., Ningbo, China).
1524273|NCT02784665|Device|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the
1524274|NCT02784665|Device|577-TL|"All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-TL arm.
100 microns light spot size, 0.05 seconds duration, 80 ~ 200 milliwatts of power"
1524275|NCT02784652|Drug|Zoledronic acid|Zoledronic acid: every 4 weeks, 6 times, 4.0 mg iv
1524276|NCT02784652|Radiation|Radiotherapy|Radiotherapy: 5 days/ week, 3 Gy * 10-13 fractions or 4 Gy * 5 fractions,
1524277|NCT02784639|Other|Plasma Analysis of circulating cell free DNA|
1524278|NCT02784639|Other|Tumor tissue analysis of circulating cell free DNA|
1524279|NCT02784626|Drug|Dexmedetomidine|Intraoperative sedation using dexmedetomidine
1524280|NCT02784626|Drug|Propofol|Intraoperative sedation using propofol
1524281|NCT02784613|Drug|Ospemifene|FDA approved medication for the treatment of vulvovaginal atrophy and dyspareunia
1524282|NCT02784600|Device|Bioinductive implant|
1524283|NCT02784587|Procedure|Stellate Ganglion Block|After induction of general anesthesia, patients will receive a stellate ganglion block using a standard and well described paratracheal technique, which typically requires about 3 minutes to perform. The patient's head will be extended and a 4-5-cm, 22-gauge needle inserted at the medial edge of the sternocleidomastoid muscle just below the level of the cricoid cartilage at the level of the transverse process of C6 (Chassaignac's tubercle) or C7 (3-5 cm above the clavicle). The non-operative hand will retract the muscle together with the carotid sheath prior to needle insertion. After advancing to the transverse process the needle will be withdrawn 2-3 mm prior to injection. A negative aspiration test will be performed in two planes before a 1-ml test dose is used to exclude unintentional intravascular injection (vertebral or subclavian arteries) or subarachnoid injection into the dural sleeve.4 A total of 10 ml of 0.25% bupivacaine will be injected.
1524284|NCT02784561|Drug|Busulfan (Zhejiang Otsuka Pharmaceutical Co. Ltd)|busulfan (3.2 mg/kg/day intravenously [i.v.], days -10 to -8)
1524285|NCT02784561|Drug|Cytarabine(Actavis Italy S.p.A)|cytarabine (1.6 g/m2/day, days -7 to -3)
1524286|NCT02784561|Drug|Fludarabine (Bayer)|fludarabine (30 mg/m2, day -7 to -3),
1524287|NCT02784561|Drug|granulocyte colony-stimulating factor (KirinKunpeng)|granulocyte colony-stimulating factor (5 ug/kg, day -8 to granulocyte recovery)
1524288|NCT02784561|Drug|rabbit ATG（Sanofi/Genzyme）|ATG; thymoglobuline, rabbit;2.5 mg/kg/day, days -5 to -2
1524289|NCT02784548|Other|Virtual Reality|Using a VR headset, motion sensors, and VR software, the investigators will create a customized VR treatment for each participant that engages them in movements and exercises involving their missing limb in a game-like environment. For example, participants may use the headset to engage in activities such as driving a race car around a course requiring both arms, ski down simulated slopes, or manipulate objects.
1524290|NCT02784548|Behavioral|Mirror therapy|Standard mirror therapy makes use of an external mirror, wherein an amputee carries out simple exercises (e.g., clenching & relaxing their fist) with their intact limb while positioned by the mirror in a manner that gives the visual illusion of the missing limb also being engaged in the exercise.
1524291|NCT02784535|Drug|Atomoxetine|norepinephrine transporter inhibitor
1524292|NCT02784535|Drug|Placebo|placebo
1524293|NCT02784522|Device|locking compression plate group|Closed reduction via shoulder lateral approach followed by locking compression plate fixation using minimally invasive technique
1524294|NCT02784522|Device|conventional locking plate group|Closed reduction via shoulder lateral approach followed by conventional locking plate fixation using minimally invasive technique
1524295|NCT02784496|Drug|Ruxolitinib|Participants take ruxolitinib tablets by mouth either 1 or 2 times each day at the same dose and schedule that they were assigned in Study 2007-016. Each study cycle is 28 days.
1524296|NCT02784496|Behavioral|Questionnaires|Questionnaires regarding quality of life completed every 6 cycles and at end of study visit.
1524297|NCT02784483|Drug|Atezolizumab (1200mg via IV infusion)|
1524298|NCT02784470|Device|gastroduodenal stent placement|
1524299|NCT02784470|Procedure|gastrojejunostomy|
1524300|NCT02784457|Drug|Cetrorelix|
1524303|NCT02784418|Procedure|Chronic Total Occlusion Percutaneous Coronary Intervention|Chronic Total Occlusion Percutaneous Coronary Intervention (CTO PCI), as per standard clinical practice
1524304|NCT02784418|Procedure|Sham Procedure|Sham Procedure: Bilateral arterial access, without angiography or PCI being performed
1524305|NCT02784392|Drug|Ulimorelin|Active
1524306|NCT02784392|Drug|Metoclopramide|Comparator
1524307|NCT02784353|Behavioral|Perioperative rehabilitation program|"Perioperative rehabilitation program
preoperative rehabilitation : 2 weeks prior to operation
postoperative rehabilitation : 3 months after operation"
1524308|NCT02784353|Behavioral|Conventional|conventional perioperative management without rehabilitation program
1524309|NCT02784340|Drug|Dexamethasone|16 mg Dexamethasone IV drip
1524310|NCT02784340|Drug|Dexamethasone|16 mg Dexamethasone subcutaneous injection around the caesarean section scar after skin closure
1524311|NCT02784340|Drug|Saline (IV fluids)|IV fluids 500 cc saline infusion
1524312|NCT02784340|Drug|Bupivicaine and Fentany|
1524317|NCT02784301|Device|Belly breathing with biofeedback app|This intervention consists of learning how to belly breathe using a smartphone biofeedback application that coaches children how to breathe slowly and deeply. The app consists of a cartoon avatar in a hot air balloon that inhales and exhales bubbles. The goal of the biofeedback game is to a) teach a voluntary deep breathing protocol, b) detect compliance to the breathing protocol using the attached audio-based pulse oximeter sensor and c) to raise the hot air balloon in accordance to this compliance in order to motivate the children. Scenery changes as the balloon rises, driven by biofeedback, until it eventually reaches outer space.
1524318|NCT02784301|Behavioral|Belly breathing without biofeedback app|This intervention consists of learning how to belly breathe without the biofeedback application prior to the blood collection and continuing with self-directed belly breathing during the procedure itself.
1524319|NCT02784301|Behavioral|Belly breathing + visual distraction|This intervention consists of learning how to belly breathe without the application plus receiving visual distraction by watching a cartoon avatar in the hot air balloon rising through space. The avatar will not coach the child to breathe as the visual cues for breathing (words and bubbles) will not be present and the avatar will not rise in response to correct belly breathing. Participants will be instructed to continue with self-directed breathing while also watching the visual distraction during the blood collection procedure.
1524320|NCT02784288|Procedure|Neck Dissection|All patients will undergo neck dissection.
1524321|NCT02784288|Procedure|Transoral Surgery of Primary Site|Patients with a single lymph node that measures less than six centimeters, have no extracapsular extension in the lymph node, and have no perineural or perivascular invasion of the primary biopsy will undergo transoral surgery of the primary site.
1524322|NCT02784288|Radiation|Radiation|Patients who have 2 positive nodes with no extracapsular extension, or have perineural or perivascular invasion of the primary biopsy will undergo radiation.
1524323|NCT02784288|Drug|Carboplatin|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
1524324|NCT02784288|Drug|Paclitaxel|Patients who have extracapsular extension in any number of lymph nodes or in those patients in whom negative margins are unable to be obtained after the completion of transoral surgery will undergo chemoradiation (Radiation, Carboplatin and Paclitaxel).
1524325|NCT02784275|Drug|Cyclo-Z|
1524326|NCT02784275|Drug|Placebo|
1524327|NCT02784262|Drug|botox injection Multiguide|botox injection under CT/MR navigation and with the navigation tool MultiGuide
1524328|NCT02784249|Procedure|Goniotomy|Procedure: Goniotomy and trabecular excision with a novel ophthalmic knife in combination with planned cataract extraction via Phaco and PCIOL implant.
1524329|NCT02784249|Device|Trabecular Micro-Bypass Stent|Procedure: Trabecular Micro-Bypass stent implantation in combination with planned cataract extraction via Phaco and PCIOL implant.
1524330|NCT02784249|Procedure|Cataract Extraction|Cataract extraction via Phaco and PCIOL implant.
1524331|NCT02784236|Device|telemedicine|The study population corresponds to patients> 18 and <65 years with DM1 of> 1 year of evolution, and treated with MDI HbA1c> 7%. It is changing one group of subjects between two observation times due to any intervention in this case the addition of a tele
1524332|NCT02784223|Device|Radiation : PET-CT with F18-choline examination|PET-CT with F18-choline examination will be performed before surgery
1524338|NCT02784158|Drug|Brigatinib|Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC who are resistant or intolerant to a prior ALK inhibitor at a dose of 180 mg QD with a 7 day lead-in at 90 mg QD, continuously, with or without food.
1524339|NCT02784145|Dietary Supplement|Resistant starch|
1524340|NCT02784145|Other|Recommendation with regard to nutrition|Subjects in this arm will receive General recommendations with regard to nutrition based on the guidlines of the German Society for nutrition
1524341|NCT02784132|Other|Video diversion|The intervention is playing a video on a computer or iPad (using www.youtube.com) while performing fundoscopy.
1524342|NCT02784119|Procedure|temporary porto-caval shunt|
1524343|NCT02784106|Drug|M2951|M2951: 2 capsules twice daily for 12 weeks (Double Blind treatment period).
1524344|NCT02784106|Drug|Placebo|Placebo matching M2951: 2 capsules twice daily for 12 weeks (Double Blind treatment period).
1524345|NCT02784106|Drug|M2951|M2951 tablets twice daily for 6 months (Open Label extension period).
1524346|NCT02784093|Drug|Gastrograﬁn|
1524347|NCT02784093|Procedure|enemas|
1524348|NCT02784080|Other|HLA-alloantibodies exposure|"Following analyzes will be done:
LABScreen® Mixed, One Lambda, CA LABScreen® Single Antigen, One Lambda, CA C1qScren™, One Lambda, CA PE-conjugated IgG3 antibody"
1524349|NCT02784067|Drug|Sucraid|Study drug
1524350|NCT02784067|Drug|Placebo|Sucraid placebo
1524351|NCT02784054|Drug|Carboplatin|
1524352|NCT02784054|Drug|Etoposide|
1524353|NCT02784054|Drug|Cyclophosphamide|
1524354|NCT02784054|Drug|Bleomycin|
1524355|NCT02784054|Drug|Thiotepa|
1524356|NCT02784054|Drug|Melphalan|
1524357|NCT02784054|Radiation|Reduced dose radiotherapy|
1524358|NCT02784041|Drug|single adductor-canal-block|Single adductor-canal-block is performed before the surgery. A 12Hz linear ultrasound transducer is placed on the medial part of the thigh with the leg slightly externally rotated. The femoral artery was identified in short axis in the adductor canal, underneath the sartorius muscle. After skin disinfection , an 18-gauge needle (B.Braun Medical, Melsungen, Germany) is inserted in-plane from the lateral side of the transducer. The needle tip was placed underneath the sartorius muscle, just lateral to the artery and saphenous nerve, using 2-3 ml of saline to ensure correct placement. 25 ml of 0.35% ropivacaine is slowly injected with repeated aspiration.
1524412|NCT02783729|Drug|Zolpidem tartrate|Zolpidem tartrate extended release 6.25 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
1524886|NCT02780115|Drug|AGN-190584 Vehicle|Vehicle to AGN-190584
1524359|NCT02784041|Drug|periarticular infiltration|The periarticular infiltration of multimodal agents will involve the preparation of a mixture of 100 ml solution. The mixture contains 30ml (300mg) ropivacaine, 0.5ml (5 mg) morphine, 2 ml (50 mg) flurbiprofen and 0.5 ml of 1:1000 epinephrine, and then is diluted with 0.9% normal saline to a total volume of 100ml. 50 ml of mixture will be injected into the anterior, medial and lateral soft tissues after the implantation of the joint prostheses. The remaining 50 ml of mixture will be injected into intraarticular space after the closure of articular capsule.
1524360|NCT02784028|Other|SGM-101|Administration of SGM-101 prior surgery
1524361|NCT02784015|Drug|Cisplatin|
1524362|NCT02784015|Drug|Etoposide|
1524363|NCT02784015|Drug|Doxorubicin|
1524364|NCT02784015|Drug|Cyclophosphamide|
1524365|NCT02784015|Drug|Ifosfamide|
1524366|NCT02784015|Drug|Carboplatin|
1524367|NCT02784015|Radiation|Radiotherapy|
1524368|NCT02784015|Drug|Thiotepa|
1524369|NCT02784015|Drug|Melphalan|
1524372|NCT02783989|Other|white wine|A dietary beverage: a market white wine, 13º alcohol
1524373|NCT02783989|Dietary Supplement|tyrosol|tyrosol in capsules
1524375|NCT02783963|Device|OCT and CMR imaging|"OCT: Imaging for the presence and vulnerability of coronary plaque as well as plaque disruption.
CMR: Imaging for identification of myocardial injury (late gadolinium enhancement and myocardial edema) as well as other concomitant findings."
1524376|NCT02783950|Other|Decipher Prostate Cancer Classifier|The Decipher test (GenomeDx Biosciences, San Diego, CA) is a genomic test that predicts high grade disease, the probability of metastasis and prostate cancer-specific mortality for men with prostate cancer.
1524377|NCT02783937|Biological|Filgrastim|"Each case will have two intervention phases done blindly at random with a wash-out period of 6 months:
Phase A:
Filgrastim vial (30 million IU/ml) SC injection twice daily for five consecutive days.
Phase B:
Injection of saline SC injection twice daily for five consecutive days."
1524378|NCT02783937|Drug|Saline|Injection of saline SC injection twice daily for five consecutive days
1524379|NCT02783924|Drug|Cholecalciferol|Vitamin D preparation
1524380|NCT02783924|Drug|Placebo|placebo
1524381|NCT02783911|Device|MTA|Mineral Trioxide Aggregate grey paste
1524382|NCT02783911|Drug|Ferric Sulfate|Ferric Sulfate paste
1524384|NCT02783885|Drug|immunotherapy|
1524385|NCT02783859|Drug|Amoxicillin-clavulanic Acid|
1524386|NCT02783859|Drug|Placebo (for Amoxicillin-clavulanic Acid)|
1524387|NCT02783846|Other|normal saline|receive equal volume of normal saline
1524388|NCT02783846|Drug|dexmedetomidine 0.5 µg/kg|receive dexmedetomidine 0.5 µg/kg
1524389|NCT02783846|Drug|dexmedetomidine 1.0 µg/kg|receive dexmedetomidine 1.0 µg/kg
1524390|NCT02783833|Drug|MMV390048 40mg|
1524391|NCT02783833|Drug|MMV390048 dose to be determined mg|Cohort 2 will receive a single dose of MMV390048. Depending on the data obtained from the 40mg cohort, the dose in Cohort 2 will be determined.
1524392|NCT02783820|Drug|MMV390048 40 mg|
1524393|NCT02783820|Drug|Placebo to match MMV390048 40 mg|
1524394|NCT02783820|Drug|MMV390048 80 mg|
1524395|NCT02783820|Drug|Placebo to match MMV390048 80 mg|
1524396|NCT02783820|Drug|MMV390048 120 mg|
1524397|NCT02783820|Drug|Placebo to match MMV390048 120 mg|
1524400|NCT02783794|Drug|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.7 ml/kg) intramuscularly once daily for 32 consecutive days
1524401|NCT02783794|Drug|Placebo|Placebo, solution for injections; doses: 0.7 ml/kg body weight intramuscularly once daily for 32 consecutive days
1524403|NCT02783768|Device|E-cigarette|The study e-cigarette exposure will be 10 puffs with 30-second inter-puff intervals, as directly observed by a trained research assistant, using a standardized e-cigarette. Cartomizers, batteries, and e-liquids will be obtained from commercial suppliers. The e-cigarette device will be loaded with 1 mL of flavorless e-liquid with a ratio of PG to vegetable glycerin of 70:30 and 1.8 mg/dL of nicotine.
1524404|NCT02783768|Other|Sham|"The unexposed condition will be breathing from the study e-cigarette (10 puffs with 30-second inter-puff intervals) with the battery off."
1524405|NCT02783768|Drug|Hyperpolarized 3-Helium|Hyperpolarized 3-Helium will be used as an experimental contrast agent for the Ventilation MRIs performed twice per participant in both experimental arms. Approximately 250-600 mL of hyperpolarized 3He mixed with 300-750 mL nitrogen will be inhaled through a one-way valve in one inhalation starting approximately at residual volume.
1524406|NCT02783768|Drug|Gadolinium|Gadolinium contrast will be injected into the antecubital vein through an 18-20 gauge IV. The type of gadolinium will be 0.03 mmol/kg bodyweight of dotarem (gadoterate meglumine).
1524407|NCT02783755|Behavioral|Device: smartphone|Coping Skills Training for pain will be delivered to participants using video-conferencing
1524408|NCT02783742|Behavioral|Communication coaching|Study coaches will conduct tailored individual sessions with participating providers to teach and improve communication techniques. Coaches will then shadow or audio-record patient encounters and deliver feedback to providers on their communication during these encounters.
1524409|NCT02783729|Drug|Lemborexant|Lemborexant 5 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
1524410|NCT02783729|Drug|Lemborexant|Lemborexant 10 mg will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
1524411|NCT02783729|Drug|Lemborexant-matched placebo|Lemborexant-matched placebo be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
1524413|NCT02783729|Drug|Zolpidem-matched placebo|Zolpidem-matched placebo will be administered orally in tablet form at home each night, immediately before the time the participant intends to try to sleep.
1524414|NCT02783716|Device|Cardiac Resynchronization Therapy Implantation|An implanted cardiac resynchronization device is a medical device used in cardiac resynchronization therapy (CRT). It resynchronizes the contractions of the heart's ventricles by sending tiny electrical impulses to the heart muscle, which can help the heart pump blood throughout the body more efficiently.
1524415|NCT02783716|Device|Implantable Cardioverter-defibrillator (ICD)|An implantable cardioverter-defibrillator (ICD) — a pager-sized device — is placed in the chest to reduce risk of dying if the lower chambers of the heart (ventricles) go into a dangerous rhythm and stop beating effectively
1524416|NCT02783703|Dietary Supplement|Medium chain triglycerides (MCT)|Subjects will consume 30 grams per 2000 kilocalories daily of medium chain triglyceride oil by mouth
1524417|NCT02783690|Radiation|Hypofractionation|40 Gy (RBE) in 15 daily fractions
1524418|NCT02783677|Procedure|Percutaneous balloon angioplasty|
1524419|NCT02783664|Other|Questionnaires to Evaluate Anxiety Related to Genetic Testing|"A health team member will outline the study parameters to the patient prior to the genetic counseling visit.
Visit 1: At the genetic counseling appointment (prior to counseling) patients will receive the following: the State-Trait Anxiety Inventory (STAI) for Adults) to measure baseline anxiety, the Health Anxiety Inventory (HAI) to measure baseline health anxiety, the modified Cancer Worry Scale (CWS) to measure baseline cancer worry in addition to some additional questions about the patient's background. The patient will complete the questionnaires privately and then return them to the genetic counselor.
Follow-up: One week following disclosure of genetic testing results (3 weeks after the initial appointment), a research team member will call the patient and administer the HAI and CWS over the phone. This will be repeated at 5 weeks, 3 months, and 6 months after initial visit.
Time to take initial surveys: 15-20 minutes total. Follow-up calls: 10-15 minutes total."
1524421|NCT02783638|Drug|YHD1119|2 by 2
1524422|NCT02783638|Drug|Lyrica|2 by 2
1524423|NCT02783625|Drug|Romidepsin|
1524424|NCT02783625|Drug|Bortezomib|
1524425|NCT02783625|Drug|duvelisib|
1524426|NCT02783612|Other|glucose buddy application|
1524429|NCT02783586|Procedure|Quadratus Lumborum Block type II|Local anaesthetic injection on the posterior border of the quadratus lumborum muscle
1524430|NCT02783586|Procedure|Transversus Abdominalis Plane Block|Local anaesthetic injection between internal oblique and transversus abdominis muscle
1524431|NCT02783586|Drug|Bupivacaine|20 ml of bupivacaine with adrenaline
1524432|NCT02783586|Device|Ultraplex|A non-stimulating echogenic single-shot needle designed for regional analgesia under ultrasound guidance.
1524435|NCT02783560|Behavioral|The Sleep Train Program|This modular behavioral sleep intervention includes required modules on sleep routines and sleep habits, and optional modules on bedtime problems, fears, anxiety, and independent sleep.
1524436|NCT02783560|Behavioral|The Family Mealtimes Program|This modular behavioral mealtime intervention includes required modules on mealtime routines and healthy mealtime habits, and optional modules on picky eating and mealtime behavior difficulties.
1524437|NCT02783547|Drug|SyB C-1101 and Azacytidine|"This study is a multi-center open-label study to assess the tolerability of oral administration of SyB C-1101 twice daily from Day 1 to Day 21 in combination with subcutaneous administration or intravenous drip infusion of azacitidine once daily at a dose of 75 mg/m2 (body surface) for 7 days during the period between Day 8 and Day 16, and to estimate the recommended dose (RD) of C-1101.
SyB C-1101 will be administered at a daily dose of 560 mg or 840 mg in each of the 2 cohorts for a treatment period of 1 cycle for 28 days, including 21 days for SyB C-1101 treatment followed by 7 days of follow-up."
1524438|NCT02783534|Device|Verum acupuncture|"Participants allocated to VA group will receive traditional acupuncture treatment on the Guanyuan(RN 4), bilateral Sanyinjiao(SP 6), bilateral Zigong(EX-CA1), bilateral Xuehai(SP 10). Additional points will be chosen according to TCM syndrome differentiation constitution of patients. If patients with deficient syndrome, bilateral Zusanli (ST 36) will be included. If patients with sufficiency syndrome, bilateral Diji (SP 8) will be included. The NO.16 special type of acupuncture needle (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
1524439|NCT02783534|Device|Sham acupuncture|We use a non-insertive sham control produced by Asia-med Company in Germany—the streitberger placebo-needle. Sham points are described as follows: 1) 5 inch lateral to the seventh thoracic spine; 2) 5 inch lateral to the eighth thoracic spine; 3) 5 inch lateral to the ninth thoracic spine; and 4) 5 inch lateral to the tenth thoracic spine.
1524440|NCT02783534|Behavioral|Usual care|Patients in usual care group will not receive acupuncture treatment but enhance usual care by providing them with detailed information via propaganda booklets or the internet in the form of health education.
1524443|NCT02783508|Drug|IV Meperidine|"Intravenous meperidine 50mg in 100cc NaCl 0.9% . Repeated doses (if needed): intervals of 2 hours minimum until a maximum of 4 doses.
In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.
If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, inhaled nitrous oxide or epidural analgesia will be offered."
1524444|NCT02783508|Drug|Nitrous Oxide|"Nitrous oxide in a 50/50 mix with oxygen given via self-administered face mask. The parturient will be advised to place the mask tightly on her face and to breathe through it at the first sign of forthcoming uterine contraction. Between contractions, she will be advised not to breathe through the mask.
In cases of nausea or vomiting intravenous metoclopramide 10mg will be offered to the parturient.
If pain intensity (according to visual analogue scale), 20 to 30 minutes from administration, will not decline or the parturient will ask for a different type of analgesia, intravenous meperidine or epidural analgesia will be offered."
1524445|NCT02783495|Behavioral|Device: iPad|All patients will receive baseline neurocognitive and quality of life testing, followed by 3 months of the iPad-based intervention, and 3 and 6 month follow-up neurocognitive and quality of life testing.
1524446|NCT02783482|Biological|GC5107|GC5107 20g/200mL, intravenously, dose of 300 - 900 mg/kg (of body weight) every 21 or 28 days for 12 months, follow-up for 3 months
1524447|NCT02783469|Genetic|Identification of genetic causes of diabetic neuropathic pain|
1524448|NCT02783456|Procedure|Noise|The patient is exposed 30 min to the first sound pattern and during the renal hemodynamics will be measured. The following is a 1-hour break.
1524449|NCT02783456|Procedure|Silence|The patient is exposed 30 min to the second sound pattern and during the renal hemodynamics will be measured.
1524452|NCT02783430|Drug|Ketamine|One single perfusion of 0.5 mg/kg during 40 minutes at the beginning of the inclusion
1524453|NCT02783430|Drug|Milnacipran|One or two caps per day from the beginning of the inclusion. Milnacipran dosage depending of glomerular filtration rate of patient, during 16 days (doses of 25 or 50 mg or 100mg per day)
1524454|NCT02783430|Drug|Placebo|One single perfusion during 40 minutes at the beginning of the inclusion
1524456|NCT02783404|Drug|Amoxicillin|Receiving 2 gr oral Amoxicillin before dental any manipulation and following endotracheal intubation
1524457|NCT02783404|Drug|Amoxicillin-Potassium Clavulanate|"Receiving 2 gr/125 mg oral Amoxicillin-Potassium Clavulanate before any dental manipulation and following endotracheal intubation
Intervention: Drug: Amoxicillin-Potassium Clavulanate"
1524458|NCT02783391|Device|ECoG and intracortical electrodes|
1524459|NCT02783378|Drug|Gaviscon Syrup|
1524460|NCT02783365|Behavioral|Photo-elicitation and online group support|See above information.
1524461|NCT02783352|Procedure|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair
1524462|NCT02783352|Procedure|autologous micro-fragmented adipose tissue|injection of autologous micro-fragmented adipose tissue (10 mL) after arthroscopic rotator cuff repair, in dry arthroscopy condition
1524463|NCT02783326|Other|Rehabilitation|Pulmonary rehabilitation, exercise in COPD individuals and health individuals
1524464|NCT02783313|Device|Pathogen reduced plasma-stored platelet concentrates|Platelet concentrates treated with the Mirasol PRT system (pathogen reduction technology) and stored in plasma.
1524465|NCT02783313|Other|Plasma-stored platelet concentrates|Platelet concentrates stored in plasma
1524466|NCT02783300|Drug|GSK3326595 Capsules|The capsules will be of Opaque White for 100 mg, Opaque Light Green for 25 mg, Opaque Dark Pink for 10 mg, and Opaque White for 2.5 mg. The capsules will be administered orally with water (approximately 200 mL) at approximately the same time of day (+/- 4 hours) with no food or antacids for 1 hour before and 2 hours after each dose.
1524467|NCT02783287|Behavioral|Text message reminder for medication adherence|Patients randomized to this arm receive one text message per day (at the scheduled time) reminding them to take their medication.
1524468|NCT02783287|Behavioral|Text message reminder for exercise regimen|Patients randomized to this arm receive 4 daily text messages reminding them to exercise for 30 minutes per day.
1524469|NCT02783274|Device|Actis Total Hip System|Total Hip Replacement and Hemi-hip Replacement
1524470|NCT02783261|Other|CT volumetric measurement after Y90 radioembolization|Liver volume will be measure at 3 time points. All patients will undergo CT volumetry at baseline, 4-6 weeks and 8-12 weeks after SIRT. The images are then measured using a commercially available 3D software (Vital's Vitrea Advanced CT Liver Oncology package) and manually corrected, reviewed and resected by a single senior radiologist to ensure consistency in following the same anatomical landmarks.
1524471|NCT02783235|Other|cervical cancer screening|for 50 ANMs/ASHAs/PHWs/ in conducting cervical cancer related health education , screening for cervical cancers using VIA, collection of PAP smears and HPV samples.
1524472|NCT02783235|Device|The video-based tutorials|
1524473|NCT02783222|Drug|Nab-paclitaxel|comparison of different dosages of drug
1524474|NCT02783209|Procedure|Cataract surgery|
1524475|NCT02783196|Drug|Liraglutide|In the LIR arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of LIR. From day 1 to day 10, with LIR daily dose of 0.6 mg (0.1 ml), followed by other 10 day courses (from day 11 to day 20) with LIR 1.2 mg (0.2 ml), then will be up-titrated to high dose 1.8 mg (0.3 ml) of LIR (from day 21 to day 40). At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
1524545|NCT02782624|Drug|Empagliflozin|5 days of treatment with 10 mg BI 10773 qd until steady state
1525577|NCT02774525|Behavioral|Parenting intervention|
1524476|NCT02783196|Drug|Placebo|In the PLA arm, the participants will be provided with instructions in using pre-filled single-use plastic syringes ready for once daily subcutaneous injection of PLA. Will start with PLA with matched volume saline injections of 0.1 ml PLA during the first 10 days, followed by 10 days, with 0.2 ml PLA, thereafter PLA will be up-titrated to highest volume 0.3 ml placebo for the rest of the PLA treatment period . At crossover-day 40, the participants will undergo a 14 days wash-out period, day 41 to day 55.
1524477|NCT02783183|Drug|YHD1119|2 by 2
1524478|NCT02783183|Drug|Lyrica|2 by 2
1524479|NCT02783170|Biological|Tetanus, Diphtheria, and Pertussis Vaccine|
1524480|NCT02783170|Biological|2016-2017 Quadrivalent Inactivated Influenza Vaccine|
1524481|NCT02783157|Device|Transcutaneous Low-Level Vagal Nerve Stimulation (LLVNS)|Low-level vagal nerve stimulation will be delivered via a clip applied to the ear throughout the surgical procedure. The voltage used will be individualized to each patient, based upon the voltage necessary to slow the sinus rate during testing.
1524482|NCT02783157|Device|Sham LLVNS|A clip will be applied to the ear, but no stimulation will be delivered throughout the procedure.
1524483|NCT02783144|Procedure|TAP Block and Dexamethasone|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is added to levopubivacaine
1524484|NCT02783144|Other|TAP Block and saline|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and saline is added to levopubivacaine
1524485|NCT02783144|Drug|TAP Block and intravenously Dexamethasone|After general anesthesia and before the beginning of surgery, the ultrasound-guided is performed between the internal oblique muscle and the transversus abdominis muscle and dexamethasone is injected intravenously
1524486|NCT02783131|Device|MedNav|MedNav is a tablet based platform device that acts to help teams manage emergencies. In the way that satellite navigation devices have replaced maps on journeys mednav has replaced paper based checklist and guidelines to give teams real-time guidance as the emergency happens. In supports teams by deligating, prompting and scribing as the emergency unfolds. The intervention arm will be taught how to use this device over 30 minutes and then use it in a simulated scenario managing a post partum haemorrhage.
1524487|NCT02783118|Other|Self administered online CBT|"The app being tested has two main components: courses and exercises. Courses represent the psycho-educational and therapeutic background of the program, comprising the following topics: information on depression, psychological vulnerability, what is CBT, healthy and unhealthy negative emotions, rational and irrational thoughts, how behaviors contribute to depression, sleep hygiene, social support, and relaxation techniques. Exercises use the information presented in the courses and follow the structure of a regular therapy session and/or therapeutic homework.
The following exercises are included in the app:
The Emotional Pulse exercise
The Sticky Notes exercise
The Find Irrational Thoughts
The Change Irrational Thoughts"
1524488|NCT02783105|Other|Musical intervention|
1524489|NCT02783105|Other|Control|Patients wear headphones twice a day during 30 minutes, starting at the onset of desedation (Day 0) until day 21, but no music is provided (blank playlist): Sham
1524490|NCT02783092|Drug|Cannabidiol|
1524491|NCT02783092|Drug|Placebo|
1524492|NCT02783079|Behavioral|CBT|
1524493|NCT02783079|Behavioral|MBSR|
1524494|NCT02783066|Device|Offloading boot : PulseFlow|A new offloading boot, which may enhance balance, gait, and lower extremity blood flow
1524495|NCT02783053|Drug|Metformin|Metformin vs no metformin
1524496|NCT02783040|Drug|Midazolam|
1524497|NCT02783040|Drug|Warfarin|
1524498|NCT02783040|Drug|Omeprazole|
1524499|NCT02783040|Drug|Midazolam|
1524500|NCT02783040|Drug|Digoxin|
1524501|NCT02783040|Drug|BI 425809|
1524502|NCT02783027|Behavioral|SleepTrackTXT2|Participants will receive text-message based assessment during shift work (intra-shift) and between shifts (inter-shift). Participants that report high levels of fatigue, sleepiness, or difficulty with concentration during shift work (intra-shift) will receive tailored text-messages promoting adoption of behaviors that can improve alertness during shift work. Participants will also receive a summary of their sleep debt once a week and suggestions for paying back sleep debt. Participants will also have access to a graphic summary of their sleep hours over previous 30-days.
1524503|NCT02782988|Other|olfactory tests, otoacoustic emissions (OAE)|Two series of olfactory tests will be performed : 1) the first one with simple odorants and 2) the second one with binary mixtures of odorants. These tests of nasal chemosensory performance are based on pen-like odor dispensing devices (Sniffin' Sticks, Burghardt, Wedel, Germany) and measure odor discrimination ability of young children in less than 15 min.
1524504|NCT02782975|Drug|aducanumab|
1524505|NCT02782949|Drug|Curcumin|Given PO
1524506|NCT02782949|Other|Laboratory Biomarker Analysis|Correlative studies
1524507|NCT02782949|Other|Placebo|Given PO
1524508|NCT02782949|Other|Quality-of-Life Assessment|Ancillary studies
1524509|NCT02782936|Other|measurement of the work of breathing|"We have been evaluating breathing patterns, index of respiratory efforts and blood gases in all randomized conditions. A gas mask has been used mask (C4, Airboss Defence, Bromont, Canada).
Airway pressure, inspiratory and expiratory flows have been measured. An esophageal catheter has been introduced at the beginning of the study to measure esophageal pressure (Peso) and calculate indexes of respiratory effort (PTPeso, WOB). SpO2 has been continuously measured and capillary blood bases were drawn at the end of each condition. Each condition lasted 10 minutes, data of the last 2 minutes at a steady state has been considered for analyses."
1524510|NCT02782936|Device|Gas mask|During the conditions that involved a gas mask, the measurement of the work of breathing is achieved with a oesophageal catheter and two disposable pneumotachs. While the oesophageal catheter has been fixed to the mandibular with an hypo-allergic tape, the two pneumotachs are hooked respectively on the canister and exhalation port of the gas mask. Investigators have induced the hypoxemia with a mixture nitreous and medical gas in a plastic bag that has been setted up to the canister. The FiO2 level has been kept to 14 percent.
1524656|NCT02781753|Biological|Peginterferon 180 μg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
1524658|NCT02781727|Drug|Once weekly subcutaneous injection of TransCon hGH|Once weekly subcutaneous injection
1524511|NCT02782923|Device|STISIM driving simulator|This simulator is complete with computerized driving scenarios and driving hardware, has been validated in numerous studies and allows for a more comprehensive investigation of driving performance. The simulated course recreates standard turns, traffic intersections, pedestrian crosswalks, lane changes and several hazardous conditions routinely encountered during driving situations.
1524512|NCT02782910|Device|Smartphone-Based Ambulatory Assessment, Feedback via physician|Participants in the experimental condition SBAA+ will be contacted by their treating physician, once the predefined threshold for Smartphone activity is exceeded.
1524513|NCT02782897|Drug|Immunoglobulin Therapy|Immunoglobulin is given intravenously 0.4 g/kg per day for five consecutive days.
1524514|NCT02782897|Other|Standard management|Standard management includes: the use of mild sedation, blood pressure control, management of elevated intracranial pressure, glucose management, temperature management, airway maintenance, and management of medical complications.
1524515|NCT02782871|Device|Pneupac VR1|A portable mechanical ventilator/resuscitator for medical personnel in the hospital, ambu-lance, fire, and police services.
1524516|NCT02782858|Drug|GNbAC1|Monthly IV repeated dose
1524517|NCT02782858|Drug|Placebo|Monthly IV repeated dose
1524518|NCT02782845|Drug|Chemotherapy|The choice of CT will be as per standard of care and protocol does not specify any particular CT drug.
1524519|NCT02782845|Drug|Immunochemotherapy|The choice of ICT will be as per standard of care and protocol does not specify any particular ICT drug.
1524520|NCT02782845|Drug|Pegfilgrastim|Pegfilgrastim will be administered at a fixed dose of 6 mg subcutaneously 24 hours after the last dose of CT or ICT is received for 6 cycles.
1524521|NCT02782819|Drug|Isotonic crystalloid solution resuscitation|Patient will receive normal saline or Ringer lactate or other balance salt solution during fluid resuscitation for shock reversal.
1524522|NCT02782819|Drug|Colloid solution resuscitation|Patient will receive 5% albumin or gelatin solution during shock resuscitation
1524523|NCT02782793|Procedure|Endoscopic Mucosal Resection|
1524525|NCT02782767|Other|Wound catheter infusion|Wound catheter has multiple holes spread around 360 degrees throughout its active length. It is placed in the musculofascial plane during closure of the wound. Local anaesthetic infusion will be delivered through the catheter.
1524526|NCT02782767|Other|Epidural infusion|Epidural catheter will be placed in the level T7-T9 , and local anaesthetic infusion will be given
1524527|NCT02782754|Drug|Carboplatin|
1524528|NCT02782754|Drug|Etoposide|
1524529|NCT02782754|Drug|Cyclophosphamide|
1524530|NCT02782754|Drug|Bleomycin|
1524531|NCT02782754|Radiation|Reduced dose of radiotherapy|
1524534|NCT02782728|Behavioral|TIPS-Plus|Patients receive brief psycho-educational messages on a tablet computer following completion of questionnaire about personal experiences of intimate partner violence (IPV), sexual assault (SA), and reproductive coercion (RC). These messages are tailored to each patient and are based on their responses to specific items. The messages serve as prompts to encourage the patient to continue the discussion about various topics (healthy relationships, birth control methods, harm reduction) with their provider during their clinic visit. Simultaneously, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
1524535|NCT02782728|Behavioral|TIPS-Basic|Patients complete tablet questionnaire about personal experiences of IPV/SA/RC and based on responses, providers receive a print out with a series of scripts tailored to the patient's responses to introduce healthy relationships education, brief counseling, and harm reduction.
1524538|NCT02782702|Drug|Botulism Toxin Treatment|Injection of 50 UI of botulism toxin for treated zone
1524539|NCT02782689|Device|Kit Biflex|Two-layer reusable compression system
1524540|NCT02782689|Device|Profore|Four-layer compression system
1524541|NCT02782663|Drug|ABT-494|Oral use
1524542|NCT02782650|Other|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.
a selection of participants: focus group interviews to further perform in-depth exploration of prenatal counseling preferences"
1524543|NCT02782637|Other|survey and interview|"all participants: survey on prenatal counseling and treatment decisions at the limits of viability.
a selection of participants: individual interviews to further perform in-depth exploration of prenatal counseling preferences"
1524544|NCT02782624|Drug|Empagliflozin|5 days of treatment with 5 mg BI 10773 bid until steady state
1524546|NCT02782611|Behavioral|ENHANCE: Enduring Happiness and Continued Self-Enhancement|ENHANCE is a skill-based intervention to teach people a wide variety of strategies that have been shown to boost happiness. Each session of ENHANCE follows a similar format targeted to address three central goals. First, in each session, participants will complete an active learning module designed to educate participants about one of the ten overarching topics featured in this program (e.g., goals, close relationships). Next, participants will engage in activities that put these principles into practice. Finally, this program is designed to encourage a skill-building mindset by helping participants develop habits to integrate these principles into maintained activity in their daily lives moving forward.
1524547|NCT02782598|Device|CRT+NAVH|Cardiac Resynchronization Therapy with Negative Atrioventricular Hysteresis
1524548|NCT02782585|Other|Cervical manipulation|The therapist cradled the subject´s head with the other hand. Gentle ipsilateral side flexion and contralateral rotation to the targeted side were introduced until slight tension was perceived in the tissues at the contact point. The High velocity, low amplitude (HVLA) manipulation was directed upward and medially in the direction of the subject´s contralateral eye. The therapist monitored for cavitation or 'popping sound' accompanying the manipulations. If an audible popping sound was not heard during the first manipulative attempt, the procedure was repeated in the second time.
1524549|NCT02782585|Other|Cervical lateral glide|The upper limb of the right side of subjects was maintained in rest, with the arm along the trunk and the hand over the abdominal wall. The right hand of the treating therapist was positioned over scapula region, to depress the scapula while left hand cradled the occiput and neck above C5-C6 and left hand produced a passive lateral movement of the occipital and neck region.
1524550|NCT02782585|Other|Cervical mobilisation|The patients received a passive cervical mobilization that involved a grade III oscillatory unilateral posteroanterior mobilization to the right articular pillar of C5/C6 segment as described Maitland at a frequency of 2Hz. All the subjects were positioned in prone position as the protocol described by Sterling et al. for 3 sets of 2 minutes with 1 minute rest between sets.
1524551|NCT02782572|Other|Exercise|Exercise in acute heart failure in three different groups (conventional medical treatment; exercise with non-invasive ventilation and exercise with placebo of non-invasive ventilation).
1524552|NCT02782559|Drug|Sildenafil|
1524553|NCT02782559|Drug|Placebo|Color and size matched to active drug (sildenafil)
1524554|NCT02782546|Drug|Fludarabine|-Standard of care
1524555|NCT02782546|Drug|Cyclophosphamide|-Standard of care
1524556|NCT02782546|Radiation|Single dose total body irradiation|-Standard of care
1524557|NCT02782546|Procedure|Graft cell infusion|-Day 0
1524558|NCT02782546|Drug|Tacrolimus|-GVHD prophylaxis
1524559|NCT02782546|Drug|Mycophenolate mofetil|-GVHD prophylaxis
1524560|NCT02782546|Drug|G-CSF|-Continue until neutrophil engraftment as per institutional guidelines
1524561|NCT02782546|Procedure|CIML NK cell infusion|-Day +7
1524562|NCT02782546|Drug|ALT-803|-Start approximately 4 hours after CIML NK cell infusion
1524563|NCT02782546|Procedure|Leukapheresis|-Day +6
1524564|NCT02782533|Device|Deep Brain Stimulation V3|
1524565|NCT02782520|Drug|Ringer Lactate (10ml/kg) fluid expansion|
1524566|NCT02782520|Drug|Hypertonic saline (3ml/kg) fluid expansion|
1524568|NCT02782494|Other|Examination of latent TB by QuantiFERON-TB|Examination of latent TB by QuantiFERON-TB both QFT-plus QFT-GIT
1524569|NCT02782481|Drug|ND0612|
1524570|NCT02782481|Drug|ND0612 Placebo|
1524571|NCT02782468|Drug|Pevonedistat 25 mg/m^2|Pevonedistat 25 mg/m^2 intravenous infusion.
1524572|NCT02782468|Drug|Pevonedistat 44 mg/m^2|Pevonedistat 44 mg/m^2 intravenous infusion.
1524573|NCT02782468|Drug|Pevonedistat 10 mg/m^2|Pevonedistat 10 mg/m^2 intravenous infusion.
1524574|NCT02782468|Drug|Pevonedistat 20 mg/m^2|Pevonedistat 20 mg/m^2 intravenous infusion.
1524575|NCT02782468|Drug|Azacitidine 75 mg/m^2|Azacitidine 75 mg/m^2 intravenous or subcutaneous formulation.
1524576|NCT02782455|Drug|Flavonoids|Daflon is administered
1524577|NCT02782455|Drug|CDobi|Calcium dobesylate is administered
1524578|NCT02782442|Behavioral|Structured Cognitive Training & PRIME|The treatment condition-- 40 hours of CT over 12 weeks (~3.5 hours per week) in a structured program of 10 hours of social cognition exercises followed by 30 hours of auditory processing exercises, combined with the personalized PRIME coaching application
1524579|NCT02782442|Behavioral|Computer Games Control & PRIME|Computer games control condition which comes in the official PositScience wrapper. 40 hours of games over 12 weeks (~3.5 hours per week). combined with the personalized PRIME coaching application.
1524580|NCT02782429|Drug|Ketamine|
1524581|NCT02782429|Other|Saline|
1524582|NCT02782416|Other|Examination of latent tuberculosis|
1524585|NCT02782390|Other|Dental Restoration with Stainless Crown|Lesions allocated to this group will be treated with stainless dental crowns according to the Hall Technique protocol (Evans & Innes, 2010).
1524659|NCT02781727|Drug|Once daily subcutaneous injection of Genotropin|Once daily subcutaneous injection
1524698|NCT02781376|Other|Snoring Identification Only|Computer decision support system module that assesses snoring and alerts the PCP when caregivers endorse snoring.
1524586|NCT02782390|Other|Dental Restoration with Composite Resin|"Surfaces allocated to this group will be treated with composite resin (Z250, 3M ESPE, USA) according to the manufacturer's instructions.
Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. Then, the adhesive system (Single Bond, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions. Finally, composite resin (Z250, 3M ESPE, USA) will be applied and light cured according to the manufacturer's instructions."
1524587|NCT02782351|Biological|CAR-T|Patients will be infused with autologous CAR-T infusion in a dose escalating manner.
1524588|NCT02782338|Drug|Voltaren ophtha 0.1%|All study patients will be treated with Voltaren ophtha 0.1% after cataract surgery
1524592|NCT02782312|Drug|ICS+LABA|Seretide is inhaled for one year
1524593|NCT02782312|Other|routine therapy|routine therapy for one year
1524595|NCT02782286|Drug|Ketorolac|The patients randomised to this arm will receive 30 mg intravenous ketorolac.
1524596|NCT02782286|Drug|Morphine|The patients randomised to this arm will receive 0,1 mg/kg intravenous morphine.
1524597|NCT02782273|Drug|Ketorolac|The patients randomised to this arm they will receive 30 mg intravenous ketorolac.
1524598|NCT02782273|Drug|Morphine|The patients randomised to this arm they will receive 0,1 mg/kg intravenous morphine.
1524599|NCT02782260|Drug|Dipyridamole|
1524600|NCT02782260|Drug|Placebo|
1524601|NCT02782247|Device|Transient elastography|"Transient elastography will be measured using a Fibroscan® machine which is manufactured by echosens®. It has a CE mark of 0459.
It is a non-invasive method to accurately measure stiffness of a patient's liver without the need for a liver biopsy. This is measured by an externally placed ultrasound probe which creates an elastic shear wave at 50Hz, and measures the velocity of the echo through the liver tissue. The liver stiffness is measured in kilopascals (kPa). It has been shown to be 99% effective in detecting cirrhosis in hepatitis C and has been shown to correlate with hepatoma production in both hepatitis C and hepatitis B. Values range from - normal < 9.6 kPa, significant fibrosis 9.6-11.4kPa, cirrhosis >11.5kPa. It cannot be used in patients with ascites."
1524602|NCT02782247|Device|Indocyanine Green excretion|The machine to monitor the elimination of Indocyanine green is manufactured by PULSION medical systems (Munich, Germany) and consists of the PulsioFlex monitor and LiMON module. The LiMON module is a finger probe which measure near-infrared wavelengths between 805nm and 905nm. The absorption maximum for Indocyanine green is 800nm and emission at 830nm. This is then used to produce two calculations. The first is plasma disappearance rate of indocyanine green (PDRICG). This is based on working out the constant and backward extrapolation and expressed as a percentage per minute. The other is the retention ratio after 15 minutes (ICG15).
1524603|NCT02782234|Behavioral|Contract management|
1524604|NCT02782221|Drug|Growth Hormone|Subjects are receiving one injection of growth hormone (Genotropin) 0,5 mg
1524605|NCT02782221|Drug|Pegisomant|One the placebo day the subjects are receiving injection with pegvisomant (Somavert 30 mg) to block the action of endogenous growth hormone
1524606|NCT02782208|Drug|Acipimox|Acipimox is administered 4 times previous to and during the investigation day. Acipimox is used to suppress the lipolytic effect of GH.
1524607|NCT02782208|Drug|Placebo|Placebo is administered 4 times previous to and during the investigation day.
1524608|NCT02782208|Drug|GH substitution|GH substitution as usually
1524609|NCT02782208|Other|GH pause|GH substitution pause two days prior to the experimental day
1524610|NCT02782182|Drug|FOLFIRINOX (oxaliplatin, leucovorin, irinotecan)|FOLFIRINOX administered preoperatively and postoperatively
1524611|NCT02782169|Drug|Pregabalin|Pregabalin 300 mg capsule (over encapsulated to maintain blinding)
1524612|NCT02782169|Drug|Placebo|Matching placebo capsule with excipient to match Pregabalin
1524613|NCT02782156|Other|Process evaluation|Adherence to screening and action algorithm
1524651|NCT02781792|Other|Functional Assessment of Cancer Therapy - Brain|"23-item questionnaire that can be completed in 5 to 10 minutes with little or no assistance in patients who are not neurologically incapacitated. This brain subscale is usually used along with the core (general) questionnaire [2] that includes 27 items.
Patients rate all 5 items using a five-point Likert scale ranging from 0 not at all to 4 very much. Overall, higher ratings suggest higher QOL. Items are totaled to produce the following subscales, along with an overall QOL score: physical well-being (7 items); social/family well-being (7 items); emotional well-being (6 items); functional well-being (7 items); and concerns relevant to patients with brain tumors (23 items)"
1524617|NCT02782091|Behavioral|Multiple Errands Test (MET)|1 hour assessment in an unknown district with 2 independent raters.
1524618|NCT02782078|Biological|Clindamycin and rifampicin dosages|blood samples for clindamycin and rifampicin dosages (for each patient)
1524619|NCT02782065|Other|Not an interventional study|
1524620|NCT02782052|Drug|Nebulized ipratropium bromide|"Administration at V3 or V4 or V5 in a random order:
Placebo (P; sterile 0.9% sodium chloride solution)
Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone
Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
1524621|NCT02782052|Drug|Nebulized combination ipratropium bromide with salbutamol|"Administration at V3 or V4 or V5 in a random order:
Placebo (P; sterile 0.9% sodium chloride solution)
Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone
Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
1524622|NCT02782052|Drug|Nebulized Placebo|"Administration at V3 or V4 or V5 in a random order:
Placebo (P; sterile 0.9% sodium chloride solution)
Or nebulized ipratropium bromide (IB; 0.5mg/2mL) alone
Or nebulized combination ipratropium bromide with salbutamol (IB+SALB; 0.5mg/2mL + 2.5mg/2.5mL)."
1524623|NCT02782026|Device|Exhaled Breath Olfactory Signature (Artificial Nose)|
1524624|NCT02782000|Other|lessons,long-term supervision and message|
1524625|NCT02782000|Other|lessons,short-term supervision and message|
1524626|NCT02781987|Other|chronic pancreatitis|patients with chronic pancreatitis
1524627|NCT02781974|Other|Exercise|Strength and balance exercise in Groups, focusing on lower limb strength, back strength and static and dynamic balance
1524629|NCT02781948|Device|Optical Coherence Tomography|
1524630|NCT02781935|Procedure|DW-MRI|DW-MRI combined with Contrast Enhanced MRI will be used to confirm the status of disappearing liver metastasis prior to surgery and will be compared to findings from either histopathology of resected lesions (Rubbia-Brandt Classification of Tumor regression grading) or follow-up imaging of lesions left behind (either CT scan or MRI) after surgery. MRI will be used during the follow-up period to confirm recurrences from a previous site of DLM.
1524631|NCT02781922|Genetic|Autologous cardiac stem cells (JRM-001)|3x 10^5 cells/kg, single treatment
1524632|NCT02781909|Drug|Ibuprofen|Non-Steroid Anti-Inflammatory drug to be administered as adjunctive therapy
1524633|NCT02781909|Drug|Standard of Care TB treatment|Standard of Care (SoC) TB Treatment will be optimized and drugs selected according to the National and WHO Guidelines, sensitivity profile and as per routine.
1524634|NCT02781896|Device|pacing catheter|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the right ventricular pacing arm, rapid pacing is provided by a standard right ventricular pacing catheter.
1524635|NCT02781896|Device|valve delivery guidewire|Rapid pacing during TAVI is required to ensure transient cardiac standstill while predilatation is performed and the valve is being positioned and deployed. In the Left ventricular pacing arm, rapid pacing is provided via the valve-delivery guidewire inserted into the left ventricle. The cathode of an external pacemaker is placed on the external end of the guidewire using an alligator clamp. The TAVI catheter provides the necessary insulation. The anode is attached directly to the subcutaneous tissue at the femoral entry site (also using an alligator clamp).
1524636|NCT02781883|Drug|BP1001 in combination with LDAC|BP1001 in combination with LDAC
1524637|NCT02781870|Procedure|LiquiBand Fix8 glue fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible with LiquiBand® Fix 8™ glue fixation.
1524638|NCT02781870|Procedure|No-fixation|Patients will be operated in a standard procedure to receive the 3D ENDOLAP visible without glue fixation.
1524639|NCT02781857|Other|No intervention|
1524640|NCT02781844|Drug|25mcg rhPTH(1-84)|25mcg
1524641|NCT02781844|Drug|50mcg rhPTH(1-84)|50mcg
1524642|NCT02781844|Drug|100mcg rhPTH(1-84)|100mcg
1524643|NCT02781844|Drug|rhpth(1-84)|rhpth(1-84)
1524644|NCT02781831|Procedure|Standard rehab|Standard hospital based rehabilitation for patients with stroke
1524645|NCT02781831|Device|Robot-assisted gait rehabilitation|An extra 30 minutes of robot-assisted gait rehabilitation after receiving standard hospital based rehabilitation for patients with stroke
1524646|NCT02781818|Drug|Triamcinolone Acetonide 10mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
1524647|NCT02781818|Drug|Triamcinolone Acetonide 40mg/mL|Triamcinolone acetonide is a glucocorticoid used in intralesional treatment of many skin diseases, intra-articular treatment of inflammatory joint diseases, and intramuscular treatment for systemic management of systemic inflammatory diseases. It is commonly used in clinical practice for the treatment of acute abscesses and nodules of hidradenitis suppurativa, but little clinical trial data exist supporting its use.
1524648|NCT02781818|Drug|Normal Saline|Normal saline 0.1mL will be administered intralesionally at the selected site.
1524649|NCT02781805|Drug|Alendronate|10 mg (1 tablet) once daily for 1-3 weeks before breast surgery; drug will be discontinued the day before surgery.
1524650|NCT02781792|Drug|Temozolomide|-Given standard of care
1524652|NCT02781779|Device|Silverlon®|Silverlon wound dressings
1524653|NCT02781779|Device|AQUACEL® AG|AQUACEL® AG wound dressings
1524660|NCT02781714|Behavioral|Two-way SMS|"SMS messages will provide tailored and actionable education, counseling, and reminders specific to antenatal/postpartum timing and partner track. Messages will include questions and prompts; women and their male partners have the option of writing back to a nurse with questions or concerns, who will provide real-time responses via text and/or make referrals to a clinic. Message content will be tailored to women and couples, and will range from health benefits of child spacing and an emphasis on contraceptive options, to the hierarchy of effectiveness and information on specific methods, to simple reminders about postpartum visits.
Prior to randomization, each enrolled woman will be asked if she has a male partner, and whether she would like to refer her male partner for recruitment and enrollment into the study. The partner tracks are as follows:
Male partner invited to enroll/enrolled
Male partner not invited to enroll
Unpartnered"
1524661|NCT02781701|Device|Tongue Trainer|"The strength of participants tongue will be measured and participants will be shown how to perform tongue training exercises using a special device. Participants will be given instructions on how to perform a workout for the tongue. Each day once in the morning (am) and once in the afternoon/evening (pm), participants will train with the device and have a tongue workout that lasts about 10 minutes.
Therefore, participants will work out about 20 minutes a day for 6 weeks."
1524663|NCT02781675|Other|Dietary Intervention|3 wk dietary intervention with prescribed menus and ~50% foods provided.
1524665|NCT02781649|Drug|Zepatier|Fixed dose Grazoprevir 100 mg/Elbasvir 50 mg by mouth daily for 12 weeks
1524666|NCT02781649|Drug|Ribavirin|Ribavirin 1200 mg/d (> 75 kg) or 1000 mg/d (< 75 kg) by mouth daily in two divided doses
1524667|NCT02781649|Drug|Sofosbuvir|Sofosbuvir 400 mg daily
1524668|NCT02781636|Device|Device: StimGuard Protect System|Lead implanted adjacent to tibial nerve. Wireless rechargeable system.
1524669|NCT02781623|Procedure|MRI|
1524670|NCT02781610|Drug|Standard of care IV antibiotic(s)|IV antibiotics will be selected by the treating physician following standard of care. Duration of treatment is the assigned intervention.
1524671|NCT02781597|Drug|Tranexamic Acid|Patients will receive Inj Tranexamic acid, in IV in a loading dose of 1 g over 10 min followed by an infusion of 1 g over 8 h in 500ml normal saline
1524672|NCT02781597|Drug|Placebo|Patients will receive 0.9% normal saline
1524673|NCT02781584|Drug|SEL|Administered orally once daily
1524674|NCT02781584|Drug|GS-0976|Administered orally once daily
1524675|NCT02781584|Drug|GS-9674|Administered orally once daily
1524676|NCT02781571|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
1524679|NCT02781519|Drug|THC|Active THC (0.015mg/kg) administered over 10 minutes
1524680|NCT02781519|Drug|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC over 10 minutes
1524681|NCT02781506|Drug|Nivolumab|Nivolumab IV, 3 mg/kg q2 weeks
1524682|NCT02781506|Radiation|SAbR|SAbR (1-3 lesions)
1524683|NCT02781493|Drug|2 mg Prucalopride plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Prucalopride group will recieve 2 mg Linaclotide plus 2 L Polyethylene Glycol regimen before colonoscopy.
1524684|NCT02781493|Drug|2 mg Placebo plus 2 L Polyethylene Glycol regimen|Patients enrolled in the Placebo group will recieve 2 mg Placebo plus 2 L Polyethylene Glycol regimen before colonoscopy.
1524685|NCT02781480|Biological|AAV RPE65|Comparison of different dosages of AAV RPE65
1524686|NCT02781467|Biological|PNK-007|
1524687|NCT02781467|Drug|Cyclophosphamide|
1524688|NCT02781467|Drug|Fludarabine|
1524689|NCT02781467|Drug|Human recombinant Interleukin-2 (rhIL-2)|
1524690|NCT02781454|Drug|Mexiletine|
1524691|NCT02781454|Drug|Placebo|
1524692|NCT02781441|Behavioral|Question prompt list (QPL)|
1524693|NCT02781441|Behavioral|Education brochure of Groupe Français des Myélodysplasies|
1524694|NCT02781415|Procedure|Traditional Acupuncture Session|"Skin disinfection was made by an antiseptic solution in the sites of insertion and sterile acupuncture needles were used (0.25 x 0.5 mm).
Patients were installed in a seated position and needles were inserted perpendicularly through the skin to a depth of 1 - 2 cm until the De Qi was achieved.
The DeQi corresponds to a feeling of numbness and tingling within the range of acupoint, The insertion sites are represented by the urinary bladder meridian points to the side of the pain (UB21, UB22, UB23, UB24, UB26, UB45, UB46, UB47, UB48 and UB49)."
1524695|NCT02781415|Drug|Morphine Titration|"Morphine was previously prepared by a study nurse by diluting a 10 mg / 1 ml flakon of morphine chlorhydrate in a 9 ml solution of serum saline to obtain a 10 ml preparation (1 ml = 1 mg).
An initial bolus of 0.1 mg per Kg of actual body weight of morphine chlorhydrate solution is administered.
A titration dose of 0.1 mg / Kg of body weight was repeated every 5 minutes' interval until reaching the therapeutic goal."
1524696|NCT02781402|Procedure|4 weeks of Aerobic Training|The duration of aerobic training was 40 minutes for each session and 3 days per week with the intensity of 65% of their maximal oxygen consumption (VO2 max). The participants were needed to walk or jog on treadmill during the first 10 minutes at the intensity of 50-60% of maximal heart rate (HR max). The aerobic training was followed by 4 x 4 minutes intervals at 65% of maximal oxygen consumption (80% of maximal heart rate). The participants were given 3 minutes active breaks in between the intervals in which they can either walk or jog at 50-60% of maximal heart rate.
1524697|NCT02781376|Other|CHICA OSA|Computer decision support system module that assesses snoring, assesses additional OSA symptoms, provides guideline-based recommendation to PCPs, and reassesses for residual OSA symptoms.
1524701|NCT02781350|Other|HFHC meal|900 Cal high fat high carbohydrate fast food meal (HFHC). meal includes egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).
1524702|NCT02781350|Dietary Supplement|HFHC MEAL plus Fiber|900 Cal high fat high carbohydrate fast food meal containing egg muffin and sausage muffin sandwiches and two hash browns which contain 88g carbohydrates, 51 g fat (33% saturated) and 34 g protein (carbohydrates 41%, protein 17%, and fat 42%).with FiberOne Original cereal 14 grams (half cup) each before and after the HFHC meal
1524703|NCT02781324|Procedure|Posterior Spinal Fusion|
1524704|NCT02781324|Device|Ultrasonic Bone Scalpel|
1524707|NCT02781298|Dietary Supplement|New Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
1524708|NCT02781298|Dietary Supplement|Multicereals Infant Cereal|The infants will start the complementary feeding with the infants cereals of this study, the amount of cereal ingested will be free according to pediatricians recommendations.
1524709|NCT02781272|Procedure|Pelvic imaging|Within 60 days prior to the pelvic mass evaluation procedure, each subject must have a pelvic imaging study (e.g. ultrasound, CT scan, MRI, etc.) conducted and read to visualize the pelvic mass according to the current standard of care. Results of the pelvic imaging study(ies) will be recorded.
1524710|NCT02781272|Procedure|Blood draw|Within 30 days prior to, or on the day of the pelvic mass evaluation procedure, collect up to 35mL of whole blood into one 5mL SST tube, which must be drawn first, followed by three separate 10mL EDTA tubes.
1524711|NCT02781272|Procedure|Imaging guided biopsy, surgical biopsy or surgical excision|Imaging guided biopsy, surgical biopsy or surgical excision for evaluation of the pelvic mass will be performed by a qualified individual. Tissue samples will be sent to the local pathology department for histological examination in accordance with standard institutional practices. Results of the histopathological evaluation will be recorded, including the final diagnosis along with histological sub-type, and if available, stage and grade of cancer where disease is identified.
1524712|NCT02781259|Procedure|Axillary lymph node dissection|Lymph node dissection is performed in axillary lymph node level I and II. In case of palpable nodes in level II, additional lymph node dissection in level III is done.
1524713|NCT02781259|Drug|Indocyanine green|10cc of 20μg/mL indocyanine green is injected at the nipple-areola complex before surgery
1524714|NCT02781259|Device|Imaging devices|Near-infrared fluorescence is collected by imaging lenses and digital camera.
1524715|NCT02781246|Drug|perineural dexmedetomidine|"Children scheduled for arm and forearm surgery underwent supraclavicle brachial plexus blocks with ropivacaine and dexmedetomidine guided by ultrasound visualisation were randomly assigned five groups: Group A (perineural ropivacaine), Group B (ropivacaine plus 0.5 mcg/kg dexmedetomidine), Group C (ropivacaine plus 1 mcg/kg dexmedetomidine), Group D (ropivacaine plus 1.5mcg/kg dexmedetomidine) and Group E (ropivacaine plus 2 mcg/kg dexmedetomidine). In each group, children received a certain concentration of ropivacaine which adjusted by the Dixon up-and-down method for supraclavicle brachial plexus. The first child received 0.2% ropivacaine , and the concentration of ropivacaine varied by 0.1% according to the up-and-down method. The primary endpoint was the minimum local anesthetic concentration (MLAC)."
1524716|NCT02781233|Other|Progressive resistance training|
1524717|NCT02781233|Other|Normal daily activities|
1524718|NCT02781194|Device|3M™ Bair Hugger™|forced-air warming blanket
1524719|NCT02781194|Device|F&P HumiGard™ Surgical Humidification System|warmed, humidified insufflation
1524720|NCT02781181|Device|CAS with CPD|using a neuroprotection device
1524721|NCT02781181|Other|CAS without CPD|No Neuroprotection
1524722|NCT02781168|Device|use of earmuffs|The earmuffs are brand Natus® Pediatrics, Neonatal Noise Attenuators called MiniMuffs®, San Carlos, California, USA, which allow the reduction of sound pressure levels 7 to 12 decibels. Are devices that have oval and anatomical shape that allow proper positioning of the ears of newborns. They are made with a soft foam and has hydrogel adhesive on the outer edges for attachment to the skin.
1524723|NCT02781155|Other|Moxibustion|Participants are taught to self administer moxibustion to acupuncture point Zusanli St-36 daily throughout the course of their chemotherapy
1524724|NCT02781142|Other|Motor imagery training|The motor imagery training will be designed for the individual basis with following standard protocols. It will be applied three times a week for 6 weeks. The first three sessions will be performed in the clinic, the other will be performed at the patients' home with a telerehabilitation technique
1524725|NCT02781129|Other|electrical stimulation|Stimulation applied will be within parameters commonly used for the treatment of epilepsy during periods of encoding, recall, and memory maintenance .
1524726|NCT02781103|Other|Guided imagery plus active tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The guided imagery plus active tDCS arm will have tDCS for 20 minutes concurrently with Guided Imagery.
1524727|NCT02781103|Other|Guided imagery plus Sham tDCS|The subject will be positioned in the sitting/reclining position in a quiet room with the lights dimmed. The tDCS device and audio headphones will be placed on the subject's head. The tDCS device to be used is the Soterix Medical 1X1 device using 2.0 mA of current. The electrodes that will be used will be standard sponge electrodes. The subject will listen to a scripted guided imagery CD specifically developed for women with chronic pelvic pain through the audio headphones. The sham arm will have 30 seconds of tDCS, but after 30 seconds the device will be turned off. The device will remain in place until the subject has listened to 20 minutes of the guided imagery CD.
1524728|NCT02781090|Behavioral|PSFW+|PSFW+ is an eight session motivational/educational web-program promoting cessation for HIV-infected smokers. It includes a professionally administered social network/online support community.
1524887|NCT02780102|Other|Cognitive-Motor Rehabilitation|Cognitive-Motor Rehabilitation (CMR) group received 20 sixty-minute sessions of cognitive-motor exercises
1524729|NCT02781090|Behavioral|AHA|The AHA Getting Healthy website is a health-promoting, seven-module website developed by the American Heart Association to encourage healthy behaviors in the general population
1524730|NCT02781090|Drug|Nicotine polacrilex|All participants, in both study arms, will be offered a 3-month supply of nicotine patches
1524731|NCT02781077|Procedure|Structured, Progressive, Task-oriented exercise program|The intervention is walking related task-oriented exercise program with three progressive steps at moderate to high intensity. Each step consists of 60 minutes last ten tasks to optimize walking function of stroke individuals.
1524740|NCT02781025|Other|Blood draw|A blood sample of 10mL- 25mL will be collected before the start of radiation treatment.
1524741|NCT02780999|Device|Whale orthosis|Participants will be teach how to use the Whale orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain
1524742|NCT02780999|Device|Colditz orthosis|Participants will be teach how to use the Colditz orthotic to be carried for a period of three months during night and during the day in dose activities that cause pain.
1524743|NCT02780986|Behavioral|Female entertainment worker intervention group|"The following summarises the content of each session:
Session 1 (on-site): The peer educator will play 2 videos, demonstrating 5 sexy ways of putting on a condom in a pleasurable manner, and another one focusing on condom negotiation skills.
Session 2 (online): The peer educator will share an app game on condom usage and relevant online resources with the participants.
Session 3 (onsite): There will be discussion of common problems encountered in condom usage and condom negotiation by the participants. The peer educators will then conduct role plays with the participants to demonstrate the counter-strategies. In addition, the peer educators will get the participants who have been successful in condom negotiation to share their success stories.
Session 4 (online): The peer educator will share information about safe consumption of alcohol and tips to avoid getting drunk through the online platforms."
1524744|NCT02780986|Behavioral|Heterosexual men intervention group|"This will be delivered via 3 main activities:
Edutainment in the form of talk-shows based on 6 themes of sexual well-being and safe sex, held in the EE setting hosted by a famous female local comedian.
Web portal named THINK: This contains educational materials based on 6 themes of sexual health and safe sex, HIV risk profiling tool to calculate the risk of contracting HIV, videos on true life experiences of heterosexual men engaging in high risk sexual behaviour and another video on exit strategies to avoid casual or paid sex, online support for STI testing services and consultation with a clinical sexologist.
Public education event/photo booth: i. Distribution of pamphlets and brochures on sexual well-being and safe sex ii. Interactions with health promoters iii. Photo taking on safe sex messages iv. Free access to condoms and lubricants"
1524745|NCT02780973|Other|Wearing of an intraoral device with bovine tooth samples|Wearing of an intraoral device with bovine tooth samples
1524747|NCT02780947|Procedure|Ventricular tachycardia substrate ablation|"Study protocol
Baseline programmed ventricular stimulation performed from the LV
High density endocardial LV mapping using CARTO® 3 System
Randomized substrate ablation in half patients. Ablation end-point is considered the elimination of all endocardial late and early potentials (LPs and EPs)
Final programmed ventricular stimulation performed from the LV
Programmed ventricular stimulation with up to 4 extrastimuli from LV is performed and repeated at the end of the procedure in patients undergoing substrate ablation."
1524748|NCT02780934|Other|Pressure Dressing|Patients in this group will receive the standard post-operative bandage: a pressure dressing consisting of high absorbency gauze and retention tape.
1524749|NCT02780934|Other|Simple Adhesive Dressing|Patients in this group will receive the experimental bandage: a simple adhesive dressing consisting of a non adherent pad and transparent dressing.
1524750|NCT02780921|Procedure|prehabilitation|
1524751|NCT02780921|Other|nutritional support|
1524752|NCT02780908|Other|Graded exercise testing|All graded exercise tests will be performed on electromagnetically controlled cycle-ergometer Ergo Bike Premium. The testing protocol will commence with a 10-min resting period, to obtain the resting cardio-respiratory values, followed by a 5-min warm up at a work rate of 60 W. Thereafter the workload will increase every fourth minute by 40 W. The participants will be required to maintain a cadence of 60·min-1 throughout the whole test. The test is terminated when the participant is unable to maintain the assigned cadence.
1524753|NCT02780908|Other|Resting testing|The resting test will be performed in supine position with participants breathing normoxic air (FiO2=0.21) for 30 min and hypoxic gas for the subsequent 30-min (FiO2=0.120). During the whole protocol duration the respiration, local blood flow, ECG and EEG will be measured non-invasively.
1524888|NCT02780102|Drug|Ritalin|2 or 3 doses of 10 mg tablets of immediate-release Methylphenidate (Ritalin) per day for 8 week.
1524889|NCT02780102|Other|Active Control|Active Control group simultaneously received 20 sixty-minute sessions of low dose cognitive-motor exercises
1525619|NCT02774226|Drug|Tetrahydrobiopterin (BH4)|12 week intervention
1524754|NCT02780895|Drug|Human Stem Cells|"MRI-guided stereotactic intraputaminal cell implantation into PD patients was performed.
For target locations, measurements were made using CT-scan images fused with previous MR images. Bilateral parasagittal incisions and corresponding 14 mm burr holes were made in preparation for cell suspension injections.
To ensure complete cell suspension delivery, injections were carried out slowly for 2 min with reciprocal withdrawal of the delivery needle to avoid both damage to stem cells and brain tissue, as well as to avert reflux or bubble formation.
After surgery, patients were kept in a conventional post-operative care unit for 1 h. The day following surgery, MR images were obtained to confirm correct placement of cell suspensions. All patients were discharged 24 h after surgery."
1524755|NCT02780882|Drug|Pasireotide|
1524756|NCT02780869|Device|HEMOBLAST Bellows|
1524757|NCT02780869|Device|Absorbable gelatin sponge, USP with thrombin|
1524758|NCT02780856|Device|Imaging with the Calcivis System|Following identification of both sound and unsound tooth surfaces, the teeth will be air-dried and images of each tooth taken immediately before and after application of a small amount of disclosing solution. The images of each tooth will be overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
1524759|NCT02780843|Other|Computerized Tomography|Standard Operational Plan at admission: CT and CT-angiography
1524760|NCT02780843|Other|Magnetic Resonance Imaging|Standard Operational Plan at admission: Diffusion Weighted Imaging (DWI), T2-FLAIR, Gradient and arterial Time-of Flight (TOF)
1524761|NCT02780830|Drug|AZD2014|AZD2014 will be supplied as oral tablets. AZD2014 will be taken orally twice per day on an intermittent dosing schedule, 2 days on and 5 days off of each week.
1524762|NCT02780830|Drug|Ibrutinib|Ibrutinib will be provided in hard gelatin capsules in opaque high-density polyethylene bottles. On days of AZD2014 dosing, ibrutinib will be taken with the morning dose of AZD2014.
1524763|NCT02780817|Other|Error enhancement|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device, followed by one game with null force field, followed by 5 games as the main intervention with error enhancement force field, and another last game with null force field.
1524764|NCT02780817|Other|Control group|Participants will sit in front of a 3D robotic device and grab the robotic arm handle. The participants will carry out arm reaching tasks appear on a screen on front of them. Each game of tasks will lasts 2 minutes. The participants will carry out one game to be accustomed to device and another 7 games with null force field.
1524768|NCT02780791|Other|Transplantation into pelvic wall|Ovarian tissue will be transplanted subperitoneal into the loge of the adnexa of Uterus.
1524769|NCT02780791|Other|Transplantation into the ovary|Ovarian tissue will be transplanted contralateral into the ovary.
1524770|NCT02780778|Drug|Apatinib|Targeted therapy Apatinib：500 mg，po，qd
1524771|NCT02780778|Drug|Docetaxel|chemotherapy Docetaxel：60mg/m²，vein input 1hour，every 3w
1524772|NCT02780765|Device|heated humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using Heated Humidifier(HH)
1524773|NCT02780765|Device|mist humidifier|30 patients requiring overnight intubation but breathing spontaneously without ventilatory support will be supplied humidified oxygen using mist humidifier
1524774|NCT02780752|Drug|hymecromone|hymecromone treatment as described
1524775|NCT02780739|Behavioral|Cognitive Training - 48 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
1524776|NCT02780739|Behavioral|Fitness|Based on high intensity cardiovascular resistance training (HICRT), this intervention includes a combination of aerobic and strength training. Sessions are conducted in a group of ≤20 participants per class, with ≤5 participants per trainer. This intervention includes 28 70-min sessions (32.67 hrs) completed over 16 weeks: 3/wk weeks 1-4, 2/wk weeks 5-8, 1/wk weeks 9-16. At the first and last session, participants complete the Army Physical Readiness Test. All other sessions consist of: Warm-up; Walk/Run; 2 HICRT circuits with 3 sets of 3-4 exercises; 1-2 min jump rope and 4-min power series between HICRT segments; Drills & Skills; and Cool-down/stretch.
1524777|NCT02780739|Behavioral|Active Control|The active control condition consists of 2 tasks (change detection and visual search) with 3 variants each. This intervention includes 48 70-min sessions (56 hrs) completed over 16 weeks: 3/wk. The 6 tasks are played in random order for 10 min each session.
1524778|NCT02780739|Device|active tDCS|Active HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants receive 2.0 mA current for 30 min, split over the 2 anodal electrodes, each drawing ≤1.0 mA. Stimulation is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period.
1524779|NCT02780739|Device|sham tDCS|Sham HD-tDCS is administered during the first 30 minutes of each Mind Frontiers session. Therefore, the schedule is 20 30-min sessions (10 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The HD-tDCS devices are Soterix Medical 2x2 models, using 4 electrodes (2 anodal and 2 cathodal). Electrodes are held in place with custom, 3D-printed electrode holders inserted into EEG caps, using EEG gel. Participants do not receive sustained stimulation; it is ramped up and ramped down over 30 sec at the beginning and end of the 30-min stimulation period to elicit the sensation of simulation and make the sham condition more convincing.
1524780|NCT02780739|Behavioral|Cognitive Training - 20 sessions|Mind Frontiers cognitive training software (Aptima Inc.) is a Wild West-themed Android application played on Nexus 10 tablets. This intervention includes 20 70-min sessions (23.33 hrs) completed over 12 weeks: 1/wk weeks 5-8, 2/wk weeks 9-16. The 6 mini-games, played in random order for 10 min each session, are Ante Up (Tower of London, executive functioning); Irrigator (visuospatial reasoning); Pen 'Em Up (dual task switching, executive function); Supply Run (Keep Track, working memory updating); Riding Shotgun (visuospatial working memory); and Sentry Duty (dual n-back, working memory). There is also a meta-game in which players build a town using resources earned from the mini-games, played for 5 min each session.
1524781|NCT02780726|Drug|ASP1517|Oral
1524787|NCT02780700|Drug|Nintedanib|
1524788|NCT02780700|Drug|Capecitabine|
1524789|NCT02780687|Drug|Afatinib|
1524790|NCT02780674|Biological|MEDI7734|Three subjects (cohort 1) and six subjects (cohort 2-5) will receive MEDI7734 for a total of 27 subjects.
1524791|NCT02780674|Biological|Placebo|One subject (cohort 1) and two subjects (cohort 2-5) will receive placebo, for a total of 9 subjects.
1524792|NCT02780661|Device|Denture Cleanser Daily Use Period|One denture cleansing tablet will be soaked in a cup of very warm water (150 ml) with dentures for Day 0 to Day 7 for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
1524793|NCT02780661|Device|Denture Cleanser Weekly Use Period|One denture cleansing tablet will be soaked in cup of very warm water (150 ml) from Day 0 to Day 6 for 15 mins; and in cup of very warm water (150 ml) with 1 denture cleansing tablet on Day 7 at site for 15 mins. Brush dentures for 30 seconds using the solution, rinse under running water for 10 seconds.
1524794|NCT02780661|Other|Water|A cup of very warm water will be used to soak one denture cleansing tablet and dentures for per day (Day 0 to Day 7) or weekly (Day 0 and Day 7) treatment regimen.
1524795|NCT02780648|Radiation|Stereotactic Body Radiation|
1524796|NCT02780635|Behavioral|Mobile App + Mailed Materials for managing stress associated with PTSD|"PTSD Coach and PTSD Family Coach mobile apps plus mailed Couples Coach intervention materials and discussion board added to PTSD Family Coach app"
1524797|NCT02780635|Behavioral|Mobile App for managing stress associated with PTSD|PTSD Coach and PTSD Family Coach mobile apps
1524798|NCT02780622|Drug|Oseltamivir|Oseltamivir 75 mg orally, twice daily for 4 days and once on Day 5.
1524799|NCT02780622|Drug|Warfarin|Warfarin once daily, at a dose determined through titration by participants' usual hematologist.
1524800|NCT02780609|Drug|Selinexor|Selinexor will be given orally 2 to 3 hours prior to high dose-melphalan IV infusion. Phase I: Dose escalation beginning with 40 mg to determine the recommended Phase II dose (RPh2D). Phase II: Treatment at RPh2D.
1524801|NCT02780609|Drug|Melphalan|Melphalan 100 mg/m^2 IV over 30-45 minutes.
1524802|NCT02780609|Drug|Dexamethasone|Dexamethasone 20 mg PO (or IV) daily (on days -3, -2 and -1) will be given to participants as an antiemetic.
1524803|NCT02780609|Procedure|Autologous Hematopoietic Cell Transplantation (HCT)|Participant's own stem cells are collected from their blood, frozen, then given back to them after chemotherapy.
1524804|NCT02780596|Other|Item1|Does CHILD NAME often wake one or more times during the night?
1524805|NCT02780596|Other|Item2|Does CHILD NAME often wake one or more times per night, and does and adult go to him/her?
1524806|NCT02780596|Other|Item3|Do you think CHILD'S SLEEP is a problem?
1524807|NCT02780596|Other|Item4|Do you think CHILD NAME has a sleep problem?
1524808|NCT02780596|Other|Item5|Do you have any concerns about CHILD NAME'S sleep?
1524809|NCT02780583|Drug|kineret|anakinra administered subcutaneously every 6 hours x 72 hours along with intravenous methylprednisolone
1524810|NCT02780583|Drug|placebo|placebo injection administered every 6 hours along with intravenous methylprednisolone
1524811|NCT02780570|Procedure|Small Volume Plasma Exchange|Six sessions will be done daily for consecutive 8 days (total 48 sessions). 7 ml/body weight blood will be drawn at each session and will be separated into plasma and blood cells. Blood cells will be infused back to the patients and plasma will replaced by equal volume of fresh frozen plasma and colloid solution. At the end of each day 1200 ml plasma (total 9600 ml in 48 sessions) will be removed.
1524812|NCT02780557|Behavioral|Contingent Reading Intervention|Caregivers will be provided with 6 picture books. They will be trained to use contingent talk when looking at picture books with their infants. They will be asked to spend 10 mintues each day engaging in contingent talk while looking at picture books. The intervention will run for 4 months. Parents will be asked to keep a daily reading diary.
1524813|NCT02780557|Behavioral|Book Provision Control|Caregivers will be provided with 6 picture books. They will not be trained to read with their child. They will receive information from other sources (e.g. health visitors and Book Start schemes) as normal.
1524814|NCT02780544|Behavioral|skin-to-skin contact|skin-to-skin contact with parent during eye examination.
1524815|NCT02780544|Device|incubator|staying in incubator during eye examination.
1524816|NCT02780544|Drug|Sucrose|oral sucrose before eye examination
1524817|NCT02780518|Device|Airvo|Applying high flow nasal oxygen
1524818|NCT02780505|Drug|vitamin c|"In the current prospective, double-blind, and randomized trial, 66 patients with peritoneal dialysis were enrolled, and 43 patients were detected with serum vitamin C level below 4 μg/ml to determine the effect of vit C on anemia in patients on CAPD.
The measured clinical parameters including plasma vitamin C level, hemoglobin (Hb), Ferritin, total iron-binding capacity (TIBC), serum Fe, C-reactive protein (CRP), and transferrin saturation. Consumption of vitamin supplements such as vitamin C (or any other form of it) either oral or parenteral were discontinued three weeks before collecting the samples."
1524890|NCT02780076|Other|Functional training program|Patients treated for hip fracture participate in a functional training program during their short-term stays at nursing homes. The program is initiated by the nurses 4 times a day for 3 weeks as part of the habitual routine.
1524891|NCT02780063|Device|Lenstar Biometer|
1525060|NCT02778672|Other|Thermal imaging of infant's chest with a mobile phone|
1524819|NCT02780505|Drug|placebo|"Active (ascorbic acid 250 mg) and placebo (same weight of starch) tablets were similar in shape and size for both study and control groups. Intravenous intervention was not advantageous for hemodialysis subjects and it was impossible for PD patients, therefore, oral administration was used. All follow-up records were stored.
The erythropoietin (EPO) injections was prescribed for each patient in weekly dose, started one month before collecting blood samples for vitamin C measurement."
1524820|NCT02780492|Other|Set of assessment tools|
1524821|NCT02780479|Drug|Dexamethasone|at 24 hours from the first Dexamethasone dose given in ED.
1524822|NCT02780479|Drug|Prednisone|at 24 hours from the first Dexamethasone dose given in ED.
1524823|NCT02780453|Device|Negative pressure dressing|
1524824|NCT02780453|Device|Standard wound dressing|
1524825|NCT02780440|Behavioral|Traditional Home Based Exercise Program|Subjects in the control group will receive a traditional home Occupational Training exercise program as per conventional OT guidelines with the same home program duration.
1524826|NCT02780440|Behavioral|Unimanual Home Based Mirror Therapy Program|The affected hand will remain still in the mirror box, the unaffected hand will perform the exercises while the subject watches the mirror reflection.
1524827|NCT02780440|Behavioral|Bimanual Home Based Mirror Therapy Program|The affected hand in the mirror box will best mimic the unaffected hand, while also watching the mirror reflection.
1524828|NCT02780427|Drug|intranasal dexmedetomidine|"Phase 1, Children received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for TEE study. The first child received 2.5 mcg/kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose varied by 0.1 mcg/kg according to the up-and-down method Phase 2 was a dose-escalation study. After interim analysis of the phase 1 results, four dose levels above the calculated ED50 were defined. Dose spacing was set at 0.3 mcg/kg of intranasal dexmedetomidine consistent with the re-estimated standard deviation (SD)."
1524829|NCT02780401|Other|Laboratory Biomarker Analysis|Correlative studies
1524830|NCT02780401|Biological|pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine|Given ID
1524831|NCT02780401|Biological|Sargramostim|Given ID
1524834|NCT02780375|Procedure|Blood donation during radiotherapy|Participants will be asked to donate a blood sample at 5 time points before and during their radiotherapy
1524835|NCT02780362|Drug|Prodactariv|1 tablet contains 60 mg Daclatasvir
1524836|NCT02780362|Drug|Clatazev|1 tablet contains 60 mg Daclatasvir
1524837|NCT02780349|Device|WIRION|Embolic Protection System
1524838|NCT02780336|Other|No intervention.|Participants will complete questionnaires and interviews as well as have a neurological exam that will be video recorded. For this exam they will do simple movements (like looking at the camera, squeezing your eyes closed, moving your head, and writing).
1524839|NCT02780323|Drug|CELBESTA®|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
1524840|NCT02780323|Drug|CELEBREX®|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
1524841|NCT02780323|Drug|CELEBREX® placebo|1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
1524842|NCT02780323|Drug|CELBESTA® placebo|1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
1524843|NCT02780310|Drug|Lenvatinib|
1524844|NCT02780284|Behavioral|Physical activity intervention|150 minutes per week of moderate intensity cardiovascular exercise
1524845|NCT02780271|Behavioral|In-person education|Four in-person hands-on nutrition and physical activity education classes and cooking sessions.
1524846|NCT02780271|Behavioral|E-communication|11 months of motivational text messages, emailed newsletters, and access to a website.
1524847|NCT02780271|Behavioral|Control|Written guidelines on diet and physical activity for breast cancer survivors, a pedometer to encourage physical activity, and a brief verbal overview of diet and physical activity guidelines for cancer survivors.
1524848|NCT02780258|Device|Restylane Silk|
1524849|NCT02780245|Drug|Tranexamic Acid|At 20 minutes preoperatively, TXA of 20 mg/kg was administered in Z Solution (500•0 ml normal saline containing a prophylactic antibiotic 1•0 g).
1524850|NCT02780245|Procedure|Intraoperative Uterine Cooling|Intraoperatively immediately following delivery of the fetus the uterus was been externalized in the usual fashion, and the body of the uterus cephalad to the hysterotomy incision was been wrapped in sterile surgical towels saturated in sterile and iced normal saline. These towels came from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels was been kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
1524851|NCT02780232|Behavioral|Cuida tu animo / Care for your mood|"CUIDA TU ÁNIMO is an online program to adolescents that provides information, education and support related to the care of the mood.
Adolescents interact with the program via a monitoring e-mail that they receive every two weeks (Monitoring) and a website which allows them to access a number of links. The website have the following modules:
What is 'CUIDA TU ÁNIMO': Description and definition of the program
Psycho-educational information: Information about depression, its treatment, and opportunities for prevention
How is your mood? (Monitoring): a) Online assessment of symptoms every two weeks during three months with the PHQ-3. b) Feedback
Forums.
Blog.
Appointment (Chat or Phone call).
Contact."
1524852|NCT02780219|Other|stable amino acid infusion|stable isotopes Such as L-[ring-13C6]-Phenylalanine, L-[ring-D4]Tyrosine, L-[Methyl-D3]Tau-Methylhistidine, trans-[2,5,5-D3]4-Hydroxy-L-proline, L-[Guanido-15N2]-Arginine, L-[4,4,5,5-D4-5-13C]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-[1,2-13C2]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-[methyl-D3]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-[3,3,4,4-D4]Homocysteine, L-[1,2-13C2]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-[Dimethyl-13C2]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-[3,4-methyl-13C3]isovaleric acid, 13C3-glycerol is given IV simultaneously
1524931|NCT02779712|Procedure|Sham|4 cycles of intermittent sham procedure (1 cycle = 5 minutes inflation to 30 mmHg, 5 minutes deflation), matching the dose escalation described in the intervention
1524932|NCT02779699|Drug|AL2846|AL2846 p.o. qd
1524933|NCT02779673|Other|Yoghurt drink containing plant stanol as esters|
1524934|NCT02779673|Other|Yoghurt drink without plant stanol as esters|
1524853|NCT02780219|Other|acute exercise with amino acid infusion|resistance exercise of each limb (i.e., leg (right/left); arm (right/left) on an isokinetic exercise machine allowing control of velocity, force, etc. with stable isotopes such as L-[ring-13C6]-Phenylalanine, L-[ring-D4]Tyrosine, L-[Methyl-D3]Tau-Methylhistidine, trans-[2,5,5-D3]4-Hydroxy-L-proline, L-[Guanido-15N2]-Arginine, L-[4,4,5,5-D4-5-13C]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-[1,2-13C2]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-[methyl-D3]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-[3,3,4,4-D4]Homocysteine, L-[1,2-13C2]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-[Dimethyl-13C2]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-[3,4-methyl-13C3]isovaleric acid, 13C3-glycerol is given IV simultaneously
1524854|NCT02780219|Other|24-hour post exercise amino acid infusion|stable isotopes such as L-[ring-13C6]-Phenylalanine, L-[ring-D4]Tyrosine, L-[Methyl-D3]Tau-Methylhistidine, trans-[2,5,5-D3]4-Hydroxy-L-proline, L-[Guanido-15N2]-Arginine, L-[4,4,5,5-D4-5-13C]Citruline, L-13C5 -Ornithine, L-15N2-Glutamine, L-[1,2-13C2]Glutamic Acid, 1-13C-Glycine, L-15N3-Histidine, L-13C6-Leucine, L-[methyl-D3]Methionine, α-1-13C-ketoisocaproic acid, L-1-13C-Methionine, DL-[3,3,4,4-D4]Homocysteine, L-[1,2-13C2]Taurine, L-(Indole-D5)Tryptophan, 13C-Urea, L-1-13C-Isoleucine, L-13C5-Valine, α-[Dimethyl-13C2]ketoisovaleric acid, 2-keto-3-methyl-13C6-pentanoate, 3-hydroxy-[3,4-methyl-13C3]isovaleric acid, 13C3-glycerol is given IV simultaneously
1524856|NCT02780193|Drug|Omegaven|Therapy with Omegaven® will be initiated and maintained at 1 g/kg/day. It will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. If additional non-protein calories are needed, they will be provided as carbohydrates. No other parenteral form of fat emulsion will be used during Omegaven® therapy.The Omegaven® dose may be discontinued if the subject is receiving adequate enteral nutrition to meet metabolic and growth needs.
1524859|NCT02780167|Drug|PF-04965842|10 mg of PF-04965842 QD for 12 weeks
1524860|NCT02780167|Drug|PF-04965842|30 mg of PF-04965842 QD for 12 weeks
1524861|NCT02780167|Drug|PF-04965842|100 mg of PF-04965842 QD for 12 weeks
1524862|NCT02780167|Drug|PF-04965842|200 mg of PF-04965842 QD for 12 weeks
1524863|NCT02780167|Drug|Placebo|Placebo QD for 12 weeks
1524864|NCT02780154|Biological|PfSPZ (7G8)|PfSPZ (7G8) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
1524865|NCT02780154|Biological|PfSPZ (NF54)|PfSPZ (NF54) is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
1524867|NCT02780128|Procedure|Biopsy|Needle or incisional tumor biopsy
1524868|NCT02780128|Drug|Ceritinib|Participants will take ceritinib once per day orally for 28 days.
1524869|NCT02780128|Drug|Trametinib|Participants will take trametinib once per day orally for 28 days.
1524870|NCT02780128|Drug|HDM201|Participants will take HDM201 orally on Day 1 and Day 8 of a 28-day cycle.
1524871|NCT02780128|Genetic|Next Generation Sequencing|Tumor tissue will be sent to Foundation Medicine laboratory for molecular profiling.
1524872|NCT02780128|Procedure|Tumor Scans|Participants will undergo different types of scans to look at your tumor. These scans include CT (computerized tomography), MIBG (meta-iodobenzylguanidine) PET (positron emission tomography), and MRI (magnetic resonance imaging). Participants may have more than one type of scan.
1524873|NCT02780128|Radiation|X-ray|Participants will have x-rays of the wrist and leg.
1524874|NCT02780128|Procedure|Bone marrow Tests|Participants will have needles inserted through their hip bone to remove fluid from inside the bone marrow. This test determines if participants have tumor in the bone marrow.
1524875|NCT02780128|Other|Physical Exam|The exam includes taking participant weight, height, blood pressure, heart rate and respiratory rate and performing a examination of the participants body. The investigators may also check the participants vision with an eye chart.
1524876|NCT02780128|Other|Eye Exam|Participants will have their eyes will be evaluated using different instruments. Participants will also be asked to read an eye chart. The exams will take about 15 minutes.
1524877|NCT02780128|Other|Labs|Standard blood tests will be done to measure different types of blood cells, to measure the amount of certain substances, and tests to check how well liver and kidneys are working. When possible, the investigators will take blood from the participants central line. If this is not possible, the investigators will take blood from a vein in the participants arm. First, the investigators will put some cream on the skin so that drawing blood will not be painful. Then the investigators will put a thin needle into the vein to draw the blood.
1524878|NCT02780128|Other|Pregnancy Test|If the participant is 11 years old or older or has already started having periods, the participant will be asked to take a pregnancy test before starting this study. The results will be shared with the participant but not with the participants' parent(s). We strongly encourage the participant to share the results with the parents. If the participant is found to be pregnant, the participant will not be able to continue participation in the study. About 1 teaspoon of blood (or urine if a urine test) will be needed.
1524879|NCT02780128|Behavioral|Interviews|A team member will take the participant's medical history, along with a listing of any medications that are being taken. Throughout the study, participants will be asked to report if they think that anything bad has happened as a result of the study.
1524880|NCT02780128|Other|ECG|This is a test of electrical activity of the heart. The investigators will put electrodes (sticky pads attached to wires) on the participant's chest, arms and legs. The electrocardiogram (ECG) will not be uncomfortable, but the participant will have to lie still. It does not hurt and takes about 15 minutes.
1524881|NCT02780128|Other|echocardiogram|The participant will have an ultrasound of the heart taken to assess heart function. The investigators will put some gel on the skin and use a machine to take pictures of the heart.
1524882|NCT02780128|Drug|Ribociclib|Participants will take ribociclib once per day orally for 21 days, followed by 7 days rest.
1524883|NCT02780115|Drug|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
1524884|NCT02780115|Drug|AGN-190584 ophthalmic solution|1 drop of AGN-190584 ophthalmic solution Doses A, B, C in the eye.
1524892|NCT02780050|Other|core muscle activation using physical fitness|"2 instructors, they had physical therapy (PT) certificate, take an exam for subject's muscle strength of each muscle. After that time, subjects take a rest for 10 minutes. Researchers educate to subjects for high quality CPR including 5 to 6cm compression depth, 100 to 120 beat per minute (bpm) rate, complete chest recoil. Subjects perform chest compression to manikin with skill reporting system during 4min under guidance of 110 bpm metronome sound (first chest compression). After 1st chest compression, subjects take a rest during an hour and carry out PT. PT consist of 30 second plank for 3 sets, 12 times bridge for 3 sets and 20 times leg extension for 3 sets. Subjects take a rest during 30 seconds between sets, 1 minute every 3 sets.
After PT completion, subjects take a rest during 10 minutes, and then perform 2nd chest compression in the same way of 1st chest compression. Researchers record subject's chest compression depth and rate in 1st and 2nd chest compression."
1524893|NCT02780037|Behavioral|Regulatory frame: prevention|Exercise program presented as preventing deterioration.
1524894|NCT02780037|Behavioral|Regulatory frame: promotion|Exercise program presented as promoting improvement.
1524895|NCT02780037|Behavioral|Regulatory frame: not implied|Exercise program presented without implied consequences.
1524896|NCT02780024|Drug|Metformin|Metformin,
1524897|NCT02780011|Drug|Brentuximab Vedotin|Antibody-drug conjugate composed of the anti-CD30 chimeric immunoglobulin G1 monoclonal antibody cAC10 and the antimicrotubule drug monomethyl auristatin E connected by a protease-cleavable linker.
1524898|NCT02780011|Drug|Alsertib|Aurora A kinase inhibitor
1524899|NCT02779998|Other|non invasive ventilation|non invasive ventilation is delivered by a specific respirator with inspiratory help mode. NIV mask and parameters are adapted to obtains a Tidal volume ≤ to 8 ml/kg/cycle (if possible ≤ 6 ml/kg/cycle) and a SpO2 superior of 94%.
1524900|NCT02779998|Other|Standard oxygen therapy with facial mask|
1524901|NCT02779985|Dietary Supplement|Lycium Barbarum mixed meal|This mixed meal contains 25 grams of dried Lycium Barbarum (Goji berry, Wolfberry)
1524902|NCT02779985|Dietary Supplement|Control mixed meal|This mixed meal does not contain Lycium Barbarum, but is matched for energy and macronutrient content
1524903|NCT02779972|Other|Echo stress test|Echo stress test
1524904|NCT02779959|Drug|Prochlorperazine|
1524905|NCT02779946|Device|Fibro Scan|
1524906|NCT02779946|Genetic|PNPLA3|
1524907|NCT02779933|Other|Epidemiology od HAP|no intervention
1524908|NCT02779920|Procedure|per oral pylorotomy|The procedure is endoscopic pylorotomy. The standard procedure consists in the realization of a longitudinal incision of 2 cm at the anterior surface of the gastric antrum at 5 cm from the pylorus after a submucosal injection of a solution containing 85% saline 10% glycerol and 5% fructose. This longitudinal incision serve as an input for producing a submucosal tunnel dissected fibers gastric submucosa step. The internal circular of the pyloric muscle is then severed fiber after fiber over its entire length and its entire thickness. Once the pyloric section completed, the tunnel inlet will be closed by means of hemostatic clips.
1524909|NCT02779907|Other|No Intervention|No interventions planned for this observational study
1524910|NCT02779894|Other|Remote control of patients|Diagnosis outside the hospital (3 Home PR) CPAP (if needed) titration at home REmote control of patient's during 3 months by video or phonoconference
1524911|NCT02779881|Dietary Supplement|Extensively hydrolyzed casein formula plus LGG|
1524912|NCT02779868|Dietary Supplement|Omega-3|patients included in this group will take 2g (4 capsules) per day of eicosapentaenoic acid.
1524913|NCT02779868|Dietary Supplement|Olive oil|patients included in this group will take 4 capsules per day of olive oil.
1524914|NCT02779855|Biological|Talimogene laherparepvec|Talimogene laherparepvec injection. Phase I: Dose escalation. Phase II: Treatment at Maximum Tolerated Dose (MTD) from Phase I. The MTD dose level is defined as the highest dose level with ≤1 out of 6 patients experiencing a dose limiting toxicity (DLT).
1524915|NCT02779855|Drug|Paclitaxel|Paclitaxel chemotherapy infusion. The paclitaxel weekly dose is fixed at 80 mg/m^2.
1524916|NCT02779842|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. formulation number SR15-39-Z12-002.
1524917|NCT02779829|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. Formulation number SR15-40-Z12-006.
1524918|NCT02779803|Procedure|EC-IC bypass|To determine if cerebral revascularization via STA to MCA bypass to improve cerebral hemodynamics, cognitive function, and quality of life in a defined subgroup of symptomatic carotid occlusion patients.
1524919|NCT02779790|Other|Liquid Meal Replacements|An intervention that contains a mixture of protein, carbohydrate, and fat, along with added vitamins and minerals in liquid ready-to-drink or powder formulas that require mixing.
1524922|NCT02779751|Drug|Abemaciclib|Administered orally
1524923|NCT02779751|Drug|Pembrolizumab|Administered IV
1524924|NCT02779738|Drug|Merestinib|Administered orally
1524925|NCT02779725|Behavioral|SCC|Automated self-management coaching paired to symptom reports during daily symptom monitoring call
1524926|NCT02779725|Behavioral|Nurse Practitioner|Alerts generate if a patient reports symptoms above pre-set thresholds during daily symptom reporting calls . These alerts are monitored and follow up is given by a Nurse Practitioner.
1524927|NCT02779725|Behavioral|DSS|A Clinical Decision Support System (DSS), based on evidenced based guidelines, will be used to assist the nurse practitioner in follow up to symptom alerts.
1524928|NCT02779725|Behavioral|AT|An activity tracker will be provided to evaluate its use, acceptability and impact on fatigue severity. The purpose of providing the activity tracker is to extend the self-management coaching intervention given when participants report fatigue and receive coaching about exercise as part of the intervention.
1524929|NCT02779725|Behavioral|Symptom Severity|Automated patient-reporting of 11 common cancer treatment symptoms
1524930|NCT02779712|Procedure|Remote ischaemic conditioning|1 dose (=4 cycles) of intermittent upper limb ischaemia (1 cycle = 5minutes inflation to 20mmHg above systolic BP, 5 minutes deflation). Dose escalation: (i) Recruits 1-20 receive this cycle once (ii) Recruits 21-40 receive a second dose of 4-cycles one hour after the first. (iii) Recruits 41-60 receive further dosing, twice daily until day 4.
1524935|NCT02779660|Procedure|Remote ischemic preconditioning (RIPC)|RIPC will be induced by the application of 3 short episodes (5 minutes) of forearm ischemia by cuff sphygmomanometer inflation separated by 5 minutes of reperfusion.
1524936|NCT02779660|Procedure|sham-intervention|In the control group the cuff will be inflated for 3 times at 10 mm Hg for 5 minutes with 5-minute intervals
1524937|NCT02779647|Behavioral|The intervention consisted of physical activity based on play|The intervention consisted of physical activity based on play, with four 90-minute sessions per week for nine months (the school year). Attendance at all sessions was recommended, and the children were obliged to participate in at least two sessions every week, in order to perform the minimum level of physical activity recommended for their ages. This attendance pattern was adopted to provide flexibility for families who might have difficulty in attending all the sessions, thus enabling them to participate in the study. In parallel, twice-monthly theoretical and practical sessions of nutritional advice were given to the children and their families. The study group performed the physical activity and received the nutritional advice, while the control group received only the theoretical and practical sessions on nutrition.
1524938|NCT02779634|Drug|ubiquinol|Ubiquinol three times daily
1524939|NCT02779634|Drug|Placebo|Sugar pill three times daily
1524940|NCT02779621|Procedure|Self-collecting a vaginal sample with a swab for HPV testing|The vaginal sample self-collected with the Floq swab will be tested for Human Papillomavirus (HPV) using Abbott RealTime PCR assay.
1524941|NCT02779621|Procedure|Collection of cervical sample for routine cervical screening|This is the routine cervical screening test available to the public through the NHS. This sample is collected by a clinician (usually a Practice Nurse)
1524942|NCT02779608|Drug|intraperitoneal docetaxel|One peritoneal access port will be implanted in subcutaneous space of patients' abdominal wall after laparoscopic exploration.Then intraperitoneal docetaxel in 1litre normal saline will be administered through the port
1524943|NCT02779608|Drug|oral S-1|40mg/m² twice daily on day 1-14 every 3 weeks
1524944|NCT02779595|Other|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the the third, fifth and seventh postoperative day
1524945|NCT02779582|Drug|Oral Micronized Progesterone|The dose of 300 mg of Progesterone is a physiological one that maintains the serum progesterone at or above the luteal (normal post-ovulatory) threshold for 24 hours. This duration of action is important because Progesterone is not safely taken during waking hours because of its soporific effects.
1524946|NCT02779582|Drug|Placebo|pill with no effect
1524947|NCT02779569|Drug|decitabine|
1524948|NCT02779556|Other|ACP Living with Diabetes Guide|American Colleges of Physicians (ACP) Living Well with Diabetes Guide
1524949|NCT02779556|Other|ADA Living Well with Diabetes Workbook|American Diabetes Association (ADA) Living Well with Diabetes Workbook
1524950|NCT02779543|Device|Fitbit|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
1524951|NCT02779543|Device|Jawbone UP|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
1524952|NCT02779543|Device|Microsoft Band|Subjects will be recruited from those patients attending a regularly scheduled overnight PSG sleep study at the Weill Cornell Medical College Center for Sleep Medicine. Willing subjects, after providing informed consent, will be fitted with one of the three aforementioned sleep monitoring devices (randomly assigned) on the wrist of their non-dominant hand when prepared for the sleep study by a technician.
1524953|NCT02779530|Drug|Diclofenac|50 mg po, b.i.d for 6 days
1524954|NCT02779530|Other|Placebo|Placebo po, b.i.d. for 6 days
1524955|NCT02779517|Device|Mobile Service Robot|The goal is to build a low-cost mobile service robot that will focus on the simple, but key, repetitive, data-driven tasks that robots do well. Rather than attempt to create a robot helper that mimics humans, the goal is to free human caregivers from the time-consuming tasks that robots can accomplish with facility, thereby allowing humans to focus on tasks that humans do best (i.e. human contact).
1524956|NCT02779491|Behavioral|5-a-day fruit and vegetable mobile phone application|5-a-day fruit and vegetable mobile phone application
1524957|NCT02779478|Procedure|Bronchoscopy|
1524958|NCT02779465|Drug|Vitamin D3|Participants with chronic hepatitis B will take 800 IU of vitamin D3 per day by mouth besides the anti-virus treatment with nucleos(t)ide medicine
1524959|NCT02779439|Biological|Virus specific CTLs|Virus specific CTLs will be given to patients with persistent or recurrent viral reactivation after 2 weeks of standard anti-viral therapy
1524960|NCT02779426|Behavioral|Text messages|Daily text messages with information about atopic dermatitis and treatment reminders.
1524961|NCT02779413|Drug|insulin degludec|Patients will be treated with commercially available Tresiba® FlexTouch® according to routine clinical practice at the discretion of the treating physician.
1524963|NCT02779387|Drug|Goserelin Acetate|
1524964|NCT02779374|Other|Autologous bone marrow transplantation|Bone marrow aspiration of 10 ml/kg is done from the posterior iliac crest. The sample is put in sterile container with appropriate amount of heparin then filtered to remove bone spicules, fat, and cellular debris. The filtered sample is injected unprocessed in a peripheral vein. The process is done once.
1524965|NCT02779361|Dietary Supplement|Green tea|"Lipton pure green tea, 5 teas on the first 6 days, and 9 teas on the day 7. Teas will be ingested at 08:00 am, 10:30 am, 13:00 pm, 15:30 pm, 18:00 pm days 1-6, and 08:00 am (*), 10:30 am, 13:00 pm (*), 15:30 pm, 18:00 pm (*), 20:30 pm on day 7.
One bag of tea will be used to prepare the beverages with exception of some beverages on day 7 that will be prepared with two bags (*)."
1524966|NCT02779348|Drug|BIA 3-202|Nebicapone tablets 200 mg
1524967|NCT02779348|Drug|warfarin|Varfine® 5 mg (warfarin 5 mg) tablets
1524968|NCT02779335|Other|Enteral Formula|pediatric subjects will be fed a standard pediatric enteral formula tube feeding
1524969|NCT02779322|Procedure|Minigastric bypass|The patient will be submitted to a minigastric bypass at the time of the operation
1524970|NCT02779322|Procedure|Gastric bypass|In this case a simplified conventional gastric bypass will be performed
1524971|NCT02779309|Procedure|Home Care/RAI-HC Assessment|Home care recipients who have received a comprehensive health assessment using the Resident Assessment Instrument for Home Care (RAI-HC).
1524972|NCT02779296|Other|2-Octyl Cyanoacrylate Glue|topical
1524973|NCT02779283|Drug|Cytarabine|Given IV
1524974|NCT02779283|Drug|Dasatinib|Given PO
1524975|NCT02779283|Drug|Idarubicin|Given IV
1524976|NCT02779283|Other|Laboratory Biomarker Analysis|Correlative studies
1524977|NCT02779283|Drug|Nilotinib|Given PO
1524978|NCT02779283|Drug|Ponatinib Hydrochloride|Given PO
1524979|NCT02779283|Drug|Sorafenib Tosylate|Given PO
1524980|NCT02779283|Drug|Sunitinib Malate|Given PO
1524981|NCT02779270|Drug|BAY987518|"Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
Formulation: V27-104"
1524982|NCT02779270|Drug|Sunscreen Lotion (U77-030 Control)|Apply the assigned test product to all sun-exposed areas of the face and body while avoiding contact with mouth, eyes and eyelids.
1524983|NCT02779257|Drug|Pasireotide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
1524984|NCT02779257|Drug|Diazoxide|Pasireotide will be used, in addition to diazoxide, as a medical treatment to blunt hypoglycemia in the setting of autonomous insulin secretion.
1524987|NCT02779231|Other|Bi-directional texting|
1524988|NCT02779218|Procedure|Paired Associative Stimulation|Patient with Paired Associative Stimulation only
1524989|NCT02779218|Procedure|Paired Associative Stimulation + Motor Imagery exercises|Patient with Paired Associative Stimulation + Motor Imagery exercises
1524990|NCT02779218|Procedure|Placebo Paired Associative Stimulation + Motor Imagery exercises|Patient with placebo Paired Associative Stimulation + Motor Imagery exercises
1524991|NCT02779205|Procedure|adipose tissue sample|adipose tissue sample
1524992|NCT02779192|Drug|SPI-1005 200mg|Oral SPI-1005 capsules, 200 mg ebselen, twice daily, 7 days
1524993|NCT02779192|Drug|SPI-1005 400mg|Oral SPI-1005 capsules, 400 mg ebselen, twice daily, 7 days
1524994|NCT02779192|Drug|Placebo|Oral SPI-1005 capsules, 0 mg ebselen, twice daily, 7 days
1524995|NCT02779179|Procedure|Periodontal treatment|"Mechanical debridement (scaling, root planning, subgingival curettage)
Antimicrobial therapy (systematically administered: amoxicillin or clindamycin).
Antiseptic mouthrinses, gel or dentifrice
Oral hygiene instructions (to educate and motivate patients to control the accumulation of plaque and calculus)"
1524998|NCT02779153|Drug|Acthar low dose (40 U)|The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
1524999|NCT02779153|Drug|Acthar high dose (80 U)|The 80U group will administer 1.0 mL of study medication every day. If a patient meets dose reduction criteria, their assigned volume will be adjusted from 1.0 mL to 0.5 mL. Patients will taper study medication during Week 2 through the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
1525000|NCT02779140|Biological|NTM-1632|Monoclonal antibody mixture of XB10, XB18, and XB23
1525001|NCT02779140|Other|Placebo|Placebo
1525002|NCT02779127|Other|Medical interrogatory|Cardiovascular risk, medical history, known pathologies and actual treatments are evaluated
1525003|NCT02779127|Other|Medical examination|Systolic blood pressure, diastolic blood pressure, cardiac frequency, pulse palpation, hearth and pulmonary auscultation
1525004|NCT02779127|Other|Specific bioassay|Exhaled carbon monoxide measure and nicotine in the urine are evaluated
1525005|NCT02779127|Other|Endothelial function evaluation|Endothelial function evaluation done by echotracking determining the basale flow mediated dilatation
1525006|NCT02779127|Other|General bioassay|Fasting bioassay evaluating total cholesterol, low density lipoproteins, high density lipoproteins, triglycerides, creatine, transaminases, gamma glutamyl transferases, fibrinogen, reactive protein C, blood count and sedimentation rate.
1525007|NCT02779114|Drug|Control group|Stable dosage of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
1525008|NCT02779114|Other|Reduction group 1|Dose reduction of 50% for 12 months of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®)
1525009|NCT02779114|Other|Reduction group 2|Dose reduction of 50% of previous treatment with Decortin H®, Leflunomid (e.g. Arava®), Ciclosporin (e.g. Immunosporin®), Sulfasalazin (e.g. Azulfidine RA®, Pleon RA®), Hydroxychloroquine (e.g. Quensyl®); Azathioprin, Methotrexate (e.g. Lantarel®, Metex®), Etanercept (Enbrel®), Adalimumab (Humira®), Infliximab (Remicade®), Tocilizumab (RoActemra®), Golimumab (Simponi®), Certolizumab (Cimzia®), Abatacept (Orencia®) for 6 months and if they are still in remission therapy will be discontinued.
1525010|NCT02779101|Drug|pembrolizumab|Pembrolizumab 200 mg every 3 weeks
1525011|NCT02779088|Behavioral|strengthening exercise|L/E strength training for 30 min at frequency of biw. Lasting for 12 weeks Evaluation before and after 12-week training Body composition, balance, blood chemistry, physical fitness, gait speed.
1525012|NCT02779075|Drug|Saline|Subjects will be studied on 2 occasions, in random order. During the saline study they will be infused with saline.
1525013|NCT02779075|Drug|Exendin-9,39|Subjects will be studied on 2 occasions, in random order. During the Exendin-9,39 study day they will be infused with Exendin-9,39. Exendin-9,39 blocks the actions of specific hormones called incretins, that are produced in the gut in health and in larger quantities after gastric bypass surgery.
1525014|NCT02779062|Other|Interview|Interview
1525015|NCT02779049|Other|Blood examination|blood sampling
1525016|NCT02779036|Procedure|Task-oriented home exercise|Structured, walking related task-oriented home exercise program with three progressive steps, at moderate to high intensity, 60 minutes per session, three sessions per week for total 8 weeks.
1525017|NCT02779036|Procedure|Usual Physiotherapy Care|Deficits-oriented free active and resisted lower extremity exercises with bicycling and overground walking , 60 minutes per session, three sessions per week for total 8 weeks.
1525018|NCT02779023|Behavioral|Cognitive-Behavior Therapy for Insomnia (CBT-I)|
1525019|NCT02779010|Behavioral|Hand washing with soap and Health education|Health education on key environmental variables and hand washing with soap
1525020|NCT02778997|Procedure|CSF Shunt treatment for hydrocephalus|State after CSF shunt implantation
1525021|NCT02778984|Device|QuadraLite masks|The intervention is identical in the two group
1525022|NCT02778984|Other|standard mask|
1525023|NCT02778971|Drug|[18F]Flutemetamol|amyloid PET imaging with [18F]Flutemetamol and subsequent modification of diagnosis and management
1525024|NCT02778958|Drug|paracetamol|"iv paracetamol flakon, 1 gram infusion at 30 min;
iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
1525025|NCT02778958|Drug|ibuprofen|"iv ibuprofen flakon, 800 mg;
iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)"
1525026|NCT02778945|Drug|Rocuronium 0.9 mg/kg|Neuromuscular block with Rocuronium 0.9 mg/kg for anesthetic induction Infusion of Rocuronium 0.3mg/kg/hr titrated to maintain a post-tetanic count (PTC)0-2 during the operation.
1525027|NCT02778945|Drug|Rocuronium 0.6 mg/kg|Neuromuscular block with Rocuronium 0.6 mg/kg for anesthetic induction Intermittent bolus i.v injection of Rocuronium 0.15mg/kg for train-of-four (TOF) 1-2 during the operation
1525028|NCT02778919|Drug|KLH-2109|
1525029|NCT02778919|Drug|Placebo|
1525030|NCT02778919|Drug|Leuprorelin acetate|
1525031|NCT02778906|Drug|Abatacept|Administration of Abatacept s.c. 125mg/weekly according to the Label for Rheumatoid arthritis
1525032|NCT02778906|Drug|Placebo|Administration of the comparator s.c. weekly in comparable to verum
1525033|NCT02778893|Drug|Conmana|125mg three times a day (TID) continuously
1525034|NCT02778893|Drug|Thalidomide|100mg one a day（QD）at night continuously,If can tolerance after 1 weeks to add to 200mg;
1525035|NCT02778880|Drug|Ketamine|
1525036|NCT02778880|Drug|Fentanyl|
1525037|NCT02778867|Other|elimination diet therapy|1FED: milk elimination 6FED: milk, egg, wheat, soy, fish/shellfish, and tree nuts/peanut elimination
1525038|NCT02778867|Drug|Flovent|Flovent (fluticasone propionate): swallowed glucocorticoid
1525039|NCT02778854|Genetic|detection of driver mutation|participants are received gene detection via the liquid biopsy
1525040|NCT02778841|Other|Exercise|This study is designed to examine and comparing there intervention program on balance, mobility and knee proprioception among male elderly
1525041|NCT02778828|Drug|Linezolid|adjustment of Linezolid of based on the AUC/MIC and % T> MIC for each patient to confirm the appropriateness, in light of the peak and residual, and the interest of the split doses more frequently performed in case of too low residual or toxicity.
1525042|NCT02778815|Other|Kindness for Mums|
1525043|NCT02778789|Drug|Tocilizumab|Patients will be treated with either i.v. Tocilizumab every 4 weeks or s.c. Tocilizumab weekly according to the label
1525044|NCT02778789|Drug|TNF-alpha Inhibitor|Patients will be treated with TNF-Inhibitors either i.v. or s.c. according to the label
1525045|NCT02778776|Drug|Metformin|Metfomin in tablet presentation of 500 mg
1525046|NCT02778776|Dietary Supplement|Agave inulin|Oligofructan in powder obtained from agave plant, it was given to each patient a full 10 mg container.
1525047|NCT02778776|Other|Placebo of agave inulin|Calcinated magnesia powder
1525048|NCT02778776|Other|Metformin placebo|Calcinated magnesia tablet
1525049|NCT02778763|Drug|CBLB612|4 μg CBLB612 SQ
1525050|NCT02778763|Drug|Placebo|
1525051|NCT02778750|Procedure|Two-Bronchoscope Technique|Used to validate the use of sputum to sample the lower airway microbiome
1525052|NCT02778737|Behavioral|ACT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.
Participants will receive their AP-ACT handbook including outlines of each session, activity plan assignments, and a CD with recorded mindfulness exercises.
Session highlights and AP-ACT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
1525053|NCT02778737|Behavioral|CBT-based intervention|"Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. Although each session has specific objectives, therapists within the time frame, are encouraged to accommodate participants' discussion or other group dynamic issues that may arise.
Participants will receive their AP-CBT handbook including outlines of each session, activity plan assignments, and a CD with recorded relaxation exercises.
Session highlights and AP-CBT activities relevant to each session will be given at each meeting, so that participants will follow along with the treatment protocol. Individuals missing more than two consecutive sessions will be considered as dropouts."
1525054|NCT02778711|Drug|secukinumab|anti-IL-17
1525055|NCT02778698|Dietary Supplement|Omegaven|
1525061|NCT02778659|Drug|Zolpidem|The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
1525062|NCT02778659|Drug|Placebo|The placebo will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
1525063|NCT02778594|Drug|BIA 3-202|nebicapone 50 mg tablets; oral use
1525064|NCT02778594|Drug|Placebo|Nebicapone matching placebo tablets
1525065|NCT02778594|Drug|levodopa 100 mg / benserazide 25 mg|Madopar® HBS 125 (levodopa 100 mg / benserazide 25 mg) capsules; oral use
1525066|NCT02778581|Dietary Supplement|Lipidic Blend 1|daily intake of the content of one 45 mL bottle containing the product
1525067|NCT02778581|Dietary Supplement|Lipidic Blend 2|daily intake of the content of one 45 mL bottle containing the product
1525068|NCT02778581|Dietary Supplement|Placebo|daily intake of the content of one 45 mL bottle containing olive oil
1525069|NCT02778568|Behavioral|Resistance training|Resistance training exercises
1525070|NCT02778568|Behavioral|Control|Stretching exercises
1525072|NCT02778542|Behavioral|Electronic Pill Bottle|Patients receive electronic pill bottle for their blood pressure medication. Study team can monitor pill bottle openings. Patients also receive daily text reminders to take their blood pressure medication.
1525073|NCT02778542|Behavioral|Bidirectional Text Messaging|Patients receive daily text reminders to take their blood pressure medication. Patients are asked to text their adherence daily.
1525074|NCT02778529|Device|Bilateral assessment robots (BiAS)|The BiAS are two passive desktop robots that will be used in this study to measure right and left arm kinematics for 4 different groups of patients.
1525075|NCT02778516|Dietary Supplement|Sodium Restriction|
1525076|NCT02778503|Other|High Cost|Surfaces allocated to this group will be treated with a high-cost glass ionomer cement restoration (Fuji IX, GC America, USA), according to the manufacturer's instructions.
1525077|NCT02778503|Other|Low Cost|Surfaces allocated to this group will be treated with a low-cost glass ionomer cement restoration (Maxxion R, FGM, BRA), according to the manufacturer's instructions.
1525078|NCT02778477|Drug|PF-06423264|Multiple ascending dose of PF-06423264
1525079|NCT02778477|Other|Placebo|Multiple dose of placebo
1525080|NCT02778451|Other|Measurement of competence|This study is a psychometric validation of a generic assessment tool to evaluate ultrasonography competence among surgeons
1525081|NCT02778425|Procedure|PSE|Partial splenic embolization (PSE) is one of the intra-arterial therapeutic approaches of diseases.It has been demonstrated to effectively increase hematologic indices in cirrhotic patients with splenomegaly. This is particularly valuable amongst those cirrhotic patients who are not viable candidates for splenectomy.
1525084|NCT02778386|Drug|N-Methanocarbathymidine|Patients will receive 200 mg, 400 mg, 800 mg or 1200 mg of N-Methanocarbathymidine administered orally on day 1 after subject's full screen for each cohort. Each dose will be completely evaluated for safety and pharmacokinetics. The doses of each cohort will be given after complete evaluation of the preceding cohort for any sign of toxicity. In the absence of no observed toxicity, the next cohort will be started in the normal subjects.
1525085|NCT02778386|Other|Placebo Capsule|Two patients in Cohort 3 & 4 will receive placebo capsules which is mannitol filled into size 0 capsules.
1525086|NCT02778373|Dietary Supplement|Vitargo ®, Swecarb AB, Karlskrona, Sweden|
1525087|NCT02778373|Dietary Supplement|DE15 maltodextrin, Matrin® M160, Grain Processing Corporation, Muscatine, IA|
1525088|NCT02778373|Other|Placebo: Water|
1525089|NCT02778360|Device|Neurofeedback NFT|"The ADHD@Home Device is composed of a software for NF Training deployed on a Windows tablet, and connected to an EEG headset and an amplifier.
The training is personalized according to patient's characteristics."
1525090|NCT02778360|Drug|Methylphenidate MPH|Drug prescribed with a first titration period until an optimal dose.
1525091|NCT02778334|Other|survey|"Patients who accept will be seen in maintenance during hospitalization in Neuro-Vascular Unit (UNV) (T0 = 4 to 7 days post-stroke)
At the time of the release of the UNV two groups:
patients who return home and
patients who continued hospitalization in rehabilitation. Depression, anxiety, quality of life and coping strategies will be assessed by self-administered questionnaires. A first phase of ambulatory (ESM / EMA) will also take place following the (UNV) output: 5 times a day for 7 days patients will respond to questions evaluating depression, anxiety and coping strategies. Patients will answer these questions via a smartphone app (issues ESM).
Another ambulatory phase on the same model as that performed at T1 (5 times daily for 7 days) accompanied by a self-assessment of depression, anxiety, coping strategies and quality of life will made 2 months post-stroke (T2).
The last time the study will take place 4 months after stroke onset (T3)."
1525092|NCT02778321|Device|Uses of SpiderFlash monitor|"Investigators will use the SpiderFlash®, Holter monitor (technology Secure Data) to have a storage capacity enabling a registration up to 30 days with sufficient autonomy.
The data collected :
Demographic data: age, sex, vascular risk factors, antithrombotic therapy at the entrance, history of Transient Ischemic Accident (TIA) or Cerebral infarct (CI)
Data on the CI:
Monitoring Results scope ICU Neurovascular.
Presence palpitations
Treatment influencing the rate (beta-blockers or antiarrhythmic)
Data on cardiac monitoring:
A questionnaire evaluating the safety of SpiderFlash® will be given to the patient and the results of Holter will be communicated at the end of the recording to the blinded rhythm specialist"
1525093|NCT02778308|Drug|Gemcitabine + Cisplatin|Day 1 and day 8 Gemcitabine Day 1 cisplatin
1525135|NCT02777970|Drug|Tramadol Hydrochloride/Paracetamol|
1525136|NCT02777970|Drug|Placebo|
1525283|NCT02776748|Drug|FTC/TDF PrEP|Daily oral directly observed FTC/TDF PrEP administered to breastfeeding HIV-uninfected women
1525095|NCT02778269|Device|12-lead ECG T-shirt|The 12-lead ECG T-shirt system consists of three parts: the recording device, amplifier boards and the T-shirt.The T-shirt has 10 textile ECG electrode patches. The patches should be in contact with the patient's skin to record the electrical activity of the heart. The electrodes are made of electrically conductive textile. They are sewn into the inside of the T-shirt and are padded with foam. The cables to the device can be attached to snap fasteners on the outer side of the T-shirt on the ECG electrode patches.
1525096|NCT02778269|Device|Dexcom G4-System|Continuous Glucose Monitoring
1525097|NCT02778256|Device|Vestibular stimulation|A specific vestibular stimulation technique is applied to the experimental group
1525098|NCT02778256|Device|Sham vestibular stimulation|Sham vestibular stimulation using lower than threshold stimuli. The absence of vestibular nystagmus confirms that it is sham.
1525099|NCT02778243|Biological|steroids concentrations determination|
1525100|NCT02778230|Dietary Supplement|Pea Fiber|Snacks (2 baked goods) fortified with 5 g pea hull fiber
1525101|NCT02778230|Dietary Supplement|Control|Snacks (2 baked goods) without fiber fortification.
1525102|NCT02778217|Procedure|Culture media renwal|
1525103|NCT02778204|Drug|Maraviroc|"For Cohort 1: 8 mg/kg oral solution as a single dose.
For Cohort 2: Infants in Stratum 2A will receive maraviroc oral solution once or twice daily at the dose and frequency determined from Stratum 1A. Infants in Stratum 2B will receive maraviroc oral solution once or twice daily at the dose and frequency determined from Stratum 1B."
1525104|NCT02778191|Drug|cisplatin|100 mg/m2 day 1, 22 and 43
1525105|NCT02778191|Drug|carboplatin|carboplatin 300-350 mg/m2 day 1, 22 and 43
1525106|NCT02778191|Drug|5-FU|5-FU 600 mg/m2 days 1-4, 22-25 and 43-46
1525107|NCT02778178|Drug|ropivacaine plus clonidine|20 mL ropivacaine 3.75 mg/ml + 75 µg clonidine, per side
1525108|NCT02778178|Drug|Placebo|20 mL saline 0.9%, per side
1525109|NCT02778178|Device|ultrasound|
1525110|NCT02778165|Other|Android application|Application
1525111|NCT02778152|Device|Laser depilation|Laser depilation of natal cleft (pilonidal region)
1525112|NCT02778126|Drug|[¹⁴C]LY2606368|Administered IV
1525113|NCT02778126|Drug|LY2606368|Administered IV
1525114|NCT02778113|Drug|LY900018|Administered intranasally.
1525115|NCT02778113|Drug|Glucagon|Administered SC.
1525116|NCT02778100|Drug|LY900018|Administered intranasally.
1525117|NCT02778100|Drug|Oxymetazoline|Administered intranasally.
1525118|NCT02778087|Behavioral|Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on the mirror reflection of the unaffected arm throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: active range of motion (AROM), functional tasks with objects, and object manipulation.
1525119|NCT02778087|Behavioral|Sham Mirror Box Therapy|The BT intervention will be delivered in 15 minute increments via a self-directed program. The subject will sit comfortably at a table or desk in front of a box, which will be positioned in the mid-sagittal plane. The subject will place his or her affected arm inside the box so that it is out of view. The subject will then place his or her unaffected arm on the table and will be instructed to focus their attention on an opaque mirror throughout the intervention. The 15 minute intervention will consist of the following movements/tasks: AROM, functional tasks with objects, and object manipulation.
1525120|NCT02778074|Behavioral|Internet cognitive behavioural therapy|A nine-week tailored I-CBT program for patients with CVD. The CBT program consists of the components of psychoeducation, relaxation, problem-solving and behavioural activation.
1525121|NCT02778074|Behavioral|Moderated Discussion Forum|Participants will be allocated to an internet moderated discussion forum during 9 weeks. Patients will discuss issues related to cardiovascular disease. A new topic will be discussed every week. After 9 weeks, those in the moderated discussion forum will be offered to perform the I-CBT program.
1525122|NCT02778048|Other|MRI (magnetic resonance imaging)|Assessment of the sphincter
1525123|NCT02778048|Other|US (ultra sound)|Assessment of the sphincter
1525124|NCT02778048|Other|FLIP (functional lumen imaging probe)|Assessment of the sphincter
1525125|NCT02778048|Other|HRAM (high resolution anal manometry)|Assessment of the sphincter
1525126|NCT02778035|Device|Intermittent theta-burst stimulation, rTMS|
1525127|NCT02778022|Behavioral|PriCARE|PriCARE is a group parent training program designed to improve child behavior, improve parent-child relationships, and decrease stress for parents. PriCARE utilizes the 3 P skills (Praise, Paraphrase and Point-out-Behavior) and includes a trauma and stress education component. The training starts with parenting skills focused on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second phase of the training teaches techniques for giving children effective commands in order to set age-appropriate limits. We piloted PriCARE and demonstrated promising findings. The PriCARE intervention has been slightly modified from the pilot version to increase engagement and attendance.
1525128|NCT02778009|Radiation|iDEXA Scan|Subjects will receive pre study and post study scans to assess body mass composition
1525129|NCT02778009|Other|Wellness Lectures|Subjects in the Fit Physician Arm will be required to attend monthly wellness lectures
1525130|NCT02778009|Other|Exercise intervention|Subjects in the Fit Physician Arm will be required to attend weekly exercise interventions
1525131|NCT02778009|Other|Activity monitor|Subjects in the Fit physician arm and the activity monitor arm will receive activity monitors to assess their activity level throughout the academic year
1525132|NCT02777996|Device|Low Dose Computed Tomography|Assessment protocol were adopted from the ELCAP study (modified) for Non Calcific Nodule with a diameter of less- equal than 5 mm at baseline and 3mm at repeated.
1525133|NCT02777983|Behavioral|Educational Video App|The content of the app will be grounded in a biopsychosocial model and modeled on the Back Book, a booklet developed to help modify beliefs and behavior of patients with LBP. Essentially this will take the primary concepts and ideas often given in print or verbal form, and present it in a more engaging and dynamic fashion.
1525134|NCT02777970|Drug|Tramadol Hydrochloride/Dexketoprofen Trometamol|
1525137|NCT02777944|Behavioral|Motivate: a web-based intervention|A web-based intervention focuses on managing expectations of assessment, addressing ambivalence and increasing users' motivation and confidence to attend their initial appointment. This is achieved through the use of information, motivational tools, interactive activities and stories from other individuals with EDs spread across four 15-20 minute modules.
1525138|NCT02777931|Drug|NFC-1|NFC-1 is supplied as size 2 hard gelatin capsules.
1525139|NCT02777931|Drug|Placebo|Matching placebo capsules
1525140|NCT02777918|Behavioral|Recipe provision|6 recipes will be provided every 2 weeks by post for 12 weeks
1525141|NCT02777905|Behavioral|Mindfulness Based Cognitive Therapy|
1525142|NCT02777892|Other|Sapien S3|Patients that have undergone percutaneous implantation of an Edwards SAPIEN S3 Transcatheter Heart Valve in the pulmonic position at the time of data collection
1525143|NCT02777879|Procedure|Bronchoscopy|Flexible bronchoscopy with bronchoalveolar lavage (BAL) and bronchial brushings will be done in a standardized manner. The bronchoscope tip is sequentially wedged in sub-segments where BAL will be performed on a total of two segments of the lung (120 ml in each segment for a total of 360 ml). Two brushes will be done under direct visualization in both segments. Selection of segments to sample will be based on where abnormalities are in imaging.
1525144|NCT02777866|Drug|Infiltration of 0.5% Bupivacaine|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.5% Bupivacaine, every 1 cm, on each side of the surgical wound
1525145|NCT02777866|Drug|Placebo: Infiltration of 0.9% Saline Solution|Patients who will be non urgent operated of an open gastrointestinal surgery, where an opening of the gastrointestinal lumen occurs (bile duct, stomach, small bowel or colon), who will be infiltrated in the total thickness of the abdominal wall (Peritoneum-muscle fascia- Subcutaneous tissue) with 0.9% Saline Solution, every 1 cm, on each side of the surgical wound
1525146|NCT02777853|Dietary Supplement|Green tea|The intervention product is regular green tea brewed with hot water in a large quantity. The tea obtained is dried and the powder, with added sugar, is distributed over sealed aluminium sachets (1 gram of powder per sachet). The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
1525147|NCT02777853|Dietary Supplement|Placebo tea|A product of similar colour and taste, but not the presumed actives of tea (polyphenols), is used as placebo. The product has been cleared for consumption by Unilever's Microbiology Department and the independent Safety and Environmental Assurance Centre of Unilever.
1525148|NCT02777840|Device|face mask oxygen|oxygen given by face mask as per routine practice
1525149|NCT02777840|Device|High flow oxygen|High flow oxygen given via optiflo machine / device
1525150|NCT02777827|Drug|Abediterol 0.156 μg|Dry powder for inhalation
1525151|NCT02777827|Drug|Abediterol 2.5 μg|Dry powder for inhalation
1525152|NCT02777827|Drug|Abediterol 0.05 μg|Pressurised metered-dose inhaler
1525153|NCT02777827|Drug|Abediterol 0.156 μg|Pressurised metered-dose inhaler
1525154|NCT02777827|Drug|Abediterol 2.5 μg|Pressurised metered-dose inhaler
1525155|NCT02777827|Other|Placebo|Pressurised metered-dose inhaler and dry powder for inhalation.
1525161|NCT02777775|Procedure|Skin Biopsy|"The procedure to sample the cutaneous neurofibroma involves a skin incision and will take approximately 10 to 15 minutes. The tissue will be taken in the following way:
The skin area will be cleaned
The skin area will be numbed (by either a numbing cream or a tiny numbing shot)
Cutaneous (skin) Neurofibroma: will be taken via a small incision and removal of the neurofibroma whenever possible.
A small piece of normal (skin) tissue will be numbed as above and taken using a special skin biopsy device.
Afterward, the area will be cleaned and the skin put back together with medical super glue or 1 to 2 dissolvable stitches that will dissolve as the incision heals, they do not require removal. The purpose of taking this piece of skin is to compare normal skin with the skin of a cutaneous neurofibroma."
1525164|NCT02777749|Drug|Bupivacaine|15 cc's of 0.5% bupivacaine or 20 cc's short-acting bupivacaine (SB), intramuscular injection
1525165|NCT02777749|Drug|Liposomal Bupivacaine|20 cc's, intramuscular injection
1525166|NCT02777736|Drug|Methotrexate|i.v. or intrathecal CNS prophylaxis
1525167|NCT02777723|Drug|Xenobella|Hypotonic 0.3% Sodium Hyaluronate
1525168|NCT02777723|Drug|Isotonic 0.3% Sodium Hyaluronate|Isotonic 0.3% Sodium Hyaluronate
1525169|NCT02777710|Drug|Pexidartinib|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
1525170|NCT02777710|Drug|Durvalumab|Treatment will be administered as long as patient experience clinical benefit in the opinion of the investigator or until unacceptable toxicity or symptomatic deterioration attributed to disease progression as determined by the investigator after an integrated assessment of radiographic data and clinical status or withdrawal of consent. If a DLT or a toxicity meeting the DLT definition but occurring outside of the DLT period, resolves to Grade ≤2 or the patient's baseline level within 14 days after toxicity onset, dosing may be resumed if agreed by the Sponsor at the same DL.
1525171|NCT02777697|Other|chronic pain|
1525172|NCT02777684|Other|Qualitative study|
1525173|NCT02777671|Drug|BIA 2-093|
1525174|NCT02777671|Drug|Gliclazide|tablets containing gliclazide 80 mg (Diamicron® 80 mg)
1525175|NCT02777645|Other|Growth, feeding evaluation|Z-scores of the nutritional indicators were calculated. The dietary assessment was performed by using the 24-hour recall method. The Behavioural Paediatrics Feeding Assessment Scale (BPFAS) was used to assess both frequencies of negative feeding behaviours and parents' problematic perceptions
1525176|NCT02777632|Procedure|Living donor liver transplantation|
1525177|NCT02777619|Drug|0.0ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.0ng/ml
1525178|NCT02777619|Drug|0.4ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.4ng/ml
1525179|NCT02777619|Drug|0.6ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.6ng/ml
1525180|NCT02777619|Drug|0.8ng/ml Dexmedetomidine|Dexmedetomidine target plasma concentration is 0.8ng/ml
1525181|NCT02777619|Drug|Propofol|
1525182|NCT02777606|Drug|Si-Ni-Tang|Treatment adheres to the International guidelines for management of severe sepsis and septic shock( 2012) and the Surviving Sepsis Campaign updated bundles in response to new evidence in 2015 for both the treatment group and the control group. In addition, 150ml of Si-Ni-Tang will be given by p.o. or by a nasogastric tube once a day for 3-5 days in the treatment group.
1525183|NCT02777593|Device|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
1525188|NCT02777554|Drug|Apremilast|
1525189|NCT02777541|Dietary Supplement|Resumption of feeding 3 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
1525190|NCT02777541|Dietary Supplement|Resumption of feeding 8 hours after PEG placement|The first feeding will be with polymeric diet (1 kcal/ml). First feeding portion will have the volume equal to 1/3 of full recommended portion, volume of second feeding will be equal to 2/3 of full recommended portion and third portion will be equal to full recommended portion. Each portion will introduced thru the enteral feeding pump (Flocare Infinity, Nutricia), for 30 minutes, three-hour break between feeds. Infusion of 5% glucose solution with electrolytes will be given through intravenous line to cover maintenance fluid requirement in all subjects.
1525191|NCT02777528|Device|GORE® TAG® Thoracic Branch Endoprosthesis|Endovascular repair with the TBE Device
1525192|NCT02777528|Procedure|Revascularization Procedure|Revascularization procedure of the great vessel
1525193|NCT02777515|Behavioral|uses of electronic cigarette|"Assesment of patients, using electronic cigarette, presenting to the Rhythm of consultation for a cardiovascular evaluation by:
A compendium of history, a general physical examination (weight, height) and cardiovascular with measurement of oxygen saturation, an assessment of past and current smoking (with documentation of the concentration of nicotine in the electronic cigarette and the product brand used)
measurement of blood pressure
An electrocardiogram (ECG)
A Holter-ECG 10 minutes
A transthoracic echocardiogram"
1525194|NCT02777489|Drug|Perindopril|Perindopril Bluepharma 8 mg tablets, daily, during approximately 12 weeks
1525195|NCT02777476|Device|B-Lite- Light Weight Breast Implants|
1525196|NCT02777463|Other|diffusion-weighted MRI|Diffusion MRI Patients undergo MRI within 3 weeks before start of neoadjuvant therapy/ 5 weeks after the last dose. The setting of MRI scans for b-values is 0, 50, 800 s/mm2. The same MRI (the MRI system/scanner Intera Achieva 1.5T from Philips Medical Systems) in the independent institution is used for all patients analyzed on this study. The region of interest is determined by consensus between two experienced MR radiologists in a largest diameter based on images of abdominal CT scans avoiding the vascular area on the image of ADC map. The mean ADC values for each tumor are automatically calculated on the image of ADC map using a tomographic software program.
1525197|NCT02777450|Procedure|lumbar facet block|injection of Levobupivacaine 0,25% and corticosteroids
1525198|NCT02777437|Drug|XELOX or FOLFOX chemotherapy|4 cycles of XELOX or FOLFOX neoadjuvant chemotherapy before surgery
1525199|NCT02777424|Drug|Prothrombin Complex Concentrate|Non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S
1525200|NCT02777424|Biological|Fresh Frozen Plasma|Pooled collection of plasma from donors
1525201|NCT02777411|Biological|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
1525202|NCT02777411|Biological|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
1525203|NCT02777411|Biological|EV71 vaccine ([2 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
1525204|NCT02777411|Biological|EV71 vaccine (2 μg total protein per dose)|Two vaccinations at 28 days apart
1525205|NCT02777411|Biological|EV71 vaccine ([0.5 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
1525206|NCT02777411|Biological|EV71 vaccine ([1 μg total protein + adjuvant 150 μg AIPO4] per dose)|Two vaccinations at 28 days apart
1525207|NCT02777411|Biological|EV71 vaccine (1 μg total protein per dose)|Two vaccinations at 28 days apart
1525208|NCT02777398|Procedure|Trans-Quadrant Channel Surgery|Patients in the experimental group will be general anaesthetized and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Kirschner wire will be used to identify the position of the Quadrant channel with X-ray. After disinfection and draping, an incision of 3cm long and 2-3cm lateral to midline on the tumor side will be made. Soft tissues will be separated. Graded dilators will be used to establish Quadrant channel. Kerrison clamps will be used to expose the very local posterior spinal structures. Vertebral plate will be windowed with power drill to expose dural mater, and tumors will be removed with microsurgical techniques. Hemostasis will be performed after resection. Dural mater will be closed by titanium clips, and close incision by layers.
1525209|NCT02777398|Procedure|Conventional Open Surgery|Patients in the control group will be general anaesthetized during operation and placed in the prone position. Intra-operational electrophysiological monitoring will be used. Surgeons will locate the lesion by X-ray. After disinfection and draping, the midline incision of 7-10 cm and centered by the lesion segment will be made. Soft tissues will be cut and separated to expose posterior structure of spine. The root of spinal process and half of the vertebral plate on tumor side of certain segments will be removed. The dural mater will be opened. Then surgeons will remove tumor with microsurgical techniques. Hemostasis will be precisely performed after resection, and dural mater will be closed by suturing. Incision will be closed by layers. Drainage would be placed if necessary.
1525210|NCT02777385|Drug|Pembrolizumab|In both arms, the dose of pembrolizumab will be 200 mg (fixed dose) intravenous (IV) every 3 weeks for a total of 8 doses. In Arm 1, pembrolizumab will begin in week 10 of treatment, after cisplatin-IMRT is complete. In Arm 2, pembrolizumab will begin the week before cisplatin-IMRT.
1525211|NCT02777385|Drug|Cisplatin|Patients will receive cisplatin once weekly as an IV infusion over 60 minutes, for a total of 7 doses, at the same time as radiation.
1525212|NCT02777385|Radiation|IMRT|IMRT will be delivered in 35 fractions (treatments) over 7 weeks (five treatments per non-holiday week) in one plan.
1525214|NCT02777359|Procedure|the transcatheter closure of PFO|the transcatheter closure of PFO was performed using the made-in-China occluders approved by SFDA,clopidogrel(50mg/d, 3mon) , aspirin (0.1g/d, 6mon), i.e. oral administration of aspirin (0.1g/d) and clopidogrel (50mg/d) at 48h before the closure; the low molecular weight heparin (LMWH) was routinely given at 48h after the closure; and some pain-relief drugs could be temporarily administered in the patients with acute onset of migraine.
1525215|NCT02777346|Device|Absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.
Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
1525216|NCT02777346|Device|Non absorbable|"Wound suture by a resident physician. Two follow-up appointments (first at 4 to 21 days after the suture, according to the sutured site as defined by protocol, second at 6 months) Standardized photography of the wound before the suture and at the two subsequent follow-ups.
Evaluation of the scar with a standardised form by a specialised nurse under medical supervision at the first follow-up and by a panel of investigators at 6 months using the pictures taken at the follow-up appointments."
1525217|NCT02777333|Behavioral|Simulation training|Simulation training in a skills lab for 1 hour per week over 13 weeks on dry, bench-top box trainers and anatomical simulators
1525218|NCT02777320|Drug|paracetamol|1000 mg Paracetamol in 150 ml normal saline given as a slow intravenous infusion over 5 minutes (100 ml of saline is removed before the addition of the 100 ml paracetamol to be the same volume)
1525219|NCT02777320|Drug|Ibuprofen|400 mg Ibuprofen in 150 ml normal saline given as a slow intravenous infusion over 5 minutes
1525220|NCT02777307|Other|Hemopatch Sealing Hemostat|Place of Hemopatch Sealing Hemostat after laparoscopic cholecistectomy
1525221|NCT02777294|Behavioral|Online intervention|Therapist-facilitated, multimedia, cognitive-behavioral online intervention targeting rape-related PTSD
1525222|NCT02777294|Behavioral|Psycho-educational website|Psycho-educational self-help website about rape-related PTSD
1525223|NCT02777281|Behavioral|Shoulder pain and SCI|Shoulder pain and SCI
1525224|NCT02777281|Behavioral|Shoulder pain and able bodies|
1525225|NCT02777268|Drug|Infacort|Multi-particulate granules
1525226|NCT02777268|Drug|Hydrocortisone|Tablet
1525227|NCT02777242|Drug|Testosterone enanthate auto-injector|One or 2 SC injections of QST 50 mg, 75 mg, or 100 mg/0.5 mL
1525228|NCT02777229|Drug|Dolutegravir 50 mg|1 tablet once a day
1525229|NCT02777229|Drug|Tenofovir disoproxil fumarate 300 mg / lamivudine 300 mg|Fixed dose combination, 1 tablet once a day
1525230|NCT02777229|Drug|Efavirenz 200 mg|2 tablets once a day
1525231|NCT02777216|Device|ConfidenHT system|ConfidenHT Medical system
1525232|NCT02777203|Device|EcoSac 230|The specimen will be morcellated in the EcoSac 230.
1525233|NCT02777203|Device|EcoSac 400 ECO-T|Laparoscopy will be performed in the standard multi-port technique. The specimen will be morcellated in the EcoSac400 ECO-T bag.
1525234|NCT02777203|Device|GelPOINT Mini Advanced Access Platform|The GelPOINT Mini Advanced Access Platform will be placed at the beginning of the case.
1525235|NCT02777190|Drug|Misoprostol|Comparing dosing of misoprostol 25 mcg orally every 2 hours versus 25 mcg vaginally every 4 hours.
1525236|NCT02777164|Device|MIRA device imaging|MIRA Device imaging for adjunctive detection of breast cancer
1525237|NCT02777151|Drug|REGN3470-3471-3479|
1525238|NCT02777151|Drug|Placebo|
1525240|NCT02777125|Device|Metered Dose Inhaler|A metered dose inhaler (MDI) is a small hand held pressurized canister device that contains both a medication, in this case albuterol, and a propellant. Pressing the device delivers 90mcg of albuterol. The MDI is attached to a spacer device, which is a one way holding chamber which allows the medication to be delivered over a series of breaths.
1525241|NCT02777125|Device|Breath Actuated Nebulizer|The breath actuated nebulizer (BAN) device is a device that converts liquid medication, in this case albuterol, into an aerosol. It consists of a mouthpiece, a medication reservoir, and connective tubing that attaches to a compressor. This BAN device delivers medication when the patient takes a breath, but it can be attached to a mask and set to continuous nebulization for patients that are not able to coordinate their breaths.
1525242|NCT02777112|Other|e-mental health program|This program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking.
1525243|NCT02777112|Other|e-mental health program and job coaching|This combines the e-mental health program and interactive job coaching delivered through telephone. The e-mental health program is delivered over the Internet, which includes modules of Information (about depression, workplace factors and alcohol use), Practical Tips (Cognitive Behavioral Therapy, Mindfulness relaxation, workplace strategies), Tools (for monitoring and predicting depression and occupational functioning), and Goal Setting and Tracking. The job coaching can be accessed by appointment.
1525244|NCT02777112|Other|No intervention|Receiving generic information about men's depression from the Movember Foundation website: https://ca.movember.com/programs/mental-health
1525245|NCT02777099|Procedure|remote ischemic postconditioning|Remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion.The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to 200 mmHg for 5 min,and then deflating it for 5 min.Each patients in the PIPostC group will have the treatment once a day for 30 days.
1525246|NCT02777099|Procedure|sham remote ischemic postconditioning|Sham remote ischemic postconditioning was performed by 4 cycles of upper-limb ischemia and reperfusion. The upper-limb ischemia was induced by inflating a blood pressure cuff on a healthy upper arm to the patient's actual diastolic blood pressure for 5 min,and then deflating it for 5 min.Each patients in the sham PIPostC group will have the sham treatment once a day for 30 days.
1525247|NCT02777086|Behavioral|StaySafe|StaySafe is a self-administered tablet computer app designed to improve decision-making around health risk behaviors.
1525248|NCT02777073|Drug|Farxiga|Single dose of dapagliflozin
1525249|NCT02777073|Drug|Victoza|Single dose of Liraglutide
1525250|NCT02777073|Drug|Placebo|Single dose of generic placebo
1525251|NCT02777060|Procedure|Exergame|Subjects will perform progressive and computerized foot and ankle exercises which include weight shifting, ankle reaching task while standing, and virtual obstacle crossing task (i.e. balancing on single leg) using wearable sensors technology (Exergaming) equipment). Subjects will perform these exercises for 4-6 weeks, twice per week. The duration of exercise per session is anticipated to be 30-45 minutes.
1525252|NCT02777060|Procedure|Home based balance training|Subjects in the control group will ask to perform a standard home based balance program for 4-6 weeks. The home based program includes similar exercise components as proposed in the experimental group, however without computerized feedback and Exergaming equipment.
1525253|NCT02777047|Other|Anticoagulation Coordinated Care|see above
1525254|NCT02777034|Other|ER|"Preoperative protocols：Multidisciplinary patient information、no bowel preparation、no fasting（drink 10% glucose 1000 at 21：30 night before the surgery）.
Intraoperative protocols：Laparoscopic standardized technique、fluid restriction (max 500 ml/h)、no abdominal drains.
Postoperative protocols：no nasogastric tube、early solid dietary intake and mobilization、urinary catheter removal on postoperative day 1、restrictive fluid management（<2000ml/d）."
1525255|NCT02777034|Other|UR|"Preoperative protocols：Patient information、Mechanical bowel preparation、Fasting since midnight before operation.
Intraoperative protocols：Laparoscopic standardized technique、fluid overload (over 500 ml/h) 、place abdominal drains.
Postoperative protocols：no nasogastric tube、mobilization from postoperative day 1、fluids and solids intake after first passage of stool、Urinary catheter removal on postoperative day 2/3、no restrictive fluid management（>2000ml/d）."
1525256|NCT02777008|Drug|CTP-543|
1525257|NCT02777008|Drug|Placebo for CTP-543|
1525258|NCT02776995|Other|Thermography imaging|Thermography imaging of the treated - irradiated body area.
1525259|NCT02776982|Procedure|Confocal endomicroscopy|Confocal endomicroscopy will be performed during clinically indicated endoscopy.
1525260|NCT02776982|Procedure|Mucosal impedance|Mucosal impedance will be performed at the time of clinically indicated endoscopy.
1525261|NCT02776982|Procedure|Research biopsies|Research biopsies will be obtained during clinically indicated endoscopy.
1525262|NCT02776982|Procedure|Bravo ambulatory pH monitor|Bravo ambulatory pH capsule will be placed during clinically indicated endoscopy.
1525263|NCT02776956|Drug|atorvastatin group|Patients in atorvastatin group will orally receive 20 mg of atorvastatin per night (Pfizer) for three days before the operation and three months after the operation
1525264|NCT02776956|Drug|non-atorvastatin group|Patients in non-atorvastatin group will not receive atorvastatin before the operation and after the operation.
1525265|NCT02776943|Biological|umbilical cord mesenchymal stem cells|
1525266|NCT02776943|Device|Hyaluronic acid|
1525267|NCT02776917|Drug|Cirmtuzumab + Paclitaxel|Cirmtuzumab may be administered up to four doses. Paclitaxel may be continued after cirmtuzumab is stopped.
1525268|NCT02776904|Other|Immediate Post-concussion Assessment and Cognitive Testing|
1525269|NCT02776904|Other|Psychomotor Vigilance Task|
1525270|NCT02776891|Radiation|Gallium citrate|Ga-68 citrate will be administered on an outpatient basis at the Center for Molecular and Functional Imaging at China Basin. It will be administered a single time point intravenously prior to PET imaging. The one-time nominal injected dose will be up to 15 mCi containing 10 - 25 μg Ga-68. A simultaneous MRI (PET/MRI) of the head will be used for attenuation correction and anatomic localization of gallium-68 citrate uptake and SUV calculation.
1525271|NCT02776878|Drug|dasatinib|
1525272|NCT02776865|Drug|suprascapular nerve block|4ml 2% xylocaine
1525273|NCT02776865|Other|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
1525274|NCT02776852|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number: SR15-43-Y65-158)
1525276|NCT02776813|Biological|ACTR087|
1525277|NCT02776813|Biological|rituximab|
1525278|NCT02776800|Device|Allevyn Life|
1525279|NCT02776800|Device|Foam dressing with an integrated adhesive border|Foam dressing normally used by the home health agency
1525285|NCT02776722|Other|fructose, allulose, tagatose, or sorbose|Single-bolus feeding of fructose, allulose, tagatose, or sorbose given together with a reference carbohydrate(s) compared with the same reference carbohydrate(s) alone for acute feeding trials or chronic feeding of fructose, allulose, tagatose, or sorbose provided in substitution for other reference carbohydrates or added to a control diet compared with the reference carbohydrate(s) alone or the control diet alone for chronic feeding trials.
1525286|NCT02776709|Procedure|ERCP with cholangioscopy|
1525287|NCT02776696|Device|Advanced Hybrid Closed Loop System|
1525288|NCT02776696|Device|Hybrid Closed Loop System|
1525289|NCT02776683|Drug|BI 695502|
1525290|NCT02776683|Drug|chemotherapy|mFOLFOX (Oxaliplatin, Leucovorin, 5-Fluorouracil)
1525291|NCT02776670|Other|Propylene glycol, 0.6% eye drops|
1525292|NCT02776670|Other|Lubricant eye drops|
1525293|NCT02776670|Other|Preservative-free 0.9% saline solution|
1525294|NCT02776657|Other|Magnetic Resonance Imaging|Each participant will undergo at least one MRI scan. A small number will be asked to undergo repeat MRI scanning at one and three months following the initial scan.
1525295|NCT02776657|Device|Optical Coherence Tomography|Participants may undergo Optical Coherence Tomography (OCT) during the angiogram procedure in order to detect thrombus within the coronary arteries.
1525296|NCT02776657|Procedure|Invasive Coronary Angiography|This will be performed as part of usual care and does not constitute part of the research project.
1525297|NCT02776631|Device|Pinloc|Internal fixation device
1525298|NCT02776631|Device|Hansson Pins (LIH)|Internal fixation device
1525299|NCT02776618|Procedure|running subcuticular closure of excisional defect|Excisional defects will be repaired with deep polyglactin 910 sutures, followed by each half of the wound given randomly assigned subcuticular superficial closure as described in the treatment arms.
1525300|NCT02776605|Drug|Prednisone|Prednisone 60 mg/m2/day IV over 7 days (-7 a -1) and triple intrathecal therapy (TIT)
1525301|NCT02776605|Drug|Vincristine|Vincristine (VCR): 1.5 mg/m2 (maximum 2 mg) IV days 1, 8, 15 and 22.
1525302|NCT02776605|Drug|Daunorubicin|Daunorubicin (DNR): 45 mg/m2 IV days 1, 8, 15 and 22.
1525303|NCT02776605|Drug|Prednisone|Prednisone (PDN): 60 mg/m2/day, IV or PO, days 1 to 27.
1525304|NCT02776605|Drug|Ponatinib|Ponatinib 30 mg, PO from day 1 to consolidation
1525305|NCT02776605|Drug|Mercaptopurine|Mercaptopurine (MP): 50 mg/m2, PO days 1 to 7, 28 to 35 and 56 to 63.
1525306|NCT02776605|Drug|Methotrexate|MTX: 1,5 g/m2, IV (24 h continuous infusion) days 1, 28 and 56
1525307|NCT02776605|Drug|VP-16|VP-16: 100 mg/m2/12 h, IV, days 14 and 42
1525308|NCT02776605|Drug|ARA-C:|ARA-C: 1000 mg/m2/12 h, IV, days 14-15 and 42-43.
1525309|NCT02776605|Drug|TIT|TIT (MTX: 12 mg, ARA-C: 30 mg, hydrocortisone: 20 mg), , days 1, 28 and 56.
1525310|NCT02776605|Drug|Ponatinib|Ponatinib 30 mg/d PO, from day 1 to 15 days before HSCT.
1525311|NCT02776605|Procedure|Autologous transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and autologous transplantation
1525312|NCT02776605|Procedure|Allo transplantation|Myeloablative conditioning with cyclophosphamide and total body irradiation (TBI) whenever possible and allo transplantation
1525313|NCT02776592|Other|Cow's milk-based formula with added nutrients|
1525314|NCT02776592|Other|Cow's milk-based formula|
1525315|NCT02776579|Other|Girls-only resistance training|
1525316|NCT02776566|Other|Patient Self-Monitoring vs Anticoagulation Clinic|"Patient Self-Monitoring (intervention): entails 3 education sessions of 90-120 minutes each (week 0, week 2, week 4): 2 provided on site in clinic and 1 in the patient's home, during which, self-testing competency and barriers and facilitators to self-monitoring will be evaluated. Subjects will follow with weekly (or sooner, if clinically indicated) in-home self-monitoring and follow-up weekly phone calls over 6 months by clinical pharmacists to guide warfarin dosing and reinforce key educational messages.
Anticoagulation Clinic (control): subjects will have their INR tested in clinic monthly (or more frequently if clinically indicated) via the Coaguchek® point-of-care device (which is the standard of care in the Anticoagulation Clinic) and receive dosing instructions and standardized education related to warfarin by a clinical pharmacist who provides care in the Anticoagulation Clinic."
1525317|NCT02776553|Other|Nutritional consultation|Dietary advice will be provided at the beginning of the study and individually tailored to the participant's usual eating habits plus amino acid supplement including 10 grams of branched-chain amino acids
1525318|NCT02776553|Behavioral|Physical training program|Physical activity prescription will target ≥10,000 steps/day, taking into account all activities performed throughout the day, although the increment in activity should be no less than 3000 steps/day above the baseline.
1525319|NCT02776553|Behavioral|Behavioral modification therapy|The behavior modification theory will be applied in the form of a structured set of cues and questions between investigator and participant at each visit in order to provide individually tailored counseling to enhance internal motivation and facilitate behavior change toward physical activity and dietary improvement that are adaptable to each participant's usual habits.
1525320|NCT02776540|Drug|Clopidogrel|there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel
1525321|NCT02776540|Drug|Aspirin|there's another group will receive 400 mg Aspirin
1525322|NCT02776527|Drug|Apatinib Mesylate Tablets|taking Apatinib Mesylate Tablets 500mg/qd orally, 28 days as a cycle, till disease progresses
1525327|NCT02776501|Drug|Coppertone (BAY987521)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation: Y49-103)
1525328|NCT02776488|Drug|Glucose|Less than one fifth of one ounce of glucose mixed in standard saline solution will be administered through a standard venous drip line or through the microdialysis catheter as part of standard brain chemistry analyses.
1525329|NCT02776488|Drug|Lactate|Less than two thirds of an ounce of lactate mixed in standard saline solution will be administered through a standard venous drip line or through the microdialysis catheter as part of the standard brain chemistry analyses.
1525330|NCT02776488|Drug|Beta-hydroxybutyrate|Less than one tenth of one ounce of hydroxybutyrate mixed in standard saline solution will be administered through a standard venous drip line or through the microdialysis catheter as part of the standard brain chemistry analyses.
1525331|NCT02776475|Procedure|Sacral neuromodulation device turned off|Each patient will be to have the sacral neuromodulation device turned off for four consecutive weeks.
1525332|NCT02776462|Device|EyeBox CNS|
1525333|NCT02776436|Drug|Dexamethasone|Dose of prophylactic dexamethasone will be reduced for all patients
1525334|NCT02776436|Drug|Prednisone|standard prednisone 5 mg bid for patients with prostate cancer
1525335|NCT02776423|Procedure|Bulkamid|The procedure was standardized, identical for all patients, and entirely performed in an outpatient setting. All injections were performed by a single urogynecologist. Before injection all patients received a single dose trimethoprim (Idotrim®, Orion Pharma). The patient was placed in a supine position and given intraurethral topical 2% lidocaine hydrochloride gel (Xylocain®, Astra Zeneca) for anesthetic. Using a video-urethroscope and a 23-gauge needle, polyacrylamide hydrogel deposits of 0.3-0.4 mL were injected at 12, 4 and 8 o´clock into the submucosa approximately 1 cm from the bladder neck. Patients were discharged after successful voiding.
1525336|NCT02776410|Behavioral|Consumer reactions to tailored messages sent via app|The intervention will take 1 month. Participants from the Intervention group will receive tailored messages every 2-3 days with a push notification. Additionally, interaction with the participants via the use of app is foreseen.
1525337|NCT02776397|Dietary Supplement|Vitamin E|Two hundred patients will be recruited to a pilot randomized controlled trial (RCT), stratified by Hp 2-2 phenotype status (100 Hp 2-2 and 100 non-Hp 2-2), and randomly allocated in a 1:1 ratio to either vitamin E 400 IU supplementation daily for 6 months or a placebo group. The trial will determine whether vitamin E improves the aforementioned surrogate markers in the Hp phenotype strata.
1525338|NCT02776397|Other|Placebo|Placebo arm
1525339|NCT02776384|Other|Observational study|
1525340|NCT02776371|Drug|Modified non-clarithromycin triple therapy|H. pylori infected patients treated with 20 mg esomeprazole twice a day, and 1g amoxicillin, 500 mg tinidazole three times a day for 10 days.
1525341|NCT02776371|Drug|Sequential therapy|H. pylori infected patients treated with 20 mg esomeprazole and 1 g amoxicillin, twice daily for 5 days, followed by 20 mg esomeprazole, 500 mg clarithromycin, and 500 mg tinidazole, twice daily for the next 5 days.
1525342|NCT02776358|Other|High Fidelity Simulation|"A HFS session for an asthma attack require:
a 5 minutes briefing session: case and equipments presentation and choice of participants
15 minutes of actual simulation
40 minutes of debriefing
A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.
Also, another test will be done after 7 days of the course."
1525343|NCT02776358|Other|Video case|"a video case (or video box) session in which students will attend a video-projection of a real case of an asthma attack and discuss with the trainer the different steps of the assessement and management of an asthma attack.
A pre and a post test will be taken by the students before and after the session and a satisfaction questionnaire at the end of the course.
Also, another test will be done after 7 days of the course."
1525344|NCT02776345|Other|Ultrasound guided Needle Fragmentation|Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudocapsule. The needle tip will be retracted into the subacromial bursa and 3 ml of 0.5% sensorcaine and 1 ml of steroid ( Depomedrol- 40mg/ml) will be injected into the bursa. The needle will then be removed.
1525345|NCT02776345|Other|US guided needle fragmentation & Lavage|Using local anesthetic and strict aseptic precautions, the tip of the 18-20 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 2ml. of local anesthetic ( 1% xylocaine) will be injected into the bursa. The needle tip will be advanced into the supraspinatus tendon and ½ ml or less of 0.5% Sensorcaine will be injected into the pseudo capsule around the calcification. Using 15-20 to and fro gentle movements of the needle tip, the calcification will be fragmented, with the needle tip within the pseudo capsule. During this procedure, or after the fragmentation, using a syringe of saline or local anesthetic( 1% xylocaine) and with pumping action of the syringe the calcification with be sucked into the syringe.
1525346|NCT02776345|Other|Ultrasound guided subacromial injection|Using local anesthetic and strict aseptic precautions, the tip of the 22 gauge needle will be advanced into the sub acromial bursa under ultrasound guidance and 4 ml. of local anesthetic ( 0.5% xylocaine) and 1 ml of steroid( Depomedrol 40 mg/ml) will be injected into the bursa. The needle will then be removed. Post procedure US images in the short and long axis planes will be obtained and documented. The patient's post procedure pain on a scale of 10 and their range of shoulder movement (abduction) will be assessed and documented.
1525347|NCT02776332|Procedure|Manual Expression of Breastmilk|Breastfeeding log for 14 days after delivery Video of manual expression for teaching and reinforcement Complete breastfeeding self-efficacy scale at 1 day and 14 days after delivery
1525348|NCT02776319|Device|Non-invasive brain stimulation (active)|Non-invasive brain stimulation (active)
1525349|NCT02776319|Device|Non-invasive brain stimulation (sham)|Non-invasive brain stimulation (sham)
1525350|NCT02776306|Other|Mirror Box therapy|In mirror box therapy the patient uses the reflection of their good arm to trick to brain into thinking that the effected arm is working.
1525351|NCT02776293|Behavioral|Relaxation|
1525352|NCT02776293|Behavioral|Music|
1525353|NCT02776280|Other|Meal|Typical Brazilian meal consisting of rice, beans and meat with vegetables
1525354|NCT02776267|Device|Angiolite stent|Following index PCI, patients will be followed via scheduled clinic and/or phone contact at 1-, 3-, 6-, 12- and 24-month. Patient will be randomized to undergo a scheduled repeat coronary angiogram and OCT evaluation at either at 3- or 6-month post index PCI.
1525355|NCT02776254|Other|START|Point of care testing for rapid ART initiation
1525356|NCT02776254|Other|CAG|Community Adherence Group
1525357|NCT02776254|Other|UAG|Urban Adherence Group
1525358|NCT02776254|Other|FAST-TRACK|Prescription refill only
1525359|NCT02776241|Other|water|
1525360|NCT02776228|Drug|Brotizolam|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg brotizolam once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
1525361|NCT02776228|Drug|placebo|Every patient which will enroll to the study will fill up The Pittsburgh Sleep Quality Index in there admission to the cardiac surgery unit. in the discharge day the patient will receive 0.25 mg LACTOSE once a day before sleep for six weeks. one week and six weeks after discharge day, there is routine follow up in our outpatient clinic. in those appointed time the patient will fill again The Pittsburgh Sleep Quality Index.
1525362|NCT02776215|Drug|tasimelteon|Melatonin receptor agonist
1525363|NCT02776202|Drug|Fludarabine monophosphate|"The HSCT preparative regimen will consist of
Thymoglobulin: 2.5 mg /kg/day intravenously (IV) on Days -8 through -5
Fludarabine: 35 mg/m2/day IV on Days -8 through -4
Melphalan: 140 mg/m2 IV on Day -3
Rest on Day -2 and -1
Day 0 is the day of transplant
GVHD prophylaxis: sirolimus beginning on Day -1 for at least one year and mycophenolate mofetil (MMF) from Day -3 to +45 or to 7 days after neutrophil engraftment, whichever is later."
1525364|NCT02776189|Drug|Dexmedetomidine|intravenous dexmedetomidine 1 mcg per kg body weight over 10 minutes followed by infusion of dexmedetomidine at dose of 1 mcg per kg body weight per hour till end of procedure
1525365|NCT02776189|Drug|propofol|intravenous propofol 2mg per kg body weight followed by infusion of propofol at a dose of 100 mcg per kg body weight per min till end of procedure
1525366|NCT02776189|Drug|Midazolam|Intra nasal midazolam 0.2 mg per kg body weight before intravenous canulation
1525367|NCT02776176|Procedure|Enhanced Recovery After Surgery Program|optimized peri-operative protocol
1525368|NCT02776176|Procedure|Traditional Program|traditional standard protocol
1525369|NCT02776163|Drug|Cisplatin|Cisplatin 80mg/m^2，D1-3，2 cycles
1525370|NCT02776163|Drug|Docetaxel|Docetaxel 70mg/m^2，D1，2 cycles
1525371|NCT02776163|Radiation|Intensity-modulated radiotherapy|a total dose of 60-66Gy in 30-32 fractions over 6-7 weeks
1525372|NCT02776137|Drug|Docetaxel|Docetaxel: 20mg/m2/w for 6 weeks
1525373|NCT02776137|Radiation|Intensity-modulated radiotherapy|a total dose of 60Gy in 30 fractions over 6 weeks
1525374|NCT02776124|Dietary Supplement|Healing Elements,Methuselah Medical Technology|ONS group will receive Healing Elements ONS everyday during CRT
1525375|NCT02776111|Other|Blood Sample|A one time blood sample will be provided.
1525376|NCT02776059|Drug|Standard of care + pegfiltrastim|prednisolone or pentoxifyline orally for 28 days + pegfilgrastim (Neulasta®) 6 mg in 0.6 mL SQ
1525377|NCT02776059|Drug|Standard of care|Oral prednisolone or pentoxifyline for 28 days only
1525378|NCT02776046|Drug|High FiO2|High FiO2 with a perioperative open lung strategy
1525379|NCT02776046|Drug|Conventional FiO2|Conventional FiO2 with a perioperative open lung strategy
1525380|NCT02776033|Drug|GSK2982772|GSK2982772 will be supplied as a white to almost white, round, film coated 30 mg oral tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
1525381|NCT02776033|Drug|Placebo|Matching placebo will be supplied as a white to almost white, round film coated tablets; two tablets to be taken in the morning and two in the evening, as directed for Cohort 1 and for Cohort 2 two tablets to be taken three times daily as directed.
1525382|NCT02776020|Device|CorrecDose Infrared Monitor|The monitor is attached to patient's wrist and ear in order to measure changes in propofol concentrations in blood
1525385|NCT02775994|Drug|Canakinumab|interleukin beta (IL-1) antagonist
1525386|NCT02775981|Drug|RX0041-002|
1525387|NCT02775968|Drug|Cephalosporins and Macrolide Antibiotics|The intervention drugs are prescribed by treating caregiver.
1525388|NCT02775955|Drug|RX0041-002|Analgesic
1525389|NCT02775942|Biological|IMOVAC-POLIO|IMOVAC-POLIO (Sanofi Pasteur), liquid form composition: Type 1 (Mahoney) 40DU, Type 2 (MEF1) 8DU, Type 3 (Saukett) 32 DU, Subcutaneous route 0.5ml/dose, 3 doses, 4-week interval
1525390|NCT02775942|Biological|IPOVAC 1.5:5:5|IPOVAC- POLYVAC Vietnam Composition: Type 1: 1.5DU, Type 2: 5DU, Type 3:5DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
1525391|NCT02775942|Biological|IPOVAC, 3:10:10|IPOVAC- POLYVAC Vietnam Composition: Type 1: 3DU, Type 2: 10DU, Type 3:10DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
1525392|NCT02775942|Biological|IPOVAC, 6:20:20|IPOVAC- POLYVAC Vietnam Composition: Type 1: 6DU, Type 2: 20DU, Type 3:20DU Subcutaneous inj 0.5ml/dose, 3 doses, interval 30days +/- 3 days Liquid form
1525393|NCT02775929|Drug|FTC-TDF PrEP|FTC-TDF PrEP for HIV-1 uninfected partners
1525394|NCT02775929|Drug|ART|ART for HIV-1 infected partners
1525395|NCT02775916|Drug|CDZ173|
1525396|NCT02775916|Drug|Placebo|
1525397|NCT02775903|Drug|Azacitidine|
1525398|NCT02775903|Drug|Durvalumab|
1525399|NCT02775890|Behavioral|Eating wild game shot with lead bullets|Participants will eat meat harvested with lead bullets, prepare mince meat and eat at least a standard serving (>85 grams).
1525400|NCT02775877|Drug|Letrozole|
1525401|NCT02775877|Drug|clomiphene|
1525402|NCT02775877|Drug|HMG|
1525403|NCT02775864|Drug|Antipsychotic|New initiation of any antipsychotic medication
1525404|NCT02775864|Drug|Antidepressant|New initiation of any antidepressant medications
1525405|NCT02775864|Drug|Benzodiazepine|New initiation of any benzodiazepine
1525406|NCT02775864|Drug|Mood stabilizer|New initiation of lithium or any mood stabilizing anti-epileptic drug
1525407|NCT02775851|Other|Laboratory Biomarker Analysis|Correlative studies
1525408|NCT02775851|Biological|Pembrolizumab|Given IV
1525409|NCT02775851|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
1525410|NCT02775838|Drug|Indocyanine green|perioperative application of Indocyanine green (ICG)
1525411|NCT02775825|Other|survey|
1525416|NCT02775799|Other|Registration|Registration according to approved data sets
1525417|NCT02775786|Other|MRIs with and without intravenous contrast (up to 2)|Participants will undergo up to two MRIs with and without intravenous contrast. The first MRI will be performed using an extracellular contrast agent and the second 1-14 days later, with a macromolecular contrast agent. If patient cannot undergo the second MRI for any reason eg. not enough time before surgery, one MRI with either contrast agent will still be used for analysis.
1525418|NCT02775773|Drug|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
1525419|NCT02775773|Drug|Oxytocin|2 vials (=10 IU/International Unit) of Oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
1525420|NCT02775760|Behavioral|Cardiovascular endurance|Physical exercise at the Boston University Fitness and Recreation Center
1525421|NCT02775760|Behavioral|Strength, balance, and flexibility|Physical exercise at the Boston University Fitness and Recreation Center
1525424|NCT02775734|Drug|N-acetyl-cysteine|N-acetyl-cysteine + Clomiphene citrate + Laparoscopic ovarian drilling
1525425|NCT02775734|Drug|Clomiphene citrate|Clomiphene citrate + Laparoscopic ovarian drilling
1525426|NCT02775721|Other|Nursing Education related to Gastrostomy Tube Care|The research nurse will provide educational intervention at each study visit utilizing the nursing process.
1525427|NCT02775721|Other|Speech Therapy Education and Evaluation|Speech therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Speech therapy and evaluation is assessed per the attending speech therapist. The study team will collect all data related to speech therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
1525428|NCT02775721|Other|Nutritional Therapy Education and Evaluation|Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.
1525429|NCT02775721|Other|Quality of Life Questionnaire C30 version 3|30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.
1525430|NCT02775721|Other|Quality of Life Questionnaire EORTC QLO - H&N35|35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
1525432|NCT02775695|Drug|Doxycycline|Treatment with doxycycline hyclate will be administered as an oral agent on an outpatient basis. Patients will receive doxycycline 100 mg twice daily for a period of 8 weeks (56 days). Upon registration (baseline) and at the first, third, and fifth days of doxycycline therapy, patients will be seen to obtain trough serum concentrations for pharmacokinetic studies. Additional serum levels will be checked on days 8, 15, 22 and 29.
1525433|NCT02775630|Procedure|hypnosis|It will be proposed to the patient to participate in a study to assess the tolerance of Examination under hypnosis The examination is then conducted in endoscopy room. The patient will benefit from an induction technique of hypnosis by a doctor trained in hypnosis and local anesthesia performed by the endoscopist. In the control group, only local anesthesia is practiced by the endoscopist. The waning, it will ask the patient and endoscopist to complete an evaluation form tolerance of the review
1525437|NCT02775604|Behavioral|Home-Based Video|The participant will use GoPro technology and follow standardized instructions to inspect each room of their house. They will navigate through their home wearing the GoPro camera, recording images about their home and their usual activities and use a talk-aloud approach to describe what they are doing and seeing. The evaluator will provide no feedback during the assessments.
1525438|NCT02775604|Behavioral|Paper Checklist|A paper checklist for fall hazards in the home will be completed by the participants based on standardized verbal instruction.
1525439|NCT02775591|Drug|DA-9701|DA-9701 30mg Tablet
1525440|NCT02775591|Drug|DA-9701 placebo|Placebo pill manufactured to mask DA-9701 30mg Tablet
1525441|NCT02775578|Procedure|Coronary Artery Bypass Grafting|Using coronary artery bypass grafting surgery as the coronary revascularization therapy for patients enrolled.
1525442|NCT02775578|Procedure|Percutaneous Coronary Intervention|Using percutaneous coronary intervention as the coronary revascularization therapy for patients enrolled.
1525443|NCT02775578|Procedure|Hybrid Coronary Revascularization|Patients enrolled will take coronary artery bypass grafting surgery at first, then treated with percutaneous coronary intervention.
1525444|NCT02775565|Device|AngioVac|
1525984|NCT02771704|Other|Silver diamine fluoride and potassium iodide|
1525445|NCT02775552|Behavioral|A&T community-based interventions|"Interpersonal communication delivered by health workers and community volunteers at the health post and during home visits to:
- Increase mothers' knowledge about adequate child feeding practices
Interpersonal communication delivered by agricultural extension workers to:
- Increase fathers' knowledge about nutrition-sensitive agriculture and child feeding
Community mobilization activities to:
Raise awareness of child feeding practices among community members, and increase support to mothers (enhanced community conversations)
Increase mothers' knowledge about preparation of complementary foods (cooking demonstrations)
Raise awareness of adequate child feeding during fasting among family and community members (church sermons)
Enhanced training of government health and agricultural extension workers in infant and young child feeding to:
Improve their ability to provide timely and appropriate information and support to mothers and families"
1525446|NCT02775552|Behavioral|Mass media|Radio campaign - radio drama series, spots, and jingles
1525447|NCT02775539|Drug|Mirabegron|Patients will receive 50 to 200 mg of mirabegron once a day during 16 weeks. Dose will be titrated during the first 8 weeks.
1525448|NCT02775539|Drug|Placebo|
1525449|NCT02775526|Procedure|TOT|70 patients
1525450|NCT02775526|Procedure|TVT|70 patients
1525451|NCT02775526|Procedure|Burch Colposuspension|70 patients
1525452|NCT02775500|Drug|apremilast|Comparison of women exposed during pregnancy versus women who are not exposed to apremilast
1525453|NCT02775474|Drug|Use of Intraoperative Intravenous Methadone|The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
1525454|NCT02775474|Drug|Use of Intraoperative Intravenous Fentanyl|The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
1525455|NCT02775448|Drug|Carduus marianus 6cH|
1525456|NCT02775448|Drug|Carduus marianus 12cH|
1525457|NCT02775448|Drug|Carduus marianus 30cH|
1525458|NCT02775448|Drug|Placebo|
1525459|NCT02775448|Behavioral|Exercise|aerobic exercise, 30 minutes, daily
1525460|NCT02775448|Other|Diet|1600 calories
1525466|NCT02775422|Biological|Serological Test s for the Virus Chicken Pox Virus|
1525467|NCT02775409|Procedure|Subcutaneous placement|The tissue expander will be placed above the muscle.
1525468|NCT02775409|Procedure|Submuscular placement|The tissue expander will be placed below the muscle
1525469|NCT02775396|Device|Spectacle lens|Wearing a spectacle lens design with corrective prescription power while playing computer game using an iPad tablet computer. Two lens designs were prescribed for each participant: the conventional single-vision lens and a new progressive addition lens designed for handheld digital device. Primary outcome measures were performed immediately after each lens delivery and one-month of lens wear.
1525470|NCT02775383|Other|Therapeutic|Observational Study
1525471|NCT02775370|Drug|Apatinib Mesylate|Apatinib Mesylate will be administered orally at 500 mg once daily for 5 consecutive days, and this was followed by a 2-day rest every week; each cycle consisted of 28 days
1525472|NCT02775357|Behavioral|Measurement and communication of HIV risk|Measurement and communication of HIV risk in the context of HIV testing and counseling to inform HIV risk reduction counseling
1525473|NCT02775357|Behavioral|Standard HIV testing and counseling|Participants received HIV testing and counseling following standard Ministry of Health guidelines
1525474|NCT02775344|Device|Three dimension laparoscopy|Surgery will be performed either with three dimension laparoscopy or two dimension laparoscopy.
1525475|NCT02775331|Other|Shift planning with self-rostering and shift ergonomics|Employees working in shift planning units (clusters) using an interactive shift planning software (Titania1) with sub-tools for individual shift planning (self-rostering) and an option for shift ergonomics evaluation to both the shift planner and the employees
1525476|NCT02775331|Other|Shift planning with shift ergonomics|Employees working in shift planning units (clusters) where shift planners use a non-interactive shift planning software (Titania2) providing guidance for health-supporting shift ergonomics.
1525477|NCT02775318|Procedure|Stellate Ganglion Block|Under aseptic conditions, transducer is placed on the surface of the neck at the level of C6 vertebrae. The internal jugular vein, carotid artery, thyroid gland, trachea, C6 vertebrae, transverse process of C6, esophagus , longus colli with its covering prevertebral fascia and esophagus are visualized. A 25-gauge Quincke spinal needle was inserted paratracheal towards the middle of the longus colli muscle. The endpoint of the injection was the ultrasound image of the tip of the needle as it penetrates the prevertebral fascia covering the longus colli muscle. The drug is then injected and spread of drug is visualized in real time.
1525478|NCT02775318|Drug|Bupivacaine|10 ml of 0.5% injection bupivacaine is used for giving stellate ganglion block on the side of cerebral vasospasm
1525479|NCT02775318|Procedure|Transcranial Doppler|The principle on which the TCD works is that with arterial narrowing, the blood flow velocity within the vessel increases. A good correlation has been found between the TCD blood flow velocities and vasospasm. The MCA velocity greater than 120 cm/sec indicates mild vasospasm , velocity greater than 130 cm/sec indicates moderate vasospasm and velocity greater than 200 cm/sec indicates severe vasospasm.
1525480|NCT02775318|Procedure|Digital Subtraction Angiography|Digital subtraction angiography is a direct method for the assessment of vessel caliber. It generates high resolution, high contrast and low artifact images using digital subtraction technology. Direct visualization using DSA is the gold standard for the radiographic diagnosis of cerebral vasospasm
1525533|NCT02774863|Other|Home passages|Three home passages between the 2nd and 3rd months of follow up.
1525534|NCT02774837|Drug|Tenofovir disoproxil|Tenofovir disoproxil 300mg once daily for 96 weeks
1525535|NCT02774837|Drug|Telbivudine|Telbivudine oral tablets 600mg once daily for 96 weeks
1525536|NCT02774811|Drug|Prostaglandin analogue|Topical therapy
1525537|NCT02774811|Procedure|Selective laser trabeculoplasy|Laser therapy into drainage angle
1525538|NCT02774811|Device|laser|
1525481|NCT02775305|Behavioral|Frail|"Slowness/weakness: Physical therapy(PT) strength and gait training. A standardized strengthening program will be prescribed, to be performed at home. Additional in-person PT training will be provided to those who are severely deconditioned .
Weight loss/malnutrition: A licensed nutritionist specializing in kidney disease will meet with participants for 3 one-hour one-on-one nutritional counseling.
Low physical activity: Participants will receive individualized walking recommendations using a pedometer. Walking activity will be assessed weekly, and new goals for increasing steps in the following week will be set.
Exhaustion: Those who meet criteria for severe depression using the center for epidemiologic studies depression (CES-D) scale will be immediately referred to psychiatry for counseling for patient safety. All others will participate in cognitive behavioral coping techniques."
1525482|NCT02775292|Biological|Aldesleukin|Given SC
1525483|NCT02775292|Drug|Cyclophosphamide|Given IV
1525484|NCT02775292|Drug|Fludarabine Phosphate|Given IV
1525485|NCT02775292|Other|Laboratory Biomarker Analysis|Correlative studies
1525486|NCT02775292|Biological|Nivolumab|Given IV
1525487|NCT02775292|Biological|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
1525488|NCT02775292|Biological|NY-ESO-1(157-165) Peptide-pulsed Autologous Dendritic Cell Vaccine|Given ID
1525489|NCT02775292|Procedure|Positron Emission Tomography|Correlative studies
1525490|NCT02775266|Other|Alpha lipoic acid|Scaling and root planing will be done at baseline and systemic antioxidant Alpha lipoic acid 1800mg/day in 3 divided doses for a period of 3 months.
1525491|NCT02775266|Procedure|Scaling and Root planing|Scaling and root planing will be done at baseline.
1525492|NCT02775253|Other|Chronic cold acclimation|
1525496|NCT02775227|Drug|Hydrocortisone|
1525497|NCT02775227|Drug|Pasireotide|
1525498|NCT02775214|Device|Video Laryngoscopy|
1525499|NCT02775201|Procedure|Plantaris release under ultrasound guidance|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be released using a small incision at the medial ankle under ultrasound guidance by a consultant radiologist
1525500|NCT02775201|Procedure|Plantaris excision surgically|In patients diagnosed with Achilles tendinopathy the plantaris tendon will be excised in theatre by a consultant orthopaedic surgeon
1525501|NCT02775188|Device|interACTION|
1525502|NCT02775188|Other|Standard of Care Physical Therapy|
1525503|NCT02775175|Behavioral|Modified Ramadan Fasting|The intervention aims to provide knowledge about fasting and its effects on the body/mind, and health advice around nutrition to support health and well-being of participants during Ramadan.
1525504|NCT02775162|Device|Normothermic Machine Perfusion (NMP)|
1525505|NCT02775162|Other|Standard of Care (Ice)|
1525506|NCT02775149|Other|Collection of saliva samples|Collection of saliva samples
1525507|NCT02775149|Other|Visual detection of BEWE-index|Visual detection of BEWE-index
1525508|NCT02775136|Device|HS-1000 recording|
1525509|NCT02775123|Device|Cytosorb|A cytoadsorbent cardridge (Cytosorb) will be added to the extra-corporeal circuit (CPB).
1525510|NCT02775110|Other|Natalizumab discontinuation|Patients will be randomized to one of two groups: The Immediate Discontinuation Group (stop natalizumab immediately and continue with new DMT 1 month afterward) and the Taper-off Group (two additional infusions of natalizumab, one at 6 weeks and the next at 8 weeks following discontinuation. A new DMT will be initiated within 2 months of final natalizumab infusion).
1525511|NCT02775097|Device|OCT|OCT for all Arms
1525512|NCT02775084|Dietary Supplement|Fish Oil|4 capsules twice daily with food for 6 weeks
1525513|NCT02775084|Dietary Supplement|Olive Oil|4 capsules twice daily with food for 6 weeks
1525514|NCT02775058|Device|synergoss Pxx|dental grafting
1525516|NCT02775032|Behavioral|Advance care planning conversations between patients and their GP|
1525517|NCT02775019|Dietary Supplement|Lactobacillus reuteri|2 x daily repeated consumption of a lozenge containing 10E9 CFU Lactobacillus reuteri for 42 days
1525518|NCT02775019|Dietary Supplement|Placebo|2 x daily repeated consumption of a lozenge being void of Lactobacillus reuteri for 42 days
1525521|NCT02774993|Drug|Doxycycline|
1525522|NCT02774993|Drug|placebo|
1525523|NCT02774980|Behavioral|Recurrent depression|
1525524|NCT02774967|Procedure|root coverage|Root coverage with acellular dermal matrix using two techniques: advanced positional flap ou tunneling,
1525525|NCT02774954|Behavioral|Change the Cycle|See previous response
1525526|NCT02774902|Drug|TAK-438|TAK-438 tablets
1525527|NCT02774902|Drug|Clarithromycin|Clarithromycin tablets
1525528|NCT02774889|Behavioral|Stepping Online|"Stepping Online is a password-protected website with Stepping On graduates, whose groups are randomized to Stepping Online and will have access to and training in a password-protected website. The website includes:
Fall prevention tips
Fall prevention exercise videos with narrations for proper technique and safety precautions
Guest expert videos with online access to the guest expert to ask questions
Tools to set exercise goals, get reminders and track progress
Access to a fall prevention specialist for personal feedback and suggested group homework
Group discussion and messaging (one-to-one and with their fellow Stepping On workshop participants group, or with all Stepping Online participants and leaders)
Fall prevention resources"
1525539|NCT02774785|Device|MarginProbe|Surgery to take place as per standard care. When the surgery is nearly concluded, patient to be randomised. If randomised to device arm, the MarginProbe device will be used on the outer edge of the tumour and shavings. If the MarginProbe device indicates that cancer is detected, a further shaving is to be taken. Surgery then to be concluded as per standard care.
1525540|NCT02774759|Device|Accelerometer|Participant wears an accelerometer for 7 days before baseline visit to record activity levels, and again before their 6 month visit.
1525541|NCT02774759|Behavioral|Questionnaires|"Questionnaires completed at baseline regarding quality of life and diet.
Questionnaires completed at 3 and 6 months regarding quality of life, diet, physical activity, etc."
1525542|NCT02774759|Behavioral|Fitness Test|Fitness test given covering various physical activities at baseline and at 6 month visit.
1525543|NCT02774759|Behavioral|Resistance Training|Physical activity guidelines workbook distributed along with activity monitor. Participants receive resistance bands to perform resistance exercises. Exercise handouts and an iPad mini with training videos used to video chat with a research team member. Information from wireless scale and Fitbit sent to Fitbit website to monitor levels.
1525544|NCT02774759|Behavioral|Aerobic Exercise|Participants placed into an exercise plan focused on physical activity only. Physical activity guidelines workbook distributed along with activity monitor.
1525545|NCT02774759|Behavioral|Telephone Coaching/Phone Calls|Participants called 4 times during the first month, 2 times during the second month, and 1 time per month for the rest of the study. Participants also receive a follow-up call at the end of the study.
1525546|NCT02774759|Behavioral|Video Chat Sessions|Video chatting between the research team and participants occurs 2 times per month during the first and third months, when new exercises are introduced. Video chatting offered monthly as needed by participants during months 2, 4, 5, and 6.
1525549|NCT02774733|Device|spirometer;Intraocular pressure;Color doppler imaging|
1525550|NCT02774720|Behavioral|Centre-based exercise|Participants will come to a centre (University of Waterloo or Toronto Rehabilitation Institute) for a one-hour, small group exercise class each week. The classes will include progressive aerobic and resistance exercise. They will be prescribed additional exercise to be performed independently (either at home or in the community).
1525551|NCT02774720|Behavioral|Home-based exercise|Participants will be prescribed aerobic and resistance exercise to be performed independently (either at home or in the community). They will receive monthly phone calls to discuss achievements and barriers and to tje adjust exercise prescription.
1525552|NCT02774694|Device|"nociceptive flexion reflex (NFR) threshold (Paintracker, Dolosys GmbH, Berlin, Germany)"|"measurement of the NFR threshold using the Paintracker device"
1525553|NCT02774681|Procedure|Cognitive Assessment|Ancillary studies
1525554|NCT02774681|Drug|Palbociclib|Given PO
1525555|NCT02774681|Procedure|Quality-of-Life Assessment|Ancillary studies
1525556|NCT02774681|Biological|Trastuzumab|Given IV
1525557|NCT02774668|Other|"Grab-and-Go meal plan"|"The Grab-and-Go meal plan will provide Atkins shakes and bars for breakfast, lunch, and snacks. For dinner, the participant will receive a freshly-prepared meal. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan.
The amount of weight loss caused by these two meal plans is not expected to differ."
1525558|NCT02774668|Other|"Jump-Start meal plan"|"The Jump-Start plan will provide Atkins frozen meals at breakfast, lunch and dinner and these meals will be supplemented with fresh salads and vegetables. There will be no difference in terms of calories or nutrient composition between Grab-and-Go meal plan versus Jump-Start meal plan. The amount of weight loss caused by these two meal plans is not expected to differ."
1525559|NCT02774655|Device|Pai APP|prescribed 100 PAI weekly
1525560|NCT02774655|Device|FitBit APP|prescribed 10000 steps daily
1525561|NCT02774642|Behavioral|CBTI-PE|Integrates CBT-I and PE with the goal of enhancing both insomnia and PTSD outcomes. Integrated treatment will be delivered in 14 90-minute weekly sessions. CBTI-PE starts with VA rollout CBT-I for the first 3 weeks with a focus on the effects of PTSD on insomnia. PE protocol (psychoeducation) begins on week 4 of treatment and both treatments overlap till week 6 when CBT-I ends and the active treatment of PE begins (i.e., imaginal and in-vivo exposures). However, CBT-I sleep diary review and sleep time adjustment will continue till the end of treatment to increase adherence
1525562|NCT02774642|Behavioral|Hygiene-PE|The investigators have included a non-active sleep control arm (3 Sessions)to allow for the dose response of 14 90 minute sessions. The non-active sleep control condition used in this study is a manualized protocol developed to exclude the active components of standard CBT-I treatment. Hygiene includes presentation of sleep hygiene education and reviewing daily stressors that may impact sleep before starting PE on week 4.
1525563|NCT02774629|Other|prick and patch test|The cases are pricked and patched with local food allergen extract at different storage times (0, 3 and 6 months after preparation)
1525566|NCT02774603|Other|Aquatic Locomotor Training|
1525567|NCT02774603|Other|Land Locomotor Training|
1525568|NCT02774590|Drug|Timolol|Apply timolol on half of the participant's face for 8 weeks. Then treat both sides of face for 8 weeks.
1525571|NCT02774564|Drug|BIA 3-202|Nebicapone tablets 50 mg, oral administration
1525572|NCT02774564|Drug|Placebo|Nebicapone matching placebo tablets
1525573|NCT02774564|Drug|Sinemet®|Sinemet® CR 200/50 (levodopa 200 mg / carbidopa 50 mg) tablets
1525574|NCT02774551|Behavioral|Physical activity intervention group|150 minutes of minimum intensity activity during a week (e.g. walking, swimming) and five strength training exercises (10 repetitions and 2 sets of: squats, wall push ups, rowing with resistance band, shoulder press with resistance band, hip abduction) targeting the major muscle groups to do twice a week.
1525576|NCT02774525|Behavioral|Reinforcement for drug & alcohol abstinence|
1525578|NCT02774525|Behavioral|Treatment as usual (TAU)|Outpatient substance-abuse therapy plus drug & alcohol screening plus support for personal goal setting
1525579|NCT02774512|Drug|Nilotinib|Each patient will receive nilotinib 800 mg/day every day for 7 days. Study treatment will be taken twice a day (400 mg - 2 capsules) by oral route with an interval of approximately 12 hours between two doses and should not be taken with food. The entire capsule should be swallowed with water. No food should be consumed for 2 hours before taking the drug and for at least 1 hour after it.
1525580|NCT02774499|Drug|Methadone|0.3mg/kg of methadone given preoperatively (to maximum of 30mg)
1525581|NCT02774499|Drug|Placebo|equivalent volume (5mL) of syrup given preoperatively
1525582|NCT02774486|Device|IQP-AK-102|IQP-AK-102 has been qualified as a medical device (CE certificate has been ob- tained), class IIb, according to MDD 93/42/EEC, annex IX, rule 5.
1525583|NCT02774473|Device|[18F]FLT PET/CT|
1525584|NCT02774473|Drug|Paclitaxel|
1525585|NCT02774460|Drug|Zestril®|Treatment step up: 1-2 weeks (10 mg tablet) Target dose: 5-7 weeks (20 mg tablet)
1525586|NCT02774460|Drug|Atacand®|Treatment step up: 1-2 weeks (8 mg tablet) Target dose: 5-7 weeks (16 mg tablet)
1525587|NCT02774460|Drug|Norvasc®|Treatment step up: 1-2 weeks (5 mg tablet) Target dose: 5-7 weeks (10 mg tablet)
1525588|NCT02774460|Drug|Hydrochlorthiazide®|Treatment step up: 1-2 weeks (12,5 mg tablet) Target dose: 5-7 weeks (25 mg tablet)
1525589|NCT02774460|Drug|Treatment X|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
1525590|NCT02774460|Drug|Treatment Y|Each patient receives all four treatments, and in addition repeats two of the treatments, labeled X and Y. The repeated arms will be given with the same duration and dosing as the other arms.
1525591|NCT02774460|Drug|Placebo|This is an unblinded placebo run-in which we use to generate baseline values. Each patient will initiate their participation with these 2 weeks of placebo treatment, taking 1 capsule daily.
1525592|NCT02774447|Procedure|ileostoma closure|The operation procedure is standardized as described above (see group description).The patients will be observed for 23 hours, and if there are no contraindications according to described criteria the patient can be discharged form the hospital, however all patients will have follow-up telephone contact on a daily basis with a nurse for the first week. Patients will meet the surgeon 3 days after discharge and after 4 weeks.
1525593|NCT02774434|Device|JM-105|Measurement of TcB via the JM-105 device
1525594|NCT02774421|Drug|Trastuzumab after SubQ GM-CSF|
1525595|NCT02774421|Drug|Trastuzumab in combination with SubQ GM-CSF|
1525596|NCT02774408|Device|Saturation sensitive backup ventilation|
1525597|NCT02774382|Drug|Vancomycin|Already incl. in arm description
1525598|NCT02774382|Drug|Fecal microbiota transplantation|Already incl. in arm description
1525599|NCT02774382|Drug|Rectal bacteriotherapy|Already incl. in arm description
1525600|NCT02774369|Behavioral|Physical exercise|Individualized aerobic intervention program
1525601|NCT02774369|Behavioral|Cognitive-behavioral therapy|Psychological intervention combining behavioral, cognitive, and educational strategies
1525602|NCT02774343|Drug|Pioglitazone|Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
1525603|NCT02774343|Drug|Placebo|Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
1525604|NCT02774330|Other|Policy|This local policy change (i.e., the Minneapolis Staple Foods Ordinance) establishes minimum stocking criteria for a wide array of healthy foods as a requirement of food store licensing. To our knowledge, it is the first and only policy of its kind in the U.S. This Staple Foods Ordinance requires stores to stock specific types of foods in minimum quantities and varieties, including fruits and vegetables, low-fat dairy, and whole grains. A full list of all requirements can be found online through the City of Minneapolis: http://www.minneapolismn.gov/health/living/eating/staple-foods.
1525608|NCT02774291|Biological|Aldesleukin|Given IV
1525609|NCT02774291|Biological|Anti-thyroglobulin mTCR-transduced Autologous Peripheral Blood Lymphocytes|Given IV
1525610|NCT02774291|Drug|Cyclophosphamide|Given IV
1525611|NCT02774291|Biological|Filgrastim|Given SC
1525612|NCT02774291|Drug|Fludarabine Phosphate|Given IVPB
1525613|NCT02774291|Other|Laboratory Biomarker Analysis|Correlative studies
1525614|NCT02774278|Drug|Erlotinib|Erlotinib will be administered at 150 milligrams (mg) orally daily until disease progression, unacceptable toxicity or death.
1525617|NCT02774252|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation number - Y49-103)
1525618|NCT02774239|Drug|Human normal immunoglobulin G (IgG)|"Study medication is available in the following forms: 5 mL (1 g IgG) in a 5 mL infusion bottle, 10 mL (2 g IgG) in a 10 mL infusion bottle, 20 mL (4 g IgG) in a 20 mL infusion bottle, 50 mL (10 g IgG) in a 50 mL infusion bottle.
Patients will be receiving 2gm/kg (150gm for a 75kg patient) of 20% SCIG (Hizentra) infused over four weeks in a dose escalating manner."
1525620|NCT02774226|Dietary Supplement|Antioxidant Cocktail|12 week intervention
1525621|NCT02774213|Other|Questionnaires completion|
1525622|NCT02774213|Other|Clinical Pain Assessments|
1525623|NCT02774200|Drug|Apatinib|Apatinib 500 mg, po, qd, continuous medication for a period of eight weeks.
1525628|NCT02774148|Drug|IV Acetaminophen|The patient will receive 1,00mg IV Acetaminophen every 8 hours until 3 doses have been received post-operatively.
1525629|NCT02774148|Drug|PO Acetaminophen|The patient will receive 1,000mg po Acetaminophen every 8 hours.
1525630|NCT02774135|Other|direct occupational therapy intervention|Short term direct individual occupational therapy (9-12 weeks).Participants will receive occupational therapy intervention according to health law. The study will document the therapeutic intervention implemented in practice using the Documentation of Occupational Therapy Session during Intervention (DOTSI).
1525631|NCT02774122|Device|CAABT|CAABT was an innovative tinnitus intervention which based on neural science and cochlear plastic research and aimed to reprogram the central auditory system to neutralize the discordant responses of the dysfunctioning cochlea via acoustic beaming stimuli.
1525632|NCT02774122|Device|masking therapy|Masking intervention was a standard monophone tinnitus masking therapy.
1525633|NCT02774109|Dietary Supplement|Fish oil|Five 1000mg fish oil soft capsules per day (each capsule containing 350mg EPA and 250mg DHA) for 8 weeks
1525634|NCT02774109|Dietary Supplement|Placebo|Five 1000mg sunflower oil soft capsules per day for 8 weeks
1525635|NCT02774109|Procedure|Hotpacking|Hotpacking 15min on low back, three times a week for 8 weeks
1525636|NCT02774109|Procedure|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) 15min on low back, three times a week for 8 weeks
1525637|NCT02774096|Drug|xenon|
1525638|NCT02774083|Behavioral|Feuerstein Program|Mediated learning cognitive enhancement program
1525639|NCT02774083|Behavioral|Adler Program|Social and emotional group program
1525640|NCT02774070|Radiation|Plain X-ray|antero-posterior, lateral neutral, flexion, extension and open-mouth views
1525641|NCT02774070|Radiation|Magnetic resonance imaging|Magnetic resonance imaging sagittal T1W,T2W and STIR, axial T1W and coronal T2W and post contrast sagittal and axial sequences
1525642|NCT02774057|Drug|Captafer®|"2 pills daily. Contains
Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;
Vitamin E, an antioxidant, along with vitamin C it protects Fe++;
Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;
Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems"
1525643|NCT02774057|Drug|Iron Sulfate|195 mg Iron supplement
1525644|NCT02774044|Drug|Cadisurf|Cadisurf Intratracheal suspension is a sterile, non-pyrogenic pulmonary surfactant intended for intratracheal use only. It is a natural lung extract containing phospholipids and surfactant-associated proteins. The resulting composition provides 25 mg/mL phospholipids and less than 1.0 mg/ml protein. It is suspended in 0.9% sodium chloride solution. Cadisurf contains no preservatives. Each ml of Cadisurf contains 25 mg of phospholipids. It is a creamy white suspension supplied in single-use glass vials containing 8 mL (200 mg phospholipids).
1525645|NCT02774044|Drug|Survanta|
1525646|NCT02774031|Device|Aisys with Et control|
1525647|NCT02774031|Device|Aisys conventional|
1525648|NCT02774031|Device|Flow-i with ACG|
1525649|NCT02774031|Device|Flow-i conventional|
1525650|NCT02774018|Behavioral|Mindfulness-Based Stress Reduction (MBSR) program|
1525651|NCT02774005|Drug|Idebenone|
1525652|NCT02773992|Behavioral|The IoT|"For the IoT group, three plus two type pulmonary nodule diagnosis： ① gather information: smoking history, tumor personal and family history, copd history, etc.; ② noninvasive examination: tumor markers, lung function and chest low-dose CT thin layer; ③ information mining in-depth:through the software for three-dimensional reconstruction of pulmonary nodules, depth excavation, accurate calculation of the density of the volume, assessment of the surrounding and infiltration of lung nodules and related vascular growth status; two solutions: ① Pathological diagnosis in highly suspected patients: fiber bronchoscope, ultrasonic bronchoscope, thoracoscope and CT guided percutaneous lung biopsy, etc.; ② Close scientific follow-up to the person who can not be qualitative: doctors follow up and manage patients scientifically in accordance with the follow-up management tables through the Internet of things platform."
1525653|NCT02773979|Drug|Chloroquine|Administered as 600mg PO, day 1, 300mg PO days 8, 15, 22.
1525654|NCT02773979|Biological|PfSPZ|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
1525655|NCT02773979|Other|Placebo|Placebo
1525658|NCT02773953|Device|T4PTelemonitoring|addition of a Telemonitoring unit on the CPAP line to standard care.
1525659|NCT02773953|Device|CPAP|CPAP treatment for treatment of obstructive sleep apnea syndrome
1525660|NCT02773940|Device|ClariCore System|Biopsy tissue and correlative spectral data will be acquired using the ClariCore System during a patient's already scheduled radical retropubic prostatectomy (RRP) surgery.
1525661|NCT02773927|Drug|Metformin|Metformin in tablet presentation of 500 mg
1525662|NCT02773927|Dietary Supplement|Agave inulin|Inulin in powder obtained from agave plant, it was given to each patient a full 10 mg container.
1525663|NCT02773927|Other|Placebo of agave inulin|Calcinated magnesia powder
1525664|NCT02773927|Other|Metformin placebo|Calcinated magnesia tablet
1525665|NCT02773914|Other|Comprehensive Geriatric Assessment|Comprehensive Geriatric Assessment intervention
1525666|NCT02773901|Device|HS-1000|
1525667|NCT02773888|Device|HS-1000|
1525668|NCT02773875|Device|Artificial pancreas system (Algorithm + CGM + pump)|The AP system using fault detection algorithms will determine whether insulin infusion problems are occurring and may prevent severe hyperglycemia due to its predictive nature
1525669|NCT02773862|Device|HS-1000|
1525670|NCT02773849|Biological|INSTILADRIN|
1525672|NCT02773823|Behavioral|Intervention group|Diet instruction for 3-4 times/semester,exercise 60min/day for 5d/week for 8 months.
1525673|NCT02773810|Other|Integrated Family Planning Services|Women who agree to enrollment will undergo our intervention, which will include an educational intervention and free on-site provision of all reversible contraceptive options, including LARC. This educational 5 intervention will be a one-on-one educational session on all available methods of contraception, with an emphasis on the safety and efficacy of long-acting reversible contraception (LARC) and the importance of planning a pregnancy in women with medical conditions requiring anticoagulation. A provider (clinic officer, nurse or physician) trained in family planning counseling and provision will provide all counseling and discussions in Kiswahili. Women will then be offered free, on-site provision of whichever contraceptive method they choose by a trained provider.
1525674|NCT02773797|Drug|IN-DEX 1.0 mcg/kg, intranasal saline|
1525675|NCT02773797|Drug|IN-DEX 1.5 mcg/kg, intranasal saline|
1525676|NCT02773797|Drug|Placebo - Saline|
1525677|NCT02773784|Other|immunohistochemistry and/or FISH|Patients with invasive breast cancer diagnosed by core needle biopsy (CNB) and not to receive neoadjuvant system therapy are eligible for this study. ER, PR, Her-2 and Ki67 are determined by immunohistochemistry (IHC) in CNB and surgical specimen. FISH analysis will be carried out in all HER2 2+ samples.
1525678|NCT02773771|Dietary Supplement|beta-hydroxy-beta-methylbutyrate|HMB is a leucine metabolite that may also be a potent mediator of anabolic processes in skeletal muscle; subjects will not receive >3g of HMB/ day.
1525679|NCT02773771|Dietary Supplement|Placebo|The placebo is cornstarch and will be mixed in with Vital HP. The solution will look identical to the intervention arm.
1525680|NCT02773771|Dietary Supplement|Vital HP®|Vital HP® is a form of enteral nutrition a part of the Massachusetts General enteral formulary
1525681|NCT02773758|Other|Stannous Fluoride Dentifrice|Experimental dentifrice containing 0.454%w/w stannous fluoride (1100ppm fluoride)
1525682|NCT02773758|Other|Sodium monofluorophosphate Dentifrice|Dentifrice containing 0.76% w/w sodium monofluorophosphate (1000ppm fluoride)
1525683|NCT02773745|Behavioral|Aquatic Prehab|Pool therapy
1525684|NCT02773732|Drug|Ciprofloxacin|"Ciprofloxacin will be taken orally twice daily on Days 1 to 10 of each 28-day cycle.
Dose Level 0 Ciprofloxacin 750 mg Dose Level +1 Ciprofloxacin 1000 mg Dose Level -1 Ciprofloxacin 500 mg"
1525685|NCT02773732|Drug|Etoposide|Etoposide 200 mg will be taken orally once daily on Days 2 to 8 of each 28-day cycle.
1525686|NCT02773719|Other|True Biofield therapy|
1525687|NCT02773719|Other|Fake Biofield therapy|
1525688|NCT02773706|Other|Automated Psychology Services|The automated screening tool determines a positive or negative screen, then informs the clinician, and also automates a psychology visit.
1525689|NCT02773706|Other|Notification of Subspecialist|The automated screening tool determines a positive or negative screen, then informs the clinician.
1525690|NCT02773693|Behavioral|Cognitive Processing Therapy-Cognitive Only (CPT)|Twice weekly CPT over 6 weeks.
1525691|NCT02773693|Behavioral|Cognitive Behavioral Therapy of Insomnia and Nightmares (CBTin)|Cognitive behavioral therapy of insomnia and nightmares weekly over 6 weeks.
1525692|NCT02773693|Behavioral|Continuation Cognitive Processing Therapy-Cognitive Only (CPT)|Once weekly continuation CPT over 6 weeks.
1525693|NCT02773680|Device|"electrical impedance tomography"|One continous electrical impedance tomography (EIT) measurement per subject of approximately 5 minutes duration (2 min prior to MDCT scanning, during end-inspiratory MDCT acquisition and 2 min after MDCT scanning)
1525694|NCT02773654|Other|Healthy Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
1525695|NCT02773654|Other|Symptomatic Volunteers|Scapula static position of subjects with and without shoulder symptoms will be recorded utilizing a mobile phone application placed on their scapula by either the examiner's hands or with a handle, held by the examiner.
1525696|NCT02773641|Drug|Botulinum Toxin Type A|
1525697|NCT02773641|Drug|Placebo|
1525698|NCT02773628|Device|Acar'up system|
1525699|NCT02773628|Device|Acar'up placebo system|
1525700|NCT02773615|Procedure|Cardiac computed tomography|Non-invasive CT scan of the heart
1525704|NCT02773589|Procedure|Peroral endoscopic myotomy|Peroral endoscopic myotomy
1525705|NCT02773576|Drug|Risperidone implant|
1525706|NCT02773563|Other|EUS with air insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using air insufflation
1525707|NCT02773563|Other|EUS with CO2 insufflation|Diagnostic procedure using an echoendoscope for the study of pancreaticobiliary or gastrointestinal diseases using CO2 insufflation
1525708|NCT02773550|Drug|Bortezomib|Low dose of bortezomib
1525709|NCT02773550|Drug|Melphalan|
1525710|NCT02773550|Drug|Prednisone|
1525985|NCT02771704|Other|Physiological saline|
1525711|NCT02773537|Drug|Femoral nerve catheter and sciatic nerve block|This nerve block is believed to cause both muscle weakness and numbness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes both the front and the back of the knee to be numb.
1525712|NCT02773537|Drug|Adductor canal catheter and selective tibial block|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it to control pain. This technique causes both the front and the back of the knee to be numb.
1525713|NCT02773537|Drug|Adductor canal catheter only|This nerve block is believed to cause numbness only, without any muscle weakness. A catheter remains in place for up to 36 hours after surgery for the purpose of adding additional medication should the patient require it. This technique causes only the front of the knee to be numb
1525714|NCT02773524|Drug|Regorafenib|"Regorafenib will be provided by the manufacturer. The regorafenib 40 mg tablet is coated, non-divisible, grey-orange-red, oval-shaped (length 16 mm, width 7 mm, thickness 4.9-5.6 mm) and 472 mg each in total weight. The packaging configuration is 30 tablets and a 3g desiccant capsule per bottle of regorafenib 40 mg.
The tablets are stored in high-density polyethylene (HDPE) bottles with a desiccant cartridge inside. The tablets have to be stored in the original bottle at the temperature indicated on the bottle label. Depending on the packaging design (desiccant type, bottle size), storage Temperature can be either not above 25°C or not above 30°C as specified on the bottle label.
The bottle has to be kept tightly closed after first opening, and the desiccant has to remain in the bottle. Once the bottle is opened the tablets have to be discarded after 7 weeks."
1525715|NCT02773524|Other|Placebo|Matching placebo will be provided by the manufacturer. Placebo tablets will be matched in appearance to the Regorafenib.
1525716|NCT02773511|Procedure|Surgical treatment|Closed reduction and Kirschner wire fixation
1525717|NCT02773498|Procedure|conventional TESE|usual procedure for sperm extraction
1525718|NCT02773498|Procedure|Micro TESE|procedure of extraction is performed under the operating microscope
1525719|NCT02773485|Radiation|High Dose Radiation|The aim will be to deliver 52.5-60 Gy/ 25 fractions to the gross disease and 45 Gy/ 25 fractions to suspected microscopic disease along with weekly gemcitabine (300 mg/ m2) .
1525720|NCT02773485|Drug|Systemic chemotherapy|This arm will receive maximum 8 cycles of gemcitabine 1000 mg/m2 and cisplatin 25 mg/m2 delivered on day 1 and 8 every 3 weekly.
1525721|NCT02773472|Device|electroacupuncture|The acupoints that will be stimulated are: daheng, tianshu, zhongwan, xiawan, qihai, guanuian, hegu, guchi, zusanli, sanyinjiao, gongsun. An alternating fast-slow frequency of 20Hz/6Hz will be used with an interval of 250msec. The intensity (mA) will be adjusted to a level tolerated by each individual patient.
1525722|NCT02773472|Drug|morphine|Patient will not receive electroacupuncture. Patient will use morphine for analgesia.
1525723|NCT02773459|Drug|MEK162+capecitabine|In phase 1 part: capecitabine(mg/m2) will be given twice a day, 2 week on/1week off Q 3weeks + MEK162 twice a day, continuously, starting at 1000mg/m2 and 30mg/m2 respectively. Expansion part will be treated with the dose found at phase 1 part.
1525724|NCT02773446|Biological|ETEC strain B7A (O148:H28 CS6+ LT+ST+) (Lot 0481) in Buffer|ETEC Bacteria
1525725|NCT02773433|Other|Proportional Assist Ventilation|
1525726|NCT02773420|Procedure|HET Application|The HET device is a modified anoscope equipped with LED lighting, a tissue clamping mechanism and a bipolar energy source used to treat multiple hemorrhoidal columns in one sitting. Three columns of hemorrhoids were treated with 2 heat energy applications per column
1525727|NCT02773407|Drug|Azithromycin|
1525728|NCT02773407|Drug|Co-trimoxazole|
1525733|NCT02773355|Drug|No treatment given|Patients will be treated with commercially available Saxenda® prescribed according to routine clinical practice at the discretion of the treating physician.
1525734|NCT02773329|Other|sensor-based interactive exercise (game-based exercise)|This intervention includes interactive game-based balance training including repetitive weight shifting and virtual obstacle crossing tasks. Wearable sensors will provide real-time visual/auditory feedback from foot and ankle position and allowed perception of motor-errors during each motor-action.
1525735|NCT02773329|Other|Intervention without game-based exercise|Subjects are asked to perform non-technology based foot and ankle exercises, which include body weight shifting and obstacle crossing tasks.
1525736|NCT02773316|Drug|MR902|
1525737|NCT02773316|Drug|IR morphine sulphate|
1525740|NCT02773290|Biological|Romiplostim|Weekly SC administration
1525741|NCT02773277|Other|head-impulse testing|all patients will receive quantitative head impulse testing using video goggles for all six semicircular canals.
1525742|NCT02773264|Device|Ultrasound|Ultrasound Elastography of soft tissue and organ lesions
1525743|NCT02773251|Drug|hyaluronic acid-carboxymethylcellulose|
1525744|NCT02773238|Procedure|Computed Tomography|Undergo FDG PET/CT
1525745|NCT02773238|Procedure|Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA
1525746|NCT02773238|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
1525747|NCT02773238|Other|Laboratory Biomarker Analysis|Correlative studies
1525748|NCT02773238|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
1525749|NCT02773238|Radiation|Radiation Therapy|Undergo functional avoidance radiation therapy
1525750|NCT02773238|Procedure|Single Photon Emission Computed Tomography|Undergo Tc-99m MAA or Tc-99m DTPA SPECT/CT
1525751|NCT02773238|Radiation|Technetium Tc-99m Albumin Aggregated|Undergo Tc-99m MAA SPECT/CT
1525752|NCT02773238|Drug|Technetium Tc-99m DTPA|Undergo Tc-99m DTPA SPECT/CT
1525753|NCT02773225|Drug|Eltrombopag|"CSA + Eltrombopag, evaluation after three month therapy start regarding dose escalation
6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> partial or complete remission Eltrombopag and slow tapering of CSA
12 month after therapy start --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment"
1525754|NCT02773225|Drug|Placebo (for Eltrombopag)|"CSA + Placebo, evaluation after three month therapy start regarding dose escalation
6 month after therapy start --> evaluation and report of remission status of the study office --> unblinding by study office --> no complete remission: CSA + Eltrombopag and evaluation 3 months after therapy start --> dose escalation
12 month after start of eltrombopag --> evaluation and report of remission status --> complete and partial remission --> tapering/end of study treatment"
1525758|NCT02773199|Other|Preoperative Fasting for 8 hours|Patients will be exposed to preoperative fasting
1525759|NCT02773199|Other|Preoperative Fasting for more than 12 hours|Patients will be exposed to preoperative fasting
1525760|NCT02773199|Drug|Spinal Anesthesia with Bupivacaine|Spinal Anesthesia with heavy bupivacaine 0.5% is provided.
1525761|NCT02773186|Other|monitoring cerebral oxygen saturation|Children undergoing urological surgery also required of locoregional blockade. Anesthetic induction was achieved with high concentration sevoflurane 6-8% (Sevorane®, Abbvie) and oxygen 50%. Anesthetic maintenance was done with sevoflurane 2-3%, 50% O2/air mixture, fentanyl 1 µg.kg.-1 iv, and rocuronium 0.3 µg.kg.-1 iv if required. Electrocardiogram (ECG), non-invasive arterial pressure, pulse oximetry, end-tidal carbon dioxide and cerebral NIRS oximetry was monitoring by using an INVOSTM5100 (Somanetics Corporation, Troy, MI, USA).
1525762|NCT02773173|Procedure|IPP in colorectal laparoscopic surgery|Deep neuromuscular blockade can only be reversed with sugammadex, so in the IPP group, it will be used as neuromuscular blocking agent and its effect will be reversed with sugammadex (4mg / kg) at the end of the surgery. During surgery: deep neuromuscular blockade (PTC 1-5), Protective ventilation strategy, Optimal position and Pre stretching as a tool to decrease intraabdominal pressure maintaining optimal workspace.
1525763|NCT02773173|Procedure|SPP in colorectal laparoscopic surgery|A depolarizing neuromuscular blocking will be used (as routine clinical practice at each center) to maintain moderate neuromuscular blockade and its effect will be reversed with anticholinesterase at the end of the surgery. During surgery: Moderate neuromuscular blockade ( TOF 2-4) , position to surgeon criteria, no prestretching and Protective ventilation. Fixed IAP (12mmHg).
1525764|NCT02773160|Other|Sensor-based postural feedback|Motion tracking sensors will provide feedback to subjects during the learning phase of a motor control task
1525765|NCT02773160|Other|Mirror feedback|Subjects will receive feedback from a mirror during the learning phase of a motor control task
1525766|NCT02773160|Other|Control group|Subjects will receive no feedback during the learning phase of a motor control task
1525767|NCT02773147|Drug|Cyanocobalamin|
1525768|NCT02773147|Drug|Folate|
1525769|NCT02773147|Drug|Pyridoxine|
1525770|NCT02773134|Other|Brace Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.
All patients will complete the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (preoperatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
1525771|NCT02773134|Other|Control Group|"All eligible patients will undergo a Posterior Spine Instrumented Fusion (PSIF) with the use of autologous local and iliac crest bone graft, and all pedicle screw instrumentation. A deep wound drain will be placed in all patients for 48 hours.
Bracing will not be prescribed postoperatively for this group. All patients will the Oswestry Disability Index (ODI) questionnaire, the SF-12v2 General Health Survey and the Visual Analogue Scale (VAS) for back pain at baseline visit (pre-operatively) and post-operatively at 6 weeks and 3 months follow up. Clinical and radiographic assessments will be performed by independent blinded observers not involved in patient care."
1525772|NCT02773121|Behavioral|Physical Activity|Trainer-guided at-home behavioral intervention
1525773|NCT02773095|Other|Novartis Access|Eight counties will be matched in pairs and randomized within each pair to either receive Novartis Access portfolio low-cost medications or to remain a control county.
1525774|NCT02773082|Device|Reclaim™ DBS Therapy|The Medtronic Reclaim DBS Therapy is indicated for bilateral stimulation of the anterior limb of the internal capsule, AIC, as an adjunct to medications and as an alternative to anterior capsulotomy for treatment of chronic, severe, treatment-resistant obsessive compulsive disorder (OCD) in adult patients who have failed at least three selective serotonin reuptake inhibitors (SSRIs). Medtronic received humanitarian device exemption (HDE) approval for Reclaim DBS Therapy for the management of OCD on February 19, 2009.
1525776|NCT02773056|Device|Ischial Ramus Containment (IRC)|Ischial Ramus Containment (IRC) is the standard of care socket
1525777|NCT02773056|Device|Dynamic Socket Ischial Ramus Containment (IRC)|Dynamic Socket Ischial Ramus Containment (IRC) is a comparator study socket
1525778|NCT02773056|Device|Sub-Ischial Interface (Sub-I)|Sub-Ischial Interface (Sub-I) is a comparator study socket
1525779|NCT02773043|Device|CZT SPECT camera|
1525780|NCT02773030|Drug|CC-220|
1525781|NCT02773030|Drug|Dexamethasone|
1525782|NCT02773017|Drug|Dexmedetomidine A|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
1525928|NCT02772003|Biological|INO-8000|INO-8000 delivered intramuscular (IM) followed by electroporation (EP)
1525783|NCT02773017|Drug|Dexmedetomidine B|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
1525784|NCT02773017|Drug|Dexmedetomidine C|initial dose was 1.0 μg/kg dexmedetomidine, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last three turning points.
1525785|NCT02773004|Other|EPClin genomic test|
1525786|NCT02772991|Other|troponin measurement|Cardiac catheterization (for patients with >50% lesions) or discharge or in patients with intermediate risk.
1525789|NCT02772965|Drug|Methotrexate|"Oral methotrexate (MTX): The weekly dose will be 15 mg for children ≥ 40kg, 12.5 mg for children 30 to <40 kg, and 10 mg for children 20 to <30 kg.
A twice per week, 4mg dose of ondansetron will be provided as pre-treatment to prevent nausea (study provider may opt-out of this component based on clinical judgement).
A 1 mg dose of folic acid per day will be provided. This will help to reduce the risk of side effects in the MTX group.
Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 104 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
1525790|NCT02772965|Other|Sugar pill (placebo)|"Placebo for methotrexate: The weekly dose will mimic that of methotrexate.
Placebo for ondansetron: The weekly dose will mimic that of ondansetron (study provider may opt-out of this component based on clinical judgement).
A 1 mg dose of folic acid per day will be provided to maintain blinding.
Drug kits will contain a 3 month supply of each medication. Refills will be provided every 3 months until week 104 unless there is a failure to induce and maintain remission, development of unacceptable toxicity, pregnancy in a female participant, or failure of the participant to attend scheduled study visits."
1525791|NCT02772952|Other|Control Intervention|Control Intervention: review medication + adequacy of diet + health education (physical activity recommendation (within a comprehensive advice on healthy lifestyles)
1525792|NCT02772952|Other|Multimodal Intervention|Multimodal Intervention: therapeutic exercise + review medication + adequacy of diet + health education program
1525793|NCT02772939|Device|Renal sympathetic denervation (RDN)|Catheter based renal sympathetic denervation for therapy resistant arterial hypertension
1525794|NCT02772926|Dietary Supplement|Benfotiamine|Benfotiamine (S-Benzoylthiamine O-monophosphate) 900 mg per day
1525795|NCT02772926|Dietary Supplement|Placebo|Placebo 900 mg per day
1525796|NCT02772900|Other|Beetroot-based nutritional gel|100 g of beetroot-based nutritional gel containing approximately 12 mmol of nitrate.
1525797|NCT02772900|Other|Placebo|100 g of apple-based nutritional gel containing approximately 0.02 mmol of nitrate.
1525798|NCT02772887|Dietary Supplement|L-Citrulline|amino acid supplement
1525799|NCT02772887|Other|Placebo|placebo
1525800|NCT02772874|Other|No intervention|No intervention
1525801|NCT02772861|Dietary Supplement|Amino Acid Supplement - One dose|20gr
1525802|NCT02772861|Dietary Supplement|3-Methylhistidine|120mgr
1525803|NCT02772835|Device|Medin-cno|Medin-cno is a noninvasive ventilator. With this device we can practice either nCPAP and nHFOV ventilation.
1525804|NCT02772822|Drug|SCT400 plus CHOP|
1525805|NCT02772822|Drug|Rituximab plus CHOP|
1525806|NCT02772809|Device|Haptic Robot Therapy with Games|Commercial Joystick and Wheels Plus the Haptic TheraDrive Robot will be used. Haptic Theradrive is a low-cost robotic system for post-stroke upper extremity rehabilitation. The system uses off-the-shelf computer gaming wheels with force feedback to help reduce motor impairment and improve function in the arms of stroke survivors.
1525807|NCT02772796|Drug|SENS-218|Oral Administration
1525808|NCT02772783|Other|high GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A high glycemic index of ~90 is achieved by using corn syrup as a carbohydrate source.
1525809|NCT02772783|Other|low GI meal|High and low GI liquid test meals are matched for macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. Meals will provide 25% of individual daily energy requirements as estimated by the Harris Benedict equation. A low glycemic index of ~40 is achieved by using uncooked corn starch as a carbohydrate source.
1525810|NCT02772783|Drug|euglycemic insulin clamp|Insulin will be given intravenously for 5 hours. During the entire clamp protocol, glucose levels will be measured every 5 minutes. A basal insulin infusion will be started at 80% of the patients insulin pump basal rate, and will be adjusted between 0.1 and 2.5 mU/kg•min, depending upon the patient's plasma glucose level in relation to the target range target of 90-100 mg/dl.
1525811|NCT02772783|Drug|primed-variable insulin infusion|A primed-variable infusion of insulin will be administered at the rate established to achieve euglycemia after a low glycemic index meal. This is expected to result in moderate hyperglycemia as the high GI meal is associated with higher insulin requirements. For patient safety, glucose levels will be measured every 30 minutes. If glucose levels are > 400 mg/dl or < 60 mg/dl, insulin infusion will be adjusted to maintain glucose levels target of 60-400 mg/dl.
1525812|NCT02772770|Other|Non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions|The non-operative treatment group will undergo standardized treatment which will include rehabilitation, bracing and certain activity restrictions.
1525813|NCT02772770|Procedure|Surgical technique: Transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for transphyseal reconstruction with soft tissue graft and metaphyseal fixation.
1525929|NCT02772003|Biological|INO-8000 + INO-9012|INO-8000 + INO-9012 delivered IM followed by EP
1525986|NCT02771691|Other|Mentalization-Based Group Therapy for Adolescents|
1525814|NCT02772770|Procedure|Surgical technique: Partial transphyseal reconstruction|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include partial transphyseal reconstruction (tibial transphyseal and femoral epiphyseal) with soft tissue graft.
1525815|NCT02772770|Procedure|Surgical technique: Physeal sparing reconstruction by the Anderson method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include standardized surgical techniques for physeal sparing epiphyseal reconstruction with soft tissue graft (Anderson technique).
1525816|NCT02772770|Procedure|Surgical technique: Physeal sparing reconstruction by the Micheli/Kocher method|Study physicians will have the option to treat ACL injuries operatively or non-operatively, according to their standard of care. However, once the decision is made to manage the injury operatively or non-operatively, the physician must follow the appropriate standardized treatment protocol developed for the study. The operative treatment protocol will include physeal-sparing with Iliotibial band combined extra-articular and intra-articular reconstructions (Micheli/Kocher Technique).
1525817|NCT02772757|Behavioral|standard hearing aid fitting|standard hearing aid, face-to-face fitting
1525818|NCT02772757|Behavioral|coupler-based fitting|coupler-based fitting using average RECDs
1525819|NCT02772757|Behavioral|coupler-based fitting|coupler-based fitting using measured RECDs
1525825|NCT02772718|Drug|XOMA 358 single dose level A|XOMA 358 single dose level A administered by intravenous infusion
1525826|NCT02772718|Drug|XOMA 358 single dose level B|XOMA 358 single dose level B administered by an intravenous infusion
1525827|NCT02772718|Drug|XOMA 358 single dose level C|XOMA 358 single dose level C administered by an intravenous infusion
1525828|NCT02772718|Drug|XOMA 358 multiple dose level 1|XOMA 358 multiple dose level 1 administered by an intravenous infusion
1525829|NCT02772692|Behavioral|Squatting pan|Using squatting pans to replace standard-sized toilets in one group of the included constipation patients
1525830|NCT02772679|Biological|PolyTregs+IL-2|PolyTregs will be infused into the patient in a single infusion. The first cohort will receive 3 x10^6 cells. The second cohort will receive 20x10^6 cells. Following the day 0 infusion of polyclonal Tregs, subjects will receive two 5-day courses of IL-2 (1 x 106 IU daily), the first on days 3-7 and the second on days 38-42. Administration of the second course of IL-2 may be delayed or withheld depending on threshold criteria for peripheral blood Treg frequencies and MMTT-stimulated C-peptide levels determined on day 28.
1525831|NCT02772666|Device|O-Glass|The new diagnostic device to distinguish relative afferent pupillary defect(RAPD).
1525832|NCT02772666|Other|Swinging Flashlight Test|The swinging-flashlight test is used to help a practitioner identify a relative afferent pupillary defect.For an adequate test, vision must not be entirely lost. In dim room light, the examiner notes the size of the pupils. The patient is asked to gaze into the distance, and the examiner swings the beam of a penlight back and forth from one pupil to the other, and observes the size of pupils and reaction in the eye that is lit.
1525833|NCT02772653|Other|Blood Lactate|Analyzed at the 1rst, 8th and 24th hour from hospital admission
1525834|NCT02772653|Other|Blood Base Excess|Analyzed at the 1rst, 8th and 24th hour from hospital admission
1525835|NCT02772653|Other|Blood B-type Natriuretic Peptide|Analyzed at the 1rst, 8th and 24th hour from hospital admission
1525836|NCT02772653|Other|Blood Thromboelastometry (ROTEM)|Analyzed at the 1rst, 8th and 24th hour from hospital admission
1525837|NCT02772653|Other|Near-infrared spectroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
1525838|NCT02772653|Other|Sublingual videomicroscopy|Analyzed at the 1rst, 8th and 24th hour from hospital admission
1525839|NCT02772640|Drug|Rosuvastatin and Ezetimibe morning or evening administration|"Timing of the drug administration:
morning -> evening evening -> morning"
1525840|NCT02772627|Drug|Nebicapone|Nebicapone 100 mg tablets; oral route.
1525841|NCT02772627|Drug|Placebo|Placebo tablets; oral route.
1525842|NCT02772614|Drug|BIA 3-202 (200 mg)|200 mg powder for oral use of unlabelled BIA 3-202
1525843|NCT02772601|Drug|Caffeine|
1525844|NCT02772601|Drug|Warfarin|
1525845|NCT02772601|Drug|Omeprazole|
1525846|NCT02772601|Drug|Metoprolol|
1525847|NCT02772601|Drug|Midazolam|
1525848|NCT02772601|Drug|Risankizumab|
1525853|NCT02772575|Procedure|Hepatic trans-arterial embolization (TAE)|
1525854|NCT02772575|Device|MRI/CT scan|
1525855|NCT02772575|Procedure|biopsy|
1525856|NCT02772575|Other|blood draw|
1525858|NCT02772536|Other|Visual Stimulus Condition Set|"In this single arm study, all participants are subject to a set of three visual stimulus conditions.
Low ambient light for 10 mins: Self selected tinted light (20 Mins); White light (20 mins).
VAS/CGI scores for each stimulus condition in the above set are reported at five minute intervals."
1525859|NCT02772523|Other|Lifestyle recommendations|Dietary, and physical, cognitive and social activity recommendations
1525860|NCT02772510|Device|Smart glove system with functional electrical stimulation|Game-based virtual reality rehabilitation system (Smart glove system) combined with functional electrical stimulation on distal upper extremity
1525861|NCT02772510|Device|Functional electrical stimulation|Functional electrical stimulation on distal upper extremity
1525862|NCT02772497|Drug|Ziv aflibercept|Intravitreal ziv aflibercept 1.25 mg (0,05ml) every 4 weeks
1525863|NCT02772484|Device|HS-1000|
1525864|NCT02772471|Device|HS-1000|
1525866|NCT02772445|Behavioral|STROKE-CARE|In STROKE-CARE, caregivers will learn a problem-solving strategy. They will (1) identify barriers to performance, (2) generate strategies to address barriers, and (3) apply these strategies to support care-recipients in occupations.
1525867|NCT02772432|Behavioral|Relaxation Response Resiliency Training for Parents of SPLD|
1525871|NCT02772406|Device|Linked Color Imaging|
1525872|NCT02772406|Device|white light imaging|
1525873|NCT02772380|Device|Defibrillation following induction of VT/VF|Up to 10 attempts to induce two VF/VT episodes for defibrillation testing
1525874|NCT02772367|Procedure|skin punch biopsy|
1525875|NCT02772354|Procedure|Radiofrequency catheter ablation|Biosense Webster: NAVI-STAR ThermoCool, NAVI-STAR® RMT ThermoCool
1525876|NCT02772354|Drug|Metoprolol|"Antiarrhythmic therapy of premature ventricular complexes
Metoprolol 12-50 mg"
1525877|NCT02772354|Drug|Verapamil|Verapamil 20-240 mg
1525878|NCT02772354|Device|NAVI-STAR® RMT ThermoCool|
1525879|NCT02772341|Device|Salt room with halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room with salt aerosol produced by a halogenerator (study group) or halotherapy without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values. The halogenerator is located outside the salt room.
1525880|NCT02772341|Other|Salt room without halogenerator|Patients were assigned to 14 sessions (7 weeks, twice weekly, 45 minutes each treatment) sitting in a salt room without salt aerosol (placebo). Both the walls and the ceiling of the salt room are completely covered with ESCO-(European Salt Company) type certified-origin rock salt. The temperature (20-24°C) and humidity (44-60%) are at constant values.
1525881|NCT02772328|Behavioral|Peer Mentor|comparison of communication training to equal attention control
1525882|NCT02772315|Other|omics|diagnostic procedures applying omics results
1525883|NCT02772302|Device|mindBEAGLE EEG-based brain-computer interface|
1525884|NCT02772289|Biological|Mesenchyme Stem Cells low-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous three days and then receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous next three days.
1525885|NCT02772289|Biological|Mesenchyme Stem Cells high-dose group|Participants will receive transdermal one dose of 1*10^6 cells of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
1525886|NCT02772289|Biological|Placebo|Participants will receive transdermal placebo without of Perinatal Tissue Mesenchyme Stem Cells in the gel once a day for continuous six days.
1525887|NCT02772276|Drug|MB-102|Intravenous
1525888|NCT02772276|Drug|Iohexol|Intravenous
1525889|NCT02772276|Device|QuantumLeap|Optical Renal Function Monitor (ORFM)
1525890|NCT02772276|Device|Radiance|Optical Renal Function Monitor (ORFM)
1525891|NCT02772276|Other|Intravenous saline flush|Following each intravenous administration of MB-102 and iohexol, participants will receive 10 mL normal saline intravenously.
1525892|NCT02772263|Other|CHAP-EMS|The CHAP-EMS program is a low cost community program that is designed to assess community dwelling seniors for lifestyle risk factors that may impact their health and well-being and to provide targeted education to address the pertinent risk factors. Each participant is guided through a structured health-risk assessment focused on diabetes, cardiovascular disease and other potential health issues. The assessment is conducted by a trained paramedic in a common area within the community housing building. Data gathered are used to develop individualized action plans concerning health-risk reduction, to direct participants to local health activities or resources, educate on promoting health and to transmit this information to a participants' family physician.
1525893|NCT02772250|Behavioral|telephone re-education(TRE)|Subjects who are randomized into this group receive regular instructions at the time of their appointment to discuss colonoscopy (a nurse provides education of 5 minutes and meanwhilet sent a bookle to the patient) and a TRE which was conducted by one investigator at 15:00-17:00 on the day before colonoscopy.
1525894|NCT02772250|Behavioral|face-to-face re-education (FFRE)|Subjects who are randomized into this group receive regular instructions on the day of their appointment to discuss colonoscopy and also a FFRE which was conducted by a investigator on the same-day of procedure at hospital.
1525895|NCT02772237|Biological|Riboflavin|Riboflavin 400mg daily
1525896|NCT02772237|Biological|Placebo|
1525930|NCT02771990|Device|Sham transcranial direct current stimulation|sham stimulation
1525931|NCT02771990|Device|transcranial direct current stimulation|2 milliamp (mA) 20 minutes
1525932|NCT02771977|Other|Generic Alert|A generic alert, informing the provider of the presence of AKI will be fired.
1525933|NCT02771977|Other|Drug-specific alert|A drug-specific alert, informing the provider of the presence of AKI as well as recent exposure to a potentially nephrotoxic agent, will be fired.
1525897|NCT02772224|Device|Drug eluting balloon angioplasty|In the DEB group, the guide wire will be passed through the occluded or stenosed lumen and the predilatation of the target lesion with standard balloon(s) will be performed before dilatation with a paclitaxel-eluting balloon of the diameter, at least about that of the pre-dilatation balloon (Arteryguard, Rientech, Dezhou, China). The drug eluting balloons will then be inflated according to the manufacturer recommendations. The patients will then be followed every six months for a year to compare its treatment efficacy and safety with that of conventional balloon angioplasty group.
1525898|NCT02772224|Device|Conventional balloon angioplasty|The guide wire will be passed through the occluded or stenosed lumen and the conventional balloons will be inflated as recommended by the manufacturer. The primary and secondary outcome will then be assessed and compared with DEB group, on follow up at six and 12 months.
1525899|NCT02772211|Drug|Ketamine|"Patients will undergo 6 ketamine infusions within a 3-week period. Intravenous ketamine will be administrated by a senior anesthesiologist and under the supervision of a senior psychiatrist hence ensuring patient safety. The procedure will be explained in detail to each patient, and written consent will be obtained.
After a psychiatric and medical evaluation by a senior psychiatrist and a senior anesthesiologist, patients will be given ketamine infusion added on to their antidepressant therapy. A slow ketamine infusion of 0.5mg/kg over 40 minutes will be given to the patients. Patients will be monitored by the experienced staff which includes a senior anesthesiologist and a nurse as well as a psychiatrist who will be available nearby. All patients will be monitored continuously for heart rate and rhythm and oxygen saturation, and blood pressure will be measured at 10 minutes intervals."
1525900|NCT02772211|Drug|D-cycloserine|"Following completion of Ketamine infusions. patients in the experimental group will start receiving D-cycloserine pills titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:
Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.
Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day
Week 7: Day 43-49 - 750mg/d, three pills per day
Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
1525901|NCT02772211|Drug|Placebo|"Following completion of Ketamine infusions. patients in the experimental group will start receiving placebo titrated slowly up to 1000mg/d over the next 8 weeks [2] in the following manner:
Week 4: Days 22-24 - 250mg/d, one pill per day Well-being assessment and adverse effect evaluation before drug elevation.
Mid-week 4 to end of week 6: Days 25-42 - 500mg/d, two pills per day
Week 7: Day 43-49 - 750mg/d, three pills per day
Weeks 8-11: Days 50-77 - 1000mg/d four pills per day"
1525902|NCT02772198|Biological|CD19 CAR T cells|Autologous T cells activated and transduced with a chimeric antigen receptor targeting CD19
1525903|NCT02772185|Device|active tDCS|Duration: 30 minutes; Intensity: 2 mA; Placement:left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus
1525904|NCT02772185|Device|sham tDCS|The procedure is the same as for active tDCS, but the in the placebo tDCS the stimulation is non-active / sham.
1525905|NCT02772185|Behavioral|real CT|Cognitive tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left inferior frontal gyrus and left superior temporal gyrus).
1525906|NCT02772185|Behavioral|placebo CT|Videos (short films) will be presented during the neurostimulation
1525907|NCT02772172|Device|Surgical Template|
1525908|NCT02772159|Drug|TD-4208|One dose each of treatments A: [14C] TD-4208 20 μg IV administered in a fasted state over 30 minutes. B: [14C] TD-4208 200 μg oral solution administered in a fasted state.
1525909|NCT02772146|Device|CLS UF|One single ultrafiltration session of 10 hours.
1525910|NCT02772133|Procedure|Primary PCI|
1525911|NCT02772120|Drug|Vaginal progesterone gel (Crinone® 8%)|Crinone® 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) is administered once 5 days prior to embryo transfer, then twice per day until the pregnancy test is negative or until the 10th week of pregnancy.
1525912|NCT02772120|Drug|Intramuscular Progesterone|Progesterone—25 mg intramuscularly once 5 days prior to embryo transfer, then 50 mg once per day until the pregnancy test is negative or until the 10th week of pregnancy.
1525913|NCT02772107|Drug|Temozolomide|Temozolomide is a nonclassic oral alkylating agent. Temozolomide will be given alone as maintenance therapy in patients who have achieved study entry hematologic criteria and who do not have progressive disease or severe toxicity. During temozolomide maintenance therapy, patients will receive temozolomide at 150mg/m2/d for 5 days of a 28-day cycle orally daily. Temozolomide maintenance therapy will continue until progressive disease or irreversible toxicity occurs.
1525914|NCT02772107|Drug|first-line chemotherapy|first-line chemotherapy must be platinum-based: cisplatin(75mg/m2 for d1) or carboplatin（AUC 5 for d1) combined with etoposide（100mg/m2 for d1-d3）
1525915|NCT02772107|Radiation|Prophylactic cranial irradiation|Prophylactic cranial irradiation was allowed if necessary
1525916|NCT02772107|Radiation|thoracic radiotherapy|thoracic radiotherapy was allowed if necessary
1525917|NCT02772094|Biological|Single arm, open-label|"Biological: ADCTA-G. Biological: autologous DC loaded with irradiated autologous tumor cells. Biological: dendritic cell vaccine. Drug: 180mg/m2•per day temozolomide prior and concomitant with radiotherapy. Radiotherapy: Local ionizing radiation 200 centigray(cGy)/day, 5 successive days per week for 6 weeks, total dose of 6000 cGy.
Drug: Adjuvant chemotherapy-temozolomide (TMZ) monthly cycle, 200mg/m2•per day continued for 5 days in the beginning of every month, 6 cycles of TMZ."
1525918|NCT02772081|Drug|LISA combination product (Curosurf+catheter CHF6440)|
1525919|NCT02772081|Drug|Curosurf through conventional administration (endotracheal tube)|
1525922|NCT02772055|Other|Moxibustion|Moxibustion at three acupuncture point(EX-LE04,ST35,ST36).12 sessions of moxibustion treatment over a period of 4 weeks, 3 sessions per week.Each session will last 30 minutes.
1525923|NCT02772055|Other|Moxa smoke purification device|Investigators place a purification device(Shenzhen Conyson Electronic Technology Co, Ltd,C200 moxa smoke purification device,Shenzhen,China) at the top of the moxibustion to remove the moxa smoke.
1525924|NCT02772042|Other|Intervention Group|
1525925|NCT02772042|Other|Control Group|
1525926|NCT02772029|Drug|Apatinib Mesylate Tablets|Apatinib 750 mg is administered orally daily, until disease progression or untolerable toxicity.
1525934|NCT02771964|Other|Quality of life survey|"All enrolled patients complete a survey of baseline health during their visit to the preoperative assessment clinic and then complete a follow-up survey approximately 30 days after surgery.
The intervention for this study is to compare self-reported quality of life (How would you rate your quality of life now? (better/same/worse)) to the quantitative change in their VR-12 quality of life scores between the baseline survey and 30-day follow-up survey."
1525935|NCT02771951|Behavioral|"Lights of Change"|
1525936|NCT02771951|Behavioral|Usual Care|
1525937|NCT02771938|Other|Radiotherapy before surgery|Radiotherapy followed by mastectomy and DIEP flap reconstruction
1525938|NCT02771925|Drug|Gabapentin 2g/day divided in two doses for 24 weeks|"Total subjects 100 (Alcoholic liver disease:Alcoholics with no liver disease= 1:1) each will receive Gabapentin 2000mg/day divided in two doses for 24 weeks.
All patients will receive standard of care treatment."
1525939|NCT02771925|Drug|Placebo 2g/day divided in two doses for 24 weeks|Total subjects 100 (Alcoholic liver disease: Alcoholics with no liver disease= 1:1)) each will receive Placebo 2000mg/day divided in two doses for 24 weeks. All patients will receive standard of care treatment. Concurrent with study medication, study clinicians will provide participants with 20 minutes of weekly manual-guided counseling designed to increase motivation, abstinence, and medication compliance.
1525940|NCT02771912|Drug|Propofol|Propofol and excipients
1525941|NCT02771912|Drug|Placebo|Qualitative composition of Propofol lipuro 2% excipients
1525942|NCT02771899|Device|sterEOS software|During a full-length exam from head to feet in the standing position, 3D reconstructions of the spine, the pelvis and lower extremities using spine workflow and global postural assessment workflow on sterEOS software will be performed.
1525943|NCT02771899|Device|EOS|The system performs a full-length exam from head to feet in the standing position. 2D parameters will be obtained per standard of care.
1525944|NCT02771886|Behavioral|Surf the Urge|"The intervention teaches clients to be aware of and accept their feelings, thoughts, and sensations in a non-judgmental manner. Clients learn to remain present within the moment, become aware of their urges, and focus on accepting thoughts and feelings rather than suppressing or changing them. It utilizes visual imagery to assist clients in utilizing more acceptance skills; the client imagines his urges as waves within the ocean and then imagines surfing the waves.
Some interventionists also provide psychoeducation. Clients learn that urges will not last forever; clients are also taught information about reinforcing urges. The interventionist explains that if clients do not reinforce urges (e.g., do not smoke when an urge to smoke arises) they will eventual subside; however, reinforcing urges (smoke when an urge to smoke arises) will produce stronger urges. Emphasis is placed on the belief that clients have the choice to refrain from engaging in urge-related behaviors."
1525945|NCT02771873|Behavioral|Integrated cardiovascular disease risk management.|Health promotion intervention
1525946|NCT02771860|Drug|denosumab|60mg sc
1525947|NCT02771860|Drug|Placebo|identical syringe
1525948|NCT02771860|Dietary Supplement|Calcium/Vit D supplementation|Daily dosage Calcium 1000mg / Vit D 880 IU
1525949|NCT02771847|Behavioral|survey|anonym survey is given to people
1525950|NCT02771834|Other|Biomechanical analysis|
1525951|NCT02771834|Other|Kiphosis analysis|
1525952|NCT02771834|Other|Vitamin D level|
1525953|NCT02771821|Other|Operative groups based on methodology of problematization|"The educational intervention based on the methodology of problematization consisted of the survey prior knowledge on the subject; planning; Implementation and Evaluation through verbalization solutions applicable to the reality of the elderlies.
Each operative group was composed of an average of 12 to 15 elderlies diabetics who participated in monthly activities lasting 2 hours, for six consecutive months."
1525954|NCT02771808|Other|biomarker samples|biomarker samples for haptoglobin genotype (RT-PCR) and phenotype (hemoglobin electrophoresis) general markers for oxidative stress (isoprostane f2 alpha, malondialdehyde) markers of inflammation (CRP, IL-1, 2, 6, 10 and TNF) markers of cardiac injury (CPK, troponins and BNP) markers of kidney injury (cystatin C, creatinine, GFR)
1525955|NCT02771795|Drug|Herceptin (trastuzumab)|Intravenous administration
1525956|NCT02771795|Drug|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
1525957|NCT02771782|Biological|BCG vaccine (SSI)|
1525958|NCT02771782|Biological|TDaP-IPV vaccine|
1525959|NCT02771769|Other|blood draw|Participants will have a venous blood draw of ~20mLs before prostate biopsy. The biopsy will then be performed and histologically graded for any malignancy present. This grade will be statistically analyzed with respect to the Copy Number Instability (CNI) determined from the results of the molecular examination of the cell-free DNA in the blood.
1525960|NCT02771756|Dietary Supplement|zhen qishen capsule and Oral Supplement of Yuyikang|
1525961|NCT02771756|Dietary Supplement|zhen qishen capsule placebo and Oral Supplement of Yuyikang placebo|
1525962|NCT02771756|Radiation|chemotherapy|
1525963|NCT02771756|Other|nutrition education|
1525964|NCT02771743|Drug|Cisplatin|
1525965|NCT02771743|Drug|Doxorubicin|
1525966|NCT02771743|Drug|Etoposide|
1525967|NCT02771743|Drug|Cyclophosphamide|
1525968|NCT02771743|Drug|Ifosfamide|
1525969|NCT02771743|Drug|Carboplatin|
1525970|NCT02771743|Procedure|Tandem HDCT/auto-SCT|
1525971|NCT02771743|Radiation|Radiotherapy|
1525972|NCT02771743|Drug|Interleukin-2|
1525973|NCT02771743|Drug|Isotretinoin|
1525974|NCT02771743|Radiation|MIBG|
1525975|NCT02771730|Biological|Ad4-mgag|A live replication-competent Adenovirus type-4 vector encoding a mosaic HIV Gag antigen, delivered orally by enteric-coated capsules.
1525976|NCT02771730|Biological|Ad4-EnvC150|A live replication-competent Adenovirus type-4 vector encoding an HIV clade C Env protein (gp150 1086.C), delivered orally by enteric-coated capsules.
1525977|NCT02771730|Other|Placebo Comparator|Oral sucrose capsules
1525978|NCT02771730|Biological|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered intramuscularly (IM).
1525979|NCT02771717|Drug|Budesonide (Pulmicort)|Budesonide (Pulmicort) - inhaled low dose inhaled steroid - I puff to be taken twice daily
1525980|NCT02771717|Drug|Placebo - dummy inhaler|Placebo - dummy inhaler to be taken 1 puff twice daily.
1525981|NCT02771704|Other|Silver Diamine fluoride|
1525987|NCT02771665|Other|Mammographic breast density at diagnosis|Mammographic breast density at diagnosis
1525988|NCT02771652|Behavioral|e-training|The e-training intervention is a home-based aerobic and resistance training program. Resistance training was prescribed twice weekly for a period of 12 weeks. No special equipment was necessary except an elastic exercise band or a large gymnastic ball. In addition, endurance training was to be carried out once a week. Training intensity was regulated by the participant's subjective, perceived exertion, which was rated between 6 and 20 on the BORG Scale. The form of activity for the endurance training was freely selected, duration (between 10-60 min) was adjusted to individual fitness levels. Therapists aimed at eliciting a BORG Feedback of between 11 (fairly light) and 16 (hard). The exercise training was home-based and supervised via the internet. Participants continued exercise training for another 12 weeks after the 3month assessment.
1525989|NCT02771652|Other|Control|After the initial assessment on entry, those assigned to the control group were instructed to maintain their previous physical activity behaviour. After waiting three months, they received the same e-training intervention as the intervention group had received from the start.
1525990|NCT02771639|Procedure|Hip arthroplasty|Treatment with a hip arthroplasty (semi- or total hip arthroplasty) for a displaced femoral neck fracture
1525991|NCT02771626|Drug|CB-839|Glutaminase inhibitor
1525992|NCT02771626|Drug|Nivolumab|PD-1 inhibitor
1525993|NCT02771613|Other|Multi professional in situ simulation|After the analysis of adverse effects in Morbidity Mortality reviews, we will create scenarios adapted to these events. Education of the randomized department's arm's staff will be performed by multi professional in situ simulation with these scenarios
1525994|NCT02771613|Other|Large diffusion of information|After the analysis of adverse effects in Morbidity Mortality reviews a large scale dissemination activity of information about discussions and decisions towards the staff of the randomized departments' arms will be carried out
1525995|NCT02771600|Device|Buzzy|See arm description
1525996|NCT02771600|Drug|Topical anaesthetic cream|See arm description
1525997|NCT02771587|Dietary Supplement|Alcohol and energy drink|Multiple oral dose of alcohol Multiple oral dose of energy drink
1525998|NCT02771587|Dietary Supplement|Alcohol|Multiple oral dose of alcohol
1525999|NCT02771587|Dietary Supplement|Energy drink|Multiple oral dose of energy drink
1526000|NCT02771587|Dietary Supplement|Placebo|Multiple oral dose of water Multiple oral dose of non-caffeinated soft drink
1526001|NCT02771574|Drug|Exendin (9-39)|
1526002|NCT02771561|Procedure|Patent Foramen Ovale Closure|Transoesophageal guided percutaneous patent foramen ovale closure using Gore™ septal occluder device
1526004|NCT02771535|Behavioral|D-MCT|Metacognitive Training for Depression (D-MCT), 8 sessions (60min); twice a week over a period of 4 weeks. Metacognitive Training for depression (D-MCT) is a low-threshold, easy to administer group intervention. It aims at the reduction of depressive symptoms by changing cognitive biases; not only biases targeted in cognitive behavioral therapy but also those identified by basic research.
1526005|NCT02771535|Behavioral|Health Training|Health Training Group (Walking/ Psychoeducation on health); 8 sessions (60min), twice a week over a period of 4 weeks
1526006|NCT02771522|Device|Calcivis System|Following de-bond, and identification of active post-orthodontic white spot lesions at baseline with the Calcivis System, each active tooth will be again be imaged at 2, 4, 8 and 12 weeks. The images of the teeth are taken immediately before and after application of a small amount of disclosing solution. The images of each tooth are overlaid and a resulting demineralization map of the tooth produced, indicating areas of elevated bioluminescence corresponding to free calcium ions on the surface of the tooth (active caries)
1526007|NCT02771509|Drug|BB3|6 mg/mL BB3, IV, 4 days in a row, first dose must be within 4 hours after surgery, the next three doses will be approx. 24 hours after the last dose
1526008|NCT02771509|Drug|Placebo|
1526009|NCT02771496|Other|Other: observational only- no intervention|Other: observational only- no intervention
1526010|NCT02771470|Drug|Probiotics|Microbial composition using probiotic
1526011|NCT02771470|Drug|placebo|Microbiota modulation using placebo
1526012|NCT02771457|Drug|Infliximab at weeks 0,2, and 6|
1526013|NCT02771457|Drug|Infliximab at weeks 0,4, and 8|
1526014|NCT02771457|Drug|Infliximab at weeks 0 and 8|For physicians who do not feel comfortable enrolling patients in a randomized trial of infliximab re-induction they will have the option of enrolling their patients in an arm that resumes maintenance therapy only instead at 0 and 8 weeks.
1526015|NCT02771444|Device|Tomo Assessment|A four-view tomosynthesis examination
1526016|NCT02771431|Other|Tele-rounding in post operative care|Both groups will receive standard of care. The only difference between these groups would be the physical presence of the attending in the room. Both groups will receive a physical exam with supervision of the attending, one group will have attending in the room and the other will have the attending present via I-pad. In both cases if there was something of concern the attending would step in for the physical exam if needed, regardless of which group they were randomized for.
1526017|NCT02771418|Drug|Propofol|Intravenous induction and maintenance of general anesthesia with propofol is a routine practice for this intervention
1526018|NCT02771418|Drug|Sevoflurane|Volatile induction and maintenance of general anesthesia with sevoflurane is a generally acceptable clinical approach for this intervention
1526019|NCT02771418|Procedure|Elective carotid endarterectomy|
1526020|NCT02771405|Drug|Sofosbuvir|Sofosbuvir 400 mg orally once daily
1526021|NCT02771405|Drug|Ribavirin|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1526022|NCT02771405|Drug|Simeprevir|Simeprevir 150 mg orally once daily
1526023|NCT02771405|Drug|daclatasvir|Daclatasvir 60 mg orally once daily
1526024|NCT02771405|Drug|Ledipasvir|Ledipasvir 90 mg orally once daily
1526025|NCT02771392|Drug|Ophthalmic Tetracaine|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
1526026|NCT02771392|Other|Normal Saline|1-2 drops to affected eye every 15-30 minutes over 24-48 hours as need
1526027|NCT02771379|Drug|Idebenone|Raxone 900mg/day as per Raxone SmPC and medical judgement of treating physician.
1526028|NCT02771366|Drug|Fermented Papaya Preparation|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
1526029|NCT02771366|Other|Granulated Sugar|This will be provided in a 3g sachet for use 3 times a day 30-40 minutes before a meal. This will be done for 8 weeks.
1526030|NCT02771366|Procedure|Magnetic Resonance Spectroscopy|MRS will be performed during weeks 0, 8, 14, and 22.
1526031|NCT02771366|Procedure|functional magnetic resonance imaging|MRS will be performed during weeks 0, 8, 14, and 22.
1526032|NCT02771366|Behavioral|RAND 36-item Health Survey (SF-36)|This survey will be completed at each assessment visit.
1526033|NCT02771366|Dietary Supplement|Blood Samples|Blood samples will be taken for inflammation markers.
1526034|NCT02771366|Behavioral|Functional Assessment of Chronic Illness Therapy-Fatigue|These questionnaires will be completed at each assessment visit.
1526035|NCT02771353|Radiation|WT_vDIBH|
1526036|NCT02771353|Radiation|VMAT_FB|
1526037|NCT02771340|Biological|ICON-1|Intravitreal injection of ICON-1
1526038|NCT02771327|Device|CPAP plus Gas|
1526039|NCT02771327|Device|ventimask plus gas|
1526040|NCT02771314|Drug|AZD9291|AZD9291, 80 mg (tablets) once daily, administered orally in the fasted state
1526041|NCT02771301|Biological|dendritic cells|Concurrent of radiotherapy and chemotherapy plus 12 cycles of dendritic cells and cytotoxic lymphocytes treatment
1526042|NCT02771288|Device|Bioresorbable Vascular Scaffold|
1526043|NCT02771275|Device|Harpoon Medical device|Implanting ePTFE sutures as artificial chordae tendineae using the Harpoon Medical device
1526044|NCT02771262|Other|Pulmonary Rehabilitation|
1526048|NCT02771210|Biological|AIN457/Secukinumab|Induction: Week 0,1,2,3 150 mg or 300 mg Secukinumab s.c. Maintenance: 150 mg or 300 mg Secukinumab s.c. every 4 weeks starting at Week 4
1526049|NCT02771210|Drug|AIN457/Secukinumab Placebo|Induction: Week 0,1,2,3 Secukinumab Placebo s.c. Maintenance: Secukinumab Placebo s.c. every 4 weeks starting at Week 4 until Week 24 followed by 150 or 300 mg Secukinumab s.c. every 4 weeks
1526050|NCT02771197|Drug|Fludarabine|
1526051|NCT02771197|Drug|Melphalan|
1526052|NCT02771197|Drug|Pembrolizumab|
1526053|NCT02771184|Device|Lung Sound Recording System|The lung sounds are recorded over the posterior chest in supine position on an examination table. A foam pad with several lung sound transducers is placed under the back of the subjects. During the recording the subjects wear a nose clip and hold a pneumotachograph with both hands. The subjects are instructed to breath at a certain airflow rate during inspiration, with natural breathing during expiration. Therefore, they receive a real-time feedback for the airflow rate. The airflow signal and the lung sounds from 16 lung sound transducers are recorded simultaneously for 30 seconds.
1526055|NCT02771158|Drug|Midodrine|midodrine is metabolized to an active metabolite, desglymidodrine, which is an alpha adrenergic antagonist that causes vasoconstriction of both venous and arterial vasculature, thereby increasing blood pressure
1526056|NCT02771158|Drug|placebo|placebo will be administered to double blind the study
1526057|NCT02771145|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution that uses a platinum catalyst for neutralization and is intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
1526058|NCT02771145|Device|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (180 days). A fresh pair will be dispensed on Day 0, Day 30, Day 60, and Day 135.
1526059|NCT02771145|Device|SCL preservative solution|Commercially available solution for rinsing soft contact lenses
1526060|NCT02771132|Behavioral|"12-hr IMPower empowerment self defense course"|"The purpose of the 12-hr IMPower empowerment self defense course intervention for girls is to empower then to avoid risky situations, advocate for themselves, and, if needed, defend themselves against an attack."
1526061|NCT02771132|Behavioral|12-hr Source of Strength for boys|The 12-hr Source of Strength for boys curriculum is specifically designed for 10-13 year-old boys and focused on promoting gender equality, developing positive masculinity, and teaching safe and effective bystander intervention techniques.
1526062|NCT02771132|Behavioral|Life-skills course|A 1.5-2 hour life skills class that is based on the Kenyan Ministry of Education life skills course and includes a wide range of topics, including sexual assault but also sanitation, food safety, and personal rights. All school-aged children who attend school typically receive this type of curriculum.
1526063|NCT02771106|Other|neuro vision rehabilitation|Neuro vision rehabilitation used to treat vision dysfunction following TBI
1526064|NCT02771093|Drug|Trelagliptin|Trelagliptin 100 mg tablet
1526065|NCT02771093|Drug|Alogliptin|Alogliptin 25 mg tablet
1526066|NCT02771080|Procedure|Cardiac surgery|
1526067|NCT02771067|Procedure|Fluid infusion|Fluid infusion will be performed using 6% hydroxyethyl starch. Pulse pressure variation and stroke volume will be measured before and after fluid infusion.
1526068|NCT02771054|Drug|TAF/FTC|Change of nucleoside backbone
1526069|NCT02771041|Procedure|medical consultation 8 days before surgery|"This consultation would serve to explain to the patient the early course of care, give advice and help to anticipate acts for its release post-operative as, for example, contact a physical therapist and a nurse or check to their community pharmacy if their heparin stock is enough and to answer any questions."
1526070|NCT02771028|Behavioral|Emotional Freedom Techniques|
1526071|NCT02771015|Device|Mepilex Border®|randomization
1526072|NCT02771015|Device|Cosmopor steril®|randomization
1526073|NCT02771002|Device|Peripheral Perfusion index by Carescape Patientenmonitor|Peripheral Perfusion index measured with pulse-oximetry by Carescape Patientenmonitor
1526074|NCT02770989|Procedure|Vimecon Laser CAI percutaneous cardiac ablation|The Vimecon Laser CAI catheter is entered through the femoral vein to access the pulmonary vein (PV) area in the heart in order to ablate the cardiac wall near the PV to create scar tissue and to isolate the PV in order to treat atrial fibrillation.
1526075|NCT02770976|Device|Increasing and decreasing NAVA levels with 10-min intervals|
1526076|NCT02770963|Procedure|Acupuncture|"Shenshu (BL23) on bilateral sides and Dachangshu (BL25), Weizhong (BL40), and Chengshan (BL57) on the affected side will be applied.
A Huatuo Brand needle (0.3*75 mm) for BL25 will be inserted at a depth of 40-70 mm vertically until the patient feels soreness and a distension sensation that radiates to the leg. The needle will be lifted 1-2 mm without rotating or lifting. Huatuo Brand needles (0.3*40 mm) at the other acupoints (BL23, BL40 and BL57) will be inserted 30 mm and manipulated by lifting, thrusting, twirling evenly until the Deqi sensation is achieved. The needles in these acupoints will be manipulated by small evenly applied lifting, thrusting, and twirling movements 3 times every 10 minutes."
1526077|NCT02770963|Procedure|Sham acupuncture|"Specially designed sham needles (0.3*25 mm) will be used. The sham needle consists of a needle handle, needle body, blunt tip and a sterile polyethylene cylindrical foam pad (identical to the pads in the acupuncture group).
The acupoints will be the same as the acupuncture group. The needle will be inserted vertically until pressed against the skin without penetration. The manipulation will be consistent with the acupuncture group and blind to the patients."
1526078|NCT02770950|Drug|Zushima plaster with high dose|Patients in high dose Zushima plaster group will use Zushima plaster topically on knee(s) for 24h per day.
1526079|NCT02770950|Drug|Zushima plaster with low dose|Patients in low dose Zushima plaster group will use Zushima plaster topically on knee(s) for 12h per day.
1526080|NCT02770950|Drug|Indometacin Cataplasms|Patients in Indometacin Cataplasms group will use Indometacin Cataplasms on knee(s)for 24h per day.
1526081|NCT02770937|Other|Virtual reality simulator|The virtual reality simulator group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) using the Simbionix simulator on laparoscopic suturing.
1526082|NCT02770937|Other|Box trainer|The box trainer group will receive a maximum of 4 hours of training (2 sessions, 2 hours each) on a box trainer.
1526083|NCT02770937|Device|Simbionix|
1526084|NCT02770924|Device|AT LISA TRI TORIC|phacoemulsification with IOL implantation
1526085|NCT02770924|Device|AT LISA TRI|phacoemulsification with IOL implantation
1526086|NCT02770911|Procedure|"without Dog Ear group"|a modified double-stapling technique with eliminating the dogears in laparoscopic anterior resection
1526087|NCT02770911|Procedure|"with Dog Ear group"|a traditional double-stapling technique without eliminating the dogears in laparoscopic anterior resection
1526088|NCT02770898|Behavioral|Family Holistic Health|Interventions for probationers will aim to promote physical and psychosocial health, family relationships and Family 3H (happiness, harmony and health).
1526089|NCT02770885|Drug|Dulaglutide|Treatment with dulaglutide for 3 weeks.
1526090|NCT02770885|Drug|Placebo|Treatment with Sodium Chloride 0.9% (Placebo) for 3 weeks.
1526091|NCT02770872|Other|Observation of SAA on apoB containing lipoproteins|attempting to elicit the conditions by which SAA shifts from apo-A1 containing lipoproteins to apoB containing lipoproteins
1526092|NCT02770859|Procedure|POEM (Per Oral Endoscopic Myotomy)|Per-Oral endoscopic myotomy (creating a muscle [esophagus] opening), an incision-less (no cutting of the surface of the body) endoscopic procedure, is an effective non-surgical alternative to release the muscle & sphincter of the LES for the treatment of achalasia
1526093|NCT02770846|Procedure|Immediate loading|
1526094|NCT02770846|Procedure|Delayed loading|
1526095|NCT02770833|Other|Fish and carbohydrats with low or high GI|
1526096|NCT02770833|Other|Veal and carbohydrats with low or high GI|
1526097|NCT02770820|Biological|Aldesleukin|Given SC
1526098|NCT02770820|Biological|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
1526099|NCT02770820|Other|Laboratory Biomarker Analysis|Correlative studies
1526103|NCT02770794|Drug|Infliximab|Discontinue infliximab; receive Infliximab when relapse
1526104|NCT02770781|Other|Exercise regimen|Subjects will receive a personal exercise regimen based on their health history and individual capability.
1526105|NCT02770768|Drug|Flibanserin|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
1526106|NCT02770768|Drug|Placebo|Observational study using electroencephalogram (EEG) and eye movement tracking device at baseline, week 4, and week 8 while subjects are taking either Flibanserin or matching placebo.
1526109|NCT02770716|Drug|Terlipressin acetate|Lyophilized terlipressin acetate, IV, 1 mg by bolus injection q 6 hours
1526110|NCT02770716|Other|Placebo Comparator|11 mg mannitol reconstituted with 5 ml of sterile 0.9% sodium chloride solution
1526111|NCT02770703|Device|DynaMesh visible mesh|Implantation of a MRI visible mesh
1526112|NCT02770690|Drug|ethyl chloride spray|apply the spray for 5 seconds on the dorsal hand before propofol iv injection
1526113|NCT02770690|Drug|lidocaine|apply lidocaine under the tourniquet state before propofol iv injection
1526114|NCT02770690|Drug|placebo|apply normal saline before propofol iv injection
1526115|NCT02770677|Other|Modified Dantien Salee Yoga Training Program|The intervention aims to improve pulmonary function and functional fitness.
1526116|NCT02770664|Drug|Placebo|Placebo
1526117|NCT02770664|Drug|LC28-0126 Dose A|LC28-0126 Dose A
1526118|NCT02770664|Drug|LC28-0126 Dose B|LC28-0126 Dose B
1526119|NCT02770664|Drug|LC28-0126 Dose C|LC28-0126 Dose C
1526120|NCT02770651|Device|Everolimus-Eluting stent|Everolimus-Eluting stent with bioabsorbable polymer
1526121|NCT02770651|Device|Zotarolimus-Eluting stent|Zotarolimus-Eluting stent with permanent polymer
1526203|NCT02770157|Drug|DA-3002|
1526122|NCT02770638|Device|Scoop Stretcher|Participants recruited by community advertisement. Participant will complete forty five minutes on scoop stretcher first, followed by forty five minute washout period, finished with forty five minutes on the long back spinal board. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
1526123|NCT02770638|Device|Long Back Spinal board|Participants recruited by community advertisement. Participant will complete forty five minutes on the long back spinal board first, followed by forty five minute washout period, finished with forty five minutes on the scoop stretcher. Tissue pressures will be automatically recorded throughout the forty five minute period laid on either spinal board. In addition, participants will be asked to report their comfort levels at five minute intervals.
1526124|NCT02770625|Drug|ISU302|60 U/kg given intravenously
1526126|NCT02770599|Other|IBD multidisciplinary team model including IBD nurse|IBD multidisciplinary team model including IBD nurse
1526127|NCT02770586|Device|Breast PET|imaging of the breast using the Breast PET system
1526128|NCT02770573|Other|Cavex Bite&White ExSense|a water-based mint aroma gel containing hydroxyapatite and potassium nitrate.
1526129|NCT02770573|Other|Kuraray Teethmate™ Desensitizer|Calcium-Phosphate-based powder and a liquid mainly water-based.
1526130|NCT02770573|Other|Ghimas Dentin Desensitizer|a fluid desensitizing gel with 30% of nano-hydroxyapatite, added to 70:100 thousandths of micron-sized crystals of nano- hydroxyapatite.
1526131|NCT02770560|Device|Urokinase locking solution|On basis of the prescription : one single administration of thrombolytic locking solution versus multiple administrations (during 3 consecutive dialysis sessions)
1526132|NCT02770547|Device|Low Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies low heat to the subject's leg.
1526133|NCT02770547|Device|High Heat Thermotherapy|Subject will wear a High Density LCG (Liquid Circulating Garment). Water will be heated and circulated through the garment, which in turn supplies high heat to the subject's leg.
1526135|NCT02770521|Drug|Treprostinil|Administered SC.
1526136|NCT02770521|Drug|Placebo|Administered SC.
1526137|NCT02770521|Drug|LY900014|Administered SC.
1526138|NCT02770521|Drug|Insulin Lispro|Administered SC.
1526139|NCT02770508|Drug|darunavir/ritonavir|
1526140|NCT02770508|Drug|Lamivudine|
1526141|NCT02770508|Drug|emtricitabine-tenofovir(FTC/TDF)|
1526142|NCT02770495|Other|blood sample|
1526143|NCT02770482|Biological|spinal fluid collection|
1526144|NCT02770469|Behavioral|Linguistically and Culturally Tailored Information|Participants received linguistically and culturally tailored information on diet and nutrition, physical activity, managing treatment side effects, follow-up care plans, complementary and alternative medicine, reducing environmental exposure to estrogen, navigating cancer-related financial issues, family history, body image, sexuality, and advances in breast cancer research.
1526145|NCT02770469|Behavioral|Cognitive-Behavioral Stress Management|Participants learned and practiced skills related to mindfulness, relaxation, stress reduction, rational thinking, improving coping, enhancing social support, anger management, and assertiveness training.
1526146|NCT02770456|Dietary Supplement|High dose fish oil|Four 0.72-gram gelatine capsules per day with fish oil providing 2.0 g/d lc-n3FA
1526147|NCT02770456|Dietary Supplement|Low dose fish oil|Four 0.72-gram gelatine capsules per day with a mixture of fish oil and olive oil providing 0.5 g/d lc-n3FA
1526148|NCT02770456|Dietary Supplement|Olive oil|Four 0.72-gram gelatine capsules per day with olive oil providing 0 g/d lc-n3FA
1526149|NCT02770443|Drug|withdrawal|withdrawal of beta blocker and ACE inhibitors
1526150|NCT02770443|Drug|standard of CARE|STANDARD OF CARE, NO WITHDRAWAL OF MEDICAL THERAPY
1526151|NCT02770430|Biological|mesenchymal stem cells|MSCs derived from bone marrow (BM) will be isolated and expanded in the laboratory under conditions of Good Manufacturing Practice. The quality control involves immunophenotyping, differentiation, microbiological control, mycoplasma and endotoxin tests. Patients will receive five infusions of MSC. Dosage: 2x10E6 cells/Kg
1526152|NCT02770430|Drug|conventional treatment|"Basiliximab 20mg dose for adults and 10mg for children, 1 time a week or every 3 days if worsens the stage of GVHD until reaching Very Good Partial Response (VGPR) or for a maximum of 4 doses, whichever comes first.
If after the item (1) will not obtained VGPR: Infliximab 5 to 10 mg/kg dose, 1 time a week, four weeks or even VGPR."
1526153|NCT02770417|Dietary Supplement|beta-alanine|Patients receive beta-alanine
1526154|NCT02770417|Dietary Supplement|placebo|Patients receive placebo
1526155|NCT02770417|Other|control|Healthy controls will be assessed to compare baseline muscle carnosine levels
1526156|NCT02770404|Drug|Nafithromycin|100, 200, or 400 mg of nafithromycin
1526157|NCT02770404|Drug|Placebo|IV matching placebo
1526158|NCT02770391|Drug|Leuprolide acetate|Leuprolide acetate, Intramuscular injection - 7.5 mg, one time dose on day (-28) ± 3
1526159|NCT02770391|Drug|ARN-509|ARN-509, PO, 240 mg daily, starting day (-28) ± 3 until the day before radical prostatectomy. ARN-509 will be initiated the same day patients receive their leuprolide acetate injection.
1526160|NCT02770391|Procedure|Radical prostatectomy|
1526161|NCT02770378|Drug|Temozolomide|Patients will receive temozolomide at a dose of 20 mg/m² BSA twice daily with start day 1 during induction and treatment cycles
1526162|NCT02770378|Drug|Aprepitant|Patients will receive aprepitant at a dose of 80 mg p.o. once daily with start day 1 during induction and treatment cycles
1526163|NCT02770378|Drug|Minocycline|Induction cycle day 3-4: minocycline 50 mg p.o. twice daily from day 19-20; minocycline 100 mg p.o. twice daily during treatment cycle 1-12 (28 days); minocycline 100 mg p.o. twice daily
1526164|NCT02770378|Drug|Disulfiram|Induction cycle day 5-6: disulfiram 250 mg p.o. once daily from day 21-22; disulfiram 250 mg p.o. twice daily during treatment cycle 1-12 (28 days); disulfiram 250 mg p.o. twice daily
1526204|NCT02770157|Drug|Genotropin®|
1526798|NCT02765854|Drug|Lenalidomide|Given PO
1526165|NCT02770378|Drug|Celecoxib|Induction cycle day 1-35: day 7-8: celecoxib 200 mg p.o. twice daily from day 23-24; celecoxib 400 mg p.o. twice daily during treatment cycle 1-12 (28 days); celecoxib 400 mg p.o.twice daily
1526166|NCT02770378|Drug|Sertraline|Induction cycle day 1-35: day 9-10: sertraline 50 mg p.o. twice daily, day 31-32: sertraline 100 mg p.o. twice daily; treatment cycle 1-12: sertraline 100 mg p.o. twice daily
1526167|NCT02770378|Drug|Captopril|Induction cycle day 1-35: day 11-12: captopril 25 mg p.o. twice daily, day 25-26: captopril 50 mg p.o. twice daily; treatment cycle 1-12 (28 days): captopril 50 mg p.o. twice daily
1526168|NCT02770378|Drug|Itraconazole|Induction cycle day 1-35: day 13-14: itraconazole 200 mg p.o. once daily day 27-28; itraconazole 200 mg p.o. twice daily; treatment cycle 1-12 (28 days): itraconazole 200 mg p.o.twice daily
1526169|NCT02770378|Drug|Ritonavir|Induction cycle day 1-35: day 15-16: ritonavir 200 mg p.o. once daily, day 29-30: ritonavir 200 mg p.o. twice daily, day 35: ritonavir 400 mg p.o. twice daily; treatment cycle 1-12 (28 days): ritonavir 400 mg p.o. twice daily
1526170|NCT02770378|Drug|Auranofin|Induction cycle day 1-35: day 17-18: auranofin 3 mg p.o. once daily, day 33-34 auranofin 3 mg p.o. twice daily; treatment cycle 1-12 auranofin 3 mg p.o. twice daily
1526171|NCT02770365|Drug|estrace cream (Perrigo)|
1526172|NCT02770365|Drug|estrace cream (Reference)|
1526173|NCT02770365|Drug|Placebo cream|
1526174|NCT02770326|Biological|Fecal Microbiota Transplantation (FMT)|
1526175|NCT02770313|Behavioral|Intermittent Fasting|Subjects allocated to the fasting arm will undergo a fasting regimen of twice-per-week 24-hour fasting on non-consecutive days during the first 4 weeks of the study, then once-per-week 24-hour fasting during the rest of the study (22 weeks).
1526176|NCT02770300|Device|Arm Light Exoskeleton Rehab Station (ALEx RS)|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress.
1526177|NCT02770300|Device|Arm Light Exoskeleton Rehab Station (ALEx RS) - automatically personalized|ALEx RS is a complete system specifically designed to support the rehabilitation of stroke patients. In particular, this system is equipped with a robotic arm exoskeleton conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. It is proven that the use of this type of devices in rehabilitation can provide high intensive, repetitive, task specific, and interactive treatment of the impaired arm and an objective and reliable mean for monitoring patients' progress. The movements to be performed by the patient are automatically decided by the exoskeleton.
1526178|NCT02770287|Device|Venus Freeze Diamond Polar|The Venus Freeze Diamond Polar is a non-invasive dermatological treatment system combines Multi Polar Radiofrequency and Pulsed Magnetic Fields. The radiofrequency energy penetrates the skin and results in tissue heating that has known effect on skin laxity, the magnetic field that is simultaneously induces increases fibroblast collagen production through non thermal mechanism and contributes to the clinical effect of skin laxity improvement. Only the Diamond Polar applicator will be used in this study for the treatment of the Mons pubis, vaginal introitus and Labia. Minor modification to the hand-piece for operator and/or patient comfort may occur mid-study, however no change in range of energy modality or amount of energy delivered will occur at any point during the study.
1526179|NCT02770274|Drug|Cilostazol|Dual therapy with Cilostazol 100 mg twice daily
1526180|NCT02770274|Drug|Aspirin|Monotherapy with aspirin 100 mg once daily
1526181|NCT02770261|Drug|DP-R208|DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo
1526182|NCT02770261|Drug|Candesartan32mg|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
1526183|NCT02770261|Drug|Rosuvastatin 20mg|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
1526184|NCT02770261|Drug|DP-R208 Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
1526185|NCT02770261|Drug|Candesartan32mg Placebo|DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
1526186|NCT02770261|Drug|Rosuvastatin 20mg Placebo|DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
1526187|NCT02770248|Drug|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
1526188|NCT02770248|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
1526189|NCT02770235|Other|DE assessment|by a validated self-administered questionnaire: Index International erectile function (IIEF-15)
1526190|NCT02770235|Other|AGE measurement|By AGE-ReaderTM
1526191|NCT02770222|Drug|Selexipag|Two selexipag film-coated tablets of 200 µg as single oral dose (total dose = 400 µg)
1526192|NCT02770222|Drug|Gemfibrozil|Gemfibrozil film-coated tablet of 600 mg administered orally b.i.d. from Day 1 to Day 9
1526193|NCT02770222|Drug|Rifampicin|Rifampicin film-coated tablet of 600 mg administered orally o.d.from Day 1 to Day 9
1526194|NCT02770209|Biological|biomimetic cartilage matrix + autologous chondrocytes|
1526195|NCT02770209|Procedure|arthroscopic debridement|
1526196|NCT02770209|Procedure|microfracture surgery|
1526197|NCT02770196|Behavioral|CO-CSA plus Nutrition Education|Participants will receive subsidized share of CSA produce (50% standard member price) weekly for approximately 20 weeks each year. In addition, they will attend nine skill-based, nutrition education sessions focused on use of CSA produce.
1526198|NCT02770183|Device|Imacor|"In ICU, the doctors in charge places the probe in the esophagus, executing a series of morphological evaluations and semi-quantitative evaluations. Each image is saved as a video loop or a static image, to have a basic data for each patient and perform an off-line analysis. At the end of the first recording, the esophageal probe is left in the neutral position in the stomach, to eliminate any risk associated with a local increase of pressure.
During the stay in the intensive care unit until the end of the study, the esophageal probe will be left in the neutral position, to run every two hours a new echocardiographic assessment on the main window, similar to the first evaluation, always recording loop-video and photographs, to have a time course of recovery of cardiac contractile function. All images will be stored in a digital archive."
1526207|NCT02770118|Behavioral|Partial Sleep Restriction|4 hour time in bed (TIB), participants will go to bed 4 hours later than during the HS condition. Wake-up times will be the same. During the in-lab portion of the PSR, meals, fulfilling weight-maintenance energy requirements, will be supplied by the research staff as BOOST shakes.
1526208|NCT02770118|Behavioral|Total Sleep Deprivation|0 hour time in bed (TIB), participants will remain awake throughout the night. Meals will be provided as BOOST shakes at the same meal.
1526209|NCT02770118|Behavioral|Habitual Sleep|8 hours time in bed (TIB), for 3 nights, with fixed bed and wake times, while at home. During the 3-d HS phase, participants will be provided will BOOST meal replacement shakes in amounts required to achieve weight maintenance.
1526210|NCT02770105|Other|Theanine|Oral administration of 200mg of L-theanine powder dissolved in 200ml of distilled water
1526211|NCT02770105|Other|Caffeine|Oral administration of 160mg of anhydrous caffeine powder dissolved in 200ml of distilled water
1526212|NCT02770105|Other|Theanine-Caffeine Combination|Oral administration of 200mg of L-theanine and 160mg of anhydrous caffeine powder, dissolved in 200ml of distilled water
1526213|NCT02770105|Other|Placebo|Oral administration of 200ml of distilled water
1526214|NCT02770092|Other|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
1526216|NCT02770053|Procedure|Foraminal enlargement|After determining the working length, a flexible size 30 K-file will be inserted 1 mm beyond the WL and the apical foramen will be enlarged.
1526217|NCT02770040|Drug|Infliximab|INFLIXIMAB (REMICADE) in the form of a freeze-dried compound is conditioned in 100mg vials. Treatment will first be reconstituted in 250ml isotonic saline solution and infused
1526218|NCT02770027|Drug|Intravenous Crystalloid|Crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
1526219|NCT02770027|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
1526220|NCT02770014|Drug|Erlotinib|
1526223|NCT02769936|Drug|D-cycloserine|100 mg D-cycloserine administered orally as encapsulated pill
1526224|NCT02769936|Other|Placebo|Placebo administered orally as encapsulated pill
1526225|NCT02769923|Device|Westpharma ID adapter|device used for administering intradermal injection
1526226|NCT02769923|Device|Star ID syringe|device used for administering intradermal injection
1526227|NCT02769923|Device|BCG NS|syringe used for administering intradermal injection
1526228|NCT02769910|Drug|Capsaicin 24 Hours|Dermal patches for transdermal application of Capsaicin, applied for 24 hours
1526229|NCT02769910|Drug|Capsaicin 1 Hour|Dermal patches for transdermal application of Capsaicin, applied for 1 hour
1526230|NCT02769910|Other|Qutenza Demo Patch|Dermal patches mimicking active Qutenza patches. Used as control in comparison of Capsaicin efficacy. Applied for 24 hours.
1526231|NCT02769897|Behavioral|Physical exercise|The sessions will last two hours (one hour of physical exercise and the second time divided into nutritional counseling, postural, psychological and oral) with a frequency of three times a week.
1526232|NCT02769884|Device|MMPPC algorithm artificial pancreas|An artificial pancreas system using the MMPPC algorithm, Roche insulin pump, and Dexcom CGM
1526233|NCT02769871|Behavioral|Neuroimages of stroke|Participants in the intervention group will be shown computer images of head CT or brain MRI (DWI/FLAIR series) of their strokes. Basic orientation to neuroimaging (laterality, positioning, parts of the brain) will be provided first, and then the image of the stroke itself will be reviewed. Participants will be provided with a paper copy of the slice demonstrating the largest volume of stroke to keep. In comparison, patients will also be shown images of a normal healthy, and images of a patient with recurrent strokes due to smoking. Patients will be told that smoking cessation would help to prevent additional stroke, but that it would not repair the damage already done, as visualized on the neuroimaging.
1526234|NCT02769871|Behavioral|standardized smoking cessation counseling|Standardized smoking cessation counseling will be provided at their initial interview. They will be provided pamphlets from the National Stroke Association and the American Heart Association regarding risk factor reduction. Packets will include general information on risks associated with smoking along with the benefits of cessation, and methods to quit. Pamphlets will include Life's Simple 7 (American Heart Association, 2014) and Be Smoke Free: Facts about Smoking and Stroke Risk (National Stroke Association, 2009). Counseling will be scripted and standardized to ensure similar language with all participants.
1526235|NCT02769858|Device|Light therapy|Light therapy glasses
1526236|NCT02769845|Drug|Hydroxyurea|drug to be administered
1526267|NCT02769598|Device|ANI Index for Hospitalized children|Each file consists of a simultaneous recording of an ECG signal, according to usual practice, coupled with a record of ANI Index (Analgesia Nociception Index) by MetroDoloris®. The ECG signals and the ANI index are recorded simultaneously on a computer.
1526237|NCT02769845|Procedure|TCD examination|TCD examinations on children with SCA between ages 3-15 years will be completed to evaluate their risk of stroke. All enrolled children will undergo yearly TCD examination. Participants with conditional TCD velocities on hydroxyurea therapy per study protocol will undergo TCD examinations every 6 months.
1993633|NCT03163095|Other|Closed Abdomen Management|"Primary closure of the abdominal fascia with placement of an intra-peritoneal drain (such as a Jackson-Pratt drain).
This strategy will allow drainage of intra-peritoneal fluid for both clinical reasons and to facilitate intra-peritoneal fluid testing. Closure or not of the skin will be left to the attending surgeons discretion. Any decision to perform a relaparotomy (Relaparotomy on Demand) will be at the discretion of the treating critical care teams, and in no way mandated by this recruitment.
Blood samples and peritoneal fluid (if available) will be drawn up to 72 hours after enrollment."
1526241|NCT02769806|Procedure|MRI|
1526242|NCT02769793|Drug|Levodopa dispersible|Levodopa dispersible 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
1526243|NCT02769793|Drug|Levodopa|Levodopa 100mg/tablet, PO, 1 tablet in the morning, once daily for 4 weeks (crossover)
1526244|NCT02769767|Genetic|Polymorphism of Interleukins, Glypican, and Human Leukocyte Antigen Genes.|The frequencies of the polymorphic variants in subjects with MS and healthy subjects were evaluated. Also in subjects with MS, the response to treatment with the number of relapses and EDSS was assessed; to compare the allele frequencies of SNPs of Interleukins, Glypican, and Human Leukocyte Antigen Genes, between responders and no responders MS patients.
1526245|NCT02769754|Device|Hemopatch|Hemopatch will be apply once the standard surgical hemostasis is achieved.
1526246|NCT02769754|Other|Control|No additional treatment will be applied after performing the usual surgical hemostasis.
1526247|NCT02769741|Other|Cashews followed by Control|Participants will receive the active diet with cashew nuts as a daily snack during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the control diet at the same calorie level, but with a control snack instead of cashew nuts during Test Period II.
1526248|NCT02769741|Other|Control followed by Cashews|Participants will receive a controlled diet without cashew nuts during Test Period I at a calorie level to achieve weight maintenance, and with a macronutrient composition representative of a typical diet for 28 days. Following a 14-day washout period, subjects will receive the active diet at the same calorie level, but with cashew nuts as a daily snack during Test Period II.
1526249|NCT02769728|Device|EndoBarrier|implantation of a duodeno-jejunal bypass liner for weight reduction in obese subjects with type 2 diabetes mellitus
1526250|NCT02769715|Device|Laser-sintered removable partial denture|The master cast was scanned using 3D scanner. In the digital file, the path of insertion was determined using a special software. The survey line was drawn and all undesirable undercuts were eliminated. After that, the entire framework design was built virtually 3 dimensionally using a special software (3Shape Software) according to the specified design in three steps: deciding the contour of the component, building the tissue surface then creating the polished surface. The file was saved in STL file and was transferred to rapid prototyping machine. Framework was produced by selective laser sintering technique using the alloy powder (Sintech Metal).
1526251|NCT02769715|Other|cast removable partial dentures|The denture was fabricated traditionally using lost-wax casting technique.
1526252|NCT02769702|Drug|Acthar|Acthar 80 IU SC twice a week
1526253|NCT02769689|Drug|Methylprednisolone|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
1526254|NCT02769689|Drug|Placebo|Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
1526255|NCT02769689|Drug|natalizumab (NTZ)|Patients with MS receiving NTZ for at least 18 months and without any disease activity during the previous year will be eligible. Included patients will receive either methylprednisolone (1 gramme, 1 day every 4 weeks for a total of 3 grammes) or undistinguishable capsules of placebo
1526256|NCT02769689|Drug|fingolimob (FTY)|Every patient will initiate a treatment with FTY 7 weeks after the last NTZ perfusion. Methylprednisolone or placebo will be taken 4, 8 and 12 weeks (W4, W8 and W12) after NTZ discontinuation.
1526257|NCT02769676|Other|3-week visit|The intervention will be an additional visit to the usual postpartum care provider at 3-weeks postpartum.
1526258|NCT02769676|Other|usual care|Participants in the usual care arm will receive no additional interventions.
1526259|NCT02769663|Behavioral|questionnaires and neuropsychological assessments|
1526260|NCT02769650|Procedure|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
1526261|NCT02769650|Drug|Optimal medicamentous treatment|
1526262|NCT02769650|Procedure|Stress-MRI|A standard stress-MRI test with adenosine
1526263|NCT02769637|Drug|PPI treatment|PPI treatment or no PPI treatment
1526264|NCT02769624|Drug|Treprostinil|A dose of 18mcg (3 breaths) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
1526265|NCT02769624|Drug|Placebo|3 breaths of placebo (via inhalation devices) will be administered 3 times: at baseline, 1.5 hrs. post baseline and then again 2 hrs later following maximal exercise testing.
1526266|NCT02769611|Drug|Ruboxistaurin|Dose escalation trial. 1st ten patients to receive 64 mg, next 10 patients to receive 128 mg, next 10 patients to receive 256 mg.
1526268|NCT02769585|Behavioral|Self-hypnosis|Self-hypnosis
1526799|NCT02765841|Drug|Lomitapide|
1526269|NCT02769585|Behavioral|CDE training|standard CDE training for an obese diabetic
1526270|NCT02769572|Other|real moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
1526271|NCT02769572|Drug|placebo gel|4 grams per knee, 4 times per day, for 4 weeks
1526272|NCT02769572|Drug|diclofenac sodium gel|4 grams per knee, 4 times per day, for 4 weeks
1526273|NCT02769572|Other|sham moxibustion|3 times a week for 4 consecutive weeks,totally 12 sessions at 3 acupoints (ST35, EX-LE4, ST36 )
1526274|NCT02769559|Procedure|Reduction mammaplasty|Surgical removal of excess breast tissue
1526275|NCT02769546|Other|Surveys|
1526276|NCT02769533|Drug|OTL0038|
1526277|NCT02769533|Drug|Benadryl|
1526278|NCT02769533|Device|intraoperative imaging|
1526279|NCT02769520|Drug|Pembrolizumab|
1526280|NCT02769520|Other|Placebo|
1526281|NCT02769507|Device|DC Stimulator PLUS (NeuroConn)|
1526282|NCT02769494|Drug|Mesalazine Sustained-Release Tablets|Mesalazine sustained-release tablets 500mg and 0.02L glycerol mixed, the preparation of 2.5% the mesalazine glycerol suspension liquid, gently apply to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
1526283|NCT02769494|Drug|Riboflavin Sodium Phosphate Injection|gently apply the riboflavin sodium phosphate injection to the ulcer surface, 3 times/day. The application time of the drug is 8:00,12:00, 16:00. Daily 20:00 measure the size of the mouth ulcers and record the symptoms in the diary card.
1526288|NCT02769468|Other|The Back|
1526289|NCT02769468|Other|Chest|
1526290|NCT02769468|Other|Left Axilla|
1526291|NCT02769455|Other|Reference intakes|"FOP nutrition label which is already in use on a portion of food products in France: the 'Reference Intakes' (RIs). The RIs are a chain of rectangles presenting the contribution of a portion of the product to a reference balanced diet of an average person (2000kcal) for each of the following nutrients: energy, lipids, saturated fat, sugars and sodium.
The presentation of the products will always include the label affixed on it. Moreover, the product pages will include two pictures of the product: one with only the package (including the RI as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant. These elements ensure higher visibility, awareness and understanding of the label."
1526292|NCT02769455|Other|5-CNL|"The 5-CNL was developed as a colour-coded summary system nutrition label, following the elements pointed out in reviews.
The format includes five categories, ranging from green (Associated with the A grade) for foods of the highest nutritional quality to red (associated with the E grade), for products with lower nutritional quality. The format is presented in the form of a continuous chain of rectangles, each with its own letter/colour, the one corresponding to the product being enlarged.
The presentation of the products will always include the label affixed on it. Two pictures of the product will be included: one with only the package (including the 5-CNL as FOP labelling), and a picture with both the package and a larger version of the label, so that it is more visible to the participant."
1526293|NCT02769442|Device|Terumo SurFlash Plus catheter|
1526294|NCT02769442|Device|BD Insyte Autoguard catheter|
1526297|NCT02769416|Other|Data and sample repository|Subjects with spinal cord and/or traumatic brain injury, family members and healthy volunteers will provide data and samples.
1526298|NCT02769403|Device|HeartMath EmWAVE Pro|"The following information will be recorded about HeartMath use:
Self-report: adherence (whether the daily session was completed), coherence score, any comments/notes about the daily session From the application: coherence ratio, coherence score, achievement score, session time, average heart rate"
1526299|NCT02769403|Other|Questionnaires|All participants will complete questionnaires at baseline, week 6, and week 12 about demographics, job satisfaction, and job performance.
1526300|NCT02769403|Other|Blood Pressure and Heart Rate|All participants will have blood pressure and heart rate collected at baseline, week 6, and week 12.
1526301|NCT02769403|Other|Sick Days|Sick days during the 12 week study period will be collected
1526302|NCT02769403|Other|Patient Satisfaction|This will include patients who complete the satisfaction survey for the 12 weeks prior to the study and during the 12 week study period. Each patient satisfaction survey is tied to a specific healthcare provider (physicians, Advanced Registered Nurse Practitioner (ARNP) & Physician Assistants [advance practice clinicians], and nurses) and will be linked to the consented research participant.
1526303|NCT02769390|Drug|Clonidine 1 mcg/Kg|Clonidine 1 mcg/Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
1526304|NCT02769390|Drug|Clonidine 2 mcg/ Kg|Clonidine 2 mcg//Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
1526305|NCT02769390|Drug|Clonidine 3 mcg/ Kg|Clonidine 3 mcg //Kg associated with bupivacaine 0,166% 1 ml/Kg administred epidural caudal in children for hypospadias surgery
1526306|NCT02769377|Device|Breeze2 glucometer|Breeze2 glucometer for self-monitoring of blood glucose
1526307|NCT02769377|Device|Breeze2 glucometer and H2|Breeze2 glucometer and Health2Sync Mobile App for data transfer
1526308|NCT02769351|Device|periph. minimal invasive ultrafiltration|ultrafiltration via a peripheral single-needle
1526309|NCT02769338|Other|Quality Improvement Program|The Intervention is a QI Program that will include multiple components as described above.
1526310|NCT02769325|Drug|Atropine|IV atropine 0.1%, 10 ml
1526311|NCT02769325|Drug|Placebo|IV saline, 10 ml
1526312|NCT02769325|Drug|Sevoflurane|All patients will receive anaesthesia based on sevoflurane, titrated to a bis of 45-60
1526838|NCT02765633|Drug|Cangrelor|
1526313|NCT02769325|Drug|sugammadex|Patients will receive sugamadex for neuromuscular reversion, if necessary
1526314|NCT02769325|Drug|Ketorolac|60 mg IV ketorolac will be administered at induction, and patients will receive 30mg/8h on the postoperative period
1526315|NCT02769325|Drug|Morphine PCA|Patients will receive a PCA of morphine with a program of 0 (continuous infusion), 1 mg bolus and 8 minutes lockout
1526316|NCT02769325|Drug|rocuronium|general anaesthesia will use rocuronium 0.6 mg/kg to facilitate intubation
1526317|NCT02769325|Drug|propofol|for anaesthesia induction, patients will receive 2-3 mg/kg iv propofol
1526318|NCT02769312|Device|Theta burst stimulation|Theta burst transcranial magnetic stimulation
1526319|NCT02769312|Device|Sham stimulation|Sham Theta burst transcranial magnetic stimulation
1526320|NCT02769299|Radiation|Radiation Therapy|less than 1 Gy with protons to 4-8 Gy with photons
1526321|NCT02769286|Drug|Osimertinib|Treatment efficacy of osimertinib will be assessed in patients with lung cancer harboring EGFR mutations (cohort 1) and those harboring T790M (cohort 2) which were detected from circulating tumor DNA
1526322|NCT02769273|Device|Percutaneous Transluminal Angioplasty|
1526323|NCT02769260|Other|Toothbrushing|Normal toothbrushing without toothpaste or antiseptic mouthwash.
1526324|NCT02769247|Drug|Naproxen|Oral naproxen vs placebo
1526325|NCT02769247|Drug|Lidocaine|Intrauterine lidocaine vs normal saline
1526326|NCT02769247|Drug|placebo|either normal saline or empty oral capsule
1526327|NCT02769234|Procedure|ERP/EEG test|The testing protocol consists of an auditory oddball ERP paradigm, followed by the collection of 3min of resting EEG. During the ERP paradigm a variety of auditory stimuli are played through the system's earphones while voltage potentials are recorded from the subject's scalp. At the end of the ERP session, 3 minutes of EEG data will be recorded while the subject is resting. The entire procedure, including set up, instructions to the subject and actual test is expected to take 45-60 minutes.
1526328|NCT02769234|Procedure|Psychometric testing|Subjects that complete ERP/qEEG testing successfully will move on to clinical and neuropsychological evaluation. Demographic information with also be collected.
1526329|NCT02769221|Device|Rigid video stylet|
1526330|NCT02769221|Device|Video laryngoscope|
1526331|NCT02769208|Device|Central air handling unit air purification technologies|As described in the arm descriptions, the interventions involve changing the baseline pre-filter + HEPA + ESP conditions by removing either just the ESP or both the ESP and the HEPA for a five week period.
1526332|NCT02769182|Device|Monitoring and training using the system|subjects and caregivers will be trained on using the system and receive a 'user manual' delineating all procedures and possible applications of the system, as well as operations for daily charging of the sensors and smart phone. They will then be fitted with the sensors. The clinician will set all necessary applications, including setting the cognitive games application and the 'network of users'. Users and care givers will be informed of the personalized recommendations system that will provide the user with daily feedback on activity and weekly recommendations and goals for duration of the study. A helpline will be provided in case technological problems occur or for routine support.
1526333|NCT02769182|Behavioral|Standard of care|Subjects in this group will not receive the system but will encouraged to continue with their daily living routine and provided with recommendations for stretching and strengthening exercises. The control group subjects will be assessed at the same three time points as those in the experimental group. Subjects in both groups will also receive written information about the importance of activity, cognitive enhancing tasks, avoidance of falls and home hazards. In Israel, this information combined with an exercise prescription is considered the 'standard of care' for community-dwelling older adults.
1526334|NCT02769169|Drug|Lucentis® (Raibizumab) double-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
1526335|NCT02769169|Drug|Lucentis® (Raibizumab) regular-dose|Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
1526336|NCT02769156|Drug|OTL38|
1526337|NCT02769156|Device|Artemis and/or the Karl Storz DP camera|
1526338|NCT02769156|Drug|Benadryl|25 mg
1526339|NCT02769143|Other|Whole-Body Vibration|Will be performed six months of WBV exercises
1526340|NCT02769143|Other|Pilates|Will be performed six months of Pilates exercises
1526341|NCT02769130|Drug|Losartan|Losartan is given for 12 months
1526342|NCT02769117|Procedure|Ultrasound on fractured bone|A new ultrasound technique for children and adults who have sustained forearm fractures
1526343|NCT02769117|Procedure|Ultrasound on contralateral intact bone|A new ultrasound technique for the intact bone as the control for children and adults who have sustained forearm fractures
1526344|NCT02769104|Drug|Letrozole (Aromatase Inhibitors)|Letrozole (Aromatase Inhibitors) for 5 years
1526345|NCT02769104|Drug|AC*4-T*4|CTX800mg/m2 d1+Anthracyclines75mg/m2 d1, every 3 weeks*4 cycles, be sequential with Docetaxel 75mg/m2 d1, every 3 weeks*4cycles
1526346|NCT02769091|Drug|TEV-45478|80 mg (2x40mg) tablets once daily for up to 24 weeks
1526347|NCT02769091|Drug|Placebo|
1526348|NCT02769078|Drug|dabigatran|
1526349|NCT02769078|Drug|rivaroxaban|
1526350|NCT02769078|Drug|apixaban|
1526351|NCT02769078|Drug|warfarin|
1526352|NCT02769065|Drug|TAK-071|TAK-071 capsules
1526353|NCT02769065|Drug|Donepezil|Donepezil over-encapsulated tablet
1526354|NCT02769065|Drug|TAK-071 Placebo|TAK-071 placebo-matching capsules
1526355|NCT02769065|Drug|TAK-071|TAK-071 tablets
1526356|NCT02769065|Drug|Donepezil Placebo|Donepezil placebo-matching over-encapsulated tablet
1526357|NCT02769052|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy through self-applied device .
1526358|NCT02769039|Other|No intervention. Observational studies of sleep, movement and brain imaging|Participants will be asked to visit the University for 3 baseline visits which include a screening visit & sleep study, movement tests and magnetic resonance imaging (MRI) scans. Three years later the participant will be asked to repeat the same visits.
1526978|NCT02764619|Drug|Placebo|
1526363|NCT02769000|Radiation|10 GY in 5 daily fractions|Subjects 1-15 10 GY in 5 daily fractions
1526364|NCT02769000|Radiation|20 GY in 10 daily fractions|Subjects 16-30 20 GY in 10 daily fractions
1526366|NCT02768974|Drug|OPRX-106|Oral delivery, once daily.
1526367|NCT02768961|Drug|sofosbuvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.
Sofosbuvir will be used in association with ledipasvir. In some cases, ribavirin can be added to this combination according to current guidelines"
1526368|NCT02768961|Drug|ledipasvir|"Subjects will be treated according to the current guidelines on HCV treatment taking into account the stage of fibrosis, genotype, previous treatments, etc.
Ledipasvir will be used in association with sofosbuvir. In some cases, ribavirin can be added to this combination according to current guidelines"
1526369|NCT02768948|Drug|telmisartan during 6 months|
1526370|NCT02768948|Drug|Losartan during 6 months|
1526371|NCT02768948|Procedure|blood sample|
1526372|NCT02768935|Procedure|blood sample|blodd sample at 12 months
1526373|NCT02768922|Other|Aphasia telerehabilitation|Speech and language therapy delivered by speech and language therapist via computer and telemedicine
1526374|NCT02768922|Other|Standard face-to-face aphasia rehabilitation|Speech and language therapy delivered by speech and language therapist face-to-face (treatment as usual)
1526375|NCT02768909|Device|E-Nose|1.They will be asked to perform a respiration for 5 minutes trough the E-Nose Device, with a nose clamp.
1526376|NCT02768909|Other|Survey & Physical Exam|2. Perform a oriented survey for risk factors and a complete physical exam.
1526377|NCT02768909|Other|Chest X-ray|Perform anteroposterior chest X-ray
1526378|NCT02768909|Other|Sputum Samples|Sputum samples for Ziehl Neelsen smear and Culture in L-J.
1526379|NCT02768909|Device|Follow Up 5 days after beginning of Tx.|"Patients will be asked to come 5 days after initiation of treatment, to perform another measurement with the device.
Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
1526380|NCT02768909|Device|Follow Up 15 days after beginning of Tx.|"Patients will be asked to come 15 days after initiation of treatment, to perform another measurement with the device.
Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
1526381|NCT02768909|Device|Follow Up 30 days after beginning of Tx.|"Patients will be asked to come 30 days after initiation of treatment, to perform another measurement with the device.
Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
1526382|NCT02768909|Device|Follow Up 60 days after beginning of Tx.|"Patients will be asked to come 60 days after initiation of treatment, to perform another measurement with the device.
Also will perform a Medical History, including Symptom based Survey, Physical Exam, Anthropometric measurement, to determine progress of treatment."
1526383|NCT02768896|Behavioral|Baseline|Patients will walk naturally with EEG measuring brain waves
1526384|NCT02768896|Behavioral|visual stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses
1526385|NCT02768896|Behavioral|Auditory stimuli|Patients will walk naturally with EEG measuring brain waves while hearing an auditory stimuli
1526386|NCT02768896|Behavioral|Visual and auditory stimuli|Patients will walk naturally with EEG measuring brain waves while seeing a grid through glasses and hearing an auditory stimuli simultaneously
1526387|NCT02768883|Behavioral|Respira Sano|The intervention is all three components: clinic + home + community.
1526388|NCT02768870|Device|Harpoon Medical TSD-5|The Harpoon Medical device (TSD-5) will be used to implant 1 or more ePTFE sutures to reduce or eliminate mitral regurgitation.
1526389|NCT02768857|Behavioral|Sensorimotor reeducation programs|
1526390|NCT02768844|Device|Stochastic Vibrotactile Stimulation (SVS)|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available; designed by TheraSound, Bellingham WA, or Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
1526391|NCT02768831|Other|CPAP|Sealing the airway by holding CPAP of 20 cmH2O in the anesthesia circuit and slowly inflating the cuff until no air leak is heard with a stethoscope placed in the suprasternal notch.
1526392|NCT02768831|Other|Tidal volume|The ratio of the inspired to expired tidal volume will be determined using the following formula: (TVinspired - TV¬expired)/TVinspired. The peak inflating pressure (PIP) required to achieve the set TV will be noted. The air in the cuff will then be increased or decreased as needed to achieve a set delivered ratio of 0.9-1.0.
1526393|NCT02768818|Dietary Supplement|Probiotic VIVOMIXX™|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
1526394|NCT02768818|Dietary Supplement|Placebo|The patients will be randomly assigned to the VIVOMIXX™ (intervention) or the control (placebo) group through a randomization list elaborated by a specific software.
1526395|NCT02768805|Biological|15 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
1526396|NCT02768805|Biological|30 µg/strain of Quadrivalent VLP Vaccine|Single dose of non-adjuvanted Quadrivalent VLP Vaccine
1526397|NCT02768805|Biological|15 µg/strain of the licensed quadrivalent vaccine|Single dose of the licensed quadrivalent vaccine
1526398|NCT02768792|Drug|pembrolizumab,|Pembrolizumab 200 mg is administered IV once as monotherapy, 14 days after the initiation of HiDAC salvage induction chemotherapy. Patients who have a response (i.e., PR/CR/CRi) to induction phase will receive maintenance pembrolizumab at 200 mg IV every 3 weeks for up to 2 years of maintenance therapy (i.e., beginning on day 1 of maintenance).
1526399|NCT02768779|Other|Hair analysis|Within the laboratory, experimental factors controlling IR-MALDESI response to key ARVs representing various drug classes will be systematically evaluated using the design of experiments (DOE) statistical approach (41,127) for an unbiased optimization of IRMALDESI response to each of the ARVs and their major metabolites. The goal will be to achieve a lower limit of quantification (LLOQ) below clinically relevant hair strand concentrations.
1526400|NCT02768766|Drug|Selumetinib|"100mg, 125mg, 150mg, 175mg, 200mg or 225mg of oral capsules
An orally active, small molecule with potential antineoplastic activity. Selumetinib is an ATP-independent inhibitor of mitogen-activated protein kinase kinase (MEK or MAPK/ERK kinase) 1 and 2. Inhibition of both MEK1 and 2 by selumetinib prevents the activation of MEK1/2 dependent effector proteins and transcription factors, thereby leading to an inhibition of cellular proliferation in various cancers."
1526401|NCT02768753|Procedure|The Axillary Bilateral-breast Approach|
1526402|NCT02768753|Procedure|The bilateral Axillo-breast Approach|
1526403|NCT02768740|Drug|Hydrocortisone hemisuccinate|In the 200-mg group, patients received an intravenous bolus of 50 mg of hydrocortisone every six hours for seven days associated with a continuous infusion of placebo for five days. In the 300-mg group, patients received an initial bolus of 100 mg of hydrocortisone followed by a continuous infusion of 300 mg per day for five days associated with a bolus of placebo every six hours for seven days.
1526404|NCT02768727|Drug|Xenon|drug given in concentrations of 0% to 75% over period of 4 hours
1526405|NCT02768714|Drug|Eurofarma's pegfilgrastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
1526406|NCT02768714|Drug|Neulastim|Eurofarma's pegfilgrastim is a clear, colourless solution for injection (6 mg/0.6 mL) provided in a single use prefilled syringe. Subjects randomised to Eurofarma's pegfilgrastim will receive 6 mg administered as a single SC injection in the abdomen, upper arm, or thigh on Day 2 of each CTX cycle, approximately 24 hours after
1526409|NCT02768688|Other|Brain connectivity and physiology|MRI to measure glymphactic flow during simulated natural sleep and again on return to wakefulness.
1526410|NCT02768688|Drug|Dexmedetomidine|Administering of 0.5-1.0 mcg/kg/hr of dexmedetomidine to ensure subject's loss of consciousness.
1526411|NCT02768675|Device|LOADPRO|The Intellirod LOADPRO sensor is a single-use, disposable instrument for the intra-operative measurement of posterior instrumented, spine rod strain.
1526412|NCT02768662|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
1526413|NCT02768649|Drug|RBP-7000|Sequential dosing of each cohort
1526414|NCT02768649|Drug|risperidone|All eligible subjects received a test dose of risperidone to ensure tolerability prior to dosing with RBP-7000.
1526415|NCT02768636|Dietary Supplement|Omega-3|Omega-3 or Fish oil (1000 mg.) is taken for one capsule a day in 30 days duration. Heart rate variability is tested before at starting day and later follow up it again in the next 30 days appointment.
1526416|NCT02768623|Other|Pharmacist led Asthma Management|
1526417|NCT02768623|Other|Pharmacist Intervention (when requested by patient)|
1526418|NCT02768610|Drug|Dexmedetomidine|
1526419|NCT02768610|Drug|Normal Saline|
1526420|NCT02768597|Device|ReUnion System with a Large-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +2 mm offset
1526421|NCT02768597|Device|ReUnion System with a Small-Diameter Glenosphere +2 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +2 mm offset
1526422|NCT02768597|Device|ReUnion System with a Large-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Large-Diameter Glenosphere +6 mm offset
1526423|NCT02768597|Device|ReUnion System with a Small-Diameter Glenosphere +6 mm offset|Primary Reverse Shoulder Arthroplasty using the ReUnion System with a Small-Diameter Glenosphere +6 mm offset
1526424|NCT02768571|Drug|Cerebrolysin|Cerebrolysin- cerebrolysin 30 ml with 100 ml dilution/day * 21 days with rehabilitation
1526425|NCT02768571|Drug|Placebo|Placebo- saline 100 ml/day * 21 days with rehabilitation
1526426|NCT02768558|Radiation|Thoracic RT|High-precision radiation therapy
1526427|NCT02768558|Drug|Cisplatin|Anti-cancer alkylating agent
1526428|NCT02768558|Drug|Etoposide|Cytotoxic agent
1526429|NCT02768558|Drug|Nivolumab|Anti-PD-1 targeted immunotherapy
1526430|NCT02768558|Other|Placebo|0.9% Sodium Chloride solution or 5% Dextrose solution
1526431|NCT02768545|Drug|Ezetimibe|Ezetimibe 10 mg per day before and after transplant
1526432|NCT02768532|Drug|Vedolizumab|"During each 8 visits (screening, V0, V1, V2, V3, V4, V5, V6) at weeks-1, 0, 2, 6, 10, 14, 22, 54, respectively), the following parameters will be systematically recorded: Crohn's disease Activity Index (CDAI), adverse events.
Blood and fecal samples will be systematically collected at weeks 0, 2, 6, 10, 14, 22 and 54 for routine serum ultrasensitive CRP (C-Reactive Protein) and fecal calprotectin assessments and for vedolizumab pharmacokinetic parameters, including the vedolizumab trough levels and the specific anti-Vedolizumab antibodies. In case of loss of response, an additional measurement of serum CRP (C-Reactive Protein), fecal calprotectin and Vedolizumab pharmacologic parameters will be performed."
1526433|NCT02768519|Drug|OTS167IV|diluted to final concentration with cherry syrup
1526434|NCT02768519|Other|Cherry syrup|
1526435|NCT02768493|Drug|1.0 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
1526436|NCT02768493|Drug|1.5 ml/kg of 0.15% ropivacaine|Randomly selected patients of the high dose group are given 1.5 ml/kg of 0.15% ropivacaine for caudal block before their surgery. In contrast, patients in the low dose group are given 1.0 ml/kg of 0.15% ropivacaine for caudal block before surgery.
1526437|NCT02768480|Other|Primary Care|Patients will be followed by primary care team according to the usual health system routine.
1526438|NCT02768480|Other|Phone Calls Support and Primary Care|Patients in intervention group will receive periodic phone calls (every three months) and will have a toll-free number to resolve questions about the disease management. The phone-calls will be performed by trained nurses and will follow a structured format. Nurses will address some topics: patient's treatment adherence, technique of insulin administration, disease understanding, hypoglycaemia management, healthy diet, smoke cessation and foot care.
1526439|NCT02768467|Procedure|Tissue Matrix Graft Placement|Subject will receive a covering for the wound post buccal mucosa removal.
1526440|NCT02768467|Procedure|No Stitches|Subject will not receive stitches post buccal mucosa removal.
1526441|NCT02768454|Drug|medical review of controlled broad-spectrum antibiotics|medical review of outcome of antibiotics stewardship by pharmacists and infectious disease physicians
1526442|NCT02768441|Drug|Dexamphetamine|Participants will receive 60 mg Dexamphetamine SR daily for 5 consecutive days
1526443|NCT02768428|Other|Video-Audio Media|each arm spends 15 mins for watching the video or study the handbooks
1526444|NCT02768415|Drug|Apatinib|
1526445|NCT02768415|Drug|Oral Vinorelbine|
1526446|NCT02768402|Device|Caisson TMVR System|Transcatheter mitral valve replacement is a percutaneous procedure used to treat mitral valve regurgitation with a prosthetic valve implantation.
1526447|NCT02768389|Drug|Bevacizumab|Subjects receive Bevacizumab as standard of care
1526448|NCT02768389|Behavioral|Modified Atkins Diet|The modified Atkins diet (MAD) includes high fat, unlimited protein, and restricted carbohydrates (< 20gm/day).
1526449|NCT02768376|Drug|Bupivacaine with Fentanyl (Spinal Anesthesia)|Intrathecal injection of 15 mg Bupivacaine 0.5% at L 2-3 level mixed with 20 µ Fentanyl. Patients head will be lowered till sensory level of T 6 is abstained.
1526450|NCT02768376|Drug|General anesthesia|Induction by propofl 1.5-2 mg/kg, Fentanyl 1-2 mic/kg and atracrium 0.5 mg/kg Then maintained using Sevoflurane based anesthesia aiming to maintain Bispectral index 40-60..
1526454|NCT02768350|Procedure|Ventilator hyperinflation technique|"Hyperinflation using a ventilator or ventilator hyperinflation technique (VHI) was developed from the manual hyperinflation (MHI) technique. There is no need to disconnect the patient when using the VHI technique and consequently there is no loss of PEEP and little or no risk of the adverse effects associated with MHI."
1526455|NCT02768350|Procedure|Conventional treatment|Conventional treatments are the routine treatment that patients were received from the physical therapist who take care them. The routine treatments are consist of chest physical therapy techniques (i.e. vibration, positioning, etc.) and others treatment (i.e. passive movement).
1526456|NCT02768337|Drug|Afatinib|
1526457|NCT02768337|Radiation|2 Gy targeted radiotherapy|
1526458|NCT02768337|Radiation|4 Gy targeted radiotherapy|
1526459|NCT02768311|Procedure|neolix rotary system (continuous rotation system)|Procedure: neolix rotary system
1526460|NCT02768311|Procedure|waveone rotary system (reciprocating system)|Procedure: waveone rotary system
1526461|NCT02768311|Procedure|hand files k-files|Procedure: hand files k-files
1526462|NCT02768298|Drug|LCZ696|LCZ696 50 mg, 100 mg or 200 mg film-coated tablets
1526463|NCT02768298|Drug|enalapril|Enalapril 2.5mg, 5 mg and 10 mg film-coated tablets
1526464|NCT02768298|Drug|Enalapril matching placebo|Placebo to enalapril 2.5mg, 5 mg and 10 mg film-coated tablets
1526465|NCT02768298|Drug|LCZ696 matching placebo|Placebo to LCZ696 50mg, 100mg and 200mg film-coated tablets
1526467|NCT02768272|Device|PCEA vs PIEB|We evaluate the relation between the distribution of L-bupivacaine plus fentanyl in the epidural space and the incedence of breaktrough pain during labor
1526468|NCT02768272|Procedure|Epidural vs CSE|We evaluate the relation between the type of epidural technique and the incedence of breaktrough pain during labor
1526469|NCT02768246|Device|BVGA|The BVGA enables the direct connection of a bag valve device to a guedel, eliminating the need for a face mask during ventilation
1526470|NCT02768246|Device|Face Mask|Classic face mask
1526471|NCT02768233|Behavioral|Educational programme|The 6-session educational programme is based on theory of motivational interviewing, and patients can choose between individualized education or education in groups. The standard treatment consists of withdrawal and consultations by neurologist.
1526472|NCT02768220|Drug|empagliflozin|Test to see how 30 days of jardiance changes serum and urinary advanced glycation end product levels
1526473|NCT02768220|Drug|linagliptin|Test to see how 30 days of tradjenta changes serum and urinary advanced glycation end product levels
1526474|NCT02768207|Drug|Cobimetinib|Participants will receive cobimetinib 60 mg tablets (three 20 mg tablet) orally OD for 21 consecutive days (Days 1 to 21), followed by a 7 day break (Days 22 to 28); in each 28-day cycle of treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
1526475|NCT02768207|Drug|Vemurafenib|Participants will receive vemurafenib 960 mg tablets (four 240 mg tablet) orally BID from Day 1 to Day 28 of each 28-day cycle of the treatment phase until disease progression, consent withdrawal, or the development of unacceptable toxicity.
1526557|NCT02767635|Drug|triamcinolone acetonide (Steroid)|injected 40mg of triamcinolone acetonide into lateral epicondyle in Steroid group
1526558|NCT02767622|Procedure|Liver transplantation|
1993637|NCT03162848|Behavioral|SystemCHANGE|At initial home visit, the PI will work with the participant to identify important people for medication taking, routines, and cycles of routines. Possible solutions to incorporate medication taking into routines will be identified by the participant and PI and the participant will start implementing these solutions. Medication adherence will continuously be monitored using medication event monitoring systems. At one month, the participant will be sent a report on medication taking and a phone call will occur with the PI to discuss if solutions improved medication adherence or if other solutions need to be implemented. At month two, the intervention will end but participants are urged to continue to use solutions long term.
1526479|NCT02768181|Behavioral|Nutrition-specific Behaviour change communication (BCC)|Door-to-door counseling on nutrition during pregnancy and exclusive breastfeeding from enrolment into study till birth; exclusive breastfeeding and nutrition of lactating mothers during post-natal 6 months; timely and appropriate complementary feeding with continued breastfeeding until 2 years of child's age, and nutrition of lactating mothers during post-natal 6-24 months; all counseling would be supplemented with associated issues including hygiene and sanitation, mother's sleep and rest, maternal and child healthcare seeking etc.
1526480|NCT02768181|Dietary Supplement|Nutritional supplement to pregnant women|"A lipid-based micronutrient supplement (LNS) is packed in ~10g sachets. Formulation: Vegetable fat (soy), skimmed milk powder, peanuts, vitamin and mineral complex, sugar, stabilizer: fully hydrogenated vegetable fat, and antioxidant : tocopherols. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc.
Dose: 1 sachet/pregnant woman/day starting from the first counseling session (GA ~125∓15 days) continued till birth of baby. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
1526481|NCT02768181|Dietary Supplement|Nutritional supplement to children 6m to 2 years|"A lipid-based micronutrient supplement (LNS) is packed in ~10g sachets. Formulation: Vegetable fat, skimmed milk powder, peanuts, sugar, vitamin and mineral complex, maltodextrin, and emulsifier: lecithin. Each sachet contains 70-75% of recommended dietary allowance for most of the micronutrients, including iron, folic acid, zinc, calcium, iodine, vitamins A, B1, B2, niacin, B12 etc. Each 20 g of LNS provide ≥4.46g LA (Linoleic Acid) and ≥0.42g ALA (α-Linolenic Acid).
Dose: 2 sachets ~(10+10=20g)/child/day from 5th completed months (181 days) to 24 completed months of child's age. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. Supplement should be taken with food in room temperature, and must not be heated, or mixed with hot food. To avoid overdose, respondents receiving this supplement should stop taking any other micronutrient supplement or drink."
1526487|NCT02768142|Other|Natural cesarean delivery|Natural cesarean delivery
1526488|NCT02768142|Other|Standard cesarean delivery|Standard cesarean delivery
1526489|NCT02768129|Device|transcranial direct current stimulation|active stimulation: 2 milliamp (mA), 20 mins
1526490|NCT02768129|Device|sham transcranial direct current stimulation|sham stimulation
1526491|NCT02768116|Procedure|Sirolimus Drug-eluting Stent via Active Transfer of Plaque|
1526492|NCT02768116|Procedure|Sirolimus Drug-eluting Stent implantation via Provisional T Stenting|
1526494|NCT02768090|Device|Skin Patch|Sweat will be collected by applying a diagnostic skin patch to inflammatory and neoplastic cutaneous lesions for proteomic analysis with mass spectrometry.
1526495|NCT02768077|Drug|Melatonin(Circadin®)|
1526496|NCT02768077|Drug|Placebo|
1526497|NCT02768064|Device|temporary pacemaker insertion|Insertion of pacemaker electrode (Medtronic flow direct pacing catheter), connect to external pacemaker (Medtronic).
1526498|NCT02768051|Procedure|AF Ablation|
1526500|NCT02768025|Other|Traditional & Complementary Medicine treatment|Body acupuncture, Ear acupuncture and aromatic therapy
1526501|NCT02768025|Other|NRT, counselling|Nicotine Replacement Therapy, counselling
1526503|NCT02767999|Drug|Fluoxetine|20 mg of fluoxetine capsule per day from D0 to D90
1526504|NCT02767999|Drug|Placebo|cellulose placebo per day from D0 to D90
1526505|NCT02767999|Radiation|fMRI|functional resting state MRI
1526506|NCT02767973|Other|Wood Smoke Particles (WSP)|After baseline (pre-exposure) assessment (which includes recovery of induced sputum), these volunteers will then undergo an exposure to 500μg/m3 wood smoke particles for 2 hours, with alternating 15 min of exercise (cycle ergometer) with 15 min rest to achieve 25 l/m2 body surface/min minute ventilation, followed by sputum induction after 6 and 24 hours after initiation of the challenge.
1526507|NCT02767947|Drug|Luliconazole Cream 1%|Cream
1526508|NCT02767947|Drug|Vehicle Cream|Vehicle Cream
1526511|NCT02767921|Other|Cytology Specimen Collection Procedure|Correlative studies
1526512|NCT02767921|Other|Laboratory Biomarker Analysis|Correlative studies
1526513|NCT02767921|Procedure|Radical Cystectomy|Undergo robotic-assisted radical cystectomy
1526514|NCT02767921|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
1526515|NCT02767921|Procedure|Therapeutic Conventional Surgery|Undergo robotic-assisted radical or partial nephrectomy
1526795|NCT02765867|Drug|RBP-6000|A single injection of RBP-6000 containing a low dose of buprenorphine in the Atrigel delivery system
1526516|NCT02767908|Other|Intervention|Participants will receive a tailored support package which will include; Nicotine replacement products, behavioural support, including telephone support, Carbon dioxide measurements, home air quality measurements, signposting to support groups, and self-help materials.For participants who decline a home visit, the above support options will be offered as far as possible through telephone contact and delivered to the extent accepted by the participant. Those who report cessation at 4 weeks and/or three months will be requested to agree to a home visit for CO validation.
1526517|NCT02767895|Behavioral|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
1526518|NCT02767882|Drug|Dexamethasone|Bolus injection of different dose of dexamethasone will be given intravenously prior to incision.
1526519|NCT02767882|Drug|Saline|Bolus injection of 4ml 0.9% saline will be given intravenously prior to incision.
1526520|NCT02767869|Drug|Banaba|Banaba capsules of 500 mg two times per day before meals with a total dosis of 1000 mg per day.
1526521|NCT02767869|Drug|placebo|Calcined magnesia capsule, 500 mg, two times per day before meals with a total dose per day of 1000 mg
1526522|NCT02767856|Device|IO-therapy Glasses|
1526523|NCT02767843|Device|continuous negative external pressure (cNEP)|soft silicone collar placed on the anterior neck, to which a negative pressure is introduced
1526524|NCT02767830|Behavioral|Excercise and Nutrition Program|
1526525|NCT02767817|Procedure|Stereotactic Hematoma Evacuation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and then the drainage tube was pulled out.
1526526|NCT02767817|Biological|MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas,and 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
1526527|NCT02767817|Biological|Injectable Collagen Scaffold with MSCs Transplantation|Stereotactic intracranial hematoma and insert the drainage tube to inhale haematoma. The drainage tube stayed in the position for 1-2 days until adequate drainage of hematomas, and injectable collagen scaffold combined with 10 million MSCs were transplanted into the hematoma cavity before the drainage tube was pulled out.
1526528|NCT02767804|Drug|X-396 (ensartinib)|oral ALK inhibitor
1526529|NCT02767804|Drug|crizotinib|oral ALK inhibitor
1526530|NCT02767791|Other|Acupuncture|Acupuncture
1526531|NCT02767791|Other|Auriculotherapy|Auriculotherapy
1526532|NCT02767778|Device|REAL Pulsed ELF-MF stimulation|Within 48 hours from the onset of the stroke, the enrolled patients will undergo to 120 min, daily, pulsed ELF-MF treatment for 5 consecutive days, during their hospital stay.Pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy) producing a single-pulsed signal at 75±2 Hz, with a pulse duration of 1.3 ms and a peak intensity of the magnetic field of 1.8±0.2 mT.
1526533|NCT02767778|Device|SHAM Pulsed ELF-MF stimulation|SHAM pulsed ELF-MF stimulation will be administrated by a rectangular, flexible coil, positioned upon the ischemic hemisphere and connected to the pulse generator (B-01; IGEA, Carpi, Italy). The device for SHAM stimulation is identical and produces the same auditory sensation of the device for REAL stimulation but the SHAM device has no stimulating effect on the brain.
1526534|NCT02767765|Drug|r-HuEPO|All participants will receive r-HuEPO for 4 weeks, at a dose of 10000 international units per day (IU/day) according to 6 days/week schedule for first 2 weeks and at a dose of 10000 IU/day according to 3 days/week schedule (participants with response to treatment at end of Week 2) or according to 6 days/week schedule (participants without response to treatment at end of Week 2) for next 2 weeks.
1526535|NCT02767752|Dietary Supplement|T-ChOS|
1526536|NCT02767752|Drug|Gemcitabine|
1526537|NCT02767752|Dietary Supplement|Placebo|
1526538|NCT02767752|Drug|Capecitabine|
1526539|NCT02767739|Behavioral|Physical, social and cultural activities|This intervention included two 60-min aerobic exercise sessions per week. Each session was supervised by a physical activity specialist and walking and stretching exercises were performed after programmed exercise sessions. PHC nurses were prepared to advise patients about the health benefits of PA and used different strategies to encourage the adherence of participants to the program. In addition, social and cultural support activities were included in this intervention program. These activities were performed once a month and they included: visits to museums and libraries, cultural exhibitions, tourist attractions and dance lessons.
1526540|NCT02767726|Device|non-invasive multimodal imaging|
1526541|NCT02767713|Drug|Dexamethasone|Intravenous dexamethasone (0.1 mg/kg) was administered 10 hours before surgery.
1526542|NCT02767713|Other|Placebo|Normal saline (placebo) in the equal volume as active treatment was administered 10 hours before surgery.
1526543|NCT02767700|Genetic|NGS|Next generation sequencing
1526544|NCT02767687|Other|Noninvasive ventilation|Twenty minutes after extubation all subjects will receive noninvasive ventilation delivered through a facial mask with an ICU ventilator with NIV option for 60 minutes. NIV associates pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O).
1526545|NCT02767674|Drug|Rituximab|375 mg/m2 IV day0
1526546|NCT02767674|Drug|Gemcitabine|Gemcitabine 1 g/m2 IV day 1
1526547|NCT02767674|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day1
1526548|NCT02767674|Drug|Cyclophosphamide|Cyclophosphamide 400 mg/m2 IV d1
1526549|NCT02767674|Drug|Doxorubicin|Doxorubicin 25 mg/m2 IV d1
1526550|NCT02767674|Drug|Vincristine|Vincristine 1 mg IVP d1
1526551|NCT02767674|Drug|Prednisone|Prednisone 40mg/m2 PO d1-5
1526552|NCT02767661|Drug|Capecitabine|Capecitabine, 625mg/m2, orally twice daily (continuously)
1526553|NCT02767661|Drug|Aromatase Inhibitor|Aromatase Inhibitor (Anastrozole, 1mg, orally once daily or Letrozole, 2.5mg, orally once daily or Exemestane , 25mg, orally once daily)
1526554|NCT02767648|Other|proteomic urine analysis|proteomic urine analysis
1526555|NCT02767635|Drug|Botox-Epic|injected 20 units of Botox into lateral epicondyle in Botox-Epic group
1526556|NCT02767635|Drug|Botox-Tend|injected 20 units of Botox into tender point of muscles in Botox-Tend group
1526559|NCT02767609|Device|Magnetic Resonance Imaging|All participants will have be given a MRI using a pseudo-continuous arterial spin labeling perfusion sequence.
1526560|NCT02767596|Drug|Lixisenatide|
1526561|NCT02767596|Drug|Basal insulins|patients are on basal insulin treatment
1526562|NCT02767583|Device|Exams|Patients the eligibility criteria will be proposed at the first consultation in central obesity, participate in a clinical study to assess the prevalence of subclinical damage peripheral nerves by simple and painless rapid measurement of skin conductance on the palm of the feet with the Sudoscan® device during the consultation and a Thermotest®, as well as monitoring during the various follow-up consultation after any bariatric surgery or not. This monitoring will be done by the same neurophysiological tests.
1526563|NCT02767570|Other|Gait Training; Altered Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with real-time, haptic feedback to encourage them to adopt a new foot progression angle. Participants will walk for an additional ten minutes per day to internalize their new foot progression angle over 52 weeks.
1526564|NCT02767570|Other|Gait Training; Consistent Foot Progression Angle|Participants will receive personalized gait training while walking on a treadmill with haptic feedback to encourage them to maintain a consistent foot progression angle. Participants will walk an additional ten minutes per day to internalize the consistency of their foot progression angle over 52 weeks.
1526565|NCT02767557|Drug|Tocilizumab|Intravenous infusion
1526566|NCT02767557|Drug|Gemcitabine|Intravenous infusion
1526567|NCT02767557|Drug|nab-Paclitaxel|Intravenous infusion,
1526568|NCT02767544|Procedure|Vaginal wound local analgesia after laparoscopic hysterectomy|
1526569|NCT02767531|Drug|Orlistat|Orlistat is a gastric and pancreatic lipase inhibitor that is approved by the FDA for weight loss. It is available over-the-counter as 60 mg tablets under the trade name Alli, and available by prescription as 120 mg capsules under the trade name Xenical.
1526570|NCT02767518|Behavioral|Prehabilitation|Participants will receive an informational DVD, a pedometer, an incentive spirometer and access to the program website to help promote healthful behaviors and improved well-being in the days leading up to surgery.
1526571|NCT02767505|Other|gastric bypass|Type of surgery: gastric bypass
1526572|NCT02767505|Other|Sleeve gastrectomy|Typ of surgery: sleeve gastrectomy
1526573|NCT02767492|Device|BioD Restore|Investigational product, BioD Restore, will be injected into the articular space of the knee.
1526574|NCT02767492|Drug|Kenalog|Active comparator, Kenalog steroid, will be injected into the articular space of the knee.
1526575|NCT02767479|Drug|rabeprazole-based regimen|This group is treated with rabeprazole 10 mg bid, AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
1526576|NCT02767479|Drug|esomeprazole^based regimen|This group is treated with esomeprazole 20 mg bid , AMPC 750 mg bid and CAM 200 mg bid for 1 week. Success or Failure of eradication of H. pylori is assessed by 13C-UBT 1 month after the treatment.
1526577|NCT02767466|Procedure|Physical therapy and robotic assisted gait training|
1526578|NCT02767453|Device|Hemovac Drain|A hemovac drain removes blood/fluid from a space created during a surgical procedure. Typically, surgeons place a plastic tube in the shoulder joint to drain fluids that may accumulate after surgery. Hemovac drain is a FDA-approved device routinely used or wound drainage; however, there is no known evidence whether this improves outcomes of surgery.
1526579|NCT02767453|Procedure|Total Shoulder Arthroplasty|Standard procedure for treating the severe pain and stiffness that often result at the end stage of various forms of arthritis or degenerative joint disease of the shoulder joint. The primary goal of shoulder replacement surgery is pain relief, with a secondary benefit of restoring motion, strength, function, and assisting with returning patients to an activity level as near to normal as possible.
1526580|NCT02767453|Device|Shoulder prosthesis|"Standard artificial device to replace both components of the ball and socket joint during TSA."
1526581|NCT02767440|Behavioral|Families on Track Intervention|Parents will receive the standard of care activities at the Healthy Lifestyles clinic at Duke University. They will also receive a modified version of the previously conducted Track intervention, a digital health weight loss intervention for adults in community health centers . The intervention will utilize the Interactive Obesity Treatment Approach (iOTA). iOTA uses a computer algorithm to assign 3 personalized behavioral goals known to create an energy deficit to produce weight loss (e.g., sugary drinks, fast food consumption walk 10,000 steps/day, etc). Participants will track these goals via interactive voice response (IVR) and text messaging technologies each week. They will receive immediate feedback based on self-monitoring data and skills training videos to learn how to make the behavioral changes necessary for weight loss. Intervention participants will also receive an analog bathroom scale and a pedometer to self-monitor daily weights and steps.
1526582|NCT02767427|Device|Chlorhexidine Wipes|(Standard of Care) Chlorhexidine wipes are a commonly used pre-operative skin cleansing measure, designed to reduce bacterial load on the skin of the surgical site.
1526583|NCT02767427|Other|No intervention|Chlorhexidine wipes will not be used though it is a commonly used pre-operative skin cleansing measure.
1526584|NCT02767414|Device|Respirio Flu Test|The Respirio Flu Test is a rapid in vitro diagnostic test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
1526585|NCT02767414|Device|eLab Flu Test|The eLab Flu Test is an in vitro diagnostic test intended to be used at point-of-care for the detection of influenza A or influenza B in nasopharyngeal swab samples. The eLab Flu Test generates a result within 10 minutes.
1526586|NCT02767414|Device|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
1526587|NCT02767401|Device|stenting or balloon expansion|all species of drug-eluting stent ((such as Xience, Endeavor, Taxus, Excel, Firebird) implantation or balloon expansion (POBA)
1526673|NCT02766738|Other|GrACE program|to compare with the GrACE + gait programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
1526588|NCT02767401|Drug|aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc|Optimal medical therapy includes dual antiplatelet therapy and statins (aspirin, clopidogrel, ticagrelor, atorvastatin, rosuvastatin, betaloc). And optimal medical therapy should include adequate ventricular rate-limiting medication (i.e. Beta-blocker or rate-limiting calcium antagonist) where appropriate. Anti-anginal therapy should be used if the patients have symptom.
1526589|NCT02767375|Drug|Oxaliplatin(OXA), 5-fluorouracil (5-FU)|for the HAIC treatment group OXA 85mg/m2, d1，0-4h 5-FU 1500mg/m2 d1, 4-24h 24 hours in d1 & 2 , IA，q4-6 Weeks
1526590|NCT02767375|Procedure|Hepatic arterial catheter implantation|for the the HAIC treatment group: Hepatic arterial catheter implantation for HAIC
1526591|NCT02767362|Drug|Atorvastatin|Once enrolled on this pre-operative window study, patients with endometrial cancer will be treated with the standard clinical dose of atorvastatin (80 mg once daily orally) for an average of 2-4 weeks prior to surgical staging. Patients will need to be able to undergo atorvastatin treatment for a minimum of 2 weeks but no more than a maximum of 4 weeks prior to surgical staging.
1526592|NCT02767349|Drug|MNK-155|2 or 3 tablets initial dose, followed by two tablets every twelve hours
1526593|NCT02767336|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
1526594|NCT02767323|Device|rTMS|excitatory 5Hz rTMS will be used
1526595|NCT02767323|Device|Sham rTMS|an electrical sham coil reproducing the same clicking sound and tactile sensation than the active rTMS will be used
1526596|NCT02767310|Drug|Rosuvastatin 20 mg film-coated tablets|Single oral dose of 20 mg
1526597|NCT02767310|Drug|Crestor 20 mg film-coated tablets|Single oral dose of 20 mg
1526598|NCT02767297|Drug|FDL169|
1526599|NCT02767284|Device|UCST-V1|A previously developed device, Uppsala Contrast Sensitivity Tester - UCST-V1, that quickly measures the human CSF in one stimulus.
1526600|NCT02767284|Device|UCST-V2|A refined version of the UCST-V1 that randomizes frequency order.
1526601|NCT02767284|Device|UCST-V3|A version that utilises eye-tracking technology to make the measurements more accurate.
1526602|NCT02767284|Device|Quick-CSF (QCSF)|A fast contrast sensitivity measurement method using a Bayesian algorithm.
1526603|NCT02767284|Device|Pelli-Robson|A standard method developed using a Sloan-letter chart with decreasing contrast.
1526604|NCT02767284|Device|Optec 6500|A standard test using sinusoidal gratings to measure the contrast sensitivity function.
1526605|NCT02767271|Drug|Luliconazole Cream 1%|Luliconazole
1526606|NCT02767258|Device|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
1526607|NCT02767258|Device|VIDISIC® GEL|Carbomer based gel, used in the treatment of dry eye.
1526608|NCT02767245|Drug|Thiamine|Thiamine IV 100 mg/day
1526609|NCT02767232|Drug|Recombinant tissue plasminogen activator (rt-PA)|Catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
1526610|NCT02767232|Drug|Standard Anticoagulation Therapy|Standard anticoagulation determined by physician for a period of 3-6 months
1526611|NCT02767219|Drug|bevacizumab|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 2 will receive a subconjunctival injection of bevacizumab and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given for 4 consecutive weeks from time of entry into trial.
1526612|NCT02767219|Drug|5-fluorouracil|Patients will be randomised to study arms with a 1:1 ratio. Once randomised, Group 1 will receive a subconjunctival injection of 5-fluorouracil and a subconjunctival injection of dexamethasone 3.3mg/ml. This will be given as required for 4 consecutive weeks from time of entry into trial. This is current standard practice.
1526613|NCT02767219|Drug|Dexamethasone|Both intervention groups will be given a subconjunctival injection of dexamethasone at the time of injection of either bevacizumab or 5-fluorouracil
1526614|NCT02767193|Biological|DCV3|"Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus.
Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4"
1526615|NCT02767193|Biological|DCV3 with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded pulsed with autologous inactivated HIV virus with PEG_INF Patients will receive three immunizations of dendritic cells during weeks 0, 2 and 4 and INF during weeks 4,5 and 6
1526616|NCT02767193|Biological|Placebo|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4
1526617|NCT02767193|Biological|Placebo with PEG-INF|Autologous differentiated adult dendritic cells from monocytes of peripheral blood non expanded with PEG_INF Patients will receive three immunizations saline + 1% albumin during weeks 0, 2 and 4 and INF during weeks 4,5 and 6.
1526618|NCT02767167|Other|Semi-skimmed cow's milk|430ml of semi-skimmed cow's milk / day for 12 weeks
1526621|NCT02767141|Behavioral|Coping Strategies|Coping strategies for households in the US with food insecurity
1526625|NCT02767115|Dietary Supplement|2% GSE mucoadhesive gel|2% GSE mucoadhesive gel administered in periodontal pockets of GSE group at T0 and 3, 6, and 9 days after T0
1526626|NCT02767115|Other|GSE free mucoadhesive gel|GSE free mucoadhesive gel administered in periodontal pockets of Control group at T0 and 3, 6, and 9 days after T0
1526627|NCT02767102|Other|Red wine with melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine rich in MLT (10 ng mL-1)
1526628|NCT02767102|Other|Red wine without melatonin|Twelve healthy volunteers will be recruited to receive both 125 mL of red wine without MLT
1526760|NCT02766127|Other|Universal Dentin Sealant|non-polymerizable, high molecular weight resin sealant
1526796|NCT02765854|Drug|Dexamethasone|Given PO
1526629|NCT02767089|Drug|Prednisone|Subjects will receive oral prednisone and/or placebo tablets (total of 4 tablets) to achieve the required dose according to the treatment sequence group they were randomized. Subjects are to be dosed each morning for 7 days. A 14 day washout period is required between each period. Prednisone was supplied in the 2.5 and 20 mg dosage strengths.
1526630|NCT02767089|Drug|Placebo|Placebo tablets similar to Prednisone 2.5 mg and 20 mg were supplied to make the trial doses.
1526631|NCT02767076|Procedure|conventional paramedian spinal anesthesia|land mark guided paramedian spinal anesthesia
1526632|NCT02767076|Device|ultrasound guided paramedian spinal anesthesia|real time ultrasound guided paramedian spinal anesthesia
1526633|NCT02767063|Drug|Pioglitazone|PIOGLITAZONE (Actos®): 30 mg per day for 12 months. The dose will be increased to 45 mg per day after 2 months in the absence of grade >1 related AE.
1526634|NCT02767037|Device|Sudoscan and clinical assessment|The primary variable will be electrochemical skin conductance (ESC), as assessed by the SudoScan (Impeto Medical, France). The clinical assessment will include a neurological evaluation (including MDS-UPDRS), evaluation of autonomic symptoms and signs, EKG, evaluation of possible neuropathy and evaluation of non-motor variables.
1526635|NCT02767037|Genetic|Skin biopsy|Evaluation of the denervation and synuclein deposition of skin biopsy
1526636|NCT02767024|Drug|Sodium nitroprusside|
1526637|NCT02767024|Drug|Dobutamine|
1526638|NCT02767024|Drug|Furosemide|
1526639|NCT02767011|Other|Tele-Health Electronic Monitoring (THEM)|Patients in the intervention group (THEM) will receive a tablet computer and home monitoring medical devices with sensors to transmit the information to a central website that will be monitored by care managers. Medical devices will include weight scales, blood pressure cuffs and blood glucometers. Clinical care mangers will remotely monitor the patients and all electronic readings. Clinical care managers will call or send text messages to the patients based on alerts generated by the tele-health monitoring system.
1526640|NCT02766998|Procedure|Preserved umbilical vein as shunt/conduit|All subjects will have umbilical vein harvested and stored for use in first cardiac surgery requiring shunt or conduit.
1526642|NCT02766959|Other|Observational study|
1526643|NCT02766946|Device|Ultrasound|An ultrasound of the right diaphragm will be performed on day 1, day 3, day 5 and day 10
1526644|NCT02766946|Device|Ultrasound|An ultrasound of the pectoral muscle will be performed on day 1, day 3, day 5 and day 10
1526645|NCT02766946|Other|Neuromyopathy score|A neuromyopathy score will be assessed on the extubation day
1526646|NCT02766946|Other|Respiratory performances|An assessment of the respiratory performances will be done on the extubation day, including higher expiratory pressure, higher inspiratory pressure, and occlusion pressure
1526647|NCT02766907|Device|cryopreserved amniotic membrane|placement of cryopreserved amniotic membrane after routine debridement procedure for EBMD
1526648|NCT02766894|Device|EEG monitoring|EEG will be performed. Data obtained will be analyzed using software. Anesthesiologists will enter their assumption in a blinded fashion and data obtained will be compared with EEG data
1526649|NCT02766868|Drug|FACE-Flu/Bu/Cy|Chemotherapy with Fludarabine+cytarabine+cyclophosphamide+etoposie followed by conditioning regimen with Fludarabine, busulfan and Cyclophosphamide
1526651|NCT02766842|Procedure|EUS-FNB with ProCore needle|The use of the standard ProCore needle to acquire diagnostic tissue
1526652|NCT02766842|Procedure|EUS-FNB with SharkCore needle|The use of new SharkCore needle to acquire diagnostic tissue
1526653|NCT02766842|Device|ProCore needle|This is the standard needle used currently to procure tissue from lesions under endoscopic ultrasound guidance
1526654|NCT02766842|Device|SharkCore needle|This is the new FDA approved needle for tissue procurement under endoscopic ultrasound guidance.
1526655|NCT02766829|Procedure|Cross leg sitting position|Subjects were set on cross leg sitting position before spinal anesthesia begun.
1526656|NCT02766829|Procedure|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
1526657|NCT02766816|Biological|Part 1 study - BBio bOPV|A single dose of 2 drops (0.1 ml) orally of BBio bOPV to 20 children 60 to 83 months of age.
1526658|NCT02766816|Biological|Part 2 study - BBio bOPV Lot 1|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 1 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
1526659|NCT02766816|Biological|Part 2 study - BBio bOPV Lot 2|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 2 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
1526660|NCT02766816|Biological|Part 2 study - BBio bOPV Lot 3|Three doses of 2 drops (0.1 ml) orally of BBio bOPV Lot 3 to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
1526661|NCT02766816|Biological|Part 2 study - Licensed bOPV|Three doses of 2 drops (0.1 ml) orally of a licensed bOPV to 270 infants at 6-8, 10-12 and 14-16 weeks of age.
1526662|NCT02766816|Biological|Part 1 study - Licensed bOPV|A single dose of 2 drops (0.1 ml) orally of a licensed bOPV to 20 children 60 to 83 months of age.
1526663|NCT02766803|Drug|Simvastatin and micronized trans-resveratrol|
1526664|NCT02766790|Dietary Supplement|TA-65MD|TA-65, a purified small molecule extracted from Astragalus root
1526665|NCT02766790|Other|Placebo|Placebo, an inactive formulation
1526666|NCT02766777|Drug|Lubiprostone|
1526667|NCT02766764|Drug|DHEA|Women will receive oral DHEA 25 mg t.d.s. for 12 weeks before ICSI.
1526668|NCT02766764|Drug|Growth hormone|Women will receive GH subcutaneous injections daily from day 6 of hMG administration until the day of hCG administration.
1526669|NCT02766764|Drug|Placebo 1|Women will receive an oral placebo similar to DHEA t.d.s for 12 weeks before ICSI
1526670|NCT02766764|Drug|Placebo 2|Women will receive subcutaneous placebo injections similar to GH daily starting from day 6 of hMG injections until the day of hCG injection
1526671|NCT02766751|Behavioral|HIVPASS|The 7-session HIVPASS intervention is provided to individuals randomized to the HIVPASS study arm.
1526672|NCT02766751|Behavioral|Health Education|The 7-sessions of Health Education is provided to individuals randomized to the Health Education study arm.
1526761|NCT02766127|Other|Clearfil Protect Bond|methacrylate-based resin, self-etching adhesive system
1526674|NCT02766738|Other|GrACE + gait|to compare with the GrACE programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention and control group
1526675|NCT02766725|Drug|preparation F12 sildenafil in situ gel|in situ vaginal gel
1526676|NCT02766725|Drug|preparation F2 sildenafil in situ gel|in situ vaginal gel
1526677|NCT02766725|Drug|placebo gel|vaginal gel
1526678|NCT02766712|Procedure|Pace During 1st Half of Lesion|
1526679|NCT02766712|Procedure|Pace During 2nd Half of Lesion|
1526680|NCT02766699|Drug|EGFR(V)-EDV-Dox|EGFR(V)-EDV-Dox using EnGeneIC EDV™ technology is a bacterially derived minicell which packages a toxic payload, Doxorubicin, into a 400 nm particle which targets specific cancer cells using bispecific antibodies (BsAb). BsAb-targeted, payload-packaged EDV nanocells only exit the leaky blood vessels associated with tumors and enter into the tumor microenvironment. The BsAb binds to the tumor cell-surface receptor, where the EDV is taken up, broken down within the cancer cell and releases the Doxorubicin. The residual EDVs that do not make it into the tumor microenvironment, are engulfed by cells of the immune system and since the EDVs are derived from bacteria, they carry potent immuno-stimulating components which appear to bypass the immuno-suppression caused by the tumor.
1526681|NCT02766686|Radiation|Radiotherapy with protons|
1526682|NCT02766686|Radiation|Radiotherapy with photons|
1526683|NCT02766673|Drug|Albuterol Sulfate|Subjects will receive a dose of study medication every 4 hours for 24 total hours
1526684|NCT02766673|Drug|Sterile Saline|Subjects will receive a dose of study medication every 4 hours for 24 total hours
1526685|NCT02766660|Device|Optical Coherence Tomography|All groups were measured by optical coherence tomography.
1526686|NCT02766647|Biological|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
1526687|NCT02766647|Biological|US-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection
1526688|NCT02766634|Biological|Filgrastim Hospira (US)|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
1526689|NCT02766634|Biological|U.S.-approved Neupogen®|5 micrograms/kilogram (ug/kg) subcutaneous (SC) injection once a day for 5 days
1526690|NCT02766621|Biological|PF-06823859|Comparison of different dosages of PF-06823859 to placebo
1526691|NCT02766621|Drug|Placebo injection SC/IV|Comparison of Placebo to different doses of PF-06823859
1526692|NCT02766608|Drug|BFF MDI 320/9.6 μg|Blinded Treatment
1526693|NCT02766608|Drug|BFF MDI 160/9.6 μg|Blinded Treatment
1526694|NCT02766608|Drug|FF MDI 9.6 μg|Blinded Treatment
1526695|NCT02766608|Drug|BD MDI 320 μg|Blinded Treatment
1526696|NCT02766608|Drug|Symbicort® TBH 400/12 μg BID|Open Label
1526697|NCT02766595|Other|hyperventilation while sitting up during routine EEG|Child will be asked to perform hyperventilation while lying down as well as while sitting up
1526698|NCT02766582|Drug|Pembrolizumab|IV every 21 days at 200 mg
1526699|NCT02766582|Drug|Carboplatin|IV every 21 days
1526700|NCT02766582|Drug|Paclitaxel|IV infusion (80mg/m2) every 21 days for 6 cycles
1526701|NCT02766569|Device|ASD closure with the Occlutech Flex II ASD closure device|Monitoring of possible device related side effects with a minumum of 1 year follow-up.
1526702|NCT02766556|Drug|dexmedetomidine|ISB with ropivacaine with dexmedetomidine or normal saline
1526703|NCT02766556|Procedure|ISB|ISB with ropivacaine with dexmedetomidine or normal saline
1526704|NCT02766556|Drug|Ropivacaine|ISB with ropivacaine with dexmedetomidine or normal saline
1526706|NCT02766530|Other|PETMR study|Use of PETMR study to evaluate the treatment response of breast cancer women
1526707|NCT02766517|Drug|Capsaicin|Administered topically
1526708|NCT02766504|Device|airway ultrasound|airway assessment using ultrasound
1526709|NCT02766491|Other|Strengthening and stretching|"Strengthening exercises will be performed 4 times a week for 10 weeks. Single leg heel raises will be the preferred exercise performed. The group of participants will have a wide range of strength and functional abilities, this will be accounted for with individualised programmes. The exercise load can be reduced by switching to bilateral heel raises, giving external support, reducing the range of motion or performing the heel raises while seated. Exercise load will be progressively increased by adding weight in the form of water bottles to a rucksack worn on the participant's back.
For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
1526710|NCT02766491|Other|conventional stretching|"This group will perform seated biceps curls 4 times a week for 10 weeks, where extra load can be added progressively by holding water bottles in the hand.
For the final six weeks of the intervention, stretching exercises of the calf muscles will be performed."
1526713|NCT02766465|Drug|Busulfan|Busulfan dose will be 3.2 mg/kg administered as a single daily dose IV on days -8 through -5 with dosing adjusted using targeted pharmacokinetics.
1526714|NCT02766465|Drug|Fludarabine|Fludarabine dose will be 35 mg/m^2/day administered IV on days -7 through -3 (total fludarabine dose is 175 mg/m^2).
1526715|NCT02766465|Drug|r-ATG|r-ATG will be administered IV on day -6 at 0.5mg/kg, on day -5 at 1 mg/kg and on days -4, -3 and -2 at 1.5mg/kg (total r-ATG dose is 6 mg/kg).
1526716|NCT02766465|Procedure|Bone Marrow Transplant|Day 0 is the day of bone marrow transplantation.
1526717|NCT02766465|Drug|Tacrolimus|Tacrolimus commences on day -3 and extends through day +180 after transplantation with doses adjusted to maintain appropriate levels according to institutional guidelines.
1526718|NCT02766465|Drug|Methotrexate|Methotrexate will be administered intravenously on day+1 at 15mg/m^2, day+3 at 10mg/m^2, day+6 at 10mg/m^2, and day+11 at 10mg/m^2.
1526719|NCT02766465|Procedure|Standard of Care|Continue to receive standard of care treatment per patient's SCD physician.
1526720|NCT02766452|Behavioral|"You and your child in the recovery room DVD"|
1526762|NCT02766127|Other|Flor-Opal® Varnish|fluoride-based varnish
1526721|NCT02766452|Behavioral|Standard pre-operative preparation|Attendance to the Pre-anesthetic assessment clinic to meet with registered practical nurse and anesthesiologist (physical assessment and medical history). Completion of the Surgery Virtual Tour.
1526722|NCT02766439|Drug|etanercept|25-mg etanercept injection subcutaneously twice a week
1526723|NCT02766426|Behavioral|Lifestyle change program|"Women attended a multidisciplinary counseling (by both the dietitian and the gynecologist). They were given nutritional advice about lifestyle and physical activity, in agreement with the Italian Guidelines for a healthy diet during pregnancy. The diet given comprised 1500 kcal/day and consisted of 3 main meals and 3 snacks (breakfast, snack, lunch, snack, dinner, and evening snack) that corresponds to the baseline metabolism of a pregnant woman. In view of the physical activity program, the dietitian added an amount of 200 kcal/day for obese or 300 kcal/day for overweight women.
The exercise intervention was focused on increasing walking and developing a more active lifestyle. The recommendation for physical activity was to perform 30 min of moderate intensity activity at least 3 days a week."
1526724|NCT02766400|Behavioral|Guided Training|
1526725|NCT02766400|Behavioral|Directed Training|
1526726|NCT02766387|Other|Evaluation of the correlation between walking speed in the 6MWT and in 2MWT, and the walking speed observed in the continuous 2km walk test and in the 10 meters walk test.|
1526727|NCT02766374|Behavioral|Heart rate variability biofeedback|"Biofeedback teaches voluntary control of physiological functions by providing instantaneous feedback of variations in that bodily activity. Feedback usually is given in the form of visual and/or auditory signals derived from physiological recording devices. Among its salutary effects is a sense of medical self-efficacy, i.e., less dependency on medical professionals for maintaining personal health.
The HRV-BF protocol we have developed and propose to examine herein works by a different pathway. It involves teaching the individual to increase the amplitude of heart rate accelerations during inhalation and de-celerations during exhalation, thus increasing the amplitude of respiratory sinus arrhythmia (RSA)."
1526728|NCT02766374|Behavioral|Placebo|"The method consists of: 1) receiving EEG/music biofeedback (actually, a mildly relaxing intervention, using EEG biofeedback to alternately increase and decrease frontal/occipital EEG alpha rhythms while listening to relaxing music), and 2) listening to recorded sounds of nature along with relaxing music with instructions to maintain a condition of relaxed alertness. For home training, subjects will be given placebo StressEraser programmed to give feedback to maintain their breathing at baseline rate."
1526731|NCT02766348|Drug|gemcitabine|gemcitabine 1000mg/m2 IV on day 1 an day 8, repeat every 3 weeks
1526732|NCT02766348|Biological|DC-CTL|8×10^9 DC-CTL cells for each infusion, IV(In the vein) for 3 cycles, each cycle received four infusions on day 14,16,30 and 32
1526733|NCT02766348|Drug|cisplatinum|cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
1526734|NCT02766335|Drug|Docetaxel|Given IV
1526735|NCT02766335|Biological|Durvalumab|Given IV
1526736|NCT02766335|Other|Laboratory Biomarker Analysis|Correlative studies
1526737|NCT02766322|Other|Oral Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
1526738|NCT02766322|Other|Oral Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
1526739|NCT02766322|Other|Intravenous Alcohol Challenge Test (Clamp)|Subjects will be evaluated with an alcohol clamp (i.e. alcohol will be infused intravenously until reaching 60mg/dl and this blood alcohol concentration will be kept constant for two hours). We will record subjective responses to alcohol throughout different times of the clamp.
1526740|NCT02766322|Other|Intravenous Alcohol Self-administration Test|"Subjects will be asked to press a button (work) to receive either a drink or saline through an IV catheter. The amount of alcohol infused after earning their reward will be based on their body composition and will raise their blood alcohol level by 10 mg/dl (eight time less than the legal limit for driving). We will set a safety limit to 150 mg/dl so that subjects will not be allowed to work for alcohol until their blood alcohol levels go below that limit."
1526741|NCT02766309|Other|Sf12-v2|structured questioner Sf-12v2, developed by Ware.et al (Ware, Kosinski, Turner-Bowker & Gandeck, 2002).
1526742|NCT02766296|Behavioral|Active Emotional Working Memory Training|This training regimen has adapted the existing n-back paradigm, which has been widely used in the field. Training requires participants to shift between visual and auditory information while continually updating their working memory.
1526743|NCT02766296|Behavioral|Control Working Memory Training|This training utilized a fixed dual 1-back training paradigm.
1526745|NCT02766270|Drug|Temozolomide|RT with daily temozolomide (75 mg/m2/day, 7 days/week for up to 7 weeks) and adjuvant temozolomide (150-200 mg/m2 PO QD for 5 days, repeats every 28 days for up to 12 courses).
1526746|NCT02766270|Radiation|Radiotherapy|
1526747|NCT02766257|Procedure|Anesthesia for ambulatory paediatric surgery|
1526748|NCT02766244|Device|ICG/SPY|indocyanine green fluorescence imaging
1526749|NCT02766244|Drug|Antibiotic Ointment|Antibiotic ointment
1526750|NCT02766231|Device|Physica CR|Cruciate tretaining total knee replacement
1526751|NCT02766231|Device|Physica PS|Posterior Stabilized total knee replacement
1526752|NCT02766192|Drug|Ketamine|
1526753|NCT02766192|Behavioral|TIMBER Psychotherapy|
1526754|NCT02766192|Drug|Placebo (normal saline)|
1526757|NCT02766140|Drug|SHR1020 plus Docetaxel|SHR1020 20mg qd 2-21days, Docetaxel 60 mg/m^2 IV Day1/3weeks
1526758|NCT02766140|Drug|Placebo plus Docetaxel|Placebo matching SHR1020 qd 2-21days, Docetaxel 60 mg/m^2 IV Day1/3weeks
1526759|NCT02766127|Other|Veritise Flow|Self-adhering composite
1526763|NCT02766114|Procedure|Carpal tunnel release through Mini Transverse Approach|Carpal tunnel release through a transverse cosmetic small incision over the distal wrist crease.
1526764|NCT02766101|Behavioral|Aerobic Exergaming PE Curriculum|Sustained aerobic exercise.
1526765|NCT02766101|Behavioral|Standard PE|Non-aerobic skill building.
1526766|NCT02766088|Procedure|Blood sample collection|All participants will have an enrolment visit with collection of a blood sample and a termination contact/visit. Participants or their parents/guardians will be contacted weekly or every two weeks to monitor the occurrence of febrile episodes. Additional visits will be made if febrile episodes occur. In case of dengue suspicion, a blood sample will be collected.
1526767|NCT02766075|Behavioral|Supervised TAVR Exercise Program|Individualized exercise program designed and implemented by licensed physical therapy clinicians in three 60-minute sessions per week for four weeks. Upon randomization, subjects in the Intervention Group will undergo an initial Dynamic Gait & Balance Assessment by a licensed physical therapy clinician. The physical therapy clinician will use this assessment to design and implement an individualized STEP in three 60-minute sessions per week for four weeks. Subjects will proceed with their pre-TAVR testing in conjunction with the STEP sessions.
1526769|NCT02766049|Biological|DC|Autologous dendritic cells (3x10e7)
1526770|NCT02766049|Biological|DC10e6+HIV-AT2|Autologous dendritic cells (3x10e6), pulsed with chemically inactive autologous HIV
1526771|NCT02766049|Biological|DC10e7+HIV-AT2|Autologous dendritic cells (3x10e7), pulsed with chemically inactive autologous HIV
1526772|NCT02766036|Drug|Propolis|Patients will receive 500 mg / day of the propolis extract in the form of tablets split in two daily doses
1526773|NCT02766036|Drug|Placebo|Patients will receive 500 mg / day of the propolis-placebo extract in the form of tablets split in two daily doses
1526777|NCT02766010|Device|TensorTip|Non Invasive screening of various physiological and hematological parameters.
1526778|NCT02765997|Biological|Unmanipulated UCB|Unmanipulated UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen [G-CSF] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
1526779|NCT02765997|Biological|SR-1 UCB|SR-1 UCB infusion given on Day 0. All patients will receive the same conditioning and immunoprophylaxis for the prevention of acute and chronic GVHD, previously demonstrated to offer the best outcomes in recipients of partially HLA matched UCB. Standard supportive care, including the use of Neupogen [G-CSF] and prophylactic anti-bacterial, protozoal, viral and fungal agents, will also be prescribed. Supportive care will be modified throughout the transplant course at the treating physician's judgement.
1526780|NCT02765984|Device|Transvaginal ultrasound|transvaginal ultrasound done before 10 weeks gestational age measuring the distance between the lower end of the hyperechoic trophoblast ring of the gestational sac and the inner cervical os
1526781|NCT02765971|Other|gums|Group A, 180 women will receive sugarless gum after their operating room discharge by 3 hours for at least half an hour at two hours interval.
1526782|NCT02765971|Drug|picolax drops|Group B, 180 women will receive laxatives after their operating room discharge by 3 hours.
1526783|NCT02765971|Drug|normal saline|Group C received 500 cc of normal saline, Intravenous fluid
1526784|NCT02765958|Device|portable ECG devise|
1526785|NCT02765945|Other|Supervised exercise program|Subjects were enrolled in a hospital-based wellness center where, after analysis of their medical history and previous levels of physical activity ands documentation of a normal exercise stress test, they chose individually tailored exercise programs
1526786|NCT02765932|Procedure|Dummy Movements|The placebo group will be asked to perform the same touch technique and count backwards from 50 while removing petals from a flower. Patients will also perform these techniques before rehab and sleep.
1526787|NCT02765932|Procedure|Psychosensory Therapy|The research assistant will administer one of the several psychosensory touch techniques prior to surgery. This will involve the touching of upper arms, palms, and a visualization process. This will last no longer than 10 minutes. These techniques will also be performed by the patients prior to any rehab sessions and before going to sleep. The patients will be asked to perform these touch techniques with the eyes closed and imaging having no pain. The patients will also be asked to keep a record of all medications.
1526788|NCT02765919|Radiation|HDR Brachytherapy of 9 Gy in 2 fractions|Two fractions of HDR brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
1526789|NCT02765919|Radiation|HDR Brachytherapy of 7 Gy in 3 fractions|Three fractions of HDR Brachytherapy following standard dose CCRT in locally advanced carcinoma cervix
1526790|NCT02765906|Other|Graphic card|A randomized controlled trial comparing patient education on preeclampsia with a graphic card vs. patient education with a written pamphlet vs. no patient education showed that patient education improved significantly when patients were provided with a graphic card depicting signs and symptoms of preeclampsia and that this improvement occurred regardless of health literacy score (You WB, Wolf MS, Bailey SC, Grobman WA. Improving patient understanding of preeclampsia: a randomized controlled trial. American Journal of Obstetrics & Gynecology. 2012;206:431.e1-431.e5.). The graphic card is now available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/market-place/educational-illustrated-signs-symptoms-pad-detail).
1526791|NCT02765906|Other|Video|This an informational video available on the Preeclampsia Foundation's website (http://www.preeclampsia.org/component/allvideoshare/video/featured/7-symptoms-every-pregnant-woman-should-know?Itemid=479). The effectiveness of this video has not yet been tested as an educational tool.
1526793|NCT02765880|Other|fMRI|
1526800|NCT02765828|Other|Observational study|The following exams will be done in all cohorts: tongue manual muscle testing (MMT), tongue quantitative muscle testing, tongue ultrasound measurements
1526801|NCT02765815|Drug|Liposomal bupivacaine, 266mg|
1526802|NCT02765815|Drug|Bupivacaine 0.5 % with Epinephrine|
1526803|NCT02765815|Drug|Ketorolac 30mg|
1526804|NCT02765815|Drug|Morphine 10mg|
1526805|NCT02765815|Drug|Bupivacaine 0.25% with Epinephrine|
1526806|NCT02765802|Drug|Lambda|
1526807|NCT02765789|Device|Immunoadsorption (Immunosorba)|
1526808|NCT02765776|Other|Observational retrospective cohort to describe RAL data|"This is an observational retrospective cohort in real world to describe RAL data, including NUC-sparing regimens, in aged HIV patients.
In this retrospective analysis all naïve patients on raltegravir-based regimens and all patients switched to raltegravir-based regimens will be considered. For raltegravir-based regimens the investigators mean raltegravir as third agent in a triple regimen with NRTIs and also raltegravir-based regimens in NUC-sparing therapies. Data will be collected from medical records. The Time horizon for patient follow-up for outcome is at least 12 months."
1526809|NCT02765763|Drug|2-Minute Reveal Masque|
1526810|NCT02765763|Drug|24/7 Barrier Repair Cream|
1526811|NCT02765763|Drug|8-in-1 BioSerum|
1526812|NCT02765763|Drug|Null Formula 2-Minute Reveal Masque|
1526813|NCT02765763|Drug|Null Formula 24/7 Barrier Repair Cream|
1526814|NCT02765763|Drug|Null Formula 8-in-1 BioSerum|
1526815|NCT02765750|Behavioral|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 40-60."
1526816|NCT02765750|Behavioral|Intraoperative positive messages|"The message You are in the operating room. Everything is going very well. When you wake up you will be very calm, you will not feel pain and you will not have nausea will be played in greek language by headphones to the patient when the Bispectral Index (BIS) is 20-40."
1526817|NCT02765750|Behavioral|No message|The headphones will be placed on patient's ears but no message will be played.
1526818|NCT02765737|Other|Dehydrated Human Amnion/Chorion Membrane|Dehydrated human amnion/chorion membrane (dHACM) product and is regulated as a Human Cells, Tissues and Cellular and Tissue Based Product (HCT/P) under Section 361 of the Public Health Service Act by the Food and Drug Administration (FDA).
1526819|NCT02765737|Device|Mepilex Ag|
1526820|NCT02765724|Drug|Pacritinib|Pacritinib 400 mg (4 capsules of 100 mg each), single dose, oral administration
1526821|NCT02765685|Device|brace ODRA (PROTEOR company)|Port of the orthosis ODRA during day during 12 months, Complement to their usual care. The subjects will have for instruction to wear the brace a minimum of 6 hours a day, 5 days a week, And to remove it during the rest periods in lengthened position.
1526822|NCT02765685|Other|Usual care|"The patients will benefit only from the coverage proposed usually, by their regular doctor and according to the notices of the medical and paramedical specialists taking care of this pathology (physiotherapists, orthopaedic osteopaths, sports medicine physician, surgeon, rheumatologists, rehabilitative doctors, etc.). In the absence of recommendations on the modalities of coverage of the gonarthrose and in front of diverse clinical habits, the usual said coverage can be at the same time medicinal (anti-inflammatory, painkilling, …), non-medicinal (physiotherapy, port of an orthosis, …), even surgical, according to the influencers."
1526823|NCT02765672|Behavioral|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
1526824|NCT02765672|Other|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Mini-Mental State Examination (MMSE) and Strength tests. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
1526825|NCT02765672|Behavioral|Propensity for Angry Driving Scale|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
1526826|NCT02765672|Behavioral|Community Integration Questionnaire|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1)
1526827|NCT02765672|Behavioral|Satisfaction with Life|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test 1
1526828|NCT02765672|Behavioral|Fitness-to-Drive Screening Measure (FTDS)|Fitness-to-Drive-Screening Measure will be completed twice, at baseline and at end of study
1526829|NCT02765672|Procedure|Simulated Driving Evaluation|This involves driving a simulator fitted simulated drives engineered to to address Veteran's driving concerns such as reactions to other drivers and road conditions(e.g. debris). The simulator is used at baseline and at post-test1 and 2. The intervention and traffic safety education session 3 also occurs using the driving simulator.
1526830|NCT02765672|Procedure|Driving Safety Education|This involves the following: Session1: general traffic safety discussion; Session 2: Rules of the road and acknowledgement of the road discussion and Session 3: driving the simulator without any feedback from traffic safety professional
1526831|NCT02765672|Procedure|Occupational Therapy Driving Intervention (OT-DI)|This has three sessions: 1. Driving evaluator reviews explicit driving errors with Combat Veteran; 2. driving evaluator provide tailored strategies to mitigate errors; Combat Veteran drives simulator with targeted feedback from driving evaluator.
1526832|NCT02765672|Procedure|On-road driving test|This involves and on-road driving test supervised by Driving Rehabilitation Specialist. To be completed at baseline and at month 5
1526833|NCT02765672|Procedure|Driving triggers evaluation|The simulator-drives evaluation group will evaluate the current simulator-triggers prior to baseline testing
1526834|NCT02765659|Behavioral|Mzake ndi Mzake T1|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after baseline
1526835|NCT02765659|Behavioral|Mzake ndi Mzake T2|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T2 evaluation
1526836|NCT02765659|Behavioral|Mzake ndi Mzake T3|a 6-session peer group intervention focusing on primary HIV prevention and early testing and entry to treatment for secondary prevention - offered immediately after post-T3 evaluation
1526839|NCT02765620|Other|drug&radiation|"Early treatment response assessment: using baseline data and early follow-up data
Evaluate treatment response: using baseline data, early follow-up data and final data
Compare PERCIST to RECIST criteria: correlation analysis
Evaluate prognostic value: using baseline data, early follow-up data, final data as well as follow up PFS and OS time (Kaplan-Meier survival plot)"
1526840|NCT02765607|Procedure|Heart surgery|
1526841|NCT02765594|Drug|Hydroxychloroquine Sulfate|200mg bid
1526842|NCT02765594|Drug|Valsartan|160mg qd
1526843|NCT02765581|Device|Verum acupuncture|"The main acupuncture points are bilateral Hegu (L14) and Taichong (LR3), unilateral Taiyang(EX-HN5), Fengchi (GB20) and Shuaigu (GB8). Additional points can be chosen according to individual syndrome differentiation of meridians: (1) Yangming headache: Touwei (ST8); (2) Taiyang headache: Tianzhu (BL10); (3) Jueying: Baihui (GV20). The NO.16 special type of acupuncture (0.30 x 30 mm) produced by German asia-med company will be applied.The needles will be inserted into the skin of acupuncture points and manipulated manually by using the techniques such as lifting, thrusting, and twirling, until the internal compound sensation known as deqi."
1526844|NCT02765581|Device|Sham acupuncture|"We use a non-insertive sham control produced by Asia-med Company in Germany—the streitberger placebo-needle. Sham points are described as follows: 1) Bilateral of midpoint between acupoint Jianjin(GB21) and Jugu(LI16); 2) 5 cun lateral to the seventh thoracic spine; 3) 5 cun lateral to the eighth thoracic spine; 4) 5 cun lateral to the ninth thoracic spine. Cun is a distance measure unit used in locating acupoints in traditional Chinese medicine (TCM) acupuncture, and the width of patient's thumb interphalangeal joint is regarded as one cun."
1526845|NCT02765581|Behavioral|Usual care|Health education is provided in three aspects: lifestyle changes, behavioral therapies and migraine self-management.
1526846|NCT02765568|Behavioral|High Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks
1526847|NCT02765568|Behavioral|Moderate Intensity Continuous Exercise Training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
1526848|NCT02765568|Behavioral|Nordic Walking|Participants will complete supervised exercise sessions. Participants will attend on-site Nordic walking training two times weekly for 12 weeks
1526849|NCT02765555|Drug|RBP-7000|Single dose
1526850|NCT02765542|Other|Automated disease assessment & self-care support phone calls|Automated disease assessment & self-care support phone calls for up to 12 weeks.
1526851|NCT02765529|Procedure|Blood sampling|
1526852|NCT02765516|Other|Plant sterols|2.0g/day of plant sterols incorporated into margarine to be consumed for 28 days
1526853|NCT02765516|Other|Placebo|Identical margarine without additional plant sterols to be consumed for 28 days
1526854|NCT02765503|Radiation|External beam radiotherapy|External beam radiotherapy using megavoltage radiotherapy with radical intent.
1526855|NCT02765490|Drug|AL-335|AL-335 800 mg (2*400) tablet will be administered once daily.
1526856|NCT02765490|Drug|Odalasvir|Odalasvir 25 mg tablet will be administered once daily.
1526857|NCT02765490|Drug|Simeprevir|Simeprevir 75 mg capsule will be administered once daily.
1526858|NCT02765451|Behavioral|interventions of the Cancéropôle Nord-Ouest|"During the time defined by the randomization, the Cancéropôle Nord-Ouest offers to help to develop a clinical research activities in the centers. The various aids are : Structuring clinical research at the local level, Support (strategy, logistics, technical, Data management, methodology), a portfolio of straightforward studies ( French National Cancer Institute, cooperative groups conducting cancer clinical research, New Project), Good Clinical Practice training, Clinical research technician, Others,....."
1526859|NCT02765438|Device|BOBO|"Each subject will play four games with the BOBO system."
1526860|NCT02765425|Device|AMES|Subjects will be trained while seated on the AMES device. As the footplate of the device rotates the ankle ±15 deg in dorsiflexion and plantarflexion, the participant will assist that motion. Vibration (2-3 mm at 60 pulses/s) will be applied to the tibialis anterior tendon during plantarflexion and to the Achilles tendon during dorsiflexion. To assist participants in the assisted movement task, the AMES biofeedback screen will provide real-time visual feedback of the volitional ankle torque that the participants actively apply to the AMES device. Each training session will include 15 min of training of each ankle; training sessions will be conducted 3 times/week over a 12-week period, for a total of 9 hours of training on each ankle.
1526861|NCT02765412|Other|Webinar, Promotion, and Tool Access|All sites will receive a professionally developed, 15-minute webinar that describes the tool's development (e.g., how the algorithm was designed) and a tutorial on how to use the web-site. The investigators will promote the webinar and using the tool through key local leaders. A web-link to use the tool will be placed within the lung cancer screening clinical reminder.
1526862|NCT02765412|Other|LEAP|Sites randomized to intensive implementation will be offered participation in the LEAP program. LEAP (Learn. Engage. Act. Program) is a multi-week, online learning collaborative using systems redesign techniques to help sites identify and overcome barriers to implementation of shared decision making (use of the Decision Precision tool).
1526863|NCT02765412|Other|Audit and Feedback|Providers at all sites will have access to this system. It will provide feedback on the screening and shared decision making process (e.g., number of provider's eligible patients screened for lung cancer, use of the tool, patient knowledge and satisfaction from patient surveys).
1526864|NCT02765399|Drug|Liraglutide|
1526865|NCT02765399|Drug|Placebo|
1526866|NCT02765386|Device|Hybrid fittings for cochlear implant recipients|
1526867|NCT02765373|Drug|Exemestane|
1526868|NCT02765373|Drug|Letrozole|
1526869|NCT02765373|Drug|Anastrozole|
1526870|NCT02765360|Other|Treatment Group|"Participants will be established on the randomised mode of ventilation and will have continuous assessment of the following during the assessment period:
Electrical impedance tomography
EMGpara
SpO2
tcCO2
Pneumotachography
End-tidal CO2 monitoring"
1526983|NCT02764593|Radiation|IMRT|High-precision radiotherapy
1526873|NCT02765334|Device|nBETTER|60 minutes of nBETTER training followed by 30 minutes of conventional therapy occupational therapy. Total of 18 sessions over 6 weeks.
1526874|NCT02765321|Behavioral|Healthy lifestyle promotion|Healthy lifestyle changes (i.e., increase in physical activity levels and improvement in eating habits) will be promoted via population-based counselling through media (i.e., radio, newspapers, magazines, television, banners), cell phone applicative, workshops, specific programs at schools and companies, and community physical activity programs.
1526875|NCT02765295|Device|medical ultrasonic hydrogen/oxygen nebulizer (MUNHO)|The medical ultrasonic nebulizers with hydrogen/oxygen generating function (MUNHO) will be provided exclusively by the sponsor, Asclepius Meditec Inc (Shanghai, China). The MUNHO consists of a electrolytic tank which, by using direct current converted from alternating current (220 V), generates the hydrogen and oxygen gas from pure water (2:1 in volume). The MUNHO is also capable of nebulizing the water via ultrasounds with the hydrogen-oxygen mixed gas which is finally delivered to the patient's airways via the facial mask through a plastic tube. Typically, the volume of hydrogen-oxygen mixed gas is 3 liters per minute (3 L/min).
1526876|NCT02765295|Device|Medical molecular mesh oxygen generator|"medical molecular mesh oxygen generator, type: OLO-1, oxygen flow: 3L/min; Shanghai Ouliang Medical Instrument Inc., Shanghai, China; Registration No.: Shanghai Medical Instrument approval No. 20152540046.
This device has an identical appearance as compared with the MUHNO so that the patients could not readily discriminate with the MUHNO, and is also capable of displaying the actual cumulative duration of oxygen inhalation."
1526877|NCT02765282|Device|Algorithm based programming using Kinesia-based assessment|DBS-Expert includes a tablet-based software application (app) for guiding DBS programming and a Kinesia motion sensor unit for automated motor assessment. Algorithms search the programming parameter space to resolve an optimal set of programming parameters.
1526878|NCT02765269|Device|Intelligent Pain Management System|A mobile phone application which can record the pain the cancer patients have and can deliver these records to doctors in order that doctors give patients prescriptions promptly.
1526885|NCT02765243|Biological|Anti-GD2 CART|Anti-GD2 4th Generation Chimeric Antigen Receptor-modified T Cells
1526886|NCT02765217|Drug|Lactobacillus reuteri DSM 17938|Comparison the effects of L. reuteri and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on efficacy.
1526887|NCT02765217|Drug|Placebo|Comparison the effects of L. reuteri and placebo for prevention of antibiotic associated diarrhea and also plan to compare the duration of treatment for on
1526888|NCT02765217|Drug|Amoxicillin-Clavulanic Acid|All study patients will received amoxicillin-clavulanic acid at the dose of 50-90 mg/kg/day.
1526889|NCT02765204|Drug|Dapagliflozin|
1526890|NCT02765204|Drug|Saxagliptin|
1526891|NCT02765204|Drug|Glucose|
1526894|NCT02765178|Other|Children's Motivation Scale|A 16-item questionnaire to evaluate level of motivation in children and adolescents completed by the primary caregiver.
1526895|NCT02765178|Other|Yale Global Tic Severity Scale (YGTSS)|Clinician administered questionnaire given to Tourette patients. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
1526896|NCT02765178|Other|Studies Depression Scale for Children (CES-DC)|"Clinician administered questionnaire given to Tourette patients. Consisting of 20 items, respondents are asked to indicate how strongly they have felt a certain way during the past week using a Likert-type scale that ranges from not at all to a lot. Only two items on the questionnaire relate specifically to sleep or fatigue. CES-DC is a validated score for assessing depression in children and adolescents"
1526897|NCT02765178|Other|Gilles de la Tourette Syndrome Quality Of Life scale|Clinician administered questionnaire given to Tourette patients. Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL) is a recently validated score for the assessment of quality of life in patients with Tourette syndrome. Consisting of a 27-item GTS-specific HR-QOL scale (GTS-QOL) with four subscales (psychological, physical, obsessional, and cognitive).
1526898|NCT02765178|Other|Demographic Data|Data will be collected including: age, age at disease onset, gender, current medication regimen and presence of co-morbidities (like a diagnosis of ADHD, OCD, depression or insomnia).
1526899|NCT02765165|Drug|USL311|Administered once weekly in a 21-day cycle
1526900|NCT02765165|Drug|USL311|Administered once weekly in a 42-day cycle
1526901|NCT02765165|Drug|Lomustine|Administered once every 6 weeks in a 42-day cycle
1526902|NCT02765152|Other|Conventional Physical Therapy|Combination of joint mobility exercises, specific exercises for muscle strength and motor coordination exercises, unilateral and bilateral motor tasks as well as task-oriented training of the upper limb with a focus on functional tasks. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week)
1526903|NCT02765152|Other|Discrete movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The starting point of the movement and its target are predetermined. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
1526979|NCT02764606|Biological|Serum and plasma samples|Serum and plasma are collected at time of diagnosis, after surgery, and at time of progression to evaluate the value of new serum markers to predict the occurrence of metastases.
1526980|NCT02764593|Drug|Nivolumab|Anti-PD-1 targeted immunotherapy
1526981|NCT02764593|Drug|Cisplatin|Anti-cancer alkylating agent
1526904|NCT02765152|Other|Rhythmic movement training group|Aiming movements training with the affected upper limb (unilateral training) or both limbs (bilateral training) on the surface of a table. The movement begins in a predetermined starting point, directed to a target and returns to the starting point. This activity is performed several times with rhythmic movements. Targets will be placed in different directions and distances from the starting point and the therapist ask for variations on speed and assistance, if necessary.
1526905|NCT02765139|Behavioral|Engaging Men through Accountable Practice|Engaging Men through Accountable Practice aims to engage men as agents of change through structured, weekly discussions with committed groups of men. It aims to address entrenched views of gender roles and identify positive models of masculinity. The approach follows a structured series of discussions designed to explore existing understandings of masculinity and create more positive models of what it means to be a 'good' man, promoting self-reflection and pushing men to analyze and change their own power and privilege. This methodology begins with a series of discussions with women to inform men's dialogue groups, and includes continuous feedback loops with women throughout the process so that the work with men is grounded in, and accountable to, women's views and objectives.
1526906|NCT02765139|Other|Alternative intervention|Control communities will receive an alternative intervention focused on a non-gender topic of 16 weekly sessions for men only.
1526907|NCT02765126|Biological|Seasonal influenza vaccine|Intramuscular standard seasonal influenza vaccine
1526908|NCT02765126|Biological|Diphtheria-tetanus-acellular pertussis vaccine|Intramuscular DTaP vaccine
1526909|NCT02765113|Procedure|Facial nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.
MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
1526910|NCT02765113|Procedure|Facial and Trigeminal nerve combing|"Facial nerve combing:To sort out the facial nerve using the nerve combing knife.
Trigeminal nerve combing:To sort out the trigeminal nerve using the nerve combing knife.
MVD: explore the facial nerve and trigeminal nerve and then perform microvascular decompression."
1526911|NCT02765100|Drug|Minocycline|In various models of neurodegenerative disease, minocycline has demonstrated neurorestorative as well as neuroprotective properties.
1526912|NCT02765087|Other|Medical History|Oriented Survey and complete physical exam.
1526913|NCT02765087|Device|E-Nose|Patient will breath trough the device for 5 minutes, and during and after the intervention will be assessed for adverse effects related to the use of the e-Nose, according to the CTCEA
1526914|NCT02765087|Other|Chest CT|
1526915|NCT02765087|Other|Pleural Fluid Analysis|Cytomorphology Cytochemistry Adenosine Deaminase Value
1526916|NCT02765074|Drug|subcutaneous tocilizumab|162 mg subcutaneous, once a week during 12 months
1526917|NCT02765048|Behavioral|GAIN Program|Receives GAIN, a 10-session program that incorporates cognitive behavioral therapy skills in a group format to address symptoms of trauma such as PTSD and depression related to histories of child maltreatment. GAIN includes the following elements: 1) assertive communication skills and relationship boundaries, 2) understanding the connection between feelings, thoughts, and behaviors, 3) increased personal confidence, 4) how to have healthy relationships and personal safety, and 5) how to cope with stress and anxiety.
1526918|NCT02765035|Device|C-Leg 4|Microprocessor Controlled Knee
1526919|NCT02765035|Device|C-Leg 3|Microprocessor Controlled Knee
1526920|NCT02765022|Device|Clip closure|Complete clip closure of secondary lesions after the endoscopic mucosal resection
1526921|NCT02765022|Procedure|No clip closure|Observation: no clip closure of secondary lesions after the endoscopic mucosal resection
1526922|NCT02765009|Drug|diuretics|Used to reduce fluid overload as evidenced by weight gain
1526923|NCT02765009|Drug|albumin|Used to reduce fluid overload in addition with diuretics in hypoalbuminemic patients
1526924|NCT02765009|Other|fluid restriction|Used to reduce fluid overload
1526925|NCT02765009|Device|renal replacement|Used to reduce fluid overload in patients with renal replacement
1526926|NCT02764996|Device|Acupuncture|
1526927|NCT02764983|Behavioral|Driving Behavior Interview|This will be completed thrice, at baseline, post-test1 and at post-test2
1526928|NCT02764983|Behavioral|Fitness-to-Drive Screening Measure|This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
1526929|NCT02764983|Other|Clinical Driving Assessment|Clinical Driving Assessment includes Optec vision screening, Useful Field of View, Range of Motion, Strength. This will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
1526930|NCT02764983|Behavioral|Propensity for Angry Driving Scale|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
1526931|NCT02764983|Behavioral|Community Integration Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
1526932|NCT02764983|Behavioral|Satisfaction with Life Questionnaire|This questionnaire will be completed thrice, at baseline, post-test1 and at post-test2 (3 months after post test1)
1526933|NCT02764983|Procedure|Driving simulator evaluation|The driving simulator evaluation uses a driving simulator with simulated drives engineered to address Veteran driving concerns such as reactions to other drivers and road conditions (e.g., debris). The simulator is used at baseline and post-tests 1 and 2. The intervention sessions (X3) also occur using simulator.
1526934|NCT02764983|Other|Focus Group Discussion Interview Guide|Focus group discussion will occur once using the interview guide
1526936|NCT02764957|Dietary Supplement|green coffee extract|
1526937|NCT02764957|Dietary Supplement|placebo|
1526938|NCT02764944|Procedure|simple non-exposure EFTR|This intervention includes the steps of laparoscopic seromuscular suturing with a barbed suture thread (V-Loc), which results in inversion of the stomach wall; EFTR of the inverted stomach wall from inside the stomach; and finally, endoscopic mucosal suturing with endoloops and clips.
1526939|NCT02764931|Other|Gluten free oats and gastrointestinal health|Subjects will be served 3 different test meals in a randomized order in the cross-over design
1526940|NCT02764905|Behavioral|information communication technology (ICT)|A personalized SMS based patient communication feedback system (Microsoft).
1526982|NCT02764593|Drug|Cetuximab|Epidermal Growth Factor Receptor (EGFR) antagonist
1526941|NCT02764905|Behavioral|intensive cognitive physical rehabilitation program|include 2 phases: a) Intensive phase: weekly 4 hour group meeting which will include computerized cognitive training, aerobic, balance and strength exercise and group discussion that will be dedicated to cognitive rehabilitation strategies development and implementation with emphasis on disease management and physical activity as well as psycho-education on various disease management aspects (medical and nutritional) b) a consolidation phase: monthly 2 hour group discussions on challenges of implementation and coping strategies.
1526942|NCT02764892|Drug|V81444|Single oral dose of V81444
1526943|NCT02764879|Dietary Supplement|Omega 3 fatty acids|omega3 received 2 times daily-for 6 months
1526944|NCT02764879|Procedure|scaling and root planing|
1526945|NCT02764879|Other|placebo soft gelatin capsules|placebo soft gelatin capsules received 2 times daily-for 6 months
1526946|NCT02764866|Other|Sleep testing|Home sleep testing
1526947|NCT02764853|Behavioral|Experimental Intervention (STEP-AD)|This experimental intervention will consist of 10 sessions- 1 session of Lifesteps (problem solving for medication adherence) and 9 sessions of an intervention specifically tailored for Black women living with HIV to address trauma/abuse, racial discrimination, HIV stigma, and gender roles expectations in order to improve health outcomes (e.g., medication adherence, viral load), increase resiliency, and enhance adaptive coping strategies.
1526948|NCT02764853|Behavioral|Enhanced Treatment as Usual (E-TAU)|Participants assigned to the E-TAU condition will receive 1 session of Lifesteps (problem solving for medication adherence) and appropriate services and referrals as needed ( and as would be typical of patients at MGH) followed by bi-weekly check-ins with a study research assistant to complete study questionnaires and review ART adherence (e.g. pocketed doses).
1526949|NCT02764840|Other|isokinetic dynamometer|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain. The first stage of the study will be crossover. The second will be split, one arm carry out the procedures in the elastic tube and the other in isokinetic dynamometer.
1526950|NCT02764840|Other|elastic tube|In the first stage a fatigue test will be applied. In the second stage, different participants will undergo a protocol for muscle strength gain.
1526951|NCT02764827|Biological|Pollen sensitization|Skin prick test with local and imported Bermuda, Johnson and careless weed allergen extracts at concentration of 10,000, 3,000, 1,000 and 300 AU/mL and measure specific IgE levels
1526952|NCT02764814|Other|Cryopreserved amniotic membrane|subjects will receive cryopreserved amniotic membrane
1993638|NCT03161639|Other|Pulpectomies|Primary teeth pulpectomy is an important treatment option for necrotic teeth. The correct working length will determine a better chemical and mechanical disinfection of the root canals, without demanding the surrounding periapical tissues and dental germs. In addition, it decreases the chance of a sub or over-filling, which also may interfere with the achievement of the success.
1526955|NCT02764788|Other|Specific auriculotherapy|Specific auriculotherapy with needles
1526956|NCT02764788|Other|non-specific auriculotherapy|non-specific auriculotherapy with needles
1526957|NCT02764788|Other|seed auriculotherapy|non-specific auriculotherapy with seeds
1526958|NCT02764775|Device|Headpod|Adaptive equipment to assist with active head movements
1526959|NCT02764762|Drug|Vedolizumab|Vedolizumab IV infusion
1526960|NCT02764762|Drug|Adalimumab|Adalimumab SC injection
1526961|NCT02764762|Drug|Methotrexate|Methotrexate Tablets
1526962|NCT02764749|Dietary Supplement|cranberry (poly)phenol containing supplement|Sustained intake of 9 grams of freeze-dried cranberry powder per day (2x 4.5 grams daily over 1 month). The powder is dissolved in water and administered as a drink.
1526963|NCT02764749|Dietary Supplement|Placebo comparator: cranberry (poly)phenol deprived supplement|Sustained intake (2x 4.5 grams daily over 1 month) of a control supplement dissolved in water
1526964|NCT02764736|Drug|Atorvastatin|Patients will be given 20mg atorvastatin daily for 12 weeks and then increased to 40mg atorvastatin daily for an additional 12 weeks.
1526965|NCT02764723|Drug|Hyperbaric bupivacaine|12.5 mg of hyperbaric bupivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
1526966|NCT02764723|Drug|Isobaric ropivacaine|15 mg of isobaric ropivacaine 0.5% for spinal anesthesia in geriatric patients undergoing total knee arthroplasty
1526967|NCT02764710|Drug|Amoxicillin-Potassium Clavulanate Combination|"Short course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily for a total of 2 doses.
Long course of postoperative treatment: amoxicillin-clavulanate 875mg, one tab twice daily up until and including postoperative day 7."
1526968|NCT02764697|Drug|H.P. ACTHAR SUBCUTANEOUS GEL INJECTION|Subcutaneous injection twice weekly
1526969|NCT02764684|Drug|Probiotic|The probiotic strain Lactobacillus rhamnosus will be self-administrated twice a day, one capsule in the morning and one in the evening for eight weeks.
1526970|NCT02764671|Biological|10μg/0.5ml recombinant hepatitis B vaccine|5000 participants who are healthy neonates receive 10μg/0.5ml recombinant hepatitis B vaccine on day 0, 30 and 60.
1526971|NCT02764658|Device|Pulmonary recovery on the AECOPD|The combination effect of negative pressure ventilation, limb muscle exercise training program and fibit monitor on acute exacerbation of AECOPD. To investigate the daily physical activity in routine care patients with after AECOPD and stable stage.
1526972|NCT02764658|Other|Routine care on the AECOPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Routine care patients wtih AECOPD and stable stage.
1526973|NCT02764658|Other|Routine care on the stable COPD|To investigate whether daily physical activity、hypoxia and hyperinflation were associated with airway inflammation and PRG4 in Non-Pulmanary recovery patients wtih stable COPD.
1526974|NCT02764645|Device|CardioGard Cannula|"CardioGard Cannula is a specially designed arterial (aortic) cannula for use in cardiac surgery for the purpose of removal of gaseous and solid embolic material emanating during the CPB procedure.
The CardioGard cannula is a double lumen cannula where the primary lumen provides blood from the heart-lung machine similar to ordinary cannulas and the secondary lumen performs suction of blood and embolic matter away from the aortic arch and back to the cardiopulmonary bypass machine for filtration."
1526975|NCT02764645|Device|22Fr curved Cannula|arterial cannula for use in cardiac surgery
1526976|NCT02764632|Procedure|Digital facilitation|
1526977|NCT02764619|Drug|Spironolactone|
1526984|NCT02764567|Other|Essential Oil|Participants in this arm will be offered one of three essential oils: ginger, lavender or calming
1526985|NCT02764541|Drug|Letrozole|
1526986|NCT02764541|Drug|Tamoxifen|
1526987|NCT02764541|Drug|Palbociclib|
1526988|NCT02764541|Drug|Endocrine Therapy|
1526989|NCT02764528|Behavioral|Clinic|Pregnant women will receive handwashing promotion from a trained facility-based health care worker during her regular antenatal visit at a healthcare clinic. To the extent feasible, everyone accompanying the pregnant woman will be invited to take part in the behavior change communication session. The participant will be provided with several bars of soap to take home and she will be encouraged to maintain a designated place for washing hands (with soap and water) at the home. A poster indicating the key events for handwashing with soap will be posted at the clinic and smaller posters will be given to the participant to post in her home. A system will be established to send regular SMS messages to the participant promote handwashing with soap during the neonatal period.
1526990|NCT02764528|Behavioral|Clinic + home|Women will receive all components of the clinic-based handwashing promotion in addition to handwashing promotion during 3-4 home visits before their expected delivery date and during the neonatal period from a community health volunteer. All household members present will be invited to join in the session, with emphasis on including all caregivers of the neonate.
1526991|NCT02764528|Behavioral|Clinic + home + handwashing device|Women will receive all components of the clinic + home-based handwashing promotion intervention in addition to one handwashing device (i.e. tap and basin to use as a handwashing station) during the first home visit by the community health volunteer. The community health volunteer will work with the woman and her family to identify the location where the neonate will be most of the time in order to position the handwashing station as close to the neonate as possible.
1526992|NCT02764515|Drug|Kunxian Capsule|Patients in the Kunxian Capsule group will take Kunxian Capsule 0.6gm orally twice daily for 24weeks
1526993|NCT02764515|Drug|Methotrexate|the Methotrexate group will take Methotrexate 10mg orally every week for 24 weeks
1526994|NCT02764502|Device|Pressure Gauge Manometer|Identification of epidural space
1526996|NCT02764476|Other|Embodied Virtual Reality Therapy|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways and involves body tracking and controlled sensory feedback reinforcing movement in real and virtual time by immersive head mounted displays. This game will have subjects fully embody and inhabit an avatar from an egocentric perspective. In addition, over consecutive sessions subjects will be asked to use a mobile smart phone based virtual reality program designed to deliver various and customized emotionally provocative stimuli.
1526997|NCT02764476|Other|Virtual reality|Participants will be asked to play a game in Stanford's Virtual Reality Human Interaction Lab that engages visual pathways.
1526998|NCT02764463|Device|Fiber Reinforced Composite Fixed Partial Dentures|All restorations were made indirectly on a plaster model using unidirectional E-glass fibers (Vectris- Ivoclar Vivadent, , liechtenstein) in combination with a laboratory resin composite (Signum, Heraeus-Kulzer)
1993639|NCT03162250|Drug|DSTA4637S|DSTA4637S will be administered as an IV infusion at 3 dose levels.
1993640|NCT03162250|Drug|Placebo|Placebo matched to DSTA4637S IV infusion will be administered as specified.
1527002|NCT02764424|Device|NIPE (MDoloris®)|Each file consists of a simultaneous recording of an electrocardiogram signal according to usual practice (cardiac monitor PHILIPS), coupled with a concomitant registration of NIPE (Newborn Infant Parasympathetic Evaluation - MDoloris®). The electrocardiogram signal, respiration rate, oxygen saturation (SpO2) and NIPE are recorded simultaneously on a computer with a capture card. The other indices of Heart Rate Variability will be analyzed offline.
1527003|NCT02764411|Drug|Brimonidine 0.33% gel|Topical application of Brimonidine 0.33% gel on Capillary Malformation (CM) lesion once daily for 12 weeks
1527004|NCT02764385|Other|Teachable Moment Communication Process|A clinician-focused intervention designed to guide an approach to discussing smoking cessation during routine primary care visits.
1527005|NCT02764385|Other|AAC|A system-based change to the EHR that allows for eReferral to the Quitline coupled with role and process changes for medical technical assistants
1527006|NCT02764372|Behavioral|Serious games|Participants played serious games developed for Kinect in the the EU FP7 STREP Project REHAB@HOME N. 306113
1527007|NCT02764372|Behavioral|Exergames|Participants played exergames existent in the Wii game console
1527008|NCT02764359|Drug|IV vancomycin|IV vancomycin for the treatment of infection. Following the vancomycin loading dose, vancomycin dosing will be at the discretion of the pharmacist and attending physician and will follow standard of care.
1527009|NCT02764346|Behavioral|iCanCope app|"In addition to standard medical care, adolescents in the experimental group will receive access to the iCanCope smartphone app for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component."
1527010|NCT02764346|Behavioral|iCanCope attention control app|"The control group is designed to control for the potential effects on outcomes of time, attention, and smartphone use during the intervention. In addition to standard medical care, adolescents in the attention control group will receive access to the iCanCope control app, with limited functionality."
1527011|NCT02764333|Biological|TPIV200|
1527012|NCT02764333|Biological|Durvalumab|
1527014|NCT02764307|Device|Constant jet nebulizer|A constant jet nebulizer (Neb-easy, Galemed Corp., Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
1527015|NCT02764307|Device|Breath enhanced nebulizer|A breath enhanced nebulizer (Pari LC plus, Pari Inc., Germany) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
1993641|NCT03162250|Drug|SOC|Anti-staphylococcal SOC antibiotics dosage and duration of therapy will be based on relevant health-authority approved indications and local and national treatment guidelines.
1993644|NCT03162744|Behavioral|Post-suicidal crisis interview|Protective factor exploration during post-suicidal crisis interview
1527016|NCT02764307|Device|Manual-actuated nebulizer|A manual-actuated nebulizer (A-T Neb, Atlantean Corporation, Taiwan) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
1527017|NCT02764307|Device|Breath-actuated nebulizer|A breath-actuated nebulizer (AeroElipes, Trudell Medical Inc, Canada) was tested with salbutamol sulfate powered by compressed gas flow at 6 L/min.
1527018|NCT02764294|Other|Music Group|Music group was listened to a music of their choise with a headset. The music intervention was started 5 minutes before cystoscopy and continued during the whole procedure. Types of music were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
1527019|NCT02764294|Other|Stress Ball Group|"Music group was given stress ball into both their palms 5 minutes before cystoscopy. Participants were instructed to squeeze the balls twice after counting up to five and repeat it until the end of the procedure."
1527020|NCT02764294|Other|DVD Group|DVD group was started to be watched a DVD of their choise 5 minutes before cystoscopy and continued during the whole procedure.
1527021|NCT02764281|Drug|MEDA|"Methotrexate, 3.0g/m2/d iv, day 1
Etoposide, 100mg/m2 iv, day 2 to day 4
Dexamethasone, 40mg/d iv, day 1 to day 4
Pegaspargase, 2500IU/m2/d im, day 4
The MEDA chemotherapy will be repeated every 3 weeks."
1527022|NCT02764281|Procedure|Auto-HSCT|Auto-HSCT will be performed with patients who responded to the initial MEDA chemotherapy with standard BEAM conditioning regimen.
1527023|NCT02764268|Drug|Apatinib|
1527024|NCT02764242|Other|Skin prick test|Skin prick tests to local and imported insect sting allergen with different concentration are performed.
1527025|NCT02764242|Other|sIgE measurement|sIgE levels to stinging insect allergen and their recombinant venom allergen are measured
1527026|NCT02764229|Drug|LYC-30937-EC|
1527027|NCT02764216|Radiation|Elective mucosal irradiaton|Patients will elective mucosal irradiaton based on nodal station, EBV/HPV status, RPN status etc. IMRT will be adopted.
1527028|NCT02764203|Other|Dark Chocolate|50g dark chocolate consumed for a period of 2 weeks
1527029|NCT02764203|Device|Wearable devices|Up to three wearable devices will be worn by the subject to measure parameters such as heart rate, blood pressure and number of steps
1527030|NCT02764190|Behavioral|I-ACT with Check Yourself|
1527031|NCT02764177|Dietary Supplement|Protein drink|The protein drink was administered during this trial
1527032|NCT02764177|Dietary Supplement|Carbohydrate drink|The carbohydrate drink was administered in this trial
1527033|NCT02764164|Device|Intervention Active tDCS|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current delivered directly to the brain area of interest via small electrodes. Placed over the temporoparietal junction to suppress auditory hallucinations.
1527035|NCT02764138|Behavioral|Building a Strong Identity and Coping Skills|Psychoeducational program to teach children coping skills, healthy identity development, and collective social action.
1527038|NCT02764099|Behavioral|Life Skills Training|The Life Skills Training (LST) program is a comprehensive competence enhancement prevention approach that teaches resistance skills while also emphasizing generic personal and social skills training. The LST program content and skills training is delivered to youth participants by trained providers through instruction, demonstration, behavioral rehearsal with feedback and social reinforcement, extended practice through homework assignments, and didactic teaching methods.
1527039|NCT02764086|Radiation|Radiation|Escalated dose of minimum 65Gy to the iGTV, with 60 Gy to PTV.
1527040|NCT02764073|Device|Bioimpedance spectroscopy|The technique involves attaching electrodes to the patient's forearm and ipsilateral ankle, with the patient in a supine position. The BCM® measures the body resistance and reactance to electrical currents of 50 discrete frequencies, ranging between 5 and 1000 kHz. Based on a fluid model using these resistances, the extracellular water (ECW), the intracellular water (ICW) and the total body water (TBW) are calculated. All calculations are automatically performed by the software of the BCM® device. Absolute fluid overload (AFO) is is defined as the difference between the expected patient's ECW under normal physiological conditions and the actual ECW, whereas the relative fluid overload (RFO) is defined as the absolute fluid overload AFO to ECW ratio.
1527041|NCT02764073|Device|Lung Ultrasonography|Examinations will be performed in the supine position. Scanning of the anterior and lateral chest will be performed on both sides of the chest, from the second to the fourth (on the right side to the fifth) intercostal spaces, at parasternal to mid-axillary lines. B-lines will be recorded in each intercostal space and were defined as a hyperechoic, coherent US bundle at narrow basis going from the transducer to the limit of the screen. B-lines starting from the pleural line can be either localized or scattered to the whole lung and be present as isolated or multiple artifacts (with a distance 7 mm between 2 artifacts). The sum of B-lines produces a score reflecting the extent of lung water accumulation (0 being no detectable B-line).
1527042|NCT02764073|Device|Echocardiography|All echocardiographic measurements will be carried out according to the recommendations of the American Society of Echocardiography by an observer unaware of the lung ultrasound and bioimpedance results. Echocardiographic evaluation will provide information about cardiac anatomy (e.g. volumes, geometry, mass) and function (e.g. left ventricular function and wall motion, valvular function, right ventricular function, pulmonary artery pressure, pericardium).
1527043|NCT02764060|Device|Tongue scraper|The patients were instructed to start cleaning the tongue by two pulling strokes along the median sulcus of the tongue, followed by two pulling strokes along the lateral edges of the tongue.
1527044|NCT02764060|Device|Toothbrush|The patients who were assigned to the tooth brush group were taught to perform three forward and backward strokes along the median sulcus and at each lateral part of the tongue.
1527045|NCT02764047|Dietary Supplement|Probiotic|L. acidophilus 10⁹, B. lactis 10⁹
1527046|NCT02764034|Device|Low level Laser diode machine|wavelength 635 Low level diode laser power control time control Continuous mode
1527047|NCT02764021|Dietary Supplement|Carbohydrate-Restricted Diet|Macronutritional composition: Carbohydrate 30 E%, Protein 30 E%, Fat 40 E%
1527048|NCT02764021|Dietary Supplement|Standard Antidiabetic Diet|Macronutritional composition: Carbohydrate 50 E%, Protein 13 E%, Fat 17 E%
1527049|NCT02764008|Drug|Bupivacaine|20 ml %0,25 bupivacaine
1527051|NCT02763995|Behavioral|Pharmaceutical care|This is a quasi-experimental study and the same group will be evaluated before and after the follow up.
1527052|NCT02763982|Other|Physical evaluation|
1527053|NCT02763969|Drug|BMS-986202|
1527054|NCT02763969|Drug|Placebo|
1527055|NCT02763969|Drug|Interferon alpha-2a recombinant|
1527056|NCT02763969|Drug|Famotidine|
1527057|NCT02763969|Drug|Ustekinumab|
1527058|NCT02763956|Device|GelStix™ Nucleus Augmentation Device|Intradiscal Gelstix insertion
1527059|NCT02763956|Other|Placebo|Intradiscal saline injection
1993647|NCT03160742|Device|Mespere VENUS 200CVP system|Non-invasive sensor placed on the neck
1527061|NCT02763930|Other|Control diet|
1527062|NCT02763930|Other|Milk diet|
1527063|NCT02763930|Other|GABA-rich cheese diet|
1527064|NCT02763917|Device|Active Air Purifier|Two portable air purifiers containing HEPA filters will be placed in the bedroom and room where the participant reports spending the most time. Participants will be instructed to run the air purifiers continually. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight.
1527065|NCT02763917|Device|Placebo Air Purifier|Homes in the control group will receive placebo air purifiers that have the internal air filters removed, but which will run normally. Participants will receive educational materials about environmental factors that are important for asthma health and environmental modification strategies, and educational materials about health benefits of maintaining a normal weight. At the end of the study, participants in the control group will receive active air purifiers. A control group is needed to ensure that reduced pollutant levels and health effects are not due to temporal trends and 'placebo effects' of being enrolled in an intervention trial. Participants will be informed that being in the study does not prevent them from purchasing and using air cleaners during the study period.
1527066|NCT02763904|Dietary Supplement|Intensive nutritional counseling|Dietary counseling + energy-dense oral nutritional supplements since admission
1527067|NCT02763904|Other|Dietary counseling|Dietary counseling alone. In case of inadequate energy intake patients will receive oral nutritional supplements since day 8 from admission (after the evaluation of the primary end point)
1527068|NCT02763891|Other|Intervention group (Body body suspension and tilting exercises)|The body suspension and tilting exercise program (Chordata Method) involved suspending the body in the apparatus while performing tilting exercises. The Chordata apparatus consists of a steel structure with special springs and a harness specifically manufactured for practicing the Chordata Method. During the training sessions, the prescribed exercises emphasize the repetition of movements designed to promote different types of muscle contractions (concentric, eccentric, static) performed in different body positions and joint angles. Thus, when using the method, patients experience maximal functional performance beyond to the body mass centre, activating trunk antagonist muscles and motor memory evocation. Each session lasts 30 minutes.
1527069|NCT02763891|Other|Control group (global muscle stretching)|Subjects receiving submitted a global muscle stretching session twice a week for eight weeks. During this period. All participants are requested to don't engage in any additional type of exercise program or physical activity throughout the study period.
1527070|NCT02763878|Procedure|Uncut Roux-en-Y anastomosis|Uncut Closure devices would be used to close the intestinal cavity on the input less than 5cm distance from the loop gastrojejunostomy anastomosis.
1527071|NCT02763878|Procedure|Billroth II anastomosis|Typical Billroth II anastomosis would be made after the Distal gastrectomy.
1527072|NCT02763865|Device|MagVenture MagProx100 Stimulator with a Cool-B65 A/P coil|"Active rTMS administration (1Hz, 1,200sec, 110% resting motor threshold (rMT); 1200 pulses total.
Resting motor threshold assessment the TMS machine will initially be set to 50% of its maximal output."
1527073|NCT02763865|Device|eSHAM system|implemented in conjunction with the Cool-B65 A/P coil to effectively blind participants to rTMS treatment (active or sham)
1527074|NCT02763852|Drug|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.
Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
1527075|NCT02763852|Drug|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
1527076|NCT02763852|Drug|Madopar® 125|Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
1527077|NCT02763839|Drug|BIA 3-202|"The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.
Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods."
1527078|NCT02763839|Drug|Placebo|Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route
1527079|NCT02763839|Drug|Sinemet 25/100|Levodopa 100 mg/carbidopa 25 mg (Sinemet 25/100, Merck Sharp & Dohme) tablets; oral route.
1527080|NCT02763826|Device|transcranial direct current stimulation|brain stimulation using progressively increasing amounts of direct currents and in a variety of electrode montages
1527081|NCT02763813|Device|Herbst (propulsion type oral appliance)|Oral appliance
1527082|NCT02763813|Device|Retention type appliance (ORM)|
1527083|NCT02763800|Drug|BIA 3-202|BIA 3-202 (50, 100 and 200 mg) was administered in the form of oral tablets, given with 200 ml potable water.
1527084|NCT02763800|Drug|Placebo|Matched placebo was administered in the form of oral tablets, given with 200 ml potable water
1527085|NCT02763787|Drug|BIA 3-202|single rising oral doses (10 mg, 30 mg, 50 mg, 100 mg, 200 mg, 400 mg, 800 mg)
1527086|NCT02763787|Drug|Placebo|Identical placebo
1527121|NCT02763553|Dietary Supplement|Ketogenic Feed|A low-carbohydrate, high-fat feed designed to induce a ketotic state.
1993648|NCT03159702|Drug|Evomela|140 mg/m2/day IV on Day: -6 for patients who are < 60 years of age. 100 mg/m2/day IV on Day: -6 for patients who are ≥ 60 years or HCT-CI score of >3
1527087|NCT02763774|Other|Walking exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs, stationary running and walking. The intensity of walk will be determined by the Borg's sujective effort perception scale - (modified from zero to 10). On first postoperative day, participants will perform exercises in supine position. From the second to the fifth postoperative day, they will perform progressive walking.
1527088|NCT02763774|Other|Stationary cycling exercise|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, they will perform progressive cycling exercise.The intensity of cycling will be determined by the Borg's sujective effort perception scale - (modified from zero to 10).
1527089|NCT02763774|Other|Neuromuscular electrical stimulation|Participants will be sumitted to progressive exercises and supervised by a physiotherapist, active-assisted to free active exercise in upper and lower limbs. From the first to the fifth postoperative day, quadriceps and gastrocnemius muscles will be percutaneous stimulated with the following parameters: Synchronic mode, 50Hz, 400uS, time on 10s, time off 20s, intensity as tolerated by the patient.
1527090|NCT02763761|Drug|Infliximab + Prednisone|Prednisone dose will be decreased every 3 days for 18 days
1527091|NCT02763761|Drug|Methylprednisolone + Prednisone|Prednisone dose will be decreased every 4 days for 40 days
1527092|NCT02763748|Procedure|Laparoscopic endoscopy combined surgery|
1527093|NCT02763748|Procedure|laparoscopic and endoscopic cooperative surgery|
1527094|NCT02763748|Procedure|Single-arch laparoscopic and endoscopic cooperative surgery|
1527095|NCT02763735|Drug|11C acetate|Radiopharmaceutical
1527096|NCT02763722|Other|Emollient spray product|All patients will be instructed to use emollients spray on entire skin at least twice a day for four weeks.
1527097|NCT02763696|Other|Composition of Viginal flora of Child-Bearing women|Use high-throughput sequencing technology to exam Composition of Viginal flora of Child-Bearing women in different menstrual cycle and type of Vaginitis
1527098|NCT02763683|Radiation|PiB and VAT|There is no intervention for this study. The PiB and VAT are used during the PET procedures to help to identify any excessive abnormal proteins in the brain.
1527099|NCT02763670|Other|PRETICARD patient care management|"A standardized and specialized network to take care of the severe cardiac insufficiency:
An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency
At 1 months, consultations and acts realized by health professionals specialized (one hospital day care)
At 2 months, a therapeutic education program for heart failure patients, approved by the Rhône-Alpes regional public health authorities (week hospital: two days and one night).
At 6 and 18 months, one cardiology consultation
At 12 and 24 months, consultations and acts realized by health professionals specialized (one hospital day care)"
1527100|NCT02763670|Other|"As usual  patient care management"|"Conventional management of heart failure patients is defined in the guide HAS (Haute Autorité de Santé) care course. Patient follow-up, however, is defined by the patient's physician and / or cardiologist at the waning of his hospitalization, according to the usual practice for patients with stage II, III or IV NYHA.
According to these recommendations, the patient should see his cardiologist at least once a year.
Usual practices are:
An initial assessment and consultations with health professionals specialized in severe cardiac insufficiency during the hospitalization for cardiac insufficiency
At 12 months, a cardiologic consultation. For the study, three evaluation points are programmed: two by phone at 6 and 18 months, two by a consultation at 24 months. This interview aimed to evaluate the number of hospitalization, consultations and acts realized by health professionals specialized (the information in the logbook)."
1527101|NCT02763657|Other|fMRI scanning|All participants are scanned while evaluating linear-order and set-inclusion reasoning problems
1527102|NCT02763644|Drug|LFG316 active drug|LFG316
1527103|NCT02763644|Other|Standard of care treatment|SoC (site specific)
1527104|NCT02763631|Other|Experimental: Treatment|Participants will be established on portable CPAP during the day with nasal pillows as an interface and requested to use it at least 8 hours/day.
1527105|NCT02763631|Other|Experimental: Run In Phase|Participants will undergo a run-in phase during which they will undergo baseline assessments. If they tolerate the portable CPAP and if their 6-MWT improves by more than 30m when performed on CPAP, they will be randomised into the trial.
1527106|NCT02763631|Other|Sham Comparator: Stand Care Arm|No change will be made to participants care
1527107|NCT02763618|Other|Neurofeedback|Neurofeedback theta/beta ratio training. See 'Neurofeedback theta/beta ratio training' in detailed study description.
1527108|NCT02763618|Other|Placebo Neurofeedback training|The placebo training will be a previously recorded Neurofeedback session of a participant in group A
1527109|NCT02763605|Other|no intervention|
1527110|NCT02763592|Drug|Lidocaine|The aim of this study is to evaluate the impact of 5% lidocaine medicated plaster on allodynic symptoms of localized neuropathic pain after knee surgery
1527111|NCT02763592|Other|placebo plaster|This is a randomized, placebo-controlled, double-blind, parallel-group clinical trial comparing 5% lidocaine medicated plaster (5LP) and placebo whether neuropathic pain symptoms (dynamic mechanical allodynia, pressure, hot and cold) have a different chronological improvement with 5LP compared to placebo. Pain intensity and pain relief, sleep and quality of life and osteoarthritis severity are also assessed.
1527112|NCT02763579|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab intravenous infusion will be administered at a dose of 1200 mg on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
1527113|NCT02763579|Drug|Carboplatin|Carboplatin intravenous infusion to achieve an initial target AUC of 5 mg/mL/min will be administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4).
1527114|NCT02763579|Drug|Etoposide|Etoposide intravenous infusion will be administered at a dose of 100 mg/m^2 on Days 1, 2, and 3 of each 21-day cycle during the induction phase (Cycles 1-4).
1527115|NCT02763579|Drug|Placebo|Placebo intravenous infusion will be administered on Day 1 of each 21-day cycle during the induction phase (Cycles 1-4) and maintenance phase (Cycle 5 onward).
1527122|NCT02763553|Dietary Supplement|Standard Feed|Standard enteral feed used in critical care patients requiring nutrition via a nasogastric tube
1993649|NCT03159702|Drug|Fludarabine|"40 mg/ m2/day IV Days: -5 -4, -3, -2 (Adults: creatinine clearance may be estimated by the Cockcroft Formula: CrCl = [(140-age) x weight (kg) x 0.85 (for women only)]/ [72 x creat (mg/dl)].) for patients who are < 60 years of age.
40 mg/ m2/day IV Days: -5, -4, -3, -2 for patients who are ≥ 60 years or HCT-CI score of >3."
1527124|NCT02763527|Behavioral|Smoking reduction|A brief intervention on smoking reduction plus a smoking reduction leaflet
1527125|NCT02763527|Behavioral|Smoking Cessation|A brief advice on quitting plus a leaflet on smoking cessation
1527126|NCT02763514|Dietary Supplement|3 g PronovaPure 150:500 EE EU|
1527127|NCT02763514|Dietary Supplement|3 g PronovaPure 500:200 EE EU|
1527128|NCT02763514|Dietary Supplement|3 g Placebo|
1527131|NCT02763488|Device|DelfiPTS tourniquet system|
1527132|NCT02763488|Other|Standard physical therapy|
1527133|NCT02763475|Drug|cyclophosphamide|60mg/kg by vein on day -6
1527134|NCT02763475|Drug|Fludarabine|25mg/m2 iv daily on day -5 to -1
1527135|NCT02763475|Procedure|NK cell infusion|"First allogeneic haploidentical NK cell iv. infusion: 5x10e7/kg, NK CD3-CD56+ immunophenotype, 24-48h after chemotherapy
Second allogeneic haploidentical NK cell iv. infusion: up to 5x10e8/kg, NK CD3-CD56+immunophenotype, 7 days after the first infusion."
1527136|NCT02763475|Drug|IL-2|1x10^6 UI/m2 three times a week for two weeks from first NK infusion (day 0)
1527137|NCT02763449|Behavioral|Self-monitoing|Participants will self-monitor their physical activity level via activity monitors
1527138|NCT02763436|Procedure|physiological-based cord clamping|The cord of the newborn infant is clamped after establishing stable breathing efforts. The suspected time ranges from 2-4 minutes.
1527139|NCT02763423|Procedure|umbilical cord mesenchymal stem cell|allogeneic umbilical cord mesenchymal stem cell transplantation by intravenous injection
1527140|NCT02763410|Other|PRBC transfusion|
1527141|NCT02763397|Device|NBM-DBS|DBS which has already been implanted aiming initially to stimulate the GPi will be reprogrammed in order to stimulate more distal structure, the NBM.
1527142|NCT02763397|Device|DBS|DBS will be switched off
1527143|NCT02763384|Drug|BL-8040|
1527144|NCT02763384|Drug|Nelarabine|
1527145|NCT02763371|Other|Dietary: high GI lunch|High GI: High-GI rice lunch ad libitum on test day 1 and low GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
1527146|NCT02763371|Other|Dietary: low GI lunch|Low-GI: Low GI-rice lunch ad libitum on test day 1 and high GI-rice lunch on test day 2. Water at libitum was constantly available on both days.
1527147|NCT02763358|Device|Bite Counter|This study is a 15-week assessment of the possible utility of a wrist-worn device, the Bite Counter, in assisting the weight loss behavior change efforts of overweight and obese individuals. The Bite Counter tracks and analyzes wrist motions to identify those associated with taking bites of food and drinking beverages. It also has a step-counter feature. This study is designed to determine if using the Bite Counter with specific goals to reduce the numbers of bites and increase the numbers of steps will result in those changes.
1527148|NCT02763345|Device|Supporting LIFE electronic Community Case Management|The SL eCCM App is smartphone application developed to run on Android operating systems 3.0 Honeycomb and above. The SL eCCM App represents an electronic format of the WHO and UNICEFs paper-based CCM clinical decision rule, currently adopted as national policy in Malawi for assessing children presenting to village clinics with acute illness.The App includes a tap-sensitive breath counter for measuring breathing rate.
1527149|NCT02763345|Other|Standard care|
1527150|NCT02763332|Other|Upper trunk group (UTG)|This bandage was placed over the upper trapezius muscle.
1527151|NCT02763332|Other|Global trunk group (GTG)|This bandage was placed globally along the back
1527152|NCT02763319|Drug|Rituximab (RTX)|Rituximab: Dose: 375 mg/m2 IV
1527153|NCT02763319|Drug|MOR208|MOR208: MOR208 dose: 12 mg/kg intravenously (IV)
1527154|NCT02763319|Drug|Bendamustine (BEN)|
1527155|NCT02763293|Other|Manual Therapy|Non-manipulative treatment osteopathic techniques combined direct and indirect soft appropriate in patients with Crohn's disease
1527156|NCT02763280|Dietary Supplement|Ginseng extract 1g|Ginseng extract 1g, parallel design
1527157|NCT02763280|Dietary Supplement|Ginseng extract 3g|Ginseng extract 3g, parallel design
1527158|NCT02763280|Dietary Supplement|Placebo|placebo, parallel design
1527159|NCT02763267|Other|Oral glucose tolerance test|75 gram oral glucose tolerance test (fasting) at: Visit 1 (pregnant [4-14 weeks gestation] and nonpregnant women); Visit 2 (pregnant subjects only at 24-28 weeks gestation); Visit 3 (pregnant subjects only at delivery)
1527160|NCT02763254|Biological|CMD-003|Autologous EBV-specific T cells
1527161|NCT02763241|Drug|Cleanoze®|Cleanoze® consists of a powder made up of Sodium chloride and Sodium Bicarbonate. This powder when dissolved in 250 ml of water is closely resembles the content of a body fluid which normally baths the outside of the cells of the body. This fluid is isotonic solution.
1527162|NCT02763241|Drug|Saline (Syringe irrigation)|Nasal irrigation using 250 ml normal saline pushing into the nostril by 20 ml syringe
1527163|NCT02763228|Behavioral|Aerobic Training - Fixed Schedule|Supervised aerobic training for 40 minutes 3x/week for 20 weeks
1527164|NCT02763228|Behavioral|Resistance Training - Fixed Schedule|Supervised resistance training for 20 minutes 3x/week for 20 weeks
1527165|NCT02763228|Behavioral|Walking program|Unsupervised walking program 1-3 days/week for 52 weeks
1527166|NCT02763228|Behavioral|Aerobic Training - Flexible Schedule|Supervised aerobic training done on the participant's own schedule for 32 weeks
1527167|NCT02763228|Behavioral|Resistance Training - Flexible Schedule|Supervised resistance training done on the participant's own schedule for 32 weeks
1527168|NCT02763228|Behavioral|Successful Survivorship Health Education and Support Group|Support groups will be held for one hour 3x/week for 20 weeks. Topics will include, but are not limited, to long-term side effects of treatment, stress management, coping with fear and uncertainty, body image, sexuality, and spirituality.
1527169|NCT02763228|Behavioral|Flexible support groups|Participants will attend 1-3 weekly group sessions of their choosing for 32 weeks.
1527320|NCT02762110|Radiation|Positron emission tomography (PET/CT) imaging|
1527170|NCT02763202|Other|CHS Transition Services|"The CHS Transition Services (CHS-TS) pathway includes the following seven components:
(i) Introduction to CHS-TS process prior to discharge (ii) Hospital follow-up evaluation within 72 hours either in home with paramedicine or in the CHS-TS clinic (iii) Medication reconciliation by a pharmacist within 72 hours (iv) Weekly contact with care management team (v) Entry into the Heart Success Program if appropriate (vi) Access to 24/7 phone support, 24/7 paramedicine visits, and same day clinic scheduling (vii) Coordinated transition to the next appropriate care location after 30 days from time of discharge"
1527171|NCT02763189|Other|Expert mentoring|Experts will provide personalized instructional review on how to use the new device for changing endotracheal tubes.
1527172|NCT02763189|Other|Self-study|All subjects will receive self-study
1527173|NCT02763163|Behavioral|Sun exposure routine|
1527174|NCT02763150|Behavioral|Lifestyle intervention|Intervention group will receive comprehensive behavioral weight loss program.
1527175|NCT02763150|Other|Health Promotion|The health promotion group will receive education on healthy eating and activity
1527176|NCT02763137|Drug|Standard LD/CD|LD/CD will be administered at patient's usual dose and frequency during 8 hours interval
1527177|NCT02763137|Drug|Semi continuous intra-oral administration of LD/CD|Semi continuous intra-oral administration of standard LD/CD at a dose equal to the total dose of standard oral LD/CD that patients would normally consume over 8 hours period.
1527178|NCT02763124|Procedure|Verion-LenSx|The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions
1527179|NCT02763111|Drug|BCD-085|
1527180|NCT02763111|Other|Placebo|
1527181|NCT02763098|Drug|Remi 0.1|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.1 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
1527182|NCT02763098|Drug|Remi 0.2|.Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.2 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
1527183|NCT02763098|Drug|Remi 0.3|Intravenous (IV) administration of 0.5 mg Atropine prior to the induction, the patients randomly (by lot) received one of the three different doses (0.3 µg/kg/min) of remifentanil infusion for two minutes.After 2-minute remifentanil infusion, 0.5 mg/kg propofol was administered via IV route increasing the dose by 10 mg every 10 seconds; 0.5 mg/kg rocuronium was administered via IV route at the time of loss of eyelash reflex and consciousness. Two minutes later, intubation was performed. After recording the baseline values of heart rate, systolic arterial pressure, mean arterial pressure and diastolic arterial pressure, which were planned to be investigated, and administering atropine, a total of six measurements at one-minute intervals were performed until the time of intubation.
1527184|NCT02763085|Device|Basic Filling Material|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Basic Filling Material). Procedures will be done using local anesthesia. The cavity is excavated and filled according to the guidelines for ordinary restorative techniques.
1527185|NCT02763072|Device|Picosecond Q-switched Laser|One Enlighten treatment
1527186|NCT02763072|Device|KTP Laser|Up to four Excel V treatments
1527187|NCT02763059|Drug|Ibuprofen 600 mg|This group receives 1 hour before surgery 600 mg ibuprofen (and another 600 mg dose 6 hours after the first dose);
1527188|NCT02763059|Drug|Dexamethasone 4 mg|This group receives 1 hour before surgery 4 mg dexamethasone (and another 4 mg 6 hours after the first dose)
1527189|NCT02763059|Drug|Placebo|This group receives 1 hour before surgery placebo.
1527190|NCT02763059|Drug|Acetaminophen 1000 mg|A Rescue medication (1000 mg acetaminophen) was given to each patient who was instructed to take it if necessary.
1527191|NCT02763046|Biological|AIN457/Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. every 4 weeks
1527192|NCT02763046|Biological|AIN457/Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. every 4 weeks
1527193|NCT02763046|Drug|AIN457/Secukinumab Placebo|Induction: 4x Secukinumab Placebo s.c. weekly Maintenance: Secukinumab Placebo s.c. every 4 weeks until Week 16 followed by 150 mg Secukinumab s.c. weekly for 4 weeks
1527196|NCT02763020|Other|Fruit extracts high in polyphenols|
1527197|NCT02763020|Other|placebo|
1527198|NCT02763007|Drug|alogliptin+pioglitazone|alogliptin and pioglitazone add on metformin
1527199|NCT02763007|Drug|alogliptin|nesina add on metformin
1527200|NCT02763007|Drug|pioglitazone|actos add on metformin
1527201|NCT02762994|Drug|BCD-085|
1527202|NCT02762994|Other|Placebo|
1527203|NCT02762981|Drug|CORT125134 with nab-paclitaxel|treatment regimen of CORT125134 with nab-paclitaxel.
1527204|NCT02762968|Dietary Supplement|Placebo|Placebo capsules similar to the experimental treatments.
1527205|NCT02762968|Dietary Supplement|HMB|Capsules containing calcium HMB.
1527206|NCT02762968|Dietary Supplement|BC30|Bacillus Coagulans GBI-30, 6086 (BC30) mixed in water.
1527447|NCT02761070|Drug|Temozolomide|
1527209|NCT02762942|Drug|Misoprostol|Administration of 25 mcg of vaginal misoprostol every 4 hours up to 5 doses
1527210|NCT02762942|Device|Foley catheter|Insertion of a Foley catheter (16French) through the internal os for a maximum of 12 hours
1527211|NCT02762929|Drug|HTX-011A|
1527212|NCT02762929|Drug|Saline|
1527213|NCT02762929|Drug|HTX-011B|
1527214|NCT02762929|Drug|HTX-002|
1527215|NCT02762929|Drug|Bupivacaine Hydrochloride Injection|
1527216|NCT02762929|Drug|HTX-009|
1527217|NCT02762916|Other|Selfmanage with the help of telemedicine program|"The intervention group patients were not followed by the usual protocol, but it used the program CONTECI (and test different directions) to guide the patient monitoring.
Both groups used antiplatelets and statines as usual protocol (these were not the interventions) We did not use drugs or device for the intervention, only a Telemedicine programme"
1527218|NCT02762903|Procedure|TSA with tenotomy technique|Standard procedure: Utilization of tenotomy for mobilization of subscapularis during total shoulder arthroplasty (TSA). The subscapularis tendon is incised close to its attachment on the humerus. The Tendon is repaired with sutures.
1527219|NCT02762903|Procedure|TSA with lesser tuberosity osteotomy technique|Standard procedure: Utilization of the osteotomy to mobilize the subscapularis during TSA. A small fleck of bone is removed from humerus, the subscapularis tendon is still attached. The fleck of bone is reattached with sutures.
1527220|NCT02762903|Device|Shoulder prosthesis|"Standard procedure: Total shoulder arthroplasty replaces both components of the ball and socket joint with a metal device."
1527221|NCT02762890|Drug|Deep neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Post-tetanic count 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 4 mg/kg will be administered to reverse neuromuscular blockade.
1527222|NCT02762890|Drug|Moderate neuromuscular blockade|neuromuscular blockade will be performed using a continuous infusion of rocuronium. Train-of-four 1-2 will be maintained during surgery. After the end of surgery, sugammadex of 2 mg/kg will be administered to reverse neuromuscular blockade.
1527223|NCT02762864|Other|platelet (P2Y12) reaction units|VerifyNow P2Y12 assay point-of-care testing
1527224|NCT02762864|Drug|ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
1527225|NCT02762864|Drug|Comparator|dual antiplatelet therapy with clopidogrel 75 mg and aspirin 100 mg daily will be continued for 6 months after the procedure for patient followed with single antiplatelet therapy with clopidogrel 75 mg daily throughout the follow-up period.
1527226|NCT02762851|Other|Sterile saline|0.5 ml dose injected intramuscularly
1527227|NCT02762851|Drug|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
1527228|NCT02762838|Biological|BCD-055|BCD-055 is infliximab biosimilar
1527229|NCT02762838|Biological|Remicade®|
1527230|NCT02762838|Drug|Methotrexate|All patients will receive methotrexate in a dose from 10 to 25 mg per week.
1527231|NCT02762838|Drug|Folic acid|All patients will receive folic acid in a dose of 5 mg per week.
1527232|NCT02762825|Behavioral|HIIT|HIIT will consist of 4 min of higher intensity work set at 90% of heart rate reserve, based on peak heart rate from CPX test. Recovery intervals will be 3-4 min in duration and set at 60-70% of heart rate reserve. Resistance training will be performed once per week.
1527233|NCT02762825|Behavioral|MCT|MCT will consist of aerobic exercise performed 3 times per week for 30 min each session, at an intensity of 60-80% of heart rate reserve, based on peak heart rate from CPX test.
1527234|NCT02762812|Biological|BCD-055|
1527235|NCT02762812|Biological|Remicade®|
1527236|NCT02762799|Biological|Leucostim®|Leucostim® is filgrastim biosimilar.
1527237|NCT02762799|Biological|Neupogen®|
1527238|NCT02762786|Behavioral|musical training|The subjects in the experimental group will receive weekly one-hour lessons on musical training for 12 weeks, conducted by the Music Children Foundation.
1527239|NCT02762773|Procedure|non-dissection of interior rectus sheath|
1527240|NCT02762773|Procedure|control|
1527241|NCT02762760|Biological|AMPION™|AMPION™, up to 3 mL, single intra-articular injection. Ampion is the ultrafiltrate of 5% HSA.
1527242|NCT02762760|Biological|Saline|Saline placebo, up to 3 mL, single intra-articular injection. Saline used as the comparator is 0.9% Sodium Chloride
1527243|NCT02762747|Procedure|preperitoneal suction drainage|preperitoneal suction drainage after laparoscopic totally extra-peritoneal hernioplasty for inguinal hernia
1527244|NCT02762734|Other|MEDIA|"The intervention for the group MEDIA is a keeping in touch intervention through sending of SMS (or mail or other new media). The patient will receive 6 SMS (or mail or other new media) during 6 months after the suicide attempt. The first one 7 days after the suicide attempt and the last one after 6 months. The first SMS (or mail or other new media) is sent soon after the suicide attempt because studies on adult suicide attempters underline the importance of an early start for the connectedness measures. The text message are evolving in time, and are adapted to the genre of the adolescent."
1527245|NCT02762708|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Subjects will be studied prior to surgical intervention and 12 weeks post surgery. Subjects in surgical arm will start diet intervention after surgery. Follow up with dietary will be per standard of care following RYGB surgery.
1527246|NCT02762708|Behavioral|Caloric Restriction|Subjects participating in caloric arm of this study will be asked to consume an identical diet that is controlled for caloric content and macronutrient composition. This is identical to that consumed by patient undergoing RYGB. Subjects in the caloric restriction arm will start the diet after the screening visit. Compliance will be monitored by alternating weekly meetings with a clinical psychologist and dietician.
1527247|NCT02762708|Drug|Exendin-9,39|"A subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
1527248|NCT02762708|Drug|Normal Saline|"subset of 4 subjects who have undergone RYGB surgery will be studied 4 weeks after surgery. Subjects will be randomized to receive an infusion of either Exendin-9,39 or normal saline. Exendin-9,39 blocks the action of specific hormones called incretins that are produced by the gut in health and in larger quantities after gastric bypass surgery."
1527249|NCT02762695|Other|Case Management|"A model of health care for chronic patients, based on Case Management and guided by a nurse which targets the patient´s risk.
The core elements of this strategy are: a. processes to identify specific population and their risk; b. evidence-based practice guidelines according to risk (higher risk, more interventions and monitoring by a nurse, lower risk, higher emphasis on self-care); c. Practice models based on collaboration between health team members leaded by a nurse; d. self-management education for patients; e. monitoring patients face to face or by telephone to ensure to follow the care program (blood test, medical consultation, for example); e. measurement of process and outcomes."
1527250|NCT02762695|Other|Usual Care|Usual Care at Primary Health Care Center
1527251|NCT02762669|Drug|Oxytocin|Oxytocin, 10-7mol/L to 10-5mol/L
1527252|NCT02762656|Drug|Lidocaine|Lidocaine drip during surgery
1527253|NCT02762643|Drug|DP-R213|Investigational product is prescribed to all of randomized subjects
1527254|NCT02762643|Drug|Raloxifene|Investigational product is prescribed to all of randomized subjects
1527255|NCT02762643|Drug|Cholecaliferol|Investigational product is prescribed to all of randomized subjects
1527256|NCT02762630|Device|Carestream Health Inc. weight bearing cone beam CT scanner|
1527257|NCT02762617|Drug|Tenofovir disoproxil fumarate intravaginal ring|The TDF intravaginal ring is a torus-shaped, flexible polyurethane ring. The ring will be inserted by the study clinician and worn for 28 day intervals for a total of 3 months (84 days). The ring will be removed and replaced with a new ring at each 28 day interval.
1527258|NCT02762617|Drug|placebo (for TDF)|Torus-shaped, flexible polyurethanes ring
1527261|NCT02762591|Drug|Pimavanserin tartrate|Pimavanserin tartrate 40 mg, tablet, taken as two 20 mg tablets, once daily by mouth
1527262|NCT02762578|Drug|insulin degludec/insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
1527263|NCT02762578|Drug|biphasic insulin aspart|Twice daily subcutaneous (sc, under the skin) injection.
1527264|NCT02762565|Device|PEFS system (Product Name: Intelligent Breast Exam™ or iBE™|
1527265|NCT02762552|Device|Transcranial-holter monitoring|Transcranial holter with an 4 hour-recording
1527266|NCT02762539|Drug|omega-3 enriched SMOF lipid emusion|
1527267|NCT02762526|Procedure|Lipoabdominoplasty|
1527268|NCT02762513|Drug|Axitinib|
1527269|NCT02762500|Drug|LYC-30937-EC|
1527270|NCT02762500|Drug|Placebo|
1527272|NCT02762474|Drug|nab-paclitaxel group|Weekly Regimens of Nab-paclitaxel Plus Cispaltin Combined With Concurrent IMRT
1527273|NCT02762461|Procedure|IVF or ICSI|
1527274|NCT02762448|Drug|Daclatasvir+ Asunaprevir|HCV clearance and complete regression of NHL by ASV+ DCV
1527275|NCT02762435|Other|sham|light touch at established points on hand and wrist
1527276|NCT02762435|Other|control|no contact with the subject
1527277|NCT02762435|Other|acupressure|moderate pressure at established points on hand and wrist
1527278|NCT02762422|Other|Phlebotomy|Removal of 500 cc of blood via forearm vein
1527279|NCT02762409|Other|experimental|corresponding to surviving individuals of a hospitalization in intensive care in a department having set up the program of reduction of the discomforts collected by the patients of intensive care during a minimal period of 5 months. The program is so defined as factor of exposure and supposed protector of development of anxio-depressive disorders.These patients will have been included in the study IPREA3 in 17 centers of the interventional group of the study IPREA3 during the months of April, 2015 and October, 2015
1527280|NCT02762409|Other|control|"The patients not exposed in the supposed factor protector of development of anxio-depressive disorders will be constituted by the patients estimated in the study IPREA3 corresponding to surviving individuals of a hospitalization in intensive care in a department having never operated the program of reduction of the discomforts collected by the patients of intensive care. These patients will have been included in the study IPREA3 in 17 centers of the group control some study IPREA3 during October 2014 and April, 2015"
1527281|NCT02762383|Drug|Peginterferon Alfa-2|Peginterferon alfa-2a will be administered as 90 micrograms (mcg) via subcutaneous (SC) injection once weekly.
1527284|NCT02762357|Device|Novosyn® Quick|Episiotomy closure
1527285|NCT02762344|Drug|heparin|routinary heparin administration during coronary angiography/PCI
1527286|NCT02762331|Drug|Ascorbic Acid|Comparing safety and efficacy of IV Vitamin C in CABG patients
1527287|NCT02762331|Drug|Placebo|Placebo intervention
1527288|NCT02762318|Other|Samples With DNA|"After consenting, all subjects have to undergo the following procedures:
Up to 25 ml of blood will be withdrawn. If for any reason, the blood sample cannot be obtained, a swab will be applied to the inside of the cheek to obtain saliva.
A questionnaire will be used to collect information about individual A routine physical exam will be performed. The subject's medical record will be reviewed To well document some of the specific phenotypes and conditions, physicians might take photographs of the affected body area.
For secondary subjects (relatives or family members), normal examination and routine lab tests/ imagining will be done if needed as per the related standard care."
1527289|NCT02762305|Other|RSVP Bone Builders Group Exercise|
1527317|NCT02762123|Drug|BMS Drug-drug interaction cocktail (montelukast, flurbiprofen, omeprazole, midazolam, and digoxin)|
1527318|NCT02762123|Drug|BMS-986142 350mg|
1527319|NCT02762110|Drug|N-(4-(6,7-dimethoxy-3,-4-dihydroisoquinolin-2(1H)-yl)butyl)-2-(2-[18F]- fluoroethoxy)-5-methylbenzamide (18F-3c) ([18F]ISO-1)|
1527290|NCT02762292|Device|Measurement of work of breathing using indirect calorimeter|"Preparation:
Patient baseline characteristics will be collected.
Connection of the Indirect Calorimeter to the respiratory circuit.
Nasogastric tube installation: a specific modified Neurally Adjusted Ventilatory Assist (NAVA) catheter equipped with both microelectrodes for Electrical Activity of the diaphragme (EAdi) monitoring and an esophageal balloon (for esophageal pressure (PES) monitoring) will be installed.
Simultaneous recordings of: Oxygen Consumption (VO2) and Energy Expenditure (EE); Esophageal Pressure (PES), Airway Pressure (PAW), respiratory volume and flow; EAdi during (i) Conventional mechanical ventilation (ii) Spontaneous Breathing Trial in Continuous Positive Airway Pressure and (iii) Second period of Conventional mechanical ventilation with the same ventilator parameters set in STEP 1.
End of the physiological recordings. Collection of Pediatric Intensive Care Unit (PICU) outcome of patients."
1527291|NCT02762279|Other|esophageal and pleural pressure measurement|Esophageal pressure will be monitored by a dedicated catheter and pleural pressure will be measured into the chest tube already in place
1527292|NCT02762266|Procedure|Computed Tomography|Undergo CT
1527293|NCT02762266|Other|Laboratory Biomarker Analysis|Correlative studies
1527294|NCT02762266|Procedure|Magnetic Resonance Imaging|Undergo MRI
1527295|NCT02762266|Other|Quality-of-Life Assessment|Ancillary studies
1527296|NCT02762266|Other|Questionnaire Administration|Ancillary studies
1527297|NCT02762266|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1527298|NCT02762266|Procedure|Transarterial Chemoembolization|Undergo TACE
1527299|NCT02762266|Drug|Chemotherapy agent|"Acceptable chemotherapeutic agents include (excluding drug eluting beads):
Doxorubicin
Epirubicin
5-fluorouracil
Mitomycin C
Gemcitabine
Cisplatin
SMANCS (styrene maleic acid neocarzinostatin)"
1527300|NCT02762266|Drug|embolic agent|". Acceptable embolic agents include:
Gelatin sponge (gelfoam)
Polyvinyl alcohol (PVA) particles
Microspheres / Embolic beads"
1527301|NCT02762266|Drug|lipiodol|
1527302|NCT02762253|Drug|Riboflavin drops|Riboflavin drops were used every 2 minutes for 30 minutes on the cornea then exposed to 5 minutes of Ultraviolet light at an intensity of 18mW/cm2
1527303|NCT02762240|Other|DHQP 2016|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
1527304|NCT02762240|Other|DHQP 2018|DHQP for general practice consists of 16 standards with associated indicators within the following areas: 1. Quality and patient safety, 2. Patient safety critical standards, 3. Good patient continuity of care, 4. Management and organisation.
1527305|NCT02762227|Device|Abdominal high resolution CT|CT examinations were performed using a 64-slice CT scanner. Arterial phase scanning was triggered by bolus tracking technique after 100 to 120 mL nonionic contrast material was injected through the antecubital vein. With a delay of 60 and 140 s after the beginning of contrast medium injection, portal venous and equilibrium phase image scanning were followed.
1527306|NCT02762227|Device|Contrast-enhanced ultrasonography (CEUS)|CEUS examinations were performed using a Philips iU 22 scanner with a 1-5 MHz（Mega Hertz, MHz）vector transducer. Traditional transabdominal ultrasound and CEUS were performed by the same investigator, one with more than 3 years experiences in CEUS. Traditional ultrasound was used initially to locate the lesion. The plane with the bottom of the lesion was selected for further examination. When multiple lesions were existed, the largest one was selected to evaluate. The target was placed in the center of the screen and was kept stable. Pulse inversion harmonic imaging with an index of 0.06 was used in CEUS examination. SonoVue, which contained sulfur hexafluoride microbubbles, was used as the contrast agent.
1527307|NCT02762227|Procedure|Cholecystectomy|Cholecystectomy is performed by method of either laparoscopic cholecystectomy or open cholecystectomy.
1527308|NCT02762214|Device|Clermont-Ferrand Uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1).
After tubal coagulation, Clermont-Ferrand Uterine Manipulator is installed inside the uterus. At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
1527309|NCT02762214|Other|No uterine Manipulator|"Pelvic cytology is obtained before starting surgical procedures (washing number 1). None uterine manipulator is used and the cervix is closed with a cross stitch.
Tubal coagulation, At the end of the hysterectomy, after colporrhaphy, a second cytology is obtained (washing number 2)"
1527310|NCT02762201|Procedure|PASI|"Implant-secured removable partial denture will be delivered in 2 large steps: implant delivery followed by denture delivery.
Implant delivery will take 4 dental consultations : a pre-implant study at Day14 after inclusion, the surgical implant insertion at D28 after inclusion, stitches removal at D35 after inclusion, and finally functional implant delivery between 3 or 6 month after surgery (to allow implant osteointegration).
Denture delivery will take 6 weekly dental consultations between Week 3 and Week 8 after the functional implant delivery."
1527311|NCT02762201|Procedure|PAC|Metalic standard removable partial denture, the standard treatment, will be delivered in 4 steps at Day 7, D14, D21, D28 after inclusion, as classically.
1527312|NCT02762188|Device|Genotype analysis|"After signing informed consent, a blood sample is taken and DNA extracted according to standard procedures. The samples are genotyped with the Mass Array iPlex Gold. Processing of the data is done using the previously described protocol by Lambrechts and co.
Statistical analysis will be done to evaluate the association between the different genetic variants and the clinical outcomes collected during the standard of care follow-up for ARMD."
1527313|NCT02762149|Device|Nerve stimulator|The nerve stimulator (Stimpod NMS 450: Xavant technology (PTY) Ltd; Pretoria, South Africa or similar nerve stimulator) will be connected to the epidural catheter through an adapter (Johans ECG Adapter, Arrow International Inc., Reading). The epidural catheter and the adapter will be primed with a standard volume of 3 ml of sterile normal saline to allow for effective electrical conduction. Secured connections and avoidance of any air within in the system must be ensured to avoid high impedance in the circuit, which could result in false negatives. The cathode terminal of the stimulator will then be attached to the metal hub of the adapter and the anode terminal will be connected to the electrode placed over the deltoid muscle.
1527314|NCT02762136|Drug|placebo|
1527315|NCT02762136|Drug|Xiang-sha-liu-jun granules|The Xiang-sha-liu-jun granules comprises 10 herbs, Astragalus membranaceus (Huangqi) 15g, Codonopsis pilosula (Dangshen) 15 g, fructus aurantii (Zhiqiao) 15g, fructus amomi(Sharen) etc
1527316|NCT02762123|Drug|BMS-986142 200mg|
1527448|NCT02761070|Drug|Bevacizumab|
1527321|NCT02762097|Procedure|polypectomy|. During the second visit after she consents to removal of polyp revealed on prior saline sonography, a dilatation and curettage would be performed under ultrasound guidance and after successful removal of polyp (polypectomy) saline sonography would be repeated to ensure completeness of removal.
1527322|NCT02762097|Procedure|saline sonography|saline infusion sonography (SIS) on 8th to 11th day of menstrual cycle. On the day of admission SIS will be performed in an outpatient setting .Taking all aseptic measures a speculum will be inserted vaginally and up to 20 ml of sterile saline solution will be infused into the uterine cavity through a cervical foley's catheter of 5 french to distend the endometrial cavity. A transvaginal transducer will be used to scan the uterine cavity. In case the patient has polyps she would be offered removal under general anaesthesia on a subsequent visit as a day case procedure.
1527323|NCT02762097|Drug|normal saline|Normal saline would be injected into uterine cavity to delineate defects
1527324|NCT02762084|Drug|patidegib|patidegib gel 2% or 4%, applied topically, twice daily for 26 weeks
1527325|NCT02762084|Drug|vehicle gel|vehicle gel, applied topically, twice daily for 26 weeks
1527326|NCT02762071|Drug|Liposomal bupivacaine|Patients in this group will receive a periarticular injection containing liposomal bupivacaine during surgery. The injection will be administered by the surgeon.
1527327|NCT02762071|Drug|Interscalene Nerve Block|Patients in this group will receive an interscalene nerve block containing the local anesthetic ropivacaine prior to surgery. The nerve block will be administered by a fellowship-trained anesthesiologist.
1527328|NCT02762058|Device|Virtual Reality Mirror Therapy|Virtual Reality Mirror Therapy system using occulus rift as virtual headset and kinect as motion tracking sensor.
1527329|NCT02762058|Procedure|Traditional Mirror Therapy|Traditional Mirror Therapy system consisting of a mirror in which patients view their healthy limb over the affected to trick brain during dual motion tasks. This therapy has been shown to improve upper extremity function in patients with acquired brain injury.
1527330|NCT02762045|Biological|Ad5-gag|Ad5-gag is used as vaccine in all arms.
1527331|NCT02762045|Biological|Placebo|Preservation Solution is used as control in all arms.
1527332|NCT02762032|Dietary Supplement|PrimaVie Herbal Supplement 125|125 mg to take BID for 14 weeks in Arm 1
1527333|NCT02762032|Dietary Supplement|PrimaVie Herbal Supplement 250|250 mg to take BID for 14 weeks in Arm 2
1527334|NCT02762032|Drug|Placebo|Placebo supplement to take BID for 14 weeks in Arm 3
1527335|NCT02762019|Device|Laser therapy|Treatment with K-Laser Cube3 during 4 consecutive days, with the following protocol: 660-970 nm wavelength, 3,2W mean power (6.4W pulsating at 50%), 3'51'' duration, 1-20000 Hz frequency, and 1 cm2 spot size. Laser application was performed all over the oral cavity.
1527336|NCT02762019|Device|Sham therapy|Only the laser pointer movement, without laser activation, during 4 consecutive days, all over the oral cavity.
1527337|NCT02762006|Drug|Durvalumab|
1527338|NCT02762006|Drug|Tremelimumab|
1527339|NCT02761993|Biological|ST266|1X ST266 applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. ST266 will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
1527340|NCT02761993|Drug|Saline (0.9% NaCl)|Saline applied in a dose of 20 microliters per tooth. Total daily dose will be less than 1 milliliter. Saline will be applied directly to the marginal gingiva around each tooth (buccal and lingual).
1527345|NCT02761967|Behavioral|Physical activity|Women from the 20th week of moderate physical exercise performed in water character designed following the guidelines in the SWEP method will end in week 37 of gestation. After the postpartum period, women begin a program based on postpartum recovery exercises Fitness Low Pressure method 12-week, 3 days a week, in sessions of 60 minutes.
1527346|NCT02761928|Other|Beighton score for hypermobility|The beighton score is a 9 point score of flexibility, used for patients with disorders of collagen.
1527347|NCT02761915|Genetic|1RG-CART/m^2 (Dose Level 1)|Patients in Dose Level1 will receive 1x10^7 1RG-CART/m^2 on Day 0 (intravenously).
1527348|NCT02761915|Genetic|1RG-CART/m^2 (Dose Level 2)|Patients in Dose Level 2 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -4 to -1) followed by 1x10^7 1RG-CART/m^2 on Day 0.
1527349|NCT02761915|Genetic|1RG-CART/m^2 (Dose Level 3)|Patients in Dose Level 3 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^7 1RG-CART/m^2 on Day 0.
1527350|NCT02761915|Genetic|1RG-CART/m^2 (Dose Level 4)|Patients in Dose Level 4 will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 1x10^8 1RG-CART/m^2 on Day 0.
1527351|NCT02761915|Drug|Cyclophosphamide|
1527352|NCT02761915|Drug|Fludarabine|
1527353|NCT02761915|Genetic|1RG-CART/m^2 (Dose Level 5)|If the required level of 1RG-CART survival is not reached, a further cohort of patients (Dose Level 5) will receive 300mg/m^2/day of cyclophosphamide for four days (Days -7 to -4) and 25 mg/m^2/day of fludarabine for five days (Days -8 to -4), followed by 5-10x10^8 1RG-CART/m^2 on Day 0 .
1527354|NCT02761889|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Previously untreated patients with prostate cancer will be treated with 45 Gy in five fractions of 9 Gy over 5 consecutive days.
1527355|NCT02761889|Procedure|Image-guided, volumetric intensity-modulated arc radiotherapy (IGRT-VMAT)|Patients enrolled in the study will undergo IGRT-VMAT with state-of-the-art treatment-planning and quality assurance procedures with emphasis on normal tissue sparing and delivery accuracy via the use of devices that ensure stability and beam location reproducibility.
1527356|NCT02761889|Device|Rectal balloon with air filling|A rectal balloon with air filling will be used for prostate target immobilization and anatomical reproducibility.
1527357|NCT02761889|Device|Urethral catheter loaded with beacon transponders|A urethral catheter loaded with beacon transponders will be used to ensure set-up reproducibility and online target tracking.
1527361|NCT02761863|Other|CD 74, VEGF detection|"All MPM samples will be subjected to immunohistochemistry with CD74 and VEGF antibodies.
The VEGF will be scored using a 0-3 scoring system to represent the percentage of cytoplasmic positively stained cells in the tumor portion, as follows: 0-10%, 11-30%, 31-60% and 61-100% positive staining correspond to score 0, 1, 2 and 3 respectively. Both CD74 and VEGF immunohistochemical markers will be furtherly categorized in the statistical analyses as none (0)/low (1) vs medium (2)/high expression(3).
The CD74 expression will be recorded in the tumor and the stroma semiquantitatively using the histoscore method using four representative fields with the final score resulting from the percentage of tumor cells staining positively multiplied by the staining intensity grade."
1527364|NCT02761824|Other|Camp Discovery|Activities included physical, social, emotional, sensory and spiritual activities.
1527365|NCT02761811|Device|SyMapCath I™ catheter and SYMPIONEER S1™ Stimulator/Generator|Radiofrequency ablation of renal arterial sympathetic nerves
1527366|NCT02761798|Device|Automated Mobile Interactive Audiometer|iPad game
1527367|NCT02761746|Behavioral|MESA|MESA is tailored based on how important and how confident the participant feels about taking medications as prescribed. If the participant does not believe taking medications is important, they engage in a decisional balance exercise. If the participant believes taking medications is important, they move directly to confidence modules and goal setting. If the participant does not feel confident about taking medications, they engage in activities to boost self-efficacy. Participants are also offered personalized feedback regarding immune status and HIV knowledge with actual adherence feedback provided in the second session. Finally, goal setting is an option, and feedback regarding adherence behavior over the previous month.
1527368|NCT02761733|Behavioral|Moving Patient Outcomes toward Wellness and Recovery (mPOWR)|An mPOWR intervention and toolkit that consists of strategies, prompts, and decision aids designed to foster patient involvement in treatment. The mPOWR intervention includes a questionnaire that assesses quality of life and consumer functioning for use in the development of consumer-centered goals and outcomes within the mPOWR intervention.
1527369|NCT02761720|Other|No Intervention|
1527370|NCT02761707|Other|Electrical Brainstem Responses|Eye blink responses will be induced using standard stimulating electrodes employed in surface electromyography (EMG). The subjects will recline with their eyes gently closed. Sticky electrodes will be placed to the left and below the left eye. 6 different facial regions will be stimulated. The electrical stimulation will be kept constant during the test sessions. To prevent habituation, the stimuli will be delivered randomly at intervals of 45-60 sec. Four 0.2 msec pulses will be presented. In some cases, paired pulse stimulation will be performed, and a conditioning stimulus will be applied to the target facial regions at the following intervals: 10, 200, 400, 600 and 800 msec. 4 pulses will be presented at each stimulus interval with randomized interval and pulse sequences.
1527371|NCT02761707|Other|Olfactory Tests|Olfactory testing will be performed using standard tests. The University of Pennsylvania Smell Identification Test (UPSIT) assesses a subjects ability to identify odors in a forced choice format. The Snap and Sniff Threshold Test provides a threshold measure of phenyl ethyl alcohol. Short-term odor memory will be assessed using a standardized 12-item four-alternative forced-choice Odor Memory Test. This non-lexical test employs 10-, 30-, and 60-second delay intervals between the presentation of the target odorant and the first of four successively presented odors from which the target is to be selected.
1527372|NCT02761707|Other|Visual Deprivation|During a 2-hour visual deprivation period, subjects will wear comfortable light-tight goggles with lenses that have been blackened by flat black paint. Subjects will be given the opportunity to recline comfortable in a padded reclining chair during this time.
1527373|NCT02761707|Other|Peripheral Nerve Stimulation|Electrical stimulation will be applied to a nerve of your arm. Sticky electrode pads will also be placed on a hand muscle. You will receive electrical stimulations that lasts less than a second. The stimulations will make your muscle twitch.
1527375|NCT02761681|Behavioral|ACT-CL Web-based guided self-help|
1527376|NCT02761681|Behavioral|Control Web-based guided self-help|
1527377|NCT02761668|Procedure|ParS+Ortho 4W|Orthodontics 4 weeks post surgical
1527378|NCT02761668|Procedure|ParS+Ortho 6M|Orthodontics 6 months post surgical
1527379|NCT02761655|Behavioral|Memory Strategies|Memory strategies on encoding retention, retrieval, execution and monitoring
1527381|NCT02761629|Drug|Peg-Interferon Alpha-2A|Peg-IFN-Alpha-2A will be administered at 180 micrograms (mcg) once weekly via subcutaneous injection.
1527454|NCT02761018|Behavioral|Fitness Tracker with Group Participation|
1527382|NCT02761629|Drug|Ribavirin|Ribavirin will be administered as either 1000 milligrams (mg) (2*200 mg tablets in morning and 3*200 mg tablets in evening) for participants weighing less than (<) 75 kilograms (kg) or as 1200 mg (3*200 mg tablets in morning and 3*200 mg tablets in evening) for participants weighing greater than or equal to (>/=) 75 kg.
1527383|NCT02761616|Other|eBC treated participants|No intervention administered in this retrospective observational study.
1527384|NCT02761603|Behavioral|Healthy Aging Practice-centered Instruction (HAPI)|"Sessions will include interactive activities derived from the CDC's Program to Encourage Active and Rewarding LiveS (PEARLS) and will include lectures based on health-related topics from presentations given by experts as part of the UC San Diego Stein Institute of Aging's Successful Aging project. The PEARLS Problem Solving Treatment (PST) group discussions will be facilitated by a trained instructor in order for participants to identify problems or barriers they have in engaging in healthy behaviors relevant to each of 12 topic areas (e.g. sleep, nutrition, mental health, social support, bone health, diabetes prevention, cognitive wellness, and resilience). Each session will be composed of: Successful Aging video (45 min), discussion (40 min), and identifying problem solving strategies (25 min) with a homework assignment each week, for a total of 24 hours of in-class instruction and discussion."
1527385|NCT02761603|Behavioral|Tai Chi (CHI)|Sessions will include expert instruction in the brief Yang-style 8-form Tai Chi meditative movements. Each class will include a 10-minute warm-up and cool-down plus 40 minutes of Tai Chi instruction and or practice, for a total of 24 hours of in-class instruction
1527386|NCT02761590|Other|Circuit training protocol|The construction of own model of periodization to be used complies with the biological principle of interdependence volume vs. intensity, and duration of 14 weeks, proposing a week of recuperative exercises after two weeks of stress, gradually increasing the intensity with respective volume settings. This model is based on the concepts described by Turner et al. which concludes in favor of the organization of training adapted to the reality of the public to be trained.
1527387|NCT02761577|Drug|Sodium bicarbonate|3 mL/kg/hour of Sodium bicarbonate, an hour prior to angiography and 1 mL/kg/hour, within six hours after angiography
1527388|NCT02761577|Drug|N-acetylcysteine|N-acetylcysteine (1200 mg twice a day, IV (in vein) ) one day before angiography, on the day of the angiography, and one day after the diagnostic procedure
1527389|NCT02761564|Other|Red blood cell tranfusion|Red blood cell transfusion according to transfusion guidelines.
1527390|NCT02761564|Other|ScvO2 measure|ScvO2 (oximetry) is measured at the distal lumen of the central venous catheter placed in the superior vena cava. Transfusion is performed if ScvO2 is inferior or equal to 65%.
1527391|NCT02761551|Behavioral|Reminder notifications via autodialer|
1527392|NCT02761538|Behavioral|AVIITAM|The purpose of the project is to test the medico economic impact related to the utilization of the Aviitam online platform in primary care.
1527393|NCT02761525|Other|silver nanoparticles|Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into an innocuous gel and dished in oral mucosa surface to then compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential.
1527394|NCT02761525|Other|placebo|Compare with another innocuous gel without silver nanoparticles to reduce microbial colony forming units of pathogenic potential using the same procedure to dished the gel.
1527395|NCT02761512|Drug|CJ-12420 50 mg QD|CJ-12420 50 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 50 mg.
1527396|NCT02761512|Drug|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of CJ-12420 100 mg.
1527397|NCT02761512|Drug|Lansoprazole 30 mg QD|Lansoprazole 30 mg capsule will be orally administered, once daily, for up to 8 weeks. For subjects whose gastric ulcer is not endoscopically healed(S1 or S2 stage) at Week 4, subjects will receive additional 4 weeks treatment of Lansoprazole 30 mg.
1527398|NCT02761499|Device|U-Motion II+ Acetabular System|U-Motion II+ Acetabular System (1) U-Motion II+ acetabular cup, (2) U-Motion II+ acetabular liner, (3) Cobalt-Chrome or BIOLOX delta ceramic femoral heads, and the 4) UTF Reduced Stem
1527399|NCT02761486|Drug|Aspirin|325mg aspirin per day
1527400|NCT02761486|Drug|Placebo|placebo in matching capsules
1527401|NCT02761473|Other|skin biopsy|A skin biopsy will be obtained from a typical UP lesion in affected patients
1527402|NCT02761473|Other|blood draw|Blood will be obtained from subjects, parents and unaffected siblings
1527403|NCT02761460|Drug|PEG-rhG-CSF|PEG-rhG-CSF 6mg is given for patients Greater than or equal to 45 kg, 3mg is given for those less than 45kg 24-48 hours after chemotherapy
1527406|NCT02761434|Other|Hypertonic Saline (3% NaCl)|0.1 ml of 3% NaCl per kg of body weight per minute
1527407|NCT02761434|Other|Isotonic Saline (0.9% NaCl)|0.1 ml of 0.9% NaCl per kg of body weight per minute
1527408|NCT02761421|Other|observation study|observation study
1527455|NCT02761018|Behavioral|Fitness Tracker|
1527409|NCT02761395|Procedure|Al-hijamah|"Strict sterilization of selected anatomical sites.
Suction using sterile plastic disposable sucking cups
Skin scarifications (shartat mihjam): through inducing superficial (0.1 mm in depth), small (2 mm in length), multiple and evenly distributed skin incisions."
1527410|NCT02761395|Drug|Deferasirox|20-40 mg/kg/day orally
1527411|NCT02761382|Other|Mindfulness-based psychological treatment|
1527412|NCT02761382|Other|Non-specific psychological treatment|
1527413|NCT02761369|Device|A multi-channel deep TMS device with an H-coil (Brainsway Ltd)|A 3-week long treatment (15 days). Treatment session consist of 300 rapidly occurring pairs of pulses over the dorsolateral prefrontal cortex (at a frequency of 10 Hz and intensity of 110% of individual's motor threshold), with a 5-seconds interval, for a duration of 1800 seconds in total.
1527414|NCT02761356|Other|Tc99-MAA|To evaluate the fisibility of Tc99-MAA injected intra epatic artery to predict uptake of Yttrium-90 SIRT in patients with liver malignancies
1527415|NCT02761343|Other|MRI scan|Following the clinically indicated cardiac ablation procedure, a post ablation MRI scan will be performed.
1527416|NCT02761330|Drug|Ketamine|Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
1527417|NCT02761330|Procedure|Electroconvulsive Therapy|Dose of the ECT charge will be determined during titration session prior to randomization.
1527418|NCT02761317|Drug|standard preparation (2L PEG-ELS)|Subjects who are randomized into group A will receive standard bowel preparation (2L PEG-ELS) on the same-day of procedure.
1527419|NCT02761317|Drug|low-volume preparation (10 mg bisacodyl plus 2L PEG-ELS)|Subjects who are randomized into group B will receive 10mg bisacodyl at 6 pm on the evening before the colonoscopy and 2L PEG-ELS on the same-day of procedure.
1527420|NCT02761317|Drug|high-volume preparation (4L PEG-ELS)|Subjects who are randomized into group C will receive 2L PEG at 6 pm before the procedure and another 2L PEG-ELS on the same-day of procedure.(4L PEG)
1527421|NCT02761304|Procedure|Ultrasound|
1527422|NCT02761291|Drug|Gemcitabine|Gemcitabine will be administrated 600~1250 mg/m^2 intravenously according to the body surface area at day 1 and day 8 in a 28 day-treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times. The first dose level of gemcitabine will be started at 800 mg/m^2. If no subject suffered the dose limit toxicity, 1000 mg/m^2 and even 1250 mg/m^2 will be started by order. If subjects suffered the dose limit toxicity in 800 mg/m^2, the 600 mg/m^2 will be started.
1527423|NCT02761291|Drug|Valproic acid|Valproic acid will be administrated orally by the fixed dose 12.5 mg/kg/day according to instructions from day 1 to day 14 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
1527424|NCT02761291|Drug|Valganciclovir|Valganciclovir will be administrated orally by the fixed dose 1350 mg/day (creatinine clearance rate ≥ 60 mL/min) or 900 mg/day (creatinine clearance rate ≥ 40 mL/min and < 60 mL/min) from day 9 to day 15 in one treatment cycle. The treatment cycle of 28 days will be repeated maximum 6 times.
1527425|NCT02761278|Procedure|Endometrial biopsy|
1527426|NCT02761265|Procedure|Surgical intervention|Surgery to correct spinal deformity
1527427|NCT02761265|Other|None (Asymptomatic group)|Gait and balance testing performed, no treatment in this asymptomatic group
1527428|NCT02761252|Drug|Bilastine 20mg|
1527429|NCT02761252|Drug|Montelukast 10mg|
1527430|NCT02761252|Drug|Placebo Bilastine 20mg|
1527431|NCT02761252|Drug|Placebo Montelukast 10mg|
1527432|NCT02761239|Device|The NIM 3.0 Nerve Monitoring System|Electromyography recordings were accomplished with a pair of needle electrodes inserted through the CP muscle, which were plugged into the third and fourth channels of interface-connector box.The recurrent laryngeal nerve(RLN), vagus nerve, external branch of the superior laryngeal nerve(EBSLN) and pharyngeal plexus were stimulated with a current of 1 mA and a frequency of 4 MHz and the event threshold at 100 microV.
1527433|NCT02761226|Procedure|Platform Matched Design (Group A)|10 patients with missing upper posterior teeth will receive dental implant with platform matched design (the patients will receive implant 4.2mm with same abutment diameter 4.2mm)
1527434|NCT02761226|Procedure|Platform Switching Design (Group B)|10 patients with missing upper posterior teeth will receive dental implant with platform switching design(the patients will receive implant 4.2mm with smaller abutment diameter 3.5 mm
1993650|NCT03159702|Radiation|Total Body Irradiation|200 cGy Day: -1 for patients who are < 60 years of age. 200 cGy; Days: -2, -1 (total of 400cGy) for patients who are ≥ 60 years or HCT-CI score of >3.
1993651|NCT03158974|Drug|VIR007|Cream containing 10% EISO
1527438|NCT02761174|Drug|Brimonidine|Patients receive brimonidine to half of their face, whereas the other half receives no treatment and thereby patients are their own control
1527439|NCT02761174|Other|IPL+air-cooling|IPL+air-cooling are applied to the whole face and the control side thereby only receives IPL+air-cooling
1527440|NCT02761161|Drug|Mianserin|mianserin is add-on treatment to treatment as usual. Max dose 30 mg day.
1527441|NCT02761161|Behavioral|Imagery Rehearsal Therapy|IRT is add-on treatment to treatment as usual.
1527442|NCT02761122|Procedure|Human biological samples|"Blood sample
Skin or mucosal brushing
Skin or mucosal biopsy"
1527443|NCT02761096|Device|acupuncture|"Acupuncture, electroacupuncture, and intradermal acupuncture will be performed at every session.
Sterile disposable stainless steel acupuncture needles (0.25 mm × 30 mm) will be used. Acupuncture needles will be inserted bilaterally at the following acupuncture points: LI4, LI11, PC6, ST36, GB39 and LR3, and GV20. If GV20 is close to the surgical site, this acupoint may be excluded.
An electric stimulator will be connected to the handle of each needle at LI4, LI11, ST36, and LR3 and a current of 5 Hz will be applied.
After the needles are removed, intradermal acupuncture needles with tape (DB130A; 0.25 mm × 1.5mm) will be inserted at the same acupoints (LI4, LI11, PC6, ST36, GB39, and LR3 bilaterally, and GV20) and left in place until the next session."
1527444|NCT02761096|Other|conventional treatment|The subjects in the control group will only receive conventional treatment. This involves general management after craniotomy in the department of neurosurgery and includes stabilizing vital signs, pain control, prevention and treatment of infections, and other IV fluid or drug therapy required based on the condition of the patient.
1527445|NCT02761083|Device|Novosyn® Quick|Eye surgery
1527446|NCT02761083|Device|Vicryl® Rapid|Eye surgery
1527456|NCT02761005|Drug|Eradication of H. pylori|For the eradication of H. pylori, patients diagnosed to be infected with strain with mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, metronidazole 500 mg and amoxicillin 1500 mg for 1 week. Patients diagnosed to be infected with strain without mutation of 23S rRNA, their H. pylori strains are considered to be resistant to clarithromycin. Then, they are treated with vonoprazan 40 mg, clarithromycin 400 mg and amoxicillin 1500 mg for 1 week.
1527457|NCT02760992|Drug|IV Baclofen|Baclofen intravenous solution 2 mg/mL manufactured and provided by Allaysis, LLC
1527458|NCT02760992|Drug|Oral Baclofen|10 mg tablet
1527459|NCT02760979|Drug|Denosumab|Denosumab treatment one year after surgery
1527460|NCT02760979|Drug|Placebo|Serum one year after surgery
1527461|NCT02760966|Other|Alcohol 70º|
1527462|NCT02760966|Other|Soap|
1527464|NCT02760940|Drug|oral liposomal iron|After screening, anemic patients will be treated during 8 weeks with 28mg of oral liposomal iron per day and then the investigators will report data assessing the tolerability and efficacy of oral liposomal iron treatment in these patients.
1527465|NCT02760927|Device|Endotracheal Tube Fastener|The AnchorFast Guard oral endotracheal tube fastener provides a convenient means to hold an oral endotracheal tube securely in place without the use of adhesive tape. The oral endotracheal tube fastener allows repositioning of the tube in either direction along the track without removal of the device.
1527466|NCT02760901|Drug|Acetazolamide|patients received acetazolamide 250 mg half an hour before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
1527467|NCT02760901|Drug|Acetylcysteine|patients received NAC (600 mg every 12 hours) for 4 doses beginning 24 hours before cisplatin with saline hydration.for prevention of cisplatin nephrotoxicity
1527468|NCT02760901|Drug|Mannitol|patients received mannitol 20 % 100 ml half an hour before cisplatin and saline hydration.
1527469|NCT02760901|Drug|saline|saline hydration 2500 ml before cisplatin therapy
1527470|NCT02760901|Drug|Cisplatin|patients with tumours already prescribed cisplatin
1527471|NCT02760888|Drug|Tramadol|Women will receive a oral Tramadol 100mg 1 hour before the procedure
1527472|NCT02760888|Drug|Diclofenac|Women will receive oral Diclofenac 100mg 1 hour before the procedure
1527473|NCT02760888|Drug|Placebo|Women will receive a Placebo 1 hour before the procedure
1527474|NCT02760875|Behavioral|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
1527475|NCT02760862|Drug|hydrocortisone 100mg.|Group (I), received hydrocortisone 100mg, dissolved in 2ml normal saline, intravenously/8 hours for 48 hours
1527476|NCT02760862|Drug|mannitol 20% intravenous fluid|group (II), received mannitol 20% 100ml intravenously which was given over 30 minutes and followed by 100 ml on a 12hour basis. Urinary catheter was inserted for patients in group (II) under complete aseptic conditions by the anesthesia resident before the start of mannitol infusion and removed after its discontinuation, accompanied by the intravenous fluid infusion over 48 hours of 500ml of normal saline or Ringer's solution every 8 hours and the input/output fluid chart for evaluation of fluid balance.
1527477|NCT02760849|Procedure|Salpingectomy|During salpingectomy, the inside of the abdomen is looked at and both fallopian tubes removed.
1527478|NCT02760849|Procedure|Oophorectomy|During oophorectomy, the inside of the abdomen is looked at and both ovaries removed.
1527479|NCT02760849|Behavioral|Questionnaires|"ISDO Group: Quality-of-life questionnaires completed at baseline, 6 months after salpingectomy, and every year or until delayed oophorectomy.
Quality-of-life questionnaires completed before oophorectomy, and at 6 months, 1 year, and 2 years after oophorectomy.
RRSO Group: Quality-of-life questionnaire completed at baseline, 6 months, 1 year, and 2 years after salpingo-oophorectomy surgery."
1527480|NCT02760823|Drug|Alpha Lipoic Acid (Thioctacid)|600 mg/12 hours, IV (in the vein)
1527481|NCT02760823|Drug|Placebo (for Alpha Lipoic Acid)|Normal saline in syringe simulating Alpha Lipoic Acid 600mg
1527482|NCT02760810|Device|Marketed Contact Lens|Narafilcon A
1993652|NCT03159442|Drug|AZD8871|Powder for inhalation administered via single dose DPI 300 and 600 µg/inhalation.
1993653|NCT03159442|Drug|Placebo|Powder for inhalation administered via single dose DPI
1527485|NCT02760784|Behavioral|Early weight bearing|The intervention implies that the selected patients, will be allowed to bear weight on the injured leg form day 1 while wearing the orthosis, in contrast to the control group, who must wait 6 weaks.
1527486|NCT02760771|Other|with BAV|balloon dilation of the aortic valve prior to implantation of the THV
1527487|NCT02760771|Other|without BAV|no balloon dilation of the aortic valve prior to implantation of the THV
1527488|NCT02760758|Drug|CDI-31244|NNI
1527489|NCT02760758|Drug|Placebo|no active ingredients
1527490|NCT02760745|Other|Ancillary tests|Blood culture, complete blood count, crp, urinalysis for all patients. If clinically indicated: Urine culture, chest x ray, csf culture, stool culture, joint fluid culture
1527491|NCT02760732|Device|drug eluting balloon; cutting balloon|Patients eligible for inclusion criteria were randomised to study group for percutaneous transluminal coronary angioplasty with a strategy of cutting balloon pre-dilation first and then drug eluting balloon.
1527492|NCT02760732|Device|drug eluting stent|with a strategy of drug-eluting stent implantation alone for de novo coronary artery lesions.
1527493|NCT02760719|Drug|nebulized 3% hypertonic solution|already described
1527494|NCT02760706|Device|Computed Tomography scan|
1527495|NCT02760680|Device|WatchPAT 200 (TM)|The WatchPAT 200 (TM) is a wrist worn diagnostic device for detecting SDB. Its main part is the measurement of the peripheral arterial tone (PAT) via a plethysmographic based finger-mounted probe. It can measure the level of sympathetic activation of the autonomic nervous system. Pulse rate, oxygen saturation and snoring/body position levels are calculated, too. A software program (zzzPAT (TM)) with a special algorithm analyzes the raw data and creates a sleep report. Therefore the property of the WatchPAT 200 (TM) proclaims that the WatchPAT 200 (TM) can detect sleep events and SDB.
1527637|NCT02759809|Other|Preterm formula|
1527496|NCT02760680|Other|Polysomnography|"The PSG is known as the Gold Standard for detecting SDB: experienced sleep physicians and technicians score events (apnea/hypopnea) using current AASM Guidelines."
1527497|NCT02760667|Drug|Cisplatinum|Cisplatin 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
1527498|NCT02760667|Drug|Docetaxel|Docetaxel 75mg/m2 every 3 weeks for a maximum of 3 cycles during the induction phase
1527499|NCT02760667|Drug|Carboplatin|Carboplatin AUC=5 every 3 weeks for a maximum of 3 cycles during the induction phase (if subject are unable to tolerate cisplatin)
1527500|NCT02760667|Procedure|Transoral Robotic Assisted Surgery|TORS will be performed for the patients who responded to the induction treatment (80% reduction)
1527501|NCT02760654|Device|Proactive Self Management Program for Effects of Cancer Treatment|
1527502|NCT02760641|Other|Egg-based diet (EBD)|Participants will be asked to consume a carbohydrate-restricted diet including whole eggs for 8 weeks. Eggs will be provided.
1527503|NCT02760641|Other|Carbohydrate-based diet (CBD)|Participants will be asked to consume a low fat, carbohydrate-based diet for 8 weeks. Breakfast food items will be provided.
1527504|NCT02760628|Behavioral|The First Twenty (TF20)|TF20 is an online wellness program for firefighters focused on improving cardiovascular risk factors through behavioral changes.
1527505|NCT02760628|Behavioral|Life Simple 7 (LS7)|LS7 is a wellness program designed and implemented by the American Heart Association focused on improving cardiovascular health.
1527506|NCT02760615|Drug|Caffeine|Caffeine tablets
1527507|NCT02760615|Drug|Losartan|Losartan tablets
1527508|NCT02760615|Drug|Omeprazole|Omeprazole capsules
1527509|NCT02760615|Drug|Dextromethorphan|Dextromethorphan capsules
1527510|NCT02760615|Drug|Midazolam|Midazolam syrup
1527511|NCT02760615|Drug|Vedolizumab|Vedolizumab solution for IV infusion
1527512|NCT02760602|Drug|Solanezumab|Administered IV
1527513|NCT02760602|Drug|Placebo|Administered IV
1527514|NCT02760576|Drug|BAY 987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1527515|NCT02760563|Drug|BAY 987517|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application (Formulation number V26-160)
1527516|NCT02760550|Other|No intervention|Participants of all three groups completed a questionnaire.
1527517|NCT02760537|Behavioral|Lay Health Worker Intervention|Lay Health Worker Phone Intervention The second phase addressed phone intervention training, where LHWs who had completed the first phase and were willing to participate in the second phase learned the process for calling participants to remind them to complete a series of HBV vaccinations. The LHWs assigned to the intervention group conducted phone interventions by reminding participants about completing a series of vaccinations at Months 1, 2, and 6, and also provided accompanying resources and support.
1527518|NCT02760537|Behavioral|Placebo (a list of resources)|Those in the control group received a list of resources along with their results by mail that offered free vaccinations, such as local health departments.
1527519|NCT02760524|Behavioral|NET Intervention|Neuro-emotional Technique
1527520|NCT02760511|Dietary Supplement|Anthocyanin|Capsules with different anthocyanin content
1527521|NCT02760511|Dietary Supplement|Placebo|Placebo capsules
1527522|NCT02760498|Drug|REGN2810|
1527523|NCT02760485|Drug|itacitinib|Phase 1 will evaluate itacitinib at the protocol-specified starting dose, with a possible increase or decrease depending on tolerability. Phase 2 will evaluate the recommended dose determined in Phase 1.
1527524|NCT02760485|Drug|ibrutinib|
1527525|NCT02760472|Drug|SMOFlipid|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
1527526|NCT02760472|Drug|Clinoleic|Parenteral fatty acid supplementation to preterm infants in preventing retinopathy of prematurity
1527527|NCT02760459|Drug|Dexamethasone|
1527528|NCT02760459|Drug|Normal saline solution|
1527529|NCT02760446|Behavioral|CAM-ICU.fr|Neuropsychological testing
1527530|NCT02760433|Drug|Olokizumab q4w|
1527531|NCT02760433|Drug|Olokizumab q2w|
1527532|NCT02760433|Drug|Placebo q2w|
1527533|NCT02760420|Drug|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
1527534|NCT02760420|Drug|Placebo|Oral placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
1527535|NCT02760407|Drug|Olokizumab 64mg q4w|
1527536|NCT02760407|Drug|Olokizumab 64mg q2w|
1527537|NCT02760407|Drug|Adalimumab 40mg q2w|
1527538|NCT02760407|Drug|Placebo q2w|
1527539|NCT02760394|Device|HBOT|40 daily sessions, 90 minutes of 100% oxygen at pressure of 2 ATA each, five days a week for 8 weeks.
1527540|NCT02760381|Device|NBI + Acetic Acid (AA)|Patients belonging to the Routine colonoscopy Cohort will receive NBI + Acetic Acid (AA) chromoendoscopy for optical predictions of colonic polyps.
1527541|NCT02760368|Drug|Olokizumab q4w|
1527542|NCT02760368|Drug|Olokizumab q2w|
1527543|NCT02760368|Drug|Placebo q2w|
1527544|NCT02760355|Drug|Ledipasvir 90 mg/Sofosbuvir 400 mg|Oral administration on one fixed dose combination tablet for 12 weeks
1527545|NCT02760355|Drug|Ribavirin|Oral administration of body weight-dose adjusted, 200 mg-tablets of ribavirin (1,000 mg in two administration in patients <75 Kg of body weight, or 1,200 mg in two administrations for those >75 Kg) for 12 weeks.
1527546|NCT02760342|Drug|ASP015K|Oral
1527547|NCT02760342|Drug|Metformin|Oral
1993654|NCT03158051|Behavioral|Home Blood Pressure Monitoring|Intervention arm participants will receive a home blood pressure monitor, home blood pressure log, and training on accurate home monitoring. They will be asked to share their home blood pressure readings during health coach telephone calls.
1527561|NCT02760303|Behavioral|Cognitive Behavioral Therapy|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be the thought-emotion-behavior linkages as outlined by cognitive-behavioral theory. Activities will illustrate how thoughts affect emotions and behaviors, the application of these activities to current stressors, and strategies to apply these new skills to future stressors.
1527562|NCT02760303|Behavioral|Mindfulness Based Stress Reduction|Participants will attend group therapy sessions, once a week for 9 weeks. The focus of these sessions will be understanding how to gain control over one's thoughts and feelings using relaxation, meditation, and other mindfulness-based techniques. Activities will focus on the instruction and practice of mindfulness techniques, such as meditation and yoga, and the application of these practices to everyday activities.
1527563|NCT02760303|Behavioral|Diabetes Support and Education|Participants will attend group therapy sessions, once a week for 9 weeks. Participants will receive diabetes education via a support group format. The focus of these sessions will be peer group social support and non-adherence diabetes education topics (e.g., emergency preparedness, smoking and diabetes).
1527564|NCT02760290|Procedure|Extraperitoneal cesarean section|
1527565|NCT02760290|Procedure|Intraperitoneal cesarean section|
1527566|NCT02760277|Drug|Vamorolone 0.25 mg/day/day|Oral administration of 0.25 mg/kg/day daily for 24 weeks.
1527567|NCT02760277|Drug|Vamorolone 0.75 mg/day/day|Oral administration of 0.75 mg/kg/day daily for 24 weeks.
1527568|NCT02760277|Drug|Vamorolone 2.0 mg/day/day|Oral administration of 2.0 mg/kg/day daily for 24 weeks.
1527569|NCT02760277|Drug|Vamorolone 6.0 mg/day/day|Oral administration of 6.0 mg/kg/day daily for 24 weeks.
1527570|NCT02760264|Drug|Vamorolone 0.25 mg/kg/day|Oral administration of 0.25 mg/kg/day daily for 14 days.
1527571|NCT02760264|Drug|Vamorolone 0.75 mg/kg/day|Oral administration of 0.75 mg/kg/day daily for 14 days.
1527572|NCT02760264|Drug|Vamorolone 2.0 mg/kg/day|Oral administration of 2.0 mg/kg/day daily for 14 days.
1527573|NCT02760264|Drug|Vamorolone 6.0 mg/kg/day|Oral administration of 6 mg/kg/day daily for 14 days.
1527574|NCT02760251|Drug|romiplostim|
1527576|NCT02760225|Drug|89Zr-Pembrolizumab|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
1527577|NCT02760225|Device|89Zr-Pembrolizumab PET|In part A of the imaging trial, a dose finding imaging study will be performed to assess the optimal tracer protein dose of 89Zr-pembrolizumab and the optimal interval between tracer injection and scanning. Approximately 3 cohorts of about 2-3 patients each will undergo 89Zr-pembrolizumab-PET imaging before start of treatment with pembrolizumab. In part B, 12 eligible patients will undergo 89Zr-pembrolizumab-PET imaging at baseline, with the optimal tracer protein dose and scanning schedule as determined in part A.
1527578|NCT02760212|Device|Radial Shockwave Therapy|5 treatments in total scheduled weekly; RSWT to the painful areas will be undertaken with 500 shocks (1.5 bar, 15 Hz), then 1000 shocks (2 bar, 8 Hz), and finally 500 shocks (1.5 bar, 15 Hz) to the most painful spot within each of the 3 most painful regions as described by the participant.
1527579|NCT02760212|Other|Placebo Comparator: Group 2 - Placebo Group|5 treatments in total scheduled weekly; placebo to the painful areas will be undertaken with 2000 shocks to the most painful spot within each of the 3 most painful regions as described by the participant.
1527580|NCT02760199|Drug|89Zr-AMG211|Injection of 89Zr-AMG211 for imaging.
1527581|NCT02760199|Device|89-ZrAMG211 PET|89Zr-AMG211 PET scan(s).
1527582|NCT02760186|Procedure|Altitude Exposure|Altitude Exposure
1527583|NCT02760173|Other|perception of vertical after static roll-tilt over 5min|subjects will indicate perceived direction of vertical after 5min of static whole-body roll-tilt.
1527584|NCT02760160|Other|Reconstituted grape powder|To prevent UV-induced skin cancers. Each subject's will have one arm exposed to 6 separate doses of UV (J/m2) [114, 217, 343, 500, 619, 848].
1527585|NCT02760147|Device|Pressure Support Over Support|Pressure Support Level upward by 50%, 2 hours
1527586|NCT02760147|Device|Pressure Support Under Support|Pressure Support Level downward by 50%, 2 hours
1527587|NCT02760147|Device|PEEP Over Level|PEEP Level upward by 50%, 2 hours
1527588|NCT02760147|Device|PEEP Under Level|PEEP Level downward by 50%, 2 hours
1527589|NCT02760134|Procedure|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
1527590|NCT02760121|Drug|Acetazolamide|
1527591|NCT02760121|Drug|Methazolamide|
1527592|NCT02760121|Drug|Placebo|
1527595|NCT02760082|Other|Qualitative evaluation|
1527596|NCT02760069|Drug|Inhaled isopropyl alcohol|Patients will inhale from isopropyl alcohol pads as needed for nausea up to q30 minutes.
1527597|NCT02760069|Drug|Oral ondansetron|Patients will drink elixir containing 4 mg ondansetron in 5 ml of solution. National Drug Code (NDC) 0054-0064-47.
1527598|NCT02760069|Drug|Inhaled normal saline|Patients will inhale from normal saline pads as needed for nausea up to q30 minutes.
1527599|NCT02760069|Drug|Oral placebo|Subjects will drink solution comprised of 0.25 ml of Oral Sweet Sugar Free NDC 0574-0302-16 with 4.75 ml of sterile water for dilution NDC 0264-2101-00
1527673|NCT02759471|Device|comfilcon A asphere lens (test)|contact lens
1527674|NCT02759458|Device|Smith & Nephew Healicoil Anchor|
1527675|NCT02759458|Device|Smith & Nephew Twinfix Anchor|
1527789|NCT02758626|Drug|Placebo|Powder formulation
1993655|NCT03158051|Behavioral|Telephone Health Coaching|Intervention arm participants will receive a health coach phone call every 2 weeks for 6 months, for a total of 12 calls. During each call, the health coach will review and discuss home blood pressures and address barriers and concerns to hypertension management. During each telephone call, the coach will guide the participant on selecting health behavior goals. Intervention arm participants will also receive handouts about hypertension management during the study visits and after health coach calls.
1993656|NCT03156426|Other|Event of interest: Acute kidney injury|AKI as defined by AKIN staging
1527602|NCT02760043|Drug|Dexamethasone|8mg (2mL) of Dexamethasone added to standard LIA mixture
1527603|NCT02760043|Other|0.9% NaCl Placebo|2mL of 0.9% NaCl placebo (saline) added to standard LIA mixture
1527604|NCT02760043|Drug|LIA Combination Mixture|150mL 2% Ropivacaine, 30mg Ketorolac and 0.6mg of Epinephrine
1527605|NCT02760030|Drug|Fulvestrant|Given IM
1527606|NCT02760030|Other|Laboratory Biomarker Analysis|Correlative studies
1527607|NCT02760030|Drug|Palbociclib|Given PO
1527608|NCT02760030|Other|Questionnaire Administration|Correlative studies
1527609|NCT02760017|Drug|B. forficata|
1527610|NCT02760017|Drug|Placebo|
1527611|NCT02760004|Behavioral|PRogram In Support of Moms (PRISM)|"PRogram In Support of Moms Toolkit with Stepped Care Algorithms
Support clinic specific implementation using the Addressing Problems Through Organizational Change (APTOC) platform
Customization of depression screening for each practice
Proactively engage and track all women who screen +ve on the Edinburgh Postnatal Depression Scale(EPDS)
Employ psychoeducation and Motivational Interviewing to engage patients with depression
medical assistant champion and psychiatrist contact bi-weekly to review cases
Stepped care treatment to depression screening/assessment"
1527612|NCT02760004|Behavioral|Enhanced Usual Care group (Access to MCPAP for Moms)|"30-60 minute presentation on perinatal depression
Access to telephonic psychiatric consultation with MCPAP for Moms perinatal psychiatrist for Ob/Gyns
Access to Ob/Gyn provider assessment and treatment recommendations via one-time face-face MCPAP for Moms psychiatrist patient evaluation
Access to assessment and treatment protocols in Provider Toolkit
Resource provision/referrals"
1527613|NCT02759991|Drug|Hecolin|0.6ml Hecolin vaccine im. on day 0, 1 month and 6 months.
1527614|NCT02759991|Drug|Hepa-B|1ml Hepa-B vaccine im. on day 0, 1 month and 6 months.
1527615|NCT02759978|Other|diagnostic workup|Our primary objective is to test whether the proportion of patients diagnosed correctly with the use of 18F-FDG-PET/CT, MD-CTA, and 18F-FDG-PET/MD-CTA added to the gold standard in current clinical practice, the modified Duke criteria by Li et al. 2000, is significantly higher as compared with the modified Duke criteria on itself. The gold standard is clinical judgement after clinical follow-up by a multidisciplinary team with medical specialists.
1527616|NCT02759939|Other|Video + Prompt Card|"A brief video (available in English and Spanish) intended to be viewed by patients immediately before the health care visit. The video aims to enhance patients' motivation, skills, and self-efficacy to ask their health care providers three specific questions: (1) What are my options? (2) What are the pros and cons of those options? and (3) How likely are those pros and cons to happen to me?
A prompt card (available in English and Spanish) intended to be provided to patients when they view the video and kept. The card aims to remind patients of the three questions presented in the video."
1527617|NCT02759939|Other|Decision Aids + Training|"Seven one-page decision aids on contraceptive methods (available in English and Spanish) intended to be used by health care providers with patients during the health care visit.
A five-minute training video and accompanying written guidance (available in English) intended to be reviewed by health care providers before implementing the decision aids (and as frequently as desired thereafter). The training aims to enhance providers' motivation, skills, and self-efficacy to use the decision aids to facilitate shared decision-making in the health care visit."
1527618|NCT02759926|Drug|Denatonium benzoate|
1527619|NCT02759926|Drug|Quinine hydrochloride|
1527620|NCT02759926|Drug|Tap water|
1527621|NCT02759913|Procedure|Lumbar puncture|Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics
1527622|NCT02759900|Device|Non-thermal, atmospheric plasma|Non-thermal, atmospheric plasma treatment of affected area
1527623|NCT02759887|Procedure|biospecimen collection|Blood: ApoE genotyping, comprehensive metabolic panel, RNA sequencing. Urine: beta-hCG (human corionic gonadotropin) testing.
1527624|NCT02759887|Other|cognitive assessments|Dementia Questionnaire for People with Learning Disabilities; Mini-Mental State Examination; Severe Impairment Battery; Vineland Adaptive Behavior Scale; Arizona Memory Assessment for Intellectual Disability; Kaufman Brief Intelligence Test; Nepsy Mazes; and, Timed Up and Go.
1527625|NCT02759887|Other|caregiver questionnaire|
1527626|NCT02759887|Procedure|Florbetapir F18 imaging|Used in small doses to image brain amyloid-beta deposits in human beings. Radioactivity necessary to create the positron emission tomography (PET) images. Radiation exposure is slightly more than a person would receive from a routine clinical head computed tomography scan.
1527627|NCT02759887|Procedure|MRI|Magnetic resonance imaging of the head and brain.
1527628|NCT02759887|Procedure|Fludeoxyglucose F18 (FDG)|Injected intravenously during a PET scan and is a marker for the tissue uptake of glucose; a radiopharmaceutical compound.
1527629|NCT02759887|Procedure|Tau Pet|Administered during a PET, in small amounts, necessary to create the scan images. Radioactive. The total amount of radiation is about the same that a patient receives from a routine abdominal/pelvis computerized tomography.
1527630|NCT02759887|Procedure|Actigraphy|A non-invasive method of monitoring human rest and activity cycles. A small actigraph unit is worn to measure gross motor activity. The unit is usually worn on the wrist.
1527631|NCT02759874|Device|specialized breathalyzer w face recognition technology|
1527632|NCT02759861|Drug|harvoni|8 or 12 weeks of harvoni therapy with monthly nursing visiting to monitor alcohol and adherence of harvoni therapy
1527635|NCT02759822|Procedure|Haploidentical Stem Cell Transplantation|Haploidentical Stem Cell Transplantation from a related donor (partially matched sibling, father, mother, son or daughter).
1527636|NCT02759809|Other|Pasteurized donor human breastmilk|
1527638|NCT02759796|Procedure|Tailoring the flap according to clinical assessment|After microvascular anastomosis is performed, the investigators clinically assess flap vascularization and the well vascularized tissue is marked by means of a dermographic pencil. Then the investigators administer 0,2mg/kg of ICG intravenously. The vascularization of the flap is also checked by means of the Photo Dynamic Eye (Pulsion Medical System) but finally the decision of discarding the poorly vascularized areas of the flap is made by clinical assessment.
1527639|NCT02759796|Procedure|Tailoring the flap according to ICG Angiography assessment|After microvascular anastomosis is performed, the investigators administer 0,2mg/kg of ICG intravenously. Then the investigators check the vascularization of the flap by means of the Photo Dynamic Eye (Pulsion Medical System) and the poorly vascularized areas of the flap are discarded guided by ICG perfusion test.
1527640|NCT02759783|Radiation|SBRT|Patients will receive a dose and fractionation regimen dependent on the metastatic site and proximity to normal tissues. If allocated to SBRT, SBRT will precede SOC. All patients should commence SOC therapy within 4 weeks of completing SBRT treatment.
1527641|NCT02759783|Other|Standard of Care|Choice of standard of care treatment at the discretion of the local oncologist. This may include: Chemotherapy, Endocrine therapy, surgery, palliative radiotherapy
1527642|NCT02759770|Other|no intervention|
1527643|NCT02759757|Other|Kinesio Taping|This is a tape that can be placed in different parts of the body using different shapes and tensions. In theory, this tape can change muscle activity.
1527644|NCT02759757|Other|Placebo|A micropore tape will be used as placebo
1527647|NCT02759718|Biological|Chromogranin A|The plasma level of chromogranin A (CgA) was measured in enrolled patients who was diagnosed as PNET in preoperative condition.After surgical resection, the CgA level was only measured in the the patient with PNET. In the PNET group, the CgA level was regularly checked in a 3, 6, 12, and 24 months after surgical resection.
1527648|NCT02759692|Device|TEST Contact Lens|
1527649|NCT02759692|Device|CONTROL Contact Lens|
1527650|NCT02759679|Other|Human breath samples|
1527651|NCT02759666|Drug|SHR3162|SHR3162 capsule(s) is administered orally QD.
1527652|NCT02759640|Drug|HS-10241|HS-10241 is administered orally starting at 100 mg/day.
1527653|NCT02759627|Other|Robotic-Assisted Gait Training|"There were three intervention arms in this study,
Robotic-Assisted Gait Training,
Conventional Training,
Combined Training."
1527654|NCT02759614|Drug|Bevacizumab|Bevacizumab15mg/kg by intravenous drip infusion on day 1 of a 21-day (within 3 days) cycle and Erlotinib orally once daily at 150mg/day
1527655|NCT02759614|Drug|Erlotinib|Erlotinib 150mg, orally once a day
1527656|NCT02759601|Drug|Tefinostat|Tefinostat is a novel type of HDACi used in cancer targeted specifically to cell of monocyte - macrophase lineage
1527657|NCT02759588|Biological|GL-ONC1|A genetically-engineered oncolytic vaccinia virus administered via intraperitoneal infusion as multiple doses.
1527658|NCT02759575|Drug|Pembrolizumab|200mg every 3 weeks starting 3 weeks prior to chemoradiotherapy. Maximum of 4 doses
1527659|NCT02759575|Radiation|Radiation Therapy|70 Gy in 35 fractions over 7 weeks
1527660|NCT02759575|Drug|Cisplatin|100 mg/m2 every 3 weeks starting on day 1 of chemoradiotherapy. Maximum of 3 doses.
1527661|NCT02759562|Drug|Andecaliximab|Administered subcutaneously
1527662|NCT02759562|Drug|Placebo|Administered subcutaneously
1527663|NCT02759549|Behavioral|eSMART-MH|eSMART-MH (Electronic Self-Management Resource Training for Mental Health) is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programmed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. eSMART-MH will be used once a week throughout the duration of radiation treatment.
1527664|NCT02759549|Other|Mobile Mood Tracking (Mood 24/7)|Public social media data posted by participants will be accessed and downloaded to a computer program. Permission for the study team to access this data is optional.
1527665|NCT02759549|Behavioral|Theater Testing Workshop|The theater testing workshop consists of one to two one-on-one sessions with study staff during which participants will review a computer program for its content and usability, as well as discuss areas for improvement. Participants will also be asked to complete questionnaires and a attend a brief interview regarding any suggested improvements for the computer program.
1527666|NCT02759536|Radiation|Boronophenylalanine and IHNI-based BNCT|Patients will be infused Boronophenylalanine (BPA)-fructose solution intravenously at a dose of 350mg/kg over 90 minutes. After BPA infusion, patients will receive neutron irradiation in IHNI for a certain period of time based on his boron bio-distribution curve and BPA concentration in the blood.
1527667|NCT02759510|Drug|Norepinephrine|Hypotension (systolic BP <80% of baseline) will be treated with intravenous boluses of norepinephrine 2 μg.
1527668|NCT02759510|Drug|Phenylephrine|Hypotension (systolic BP <80% of baseline) will be treated with intravenous boluses of phenylephrine 40 μg.
1527669|NCT02759497|Other|serum amyloid A level|serum amyloid A level (SAA)
1527670|NCT02759484|Behavioral|Home Based Enhanced Education|The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home. Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study. The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
1527671|NCT02759484|Behavioral|Clinic Based Enhanced Education|The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator. Participants in this arm will also receive 24 newsletters with diabetes self-management education.
1527672|NCT02759471|Device|comfilcon A sphere lens (control)|contact lens
1527676|NCT02759445|Other|routine treatment|No intervention, only observation and describing
1527679|NCT02759406|Device|coronary stent|
1527680|NCT02759393|Drug|Dexlansoprazole|receiving 8-week PPI
1527681|NCT02759393|Drug|Lansoprazole|receiving 8-week PPI
1527683|NCT02759367|Other|High potassium diet|An increase in consumption of high potassium fruits and vegetables
1527685|NCT02759341|Other|Manual for the Assessment and Documentation of Psychopathology (AMDP 8)|
1527686|NCT02759341|Other|Million Clinical Multiaxial Inventory 3 (MCMI-III)|
1527687|NCT02759341|Other|State-Trait Anxiety Inventory form Y (STAI-Y)|
1527688|NCT02759341|Other|SF-36 Health-Related Quality of Life|
1527689|NCT02759341|Other|Blood oxygenation level dependent- functional Magnetic Resonance Imaging (BOLD-fMRI)|
1527690|NCT02759328|Behavioral|Xbox Kinect™ training|Xbox Kinect™ (Xbox 360, Microsoft, United States) game console which is one of the commercial interactive game consoles was used. It was comprised of 3 components; Kinect™ sensor, Xbox 360™ game console and 42 inch Liquid crystal display (LCD) television.
1527691|NCT02759328|Behavioral|Conventional rehabilitation|The conventional rehabilitation program consisted of passive and active range of motion exercises, therapeutic stretching, muscle strengthening, neurophysiologic exercises, sitting, standing, balance and gait exercises, occupational therapy and activities of daily living training such as eating, grooming, dressing, toileting and transfer.
1527694|NCT02759263|Behavioral|Cogmed Working Memory Training|Cogmed Working Memory Program will be used as a computerized home-based intervention. Families will receive a link for downloading a web-based software program. The program will be installed on a computer at a family's home by a research assistant. Parents and adolescents will be actively involved, and during the installation session, adolescents will complete several practice trials. The 25 sessions will be completed individually by the adolescent with parental supervision. For the first 5 sessions, the participant trains on the same set of games; on the 6th session and every 5th session thereafter, a new task is introduced and replaces one of the initial tasks. At the end of each session, the adolescent can play an age-appropriate computerized game as a reward. After each session, results are uploaded by parents to a secure website, to keep track of the participant's progress. Families will be contacted weekly to check program function and discuss concerns.
1527695|NCT02759250|Drug|ARGX-110|
1527696|NCT02759237|Device|CoreValve System Family|"Bioprosthesis: Transcatheter Aortic Valve Implant (TAV - Heart Valve) -Different Models/Sizes of CoreValve/CoreValve Evolut R.
Delivery Catheter System: ACCUTRAK & EnVeo R - Used to facilitate the placement of the bioprosthesis within the annulus.
Loading System: Compression Loading System & EnVeo R Loading System - Used to load the TAV onto the delivery system"
1527697|NCT02759224|Drug|BRI-1501|
1527698|NCT02759224|Drug|Lafutidine|
1527699|NCT02759224|Drug|Irsogladine maleate|
1527700|NCT02759211|Other|Backwards Walking|The Backwards Walking Group will perform backwards walking for the entire treatment intervention.
1527701|NCT02759211|Other|Forwards Walking|The Forwards Walking Group will perform forwards walking for the entire treatment intervention.
1527702|NCT02759198|Drug|YH23537|Drug: YH23537 750mg Drug: YH23537 1500mg Drug: YH23537 3000mg
1527703|NCT02759198|Drug|Celecoxib|Drug: Celecoxib 200mg
1527704|NCT02759198|Drug|YH23537 placebo|Drug: YH23537 750mg placebo Drug: YH23537 1500mg placebo Drug: YH23537 3000mg placebo
1527705|NCT02759185|Drug|High THC Marijuana|Three weeks of smoking marijuana containing more THC than CBD, with amount smoked limited to no more than 1.8 g per day.
1527706|NCT02759185|Drug|High CBD Marijuana|Three weeks of smoking marijuana containing more CBD than THC, with amount smoked limited to no more than 1.8 g per day.
1527707|NCT02759185|Drug|High THC/high CBD marijuana|Three weeks of smoking marijuana containing equal amounts of THC and CBD, with smoking limited to no more than 1.8 g per day.
1527708|NCT02759185|Drug|Placebo marijuana|Three weeks of smoking marijuana with low levels of THC and CBD, with smoking limited to no more than 1.8 per day.
1527709|NCT02759172|Behavioral|Safety Planning Intervention|Brown and Stanley's Safety Planning Intervention (SPI) is a brief, adjunctive intervention designed to reduce subsequent suicidal behavior in high-risk populations. The core element of SPI is the collaborative development of the Safety Plan, which is a prioritized written list of coping strategies and supports that individuals can use during or preceding suicidal crises. In this study, safety planning will occur during pretrial jail detention, with telephone follow-up in the community to conduct risk assessment, review the Safety Plan, problem-solve obstacles to treatment, and assist with linkage to services.
1527710|NCT02759159|Procedure|true acupuncture|"acupuncture at the four-gateacupoints, three times per week and last for 6 months"
1527711|NCT02759159|Procedure|sham acupuncture|"acupuncture at the places 1cm from the true four-gate acupoints,three times per week and last for 6 months"
1527712|NCT02759146|Other|Reflexology|Reflexology is a specialized foot therapy that applies a firm walking motion pressure to the feet. It is based on the premise that the foot has reflexes that mirror the rest of the body. It has been shown to reduce symptoms.
1527713|NCT02759146|Other|Meditative Practices|Meditative Practices include elements of meditation, gentle yoga and breathing exercises. These practices focus purposeful attention to the present moment and have been shown to enhance one's ability to adapt to serious health concerns
1527714|NCT02759133|Device|Metal wire|Localization technique for breast surgery using metal wire
1527715|NCT02759133|Device|Radioactive Iodine Seed|Localization technique for breast surgery using Radioactive Iodine Seed
1527716|NCT02759120|Drug|Antimicrobial therapy: Co-trimoxazole or Doxycycline|160mg trimethoprim/800mg sulfamethoxazole (double strength co-trimoxazole) twice daily plus folic acid 5 mg daily OR doxycycline 100mg once daily if weight < 50 kilograms or 100mg twice daily if weight > 50 kilograms for up to 42 months
1527717|NCT02759120|Other|No Intervention: Standard of Care|Standard of care
1527718|NCT02759107|Drug|LY3298176|Administered SC
1527719|NCT02759107|Drug|Placebo|Administered SC
1527720|NCT02759107|Drug|Dulaglutide|Administered SC
1527721|NCT02759094|Device|Treatment with RefluxStop|A standard laparoscopic approach will be used to reposition the lower oesophageal sphincter (LES) to its intra-abdominal position. The RefluxStop device will be then positioned and fixed in the gastric funds to ensure intra-abdominal positioning of the GEJ (Gastro-oesophageal Junction) at all time. After confirming proper placement, the laparoscopic implant procedure will be completed and access points will be closed.
1527722|NCT02759081|Device|cap-assisted water exchange|a transparent cap was mounted to the tip of colonoscopy when water exchange was performed.
1527723|NCT02759081|Procedure|water exchange|water was infused and suctioned at the same time during insertion of colonoscope
1527724|NCT02759068|Behavioral|sounds and odors|presentation of sounds and odors
1527725|NCT02759055|Other|Clinical Decision Support|an EHR-linked, Web-based clinical decision support (CDS) system that identifies patients with prediabetes and provides patients and their primary care providers personalized, evidence-based CDS and follow up to reduce risk of heart attacks or stroke
1527726|NCT02759042|Drug|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
1527727|NCT02759029|Drug|eradication of Helicobacter pylori|"clarithromycin-based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk
concomitant therapy group Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Clarithromycin 500mg, PO, BID, 1wk Metronidazole 500mg, PO, BID, 1wk
bismuth based quadraple therapy Pantoloc 40mg, PO, BID, 1wk Bismuth, 300mg, PO, QID, 1wk Tetracycline, 500mg, PO, QID, 1wk Metronidazole, 500mg, PO, TID, 1wk
levofloxacine based triple therapy Pantoloc 40mg, PO, BID, 1wk Amoxacillin 1g, PO, BID, 1wk Levofloxacin 500mg, PO, QD, 1wk"
1527728|NCT02759016|Drug|BI 836826|
1527729|NCT02759016|Drug|Ibrutinib|Standard of Care
1527730|NCT02759003|Procedure|Nightime NIV initiation|In-hospital vs home
1527731|NCT02758990|Dietary Supplement|Vitamin A|Subjects will be asked to increase vitamin A intake by 8000 International Units per day.
1527732|NCT02758990|Dietary Supplement|Vitamin B6|Subjects will be asked to increase vitamin B6 intake by 50 mg per day.
1527733|NCT02758990|Dietary Supplement|Vitamin C|Subjects will be asked to increase vitamin C intake by 500 mg per day.
1527734|NCT02758990|Dietary Supplement|Nicotinamide|Subjects will be asked to increase Nicotinamide intake by 500 mg per day.
1527735|NCT02758990|Dietary Supplement|Vitamin D3|Subjects will be asked to increase Vitamin D3 intake by 1000 International Units per day.
1527736|NCT02758990|Dietary Supplement|Vitamin E|Subjects will be asked to increase vitamin E intake by 400 International Units per day.
1527737|NCT02758990|Other|Broccoli|Subjects will be asked to increase broccoli intake by 8 fluid ounces (~91 grams) per day.
1527738|NCT02758990|Other|Spinach|Subjects will be asked to increase spinach intake by 8 fluid ounces (~30 grams) per day.
1527739|NCT02758990|Dietary Supplement|Caffeine|Subjects will be asked to increase caffeine intake by taking 200mg caffeine orally once per day.
1527740|NCT02758990|Other|Coffee|Subjects will be asked to increase coffee intake by drinking 2 cups (177 mL each) of coffee per day.
1527741|NCT02758990|Device|Axon Eyewear|Subjects will be asked to utilize the therapeutic eyewear when exposed to bright or fluorescent light.
1527742|NCT02758990|Other|Chocolate|Subjects will be asked to increase chocolate intake by eating 57g per day.
1527743|NCT02758977|Procedure|ALPPS|For detailed information please refer to description of experimental arm
1527744|NCT02758977|Procedure|TWO STAGE HEPATECTOMY|For detailed information please refer to description of active comparator arm
1527745|NCT02758964|Other|MRI, neurocognitive Testing|A cerebral MRI and neurocognitive testing will be performed before TAVR, before hospital discharge and after 3 months
1527746|NCT02758951|Drug|Perioperative systemic therapy|"Neoadjuvant setting
1.1 CAPOX + bevacizumab
Three 3-weekly cycles of capecitabine (1000 mg/m2), oxaliplatin (130 mg/m2), and bevacizumab (7.5 mg/kg). In case of stable or responsive disease, a 4th cycle of CAPOX without bevacizumab is administered.
1.2 FOLFOX + bevacizumab
Four 2-weekly cycles of leucovorin (400 mg/m2), bolus 5-FU (400 mg/m2), continuous 5-FU (2400 mg/m2), oxaliplatin (85 mg/m2), and bevacizumab (5 mg/kg). In case of stable or responsive disease, a 5th and 6th cycle of FOLFOX without bevacizumab are administered.
NB: in patients with toxicity to oxaliplatin, FOLFOX/CAPOX may be switched to FOLFIRI (irinotecan: 180 mg/m2).
Adjuvant setting
FOLFOX or CAPOX without bevacizumab, according to the neoadjuvant regimens. In patients with toxicity to oxaliplatin, FOLFOX/CAPOX may be switched to 5-FU/capecitabine monotherapy."
1527747|NCT02758951|Procedure|Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC)|"Median laparotomy
Inspection with PCI assessment
Cytoreductive surgery with omentectomy (always), peritonectomy (only if indicated) and visceral resections (only if indicated)
In case of a complete cytoreduction (CC0/1), HIPEC (Coliseum) is performed with mitomycin C or oxaliplatin, according to the preference of the treating hospital.
In case of HIPEC with oxaliplatin: IV 5-fluorouracil (400 mg/m2) and leucovorin (20 mg/m2), followed by IP oxaliplatin (460 mg/m2, 30 minutes).
In case of HIPEC with mitomycin C: IP mitomycin C (35mg/m2, 90 minutes).
Aspiration of peritoneal fluid
Reconstruction with bowel anastomoses if indicated.
Formation of ostomy if indicated.
Drain placement & closure"
1527748|NCT02758938|Other|Urologic biofeedback software|All subjects (end users) will be walked through the urologic biofeedback software training suite. Each end user will follow a protocol that is specific to their role. Upon completing their session(s) with the software, each end user will provide appropriate feedback.
1527749|NCT02758925|Drug|Rituximab|375mg/m2 IV day 1
1527750|NCT02758925|Drug|Bendamustine|90mg/m2 IV day 1-2
1527751|NCT02758925|Drug|Cytarabine|1000mg/m2 or 750mg/m2 at day 2 if patients aged more than 70 years or toxicity grade 3/4
1527752|NCT02758912|Drug|оral intake of study drug capsules; study drug - Cardionat ® (trimethylhydrazinium propionate dihydrate), oral capsules 250 mg|
1527788|NCT02758626|Drug|ataluren|Powder formulation
1527753|NCT02758886|Behavioral|Animal assisted activity|Allowed to interact (e.g. talking, petting, scratching, feeding treats, playing with) live animals
1527754|NCT02758886|Behavioral|Animal photos|A 10 minute, silent, PowerPoint slide show of a variety of dogs and cats
1527755|NCT02758873|Genetic|Personalised medicine (Salmeterol)|If participants require add-on medication and have the Gly/Gly variant on the ADRB2, salmeterol will be prescribed.
1527756|NCT02758873|Genetic|Personalised medicine (Montelukast)|If participants require add-on medication and have the Arg/Arg or Arg/Gly variant on the ADRB2, montelukast will be prescribed.
1527757|NCT02758873|Other|Standard care|If participants require add-on medication in the arm, they will be prescribed either salmeterol or montelukast according to health professional's choice based on current guidelines.
1527758|NCT02758860|Procedure|Colonoscopy|Patients will be submitted to diagnostic colonoscopy
1527759|NCT02758847|Device|Angiogram, Medtronic DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. Each participant will receive angiogram with DCB (drug coated balloon)/stenting with wound debridement. 50% of subjects will receive an Angiogram, Medtronic DCB (paclitaxel)/stent. Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
1527760|NCT02758847|Device|Angiogram, Bard DCB (paclitaxel)/stent|Paclitaxel® coated balloons will be used for patients identified with Critical Limb Ischemia (CLI) and Tissue Loss. 50% of subjects will receive 'Angiogram, Bard DCB (paclitaxel)/stent' . Tissue samples will be sent to pathology for specific staining to evaluate trace evidence of the drug paclitaxel.
1527761|NCT02758821|Other|No CRP will be measured onsite|No CRP will be measured onsite
1527762|NCT02758821|Other|CRP cut-off of 20mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever < 20mg/L.
1527763|NCT02758821|Other|CRP cut-off of 40mg/L.|Health care worker will be given an advice to prescribe antibiotic to patient who has CRP lever < 40mg/L.
1527764|NCT02758795|Dietary Supplement|CONTROL|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
1527765|NCT02758795|Dietary Supplement|NUTRIENT|Following an overnight fast, participants submit to cannulation of a superficial arm vein from which are drawn serial samples of blood prior to and for 3 hours following ingestion of a prescribed protein 'shake'
1527766|NCT02758782|Biological|Golimumab|
1527767|NCT02758782|Drug|Celecoxib|
1527769|NCT02758756|Other|Massage|Treatments will be on a massage table and last up to 75 minutes. We do not specify what will occur during the massage treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. We specify that energy healing techniques not be used, because that is our research comparison condition. We also specify that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
1527770|NCT02758756|Other|Reiki|Reiki treatments will be provided by Reiki Masters on a massage table and last up to 75 minutes. We will not specify what will occur during the Reiki treatments. Instead we will follow the model of relying on the professional expertise of the therapist in combination with input from the client to determine what should happen in the session. That being said, we will ask that two specific things be kept to a minimum. The first is that we ask that Swedish massage techniques not be used, because that is our research comparison condition. The second is that conversation between the massage therapist and the patient be kept to the minimum necessary to effectively provide the treatment. This is not meant to be talk therapy.
1527771|NCT02758743|Drug|Acetium Lozenge|Slow-release L-Cysteine to block smoke.derived acetaldehyde in saliva thereby inhibiting the formation of harmans
1527772|NCT02758743|Drug|Placebo|Placebo with no active substance will not have the effect on intervention device.
1527773|NCT02758730|Biological|AFFITOPE® PD01A + Adjuvant|s.c. injection
1527774|NCT02758730|Biological|Adjuvant without active component|s.c. injection
1527778|NCT02758704|Other|High stress|Generation of a stressful environment during a neonatal intubation procedure.
1527779|NCT02758704|Other|Low stress|Absence of stressful stimuli during neonatal intubation procedure
1527780|NCT02758704|Other|Endotracheal intubation on mannequin|Endotracheal intubation will take place at the simulation centre on a mannequin.
1527781|NCT02758691|Drug|Intranasal Insulin|All participants in the devise testing portion of the study will self-administer a 20 IU dose of intranasal insulin. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 IU dose of intranasal insulin.
1527782|NCT02758691|Drug|Intranasal Saline|All participants in the devise testing portion of the study will self-administer a 20 mL dose of intranasal saline. Half of the participants in the function Magnetic Resonance Imaging portion of the study will also self-administer a 20 mL dose of intranasal saline.
1527783|NCT02758678|Biological|A single 2 ml heparinised peripheral blood sample|A single 2 ml heparinised peripheral blood sample was centrifuges to get serum specimens. Serum separation and Raman spectroscopy analysis:
1527784|NCT02758665|Drug|ibrutinib|
1527785|NCT02758665|Drug|obinutuzumab|
1527786|NCT02758665|Drug|venetoclax|
1527787|NCT02758639|Behavioral|Wonders & Worries Psychosocial Intervention|Session 1: Getting to Know Each Other The goal is to create a sense of safety within the group so that the children feel comfortable discussing difficult topics. Session 2: Cancer Education to provide developmentally appropriate education about the illness, treatment, and side effects. Session 3: Cancer Treatment Center Tour: This session consists of a treatment center tour and education about treatment plan involved in family's care in a safe environment. Session 4: Feelings: The focus of this session is expression and validation of all feelings the children may experience. Session 5: Stress and Coping: Goal is to emphasize the different ways individuals cope and differentiate positive vs. negative coping strategies. Session 6: Hopes for the Future/Closure: An emphasis is made on the idea that positive things may evolve from the most difficult circumstances.
1527792|NCT02758600|Other|Cycle ergometer exercise rehabilitation protocol|Patients will be submitted to a progressive and moderate exercise protocol with a portable cycle ergometer.
1527793|NCT02758587|Drug|Defactinib|cross reference with arm/group descriptions
1527794|NCT02758587|Drug|Pembrolizumab|cross reference with arm/group descriptions
1527795|NCT02758574|Procedure|CDT without ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus a standard infusion catheter will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus.
1527796|NCT02758574|Procedure|CDT with ultrasound acceleration|A pulmonary arteriogram will be performed. Upon confirmation of the pulmonary embolus an infusion catheter that incorporates an ultrasound emitting wire will be placed within the clot. The catheter will be used for infusion of thrombolytics to treat/dissolve the pulmonary embolus. The wire will be connected to an ultrasound generating device.
1527797|NCT02758561|Behavioral|Workshop|"The first 15 minutes will be an information session on either Urinary Incontinence (UI) or Pelvic Organ Prolapse (PO) led by a Nurse Continence Advisor.
The following 60 minutes will comprise a psychologist-led group discussion. The structured discussion will encourage participants to share experiences, thoughts, and feelings on pelvic floor disorders. Resistances and barriers to seeking treatment will be discussed. Decision-making processes will be explored.
During the final 15 minutes, participants will be asked to complete a survey to evaluate the workshop. The survey will assess satisfaction with the information provided, quality of group discussion, comfort level with the group experience, and their satisfaction with the roles of the nurse continence advisor and psychologist."
1527798|NCT02758548|Procedure|Blood sample|Fingerprick and venous
1527799|NCT02758548|Device|POCT device|Investigational device
1527800|NCT02758535|Device|coaxial renal biopsy|In this method, a larger introducing needle is used for the puncture. The introducing needle is advanced just to the outer cortex of the kidney, and the needle angle is adjusted so that the needle pathway became mostly in the renal cortex, then the biopsy needle is inserted throughout the introducing needle and at least 4 cores are obtained. In this technique, the skin surface is punctured only once during the procedure.
1527801|NCT02758535|Device|noncoaxial renal biopsy|In this method, introducing needle is not used. Biopsy needle punctures the skin surface and the needle is advanced to about 10-15 mm into the renal cortex, and tissue sampling is done. After each sampling, the needle is removed and then for the next biopsy, the whole procedure is repeated until four cores being taken.
1527802|NCT02758522|Drug|Once-daily Insulin|Patients will receive NPH insulin in a once-daily regimen. The starting dose is calculate according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the once-daily regimen will be administered subcutaneously before breakfast. Regular insulin subcutaneously wil be given in three equally divided doses before each meal.
1527803|NCT02758522|Drug|Twice-daily Insulin|Patients receive NPH insulin in twice-daily regimen. The starting dose is calculated according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will de fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the twice-daily regimen will be administered subcutaneously before breakfast and before dinner. Regular insulin will be given in three equally divided doses before each meal.
1527804|NCT02758522|Drug|Triple-daily Insulin|Patients receive NPH insulin in a triple-daily regimen. The starting dose was calculated according to body mass index (BMI): 0.3 U/kg for BMI < 18 kg/m2, 0.4 U/kg for BMI 18-24.9 kg/m2, 0.5 U/kg for BMI 25-29.9 kg/m2 and 0.6 U/kg for BMI ≥ 30 kg/m2. The resulting dose will be fractioned to be given 60% as basal insulin (NPH) and 40% as prandial insulin (Regular). NPH insulin in the triple daily regimen will be administered subcutaneously before each meal. Regular insulin will be given in three equally divided doses before each meal.
1527805|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin|
1527806|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin + Boceprevir|
1527807|NCT02758509|Drug|Pegylated interferon alfa-2a + Ribavirin +Telaprevir|
1527808|NCT02758509|Drug|Ledipasvir/Sofosbuvir|
1527809|NCT02758509|Drug|Ombitasvir/paritaprevir/ritonavir+Dasabuvir|
1527810|NCT02758509|Drug|Daclatasvir+Sofosbuvir|
1527811|NCT02758509|Drug|Simeprevir+Sofosbuvir|
1527812|NCT02758496|Other|MeRT Efficacy Chart Review|There will be not intervention. This is a chart review.
1527813|NCT02758483|Other|Control diet|Diet with a little quantity of sugars (30.40g; 12.7% of total carbohydrates of the diet).
1527814|NCT02758483|Other|Test Diet|Diet with foods containing moderate quantity of sucrose in composition (80.22g; 30.2% of total carbohydrates of the diet).
1527815|NCT02758470|Drug|Acetazolamide|250 mg, taken orally three times per day
1527816|NCT02758470|Drug|Methazolamide|100mg, taken orally two times per day. A placebo pill will be taken between each dose of methazolamide to match the timing of doses and the number of pills between study arms.
1527817|NCT02758470|Other|Placebo|A placebo will be taken three times per day
1527818|NCT02758457|Device|dental crowns|
1527819|NCT02758444|Dietary Supplement|Micronutrient Powder (MNP) + 15 mg Zn|Children will have the supplement powder added to one meal on study day 1. Absorption of zinc from this meal will be measured using zinc stable isotope techniques.
1527820|NCT02758444|Dietary Supplement|MNP + 10 mg Zn|Same as above except MNP will contain 10 mg Zn
1527821|NCT02758444|Dietary Supplement|MNP + 5 mg Zn|Same as above except MNP will contain 5 mg Zn
1527822|NCT02758444|Dietary Supplement|MNP without Zn|Same as above except MNP will not contain Zn
1527823|NCT02758431|Drug|Acyline|Acyline 300ug/kg injection will be administered on Day 0 and on day 14
1527824|NCT02758431|Drug|Placebo Gel|Placebo gel packet applied daily for 28 days.
1527825|NCT02758431|Drug|Placebo Tablet|Placebo oral tablet taken daily for 28 days.
1527826|NCT02758431|Drug|Testosterone Gel|Testosterone Gel applied daily for 28 days
1527827|NCT02758431|Drug|Arimidex|Arimidex Oral Tablet 1mg taken orally daily for 28 days
1527828|NCT02758418|Other|TAO|"TAO is a self-applied online treatment program and consists on the computerized version of the traditional CBT protocol for Adjustment Disorders.
The treatment protocol comprises different therapeutic components (see section Intervention) which are presented to the patients through 7 modules (one of them introductory). The Internet platform allows audiovisual resources (videos, illustrations, music and exercises that provide quick feedback) to be included, that makes the program more interactive."
1527829|NCT02758418|Other|Bibliotherapy|This group receives the same CBT protocol for Adjustment Disorders described above. In this case, the 7 modules are sent to the participants by e-mail in PDF format. Although the treatment manuals do include illustrations, the users do not have access to other audiovisual resources.
1527830|NCT02758405|Drug|Bupivacaine|0.125% Bupivacaine plus fentanyl 2mcg/ml
1527831|NCT02758405|Drug|Fentanyl|0.125% Bupivacaine plus fentanyl 2mcg/ml
1527832|NCT02758405|Device|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
1527833|NCT02758392|Drug|JNJ-61178104 Intravenous|Participants will receive JNJ-61178104 Intravenously on Day 1.
1527834|NCT02758392|Drug|JNJ-61178104 Subcutaneous|Participants will receive JNJ-61178104 Subcutaneously on Day 1.
1527835|NCT02758392|Drug|Placebo|Participants will receive placebo on Day 1.
1527836|NCT02758379|Device|Shockwave Coronary Lithoplasty System|Lithotripsy shockwaves are used to fracture calcified lesions in the coronary arteries
1527837|NCT02758366|Drug|Doxorubicin|
1527838|NCT02758353|Drug|Community distribution of SP|SP delivered at both the community and facility level by trained CBHVs in three LGAs.
1527839|NCT02758340|Drug|Misoprostol|Women would be given misoprostol tablet by mouth
1527840|NCT02758340|Device|foley's balloon catheter|foley's balloon catheter would be inserted through vagina into cervix.
1527841|NCT02758327|Drug|TheraTears Lubricating Eye Drops|Sodium Carboxy-methylcellulose 0.25% eye Lubricant
1527842|NCT02758314|Other|Evaluation of PD-1/PDL-1 expression.|Evaluate the expression of PD-1 / PD-L1 on T-cell subpopulations of peripheral blood by flow cytometry and in tumor tissue by immunohistochemistry in NSCLC, free treatment and healthy subjects
1527843|NCT02758301|Device|Reveal LINQ™ Insertable Cardiac Monitor (ICM)|Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download
1527844|NCT02758288|Other|New Protocol - BK viremia or BK virus nephropathy|Data collected prospectively that will follow new clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
1527845|NCT02758288|Other|Standard Protocol - BK viremia or BK virus nephropathy|Data collected retrospectively that followed standard clinical practice guidelines that were developed by Loma Linda Nephrology group with collaboration with Transplant surgeons to improve care of patients complicated with BK viremia or BK virus nephropathy.
1527847|NCT02758262|Device|Noninvasive brain stimulation|
1527848|NCT02758249|Drug|Sevoflurane|patients are anesthetized by using sevoflurane inhalation
1527849|NCT02758249|Drug|propofol|patients are anesthetized by using propofol infusion
1527850|NCT02758236|Other|No Intervention|No Intervention
1527851|NCT02758223|Biological|TCM allogeneic humane central memory T cells, cryopreserved|Experimental: TCM allogeneic humane central memory T cells, cryopreserved Solution for injection (intravenous use) up to 65*10^4 TCM /kg body weight patient will receive investigational product 3 times (Day 30, Day 60, Day 90 after alloHSCT)
1527852|NCT02758210|Device|Use of a Tablet|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using Tablet and while using the Tablet. The measured position of the Tablets tested will be normal routine position (noting at least 6 inches/15 centimeters from their pacemaker).
1527853|NCT02758210|Device|Use of a Smart Phone|Testing of the electromagnetic field exposure and it's affect on the participant's previously implanted MICRA device is assessed by interrogation of the device before using a Smart phone and while using the Smart phone. The position of the Smart phone tested will be normal position at the ear and while texting (noting at least 6 inches/15 centimeters from their pacemaker).
1527854|NCT02758197|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Participants assigned to this group will be enrolled in an Mindfulness-Based Stress Reduction (MBSR) course directly following medical treatment optimization. The MBSR course consists of eight weekly 2-hour sessions and one 6 hour session midway through the course and involves psychoeducation, relaxation techniques, gentle stretching (very mild form of yoga), and different forms of meditation. Participants will learn ways to better cope with their pain and the disability and distress related to it with a goal of reducing the stress response that is our body's normal reaction to pain. All sessions will be conducted by a psychologist or social worker with a minimum of 2 years of experience in chronic pain management, formal MBSR training and 2 years of experience leading MBSR groups.
1527855|NCT02758184|Device|ROTEM-based coagulation monitoring|
1527887|NCT02757950|Biological|Combined diphtheria, tetanus and tricomponent acellular pertussis vaccine [Refortrix (Tdap)]|Subjects were included in the Exposed cohort if they received Refortrix as part of the maternal immunization program in Brazil.
1527859|NCT02758145|Other|Flu vaccination information in 3 phases|"An oral information is given by the nurse during the recruitment visit at the occupational medicine unit. She initiates the discussion on flu and asks the employee if he usually receives the vaccine. Then she provides a brief standardized information on recommendations concerning flu vaccination, and the annual influenza vaccination campaign in CHUV and PMU. She responds to questions.
After the interview, she gives an informative document with key messages (information about the disease, benefits to be vaccinated, vaccine safety, etc.). The document includes frequently asked questions, website address, and the email address of the occupational medicine unit in case of questions.
The third phase consists of sending to the employee shortly after the start of the next campaign of flu vaccination (November 2016), a postal mail recalling the information provided during the recruitment examination and inviting them to get vaccinated."
1527860|NCT02758132|Biological|Denosumab|One 120 mg subcutaneous injection every four weeks. Protocol therapy will consist of 28-day cycles until no clinical benefit, confirmed disease progression or unacceptable toxicity.
1527861|NCT02758132|Drug|Enzalutamide|160 mg enzalutamide by mouth daily
1527862|NCT02758132|Drug|Abiraterone|1000 mg abiraterone by mouth daily
1527863|NCT02758132|Drug|Prednisone|5 mg prednisone by mouth twice daily
1527864|NCT02758119|Other|Serious Game|
1527865|NCT02758119|Other|Online course|
1527866|NCT02758106|Device|Vest Airway Clearance System Model 105|HFCWO for 15 minutes then sputum suction.
1527867|NCT02758106|Device|placebo intervention|CCPT for 15 minutes then sputum suction.
1527872|NCT02758067|Drug|brexpiprazole|2- 4 mg/day, tablets, oral, 28-weeks
1527873|NCT02758067|Drug|risperidone|4-6 mg/day, tablets, oral, 28-weeks
1527874|NCT02758054|Behavioral|Patient Navigation|Patient navigated reminder calls containing information about screening appointments, reminders, hints to facilitate communication with physicians, and smoking cessation.
1527875|NCT02758041|Device|Sebacia Microparticles|
1527876|NCT02758028|Behavioral|Brief counseling|"Peer counselling is delivered based on the queries and the needs of individual clients, according to the smoking status, dependency level and the perceived barriers of each individual with the use of motivational intervention approach. Counsellors will emphasizes the identification, use, and modification of personally relevant coping strategies. Advice will be provided on overcoming expected difficulty, withdrawal symptoms and relapse prevention during quitting.
The subjects will be followed up at 1-week, 1-, 3-, 6-, 9-, 12- and 24-month via telephone assessing their smoking status and reinforce intervention. Self-reported quitters at 6- and 24-month were invited to perform saliva cotinine test (using NicAlert strip) and exhaled carbon monoxide to validate the smoking status, and incentives ($300) will be given to the successful quitters."
1527877|NCT02758015|Other|Standardized Meal|
1527878|NCT02758015|Dietary Supplement|Betaine Hydrochloride 1500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
1527879|NCT02758015|Dietary Supplement|Betaine Hydrochloride 3000mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
1527880|NCT02758015|Dietary Supplement|Betaine Hydrochloride 4500mg|Betaine hydrochloride (natural supplement) administered after standardized meal.
1527881|NCT02758002|Procedure|Firm ablation for transitional AF rotors|Transitional AF rotors will be mapped and ablated as part of this study. All subjects will undergo this ablation after standard PVI and Firm ablation for sustained rotors.
1527882|NCT02757989|Other|transplantation|allogeneic hematopoietic stem cell transplantation in patients with donor
1527883|NCT02757976|Device|Conventional CRT|Patients randomized to the Conventional CRT will receive a CRT device with or without ICD. The RA lead will be placed in the RA appendage or high RA. The RV lead should be placed at the RV apex or distal RV septum. The LV lead should be positioned through the CS to an LV branch. The lead should be placed at one of the left ventricular venous branches. Electrical testing, and programming of the devices will be standardized. Medtronic market release implant tools, leads and devices will be used. Acute hemodynamic measurement will be obtained in patients randomized to both treatment groups, to record LV pressure and to compute dP/dT. The site that results in the best dP/dT will be chosen for permanent LV lead implant.
1527884|NCT02757976|Device|LV endocardial CRT|Patients randomized to LV endocardial CRT will receive a CRT device with or without ICD, RA and RV leads implanted as the conventional CRT group. The device will be implanted in a facility that has the capacity to perform trans-atrial septal puncture with ultrasound guidance (TEE or ICE) at the time of implantation. The LV lead will be placed using a trans-atrial septal approach using a specially designed puncture tools and LVendo delivery tool kits specifically designed for this study. Acute hemodynamic measurement will be obtained in patients randomized to both treatment groups, to record LV pressure and to compute dP/dT. The site that results in the best dP/dT will be chosen for permanent LV lead implant.
1527885|NCT02757963|Other|Benign prostatic enlargement (BPE)/Benign prostatic obstruction (BPO) screening tool|The BPE/BPO screening tool has been developed using the currently recommended Food and Drug Administration (FDA) 2009 guidelines for developing patient-completed questionnaires such as Patient Reported Outcomes. The tool to be used in this study in the General Practice setting has undergone validation in a urology setting to demonstrate the validity of the tool in populations with and without a definite diagnosis of BPH. Subjects who have a positive score on the BPE/BPO screening tool (total score >=3) and meet all other eligibility requirements will be enrolled in Part I of the study.
1527886|NCT02757963|Other|International Prostate Symptom Score (IPSS) screening tool|The International Prostate Symptom Score (IPSS) score is a validated tool to assess the severity of LUTS symptoms, and has similarly been used for assessing symptomatic efficacy of treatments for BPH. Subjects who have a positive score on the IPSS tool (score >=8) and meet all other eligibility requirements will be enrolled in Part I of the study.
1527888|NCT02757937|Behavioral|Health & Wellness Website|Educational website for patients with chronic disease (i.e., Type 2 diabetes, asthma, high blood pressure, high cholesterol). The website is a free interactive resource to help patients manage their health condition(s) each day and to help them achieve their goals. It is a multichannel health and wellness platform to help patients adhere to their treatment and care plans between office visits.
1527889|NCT02757937|Other|Control Arm|Continue with standard diabetes care without getting access to the intervention website.
1527890|NCT02757924|Other|Infant formula supplemented with prebiotics|Sole source nutrition
1527891|NCT02757911|Genetic|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing XCGD gene. The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector. These transduced cells will be cryopreserved until safety testing and infusion into the patient.
1527892|NCT02757898|Drug|Biotin-Labeled Red Blood Cells (RBCs)|"500mL of blood will be drawn from each participant. The blood will be processed into a packed RBC unit.
For participants 1 and 2, the RBCs will be labeled with biotin at three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and the labeled RBCs will be re-infused into the participant on the same day of collection.
For participants 3 through 8, the RBCs will be stored at 2-6C for 40-42 days before being labeled with three pre-defined concentrations of biotin labeling reagent (2, 6, 18 µg/mL of RBCs) and re-infused into the participant.
Participants will have a 5 mL blood sample drawn within a few minutes of the re-infusion, the day after the re-infusion and then weekly for 70 days (10 weeks) to track the survival of the infused biotin labeled RBCs."
1527893|NCT02757885|Procedure|Bone Marrow Transplant (BMT)|Participants will receive a bone marrow infusion from a human leukocyte antigen (HLA) matched donor through a central venous catheter.
1527894|NCT02757885|Procedure|Bone Marrow Harvest (Donation)|The donation of bone marrow is a surgical procedure in which bone marrow is removed from the back of both of the hip bones through a large, hollow needle. At least two small cuts (less than ¼ inch) will be made in the skin to put the needle into the bone. Many small samples are collected through the needle into syringes. The total amount of marrow take will be up to ¼ ounce of marrow per pound. Bone marrow harvest is done under general anesthesia. Participants will be in the hospital for 8 to 10 hours.
1527895|NCT02757885|Drug|Hydroxyurea|Hydroxyurea is part of the bone marrow transplant preparative regimen. Hydroxyurea will be administered at a dose of 30 mg/kg orally as a single daily dose for 90 days (from day -100 to day-10). Hydroxyurea dosing will be based on adjusted body weight in participants weighing >125% ideal body weight.
1527896|NCT02757885|Drug|Thiotepa|Thiotepa is part of the bone marrow transplant preparative regimen. Thiotepa will be administered at a dose of 10mg/kg intravenously (IV) over 2 hours or per institutional guidelines on day -7. Thiotepa dosing will be based on adjusted body weight in patients weighing >125% ideal body weight.
1527897|NCT02757885|Drug|Fludarabine monophosphate|Fludarabine is part of the bone marrow transplant preparative regimen. Fludarabine 30 mg/m2/day will be administered from day -7 to day -3 (for a total of 150 mg/m2 over 5 consecutive days) and administered intravenously (IV) over a minimum of 30 minutes. In participants weighing > 125% ideal body weight, fludarabine will be dose based upon adjusted body weight.
1527898|NCT02757885|Drug|Cyclophosphamide|"Cyclophosphamide is part of the bone marrow transplant preparative regimen. Cyclophosphamide will be administered on days -6 and -5 prior to bone marrow infusion at a dose of 14.5 mg/kg intravenously (IV) infused over 1-2 hours.
Post bone marrow infusion cyclophosphamide will be infused on days +3 (between 60 and 72 hours post marrow infusion) and +4 (approximately 24 hours after day +3 dose) at a dose of 50 mg/kg IV infused over 1-2 hours.
For participants weighing more than 125% of their ideal body weight, dosing will be based on adjusted ideal body weight."
1527899|NCT02757885|Other|Rabbit Anti-thymocyte Globulin|Rabbit anti-thymocyte globulin (ATG) is part of the bone marrow transplant preparative regimen. It is an infusion of rabbit-derived antibodies against human T cells used for prevention of acute rejection in organ transplantation. Rabbit ATG will be administered on day -9 at 0.5 mg/kg and on days -8 and -7 at 2 mg/kg (for a total dose 4.5 mg/kg).
1527900|NCT02757885|Radiation|Total Body Irradiation|Participants will receive 200 cGy of TBI in a single fraction.
1527901|NCT02757872|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
1527902|NCT02757872|Drug|Omega-3 Fatty acids|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
1527903|NCT02757872|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
1527904|NCT02757872|Dietary Supplement|Fish oil placebo|Fish oil placebo
1527907|NCT02757833|Other|A 3 Tesla MRI scanner (Siemens, Erlangen Germany), will be used to measure levels of GSH in the brain.|Using the MEGA-PRESS pulse sequence, high resolution T1-weighted sagittal anatomic images covering the brain using an inversion-prepared MP-RAGE pulse sequence to produce high grey/white matter contrast will be acquired. These will be used to localize the spectroscopy voxel in the vmPFC. Magnetic field homogeneity will be optimized in the voxel using an automated map shimming procedure. MEGA-PRESS spectra will be acquired to detect the glutathione cysteinyl ß-CH2 peak at 2.95 ppm with the editing pulse set at the j-coupled a-CH resonance at 4.95 ppm. A reference unsuppressed water spectrum will be acquired for absolute quantification. Metabolite spectra will be fitted in the time domain using a Levenberg-Marquardt least squares minimization routine. The contribution of each metabolite to the in-vivo spectrum can be scaled to the water signal intensity from within the voxel of interest to obtain an absolute measurement of metabolite concentration.
1527908|NCT02757820|Device|LMA Classic|Patients will be anesthetized using Classic laryngeal mask airway that will be inserted lubricated with partially deflated cuff. After insertion, the cuff will be inflated with the recommended volume of air.
1527909|NCT02757820|Device|i- gel|Patients will be anesthetized using I-gel LMA with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
1527910|NCT02757820|Device|Air-Q|Patients will be anesthetized using Air-Q_ ILA, with its lubricated cuff inserted along the hard palate until resistance is felt, as recommended by the manufacturer.
1528055|NCT02756806|Device|Picosecond Q-switched laser|Each subject will receive up to 6 laser treatments.
1527911|NCT02757807|Behavioral|Utilization of Serenita for Relaxation|Users to use Serenita daily and before sexual interaction in order to assess stress and reduce it
1527912|NCT02757794|Other|computerized cognitive remediation program|a computer program online re-educating the working memory is completed by the parents and the child. The child made a series of interactive exercises accompanied by parents or a practitioner. The exercises are adapted automatically and individually to the performance at each session.
1527913|NCT02757794|Other|standard remediation|A speech therapy and / or academic support is realized.
1527914|NCT02757781|Behavioral|Community of Practice|The intervention group will be offered participation for 12 months in a virtual CdP based on a web 2.0 platform. The control group will receive usual training.
1527915|NCT02757768|Drug|Mirabegron|Oral
1527916|NCT02757768|Drug|Placebo|Oral
1527917|NCT02757768|Drug|Tamsulosin Hydrochloride|Oral
1527918|NCT02757755|Biological|AB-SA01 (10^8 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
1527919|NCT02757755|Biological|AB-SA01 (10^9 PFU per phage)|Gauze pads will be saturated with AB-SA01 and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
1527920|NCT02757755|Biological|Placebo (for Cohort 10^8)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
1527921|NCT02757755|Biological|Placebo (for Cohort 10^9)|Gauze pads will be saturated with Placebo and then applied to each subject's volar forearm and covered with occlusive dressing once daily for 3 consecutive days. Placement of the gauze to each subject's right or left volar forearm will be randomized and double-blinded.
1527922|NCT02757729|Drug|PAC-14028 cream 0.1%|Topical application
1527923|NCT02757729|Drug|PAC-14028 cream 0.3%|Topical application
1527924|NCT02757729|Drug|PAC-14028 cream 1.0%|Topical application
1527925|NCT02757729|Drug|PAC-14028 cream vehicle|Topical application
1527926|NCT02757716|Other|Questionnaire|Every patient who undergo surgery will fill out a questionnaire containing validated scales concerning food, alcohol, nicotine, internet and sport addiction prior and 6, 12 and 24 month after surgery.
1527927|NCT02757703|Drug|Somatostatin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
1527928|NCT02757703|Drug|Terlipressin|A decision to use vasoactive drugs (either somatostatin or terlipressin) depended on the favorite of participating attending physicians who were requested to fill out the enclosed questionnaires immediately after the administration of the first dose for further understanding the underlying reason of the chosen medication.
1527929|NCT02757703|Drug|Pantoprazole|Both study groups were administered with 40mg pantoprazole intravenously after EVL for 3 days, and following oral form for 12 days to hasten the process of healing of ulcers induced by ligation.
1527930|NCT02757703|Device|Endoscopic variceal ligation|Two experienced endoscopists performed emergent EVL for the enrolled patients with acute EVB. Pneumoactive ligation device (Sumitomo Bakelite Co., Ltd, Tokyo, Japan) and endoscopes (GIF XQ260; Olympus Co. Ltd, Tokyo, Japan) were applied. The targeted varix was suctioned and entrapped by a cap on endoscope. Ligation was aimed at active bleeding sites, red color spots or white nipple signs during the procedure.
1527931|NCT02757690|Device|3-dimensional distal pancreatectomy|3D laparoscopy
1527932|NCT02757690|Device|2-dimensional distal pancreatectomy|2D laparoscopy
1527933|NCT02757677|Device|Optical Coherence Tomography based Angiography|A contrast-free, noninvasive technology to identify blood vessels in the eye
1527934|NCT02757664|Device|Shock Wave Therapy|Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
1527935|NCT02757664|Other|Eccentric Exercises|12 weeks, starting on the same day of the first appliance. The patient will practice the exercises standing on tiptoes and will perform exercises of passive ankle extension (dorsiflexion), three series of 15 repetitions, with the knee stretched, and three series of 15 repetitions with the knee flexed by 20 degrees.
1527936|NCT02757664|Device|Placebo|Placing of the apparatus´ therapeutic head with the support that impedes the shock wave propagation directly on the appliance field; Appliance of radial shock waves with the BLT600 equipment (BTL Medical Technologies - Canada), the intensity being 2000 to 3000 pulses, 7 to 10Hz of frequency, and 1,5 a 2,5Bar of intensity per application; Appliance on the first day of treatment (D0), repeated on the second week after the first intervention (2nd week) and four weeks after the first intervention (4th week).
1527937|NCT02757651|Drug|Hydrogen Peroxide|
1527939|NCT02757625|Drug|Dexmedetomidine hydrochloride|"45 weeks CGA to < 6 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.4 µg/kg/h according to the pediatric subject's sedative state
6 years old to < 17 years old: Maintenance infusion will be started at 0.2 µg/kg/h. The infusion rate will be adjusted within a range of 0.2 to 1.0 µg/kg/h according to the pediatric subject's sedative state"
1527940|NCT02757612|Radiation|laser diode|laser diode
1527941|NCT02757599|Other|Ultrasound training|Training on the transvaginal ultrasound simulator.
1527942|NCT02757586|Genetic|shRNA|Using shRNA interfered the expression of the gene of CLL
1527943|NCT02757573|Procedure|Hypercarbia|PaCO2 is elevated from 5 to 7.5 kPa by controlled ventilation.
1527944|NCT02757560|Other|SFA diet|SFA versus control diet
1527945|NCT02757560|Other|MUFA diet|MUFA versus control diet
1527946|NCT02757560|Other|CARB diet|CARB versus control diet
1527947|NCT02757547|Device|Transcranial magnetic stimulation - placebo arm|Each seizure patient (subject) will receive 5 days in a row either of placebo (sham) magnetic stimulation followed 3 months later by active magnetic stimulation or treatment in the reverse order.
1527948|NCT02757547|Device|Transcranial magnetic stimulation - active arm|Each seizure patient (subject) will receive 5 days in a row either of placebo (sham) magnetic stimulation followed 3 months later by active magnetic stimulation or treatment in the reverse order.
1527949|NCT02757534|Drug|Domperidone|The study drug will be given to relieve the symptoms of gastroparesis, including nausea and vomiting.
1527950|NCT02757521|Drug|Nitrous Oxide|50% nitrous oxide/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
1527951|NCT02757521|Drug|Placebo|50% nitrogen {inert}/ 50% oxygen, 3 one hour inhalation treatments per Stage, every other day (M,W,F)
1527952|NCT02757508|Dietary Supplement|protein powder supplement|
1527953|NCT02757508|Dietary Supplement|Vitamins/minerals|
1527954|NCT02757495|Drug|Dexmedetomidine|Single dose caudal epidural injection will be done using 25 G needle. patients of Group BD will be given dexmedetomidine (precedex 100 µg/mL parenteral preparation (Hospira ® ) 2 µg/kg in 1 ml/kg bupivacaine 0.25%,
1527955|NCT02757482|Other|training|
1527956|NCT02757469|Drug|Drospirenone and ethinyl estradiol combination (Yasmin)|Female oral combined contraceptive containing 30 mcg (0.030 mg) Ethinyl Estradiol and 3 mg drospirenone (Androstenes)
1527957|NCT02757456|Behavioral|Aerobic Exercise program|The 16-week program will consist of aerobic-type steady-state or interval exercises using a pedals attachable to the dialysis chairs. The purpose will be to slowly increase exercise duration by 5 minute increments to reach the goal of 30 min/treatment. The exercise program during hemodialysis sessions will contain a combination of aerobic and flexibility exercises, about 30 minutes of cycling with 10 minutes of warm up/stretching exercises and 10-15 minutes cool down. The frequency of exercise will be three sessions a week, during the first hour of dialysis treatment for the duration of 16 weeks. Blood pressure and heart continuous monitoring will be carried out during the exercise program. Exercise log sheets will be filled for each session for the 16 weeks.
1527958|NCT02757456|Other|Control|No aerobic exercise is offered but baseline and end of study testing of the outcomes occur
1527959|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate after anaesthesia induction|after anaesthesia induction 2 g of Phosphocreatine (PCr) prepared in 50 mL of glucose 5% during 30 min intravenous (IV)
1527960|NCT02757443|Drug|5% Glucose after anaesthesia induction|after anaesthesia induction 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
1527961|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate added to cardioplegia|together with cardioplegia 2.5 g of PCr prepared in 50 mL of glucose 5% and added to every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany; concentration = 10 mmol/L)
1527962|NCT02757443|Drug|5% Glucose|together with cardioplegia 50 mL of glucose 5% is added in every 1 L of cardioplegic solution (Custodiol, Dr. F. KOHLER CHEMIE, GmbH, Germany)
1527963|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 2 g of PCr prepared in 50 mL of glucose 5% during 30 min IV
1527964|NCT02757443|Drug|5% Glucose after heart recovery|immediately after heart recovery (spontaneous or paced myocardium contraction) after aorta declamping 50 mL of glucose 5% IV delivered by an identical infusion pump during 30 minutes
1527965|NCT02757443|Drug|Phosphocreatine sodium tetrahydrate after ICU admission|immediately after ICU admission 4 g of PCr in 100 mL of glucose 5% during 60 min IV
1527966|NCT02757443|Drug|5% Glucose after ICU admission|immediately after ICU admission 100 mL of glucose 5% IV delivered by an identical infusion pump during 60 minutes
1527967|NCT02757430|Procedure|Cardiac Ablation|
1527968|NCT02757417|Drug|sodium fluorescein|
1527969|NCT02757417|Drug|phenazopyridine|
1527970|NCT02757404|Procedure|Ultrasonography guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the ultrasonography guidance.
1527971|NCT02757404|Procedure|Electrical stimulation guidance injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the electrical stimulation guidance.
1527972|NCT02757404|Procedure|Manual needle placement injection of Meditoxin®.|Meditoxin® will be injected to upper limb spasticity by using the manual needle placement.
1527973|NCT02757391|Drug|Standard Chemotherapy|Participant has least 1 type of chemotherapy after enrollment in this study, but before T cell dose. Chemotherapy used at the discretion of treating physician.
1527974|NCT02757391|Drug|Cyclophosphamide|300 mg/m2 by vein on Day -2, 48 to 72 hours prior to T cell infusion.
1527975|NCT02757391|Biological|Adoptive T Cell Infusion|On Day 0 participants receive adoptive t cell infusion. A target of at 20 x 10^9 T cells / m2 infused.
1527976|NCT02757391|Drug|IL-2|250,000 units/m2 subcutaneously On Day 0 to Day +13 every 12 hours within 6 hours of T cell infusion and continue for a total of 14 days (28 doses).
1527977|NCT02757391|Drug|Pembrolizumab|200 mg by vein on Day +1 and Weeks 3, 6, 9, 12, and 15,
1527978|NCT02757391|Behavioral|Phone Calls|Participant called twice by study staff in the 6 months after they are off the study.
1527979|NCT02757378|Procedure|Neuroplasticity Explanation (Experimental)|Patients were given an explanation of how the brain uses the information from a manual therapy technique to help it remain sharp in identifying where this input is coming from.
1527980|NCT02757378|Procedure|Biomechanical Explanation (Control)|Patients were given an explanation of how the manual therapy technique affects the anatomy and physiology of the back.
1527981|NCT02757365|Drug|aspirin|
1527982|NCT02757365|Drug|Levofloxacin|
1527985|NCT02757326|Drug|ABC294640|
1527986|NCT02757313|Drug|Low dose THC marijuana|
1527987|NCT02757313|Drug|High dose THC marijuana|
1527988|NCT02757313|Drug|Placebo marijuana|
1527989|NCT02757300|Device|Hypopharyngeal packing|After introduction and orotracheal intubation a hypopharyngeal packing soaked with Chlorhexidinbis (D-gluconat) is placed.
1527990|NCT02757300|Device|Without Hypopharyngeal packing|After introduction and orotracheal intubation the patient will pass the operation without hypopharyngeal packing with a short tip coming out the mouth to imitate a packing.
1527991|NCT02757287|Drug|FSH-CTP + DESOGESTREL|"Hormones measured on day of 7th menstrual cycle day , day of pre-ovulatory bolus of GnRH and the day after the bolus ( estradiol, FSH, Progesterone, LH)
- Quality of Life questionnaire the day after the bolus"
1527992|NCT02757261|Device|Laser|Low-level laser therapy administrated to acupoints
1527993|NCT02757261|Device|Occlusal splint|Occlusal splint with expander
1527994|NCT02757261|Device|Placebo laser|Placebo laser (Low-level laser therapy administrated to acupoints)
1527995|NCT02757248|Drug|Volasertib|Volasertib 75-150mg/m2 given intravenously on days 1 and 8
1527996|NCT02757248|Drug|Romidepsin|Romidepsin 12-14mg/m2 given intravenously on days 1, 8 and 15
1527997|NCT02757235|Procedure|Irrigation fluid of body temperature|Irrigation fluid of body temperature will be used during burr hole evacuation of chronic subdural hematoma
1527998|NCT02757235|Procedure|Irrigation fluid of room temperature|Irrigation fluid of room temperature will be used during burr hole evacuation of chronic subdural hematoma.
1527999|NCT02757222|Radiation|Escalated Dose|"Boost Target Volume (BTV): The PET CT GTV (thresholding at 40% of SUV max) with a 3mm margin will form the BTV.
CTV1: A 3mm area around the BTV avid primary or 2mm area around the node will form the CTV1.
CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal metastatic disease and not already included in CTV1.
Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.
BTV receives 73.5Gy in 30 fractions. PTV 1 receives 63Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.
All patients receive concurrent platinum chemotherapy."
1528000|NCT02757222|Radiation|Standard Dose|"CTV 1 includes 6mm isotropic margin around the entire PET-CT avid (thresholding at 40% of SUV max) larynx/ hypopharynx /oropharynx and 5mm isotropic margin around nodes.
CTV 2: This (CTV 2) includes the area around the primary or nodal levels at risk of harbouring microscopic primary or microscopic nodal involvement, or at risk nodal areas, and not already included in CTV1.
Planning Target Volume: PTV - A margin of 5mm will be added to each of the CTV to obtain the PTV.
PTV 1 receives 66Gy in 30 fractions. PTV 2 receives 54 Gy in 30 fractions.
All patients receive concurrent platinum chemotherapy."
1528001|NCT02757209|Device|Spiromax (budesonide/formoterol)|"DuoResp Spiromax 160 (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate), either one inhalation twice a day (morning and evening) or two inhalations twice a day (morning and evening), for 1 week.
Additional 8 weeks in one subgroup"
1528002|NCT02757209|Device|Turbohaler (budesonide/formoterol)|Turbohaler® (160 micrograms budesonide/4.5 micrograms formoterol fumarate dihydrate)- Symbicort® 160/4.5. Dose of one inhalation twice a day (mornig and evening) or two inhalations twice a day (morning and evening), for 1 week. Additional 8 weeks in one subgroup
1528003|NCT02757209|Device|Diskus(50mcg salmeterol &250/500 mcg fluticasone propionate)|Diskus® inhaler(50mcg salmeterol&250/500mcg fluticasone propionate)-Seretide Diskus 50/250mcg® or 50/500mcg.Dose of 1inhalation twice a day for1 week.Additional 8 weeks in1subgroup
1528004|NCT02757196|Drug|Rituximab plus methylprednisolone|rituximab （1000mg IV day1, week 3, week 17 , and week 19）
1528005|NCT02757196|Drug|methylprednisolone|1mg/kg, oral or IV; begin to reduce at week 4, reduce 8mg every 2 weeks, then another 8 weeks later reduce 2-4mg every 2-4 weeks
1528006|NCT02757183|Device|"IntelliH"|"IntelliH is a mobile health and a web-based software application that allows patients to enter their blood glucose, weight, medication, diet and other life-style data for review by their providers and monitor their health remotely."
1528007|NCT02757170|Device|Thromboelastography|Patients whole blood will be subjected to undergo coagulation process under monitoring with thromboelastography and various tracings will be recorded and will be interpreted as results.
1528008|NCT02757157|Behavioral|Water-based walking|"Participants will walk in the water for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.
During walking in water, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
1528009|NCT02757157|Behavioral|Land-based walking|"Participants will walk on land for 15 minutes at an intensity rating of five on the modified Borg scale for dyspnoea or perceived exertion, whichever is the highest. Walking intensity will be measured every three minutes during each walking session. If the intensity level is reported as below five, participants will be encouraged to increase the intensity by increasing their walking speed.
During walking on land, VO2 and VE will be measured breath-by-breath using the Oxycon mobile. Every three minutes during the walking, heart rate, oxygen saturation, dyspnoea and exertion will be measured."
1528010|NCT02757144|Drug|DWP14012|DWP14012 tablets
1528011|NCT02757144|Drug|Placebo|DWP14012 placebo-matching tablets, Active control placebo-matching tablets
1528012|NCT02757144|Drug|Esomeprazole|Nexium®
1528013|NCT02757131|Other|Ambulation|"Patients randomized to the intervention group will be asked to participate in the ambulation protocol outlined by the PT staff 3 times daily under the supervision of the dedicated ambulator PCNA. This protocol will involve four exercise levels (mobilization, standing, walking, stairs) that may be implemented depending on the current physical capacity of the patient. The cohort of patients randomized to ambulator protocol will also receive the usual care by primary nursing.
In an effort to best characterize mobility in these patients, the team will collect Braden Scale Activity data from the electronic health record, and provide each patient a mobility tracking device to directly record daily steps taken while the patient is in the hospital. Daily step counts will be collected on a weekly basis from each device. The Braden Scale is entered by nursing on each patient at least daily and measures current activity level on a 4-point scale."
1528014|NCT02757118|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
1528015|NCT02757118|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
1528016|NCT02757105|Drug|BEKINDA|
1528017|NCT02757105|Drug|Placebo|
1528018|NCT02757092|Other|Pulmonary Rehabilitation|smoking cession, breathing exercise, extremities exercise, breathing muscle training, incentive spirometry (Triflo-II) training, intermittent positive pressure ventilation, and chest physical therapy for 6 weeks.
1528019|NCT02757079|Drug|NPC-15|NPC-15, Melatonin granule 1 mg, 2 mg or 4 mg, once a day, is administered orally before going to bed for 26 weeks after a screening phase of 2 weeks with placebo administration.
1528020|NCT02757066|Drug|NPC-15 Granules Lower Dose|NPC-15 granule which contains 1mg melatonin
1528021|NCT02757066|Drug|NPC-15 Granules Higher Dose|Melatonin granule which contains 4 mg melatonin
1528022|NCT02757066|Drug|NPC-15 Placebo Granule|Melatonin placebo granule which does not contains melatonin.
1528023|NCT02757053|Device|Guardian Cap|The Guardian Cap is a third party add-on device attached to the facemask of a football helmet that covers the outside of the helmet with a soft material to reduce the initial impact severity, thus reducing the forces transmitted to the brain
1528024|NCT02757040|Drug|Ibrutinib combined with As2O3|arsenic trioxide combined with ibrutinib in CLL
1528025|NCT02757040|Drug|ibrutinib|ibrutinib
1528026|NCT02757027|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
1528027|NCT02757027|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
1528028|NCT02757014|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number - R84-087)
1528029|NCT02757001|Other|Inferior vena cava filter placement and retrieval|"There are really no interventions in this study. This is an prospective observational study of patients that have been implanted a inferior vena cava filter with intention to be retrieved.
Patients are recruited when the filter is implanted, and the investigators observe when is it finally retrieved, and if there is any complication at the retrieval of the filter."
1528030|NCT02756988|Drug|Coppertone (BAY987704)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Number: X71-109)
1528031|NCT02756975|Device|coaxial prostate biopsy|In this method, a larger introducing needle is needed for the puncture. The introducing needle is placed over the perineum. The biopsy needle is inserted throughout the introducing needle.Then, the direction of the biopsy is changed by tilting the coaxial needle. The investigator needs to puncture the prostate capsule only once for sampling at each each side of the prostate (right and left sides).
1528032|NCT02756975|Device|noncoaxial prostate biopsy|"In this method, there is no introducing needle. Biopsy needle is inserted repeatedly for each tissue sampling (at least fourteen times). A smaller biopsy needle is used for the puncture in this method.
The main disadvantage of the coaxial technique is that a larger introducing needle is needed for the puncture (12). On the other whand, the advantage of noncoaxial method is that the needle is within the prostate for only a few seconds to document needle position with ultrasonography before firing"
1528033|NCT02756962|Drug|Cytarabine|
1528034|NCT02756962|Procedure|Allogeneic stem cell transplant|
1528035|NCT02756962|Procedure|Bone marrow aspiration|"Baseline
Approximately 30 days after cytotoxic induction therapy
End of treatment"
1528036|NCT02756962|Procedure|Punch skin biopsy|"The first will be obtained with the initial blood and bone marrow collections, whenever possible.
The second will be obtained at the time of re-biopsy to confirm remission."
1528037|NCT02756962|Drug|Midostaurin|-For patients with the FLT3-ITD or a FLT3-TKD mutation
1528038|NCT02756949|Other|Smartphone application|Laboratory result data will be presented in the app with simple explanations on every screen. English and Zulu languages will be offered in the same app and written at a grade 4 reading level (as per WHO guidelines on literacy). Laboratory results will be supplemented with informative and relevant information explaining the result that has been shown and the recommended action for the patient to take. Patients will also be able to view additional HIV-related information and a Frequently Asked Questions (FAQ) through the app.
1528039|NCT02756949|Device|Smartphone|
1528040|NCT02756936|Drug|Daclatasvir Zeta|1 tablet contains 60 mg Daclatasvir
1528041|NCT02756936|Drug|Clatazev|1 tablet contains 60 mg Daclatasvir
1528042|NCT02756910|Device|iThermonitor (WT701)|Continuously monitor the axillary temperature during surgery
1528045|NCT02756884|Procedure|Lipoaspiration|
1528046|NCT02756884|Other|Intravenous injection of Adipose Derived Stem Cells|Minimally manipulated Stromal Vascular Fraction containing Adipose Derived Stem Cells. Cells will be infused intravenously.
1528047|NCT02756884|Other|Intra-adventitia (proximal to the lesion) injection of Adipose Derived Stem Cells|Minimally manipulated Stromal Vascular Fraction containing Adipose Derived Stem Cells. Cells will be injected using the Bullfrog micro-infusion catheter (Mercator)
1528048|NCT02756884|Other|Intra-muscular injection of Adipose Derived Stem Cells|Minimally manipulated Stromal Vascular Fraction containing Adipose Derived Stem Cells. Cells will be injected intramuscularly along the affected vessel.
1528049|NCT02756884|Other|Low Frequency Ultrasound (LoFU) Delivery|"1 Megahertz (40 Watts), 4 MPa (Megapascal) rarefactional pressure pulse, 50 msec on, 50 msec off. LoFU wil be delivered along the path of the affected vessel."
1528050|NCT02756871|Other|online guided self-help intervention for perfectionism|"CBT based online guided self-help intervention for perfectionism based on CBT manual for treatment of perfectionism, Cognitive Behavioural Treatment of Perfectionism by Sarah Egan, Tracy Wade, Roz Shafran and Martin Antony"
1528051|NCT02756858|Drug|ANAVEX2-73|
1528052|NCT02756845|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into injectable cutaneous, subcutaneous, nodal tumors, and other non-visceral tumors with or without image ultrasound guidance. The first dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 PFU/mL administered on day 1. The second injection, up to 4.0 mL of 10^8 PFU/mL (or up to 4.0 mL of 10^6 PFU/mL for a dose de-escalated cohort), will be administered 21 (+3) days after the initial injection. All subsequent injections, up to 4.0 mL of 10^8 PFU/mL (or up to 4.0 mL of 10^6 PFU/mL for a dose de-escalated cohort), will be administered every 14 (± 3) days. The treatment cycle interval may be increased due to toxicity.
1528056|NCT02756793|Radiation|Stereotactic Ablative Radiotherapy (SABR)|Patients will receive stereotactic ablative radiotherapy to all sites of progressive disease, with continuation of current systemic agents.
1528057|NCT02756793|Other|Standard of Care Treatment|"May include:
Continue with current systemic agent(s)
Observation
Switch to next-line treatment
Palliative radiotherapy is allowed in this arm."
1528058|NCT02756780|Other|Tenovus Cancer Choir|Choir sessions will take place at both of the Royal Marsden Hospital sites on a weekly basis. Sessions typically consist of learning popular songs with messages of support. Songs are learnt without sheet music, using specially created backing tracks. These are also made available to participants at home so they can continue singing away from the sessions. No singing experience is required and the main aim of the sessions is enjoyment and meeting other people. Sessions will take place in the early evening so that participants have the option of staying to socialise afterwards.
1528059|NCT02756767|Other|Survey|
1528060|NCT02756754|Device|Radiofrequency ablation|The radiofrequency system will be used as the RFA generator device standard cycle of ablation will be applied in the patient. During RFA, blood pressure, pulse and oxygen saturation will be continuously monitored.
1528061|NCT02756741|Drug|ALBUMIN|Albumin in two different doses
1528062|NCT02756728|Biological|BI-505|Treatment with BI-505 10 mg/kg bi-weekly infusion, up to 9 doses over 4 months
1528063|NCT02756728|Other|High dose melphalan|High dose melphalan (HDM)
1528064|NCT02756728|Other|Autologous stem cell transplantation|Autologous stem cell transplantation (ASCT)
1528065|NCT02756715|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation.
1528066|NCT02756715|Drug|Desflurane group|Patient will be anesthetized by using desflurane inhalation during operation.
1528067|NCT02756702|Device|All-Poly|Implantation of the VEGA PS using all-polyethylene tibia components
1528068|NCT02756689|Other|Inpatient cervical ripening|Subjects will undergo cervical ripening in the inpatient setting.
1528069|NCT02756689|Other|Outpatient cervical ripening|Subjects will undergo cervical ripening in the outpatient setting. The patients will then be scheduled to return the next morning for induction of labor.
1528070|NCT02756676|Procedure|Multidisciplinary Intensive Rehabilitation Treatment (MIRT)|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle- stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in daily living activities. The last session includes one hour of speech therapy.
1528071|NCT02756663|Drug|panobinostat (capsules)|Panobinostat capsules, oral: 10mg, 15mg, 20mg dosing 3x a week, 1 week on / 1 week off, in a 4 week cycle (28 days). Treatment arm A: only capsules of 10mg will be used Treatment arm B: capsules of 10mg and 15mg are foreseen for dose reduction only.
1528072|NCT02756663|Drug|carfilzomib (infusion)|Carfilzomib infusion; 20 mg/m2 i.v. on C1D1 and C1D2; 56 mg/m2 i.v. on subsequent dosing days (2x a week; 3 weeks on/1 weeks off ); 4 week cycle (28 days)
1528073|NCT02756663|Drug|dexamethasone (tablets)|Dexamethasone tablets p.o. 20 mg on days of carfilzomib infusion (2x week) and on D22 and D23 of each 4 week cycle (28 days)
1528074|NCT02756650|Drug|drug administration|monthly canakinumab will be administered
1528075|NCT02756624|Drug|AC-170 0.24%|
1528076|NCT02756624|Drug|AC-170 Vehicle|
1528078|NCT02756598|Drug|Sufentanil I|bolus dose of sufentanil 1 microgram/kg
1528079|NCT02756598|Drug|Sufentanil II|bolus dose of sufentanil 0.5 microgram/kg
1528080|NCT02756598|Drug|Propofol I|Continued dose of propofol 0.03 mg/kg/min
1528081|NCT02756598|Drug|Propofol II|Continued dose of propofol 0.06 mg/kg/min
1528082|NCT02756585|Radiation|ct perfusion|computed tomography perfusion of the head
1528083|NCT02756572|Drug|Cladribine|Given IV
1528084|NCT02756572|Drug|Cyclosporine|Given PO
1528085|NCT02756572|Drug|Cytarabine|Given IV
1528086|NCT02756572|Biological|Filgrastim|Given SC
1528087|NCT02756572|Drug|Fludarabine Phosphate|
1528088|NCT02756572|Procedure|Hematopoietic Cell Transplantation|Undergo HCT
1528089|NCT02756572|Other|Laboratory Biomarker Analysis|Correlative studies
1528090|NCT02756572|Drug|Melphalan|Given IV
1528091|NCT02756572|Drug|Mitoxantrone Hydrochloride|Given IV
1528092|NCT02756572|Drug|Mycophenolate Mofetil|Given PO
1528093|NCT02756572|Other|Questionnaire Administration|Ancillary studies
1528094|NCT02756572|Drug|Sirolimus|Given PO
1528095|NCT02756572|Radiation|Total-Body Irradiation|Undergo TBI
1528096|NCT02756546|Drug|Cyclophosphamide|
1528097|NCT02756546|Drug|Hydroxychloroquine|
1528098|NCT02756546|Drug|Hydrocortisone|
1528099|NCT02756533|Other|Telemonitoring of daily parameters recorded by NIV|"Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. When an alert is received, a nurse will evaluate the symptoms of the patient by a standardized phone call questionnaire. The results will be transmitted to a referent practitioner who will decide what the patient should do.
Recommendations will be transferred to the patient within 36 hours."
1528100|NCT02756533|Other|Placebo|Daily telemonitoring of breathing rate, % of trigger cycles, daily usage of the NIV will go through an algorithm generating alerts when variations will go beyond normal. Alerts will only be collected, the patient will not be contacted by phone during the alert.
1528101|NCT02756520|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
1528102|NCT02756507|Behavioral|video-based transdiagnostic REBT|The video-based transdiagnostic REBT consists of 6 sessions delivered in a group format.
1528103|NCT02756507|Behavioral|Wait list|Delayed intervention
1528104|NCT02756494|Biological|Ischemic Stroke|Ischemic Stroke in Chinese Young Adults
1528946|NCT02750254|Radiation|Single dose total body irradiation|
1528105|NCT02756468|Other|pts operated for pancreatic cancer|measuring CRP and PCT in 3rd and 5th POD after pancreatic cancer resection
1528106|NCT02756455|Other|gastric cancer pts undergoing surgery|Measure PCT (procalcitonin), CRP (C-reactive protein) and WBC (white blood cell count) in 3rd and 5th postoperative day and registration of all intra and postoperative complications
1528107|NCT02756442|Other|Respiratory disorder assessment during sleep|
1528108|NCT02756429|Other|blood samples|Patients with atrial fibrillation for whom electrophysiology exploration or ablation are programmed; All blood samples will be taken through the exploration catheter. For the peripheral blood sample, blood will be taken at the introduction of the catheter into the femoral vein. Then the blood samples in the coronary sinus and in the left atrium will be made at progressively exploration.
1528109|NCT02756416|Device|MRI brain|Standard MRI brain will be performed on each participant to look at brain structure and exclude complications of RCVS (if any).
1528110|NCT02756416|Device|ASL-MRI brain|ASL-MRI is a non-contrast scan used to measure cortical cerebral blood flow (CBF) in areas supplied by major arteries (Circle of Willis).
1528111|NCT02756416|Device|MRA brain|MR angiography scan looks at blood vessels structure. We expect to see constriction (narrowing) of the major arteries in RCVS cases.
1528112|NCT02756403|Drug|Azithromycin|500 mg
1528113|NCT02756403|Drug|Doxycycline|200 mg
1528114|NCT02756403|Drug|Metronidazole|500 mg
1528115|NCT02756403|Drug|Placebo|Placebo pills will be given before the uterine aspiration. Antibiotics will be given after the uterine aspiration.
1528116|NCT02756390|Behavioral|CBTI-CS|CBTI-CS is a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia. Cognitive factors are addressed via cognitive restructuring and psychoeducation. Behavioral factors are addressed by structured sleep restriction, stimulus control and sleep hygiene techniques. Cancer treatment late-effects affecting sleep are addressed as potential contributors to these cognitive and behavioral factors, and as symptoms that may benefit from referral for medical evaluation/management. Participants are instructed in these cognitive-behavioral strategies as a group, but using analysis of personal sleep-log data, symptom self-reports and targeted workbook exercises, they are helped to tailor the intervention to address their specific needs.
1528117|NCT02756390|Behavioral|Sleep Hygiene|Education on health behaviors, sleep habits and environmental practices intended to promote good quality sleep. Recommendations target exercise and natural light exposure,use of stimulants and alcohol, daytime napping, timing of meals, creating a comfortable non-stimulating sleep space, and creating sleep rituals.
1528118|NCT02756390|Behavioral|CBTI-CS via Telehealth|The CBTI-CS intervention, a multi-modal intervention designed to address both cognitive and behavioral factors that perpetuate insomnia, will be administered via live video. conferencing. Participants will have a single in-person training session and subsequent CBTI-CS group sessions will be conducted by live video conference.
1528119|NCT02756377|Drug|cetylpyridinium chloride mouthwash|cetylpyridinium chloride mouthwash, 10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
1528120|NCT02756377|Drug|Chlorhexidine mouthwash|Chlorhexidine mouthwash,10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
1528121|NCT02756364|Drug|Fulvestrant|Fulvestrant IM injection
1528122|NCT02756364|Drug|MLN0128|MLN0128 capsule
1528123|NCT02756351|Device|CytaCoat Nasal Prong|
1528124|NCT02756351|Device|Inspiration Healthcare Inspire nCPAP Nasal Prong|
1528125|NCT02756338|Device|BioMonitor 2 Insertable Cardiac Monitor|
1528126|NCT02756325|Device|MRI|Imaging will be performed using a clinical whole-body MRI and a pelvic phased-array coil. No intravenous contrast will be administered. Sequences will include Diffusion weighted imaging (DWI), T2 mapping, arterial spin labeling, and spectroscopy. The acquisition is expected to take approximately one hour
1528127|NCT02756312|Other|IV Anesthesia|The patients will receive intravenous anesthesia
1528128|NCT02756312|Other|IH anesthesia|The patients will receive inhalation anesthesia
1528129|NCT02756299|Other|Educational Support|General information about OSA and PAP treatment at baseline and additional polysomnography chart viewing from both diagnostic and titration nights
1528130|NCT02756299|Other|Standard Support|General information about OSA and PAP treatment at baseline
1528131|NCT02756286|Other|NAT electroencephalography (EEG) test|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
1528132|NCT02756273|Device|bridge device|
1528133|NCT02756273|Device|no bridge device|
1528136|NCT02756221|Dietary Supplement|Probiotics|One capsule per day for 90 days. Containing 8 x 109 CFU of bacteria /capsule Lactobacillus heleveticus Lafti L10 Bifidobacterium animalis ssp lactis Lafti B94 Enterococcus faecium Rosell-26 Bifidobacterium longum RO175 Bacillus subtills Rosell-179 Inactive ingredients: potato starch, magnesium stearate, ascorbic acid White vegetable capsule size 1
1528137|NCT02756221|Other|Placebo|Placebo capsules identical in shape and color to the probiotics capsules, one capsule per day for 90 days
1528138|NCT02756208|Biological|0.25 mL FLSC Vaccine Group|FLSC vaccine 75 mcg (0.25 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
1528139|NCT02756208|Biological|0.25 mL Placebo Group|Placebo saline 0.25 mL given by intramuscular injection into the arm on study Days 0, 28, 56, 168
1528140|NCT02756208|Biological|0.5 mL FLSC Vaccine Group|FLSC vaccine 150 mcg (0.5 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
1528141|NCT02756208|Biological|0.5 mL Placebo Group|Placebo sterile saline 0.5 mL given by intramuscular injection into the arm on study Days 0, 28, 56, 168
1528142|NCT02756208|Biological|1.0 mL FLSC Vaccine Group|FLSC vaccine 300 mcg (1.0 mL) given by intramuscular injection into the arm on study Days 0, 28, 56, 168
1528143|NCT02756208|Biological|1.0 mL Placebo Group|Placebo sterile saline 1.0 mL given by intramuscular injection into the arm on study Days 0, 28, 56, 168
1528144|NCT02756182|Device|TDOC air-charged catheter|Urodynamic study utilizing a single catheter technique to measure WP & AC measurements
1528147|NCT02756130|Drug|Birinapant|Birinapant - carboplatin/paclitaxel co-therapy
1528148|NCT02756130|Drug|Paclitaxel|
1528149|NCT02756130|Drug|Carboplatin|
1528150|NCT02756117|Drug|L-Lysine|
1528151|NCT02756117|Drug|Normal (0.9%) Saline|
1528152|NCT02756104|Other|phenotyping Tcells|Collecting blood for analyses of the T cells phenotypes
1528153|NCT02756104|Other|Supplementation in vitamin D|Supplementation in vitamin D for the patients who are deficient on vitamin D
1528154|NCT02756091|Other|No study-specific intervention|
1528157|NCT02756065|Other|no intervention|no intervention is used
1528158|NCT02756052|Device|Anodal Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Anodal tDCS: 45 second ramp up to 1milliamp, 20 minute current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
1528159|NCT02756052|Device|Sham Transcranial direct-current stimulation|NeuroConn Direct-Current Stimulator. Sham tDCS: 45 second ramp up to 1milliamp, 60 second current hold at 1milliamp, 45 second ramp down to 0milliamp. Anode positioned 2cm posterior to the left primary motor cortex, and the cathode over the contralateral supraorbital area.
1528160|NCT02756026|Dietary Supplement|Multiple micronutrient supplement (Nutri-Fem)|Multiple micronutrient supplement (Nutri-Fem) manufactured by Thorne, containing the Recommended Dietary Intake (RDA).
1528161|NCT02756013|Drug|Paclitaxel|80mg/m2 IV days 1,8, and 15 every 21 days x 6-9 cycles
1528162|NCT02756013|Drug|Carboplatin|area under the curve (AUC) 6 IV day 1 every 21 days x 6-9 cycles
1528163|NCT02756000|Procedure|PCI|percutaneous angioplasty and stent implantation in coronary artery with significant atherosclerosis and stenosis
1528164|NCT02756000|Procedure|dobutamine stress echocardiography|Echocardiographic stress test of provoked myocardial ischemia using dobutamine
1528165|NCT02755987|Drug|ANG1005|
1528166|NCT02755961|Behavioral|Dietary education|
1528167|NCT02755961|Behavioral|Education on phosphate binder use|
1528168|NCT02755948|Biological|RSV A Memphis 37|Good Manufacturing Practices-certified RSV Memphis 37 10(4) PFU in 1 mL 25% sucrose/DMEM delivered by intranasal drops
1528169|NCT02755948|Biological|Influenza A/California/04/2009|Good Manufacturing Practices-certified Influenza A/California/04/09 3.5x10(4) TCID50 in 1 mL in DPBS delivered by intranasal drops
1528170|NCT02755935|Device|Cochlear Nucleus CI532|cochlear implantation
1528171|NCT02755922|Biological|Application of autologous mesenchymal stem cells|within the surgical procedure, mesenchymal stem cells, were applied on the fracture site. Imaging by X-ray and CT and imaging analysis was done after fracture repair, at week 4 and week 12
1528172|NCT02755909|Behavioral|Pre-anesthetic Education|Education was done before the anesthetic procedure, using a flip chart made by the researchers.
1528173|NCT02755896|Radiation|Arm 1 600 cGY x 5 fractions|Patients who are randomized to Arm 1 will receive either 600 cGY x 5 fractions over 5 consecutive days
1528174|NCT02755896|Radiation|Arm 2 800 cGY x 3 fractions|Patients who are randomized to Arm 2 will receive 800 cGY x 3 fractions given every other day
1528175|NCT02755883|Behavioral|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
1528176|NCT02755883|Behavioral|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
1528177|NCT02755870|Other|CNM-Au8|Clene's technology integrates nanotechnology, materials science, plasma conditioning (corona discharge), and hydro-electrocrystallization to create a first in biopharmaceutical drug development: a new class of drugs (CSNTM), which are neither small molecules derived from organic chemistry nor large molecule biological proteins such as monoclonal antibodies.
1528178|NCT02755870|Other|Placebo|Placebo oral suspension which matches the volume of the experimental nanocrystal suspension
1528179|NCT02755857|Drug|Lozanoc|65 mg
1528180|NCT02755844|Drug|Olaparib|"Olaparib tablet dose will be dose-escalated on 4 dose levels , guided by a continual reassessment method (CRM).
One cycle will be 28 days (4 weeks) in duration, except for cycle 1 which will be 6 weeks."
1528181|NCT02755844|Drug|metformin|From week 3 metformin will be gradually escalated from 500 mg/day to 1500 mg/day with weekly 500 mg dose escalation levels
1528182|NCT02755844|Drug|metronomic cyclophosphamide|from week 2 Metronomic cyclophosphamide will be given continuously on an oral daily basis at 50 mg qd
1528183|NCT02755831|Device|CPAP|Continuous Positive Airway Pressure (CPAP) Therapy for Obstructive Sleep Apnea
1528184|NCT02755831|Other|Pre-natal care|Standard Pre-Natal Care
1528186|NCT02755805|Behavioral|CO-OP|
1528187|NCT02755805|Behavioral|Attention Control|
1528188|NCT02755792|Behavioral|Calligraphy Training|
1528189|NCT02755792|Behavioral|iPad Training|
1528190|NCT02755753|Drug|Lansoprazole|Oral administration of Lanston® (lansoprazole) 30 mg, 1 capsule, PO, qd, 30 min before breakfast
1528191|NCT02755753|Drug|Rebamipide|Oral administration of Mucosta (rebamipide) 100 mg, 1 tablet, PO, tid, 30 minutes before breakfast, lunch, and dinner
1528192|NCT02755753|Drug|Rebamipide-placebo|Oral administration of Mucosta®-placebo, 1 tablet, PO, tid, 30 minutes before breakfast, lunch and dinner
1528258|NCT02755220|Device|Cingularbio® Aortic valve replacement|the patients will be replaced by Cingularbio heart valve
1528194|NCT02755727|Procedure|Platelet Rich Plasma Injection|See Arms
1528195|NCT02755727|Procedure|Open Surgical Release|See arms
1528196|NCT02755714|Drug|Ipratropium bromide spray|The patient will - or will not - receive Ipratropium bromide spray (MDI) 20 μg given through a plastic spacer two puffs 1 hour before a continuous laryngoscopy exercise test (CLE-test)
1528197|NCT02755701|Drug|Branched-chain Amino Acid|BCAA (livact) will be administered 3 times a day during 24 weeks
1528198|NCT02755701|Drug|Placebo|Placebo will be administered in the same way
1528199|NCT02755688|Procedure|Thoracoscopic Surgical ablation|Thoracoscopic approach to isolate pulmonary veins, ganglionic plexi ablation and left atrial appendage exclusion
1528200|NCT02755688|Procedure|Catheter ablation|Ablation using contact force technology to isolate pulmonary veins and create linear lesions.
1528201|NCT02755675|Other|68Ga-NOTA-AE105 PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to PET/CT
1528202|NCT02755662|Device|Mandibular Retention Device|
1528203|NCT02755649|Drug|Dupilumab|
1528204|NCT02755649|Drug|Placebo|
1528205|NCT02755636|Behavioral|PCPHC|Mobile-delivered health risk intervention (HRI), computer-tailored interventions (CTIs), text messages; provider-delivered one-on-one session guided by clinical dashboard
1528206|NCT02755636|Other|Usual care|Primary care as usual
1528207|NCT02755623|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants are sequentially randomly assigned to either 20 active rTMS sessions or 20 sham rTMS sessions that were applied over the left temporoparietal junction. Treatments are administered daily, over a period of two weeks.
1528208|NCT02755623|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|
1528209|NCT02755610|Other|PD Product Check List|
1528210|NCT02755597|Drug|Venetoclax|Tablet
1528211|NCT02755597|Drug|Placebo|Tablet
1528212|NCT02755597|Drug|Bortezomib|Solution for subcutaneous injection
1528213|NCT02755597|Drug|Dexamethasone|Tablet
1528214|NCT02755558|Behavioral|Low energy density|Low energy density milk served
1528215|NCT02755558|Behavioral|High energy density|High energy density milk served
1528216|NCT02755558|Behavioral|Small portion|Small portion of milk served
1528217|NCT02755558|Behavioral|Large portion|Large portion of milk served
1528218|NCT02755545|Drug|Product A (adapalene)|Product A applied topically to the entire face or other affected area of the skin once daily
1528219|NCT02755545|Drug|Product B (salicylic acid)|Product B applied topically to affected area of the skin 1 to 3 times daily
1528220|NCT02755532|Drug|Bupivacaine 0,25%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==>140.1 m/z. The methodology was validated according to the international FDA recommendations.
1528221|NCT02755532|Drug|Bupivacaine 0,5%|Venous blood samples were collected prior to blocking , every 15 min during the first hour after completion of the blocking and every 30 min during the second hour after completion using an exclusive cannula. Then, 5 ml was drawn off and was stored in two EDTA tubes (BD, Franklin Lakes, NJ, USA). The EDTA tubes were centrifuged at 3,500xg for 10 min to obtain the blood plasma. This plasma was then stored in cryogenic tubes in a freezer at -80 °C until the time of the analysis. A high-performance liquid chromatography apparatus (Shimadzu, Kyoto, Japan) coupled to a Bruker mass spectrometer (MS), model Amazon (USA), with electrospray source ionization and a sequential mass spectrometry system (MS/MS) were used for the analysis. After obtaining the precursor ion, a fragment was obtained via a collision-induced dissociation process. The following molecular ions were selected: 289.0 m/z==>140.1 m/z. The methodology was validated according to the international FDA recommendations.
1528222|NCT02755506|Device|endobronchial ultrasound elastography|Before endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA), patients will undergo the examination of endobronchial ultrasound elastography
1528223|NCT02755493|Behavioral|Sleep deprivation|
1528224|NCT02755480|Device|Ultralow Dose Thoracic Computed Tomography|Ultralow dose chest CT (uLDCTT) at a radiation dose comparable to 2 chest X-rays
1528225|NCT02755467|Device|KTP laser|Dual Wavelength Laser Emitting 532 nm Laser Energy
1528226|NCT02755454|Device|Perfusion CT Imaging|
1528227|NCT02755428|Biological|retinal pigment epithelium transplantation|Transplant retinal pigment epithelium derived from human embryonic stem cells into subretinal space of patients with dry age-related macular degeneration(dry AMD).
1528228|NCT02755415|Device|HIWIN Robotic Gait Training System|HIWIN Robotic Gait Training System is an automatic training system that combines weight-bearing standing, repetitive stepping and gait training
1528229|NCT02755415|Other|Static Standing Table|As part of the standard hospital rehabilitation, static standing table allows patient to be in a fully supported standing position
1528230|NCT02755402|Device|Xpert HCV Viral load|
1528231|NCT02755402|Device|Transient elastography|
1528259|NCT02755194|Other|No intervention|This is an observational study. The exposure of interest includes taking specific prescribed medications during breastfeeding.
1528947|NCT02750254|Drug|Melphalan|
1528232|NCT02755389|Drug|0 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be no oxygen flowing through the cannulae in this group during the study.
1528233|NCT02755389|Drug|15 L/min oxygen via conventional nasal cannulae|Patients will have conventional nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 15 L/min of oxygen flowing through the cannulae in this group during the study.
1528234|NCT02755389|Drug|60 L/min oxygen via high-flow nasal cannulae|Patients will have high-flow nasal cannulae placed under chin prior to induction of anesthesia. Immediately post-induction these will be placed into the nares. They will be removed from the nares at the end of the study when the airway has been secured. There will be 60 L/min of oxygen flowing through the cannulae in this group during the study.
1528235|NCT02755376|Biological|Cartistem(TM)|ACL reconstruction and injection of Cartstem(TM), human cord blood derived mesenchymal stem cell under arthroscopy.
1528236|NCT02755376|Biological|hyaluronic acid|ACL reconstruction and injection of hyaluronic acid under arthroscopy.
1528237|NCT02755376|Procedure|ACL reconstruction only|ACL reconstruction only without any injection under arthroscopy
1528238|NCT02755363|Other|osteopathic manual therapy|"suboccipital decompression - atlanto-occipital joint relaxation technique.
deep cervical fascia release - the technique aims to improve mobility of the first and second ribs during expiration and to relaxation of the vagus and phrenic nerve course area.
thoracic lymphatic pump with activation is designed to reduce the tension of mediastinal structures, improve lymphatic flow, and thus reduce the breathing resistance.
stretching the diaphragm in order to relax and reduce adhesion within the fascial system between the diaphragm and abdominal organs."
1528239|NCT02755363|Other|control group|"manual mobilization techniques of the slides in the shoulder joint toward the front, rear and bottom.
manual techniques to increase range of motion in the shoulder joints using the patient's breathing manoeuvres."
1528240|NCT02755350|Drug|Truvada|Daily oral PrEP will be provided to a cohort of 2100 participants (female sex workers, men who have sex with men and young women at high HIV risk) in Kenya. Baseline data will be collected from all participants at enrolment. PrEP users will be followed up at multiple intervals, in months 1, 4, 7, 10 and 12) for 12 months. The PrEP users will attend 7 visits at the project sites over the project period and in between these visits, they will return to the pharmacy for PrEP refill, adherence counselling and assessment of side effects.
1528241|NCT02755324|Biological|male Schistosoma mansoni cercariae|Viable male Schistosoma mansoni cercariae of the Puerto Rican strain
1528242|NCT02755311|Procedure|liver resection|Intraoperative ultrasound was routinely used during surgery. Anatomic resection was carried out in the form of segmentectomy or/and subsegmentectomy.In segmentectomy, the hepatic parenchyma was transacted at the intersegmental plane as described by Couinaud. If the hepatic parenchymal transaction plane needed to go beyond the intersegmental plane to achieve the desired extent of resection margin, the small portal branches supplying the liver parenchyma up to the intended transaction plane were punctured under US guidance and injected with methylthioninium chloride, and then liver subsegmentectomy was performed either alone or in combination with segmentectomy along the plane of demarcation as delineated by the injected methylthioninium chloride. Nonanatomic resection with a negative resection margin was performed when anatomical resection may cause inadequate liver remnant. Pringle's maneuver was used if necessary with a clamp/unclamp time of 10 min/5 min.
1528243|NCT02755311|Procedure|transarterial chemoembolization|A microcatheter was inserted into the feeding arteries as selectively as possible through the lobar, segmental, or subsegmental arteries, dependent on the tumor distribution and hepatic functional reserve. Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin. Subsequently, chemolipiodolization was performed mixed with 5 ml of lipiodol. According to the number and size of the lesions, and liver and kidney function of the patient, the chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team. If residual flow remained after infusion of these agents, additional lipiodol was injected. Embolization was performed with absorbable gelatin sponge particles 350-560 μm in diameter.
1528244|NCT02755311|Drug|carboplatin|Hepatic artery infusion chemotherapy was performed using 300 mg carboplatin (Bristol-Myers Squibb, New York, NY).
1528245|NCT02755311|Drug|lipiodol|Chemolipiodolization was performed mixed with 5 ml of lipiodol (Lipiodol Ultra-Fluide; André Guerbet Laboratories, Aulnay-sous-Bois, France).
1528246|NCT02755311|Drug|epirubicin , pirarubicin , hydroxycamptothecin and fluorouracil|The chemotherapeutic agents, including epirubicin (50-100 mg), pirarubicin (30-50 mg), hydroxycamptothecin (10-30 mg) and fluorouracil (500-1000 mg), were determined by the multidisciplinary team.
1528247|NCT02755311|Other|absorbable gelatin sponge particles|Embolization was performed with absorbable gelatin sponge particles (Gelfoam; Hangzhou Bi-Trumed Biotech Co., Ltd., Hangzhou, Zhejiang, China) 350-560 μm in diameter.
1528248|NCT02755298|Drug|Acetazolamide|
1528249|NCT02755298|Drug|Placebo|
1528250|NCT02755272|Drug|Pembrolizumab|IV Infusion of 200 mg given on day one of each 21 day treatment cycle.
1528251|NCT02755272|Drug|Carboplatin|IV infusion of a calculated dose (AUC 2 mL/min) given on days one and eight of each 21 day treatment cycle.
1528252|NCT02755272|Drug|Gemcitabine|IV infusion of 800 mg/m^2 given on days one and eight of each 21 day treatment cycle.
1528253|NCT02755259|Drug|Acetazolamide|
1528254|NCT02755259|Drug|Placebo|
1528255|NCT02755246|Dietary Supplement|Polyamine supplementation|3 months of polyamine supplementation (3 capsules/day)
1528256|NCT02755246|Dietary Supplement|Placebo supplementation|3 months of placebo intake (3 capsules/day)
1528257|NCT02755233|Other|Pulmonary Function|Spirometry and DLCO were measured according to performance standards based on the statements from the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Values of DLCO were adjusted for the patient's current hemoglobin value, and the patients were asked to withhold cigarette smoking at least four hours before pulmonary function testing. Lung volumes and DLCO were measured with a commercial ZAN300 CO Diffusion system (nSpire Health GmbH, Oberthulba, Germany)
1528948|NCT02750254|Drug|Granulocyte-colony stimulating factor|
1528261|NCT02755168|Procedure|External Pop-Out Cesarean Section|During fetal head extraction, the obstetrician puts four fingers of his right hand on the lower segment at uterovesical pouch. The palmar aspect of the fingers will be resting on the uterovesical peritoneal reflection not on directly on the fetal head. While the palmar aspect of the fingers was facing the lower segment they were pushed deep below the fetal head.
1528262|NCT02755168|Procedure|Classic technique|During fetal head extraction, the obstetrician puts four fingers of his right hand inside the uterus.
1528263|NCT02755155|Drug|Human serum albumin infusion 4%|Continuous infusion of 15mL/kg of bodyweight over 24h/day
1528264|NCT02755155|Drug|Human serum albumin infusion 20%|Specify details not covered in associated Arm Description. Intermittent infusion up to 200 ml/8h/day until the plasma albumin concentration is in the range 30+3g/L
1528265|NCT02755142|Biological|Gliolan|
1528266|NCT02755129|Other|Walking Exercises-Six Minute Walk (6MW) Test|The Six Minute Walk (6MW) Test measures the distance an individual is able to walk over a total of six minutes on a flat surface. The goal is for the individual to walk as far as possible in six minutes. The Six Minute Walk (6MW) test will be performed within the Computer Assisted Rehabilitation Environment (CAREN) system system environment - single arm
1528267|NCT02755129|Other|Walking Exercises-4 Meter Gait Speed (4MGS) Test|"The 4 Meter Gait Speed (4MGS) Test measures the gait speed an individual is able to walk over 4 meters on a flat surface. The goal is for the individual to walk as fast as possible over 4 meters.
It will be repeated 3 times within the aforementioned 6MW test (after approximately 1, 3 and 5 minutes) to get variability due to subject tiredness. The test will be performed within the CAREN system environment. - single arm"
1528268|NCT02755129|Other|Walking Exercises-Five Times Sit to Stand (FTSTS) Test|The Five Times Sit to Stand (FTSTS) Test measures the time a subject takes to stand up from an armchair 5 times in a row, without stopping in between. It is a short test which measures dynamic balance and functional mobility - single arm
1528269|NCT02755129|Other|Walking Exercises-Expanded Timed Get-Up-and-Go (ETGUG) Test|The Expanded Timed Get-Up-and-Go (ETGUG) Test measures the time it takes a subject to stand up from an armchair, walk a distance of 10 m, turn, walk back to the chair, and sit down. It is a short test of basic mobility skills for frail community-dwelling elderly. - single arm
1528270|NCT02755129|Other|Reveal LINQ accelerometer|Walking exercises test
1528271|NCT02755129|Other|3D accelerometer|Walking exercises test
1528272|NCT02755116|Drug|Olanzapine|10mg of olanzapine by mouth prior to anesthetic induction
1528273|NCT02755116|Drug|Placebo|placebo by mouth prior to anesthetic induction
1528274|NCT02755103|Behavioral|Mindfulness Based Relapse Prevention (MBRP)|MBRP integrates coping skills from cognitive-behavioral relapse prevention therapy with Mindfulness Meditation (MM) practices, raising awareness of substance use triggers and reactive behavioral patterns, and teaching skillful coping responses.
1528275|NCT02755090|Drug|Nitrous Oxide|Participants in the nitrous oxide group will receive a scented face mask through which nitrous oxide will be administered. The nitrous content of the gas will be titrated up by 20% every 5 breaths with a goal of 70% N2O/ 30% O2 as tolerated by the participant. This group will also receive saline through an IV. All participants will receive local anesthesia in the form of a paracervical block and ibuprofen pre-operatively.
1528276|NCT02755090|Drug|IV Saline|
1528277|NCT02755077|Procedure|Head rotation during mask ventilation|Patient's head position is axially rotated 45 degrees to the right.
1528278|NCT02755064|Drug|Erythromycin lactobionate|In Phase 1 of the study, during the second visit, erythromycin was given as an initial bolus of 0.5 mg/kg over 10 min immediately before the meal. Thereafter, an infusion of 1.5 or 2.5 mg/kg was given over the next 50 min with the same infusion pump. The goal of testing 2 different doses was not to assess dose-related effects but to compare glycemic indices against a spectrum of gastric emptying rates.
1528279|NCT02755064|Drug|Placebo IV|In Phase 1 of the study, during the second visit, saline was given as an initial bolus over 10 min immediately before the meal. Thereafter, an infusion of saline was given over the next 50 min with the same infusion pump.
1528280|NCT02755064|Drug|[13C]-Spirulina|The subject consumed the test meal containing 13C-Spirulina in no more than 10 minutes. Breath samples were collected at baseline obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points.
1528281|NCT02755064|Drug|Erythromycin Ethylsuccinate Suspension|In Phase 2 of the study, subjects randomized to this arm will receive Erythromycin Ethylsuccinate Suspension 250 mg tid orally for a total period of 7 days.
1528282|NCT02755064|Drug|Placebo Suspension|In Phase 2 of the study, subjects randomized to this arm will receive an oral placebo prepared to mimic the Erythromycin Ethylsuccinate Suspension for a total period of 7 days.
1528283|NCT02755051|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavioral Therapy for children with Chronic Insomnia and Autism Spectrum Disorder involves 8, one-hour sessions of a non-drug cognitive behavioral intervention. Session content listed below:
Sleep education
Sleep scheduling, limit setting, and stimulus control
Teaching relaxation strategies and other adaptive coping skills
Parenting strategies (differential attention, rewards, consequences)
Identification of maladaptive & adaptive cognitions
Problem solving & communication skills
Sleep restriction; bright light to change circadian rhythms
Review gains and plan for long-term maintenance"
1528284|NCT02755025|Other|Automated SOFA scoring calculator|Automated SOFA scoring will be activated within an existing electronic patient care dashboard for ICU patients.
1528285|NCT02754999|Drug|SANGUINATE™|As needed (PRN) infusions of 500 mL of SANGUINATE
1528286|NCT02754986|Other|Analysis of the holter electrocardiogram|
1528287|NCT02754973|Behavioral|an integrated experiential training program with coaching|The intervention will be implemented to each participant by a designated coach who is a trained nursing student during 28 home visits throughout a 6-month period (24 weeks) and each visit will last for about 1 hour. The 1-hour program consists of a 30-minute English tutorial session, and a 30-minute physical activity session with the coach. The same coach will pay a visit to a participant at twice a week for the first 4 weeks and then once a week for the subsequent 20 weeks. 4 levels of physical activity will be taught to the participants gradually according to their ability. Feasible individualized action plans will also be designed.
1528330|NCT02754726|Drug|Albumin-bound paclitaxel|125 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
1528331|NCT02754726|Drug|Paricalcitol|25 micrograms IV on days 1,4,8,12,15,18,22,26,29,32,36,39 (+/-1 day allowed for dosing per 42 day cycle
1528288|NCT02754973|Behavioral|Placebo Control|When discharged home, participants will receive an amount of time and attention (home visits by research assistants) that mimicked that received by the experimental group, but which is thought not to have any specific effect on the outcome measures. The activities during the home visits may include playing cards or chess games, health advice on the prevention of influenza and healthy diet.
1528289|NCT02754960|Drug|Thalidomide|Interventions administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
1528290|NCT02754960|Drug|Placebo|Placebo administered (dosage, 100mg; dosage form, 25mg; frequency of administration, 1 time daily at 10 p.m)
1528291|NCT02754934|Other|Cervical range of motion|Patients will fill out the Neck Disability Index, Visual Analogue Pain Rating Scale and the Self-administered Neck range of motion questionnaire.
1528292|NCT02754921|Procedure|percutaneous dilatational tracheostomy using Ultra-Perc|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ultra-Perc
1528293|NCT02754921|Procedure|Percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin|Procedure difficulties and complications faced while doing percutaneous dilatational tracheostomy using Ciaglia Blue Dolphin
1528294|NCT02754908|Behavioral|musical training|The subjects in the experimental group will receive weekly 45-minute lessons on musical training for one year (52 weeks), conducted by the Music Children Foundation.
1528295|NCT02754908|Behavioral|tutoring classes|They will be invited to attend free, weekly 45-minute tutoring classes organised by the community for one year (52 weeks).
1528296|NCT02754895|Other|Positive Psychology (PP)|Positive psychology (PP) interventions aim to improve the frequency and intensity of positive emotional experiences. This positive psychology intervention focuses on targeted activities in several domains, including altruism (e.g., performing acts of kindness), gratitude (e.g., systematically recalling positive life events), using one's personal strengths in a deliberate manner, and optimism (e.g., thinking about past successes and applying these skills to the future).
1528297|NCT02754895|Other|Motivational Interviewing (MI)|"MI is a goal-oriented, patient-centered approach to helping patients resolve their ambivalence to change their health behaviors.
Each session follows the same structure. Study trainers will: (a) ask participants about their health goals, (b) advise them about current health guidelines and/or refer them to their treatment team, (c) assess readiness to set a goal by identifying how important participants feel the goal is, how confident participants are about making a change, and what the participants' pros and cons for making a change, (d) assist participants in clarifying their goals and problem-solving barriers to reaching those goals, and (e) arrange for the next session by summarizing the participant's plan and scheduling the next session."
1528298|NCT02754882|Drug|Bevacizumab|Avastin® 15 mg/kg IV every 3 weeks on Day 1
1528299|NCT02754882|Drug|SB8|SB8 15 mg/kg IV every 3 weeks on Day 1
1528300|NCT02754882|Drug|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 for 4-6 cycles
1528301|NCT02754882|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 4-6 cycles
1528302|NCT02754856|Drug|Tremelimumab|Tremelimumab 75 mg by vein as a flat dose during Week 11.
1528303|NCT02754856|Drug|MEDI4736|MEDI4736 1500 mg by vein as a flat dose during Week 11. After Week 11, participant receives MEDI4736 alone by vein during Weeks 21, 25, 29, and 33.
1528304|NCT02754856|Procedure|Liver Resection|Participant undergoes scheduled liver resection between Weeks 15 and 17.
1528305|NCT02754843|Device|Phonak's equivalent newly developped power BTE|
1528306|NCT02754843|Device|Equivalent competitor device|
1528307|NCT02754830|Drug|LY3303560 - IV|Administered IV
1528308|NCT02754830|Drug|Saline Solution - IV|Administered IV
1528309|NCT02754830|Drug|LY3303560 - SC|Administered SC
1528310|NCT02754817|Drug|insulin degludec/liraglutide|This is a non-interventional, chart review study and the patients are treated according to current clinical practice and local licenses upon the treating physicians' decision.
1528311|NCT02754804|Device|Biomechanic parameters|recording of biomechanic parameters and surface electromyography at the thigh and calf level throughout the walking period, in PAD patients .
1528312|NCT02754791|Device|Steripath|A device that diverts the first 2 ml of blood drawn in order to reduce contamination
1528313|NCT02754791|Device|Soluprep|Wipes containing alcohol (70%) and chlorhexidine (2%) to achieve skin sterilization
1528314|NCT02754778|Behavioral|conditional workout|6 month of regular conditional workout 1-3 times a weak
1528315|NCT02754765|Drug|Bedaquiline|
1528316|NCT02754765|Drug|Delamanid|
1528317|NCT02754765|Drug|Clofazimine|
1528318|NCT02754765|Drug|Levofloxacin|
1528319|NCT02754765|Drug|Moxifloxacin|
1528320|NCT02754765|Drug|Linezolid|
1528321|NCT02754765|Drug|Pyrazinamide|
1528322|NCT02754752|Procedure|Electro-Acupuncture|Participants receive up to 10 electro-acupuncture sessions over 4 weeks. Fixed core points used for the treatment of PMPS and supplemented by the addition of other fixed points based on location of pain and the one additional symptom causing the patients the most problems (i.e., fatigue, sleep disturbance, or mood problems).
1528323|NCT02754752|Procedure|Sham Electro-Acupuncture|Participants receive up to 10 electro-acupuncture sessions over 4 weeks using slightly different techniques. Fixed core points used for the treatment of PMPS and supplemented by the addition of other fixed points based on location of pain and the one additional symptom causing the patients the most problems (i.e., fatigue, sleep disturbance, or mood problems).
1528324|NCT02754752|Other|Standard of Care|Participants in WLC group receive standard medical care as prescribed by their oncologists/primary care physicians.
1528325|NCT02754752|Behavioral|Questionnaires|"Questionnaires completed at baseline, week 4, and week 8 regarding participant's pain, arm and shoulder movement, fatigue, mood, their expectations about treatment, partner/caregiver support, and quality of life.
Questionnaire completed during weeks 1 - 3 regarding participant's level of pain."
1528326|NCT02754739|Drug|Pravastatin|Pravastatin 40mg once daily for 24 weeks and nutritional education by a nutritionist
1528327|NCT02754739|Drug|Placebo (for Pravastatin)|Pill manufactured to mimic pravastatin 40mg tablet once daily for 24 weeks and nutritional education by a nutritionist
1528328|NCT02754739|Behavioral|Nutritional education only|Only nutritional education by a nutritionist
1528329|NCT02754726|Drug|Nivolumab|Nivolumab 240mg 240 mg as a 60 minute infusion on days 1, 15, 29 per 42 day cycle
1528332|NCT02754726|Drug|Cisplatin|25 mg/m2 over 60 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
1528333|NCT02754726|Drug|Gemcitabine|1000 mg/m2 over 30 minutes IV infusion on days 1, 8 and 22, 29 per 42 day cycle
1528334|NCT02754700|Other|Neuromuscular Training|Standardized, comprehensive neuromuscular training
1528335|NCT02754700|Other|Hip Focused ROBUST Training|Biofeedback training focused on the hip extensors
1528336|NCT02754700|Other|Knee Focused ROBUST Training|Biofeedback training focused on knee abduction
1528337|NCT02754687|Drug|Placebo|Placebo with capsules that look like the 11β-MNTDC capsules but with no active ingredients
1528338|NCT02754687|Drug|11βmethyl nortestosterone dodecylcarbonate|Escalating doses of 100, 200, 400, and 800 mg 11β-MNTDC
1528339|NCT02754674|Procedure|type of anterior cruciate ligament reconstruction|comparison of different types of anterior cruciate ligament reconstruction. transportal technique is double bundle graft using flexible reamer, outside-in technique is single bundle graft with remnant preservation
1528340|NCT02754661|Device|COLON Capsule endoscopy|
1528341|NCT02754661|Device|Computed Tomographic Colonography|
1528342|NCT02754648|Procedure|laparoscopic ovarian endometriotic cyst|
1528343|NCT02754635|Other|Induction of labour|Induction of labour
1528344|NCT02754635|Other|Expectant management|Expectant management
1528345|NCT02754622|Other|Observational Group|Indirect calorimetry measurement during Physical Rehabilitation. Observing planned physical rehabilitation session to determine the rehabilitation activity achieved with IC utilised to determine the number of calories used per session
1528346|NCT02754609|Other|Gluten micro-challenge|From week 12 to week 24, all participants will start a gluten micro-challenge from 10mg/day for the first 2 weeks escalating over the this period to 50mg/day at the end of week 24.
1528347|NCT02754609|Other|Inadvertent gluten challenge|From week 24 to week 36, all participants will be on gluten 50mg/day and 1g twice weekly.
1528348|NCT02754609|Other|Moderate gluten challenge|From week 36 to week 42, all participants will be on gluten 2g/day.
1528349|NCT02754609|Other|Liberal diet|From week 42, all participants will be unblinded and those who have received hookworm therapy have the option to go on a liberal diet of more than 10g of gluten/day from week 42 to week 94.
1528350|NCT02754609|Other|Necator americanus-hookworm larvae L3-10|A total of 40 participants at week 0 and week 8 will have hookworms L3-10 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
1528351|NCT02754609|Other|Tabasco® Sauce|Arm: Placebo Comparator: Tabasco® Sauce A total of 10 participants at week 0 and week 8 will have Tabasco® Sauce present in 2-3 drops of water applied to their skin and covered in a light dressing
1528352|NCT02754609|Other|Necator americanus-hookworm larvae L3-20|A total of 40 participants at week 0 and week 8 will have hookworms L3-20 present in 2-3 drops of water applied to their skin and then covered in a light dressing.
1528353|NCT02754609|Other|Gluten free diet|From week 0 to week 12, all participants will be on a gluten free diet.
1528354|NCT02754596|Drug|Travoprost Intraocular Implant, high elution|Surgical implant placed within the eye to elute travoprost.
1528355|NCT02754596|Drug|Travoprost Intraocular Implant, low elution|Surgical implant placed within the eye to elute travoprost
1528356|NCT02754596|Drug|Timolol Maleate Ophthalmic Solution, 0.5%|Instillation of one drop of timolol in the study eye twice daily
1528357|NCT02754583|Behavioral|Water, sanitation, and hygiene (WASH) intervention|WASH arm: Communities will receive the water, sanitation, and hygiene (WASH) intervention including water point construction, hygiene and sanitation promotion, and educational materials.
1528358|NCT02754583|Behavioral|Standard of care WASH intervention|Stand of care WASH arm
1528359|NCT02754583|Drug|Azithromycin|
1528360|NCT02754583|Drug|Tetracycline|Tetracycline will be administered in lieu of azithromycin if individual is under 6 months, has a known azithromycin allergy, or is severely ill.
1528361|NCT02754583|Other|Control|The control group will receive no intervention during the trial. They will be enrolled in mass antibiotic treatment at the conclusion of the trial.
1528362|NCT02754583|Drug|Albendazole|
1528363|NCT02754570|Drug|Pilocarpine|Pilocarpine will be administered 3 times in addition to latanoprost.
1528364|NCT02754557|Other|Breath Focused Meditation|"During the breath focus task, participants are asked to alternatively focus their breathing (1.5 minutes of breathing and 15 seconds of rest). Participants will be asked to attend to the changing patterns of physical sensations as the breath moves in and out of your body. Focus your awareness on any sensations you may experience (e.g., your abdominal wall rising). Follow the sensations as you breathe in and all the way through until your breath leaves your body."
1528365|NCT02754557|Other|Physiological Feedback|Participants will receive breath feedback, via dynamic velocity estimates from a respiration belt, which allows an analog of breath to be felt as vibration on their wrist via a tactile transducer on a table. The transducer is tuned to produce low frequencies so there is more vibration and less of an audible component than a regular speaker would produce.
1528366|NCT02754544|Procedure|Electrocorticography (ECoG) with PMT Grids|Electrocorticography (ECoG) mapping takes place during participant's scheduled surgery. PMT grids with fixed contact diameter used during ECoG.
1528367|NCT02754544|Procedure|Electrocorticography (ECoG) with CorTec Grids|Electrocorticography (ECoG) mapping takes place during participant's scheduled surgery. CorTec high resolution hybrid grids used during ECoG.
1528368|NCT02754544|Procedure|Digital Glove Procedure|When grid is in place, participant awakened and asked to wear digital glove and perform hand movements. This should take about 20 minutes.
1528369|NCT02754544|Procedure|Neurological Exam|Neurological exam (tests to check the functioning of participant's nerves, including tests of their balance and reflexes) performed one day after surgery. Exam also performed at 1 and 3 months after surgery.
1528370|NCT02754544|Procedure|Electrocorticography (ECoG) with Ad-Tech Grids|Electrocorticography (ECoG) mapping takes place during participant's scheduled surgery. Ad-Tech Grids used during ECoG.
1528371|NCT02754544|Procedure|Direct Electrical Stimulation Mapping|During surgery neurosurgeon performs standard tests to learn which parts of the brain near the tumor control the arms and legs. These areas of the brain stimulated with a small-dose electrical current to see which limbs will move.
1528683|NCT02752295|Behavioral|additional two days follow-up weekend|A two-days follow-up which recapitulates previous treatment elements.
1528372|NCT02754544|Procedure|Grip Sensor Procedure|Continuous grasp force levels and resting state measured with a grip sensor. Participants asked to grasp and squeeze the force sensor for 2-3 sec for 30 trials.
1528373|NCT02754531|Device|USG|USG used was SonoSite® M-Turbo Bothell, WA, USA, probe linear (Array HFL 38 frekuensi 6-13 MHz). Internal subglottic diameter equals external diameter of the uncuffed endotracheal tube or trachea diameter, result rounded to the smallest uncuffed endotracheal tube size.
1528374|NCT02754531|Other|Cole Formula|Internal diameter of the uncuffed endotracheal tube equals (age in years/4) + 4mm.
1528375|NCT02754518|Drug|Entresto|
1528376|NCT02754505|Other|Early rehabilitation|The early rehabilitation program consisted of a coordinated exercise therapy and neuromuscular electrical stimulation, for two hours and five days a week until discharge from the acute hospital. Exercise therapy included strength training (three days/week, one to three sets of 12-15 repetitions, 8-10 exercises involving the major muscle groups: thighs, calves, buttocks, trunk, shoulder girdle), aerobic exercise (large muscle activities five days/week, 10-30 min/session, 50-80% maximal heart rate) and active breathing techniques. For neuromuscular electrical stimulation we applied Compex-P© devices producing biphasic symmetric impulses with a frequency of 50 Hz and a pulse width of 0.35 ms (stimulus regime: 8 s on/24 s off) five days/week, 30 min/session involving the anterior thighs and buttocks.
1528377|NCT02754505|Other|Usual care|exercise therapy, respiratory therapy, neuromuscular electrical stimulation (as described above).
1528378|NCT02754492|Device|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
1528379|NCT02754479|Device|Nd:YAG laser|Treatment of lower extremity spider veins
1528380|NCT02754466|Other|Subjective vs objective criteria in selective excavation|Subjective vs Objective criteria (Polymer burs) to perform selective excavation of dentin caries in deep lesions
1528381|NCT02754466|Other|Glass-ionomer vs Bulk fill composites in the ART approach|High-viscosity glass-ionomer vs Bulk fill composite to restore shallow and medium depth dentin lesions using the ART approach
1528382|NCT02754453|Behavioral|Behavioral lifestyle intervention|20 session lifestyle behavioral intervention with the goal of altering diet and physical activity and decreasing problematic behaviors associated with weight regain and session behavioral intervention addressing increasing physical activity, improving adherence to dietary recommendations and altering problematic eating behaviors.
1528384|NCT02754427|Behavioral|Prospective Surveillance Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the surveillance group underwent the same arm assessment at 3, 6, and 9 months post-surgery. If arm morbidity was detected at any of those time points, then the participant was referred to individual physiotherapy treatment until the issue was resolved.
1528385|NCT02754427|Behavioral|Education Group|Participants received a pre-surgery arm assessment for shoulder mobility, upper body muscle strength, upper body function, and arm volume. Same assessment was repeated at 12 months post-surgery. After surgery, participants randomized to the education group were asked to attend three patient education sessions on nutrition, stress management, and fatigue management of approximately 1 hour, delivered at 3, 6, and 9 months by study staff.
1528386|NCT02754414|Procedure|Apheresis platelet collection|A single apheresis platelet unit will be collected from a healthy adult volunteer subject using the Trima Accel® Automated Blood Collection System. Concurrent plasma will be collected.
1528387|NCT02754414|Other|Refrigerated storage of apheresis platelets in plasma|The apheresis platelet unit will be stored, without agitation, at 4°C, for up to 20 days.
1528388|NCT02754414|Radiation|Infusion of aliquot of autologous radiolabeled platelets|Fresh and stored aliquots will be labeled with Indium-111. We are administering ≤30 microcuries in both infusions for a total dose of 0.8 mSv.
1528389|NCT02754414|Other|In vitro tests|Tests to evaluate platelet function will be performed on the platelet unit on day of collection and end of storage
1528390|NCT02754401|Other|16 Items|Patients took part in the questionnaire and were examined using the PSI (periodontal screening index).
1528391|NCT02754401|Other|PSI|The PSI scores (0 to 4) were recorded: score 0=healthy, score 1=bleeding, score 2=supra-/subgingival calculus, score 3=probing depths from 3.5mm to max. 5.5mm, score 4=probing depths greater than 5.5mm. Only the highest finding was noted for each sextant. Persons with findings of code 0 to code 2 were classified as non-periodontitis persons (group 1), whereby codes 3 and 4 were considered a probable periodontitis persons (group 2).
1528392|NCT02754375|Procedure|rTMS|
1528393|NCT02754362|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor (VEGF), a proangiogenic factor which aids in tumor vessel formation.
1528394|NCT02754362|Biological|Peptide Vaccine|"Vaccine of long synthetic peptides encoding T cell epitopes in tumor associated antigens.
Vaccine Consists of:
EGFRvIII peptide 100 mcg IL13Ralpha peptide 100 mcg EphA2 peptide 100 mcg Her2/neu peptide 100 mcg YKL-40 peptide 100 mcg"
1528395|NCT02754362|Drug|Poly-ICLC as immune adjuvant|Poly-ICLC is a toll like receptor 3 agonist which directly activates dendritic cells and triggers natural killer cells to kill tumor cells.
1528396|NCT02754362|Drug|Keyhole limpet hemocyanin (KLH)|Potent Immunogen used in vaccine approaches for a number of diseases including cancer, AIDS, and infectious diseases
1528397|NCT02754349|Device|SphygmoCor version 7, AtCor Medical, Sydney, Australia|Pulse wave velocity, augmentation index and central blood pressure measurement with applanation tonometry before and after electrical cardioversion
1528398|NCT02754336|Behavioral|Cogmed Robomemo, working memory training|
1528399|NCT02754336|Behavioral|Othmer, neurofeedback|
1528400|NCT02754323|Device|Apparatus CODESNA|The inclusion period is evaluated at one month and the participation of each patient is two days. One day or the subject performs the evaluation of chronic stress by CODESNA and following through questionnaires and another day to 3 weeks / one month apart, to perform a second chronic stress measurement with tool CODESNA to evaluate its reproducibility and reliability.
1528401|NCT02754310|Other|Variation of scenarios|Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.
1528402|NCT02754310|Other|Repeated scenarios|The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
1528403|NCT02754297|Drug|177Lu-Octreotate|"The induction course will consist in 4 cycles at 8-10 weeks intervals.
Concomitant amino acids will be administered for renal protection.
Intra-arterial LuTate administration will be allowed in suitable cases.
Dosimetry will be based on quantitative SPECT/CT imaging.
In patients with hormonal symptoms, somatostatine analogues can be given between P-PRRT cycles."
1528404|NCT02754284|Biological|Autologous fat transplantation|Autologous abdominal fat will be injected into vocal cord beneath mucous under surgery microscope.
1528405|NCT02754284|Biological|Functional collagen scaffold transplantation|Injectable collagen scaffold combined with adipose derived stem cells that are isolated from abdominal adipose tissue will be injected into vocal cord beneath mucous under surgery microscope.
1528406|NCT02754271|Other|Fit for Dialysis|A 15-minute research-based film that explores the barriers and facilitators regarding exercise participation by older hemodialysis patients and support by nephrology staff and family caregivers, and a 16-week exercise program involving activities during dialysis, at home, and in the community.
1528407|NCT02754258|Drug|MPH|60 days on oral methylphenidate administered 2 times daily before lunch and supper.
1528408|NCT02754258|Drug|Placebo|60 days on oral placebo administered 2 times daily before lunch and supper
1528409|NCT02754232|Other|Telemedical training|Intervention will involve resistance training and anaerobic training
1528410|NCT02754219|Drug|Evogliptin|DPP4-inhibitor, Evogliptin
1528411|NCT02754193|Other|moderate hypothermia|moderate hypothermia will be induced using the heat controller of the VA-ECMO circuit. Temperature will be maintained between 33°C≤ T°C ≤34°C during 24 hours ± 1h followed by a progressive reheating (0.2±0.1°C/h) to reach 37 °C. Temperature at 37°C ± 0.3°C will be maintained during 48 hours ± 4h after having reached 37 °C.
1528412|NCT02754180|Drug|Gemcitabine|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles
1528413|NCT02754180|Radiation|TS-1 with radiation|gemcitabine 1g/m2 iv d1, 8, 15, q4wks. 6 cycles. Followed by TS-1 based chemoradiation. TS-1 40mg/m2 bid, 5 days/week, with radiation.
1528422|NCT02754128|Behavioral|BeFAST|The motor learning (ML)-based gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined training/home imagery) will be five per week.
1528423|NCT02754128|Behavioral|BeSTRONG|The functional strength training program is designed to improve gait-related skills. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down. Children will be given a 3- to 5-min home program of strength exercises to practice on days when they do not have active training sessions. The total number of sessions (combined training/home program) will be five per week.
1528424|NCT02754115|Other|Hyperthermic intraperitoneal chemotherapy|Perioperative data of all the patients posted for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy will be collected prospectively
1528425|NCT02754102|Other|Sunscreen Spray- Liquid (BAY987516)|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back.
1528426|NCT02754089|Drug|Rhus Coriaria L.(Rhus)|500 mg twice daily after meals for 6 weeks
1528427|NCT02754089|Drug|Placebo|500 mg twice daily after meals for 6 weeks
1528428|NCT02754076|Drug|BMN 250|Chimeric fusion of recombinant human alpha-N-acetylglucosaminidase and truncated human insulin-like growth factor 2 (rhNAGLU-IGF2)
1528429|NCT02754063|Device|PbtO2 probes|PbtO2/ICP/CPP-directed therapy according to international recommendations
1528430|NCT02754063|Other|No PbtO2 probes|ICP/CPP-directed therapy according to international recommendations
1528431|NCT02754050|Device|Tandem Snare|
1528432|NCT02754037|Radiation|FDG-PET|FDG-PET has been utilized in multiple disease processes that have inflammation as the key driver of the disease and has found potentials to be used for imaging of steatohepatitis. Dynamic PET acquires images at multiple time points and enables parametric imaging of FDG kinetics, providing fundamental quantitative information about the kinetic process of glucose metabolism in the liver tissue. Our group at UC Davis has developed a novel kernel-based dynamic (KBD) PET imaging method. The resulting KBD PET method has demonstrated a five-fold gain in signal-to-noise ratio (SNR) when tested on a small group of patients with breast cancer. With this substantial SNR gain, the study group believes the approach has great potential to allow accurate characterization of FDG kinetics in the liver.
1528433|NCT02754037|Radiation|MRI-PDFF|Novel non-invasive MRI based tools to assess liver fat and fibrosis. Potential risks include a sensation of claustrophobia. No contrast dye is used and thus no risk of contrast allergy. Inflammation of the liver may be assessed by MRI software after processing of images and does not require additional patient involvement or change in MRI protocol.
1528434|NCT02754024|Procedure|Total shoulder arthroplasty (TSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
1528435|NCT02754024|Procedure|Hemi shoulder arthroplasty (HSA)|stemless humeral head implant: Eclipse™ (Arthrex Inc., Naples, FL, USA)
1528436|NCT02754024|Device|Eclipse™ (Arthrex Inc., Naples, FL, USA)|stemless humeral head implant
1528437|NCT02754011|Drug|Combination of ribociclib + capecitabine|RIBOCICLIB from 200 to 600mg once daily + CAPECITABINE from 750 to 1000 mg/m² BID, cycles are defined in 21-day periods, 2 weeks on treatment, 1 week off treatment
1528774|NCT02751541|Other|Untreated Skin|This site is patched without treatment as irradiated control.
1528441|NCT02753985|Other|Survey|
1528442|NCT02753972|Behavioral|Mindful Eating and Living|8 week mindfulness skills intervention
1528443|NCT02753972|Behavioral|Active Weight Loss Control|8 week active weight loss control group
1528444|NCT02753959|Other|Acute Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:
Electrical impedance tomography (EIT)
EMGpara
SpO2
tcCO2
Respiratory inductance plethysmography
EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention
Interventions will be set as follows with a 30 minute washout period between modes:
Manual techniques only
MIE at low pressure (+30 to -30)
MIE at high pressure (+60 to -60)"
1528445|NCT02753959|Other|Stable Intervention|"Patients will be set up onto their Non Invasive Ventilator and assessed for an hour prior to, during and following secretion clearance and will have the following assessed:
Electrical impedance tomography (EIT)
EMGpara
SpO2
tcCO2
Respiratory inductance plethysmography
EIT will be performed as 2 to 10-minutes recording of quiet breathing before and after each intervention
Interventions will be set as follows with a 30 minute washout period between modes:
Manual techniques only
MIE at low pressure (+30 to -30)
MIE at high pressure (+60 to -60)"
1528446|NCT02753946|Drug|ZTI-01|6g ZTI-01 intravenous infusion TID q8 hours
1528447|NCT02753946|Drug|Piperacillin-tazobactam|4.5g piperacillin-tazobactam intravenous infusion TID q8 hours
1528448|NCT02753933|Other|MRI scan|MRI head scan to be performed as the first Secondary Care contact.
1528449|NCT02753933|Other|Neurology Appointment|Outpatient appointment with Neurologist as the first Secondary Care contact
1528450|NCT02753920|Other|voiding trial|1 of 2 tests to assess bladder function after vaginal apex suspension surgery with or without mid-urethral sling
1528451|NCT02753920|Device|Foley catheter|If subject is unable to void adequately, a Foley catheter will be placed as per protocol and the subject discharged home with catheter. The subject will follow up in the office for removal of catheter.
1528452|NCT02753907|Dietary Supplement|Low LA|Individuals who replaced 10 mL soy oil with one apple
1528453|NCT02753907|Dietary Supplement|High LA|Individuals who reduced 1/3 cup of cooked refined rice and consumed 9.9g (9 of 1.1g capsules, 3 capsules at every 3 meals a day) of soy oil as a supplement
1528454|NCT02753894|Drug|ASP1585|Oral
1528457|NCT02753868|Behavioral|exercise|Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
1528458|NCT02753868|Procedure|Hemodialysis treatment|Participants will receive a standard hemodialysis treatment during the study period
1528459|NCT02753855|Drug|Telavancin|A single dose of telavancin as a 1-hour intravenous infusion
1528460|NCT02753842|Device|Fitted condoms|"Fitted condoms are available in 56 sizes based on combinations of length (approximately 10mm increments) and circumference (approximately 2 mm increments). Fitted condom thickness is 70 microns ± 10 microns. Appropriate condom size is user-determined with a paper template fitting tool graduated with non-sequential numbering and lettering for maximum privacy.
Participants will receive 5 fitted condoms in plain aluminum foils, identifiable only by a two-digit number printed on the foil. Participants will also receive ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
1528461|NCT02753842|Device|Thin condoms|"Thin condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 50 microns ± 5 microns thick.
Participants will receive 5 thin condoms in plain aluminum foils, identifiable only by a two-digit number printed on the foil. Participants will also receive ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
1528462|NCT02753842|Device|Standard condoms|"Standard condoms have dimensions of 185mm ± 10mm length, 53mm ± 2mm width, and 70 microns ± 10 microns thick.
Participants will receive 5 thin condoms in plain aluminum foils, identifiable only by a two-digit number printed on the foil. Participants will also receive ten plain foil packets of 10ml commercially available condom-compatible water-based lubricant."
1528463|NCT02753829|Procedure|Cardiovascular rehabilitation program using Kinect of Xbox|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.
It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
1528464|NCT02753829|Procedure|Cardiovascular rehabilitation program using paper manual|"Participants perform a program of specific exercises. The exercise protocol was adapted to the home context and presented two progressive levels of intensity of exercise, having the second level being introduced after 3 months. The exercise protocol was performed at a moderate intensity, initiated, using data from the stress test, maximal heart rate, the Karvonnen formula, with 65% of the reserve heart rate, progressing for 70%.
It was given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks."
1528465|NCT02753829|Other|Educational component|It was only given the educational component about the control of cardiovascular risk factors and was encouraged to carry out the daily walks.
1528466|NCT02753816|Drug|Tranexamic Acid|
1528467|NCT02753816|Drug|Placebo Comparator|
1528468|NCT02753803|Drug|Evogliptin, Pioglitazone, Evogliptin+Pioglitazone|Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
1528469|NCT02753803|Drug|Pioglitazone, Evogliptin, Evogliptin+Pioglitazone|Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD
1528470|NCT02753803|Drug|Evogliptin, Evogliptin+Pioglitazone, Pioglitazone|Evogliptin : Evogliptin 5mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD
1528892|NCT02750605|Device|DEB|Intervention with drug eluting balloon.
1528471|NCT02753803|Drug|Pioglitazone, Evogliptin+Pioglitazone, Evogliptin|Pioglitazone : Pioglitazone 30mg QD Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
1528472|NCT02753803|Drug|Evogliptin+Pioglitazone, Evogliptin, Pioglitazone|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD Pioglitazone : Pioglitazone 30mg QD
1528473|NCT02753803|Drug|Evogliptin+Pioglitazone, Pioglitazone, Evogliptin|Evogliptin+Pioglitazone : Evogliptin 5mg QD + Pioglitazone 30mg QD Pioglitazone : Pioglitazone 30mg QD Evogliptin : Evogliptin 5mg QD
1528474|NCT02753790|Radiation|Intensity Modulated Radiotherapy|"Whole brain radiation using IMRT: 60 Gy to gross disease (planning treatment volume [PTV] 60) or 45 Gy to gross disease (PTV 45) and 30 Gy to subclinical sites (PTV 30) over 15 fractions.
Patients will be treated Monday through Friday (5 days per week) for 3 weeks. Patients with either a single metastasis greater than 15 cubic centimeters (cm) or total volume of metastases greater than 26 cubic cm will receive the lower dose of 45 Gy to visible brain metastases. 45 Gy may also be prescribed per physician discretion.
Gross disease which has received prior radiosurgery will receive 30 Gy."
1528475|NCT02753777|Other|Questionnaires|
1528476|NCT02753764|Drug|AZD7624|
1528477|NCT02753764|Drug|prednisone|oral prednisone 20 mg bid for one week
1528478|NCT02753764|Drug|Placebo|
1528479|NCT02753751|Other|AKI Alert|"Provider's will receive a pop-up alert in the electronic health record until AKI is documented in the problem list or AKI resolves."
1528480|NCT02753738|Drug|Escitalopram|Tablet 10mg, 21 days
1528481|NCT02753738|Drug|Placebo|Tablet, 21 days
1528482|NCT02753738|Other|3xMR scan (fMRI, DTI, strucutral MRI)|3 Tesla PRISMA MAGNETOM MR scanner; performed at baseline, after 21 days of performing learning paradigms and after 21 days of drug/placebo treatment and re-learning paradigms
1528483|NCT02753738|Behavioral|Association learning paradigm|21 daily internet-based sessions (20min) of learning associations (pairs) of stimuli
1528484|NCT02753738|Behavioral|Association re-learning paradigm|21 daily internet-based sessions (20min) of learning new associations (pairs) of stimuli performed during escitalopram/placebo treatment
1528485|NCT02753725|Drug|Fentanyl|The intervention arm will comprise Fentanyl given at a dose of one microgram per kilogramme body weight administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed.
1528486|NCT02753725|Drug|Normal saline|the placebo arm will be given normal saline at a volume equivalent to Fentanyl dose per body weight,administered approximately ten minutes to the end of surgery determined by the time when the mouth gag will be removed
1528487|NCT02753712|Drug|Fluticasone/Formoterol BAI|
1528488|NCT02753712|Drug|Fluticasone/Vilanterol DPI (Relvar Ellipta DPI)|
1528489|NCT02753699|Drug|Alisporivir|Intervention of interest; follow-up after ALV-active study
1528490|NCT02753686|Drug|Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant|
1528491|NCT02753686|Drug|Endocrine therapy in combination with targeted therapy may include: everolimus plus exemestane or CDK4/6 inhibitor plus endocrine therapy|
1528492|NCT02753673|Behavioral|qualitative interviews with patients|
1528493|NCT02753673|Behavioral|questionnaires|
1528494|NCT02753660|Procedure|Traditional sitting position|Subjects were set on traditional sitting position before spinal anesthesia begun.
1528495|NCT02753660|Procedure|Pendant position|Subjects were set on pendant position before spinal anesthesia begun.
1528496|NCT02753647|Drug|Rituximab|
1528497|NCT02753647|Drug|Cyclophosphamide|
1528498|NCT02753647|Drug|Doxorubicin|
1528499|NCT02753647|Drug|Vincristine|
1528500|NCT02753647|Drug|Prednisone|
1528501|NCT02753647|Drug|Chidamide|
1528502|NCT02753634|Behavioral|Square-stepping exercise|Participants are asked to remember and repeat stepping patterns across a gridded mat as shown to them by an instructor.
1528503|NCT02753621|Behavioral|Group singing|Weekly group singing classes led by professional choir instructor, lasting 90 minutes. 12 classes over 12 consecutive weeks.
1528504|NCT02753621|Behavioral|Facilitated Discussion Group|Weekly facilitated discussion group led by Parkinson Disease educator, lasting 90 minutes. 12 sessions over 12 consecutive weeks.
1528505|NCT02753608|Other|Collection of exhaled breath condensate|An sampling device (authorized for this use) will be connected to the expiratory line of the ventilator. Exhaled breath condensates accumulate in a cooled container.
1528506|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m2 or 1.1 mg/m2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle
1528507|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m2 or 1.1 mg/m2, depending on RP2D, as IV infusion on Day 1 and 8 of each 21-day cycle
1528508|NCT02753595|Drug|Eribulin mesylate|Eribulin mesylate will be administered at 1.4 mg/m2 as IV infusion on Day 1 and 8 of 21-day cycle
1528509|NCT02753595|Other|Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20 will be administered at 3.0 μg/kg or 1.6 μg/kg as IV infusion on Day -1 and 7 of 21-day cycle
1528510|NCT02753595|Other|Biologic: PEGylated recombinant human hyaluronidase|PEGPH20 will be administered at 3.0 μg/kg or 1.6 μg/kg, depending on RP2D, as IV infusion on Day -1 and 7 of each 21-day cycle
1528511|NCT02753582|Dietary Supplement|SOD+Gliadin Capsule|
1528512|NCT02753582|Dietary Supplement|Placebo|
1528513|NCT02753569|Other|Imaging - DW-MRI|
1528514|NCT02753569|Radiation|FDG PET-CT|
1528515|NCT02753543|Drug|Chidamide|
1528516|NCT02753530|Drug|Arimoclomol|2 200mg pills taken 3 times per day during breakfast, early afternoon and at bedtime
1528517|NCT02753530|Other|Placebo|2 matched placebo pills to be taken 3 times per day during breakfast, early afternoon and at bedtime
1528518|NCT02753517|Device|Hepatobiliary scintigraphy|hepatobiliary scintigraphy with functional assessment of the future remnant liver before an extended hepatectomy of 4 or more segments
1528519|NCT02753504|Drug|CKD-519|
1528520|NCT02753504|Drug|placebo|
1528521|NCT02753491|Behavioral|Motivational short interview|New designed motivational short interview model
1528522|NCT02753478|Other|intracoronary infusion with saline on 22 and 4°C|"Routine primary percutaneous intervention will be commenced. Patient will be asked to participate in the study.
Before reperfusion, saline on room temperature will be infused though the occlusion in the infarct related artery using an over the wire balloon catheter during 10 minutes. The balloon will be inflated to prevent reperfusion in that phase. After 10 minutes the balloon will be deflated allowing reperfusion and infusion with saline on 4°C will be continued for 10 minutes. After this, a coronary stent will be placed."
1528523|NCT02753465|Procedure|left colic artery|Laparoscopic D3 Lymph Node Dissection with preservation of left colic artery
1528524|NCT02753465|Procedure|High ligation|Laparoscopic D3 Lymph Node Dissection with ligation above the left colic artery
1528525|NCT02753452|Behavioral|Residential Immersive Life Skills programming|
1528526|NCT02753452|Behavioral|Non-residential life skills programming|
1528527|NCT02753439|Drug|Geistlich Bio Oss|Extraction of Impacted 3rd Molars,
1528530|NCT02753413|Biological|RSV vaccine GSK3003891A|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
1528531|NCT02753413|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
1528532|NCT02753400|Drug|emixustat hydrochloride|Tablet for oral administration
1528533|NCT02753400|Other|Placebo|Placebo tablets for oral administration contain only inactive ingredients
1528534|NCT02753387|Drug|Chlorhexidine|4 mouthwashes during 30 seconds with Eludril Perio 10 ml and 1 application after intubation with Eludril Perio
1528535|NCT02753387|Device|NaCl 0.9 %|4 mouthwashes during 30 seconds with NaCl 0.9 % 10 ml and 1 application after intubation with NaCl 0.9 %
1528537|NCT02753348|Other|Echocardiography|
1528538|NCT02753348|Other|Blood analysis from umbilical cord blood|
1528539|NCT02753348|Other|ECG|
1528540|NCT02753348|Other|Measurement of oxygen saturation|
1528541|NCT02753335|Behavioral|GMI and Desensitization|"Graded Motor Imagery (GMI) is used to treat chronic pain conditions and movement problems related to alterations in the nervous system such as CRPS, postamputation limb pain and back pain. The patient is trained in monitored steps. The three treatment components include left/right discrimination training, motor imagery exercises and mirror observations of the unaffected limb, appearing as the affected limb. They are performed sequentially, but require a flexible approach to suit the individual patient. The imagined movements have been demonstrated to activate motor cortical areas similar to those activated in the actual execution of that movement.
Desensitization (D) is used to decrease hyperalgesia by repeated tactile stimulation of the affected area with various materials."
1528542|NCT02753335|Behavioral|Desensitization|Desensitization (D) is used to decrease hyperalgesia and allodynia by repeated tactile stimulation of the affected area with various materials.
1528543|NCT02753322|Other|Dual task training|Balance and walking exercises with simultaneously engaging in attention demanding tasks
1528544|NCT02753322|Other|Single-task training|Balance and walking exercises and and attention demanding task performed separately
1528545|NCT02753322|Other|Limbs exercise|Stretching and strengthening exercises
1528546|NCT02753309|Drug|Sirolimus|
1528547|NCT02753283|Drug|denosumab|Semi-annual dose: 60 mg injection; Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
1528548|NCT02753283|Drug|Placebo|Semi-annual saline injection
1528549|NCT02753283|Dietary Supplement|Calcium and Vitamin D|Dietary supplement: Vitamin D 800-1000 IU/daily and Calcium approximately 1200 mg/daily (dietary + supplement)
1528550|NCT02753270|Procedure|Short catheter|Ultrasound Guided Foam Sclerotherapy in Great Saphenous Vein, measuring from 6 to 10 mm, with Short Catheter.
1528551|NCT02753270|Procedure|Long catheter preceded by tumescence|Ultrasound Guided Foam Sclerotherapy Transcatheter in Great Saphenous Vein, measuring from 6 to 10 mm, Preceded by Tumescence.
1528552|NCT02753257|Other|Non-Interventional|Non-Interventional
1528553|NCT02753244|Other|Motion Based Cognitive Video Games Software|Intendu FBT motion based cognitive video games software
1528554|NCT02753244|Other|iPad Apps|Commercially available iPad game applications
1528555|NCT02753231|Behavioral|Low physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
1528556|NCT02753231|Behavioral|High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
1528557|NCT02753231|Behavioral|Low and High physical activity program|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
1528558|NCT02753231|Behavioral|Conventional physical activity program|One Physical Education sessions / week
1528559|NCT02753218|Drug|Midazolam|
1528560|NCT02753218|Drug|LEO 32731|
1528561|NCT02753205|Drug|Dexmedetomidine|infusion of dexmedetomidine 0.5ug/kg/h for 10 min and after that, infusion of dexmedetomidine 0.4ug/kg/h until the end of surgery
1528562|NCT02753205|Drug|normal saline|infusion of normal saline
1528563|NCT02753192|Other|Patients|Individuals with PD will be enrolled in the study in Aix-en-Provence, France (N = 60) and Lisbon, Portugal (N = 60). Their global motor disability and orofacial motor functions will be assessed with specific clinical rating scales, without (OFF) and with (ON) medical treatment. Two groups of 60 healthy age-matched volunteers will provide the reference for between-group comparisons. Along with the clinical examinations, several speech tasks will be recorded to obtain acoustic and perceptual measures. Self-evaluation questionnaires will be used to assess the psychosocial impact of dysarthria on quality of life.
1528564|NCT02753179|Other|Head Impulse Tests|Head Impulse Tests are performed by the clinician who holds the patient's head in his hands, while he is looking straight at an earth-fixed target; then by turning the patient's head abruptly and unpredictably to the left or right, up or down through a small angle (only 10-20 degrees - not a large angle). 20 impulses in each directions (6) will be performed.
1528565|NCT02753179|Other|Dynamic visual acuity Test (DVAT)|Dynamic visual acuity Test (DVAT) assesses visual acuity during head movement relative to baseline static visual acuity. DVA will be assessed actively during self-generated rotations of the head in different directions.
1528566|NCT02753179|Other|VEMPs & VEMPo|VEMPs & VEMPo are sound evoked muscular contractions of the neck or eye. They are recorded using an evoked response computer, a sound generator, and surface electrodes to pick up neck or eye muscle activation.
1528567|NCT02753179|Other|Dizziness Handicap Inventory|Dizziness Handicap Inventory is a questionnaire that identify difficulties that patient may be experiencing because of dizziness, yielding to a score ranging from 0 to 100
1528568|NCT02753179|Other|Oscillopsia severity questionnaire|Oscillopsia severity questionnaire is a 9 items questionnaires that identify oscillopsia in different circumstances.
1528569|NCT02753166|Drug|Dexamethasone|After six (6) hours of the accident, subject will take 5 mg of DEX in the Emergency Department (ED). Within twenty-four (24) hours, the subjects will send in a saliva sample. After sexen (7) days, subjects will participate in a phone interview. After thirty (30) days, subjects will participate in an online assessment and return for a one month follow-up visit. Subjects will then participate in online assessments at months 3,6,9, and 12 months.
1528570|NCT02753153|Procedure|Control surgical protocol|"A connective tissue graft will be harvested to the palate or posterior maxilla tuberosity. The dimension of the graft will be previously calculated according to the socket dimensions. The harvesting site will be made with a single edge incision and sutured with 4.0 silk (uninterrupted suture). The connective tissue graft will be reshaped if necessary to be 1-2mm thick and inserted into buccal pouch and sutured with 2 vertical interrupted sutures to be stabilized on the buccal aspect.
The connective tissue graft is then positioned to caver the socket and inserted and sutured in the palatal pouch also by the means of vertical interrupted sutures (polypropylen 6.0)."
1528571|NCT02753153|Procedure|Test surgical protocol|The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction.
1528572|NCT02753153|Procedure|Socket preservation|"An atraumatic extraction will be performed in order to preserve the socket bone wall as well as the cervical soft tissues.
Split- thickness pockets will be performed 5-6 mm deep buccally and 3-4 mm deep palatally preserving interproximal papillae. The filling biomaterial (Bio-Oss®, Geistlich), previously humidified with a saline solution containing doxycycline (1mg/ml) and inserted into the socket without heavy compaction. At this level of the surgery, the randomization envelope will be open and either the control or the test surgical protocol will be applied."
1528573|NCT02753140|Drug|Cetuximab|
1528574|NCT02753140|Radiation|radiation|
1528575|NCT02753140|Drug|Docetaxel|
1528576|NCT02753140|Drug|Cisplatin|
1528582|NCT02753114|Drug|Ketamine|Intranasal Ketamine administered via mucosal atomization device at 0.5 - 1 mg / kg IN.
1528583|NCT02753114|Drug|Normal Saline|Intranasal Normal Saline administered via mucosal atomization device.
1528585|NCT02753088|Drug|BCD-063|
1528586|NCT02753088|Drug|Copaxone-Teva|
1528587|NCT02753088|Drug|Placebo|
1528588|NCT02753075|Device|Experimental Oral Rinse 1|Oral rinse containing 1.5% w/w KOX, 0ppm F, pH 4.5
1528589|NCT02753075|Device|Experimental Oral Rinse 2|Oral rinse containing 2.0% w/w KOX, 45ppm F, pH 4.5
1528590|NCT02753075|Other|Placebo Oral Rinse|Oral rinse containing 0% w/w KOX 0ppm F, pH 4.5
1528591|NCT02753075|Drug|Fluoride toothpaste|Oral rinse containing 1000ppm fluoride as sodium monofluorophosphate
1528592|NCT02753062|Drug|bendamustine, rituximab|subjects will receive rituximab 375mg/m2 on day 1 and bendamustine 120mg/m2 by intravenous infusion on day 2 and 3 in the first cycle. From the 2nd to 6th cycle, rituximab will be administered subcutaneously at a fixed dose of 1400mg and bendamustine 120mg/m2 by intravenous infusion on day 1 following administration of rituximab and day 2.
1528593|NCT02753049|Behavioral|Peer led mHelath behavioral intervention|A trained peer adherence coach will schedule five, weekly-60 minute, 'ACCESS' sessions, delivered to participants via remote videoconferencing, using smartphones. Cognitive behavioral strategies will be employed to target beliefs about antiretroviral treatment (ART), knowledge of ART, and adherence self-efficacy.
1528594|NCT02753036|Drug|Paclitaxel|ovarian: carboplatin + paclitaxel breast: epirubicin + cyclophosphamide + paclitaxel
1528595|NCT02753023|Other|no intervention|No intervention related
1528596|NCT02753010|Procedure|Gastric emptying of carbohydrate-rich beverage|Old women with acute hip fracture with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied for retention in the elderly with acute trauma.
1528597|NCT02753010|Procedure|Gastric emptying of carbohydrate-rich beverage|Old women on waiting list for hip joint replacement with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in the elderly without acute trauma..
1528598|NCT02753010|Procedure|Gastric emptying of carbohydrate-rich beverage|Young healthy women with intake of carbohydrate-rich beverage in order to improve metabolic control. Gastric emptying studied as comparator in young women.
1528599|NCT02752997|Other|Pharmacist discharge medication services|Included in arm descriptions
1528600|NCT02752971|Drug|Bupivacaine|
1528601|NCT02752971|Drug|Sodium diclofenac|
1528602|NCT02752958|Drug|stannous fluoride|0.454% w/w (weight per weight) stannous fluoride
1528603|NCT02752945|Other|One-day CBT workshop|One-day long CBT workshop, with between 4-15 participants, facilitated by clinical psychologists. Following introductions, ice breakers and an explanation of the CBT model, CBT techniques are then introduced and practised using a variety of methods. One week after the workshop, any personal goals set during the workshop are reviewed with one of the workshop facilitators in a 'telephone goal review.'
1528604|NCT02752945|Other|Usual care|Usual care afforded by local CAMHS services
1528606|NCT02752919|Drug|Galunisertib|Administered orally
1528607|NCT02752906|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
1528608|NCT02752906|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
1528609|NCT02752880|Drug|YH1|
1528610|NCT02752880|Drug|placebo|
1528611|NCT02752867|Drug|Jianpi Yishen Huatan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
1528612|NCT02752867|Other|the placebo|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
1528613|NCT02752854|Other|pain threshold measurement|pressure algometer
1528614|NCT02752841|Dietary Supplement|Nutritional vitamin D repletion and maintenance|Ergocalciferol (50,000 IU weekly for 12 weeks) for vitamin D repletion, ergocalciferol (50,000 IU monthly) or cholecalciferol (1000 IU daily) for maintenance of vitamin D
1528618|NCT02752815|Drug|Rituximab|
1528619|NCT02752815|Drug|Cyclophosphamide|
1528620|NCT02752815|Drug|Epirubicin|
1528621|NCT02752815|Drug|Vincristine|
1528622|NCT02752815|Drug|Prednisone|
1528623|NCT02752802|Device|Diagnostic Coronary Angiogram|Diagnostic angiographic procedure with the use of the DyeVert System.
1528624|NCT02752776|Drug|Secukinumab|Secukinumab will be used as commercially available PFS of 150 mg. Patients will receive PFS at the site and will be instructed to administer Secukinumab as needed (300 mg each application).
1528625|NCT02752763|Drug|%40 diluted Autologous serum|Serum that obtained after centrifugation of blood sample
1528626|NCT02752763|Drug|Preservative free artificial tears(Tears naturale free, Refresh single dose eye drop)|Preservative free artificial tears is a group naming for drops commonly used for drye disease
1528627|NCT02752750|Other|MRI|MR imaging (MRI) at 3 Tesla
1528628|NCT02752724|Drug|Ketamine|Ketamine anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
1528629|NCT02752724|Drug|Methohexital|Methohexital anesthesia for ECT index course with measurement cerebral metabolic regional oximetry, EEG seizure quality, cognitive scoring and serum metabolites.
1528630|NCT02752711|Procedure|the PECARN clinical decision rule|the PECARN clinical decision rule for the detection of clinically-important traumatic brain injuries in children with minor head trauma
1528631|NCT02752698|Procedure|robotic surgery|robotic group：30 patients undergo robotic surgeries laparoscopic group：30 patients undergo laparoscopic surgeries
1528632|NCT02752685|Drug|Pembrolizumab|
1528633|NCT02752685|Drug|Nab-Paclitaxel|
1528634|NCT02752659|Procedure|Self-measured arm circumference, therapist-measured arm-circumference, perometer-measured arm circumference|
1528635|NCT02752646|Drug|nepafenac 0.3%|Patients in this group will receive nepafenac 0.3% eye drops once daily after cataract surgery.
1528636|NCT02752646|Drug|ketorolac|Patients in this group will receive ketorolac 0.5% eye drops four times daily after cataract surgery.
1528639|NCT02752620|Other|Osteopathic Manipulative Treatment|
1528640|NCT02752620|Other|Exercise Therapy|
1528643|NCT02752581|Device|Suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
1528644|NCT02752581|Device|No suction drain|A suction drain is used to remove excess fluid from tissues after surgery.
1528645|NCT02752568|Procedure|endometrial scratch|midluteal endometrial scratch using Novak curette under general anesthesia in the cycle preceding stimulation
1528646|NCT02752568|Procedure|assisted hatching|using Octax laser 20120644-laser 5452
1528647|NCT02752568|Procedure|controlled ovarian hyperstimulation|using merional&/ or fostimon doses individualized as judged by patient age & ovarian reserve & monitored by follicular size & serum estradiol
1528648|NCT02752555|Other|Antioxidant (l-cratinine) + modifiable lifestyle factors|All participants were subjected to the same three-month period treatment protocol, which included 1) antioxidant treatment with L-Carnitine (2g daily); 2) frequent ejaculation every 2 days; and 3) minimizing adverse lifestyle factors.
1528649|NCT02752542|Behavioral|Cognitive Behavioral Therapy|CBT will be delivered in a one-to-one face-to-face format by trained Masters or PhD level CBT therapists who will follow a protocol adapted from existing manuals and piloted in the participating centres. Up to 20 sessions will be offered over 18 weeks, initially twice per week, then weekly and later spaced to every other week. The treatment will have core obligatory modules and flexible elements adaptable to participant's maintaining factors.
1528680|NCT02752308|Drug|neostigmine and atropine|Injection of 0.04 mg/Kg of neostigmine and 0.02 mg/Kg of atropine, intravenously at the end of operation.
1528681|NCT02752308|Procedure|Hypospadias repair|Surgical repair of hypospadias, using tubularized incised plate technique
1528682|NCT02752295|Behavioral|stress-coping week|The multidisciplinary team will offer Mindfulness-Based Stress Reduction (MBSR), group psychotherapy (resilience, Cognitive Behavioral Analysis System of Psychotherapy CBASP, psychodynamic therapy), relaxation training, nutrition course, stress-coping and physical training in a group setting.
1528650|NCT02752542|Drug|Pharmacotherapy|Pharmacotherapy will be prescribed and adjusted by psychiatrists in 20-30 minute pharmacotherapy sessions once every two weeks. The manual-guided best-evidence pharmacotherapy will follow current guidelines for first, second and third line treatment.41 The primary focus will be on serotonin-reuptake inhibiting antidepressant (escitalopram 5-20mg, sertraline 50-200 mg daily) monotherapy, which may remain the only treatment for the majority of participants. Augmentation (aripiprazole 2-10mg, bupropione 150-450mg) will be offered to participants with partial response. The manual, developed as part of Canadian Biomarker Integration Network in Depression (CAN-BIND).43, also specifies admissible supportive therapeutic elements and prohibits CBT-specific techniques.
1528651|NCT02752529|Drug|Tacrolimus（FK506）|
1528652|NCT02752516|Drug|Anlotinib|Anlotinib QD po. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
1528653|NCT02752503|Drug|Nalmefene|
1528656|NCT02752477|Drug|Opioid-free general anesthetic|An opioid-free general anesthetic technique utilizing dexmedetomidine, ketamine, and lidocaine infusions
1528657|NCT02752477|Drug|Traditional general anesthetic|Traditional general anesthetic technique utilizing sufentanil, fentanyl or remifentanil
1528658|NCT02752464|Behavioral|Counseling|Up to 12 sessions of behavioral counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 12 week period. Counselors will be guided in their sessions by a computer program called CuesWeight. Participants also receive text messages to enable participants to track their behaviors; this information is relayed to the counselors to inform the counseling sessions.
1528659|NCT02752464|Behavioral|feedback report|All participants receive a brief printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
1528660|NCT02752451|Other|Non-Anatomic Arthroscopy Simulation|Knee arthroscopy training using Cigar Box Arthroscopy Trainer
1528661|NCT02752451|Other|Anatomic Arthroscopy Simulation|Knee arthroscopy training using Anatomic Knee Arthroscopy Trainer
1528662|NCT02752451|Other|Pre-assesment education|Reading material and lecture with only still images about performing diagnostic knee arthroscopy
1528663|NCT02752438|Device|HFOV|HFOV is a kind of respiratory support with a rate higher than physiological but with lesser volume.
1528664|NCT02752425|Device|Visual feedback|Use of ultrasound echography for tongue articulatory visual feedback
1528668|NCT02752386|Behavioral|Biofeedback Training|Participants will received biofeedback training to reduce arousal and pain
1528669|NCT02752373|Device|Brain Sentinel Seizure Detection and Information System|The Brain Sentinel® GTC Seizure Detection and Information System is an ambulatory system designed to continuously monitor and perform real-time analysis of surface electromyography (sEMG) data to detect GTC seizures and to provide an alarm to alert caregivers within 30 seconds of bilateral, appendicular, tonic extension that a seizure is occurring. The System is for recording and storing sEMG data, which is subsequently reviewed by a trained healthcare professional in the outpatient clinical setting. The Brain Sentinel® GTC Seizure Detection and Information System is intended for real time monitoring of pediatric and adult patients who have an arm circumference ranging from at least 16 cm to no greater than 51 cm at the biceps. It may be used in the home or healthcare facilities for real-time monitoring during the day, night, or for continuous monitoring, including during the titration of, or the withdrawal from anti-epileptic drugs.
1528670|NCT02752360|Procedure|Biodegradable Stenting Anastomoses|Biodegradable Stenting Anastomoses(BSA) is a new method and device which helps to make intestinal anastomosis easily. According to the measurement of intestinal canal diameter, chose an appropriate size of BSA and use the Seromuscular layer Purse-string Suture to stitch with an absorbable line (VCP311, Ethicon, Inc.) away from the end 0.5 to 1.0 cm and not knot temporarily, then open and sterilize intestinal canal fully, and place the BSA into the intestinal canal at appropriate position before tightening knot. Last, the interrupted whole layer inversion suture is used to fix.
1528671|NCT02752360|Procedure|Double-layer Hand Sutures|Double-layer Hand Sutures(DHS)is a surgery way that is to use the single-layer continous Hand Sutures,then Lembert to stitch with an absorbable line (VCP311, Ethicon, Inc.).
1528673|NCT02752334|Drug|Magnesium Sulphate|Magnesium has antinociceptive effects in animal and human models, principally related to blocking the N-methyl-D-aspartate (NMDA) receptors and regulation of calcium influx into cells.
1528674|NCT02752321|Device|eDischarge|Patients will be enrolled in the eDischarge technology during their inpatient hospital stay. A completed electronic discharge packet (EDP) will be given to patients on the day of hospital discharge.
1528675|NCT02752308|Drug|Bupivacaine|Injection of Bupivacaine in the epidural space (0.25%, 0.33mg/Kg)
1528676|NCT02752308|Procedure|General anesthesia|Induction with thiopental sodium 5 mg/Kg, atracurium 0.4 mg/Kg and fentanyl 2 mcg/Kg and maintenance with isoflurane and a combination of oxygen and nitrous oxide
1528677|NCT02752308|Drug|Dilute epinephrine injection|Injection of 1/100000 epinephrine solution along all incision lines
1528678|NCT02752308|Drug|Fentanyl|fentanyl 2 mcg /Kg that is repeated during surgery whenever the heart rate or blood pressure increased more than 20% of its baseline
1528679|NCT02752308|Drug|dextrose plus sodium chloride.|Four mL/Kg/hr of 5% dextrose plus 0.04 mL/Kg/hr of 20% sodium chloride. Each mL of blood loss was replaced by 3 ml of Ringer's solution
1528893|NCT02750605|Device|POBA|Intervention with old technology as comparison
1528684|NCT02752282|Other|Anticipatory Counseling|Anticipatory Counseling provides information on expected side-effects that may change or go away over time, or stay for the duration of the treatment. Anticipatory counseling can also help patients understand when their side-effects are normal and when to seek medical attention.
1528685|NCT02752282|Other|Cancer Screening Guidelines|Anticipatory Counseling on United States Preventative Services Task Force (USPSTF) updated pap screening guidelines
1528686|NCT02752256|Drug|Tissue Plasminogen Activator|
1528687|NCT02752243|Drug|CIK-Cells|IL-15 activated CIK cells individually generated from PB mononuclear cells of the original stem cell donors.
1528688|NCT02752230|Procedure|Laparoscopic Roux en Y gastric bypass|Laparoscopic Roux en Y gastric bypass
1528689|NCT02752230|Procedure|Laparoscopic Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy
1528692|NCT02752204|Drug|AZD 2014|AZD2014 125mg BD - 2 days on 5 days off in a 28 day cycle
1528693|NCT02752204|Drug|Rituximab|Rituximab 375mg/m2 will be administered intravenously on day 1 of a 28 day cycle for a total of 6 cycles.
1528694|NCT02752191|Drug|ferumoxytol|ferumoxytol as an MRI contrast agent infused over several minutes
1528695|NCT02752191|Drug|gadofosveset|gadofosveset as an MRI contrast agent injected over several seconds
1528696|NCT02752178|Other|MA|Monoaminergic antidepressant use
1528697|NCT02752178|Other|DEP|Depression measured using the Hamilton Depression (HAM-D) questionnaire
1528698|NCT02752165|Other|TEAM-ED|Facilitation of preventive asthma management through telemedicine assessment and follow-ups in addition to guideline-based provider prompting
1528699|NCT02752165|Other|Enhanced Usual Care|Report of symptoms to primary care physician
1528700|NCT02752152|Behavioral|Computer-assisted counseling|The counselor opens the computer-assisted information/educational interactive counseling program on the tablet computer and invites the participant to use the program.
1528701|NCT02752152|Behavioral|On-demand counseling|The counselor only invites the participants to ask questions about HIV and other STIs.
1528702|NCT02752152|Behavioral|Standard counseling|The counselor gives face-to-face general information/education
1528703|NCT02752126|Radiation|Conventional radiotherapy|Patients will receive standard palliative radiation in dose of 30Gy in 10 fractions, or 20Gy in 5 fractions.
1528704|NCT02752126|Radiation|Esophageal-Sparing Intensity-Modulated Radiotherapy|Patients will receive esophageal-sparing intensity-modulated radiotherapy, of 30Gy in 10 fractions or 20Gy in 5 fractions.
1528705|NCT02752113|Drug|Empagliflozin and Linagliptin|Empagliflozin and Linagliptin
1528706|NCT02752113|Drug|Metformin and Insulin sc|Metformin and Insulin sc
1528707|NCT02752100|Procedure|Percutaneous transluminal angioplasty|
1528708|NCT02752087|Drug|LY900014|Administered SC
1528709|NCT02752074|Drug|pembrolizumab + epacadostat|"Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
Epacadostat will be administered orally daily starting at Day 1 (Week 1)"
1528710|NCT02752074|Drug|pembrolizumab + placebo|"Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
Placebo will be administered orally daily starting at Day 1 (Week 1)"
1528711|NCT02752061|Other|Potlako intervention|"Multicomponent intervention including:
provider training on early detection and diagnostic approaches to cancer
patient education on importance of obtaining timely cancer diagnosis
provision of a patient navigator to facilitate diagnosis and entry into care
provision of transportation support to vulnerable patients"
1528712|NCT02752048|Drug|TAS-205|2 groups: Low dose group, High dose group. Oral administration for 24 weeks, bis in die (BID) after meal
1528713|NCT02752048|Drug|Placebo|1 group: Placebo group. Oral administration for 24 weeks, BID after meal
1528714|NCT02752035|Drug|gilteritinib|Tablet, oral
1528715|NCT02752035|Drug|Azacitidine|Subcutaneous injection or intravenous infusion
1528716|NCT02752009|Procedure|Axillary Lymph Node Sampling Clip|
1528717|NCT02751996|Drug|SB 9200|SB 9200
1528718|NCT02751996|Drug|Placebo|
1528719|NCT02751983|Behavioral|ACT for Life|A novel protocol detailing the application of Acceptance and Commitment Therapy (ACT) to recovery from suicidal crises. Consists of three modules designed to be delivered in three to four 60-minute individual talk therapy sessions. Nearly all of the metaphors and experiential exercises are adaptations of core ACT techniques included in various empirically-supported applications of ACT to other health conditions. Additionally, the adjunctive intervention is designed to augment safety planning (a hierarchical list of strategies to recognize and cope with a suicidal crisis).
1528720|NCT02751983|Other|Treatment as usual|All participants will be able to engage in treatment as usual. Psychiatric inpatient care typically consists of behavioral mental health group and/or individual therapy and pharmacological treatment. Outpatient care is offered upon discharge. This typically consists of both group and individual therapy and medication management.
1528721|NCT02751970|Procedure|Dental restoration|Methacrylate resins will be used to complement the cavity restoration after of adhesive procedure
1528722|NCT02751970|Procedure|3 step ER|Enamel and dentin will be conditioning with 35% phosphoric acid, then applied primer, and then applied adhesive resin.
1528723|NCT02751970|Procedure|2 step ER|Enamel and dentin will be conditioning with 35% of phosphoric acid, then applied primer/adhesive resin.
1528724|NCT02751970|Procedure|2 step SE|Enamel and dentin will be conditioning with acidic primer, then applied primer/adhesive resin.
1528725|NCT02751970|Procedure|1 step SE|Enamel and dentin will be conditioning with acidic primer/adhesive resin.
1528726|NCT02751957|Behavioral|Early Start Denver Model|The Early Start Denver Model is an evidence based, behavioral intervention for young children who have an autism spectrum disorder. It is a behavioral treatment informed by the principles of applied behavior analysis.
1528727|NCT02751944|Dietary Supplement|NEM|Dietary supplement for the support of joint health.
1528728|NCT02751944|Dietary Supplement|Placebo|Placebo
1528949|NCT02750254|Procedure|Stem cell transplant|
1528950|NCT02750254|Drug|Azacitidine|
1528732|NCT02751905|Drug|BIIB074|Administered orally as specified in treatment arm
1528733|NCT02751892|Behavioral|Active lifestyle programme|The intervention is an activity lifestyle programme to increase physical activity behaviour post-intervention and to facilitate behaviour change maintenance at 3 months post-intervention.
1528734|NCT02751866|Dietary Supplement|Berry fruit powder OR nutritional ketosis|Daily supplementation with berry fruit powder OR carbohydrate restriction to achieve nutritional ketosis
1528735|NCT02751866|Dietary Supplement|Placebo powder OR higher carbohydrate|Daily supplementation with placebo powder OR higher carbohydrate intake
1528736|NCT02751853|Device|Conductance catheter|Continuous online measurements of left ventricular pressure and volume using conductance catheters
1528737|NCT02751840|Dietary Supplement|Caffeine|200 mg of caffeine capsule before RMR measurement
1528738|NCT02751840|Dietary Supplement|Placebo|Placebo capsule (starch) before RMR measurement
1528739|NCT02751840|Other|Coffee|9 grams of black coffee in boiling water consumed before RMR measurement
1528740|NCT02751840|Other|Decaffeinated|9 grams of decaffeinated black coffee in boiling water consumed before RMR measurement
1528741|NCT02751827|Other|Blood sample|"One blood sample before treatment initiation (Cycle 1 Day predose) for pharmacogenomics
One blood sample at the end of the firth month of treatment (postdose) for pharmacokinetic"
1528742|NCT02751801|Other|no intervention|
1528743|NCT02751762|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ).|
1528744|NCT02751762|Other|Psychiatric Research Interview for Substance and Mental Disorders, adapted for assessing addiction to opioid analgesics (PRISM-5-Op).|
1528745|NCT02751762|Other|Events in Medical Records|
1528746|NCT02751749|Behavioral|Unified Protocol|
1528747|NCT02751736|Dietary Supplement|CJLP243|Perioperative administration till postoperative weeks 3
1528748|NCT02751736|Dietary Supplement|Placebo|Perioperative administration till postoperative weeks 3
1528749|NCT02751723|Other|validated questionnaires|
1528750|NCT02751710|Other|Whole-body FDG PET-CT alone|FDG PET-CT imaging
1528751|NCT02751671|Procedure|POCUS|The use of Point-of-care ultrasound before urine sample procedure
1528752|NCT02751671|Procedure|Standard|Urine sampling procedure without prior ultrasound
1528753|NCT02751658|Other|mouth swab|Levy to make inside of the mouth with a swab on the day of admission to hospital and the day of release at the patients in the Otorhinolaryngology
1528754|NCT02751645|Procedure|Acute Normovolemic hemodilution|ANH is a technique in which a portion of the patients' own blood is removed before any surgical bleeding occurs. It is stored until the end of the operation, at which point it is returned to the patient.
1528755|NCT02751632|Behavioral|Support and Problem Solving Therapy|Support and Problem Solving Therapy involves providing participants with emotional support and helping them to resolve their problems in day-to-day life.
1528756|NCT02751632|Behavioral|Cognitive Behavioural Case Management|CBCM has a number of different elements including: strategies to help with stress management; therapy that targets thinking and behavioural patterns; practical assistance, as well as yoga and mindfulness.
1528757|NCT02751632|Drug|Fluoxetine|Participants will commence on 1 capsule of fluoxetine 20 mg, to be taken in the morning. The medication can be increased to fluoxetine 40 mg daily if there has been a poor clinical response after the first 6 weeks of treatment.
1528758|NCT02751632|Drug|Placebo|Participants will commence on 1 capsule of the placebo pill, to be taken in the morning. The medication can be increased to 2 placebo capsules if there has been a poor clinical response after the first 6 weeks of treatment.
1528759|NCT02751632|Behavioral|3-monthly monitoring|Study participants will be contacted on a 3-monthly basis by a study clinician who will be assessing the participant's risk.
1528760|NCT02751619|Drug|Lidocaine patch 5%|Lidocaine patch 5% was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
1528761|NCT02751619|Drug|Placebo patch|A patch without lidocaine was applied to cover the planned skin incision for 12 hours during the night and then was removed for the subsequent 12 hours during the day. This process was continued for 3 days before thoracotomy
1528762|NCT02751606|Drug|ferumoxtran-10|ferumoxtran-10 will be administered intravenously one day prior to the MRI scan
1528763|NCT02751606|Device|7 Tesla MRI|Subjects undergo a 7 Tesla MRI scan
1528764|NCT02751606|Device|3 Tesla MRI|Subjects undergo a 3 Tesla MRI scan
1528765|NCT02751593|Drug|Dexamethasone|dexamethasone 40mg/d for 4 days
1528766|NCT02751580|Other|Telemedicine|Attend a virtual visit via the JeffConnect telehealth app
1528767|NCT02751580|Other|Questionnaire Administration|Ancillary studies
1528768|NCT02751567|Other|BAY987516|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
1528769|NCT02751567|Other|Untreated skin|One site is patched without treatment as control
1528773|NCT02751541|Drug|Sunscreen Sport Spray (BAY987519)|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB#Y51-002)
1528775|NCT02751528|Biological|ETBX-021|ETBX-021 is a HER2-targeting vaccine comprising an Ad5 vector and a modified HER2 gene insert.
1528776|NCT02751515|Other|Bain De Soliel - Solid|0.05gm/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
1528777|NCT02751515|Other|Untreated skin|One site is patched without treatment as control
1528778|NCT02751502|Device|m2 Bimanual Arm Trainer (BAT)|Patients in the device group will be asked to train specific movements repeatedly with the device for 45 minutes five days a week for 6 weeks and compliance will be monitored through training logs and remotely
1528779|NCT02751489|Other|Bain De Soliel - Solid|0.05 gm/cm2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.
1528780|NCT02751476|Other|Point of Use (PoU) water treatment flocculent disinfectant.|A household level point of use water treatment of a flocculent disinfectant will be tested.
1528781|NCT02751476|Other|Point of Use (PoU) water treatment chlorine disinfectant|A household level point of use water treatment of a chlorine disinfectant will be tested.
1528782|NCT02751476|Device|Point of Use (PoU) ceramic water filter|A household level point of use water treatment of a ceramic water filter will be tested.
1528783|NCT02751476|Other|Standard Severe Acute Malnutrition Treatment|Standard CMAM treatment.
1528784|NCT02751463|Drug|Sunscreening Sport Spray Rest (BAY987519)|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.(Formulation Number - RB# Y51-002 )
1528785|NCT02751463|Other|Untreated skin|One site is patched without treatment as control
1528786|NCT02751450|Device|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
1528787|NCT02751450|Other|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
1528788|NCT02751437|Dietary Supplement|Arginine|
1528789|NCT02751424|Drug|GSK3342830|A pyrogen free lyophilized formulation, white to yellowish brown powder containing 1000 mg of GSK3342830A (as free base) per vial. The reconstituted solution looks like a clear, colorless to yellow or brownish yellow liquid, free from visible particulate matter will be administered as IV infusion over 1 hour.
1528790|NCT02751424|Drug|Placebo|A clear and colorless solution containing 0.9% sodium chloride. It will administered as IV infusion over 1 hour.
1528791|NCT02751411|Device|micro-enema with Promelaxin|The intervention has a lubricating, protective action on the anus and rectum and a balanced osmotic action which elicits the evacuation reflex.
1528792|NCT02751411|Drug|Macrogol 4000|Stool softener
1528793|NCT02751398|Drug|Dapagliflozin 10mg|
1528794|NCT02751398|Drug|Placebo 10mg|Matching placebo for dapagliflozin 10 mg
1528795|NCT02751385|Drug|Microgynon|
1528796|NCT02751385|Drug|Nintedanib|
1528797|NCT02751372|Drug|BAY 987517|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.
1528798|NCT02751372|Other|Untreated Skin|This site is patched without treatment as irradiated control
1528799|NCT02751359|Drug|Cannabidiol|200, 400, or 800 mg Cannabidiol
1528800|NCT02751359|Drug|Placebo|0 mg Cannabidiol
1528801|NCT02751333|Procedure|FCSEMS with Endostitch (ES)|The fixation of FCSEMS using endostitch (ES) with the OverStitchTM system to prevent migration.
1528802|NCT02751333|Procedure|FCSEMS with No Suturing (NS)|The insertion of FCSEMS with no suturing.
1528803|NCT02751333|Device|Fully Covered Self-Expanding Metal Stents (FCSEMS)|This is the stent that will be used to treat the esophageal pathology in both groups
1528804|NCT02751333|Device|EndoStitch (ES) with the OverStitchTM system|This is the device used to apply the stitches to the stent in participants randomized to stent suturing.
1528811|NCT02751307|Drug|metformin 500 mg|metformin 500 mg QAM for metformin 500 mg/d group; metformin 500 mg 1 BID for metformin 1000 mg/d
1528812|NCT02751307|Drug|clozapine 100 mg|Clozapine dose remained unchanged during metformin intervention period in recruited patients.
1528813|NCT02751294|Drug|Tafenoquine Control|It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine
1528814|NCT02751294|Drug|Tafenoquine dissolution profile X|"It will be supplied as a dark pink, capsule-shaped, film-coated tablet plain on both sides containing 150 mg tafenoquine and will be intermediate aged TQ Product."
1528815|NCT02751294|Drug|Tafenoquine SIL|It will be compounded at site and will be administered as 0.3 mg/mL (100mL to be dosed, equivalent to 30 mg) aqueous Solution of SIL Tafenoquine.
1529106|NCT02748993|Drug|PAC-14028 Cream Vehicle|Topical application
1528816|NCT02751281|Procedure|Pneumatic percutaneous nephrolithotomy|Pneumatic percutaneous nephrolithotomy is type of surgery that we use pneumatic lithotripter to treat kidney stone
1528817|NCT02751281|Procedure|Ultra-sonic percutaneous nephrolithotomy|Ultra-sonic percutaneous nephrolithotomy is type of surgery that we use ultra-sonic lithotripter to treat kidney stone
1528818|NCT02751268|Drug|Normal Saline|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with normal saline
1528819|NCT02751268|Drug|Ropivacaine|Bilateral infraorbital and infratrochlear nerve block before general anesthesia with 0.5% ropivacaine
1528820|NCT02751255|Drug|all-trans retinoic acid (ATRA)|Phase 1 and 2: daratumumab 16 mg/kg, first 8 infusions are given weekly, then 8 infusions every 3 weeks, then every 4 weeks until progression Phase 1: ATRA 15, 30, or 45 mg/m2/day for 3 days. Phase 2: ATRA will be administered twice daily as an oral formulation at the MTD dose, or if no MTD is reached, at the dose of 45 mg/m2/day for 3 days. The first administration of ATRA will be given in the morning, two days before the scheduled daratumumab infusion. The last administration of ATRA will be given in the evening of the day that daratumumab was administered (days -2, -1, and 0; day 0 is the day of daratumumab infusion).
1528821|NCT02751229|Behavioral|Honest Open Proud (HOP)|"five lessons in three modules, two for each two-hour session
Considering pros and cons of disclosing:
hurtful and helpful attitudes about mental illness
identify beliefs participants hold about themselves
explore five-step process to challenge their personally hurtful beliefs
weigh pros and cons of coming out in order to facilitate a decision on whether to disclose
Different ways to disclose:
different levels of (non-) disclosure and how to weigh the cons and pros
disclosure via social media versus disclosing face to face
how to find people that are better to disclose to than others and how to 'test them out'
participants will discuss how others might respond to their disclosure and how that will affect them
Telling your story:
how to tell one's story in a personally meaningful way, how to identify peers who might help with the coming out process, to review how telling one's story felt"
1528823|NCT02751203|Behavioral|Make Safe Happen App|The Make Safe Happen app is a mobile app (available for free download android and iOS) developed by the safety experts in the Center for Injury Research and Policy. Parents and caregivers can use the app to learn how to make their homes safer with room-to-room safety checklists and links to recommended products. App users can also create to-do lists, set reminders and track their progress.
1528824|NCT02751190|Procedure|Totally ExtraPeritoneal (TEP) repair|
1528825|NCT02751190|Procedure|TransAbdominal PrePeritoneal (TAPP) repair|
1528826|NCT02751190|Procedure|Open anterior mesh repair|
1528827|NCT02751190|Procedure|Open Anterior Non Mesh|
1528828|NCT02751190|Procedure|Combined anterior and posterior repair|
1528829|NCT02751190|Procedure|Open preperitoneal mesh repair|
1528831|NCT02751164|Other|Day/time of admission to the critical care unit|
1528832|NCT02751151|Other|have Levulan Kerastick (aminolevulinic acid) solution|Levulan Kerastick (aminolevulinic acid) solution applied to the face and/or scalp (if both are needed, treated separately on back to back days); with an incubation period of 2.5 hours. Blue light photodynamic therapy utilizing the DUSA BLU-U device, illumination: 1000 seconds (16 min, 40 secs), will be administered
1528834|NCT02751125|Drug|BCP with autologous mesenchymal stem cells (MSC).|Augmentation of narrow alveolar ridge with BCP and MSC
1528836|NCT02751099|Other|transplanted patients|bone biopsy, echocardiogram, blood samples
1528837|NCT02751086|Procedure|Robotic Gastrectomy|Minimally invasive surgical approach, related to the availability of a robotic surgical system (eg Da Vinci surgical system), that allows a surgeon to perform surgery through a console and dedicated devices.
1528838|NCT02751086|Procedure|Laparoscopic Gastrectomy|Minimally invasive surgical approach performed through traditional laparoscopy.
1528839|NCT02751060|Other|No intervention|
1528840|NCT02751047|Other|manual ventilation|Facemask ventilation is performed by manual bagging with reservoir bag.
1528841|NCT02751047|Other|Pressure controlled mechanical ventilation|Facemask ventilation is performed with mechanical ventilator by pressure controlled mode.
1528842|NCT02751034|Device|Neuramis® Deep Lidocaine|HA filler
1528843|NCT02751034|Device|Restylane® PERLANE-L|HA filler
1528844|NCT02751021|Other|pacemaker diagnostic algorithm|evaluation of the respiratory disturbance index by measurement of transthoracic impedance variation, to detect sleep apnea
1528845|NCT02751021|Other|Attended cardiorespiratory sleep study|sleep study with portable monitor resulting in the apnea hypopnea index, to confirm sleep apnea diagnosis
1528846|NCT02750995|Biological|NPMW-peptide vaccine|Peptide vaccine against long peptide sequences from NY-ESO-1, PRAME, MAGE-A3, WT-1.
1528847|NCT02750995|Drug|Azacitidine|Standard therapy. All participants receive azacitidine 6 months prior to inclusion, which continues during the study period.
1528848|NCT02750982|Other|Laughter Therapy|Laughter Therapy (LT) involves simple exercises using playfulness, eye contact and chanting in forms of laughter. LT will be taught by a certified LT instructor in a group session. There will be 8 sessions per group with each session attended by 8-12 participants and lasting 60 minutes
1528849|NCT02750969|Device|Lidoderm patch (Lidocaine 5% patch)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.
tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
1528850|NCT02750969|Other|Tegaderm patch. (neutral patch, containing no drug)|"The investigator will attach the patches on the patient's back for 12 consecutive hours.
tinnitus questionnaires will be fulfilled by the patient before and after the patches usage . blood test for serum lidocaine level will be measured after the usage of this patch"
1528894|NCT02750592|Drug|secukinumab 150mg|Baseline, 1, 2, 3, 4 week. After 4 week, administered every 4 weeks.
1528895|NCT02750579|Procedure|Percutaneous coronary intervention for revascularization|Percutaneous coronary intervention for revascularization with anticoagulant and antiplatelet therapy (routine care)
1528851|NCT02750969|Procedure|blood test- serum lidocain levels|"each participant will undergo blood test. the participant's group that start the trial with the lidoderm patch and later will use the tegaderm patch will have 2 blood tests for werum lidocain level test. the group taht start the trial with the tegaderm patch and later the lidoderm patch will have only one blood test measuring lidocaine serum level.
the tubes containing the serum will be shipped abroad via an international medical cargo company for lidocaine levels tests."
1528852|NCT02750969|Other|Hearing tests|each participant that have not done hearing test in the last 1 year previous to the trial will have one in the first day of the trial.
1528853|NCT02750956|Procedure|Non-surgical periodontal treatment|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
1528856|NCT02750930|Drug|Albiglutide|Albiglutide liquid drug product is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid drug product (50 mg). Subjects will receive albiglutide 50 mg through subcutaneous injection in the abdomen, thigh or upper arm region via auto-injector. Albiglutide is a glucagon-like peptide-1 agonist (GLP-1 agonist).
1528857|NCT02750930|Device|Auto-injector|The auto-injector delivers the albiglutide liquid drug product in an injection volume of 1.0 mL for the 50 mg dose.
1528860|NCT02750904|Behavioral|Experimental plus Nicotine Replacement Therapy|"Behavioral: Experimental plus Nicotine Replacement Therapy will be built to specifically address challenges of smoking cessation for individuals with bipolar disorder.
Includes four in person and four phone visits.
Therapy information is withheld to protect the integrity of the study."
1528861|NCT02750904|Behavioral|Control plus Nicotine Replacement Therapy|Includes four in-person and four phone visits
1528862|NCT02750891|Drug|DSP-7888|Phase1 portion: 1.75 or 3.5 mg/body, Id every 1-4 weeks Phase 2 portion: recommended phase 2 dose, Id every 1-4 weeks
1528863|NCT02750878|Other|Informational Handout|
1528864|NCT02750865|Behavioral|Embodied Conversational Agent (ECA)|The ECA is a computer generated character who will interact with the subject on a daily basis via a touch-screen tablet. The system is designed to provide the following functions: (1) medication counseling; (2) physical activity promotion; (3) symptom management and continual screening for adverse events; and (4) alleviation of stress and anxiety. The investigators will augment the system to include: (5) spiritual needs assessment; and (6) advanced care planning.
1528865|NCT02750852|Procedure|Total hip arthroplasty, blood loss analysis|Data analysis about blood loss in total hip replacement
1528866|NCT02750839|Procedure|proximal humerus fracture fixation|Mini-invasive proximal humerus fixation with plate, patient in beach chair position, general anesthesia, a small incision lateral to shoulder is made to insert the plate under scope control
1528867|NCT02750826|Other|Health Education Program|
1528868|NCT02750826|Other|Weight Loss Intervention|
1528869|NCT02750813|Device|Delefilcon A contact lenses|
1528870|NCT02750813|Device|Senofilcon A contact lenses|
1528871|NCT02750787|Other|Nutritional Study Product|Two 220 ml servings per day
1528872|NCT02750774|Behavioral|Low-glycemic index group|"The dietary intervention consisted of the prescription of a Mediterranean style, low-glycaemic, low-fat, exchange diet (3 main meals and 3 snacks) with a total intake of 1500 kcal/day. In light of the PA, the dietitian adds 200 kcal/day for obese, 300 kcal/day for overweight women. The diet had a target macronutrient composition of 55% carbohydrates (80% complex carbohydrates with a low glycaemic index and 20% simple carbohydrates), 20% protein (50% animal and 50% vegetable) and 25% fat (12% mono-unsaturated, 7% polyunsaturated and 6% saturated) with moderately low saturated fat levels. The daily intake of carbohydrates was at least 225 g/day. The exercise intervention was focused on developing a more active lifestyle. The PA prescription is consistent with recommendations by the ACOG and ACSM for pregnant women. The talk test (being able to maintain a conversation during activity) was suggested to monitor the exercise intensity."
1528873|NCT02750774|Other|Standard Care Group|Women randomized to the Standard Care Group received general information about healthy lifestyle during pregnancy, according to the Guidelines
1528876|NCT02750748|Drug|Naltrexone|
1528877|NCT02750748|Other|Intravail|
1528878|NCT02750722|Device|Flutter®|Acute exercise with Flutter® breathing therapy.
1528879|NCT02750722|Device|No Flutter®|Acute exercise without Flutter® breathing therapy.
1528880|NCT02750709|Drug|Nitisinone|A single oral dose of Nitisinone 10 mg tablet will be administered in fasted state.
1528881|NCT02750709|Drug|Nitisinone 10 mg Tablet High Compritol|A single oral dose of Nitisinone 10 mg High Compritol tablet will be administered in fasted state.
1528882|NCT02750709|Drug|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered in fasted state.
1528883|NCT02750696|Drug|Fixed-dose oral tablet of codeine/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
1528884|NCT02750696|Drug|Fixed-dose oral tablet of tramadol/ acetaminophen every 4 hours for 3 days|Patients in this group received opioid/ non-opioid analgesic combination.
1528885|NCT02750670|Drug|Obinutuzumab|Type II anti-CD20 monoclonal antibody
1528886|NCT02750670|Drug|Gemcitabine|Antineoplastic agent
1528887|NCT02750670|Drug|Dexamethasone|Corticosteroid
1528888|NCT02750670|Drug|Cisplatin|Antineoplastic Agent
1528889|NCT02750657|Genetic|Molecular Profiling|Whole Genome Sequencing
1528890|NCT02750631|Other|Triple Therapy|The intervention consists of three interventions: missing a night of sleep, early morning bright lights and sleep phase advance
1528891|NCT02750618|Drug|KRN23|
1528945|NCT02750254|Drug|Cyclophosphamide|
1528896|NCT02750566|Procedure|Osteopathic Manipulative Treatment|Manual treatment of musculoskeletal restrictions that may be prevent proper healing post-concussion.
1528897|NCT02750566|Other|Counseling|Patients will be counseled on concussion awareness, symptoms, and treatment for 30 minutes by a physician.
1528898|NCT02750553|Drug|SHR0534|
1528899|NCT02750553|Drug|Placebo|
1528900|NCT02750540|Drug|Tenofovir enema|
1528901|NCT02750540|Other|Saline enema|
1528906|NCT02750501|Device|Relizorb|Novel enteral feeding in-line digestive enzyme cartridge
1528907|NCT02750501|Other|Impact Peptide 1.5|Impact Peptide 1.5 at a volume of administration from 500 mL to 1,000 mL per enteral feeding
1528908|NCT02750488|Drug|BAY987517|50 μl/ cm2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures.
1528909|NCT02750488|Other|Untreated skin|One site is patched without treatment as control
1528910|NCT02750475|Drug|Sunscreen Sport Lotion (BAY987516)|50 μl/cm*2 or 0.05 gm/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each). After the test articles have dried for 5 to 15 min, the sites are covered by the appropriate patch.24 hours later, the set of patches covering the product are removed. Three (3) μl/ cm2 or 0.003 gm/cm*2 of the test product is reapplied to the test site, air dried for 5 to 15 minutes for volatilization and then the test site is exposed to UVA radiation.(Formulation number - RB# Y65-110)
1528911|NCT02750475|Other|Untreated Skin|This site is patched without treatment as irradiated control
1528912|NCT02750462|Other|Immediate coronary angiography|Immediate coronary angiography in survivors of out-of-hospital cardiac arrest without ST-segment elevation
1528913|NCT02750462|Other|Delayed/selective coronary angiography|Initial intensive care evaluation to further stratify the etiology of out-of-hospital cardiac arrest with delayed/selective coronary angiography if indicated
1528914|NCT02750449|Drug|Sun screening Sport Lotion, (BAY987516)|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. 24 hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3 μl/ cm*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. 48 hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation Number - RB# Y65-110)
1528915|NCT02750449|Other|Untreated skin|This site is patched without treatment as control
1528916|NCT02750436|Device|Ultrasound guided|This group will be treated using an ultrasound imaging device
1528917|NCT02750436|Device|Fluoroscopy guided|This group will be treated using a fluoroscopy imaging device
1528918|NCT02750423|Procedure|DHCA+RCP|During deep hypothermic circulatory arrest and retrograde cerebral perfusion (DHCA+RCP) the participant is placed on cardiopulmonary bypass (heart-lung machine) and their body temperature is lowered to a range of 14-18 °C. Once the goal temperature has been achieved, the circulation is stopped and aortic arch replacement is performed in a bloodless surgical field. Blood will be pushed to the brain through arterial vessels, much like the natural blood flow pattern. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
1528919|NCT02750423|Procedure|MHCA + SACP|During moderate hypothermic circulatory arrest and unilateral selective antegrade cerebral perfusion (MHCA + SACP) the participant is placed on cardiopulmonary bypass (heart-lung machine0 and the native blood flow to the brain is temporarily suspended. The body is cooled to temperatures of ≤28°C and blood is administered to the brain via an artery in the neck during the period of arch reconstruction. Once the aortic arch repair is complete, cardiopulmonary bypass is reinstituted, the participant is rewarmed, and separated from cardiopulmonary bypass.
1528920|NCT02750410|Drug|Dulaglutide|Administered subcutaneously (SC)
1528921|NCT02750410|Drug|Placebo|Administered SC
1528922|NCT02750384|Drug|DSM265 50% SDD granules|Single oral dose 400 mg
1528923|NCT02750384|Drug|DSM265 25% SDD powder for suspension|Single oral dose 400 mg
1528924|NCT02750371|Other|Evaluation of autobiographical memory|Patients will answer several questionnaires one and two years after irradiation treatment end.
1528927|NCT02750345|Drug|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
1528928|NCT02750345|Drug|Nitisinone Baked Tablet|A single oral dose of Nitisinone 10 mg Tablet (6 months @ 40°C/75% RH) will be administered.
1528929|NCT02750345|Drug|Orfadin|A single oral dose of Orfadin 10 mg hard capsule will be administered.
1528930|NCT02750332|Drug|Nitisinone|A single oral dose of Nitisinone 10 mg Tablet will be administered.
1528939|NCT02750280|Device|MatriStem® [Urinary Bladder Matrix (UBM)]|Porcine derived urinary bladder extracellular matrix
1528940|NCT02750280|Device|Mepilex® [Silicone foam dressing]|primary wound dressing
1528941|NCT02750267|Device|Diabetes Assistant (DiAs) with Closed-Loop|All subjects will use DiAs Medical Platform, a study insulin pump and continuous glucose monitor (CGM) in closed-loop mode during a Research House/Hotel admission that will last up to 72 hours.
1528942|NCT02750254|Drug|Fludarabine|
1528943|NCT02750254|Radiation|Fractionated total body irradiation|
1528944|NCT02750254|Drug|Busulfan|
1528951|NCT02750241|Behavioral|Active video game-based intervention|"Attend 12 weekly group session at the UTMB Breast Health Clinic to play the active video games using Wii Fit U or Xbox 360.
Participate in self-paced home sessions
Monitor daily, weekly, and monthly steps using Wii Fit Meter
Feedback on physical activity and physical function"
1528952|NCT02750241|Behavioral|Pedometer|"Attend 3 monthly UTMB Breast Cancer Support Group Sessions
Monitor daily, weekly, and monthly steps using a pedometer (Digi-walker CW-700/701)
Feedback on physical activity and physical function"
1528953|NCT02750215|Drug|Capmatinib (INC280)|treatment with Capmatinib (INC280)
1528954|NCT02750202|Biological|Quadrivalent HPV vaccine|Quadrivalent HPV vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
1528955|NCT02750202|Biological|Hepatitis B vaccine|Hepatitis B vaccine doses administered intramuscular as 3 separate 0.5 ml doses at month 0, month 2 and month 6.
1528956|NCT02750189|Other|Direct cost|Money spent to treat COPD in medical institute based on HIRA
1528957|NCT02750189|Other|Indirect cost|extra-expanses excluding hospital fees
1528958|NCT02750176|Other|Closed chain exercises|Closed-chain strengthening will be performed with the shoulder moving over a fixed hand. Resistance will be provided by body weight against gravity. To off-load and progress the amount of body-weight resistance, elastic bands will be used to support body weight using a exercise frame. Patients will perform 6 exercises.
1528959|NCT02750163|Drug|paracetamol|Paracetamol will be given to febrile septic patients
1528960|NCT02750150|Drug|Freezed-dried plasma|early transfusion of 4 units of freezed dried plasma
1528961|NCT02750150|Drug|Fresh-frozen plasma|
1528962|NCT02750137|Drug|Tetracaine|Application of Ametop prior to intravenous cannulation
1528963|NCT02750124|Device|Cobas PCR Female swab sample Packet|The cobas® PCR Female Swab Sample Kit is used to collect and transport vaginal swab specimens self-collected.
1528964|NCT02750124|Other|Routine practice|The standard, annual renewed invitation to cervical screening.
1528965|NCT02750098|Other|Glucose measurement|"Elective cataract surgery
Blood glucose measurement - glucometer
Aqueous humor glucose measurement - at beginning of cataract surgery - glucometer
Perioperative Hemoglobin A1c level - blood laboratory test"
1528966|NCT02750072|Procedure|Infrapatellar Approach|Infrapatellar approach using the surgeon's incision of choice (i.e. patellar tendon split, tendon retraction medial, tendon retraction lateral)
1528967|NCT02750072|Procedure|Suprapatellar Approach|Semi-extended suprapatellar approach using quadriceps split combined with purpose designed percutaneous instrumentation
1528968|NCT02750059|Drug|TDF/3TC/EFV + Telmisartan|The subject will receive 40mg telmisartan daily for 4 weeks followed by 80mg telmisartan daily for 44 weeks in addition to ART. Subjects unable to tolerate 80mg of telmisartan will be able to de-escalate to 40mg daily
1528969|NCT02750059|Drug|TDF/3TC/EFV only|Starting from the first visit, all participants will be placed on an ART regimen to treat HIV. This is the standard route of care for HIV patients.
1528970|NCT02750046|Procedure|total hip arthroplasty or proximal femoral nails|Bone samples from Hip fracture were collected when total hip arthroplasty or proximal femoral nails was performed.
1528971|NCT02750033|Device|Multimodal Spectroscopy (MMS)|surgical margin assessment with multimodal optical spectroscopy (MMS) device
1528972|NCT02750020|Other|Questionnaire|Current study is a retrospective telephone survey based on questionnaires. It aims to investigate the level of public support on current and future tobacco control measures and taxation policies and to address the timely impacts of smoke-free policies, substantiate public support on further tobacco control measures and assist COSH in shaping policy direction for government. The telephone survey will be conducted by a telephone survey agent under the monitor of applicants.
1528973|NCT02750007|Drug|HS-20004|
1528974|NCT02749994|Drug|Rosuvastatin|
1528975|NCT02749994|Drug|Ezetimibe|
1528976|NCT02749981|Procedure|blood and tissue sampling|
1528979|NCT02749955|Behavioral|PS-PrEP Intervention Group|This group will involve working with a PS-PrEP social worker to learn about PrEP. The PS-PrEP social worker will help subjects develop a care plan based on the subject's decision about whether or not to use PrEP. This may include referrals for PrEP, other services, and/or HIV testing. Personal contact will continue by way of phone calls, and messages in between visits.
1528980|NCT02749955|Behavioral|PrEPLine Control Group|This group follows routine department of public health care as a Linkage to Care Specialist from the PrEPLine provides subjects with PrEP education and the ability to schedule an initial PrEP appointment. In addition to this care, subjects will be referred for additional testing for STIs/HIV and subjects will be given information about programs available to prevent HIV infection, which include PrEP.
1528981|NCT02749942|Device|AutoRIC: Remote Ischemic Conditioning|"4 cycles of 5 minute forearm ischemia/reperfusion (200 mmHG) using the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
1528982|NCT02749942|Device|AutoRIC: Sham device treatment|"4 cycles of 5 minute forearm sham treatment (no ischemia/reperfusion, 0 mmHG pressure) with the reusable fully automated RIC device AutoRIC from CellAegis Devices, Canada"
1528983|NCT02749929|Other|Low level laser therapy|The laser is an infrared (invisible) 60 mW 904 nm Irradia Midlaser
1528984|NCT02749929|Other|Placebo Low Level Laser Therapy|The placebo laser is an identical device to the active laser, made by Irradia Midlaser
1528985|NCT02749916|Other|Methods of carotid wall imaging|
1528986|NCT02749903|Drug|enzalutamide|oral
1528990|NCT02749877|Behavioral|Working Memory Training|(Training Details already described above)
1528991|NCT02749877|Behavioral|Physical Training|(Training Details already described above)
1529226|NCT02748135|Drug|TB-403 50mg/kg|Up to 12 bi-weekly intravenous doses of TB-403 50mg/kg
1528992|NCT02749851|Device|MRI|Recently-developed placenta-specific magnetic resonance imaging (MRI) tools will be used to quantify maternal perfusion and oxygen transfer throughout pregnancy in 3 groups of human subjects: 1) non-smokers, 2) smokers, 3) individuals at high risk for adverse outcome. The objective of this work is to develop a new non-invasive clinical tool for early identification of placental dysfunction.
1528993|NCT02749825|Drug|Trelstar|As labeled
1528994|NCT02749825|Drug|Lupron|As labeled
1528995|NCT02749825|Drug|Zoladex|As labeled
1528996|NCT02749812|Device|Constant Continuous Positive Airway Pressure|
1528997|NCT02749812|Device|Automatic continuous Positive Airway Pressure|
1528998|NCT02749799|Drug|DFD-01|
1528999|NCT02749786|Genetic|Skin Biopsy|Skin biopsies will be performed via the Keys punch technique from normal facial skin.
1529000|NCT02749773|Device|Oocyte Aspiration needle|Oocyte aspiration in women go through an IVF procedure,.
1529001|NCT02749760|Other|Strengthening program|Strengthening programs may be established to target the stabilizers of the elbows
1529002|NCT02749760|Other|Exercise program|Exercise program may be established to target the stabilizers of the elbows.
1529003|NCT02749747|Drug|Sulpiride use|50mg sulpiride once a day use for 60 days
1529004|NCT02749747|Drug|Placebo|50mg placebo once a day use for 60 days
1529005|NCT02749734|Procedure|Subretinal transplantation|Transplant hESC-RPE into subretinal space of patients with macular degeneration
1529006|NCT02749721|Drug|vortioxetine|
1529007|NCT02749708|Drug|IRX5183|"IRX5183 will be administered orally daily on days 1-28 of each cycle for 2 cycles of induction. In the phase I part of the study, there will be 3 dose levels (dose level 1 [DL1] with 50 mg, DL2 with 75 mg, and DL3 with 100 mg), with 1 additional dose level to be only used if excessive toxicity noted at the DL1. There will be no intra-patient dose escalation.
In the phase II part of the study, the investigators will use the optimal dose identified in phase I and will aim to recruit a total of 27 patients per a Simon's 2 stage design. After induction, all patients who do not experience significant toxicity or disease progression will continue on a consolidation/maintenance phase of the study in which 4 additional 28-day cycles of IRX5183 will be administered. This phase will use the same dose used in the induction phase for each individual patient."
1529008|NCT02749695|Drug|Melsmon|Placental extract Melsmon® (Japan): 2 ml (100 mg), subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
1529009|NCT02749695|Other|Placebo|2 ml subcutaneously, every 2nd day for 2 weeks, then twice a week (30 injections for 4 months in total).
1529010|NCT02749669|Other|Qualitative research|Semi-structured Interviews
1529011|NCT02749656|Drug|0.25% Desoximetasone cream (Topoxy®)|apply on the scalp psoriasis lesion twice a day
1529012|NCT02749656|Drug|0.25% Desoximetasone cream (Topicorte®)|apply on the scalp psoriasis lesion twice a day
1529013|NCT02749656|Drug|Placebo|apply on the scalp psoriasis lesion twice a day
1529014|NCT02749643|Device|Vibrotactile feedback system|
1529017|NCT02749617|Drug|apixaban|2.5 mg PO BID
1529018|NCT02749604|Procedure|Non-ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate
1529019|NCT02749604|Procedure|Ejaculatory sparring PVP|Greenlight laser photoslective vaporization of the prostate with preservation of the ejaculatory hood
1529020|NCT02749591|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity upper extremity for stroke patients.Doses and muscles selected for BoNT-A injection are individualized on the basis of a number of factors, including the spasticity patterns, severity of spasticity, and treatment goals
1529021|NCT02749591|Other|Robot-assisted therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the RT group will receive a 45 minutes of robotic training and 30 minutes of training in functional training.
1529022|NCT02749591|Other|Mirror therapy|After injecting Botulinum toxin type A on the spasticity upper extremity, the MT group will receive a 45-minute MT per session followed by 30 minutes of task-oriented functional training.
1529023|NCT02749591|Other|Control intervention|After injecting Botulinum toxin type A on the spasticity upper extremity, the CI group will receive 75-minute rehabilitation program, focusing on upper extremity training and including neurodevelopmental techniques, trunk-arm control, weight bearing by the affected arm, fine motor tasks practice, functional task practice, and practice on compensatory strategies for daily activities.
1529024|NCT02749578|Drug|Atorvastatin|
1529025|NCT02749578|Drug|MGL-3196|
1529026|NCT02749565|Device|continuous positive airway pressure (CPAP)|The choice of CPAP treatment in asthmatic patients with OSA is depend on the decision of clinician and patient himself/herself.
1529027|NCT02749552|Behavioral|Acceptance and Commitment Therapy|weight-related interventions using values, acceptance, and mindfulness based on Acceptance and Commitment Therapy
1529028|NCT02749539|Device|Kinesio tape|Standard 2 -inches ( 5-m) Kinesio TexR tape was used for application in the experimental group
1529029|NCT02749539|Procedure|physiotherapy program|active-assistive range of motion exercises (AAROME), active stretching exercises and strengthening exercises for the shoulder joint. Likewise, patients also received postural correction exercises
1529030|NCT02749526|Drug|"Endostar"|30mg civ24h d0-6.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
1529031|NCT02749526|Drug|Liposo|135mg/m2 D1.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
1529032|NCT02749526|Drug|cisplatin|25mg/m2 D1-3.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
1529033|NCT02749526|Drug|Gimeracil and Oteracil Potassium （Tegafur）|40mg bid，D1-14.A course of 3 weeks, after two course of chemotherapy the CT/MR/ultrasonic gastroscopy.
1529034|NCT02749513|Drug|Itraconazole|
1529035|NCT02749500|Other|Conventional Occupational Therapy (OT)|Standard of care occupational therapy for stroke recovery
1529036|NCT02749500|Device|m2 BAT|Conventional OT plus 1 hour additional bimanual-to-unimanual device-assisted therapy.
1529107|NCT02748967|Drug|ExPEC4V|Participant will receive single dose 0.5 ml of ExPEC4V as intramuscular injection on Day 1.
1529037|NCT02749487|Other|Neutrophil Lymphocyte Ratio|Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.
1529038|NCT02749461|Procedure|heel stick|Consecutive routine blood sampling heel sticks
1529039|NCT02749448|Other|mesenchymal stem cell|There are complex sets of non-hematopoietic cells in bone marrow called mesenchymal progenitor cells (MPCs). MSCs are well-known as multipotent cells that have the ability to self-renew and differentiate into a great variety of cells. MSCs can be isolated from bone marrow, umbilical cord, peripheral blood and adipose tissue, and cultured in specific media. MSC colony formation, which is known as marrow-like stromal cells and MPCs, is similar to fibroblast colony forming unit (CFU-F) in in vitro condition. According to the International Society for Cellular Therapy (ISCT), MSCs can be easily detected or identified from other cells using flow cytometric analysis to detect specific surface markers
1529042|NCT02749409|Drug|Parecoxib|
1529043|NCT02749409|Drug|Morphine|
1529051|NCT02749383|Drug|PAC-14028 cream 0.3%|Topical application
1529052|NCT02749383|Drug|PAC-14028 cream 1.0%|Topical application
1529053|NCT02749383|Drug|PAC-14028 cream vehicle|Topical application
1529054|NCT02749370|Drug|Etanercept|Etanercept 50 mg subcutaneously twice weekly for 12 weeks followed by 50 mg once weekly for additional 12 weeks.
1529055|NCT02749357|Device|30 minutes Lokomat|"30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 30 minutes.
The initial training speed will be the comfortable one for each patient, as assessed by Swinnen (20). The training progression will consist in a 10% weekly increase in speed, and a 5% weekly reduction of partial weight support."
1529056|NCT02749357|Device|60 minutes Lokomat|30 training sessions in robotic orthosis with duration of 30 or 60 minutes during 6 weeks, duration of 60 minutes.
1529057|NCT02749344|Other|FET after endometrial preparation|Patients included in the protocol will begin progesterone supplementation 48 hours before scheduled embryo transfer once it has been established that the endometrium is at least 7 mm and there is a leading follicle.
1529058|NCT02749331|Drug|AdVince|Virus solution for infusion in intrahepatic artery
1529059|NCT02749318|Genetic|IL-1 genetic test for risk of severe periodontitis|DNA obtained by cheek swab analyzed for four variations (SNPs) in the IL-1beta gene to determine whether patient is at elevated risk for more severe periodontal disease.
1529060|NCT02749305|Other|Collection of patient-reported outcome measures|Pre- and posto-perative metabolic and bariatric surgery patients will be asked to electronically complete a set of PROMs up to 21 days before surgery and annually on their surgical anniversary they will be asked to complete a postoperative PROM.
1529061|NCT02749292|Drug|Rituximab|re-dosing dependent on interventional arm parameter.
1529062|NCT02749266|Other|Chiropractic adjustment|Participant will receive a chiropractic adjustment utilizing a handheld chiropractic instrument called an Activator.
1529063|NCT02749266|Other|Sham chiropractic adjustment|Participants will receive a simulated chiropractic adjustment with a handheld adjusting instrument called an Activator.
1529064|NCT02749253|Other|Sudarshan Kriya Yoga Tauma Relief Program (SKY).|Sudarshan Kriya Yoga Trauma Relief Program (SKY) participants will undergo a 12-week training course in SKY conducted by certified instructors from the Art of Living Foundation
1529065|NCT02749240|Other|Youth Empowerment Seminar, YES!|An 8-week innovative bio-psycho-social program.
1529066|NCT02749227|Drug|Pasireotide LAR|"Pasireotide LAR (SIGNIFOR® LAR) is a somatostatin analog indicated for the treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. It is a long acting release injectable suspension for intramuscular use.
The starting dose is Pasireotide LAR 40 mg/month IM, this will be increased to 60 mg/month at 6 months if a fall in POMC levels and/or tumor shrinkage are not attained."
1529069|NCT02749201|Device|Gastrisail|Light Intensity and gastric wall thickness assessment
1529108|NCT02748967|Drug|Placebo|Participant will receive single dose of Placebo on Day 1.
1529070|NCT02749188|Other|Bladder stimulation|Bladder stimulation as a noninvasive technique of urine collection. The renal and bladder stimulation will be performed in less than 3 minutes, with a maximum of two attempts spaced about 20 minutes
1529071|NCT02749175|Device|Cricoid force sensor monitor system|Comprise of a sensor and a monitor system
1529072|NCT02749175|Device|Sham Cricoid force sensor monitor system|Comprise of a sensor and a sham monitor system
1529073|NCT02749175|Device|Current standard|No device
1529074|NCT02749162|Drug|Dexamethasone phosphate|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
1529075|NCT02749162|Drug|Paracetamol|After the block regression, at the first analgetic request the patients received the analgesia protocol
1529076|NCT02749162|Drug|Morphine|After the block regression, at the first analgetic request the patients received the analgesia protocol
1529077|NCT02749162|Drug|Lidocaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
1529078|NCT02749162|Drug|Ropivacaine|At the end of surgery the patients received single shot VIB block with the mixture according to the group allocation
1529079|NCT02749136|Drug|Preoperative modified FOLFIRINOX and postoperative gemcitabine|"Preoperative mFOLFIRINOX, every 2 weeks, 8 cycles
Oxaliplatin IV 85 mg/m2 Day (D) 1
Irinotecan IV 180 mg/m2 D1
5-FU continuous IV infusion 2,400 mg/m2 over 46 hours D1-2
Leucovorin IV 400 mg/m2 D1
Postoperative gemcitabine, every 4 weeks, 3-6 cycles - Gemcitabine 1,000 mg/ m2 D1, 8, and 15"
1529080|NCT02749123|Drug|lidocaine 5% patch|10cmx 14 cm transdermal patch sealed in its own pouch
1529081|NCT02749123|Drug|lidocaine 3.6%, menthol 1.25%|10cmx 14 cm transdermal patch sealed in its own pouch
1529082|NCT02749123|Drug|Placebo|patch with no active manufactured to have the same look and feel as Lidoderm 10cmx 14 cm transdermal patch sealed in its own pouch
1529083|NCT02749110|Device|Vaginal self-sampling brush|Self-collection by unscreened women aged from 30 to 65 of a vaginal sample with the device. After collection, the whole device is mailed in a normalized for biological samples package to the virology lab of the University Hospital of Lille where a HPV test is conducted using a Cobas 4800 technique.
1529084|NCT02749097|Drug|SHR0534|
1529085|NCT02749097|Drug|Placebo|
1529086|NCT02749084|Biological|T reg DLI|"Purified Treg cells will be obtained from the original HSC donor (T reg DLI).
Tregs preparation will start with unstimulated donor leukapheresis from the original stem cell donor.
The apheresis product will be provided to the Cell Factory Calori,Milano, where T reg purification will take place.
T reg cells will be PURIFIED utilizing the CliniMACS Plus Systems for depletion of CD8 and CD19 positive cells and enrichment for CD25high cells.
Release Criteria of Treg cell preparation will be defined.
The product will be infused into the recipient through a venous catheter."
1529087|NCT02749071|Procedure|Laparoscopic implantation surgery|Laparoscopic surgery to implant the pulse generator and bipolar lead.
1529088|NCT02749071|Device|EndoStim stimulation for first six months of study|Lower esophageal stimulation
1529089|NCT02749071|Device|EndoStim stimulation from Month 6 thru end of study|Lower esophageal stimulation
1529090|NCT02749071|Device|Sham EndoStim stimulation for first six months of study|"EndoStim device remains off (no stimulation delivered)"
1529091|NCT02749058|Procedure|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
1529092|NCT02749058|Procedure|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
1529093|NCT02749045|Radiation|SPECT imaging|myocardial perfusion imaging
1529094|NCT02749032|Other|Mixed meal test|Mixed meal test were performed in the morning after an overnight fast. The standardized mixed meal was composed of 2 eggs (100 g), 1 slice (50 g) of whole grain rye bread, 1 slice (50 g) of rye flour bread, 10 g of fat-reduced margarine, 20 g of boiled ham, and 25 g of diet jam, amounting to 450 kcal, 50 % carbohydrate, 20 % protein, and 30 % fat (based on calorie count). Patients were allowed to drink tea (black or fruit-based) or de-caffeinated coffee ad libitum.
1529095|NCT02749032|Drug|Vildagliptin|Vildagliptin (50 mg per tablet) was administered orally twice daily (15 minutes prior to breakfast or test meal, on the last day of treatment period) and without a defined temporal relation to dinner in the evening, irrespective of the stratum defined by the background diabetes treatment.
1529096|NCT02749032|Drug|Sitagliptin|The dosage of sitagliptin depended on the stratum defined by the background diabetes medication. In patients treated with diet and exercise (no other glucose-.lowering medication), sitagliptin was given as one 100 mg in the morning (15 minutes prior to breakfast or the test meal, on the last day of the treatment period), and a corresponding placebo tablet was administered in the evening (no temporal relation to dinner required).
1529097|NCT02749032|Drug|Placebo|Placebo was administered orally twice daily: 15 minutes prior to breakfast or the test meal on the last day of treatment period) and one dose in the evening (no temporal relation to dinner required).
1529098|NCT02749032|Drug|Metformin|For patients continuing with pre-existing metformin treatment, 1000 mg film coated tablets from commercial sources. In half of the patients (stratum: metformin as background medication), metformin was administered orally twice daily at 1000 mg of active compound during of after breakfast and dinner.
1529099|NCT02749032|Other|Diet and exercise|Patients treated their diabetes mellitus type 2 with diet/exercise only
1529100|NCT02749019|Drug|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
1529101|NCT02749006|Device|iTBS repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS is a non-invasive procedure in which cerebral electrical activity is influenced by a rapidly changing magnetic field. The magnetic field is created by a plastic-encased coil which is placed over the patient's scalp. The magnetic field can be directed onto specific areas of the brain. rTMS can modulate cerebral activity by low or high frequencies. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region and help symptoms of bipolar depression.
1529102|NCT02749006|Device|Sham rTMS|Sham rTMS involves a click replicating the sound of the magnetic discharge, without any magnetic pulse being delivered.
1529103|NCT02748993|Drug|PAC-14028 Cream 0.1%|Topical application
1529104|NCT02748993|Drug|PAC-14028 Cream 0.3%|Topical application
1529105|NCT02748993|Drug|PAC-14028 Cream 1.0%|Topical application
1529109|NCT02748954|Behavioral|Thoughts|"Thoughts. Increasing helpful thoughts consisted of two psychoeducational segments (i.e., thoughts affect emotions, and how to manage harmful thoughts), and a list of helpful thoughts that participants could choose to use to increase their mood for the next week."
1529110|NCT02748954|Behavioral|Activities.|"Increasing activity level included a brief description of how activities affect mood. Participants were then asked to choose the activities they could use to improve their mood from an available list of helpful activities; users were also able to generate their own helpful activities. Participants were also presented with examples of unhelpful activities such as staying in bed and being isolated"
1529111|NCT02748954|Behavioral|Assertiveness.|Increasing assertiveness, consisting of tips for communicating assertively, and an example of an assertive statement. Participants were asked to describe a recent conflict and apply the intervention's assertiveness techniques to address the conflict.
1529112|NCT02748954|Behavioral|Sleep hygiene|"Increasing sleep hygiene included a description on how sleep can affect mood. Participants were also asked to select from a list of helpful sleep hygiene suggestions to be practiced within the next week such as, Don't take naps during the day and Use the bed/bedroom for sleep or sex only."
1529113|NCT02748954|Behavioral|Own Methods|wherein participants were asked to identify four of their own personal strategies that have helped them improve their mood in the past.
1529114|NCT02748941|Device|HITS quantification, Ultrasound examinations, High Resolution MRI|"Simultaneously measure the occurrence of the event (ischemic stroke) and the characteristics of the atheromatous plaque
Description of different modalities:
HITS quantification
Ultrasound examinations:
Ulceration >2 mm
Plaque thickness
GSM: computer analysis after normalization of most informative longitudinal view (image with maximum plaque area) using Photoshop
CEUS: plaque vascularization detection after bolus injection of SONOVUE on a video recording from the injection of the contrast (Vuebox - Bracco imaging)
High Resolution MRI:
Stenosis severity, intraplaque hemorrhage, large lipid-rich necrotic core, ulceration or cap rupture and Brain MRI will be evaluated
Quantification of shear stresses (Pa) on the surface of the plaque
mi-RNA identification and quantification"
1529115|NCT02748928|Device|UltraShape Power|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
1529116|NCT02748915|Other|Electrophysiological and psychoacoustic tests|
1529117|NCT02748902|Drug|ingenol mebutate 0.05% gel|Ingenol mebutate 0.05% gel applied to a minimum of two and a maximum of five common warts on days 1 and 2.
1529118|NCT02748889|Drug|Carboplatin|Standard chemotherapy
1529119|NCT02748889|Drug|Etoposide|Standard chemotherapy
1529120|NCT02748889|Biological|MPDL3280A|Experimental biologic
1529121|NCT02748876|Other|His-Ventricular (HV) optimisation|Optimisation of atrioventricular pacing interval
1529125|NCT02748850|Biological|blood sample|a blood sample 20 milliliter
1529126|NCT02748850|Biological|Stem cell donation|The volume of stem cells remained in the tube is recovered
1529127|NCT02748837|Drug|ERY974|
1529128|NCT02748811|Other|Intervention group|The intervention group also receives standard treatment with 6 months of adjuvant chemotherapy or first -line chemotherapy until operation, other scheduled change of treatment or progression. The participants will simultaneously receive full geriatric assessement and intervention. The clinical examination includes laboratory parameters, review of medication list, psycho-cognitive assessement, screening for malnutrition and need of physiotherapy, optimizing social support. Validated quality of life questionnaires will be filled in prior to start, after 2 months and at the end of treatment.
1529138|NCT02748772|Drug|Two Anti-angiogenesis Drugs（Endostar and Thalidomide）|Endostar:30 mg/d, CIV (continous intravenous pumping) on day 7 of each 21 day cycle，5 days before the chemotherapy is the first day; Thalidomide:100-200mg/d,PO (peros) on day 14 of each 21 day cycle Number of Cycles: 6 cycle or progression or unacceptable toxicity develops.
1529139|NCT02748772|Drug|Pure chemotherapy（Xelox）|"CapeOX (also called XELOX) is a chemotherapy regimen consisting of capecitabine (trade name Xeloda) combined with oxaliplatin.
Oxaliplatin 130mg/m2 IV over 2 hours,day1 Capecitabine 850-1000mg/m2 twice daily PO for 14 days Repeat every 3 weeks Number of Cycles: 6 cycle or progression or unacceptable toxicity develops."
1529140|NCT02748759|Device|CPM|15 repetitions of flexo-extensión with a commercially available CPM device (Kinetec Advanced Prima)
1529141|NCT02748759|Other|Manual mobilization|Manual mobilization using the Kaltenborn approach, in which 15 tibiofemoral glides were applied by a physiotherapist
1529142|NCT02748746|Device|Bio Impedance Analysis Measurement|Self-adhesive electrodes will be placed to related side's hand dorsum and foot dorsum regarding to calculate for left or right upper extremity's impedance. After completing the measurements for each side, results will be saved by device and documented on paper. A patient total measurement time lasts approximately 3 minutes.
1529143|NCT02748746|Device|Tissue Dielectric Constant Measurement|In this study, TDC device (Moisture Meter-D compact-MMDc will be implemented to upper extremity both affected and unaffected side. 6 cm lower point of cubital crease, 8 cm upper point of cubital crease and 10 cm lower point of armpit will be marked on two sides with a soft pen before measurement. A gentle pressure must required to have accurate sub-tissue fluid percent. Triplicate measurements will be done and taken those average value for each point in order to reach sensitive screening. Computer software simultaneously save these measurements results automatically. A patient total measurement time approximately lasts 5 minutes.
1529144|NCT02748733|Other|Adapted double mini PET|The modified double mini PET mimics the treatment of adapted PD and thus allows its validation
1529145|NCT02748733|Other|Standard double mini PET|The standard double mini PET reflects the routine PD treatment in children and is used for standardized comparison
1529146|NCT02748720|Other|RFM (device) Visible|Will measure the expire tidal volume, end tidal CO2 and peak pressure changes according to clinical improvement and tidal volume
1529147|NCT02748707|Drug|Arm1|Drug (Celecoxib as 200mg twice daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
1529148|NCT02748707|Drug|Arm 2|Drug (ERLOTINIB 150 mg daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
1529149|NCT02748707|Drug|Arm 3|Drugs (Celecoxib 200mg twice daily and Erlotinib 150mg once daily) given orally for 21 days after confirmation by biopsy and before definitive treatment by surgery
1529150|NCT02748707|Other|Arm 4|Patients randomized to this arm will be observed for 21 days before definitive treatment by surgery.Having a control group is ethically justifiable because the average waiting time in our hospital prior to definitive treatment is 30 days after diagnosis.
1529151|NCT02748694|Drug|TAK-041|TAK-041 suspension
1529152|NCT02748694|Drug|TAK-041 Placebo|TAK-041 placebo-matching suspension
1529153|NCT02748681|Device|Auto CPAP AirSense™ 10(Resmed)|AutoSet CPAP without telemedicine monitoring
1529154|NCT02748668|Other|Blood specimen collection|
1529155|NCT02748655|Other|Alkaline ionized water|
1529156|NCT02748655|Other|Tap water|
1529157|NCT02748642|Drug|BITS7201A|BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
1529158|NCT02748642|Drug|Placebo|Placebo matched to BITS72014A will be administered on Day 1 in Part A and on Days 1, 28, and 57 in Part B.
1529159|NCT02748629|Device|Covidien Parietex ProGrip Self-Fixating Mesh|
1529160|NCT02748629|Device|Lightweight Polypropylene Mesh (<38g/m2 after absorption)|Serag Wiessner SERAMESH® PA 15x10 cm
1529161|NCT02748616|Drug|Ursodiol|Subjects will begin to take 300 mg Ursodiol 2 (two) weeks after Visit #1 for a total of 8 (eight) weeks.
1529162|NCT02748590|Device|InterStim II Neurostimulator Model 3058|The neuromodulation will be carried out according to the usual protocol: Hospitalization for the establishment of percutaneous electrode in the operating room under general anesthesia with fluoroscopic control. The pacemaker startup will be performed within 12h after surgery
1529165|NCT02748564|Biological|Aldesleukin|Given IV
1529166|NCT02748564|Other|Laboratory Biomarker Analysis|Correlative studies
1529167|NCT02748564|Biological|Pembrolizumab|Given IV
1529168|NCT02748551|Procedure|Laparoscopic procedures|Laparoscopic surgery
1529169|NCT02748551|Procedure|Open Surgery|Open surgery
1529170|NCT02748525|Other|Milk|Milk, in the form of 8 oz. half and half, administered after CCK scan, and patient is rescanned and ejection fraction measured to determine if ejection fraction is low.
1529171|NCT02748525|Biological|CCK|CCK is standard of care, used in HIDA scans for gallbladder function evaluation. It is given intravenously to cause the gallbladder to contract. The usual dose of CCK is 0.02mg/kg slowly over 3 minutes as per standard.
1529172|NCT02748512|Drug|FAI insert|
1529173|NCT02748499|Other|Healthy Beat Accupunch (HBA) exercise program|HBA has three phases and takes 40 minutes to complete.
1529174|NCT02748499|Other|Control|Participants maintain their daily acitvities.
1529175|NCT02748486|Behavioral|Metacognitive Training Jumping to Conclusion|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - jumping to conclusion.
1529176|NCT02748486|Behavioral|Group discussion|Group discussion of current events
1529177|NCT02748486|Behavioral|Metacognitive Training To Empathize|Therapeutical intervention based on cognitive-behavioural therapy paradigm. Addresses cognitive bias of schizophrenia patients - Theory of Mind deficits.
1529178|NCT02748473|Other|Pilates Exercises program|"The volunteers were divided in two groups:
Group I: Pilates exercise program involving only the Pilates exercises protocol Group II: Pilates exercises program with voluntary pelvic floor muscle contraction.
The protocol of both groups consisted of 24 bi-weekly 1-h individual sessions of Pilates exercises program.
Both groups performed the same protocol . For the group PEP + PFMC the instructor asked for the maximum contraction muscle of the pelvic floor muscle, during expirations with 5 repetitions performed alternately, thus avoiding pelvic floor muscle exhaustion.
After the 24 sessions, both groups were retested with the same measured methods of the baseline."
1529179|NCT02748473|Other|Pelvic floor muscle strength|evaluated the pelvic floor strength by oxford scale and vaginal pressure before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
1529180|NCT02748473|Other|3D perineal ultrasound|evaluated the pubovisceral muscle thickness and levator hiatus area by 3D perineal ultrasound before and after the 12 sessions with Pilates Exercises Program on sedentary nulliparous women
1529181|NCT02748447|Device|Automated FiO2 adjustment|AVEA ventilator according to SpO2 target range delivers an automated FiO2
1529182|NCT02748434|Other|Lipohypertrophy|
1529183|NCT02748434|Other|Normal Subcutaneous Tissue|
1529184|NCT02748421|Procedure|Lumera Microscope with OCT RESCAN|macular membrane dissection with OCT RESCAN
1529185|NCT02748421|Procedure|Conventional Microscope|macular membrane dissection without OCT RESCAN
1529186|NCT02748408|Device|SMS femoral stem|
1529187|NCT02748395|Drug|Triamcinolone|
1529188|NCT02748395|Other|Placebo|
1529189|NCT02748395|Drug|Lidocaine|
1529190|NCT02748382|Other|higher chloride crystalloid|Normal saline
1529191|NCT02748382|Other|higher chloride albumin|5% Octalbin
1529192|NCT02748382|Other|lower chloride crystalloid|Ringers Lactate
1529193|NCT02748382|Other|lower chloride albumin|5% Plasbumin
1529194|NCT02748369|Drug|Somatostatin|Somatostatin infusion to create a low insulin state.
1529195|NCT02748369|Drug|Glucagon|Glucagon infusion in the setting of ongoing somatostatin.
1529196|NCT02748356|Drug|Lactobacillus|Eligible patients will undergo 1 Lactobacillus pediatric dose (Culturelle GG 10 Billion live organisms) instillation by study personnel at the study site. For the intravesicular Lactobacillus instillation, the contents of 1 Lactobacillus capsule will be mixed into sterile 0.9% saline using an age-based estimate of bladder capacity. Similar to adults, this bladder instillation will represent 10% of the estimated maximum bladder volume based on age.
1529197|NCT02748343|Device|allograft bone|Use of the allograft bone to treat the bone defect in patients
1529198|NCT02748343|Device|tissue-engineered bone|Use of the tissue-engineered bone to treat the bone defect in patients
1529199|NCT02748330|Drug|Ticagrelor|Ticagrelor
1529200|NCT02748330|Drug|Clopidogrel|Clopidogrel
1529201|NCT02748330|Drug|Aspirin|Acetylsalicylic acid
1529202|NCT02748317|Drug|Lactobacillus rhamnosus GG|For the intravesicular Lactobacillus instillation, participants will be instructed to mix the contents of 1 Lactobacillus capsule into 45 cc sterile 0.9% saline.5,6 After mixing, participants will draw up the 45 cc of the liquid Lactobacillus mixture into a 60cc catheter tip syringe and instill via the intermittent catheter after the last catheterization prior to going to bed. Participants will receive 10 Lactobacillus GG tabs at the beginning of treatment phase. At the end of each month, the coordinator or RA will ask how many remaining tablets the participant has, and if needed dispense the next supply of 10 tablets Participants will be instructed to complete the USQ-NB weekly.
1529203|NCT02748304|Other|control|just follow up
1529204|NCT02748304|Drug|sorafenib|sorafenib 400mg bid po
1529205|NCT02748304|Drug|aspirin|aspirin 100mg qd po
1529206|NCT02748291|Other|Walking|"The intervention group will be asked to walk a minimum 6,000 steps per day (7 days a week).
Participants will be provided with a pedometer and daily diary to record step counts.
Weekly scores will be collected via telephone contact.
Followup questionnaires will be at 6, 12 and 24 months."
1529207|NCT02748291|Other|Department of Health Physical Activity Guidelines|"Adults should aim to be active daily. Over a week, activity should add up to at least 150 minutes (2½ hours) of moderate intensity activity in bouts of 10 minutes or more - one way to approach this is to do 30 minutes on at least 5 days a week.
Alternatively, comparable benefits can be achieved through 75 minutes of vigorous intensity activity spread across the week or combinations of moderate and vigorous intensity activity.
Adults should also undertake physical activity to improve muscle strength on at least two days a week.
All adults should minimise the amount of time spent being sedentary (sitting) for extended periods."
1529210|NCT02748265|Drug|Inhaled Epoprostenol and phenylephrine|After 30 minutes of one-lung ventilation, Epoprostenol 50 ng/kg/min is administered via nebuliser in the anesthesia circuit with phenylephrine administered intravenously
1529211|NCT02748265|Drug|Sevoflurane|Volatile maintenance anesthesia
1529212|NCT02748265|Drug|Propofol|Intravenous maintenance anesthesia
1529213|NCT02748252|Other|stroke center referral|
1529214|NCT02748239|Behavioral|MEDIAS 2 CT|The MEDIAS 2 CT is a education program for the initiation of a conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
1529215|NCT02748239|Behavioral|Current CT program|The Current CT program is currently used for the initiation of conventional insulin therapy in type 2 diabetic patients. The program consists of 6 lessons and is conducted in group settings (4-8 participants).
1529216|NCT02748226|Procedure|endovascular treatment|endovascular treatment
1529217|NCT02748213|Drug|Xeloda|Participants will receive oral Xeloda, 950 mg/m^2 twice a day on Days 1 to 14 of each 21-day cycle.
1529218|NCT02748213|Drug|Taxotere|Participants will receive Taxotere, 75 milligrams per meter-squared (mg/m^2) in the Herceptin + Taxotere + Xeloda arm or 100 mg/m^2 in the Herceptin + Taxotere arm, via IV infusion on Day 1 of each 21-day cycle. The lower starting dose will be used in the triple-therapy arm.
1529219|NCT02748213|Drug|Herceptin|Participants will receive Herceptin, 6 milligrams per kilogram (mg/kg) via IV infusion, on Day 1 of each 21-day cycle. The first dose will be a loading dose of 8 mg/kg in Cycle 1; the dose of 6 mg/kg will be given from Cycle 2 onward.
1529220|NCT02748200|Radiation|external beam radiotherapy (EBRT)|EBRT: 3 dose escalation levels
1529221|NCT02748187|Other|CBASP|Interpersonal psychotherapy for chronic depression
1529224|NCT02748148|Other|Medication therapy management|Implementation of a systematic approach to evidence- and personalized-based medicine through a pharmacist-guided medication therapy management service
1529225|NCT02748135|Drug|TB-403 20mg/kg|Up to 12 bi-weekly intravenous doses of TB-403 20mg/kg
1529227|NCT02748135|Drug|TB-403 100mg/kg|Up to 12 bi-weekly intravenous doses of TB-403 100mg/kg
1529228|NCT02748135|Drug|TB-403 ≤175mg/kg|Up to 12 bi-weekly intravenous doses of TB-403 ≤175mg/kg
1529232|NCT02748096|Procedure|Patient Specific Instrumentation|Patients will undergo a medial unicompartmental knee replacement. This knee replacement is implanted using patient specific cutting guides that have been produced based on the patient's individual anatomy (using plans from pre-operative MRI scans of the patient's knee).
1529233|NCT02748096|Procedure|Conventional Instrumentation|Patients will undergo a medial unicompartmental knee replacement using standard conventional instruments.
1529234|NCT02748083|Device|tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The tDCS group will have 10 active or sham tDCS sessions. The active group will be stimulated with a 2 mA current for 20 minutes.
1529235|NCT02748083|Device|Sham tDCS|Electrodes for tDCS will have the anode placed over the left DLPFC (F3) and the cathode over the contralateral (right) supraorbital ridge. The exact location of electrodes will be determined by the 10/20 EEG method with EEG cap. Subjects will have tDCS sessions on consecutive days (weekends and holidays excluded). The sham tDCS group will have 10 active or sham tDCS sessions. The sham group will have stimulation lasting only 40 seconds though the electrodes will remain in place for 20 min.
1529236|NCT02748070|Drug|Prednisone|
1529237|NCT02748070|Drug|Flonase|
1529240|NCT02748044|Device|CC-Cruiser|An artificial intelligence to make comprehensive evaluation and treatment decision of congenital cataracts
1529241|NCT02748031|Procedure|slit-lamp-adapted anterior segmental photography|The eligible patients underwent pupil dilation and slit-lamp-adapted anterior segmental photography to electronically record and monitor the morphology of their cataractous lens.
1529242|NCT02748018|Device|670G Insulin Pump|Medtronic 670G Hybrid Closed Loop (HCL) ambulatory insulin pump system
1529243|NCT02748018|Device|Subject's Current Diabetes Therapy|Subject will use current diabetes therapy: CSII (Continuous Subcutaneous Insulin Infusion), MDI (Multiple Daily Injections) or SAP (Sensor Augmented Pump).
1529244|NCT02748005|Dietary Supplement|Fenugreek seeds extract 500 mg|one cap once a day
1529245|NCT02747979|Other|hemodialysis only|hemodialysis treatment only
1529246|NCT02747979|Other|hemodialysis plus hemoperfusion(HA330)|combination of hemodialysis and hemoperfusion (HA330) treatment
1529247|NCT02747979|Other|hemodialysis plus hemoperfusion(HA130)|combination of hemodialysis and hemoperfusion (HA130) treatment
1529248|NCT02747953|Drug|Gilotrif|50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.
1529249|NCT02747940|Drug|flunarizine and/or pregabalin|
1529250|NCT02747927|Biological|Takeda's Tetravalent Dengue Vaccine Candidate|TDV subcutaneous injection
1529251|NCT02747927|Drug|TDV Placebo|Takeda's TDV placebo-matching vaccine
1529254|NCT02747901|Other|KINESIOTAPING|Kinesiotaping group received kinesiotape for lymphatic correction and rectus femoris facilitation technique.
1529255|NCT02747901|Other|COLD THERAPY|Cold therapy group received cold packs immediately after operation and following postoperative days
1529256|NCT02747888|Genetic|•Referral to Genetic Counselor, if indicated|
1529257|NCT02747875|Drug|Methadone|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 0.3 mg/kg of methadone prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
1529258|NCT02747875|Drug|Fentanyl|The treatment phase will begin at the induction of general anesthesia and finish at the end of the surgical procedure. Under the direction of the cardiac anesthesiologist subjects will be premedicated and general anesthesia will be induced with standard anesthetic monitoring and management. Participants will receive 20 mcg/kg of fentanyl prior to surgical incision, over 20 minutes. General anesthesia will be maintained with inhalational anesthetics and paralytics. The subject will continue to be evaluated for hemodynamic stability, bleeding, and respiratory effort. The postoperative intensive care phase will begin at time of room admission and end at day three of hospital stay. All subjects will receive morphine or oxycodone analgesics and sedation medication based on the hospital's postoperative pain control and agitation protocol. Standard electronic documentation will be maintained throughout and include: medications, vital signs, and events.
1529259|NCT02747862|Other|Chart Review|"Database queried for the presence of cases meeting criteria (attenuated FAP, classical AFP [i.e. identifiable APC mutation], and/or a compatible family history or personal adenoma burden of > 50 adenomas).
The data related to the patients with attenuated FAP and classical AFP who underwent endoscopic surveillance or surgery collected through chart review and all data is retrospective as of February 15, 2016."
1529297|NCT02747498|Procedure|Procedure with circumferential pulmonary vein isolation|
1529260|NCT02747849|Device|TENS|In our pilot study, transcutaneous foot stimulation of the tibial nerve appears to be a safe and effective novel treatment to decrease the number of wet nights in children. A placebo-controlled study is currently in accrual to strengthen the evidence in support of transcutaneous foot stimulation in this population.
1529261|NCT02747836|Other|Ultrasound of the wrist|using sound waves to create images capturing the movement of the SSCT and flexor tendon and transformation of the median nerve in the wrist
1529262|NCT02747823|Biological|CBT124|1 mg/kg IV infusion
1529263|NCT02747823|Biological|EU Sourced Avastin®|1 mg/kg IV infusion
1529264|NCT02747823|Biological|US Sourced Avastin®|1 mg/kg IV infusion
1529265|NCT02747810|Device|NewTENS Design|This device functions the same as the FDA approved TENS unit, but provides a small, inexpensive unit that will be easy for a child to use. The stimulation characteristics include a continuous frequency of 5 Hz, pulsewidth 0.2 ms, and intensity 2-4 times the threshold voltage required for inducing toe twitching - or the intensity that the subject feels comfortable with. The subjects will also be instructed how to use the stimulator and where to attach the electrodes on the foot at the beginning of the study. The investigator will provide the stimulator and electrodes. The subjects will be asked to wear socks to prevent the electrodes from detachment and to stop the stimulation during walking or in any non-resting situation. Subjects will be asked to use the stimulator for a MINIMUM of 60 minutes in the evening prior to bedtime at home for two weeks. They will be encouraged to use the stimulator for more time than the minimum as long as they accurately record the total duration.
1529266|NCT02747797|Drug|Lucitanib|10 mg orally daily
1529267|NCT02747784|Behavioral|Cognitive training program RehaCom®|Cognitive training program RehaCom®
1529268|NCT02747771|Behavioral|Cognitive behavioral therapy|10 sessions Group therapy during 10-12 weeks. The first three sessions focus on habit reversal training, the fourth to sixth session on acceptance and commitment therapy and the last four sessions aims at integrating the two approaches.
1529269|NCT02747758|Device|cathodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using cathodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
1529270|NCT02747758|Device|sham transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using a sham-stimulation including ramp up and ramp down of current.
1529271|NCT02747758|Device|anodal transcranial direct current stimulation (tDCS)|transcranial direct current stimulation (tDCS) is applied in active groups using anodal active M1 stimulation. Active stimulation is applied with 2mA direct current via 20cm² electrodes.
1529272|NCT02747745|Behavioral|Four risk areas reflecting the great needs of FCGs of PWDs|The intervention involves home visits & phone calls from the case manager to the dyads, and receiving telephone calls from FCGs. The case manager will target the prioritized risk from the 4 risk areas of FCG problems and healthy behaviors. The intervention mainly consists of needs assessment and nursing education on home environment modification and safety, behavioral management and communication skills; home-based cognitive stimulation on PWD with simple mathematical practice, patient preferred leisure activities and reminiscence by old time photos, stories and toys; brief consultation on 4 risk areas related to FCG stress; and case management to refer the dyads to the hospital-based dementia centers and community resources.
1529273|NCT02747732|Drug|Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6|"Therapy initiation 30 days max from screening.
Bendamustine 90 mg/m2 IV on Days 1-2, Cycles 1-6 Rituximab 375 mg/m2 IV Day 1, Cycles 1-6; a cycle is defined as 28 days Ibrutinib, 560 mg orally, once daily, continuously starting on Cycle 1, Day 1 until disease progression, toxicity or referral for allo-SCT"
1529274|NCT02747719|Behavioral|Light and exercise|Exposure to light and exercise
1529275|NCT02747706|Behavioral|Parent-to-parent mentoring|phone, SMS/text, and smartphone-based support
1529276|NCT02747680|Other|hypoglycemia (low blood sugar) in MRI|hypoglycemia (low blood sugar) in MRI
1529277|NCT02747654|Genetic|genotype|Patients were randomly assigned to a standard treatment group; INH dose of 300 mg or 200 mg based on the body weight) or model-based treatment group; INH dose determined based on developed model,
1529278|NCT02747641|Procedure|Pixel CO2 Laser System|
1529279|NCT02747628|Drug|Placebo|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
1529280|NCT02747628|Drug|transdermal therapeutic system- nicotine.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
1529281|NCT02747628|Drug|transdermal therapeutic system- melatonin.|Postoperative pain was evaluated based on visual analogue scale, first time to ask for rescue analgesia and total pethidine requirements (mg) in 12 hours postoperatively were also recorded.
1529282|NCT02747615|Other|transfused pre-operatively donated autologous blood.|
1529283|NCT02747615|Drug|intravenous tranexamic acid (TXA) infusion|
1529284|NCT02747615|Other|transfused only allogeneic blood.|
1529285|NCT02747602|Drug|AC-1204|40 g (120 mL) AC-1204 administered 30 minutes after the start of a standard breakfast.
1529286|NCT02747602|Drug|caprylic triglyceride oil (standard breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a standard breakfast.
1529287|NCT02747602|Drug|caprylic triglyceride oil (high fat breakfast)|20 g CT oil (21 mL) administered 30 minutes after the start of a high fat breakfast.
1529288|NCT02747589|Procedure|Surgical device implant in brain|Neuropace RNS implant ove visual cortex
1529289|NCT02747563|Other|Blood test (PSA)|Measurement of blood PSA levels
1529290|NCT02747550|Procedure|LM with TESTO|In subjects allocated to the experimental group, the temporary simultaneous two-arterial occlusions (TESTO) procedure was performed to minimize operative blood loss during laparoscopic myomectomy.
1529291|NCT02747550|Procedure|LM without TESTO|In the control group, no intervention for the temporary simultaneous two-arterial occlusions (TESTO) procedure was made during laparoscopic myomectomy
1529292|NCT02747537|Drug|Sorafenib|
1529293|NCT02747537|Drug|Irinotecan|
1529295|NCT02747511|Drug|Haloperidol|
1529296|NCT02747511|Drug|Placebo|
1530103|NCT02741518|Biological|Fecal Microbiota Transplantation|
1529298|NCT02747498|Procedure|Procedure with linear ablation in addiction to pulmonary vein isolation|
1529299|NCT02747485|Device|Cardiac MRI|
1529300|NCT02747485|Biological|blood samples|Serum levels of biomarkers of myocardial fibrosis (galectine-3 and ST2) will be measured
1529301|NCT02747485|Procedure|myocardial biopsy|
1529302|NCT02747485|Genetic|blood samples|extract DNA to look for genomic mutations associated with the disease.
1529303|NCT02747472|Drug|GIP-A|GIP receptor antagonist
1529304|NCT02747472|Drug|GIP(1-42)|GIP receptor agonist
1529305|NCT02747472|Other|Saline|Placebo
1529306|NCT02747459|Behavioral|Sensory Supported Swimming|A swimming and water safety program for children with autism spectrum disorders. Individualized instruction utilizing evidence-based teaching methods and sensory modifications.
1529307|NCT02747446|Dietary Supplement|added sugar|isocaloric substitution of added sugars (honey or FG) for starch
1529308|NCT02747433|Device|Robot-Assisted Therapy (RT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (1 hr sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Robot training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home & community.
1529309|NCT02747433|Device|Robot & Task-Oriented Training (RT-TOT)|Highly repetitive robot-assisted therapy for paretic arm with Armeo (30 min sessions, 3x week for 3 weeks) followed by robot-assisted therapy for hand motions with Amadeo (3x week for 3 weeks). Task oriented training will be delivered for remaining 30 mins of each treatment session. Robot and task oriented training to be accompanied with ALPS motor learning program directed toward UE self management and transfer of training to daily activities in home & community.
1529310|NCT02747420|Device|NURO TM|The lower extremity will be palpated and a needle insertion site will be identified 5 cm from the medial malleolus and posterior to the tibia. Between the posterior margin of the tibia and the soleus muscle, a 34-gauge acupuncture-like needle will be inserted 3-4 cm to the tibial nerve. A grounding pad will be placed on the bottom of the foot just below the smallest toe. An inactive grounding pad will be placed on top of the foot above the small toe to be consistent with the sham pad placement. The needle and grounding pad will be connected to the stimulator and the stimulation will be increased from 0 to 10 Milli-ampere. The needle will be taped. The electrical current will be set by the subject and the mA will be recorded. A 30 minute stimulation session will be given at 20 Hz.
1529311|NCT02747420|Device|Sham|"A needle will be inserted into the lower extremity approximately 5 cm cephalad from the medial malleolus and posterior to the tibia. A sham needle will be used a the tibial nerve insertion site. This will stimulate needle placement without puncturing the skin. The needle will be taped in place. The grounding pad from the transcutaneous electrical nerve stimulation (TENS) unit device will be placed on the bottom of the foot below the smallest toe. Another electrode will be placed on the top of the foot above the small toe for conduction. The TENS electrode will be connected to the TENS unit, at 20 Hz (the same as the PTNS group). The unit will be turned on and the stimulation will be increased to the subject's first sensory level. The subject will sense stimulation to either the bottom of the foot or the toe. the TENS unit will be on for a 30 minute test period. The TENS unit will be removed and the needle will be discarded."
1529312|NCT02747407|Biological|Hepatitis A Vaccine|
1529313|NCT02747407|Other|Laboratory Biomarker Analysis|Correlative studies
1529314|NCT02747407|Biological|Tetanus Toxoid Vaccine|
1529315|NCT02747407|Biological|Trivalent Influenza Vaccine|
1529316|NCT02747394|Other|Working Memory Training|
1529317|NCT02747381|Dietary Supplement|Alfacalcidol|1-alpha hydroxy cholecalciferol 1 mcg
1529318|NCT02747368|Device|Ocusweep system|Comparison of Ocusweep system to conventional visual acuity, contrast sensitivity and visual field testing.
1529319|NCT02747342|Drug|SHR3680|SHR3680 will be administered orally at the starting dose of 40 mg/day.
1529320|NCT02747329|Device|BuMA Supreme™ stent|
1529321|NCT02747329|Device|Xience V/Prime stent|
1529322|NCT02747316|Other|Stable iron isotope 57 (57Fe) labeled iron solution|test meal labeled with 12 mg 57Fe
1529323|NCT02747316|Other|Stable iron isotope 58 (58Fe) labeled iron solution|test meal labeled with 12 mg 58Fe
1529324|NCT02747303|Procedure|Stereotactic Radiosurgery|The SRS dose will depend on the maximum diameter of the gross tumor volume (GTV)
1529325|NCT02747290|Drug|68Ga-NOTA-BBN-RGD|68Ga-NOTA-BBN-RGD were injected into the patients before the PET/CT scans
1529326|NCT02747264|Device|eRAPID|eRAPID is an online system for patients to self-report symptoms and AE during and after cancer treatments. eRAPID allows AE reporting from home or hospital and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for severe AE to the relevant clinical team and providing patient advice on managing mild and moderate AE.
1529327|NCT02747251|Other|Strengthen your Shoulder|A simple home-based elastic band strengthening exercise intervention. This program consists of progressive high volume resistance training exercises with an elastic band.
1529328|NCT02747251|Other|Usual Care|"Usual care, consisting of a referral to general rehabilitation in the municipal under the Danish Health Act § 140, most often with the alternative option to choose a private physiotherapeutic clinic, partly at their own expense. Also includes any additional treatment the patient receives between baseline and follow-up, except that included in Strengthen your Shoulder."
1529329|NCT02747238|Device|Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
1529330|NCT02747238|Procedure|No ultrasound|Palpation of anatomical landmarks is used for placement of labor analgesia
1529331|NCT02747238|Procedure|Epidural infusion|An epidural infusion will be started in both groups, regarding of the technique used for placement, and the same solution of Bupivacaine 0.0625% with 2mcg fentanyl/cc will be used in both groups
1530104|NCT02741518|Other|Placebo|
1529332|NCT02747225|Device|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue.
1529333|NCT02747212|Device|network analyzer|The dielectric properties of the tissues were measured using the open-ended coaxial line method. The measurement system consisted of a network analyzer (Model 4395A, Agilent Corp., Santa Clara, CA) associated with an S-parameter test set (Model 87511A, Agilent Corp., Santa Clara, CA). A semi-rigid coaxial line with a diameter of 3.58 mm was connected to the network analyzer system by using a Bayonet Neill-Concelman connector. The other tip of the coaxial line (probe) was placed on the flat bare surface of the tissue that placed on a measurements experiment platform.
1529334|NCT02747199|Device|SYNERGY stent|
1529335|NCT02747199|Device|BVS ABSORB scaffold|
1529336|NCT02747186|Drug|Lidocaine|Intraoral maxillary field block
1529337|NCT02747186|Drug|Epinephrine|
1529338|NCT02747160|Behavioral|Managing Anxiety from Cancer (MAC)|The intervention consists of six telephone-administered sessions. Session topics include psychoeducation on anxiety, behavioral strategies for managing anxiety, cognitive restructuring, communication skills training, acceptance techniques (patient only), problem-solving strategies (caregiver only), and planning for future anxiety. Session content is tailored for older adults and caregivers of older adults with cancer.
1529339|NCT02747147|Device|TIVA blood collection device|the device is attached to a peripheral IV catheter for use as a direct blood draw device into a vacuum tube or a syringe
1529340|NCT02747134|Behavioral|Emotion Regulation and Mindfulness skills|
1529341|NCT02747121|Behavioral|External inspection of health services|The intervention is external inspections of acute hospitals addressing early detection and treatment of sepsis. The intervention is delivered on an organizational level. Individuals are not assigned to an intervention. The investigator use data from individuals to assess if the organizational intervention affects care. Therefore the investigator argues that that the study is observational. The inspection will have two components, a system revision and a follow up audit with verification of patient records 8 months later. The inspection can be considered a complex intervention. The study does not intend to evaluate the individual effects of the different components of the inspection, rather the effect of the inspection as a whole.
1529342|NCT02747108|Behavioral|Blood Test Group Intervention|Patients randomly assigned to the Blood Test Group will complete an HbA1c blood test around the time of their next primary care appointment. Following the HbA1c test, their VA primary care provider will be notified of the test result and will be provided with a detailed interpretation of the result. Trained study staff will then provide brief counseling by phone and written information by mail about their test result. The brief counseling and written information will be based on the American Diabetes Association and National Diabetes Prevention Program guidelines and will emphasize the risk of progression to type 2 diabetes mellitus and the rationale for preventive strategies, encourage aerobic exercise and a calorie-restricted diet to promote and maintain weight loss, and set a goal of achieving and sustaining a weight loss of at least 5% of body weight.
1529343|NCT02747108|Behavioral|Brochure Group Intervention|Participants will be asked to review a handout from the National Center for Health Promotion and Disease Prevention (NCP) on recommended screening tests and immunizations on or around the same date as their next primary care appointment.
1529344|NCT02747095|Device|IQon Spectral CT|Using IQon Spectral CT, Assess the added diagnostic value and impact on workflow of spectral images
1529345|NCT02747082|Procedure|Retreatment of root-filled teeth with infection|Root-filled teeth with infection are being treated with either 1% NaOCl or 2% CHX as disinfection irrigation solution.
1529346|NCT02747069|Device|NICU electronic stethoscope|Assessment of heart rate using the electronic stethoscope for up to 10 minutes compared to ECG and pulse oximetry devices used to monitor neonates whilst on NICU
1529347|NCT02747069|Device|Newborns <32 weeks and ECG|The three leads from the ECG device will be pre placed onto a plastic bag prior to delivery. The pre term infant (<32 weeks) placed into the bag at the time of delivery and heart rate will be assessed for up to 30 minutes
1529348|NCT02747056|Other|clinical, psychological and neuropsychological assessment|the subjects will do 3 tests about executive functions, complete 3 questionnaires about autism and 3 questionnaires about the self concept
1529349|NCT02747056|Other|Autobiographical memories Assessment|The investigators will ask subjects to tell autobiographical memories freely first and, secondly, to specify participants'characteristics by answering focused questions.
1529350|NCT02747056|Other|Autobiographical memories assessment characteristics|During the second time point, the investigators will ask subjects to say the self statements which define them. Then, subjects will have to tell and to specify the characteristics of the autobiographical memories linked to these self statements.
1529353|NCT02747030|Drug|Ocriplasmin intravenously|Retinal vein cannulation with Ocriplasmin infusion
1529357|NCT02746991|Drug|Sham Injection|
1529358|NCT02746991|Drug|FAI Insert|
1529359|NCT02746978|Other|Peer directed education|No drug or device is included. The intervention of interest is the redesigned approach to inpatient education that follows the Stanford chronic disease self management approach which includes peer-led problem solving discussions compared to traditional didactic education lectures provided by nurse educators
1529360|NCT02746978|Other|Patient Engagement Portal|No drug or device interventions. The Engagement Portal is populated by electronic medication record information (demographics, medications, supplies) then owned/maintained by patient after discharge. This approach to managing information and conditions associated with injury will be compared to the traditional approach of providing patients with a large instruction manual to carry home with them.
1529397|NCT02746692|Other|Endurance|Moderate intensity ergometer training. Total duration 50 minutes
1530235|NCT02740712|Drug|Rucaparib|200 & 300 mg tablet
1529361|NCT02746965|Device|Magpro X100 + Option|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of MST in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
1529362|NCT02746965|Device|ThymatronSystem Ⅳ Electroconvulsive System|In addition to treatment as usual (TAU), participants were supposed to receive ten sessions of modified ECT in four weeks, with three sessions per week in the first two weeks and two sessions per week in the following two weeks.
1529363|NCT02746965|Other|treatment as usual (TAU)|Participants will engage in their inpatient treatment program as-usual.
1529364|NCT02746952|Genetic|UCART19|
1529365|NCT02746939|Behavioral|InSciEd Out Fitness and Nutrition Curriculum|Science curriculum is designed in partnership with 3rd and 4th grade teachers and InSciEd Out scientists. The curriculum is designed to focus on inquiry driven science, and also aims to decrease high risk behaviors that can lead to obesity in the students.
1529366|NCT02746926|Drug|tafamidis|
1529367|NCT02746913|Device|Urodynamics|Urodynamics is performed with the Aquarius XT Laborie system and a fluoroscopic images are obtained with a GE OCE 9800 c-arm fluoroscopy unit. Urodynamic testing will be performed in a seated position with a pessary from the ambulatory pessary trial in place. Post residual void will be measured at the start of the urodynamics.
1529368|NCT02746913|Device|Pessary|A pessary is a silicone disc that is used in to support the uterus and vagina of women with vaginal prolapse. During this study, the pessary that will be used is a ring with support. This is a disc shape with a membrane stretched across the center. It is a device used in standard practice and is safe to keep in place for up to 3 months at a time. The subjects will be fit with a pessary asked to wear the pessary for 3 days.
1529369|NCT02746900|Procedure|Cervical cerclage|McDonald cervical cerclage
1529370|NCT02746887|Other|Preterm/term cohort|
1529371|NCT02746874|Procedure|Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected prior to lesioning.
1529372|NCT02746874|Procedure|Simulated Radiofrequency Ablation (RFA)|The radiofrequency generator which will be turned on but will not be in the patient's view. The skin overlying the target sites identified with image guidance will be numb using lidocaine 1%. A needle will be placed through the skin to be optimally positioned according to the three targets. Sensory and motor testing will be performed to confirm appropriate placement. Lidocaine 2% 1-2cc will be injected. A simulate sham lesion will be performed at each target site.
1529373|NCT02746861|Behavioral|Peer-Supported DSMS|Phone, SMS/text, and smartphone-based intervention.
1529374|NCT02746848|Biological|Amniotic Membrane Extract Eye Drop|Amniotic Membrane Extract use as eye drop for patients with corneal injury.
1529375|NCT02746835|Other|Exercise program for fall prevention|"Set of exercises to improve the following parameters:
balance, endurance, muscle strength, flexibility."
1529376|NCT02746809|Device|CoreValve Evolut 34R TAVR system|"The CoreValve Evolut 34R System is a transcatheter aortic valve implantation system comprised of the following three components:
Evolut 34R Transcatheter Aortic Valve (TAV)
EnVeo R Delivery Catheter System (DCS) with EnVeo R InLine Sheath
EnVeo R Loading System (LS)"
1529377|NCT02746796|Drug|ONO-4538|
1529378|NCT02746796|Drug|Oxaliplatin|
1529379|NCT02746796|Drug|Tegafur- Gimeracil-Oteracil potassium|
1529380|NCT02746796|Drug|Capecitabine|
1529381|NCT02746796|Drug|Placebo|
1529382|NCT02746783|Drug|Single dose MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
1529383|NCT02746783|Drug|Double dose of MUTAGRIP® influenza vaccine|All subjects will receive either a single or double doses of MUTAGRIP® containing A/California/7/2009 (H1N1); A/Texas/50/2012 (H3N2); B/Massachusetts/2/2012. The double dose regimen will be administered at the same time.
1529384|NCT02746770|Other|Experimental: Cawthorne and Cooksey exercises group|Experimental: intervention group. Patients assigned to the experimental group will perform the Cawthorne and Cooksey exercises for vestibular rehabilitation in addition to their habitual treatment.
1529385|NCT02746757|Other|Remote conditioning|
1529386|NCT02746757|Drug|Exendin 9-39|
1529390|NCT02746731|Other|Cardiorespiratory and resistance training.|"A cardiorespiratory and resistance training program for at least 2 to 3 weeks will be conducted 3-times per week, of which two sessions will be supervised by a qualified person of the institute of physiotherapy and one session will be unsupervised and home-based.
Physiotherapy consists of one hour, moderate to intense interval training combined with muscle strength training."
1529391|NCT02746731|Other|Reference|No preoperative physical therapy training. Patients will be informed to remain physically active (as usual) until surgery.
1529392|NCT02746718|Other|Blood sample|A blood sample for CPK dosage and pompe disease test
1529393|NCT02746705|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a therapeutic development that utilizes low amplitude direct currents to induce changes in cortical excitability. tDCS is expected to produce neuronal polarization of less than one mV (millivolt) 9. tDCS produces relatively diffuse current flow, as demonstrated by imaging studies and computational models
1529394|NCT02746705|Device|Sham Transcranial Direct Current Stimulation|During a sham session, the device is programmed to ramp up to the desired intensity (target 2.0 mA) and ramp down for the initial 60 seconds, with no current delivery during the session, and then again at the end of the session. These brief periods of stimulation serve to mimic the effects of a true stimulation session.
1529395|NCT02746705|Behavioral|Cognitive Training Program|
1529396|NCT02746692|Other|Fit15|"Group-based high-intensity circuit training based on functional movement patterns (e.g. squats, push-ups, burpees, jumps, ropeskipping).
Total duration 15 minutes circle training: 20s workout, 10 rest"
1529398|NCT02746679|Other|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction programs have been shown to be effective, however, the potential benefits of Mindfulness Based Stress Reduction to decrease depression, anxiety, stress in other diseases. Therefore, the purpose of this study was to examine whether MBSR is effective, and has potential as an intervention to decrease depression, anxiety ,and to improve quality of life of intrauterine adhesion patients.
1529399|NCT02746666|Behavioral|Pharmacist's behavioral intervention|Pharmacist's 30 min counselling on antiemetic therapy, causes of nausea or vomiting and ways to prevent them during chemotherapy.
1529400|NCT02746653|Device|TroClose1200(TM)|Creation of access port and closure it by the same device, TroClose1200(TM)
1529401|NCT02746640|Procedure|Cardiopulmonary resuscitation (CPR)|If there is a cardiopulmonary arrest, investigators observe the working processes of cardiopulmonary resuscitation.
1529402|NCT02746627|Behavioral|Positive Affect|Positive psychology intervention to improve motivation for diabetes management.
1529403|NCT02746627|Behavioral|Education|Educational materials on diabetes management
1529404|NCT02746614|Other|Psychomotor Therapy|Psychomotor Therapy
1529405|NCT02746601|Behavioral|Risk Assessment, Counselling & Resources|A risk assessment tool is completed on a tablet. The results are scanned into the patient's electronic medical record. A healthcare provider gives behavioural counselling on identified risk factors. The patient is given a customized handout that includes health recommendations and resources based on the participant's identified risk factors.
1529406|NCT02746588|Other|Office hysteroscopy|Diagnostic hysteroscopy with biopsy
1529407|NCT02746575|Drug|metoprolol|
1529408|NCT02746562|Procedure|Freeze all|Freezing of all blastocyst stage embryos with thawing and transfer in a subsequent natural cycle
1529409|NCT02746549|Other|renal perfusion|measurement of renal perfusion with MRI arterial spin labelling technique
1529410|NCT02746536|Other|Slow chest compression|"During the SCC, the patient will remain in the sitting position; a bimanual slow compression on his/her upper chest will be performed always by the same evaluator, who will stand behind the patient. This compression will be done only in the expiratory phase, during one minute, in all respiratory cycles, respecting the chest mobility of each patient.
A standardized verbal command will be given: Exhale all the air."
1529411|NCT02746536|Other|No slow chest compression|"The patient will remain seated at rest for one minute after the 6MST and 6MWT. A standardized verbal command will be given: Exhale all the air."
1529412|NCT02746523|Other|Sensory Organization Test|Balance and proprioception test
1529413|NCT02746523|Genetic|Biomarkers|Blood, urine, and saliva biomarkers
1529414|NCT02746523|Other|Conners' Adult ADHD Rating Scale (CAARS)|Adult ADHD rating scale
1529415|NCT02746523|Other|Depression Scale|Becks Depression Inventory and Patient Health Questionnaire 9 (PHQ-9)
1529416|NCT02746523|Other|Cognitive Assessment|Montreal Cognitive Assessment (MoCA)
1529417|NCT02746510|Genetic|Array comparative genomic hybridization|For each of the 150 patients deoxyribose nucleic acid (DNA) exactracted from a jugal mucosae sample will be analysed by the cytogeneticist and a CGH-a will be performed.
1529418|NCT02746497|Procedure|Acupuncture|"Acupuncture style; Western Medical Acupuncture (WMA). In WMA all types of sham (placebo) acupuncture are believed to produce a certain amount of sensory stimulation and thereby a possible therapeutic effect. In addition, other studies have shown that sham acupuncture is associated with a moderately large nonspecific effect and compared to other inert placebo intervention the effect associated with sham acupuncture might be larger. Thus we use a control group instead of a placebo group.
Needles; sterile disposable needles (Plandent) size 0.30x30mm. The needles will be inserted perpendicularly and rotated manual between finger and thumb for a few seconds to elicit de-qi. Needle retention time will be 10 minutes. Afterward the needle will be removed. Acupuncture points; CV-3, CV-4, LR-8, SP-6, SP-9. In total 8 points as LR-8, SP-6, SP-9 are given bilaterally."
1529419|NCT02746484|Other|Ability platform program|The Ability program is an at home participant-tailored and technology-enhanced platform a) delivering tablet-based intensive (five days/a week for six weeks) motor and cognitive activities; b) monitoring from remote vital and physical health parameters (i.e., weight, Heart Rate, O2 saturation, daily steps, sleep activity).
1529420|NCT02746484|Other|Usual care program|Usual care at home program (paper and pencil cognitive activities; promotion of physical activity according to healthcare professional's advice)
1529421|NCT02746458|Other|Blood Flow Restriction|Brief and intermittent blood flow restriction via a Delfi PTSII Tourniquet System will be used during physical therapy.
1529422|NCT02746458|Device|Delfi PTSII Tourniquet System|
1529423|NCT02746445|Other|No intervention|No intervention. This is a longitudinal study looking at subjects who received MeRT treatment.
1529424|NCT02746432|Drug|Hyper insulinemic euglycemic clamp|After obtaining a baseline preoperative lab set blood glucose value, 2 U/kg bolus of insulin (Human regular insulin) to be administered IV followed by an infusion of 2 U/ kg/min.fiver - Ten minutes after starting the insulin infusion, and when the blood glucose is <6.1 mmol /L (110 mg /dL). an Infusion of dextrose 20% supplemented with pottasium phosphate (30 mmol/L ) to be administered. In the operating room, blood glucose levels were measured every 5-15 minutes, and the dextrose infusion rate was adjusted to maintain arterial glycemia between 3.5 and 6.1 mmol/L (63-110 mg/dL). timed intra operative lab assessment to be obtained.
1529426|NCT02746406|Device|Peritron+|Peritron+ device to measure intravesical pressure
1529429|NCT02746380|Drug|LBAL|Adalimumab
1529430|NCT02746380|Drug|Humira®|Adalimumab
1529431|NCT02746367|Other|Diagnostic test (LDT)|Proteomic assay
1529432|NCT02746354|Other|The MySupport tool|Utilization of the MySupport tool, a tailored patient-centered assessment
1529433|NCT02746328|Drug|GTx-024 9 or 18 mg|Patients enrolled in G200802 receiving GTx-024 9 or 18 mg
1529434|NCT02746315|Drug|HS-20004|
1529435|NCT02746315|Drug|Placebo|
1529436|NCT02746302|Drug|HS-20004|
1529437|NCT02746302|Drug|Placebo|
1529644|NCT02744612|Drug|Ibrutinib|Given PO
1531293|NCT02732548|Other|Negative Pressure Wound Therapy (NPWT)|
1529438|NCT02746276|Drug|Ceftriaxone|Ceftriaxone is active against a broad spectrum of gram positive and gram negative bacteria, including intracellular bacteria (e.g. Salmonellae, Staphylococci). Its antibacterial effect is dependent on time above the minimum inhibitory concentration(MIC). Ceftriaxone is highly protein-bound and elimination depends on glomerular filtration rate. In severely ill adults, elimination is highly variable. Alteration in plasma proteins, volume of distribution and renal function in sick severely malnourished children could significantly alter pharmacokinetics (PK). Despite several published studies on the PK of ceftriaxone in children, none have included severe malnutrition.
1529439|NCT02746276|Drug|Metronidazole|Metronidazole is effective against Giardia, which is common amongst children with SAM; and against other anaerobic infections, including small bowel bacterial overgrowth and Clostridium difficile colitis. Small cohort studies suggest there may be benefits for nutritional recovery. However, metronidazole can cause nausea and anorexia, potentially impairing recovery from malnutrition and may also cause liver and neurological toxicity. Changes in body composition as well as metabolic and drug elimination mechanisms may alter the potential toxicity or effective dose.
1529440|NCT02746263|Drug|IV acetaminophen|
1529441|NCT02746263|Drug|Oral acetaminophen|
1529442|NCT02746263|Drug|Morphine|Patient controlled analgesia
1529443|NCT02746250|Drug|Amitriptyline|The investigator recruits patients who have already discussed and agreed to the amitriptyline treatment with their physician. The patients start the treatment after the investigator have measured them once.
1529444|NCT02746237|Drug|KAR5585 Capsules|Single and multiple ascending doses of KAR5585 (100 mg initial dose)
1529445|NCT02746237|Drug|Placebo Capsules|Single and multiple ascending doses of placebo (100 mg initial dose)
1529446|NCT02746224|Procedure|Initially dissection of inferior mesenteric vein|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1A the surgical technique initially dissects the inferior mesenteric vein (IMV)
1529447|NCT02746224|Procedure|Initially dissection of inferior mesenteric artery|Laparoscopic left hemicolectomy for left colon cancer or laparoscopic low anterior resection for rectal cancer. In the group 1B the surgical technique initially dissects the inferior mesenteric artery.
1529448|NCT02746224|Procedure|Latero-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
1529449|NCT02746224|Procedure|Termino-terminal colorectal anastomosis|The patients who will undergo a colorectal anastomosis will be included in the study 2 and will be randomized to group 2A and group 2B: in group 2A the patients will have a latero-terminal colorectal anastomosis and in group 2B a termino-terminal colorectal anastomosis.
1529450|NCT02746211|Biological|High Titre Influenza virus|High Titre Influenza virus
1529451|NCT02746211|Biological|Medium - High Influenza virus|Medium - High Influenza virus
1529452|NCT02746211|Biological|Medium Low Titre Influenza virus|Medium Low Titre Influenza virus
1529453|NCT02746211|Biological|Low titre|Low titre
1529454|NCT02746198|Other|probiotic dairy drink|
1529455|NCT02746198|Other|acidified milk|
1529456|NCT02746185|Drug|rivaroxaban|rivaroxaban, 15 mg BD (Bis in die) for 3 weeks followed by 20mg OD (Omni die) for 9 weeks
1529457|NCT02746185|Drug|Low-molecular-weight heparin|dalteparin, 200 IU/kg OD for 4 weeks followed by 150 IU/kg OD for 8 weeks
1529458|NCT02746172|Device|Cochlear implant with in-situ audiometry|
1529460|NCT02746146|Other|Systematic use of a prognostic score|The prognostic score is given in Dusseux et al 2015. It will be used as soon as possible after the initiation of dialysis.
1529461|NCT02746133|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
1529462|NCT02746107|Other|decision aid|decision aid with one/two diagrams decision aid with risk over one/five years decision aid with CHA2DS2-VASC risk score 1 to 5 target of the prescription: patient / physician hinself
1529463|NCT02746094|Device|8 bi-weekly LIESWT sessions|"LIESWT = Low-Intensity Extracorporeal Shock Wave Therapy
The treatment protocol consists of eight bi-weekly treatment sessions (weeks 0 ot 4). During each session 3600 shocks at 0.09 mJ/mm are applied. Shocks are applied to the penis shaft at the right corpus cavernosum and the left corpus cavernosum, and at the crura at the right crus and the left crus. 900 shocks are administered to each area. The treatment areas are the same for each session, so that at the end of the full treatment (8 sessions) each area will have received 7200 shocks at 0.09 mJ/mm.
In general, the patient is placed on an examination table. A series of focused shockwaves produced by the electromagnetic transducer are coupled to a patient's penile shaft and crura and are made to converge along the penis/crura volume. The operator controls treatment parameters including shockwave intensity and shockwave rate.
mJ = millijoule."
1529465|NCT02746068|Drug|AXS-02|
1529466|NCT02746068|Drug|Placebo|
1529467|NCT02746042|Drug|Sinupret extract coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
1529468|NCT02746042|Drug|Placebo coated tablets|1 coated tablet 3 times a day for 16-weeks (1-1-1)
1529469|NCT02746029|Other|Clinical examination|
1529470|NCT02746016|Other|Infant Formula supplemented with Oligosaccharides|sole source nutrition
1529471|NCT02746003|Other|Managed Aquifer Recharge water|Rain water will be recharged through slow sand filter and recharge wells into the confined underground aquifer and the surrounding community will abstract the water for drinking and cooking purposes
1529472|NCT02745990|Drug|Recombinant human erythropoietin|rhEPO 500U/kg will be injected from the time of infants enrolled, and until to 32 weeks postmenstrual age.
1529473|NCT02745977|Other|Dairy Free Diet|Dairy Free Diet x 3 stool guaiacs. If positive, dairy is reintroduced to diet.
1529474|NCT02745964|Device|LMA supreme|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
1529475|NCT02745964|Device|I-gel|Anesthesia is maintained using LMA supreme in LMA supreme group or using I-gel in I-gel group according to the randomly allocated groups.
1529476|NCT02745951|Other|Heliox|Half of the study population will be randomly assigned to receive cardioplegia enriched with a 70:30 (Helium:Oxygen) via a D100 pediatric oxygenator. The Heliox itself will need to be administered via an oxygen regulator using a low flowmeter.
1529477|NCT02745951|Other|Standard of care|The other half will be randomized to Nitrogen:Oxygen mixture. This will be done through the standard of care cardioplegia apparatus. There will be no novel interventions administered in this group.
1529478|NCT02745925|Drug|Ibuprofen|
1529479|NCT02745912|Drug|Naltrexone/Bupropion|Naltrexone/Bupropion extended-release tablets.
1529480|NCT02745912|Drug|Metformin|Metformin immediate-release tablet.
1529481|NCT02745899|Dietary Supplement|Cow milk|Ingestion of 240 ml cow milk
1529482|NCT02745899|Dietary Supplement|Soy milk|Ingestion of 240 ml soy milk
1529483|NCT02745886|Drug|metformin 0.85 twice daily for 6 months|
1529484|NCT02745886|Behavioral|Calorie restriction|
1529485|NCT02745873|Drug|Ascorbic Acid|Ascorbic Acid (vitamin-c) 500 mg in tablet form was used.
1529486|NCT02745860|Drug|Selexipag (adult formulation)|One selexipag film-coated tablet of 200 µg
1529487|NCT02745860|Drug|Selexipag (pediatric formulation)|Four selexipag film-coated tablets of 50 µg
1529488|NCT02745847|Radiation|Re-irradiation with SBRT|Patients previously treated with SBRT with relapsed pancreatic cancer will be re-irradiated with SBRT.
1529489|NCT02745834|Other|Gait analysis|Gait will be analysed while participants will walk on a treadmill at different self selected speeds, using the OPTOGait system. Spatiotemporal measures are collected without the use of any markers.
1529490|NCT02745821|Device|Pressure Wire Certus, St. Jude Medical, USA|FFR. CFR and IMR will be measured using the Pressure Wire Certus, St. Jude Medical, USA in target and non-target vessels. Changes in FFR, CFR and IMR post PCI of target vessels will also be recorded.
1529491|NCT02745808|Biological|HUC-MSCs|The subjects will receive intracavernous injection of HUCMSC.
1529492|NCT02745808|Biological|Injectable Collagen Scaffold + HUC-MSCs|The subjects will receive intracavernous injection of the mixture of injectable collagen scaffold and HUC-MSCs.
1529493|NCT02745795|Behavioral|Motivational Interview|Three face-to-face interviews using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
1529494|NCT02745795|Behavioral|Conventional Interview|Three face-to-face interviews without using motivational interview techniques to elicit motivation for adhesion to a diet and physical activity plan intended to loose weight. The interviews will be done at schools with three months intervals.
1529495|NCT02745782|Other|Observational Study|Observational Study
1529499|NCT02745756|Procedure|Autologous Hematopoietic Progenitor Cell Transplant|Autologous Hematopoietic Progenitor Cell (HPC) Transplant (HPCT). Blood stem cells will be collected by apheresis during the induction phase as part of standard treatment. During apheresis, the participant's blood is collected into a machine that filters out the stem cells and the filtered blood is returned to their body. The stem cells will be separated by the type of protein within the cells. Only the stem cells with a protein called CD34 will be used for the stem cell transplant.
1529500|NCT02745756|Biological|KLH and Tumor Lysate Pulsed DC Vaccine|Keyhole limpet hemocyanin (KLH) pulsed dendritic cell (DC) vaccine. Post-transplant vaccine days: +14, +28, +56 (± 10 days), +84 (± 10 days). Vaccines will be administered by intradermal injection of 0.5 mL at two nodal basins.
1529502|NCT02745730|Other|Glucose|
1529503|NCT02745730|Other|Fructose|
1529504|NCT02745730|Other|Sucralose|
1529505|NCT02745730|Other|Allulose|
1529506|NCT02745717|Procedure|IST|ATG 3.5mg/kg/d (Thymoglobuline®, Genzyme) is administrated for 5 days intravenously, and oral CSA is administrated from 5mg/kg/d and adjusted to maintain trough serum concentration of 200-300ng/ml
1529507|NCT02745717|Biological|cord blood transfusion|one unit of cord blood having no more than 2 HLA-A,B and DRB1 mismatches is transfused 24 hours after last dose of ATG administration
1529508|NCT02745717|Drug|Thymoglobuline® and oral CSA|
1529509|NCT02745704|Drug|Peginterferon alfa|peginterferon alfa-2b 80 micrograms/week or peginterferon alfa-2a 180 micrograms/week
1529510|NCT02745691|Other|Surgery|Thoracic surgery for lung cancer
1529511|NCT02745691|Other|Radiochemotherapy|Either chemotherapy or radiotherapy alone or combination of both (either subsequent or concurrent)
1529512|NCT02745691|Other|Targeted therapy|New targeted therapies for lung cancer
1529513|NCT02745691|Other|Immunotherapy|New immunotherapies for lung cancer
1529514|NCT02745678|Drug|Thermosensitive gel rectal formulation|
1529515|NCT02745665|Other|flow mediated dilation (endothelial function)|
1529516|NCT02745665|Other|ABPI|
1529517|NCT02745665|Other|Pulse wave velocity and augmentation index|
1529518|NCT02745665|Other|blood pressure|
1529519|NCT02745665|Other|ramp test|
1529520|NCT02745652|Device|pulsed electromagnetic field|it is a magnetic device for magneto-therapy, it has an appliance, motorized bed, and applicable large solenoids which can be moved in 4 different positions according to the treatment area, and the additional small solenoid for hand treatment with 30 cm diameter
1529521|NCT02745652|Device|Therapeutic ultrasound|Ultrasound is applied using a transducer or applicator that is in direct contact with the patient's skin. Gel is a medium which is used on all surfaces of the head to reduce friction and assist transmission of the ultrasonic waves
1529522|NCT02745639|Radiation|VMAT-SIB|Radiation dose prescribed to PTV2 was 45 Gy (1.8 Gy/fraction), five sessions weekly in 25 daily fractions. A simultaneous boost was delivered on PTV1 with a total dose of 57.5 Gy (2.3 Gy/fraction). Dose-volume histograms (DVHs) were calculated for the PTV1, PTV2 and OARs. Patients were treated only if the relative variations of the bone markers between the images were within 3 mm along the three spatial directions. Planning and delivery processes underwent to systematic independent-check procedures.
1529523|NCT02745639|Drug|XELOX|The prescribed concurrent chemotherapy consisted of oxaliplatin infusion 130 mg/m2 on days 1, 17, 35 and capecitabine 1650 mg/m2 daily (825 mg/m² twice daily, 5 days/week) over all the treatment. An adequate blood count was necessary to start each chemotherapy infusion. Adjuvant chemotherapy was recommended on patients with high risk factors at pathological examination and decision was left to medical oncologists discretion.
1529524|NCT02745626|Device|Appliance|Orthodontic appliance to carry out orthodontic tooth movement.
1529525|NCT02745613|Other|8 weeks of combined exercise intervention|The subjects will undergo an 8 week combined exercise intervention
1529526|NCT02745600|Device|RFA therapy simulator|Computer assisted RFA of liver tumors: Planning, simulation, and follow up,
1529527|NCT02745587|Radiation|radiotherapy|high dose external beam radiotherapy limited to the prostate(bed)
1529528|NCT02745574|Procedure|Combined maneuver|Combined maneuver (Intraperitoneal normal saline infusion and Pulmonary recruitment maneuver): the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity. Then, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
1529529|NCT02745574|Procedure|Intraperitoneal infusion|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the 0.9% normal saline fluid in the abdominal cavity.
1529530|NCT02745561|Drug|Endostatins|Endostatin will be administered at a dose of 7.5 mg/m2/day concurrent with radiotherapy.
1529531|NCT02745561|Drug|Oxaliplatin|Oxaliplatin (135mg/m², d1) will be administered on Day 1 and Day 29 of radiotherapy.
1529532|NCT02745561|Radiation|Radiotherapy|Radiotherapy will be delivered with a daily fraction of 2.0 Gy to a total dose of 60 Gy over 6 weeks.
1529533|NCT02745535|Drug|Sofosbuvir/Velpatasvir/Voxilaprevir|
1529534|NCT02745522|Drug|Oxytocin|
1529535|NCT02745522|Drug|Placebo|
1529536|NCT02745509|Other|Extensive Intraoperative Peritoneal Lavage|Extensive Intraoperative Peritoneal Lavage
1529537|NCT02745496|Procedure|TRUS Biopsy|Standard of Care Treatment
1529538|NCT02745496|Procedure|TRUS/FUSION Biopsy|Interventional Treatment
1529539|NCT02745483|Device|Separable clustered electrodes|patients who signed informed consent, RFA was performed using separable clustered electrodes (Octopus®) in which, inter-tine distances can be flexibly adjusted by an operator.
1529540|NCT02745470|Drug|Lixisenatide|Colorless, transparent liquid contained in a glass prefilled syringe pen-like injection (GLP-1 receptor agonist)
1529541|NCT02745470|Other|Placebo|Normal saline injection before performing fMRI
1529542|NCT02745444|Dietary Supplement|low-calorie formula diet|
1529543|NCT02745444|Dietary Supplement|protein-restricted diet|
1529544|NCT02745431|Drug|Oxytocin|
1529545|NCT02745431|Drug|Placebo|
1529546|NCT02745405|Other|Fat Suit|Participants wear a fat suit.
1529547|NCT02745405|Other|Control Condition|Participants wear same clothing as intervention, but in their own size.
1529548|NCT02745392|Drug|ZP-Zolmitriptan|ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system
1529549|NCT02745392|Drug|Placebo|Placebo patch(es) to match ZP-Zolmitriptan single administration delivered via intracutaneous microneedle patch delivery system (one or two patches)
1529550|NCT02745379|Procedure|BFPSCs+ DFDBA+ PRF|
1529551|NCT02745379|Procedure|DFDBA + PRF|
1529552|NCT02745366|Procedure|BFPSC+FDBA+PRF|
1529553|NCT02745366|Procedure|FDBA+PRF|
1529554|NCT02745353|Drug|naloxegol|
1529555|NCT02745340|Other|Acetate by Citrate substitution and vice versa|substitution of acetate by citrate in dialysis fluid
1529556|NCT02745314|Other|Frailty measurement|Frailty measurement under Fried at el criteria
1529557|NCT02745314|Other|Comprehensive Geriatric Assessment|Multidimensional Geriatric Assessment
1529558|NCT02745301|Other|Collection of urine and bladder tumor specimens|Voided urine (pre- and post surgical) and intraoperative bladder tumor specimens to be processed for the presence of specific biomarkers.
1529559|NCT02745288|Procedure|inferior alveolar nerve block|"A long acting local anaesthetic agent Inj Bupivacaine hydrochloride 0.5% (2 ml) will be given after induction by open mouth technique by landmark method.
The mucobuccal fold will be palpated and traced till coronoid notch. The finger will be moved medially across the retromandibular trigone on internal oblique ridge. The 25G needle will be inserted till bone is felt. 2 ml of 0.5% bupivacaine will be injected slowly after withdrawing needle by 1mm and confirming negative aspiration of blood."
1529560|NCT02745275|Behavioral|Peer-led Health Education|Peer-led health education
1529561|NCT02745262|Other|Collect retrospectively the follow-up data|Collect retrospectively the follow-up data. Each patient is called in order to request data authorization, to complete and track information.
1529562|NCT02745249|Behavioral|Maternal Nutrition Behavior change|
1529565|NCT02745223|Drug|PresbiDrops (CSF-1)|PresbiDrops (CSF-1) is a topical ophthalmic drug.
1529566|NCT02745223|Drug|Placebo|Placebo drops contains the same ingredients as PresbiDrops except for the active ingredients.
1529567|NCT02745210|Device|magnetic resoance imaging|acquisition of 13C spectroscopy in the brain
1529568|NCT02745197|Dietary Supplement|Nutritional Supplement|Participants will take 2 capsules, containing the nutritional supplement, 3 times per day.
1529569|NCT02745197|Dietary Supplement|Placebo|Participants will take 2 capsules, containing a placebo, 3 times per day.
1529570|NCT02745184|Biological|Lung stem cells|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade lung stem cells (LSCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
1529571|NCT02745171|Other|physical therapy|Will be held 15 sessions, 2 times a week, lasting 50 minutes, a physical therapy protocol developed by the Pro-Parkinson Physiotherapy based on the Guide of the Dutch Society of Physiotherapy (Keus, 2004).
1529575|NCT02745132|Other|Neuropsychological evaluation and Brain MRI|"This is a prospective study. The only intervention planned will consist of performing neuropsychological tests and cerebral MRI that will be carried out on a single group cohort at different times.
Notwithstanding, we will record the exposure to DAA to assess any change in neurocognitive function and MRI imaging.
Anti-HCV regimens will be used according to clinical practice as indicated into the current guidelines (1)
(1)European Association for Study of Liver. EASL Recommendations on Treatment of Hepatitis C 2015. J Hepatol. 2015 Jul;63(1):199-236. doi: 10.1016/j.jhep.2015.03.025. Epub 2015 Apr 21. PubMed PMID: 25911336."
1529577|NCT02745106|Procedure|Radiofrequency pulmonary artery denervation|Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
1529578|NCT02745106|Device|Ablation catheter|4MM RF CONDUCTR (MULTI-CURVE) SERIES ABLATION CATHETER Standart procedure for radiofrequency ablation: Radiofrequency ablation of pulmonary artery will be performed with standard electrophysiological catheter and non-fluoroscopic 3D-navigation system. Right heart catheterization (thermodilution method with Swan-Ganz catheter) will be performed before and after procedure. The radiofrequent impact will be performed 2mm after pulmonary artery bifurcation in both right and left main pulmonary artery branches. The radiofrequent impact will be performed at temperature 40-42 C, up to 12 watts and 60 second duration in every ablation point under impedance control.
1529579|NCT02745106|Device|Swan-Ganz catheter for right heart catheterization|"Standart procedure of right catheterization:
punction of right jugular vein with Seldinger technique, introducer placement
insertion of Swan-Ganz catheter via introducer in jugular vein under fluoroscopic control and wave form of monitor's curve.
positioning of swan-ganz catheter in pulmonary artery
direct central hemodynamics measurements: systolic/diastolic/mean pulmonary artery pressure, pulmonary capillary wedge pressure, cardiac output (thermodilution technique)
calculating of indirect parameters (pulmonary vascular resistance)"
1529580|NCT02745093|Drug|Mifepristone|Women at 64-84 days' gestation will use the following dosing regimen: 200 µg mifepristone administered orally in the clinic on Day 1.
1529581|NCT02745093|Drug|Misoprostol|The client will then be given a total of 2400 µg misoprostol tablets to take home, and will be instructed to take 800 μg misoprostol administered sublingually 24-48 hours later at home and to administer a subsequent dose of 400 μg misoprostol sublingually every 3 hours up to a total of four further doses or until expulsion of the products of conception, whichever comes first.
1529582|NCT02745080|Biological|Secukinumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
1529583|NCT02745080|Biological|Adalimumab|Eligible subjects are randomized to one of two treatment arms in a 1:1 ratio
1529584|NCT02745067|Behavioral|enhanced cognitive behavioral therapy|
1529585|NCT02745054|Other|mgt of bleeding concerns/complications of oral anticoagulants|observational study of clincians' management of patients taking oral anticoagulants and having acute significant bleeding or requiring management of bleeding risk before an emergent procedure; observation limited to index hospitalization only
1529586|NCT02745041|Drug|Fibrinogen Concentrate|"Fibrinogen Replacement using Fibrinogen Concentrate as per ROTEM guided treatment algorithm [FIBTEM ≤ A5 10mm]
FIBTEM A5 0mm (Flat Line) = 6g FC FIBTEM A5 1 - 4mm = 5g FC FIBTEM A5 5 - 6mm = 4g FC FIBTEM A5 7 - 8mm = 3g FC FIBTEM A5 9 - 10mm = 2g FC"
1529587|NCT02745041|Other|Cryoprecipitate|"Fibrinogen replacement using Cryoprecipitate as per ROTEM guided treatment algorithm [FIBTEM A5 ≤ 10mm]
FIBTEM A5 0mm (Flat Line) = 20 Units Cryo FIBTEM A5 1- 4mm = 16 Units Cryo FIBTEM A5 5 - 6mm = 14 Units Cryo FIBTEM A5 7 - 8mm = 10 Units Cryo FIBTEM A5 9 - 10mm = 8 Units Cryo"
1529588|NCT02745028|Dietary Supplement|Monosodium glutamate|A single dose of weight adjusted monosodium glutamate will be added at the time of a repeat radionuclide gastric emptying study
1529589|NCT02745015|Procedure|non-surgical periodontal treatment|full-mouth scaling and root planing
1529590|NCT02745002|Device|navigated bronchoscopy|
1529591|NCT02744989|Device|Neuroconn or Neuroelectric tDCS stimulator|Stimulation parameters were chosen in conformity with those for the treatment of schizophrenic symptoms (Brunelin et al, 2012), adapted according to the latest data from the literature and the tDCS operating stimulator. The experimental group will receive the active stimulation: Intensity = 2 mA. Sequence duration = 20 minutes (ramp ud/ramp down 30 seconds). Total number of sessions = 10 (sessions twice daily for 5 days)
1529592|NCT02744989|Device|Sham tDCS|The control group will receive the sham stimulation (placebo) following the same regimen. Sham stimulation consists of a 20 minutes session including 1 minute active stimulation (ramp up/ramp down 30 seconds, 2 mA) at the beginning and ending of the sessions.
1529593|NCT02744976|Drug|Metformin|In order to minimize gastrointestinal discomfort, metformin treatment will be started with a dose of 500 mg p/o once daily, then gradually increased to 2000 mg p/o once daily for 24 months
1529594|NCT02744976|Behavioral|Lifestyle recommendations|Standard lifestyle recommendations
1529595|NCT02744963|Other|Free and convenient medicine access|
1529596|NCT02744950|Procedure|Pulley stitches|
1529597|NCT02744950|Procedure|Intermediate Repair|
1529598|NCT02744937|Drug|Aspirin|aspirin is continued by its regular dosing
1531294|NCT02732548|Other|MIRODERM Application(s)|
1529599|NCT02744924|Behavioral|Physical activity intervention|"The intervention is comprised of 5 steps:
Goal setting: Over a step-counter (smartphone app) participants learn about their daily average step count. They are coached to set individual goals
Fitness assessment: To recommend suitable frequency and intensity of walking program using mapped trails
Structured walking groups: Promoted and communicated via app. Participants can additionally organize walking groups of their own.
Feedback: Participants will see individual and group data over the step-counter app, and they can communicate with others via a communication app. They will be incentivized to reach goals through a gamification approach.
Invite friends: After 12 weeks, participants are encouraged to invite people who fulfil the inclusion criteria to join the project"
1529600|NCT02744911|Device|SpeechVive device|The SpeechVive is a wearable device that plays multi-talker babble noise in one ear while the person wearing it is talking. The noise is voice-activated (only present when the person speaks). The noise does not interfere with the ability to hear communication partners. The noise coming from the device functions as a natural external cue for people with Parkinson's disease to talk more loudly and clearly. Treatment will involve asking the participants to wear the device daily during the treatment period.
1529601|NCT02744911|Behavioral|Telemedicine interaction|Participants will interact with the speech-language pathologist using the telemedicine platform from their home.
1529602|NCT02744911|Behavioral|In person interaction|Participants will interact with the speech-language pathologist in-person at the speech pathologist's office
1529604|NCT02744885|Dietary Supplement|Crave Crush|Crave Crush is a dietary supplement that affects sweet taste receptors on the tongue.
1529605|NCT02744885|Dietary Supplement|Placebo Comparator: Placebo|The placebo tablet is comparable in taste and is comprised primarily of sorbitol.
1529606|NCT02744872|Drug|Felodipine|Felodipine 10 mg once daily or identical placebo
1529607|NCT02744872|Drug|Placebo|Placebo
1529608|NCT02744859|Other|Label Condition|Labels will be presented in front of drinks. We will vary the messaging presented to the consumer.
1529609|NCT02744846|Drug|Antibiotics exposure|
1529610|NCT02744833|Drug|GMI-1271|
1529611|NCT02744833|Drug|Enoxaparin Sodium (Lovenox®)|
1529614|NCT02744807|Other|Chronic endometritis|with or without Chronic endometritis
1529615|NCT02744781|Device|Lumbar disc degeneration; LDD|All MR images, taken at 5 lumbar intervertebral disc levels from the first lumbar (L1) vertebra to the first sacral vertebra (S1), were independently evaluated by 2 experienced orthopedic specialists in a random order using a grading system for LDD assessment. Using a comprehensive grading system for LDD, discs were classified into 5 grades, as described by Pfirrman et al. This system uses characteristics of disc structure, distinction between the nucleus and annulus, MRI signal intensity, and intervertebral disc height for grading, and has been accepted as a standardized and reliable evaluation tool for assessment of MRI disc morphology.
1529618|NCT02744755|Biological|Adalimumab - GP2017|Adalimumab - GP2017
1529619|NCT02744755|Biological|Adalimumab - US licensed Humira|Adalimumab - US licensed Humira
1529624|NCT02744729|Drug|99mTc-3PRGD2|For patients in suspicion of esophagus cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
1529625|NCT02744716|Drug|Aspirin|low dose of Aspirin after operation
1529626|NCT02744716|Device|intrauterine balloon|insert intrauterine balloon after operation
1529631|NCT02744690|Drug|Mitomycin-C (MMC)|Mitomycin-C is routinely applied to the eye prior to trabeculectomy at Menelik II Hospital
1529633|NCT02744664|Procedure|Cryotherapy|After entering the group subject receive Cryotherapy on lung cancer
1529634|NCT02744664|Drug|Icotinib|After Cryotherapy, subjects begin Icotinib administration
1529635|NCT02744651|Device|EUS-FNA|"Please note the text in section Arm description"
1529636|NCT02744651|Device|EUS-Endodrill biopsy|"Please note the text in section Arm description"
1529637|NCT02744638|Other|probiotic yoghurt|verum is a liquid probiotic yoghurt containing all four probiotics as described in the arm description. Study participants consume daily two bottles (125g) during an intervention period of four weeks.
1529638|NCT02744638|Other|chemically acidified milk|Placebo is chemically acidified milk without bacterial strains. Study participants consume daily two bottles (125g) during an intervention period of four weeks (randomly assigned).
1529639|NCT02744638|Drug|Arilin|2 tablets Arilin 500mg for 7 days
1529640|NCT02744625|Drug|Higher doses of vasopressor therapy for a MAP of 75 mmHg|
1529641|NCT02744625|Drug|Lower doses of vasopressor therapy for a MAP of 65 mmHg|
1529642|NCT02744625|Drug|Propofol for light sedation|Propofol for light sedation
1529643|NCT02744612|Drug|Brentuximab Vedotin|Given IV
1529645|NCT02744599|Device|Prompting breaths via recorded voice, vibrating massager, and/or muscle tetany|Prompt volunteer to breathe using device to play recorded voice, massage the body, and/or apply muscle tetany
1529646|NCT02744586|Behavioral|Strengthening Our Vows (SOV)|"Participants, led by a counselor, will discuss options to keep HIV from entering their relationship including both sex partners remaining monogamous, using condoms every time they have sex with outside partners, and being tested together with outside partners to ensure they are HIV negative (Together HIV Free Plan). Participants will discuss options in the event of an outside exposure to HIV including abstaining from having sex with their spouse or by using condoms every time they have sex with their spouse until they can be retested for HIV after 30 days (Protecting my Spouse Plan).
Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners."
1529647|NCT02744586|Behavioral|Good Health Package Plus (GHPP)|Participants, led by a counselor, will discuss how to prevent, screen, and treat neglected tropical diseases (helminths and schistosomiasis), non-communicable diseases (hypertension and diabetes) and diarrheal diseases through basic hygiene and sanitation. The facilitator will demonstrate proper handwashing techniques and chlorination of water and discuss diet and lifestyle changes. Participants will be screened for hypertension, diabetes, schistosomiasis, HIV, syphilis, and trichomonas vaginalis and the presence of sperm (women only). Health problems will be treated or referred. Couples will also be administered questionnaires that record self-report of sexually transmitted infections, number of outside partners, and reports of sex without a condom with outside partners.
1529648|NCT02744560|Dietary Supplement|spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
1529649|NCT02744547|Dietary Supplement|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
1529653|NCT02744521|Other|Symptom-based screening intervention|The objective of this study is to evaluate whether empowering and involving inmate peer educators in TB control has an impact on increasing TB case detection rate and improving treatment success in resource-limited prison settings. In this interventional study, inmate peer educators will be trained about TB, its prevention, and control. Once tested for their capability, peer educators will then provide education about TB, its prevention and control for their fellows every two weeks on a regular basis for one year. They will also undertake routine TB screening using a standardized TB screening protocol to identify presumptive TB cases for a referral.
1529654|NCT02744508|Drug|palonosetron|
1529655|NCT02744508|Drug|palonosetron with dexamethasone|
1529656|NCT02744495|Drug|Betamethasone|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
1529657|NCT02744495|Drug|Droperidol|Prophylaxis if risk score is over 2. Prophylaxis of postoperative nausea and vomiting by betamethasone / Celestene (4mg) and/or droperidol / Droleptan (0.625mg) immediately after cardiac surgery, depending on risk factors in the intervention arm.
1529658|NCT02744482|Drug|risedronate|risedrante tablet (75 mg)
1529659|NCT02744482|Drug|placebo|risedrante placebo tablet (75 mg)
1529660|NCT02744469|Other|No intervention (observational study)|
1529661|NCT02744456|Drug|Losartan|An angiotensin II receptor antagonist drug used mainly to treat high blood pressure.
1529662|NCT02744456|Drug|Amlodipine|A calcium channel blocker and may be used alone or in combination with other antihypertensive and antianginal agents for the treatment of hypertension.
1529663|NCT02744456|Drug|Hydrochlorothiazide|A diuretic medication often used to treat high blood pressure and swelling due to fluid build up.
1529664|NCT02744443|Dietary Supplement|Leucine|
1529665|NCT02744443|Dietary Supplement|Placebo|
1529666|NCT02744430|Drug|Mirabegron|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
1529667|NCT02744430|Other|Placebo|Randomized 1:1 ratio using a randomized block design, stratified by stone size (≤5 mm versus >5 mm) and location (upper versus lower ureter). The randomization will be implemented through a database with software designed by the Director of Research Informatics at the Baylor College of Medicine's Dan Duncan Institute of Clinical and Translational Research. It will be a HIPPA-compliant secure database accessible via internet.
1529668|NCT02744417|Behavioral|Smoking cessation counseling|Multidisciplinary smoking cessation counseling, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures delivered by physicians, psychologist-assisted cognitive behavioural therapy, and counseling provided by dentists during the active phase of the treatment and maintenance session, using motivational interviewing techniques
1529669|NCT02744417|Procedure|Non-surgical periodontal therapy|Full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
1529670|NCT02744417|Drug|Nicotine replacement therapy|Nicotine replacement therapy: chewing gum (Nicorette chewing gum 2-4mg) and patches (Nicorette patches 15-25mg)
1529671|NCT02744417|Drug|bupropion hydrochloride|bupropion hydrochloride 150mg
1529672|NCT02744417|Drug|Varenicline|Varenicline 0,5mg
1529673|NCT02744404|Device|POC EID|
1529674|NCT02744391|Drug|Levodopa|
1529675|NCT02744378|Drug|Tacrolimus 0.1%|This group was randomly allocated to receive topical Tacrolimus 0.1% for 3 consecutive weeks
1529676|NCT02744378|Drug|Clobetasol 0.05%|This group was randomly allocated to receive topical Clobetasol 0.05% for 3 consecutive weeks
1529677|NCT02744365|Other|Observational|"All women of the biobank have provided:
blood samples (plasma, serum and Buffy-coat)
urine samples
demographic and clinical data (maternal age, BMI, smoking status, obstetrical and medical history)
mean arterial blood pressure
ultrasound examination (datation of pregnancy at recruitment, uterine arteries doppler, placental volume, nuchal translucency in the majority of the cases)
access to medical record (for pregnancy/delivery outcomes, newborn birthweight, gestational age at delivery)"
1529680|NCT02744339|Drug|Riociguat|Adempas up-titrated to max. 1.5mg TID
1529681|NCT02744339|Drug|Placebo|Placebo sham-titrated TID
1529682|NCT02744326|Behavioral|Text message reminders|Patients assigned to the intervention group will receive a series of 7 to 10 text message reminders to schedule or attend their follow-up appointment.
1529683|NCT02744300|Behavioral|BABI-2 Lifestyle Intervention|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips.
1529684|NCT02744287|Biological|BPX-601|Autologous T cells genetically modified with retrovirus vector containing PSCA-specific CAR and an inducible MyD88/ Cluster Designation (CD)40 (iMC) co-stimulatory domain
1529685|NCT02744287|Drug|Rimiducid|Dimerizer infusion to activate the iMC of the BPX-601 cells for improved persistence
1529686|NCT02744274|Other|Verum acupuncture|"Patients will lay supine. The acupuncture physicians will disinfect the selected acupuncture points with alcohol and then needle them (30 gauze, 1.5-inch, Yuguang, Taiwan) with a plastic device is fixed needle body, so that the patient achieves a de qi sensation, which is often described as a pressure or achiness feeling. The acupuncture point will be bilateral Quchi, Waiguan, hegu, baxie, Zusanli, Yanglingquan, Sanyinjiao, Taichong, bafeng. Acupuncture needles will be left in place for approximately 30 minutes, and every 10 minutes twisting stainless steel needle to get a de qi."
1529687|NCT02744248|Drug|IOP Injection|IOP Injection 20 mg Fe/ml, intravenous injection
1529688|NCT02744248|Drug|0.9% normal saline|0.9% normal saline 10 ml, intravenous injection
1529689|NCT02744235|Device|Polysomnography Data|
1529690|NCT02744235|Device|Jawbone UP®|
1529691|NCT02744235|Device|Fitbit Charge ®|
1529692|NCT02744222|Biological|BCD-054 180 mcg|180 mcg intramuscularly once every two weeks
1529693|NCT02744222|Biological|Avonex®|30 mcg intramuscularly once a week
1529694|NCT02744222|Biological|BCD-054 240 mcg|240 mcg intramuscularly once every two weeks
1529695|NCT02744222|Other|Placebo|intramuscularly once a week (0,5 ml)
1529696|NCT02744196|Biological|Acellbia|Acellbia is rituximab biosimilar, monoclonal antibody which binds CD20.
1529697|NCT02744196|Drug|Placebo|Placebo solution will look identical to the Acellbia solution.
1529698|NCT02744196|Drug|Methotrexate|
1529699|NCT02744183|Behavioral|Exercise|Moderate intensity exercise
1529700|NCT02744183|Behavioral|Breakfast|Breakfast consumption
1529701|NCT02744183|Behavioral|Maintain habitual habits|Normal physical activity and dietary behaviors maintained
1529702|NCT02744170|Device|1 continuous flow oxygen supplementation|This oxygen Supplementation is used in special order
1529703|NCT02744170|Device|2 demand delivery liquid oxygen supplementation|This oxygen Supplementation is used in special order
1529704|NCT02744170|Device|3 demand delivery oxygen supplementation via concentrator|This oxygen Supplementation is used in special order
1529705|NCT02744157|Behavioral|Longterm effects after a structured lifestyle program|present study was to describe a structured intervention to reduce cardiovascular risk in a clinical setting and to study the effects of the program on lifestyle habits and quality of life in individuals at risk after six months and one year.
1529706|NCT02744131|Drug|Oral contraceptive pill combination of ethyl estradiol and Cyproterone acetate|
1529707|NCT02744131|Drug|Metformin 1500mgs per day|
1529708|NCT02744118|Other|5A's Model|"The adapted 5A's model will include the following elements:
Ask the patient about their marijuana use
Advise every patient to quit/reduce marijuana use using clear, specific personalized advice
Assess factors affecting choice of behavior and behavior change
Assist abstinence/reduction in in marijuana use using behavior change techniques to aid the patient
Arrange follow-up for ongoing assistance and support, and to adjust treatment plans"
1529709|NCT02744118|Other|Healthy Internet Use Model|"The Healthy Internet Use Model provides a framework for conversations between pediatric practitioners and their adolescent patients. It focuses on 3 key areas of social media behavior:
Balance
Boundaries
Communication"
1531427|NCT02731612|Other|Placebo|Inactive substance
1529710|NCT02744105|Dietary Supplement|Spirulina|Spirulina in a dose of 250 mg/kg/day will be given orally for 3 months.
1529719|NCT02744079|Behavioral|Low carbohydrate diet|45 subjects will be randomized to a dietary arm consisting of a complete, prepared very low carbohydrate diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal
1529720|NCT02744079|Behavioral|Low fat diet|20 subjects will be randomized to a dietary arm consisting of a complete, prepared low fat diet, delivered to their homes, for the interval between positive breast biopsy and surgical tumor removal.
1529721|NCT02744066|Device|NEATCAP|Neonates will be sized and fitted to wear the non-invasive novel hearing protection device over a set period of time in the NICU. Vitals will be monitored.
1529722|NCT02744053|Procedure|Dynamic Contrast Enhanced Molecular Resonance Imaging (DCE-MRI)|Participant receives DCE-MRI before they start anthracycline therapy, when they finish receiving anthracycline therapy, and when they finish receiving neoadjuvant therapy. Each DCE-MRI takes 45 minutes to an hour total, and is performed like a normal MRI.
1529723|NCT02744053|Procedure|Tc99m Sestamibi Molecular Breast Imaging (MBI)|Participant receives DCE-MRI before they start anthracycline therapy, when they finish receiving anthracycline therapy, and when they finish receiving neoadjuvant therapy. MBI scan performed about 5 minutes after Tc99m sestamibi injection. MBI scan takes about an hour.
1529724|NCT02744053|Drug|99mTc Sestamibi|Before each MBI scan, participant receives an injection of 99mTc Sestamibi.
1529725|NCT02744040|Drug|ART initiation at time of HIV diagnosis|Immediate ART initiation
1529726|NCT02744040|Drug|ART at 24 weeks|ART initiation 24 weeks after enrollment
1529727|NCT02744027|Other|Dynamic Contrast Enhanced Magnetic Resonance Lymphangiography (DCMRL)|Following completion of the T2 lymphatic mapping, contrast agent administered will be calculated based on weight. Investigators will use dosage of 0.1cc/kg of contrast which will be injected by hand simultaneously into each lymphatic node (LN) at a rate of 0.5-1 cc per min. One minute after the injection, scanning will be initiated using high spatial and temporal resolution magnetic resonance angiography (syngo time-resolved angiography with stochastic trajectories [TWIST]) sequence. The sequence parameters will be adjusted with a time delay such that a complete volume will be acquired approximately every 20-60 seconds. This will be followed by additional scans with a high-resolution navigator gated 3-dimensional flash inversion recovery (IR) sequence. In all subjects the scan area covered the neck, chest, and abdomen as caudal as feasible.
1529728|NCT02744027|Other|Heavy Weighted T2 Imaging (T2W)|Magnetic Resonance imaging (MRI) will be performed and T2W MRI lymphatic mapping will be performed using a respiratory navigated and cardiac gated 3 dimensional turbo spin echo sequence with pre-set parameters. Scan time varies from 2-5 min depending upon the size of the subject.
1529729|NCT02744027|Other|Lymph Node Access|"The procedure will be performed under sedation and anesthesia if participants are aged 16 or under. The procedure will be performed with local anesthesia for participants aged over 16 years old.
Using ultrasound guidance two inguinal lymph nodes (one each side) will be directly accessed with 25-gauge spinal needles attached to a short connector tubing. A shallow angle for puncture will be used to create a long subcutaneous tract to assist in stabilizing the needle. A small amount of an oil-based contrast or water soluble contrast will be injected under fluoroscopy guidance to confirm the correct position of the needles inside the lymph nodes. After stabilizing the needle, the subjects will be transferred into the MRI suite."
1529730|NCT02744014|Behavioral|Add-on Therapy for Axial Spondyloarthritis|
1529731|NCT02744001|Other|Low Added Sugar Diet|1-week intake of Low Added Sugar Diet 3 day rotating menu
1529732|NCT02743988|Drug|Oxygen|Adapt inspired oxygen to achieve desired SpO2 target range
1529736|NCT02743949|Drug|Vonoprazan|Vonoprazan over-encapsulated capsules
1529737|NCT02743949|Drug|Esomeprazole|Esomeprazole over-encapsulated tablets
1529738|NCT02743949|Drug|Esomeprazole Placebo|Esomeprazole placebo-matching capsules
1529739|NCT02743936|Device|Nasal cannula|Placement of nasal cannula under non-invasive positive pressure ventilation mask
1529740|NCT02743936|Device|Non-invasive positive pressure ventilation|Non-invasive positive pressure ventilation
1529746|NCT02743910|Other|ptDNA|Pre-operative blood samples for ptDNA will be collected at the time of diagnosis/prior to NAT, post-cycle 1/pre-cycle 2 of NAT, after all NAT/immediately before surgery, and post-operatively at 6, 12, 24, and 36 months, and annually thereafter if funding allows.
1529747|NCT02743910|Other|Tissue sample|Representative tissue sample will be collected from the diagnostic biopsy (in all participants) and definitive surgery (if available).
1529748|NCT02743897|Drug|Zepatier|
1529749|NCT02743884|Device|Esophageal Warming|30 minutes of warming from circulating water at about 42 degrees C through an esophageal heat exchanger.
1529750|NCT02743884|Device|Esophageal Cooling|30 minutes of cooling from circulating water at about 7 degrees C through an esophageal heat exchanger.
1529764|NCT02743832|Procedure|Resection for primary lesion and cervical lymph node dissection|Resection for primary lesion and cervical lymph node dissection are performed in the early-stage oral squamous cell carcinoma.
1529765|NCT02743832|Procedure|Resection for primary lesion|Resection for primary lesion is performed in the early-stage oral squamous cell carcinoma.
1529766|NCT02743819|Drug|Pembrolizumab and Ipilimumab combination|
1529767|NCT02743806|Drug|Vedolizumab|Vedolizumab IV infusion
1529768|NCT02743793|Procedure|Blood Draw|
1529769|NCT02743780|Drug|MGV354 ophthalmic suspension|
1529770|NCT02743780|Drug|MGV354 placebo|Inactive ingredients used as placebo comparator
1529771|NCT02743767|Procedure|Introducing five different treating adaptations|Immediate Bag-valve mask ventilation after administering of muscle relaxants, optimized preoxygenation, introducing of a preinterventional checklist, increased usage of video laryngoscopy and immediate hand alternately if frustrated intubation.
1529772|NCT02743754|Other|Standard therapy|The standard of care for improving oxygen delivery to the kidney. These may include blood transfusions for anemia, treatment of low blood pressure and oxygen for low blood oxygen levels.
1529773|NCT02743754|Other|Hyperbaric Oxygen|The standard of care therapies and in addition will be treated in the hyperbaric chamber within 12 hours of surgery. There will be 4 hyperbaric oxygen treatments in 48 hours (1 every 12 hours), each treatment will last 90 minutes with 100% oxygen at 2.4 ATA.
1529774|NCT02743741|Drug|Lutetium-177 Octreotate|Radiopharmaceutical
1529775|NCT02743728|Device|Magnetic Resonance Imaging|Anatomical and Diffusion Tensor Imaging Analysis.
1529776|NCT02743728|Device|Transcranial Magnetic Stimulation|Assessment of brain (cortical) excitability
1529777|NCT02743728|Behavioral|General Movement Assessment|Spontaneous movement assessment of infant while lying in unperturbed state.
1529778|NCT02743715|Device|Active tDCS (transcranial direct current stimulation)|An electrical current of 2mA is delivered to the cathode, positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in 30-minute sessions, 5 days a week (Mondays through Fridays) for four consecutive weeks.
1529779|NCT02743715|Device|Sham tDCS|The cathode is positioned bilaterally in the cranial region corresponding to the supplementary motor cortex, with the anode positioned in the deltoid (neutral region), in a 30-minute session, 5 days a week (Mondays through Fridays) for four consecutive weeks, without delivery of the electric current.
1529780|NCT02743702|Other|RESPIRATORY PHYSIOTHERAPY|"The protocol designed was composed of the following exercises:
supine position: inhalation and exhalation with abdominal and thoracic pressures. 5 times
lateral decubitus, with incentive spirometer lung inflation are made on right/left sides. 3 sets on each side
sitting position, with the body leaning slightly forward, head and shoulders bent inwardly directed. It inspire called for 3 times, sent off in air through the mouth, after that the child was coughing
diaphragmatic breathing in a sitting position: after a slow exhalation requested, child should steam a mirror with his mouth slightly open. 3 replications
in a sitting position, with help of an ambu bag, we made inflations. Repeated 3 times
exercises of upper member coupled to respiratory rhythm: shoulder flexion and extension was carried out during the inspiratory phase and the extension and adduction of them during expiration. 3 times"
1529781|NCT02743702|Other|USUAL THERAPIES|
1529782|NCT02743663|Procedure|Bronchodilator response|Bronchodilator (Salbutamol - dose dependent on participant prescription) to wheezing subjects. 15 minutes after bronchodilator, spirometry and FOT repeated.
1529783|NCT02743663|Procedure|Allergy Skin Test|Child will be tested for allergies to 17 different allergens, and positive (histamine) and negative (glycerin) controls, for a total of 19 allergens.
1529784|NCT02743663|Procedure|Multiple-Breath Washout|Facemask in children 3-5 yrs, Wash-in phase: medical air inhaled during tidal breathing until steady state. Bias flow switched to 100% oxygen. Wash-out phase: patient breathes in 100% oxygen until nitrogen levels reach ~2%. Each test in duplicate and average is calculated.
1529785|NCT02743663|Procedure|Forced Oscillation Technique|Sterile mouthpiece attached to FOT device. Patient is tested seated with noseclips and mouthpiece. FOT device produces oscillations at different frequencies (from that flow into lungs. Device measures resistance and reactance in lungs.
1529786|NCT02743663|Procedure|Spirometry|Forced exhale manoeuvre completed by participant into flow meter, measuring forced exhale volumes and speed.
1529787|NCT02743663|Drug|salbutamol|Given during bronchodilator response.
1529788|NCT02743663|Procedure|Nasal Brush|Nasal brush of 1 inferior turbinate to collect epithelial cells. Collected on either nare, choice dependent on how clear the nare is (i.e. no mucous, no nasal mucosal edema, no major structural impediments).
1529789|NCT02743663|Procedure|Blood sample|8mLs of venous blood collected using a butterfly needle of appropriate gauge. Blood sample used to collect CBC values, total IgE, serum, DNA, plasma, and whole blood.
1529790|NCT02743663|Procedure|Basophil activation test|Collect basophils from whole blood sample, and expose cells to food allergens in flow cytometry machine to measure allergic response, if any.
1529791|NCT02743663|Procedure|Nasal swab|Gentle swabbing of both nasal openings to collect mucous sample for analysis of microbial contents (i.e. bacteria, virus, fungi).
1529792|NCT02743650|Dietary Supplement|Sodium bicarbonate|The initial dose of sodium bicarbonate is 0.3 mEq/kg/d. If a subject meets the protocol criteria, the dose will be increased to 0.6 mEq/kg/d.
1529793|NCT02743637|Drug|SDX-7320|SDX-7320 is a synthetic copolymer-drug conjugate of a novel MetAP2 inhibitor.
1529794|NCT02743624|Procedure|Variation of the level of pressure support during the mechanical ventilation|The pressure support of the patient was changed form the baseline to 20 cmH20 and then stepwise decreased to 2 cmH20,
1529795|NCT02743611|Biological|BPX-701|TCR modified T cells
1529796|NCT02743611|Drug|Rimiducid|dimerizer that activates suicide gene in TCR modified T cells
1529798|NCT02743585|Device|Filmarray Blood Culture ID (BCID) panel|The BCID panel is an FDA-approved nucleic acid amplification test (based on nested polymerase chain reaction) which detects Gram positive, Gram negative, the major Candida species and antimicrobial resistance markers (mecA for methicillin resistance, van A/B for vancomycin resistance, blaKPC for KPC carbapenemase) directly from positive blood cultures in < 1 - 1.5 hours
1529799|NCT02743585|Device|Rosco Diagnostica ESBL/carbapenemase screen kit|These kits are CE-marked (Approved in the European Union) rapid chromogenic tests for extended-spectrum beta-lactamase / carbapenemase detection from both blood cultures and cultured bacterial colonies.
1529800|NCT02743572|Other|iron sucrose-1|iron sucrose-1 group with PN of iron supplementation of 100μg/kg/d
1529801|NCT02743572|Other|iron sucrose-2|iron sucrose-2 group with PN of iron supplementation of 200μg/kg/d
1529802|NCT02743572|Other|iron sucrose-3|iron sucrose-3 group with PN of iron supplementation of 300μg/kg/d
1529803|NCT02743572|Other|iron sucrose-4|iron sucrose-4 group with PN of iron supplementation of 400μg/kg/d
1529804|NCT02743559|Device|Mechanical Stimulation using whole body vibration|All participants will undergo whole body vibration (WBV) by standing on the LivMD WBV platform on 5 consecutive mornings
1529807|NCT02743520|Device|The Lifestar Act III|
1529810|NCT02743455|Drug|ISA-720|
1529811|NCT02743455|Biological|MVA Smallpox Vaccine|MVA (Modified Vaccinia Ankara) Smallpox Vaccine is a highly attenuated live vaccinia virus.
1529812|NCT02743455|Biological|MVA-BN Yellow Fever Vaccine|
1529813|NCT02743455|Other|Placebo|Placebo
1529814|NCT02743455|Biological|YF Vax 17D Strain|
1529815|NCT02743442|Device|da Vinci® Si™|
1529816|NCT02743429|Drug|dinutuximab beta|"Up to 5 cycles of continuous infusion of ch14.18/CHO is administered at a dose of 10 mg/m2/day over 10 days (total dose 100 mg/m2/cycle).
Cycle duration: 35-days."
1529817|NCT02743416|Other|ECG screening (Zenicor-ECG) for atrial fibrillation|Determination of the biomarker NT-proBNP together with single-lead ECG screening for silent atrial fibrillation.
1529818|NCT02743403|Device|Neurodyn Portable activeTENS, IBRAMED®|Randomization and secret Allocation active TENS (GI / n = 27)
1529819|NCT02743403|Device|Neurodyn Portable placeboTENS, IBRAMED®|Randomization and secret Allocation placebo TENS (GII / n = 27)
1529820|NCT02743403|Device|Carboxyderm S20-1C|Randomization and secret Allocation control group (CG / n = 27).
1529821|NCT02743390|Biological|Infliximab|Monoclonal antibody biologic drug that inhibits tumour necrosis factor alpha (TNF-α), 3 mg/kg for 2 hours (250mL)
1529822|NCT02743390|Other|Saline|Saline for 2 hours (250mL)
1529825|NCT02743364|Other|Laboratory Biomarker Analysis|Correlative studies
1529826|NCT02743364|Other|Placebo|Given PO
1529827|NCT02743364|Other|Quality-of-Life Assessment|Ancillary studies
1529828|NCT02743364|Drug|Simvastatin|Given PO
1529831|NCT02743338|Behavioral|Sleep Restriction|Behavioral component of CBT-i. Sleep restrictions includes curtailing bed time to match sleep time as registered during the first week of treatment, and expanding bed time contingent upon increased sleep efficiency, until optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
1529832|NCT02743338|Behavioral|Sleep Compression|Behavioral component of CBT-i. Sleep compression includes gradually compressing bed time over several weeks to approach sleep time as registered during the first week of treatment, and stopping compression when optimal balance between sleep time and sleep efficiency is reached. The first five weeks, therapist support is provided via written messages. The next five weeks, patient works independently. At the end of tenth treatment week, therapist and patient make plan for future.
1529833|NCT02743338|Behavioral|Additional CBT-i components|After 5+5 weeks of either Sleep Restriction or Sleep Compression, a randomized sample from each treatment Group is offered additional components of CBT-i, such as Stimulus Control, Cognitive Restructuring, Relaxation and Visualization for 10 weeks, without therapist support. Component allocation based on individual analysis.
1529834|NCT02743325|Procedure|SVT ablation by ALARA protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The usage of CartoUnivuTM allows a seamless combination of a fluoro image and Carto® 3 System maps into a single view.
1529835|NCT02743325|Procedure|SVT ablation by conventional protocol|Catheter ablation is a procedure that uses radiofrequency energy (similar to microwave heat) to destroy a small area of heart tissue that is causing arrhythmias. Destroying this tissue helps restore your heart's regular rhythm. The convention Ablation procedure works without a 3D navigation System.
1529836|NCT02743312|Device|Balance-Based Torso-Weighting (WT)|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss.
1529837|NCT02743312|Device|Sham Weights (SW)|Following assessment of an individual's directional instability, small weights are applied to a vest-like garment to correct balance loss. The garment is then taken by another investigator and the actual weights are replaced with sham weights.
1529838|NCT02743312|Device|Fitbit Flex|Potential effect on participants' physical activity to see their own step count using this wrist-worn remote monitoring device.
1529839|NCT02743299|Device|Handivent Ventilator|CPR with use of a turbine-driven ventilator (Handivent)
1529840|NCT02743286|Behavioral|Frequent sit-to-stands|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 15 2-minute standing interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
1529841|NCT02743286|Behavioral|Walking breaks|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 2-minute walking interruptions, 3 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
1529842|NCT02743286|Behavioral|Stand more|Participants will visit the clinic for a 6-hour monitoring period. Following a 1-hour sitting run-in period, participants will sit for an additional 5-hour period including 5 10-minute standing interruptions, 1 per hour. Baseline, mid-point, and end-of-visit bathroom breaks for urine sample collection will be conducted, with additional bathroom breaks allowed as needed.
1529843|NCT02743260|Drug|pitavastatin|
1529844|NCT02743260|Drug|Metformin|
1529845|NCT02743260|Drug|digoxin|
1529846|NCT02743260|Drug|Adefovir|
1529847|NCT02743260|Drug|sitagliptin|
1529848|NCT02743247|Drug|Tacrolimus|
1529849|NCT02743247|Drug|Mycophenolate mofetil|
1529850|NCT02743234|Other|Fecal microbiota transplantation|FMT follows 4-10 days of vancomycin 125 mg x 4 daily
1529851|NCT02743234|Drug|Fidaxomicin|Fidaxomicin 200 mg x 2 daily for 10 days
1529852|NCT02743234|Drug|Vancomycin|Vancomycin 125 mg x 4 daily for 10 days
1529853|NCT02743221|Drug|Trifluridine/tipiracil hydrochloride (S 95005)|film-coated tablets containing 15mg of trifluridine and 7.065mg of tipiracil hydrochloride, or 20mg of trifluridine and 9.42mg of tipiracil hydrochloride, taken orally twice a day at the dose of 35 mg/m2/dose, until a discontinuation criterion is met
1529854|NCT02743221|Drug|Capecitabine|Capecitabine film-coated tablets containing 150 mg or 500 mg of capecitabine taken orally twice a day at the dose of 1250 mg/m2/dose, until a discontinuation criterion is met
1529855|NCT02743221|Drug|Bevacizumab|concentrate for solution for infusion containing 25mg/ml of bevacizumab administered intravenously at the dose of 5 mg/kg, until a discontinuation criterion is met
1529856|NCT02743221|Drug|Bevacizumab|concentrate for solution for infusion containing 25mg/ml of bevacizumab administered intravenously at the dose of 7.5 mg/kg, until a discontinuation criterion is met
1529857|NCT02743208|Device|Short stem hip arthroplasty (SHA)|Furlong Evolution femoral stem
1529858|NCT02743208|Device|Total hip arthroplasty (THA)|Furlong H-A.C. femoral stem
1529859|NCT02743195|Dietary Supplement|Polyphenol/prebiotic blend|
1529860|NCT02743182|Drug|Pegylated interferon alfa-2a|
1529861|NCT02743169|Other|Spatially-Optimized|Spatial analysis of retrospective data will be used to optimize the placement of ambulances to decrease response time from the time the call is received until the time the ambulance arrives at the patient's location.
1529862|NCT02743156|Procedure|IVUS-guided PCI|intravascular ultrasound-guided percutaneous coronary intervention
1529863|NCT02743156|Procedure|Angiography-guided PCI|Angiography-guided percutaneous coronary intervention. This is the conventional treatment.
1529864|NCT02743143|Behavioral|Exercise therapy|
1529865|NCT02743143|Other|Follow-up care as usual|
1529866|NCT02743130|Dietary Supplement|Blackcurrant Nectar|Consumption of a single dose (300 ml)
1529867|NCT02743130|Dietary Supplement|Lingonberry Nectar|Consumption of a single dose (300 ml)
1529868|NCT02743130|Dietary Supplement|Reference|Consumption of a single dose (300 ml)
1529869|NCT02743117|Biological|Monovalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU strain of monovalent influenza vaccine will be administered as intranasal spray on Day 1.
1529870|NCT02743117|Other|Placebo|A single dose of placebo matched to monovalent influenza vaccine will be administered as intranasal spray on Day 1.
1529871|NCT02743104|Drug|Ketamine|
1529872|NCT02743104|Drug|Propofol|
1529873|NCT02743104|Drug|midazolam and atropine|
1529874|NCT02743104|Drug|Lidocaine|
1529877|NCT02743065|Device|HepaSphere with 50-75mg Doxorubicin|HepaSphere with 50-75mg Doxorubicin
1529913|NCT02742779|Drug|GDC-0310|Participants will receive single or multiple ascending doses of GDC-0310 orally in fasted or fed state.
1529878|NCT02743052|Drug|Anticoagulation treatment.|Details of anticoagulation treatment information will be gathered including low molecular-weight heparin (enoxaparin 1 mg/kg) vs. NOAC (rivaroxaban 15 or 20 mg), vs. warfarin (target INR2.0-3.0) or no use of anticoagulation per physicians' decision and patients' conditions.
1529879|NCT02743039|Behavioral|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
1529880|NCT02743026|Behavioral|FOXY|This study will evaluate an arts-based HIV prevention program, Fostering Open eXpression among Youth (FOXY) in the NWT, Canada that works with Northern and Indigenous youth to promote sexual health and reduce exposure to HIV/STI. FOXY explores sexual health, HIV/STIs, sexuality and healthy relationships with young women in the NWT. The program's goal is to use arts-based methods and peers to facilitate education and foster more open expression and communication regarding sexual health and sexuality. FOXY uses arts-based approaches in program delivery; for example, drama techniques are used to facilitate discussion and learning about healthy relationships and making positive choices in realistic sexual scenarios.
1529881|NCT02743013|Drug|CHF 5993 100/6/12,5 pMDI|
1529882|NCT02743013|Drug|CHF 5993 100/6/12,5 DPI Test 1|
1529883|NCT02743013|Drug|CHF 5993 100/6/12,5 DPI Test 2|
1529884|NCT02743013|Drug|CHF 5993 100/6/12,5 pMDI replicate|
1529885|NCT02743013|Drug|CHF 5993 100/6/12,5 pMDI with Valved Holding Chamber|
1529886|NCT02742987|Drug|Ticagrelor|Ticagrelor 90 mg twice daily
1529887|NCT02742987|Drug|Clopidogrel|Clopidogrel 150 mg once daily
1529888|NCT02742987|Drug|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
1529889|NCT02742974|Device|FloTrac™ and EV1000™|Interventions to improve cardiovascular performance will be made in all patients whose cardiovascular function is sub-optimal in accordance with routine clinical management during trauma resuscitation. Patients who meet inclusion criteria will be assigned to the intervention or control arm of the study based on the process outlined in the protocol. Patients assigned to the intervention arm will have intra-operative hemodynamic monitoring performed by the anesthesia staff and cardiovascular interventions will be based off of the algorithm described in the protocol. Members of anesthesia or the surgical team can initiate interventions as indicated during routine ICU care or intra-operatively.
1529890|NCT02742961|Other|Peripheral nerve block|A physician billing code for deposition of a local anesthetic solution around an anatomically defined nerve or nerve plexus
1529891|NCT02742948|Drug|ceftriaxone|IV ceftriaxone (2g) will be given to all participants
1529892|NCT02742935|Biological|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
1529893|NCT02742922|Behavioral|Culturally adapted therapy (C-MAP)|C-MAP is a brief problem focused therapy, comprising of six sessions delivered within three months. C-MAP is a manual assisted intervention based on the principles of CBT .In this intervention there is an evaluation of the self-harm attempt, crisis skills, problem solving and basic cognitive techniques to manage emotions, negative thinking and relapse prevention strategies.
1529894|NCT02742909|Drug|rhBNP|rhBNP was administered as a continuous infusion for 24 hours before or after placebo
1529895|NCT02742909|Drug|placebo|normal saline as a placebo was administered as a continuous infusion for 24 hours
1529896|NCT02742896|Other|Erectile dysfunction|"The changes of erectile function by using official questionnaire-The International Index of Erectile Function (IIEF)-5 1 year after conversion to sinus rhythm.
The changes of cognitive function by using validated assessment form-The Montreal Cognitive assessment (MoCA) 1 year after conversion to sinus rhythm."
1529897|NCT02742883|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with diffuse intrinsic pontine glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
1529898|NCT02742870|Other|Correlation of MRI results with clinical characteristics of the adnexal mass|"Quantitative analysis of the magnetic resonance images realised with the Ingenia 3 Tesla Engine (Philips) and the Area 1,5 Tesla Engine (Siemens), based on the ADC cartography.The post-processing will be realized with the Syngo Onco Care application of Siemens, that allows an histogram analysis of the ADC of all sections of the adnexal mass, as opposed to a section per section approach with the Region of Interest (ROI) method.
The results will be correlated with the clinical data regarding the adnexal mass: anatomo-pathology status (malignancy and aggressiveness of the tumor) and the gynecological follow-up."
1529899|NCT02742857|Biological|BQ-A Peptide Extract|BQ-A Peptide Extract
1529900|NCT02742857|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cells
1529901|NCT02742857|Device|Transcranial Laser Therapy|Transcranial Laser Therapy
1529902|NCT02742857|Device|Median Nerve Stimulator|Median Nerve Stimulator
1529903|NCT02742844|Biological|APZ2 application|Application of IMP on patients wound.
1529904|NCT02742831|Behavioral|Intervention|"The intervention group will receive a 6-session intervention. The overview of the 6 sessions is as follows:
Behavioral chain analysis of episode where parent felt stressed with child and episode where things went well. Identification of sources of interpersonal support.
Stress relief techniques. Identification of short and long-term goals. Development of a detailed crisis plan.
Problem solving techniques.
Emotional regulation. Exercises to identify moods and explore connections between feelings, thoughts, and behavior.
Positive parenting, review of common and specific parenting challenges, child development, short and long-term effects of different discipline approaches.
Reflection, repeat behavioral chain analysis. Update crisis plan."
1529905|NCT02742831|Other|Control|The families in the control group will be contacted by a member of the study team 6 times in 12 weeks to approximate the frequency of contact that the intervention group receives. The study team member will check in with families on the telephone or in person and will help them connect with clinic and community resources as needed.
1529906|NCT02742818|Device|522 upper body blanket, Bair Hugger, 3M|
1529907|NCT02742818|Device|635 full access underbody blanket, Bair Hugger, 3M|
1529908|NCT02742805|Dietary Supplement|Vitamin D (4,000 IU/day)|High Dose of 4,000 IU/day.
1529909|NCT02742805|Dietary Supplement|Vitamin D (400 IU/day)|Low Dose of 400 IU/day.
1529910|NCT02742805|Drug|Omalizumab|Standard of care dose.
1532310|NCT02725606|Biological|GW003|subcutaneous
1529914|NCT02742779|Drug|Placebo|Participants will receive placebo matched to GDC-0310 as single or multiple oral dose in fasted or fed state.
1529915|NCT02742766|Drug|GSK3008356|This intervention is available as 0.5, 1, 5, and 25 mg white oral tablet. The formulation will be used to administer dose of 5 mg, 10 mg, 30 mg, 45 mg, 75 mg, 90 mg, 125 mg, 180 mg, 200 mg, and 250 mg total daily dose during the study.
1529916|NCT02742766|Drug|Placebo|This intervention is available as white oral tablet. The formulation will be used as a matching placebo for GSK3008356 during the study.
1529917|NCT02742753|Other|Data collection|Data will be collected retrospectively linking regional patient-level data prospectively captured in real-world clinical setting with mandatory national healthcare registries from 2004 to 2013.
1529918|NCT02742740|Behavioral|Chemo Buddy|The Study Buddy ECA acts as an advisor to patients on chemotherapy regimens, promoting protocol adherence and retention, providing anticipatory guidance and answering questions, serving as a conduit to capture information about complaints or adverse events, providing a venue for communicating about updates.
1529919|NCT02742727|Biological|anti-CD7 CAR-pNK cells|The allogeneic NK cells (NK-92 cell line for clinical use) are engineered to contain anti-CD7 attached to TCRzeta, CD28 and 4-1BB signaling domains. These modified cells are called chimeric antigen receptor NK cells with specificity for CD7.
1529920|NCT02742714|Device|PillCam SBC system|The PillCam SBC system to be tested in this study, is a new system composed of capsule, Data recorder and a new software Pillcam Desktop Software (version 9.0). The main features of the SBC capsule are panoramic field of view and adaptive frame rate customized for complete coverage of both small bowel and colonic mucosa.
1529921|NCT02742701|Other|diagnosis|Measurement of glycosuria
1529922|NCT02742688|Dietary Supplement|Pyrus pyrifolia var. culta(Makino) NaKai peel extract|Pyrus pyrifolia var. culta(Makino) NaKai peel extract(4g/day)
1529923|NCT02742688|Dietary Supplement|Placebo|Placebo(4g/day)
1529924|NCT02742675|Drug|Bicalutamide|Given orally
1529925|NCT02742675|Drug|goserelin acetate|Given subcutaneously or as an injection
1529926|NCT02742675|Drug|flutamide|Given orally
1529927|NCT02742675|Drug|leuprolide acetate|Given subcutaneously or as an injection
1529928|NCT02742675|Drug|triptorelin|Given subcutaneously or as an injection
1529929|NCT02742675|Procedure|Definitive Treatment|surgery to remove prostate or radiation therapy to the prostate.
1529933|NCT02742649|Drug|Fixed Combination|continuous elution from the Ocular Insert over 70 days.
1529934|NCT02742649|Drug|Bimatoprost|continuous elution from the Ocular Insert over 70 days. This is an active control arm.
1529935|NCT02742649|Drug|Timolol|continuous elution from the Ocular Insert over 70 days. This is an active control arm.
1529936|NCT02742636|Device|Foley catheter|The aim of this study is to evaluate if direct removal of the urine catheter after an LH (total laparoscopic hysterectomy and laparoscopic supracervical hysterectomy) is associated with similar (or better) outcomes compared to delayed catheter removal after surgery.
1529938|NCT02742610|Behavioral|Mindfulness with Contingency Management|
1529939|NCT02742610|Behavioral|Active Control|
1529940|NCT02742597|Behavioral|TIP / IMPACT Plus Care Coordination|The intervention will involve the patient attending an interdisciplinary team meeting, either through the Ontario Telemedicine Network's teleconferencing technology or in person, along with their caregiver(s), the referring practitioner, inter-professional (IP) teams and home care coordinators to discuss and uncover the patient's condition covering a diverse range of medical, functional and psycho-social issues and the development of a patient-centred treatment plan. The care plans are documented, shared, implemented and monitored by an assigned nurse from the program.
1529941|NCT02742584|Procedure|Cough Stress Test|Varying bladder volumes during cough stress test.
1529942|NCT02742571|Other|non applicable|
1529943|NCT02742558|Biological|Cholvax|Incepta vaccine Limited, a leading pharmaceutical company in Bangladesh is now producing the OCV, Cholvax with technological support from International Vaccine Institute (IVI), which meets international Good Manufacturing Practice (GMP) standards and WHO production guidelines. Cholvax has the same formulation as ShancholTM in terms of strains and formulation.
1529944|NCT02742558|Biological|Shanchol|The vaccine is manufactured by Shantha Biotechnics, in Hyderabad, India and is prequalified by the WHO. Shanchol™ is available in a single dose vial.This vaccine is used as two dose regimen.
1529945|NCT02742545|Behavioral|MayoExpertAdvisor|Access to MayoExpertAdvisor (MEA) in the electronic medical record (EMR). MEA will provide patient-specific knowledge and treatment suggestions for patients with hyperlipidemia, atrial fibrillation, and/or heart failure via a clickable tab in the Mayo Clinic EMR.
1529948|NCT02742519|Drug|ivacaftor|
1529949|NCT02742519|Drug|Placebo|
1529950|NCT02742506|Other|Electroencephalography (EEG)|EEG will be performed to assess brain activity in response to sounds of different nature, including music and the given name of the registered person
1529951|NCT02742493|Other|0.028 bonded to canines|lower fixed canine and canine retainer (0.028 stainless steel bonded to canines) and upper removable Hawley (Intervention A)
1529952|NCT02742493|Other|0.027 7-strand bonded to all 6|lower fixed canine to canine retainer (7-strand Twistflex 0.027 bonded to all six anterior teeth) and upper removable Hawley (Intervention B)
1529953|NCT02742493|Other|removable Hawley-type|lower Hawley-type and upper Hawley removable retainer (Control)
1529954|NCT02742480|Drug|Dabigatran|
1529955|NCT02742480|Drug|Acenocoumarol|
1529956|NCT02742467|Drug|Perindopril plus Amlodipine|
1529957|NCT02742467|Drug|Perindopril plus Hydrochlorothiazide|
1529958|NCT02742467|Drug|Amlodipine plus Hydrochlorothiazide|
1529963|NCT02742428|Device|Systematic ascites evacuation|Systematic ascites evacuation via indwelling catheter inserted into abdominal cavity, sutured to the skin. Drainage performed by the patient, on demand with day limit of 2000ml, in ambulatory settings.
1529964|NCT02742428|Procedure|Acute paracentesis.|Evacuation of a large (>5000ml) volume of ascites via single abdominocentesis. Allowed in observational arm only, in case of acute symptoms concerned with ascites.
1529965|NCT02742428|Behavioral|Interview.|Interview according to provided chart in order to collect data concerning symptoms, co-morbidities.
1529966|NCT02742428|Behavioral|Quality of life.|Patients will be asked to fill in a quality of life questionnaire (EORTC-C15-PAL) before randomization and 7 days later.
1529967|NCT02742428|Behavioral|Nutritional status.|Patients will be asked to fill in (together with a physician) a questionnaire to assess risk of malnutrition (SGA) before randomization and 7 days later.
1529968|NCT02742415|Behavioral|Caring Hand Massage|Caring Hand Massage is a hand massage therapy program with several steps and techniques.
1529969|NCT02742402|Other|Diagnostic imaging|Abdominal ultrasound, followed by abdominal computed tomography when necessary
1529970|NCT02742402|Other|Observation|Observation for 6 to 8 hours. After observation period repeated clinical examination and repeated blood test for calculation of Adult Appendicitis Score is done.
1529971|NCT02742389|Other|Preprocedure Telephone Call|The participants will receive a phone call from the investigators 1 week before their testing to talk about the procedure and answer any questions that patients may have . The investigator calling the participant will document the duration of the phone call and any questions asked by the participant
1529972|NCT02742376|Other|Soft surface|A sponge rectangle used in physiotherapy will be placed on the floor,
1529973|NCT02742376|Other|Floor|A marked path on the floor where the subject is instructed to walk.
1529974|NCT02742376|Other|Kyboot shoes|Special shoes will be worn by the subject.
1529975|NCT02742363|Other|Collecting data|
1529976|NCT02742350|Device|IMT - POWERbreathe Plus Light Resistance®, SP, BR|POWERbreathe Plus Light Resistance®, SP, BR
1529977|NCT02742324|Drug|Ruxolotinib|Ruxolitinib is administered orally twice a day (bid) everyday in 28-day treatment cycles. The starting dose is 10 mg BID and may go up to 20 mg BID. Ruxolotinib therapy starts on Cycle 1 day 1.
1529978|NCT02742324|Drug|peg-IFN alpha -2a|Peg-IFN-alpha-2a is administered subcutaneously once a week. The doses tested are 45, 90 and 135 mcg/week. .Peg-IFN-alpha-2a therapy starts at Cycle 1Day 15.Of note, Peg-IFN-alpha-2a will only be started if the platelet count is ≥ 50x109/L at C1D15.
1529979|NCT02742311|Procedure|Endoscopic disectomy|Endoscopic discectomy is an established method for treatment of lumbar disc herniation. Edoscopic discectomy provides a safe and minimal access corridor for lumbar discectomy. The technique also allows early postoperative mobilization and faster return to work.
1529982|NCT02742285|Drug|Artemether + lumefantrine|A single adult dose of artemether-lumefantrine will be administered on a unique occasion together with food. Venous and capillary blood samples will be collected at 6 to 10 time points, as defined before drug administration with each volunteer.
1529983|NCT02742259|Device|Blood Draw|Blood draws only - non-diagnostic, non-treatment
1529984|NCT02742246|Behavioral|Individual clinician-provided CBT|Individual clinician-provided CBT
1529985|NCT02742246|Behavioral|CBT4CBT|CBT computer program assisted therapy
1529986|NCT02742233|Drug|saxagliptin|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.
Treatment Period: Participants will receive saxagliptin with regular treatment"
1529987|NCT02742233|Drug|placebo|"Qualifying Period: Participants will receive regular treatment for diabetic ulcer without DPP4i.
Treatment Period: Participants will receive placebo with regular treatment"
1529988|NCT02742220|Other|Isometric Handgrip Training Group|Intervention period will last eight weeks. Experimental group will perform three sessions per week of home-based handgrip exercise. The exercise protocol will consist of four unilateral sets (dominant arm) with two minutes of isometric contraction, with 30% of maximum voluntary contraction, and four minutes of interval between sets. Patients will receive a diary to record the sessions and report difficulties during the training. Visits will be scheduled at weeks 1 and 5 to provide feedback to individuals, discuss possible problems during the training and adjust the intensity of the exercise. In addition the patients be recommended to increase daily physical activity levels, and weekly, there will be phone contacts with the patients to reinforce the exercise recommendations.
1529989|NCT02742220|Other|Control Group|Intervention period will last eight weeks. Patients will be recommended to increase daily physical activity levels, and weekly, there will be phone contacts to reinforce the recommendations.
1529990|NCT02742207|Other|No intervention|
1529991|NCT02742194|Dietary Supplement|Dry extract of ginger|Restrictive diet plus three capsules of 200 mg of dry extract of ginger (5% active ingredient) to be taken three times a day for six months.
1529992|NCT02742194|Dietary Supplement|Placebo|Restrictive diet plus three capsules of 200 mg of cellulose to be taken three times a day for six months.
1529993|NCT02742181|Drug|Alvimopan|Subjects diagnosed with a post operative ileus after surgery will be given alvimopan
1529994|NCT02742181|Other|Control Group|Standard postoperative care
1530036|NCT02741856|Drug|Capecitabine|For more information please see the arm descriptions section.
1530037|NCT02741856|Radiation|Radiotherapy|For more information please see the arm descriptions section.
1530038|NCT02741843|Behavioral|Patient Education|
1530070|NCT02741661|Other|No intervention. Observational study|No intervention
1530102|NCT02741531|Other|saline solution|Saline solution will be used to partially fill patients' bladders
1529995|NCT02742168|Radiation|99mTc-3PRGD2|"Diagnostic group：For patients in suspicion of breast cancer, single intravenous bolus injection of nearly 0.3 mCi/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and lesions SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
Efficacy evaluation group：patients firstly diagnose with malignant lesions ,and prepare to chemotherapy(including neoadjuvant chemotherapy) or radiotherapy.the same dose of 99mTc-3PRGD2 will be intravenously injected into the patients before treatment ,the second period,the sixth period( almost three months after the initial treatment)，whole-body planar and lesions SPECT/CT to assess the value of 99mTc-3PRGD2 in evaluation of cancers."
1529998|NCT02742142|Other|water as placebo|topical application of water as a placebo in the control arm
1529999|NCT02742142|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
1530000|NCT02742129|Drug|Nebulized Sodium Nitrite|Inhaled, nebulized inorganic sodium nitrite vs. inhaled, nebulized placebo at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
1530001|NCT02742129|Drug|Placebo|Inhaled, nebulized placebo vs. inhaled, nebulized inorganic sodium nitrite at a dose of 80 mg (or maximally tolerated dose) administered at a minimum of 4 hours apart, three times per day, during the active part of the day.
1530002|NCT02742116|Genetic|DNA screening before Pregnancy|"Saliva/swab shall be collected from couple for Hereditary Disease DNA screening test. Blood sample shall be taken by venipuncture of women for Fragile X carrier screening A pre-test questionnaire will be conducted to assess subject's knowledge, views and preferences in receiving expanded carrier screening, choice of having concurrent or sequential screening, factors affecting their choices, anxiety level, and their willingness to pay for the test.
A post-test self-administered questionnaire shall be filled in by the patient on receiving the test results.
Couples who receive a screen positive result shall be subsequently referred to Queen Mary Hospital for joint counselling by clinical geneticist and gynaecologist. This consultation shall be audiotaped or videotaped."
1530003|NCT02742103|Biological|CSL_112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
1530004|NCT02742103|Other|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
1530005|NCT02742090|Drug|TGR-1202|
1530006|NCT02742077|Device|Robotic-assisted peripheral vascular intervention|Remote delivery and manipulation of guidewires and rapid exchange catheters during percutaneous vascular interventions.
1530007|NCT02742064|Other|Cogito Companion Mobile Phone Application|
1530008|NCT02742051|Drug|Everolimus|Neoadjuvant endocrine therapy
1530009|NCT02742051|Drug|Letrozole|Neoadjuvant endocrine therapy
1530010|NCT02742051|Drug|Fluorouracil|Neoadjuvant chemotherapy
1530011|NCT02742051|Drug|Epirubicin|Neoadjuvant chemotherapy
1530012|NCT02742051|Drug|Cyclophosphamide|Neoadjuvant chemotherapy
1530014|NCT02742025|Other|Inclusion visit|This visit takes place between days -15 and -7 preceding a coronarography scheduled for Day 0. It is part of standard care and corresponds to a required cardiology consultation.
1530015|NCT02742025|Other|Nurse consultation|This visit takes place on the same day as the inclusion visit and includes practical advice concerning the hospital stay, explanations concerning the surgical act and practical advice on its implementation, information on the length of stay and after. An explanatory booklet concerning the surgical procedure is provided to the patient.
1530016|NCT02742025|Other|Telephone contact|A nurse will telephone the patient 72h to 48h before the coronarography scheduled for day 0. During the telephone conversation the nurse will assess the patient's knowledge about his/her pathology, his/her examination and the course of hospitalization. The nurse will answer any questions and if needed provide further information.
1530017|NCT02742025|Procedure|Coronarography on day 0|This coronarography is scheduled as part of the patient's routine care. This is not an experimental intervention under evaluation.
1530018|NCT02742012|Other|the study is observational|the study is observational
1530019|NCT02741986|Other|Risk estimation|"Physicians will be asked to provide their risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for the same patients that IPS is producing the scores. Physicians will provide scores both before and after reviewing the risk scores produced by the IPS.
The IPS system will generate risk scores (ranging from 0 to 100) for postoperative complications prior to surgery and immediately after the surgery for patients taken care by the physicians enrolled in the study."
1530020|NCT02741973|Other|Yoga|
1530021|NCT02741973|Other|School sport|
1530022|NCT02741960|Drug|metformin|500 mg metformin three times daily
1530023|NCT02741960|Drug|placebo|500 mg placebo three times daily
1530024|NCT02741947|Drug|Levodopa Benserazide Madopar|Madopar 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
1530025|NCT02741947|Drug|Levodopa Benserazide Teva Italia|Levodopa benserazide Teva 100+25mg and 200+50mg, tablet, tid e qid, for four weeks
1530026|NCT02741921|Device|VivaSight DL|intubation using VivaSight DL tube
1530027|NCT02741921|Device|conventional double-lumen tube|intubation using conventional double-lumen tube
1530028|NCT02741908|Behavioral|Calorie counting diet|
1530029|NCT02741908|Behavioral|Fixed diet plan|
1530030|NCT02741895|Behavioral|Fitbit monitoring|Patients will be fitted with a Fitbit after surgery, which will monitor steps and active minutes for the duration of hospitalization.
1530031|NCT02741882|Other|Questionary|Questionary with clinical, demographic and behavior outcomes at the pregnancy period
1530032|NCT02741869|Device|photodynamic therapy (Ondine: MRSAid™)|Photodisinfection using MRSAid™ for the decolonization of S. aureus in hemodialysis patients
1530033|NCT02741856|Drug|Carboplatin|For more information please see the arm descriptions section.
1530034|NCT02741856|Drug|Paclitaxel|For more information please see the arm descriptions section.
1530035|NCT02741856|Drug|Cisplatin|For more information please see the arm descriptions section.
1530039|NCT02741817|Drug|Aspirin|The intervention has been described previously in both arms individually. Group A will receive 20mg of soluble Aspirin and group B with 75mg of soluble Aspirin. As this is a crossover study, all patients will fall under both groups throughout the duration and be un-blinded.
1530040|NCT02741804|Dietary Supplement|BBH-1001 Brain Health Supplement|Treatment with supplement consisting of turmeric, fish oil, vitamin D and green tea extract OR placebo.
1530041|NCT02741804|Other|Lifestyle Intervention|All patients will be given lessons on 6 areas of lifestyle: nutrition, physical activity, meditation, sleep hygiene, cognitive activity, and social activity.
1530042|NCT02741804|Dietary Supplement|Brain Health Placebo|Treatment with placebo consisting of soybean oil
1530043|NCT02741791|Drug|AXS-05|AXS-05 taken daily for 6 weeks.
1530044|NCT02741791|Drug|Bupropion|Buproprion taken daily for 6 weeks.
1530045|NCT02741778|Procedure|Minimally invasive group|In this group, all manipulations are finished by laparoscopy and thoracoscopy.
1530046|NCT02741778|Procedure|Open group|Right lateral position, Traditional thoracotomy through the 7th intercostal incision.
1530047|NCT02741765|Behavioral|Sham rTMS|Subjects will participate in daily sessions of sham-rTMS
1530048|NCT02741765|Device|Real rTMS|Subjects will participate in a combination of rTMS
1530049|NCT02741765|Behavioral|Supervised aerobic exercise|
1530050|NCT02741752|Procedure|Decortication|cortical bone perforation
1530051|NCT02741739|Drug|REGN1033|
1530052|NCT02741726|Device|acupoint stimulation|Electric stimulation was given through electrode attached to acupoints
1530053|NCT02741726|Device|no stimulation|patients were only attached electrodes without electric current
1530054|NCT02741713|Procedure|"PECS Pectoralis 1 and 2 Blocks"|"An interscalene and a PECS Pectoralis 1 and 2 block will be performed on the subjects."
1530055|NCT02741713|Procedure|Interscalene Block|An interscalene block will be performed on the subjects.
1530056|NCT02741713|Procedure|Sham Block|
1530057|NCT02741713|Drug|Solution for Injection in Interscalene Block|20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine
1530058|NCT02741713|Drug|Solution for Injection in Sham Block|Lidocaine 1%
1530059|NCT02741713|Drug|Solution for Injection PECS Blocks|10mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS1 location and 20mL of 0.25% bupivacaine with 1:400,000 epinephrine and 1:600,000 clonidine dosed at the PECS2 location
1530060|NCT02741700|Behavioral|Improvement of Medication Adherence|The investigators have developed a storytelling intervention for African-Americans with gout, to address barriers to optimal gout management and provide cues for better disease management. The objective of this study is to assess the efficacy of a novel storytelling intervention in Veteran's own voices to improve medication adherence and patient outcomes in African-American Veterans with gout.
1530061|NCT02741687|Drug|Sitagliptin|Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) > 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
1530062|NCT02741687|Drug|Placebo|Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
1530063|NCT02741687|Drug|Supplemental insulin (insulin lispro)|"Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.
For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin lispro
BG between 221-260 mg/dL; 3-5 units of insulin lispro
BG between 261-300 mg/dL; 4-6 units of insulin lispro
BG between 301-350 mg/dL; 5-7 units of insulin lispro
BG between 351-400 mg/dL; 6-8 units of insulin lispro
BG > 400 mg/dL; 7-9 units of insulin lispro"
1530064|NCT02741687|Drug|Supplemental insulin (insulin aspart)|"Supplemental insulin aspart will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.
For subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin lispro
BG between 221-260 mg/dL; 3-5 units of insulin lispro
BG between 261-300 mg/dL; 4-6 units of insulin lispro
BG between 301-350 mg/dL; 5-7 units of insulin lispro
BG between 351-400 mg/dL; 6-8 units of insulin lispro
BG > 400 mg/dL; 7-9 units of insulin lispro"
1530065|NCT02741687|Drug|Long acting basal insulin (insulin detemir)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:
Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change
Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day
Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day
Fasting and pre-meal BG <100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
1530066|NCT02741687|Drug|Long acting basal insulin (insulin glargine)|"Long acting basal insulin therapy will be provided as needed, and will be given once daily, at the same time of day. Participants with blood glucose (BG) >180 mg/dL= start detemir at 0.2 units per kg weight per day and will follow the following adjustment schedule:
Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change
Fasting and pre-meal BG between >180-240 mg/dl: increase detemir or glargine dose by 10% every day
Fasting and pre-meal BG >241 mg/dl: increase detemir or glargine dose by 20% every day
Fasting and pre-meal BG <100 mg/dl: reduce detemir or glargine by 20% or stop if patient is already on less than 0.1 units/kg of body weight"
1530071|NCT02741648|Device|Near Infrared Spectroscopy|INVOS 5100C Cerebral/Somatic Oximeter is an FDA-approved device used to measure renal and mesenteric tissue oxygenation, as defined by regional oxygenation saturation levels (rSO2). Two probe site monitoring will be used to evaluate differential tissue bed oxygenation. Adhesive sensor probes are applied to the periumbilical area for mesenteric monitoring and to the flank area for renal monitoring.
1530072|NCT02740543|Drug|Fluticasone propionate HFA 220|Subjects will take two (2) puffs of Fluticasone propionate HFA 220 twice a day.
1530073|NCT02740543|Drug|Placebo|
1530074|NCT02740530|Device|Magstim® Rapid 2 machine|See Arms description
1530076|NCT02740465|Behavioral|Anxiety Inventory for Respiratory Disease (AIR)|An initial version of the AIR was developed through a mixed-methods approach to item development, incorporating both emic and etic perspectives. This included an extensive review of extant anxiety scales (etic perspectives) and in-depth qualitative interviews with patients with COPD and self-reported anxiety (emic perspectives). AIR has ten items on a scale from 0 to 3. It provides a score of 0-30. High score indicates elevated level of clinically relevant anxiety symptoms.
1530077|NCT02740465|Behavioral|Hospital Anxiety and Depression Scale (HADS)|The Hospital Anxiety and Depression Scale (HADS), a self-assessment scale, was developed to detect states of depression, anxiety and emotional distress amongst patients who were being treated for a variety of clinical problems.
1530078|NCT02740452|Device|ligamys technique|Ligamys technique (device) or standard technique
1530079|NCT02740452|Other|standard technique (anatomic reconstruction)|Ligamys technique (device) or standard technique
1530080|NCT02740439|Other|Avocado|The intervention meals will contain 1 large avocado.
1530081|NCT02740439|Other|Control|The control meals will be isocaloric to the intervention meals but will not contain avocado.
1530082|NCT02740426|Drug|Pirarubicin|single immediate intravesical dose of pirarubicin (THP) intravesical therapy (THP 40 mg for 30 min) within 24 hours of ureteroscopy.
1530083|NCT02740400|Procedure|EBUS-GS|The equipment for EBUS-GS includes super-thin bronchoscope BF-P260F, endobronchial ultrasonic system EU-M30S, ultrasonic probe UM-S20-17S, and guided sheath kit K201. All facilities are provided by Olympus Co. The EBUS-GS procedure was performed by thoracic surgeons. The patient was in supine position, under general anesthesia, and provided ventilatation through laryngeal mask. First, the operator placed super-thin bronchoscope into the bronchus of interest, inserted the probe covered with GS through a work channel. Later, adjusted the bronchoscope and probe to obtain classical ultrasonic graphs. The assistant fixed the bronchoscope, pulled the probe out, and placed the brush and biopsy forceps, respectively, through the GS. This process was assisted using x-ray fluoroscope or not.
1530084|NCT02740400|Procedure|CT-TTNB|The devices for CT-TTNB includes Lightspeed VCT spiral CT(GE co.) and Quickcore(COOK Co.) biopsy kit. The kit includes a sheath(5cm in length and 16G in outer diameter) and a automatic biopsy needle(15cm in length and 18G in outer diameter). The patient stays in supine, prone or lateral position according to the lesion's location. The first chest CT scan is performed to confirm the location of the lesion and make an optimal entry point. Then, after sterilization and 2% lidocaine local anesthesia, the sheath is stabbed into chest wall through the entry point. The second CT scan is performed to make sure that the sheath stays in proper angle and depth. The operator places the needle through the sheath and enter the lesion. Then fire the biopsy needle and repeat the procedure twice or third time. The last CT scan is conducted to determine whether pneumothorax or hemorrhage occurred.
1530085|NCT02741622|Behavioral|High aerobic intensity training (HIT)|One training session, high aerobic intensity training (HIT) at 90-95 % of the maximal heart rate (HRmax)
1530086|NCT02741622|Behavioral|Long slow distance training (LSD)|One training session, long slow distance training (LSD) at 70 % of the HRmax
1530087|NCT02741609|Device|Borrelia Diagnostic Test|The ALSI BDT is a high-yield in vitro cultivation method for Borrelia burgdorferi from venous whole blood samples.
1530090|NCT02741583|Other|altitude rehabilitation program|altitude exposure
1530091|NCT02741583|Other|rehabilitation program|Rehabilitation at low altitude
1530098|NCT02741557|Drug|DTG|DTG is provided as a white, film-coated, round tablet containing DTG 50 mg, debossed with SV 572 on one side and 50 on the other side. Subjects will receive a single oral dose of DTG 50 mg tablet with 240 mL of water.
1530099|NCT02741557|Drug|RPV|RPV is provided as a white to off-white, film-coated, round, biconvex tablet containing RPV 25 mg, debossed with TMC on one side and 25 on the other side. Subjects will receive a single oral dose of RPV 25 mg tablet with 240 mL of water.
1530100|NCT02741557|Drug|DTG/RPV FDC|DTG/RPV FDC is provided as a pink, film coated, oval biconvex tablet containing FDC of DTG 50 mg and RPV 25 mg, debossed with SV J3T on one face. Subjects will receive a single oral dose of DTG/RPV 50 mg/25 mg FDC tablet with 240 mL of water.
1530101|NCT02741531|Other|Bladder filled with saline solution|Patients in this arm will have their bladders filled with 150 cc of saline solution.
1530105|NCT02741505|Device|Actigraph|Participants will be asked to wear an actigraph
1530106|NCT02741492|Procedure|Transversus Abdominis Plane Block|Continuous Nerve Block
1530107|NCT02741492|Procedure|Sham Block|Continuous Sham Catheter
1530108|NCT02741479|Other|Airplane Test|"The airplane test requires the subject to bend forward, bringing the upper body and one leg horizontal, making a T position with the body with the arms out to the sides while in single-leg stance; they then bend the supporting leg, bringing the finger tips towards the floor, followed by straightening the supporting leg and bringing the arms back out to the sides. This motion is repeated five times on each leg per trial. The airplane will be performed to a metronome to standardize performance time"
1530109|NCT02741466|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. Formulation number - SR16-01.
1530110|NCT02741453|Procedure|Standard Practice|
1530111|NCT02741453|Procedure|Bilateral IJ Ultrasound Scanning|
1530112|NCT02741427|Other|Conventional toothpaste|The participants should brush their teeth with conventional toothpaste for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on their toothbrushes, use dental floss, but not mouth rinse.
1530113|NCT02741427|Other|Whitening toothpaste|The subjects should brush teeth with whitening toothpaste containing blue pigment for 90 seconds, twice per day, during two weeks.They should place a pea-size amount of toothpaste on toothbrushes, use dental floss, but not mouth rinse.
1530114|NCT02741427|Other|10% carbamide peroxide|"The subjects should dispense the bleaching gel at night into the trays (maxillary and mandibular) and to insert them to cover at least the anterior teeth for a period of 4 h per day, over a 2-week period. Both arches should be bleached at the same time. During the period of bleaching, volunteers should receive the same toothpaste used by G1, in other words, without whitening agents, to standardize their oral hygiene regimen"
1530115|NCT02741414|Device|The result of H pylori culture based on gram staining and enzyme activity testing|This intervention aimed at patients with the positive result of 13C-urea breath test. Patients with negative result of H pylori culture was H pylori culture negative group. Patients with positive result of H pylori culture were belonged into the first successful eradication group and the refractory infection of H. pylori group.
1530116|NCT02741414|Device|The result of 13C-urea breath test after treatment based on the selection of clarithromycin, levofloxacin, metronidazole, amoxicillin，tetracycline，furazolidone and the dose of esomeprazole|The intervention focused on the results from the result of 13C-urea breath test after treatment. The first successful eradication group and the refractory infection of H. pylori group were treated according to the antibiotic susceptibility testing and CYP2C19 gene polymorphism. Eight weeks after treatment, a 13C-urea breath test was performed on patients. The first successful eradication group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients with positive in 13C-urea breath tests after the second standardized treatment.
1530117|NCT02741414|Device|The result of Amoxicillin resistance in vitro based on antibiotic susceptibility testing|The intervention focused on the results from the result of Amoxicillin susceptibility testing in vitro. In this study, the investigators selected the patients with Amoxicillin resistance from the first successful eradication group and the refractory infection of H. pylori group.
1530118|NCT02741401|Other|Usual post-operative care|Usual post-operative care concerning patients who underwent surgery because of gastrointestinal malignancy
1530119|NCT02741401|Other|Hand-foot massage|Hand-foot massage administered during 5 consecutive days postoperatively by trained volunteers, concerning patients who underwent surgery because of gastrointestinal malignancy
1530120|NCT02741388|Drug|selinexor|
1530121|NCT02741388|Drug|Rituximab|
1530122|NCT02741388|Drug|Dexamethasone|
1530123|NCT02741388|Drug|Oxaliplatin|
1530124|NCT02741388|Drug|Cisplatin|
1530125|NCT02741388|Drug|Cytarabine|
1530126|NCT02741388|Drug|Gemcitabine|
1530127|NCT02741375|Device|Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA)|All patients underwent at least 6-h NIRS monitoring using a Somanetics 5100c (Invos oximeter cerebral/somatic Troy, MI, USA) cerebral oximeter in order to determined cerebral oximetry changes.
1530128|NCT02741362|Other|Intravenous injection of Stromal Vascular Fraction Cells (SVF) containing ADSCs|
1530129|NCT02741362|Other|Lipoaspiration|
1530130|NCT02741336|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"Cognitive-behavioral therapy is a short-term, focused psychotherapy for a wide range of psychological and behavioral issues including depression, anxiety, anger, and non-compliance. The focus of the intervention is on how one thinks, behaves, and communicates in real time, as opposed to a focus on one's early childhood experiences. The therapist assists the patient in identifying specific distortions and biases in thinking and provides guidance on how to modify these beliefs. CBT helps the patient learn effective self-help skills that are used in homework assignments that ultimately help change the way one thinks, feels and behaves. The
￼ intervention is action-oriented, practical, rational, and helps the patient gain independence and effectiveness in dealing with real-life issues. Techniques utilized in CBT-I include psychoeducation, sleep hygiene, cognitive restructuring, stimulus control, sleep restriction, and relaxation training."
1530131|NCT02741336|Behavioral|Self-Monitoring|
1530134|NCT02741310|Drug|Placebo|Placebo for Group A (Placebo Arm)
1530135|NCT02741310|Drug|Sumatriptan|Sumatriptan for Group A (Placebo Arm)
1530136|NCT02741310|Drug|Placebo|Placebo for Group B (AMG 334 Arm)
1530137|NCT02741310|Drug|Sumatriptan|Sumatriptan for Group B (AMG 334 Arm)
1530138|NCT02741310|Drug|AMG 334|AMG 334 for Group B (AMG 334 Arm)
1530139|NCT02741297|Device|Spinal Cord Stimulation (SCS) System|Boston Scientific (BSC) PRECISION SCS System with MultiWave Technology
1530140|NCT02741284|Drug|Room air|
1530141|NCT02741284|Drug|10L Oxygen by nonrebreather mask|
1530142|NCT02741271|Drug|MF/F 100/10 mcg BID|mometasone furoate/formoterol fumarate (MF/F) administered by metered-dose inhaler (MDI) as 100/10 mcg twice daily (BID)
1530143|NCT02741271|Drug|MF 100 mcg BID|mometasone furoate (MF) MDI, administered as 100 mcg BID
1530144|NCT02741271|Drug|Albuterol/Salbutamol PRN|Short-acting beta agonist to be used as needed (PRN) for the relief of asthma symptoms
1530145|NCT02741271|Drug|Prednisone/Prednisolone|Oral systemic corticosteroid to be used for acute asthma worsening per investigator discretion
1530146|NCT02741258|Device|Mepitel Film|Placement of Mepitel Film to prevent skin toxicity
1530147|NCT02741258|Drug|skin cream|cream to treat skin erythema due to radiotherapy
1530148|NCT02741245|Drug|Ezetimibe 10 mg|
1530149|NCT02741245|Drug|Rosuvastatin 2.5 mg|
1530150|NCT02741245|Drug|Placebo for Ezetimibe|
1530151|NCT02741245|Drug|Placebo for Rosuvastatin|
1530152|NCT02741232|Drug|Lidocaine 1% with epinephrine 1/400000|
1530153|NCT02741232|Other|sham block|
1530154|NCT02741219|Drug|Normal saline|Control Group receives normal saline bolus after delivery
1530155|NCT02741219|Drug|Dexmedetomidine|Dex Group receives dexmedetomidine bolus 0.5mcg/kg after delivery
1530156|NCT02741219|Drug|Sufentanil|sufentanil PCA after surgery
1530157|NCT02741219|Drug|Sufentanil and dexmedetomidine|sufentanil combined with dexmedetomidine PCA after surgery
1530158|NCT02741206|Behavioral|Bellevue ROSE Intervention|
1530159|NCT02741206|Behavioral|Psycho-education session and usual, Standard of care Control|Psycho Education and usual, standard of care
1530160|NCT02741206|Behavioral|One Psycho-education session and usual, standard of care Control|
1530161|NCT02741193|Device|The Magstim Rapid2,|"Transcranial Magnetic Stimulation, which is a microprocessor-controlled machine which delivers both single and repetitive transcranial magnetic stimulation (TMS).
single and repetitive transcranial magnetic stimulation (TMS). TMS will be applied as single pulses to determine motor evoked potentials (MEPs), there will be no modulation of cortical excitability."
1530164|NCT02741167|Procedure|CRS and HIPEC|During CRS, all visible peritoneal tumors are removed. Consequently micrometastasis are removed with hyperthermic intraperitoneal chemotherapy
1530165|NCT02741154|Drug|induction with aromataze inhibitor|letrozole 2.5mg once daily start in the first day of menses for 5days
1530166|NCT02741154|Drug|HMG|HMG 300 IU injection once daily start at first day of menses with follow up by trans vaginal ultrasound (TVUS ) till at least three follicles reach 14 mm in diameter
1530167|NCT02741154|Drug|GnRh a|antagonist given 0.1 ml injection once daily with continous follow up when at least three follicles reach 17mm in diameter HCG 10.000 IU injection and ovum pick up 24-36hours after injection
1530168|NCT02741154|Drug|HCG|10.000 IU HCG injection when at least three follicles reach 17mm in diameter
1530169|NCT02741141|Other|New partograph based on the studies of Neal and Lowe|"The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.
Eventually, the only difference between the two arms is the moment when the active management of labour is started.
The oxytocin is administrated according to the department protocol."
1530170|NCT02741141|Other|Classical partograph|Classical partograph used as standard care
1530171|NCT02741128|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
1530172|NCT02741128|Biological|Placebo (NaCl 0.9%) vaccine group|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
1530173|NCT02741115|Drug|Udenafil|Active drug
1530174|NCT02741115|Drug|Placebo|Matching Placebo
1530175|NCT02741102|Procedure|Uterine Transplant|Treating Absolute Uterine Factor Infertility by Uterus Transplant. Potential recipients undergo IVF to obtain 6 embryos for cryopreservation followed by live donor uterine transplant. After 1 year, embryo transfer is done to achieve pregnancy. Delivery is by Caesarian section. The recipient may have up to 2 children by these methods and then the uterus is removed so that immunosuppression can be stopped.
1530176|NCT02741089|Procedure|Indication for a flexible bronchoscopy|"The data of patients are collected within the hospital routine documentation during the flexible bronchoscopy. The bronchoscopy is performed regardless of this study. Following the bronchoscopy the patients are asked a few questions about their health and their perception.
The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient."
1530177|NCT02741076|Drug|Morphine Sulfate ER|
1530178|NCT02741076|Drug|Oxycodone ER|
1530179|NCT02741076|Drug|Oxymorphone ER|
1530180|NCT02741063|Behavioral|screen low autistic subjects|screen subjects with low ASQ score
1530181|NCT02741063|Behavioral|screen high autistic subjects|screen subjects with high ASQ score
1530182|NCT02741063|Drug|oxytocin|intranasal administration of oxytocin (24 IU)
1530183|NCT02741063|Drug|placebo|intranasal administration of placebo (24 IU)
1530184|NCT02741050|Behavioral|Tailored Physical Activity Intervention|The Tailored Internet intervention is based on constructs of the Transtheoretical Model (TTM) and Social Cognitive Theory (SCT). During the 6-month intervention period, participants will receive monthly mailed questionnaires that assess current motivational readiness for physical activity and other TTM and SCT constructs (e.g., process of change, self-efficacy) and monthly logs to record their current activity.
1530185|NCT02741050|Behavioral|Standard of Care|Those assigned to the control group will continue to receive standard of care through the Family Medicine clinic. This currently entails commonly accepted medication treatment strategies, educational materials and counseling for self-management and medication adherence, screening for depression or other conditions that would impair self-management, and national and state quality of care guidelines for lab testing and control targets (HbA1c, lipids, blood pressure). Participants in the control group will also receive monthly questionnaires on topics other than physical activity (e.g. diet) to fill out and return in order to have the same opportunities for compensation as those in the intervention condition.
1530186|NCT02741037|Behavioral|Dyadic lifestyle intervention|Dyadic lifestyle intervention: The dyadic behavioral lifestyle intervention was modeled after the Diabetes Prevention Program (DPP), and was adapted to make it more easily accessible to low-income Latinas. In addition, this intervention arm has a dyadic component to examine the effectiveness of mothers and daughters engaging in the lifestyle intervention together as partners. Participants also will receive usual care.
1530187|NCT02741037|Behavioral|Individual lifestyle intervention|Individual lifestyle intervention: The individual behavioral lifestyle intervention was modeled after the Diabetes Prevention Program, and was adapted to make it more easily accessible to low-income Latinas. Mothers participate in the Unidas intervention alone, without their related daughters. Unrelated daughters participate in the Unidas intervention alone without their related mothers. Participants also will receive usual care.
1530188|NCT02741037|Other|Usual Care|Usual Care: Mother and daughter participants will receive Usual Care.
1530189|NCT02741024|Drug|Amodiaquine-Artesunate (ASAQ)|Treatment on site with Amodiaquine-Artesunate according to the manufacturer's dose and instruction and follow-up for a period of 42 days. Drugs will be given under direct supervision, either at the clinic or at home
1530190|NCT02741024|Drug|Artemether-Lumefantrine (AL)|Treatment on site with Artemether-lumefantrine combination according to the manufacturer's dose and instruction and follow-up for a period of 42 days.
1530191|NCT02741011|Other|Radiological examination|During the period of two years, mentally handicapped patients were enrolled in this study. First a radiological examination was performed under sedation anesthesia and then an oral examination was performed when patient underwent general anesthesia for dental treatments. Oral and radiological examinations were compared with each other and also with treatment results to define the necessity of the radiological examination of mentally handicapped patients.
1530194|NCT02740972|Drug|NS-065/NCNP-01|
1530195|NCT02740972|Drug|Placebo|
1530196|NCT02740959|Drug|Astragalus Polysaccharides 500 mg|PG2 Injection 500 mg PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
1530197|NCT02740959|Drug|Astragalus Polysaccharides 250 mg|PG2 Injection 250 mg PG2 (250 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
1530198|NCT02740946|Other|Exercise therapy|5 months of exercise therapy with two strengthening exercises focusing on m. deltoideus anterior and m. teres minor. Furthermore, a warm up exercise was applied.
1530199|NCT02740933|Drug|Demeclocycline|
1530200|NCT02740920|Drug|Pembrolizumab|
1530201|NCT02740920|Procedure|CT Scan|
1530202|NCT02740907|Procedure|premolar autotransplantation|Autogenous tooth transplantation of premolars to the anterior maxilla to stimulate bone and soft tissue growth.
1530203|NCT02740894|Drug|Gefitinib|
1530204|NCT02740881|Other|Counselor Training Methods|
1530205|NCT02740868|Drug|Xenon-129|Xenon gas to be inhaled by research participants
1530206|NCT02740868|Device|Magnetic Resonance Imaging|Lung imaging will be performed for participants using MRI for all 3 arms
1530207|NCT02740868|Device|Lung Clearance Index|Lung clearance index (measure of lung health) will be performed for all participants of all 3 arms
1530208|NCT02740855|Device|Alcomed 3011®|Endtidal ethanol measurement
1530209|NCT02740842|Behavioral|Interpersonal behavioral change communication|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
1530210|NCT02740842|Behavioral|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
1530211|NCT02740829|Drug|Intranasal glucagon|Glucagon will be administered via a nasal dispenser
1530212|NCT02740829|Drug|Intranasal placebo|Placebo
1530213|NCT02740816|Other|Comparative blood analysis|Collection of menstrual blood and systemic blood
1530214|NCT02740803|Other|Sodium fluoride toothpaste 1,450 ppmF|
1530215|NCT02740803|Other|sodium monofluorophosphate toothpaste 1,450 ppmF|
1530216|NCT02740803|Other|stannous fluoride combined with sodium fluoride toothpaste 1,450 ppmF|
1530217|NCT02740803|Other|sodium fluoride combined sodium monofluorophosphate toothpaste 1,450 ppmF|
1530218|NCT02740803|Other|Amine fluoride toothpaste 1,400 ppmF|
1530219|NCT02740803|Other|Non-fluoridated toothpaste 0 ppmF|
1530220|NCT02740790|Biological|HPV vaccine|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
1530221|NCT02740790|Biological|Placebo|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
1530222|NCT02740777|Biological|HPV-16/18 vaccine|HPV 16 L1 virus like particles (VLP) 40μg; HPV 18 L1 VLP 20μg; Aluminium phosphate 225μg; NaCl 0.32M; Histidine buffer 10mM; Tween-80 0.01%.
1530223|NCT02740764|Other|Optimization of drug prescribing|The patients included in this group will have the intervention. The optimization of drug prescribing consists to a history of the drugs prescribing leading to pharmaceutical recommendations by the pharmacist-clinician, accepted by the specialist physicians in charge of the patient at the hospital and sent to the referring physicians of patients, who can accept or not the recommendations.
1530224|NCT02740751|Dietary Supplement|Still-Tee|The mothers of the babies will receive Still-Tee galactogogue tea
1530225|NCT02740738|Device|Wagner Pain Algometer|applied at a 90 degree angle to the skin at a constant rate of 10kPa/s to minimize the impact of the examiner's reaction time on recorded pain thresholds
1530226|NCT02740738|Device|Dynamometer|Dominant Hand Grip strength measured by the average of 3 attempts
1530227|NCT02740725|Other|Patching Therapy|Occlusion of a dominant eye with better best corrected visual acuity
1530228|NCT02740725|Device|Interactive Binocular Treatment System|Dissociation of two eyes with more foveal stimulation to the amblyopic eye
1530229|NCT02740712|Drug|Caffeine|200 mg (4 x 50mg) Tablet
1530230|NCT02740712|Drug|Warfarin|10 mg (2 x 5mg) Tablet
1530231|NCT02740712|Drug|Omeprazole|40 mg Tablet
1530232|NCT02740712|Drug|Midazolam|5 mg/mL
1530233|NCT02740712|Drug|digoxin|.25 mg Tablet
1530234|NCT02740712|Drug|Vitamin K|10 mg Tablet
1530238|NCT02740686|Other|Sample collection|Frequent exacerbators and infrequent exacerbators will have blood and sputum samples obtained around pulmonary rehabilitation. No other intervention will be administered. Healthy controls will have resting blood samples taken.
1530239|NCT02740673|Device|Driving simulator|
1530240|NCT02740660|Drug|Caffeine 100mg / Albuterol 4mg|
1530241|NCT02740660|Drug|Placebo|
1530242|NCT02740660|Behavioral|Family weight management counseling|
1530243|NCT02740647|Drug|Amoxicillin Clavulanate|getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery
1530244|NCT02740647|Drug|Placebo|50 ml of 0.9% sodium chloride three times a day
1530245|NCT02740634|Drug|F-18 AV 1451|Tau binding agent
1530246|NCT02740634|Drug|C-11 PiB|Amyloid binding agent
1530247|NCT02740608|Device|OrganOx metra|Normothermic Machine Liver Perfusion
1530248|NCT02740595|Other|one time exposure to e-cig with nicotine|one time exposure to e-cig vapor with nicotine
1530249|NCT02740595|Other|one time exposure to e-cig without nicotine|one time exposure to e-cig without nicotine
1530250|NCT02740595|Other|one time exposure to empty e-cig|one time exposure to empty e-cig (sham control
1530251|NCT02740582|Drug|Tolcapone|
1530252|NCT02740582|Drug|Placebo|
1530253|NCT02740569|Other|No intervention|Observational study. Intervention according to the clinical routines (not included in this part)
1530254|NCT02740556|Other|HepCure ToolKit|"HepCure is a web-based tool kit in the form of a dashboard for providers and an application (or app) for patients. The app allows patients to become active participants in their treatment by enabling them to enter prescribed treatment, add medications to Pill Box, log doses, visualize adherence, and includes several additional resources."
1530255|NCT02740556|Device|AdhereTech Active Features|AdhereTech, a wireless pill monitoring device that measures the dosage and time a medication was taken. It is a HIPAA-compliant, FDA-registered Class I medical device. Using cellular technology, AdhereTech can be used passively to collect data on when a medication is taken, when a refill is needed, and how often the bottle is opened. AdhereTech also can be used actively to monitor adherence and provide feedback to subjects using the device. When actively monitoring, AdhereTech can be set up to provide live feedback to a subject by lighting up, sounding chimes, and sending phone/text/email alerts to remind patients to take their medication.
1530256|NCT02740556|Other|AdhereTech Passive Monitoring|AdhereTech passively monitors adherence (no chimes or reminders)
1530257|NCT02740387|Drug|OTO-104|
1530258|NCT02740374|Device|ROTEM|ROTEM coagulation assessment and guided transfusion management.
1530259|NCT02740374|Other|Standard of Care|Standard Coagulation Tests assessment and guided transfusion management
1530260|NCT02740361|Behavioral|Deprexis, DeprexisPlus|Online program Deprexis, either as a stand-alone internet-based intervention (Deprexis) or with added standardized email support by a clinical psychologist (DeprexisPlus). In this trial, we will use a Version of Deprexis that has been adapted to MS-specific needs.
1530261|NCT02740348|Behavioral|ZocDoc Assistance|Research assistant sets up a follow-up appointment for a subject with a primary care doctor using ZocDoc
1530262|NCT02740348|Behavioral|ZocDoc Information|Providing ZocDoc information to subjects so that they can make a follow-up appointment with a primary care doctor themselves
1530268|NCT02740309|Behavioral|Integrated Brief Behavior Therapy (IBBT) Intervention|The 4 sessions will empower and support families and youth to continue treatment autonomously with home practice
1530269|NCT02740309|Behavioral|Treatment as usual|Facilitated community referral for mental health treatment
1530270|NCT02740296|Other|No intervention|
1530271|NCT02740283|Behavioral|glycemic monitoring|
1530272|NCT02740283|Dietary Supplement|dietary guide|
1530273|NCT02740270|Drug|GWN323|
1530274|NCT02740270|Drug|PDR001|
1530275|NCT02740257|Other|Photos|Photos will be taken of skin lesion markings using a smart phone or tablet
1530276|NCT02740244|Device|active iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a figure-eight coil (MCF-B65)
1530277|NCT02740244|Device|sham iTBS|Transcranial magnetic stimulation. MagProX100 (MagVenture, Denmark) with a sham figure-eight coil (MCF-P-B65)
1530278|NCT02740231|Drug|JTA-004 intra-articular injection|Each patient will undergo a single injection of JTA-004 into the knee joint
1530279|NCT02740231|Device|Reference product intra-articular injection|Each patient will undergo a single injection of Reference product into the knee joint
1530280|NCT02740218|Other|Patient questionnaire|Patients will be asked to complete a questionnaire regarding their expectations, experience and satisfaction in taking OTEZLA (apremilast) treatment
1530281|NCT02740205|Other|Algorithm for enteral nutrition support|Enteral nutrition support prescribed by the Clinical Nutrition Service under the instructions of the algorithm based on evidence
1530282|NCT02740192|Procedure|Adductor Canal Block|Post-op adductor canal block using Bupivacaine
1530283|NCT02740192|Procedure|Periarticular Injection|Intra-op periarticular injection of Ropivacaine
1530284|NCT02740192|Drug|Ropivacaine|Ropivacaine was used for the periarticular injection
1530285|NCT02740192|Drug|Bupivacaine|Bupivacaine was used for the periarticular injection
1530286|NCT02740179|Drug|Eplerenone|Eplerenone 50mg by mouth daily
1530287|NCT02740179|Drug|Placebo|Placebo by mouth daily
1530288|NCT02740179|Behavioral|Lifestyle Modification|Counseling regarding diet and healthy activity
1530289|NCT02740166|Drug|propranolol|Patients randomized to propranolol group continue propranolol after eradication of esophageal varices.
1530290|NCT02740153|Other|No Intervention Given|
1530291|NCT02740127|Procedure|Caudal Nerve Block (CNB)|General anesthesia given in the OR using Propofol titrated for induction. CNB given as bolus injection into the caudal canal in the operating room (OR) by attending anesthesiologist using 1% Ropivacaine (max 5mg/kg) + 1:400,000 Epinephrine + Decadron 10 mg + Clonidine 100 mcg.
1530292|NCT02740127|Drug|Ropivacaine|Ropivacaine 1 % (max 5mg/kg) by bolus injection given by anesthesiologist in OR.
1530293|NCT02740127|Drug|Epinephrine|Epinephrine 1:400,000 by bolus injection given by anesthesiologist in OR.
1530294|NCT02740127|Drug|Decadron|Decadron 10 mg by bolus injection given by anesthesiologist in OR.
1530295|NCT02740127|Drug|Clonidine|Clonidine 100 mcg by bolus injection given by anesthesiologist in OR.
1530296|NCT02740127|Drug|Propofol|General anesthesia given in the OR using Propofol titrated for induction.
1530297|NCT02740127|Behavioral|Phone Call|Study staff calls participant about 3 days after surgery to ask about their pain, amount of pain drugs they have taken, and how satisfied they are with the type of anesthesia and pain control they received. This call should last about 5-10 minutes.
1530298|NCT02740114|Drug|Bupivacaine|150 mg (0.25%) injected on each side of the wound at the end of surgery before wound closure.
1530299|NCT02740114|Drug|Liposomal Bupivacaine|266 mg injected on each side of the wound at the end of surgery before wound closure.
1530300|NCT02740114|Drug|Oxycodone|1-2 tabs (5 mg) by mouth every 4 hours as needed for pain.
1530301|NCT02740114|Behavioral|Pill Diary|Participants complete a pill diary every day for 30 days after hospital discharge.
1530302|NCT02740114|Behavioral|Symptom Questionnaire|Participants called or emailed and asked questions about symptoms three (3) and 7 days after hospital discharge, and then 1 time every week after that for a total of 8 weeks.
1530303|NCT02740101|Drug|oxytocin treatment|intranasal administration of oxytocin (40 IU)
1530304|NCT02740101|Drug|placebo treatment|intranasal administration of placebo (40 IU)
1530305|NCT02740088|Other|Imaging test: 18F-NaF PET/CT|18F-NaF PET/CT as an imaging test
1530306|NCT02740062|Device|NIBS system for evaluation and non invasive current stimulation|
1530307|NCT02740049|Drug|VR588|Evaluation of the efficacy of a novel JAK/STAT inhibitor, VR588, in isolated epithelial cells from asthma patients
1530308|NCT02740036|Device|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
1530309|NCT02740023|Device|Hearing Aid (Successor of Phonak Audéo V90)|Successor of Phonak's Receiver-In-the-Canal (RIC) hearing aid Audéo V90.
1530310|NCT02740010|Device|MIOL MINI WELL|MIOL implant
1530311|NCT02739997|Drug|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
1530312|NCT02739997|Drug|metronidazole 500 mg|metronidazole 500 mg administered as an IV infusion
1530313|NCT02739984|Biological|Evolocumab|Subjects will receive Evolocumab (AMG 145) subcutaneous monthly.
1530314|NCT02739984|Other|Placebo to Evolocumab|Subjects will receive Evolocumab (AMG 145) matching placebo subcutaneous monthly.
1530315|NCT02739971|Behavioral|Nutritional counseling to reduce AGEs content in diet|in the intervention group, subjects will receive oral and written instructions on how to reduce AGEs in diet mainly by changing cooking methods
1530316|NCT02739971|Behavioral|Nutritional instructions for type 2 diabetes|all subjects will receive nutritional instructions for type 2 diabetes
1530317|NCT02739958|Drug|Propofol group|Anesthesia is maintained with continuous infusion of propofol 1.5-2mg/kg/h and dexmedetomidine 0.2-1ug/kg/h.
1530318|NCT02739958|Drug|Isoflurane group|Anesthesia was maintained with isoflurane at a concentration of 2-2.5%. fentanyl 50 ug increments
1530319|NCT02739945|Procedure|Cubital tunnel release|The ulnar nerve is decompressed proximally at the intramuscular septum, decompressed more distally through the cubital tunnel and then exposed between the two heads of the flexor carpi ulnaris muscle. Care is taken to ensure that any point that might compress the ulnar nerve either proximally or distally is evaluated.
1530320|NCT02739906|Drug|BioChaperone Human Insulin (HinsBet®)|BioChaperone Human Insulin (HinsBet®) individualised single subcutaneous injection followed by test meal intake
1530321|NCT02739906|Drug|Insulin Lispro (Humalog®)|Insulin Lispro (Humalog®) individualised single subcutaneous injection followed by test meal intake
1530322|NCT02739906|Drug|Regular human insulin (Huminsulin® Normal)|Regular human insulin (Huminsulin® Normal) individualised single subcutaneous injection followed by test meal intake
1530323|NCT02739893|Procedure|Scope Guide Assist|"Olympus has developed a new instrument which provides physicians a real-time, three dimensional visualization of position and configuration during colonoscopy. The Olympus ScopeGuide technology has received FDA clearance and can be used within the United States. The new technology called the 'scopeguide' has been developed that uses magnetic coils embedded into the scope to create a 3 D image of the shape of the entire scope inside the body that is projected onto the monitor to see. This acts as a GPS and shows the advancement of the scope through bends providing information on loops and thereby eliminating chances of loop formation, helping in loop reduction and also reducing the number of external maneuvers that may be required for the completion of colonoscopy."
1530324|NCT02739893|Procedure|Standard procedure for colonoscopy|
1530325|NCT02739880|Device|DESIRIAL® (Intra-mucosal Injections of Cross-linked Hyaluronic Acid)|"Multi-point Intra-mucosal Injections of Cross-linked Hyaluronic Acid (DESIRIAL®) in the Vaginal Vestibule
The intervention is Intended for intra-mucosal injection in women for biostimulation / rehydration of the surface layers of the lining of the genital areas, vaginal hypotrophies and / or treatment of female sexual dysfunction related to subsidence G spot or area of Gräfenberg .
Following disinfection and topical anesthesia (lidocaine gel), the vesitbule is injected using a multi-point technique. The optimal volume of DESIRIAL® to be used for injection into the vestibule is approximately 0.3 ml in total."
1532417|NCT02724917|Drug|Placebo|Placebo to match
1530326|NCT02739841|Other|Ventilator hyperinflation|4 sets of 6 hyperinflation breath were applied by mechanical ventilator at 150% of tidal volume (VT) at initial.
1530327|NCT02739841|Other|Chest physical therapy|The patient will be received vibration and passive of the both upper extremity.
1530329|NCT02739815|Drug|Normal Saline containing a prophylactic Antibiotic 1 g|500 ml of normal saline containing a prophylactic Antibiotic 1 g.
1530330|NCT02739815|Drug|Tranexamic Acid|Tranexamic acid
1530331|NCT02739802|Drug|Coppertone(BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.Formulation number - SR16-02.
1530332|NCT02739789|Device|tDCS|tDCS
1530333|NCT02739789|Device|Sham tDCS|Sham tDCS
1530334|NCT02739776|Device|Thermographic imaging|Using infrared-recording camera will obtain thermographic images of the lower extremities before and after the epidural blockade
1530335|NCT02739763|Biological|Plasmodium falciparum sporozoite (PfSPZ)|Plasmodium falciparum sporozoites
1530336|NCT02739750|Other|No intervention|There is no intervention for this study. It is a MRS.
1530337|NCT02739737|Other|Blinded manuscript|Blinded version of sham manuscript
1530338|NCT02739737|Other|Unblinded manuscript|Unblinded version of sham manuscript
1530339|NCT02739724|Procedure|Adnexal surgery|
1530340|NCT02739711|Drug|Glycoprotein IIb/IIIa inhibitors|Glycoprotein IIb/IIIa inhibitors intravenous bolus followed by an intravenous infusion for 12/18 h plus medical standard therapy
1530341|NCT02739698|Drug|Paclitaxel|
1530342|NCT02739698|Procedure|Radical surgery-peritonectomy|
1530343|NCT02739685|Device|Everolimus-eluting bioresorbable vascular scaffold|Implantation of everolimus-eluting bioresorbable vascular scaffold in chronic total occlusion
1530344|NCT02739685|Device|Everolimus-eluting stent|Implantation of everolimus-eluting stent in chronic total occlusion
1530345|NCT02739672|Drug|TAH Tablet (Telmisartan/Amlodipine besylate/Hydrochlorothiazide)|Telmisartan 80.0 mg, Amlodipine besylate 13.87 mg (Amlodipine 10 mg), Hydrochlorothiazide 25 mg combination-drug would be administered orally once
1530346|NCT02739672|Drug|TWYNSTA(Telmisartan+Amlodipine besylate)|TWYNSTA 2 Tab. 40/5mg(Telmisartan 40 mg, Amlodipine besylate 6.935 mg(Amlodipine 5 mg) would be administered orally once
1530347|NCT02739672|Drug|Hydrochlorothiazide|Dichlozid 1 Tab.(Hydrochlorothiazide 25.0 mg) would be administered orally once
1530348|NCT02739659|Device|carbon-ion radiotherapy|
1530350|NCT02739633|Drug|Genexol-PM|125 mg/m2 given intravenously over 60 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
1530351|NCT02739633|Drug|Gemcitabine|1000 mg/m2 given intravenously for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
1530352|NCT02739620|Device|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation will be performed 5 times/week for one hour each day for 2 months.
1530354|NCT02739594|Drug|Ibandronate|Ibandronate will be administered via 15-minute intravenous (IV) infusion as 6 milligrams (mg) every 4 weeks for 92 weeks.
1530355|NCT02739594|Drug|Zoledronate|Zoledronate will be administered via 15-minute IV infusion as 4 mg every 4 weeks for 92 weeks.
1530356|NCT02739581|Procedure|Endoscopic Variceal Ligation|
1530357|NCT02739581|Drug|Non selective beta blocker|
1530358|NCT02739581|Other|Placebo|
1530359|NCT02739568|Drug|Pitolisant (BF2.649)|
1530360|NCT02739568|Drug|Placebo|
1530361|NCT02739555|Device|Thermal destruction with radiofrequency or laser|
1530362|NCT02739555|Drug|Acide Zoledronique MEDAC|
1530363|NCT02739542|Drug|Tecfidera|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
1530364|NCT02739542|Drug|Placebo|Blinded drug wallets will be dispensed during routine study appointments in 3 month supply, so that compliance can be reconciled at follow up visits and telephone consultations, and recorded in accountability logs.
1530365|NCT02739529|Drug|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
1530366|NCT02739516|Drug|Human chorionic gonadotropin|In letrozole stimulated cycle; Human chorionic gonadotropin ( hCG) 10000 IU was given intramuscular when the mean ovarian follicle diameter was ≥18 mm.
1530367|NCT02739516|Drug|FSH co-trigger|In letrozole stimulated cycle; FSH (urofollitropin; Fostimon, IBSA, Bazel, Swiz; 75 IU amp) 150 IU injected once intramuscular when the mean ovarian follicle diameter was ≥18 mm.
1530368|NCT02739516|Drug|Letrozole|Letrozole oral tablets (Femara 2.5 mg tablet; Novartis Pharma Services, Switzerland) 2.5 mg tab twice daily for 5 days from cycle day 3.
1530369|NCT02739503|Device|Ultrasound|Patients will receive ultrasound in the ultrasound unit at Hillel Yaffe Medical Center within 10 days before onset of induced or spontaneous labors. The ultrasound team has been trained in FHC , Estimated Fetal Weight (EFW) and Biparietal Diameter (BPD) measurement .Optimal ultrasound measurements of FHC and BPD will be obtained. The average of 3 fetal head circumference measurements will be recorded. Investigators consider the FHC and BPD to be optimal when a clear outline of the entire fetal skull is measured, and the landmarks (the thalamus, cavum septum pellucidum and choroid plexus in the atrium of the lateral ventricles) are visualized. Subsequent information of labor outcome as well as normal head circumference ,post-delivery will be obtained from maternal and neonatal medical records.
1530370|NCT02739490|Procedure|Core Training Group|Performs oriented exercise segmental stabilization lumbar-pelvic.
1530414|NCT02739087|Procedure|MRI guided cardiac catheterization|Magnetic resonance imaging will be used to guide cardiac catheterization procedures whenever possible to avoid or minimize x-ray radiation exposure.
1530371|NCT02739477|Drug|Favipiravir|"Cohort 1: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600 mg (1800 mg bid).
Cohort 2: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohort 1 results.
Cohort 3: Day 1 (inclusion) 4800 mg (2400 mg bid). Day 2 to Day 14: 3600, 4200, 4800 mg per day depending on cohorts 1 and 2 results."
1530372|NCT02739464|Other|Exercise + SOC PT/OT|
1530373|NCT02739464|Other|Standard of Care PT/OT|
1530374|NCT02739451|Procedure|standard oxygen|"Devices used to treat spontaneously ventilating patients in the ICU who require supplemental oxygen. They deliver either
low-flow oxygen [including nasal cannula, Ventimask® without Venturi effect, and non-rebreather mask]
or medium-flow oxygen [Venturi masks and medium-flow facemasks]"
1530375|NCT02739451|Procedure|HFNO|The intervention is the use of a device that allows to deliver high flow humidified and warmed oxygen. The device used is the Optiflow™ (Fisher&Paykel, Courtaboeuf, France).
1530376|NCT02739438|Other|Electronic cigarette use|Subjects who use electronic cigarettes daily and have not used conventional cigarettes in the previous 3 months.
1530377|NCT02739438|Other|Cigarette use|Subjects who smoke at least ¼ pack cigarettes per day for the past 1 year, with no history of electronic cigarette use in the last 30 days.
1530378|NCT02739438|Other|Control group|Subjects with no history of prior conventional cigarette (< 100 cigarettes lifetime) or electronic cigarette use.
1530379|NCT02739425|Device|Sentimag Device|The programme will compare the Sentimag with the conventional sentinel lymph node detection with radioactive tracer combined with blue dye (in centres using the combined technique) and thereby determine whether the new technique is equivalent to the standard technique for SLNB
1530380|NCT02739412|Biological|Interleukin-2|Subjects will self-administer low dose IL-2 as subQ injection (1.0MIU per meter squared body surface area) for 4 weeks.
1530381|NCT02739399|Drug|Phenylephrine|Intravenous administration
1530382|NCT02739386|Biological|Ipilimumab|Intravenous monoclonal antibody injection
1530383|NCT02739373|Drug|BMS-986189|
1530384|NCT02739373|Other|Placebo|
1530385|NCT02739360|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
1530386|NCT02739347|Device|Active Trans-cranial direct-current stimulation|Active stimulation group will receive 20 min of 2 mA direct current stimulation.
1530387|NCT02739347|Device|Sham Trans-cranial direct current stimulation|This will be an active sham involving brief (15 msec) low current (0.11 mA) pulses every 550 ms.
1530388|NCT02739334|Behavioral|ENRICH|The intervention, called ENRICH (Encouraging Nurturing Responsiveness to Improve Child Health), is a 10-week home-based parent-centered curriculum designed to facilitate parents' mastery of skills for interacting with their toddler to increase opportunities for healthy eating and activity. Each weekly session is a 60 minute session implemented by a trained coach.
1530389|NCT02739334|Behavioral|Control - monthly handouts|The control group receives monthly handouts (one per month) for 3 months that provides information on various topics including child cognitive and language development and child behaviors as it pertains to 2 and 3 year old children.
1530391|NCT02739308|Other|Proprioceptive Training|In this study the training program will be developed for 12 weeks and will be applied during the heating of the athletes , three times a week and the duration of each session is 30 minutes. Each week will be chosen three of the 14 exercises adapted for fencing athletes , and preferably one of each category.
1530392|NCT02739308|Other|Control Group|The control group will not make the intervention and will continue with usual training fencing.
1530393|NCT02739295|Drug|recombinant granulocyte - colony stimulating factor|
1530394|NCT02739295|Drug|NaCl 0.9%|
1530395|NCT02739282|Other|Systematic therapeutic drug monitoring|Blood samples with antiepileptic drug level measurement
1530398|NCT02739256|Procedure|Retrograde voiding trial|A bladder test is performed after surgery for prolapse to make sure the patient can empty their bladder prior to discharge from the hospital. The test consists of filling the bladder with 300 mL of water and removing the catheter. Then the patient voids.
1530399|NCT02739243|Behavioral|Tailored group intervention (PREPARE)|
1530400|NCT02739243|Behavioral|Individual treatment as usual|
1530401|NCT02739230|Drug|Exparel|
1530402|NCT02739230|Drug|On-Q pain intra-articular catheter|
1530403|NCT02739217|Drug|PBI-4050|Four 200 mg capsules (800 mg total) administered orally, once daily.
1530404|NCT02739204|Drug|Celecoxib|200 mg of Celecoxib daily for 6-month treatment after surgery within 1 - 6 months
1530405|NCT02739191|Device|PICO, Smith & Nephew|Direct application of negative pressure wound therapy following Foot and Ankle surgery
1530406|NCT02739178|Other|GSF Intervention|Intervention utilizes community-based demand generation matched with supply side improvements to improve access and use of sanitation facilities in rural communities. This is complimented with multi-stakeholder engagement to promote cooperation and coordination with national, state, and local stakeholders.
1530407|NCT02739165|Drug|ART-123|380 U/kg/day by intravenous drip infusion in addition to standard of care steroid therapy
1530408|NCT02739165|Drug|Placebo|Placebo by intravenous drip infusion in addition to standard of care steroid therapy
1530409|NCT02739139|Dietary Supplement|AlphaBrain|Alpha BRAIN® (Onnit Labs LLC) is a multi-ingredient nutritional supplement that purports to enhance cognitive function in healthy adults. The commercially available product contains 12 naturally occurring compounds
1530410|NCT02739126|Procedure|Radial EBUS biopsy|Radial EBUS is an endobronchial USS which is used to obtain biopsies from a peripheral lung mass.
1530411|NCT02739126|Device|Types of Radial Ultrasound probes|The Radial USS probe comes in two sizes. A thick USS probe that is 1.7mm and the thin USS is 1.4mm in diameter.
1530415|NCT02739087|Device|Magnetic resonance imaging|
1530597|NCT02737618|Device|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
1530416|NCT02739061|Behavioral|cognitive behavioral group therapy|"Establish closed every collection of six or so patients structured group. Each group patients were treated for 12 times, once a week, 120 minutes at a time.
Treatment for 1 to 3 times to obsessive-compulsive disorder and cognitive behavioral therapy as the theme of psychological education; 4 to 6, 8 to 10 times exposed step by step and reaction treatment and prevention of training;7 and 11 times invite patients family members or other caregivers, make education about obsessive-compulsive disorder cognitive behavioural therapy, to promote patients exposed response prevention homework completion and social support; The 12th time treatment is self assessment and treatment guidelines for a long time."
1530417|NCT02739061|Drug|sertraline, fluvoxamine|Select specified drugs (sertraline, fluvoxamine)
1530418|NCT02739061|Other|cognitive behavioral group therapy and drug therapy|Select specified drugs (sertraline, fluvoxamine) and start group cognitive behavior therapy for 12 weeks at the same time
1530419|NCT02739035|Drug|Dexamethasone|8 mg of IV dexamethasone immediately before MUA.
1530420|NCT02739035|Drug|Celecoxib|2 weeks per mouth of celecoxib (200 mg daily)
1530422|NCT02739009|Drug|MOR106 single ascending doses, intravenous|
1530423|NCT02739009|Drug|Placebo single ascending doses, intravenous|
1530424|NCT02739009|Drug|MOR106 multiple ascending doses, intravenous|
1530425|NCT02739009|Drug|Placebo multiple intravenous administrations|
1530426|NCT02738996|Behavioral|Sedentary time breaks either every 60 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 60 min
1530427|NCT02738996|Behavioral|Sedentary time breaks either every 30 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 30 min
1530428|NCT02738996|Behavioral|Sedentary time breaks every 15 minutes|Sitting for 8 hours interrupted by 3 min of light intensity walking (LIW, 3.2 km/h) breaks every 15 min
1530429|NCT02738983|Drug|Erlotinib (trade name: Tarceva®) or Icotinib (trade name: Conmana®)|Erlotinib (trade name: Tarceva®) (150mg oral daily) or Icotinib (trade name: Conmana®) (125mg oral three times a day).
1530430|NCT02738983|Radiation|Radiotherapy|Concurrent radiotherapy total dose 60-66 Gy in 2 Gy fractions. One fraction per day, and 5 fractions per week.
1530433|NCT02738957|Behavioral|Prenatal Counseling Group|"Specific counseling on breastfeeding consisting of three different counseling sessions during prenatal visits given by one of the two midwives involved in the study. The information provided include the following: breastfeeding importance; how to prepare the nipples and breast for breastfeeding; the main complications and difficulties during the breastfeeding process and how to identify and overcome them; breastfeeding techniques and alternative positions for the simultaneous breastfeeding of twins, for example, double cradle, cradle-football or double-football, using illustrations and hands-on demonstration with doll models."
1530434|NCT02738944|Behavioral|Telepsychiatry Collaborative Care|The telepsychiatrist will also conduct an initial consultation with the patient via interactive video to establish the diagnosis and recommend medications to prescribe. Onsite primary care providers prescribe psychotropic medications. Onsite care managers work with patients either face-to-face or by phone to promote adherence to treatment and assess treatment response. Care managers provide Behavioral Activation either face-to-face or by phone. Care managers have weekly provider-to-provider consultations with the telepsychiatrist to review treatment plans for patients not responding to treatment. The telepsychiatrist will make revised treatment recommendations to the primary care provider.
1530435|NCT02738944|Behavioral|Telepsychiatry Enhanced Referral|"The offsite telepsychiatrist and/or telepsychologist delivers the treatment via interactive video to patients located at primary care clinics. Telepsychiatrists/telepsychologists administer symptom rating scales at each session. The first encounter will be with the telepsychiatrist to establish diagnosis and develop a treatment plan consisting of algorithm-informed medication management and/or evidence-based psychotherapy. The telepsychiatrists will prescribe medications. Psychotherapy options include Cognitive Processing Therapy and Cognitive Behavioral Therapy.
If a patient does not engage in treatment (<=2 encounters) in the first six months, they will be randomized a second time to continued Telepsychiatry Enhanced Referral or Telephone Enhanced Referral for the second six months. Phone Enhanced Referral involves delivering psychiatric and/or psychological treatment (either initially or exclusively) by telephone to patients in their home."
1530436|NCT02738931|Drug|Dolutegravir 50 mg tablet|A white, film-coated, round tablet debossed with SV 572 on one side and 50 on the other side. Single dose of one tablet will be administered with 240 mL of water.
1530437|NCT02738931|Drug|Lamivudine 300 mg tablet|"Gray, diamond-shaped tablet, engraved GX EJ7 on one side and plain on the other side. Single dose of one tablet will be administered with 240 mL of water."
1530438|NCT02738931|Drug|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AA)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
1530439|NCT02738931|Drug|Dolutegravir/Lamivudine 50 mg/300 mg Tablet (Product Code AB)|Immediate release oval tablet embossed 'gsk' on one face with white film coat. Single dose of one tablet will be administered with 240 mL of water.
1530440|NCT02738918|Drug|Nulojix (Belatacept)|Nulojix Administration will start the day of transplantation (day 1 and first dosing day);10 mg/kg : (day1, 5,14,28 ), Week 8 and 12 and then 5 mg/kg every 4 weeks until Month 12
1530442|NCT02738879|Drug|Sitagliptin|Sitagliptin 100 mg, oral, once daily for 30 weeks
1530443|NCT02738879|Drug|Placebo to stiagliptin|Placebo to sitagliptin, 100 mg, oral, once daily for 30 weeks
1530444|NCT02738879|Drug|Metformin|At least 1500 mg/day, oral, twice daily for participants entering the study on immediate-release metformin + sitagliptin or a fixed dose combination (FDC).
1530445|NCT02738879|Drug|Metformin XR|At least 1500 mg/day, oral, once daily for participants entering the study on extended-release metformin + sitagliptin or a FDC.
1530446|NCT02738879|Drug|Insulin glargine|Insulin glargine (LANTUS®) initiated at 10 units and titrated based on a treat-to-target algorithm to achieve fasting glucose levels of 72-100 mg/dL (4-5.6 mmol/L); administered once daily subcutaneously.
1530447|NCT02738866|Drug|Palbociclib|Palbociclib will be given orally, continued at the same dose as was received previously; the maximum starting dose will be per the approved label, a dose of 125 mg once daily. Palbociclib will be taken days 1-21, then seven days off treatment to complete one 28 day cycle.
1530448|NCT02738866|Drug|Fulvestrant|Fulvestrant 500 mg should be administered intramuscularly into the buttocks slowly (1-2 minutes per injection) as two 5 mL injections, one in each buttock, on days 1, 15, and 29 (i.e., Cycle 2 Day 1) and once monthly thereafter (i.e., day 1 of each cycle).
1530450|NCT02738840|Procedure|MRI scan|MRI scan
1530451|NCT02738827|Procedure|Laser treatment|Intervention is diode laser treatment of bladder cancer through a cystoscope in the outpatient department
1530452|NCT02738814|Drug|propofol|When severe emergence agitation(PAED > 13) is occurred, Pharmacologic treatment of emergence agitation relies on the administration of IV propofol 0.8 or 1 mg/kg.
1530453|NCT02738801|Drug|GLPG1690 group 1|600 mg GLPG1690 q.d., administered as oral capsules
1530454|NCT02738801|Drug|Placebo group 2|Oral capsules matching those of GLPG1690 group 1
1530455|NCT02738788|Other|Intubation|"The patient's airway will be visually assessed and photographed while the patient is resting comfortable in bed with the head up at 30-45 degrees and classified into one of 4 MMS categories. Digital photographs will be taken and the stored image prepared by the investigators in such a way that the patient cannot be individually identified (mouth only).
Neck circumference will be measured at the level of the thyroid cartilage using a tape measure, with temporary ink marks on the skin to allow for subsequent measurements at the same point.
After the patient has been extubated and recovered in the PACU for 30 minutes, their airway will be re-assessed and documented. These evaluations will be repeated at 2, 3, and 4 hours, as well as the next morning."
1530458|NCT02738762|Other|glutamine supplementation|glutamine supplementation guided by glutamine levels in plasma
1530459|NCT02738749|Device|Implantable cardioverter-defibrillator (ICD)|Patients with newly implanted implantable cardioverter-defibrillators (ICDs) for primary prevention will be enrolled.
1530460|NCT02738736|Behavioral|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions
1530461|NCT02738723|Radiation|SBRT|40 Gy for each patient. Patients receiving once-daily therapy ,4 Gy daily in 10 treatments over a period of two weeks.
1530462|NCT02738723|Radiation|IMRT|45 Gy for each patient，Accelerated twice-daily thoracic radiotherapy involved the administration of 1.5 Gy in 30 treatments over a period of three weeks.
1530463|NCT02738723|Drug|EP|Etoposide 75mg/m2/iv over 90min through day 1 to day 4 and cisplatin 25mg/m2/iv over 30min through day 1 to day 3, repeat Q 3weeks. Continuous administration to six cycles or to disease progression, unacceptable toxicity or patients' refusal.
1530464|NCT02738710|Procedure|transumbilical incision|incision within umbilicus
1530465|NCT02738710|Procedure|Infra umbilical incision|incision about 1 cm below umbilicus
1530466|NCT02738697|Drug|Adjuvant chemotherapy|8~12 cycles of adjuvant chemotherapy with FOLFOX were performed 4-6 weeks after radical surgery
1530467|NCT02738697|Procedure|Follow-up|Patients received just follow-up instead of adjuvant chemotherapy
1530468|NCT02738671|Behavioral|Cognitive assessment|
1530469|NCT02738671|Other|functional magnetic resonance imaging|
1530470|NCT02738671|Other|olfactory function measurement|
1530471|NCT02738671|Procedure|bariatric surgery|Only a subgroup of the subjects will have the bariatric surgery.
1530472|NCT02738658|Device|Bioresorbable vascular scaffold|
1530473|NCT02738658|Device|Everolimus-eluting stent|
1530474|NCT02738645|Other|pneumonia|
1530475|NCT02738632|Drug|Telmisartan/Amlodipine+Hydrochlorothiazide|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg 1 Tab.QD
Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg 1 Tab.QD"
1530476|NCT02738632|Drug|Telmisartan/Amlodipine|"Treatment1:Telmisartan/Amlodipine 40/5mg 1 Tab.and Hydrochlorothiazide 12.5mg Placebo 1 Tab.QD
Treatment2: Telmisartan/Amlodipine 40/5mg 2 Tab.and Hydrochlorothiazide 25mg Placebo 1 Tab.QD"
1530477|NCT02738632|Drug|Placebo for Hydrochlorothiazide|
1530478|NCT02738619|Drug|Vitamin D3|1600 UI
1530479|NCT02738619|Drug|placebo|placebo
1530480|NCT02738606|Procedure|Liver Resection Surgery|Participants undergo standard of care liver resection surgery.
1530481|NCT02738606|Drug|Chemotherapy|Standard of care chemotherapy decided by participant's physician.
1530482|NCT02738606|Behavioral|Survey|Quality of life survey completed at baseline and every 3-6 months at follow up.
1530483|NCT02738580|Drug|COS with GnRH antagonists and rFSH|Controlled ovarian hyperstimulation with GnRH antagonists and rFSH in women with normal ovarian function.
1530484|NCT02738580|Drug|COS with GnRH antagonists and HP-HMG|Controlled ovarian hyperstimulation with GnRH antagonists and HP-HMG in women with normal ovarian function.
1530485|NCT02738567|Procedure|patients undergoing surgery or medical procedure|
1530486|NCT02738554|Other|Treatment cessation|Cessation of nucleoside analogue therapy following Asia-Pacific Association for the Study of Liver Diseases guidelines
1530487|NCT02738541|Drug|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE|DENTRIFICE CONTAINING 5% SODIUM AND POTASSIUM PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
1530488|NCT02738541|Drug|PLACEBO DENTRIFICE WITHOUT PROPHOSPHATE|PLACEBO DENTRIFICE WITHOUT PYROPHOSPHATE WAS ADVISED TWICE DAILY FOR 6 MONTHS
1530489|NCT02738528|Other|Mental practice and brushing guidance in patients with Parkinson Disease|
1530532|NCT02738151|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1530490|NCT02738515|Drug|0.75 % Boric Acid|After Scaling and Root Planing placement of 0.75% Boric Acid gel in Mandibular degree 2 Furcation defect.
1530491|NCT02738515|Drug|placebo|After Scaling and Root Planing placement of Placebo gel in Mandibular degree 2 Furcation defect.
1530492|NCT02738502|Drug|darunavir monotherapy|darunavir 600 mg + ritonavir 100 mg 2 times 24 (DRV/r) monotherapy started after checking the tolerance of DRV/r600 mg/100 mg twice daily to replace whatever prior ARVs were used, while maintaining the NRTI backbone for 2 weeks.
1530493|NCT02738489|Biological|SHR-1210|A fully human monoclonal immunoglobulin (IgG4 subtype)
1530494|NCT02738476|Procedure|Patellofemoral arthroplasty|
1530495|NCT02738450|Biological|ACI-24 low dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
1530496|NCT02738450|Biological|ACI-24 high dose|ACI-24 administered as a sterile suspension in PBS via s.c. injection.
1530497|NCT02738450|Biological|Placebo|Placebo is a standard PBS sterile solution administrated via s.c. injection.
1530498|NCT02738437|Device|Kryptonite-bone cement|
1530499|NCT02738424|Other|Calculate the ADC scores|The MRI will be performed on the two groups of patients in the usual care. The intervention will be based on the ADC scores calculation. The scores will be obtained with three types of post-processing softwares : Siemens, PACS Carestream, Osirix.
1530500|NCT02738398|Radiation|FDG PET/CT|
1530501|NCT02738385|Behavioral|High Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
1530502|NCT02738385|Behavioral|Moderate Intensity Interval Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
1530503|NCT02738372|Other|Diagnosis/Prognosis|The present study will be a 24 months multi-center, triple-blind, prospective, cohort study which will be carried out between April 2016 and March 2018. Subjects diagnosed of rotator cuff (RC) tendinopathy, adhesive capsulitis (AC), glenohumeral instability, SLAP lesion, and/or acromioclavicular pathology and fulfill the inclusion criteria will be asked for participating in our study. Several questionnaires that will test the influence of different biopsychosocial factors and the presence of Central Sensitization will be administrated to these subjects. The outcomes will be assessed at baseline and 5 follow-ups (after 3, 6, 12, 18 and 24 months, t1-t6).
1530504|NCT02738359|Procedure|optical colonoscopy|optical colonoscopy
1530505|NCT02738359|Procedure|colon capsule endoscopy|colon capsule endoscopy
1530506|NCT02738359|Diagnostic Test|fecal immunological test (FIT)|fecal immunological test (FIT)
1530507|NCT02738346|Drug|Carboplatin|Intravenous administration of Carboplatin AUC 5 at Day 1, Every 3 weeks, maximum 6 cycles
1530508|NCT02738346|Drug|Etoposide|Intravenous administration of 100mg/m²/day of Etoposide, Day 1 to Day 3 Every 3 weeks, maximum 6 cycles
1530509|NCT02738346|Drug|Topotecan|Per os administration of 2.3 mg / m2 of Topotecan, Day 1 to Day 5 Every 3 weeks, maximum 6 cycles
1530510|NCT02738346|Device|CT scans|The CT scan evaluations will be conducted during chemotherapy every 6 weeks
1530511|NCT02738333|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
1530512|NCT02738333|Drug|SOF|400 mg tablet administered orally once daily
1530513|NCT02738333|Drug|RBV|Capsules administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
1530514|NCT02738320|Other|NHCPlus|A decision-aid tool that will interface with Nursing Home Compare and improve consumers' ability to assimilate and incorporate the information into their process of choosing a nursing home.
1530515|NCT02738307|Other|Altitude exposure|Acute high altitude exposure followed by 8 day acclimatization and re-exposure for 8 days after 6 days at low altitude
1530516|NCT02738294|Device|ME-NBI observation and ME-NBI targeted biopsy|The endoscopist assessed lesions which were suspected EGC carefully with ME-NBI. After assessing suspected EGC in ME-NBI view, ME-NBI targeted biopsy was performed where abnormal phenomenon was identified in ME-NBI view.
1530517|NCT02738268|Device|Low-level laser therapy|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment in combination with the standard skin care.
1530518|NCT02738268|Device|sham laser|
1530519|NCT02738255|Device|Varnum mouthpiece|
1530520|NCT02738242|Device|Novus system|The Novus system is a FES based neuroprosthesis, which intended to provide ankle dorsiflexion and knee flexion or extension in individuals with foot drop and thigh muscle weakness, following an upper motor neuron injury or disease.
1530521|NCT02738229|Drug|Valacyclovir|
1530522|NCT02738229|Drug|placebo|
1530523|NCT02738216|Behavioral|Prenatal Yoga|As part of the yoga program, participants will be asked to go to one 75-minute prenatal yoga class each week for 9 weeks. The yoga classes will be designed to be safe for pregnant women. In addition to classes, the yoga teacher will ask them to practice yoga at home during the program. Each participant will be given a yoga mat and a prenatal yoga DVD to take home.
1530524|NCT02738216|Behavioral|Mother Baby Wellness|This workshop is aimed at promoting moms' and babies' good health and will involve attending one 75-minute class each week for 9 weeks. Classes will cover topics such as: child development in the first year, child eating and sleeping in the first year, maintaining good health as a mom of an infant, and recent advances in women's healthcare. In addition to classes, participants will be given materials to review/ read at home.
1530527|NCT02738190|Drug|Albumin|Albumin 5% added to blood priming solution
1530528|NCT02738190|Biological|Fresh Frozen Plasma|Fresh Frozen Plasma added to blood priming solution
1530529|NCT02738177|Drug|Misoprostol|2 tablets of misoprostol (i.e. 400 ug) 4 hrs prior to surgical evacuation high up in the posterior fornix (misoprostol group)
1530530|NCT02738177|Drug|Isosorbide-5-mononitrate|2 tablets of Effox (i.e. 40 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (effox group)
1530531|NCT02738177|Drug|misoprostol and Isosorbide-5-mononitrate|1tablets of misoprostol (i.e.200 ug) & 1 tablets of Effox (i.e. 20 mg) 4 hrs prior to surgical evacuation high up in the posterior fornix (combination therapy group)
1530533|NCT02738151|Drug|Insulin degludec|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1530534|NCT02738151|Drug|GLP-1 receptor agonist|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1530535|NCT02738151|Drug|Glimepiride|"Pharmaceutical form: tablet
Route of administration: oral"
1530536|NCT02738151|Drug|Metformin|"Pharmaceutical form: tablet
Route of administration: oral"
1530537|NCT02738138|Drug|ABT-493/ABT-530|Tablet
1530538|NCT02738112|Device|Encore System|Hyo-mandibular suspension
1530539|NCT02738086|Behavioral|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning.
1530540|NCT02738086|Behavioral|Physical Activity Behavior Change (PABC)|Home-based weekly sessions (30 min) using behavior change methods for promoting physical activity. Sessions will occur using home-based computer tablets for real-time video interface between the participant and therapist. Participants will wear wrist-mounted activity sensors with direct physical activity feedback during the intervention period to allow for behavioral feedback and action planning
1530541|NCT02738073|Drug|Control: Saline|
1530542|NCT02738073|Drug|Tranexamic Acid|
1530543|NCT02738060|Dietary Supplement|Baked Milk|"The patients in case group will be received baked milk daily in the form of muffin(30 cc milk (equal to 1/3 of milk's proteins) heated in 350 F or 180 C for 30 mints) for 6 months. They will be visited weekly in the first month and every 2 weeks in other 5 months. At the end of the 6 months, the patients will undergo oral food challenge by 30 grams baked cheese in the form of pizza cheese. If the test will be negative, they will receive pizza cheese 4 or 7 days per week for other 6 months. The patients will be followed every 2 weeks during this period.
Skin prick test and serum IgE levels will be done at the beginning of the study, at 6 and 12 months. IgG4, being specific for milk allergens, will also measured at the beginning and at 12 months of the study."
1530545|NCT02738021|Behavioral|STRONG|A brief 3-session IPT-based preventive intervention, on maternal and child health outcomes.
1530546|NCT02738008|Drug|ARC-520 Injection|Intravenous injection
1530547|NCT02737995|Drug|Ferric carboxymaltose infusion|Subjects with functional iron deficiency determined by the results of iron biomarker results at Visit 2 will receive a single dose of intravenous ferric carboxymaltose . The dose of Injectafer will be calculated from a modified Ganzoni equation adapted from previous heart failure clinical trials The maximum dose of Injectafer will be 750 mg. The calculated dose of Injectafer will be diluted in normal saline solution (4 mg/ml) and administered via a volumetric pump administered over 30 minutes.
1530548|NCT02737982|Procedure|percutaneous coronary intervention|coronary angiography with or without stent implantation, measurement of indexes of epicardial and microvascular reperfusion
1530549|NCT02737969|Device|Transesophageal Echocardiography/angiography (TEE/Angio)|"The TEE probe will be inserted into the patient's esophagus, after anesthetic induction or conscious sedation is administered, and removed after the completion of the procedure. Once the TEE probe is placed, the interventional cardiologist will acquire 2 fluoroscopic images with the TEE probe. These images will be used to co-register the ultrasound and fluoroscopy systems. As part of routine care, TEE and fluoroscopy images will be acquired throughout the procedure for clinical purposes. As new fluoroscopy images are acquired, the prototype software will automatically track the location of the TEE probe. When the echocardiographer has an image of a cardiac structure of interest, he may use the prototype software to place landmarks.
The echocardiographer may then press a button to have the landmarks displayed on the fluoroscopy image that is only visible on an assist monitor and will not interfere with the standard fluoroscopy imaging monitor."
1530550|NCT02737943|Drug|Moist Exposed Burn Ointment (MEBO)|is a registered USA patented formulation since 1995. MEBO is pure herbal, natural in origin, containing beta-sitosterol phellodendron amurense, scutellaria baicalensis, coptis chinensis, pheretima aspergillum, Beeswax and sesame oil. 15, 19 The pharmacological effects are attributable to: beta-sitosterol, isolated from phellodendron amurense, flavonoids mainly baicalin isolated from scutellaria baicalensis, alkaloids mainly berberine, isolated from coptis chinensis, Beeswax and sesame oil.
1530551|NCT02737943|Drug|Zagazig|Standard care is an antibiotic ointment in combination of analgesic for relief of pain.
1530552|NCT02737930|Drug|Fluoxetine|
1530553|NCT02737930|Drug|Placebo|
1530556|NCT02737904|Other|APT|APT for 30 minutes per day on 5 days per week for 4 weeks: 2 minute warm up consisting of passive cycling, where the legs of the participant are moved passively by the APT at 10 revolutions per min (rpm). Next, the participant will cycle for up to 26 minutes, at 60rpm. In this phase, the participant is required to actively cycle and to maintain a symmetrical pattern of movement using the feedback on the display. If the participant is unable to actively cycle at any point during the 26 minute exercise period, or if they have a spasm, the MOTOmed APT will revert to the passive mode. The final phase is a cool down where participants again will have 2 minutes of passive cycling at 10rpm.
1530557|NCT02737904|Other|Usual care|Personalised in-patient rehabilitation programme
1530560|NCT02737878|Behavioral|Aerobic Training|Six months of twice-weekly aerobic training that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
1530561|NCT02737878|Behavioral|Resistance Training|Six months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
1530562|NCT02737878|Behavioral|Balance and Tone Training|Six months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
1530563|NCT02737878|Behavioral|Balance and Tone Program|Six months of four times a week stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
1530564|NCT02737865|Drug|Sonazoid|Sonazoid: Commercially available contrast material for ultrasonography
1530565|NCT02737865|Device|Superb-Microvascular imaging|Superb-Microvascular imaging: new sonographic software technique on ultrasonography to detect low-vascular flow without use of contrast media for ultrasonography
1530566|NCT02737852|Device|"Trojan Chameleon Personal Lubricant"|silicone base with sensate
1530567|NCT02737839|Other|Stepping On Education Program|
1530568|NCT02737839|Other|Home visit|
1530569|NCT02737839|Other|Patient Questionnaire|-Includes questions about demographics, activity level, performance status, falls, medication, comorbidities, hearing, vision, pain, and neuropathy
1530570|NCT02737826|Drug|Buprenorphine - Phase I|In Phase I, we will determine buprenorphine tolerability using a one-day outpatient buprenorphine initiation protocol.
1530571|NCT02737826|Drug|Gabapentin - Phase II|Subjects who tolerate buprenorphine initiation (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
1530572|NCT02737826|Drug|Placebo - Phase II|Subjects who tolerate buprenorphine initiation (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
1530573|NCT02737826|Drug|Buprenorphine taper - Phase II|Subjects who tolerate buprenorphine initiation (determined by pain level ≤ to baseline, withdrawal measures ≤ to baseline, and willingness to continue with taper) will proceed to Phase II, which will involve randomization to gabapentin or placebo, buprenorphine stabilization, and buprenorphine tapering.
1530574|NCT02737813|Drug|Isobaric marcaine|Isobaric marcaine 2.2 mL for spinal block
1530575|NCT02737813|Drug|Hyperbaric marcaine|Hyperbaric marcaine 2.2 mL for spinal block
1530576|NCT02737800|Procedure|endometrioma aspiration|Transvaginal ultrasound guided aspiration
1530577|NCT02737800|Drug|GnRh agonist ( Decapeptyl )|3 monthly doses of Decapeptyl 7.5mg intramuscular
1530578|NCT02737800|Procedure|standard long stimulation protocol|Decapeptyl 3.75mg in the mid luteal phase followed by human menopausal gonadotropins(HMG);fostimon, or merional injections after bleeding, doses are individualization according to each patient, monitored by follicular size &serum estradiol.
1530579|NCT02737787|Biological|WT1 Vaccine|
1530580|NCT02737787|Drug|Nivolumab|
1530581|NCT02737774|Drug|Icotinib|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin. After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
1530582|NCT02737774|Drug|Pemetrexed/Carboplatin|All cases that meet the criteria take Icotinib for 18 weeks, If there is no disease progression, then after 14 days of washout period, received 4 cycles of pemetrexed / carboplatin (standard solution, 3 weeks for a cycle of chemotherapy : pemetrexed 500mg/m2 iv , 4 cycles. carboplatin AUC=5 iv ,4 cycles.). After the chemotherapy, continue with Icotinib, 125mg Tid，PO. until disease progression.
1530583|NCT02737761|Behavioral|Qualitative Interview and Adherence Measurements|Subjects will undergo an open-ended, semi-structured interview within two weeks of enrollment. The interview will be approximately 1 hour in length, performed by study staff who have been trained in qualitative research methods. This interview will be completed again 12 weeks later. Subjects will complete the MOS SAS, Automated Self-Administered 24-hour recall (ASA24), Life Orientation Test-Revised (LOT-R), Positive and Negative Affect Schedule (PANAS), Hospital Anxiety and Depression Scale (HADS), Kansas City Cardiomyopathy Questionnaire (KCCQ), and Medical Outcomes Study Short Form-12 (SF-12) at baseline and again at 12 weeks.
1530584|NCT02737748|Drug|TWB-103 add-on Tegaderm|TWB-103 is the primary therapeutics with the use of Tegaderm as a wound-site protection
1530585|NCT02737748|Drug|Placebo+Tegaderm|Placebo to TWB-103 with the use of Tegaderm as a wound-site protection
1530586|NCT02737735|Drug|standard chemotherapy medicine combined with Chinese herbs|
1530587|NCT02737735|Drug|standard chemotherapy medicine|
1530588|NCT02737722|Drug|Bisphosphocin Nu-3|
1530589|NCT02737722|Drug|Placebo|
1530590|NCT02737709|Drug|Paclitaxel and Carboplatin regimen|Chemotherapy regimen:Paclitaxel: 175mg/m2, d1; Intravenous drip injection with 500ml N.S；Carboplatin: AUC=5, d1; Intravenous drip injection with 500ml G.S Paclitaxel injection at first, followed with Carboplatin injection.
1530591|NCT02737696|Behavioral|Web-based prescription opioid prevention for adolescents|The intervention focuses on individual skills factors (e.g., promoting accurate knowledge about risks), as well as peer and societal influences on prescription opioid abuse (e.g., training skills to refuse offers to misuse opioids). When accessing the program, users see pictures of youth who have been in treatment for opioid dependence, and may choose to click on links to: 1) listen to or read real stories of problematic involvement with prescription opioids, 2) view youth' trajectories of important decision points related to prescription opioid misuse, 3) view videos that provide key information or teaches a skill that might help a young person make healthier choices (e.g., refusing offers to misuse prescription opioids), 4) or take quizzes to assess information/skill acquisition.
1530592|NCT02737696|Behavioral|JustThinkTwice.gov website (DEA)|The JustThinkTwice.com website is educational (a large percentage of the website content focuses on opioids) with a menu including: Drug Information, True Stories (of youth who have lost their lives to drugs), Consequences, Facts/Statistics, Videos (e.g., the Life of an Opiate Addict, and Synthetic Drugs), and a brief Quiz.
1530593|NCT02737670|Drug|Sulodexide|25 mg morning and evening for 40 days
1530594|NCT02737670|Drug|Placebo|1 tablet morning and evening for 40 days
1530595|NCT02737644|Other|observation|This is an observational study
1530596|NCT02737631|Device|"Trojan Chameleon Personal Lubricant"|
1530598|NCT02737605|Drug|Intranasal Esketamine|Participants will receive 84 mg intranasal esketamine as 3 devices, each with 28 mg esketamine.
1530599|NCT02737605|Drug|Intravenous Esketamine|Participants will receive 0.8 milligram per kilogram body weight esketamine, 40 minutes, intravenous infusion.
1530600|NCT02737605|Drug|Moxifloxacin|Participants will receive 400 mg Moxifloxacin orally.
1530601|NCT02737605|Drug|Oral Placebo|Participants will receive matching placebo orally.
1530602|NCT02737605|Drug|Intravenous Placebo|Participants will receive placebo 40 minutes, intravenous infusion.
1530603|NCT02737605|Drug|Intranasal Placebo|Participants will receive intranasal placebo (1 spray in each nostril at 0, 5, and 10 minutes).
1530604|NCT02737592|Device|"Trojan Simply Pleasure Personal Lubricant"|silicone base without sensate
1530605|NCT02737579|Procedure|XFM guidance|X-ray images and MRI roadmaps are aligned, during the medically indicated catheterization procedure, both conventional X-ray and investigational XFM images are displayed side-by-side. The operator may choose to be guided by either.
1530606|NCT02737566|Behavioral|Standard Care + Financial Incentives|Tobacco cessation counseling plus pharmacotherapy and financial incentives for quitting.
1530607|NCT02737566|Other|Standard Care|Tobacco cessation counseling plus pharmacotherapy.
1530608|NCT02737553|Procedure|Enclosed morcellation|After extirpation of the myoma from the uterus and repair of the uterine defect, the myoma will be removed from the abdomen with an enclosed laparoscopic electromechanical morcellation as described in the literature by Akdemir et al with using surgical glove (Akdemir A et. al, Innovative technique for enclosed morcellation using a surgical glove. Obstet Gynecol. 2015 May;125(5):1145-9. doi: 10.1097/AOG.0000000000000823.).
1530609|NCT02737553|Procedure|vaginal morcellation|After extirpation of myoma from uterus and repair of the uterine defect, myoma will be removed through the vagina with posterior colpotomy. In this group myoma will also be removed in a enclosed fashion with using endo bag.
1530610|NCT02737527|Procedure|24G intravenous route for Lumbar Sympathetic Block (LSB):|Enrolled subjects enter the operative room with a 24G intravenous route, and then non-invasive blood pressure and pulse oxygen saturation level are continuously monitored during and after the procedure.
1530611|NCT02737527|Device|15-cm Chiba needle for Lumbar Sympathetic Block (LSB)|The skin entry point is infiltrated using 1% lidocaine. A curved 21 G, 15-cm Chiba needle (Cook Inc., Bloomington, IN, USA) is then advanced toward the anterolateral edge of target vertebral body by posterolateral approach in patients with prone position.
1530612|NCT02737527|Device|Ultrasound for Lumbar Sympathetic Block (LSB)|Using Ultrasound, the L3 is identified by locating the lumbosacral junction on a paramedian sagittal scan and then counting cranially. After marking the level of L3 vertebra, the modified transverse scan through lumbar intertransverse space (ITS) is obtained with the transducer positioned 4-6 cm lateral to the mid-line at the L2-L3 intervertebral level. The needle is inserted from a lateral to medial direction using in-plane technique. The needle tip is inserted towards the anterior fascia of the psoas major muscle as close as paravertebral space.
1530613|NCT02737527|Device|Fluoroscope for Lumbar Sympathetic Block (LSB)|Briefly, fluoroscopic guided LSBs are performed at the lower third of the L2 or the upper third of the L3 vertebra. A targeted lumbar vertebral is identified by AP fluoroscopic imaging and the fluoroscopic C-arm is adjusted 25-35° laterally to avoid the transverse process over the needle pathway. After the skin infiltration, the needle is advanced toward the anterolateral edge of the target lumbar vertebra under fluoroscopic guidance using the tunnel vision technique.
1530614|NCT02737527|Drug|10 ml of 0.25% levobupivacaine injection for LSB|After excluding vascular injection with contrast media by a C-arm image intensifier on anteroposterior (AP) and lateral view, 10 ml of 0.25% levobupivacaine is injected through the Chiba needle.
1530615|NCT02737527|Procedure|Temperature measurement for Lumbar Sympathetic Block (LSB)|Temperature monitoring and measurement: skin-surface temperatures are monitored with small, adhesive thermocouple probes attached bilaterally to the plantar surface of the feet using transparent patches at 1-min intervals for a maximum of 20 min.
1530616|NCT02737527|Procedure|Postprocedure care for LSB|Adverse events such as genitofemoral nerve block, lumbar plexus block (transient unilateral leg weakness), or others are documented during and after the procedure for 30 min.
1530617|NCT02737514|Procedure|Air insufflation|Insufflation during colonoscopy including insertion phase
1530618|NCT02737514|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
1530619|NCT02737514|Procedure|water exchange|Water will infused and removed during insertion phase of colonoscopy
1530620|NCT02737501|Drug|Brigatinib|Brigatinib will be administered orally to eligible patients with locally advanced or metastatic ALK+ NSCLC naïve to ALK inhibitors at a dose of 90 mg QD for 7 days, then 180 mg QD, continuously, until disease progression, unacceptable toxicity, withdrawal of consent or death.
1530621|NCT02737501|Drug|Xalkori (crizotinib)|Crizotinib will be administered to eligible patients with locally advanced or metastatic ALK+ NSCLC naïve to ALK inhibitors as 250 mg orally BID, until disease progression, unacceptable toxicity, withdrawal of consent or death.
1530622|NCT02737488|Behavioral|Trauma Systems Therapy (TST)|Treatment will be delivered by clinicians and trainees working at the CSC who have been trained in delivering TST. Participants who begin treatment in the safety-focused phase will have their treatment sessions in their homes. Whenever a child enters a different phase of treatment, he or she will go to the site for office visits. At the beginning of treatment, TST clinicians will do a brief diagnostic assessment. All documentation that is completed by the clinician as part of TST treatment at the NYU Langone Medical Center will be documented using Epic, a standard of care integrated health information system for patient safety. Although we are not providing the CSC's standard of care in this study,we are replicating standard care as TST is standard care in other settings. Providing medication is part of standard TST treatment and conforms to good usual practice integrated with psychotherapy. Medication will not be prescribed for research purposes.
1530665|NCT02737228|Drug|Gemcitabine|1000 mg/m^2 intravenously every week three times per cycle (4 weeks)
1530666|NCT02737228|Drug|Erlotinib|100 mg per oral daily per cycle (4 weeks)
1530667|NCT02737215|Device|CPAP|patients will receive CPAP therapy with Auto-CPAP
1530623|NCT02737488|Behavioral|Treatment as Usual (TAU)|"Youth in the control group will be referred to a mental health clinic in close proximity to their residence, in order to receive an evaluation and trauma treatment as usually provided. It cannot be specifically determined, in advance, the nature of this treatment.
The clinics will be contacted after the family enrolls to determine if there was a specific protocol followed. An NYU CSC research coordinator will contact the clinic and assist in scheduling the subject's first visit. Families who do not enroll in any community treatment or dropout of treatment will be followed according to the research protocol for data collection. At the 3, 6, and 9 month assessments, the research coordinator will request the patient's records from the community treatment clinic they are attending in order to track and keep record of the youth's treatment modality, progress, and visit frequency."
1530627|NCT02737462|Drug|CG200745 PPA|CG200745 PPA intravenously daily for first 5 consecutive days per cycle (4 weeks)
1530628|NCT02737436|Drug|Intranasal Oxytocin|Intranasal oxytocin (24IU) given 50 minutes prior to behavior assessment or scanning
1530629|NCT02737436|Drug|Placebo|Intranasal placebo spray given 50 minutes prior to behavior assessment or scanning
1530630|NCT02737423|Drug|cholecalciferol|Effect of Vitamin D on the symptoms of diabetic neuropathy
1530631|NCT02737410|Behavioral|Gut-directed Hypnotherapy|The GHT protocol used was the Manchester protocol of GHT and consisted of 10 weekly sessions (45 min), with six patients per group over a treatment period of 12 weeks. GHT was performed at the University Hospital by two experienced physicians trained in Manchester (UK).
1530636|NCT02737384|Biological|Depletion in CD45RA graft donor|"Experimental treatment: negative fraction after CD34+ selection from PBSC graft is depleted of naïve CD45RA+ cells. this fraction is reinjected to the recipient and is the experimental product.
Conditioning regimen:
Up-front ATG from D-14 toD-11 Busulphan IV from D-8 to -5 Fludarabine from D-7 to D-4 Thiothepa D-3 to D-2
Graft: CD34+ cells positively selected cells from PBSC of the donor
Post transplant immunosuppression: ciclosporin started at D-1 to D+100"
1530637|NCT02737371|Drug|F901318 Dose level A oral|Adverse events days 1-10
1530638|NCT02737371|Drug|Placebo dose level A oral|Placebo adverse events days 1-10
1530639|NCT02737371|Drug|F901318 Dose level B oral|F901318 adverse events days 1-10
1530640|NCT02737371|Drug|Placebo dose level B oral|Placebo adverse events days 1-10
1530641|NCT02737371|Drug|F901318 Dose level C oral|F901318 adverse events days 1-10
1530642|NCT02737371|Drug|Placebo Dose level C oral|Placebo adverse events days 1-10
1530643|NCT02737358|Drug|N-acetylcysteine (NAC)|NAC or matched placebo will be given to study participants for 8 weeks.
1530644|NCT02737358|Other|Placebo|Matched placebo (2 capsules taken in the morning and evening) will be taken by study participants for eight weeks. All participants will receive brief smoking cessation counseling and support.
1530645|NCT02737345|Other|Rotem|
1530646|NCT02737332|Drug|Zytiga® (Abiraterone Acetate)|Zytiga® 1,000 mg (4 x 250 mg qd) Compared to SoluMatrix™ Abiraterone Acetate 500 mg
1530647|NCT02737332|Drug|SoluMatrix™ (Abiraterone Acetate)|SoluMatrix™ Abiraterone Acetate 500 mg Compared to Zytiga® 1,000 mg (4 x 250 mg qd)
1530648|NCT02737319|Drug|Rosuvastatin|40 mg of rosuvastatin before angioplasty
1530649|NCT02737306|Drug|PRO 140|Two 1 mL injections, 175mg/ml each, of PRO 140 to opposite sides of the abdomen.
1530650|NCT02737306|Drug|Placebo|Two 1 mL injections of the Placebo to opposite sides of the abdomen.
1530651|NCT02737293|Other|Control Diet|4-week intake of Control Diet 5 day rotating menu
1530652|NCT02737293|Other|Med Diet|4-week intake of Med Diet 5 day rotating menu
1530653|NCT02737293|Other|Med Diet + Whole Egg|4-week intake of Med Diet plus Whole Egg 5 day rotating menu
1530656|NCT02737267|Behavioral|Moderately high protein diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction."
1530657|NCT02737267|Behavioral|Low fat diet|"After the recruitment randomization of the study participants, the study will consists of a 4-month nutritional intervention (body weight loss period) followed by a second 6-month period (body weight maintenance period) in which the subjects of the study will continue with the assigned diet, but without any energy restriction.the energy derived from fat"
1530658|NCT02737254|Drug|Oxytocin|40 IU/ML nasal spray. One administration: children <40kg administer 12IU, children >40kg administer 24IU.
1530659|NCT02737254|Drug|Placebo|NaCl 0,9 % nasal spray.
1530660|NCT02737254|Other|Secure CBM training|Children are trained to interpret ambiguous maternal behavior in a secure way.
1530661|NCT02737254|Other|Neutral CBM training|Children receive a training unrelated to the interpretation of maternal behavior.
1530664|NCT02737228|Drug|CG200745 PPA|CG200745 PPA IV every week three times per cycle (4 weeks)
1532559|NCT02723994|Drug|Methotrexate|
1530668|NCT02737202|Drug|saracatinib|Subjects will receive enough tablets for 90 days +/- 14 days at each visit. Subject will have visits every 90 days for drug accountability as well as safety and efficacy testing to include pulmonary function testing, laboratory testing to include liver and kidney profile, urine pregnancy testing at each visit, vital signs, physical examination - any medically significant changes from baseline visit will be recorded, all adverse events will be monitored until resolution.
1530669|NCT02737189|Procedure|Mechanical embolectomy|Mechanical embolectomy with Solitaire stentriever in conjunction with manual aspiration
1530670|NCT02737189|Drug|Medical Treatment|Best Medical Treatment and maximum supportive care, not including mechanical thrombectomy, no intra arterial treatment
1530671|NCT02737176|Other|Tobacco cessation intervention|"The nicotine dependence status is evaluated by the Fagerstrom Test for Nicotine Dependence test; those who 3 or more score are eligible for the intervention.
During the study, attending doctors implement a tobacco cessation intervention with standard treatments for above oral diseases.
Even if the subjects failed to abstain from smoking, the treatment is continued.
In case of the use of the nicotine replacement therapy, The investigators supply NRTs (nicotine patch or gum) for 2 weeks as a free of charge, and later the subjects themselves purchase it as over the counter (OTC) drugs at a pharmacy."
1530672|NCT02737150|Device|CoreValve Evolut R|
1530673|NCT02737150|Device|Edwards Sapien 3|
1530674|NCT02737150|Procedure|Local anesthesia with conscious sedation|
1530675|NCT02737150|Procedure|General anesthesia|
1530676|NCT02737137|Procedure|Manual measurement|Monitoring by ultrasound, Neurostimulation and Measurement Manual of the injection pressure of the local anesthetic
1530677|NCT02737137|Procedure|Measurement with a gauge|Monitoring by ultrasound, Neurostimulation and measurement with a gauge of the pressure of injection of the local anesthetic
1530678|NCT02737124|Drug|Acetaminophen|Acetaminophen will be given 24 hours before scheduled surgery.
1530679|NCT02737124|Other|Placebo|Placebo will be given to subjects 24 hours before scheduled surgery.
1530680|NCT02737111|Behavioral|Initial Screening Process|The doctor who meets with the family to share the diagnosis will give the participants a flyer about the research study at the end of their consultation and will briefly explain the study aim and purpose. Following this, the ICC Service Clinical Nurse Specialists (CNS) and the primary researcher will identify patients who meet the inclusion and exclusion criteria and all patients who are eligible to take part will be contact by a CNS shortly after a child receives a diagnosis to follow up with the family, and ask permission for the primary researcher to contact the child's parents to discuss the study.
1530681|NCT02737111|Behavioral|Information and Informed Consent|The researcher will contact parents of patients who agreed some weeks after receiving the diagnosis, check inclusion criteria, and information sheets will be provided. Individuals who consent to participate will arrange to meet with the researcher in their family home or at the hospital. When they meet, the researcher will go through the participant information sheet with the individuals, and gain written consent for participation
1530682|NCT02737111|Behavioral|Interview|Families who wish to take part will be invited to participate in an interview 2-3 months after they received the diagnosis from the hospital. At least ten families (and therefore at least 30 individuals including children with the diagnosis, parents and siblings) will be interviewed separately, about their experiences of the communication about the diagnosis to them, their child or their siblings. Younger children may do some drawings with the researcher about their experiences, and the researcher will ask questions about these drawings.Participants can be included even if not all family members wish to take part.
1530683|NCT02737111|Behavioral|Validated Questionnaires|Each member of the family will complete the mood and quality of life questionnaires.
1530684|NCT02737111|Behavioral|Debrief|At the end of each interview the research will explore with the individual to discuss how they found the experience and answer any questions they might have and review the questionnaires that they completed. The researcher will then meet with children and parents together to discuss the experience as a family.Information will be shared with families about options for accessing support including the paediatric psychology service at the hospital or local support services, if they wish. After the interviews, the researcher will send a letter to participants GP and medical team to inform them that they are taking part.
1530685|NCT02737098|Other|Enhanced Implementation Strategy|The enhanced implementation strategy will add external facilitation to the standard VA implementation strategies. External facilitation will begin with an assessment of the current workflow at the VHA Medical Center and the affiliated CBOCs using System Redesign methods. The external facilitation team will then generate a clinical workflow chart that describes the current process of care. With advice from the external facilitation team, the local champion will then incorporate the clinical process of the TOP intervention into the current clinical workflow chart, making changes to the TOP intervention and/or current clinical workflow as needed. The local champion will also meet monthly with external facilitators to troubleshoot and make refinements.
1530686|NCT02737098|Other|Standard Implementation Strategy|Standard VA implementation strategies will include disseminating a clinical intervention manual, a local champion guide, care manager training materials, PTSD case-finder tool, and technical support from the facility level telehealth technician. Internal facilitation will be conducted by the designated local champion. In addition, each VAMC will receive funds to hire a full time telephone care manager.
1530687|NCT02737085|Biological|Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells|Patients receive autologous-derived CD19-targeted CAR-T cells following CD20-targeted CAR-T cells after receiving lymphodepleting chemotherapy.
1530688|NCT02737072|Drug|LY2510924|Administered SQ
1530689|NCT02737072|Drug|Durvalumab|Administered IV
1530690|NCT02737059|Drug|Naloxegol|25mg daily
1530691|NCT02737059|Drug|Codeine|30mg 4 times daily
1530692|NCT02737059|Drug|codeine placebo|4 times daily (placebo will be made to match the codeine)
1530693|NCT02737059|Drug|naloxegol placebo|placebo will match naloxegol, given daily
1530698|NCT02737033|Drug|Rhodiola|Rhodiola rosea 800mg
1530699|NCT02737033|Drug|Placebo|innocuous pill manufactured to mimic Rhodiola
1530700|NCT02737020|Drug|Rhodiola|Rhodiola rosea 200mg pill up to four times a day
1530701|NCT02737020|Drug|Placebo|up to four times a day
1530702|NCT02737007|Drug|[14C]-GSK3191607|[14C]-GSK3191607 is a solution to be administered intravenously as a single dose infusion over 15 minutes. It is a radio-labeled product; 100 mcg of [14C]-GSK3191607 contains approximately 7.4 kilobecquerel (kBq) of [14C] radioactivity.
1530703|NCT02736994|Drug|PIP toothbrush cleaner® (Chrisal, Lommel, Belgium).|Probiotic
1530704|NCT02736994|Drug|Corega Tabs Anti-bacteria®|Cleansing tablet -Corega Tabs Anti-bacteria® (GlaxoSmithKline Consumer Healthcare SA, Genval, Belgium)
1530705|NCT02736994|Other|Water|Water
1530706|NCT02736981|Behavioral|Behavioral Weight Loss (BWL)|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching.
1530707|NCT02736981|Behavioral|BWL + Autonomous Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will receive coaching that places an increased emphasis on their values and personal choices, and also have the option to attend several experiential group sessions that will help those interested to apply the material and skills they are being taught (e.g., cooking demonstration, circuit training class).
1530708|NCT02736981|Behavioral|BWL + Extrinsic Motivation|The intervention represents an adapted version of gold-standard evidence based adult behavioral weight loss that has been tailored specifically to meet the needs of 18-25 year olds. The program includes personalized dietary and physical activity prescriptions, training in behavioral strategies, weekly lesson content, and reporting of key behaviors and personalized feedback and coaching. Participants in this arm will have the opportunity to receive small monetary incentives in weeks 2-24 for tracking weight and calorie intake, and will be eligible for a raffle based on weight loss.
1530709|NCT02736968|Drug|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules
1530710|NCT02736968|Other|Placebo|Placebo
1530711|NCT02736955|Drug|Valbenazine|
1530712|NCT02736942|Procedure|Laparoscopic TME|Laparoscopic Total Mesorectal Excision
1530713|NCT02736942|Procedure|TaTME|Transanal Total Mesorectal Excision
1530714|NCT02736929|Behavioral|Cognitive Processing Therapy - Cognitive|CPT-C is a brief cognitive behavioral treatment for PTSD. It consists of 2 hours of therapy each week for 6 weeks (i.e., two sessions).
1530715|NCT02736916|Radiation|HS-WBRT PCI|LD-SCLC patients with HS-WBRT PCI
1530716|NCT02736916|Radiation|Conventional PCI|LD-SCLC patients with conventional PCI
1530717|NCT02736903|Behavioral|PennFit mobile individual intervention|PennFit (individual) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (individual) to record and monitor their own physical activity progress.
1530718|NCT02736903|Behavioral|PennFit mobile online network intervention|PennFit (online network) is a mobile app intervention. Participants received a Fitbit physical activity tracking device and an introductory physical activity promotion session emphasizing the health benefits of physical activity and building skills for daily exercises. Participants used the PennFit app (online network) to record and monitor their own physical activity progress. They could see both their own information and the profiles and activity logs of the three other women assigned to their network. In addition, they could send messages to the network through an instant chatting tool.
1530719|NCT02736890|Drug|Botulinum Toxin A|Subjects will receive subcutaneous Botulinum Toxin A injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
1530720|NCT02736890|Drug|Placebo|Subjects will receive subcutaneous placebo injections into the marked painful region. The syringes will be prepared by a third party prior to the injection and the administrator of the procedure will be blinded to syringe content. This physician will be performing the injections under sterile conditions. Local anesthesia, EMLA (lignocaine/prilocaine eutectic mixture) cream, up to 4 grams, will be applied topically for local anesthesia. After 50 minutes, the cream will be cleaned off. Overlying skin will be sterilized with either betadine or alcohol solution.
1530721|NCT02736877|Procedure|Lumera Microscope with OCT RESCAN|corneal transplantation guided by Lumera Microscope with OCT RESCAN
1530722|NCT02736877|Procedure|Conventional Microscope|corneal transplantation guided by Conventional Microscope
1530723|NCT02736851|Other|Home-based telemedicine group|"All patients referring to the rehabilitation service as out-patients underwent in-hospital a specific exercise program for the neck. Patients are instructed individually by a physical therapist to perform several types of exercises and, from the first rehabilitation session, are encouraged to exercise regularly at home. Written and illustrated material reporting home exercises is provided to all patients.
At the end of out-rehabilitation program, according to a randomization list, patients are randomized in 2 groups and those included in a Home-Based Telemedicine (HBT) program are followed up by a nurse tutor at home for a 6-month period."
1530768|NCT02736552|Drug|S-1 for 1 year|1 year S-1 after D2 resection
1530769|NCT02736539|Drug|CBS 2004 (galacto-oligosaccharides)|CBS 2004 active treatment
1530770|NCT02736539|Drug|Placebo|Placebo treatment
1530771|NCT02736526|Procedure|recession or resection of the horizontal extraocular muscles|
1530724|NCT02736838|Device|tcpO2|Skin oxygenation will be measured by tcpO2, and microvascular flow with Laser Doppler. Measurements will be made inserting probes in sacrum, trochanters, elbows and heels, before and after the end of each decubitus lying period, and in every position and angle. Pressure: Continuous pressure measurements will be made in sacrum, trochanters, elbows and heels. Measures will be carried out at sessions separated at intervals of 7 days, with 0 to 4 hours of experimental exposure to pressure, different bed angles (0º, 30º, 45º), and lateral decubitus tilts (30, 90). Bioimpedance will be performed at baseline early in the morning, fasting and after emptying the bladder. Subjects will be lying without clothes, in a supine position on the bed, with a distance of at least 25 cm between thighs. The measurement will be made in single frequency mode (50 kHz , 400 μARMS) with a tetrapolar electrode arrangement.
1530725|NCT02736838|Device|Laser Doppler|
1530726|NCT02736825|Device|Ultherapy®|Focused ultrasound energy delivered below the surface of the skin
1530727|NCT02736825|Device|Standard transducer|Commercially available transducer designed to deliver focused ultrasound energy below the surface of the skin, delivering one line of treatment at a time.
1530728|NCT02736825|Device|Simulines transducer|New transducer designed to deliver focused ultrasound energy below the surface of the skin, delivering two lines of treatment simultaneously.
1530729|NCT02736812|Biological|French Lyophilized Plasma|"During the pre-hospital phase, the main events related to this arm are
Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)
Usual pre-hospital care according to recommendations in best practices
Administration of FLYP"
1530730|NCT02736812|Biological|Normale Saline Solution|"During the pre-hospital phase, the main events related to this arm are
Blood samples taken before treatment (TP, fibrinogen, platelets, RBC, grouping)
Usual pre-hospital care according to recommendations in best practices
Administration of Normale Saline Solution"
1530731|NCT02736799|Device|Sham vibrating capsule|Sham device without vibration
1530732|NCT02736799|Device|Vibrant Capsule (1 vibration)|1 vibration/min
1530733|NCT02736799|Device|Vibrant Capsule (3 vibration)|3 vibration/min
1530734|NCT02736799|Device|Vibrant Capsule (5 vibration)|5 vibration/min
1530735|NCT02736773|Other|xenograft material to slow resorption|xenograft material to slow resorption (Bio-Oss®)
1530736|NCT02736760|Drug|Daylight photodynamic therapy using Methylaminolevulinate (MAL)|"In the Daylight photodynamic therapy arm the patients will apply a sunscreen to the whole face which is followed by lesion preparation of AKs. Following this, MAL will be applied in a thin layer to the whole face. Within 30 min after MAL application patients expose themselves to daylight for 2 hours.
5 photodynamic therapy treatment sessions (visits 1-5) will be performed within 18 months."
1530737|NCT02736760|Procedure|Cryosurgery|In the control group, cryosurgery as standard reference therapy will be performed at visit 1, and in case of non-cleared or newly occurred AKs at visits 2-5. Cryosurgery of AK lesions will be investigated as standard reference therapy. Single freeze-thaw cryosurgery is performed using an open spraying procedure with liquid nitrogen with nozzle size C. After formation of an ice-ball of the required size, freeze time starts. Freeze time should lie between 5 s and 10 s.
1530738|NCT02736747|Other|Cryotherapy|
1530739|NCT02736747|Other|Placebo|
1530740|NCT02736734|Drug|CRH|CRH injection: 100 µg CRH powder for injection (CRH Ferring) dissolved in 1ml NaCl 0.9%, administration intravenously over the course of 1 minute to avoid side effects.
1530741|NCT02736721|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a in doses between 90 and 450 mcg will be administered subcutaneously once weekly until medically indicated as judged by the treating investigator.
1530742|NCT02736708|Device|probe based confocal laser endomicroscopy|real-time, microscopic imaging of tissue at the cellular level via a small diameter probe.
1530744|NCT02736682|Drug|Single dose antibiotic|Single dose arm receive 2g of IV Ceftriaxone and 500 mgs ofIntra venous Metronidazole given to the mothers 30-60 minutes pre operative.
1530745|NCT02736682|Drug|Multiple dose antibiotic|Multiple dose arm receive 1 g of IV Cetriaxone plus 500 mgs during surgery and there after IV ceftriaxone once a day for 3 days and IV Metronidazole 500mgs during surgery and there after every 8 hours for 3 days.
1530746|NCT02736669|Behavioral|Energy Reduction|
1530747|NCT02736656|Drug|SPN-812 ER|
1530748|NCT02736630|Other|body temperature|intermittant tympanic temperature measurement during surgery
1530749|NCT02736617|Drug|Ibrutinib|Given PO
1530750|NCT02736617|Other|Laboratory Biomarker Analysis|Correlative studies
1530751|NCT02736617|Biological|Obinutuzumab|Given IV
1530752|NCT02736604|Drug|nitrous oxide anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with Nitrous Oxide and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
1530753|NCT02736604|Drug|air anesthesia|General anesthesia will be maintained by 40% oxygen (FiO2 0.4) with air and volatile anesthetic sevoflurane through laryngeal mask airway (LMA Supreme Size 3/4) or endotracheal tube (Size 7.0-7.5). All patients will receive standard anesthetic care and monitoring
1530754|NCT02736604|Device|laryngeal mask airway (LMA Supreme Size 3/4|
1530755|NCT02736604|Drug|sevoflurane|
1530756|NCT02736591|Drug|DHEA|Women will receive oral DHEA 25 mg t.d.s. 12 weeks before ICSI.
1530757|NCT02736591|Drug|Growth Hormone-Releasing Hormone|Women will receive 4 IU of growth hormone on day 6 of hMG stimulation in a daily dose of 2.5 mg SC until the day of hCG triggering
1530758|NCT02736591|Drug|Placebo 1|Women will receive an oral placebo similar to DHEA for 12 weeks before ICSI.
1530759|NCT02736591|Drug|Placebo 2|Women will receive a placebo injection similar to growth hormone daily from day 6 of hMG stimulation until the day of hCG triggering.
1530760|NCT02736578|Drug|Cetuximab-IRDye 800CW|Given IV
1530761|NCT02736578|Procedure|Intraoperative Imaging|Undergo intraoperative imaging
1530762|NCT02736578|Other|Laboratory Biomarker Analysis|Correlative studies
1530763|NCT02736578|Other|Pharmacological Study|Correlative studies
1530764|NCT02736578|Procedure|Photoacoustic Imaging|Correlative studies
1530765|NCT02736578|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1530766|NCT02736565|Biological|pbi-shRNA™ EWS/FLI1 Type 1 LPX|
1530767|NCT02736552|Drug|S-1 for 6 months|6 months S-1 after D2 resection
1530772|NCT02736513|Drug|AZD9291|Patients will receive AZD9291 at a dose of 80 mg once daily.
1530773|NCT02736500|Drug|28 GBq 177Lu-DOTATATE|Patients without risk factors (particularly long standing and poorly controlled diabetes and hypertension) for late renal toxicity will be administered with 5 cycles of 5.5 GBq (150 mCi) each, up to the total cumulative activity of 28 GBq (750 mCi) of 177Lu-DOTATATE.
1530774|NCT02736500|Drug|22 GBq 177Lu-DOTATATE|Patients with risk factors for late renal toxicity will be administered with 6 cycles of 3.7 GBq (100 mCi) each, up to the total cumulative activity of 22 GBq (600 mCi)177Lu-DOTATATE
1530775|NCT02736487|Device|True-Washout-Sham Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of true air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of sham air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
1530776|NCT02736487|Device|Sham-Washout-True Air Filtration Intervention|This intervention involved three sequential steps: (1) 12 to 20 hours of sham air filtration intervention; (2) at least two weeks of washout period; (3) 12 to 20 hours of true air filtration intervention. In the indoor environment, the portable filtration device drew room air, sent it through filter and active carbon (for true filtration) or active carbon alone (sham filtration) and then delivered processed air back to room air. In the study the portable filtration device processes 2.8 cubic meter of room air per minute. The washout period lasted for at least two weeks where no filtration intervention was implemented.
1530777|NCT02736474|Drug|Naltrexone|3 tablets（15mg） once per day in the first two weeks，then Naltrexone 5 tablets（25mg） once per day during the rest of the study.
1530778|NCT02736474|Drug|Placebo Naltrexone|Placebo Naltrexone created and masked by the pharmacy to be used as a control.
1530779|NCT02736474|Drug|Bupropion|1 capsule（150mg） once per day in the first two weeks，then 2 capsules（300mg） once per day during the rest of the study.
1530780|NCT02736474|Drug|Placebo Bupropion|Placebo Bupropion created and masked by the pharmacy to be used as a control.
1530782|NCT02736448|Drug|Capecitabine|oral low dose of capecitabine
1530783|NCT02736448|Drug|Lu-PRRT|Lu-PRRT (at 3.7Gbq per cycle x 7 cycles)
1530784|NCT02736448|Drug|SS-LAR|long acting octreotide or lanreotide
1530785|NCT02736435|Device|Magnetic Resonance Guided High Intensity Focused Ultrasound|
1530786|NCT02736435|Drug|leuprolide acetate for depot suspension|
1530787|NCT02736422|Other|Hyperpolarised Xenon|Hyperpolarised gas Magnetic resonance imaging (MRI) (3He and 129Xe) has enabled novel methods of in-vivo functional lung imaging that do not rely on the use of ionising radiation.
1530788|NCT02736409|Drug|Oral Budesonide Suspension (OBS)|OBS 2mg twice daily
1530789|NCT02736409|Drug|Placebo|Matching Placebo dose
1530790|NCT02736396|Other|fMRI|Functional MRI scan to be performed
1530791|NCT02736396|Other|Neuropsychological tests|Cognitive assessments will be performed, including Mini Mental State Examination, Rey Auditory Verbal Learning Test, Stroop, Visual Short Term Memory Assessment.
1530792|NCT02736344|Device|BioNIR Ridaforolimus Eluting Coronary Stent|
1530793|NCT02736331|Dietary Supplement|Treatment 1|Treatment 1 Beverage
1530794|NCT02736331|Dietary Supplement|Treatment 2|Treatment 2 Beverage
1530795|NCT02736318|Other|processed osteochondral allograft|
1530796|NCT02736305|Drug|Regorafenib|Once a day for 21 days in a 28 days cycle
1530798|NCT02736279|Drug|Dimethyl fumarate|Observation of impact of dimethyl fumarate treatment initiation on mood and gut microbiome over the first 6 months of therapy
1530799|NCT02736266|Drug|Pembrolizumab (MK-3475)|Pembrolizumab given intravenously in 30 min. infusion every 3 weeks
1530800|NCT02736240|Biological|7-valent pneumococcal conjugate vaccine|
1530801|NCT02736240|Biological|13-valent pneumococcal polysaccharide conjugate vaccine|
1530802|NCT02736227|Drug|Tacrolimus Withdrawal and Everolimus Monotherapy|During the first month post-transplant, the subject receives everolimus (about 5-8 ng/mL) and tacrolimus with or without mycophenolic acid as part of standard of care procedures. At one month post-transplant, mycophenolic acid will be stopped and tacrolimus dosage will be reduced while continuing the dosage of everolimus. At three months post-transplant, tacrolimus dosage will be reduced by 50% of the daily dose each week. At four months post-transplant, tacrolimus will be discontinued.
1530803|NCT02736214|Behavioral|Reproductive Life Plan (RLP)|A structured discussion based on the RLP, including information about reproduction and a brochure with the same information.
1530804|NCT02736201|Device|Capacitive diathermy (T-CaRe®)|The instrumental manual therapy with the switched on capacitive diathermy electrode (IMT+ T-CaRe® on; n = 10) and the instrumental manual therapy with the switched off capacitive diathermy electrode (IMT+ T-CaRe® off; n = 10) will be bilaterally treated for 4 weeks (1 treatment per week during 10 minutes) in the lumbopelvic region.
1530805|NCT02736201|Other|Instrumental manual therapy|Bilateral longitudinal massage in the lumbar region (110 mm; 5 minutes in each side)
1530806|NCT02736188|Drug|Aceneuramic Acid Extended-Release Tablets|
1530809|NCT02736162|Other|No treatment (intervention) was administered|
1530810|NCT02736149|Drug|ubenimex|
1530811|NCT02736136|Behavioral|joint observation and video feedback|
1530812|NCT02736123|Drug|Nivolumab - Arm A|Nivolumab will be given during the induction phase of the study for 6 weeks. This is followed by surgery. Then maintenance therapy (after recovery from surgery).
1530813|NCT02736123|Drug|Nivolumab + Ipilimumab - Arm B|Nivolumab + ipilimumab during the induction phase of the study for 6 weeks. This is followed by surgery (week 6-8+). Then maintenance therapy will be initiated for up to one year from study drug initial administration ((after recovery from surgery).
1530814|NCT02736084|Behavioral|Positive Psychology|The Positive Psychology intervention consists of 7 exercises that will be completed by the participant with the guidance of a trainer.
1530815|NCT02736071|Drug|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
1530816|NCT02736071|Drug|Tramadol|Women will receive oral Tramadol 100mg 2 hours before the procedure
1530817|NCT02736071|Drug|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure
1530818|NCT02736071|Drug|Placebo 2|Women will receive an oral placebo similar to Celecoxib 2 hours before the procedure
1530819|NCT02736058|Device|Trans- abdominal sonography|
1530820|NCT02736058|Device|Trans-vaginal sonography|
1530821|NCT02736058|Procedure|post-operative pathological specimen examination|
1530822|NCT02736045|Device|emWave|Our approach will be to test the impact of this intervention through a smartphone application, emWave software, which will be provided to all our subjects. emWave is a tool that reduces stress by allowing individuals to be less reactive, think clearly, and make good decisions, especially under pressure. Fifty medical residents with high burnout symptoms will be randomized to receive an 8-week intervention (emWave - computer based resilience training program).
1530823|NCT02736032|Procedure|Embryo transfer|The transfer of cryopreserved-thawed embryos inside the uterus aiming to achieve pregnancy
1530824|NCT02736032|Procedure|Serum Estradiol and Progesterone levels|Serum estradiol and serum progesterone levels in blood on the day of start of progesterone supplementation
1530825|NCT02736032|Drug|GnRH agonist|GnRH agonist given on day 21 of the cycle preceding the embryo transfer
1530826|NCT02736032|Drug|External Estradiol|Estradiol started on day1 of the cycle for endometrial prepartaion
1530827|NCT02736032|Drug|Progesterone|progesterone as luteal phase support start after endometrium is well prepared
1530828|NCT02736019|Drug|Celecoxib|Women will receive oral Celecoxib 200mg 2 hours before the procedure
1530829|NCT02736019|Drug|Tramadol|Women will receive oral Tramadol 100 mg 2 hours before the procedure
1530830|NCT02736019|Drug|Placebo 1|Women will receive an oral placebo similar to Tramadol 2 hours before the procedure.
1530831|NCT02736019|Drug|Placebo 2|Women will receive an oral placebo similar to celecoxib 2 hours before the procedure
1530832|NCT02736006|Other|20 meters air dive|"A dive in the depth of 20 m during 40 minutes. The divers will be evaluated before and 30, 60, 180 minutes after a 20 meters air dive. Venous bubbles will be detected by precordial Doppler 30 minutes after the dive.
In association with this Doppler, Flow Mediated Dilation, blood samples analysing inflammatory and thrombotic factors and other biomarkers will be explored before and after the dive in order to know how vascular and respiratory tracts in this environment react."
1530834|NCT02735967|Other|manual therapy|the positional release techniques will be performed while maintaining this position for 90 seconds procedure is repeated 3 times. Then, the therapist performs the ischemic compression technique on the myofascial trigger point, the compression is maintained for 90 seconds by 3 replications.
1530835|NCT02735967|Device|diadynamic current|Through an electrotherapy device were applied diadynamic in that myofascial trigger point previously marked. 4 minutes from the fixed two-phase mode will be applied (DF), 4 minutes long periods (LP) and 4 minute short periods (CP), the first and second intensely in the sensitive line and the third motor threshold, both supportable according to each patient.
1530836|NCT02735954|Other|Marijuana|This is an observational study looking at the effects of marijuana on health, including lung health and sleep.
1530837|NCT02735928|Device|Pressurized intraperitoneal aerosol chemotherapy with cisplatin and doxorubicin|After insufflation of a 12 mmHg of capnoperitoneum at 37 °C, two balloon trocars will be placed. Parietal biopsies will be taken and ascites (< 500cc) will be removed. A nebulizer will be connected to a high-pressure injector and will be inserted into the abdomen through a trocar. A pressurized aerosol containing cisplatin at a dose of 7.5 mg/m2 body surface in 150 ml NaCl 0.9 % followed by doxorubicin at a dose of 1.5 mg/m2 body surface in a 50 ml NaCl 0.9% solution will be applied via a nebulizer immediately. Then, the system will be kept in steady-state for 30 min (i.e.: application time).
1530838|NCT02735915|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
1530839|NCT02735902|Drug|AVK|The AVK treatment will be administered to obtain an International Normalized Ratio between 2 and 3 as recommended.
1530840|NCT02735902|Drug|Aspirin|"Daily dose is between 75 mg and 100 mg.
Allergic reactions to aspirin may be observed in rare cases. In case of suspicion of allergy, treatment with aspirin is stopped."
1530841|NCT02735889|Other|No Carbonation|500 ml of beverage consisting of water + 10% glucose and no carbonation
1530842|NCT02735889|Other|Low carbonation|500 ml of beverage consisting of water + 10% glucose and low carbonation
1530843|NCT02735889|Other|High carbonation|500 ml of beverage consisting of water + 10% glucose and high carbonation
1530844|NCT02735876|Drug|acalabrutinib|
1530845|NCT02735876|Drug|ibrutinib|
1530846|NCT02735876|Drug|rituximab|
1530847|NCT02735863|Drug|ABX464|50 mg or 150mg once daily for 28 days
1530848|NCT02735863|Drug|Placebo|ABX464 matching placebo
1530849|NCT02735850|Drug|L19-IL2|L19-IL2 added to SBRT
1530850|NCT02735850|Radiation|SBRT|
1530851|NCT02735850|Other|No intervention|
1530852|NCT02735837|Drug|Doxycycline Group|Doxycycline 3% topical gel was put into the periodontal pocket using an insulin syringe
1530853|NCT02735837|Drug|placebo topical gel|placebo topical gel was put into the periodontal pocket using an insulin syringe
1530854|NCT02735824|Procedure|blood sampling and skin biopsy|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
1530855|NCT02735824|Procedure|blood sampling or mouth swap|specimen will be used for genetic testing, results compared to patients
1530856|NCT02735824|Procedure|blood sampling|Nucleated blood cells and/or fibroblasts from skin biopsy will be used for genetic testing and functional assays. Blood serum will be used for antibody and cytokine measurement.
1530857|NCT02735811|Device|Assesment of long-term outcome of ICD patients|Evaluation during follow-up of the occurrence of complications related to ICD implantation and of death
1530858|NCT02735798|Drug|MM-302|
1530859|NCT02735798|Drug|Trastuzumab|
1530860|NCT02735785|Behavioral|Harnessing Online Peer Education (HOPE) Social Media Intervention|
1530918|NCT02735421|Drug|Adapalene 0.3% / BPO 2.5% gel|
1530861|NCT02735772|Procedure|transobturator approach for paravaginal repair|using TOT needle to apply suturs to white line
1530862|NCT02735759|Device|Photoacoustic flow cytometry device|The device for subjects enrolled on cohort 2 will be completed on day 0 (immediately after venous thromboembolism diagnosis and prior to anticoagulation therapy), day 7 ± 3 days after initiation of anticoagulation therapy, one week ± 3 days after completion of planned anticoagulation therapy and one month ± 3 days after completion of planned anticoagulation therapy. Anticoagulation therapy is part of the patient's normal standard of care and is not part of this study however data from what therapy was received may be captured. Patients will then be followed in hematology clinic to monitor the venous thromboembolism recurrence every 3 months for one year.
1530863|NCT02735746|Radiation|4D Computed Tomography (CT)|The initial 4DCT imaging obtained as part of a subject's planning CT for their standard radiation treatment.
1530864|NCT02735746|Radiation|Cone Beam CT|Daily cone beam CT imaging at each radiation treatment visit, as part of standard care
1530865|NCT02735746|Radiation|Low-dose Cinefluorography|A series of images consisting of five six-second cinefluorographs (real time fluoroscopic movies, for a total each time of 30 seconds of fluoroscopy) of the lungs while the subject is breathing, each at precisely measured angles to the subject, on 4 different occasions.
1530866|NCT02735746|Device|Pulmonary Function Tests|"Pulmonary Function Testing (PFT) gives global functional data for the lungs as a whole, but is relatively insensitive to early pathological changes. It involves taking very deep breaths and exhaling as forcefully as possible.
Research PFTs will be conducted at 4 and 12-months post radiation therapy"
1530867|NCT02735733|Device|Cold Bakri Balloon|In the room temperature arm, the bakri balloon will be inserted through the vagina and placed inside the uterus and filled with room temperature saline. In the cold arm, the same intervention will performed, however, the bakri balloon will be filled with cold saline at 32 degrees Fahrenheit.
1530868|NCT02735720|Other|TEVAR|Thoracic endovascular aortic repair, which includes the implantation of stent-graft in the thoracic aorta to repair the lesion. This may be done with a variety of stent-graft brands and types. The type and brand of stent-graft is left to the discretion of the care taking physician.
1530869|NCT02735720|Other|Non-TEVAR medical treatment|Any clinical management by physicians caring for these patients. This includes whatever blood pressure and heart rate medication is prescribed by the treating physician, without any surgery. The type and dosage of medication is left to the discretion of the care taking physician.
1530870|NCT02735707|Drug|Antibiotic A|Comparison of 3rd generation cephalosporins plus macrolide versus a respiratory quinolone.
1530871|NCT02735707|Drug|Antibiotic B|Comparison of 3rd generation cephalosporins plus macrolide versus a respiratory quinolone.
1530872|NCT02735707|Drug|Hydrocortisone|Hydrocortison 100 mg iv every 8 hours for 7 days versus no hydrocortisone
1530873|NCT02735707|Device|Minimal distension|"Comparison of minimal distension strategy versus maximal recruitment strategy. A third comparison (only in selected sites) is ultra-protective with maximum of 4 ml/kg ventilation plus ECCO2R."
1530874|NCT02735707|Device|Maximal recruitment|"Comparison of minimal distension strategy versus maximal recruitment strategy. A third comparison (only in selected sites) is ultra-protective with maximum of 4 ml/kg ventilation plus ECCO2R."
1530875|NCT02735707|Device|ECCO2R|"Comparison of minimal distension strategy versus maximal recruitment strategy. A third comparison (only in selected sites) is ultra-protective with maximum of 4 ml/kg ventilation plus ECCO2R."
1530876|NCT02735694|Drug|Cycloserine|Capsule containing 250 mg of Cycloserine
1530877|NCT02735694|Drug|Placebo|Sugar capsule manufactured to mimic Cycloserine 250 mg capsule
1530878|NCT02735681|Procedure|meibomian gland probing|Investigator will do baseline (OSDI) questionnaires prior to probing as well as at 1 week (at home), 1 month, 3months, and 6 months at office visits.
1530879|NCT02735681|Procedure|Left eye Meibomian Gland Probing Control Group|There will be no probing in the left eye. This will be used as a control for the right eye.
1530880|NCT02735668|Other|Shoulder Conventional Exercises|"The treatment duration is 3 days per week during 3 weeks. The aproximate duration of the season is 45 minutes. The protocol consists in:
• Flexibility and Strengthening Exercises of the shoulder muscles conventionally performed in shoulder pathology treatment:
Mobilisation Joint Exercises in all planes of movement.
Isometrics and Resisted Exercises (elastic bands) in all planes of movement."
1530881|NCT02735668|Other|Invasive PT|"The treatment duration is 3 days per week during 3 weeks. The aproximate duration of the season is 45 minutes. The protocol consists in:
Dry Needling in active myofascial trigger points related to shoulder joint (optimal hygiene and disinfection before and after needling). Special care in muscles located in the arm in women with axillary node dissection."
1530882|NCT02735668|Device|Control Motor Exercises|"The treatment duration is 3 days per week during 3 weeks. The aproximate duration of the season is 45 minutes. The protocol consists in:
Motor Control Exercises with Motor Imaginary according joint dyskinesis with help of a motion capture system through a spatial vision camera Kinect® of Microsoft."
1530883|NCT02735668|Behavioral|Therapeutic Education|"The treatment duration is 3 days per week during 3 weeks. The aproximate duration of the season is 45 minutes. The protocol consists in:
Therapeutic Education about chronic shoulder pain using a slide show, anatomical models, providing information and analysis of real clinical cases."
1530884|NCT02735655|Other|Physician's opinion|To get physician's opinion about the current global state of gastrointestinal endoscopy training programs and to identify the unmet needs and how to improve it through a web based questionnaire.
1530885|NCT02735642|Behavioral|SMART Randomization 1 - Referral|Participants will be randomized to receive standard referral to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
1530886|NCT02735642|Behavioral|SMART Randomization 1 - Referral and SMS|Participants will be randomized to receive referral plus SMS to link to HIV care. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
1530919|NCT02735421|Drug|Vehicle gel|
1530920|NCT02735408|Other|Kinesiotape (KT)|
1531255|NCT02732912|Drug|Zopiclone|This night sedation will be given to any patient requesting it, in either group
1530887|NCT02735642|Behavioral|SMART Randomization 2 - SMS|Those that have not linked to care after the first randomization, will be re-randomized to receive an SMS message. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
1530888|NCT02735642|Behavioral|SMART Randomization 2 - Incentive|Those that have not linked to care after the first randomization, will be re-randomized to receive a one-time economic incentive. When successfully linked to care, they will receive SMS reminders combined with health status surveys at 3, 6, 9, and 12 months. All participants will have viral loads and CD4 collected at baseline and at 12 months, viral loads collected again and an exit interview completed.
1530889|NCT02735642|Behavioral|High Risk Negative Cohort (N=100)|A subset of negatives identified as 'high risk' from the CAPI baseline survey will be invited to participate in the primary prevention intervention (N=100). They will receive an SMS health promotion message with survey at 6 and 12 months. At 12 months, they will be re-tested for HIV and an exit interview completed.
1530890|NCT02735642|Other|All participants. Approximately (N=1200)|"HIV testing approaches that females can choose from include: (1) oral fluid HIV self-testing (OHIVST) at their convenience; (2) immediate staff-aided testing at home/mobile site; and (3) a referral to a health care facility where HIV testing will be done by a health care provider (standard facility-based HTS).
All participants will receive a behavioral CAPI survey at baseline visit, an SMS HIV test experience satisfaction survey, and for those who choose the self-testing option, a staff-administered questionnaire."
1530895|NCT02735603|Drug|Naltrexone HCl/bupropion HCl|Naltrexone HCl/bupropion HCl extended-release tablet.
1530896|NCT02735603|Other|Placebo|Naltrexone/bupropion placebo-matching tablets.
1530897|NCT02735603|Drug|Moxifloxacin|Moxifloxacin tablet.
1530898|NCT02735590|Drug|Isoniazid|Participants in the Treatment Arm will receive high dose Isoniazid - 15mg per kg body weight, rounded up to the nearest 100 mg; maximum dose 900 mg with Pyridoxine supplementation (25mg).
1530899|NCT02735590|Drug|Rifapentine|Rifapentine based on body weight (>32kg - 50kg: 750 mg; >50kg: 900 mg), given weekly as 12 directly observed treatment (DOT) oral doses, ideally with food, over 3 months.
1530901|NCT02735564|Procedure|Bariatric Surgery|
1530902|NCT02735551|Drug|Long Acting Reversible Contraception (LARC)|Same day LARC placement (intervention) of Mirena, Skyla, Paragard, Implanon
1530903|NCT02735551|Other|Referral for Long Acting Reversible Contraception (LARC)|Referral to local clinic for LARC placement of choice (Mirena, Skyla, Paragard, Implanon, etc.)
1530904|NCT02735551|Other|Prescription for Short-Acting Hormonal Contraception|Participants who chose a short-acting hormonal method (e.g. contraceptive pills, ring, or patch) will receive a prescription to the pharmacy of their choice
1530905|NCT02735538|Procedure|osteonecrosis of femoral head group|The patients with osteonecrosis of femoral head will undergo total hip replacement.
1530906|NCT02735538|Procedure|osteoarthritis group|The patients with osteoarthritis will undergo total hip replacement.
1530907|NCT02735525|Device|Smartphone monitoring|Patients will be trained to use the smartphone and the wound surveillance app prior to discharge. Patients will use the app from home to take send digital images of their postoperative wounds and answer a short survey, all of which will be transmitted to a secure database maintained by the UW Department of Surgery and accessible only to UW-employed study personnel. These data will be evaluated by one of three vascular surgery service nurse practitioners (NPs) daily. Patients who have concerning findings either in their images or in their survey answers will be contacted for further evaluation.
1530908|NCT02735512|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
1530909|NCT02735512|Other|Laboratory Biomarker Analysis|Samples undergo MDSC clinical assay
1530911|NCT02735486|Dietary Supplement|Ginger drink|300 ml ginger drink
1530912|NCT02735486|Dietary Supplement|Placebo: Super pure water|Placebo: Super pure water
1530913|NCT02735473|Drug|Choline bitartrate|
1530914|NCT02735473|Drug|Placebo|
1530915|NCT02735460|Device|Andago V2.0|The Andago V2.0 is tested in 2 sessions, the first being a training session to define the probably optimal settings for the subsequent therapy session. In the therapy session the participant performs a specific parcours. Usually this parcours can be done within 10 minutes. However, the session is stopped as soon as the patient feels too exhausted or becomes too weary.
1530916|NCT02735434|Behavioral|Internet-based ACT|The guided internet program consists of 7 modules activated consecutively over a period of 12 weeks. The content is written psycho education, patient videos, audio-exercises and behavioural exposure exercises. The program is therapist-guided; hence all patients will receive support from primarily the same therapist during the 12 weeks.
1530917|NCT02735434|Other|Internet-based discussion forum|The online discussion forum consists of 7 themes touching upon the impact of health anxiety and the patients own coping strategies. The themes are activated consecutively over a period of 12 weeks. The discussion forum is text-based, and only patients will participate in the discussion. The written discussions will be reviewed by a professional for ethical reasons. The discussion forum aims to control for the effect of attention and contacts to the health care system. After 9 months patients in the discussion forum are offered active treatment, but not as part of the research project.
1530921|NCT02735395|Procedure|Scaling and root planing (SRP)|SRP performed in four to six appointments lasting approximately 1 h each, using manual curettes (Hu-Friedy, Chicago, IL, USA) and ultrasonic device (Cavitron Select SPC, Dentsply professional, York, PA, USA) under local anesthesia. The deep sites will be scaled throughout the first week and treatment of the entire oral cavity will be completed in 14 days.
1530922|NCT02735395|Drug|Metronidazole 250 (7 days)|Subjects will intake Metronidazole 250 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
1530923|NCT02735395|Drug|Metronidazole 400 (7 days)|Subjects will intake Metronidazole 400 mg. for 7 days, starting immediately after the first session of Scaling and Root Planing.
1530924|NCT02735395|Drug|Metronidazole 250 (14 days)|Subjects will intake Metronidazole 250 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
1530925|NCT02735395|Drug|Metronidazole 400 (14 days)|Subjects will intake Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
1530926|NCT02735395|Drug|Amoxicillin|Subjects will intake Amoxicillin 500 mg. for 14 days, starting immediately after and the first session of Scaling and Root Planing.
1530927|NCT02735395|Other|Placebo 250 (7 days)|Subjects will intake placebo of Metronidazole 250 mg. for 7 days, starting immediately after to intake Metronidazole 250 mg.
1530928|NCT02735395|Other|Placebo 400 (7 days)|Subjects will intake placebo of Metronidazole 400 mg. for 7 days, starting immediately after to intake Metronidazole 400 mg.
1530929|NCT02735395|Other|Placebo 400 (14 days)|Subjects will intake placebo of Metronidazole 400 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
1530930|NCT02735395|Other|Placebo 500|Subjects will intake placebo of Amoxicillin 500 mg. for 14 days, starting immediately after the first session of Scaling and Root Planing.
1530931|NCT02735382|Behavioral|Tobacco quitline EHR referral|Using an EHR-based referral to the tobacco quitline from primary care outpatient clinics.
1530932|NCT02735382|Behavioral|Tobacco quitline Fax referral|Using an Fax--based referral to the tobacco quitline from primary care outpatient clinics.
1530933|NCT02735369|Drug|2% OC-10X|2% OC-10X
1530934|NCT02735369|Drug|Placebo Comparator|Placebo
1530935|NCT02735356|Drug|Itraconazole|Applied topically
1530936|NCT02735356|Other|Placebo|Applied topically
1530937|NCT02735343|Drug|Compazine|Compazine 10mg with diphenhydramine 25 mg IV
1530938|NCT02735343|Drug|Ketamine|Ketamine 0.3 mg/kg along with ondansetron 4 mg IV
1530939|NCT02735330|Procedure|celiac plexus neurolysis using absolute alcohol|celiac plexus blockade with 40 ml of diluted absolute alcohol(50%) 20 ml on either side of celiac axis in a 4 quadrant fashion
1530940|NCT02735330|Procedure|Placebo celiac plexus injection using saline|Placebo celiac plexus injection with 40 ml of saline 20 ml on either side of celiac axis in a 4 quadrant fashion for blinding
1530941|NCT02735330|Procedure|Frey's procedure|Pancreatic head is partially resected (cored) along with longitudinal opening of duct along its entire length with limit of excavation of the head in the plane of the posterior wall of the Wirsung's duct and duct of Santorini is opened in the uncinate process. All the tissue above the plane, including the duct of Santorini is excised. The reconstruction is done with covering with a loop of jejunum in Roux-en-Y fashion which continues with the main pancreatic duct in the pancreatic body and tail.
1530942|NCT02735317|Drug|Oral Ulcer Gargle (FORRAD®)|Oral Ulcer Gargle (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start application of Oral Ulcer Gargle (FORRAD®) at the onset of radiotherapy, four times a day (after meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade ＞ 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
1530943|NCT02735317|Drug|Quadruple mixture, composed of dexamethasone, gentamicin, vitamin B12, and procaine|Quadruple mixture is prescribed at the beginning of radiotherapy. Patients are asked to start application of quadruple mixture at the onset of radiotherapy, four times a day (before meals and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation-induced oral mucositis. When grade ＞ 3 OM happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted.
1530944|NCT02735304|Other|Impression intervention|The 1st intervention will compare two clinical impression techniques The Innovation treatment arm will receive the innovation treatment first and then crossover to receive the standard clinical practice treatment. The standard clinical practice treatment will receive the standard clinical practice treatment first and then crossover to receive the innovation treatment.
1530945|NCT02735291|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months..
1530946|NCT02735278|Other|different test paradigms|
1530947|NCT02735265|Behavioral|Virtual reality|12 training sessions (90 minutes a time, 2 times a week) IG:45 minute of Kinect for Xbox games and 45 minute of standard treatment.
1530948|NCT02735265|Behavioral|Standard treatment|CG: 90 minute of standard treatment. 12 training sessions (90 minutes a time, 2 times a week)
1530949|NCT02735252|Other|Systemic therapy|
1530950|NCT02735239|Drug|Durvalumab|
1530951|NCT02735239|Drug|Tremelimumab|
1530952|NCT02735239|Drug|Oxaliplatin|IV administered Chemotherapy
1530953|NCT02735239|Drug|Capecitabine|orally-administered chemotherapy
1530954|NCT02735239|Radiation|Radiotherapy|
1530955|NCT02735226|Other|stroke network and policy intervention|Shanghai stroke service and network contributes to update the ability of stroke care of comprehensive and primary stroke center,to improve radiation ability of comprehensive stroke centers and try to form a close relationship between comprehensive stroke centers and its primary stroke centers.
1530956|NCT02735213|Device|577-MPL|9 spots multispot micropulse mode(without spacing between the spots),160 um spot size, 0.2 second duration, 5% duty cycle(ON time 0.1ms + OFF time 1.9ms), and 250~400 milliWatts of power(50% threshold power),150~200 spots, the laser area is the corresponding leakage on mid-phase FA and around leakage.
1530957|NCT02735213|Device|TLT|contimuous wave,100um spot size, 0.05 seconds duration, 55~60 milliwatts of power, 18~27 spots,the laser area is the corresponding leakage on mid-phase FA.
1530958|NCT02735200|Drug|Application of topical vitamin d3 (Top-D)|Topical Vitamin D3 will be applied on the skin, externally, 1 gram daily for 120 days
1530959|NCT02735200|Other|Application of Aloe vera gel|"aloe vera gel will be applied
Dosage: 1 gram Duration: 120 days Frequency: Daily"
1530962|NCT02735174|Device|Sensor cap system for inhalers|All subjects will be given a commercially available inhaler cap with monitoring sensor on clinically prescribed asthma inhalers.
1530963|NCT02735174|Other|App for SmartPhone|All subjects will be given smart phone with mobile software management platform to motivate and record medication adherence.
1530964|NCT02735174|Behavioral|Motivational interviews|All subjects will have motivational telehealth visits to assess adherence and promote problem-solving skills
1530965|NCT02735174|Other|Telehealth clinic visits|All subjects will have asthma medical visits via telehealth technology to assess asthma control.
1530966|NCT02735161|Other|Muscle strength training|Two different muscle strength training protocols will be compared; one exercise session with high load/low repetitions (4 sets x 5RM) versus one exercise session with low load/high repetitions (2 sets x 25RM). Both session will be conducted at four different exercises; seated leg press, chest press, cable lat pull down and seated rowing.
1530967|NCT02735161|Other|Endurance exercise training|Two different endurance exercise training protocols will be compared; one exercise sessions is interval training with high intensity (85-95% of HRmax) versus one of moderate intensity (70-75% of HRmax) with longer duration.
1530968|NCT02735148|Other|Body Weight Supported Treadmill Training|"There were three intervention arms in this study,
Body Weight Supported Treadmill Training,
Conventional Training and
Combined Training."
1530969|NCT02735135|Device|AIRSOFT DUO for 1 day|The patient is placed on an AIRSOFT DUO mattress for 1 day.
1530970|NCT02735135|Device|SENTRY 1200 for 1 month|The patient is placed on a SENTRY 1200 mattress for 1 month.
1530971|NCT02735135|Device|SENTRY 1200 for 1 day|The patient is placed on a SENTRY 1200 mattress for 1 day.
1530972|NCT02735135|Device|AIRSOFT DUO for 1 month|The patient is placed on an AIRSOFT DUO mattress for 1 month.
1530973|NCT02735122|Drug|Test acetaminophen|2 Test acetaminophen 500 mg tablets, 2 placebo caplets, and 2 placebo liquid-filled capsules
1530974|NCT02735122|Drug|Commercial acetaminophen|2 acetaminophen 500 mg caplets, 2 placebo tablets, and 2 placebo liquid-filled capsules
1530975|NCT02735122|Drug|Commercial ibuprofen|2 ibuprofen 200 mg soft-gels, 2 placebo tablets, and 2 placebo caplets
1530976|NCT02735122|Other|Placebo Comparator|2 placebo tablets, 2 placebo caplets, and 2 placebo liquid-filled capsules
1530977|NCT02735109|Other|photographies|cells description by taken photographies vith confocal microscope (VivaScope 3000)
1530978|NCT02735109|Procedure|biopsy normal area|biopsy done to compare with abnormal area
1530979|NCT02735096|Device|EquiCue (Intraoral Electronic Balance Aid)|When the device is worn, a subject will receive small electrical pulses on roof of the mouth as alternative feedback of head tilting or movement.
1530980|NCT02735083|Genetic|UCART19 follow-up|UCART19 will not be administered during the study period. All patients who have previously received UCART19 will be rolled-over to this long term follow-up study at the end of the parent study or at any time after UCART19 administration in case of premature discontinuation from the parent study.
1530981|NCT02735070|Drug|Resfenol|Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
1530982|NCT02735070|Drug|Coristina d|Patients included in the study will take the drugs 4 times a day, orally. Patients should take the study medication without breaking or chewing together with a cup containing approximately 200 ml of water. The patient should ingest the study drug after fasting for at least 30 minutes.
1530983|NCT02735057|Drug|Carboplatin|
1530987|NCT02735031|Drug|Exenatide|6 weeks treatment with exenatide on top of insulin treatment
1530988|NCT02735031|Drug|Placebo|6 weeks treatment with placebo on top of insulin treatment
1530991|NCT02735005|Other|SMAF assessment|"After written information and non opposition expression, each enrolled patient will be assessed with the Functional Autonomy Measurement System (SMAF) tool during a 1 hour interview.
The French authority has considered this study as an interventional study with minimal risk because we use a tool (SMAF) that was not developped nor validated in this specific population (disabled people older than 40y). The SMAF assessment is not made in routine in this specific population (ID RCB : 2015-A00642-47)"
1530992|NCT02734992|Behavioral|ACT+ MTAU|Participants will be randomly assigned to one of the two groups: ACT-based intervention, plus their usual health care or Medical Treatment as Usual only (MTAU). The MTAU group will follow their usual medical treatment (prescribed headache medication). Treatment sessions will be conducted weekly by two co-therapists in groups of approximately 8-10 participants for 1 ½ hours. The control group will receive the ACT intervention following the completion of the Tx group. Participants will fill out questionnaires before and after the intervention and at a 3, 6 and 12-month follow-up. The ACT protocol and the patients' workbook were developed for the needs of the Algea project (Vasiliou & Karekla, 2015). Techniques will focus on key ACT processes aiming to promote psychological flexibility.
1530993|NCT02734992|Behavioral|Waitlist Control +MTAU|Participants in the Waitlist control+ MTAU will not receive any active intervention. Upon completion of ACT+MTAU group, participants allocated in the Waitlist control+MTAU will receive the ACT intervention.
1530994|NCT02734979|Device|Biobridge and lymph node transfer|Biobridge is surgically implanted with conventional vascularized lymph node transfer surgery
1530995|NCT02734966|Drug|Magnesium Isoglycyrrhizinate Injection 100mg OD|Magnesium Isoglycyrrhizinate Injection 100mg OD
1530996|NCT02734966|Drug|Magnesium Isoglycyrrhizinate Injection 200mg OD|Magnesium Isoglycyrrhizinate Injection 200mg OD for 4 weeks
1530997|NCT02734966|Drug|Tiopronin Injection|Tiopronin Injection 200mg OD
1530998|NCT02734953|Drug|Nitric Oxide|Ambulatory inhaled nitric oxide delivery system and 6 minute walk distance test
1530999|NCT02734940|Drug|Lidocaine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
1531000|NCT02734940|Drug|Unrestricted Fentanyl|No changes to current practices, using unlimited narcotic medications intraoperatively.
1531001|NCT02734940|Drug|Ketamine|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
1531002|NCT02734940|Drug|Precedex|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
1531003|NCT02734940|Drug|Duramorph|This model would use a combination of intravenous (Dexmedetomidine, Ketamine, Lidocaine) and Spinal (Morphine) drugs.
1531004|NCT02734927|Other|realization of computerized exercises|
1531005|NCT02734914|Device|SF-URS with automatic control of RPP|A new F-URS monitoring and control of RPP using intelligent pressure control device
1531006|NCT02734914|Device|conventional F-URS|Ureteroscopy will be conducted using the ureteral access sheath from Cook Medical to treat renal calculi.
1531007|NCT02734901|Dietary Supplement|400 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
1531008|NCT02734901|Dietary Supplement|200 g frozen raspberries|1x daily intake of 600 mL red raspberry beverage
1531009|NCT02734901|Dietary Supplement|Placebo|1x daily intake of 600 mL raspberry deprived supplement
1531010|NCT02734888|Other|No drug or device, only a test. The test is called a PET/CT|A single PET/CT scan will be performed
1531011|NCT02734875|Other|Intervention|The intervention arm offers primary care providers additional information on patient risks and benefits as well as an offer of assistance with managing a patient's anticoagulation from a respected service at BWH.
1531017|NCT02734849|Drug|AK001 low dose|A low dose of AK001 will be administered as multiple doses
1531018|NCT02734849|Drug|AK001 high dose|A high dose of AK001 will be administered as multiple doses
1531019|NCT02734849|Drug|Placebo|Placebo will be administered as multiple doses
1531020|NCT02734836|Device|Ballon Angioplasty|
1531021|NCT02734836|Other|Optimal Coherence Tomography|
1531022|NCT02734823|Other|Cytology Specimen Collection Procedure|Undergo collection of serum
1531023|NCT02734823|Other|Laboratory Biomarker Analysis|Correlative studies
1531024|NCT02734823|Other|Questionnaire Administration|Ancillary studies
1531025|NCT02734823|Procedure|Ultrasonography|Undergo transvaginal pelvic ultrasonography
1531026|NCT02734810|Drug|Liprotamase Powder for Oral Solution|Oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement therapy
1531027|NCT02734784|Procedure|Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). Teeth with furcation lesion will increase over 60 seconds into the lesion. Before the application, the supragingival plaque will be removed.
1531028|NCT02734784|Procedure|Sham Photodynamic Therapy|After a surgical access, the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. Before the application, the supragingival plaque will be removed.
1531029|NCT02734771|Drug|Brentuximab vedotin|
1531030|NCT02734771|Drug|Rituximab|
1531031|NCT02734771|Drug|Cyclophosphamide|
1531032|NCT02734771|Drug|Doxorubicin|
1531033|NCT02734771|Drug|Prednisone|
1531034|NCT02734745|Device|flash glucose monitoring|Patients will use Freestyle Libre for 14 days at home, during this period they will have to perform at least 7 measurements of capillary blood glucose per day . Patients also will go to our clinical center on two separate occasions , to run a test breakfast. In one of the two occasions it will be specifically induced a moderate initial hyperglycemia and subsequent hypoglycemia . During the test meal and in the subsequent hours for a total of 6 hours , will be carried out frequent blood sampling for measurement of blood glucose using the Yellow Springs glucose analyzer ( YSI system ) , simultaneous measurements with Freestyle Libre and with glucometer.
1531035|NCT02734732|Drug|Trimethoprim/Sulfamethoxazole|
1531036|NCT02734732|Drug|Ciprofloxacin|
1531038|NCT02734706|Dietary Supplement|LRC™ capsule|Twice per day (BID), 9 weeks
1531039|NCT02734706|Other|Placebo capsule|Twice per day (BID), 9 weeks
1531040|NCT02734693|Drug|dasotraline 4mg|dasotraline 4mg/day
1531041|NCT02734693|Other|Placebo|placebo/day
1531042|NCT02734680|Radiation|Concurrent chemoradiotherapy(CCRT)|Radiation and take gemcitabine(GEM)
1531043|NCT02734680|Radiation|Stereotactic Radiotherapy(SBRT)|Stereotactic Radiotherapy(SBRT) (total dose: 45 Gy; single dose: 3 Gy; Frequency:15)
1531044|NCT02734680|Drug|S-1|Taking S-1 orally after radiation
1531045|NCT02734667|Device|CGM at diagnosis of T1D|Initiation of non-adjunctive CGM use at diagnosis of T1D
1531152|NCT02733705|Drug|propofol|propofol infusion
1531155|NCT02733679|Drug|Pioglitazone|Pioglitazone will be given orally, regularly for eight weeks. Dose starts at 15mg once daily and after one week increases to 30mg once daily.
1531046|NCT02734654|Procedure|remote ischemic preconditioning (RIPC)|Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
1531047|NCT02734628|Drug|Dexpanthenol (Bepanthen® Wund- und Heilsalbe, BAY81-2996)|30 g of 5% of the active ingredient dexpanthenol plus other ingredients as ointment
1531048|NCT02734628|Drug|Placebo|Placebo to Bepanthen® ointment without active ingredient dexpanthenol
1531049|NCT02734615|Drug|LSZ102|LSZ102
1531050|NCT02734615|Drug|LEE011|LEE011
1531051|NCT02734615|Drug|BYL719|BYL719
1531052|NCT02734602|Drug|Ketamine|Ketamine will be administered after the initial PET scan.
1531053|NCT02734602|Behavioral|Cognitive Testing|Verbal and computer assessments will be given.
1531054|NCT02734602|Radiation|PET|PET scan will involve infusion of a radiotracer.
1531055|NCT02734602|Device|MRI|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale.
1531056|NCT02734589|Other|Fecal transplantation|Transplantation of fecal bacteria from a healthy individual into a recipient- ulcerative colitis patient via colonoscopy and enemas
1531057|NCT02734589|Other|Unique novel Diet for UC and Unique novel Diet for the donor + FMT|A developed unique diet that is geared to induces remission and decreases inflammation in patients with active UC. Also a conditioning diet for healthy subjects to be used by the donor prior to transplantation- a developed unique diet for two weeks.
1531058|NCT02734589|Other|Unique novel Diet for UC|A developed diet that is geared to induces remission and decreases inflammation in patients with active UC.
1531059|NCT02734576|Device|Venous Sinus Stenting|
1531060|NCT02734563|Other|Collagen turnover|Type IV and V collagen synthesis and breakdown
1531061|NCT02734550|Other|Standard of care|Patients are treated according to the ESCMID guidelines. Antifungal therapy is started if fungi are detected in the blood culture or other primary sterile body fluids.
1531062|NCT02734550|Other|(1,3)-β-D-glucan guided therapy|Serum for (1,3)-β-D-glucan measurement is obtained after enrollment and 24 hours later. Antifungal therapy is started if at least one sample is 80 pg/ml or higher. If concomitantly taken microbiological cultures remain negative, antifungal therapy is continued only, if both (1,3)-β-D-glucan were at least 80 pg/ml. Blood cultures or other samples from primary sterile body fluids positive for fungi are treated with antifungals irrespective the (1,3)-β-D-glucan results.
1531063|NCT02734537|Drug|Cisplatin|Given IV
1531064|NCT02734537|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1531065|NCT02734537|Other|Laboratory Biomarker Analysis|Correlative studies
1531066|NCT02734524|Biological|NK cells|Natural killer cell infusion is an intervention between two arms. Dosage of infused cell ＞1×10^9，q28d*4
1531067|NCT02734524|Drug|Taxol|135-175mg/m2,q28d*4
1531068|NCT02734524|Drug|Carboplatin|AUC=5,q28d*4
1531069|NCT02734511|Drug|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
1531070|NCT02734498|Device|Electroconvulsive Treatment (ECT)|Intervention is electroconvulsive treatment (ECT). Arm 1 has Right unilateral (RUL) ECT and Arm 2 has Bilateral (BL) ECT. Control group will have no interventions.
1531071|NCT02734485|Device|active Deep TMS|"The Brainsway DTMS produces a time-varying magnetic field and, based on Faraday's Law, it can be assumed that a time-varying magnetic field generates an electrical current in a nearby conductive substance. The induced electric current in the cortex travels in an orthogonal path in the direction of the magnetic field with the maximum strength and current located beneath the coil in the helmet placed on the patient's head and transmits magnetic pulses to the patient's brain. The induced current is tangential to the scalp at the cortical surface, and decreases in magnitude with increasing depth.
Patients underwent 12 sessions, 3 times a week, of repetitive DTMS using the novel H2-coil (Brainsway LDT)."
1531072|NCT02734485|Device|sham Deep TMS|The Sham DTMS consisted in the same protocol of active treatment with the same preparation of the subject and settings of the instrument but with an INACTIVE DTMS coil.
1531073|NCT02734472|Other|Incidence and risk factors of hypertension|During the follow-up period,General information(age, sex, BMI, blood pressure, the history of drink and smoke, medical history, etc).Blood biochemistry parameters（Lipid, hsCRP levels, etc）and other laboratory examination parameters(arterial stiffness,IMT, FMD) will be collected.
1531074|NCT02734459|Drug|cataract surgery|"the patient will be dosed with the study drug into the V pocket is formed between the eye ball and the lower eyelid during cataract surgery."
1531075|NCT02734446|Drug|Reuterin D3 drops|5 drops/day for 3 months
1531076|NCT02734446|Other|Placebo|5 drops/day for 3 months
1531077|NCT02734433|Drug|Pexidartinib|
1531078|NCT02734420|Drug|PapacarieMBlue and PDT|Initial periapical and interproximal radiographs Microbiological sample with otoscope curette to standardize volume of carious tissue; Application on PapacarieMBlue (addition of toluidine blue) for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with non-cutting curette; No removal of carious tissue on pulp floor; Irradiation of dental tissue for one minute on a single point; Second microbiological sample of remaining dentin with curette; Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE); Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
1531079|NCT02734420|Drug|Toluidine Blue O and PDT|Initial periapical and interproximal radiographs;Microbiological sample with otoscope curette to standardize volume of carious tissue;Application of Toluidine Blue O for 5 minutes to potentiate effect of PDT; Removal of carious tissue around lateral walls of the cavity with sharp curette; No removal of carious tissue on pulp floor;non-cutting curette; Irradiation of dental tissue for one minute on a single point;Second microbiological sample of remaining dentin with curette;Clinical evaluation by inspection of texture of remaining dentin with exploratory probe; Restoration with glass ionomer cement (Ketac Molar EasyMIx 3M ESPE);Follow up;Radiographic control: periapical and interproximal radiographs at 3, 6 and 12 months.
1531080|NCT02734420|Device|Laser|
1531153|NCT02733692|Behavioral|Understanding Reproductive Health for Ladeez (GURHL) Code|Understanding Reproductive Health for Ladeez (GURHL) Code is an acceptability study to test a web-based application designed with and for young women of color 18 to 25 years old.
1531081|NCT02734407|Procedure|Assigned Intervention|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study as assigned intervention. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
1531082|NCT02734407|Drug|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
1531083|NCT02734394|Behavioral|Exercise|Cardiovascular and resistance exercise training
1531084|NCT02734381|Other|Elderly patients|Elderly patients who visited the Emergency Department
1531085|NCT02734368|Drug|Hyperpolarized Helium-3|
1531086|NCT02734355|Drug|Telmisartan 80 mg and amlodipine 5 mg|
1531087|NCT02734355|Drug|Placebo (for telmisartan and amlodipine)|Sugar pill manufactured to mimic telmisartan 80 mg and amlodipine 5 mg tablet
1531088|NCT02734342|Other|exercise|Participants will be asked to attend eight exercise sessions within a group class environment that will last for 1 hour. The exercise programme has been developed through clinical and research evidence. During the hour, a 5 minute warm up followed by 14 exercises specific to strengthening the lower limb and improving aerobic capacity. Each exercise will be timed for two minutes with the participant reporting number of repetitions counted. A cool down will be completed at the end of the class. After each exercise class, the participant will be advised to have a recovery day to prevent overloading (De Carlo & Armstrong, 2010). Progression of exercises will be patient led. Participants will attend twice per week for four weeks.
1531089|NCT02734329|Procedure|conventional laparoscopic partial nephrectomy|renal artery will be clamped during surgery.
1531090|NCT02734329|Procedure|zero ischemia laparoscopic RFA/MVA assisted tumor enucleation (TE)|
1531091|NCT02734316|Other|endoscopic procedure|Evaluation of adverse events in patients on DOACs undergoing GI endoscopy
1531092|NCT02734290|Drug|Pembrolizumab|Pembrolizumab 200mg every 3 weeks by IV infusion on Day 1 of each 3 week cycle
1531093|NCT02734290|Drug|Paclitaxel|Paclitaxel 80mg/m2 every 3 weeks by IV infusion on Days 1, 8, and 15 of each 3 week cycle
1531094|NCT02734290|Drug|Capecitabine|Capecitabine 2000mg every two weeks by mouth twice each day on days 1-7 of each 2 week cycle.
1531095|NCT02734251|Dietary Supplement|Relora|750 mg/day
1531096|NCT02734251|Dietary Supplement|Placebo|
1531097|NCT02734238|Drug|Sesame Oil|200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35
1531098|NCT02734238|Drug|testosterone enanthate|200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35
1531099|NCT02734225|Other|Functional Recovery|Rehabilitation protocol based on muscle strengthening with isometric, isotonic and counter-resistance with progressive load exercises. Intervention consisted of warm-up phase with passive, active-assisted and active movements, and a work-out phase
1531100|NCT02734225|Other|Balance Training|Balance and proprioception training using parallel bars, unstable plates, ramps and stairs
1531101|NCT02734225|Other|Dynamometric Platform Training|Stability tests, weight changes and stability limits, performing both anterior-posterior and medial-lateral movements simultaneously in some cases
1531102|NCT02734212|Behavioral|Ending Self Stigma for PTSD|Ending Self Stigma for PTSD (ESS-P) is a 9-session small-group (6-8 persons) course designed to help individuals with PTSD develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
1531103|NCT02734212|Other|Enhanced Treatment as Usual|The comparison condition will consist of providing a pamphlet that discusses societal stigma and internalized stigma, and provides resources to help combat the effects of both. Participants will be given the informational pamphlet and study staff will discuss its content with the participant.
1531105|NCT02734173|Drug|ABT450r-ABT267-ABT333 +/- Ribavirin|12 week duration of HCV antiviral therapy with ABT450r-ABT267-ABT333 +/- Ribavirin
1531106|NCT02734160|Drug|Galunisertib|Administered orally
1531107|NCT02734160|Drug|Durvalumab|Administered IV
1531108|NCT02734147|Drug|Ascorbic Acid|
1531109|NCT02734147|Other|Normal Saline|
1531110|NCT02734134|Procedure|One-stage exchange joint replacement surgery|
1531111|NCT02734134|Procedure|Two-stage exchange joint replacement surgery|
1531112|NCT02734121|Behavioral|pre-consultation educational group intervention|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.
Surgeon (40 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities
Registered nurse (20 mins): preparing for surgery, postoperative recovery and how to navigate the health care system
Social worker (30 mins): values clarification exercise
Breast reconstruction patient volunteers (30 mins) questions and answers about their personal experience"
1531113|NCT02734108|Device|Transcranial direct current stimulation|Anodal transcranial direct current stimulation over the dorsolateral prefrontal cortex
1531114|NCT02734095|Device|Ultrasound|Intravascular ultrasound measurements after percutaneous transluminal angioplasty and stenting in the treatment of femoropopliteal lesions.
1531115|NCT02734069|Drug|Carboplatin|Patients will receive carboplatin according to the carboplatin area under the curve dose calculation for 2 cycles to evaluate toxicity.
1531116|NCT02734056|Other|Music|Listening to music that the patient likes
1531117|NCT02734056|Other|Control|Control
1531118|NCT02734017|Other|pharmacist-led standardized medication review|the goal of this study is to assess the impact of the standardized medication review on the rate of readmissions and/or death at 30 days following initial hospitalization discharge.
1531154|NCT02733679|Drug|Metformin|Metformin will be given orally, regularly for eight weeks. Dose starts at 500mg once daily for one week, increasing by 500mg per week, to final dose of 1000mg twice daily.
1531121|NCT02733991|Device|MiniMed™640G and Suspend before low|"All enrolled subjects will start a run in phase, receive training and start pump therapy with the MiniMed™640G insulin pump and usage of blinded Continuous Glucose Monitoring. Eligible subjects that meet the randomization criteria assessed after the running phase will be randomized into the treatment or control arm. Treatment Arm: training and start of Sensor Augmented Pump therapy with Suspend before Low feature of SmartGuard turned ON.
Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks during the treatment phase."
1531122|NCT02733991|Device|MiniMed™640G|Control Arm: continuation of pump therapy alone with blinded continuous glucose monitoring for a total of 6 weeks.
1531123|NCT02733978|Device|the ozone generator device (Human Pro medic, German)|noninvasive oxygen-ozone treatments with 52 ug/mL ozone (total volume: 20-50 mL) in a special bag for 30 min per day for 20 days using the ozone generator device (Human Pro Medic, German)
1531124|NCT02733965|Other|Pharmaceutical Consultations|"The first part of the pharmaceutical consultation focuses on a complete clinical medication review, the effective use of drugs will be discussed with the patient.
Study of health behaviors Concerning self-medication and alternative medicine Addictions Drug adherence List and grade (NCI version 4) of clinical signs and laboratory abnormalities The biological data will be obtained Clinical signs will be obtained from patient questioning The second part of the consultation is to achieve firstly a pharmaco-therapeutic analysis of the treatment in order to detect problems with drugs as classified by the French Society of Clinical Pharmacy The third step consists on providing pharmaceutical interventions following the pharmaco-therapeutic analysis (18).
These pharmaceutical interventions might concern the prescribers, the other caregivers, or the patient himself. T"
1531125|NCT02733965|Other|No Pharmaceutical Consultations|
1531126|NCT02733952|Drug|Tranexamic Acid|
1531127|NCT02733952|Procedure|Pericervical Tourniquet|
1531128|NCT02733939|Device|Home monitoring kit|"The home monitoring kits notify the caregivers about potentially dangerous situations, such as when the person with dementia:
leaves the home without notice, since this might occur in a moment of disorientation;
leaves a water tap open;
forgets something on the stove;
gets out of bed during the night and doesn't come back within a certain time interval;
never goes to the bathroom in 24 hours;
never opens refrigerator door in 24 hours.
Depending on the personal choice of the study participants, the kit will also :
automatically turn on a light to help avoid a fall during the night;
alert the caregiver when the temperature in the house falls or rises excessively;
act as burglar alarm in some areas of the home."
1531129|NCT02733926|Other|Adding of vegetation into the backyards of kindergarten|Living plants are transferred into the backyards of kindergartens. This is assumed to affect the measured variables of children.
1531130|NCT02733900|Procedure|femoral head removal|
1531131|NCT02733887|Device|magnetic resonance imaging|MRI was performed on a 3 Tesla system (GE Discovery 750W). A single-shot,echo-planar imaging-based, spectral adiabatic inversion recovery DWI sequence was obtained with b values of 0,30,50,80,100,150,200,400,600,800 and 1,000.
1531132|NCT02733887|Device|positron emission tomography/computed tomography|18F-FDG-PET/CT was performed using a multidetector PET/CT system (GE Discovery ST16). Patients fasted for 6 hours before imaging.
1531133|NCT02733887|Radiation|fludeoxyglucose F 18|Patients fasted for 6 h before receiving FDG intravenously. A dose of 5.18-7.4 MBq/kg was used.
1531134|NCT02733874|Drug|Compound Clobetasol Propionate Ointment|
1531135|NCT02733874|Drug|Calcipotriol Betamethasone Ointment|
1531136|NCT02733848|Drug|Creon|"Creon is a porcine derived pancreatic enzyme supplement that comes in in fixed dose combinations of lipase, protease, and amylase, respectively. Dosing is based on lipase per kilograms per meal (i.e. lipase units/kg/meal). Subjects will be started at a dose of 500 units of lipase/kg/meal and snacks at week 4 and continued until week 8. A follow-up visit at week 6 will assess patient for tolerance to Creon and need for dosage adjustment.
Formulations come in different fixed dose combinations as follows:
Creon: Lipase 3000 USP units, protease 9500 USP units, and amylase 15,000 USP units
Creon: Lipase 6000 USP units, protease 19,000 USP units, and amylase 30,000 USP units
Creon: Lipase 12,000 USP units, protease 38,000 USP units, and amylase 60,000 USP units
Creon: Lipase 24,000 USP units, protease 76,000 USP units, and amylase 120,000 USP units
Creon: Lipase 36,000 USP units, protease 114,000 USP units, and amylase 180,000 USP units"
1531137|NCT02733848|Other|Diet|A registered dietician will meet with the subject and take a thorough review of the patient's dietary history. The subject will then be counseled on a lower carbohydrate and higher protein diet. This diet will be continued for the entire 12 week of the study. The registered dietician will reinforce dietary recommendations by phone on week 2, 4 and 8, respectively.
1531138|NCT02733848|Other|Placebo|Placebo will be given to the patient in single blind fashion with the subject unaware but PI aware of study drug assignment from week 8-12. Placebo tablets will be given with meals and snacks similar to CREON to maintain patient blinding to study drug assignment. A follow-up visit on week 10 to review patient tolerance, side effects and possible drug adjustment.
1531139|NCT02733835|Drug|Remifentanil|Vital signs-controlled, patient assisted intravenous analgesia using remifentanil
1531140|NCT02733822|Drug|Naloxone|
1531141|NCT02733809|Drug|Sorafenib|Liver lesion biopsy (HCC) and blood samples will be taken from the subjects before starting the treatment course, and another biopsy and blood samples when they devolve a resistance.
1531142|NCT02733783|Device|Cold dry air machine|Cold Dry Air (CDA)- nasal provocation: Compressed dry air is delivered through a transparent anaesthesia mask placed over the nose and mouth of the patients. Subjects are instructed to breath through the nose only. Exposure to CDA lasts for 15 minutes. The flow, measured by a gas flow analyzer of Dräger was set at 12,5 l/min. The temperature of the air reaching the nose is at -10° C with a relative humidity of 10%-15%.
1531143|NCT02733770|Procedure|Laparoscopic sleeve gastrectomy|Doppler ultrasound.
1531144|NCT02733770|Procedure|Laparoscopic mini gastric bypass|Doppler ultrasound.
1531145|NCT02733757|Drug|Clonidine|Clonidine 1 µg/kg plus 2% lidocaine
1531146|NCT02733744|Biological|Fecal Microbiota Transplantation (FMT)|FMT will be given through the ingestion of 30 capsules (15 capsules daily x 2 consecutive days)
1531147|NCT02733731|Drug|Chinese Herbal Compound Ointment|
1531148|NCT02733731|Drug|Estriol|
1531149|NCT02733718|Device|NIRS (near-infrared spectroscopy)|mesenteric oxygenisation measurement
1531150|NCT02733705|Other|Control|normal saline IV
1531151|NCT02733705|Drug|Fentanyl|fentanyl 0.5 mcg/kg ideal BW
1531156|NCT02733666|Procedure|Absorbable screw group|Open reduction was performed and one absorbable screw was used for fixation in the experimental group
1531157|NCT02733653|Device|Jetstream Atherectomy System|A rotating, aspirating, expandable catheter system for active removal of atherosclerotic debris and thrombus in the SFA and/or PPA
1531158|NCT02733640|Drug|Pantoprazole|pantoprazole 40 mg once-daily
1531159|NCT02733640|Drug|Ranitidine|ranitidine 150 mg twice-daily
1531160|NCT02733627|Drug|BI 1467335 low dose|
1531161|NCT02733627|Drug|BI 1467335 medium dose|
1531162|NCT02733627|Drug|BI 1467335 high dose|
1531163|NCT02733627|Drug|Placebo|
1531164|NCT02733614|Drug|SRX246|novel V1a receptor antagonist
1531165|NCT02733614|Drug|Placebo|matching placebo
1531166|NCT02733601|Other|NIS (Non Interventional Study) observational study|NIS observational study : Epidemiologic registry
1531167|NCT02733588|Drug|G-Pump™ (glucagon infusion)|0.15 or 0.3 mg G-Pump™ (glucagon infusion) administered from OmniPod® pump
1531168|NCT02733575|Other|Compassion Focused Therapy|Up to 26 sessions of Compassion Focused Therapy
1531169|NCT02733549|Other|LFTs|"A single 5-ml peripheral venous blood sample was collected from each participant.
Serum ALT, AST, ALP, GGT, total bilirubin, conjugated bilirubin, and albumin level, Platelet count, INR and aPTT were analyzed."
1531170|NCT02733536|Device|Standard endotracheal tube|1) Direct laryngoscopy using a Macintosh laryngoscope with size 3 blade (Mercury Medical, Clearwater, FL, USA) with a conventional 7.0 mm internal diameter (ID) tracheal tube
1531171|NCT02733536|Device|C-MAC|C-MAC introduced with a h size 3 blade.
1531172|NCT02733523|Behavioral|"Program Sentirnos bien (Feeling well)"|"Group-based intervention delivered face-to face and held once a week during 3 months. It comprises:
Promoting the uptake of self-care healthy habits: providing information, setting personal goals and sharing experiences to facilitate behavioural change, specially on physical activity and healthy dietary habits.
Promoting social capital at individual level: facilitating mutual knowledge and mutual support among participants and fostering participation in sociocultural and community activities in the neighbourhood through visits to the community assets accompanied by volunteers.
Promoting health literacy: improving navigation through the health care system, communication with health professionals, as well as the understanding and decision making when buying food."
1531173|NCT02733510|Drug|methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
1531174|NCT02733497|Procedure|Sympathectomy|Resection of ganglia at T3 level
1531175|NCT02733497|Procedure|Sympathicotomy|Cutting of symptahetic chain at T3 level without ganglia excision
1531176|NCT02733484|Dietary Supplement|Probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
1531177|NCT02733484|Dietary Supplement|Placebo|the patients in this arm will receive placebo intervention
1531178|NCT02733471|Drug|Lidocaine|
1531179|NCT02733471|Drug|Placebo|Placebo
1531180|NCT02733458|Drug|GELAD|Gemcitabine, 1.0g/m2/d IV, day 1 Etoposide, 60mg/m2 IV, day 1 to day 3 Dexamethasone, 40mg/d IV, day 1 to day 4 Pegaspargase, 2000IU/m2/d IM, day 4
1531181|NCT02733458|Radiation|Radiotherapy|Radiotherapy: 50-56Gy
1531182|NCT02733445|Drug|dasatinib|
1531183|NCT02733445|Drug|nilotinib|
1531184|NCT02733432|Drug|CD101 gel (3%)|intravaginally applied topical gel on Days 1 and 2
1531185|NCT02733432|Drug|CD101 gel (1%)|externally applied topical gel twice daily up to 3 days as needed
1531186|NCT02733432|Drug|CD101 ointment (6%)|intravaginally applied topical ointment on Day 1
1531187|NCT02733432|Drug|CD101 ointment (1%)|externally applied ointment twice daily up to 3 days as needed
1531188|NCT02733432|Drug|Fluconazole|oral fluconazole (150mg) on Day 1
1531189|NCT02733419|Drug|Enfuvirtide|Participants will receive 90 mg enfuvirtide subcutaneously (SC) b.i.d.
1531190|NCT02733419|Drug|Optimized background antiretroviral regimen (OB)|Participants will receive OB (nucleoside and or non-nucleoside reverse transcriptase inhibitor and protease inhibitor) as per investigator's discretion. Protocol does not specify any particular OB drugs.
1531193|NCT02733393|Procedure|Sphenopalatine Ganglion (SPG) Block|Patients who are undergoing a thoracotomy will be informed that they may develop moderate to severe postoperative ISP and may have the option to receive an SPG block. The SPG block will be performed every three minutes for 20 minutes, 0.1mL of the 4% lidocaine will be administered through. After 20 minutes and various intervals thereafter the patient will be asked to rate their shoulder pain.
1531194|NCT02733393|Drug|lidocaine|
1531195|NCT02733380|Drug|Chidamide|30mg , Oral twice a week(with an interval of no less than 3 days,;e.g. Monday and Thursday，Tuesday and Friday) until disease progression or unacceptable toxicity develops
1531196|NCT02733380|Drug|Vinorelbine|20mg/m2， IV on day 1 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
1531197|NCT02733380|Drug|Liposomal Doxorubicin or mitoxantrone|20mg/m2, IV on day 1 of each 14 day cycle（Note：for patients who can not afford the liposomal doxorubicin，may be replaced into mitoxantrone 8mg/m2, IV on day1 of each 14 day cycle） until disease progression or unacceptable toxicity develops, up to 12 cycles
1531198|NCT02733380|Drug|Dexamethasone|10mg/m2 , IV on day 1-5 of each 14 day cycle until disease progression or unacceptable toxicity develops, up to 12 cycles
1531199|NCT02733380|Drug|Thalidomide|100mg,Oral at night on each day until disease progression or unacceptable toxicity develops, up to 24 weeks
1531200|NCT02733367|Drug|Infacort®|Infacort® is a dry granule formulation of hydrocortisone stored in capsules that will be available in different strengths (0.5, 1.0, 2.0 and 5.0 mg).
1531201|NCT02733354|Device|watch viedo|
1531202|NCT02733341|Drug|Cangrelor|
1531203|NCT02733341|Drug|Ticagrelor|
1531204|NCT02733328|Procedure|CPB Surgery|
1531253|NCT02732912|Device|Ear plugs|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
1531254|NCT02732912|Device|Eye Mask|The patient will be given a plastic wallet containing an eye mask and ear plugs, to be used when trying to sleep.
1531258|NCT02732886|Device|Medifoam®|Foam Dressing
1531205|NCT02733315|Behavioral|Diabetes Conversation Map Program|"The experiment group received seven DCMP-based group education sessions for seven consecutive weeks in addition to routine health education at a private room in the outpatient unit. One registered nurse who received DCMP facilitator training, from the Taiwanese Association of Diabetic Educators, served as the class facilitator. DCMP sessions were conducted using seven colored maps covering different topics, including walk with diabetes, what is diabetes?, a healthy diet and exercise, walk with insulin, diabetes complications and related risk factors, foot care for diabetes patients, and a type 1 diabetes patient in the home. Each map, a laminated 3-by-5-foot table-top visual with colorful drawings as metaphors of situations familiar to DM patients, was placed on a table with participants gathered around it. This procedure served to create mutual imagery to be shared with participants."
1531207|NCT02733276|Other|electroacupuncture|Electroacupuncture: Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
1531208|NCT02733276|Other|Sham: Electroacupuncture sham|Sham comparator (Electroacupuncture sham): Using an electroacupuntor with different frequencies during 20 minutes. Needles are connected to the electrodes.
1531209|NCT02733263|Dietary Supplement|15 g RMD|15 grams of resistant maltodextrin
1531210|NCT02733263|Dietary Supplement|25 g RMD|25 grams of resistant maltodextrin
1531211|NCT02733263|Dietary Supplement|0 g RMD|0 grams of resistant maltodextrin
1531212|NCT02733250|Biological|Pembrolizumab|200mg IV Day 1 of each 21 cycles
1531213|NCT02733250|Drug|Nab-Paclitaxel|100mg/m2 IV Day 1, 8 and 15 of every 21 day cycles
1531214|NCT02733237|Drug|oxytocin treatment|intranasal administration of oxytocin (40 IU)
1531215|NCT02733237|Drug|placebo treatment|intranasal administration of placebo (40 IU)
1531216|NCT02733211|Device|MD- Logic Closed Loop System|
1531217|NCT02733211|Device|sensor augmented pump therapy|
1531218|NCT02733198|Other|Prognosis-guided therapy|
1531219|NCT02733185|Drug|disodium EDTA|
1531220|NCT02733185|Dietary Supplement|Oral Multi Vitamins/Minerals (OMVM)|
1531221|NCT02733185|Drug|Placebo disodium EDTA|
1531222|NCT02733185|Dietary Supplement|Placebo Oral Multi Vitamins/Minerals (OMVM)|
1531223|NCT02733159|Drug|pembrolizumab|anti PD-1
1531224|NCT02733146|Other|cardiac arrest|
1531226|NCT02733120|Other|stable isotope infusion|stable isotopes such as 15N2, TRP, 2H3-Leucine, L-[2H3]-3-Methylhistidine, 2H2-Glycine, 2-D-hydroxyproline, 1-13C-ketoisocaproic acid (KIC), L-[Guanido-15N2]-Arginine, L-[ureido-13C-2H2]-Citrulline), L-Glutamine-amide-15N, 1,2-13C2-L-Glutamic acid, 1,2-13C2Taurine, and 13C-Urea is given IV simultaneously
1531227|NCT02733107|Drug|Apatinib|Apatinib, 250mg daily, po, continue until disease progression
1531228|NCT02733107|Drug|Etoposide|Etoposide, 50mg daily, po, day 1 to day 20, repeat Q 4 weeks until disease progression
1531229|NCT02733094|Drug|Secukinumab|
1531231|NCT02733068|Biological|HPV-16/18 vaccine|0.5ml of recombinant human papillomavirus virus-like particle vaccine (Type 16 and 18 L1 Proteins, Yeast) on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
1531232|NCT02733068|Biological|HPV-16/18 placebo|0.5ml of placebo on upper arm deltoid muscle with a three-dose-schedule (0, 2, 6 months).
1531233|NCT02733055|Other|posturographic evaluation|subjects will undergo CDP testing using one of the ext_mCTSIB tests without (baseline) and with oculomotor task
1531234|NCT02733042|Drug|Durvalumab|
1531235|NCT02733042|Drug|Lenalidomide|
1531236|NCT02733042|Drug|Rituximab|
1531237|NCT02733042|Drug|Ibrutinib|
1531238|NCT02733042|Drug|Bendamustine|
1531239|NCT02733029|Drug|Sonazoid|Sonazoid (GE Healthcare) is a contrast agent that is a lipid-stabilized suspension of perfluorobutane microbubbles
1531240|NCT02733029|Device|contrast enhanced ultrasonography|
1531241|NCT02733003|Behavioral|Women's Health CoOp (WHC)|Participants in this group will participate in two workshops of the woman-focused intervention about HIV/STIs, sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Personalized risk reduction action plans will be created at the end of the second intervention session.
1531242|NCT02732990|Behavioral|Exercise training|All gruoups will undergo 6 weeks of training intervention either with a small musclemass (one-legged exercise) or whole body exercise (two-legged cycling)
1531243|NCT02732977|Other|expert system development|data collection (imaging, biology physiology ... ) of patients with systolic heart failure complicated by mitral regurgitation and / or cardiac synchronization before and after implementation of the recommended standard treatments and modeling using mathematical and statistical models fed all data .
1531248|NCT02732938|Drug|PF-04136309|PF-04136309 oral dosing
1531249|NCT02732938|Drug|Nab-paclitaxel|Nab-paclitaxel IV dosing
1531250|NCT02732938|Drug|Gemcitabine|Gemcitabine IV dosing
1531251|NCT02732925|Device|Arm 2 Balloon Kyphoplasty|"Arm 2 Balloon Kyphoplasty (Medtronic LCC) and Conservative Treatment
Subjects will be blinded and randomised to Arm 2 and will undergo a general anaesthetic and undergo a balloon kyphoplasty surgical procedure. They will also be treated with conservative management.
Below is a list of the conservative management they will be managed by their Doctor:
Bisphosphonates
Pain relief
Systemic chemotherapy for Myeloma disease
Bed rest
Radiotherapy
Physiotherapy"
1531252|NCT02732925|Procedure|Conservative Management|"Patients recruited to Arm 1 and Arm 2 will undergo conservative management for Multiple Myeloma recommended by their Consultant Hematologist.
Concomitant treatment with bisphosphonates
Pain relief as required
Systemic chemotherapy for Myeloma disease
Bed rest
Radiotherapy
Physiotherapy"
1532560|NCT02723994|Drug|Pegaspargase|
1531259|NCT02732886|Device|Betafoam®|Foam dressing including Betadine iodine
1531260|NCT02732873|Device|FibroFix Meniscal Scaffold|FibroFix™ Meniscus scaffold is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear.
1531261|NCT02732860|Other|Molecular Profiling & In Vivo drug testing in pPDX|Molecular profiling of host tumour sample and pPDX will be performed and analyzed by an expert panel. Matched treatment recommendation based on profiling and in vivo pPDX drug testing results will be made, if available. This recommendation will be communicated to the primary oncologist.
1531262|NCT02732847|Other|A delayed prescription dated 2 days after clinical office visit|
1531263|NCT02732847|Drug|Usual Dated|
1531264|NCT02732834|Behavioral|Questionnaire|patients will fill out a questionnaire about their perceived stigma, satisfaction with communication, and psychological distress.
1531265|NCT02732834|Behavioral|Patient Interview|Then they will participate in a brief in-person interview about their perceived stigma during the clinical consultation
1531266|NCT02732834|Behavioral|Audio recordings of clinical consultations|
1531268|NCT02732808|Drug|Ovulation stimulation|"Double stimulation in 2 phases:
Phase I: Clomiphene citrate (Ovumid®) 25 mg/day with co-treatment of Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. Letrozole (Letrofem®) 2.5 mg/day are given from cycle day 3 onwards. human menopausal gonadotrophin (HMG) Menopur®150 IU every other day beginning on cycle day 6. triptorelin (Decapeptyl®) 100 μg follows by ibuprofen 600 mg.
Phase 2:A total of 225 IU HMG(Decapeptyl®) and letrozole (Letrofem®) 2.5 mg is administered daily .Daily administration of medroxyprogesterone acetate (Progestrone®)10 mg. . the final stage of oocyte maturation is induced again with triptorelin (Decapeptyl®)100 μg by injection."
1531269|NCT02732795|Drug|Ideal versus Actual body weight dosing of morphine|Groups randomized to receive ideal versus actual body weight dosing of morphine.
1531270|NCT02732782|Other|Isometric exercise|
1531271|NCT02732782|Other|Eccentric exercise|
1531272|NCT02732769|Device|GammaKnifePerfexion®|neurosurgery
1531273|NCT02732769|Device|GammaKnifeIcon®|neurosurgery
1531274|NCT02732769|Device|Efficast®|Thermoformed mask
1531275|NCT02732769|Device|MRI|
1531278|NCT02732743|Dietary Supplement|Physiomanna® Baby|Dosage 1g/kg body, 2 cycles (if applicable)
1531279|NCT02732730|Drug|Truvada|400 women who accept to initiate PrEP
1531280|NCT02732717|Other|ultrasound (observation)|"Important sonographic indices are to be collected from 11-14 weeks, 16-18 weeks, 22-24 weeks, 30-32 weeks and 37-39 weeks,including crown-rump length, nuchal translucency, amniotic fluid, umbilical artery flow, middle cerebral artery flow,ductus venous flow. It is observational.
Conditions as below are thought abnormal: discordance of crown-rump length more than 20%, discordance of nuchal translucency more than 20%, either of twin with abnormal amniotic fluid (polyhydramnios or oligoamnios), either of twin with abnormal umbilical artery flow (elevated resistance index, absent or reverse diastolic flow), either of twin with abnormal middle cerebral artery flow (more than 1.5Mom), either of twin with abnormal ductus venous flow (absent or reverse a-wave)."
1531281|NCT02732704|Device|JenaValve Pericardial TAVR System|In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat severe aortic regurgitation. The JenaValve replacement valve is placed inside the aortic valve by using the JenaValve delivery system.
1531282|NCT02732691|Device|JenaValve Pericardial TAVR System|In this study, transcatheter aortic valve replacement (TAVR) will be performed using the JenaValve Pericardial TAVR System, which is intended to help treat severe aortic stenosis. The JenaValve replacement valve is placed inside the aortic valve by using the JenaValve delivery system.
1531283|NCT02732678|Drug|PROPRANOLOL|
1531284|NCT02732639|Drug|Pegylated Interferon (PEG-IFN) alfa-2a|Participants received pegylated interferon (PEG-IFN) alfa-2a 180 microgram (mcg) subcutaneously (SC) weekly for 48 weeks.
1531285|NCT02732626|Procedure|radiofrequency ablation|
1531286|NCT02732613|Device|Laryngeal Mask Airway|If there were any conflicts of the Laryngeal Mask Airway classic size selection in slim patients by the actual or ideal body weight, size selection will based on actual body weight in Actual weight Group while ideal body weight in Ideal weight Group.
1531287|NCT02732600|Other|Facilitated Implementation|Facilitated Implementation sites will receive one year of support based on the i-PARIHS implementation model which includes training, implementation planning, ongoing external facilitation, feedback and consultation
1531288|NCT02732587|Drug|Saracatinib|Subjects will receive 125 mg Saracatinib for 8-11 days followed by an alcohol interaction lab session
1531289|NCT02732574|Device|Oscilatory Positive Expiratory Pressure (OPEP) device|OPEP devices will be set to the highest pressure setting tolerated on POD #1. If the highest pressure setting is not achieved on POD#1, the PT will increase the pressure daily with the aim to achieve the highest pressure setting as soon as tolerated by the patient or POD#3, whichever comes first. Patients will be instructed to complete 15 breaths in a seated position with the OPEP device twice per waking hour. This will occur in addition to usual care.
1531290|NCT02732574|Device|SHAM Device Group|SHAM devices will be provided to patients on POD #1 and set to the highest pressure setting externally, however no positive expiratory pressure will be provided as the internal pressure regulating mechanism has been removed. Patients will be instructed to complete 15 breaths in a seated position with the sham device twice per waking hour. This will occur in addition to usual care.
1531291|NCT02732561|Device|Alpha Stim device|cranial electrotherapy stimulation device
1531292|NCT02732561|Device|Sham device|Sham device
1531295|NCT02732548|Other|Standard Care|wound measurement, debridement, photography of wound, moist wound environment, infection management, nutritional support
1531296|NCT02732535|Procedure|sleeve gastrectomy , roux-en-y gastric bypass|laparoscopic sleeve gastrectomy or laparoscopic gastric bypass
1531297|NCT02732522|Drug|Sublingual misoprostol|
1531298|NCT02732522|Drug|Vaginal misoprostol|
1531299|NCT02732496|Behavioral|Targeted Cognitive Training (TCT)|The instructors have selected a set of computer exercises designed to specifically target working memory, which is a cognitive construct relevant to ADHD and Tourette Syndrome. The tasks were designed to benefit subjects through principles of learning-dependent plasticity.
1531300|NCT02732496|Other|Youth Appropriate Online Games|Engaging games not designed to improve cognition.
1531301|NCT02732483|Drug|Endo-Clot(TM)|The patients agreed in this study, bleeding control will going to be done with Endo-Clot(TM)
1531302|NCT02732470|Other|Qi Gong|The aim of this study is to evaluate the effects of Qi Gong on quality if life in patients with Systemic Lupus Erythematosus
1531303|NCT02732431|Other|Sleep Symptom|Questionnaires, skin allergy test, overnight polysomnography
1531304|NCT02732418|Drug|Depo-Provera CI|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA)
1531305|NCT02732418|Drug|Depo-subQ 104|The active ingredient in Depo-Provera is Medroxyprogesterone acetate (MPA). Depo-subQ provera 104® (medroxyprogesterone acetate injectable suspension, 104 mg/0.65mL) for subcutaneous injection
1531306|NCT02732405|Drug|MK5172 /MK8742|tablets of MK-5172 100 mg/MK-8742 50 mg will be administered orally, daily for 12 weeks without ribavirin
1531307|NCT02732392|Procedure|standard lymphadenectomy|
1531308|NCT02732392|Procedure|lymphadenectomy radio-isotope method|
1531309|NCT02732379|Procedure|Lavender Aromatherapy|the two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
1531310|NCT02732379|Procedure|Rose Aromatherapy|the two drops of rose essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
1531311|NCT02732379|Procedure|Ginger Aromatherapy|the two drops of ginger essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes.
1531312|NCT02732379|Procedure|Placebo Aromatherapy|the two drops of pure water will be dropped into the gauze and the patient will inhale it for 5 minutes
1531313|NCT02732366|Behavioral|Group-based exercise and peer coaching|Group-based exercise and peer coaching will take place over 6 weeks plus one booster visit after 3 months, and include physical therapist-led 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions) to include: progressive strengthening, balance and mobility exercises; patient goal setting; peer coaching training activities to teach group members ways to help each other to meet their exercise goals during and after classes are over. There will be an individualized home program including flexibility, strengthening, walking, and balance, as well as activity monitoring.
1531314|NCT02732366|Other|Usual PT and attention control grp class|The usual PT and attention control group class will receive standard one-on-one PT strength, balance, gait and education intervention, and group classes to provide valuable information about healthy living, including nutrition, relaxation, and stress management. The attention control - healthy living group classes will take place over 6 weeks plus one booster visit after 3 months, and include 1 hour sessions 2 times per week for 2 weeks followed by once per week for 4 weeks (8 sessions).
1531315|NCT02732353|Dietary Supplement|Minced beef|Cow meat protein supplement
1531316|NCT02732353|Dietary Supplement|Hydrolyzed beef|Cow meat protein supplement
1531317|NCT02732340|Procedure|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
1531318|NCT02732340|Procedure|hemi-arch replace|Half aortic arch resection was performed along the greater curvature of the aortic arch at 1 cm proximal of the innominate artery to the lesser curvature of the aortic arch at the origin of the descending aorta.Then the half aortic arch was replaced by the Dacron graft.
1531319|NCT02732327|Drug|CAZ-AVI|Ceftazidime-Avibactam (2 g ceftazidime and 0.5 g avibactam)
1531320|NCT02732327|Drug|Vancomycin|15 mg/kg
1531321|NCT02732327|Drug|Linezolid|600 mg
1531322|NCT02732327|Drug|Cefepime|2 g
1531323|NCT02732327|Drug|Meropenem|1 g
1531324|NCT02732327|Drug|Piperacillin/tazobactam|4.5 g
1531325|NCT02732314|Drug|Investigational OTC Cream|
1531326|NCT02732314|Other|Cosmetic Eczema Cream|
1531327|NCT02732314|Drug|0.05% Desonide Cream|
1531328|NCT02732314|Other|Placebo Cream|
1531329|NCT02732288|Dietary Supplement|melatonin|After measuring the subject's own timing of release of melatonin, subjects will be provided a dose of melatonin at 8pm to test the effects on the electrical activity of sleep, measured using electroencephalography. The same intervention will be given to healthy, non-brain injured controls.
1531331|NCT02732262|Drug|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 1.00 mg.
1531332|NCT02732262|Drug|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.03 mg/kg.
1531333|NCT02732262|Drug|Oxycodone, 0.02 mg/kg dose|Intravenous oxycodone is provided as patientcontrolled analgesia after surgery with bolus dose of 0.02 mg/kg.
1531334|NCT02732249|Drug|Esomeprazole|Given 30 min before morning and evening meals
1531335|NCT02732249|Drug|Bismuth Potassium Citrate|Given 30 min before morning and evening meals
1531336|NCT02732249|Drug|Clarithromycin|Given 30 min after morning and evening meals
1531337|NCT02732249|Drug|Metronidazole|Given 30 min after meals or at bedtime
1531338|NCT02732236|Other|Rituximab|Cohort observation study
1531339|NCT02732223|Dietary Supplement|Functional treatment|Omega 3 fatty acids, plant sterols and polyphenols
1531340|NCT02732223|Dietary Supplement|Control treatment|placebo supplements
1531341|NCT02732197|Drug|Sedation|Parturients who received IV thiopental 2 mg kg-1 and if necessary additional 50 mg immediately after spinal anesthesia until reaching at least Ramsay sedation score of 3 (1: patient anxious, agitated or restless, 6: patient with no response to light glabella tap or loud auditory stimulus.).
1532561|NCT02723994|Drug|Prednisone|
1531342|NCT02732197|Drug|No sedation|Parturients did not receive any type of sedation after spinal anesthesia.
1531344|NCT02732171|Other|Plasma/Buffy Coat|3 x 10ml EDTA Tube
1531345|NCT02732171|Other|Serum|1 x 8.5ml Serum Separator Tube
1531346|NCT02732171|Other|Bone Marrow Aspirate|1 x 10ml EDTA Tube
1531347|NCT02732158|Other|Nutrition Products|a sachet containing AN777and amino acids; a carotenoid capsule
1531348|NCT02732145|Other|ISSVD Questionnaire|Questionnaire: Patient characteristics, symptoms description, other conditions..
1531349|NCT02732145|Procedure|Three Rings Vulvoscopy|"Mapping of the vulvar lesions according to the three vulvar rings and specificity of the lesions during colposcopy examination of the vulva using Three Rings Vulvoscopy technique (TRIV Form Data)."
1531350|NCT02732145|Procedure|Histopathology|Biopsy of the vulva in symptomatic patients, vulvar samples after labiaplasty in asymptomatic patients.
1531351|NCT02732132|Drug|Ketamine and Midazolam|This group was injected intravenous midazolam 0.1 mg/kg (maximum 4 mg), two minutes later, ketamine 1 mg/kg was given intravenously before the start of endoscopy.
1531352|NCT02732132|Drug|Propofol and Fentanyl|This group was injected intravenous fentanyl 1 mcg/kg, and two minutes later, propofol 1 mg/kg was given intravenously before the start of endoscopy.
1531353|NCT02732119|Drug|Ribociclib|ribociclib + everolimus + exemestane daily
1531354|NCT02732119|Drug|Everolimus|ribociclib + everolimus + exemestane daily
1531355|NCT02732119|Drug|Exemestane|ribociclib + everolimus + exemestane daily
1531356|NCT02732093|Procedure|stellate block|
1531357|NCT02732093|Drug|Na.Cl 0.9% (placebo)|
1531358|NCT02732093|Drug|lidocaine 2%|
1531359|NCT02732080|Device|deferred coronary stenting|Final coronary stenting will be performed when coronary auto regulation was recovered (approximately 30 minutes after establishment of TIMI III flow şn the infarct related artery)
1531360|NCT02732080|Device|immediate stenting|Stent implantation will be performed immediately after balloon angioplasty (or thrombectomy or wire crossing) as it is performed in daily routine.
1531361|NCT02732067|Other|anesthesia related deaths|number of anesthetized patients who died in the perioperative period inside the hospital
1531362|NCT02732054|Biological|Recombinant Hepatitis B vaccine [(CIGB) La Habana, Cuba]|Different HBV vaccine regimen in each group
1531363|NCT02732015|Drug|Rolapitant|180 mg by mouth on Day 1 of each 21 day cycle.
1531364|NCT02732015|Drug|Fosaprepitant|150 mg administered by vein on Day 1 of each 21 day cycle.
1531365|NCT02732015|Behavioral|Questionnaires|Questionnaires about nausea and vomiting completed at baseline, 1 week before each 21 day cycle, and at end of study visit.
1531366|NCT02732015|Drug|Dexamethasone|12 mg by vein on Day 1, and 8 mg by vein on Days 2 - 5.
1531367|NCT02732015|Drug|Ondansetron|16 mg by vein daily for 5 days.
1531368|NCT02732015|Drug|Doxorubicin|25 mg/m2/day by vein on Days 1, 2, 3, completing infusion on day 4 (total dose: 75 mg/m2).
1531369|NCT02732015|Drug|Mesna|Mesna given prior to Ifosfamide (Day 1) - 500 mg/m2 (20% of Ifosfamide dose) given simultaneously with Ifosfamide and then daily continuous infusion (Days 1 - 4 completing infusion on day 4) - 1,500 mg/m2/day (60% of daily ifosfamide dose) for a total of 6 gm/m2. Mesna infusion completes 24 hours after the last dose of Ifosfamide.
1531370|NCT02732015|Drug|Ifosfamide|2.5 g/m2 by vein on Days 1, 2, 3, 4 (total dose: 10 g/m2).
1531371|NCT02732015|Drug|Vincristine|2 mg by vein on Day 1 may be given to participants with sarcomas of small cell histology.
1531372|NCT02732002|Procedure|OCBRA ( Objective Criteria Based REhabilitation Algorithm|The patient will complete the initial functional and clinical evaluation in the medical room and laboratory. Afterwards, all the gathered information will be assembled to generate the patient-specific functional and clinical status-based rehabilitation program. This program will be generated in conjunction with the physical therapy staff. For each of the functional or clinical deficits observed during the examination, the physical therapist will identify the precise exercise and goal-based progression from a previously standardized goal-based rehabilitation algorithm adapted from previously published investigations targeting this issue
1531373|NCT02731976|Other|Dietary intervention|
1531374|NCT02731963|Drug|Polyethylene glycol|Patients with colorectal pathology who underwent elective colorectal anastomosis, that were randomized into two groups; one of them received mechanical bowel preparation with polyethylene glycol (study group), and the other one received clear liquid diet(control group) .
1531375|NCT02731950|Drug|Magnesium Sulfate and Bupivacaine 0.125%|Each patient will receive bupivacaine 0.125% with 5% magnesium sulphate by infusion through a catheter used for epidural analgesia, positioned presternal.
1531376|NCT02731937|Device|GE Healthcare Revolution CT Scanner (CT Scanner)|Raw CT Scan Data
1531377|NCT02731924|Procedure|Ultrasound for Appendicitis|Point-of-care ultrasound to evaluate emergency department patients for suspected appendicitis
1531378|NCT02731911|Drug|dexamethasone intravitreal implant|Ozurdex® treatment for diabetic macular oedema as per standard of care in clinical practice.
1531379|NCT02731885|Drug|ABX464 Single dose|Two-periods, subjects received a single dose of 50mg of ABX464 in fed and fasted condition, separated by a wash-out period of at least 45 days.
1531380|NCT02731885|Drug|ABX464 Repeated dose|Subjects received 50mg of ABX464 every 3 days during 10 days in fasted or fed condition.
1531381|NCT02731872|Device|Airvo humidifier|"The Airvo humidifier has adjustable flow settings for delivery of fully saturated breathing gases at 37 °C, 100% humidity.
Flow rates are adjustable between 15 and 45 l/min. Ambient air is drawn in by a low-capacity motor. When coupled to a medical oxygen supply, the regulation of delivered oxygen concentration is ensured."
1531382|NCT02731859|Device|Insertion of EndoBarrier for approximately one year|Insertion of EndoBarrier for approximately one year then explantation and follow-up
1531383|NCT02731846|Drug|Fluticasone furoate 100 mcg + Umeclidinium 62.5 mcg+Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler(2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Umeclidinium 62.5 mcg and Vilanterol 25 mcg per blister), administered as one inhalation of FF/UMEC/VI (100/62.5/25 mcg) once-daily in the morning
1531730|NCT02729467|Drug|JNJ-53718678|JNJ-53718678 will be applied twice at doses of 250 mg (in Panel 1, Day 1 and Day 9) and 3 times at 500 mg (Panel 2, Day 1, 4 and 9).
1531384|NCT02731846|Drug|Fluticasone furoate 100 mcg + Vilanterol 25 mcg|Dry white powder delivered via ELLIPTA inhaler (2 strips with 30 blisters each, first containing fluticasone furoate 100 mcg per blister and second containing Vilanterol 25 mcg per blister), administered as one inhalation of FF/VI (100/25 mcg) once-daily in the morning
1531385|NCT02731846|Drug|Umeclidinium 62.5 mcg|Dry white powder delivered via ELLIPTA inhaler (1 strip with 30 blisters containing Umeclidinium 62.5 mcg, administered as one inhalation once-daily in the morning
1531386|NCT02731846|Device|Placebo ELLIPTA inhaler|Placebo will be administered via ELLIPTA inhaler. Dry white powder administered as one inhalation each morning (1 strip with 30 blisters containing placebo)
1531387|NCT02731846|Drug|Albuterol/Salbutamol|Albuterol/salbutamol will be administered via metered-dose inhaler (MDI) with a spacer as needed throughout the study as a rescue medication
1531388|NCT02731833|Other|stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100ppm fluoride
1531389|NCT02731833|Other|sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000ppm fluoride
1531394|NCT02731807|Dietary Supplement|Dose A: TA-65 24mg, powder|
1531395|NCT02731807|Dietary Supplement|Dose B: TA-65, 8mg, powder|
1531396|NCT02731807|Dietary Supplement|Dose C: TA-65 3.2mg, capsule|
1531397|NCT02731807|Dietary Supplement|Dose D: TA-65 8mg, capsule|
1531398|NCT02731807|Dietary Supplement|Dose E: TA-65 32mg, capsule|
1531399|NCT02731794|Device|left ventricular assist|In left ventricular assist group, 100 IU/kg heparin was given to activated clotting time (ACT) greater than 180 seconds. A 22 French arterial cannula (Maquet, Irrlingen, Germany) was introduced into the ascending aorta, and a 26 French cannula (Eurosets, Medolla, Italy) into the left atrium and advanced into the left ventricle. The two cannulas are directly connected through a short, heparin-coated circuit to a centrifuge pump (Maquet, Getinge Group, Germany). A flow of 1.0 to 4.0 L/min/m2 is obtained and mean blood pressure was maintained 55-75 mm Hg. Note: Both LVA group and BiVA group have the operative protocols itself,includes different prime fluid and cannula pathway. The investigators think it is inapplicable to assign the different operative protocols to the Treatment Arm.
1531400|NCT02731794|Procedure|Biventricular assist|In biventricular assist group, the patients were routinely heparinized with a dose of 300 IU/kg heparin to ACT greater than 480 seconds. Cardiopulmonary bypass with a centrifuge pump (Maquet, Getinge Group, Germany) was established by 22 French aortic cannulation and 34 French two-stage venous cannula through the right atrial appendage. The extracorporeal circuit was primed with 2000 mL of lactated Ringer's solution, albumin, 25% mannitol and 5% NaHCO3. The flow was 1.0 to 4.0 L/min/m2 and mean blood pressure was maintained 55-75 mm Hg.
1531401|NCT02731781|Other|NONE . OBSERVATIONAL|OBSEVATION AND FOLLOW UP
1531402|NCT02731768|Behavioral|Standard|Participants will receive an evidence-based behavioral weight control program focused on physical activity and reducing caloric intake. They will be provided with a Fitbit Zip and digital body weight scale for self-monitoring of physical activity and body weight, respectively.They will track caloric intake via the MyFitnessPal smartphone application. They will have access to a study website and attend weekly, in-person group counseling sessions.
1531403|NCT02731768|Behavioral|Social support-enhanced|Participants will receive the same intervention components as the Standard group.Participants will also be provided with two extra Fitbit Zips and digital body weight scales to share with up to two persons in their social circle who will be invited to serve as their support partners.
1531404|NCT02731768|Device|Fitbit Zip|
1531405|NCT02731768|Device|Digital body weight scale|
1531406|NCT02731755|Other|Oat|The study oat intervention products will consist of porridge containing 66.8g flaked oats.
1531407|NCT02731755|Other|Control|60g cream of rice
1531408|NCT02731742|Biological|MK-1966|MK-1966 administered as an intravenous (IV) infusion
1531409|NCT02731742|Drug|SD-101|SD-101 administered intratumorally
1531412|NCT02731716|Behavioral|New Payment Model|Providers will no longer be paid based upon FFS, but on the new payment model, which includes PMPM and quality incentives.
1531413|NCT02731716|Behavioral|Social Comparisons|Providers will receive weekly emails showing comparisons in quality metrics and total cost of care. They will be compared to other providers in their provider organization.
1531414|NCT02731716|Behavioral|A1c Member/Provider Incentive|Attributed members and their PCPs will receive up to $75 for a reduction of a1c by 0.5% per quarter (2 quarters).
1531415|NCT02731703|Device|Overdenture treatment|Conventional, FDA-approved prosthetics will be used in accordance with their labeling and pre-study prescribed standard treatment approach
1531416|NCT02731690|Drug|Aceneuramic Acid Extended-Release Tablets|
1531417|NCT02731677|Other|Acupuncture|Acupuncture was applied on the acupoints F3 - BP6- VB34- IG4 - TA5 - C7 - PC6 - IG11 - VB20 - XIAOCHANXUE, once a week, eight sessions in the experimental group.
1531418|NCT02731664|Biological|GLP-1|Intravenous infusion of GLP-1
1531419|NCT02731664|Biological|Intravenous saline|Control
1531420|NCT02731651|Procedure|open hysterectomy|Hysterectomy with laparotomy incision.
1531421|NCT02731651|Procedure|laparoscopic assisted vaginal hysterectomy|Hysterectomy with laparoscopic assisstance.
1531422|NCT02731638|Drug|Intrastromal voriconazole|Subjects will receive three intrastromal voriconazole injections over 10 days. Intrastromal voriconazole injection is a routine procedure performed by Aravind Eye Hospital for fungal keratitis.
1531423|NCT02731638|Drug|Natamycin|Subjects will receive topical 5% natamycin drops hourly for 3 days.
1531424|NCT02731625|Other|Kettlebell training|Kettlebell training will be performed in 30 second work:rest intervals. Total training time will progress from 10 minutes at the beginning of the study to 20 minutes at the end.
1531425|NCT02731625|Other|Army Physical Readiness Training|Army Physical Readiness Training per Army Field Manual 7-22
1531426|NCT02731612|Drug|lurasidone|Atypical Antipsychotic
1531428|NCT02731599|Procedure|treadmill training with cues|20-minutes treadmill training per day, 6 times a week, for 4 weeks. Treadmill speed was previously set at 2.0 km/h and progressively increased until a maximum of 3.5 km/h, taking always into account the patients' physical abilities. All patients were evaluated at the enrolment and at the end of the 4-weeks treatment. The first evaluation consisted in one-minute walking on treadmill without the use of cues at 1.5 km/h speed, for all patients. The outcome measurements were: the average length of the right step, the average length of the left step, the coefficient of variance of both steps, and the gait cycle.
1531429|NCT02731586|Drug|Allogenic Mesenchymal stem cells|Allogenic mesenchymal stem cells are introduced during placement of dental implants.
1531433|NCT02731547|Behavioral|Education Against Tobacco School-Based Intervention|
1531434|NCT02731534|Drug|Z-213|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV on day 1, 8 and 15 (if needed)
1531435|NCT02731534|Drug|Saccharated Ferric Oxide|The total iron dosage is calculated based on hemoglobin value and the patients' weight, IV two or three times per week
1531436|NCT02731521|Device|3 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
1531437|NCT02731521|Device|7 Tesla Scanning|Approximately 120 brain tumor patients 50 patients with non-glioma disease, and 5 healthy volunteers will be scanned at either 3 Tesla or 7 Tesla.
1531438|NCT02731508|Device|Bihemispheric transcranial direct current stimulation|5x5 cm tDCS electrode over C3 or C4 (10-20 system) with concurrent rehabilitation
1531439|NCT02731495|Dietary Supplement|EGCG|EGCG (Epigallocatechin -3-gallate)
1531440|NCT02731495|Dietary Supplement|Placebo (deionized water)|
1531441|NCT02731482|Other|Training Group|"Three sessions per week, each lasting 50 minutes, during eight weeks.
Aerobic training in stepping training.
Resistance training: Three sets of eight repetitions each, in both simultaneous members, using an elastic band. The trained muscles are quadriceps, hamstrings, deltoid and biceps.
Once a week, patients will receive a phone call and every two weeks, patients will get a visit of the researcher at his home."
1531442|NCT02731482|Other|Control Group|"The participants will receive verbal and written information about the importance of physical activity and walk in moderate intensity, at least, three times a week for 30 minutes.
Participants will not receive any supervised physical training.
Once a week, patients will receive a phone call to provide support and general advice."
1531443|NCT02731469|Biological|BCD-131|
1531444|NCT02731469|Biological|Mircera®|
1531445|NCT02731469|Biological|Aranesp®|
1531446|NCT02731456|Other|altitude exposure|altitude exposure
1531447|NCT02731443|Procedure|Epilepsy surgery|Epilepsy surgery is a procedure that removes an area of the brain where seizures originate.
1531448|NCT02731443|Procedure|Depth electrodes insertion|Depth electrodes are inserted for monitoring/mapping the subsurface levels of the brain for the surgical treatment of epilepsy.
1531449|NCT02731430|Drug|intrathecal morphine|received 0.3mg morphine (0.3ml) added to 1.2ml of bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
1531450|NCT02731430|Drug|intrathecal saline|received 0.3ml saline added to 1.2mlof bupivacaine 0.5% (total volume 1.5ml), intrathecally, immediately before induction of general anesthesia.
1531451|NCT02731417|Other|acupuncture|Acupuncture for women with post partum urinary retention
1531452|NCT02731417|Device|Foley catheter|Foley catheter insertion for women with post partum urinary retention.
1531453|NCT02731404|Procedure|HFJV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
1531454|NCT02731404|Procedure|IPPV ventilation|The investigators used the Perkins tonometer for monitoring intra-ocular pressure. Evaluation of intra-ocular pressure was done before induction of anesthesia, end of induction, during surgery and at the end of surgery.
1531455|NCT02731391|Procedure|Pelvic floor reconstruction（with or without mesh）|
1531456|NCT02731378|Drug|Erythropoietins (EPO)|A routine dose 10,000 IU of EPO, three times weekly by subcutaneous injections.
1531457|NCT02731378|Drug|Aggressive iron dextran supplementation|Iron dextran 100 mg, BIW, through 90 minutes of IV infusion, for the first consecutive 5 weeks
1531458|NCT02731378|Drug|Erythropoietins (EPO)|Doubling EPO dosage to 20,000 IU, three times weekly by subcutaneous injections with a maximum of 5 doses
1531459|NCT02731378|Drug|Sustained iron dextran supplementation|Iron dextran 200 mg, Q3W, through 90 minutes of IV infusion and a maximum of 5 doses
1531460|NCT02731365|Device|Activa PC+S|The Activa PC+S is a newly developed Medtronic DBS implantable system and is available for use in clinical research. This system has a mechanism for both sensing of LFP and the ability to provide deep brain stimulation therapy. The sensing capabilities are controllable with data management using a clinician sensing tablet programmer that has a USB extension allowing for telemetry to an encrypted, locked computer.
1531461|NCT02731352|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o. in differentiated thyroid cancer
1531462|NCT02731339|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
1531463|NCT02731339|Behavioral|Low back pain intensity measurement|Low back pain intensity of the patients was questioned by Visual Analogue Scale
1531464|NCT02731339|Behavioral|Urogenital symptoms measurement|The presence and severity of various urogenital symptoms was assessed with the Urogenital Distress Inventory-6
1531465|NCT02731339|Behavioral|Disability caused by low back pain|Disability caused by low back pain was assessed with the Oswestry Disability Index
1531466|NCT02731326|Device|AliveCor|"The AliveCor Heart Monitor, an FDA-approved smartphone technology, snaps on to the patient's study smartphone similar to a protective case and works through a free application, AliveECG. It captures a highly sensitive (98%), specific (97%), and accurate (97%) single-lead ECG recording through two electrodes on the back of the patient's smartphone. When the application is opened, recording begins automatically when both electrodes make contact with skin. Transmissions are automatically uploaded to the study patient portal within the AliveCor cloud."
1531467|NCT02731326|Behavioral|Behavioral Altering Messaging|Behavioral altering messages relating to the participant's AF and underlying cardiac risk factors will be systematically selected from a bank of text messages developed through collaboration by the study team and an expert interdisciplinary panel from the American Heart Association. The content of the text messages will not include PHI. The final text message bank will be housed internally and maintained by the Data Manager and text messages will be pushed automatically from this database. The only identifying link to participants included in this database will be their study-provided phone number
1531468|NCT02731313|Biological|Trastuzumab|Trastuzumab was not administered in this study. This study informs future trastuzumab treatment decisions.
1531469|NCT02731300|Device|tDCS|brain stimulation by cathodal electrode at motor cortex
1531470|NCT02731287|Drug|Timolol|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
1531471|NCT02731287|Drug|Placebo|The patient will be treated with 2 drops twice a day over the lesion and rub with the finger (no occlusive) for 24 weeks
1531472|NCT02731274|Other|Regular physical activity in Motor memory consolidation|After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training. For the analysis of the results, descriptive and inferential statistics were used.
1531473|NCT02731261|Other|Motor memory consolidation|Subjects were divided in two groups: a control group and an experimental group. Before the intervention of a physical exercise program, subjects performed a Finger Tapping Sequence to measure baseline performance. After the intervention, the assessment of the impact of exercise on motor memory consolidation was held in three stages: Training; 1 hour after training and 24 hours after training.
1531474|NCT02731248|Other|Prospective screening study|Prospective screening study in newborns
1531475|NCT02731235|Other|High-intensity training|high intensity training 5 days a week for 12 weeks
1531476|NCT02731235|Drug|prophylactic stroke medication|Usual care medication for stroke prophylaxis
1531477|NCT02731235|Behavioral|Recommendations for lifestyle changes|Advise on diet, alcohol, smoking and exercise
1531478|NCT02731222|Other|observational cross-sect. analytical inferential unicentric|collecting data from patients of the Service of Angiology and Vascular Surgery of the Hospital de Sant Pau
1531479|NCT02731209|Device|urinary catheter|
1531480|NCT02731196|Behavioral|Exercise Intervention|Early versus later stabilization and neurodynamic exercise intervention following a post-op lumbar microdiscectomy
1531481|NCT02731183|Procedure|fecal microbiota transplantation|Patients received frozen FMT on 6 consecutive days through nasojejunal tubes.
1531482|NCT02731170|Behavioral|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
1531483|NCT02731157|Drug|Rejuvesol|
1531484|NCT02731157|Procedure|Blood transfusion|Only transfusions necessary for the treatment of the sickle cell disease will be given for the purpose of the study.
1531485|NCT02731144|Other|Peptamen intense|
1531486|NCT02731144|Other|Novasource senior|
1531487|NCT02731131|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered as 180 micrograms (mcg) once weekly via subcutaneous (SC) injection.
1531488|NCT02731131|Drug|Ribavirin|Ribavirin will be administered as 1000 to 1200 milligrams (mg) per day in divided oral doses.
1531489|NCT02731118|Dietary Supplement|Salovum|AF-enriched egg yolk
1531490|NCT02731118|Dietary Supplement|Placebo|egg yolk
1531491|NCT02731105|Drug|Acnatac® Gel left face|topical application
1531492|NCT02731105|Drug|Epiduo® Gel right face|topical application
1531493|NCT02731105|Drug|Acnatac® Gel right face|topical application
1531494|NCT02731105|Drug|Epiduo® Gel left face|topical application
1531495|NCT02731092|Dietary Supplement|Lactoferrin|Bovine Lactoferrin 100 mg/ml dissolved in sterile water
1531496|NCT02731079|Device|Covidien iDrive|Surgery performed with Covidien powered stapler
1531497|NCT02731079|Device|Ethicon Echilon|Surgery performed with Ethicon powered stapler
1531498|NCT02731066|Other|Standard pro|Volunteers will receive dietary protein at 1.0 ± 0.2 g/kg/d.
1531499|NCT02731066|Other|High pro|Volunteers will receive dietary protein at 2.0 ± 0.2 g/kg/d.
1531500|NCT02731066|Other|carbo bev|During aerobic performance testing, volunteers will receive a beverage containing 80 g glucose + 65 g fructose consumed at a rate providing ~1.8 g carbohydrate/min.
1531501|NCT02731066|Other|placebo bev|During aerobic performance testing, volunteers will receive a volume and flavor-matched, non-nutritive placebo beverage.
1531502|NCT02731053|Behavioral|Blues program|Participants will attend 6 weekly 1-hour sessions of group cognitive-behavioral therapy administered by school staff, and will do home practice between sessions and after the program individually using a web site (called the Blues App)
1531503|NCT02731040|Drug|Bisphosphonate|
1531504|NCT02731014|Other|Dry Needling|Dry Needling targeting the posterior musculature of the cervical and thoracic spine.
1531505|NCT02731014|Other|Sham Dry Needling|Sham Dry Needling performed with Park sham acupuncture needles (Acuprime, UK) will be used to perform sham dry-needling. The device consists of 2 plastic tubes that slide into one another and cause a pricking sensation when pushed against the skin.
1531506|NCT02731014|Other|Manual Therapy|Manual Therapy(mobilization/ manipulation) to address joint mobility of the cervical and thoracic spine.
1532562|NCT02723994|Drug|Thioguanine|
1531507|NCT02731014|Other|Exercise|Exercise designed to improve performance of both the deep neck flexor musculature as well as the scapular musculature. The exercise portion will also include a stretching program targeting the cervicothoracic muscles which have been placed in a shortened position as a result of poor postures.
1531508|NCT02731001|Radiation|Proton therapy|
1531509|NCT02731001|Radiation|Photon therapy|
1531510|NCT02730988|Behavioral|Weight Stable Group|The weight stable control group is monitored bi-weekly by study staff to ensure weight stability over the course of the study. During group sessions, participants are weighed and encouraged to maintain weight within ±5% of baseline. They also receive non-weight loss health related topics presented by study staff. If participants attend 75% of the educational sessions, all baseline and follow-up testing sessions, and maintain weight stability over the course of the study (defined as less than a 5% differential between weight measured at week 0 and 24), they will be eligible to receive up to 3 months of Medifast MRPs along with a 30-60 minute RD-led dietary instruction session on how to follow the Medifast 4 & 2 & 1 Plan.
1531511|NCT02730975|Drug|AA Reduced dose-normal diet (A)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined normal diet, described with specific caloric and fat content.
1531512|NCT02730975|Drug|AA reduced dose-fat diet (B)|Cycles of 28 days length of AA at reduced doses (250 mg) administered with a pre-defined fat diet, described with specific caloric and fat content.
1531513|NCT02730975|Drug|AA normal dose-fasting conditions (C)|Cycles of 28 days length of AA at approved doses (1000 mg) administered in fasting conditions.
1531514|NCT02730962|Drug|Vancomycin|Vancomycin 3 times a day for 7 days
1531515|NCT02730962|Other|Placebo|Placebo pills identical in appearance to each antibiotics to be taken on the same schedule as each antibiotic
1531516|NCT02730962|Drug|Neomycin|Neomycin 3 times a day for 1 day
1531517|NCT02730962|Drug|Clindamycin|Clindamycin 3 times a day for 5 days
1531518|NCT02730962|Procedure|Fecal Microbiota Transplantation|FMT conducted via colonoscopy
1531519|NCT02730949|Dietary Supplement|D-chiro-inositol|Treated group
1531520|NCT02730949|Dietary Supplement|Folic Acid|Control group
1531521|NCT02730936|Device|Antimicrobial Hernia Repair Device|hernia repair
1531522|NCT02730923|Drug|AZD2014|"Following inclusion, patients will be randomized (2:1) to receive Arm A : AZD2014 + anastrozole Arm B : anastrozole alone
Mode of Action Selective and specific mTOR kinase inhibitor targeting both mTORC1 and mTORC2 complexes.
Route of Administration Oral
Dosage regimen 125mg BID with intermittent schedule (2 days of treatment followed by 5 days off (500mg/week))
Duration of treatment Until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
1531523|NCT02730923|Drug|Anastrozole|"Therapeutic Class Aromatase inhibitor
Mode of Action Potent and highly selective non-steroidal aromatase inhibitor.
Route of Administration Oral
Dosage regimen
1 mg tablet once a day
Duration of treatment Patients may continue treatment with anastrozole until the patient experiences unacceptable toxicity, disease progression and/or treatment is discontinued per patient or investigator request."
1531524|NCT02730910|Other|Purple Wheat Crackers|Whole grain crackers manufactured with purple wheat
1531525|NCT02730910|Other|Purple Wheat Granola Bars|Whole grain granola bars manufactured with purple wheat
1531526|NCT02730897|Procedure|Central/Peripheral|Central versus peripheral location of the primary tumor
1531527|NCT02730884|Drug|Rigosertib|Participants take 560 mg Rigosertib by mouth in the morning (two 280 mg capsules) and 560 mg Rigosertib in the afternoon.
1531528|NCT02730884|Behavioral|Questionnaire|Quality of life questionnaire completed on Day 1 of Cycle 1. It should take about 10-15 minutes to complete.
1531529|NCT02730871|Drug|Brinzolamide 1%/Brimonidine 0.2% suspension|
1531530|NCT02730871|Drug|Brinzolamide/Brimonidine vehicle|Inactive ingredients used as placebo comparator
1531531|NCT02730871|Drug|Travoprost 0.004%/Timolol 0.5% solution|1 drop instilled in the affected eye(s) daily in the morning (at 9:00) or in the evening (at 21:00) for up to 10 days during the Screening/Eligibility Phase and 42 days during the Treatment Phase
1531532|NCT02730858|Behavioral|Palliative and Oncology Care|Patients randomized to the intervention will receive collaborative care from palliative care and oncology for the remainder of their illness. The initial five visits with palliative care will be conducted in accordance with the study specific clinical practice guidelines and occur at least monthly.
1531533|NCT02730858|Behavioral|Standard Oncology Care|Patients randomized to oncology care alone will continue to receive routine care identical to what they would have received if they had not participated in the trial. Either patients or their oncologists can request palliative care consultation at any point in time.
1531534|NCT02730845|Drug|Intra-articular dexmedetomidine|Patients will receive an intra-articular mixture of 19 ml bupivacaine 0.5% with epinephrine 1:200.000 added to 1ml (1 µg/kg) of dexmedetomidine (total volume 20 ml), and i.v. saline 20 ml infused over 10 min starting with local anesthesia
1531535|NCT02730845|Drug|Intravenous dexmedetomidine|Patients will be injected intra-articularly with mixture of 19 ml 0.5% bupivacaine with epinephrine 1:200.000 and 1 ml of isotonic saline (total volume 20 ml), in addition to i.v. 20 ml saline containing 1 µg/kg dexmedetomidine over 10 min infusion starting with local anesthesia.
1531536|NCT02730832|Other|Questionnaires completed at D0|
1531537|NCT02730832|Other|Questionnaires completed at D15 (test-retest for 30 patients)|
1531539|NCT02730806|Behavioral|Group Therapy|The Group Therapy will be implemented on 5-12 women each time. The intervention will include, among others, CBT methods.
1531540|NCT02730806|Behavioral|NLP|NLP techniques, such as VKD, visual/auditory/kinesthetic swishes, modified especially for PTSD, will be implemented one-on-one with each woman in this arm.
1531541|NCT02730793|Drug|Oral Aztreonam|Standard Therapy Comparator (Oral Cayston 75mg three times a day)
1531542|NCT02730793|Drug|Nasal Aztreonam|Study Therapy (nasal Aztreonam 75mg twice per day)
1531543|NCT02730793|Drug|Nasal Placebo|Placebo (nasal saline twice per day)
1531544|NCT02730780|Dietary Supplement|Low-Salt Diet|The low-salt diet (7 days) will consist of meals, snacks and water provided by Vanderbilt's metabolic kitchen.
1531731|NCT02729467|Drug|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules of 100 mg) from Day 4-11.
1532563|NCT02723994|Drug|Vincristine Sulfate|
1531545|NCT02730780|Dietary Supplement|High-Salt Diet|The high-salt diet (7 days) consists of each subjects usual diet, supplemented each day with 2 bullion broth packets, which will be provided to the subject by the study staff.
1531546|NCT02730767|Behavioral|partially supervised exercise intervention|
1531547|NCT02730741|Drug|Lcr restituo® sachet|symptomatic treatment of diarrhoea
1531548|NCT02730741|Drug|Placebo|
1531549|NCT02730728|Drug|20ml bolus of 0.5% ropivicaine|Local anesthetic
1531550|NCT02730728|Drug|0.2% Ropivicaine at 8 milliliter/hour|Local anesthetic
1531551|NCT02730728|Drug|5ml bolus of 0.5% ropivicaine|Local anesthetic
1531552|NCT02730715|Drug|Basiliximab|Periodic blood collection to monitor Treg cells
1531553|NCT02730715|Drug|Thymoglobulin|Periodic blood collection to monitor Treg cells
1531554|NCT02730702|Device|LEBS - Low coherence enhanced backscattering|Unprepped patients will have the LEBS probe brought into contact with the rectal mucosa, upon which 10 random readings will be obtained.
1531555|NCT02730689|Drug|DP-R207|
1531556|NCT02730689|Drug|Rosuvastatin|
1531557|NCT02730689|Drug|Ezetimibe|
1531558|NCT02730676|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarettes (original flavor, 29 mg nicotine)
1531559|NCT02730676|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarettes (menthol flavor, 29 mg nicotine)
1531561|NCT02730650|Biological|Platelet Rich Therapy (PRT)|Platelet Rich Therapy (PRT) involves injection of patient's own platelets and fibrin.Topical anesthetic will be applied to the face for a period of fifteen minutes prior to the injection. For PRP preparation, 8 cc of blood will be collected from each patient just before each procedure. Approximately 0.3-0.4 cc of PRP will be injected into each standardized injection point in a superficial manner. The injections points are 6 points on each side of the face along the inferior border of cheek and mid-cheek (12 total). The PRP injection will be followed by 10-15 minutes of icing.
1531563|NCT02730624|Drug|Piperacillin-tazobactam|4.5 g of piperacillin/tazobactam in 100 ml of normal saline solution was administered via an infusion pump at a constant flow rate 30 min every 6 h and blood sample were obtained by direct venepuncture at 0, 0-0.5, 0.5-2, 2-4 and 4-6 hour after drug administration
1531564|NCT02730598|Device|Hybrid Training System (HTS)|Electrodes (15 cm x 6 cm) will be placed over the quadriceps and electrodes (11 cm x 6 cm) (Sekisui Plastics Co., Tokyo, Japan) will be placed over the hamstrings. Electrical stimulation parameters will be based on a standard Russian waveform in which a 5,000 Hz carrier frequency is modulated at 40 Hz (2.4 ms on, 22.6 ms off) to deliver a rectangular voltage biphasic pulse. Acceleration sensors as a joint motion sensor (EWTS9PD, Home Appliances Development Center Corporate Engineering Division, Appliances Company Panasonic Corporation 2-3-1-2 Noji-higashi,Kusatsu City, Shiga, Japan) is placed on the front of each leg 88mm above the patellar edge. It analyzes the algorithm of each exercise pattern, and stimulates the antagonist of the motion of each bilateral knee joint during exercise. Electrical stimulation intensity will be set to ~50-60% of 1RM based on the subject's tolerance. The subject's tolerance gradually increases, and electrical stimulation intensity is reset every 2 weeks.
1531565|NCT02730598|Device|Sensory TENS|The electrical stimulation intensity will be set under the muscle contraction threshold (but at a level at which the subject can perceive as sensory TENS). Electrical stimulation parameters (i.e. waveform and pulse duration) will be the same of HTS, while the amplitude will be lower. The subject will be stimulated using the same device as for HTS.
1531566|NCT02730585|Biological|C-reactive protein measurement|All patients included in this study underwent a blood sample analysis for C-reactive protein concentrations at admission and 3 hours later.
1531567|NCT02730572|Drug|Concerta|This is an observational study. Participants who have been on Concerta for at least 60 days will be observed.
1531568|NCT02730572|Drug|Concerta AG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to authorized generic will be observed.
1531569|NCT02730572|Drug|Concerta EG formulation|This is an observational study. Participants who have been on Concerta for at least 60 days and switch to equivalent generic will be observed.
1531570|NCT02730559|Other|Motivational Interviewing/Counselling|Motivational Interviewing/Counselling
1531571|NCT02730546|Drug|Carboplatin|Given IV
1531572|NCT02730546|Procedure|Computed Tomography|Undergo CT scan
1531573|NCT02730546|Drug|Fluorouracil|Given IV
1531574|NCT02730546|Other|Laboratory Biomarker Analysis|Correlative studies
1531575|NCT02730546|Drug|Leucovorin Calcium|Given IV
1531576|NCT02730546|Drug|Oxaliplatin|Given IV
1531577|NCT02730546|Drug|Paclitaxel|Given IV
1531578|NCT02730546|Biological|Pembrolizumab|Given IV
1531579|NCT02730546|Procedure|Positron Emission Tomography|Undergo PET scan
1531580|NCT02730546|Radiation|Radiation Therapy|Undergo radiation therapy
1531581|NCT02730546|Procedure|Therapeutic Conventional Surgery|Undergo curative-intent surgery
1531582|NCT02730533|Drug|Esomeprazole|Proton pump inhibitor
1531583|NCT02730533|Drug|No PPI treatment|No PPI treatment before ESD procedure
1531584|NCT02730520|Other|Retrospective analysis of patient files|The results of the allergen skin tests will be encoded as the edema diameter. The allergenicity score (mean of the skin reactivities for each allergen) will be compared between each age groups. The impact of tabagism, gender, BMI and residential area on the allergic reactivity will also be assessed in the overall population and within each age group.
1531585|NCT02730507|Device|Surgery with patient-specific rod|Bras A: PSRs must be used with the appropriate instrumentation designed by the same manufacturer. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation must be the same (except the use of standard straight rod) in both groups. The surgical method to implement the PSR will be the same as the one to implement the conventional rod. Except for the bending procedure (patient specific rod or conventional rod with perioperative manual bending), the characteristics of implantable devices (biomaterial and diameter of the rod, design, type of screw, etc.) will be the same in each center.
1531732|NCT02729467|Drug|Rifampicin|Participants will receive 600 mg rifampicin (2 capsules of 300 mg) from Day 4-11.
1531733|NCT02729454|Other|Mental practice and physical therapy|
1531586|NCT02730507|Device|Conventional straight rod|Bras B: The control group is composed of patients operated with standard straight rods, which are bent in the operating room by the surgeon. In order to minimize potential bias derived from using different spinal systems or reduction techniques, the posterior instrumentation used in the control group must be the same (except the use of PSRs) than the experimental group.
1531587|NCT02730494|Device|Lcr Regenerans® vaginal capsules|
1531588|NCT02730494|Device|Lcr Regenerans® vaginal tablet|
1531589|NCT02730481|Drug|Oraxol|Oraxol will be supplied as paclitaxel capsules and HM30181AK-US tablets.
1531592|NCT02730442|Drug|F901318|Administration of F901318 intravenously
1531593|NCT02730442|Drug|Fluconazole|Oral administration
1531594|NCT02730429|Drug|Palbociclib/placebo|Palbociclib or a placebo is administered together with standard of care letrozole
1531595|NCT02730429|Drug|Letrozole|Letrozole is standard of care in both arms
1531596|NCT02730416|Drug|Nintedanib or Placebo; Carboplatin, Paclitaxel|Arm A: Nintedanib: 200mg orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD Arm B: Placebo: orally twice daily d 2-21 q 21 days x 6 courses; afterwards daily dosing, until PD In both arms: 6 courses of standard carboplatin and paclitaxel: Carboplatin AUC 5 iv every 21 days; Paclitaxel 175mg/m2 iv every 21 days. Both drugs are continued for maximum six courses or until unacceptable toxicity
1531597|NCT02730403|Other|Treatment As Usual|
1531605|NCT02730364|Drug|Paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Night powder containing paracetamol, phenylephrine HCl, pheniramine maleate, and vitamin C as oral solution.
1531610|NCT02730338|Behavioral|High intensity aerobic and resistance training|
1531611|NCT02730338|Behavioral|Psychosocial support|
1531612|NCT02730325|Other|Serum-derived bovine immunoglobulin/protein isolate (SBI)|
1531613|NCT02730325|Other|Placebo|
1531614|NCT02730312|Biological|XmAb14045|Administered IV weekly up to 8 weeks
1531617|NCT02730286|Other|observational study|application of several standard instruments in patients with rheumatoid arthritis
1531618|NCT02730273|Device|Trial Nasal mask|Nasal mask for the treatment of obstructive sleep apnea (OSA)
1531619|NCT02730260|Behavioral|Nondirective smoking cessation coaching|Quitline coach allows participant to set agenda for each call.
1531620|NCT02730260|Behavioral|Directive smoking cessation coaching|Quitline coach follows a pre-specified agenda for each call, and does not allow participant to deviate from the agenda.
1531621|NCT02730247|Drug|ramucirumab|it is administered through a vein in the arm as a 60 minute infusion at a dose of 8 mg/kg on days 1 and 15 of a 28-day cycle.
1531622|NCT02730247|Drug|nab-paclitaxel|it is administered through a vein in the arm as a 30 minute infusion at a dose of 100 mg/m2 on days 1, 8 and 15 of a 28 day cycle.
1531623|NCT02730234|Device|JetStream XC with balloon angioplasty|JetStream XC to treat femoropopliteal in-stent restenosis followed by adjunctive balloon angioplasty (same arm). The control arm in this study is historic.
1531624|NCT02730208|Drug|VX-661|
1531625|NCT02730208|Drug|ivacaftor|
1531626|NCT02730208|Drug|Placebo|
1531627|NCT02730195|Drug|Pioglitazone|Given PO
1531628|NCT02730195|Drug|Tyrosine Kinase Inhibitor (TKI)|Given TKI therapy
1531629|NCT02730182|Other|altitude exposure|altitude exposure
1531630|NCT02730169|Drug|BGS649|Capsules will be taken weekly for a maximum of 24 weeks
1531631|NCT02730169|Drug|Placebo|Capsules will be taken weekly for a maximum of 24 weeks
1531632|NCT02730156|Other|Altitude exposure|Altitude exposure
1531633|NCT02730143|Other|Altitude exposure|Altitude exposure
1531634|NCT02730130|Drug|Pembrolizumab|
1531635|NCT02730130|Radiation|Radiotherapy|
1531636|NCT02730117|Device|Dialysis with continuous renal replacement therapy|Continuous renal replacement therapy is a form of 24-hour dialysis in the ICU
1531637|NCT02730117|Device|Mechanical ventilator|Invasive or noninvasive form of respiratory support
1531638|NCT02730117|Drug|Anti-Bacterial Agents|Antibacterial agents deemed appropriate by physicians in the ICU
1531639|NCT02730117|Drug|Vasopressors|Vasopressors such as Norepinephrine, dopamine, milrinone, dobutamine
1531640|NCT02730091|Drug|Letrozole|Letrozole 2.5 mg daily
1531641|NCT02730091|Drug|Anastrozole|anastrozole 1 mg daily
1531642|NCT02730091|Drug|Vinorelbine|50 mg three times a week (Monday Wednesday and Friday)
1531734|NCT02729454|Other|physical therapy|
1531735|NCT02729441|Drug|ramipril|Comparison of two renin angiotensin aldosterone inhibitors
1531645|NCT02730065|Behavioral|Structured Aerobic Dance Training Group|Systematic physical activity
1531646|NCT02730065|Behavioral|Stretching plus education|Weekly group based stretching with psychoeducation and health education
1531647|NCT02730052|Device|Omron 9200T plus Telemonitoring|Telemonitoring of the self-measured blood pressure at home. After each blood pressure measurement the values are transmitted to and stored into a central station where a condensed weekly report is elaborated and delivered to the doctor (investigator).
1531648|NCT02730052|Device|Omron 9200T without Telemonitoring|Self-measured blood pressure at home and register the values in a diary card. Participants will perform 2 consecutive blood pressure measurements twice a day for a 7 day period, previous to the visit to the doctor's (investigator) office.
1531649|NCT02730039|Behavioral|workshop|
1531650|NCT02730039|Behavioral|follow-up calls & webinars|
1531651|NCT02730039|Behavioral|assessments|
1531652|NCT02730026|Drug|Ketoprofen|Clinical efficacy of the Ketoprofen 100 mg was study after lower third molar surgery.
1531653|NCT02730026|Drug|Ketoprofen and Omeprazole|Clinical efficacy of the Ketoprofen 200 mg and Omeprazole 20 mg will be study after lower third molar surgery.
1531654|NCT02730013|Behavioral|Square Stepping Exercise|"Square Stepping Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids.
In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged."
1531655|NCT02730000|Procedure|ART with Equia|Occlusal-proximal ART restorations in primary molars using Equia (Easy/Quick/Unique/ Intelligent/Aesthetic) will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
1531656|NCT02730000|Procedure|ART with Riva Self Cure|Occlusal-proximal ART restorations in primary molars using Riva Self Cure will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
1531657|NCT02729987|Behavioral|WorkGuru|A multi-modal stress management intervention accessed over 8 weeks, incorporates CBT, positive psychology and Mindfulness. Delivered via the internet.
1531658|NCT02729974|Procedure|ROTEM|rapid testing of blood clot formation
1531659|NCT02729974|Procedure|standard treatment|visual assessment of blood loss and clotting function every 30 minutes, combined with standard laboratory testing when indicated
1531664|NCT02729948|Other|Survey Administration|Ancillary studies
1531665|NCT02729948|Device|Tethered Capsule Endoscope|Undergo TCE
1531666|NCT02729935|Drug|Parecoxib|40 mg of intravenous parecoxib 30 min before surgery
1531667|NCT02729935|Drug|Placebo|An equal volume of saline
1531668|NCT02729922|Device|Cardiomems|Eligible patients will undergo implantation of a pulmonary artery sensor (CardioMEMS), a wireless implantable hemodynamic monitoring system in the cardiac catheterization laboratory. This system has a passive wireless, radiofrequency sensor without batteries or leads. Patients transmit data through a device in their home that interacts wirelessly with the sensor. Clinicians retrieve this data via a web interface to use in making management decisions for patients.
1531669|NCT02729909|Drug|Lubiprostone|Lubiprostone capsules
1531670|NCT02729909|Drug|Placebo|Lubiprostone placebo-matching capsules
1531736|NCT02729441|Drug|perindopril|Comparison of two renin angiotensin aldosterone inhibitors
1531675|NCT02729883|Other|Quality-of-Life Assessment|Ancillary studies
1531676|NCT02729883|Other|Questionnaire Administration|Complete interviews
1531677|NCT02729883|Procedure|Supportive Care|Receive patient navigation via the Take the Fight strategists
1531678|NCT02729870|Drug|Oral Glucose Gel|This group will receive the following: are less than 3 year of age will receive 7.5 gram oral glucose gel 40% (0.66 oz, 20ml) which will be a one time dose and the subjects who are ages 3-7 will receive 15 gram oral glucose gel (1.3 oz, 40ml) which is a one time dose.
1531679|NCT02729870|Other|Placebo|This group will receive carboxymethylcellulose (2%) oral gel. The subjects who are less than than 3 years of age will receive carboxymethylcellulose (2%) oral gel, 20ml which will be a one time dose and the subjects ages 3-7 will receive carboxymethylcellulose (2%) oral gel, 40ml which will be a one time dose.
1531680|NCT02729857|Dietary Supplement|SFA muffin|Muffin rich in saturated fat.
1531681|NCT02729857|Dietary Supplement|PUFA muffin|Muffin rich in polyunsaturated fat.
1531682|NCT02729831|Behavioral|Interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
1531683|NCT02729831|Behavioral|Video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
1531684|NCT02729831|Behavioral|Provider Report|A short report that includes the patients' goals and treatment preferences
1531685|NCT02729805|Drug|Saline|10ml bolus injection of saline followed by intravenous infusion of saline during the operation
1531686|NCT02729805|Drug|Ketamine 0.5mg/kg|0.5mg/kg intravenous ketamine injection followed by 0.25mg/kg/hr intravenous ketamine infusion during the operation
1531687|NCT02729805|Drug|Ketamine 0.75mg/kg|0.75mg/kg intravenous ketamine injection followed by 0.5mg/kg/hr intravenous ketamine infusion during the operation
1531688|NCT02729792|Device|rTMS|intermittent theta burst stimulation (iTBS)
1531689|NCT02729779|Other|Pilates Group|Elderly will be submitted to a specific exercise program of modified Pilates method performed in the mat and apparatus. In the first session, participants will receive basic guidance on the Pilates training and activation of the power house. The session will be divided in: global warming and stretching (5 minutes), Pilates exercises for upper and lower limbs, abdomen and spine (45 minutes), global stretching (5 minutes) and local relaxing massage (5 minutes).The session will consist of a minimum of 5 exercises and a maximum of 15 Pilates exercises. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
1531690|NCT02729779|Other|Aerobic Group|Elderly will be submitted to an exercise program with global stretching (for lower and upper limbs and column with two repetitions and 30 seconds of maintenance in each segment) for 10 minutes, walking on a treadmill for 20 to 40 minutes, and relaxing massage for 5 minutes. The intensity of the effort during walking on a treadmill will be based on a combination of heart rate (based on the percentage of maximum heart rate: 208 - (0.7 x age)) and rate of perceived effort assessed by the Borg scale. Exercise will be performed respecting the fraction of 50-75% of maximum heart rate and levels between 12 to 13 (moderate intensity) of the Borg scale. The elderly will receive 16 individual sessions with duration of 60 minutes, twice a week, with a total of eight weeks of treatment.
1531691|NCT02729766|Other|Induced hypotonic hyponatremia - SIAD model|
1531692|NCT02729766|Drug|Empagliflozin 25mg Tbl|
1531693|NCT02729766|Drug|Placebo P-Tablet|
1531694|NCT02729753|Device|CryoBalloon™ Full Ablation System|Tissue Ablation using CryoBalloon™ Full Ablation System
1531695|NCT02729740|Device|Penumbra SMART CoilTM|Current coils available to physicians have three principal levels of softness, Standard, Soft and Extra Soft. A conventional coil currently has only one level of softness, derived from using smaller platinum filaments than a Standard coil to make Soft and Extra Soft coils. The level of softness of the Penumbra SMART Coil is determined not only by the diameter of the platinum filament, but also by a proprietary structural element inside the coil. This unique development enables the Penumbra SMART Coil to become progressively softer along the length of a single individual coil as it is being deployed.
1531696|NCT02729740|Device|Penumbra Coil 400TM (PC400), Penumbra Occlusion DeviceTM(POD)|Other Penumbra Coils available as standard of care
1531697|NCT02729727|Device|CryoBalloon Ablation System|Tissue Ablation using CryoBalloon Ablation System
1531698|NCT02729714|Drug|Suvorexant|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
1531699|NCT02729714|Drug|Placebo|10 mg Suvorexant or matching Placebo orally at bedtime with optional up-titration to 15 mg Suvorexant or matching Placebo orally at bedtime after 2 weeks.
1531700|NCT02729701|Drug|Duavee|Once daily tablet of Duavee (Bazedoxifene (20 mg) plus conjugated estrogen (0.45 mg))
1531701|NCT02729688|Device|customized pressure guide bandage|"Investigators developed the customized pressure guide elastic bandage (CPG-EB). The experienced nurse applied the elastic bandages to each patient with sub bandage pressure monitoring. The target pressure was 35-45 mmHg. Measurements of the pressure applied by bandages was performed at point B1 corresponding to the height where the Achilles' tendon turns into the gastrocnemius muscle with Picopress (MicroLAB Elettronica, Ponte S. Nicolo, Italy). If the target pressure 35-45 mmHg was achieved, the circular ink stamp was applied into the entire bandages. The markers in CPG-EB had elliptical shape when they were not stretched. They turned into circular shape when they were stretched.
For the OEB, Bandaging was applied by spiral methods. Three EB were applied with 50 % stretching and 50% overlapping from foot to just below knee level."
1531702|NCT02729688|Device|Ordinary elastic bandage|Bandaging was applied by spiral methods. Three ordinary elastic bandages were applied with 50 % stretching and 50% overlapping from foot to just below knee level.
1531738|NCT02729415|Procedure|Stromal Vascular Fraction Cells (SVF Cells) Injection|The procedure involves the injection of stromal vascular fraction cells (SVF Cells) into the scalp. The injection will be performed once in the middle of two perpendicular sides of a 2 x 2 cm area.
1531739|NCT02729415|Procedure|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue to harvest the stromal vascular fraction cells (SVF Cells).
1533962|NCT02713607|Drug|Doxycycline|Given doxycycline to acne subjects
1531703|NCT02729675|Other|Access Intervention|The 7 worksites in this arm received year-round, weekly mobile F&V markets (Fresh To You - FTY) selling local and non-local fresh produce at or below local supermarket prices. The markets carried 50 to 70 different produce items and were held both indoors and outdoors depending on the weather and worksite preference. When held indoors, F&V were sold in a cafeteria or other highly trafficked area. In good weather, the markets were held outside on the worksite property in a retrofitted a car trailer. Each market lasted two hours. On average, FTY prices were 15% to 25% lower than local retail supermarket prices. Signs, posters, email blasts and flyers advertised the markets. The FTY intervention at each worksite began with a Kick-Off event, which included the first FTY market. Each employee who attended the first market received a large, reusable shopping bag with the FTY logo on it and a freezer pack to keep F&V fresh.
1531704|NCT02729675|Behavioral|Enhanced Intervention|The 7 worksites in this arm received the Access intervention described above as well as set of educational/behavioral interventions. At the Kick-Off, employees received the first month's newsletter and an educational digital video disk (DVD) in the reusable shopping bag. They also received a chef-run cooking demonstration/taste-testing along with recipes and information about the upcoming intervention activities. Intervention activities included two 6-week campaigns (Just Add Two and Choose Color, Choose Health); a 90 minute DVD with cooking demonstrations about preparing quick, healthy inexpensive meals and unusual F&V; a two-page, full-color newsletter distributed monthly; Food demonstrations/tastings delivered once a month by chefs including an easy to prepare, F&V-based recipe; a total of 12 recipe handouts that correlated with the monthly cooking demonstration; a Good to Go website; and a project bulletin board.
1531705|NCT02729675|Behavioral|Comparison Behavioral Intervention|Brown University contracted with the Greater Providence Young Men's Christian Association (YMCA) to provide a physical activity and stress reduction intervention at the 7 worksites in the comparison group. Two, six-week campaigns were developed jointly by the Brown study team and YMCA staff. These campaigns followed the same format as the enhanced intervention group campaigns and were provided during the same time periods as those at the enhanced intervention sites. Everyone who participated in the campaigns also received a free, 6-week membership to the YMCA.
1531706|NCT02729662|Drug|Tolvaptan|"Before administration of tolvaptan
TKV・Liver capacity: Once/year (an additional measurement within 3 months before start of administration)
24-hour urine collection・Hematology/urinalysis: Once/year
Physical findings: Blood pressure and medical interview at ambulatory visit
Hospitalization for education and examination at the start of tolvaptan administration
24-hour urine collection・Hematology/urinalysis・Inulin clearance
Physical findings: Body weight, blood pressure
Adverse Events
After administration of tolvaptan
TKV・Liver capacity・inulin clearance: Once/year
24-hour urine collection: Once/6 months
Hematology/urinalysis: Once/month in principle
Physical findings: Blood pressure and medical interview at ambulatory visit
Adverse Events"
1531707|NCT02729649|Device|ArmAssist robotic training|
1531708|NCT02729649|Other|Conventional therapy|
1531709|NCT02729649|Other|Extended conventional therapy|
1531710|NCT02729636|Device|multipad electrical stimulation (FES)|
1531711|NCT02729636|Other|Conventional therapy|
1531712|NCT02729623|Drug|Kite Systems cannaHALER cannabis Inhaler.|
1531713|NCT02729610|Device|double-lumen endotracheal tube (DLT group)|In this arm, after anesthesia induction, a double lumen endotracheal tube will be intubated for one-lung ventilation
1531714|NCT02729610|Device|endobronchial blocker (BB group)|In this arm, after anesthesia induction, an endobronchial blocker will be intubated for one-lung ventilation
1531715|NCT02729597|Other|medical history|The complete medical history (including cardiovascular risk factors and medication) will be assessed at baseline and follow-up.
1531716|NCT02729597|Other|neurological clinical examination|Neurological examination will be performed at baseline and follow-up.
1531717|NCT02729597|Other|neuropsychological testing|Neuropsychological testing using a 13 item test battery will be performed at baseline and follow-up.
1531718|NCT02729597|Other|brain MRI|Brain MRI ( 3.0 T) will be performed using the same hard- and software at baseline and follow-up.
1531719|NCT02729571|Biological|MTBVAC|Live-attenuated tuberculosis vaccine
1531720|NCT02729571|Biological|BCG|Commercially available live-attenuated tuberculosis vaccine
1531721|NCT02729558|Radiation|local SRT|local stereotactic radiotherapy in three fractions of 8 Gy to the surgical cavity
1531722|NCT02729545|Other|acupuncture|the points are:fuke point, huanchao point,SP6,SP9,EX-CA1 bilaterally,RN4
1531723|NCT02729545|Drug|Diane-35|cyproterone acetate 2mg and ethinylestradiol 0.035mg
1531724|NCT02729532|Device|Xpert|The Xpert MTB/RIF assay is a nucleic acid amplification (NAA) test that uses a disposable cartridge with the GeneXpert Instrument System
1531725|NCT02729519|Procedure|TAVI|standard procedure TAVI performed with systematic pre dilatation (With prior balloon dilatation) (ARM A) ou without pre dilatation (ARM B)
1531726|NCT02729506|Procedure|Transarterial Radioembolization|Yttrium-90 radioembolization (90Y) is a relatively new technique involving the trans-arterial administration of glass or resin microspheres loaded with Yttrium-90, a β-emitting isotope, delivering selective internal radiation to the tumor.
1531727|NCT02729506|Procedure|Transarterial Chemoembolization using drug-eluting beads|"TACE is a procedure in which a catheter is introduced into the branches of the hepatic artery supplying the tumor. Embolic material and chemotherapeutic agents are deployed through the catheter directly into the tumor vasculature. This technique potentially enhances the cytotoxic effect by inducing ischemia and retention of the therapeutic agent in the vicinity of the tumor.
The drug-eluting beads (DEBs) enable standardization of TACE since DEBs act as both an occluding agent as well as a drug-loaded carrier, achieving local ischemia and cytotoxic death of the tumor with one device."
1531728|NCT02729493|Biological|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
1531729|NCT02729480|Device|Halo Craniofacial Nerve Stimulator System|The Halo Craniofacial Nerve Stimulator System is a wirelessly powered neurostimulator for pain in the face or head (not for headaches or migraine). This technology includes an implanted stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin to the receiver.
1531971|NCT02726724|Other|5 observers|
1531740|NCT02729415|Other|Hair Measurements|Hair measurements will be performed using a computerized handheld USB camera at baseline, 6 weeks, and months 3 and 6 after treatment.
1531741|NCT02729402|Other|Cognitive Testing|We will use a battery of neurocognitive tests to assess cognitive function before and after surgery
1531742|NCT02729389|Behavioral|High Social Status Condition|Participants will be provided with a high degree of privilege in a game of Monopoly.
1531743|NCT02729389|Behavioral|Low Social Status Condition|Participants will be provided with a low degree of privilege in a game of Monopoly.
1531744|NCT02729376|Drug|galeterone|
1531745|NCT02729363|Behavioral|Guided Relaxation video clip|This intervention is a 12-minute guided audio-visual relaxation intervention.
1531746|NCT02729363|Behavioral|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute computer-administered sickle cell disease experience discussion.
1531749|NCT02729337|Behavioral|ITG (In This Together)|Comprehensive, mHealth-based HIV prevention program for Ugandan adolescents 18-22 years of age.
1531750|NCT02729324|Drug|Medical Radiation Protectants (FORRAD®)|Medical Radiation Protectants (FORRAD®) is prescribed at the beginning of radiotherapy for free. Patients are asked to start topical application of Medical Radiation Protectants (FORRAD®) on irradiated skin at the onset of radiotherapy, three times a day (30 minutes before radiotherapy, after radiotherapy, and before bedtime), until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. When grade 2 or higher radiation dermatitis is developed, patients can continue using Medical Radiation Protectants (FORRAD®). When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
1531751|NCT02729324|Drug|Trolamine (Biafine)|Trolamine (Biafine) is prescribed at the beginning of radiotherapy. Patients are asked to start topical application of trolamine (Biafine) on irradiated skin at the onset of radiotherapy, three times a day, until completion of their radiotherapy. All patients will receive conventional health education and medical care for prevention and treatment of radiation dermatitis. No other prophylactic creams, lotions, or gels are allowed. When grade 2 or higher radiation dermatitis is developed, patients cannot use trolamine any more, and they will receive other conventional medical care for treatment of radiation dermatitis in the investigators institution. When grade 3 or higher radiation dermatitis happened, other interventions, such as prophylactic or therapeutic antibacterial therapy, will be used, and radiotherapy should be interrupted, until moist desquamation is cured.
1531753|NCT02729298|Drug|TP-0903|"Stage 1: Single oral daily doses on Days 1-21 of each 28 day cycle. Starting dose is 1.5 mg/m2 with subsequent dose escalation using a modified Fibonacci dose escalation schema.
Stage 2: Upon confirmation of MTD, 2 additional cohorts of up 10 patients each (20 additional patients total) will receive single oral daily doses of this dose on Days 1-21 of each 28 day cycle."
1531754|NCT02729285|Drug|Ketorolac Tromethamine|On operation day, the patients were randomly assigned to receive intramuscular Ketorolac 60-mg 30 min before scleral buckle surgery.
1531755|NCT02729285|Drug|placebo|On operation day, the patients were randomly assigned to receive placebo 30 min before scleral buckle surgery.
1531756|NCT02729285|Procedure|scleral buckle|Surgical procedure of scleral buckle under retrobulbar block anesthesia
1531757|NCT02729272|Procedure|Laparoscopic colpotomy by ultrasonic ESD|In this intervention, laparoscopic colpotomy was performed by ultrasonic ESD (Harmonic Synergy Hook Blades; Ethicon Endo-Surgery, Cincinnati, OH, USA).
1531758|NCT02729272|Procedure|Laparoscopic colpotomy by monopolar ESD|In this intervention, laparoscopic colpotomy was performed by monopolar ESD (hook electrode with 90 watts of unmodulated current; Karl Storz, Tuttlingen, Germany).
1531759|NCT02729272|Device|Monopolar ESD|
1531760|NCT02729272|Device|Ultrasonic ESD|
1531761|NCT02729259|Behavioral|Virtual Reality Snowworld|The subjects will receive Virtual Reality Snowworld during their wound care procedure. The nurse will be doing their wound care.
1531762|NCT02729259|Behavioral|Virtual Reality slides of nature|The subjects will receive Virtual Reality Slides of Nature during their wound care procedure. The nurse will be doing their wound care.
1531763|NCT02729259|Behavioral|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
1531764|NCT02729246|Procedure|Laparoscopic Gastric Bypass|
1531765|NCT02729233|Other|patients receiving biopsies|Six mucosal biopsies will be collected from each site (terminal ileum and rectum) for histologic verification of pCLE findings at baseline, and again at month 12 for a total of 12 research samples per colonoscopy, or 24 research biopsy samples during the course of the study. The study subjects will be followed for a total of 1 year after initial colonoscopy with pCLE. The primary study end-point is clinical response at 3 months following initiation of golimumab.
1531766|NCT02729220|Other|Bronchoscopy|Sampling of airways
1531767|NCT02729207|Drug|Esflurbiprofen Hydrogel Patch|One patch per day for 7 days
1531770|NCT02729181|Device|DRX9000|
1531771|NCT02729168|Biological|Human rabies vaccine|
1531772|NCT02729155|Procedure|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
1531773|NCT02729155|Procedure|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
1531774|NCT02729155|Procedure|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
1531775|NCT02729155|Procedure|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
1531972|NCT02726724|Other|1 observer|
1531776|NCT02729142|Procedure|Tibial cortical density evaluation|Bone evaluation in transplant patients will be performed by HR-pQCT at baseline (either within 6 months before surgery or within 15 days following surgery) and 6 months post-intervention in order to assess its evolution.
1531777|NCT02729129|Other|Diesel exhaust exposure with filtered facemask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a filtered facemask.
1531778|NCT02729129|Other|Diesel exhaust exposure with sham mask|1 hour exposure to dilute diesel exhaust (approximate particle matter concentration 300 mcg/m3) during intermittent exercise while wearing a sham facemask.
1531779|NCT02729116|Drug|Sitafloxacin|Patients are given intravenous empirical antibiotics for 3 days. The patients are allocated to the sitafloxacin group or ertapenem group using of a computer-generated random number allocation schedule and block size of four.
1531780|NCT02729116|Drug|Ertapenem|Patients are given IV ertapenem for 14 days
1531781|NCT02729103|Drug|Xofigo (Radium 223 dichloride,BAY88-8223)|Retrospective claims analysis. Descriptive analyses of treatment patterns.
1531782|NCT02729090|Other|Device: treadmill|Aerobic training on a treadmill continuously with speed and wave periodization. Frequency twice per week ( 2x ) for twelve weeks. Device: treadmill.
1531783|NCT02729090|Other|Device: treadmill Train_Comb_aerobic|Device: treadmill Train_Comb_aerobic. strength training with free weights, followed by active recovery on a treadmill with fixed intervals of 60 to 120 seconds between each workforce of series. Device: treadmill Train_Comb_aerobic
1531784|NCT02729077|Device|Pulse Oximetry|Use of pulse oximetry device for 48 hours after surgery.
1531785|NCT02729064|Drug|Humulin R|Study subjects will receive intranasal insulin (Humulin R) via a metered nasal dispenser.
1531786|NCT02729064|Drug|Normal Saline|Study subjects will receive intranasal placebo (normal saline) via a metered nasal dispenser.
1531787|NCT02729051|Drug|FF/UMEC/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains UMEC and VI blended with lactose and magnesium stearate. It is available as dry white powder, 62.5 mcg per blister UMEC, 25 mcg per blister VI. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
1531788|NCT02729051|Drug|FF/VI|This intervention is provided in two strips. First strip contains FF blended with lactose. It is available as dry white powder, 100 mcg per blister. Second strip contains VI blended with lactose and magnesium stearate. It is available as dry white powder, 25 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (2 strips with 30 blisters per strip).
1531789|NCT02729051|Drug|UMEC|This intervention is available in one strip. The strip contains UMEC blended with lactose and magnesium stearate. The formulation is available as dry white powder, 62.5 mcg per blister. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
1531790|NCT02729051|Drug|Placebo|This intervention is available in one strip. The strip contains lactose. The formulation is available as dry white powder. The intervention is inhaled via the DPI, once daily in the morning. DPI contains 30 doses (1 strip with 30 blisters).
1531791|NCT02729051|Drug|Albuterol/salbutamol|This is a rescue medication administered via metered-dose inhaler (MDI) with a spacer which will be used when needed during the study.
1531792|NCT02729038|Drug|Gepotidacin|Gepotidacin after reconstitution is a clear, dark brown to dark brownish-yellow solution, free from visible particulate matter. Subjects will receive gepotidacin 750 mg single IV dose over 2 hours.
1995916|NCT02613039|Drug|Combined Estrogen-Progestin Oral Contraceptives|All patients enrolled will undergo Combined Estrogen-Progestin Oral Contraceptives. Different compounds will be chosen according to the approved indications and clinical practice. Therefore it is not possible to provide a specific trade and/or generic name.
1531795|NCT02729012|Drug|hypertonic saline solution (NACL 3%+NAHCO3)|Treatment with nebulized hypertonic saline solution (NACL 3%+NAHCO3)
1531796|NCT02729012|Other|Saline Solution (NACL 0,9%)|Treatment with nebulized Saline Solution (NACL 0,9%)
1531797|NCT02728999|Procedure|Steep Trendelenburg|"•Subjects who undergo steep Trendelenburg will remain in 30 degrees of Trendelenburg, and the da Vinci robot will be docked.
After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
1531798|NCT02728999|Procedure|Decreased Trendelenburg|"•Subjects who undergo decreased Trendelenburg will be taken out of Trendelenburg to the minimal angle possible that enables adequate visualization, as determined by the primary surgeon, at which time robot will be docked.
After subjects are asleep an arterial line will be place in one wrist by the anesthesiologist. It will be removed at the conclusion of the procedure."
1531799|NCT02728986|Device|Profore|Profore multilayer compression bandage + standard regimen for wound care according to investigator's choice
1531800|NCT02728986|Device|Coban2|Coban2 compression system + standard regimen for wound care according to investigator's choice
1531801|NCT02728973|Other|ERAS program|The main elements of this program were: preoperative advice, no colon preparation, provision of carbohydrate-rich drinks one day prior and on the morning of surgery, goal directed fluid administration, body temperature control during surgery, avoiding drainages and nasogastric tubes, early mobilization, and the taking of oral fluids in the early postoperative period.
1531802|NCT02728960|Procedure|MRI of the Brain (No Contrast) Scan|DSI data will be acquired on 3T Tim Trio System (Siemens) using a 32-channel coil
1531803|NCT02728947|Drug|ROTIGOTINE|1 week at each dose
1531804|NCT02728934|Biological|Golimumab Intravenous (IV)|This is an observational study. Patients who will receive golimumab IV will be observed for 3 years.
1531805|NCT02728934|Biological|Infliximab|This is an observational study. Patients who will receive infliximab will be observed for 3 years.
1531806|NCT02728934|Biological|Biosimilar Infliximab|This is an observational study. New patients who will receive biosimilar infliximab will be observed for 3 years (maximum). Biosimilar Infliximab patients will be included in Exploratory analyses only and will not be included in Primary or Secondary outcome measures analyses.
1531807|NCT02728921|Drug|5% Albumin infusion 30 min|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 30 minutes. Dose is based on ideal weight.
1531808|NCT02728921|Drug|5% Albumin infusion 3 hours|Intravenous infusion of 5% Albumin at a dose of 10 ml/kg during 3 hours. Dose is based on ideal weight.
1531809|NCT02728908|Device|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100
1531810|NCT02728895|Drug|Vedolizumab|Vedolizumab Injection
1531811|NCT02728882|Biological|CD19-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-CD19-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
1531812|NCT02728869|Biological|Heat Stable Rotavirus (HSRV) Vaccine|It is a lyophilized live attenuated pentavalent (G1-G4 and P1[8]) heat-stable rotavirus vaccine (HSRV) comprising of all the five rotavirus strains as in licensed RotaTeq® vaccine for protection against rotavirus infection
1531813|NCT02728869|Biological|Placebo for Heatstable Rotavirus vaccine|It is a lyophilized formulation comprising of all the inactive ingredients as in heat stable rotavirus vaccine without any rotavirus
1531814|NCT02728869|Biological|RotaTeq®|It is a pentavalent human-bovine (WC3) reassortant live-attenuated, oral vaccine developed by Merck Research Co., West Point, Pennsylvania, USA. This vaccine contains five live reassortant rotaviruses. Four reassortant rotaviruses express the VP7 protein (G1, G2, G3, or G4) from the human rotavirus parent strain and the attachment protein (P7[5]) from bovine rotavirus parent strain WC3. The fifth reassortant virus expresses the attachment protein (P1A[8]) from the human rotavirus parent strain and the outer capsid protein G6 from the bovine rotavirus parent strain.
1531815|NCT02728856|Other|Sunscreen Spray SPF50 Z15-034(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
1531816|NCT02728856|Other|Shampoo Control|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
1531817|NCT02728856|Other|Sunscreen Spray SPF50 Z15-038(BAY987516)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
1531820|NCT02728830|Drug|Pembrolizumab|Pembrolizumab 200mg IV
1531821|NCT02728817|Procedure|End-cephalic vein to side-radial artery fistula creation|"Circumferential dissection of the cephalic vein (4-5cm long)
Longitudinal arteriotomy (~10mm)
End-vein to side-artery anastomosis using 7-0 polypropylene continuous suture"
1531822|NCT02728817|Procedure|RADAR fistula creation|"Dissection of the anterior-medial aspect of the cephalic vein (~15mm) without grasping or clamping the venous wall
Circumferential dissection of the radial artery pedicle (5cm long) and ligation of collaterals with surgical microclips
Ligation and section of the radial artery (distal)
Longitudinal venotomy (~10mm)
End-artery to side-vein anastomosis using 7-0 polypropylene continuous suture"
1531823|NCT02728804|Other|Quality-of-Life Assessment|Complete questionnaire
1531824|NCT02728804|Other|Questionnaire Administration|Complete questionnaires
1531825|NCT02728778|Drug|incobotulinumtoxin A|Application of botulinum toxin A into the forehead
1531826|NCT02728778|Procedure|Acupuncture|Application of acupuncture into the forehead
1531827|NCT02728765|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard treatment for patients with obstructive sleep apnea (OSA). In a previous trials comparing therapeutic CPAP vs subtherapeutic CPAP, CPAP could reduce 24-hour mean blood pressure in mildly sleepy patients with OSA over 3 months whereas our one-year prospective study has shown that reduction of carotid artery intima-media thickness of OSA patients occurred mostly in the first 6 months and was sustained at 12 months in patients with CPAP compliance about 4.7 hours per night.
1531830|NCT02728739|Procedure|Transthoracic Echocardiogram (TTE) Assesment|Transthoracic Echocardiogram (TTE) will be carried out on all heart failure patients with elevated BNP level (>30 pg/ ml) for grading of MR severity within 7 days.
1531831|NCT02728726|Drug|sugammadex|
1531832|NCT02728726|Drug|Placebo|
1531833|NCT02728713|Procedure|Cranial Manipulation|Performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
1531834|NCT02728713|Procedure|Sham/Placebo|A laying on of hands with no actual treatment being performed.
1531835|NCT02728700|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
1531836|NCT02728700|Other|Laboratory Biomarker Analysis|Correlative studies
1531837|NCT02728700|Drug|Mycophenolate Mofetil|Given IV
1531838|NCT02728700|Drug|Sirolimus|Given PO
1531839|NCT02728687|Drug|Mannitol|Apply cream as needed up to 4 times daily to the painful foot and leg
1531840|NCT02728687|Drug|Menthol|Apply cream as needed up to 4 times daily to the painful foot and leg
1531841|NCT02728674|Other|Person in the case is a male.|Person in the case is a male.
1531842|NCT02728674|Other|Person in the case is a female.|Person in the case is a female.
1531843|NCT02728674|Other|Symptom in the case is breathlessness.|Symptom in the case is breathlessness.
1531844|NCT02728674|Other|Symptom in the case is pain.|Symptom in the case is pain.
1531845|NCT02728661|Behavioral|PACE|PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts up to 6 weeks prior to surgery.
1531846|NCT02728661|Behavioral|Delayed PACE|Delayed PACE is an 14 week behavioral weight loss intervention developed specifically for knee replacement patients that starts 12 weeks after surgery.
1531847|NCT02728648|Drug|Oxycodone|Pain Management
1531848|NCT02728635|Other|Dual-energy X-ray absorptiometry (DEXA)/ Magnetic resonance imaging (MRI) and Magnetic resonance spectroscopy (MRS)|A DEXA scan for body composition will also be completed. After a MRI safety screening a whole body MRI for the volumetric measurement of visceral fat, subcutaneous fat, liver, kidneys, heart, brain, skeletal muscle and intramuscular adipose tissue (IMAT) and hepatic lipid by MRS will be performed. Whole body imaging will include low resolution positioning images, followed by several sets of 3D images which will be digitally connected to create a 3D image the entire length of the body. The liver spectroscopy will be performed using PRESS (point resolved spectroscopy) and STEAM (Stimulated Echo Acquisition Mode) sequence during the same imaging session, using the whole body images for positioning.
1531849|NCT02728635|Procedure|Adipose tissue biopsies|Two biopsies will be performed to collect fat tissue from the abdomen and thigh region.
1531850|NCT02728635|Other|FSIGTT/ RMR|Insertion of two intravenous (IV) catheters for performing a Frequently Sampled Intravenous Glucose Tolerance Test (FSIGTT) to measure the acute insulin response to glucose (AIRg) and insulin sensitivity (Si) will be performed. Resting metabolic rate (RMR) will be used to measure metabolic flexibility. Point of care blood glucose measurements will be taken frequently to ensure safety.
1531851|NCT02728622|Drug|Tamoxifen|endocrine treatment
1531852|NCT02728622|Drug|Chemotherapy|Paclitaxel or pegylated liposomal doxorubicin
1531853|NCT02728609|Device|ABThera vacuum device|This intervention uses a commercially available vacuum device to temporarily close the abdomen following surgery.
1531854|NCT02728609|Device|Blue towel: vacuum pack device|This intervention uses operating room towels and the application of suction to temporarily close the abdomen following surgery.
1531855|NCT02728596|Other|Preventive Intervention|Receive PP-CSF
1531856|NCT02728596|Other|Quality-of-Life Assessment|Ancillary studies
1531857|NCT02728596|Other|Questionnaire Administration|Ancillary studies
1531858|NCT02728583|Dietary Supplement|Margarine enriched with plant sterols and fish oil|
1531859|NCT02728583|Dietary Supplement|Placebo margarine|
1531860|NCT02728570|Other|High Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing high levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
1531861|NCT02728570|Other|Low Dietary Flavonoids|A prepared diet consisting of whole foods with a macronutrient composition of 17% en from protein, 30% en from fat and 53% energy from carbohydrate and containing low levels of dietary flavonoids including anthocyanins, flavanones, flavan-3-ols, flavonols, flavones, and polyflavonoids.
1531862|NCT02728557|Behavioral|Supportive-Expressive Therapy|Supportive-expressive psychotherapy for depressive disorder for 16 weeks.
1531863|NCT02728557|Behavioral|Supportive Therapy|Supportive psychotherapy for depressive disorder for 16 weeks.
1531864|NCT02728544|Other|exercise and blood tests|At an initial one-hour meeting study participants will learn to perform aerobic (treadmill) exercise and resistance training under the supervision of an experienced exercise physiologist. Exercise intensity will be assessed by direct measurement of VO2 m
1531865|NCT02728531|Drug|Bendamustine|
1531866|NCT02728531|Drug|Rituximab|
1531867|NCT02728531|Drug|Cytarabine|
1531868|NCT02728531|Drug|Pegfilgrastim|
1531869|NCT02728531|Procedure|Leukapheresis|
1531870|NCT02728531|Drug|Filgrastim|
1531871|NCT02728531|Procedure|Autologous stem cell transplant|
1995917|NCT02613754|Behavioral|Contingency Management|See arm description.
1995918|NCT02613754|Behavioral|Treatment as Usual|See arm description
1531874|NCT02728505|Drug|SinuSurf irrigation twice daily|
1531875|NCT02728505|Drug|NeilMed Sinus rinse irrigation twice daily|
1531876|NCT02728492|Drug|Quisinostat|
1531877|NCT02728492|Drug|Paclitaxel|
1531878|NCT02728492|Drug|Carboplatin|
1531879|NCT02728492|Drug|Gemcitabine|
1531880|NCT02728492|Drug|Cisplatin|
1531881|NCT02728466|Dietary Supplement|Flavanol and procyanidin supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing flavanols (monomers) and procyanidins (dimers to decamers)
1531882|NCT02728466|Dietary Supplement|Procyanidin-containing supplement|Sustained intake (2x daily over 1 month) of a cocoa-based supplement containing procyanidins (dimers to decamers)
1531883|NCT02728466|Dietary Supplement|control supplement deprived of flavanols and procyanidins|Placebo comparator: flavanol and procyanidin deprived supplement Sustained intake (2x daily over 1 month) of a macro-and micronutrient matched supplement
1531884|NCT02728453|Drug|Empagliflozin|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
1531885|NCT02728453|Drug|Glimepiride|Treatment with empagliflozin vs. glimepiride to understand whether empagliflozin may reduce left ventricular mass in patients with type 2 Diabetes mellitus.
1531886|NCT02728440|Drug|human chorionic gonadotropin, human menopausal gonadotropin|drug for the treatment of male hypogonadism
1531887|NCT02728427|Device|Suprapubic catheterization using central venous catheter(CVC-2 7F)|Suprapubic catheterization using central venous catheter(CVC-2 7F) will be performed for patients after laparoscopic surgery for rectal cancer.Suprapubic catheterization is inserted at the end of the procedure. It will be clamped depending on surgeon's specific instruction and removed if the urinary residual is less than 50 cc.
1531888|NCT02728427|Device|Transurethral catheterization using Foley catheter|Traditional transurethral catheterization using Foley catheter will be performed for patients.The catheterization is removed on day 5 in patients without complication.
1531889|NCT02728414|Dietary Supplement|probiotics|the patients in this arm will receive probiotics with a dose for 2g/d for 3 months.
1531890|NCT02728414|Dietary Supplement|placebo|the patients in this arm will receive placebo intervention
1531891|NCT02728388|Procedure|PDT Treatment|"Drug: Levulan Kerastick
Drug: Topical placebo
Device: Omnilux Revive
Procedure: Photodynamic therapy
Other: Tumor growth rate measurements"
1531892|NCT02728375|Other|computer game based rehabilitation protocol|Participants who consent to take part in the study will be asked to use objects instrumented with the miniature motion mouse to play various therapeutic yet entertaining games while handling and moving the test therapeutic objects as a part of experimental therapy protocol. The objects used will be everyday items; a) lifting/rotating a sports ball small beach ball which requires bimanual handling, b) rolling a cylinder object (diameter 6-10 cm with fingers extended and using elbow and shoulder motion, c) grasping grasp small glass and then a sponge ball with whole hand and rotating (supination- pronation motion) d) motion of a small wand (pencil) with 3-finger pinch grip and using hand-wrist motion, and e) turning of a key with 2-finger pinch fine finger control. These objects represent a wide range of physical properties requiring different modes of manipulation and functional demands sufficient to test the assessment tool.
1531973|NCT02726711|Drug|Trimethaphan|Trimethaphan will be infused (0.5 - 4.0 mg IV)
1531974|NCT02726711|Drug|Placebo|0.5 - 4.0 mg IV to be infused
1531893|NCT02728375|Other|Conventional therapy protocol|In control group: 1) Stretching of Biceps, Lattisimusdorsi, Pronators, Thumb muscles. 2) Weight Bearing Exercises. 3) CIMT for 20 min per day for 3-4 weeks, repeat each task 15-20 times. Pegboard activities, Rings: reaching- removing and putting back, Ball throw (under and over arm) - at basket which is kept 10 to 15 meter distance, opening bottle cap (large size bottle), Opening and closing door handle activity, Holding water bottle, bag in hand and transfer to 10 to 20 meter distance, Crumbling paper, Clay activities, Picking marbles from sand 4)Hand arm bimanual activities: Throwing ball with both hands, Holding ball with both hands and transfer, Holding bolster and keeping at place, Holding notebook in both hands, Holding rack with both hands, Holding plate in one hand and spoon in other hand, Pushing door or wall both hands.
1531894|NCT02728349|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
1995919|NCT02613507|Drug|Nivolumab|
1531896|NCT02728323|Drug|Levobupivacaine|100 mg of Levobupivacaine by intramuscular injection, at the end of surgery
1531897|NCT02728323|Drug|Saline|20 ml of saline saline by intramuscular injection, at the end of surgery
1531898|NCT02728310|Drug|Levobupivacaine|An infusion rate of 10 ml/h of 1500 mg of 0.5 % of levobupivacaine for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
1531899|NCT02728310|Drug|Saline|An infusion rate of 10 ml/h of 300 ml of saline solution for the first 30 h and 5 ml/h for the second 30 h (LCWI) were injected into the surgical wound.
1531900|NCT02728297|Procedure|Staged ETS|Thoracoscopic approach of sympathetic ganglia T3-T12 on one side, retraction of the diaphragm and lung laterally to expose the ganglia then ablation of each ganglion using electrocauterization.
1531903|NCT02728271|Biological|HPC cell infusion|"Administration of total lymphatic irradiation, antithymocyte globulins, and high dose cyclophosphamide, followed by the infusion of autologous stem cells.
Patients will not receive any cyclosporin A, rituximab, or azathioprine post transplant."
1531904|NCT02728258|Drug|Copanlisib|Given IV
1531905|NCT02728258|Other|Laboratory Biomarker Analysis|Correlative studies
1531909|NCT02728232|Procedure|internal iliac artery ligation|
1531910|NCT02728232|Procedure|Cesarean Hysterectomy|
1531911|NCT02728219|Procedure|TACE|In this study we prospectively select some early diagnosed recurrent HCC patients after radical resection with AFP conversion, then they will be treated with transcatheter arterial chemoembolization (TACE)
1531912|NCT02728219|Procedure|Hepatectomy|Repeat Hepatectomy after postoperation recurrence
1531914|NCT02728193|Procedure|RFA|
1531915|NCT02728193|Procedure|MWV|
1531916|NCT02728193|Procedure|PEI|Percutaneous ethanol injection
1531919|NCT02728167|Device|Pre-coagulation of the liver parenchyma with HIFU|6 to 10 (or more if necessary) side-to-side 40-seconde HIFU treatments
1531920|NCT02728154|Other|Blood Sample|One tablespoon of blood will be drawn once during the study.
1531921|NCT02728154|Other|Stool Sample|One stool sample will be collected.
1531922|NCT02728141|Other|Water|2 ml distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
1531923|NCT02728141|Other|Sucrose|2 ml 25% sucrose in distilled water by syringe one time in the newborn's mouth 2 minutes before heel stick
1531924|NCT02728115|Biological|Cellavita HD Lower Dose|The first three participants enrolled in the study will be assigned to the lower dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. Both participants will receive a total of 3 intravenous administration, one every 30 days.
1531925|NCT02728115|Biological|Cellavita HD Higher dose|The last three participants enrolled in the study will be assigned to the higher dose arm with staggered treatment, with an interval of 30 days between the first administration of the first participant and the first administration of the second participant assigned to this arm. Both participants will receive a total of 3 intravenous administration, one every 30 days.
1531926|NCT02728102|Procedure|Tumor Cell Collection|Patients will undergo aspiration of 30 mL of bone marrow from which myeloma cell preparations will be generated. Myeloma cells will be isolated and frozen for subsequent vaccine generation for patients randomized to the vaccine arm (randomization occurs after transplant and recovery).
1531927|NCT02728102|Procedure|Autologous Stem Cell Transplant|Patients will receive an autologous graft with a minimum cell dose of 2.0 x 10^6 CD34+ cells/kg patient actual body weight per autologous transplantation.
1531928|NCT02728102|Drug|Melphalan|Autologous hematopoietic cell transplant will be done with high-dose melphalan of 200mg/m^2 at the schedule and timing according to institutional practices.
1531929|NCT02728102|Procedure|Leukapheresis|Blood samples will be collected through a catheter in the neck or chest and leukapheresis will be performed using standard clinical procedures.
1531930|NCT02728102|Biological|Myeloma vaccine|Three doses of 3 x 10^6 fusion cells will be prepared. A minimum of 2 doses will be required to proceed with treatment. Patients will receive the DC/MM fusion vaccine on day 1 of cycles 2, 3, and 4 of lenalidomide maintenance. Vaccine will be administered by subcutaneous injection in the upper thigh.
1531931|NCT02728102|Drug|GM-CSF|100 ug GM-CSF will be given subcutaneously in the upper thigh and daily for a total of 4 days of each cycle.
1531975|NCT02726685|Other|respiratory training.|breathing exercise.
1532345|NCT02725385|Other|Questionnaire Administration|Complete questionnaire
1995920|NCT02613507|Drug|Docetaxel|
1995921|NCT02613182|Drug|NEOD001|NEOD001
1531932|NCT02728102|Drug|Lenalidomide|Maintenance therapy with lenalidomide will begin between 90 and 100 days after stem cell infusion. Lenalidomide will be administered initially at a dose of 10 mg per day continuously. Cycle duration during maintenance therapy is 28 days. Patients will continue lenalidomide for two years from initiation of therapy.
1531933|NCT02728089|Drug|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g)|MK-7625A 1.5 g (ceftolozane 1 g/tazobactam 0.5 g) administered as an intravenous (IV) infusion
1531934|NCT02728076|Other|Phase II - Preoperative Radiation followed by Lumpectomy.|Selected patients will undergo a radiation planning procedure utilizing magnetic resonance imaging (MRI). Once this is completed, patients will receive five radiation treatments given every other day. After 28 days (four weeks), patients will have another MRI scan to compare tumor response to the radiation therapy. Following the MRI scan, roughly five to eight weeks later, patients will have a lumpectomy and possibly a sentinel lymph node biopsy. After surgery, tests will be performed on the tumor tissue to determine if genes expressed in the sample have changed. Following surgery, patients will receive chemotherapy and/or antihormone therapy at the discretion of the patient and physician.
1531935|NCT02728063|Dietary Supplement|Lactibiane Tolerance|probiotics
1995922|NCT02611232|Drug|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
1995923|NCT02611232|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 24 months.
1995924|NCT02609386|Biological|IRX-2|Method of Administration: Administered for 10 days as subcutaneous bilateral injections in the upper neck.
1995925|NCT02609386|Drug|Cyclophosphamide|Method of Administration: Cyclophosphamide is administered once by IV
1995926|NCT02609386|Drug|Indomethacin|Method of Administration: Indomethacin is administered orally for 21 days.
1531943|NCT02728037|Procedure|Magnesium-Based Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the magnesium-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 50% magnesium sulfate, 2) 20ml of 8.4% bicarbonate, and 3) 20ml of 50% dextrose.
At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine, 0.8% sodium bicarbonate, 6.0% dextrose, and 2.5% magnesium sulfate."
1531944|NCT02728037|Procedure|Lidocaine-Only Injection Formulation|"Each study kit will include 4 10cc syringes containing 7ml of 1% lidocaine, and 3 numbered glass vials. For those in the lidocaine-based injection formulation arm the glass vials will be prepared as follows; 1) 10ml of 0.9% sodium chloride, 2) 20ml of 0.9% sodium chloride, and 3) 20ml of 0.9% sodium chloride.
At the visit a study investigator will mix 2cc of vial 1, 5cc of vial 2 and 5cc of vial 3, for a total of 12cc of additive mixture. 3cc of this additive mixture will be then drawn in to each of the 4 pre-packaged lidocaine syringes, for a total of 10cc of final mixture per syringe. The concentration of components in the final mixture is 0.7% lidocaine."
1531945|NCT02728037|Drug|lidocaine|
1531946|NCT02728037|Drug|magnesium sulfate, bicarbonate, dextrose.|
1531947|NCT02728024|Other|Missing items, Errors in Completion, Difficulties|
1531948|NCT02728011|Other|Scientific Brain Training (SBT)|Cognitive training
1531949|NCT02728011|Other|Tetris|
1531950|NCT02727998|Drug|Ketamine|Prolonged exposure therapy combined with a single infusion of 0.50 mg/kg/hour for 40 min on day 2.
1531951|NCT02727998|Drug|Midazolam|Prolonged exposure therapy combined with a single infusion of 0.045 mg/kg/hour for 40 min on day 2.
1531953|NCT02727972|Behavioral|Cognitive Testing|Verbal assessments as well as computer testing.
1531954|NCT02727972|Other|MRI|Anatomical MRIs will be performed on a Siemens 3T Trio at Yale. MR acquisition will be a Sag 3D magnetization-prepared rapid gradient-echo (MPRAGE) sequence with 3.34 ms echo time, 2,500 ms repetition time, 1,000 ms inversion time, 7 degree flip angle, and 180 Hz/pixel bandwidth. The image dimensions will be 256 x 256 x 176 and pixel size 0.98 x 0.98 x 1.0 mm. Resting state MRIs will also be obtained as follows: We will be doing 2 six minute scans with subjects in the scanner, eyes open, fixating a cross. TR = 3 secs 45 slices x 3 mm slice thickness = 13.5 cm. In plane resolution = 3 x 3 mm, slice acquisition order = ascending.
1531955|NCT02727972|Radiation|PET|High Resolution Research Tomograph (HRRT), the highest resolution human brain scanner available, or HR+ will be used to image subjects. Vital signs (blood pressure, pulse, respiration) will be obtained before and after radiotracer administration. An antecubital venous catheter will be used for IV administration of the radiotracer and for venous blood sampling. A radial artery catheter will be inserted by an experienced physician before the PET scan. At the beginning of each scan, the subject's head will be immobilized and a 6 minute transmission scan using an orbiting 137Cs (HRRT) or 68GE (HR+) point-source is obtained and used for attenuation correction. PET scans will be acquired using bolus or bolus plus constant infusion administration of FPEB, ABP688, or SV2A.
1531956|NCT02727946|Other|optimal resuscitation|optimal resuscitation to achieve mean arterial blood pressure above 65 mmHG , Central venous pressure more than 8 mmHg , urine out put more than 0.5 ml /Kg/hour
1531957|NCT02727920|Dietary Supplement|Energy drink|
1531958|NCT02727920|Other|Placebo|placebo drink
1531959|NCT02727907|Drug|BCD-033 (interferon beta 1a)|Subcutaneous injection of BCD-033, 44 µg (0,5 ml) 3 times per week, every other day, for 92 weeks
1531960|NCT02727907|Drug|Rebif (interferon beta 1a)|Subcutaneous injection of Rebif, 44 µg (0,5 ml) 3 times per week, every other day, for 48 weeks
1531961|NCT02727907|Drug|Placebo|Subcutaneous injection of placebo, 0,5 ml 3 times per week, every other day, for12 weeks
1531962|NCT02727881|Drug|Squalamine lactate ophthalmic solution, 0.2%|Squalamine lactate ophthalmic solution, 0.2%
1531963|NCT02727881|Drug|Placebo Ophthalmic solution|Placebo Ophthalmic solution
1531964|NCT02727881|Drug|ranibizumab|ranibizumab
1531965|NCT02727868|Genetic|blood samples|
1531966|NCT02727855|Biological|Shanchol|Oral Cholera Vaccine
1531968|NCT02726737|Drug|sodium bicarbonate|
1531969|NCT02726737|Drug|Lidocaine|
1531970|NCT02726737|Drug|sterile distilled water|
1531976|NCT02726685|Other|sham training.|range of motion (ROM) exercise, stretching exercise or positioning exercise.
1531977|NCT02727829|Device|pefusion index measurement|perfusion index measurement using massimo radical 7 device
1995927|NCT02609386|Dietary Supplement|Zinc-containing multivitamin|Method of Administration: Zinc-containing multivitamin is administered orally for 21 days.
1995928|NCT02609386|Drug|Omeprazole|Method of Administration: Omeprazole is administered orally for 21 days
1995929|NCT02611167|Biological|Allogeneic bone marrow-derived MSCs|Bone marrow-derived allogeneic MSCs will be delivered intravenously in escalating doses of 1 x 10 6 MSC/kg, 3 x 10 6 MSC/kg, 6 x 10 6 MSC/kg, or 10 x 10 6 MSC/kg of body weight to a population of patients with idiopathic Parkinson's disease (iPD).
1531984|NCT02727803|Drug|Busulfan|Busulfan 32 mg/m2 by vein test dose administrated either as an outpatient before Day -14 or as an inpatient on Day -9. Busulfan pharmacokinetics performed. Doses of days -7 to -4 subsequently adjusted to target an area under curve (AUC) of 4,000 microMol.min-1. In the event that PK adjusting was not possible a dose of busulfan of 130 mg/m2 administered.
1531985|NCT02727803|Drug|Fludarabine|"Treatment Plan #1: 10 mg/m2 by vein on Days -7 to -4. Participants </= 2 years of age receive Fludarabine 1.3 mg/kg.
Treatment Plan # 2: 40 mg/m2 by vein on Days -6 to -3.
Treatment Plan # 3: 40 mg/m2 by vein on Days -5 to -2."
1531986|NCT02727803|Drug|Clofarabine|30 mg/m2 by vein on Days -7 to -4.
1531987|NCT02727803|Drug|Rabbit ATG|Treatment Plan # 1: 1.25 mg by vein on Day -9 and 1.75 mg by vein on Day -8. Treatment Plan # 2 1.25 mg by vein on Day -8 and 1.75 mg by vein on Day -7. Treatment Plan # 3: 1.25 mg by vein on Day -7 and 1.75 mg by vein on Day -6.
1531988|NCT02727803|Radiation|Total Body Irradiation (TBI)|"Treatment Plan #1: TBI 2 Gy in AM on Day -3.
Treatment Plan #2: TBI 2 Gy on Day -1."
1531989|NCT02727803|Procedure|Cord Blood Infusions|Cord blood infusions on Day 0.
1531990|NCT02727803|Drug|Rituximab|375 mg/m2 by vein on Day -9 for participants with CD20+ malignancies.
1531991|NCT02727803|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6.
1531992|NCT02727803|Procedure|Natural Killer Cell Infusion|NK Cell Infusion (C2C2 subgroup only) on Day +30 to Day +80.
1531993|NCT02727803|Drug|Melphalan|"140 mg/m2 by vein on Day -2.
For participants < 2 years of age: Melphalan 4.7 mg/kg."
1531994|NCT02727803|Drug|Mesna|Mesna by vein on Day -6, after cyclophosphamide to help lower the risk of side effects to the bladder.
1531995|NCT02727790|Device|Stimulator|
1531996|NCT02727777|Drug|TAK228|Starting dose of TAK228: 3 mg by mouth every day of a 28 day cycle.
1531997|NCT02727777|Other|Blood Sugar Testing|Participant given a glucometer to check pre-dose blood sugar levels at home every day.
1531999|NCT02727751|Drug|Tenapanor|
1532000|NCT02727738|Dietary Supplement|Selenium|Selenium 80 mg bid for 90 days
1532001|NCT02727738|Drug|Methimazole|Methimazole starting dose depending on FT3 values (15 mg/day or 20 mg/day or 30 mg/day, for FT3 values <10 pg/ml, 10-15 pg/ml, >15 pg/ml, respectively) to be tapered by 5 mg/day every 15 days down to values sufficient for FT3 to be normal
1532002|NCT02727725|Other|Traminer MRI Sequence|The Traminer MRI sequence will be added to the standard IR Turbo-Flash sequence and last 2-5 minutes.
1532003|NCT02727712|Procedure|bilateral thoracic paravertebral block|group A under TPVB((TPVB T2/3+T5/6) by ropivacaine(0.3%,10ml*4)program
1532004|NCT02727712|Device|Transesophageal Echocardiography（TEE）|"Apply Transesophageal Echocardiography（TEE）after anesthesia induction and draw 400ml autologous blood (Haemonetics®)used for the postoperative transfusion;
Goal-directed fluid management"
1532005|NCT02727712|Device|Lung protection measure during the surgery（Dräger Primus）|Protective ventilation strategy(Low tidal volume about 6~7ml/kg, joint use of PEEP)
1532006|NCT02727712|Drug|Anesthesia drugs during the surgery|"Bilateral thoracic paravertebral block before induction of anesthesia;
Fast channel anesthesia • Induction use Sufentanil 0.5~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2~0.6mg/kg; ②. Maintain use Sufentanil Hydrochloride for Injection 0.01~0.04ug/kg•min, Sevoflurane 0.5~1.5MAC（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg•h,Vecuronium 0.06~0.12mg/kg•h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
1532007|NCT02727712|Procedure|thoracic paravertebral block|group B under(TPVB T3/4)by ropivacaine(0.3%,20ml*2)program
1532008|NCT02727699|Drug|Xanamem™|Xanamem™ is formulated in green and cream coloured size 3, Coni-Snap shaped gelatin capsules as an excipient blend at a dose of 10mg. It contains active pharmaceutical ingredient of UE2343
1532009|NCT02727699|Drug|Placebo (for Xanamem™)|Excipient blend capsules manufactured to mimic Xanamem™ capsules
1532010|NCT02727686|Other|Water Load (WL) Post-Operative Day 1|Patient will have normonatremic 0600 hr sodium level (Serum Sodium = 135 - 145 mmol/L), ability to safely take water by mouth, and cleared to continue by treating surgeon. WL will be calculated (20 mL/kg body weight) and supplied at the bedside. Vasopressin level will be determined. Patient will have 30 minutes to consume WL, or will be excluded. Included patients will have data collected as follows: 1 hour - serum sodium, urine output; 2 hour - serum sodium, urine output, vasopressin level; 6 hours - serum sodium, urine output.
1532011|NCT02727660|Drug|BFF MDI (PT009) 320/9.6 μg|Blinded Treatment
1532012|NCT02727660|Drug|BFF MDI (PT009) 160/9.6 μg|Blinded Treatment
1532013|NCT02727660|Drug|FF MDI (PT005) 9.6 μg|Blinded Treatment
1532014|NCT02727647|Drug|FVIII|FVIII concentration 35-40 U/kg/dose 1 time/week for 5 months
1532015|NCT02727647|Drug|FVIII|FVIII concentration 15-20 U/kg/dose 1 time/week for 5 months
1532055|NCT02727374|Other|Physiotherapy intervention|Physiotherapy intervention consists of conventional exercise program administered to this kind of patients at Hospital Clinico, including strengthening and balance exercises
1532056|NCT02727374|Behavioral|Cognitive-behavioural Intervention|Psychological treatment consists of group talks to treat the fear to fall
1532057|NCT02727361|Radiation|PET (Positron Emission Tomography) imaging|Molecular imaging using a PET radiotracer of the vesicular acetylcholine transporter.
1532058|NCT02727361|Other|MRI : Magnetic Resonance Imaging|Multimodal MRI, MRI diffusion tensor (to study the microscopic structure of white matter) and functional MRI of the resting state (to study the functional organization of cerebral cholinergic networks at rest).
1532416|NCT02724917|Drug|APN1125|Oral solid dose form of APN1125
1532016|NCT02727634|Other|Comparison cardiac power and cardiac power output at different time points in the perioperative period|The intervention is a comparison between two methods of calculating the heart's energy delivery, cardiac power, measured in watts. A tertiary measurement is calculation of arterioventricular coupling. All patients will have cardiac power output calculated through the use of Doppler echocardiography. The echocardiography based cardiac output will be done through the velocity time integral of the left ventricular outflow tract (LVOT). This will be compared against total power as measured by our Ultrapower approach which involves instantaneous doppler measurement of cardiac output through LVOT multiplied with simultaneous radial artery pressure. This and ejection fraction (for calculation of ventriculoarterial coupling) will be recorded at rest in neutral position preoperatively, directly post operatively and the day after operation. Directly postoperatively the power measurements will also be repeated in Trendelenburg and anti Trendelenburg position.
1532017|NCT02727621|Drug|Dexmedetomidine|Anesthesia will be maintained with continuous infusion of dexmedetomidine 0.5-0.7 µg/kg/h in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
1532018|NCT02727621|Drug|propofol|Anesthesia will be maintained with continuous infusion of propofol 50-100 µg/kg/min in addition to sevoflurane supplementation as required, to maintain arterial blood pressure and heart rate within 20% of preoperative values. Muscle relaxation will be maintained with continuous rocuronium infusion 0.6 mg/kg/h.
1532019|NCT02727608|Drug|Eculizumab|Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.
1532020|NCT02727595|Device|CyclaPlex Implant|Button and suture type implant that will be implanted between the first and second metatarsal
1532021|NCT02727569|Device|New visual field algorithm with DLS|Mathematical model (software based) to derive retinal sensitivity.
1532022|NCT02727569|Device|SITA algorithm|Mathematical model (software based) to derive retinal sensitivity. Commercially available.
1532023|NCT02727569|Device|New visual field algorithm with MMDT|Mathematical model (software based) to derive retinal sensitivity.
1532024|NCT02727556|Behavioral|visual images|
1532025|NCT02727543|Other|Medisafe|"Medisafe is a smartphone application available to download for free on any iOS or Android device. Medisafe addresses non-adherence by providing alerts to patients when it is time to take their medications. Other features include the ability to allow a Medfriend to check in if a medication is not taken, weekly reports of medication adherence, and monitoring of biometric measurements"
1532026|NCT02727530|Other|VISCERAL MANUAL THERAPY-ADVICES|The subjects of this group will receive an amount of two sessions of visceral manual therapy that will be applied within two weeks. In the first session will be applied procedures in the most superficial body structures. And, in the second session will be applied procedures in the most deep body structures.
1532027|NCT02727530|Other|ADVICES|Advices for parents to improve the management of infant colic
1532028|NCT02727517|Procedure|Early (≤ 60 seconds) cord clamping|If the infant don't breathe, the umbilical cord is clamped (≤ 60 seconds) and cut and resuscitation will be provided at a resuscitation table
1532029|NCT02727517|Procedure|Delayed (≥ 180 seconds) cord clamping|If the infant don't breathe, the umbilical cord is not clamped and cut until after 180 seconds. Initial resuscitation will be provided bedside to the mother
1532030|NCT02727504|Device|Electrocardiogram|ECG at inclusion and M12
1532031|NCT02727504|Device|2D and 3D echocardiography|2D and 3D echocardiography at inclusion and M12
1532032|NCT02727504|Device|Dobutamine stress echocardiography|dobutamine stress echocardiography at inclusion
1532033|NCT02727504|Biological|Blood tests|Blood test electrolytes, creatinine, hemoglobin, NT-proBNP, CRP, ST-2 at inclusion and M12
1532034|NCT02727504|Device|Cardiac MRI|Cardiac MRI at inclusion
1532035|NCT02727504|Device|Cardiac scanner|Cardiac scanner at inclusion
1532036|NCT02727504|Other|6-minutes walking test|6-minutes walking test at inclusion and M12
1532037|NCT02727504|Other|Duke Activity Score|Duke Activity Score at inclusion and M12
1532038|NCT02727491|Drug|Dextromethorphan|Dextromethorphan is a drug of the morphinan class with sedative, dissociative, and stimulant properties (at higher doses). Dextromethorphan has been explored for a number other uses in medicine, including pain relief (as either the primary analgesic, or an opioid potentiator).
1532039|NCT02727491|Drug|Placebo|Placebo syrup identical to active comparator in taste, appearance and volume but is inactive. Placebo comparator will be used in the placebo arm of the trial.
1532040|NCT02727478|Other|HiBalance training program|The program consists of physiotherapist led highly challenging balance exercises, which are adapted and progressed on both a group and individual basis throughout the training period.
1532041|NCT02727465|Other|Meningitis cases|None - blood draw only
1532042|NCT02727452|Other|Skin-to-skin contact|
1532043|NCT02727439|Other|Acute Exhausting Exercise (AE)|A single progressive rowing training to maximal exhaustion (AE).
1532044|NCT02727426|Other|Low Salt (LS) diet|Intake of less than 2.3 g of salt per day for 7 days.
1532045|NCT02727426|Other|High Salt (HS) diet|Intake of 11.2 g of salt per day for 7 days.
1532046|NCT02727413|Procedure|Blood sample collection|Drawing of 10 ml blood at inclusion, at the time of CPB connection, 60 min under CPB, at the time of CPB disconnection, 6, 24 and 48 hours post-surgery
1532047|NCT02727413|Other|Assessment of signs of organ dysfunction|Assessment of signs of organ dysfunction based on medical data prior to surgery, 24 and 48 hours post-surgery, and at the time of ICU discharge
1532048|NCT02727387|Drug|TEMIRI|Window therapy frontline for VHR patients
1532049|NCT02727387|Drug|ADM|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Etoposide
1532050|NCT02727387|Drug|IFO|Drug used in the Induction phase in association with Vincristine, Adriamycin, cyclophosphamide and Etoposide
1532051|NCT02727387|Drug|CYC|Drug used in the Induction phase in association with Vincristine, Ifosfamide, Adriamycin and Etoposide
1532052|NCT02727387|Drug|ETO|Drug used in the Induction phase in association with Vincristine, Ifosfamide, cyclophosphamide and Adriamycin
1532053|NCT02727387|Drug|BUMEL|Consolidation phase
1532054|NCT02727387|Drug|VIN|Drug used in the Induction phase in association with cyclophosphamide , Ifosfamide, Adriamycin and Etoposide
1532059|NCT02727348|Procedure|Sciatic with or without femoral block|Sciatic with or without femoral block performed either with ultrasound and/or nerve stimulator on the patient with 3mg/kg of ropivacaine
1532060|NCT02727348|Procedure|Spinal anaesthesia|Spinal anaesthesia with up to 3mls of 0.5% bupivacaine
1532061|NCT02727322|Drug|Nitrofurantoin|Patients will receive nitrofurantoin 100mg once daily or a placebo. Pills will be identical.
1532062|NCT02727322|Drug|Placebo|Placebo
1532063|NCT02727309|Drug|Apatinib|Apatinib: 750 mg is administered orally daily, until disease progression or untolerable toxicity.
1532064|NCT02727296|Drug|sevoflurane|
1532065|NCT02727296|Drug|propofol|
1532066|NCT02727283|Drug|GSK3179106|GSK3179106 will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength of 5 mg, 25 mg and 100 mg
1532067|NCT02727283|Drug|Placebo|Placebo will be provided as white to slightly colored round or oblong tablet for oral administration with unit dose strength to match actives across all strengths
1532068|NCT02727270|Other|No Intervention - Observational Study|No Intervention - Observational Study
1532069|NCT02727257|Procedure|MIRT|MIRT consists of a 4-week physical therapy that entails four daily sessions, five days a week, in a hospital setting. The duration of each session, including recovery periods, is about one hour. The first session comprise cardiovascular warm-up activities, relaxation, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in the supine position. The second session includes aerobic exercises to improve balance and gait using a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in day living activities. The last session includes one hour of speech therapy.
1532070|NCT02727244|Procedure|urgent or elective cesarean section|a kind of surgical procedure to deliver a baby
1532071|NCT02727231|Device|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
1532072|NCT02727231|Device|CSII with CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with continuous glucose monitoring (CGM)
1532073|NCT02727218|Procedure|Chest tube removal|chest tube removal post thoracoscopic surgery
1532074|NCT02727205|Drug|Rotigotine Transdermal System|
1532075|NCT02727192|Device|CPAP|Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
1532076|NCT02727179|Procedure|Liver resection|The investigators perform an anatomical liver resections or wedge resections depending on tumour's location and tumour's characteristics
1532077|NCT02727166|Dietary Supplement|Inulin|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
1532078|NCT02727166|Dietary Supplement|Maltodextrine|Administered in 4 g sacchets taken in 200 mL liquid during breakfast and dinner for 4 week intervention period
1532079|NCT02727153|Other|"Ultra E.R.A.S."|
1532080|NCT02727153|Other|Classic E.R.A.S.|
1532081|NCT02727140|Behavioral|Yoga with Asana (yoga postures)|Yoga intervention consisting of asana, breathing and relaxation, meditation
1532082|NCT02727140|Behavioral|Yoga without Asana (yoga postures)|Yoga intervention without asanas, consisting only of breathing, relaxation and meditation
1532083|NCT02727114|Other|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm, the deltoid region and medial site of the thigh (till 2 years) will be measured using imaging technology, more specifically high-frequency ultrasound (20-70 MHz) in B-mode (VEVO 2100® & VEVO 3100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.
The echographic measurement will be performed on the left and right deltoid and medial thigh region, and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
1532084|NCT02727101|Drug|perampanel|Each group of 6 patients will be followed for 12 weeks of baseline observation on baseline medication. Seizure frequency will be counted, using subjects' self-reported seizure diaries. Perampanel will be titrated to 8-12 mg/day, with the final dose determined by side effects and tolerability of Perampanel at 8-12 mg/day doses. Titration will occur at the rate of 2 mg/week or two weeks, as tolerated.
1532085|NCT02727088|Procedure|Pulpotomy|Conservative pulp management (experimental treatment): ablation of the coronal part of the pulp
1532086|NCT02727088|Procedure|Pulpectomy|ablation of the whole dental pulp, preparation and filling of the whole root canal system
1532087|NCT02727062|Other|OM Pain App|"Each study participant will be issued an Android smartphone, or he or she may use his/her own compatible device (whether or not it has an active data service) to which the OM Pain App will be downloaded and installed.
Subjects will receive a preprogrammed alarm four times a day from their smartphones prompting them to directly enter OM pain levels on the device. Patients may submit as many pain entries as they wish beyond the four minimum levels.
Each patient will be issued an accelerometer and will be encouraged to wear it continuously during the study period."
1995930|NCT02610868|Drug|MYOBLOC|After a screening period (up to 21 days), subjects who satisfy all eligibility criteria may receive single dose injections of 3,500 Units of MYOBLOC every 13 weeks (±2 weeks) for a total of 4 treatments via injections into the submandibular and parotid glands. Subjects will undergo safety and effectiveness assessments at Weeks 4, 8, 13, 17, 26, 30, 39, 43, and 52, and telephone follow up will occur at Weeks 21, 34, and 47
1532091|NCT02727023|Other|Osteopathic Manipulative Medicine|The procedures are picked for their generalized effect on the lymphatic system based on osteopathic literature and research. Our goal is to mobilize the lymphatic fluid to induce an increase of endocannabinoids. These procedures are similar to mechanical motion seen in exercise in regards to lymphatic movement. Each technique will be performed for a total of four minutes each
1532184|NCT02726581|Drug|Dexamethasone|Specified dose on specified days, PO
1532185|NCT02726568|Drug|Icotinib|375 mg Tid (1125 mg per day)
1532186|NCT02726568|Radiation|WBRT|If intracranial PD, then the subjects get whole brain radiation therapy 37.5G/15f/3 weeks combine Icotinib 375mg Tid.
1532092|NCT02726997|Drug|Durvalumab|"Phase I (Safety Lead-In) Starting Dose: 750 mg by vein every two weeks in one, 21 day cycle
Phase II Starting Dose: 750 mg by vein every 2 weeks (pending confirmation in Phase I lead in) for three, 21 day cycles. After surgery, participants receive three more 21 day cycles.
Maintenance Phase: 750 mg by vein on Day 1 and Day 15 of each 28 day cycle for 7 cycles."
1532093|NCT02726997|Drug|Carboplatin|"Phase I (Safety Lead-In) Starting Dose: Area under curve (AUC) 6 by vein every three weeks in one, 21 day cycle.
Phase II Starting Dose: AUC 6 by vein on Day 1 every three weeks for 3, 21 day cycles. After surgery, participants receive three more 21 day cycles."
1532094|NCT02726997|Drug|Paclitaxel|"Phase I (Safety Lead-In) Starting Dose: 80 mg by vein every week in one, 21 day cycle.
Phase II Starting Dose: 80 mg by vein on Day 1, Day 8, and Day 15 for 3, 21 day cycles. After surgery, participants receive three more 21 day cycles."
1532095|NCT02726997|Behavioral|Questionnaires|Questionnaires completed at baseline, week 1 of cycles 7 - 13 during Maintenance Phase, end of treatment visit, and at follow up visit 30 days after Durvalumab therapy.
1532096|NCT02726997|Procedure|Debulking Surgery|Surgery performed after three, 21 day cycles of study drug combination.
1532097|NCT02726984|Drug|18F-sodium fluoride PET/MR|18F-sodium fluoride PET/MR combining 3Tesla (3T) MR and PET producing 127 slices of 2 mm on an axial field of view of 26 cm. 18F-sodium fluoride (2 à 4 megabecquerel/kilogram (MBq/kg)) will be injected 60 min before.
1532098|NCT02726971|Drug|Femoston|Femoston is a Complex Packing Estradiol Tablets and Estradiol and Dydrogesterone.
1532099|NCT02726945|Device|GID SVF-2|The GID SVF-2 device is a sterile single-use disposable canister used for harvesting, filtering, separating, and concentrating autologous stromal vascular fraction cells from adipose tissue for reintroduction to the same patient during a single surgical procedure for treatment of pain associated with joint osteoarthritis.
1532100|NCT02726945|Other|Placebo|Placebo Control
1532101|NCT02726932|Other|No intervention, merely observational|
1532102|NCT02726919|Drug|Clobazam|Following a baseline of 12 weeks patients will be started on clobazam, administered orally in b.i.d. schedule. In patients in whom seizure diaries have been kept prospectively prior to study screening visit, retrospective baseline will be accepted. Patients will be titrated up to either seizure freedom, to side effects or to 40 mg/day, whichever comes first
1532103|NCT02726906|Behavioral|Moderate-aerobic walking|
1532104|NCT02726906|Radiation|Positron Emission Tomography (PET) scan|Radioligand that binds to proteins using a PET/CT scanner.
1532105|NCT02726906|Behavioral|Healthy living education|
1532106|NCT02726906|Device|Physical activity monitor|Wrist device that will track daily physical activity
1532107|NCT02726893|Other|no intervention|
1532108|NCT02726880|Behavioral|Behavioral therapy|6-week behavioral intervention designed to assist with better monitoring and regulating the child's game playing behaviors.
1532109|NCT02726880|Behavioral|Referral for care|Referral for mental health issues and family support services
1532110|NCT02726867|Drug|levetiracetam|Treatment will consist of LEV 4000 mg i.v. over 10 minutes.
1532111|NCT02726867|Drug|lacosamide|Treatment will consist of LCM 600 mg i.v. over 10 minutes
1532112|NCT02726867|Drug|Ketamine|Treatment will consist of KET 2.5 mg/kg over 10 minutes
1532113|NCT02726867|Drug|Phenobarbital|Treatment will consist of PHB 15 mg/kg mg i.v. at 100 mg/minute rate
1532114|NCT02726854|Drug|Apatinib|Patients with pancreatic cancer who are failed of receiving first-line chemotherapy and cannot tolerate second-line chemotherapy or unwilling to receive second-line chemotherapy will receive Apatinib Tablets (850mg once daily, orally) 30 minutes after meal with warm water. Take 28 days as a cycle, patients will receive this treatment until they have got disease progressed.
1532115|NCT02726841|Procedure|Open thoracoabdominal aortic repair + abdominal stenting|Thoracoabdominal aortic dissection (TAAD) repair + bare aortic stent (Djumbodis) implantation
1532116|NCT02726841|Procedure|Classic thoracoabdominal aortic repair|Thoracoabdominal aortic dissection (TAAD) repair
1532117|NCT02726828|Drug|intrathecal morphine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.3 mg intrathecal morphine1 ml volume.
1532118|NCT02726828|Drug|intrathecal ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and 0.1 mg/kg intrathecal ketamine in 1ml volume.
1532119|NCT02726828|Drug|intrathecal morphine + ketamine|patients received 10 mg of hyperbaric bupivacaine 0.5% in 2 ml volume and intrathecal morphine + ketamine 0.3 mg and 0.1 mg/kg respectively in 1 ml volume.
1532120|NCT02726815|Other|Questionnaire|Questionnaire based study using a symptom assessment tool
1532121|NCT02726802|Other|physical therapy vs. primary care interventions|Subjects with acute (< 3 months onset) will be randomized to see either a physical therapist or a primary care provider as their initial entry into the healthcare system
1532122|NCT02726789|Drug|REP 2139-Ca|the nucleic acid polymer REP 2139 formulated as a calcium chelate complex
1532123|NCT02726789|Drug|pegylated interferon|immunotherapy
1532124|NCT02726789|Drug|entecavir|local generic entecavir
1532125|NCT02726776|Other|Suspension in a harness|
1532126|NCT02726776|Other|Climbing|
1532127|NCT02726763|Device|Transcranial Direct Current Stimulation (tDCS)|
1532128|NCT02726763|Behavioral|Questionnaires|
1532129|NCT02726672|Device|respiratory rehabilitation using Powerbreathe|10 minutes 2 times a day : 30 inspirations per session during 10 weeks
1532130|NCT02726659|Drug|Celecoxib|Adjunct celecoxib
1532131|NCT02726659|Drug|Placebo|Adjunct placebo
1532135|NCT02726620|Procedure|Attending real-time decision support|Near real-time decision support elements will notify the attending anesthesiologists of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the pager system. The page will also display the associated increased risk of organ injury due to organ ischemia.
1532136|NCT02726620|Procedure|In-room real-time decision support|Near real-time decision support elements will notify the in-room anesthesia provider of a blood pressure drop below the threshold for intraoperative hypotension (mean arterial pressure below 60 mmHg). The notification is presented through the anesthesia information management system. The decision support system will display the associated increased risk of organ injury due to organ ischemia.
1532137|NCT02726620|Procedure|Attending feedback emails|Attending anesthesiologists will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
1532138|NCT02726620|Procedure|In-room provider feedback emails|In-room anesthesia providers will be notified through email within 24 hours after the end of an anesthetic case, when the patient had an episode of intraoperative hypotension (mean arterial pressure below 60 mmHg or lower for a particular duration) that is associated with an increased risk of organ injury due to organ ischemia.
1532139|NCT02726620|Device|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
1532140|NCT02726620|Device|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the postoperative feedback emails.
1532141|NCT02726620|Procedure|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
1532142|NCT02726620|Device|Pager system|The mobile pager system through which alerts can be sent
1532143|NCT02726620|Procedure|Central neuraxial anesthesia|Regional anesthesia effectuated through the placement of local anesthetics around the nerves of the central nervous system, e.g. spinal anesthesia and epidural anesthesia.
1532144|NCT02726620|Procedure|Non-cardiac surgery|Any surgical intervention that is not aimed at surgical correction of the heart
1532145|NCT02726620|Drug|Propofol|Anesthetic drug used to maintain general anesthesia
1532146|NCT02726620|Drug|Sevoflurane|Anesthetic drug used to maintain general anesthesia
1532147|NCT02726620|Drug|Desflurane|Anesthetic drug used to maintain general anesthesia
1532148|NCT02726620|Drug|Isoflurane|Anesthetic drug used to maintain general anesthesia
1532149|NCT02726620|Drug|Ephedrine|Cardiovascular drug used to treat intraoperative hypotension
1532150|NCT02726620|Drug|Phenylephrine|Cardiovascular drug used to treat intraoperative hypotension
1532151|NCT02726620|Drug|Norepinephrine|Cardiovascular drug used to treat intraoperative hypotension
1532152|NCT02726620|Drug|Epinephrine|Cardiovascular drug used to treat intraoperative hypotension
1532153|NCT02726620|Drug|Dobutamine|Cardiovascular drug used to treat intraoperative hypotension
1532154|NCT02726620|Drug|Dopamine|Cardiovascular drug used to treat intraoperative hypotension
1532155|NCT02726620|Drug|Isoproterenol|Cardiovascular drug used to treat intraoperative hypotension
1532156|NCT02726620|Drug|Milrinone|Cardiovascular drug used to treat intraoperative hypotension
1532157|NCT02726620|Drug|Atropine|Cardiovascular drugs used to treat intraoperative hypotension
1532158|NCT02726620|Drug|Glycopyrrolate|Cardiovascular drug used to treat intraoperative hypotension
1532159|NCT02726620|Drug|Vasopressin|Cardiovascular drug used to treat intraoperative hypotension
1532160|NCT02726620|Drug|Terlipressin|Cardiovascular drug used to treat intraoperative hypotension
1532161|NCT02726620|Drug|Sodium Chloride 0.9%|Intravenous fluid used to treat intraoperative hypotension
1532162|NCT02726620|Drug|Ringer's lactate|Intravenous fluid used to treat intraoperative hypotension
1532163|NCT02726620|Drug|Hydroxyethyl starch solutions|Intravenous fluid used to treat intraoperative hypotension
1532164|NCT02726620|Drug|Fresh Frozen Plasma|Intravenous fluid used to treat intraoperative hypotension
1532165|NCT02726620|Drug|Packed Red Blood Cells|Intravenous fluid used to treat intraoperative hypotension
1532166|NCT02726620|Drug|Albumin solutions|Intravenous fluid used to treat intraoperative hypotension
1532167|NCT02726620|Drug|Plasma-Lyte|Intravenous fluid used to treat intraoperative hypotension
1532168|NCT02726620|Drug|Lidocaine|Local anesthetic used for central neuraxial anesthesia.
1532169|NCT02726620|Drug|Bupivacaine|Local anesthetic used for central neuraxial anesthesia.
1532170|NCT02726620|Drug|Levobupivacaine|Local anesthetic used for central neuraxial anesthesia.
1532171|NCT02726620|Drug|Ropivacaine|Local anesthetic used for central neuraxial anesthesia.
1532172|NCT02726620|Drug|Mepivacaine|Local anesthetic used for central neuraxial anesthesia.
1532173|NCT02726620|Drug|Tetracaine|Local anesthetic used for central neuraxial anesthesia.
1532174|NCT02726620|Drug|Prilocaine|Local anesthetic used for central neuraxial anesthesia.
1532175|NCT02726620|Drug|Procaine|Local anesthetic used for central neuraxial anesthesia.
1532176|NCT02726620|Drug|Chloroprocaine|Local anesthetic used for central neuraxial anesthesia.
1532177|NCT02726620|Drug|Benzocaine|Local anesthetic used for central neuraxial anesthesia.
1532178|NCT02726620|Drug|Articaine|Local anesthetic used for central neuraxial anesthesia.
1532179|NCT02726607|Behavioral|HIV Infant Tracking System (HITSystem) 2.0|The HITsystem 2.0 intervention will be designed to: (1) utilize electronic prompts to notify providers and program managers when actions are required, and (2) send text messages to women's mobile phones to (a) motivate adherence to medication, (b) remind women of antenatal (ANC) appointments and medication refills, (c) prompt preparation for a hospital delivery, and (d) support early infant testing. Given advancements in the approach and protocols for care, HITSystem 2.0 will continue to engage mothers and encourage postnatal medication adherence. The researchers will design HITSystem 2.0 to integrate seamlessly into the existing HITSystem to link PMTCT and early infant diagnosis (EID) services through one coordinated system-level intervention.
1532180|NCT02726607|Behavioral|Standard of PMTCT care|Pregnant women enrolled in PMTCT services at the control site will receive the current standard of PMTCT care and will not be enrolled in the HITSystem 2.0.
1532181|NCT02726581|Biological|Nivolumab|Specified dose on specified days, IV (intravenous)
1532182|NCT02726581|Biological|Elotuzumab|Specified dose on specified days, IV
1532183|NCT02726581|Drug|Pomalidomide|Specified dose on specified days, PO (by mouth)
1532187|NCT02726568|Drug|chemotherapy|If extracranial PD, then the subjects get chemotherapy which is decided by the investigator.
1532188|NCT02726555|Drug|Red yeast rice and atorvastatin|Participants will receive 2 capsules of 300mg red yeast rice and 2 capsules of 10mg atorvastatin for 24 weeks.
1532189|NCT02726555|Drug|Atorvastatin alone|Participants will receive 2 capsules of placebo and 2 capsules of 10mg atorvastatin for 24 weeks.
1532190|NCT02726542|Drug|somatropin|Norditropin (growth hormone) given by injection using a pen-device
1532191|NCT02726529|Behavioral|Brighter Bites|
1532192|NCT02726529|Behavioral|CATCH|The comparison schools received training in implementing the Coordinated Approach to Child Health (CATCH) school-based health promotion program
1532193|NCT02726516|Dietary Supplement|PRJ-205|1 sachet per day
1532194|NCT02726516|Other|Placebo|1 sachet per day
1532195|NCT02726503|Drug|Lenvatinib|"All patients will receive lenvatinib 24 mg orally once daily at almost the same time. The treatment will be started within 1 week after enrollment. 1 cycle consists of 4 weeks.
The administration will be continued until patients meet withdrawal criteria. If any toxicity manifested that cannot be ruled out causal association with the study drug, drug withdrawal or dosage reduction will be conducted in accordance with drug withdrawal/dosage reduction criteria."
1532196|NCT02726490|Drug|Glyburide|glyburide 2.5milligrams (mg) at bedtime (qhs) increased as needed to a maximum of 20mg/day usually taken twice a day (BID)
1532197|NCT02726490|Drug|Glucovance|glucovance (2.5/500) 1 taken orally (PO) at bed time (QHS) increased as needed to a maximum dose of (20/2000)/day usually taken twice a day (BID)
1532198|NCT02726477|Drug|Wuling San|Patients will be administrated with Wuling San at a dosage of 1g/kg twice a day after randomisation.
1532199|NCT02726477|Drug|placebo|Patients will be administrated with placebo powder at a dosage of 1g/kg twice a day after randomisation.
1532200|NCT02726451|Other|Basic Skin Care|Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
1532201|NCT02726451|Other|Active Skin Care|Sensi Peel®, Rejuvenating Serum, and C&E Strength Max skin care products (PCA SKIN®) in addition to the Facial Wash, Hydrator Plus Broad Spectrum SPF 30, and Rebalance skin care products (PCA SKIN®)
1532203|NCT02726425|Behavioral|Diabetes Self Management Medical Group Visits|The Women in Control DSM intervention involves: (1) 8-wk series of interactive, educational medical group visit sessions with groups of 10-12 participants, led by clinicians & peer leaders lasting ~100'' in length conducted either in Spanish or English and (2) Individual consultation with a clinician lasting 10-15 minutes. Group visits will consist of experiential and discussion based learning of topics including the importance of diet, physical activity, medications, mindfulness and stress reduction to diabetes self management.
1532204|NCT02726412|Procedure|Acute vs elective|non-intverention study
1532205|NCT02726399|Drug|Ramucirumab|
1532206|NCT02726399|Drug|Trastuzumab|
1532207|NCT02726399|Drug|Capecitabine/Cisplatin|
1532208|NCT02726386|Drug|ND0612|ND0612, a solution of levodopa/carbidopa (LD/CD) delivered continuously subcutaneously (SC) via an infusion pump system
1532209|NCT02726373|Other|type of walking|Subjects walked either intermittently or continuously twice a week for 4 weeks, then crossed over
1532210|NCT02726360|Behavioral|survey|The ILR Scale, a non-English language proficiency self-assessment.
1532211|NCT02726360|Behavioral|Audio record|Audio record the initial visits between patients and their treating physician
1532212|NCT02726347|Biological|PPV-23|one hundred forty subjects will have pre-vaccination titers checked. All will be given vaccination as standard of care. Approximately 4 weeks later subjects will have post-vaccination titers checked for the same serotypes.
1532213|NCT02726334|Drug|BNC101 Solution for Infusion|Administration: Administered via IV infusion once a week over 60 minutes (1 hour).
1532214|NCT02726334|Drug|BNC101 in combination with FOLFIRI|"BNC101 - Starting dose as determined by Arm A portion (one dose level below recommended Phase 2 dose).
BNC101 Administration: Administered via IV Infusion once a week over 60 minutes (1 hour).
FOLFIRI components:
Irinotecan (IRI) - Starting dose 180 mg/m2 (over 90 minutes on Day 1) Leucovorin (LV) - Starting dose 400 mg/m2 (administered over 120 minutes on Day 1 concurrently with IRI) 5-FU bolus - Starting dose 400 mg/m2 (administered after LV on Day 1, then) 5-FU infusion - Starting dose 2400 mg/m2 (administered over 48 hours starting on Day 1)
FOLFIRI Cycles are repeated every 14 days."
1532215|NCT02726308|Drug|Dexamethasone|5 mg I.V. Dexamethasone just before induction
1532216|NCT02726308|Drug|10 ml/kg Ringer's lactate|Intra-operative 10 ml/kg Ringer's lactate solution .
1532217|NCT02726308|Drug|30 ml/kg Ringer's lactate|Intra-operative 30 ml/kg Ringer's lactate solution .
1532218|NCT02726295|Drug|E. coli Nissle 1917(Mutaflor®)|
1532219|NCT02726295|Drug|Placebo|
1532220|NCT02726269|Drug|CLA (Clarithro+Lanso+Amoxi)|Tablets of oral administration administered to subjects randomized to this group twice daily for 10 days.
1532221|NCT02726269|Drug|PLA (Panto+Levoflox+Azithro)|Tablets of oral administration to subjects randomized to this group once daily for 10 days.
1532222|NCT02726230|Behavioral|Ananya|The Ananya program was developed and implemented via a partnership of the Bill and Melinda Gates Foundation and the Government of Bihar as a means of improving reproductive, maternal, newborn and child health (RMNCH) outcomes in the state, in particular focusing on improving health behaviors and service utilization in the final trimester of pregnancy and early postpartum period. Ananya was designed as a series of supply- and demand-side efforts to improve health. Efforts were focused on strengthening outreach services in quantity and quality, improving quality of facility services, and mobilizing communities to improve health behaviors. The Ananya program included training, mobilizing, and monitoring of government frontline health workers (FLWs, including anganwadi workers- AWWS, auxiliary nurse midwives- ANMs, and community health workers-ASHAs) to increase quantity and quality of home visits for RMNH screenings and services, and media messages to increase demand for services.
1532273|NCT02725853|Device|tDCS|Application of 1.5 mA tDCS for 30 minutes
1532274|NCT02725853|Device|sham tDCS|Application of sham tDCS for 30 minutes
1532275|NCT02725853|Behavioral|personalized practice|arm exercise consisting of whole arm movement within a restricted elbow range of motion
1532276|NCT02725853|Behavioral|non-personalized practice|arm exercise consisting of unrestricted whole arm movement
1532223|NCT02726217|Behavioral|CareSmarts Mobile Health Diabetes Program|Nurses from Diabetes Clinic will use a web-based enrollment form that includes the patient's mobile phone number, diabetes care plan, and preferred times for receiving messages. Participants in the program receive text messages about diabetes self-care. The contents of the messages that the participants receive are modified through software every two weeks as needed, based on their interactions with the system. Participants follow a flexible education curriculum in which they move from one topic to the next at their own pace.
1532224|NCT02726217|Behavioral|Standard of Care Reminders and Self Assessments|
1532225|NCT02726204|Other|Gravity Elimination Alone|CAREX will compensate for the gravity of the subject's arm, i.e. subject can move their arm to a specific position and relax all the arm muscles, CAREX will hold the arm in that configuration
1532226|NCT02726204|Other|Path Assistance Alone|CAREX will push subject's arm to a pre-specified path. If the arm is not in the path, CAREX will generate some force that is proportional to the distance between the hand and the path. The subject will feel like having a spring connected between his hand and the path
1532227|NCT02726204|Other|Path Assistance and Gravity Elimination|
1532228|NCT02726191|Behavioral|Spatial Match Exercise|
1532229|NCT02726191|Behavioral|Temporal Sequence Reconstruction Exercise|
1532230|NCT02726191|Behavioral|Token Task Exercise|
1532231|NCT02726191|Behavioral|Story Recall Exercise|
1532232|NCT02726191|Behavioral|Sample-Match (Within Modality) Exercise|
1532233|NCT02726191|Behavioral|Pair-Match (Across-Modality) Exercise|
1532234|NCT02726191|Behavioral|Triad-FiguresExercise|
1532235|NCT02726191|Behavioral|Monster Garden Exercise|
1532236|NCT02726191|Behavioral|Memory Match Exercise|
1532237|NCT02726191|Behavioral|Memory Matrix Exercise|
1532238|NCT02726191|Behavioral|Familiar Faces Exercises|
1532239|NCT02726191|Behavioral|Lost in Migration Exercise|
1532240|NCT02726191|Behavioral|Playing Koi Exercise|
1532241|NCT02726178|Drug|Advil® Pediatric drops for infants|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
1532242|NCT02726178|Drug|Placebo|Study the effect of inhibition of prostaglandins with ibuprofen vs placebo administration on cardio respiratory events in preterms infants
1532243|NCT02726152|Procedure|Polymer clips for closure of the appendiceal stump|Application of polymer clips to the appendiceal stump
1532244|NCT02726152|Procedure|Endoloops for closure of the appendiceal stump|Application of endoloops to the appendiceal stump
1532245|NCT02726126|Drug|Comparative study between transdermal fentanyl and melatonin patches on postoperative pain relief after lumber laminectomy|
1532246|NCT02726113|Drug|cholecalciferol|softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).
1532247|NCT02726113|Other|placebo|softgel containing no active ingredient daily for approximately two months prior to surgery (prostatectomy).
1532248|NCT02726100|Behavioral|SMARTHealth Diabetes|SMARTHealth Diabetes is an interactive mobile health platform to promote improved self-management for people with T2DM.
1532249|NCT02726087|Procedure|ministernotomy|"Partial upper J hemisternotomy trough 4th right intercostal space)"
1532250|NCT02726087|Procedure|Full sternotomy|Conventional full median sternotomy
1532251|NCT02726074|Drug|Perampanel|
1532252|NCT02726061|Behavioral|Computer Based PST|A behavioral therapy called Problem Solving Therapy will be administered via an interactive multimedia program (DrPST) to participants referred from their Employee Assistance Program for the treatment of depression.
1532253|NCT02726048|Device|Simplus/Eson|Released product Simplus and Eson masks
1532254|NCT02726035|Drug|Naltrexone|oral naltrexone 50 mg daily
1532255|NCT02726035|Other|Placebo|oral placebo (appearing identical to naltrexone) once daily
1532256|NCT02726022|Drug|Peginterferon alfa-2a|As per treating physician discretion and according to summary of product characteristics.
1532257|NCT02726022|Drug|Ribavirin|As per treating physician discretion and according to summary of product characteristics.
1532259|NCT02725996|Biological|NK cells|Adjuvant adoptive immune therapy using NK cell 4 times
1532260|NCT02725996|Other|Curative therapy|Patients who had undergone curative treatment(surgical resection or radiofrequency ablation for HCC of pretreatment clinical stage I or II were eligible for this study with no adjuvant treatment
1532261|NCT02725983|Behavioral|SPT consultation|
1532262|NCT02725983|Device|SOPROCARE®|
1532263|NCT02725970|Other|survey|Cross-sectional survey
1532266|NCT02725944|Device|Implantation of ICRM|All patients will be implanted with ICRM in order to detect an occult PAF.
1532267|NCT02725931|Behavioral|Pulmonary rehabilitation (PR) plus PA-focused intervention|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychosocial support and education sessions (once a week). Patients will also have their PA levels monitored on weeks (W) 1, 7 and 12 and receive feedback in the following weeks.
1532268|NCT02725918|Drug|Pemetrexed|500 mg/m2,iv,d1,q3w,until PD
1532269|NCT02725918|Drug|Cisplatin|75 mg/m2,iv,d1,q3w,×4 cycles
1532270|NCT02725905|Behavioral|Multi-Modal Education (MME)|"The MME curriculum focuses on developing weight management counseling (WMC) skills through several components: 1) a web course focused on WMC knowledge and clinical skill competencies; 2) WMC role-play exercises for an opportunity to use an algorithm to practice patient-centered WMC; 3) personal weight management exercises to increase awareness of Assist activities (e.g. daily food monitoring using mobile apps, etc); 4) obesity bias assessments, video, and discussions to modify attitudes of implicit weight bias; 5) a formative web-based encounter to interact with and receive feedback from a standardized patient; and 6) an enhanced clerkship rotation focusing on providing learning to preceptors and allowing students to observe preceptors counseling patients who are overweight or obese."
1532271|NCT02725905|Behavioral|Traditional Education (TE)|Current curriculum may consist of topics related to biology, population health, or counseling skills. TE also may include sporadic stand-alone lectures or small group discussions conducted separately or as a part of a patient interviewing or behavioral course.
1532277|NCT02725840|Radiation|Proton beam radiation therapy.|Proton bean radiation therapy interact differently with tissue with the result that protons are absorbed completely within the tissue instead of primarily passing through the entire body. The maximal depth of penetration is dependent upon the incoming velocity (energy) of the protons. Proton therapy utilizes this property to deliver radiation with very little dose beyond the targeted lesion. The dose-rate will be managed as part of the standard of care.
1532278|NCT02725840|Radiation|X-ray based radiation therapy|The three-dimensional (3D) mapping of radiation dose distributions permits detailed assessment of local vascular damage as a function of treatment factors of dose, dose-rate. The dose-rate will be managed as part of the standard of care.
1532279|NCT02725840|Procedure|Computed Tomography (CT) Scan|Computed Tomography (CT) Scan of the chest will be performed at 1, 3, 6, 12, 18 and 24 months
1532280|NCT02725840|Procedure|Pulmonary Function Test (PFT)|Pulmonary function test (PFT) will be performed at pre-treatment, and at 6 and 12 months.
1532281|NCT02725827|Other|EmbryoGlue (Vitrolife)|A hyaluronan-enriched embryo transfer medium
1532282|NCT02725827|Other|Control medium|The usual embryo transfer medium used in the study centres.
1532283|NCT02725814|Other|Sucrose|Two minutes prior to the start of a painful procedure neonates will receive 0.12ml of TootSweet 24% sucrose solution, over a period of no more than 1 minute. A pacifier will be offered immediately following sucrose administration for non-nutritive sucking if the infant is able to hold the pacifier securely. The sucrose study dose is to be repeated as needed based on pain response and procedure duration.
1532284|NCT02725801|Device|Allergen one-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
1532285|NCT02725801|Device|AlloX2 two-port tissue expander placement|patients will be randomized to receive a one port or two port tissue expander for breast reconstruction
1532286|NCT02725788|Device|New PIV Dressing|A commercially available breathable, transparent film dressing with a soft-cloth border, notch and securement tape strip. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until the PIV catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
1532287|NCT02725788|Device|Standard PIV Dressing|A commercially available breathable, transparent film dressing used with a one inch width piece of Transpore™ medical tape. The dressing system is used in the study to cover a peripheral intravenous catheter insertion site and secure the catheter. Dressing system is to remain in place until catheter is discontinued which is anticipated to be 72 hours. The dressing and PIV site will be observed daily. If dressing excessively lifts from the skin, the dressing system will be replaced with the same, assigned dressing system. The number of dressing replacements and the duration of wear will be measured while the same study PIV catheter dwells, an average of 72 hours during the subject's hospitalization.
1532288|NCT02725775|Dietary Supplement|100% Florida OJ|
1532289|NCT02725775|Dietary Supplement|Placebo Equicaloric Orange Drink|
1532290|NCT02725762|Device|LT-300 Active (PBM)|
1532291|NCT02725762|Device|LT-300 Inactive (Sham)|
1532292|NCT02725749|Radiation|Laser|Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
1532293|NCT02725749|Other|EXE|"Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.
The participants performed the exercises three times a week for eight weeks."
1532294|NCT02725749|Radiation|Laser + EXE|"Laser used were GaAs (904 nm, 60 mW), in continuous emission. The participants received application of laser three times or week for eight weeks, on 9 shoulder points (3 Joules/point) per session.
Isotonic strengthening exercises were performed for the scapular pivot, scapula stabilizer, and humeral propellant muscle groups. Three sets of 15 repetitions of each isotonic strengthening exercise were performed. The isometric exercises were performed in ten sets of ten seconds each. Analytical stretching of each muscle group was performed at the beginning of the session for 30 seconds.
The participants performed the exercises three times a week for eight weeks."
1532295|NCT02725736|Drug|Atosiban|"After random allocation to a treatment group, women will receive Atosiban as follows:
Atosiban was given as a single loading intravenous dose, 6.75 mg in 0.9% sodium chloride solution, followed by an intravenous infusion of 300 micrograms/min in 0.9% sodium chloride solution for the first 3 hours and then 100 micrograms/min for another 45 hours. The choice of the dose regimen for Atosiban was consistent with the recommendations of the product labeling."
1532296|NCT02725736|Drug|Nifedipine|"After random allocation to a treatment group, women will receive Nifedipine as follows:
Nifedipine was given as a loading dose of 20 mg orally followed by another two doses of 20 mg, 20-30 minutes apart as needed. Maintenance was started after 6 hours with 20-40 mg four times a day for a total of 48 hours."
1532297|NCT02725723|Device|Therm-AppTM TH, thermographic camera|
1532298|NCT02725723|Drug|epidural injection|
1532299|NCT02725710|Drug|Gabapentin|600mg Gabapentin administered orally 1-2 hours prior to procedure
1532300|NCT02725710|Drug|Placebo|Identical looking pill to the 600mg Gabapentin pill administered orally 1-2 hours prior to procedure
1532301|NCT02725697|Other|TCM treatment|
1532303|NCT02725671|Device|Explorer|ECG device which records comprehensive voltage potential data in the myocardium
1532304|NCT02725658|Device|DOSI|Breast tissue properties scanning
1532305|NCT02725645|Other|loading conditions|Different backpack loading conditions 0%, 10%, 15% and 20% allocated randomly
1532306|NCT02725632|Device|CPAP|The patients on CPAP treatment will be followed-up for 1 month.
1532307|NCT02725619|Behavioral|CBT|
1532308|NCT02725619|Behavioral|PST|
1532309|NCT02725606|Biological|Pegylated Recombinant Human G-CSF|subcutaneous
1532313|NCT02725580|Drug|scAVV9.CB.CLN6|Six subjects with diagnosis of CLN6 disease will receive scAVV9.CB.CLN6 administered by intrathecal injection.
1532315|NCT02725554|Device|StimRelieve Halo System|The StimRelieve Halo System is intended as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach for chronic migraine as defined by the Third edition of the International Classification of headache disorders (ICDH-3). The system provides treatment by delivering small controlled electrical pulses to the occipital and supraorbital nerves, as it has been shown that for chronic migraine headaches the response to combined systems appears to be substantially better than occipital nerves stimulation alone.
1532316|NCT02725541|Drug|Trastuzumab emtansine|HER2-targeted antibody drug conjugate of trastuzumab and DM1
1532317|NCT02725528|Procedure|collagenase injection|injection
1532318|NCT02725528|Procedure|limited palmar fasciectomy|surgery
1532319|NCT02725515|Biological|XmAb5871|
1532320|NCT02725515|Biological|Placebo to match XmAb5871|
1532321|NCT02725502|Drug|Linagliptin|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
1532322|NCT02725502|Drug|Placebo|Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
1532325|NCT02725476|Biological|XmAb5871|
1532326|NCT02725463|Device|Labyrinth Devices MVI™ Multichannel Vestibular Implant|
1532327|NCT02725450|Behavioral|Motor Imagery + Psychomotor Battery of fine motor skills|Subjects were randomly divided in two groups: a control group and an experimental one. The study procedures were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month. Motor imagery sessions were added on in the experimental group. Participants on the experimental group were asked to mentally imagine themselves recreating tasks they had performed earlier on the initial assessment.
1532328|NCT02725450|Behavioral|Psychomotor Battery of fine motor skills Practice|Subjects were randomly divided in two groups: in the control group were applied on five different tasks of the Psychomotor Battery of fine motor skills (BPM). This instrument was applied in two stages, at the beginning of the study (pretest) and at the end of the 4 weeks (posttest). Both groups performed the tasks twice a week for a month.
1532329|NCT02725437|Biological|Clostridium difficile Vaccine|0.5 mL intramuscular injection
1532330|NCT02725437|Biological|Placebo|0.5 mL intramuscular injection
1532331|NCT02725424|Drug|S-1|Her-2 Positive patients with SOX Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas<1.25m2) , 100mg(Body Surface Areas>1.25m2, <1.5 m2), 120 mg／day(Body Surface Areas>1.5m2), po,Bid， d1-14 Every 3weeks.
1532332|NCT02725424|Drug|Trastuzumab|Her-2 positive patients with SOXT Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas<1.25m2) , 100mg(Body Surface Areas>1.25m2, <1.5 m2), 120 mg／day(Body Surface Areas>1.5m2), PO,BID， d1-14 Trastuzumab :6 mg/kg, iv, d1 ：8 mg/kg Every 3weeks.
1532333|NCT02725424|Drug|Oxaliplatin|HER-2 Negative Patients：SOX Oxaliplatin： 130 mg/m2, iv, d1 S-1： 80mg(Body Surface Areas<1.25m2) , 100mg(Body Surface Areas>1.25m2, <1.5 m2), 120 mg／day(Body Surface Areas>1.5m2), PO,BID， d1-14 Every 3 weeks
1532334|NCT02725424|Drug|Docetaxel|Her-2 Negative patients with DOS Docetaxel： 60 mg/m2, iv, d1 Oxaliplatin：100 mg/m2, iv, d1 S-1 60 mg/m2，po，Bid， d1-14 Every 3 weeks
1532340|NCT02725398|Drug|Buscopan|Buscopan is administered by endoscopic nurse in the Buscopan group,and then recording the outcome measures.
1532341|NCT02725398|Drug|Scopolamine|Scopolamine is administered by endoscopic nurse in the Scopolamine group,and then recording the outcome measures.
1532342|NCT02725398|Drug|physiological saline|Physiological saline is administered by endoscopic nurse in the physiological saline group,and then recording the outcome measures.
1532343|NCT02725385|Other|Laboratory Biomarker Analysis|Correlative studies
1532344|NCT02725385|Other|Physiologic Testing|Undergo Trier Social Stress Test
1532346|NCT02725372|Drug|Inhaled Nitric Oxide 75 mcg/kg IBW/hr|Inhaled Nitric Oxide 15mcg/Kg IBW/hr for two week run in period dose titrated to Inhaled Nitric Oxide 75 mcg/kg IBW/hr at randomizationTreatment Period (Week 3 to Week 18)
1532347|NCT02725372|Drug|Placebo|Placebo arm: Inhaled Nitric Oxide 15mcg/Kg IBW/hr
1532348|NCT02725359|Drug|Placebo|Group Placebo: will receive a placebo pill 1 hour before surgery
1532349|NCT02725359|Drug|Tizanidine|Group T: 6 mg tizanidine1 hour before surgery
1532350|NCT02725359|Drug|Bupivacaine|Group Bupivacaine will receive USG guided SCPB with %0,25 bupivacaine bilaterally 10 ml each side
1532351|NCT02725359|Drug|Saline|USG guided SCPB with saline bilaterally 10 ml each side
1532352|NCT02725346|Procedure|Acromioplasty with planning|
1532353|NCT02725346|Procedure|Acromioplasty without planning|
1532354|NCT02725333|Procedure|Shoulder Stabilization|Open Latarjet was performed as the standard and well-described Latarjet-Patte procedure with subscapularis split and triple locking mechanism.14 The graft was intra-articular in every case, the capsule was systematically reattached to glenoid according to Favard's modification,15 and a capsular shift was added. Arthroscopic Latarjet was carried out in one case according to a modified Lafosse technique.16 In the latter treatment option, no reattachment of the capsule was realized. The arthroscopic Bankart repair consisted in a mobilization of the anteroinferior capsule and the labrum with an arthroscopic elevator. The glenoid rim and neck were then prepared with a mechanical shaver device. Two loaded anchors were inserted at the 5 and 3 o'clock position, and sutures were shuttled across the inferior glenohumeral ligament and labrum, starting at the inferior position and progressing in a superior direction.
1532355|NCT02725307|Device|Noninvasive pulse wave analysis sensor, ECG-sensor|Noninvasive pulse wave sensors and ECG-sensors are attached
1532356|NCT02725294|Other|This is an observational study without an intervention|Not applicable. This is an observational study without an intervention.
1532362|NCT02725255|Dietary Supplement|Ujiplus|Maize flour fortified with micronutrients and dried ground papaya (Carica papaya) seeds. The flour was used to prepare porridge and each child given a serving of 300 ml every school day for 60 days.
1532363|NCT02725255|Drug|Albendazole|400mg of albendazole given to each child once at the beginning of the study and maize flour porridge fortified only with micronutrients cooked and served to each child, 300ml per day for 60 days.
1532364|NCT02725255|Dietary Supplement|uji|maize flour porridge fortified only with micronutrients, cooked and served to each child 300ml per day for 60 days.
1532365|NCT02725242|Drug|Budesonide/formoterol (160/4.5 μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide/formoterol (160/4.5 μg/d)
1532366|NCT02725242|Drug|Budesonide (400μg/d)|After the patients who have all criteria, they will be randomization to take Budesonide (200 ug) twice daily
1532367|NCT02725229|Procedure|parasternal block|parasternal block and PCA for sternotomy pain
1532368|NCT02725229|Device|TENS group|TENS and PCA for sternotomy pain
1532369|NCT02725229|Device|control group|PCA for sternotomy pain
1532370|NCT02725203|Behavioral|Activate|The Activate intervention consists of four nurse-led consultations in a thee-month period. In the consultations patients receive structured and comprehensive support in achieving an improved level of physical activity. The Behavior Change Wheel was used to develop the Activate intervention, and led to a selection of 17 behavior change techniques, which are integrated in the Activate intervention
1532371|NCT02725190|Behavioral|Sleepless night|Each subject will undergo 28 hours of sleep deprivation.
1532372|NCT02725190|Behavioral|Normal sleep night|Normal sleep at home before trial.
1532373|NCT02725177|Drug|Repository Corticotropin Injection|"Treatment with ACTHAR Gel for 24 weeks
Initial treatment with 80 units daily for ten days (induction phase)
Maintenance treatment with 80 units twice weekly (maintenance phase)"
1532374|NCT02725177|Drug|Repository Corticotropin Injection -Treatment Extension|24 open label extension permitted in subjects who respond to treatment
1532375|NCT02725164|Drug|oxygen concentration|oxygen concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
1532376|NCT02725164|Drug|nitrous oxide concentration|nitrous oxide concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
1532377|NCT02725164|Drug|carbon dioxide concentration|carbon dioxide concentration will be measured from the tracheal tube and in the oropharynx during spontaneous or controlled ventilation
1532378|NCT02725164|Drug|sevoflurane concentration|sevoflurane concentration will be measured in the tracheal tube and oropharynx during spontaneous or controlled ventilation
1532379|NCT02725138|Dietary Supplement|Probiotic|Probiotic containing Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
1532380|NCT02725138|Other|Placebo|Placebo without Lactobacillus acidophilus and Lactobacillus rhamnosus produced by the Taiwan Sugar Cooperation, 1pack, twice daily, for 4 weeks
1532381|NCT02725125|Biological|EPCAM-targeted CAR-T cells|This study have only one arm that is CAR-T experimental arm. Firstly all participators will be attended the screening, who passed the screening for the treatment of CAR-T cells, the CAR-EPCAM-modified T cells can recognize and kill tumor cells in the body，follow-up 35 months.
1532382|NCT02725112|Drug|Pregabalin ER|A: Pregabalin ER tablet formulation, Target release rate, 1 x 330 mg, Oral.
1532383|NCT02725112|Drug|Pregabalin ER|B: Pregabalin ER tablet formulation, Slow release rate, 1 x 330 mg, Oral.
1532384|NCT02725112|Drug|Pregabalin ER|C: Pregabalin ER tablet formulation, Fast release rate, 1 x 330 mg, Oral.
1532385|NCT02725112|Drug|Pregabalin ER|D: Pregabalin IR capsule formulation, 1 x 300 mg, Oral.
1532386|NCT02725112|Drug|Pregabalin ER|E: Pregabalin ER tablet formulation, Target release rate, 1 x 82.5 mg, Oral.
1532387|NCT02725112|Drug|Pregabalin ER|F: Pregabalin ER tablet formulation, Aberrant fast release rate, 1 x 330 mg, Oral.
1532388|NCT02725099|Drug|Chewing Ticagrelor|180 mg Chewing Ticagrelor
1532389|NCT02725099|Drug|Oral Ticagrelor|180 mg oral Ticagrelor
1532390|NCT02725086|Drug|Leucostim®|
1532391|NCT02725086|Drug|Neupogen®|
1532392|NCT02725073|Procedure|Photodynamic therapy|Photolon (Belmedpreparaty, Minsk, Republic of Belarus), was administered intravenously at a dose of 2.5 mg/kg at 3 hours before illumination. After advancing a catheter (7 F inner sheath of a plastic stent delivery catheter [MAJ-1419; Olympus America, Center Valley, Pa., USA]) across the biliary stricture using a 0.035-in guidewire, the cylindrical diffuser is inserted into a catheter at the level of the stricture to be treated. Photoactivation (660 nm with a light dose of 100-150J/cm2, and fluence of 0.8-1W/cm2; UPL- FDT; LEMT Research & Development Private Unitary Enterprise, Minsk, Republic of Belarus) is performed
1532393|NCT02725060|Drug|phenylephrine|Phenylephrine is a selective α1-adrenergic receptor agonist. It will be given in IV bolus injections starting from 12.5 ug. Incremental doses will be given every ~3 min up to 800 ug or until systolic blood pressure increases by 25 mmHg
1532394|NCT02725060|Drug|isoproterenol|Isoproterenol is non-selective beta-adrenergic agonist. It will be given in IV bolus injections starting from 0.025 ug. Incremental doses will be given every ~3 min until heart rate increases by 25 bpm
1532395|NCT02725060|Radiation|25 micro-Ci of radiation|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
1532396|NCT02725060|Procedure|Posture study with blood samples|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume. An additional sample will be collected in the supine position for the autoantibody assessment.
1532397|NCT02725060|Procedure|24-hour heart rhythm and blood pressure monitoring|Blood pressure, heart rate and ECG monitoring for 24 hours
1532398|NCT02725060|Procedure|Quantitative Axonal Sudomotor Reflex Testing|The QSART assesses the ability of sympathetic nerve terminals in the skin to release acetylcholine and increase sweat production. The test is performed at 4 sites over the forearm, proximal lateral leg, medial distal leg and proximal foot.
1532399|NCT02725060|Procedure|Autonomic function tests|The autonomic function tests will determine how well the autonomic nervous system regulates blood pressure and heart rate. These tests include breathing deeply for two minutes, breathing fast for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, and placing the hand in ice water for 1 minute. In addition, participants will be tilted up on a tilt table for up to 10 minutes while recording their heart rate, blood pressure and cardiac output.
1532400|NCT02725047|Other|Cryotherapy|Crushed ice (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the ice bags, they will be fixed with an elastic bandage (compression). To protect the skin against frost bites, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton)
1532401|NCT02725047|Other|Placebo - Sand|Sand (1kg) inside a plastic bag (24x34x0,08 cm). The positioning of the plastic bags will cover the entire knee surface (Anterior, lateral and posterior region). After the positioning of the sand bags, they will be fixed with an elastic bandage (compression). Also, all the knee surface will be covered with a moistened operative field (45x50x0,01 cm, 100% cotton) to mimic the experimental group.
1532402|NCT02725034|Device|Standard endoscopy|
1532403|NCT02725034|Device|High definition endoscopy with Optic Enhancement|
1532404|NCT02725021|Behavioral|Education Against Tobacco school-based intervention by medical students|
1532405|NCT02725008|Drug|Dexamethasone|
1532406|NCT02725008|Drug|placebo|to be given to the experimental group on the day after discharge from the ED in lieu of the second dose of dexamethasone
1532407|NCT02724969|Behavioral|MILK or Text4Baby text message intervention|MILK text message intervention encompasses prenatal and postpartum breastfeeding support and education text messages. Text4Baby text message intervention encompasses prenatal and postpartum text messages about pregnancy, infant care, and postpartum issues.
1532410|NCT02724943|Behavioral|BMI screening|Physician screening of patients to identify patients who are overweight or obese.
1532411|NCT02724943|Behavioral|Next Steps brief clinical intervention|This intervention included identification of children who were overweight or obese, and Next Steps brief counseling materials for the healthcare provider (prior to enrollment in the intervention).
1532412|NCT02724943|Behavioral|MEND/CATCH|MEND 2-5 and MEND/CATCH 6-12 programs are multi-component interventions including behavioral, nutrition, and physical activity sessions. In the intensive (first 3 months) phase, MEND 2-5 entailed nine weekly sessions and MEND 6-12 entailed 18 twice weekly sessions.
1532413|NCT02724943|Behavioral|MEND/CATCH Transition Phase|The transition phase (next 9 months of the 12-month program) included monthly 90-minute sessions for parents and children included MEND reviews, cooking classes, Being Well book, CATCH activities and MEND World activities. Children were enrolled in YMCA sports teams or programs offered twice weekly to encourage physical activity. Weekly text messages were sent to parents to reinforce behavioral objectives of the intervention.
1532414|NCT02724943|Behavioral|Next Steps Self-Paced Booklet|Next Steps booklet for parents and children to work on nutrition and physical activity targets in a self-directed manner. Families were encouraged to seek repeated clinical visits to address child obesity as a follow up to the self-paced booklet.
1532415|NCT02724930|Behavioral|Enhanced facilitation of COPES|Enhanced facilitation of COPES implementation consists of promotional meetings, automated case finding and proactive outreach to recruit patients, marketing and educational materials, local champion, and academic detailing.
1532418|NCT02724904|Procedure|Allogeneic stem cell transplantation|Reduced intensity allogeneic stem cell transplantation from a fully matched related or unrelated donor
1532419|NCT02724904|Drug|Fludarabine|Standard Treatment
1532420|NCT02724904|Drug|Thiotepa|Standard Treatment
1532421|NCT02724904|Drug|Methotrexate|IV Bolus
1532422|NCT02724891|Other|paper form|questionnaires in paper form
1532423|NCT02724891|Other|web/smartphone form|questionnaires in web/smartphone
1532424|NCT02724878|Drug|Bevacizumab|Monoclonal antibody that binds circulating vascular endothelial growth factor
1532425|NCT02724878|Drug|Atezolizumab|Monoclonal antibody that binds programmed death ligand-1
1532426|NCT02724865|Device|Somnodent® (Oral appliance therapy)|
1532427|NCT02724865|Device|Herbst® (Oral appliance therapy)|
1532428|NCT02724852|Biological|0.5 ml of MMR vaccine|Participants in each arm received the same vaccine, a 0.5 ml of MMR vaccine at deltoid region
1532429|NCT02724839|Behavioral|Group nutrition sessions|The intervention will consist of 6 nutrition group sessions co-led by parent and a professional from the community who will rotate at each session. Group nutrition sessions will consist of a facilitated discussion of benefits and barriers to healthy eating, a short lesson led by the content expert, and a fun game or activity to reinforce the lesson. Two non-concurrent phases of the study will compare the efficacy of the group sessions when offered biweekly (first phase) and monthly (second phase). Participants will participate in only one phase.
1532430|NCT02724839|Device|Fitbit|Parent and child dyads will each receive a Fitbit Flex wearable device at the second session. This device will be used by participants and investigators to motivate and track participants' physical activity for up to 8 months
1532431|NCT02724826|Behavioral|Qigong therapy|Medical qigong
1532432|NCT02724826|Behavioral|Exercise therapy|Regular exercise
1532433|NCT02724813|Behavioral|Cognitive Orientation to Occupational Preformance (COOP)|
1532434|NCT02724800|Behavioral|CBTI|48 Veterans with chronic insomnia will be randomized to CBTI. The intervention will be delivered in 5 face-to-face session within an 8 week time period. The intervention will be delivered at the VA Pittsburgh Healthcare System. Treatment visits will last approximately 45 minutes.
1532435|NCT02724800|Behavioral|BBTI|48 Veterans with chronic insomnia will be randomized to BBTI. The intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3 (option for telephone), and telephone appointments on Weeks 2 and 4. Interventions will be delivered at the VA Pittsburgh Healthcare System. The duration of the first treatment visit is approximately 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
1532436|NCT02724787|Behavioral|Manage Emotions to Reduce Aggression (MERA)|MERA is a 3-session group treatment that teaches Veterans the purpose of emotions, how trauma and combat can increase emotions, and how to better regulate them. The skills use cognitive-behavioral and mindfulness techniques to help Veteran better regulate their emotions. These skills are commonly used in clinical practice, but have not been delivered in 3 sessions.
1532437|NCT02724774|Behavioral|Promoting First Relationships®|"PFR is based on attachment theory and is strengths-based. The 10 week intervention is delivered in the home of the family. Each week has a theme for discussion, handouts, an activity, and time for joining - checking in with the parent, listening to her concerns, and establishing a positive, supportive relationship. The PFR provider videotapes playtime between parent and child, and alternates every other week with watching the video with the parent, reflecting about the needs of both parent and child. The provider helps the parent develop greater empathy and understanding of the child's needs and feelings, and helps the parent to identify her own feelings and needs around parenting."
1532438|NCT02724761|Drug|Racemic Epinephrine|1 inhalation of 0.5 mL of 2.25% Nebulized Racemic Epinephrine every 8 hours for 24 hours after surgery
1532439|NCT02724761|Drug|Placebo (for racemic epinephrine)|0.5 mL of normal saline will be prepared in an identical amber syringe as the drug intervention (racemic epinephrine)
1532440|NCT02724748|Behavioral|Educational intervention|Educational intervention for staff members will encourage collaboration between patients, relatives and staff members. Skills, intellectual resources, motivation and encouragement among staff members to make changes on the unit will be supported. More detailed content of the intervention to be used in each unit will be tailored based on preparatory phase of the study and individual needs of the unit. The educational intervention will be carried out beside usual care.
1532441|NCT02724735|Drug|NSI-189|0 Milligrams, 40 Milligrams or 80 Milligrams administered in the acute study only
1532442|NCT02724722|Behavioral|Assigned intervention|a simple flyer plus face-to-face health education and give one bag containing stainless steel-made tableware for eating out use
1532443|NCT02724722|Behavioral|No intervention|a simple flyer only with no face-to-face health education and give one bag not containing stainless steel-made tableware for eating out use
1532444|NCT02724709|Procedure|Three-dimensional transoesophageal echocardiography|Three-dimensional transoesophageal echocardiography, analysed by eSie valve software (Siemens)
1532445|NCT02724709|Procedure|Computed tomography|Computed tomography, analysed by Synovia Workstation (Siemens)
1532446|NCT02724683|Device|Ascites drainage with vascular catheter.|In case of symptomatic malignant ascites, the procedure of vascular catheter insertion into abdominal cavity will be performed, followed by slow, systematic drainage, on patient's demand.
1532447|NCT02724683|Behavioral|Interview.|Interview with patients will be performed according to attached chart. The aim is to collect data concerning patient's symptoms, co-morbidity, and basic clinical data about the primary malignancy and treatment status.
1532448|NCT02724683|Behavioral|Quality of life.|Quality of life questionnaire (QLQ). Patients will be asked to complete QLQ at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
1532449|NCT02724683|Device|Quality of procedure.|Patients will be asked to complete quality of procedure questionnaire at one time point: one or two weeks after the procedure.
1532450|NCT02724683|Other|Nutritional status|Risk of malnutrition and ability to feed normally will be assessed with specific questionnaire at two time points: 1. immediately before the procedure, 2. one or two weeks after the procedure.
1532451|NCT02724670|Radiation|IGRT|MR-based IGRT
1532452|NCT02724657|Other|Buteyko Method|Intervention will be held twice a week during 3 weeks.
1532455|NCT02724631|Device|TubeClear® intervention|The TubeClear® device is deemed by the Food and Drug Administration (FDA) to be non-significant risk (NSR) for use in this study. It is a control box and a single use clearing stem used to resolve the clog in an enteral access device within five minutes following the intervention.
1532459|NCT02724605|Biological|Red blood cells unit age 14 days or less|30 Patients who will receive units of packed red blood cells stored stored for 14 days or less
1532460|NCT02724605|Biological|Red blood cells unit age more than 14 days|30 patients who will receive units of packed red blood cells stored for more than 14 days
1995941|NCT02609581|Drug|Sublingual Immunotherapy with tablets (mites)|Sublingual immunotherapy involves putting a tablet of allergen extracts (mites) under the tongue to swallow the extract.
1532463|NCT02724579|Drug|Cisplatin|Given IV
1532464|NCT02724579|Drug|Cyclophosphamide|Given IV
1532465|NCT02724579|Other|Laboratory Biomarker Analysis|Correlative studies
1532466|NCT02724579|Drug|Lomustine|Given PO
1532467|NCT02724579|Radiation|Radiation Therapy|Undergo craniospinal radiation therapy
1532468|NCT02724579|Drug|Vincristine Sulfate|Given IV or via minibag
1532469|NCT02724566|Drug|apelin|Assessing the difference between the insulin sensitivity measured during hyperinsulinemic euglycemic clamps in the presence of a 2 hours continuous infusion of (PYR1)-apelin-13 (30nmol/kg) versus a 2 hours continuous infusion of placebo (vehicle alone).
1532470|NCT02724566|Drug|placebo|2 hours continuous infusion of placebo (vehicle alone) to compare with 2 hours infusion of apelin
1532471|NCT02724553|Device|Acrylic lens implantation|
1532472|NCT02724540|Device|Lobar or segmental bland embolization with tris-acryl gelatin microspheres (100-500 microns) to 2-5 heartbeat stasis|
1532473|NCT02724540|Device|Lobar or segmental lipiodol chemoembolization|
1532474|NCT02724540|Drug|Doxorubicin 50 mg, and Mitomycin C 10 mg dissolved in 10 mL dilute contrast and emulsified with 10 cc iodized oil, followed by 100-500 μm tris-acryl gelatin microspheres.|
1532475|NCT02724540|Device|Lobar or segmental hepatic chemoembolization with DEBDOX (100-300 or 300-500 micron beads loaded with doxorubicin per manufacturer IFU|
1532476|NCT02724527|Drug|Cavosonstat|CFTR modulator that stabilizes CFTR
1532477|NCT02724527|Drug|Placebo|Matched Placebo capsule
1532478|NCT02724514|Other|non-invasive image & bioimpedance based techniques|Ultrasound scans, bioimpedance measurements, clinical photographs and questionnaires will be performed before and after the massage.
1532479|NCT02724501|Behavioral|questionnaire|Using questionnaire to obtain patient's medical and family history of cancer.
1532480|NCT02724501|Procedure|Blood sample-DNA testing / Tumour-genetic markers|Using Samples obtained to produce summary statistics on the tumour markers
1532481|NCT02724475|Procedure|LA|Ultrasound-guided puncture to the front of the thrombus with a power of 30 watts and pulse time of 0.3-0.4 seconds with 1 second interval until the thrombus was totally eliminated
1532482|NCT02724475|Procedure|3D-CRT|γ-knife treatment with radiation dose of 48-63 Gy/6-9 times
1532483|NCT02724462|Behavioral|Smartphone-delivered Intervention (SmartQuit)|The experimental arm includes an intervention using a novel smartphone smoking cessation app.
1532484|NCT02724462|Behavioral|: Smartphone-delivered Intervention (Standard of care app)|The control intervention uses a standard of care smartphone smoking cessation app.
1532485|NCT02724449|Device|Cavilon Advanced Barrier Film|Cavilon Advanced Barrier Fim's application applied twice a week
1532486|NCT02724436|Procedure|TACE|
1532487|NCT02724436|Procedure|radioembolization with Y-90|radioembolization with Y-90
1532488|NCT02724423|Drug|NRL-1|
1532489|NCT02724410|Drug|home intravenous ertapenem|see arm description
1532490|NCT02724410|Drug|home oral amoxicillin-clavulanate|see arm description
1532491|NCT02724410|Device|peripheral inserted central Catheter|All patients undergoing home intravenous ertapenem will require placement of peripheral inserted central Catheter (PICC) for home delivery of antibiotics.
1532492|NCT02724397|Device|LCI/BLI then white endoscopy|First use of Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) and then White Light Endoscopy to detect colonic adenomas.
1532493|NCT02724397|Device|White endoscopy and then LCI/BLI|First use of White Light Endoscopy and then Linked Color Imaging/Magnifying Blue Laser Imaging (LCI/BLI) to detect colonic adenomas.
1532494|NCT02724384|Device|MOE Plasma Delivery System A|Plasma treatment
1532495|NCT02724384|Device|MOE Plasma Delivery System B|Plasma treatment
1532497|NCT02724358|Procedure|TACE|iodized oil (5ml) + Pirarubicin (20mg)
1532498|NCT02724358|Drug|Rg3|20mg, BID, maintained though Month 12.
1532499|NCT02724358|Other|TACE + Rg3|
1532500|NCT02724358|Procedure|protective therapy|standard liver protective therapy
1532501|NCT02724332|Drug|Rapamycin|2mg,po,bid
1532502|NCT02724319|Device|SpartanRX|A buccal swap genetic sample will be collected from eligible patients who provide written informed consent for CYP2C19 testing. Genotyping will be performed by the SpartanRX system as a clinical test at the UF Health Pathology Laboratory in Jacksonville.
1532503|NCT02724306|Behavioral|Active Lifestyle Programme|
1532504|NCT02724293|Drug|pregabaline 300 mg once.|patients received pregabaline 300 mg 2 hours pre-operatively.
1532505|NCT02724293|Drug|pregabaline 300 mg twice.|patients received pregabaline 300 mg 2 hours pre-operatively, and 12 hours later.
1532506|NCT02724293|Drug|pregabaline 600 mg once.|patients received pregabaline 600 mg 2 hours pre-operatively.
1532507|NCT02724293|Drug|placebo|patients received placebo
1995942|NCT02607306|Drug|insulin degludec/liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
1532508|NCT02724280|Device|WLE and then LCI|The gastric mucosa was evaluated with WLE and then LCI by two different endoscopists.
1532509|NCT02724280|Device|LCI and then WLE|The gastric mucosa was evaluated with LCI and then WLE by two different endoscopists.
1532510|NCT02724267|Biological|131I-chTNT-1/B|29.6 MBq/kg,intravenous administration in 1 hour，1-3 course of treatment
1532511|NCT02724254|Drug|AP611074 5% gel|
1532512|NCT02724254|Drug|AP611074 matching placebo|
1532513|NCT02724241|Other|one time exposure to e-cig with nicotine|one time exposure to e-cigarette vapor with nicotine
1532514|NCT02724241|Other|One time exposure to e-cigarette without nicotine|One time exposure to e-cig without nicotine
1532515|NCT02724241|Other|one time exposure to empty e-cigarette|one time exposure to empty e-cigarette (sham control)
1532516|NCT02724228|Drug|BMN 111|BMN 111 will be administered daily for up to 260 weeks.
1532518|NCT02724202|Drug|Curcumin|Curcumin is supplied as soft-gel capsule. It is a micronized rhizome extract containing phospholipids and 500mg of pure curcuminoids (95% curcumin, 5% desmethoxycurcumin) suspended in turmeric essential oil.
1532519|NCT02724202|Drug|5-flurorouracil|Fluorouracil is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Fluorouracil is classified as an antimetabolite.
1532520|NCT02724189|Device|MyPreOp assessment|MyPreOp is an online preoperative assessment programme created by a medical software company called Ultramed.
1532521|NCT02724189|Other|Nurse led assessment|Standard practise is where patients undergo a face to face preoperative assessment led by a qualified nurse specialising in this field.
1532522|NCT02724176|Drug|carbon nanoparticles|0.1 ml of CN suspension was injected per spot into the tissue surrounding the tumor using a skin test syringe. Two or three randomly selected spots were injected slowly for each tumor, and the total amount injected was no more than 0.5 mL per lobe.
1532530|NCT02724150|Drug|Omeprazole High dose|High regimen of Proton Pump Inhibitors in treatment of bleeding ulcer 80 mg loading dose then 8 mg/h iv for 3 days
1532531|NCT02724150|Drug|Omeprazole Low dose|low regimen of Proton Pump Inhibitors in treatment bleeding ulcer 80 mg loading dose then 40 mg two times per day for 3 days
1532532|NCT02724137|Behavioral|Fitbit®|Participants can read how many steps/day they walked on the Fitbit® daily. The treating physical therapist reviews Fitbit® recorded steps from the previous week and together with the patient sets a new step goal. The physical therapist discusses barriers to meeting step goals are discussed. Self-reward for meeting step/goal is set weekly. Participants in this group will also receive 1-month phone calls for 6-months after completing physical therapy rehabilitation to discuss physical activity, set monthly step count goal, barriers to overcoming goal and to continue to develop a reward system for when the participant achieves their step count goal.
1532533|NCT02724137|Other|Physical Therapy Rehab|Standard of care physical therapy after total knee replacement. The goals of physical therapy are to increase knee range of motion and strength, improve balance and agility, and increase daily walking. Physical therapy appointment times range from 45-60 minutes with appointments occurring 2 times a week for 6-8 weeks.
1532534|NCT02724124|Other|Static Stretching|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
1532535|NCT02724124|Other|warm up|Warm-up for 10 minutes at 70-80% of maximum heart rate.
1532536|NCT02724124|Other|static stretching + warm up|3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets + Warm-up for 10 minutes at 70-80% of maximum heart rate.
1532537|NCT02724124|Other|warm up+static stretching|Warm-up for 10 minutes at 70-80% of maximum heart rate + 3 sets of 30-second self static hamstring stretch (IT), quadriceps (QD) and sural triceps (TS) of both lower limbs, with an interval of 30 seconds of rest between sets
1532538|NCT02724124|Other|Control|No intervention
1532541|NCT02724098|Drug|Dexmedetomidine|
1532542|NCT02724085|Drug|TP-271|TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg
1532543|NCT02724072|Device|Thoraflex™ Hybrid Device|Single-use medical device sterilized by ethylene oxide which is pre-loaded into a delivery system. The device comprises a gelatin sealed vascular graft combined with a stented graft.
1532544|NCT02724059|Procedure|EBUS with elastography followed by TBNA|Endo bronchial ultrasound (EBUS) with elastography followed by TBNA from mediastinal lesions or lymph nodes
1532545|NCT02724046|Drug|Ciprofloxacin|Single-dose oral ciprofloxacin
1532546|NCT02724033|Procedure|regional nerve block|regional nerve block
1532547|NCT02724033|Drug|Antiemetic|Antiemetic
1532548|NCT02724020|Drug|Everolimus|Everolimus capsules
1532549|NCT02724020|Drug|MLN0128|MLN0128 capsules
1532550|NCT02724020|Drug|MLN1117|MLN1117 capsules
1532551|NCT02723994|Drug|Ruxolitinib|In Part 1, ruxolitinib will be administered at a protocol-defined starting dose in combination with chemotherapy, with dose escalation and de-escalation following the rolling 6 study design. The established recommended starting dose will be taken forward into Part 2.
1532552|NCT02723994|Drug|Asparaginase Erwinia Chrysanthemi|
1532553|NCT02723994|Drug|Cyclophosphamide|
1532554|NCT02723994|Drug|Cytarabine|
1532555|NCT02723994|Drug|Dexamethasone|
1532556|NCT02723994|Drug|Doxorubicin|
1532557|NCT02723994|Drug|Leucovorin Calcium|
1532558|NCT02723994|Drug|Mercaptopurine|
1532564|NCT02723981|Device|COMBO-Stent|The OrbusNeich COMBO Bio-engineered Sirolimus Eluting Stent (COMBO Stent) consists of a 316L stainless steel alloy abluminally coated with a biocompatible, biodegradable poly-mer containing sirolimus. Covalently attached to the surface of the stent is a layer of murine, monoclonal, anti-human CD34 antibody. The antibody specifically targets circulatory CD34+ cells (endothelial progenitor cells) thus favoring endothelialization.
1532565|NCT02723981|Drug|Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|Anticoagulant medication after stent Implantation: (N)OAC and clopidogrel for 3 months followed by (N)OAC
1532566|NCT02723981|Device|Any drug eluting stent oder bare metal sent|Implantation of traditional bare metal stents and/or drug eluting stents (any device approved on the market, implanted according to CE marking and IFU) and medication regimen in accordance with ESC Guidelines
1532567|NCT02723981|Drug|ASA, Clopidogrel, Vitamin K Antagonist, Rivaroxaban, Dabigatran|A combination of antiplatelet and anticoagulant therapy according to ESC guidelines (2014)
1532568|NCT02723968|Other|glucose solution at a dose of 1.75 g/kg (up to a maximum of 75 g) for the OGTT and glucose solution at a dose of 0.5 g/kg (up to a maximum of 35 g) was injected in 2.5-3 min for the IGTT|At the first visit at day 1an OGTT will be performed then the CGMS is implanted. Capillary glycaemia will be taken four times a day to set up the CGMS. A second visit is scheduled at day 4, where the intravenous glucose tolerance test is performed as well as the HbA1C level.
1532569|NCT02723968|Procedure|HGPIV diagnosis test|
1532570|NCT02723968|Procedure|HOMAR-IR diagnosis test|
1532571|NCT02723955|Drug|GSK3359609 IV infusion|GSK3359609 will be administered intravenously to the subjects. Diluted product will be administered as IV Infusion once Q3W
1532572|NCT02723955|Drug|Pembrolizumab 200 mg IV infusion|Pembrolizumab 200 mg will be intravenously administered to subjects.
1532573|NCT02723942|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at GPC3 antigen.
1532574|NCT02723929|Device|active low-intensity transcranial electrical stimulation/active transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.
Subjects will also undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for the full 20 minutes."
1532575|NCT02723929|Device|Sham low-intensity transcranial electrical stimulation/sham transcranial ultrasound|"Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation, as in the active condition; however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
Subjects will also undergo 20 minutes of transcranial ultrasound in the same par. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes."
1532576|NCT02723916|Behavioral|ezParent Program|Tablet-based behavioral parent training program.
1532577|NCT02723916|Behavioral|Health-e Kids Control App|Tablet based health promotion information App
1532578|NCT02723903|Drug|Deanxit|we use Deanxit for the patient with anxiety
1532579|NCT02723903|Drug|Prozac|we use Prozac for the patient with depression
1532580|NCT02723903|Procedure|coronary artery disease treatment|including medication, coronary artery stent implantation according to the severity of stenosis of the coronary arteries
1532581|NCT02723890|Device|Tyto Device|
1532582|NCT02723877|Drug|PQR309|Dual phosphatidylinositol 3-kinase phosphoinositide 3-kinase/ mammalian target of rapamycin Inhibitor (= PI3K/mTOR Inhibitor)
1532583|NCT02723877|Drug|Eribulin|non.taxane microtubule dynamics inhibitor
1532585|NCT02723851|Device|Corsens|Recording and calculating Peak Endocardial Acceleration (PEA) Myocardial Contractility Index [MCI] and isovolumetric contraction (IVCT). Measurements will not affect the treatment provided to the patients.
1532586|NCT02723838|Biological|REOLYSIN®|3 cycles (each cycle = 21 days). Cohort 1: 3x10E10 TCID50 intratumoral via cystoscopy on Day 1 of each cycle. Cohort 2: 3x10E10 TCID50 intratumoral via cystoscopy on Day 2 of each cycle.
1532587|NCT02723838|Drug|Gemcitabine|3 cycles (each cycle = 21 days). Cohort 1: 1000mg/m2 intravenously on Day 2 and Day 9 of Cycle 2 and Cycle 3. Cohort 2: 1000mg/m2 intravenously on Day 1 and Day 8 of each cycle.
1532588|NCT02723838|Drug|Cisplatin|3 cycles (each cycle = 21 days). Cohort 1: 70 mg/m2 intravenously on Day 2 of Cycle 2 and Cycle 3. Cohort 2: 70 mg/m2 intravenously on Day 1 of each cycle.
1532589|NCT02723825|Procedure|Closed reduction|Treated with Manipulatio, using plywood, gypsum or external fixation support to fixed
1532590|NCT02723825|Procedure|Open reduction|Open reduction and internal fixation
1532591|NCT02723812|Biological|GCFLU® Influenza vaccine (Split virion, Inactivated)|
1532592|NCT02723799|Behavioral|Hope Promotion Program (HPP)|"HPP is based on literature review and qualitative research in hope at the end-of-life. The film Hopeful living reflects the findings of the grounded theory study. Hope activity book is the final product of the literature review on hope interventions and its activities were tested in their feasibility and suitability in our previous research with persons with advanced cancer and their families."
1532593|NCT02723799|Other|Standard Treatment Protocol|Regular assessment and care by the hospital outpatient health care team.
1532594|NCT02723786|Biological|GSK1070806|Injectable solution of 100 milligram/millilitre (mg/mL), administered as a single dose of 3 milligram/kilogram (mg/kg) (maximum of 10 mg/kg) diluted in 100 mL sterile IV infusion bag of 0.9% Sodium Chloride.
1532595|NCT02723786|Drug|1) basiliximab 2) mycophenolate mofetil (MMF) OR azathioprine 3) tacrolimus 4) corticosteroids|This immunosuppressant regimen may be revised based on the clinical judgment of the investigator including titration of tacrolimus levels.
1532597|NCT02723760|Drug|99mTc-3PRGD2|"SPECT/CT scanning: single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on rheumatoid arthritis patients, whole-body planar and lesions section for determination the accumulation of 99mTc-3PRGD2 in the joints and other parts of the body.
For diagnosis study, each patient will be carried out SPECT/CT scanning once. For efficacy evaluation study, each patient will be carried out SPECT/CT scanning three times (before treatment, the midterm treatment and late stage treatment)."
1532599|NCT02723734|Other|Decipher® Testing|Decipher® Prostate Cancer Classifier (Post-Op and Biopsy), a Genomic Classifier (GC) test. Biopsy and prostatectomy specimens will be collected for GC testing.
1532600|NCT02723721|Drug|Picato gel|apply on and 1 cm around the lesion, 0.47 g of Picato® gel 150 µg/g, once a day on 3 consecutive days.
1532601|NCT02723708|Other|Real-Time functional Magnetic Resonance Imaging Feedback (RTFF)|During the Activate trials, the thermometer will display the weighted average of VTA BOLD activation, dynamically updated every second. This continuously updated thermometer is the primary feedback mechanism.
1532602|NCT02723695|Other|Evaluation of postural performances|Postural tests
1532603|NCT02723682|Other|Collect 24-hour urine specimen|A random half sample of NHANES participants 20-69 examined in the mobile examination center were asked to collect a 24-hour urine specimen.
1532604|NCT02723669|Drug|AR10|effervescent tablet
1532605|NCT02723669|Drug|acetylcysteine|oral solution
1532606|NCT02723656|Behavioral|Online Referral NYS Quitline|Care coordinator will make an online referral to the NYS Quitline.
1532607|NCT02723656|Behavioral|Tobacco cessation counseling and coordination of cessation medications|Care coordinator will obtain verbal consent to transfer the patient to the NYS Quitline via 3-way call (warm transfer). The care coordinator will also assist the patient in obtaining NRT from a regular care provider, then call the patient every three months for 12 months to assess current smoking and offer to help smokers obtain additional cessation counseling and medications.
1532608|NCT02723630|Drug|Lenvatinib 10 mg|"Treatment 1: low Type-C crystal level <12%
Treatment 2: reference* Type-C crystal level 12% to 26%
Treatment 3: high Type-C crystal level >26%"
1532613|NCT02723604|Device|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
1532614|NCT02723591|Drug|Tacrolimus|Oral
1532615|NCT02723591|Drug|Tacrolimus immediate release|Oral
1532616|NCT02723578|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days
1532617|NCT02723578|Drug|Erlotinib|Erlotinib 150 mg PO once daily on days 1-21 every 21 days
1532618|NCT02723552|Behavioral|Aerobic Exercise|40 minute aerobic exercise sessions 3x/week.
1532619|NCT02723539|Drug|MBN-101|Topical application
1532620|NCT02723539|Drug|Placebo|Topical application
1532621|NCT02723526|Other|Blood drawing|
1532622|NCT02723513|Other|Hyperpolarized Xenon-129|"Hyperpolarized Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.
Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
1532623|NCT02723500|Device|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
1532624|NCT02723487|Drug|Bupivacaine 0.125%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.125%), 0.5 ml/kg on each side.
1532625|NCT02723487|Drug|Bupivacaine 0.25%|Patients will receive bilateral Transversus Abdominis Plane Block guided by ultrasound device using bupivacaine (Marcaine, 0.25%), 0.5 ml/kg on each side.
1532626|NCT02723474|Device|MRI at baseline and over time|Hyperpolarized noble gas MRI has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI, Helium-3 and Xenon-129 gas is used as a contrast agent to directly visualize ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
1532627|NCT02723461|Drug|Pulsatile Oxytocin|Using a programmable syringe pump, oxytocin will be administered for 10 seconds every 6 minutes and the dose (2 mU/pulse) doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
1532628|NCT02723461|Drug|Continuous Oxytocin|Oxytocin will be administered at starting dose (2 mU/min) in a continuous manner doubled every 30 minutes until uterine contractions will be established (3-4 in 10 minutes).
1532629|NCT02723448|Drug|aclarubicin|Aclarubicin (3 mg/m²) will be administered intravenously through a central venous access device over 1 hour for four consecutive days per 28 day cycle. There is no maximum number of cycles.
1532630|NCT02723435|Other|Laboratory Biomarker Analysis|Correlative studies
1532631|NCT02723435|Drug|Midostaurin|Given PO
1532632|NCT02723422|Procedure|Prehabilitation visit/increased physical therapy post-TAVR|Prior to TAVR, patients randomized to the intervention arm will meet with a licensed physical therapist for a 30-minute session in the ambulatory setting. Following TAVR, patients randomized to the intervention arm will receive 4 days per week of home-based physical therapy by a licensed physical therapist working for Revival Home Health Care
1532633|NCT02723422|Procedure|Standard of Care Arm|Patients randomized to the usual care arm will receive home-based physical therapy for 2 days per week by Revival Home Health Care, which is the current standard of care.
1532634|NCT02723409|Procedure|Round Procedure Umbilicoplasty|"Umbilicoplasty surgery (belly button reshaping) is performed using the Round Procedure"
1532635|NCT02723409|Procedure|"Scarless round procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Scarless round procedure"
1532636|NCT02723409|Procedure|"Inverted U Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted U Procedure"
1532637|NCT02723409|Procedure|"Inverted VProcedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Inverted V Procedure"
1532638|NCT02723409|Procedure|"Y deepithelialized Procedure"|"Umbilicoplasty surgery (belly button reshaping) is performed using the Y deepithelialized procedure"
1532639|NCT02723383|Drug|BACLOFEN|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the treatment will be administered via the nasogastric feeding tube. After extubation, the treatment will be administered either via the nasogastric tube or the oral route.
1532640|NCT02723383|Drug|PLACEBO|Daily doses will be adapted to daily MDRD creatinine clearance from 150 to 50mg. On the day of randomisation, the patient will receive the full daily dose in a one-shot administration. Then daily doses will be divided into 3 intakes on the following days. During the mechanical ventilation period, the placebo will be administered via the nasogastric feeding tube. After extubation, the placebo will be administered either via the nasogastric tube or the oral route.
1532641|NCT02723370|Behavioral|Staff multi-component implementation strategy|Staff will receive a multi-component implementation strategy for evidence based practices (EBPs) for colonoscopy, including split-dosing of bowel preparation, low literacy education materials for patients, and teach-back procedure. The implementation strategy includes a supply of low-literacy patient education materials for split-dosing the medication of their choice, poster and pocket-card with teach-back prompts, consultation to integrate materials and teach-back into workflow and a website with additional training and patient materials.
1532644|NCT02723344|Dietary Supplement|of Lactobacillus reuteri (L. reuteri; DSM 17938)|Commercially available L. reuteri (deposited in the Deutsche Sammlung von Mikroorganismen und Zellkulturen (DSMZ) and referenced as DSM 17938; Gerber Soothe Colic Drops, 100 million CFU/5 drops; formerly known as L. reuteri ATCC 55730) will be used in the proposed study. L. reuteri (phylum Firmicutes) is a gram-positive anaerobic commensal bacteria found in the gut microbiome of humans. Independent testing of the viability of the commercial product will be conducted in our laboratories by diluting drops, plating on agar in triplicate, and anaerobic culturing at 37 oC. The commercial strain (DSM 17938) has been used to improve intestinal functions in infants and reduce symptoms of infantile colic.
1532645|NCT02723344|Other|Sunflower and medium chain triglyceride oils|Placebo
1532650|NCT02723305|Other|No intervention|
1532651|NCT02723292|Behavioral|TOP|
1532652|NCT02723292|Behavioral|Control intervention|
1532653|NCT02723279|Behavioral|EPNS|Electrical pudendal nerve stimulation Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
1532654|NCT02723279|Drug|TT|Tolterodine tartrate (GSK， UK) 4mg per day is taken orally for six weeks
1532655|NCT02723266|Behavioral|STOPPING-GDM|Educational counseling and skills building Intervention
1532656|NCT02723253|Radiation|Radiotherapy|Radiotherapy was applied as conformal 3-D technique and was delivered with photon energies of 10 - 15 MV. The beams were delivered by an Elekta Precise Linac equipped with standard multi leaf collimators (MLC). A daily online check of isocenter position was performed using portal imaging, with set-up correction in case of displacement > 0.5 cm in any direction. Radiation dose delivered to PTV2 was 45 Gy (1.8 Gy/fraction) with a concomitant boost dose to the PTV1 of 10 Gy with accelerated fractionation at 2.2 Gy/fraction, five consecutive days for week.
1532657|NCT02723253|Drug|Tom-OX|The concurrent chemotherapy consisted of 15 min intravenous infusion Raltitrexed (Tomudex ®) 3 mg/m2 and a two-hours intravenous infusion of Oxaliplatin (Eloxatin ®) at 130 mg/m 2, 20 min after raltitrexed, on days 1, 17, 35.
1532658|NCT02723240|Drug|NUC-3373|
1532661|NCT02723214|Procedure|Brain biopsy|Brain biopsy using either the frame-based stereotactic technique, or a frameless fiducial-less brain biopsy method using an optical based navigation system and a mini frame apparatus - trajectory guide.
1532667|NCT02723188|Device|Sham stimulation (1.5 milliampere,30 seconds)|
1532668|NCT02723188|Device|DC stimulation (1.5 milliampere, 20 minutes)|
1532669|NCT02723188|Device|AC stimulation (1.5 milliampere,1.5 Hertz frequency)|
1532670|NCT02723175|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is a minimally invasive technique that uses a small amount of electricity (2mA) to temporarily stimulate specific brain areas in awake people.
1532671|NCT02723162|Drug|Varenicline (VRN)|VRN will be provided at the standard recommended dose (0.5 mg daily for 3 days, then 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for the remaining 21 days of active treatment.
1532672|NCT02723162|Drug|N-Acetylcysteine (NAC)|NAC will be dosed at 1200 mg twice daily throughout the 28-day active treatment
1532673|NCT02723162|Drug|Placebo|Matched placebo
1532674|NCT02723149|Behavioral|Marijuana Approach Avoidance Training|Approach Avoidance Training (AAT) is a novel computerized procedure that modifies implicit approach tendencies by training individuals to selectively avoid drug- related stimuli, thereby overriding habitual approach tendencies. Participants are randomized to either the treatment or sham condition. Treatment duration involves 6 training sessions of approximately 15 minutes each (400 trials). AAT requires minimal training and involves only a computer and a joystick, in which participants are either pulling or pushing the joystick when different marijuana or non-marijuana images are displayed with either yellow (pull) or blue (push) border.
1532675|NCT02723136|Device|Smartphone Application|Smartphone application developed by internists and engineers. Will be made available on iOS(R) and Android(R) operating systems.
1532676|NCT02723123|Other|Recording of cardio-respiratory signals|Biological signals: ECG, RIP, SpO2 and Pulse rate will be recorded during the interventions and analyzed offline.
1532677|NCT02723110|Other|4 Hour Frequently Sampled Oral Glucose Tolerance Test|Blood glucose level(BGL) every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
1532678|NCT02723110|Other|Isoglycaemic Clamp|Glucose infusion over 4 hours to reproduce OGTT glucose curve to allow measurement of incretin effect. BGL every 5 min, blood for hormone, biochemical analysis at -15,0,15,30,45,60,90,120,180, 240
1532680|NCT02723084|Drug|ABT-493/ABT-530|Tablet
1532681|NCT02723084|Drug|Sofosbuvir|Tablet
1532682|NCT02723084|Drug|Ribavirin|Capsule
1532683|NCT02723071|Drug|Ocrelizumab|Participants will receive a total of 8 intravenous (IV) infusions of ocrelizumab given at intervals of 3 weeks, until disease progression or unacceptable toxicity.
1532684|NCT02723058|Behavioral|ICMHM|ICMHM participants receive a collaborative care model adapted to include an engagement interview, attention to co-morbid conditions, and attention to basic needs.
1532685|NCT02723045|Procedure|Open Lichtenstein Hernioplasty|
1532686|NCT02723045|Procedure|Laparoscopic TEP Hernioplasty|
1532687|NCT02723032|Device|OxyFrame|Validation of a miniaturized pulse oximetry sensor for integration into the frame of oxygen delivery glasses.
1532688|NCT02723019|Behavioral|Volunteer Peer Mentor+Behavioral Hlth Nurse|Intervention group participants receive intervention services from a Volunteer Peer Mentor and a Behavioral Health Nurse
1532689|NCT02723006|Drug|TAK-580|TAK-580 tablets
1532690|NCT02723006|Drug|TAK-202|TAK-202 infusion
1532691|NCT02723006|Drug|vedolizumab|vedolizumab infusion
1532692|NCT02723006|Drug|nivolumab|nivolumab infusion
1532693|NCT02723006|Drug|ipilimumab|ipilimumab infusion
1532694|NCT02722993|Dietary Supplement|Probiotics|
1532695|NCT02722993|Dietary Supplement|Placebo|
1532696|NCT02722980|Dietary Supplement|Placebo|The intervention consists of capsules containing placebo.
1532697|NCT02722980|Dietary Supplement|: Probiotic capsules|The intervention consists of capsules containing probiotics.
1532698|NCT02722967|Drug|Aripiprazole + IEM (Ingestible Event Marker)|Oral aripiprazole (2, 5, 10, 15, 20, or 30 mg) with an ingestible event marker in a single daily dose for duration of the trial.
1532699|NCT02722954|Drug|Demcizumab|Drug: Demcizumab at starting dose of 2.5mg/kg administered intravenously (IV).
1532700|NCT02722954|Drug|Pembrolizumab|Drug: Pembrolizumab administered 2mg/kg IV every 3 weeks
1532701|NCT02722941|Drug|Panobinostat|Maintenance therapy dosing as outlined in Cohorts A and B.
1532702|NCT02722928|Other|Controlled Ventilation with 100% oxygen|Patients in group B will be switched from conventional 1:1 oxygen / air ventilation to 100% oxygen controlled ventilation once tumor resection is completed and hemostasis started. They will inhale 100% oxygen until extubation
1532703|NCT02722915|Procedure|fMRI|collection of functional brain data for 1 hour per day
1532704|NCT02722915|Behavioral|Neurofeedback|Task of the participants is to increase or decrease the connectivity between selected brain regions in double-blind, randomized order. After the regulation they will get a feedback about the regulation success. (Patients and controls with AVH: days 3 & 4; controls without AVH: Days 2 & 3)
1532705|NCT02722915|Other|PANAS|to assess the mood before and after the fMRI and after 1 week during a telephone interview
1532706|NCT02722915|Other|AVHRS|to assess the intensity and quality of the hallucinations before and after the fMRI and after 1 week during a telephone interview
1532707|NCT02722915|Other|SF36|questionnaire about life quality after 1 week during a telephone interview
1532708|NCT02722902|Drug|Carnitor|"CARNITOR® (levocarnitine) is a carrier molecule in the transport of long-chain fatty acids L-Carnitine will be administrated intravenously as continuous infusion during the 6-hour hyperinsulinemic euglycemic clamp. The administration will start with a bolus of 15mg/kg for 10 minutes. Subsequently, continuous L-carnitine infusion of 10mg/kg will start for the remaining 350 minutes.
across the inner mitochondrial membrane."
1532709|NCT02722902|Dietary Supplement|IntraLipid|Lipid emulsion for infusion
1532710|NCT02722902|Dietary Supplement|Placebo|Saline will be used as placebo
1532711|NCT02722876|Other|Contralateral Rehabilitation|Patients will undergo resistance training of the thigh musculature of the non-injured (contralateral) limb 3 times per week. The exercises will consist of unilateral: knee extensions; knee flexions and; leg-press, all performed on commercially-available resistance training machines. To optimise strength gains, patients will work to the 5 repetition-maximum rule (Kraemer et al. 2002); 3 sets of each exercise will be performed and a 2-minute rest will separate each set. Sessions will take no longer than 15-20 minutes, including rest.
1532712|NCT02722876|Other|Placebo flexibility exercise|Patients will perform 'placebo' flexibility training of the upper limb, which will involve a time-matched stretching programme targeting the latissimus dorsi, triceps brachii, biceps brachii, trapezius and pectoral muscles of both limbs. Each stretch will be performed twice, held for 20-30 seconds each time and will be followed by a 30-second rest (McCrary et al. 2015)
1532713|NCT02722850|Behavioral|ALIVE|ALIVE is an email-based platform designed to help participants increase their physical activity, increase fruit and vegetable consumption, and decrease their intake of saturated and trans fats and added sugars. This automated system contains content and tailoring that is delivered in the form of emails obtained directly from cancer patients. Additional information they will receive included: tips for achieving those goals, health information, and opportunities for interaction and engagement.
1532714|NCT02722837|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
1532715|NCT02722824|Device|Electro-stimulation|
1532716|NCT02722824|Other|Placebo|
1532717|NCT02722811|Drug|Etanercept|etanercept of 50 mg/w, subcutaneous injection; treatment: 8 weeks
1532718|NCT02722811|Other|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 8 weeks
1532720|NCT02722785|Behavioral|Aerobic and Resistance Exercise Training|Supervised aerobic and resistance exercise program consisting of 2 weekly sessions of approximately 60 minutes. Patients will perform a test of maximum cardio-respiratory (Watt-max test) and muscle strength (1 repetition maximum [1-RM] test) capacity. Using the patient's individual capacity score (Watt-max and 1RM), a personalized exercise program will be prescribed. After a light warm-up, patients will perform 20-30 min of aerobic interval training of stationary bicycle. Resistance training comprises 4 exercises for the major muscle groups: chest press, leg press, lateral pull, and knee extension with 3-4 sets of 8 to 15 repetitions. Each session will be supervised by trained instructors to ensure proper technique, and progression in training load.
1532721|NCT02722772|Drug|Etanercept|Intra-articular injection of etanercept of 25mg/w/joint for 5 weeks.
1532722|NCT02722772|Other|Health education, exercise and diet guidance|Health education, exercise and diet guidance in patient; treatment: 5 weeks
1532724|NCT02722746|Drug|Ropivacaine|Epidural block infusion with Ropivacaine 0.2% will be provided as the anesthesia per standard of care during the procedure.
1532725|NCT02722746|Drug|Epinephrine|Participants will receive epinephrine in their epidural block infusion during the procedure. The amount of epinephrine provided during the procedure will be based on the group assignment.
1532726|NCT02722733|Drug|G-CSF (filgrastim)|
1532727|NCT02722733|Drug|Cytosine arabinoside with G-CSF (filgrastim)|
1532728|NCT02722720|Procedure|Transradial carotid artery stenting|The radial artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
1532729|NCT02722720|Procedure|Transfemoral carotid artery stenting|The common femoral artery is punctured with a trocar. A guidewire is advanced through its lumen, and the trocar is withdrawn. An introducer is passed into the vessel. Then a standard endovascular procedure is carried out under local anesthesia and fluoroscopic control. To prevent cerebral embolism, a protection device is positioned distally of target lesion in internal carotid artery. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control stent is implanted. After removing all of devices a control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix (clopidogrel) in dose 300-600 mg prescription before the procedure and heparin sodium injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and Plavix (clopidogrel) in dose 75/d should be prescribed within 2 months.
1532730|NCT02722707|Device|magnetic anal sphincter augmentation for fecal incontinence|Surgical placement of HUD called FENIX for female patients that have failed conservative therapy and less invasive therapies or who are not candidates for such therapies
1532731|NCT02722694|Drug|Subcutaneous(SC) Abatacept|Subjects received 125mg weekly SC abatacept injections for 24 weeks. All subjects who complete 24 weeks double-blind treatment are eligible to enter open label period. During this period, subjects in placebo group will be switched to receive abatacept 125mg administered SC weekly till week 52. Subjects in abatacept group will continue to receive abatacept 125mg weekly.
1532732|NCT02722694|Other|Placebo|Subjects received weekly SC placebo injections for 24 weeks
1532733|NCT02722694|Drug|Methotrexate|All Subjects received backup Methotrexate treatment.
1532734|NCT02722681|Procedure|Blood and urine sampling|Collection of blood and urine samples taken during usual clinical management
1532735|NCT02722681|Procedure|Cerebrospinal fluid sampling|Collection of cerebrospinal fluid samples taken during usual clinical management
1532736|NCT02722668|Drug|Fludarabine|Both Arms: 30 mg/m^2 IV over 1 hour Day -6 to Day -2
1532737|NCT02722668|Drug|Cyclophosphamide|Arm 1: 50 mg/kg IV over 2 hours Day -6
1532738|NCT02722668|Drug|MMF|"Both Arms:
Mycophenolate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning Day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.
Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute graft versus host disease (GVHD). (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]). If no donor engraftment, do not stop MMF."
1532739|NCT02722668|Drug|Sirolimus|"Both Arms:
Adult Dosing: Sirolimus will be administered starting at Day -3 with 8-12 mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines. In the absence of acute GVHD sirolimus may be tapered starting at Day +100 and eliminated by Day +180 post-transplantation.
Pediatric Dosing: Sirolimus will be administered starting on Day -3 with an oral loading dose of 10 mg followed by maintenance dosing of 2.5 mg/m^2/day (Maximum total daily dose of 4mg) as per institutional guidelines. Target serum concentration goals are 3 to 12 mg/mL by high-performance liquid chromatography (HPLC) and will be monitored per institutional guidelines."
1532740|NCT02722668|Radiation|TBI|Both Arms: 200 cGy on Day -1
1532741|NCT02722668|Biological|Umbilical cord blood cell infusion|Both Arms: Day 0
1532742|NCT02722668|Biological|ATG|Arm 2: 15 mg/kg IV every 12 hours Day -6 to Day -4
1532743|NCT02722642|Biological|Bronchial basal cells|Patients will receive 10^6 (1 million) /Kg/person cells of clinical grade bronchial basal cells (BBCs) injected via fiberoptic bronchoscopy after fully lavage of the localized lesions.
1532744|NCT02722629|Procedure|FEESST|Flexible Endoscopic Evaluation of Swallowing with Sensory Testing
1532745|NCT02722616|Device|Ultrasound scan of the pancreas|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the pancreas motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup can be reproduced during treatment delivery.
1532746|NCT02722616|Device|Ultrasound scan of the Liver|A 4D ultrasound scan will be acquired at the time at simulation and used as a reference ultrasound image for localizing tracking target. The ultrasound probe will be placed at the abdominal area to monitor the liver motion. The probe will remain in place during the CT scan. Patient setup and the ultrasound probe location will be recorded so that the same setup could be reproduced during treatment delivery. The ultrasound probe in the CT image will be contoured and radiation beams that directly pass through the ultrasound probe will be avoided.
1532747|NCT02722616|Drug|Reference ultrasound|A reference ultrasound scan will be conducted on each subject during breath-hold. Subjects will be required to lie in supine position and engaged with ABC; an ultrasound probe will be placed at the abdomen area with minimal pressure applied. Continuous motion monitoring is achieved by acquiring 4D ultrasound images using a motorized 3D ultrasound probe to image the pancreas, liver and other intra-abdominal organs continuously. Several 4D ultrasound scans will be collected during subsequent breath-holds that serve as secondary images.
1532748|NCT02722603|Drug|gabapentin|75 mg/ml gabapentin syrup
1532749|NCT02722603|Drug|tramadol|100 mg/ml tramadol oral drops
1532750|NCT02722603|Other|placebo tramadol|placebo tramadol oral drops
1532751|NCT02722603|Other|placebo gabapentin|placebo gabapentin syrup
1532752|NCT02722577|Procedure|Radio-frequency Ablation|A procedure that uses radiofrequency energy to destroy a small area of heart tissue that is causing rapid and irregular heartbeats.
1532753|NCT02722564|Behavioral|self estimation of breath alcohol content|
1532754|NCT02722564|Device|breath alcohol content as measured by Alco Sensor IV device|
1532755|NCT02722564|Other|drink a beer|drink a beer, repeat until breath alcohol content 0.1
1532756|NCT02722551|Device|Transcatheter Mitral Valve Re-placement (TMVR) with the CardiAQ-Edwards™ Transcatheter Mitral Valve|Replacement of the mitral valve through a transcatheter approach
1532757|NCT02722538|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)/TAR-200|TAR-200 is a passive, nonresorbable gemcitabine-releasing intravesical drug delivery system, regulated as a drug, whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7-day period.
1532758|NCT02722525|Procedure|Magnetic Resonance Imaging|Undergo treadmill stress CMR
1532759|NCT02722525|Behavioral|Exercise Intervention|Complete treadmill exercise
1532760|NCT02722525|Radiation|Gadopentetate Dimeglumine|Undergo gadopentetate dimeglumine perfusion MRI
1532761|NCT02722525|Procedure|Perfusion Magnetic Resonance Imaging|Undergo gadopentetate dimeglumine perfusion MRI
1532762|NCT02722525|Behavioral|Exercise Intervention|Complete resistive lower extremity exercise
1532763|NCT02722525|Procedure|Spectroscopy|Undergo skeletal muscle PMRS
1532764|NCT02722525|Other|Laboratory Biomarker Analysis|Correlative studies
1532765|NCT02722512|Biological|Heat Shock Protein Peptide Complex-96 (HSPPC-96)|The vaccine is patient specific, created from the patient's own brain tumor resected at a clinically necessary surgery. The vaccine is administered intradermally on a weekly basis.
1532766|NCT02722512|Procedure|Tumor Resection|Clinically-indicated removal of the tumor
1532767|NCT02722512|Radiation|Radiation|Focal Radiation Therapy
1532768|NCT02722499|Behavioral|Financial Incentive Augmented Education and Skills Training|The intervention is based on the IMB model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Subjects will receive weekly telephone-delivered diabetes knowledge/information, patient activation (list of 5 questions to ask their provider at every visit and training on how to ask the questions), patient empowerment (diabetes responsibility contracts, personal goals, and flow charts for patients to record lab results/medications and training on how to use the empowerment tools), and behavioral skills training delivered via telephone. The intervention will be delivered by telephone once a week for 12 weeks with each session lasting ~30 minutes
1532769|NCT02722486|Device|Vestibular Rehabilitation/Balance Belt|With this device, a subject stands on a force platform on the ground, which measures his/her center of pressure. Additionally, there is laptop displaying the video-based exercise programs and a camera that senses the subject's linear sway, roll, and pitch. Information about the subject's position is transmitted via Bluetooth technology to a non-invasive vibrotactile belt which fits comfortably around the subject's waist, over his/her clothing. Using the Sensory Kinetics software, the subject will play a series of games projected on the laptop screen, which prompt him/her to sway in various directions while keeping both feet planted on the force platform.
1532770|NCT02722486|Other|Standard Vestibular Rehabilitation|This is the standard three-month vestibular rehabilitation therapy that patients are routinely referred to at Boston Children's Hospital.
1532771|NCT02722473|Biological|"NSE dosage hypothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management between 33° and 37°C.
1532772|NCT02722473|Biological|"NSE dosage normothermia arm"|There 3 dosage of NSE per patient included: day 1, day 2 and day 3 during targeted temperature management at 37°C.
1532773|NCT02722447|Drug|rivaroxaban|Rivaroxaban 20 mg for 6 weeks
1532774|NCT02722447|Drug|Placebo|Placebo for 6 weeks
1532775|NCT02722434|Other|Laboratory Biomarker Analysis|Correlative studies
1532776|NCT02722434|Other|MC5-A Scrambler Therapy|Undergo Scrambler therapy
1532777|NCT02722434|Other|Questionnaire Administration|Ancillary studies
1532778|NCT02722434|Other|Transcutaneous Electrical Nerve Stimulation|Undergo TENS
1532779|NCT02722421|Drug|Levonorgestrel|Increased dose levonorgestrel implant plus efavirenz-based antiretroviral therapy.
1532780|NCT02722421|Drug|Efavirenz|Participants will receive efavirenz-based ART as part of standard of care
1532781|NCT02722408|Drug|Gemcabene 300 mg|1-300 mg tablet, QD, 28 days
1532782|NCT02722408|Drug|Gemcabene 600 mg|2-300 mg tablets, QD, 28 days
1532783|NCT02722408|Drug|Gemcabene 900 mg|3-300 mg tablets, QD, 28 days
1532784|NCT02722382|Other|Patient-Centered Kidney Transitions Care|In a multi-faceted pragmatic approach, the intervention will 1) implement new electronic health information tools to help providers recognize patents in need of Kidney Transitions Care and focus their attention on patients' values and treatment preferences; and 2) implement a Kidney Transitions Specialist who will provide and facilitate integrated delivery of patient support programs that provide patients with knowledge, skills, and assistance to manage their disease, make high-quality treatment decisions, obtain needed psychosocial support, and navigate complex treatment plans.
1532789|NCT02722356|Drug|Oxytocin|Oxytocin administered per oxytocin group or standard practice group (see above)
1532790|NCT02722343|Drug|Tenofovir intravaginal ring|The participant will wear the intravaginal ring consecutively for 14 days and nights. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
1532791|NCT02722343|Drug|Truvada|The participant will take the tablet for 14 days. taking one tablet each morning. Following study product use and at study visit 4, blood and genital tract samples will be taken (to include cervico-vaginal fluid and tissue)
1532792|NCT02722330|Device|Baha 5 SuperPower on Baha Attract System|The Investigational device involves the following parts: the sound processor unit, an actuator unit and a cable that connects the sound processor and actuator units. The actuator unit is attached to the Sound Processor Magnet (SP Magnet) of the Baha Attract System which is pulled towards the BIM400 Baha Implant Magnet that is fixated to the BI300 Implant. The actuator unit can also be connected to the Baha Softband via a snap coupling.
1532793|NCT02722317|Behavioral|psychological support|psychological support was given to men by the service, the researcher didn't interfered in the intervention, just ask questions about it.
1532799|NCT02722291|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|
1532800|NCT02722278|Drug|Oral Testosterone Undecanoate|Subjects assigned to oral TU treatment will begin at 237 mg TU twice daily. Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg < 350 ng/dL, decreased if > 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL.
1532801|NCT02722278|Drug|Axiron Testosterone Topical Solution|"Subjects assigned to Axiron treatment will begin at 60 mg Axiron every morning. Axiron is applied to the axilla only.
Serial PK samples over 24 hours will be obtained after 21 days and 56 days of treatment. Dose adjustments may be made on Day 35 and Day 70, based on the T Cavg results obtained at Day 21 and Day 56, respectively. Dose will be increased if Cavg < 350 ng/dL, decreased if > 800 ng/dL and maintained if Cavg = 350 ng/dL to 800 ng/dL."
1532802|NCT02722265|Drug|CS-3150|CS-3150 2.5mg to 5mg, orally, once daily for 28 or 52 weeks
1532803|NCT02722252|Device|Embryoscope|
1532804|NCT02722252|Device|Embryo culture system without incorporated camera|
1532808|NCT02722226|Other|Simulation|High fidelity simulation based sedation learning program
1532809|NCT02722226|Device|Airway management|Workshop on using airway management and oxygenation devices.
1532810|NCT02722226|Behavioral|Crisis resource management|Learning crisis resource management principles
1532811|NCT02722213|Behavioral|Mindfulness-Based Stress Reduction (MBSR).|MBSR is a combination of mindfulness meditation, breathing practices, gentle yoga, and other relaxation techniques; it is taught in a manualized 8-week program, does not require special equipment, and can be practiced safely by people of all abilities
1532814|NCT02722187|Procedure|subinguinal microscopic varicocelectomy|
1532815|NCT02722187|Procedure|laparoscopic varicocelectomy|
1532816|NCT02722161|Drug|[14C]BI 1482694|
1532818|NCT02722135|Drug|Volasertib|
1532819|NCT02722122|Drug|AIR DNase™|
1532820|NCT02722109|Other|No intervention|No intervention will be done
1532821|NCT02722096|Drug|Axillary block anesthesia with Ropivacaine and Lidocaine|Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
1532822|NCT02722096|Drug|Local anesthesia with Ropivacaine and Lidocaine|Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
1532823|NCT02722083|Drug|Chlorpheniramine maleate (BAY X002134)|4 mg tablet, single dose, orally
1532824|NCT02722083|Drug|Placebo|placebo tablet, single dose, orally
1532825|NCT02722070|Device|3 Tesla Siemens Skyra MRI scanner|Standardly used Magnetic resonance imaging (MRI) protocols, including resting state fMRI, task fMRI, T1 weighted imaging
1532826|NCT02722044|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
1532827|NCT02722018|Drug|GDC-0810 Phase II Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
1532828|NCT02722018|Drug|GDC-0810 Phase III Prototype Tablet|Participants will receive dose level A (in Parts 1 and 2) or dose level B (in Part 3) tablets.
1532831|NCT02721992|Other|No intervention|No intervention
1532835|NCT02721966|Biological|AIN457|Anti IL-17a monoclonal antibody
1532836|NCT02721966|Drug|AIN457 Placebo|Placebo matching AIN457
1532837|NCT02721953|Dietary Supplement|Butyrate|Butyrate
1532838|NCT02721953|Other|Placebo|Placebo
1532839|NCT02721940|Procedure|Control group|Patients in the control group will be subjected to arthroscopic debridement and microfracture surgery.
1532840|NCT02721940|Biological|Mononuclear Cells|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
1532841|NCT02721940|Biological|Platelets|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
1532842|NCT02721940|Drug|Zoledronic Acid|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
1532843|NCT02721940|Drug|Normal saline|In the treatment group, patients will be given 200 μg zoledronic acid and purified bone marrow mononuclear cells will be injected into the necrotic zone, followed by injection of 5-10 mL normal saline. Finally, the holes for core decompression will be sealed with a small amount of bone wax to prevent leakage.
1532844|NCT02721927|Other|Syrian Refugees|Adult Syrian patients who visited the Emergency Department
1532845|NCT02721914|Procedure|GROUP RECEIVING MASSOTHERAPY- HYPOPRESSIVE ABDOMINAL GYMNASTIC|The subjects of this group will receive an amount of eight sessions that will be applied within five weeks; four massotherapy sessions and another 4 of H.A.G. The three first weeks one session of each methodology will be applied, starting always with massotherapy (with sessions on Mondays and Thursdays or on Tuesdays and Fridays). On the fourth week a session of massotherapy will be applied on the same day as usual. And, finally, on the fifth week a session of H.A.G will be applied on the same day as massotherapy is applied.
1532846|NCT02721914|Procedure|GROUP RECEIVING MASSOTHERAPY|"The sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.
Massotherapy technics will be applied all over the back, covering the thoracolumbar area as well as upper areas reaching the cervix and occiput.
In particular, posterosuperior iliac spines, iliac crests, ribs, shoulder girdle and the entire spine (sacral bone- lumbar area-backbones-cervical vertebrae) and its attached tissues will be worked down.
Massotherapy protocol will be applied by the physical therapist, always respecting the postural ergonomics. This enables the verticality of the body (avoiding the slopes) which makes work much easier thanks to the inertia triggered by the load transfer in the lower extremities in both sagittal and horizontal plane."
1532976|NCT02720991|Drug|Mifepristone|200 mg of oral mifepristone
1532977|NCT02720991|Drug|Sublingual misoprostol|400 ug of misoprostol sublingually following mifepristone
1532847|NCT02721914|Procedure|GROUP RECEIVING HYPOPRESSIVE ABDOMINAL GYMNASTIC|"The subjects of this group will receive a total of 8 sessions of 20 minutes each; sessions will be applied for 5 weeks. The first three weeks 2 sessions per week will be applied (whether on Mondays and Thursdays or Tuesdays and Fridays), and during the remaining two weeks only a session will be applied per week, on the first day of the week same as applied before.
The techniques applied are an assembly of rhythm, postural and breathing exercises that have to be done in a systematically. The physical therapist will check that all of the group subjects have assimilated properly the H.A.G and the breathing patterns from the exercises protocol. If they have, then the practical session which comprises 6 hypopressive exercises, can be started.
The subjects must remain in each position between 10 and 30 seconds and repeat the exercise three times, with a rest period among each that will last at least 20 seconds."
1532850|NCT02721888|Drug|Liraglutide|
1532851|NCT02721888|Drug|MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)|
1532852|NCT02721888|Biological|Blood sample|
1532853|NCT02721888|Other|Kinetic substudy (10 patients)|
1532857|NCT02721862|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid, is FDA approved for the reduction in gallstone formation in obese patients undergoing rapid weight loss.Ursofalk is indicated in the treatment of primary biliary cirrhosis (PBC) and for the dissolution of radiolucent gallstones in patients with a functioning gall bladder.
1532858|NCT02721862|Drug|Placebo|The placebo has the same color and size as the ursodeoxycholic acid 250 mg pill
1532859|NCT02721862|Radiation|Gallbladder Ultrasound|Each patient will undergo a total of three abdominal ultrasounds (at 6 months, at 12 months, and at 18 months after sleeve gastrectomy) to check for gallstones. Patients should be gallstone free on an initial ultrasound to satisfy the study inclusion criteria. Ultrasound testing is radiation free and does not pose any additional risk to the subjects.
1532860|NCT02721849|Behavioral|Yoga for adolescents|12 week hatha yoga course for adolescents
1532861|NCT02721849|Behavioral|Yoga for parents|12 week hatha yoga course
1532862|NCT02721836|Behavioral|Yoga|Yoga intervention 12 weeks, twice weekly 75-minute intervention Yoga postures, breathing, relaxation, and meditation
1532863|NCT02721836|Behavioral|Nutrition Counselling|Evidence-based Nutrition Counselling, 3 appointments within 12 weeks
1532864|NCT02721823|Behavioral|lifestyle-modification|The group intervention is carried out once a week for 10 weeks for a total of 60 hours with elements of mindfulness-based stress reduction (MBSR) and further process of the mind / body medicine. In this project, this program will be adapted to the specific needs of colitis patients.
1532865|NCT02721823|Behavioral|Control group|Participants in this group receive a one-time education unit within the scope of 3 hours on the influence of lifestyle factors on the disease, also self-help materials for independent training offered. Following the follow-up measure also this group is given the opportunity to participate in the multimodal stress reduction- and lifestyle modification program.
1532866|NCT02721810|Behavioral|Consideration of 3-month functional prognosis|
1532867|NCT02721797|Procedure|Orthopaedic & Gynaecology surgery|Patients will have the surgery they require for their treatment. During surgery, debrided tissues will be retained for research. No treatment plans will be altered for this research.
1532868|NCT02721784|Device|mpMRI/VERDICT|Combined MRI sequences of T2, DCE, Diffusion and VERDICT
1532869|NCT02721784|Radiation|External Beam Radiotherapy|78Gy (Gray) to Prostate +/- Pelvic
1532870|NCT02721771|Procedure|Ultrasound examination|echocardiographic diastology and bilateral B-line pattern will be assessed. Optic nerve sheath diameter will be assessed.
1532871|NCT02721758|Behavioral|Brief Motivational Intervention|
1532872|NCT02721745|Behavioral|Natural Fatigue|Experimental: EEG Indirect Calorimetry Pupillometry
1532873|NCT02721745|Device|tDCS|Experimental: EEG Indirect Calorimetry Pupillometry
1532874|NCT02721745|Device|TMS|Experimental: EEG Indirect Calorimetry Pupillometry
1532877|NCT02721706|Other|CIPA nutritional screening tool|The new nutritional screening tool termed CIPA includes Control of food Intake, Protein, and Anthropometry (CIPA) results positive when at least one of the following parameters is met: control of food intake for 72 h <50%, serum albumin <3 g/dl, body mass index <18.5 kg/m2 or mid-upper arm circumference ≤ 22.5 cm.
1532878|NCT02721693|Device|Treadmill exercise test|Patients are subjected to an incremental exercise test to exhaustion on a treadmill
1532879|NCT02721680|Other|Internal Awareness Training Program|
1532880|NCT02721680|Other|External Awareness Training Program|
1532881|NCT02721667|Device|Telemonitoring|Secure, wireless transmission of home blood pressure measurements that are summarized in a secure health portal for healthcare providers use for clinical management decisions, including calculation of mean BP and graphing of temporal trends.
1532882|NCT02721667|Other|Case Management|Case managers work collaboratively with patients and physicians to optimize health behaviours, monitor risk factors, implement therapeutic adjustments, encourage adherence, and coordinate follow-up care.
1533143|NCT02719678|Other|General health checks|The intervention group is invited to up to three general health checks over a 10-year period
1532883|NCT02721654|Drug|Plasma-Lyte 148®|Plasma-Lyte 148 (approx pH 7.4) IV infusion is a sterile, clear nonpyrogenic isotonic solution & when administered intravenously it is a source of water, electrolytes & calories. Plasma-Lyte 148 intravenous infusion is indicated as a source of water & electrolytes or as an alkalinising agent.
1532884|NCT02721654|Drug|0.9% sodium chloride|The active ingredient is sodium chloride formulated in Water for Injections. The chemical name is sodium chloride with molecular formula NaCl. Sodium Chloride (0.9%) intravenous infusion preparation is a sterile & non-pyrogenic solution & is indicated for extracellular fluid replacement & in the management of metabolic alkalosis in the presence of fluid loss, & for restoring or maintaining the concentration of sodium & chloride ions. As sodium chloride intravenous infusion is administered to the systemic circulation by intravenous infusion, the bioavailablity (absorption) of the active components is complete (100 per cent).
1532885|NCT02721641|Drug|Herceptin|Herceptin will be administered as either 2 milligrams per kilogram (mg/kg) once weekly (first dose as a 4-mg/kg loading dose) or 6 mg/kg every 3 weeks (first dose as an 8-mg/kg loading dose) via IV infusion over 90 minutes.
1532886|NCT02721628|Procedure|Epi-keratoplasty|Femtosecond laser assisted Epi-keratoplasty
1532887|NCT02721628|Procedure|Collagen Cross-Linking|Collagen Cross-Linking: Standard procedure, which is descriptor bellows: Corneal epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated by a UVA light for 3mW/cm2 during 30 minutes
1532888|NCT02721628|Device|Femtosecond laser|Use in the epic-keratoplasty surgery
1532889|NCT02721615|Procedure|Insertion of intra spinal sub dural pressure monitor|
1532890|NCT02721615|Procedure|Insertion of sub dural microdialysis probe|
1532891|NCT02721602|Behavioral|Families Preventing Diabetes Together|Families in the intervention group will be asked to participate in four in-person sessions at a local Fairview North metropolitan area clinic over the course of two months. Sessions will focus on age-appropriate nutrition and diabetes education, meal planning and cooking skills, healthful eating, and eating meals as a family. All family members will be asked to attend and will be involved in all four, two-hour sessions. The parent with diabetes will also complete one goal setting telephone call based on motivational interviewing techniques during the intervention period.
1532892|NCT02721589|Drug|SHR-1210|PD-1 antibody
1532893|NCT02721576|Drug|Sodium Glycididazole|Sodium Glycididazole 800mg/m2.Three times a week (once every other one day),before radiation therapy, total 5-6 weeks.
1532894|NCT02721563|Drug|Sodium Glycididazole|Sodium Glycididazole 700mg/m2.Three times a week (once every other one day),before radiation therapy, total 6 weeks.
1532895|NCT02721563|Drug|Placebo|Placebo:three times a week (once every other one day),before radiation therapy, total 6 weeks.
1532896|NCT02721550|Drug|Sodium Glycididazole|800mg/m2，dissolved in 100ml physiological saline(Now with chef),ivgtt,finished in 30 minutes,within 60 minutes after intravenous drip for radiation therapy.Three times a week (once every other one day),before radiation therapy, total 4 weeks course.
1532897|NCT02721537|Dietary Supplement|Nicotinamide Riboside|Three capsules, twice per day for 84 days
1532898|NCT02721537|Other|Matching placebo|Three matching capsules, twice per day for 84 days
1532899|NCT02721524|Procedure|Tricuspid Annuloplasty|Patients will undergo repair of tricuspid regurgitation
1532900|NCT02721511|Drug|Furosemide Injection Solution 8mg/mL|Furosemide Injection Solution, 8 mg/mL, (total dose =80 mg) administered subcutaneously as 30 mg over the first hour and then as 12.5 mg per hour over the subsequent 4 hours by means of the B. Braun Perfusor® Space Infusion Pump System.
1532901|NCT02721498|Procedure|Airway clearance session using the Active Cycle of Breathing Techniques (ACBT)|An airway clearance technique incorporating thoracic expansion exercises, breathing control (normal diaphragmatic breathing) and the forced expiration technique (or huffing)
1532902|NCT02721498|Other|Rest period|A 30-60 minute of resting
1532903|NCT02721485|Other|Ringer's Lactate|After a 28 day washout, participating hospitals will be crossed over to using Ringer's Lactate as 250, 500 or 1000 ml boluses or infusions as specified by the treating physicians for the second 90-day test period.
1532904|NCT02721485|Other|Normal Saline|After a 28 day washout, participating hospitals will be crossed over to using Normal Saline as 250, 500 or 1000 ml boluses or infusions as specified by the treating physicians for the final 90-day test period.
1532905|NCT02721472|Procedure|micro- and macro-circulatory vascular remodelling measures not practice in routine care|Vascular measures : reactive hyperaemia index (RHI) assessed by Endo-PAT, central aortic blood pressure, aortic augmentation index, carotid-femoral pulse wave velocity
1532906|NCT02721472|Procedure|Biological measures not practice in routine care|Biological measures : Plasma DNA level, NETs (plasma nucleosome levels), Microparticules (MPs) (total, associated with red blood cells, neutrophils, platelets), haem (total and bound to MPs), Myeloperoxydase and elastase activity, neutrophils/DNA, RNA and TSP1
1532907|NCT02721459|Drug|XL888|"Level 1: XL888 30 mg by mouth (PO) twice weekly (BIW). Level 2: XL888 45 mg PO BIW.
Level 3: XL888 60 mg PO BIW. Level 4: XL888 90 mg PO BIW."
1532908|NCT02721459|Drug|Vemurafenib|Vemurafenib 720 mg by mouth twice a day (BID)
1532909|NCT02721459|Drug|Cobimetinib|Cobimetinib 40 mg by mouth once daily (QD). Administered 3 weeks on, 1 week off.
1532910|NCT02721446|Behavioral|Standard|"Investigators will develop a standard informational stroke risk message that will not undergo iterative review. This will inform the patient that based on information in the healthcare system, the patient is at higher risk of stroke than many others receiving care in the patient's healthcare system; it will describe options for working with their health care team to reduce the risk of stroke; and encourage the patient to call the health navigator to discuss these options and make a decision about next steps to take to reduce the patient's risk of stroke."
1532911|NCT02721446|Behavioral|Incentive|Investigators anticipate that the baseline incentive stroke risk message will inform the patient that they are at higher risk of stroke than many others receiving care in the patient's healthcare system, and will provide information about obtaining an incentive if the patient calls to make contact with a health navigator who will help them plan a next step to reduce their stroke risk. The investigators also anticipate including information that all patients who call will also be entered in a random drawing to receive an additional incentive, with up to six patients receiving this incentive.
1533181|NCT02718430|Drug|VXM01|Oral immunotherapy targeting VEGFR2
1532912|NCT02721446|Behavioral|Salience|"Investigators anticipate that the baseline salience stroke risk message will inform the patient that they are at higher risk of stroke than many other patients receiving care in the patient's healthcare system, and will specifically focus on the patient's own risk factors (rather than all stroke risk factors). The salience message will also include visual depictions of stroke patients that are gender and ethnically matched to each subject. This is intended to prompt action by emphasizing that stroke is a real possibility for patients like me."
1532913|NCT02721446|Behavioral|Incentive + Salience|Combined message of incentive plus salience.
1532914|NCT02721433|Drug|Pamidronate|Bone-targeted agent as standard of care
1532915|NCT02721433|Drug|Denosumab|Bone-targeted agent as standard of care
1532916|NCT02721433|Drug|Zoledronate|Bone-targeted agent as standard of care
1532917|NCT02721420|Drug|dihydroartemisinin-piperaquine|
1532918|NCT02721420|Other|message(SMS) reminder|
1532919|NCT02721420|Other|Health worker reminder|Health surveillance assistants reminders prior to each treatment course
1532920|NCT02721420|Other|short message(SMS) reminder|
1532921|NCT02721407|Drug|Retroviral vector-transduced autologous T cells to express CD22-specific CARs|
1532922|NCT02721394|Behavioral|Functional Communication Training|Functional Communication Training (which aims to teach the child a communicative alternative to challenging behaviour) implemented by either the researcher or family carer.
1532923|NCT02721381|Behavioral|ImPACT Online|ImPACT Online is an interactive, web-based telehealth intervention that teaches parents to promote their child's social-communication skills during play and daily routines. The intervention content was adapted from Project ImPACT, a manualized parent training curriculum that uses a blend of developmental and naturalistic behavioral intervention techniques, including following the child's lead, imitating the child, using heightened animation, using simplified language around the child's focus of attention, environmental arrangement strategies, prompting, and natural reinforcement during child-directed activities. There is strong empirical support for the intervention techniques for increasing social communication in children, increasing parent fidelity, and child language skills.
1532924|NCT02721368|Device|Neuramis® Volume Lidocaine|hyaluronic acid filler
1532925|NCT02721368|Device|Juvederm® Voluma® with Lidocaine|hyaluronic acid filler
1532926|NCT02721355|Dietary Supplement|GastimunHP|Health food supplement containing specific IgY against urease of H. pylori
1532927|NCT02721342|Drug|Ramipril, Irbesartan and Atorvastin|
1532928|NCT02721329|Device|APAP|Automatic Continuous Positive Airway Pressure
1532929|NCT02721329|Device|APAP with SensAwake|Automatic Continuous Positive Airway Pressure with SensAwake enabled. SensAwake is a pressure relief technology that detects the transition from sleep to wake, and promptly reduces the pressure during wakeful periods.
1532930|NCT02721316|Other|Supported with intensive nursing follow post hospitalization|Intensive nursing follow post - hospitalization
1532931|NCT02721303|Dietary Supplement|3-day diet Run-in|Participants will be studied on one occasion after a 3-day diet run-in. This will be followed by a breakfast meal.
1532932|NCT02721303|Procedure|fMRI|After a 3-day diet run-in, participants will undergo a functional magnetic resonance imaging procedure (fMRI). Repeat fMRI will be performed 30 minutes after the meal.
1532933|NCT02721303|Procedure|Intravenous catheter placed for blood draws|On the study day participants will present in the fasting state, have an intravenous catheter placed for blood draws and have baseline blood samples taken. Blood and appetite measures will be performed every half hour for 3 hours.
1532934|NCT02721290|Procedure|Femoral nerve block using Ultrasound and neurostimulator|
1532935|NCT02721290|Procedure|Femoral nerve block using Ultrasound|
1532936|NCT02721290|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% (20cc total) will be injected for the performance of the block in the two arms of the study.
1532937|NCT02721277|Drug|SMOFlipid|SMOFlipid contains a mixture of 4 different lipid sources: soybean oil which provides essential fatty acids, olive oil which is high in monounsaturated fatty acids that are less susceptible to lipid peroxidation than polyunsaturated fatty acids, medium-chain triglycerides which show a faster metabolic clearance than long-chain triglycerides, and fish oil which provides the supply of omega-3 fatty acids.
1532938|NCT02721264|Biological|Fecal Microbiota Transplant|
1532939|NCT02721264|Other|Standard Medical Treatment|
1532940|NCT02721251|Behavioral|Exercise|16 weeks. 4 days per week of aerobic exercise; 45 min for 2 days and for 30 min for two days. 2 days per week of resistance exercise for 15 min (coinciding with the days involving 30 min of aerobic exercise)
1532941|NCT02721251|Behavioral|Weight Loss|16 week. the goal is 10% weight loss.
1532942|NCT02721251|Behavioral|Exercise + Weight Loss|Combined exercise and weight loss components of the other arms
1532943|NCT02721238|Biological|20% Albumin|
1532944|NCT02721238|Other|Plasmalyte|
1532945|NCT02721225|Dietary Supplement|Fructooligosaccharide|"A prebiotics defined as selectively fermented ingredients that allow specific changes, both in the composition and/or activity in the gastrointestinal microbiota that confers benefits upon host well-being and health"
1532946|NCT02721225|Dietary Supplement|Pocari-Sweat|Commercially used isotonic solution produced by Otsuka Pharmaceuticals Co. Ltd., Tokyo, Japan.
1532947|NCT02721212|Device|Armeo Spring|"All patients of experimental group were treated according to an established protocol for ARMEO Spring. In the first session the device was adjusted for patients arms. The physiotherapist controlled functional space of upper limb movement and correct position of working station.
Each training session consisted of two parts with 30 minutes per session with Armeo Spring and 30 minutes per session with conventional treatment 5 days per week, for 6 weeks."
1532948|NCT02721212|Other|Conventional Rehabilitation|"The conventional treatment, under control of physiotherapist, consists of passive and active assisted mobilization of the upper limbs traditional training based on the Bobath concept (neuromuscular facilitation, postural control and proprioception exercises, verticalization and gait training).
Each training session consisted of 60 minutes with conventional treatment 5 days per week, for 6 weeks in a control group.
The conventional session in the experimental group lasted 30 minutes with the same techniques and methods."
1532949|NCT02721199|Other|Neural Respiratory Drive Automated EMGpara assessment|Neural respiratory drive will be measured using surface electrodes and nasal cannula . The 2nd intercostal space will be identified by bony landmarks and skin preparation will be performed using detergent wipes, followed by EMG preparation gel with final cleaning to remove exfoliated skin. Wet gel electrodes will be placed immediately adjacent to the sternal border in the 2nd intercostal space and will be connected to the automated EMG analysis system. Electrodes will remain in place for the duration of the study. A nasal cannula will be placed in the nose and detect pressure changes during respiration in order to ensure accurate detection of inspiratory cycle. In addition, an accelerometer will be attached to the thorax of the patient
1532950|NCT02721186|Drug|MDA with DHAp and SLD Primaquine|
1532951|NCT02721173|Drug|Tazarotene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and tazarotene will be applied 5-10 minutes later.
1532952|NCT02721173|Drug|Adapalene 0.1% gel plus clindamycin 1% gel|Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
1532953|NCT02721160|Other|Nutrition PBF|"Nutrition PBF focuses on children under five years old. It follows the standard PBF model in Burundi and combines quantitative indicators to encourage an increase in service delivery (see Table below) and qualitative indicators. Quality of nutrition activities is assessed quarterly, and a bonus or penalty is applied to subsidies received by the facilities according to their quality score.
Table: Incentivized indicators
CHW level
nb of cases screened and referred to HC for acute malnutrition (AM)
nb of classes promoting good nutrition
HC level
nb of cases screened and cared for severe and moderate AM
nb of growth follow-ups
Hospital level
nb of treated severe AM cases with complications
length of the stay
All hospitals with nutrition services fall under the Nutrition PBF program. At lower levels, only HCs in the intervention group and the CHW that refer to them are subject to the Nutrition PBF."
1532954|NCT02721147|Behavioral|Intimacy Enhancing Intervention|Participants attend 4 intimacy enhancement intervention sessions over 75 minutes every other week for 4 weeks. The intimacy enhancement intervention comprises 4 main sessions: understanding impact of breast cancer on sex and intimacy, communication about sex/intimacy, problem-solving and changing thoughts, and planning ahead and preparing for challenges. Participants are encouraged to participate in written and behavioral activities at home.
1532955|NCT02721147|Behavioral|Educational Control|Participants receive educational information and support about breast cancer every other week for 4 weeks. The educational information and support comprises topics about breast cancer, its treatments, sleep, energy, stress, stress management, nutrition, and diet. Participants are encouraged to read educational materials.
1532956|NCT02721147|Behavioral|Partner-Assisted Coping Skills Training|Receive couple-based intimacy enhancement intervention
1532957|NCT02721147|Behavioral|Behavioral, Psychological or Informational Intervention|Receive educational information and support
1532958|NCT02721134|Other|additional blood tubes|four whole blood tubes 5 ml (2 + EDTA tubes separating gel and dry tubes 2 + separating gel ) will be taken in order to assay more bacterial biomarkers on day 0 , J1, J2, J3 and J5
1532959|NCT02721121|Procedure|circumferential pulmonary vein isolation|
1532960|NCT02721121|Procedure|Linear ablation in addiction to circumferential pulmonary vein isolation|
1532961|NCT02721108|Behavioral|Mindfulness meditation|The meditation content is a structured and progressive course, layering in new techniques and concepts over successive sessions. The course was created and narrated by a former monk - Andy Puddicombe - drawing on a secularised version of the techniques he was taught over 10 years' experience in monasteries around the world. The first 30 days cover basic techniques, assuming no previous experience of meditation. The second 30 days focus specifically on the use of these techniques with respect to pain. The duration of individual sessions builds over time. Days 1-10 are 10 minutes in duration, days 11-20 are 15 minutes in duration, and days 21-60 are 20 minutes in duration.
1532962|NCT02721108|Behavioral|Relaxation app|The Active Control group will use the same app, but the app will be configured so that they will hear a series of non-meditative progressive muscle relaxation instructions, also narrated by Andy Puddicombe. These sessions will be identical every day, except that their duration will increase to mirror the increasing duration of the meditation content being listened to by the Intervention group.
1532963|NCT02721095|Other|KCl plus 0.9%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
1532964|NCT02721095|Other|KCl plus 0.45%NaCl|comparison of KCl plus 0.9%NaCl and KCl plus 0.45%NaCl for correction of hypokalemia
1532965|NCT02721082|Behavioral|Treatment Program|UKanQuit staff will complete a treatment plan for participant's who are ready to quit smoking. For patient's not ready to quit, motivational counseling will be provided to participants based on principles of Motivational Interviewing.
1532966|NCT02721082|Behavioral|Counseling|UKanQuit staff provide cessation-focused counseling to smokers ready to quit and motivational counseling for those not ready to quit.
1532967|NCT02721082|Drug|Nicotine Replacement Therapy|Participants ready to quit will be provided with a 14 day supply of the nicotine patch or nicotine mini-lozenges, depending on study related criteria.
1532968|NCT02721069|Drug|NRL-1|
1532969|NCT02721056|Radiation|NBTXR3, IL or IA injection + SBRT|Patients will receive a single administration of NBTXR3 on day of injection, as intralesional or super selective transcatheter arterial injection activated by Stereotactic Body Radiation Therapy starting 24 hours post injection. The total radiotherapy dose will be maximum 45 Gy, delivered as three fractions of 15 Gy each max, over 5 to 7 days (45 Gy, 3x15 Gy, over 5 to 7 days).
1532970|NCT02721043|Biological|Peptides|Each subject will receive ten (10) total doses of PGV001. PGV001 will be administered on study visit: v4, v6, v8, v10, v12, v14, v16, v18, v20 and v22.
1532971|NCT02721043|Drug|Poly-ICLC|Each subject will receive ten additional (10) total doses of the Poly-ICLC. The additional Poly-ICLC dose will be administered on study visit: v5, v7, v9, v11, v13, v15, v17, v19, v21 and v23.
1532972|NCT02721043|Drug|Lenalidomide|10mg once daily oral dose for maintenance therapy in multiple myeloma patients.
1532973|NCT02721017|Device|Cryoanalgesia|
1532974|NCT02721017|Drug|Thoracic epidural (ropivicaine, fentanyl)|
1532975|NCT02721004|Drug|Tocilizumab|Tocilizumab administered as an intravenous infusion every 4 weeks according to product label/per standard practice for a maximum of 12 months will be observed in this study.
1532978|NCT02720978|Drug|Intravenous oxytocin|"Intravenous oxytocin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.
Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
1532979|NCT02720978|Drug|vaginal prostaglandin|"Vaginal prostaglandin chosen randomly. we will collect basic and obstetric data, laboratory results and physical examination, monitoring and sonar.
Induction according to departmental protocol of each delivery way. Data collecting after the delivery."
1532980|NCT02720965|Other|Remote-controlled perineural local anesthetics delivery|Remote-controlled perineural local anesthetics delivery
1532981|NCT02720952|Drug|Infacort®|dry granule formulation of hydrocortisone
1532982|NCT02720926|Drug|Xeloda,|Capecitabine (xeloda): 2000mg/m2, twice a day on Day 1-14;
1532983|NCT02720926|Drug|Oxaliplatin|Oxaliplatin: 130mg/m2 day 1 every 21days
1532984|NCT02720926|Drug|TKI258|4 dose levels of TKI258: 200mg, 300mg, 400mg, 500mg once daily, 5days on and 2 days off;
1532985|NCT02720913|Device|COR-KNOT|The COR-KNOT device was developed to make suture fixation faster and save operative time. With a single squeeze of the lever, the device remotely and automatically secures sutures with a titanium fastener, while also simultaneously trimming excess suture tails.
1532986|NCT02720913|Procedure|Standard Suture Tying|Standard Suture Tying
1532987|NCT02720900|Dietary Supplement|B-GOS|1.8 g/day for 6 weeks
1532988|NCT02720900|Dietary Supplement|Maltodextrin|1.8 g/day for 6 weeks
1532990|NCT02720874|Behavioral|Rheumatoid arthritis educational booklet|Participants will receive a low-literacy rheumatoid arthritis educational booklet that provides general disease state information.
1532991|NCT02720874|Behavioral|Multidisciplinary rheumatologic care|At each regularly scheduled clinic appointment, participants will receive treatment from their assigned rheumatologist, undergo an in-clinic physical therapy evaluation and, if indicated, a psychological evaluation. Physical therapy and psychology follow-up sessions will occur as directed by the individual services.
1532992|NCT02720874|Behavioral|Nurse education and monthly calls|Participants will meet one-on-one with a rheumatology nurse for a tailored educational session encompassing disease state education, an introduction of the treat to target concept, an overview of treatment options, and goal setting and planning. During monthly follow-up calls, participant educational needs will be addressed; goal setting, planning and review will also be conducted.
1532993|NCT02720874|Behavioral|Monthly healthcare coordinator calls|During monthly calls with the healthcare coordinator, specific questions and concerns raised by participants may be addressed. The primary purpose of these calls is to control for potential benefit derived from time on the phone with a health professional.
1532994|NCT02720874|Behavioral|Technology-based symptom monitoring and reporting|When at home patient self-monitoring reports indicate a significant increase in RA disease activity, participants will be promptly contacted and scheduled for an ad hoc evaluation with their treating rheumatologist.
1532995|NCT02720861|Genetic|DNA sequencing|withdraw 3m blood from vein only once during the whole design to analyse on DNA sequencing on RNF213 rs112735431 Gene
1532996|NCT02720848|Device|Stiffening wire|The stiffening wire will be inserted into the double/single balloon enteroscope.
1532997|NCT02720848|Device|Standard technique|The double/single balloon enteroscope will be used without the stiffening wire as per standard technique.
1532998|NCT02720822|Drug|Placebo|Treatment with placebo is given as one double-blind capsule in the morning.
1532999|NCT02720822|Drug|Morphine Sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
1533000|NCT02720822|Drug|Plus laxative (Docusate with senna)|If patients are taking morphine, a laxative will be offered. This applies whatever the dose of morphine being taken (8mg, 16mg, 24mg or 32 mg).
1533001|NCT02720822|Drug|Plus placebo laxative|If the patients are taking placebo, a placebo laxative will be offered.
1533002|NCT02720822|Device|FitBit charge HR (Accelerometer)|A Fitbit will be worn by patients during week 1 and week 3.
1533003|NCT02720796|Other|PDX drug sensitivity testing|Patient derived xenograft (PDX) models will be developed for each patient and drug activity assessed in their personalized PDX model. PDX drug sensitivity information will be provided to the treating physician.
1533004|NCT02720783|Drug|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary|Econazole nitrate 150 mg plus Benzydamine HCl 6 mg vaginal pessary
1533005|NCT02720783|Drug|Placebo plus Econazole nitrate 150 mg vaginal pessary|
1533006|NCT02720783|Drug|Placebo plus Benzydamine HCl 6 mg vaginal pessary|
1533007|NCT02720783|Drug|Placebo vaginal pessary|
1533008|NCT02720770|Drug|norditropine simplex|
1533014|NCT02720705|Drug|Dexmedetomidine|oral dexmedetomidine
1533015|NCT02720705|Drug|saline|2ml 0.9% saline administered orally half an hour before induction of anesthesia
1533016|NCT02720692|Drug|N1539|
1533017|NCT02720692|Drug|Intravenous Placebo|
1533018|NCT02720666|Drug|K-001|In case of severe adverse reactions associated with the test drug, or if half of the participants show adverse reactions at Ⅲ level and above, the test should be terminated. The maximum dosage not causing the above-described situation shall be considered as the maximum tolerated dose or the biologically effective dose. After the test, continuous medication shall be given upon request from patients.
1533019|NCT02720653|Procedure|Endoscopic sinus surgery|
1533020|NCT02720640|Device|Implant 'on' vs implant 'off'|Single group assignment
1533021|NCT02720627|Drug|cortexolone 17α-propionate|CB-03-01 cream is a topical steroidal antiandrogen that is being developed for the potential treatment of acne vulgaris, an androgen-dependent skin disorder.
1534122|NCT02712528|Drug|remifentanil-based|
1533023|NCT02720601|Drug|Irinotecan & Capecitabine|Irinotecan will be administered at infusion room over 60 minutes. Capecitabine will be administered by the patients at home. Unless there is early progression of disease, at least two courses will be administered to each patient. Repeated courses may be given to the patients who benefit from the treatment (either complete or partial remission, or stabilization of disease)
1533024|NCT02720575|Other|Consumption of capsule/bread with vitamin D|
1533025|NCT02720549|Procedure|remote ischemic postconditioning|Remote ischemic postconditioning post group will take a remote ischemic postconditioning with tourniquet in their lower extremity under thigh. The conditioning is 5 minutes of inflation, and 5 minutes of deflation, repeated 3 cycles.
1533026|NCT02720549|Procedure|valvular surgery with bypass|valvular surgery with bypass
1533027|NCT02720536|Drug|Deferasirox|Deferasirox FCT will be provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
1533030|NCT02720510|Drug|Revlimid|Revlimid is used with dexamethasone to treat patients with multiple myeloma
1533031|NCT02720510|Drug|Velcade|Velcade is a proteasome inhibitor indicated for treatment of patients with multiple myeloma
1533032|NCT02720510|Drug|dexamethasone|Dexamethasone is a steroid used to treat patients with multiple myeloma.
1533033|NCT02720510|Drug|Farydak|FARYDAK® (panobinostat) capsules is a prescription medicine used, in combination with bortezomib and dexamethasone, to treat adults with a type of cancer called multiple myeloma after at least 2 other types of treatment have been tried.
1533034|NCT02720497|Behavioral|60-minute Prolonged Exposure Therapy|This treatment condition is a modified version of Prolonged Exposure therapy for PTSD. It consists of weekly weekly 60-minute sessions, with 20 minutes imaginal exposure.
1533035|NCT02720497|Behavioral|90-minute Prolonged Exposure Therapy|Prolonged Exposure Therapy for PTSD consists of weekly 90-minute sessions, with 40 minutes imaginal exposure.
1533036|NCT02720484|Other|Laboratory Biomarker Analysis|Correlative studies
1533037|NCT02720484|Drug|Nivolumab|Given IV
1533038|NCT02720471|Drug|Locoregional anesthesia|classical analgesia by ultrasound guidance by blocks of the femoral and cutaneous nerves side of the thigh
1533039|NCT02720471|Drug|peroperative infiltration of local anesthetics|peroperative infiltration of local anesthetics
1533040|NCT02720458|Other|Standardized gradual hypnotic taper|The gradual hypnotic taper is standardized and is adjusted depending on the hypnotic treatment and the initial weekly dose. The practitioner will give to the patient a calendar for the taper period with the specific dose for each day (name of hypnotic, quantity and dose of pills).
1533041|NCT02720458|Behavioral|Short-term simple self-help program|"The short-term simple self-help program consists in:
Restriction of time in bed
Stimulus control instructions
The restriction of time in bed would be delivered by an e-health tool (web site). The patient will have to connect to the web site with an individual connexion password. He will connect every day to complete an on-line sleep diary during the period of the simple short-term behavioural program (5 weeks). After this period, patients will have the choice to continue connecting to the website and using the program or to stop using the program."
1533044|NCT02720432|Other|CIMT|Constraint-induced movement therapy
1533045|NCT02720432|Other|HABIT|hand-arm bimanual intensive training
1533046|NCT02720432|Other|baby-massage|instructions for baby-massage
1533047|NCT02720406|Drug|Intravenous ketamine0.5mg/kg|Intravenous ketamine 0.5mg/kg after anesthesia and before surgery.
1533048|NCT02720406|Drug|Nebulized Ketamine 0.5mg/kg|Nebulized Ketamine 0.5mg/kg given by neutralizer before anesthesia.
1533049|NCT02720406|Drug|Nebulized Ketamine 1mg/kg|Nebulized Ketamine 1mg/kg given by neutralizer before anesthesia.
1533050|NCT02720393|Other|No-carrageenan diet|Diet of food items that have no carrageenan as selected by study dietician.
1533051|NCT02720393|Other|Regular Diet|Diet of food items that have carrageenan as selected by study dietician
1533052|NCT02720380|Other|Buteyko|Intervention will be held twice a week during 3 weeks.
1533053|NCT02720380|Other|Asthma education|Educational interventions in relation to asthma will be given to children assigned to the control group.
1533054|NCT02720367|Drug|Gemcitabine-Releasing Intravesical System (GemRIS)|GemRIS is a passive, nonresorbable gemcitabine-releasing intravesical system whose primary mode of action is the controlled release of gemcitabine into the bladder over a 7 day period.
1533056|NCT02720341|Device|ARMin|single sessions of about one hour each
1533057|NCT02720328|Biological|Blood samples for DOAC measurement|
1533058|NCT02720315|Procedure|Intensive cryotherapy|Application of ice inside a plastic bag wrapped to the patient's site of pain, and held in place for 20min.
1533059|NCT02720302|Behavioral|SOFT|SOFT is based on systemic and solution-focused theories to change lifestyle and has shown positive effects on children with respect to the degree of obesity, physical fitness, self-esteem and family functioning.
1533060|NCT02720302|Behavioral|TeleSOFT|The therapists communicate with the overweight child and his/her family by the SOFT method on distance by use of video.
1533061|NCT02720289|Other|Video-based social learning class|Brief child passenger safety lecture by a child passenger safety technician and viewing of a car seat video.
1533062|NCT02720289|Other|Traditional didactic class|Child passenger safety lecture by a child passenger safety technician.
1533107|NCT02719964|Other|Visual Attention Program (UCR Games)|This program is an individual-directed computerized cognitive rehabilitation program based on perceptual learning approaches to enhance visual attention. Training incorporates a diverse set of stimuli, optimized stimulus presentation, multisensory facilitation, and consistently reinforcing training stimuli. This will be completed in a group setting with an instructor available to facilitate questions.
1533271|NCT02718742|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1533272|NCT02718742|Other|Quality-of-Life Assessment|Ancillary studies
1534123|NCT02712528|Drug|sevoflurane-sufentanil balanced|
1533063|NCT02720276|Other|Training after acute stroke|Outdoor walking: Participants will receive daily training instructions via Short message Service (SMS) over 12 weeks. The walks are increased in frequency and intensity. The intensity are rated using the Borg scale to 12-15. The first 2 weeks begins with daily walks of 10 minutes. The last 4 weeks the walk training will partly be performed in intervals in combination with conventional outdoor walks. The interval training includes warming-up (5 minutes), fast walking for 4 minutes alternated with slower walking for three minutes. This is repeated 3 times, followed by cooling down for about five minutes. Strength training: to repeatedly get up from sitting. Number of repetitions will increase from 5-20 per set and will be performed daily in 3 sets with a short rest between each set.
1533064|NCT02720263|Drug|ASP4345|Oral
1533065|NCT02720263|Drug|Matching Placebo|Oral
1533066|NCT02720250|Dietary Supplement|Omega-3 chicken eggs|Intake of 3 omega-3 fatty acids enriched chicken eggs per day for three weeks.
1533067|NCT02720250|Dietary Supplement|Regular chicken eggs|Intake of 3 regular chicken eggs per day for three weeks.
1533068|NCT02720237|Behavioral|Brief Intervention|In-person individual sessions (occurring one month apart) and booster phone sessions (occurring 2-3 weeks after each in-person session), delivered by a trained counselor.
1533069|NCT02720237|Behavioral|Motivational Enhancement Therapy (MET) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
1533070|NCT02720237|Behavioral|Cognitive Behavioral Therapy (CBT) Intervention|In-person individual sessions (one session per week) and optional group sessions, delivered by a trained counselor.
1533071|NCT02720224|Drug|Estetrol|15 mg [14C]-estetrol containing approximately 2.8 MBq (76 μCi) 14C
1533072|NCT02720211|Device|Gray tinted spectacle lenses|A neutral gray optical tint designed to block all wavelengths in the visible spectrum
1533073|NCT02720211|Device|Thin-Film spectacle lenses|A thin film optical notch filter designed to block 480-nm light in the visible spectrum
1533074|NCT02720198|Drug|Levomilnacipran|treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
1533075|NCT02720198|Drug|Quetiapine|Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
1533076|NCT02720185|Drug|Dasatinib|100mg oral once daily dasatinib taken for 7-10 days up to the day prior to planned surgery or research biopsy (neoadjuvant chemotherapy group)
1533077|NCT02720185|Procedure|Conventional Surgery|Undergo surgery
1533078|NCT02720185|Other|Laboratory Biomarker Analysis|Correlative studies
1533079|NCT02720172|Behavioral|Early Home Exercise Program|The early home exercise program is a 6-week program of home exercises with weekly phone calls to monitor progression and compliance.
1533080|NCT02720172|Other|Usual Care|Usual care involves standard postoperative management under the direction of the treating surgeon.
1533081|NCT02720159|Device|Percutaneous Osseintegrated Prosthesis|
1533082|NCT02720133|Biological|biochemical parameters|"patients will be collected for analysis of blood standard examinations such as blood glucose, electrolytes (potassium, sodium, magnesium calcium), renal function and also the blood count, platelet aggregation.
All these tests should be practice before, during and after Ramadan fasting for comparison."
1533083|NCT02720120|Drug|Ocrelizumab|Participants will receive single IV infusion of ocrelizumab at 400, 1000, 1500, and 2000 mg.
1533084|NCT02720120|Drug|Placebo|Participants will receive single IV infusion of placebo.
1533085|NCT02720107|Other|Sampling of blood and urine|Sampling of blood and urine - primarily for biomarker analyses
1533086|NCT02720094|Drug|Cabotegravir tablets|30 mg tablets
1533087|NCT02720094|Drug|TDF/FTC tablets|300 mg/200 mg fixed-dose combination tablets
1533088|NCT02720094|Drug|TDF/FTC placebo tablets|
1533089|NCT02720094|Drug|CAB placebo tablets|
1533090|NCT02720094|Drug|CAB LA|Administered as one 3 mL (600 mg) IM injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
1533091|NCT02720094|Drug|Placebo for CAB LA|Administered as one 3 mL (600 mg) injection in the gluteal muscle at two time points 4 weeks apart and every 8 weeks thereafter
1995943|NCT02607306|Drug|insulin degludec|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
1995944|NCT02607306|Drug|liraglutide|Injected s.c. / subcutaneously (under the skin) once daily (OD) , in combination with pre-trial OAD (oral antidiabetic drug)kept in unchanged dose.
1995945|NCT02608476|Drug|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
1533098|NCT02720055|Other|Psychological workbook|
1533099|NCT02720055|Other|Basic information workbook|Basic rehabilitation information that represents current practice.
1533100|NCT02720042|Device|Phasix™ Mesh|A resorbable mesh prepared from poly-4-hydroxybutrate (P4HB)
1533101|NCT02720029|Device|pH/impedance monitor|Placement of pH/impedance monitor via the nasogastric route with monitoring for 24 hours, followed by removal.
1533102|NCT02720016|Behavioral|CBCT-Home Based (CBCT-HB)|Couples in CBCT-HB will receive 15 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks to the Veterans home via home-based clinical video teleconferencing (CVT).
1533103|NCT02720016|Behavioral|CBCT-Office Based (CBCT-OB)|Couples in CBCT-OB will receive 15 sessions of standardized Cognitive-Behavioral Conjoint Therapy (CBCT), a manualized couple-based intervention for PTSD designed to simultaneously reduce PTSD and enhance relationship and functioning. The psychotherapy is administered over 8 to 15 weeks in-person in the therapist's office.
1533105|NCT02719990|Drug|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously twice-monthly
1533273|NCT02718729|Procedure|Laparoscopic resection for rectal cancer|Formal curative radical laparoscopic rectal resection.
1995946|NCT02608476|Drug|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
1533108|NCT02719964|Other|Speech Pathologist-Directed Therapy|This is a speech pathologist-directed arm and will provide a traditional clinician-directed individualized cognitive rehabilitation program. Cognitive treatment is a systematic, functionally oriented program of therapeutic activities that focuses on strengthening previously learned patterns of behavior, establishing new patterns through use of internal and external compensatory cognitive strategies, and enabling the individual to adapt to the changes in his or her revised approaches to cognitive functioning. Increased performance success is reinforced through repetition, errorless learning, and gradually increasing task stimuli and complexity in a structured systematic approach.
1533109|NCT02719964|Other|General Cognitive Rehabilitation Games (Lumosity)|Lumosity is a commercially available computerized program purported to enhance cognitive functioning through a variety of computerized programs that utilize various cognitive abilities.
1533110|NCT02719951|Drug|[18F]FPEB PET imaging|PET exam
1533111|NCT02719951|Other|Biological samples|blood sample and urine sample
1533112|NCT02719951|Other|MRI|MRI exam
1533113|NCT02719938|Behavioral|Specialty Palliative Care|Specialty inter-disciplinary Palliative Care consultation during hospitalization with post-discharge collaborative care by a Palliative Care Nurse Practitioner and outpatient primary care physician. Clinical care will be augmented by evidence-based educational materials for dementia caregivers.
1533114|NCT02719925|Other|Mg(+)|"1,5 L per day during 30 days
No livestyle counseling"
1533115|NCT02719925|Other|Mg(-)|1,5 L water per day during 30 days No lifestyle counseling
1533116|NCT02719912|Device|mitral valve replacement|transcatheter mitral valve replacement
1533117|NCT02719886|Device|Ultrasound|Estimation of fetal weight by ultrasound
1533118|NCT02719873|Other|The impact of maternal obesity on pregnancy outcomes|observation of maternal obesity effect in foetal and maternal outcome
1533119|NCT02719860|Dietary Supplement|Green tea|4 cups/day of green tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
1533120|NCT02719860|Dietary Supplement|Black tea|4 cups/day of black tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
1533121|NCT02719860|Dietary Supplement|Placebo tea|4 cups/day of placebo tea for 6 months; each cup is prepared by brewing 2 tea bags in 12 oz of water
1533122|NCT02719847|Procedure|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed after PET/CT, and before participant receives stereotactic body radiation therapy (SBRT). EBUS-TBNA results compared with the results of PET/CT.
1533123|NCT02719834|Drug|Acetaminophen|Acetaminophen (regular strength) will be provided in two capsules: 325 mg, take two capsules 3 times/day for 28 days (1,950 maximum daily dose). Capsules will be labeled to maintain blinding.
1533124|NCT02719834|Other|Placebo|The placebo will be provided in the same type of capsules as the acetaminophen. Two capsules, given 3x a day for 28 days. Capsules will be labeled to maintain binding.
1533125|NCT02719821|Behavioral|Behavioral techniques|"Learning behavioral techniques designed to improve nighttime sleep quality and daytime activity for approximately 45-60 minutes on three occasions.
Device: Actiwatch-2 (Philips Respironics)"
1533126|NCT02719808|Drug|Tenofovir1|receive tenofovir （300mg/d）from （28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
1533127|NCT02719808|Drug|Tenofovir2|receive tenofovir （300mg/d）from（28±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
1533128|NCT02719808|Drug|Tenofovir3|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one month after delivery, it is the observational exposure.
1533129|NCT02719808|Drug|Tenofovir4|receive tenofovir （300mg/d）from （20±2）weeks of pregnancy to one week after delivery, it is the observational exposure.
1533130|NCT02719795|Drug|Ropivacaine|Local injection of local anesthetic into the fascial spaces
1533131|NCT02719795|Drug|Normal saline|Sodium chloride solution commonly used in clinical which equal to human plasma osmotic pressure.
1533132|NCT02719782|Other|Biological: HBV antigen specific TCR redirected T cell|Patients will receive escalating doses of HBV specific TCR redirected T cell infusion
1533133|NCT02719756|Drug|Metformin|Metformin tablets 1000 mg
1533134|NCT02719756|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets
1533135|NCT02719756|Drug|Metformin up-titration|
1533136|NCT02719743|Biological|Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).|All subjects will receive intramuscularly a two-dose primary series (adjuvanted) at a 21 day interval, and a booster dose (unadjuvanted) at Day 385 of GSK1557484A vaccine.
1533137|NCT02719730|Behavioral|Reimbursement for whole grain purchases|All participants will receive education about whole grain foods. Those in the experimental arm will have a monthly financial incentive for purchases of specific whole grain foods foods during the 12-week study period, whereas the control group will not have a financial incentive for whole grain purchases during the study period.
1533138|NCT02719717|Device|Harmonic Ace+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy
1533139|NCT02719704|Behavioral|"MEXA-SE"|"MEXA-SE (move yourself) was structured into three main components: A) Physical fitness: The first component was to increase time in moderate to vigorous physical activity during Physical Education lessons. There were also prompts to help students to engage in increased physical activity during school recess; B) Eating habits: The second component consisted of six sessions (45 minutes per session) designed to promote reflection and positive changes in eating habits and health care (to improve knowledge and eating habits), conducted by nutritionist; C) Body image: The third component was composed of 3 sessions (45 minutes per session) focused on body image satisfaction (Espelho, espelho meu: School based Intervention) conducted by Physical Education researcher."
1533140|NCT02719704|Behavioral|"Espelho, espelho meu"|"Behavioral: Espelho, espelho meu: School based intervention on body image. Body image is worked in four 45 minutes sessions, conducted with a frequency of once a week by a researcher. The topics covered in these sessions refer to: Beauty Standards (media influence and formation of body image), individual qualities (individual and classmates qualities) and selfesteem. These meetings will be held through video, lecture, dynamics, photo sessions and preparation of posters."
1533141|NCT02719691|Drug|Alisertib|Participants will receive Alisertib in the dose-escalation and the dose-expansion part of the study.
1533142|NCT02719691|Drug|MLN0128|Participants will receive MLN0128 in the dose-escalation and the dose-expansion part of the study.
1533152|NCT02719600|Behavioral|Virtual reality|Evaluation of observational motor learning using virtual reality
1533153|NCT02719587|Procedure|Placebo|placebo drug identical except for the fish oil supplement, were only performed at baseline.
1533154|NCT02719587|Procedure|Omega-3|omega-3 PUFAs supplement, were only performed at baseline.
1533155|NCT02719587|Procedure|SRP|Instrumentation was performed until the root surface was considered smooth and clean, according to the operator's clinical judgement.
1533156|NCT02719574|Drug|FT-2102|FT-2102 will be supplied as 50 mg or 150 mg capsules and will be administered per the protocol defined frequency and dose level
1533157|NCT02719574|Drug|Azacitidine|azacitidine will be administered per site's standard of care
1533158|NCT02719561|Behavioral|Fatigue Intervention|The Fatigue Intervention will include education, energy conservation and activity promotion
1533159|NCT02719548|Device|Soft edge oval - Hard oval - Modified PF breast shield|"Treatment order:
soft-edge oval breast shield
Hard oval breast shield
modified PersonalFit breast shield"
1533160|NCT02719548|Device|Modified PF breast shield - Soft edge oval - Hard oval|"modified PersonalFit breast shield
soft-edge oval breast shield
Hard oval breast shield"
1533161|NCT02719548|Device|Hard oval - Soft edge oval - Modified PF breast shield|"Hard oval breast shield
soft-edge oval breast shield
modified PersonalFit breast shield"
1533162|NCT02719535|Other|Corneal reshaping therapy|Reshaping the corneal curvature from wearing specific designed rigid gas permeable lenses
1533163|NCT02719522|Device|Pipeline™ Flex Embolization Device with Shield Technology™|"Pipeline™ Flex Embolization Device with Shield Technology™ utilizes a phosphorylcholine (PC) surface treatment to the implant combined with the PFED delivery system. The Shield Technology™ surface treatment applied to the implant is an inert polymer material created to mimic the outer membrane of a human red blood cell.
The Pipeline™ Flex Embolization Device with Shield Technology™ is intended for endovascular embolization of cerebral aneurysms and is designed to be placed across the opening (or 'neck') of a brain aneurysm and redirect blood flow away from the aneurysm, causing the blood within the aneurysm to clot."
1533164|NCT02719509|Procedure|Cardiac Ultrasound|
1533165|NCT02719496|Drug|IBEROGAST|
1533166|NCT02719483|Device|Swiss DolorClast|"Radial (blue) handpiece; one rESWT session per week for three months, with 1500 radial shock waves per session and leg, i.e., a total of 3000 radial shock waves per session or a total of 36.000 radial shock waves within twelve weeks; radial shock waves evenly distributed over the gastrocnemius and soleus muscles; air pressure of the device set at 0.6 bar, resulting in a positive energy flux density (EFD+) of 0.03 mJ/mm2; radial shock waves applied at a frequency of 8 Hz; local or general anesthesia not applied."
1533167|NCT02719483|Procedure|Traditional conservative therapy|Physical therapy, Chinese massage, meridian mediation and muscle stimulation for three months (six days per week, 30 min per type of therapy).
1533168|NCT02719470|Behavioral|MIRT|MIRT consists of a 4-week physical therapy, in a hospital setting, which entails four daily sessions for five days and one hour of physical exercise on the sixth day. The duration of each session is about one hour. The first session consists of a one-to-one session with physical therapist involving muscle stretching. The second session includes aerobic exercises to improve balance and gait using different devices: a stabilometric platform, treadmill plus, crossover and cycloergometer. The third is a session of occupational therapy to improve autonomy in everyday activities. The last session includes one hour of speech therapy
1533169|NCT02719457|Other|6 minute walk test (6 MWT)|6 minute walk test is the standard testing for COPD patients to evaluate their exercise capacity
1533170|NCT02719457|Other|Spot marching test (SMT)|Spot marching test is a new test that developed to evaluate their exercise capacity of COPD patients. This test is alternative method and practical to evaluate exercise capacity. The main benefit of this testing is use a small area to test and movement pattern involve both arm and leg. We expect that SMT may make COPD patient to more dyspnea in a short period of exercise.
1533171|NCT02719431|Drug|Warfarin|
1533172|NCT02719431|Drug|K-877|
1533173|NCT02719418|Drug|Tinzaparin|3500 Unit or 4500 Unit subcutaneous once daily
1533174|NCT02719405|Dietary Supplement|Lactobacillus GG|Lactobacillus GG
1533175|NCT02719405|Dietary Supplement|Extensively Hydrolyzed Casein Formula|Extensively Hydrolyzed Casein Formula
1533176|NCT02719405|Dietary Supplement|Amino Acid Formula|Amino Acid Formula
1533177|NCT02719392|Dietary Supplement|N-acetylcysteine|NAC is an FDA-approved mucolytic (a type of drug used to relieve respiratory difficulties) and is also used for the treatment of acetaminophen toxicity.
1533178|NCT02719392|Drug|Minocycline|Minocycline is an FDA-approved antibiotic commonly used to treat bacterial infections.
1533179|NCT02719392|Other|Placebo|The placebo control is an inactive sugar pill that mimics the active comparators in appearance.
1533186|NCT02718404|Procedure|MR-HIFU Treatment|"The Philips MR-HIFU Sonalleve System integrates a high intensity phased array focused ultrasound transducer with a 3 Tesla Magnetic Resonance (MR) imaging system and electromechanical transducer positioning system to deliver spatially and temporally controlled ultrasound energy and thermal heat to tissues non-invasively.
At HIFU day (day 0) before treatment patient will be performed a bone lesion MRI and a functional brain MRI."
1533187|NCT02718404|Drug|MR contrast media and medications|During the treatment procedure, an intravenous catheter will deliver MR contrast media and medications (such as sedation and analgesics if required) within the MR room.
1533188|NCT02718404|Procedure|MR images|Following the MR-HIFU procedure, a set of MR images of the target region will be acquired with the use of a MR contrast agent, together with a functional brain MRI.
1533189|NCT02718391|Biological|Autologous Dendritic Cell vaccine|The Dendritic Cells vaccine is given intradermally with 5 injections in sites close to inguinal or axillary lymphnode stations that had not site of previous surgical exeresis; as a rule, vaccine administrations should be performed by alternating injections sites. Two days after each vaccine administration, daily 3 MU Interleukin 2 will be administered subcutaneously for 5 days.
1533190|NCT02718378|Drug|estetrol|
1533191|NCT02718378|Drug|placebo|
1533192|NCT02718365|Procedure|Wedge resection|A wedge resection is the surgical removal of the lung tumor with a small portion of the lung that surrounds the tumor. Hilar and mediastinal lymph nodes should be resected or sampled.
1533193|NCT02718365|Procedure|Segmentectomy|A segmentectomy removes a segment of a lung lobe anatomically, or inclusion of a portion of adjacent segment, but does not remove the whole lung lobe. Hilar and mediastinal lymph nodes should be resected or sampled.
1533194|NCT02718352|Other|Naturalistic Prospective Cohort|Follow subjects through 1 year of naturalistic buprenorphine treatment
1533195|NCT02718339|Behavioral|Intensive counseling|
1533196|NCT02718326|Drug|Intravitreal aflibercept injection [IAI]|
1533197|NCT02718326|Drug|Sham|
1533198|NCT02719340|Procedure|short segment fixation|posterior short-segment decompression and reconstruction (instrumentation on 1 level above and 1 level below the fractured vertebrae with posterolateral fusion)
1533199|NCT02719327|Drug|icosapent ethyl (IPE)|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
1533200|NCT02719327|Other|gel cap placebo|Participants will be randomized in a 1:1 ratio to receive icosapent ethyl 4 g daily vs. matching gel cap placebo
1533201|NCT02719314|Drug|Glucocorticoid treatment|Glucocorticoid treatment
1533202|NCT02719288|Biological|CLARIX® CORD 1K graft|
1533203|NCT02719275|Behavioral|Social Media Monitoring|Retrospective analyses of social media activity prior to crisis.
1533204|NCT02719262|Device|installing ventilation in the workplace|Environmental improvement by installing/ exhaust ventilation (FUDIN SYSTEM ENGINEERING CO.,LTD.)
1533205|NCT02719249|Other|Dried blood spot test|
1533206|NCT02719236|Procedure|direct anterior approach|"The procedure begins by positioning the patient supine on a normal table . Both feet are draped separately to assist with dislocating and proximal femural shaft exposure.The surgical incision begins 2-4 cm lateral to the anterior superior iliac spine of the pelvis . It is then carried distally and laterally for about 8-12 cm. After protecting the lateral femoral cutaneous nerve, the fascia overlying the tensor fascia latae (TFL) is incised, and a plane is then developed between the TFL and sartorius. After coagulating the ascending branch of the lateral femoral circumflex artery, a capsulectomy is performed. Placement of the final acetabular component is facilitated by the use of an offset inserter handle.
Femoral preparation begins by placing the operative limb in a position of extension, adduction and external rotation to improve the accessibility of the proximal femur.
Once the final implants are in situ, the hip is reduced and assessed."
1533207|NCT02719236|Procedure|direct lateral approach|"The procedure begins by positioning the patient in the supine decubitus position.
A longitudinal incision is made extending 3-5 cm proximal and about 5-8 cm distal to the tip of the greater trochanter . The fascia is split at the interval between the TFL and gluteus. The tendon and muscle fibres of the gluteus medius are then visualized and split . The gluteus minimus and joint capsule are split. The surgeon then dislocates the femoral head, and performs a femoral neck osteotomy.
The acetabulum is prepared .Soft tissue landmarks and reamer positioning relative to the floor are used to verify acetabular version and inclination.
When preparing the proximal femur, the hip is adducted and externally rotated, with the knee flexed. The femural stem is then press-fitted. Once the final implants are in situ and the hip is reduced, the stability of the construct is assessed."
1533208|NCT02719223|Device|NICaS|The NICaS is a non invasive device for measuring and calculating of hemodynamic parameters including mean arterial pressure (mm/Hg), cardiac index (l/min/m2) and total peripheral resistance (dynes/sec/cm5).
1533209|NCT02719210|Biological|High Volume Plasma Exchange|
1533210|NCT02719210|Drug|Hypertonic 3% saline|
1533211|NCT02719210|Drug|Mannitol|
1533212|NCT02719210|Device|Elective positive pressure ventilation|
1533213|NCT02719197|Drug|AC-083|Hard gelatin capsules for oral administration formulated at a strengths of 1, 10 and 100 mg
1533214|NCT02719197|Drug|Placebo|Placebo capsules matching AC-083 capsules
1533215|NCT02719171|Drug|ABBV-066|
1533216|NCT02719171|Drug|Placebo for ABBV-066|
1533217|NCT02719158|Drug|6 mg ciprofloxacin|Single administration of OTO-201
1533218|NCT02719158|Drug|12 mg ciprofloxacin|Single administration of OTO-201
1533219|NCT02719158|Other|Sham|
1533220|NCT02719132|Drug|Dapagliflozin|Dapagliflozin, 10 mg
1533221|NCT02719132|Drug|Metformin|Metformin, up to 2500 mg
1533222|NCT02719119|Procedure|monthly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation monthly.
1533223|NCT02719119|Procedure|bi-weekly Endoscopic Variceal Ligation (EVL)|Patients in this group will underwent endoscopic variceal ligation bi-weekly.
1533224|NCT02719106|Device|Ultimaster stent|
1533225|NCT02719093|Drug|recombinant FSH|Subcutaneous injection
1533269|NCT02718755|Drug|Erwinase|"Induction Phase:
25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes on Days 1 - 7 of a 28 day cycle.
Consolidation Phase:
25,000 Units/m2 by vein (or intramuscularly) over 90-120 minutes every other day on Days 1, 3, 5, 7, 9, 11, 13, 15 of a 28 day cycle."
1533270|NCT02718742|Other|Laboratory Biomarker Analysis|Correlative studies
1533226|NCT02719054|Behavioral|Cognitive behavioral therapy: Alter of negative thinking, positive thinking and social support and psychosocial stimulation: play stimulation and parenting|"A:Cognitive Behavioral Therapy specifically focused on changing thinking style toward positive and not associated with any medication. CBT found to be effective in managing or treating not only depression, also a variety of other conditions-e.g. mood, personality, stress, eating habit, tic etc.
B: Psycho social stimulation will follow a set of culturally appropriate, semi-structured, child's age appropriate curriculum."
1533227|NCT02719041|Other|Immunohistochemistry staining method|
1533228|NCT02719028|Drug|Antroquinonol|Antroquinonol will be provided as capsules of 50 mg
1533229|NCT02719028|Drug|placebo|The matching placebo will be packaged as Antroquinonol with appearance identical in all aspects, however, don't have the active compound(antroquinonol)
1533230|NCT02719015|Drug|rAd.CD40L|"Dose Escalation Phase Starting Dose: 5x10^10 vp per tumor as an injection directly into 1-3 tumors every 3 weeks. Same tumors injected for each of the 4 injections at week 0, 3, 6 and 9. If the dose well tolerated, the rAd.CD40L escalated to 1x10^11 vp. Subsequently enrolled patients injected at the same dose of 1x10^11 vp. Number of injected sites/tumors increased to two sites/lesions if patients have >/=2 injectable lesions, at the same injection dose of 1x10^10 up to three separate sites/lesions if patients have > 3 injectable lesions.
Dose Expansion Phase Starting Dose: MTD from Dose Escalation Phase."
1533231|NCT02719015|Drug|Pembrolizumab|Dose Escalation and Expansion Phases: 2 mg/kg by vein every 3 weeks.
1533232|NCT02719002|Device|spectral domain optical coherence tomography C-scan and multifocal electroretinogram|
1533233|NCT02718989|Device|Transcutaneous Electrical Stimulation|TENS transcutaneous electrical stimulation over the back the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1533234|NCT02718989|Device|10Kilohertz (KHz)|10 KHz transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1533235|NCT02718989|Device|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1533236|NCT02718976|Procedure|Ultrasound/MR image fusion guided lumbar plexus block (Shamrock)|
1533237|NCT02718976|Procedure|Ultrasound guided lumbar plexus block (Shamrock)|
1533238|NCT02718976|Drug|Lidocaine-epinephrine added gadoterate meglumine|Perineural injection of 20 ml 2% lidocaine with 0.0005% epinephrine added 1 ml of gadoterate meglumine (0.13 ml) and sodium chloride (NaCl, 0.87 ml). The 1 ml of gadoterate meglumine-NaCl is added to the local anesthetic prior to the perineural injection in order to enhance visualization of the local anesthetic on MRI scanning after the intervention.
1533239|NCT02718963|Device|Synchronized Electrical Stimulation Device|electrical stimulation at muscles which related with deglutition
1533240|NCT02718950|Drug|Liraglutide 3.0 mg|Subjects will use liraglutide 3.0 mg for 2 weeks
1533241|NCT02718937|Drug|BTA-C585 oral capsule|
1533242|NCT02718937|Drug|Matching placebo capsules|
1533243|NCT02718911|Drug|LY3022855|Administered IV
1533244|NCT02718911|Drug|Durvalumab|Administered IV
1533245|NCT02718911|Drug|Tremelimumab|Administered IV
1533246|NCT02718898|Drug|Ixekizumab|Administered SC
1533247|NCT02718898|Drug|Placebo|Administered SC
1533248|NCT02718885|Dietary Supplement|Inulin|Females will ingest 2 doses of 5g/inulin for a total of 10g/inulin/day for four weeks Males will ingest 2 doses of 7.5g/inulin for a total of 15g/inulin/day for four weeks
1533249|NCT02718885|Dietary Supplement|Maltodextrin|Females will ingest 2 doses of 5g/maltodextrin for a total of 10g/maltodextrin/day for four weeks Males will ingest 2 doses of 7.5g/maltodextrin for a total of 15g/maltodextrin/day for four weeks
1533250|NCT02718872|Behavioral|Tobacco cessation online training|"The original course has been developed in the online platform e-oncologia (http://www.e-oncologia.org/en/) based on the in-person courses offered during the last 10 years by the Tobacco Control Unit of the Catalan Institute of Oncology. The theoretical framework underpinning the training program is the Stages of Change Model and the curriculum was developed with the content of numerous meta-analysis and clinical practice guidelines. We created a fully referenced curriculum online, with feedback from an expert advisory group that oriented in the instructional design to ensure the course content was palatable for an online format and aligned with the learning objectives. The final curriculum content of the Brief Intervention for Smoking Cessation Training Program is composed of 4 modules."
1533251|NCT02718859|Biological|NK cells|The pancreatic cancer patients will receive nature killer(NK) cells infusions,qd
1533252|NCT02718859|Procedure|irreversible electroporation (IRE )|The pancreatic cancer patients will receive the therapy of irreversible electroporation (IRE )
1533253|NCT02718846|Drug|Meniace|6 mg of Meniace tablets were administered 3 times per day after meals
1533254|NCT02718846|Drug|Isobide|an initial dosage of 90 mL of Isobide solution was administered orally 3 times a day after meals
1533255|NCT02718833|Drug|Elotuzumab|
1533256|NCT02718833|Drug|Pomalidomide|
1533257|NCT02718833|Drug|Bortezomib|
1533258|NCT02718833|Drug|Dexamethasone|
1533259|NCT02718820|Drug|Docetaxel|Docetaxel 75mg/m2; q21
1533260|NCT02718820|Drug|Pembrolizumab|Pembrolizumab 200mg, q21
1533261|NCT02718807|Other|RP model explanation and questionnaire|Rapid prototyping models of anatomy will be used to demonstrate an anatomic and medical condition and participants will grade the experience on a questionnaire.
1995947|NCT02608450|Drug|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
1533264|NCT02718781|Behavioral|Health talk|Health talk on zero-time exercise.
1533265|NCT02718781|Behavioral|Regular contact with community leaders|Regular contact with community leaders to remind them do zero-time exercise.
1533266|NCT02718781|Device|Handgrip|This is a home-based equipment
1533267|NCT02718755|Drug|Fludarabine|"Induction Phase:
30 mg/m2 by vein over 15-30 minutes on Days 1 - 5 of a 28 day cycle.
Consolidation Phase:
30 mg/m2 by vein over 15-30 minutes on Days 1 - 4 of a 28 day cycle."
1533268|NCT02718755|Drug|Cytarabine|"Induction Phase:
2 grams/m2 by vein over approximately 2 hours on Days 1 - 5 of a 28 day cycle.
Consolidation Phase:
2 grams/m2 by vein over approximately 2 hours on Days 1 - 4 of a 28 day cycle."
1533275|NCT02718703|Device|Blood Glucose Monitoring System.|In vitro diagnostic medical device
1533276|NCT02718690|Device|TENS|TENS transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1533277|NCT02718690|Device|Sham stimulation|Sham transcutaneous electrical stimulation over back through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1533278|NCT02718664|Other|Test meal (breakfast)|Standardized test meal, in accordance with high-fat and high-calorie meal as described in the FDA guidance, but ingredients are changed to Dutch standards and ingredients are added that are expected to have the largest effects on dihydrouracil and uracil levels
1533279|NCT02718638|Other|physical exercises|Physical exercises were performed during HD sessions, at second hour of HD, three times per week for 3 months. The first exercise was knee extension from 90° to 0°. The patient remained in the 0° position for 5 seconds (an isometric contraction) and then returned to the starting position (90º). 2) The second exercise consisted of a triple flexion followed by extension of the lower limbs. The patient flexed the thigh, knee and ankle (elastic band placed at the level of the metacarpals) followed by a double extension of the thigh and knee. 3) In a co-isometric contraction, the patient performed a leg extension against the ankle-cuff resistance (located under the distal third of the leg at the level of the malleolus) for 10 seconds. 4) The patient performed a unilateral hip joint flexion of the lower limb with the knee extended by rising to their functional limit.
1533280|NCT02718625|Biological|Santyl|Collagenase ointment applied topically
1533281|NCT02718625|Biological|SoloSite®|SOLOSITE is a hydrogel wound dressing with preservatives. It can donate moisture to rehydrate non-viable tissue. It absorbs exudate while retaining its structure in the wound.
1533282|NCT02718599|Drug|terlipressin|Terlipressin will be started at the beginning of surgery as an initial bolus dose of 1 mg over 30 mints(1 mg/50 ml normal saline at a rate of 100 ml/h) followed by a continuous infusion of 2 μg/kg/h(1 mg/50 ml at a rate equal to wt/10 ml per hour) and weaned in the postoperative period over 4 hours.
1533283|NCT02718599|Drug|normal saline|Patients receive 50 ml normal saline at a rate of 100 ml/h followed by a continuous infusion of 50 ml at a rate equal to wt/10 ml per hour and weaned in the postoperative period over 4 hours.
1533284|NCT02718560|Behavioral|Writing|Writing exercise with or without cues for 1 hour per day for 4 days at week for 4 weeks
1533285|NCT02718547|Drug|Combigan|Each Participant will be instructed to instill Combigan eye drops twice daily in one of his eyes (randomly chosen)
1533286|NCT02718521|Procedure|Hydration Combined With Intravenous Infusion of Isosorbide Dinitrate|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration conbined with isosorbide dinitrate in all patients 6 hours before angiography and 12 hours after angiography
1533287|NCT02718521|Drug|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
1533288|NCT02718521|Drug|0.9% sodium chloride ﬂuid administration|
1533289|NCT02718521|Drug|isosorbide dinitrate|
1533290|NCT02718508|Behavioral|eParenting|The second group will continue to receive the same institutional standard care plus the parent will receive an e-parenting skills intervention consisting of: the online parent training program, Parenting Wisely (PW), plus text messaging and a web-based message board.
1533293|NCT02718482|Drug|Gemcitabine and Docetaxel|Treatment with gemcitabine and docetaxel at day 1 and day 8 n a 3 weeks cycle
1533294|NCT02718482|Drug|Ifosfamide|Treatment arm with high doses of ifosfamide continous infusion for 14 days in a 3 weeks cycle
1533295|NCT02718469|Biological|Ebola Vaccine - low dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
1533296|NCT02718469|Biological|Ebola Vaccine - mid dose|2 x 0.5ml vaccine will be given as intramuscular injections on each of day 1 and day 28
1533297|NCT02718469|Biological|Ebola Vaccine - high dose|2 x 1.0ml vaccine will be given as intramuscular injections on each of day 1 and day 28
1533298|NCT02718469|Biological|Placebo|2 x 0.5ml or 2 x 1.0ml placebo will be given as intramuscular injections on each of day 1 and day 28 depending on cohort
1533299|NCT02718456|Behavioral|Expedited CD4 testing|
1533300|NCT02718456|Behavioral|Supplemental peer counseling|
1533301|NCT02718443|Drug|VXM01|Oral immunotherapy targeting VEGFR2
1533302|NCT02718300|Drug|INCB050465|Up to 3 oral once a day (QD) doses of INCB050465. Doses will be taken once daily for 8 weeks, followed by once weekly dosing at the same dose level.
1533303|NCT02718300|Drug|INCB050465|Two recommended oral QD doses of INCB050465. Once daily doses of INCB050465 will be taken for 8 weeks, followed by once weekly dosing at the same dose level.
1533304|NCT02718300|Drug|Ruxolitinib|The dose of ruxolitinib will be that which the subjects had been taking for at least 8 weeks before the first dose of INCB050465.
1533305|NCT02718287|Behavioral|Home visiting intervention PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized treatment micro-areas will receive home visits by community health workers trained in the PCCSF curriculum in addition to the basic health curriculum. The community health workers are supervised by trained and experienced nurses.
1533306|NCT02718287|Behavioral|Home visiting without PCCSF (220 clusters)|Low income mothers of children 0-2.5 years of age in the randomized control micro-areas will receive home visits by community health workers trained in the standard basic health curriculum (no PCCSF).
1533307|NCT02718274|Device|OraQuick ADVANCE HIV I/II test kits, packaged for self-use (manufactured in Thailand)|Community based distribution of self-tests
1533308|NCT02718274|Other|Home-based initiation of ARVs|Home-based initiation of ARVs by study nurse linked to follow-up at clinic
1533309|NCT02718261|Drug|Pantoprazole|
1533310|NCT02718261|Drug|Saline 0.9% (matching placebo)|
1995948|NCT02608450|Drug|Vehicle cream|Vehicle cream manufactured to mimic look and feel of CB-03-01 but without the active ingredient cortexolone 17α-propionate.
1995949|NCT02607865|Drug|semaglutide|Oral administration once-daily
1533313|NCT02718235|Other|Overall survival|Observation of overall and disease free survival
1995950|NCT02607865|Drug|sitagliptin|Oral administration once-daily
1995951|NCT02607865|Drug|placebo|Oral administration once-daily
1533314|NCT02718222|Device|Post-partum IUD|The PPIUD intervention aims to address the postpartum contraceptive needs of women by training community midwives, health workers, doctors and delivery unit staff in postpartum IUD counselling and insertion.
1533315|NCT02718209|Device|Mid-Infrared Spectroscopy with ATR|
1533316|NCT02718196|Behavioral|Sleep Training smartphone application|Every evening the application provides a list of the planned bedtime activities as well as the recommended bedtime. The steps are 1) positive bedtime routine 2) bedtime fading 3)addressing nocturnal feeding 4) extinction protocol
1533317|NCT02718183|Other|Hydrogen Peroxide 35% (Opalescence Endo - Ultradent, USA)|bleaching teeth gel to intracameral use.
1533318|NCT02718183|Other|carbamide peroxide 37% (Whiteness Superendo, FGM, Brazil).|bleaching teeth gel to intracameral use.
1533319|NCT02718170|Procedure|Buried Intramedullary K-wire Fixation|
1533320|NCT02718170|Procedure|Plate and Screw Fixation|
1533321|NCT02718157|Device|Comparison between GenePOC PCR and Reference Method|Antepartum women swab specimen incubated in Lim Broth will be tested with the GenePOC GBS test on the GenePOC Instrument. The results will be compared to Reference Method defined as incubated Lim broth subcultured onto blood agar plate for observation of a Streptococcus agalactiae strain.
1533322|NCT02718144|Drug|Estetrol|Estetrol formulated in tablets, in escalating doses, will be investigated in patients with estrogen receptor positive (ER+) locally advanced or metastatic breast cancer.
1533323|NCT02718131|Device|INFUSE Bone Graft (BMP-2)|The INFUSE bone graft, containing BMP-2 on a collagen sponge, will be wrapped around the tibia during the surgical process.
1533324|NCT02718131|Procedure|Control Group|The control group will receive the standard surgical protocol, without addition of the INFUSE device.
1533325|NCT02718118|Device|Dysport reconstituted at 1.5 mL (0.05 mL/injection)|Subjects will be treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
1533326|NCT02718118|Device|Dysport reconstituted at 2.5 mL (0.08 mL/injection)|Subjects will be treated for moderate to severe (GLSS = 2 or 3) glabellar lines at maximum frown.
1533327|NCT02718105|Genetic|KIR HLAC determinations|We will take blood samples for KIR HLA-C determinations.
1533328|NCT02718092|Device|Plastic Stent|Subjects who are randomized to this arm will receive a plastic stent
1533329|NCT02718092|Device|Axios Fully Covered Self Expanding Metal Stent|Subjects who are randomized to this arm will receive the Axios FCEMS
1533330|NCT02718079|Biological|High Volume Plasma Exchange|
1533331|NCT02718079|Other|Management of cerebral edema/intracranial hypertension:|
1533332|NCT02718079|Other|Transfer to Intensive Care Unit|
1533333|NCT02718079|Drug|Prophylactic Antibiotics|
1533334|NCT02718079|Other|Intubation of trachea|
1533335|NCT02718079|Other|Administration of mannitol or 3% saline for severe elevation of Intra Cranial Pressure|
1533336|NCT02718079|Other|Volume Replacement|
1533337|NCT02718079|Other|Pressor Support|
1533338|NCT02718079|Drug|N-acetyl-L-cysteine|
1533339|NCT02718079|Other|Correction of metabolic parameters|
1533340|NCT02718079|Dietary Supplement|Correction of nutrition|
1533341|NCT02718066|Drug|HBI-8000 in combination with nivolumab|Phase 1b: HBI-8000, orally, twice a week, dose escalation 20 mg, 30 mg, 40 mg; in combination with nivolumab 3 mg/kg by 60 minutes intravenous infusion once every 2 weeks; for Phase 2: HBI-8000 MTD or 40 mg; in combination with nivolumab 3 mg/kg by 60 minutes intravenous infusion once every 2 weeks.
1533342|NCT02718053|Other|L-stiff|spasticity measurement with Lokomat
1533343|NCT02718053|Other|Ashworth|spasticity measurement with Ashworth scale
1533344|NCT02718040|Device|Emervel Classic and/or Deep Treatment Group|"Severity of Wrinkle Severity to be treated by product type:
Emervel Classic:
Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3
Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4
Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)"
1533345|NCT02718014|Other|scaling and root planing (srp)|
1533346|NCT02718001|Device|Transcatheter Mitral Valve Replacement (TMVR)|Replacement of the mitral valve through a transcatheter approach
1533349|NCT02717975|Procedure|Use of catheter valve before 'trial removal of catheter'|The investigators are comparing two groups of patients (Group A) Trial removal of urinary catheter in patients with urinary retention after applying catheter valve and closing it 3-4 hours before catheter removal.
1533350|NCT02717975|Procedure|Trial removal of catheter in patients with urinary retention|The investigators are comparing two groups of patients (Group B) Trial removal of urinary catheter in patients with urinary retention without using catheter valve - 'Traditional method'
1533355|NCT02717936|Procedure|Immunohistochemistry using Pancytokeratin Staining|
1533388|NCT02717689|Other|Biomarker based adjustment of corticosteroid dose|The subject's corticosteroid dose will be adjusted based upon biomarker results (FeNO, eosinophils and periostin)
1533389|NCT02717676|Procedure|Episiotomy|episiotomy will be done after crowning of the fetal head
1533357|NCT02717910|Behavioral|Health game|Health game intervention consists of 20 minutes guided training session with the health game at school and 2 weeks free usage of the health game via own smart phone or tablet computer during free time. The health game includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized content is presented in a format of a game including tasks, rules, goals, rewards and opponents. There are also sound effects and background music included in the game.
1533358|NCT02717910|Behavioral|Web page|Web page intervention consists of 20 minutes guided training session with the web page at school and 2 weeks free usage of the web page via own smart phone or tablet computer during free time. The web page includes textual information about the consequences of tobacco use, but also visualized elements that aim at supporting understanding of the information, and motivation and ability to use the information in daily life situations. The visualized elements are presented with pictures and video clips. These visualized elements do NOT contain game elements (NO activating tasks, rules, goals, rewards or opponents). The video clips contain sound effects, but no background music.
1533359|NCT02717897|Other|No intervention|This study is not interventional
1533360|NCT02717884|Drug|tranylcypromine|"TCP p.o., daily either 20, 40**, 60**, 80** mg/day, (28d/cycle)
**TCP doses will be slowly increased during cycle 1 and slowly decreased at end of treatment (for details see study protocol)"
1533361|NCT02717884|Drug|all-trans retinoic acid|45mg/m2 (days 10-28), CAVE: ATRA will be administered without interruption until inclusively cycle 3. At the beginning of the cycle 4 a nine-day break corresponding to the first nine days of the AraC treatment will be performed, thereafter the ATRA-therapy will be continued with a nine-day interruption every fourth cycle. That means that the therapy in cycles 1, 4, 7, 10, 13 etc. In other cycles ATRA will be given without interruption
1533362|NCT02717884|Drug|cytarabine|40mg s.c. (days 1-10)
1533363|NCT02717871|Device|PACK-CXL|"Local anesthesia
- Oxybuprocaine or Tetracaine, 1 drop each, applied together, every 3 minutes, total of 3 times
Abrasio - Abrasio: 1 mm around the borders of the infiltrate/ulcer
Corneal scrape
Hypo-osmolaric riboflavin solution
- Apply one drop every 2 minutes for 20 minutes
UV-A irradiation
3 mW/cm2 for 30 minutes or 9 mW/cm2 for 10 minutes, 18 mW/cm2 for 5 minutes, 30 mW/cm2 for 3 minutes all allowed (see paper Richoz et al)
Treatment diameter: use a irradiation diameter of 6 to 8 mm, keep the infiltrate/ulcus centered.
Additional postoperative treatment
Homatropin or Scopolamin, if anterior chamber reaction
Systemic NSAID/NSAR, if substantial pain
Do not use: topical or systemic steroids, topical NSAID/NSAR, paracetamol, vitamin A ointment, patching"
1533364|NCT02717871|Drug|Cefazolin in combination with either tobramycin or gentamicin|"Control arm consists of standard topical antimicrobial therapy recommended for the treatment of microbial keratitis by the American Academy of Ophthalmology.
Initial empiric topical antibiotic therapy (eye drops or ocular ointment):
1a. Cefazolin (50mg/ml) in combination with either tobramycin (9-14mg/ml) or gentamicin (9-14mg/ml)."
1533365|NCT02717871|Drug|Cycloplegic agents (cyclopentolate 1% eye drops)|Cycloplegic agents (cyclopentolate 1% eye drops): to decrease pain and synechia risk is at the physician discretion.
1533366|NCT02717871|Drug|Fluoroquinolones (Besifloxacin ; ciprofloxacin ; gatifloxacin ; levofloxacin ; moxifloxacin ; ofloxacin )|Fluoroquinolones (Besifloxacin 6 mg/ml; ciprofloxacin 3 mg/ml; gatifloxacin 3 mg/ml; levofloxacin 15 mg/ml; moxifloxacin 5 mg/ml; ofloxacin 3 mg/ml)
1533367|NCT02717871|Drug|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops)|Corticosteroids (prednisolone acetate 0.5% or 1% eye drops): use of corticosteroids for patients included in the study only after complete closure of the epithelium
1533368|NCT02717858|Drug|liraglutide|Injected s.c./subcutaneously (under the skin) Dose escalation period starting with liraglutide 0.6 mg per day and escalated with weekly increments of 0.6 mg until the target dose 3.0 mg is reached.
1533369|NCT02717858|Drug|placebo|Injected s.c./subcutaneously (under the skin) once daily.
1533370|NCT02717845|Device|Ellipse|diagnostic CT scan imaging
1533371|NCT02717845|Device|Tomofix|diagnostic CT scan imaging
1533373|NCT02717819|Dietary Supplement|Protein|Daily intake of supplement
1533374|NCT02717819|Dietary Supplement|Placebo|Daily intake of supplement
1533375|NCT02717819|Other|Resistance training|Resistance training (offered daily while hospitalized, and encouragement of 4 x/week as self-training after discharge)
1533376|NCT02717819|Dietary Supplement|Vitamin D|Aiming at a dose of 20 ug/day. 20 ug/day will be handed out to study participants who do not get vitamin D supplements from the hospital while admitted and to those who are not already taking vitamin D supplements themselfes e.g. as part of a combination tablet.
1533377|NCT02717806|Behavioral|PATHway|Patients will use the PATHway platform for 6 months
1533378|NCT02717793|Other|Strength testing|"isometric muscle strength
1RM measurement of muscle strength"
1533379|NCT02717780|Drug|Fentanyl and sevoflurane|
1533380|NCT02717780|Drug|Remifentanil and desflurane|
1533381|NCT02717767|Other|Autofluorescence of white corpuscle|Measure of auto-fluorescence of white corpuscles cells harvested from tracheal aspirate and/or bronchoalveolar lavages
1533382|NCT02717754|Drug|Oseltamivir|Oseltamivir will be administered at 100 or 200 mg intravenous BID for 5 days.
1533383|NCT02717754|Drug|Placebo|Oseltamivir matched placebo will be administered intravenous for 5 days.
1533384|NCT02717741|Drug|tafetinib|
1533385|NCT02717728|Procedure|Drug group Fascia iliaca nerve block|"Device: Fascia Iliaca Catheter. Placement: Site prepared using aseptic technique.
Device: Portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath. 18g x 10mm echogenic enhanced needle, 20G catheter inserted 3 cm beyond needle tip.
Drug: Local anesthetic bolus: Ropivacaine 0.2% 0.5 ml/kg total in divided doses Device: Dressing Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
1533386|NCT02717728|Procedure|Control group sham nerve block|"Device: Fascia Iliaca Catheter placement: Site prepared using aseptic technique.
Device: portable ultrasound: Localization of target site. Aseptic preparation of probe with sterile sheath.
Device: Dressing
Drug: Infusion of Ropivacaine 0.1%, rate: 0.3 ml/kg/hr; to start within the first hour after the block is placed. Infusion will be maintained for 24hs."
1533387|NCT02717715|Behavioral|Home base stroke rehabilitation|The intervention consists of physiotherapy exercises targeting functional and physical capacity.
1533390|NCT02717663|Behavioral|Adaptive Goals|Prescribed goals change daily based on participant's performance
1533391|NCT02717663|Behavioral|Static Goals|Prescribed goals remain the same throughout study
1533392|NCT02717663|Behavioral|Delayed (non-contingent) Incentives|Incentives are provided on bi-monthly basis for participation
1533393|NCT02717663|Behavioral|Immediate Micro-Incentives|Incentives are provided immediately for each goal attained
1533394|NCT02717650|Other|A-STEP|Study A) Study A) Observational Feasibility Study (no comparator). Externally paced incremental step test without breath-by-breath analysis. Standardized step height.
1533395|NCT02717650|Other|A-STEPmax|Study B) Crossover Validity Study (random allocation). Externally paced incremental step test with breath-by-breath gas analysis. Standardized step height anticipated. Test may be repeated with modified step height.
1533396|NCT02717650|Other|Comparator: CPET Godfrey Protocol|"Study B) Crossover Validity Study (random allocation). Incremental progressive exercise test with breath-by-breath gas analysis. The gold standard cardiopulmonary exercise test (CPET) on a cycle ergometer. Test wattage and design as per the Godfrey Protocol."
1533397|NCT02717624|Drug|acalabrutinib in combination with BR|
1533398|NCT02717611|Drug|ACP-196 (acalabrutinib)|
1533399|NCT02717598|Procedure|cold snare polypectomy|CSP was performed by using a disposable oval snare with a diameter of 10 mm under gentle suction to reduce colon wall tension. The tip of the endoscope was deflected toward the polyp base to ensnare 1 to 2 mm of normal mucosa surrounding the polyp. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding.Cross-sections of the EMR specimens were collected at 1-mm intervals.
1533400|NCT02717598|Procedure|hot snare polypectomy|HSP, which is using electrocoagulation on the basis of using cold snare.After HSP, another independent endoscopic surgeon judged whether the endoscopic eradication was successful. Afterward, additional EMR was performed at the polypectomy site to evaluate for the presence of residual polyp tissue,including an additional 1 to 2 mm clear margin, was resected by the snare and Endocut current after submucosal injection of a mixed solution.In the event that no tissue could be removed or if EMR failed to get in situ mucosal specimens. At least four cold biopsies using forceps on the remaining margins were obtained.After each procedure, the polypectomy site was observed for 30 seconds to confirm the absence of immediate bleeding, the specimens were retrieved and stored in formalin. Cross-sections of the EMR specimens were collected at 1-mm intervals; accurate tissue section of the marked site was ensured.
1533401|NCT02717585|Device|Continuous Positive Airway Pressure Therapy (CPAP)|Continuous Positive Airway Pressure Therapy (CPAP) consists of a mask, fitted to the patient's face and hooked to a machine that generates positive pressure at the end of expiration to abolish obstructive apneic episodes during sleep.
1533402|NCT02717572|Radiation|Fludeoxyglucose F 18|
1533403|NCT02717572|Device|Positron Emission Tomography|
1533404|NCT02717572|Device|Computerized Tomography|
1533405|NCT02717572|Device|Magnetic Resonance Imaging|
1533406|NCT02717546|Device|Zimmer MotionLoc Screw|Patients with distal tibia fractures (AO 43-A and C) requiring surgical intervention eligible for locked plating.
1533407|NCT02717533|Other|dry weight adjustment|dry weight change to match ideal blood volume obtained by blood volume measurement.
1533408|NCT02717520|Device|EQUIA Forte|The site will be isolated with cotton rolls. A sectional metal matrix system and wedge will be placed. GC cavity conditioner (20% polyacrylic acid, GC) will be applied for 10 sec., rinsed and the cavity will be dried with a cotton pellet. EQUIA Forte (GC) will be prepared according to the manufacturer instructions, applied in bulk and compacted with a condenser. The self-curing restoration will be finished after hardening, approximately 2 minutes 30 seconds after the start of the capsule mixing, using Arkansas stones under water cooling. EQUIA Forte Coat (GC) will be applied to the surfaces using a micro-tip applicator. The coated surface will be light cured with D-light (GC) for 20 seconds.
1533409|NCT02717520|Device|Tetric EvoCeram|The site will be isolated with rubber-dam. A sectional metal matrix system will be placed. Enamel will be etched with 37% orthophosphoric acid for 10 sec. (Ivoclar Vivadent, Schaan, Liechtenstein). After the acid gel removal, the cavity will be carefully dried. The adhesive (Adhese 2, Ivoclar Vivadent) will be applied and light cured with D-light (GC, 1200 mW/cm2, slow mode) for 10 sec. The composite resin (Tetric EvoCeram, Ivoclar Vivadent) will be placed with an incremental technique (2 mm layers), and light-cured with D-light (20 sec). Restorations will be finished with fine diamond and carbide burs in slow and high-speed hand-piece, and polished using flexible polishing discs, rubber points (Compo system, Komet) with a diamond particle paste.
1533416|NCT02717494|Biological|PPV-23|PPV-23 is a polysaccharide PNC vaccine, licensed in Brazil, that is directed against 23 serotypes.
1533417|NCT02717494|Biological|PCV-10|PCV-10 is a conjugate PNC vaccine, licensed in Brazil, directed against 10 serotypes.
1533418|NCT02717494|Other|NaCl|NaCl is the placebo for the study against which the two vaccines will be compared during pregnancy.
1533419|NCT02717481|Device|US-CT Fusion examination|Patients will undergo an US examination using an US device with US-CT Fusion capabilities.
1533420|NCT02717468|Device|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the digital artery (ClearSight®)|
1533421|NCT02717468|Device|Cardiac output and stroke ejection volume monitoring with arterial waveform analysis in the radial artery (Pulsioflex®).|
1533450|NCT02717247|Device|Sham tRNS|The intervention consists in placebo or sham tRNS stimulation electrode are above F3 and F4. Voltage will be ramped at the begin and end of a stimulation for 30 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
1533422|NCT02717455|Drug|LBH589|"STRATUM 1: Recurrent/progressive DIPG. Panobinostat will be given every other day, 3 times/ week, p.o. preferably on Mon/Wed/Fri, for three weeks, followed by one week off of therapy. Three weeks of therapy plus the one week rest period (4 weeks) will constitute one course. Treatment will continue for up to 26 courses (about 2 years) barring progressive disease or unacceptable toxicity.
STRATUM 2: Non-progressed DIPG. Panobinostat will be given every other day, 3 times/week, every other week p.o. preferably on Mon/Wed/Fri. Four weeks will constitute one course. Treatment will continue for up to 26 courses (about 2 years) unless the patient experiences progressive disease, unacceptable toxicity or any of the off-treatment criteria."
1533423|NCT02717442|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
1533424|NCT02717442|Drug|Placebo|Single intratympanic injection of placebo
1533425|NCT02717429|Behavioral|Mindfulness Meditation|The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn. The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices. For example, for the first two weeks, the investigators use breath as an anchor for attention. With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
1533426|NCT02717429|Behavioral|Computerized Cognitive Training|The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach. In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability. The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
1533427|NCT02717416|Device|Endo-Clot|After epinephine injection therapy, Endo-Clot is applied immediately onto the bleeding lesion. A total of 2 g of AMP® particle powder will be sprayed onto the bleeding lesion by a catheter inserted through a working channel of the endoscope under continuous air flow.
1533428|NCT02717416|Device|Hemoclip|After epinephrine injection therapy, hemoclip (HX-610-135, Olympus, Japan) will be applied onto the bleeding lesions. The number of hemoclip will be decided by endoscopist.
1533429|NCT02717403|Behavioral|Questionnaires|Participants complete a self response electronic questionnaire at baseline, and at three and six months.
1533430|NCT02717403|Behavioral|Facebook|Participant accesses Facebook page regarding rheumatoid arthritis.
1533431|NCT02717403|Behavioral|Educational Website|Participant accesses Educational Website on the internet about rheumatoid arthritis.
1533432|NCT02717403|Behavioral|Phone Interview|Research staff calls participant to obtain feedback about the websites. The interview will last approximately 30 minutes.
1533433|NCT02717390|Behavioral|Bright By Three (BB3)|The purpose of the BB3 intervention (annual home visit, written materials, and BB3 mobile application 'app') is to increase parental talking, reading, playing, and praise (TRPP) behaviors and improves children's social-emotional and language development at ages 2, 3, and 4 years.
1533434|NCT02717390|Behavioral|Texts for Child Safety (TCS)|The purpose of the injury prevention arm is to reduce the prevalence of safety hazards in the home and car environments, decrease the number of self-reported and medically-attended injuries among children, and increase caregiver's self-reported safety behaviors and knowledge of child safety. The Investigators will compare the results of our tailored child safety intervention (Texts for Child Safety [TCS]) among participants in the injury prevention arm with those randomized to the BB3 arm.
1533435|NCT02717377|Behavioral|physical activity|
1533437|NCT02717351|Drug|Coppertone (BAY 987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation- SR16-07)
1533438|NCT02717338|Behavioral|Competence|Participants will be assigned to review our donor coping website that combines text, videos, and interactive features to directly address common donor fears and to offer advice on empirically-validated strategies to reduce fear, pain, and syncopal reactions.
1533439|NCT02717338|Behavioral|Autonomy|Participants will be assigned to receive a brief telephone interview that we have developed that encourages blood donors to reflect upon their unique motivations for giving and how the act of donating is consistent with their broader life goals and values.
1533440|NCT02717338|Behavioral|Relatedness|Participants will be asked to join a closed Facebook group for one month. The group encourages participants to discuss their experiences with blood donation, including such things as posting images of their donations and/or reasons for donating. Posts will be designed to encourage social interaction around donation experiences, identity formation and group affiliation.
1533441|NCT02717325|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.(Formulation- SR16-08)
1533442|NCT02717299|Device|Verasense|Verasense will collect balancing data on all patients in this trial.
1533443|NCT02717286|Procedure|restorative|It was performed direct restoration using two kinds of adhesive system (total-etching adhesive and self-etching adhesive)
1533444|NCT02717273|Drug|standard|peri-operative antibiotic regimen only
1533445|NCT02717273|Drug|extended|extended three-day course of antibiotics
1533446|NCT02717273|Drug|steroids|500mg methylprednisolone intravenously
1533447|NCT02717273|Other|liver transplant|orthotopic liver transplantation
1533448|NCT02717260|Device|transcranial random noise stimulation (tRNS) (Starstim)|subjects are stimulated 3 times in a day by transcranial random noise stimulation (tRNS) (Starstim). each 20 minutes stimulation are separated by a period of at least 30 minutes. before and after each stimulation, inhibition is evaluated by cognitive tests: go nogo test, stroop test, Hayling test and by the BIS 10 scale. During the stimulation, subjects compleat the STAXI and STAI scales. Cognitive tests are repeated 24 hours and 8 days after the stimulation to evaluate duration of the effect. Possible side effects will be notified throughout the protocol.
1533449|NCT02717247|Device|Active tRNS|"The intervention consists in active tRNS stimulation with cathode above the left dorsolateral prefrontal cortex (DLPFC) which corresponds to the F3 location given by the 10-20 system. Anode is above the right dorsolateral prefrontal cortex (F4).
100Hz-650Hz, 2mA, 30min, twice daily, 5 days"
1533451|NCT02717234|Other|Oral Nutrition Supplement|Oral nutrition supplement intended for consumption at 3 servings per day
1534023|NCT02713165|Other|Raisins|Participants will consume 84g of raisins per day for 14 days.
1533452|NCT02717221|Other|18F-MPG|N-(3-chloro-4-fluorophenyl)-7-(2-(2-(2-(2-[18F] fluoroethoxy) ethoxy) ethoxy) ethoxy)-6-methoxyquinazolin-4-amine (18F-MPG)
1533453|NCT02717208|Biological|HL036|
1533454|NCT02717208|Biological|Vehicle|
1533455|NCT02717195|Drug|Risperidone|4-6 mg/day, encapsulated tablets, orally
1533456|NCT02717195|Drug|Olanzapine|15-20 mg/day, encapsulated tablets, orally
1533457|NCT02717195|Drug|Lu AF35700|10 mg/day, encapsulated tablets, orally
1533458|NCT02717195|Drug|Lu AF35700|20 mg/day, encapsulated tablets, orally
1533459|NCT02717182|Other|interviews|interviews
1533460|NCT02717169|Device|Biometrical tracker|35 participants are wearing a activity, sleep and heart rate tracker day and night time over a period of 5 month. The wrist watch is equipped with accelerometer, heart rate monitor using oximetry sensor, 3 led lights and vibrating alarm. The tracker is connected over Bluetooth with a smartphone App displaying the measured values and permitting to show different statistics related to amount of steps, sleep duration and heart rate over days, weeks and months.
1533461|NCT02717156|Procedure|Computed Tomography|Correlative studies
1533462|NCT02717156|Other|Laboratory Biomarker Analysis|Correlative studies
1533463|NCT02717156|Biological|Pembrolizumab|Given IV
1533464|NCT02717156|Procedure|Positron Emission Tomography|Correlative studies
1533465|NCT02717156|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
1533466|NCT02717130|Drug|Aripiprazole|
1533467|NCT02717117|Other|Soup meal|Soup meal as above
1533468|NCT02717091|Drug|FOLFIRINOX|
1533469|NCT02717091|Drug|gemcitabine + nab-paclitaxel|
1533470|NCT02717078|Other|Diet Therapy|The intervention for both study groups will be a change in diet.
1533471|NCT02717065|Other|Tone|Band-limited white noise stimulus or frequency-matched tone presented at a comfortable loudness level via headphones or earphones.
1533472|NCT02717065|Other|Video|Silent video recording of a person speaking or a still face with an expanding circle over the mouth presented on a computer or tablet screen.
1533473|NCT02717052|Drug|(S)-ketamine (Main study)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
Dosis: 0.25mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
1533474|NCT02717052|Drug|(S)-ketamine (Pilot II)|"Ketanest® S (Esketaminhydrochlorid) 5mg/ml and 25mg/ml ampoules; Actavis Italy S.P.A./Pfizer Corporation Austria GmbH
Dosis: 0.10mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.30mg/kg bodyweight i.v. applied over the course of 130 minutes."
1533475|NCT02717052|Drug|(R,S)-ketamine (Pilot II)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
Dosis: 0.20mg/kg bodyweight i.v. bolus applied over 5 minutes (starting 15 minutes before PET measurement) and continuous infusion of 0.60mg/kg bodyweight applied i.v. over the course of 130 minutes."
1533476|NCT02717052|Drug|Placebo|0.9% saline solution i.v. over 40 Minutes (ending 10 minutes before PET measurement)
1533477|NCT02717052|Other|PILOT Study II: PET1|[11C]DASB PET
1533478|NCT02717052|Other|PILOT Study II: PET2|[11C]DASB PET
1533479|NCT02717052|Other|Main Study: PET1|[11C]DASB PET
1533480|NCT02717052|Other|Main Study: PET2|[11C]DASB PET
1533481|NCT02717052|Other|PILOT Study I: PET1|[11C]DASB PET
1533482|NCT02717052|Other|PILOT Study I: PET2|[11C]DASB PET
1533483|NCT02717052|Drug|(R,S)-ketamine (Pilot I)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
Dosis: 0.50mg/kg bodyweight i.v. over 40 Minutes (ending 10 minutes before PET measurement)"
1533484|NCT02717052|Drug|(R,S)-ketamine (Pilot III)|"Ketamin-hameln (Ketaminhydrochlorid) 50mg/ml Ampullen; Hameln Pharma Plus GmbH; Sanova Pharma
Dosis: 0.80mg/kg bodyweight i.v. over 50"
1533485|NCT02717052|Other|PILOT Study III: PET1|[11C]DASB PET
1533486|NCT02717052|Other|PILOT Study III: PET2|[11C]DASB PET
1533487|NCT02717039|Procedure|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
1533488|NCT02717026|Device|Optical coherence tomography|Sections including the retinal vasculature will be taken.
1533489|NCT02717026|Device|Fluorescein angiography|Video fluorescein angiography from one eye of each subject will be performed
1533490|NCT02717026|Device|Fundus photography|30 and 50 degree fundus images
1533491|NCT02717013|Dietary Supplement|Placebo|Placebo capsules containing calcium lactate similar to the HMB capsules.
1533492|NCT02717013|Dietary Supplement|HMB|HMB capsules supplying 3 grams per day of calcium beta-hydroxyl-beta-methylbutyrate.
1533493|NCT02716987|Drug|TAK-831|TAK-831 Suspension
1533494|NCT02716987|Drug|[18F]PGM299|[18F]PGM299 Injection
1533495|NCT02716974|Drug|Leuprolide Acetate|22.5mg by intramuscular (IM) injection every 3 months
1533496|NCT02716974|Drug|Bicalutamide|bicalutamide (Casodex) 50mg by mouth daily
1533497|NCT02716974|Drug|Docetaxel|Docetaxel (taxotere) 75 mg/m2 IV will be given on day 1 every 3 weeks, up to 6 cycles.
1533498|NCT02716974|Procedure|Prostatectomy|Removal of the entire prostate gland, plus some surrounding tissue.
1533499|NCT02716974|Radiation|Radiation|5 high dose radiation treatments to the metastatic (tumor has spread to other parts of the body) sites.
1533500|NCT02716961|Drug|Gemcitabine, cisplatin|Patients who were pathologically confirmed as moderate-high risk NMIBC. Epirubicin was immediately instilled in 24h after TURBT and regularly conducted for a year. GC scheme systematic chemotherapy was underwent 5 days after TURBT, which contained gemcitabine 1000-1200mg/m2. Cisplatin (70mg/m2) was intravenous dripped in the first and 8th day after TURBT. Intravenous rehydration was conducted in the second day.
1533501|NCT02716948|Other|Laboratory Biomarker Analysis|Correlative studies
1533502|NCT02716948|Biological|Nivolumab|Given IV
1533503|NCT02716948|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
1533504|NCT02716935|Dietary Supplement|Fortified lipid based nutrient supplement|6 months intervention: participant will take a daily dose of 20g supplement. The product contains 3 g of a mixture (1:1) of inulin and fructan-oligosaccharide
1533698|NCT02715544|Other|Healthy lifestyle|The families will receive a designed for these purposes intervention
1533505|NCT02716935|Dietary Supplement|lipid based nutrient supplement|Dietary Supplement: lipid based nutrient supplement (Nutributter) 6 months intervention: participant will take a daily dose of 20g supplement.
1533506|NCT02716922|Procedure|Cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix Cerclage type: McDonald Cerclage Suture: Permanent monofilament Pericerclage antibiotics: none Pericerclage tocolytics: none Bed rest: not recommended (in both groups)
1533507|NCT02716909|Device|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB Pessary will be placed between 18 and 23 6/7 weeks gestation, and will be removed during the 37th week of pregnancy (or earlier, if indicated)
1533508|NCT02716896|Radiation|Radiation and chemotherapy|Radiation and chemotherapy will be administered concurrently to those who are randomized to this group.
1533509|NCT02716896|Procedure|Radical cystectomy|Radical cystectomy will be performed on those who are randomized to this group.
1533510|NCT02716883|Procedure|AMT|"The AM was trimmed in two layers to fit the corneal ulcer and was placed with its epithelium (basement membrane) side up, secured with 10/0 nylon sutures, supported by a therapeutic contact lens. The operated eye was patched for 2 h, and then administration of the medical treatment agents was resumed.
In patients in the case group AMT was performed during days 2-5 of antibiotic therapy when initial clinical response to the treatment was observed."
1533511|NCT02716870|Other|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
1533512|NCT02716857|Drug|Oxycodone extended-release|
1533513|NCT02716857|Drug|Placebo of oxycodone extended-release|
1533514|NCT02716844|Other|Exercise|Clinical Pilates exercise were given for 6 weeks, 3 days in a week
1533515|NCT02716831|Behavioral|Nutritional Counseling & Acceptance-based Therapy|
1533516|NCT02716831|Behavioral|Cognitive Behavioral Therapy for Eating Disorders|
1533517|NCT02716818|Drug|Chronocort®|Chronocort® is a patented oral modified release formulation of hydrocortisone which is intended to mimic, or closely match, the serum levels of endogenous cortisol.
1533518|NCT02716818|Drug|standard glucocorticoid therapy|Subjects in this arm will continue on their standard hydrocortisone therapy
1533519|NCT02716805|Drug|Tremelimumab|
1533520|NCT02716805|Drug|Durvalumab|
1533521|NCT02716792|Drug|Ibandronate|Participants will receive ibandronate, 6 mg via IV infusion, every 3 weeks for up to 9 cycles. The infusion interval will be either 15 or 60 minutes depending upon treatment group assignment every 3 weeks (9 treatment cycles in total).
1533522|NCT02716779|Drug|Pegylated Interferon (PEG-IFN) alfa-2a|Pegylated interferon (PEG-IFN) alfa-2a (40 kilodalton [KD]) 180 microgram (mcg) subcutaneously (SC) weekly, for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
1533523|NCT02716779|Drug|Placebo|Ribavirin matching placebo orally (PO) twice daily for 6 weeks.
1533524|NCT02716779|Drug|Ribavirin|Ribavirin, 1000 mg orally (PO) (400 mg in the morning [=2 tablets] and 600 mg in the evening [=3 tablets]) in participants with a body weight less than 75 kilogram (kg) or 1200 mg PO (600 mg at each time =3 tablets, in the morning and evening, respectively) in participants with a body weight greater than or equal to 75 kg, PO daily for 6 weeks during monotherapy and/or 12 weeks during combination therapy.
1533525|NCT02716766|Drug|Sorafenib|PO
1533526|NCT02716766|Drug|Capecitabine|PO
1533527|NCT02716766|Drug|Oxaliplatin|IV
1533528|NCT02716753|Biological|seminal plasma|
1533529|NCT02716753|Biological|Physiological NaCL solution|
1533530|NCT02716740|Dietary Supplement|Leucine-enriched amino acid supplementation and 30 minutes of physical training 3 times per week|After 3 months of obesity-surgery, if patients lost more than 15% of muscular weight, they will take a leucine-enriched amino acid supplementation during 3 months added with a regular physical training (30 minutes, 3 times/week). Arm A will take 2.46g/day of leucine-enriched amino acid supplementation and arm B 4g/day.
1533531|NCT02716727|Device|Aquasil Ultra Cordless, Dentsply|Cordless gingival displacement procedure
1533532|NCT02716727|Device|Ultrapak, Ultradent cord|Cordless gingival displacement procedure
1533535|NCT02716701|Behavioral|Exercise Group|
1533536|NCT02716701|Other|Control Group|
1533537|NCT02716701|Device|wristband activity tracker|
1533538|NCT02716688|Drug|S-1|S-1 will be administered orally twice daily for 14 days at a dose of 70 mg/m2/day with concurrent radiotherapy for 2 cycles. Patients who showed a response greater than that of stable disease underwent additional S-1 until disease progression, serious adverse events, or patient refusal up to six cycles.
1533539|NCT02716688|Radiation|radiotherapy|Radiotherapy wiil be delivered with a daily fraction of 1.8-2.0Gy to a total dose of 54-60Gy.
1533540|NCT02716675|Biological|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
1533541|NCT02716675|Biological|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
1533543|NCT02716649|Other|No intervention|
1533544|NCT02716636|Procedure|Slow placement of the tenaculum|Slow placement of the tenaculum on the cervix
1533545|NCT02716623|Other|CR diet|Diet consists of meals lower in carbohydrates but does not restrict the number of calories that participants can consume.
1533546|NCT02716623|Behavioral|Exercise|Participants will be asked to undergo specific exercise schedule. Exercise will be tracked using a fitness device.
1533547|NCT02716610|Drug|INH 69 U (low)|inhaled human insulin
1533548|NCT02716610|Drug|INH 69 U (high)|inhaled human insulin
1533549|NCT02716610|Drug|INH 139 U|inhaled human insulin
1533550|NCT02716610|Drug|INH 208 U|inhaled human insulin
1533551|NCT02716610|Drug|LIS 18 U|subcutaneous insulin lispro
1533699|NCT02715544|Other|physical activity and dietary guidelines|The families will receive a designed for these purposes intervention
1533554|NCT02716584|Behavioral|Physical exercise|Veterans in the physical exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups, held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age).
1533555|NCT02716584|Behavioral|Stretching exercise|Veterans in the control condition will participate in instructor-led, non-aerobic stretching exercises conducted in small groups, held 3 times per week.
1533556|NCT02716571|Other|Leukapheresis or Plasmapheresis|"Leukapheresis: Donate 5x10^9 white blood cells and 400 ml of plasma. Plasmapheresis: Donate 400ml of plasma.
Donated white blood cell and plasma will be manufactured MG4101(allogeneic natural killer cell) to use for Hepatocellular carcinoma(HCC) patients after Transarterial Chemoembolization(TACE)."
1533557|NCT02716558|Other|ART Sealant Application|application of the ART sealant using high viscosity glass inomer cements.
1533558|NCT02716558|Other|Resin sealant application|application of the moisture tolerant sealant according to the manufacturers instructions.
1533559|NCT02716545|Device|balloon assisted enteroscopy|Patients with recurrent bleeding (>2 times for one year) will undergo balloon assisted enteroscopy and be treated with endoscopic therapy if necessary. Currently available endoscopic modalities are argon laser, bipolar electrocoagulation (BiCAP), band ligation, cryotherapy, radiofrequency ablation and argon plasma coagulation (APC). Among these options, APC is the most promising.
1533560|NCT02716532|Dietary Supplement|Peptamen AF|Each patient will receive Peptamen AF throughout the trial.
1533561|NCT02716519|Biological|Santyl|Collagenase ointment applied topically once per day for up to six weeks
1533562|NCT02716519|Other|Standard Care|Standard Care not specified by the protocol; Investigators choose the appropriate standard care treatment for each participant
1533563|NCT02716506|Procedure|POP surgery|Any surgical procedure that is done to treat the symptomatic POP
1533564|NCT02716493|Behavioral|Telerehabilitation program|"The intervention was an 8-week home-based telerehabilitation program (three sessions of about 75 minutes per week) using the eChez-Soi telerehabilitation platform.
Through a unique software interface, the eChez-Soi allows for the following three technological aspects: 1- continuous data acquisition and recording from commercial biometric sensors; 2- continuous transmission of the collected data via the Internet to the clinician's computer, allowing the clinician to visualize the biomechanical and physiological parameters in real time; and 3- a challenging gaming environment with interactive exercises performed on musical rhythms.
In total, 15 supervised sessions and 9 unsupervised sessions were planned for a total of 24 exercise sessions"
1533565|NCT02716480|Behavioral|Mobility coaching|"The intensive follow-up for the patients of Mobility Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by a Mobility coach. The web platform allows self-administration of a questionnaire to establish patient's diagnosis of mobility to enable personalized coaching. The web platform can also track the parameters collected by connected devices (pedometer and connected scale), organize appointments with patients and ensure the traceability of exchanges with patients. A smartphone application tracks different modes of locomotion used."
1533566|NCT02716480|Behavioral|Diet coaching|"The intensive follow-up for the patients of Diet Coaching  arm will consist on a monthly remote coaching of 20 to 30 minutes led by dietitian trained in the care of patients undergoing bariatric surgery."
1533567|NCT02716467|Other|intercessory prayer|Intercessory prayer will be offered by a group of six Christian people.
1533568|NCT02716467|Radiation|Radiotherapy|All participants will receive treatment by radiotherapy
1533569|NCT02716454|Procedure|Ileocaecal resection|laparoscopic ileocaecal resection with primary anastomosis
1533570|NCT02716441|Device|Radio-opaque Tissue Markers|All participants will undergo implantation of radio-opaque tissue markers on their repaired rotator cuff at the time of surgery.
1533574|NCT02716415|Drug|Calmoseptine Ointment|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.
The regimen includes:
regular diaper changing,
gentle cleansing
application of the trial ointment"
1533575|NCT02716415|Drug|Destin Maximum Strength 40% Zinc|"A full structured skin care regimen is provided in a consistent fashion either by study personnel or by the participant's primary carer (family or ward staff) at each diaper change. Study nurse sub-investigator visit each participant twice per nursing shift (six times per day) either to deliver the care regimen or to observe that it is being delivered.
The regimen includes:
regular diaper changing,
gentle cleansing
application of the trial ointment"
1533576|NCT02716402|Radiation|Cerebral MRI and V/Q SPECT/CT|Cerebral MRI and V/Q SPECT/CT
1533577|NCT02716389|Other|Zebris CMS 70|
1533578|NCT02716389|Other|3-D Bulls Eye Spirit Meter|
1533579|NCT02716376|Device|Otovent®|Otovent® is a special designed balloon that is blown up through the nose, also referred to as auto-inflation of the eustachian tube. The patients use the Otovent® 5 times a day.
1533580|NCT02716363|Device|Rotational Atherectomy by Rotablator|
1533581|NCT02716350|Dietary Supplement|B-GOS|comparison versus placebo
1533582|NCT02716350|Dietary Supplement|Maltodextrin|placebo
1533583|NCT02716337|Dietary Supplement|Addition of human milk fortifiers according to human milk analysis|
1533584|NCT02716324|Behavioral|Care Manager|The CM is an individual responsible for communicating and coordinating ADHD care. The CM establishes rapport with families and communicates with them weekly to every 3 months to assess treatment use, identify new concerns, and help problem-solve. The CM also communicates with the patient's ADHD care team (pediatrician, teacher, mental health providers) to clarify family goals, communicate information, and coordinate treatment.
1533624|NCT02716012|Drug|MTL-CEBPA|"Intravenous administration into a vein (peripheral or central) on day 1, 8 and 15 of each 28-day cycle.
Number of Cycles: until progression or unacceptable toxicity develops."
1533700|NCT02715531|Drug|5-FU|5-FU (400 mg/m^2) will be administered as an IV bolus, followed by 2400 mg/m^2 by continuous IV infusion over 46 (± 1) hours, q2w.
1533585|NCT02716324|Other|ADHD Portal|The ADHD portal is a web-based platform that permits access to parts of the hospital's electronic health record. The portal permits (1) capture and sharing of patient and family treatment preferences and goals, (2) monitoring of ADHD symptoms, treatment receipt, and side effects, and (3) assessing goal attainment. The system prompts for completion of periodic check-in surveys (bi-weekly to 3 months) with parents and teachers. Within the portal, preferences and goals for ADHD treatment are measured using the ADHD Preference Goal Instrument (PGI) (Fiks et al., 2012). Parents are encouraged to consult with their children when completing the tool.
1533586|NCT02716311|Drug|Afatinib|
1533587|NCT02716311|Drug|Cetuximab|
1533588|NCT02716298|Device|fanfilcon A|contact lens
1533589|NCT02716298|Device|lotrafilcon B|contact lens
1533590|NCT02716285|Drug|Tempocol-ColoPulse® (Peppermint oil)|Peppermint oil, menthae piperitae aetheroleum
1533591|NCT02716285|Drug|Placebo|Placebo capsule, containing microcrystalline cellulose
1533592|NCT02716285|Drug|Tempocol® (Peppermint oil)|Peppermint oil, menthae piperitae aetheroleum
1533593|NCT02716272|Drug|Nivolumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks
1533594|NCT02716272|Drug|Nivolumab + Ipilimumab|Nivolumab administered IV over 60 minutes at 3mg/kg every 2 weeks, combined with Ipilimumab administered IV over 90 minutes at 1mg/Kg every 6 weeks
1533595|NCT02716259|Procedure|Scaling and root planing|Two sessions of scaling and root planing under local anesthesia and clorhexidine rinse twice/day, 15 days
1533596|NCT02716259|Procedure|Supragingival prophylaxis|Two sessions of scaling and root planing under local anesthesia and sodium fluoride rinse, twice/day, 15 days
1533597|NCT02716246|Biological|scAAV9.U1a.hSGSH|Self-complementary adeno-associated virus serotype 9 carrying the human SGSH gene under the control of a U1a promoter (scAAV9.U1a.hSGSH) will be delivered one time through a venous catheter inserted into a peripheral limb vein.
1533598|NCT02716233|Drug|pegaspargase 1250 IU/m2 x 2|only for ALL of standard risk and medium risk
1533599|NCT02716233|Drug|pegaspargase 2500 IU/m2 x 1|only for ALL of standard risk and medium risk
1533600|NCT02716220|Device|Percutaneous Coronary Intervention|Implanttaion fo the DREAMS 2G Scaffold
1533601|NCT02716207|Device|CyberKnife|Radiation Therapy
1533604|NCT02716181|Device|"Атопик Soothing Cream"|Topical application of a study cream to involved skin areas twice a day.
1533605|NCT02716181|Device|Placebo|Topical application of a study placebo cream to involved skin areas twice a day.
1533606|NCT02716168|Other|Shared video consultation between patient, general practitioner and oncologist|At the start of the patients chemotherapy treatment a shared video consultation between the patient, general practitioner and oncologist will bee arranged. The video consultation should address distribution of roles, comorbidity, medicine, depression and anxiety symptoms, relatives and social resources.
1533607|NCT02716142|Drug|rectal misoprostol|patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
1533608|NCT02716142|Drug|sublingual misoprostol|patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
1533609|NCT02716129|Drug|Morphine|35 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
1533610|NCT02716129|Drug|Morphine plus Nalbuphine|35 patients of this group will receive 10 mg of 0.5% hyperbaric bupivacaine (Buvanest Spinal 0.5% Heavy) with 0.2 mg morphine (Infumorph - Injection 10 mg/mL) plus 0.2 mg nalbuphine (NALUFIN 20MG/ML AMP) in 0.5 ml volume (total volume 2.5 mL). Patients will be preloaded with 10 ml/kg Ringer's lactate solution intravenous.
1533611|NCT02716116|Drug|AP32788|AP32788 capsules
1533612|NCT02716103|Other|blood collection|
1533613|NCT02716103|Other|bone marrow collection|
1533614|NCT02716090|Drug|Adapalene and Benzoyl peroxide Dalap Duo®|
1533615|NCT02716090|Drug|Adapalene and Benzoyl peroxide Epiduo®|
1533616|NCT02716077|Radiation|FDG PET/CT imaging|
1533617|NCT02716064|Behavioral|TAP-CM Intervention|The intervention includes: 1) Healthy Lifestyle App Goal Setting and Prioritization and modules, 2) TAP-CM Report triage Huddle with Interprofessional Team 3) The connection of patients to appropriate community resources 4) Volunteer helping with technology use
1533618|NCT02716051|Device|MRI|Whole body MRI with cardiac and pulmonary synchronization
1533619|NCT02716051|Device|PET|
1533620|NCT02716038|Drug|MPDL3280A|MPDL3280A is a human, Fc optimized, monoclonal antibody directed against the protein ligand PD-L1 (programmed cell death-1 ligand 1), with potential immune checkpoint inhibitory and antineoplastic activities. Atezolizumab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1) expressed on activated T-cells, which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. MPDL3280A 1200 mg will be administered as a 60 minute IV infusion on first administration, then over 30 minutes subsequently if tolerated.
1533621|NCT02716038|Drug|Carboplatin|Carboplatin is a second-generation platinum compound with a broad spectrum of antineoplastic properties. Carboplatin contains a platinum atom complexed with two ammonia groups and a cyclobutane-dicarboxyl residue. This agent is activated intracellularly to form reactive platinum complexes that bind to nucleophilic groups such as GC-rich sites in DNA, thereby inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These carboplatin-induced DNA and protein effects result in apoptosis and cell growth inhibition. Carboplatin AUC=6 will be administered as a 30 minute IV infusion immediately after nab-paclitaxel.
1533622|NCT02716038|Drug|Nab-paclitaxel|Nab-paclitaxel is a Cremophor EL-free, albumin-stabilized nanoparticle formulation of the natural taxane paclitaxel with antineoplastic activity. Nab-paclitaxel binds to and stabilizes microtubules, preventing their depolymerization and so inhibiting cellular motility, mitosis, and replication. Nab-paclitaxel 100 mg/m2 will be administered as a 30 minute IV infusion.
1533623|NCT02716025|Procedure|Upper gastrointestinal endoscopy|Thorough examination of the esophagus, stomach and duodenum to the second part was done to all patients using Olympus CV-150 or Pentax EPM-3500.
1534540|NCT02709785|Drug|SmartMouth ACF rinse|
1533625|NCT02715999|Procedure|Quadratus Lumborum Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory.All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally at the posterior border of the quadratus lumborum muscle
1533626|NCT02715999|Procedure|Transversus Abdominis Plane Block|After preoxygenation for three minutes, anesthesia would be induced with 8% sevoflurane inhalation in 50% oxygen and % 50 air ; 1ug/kg fentanyl and 3 mg/kg propofol is administered intravenously. Then laryngeal mask is inserted when conditions are satisfactory. All patients will be in the lateral position . Under ultrasound guidance a 22 Gauge, Pajunk Sonoplex(medical Germany) needle will be used for both techniques. Under ultrasound 0.5 ml/kg bupivacaine 0.2 % injected unilaterally between internal oblique and transversus abdominis muscles.
1533628|NCT02715973|Dietary Supplement|Nutritional Supplement|Energy dense supplement appox. 2 kcal/mL, prepared from locally available, affordable, socially acceptable food items - milk, sugar, edible coconut oil, egg and custard powder as base) in addition to standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age.
1533629|NCT02715973|Dietary Supplement|Standard Nutritional Treatment|Standard nutritional counseling by a trained dietician as per the recommended daily allowance according to gender and age
1533630|NCT02715960|Drug|Acitretin Capsules|During The first treatment stage:10mg per day, 3 days,oral; The second stage: 20mg per day, 3 days,oral; The third stage: 30mg per day, and maintain this dose,oral.
1533631|NCT02715947|Drug|Methotrexate|During The first week: 7.5mg per week, oral; The second and third weeks: 10mg per week, oral; The fourth and fifth weeks: 12.5mg per week,oral; The sixth week:15mg per week, and maintain this dose, oral.
1533632|NCT02715934|Other|Glucose to Goal|The Glucose to Goal intervention applies elements of the Patient Centered Medical Home (i.e., practice design, decision support, population management, etc) to diabetes education services and operationalizes the current DSME objectives in the primary care setting.
1533633|NCT02715934|Other|Usual Care|The control group will follow the traditional DMSE delivery model, which includes primary care providers referring patients to an outpatient, hospital-based diabetes educator for DSME, but in a passive manner (i.e., without proactive patient identification), which is the usual process for referrals.
1533634|NCT02715921|Other|Tele-exercise|
1533635|NCT02715908|Drug|LBEC0101|Etanercept
1533636|NCT02715895|Dietary Supplement|Friso|Friso formula feeding on demand for 3 months
1533637|NCT02715895|Dietary Supplement|Wyeth|Wyeth formula feeding on demand for 3 months
1533638|NCT02715895|Dietary Supplement|Breast milk|Breast milk feeding on demand
1533639|NCT02715882|Drug|CBLB502|
1533640|NCT02715882|Drug|Placebo|
1533641|NCT02715869|Drug|A pharmacologic cardiac preconditioning (Sevoflurane)|A (10 patient). Patients are anaesthetized by Sevoflurane more than 1 mac.
1533642|NCT02715869|Procedure|B ischeamic preconditioning|B (10 patients ) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
1533648|NCT02715843|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
1533649|NCT02715830|Procedure|Angioplasty of distal arteries|angioplasty of the arteries bellow-the-knee
1533650|NCT02715817|Other|Virtual Rehabilitation|It is the use of the NW games for rehabilitation of balance in post-stroke patients.
1533651|NCT02715817|Other|PNF Method|It is the use of the therapeutic exercises based on the PNF diagonals for rehabilitation of balance in post-stroke patients.
1533652|NCT02715817|Other|Virtual Rehabilitation and PNF Method|It is the use of the exercises based on the PNF diagonals and of the NW for rehabilitation of balance in post-stroke patients.
1533653|NCT02715804|Other|Biological: PEGylated Recombinant Human Hyaluronidase (PEGPH20)|PEGPH20 will be administered at a dose of 3.0 micrograms per kilograms (μg/kg) as an intravenous (IV) infusion, twice weekly for Weeks 1 to 3 of Cycle 1 (each cycle consisting of 4 weeks), then once weekly for Weeks 1 to 3 of Cycle 2 and beyond.
1533654|NCT02715804|Drug|Placebo|Matching placebo for PEGPH20
1533655|NCT02715804|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered as an IV infusion at 125 milligrams per square meter (mg/m2), once weekly for Weeks 1 to 3 of all treatment cycles.
1533656|NCT02715804|Drug|Gemcitabine|Gemcitabine will be administered as an IV infusion at 1000 mg/m2, once weekly for Weeks 1 to 3 of all treatment cycles.
1533697|NCT02715557|Behavioral|Relapse prevention program|The relapse prevention program is an innovative computer-based coping skills educational program for adolescent substance abuse treatment completers.
1534541|NCT02709785|Drug|0.12% chlorhexidine rinse|
1533657|NCT02715791|Behavioral|TAP-HC-DM|"Patients randomized to the intervention group will complete the Healthy Lifestyle App modules. Their results will create a report with a suggested list of tip sheets that patients, volunteers, and clinics will see.
Patients will also be encouraged to access the McMaster PHR in order to track their health, and communicate with volunteers or the clinic.
Volunteer health connectors will connect with patients at least weekly, by phone, McMaster PHR message, or in person (depending on patient preference). They will be motivating, providing tip sheets or other education, doing tech support, providing community resources, and building a volunteer-patient relationship with the client.
Clinicians will see and triage the reports, and may follow up on various aspects identified."
1533658|NCT02715791|Other|Usual Care|Patients randomized to the control group will receive usual care and upon the end of the intervention arm of the study will receive the TAPESTRY-HC-DM intervention as detailed in the intervention group.
1533659|NCT02715765|Device|Transcranial Direct Current Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current is held constant for the entire session. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
1533660|NCT02715765|Device|Transcranial Random Noise Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. Current delivery is initiated in a ramp-like fashion over 10s from 0mA to 2mA. Once at 2mA, the current alternates at 2mA with a 0mA offset applied at random frequencies over a range of 0.1 to 100 Hz. At the end of stimulation, current is decreased in a ramp-like fashion over 10s from 2mA to 0mA. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
1533661|NCT02715765|Device|Transcranial Sham Stimulation|Energetic parameters are 2mA for 20 min with SPONSTIM-25 25cm2 electrodes. The sham procedure involves only 40 sec stimulation at 2mA and then drops to 0mA with 15msec pulses every 550msec. Should the participant not be able to tolerate a current of 2mA due to pain or irritation, the current will be decreased down to a minimum of 1.5mA. If 1.5 mA is still not tolerable, the participant will be removed from the study. Electrode placement is based on the international 10-20 electrode placement system. The anode is placed at the midpoint between F3 and FP1, a location corresponding approximately to the left dorsolateral prefrontal cortex, and the cathode placed at the midpoint between T3 and P3, a location corresponding to left temporo-parietal junction
1533662|NCT02715752|Dietary Supplement|Gene-Eden-VIR/Novirin|
1533663|NCT02715739|Other|No intervention|
1533671|NCT02715700|Drug|Maintenance Methadone|Methadone 20 - 200 mg (10 mg/mL if oral solution concentrate) oral tablets once daily. Participants will receive their stable maintenance methadone at their usual clinic for at least 2 weeks before Day 1. Beginning on Day 1, participants will receive the same formulation and dose of methadone (after an overnight fast) at the study site. On Day 6, participants will be discharged from the study site and resume their maintenance methadone therapy at their usual clinic.
1533672|NCT02715700|Drug|MK-1439|MK-1439 100 mg oral tablet once daily after an overnight fast from Day 2 to Day 6
1533673|NCT02715687|Drug|Amiodarone|Will receive 30 days treatment with oral amniodarone of 200mg
1533674|NCT02715687|Drug|Placebo|Will receive 30 days treatment with oral placebo of 200mg
1533675|NCT02715674|Device|Plasti-med TRIFLO|
1533676|NCT02715674|Device|BIPAP VISION|
1533677|NCT02715674|Device|Plasti-med oxygen therapy mask|
1533678|NCT02715661|Other|exercise|six-month interval of exercise
1533679|NCT02715648|Drug|Phenazopyridine|
1533680|NCT02715635|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
1533681|NCT02715635|Dietary Supplement|Concentrate beetroot Juice|140 ml containing ~8 mmol of inorganic nitrate
1533682|NCT02715635|Dietary Supplement|Concentrate beetroot Juice (Placebo)|140 ml which is nitrate-depleted
1533683|NCT02715622|Procedure|Hernia repair|Patient undergoing Hernia repair using different surgical modalities as per the surgeon's standard of care practice
1533684|NCT02715609|Drug|Disulfiram|
1533685|NCT02715609|Drug|Copper Gluconate|
1533686|NCT02715609|Procedure|Surgery|
1533687|NCT02715609|Radiation|Radiation|
1533688|NCT02715609|Drug|Temozolomide|
1533689|NCT02715596|Dietary Supplement|EPA supplementation|2.7 g EPA supplementation in a 15 cc emulsion stick-pack
1533690|NCT02715596|Other|Placebo|placebo in 15 cc emulsion stick-pack
1533691|NCT02715583|Drug|11C-Acetate|
1533692|NCT02715583|Drug|Ra-223 therapy|
1533701|NCT02715531|Drug|Atezolizumab|Participants will receive atezolizumab in a flat dose of 1200 mg q3w (Arm A, Group D2, and Group E2) or 840 mg q2w (Arm B, Arm C, Group D1, and Groups E1 and E3).
1533702|NCT02715531|Drug|Bevacizumab|Participants will receive bevacizumab at 15 mg/kg q3w (Arm A and Group D2) or 10 mg/kg q2w (Arm B).
1533703|NCT02715531|Drug|Gemcitabine|Gemcitabine will be administered according to the local prescribing information. The starting dose-level of gemcitabine (1000 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
1533704|NCT02715531|Drug|Leucovorin|Leucovorin 200 mg/m^2 or 400 mg/m^2 will be administered IV over 120 (± 15) minutes, q2w.
1533705|NCT02715531|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered according to the local prescribing information. The starting dose-level of nab-paclitaxel (125 mg/m^2) will be administered intravenously over 35 (± 5) minutes on Days 1, 8, and 15 of each 28-day cycle (3-weeks-on/1-week-off schedule).
1533706|NCT02715531|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 will be administered IV over 120 (± 5) minutes q2w.
1533707|NCT02715531|Drug|Capecitabine|Capecitabine may be administered after 6 months at the discretion of the investigator (range of 650-1000 mg/m^2) twice daily on Days 1-4 of a 21-day cycle.
1533708|NCT02715531|Drug|Cisplatin|Cisplatin will be administered as 80 mg/m^2 IV over 120 minutes q3w (Group E2).
1533709|NCT02715531|Drug|Vanucizumab|Vanucizumab will be administered at a flat dose of 2000 mg IV q2w (Group D1).
1533710|NCT02715518|Device|PCI using 2nd generation drug-eluting stent|"Percutaneous coronary intervention (PCI) using 2nd generation drug-eluting stent for non-IRA stenosis will be decided according to the allocated arms.
FFR-guided strategy arm
Angiography-guided strategy arm"
1533711|NCT02715505|Drug|Umbilical cord blood transplantation with HSC835|Hematopoietic Stem cell transplantation will be done with the cell therapy product HSC835
1533712|NCT02715492|Drug|LMWH|(Enoxheparin) 1 IU/kg per dose twice daily for 2 weeks from the 1st day of TACE
1533713|NCT02715492|Procedure|TACE|Trans arterial chemoembolization
1533714|NCT02715479|Drug|Dolutegravir|Dolutegravir
1533715|NCT02715479|Drug|BMS955176|BMS955176
1533716|NCT02715466|Drug|Balanced gelatine solution|Gelaspan combined with Sterofundin ISO
1533717|NCT02715466|Drug|Balanced electrolyte solution|Sterofundin ISO
1533718|NCT02715453|Other|Intervention on frailty|"Multidisciplinary team (physicians, nurses, physiotherapists, and nutritionists):
Nutritional evaluation and intervention after randomization and regularly during follow-up
Physiotherapy sessions for 3 months after randomization and home exercise program for 1 year
Psychiatrist or psychologist assistance for 1 year after discharge"
1533719|NCT02715440|Drug|Immediate intervention|Gradual withdrawal of benzodiazepines or related drugs
1533720|NCT02715427|Other|Conventional care|
1533721|NCT02715427|Other|Enhanced recovery|
1533722|NCT02715414|Behavioral|Multiple Family Group + Clinic Implementation Team|Clinic Implementation Teams (CIT) include providers at the clinic that aim to enhance uptake and implementation of MFG through modifications of MFG (e.g., format, length of sessions), but no modification to content will occur.
1533723|NCT02715414|Behavioral|MFG|MFG is a 12-week group involving 6-8 families of children with problem behaviors. MFG aims to reduce family-level factors that are associated with the onset and perpetuation of problem behaviors. Eight of the 12 sessions are devoted to rules, responsibilities, respectful communication and relationships. Four additional sessions target family stress and social support.
1533724|NCT02715401|Drug|HCP1303|
1533725|NCT02715401|Drug|HGP1201|
1533726|NCT02715401|Drug|HIP1402|
1533727|NCT02715388|Device|GlasScope Surgical Microscope|3D visualization of the poterior chamber for silicon oil removal
1533730|NCT02715362|Drug|TAI-GPC3-CART cells|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrated to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And GPC3-CART is a 2nd CAR, with GPC3 as the target protein, 4-1BB as a co- stimulator
1533731|NCT02715349|Behavioral|Psychoeducation|3 session psychoeducation program with the family, and 3 session psychoeducation program with the patient, after psychosis is controlled. Psychoeducation focuses on explaining schizophrenia as a medical illness, the prognosis, and how the patient and family can increase the likelihood of better outcome.
1533732|NCT02715336|Drug|Ovulation induction with hCG and Lupron (GnRH agonist)|Patients treated for infertility are categorized as a low-, normal- or high responder according to their estimated ovarian response to hormonal stimulation. This classification dictates the hormonal stimulation regimen that they will receive. In contrast to hCG triggering, GnRHa triggering is characterized by simultaneous LH and FSH surges, similar to natural ovulation. A combination of GnRHa plus hCG for triggering creates simultaneous LH and FSH surges by the GnRHa, which resembles physiologic ovulation triggering, together with sustained LH-like activity from the hCG, stimulating the corpus luteum to excrete sufficient hormonal endometrial support.
1533733|NCT02715323|Other|Cross-sectional study|
1533734|NCT02715297|Radiation|SRT to the resection cavity|46 Gy total dose will be delivered in 2 Gy per fraction, or 36 Gy delivered in 3 Gy per fraction, 5 fractions within 1 week. Doses will have to cover 95% of the PTV with the prescribed dose. The clinical target volume (CTV) will be defined as the resection cavity of the recurrent glioblastoma plus a margin of 5mm. A CTV to PTV margin of 1 to 3mm will be added according to technique used for immobilisation.
1533735|NCT02715284|Biological|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
1533736|NCT02715271|Procedure|therapeutical surgery for TB|Patients undergoing therapeutical surgery for tuberculosis (DS- and MDR/XDR-TB) indicated as per clinical routine
1533737|NCT02715258|Drug|Bexagliflozin|20 mg, tablet
1533738|NCT02715258|Drug|Placebo|20 mg tablet to match active comparator
1533779|NCT02714946|Device|Percutaneous Laser Ablation|Single session with standardized approach: One or two fibers will be used for treatments including one to three illuminations with a fixed output power of 3 W, using the pullback technique. Energy for each emission will be 1200-1800J based on nodule volume. The treatment is performed under local anesthesia and conscious sedation.
1534542|NCT02709785|Drug|Placebo rinse|
1533740|NCT02715232|Drug|Testosterone|100mg testosterone undecanoat every 8-12 weeks, or alternatively 50mg testosterone transdermally, or 50mg testosterone creme
1533741|NCT02715232|Drug|Lynestrenol|2-3 tablets/day, if menstruation still occurs
1533742|NCT02715232|Drug|Cyproterone Acetate|25mg daily
1533743|NCT02715232|Drug|Estradiol|75 microgram transdermal therapeutic system twice a week, or p.o. estradiol 2x2mg/day, or estradiol gel 1,5-3mg
1533744|NCT02715232|Drug|Triptorelin acetate|4,12mg every 4-6 weeks (powder for suspension for injection s.c. or i.m.
1533745|NCT02715219|Other|Asthma Education Programme|The Asthma Education Programme consists of four items. 1. Education video for Asthmatic patient adapted from Info Sehat by Bahagian Pendidikan Kesihatan Kementerian Kesihatan Malaysia which is explaining about Asthma disease, medication and patient responsibility in Asthma management. 2. Small group discussion with subject's to help them understand better in Asthma management. 3. Face to face demonstration and teaching of inhaler technique by three trained nurse in small group range of two to five subjects. At the end of the AEP subject will received a 4. Pamphlet will be obtain from Patients' Education Unit in Ampang Hospital containing vital information about Asthma disease and management. The intervention estimated will take 1 hour to 1 hour 30 minutes to be completed.
1533746|NCT02715206|Behavioral|keepin' it REAL classic|keepin' it REAL consists of 10 classroom lessons implemented in 7th grade and 4 booster sessions implemented in 8th grade by the classroom teacher following training
1533747|NCT02715206|Behavioral|keepin' it REAL rural|keepin' it REAL rural drug prevention curriculum consists for 10 lessons taught in 7th grade and 4 booster sessions taught in 8th grade.
1533748|NCT02715206|Behavioral|control|control group continues to teach whatever prevention curriculum they were using prior to study
1533749|NCT02715193|Biological|REMD-477|
1533750|NCT02715193|Biological|Placebo Comparator|
1533751|NCT02715180|Radiation|low dose chest computed tomography|All participants were evaluated 2 scout films during LDCT screenings. The first scout film was obtained while a participant was holding a comfortable expiration with the arms at down position, and the second scout film was obtained while a full inspiration with the arms at raised position. The axial images of LDCT were taken during participants' full inspiration. The radio-opaque marker was attached to the participants' skin where the lowest part of sternum was palpable, because the sternum moves according to the position of arms and respiration.
1533752|NCT02715167|Drug|Budesonide novolizer|
1533753|NCT02715167|Drug|Placebo|
1533754|NCT02715154|Drug|Dexmedetomidine|The dexmedetomidine groups (n = 20 ) will receive i.v. infusion of 0.5 μg/kg of solution containing 5 µg/mL of dexmedetomidine, at 10 min after the level of anesthesia completed. Followed with 0.1ml/kg/hr continuous infusion until the closure of the abdominal.The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
1533755|NCT02715154|Drug|Placebo|The placebo group (n = 20) will pumped in the same volume of saline 0.9% as calculated by patients' weight in 10 min, then will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, until the closure of the abdominal. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure.
1533756|NCT02715141|Behavioral|Collection of stool sample|Collection of stool sample prior to the scheduled surveillance colonoscopy.
1533757|NCT02715128|Device|Transcranial direct current stimulation (tDCS)|non-invasive electric brain stimulation method
1533758|NCT02715115|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
1533759|NCT02715115|Drug|Placebo|Strawberry flavored solution and Water for Injection
1533760|NCT02715089|Genetic|Precise treatment|During screening stage, all patients should accept next-generation sequencing (NGS) test.
1533761|NCT02715076|Other|Ambient Temperature 19°C|Ambient Temperature 19°C
1533762|NCT02715076|Other|Ambient Temperature 21°C|Ambient Temperature 21°C
1533763|NCT02715076|Other|Ambient Temperature 23°C|Ambient Temperature 23°C
1533764|NCT02715076|Device|Forced-air cover (Bair hugger 63500, 3M)|Patients assigned to forced-air warming will also be covered with a gown and surgical drapes, but a forced-air cover (Bair hugger 63500, 3M) will be inserted between the gown and the skin surface.
1533765|NCT02715076|Other|Passive insulation|Patients assigned to passive insulation will be covered as usual with a cotton gown and single layer of cloth surgical draping.
1533766|NCT02715063|Behavioral|High Intensity Interval|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
1533767|NCT02715063|Behavioral|Resistance training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
1533768|NCT02715063|Behavioral|Plus: High Intensity Interval + Resistance Training|Exercise will be performed at three sessions per week. All sessions will be supervised by a trained health or exercise professional.
1533769|NCT02715063|Other|Usual clinical care|Dietary restriction (1300-1500kcal) 50-52% carbohydrates, 33-35% fat, 15-20% protein
1533770|NCT02715050|Device|Active or Placebo Phototherapy (MR4)|
1533771|NCT02715037|Other|Throat swabbing|
1533772|NCT02715024|Drug|Tamsulosin|Oral
1533773|NCT02715024|Drug|Solifenacin|Oral
1533774|NCT02715011|Drug|JNJ-63709178|Intravenous infusion of JNJ-63709178 once every 2 weeks. The duration of each treatment cycle is 28 days.
1533775|NCT02714998|Drug|Methotrexate|single dose systemic methotrexate administration (50 mg/m2)
1533776|NCT02714998|Procedure|salpingectomy|Laparoscopic unilateral salpingectomy
1533777|NCT02714972|Device|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
1533778|NCT02714959|Drug|Proleukin|
1533780|NCT02714946|Device|Percutaneous Radiofrequency Ablation|Single session with standardized approach: A radiofrequency generator and a 17-gauge, 15-cm electrode with a 1-cm active tip will be used. A transisthmic approach along the short axis of the nodule will be used and the nodules will be managed with the moving-shot technique. 60 W of radiofrequency outpower will be used for all nodules. The treatment is performed under local anesthesia and conscious sedation
1533781|NCT02714933|Other|MRI sequence Advanced ZTE|Evaluation of the image quality in terms of visualization of anatomical structures of the lung parenchyma in safe zone by a new imaging method of the pulmonary parenchyma by MRI (Advanced ZTE sequence).
1533782|NCT02714920|Other|CHEMRAD assay|CHEMRAD is a new biomarker research strategy based on three assays that enables the functional characterization of DNA repair capacities.
1533783|NCT02714907|Device|Cortrium C3 device|Data is read from Cortrium C3 monitor
1533784|NCT02714907|Device|Holter device|Date is read from Holter device
1533785|NCT02714894|Drug|Clozapine|Patient participants will be starting clozapine as part of their clinical care.
1533786|NCT02714881|Drug|certolizumab|Subjects who are about to start TNFi therapy as part of usual therapy will be enrolled. In this study we will provide the drug, certolizumab.
1533787|NCT02714881|Radiation|Stress myocardial perfusion PET|We will measure coronary flow reserve (CFR) using cardiac PET before the patients starts TNFi and 24 weeks after starting TNFi.
1533790|NCT02714855|Drug|Apixaban|
1533791|NCT02714842|Drug|Radiolabelled Diclofenac Tablet A|Delayed release diclofenac sodium tablet (50 mg)
1533792|NCT02714842|Drug|Radiolabelled Diclofenac tablet B|Delayed release diclofenac sodium tablet (50 mg)
1533793|NCT02714842|Drug|Radiolabelled Diclofenac tablet C|Delayed release diclofenac sodium tablet (25 mg)
1533794|NCT02714842|Drug|Diclofenac|Enteric coated delayed release diclofenac sodium tablet (50 mg)
1533795|NCT02714829|Device|Inject BMP|
1533796|NCT02714829|Device|ExcelOS Inject|
1533797|NCT02714803|Behavioral|"Connective tissue massage and Conservative applications"|Connective tissue massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
1533798|NCT02714803|Behavioral|"Classic massage group and Conservative applications"|Classic massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
1533799|NCT02714803|Behavioral|"Sham massage group and Conservative applications"|Sham massage and conservative aplications were applied 5 days per week for a total of 10 sessions for 2 weeks.
1533800|NCT02714777|Device|Autonomic nervous system activity|Autonomic nervous system activity (parasympathetic activity) will be measured by electrocardiogram (holter) during 24 hours postoperative
1533801|NCT02714751|Behavioral|Daily asynchronies information|
1533802|NCT02714738|Procedure|Ultrasound guided peripheral nerve block|Ultrasound guided peripheral nerve block
1533803|NCT02714725|Drug|Dexmedetomidine|During bypass, patients will receive dexmedetomidine infusion 0.5 mcg/kg/hr
1533804|NCT02714725|Drug|Placebo for Dexmedetomidine normal saline infusion|During bypass, patients will receive normal saline infusion
1533805|NCT02714725|Drug|Propofol infusion|During bypass, patients will receive propofol infusion 50 - 70 mcg/kg/min
1533806|NCT02714712|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180μg plus daily oral weight-based ribavirin (1,000 mg for body weight 75 kg or less, 1,200 mg for body weight greater than 75 kg) for 24 or 48 weeks
1533807|NCT02714699|Drug|diclofenac potassium|patients will take oral diclofenac potassium; one tablet (cataflam 50 mg) and one tablet placebo 30 minutes before the procedure
1533808|NCT02714699|Drug|hyoscine butyl bromide|patients will take oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
1533809|NCT02714699|Drug|placebo|patients will take oral placebo; 2 tablets 30 minutes before the procedure
1533810|NCT02714686|Behavioral|Radio Mass Media Family Planning Campaign|Short daily spots, weekly interactive shows, testimonies, and interviews with experts and community leaders on contraception and family planning
1533811|NCT02714673|Drug|anticoagulation|anticoagulation refers to any long term effective anticoagulation including antivitamin K, direct oral anticoagulants. Aspirin, clopidogrel are not included
1533813|NCT02714647|Behavioral|Attentional prime|
1533814|NCT02714647|Behavioral|Sham prime|
1533815|NCT02714634|Drug|Methotrexate + biologic administration|"Methotrexate + adalimumab or
Methotrexate + certolizumab or
Methotrexate + etanercept or
Methotrexate + golimumab or
Methotrexate + infliximab or
Methotrexate + abatacept or
Methotrexate + rituximab or
Methotrexate + tocilizumab"
1533816|NCT02714634|Drug|methotrexate + salazopyrine + hydroxychloroquine administration|
1533817|NCT02714621|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
1533818|NCT02714608|Drug|Ginsenoside H dripping pills|Experimental: Ginsenoside H dripping pills. Dosage form:pill. Dosage :20pills ( only ginsenoside H dripping pills). Frequency:two times per day. Duration: until disease progression or death.
1533819|NCT02714608|Drug|Ginsenoside H dripping pills+Placebo|Experimental: Drug: Ginsenoside H dripping pills+Placebo. Dosage form:pill. Dosage :20pills ( ginsenoside H dripping pills 10 pills and placebo 10 pills). Frequency:two times per day. Duration: until disease progression or death.
1533820|NCT02714608|Drug|Placebo|Placebo Comparator: Placebo. Dosage form:pill. Dosage :20pills ( only placebo ). Frequency:two times per day. Duration: until disease progression or death.
1533821|NCT02714595|Drug|S-649266|2 g intravenously over 3 hours every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function).
1533822|NCT02714595|Drug|Best Available Therapy|Standard of care with either a polymyxin-based or non-polymyxin-based regimen as determined by the investigator and consisting of one to three marketed antibacterial agent(s).
1533823|NCT02714582|Behavioral|Bedside shift report|Bedside shift report is a process where shift-to-shift report between nurses is, if approved by the patient, executed at the patient's bedside in order to improve the patient's involvement (Anderson & Mangino 2006).
1533824|NCT02714569|Drug|LY3202328|Administered orally
1533825|NCT02714569|Drug|Placebo|Administered orally
1533826|NCT02714569|Drug|Atorvastatin|Administered orally
1533827|NCT02714569|Drug|Simvastatin|Administered orally
1533828|NCT02714556|Other|Physiologic measures of lung function|"Respiratory function tests:
Nitrogen multiple breath washout (N2MBW) measured with an ultrasonic flowmeter (Exhalyzer D with ICU insert, Eco Medics, Duernten, Switzerland) Forced oscillation technique (FOT) measured with a tremoFlo device (Thorasys, Montreal, Canada)"
1533829|NCT02714543|Drug|aloevera juice|aloevera juice to drink twice daily for 3 months.
1533830|NCT02714543|Drug|Hydrocortisone|intralesional injection of hydrocortisone 100mg once a week for 6 weeks
1533831|NCT02714543|Drug|Hyaluronic Acid|injection hyaluronic acid 1500IU once a week for 6 weeks
1533832|NCT02714543|Drug|antioxidant|Capsules SM Fibro (antioxidants) once daily for 3 months.
1533833|NCT02714543|Drug|aloevera gel|aloevera gel one scoop to be applied 3-4 times daily for 3 months
1533834|NCT02714530|Drug|Erlotinib|Tarceva daily during radiotherapy course
1533835|NCT02714530|Radiation|Radiation|Radiotherapy
1533836|NCT02714517|Other|hydrotherapy|30 minutes sessions of physiotherapy exercises in heated pool (32°C), three times per week for four weeks
1533837|NCT02714517|Other|on land therapy|30 minutes sessions of physiotherapy exercises on land, three times per week for four weeks
1533838|NCT02714504|Drug|Voriconazole or posaconazole|Azole with activity against molds
1533839|NCT02714491|Other|Erigo + Music|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and musical stimulation."
1533840|NCT02714491|Other|Erigo + Metronome|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks) and metronome stimulation."
1533841|NCT02714491|Other|Erigo + Silence|"The patients receive daily conventional physiotherapy + fifteen 30-minutes stepping verticalization sessions with Erigo (3/week for 5 consecutive weeks), without auditory stimulation."
1533842|NCT02714478|Device|equistasi|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
1533843|NCT02714478|Device|placebo|3 devices will be placed in each patient: 1 at the spinosus process of L5; 1 at the insertion of transverse abdominis; 1 at the insertion of the gluteus medius to the femur. The devices will be kept for 55 minutes, during standard Physiotherapy
1533844|NCT02714465|Other|hyperbaric oxygen therapy|hyperbaric oxygen therapy
1533845|NCT02714452|Behavioral|Person-centred care|Person-centred and thriving promoting care
1533846|NCT02714439|Drug|Proflavine|Proflavine 0.01% applied to the cervix before high-resolution microendoscopy imaging procedure performed.
1533847|NCT02714439|Procedure|High-Resolution Microendoscopy (HRME)|High-resolution microendoscopy imaging procedure performed after colposcopy exam. Standard colposcopy procedure will then continue. Entire HRME imaging procedure should add less than 10 minutes to the standard colposcopy exam.
1533848|NCT02714426|Behavioral|Mindfulness-inspired treatment|Eight weekly group MIT sessions lasting 90-120 minutes, along with a ½ day Mindfulness Retreat at the end of the training period, will include 1) a psychoeducational component, 2) formal exercises in the form of guided practice mentioned above, and 3) thoughtful exploration of ideas and questions. Formal MIT training will follow 21 guided pre-recorded meditative Moving Picture Experts Group Layer-3 Audio (MP3) tracks from the authors for use in class and at home, promoting both fidelity to the model and uniformity in intervention across training groups. MIT activities in the protocol include mindful breathing, eating, walking, and various other practices well documented in the literature to promote mindfulness. Participants will be asked to practice MIT on their own time, and to log this.
1533849|NCT02714426|Other|Testing only|Participants receive 14 weekly sessions of testing
1533850|NCT02714413|Dietary Supplement|D-allulose|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
1533851|NCT02714413|Dietary Supplement|sucrose|All subjects will receive a standardized oral sucrose load of 50 gms
1533852|NCT02714413|Other|Placebo|Subjects will be their own controls as they will be studied sequentially for the effects of varying amounts of D-allulose given in a random order associated with standardized oral sucrose load of 50 gms. In order to limit the possibility of carry-over effect, patients will be randomized to different treatment sequences. In each sequence all four doses (2.5, 5, 7.5, and 10 gm) and placebo will be present only one time and will be administered in a different order.
1533853|NCT02714400|Drug|Venlafaxine|Venlafaxine 50mg before sleep
1533854|NCT02714400|Drug|Placebo|One piece of placebo before sleep
1533855|NCT02714387|Other|Collection of medical data|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
1533856|NCT02714374|Biological|GL-ONC1|"Dose and Regimen:
Single dose group: Cohort 1 dose is 1 × 109 pfu
Multiple dose groups:
Cohort 2 dose is 1 × 109 pfu × 5 consecutive days
Cohorts 3 and 4 dose is 2 × 109 pfu × 5 consecutive days
Cohorts 5 and 6 dose escalates at 2,3,5,5,5 × 109 pfu.
Route: GL-ONC1 is delivered as a bolus IV injection."
1533857|NCT02714361|Dietary Supplement|Vitamin D3 supplement|1500 IU (37.5 mcg) Vitamin D3 capsules daily over 8 weeks (56 days)
1533858|NCT02714361|Other|Placebo|65% olive oil capsules daily over 8 weeks (56 days)
1533859|NCT02714348|Other|Effect of helminth infection on vaccine immunogenicity|Observational; immunology
1533860|NCT02714322|Biological|MYL-1401A (Adalimumab)|MYL-1401A initial dose of 80 mg administered subcutaneously (sc), followed by 40 mg sc given every other week starting 1 week after the initial dose
1533861|NCT02714322|Biological|Humira® (Adalimumab)|Humira® initial dose of 80 mg administered sc, followed by 40 mg sc given every other week starting 1 week after the initial dose
1533862|NCT02714309|Dietary Supplement|Whey protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
1533863|NCT02714309|Other|Mixed macronutrient breakfast meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kilojoules (kJ); 468 kcal total)
1533864|NCT02714309|Other|Ad libitum lunch meal|A mixed-macronutrient lunch served to all participants ad libitum. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat
1533865|NCT02714309|Other|Low/moderate intensity exercise|A 30 minute bout of treadmill walking is performed on a motorised treadmill at a low/moderate intensity (55% estimated VO2max)
1533866|NCT02714296|Drug|Nutridrink 200 ml|Nutridrink 200 ml 6 bottles per day as a sole source of nutrition. On the day of the colonoscopy, as breakfast, allowed Nutridrink 1-2 bottles
1533867|NCT02714296|Dietary Supplement|Nutridrink compact protein|2 bottles per day. On the day of the colonoscopy, as breakfast, allowed Nutridrink compact protein 1-2 bottles
1533868|NCT02714283|Drug|inhaled corticosteroid therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
1533869|NCT02714283|Drug|macrolide therapy|We will evaluate and compare the clinical effectiveness and safety of long-term inhaled corticosteroid and macrolide antimicrobial therapies
1533870|NCT02714270|Procedure|modified partograph|
1533871|NCT02714270|Procedure|paperless partograph|
1533872|NCT02714257|Behavioral|Enhanced Usual Care plus Exercise Coaching|"For month one of the exercise intervention the investigators will conduct only strength and a few balance exercises to rehabilitate the participants. After the first month, and once the participants feel comfortable, the investigators will incorporate aerobic and additional balance exercises. The investigators will personalize participant programs based on baseline levels and increase them gradually. The exercise session will be conducted 50 minutes 3 times a week. Between sets there is a 60-second break.
Every month the coach will record steps from the pedometer and record patient adherence to exercise sessions, and every 2 months the coach will measure strength and will track resistance band color from the exercise trackers.
For the individuals exercising at home, the investigators will distribute the exercise Digital Versatile Disc (DVDs) every 9 months and the coach will continue to contact them, just as if they were joining the group. Coaches will encourage group participation."
1533873|NCT02714244|Other|Volume expansion|Volume expansion with rapid administration of 500 ml of crystalloid
1533874|NCT02714231|Drug|diclofenac sodium (cataflam)|The patients in the study group will take one tablet of cataflam 50 mg 30 min before the scheduled time of the procedure
1533875|NCT02714231|Drug|hyoscine butyl bromide (buscopan)|The patients in the study group will take one tablet of buscopan 10 mg 30 min before the scheduled time of the procedure
1533876|NCT02714218|Biological|Nivolumab 3 mg/kg IV|Followed by Nivolumab monotherapy
1533877|NCT02714218|Biological|Ipilimumab 1 mg/kg IV|Followed by Nivolumab monotherapy
1533878|NCT02714218|Biological|Nivolumab 1 mg/kg IV|
1533879|NCT02714218|Biological|Ipilimumab 3 mg/kg IV|
1533880|NCT02714218|Biological|Nivolumab 6 mg/kg IV|
1533881|NCT02714205|Drug|transdermal nitroglycerin|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
1533882|NCT02714205|Drug|Placebo|Study participants will be randomized to transdermal nitroglycerin patch or placebo patch. Participants will wear a study medication patch daily, for 12 weeks.
1533883|NCT02714192|Other|Exercise stress test (BCTT)|Participants are assessed for exercise tolerance using a treadmill with gradually increasing angle to increase workload. Stress test is stopped when there is symptom exacerbation or when participant experiences voluntary exhaustion.
1533884|NCT02714179|Drug|Paracetamol was given intravenously in both group at different times|
1533885|NCT02714166|Other|Sunscreen lotion SPF (Sun Protection Factor) 50 (BAY987521)|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
1533886|NCT02714166|Other|Ophthalmic Ointment|Study staff will administer the control in one eye and a test sunscreen in the other eye according to the assigned randomization schedule.
1533887|NCT02714153|Device|Bridge Balloon|The Bridge Balloon will be used in a non-emergent setting to allow for evaluation of how best to integrate this new technology into the investigators clinical practice. The study will focus on the effect of the Bridge balloon on the patient preparation clinical workflow, ease of insertion/positioning/deployment, and the ability to recognize proper inflation and vein sealing under fluoroscopy.
1533891|NCT02714127|Other|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
1533892|NCT02714127|Other|Cervicovaginal lavage fluid collection|During colposcopy, the cervicovaginal region is rinsed for 2 minutes with 50 ml acetic acid (5%). This fluid is not discarded like it is done usually, but the remaining lavage fluid (5% acetic acid containing cervicovaginal fluid) will be collected.
1533893|NCT02714114|Other|First-void urine collection|One time collection of ca. 20ml of first-void urine (i.e. the initial stream of the urine void) with the Colli-PeeTM device (Novosanis).
1533894|NCT02714114|Other|Blood draw|One time blood sample collection (5-10 cc) by a study nurse of Centre for the Evaluation of Vaccinations (CEV).
1533895|NCT02714101|Other|Equine assisted occupational therapy|Intervention was one 40 to 60 minute session per week. Half of the session was spent riding a horse and half was spent doing horse related activities. Children had 9 to 12 sessions
1533896|NCT02714088|Other|Novel high-intensity interval training|
1533897|NCT02714075|Other|Ferric Pyrophosphate and Zinc Oxide|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO) and micronutrients
1533898|NCT02714075|Other|Ferric Pyrophosphate and Zinc Sulphate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Sulphate (ZnSO4) and micronutrients
1533899|NCT02714075|Other|Ferric Pyrophosphate, ZnO, Citric Acid and Trisodium Citrate|Extruded rice fortified with Ferric Pyrophosphate, Zinc Oxide (ZnO), Citric Acid (CA) and Trisodium Citrate (TSC) and micronutrients
1533900|NCT02714075|Other|Ferric Pyrophosphate, ZnSO4, CA/TSC|Extruded rice fortified with Ferric Pyrophosphate, ZnSO4, CA/TSC and micronutrients
1533901|NCT02714075|Other|Ferric Pyrophosphate, ZnO, CA, EDTA|Extruded rice fortified with Ferric Pyrophosphate, ZnO, CA, EDTA and micronutrients
1533902|NCT02714075|Other|Ferrous Sulphate|Extruded rice fortified with micronutrients, Ferrous Sulphate solution will be added at consumption
1533906|NCT02714049|Behavioral|sex therapy|60 minutes each time, in person or on the telephone
1533907|NCT02714049|Drug|flibanserin|FDA approved medication for treatment of hypoactive sexual desire disorder in premenopausal women
1533908|NCT02714036|Drug|ibudilast|Ibudilast is a small molecule that crosses the blood-brain barrier after oral administration16. Its potential as a neuroprotective agent is based on in vitro and in vivo evidence of its ability to reduce microglial activation, inhibit microglia-monocyte recruitment to the central nervous system (CNS), and trigger the release of neurotrophic factors.
1533909|NCT02714023|Procedure|Normal Saline|Intra-operative irrigation with normal saline
1533910|NCT02714023|Procedure|Sterile Water|Intra-operative irrigation with sterile water
1533913|NCT02713997|Drug|etanercept|50 mg on day 0 SQ; 25 mg subcutaneous (SQ) on days 3, 7, 10, 14, and 21 relative to TPIAT
1533914|NCT02713997|Drug|Alpha 1-Antitrypsin|90 mg/kg intravenous infusion on days -1, and +3, 7, 14, 21, and 28 post-transplant
1533915|NCT02713984|Biological|Anti-HER2 CAR-T|HER-2-targeting CAR-T cells infusion in HER2 positive cancers
1533916|NCT02713971|Device|Gamepad system|Patients executed a set of tailored exercises including the control of weight-shift and body posture during static (e.g. upright sitting and standing), quasi-dynamic (e.g. sit-to-stand and gait initiation) and dynamic tasks (e.g. getting on a step, straight-line walking, walking with turns and over obstacles). Participants executed the tasks using Gamepad system which provided patients with visual and auditory feedback about their performances and assigned a score at the end of each exercise. The physiotherapist progressively adjusted training complexity by changing the reference values, including more difficult taks, changing the perceptive context, and/or including a dual-task.
1533917|NCT02713971|Other|Conventional physiotherapy|A set of tailored exercises was defined by the clinical staff following current guidelines for physiotherapy in Parkinson's disease. In particular, stretching, joint mobilization, and balance and gait exercises were provided to participants, without any instrumentation producing biofeedback or external cues.
1533918|NCT02713958|Other|Telerehabilitation|Telerehabilitation: Telerehabilitation treatment using a computerized system (MediTouch) for improving the elbow motion
1533919|NCT02713958|Other|Rehabilitation|Traditional Occupational Therapy treatment: Active exercises for elbow motion
1533922|NCT02713932|Device|Transcatheter aortic valve implantation|
1533923|NCT02713919|Behavioral|Adapted German PRO-SELF© Plus Pain Control Program|Two in-home visits (60 minutes) with at least weekly follow-up (visit or telephone call according to algorithm): Structured and tailored components; review of pain diary with participant, provision of information on pain medication, nurse coaching regarding pain self-management, detailed side-effect management plan, if distressing side-effects arise, re-evaluation together with participant at each subsequent visit.
1533924|NCT02713906|Device|X-Ray Knee Guide group|
1533925|NCT02713893|Drug|Econazole nitrate 1% plus Benzydamine HCl 0.12% intravaginal cream|
1533926|NCT02713893|Drug|Placebo plus Econazole nitrate 1% intravaginal cream|
1533927|NCT02713893|Drug|Placebo plus Benzydamine HCl 0.12% intravaginal cream|
1533928|NCT02713893|Drug|Placebo intravaginal cream|
1533929|NCT02713867|Biological|Nivolumab|
1533930|NCT02713854|Procedure|endometrial biopsy|An endometrial biopsy taken 2-3 months prior to IVF cycle
1533931|NCT02713841|Drug|inhaled human insulin (INH)|recombinant human insulin administered with Adagio-01 inhaler device
1533932|NCT02713841|Drug|sc insulin lispro (LIS)|insulin lispro administered subcutaneously
1533933|NCT02713828|Drug|Phase I: Glembatumumab Vedotin|"Escalation Phase: Three to 6 patients will be enrolled in each dose cohort based on a standard Phase I dose escalation scheme. For the dose-escalation, the starting dose of glembatumumab vedotin will be 1.9 mg/kg q3w (Cohort 1). In the event of ≥ 2 DLTs, the dose will de-escalate to Cohort -1 (1.3 mg/kg).
Dose escalation from Cohort 1 to Cohort 2 (2.2 mg/kg) may proceed if three patients in Cohort 1 complete the DLT observation period with 0 DLTs, or if six patients in Cohort 1 complete the DLT observation period with 0 or 1 DLTs."
1533934|NCT02713828|Drug|Phase II: Glembatumumab Vedotin|In Stage 1, approximately 20 eligible, treated patients will be enrolled. If ≥ 2 patients achieve a tumor response (Partial Response [PR] or Complete Response [CR]), an additional 15 eligible, treated patients will be enrolled in Stage 2, for a maximum total of 35 eligible, treated patients.
1533938|NCT02713802|Drug|Cudafol(R) (propofol, 1% [10 mg/mL])|Test product Cudafol(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
1533939|NCT02713802|Drug|Diprivan(R) (propofol, 1% [10 mg/mL])|Reference product Diprivan(R) to be administered via 1 mg/kg bolus injection, then continuous infusion at 50 ug/kg/min for 15 minutes
1533940|NCT02713789|Drug|hMaxi-K Single Treatment/ 2 escalating dose levels (8000 µg and 16000 µg injection)|
1533941|NCT02713789|Drug|Placebo (PBS-20% sucrose)|
1533942|NCT02713776|Drug|Pasireotide|Pasireotide 0.9 mg by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of pasireotide Long Acting Release (LAR) 60mg on Day 4 morning.
1533943|NCT02713776|Drug|Placebo|Placebo by subcutaneous injection twice a day during 3 days and 1 intramuscular injection of placebo on Day 4 morning.
1533944|NCT02713763|Drug|Sunitinib|Sunitinib 37.5 mg/day
1533945|NCT02713750|Other|reversible contraceptive methods|"Consistent male condom use only
Consistent female condom use only
Hormonal contraception, combined oral contraceptive pills and male/female condom
Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom
Hormonal contraception , progestin only hormonal implant and male/female condom
Intrauterine device and male/female condom"
1533946|NCT02713737|Device|heated humidified high-flow nasal cannula|HFNC device (Optiflow™, Fisher＆Paykel, Auckland, New Zealand) with a heated chamber ( Fisher＆Paykel, MR850 humidifier) and a circuit (Fisher＆Paykel,RT310). It has adjustable FiO2: 21%-100%, gas flow up to 60 L/min, to maintain arterial blood hemoglobin oxygen saturation ( SPO2) > 92%.
1533947|NCT02713737|Device|noninvasive ventilation|TBird VELA ventilator, CareFusion, USA. Pressure adjustments were to optimize patient comfort. Inspiratory pressure was raised every 5 mins until comfort was optimized. FiO2 was adjusted to maintain SPO2 > 92%.
1533953|NCT02713698|Drug|Propofol|"Induction of general anaesthesia: propofol at 200 mL/h until loss of consciousness (LOC).
Maintenance of general anaesthesia: propofol will be altered by 5 mg/mL changes targeting the BIS values between 40 and 60.
Arterial blood samples will be obtained immediately after LOC, immediately before surgery and after every 20-30 minutes during propofol infusion. After stopping propofol infusion, arterial blood samples will be acquired every 10 minutes until recovery of consciousness. The maximum blood sample per patient will be 20 mL."
1533954|NCT02713685|Procedure|Subarachnoid block|Subarachnoid block will be given using 2.5 ml of 0.5%Bupivacaine for lower limb anesthesia
1533955|NCT02713685|Procedure|combined Femoral and Sciatic nerve block|Femoral and Sciatic nerve blocks will be given using total 40 ml of 0.25%of Bupivacaine to anesthetise for lower limb surgery
1533957|NCT02713659|Behavioral|Early Literacy Promotion|Parents will receive a book with developmentally appropriate advice about reading at each well child visit from one week through 5 months of age, as well as weekly text reminders related to reading. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
1533958|NCT02713659|Behavioral|Standard Literacy Promotion|Parents will receive weekly text messages about child safety, and no books before the age of 6 months from their provider. From 6 months of age, both groups will receive standard literacy promotion and will attend study visits every six months until age 2.
1533959|NCT02713633|Other|internal Double-J stents|internal stent, we use to approaches to insert it: 1- Retrograde by cystoscopy and this will take 10 minutes before starting the surgical procedure itself and we put the stent under fluoroscopy guidance and this is the commonest way we use now to put the internal stents. 2- ante grade, and this is basically inserting the stent during the surgical procedure itself from the kidney down to the ureter and this is done without fluoroscopy
1533960|NCT02713633|Other|External Stent|we use one method, we choose were we will leave the stent and then we create a small hole in the kidney and then pull the stent through the hole and then create small hole in the abdominal fascia and then the skin, all this done under direct vision and control. So now the sent is outside the patient and connected directly to the kidney and the renal pelvis, then the distal part of the stent will be inserted across the anastomosis and before closing the renal pelvis (also under vision) toward the ureter. The external stent will be connected at the end of the procedure to a urine bag.
1533961|NCT02713620|Biological|recombinant HBV vaccine (Hepavax-Gene® Berna, Korea)|Different HBV vaccine regimen in each group
1533963|NCT02713594|Behavioral|Counseling from WTQL|Counseling from the Wisconsin Tobacco Quit Line (WTQL) consisted of 5 proactive calls to the participant to help them successfully quit tobacco use, plus ad hoc calls at the participant's initiation; also, WTQL coaches encouraged participants to see their health care provider to obtain Medicaid-approved smoking cessation medications to help them quit smoking.
1533964|NCT02713594|Other|Financial incentive to participate|Participants in the Incentive condition received $30 per call for up to five WTQL calls taken; in addition, Incentive condition participants received $40 for producing biochemical evidence of abstinence at the 6-month follow-up visit. (Note that participants in both the Control condition and the Incentive condition received $40 for completing the baseline biochemical smoking status assessment visit and $40 for completing the 6-month follow-up biochemical smoking status assessment visit.) Compensation was in the form of prepaid Visa gift cards mailed approximately 2-4 weeks after the point of contact.
1533965|NCT02713581|Biological|Blood sampling|Venous blood will be sampled for laboratory analyses (see outcomes).
1533966|NCT02713568|Other|Ultrasound examination|"Prenatal Ultrasound examinations will be carried out using transabdominal sonography only by experienced consultants in MFM. Ultrasound-Estimated Fetal Weight will be obtained between 36.0-36.6 weeks of gestation, according to Hadlock et al.
Operators performing the Ultrasound-Estimated Fetal Weight will be blinded to the results of Magnetic Resonance-Estimated Fetal Weight. The participants, general practitioners, obstetricians and midwifes of the patients will be aware of the results of Ultrasound-Estimated Fetal Weight which will be used for clinical management.
For the primary outcome measure, macrosomia during Ultrasound-Estimated Fetal Weight will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be redefined as ≥ P90 or ≥ P99 based on Yudkin."
1533967|NCT02713568|Other|Magnetic resonance examination|"MRI will be performed the same day as the Ultrasound examination, using a clinical 1.5T whole-body unit.
Operators performing Fetal Body Volume measurements will be blinded from Ultrasound-Estimated Fetal Weight results. Magnetic Resonance-Estimated Fetal Weight will be calculated using the equation 0,12+1,031*Fetal Body Volume = MR imaging weight (g) developed by Baker.
General practitioners, obstetricians and midwifes of the patients will be blinded to the results of the Magnetic Resonance-Estimated Fetal Weight.
For the primary outcome measure, macrosomia will be defined as ≥ P95 based on Yudkin et al. For secondary outcome measures, it will be defined as ≥ P90 or ≥ P99."
1533970|NCT02713542|Device|ACP|Autologous Conditioned Plasma
1533971|NCT02713542|Other|Placebo|Three Normal Saline IA injections of 3-8 mL at 1-week intervals.
1533972|NCT02713529|Biological|AMG820 and pembrolizumab|Treatment with AMG820 and pembrolizumab
1533973|NCT02713516|Other|Virtual Reality|Use of virtual reality to deliver exposure therapy
1533974|NCT02713503|Other|Driving Observation|Driving observation using the DriveSafety CDS-250 Driving Simulator.
1533975|NCT02713503|Other|VisionCoach|Visual field evaluation using VisionCoach
1533976|NCT02713490|Drug|EXPAREL|EXPAREL and bupivacaine HCl
1533977|NCT02713490|Drug|Bupivacaine|Single dose of bupivacaine HCl 0.5%
1533978|NCT02713477|Drug|Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1533979|NCT02713477|Drug|Insulin glargine HOE901|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1533980|NCT02713477|Drug|Placebo|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1533981|NCT02713464|Behavioral|maternal education|Antenatal and/or postpartum Instruction on risks of neonatal jaundice, dangerous practices, technique to evaluate jaundice, early signs of ABE, when to seek care.
1533982|NCT02713451|Drug|Modulation of Inspired Fraction of Oxygen (FiO2)|"In the two groups, if patient is not in the range of arterial oxygen pressure (PaO2), Inspired Fraction of Oxygen (FiO2) will be modified from 5 percent if difference between target is less than 5 mmHg and from 10 percent if difference from target is higher. A new arterial blood gases (ABG) will be performed 30 minutes later to check for the oxygen target range. When ABG are performed, pulsed oxymetry is compared with arterial saturation (SaO2) to adapt survey. Between each ABG, FiO2 is modified from 5 percent to 5 percent each five minutes until reaching good pulsed oxygen saturation (SpO2) target (that can be modified in function of the comparison of arterial oxygen saturation (SaO2 and SpO2 with ABG).
This management of FiO2 will be done until extubation of the patient."
1533983|NCT02713438|Behavioral|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
Each participant forms their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
1533984|NCT02713438|Behavioral|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of only one person in the dyad: the child (parent-child dyads)."
1534024|NCT02713139|Drug|Clotrimazole + Metronidazole|Vaginal cream with Clotrimazole 200mg and Metronidazole 0,75%. Apply once per day, before bedtime, for 5 (five) days.
1534025|NCT02713139|Drug|Metronidazole|Vaginal gel with Metronifdazole 100mg/g. Apply once per day, before bedtime, for 10(ten) days.
1534026|NCT02713139|Drug|Clotrimazole|Vaginal cream with Clotrimazole 20mg/g. Apply once per day, before bedtime, for 3 (three) days.
1533985|NCT02713438|Behavioral|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity).
Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter. The plan focuses on physical activity of both persons within the dyad (parent and child) and include some plans for joint physical activity."
1533986|NCT02713438|Behavioral|Education|"CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements.
The education is delivered by the experimenter to a parent-child dyad and discusses individual guidelines for both dyadic partners."
1533987|NCT02713425|Device|Entertaining Video Game|Children between 7 & 17 with a social anxiety disorder will be invited to participate in this study. They will attend a single visit. During the visit they will use the therapeutic game. They will be monitored while using the game. After the completion, they will be asked questions regarding their experience with this therapeutic game.
1533988|NCT02713412|Other|Glucose|75g glucose and 150 mg of 13C-acetate made up to 300 ml with water
1533989|NCT02713412|Other|Water|300ml water
1533990|NCT02713399|Device|Optical Coherence Tomography|
1533991|NCT02713386|Drug|Carboplatin|Given IV
1533992|NCT02713386|Other|Laboratory Biomarker Analysis|Correlative studies
1533993|NCT02713386|Drug|Paclitaxel|Given IV
1533994|NCT02713386|Drug|Ruxolitinib Phosphate|Given PO
1533995|NCT02713386|Procedure|Therapeutic Conventional Surgery|Undergo TRS
1533996|NCT02713373|Biological|Cetuximab|Given IV
1533997|NCT02713373|Other|Laboratory Biomarker Analysis|Correlative studies
1533998|NCT02713373|Biological|Pembrolizumab|Given IV
1533999|NCT02713360|Behavioral|Cognitive Therapy|
1534000|NCT02713347|Behavioral|ADAPT Intervention|"The intervention includes 3 components:
nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, and pain.
social worker provides structured counseling targeting adjustment to illness and depression and advance care planning.
collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker. The team has as-needed consultation with a cardiologist or pulmonologist. The nurse and social worker visits are in-person or by phone."
1534001|NCT02713334|Behavioral|survey|
1534002|NCT02713334|Behavioral|semi-structured interview|
1534003|NCT02713282|Drug|Paliperidone palmitate 3 month formulation (PP3M)|Participants will receive intramuscular injection of Paliperidone Palmitate 3-Month Formulation (PP3M) on Day 1 at a starting dose of 175 milligram equivalent (mg eq) up to 525 mg eq based on last Paliperidone Palmitate 1-Month Formulation (PP1M) dose (at a dose of 3.5-fold multiple of the participant's last PP1M dose). Subsequent PP3M injections will be given at Month 3, Month 6, and Month 9 and dose can be adjusted flexibly in increments within the range of 175 to 525 mg eq.
1534004|NCT02713269|Procedure|Thermal Ablation Procedure|Thermal ablation procedure performed before spine stereotactic radiosurgery. Thermal ablation heats tumor tissue using a laser, and helps to shrink the tumor by destroying tumor cells.
1534005|NCT02713269|Radiation|Stereotactic Spine Radiosurgery (SSRS)|Treatment delivered in 1 or 3 fractions per treating physician. One fraction: Gross tumor volume (GTV) prescribed to 24 or 18 Gy in a single fraction depending on the tumor histology. Radioresistant histologies such as renal cell carcinoma, sarcoma and melanoma treated to 24 Gy, and radiosensitive tumor such as breast cancer and non-small lung cancer treated to 18 Gy. Clinical target volume (CTV) prescribed to 16 Gy in a single fraction. Three fractions: GTV prescribed to 24 or 27 Gy in 3 fractions, and the CTV prescribed to 21 Gy in 3 fractions.
1534006|NCT02713269|Behavioral|Symptom Questionnaires|Symptom questionnaires completed at baseline and at follow up months 1, 3, 6, 9, 12, then every 6 months.
1534007|NCT02713256|Drug|CFZ533|Patients will receive CFZ533 intravenously over approximately one hour
1534008|NCT02713243|Drug|LJN452|Capsules containing LJN452
1534009|NCT02713243|Drug|Placebo to LJN452|Capsules containing placebo to LJN452
1534010|NCT02713230|Drug|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension,133 mg in 10 mL expanded with normal saline to 20 mL
1534011|NCT02713230|Drug|Placebo|Normal saline in 20 mL.
1534012|NCT02713217|Other|Usual Care|This condition is defined as usual care occurring within Community Based Outpatient Clinics (CBOCs), which typically does not involve substantial integration of mental health care and primary care.
1534013|NCT02713217|Other|Blended Telemedicine-Based Integrated Care|"This condition involves exposure to a blended collaborative care model that includes care management for depression and alcohol disorders and virtual co-location of doctoral-level mental health providers with prompt access through tele-video or telephone communication."
1534016|NCT02713191|Drug|Dexmedetomidine|Dexmedetomidine 1µg/Kg in 100 mL saline intravenously over 10-15 minutes immediately prior to procedure, followed by Dexmedetomidine infusion at 0.6 µg/kg/hour as maintenance dose during entire procedure
1534017|NCT02713191|Drug|Midazolam bolus|Midazolam 2 mg as slow intravenous bolus immediately prior to procedure
1534018|NCT02713191|Other|Saline placebo|100 mL saline infusion over 10-15 minutes immediately prior to procedure
1534019|NCT02713191|Drug|Rescue midazolam|Rescue boluses of 0.5 mg midazolam, if needed during procedure
1534020|NCT02713191|Drug|Fentanyl|1 µg/kg fentanyl as slow intravenous bolus immediately prior to procedure
1534021|NCT02713178|Drug|bupivacaine liposome injectable suspension|bupivacaine liposome injectable suspension 133 mg expanded with normal saline to 20 mL or 266 mg in 20 mL
1534022|NCT02713178|Drug|Placebo|Normal saline.
1534031|NCT02713113|Drug|sugammadex reversal of neuromuscular blockade|
1534032|NCT02713100|Behavioral|level of agitation|psychological pain
1534033|NCT02713087|Drug|Ephedrine|Infusion of Ephedrine 2mg/ml until MAP above 60 mmHg or until MAP has raised 20%
1534034|NCT02713087|Drug|Phenylephrine|Infusion of Phenylephrine 0,1mg/ml until MAP above 60 mmHg or until MAP has raised 20%
1534035|NCT02713074|Drug|povidone-iodine|The patients will be subjected to povidone-iodine (Betadine7.5%) for vaginal cleaning before office hysteroscopy
1534036|NCT02713074|Drug|normal saline|The patients will be subjected to normal saline (Sod. Chloride 0.9%, Nile) for vaginal cleaning
1534037|NCT02713061|Drug|TAK-850|TAK-850 injection
1534038|NCT02713048|Other|Blood sample collection|Eight blood samples in each patient within 48 hours to perform Troponin I measurement.
1534039|NCT02713035|Behavioral|Self help intervention|For participants randomized to receive the treatment, the self-help intervention will be briefly described by a member of the clinical staff, and a brief pamphlet will be distributed to the parent or guardian at the end of the visit. The pamphlet describes behavioral strategies for coping with and reducing scratching behaviors. Participants randomly selected to not receive the treatment will not receive the pamphlet at the end of the visit.
1534042|NCT02713009|Dietary Supplement|Pregnancy multi-vitamin (including 10μg vitamin D3)|
1534043|NCT02713009|Dietary Supplement|10μg vitamin D3|
1534044|NCT02713009|Dietary Supplement|0μg vitamin D (placebo)|
1534045|NCT02712996|Drug|Lisdexamfetamine|Lisdexamfetamine (Vyvanse) capsule, 20-70 mg, each morning for 6 weeks.
1534046|NCT02712996|Drug|Placebo|Placebo capsule, 20-70 mg, each morning for 6 weeks.
1534047|NCT02712983|Drug|TIP|TIP dose regimen
1534048|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
1534049|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
1534050|NCT02712983|Drug|TIP|TIP dose regimen
1534051|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
1534052|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
1534053|NCT02712983|Drug|TIP|TIP dose regimen
1534054|NCT02712983|Drug|TIP and placebo|TIP and inhaled placebo dose regimen
1534055|NCT02712983|Drug|Placebo|Inhaled placebo dose regimen
1534056|NCT02712970|Procedure|pit-picking technique|midline pits were excised removing a minimal amount of tissue (with a margin of skin of <1 mm). Incision of 1-2 cm in length was performed parallel to the most convenient side of the midline to be curetted of the chronic abscess cavity. All infected granulation tissue and hair were removed. After establishing hemostasis, the area of the excised midline pits was approximated by absorbable sutures.
1534057|NCT02712970|Procedure|Bascom Cleft Lift|The upper end of the incision was made 1-2 cm lateral to the midline on the more affected side and this was continued vertically over a distance of 1-2 mm from the midline pits. The lower end was fashioned from the midline in a V-shape in order to prevent a dog-ear deformity. The skin on this side of the natal cleft was then elevated and excised. The skin on the opposite side was undermined to the distance required to allow primary closure of the defect away from the midline without tension. Sinus tissue and its extensions were excised. The incision was then closed subcuticularly by absorbable polyglecaprone (3-0), after which a few interrupted mattress polyglecaprone (3-0) buttress sutures were also inserted.
1534058|NCT02712970|Procedure|Rhomboid excision with the Limberg Flap|The area to be excised was mapped on the skin in a rhomboid form, and the flap was designed. The skin incision was deepened to the postsacral fascia. The flap was fully mobilized and transposed medially to fill the defect without tension. The wound was closed in two layers: the subcutaneous tissue with absorbable (2/0 polyglactin) sutures and the skin with nonabsorbable (3/0 polypropylene) interrupted mattress suture
1534059|NCT02712970|Procedure|Other flap techniques|Bascom Cleft lift as described above, Rhomboid excision with the Limberg Flap as described above, V-Y advancement flap, Z-Plasty
1534060|NCT02712957|Drug|NEO6860|TRPV1 antagonist
1534061|NCT02712957|Drug|NEO6860 placebo|Inactive substance
1534062|NCT02712957|Drug|Naproxen|NSAID
1534063|NCT02712957|Drug|Naproxen placebo|inactive substance
1534066|NCT02712918|Behavioral|Brief Behavioral Activation Treatment for Depression|Behavioral treatment of depression which focuses on increasing the Level of positive reinforcement through systematic and goal directed activation of behavior. Goal and values are assessed and used to determine target behaviors.
1534067|NCT02712918|Other|Standard Care|Treatment as usual at the ward
1534068|NCT02712905|Drug|INCB059872|"Initial cohort dose of INCB059872 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose(s) will be taken forward into expansion cohorts.
INCB059872 tablets to be administered by mouth."
1534069|NCT02712892|Genetic|Non Interventional Study|
1534070|NCT02712866|Drug|Vedolizumab|Administration of intravenous Vedolizumab in inflammatory bowel disease patients
1534071|NCT02712853|Other|Saliva collection|Collection of saliva via swab for miRNA processing
1534072|NCT02712853|Other|Vineland Adaptive Behavior Scale-II Assessment|
1534073|NCT02712840|Procedure|Freeze-All Protocol|All good morphologic quality blastocysts are vitrified on day 5 or 6. The best quality vitrified blastocyst frozen on day 5 will be warmed and transferred in a subsequent cycle.
1534074|NCT02712840|Procedure|Fresh Protocol|Participants receive fresh embryo transfer of best morphologic quality blastocyst on day 5 and vitrification of all good quality supernumerary blastocysts.
1534075|NCT02712827|Procedure|Progrip|Self-fixating mesh
1534076|NCT02712827|Procedure|Non-Progrip|Non self-fixating mesh with the use of glue
1534077|NCT02712814|Drug|Topical hormonal cream (estrogen)|Patients will be instructed to stop hormonal contraception and to apply 0.1 ml topical cream containing 0.1% of estriol to the vestibule, once daily for 3 months
1534078|NCT02712814|Procedure|Pelvic floor physical therapy|PF physical therapy once weekly for 3 months
1534079|NCT02712814|Procedure|Low Level Laser therapy|non-thermal laser irradiation (low levels of red and near infrared light) is applied directly to the vestibule
1534084|NCT02712788|Drug|Milrinone|
1534085|NCT02712788|Drug|Placebo|
1534086|NCT02712775|Drug|Minocycline (yes/no)|
1534087|NCT02712775|Drug|Placebo|Saline
1534088|NCT02712762|Other|Cross-sectional study|
1534091|NCT02712736|Other|quality of life survey|subjects with PSC will be administered a survey to assess their quality of life
1534092|NCT02712723|Drug|Letrozole|Nonsteroidal aromatase inhibitor
1534093|NCT02712723|Drug|Ribociclib|Oral cyclin-dependent kinase (CDK) inhibitor
1534094|NCT02712723|Drug|Placebo|Placebo for ribociclib
1534096|NCT02712697|Drug|WM (Shentong Granules)|Shentong Granules with Prednisone
1534097|NCT02712697|Drug|Hormone (prednisone)|Oral prednisone
1534098|NCT02712684|Procedure|multiparametric MRI. Multi-parametric ultrasound|The investigators aim to test the hypothesis that multiparametric ultrasound is able to detect clinically significant prostate cancer with an accuracy that is similar to multiparametric MRI. Multi-parametric ultrasound uses different types of ultrasound images to visualise different aspects of the tissue. In other words, the standard grey-scale images shows the gross anatomy, Power Doppler and Contrast enhanced Ultrasound image blood supply (cancers have more blood supply), and Real-Time Elastography images the density of tissue (cancers are more dense).
1534099|NCT02712671|Radiation|Chest radiograph|A chest radiograph involves the participant standing in front of a film and a low dose of radiation passes through the chest. This will be used to look for evidence of tuberculosis infection.
1534100|NCT02712671|Procedure|Blood interferon gamma release assay|Test of T-lymphocytes' response to exposure with tuberculosis antigens. This test is used for the diagnosis of latent tuberculosis infection and involves a blood sample in lithium heparin tube. It will be performed in an off site laboratory (Oxford Immunotec, Abingdon, Oxfordshire, United Kingdom).
1534101|NCT02712671|Procedure|Tuberculin skin testing (TST)|An intradermal test for latent tuberculosis infection that involves a small injection of purified protein derivative (PPD) from inactivated Mycobacterium tuberculosis. The reaction is interpreted at 48-72 hours by measuring the induration produced.
1534102|NCT02712671|Procedure|Sputum induction for mycobacterial microscopy and culture|Participants will breathe in a nebuliser salt solution (3.5% normal saline) for 15 minutes and asked to cough up a sputum sample. This is undertaken in a negative pressure tent. The sample will be tested for mycobacteria under the microscope and then cultured for 42 days in liquid culture bottles the microbiology laboratory.
1534103|NCT02712671|Other|Mycobacterium tuberculosis polymerase chain reaction testing|Sputum from sputum induction will be tested using the GeneXpert system using polymerase chain reaction to identify genes present in Mycobacterium tuberculosis. This test is performed in a microbiology laboratory and tests for the presence of Mycobacterium tuberculosis in sputum, plus genes associated with drug resistance.
1534104|NCT02712671|Procedure|Spirometry|Participants will be asked to blow into a spirometer to measure how much air they can expel in one second and in a whole breath. This will be repeated six times (three times before inhaling 3.5% saline solution and three times five minutes after breathing 3.5% saline solution). The results will be used to identify those whose airways are sensitive to the solution and to look for the presence of airways disease (asthma or chronic obstructive pulmonary disease).
1534105|NCT02712658|Drug|Terbutaline|K+ transport and Ca2+ release and uptake function are stimulated by administration of terbutaline
1534106|NCT02712658|Drug|Placebo|
1534107|NCT02712619|Drug|Metformin|
1534108|NCT02712593|Dietary Supplement|Niagen™ 100|
1534109|NCT02712593|Dietary Supplement|Niagen™ 300|
1534110|NCT02712593|Dietary Supplement|Niagen™ 1000|
1534111|NCT02712593|Other|Placebo|
1534112|NCT02712580|Device|First investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by white light.
1534113|NCT02712580|Device|Second investigational device|The irradiation time is 30 minutes a day, the depth of penetration of the electrons in the skin stimulation is 1.5 uA. The irradiation is accompanied by red light.
1534114|NCT02712580|Device|ES Wetling W200 Placebo with white light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by white light.
1534115|NCT02712580|Device|ES Wetling W200 Placebo with red light|The placebo-irradiation time is 30 minutes a day. The placebo irradiation is accompanied by red light.
1534116|NCT02712567|Drug|Th-302|300 mg/m2 IV on Days 1 and 8 of a 21-day cycle.
1534124|NCT02712515|Procedure|Deep brain stimulation implantation surgery|Deep brain stimulation is a neuromodulatory therapy in which electrodes are implanted in deep brain structures. Electrical pulses are delivered through these electrodes to suppress pathological activity that are causing the symptoms of essential tremor or Parkinson's disease.
1534125|NCT02712515|Device|Ad-Tech Medical Instrumentation Corp. device|Ad-Tech Medical Instrumentation Corp. device is an intraoperative monitoring subdural strips will be placed on the surface of the cortex (non-penetrating).
1534126|NCT02712515|Device|FHC Guideline 4000+ system|Brain signals will be recorded using the clinical FHC Guideline 4000+ system, which is capable of recording during stimulation.
1534127|NCT02712502|Drug|Levofloxacin|"Levofloxacin (Levolet) 750 mg (500 mg Levolet P + P Levolet 250 mg) 1 times a day. The course of treatment is 5 days.
Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
1534128|NCT02712502|Drug|Amoxicillin-Potassium Clavulanate Combination|"Amoxicillin-Potassium Clavulanate Combination (875 mg of amoxicillin trihydrate, potassium clavulanate salt + 125 mg), 2 times a day. The course of treatment 10 days.
• Decongestants: xylometazoline 2 doses in each nostril two times daily - the first 5 days, then if necessary."
1534129|NCT02712489|Other|No intervention|
1534133|NCT02712437|Behavioral|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms, including insomnia, through non-pharmacologic approaches.
1534134|NCT02712424|Biological|DAR-901|
1534135|NCT02712424|Biological|Sterile saline placebo|
1534136|NCT02712411|Drug|HCP1303|
1534137|NCT02712411|Drug|HGP1201|
1534138|NCT02712411|Drug|HIP1402|
1534139|NCT02712398|Device|Phasix™ ST|Phasix™ ST is a fully resorbable mesh with a hydrogel coating that is also resorbable.
1534140|NCT02712385|Other|'The Healthy Brain Rehabilitation Manual'|The Healthy Brain Rehabilitation Manual is a home-based rehabilitation manual developed for the post-TIA and minor stroke population caused by ischaemic events. The manual addresses all the secondary prevention factors required post-ischaemic TIA/minor stroke, e.g. smoking cessation, physical activity promotion.
1534141|NCT02712385|Device|Pedometer|Pedometer used to measure step counts as an objective measurement of level of physical activity.
1534142|NCT02712385|Procedure|Usual care|Usual care provided by healthcare system for patients who suffer a TIA or minor stroke will be recorded and form 'active comparator' control.
1534143|NCT02712385|Behavioral|Telephone follow-up|Telephone follow-up by either a General Practitioner (GP) or Stroke nurse.
1534144|NCT02712372|Drug|AZD4831|AZD4831 1-50 mg/g oral suspension
1534145|NCT02712372|Drug|AZD4831 placebo|AZD4831 placebo oral suspension
1534146|NCT02712359|Procedure|Blood sample collection|A blood sample (~5mL) will be collected from all subjects at each cross-sectional survey (Year 8 and Year 10)
1534147|NCT02712346|Drug|Ambrisentan|Ambrisentan 5 milligrams a day or a placebo (sugar pill) for twelve weeks
1534148|NCT02712346|Drug|Placebo|One inactive pill daily for twelve weeks
1534149|NCT02712333|Behavioral|Air Purifiers|The 17 dormitory rooms and their residents were randomized into two groups: the intervention and control group. The intervention group went through a 9-day intervention with an air purifier placed in the center of the room. All rooms in this group used the same qualified air purifiers (model KJEA200e, 3M), and all participants were required to stay in their dormitory rooms with the windows/doors closed throughout intervention period. All participants and research staffs were blinded to the group assignment.
1534150|NCT02712333|Behavioral|Sham Air Purifiers|The control group went through a 9-day intervention with a sham air purifier (with its filter gauze removed) placed in the center of the room. All rooms used the same air purifiers (model KJEA200e, 3M) as the intervention group, except the filter gauze was removed. During the study period all participants were required to stay in their dormitory rooms with the windows/doors closed. All participants and research staffs were blinded to the group assignment.
1534152|NCT02712307|Drug|Phenoxymethylpenicillin|
1534153|NCT02712294|Other|Neuromuscular Electrical Stimulation|
1534154|NCT02712281|Behavioral|Autism MEAL Plan|"The Autism MEAL plan includes education on feeding issues and behavior management, and specific strategies to expand dietary diversity. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician. The first three sessions focus on understanding feeding problems and behavior management strategies in children with ASD.The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson.
The next seven sessions include child-specific feeding interventions, based on parent-report and home data collection of child meal time behavior. To promote application of new skills, homework accompanies each lesson."
1534155|NCT02712281|Behavioral|Parent Education|"The Parent Education study arm includes 10 sessions focusing on the following topics: understanding Autism Spectrum Disorder (ASD), clinical assessments for ASD, development in children with ASD, medical and genetic comorbidities in ASD, family and sibling issues, treatment alternatives, and education and treatment planning. The Parent Education arm does not include topics related to feeding problems or feeding specific interventions. Each parent receives 1.5 hours of intervention per week for 10 weeks by a masters or doctoral level clinician.
Children randomized to Parent Education will be offered the Autism MEAL Plan after completing the 10-week randomized trial."
1534156|NCT02712268|Other|Checklist|Introduction of a 5-point checklist to be used by all physicians on the internal medicine wards to review and adapt the medications of the patient.
1534218|NCT02711852|Drug|Duvelisib|Subjects will begin taking the same dose from their previous duvelisib study. All doses are taken by mouth twice daily (BID). Two dose reductions are allowed per subject, but doses may not be less than 10 mg. Subjects will take duvelisib until disease progression or unacceptable toxicity.
1534157|NCT02712255|Behavioral|Individual Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Each participant will form their plans individually, without consulting the dyadic partner, but discussing the plans with the experimenter."
1534158|NCT02712255|Behavioral|Dyadic Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.
The plan focuses on physical activity of only one person in the dyad: the patient."
1534159|NCT02712255|Behavioral|Collaborative Planning|"CONTENT: The planning materials and forms have sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans.
Action plans (referring to when, when, and how the individual will act) as well as coping plans (referring to how to overcome potential difficulties, risky situations or temptations to not engage in physical activity). Both partners in the dyad jointly form one plan. This jointly developed plan is discussed with the experimenter.
The plan focuses on physical activity of both persons within the dyad (the patient and the partner) and include some plans for joint physical activity."
1534160|NCT02712255|Behavioral|Education|CONTENT: The education materials address physical activity and healthy nutrition guidelines for age groups and chronic disease. Participants receive a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, strength and endurance training, stretching, and general nutrition guidelines in terms of meal composition, and nutrients, meal frequency. The materials exclude any planning statements. The education is delivered by the experimenter to a patient-partner dyad and discusses individual guidelines for both dyadic partners.
1534161|NCT02712242|Other|Platelet Rich Fibrin|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after PRF placing on palatal wounds.
1534162|NCT02712242|Other|Butyl cyanoacrylate|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after Butyl Cyanoacrylate application on palatal wounds.
1534163|NCT02712242|Other|Wet gauze|Immediate and delayed bleeding, pain, epithelialization, feeding habits and sensation scores were recorded after wet gauze pressure on palatal wounds.
1534164|NCT02712229|Behavioral|CONNECT|"Primary palliative care, care management intervention led by existing oncology nurses. Deployed through a series of nurse-led encounters before or after regularly scheduled oncology visits. Based on best practices in palliative oncology care, the first visit focuses on establishing rapport, addressing symptom needs and choosing a surrogate decision maker. Subsequent visits include additional focus on treatment preferences and future goals.
Visits are guided by patient-reported outcomes. During all encounters, the nurse works with patients/caregivers to complete/update individualized Shared Care Plans. After all visits, the nurse discusses patients' symptoms, preferences and goals with their oncologists via a mandatory check-in session and a follow-up call with the patient and/or caregiver."
1534166|NCT02712203|Biological|MMR vaccine / MMRV vaccine|Subcutaneous injection, two doses
1534167|NCT02712190|Device|High-frequency non-invasive ventilation|Comparison of 2 different settings of HF-NIV
1534168|NCT02712177|Biological|4CMenb|
1534169|NCT02712177|Biological|diphtheria,tetanus,pertussis+polio+Hepatitis B+HiB|
1534170|NCT02712177|Biological|conjugated pneumococcal vaccine|
1534171|NCT02712177|Biological|MMRV|
1534172|NCT02712164|Device|Modified NPWT dressing|Use of negative pressure wound therapy on split-thickness skin graft (STSG) donor sites
1534173|NCT02712164|Device|Tegaderm|Standard of care for STSG donor sites.
1534174|NCT02712151|Procedure|Abdominal Wall Block|bilateral TAP and RS blocks.
1534175|NCT02712151|Procedure|Surgical infiltration|distributed between the 4 laparoscopic port sites.
1534176|NCT02712151|Drug|Sterile saline|Placebo injection
1534177|NCT02712151|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% 1.0 ml/kg total in divided doses for bilateral TAP and RS blocks.
1534178|NCT02712151|Device|Ultrasound|For nerve localization
1534179|NCT02712151|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% 0.4 ml/kg total in divided doses distributed between the 4 laparoscopic port sites
1534180|NCT02712125|Drug|isosorbide mononitrate|20 mg isosorbide mononitrate (IMN) tablet applied vaginally once daily until delivery .
1534181|NCT02712125|Drug|Placebo|placebo vaginal tablets once daily until delivery
1534182|NCT02712112|Drug|Imatinib Mesylate|
1534183|NCT02712086|Other|protein supplementation|Protein supplementation : Protein intake of 30 grams of protein in addition to the usual inputs (to the recommended amounts of 60 to 120 g per day), upon the resumption of oral intake until the fifth week after sleeve gastrectomy.
1534184|NCT02712073|Other|Questionnaire|Self administered questionnaire to evaluate the preparation quality of colonoscopy
1534185|NCT02712060|Other|No intervention|
1534186|NCT02712047|Drug|Fluticasone furoate (FF) (100 mcg)|First blister strip contains FF blended with lactose, 100 mcg per blister
1534187|NCT02712047|Drug|Vilanterol (VI) (25 mcg)|Second blister strip contains vilanterol blended with lactose and magnesium stearate, 25 mcg per blister
1534188|NCT02712047|Drug|Placebo|Matching placebo will have two blister strips, identical in appearance to the inhaler containing active study medication; one containing lactose and the second strip containing lactose and magnesium stearate
1534219|NCT02711839|Dietary Supplement|Commercial diabetic formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
1534915|NCT02707237|Other|Verbal counseling|Verbal counseling done by physician
1534197|NCT02711982|Procedure|Optic canal and optic nerve sheath decompression|within 5 days from trauma
1534198|NCT02711982|Drug|methylprednisolone|within 5 days from trauma
1534199|NCT02711969|Drug|Apatinib mesylate|1,000mg Apatinib mesylate p.o. qd
1534200|NCT02711956|Drug|ZEN003694|
1534201|NCT02711956|Drug|Enzalutamide|
1534202|NCT02711943|Drug|Levofloxacin 500|Oral levofloxacin (Levolet®) at a dose of 500 mg once a day for 28 days
1534203|NCT02711917|Drug|MAC 0.5|0.5 MAC Sevoflurane
1534204|NCT02711917|Drug|MAC 0.75|0.75 MAC Sevoflurane
1534205|NCT02711917|Drug|MAC 1.0|1.0 MAC Sevoflurane
1534206|NCT02711917|Drug|Propofol|Propofol consumption
1534207|NCT02711917|Drug|Etomidate|Etomidate consumption
1534208|NCT02711917|Drug|Rocuronium|Consumption of Rocuronium
1534209|NCT02711904|Drug|Extubation U|"Dose of remifentanil according to the randomization; the infusions that were used to reach the PC target were:
20 years old - 6.0 mcg/Kg/h
30 years old - 5.7 mcg/Kg/h
40 years old - 5.3 mcg/kg/h
50 years old - 5.0 mcg/kg/h
60 years old - 4.6 mcg/kg/h
70 years old - 4.3 mcg/kg/h
80 years old - 4.0 mcg kg/h."
1534210|NCT02711904|Drug|Extubation T|"Dose of infusion of remifentanil to reach a PC 3 - 4 ng/ml, in the following manner:
The assistant placed the infusion balloon in such a way that it could not be seen by the treating anesthesiologist, he proceeded to open the corresponding wrapping according to the consecutive which corresponds to the patient.
The remifentanil dose was adjusted according to the randomization:
20 years old - 9.0 mcg/Kg/h
30 years old - 8.5 mcg/Kg/h
40 years old - 8.0 mcg/kg/h
50 years old - 7.5 mcg/kg/h
60 years old - 7.0 mcg/kg/h
70 years old - 6.5 mcg/kg/h
80 years old - 6.0 mcg kg/h."
1534216|NCT02711865|Biological|IGF1R antibody MK0646|
1534217|NCT02711865|Other|Saline solution|
1534220|NCT02711839|Dietary Supplement|White sweet potato formula|The formula were supplied 1500~1800 kcal daily depend on the patient's individual situation
1534221|NCT02711826|Biological|Polyclonal Regulatory T Cells|Participants randomized to polyTregs group will receive a single infusion of 400 ±100 x 10^6 polyTregs.
1534222|NCT02711826|Biological|Donor-Alloantigen-Reactive Regulatory T Cells|Participants randomized to darTregs group will receive a single infusion of 400 ±100 x 10^6 darTregs.
1534223|NCT02711826|Drug|Everolimus|
1534224|NCT02711826|Drug|Tacrolimus|
1534225|NCT02711826|Drug|Mycophenolate mofetil|All enrolled participants will be on MMF (or MPA below) at the time of study entry at a minimum dose of 1000mg per day.
1534226|NCT02711826|Drug|Mycophenolic acid|All enrolled participants will be on MPA (or MMF above) at the time of study entry at a minimum dose of 720mg per day.
1534227|NCT02711826|Drug|Acetaminophen|650 mg acetaminophen, administered 30-60 minutes prior to infusion as pre-medication.
1534228|NCT02711826|Drug|Diphenhydramine|25-50 mg diphenhydramine intravenously or by mouth, administered 30-60 minutes prior to infusion as pre-medication.
1534229|NCT02711826|Procedure|Biopsy, Kidney|
1534230|NCT02711826|Procedure|Blood Draw|
1534231|NCT02711826|Procedure|Leukapheresis|
1534232|NCT02711826|Procedure|IS regimen conversion|Conversion from Tacrolimus, a calcineurin inhibitors (CNI), to Everolimus, an mTOR inhibitor.
1534233|NCT02711813|Drug|TAB08|biologic
1534234|NCT02711813|Other|Placebo|
1534235|NCT02711800|Drug|Lactobacillus rhamnosus|The investigators will use Culturelle®, a probiotic composed of the micro-organisms Lactobacillus GG. This formulation has been used for the treatment of gastrointestinal inflammation in numerous clinical trials. Dosing will follow the manufacturer's recommendation for children (1 capsule/packet per day), and will be monitored by the study Co-PI, Dr. Seed. Weekly side effects and clinical changes will be monitored by both study therapist and caregiver using the Children's Global Assessment Scale and the Clinical Global Impression Scale (Severity, Improvement, and Efficacy). The treatment duration is 30 days.
1534236|NCT02711787|Device|Experimental group|Robotic assisted passive mobilization (Gloreha, Idrogenet, Italy) and traditional rehabilitation.
1534237|NCT02711787|Device|Control group|Physiotherapy and occupational therapy.
1534238|NCT02711787|Device|traditional rehabilitation|Assisted stretching, shoulder and arm exercises, and functional reaching tasks
1534239|NCT02711774|Device|ultrasonography|ONSD will be measured by a 6-13 MHz linear probe of the ultrasound machine.
1534240|NCT02711761|Device|central venous catheterization|"15 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 15 cm.
17.5 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 17.5 cm.
20 cm: The depth of guide wire prior to tissue dilation during central venous catheterization will be 20 cm."
1534241|NCT02711748|Device|electrostimulation|Electrostimulation using manual defibrillator
1534242|NCT02711748|Device|cardiopulmonary resuscitation|CPR according to guidelines of European Resuscitation Council. Cardiopulmonary resuscitation using manual defibrillator
1534243|NCT02711735|Biological|RUTI® Therapeutic vaccine|Participants randomised to this arm will receive one single dose of RUTI® vaccine in the right/left deltoid muscle.
1534244|NCT02711735|Biological|Matching RUTI® Placebo|Participants randomised to this arm will receive aone single dose of matching RUTI® placebo in the right / left deltoid
1534245|NCT02711722|Device|Neurally adjusted ventilatory assist|"Ventilation supported by NAVA
Blood gas analysis
Respiratory Parameters At the end of the study step Neuro-Ventilatory Efficiency and Neuro-Mechanical Efficiency are measured."
1534246|NCT02711722|Device|PScli1|Pressure support set by clinicians prior to inclusion
1534247|NCT02711722|Device|PScli2|Pressure support at the same level as prior to the study
1534248|NCT02711709|Other|Frailty Measurements|"A frailty index will be determined as a combination of factors.
An older adult is considered physically vulnerable when they experience:
muscle weakness
fatigue
low physical activity, and unintentional loss in body weight, which has been agreed upon by a consensus of experts.
This will be collected at baseline, 3, 6 and 12 months."
1534249|NCT02711709|Other|Modified Minnesota Leisure Time Activities|A questionnaire used to assess physical activity will be administered at baseline, 3, 6 and 12 months.
1534250|NCT02711709|Other|Computed tomography morphometrics|A CT scan will occur as standard of care while the patient is hospitalized. Two additional CT scans will occur at 3 and 12 months to assess for sarcopenia.
1534251|NCT02711709|Other|Mobility Monitors|Mobility monitors will be placed on the patients during the duration of their hospital stay. They will then where them at 3, 6 and 12 months for up to 10 days.
1534252|NCT02711696|Behavioral|GCED, Gluten Contamination Elimination Diet|"A Gluten Free diet based exclusively on naturally gluten-free products and foods, with the elimination from the diet of all commercially available processed food and products labeled gluten free  (Gluten Contamination Elimination Diet, GCED)."
1534253|NCT02711683|Drug|DL-3-n-butylphthalide|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
1534254|NCT02711683|Drug|Donepezil|the patients with mild to moderate AD have already been prescribed the drugs,we just observed passively.
1534255|NCT02711670|Drug|chlorthalidone|
1534256|NCT02711670|Drug|Hydrochlorothiazide|
1534257|NCT02711657|Other|Fibrocyte measurement and lung function test.|
1534294|NCT02711332|Other|capillary blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
1534295|NCT02711332|Other|venous blood sampling|Each subject will have four capillary blood collections on different fingers. A reference venous blood collection will be conducted.
1534337|NCT02711111|Device|orthodontic bone anchor|to apply force on the upper jaw (24 / 7) via intra-oral elastics on the bone-anchor
1534261|NCT02711618|Device|UltraShape Contour I V3|Tissue selectivity is achieved by a proprietary knowledge of parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
1534262|NCT02711605|Device|UltraShape focused ultrasound device|3 biweekly focused ultrasound treatments to the male chest with UltraShape.
1534263|NCT02711592|Genetic|Genetic Panel for Analgesics|All patients will receive genetic test panel to determine individualized optimal pain management following Total Knee Arthroplasty.
1534264|NCT02711579|Drug|Celecoxib|
1534265|NCT02711579|Drug|Placebo|
1534266|NCT02711566|Device|Physioassistant: Haptic training|Subjects in the Haptic training arm had to perform fast-and-accurate reaching movements in different directions. reaching was mediated by a virtual 'tool', consisting of a virtual point mass (m=5 kg) connected to the subjects' hand through a linear spring (stiffness range: Km=200-500 N/m). An additional spring (stiffness range: Kr = 20-70 N/m) was connected between hand a starting point to resist movements. Subjects were instructed to move the virtual point mass as fast as possible through suitable hand motions, so that the mass ends up and stops on the 'target' area.
1534267|NCT02711566|Device|Physioassistant: Sensorimotor training|Subjects in the Sensorimotor training arm had to perform fast-and-accurate reaching movements in different directions. The manipulandum was only used to record hand movements, but throughout the movement it generated no forces.
1534268|NCT02711553|Drug|Ramucirumab|Administered IV
1534269|NCT02711553|Drug|Merestinib|Administered orally
1534270|NCT02711553|Drug|Cisplatin|Administered IV
1534271|NCT02711553|Drug|Gemcitabine|Administered IV
1534272|NCT02711553|Drug|Placebo Oral|Administered orally
1534273|NCT02711553|Drug|Placebo IV|Administered IV
1534274|NCT02711540|Procedure|Balloon Aortic Valvuloplasty|Some patients receive BAV prior to TAVI implantation to facilitate better deployment of the TAVI valve
1534275|NCT02711527|Other|Acupunture group A|"Subjects in Group A will receive 14 needles based on the TCM theory Soothing liver-qi stagnation, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), Ligou蠡沟 (LR 5), Zhongdu 中都(LR6), Xiguan膝關 (LR 7), Ququan曲泉 (LR 8), Zhangmen章門(LR13), Qimen期門 (LR14)."
1534276|NCT02711527|Other|Acupunture group B|"Subjects in Group B will receive 14 needles based on the TCM theory Soothing liver-qi stagnation and Tonifying the heart and the spleenand Invigorating the Yang Qi, all needles will be retained for 30 minutes. Acupoint combination: Taichong太衝 (LR 3), , Sanyinjiao 三陰交 (SP 6), Xuanzhong懸鐘 (GB 39), Shenmen 神門 (HT 7), Zusanli 足三里(ST 36), Baihui 百會(DU 20), Shenting神庭(DU24), Qihai 氣海(RN6), Guanyuan 關元(RN4). Teding Diancibo Pu (abbreviation: TDP) 特定電磁波譜 will be applied to Group B immediately after the needle insertion."
1534277|NCT02711501|Procedure|Laser-assisted surgery.|laser-assisted surgery
1534278|NCT02711501|Procedure|conventional surgery by blade|conventional surgery
1534279|NCT02711488|Behavioral|Intervention group|"The proposed intervention will focus on encouraging students to change their eating habits and food consumption over 9 months (from March to November). Monthly 1-h sessions in the classroom will be given by the class teacher, and includes playing games, staging theater sketches, watching movies and puppet shows, and writing and drawing contests. The activities were designed to discourage students from consuming sugar-sweetened beverages as well as getting them to replace snacks, particularly processed foods (especially cookies) with fresh fruit or healthy homemade food. To reinforce the messages of the in-class nutritional sessions, a set of messages will be sent to the families in the form of illustrated booklets and recipes.
The secondary prevention strategy at households will be developed for those with excessive weight. The family will receive additional motivation to change these behaviors, using the community health agents as the encourager."
1534280|NCT02711462|Drug|PF-06687234|PF-06687234 will be administered via the SC or the IV route and in either single dose or multiple doses
1534281|NCT02711462|Drug|Placebo|In Cohorts 1 and 2, up to 1 subject will receive placebo. In all other Cohorts (Cohorts 3 to 11), up to 2 subjects will receive placebo.
1534282|NCT02711449|Drug|Methylprednisolone|125 mg methylprednisolone as an intravenously bolus injection approximately 30 minutes prior to skin incision.
1534283|NCT02711449|Drug|0.9% Saline|0,9% Saline as an intravenously bolus injection approximately 30 minutes prior to skin incision.
1534284|NCT02711436|Device|Computed Tomography Scan|
1534285|NCT02711436|Device|Fast Magnetic Resonance Imaging|
1534286|NCT02711423|Drug|Gantenerumab|Gantenerumab will be supplied as a high-concentration liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
1534287|NCT02711423|Drug|Placebo|Placebo will be supplied as a matching liquid formulation for SC injection into the abdomen. The single dose will be administered on Day 1.
1534288|NCT02711410|Drug|Clopidogrel|
1534289|NCT02711397|Other|Observational study|Comparison excretion levels of gluten immunogenic peptides
1534290|NCT02711371|Other|fMRI|
1534291|NCT02711358|Drug|indomethacin suppositories|The patients will be instructed to self-administer a single rectal dose of 50 mg indomethacin 30 min before the scheduled time of the procedure
1534292|NCT02711358|Drug|placebo|The patient swill be instructed to self-administer a single rectal dose of placebo 30 min before the scheduled time of the procedure
1534293|NCT02711345|Drug|LTT462|ERK Inhibitor
1535385|NCT02703766|Behavioral|overfeeding induced weight gain|
1534296|NCT02711319|Device|rTMS|For real (active) rTMS, we applied 2 seconds duration bursts of 20 Hz (40 pulses/burst) with intertrain intervals of 28 seconds, for a total of 1800 pulses over 20 minutes
1534297|NCT02711319|Device|sham rTMS|"Sham Comparator: sham rTMS (SHAM GROUP)
For sham rTMS, the double cone coil was again held over the vertex, but it was disconnected from the main stimulator unit. Instead, a second coil (8-shaped) was connected to the MagStim stimulator, and discharged under the patient's pillow (2)."
1534298|NCT02711306|Other|GMN diet first, than PN diet|The GMN diet was composed of well-cooked noodle with 2 g of konjac glucomannan in a dosage of 200 g/piece twice daily for 4 weeks.
1534299|NCT02711306|Other|PN diet first, than GMN diet|The PN diet was composed of well-cooked noodle in a dosage of 200 g/piece twice daily for 4 weeks.
1534300|NCT02711293|Other|ART home delivery|Community health workers visit participants who are clinically stable on antiretroviral therapy (ART) at home every four weeks to provide a one-month's supply of ART. Clinically stable on ART was defined as 1) taking ART for at least six months, 2) having had a CD4-cell count >350 cells/μL or a suppressed viral load at six or more months after ART initiation, and 3) the patient's most current CD4-cell count must have been >350 cells/μL or the most current viral load must have shown viral suppression, with the last measurement not taken more than six months ago.
1534301|NCT02711293|Other|Enhanced nutrition counseling|Community health workers visit participants at home to provide standard counseling (focusing on family planning, prevention of HIV transmission, and ART adherence) plus enhanced nutrition counseling (covering food production and dietary advice).
1534302|NCT02711280|Drug|Sevoflurane|
1534303|NCT02711280|Drug|Propofol|
1995954|NCT02607592|Drug|cisplatin and pemetrexed|cisplatin 25mg/m2 d1-3+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
1534312|NCT02711254|Device|Phantom System|Unloading of medial knee compartment with Phantom System
1534313|NCT02711241|Drug|Dipyrone|1 gram by slow IV infusion
1534314|NCT02711241|Drug|Papaverine|80 mg by slow intravenous infusion
1534315|NCT02711228|Biological|Subcutaneous Immune Globulin (Human) (Hizentra)|Hizentra, Subcutaneous Immune Globulin (Human) (SCIg), is a ready to use, polyvalent human normal Immunoglobulin G (IgG) for subcutaneous administration. Hizentra is a 20% IgG protein solution, is prepared from large pools of human plasma, and is stabilized by L-Proline.
1534316|NCT02711215|Diagnostic Test|PET/MR [11C]DASB|2 PET/MR scans will be performed (placebo/citalopram - double-blind randomized cross-over)
1534317|NCT02711215|Drug|Citalopram|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
1534318|NCT02711215|Drug|Escitalopram (Mirtazapine/Duloxetine/Venlafaxine)|After completion of imaging procedures, patients will receive treatment with escitalopram 10-20mg. In case of non-response, after 6 weeks, treatment will be switched to either Mirtazapine, Duloxetine or Venlafaxine
1534319|NCT02711215|Drug|Placebo|8mg citalopram or placebo (saline) will be applied during PET/MR measurements in a double-blind randomized cross-over design
1534320|NCT02711202|Drug|MabCampath,|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
1534321|NCT02711202|Drug|Remicade|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
1534322|NCT02711202|Drug|Sirolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
1534323|NCT02711202|Drug|Tacrolimus|Primary deceased donor kidney transplant recipients received 2x20 mg Alemtuzumab (day 0/day 1) followed by 5 mg/kg Infliximab (day 2). For 14 days all patients received only tacrolimus, then they were randomized to either receive tacrolimus (TAC, n=13) or sirolimus (SIR, n=7) monotherapy, respectively.
1534324|NCT02711189|Drug|Oxytocin|Oxytocin nasal spray given in dose 80
1534325|NCT02711189|Other|Placebo|
1534326|NCT02711176|Drug|Nexium|Patients in experimental group will receive the 14 day single dose of Nexium 40 mg daily
1534327|NCT02711176|Drug|Tinafas|Patients in experimental group will receive the 14 day single dose regimen of Tinafas 1 g daily
1534328|NCT02711176|Drug|Tavanex|Patients in experimental group will receive the 14 day single dose of Tavanex 500 mg daily
1534329|NCT02711176|Drug|Lanzol|Patients in active comparator group will receive the 14 day lansoprazole (Lanzol) 30 mg twice daily
1534330|NCT02711176|Drug|Klacid|Patients in active comparator group will receive the 14 day clarithromycin (Klacid) 500 mg twice daily twice daily
1534331|NCT02711176|Drug|Iramox|Patients in active comparator group will receive the 14 day amoxicillin (Iramox) 1 g twice daily
1534332|NCT02711163|Dietary Supplement|Extensively Hydrolyzed formula|
1534333|NCT02711163|Dietary Supplement|Amino acid formula|
1534334|NCT02711150|Device|PLL Length Measured through US|The PLL will be measured for each allocated position: EPD or Flexed Position
1534335|NCT02711137|Drug|INCB057643|Initial cohort dose of INCB057643 at the protocol-specified starting dose, with subsequent dose escalations based on protocol-specific criteria. The recommended treatment group-specific dose(s) will be taken forward into expansion cohorts.
1534336|NCT02711111|Device|Face mask|to apply for on the upper jaw (12 - 14 hrs / day) via extra-oral elastics to the face mask
1534338|NCT02711098|Biological|"Inflammatory biomarkers dosage Hypothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management between 33°C and 37°C.
1534339|NCT02711098|Biological|"Inflammatory biomarkers dosage Normothermia Arm"|There is 6 dosage of inflammatory biomarker per patient included: H0, H12, H24, H36, H48 and H72 during targeted temperature management at 37°C.
1534340|NCT02711085|Other|No intervention|No intervention - observational study
1534341|NCT02711072|Drug|control group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 100 µ of intrathecal Morphine+ infiltration catheter with saline 5 ml/h
1534342|NCT02711072|Drug|infiltration group|spinal anesthesia with 10 mg hyperbaric Bupivacaïne 0,5% + 2,5 µ Sufentanyl + 1ml of saline + infiltration catheter with 5 ml/h of Bupivacaïne 0,125%.
1534343|NCT02711059|Procedure|parathyroidectomy|surgical treatment of hyperparathyroidism
1534344|NCT02711046|Procedure|single stage nasolabial flap|The versatility of this flap has been attributed to the fact that there is often abundant non-hair-bearing skin in this well-vascularized region. The facial and infraorbital arteries are frequently cited in anatomic descriptions of the nasolabial flap. The venous drainage is believed to be via the angular and facial veins.
1534345|NCT02711033|Procedure|Laparoscopic-assisted total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the laparoscopic-assisted total gastrectomy (LATG) group, they will received LATG with spleen-preserving splenic hilum lymph nodes dissection.
1534346|NCT02711033|Procedure|Open total gastrectomy|When patients with advanced proximal gastric cancer are randomized in the open total gastrectomy (OTG) group, they will received OTG with spleen-preserving splenic hilum lymph nodes dissection.
1534347|NCT02711020|Behavioral|Cognitive Behavioral Therapy|Patients assigned to this arm will receive a maximum of 18 1-hour sessions of Cognitive Behavioral Therapy following the intervention techniques included in various group therapy manuals for patients with fibromyalgia, plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. Techniques are adapted to individual format in the following modules: (1) Psychoeducation, (2) Relaxation, (3) Behavioral Activation, (4) Cognitive Restructuring, (5) Problem solving, (6) Assertiveness Training, and (7) Relapse Prevention.
1534348|NCT02711020|Behavioral|Personal Construct Therapy|"Patients will receive a maximum of 18 1-hour sessions of Personal Constructs Therapy plus up to three 1-hour boost sessions between 3 and 5 months after the end of therapy. The intervention will follow a protocol designed specifically for this project based on the clinical experience of a previous pilot study. It will consist of 4 stages: (1) Analysis of patient's request, goals setting, identification of the main dilemmas, and other personal meanings relevant for self and others' construction; (2) feedback on the assessment results and problem reframing in terms of a dilemma and/or other personal meanings; (3) work on the dilemmas and/or other aspects of the self and others' construction; and (4) end of the therapeutic process outlining personal projects and future perspectives."
1534349|NCT02711007|Drug|apatinib|Apatinib is a small-molecule VEGFR tyrosine kinase inhibitor, similar to vatalanib (PTK787), but with a binding affinity 10 times that of vatalanib or sorafenib.
1534350|NCT02710994|Drug|CDFR0209|Immediate release omeprazole 40 mg and sodium bicarbonate 1,100 mg
1534351|NCT02710994|Drug|Losec|Losec 40 mg
1534352|NCT02710981|Drug|clomiphene citrate|Clomiphene citrate only arm: Patients received Clomiphene citrate induction ( (in a dose of 100 mg/ day in two divided doses starting from day 3 of the cycle for 5 days) for the 6th cycle. A gel base, without medicament (vehicle only), was applied vaginally in a dose of 5 gm twice per day, from cycle day 8 to the day of HCG injection. Sonographic assessment of endometrial thickness together with Uterine artery Doppler evaluation were done in the late proliferative phase ( Day of HCG injection).
1534353|NCT02710981|Drug|Sildenafil vaginal gel|In addition to clomiphene citrate treatment as the previous group, women in the second arm were prescribed sildenafil vaginal gel in a dose of 5 g gel applied vaginally twice daily from cycle day 8 to the day of HCG injection. The sildenafil vaginal gel consists of sildenafil acetate as a medicament loaded on an in situ gelling system based on two polymers: Pluronic p-127, and Hydroxy Ethyl Cellulose.The gel was prepared in collaboration with the department of pharmaceutics, faculty of Pharmacy, Assiut University. Sixty grams of gel were prepared in tubes and every patient was given 10 applicators like that used for administration of vaginal antimycotic creams to use them for applying the gel.
1534354|NCT02710968|Device|11540KE and Balt Goldbal 2 balloon|Fetoscopic tracheal occlusion will be performed using above devices and reversed after 4-5 weeks.
1534355|NCT02710955|Dietary Supplement|Thickened infant formula|
1534356|NCT02710942|Behavioral|SPHERE|
1534357|NCT02710942|Behavioral|PRISM|
1534358|NCT02710916|Device|SD-OCT Spectralis|All patients will undergo a complete ophthalmological examination with SD-OCT complete evaluation
1534359|NCT02710903|Procedure|Stent-induced biofilm overgrowth|Customized stents will be fabricated for each subject. Stents will be fabricated to resemble an acrylic mouth-guard but extended to cover approximately 2mm over gingival margins. Stents will form a seal and rest on the gingiva, but will be relieved on the tooth and tissue side except for the occlusal surfaces to avoid disturbing plaque or gingival tissues. Acrylic stents will abstained from brushing and flossing teeth in one maxillary and one mandibular posterior sextant during a three- week period. Patients will be monitored for safety every week and after the induction of experimental biofilm overgrowth through 21 days
1534361|NCT02710877|Device|Programmed Intermittent bolus|Programmed epidural bolus of 10 ml mixture every 75 minutes, plus patient controlled bolus of 5 ml same mixture; lock-out 15 minutes.
1534362|NCT02710877|Other|Manual epidural bolus|Epidural bolus of 15 ml levobupivacaine and sufentanyl 10 mcg or 5 mcg administered by anesthesist on maternal request.
1534363|NCT02710877|Drug|Levobupivacaine|Levobupivacaine 0,0625% through peridural catheter
1534364|NCT02710877|Drug|Sufentanil 4 mcg|Sufentanil 0,4 mcg/ml through peridural catheter
1534365|NCT02710877|Drug|Sufentanil 5 mcg|Sufentanil 5 mcg through peridural catheter
1534366|NCT02710851|Biological|low dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
1536343|NCT02697084|Other|anal cancer|Anal cancer patients with TEP TDM
1534367|NCT02710851|Biological|low dosage HPV Vaccine(1:2)|"Participants would intramuscularly receive low dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:2 ratio.
All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
1534368|NCT02710851|Biological|high dosage HPV Vaccine(1:1)|"Participants would intramuscularly receive high dosage HPV bivalent vaccine with virus-like particles type 6 and 11 at 1:1 ratio.
All participants would be invited to receive 3 doses vaccine at 0, 1, 6 month."
1534369|NCT02710851|Biological|Hepatitis E vaccine,Hecolin®|Participants would intramuscularly receive Hepatitis E vaccine for 3 doses at 0, 1, 6 month.
1534370|NCT02710838|Device|infrared endoscopy|Firstly use standard white light and narrow-band imaging to observe the lesion, and then inject the contrast medium ICG, after 2 minutes,switch to infrared light to observe, record the image data, then accomplish the examination.
1534371|NCT02710825|Other|Osteopathy|"The treatment begins, if possible, on the body part of the child whose osteopathic score is the highest , with the least elasticity and mobility. Then the other restricted joints will be treated. The set of techniques will be carried out after palpation and appropriate tensioning. The various actions will be carried out on the tissues and joints who have been particularly affected by the operation.
When a joint or tissue has a restricted mobility in a direction or a specific movement, it will require appropriate and gently manual correction, in order to reduce and improve its functionality."
1534372|NCT02710825|Other|superficial palpatory agreement|The simulated treatment also begins with the body part of the child whose osteopathic score is the highest. Then the other restricted joints will be treated. The set of techniques will be carried out with the same investments as the tests , with a superficial palpatory agreement and without tensioning so that the restricted articulation or tissue will not be corrected
1534373|NCT02710812|Procedure|Local Excision or Wait-and-See|"Local excision can be done both with traditional technique and with endoscopic technique (TEM, TAMIS, etc.).
The following principles should be respected:
A gross margin of at least 0.5 cm;
full-thickness excision including mucosa, submucosa, muscle and peri-rectal fat;
determination of the specimen on the support by pins at the edges in order to facilitate the interpretation of histological pathologist."
1534374|NCT02710799|Other|Teleconsultation|The teleconsultations will be performed by medical doctors, mostly family physicians, but also internists and endocrinologists. The teleconsultations will follow a structured format to discuss some topics on the disease and access the relevant information (based on the state's protocols). The doubts from the primary care physician will be addressed.
1534375|NCT02710799|Other|Protocol|The informations provided in the referral list will be evaluated through the state's referrals protocols.
1534376|NCT02710786|Procedure|Gastric bypass|Gastric bypass surgery, i.e., small gastric pouch and excluded main stomach
1534377|NCT02710773|Other|Backward Walking Treadmill Training|The intervention will consist of 5 minutes of forward walking (warm-up phase), 10 minutes of backward walking (intervention phase) and 5 minutes of forward walking (cool-down phase). The session will be performed on a treadmill device. The backward training speed will be increase consecutively: during the week 1, the intervention will be performed at 0,8 km/h; during the week 2 the speed will be 1,0 km/h; finally, during the week 3 the speed will be increased till 1,2 km/h.
1534378|NCT02710773|Other|Treadmill Training|The intervention will consist of 20 minutes of forward walking on a treadmill device.
1534379|NCT02710760|Other|Adoption Encouragement Treatment|Households in the Adoption Encouragement Treatment received child nutrition focused guidance on the nutritional and agronomic benefits of Quality Protein Maize (QPM) adoption, and the opportunity to order up to 6 kg of QPM seed to plant in their own fields.
1534380|NCT02710760|Other|Consumption Encouragement Treatment|Households in the Consumption Encouragement Treatment received the same guidance as households in the Adoption Encouragement Treatment, as well as additional guidance on the importance of specifically targeting foods made with QPM to young children and tools to help households keep the grain separate and remember to feed QPM-based foods to the young children.
1534381|NCT02710747|Genetic|CYP2C9;VKORC1|
1534382|NCT02710734|Drug|Methotrexate|Administered Day 1 of each 14 day cycle for 3 cycles
1534383|NCT02710734|Drug|Vinblastine|Administered Day 1 of each 14 day cycle for 3 cycles
1534384|NCT02710734|Drug|Doxorubicin|Administered Day 1 of each 14 day cycle for 3 cycles
1534385|NCT02710734|Drug|Cisplatin|Administered Day 1 of each 14 day cycle for 3 cycles
1534386|NCT02710734|Radiation|Intensity modulated radiation therapy (IMRT)|2.0 Gy per fraction to the whole bladder plus a margin for a total of 32 fractions (64.0 Gy). Radiation will be administered from Monday to Friday
1534387|NCT02710734|Procedure|Transurethral Resection of Bladder tumor|Performed at before and after AMVAC and after chemoradiation and intravesicle therapy
1534388|NCT02710734|Drug|5-FU|Continuous 24hr Intravenous infusion days 1-5 and 16-20 with radiation treatment
1534389|NCT02710734|Drug|Mitomycin C|Intravenous on day 1 with radiation treatment
1534390|NCT02710721|Other|Fasting|Patients realize a 60h-modified fasting (36h before and 24h after chemotherapy) with a dietary energy supply 350-400kcal per day with fruit and vegetable juices or, if not feasible, an established fasting-mimicking diet of 600-800 kcal according to Longo et al. Between chemotherapy a Mediterranean diet with nutrition training individually and in small groups by trained nutritionists at the Study Centre will be practiced.
1534391|NCT02710721|Other|Control|Participants of the control group will receive an individual nutrition training and in small groups according to the Mediterranean diet.
1534393|NCT02710695|Behavioral|Control|This group will receive a standardized 10 minute discussion.
1534394|NCT02710695|Behavioral|Repeat Back|This group will receive a standardized 10 minute discussion and the patient will repeat back the key concepts.
1534395|NCT02710682|Procedure|Mini-open surgery|"This treatment will be administered by an orthopedic surgeon specialized in upper limb surgery.
Skin disinfection; Local anesthesia (lidocaine 1%).
Skin incision, slightly anterior to lateral epicondyle.
Exposure of the plane between the tendon and fascia.
Extensor Carpi Radialis Longus (ECRL) tendon is lifted to expose the Extensor Carpi Radialis Brevis (ECRB) tendon.
Excision of diseased tissue of the ECRB tendon.
ECRL tendon is sutured back to the fascia. The skin is closed.
Patient is monitored for 30 minutes after procedure."
1534396|NCT02710682|Device|Ultrasound-guided Tendon fenestration|"This treatment will be administered by a fellowship-trained MSK radiologist.
Patient's elbow at 70 degrees of flexion with the forearm pronated resting on an examination table.
Skin disinfection. Local anesthesia, skin, superficial fascia and tendon, with lidocaine 1%.
Using a 22 G needle under continuous ultrasound guidance, several passes (about 20-30) within the abnormal area of the tendon, contacting the bone, until the area softens.
Patient monitored for 30 minutes, before being discharged."
1534397|NCT02710669|Drug|(R)-propafenone|
1534398|NCT02710669|Drug|(S)-Propafenone|
1534399|NCT02710669|Drug|Placebo|
1534400|NCT02710656|Device|Legflow® balloon|Percutaneous angioplasty performed with a Drug coated balloon (DCB) with Paclitaxel
1534401|NCT02710656|Device|Standard PTA|Percutaneous angioplasty performed with a standard balloon
1534403|NCT02710630|Drug|Dabigatran etexilate tablet E1|
1534404|NCT02710630|Drug|Dabigatran etexilate tablet D1|
1534405|NCT02710630|Drug|Dabigatran etexilate tablet C1|
1534406|NCT02710630|Drug|Dabigatran etexilate tablet B1|
1534407|NCT02710630|Drug|Dabigatran etexilate tablet A1|
1534408|NCT02710630|Drug|Dabigatran etexilate capsule|
1534409|NCT02710617|Device|Blood glucose monitoring systems for point-of-care-testing|
1534410|NCT02710604|Drug|CMX157|tablet
1534411|NCT02710604|Drug|TDF|300mg tablet
1534412|NCT02710591|Drug|Rimeporide|"Cohort 1:
50 mg TID in patients with a body weight ≤ 30kg at Baseline and 75 mg TID in patients with a body weight > 30kg at Baseline
Cohort 2:
100mg TID in patients with a body weight ≤ 30kg at baseline and 150 mg TID in patients with a body weight > 30kg at Baseline
Cohort 3:
150 mg TID in patients with a body weight ≤ 30kg at baseline and 200 mg TID in patients with a body weight > 30kg at Baseline
Cohort 4:
200 mg TID in patients with a body weight ≤ 30kg at Baseline and 300 mg TID mg TID in patients with a body weight > 30kg at Baseline"
1534413|NCT02710578|Drug|Alcohol|A single oral administration of an alcoholic beverage mixed in a 1:3 ratio of alcohol (Vodka) to tonic water to obtain a target BAC of 0.08mg%
1534414|NCT02710578|Drug|Placebo|A single oral administration of a beverage containing tonic water of the same volume as the alcoholic beverage.
1534415|NCT02710565|Other|Cohort|Obtaining additional EBUS TBNA samples for cell culture
1534416|NCT02710552|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 5 mg, indapamide 1,25 and amlodipine 5 mg
1534417|NCT02710552|Drug|Reaptan (perindopril, amlodipine)|Fixed combination of perindopril 10 mg and amlodipine 5 mg
1534418|NCT02710539|Drug|perindopril, indapamide , amlodipine|Free combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
1534419|NCT02710539|Drug|Tripliam (perindopril, indapamide, amlodipine)|Fixed combination of perindopril 10 mg, indapamide 2,5 mg, amlodipine 10 mg
1534420|NCT02710526|Drug|CAM2038|Long-Acting Subcutaneous Injectable Depot of Buprenorphine
1534421|NCT02710513|Dietary Supplement|Beta-glucans|2 months Mediterranean Diet-based free diet (run-in) + 2 months Mediterranean Diet-based free diet with a daily supplementation of 100 g of beta-glucans pasta (intervention). Medical visits, dietary counselling with food frequency questionnaires administration, blood, urine and feces collection were performed before (T0) and after (T2) the two months of beta-glucans intervention.
1534422|NCT02710500|Drug|rAAVrh74.MHCK7.DYSF.DV|Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.
1534423|NCT02710487|Behavioral|REMSA|Awakening from REM sleep during the last hour of the sleep period
1534424|NCT02710487|Behavioral|NREMSA|Awakening from N2 (NREM) sleep during the last hour of the sleep period
1534425|NCT02710474|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists in a randomized controlled trial (RCT) model (Part I) or applied unit-wide (either through dedicated staff or bedside nurses in Part II). Under FNI, specialists or nurses will support the parents and facilitate contact between mother and baby during the infant's NICU stay. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
1534426|NCT02710474|Behavioral|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
1534427|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test
1534428|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test right after taking the mixture of grape and pomegranate polyphenols
1534429|NCT02710461|Dietary Supplement|Mixture of grape pomace and pomegranate pomace|Oral Glucose Tolerance Test ten hours after taking the mixture of grape and pomegranate polyphenols
1534430|NCT02710448|Drug|Metformin|Metformin (Glucophage ®), oral antidiabetic, will be administered as it is usually recommended: engaged during or at the end of the meal in the evening for the single dose 500 mg (Phase 1), the evening and morning for total doses of 1000 mg, 2000 mg and 3000 mg (with, respectively, 2 tab. 500 mg, 2 tab. to 1000 mg, 1 tab. to 1000 mg and 2 tab. to 1000 mg), a fourth dose is also scheduled to stage one (3000 mg / d)
1534431|NCT02710435|Device|Neovasc Reducer System|An aid in the management of chronic refractory angina pectoris
1534432|NCT02710422|Biological|Amniotic Membrane Placement|Amniotic membranes will be placed over the neurovascular bundle after extirpative RARP, and before the urethrovesical anastomosis. The membrane will cut into two longitudinal pieces and it will be placed over each neurovascular bundle separately.
1534433|NCT02710422|Behavioral|EPIC 26|Participants will receive EPIC 26 psychosocial questionnaire at baseline, and at 3, 6, 9 and 12 months post-RARP.
1534434|NCT02710422|Other|PSA Measurement|Measurement of serum PSA levels at baseline, and at 3, 6, 9 and 12 months post-RARP.
1534435|NCT02710422|Behavioral|Sexual History Inventory for Men|Sexual History Inventory for Men (SHIM) psychosocial questionnaire administered 3,6, 9 and 12 months post-RARP.
1534436|NCT02710409|Biological|Quadrivalent influenza vaccine|0.5 ml/vial, one dose, intramuscular injection on day 0
1534437|NCT02710409|Biological|Trivalent influenza vaccine A|0.5 ml/vial, one dose, intramuscular injection on day 0
1534438|NCT02710409|Biological|Trivalent influenza vaccine B|0.5 ml/vial, one dose, intramuscular injection on day 0
1534439|NCT02710396|Drug|Pembrolizumab|"Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the immunoglobulin G4 (IgG4)/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
Pembrolizumab 200 mg will be administered IV every 3 weeks."
1534440|NCT02710357|Procedure|Mandibular Overdenture|Participants allocated to the intervention group will have an implant placed in the mandible midline and subsequently the denture will be converted to an overdenture.
1534441|NCT02710357|Procedure|Mandibular complete denture|Participants allocated to the control group will receive new conventional mandibular dentures.
1534442|NCT02710344|Behavioral|Telehealth Program|Psychiatric telehealth program, content assigned based on diagnosis, entry to study requires psychiatric instability defined as use of emergency/high cost psychiatric services.
1534443|NCT02710331|Drug|Active Dronabinol|10 mg capsule of Dronabinol will be administered orally.
1534444|NCT02710331|Drug|Placebo|Control: no alcohol, administered for ~80 minutes.
1534445|NCT02710331|Drug|Placebo|Control: Placebo pill (no active cannabinoids) administered orally.
1534446|NCT02710331|Drug|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
1534447|NCT02710318|Behavioral|Electronic immunization alert|Immunization alert in the electronic health record
1534448|NCT02710305|Drug|oral hyoscine butyl bromide tablets plus lidocaine cream|patients will take oral hyoscine butyl bromide 30 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before the procedure
1534449|NCT02710305|Drug|oral placebo tablets plus placebo cream|patients will take oral placebo 30 minutes before the procedure plus placebo cream placed into their cervix immediately before the procedure
1534450|NCT02710292|Device|Delefilcon A contact lenses|
1534451|NCT02710292|Device|Narafilcon A contact lenses|
1534452|NCT02710279|Behavioral|Trier Social Stress Test (TSST)|"For the TSST the participants are instructed to imagine having applied for their dream job and that they are now invited to a job interview. Three successive phases: (1) A preparation period (3 min), (2) a free speech: explain why you are the best candidate for the job (5 min), (3) a mental arithmetic complex task (5 min). The two tasks (task 2 and 3) are performed in front of a selection committee, three persons dressed in white lab coats, acting in a reserved manner and providing no facial or verbal feedback. Additionally, participants are told that they are video-taped and told that their performance will be evaluated. (in fact, there is no video-tape, just a false camera). After the TSST, patients have to answer to a questionnaire on their smartphone, 5 times a day during 7 days."
1534453|NCT02710279|Device|smartphone|
1534454|NCT02710266|Drug|Preoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the preoperative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
1534455|NCT02710266|Drug|Intraoperative Gabexate Mesilate group|Gabexate Mesilate is administered from the operative day and continued for 5 days. 300mg of Gabexate Mesilate is mixed with 500cc of 5% dextrose water and administered at 40cc/hr for 12 hours each day.
1534456|NCT02710266|Drug|hepatectomy with dextrose water|Gabexate Mesilate is not administered. As placebo, 500cc of 5% dextrose water is administered at 40cc/hr for 12 hours
1534457|NCT02710253|Radiation|Radiation Therapy|Radiation treatment utilized in this trial consists of standard doses to 50 Gy in 4 fractions with stereotactic radiation or 60-70 Gy in 10 fractions (6-7 Gy/fraction,) or 20-30 Gy in 5 fractions or 20-30 Gy in 5 fractions or 30-45 Gy in 10-15 fractions with conventional external beam radiation.
1534458|NCT02710240|Drug|Indocyanine Green (ICG)|
1534459|NCT02710240|Radiation|intraoperative near-infrared (NIR)|
1534460|NCT02710227|Other|(PSQI), (STQ).|Sleep quality, sleep timing parameters and circadian preference were evaluated using (PSQI), (STQ).
1534461|NCT02710214|Drug|Tissue Selective Estrogen Complex|Once-daily dosing of Duavee for 8 weeks.
1534462|NCT02710214|Drug|Placebo|Once-daily dosing of placebo for 8 weeks
1534463|NCT02710201|Behavioral|Descriptive Social Norm|
1534464|NCT02710201|Behavioral|Descriptive-plus-Injunctive Social Norm|
1534465|NCT02710188|Drug|HTL0009936 modified release|HTL0009936 modified release
1534466|NCT02710188|Drug|HTL0009936 immediate release|HTL0009936 immediate release
1534467|NCT02710175|Other|serum TSH level|
1534468|NCT02710162|Device|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flanged rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest maximum inspiratory pressure (MIP) and maximum expiratory pressure (MEP) used.
1534469|NCT02710162|Device|Iowa Oral Performance Instrument|The Iowa Oral Performance Instrument (IOPI) is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
1534470|NCT02710162|Device|Electrical Impedance Myography|The SFB7 Bioimpedance device measures the function of the tongue by calculating measures of reactance, resistance and phase once a custom electrode array is placed on the midline of the subject's tongue for approximately 2 seconds.
1534471|NCT02710162|Drug|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
1534472|NCT02710162|Procedure|Videofluoroscopic Swallowing Study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
1534503|NCT02710032|Behavioral|Social Network-Based Adherence Intervention|Participants in clusters randomized to the intervention arm will be asked to attend a series of weekly group workshops emphasizing a collective approach to HIV prevention and mutual support for PrEP adherence.
1534473|NCT02710162|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
1534474|NCT02710162|Other|Swallowing Related Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
1534475|NCT02710162|Other|Functional Oral Intake Scale|The Functional Oral Intake Scale (FOIS) will be used for participants to report their food intake habits.
1534476|NCT02710162|Other|Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised|The Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) will be used to track global disease progression in participants.
1534477|NCT02710162|Other|Eating Assessment Tool-10|The Eating Assessment Tool-10 will be used for participant reporting of swallowing system severity.
1534478|NCT02710162|Other|Communicative Effectiveness Survey|The Communication Effectiveness Survey (CES) will be used for participant reporting of communication abilities across different speech contexts.
1534479|NCT02710162|Other|The Center for Neurologic Studies Bulbar Function Scale|The Center for Neurologic Studies Bulbar Function Scale (CNS-BFS) will be used to report bulbar function in study participants.
1534480|NCT02710149|Biological|Anti-CD20-CAR-transduced T cells|Patients receive autologous-derived CD20-targeted CAR-T cells on day 1, 2 after receiving lymphodepleting chemotherapy.
1534481|NCT02710136|Biological|Glycerinated German Cockroach Allergenic Extract|"Participants will receive escalating doses intranasally. Briefly: per protocol- Phase 1a NAC: N=10 cockroach sensitive adults with asthma will undergo nasal allergen challenge with dose escalation (up to 8 doses per protocol). Phase 1b: Phase 1a subjects will have repeat NAC with dose escalation (up to 8 doses).
Phase 2: N=25 cockroach sensitive children with asthma (ages 8 - 14 years) will undergo NAC with doses determined by Phase 1a data (e.g., symptoms and safety data)."
1534484|NCT02710110|Device|PowerLung trainer|PowerLung trainer will be utilized which has both an inspiratory and expiratory loading capacity for training. A single daily training session will consist of three sets of 10 repetitions for a total of 30 inspiratory repetitions and 30 expiratory repetitions (i.e. 60 repetitions) for 5 days a week, for 3 months.
1534485|NCT02710110|Device|Micro Mouth Pressure Meter|The participant will be seated with the nose occluded using a nose clip. After inhaling to total lung capacity, the participant will place his or her lips around the mouthpiece and blow out as forcefully as possible. A flange rubber mouthpiece will be used to overcome the inability of some individuals to create tight lip seal due to facial muscle weakness. Three trials will be performed and the patients highest Maximum Inspiratory Pressures (MIP) and Maximal Expiratory Pressure (MEP) used.
1534486|NCT02710110|Procedure|Pulmonary Function Testing|Pulmonary Function testing will be performed using conventional methods and will include the following outcomes: forced vital capacity (FVC), sniff nasal inspiratory pressure (SNIP), peak expiratory flow (PEF), forced expiratory volume (FEV1) expressed as a percentage of predicted values.
1534487|NCT02710110|Procedure|Videofluoroscopic swallowing study|Videofluoroscopic swallowing study will be performed to measure the oropharyngeal swallowing.
1534488|NCT02710110|Other|Swallowing Quality of Life Questionnaire|Swallowing Quality of Life Questionnaire (SWAL-QOL) will be used for participant reporting of swallow-related quality of life.
1534489|NCT02710110|Device|Iowa Oral Pressure Instrument|The IOPI is a device that measures the peak pressure performance of lingual strength and endurance via the action of a bulb placed on the hard palate.
1534490|NCT02710110|Drug|Capsaicin|"A capsaicin challenge with three randomized blocks of 0, 50, 100, 200, and 500 μM capsaicin. The capsaicin will be dissolved in a vehicle solution consisting of 80% physiological saline, and 20% ethanol. Participants will be given the instruction cough if you need to prior to capsaicin delivery.The solution will be administered automatically upon detection of an inspired breath and there will be a minimum of one minute between each trial. This is to test the reflexive cough testing for upper airway sensitivity and motor thresholds."
1534491|NCT02710097|Drug|Active inhaled cannabis|"~450 mg of active cannabis, which is roughly equivalent to smoking 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
1534492|NCT02710097|Drug|Placebo|Approximately 4 drinks of orange juice or ginger ale covered with a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
1534493|NCT02710097|Drug|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
1534494|NCT02710097|Drug|Placebo|No active cannabinoids. Administered over 20 minutes via a vaporizer.
1534495|NCT02710084|Drug|Oxytocin|Intranasal oxytocin
1534496|NCT02710084|Drug|Saline|Placebo
1534497|NCT02710071|Drug|Nebivolol|Nebivolol 5mg then nebivolol 10 mg
1534498|NCT02710071|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg then hydrochlorothiazide 25 mg
1534499|NCT02710058|Behavioral|one-time qualitative assessment|The study involves a one-time qualitative assessment to explore key cultural influences on AMBER breast cancer survivors' health behavior. We will focus on self-efficacy in healthcare, coping with breast cancer, social networks of support, and culturally-sensitive support groups. The study investigator will administer questions from the structured interview guide, estimated to take 90 minutes.
1534500|NCT02710045|Biological|Measles Vaccine at 9 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 9 months of age
1534501|NCT02710045|Biological|Diphtheria-tetanus-whole cell pertussis vaccine at 9 months of age|Single intramuscular (i.m.) dose of DTP (Serum Institute of India Ltd.) into the thigh at 9 months of age
1534502|NCT02710045|Biological|Measles Vaccine at 18 months of age|Single standard intramuscular (i.m.) dose of measles vaccine (MV) (Edmonston Zagreb strain, Serum Institute of India Ltd., Pune, India) into the deltoid at 18 months of age
1534504|NCT02710032|Behavioral|Social Media Platform|ii) Social Media Platform: The social media component of the intervention will include structured internet platforms designed to educate, motivate, and promote discussions of PrEP adherence within the participant network, unstructured participant-generated interactions to articulate and reinforce newly developed social norms within the network, and practical tools to support daily PrEP adherence.
1534505|NCT02710019|Other|Back to Reality Series video games|Back to Reality Series are a psycho-educational video games that address the emotional harms associated with underage substance use. They also help youth learn how and where to seek help for mental health and addictions problems.
1534506|NCT02710019|Other|Control video games|The control video game will consist of digital puzzles and memory mini-games. The control games will not have any content related to mental health and addictions problems
1534507|NCT02710006|Procedure|Sonohysterography|Sonohysterography, also known as saline infusion sonography, is a special, minimally invasive ultrasound technique. Sonohysterography is a technique in which fluid is injected through the cervix into the uterus, and ultrasound is used to. It provides pictures of the inside of a woman's uterus. Three-dimensional sonohysterography is based on volumetric scanning of uterus and its cavity during saline infusion.
1534508|NCT02709993|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
1534509|NCT02709980|Behavioral|Sleep Education|The sleep education intervention will parallel the CBT-I intervention in number, format (in-person) and length of sessions. It is intended to disseminate information about sleep including sleep hygiene information that is widely available. Subjects will be instructed to read and review 6 publications from the American Academy of Sleep Medicine; sessions will review the material to ensure complete access to the information.
1534510|NCT02709980|Behavioral|Cognitive Behavior Therapy for Insomnia|Treatment will involve a standardized 6-session intervention, with demonstrated efficacy, that combines education and behavioral techniques to reduce insomnia. The core components include (1) education about sleep and insomnia, stimulus control, and sleep restriction (session 1); (2) sleep hygiene education (session 2); and 3) relaxation training, cognitive therapy, adherence monitoring, adjusting the recommended sleep-wake schedule, and addressing any problems in implementation (session 3-5). The final session will include a review of treatment content and relapse prevention.
1534511|NCT02709967|Other|Material support|Writing materials
1534512|NCT02709967|Other|Economic|Economic support (monthly cash transfer to girls, annual grant to guardians, and payment of school fees in grade 8 and 9)
1534513|NCT02709967|Behavioral|Community dialogue|Community dialogue (youth club meetings, community and parent meetings)
1534514|NCT02709954|Drug|Active inhaled delta-9-THC|"Low dose THC (~4 mg), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes via a vaporizer."
1534515|NCT02709954|Drug|Placebo|Control: Approximately 4 drinks of orange juice or ginger ale covered by a trace amount of ethanol on the surface, each administered over approximately 10 minutes.
1534516|NCT02709954|Drug|Placebo|Control: No active THC. Administered over 20 minutes via a vaporizer. approximately 10 minutes.
1534517|NCT02709954|Drug|Active Oral Ethanol|0.4 g/kg ethanol in orange juice or ginger ale to reach a target BrAC of approximately 0.04%. This dose is equivalent to consuming approximately 2 standard drinks over 1 hour. Approximately 4 drinks, each administered over approximately 10 minutes.
1534518|NCT02709941|Other|Inspiratory muscle strength training|Breathing training designed to augment inspiratory muscle strength, and thus targeted muscle groups may benefit from improved force generating capability result in improved breathing.
1534519|NCT02709941|Other|Placebo|
1534520|NCT02709928|Drug|TD-0714|
1534521|NCT02709928|Drug|Placebo|
1534524|NCT02709902|Drug|Adapalene/BP gel, 0.3%/2.5%|Gel
1534525|NCT02709902|Drug|EPIDUO® FORTE|Gel
1534526|NCT02709902|Drug|Placebo|Gel
1534528|NCT02709876|Biological|Stem Cell Transplantation|Bone marrow-derived CD34+, CD133+, CD271+ stem cells in 1.0 ml normal saline will be injected into the vitreous cavity.
1534529|NCT02709863|Drug|Sevoflurane|1-1.5 MAC, inhalation route, during operation
1534530|NCT02709863|Drug|Desflurane|1-1.5 MAC, inhalation route, during operation
1534531|NCT02709863|Drug|Propofol|6-10 mg/kg/h, iv infusion, during operation
1534532|NCT02709850|Drug|IONIS ANGPTL3-LRx|
1534533|NCT02709850|Drug|Placebo (0.9%NaCl, water, riboflavin)|
1534534|NCT02709837|Other|Nutritional|
1534535|NCT02709824|Drug|Chlorhexidine gluconate with ADS|Oral rinsing, twice a day, for 21 days
1534536|NCT02709824|Drug|Chlorhexidine gluconate without ADS|Oral rinsing, twice a day, for 21 days
1534537|NCT02709811|Drug|Electrochemotherapy|
1534543|NCT02709772|Behavioral|Electronic Record Alert|Electronic alert within the medical record indicating the ordered test or treatment may be inappropriate. The provider can indicate why the test or treatment is appropriate and complete the order.
1534544|NCT02709759|Behavioral|Motivational intervention|Involves 60 minutes of counseling delivered by videoconferencing. Provides feedback on drinking and HIV and related behaviors.
1534545|NCT02709759|Behavioral|Brief Advice|Involves 5-10 minutes of brief counseling to reduce drinking
1534546|NCT02709759|Behavioral|Interactive text messaging|Involves receiving daily text messages that enable participants to track their drinking and related consequences. Provides feedback on drinking and allow setting of goals.
1534551|NCT02709733|Behavioral|VR Motivation Training|Computerized treatment with a virtual reality-based motivation training program, administered for 1 hour per week for 8 weeks.
1534552|NCT02709720|Drug|Vinorelbine|Cycle 1 and 2 50 mg/day, (Monday, Wednesday and Friday)
1534553|NCT02709720|Drug|Cisplatin|Cycle 1 and 2 day 1, 80 mg/m2
1534554|NCT02709720|Drug|Vinorelbine|Cycle 3 and 4 30 mg/day, (Monday, Wednesday and Friday)
1534555|NCT02709720|Drug|Cisplatin|Cycle 3 and 4 day 1, 80 mg/m2
1534556|NCT02709720|Radiation|Radiotherapy|concomitant therapy during cycles 3 and 4. Total dose: 66Gy
1534557|NCT02709707|Device|Blood glucose monitor|
1534558|NCT02709694|Other|No intervention|No drug or device intervention. However, participants will receive MRI of their spine, answer questionnaires, provide clinical history as well as blood and stool sample. Joint exams will also be performed on all participants.
1534559|NCT02709681|Other|Physician standard-of-care in SCD patients|
1534560|NCT02709668|Dietary Supplement|Enlyte|gel cap of reduced B vitamins
1534561|NCT02709668|Other|placebo|identical to Enlyte
1534566|NCT02709642|Behavioral|Deposit Contract|"A deposit contract (DC) is an agreement in which study participants puts their own money at risk, with the goal of earning it back by achieving a goal, in this case maintaining prior weight loss. If DC participants successfully maintain their weight, they get their money back. If they are not successful, they lose their money. For each 10 week period for one year, DC participants will make a deposit of at least $100 but will be allowed to increase their contribution if they would prefer."
1534567|NCT02709629|Behavioral|Individualized and adaptive computerized cognitive training|
1534568|NCT02709629|Behavioral|Active control|
1534569|NCT02709616|Biological|Personalized cellular vaccine|Biological: DC-based and allogeneic PBMC based cellular vaccine. Subjects will undergo surgical resection and standard 6-week chemo/radiotherapy and cycles of TMZ treatment. They will receive a total of 12 cellular vaccines with 8 DC-based and 4 allogeneic PBMC vaccines.
1534570|NCT02709603|Drug|hyoscine butyl bromide|oral hyoscine butyl bromide; 2 tablets (buscopan 10 mg) 30 minutes before the procedure
1534571|NCT02709603|Drug|placebo|oral placebo; 2 tablets 30 minutes before the procedure
1534572|NCT02709590|Drug|diclofenac potassium + lidocaine|patients will have of oral diclofenac potassium 60 minutes before the procedure plus lidocaine anesthetic cream placed into their cervix immediately before HSG
1534573|NCT02709590|Drug|placebo|patients will have of oral placebo tablet 60 minutes before the procedure plus placebo cream placed into their cervix immediately before HSG
1534574|NCT02709577|Device|EndoBarrier Gastrointestinal Liner|The EndoBarrier is a single use, implant consisting of a tube of composite material which is placed in the proximal section of the duodenum. The implant is fixed in place with the aid of a metal anchor. The device is delivered via an endoscope. The implant facilitates the passage of food from the stomach through the tube to the proximal section of the jejunum.
1534575|NCT02709577|Other|Sham: endoscopy and standard of care|Sham subjects had an endoscopic procedure and then received standard of care treatment of their diabetes
1534576|NCT02709564|Drug|Misoprostol 400 sublingual|patients will take 2 tablets of sublingual misoprostol 400 microgram 3 hours and 1 hour before the surgery
1534577|NCT02709564|Drug|placebo 400 sublingual|patients will take 2 tablets of sublingual placebo 400 microgram 1 hour before the surgery
1534578|NCT02709551|Behavioral|HRV_Bfb|
1534579|NCT02709551|Behavioral|MBI|
1534580|NCT02709551|Behavioral|MBI_HRV_Bfb|
1534581|NCT02709538|Drug|GSP 301 NS|2 spray in each nostril twice daily for 52 weeks
1534582|NCT02709538|Drug|GSP 301 Placebo NS pH 3.7|2 spray in each nostril twice daily for 52 weeks
1534583|NCT02709538|Drug|GSP 301 Placebo NS pH 7|2 spray in each nostril twice daily for 52 weeks
1534584|NCT02709525|Drug|hyaluronic acid|
1534585|NCT02709525|Other|Placebo|
1534586|NCT02709512|Drug|ADI-PEG 20 plus Pem Cis|Investigational Drug in combination approved standard of care treatment for this indication
1534587|NCT02709512|Other|Placebo plus Pem Cis|Placebo in combination approved standard of care treatment for this indication
1534588|NCT02709499|Device|0J LLLT|perform with the machine off
1534589|NCT02709499|Device|6J LLLT|irradiation will be perform with 4J
1534593|NCT02709473|Drug|Propofol|Propofol will be used in either two arms. The injection sequence will be changed. In propofol arm of the study, general anesthesia will be started with 2 mg/kg propofol administered within 15 seconds. And, then remifentanil will be given. In remifentanil arm of the study, 2 mg/kg propofol will be applied within 15 seconds following remifentanil injection.
1534594|NCT02709473|Drug|Remifentanil|Remifentanil will be used in either two arms. The injection sequence will be changed. In remifentanil arm, general anesthesia will be started with 2 μg/kg remifentanil administered within 30 seconds. And then propofol will be given. In propofol arm of the study the same dose will be applied within 30 seconds following propofol administration.
1534595|NCT02709473|Drug|Rocuronium|Rocuronium will be used for either two study arms. Rocuronium will be given in a 0.8 mg/kg dosage in the first study subject. And then, if the intubation condition is acceptable, the dose of the rocuronium will be decreased by 0.1 mg/kg for the next patient. Otherwise, if the intubation condition is not acceptable, the rocuronium dosage will be increased by 0.1 mg/kg for the next patient. This will be continue for ten crossover points (the point that turn from unsuccessful intubation to successful intubation).
1534596|NCT02709460|Procedure|Lateral occlusion|Lateral occlusion close to the internal Iliac artery
1534597|NCT02709460|Procedure|Cervical occlusion|Cervical occlusion of the uterine artery
1534598|NCT02709447|Behavioral|Date SMART|Skills-based, group prevention program targeting emotion regulation and interpersonal skills using a cognitive-behavioral framework.
1534599|NCT02709447|Behavioral|Health Promotion|Psycho-educational group prevention program targeting knowledge and skills only
1534600|NCT02709434|Behavioral|Psychoeducational programme|Activity diary analysis and a structured programme of intervention
1534601|NCT02709434|Other|Standard care|Usual IBD management
1534602|NCT02709395|Device|Navina Smart|Transanal irrigation at the same frequency as subject used before enrollment.
1534603|NCT02709382|Drug|Cefepime and Tazobactam combination|
1534605|NCT02709356|Dietary Supplement|1-month of 60-40 MCT oil|1-month supplementation of 30 g MCT oil (60% C10 + 40% C8)/day
1534606|NCT02709356|Dietary Supplement|1-month of C8 MCT oil|1-month supplementation of 30 g MCT oil (100% C8)/day (1-month of C8 MCT oïl)
1534607|NCT02709343|Drug|Bone-marrow derived MSCs|Allogeneic ex vivo expanded, bone marrow-derived mesenchymal stromal cells
1534608|NCT02709343|Drug|Placebo|Placebo product visually very similar to mesenchymal stromal cells
1534609|NCT02709330|Drug|Lunasin Regimen|LunaRich X Capsules, Reliv Now, ProVantage
1534610|NCT02709330|Other|Historical control|Matched historical controls will be identified from the PatientsLikeMe database.
1534613|NCT02709304|Drug|Lidocaine gel|Gel used for insertion of urinary catheter containing local anesthetic to determine if patients have less discomfort postoperatively when this is used
1534614|NCT02709304|Drug|standard gel|Standard gel that is used to insert a urinary catheter that does not contain local anesthetic
1534615|NCT02709291|Behavioral|behavioral parent training|
1534616|NCT02709291|Behavioral|interventionist training|
1534617|NCT02709278|Biological|BCG|BCG SSI (Groups 1A, 1B, 1C and 1D) & BCG Bulgaria (InterVax) (Groups 2A, 2B, 2C, 2D and 2E)
1534618|NCT02709278|Other|Saline placebo|Saline placebo
1534620|NCT02709252|Device|PVI and deltaPP after trendelenburg position change|Comparison of hemodynamic parameters during surgery after position change
1534621|NCT02709239|Dietary Supplement|DHA 200mg|4 50mg capsules of DHA to be taken by mouth daily
1534622|NCT02709239|Dietary Supplement|DHA 800mg|4 200mg capsules of DHA to be taken by mouth daily
1534624|NCT02709213|Other|Diagnostic|
1534625|NCT02709200|Drug|Dexmedetomidine|
1534626|NCT02709187|Drug|DP-R208|Investigational product is prescribed to all of randomized subjects
1534627|NCT02709187|Drug|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
1534628|NCT02709187|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
1534629|NCT02709174|Procedure|blood draw|blood draw
1534632|NCT02709148|Device|Activa PC+S|DBS
1535138|NCT02705625|Drug|Placebo|Placebo manufactured to mimic MIV-711 capsule.
1995955|NCT02607592|Drug|nadaplatin+pemetrexed|nadaplatin 80mg/m2 d1+pemetrexed 500mg/m2 d1 （Every three weeks for a treatment cycle）
1995956|NCT02606825|Other|Registry of AML patients > 60 years|
1995960|NCT02604862|Other|FIB ONE|FIB ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and two types of viewer software will be used to detect FIB ONE signal in the lung.
1995961|NCT02605642|Drug|Infliximab (Inflectra™)|
1995962|NCT02600260|Drug|Enoxaparin|Patients who score higher or equal to 3, receive a prophylactic dose of enoxaparin. The first dose of enoxaparin is administered 8 hours after vaginal or abdominal delivery. Subsequent doses are administered daily for up to 15 days. The dose depends on patient weight.
1995963|NCT02600260|Other|No intervention|Hospitalized patients that score less than three are not prescribed enoxaparin.
1534633|NCT02709122|Device|ThoraQuik atraumatic set for pneumothorax decompression|pneumothorax decompression in case it is found in accordance with the actually recommendations
1534634|NCT02709109|Drug|VX-371|
1534635|NCT02709109|Drug|Saline|
1534636|NCT02709109|Drug|Placebo|
1534637|NCT02709109|Drug|Orkambi|
1534638|NCT02709096|Drug|BPX-01, 1% Topical Gel|topical gel, applied to the forehead, cheeks, nose and chin
1534639|NCT02709096|Drug|BPX-01 Vehicle Gel|topical gel, applied to the forehead, cheeks, nose and chin
1534643|NCT02709070|Procedure|resection|hepatectomy for HCC
1534644|NCT02709070|Procedure|highly-purified CTL|hepatectomy first, followed by highly-purified CTL treatment
1534646|NCT02709044|Drug|Ringer lactate|
1534647|NCT02709031|Drug|Cicletanine + magnesium|"Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD (once daily); it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,
Magnesium is being added to cicletanine in order to decrease losses of potassium and sodium, thereby enhancing cicletanine's safety at higher doses."
1534648|NCT02709031|Drug|Cicletanine|Cicletanine is an orally-dosed furopyridine drug launched or hypertension in France in 1988 (and soon thereafter in Germany by IPSEN. While the drug's maximum tolerated dose is not known, the principal concern (and so far only material concern) at higher doses is the decrease in levels of sodium and potassium. Trials so far have take n the drug up to 400 mg QD; it was well tolerated at that dose. The drug has had an excellent safety profile in its ~1.8 million patient-years of post-launch experience,
1534651|NCT02709005|Drug|5% Monolaurin Vaginal Gel|Monolaurin Vaginal Gel is a clear and colorless, non-sterile glycol-based gel for vaginal administration , and commonly referred to as glycerol monolaurate (GML). Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
1534652|NCT02709005|Other|Placebo|The placebo gel is a clear to opaque, colorless to light gray, non-sterile glycol-based gel for vaginal administration. The placebo gel contains the same excipients as the Monolaurin vaginal gel. Each subject will receive intravaginal gel twice daily for three successive days for a total of 6 doses. There will be 3 clinic visits over 30 days.
1534653|NCT02708992|Drug|Azithromycin|
1534654|NCT02708992|Drug|Cefixime|
1534655|NCT02708979|Other|University exam-period|This visit takes place one week prior to an exam at the university assuming that students will be stressed in this period.
1534656|NCT02708979|Other|University non-exam-period|This visit takes place several weeks post and prior to an exam at the university assuming that students will not be stressed in this period.
1534659|NCT02708953|Procedure|Thoracic manipulation (Manipulation Group)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
1534660|NCT02708953|Procedure|Thoracic Manipulation (Control wait-list)|Manipulation techniques will include: CT junction manipulation seated and supine, upper thoracic manipulation, middle thoracic spine manipulation in seated and supine, middle thoracic spine manipulation in prone, thoracic active range of motion exercise and instruction to maintain usual activity level within the limits of pain.
1534661|NCT02708940|Other|Participatory technology development|Creating mobile support tools by patients and their therapists
1534662|NCT02708940|Other|Usual Care|Usual care as part of the UCLA PHP and IOP programs
1534665|NCT02708914|Biological|UB-851|UB-851 (rhEPO) has been developed as a biosimilar product to Eprex®.
1534666|NCT02708914|Biological|Eprex|Eprex® is chosen as the comparator.
1534669|NCT02708888|Other|Trunk training|The experimental group receives 16 hours of additional trunk training (4 days/week, 4 weeks) focusing on trunk muscle strength, coordination and selective movements executed on stable and unstable surfaces.
1534670|NCT02708888|Other|Cognitive exercises|The control group will be receiving the same amount of repetitive cognitive exercises within arm's range to ensure no anticipatory postural adjustments of the trunk.
1534671|NCT02708875|Other|Mixed Meal Challenge|Liquid mixed meal (300 calories - fat, carbohydrate, and protein).
1534672|NCT02708875|Other|Glucose Challenge|Glucose drink (50g glucose)
1535139|NCT02705612|Drug|Cisplatin|
1534673|NCT02708862|Device|Simple mask at 60 L/min|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed in the arms above, the exhaled oxygen content will be measured.
1534674|NCT02708862|Device|Non-rebreather at 15 L/min|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed in the arms above, the exhaled oxygen content will be measured.
1534675|NCT02708862|Device|Non-rebreather at 60 L/min|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed in the arms above, the exhaled oxygen content will be measured.
1534676|NCT02708862|Device|Bag valve mask at 15 L/min|After 3 minutes of oxygen supplementation (preoxygenation), with each of the devices listed in the arms above, the exhaled oxygen content will be measured.
1534677|NCT02708849|Drug|Ketamine|The subanesthetic dose of ketamine (0.23mg/kg bolus followed by 0.58mg/kg infusion over approximately 60 minutes) will be administered via intravenous infusion
1534678|NCT02708849|Drug|Lamotrigine|lamotrigine (300 mg oral dose) or the matched-placebo control about 2-hours prior to the start of the infusion of ketamine
1534679|NCT02708849|Drug|Placebo|oral dose placebo
1534680|NCT02708836|Procedure|Induction of anesthesia|At the discretion of the primary anesthesiologist. Typically involves the administration of an analgesic agent, hypnotic agent, and neuromuscular blocking agent
1534681|NCT02708836|Device|Placement of LMA [Ambu (R) AuraGain (TM) disposable laryngeal mask]|By standard method. Sizing at the discretion of the primary anesthesiologist.
1534682|NCT02708836|Device|Laryngoscopy and placement of ETT|Via direct or indirect laryngoscopy. Sizing at the discretion of the primary anesthesiologist. Mallinckrodt (TM) Intermediate Hi-Lo cuffed endotracheal tube (Covidien)
1534683|NCT02708836|Procedure|Ventilation via the ETT|Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
1534684|NCT02708836|Procedure|Removal of the ETT|Either upon emergence of anesthesia after suctioning of the oropharynx and after a positive pressure breath or while deeply anesthetized after release of the pneumoperitoneum in the combined LMA/ETT group.
1534685|NCT02708836|Procedure|Intubation of the trachea through the LMA|With ETT using fiberoptic bronchoscope guidance.
1534686|NCT02708836|Procedure|Ventilation via the LMA|After removal of the ETT. Ventilator mode, tidal volume/ ventilation pressure, respiratory rate, positive end expiratory pressure, inspired to expired ratio at the discretion of the primary anesthesiologist.
1534687|NCT02708836|Procedure|Emergence from anesthesia|"At the discretion of primary team. Airway device (either ETT or LMA) will be removed when patient is adequately ventilating and able to respond to commands (such as open your eyes or squeeze my hand)."
1534688|NCT02708823|Other|Delirium Risk Profile (DRP) application|The DRP application is administered once to all study participants.
1534689|NCT02708810|Device|Unframed Virtual Cone|A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. This will allow for very precise targeting. During the procedure, the study doctor will also confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask (unframed) will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on the painful nerve in the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is in the range of 30 to 60 minutes. The face mask (unframed) will be removed after the treatment.
1534690|NCT02708810|Radiation|80 Gy Radiation|
1534693|NCT02708771|Drug|Polyunsaturated fatty acids omega-3|4 daily capsules of polyunsaturated fatty acids omega-3, during 4 weeks. Each capsule contains: 460 mg eicosapentaenoic acid ethyl ester and 380 mg docosahexaenoic acid ethyl ester.
1534694|NCT02708771|Drug|Placebo|4 daily capsules of similar appearance and flavor without active ingredient
1534695|NCT02708758|Behavioral|Medical Nutrition Therapy|individualized medical nutrition therapy from a qualified nutritionist which took into consideration a woman's pre-pregnancy weight, activity level, dietary intake and weight gain, instructions on how to self- monitoring capillary glucose levels two to four times daily until the levels had been in the recommended range (fasting glucose levels no more than 95 mg/dL and 1 hour postprandial less than 140 mg/dL). Drug therapy will begin with metformin or insulin when capillary glucose levels are not met the recommended levels after at least two weeks of treatment.
1534696|NCT02708745|Behavioral|Intervention Survey|
1534697|NCT02708745|Behavioral|Placebo Survey|
1534698|NCT02708719|Procedure|Pulmonary rehabilitation|Inpatient pulmonary rehabilitation has a duration of 3 weeks. This multimodal program consists of exercise training, breathing therapy, medical council, education and psychological support.
1534699|NCT02708706|Drug|hyaluronic acid (hyruan)|2cc hyaluronic acid
1534700|NCT02708706|Other|physical therapy|patient received traditional physical therapy, including therapeutic exercise and stretch exercise
1534701|NCT02708693|Drug|Triamcinolone Acetonide|ultrasound-guided injection using 1ml of 10 mg (10mg/ml) triamcinolone acetonide (Shincort)
1534702|NCT02708693|Device|thermoplastic wrist splint|thermoplastic wrist splint with wrist placed in a neutral position
1534703|NCT02708693|Drug|lidocaine hydrochloride|ultrasound-guided injection using 1 ml of 2% lidocaine hydrochloride (Xylocaine)
1534704|NCT02708680|Drug|entinostat|An orally available histone deacetylases inhibitor (HDAC)
1534705|NCT02708680|Drug|atezolizumab|A humanized, engineered monoclonal antibody of IgG1 isotype against the protein programmed cell death ligand 1 (PD-L1).
1534706|NCT02708680|Drug|Placebo|A pill containing no active drug ingredient
1534707|NCT02708654|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherence to this medication
1534751|NCT02708355|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg banded capsules (22.3 mg esomeprazole magnesium trihydrate)
1534752|NCT02708355|Drug|Placebo|Placebo capsules
1534753|NCT02708329|Procedure|T-provisional stenting|Standard endovascular T-provisional stenting technique
1534708|NCT02708654|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
1534709|NCT02708654|Behavioral|Support Partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
1534710|NCT02708654|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
1534711|NCT02708641|Drug|pembrolizumab|200 mg IV given every three weeks
1534712|NCT02708628|Drug|extract of allium cepae, allantoin and heparin|prophylactic use of a topical gel containing extract of allium cepae, allantoin and heparin two times in a day after second c-section
1534713|NCT02708628|Procedure|Scar excision|Scar excision in second c-section
1534714|NCT02708615|Other|Type of speculum vaginal insertion method|Speculum insertion type will either be vertical rotation (as per common practice in Canada) or straight horizontal insertion
1534715|NCT02708602|Genetic|β2AR polymorphism|
1534716|NCT02708589|Dietary Supplement|probiotic|
1534717|NCT02708589|Other|Placebo|
1534718|NCT02708576|Biological|NGM313|
1534719|NCT02708576|Other|Placebo|
1534720|NCT02708563|Procedure|Immediate intubation|Infants that are not vigorous at delivery will receive immediate tracheal suctioning
1534721|NCT02708563|Procedure|Immediate resuscitation|Infants that are not vigorous at delivery will receive immediate initial steps of resuscitation and PPV if needed
1534722|NCT02708550|Behavioral|Participatory Organizational Intervention|
1534723|NCT02708537|Biological|PRGF in candidates for sperm donors|PRGF application on seminal aliquots will be conducted at different concentrations assessing sperm motility.
1534724|NCT02708524|Device|Senofilcon C Contact Lens|
1534725|NCT02708524|Device|Comfilcon A Contact Lens|
1534726|NCT02708524|Device|Lotrafilcon B Contact Lens|
1534727|NCT02708524|Device|Samfilcon A Contact Lens|
1534728|NCT02708511|Diagnostic Test|Computed Tomography|Undergo PET/CT
1534729|NCT02708511|Drug|Copper Cu 64-DOTA B-Fab|Given IV
1534730|NCT02708511|Other|Laboratory Biomarker Analysis|Correlative studies
1534731|NCT02708511|Other|Pharmacological Study|Correlative studies
1534732|NCT02708511|Diagnostic Test|Positron Emission Tomography|Undergo PET/CT
1534733|NCT02708498|Behavioral|Educational Intervention|The seminar groups will be led by two experienced clinical nurses and researchers from the field of palliative care and geriatric care. The educational material consist of six themes; values in palliative care, symptom relief, dignity and a dignified death, collaborative co-creating care, support to next of kin and dialogue with older persons and next of kin about death and dying. The content of the different themes will have a common core for each nursing home but will be adjusted based on the expressed needs of each nursing home. New themes can be created related to the needs of the unique nursing home. The participants in the seminar groups will reflect together over the content of the developed binder of educational material and will relate it to their own work in order to identify areas suitable for changes and/or development.
1534735|NCT02708472|Device|synchronized Transcranial Magnetic Stimulation (sTMS)|"Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.
The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes."
1534736|NCT02708459|Device|surgically inserted Transversus abdominus plane catheter|at end of surgery, a surgeon will insert catheter in Transversus abdominus plane (TAP) between internal oblique muscle and Transversus abdominus muscle
1534737|NCT02708459|Drug|Intravenous morphine|Boluses of intravenous morphine (2 mg) will be given to patients if Visual analogue scale (VAS) more than 3
1534738|NCT02708459|Drug|Bupevecaine|
1534739|NCT02708459|Drug|Dexmedetomedine|
1534740|NCT02708446|Drug|Mifepristone|200mg oral mifepristone to both study arms
1534741|NCT02708446|Drug|Buccal misoprostol|doses of buccal misoprostol every 3 hours beginning 24 hours after mifepristone
1534742|NCT02708446|Drug|Sublingual misoprostol|doses of sublingual misoprostol every 3 hours beginning 24 hours after mifepristone
1534744|NCT02708420|Device|Glidescope|This standard GlideScope (GS) technique involves a midline laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
1534745|NCT02708420|Device|Macintosh Laryngoscope|This technique involves a laryngoscopy followed by insertion of a styletted endotracheal tube, once an adequate view of the vocal cords is achieved.
1534746|NCT02708407|Procedure|Peritoneal Dialysis|One week after insertion of a PD catheter the intervention group will received a single nightly exchange, using dialysis fluid containing icodextrin; a variable proportion of participants may require a second exchange as directed by the consultant nephrologist as part of routine care. The second exchange would use dialysis fluid containing glucose, not icodextrin. Support and training will be given to each participant by the PD specialist team.
1534747|NCT02708394|Drug|olanzapine|atypical antipsychotic
1534748|NCT02708394|Drug|placebo|placebo control
1534749|NCT02708381|Other|Screening|Screening for geriatric issues to be referred to the Moffitt Cancer Center Oncogeriatric Information Team (OGIT).
1534750|NCT02708368|Other|blood withdrawal|3 times
1534754|NCT02708329|Procedure|Mini-crush stenting|Standard endovascular Mini-crush stenting technique
1534755|NCT02708329|Procedure|CTO coronary angioplasty|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Recanalisation of coronary artery CTO is performed by the hydrophilic coronary wire, using the most appropriate technique. Then balloon angioplasty of target lesion is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
1534756|NCT02708316|Genetic|sequencing faecal metagenome|sequencing faecal metagenome is not the intervention measure.It is the observational method for investigators to detect the component of faecal microorganism.
1534757|NCT02708303|Other|Mayo Clinic Foregut Surgery Report Card Questionnaire|"Patients will be asked to complete the Mayo Clinic Foregut Surgery Report Card Questionnaire at approximately 8-10 weeks following surgery and then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
Data collected from the questionnaire will be entered into a database that will be maintained for future research."
1534758|NCT02708290|Other|MITA visual puzzles - Each game adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time|Mental Imagery Therapy for Autism (MITA) is an early-intervention application for children with Autism Spectrum Disorder (ASD). MITA app uses adaptive-learning technologies, with fun, educational exercises that adapt to a child's abilities, resulting in a highly-customized learning experience. The MITA application is available for free in the Apple Store, Google Play, and Amazon App Store.
1534759|NCT02708277|Device|loop-shaped intrauterine contraceptive device|Intrauterine contraceptive device can temporary protective layer between the endometrium wound during the most critical three weeks after the surgery to prevent adhesion reformation.
1534760|NCT02708277|Device|intrauterine balloon (Cook Medical)|The balloons used in this study is heart- shaped that resembled the shape of the uterine cavity and could fully separate the two sides of the uterine wall and the corners of the uterus compare to loop-shaped intrauterine contraceptive device.
1534761|NCT02708264|Device|Cervical pessary|The cervical pessary is a silicone device that has been used to prevent SPTB
1534762|NCT02708251|Drug|glyceryl trinitrate cream|
1534763|NCT02708251|Drug|lidocaine cream|
1534764|NCT02708251|Drug|placebo cream|
1534765|NCT02708238|Dietary Supplement|Standardized extract of Chamomilla L., Melissa Officinalis L. and tyndallized L. Acidophilus (H122)|
1534766|NCT02708238|Dietary Supplement|Lactobacillus reuteri DSM 17938 (108 CFU)|
1534767|NCT02708238|Drug|Simethicone|
1534768|NCT02708225|Behavioral|medical clown|a medical clown will assist the child during the performance of pulmonary function test
1534769|NCT02708212|Procedure|EGD and colonoscopy|Cold forceps biopsy, cold snare polypectomy, and/or hot snare polypectomy will be performed for stomach and/or colon polyps during EGD and colonoscopy examinations will be performed whenever indicated.
1534772|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
1534773|NCT02708173|Biological|One dose of Quadrivalent Influenza Virus Vaccine|
1534774|NCT02708160|Drug|Fluoride Free toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
1534775|NCT02708160|Drug|1.1% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
1534776|NCT02708160|Drug|0.243% Fluoride toothpaste|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait 1 minute before rinsing with water.
1534777|NCT02708147|Other|Physiotheraphy + Conventional treatment|The experimental group will receive 5 physiotherapy sessions at home or in a physical therapy office. The respiratory techniques follow a flowchart which begins with saline instillation into the nose and nasopharyngeal cleaning techniques. Then to clear the lung slow inspiratory and slow and forced expiratory techniques will be used. The application of vibration is also included on the flowchart. During the sessions, educational information will also be provided.
1534778|NCT02708147|Other|Conventional treatment|Medication and observation by a physician/paediatrician. Only evaluations will be made at baseline and on the 3th, 5th and 21st days and an interview 30 days after.
1534779|NCT02708121|Behavioral|Motivational Intervention|Participants complete web-based assessment and receive tailored feedback to motivate weight loss treatment initiation and informed that they have access to weight loss treatment.
1534780|NCT02708121|Other|Comparator Intervention|Participants informed that they have access to weight loss treatment.
1534781|NCT02708108|Behavioral|Dietary Intervention|Beginning at time of diagnosis, the dietary component of the intervention uses a personalized menu to implement high protein, moderate fat, and low glycemic index/high fiber diet to achieve a minimum net -10% daily caloric deficit during the induction phase of chemotherapy.
1534782|NCT02708108|Behavioral|Activity and Exercise Intervention|"Beginning at the time of diagnosis, the exercise and activity component uses an activity menu to implement a target level of 200 minutes per week of moderate exercise activity (as estimated by metabolic equivalents) during the induction phase of chemotherapy."
1534783|NCT02708095|Drug|Baricitinib|Administered orally
1534784|NCT02708095|Drug|Placebo|Administered orally
1534785|NCT02708082|Device|OCT scanning and HFA perimetry|Imaging of the optic nerve and nerve fiber layer / measurement of visual field
1534867|NCT02707536|Procedure|Socket grafting with PRF|Extraction with socket grafting using PRF.
1534868|NCT02707536|Procedure|Socket grafting with bone graft|Extraction with socket grafting using bone graft.
1534786|NCT02708069|Other|e-Unstuck|An e-learning software that delivers the evidence-based Executive Functioning intervention to parents of children with Autism Spectrum Disorder without Intellectual Disability (ASDwoID) with personalized training and feedback on the evidence-based Unstuck and On Target (UOT) curriculum. Through video modeling, intelligent games, adaptive interactive exercises, and personalized feedback, e-Unstuck will provide parents with new tools for applying UOT principles to real world settings, above and beyond learning UOT principles.
1534787|NCT02708069|Other|Unstuck and On Target|An executive functioning intervention specifically targeted to the needs of the Autism Spectrum Disorder without Intellectual Disability (ASDwoID) population.
1534788|NCT02708056|Drug|Sugammadex|
1534789|NCT02708043|Other|Flexible-Laryngeal Mask Airway|
1534790|NCT02708030|Other|Ketogenic Diet|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. The patients in KD arm will be admitted to the hospital for initiation of diet.
1534791|NCT02708030|Other|MAD|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. MAD will be initiated on out patient basis.
1534792|NCT02708030|Other|LGIT|The children with the drug resistant epilepsy will go through a run in period of 4 weeks during which each child will undergo a detailed detailed clinical evaluation according to a structured proforma, and baseline investigations. Following the run in period of 4 weeks, the patients will be randomized to the MAD or LGIT or KD arm. LGIT will be initiated on out patient basis.
1534795|NCT02708004|Drug|ACT-132577|Formulated in capsules in 2 different strengths; 2 capsules per day
1534796|NCT02708004|Other|Placebo|Matching active drug
1534797|NCT02707991|Behavioral|Nurse Case Management|Participants will receive one baseline nurse case management study visit in addition to appointment reminders one week and one day before the scheduled hepatitis clinic appointment. Those who link to the Viral Hepatitis Clinic and are identified as eligible to start hepatitis C therapy by their health care provider will have one additional study visit with the nurse case manager to coordinate drug-drug interaction prevention.
1534798|NCT02707978|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
1534799|NCT02707965|Drug|Oxcarbmazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
1534800|NCT02707965|Drug|Divalproex Sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
1534801|NCT02707965|Drug|Carbamazepine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
1534802|NCT02707965|Drug|Lamotrigine (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
1534803|NCT02707965|Drug|levetiracetam (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
1534804|NCT02707965|Drug|Topiramate (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
1989842|NCT02352350|Other|Blood Lactate Levels|Blood lactate levels will be performed on all participants.
1534805|NCT02707965|Drug|Zonisamide (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
1534806|NCT02707965|Drug|Phenytoin sodium (brand name vs generic drugs)|This is a cross-over replicate study with 2 sequences (arms) comparing brand name and generic anti-epileptic drugs. Subjects will take a brand name and a generic drug of the same intervention. While there are only 2 sequences, there are 8 possible drugs for this study, and a study patient will only take 1 out of 8 study drugs. Only pharmacists will know which sequence each patient is assigned to.
1534809|NCT02707939|Other|Observation|Patients will be observed before and after they receive anesthesia
1534810|NCT02707926|Drug|Anti-HIV Agents|Therapy to treat HIV infection
1534811|NCT02707913|Drug|BF-Amlodipine Tablet 10mg|BF-Amlodipine Tablet 10mg is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
1534812|NCT02707913|Drug|Norvasc Tablet 10mg|Norvasc Tablet 10mg will be used as a comparator drug for the BE study
1534813|NCT02707900|Drug|Vorinostat|"At Step 2 (Enrollment) - subjects receive a single oral dose of Vorinostat (VOR) 400 mg.
Step 3 - Paired VOR dosing. If there are no clinically significant adverse events and a statistically significant increase in the rca-RNA after the first VOR dose is observed, two paired doses of VOR 400 mg PO will be administered to subjects.
Step 6 - VOR dosing. Approximately 7- 10 days after the 4th dose of AGS-004 in Step 5 (Visit 13), ten (10) doses of VOR 400 mg PO will be administered at 72 hour intervals.
Steps 7 & 8 - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 7) followed by 10 doses of VOR 400 mg PO (Step 8)."
1534814|NCT02707900|Biological|AGS-004|"Step 5 - AGS-004 vaccination. AGS-004 product will be delivered in three intradermal injections of 0.2 mL (0.6 mL total volume) for a total of 1.2 x 107 viable cells. AGS-004 will be administered every 3 weeks for 4 doses.
Steps 7 & 8 - Repeat cycles of AGS-004 and VOR. Participants will undergo a second series of 4 AGS-004 vaccinations (Step 7) followed by 10 doses of VOR 400 mg PO (Step 8)."
1534815|NCT02707887|Behavioral|LETS ACT|The Life Enhancement Treatment for Substance Use (LETS ACT)
1534816|NCT02707887|Behavioral|LETS ACT-SE|Participants assigned to the smartphone-enhanced LETS ACT (LETS ACT-SE) condition will be provided the exact same treatment as outlined in LETS ACT, except that LETS ACT-SE participants will record their daily goals using smartphone technology.
1534817|NCT02707887|Behavioral|Treatment as Usual|Participants will receive the treatment typically provided to patients at the substance use treatment facility.
1534818|NCT02707874|Drug|CI 0.2% ropivacaine|Patients in Group CI will receive continuous infusion of 0.2% ropivacaine at 5 mL/hour; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
1534819|NCT02707874|Drug|PIB 0.2% ropivacaine|Patients in Group Programmed intermittent bolus (PIB) will receive automated programmed intermittent boluses of 10 mL of ropivacaine 0.2% every 2 hours; total 4-hourly consumption = 20 mL = 40 mg ropivacaine. All patients will be able to self-administer PCA boluses of 5 mL of ropivacaine 0.2% at intervals of 30 minutes as required
1534820|NCT02707861|Drug|ibalizumab|Intravenous infusion of humanized monoclonal antibody binding with a region of Domain 2 of CD4 receptor, blocking post-attachment conformational changes necessary for HIV cell entry
1534821|NCT02707861|Drug|Optimized Background Regimen|An investigator-selected, standard-of-care combination regimen of antiretroviral agents for treating HIV-1 infection, selected based upon patient treatment history and the results of previous viral resistance testing. The combination must contain at least one agent other than ibalizumab to which the patient's virus is sensitive (susceptible).
1534822|NCT02707848|Other|No intervention|
1534823|NCT02707835|Other|self massage|self massage, skin care education, manual lymph drainage exercise, compression garment
1534824|NCT02707835|Other|manual lymph drainage|manual lymph drainage by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
1534825|NCT02707835|Other|epidermis fascia taping|epidermis fascia taping by a physical therapist, skin care education, manual lymph drainage exercise, compression garment
1534826|NCT02707822|Other|Clinical and genetic factors|
1534827|NCT02707809|Drug|Dexmedetomidine|Dexmedetomidine infusion
1534828|NCT02707796|Procedure|Hemicolectomy|
1534829|NCT02707783|Device|Bioresorbable vascular scaffold (BVS) implantation|
1534830|NCT02707770|Other|Pulmonary Rehabilitation|
1534831|NCT02707757|Drug|Iron sucrose|1gram of iron sucrose (5 200mg aliquots) administered if participant's haemoglobin is less than 9.5g/dl
1534832|NCT02707757|Drug|Erythopoietin stimulating agent|Incremental increase in dose of erythropoeitin stimulating agent being administered as per a pre-defined criteria
1534833|NCT02707744|Other|no intervention|
1534834|NCT02707731|Procedure|Hydrokinesiotherapy|physical therapy technique used in a plastic bucket approved by ANVISA , with water temperature monitored at 37 ° C, water level up to the shoulders and by the physical properties of water, was allowed to mobilize the newborn facilitating the feeling of relaxation and standard suitable movement.
1534835|NCT02707718|Biological|blood sampling|during the usual blood sampling performed in the ED in patients suspected of sepsis, two additional tubes will be sampled for a panel of biomarkers measurement
1534872|NCT02707510|Other|Growing Resiliency And CouragE with Cancer™ (GRACE)|GRACE is a 6 week curriculum which includes themes illustrated via PowerPoint slides with semi-structured delivery, video presentations, a variety of mindfulness meditation practices, and selected readings that serve to reflect and capture the theme for the week of the curriculum.
1534873|NCT02707497|Drug|rhTPO|Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000u/d, qd, subcutaneous injection, daily for no more than 7 consecutive days
1534874|NCT02707497|Drug|Placebo|The control group will not use any platelet-increased drugs.
1534839|NCT02707692|Biological|Fluarix|Intramuscular injection with Fluarix® .
1534840|NCT02707692|Biological|Pneumovax|Intramuscular injection with Pneumovax.
1534841|NCT02707692|Other|Placebo|Intramuscular injection with sterile saline (placebo).
1534842|NCT02707679|Other|Mulligan's Straight leg-raise with traction|Mulligan's Straight leg raise technique was performed on patients with patellofemoral pain syndrome. The extremity on which the practice would be performed in supine position was grasped from the ankle level and was, then, subjected to traction longitudinally. Afterwards, the knee was lifted up passively while in extension and was kept for waiting for a few seconds at the point where tension was felt and was, then, returned to its initial position. The practice was repeated 10 times, and 3 sets of practice at 1-minute-intervals were performed.
1534843|NCT02707679|Other|Mulligan's Mobilization with Movement|Mulligan's Mobilization with Movement technique was performed on patients with patellofemoral pain syndrome. Each patient was tested in every direction in the course of the active knee flexion-extension movement so as to find out the best pain-free tibial gliding direction (medial-lateral part of the tibia, anterior-posterior, internal-external rotation). At the time of the active movement of the knee, the tibial gliding direction where pain was felt at the least was selected as the treatment direction of mobilization technique along with movement. The practice was performed by doing 10 repetitions for 3 sets and by providing 1-minute-resting time between the sets.
1534844|NCT02707679|Other|Kinesiotaping|Kinesiotaping was applied on patient with patellofemoral pain syndrome. To maintain proprioceptive stimulation in the quadriceps (from origo towards insertio) and to alleviate the tension of hamstring muscle, a 'Y''-shaped kinesiotape was applied by using the muscle technique.
1534845|NCT02707679|Other|Exercise|All the patients were provided with several exercises within the scope of the home exercise program, such as hamstring muscle stretching, quadriceps isometric exercises, 4-way-strengthening with exercise elastic bands for the muscles of the hip, knee locking on foot and mini-squatting exercises. They were asked to do these exercises in 3 sets a day along with 10 repetitions for a period of 6 weeks.
1534846|NCT02707666|Drug|Pembrolizumab|Neoadjuvant pembrolizumab every 21 days for three cycles
1534847|NCT02707666|Drug|Cisplatin and Pemetrexed|Adjuvant chemotherapy with cisplatin and pemetrexed every 21 days for 4 cycles
1534848|NCT02707653|Drug|Misoprostol|400 mcg sublingual misoprostol
1534849|NCT02707640|Drug|Matching Placebo|Matching Placebo, oral administration, three times daily for 24 weeks.
1534850|NCT02707640|Drug|N-acetylcysteine|N-acetylcysteine, 600 mg, oral administration, three times daily for 24 weeks.
1534851|NCT02707640|Drug|Pirfenidone|Pirfenidone, at least 1602 mg/day, oral administration, for 32 weeks, during the wash-out and screening period and for at least 8 weeks prior to randomization.
1534852|NCT02707627|Device|Ablative fractional carbon dioxide laser therapy (AFCL)|AFCL is a new form of treatment for hypertrophic burn scars.
1534853|NCT02707627|Procedure|Standard Scar Management (SSM)|SSM may include any of the following: range of motion exercises, massage, custom fit pressure garments, and silicone sheeting.
1534854|NCT02707614|Procedure|Robotic vs open prostastectomy|robotic minimal invasive surgery
1534855|NCT02707601|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) fixed dose combination (FDC) tablet administered orally once daily
1534856|NCT02707601|Drug|F/R/TAF|F/R/TAF (200/25/25 mg) FDC tablet administered orally once daily
1534857|NCT02707601|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
1534861|NCT02707575|Drug|Ranibizumab|Three monthly consecutive injections of 0.5-mg ranibizumab will be performed. Aqueous humor samples will be taken each time an intravitreal injection in indicated and performed.
1534862|NCT02707562|Drug|GLPG1837 dose 1|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
1534863|NCT02707562|Drug|GLPG1837 dose 2|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for one week
1534864|NCT02707562|Drug|GLPG1837 dose 3|two GLPG1837 tablets in the morning and two GLPG1837 tablets in the evening, for two weeks
1534865|NCT02707549|Drug|balanced crystalloid solution (components: sodium chloride, sodium gluconate, sodium acetate, potassium chloride and magnesium chloride)|
1534866|NCT02707549|Drug|0.9% sodium chloride|
1534875|NCT02707484|Drug|Thalidomide (100mg)|Patients were randomly assigned to receive a four-month course of 100 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
1534876|NCT02707484|Drug|Thalidomide (50mg)|Patients were randomly assigned to receive a four-month course of 50 mg of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China).
1534877|NCT02707484|Drug|placebo|Patients were randomly assigned to receive a four-month course of placebo (Pharmaceutical Co., Ltd. of ChangZhou, China).
1534878|NCT02707471|Behavioral|SM-AET|self-management for improving adherence and reducing symptom interference (SM-AET)
1534879|NCT02707471|Behavioral|general health education|general health education intervention that focuses on improving overall health.
1534880|NCT02707458|Drug|Probucol|"Probucol was used with good effect for more than a decade in Canada and the US to reduce plasma cholesterol. Although withdrawn from the Canadian and US markets by its manufacturer for commercial reasons, it is still widely used for this purpose in Japan and Korea. Over the past decade, long-term follow-up studies in Asian populations at high risk of cardiovascular events have shown that the drug reduces the incidence of these events in a manner not unlike statin drugs used widely in Canada and the US."
1534881|NCT02707445|Drug|Clopidogrel|Administration of conventional dual anti-platelet treatment (aspirin 100mg and clopidogrel 75mg daily) for minimum 3 months after percutaneous coronary intervention
1534882|NCT02707432|Behavioral|Heart Matters|"Heart Matters is an intervention adapted from PREMIER, an evidence-based, comprehensive lifestyle intervention that focuses on blood pressure as the primary outcome. To assess the feasibility and efficacy of adapting PREMIER for rural African Americans, Heart Matters will be delivered to multiple intervention groups, but at two different stages."
1534883|NCT02707419|Device|Experimental group|Video of the exercises
1534884|NCT02707419|Device|Control group|video of nature scenes
1534885|NCT02707419|Device|Conventional physiotherapy|Mobilization, exercises and transfer practice.
1534886|NCT02707406|Other|NEOX®CORD 1K|use of human tissue product wound covering
1534887|NCT02707406|Other|standard of care|standard wound coverings
1534895|NCT02707380|Other|Resistance Training|7 muscle-strengthening exercises using body weight resistance and elastic resistance bands
1534896|NCT02707380|Other|Standard of Care|3 exercises that do not include these 7 muscle-strengthening exercises
1534899|NCT02707354|Device|Probe based confocal laser endomicroscopy (Cellvizio)|"The probe is a miniaturized microscope in the form of a fiber which is inserted through the endoscope and brought into contact with the mucosa. It thus allows for a live virtual biopsy, that is to say, obtaining real-time microscopic virtual image of the mucosa. It requires an intra-veinous injection of 5 mL of 10% fluorescein diluted in 50 cc of saline serum. The images obtained during the examination will be recorded via the endomicroscopy console so that two endoscopists blinded from the macroscopic and histological findings can review the data."
1534900|NCT02707328|Drug|Gemcitabine|
1534901|NCT02707328|Drug|nab-paclitaxel|
1534902|NCT02707328|Radiation|CyberKnife|
1534903|NCT02707315|Drug|Gemcitabine|
1534904|NCT02707315|Radiation|Stereotactic Radiosurgery|
1534905|NCT02707302|Device|Iodophor-impregnated adhesive drapes group|Odd-numbered patients are randomized to the iodophor-impregnated adhesive drapes group.3M™ loban™2 iodophor-impregnated adhesive drape(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-impregnated adhesive drapes group.
1534906|NCT02707302|Procedure|Iodophor-free adhesive drapes group|Even-numbered patients are randomized to the iodophor-free adhesive drapes group. Iodophor-free aseptic adhesive drapes(3M Company, St. Paul, Minnesota, USA) will be used at the surgical site in the iodophor-free adhesive drapes group.
1534907|NCT02707276|Device|Active Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic treatment being investigated for its effects on mood. It uses magnetic fields that are a fraction of the strength but at a higher frequency than the electromagnetic fields used in transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT)
1534908|NCT02707276|Device|Sham Low Field Magnetic Stimulation|The sham treatment does not provide any electromagnetic stimulation. However, it is designed so that it cannot be differentiated from the active treatment.
1534909|NCT02707263|Drug|intravenous continuous infusion of heparin (IV UFH)|
1534910|NCT02707263|Drug|Subcutaneous Heparin|
1534911|NCT02707250|Drug|Placebo|Tap Block performed with normal sterile saline 20 ml on the right side and 20 ml on the left side
1534912|NCT02707250|Drug|Bupivacaine|Tap Block performed with Bupivacaine 0,25% 20 ml on the right side and 20 ml on the left side.
1534913|NCT02707250|Drug|Pethidine|Tap Block performed with pethidine 1% 10 ml on the right side and 10 ml on the left side
1534914|NCT02707250|Drug|Pethidine Local Infiltration (L.I)|Local infiltration of port sites (trocar insertion sites) with pethidine 1% 5ml each port (trocar site) ,4 ports total 20 ml pethidine 1%
1534916|NCT02707237|Other|Verbal, pictorial, written counseling|verbal counseling in addition to gestational age specific written information and pictures will be given to parents
1534917|NCT02707224|Drug|DP-R208|Investigational product is prescribed to all of randomized subjects
1534918|NCT02707224|Drug|Candesartan cilexetil|Investigational product is prescribed to all of randomized subjects
1534919|NCT02707224|Drug|Rosuvastatin|Investigational product is prescribed to all of randomized subjects
1534920|NCT02707211|Biological|Anti-oxLDL IgM antibody|Immunization
1534921|NCT02707198|Drug|kefir|4 ounces of kefir 3 times a day, with or without food.
1534922|NCT02707185|Behavioral|Simulation-Based Training|An objective assessment tool has been developed and tested in medical code scenarios during training sessions recently done in the simulation lab. The tool has five domains: Airway, Breathing, Circulation, Communications/Leadership, and Defibrillation. Each domain consists of 3-8 tasks and skills.
1534923|NCT02707172|Behavioral|handwashing with soap|handwashing with soap by a standardized 6-step handwashing technique
1534924|NCT02707172|Behavioral|handwashing with water|handwashing with water by a standardized 6-step handwashing technique
1534925|NCT02707159|Drug|Nab paclitaxel / gemcitabine|Patients will receive gemcitabine/nab-paclitaxel combination chemotherapy
1534926|NCT02707146|Behavioral|Visit Planner|The Visit Planner is an application hosted on an iPad that guides the patient in preparing for the primary care visit
1534927|NCT02707146|Other|Attention Control Pamphlet|Patients in the attention control arm will receive an approved educational handout on health lifestyle
1534928|NCT02707146|Device|iPad|
1534929|NCT02707133|Other|No intervention|
1534930|NCT02707120|Drug|PRGF-Endoret|Active treatment will be PRP eye drops obtained by the PRGF-Endoret system.
1534931|NCT02707120|Drug|Artificial tears eye-drops|Artificial tear moisturizing eyedrops (Hidrathea®, Nacl 0.9 % solution without preservatives).
1534932|NCT02707107|Drug|Intravenous infusions of WCK 5222|
1534933|NCT02707107|Drug|Placebo|
1534934|NCT02707094|Device|Biomodulator|The Biomodulator is a type of very low frequency TENS known as pulsed electromagnetic field therapy (PEMF). Unlike TENS devices that deliver 1-80 milliamperes of electrical current, PEMF devices deliver short bursts of electrical microamperes (millionths of an ampere) to injured tissues without producing heat or interfering with nerve or muscle function. Micro-current levels between 20-500 microampere appear to be most effective at relieving pain and inflammation and promoting tissue healing by realigning the natural electrical balance that exists within the cells that has become disrupted due to injury.
1534935|NCT02707094|Other|Usual Care (Medication + Exercise)|The study LP will prescribe an analgesic medication regimen based on the participant's needs. These medications may consist of Non-steroidal anti-inflammatory Drugs (NSAIDs) (ibuprofen, naproxen sodium, etc.), muscle relaxants (Flexeril, Robaxin, valium, etc.), non-narcotic analgesic medications (acetaminophen, aspirin, tramadol, etc.), or narcotic medications (Tylenol #3, Percocet, Vicodin, etc.) depending on the severity of their pain and co-morbid conditions. The RC will also provide instructions for LBP stretching and strengthening exercises. The following exercises will be recommended as a daily regimen: the partial curl, cat and camel, pelvic tilt, quadriceps, arm/leg raises,trunk rotation, single knee to chest stretch, standing hamstring stretch, and double knee to chest stretch.
1534936|NCT02707081|Drug|Intravenous normal saline|Normal saline in a volume equivalent to that used in intravenous lidocaine group
1534937|NCT02707081|Drug|Intraperitoneal normal saline|Patients received 00 ml of saline intraperitoneally
1534938|NCT02707081|Drug|Intraperitoneal Lidocaine|Patients received 1.75 ml/kg of 0.2% lidocaine (3.5mg/kg) with parietal peritoneal closure.
1534939|NCT02707081|Drug|Intravenous Lidocaine|Patients received 1.5mg/kg of intravenous 1% lidocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion of intravenous lidocaine until one hour after surgery.
1534940|NCT02707068|Behavioral|Quality Of LIfe Tool for IBD (QOLITI)|The cognitive-behavioural therapy (CBT)-inspired manual will contain several chapters each of which addresses a different topic with information, guidance in setting goals for behaviour change and accompanying tasks to aid implementation which will be completed at home in the participant's own time. Key themes are likely to include symptom management, dealing with social implications of the disease and interacting effectively with healthcare professionals among others. Each chapter will address a theme providing information, sign posting to appropriate organisations, step-by-step tasks and quotes from pwIBD among others, drawing on relevant therapeutic approaches for self-management including CBT and certain elements of Acceptance and Commitment Therapy.
1534947|NCT02707016|Other|Sevoflurane 8%|Sevoflurane 8% (high dose) during anesthesia induction
1534948|NCT02707016|Other|Sevoflurane 5%|Sevoflurane 5% (low dose) during anesthesia induction
1534949|NCT02706990|Device|Physica KR|Kinematic retaining total knee implant
1534950|NCT02706990|Device|Physica PS|Posterior stabilized total knee implant
1534951|NCT02706977|Drug|Low Dose Sinemet CR|Sinemet CR (25 mg carbidopa/100 mg levodopa) will be taken by mouth twice daily for two weeks.
1534952|NCT02706977|Drug|High Dose Sinemet CR|Sinemet CR (50 mg carbidopa/200 mg levodopa) will be taken by mouth twice daily for two weeks.
1535001|NCT02706756|Other|Education and advice|All three groups will receive standardized education on the current state of FAI interventions (with both conservative and surgical care).
1535002|NCT02706756|Other|Supervised neglect|Monitoring of group without formal intervention.
1535003|NCT02706730|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
1535140|NCT02705612|Radiation|External Beam Radiation Therapy|
1534953|NCT02706977|Device|RETeval Electroretinogram (ERG) Testing|ERG testing consists of sitting in the dark for 15 minutes. During the procedure, participants will have a single-use adhesive sensor strip placed on the skin near the eye. A hand-held device, called the RETeval, will be placed in front of the eye and a series of flashes and flickering lights presented. The light intensity level is typically not uncomfortable. When right eye imaging is complete, the procedure will be repeated on the left eye. Both eyes will be evaluated in less than 5 minutes for most participants. Electroretinogram (ERG) testing will be completed at baseline, day 1, week 2, and week 4.
1534954|NCT02706977|Other|Contrast Sensitivity Testing|Contrast sensitivity testing consists of looking at a series of moving lines on a tablet device. The lines will change from white to grey to black. Participants will be asked to determine when they can no longer distinguish between the lines. Contrast sensitivity testing will be completed at baseline, day 1, week 2, and week 4.
1534955|NCT02706977|Other|Visual Acuity Testing|Participants will be asked to look at an eye chart with letters or symbols that become smaller as they move from top to bottom of the chart. Visual acuity testing will be completed at baseline, day 1, week 2, and week 4.
1534956|NCT02706964|Device|Positron emission tomography/x-ray computed tomography|A whole-body PET/CT will be performed to identify the site and extent of spread.
1534957|NCT02706964|Device|Magnetic resonance imaging|A brain MRI will be performed.
1534958|NCT02706964|Device|x-ray computed tomography (CT)|A CT scan will be performed to identify the site and extent of spread.
1534963|NCT02706938|Other|Head of bed elevation|Head of bed elevation will be achieved with a pair of prisms of withered pine tree wood with dimensions (Height x Width x Depth) 20x18x18 cm. Each prism lying on the floor will support one of the head legs of the bed
1534964|NCT02706938|Other|Standard treatment|Standard pharmacological treatment with a proton pump inhibitor and/or sodium alginate, according to clinical judgement.
1534965|NCT02706925|Drug|BI 443651|
1534966|NCT02706925|Drug|Placebo|
1534967|NCT02706912|Behavioral|VOTA Therapy|During sessions of approximately one hour in duration, participants practice performing virtual activities of daily living (ADLs) using the VOTA system. During this practice, the participant's real-world motion is replicated by an avatar's motion in the virtual world. To complete the activities, participant's must perform a wide range of functional arm movements while interacting with virtual objects. Individuals are asked to perform three such one-hour virtual ADL practice sessions per week over a participation period of approximately eight weeks.
1534968|NCT02706899|Drug|vadastuximab talirine|
1534969|NCT02706899|Drug|Azacitidine|azacitidine 75 mg/m2 given intravenously or subcutaneously x 7 days every 4 weeks
1534970|NCT02706899|Drug|Placebo (for 33A)|Placebo supplied in single-use vials matching 33A
1534971|NCT02706886|Drug|ALN-GO1|Single or multiple doses of ALN-GO1 by subcutaneous (sc) injection
1534972|NCT02706886|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
1534977|NCT02706860|Drug|Atorvastatin|
1534978|NCT02706847|Drug|ABT-494|ABT-494 oral tablet
1534979|NCT02706847|Drug|Placebo|Oral tablet
1534991|NCT02706821|Dietary Supplement|Persimmon leaf extract|Persimmon leaf extract (PLE), crossover design
1534992|NCT02706821|Dietary Supplement|Placebo|Placebo, crossover design
1534993|NCT02706808|Dietary Supplement|'resistance starch for CKD|Intervention period (6 weeks): Group A - patients will receive 6 cookies/day containing resistant starch (18g/day); Group B - patients will receive 6 cookies/day containing placebo
1534994|NCT02706808|Dietary Supplement|Placebo|Intervention period (6 weeks): Group B - patients will receive 6 cookies/day containing resistant starch (18g/day); Group A - patients will receive 6 cookies/day containing placebo
1534995|NCT02706795|Biological|DaxibotulinumtoxinA|Low, mid, and high dose sequential treatments of daxibotulinumtoxinA in dose-escalation safety and efficacy study
1534996|NCT02706782|Drug|TAI-meso-CART|TAI as a local drug delivery pathway, so that more T cells gathered at the tumor site, less T cells to migrate to the normal tissue, thereby enhancing the efficacy of anti-tumor, reducing the potential of side effects. And meso-CART is a 2nd CAR, with mesothelin as target protein, 4-1BB as co- stimulator
1534997|NCT02706769|Drug|Placebo|Study medication contains blinded placebo
1534998|NCT02706769|Drug|Paracetamol|Study medication contains blinded paracetamol
1534999|NCT02706756|Other|Manual therapy|Hip joint and spine manual therapy techniques applied toward the impairments of the subject.
1535000|NCT02706756|Other|Exercise|Prescriptive exercise program of self-mobilization and/or strengthening program to address impairments of the subject.
1535004|NCT02706717|Drug|Visibiome|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
1535005|NCT02706717|Drug|Placebo|From week 2 to 4, participant will receive one sachet orally daily. From week 4 to 26, participant will receive one sachet orally twice daily.
1535006|NCT02706704|Drug|Adalimumab|
1535007|NCT02706691|Other|Laboratory Biomarker Analysis|Correlative studies
1535008|NCT02706691|Drug|pan FGFR Kinase Inhibitor BGJ398|Given PO
1535009|NCT02706678|Drug|Tacrolimus sustained-release capsule|Oral
1535010|NCT02706665|Other|SEDline monitor|The SEDline monitor gives us the Patient State Index (PSI), a dimensionless number within a range of 0 to100.
1535012|NCT02706613|Behavioral|Face to Face Pulmonary Rehabilitaton|6 week face to face, incremental exercise and education programme for people with COPD
1535013|NCT02706613|Behavioral|Online Pulmonary Rehab|6 week online, incremental exercise and education programme for people with COPD
1535014|NCT02706600|Behavioral|myCOPD|"myCOPD is a system that can be accessed by patients using any device that can connect to the internet and can operate in any internet browser. It contains: Educational information, Inhaler technique videos explaining the correct technique required to use different inhaler devices licensed for use in people with COPD.
Medication and symptom diaries. Appointment diary Bitesize pulmonary rehabilitation videos designed to promote and support exercises that can be done in a home setting.
Oxygen Alert Card - Users can create their own oxygen alert card online A 5 Day local weather and pollution reports - Feed for reports come from the met office and DEFRA.
A Self management plan, which consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate. The action plan is populated automatically with the information input by the patients."
1535015|NCT02706600|Behavioral|Written Self management plan|The HealthQuest written self management plan was produced in 2013. It is a one page document which contains a written self management plan which can be individualised for the patient. It consists of a traffic light system to direct patients to the most appropriate action to take should their symptoms deteriorate.
1535016|NCT02706587|Device|Neuromuscular electrical stimulation|NEMS is delivered bilaterally to the quadriceps femoris muscle using a portable battery-powered stimulator (Rehab 400, Cefar Compex, France). The electrodes are placed on the motor points of vastus medialis and vastus lateralis muscles. Electrical stimuli of 45Hz (pulse width: 380 µseconds; 6 seconds on with 1.5 second rise time; and 0.75 seconds fall time.; 5 seconds off). The current is adjusted to ensure maximum tolerable muscle contraction The protocol is applied twice daily for 25 minutes, five days a week.
1535017|NCT02706587|Device|Sham control|No electrostimulation
1535018|NCT02706561|Behavioral|questionnaires|
1535019|NCT02706561|Behavioral|three in-person sessions|
1535020|NCT02706561|Behavioral|monthly phone calls|
1535021|NCT02706561|Behavioral|Acceptance and Commitment Therapy for Erectile Dysfunction (ACT-ED)|
1535022|NCT02706561|Behavioral|Enhanced Monitoring and Education (EME)|
1535023|NCT02706548|Behavioral|Integrative Medication Self Management (IMedS) Intervention|Half of participants received a manualized 30-minute occupational therapy intervention, Integrative Medication Self-Management Intervention (IMedS). During IMedS, the interventionist and client progress through three steps in which the pair: 1) reflect on past performance of medication management, 2) set a medication goal, and 3) generate strategies to reach the goal. During strategy generation, the interventionist uses therapeutic use of self and motivational interviewing to help the client self-generate new medication management strategies, specifically addressing 1) altering the activity, 2) advocacy, 3) education, 4) assistive technology, 5) environmental modifications, and 6) securing timely refills.
1535024|NCT02706548|Behavioral|Standard Care Educational Intervention|The standard care educational intervention was a 30-minute pamphlet based educational session. In the standard care intervention group, participants and interventionist first reviewed the pamphlet, Managing Your Medicines: Our Guide to Effective Medication Management (American Heart Association & American Stroke Association, 2013). Then, the interventionist engaged in active listening, where she asked open-ended questions about the participant's medication routines and provided simple reflections. For the standard care procedures, the interventionist was prohibited from providing affirmations, complex reflections, summaries, problem-solving, or suggesting any specific interventions.
1535025|NCT02706535|Drug|GSK525762 Besylate Tablets|GSK525762 is available as a film-coated, white to slightly colored round, biconvex tablets with no markings. It is available in unit dose strength of 5 mg.
1535026|NCT02706535|Drug|Itraconazole 200 mg|Itraconazole is available as a clear yellow solution with unit dose strength of 10 mg/mL
1535027|NCT02706535|Drug|Rifampicin 300 mg|Rifampicin is available as a red capsule with printed markings and as a 300 mg unit dose strength.
1535028|NCT02706522|Dietary Supplement|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
1535029|NCT02706522|Dietary Supplement|Allocated to Placebo group|Patients received 400 mL of oral flavored water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before
1535030|NCT02706509|Drug|Tramadol|patient will receive oral Tramadol 50 mg an hour before IUD insertion
1535031|NCT02706509|Behavioral|Verbal anesthesia|patient will receive full explanation about the procedure for five minutes before IUD insertion
1535032|NCT02706509|Device|Jaydess|Patient will go through an insertion of Jaydess intrauterine device.
1535033|NCT02706483|Drug|Plecanatide|
1535034|NCT02706470|Drug|Cyclosporin A|Patients will receive oral CsA in a dose of 50mg three times a day for 20-30 days since the occurrence of positive result in human chorionic gonadotropin (HCG) test in urine and 14 consecutive days of elevated basal body temperature. The dosage of CsA will be adjusted according to baseline and peak value of CsA blood concentration. If the baseline blood concentration of CsA is lower than 40ng/ml or the peak blood concentration of CsA is lower than 500ng/ml, the dosage of CsA will be increased to 75 mg three times a day.
1535035|NCT02706470|Drug|Dydrogesterone|Patients will receive oral dydrogesterone 10 mg three times a day for 30 days since the occurrence of positive result in HCG test in urine and 14 consecutive days of elevated basal body temperature.
1535036|NCT02706457|Other|Barthel index for functionality|The Barthel Index for functionality is done standard in all patients after intensive care admission
1535037|NCT02706444|Device|Conventional Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
1535038|NCT02706444|Device|Drug-coated Balloon angioplasty|After fistulogram, full expansion of drug-coated balloon catheter under fluoroscopy guidance in > 50% venous anastomotic stenosis of hemodialysis graft and ≦4cm from venous anastomosis site in lesion length, confirmed by fistulogram. Then, participants were divided into two groups (Conventional balloon angioplasty or Drug-coated balloon angioplasty)
1535039|NCT02706431|Procedure|Hyperventilation|
1535040|NCT02706418|Procedure|Clinical Massage Therapy|
1535049|NCT02706379|Other|Local cerebral oxygen saturation|take blood culture before antibiotic use;measure the blood lactate;liquid rescisutation as 20ml/kg
1535056|NCT02706301|Behavioral|Telephone-Based Coping Skills Training (CST)|
1535057|NCT02706288|Other|Weight loss with very low fat plant-based diet and regular exercise|Participants will lose 7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
1535058|NCT02706275|Other|External warming|External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours
1535059|NCT02706262|Other|Metabolically abnormal obese - Mediterranean diet|The effect of consuming a Mediterranean diet will be examined over 3 different phases: (i) weight maintenance for 4 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a Mediterranean diet but will prepare all their food at home. No food will be provided during this portion of the study.
1535060|NCT02706262|Other|Metabolically abnormal obese - Low carbohydrate ketogenic diet|The effect of consuming a low-carbohydrate, ketogenic diet will be examined over 3 different phases: (i) weight maintenance for 4 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a low carbohydrate ketogenic diet but will prepare all their food at home. No food will be provided during this portion of the study.
1535061|NCT02706262|Other|Metabolically abnormal obese - Plant-based, very-low-fat diet|The effect of consuming a plant-based, very-low-fat diet will be examined over 3 different phases: (i) weight maintenance for 4 weeks, with all meals provided; (ii) controlled 7-10% weight loss with caloric intake reduced by 25% to achieve the desired amount of weight loss in about 4 to 5 months with all meals provided; and (iii) Independent weight loss for about 4 months. During the independent weight loss phase of the study subjects will be asked to continue to consume a plant-based, very-low-fat diet but will prepare all their food at home. No food will be provided during this portion of the study.
1535062|NCT02706249|Drug|Enoxaparin|
1535063|NCT02706236|Drug|Pancrelipase|Oral Pancrelipase, 720,000 units spread throughout the day with meals and snacks, taken daily PO for 4 weeks
1535064|NCT02706236|Drug|placebo|Placebo will consist of lactose, spread throughout the day with meals and snacks, taken daily PO for 4 weeks
1535065|NCT02706223|Other|Pharmacist Led|Trial of administering established, licensed treatments by a novel pathway, ie Community Pharmacists, which is hypothesized to improve treatment and retention in treatment of difficult to engage subjects
1535066|NCT02706223|Other|Nurse led|Trial of administering established, licensed treatments by the conventional clinical care pathway, ie Specialist nurses
1535067|NCT02706197|Device|OxyChip|The OxyChip is an investigational device
1535070|NCT02706171|Radiation|CyberKnife|
1535071|NCT02706158|Dietary Supplement|1500 mg Calcium and 1200 IU Vitamin D for 2 months|1500 mg Calcium and 1200 IU Vitamin D for 2 months
1535072|NCT02706158|Behavioral|balanced diet|participants will get a balanced diet according to pregnancy stage
1535073|NCT02706145|Other|Social norming campaign|community-level, three-year social norming campaign, using traditional and emerging media, aimed at changing norms of violence among youth 10-24
1535074|NCT02706132|Biological|Mesenchymal Stem Cells(MSCs)|Six doses of 1*10^6/kg body weight MSCs are given, intravenously.
1535075|NCT02706119|Drug|Subcutaneous glargine insulin|Glargine insuline is an insulin analogue which has a prolonged duration of action. Insulin glargine is obtained by recombinant DNA technology in Escherichia coli.
1535076|NCT02706119|Drug|Regular insulin added to TPN bag|Regular insulin is human insulin produced in Saccharomyces cerevisiae by recombinant DNA technology.
1535077|NCT02706106|Device|Knee brace|Patients will be prepared to receive the device of knee brace with or without a hole in the sit position. This intervention will be blinded. Patients will receive a mask covering their eyes and the knee brace will be placed by the researchers, then the knee area will be covered with a dark clothing bag, so the patient will not be able to guess which type of brace is wearing (with or without a hole). Patient will perform the tests without the mask covering their eyes and only the dark clot bag on their knee.
1535078|NCT02706093|Other|High Intensity Interval Training #1|(HIIT#1) 10 x 1 min. at ~90%HRmax - with low intensity warm-up, recovery, and cool down - total of 25 min/session .
1535079|NCT02706093|Other|Moderate intensity continuous training|Moderate-intensity continuous training (MICT) = steady-state exercise at 60-70%HRmax for 45min. Representing a commonly prescribed exercise program.
1535080|NCT02706093|Other|High Intensity Interval Training #2|(HIIT #2) 5 x 1 min at 90%HRmax + 10 min steady-state exercise at 70%HRmax [25min; ~150kcals; 4d/wk]
1535081|NCT02706093|Other|High Intensity Interval Training #3|(HIIT #3) 5 x 1 min at 90%HRmax [15min; ~90kcals; 4d/wk]
1535082|NCT02706080|Other|emergency|
1535084|NCT02706054|Other|saline|The patients received an IM injection of saline near the nerve root (periradicular)
1535085|NCT02706054|Drug|Meloxicam|The patients received an IM injection of meloxicam near the nerve root (periradicular)
1535088|NCT02706028|Device|underwater ultrasound|underwater US therapy with an intensity of 0.7 W/cm2 in a total of 10 sessions (10 working days) using a 830 kHz ULTRON home OE-302® device with treatment head size of 4.2 cm2.
1535089|NCT02706028|Device|sham underwater ultrasound|ULTRON home OE-302® device is not turned on
1535090|NCT02706015|Drug|Cefaliv® & Placebo|02 tablet of Cefaliv® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
1535091|NCT02706015|Drug|Neosaldina® & Placebo|02 tablets of Neosaldina® + 02 tablet of comparator placebo, VO, after the beging of migraine with with mild to moderate pain
1535092|NCT02706002|Device|fluoroscopy|in active group femural stem of hip prosthesis will implanted under fluoroscopy guidance during operation till maximum rasp size reached that fills the medullary canal. ordinary 3-5 sequences per operation
1535093|NCT02706002|Procedure|hip prosthesis|all patients in the study will undergo hip prosthesis
1535094|NCT02705989|Drug|BMS-986195|Specified dose on specified day
1535095|NCT02705989|Other|Placebo|Specified dose on specified day
1535096|NCT02705976|Other|Experimental|The algorithm is based on a model, which is designed to handle time series of daily warfarin intakes and INR values measured at designated time points. Based on these inputs the model is able to suggest a warfarin maintenance dose to achieve target INR value. Model parameters are initially set to population values and gradually, as data is entered into the model, these parameters become patient specific.
1535097|NCT02705976|Other|Active Comparator|Participants were (previously) educated in monitoring the INR values and to adjust the warfarin treatment accordingly to achieve a designated target INR range.
1535101|NCT02705950|Drug|Intrathecal baclofen bolus|An intrathecal baclofen bolus injection of 50 µg (1ml) will be injected at L3/L4 level.
1535102|NCT02705950|Other|Placebo|1 ml of physiological saline (isotonic saline) will be injected subcutaneously at L3/L4 level simulating
1535103|NCT02705937|Other|Dairy product|Dairy products are given to patients with the instruction to eat as many products as necessary to provide them with some relief (within a limit of 6 per day) for 14 days
1535104|NCT02705937|Device|Aequasyal mouth spray|The mouth spray will be used by patients as needed (according to the package leaflet) for 14 days
1535141|NCT02705612|Radiation|Internal Radiation Therapy|
1535105|NCT02705924|Behavioral|psychoeducation|"Participants will attend conferences where experts present the state of the art in various domains:
Latest knowledge in oncogenetics
Recommendations and morbidity of prophylactic breast surgeries and annexectomy
Epidemiology of HBOC and comparative mortality risks with other syndromes/life habits
How to perform the periodic breast screening
Assisted medical procreation and embryo selection
Importance of nutrition and physical activity as risk modulator
Life habits: how one can increase or lower the cancer risk (tobacco, alcohol...)?
Description of the assistance program (GENAUV) to help counselees exposed to a high cancer risk follow their medical screening.
The remaining time after this information, i.e. about half of the week-end, will comprise group activities, in particular role games (Moreno psychodrama approach) and group sharing under the supervision of a psychotherapist."
1535106|NCT02705911|Other|Isometric handgrip exercise|Participants have to perform 4 x 2 minute contractions with alternating hands, separated with 1 minute rest period using a ZonaHealth device;
1535107|NCT02705911|Other|Aerobic endurance training|To perform 150 minutes extra/week at moderate aerobic intensity
1535108|NCT02705898|Behavioral|LPA+Fitbit|
1535109|NCT02705898|Behavioral|HEC|
1535110|NCT02705885|Dietary Supplement|lozenges containing IgY|Patients consumed food supplement lozenges containing IgY after nonsurgical periodontal therapy
1535111|NCT02705885|Dietary Supplement|Placebo IgY|Placebo IgY
1535112|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml/h|Continuous epidural perfusion: Chirocaine 0.07% + Sufentanil 0.3 mcg/ml with a 10ml/hour rate
1535113|NCT02705872|Drug|Chirocaine 0.07% + Sufentanil 0.3 mcg/ml 10ml each 60 minutes|Injection of programmed intermittent boluses in the epidural space, without continuous perfusion, of the same solution (Chirocaine 0.07% + Sufentanil 0.3 mcg/ml): 10ml each 60 minutes
1535114|NCT02705859|Drug|Copanlisib|Copanlisib is a novel small molecule PI3K inhibitor being evaluated for the treatment of a wide variety of advanced and refractory malignancies either as a single agent or in combination with other investigational agents.Copanlisib has potent and selective activity against all four Class I PI3K isoforms with IC50s of 0.5-6.4nM in biochemical assays. Notably, copanlisib shows excellent anti-tumour activity in pre-clinical models with an up-regulated PI3Kα pathway suggesting a particular role for it in PIK3CA mutated cancers.
1535115|NCT02705859|Drug|Trastuzumab|A humanised IgG1 monoclonal antibody
1535116|NCT02705820|Drug|Pembrolizumab|Switch maintenance pembrolizumab treatment
1535117|NCT02705807|Drug|FLOLAN injection with currently marketed diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the currently marketed diluent (epoprostenol sodium+ powder of hydrogen [pH] 10.2 - 10.8 diluent) for Injection.
1535118|NCT02705807|Drug|FLOLAN injection with reformulated diluent|FLOLAN injection (epoprostenol 0.5 or 1.5) prepared with the reformulated diluent (epoprostenol sodium + pH 11.7 - 12.3 diluent) for Injection.
1535119|NCT02705781|Device|smARTrack Feeding Tube System|
1535120|NCT02705768|Drug|Carbamazepine|Carbamazepine will be started with a dose of 200 mg/day for one week and then increased to 400 mg/day for one week and then 600mg/day for next two weeks.
1535121|NCT02705768|Drug|Oxcarbazepine|Oxcarbazepine will be started with 10mg/kg daily dose for one week followed by 15mg/kg daily for next one week and then will be increased to 20mg/kg for next two weeks.
1535122|NCT02705755|Drug|TD-9855|
1535123|NCT02705755|Drug|Placebo|
1535124|NCT02705742|Biological|Mesenchymal Stem Cells|1.000.000 (one million) cells/kg, IV of dose in the Peripheral vein and 3.000.000 (three million) cells/kg of dose into the right hepatic artery)
1535125|NCT02705729|Device|Ketac Universal|High-viscous glass ionomer restorative material used as posterior dental filling. This material does not require a dentin conditioning step.
1535126|NCT02705729|Device|Ketac Molar Quick|High-viscous glass ionomer restorative material used as posterior dental filling. This material requires a dentin conditioning step.
1535127|NCT02705716|Other|0.454% w/w stannous fluoride (1100ppm fluoride)|Dentifrice containing 0.454% w/w stannous fluoride (1100ppm fluoride)
1535128|NCT02705716|Other|0.76% sodium monofluorophosphate (1000ppm fluoride)|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
1535129|NCT02705703|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
1535130|NCT02705690|Device|iOS Balance Application|"We have designed an iOS application and a belt. The application uses accelerometer data to calculate postural sway. Steps:
The phone is kept stable against the lower back of the participant using the belt.
The iOS application gives instructions to user to adopt the correct stance (eg: Standing Unsupported, legs side by side) Once the stance is adopted, the application turns on the accelerometer in the phone to sample acceleration along x (media lateral) and z (anterior posterior) axis.
These displacements from the mean are used to calculate the Root Mean Square of a person which acts a proxy score for Postural Sway. (Postural sway is defined as the phenomenon of constant displacement and correction of the position of the center of gravity within the base of support)"
1535131|NCT02705664|Drug|Loceryl Nail Lacquer|Topical over entire toenail plates of affected toenails once weekly in the evening (at bed time) after having filled down affected toenails to gently remove as much as affected nails and having cleaned toenails surfaces with the provided cleansing swab
1535132|NCT02705664|Drug|Urea Ointment|Topical over the infected part of the toenails only once daily under occlusion in the evening (at bed time) after having soaked toenails in warm water and having removed the soften infected toenail plates and dried the toenails
1535133|NCT02705664|Drug|Bifonazole Cream|Topical, to be rubbed sparingly over the affected toenail skin (nail bed) once daily in the evening (at bed time) after having cleaned and dried thoroughly toenails
1535134|NCT02705651|Drug|Somatostatin-Analog|A long-acting somatostatin-analog will be applied.
1535135|NCT02705638|Drug|Rituximab|All subjects will receive Rituxan 1,000 mg intravenously on days 1 and 15.
1535136|NCT02705638|Drug|Lenalidomide|All subjects will receive Revlimid 20 mg orally per day on days 1-21, 29-49, and 57-77.
1535137|NCT02705625|Drug|MIV-711|MIV-711 administered orally once daily
1535143|NCT02705586|Behavioral|Mindfulness|Mindfulness focuses on helping participants understand their personal reactions to stress, teaches skills that provide means to modify stress reactions, and promotes self-care and feelings of competence and mastery. In addition to weekly class sessions, participants are asked to do an hour of home practice the days that the class does not meet.
1535144|NCT02705573|Drug|Mannitol|
1535145|NCT02705560|Other|Cow´s milk (3.9% fat, pasteurized)|600 ml full fat milk (organic, pasteurized, 400 kcal)
1535146|NCT02705560|Other|hard, yellow cheese|100 g Swiss cheese (Le Gruyère medium ripe, 400 kcal)
1535147|NCT02705560|Other|Soy based drink|600 ml Soy drink (540 ml soy milk (232 kcal) supplemented with 60 ml soy and plant based cream (167 kcal)
1535148|NCT02705547|Drug|Rosuvastatin|Daily oral administration of Rosuvastatin (10 mg) for 3 months
1535149|NCT02705534|Drug|Sofosbuvir|400 mg, included in a combination pill with 90 mg ledipasvir
1535150|NCT02705534|Drug|Ledipasvir|90 mg, included in a combination pill with 400 mg sofosbuvir
1535151|NCT02705534|Drug|Ribavirin|1000 mg/day if <75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
1535152|NCT02705521|Device|Exergames- Laptop and MIcrosoft Kinect|Following surgery each patient will have a set of games for them to play using their affecting shoulder. These games have been designed by physiotherapists and shoulder surgeons to improve the functional range of movement in their shoulder
1535153|NCT02705508|Drug|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle.
1535154|NCT02705508|Drug|etoposide|100mg/m2，4h-intravenous infusion on day1-3 of each 21 day cycle.
1535155|NCT02705508|Drug|Pegaspargase|2500U/m2 im on day 1 of each 21 day cycle.
1535156|NCT02705508|Radiation|involved-field radiotherapy|Three-dimensional conformal radiotherapy was done by linear accelerator at 2.0 grays (Gy) per daily fraction with 5-6 weeks. The involved- field radiation (IFRT) dose was 50-56 Gy.
1535157|NCT02705495|Other|acupuncture|"Acupuncture will be performed according to the physiological concept of segmental acupuncture. A fixed schema of acupuncture points will be used irrespective of TCM diagnosis. Needles will be inserted approximately 10 mm under the skin. The deqi sensation (a sensation described as numbness, heaviness, and distension) may be obtained, but will not be specifically aimed for. The acupuncture protocol includes body and ear acupuncture."
1535158|NCT02705495|Drug|Cranberry products|Participants will receive Cranberry products (Urgenin Blasenkapseln® and/or Alpinamed Preiselbeer Granulat ®) - use is recommended but not obligatory.
1535162|NCT02705469|Drug|ZEN003694|
1535163|NCT02705456|Procedure|Tooth Brushing HA|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a non-fluoridated tooth paste containing microcrystalline hydroxylapatite.
Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
1535164|NCT02705456|Procedure|Tooth Brushing FL|"2x daily repeated cleaning of all teeth using a standardized electric tooth brush and a fluoridated tooth paste.
Professional supragingival tooth cleaning once every 4 weeks with a rubber cup followed by the application of a 1% chlorhexidine gel over the duration of the study (24 weeks)."
1535165|NCT02705443|Other|No Intervention|Standard of Care Only
1535166|NCT02705430|Dietary Supplement|EPA and DHA capsules of 2 g/day|
1535167|NCT02705430|Behavioral|Stress management phone application (Eco Fusion Mentally)|
1535168|NCT02705430|Behavioral|life style program using a mobile phone (Eco Mentally and NewMe)|
1535169|NCT02705430|Device|mobile phone|
1535170|NCT02705417|Procedure|preoperative color Doppler ultrasonographic vascular mapping|Preoperative color Doppler ultrasonographic vascular mapping was performed with linear probe. The patient extremity under scrutiny was placed under support, with tourniquet augmentation. Vessels were examined in both short (transverse) and long (longitudinal) axis. Anatomical variations, wall morphology and internal diameters at the antecubital fossa, the proximal (cranial), mid and distal (caudal) third of the arm and forearm were assessed in both extremities. Veins were evaluated for compressibility and adequate drainage to deep venous system. The presence of sclerotic, thrombosed and fibrosed segments were noted. Doppler waveforms were obtained in the long axis and volume flow (VF) calculated for arteries selected for potential access construction.
1535171|NCT02705417|Procedure|physical examination|Arterial pulse examination, differential blood pressure measurements and the Allen test in both extremities. Inspection of the superficial venous system with tourniquet enhancement in the arm was performed during venous assessment.
1535172|NCT02705417|Procedure|medical history|medical history with respects to diabetes mellitus, coronary heart disease, peripheral vascular disease
1535173|NCT02705417|Procedure|native arteriovenous fistula construction|surgigal creation of native arterial and venous anastomoses
1535174|NCT02705417|Procedure|arteriovenous graft placement|surgical placement of arteriovenous graft
1535175|NCT02705404|Genetic|Multifocal Tissue Banking|
1535176|NCT02705378|Drug|Polyethylene glycol|Intervention would be given by oro-gastric (OG) or naso-gastric (NG) tube
1535177|NCT02705378|Drug|naloxegol|Intervention would be given by OG or NG tube
1535178|NCT02705365|Other|Patient Navigation|One to one patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
1535179|NCT02705365|Other|Usual Care|Usual care during the study period. After the study period, they will be offered 1:1 patient navigation to obtain lung screening and follow-up of abnormal results, as well as smoking cessation guidance.
1535180|NCT02705352|Drug|5-Fluorouracil|Treatment medication
1535181|NCT02705352|Other|Normal saline|Placebo
1535182|NCT02705339|Drug|Rociletinib|
1535183|NCT02705339|Procedure|Biopsy|Standard of care biopsies will be taken at diagnosis and at the time of disease progression
1535184|NCT02705339|Procedure|Blood draw|-Approximately 4 teaspoons of blood will be drawn before treatment begins and at the time of disease progression to look at cell-free DNA
1535185|NCT02705326|Device|Opti-Speech|Uses visual feedback of the tongue's motion to guide speech sound production
1535187|NCT02705300|Drug|Irinotecan 165 mg/m2 iv|Max. 4 months
1535188|NCT02705300|Drug|Oxaliplatin 85 mg/m2 iv|Max. 4 months
1535189|NCT02705300|Drug|Calcium folinate 200 mg/m2 iv|Max. 6 months
1535190|NCT02705300|Drug|5-fluorouracil 3200 mg/m2|Max. 6 months
1535191|NCT02705300|Dietary Supplement|Tocotrienol|Max. 2 years or at the discretion of the investigator
1535192|NCT02705300|Drug|Placebo|Max. 2 years or at the discretion of the investigator
1535193|NCT02705287|Other|Pregnant|tracer dose of deuterated vitamin D3
1535194|NCT02705287|Other|Non-pregnant|tracer dose of deuterated vitamin D3
1535195|NCT02705274|Drug|Bevacizumab|"Drug: 1.25-mg Bevacizumab Intravitreal injection of 1.25 mg Bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
Other: Deferred panretinal photocoagulation PRP is deferred until failure/futility criteria for intravitreal injection are met."
1535196|NCT02705274|Procedure|Panretinal photocoagulation|Panretinal photocoagulation (full session completed within 42 days).
1535197|NCT02705261|Behavioral|cognitive-behavior therapy|Internet based program to support parents in developing strategies to help their children
1535198|NCT02705222|Procedure|D&C|Cervical dilatation and fractional endometrial curettage will be done in operation theatre and the curetting will be sent for histopathological examination
1535199|NCT02705222|Procedure|Hysteroscopy|Hysteroscopy will be done in operation theatre and hysteroscopic-guided curettings will also be taken and sent for histopathological examination
1535200|NCT02705209|Other|Cayenne Pepper Cataplasm|Poultice of Kaolin, Cayenne Peppfer (5%) and Water
1535201|NCT02705209|Other|Placebo Cataplasm|Poultice of Kaolin and Water
1535202|NCT02705196|Biological|LOAd703|oncolytic virus
1535203|NCT02705196|Drug|Gemcitabine|chemotherapy
1535204|NCT02705196|Drug|nab-paclitaxel|chemotherapy
1535205|NCT02705183|Radiation|Radiotherapy|Multifractionated post-operative radiotherapy, several weeks after surgery
1535206|NCT02705170|Procedure|index of microvascular resistance|Measurement of the index of microvascular resistance in the left anterior descending artery
1535207|NCT02705157|Procedure|Stabilisation of (impending) pathological fracture|Stabilisation of pathological fracture or impending fracture with prosthesis, plate, intramedullary nail, cement, or other stabilisation method
1535208|NCT02705157|Radiation|Radiotherapy of bone metastasis|Radiotherapy of bone metastasis, single or multi-fractionated
1535209|NCT02705144|Other|analysis of the number of stem cell niches|to assess stem cell compartments in their niches and their proliferative and developmental properties in vitro
1535210|NCT02705131|Device|Balance Chiropractic Therapy|patients are in the sitting position and receive the following treatments.1)Balancing tendon-regulation;2) Balancing osteopathy;3) Balance collaterals-dredging.
1535211|NCT02705131|Device|Traction Therapy|patients will received the traction therapy.The patient is sitting and wearing a cloth bag occipital jaw traction comfortable,with head bending forward about 10-15 degrees in comfort.The weight for traction of cervical spondylosis is started at 3 kg, and gradually increased to the maximum weight not more than 6kg according to the standard of 0.5kg each time. The treatment is performed 30 minutes a time per day, 10 times as a course,a total of 2 courses.
1535212|NCT02705118|Device|Automatic Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with automatic registration registration. Except the imaging registration, all other procedures for RF ablation is same.
1535213|NCT02705118|Device|Manual Imaging fusion of ultrasonography and MRI|Radiofrequency ablation for hepatic malignancies will be performed with manual registration registration. Except the imaging registration, all other procedures for RF ablation is same.
1535215|NCT02705092|Other|Subliminal priming with subliminal reward stimuli|Positive words as subliminal reward (displayed for 17 ms).
1535216|NCT02705092|Other|Subliminal priming with supraliminal reward stimuli|Positive words as supraliminal reward (displayed for 150 ms).
1535217|NCT02705079|Other|EEG Monitoring|Value of EEG monitoring as adjunct to standard monitoring
1535218|NCT02705066|Dietary Supplement|Citicoline supplement|
1535219|NCT02705066|Dietary Supplement|Placebo supplement|Cellulose
1535222|NCT02705040|Other|Normal|bone mineral density T>=-1.0
1535223|NCT02705040|Other|Osteopenia|bone mineral density -1.0>T>=-2.5
1535224|NCT02705040|Other|Osteoporosis|bone mineral density T<-2.5
1535225|NCT02705027|Device|Freka®-Trilumina versus Freka®-EasyIn|Direct placement of probe via endoscope
1535226|NCT02705014|Drug|Gonadotropin-releasing Hormone|A regimen of pulsatile GnRH (Fengyuan pharmaceutical company, Anhui province, China) administered subcutaneous via a portable infusion pump (Weichuang Medical Science Company, Shanghai city, China) at a 90-minute interval. The GnRH dosage was initially 10ug per pulse and was progressively adjusted to maintain serum testosterone levels at 6.94-17.35 nmol/L ( 200-500 ng/dL).
1535227|NCT02705001|Other|all admissions except accident and emergency|No additional intervention, retrospective study
1535228|NCT02704988|Procedure|Carnoy Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with Carnoy solution
1536257|NCT02697708|Dietary Supplement|French Fries Diet|See arm/group description.
1535229|NCT02704988|Procedure|GEWF Solution|The subjects in this group will undergo intervention by having surgery (colorectal cancer resection) and lymph node clearing technique with GEWF solution
1535230|NCT02704975|Device|Rehabilitation and Dry Needling|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months. Subjects in this group will also receive dry needling as an adjunct intervention. Dry needling treatment will be performed one time a week for four weeks and will begin four weeks post-operative.
1535231|NCT02704975|Device|Rehabilitation|Subjects will receive post-operative rehabilitation that is the standard of care for the surgical procedure they underwent. Rehabilitation will begin within one week after surgery and will continue for the duration of their recovery; two to three treatments a week for approximately 6-9 months.
1535232|NCT02704962|Drug|full-dose olanzapine|trifluoperazine 5mg/d
1535233|NCT02704949|Radiation|1/4 fluoroscopy dose|Use of 1/4 fluoroscopy dose while ureteroscopy is being performed
1535234|NCT02704949|Radiation|Full-dose|Use of full fluoroscopy dose while ureteroscopy is being performed
1535235|NCT02704923|Drug|Atropine|Atropine eye drops (1%) administered by sublingual way (2 drops) every 6 hours
1535236|NCT02704923|Drug|Placebo|Placebo eye drops characterized by saline administered by sublingual way (2 drops) every 6 hours
1535237|NCT02704910|Behavioral|Subthalamic stimulation|Assess difference of amplitude (in degree) of the postural deviation between both condition of unilateral condition of subthalamic nucleus
1535238|NCT02704897|Other|Wound Assessment Tool|A set of questions relating to the symptoms of wound infection
1535239|NCT02704884|Dietary Supplement|probiotic soy milk|
1535240|NCT02704871|Other|SeptiCyte Lab molecular diagnostic test (non-interventional)|This is not an interventional study. Rather it involves evaluation of a molecular diagnostic test to distinguish between sepsis and infection-negative SIRS based on host response.
1535241|NCT02704858|Drug|Perillyl alcohol|Intranasal administration
1535242|NCT02704832|Other|Geriatrician Intervention|Arm B : The duration of the geriatric intervention will be 12 months. The quality of life will be assessed every 3 months during the first year and at 18 months. The study's follow-up will last until 3 years after the enrollment of the last patient and data on vital status of the patient, weight, place of life and the status of the disease will be collected every 6 months.
1535243|NCT02704819|Other|Decision Support System (DSS)|"The EMBalance DSS is a program which summarises and structures clinical information. The structuring of medical information is based on algorithms that have been developed and are employed via the DSS platform. The non-specialist doctors who use the DSS will be asked to exercise their clinical judgement in order to come up with a diagnosis or management plan. The DSS use has the following characteristics:
Doctors can pace the process anyway they see fit (e.g. by switching from history taking to examination, stopping at any point, or going back to medical history) or by stopping the process entirely.
Although the EMBalance platform will propose 2-3 diagnosis (with probability estimation for each), doctors will be asked to either choose one of these or discard and choose their own."
1535244|NCT02704819|Other|Specialist Audiovestibular Consultation|"After the initial appointment with the non-specialist doctor, all patients will be invited to attend a specialist neuro-otology clinic where they will be seen by an overseeing expert in order to undergo a Gold Standard diagnostic process, and determine the management plan appropriate to the diagnosis, which will be compared to the management plan previously advised by the non-specialist doctor. The overseeing expert will review investigations carried out, results assessed by the non-specialist doctor."
1535245|NCT02704819|Other|DSS Customised Vestibular Physiotherapy|"Customised vestibular exercise programme suggested by the DSS. Such exercises are based on the eye, head, and postural exercises that provoke a patient's symptoms.
Adaptation exercises incorporating gaze fixation and head movements and postural exercises are prescribed to promote recovery of the vestibule-ocular reflex (VOR) and vestibulo-spinal reflex function. Up to 5 exercises will be practised by the patient at home for approximately 1-2 minutes each, twice daily initially at a slow speed which gradually increases as symptoms improve.
Patients presenting vestibular migraine will perform a maximum of three exercises. These exercises will be chosen by the DSS from a range of established exercises and chosen according to the patient's symptoms when performing the exercise/type of movement."
1535246|NCT02704819|Other|Standard Physiotherapy Practice|Patient will be referred to a local physiotherapy service by his/her non-specialist doctor within 18 weeks from referral. Standard vestibular rehabilitation practice consists of a customised exercise programme, this is service dependent and tailored for patient's symptoms. The rehabilitation programme might include lifestyle advice and education, sometimes accompanied by a leaflet.
1535247|NCT02704819|Other|Follow-up|All patients will be reviewed after three months follow-up by the overseeing expert.
1535248|NCT02704793|Other|Bilateral 1 Hz Cerebellar rTMS|900 pulses of 1 Hz rTMS on 90% of resting motor threshold (RMT) delivered over each cerebellar hemisphere every day for 5 consecutive days.
1535249|NCT02704793|Other|Sham (electrical stimulation)|900 pulses of 1 Hz electrical stimulation (less than 3 mili amperes) delivered over each cerebellar hemisphere every day for 5 consecutive days.
1535250|NCT02704780|Drug|Misoprostol|2 regimes of misoprostol 400 microgram and 800 microgram injections used for 2 groups of women
1535251|NCT02704767|Drug|Apatinib|a tyrosine kinase inhibitor of VEGF invented by Hengrui pharma in China
1535252|NCT02704767|Drug|Tarceva|
1535253|NCT02704767|Drug|Placebo|
1535254|NCT02704754|Drug|suvorexant|First in class orexin antagonist recently approved by the FDA for the treatment of insomnia
1535255|NCT02704754|Other|placebo|Pill with inactive ingredients
1535256|NCT02704741|Device|CO2RE|The CO2RE system device is intended for dermatological procedures requiring ablation, coagulation and resurfacing of soft tissue, including skin
1535257|NCT02704728|Other|Thetanix|Thetanix is an encapsulated lyophilised formulation of a pure culture of Bacteroides thetaiotaomicron with excipients.
1535258|NCT02704728|Other|Placebo|Placebo is encapsulated microcrystalline cellulose without Bacteroides thetaiotaomicron.
1535263|NCT02704689|Device|AccuLIF expandable TLIF cage|AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
1535264|NCT02704676|Other|marker(CA-125)|measuring CA-125 in pregnant women (normal,mild and sever pre-eclampsia)
1535265|NCT02704663|Procedure|Transumbilical removal of specimen via laparoscopy|Transumbilical removal of a benign adnexal mass from the abdominal cavity in laparoscopy
1535266|NCT02704663|Procedure|Lateral transabdominal removal of specimen via laparoscopy|Lateral transabdominal removal of a benign adnexal mass from the abdominal cavity in laparoscopy
1535267|NCT02704650|Procedure|fluid sample|taking a vaginal fluid sample
1535268|NCT02704637|Device|HS-1000|HeadSense (HS)-1000 device, a proprietary non-invasive brain monitor, is expected to safely and accurately monitor physiological signs of the brain with minimal discomfort to patients, providing information about normal or abnormal brain-related conditions and providing decision-making support for physicians
1535269|NCT02704624|Dietary Supplement|Vitamin D|investigate the relationship between musculoskeletal manifestations, in Crohn population, and the hypovitaminosis D
1535270|NCT02704624|Other|Placebo|compare the musculoskeletal manifestations of the Placebo group with the group receiving Vitamin D
1535271|NCT02704611|Device|Real tDCS|Real tDCS (2mA for 25 minutes on 5 consecutive days/week for 2 weeks with the anode centered over M1 bilaterally. Anodal tDCS for 20 minutes at 1.5mA (15 s ramp in and 15 s ramp out) will be applied daily for 10 consecutive days (5 sessions/week). The anodal electrode 24 cm² with current density of 0.08 mA (2mA/24 cm²) will be placed over the left primary motor area in group I, and the reference electrode (24 cm² will be fixed over the contralateral arm (extracephalic).
1535272|NCT02704611|Device|Sham tDCS|Sham tDCS will be applied using the above described parameters in group. For sham tDCS, the placement of the electrodes, current intensity, and ramp time was identical to real tDCS stimulation group; however, the stimulation lasted only for 30 Sec. However, since none of the patients have been experienced tDCS previously, they were unaware of which stimulation is real and which sham is. The investigator responsible for delivering tDCS had no contact with the patients.
1535273|NCT02704598|Drug|Rivaroxaban|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
1535274|NCT02704598|Drug|Warfarin|Evaluate the efficacy of the oral anticoagulants in the treatment of deep venous tromboses, assessing clinical signs and symptoms, as so the recanalization rate using DUPLEX SCAN.
1535275|NCT02704585|Device|Nellcor|Measurement of pulse oximetry in the delivery room with Nellcor pulse oximeter
1535276|NCT02704585|Device|Masimo|Measurement of pulse oximetry in the delivery room with Masimo pulse oximeter
1535278|NCT02704559|Drug|DWC20155|
1535279|NCT02704559|Drug|DWC20156|
1535280|NCT02704546|Drug|Methylphenidate|oral capsules (per os) each containing 10mg Methylphenidate.
1535281|NCT02704546|Drug|Placebo|capsules identical in shape, colour and size to the Ritalin® capsules, which contain only the inactive ingredients of the same formulation.
1535282|NCT02704533|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation-attenuated, Plasmodium falciparum sporozoites, strain NF54
1535283|NCT02704533|Biological|PfSPZ Challenge (NF54)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54
1535284|NCT02704533|Biological|PfSPZ Challenge (7G8)|Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8
1535285|NCT02704533|Other|Normal saline|0.9% sodium chloride
1535286|NCT02704520|Drug|Capecitabine|Coated tablet. Systemic chemotherapy
1535287|NCT02704520|Drug|Oxaliplatin|Concentrate for Solution for Infusion. Systemic chemotherapy
1535288|NCT02704520|Drug|5-fluorouracil|Infusion. Systemic chemotherapy
1535289|NCT02704520|Drug|Folinic Acid|Solution for infusion.
1535290|NCT02704507|Drug|Triamcinolone|topical application nightly to half the face for 4 weeks
1535291|NCT02704507|Drug|Tretinoin|topical application nightly for 8 weeks
1535292|NCT02704507|Drug|Emollient|topical application nightly to half the face for 4 weeks
1535293|NCT02704494|Drug|Resveratrol|Resveratrol 500mg daily
1535294|NCT02704494|Drug|Placebo|Placebo 1 capsule daily
1535295|NCT02704494|Drug|Losartan|Losartan 12.5mg daily
1535296|NCT02704481|Drug|Mifepristone|200mg oral mifepristone
1535297|NCT02704481|Drug|Misoprostol|800mcg buccal misoprostol
1535298|NCT02704481|Drug|Placebo mifepristone|Matching placebo pill of 200mg mifepristone
1535299|NCT02704481|Drug|Placebo misoprostol|Matching placebo pills of 800mcg misoprostol
1535300|NCT02704468|Other|CAVI and FGF-21|FGf-21 and CAVI was measured in renal transplant patients group and study correlation with arterial stiffness
1535301|NCT02704429|Drug|PRN1008|PRN1008, oral dose, 12 weeks
1535302|NCT02704416|Procedure|Catheter Ablation|catheter ablation of fragmented signal in the right ventricular outflow tract
1535305|NCT02704390|Drug|ORADUR®-Methylphenidate|ORADUR®-Methylphenidate is available in three dosage forms, 22 mg, 33 mg or 44 mg. Subjects will continue to receive ORADUR®-Methylphenidate at the previously determined optimal dose for 24 months.
1535306|NCT02704377|Other|Undergo HRV and wear accelerometer to assess therapy complications|Wear accelerometer undergo heart rate variability(HRV) testing over 10-15 minutes while both lying down and standing, complete a walking test, wear an accelerometer for a period of 1 week
1535307|NCT02704377|Procedure|Dual X-ray Absorptiometry|Undergo iDXA
1535308|NCT02704377|Other|Laboratory Biomarker Analysis|Correlative studies
1535309|NCT02704377|Other|Quality-of-Life Assessment|Ancillary studies
1535310|NCT02704377|Other|Questionnaire Administration|Ancillary studies
1535311|NCT02704364|Biological|NGM282|
1535312|NCT02704364|Other|Placebo|
1535313|NCT02704351|Procedure|Surgery|Sugammadex to reverse neuromuscular blockade
1535314|NCT02704338|Biological|Regulatory T cells|Regulatory t cells will be injected back to autoimmune hepatitis patients
1535315|NCT02704325|Biological|rAAVrh74.MCK.GALGT2|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the other side receiving saline alone.
1535316|NCT02704325|Other|PLACEBO (Saline)|Direct intramuscular injection of rAAVrh74.MCK.GALGT2 transferred to the extensor digitorum brevis muscle (EDB) of one foot and the OTHER side receiving saline alone.
1535317|NCT02704312|Radiation|Radiotherapy by Prone and decubitus|Dosimetric comparison of doses in target volumes and organs at risk
1535318|NCT02704299|Biological|Autologous T cells-Based Immunotherapy|TCM cells are the subpopulation of T lymphocytes with key characteristics including high potency and long-term memory of specific immunity.
1535319|NCT02704286|Behavioral|Internet-Based Osteoarthritis Risk Calculator|The investigators have developed a personalized risk calculator for knee osteoarthritis. This risk calculator uses the Osteoarthritis Policy Model to estimate an individual's risk of developing knee osteoarthritis within their lifetime based on demographic information and risk factors. It shows this information to the user with interactive graphs and compares their risk to the risk of an average American of the same age.
1535320|NCT02704286|Behavioral|Generic osteoarthritis information|Subjects viewed generic (i.e. not personalized) information about osteoarthritis risk factors
1535322|NCT02704247|Device|CARDIOSPACE System|"autonomic nervous system test
tilt test
ultrasound exploration at rest (heart / vessels)
laser doppler + iontophoresis test
sub-maximal exercise test"
1535323|NCT02704234|Other|Active Acupuncture|Active Acupuncture two times per week for 5 weeks
1535324|NCT02704234|Other|Placebo Acupuncture|Placebo Acupuncture two times per week for 5 weeks
1535325|NCT02704221|Device|Fitbit activity tracker|Wear a Fitbit daily for 12 weeks and meet with a research assistant once per week to download data
1535326|NCT02704221|Behavioral|Monetary rewards|Set weekly step-count goals based on the previous week's performance and receive monetary rewards for meeting the goals. The schedule of rewards increases as step-count goals increase.
1535327|NCT02704221|Behavioral|BPT training sessions|Complete 12 BPT training sessions delivered by supervised clinical child psychology doctoral students, with each session lasting approximately 60 minutes. The BPT is based upon the existing, evidence-based Everyday Parenting intervention.
1535328|NCT02704208|Behavioral|Thrive With Me Control|Those assigned to the TWM control group will receive a weekly email with static HIV informational content. Information will be focused more on quality of life and general wellbeing issues and will not be specific to medication adherence.
1535329|NCT02704208|Behavioral|Thrive With Me Intervention|Those assigned to the TWM intervention will have 150 days to access tailored content on a mobile-enhanced website. They will also have social support through a network of other HIV-positive men. Finally they will track their daily ART medication adherence and mood through SMS and website use.
1535330|NCT02704195|Procedure|Unilateral reduction of stimulation|30% unilateral reduction of Subthalamic nucleus stimulation
1535331|NCT02704195|Procedure|Chronic Subthalamic nucleus stimulation|This arm is the reference, with the best stimulation parameters
1535332|NCT02704182|Device|tDCS|25 patients received real anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
1535333|NCT02704182|Device|Sham tDCS|25 patients received sham anodal tDCS on the motor area for 20 minutes every day for 4 consecutive days.
1535334|NCT02704169|Other|Spatially registered endoscopy|
1535335|NCT02704156|Device|Cyberknife|Radiation therapy
1535336|NCT02704143|Other|combination of Cyberknife with S-1|Radiation therapy combined with chemotherapy
1535337|NCT02704130|Device|Transarterial embolization|In transarterial bland embolization, beads are delivered directly into the arterial vessels feeding the tumor, usually by a percutaneous coaxial catheter system guided by ultrasound or fluoroscopy through the common femoral artery.
1535338|NCT02704130|Procedure|Microwave Ablation|Microwave ablation is a form of thermal ablation used to treat cancer. In this procedure, electromagnetic waves in the microwave energy spectrum (300 MHz to 300 GHz) are applied to tumor tissue. The oscillation of polar molecules produces frictional heating, ultimately generating tissue necrosis within solid tumors.
1535339|NCT02704117|Device|Transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device).
1535342|NCT02704091|Drug|Smecta|
1535343|NCT02704091|Drug|Smecta placebo|
1535344|NCT02704078|Device|EBUS-TBNA|EBUS-TBNA - Patients in the Active comparator arm shall undergo mediastinal lymph node aspiration transtracheally using the EBUS scope
1535345|NCT02704078|Device|EUS-B-FNA|EUS-B-FNA - Patients in the experimental arm EUS-B-FNA shall undergo mediastinal lymph node aspiration transesophageally using the EBUS scope
1535346|NCT02704052|Drug|Real time enoxaparin dose adjustment|Patients will have steady state peak and trough anti-Xa levels drawn after their third enoxaparin dose. Patients with out of range peak anti-Xa levels will receive real time enoxaparin dose adjustment followed by repeat peak and trough anti-Xa levels.
1535347|NCT02704052|Drug|Standard enoxaparin dose|Patients will be placed on enoxaparin prophylaxis per their surgeon's discretion.
1535348|NCT02704026|Other|Assesment of nutritional status and body composition|At the time of enrollment and after 1 year, anthropometric measurements and assessment of body composition by bioelectrical impedance will be performed for each child
1535349|NCT02704013|Drug|Oxybutynin|Anticholinergic
1535350|NCT02704000|Behavioral|Home visiting program (Jamaica curriculum)|Agents will deliver bi-weekly home-visits following the curriculum developed for the Jamaica intervention study by Susan Walker and colleagues. This curriculum foresees age-appropriate tasks assigned to the caregiver during each visit.
1535351|NCT02703987|Other|Fermented infant milk formula|
1535352|NCT02703987|Other|Non-fermented infant milk formula|
1536300|NCT02697344|Drug|Lenalidomide|Given PO
1535353|NCT02703974|Behavioral|Early handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:
A raised concrete platform (built to child height)
A plastic container with a lid and spigot
Soap
The early handwashing stations will be constructed in weeks 1 and 2 of the study, after the baseline observations (Phase I) are complete."
1535354|NCT02703974|Behavioral|Late handwashing station|"A handwashing station will be a dedicated location for handwashing in each selected school and will include:
A raised concrete platform (built to child height)
A plastic container with a lid and spigot
Soap
The late handwashing stations construction will begin after Phase 2 data collection has been finished at the end of week 3."
1535355|NCT02703974|Behavioral|Nudge|"A nudge will be built in each randomly selected school and will consist of:
Connecting latrines to the handwashing station via paved pathways that are painted bright colors
Painting footprints on infrastructure guiding students to the handwashing stations and handprints on stations
The nudges will be constructed at the end of week 3 and 4, after Phase II data collection is complete within each randomly assigned nudge school."
1535356|NCT02703974|Behavioral|Education|"Hand hygiene education-based program: the hygiene promotion element will include a one month program of handwashing education involving weekly facilitator led sessions. Each session will be about 30-45 minutes long, and will cover the following topics:
Importance of handwashing
Method of handwashing
Critical times of handwashing
Finding solutions for handwashing in school and at home The sessions will involve use of flipcharts, and other IEC materials (e.g. videos) and participative learning methods.
The Hand hygiene education-based program will begin at the beginning of weeks 4 and 5, after Phase II data collection is complete in each randomly assigned education school."
1535357|NCT02703961|Drug|concurrent chemotherapy with cisplatin|in experimental group: cisplatin 60mg/m2, d1,d22;
1535358|NCT02703961|Drug|concurrent chemotherapy with docetaxel|in experimental group: docetaxel 60mg/m2, d1,d22;
1535359|NCT02703961|Radiation|pelvic radiotherapy|external beam radiotherapy for whole pelvix with 50Gy/25f boost radiotherapy for pelvic lymph node metastasis with 12-14Gy/4-7f.
1535360|NCT02703961|Radiation|brachytherapy|CT/MRI guided brachytherapy or x-ray guided brachytherapy
1535361|NCT02703961|Drug|adjuvant chemotherapy with cisplatin and docetaxel|cisplatin 75mg/m2, d43,d64; docetaxel 75mg/m2, d43,d64
1535362|NCT02703948|Device|Restylane Silk with Lidocaine|
1535363|NCT02703935|Behavioral|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included an associate professor, an assistant professor and a research student at a local university, a pediatric oncologist and oncology nurse and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer survivors.
1535364|NCT02703935|Behavioral|Placebo Control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museums and theme parks and galleries
1535365|NCT02703922|Other|color Doppler ultrasound and TAB in case of CDU negative|Screening with color Doppler ultrasound followed by TAB in case of CDU negative
1535366|NCT02703909|Drug|Rocuronium|Rocuronium will be administered to achieve either a moderate (2-3 twitches) or deep (0-1 posttetanic) block depending on the group assignment
1535367|NCT02703909|Device|Insufflation pressure|The initial insufflation pressure will be set at either 10 or 15 mm Hg depending on the group assignment
1535368|NCT02703896|Drug|Drug either PPIS or H2RA and prokinetics|"Drug intervention ( dose unit mg) Two oral doses 8:00 p.m. and 6:00 a.m. (n=60) total 10 groups
Group C (placebo),Group L (lansoprazole15 ), Group LD (Lansoprazole 15 +domperidone 10 )
Group C ,R (rabeprazole 10), RM (rabeprazole 10 + metoclopramide 10)
Group C , E (esomeprazole 20 ), and EM (esomeprazole 20 + metoclopramide 10)
Group C, P (pantoprazole 20), and PD (pantoprazole 20 + domperidone 10 mg)
Group C, O (omeprazole 20), OD (omeprazole 20 + domepridone 10), OM (omeprazole 20 + metoclopramide 10)
Group C,T (cimetidine 200), TD (cimetidine 200 + domperidone 10)
Group C , Z (ranitidine 150), ZD (ranitidine 150 + domperidone 10)
Group C , N (nizatidine 150),NM (nizatidine 150 + metoclopramide 10)
Group C, F (famotidine 20 mg), and FM (famotidine 20 mg + metoclopramide 10)
Group C,S (lafutidine 10), SD (lafutidine 10 + domperidone 10), and Group SM (lafutidine 10 + metoclopramide 10)"
1535369|NCT02703896|Procedure|orogastric intubation|OGT insertion:Insertion of orogastric tube(through an endotracheal tube placed in the upper esophagus) into the stomach after general anaesthesia.
1535370|NCT02703883|Device|BWST|BWST (six weeks, 3 times/week)
1535371|NCT02703870|Device|verum tDCS|real transcranial direct current stimulation,10 sessions, 2mA for 20 minutes
1535372|NCT02703870|Device|sham tDCS|sham transcranial direct current stimulation, 10 sessions, for 20 minutes
1535373|NCT02703870|Behavioral|VRT|Vision restoration training, 10 sessions, 20 minutes
1535374|NCT02703857|Drug|cefoxitin|Parenteral administration of 2g of cefoxitin at least 30 minutes before incision and then every 2 hours until closing
1535375|NCT02703844|Device|Caloric Vestibular Stimulation|Stimulation of the vestibular nerves
1535376|NCT02703844|Device|Sham Caloric Vestibular Stimulation|Sham stimulation of the vestibular nerves
1535377|NCT02703831|Procedure|Dual attending|Two attending spine surgeons perform surgery
1535378|NCT02703831|Procedure|Single Attending|One spine attending and an assistant perform surgery. The assistant can be a spine fellow, a resident or a physician's assistant.
1535379|NCT02703818|Device|Senza|Spinal Cord Stimulation
1535380|NCT02703805|Other|Fit For Function Program|A 12-week YMCA-based wellness program for persons with stroke, consisting of 2 group exercise sessions, one gym exercise session and one education session per week with trained instructors
1535381|NCT02703805|Other|Standard YMCA membership|A 12 week standard YMCA membership.
1535386|NCT02703753|Behavioral|Lifestyle intervention|The investigational treatment consists of a lifestyle intervention targeting on a healthy diet, physical activity and, if applicable, smoking cessation.
1535387|NCT02703740|Device|Hyaluronic acid dermal filler with lidocaine 0.3%|
1535388|NCT02703727|Behavioral|Extended polymedication check|"Behavioral: Medication review
Patients on oral anticoagulants and polypharmacy will receive extended polymedication check to identify Pharmaceutical Care Issues, Adherence Issues, Drug related problems and Knowledge Gaps
The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> 3 months) and is reimbursed by swiss health insurance. The semi-structured interview contains questions about knowledge on oral anticoagulation therapy. This extended PMC follows a structured predefined protocol.
As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
1535389|NCT02703714|Drug|Pembrolizumab|
1535390|NCT02703714|Drug|Sargramostim|
1535391|NCT02703701|Behavioral|Physician at triage|A physician embedded at triage
1535392|NCT02703701|Other|Usual Care|No physician at triage
1535393|NCT02703688|Behavioral|Healthy Homes|The Healthy Homes Behavioral Intervention (HHBI) will be delivered during 8 sessions over 10 weeks using home visitations. The first 6 sessions occur weekly and provide education about healthy dietary intake including caloric recommendations for preschool aged children, healthy sleep goals, active play and screen time limits, and family routines and organization. Each session will include a parent-child interaction component to teach child behavior management skills related to intervention goals. Two final sessions occur every other week to provide problem solving and planning for maintenance of treatment effects.
1535394|NCT02703688|Other|Usual Care|A pediatrician with experience delivering weight management treatment to children will deliver a single session, 1-hour treatment to families. Content to be delivered during the session will include lifestyle recommendations currently recommended by the AAP.
1535395|NCT02703675|Device|Excel Cryo Cooling Collar|Therapeutic hypothermia in the study will be initiated by The Excel Cryo Cooling system consisting of a unique cervical immobilization collar and a cooling element. Once activated, the cooling element achieves a temperature of -3.0 °C to -5.0 °C within seconds. The collar is fitted around the subject's neck and the cooling element is applied the the front of the neck over the carotid arteries and secured in place by the collar. The Excel System provides consistent cooling regardless of patient size or weight, by cooling of the blood traveling through the carotid triangles.
1535398|NCT02703649|Drug|Letrozole|After the decision to use Letrozole for induction of ovulation, we will obtain informed consent and randomize the patents into 2 groups Single 20 mg dose of Letrozole on day 3 of the cycle Daily dose of Letrozole 2.5 mg starting day 3 for 5 days.
1535399|NCT02703636|Drug|Rivastigmine Patch|Alzheimer's disease patient who is applicable to 1 step titration method (initial loading dose is a rivastigmine patch 9.0 mg/day and will be up-titrated after 4 weeks to reach the maintenance dose of 18 mg/day). Rivastigmine patch is a marketed drug, therefore the dose, dose regimen and titration scheme are in accordance with product label.
1535406|NCT02703610|Drug|Oxycodone/acetaminophen|
1535407|NCT02703610|Drug|Hydrocodone/acetaminophen|
1535408|NCT02703610|Drug|Codeine/acetaminophen|
1535409|NCT02703610|Drug|Ibuprofen/acetaminophen|
1535410|NCT02703597|Behavioral|Surveys|Baseline survey includes questions related to smoking behavior and attitude toward smoking, as well as demographic questions. Psychosocial surveys and social network surveys also completed.
1535411|NCT02703597|Behavioral|Focus Group|Participants engage in audio recorded group discussions that work to improve upon the online health programs.
1535412|NCT02703597|Behavioral|ASPIRE|Participants engage in four 40-minute sessions of A Smoking Prevention Interactive Experience (ASPIRE) spread over a period of 4 weeks. During ASPIRE use, participants face a laptop computer and individually watch videos and engage in computer-based activities related to the negative effects of smoking.
1535413|NCT02703597|Behavioral|GSA-ASPIRE|Participants engage in four 45-minute sessions of ASPIRE conducted over a period of four weeks. During each session, after every 9 minutes of ASPIRE use, participants engage in a 3-minute game-based social activities (GSA), for a total of 5 GSAs. During ASPIRE use, participants watch videos and engage in computer-based activities on the same computer screen. Also, participants engage in the paper-based GSAs as a team and collaborate as they complete the activities. The GSA activities contain games about the effects of smoking.
1535414|NCT02703584|Drug|Buseralin|
1535415|NCT02703584|Other|Placebo|
1535416|NCT02703584|Drug|pregnyl|
1535419|NCT02703558|Drug|Phenazopyridine|
1535420|NCT02703558|Drug|Fluorescein|
1535460|NCT02703259|Drug|Gabapentin|
1535461|NCT02703259|Drug|Acetaminophen|
1535462|NCT02703259|Drug|Celecoxib|
1535421|NCT02703532|Behavioral|CARE-CITE Education Program|"CARE-CITE is an online educational program developed to provide information that may help caregivers understand more about constraint-induced movement therapy (CIMT) and their potential roles in helping the stoke survivor gain as much benefit as possible from CIMT.
If participants do not have access to a computer or tablet, they will be loaned an electronic tablet for the 2-3 week period of the study to access the information.
Participants will be asked to review six educational modules over a period of 2-3 weeks while the stroke survivor receives CIMT.
Participants will attend three in home evaluation visits; one at the beginning of the stroke survivors therapy sessions, one at the end of his/her therapy visit series, and a third evaluation one month later in which they will be asked to complete questionnaires. Evaluation visits will take approximately 1 ½ hours to complete."
1535422|NCT02703532|Behavioral|Traditional Education|Investigators will explain constraint-induced movement therapy (CIMT) to caregivers and stroke survivors during the first home therapy session for the stroke survivor and provide traditional educational information about CIMT during therapy sessions as needed.
1535423|NCT02703532|Behavioral|Constraint-Induced Movement Therapy (CIMT)|"Constraint-Induced Movement Therapy (CIMT) is one type of therapy that helps stroke survivors gain more use of their weaker arm.This therapy involves wearing a soft mitt (like a sock or oven mitt) on the stronger arm to remind the stroke survivor to use their weaker arm for daily activities and also intensive practice of tasks with the supervision of a therapist.
Participants will attend three in home evaluation visits; one at the beginning of your therapy sessions, one at the end of your therapy visit series and a third evaluation one month later. These evaluation sessions will involve an evaluation of arm function and answering three questionnaires about how well the weaker arm works and how the stroke has affected daily activities. The interview questions and assessment will take approximately 1 ½ hours to complete."
1535424|NCT02703519|Procedure|resection of uterine scar tissue|resection of uterine scar tissue of a previous cesarean section during a second cesarean section
1535425|NCT02703506|Other|Session of Pain Education programe|Five group sessions of patient education pain of 60-120 minutes one for week with a maximum of 10 participants.
1535426|NCT02703506|Other|Control Group|Five individual sessions twice a week, will be performed of transcutaneous electrical nerve stimulation (TENS) on neck area an exercises
1535427|NCT02703493|Radiation|Stereotactic Radiosurgery|Patients will receive 6 weeks of IMRT (standard of care) followed by the stereotactic radiosurgery (SRS Boost). Dose of the boost is reliant on which cohort the patient is assigned to. Cohort 1 will receive 8 Gy, Cohort 2 will receive 10 Gy in a single fraction, Cohort 3 will receive 10 Gy split into two fractions.
1535428|NCT02703480|Biological|d-PTFE|high-density polytetrafluoroethylene (d-PTFE) membrane
1535429|NCT02703480|Biological|Ti-mesh|Titanium mesh
1535430|NCT02703454|Procedure|FIRM-guided RF ablation|
1535431|NCT02703454|Procedure|Conventional RF ablation|
1535432|NCT02703441|Other|Tablet computer|Patients randomized to the intervention group will receive a tablet computer with an app-like software solution supporting nutrition and physical activity. The patients operate the computer and order their meals from the hospital menu; register dietary intake, and receive feedback informing about their current status for protein and energy intake. Likewise, the patients use small series of brief videos instructing in daily life activities for strengthening their muscles. After this, they register their performed activities and will receive informing and motivating feedback. Nudging and prompting is part of the solution.
1535435|NCT02703402|Other|Exercise protocol|Control group will complete all the protocol of exercises with orientation and attendance directly from a professional of physical education, in the Service of Physiatry and Rehabilitation in HCPA.
1535436|NCT02703402|Other|Manual of exercises|Treatment group will complete one session of the protocol of exercises with orientation and attendance directly from a professional of Physical Education, in the service of Physiatry and Rehabilitation of HCPA, to clarify any doubts about the protocol. The further sessions will be completed at home, along weekly monitoring of the researchers through phone calls, the patients of this group will receive a manual with the sequence of the exercises
1535437|NCT02703389|Behavioral|Video|Animated video explaining acute otitis media and antimicrobial stewardship.
1535438|NCT02703389|Behavioral|Pamphlet|Contains same information as video.
1535439|NCT02703376|Drug|Oral Prednisone|Intakes of Oral Prednisone for 12 weeks after balloon dilations
1535440|NCT02703363|Drug|Minocycline|
1535441|NCT02703363|Drug|Celecoxib|
1535442|NCT02703363|Drug|Placebo|
1535443|NCT02703350|Drug|LY900014|Administered subcutaneously (SC)
1535444|NCT02703350|Drug|Insulin Lispro|Administered SC
1535445|NCT02703337|Drug|LY900014|Administered subcutaneously (SC)
1535446|NCT02703337|Drug|Insulin Lispro|Administered SC
1535447|NCT02703324|Drug|LY900014|Administered subcutaneously (SC)
1535448|NCT02703324|Drug|Insulin Lispro|Administered SC
1535449|NCT02703311|Device|Cardioband|Mitral valve repair with Cardioband implanted via transcatheter procedure under transesophageal echocardiography (TEE) and fluoroscopy guidance
1535450|NCT02703298|Drug|TRX-818 capsules|
1535451|NCT02703285|Other|Sound|task of the participants in the study to determine the chest sound based on specific sounds: Vesicular - Diminished; Expiratory Wheeze; Bronchovesicular; pneumonia; pulmonary Oedema; Stridor; Agonal respiration
1535732|NCT02701491|Dietary Supplement|Ginger|ginger
1535733|NCT02701491|Other|Placebo|Placebo
1535463|NCT02703246|Procedure|abdominal morcellation|patients will be randomized to receive abdominal morcellation
1535464|NCT02703246|Procedure|vaginal morcellation|patients will be randomized to receive vaginal morcellation
1535465|NCT02703233|Drug|Nitrous Oxide|
1535466|NCT02703233|Other|Oxygen|
1535467|NCT02703220|Other|Hyperoxia/oxygen|The ventilatory effects of brief hyperoxia will be assessed by analyzing control breaths on room air immediately preceding the hyperoxic exposure, and comparing with the primary end-point, nadir minute ventilation breath, immediately following the brief hyperoxic exposure
1535468|NCT02703220|Drug|Acetazolamide|Participants with sleep apnea will ingest capsules containing either placebo or acetazolamide 500 mg twice a day for 5 days. On the final 2 consecutive nights while still on ACZ, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG.
1535469|NCT02703220|Drug|Finasteride|Elderly males with sleep apnea and adequate testosterone levels will ingest placebo vs finasteride, at 5 mg a day for 1 month (mo). After 1 mo, while still on the drug, on the final 2 consecutive nights, the investigators will perform i) physiology tests and ii) in-lab follow-up PSG. Blood tests will be performed to check sex hormone levels. A washout period of 1 month prior to cross-over to the alternate arm (placebo).
1535470|NCT02703207|Device|Positive airway pressure|CPAP will be applied as standard of care for diagnosis of moderate to severe OSA
1535471|NCT02703207|Device|NIPPV and /or oxygen|supplemental oxygen will be applied to PAP/non-invasive positive pressure therapy
1535472|NCT02703194|Drug|Prednisone|Prednisone:A starting dose of 0. 5-0. 8mg/(kg*d) will be given. Following four-week period, the dose will be tapered gradually to 5mg/d until the end of 12 months of follow-up period.
1535473|NCT02703194|Drug|Leflunomide|Leflunomide:A starting dose of 20 mg/day will be given. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor adverse effects occur(e.g., liver enzyme elevations).
1535474|NCT02703181|Drug|Epelsiban (GSK557296)|White to off-white 0.270 inches x 0.700 inches oblong film coated tablet containing 25 mg or 100 mg epelsiban. To be swallowed whole with water, not to be chewed.
1535475|NCT02703181|Drug|Placebo to match GSK557296|White to off-white 0.270 inches x 0.700 inches oblong film coated Tablet containing placebo. To be swallowed whole with water, not to be chewed.
1535476|NCT02703155|Device|Home Oral Glucose Tolerance Test kit|Providing Home Oral glucose tolerance test kit to children with Cystic fibrosis for screening Cystic Fibrosis Related Diabetes
1535477|NCT02703142|Procedure|Patients after esophagectomy|postoperative endoscopic evaluation
1535478|NCT02703129|Other|Nutritional intervention|Women with the diagnosis of migraine received individualized diet meal plan and nutritional orientations for three months according to their nutritional diagnosis
1535479|NCT02703116|Behavioral|Alcohol Use BI|Those who are randomized to the intervention will complete eSBI, an electronic brief intervention for substance use, which is comprised of 11 topical areas, each with a single webpage, in a motivational interviewing (MI) format. MI is a client-centered behavioral change approach.
1535480|NCT02703116|Behavioral|Nutrition Intervention|Those randomized to the control will complete the attention control modules, a non-active brief time-matched attention control intervention of equal length (i.e., encouraging nutrition).
1535481|NCT02703103|Other|Manual chest compressions|2 min of Chest compressions without mechanical chest compression system
1535482|NCT02703103|Device|ARM chest compressions|2 min of Chest compressions with mechanical chest compression system LifeLine ARM
1535483|NCT02703090|Drug|Remifentanil|
1535484|NCT02703090|Drug|Normal saline|
1535489|NCT02703064|Dietary Supplement|Furocyst|Furocyst caps BD
1535490|NCT02703051|Drug|GMI-1271|
1535491|NCT02703051|Drug|Filgrastim|
1535492|NCT02703051|Drug|Placebo Injection|
1535493|NCT02703051|Drug|Placebo Infusion|
1535494|NCT02703025|Dietary Supplement|GCB-70|green coffee bean extract
1535496|NCT02702999|Device|Clinically-indicated ultrasound|Routine third trimester care with clinically-indicated ultrasound (control)
1535497|NCT02702999|Device|Serial third trimester ultrasound|Ultrasound evaluation for fetal growth and amniotic fluid will be performed every 4 weeks starting at 30 weeks (intervention group). Thus, if they continue to term, there will be 3 additional ultrasounds exams (30, 34 and 38 weeks).
1535498|NCT02702986|Procedure|immunostimulating Interstitial Laser Thermotherapy|Through a laparotomy a laser device will be inserted into the locally advanced pancreatic cancer.
1535499|NCT02702986|Device|Laser|
1535500|NCT02702973|Other|Observe the fundus characteristics after therapy.|
1535501|NCT02702960|Procedure|living related donor partial liver transplantation|HLA matched or haploidentical related living donor partial liver transplant followed by tacrolimus, prednisone, and MMF immunosuppression for >3 wks
1535502|NCT02702960|Radiation|Total body irradiation|200 cGy total body irradiation (TBI) on Day -1.
1535503|NCT02702960|Procedure|Bone marrow transplant from same donor|BMT using cells from the same Human Leukocyte Antigen (HLA)-matched or -haploidentical living related donor will be performed on Day 0
1535504|NCT02702960|Drug|Cyclophosphamide|Pre-transplantation low dose cyclophosphamide given day -6 and -5 Post-transplantation high dose cyclophosphamide (PTCy; 50 mg/kg/day) will be administered on Days 3 and 4 with hydration
1535505|NCT02702960|Drug|Mesna|administered on Days 3 and 4 with PTCy
1535506|NCT02702960|Drug|Filgrastim|administered daily starting on Day 5 until absolute neutrophil count (ANC) recovery
1536301|NCT02697344|Other|Pharmacological Study|Correlative studies
1535507|NCT02702960|Drug|Tacrolimus|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
1535508|NCT02702960|Drug|mycophenolate mofetil|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
1535509|NCT02702960|Drug|Prednisone|Given after liver transplant for through day -7, stopped on day -6 and restarted on day 5 post BMT
1535510|NCT02702960|Drug|Antithymocyte globulin|Given from Day -16 to Day -14 prior to bone marrow transplantation on day 0
1535511|NCT02702960|Drug|fludarabine|fludarabine given from Days -6 to Day -2 before BMT
1535512|NCT02702947|Dietary Supplement|Prunus domestica extract|Prosman 1 capsule twice a day
1535513|NCT02702934|Other|Test meal|Participants received in random order a test meal (900Kcal, 100g carbohydrates) containing rusks prepared with amylose-rich wheat flour or conventional flour. Blood samples were collected at fasting and every 30 minutes over 4 hours. Breath hydrogen was evaluated as a marker of intestinal fermentation. Participants underwent Visual Analogue Scale to assess subjective appetite sensations.
1535514|NCT02702921|Device|Surgeon's 'standard of care' stapler|
1535515|NCT02702921|Device|Ethicon Powered Vascular Stapler|
1535516|NCT02702908|Other|Unspecified|Historical Reference group.
1535517|NCT02702895|Behavioral|In-depth Interview (IDIs) or Focus Group Discussion (FGD)|
1535518|NCT02702882|Dietary Supplement|Fenugreek Seeds Extract|Furosap one caps OD
1535530|NCT02702856|Other|ExoIntelliScore Prostate|
1535531|NCT02702843|Procedure|Laparoscopic cholecystectomy with Xenon light|Standard laparoscopic cholecystectomy with white light
1535532|NCT02702843|Procedure|Laparoscopic cholecystectomy (fluorescent cholangiography)|Laparoscopic cholecystectomy in infrared light after injection of indocyanine green pre-operatively.
1535533|NCT02702830|Other|Cardiopulmonary Exercise Testing|Undergo CPET
1535534|NCT02702830|Procedure|Magnetic Resonance Imaging|Undergo MRI
1535535|NCT02702817|Drug|Naproxen|pale blue oval tablets
1535536|NCT02702817|Drug|Placebo|pale blue oval tablets with no active ingredients, identical in appearance to naproxen intervention
1535537|NCT02702804|Other|High Intensity Interval Training|High Intensity Interval Training
1535538|NCT02702791|Behavioral|Telecoaching|Pedeometer based goals and telecoaching support
1535539|NCT02702791|Other|pulmonary rehabilitation|Conventional pulmonary rehabilitation along the ATS-ERS guidelines, total duration 6 months.
1535540|NCT02702778|Drug|Delayed-Release (DR) Prednisone|delayed release prednisone
1535541|NCT02702778|Drug|Immediate Release (IR) Prednisone|standard prednisone
1535542|NCT02702765|Procedure|Fibroscan|Liver fibrosis will be determined using fibroscan, and reported as changes in the amount of fibrosis in the liver. The fibroscan is a non-invasive procedure
1535543|NCT02702765|Procedure|Ultrasound|Ultrasound is a non-invasive procedure
1535544|NCT02702765|Drug|Galactose|"Galactose elimination capacity is performed to evaluate metabolic liver function.
The metabolic liver function test galactose elimination capacity requires a 6-hour fast, the infusion of galactose, blood sampling from the ear lobe, and collection of urine for 4 hours."
1535545|NCT02702765|Procedure|Liver biopsy|Histological disease activity at time of diagnosis evaluating if any liver fibrosis
1535546|NCT02702765|Procedure|Functional hepatic nitrogen clearance|Functional hepatic nitrogen clearance to evaluate metabolic liver function Functional hepatic nitrogen clearance requires a 12-hour fast, two venflons, the infusion of alanine, and urine sampling for 4 hours
1535547|NCT02702752|Other|DYNASDY|Measurement of SDF-1 alpha levels i patients' blood samples.
1535548|NCT02702739|Drug|Sofosbuvir 400mg/day/Simeprevir 150mg/day /Ribavirin 800mg/day for 12 weeks|Sofosbuvir 400 mg/day/Simeprevir 150 mg/day /Ribavirin 800/day for 12 weeks
1535549|NCT02702726|Other|Congee and juice with coconut gel|25g coconut oleogel
1535550|NCT02702726|Other|Congee and juice with coconut oil|25g coconut oil
1535551|NCT02702726|Other|Congee and juice with sunflower gel|25g sunflower oleogel
1535552|NCT02702726|Other|Congee and juice with sunflower oil|25g sunflower oil
1535553|NCT02702713|Dietary Supplement|Dairy BEF|Dairy BEF: Milkshake powder enriched with 250 mg of DHA and 3g beta-glucans
1535554|NCT02702713|Dietary Supplement|Egg BEF|Egg BEF: Frozen pancakes enriched with 250 mg of DHA and 320 mg of anthocyanins
1535555|NCT02702713|Dietary Supplement|Bakery BEF|Bakery BEF: Biscuits enriched with 250 mg of DHA and 320 mg of anthocyanins
1535556|NCT02702713|Dietary Supplement|Bakery placebo|Bakery placebo: Biscuits without enrichment
1535557|NCT02702713|Dietary Supplement|Dairy placebo|Dairy placebo: Milkshake powder without enrichment
1535558|NCT02702713|Dietary Supplement|Egg placebo|Egg placebo: Frozen pancakes without enrichment
1535559|NCT02702700|Drug|Cisplatin, liposomal|Lipoplatin IV 200 mg/m2
1535560|NCT02702700|Drug|Verteporfin|Visudyne® IV 3 mg/m2
1535561|NCT02702700|Device|Device for Intrapleural Visudyne-mediated Low-Dose Photodynamic Therapy with integrated in situ light dosimetry|Intrapleural photo-induction will be realized in the chest cavity with low-dose PDT using Visudyne® 3mg/m2 as photosensitizer, activated by 689 nm laser light with a fluence of 10J/cm2 and a fluence rate of <10mWcm2.
1535562|NCT02702687|Behavioral|PEF Feedback|Intervention group will receive PEF feedback and verbal feedback sessions across 3 feedback visits and asthma education.
1535563|NCT02702687|Behavioral|Control Feedback|Control feedback group will receive feedback consisting of standardized messages and have 3 control feedback visits and asthma education.
1535564|NCT02702674|Drug|propranolol|propranolol 20 mg given before induction of labor
1535565|NCT02702674|Drug|placebo|starch tablet containing no active drug material given before induction of labor
1535566|NCT02702674|Drug|Oxytocin|intravenous infusion of oxytocin
1535567|NCT02702661|Procedure|Fascia Iliaca Compartment Block (FICB)|Fascia Iliaca Compartment Block
1535568|NCT02702661|Procedure|Local Anaesthetic Infiltration (LAI)|Local Anaesthetic Infiltration (LAI) of the portal tracts
1535569|NCT02702661|Drug|Levobupivacaine|Levobupivacaine 0.125% - 40ml
1535570|NCT02702648|Drug|AC-082|Hard gelatin capsules for oral administration
1535571|NCT02702648|Drug|Placebo|Matched placebo capsules for oral administration
1535572|NCT02702635|Procedure|DCE MRI of the brain|An MRI of the brain including a DCE sequence
1535573|NCT02702622|Other|Provitamin A-biofortified transgenic bananas|
1535574|NCT02702609|Device|easy-graft CLASSIC|easy-graft will be grafted to a single extraction socket to preserve the ridge dimension for future implant placement.
1535575|NCT02702609|Device|FDBA with collagen plug|FDBA will be grafted to a single extraction socket and covered by collagen plug to preserve the ridge dimension for future implant placement.
1535576|NCT02702596|Other|Measurement-Based Integrated Care|Measurement-Based Integrated Care (MBIC) synthesizes the science of integrated health care and incorporates the strategies of measurement-based care. concept of MBIC for the treatment of depression includes: systematic assessment of symptoms, antidepressant treatment side effects and medication adherence and incorporation of a Depression Care Manager (DCM) to track patients and keep them engaged in care using behavioral interventions
1535577|NCT02702596|Behavioral|Depression Education Fotonovela|"Depression education that uses a unique, culturally adapted depression fotonovela titled Secret Feelings developed by Cabassa, Molina and Baron (2012). The fotonovela is a popular comic-book style pamphlet that portrays a dramatic story using photographs and dialogue bubbles, which has become an effective tool for engaging Hispanic audiences and increasing knowledge about specific health issues"
1535578|NCT02702596|Behavioral|Standard Education|The the use of a pamphlet to educate people about depression.
1535579|NCT02702570|Behavioral|CASA|Each participant serves as his/her own control. Measures administered before and after the behavioral intervention.
1535580|NCT02702557|Other|Elastic Band Exercises|
1535581|NCT02702544|Device|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
1535582|NCT02702544|Device|SCHILLER, BR-102 plus - Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 1 min during leg elevation
1535583|NCT02702531|Device|FloShield Defogging and Cleaning System|
1535586|NCT02702505|Biological|NeoMTA|A new formulation of MTA was developed in which bismuth oxide was omitted
1535587|NCT02702505|Other|ProRoot MTA|Control group
1535588|NCT02702492|Drug|KPT-9274|
1535589|NCT02702492|Drug|KPT-9274 & Niacin ER|
1535590|NCT02702479|Other|High Fructose Corn Syrup|An intervention in which calories from HFCS are substituted isocalorically for sucrose in the diet
1535591|NCT02702479|Other|Sucrose|An intervention in which calories from sucrose are substituted isocalorically for HFCS in the diet
1535592|NCT02702466|Other|SPA Therapy|Immersion bath and shower ( 1 treatment ) Underwater shower with localized massage on the painful area ( 1 treatment ) or equivalent underwater massage Illutations ( 1 treatment ) or equivalent ( poultice ) Mobilization Pool ( 1 care) Education to exercise
1535593|NCT02702453|Behavioral|website|The intervention arm will consist of 12 modules, 8 of which are consistent with the trajectory of prostate cancer and its treatment. Four modules address aspects of the prostate cancer experience that are important for patients and partners as well as providers and are designed to optimize the goal of supporting patients and partners in their sexual recovery.
1535594|NCT02702440|Other|Liquid calories from sugars|
1535596|NCT02702414|Biological|Pembrolizumab|
1535600|NCT02702388|Drug|Lenvatinib|
1535601|NCT02702388|Drug|Lenvatinib matching placebo|
1535602|NCT02702375|Other|Fructose-containing Sugars|
1535603|NCT02702362|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the precuneus cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session.
1535604|NCT02702349|Other|penicillin test|children are tested for penicillin allergy and then challenged with penicillin P.O.
1535605|NCT02702336|Behavioral|EYTO-kids|To promote healthy lifestyles among young people, through the design and implementation of health promotion activities carried out by adolescents (12-14 years old) to scholars of primary education (8-10 years old), using social marketing and peer-led strategy.
1535606|NCT02702323|Drug|Apatinib|apatinib 500mg/day for 6 weeks began taking 4-7 days after TACE
1535607|NCT02702323|Procedure|TACE|one times every 4-6 weeks.
1535608|NCT02702310|Other|Quality-of-Life Assessment|At initial visit (day 1) - for determination of a baseline quality of life, patients will be given a self-reported questionnaire called the Skindex-29. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, patients will complete the Skindex-29 questionnaire.
1535609|NCT02702310|Other|Objective Grading of Skin Findings|At initial visit (day 1) , using mSWAT the radiation oncologist can follow the patient's treatment response by accurately grading the severity of the patient's skin findings. Following standard of care radiation treatments, at weeks 6 & 12, and every 3 months thereafter, mSWAT will again be determined by physician. Follow-up visits will continue until patient has a change in disease.
1535610|NCT02702297|Other|single arm|Daily monitoring of vaginal fluid IL6 and fetal ECG. Daily maternal monitoring and delivery according to standard operating procedure. Post partum diagnosis of FIRS or EOS by analysing of fetal cord blood IL6 and clinical signs of sepsis. Diagnosis of histologic amniotic infection by histological analysis.
1535611|NCT02702284|Behavioral|Advance Directives|These subject's will have a research assistant (RA) review and walk through the advance directives brochure. The RA will read all of the brochure to the patient and prompt for questions. In addition, a link to an educational video on advance directives. The advance directive link will be either texted or emailed or given in paper per the subject's preference.
1535612|NCT02702284|Behavioral|Advance Directives without assistance|This group of subjects will be provided with the advance directive and then referred to clinic staff for assistance.
1535613|NCT02702271|Device|WATCHMAN FLX LAA closure device|
1535614|NCT02702258|Behavioral|MB-BP|MB-BP (Mindfulness-Based Blood Pressure Reduction) customizes Mindfulness-Based Stress Reduction (MBSR) to participants with prehypertension/hypertension. MB-BP will consist of nine 2.5-hour weekly group sessions and an 7.5-hour one-day session. Some of the unique areas of MB-BP are education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of blood pressure determinants such as diet, physical activity, antihypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week.
1535615|NCT02702245|Dietary Supplement|Experimental: Thylakoids 5 g|75 g pure glucose + 5 g chloroplast membranes from spinach leaves in a dried powder.
1535616|NCT02702245|Dietary Supplement|Experimental: Thylakoids 10 g|75 g pure glucose + 10 g chloroplast membranes from spinach leaves in a dried powder.
1535617|NCT02702245|Other|Placebo Comparator: Control|75 g pure glucose.
1535619|NCT02702219|Behavioral|Mobility of the hamstrings muscles|
1535620|NCT02702206|Drug|corticosteroids|under US guidance, 2ml triamcinolone (1ml/10mg), 0.5ml distilled water and 1ml 1% lidocaine
1535621|NCT02702206|Drug|hyaluronic acid|under US guidance, 2.5ml HA (ARTZ, 1% sodium hyaluronate solution, 10mg/mL, molecular weight 0.9x106Da) and 1ml 1% lidocaine
1535622|NCT02702206|Drug|normal saline|under US guidance, 2.5ml normal saline (placebo group). 0.5ml distilled water and 1ml 1% lidocaine
1535623|NCT02702193|Behavioral|SET-R/Healthy Home|SET is a manualized, strength-based,directive and process-oriented family-ecosystemic intervention based on Brief Strategic Family Therapy. Healthy Home is an adaptation of SET to be delivered by nurses as an enhanced, family-strengthening, home-health intervention. Healthy Home is delivered in addition to the usual substance abuse or mental health outpatient services received by the mothers. The time-frame for the intervention is approximately 4 months, with home visits approximately every 2 weeks.
1989843|NCT02352350|Other|Neurological Outcomes|Neurological outcomes will be performed on all participants based on the Cerebral Performance Categories (CPC) Scale.
1989844|NCT02350673|Drug|Atezolizumab|Participants will receive atezolizumab IV infusion at doses of 800 mg q2w or 1200 mg q3w.
1535626|NCT02702167|Device|High-frequency rTMS|20 Hz active stimulation, twice daily
1535627|NCT02702167|Device|Low-frequency rTMS|1 Hz active stimulation, twice daily
1535628|NCT02702167|Device|Sham rTMS|Sham stimulation, twice daily
1535629|NCT02702154|Device|High-frequency rTMS|20 Hz active stimulation, twice daily
1535630|NCT02702154|Device|Low-frequency rTMS|1 Hz active stimulation, twice daily
1535631|NCT02702154|Device|Sham rTMS|Sham stimulation, twice daily
1535633|NCT02702128|Drug|Tranexamic Acid|1g of tranexamic acid on 1 hour and 1g of tranexamic acid on 8 hours
1535634|NCT02702128|Drug|saline solution|30mL of saline solution on 1 hour and 30mL of saline solution on 8 hours
1535635|NCT02702115|Biological|SB-318|A single dose of each of the three components of SB-318 [zinc finger nucleases (ZFN1, ZFN2, and hIDUA Donor)] administered via intravenous (IV) infusion.
1535636|NCT02702102|Drug|11C-PBR28|Up to 20 millicuries
1535637|NCT02702089|Procedure|Rectal cancer surgery|Rectal cancer resection
1535638|NCT02702076|Drug|Apomorphine|Continuous subcutaneous infusion of apomorphine during waking day
1535639|NCT02702076|Drug|Placebo|Continuous subcutaneous infusion of placebo during waking day
1535640|NCT02702063|Other|passive leg raising test|Patients undergoing routine echocardiography are exposed to a passive leg raising test. Change in SV will be measured by TTE and compared to changes in SV measured by EC.
1535641|NCT02702063|Procedure|right heart catheterisation|CO in patients undergoing routine right heart catheterisation will be measured and compared between 3 methodologies: right heart catheterisation, TTE and EC
1535642|NCT02702063|Other|TTE vs. EC + calibration group|Patients will undergo routine echocardiography. CO and SV will be measured by TTE and compared to measurements obtained from simultaneous EC-measurements.
1535643|NCT02702050|Other|Mechanical stimulation (LPG system; Cellu M6 Integral I)|For the mechanical stimulation group, an additional ten-minute mechanical stimulation will be provided in each of the twelve sessions of convention treatment program. The device produced skin lift through suction via a treatment head with 2 rollers installed. It was a non-invasive technique which aimed to mobilize soft tissues by creating skin folds and stretching the underlying soft tissues while manipulating the treatment head according to protocol.
1535644|NCT02702050|Other|Conventional treatment|Twelve sessions of 40-minute remedial exercises, 5-minute warm up and 5-minute cool down exercises, within a 6-week period (i.e., two sessions per week)
1535645|NCT02702037|Dietary Supplement|oral protein-rich supplement|The older person will be offered an oral protein-rich supplement (125 ml, 18 g protein (24% of RDI), 300 kcal) twice a day in conjunction with two of the four sit-to-stand exercises during 12 weeks (7 days/week).
1535646|NCT02702037|Other|Exercise|The older person will get up from a chair to stand and then sit down again repeatedly at least four times per day, 7 days during 12 weeks
1535647|NCT02702024|Procedure|Double uterine incision technique in uterus preserving surgery for placenta percreta|
1989845|NCT02350673|Drug|Cergutuzumab Amunaleukin|Participants will receive cergutuzumab amunaleukin IV infusion at escalated doses and at different dosing schedules in Part I and at MTD (or recommended dose) in Part II.
1535652|NCT02701998|Behavioral|mHealth-Enhance Physical Activity Intervention|
1535653|NCT02701998|Other|Physical Activity Intervention|
1535654|NCT02701985|Drug|Placebo|Matching-placebo capsules will be administered orally, 2 times a day with food.
1536302|NCT02697344|Drug|R-(-)-Gossypol Acetic Acid|Given PO
1535655|NCT02701985|Drug|RO5459072|RO5459072 at a dose of 100 milligrams (as capsules) will be administered orally, 2 times a day with food.
1535656|NCT02701972|Device|BACE Device|Implanted BACE device
1535657|NCT02701959|Dietary Supplement|High Nitrate Lettuce|The lettuce has been grown with high concentration of nitrogen fertilizer (150ppm) to produce the high of nitrate content in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (~530 mg nitrate derived).
1535658|NCT02701959|Dietary Supplement|Low Nitrate Lettuce|The lettuce has been grown with low concentration of nitrogen fertilizer (25ppm) to produce the low amount of nitrate in the lettuce, the nitrate content of 50 grams of high nitrate lettuce was (~3 mg nitrate derived).
1535659|NCT02701946|Procedure|Modified Robert Jones bandage|Modified Robert Jones bandage is defined as a three-layers of thick cotton wool and two-layers of elastic bandages. The wool layers are put on firmly and overlapped the previous one by half at each turn. The elastic layers were pulled snugly with more tension distally than proximally. Before wrapping in each turn, the elastic bandage was stretched approximately 2 and 1.5 inches at below and above tibial tuberosity level, respectively. The whole bandage attains a thickness of about two inches and extends above the ankle joint to six inches above the knee joint. Before applying this bandage, the sterile gauze pads were placed over the wound and followed by WebrilTM padding (Covidien, Mansfield, MA, US)
1535660|NCT02701946|Procedure|Non compressive dressing|Non-compressive dressing is made by placing the sterile gauze pads over the wound and covering with the hypoallergenic self-adhesive, non-woven fabric tape.
1535661|NCT02701933|Drug|Ketamine|Racemic ketamine, intravenous, at a concentration of 10mg ketamine per 50ml infusion
1535662|NCT02701933|Drug|Saline|Saline, intravenous infusion
1535663|NCT02701920|Device|HeartLight hat|HeartLight hat will be worn for up to 1 hour.
1535664|NCT02701920|Device|The HeartLight hat with in-built sensor|The HeartLight hat with in-built sensor will be worn.
1535665|NCT02701920|Device|HeartLight|Electronic stethoscope will be used to estimate heart rate with HeartLight sensor/hat
1535666|NCT02701920|Device|HeartLight device|HeartLight sensor/hat will be used with ECG/Pulse oximetry/electronic stethoscope
1535667|NCT02701920|Other|parental feedback|Questionnaire
1535668|NCT02701920|Other|healthcare provider feedback|Questionnaire
1535669|NCT02701907|Other|Blood sampling|
1535670|NCT02701894|Dietary Supplement|Alpha-Linolenic Acid|Meta-Analysis of Randomized Controlled Trials
1535671|NCT02701881|Device|Long stenting using drug-eluting stent (Zilver PTX)|Long stenting by full coverage of long femoropopliteal lesion with Zilver PTX after balloon angioplasty
1535672|NCT02701881|Device|Spot stenting using drug-eluting stent (Zilver PTX)|Spot stenting by coverage of residual stenosis or flow-limiting dissection with Zilver PTX after balloon angioplasty of long femoropopliteal lesion
1535673|NCT02701855|Behavioral|Cognitive tests|"Cognitive tests include:
The MMSE (Mini Mental State Examination)
Free and Cued Selective Recall Reminding Test (FCSRT).
Executive functions (fluencies, TMT A and B, span).
Tests of verbal fluency (literal and category)
Digit symbol substitution test or Wechsler adult intelligence scale (W.A.I.S)
The Clinical Dementia Rating Scale
The IADL scale evaluates autonomy.
Geriatric Depression screening Scale (GDS)"
1535674|NCT02701855|Biological|Blood test|A blood test will be performed in order to collect following parameters: Urea, BUN, Creatinine, Potassium, Sodium, hematocrit, hsCRP, NFS, Pq, LDL-C, HDL-C, Triglycerides, Lp(a), Lp-PLA2 as well as fasting glucose, HbA1C and microalbuminuria
1535675|NCT02701855|Radiation|Brain and aorta RMI|A magnetic resonance imaging exam will be performed at the Neuroimaging Research Center of the Pitié-Salpêtrière Hospital. This exam will be optimized to fit in 30 minutes. Indeed brain 3D T1 and T2 FLAIR imaging lasts 15 minutes while cine and velocity encoded imaging of the aorta lasts 15 minutes.
1535676|NCT02701855|Other|Adaptative optics|"The retina adaptative optic imaging will be performed at the Unité de prevention des maladies cardiovasculaires Pitié Salpetrière Hospital. This exam lasts 10 minutes including patient positioning and imaging."
1535677|NCT02701842|Device|ImPACT Online/Paper Pencil Tests|
1535678|NCT02701842|Device|ImPACT Online|
1989846|NCT02348515|Procedure|Heart failure or coronary disease|Small samples collected from the apex core in the heart. In addition, blood samples will be taken.
1989847|NCT02348515|Procedure|Heart transplant patients|Heart samples collected including, excess myocardial biopsy samples. In addition, blood samples will be taken.
1535682|NCT02701816|Device|innova stent (Boston scientific)|
1535683|NCT02701803|Device|Parkinson's KinetiGraph™ logger|Logger is recording device which records the movement and acceleration of upper extremity
1535684|NCT02701777|Drug|Seromycin|100mg pill of Seromycin by mouth will be administered
1535685|NCT02701777|Device|STDP|noninvasive magnetic or electrical stimulation will be applied to the brain
1535686|NCT02701777|Other|Training|following the directions of the researcher the participant will be asked to perform specific repetitive movements using their hand, arm or leg .
1535687|NCT02701777|Drug|Dextromethorphan|150mg of DExtromethorphan pill will be administered
1535688|NCT02701777|Drug|Seromycin Placebo|placebo pill will be administered
1535689|NCT02701777|Drug|Dextromethorphan Placebo|placebo pill will be administered
1535690|NCT02701777|Device|Sham STDP|noninvasive magnetic or electrical sham stimulation will be applied to the brain
1535691|NCT02701764|Drug|Pregabalin|
1535692|NCT02701764|Drug|Placebo|
1535769|NCT02701270|Dietary Supplement|Dextrose|23.89 g of dextrose diluted in 250 ml of water taken once orally.
1989848|NCT02348515|Procedure|Orthotopic Heart Transplant Patients|Myocardial tissue samples collected from the diseased heart. In addition, blood samples will be taken.
1989849|NCT02348515|Procedure|Heart Surgery Patients|Heart samples will be collected from the left atrial appendages. In addition, blood samples will be taken.
1989850|NCT02348515|Procedure|Blood Draw|All subjects will have 20 ml of blood drawn for further analysis.
1989851|NCT02347189|Device|Melody Transcatheter Pulmonary Valve PB1016|
1535695|NCT02701725|Device|CRI status|Measurement of CRI
1535696|NCT02701712|Radiation|Magnetic resonance - guided radiation therapy (MRgRT)|Use of magnetic resonance (MR) visualization for interventional radiotherapy in cancer patients
1535697|NCT02701699|Biological|18-F-FAZA|All patients enrolled in this study will receive a FAZA PET Scan prior to their first radiation therapy fraction
1535698|NCT02701686|Behavioral|quit immediately (QI)|advise to quit immediately using the AWARD model
1535699|NCT02701686|Behavioral|cut down to quit (CDTQ)|advise to reduce cigarette consumption and quit eventally using the AWARD model
1535700|NCT02701673|Drug|Busulfan|"Busulfan test dose administered by vein on Day -10. Test dose of 32 mg/m2 based on actual body weight. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -8. Doses on Days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
1535701|NCT02701673|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
1535702|NCT02701673|Drug|Glutamine|Oral Glutamine, 15 g swished, gargled and swallowed four times a day starting on Day -8.
1535703|NCT02701673|Drug|Pyridoxine|Pyridoxine 100 mg by vein or mouth three times a day staring on Day -1
1535704|NCT02701673|Drug|Belinostat|Starting dose of Belinostat 100 mg/ m2/day by vein on Day -9 through Day -2.
1535705|NCT02701673|Drug|Azacitidine|Azacitidine 15 mg/m2/day by vein on Day -9 through Day -2.
1535706|NCT02701673|Drug|Gemcitabine|Gemcitabine 75 mg/m2 by vein administered as a loading dose followed by prolonged infusion on Days -8 and -3.
1535707|NCT02701673|Drug|Melphalan|Melphalan 60 mg/m2 by vein on Days -3 and -2.
1535708|NCT02701673|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
1535709|NCT02701660|Device|electronic medication dispenser (medido)|Automated dispense of medication through an electronic dispenser
1535710|NCT02701647|Device|repetitive transcranial magnetic stimulation|Repetitive TMS (rTMS) is a painless and non-invasive technique for activation of cerebral cortex based on the principle of electromagnetic induction of an electric filed in the brain. rTMS will be delivered to the scalp over the leg area of the bilateral motor cortex by using a Magstim 200 magnetic stimulator. (Magstim Company, Whitland, UK) and 90 mm double cone coil.
1535711|NCT02701647|Other|Treadmill training|Participants will proceed to 30 minute of treadmill training after rTMS. A safety harness without body weight support will be provided. 80% of participant's over ground maximum walking speed will be halved and used for warm-up. After warming up, walking speed will be increased by 0.2 km/h every 5 minutes. Progression will be given if patients could tolerate the belt speed with appropriate step length and walk with good stability for 5 minutes. Maximum achieved speed will be maintained followed by 0.5 km/h decrements. Participants will maintain the rest of the treadmill session with this speed or further adjustment will be made if participants are unable to maintain. Positive verbal feedback will be given to encourage large strides and upright posture during training. The participants will be instructed to walk on treadmill without holding onto the handrails if possible. Participants will perform warm up and cool down exercise to minimize training related-injury.
1535712|NCT02701634|Drug|Entospletinib|Entospletinib tablet(s) administered orally twice daily under fasted conditions
1535713|NCT02701634|Drug|Placebo|Placebo to match entospletinib tablet(s) administered orally twice daily under fasted conditions
1535714|NCT02701634|Drug|Systemic Corticosteroids|Systemic corticosteroids may include prednisone or prednisone equivalent.
1535715|NCT02701621|Other|MIRT-AT|Aquatic therapy
1535716|NCT02701621|Other|MIRT|Land-based Therapy
1535717|NCT02701608|Drug|Levofloxacin|levofloxacin 500 mg x1/day (for patients ≤70kg) or levofloxacin 750 mg x1/day (for patients >70kg)
1535718|NCT02701608|Drug|Rifampicin|rifampicin 600mg x1/day (for patients ≤70kg) or rifampicin 900mg x1/day (for patients >70kg)
1535719|NCT02701608|Procedure|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine|Conventional IV treatment of staphylococci IE following European guidelines 2015 including cloxacilline, oxacilline,gentamicine,vancomycine,rifampicine
1535720|NCT02701595|Drug|Amoxicillin|amoxicillin 1500 mg x3/day (for patients ≤70kg) or 2000 mg x3/day (for patients >70kg)
1535721|NCT02701595|Procedure|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin|Conventional IV treatment of streptococci/enterococci IE following European guidelines 2015 including amoxicillin, gentamicin, amicillin, vancomycin, penicillin G, ceftriaxone, netilmicin
1535724|NCT02701569|Other|Rebound exercise|Repeated jumping on a mini trampoline was administered
1535725|NCT02701556|Device|Complete Multi-Purpose Solution|a multi-purpose solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
1535726|NCT02701556|Device|NNR06|an experimental solution for disinfecting, cleaning, conditioning, rinsing, protein removal, and storing soft contact lenses including silicone hydrogel lenses.
1535727|NCT02701543|Device|Ranger Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
1535728|NCT02701543|Device|In Pact Drug Eluting Balloon|Percutaneous transluminal angioplasty (PTA), in which a balloon is advanced and inflated in the obstructed artery for several seconds to minutes, has become the standard endovascular treatment for peripheral arteries
1535729|NCT02701530|Behavioral|Targeted smoking cessation|Smoking cessation program developed in cooperation with and aimed at smokers with low education.
1535730|NCT02701517|Drug|Cyclosporine + METHOTREXATE|MTX days +1, +3, +6 and +11 followed by rescue with folinic Ac. All patients receive CSA from day -7.
1535731|NCT02701517|Drug|Cyclosporine + CAMPATH-1H|CAMPATH-1H at a dose of 20 mg / day at 8-hour intravenous infusion on days -8 to -4. All patients will receive CSA from day -7.
1535734|NCT02701478|Drug|N2O exposure|The aim of this study is to evaluate the nociceptive response to a standardized forearm electrical stimulus applied to patients under GA, during surgery, at different End-Tidal concentrations of N2O (ET-N2O: 0%-50%-25%-0%), and to see if ANI and NoL indices show less pain when inhaled N2O is higher.
1535735|NCT02701465|Other|Exercise: local high intensity interval exercise|The subjects in this arm will receive four high intensity (80% of peak work rate) four-minute interval exercises for the abduction movement in the plane of the scapula (m. supraspinatus), supervised three times per week. In addition they will perform the exercise program described for the control group.
1535736|NCT02701465|Other|Exercise: best clinical practice|The control group will receive a best clinical practice home-exercise program, with regular follow-ups at the shoulder clinic every other week. The details are described in Granviken et al. (2015).
1535737|NCT02701452|Other|COAGO|blood samples for haemostasis and hormonal data
1535738|NCT02701439|Device|Small membrane filtration|"Following the Ugandan National Tuberculosis and Leprosy Programme (NTLP) guidelines, all enrolled TB suspects will undergo the following standardized evaluation:
Abbreviated demographic and clinical evaluation
TB history and evaluation
Obtain three sputum samples - one early morning sample and two spot samples
HIV testing (and CD4 if positive)
Chest radiograph
Small membrane filtration intervention will be administered to both arms"
1535739|NCT02701426|Behavioral|physical activity and nutritional counseling|The program will last 12 weeks, and will include three workshops on diet of the pregnant and lactating women, and the young child. Physical activity sessions will be offered once a week.
1535740|NCT02701413|Device|ApexM (Stimulation) Device|Vaginal electrical stimulation will be administered via the Apex M Device. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Stimulation session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
1535741|NCT02701413|Device|Sham Device|A sham Apex M device without electrical stimulation will be used. During each session, the patient will be supine, place conductive gel on the device, insert the device into the vagina, and inflate it to comfort. Subsequently, the device will be turned on and set to previously determined setting. Each session will last 10 minutes and occur 6 times per week for a total of 12 weeks.
1535742|NCT02701400|Biological|Durvalumab|Given IV
1535743|NCT02701400|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
1535744|NCT02701400|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1535745|NCT02701400|Biological|Tremelimumab|Given IV
1535746|NCT02701387|Device|Megagen AnyRidge dental implant|AnyRidge is an approved dental implant with a knife edge, thin thread design available in various thread widths (depth).
1535747|NCT02701387|Device|Megagen EZ Plus dental implant|EZ Plus is an approved dental implant with a standard thread design (width and depth) and that is comparable to many other dental implants currently available on the market.
1535750|NCT02701361|Behavioral|mobile mindfulness|Receives audiovisual mindfulness content via internet plus call depending on symptoms or request.
1535751|NCT02701361|Behavioral|standard mindfulness|Receives weekly calls from mindfulness expert for 4 weeks.
1535752|NCT02701361|Behavioral|education|Receives web-based content about critical illness topics. Also receives two calls from study team to describe materials and answer questions about materials.
1535753|NCT02701348|Other|Shearwave elastography|Patients with primary breast cancer receiving neoadjuvant letrozole will undergo radiological assessment with digital mammogram, ultrasound (US) including shearwave elastography (SWE). These will be performed at 3 monthly intervals until surgical intervention is considered feasible.
1535754|NCT02701348|Drug|Letrozole|Patients will be receiving neoadjuvant letrozole as standard therapy for breast cancer
1535755|NCT02701348|Procedure|Breast core biopsy|Core biopsies will be taken at diagnosis, and at the time of surgery to allow biological assessment of changes in tumour
1535756|NCT02701348|Other|Magnetic Resonance Imaging|Breast MRI scans will be performed at time of diagnosis and prior to surgery to allow comparison of MRI change and response to treatment
1535757|NCT02701335|Device|Neural mobilization|The first 6 exercises consist of active range of motion movements of the hand designed to improve joint flexibility. The remaining 3 exercises are designed to strengthen grip and pinch by using a non-latex polymer ball: the Thera-Band Hand Exerciser (The Hygenic Corporation, Akron, OH) Subjects began with 10 repetitions the first 4 sessions, progressed to 12 repetitions the next 2 sessions, then 15 (2 sessions), and finally 20, if able, during the last sessions.
1535758|NCT02701335|Device|Gloreha device|Robotic assisted passive mobilization.
1535759|NCT02701335|Device|Standardized exercise|9 exercises: active range of motion, strengthen grip and pinch
1535760|NCT02701322|Behavioral|Medical clown|
1535761|NCT02701309|Device|Non-invasive Iron detection device via Zinc-Protoporphyrin|In this study the feasability, sensitivity and specifity of a non-invasive detection method of zinc-protoporphyrin in children is evaluated. It´s a one-arm study, without control Group. Children are aged between 9m and 5y and have a clinical blood sampling indicated.
1535762|NCT02701296|Drug|Ropivacaine with Epinephrine|Posterior capsular injection - ultrasound guided infiltration of Ropivacaine with Epinephrine between popliteal artery and capsule of knee above the femoral condyles
1535763|NCT02701296|Drug|Ropivacaine|Tibial nerve block - ultrasound selective Ropivacaine tibial nerve block in the popliteal fossa
1535766|NCT02701270|Dietary Supplement|Experimental Dietary Fibre 1|22.17 g of product diluted in 250 ml of water taken once orally.
1535767|NCT02701270|Dietary Supplement|Experimental Dietary Fibre 2|21.84 g of product diluted in 250 ml of water taken once orally.
1535768|NCT02701270|Dietary Supplement|Polydextrose|21.48 g of product diluted in 250 ml of water taken once orally.
1536395|NCT02696798|Drug|Placebo|Administered SC
1535770|NCT02701257|Device|iPhone bionic pancreas|An experimental device composed of three parts: a continuous glucose monitor, control algorithms running on an iPhone, and drug delivery using Tandem insulin pumps
1535771|NCT02701257|Device|iLet bionic pancreas|An experimental device that combines the functions of the iPhone-based bionic pancreas into one device.
1535772|NCT02701257|Drug|Xeris Xerisol glucagon|A stabilized formulation of human glucagon in a solvent based primarily composed of dimethyl sulfoxide (DMSO) that has prolonged stability and can be used for multiple days in a pump
1535773|NCT02701257|Drug|Lilly glucagon|An aqueous formulation of human glucagon with limited stability that must be changed daily
1535774|NCT02701257|Device|iLet infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
1535775|NCT02701257|Device|Contact Detach infusion set|The infusion set sub-study will be studying the experimental iLet infusion set in a cross-over with the Contact Detach infusion set. These visits will be conducted separately from the iPhone and iLet BP visits.
1535776|NCT02701244|Radiation|Permanent Breast Seed Implant (PBSI)|Patients are pre-planned using Computerized Tomography (CT) simulation. Implant is performed after surgery under light sedation and local freezing (alternatively general anesthesia). Stranded seeds are inserted using a brachytherapy template that is immobilized to the planned target volume using a 'localization' needle. Patients are released the same day and Quality Assurance involves post-implant Computerized Tomography (CT).
1535777|NCT02701231|Device|Low-frequency Rotating Magnetic Therapy System|Two pairs of fan-shaped NdFeB permanent magnets were attached to a circular iron plate and arranged to establish magnetic field. The bottom two magnets rotated at certain frequency driven by a step motor, which was controlled using a functional signal generator. The top two magnets rotated synchronously due to the strong magnetic interaction. Magnetic flux density was measured at the target site using a gauss meter. The entire magnetic apparatus was located in a hood with humidity and temperature controller.
1535778|NCT02701231|Drug|Systemic anti-tumor therapy|Systemic anti-tumor therapy includes targeted therapies, chemotherapy and best supportive care, according to NCCN non-small cell lung cancer(NSCLC) and small cell lung cancer(SCLC) guidelines. SCLC patients will receive six cycles of cisplatin and etoposide. NSCLC patients will receive EGFR and ALK test. With sensitive result the first-line therapy will be Erlotinib/Gefitinib/Crizotinib. If insensitive, the patient will receive six cycles of cisplatin and pemetrexed. Then the patient will receive tumor response evaluation. The patient with response or stable disease will receive maintenance therapy with one or some of the drugs including bevacizumab, pemetrexed, gemcitabine and docetaxel until disease progression. During experience all patients will receive clinical observation. Once proven for disease progression the patient will finish the experiment.
1535779|NCT02701231|Device|Sham Low-frequency Rotating Magnetic Therapy System|Sham Low-frequency Rotating Magnetic Therapy System is a similar apparatus except that there were two rotating iron plates instead of magnets, thus lacking a magnetic field.
1535780|NCT02701218|Procedure|Canalith repositioning procedure|Canalith repositioning procedure; single or multiple cycles
1535781|NCT02701205|Biological|etanercept|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
1535782|NCT02701205|Biological|etanercept (half dose)|Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
1535783|NCT02701205|Drug|placebo|two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
1535784|NCT02701192|Other|Coccygectomy|Patient receiving coccygectomy surgery.
1535785|NCT02701179|Drug|Lignocaine 1% concentration solution|
1535786|NCT02701179|Drug|Lignocaine 2% concentration solution|
1535787|NCT02701166|Drug|Bezafibrate|bezafibrate 400mg per day
1535788|NCT02701166|Drug|Placebo|placebo 400mg per day
1535793|NCT02701140|Procedure|Coronary stenting|Within 1h after the first PCI, patients will be randomized to either ticagrelor or clopidogrel.
1535794|NCT02701140|Procedure|intracoronary ECG recording|Measurement of ST segment elevation using intracoronary ECG recording
1535795|NCT02701140|Procedure|Coronary Flow reserve|measured with an intracoronary pressure/temperature sensor-tipped guidewire
1535796|NCT02701140|Procedure|Index of Microcirculatory Resistance|measured with an intracoronary pressure/temperature sensor-tipped guidewire
1535797|NCT02701140|Procedure|Fractional Flow Reserve|measurement of Fractional Flow Reserve during hyperemic phase.
1535798|NCT02701127|Drug|Oral niacinamide, 1 gram daily|
1535799|NCT02701127|Drug|Oral niacinamide, 3 gram daily|
1535800|NCT02701127|Drug|Placebo|
1535801|NCT02701114|Procedure|Proximal Adductor Canal Block|Continuous Nerve Block
1535802|NCT02701114|Procedure|Distal Adductor Canal Block|Continuous Nerve Block
1535803|NCT02701101|Device|Use of SEM200 Scanner daily|From enrollment to exit,daily SEM Scanner readings collected on Sacrum and Heels
1535804|NCT02701101|Other|Assessment and treatment of Pressure Ulcers using SOC|Nurse review of Skin risk and skin assessment, notes in chart to assess the frequency to turn patient, use of a specialist bed to prevent or treat early pressure ulcers
1535805|NCT02701088|Drug|5Fluorouracile and Mitomycin-C|All the patients will receive radiochemotherapy with two cycles of 5FU (1,000 mg/m²/d with 96-h infusion, days 1-5 and 29-33 of SIB-IMRT) and Mitomycin-C (10 mg/m², days 1 and 29).
1535842|NCT02700828|Drug|Hydrocortisone|4 * 0,5 mg/kg /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
1535806|NCT02701088|Radiation|Simultaneously integrated boost of intensity modulated radiation therapy (SIB-IMRT) by tomotherapy|SIB-IMRT schedule of 61.2 Gy/1.7 Gy to the primary tumor, 57.60 Gy / 1.6 Gy to involved nodes, and 54 / 1.5 Gy to elective pelvic lymph nodes.
1535807|NCT02701075|Device|MC5-A Scrambler Therapy|up to 10 sessions, each session lasting 30 minutes
1535808|NCT02701075|Device|MC5-A Scrambler Therapy Sham Device|up to 10 sessions, each session lasting 30 minutes
1535809|NCT02701062|Device|AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems|
1535810|NCT02701062|Drug|Anticoagulation Therapy|Anticoagulation Therapy - Standard of Care at the discretion of the Investigator.
1535812|NCT02701023|Drug|MitoGel|The patient would then undergo instillation of MitoGel into the affected kidney. The catheter would be left indwelling in the ureter and would be externalized through a urethral catheter. The ureteral and urethral catheters would remain indwelling for the duration of the 6 treatments, which would occur twice weekly for 3 weeks. Following the final instillation, the catheters would be removed. The patient would then undergo ureteroscopic evaluation at 3 months following the final instillation of MitoGel. The total duration of study would be 3 months.
1535813|NCT02701010|Behavioral|Structured training and leaflet|"The patients who were given both explanatory verbal instructions of the educational leaflet on the structured behavioural therapy for iOAB by continence nurse and the educational leaflet were included in this group."
1535814|NCT02701010|Behavioral|Structured training|"The patients who were given only explanatory verbal instructions of the educational leaflet on the structured behavioural therapy by continence nurse were included in this group."
1535815|NCT02701010|Behavioral|Leaflet|"The patients who were given only educational leaflet were included in this group."
1535816|NCT02701010|Behavioral|Control Group|Patients who were given unstructured explanations about continence care by a healthcare worker were included in control group.
1535817|NCT02700997|Device|Vascular Clip|Application of a titanium vascular clip (size small) to the base of each delayed absorbable suture placed at the vaginal apex on the internal vaginal side to help in identification by imaging
1535818|NCT02700984|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of the eye. The device is implanted after completion of cataract surgery.
1535819|NCT02700984|Procedure|Cataract Surgery|Cataract surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
1535820|NCT02700971|Procedure|Molecular Microscope Diagnostic system|Consented patients with locally advanced or metastatic melanoma with This trial will utilize a Molecular MicroscopeTM diagnostic system (MMDxTM) that combines the molecular and histopathological features of biopsies, plus clinical and laboratory parameters, to create the first Integrated Diagnostic System. This MMDxTM will be utilized to phenotype cutaneous melanoma biopsy samples to detect an immune responsive mRNA signature.
1535821|NCT02700958|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes.
1535822|NCT02700958|Procedure|SHAM Remote ischemic preconditioning|SHAM Remote ischemic preconditioning is performed with standard blood pressure cuff on upper-arm. RIPC-SHAM will be started just before the coronarography or angiography. Time between the last inflation cycle and the beginning of the procedure will be less than 60 minutes
1535823|NCT02700945|Device|Reveal LINQ™ Insertable Cardiac Monitor|The Medtronic Reveal LINQ™ ICM is a programmable device that continuously monitors a patient's ECG (electrocardiogram) and other physiological parameters. The device records cardiac information in response to automatically detected arrhythmias and patient activation.
1535824|NCT02700932|Device|PicoWay|solid state laser capable of delivering energy at wavelengths of 1064 nm or 532 nm or wave length of 785±20 nm that was added to the system
1535825|NCT02700919|Drug|BCT197|Capsules will be taken orally with fluids over a 5 day period after randomization
1535826|NCT02700919|Drug|Placebo|Capsules will be taken orally with fluids over a 5 day period after randomization
1535827|NCT02700906|Drug|Corticosteroid|triamcinolone (10mg/ml) 1 ml will be injected to the lateral epicondyle of the affected elbow.
1535828|NCT02700906|Drug|Lidocaine|For lidocain injection, 1ml 1% lidocain will also be peppered on the same area.
1535829|NCT02700893|Drug|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
1535830|NCT02700893|Drug|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
1535831|NCT02700880|Device|LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy.
1535832|NCT02700867|Device|NIO|Intraosseous access device NIO (Defibtech)
1535833|NCT02700854|Other|5% carbon-dioxide inhalation|5% CO2 (36 mmHg) and 95% air gas mixture inhalation, for a maximum of 12 hours or until metabolic acidosis recovery occurs as measured by BE > -5 mmol/L in arterial blood gas samples
1535834|NCT02700841|Drug|Melphalan|Given IV
1535835|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--CD34 HSCT|Undergo autologous CD34 HSCT
1535836|NCT02700841|Procedure|Peripheral Blood Stem Cell Transplantation--AHSCT|Undergo AHSCT
1535837|NCT02700841|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo autologous CD34 HSCT
1535838|NCT02700841|Biological|Tetanus Toxoid Vaccine|Given IM
1535839|NCT02700841|Biological|Therapeutic Autologous Lymphocytes|Via infusion
1535840|NCT02700841|Biological|Trivalent Influenza Vaccine|Given IM
1535841|NCT02700841|Biological|XBP1-US/XBP1-SP/CD138/CS1 Multipeptide Vaccine PVX-410|Given SC
1989859|NCT02345265|Drug|Cediranib Maleate|Given PO
1989860|NCT02345265|Other|Laboratory Biomarker Analysis|Correlative studies
1989861|NCT02345265|Drug|Olaparib|Given PO
1535843|NCT02700828|Drug|Placebo|4 * 2 ml isotonic sodium chloride solution /24 hours (in every 6 hours) iv., during hypothermia treatment (max. 72 hours)
1535844|NCT02700815|Drug|Diclofenac|
1535845|NCT02700815|Drug|Capsaicin|
1535846|NCT02700815|Drug|Placebo|
1535847|NCT02700802|Other|Feed1st|Feed1st is a unique hospital-based hunger mitigation program that, since 2010, has operated low-cost, self-serve food pantries at Comer Children's Hospital. All parents and caregivers with a hospitalized child have 24/7 free access to these self-serve pantries with the option to eat food in the pantry, carry out as much food as needed, and contribute back to the pantry with food, volunteerism, or other resources. The program also offers free phone/text/email navigation for food support and other basic needs resources. We aim to conduct a 3-arm, randomized comparative effectiveness study to evaluate the impact, versus usual care, of two alternative referral strategies to increase Feed1st program utilization and impact.
1535848|NCT02700789|Procedure|Transvaginal ultrasound scan|The presence of the following structures will be recorded: an intrauterine fluid collection; the double decidual sac sign; yolk sac; and fetal pole.
1535849|NCT02700776|Other|Phlebotomy - Blood sampling for GP88 at MM|Women undergoing a screening mammogram will have a blood sample drawn to look for GP88.
1535850|NCT02700776|Procedure|SOC Tissue biopsy|standard of care tissue biopsy if clinically indicated.
1535851|NCT02700763|Other|[18F]dabrafenib molecular imaging|A [18F]dabrafenib dynamic PET scan of the brain (60 minutes) and static total body PET scan will be performed at baseline.
1535852|NCT02700750|Device|OCT exam|OCT exam
1535853|NCT02700737|Other|Image-based simulation modelling|"The first dataset will include the imaging parameters currently recommended by clinical practice guidelines (referred to as limited dataset)."
1535854|NCT02700737|Other|Imaging parameters currently recommended by clinical practice guidelines|"The second dataset will include an expanded list of parameters, inclusive of information that is available from traditional imaging parameters (as recommended by the guidelines) and simulation modeling (referred to as image-based modelling dataset)."
1535858|NCT02700711|Drug|Methylphenidate|The pharmacodynamic effects of methylphenidate maintenance will be determined during maintenance on placebo and duloxetine.
1535859|NCT02700711|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and duloxetine.
1535860|NCT02700711|Drug|Duloxetine|The pharmacodynamic effects of duloxetine will be determined during maintenance on placebo and methylphenidate
1535861|NCT02700685|Dietary Supplement|Pycnogenol|
1535862|NCT02700685|Drug|Methylphenidate|
1535863|NCT02700685|Other|Placebo|
1535864|NCT02700672|Other|Observational study|Observational study: kinematic variables, falls and executive function were analyzed
1535865|NCT02700659|Other|Cxbladder|Cxbladder is a non invasive UC detection test measuring five messenger RNA (mRNA) biomarkers present at elevated levels in patients presenting with urothelial carcinoma.
1535868|NCT02700633|Device|Pacemaker|
1535869|NCT02700620|Behavioral|Internet-delivered CBT|Guided internet treatment
1535870|NCT02700607|Drug|Intravenous Crystalloid|crystalloid is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
1535871|NCT02700607|Drug|Intravenous HES|HES is administered to maintain stroke volume variation < 15 during volume controlled ventilation (8 ml/kg tidal volume) of O2/air mixture
1535872|NCT02700594|Other|Joint mobilization|"Mobilization and manipulation are manual therapy techniques comprising a continuum of skilled passive movements to the joints and/or related soft tissues that are applied at varying speeds and amplitudes, including a small-amplitude/high- velocity therapeutic movement.16 The term joint mobilization, or nonthrust mobilization, often refers to slow, rhythmic, repetitive passive movements to the patients' tolerance, in voluntary and/or accessory range and graded according to examination findings."
1535873|NCT02700581|Procedure|low PEEP conventional ventilation|
1535874|NCT02700581|Procedure|moderate PEEP conventional ventilation|
1535875|NCT02700581|Procedure|low PEEP protective ventilation|
1535876|NCT02700581|Procedure|moderate PEEP protective ventilation|
1535878|NCT02700542|Other|Integrated Pest Management|One-time, in-home, pest intervention for children with persistent asthma living in homes with parent-reported cockroach and/or mouse infestation.
1535879|NCT02700529|Drug|ubenimex|
1535880|NCT02700529|Other|placebo|
1535881|NCT02700503|Behavioral|Encourage 2.0|Participants will be enrolled in the ENCOURAGE 2.0 family-based diabetes prevention intervention that was designed through our work in Aims 1 and 2 of the study. It is this modified population-level ENCOURAGE 2.0 family-based diabetes prevention intervention that will be studied.
1535883|NCT02700477|Dietary Supplement|Fenugreek seeds extract|Fenugreek seed extract 500mg, BD
1535884|NCT02700477|Other|Placebo|Placebo capsule containing Dicalcium Phosphate 500mg, BD
1535885|NCT02700464|Device|Bladder EpiCheck Urine Test|The Bladder EpiCheck test is an in vitro diagnostic device for the detection of DNA methylation patterns in urine that are associated with bladder cancer. It is intended for use as a noninvasive method for monitoring for tumor recurrence in conjunction with cystoscopy inpatients previously diagnosed with bladder cancer
1535886|NCT02700464|Procedure|Cystoscopy and pathology|Routine cystoscopy for bladder cancer recurrence and pathology confirmation for patients with positive cystoscopy
1535887|NCT02700451|Drug|Ketorolac|Intravenous Ketorolac 30 milligrams (mg) every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
1536341|NCT02697123|Other|antepartum and postpartum|This is a prospective observational cohort study.
1535888|NCT02700451|Drug|Acetaminophen|Intravenous Acetaminophen 1000mg every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
1535889|NCT02700451|Drug|Placebo|Intravenous Normal Saline every 6 hours for 48 hours in addition to patient-controlled analgesia and oral opioids as needed.
1535890|NCT02700438|Drug|Glyceryl trinitrate ointment|Application of 375 mg of ointment to the distal anal canal, every 12 hours for an 8-week period.
1535891|NCT02700438|Procedure|Urgent PC Neuromodulation System®|Subjects underwent one 30-min session of percutaneous posterior tibial nerve stimulation 2 days per week for 8 consecutive weeks in an outpatient clinic, with a Urgent PC Neuromodulation System®. Patients were placed in the supine position without anesthesia. PPTNS was delivered using a needle electrode that was inserted 3-4cm cephalad and 2 cm posterior to the medial malleolus at a 60º angle towards the ankle joint to a depth of approximately 0.5-1cm. Successful placement was confirmed by the presence of electric sensation 5 cm above and below the insertion site or a digital plantar flexion.
1535892|NCT02700425|Device|CRT Pacemaker|Cardiac Resynchronization Therapy (CRT) is the use of a pacemaker with two endocardial leads placed in the right atrium (RA) and right ventricle (RV). The third lead is traditionally placed in a tributary of the coronary sinus (CS) overlying the epicardial surface of the left ventricle (LV). Alternatively, the third lead may be positioned based on mapping of the common His bundle and actively fixed to achieve QRS normalization via direct His bundle capture.
1535893|NCT02700412|Drug|Epidiolex|The titration of CBD will start with a dose of 5 mg/kg/day given in two divided doses and titrated by 5 mg/kg/2 weeks up to 25 mg/kg/day; in some patients additional titration by 5mg/kg/day every 2 weeks up to 50mg/kg/day may be instituted at the discretion of the PI upon discussion with the Co-PI
1535894|NCT02700399|Device|Erigo® Hocoma|Robotics assisted tilt table, without functional electrical stimulation
1535895|NCT02700399|Device|Traditional tilt table from Rehab-Care|Traditional tilt table
1535897|NCT02700373|Drug|PDC-APB|
1535898|NCT02700373|Drug|Placebo|
1989862|NCT02345265|Other|Pharmacological Study|Correlative studies
1535901|NCT02700347|Drug|Pyrazinamide|
1535902|NCT02700347|Drug|Allopurinol|
1535903|NCT02700334|Drug|Dapagliflozin|10 mg, one per day before breakfast during 12 weeks.
1535904|NCT02700334|Drug|Placebo|one per day before breakfast during 12 weeks.
1535905|NCT02700321|Device|OPTIFLOW/ AIRVO|"Patients randomized in HFNC group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ®/AIRVO® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction."
1535906|NCT02700321|Procedure|STANDARD Face Mask|"Patients randomized in STANDARD Face Mask group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction."
1535907|NCT02700308|Device|Kyphoplasty|Placement and inflation of balloon prior to cement injection
1535908|NCT02700308|Device|Conventional vertebroplasty|Conventional vertebroplasty
1535909|NCT02700295|Device|Orthokeratology lens|
1535910|NCT02700282|Behavioral|Backpack Carrying|A 12,5% of body weight backpack will be used for each measurement. Lung function will be assessed while carrying a double strap backpack, a mono shoulder backpack and without a backpack.
1535911|NCT02700269|Other|mBEADS|Evaluate approaches using magnetic bead capture, isolation, and surface tension valve transfer of biomarkers to improve the sensitivity of already approved malaria RDTs.
1535913|NCT02700243|Behavioral|Fitbit|Participants receive a Fitbit and are followed over the course of one year to determine use and health outcomes.
1535914|NCT02700230|Procedure|Computed Tomography|Undergo CT scan
1535915|NCT02700230|Other|Laboratory Biomarker Analysis|Correlative studies
1535916|NCT02700230|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given intratumorally
1535917|NCT02700230|Other|Quality-of-Life Assessment|Ancillary studies
1535918|NCT02700230|Procedure|Single Photon Emission Computed Tomography|Undergo SPECT imaging
1535919|NCT02700217|Procedure|Bupivacaine and Diamorphine|
1535920|NCT02700217|Procedure|Remifentanil, Propofol and Cistracurium|
1535921|NCT02700217|Procedure|Bupivacaine and Rectus Sheath injection|
1535922|NCT02700204|Device|PicoWay 532nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
1535923|NCT02700204|Device|PicoWay 1064nm fractional treatment|is a solid state laser capable of delivering energy at dual wavelength of 1064 nm or 532 nm at extremely short durations in the range of 300-900 ps
1535924|NCT02700191|Device|uCor|
1989866|NCT02342665|Drug|Copanlisib (BAY80-6946)|Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
1996008|NCT02591355|Device|Autologous Platelet Rich Plasma|Autologous Platelet Rich Plasma a novel therapeutic modality used in numerous applications. In dermatology, its uses have included treatment of chronic wounds and facial rejuvenation. More recently, anecdotal reports have suggested some efficacy in the treatment of hair loss.
1996009|NCT02591355|Device|Saline solution injection|Placebo is a saline solution
1535925|NCT02700178|Other|Biofeedback|The visual biofeedback will consist of line or shape targets on a screen that the participants will aim to achieve with your movements. The auditory cues will be a tone or multiple tones to alert them when to move and/or when targets have been achieved. During the biofeedback session the study staff may also provide verbal cues and feedback.
1535926|NCT02700165|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments. Cryolipolysis is the technology of the non-invasive treatments.
1535927|NCT02700152|Device|UltraShape|Tissue selectivity is achieved by a proprietary knowledge of ultrasound parameters ensuring specific destruction of the fat cells only within the target area. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time
1535928|NCT02700139|Device|Aspheric lens|By using a special asphericity, MyLens is customized for various prescriptions and vision directions based on specific measurements, intended for myopia correction and control
1535929|NCT02700113|Other|No intervention|Intervention is not a part of this study. This is a behavioral phenotyping study of minimally verbal individuals with Autism Spectrum Disorder.
1535930|NCT02700100|Device|Bioabsorbable Pulmonary Valved Conduit (PV-001)|"The Bioabsorbable Pulmonary Valved (PV) Conduit (PV-001) is a polymer-based medical device, with a total length of 8 cm with inner diameters of 16 or 18 mm. The valve itself is formed by three leaflets, incorporated within the conduit wall.
The PV conduit is used for correction or reconstruction of the Right Ventricular Outflow Tract (RVOT) in patients with any of the following congenital heart malformations:
Tetralogy of Fallot
Truncus Arteriosus
Pulmonary Atresia
Transposition of Great Arteries with Ventricular Septal Defect (VSD)
Pulmonary Stenosis in combination with other defects in congenital heart defect (CHD) syndromes
The PV conduit can also be used for replacement of previously implanted, but dysfunctional, pulmonary homografts or valved conduits."
1535931|NCT02700087|Drug|ranitidine or famotidine|Patients with symptomatic laryngomalacia will receive ranitidine, famotidine, or placebo medications in order to see if these medications help their symptoms to resolve.
1535932|NCT02700087|Drug|Placebo|Patients with symptomatic laryngomalacia who meet inclusion criteria will be randomized to receive placebo, ranitidine or famotidine, in order to see if these medications help their symptoms to resolve.
1535933|NCT02700074|Other|No Intervention|Intervention is not a part of this study.
1535934|NCT02700061|Procedure|Robotic occupational therapy|Robotic Occupational Therapy three times a week for twelve weeks.
1535935|NCT02700061|Procedure|Induced Constraint Therapy - ICT|Standard Occupational Therapy two times a week for ten weeks, followed by two whole weeks of Induced Constraint Therapy.
1535936|NCT02700048|Drug|intra-nasal naloxone|3 doses of intra-nasal naloxone (4 mg each) will be given during controlled hypoglycemic insulin clamps
1535937|NCT02700048|Drug|Intra-nasal saline|3 doses of intra-nasal saline will be given during controlled hypoglycemic insulin clamps
1535938|NCT02700035|Other|Bii-Zin-Da-De-Dah (Listening to One Another)|Bii-Zin-Da-De-Dah (Listening to One Another) is a family-centered alcohol and drug prevention program for Anishinabe communities. It was the first American Indian adaptation of the Iowa Strengthening Families Program (now called the Strengthening Families Program). This program has been developed and adapted in partnership with multiple Anishinabe communities over a span of 13 years. Bii-Zin-Da-De-Dah has been enormously popular in communities. It is currently the center piece of a National Canadian Mental Health Promotion Program funded by the Public Health Agency of Canada. Now in its third Phase, focusing on national scale-up among first nations people, it has been adapted for eight cultures and translated into French in a recent implementation in Canada.
1535939|NCT02700022|Drug|Alisertib|Dose escalation of alisertib: level 1 - 20 mg, level 2 - 30 mg, level 3 - 40 mg PO BID on Days 1-5 of six 21-day cycles, combined with R-EPOCH Rituximab, IV infusion on day 1 of each cycle; Etoposide, IV infusion for 96 hours on days 1, 2, 3, and 4 Doxorubicin, IV infusion for 96 hours on days 1, 2, 3, and 4 Vincristine, IV infusion for 96 hours on days 1, 2, 3, and 4 Cyclophosphamide, IV infusion for 15 minutes on day 5 Prednisone, PO daily on days 1, 2, 3, 4, and 5
1535940|NCT02700009|Behavioral|Computer-assisted CBT (CCBT)|Computer-assisted psychotherapy for depression using a computer program plus clinician support
1535941|NCT02700009|Other|Treatment as Usual (TAU)|Ordinary treatment for depression in primary care setting
1535942|NCT02699996|Other|Educational Intervention|"Receive tailored survivorship educational materials from the Children's Oncology Group patient education Health Links"
1535943|NCT02699996|Other|Informational Intervention|Receive a self-management strategies brochure and general health tips via text message
1535944|NCT02699996|Other|Questionnaire Administration|Complete interview
1535945|NCT02699996|Behavioral|Telephone-Based Intervention|Complete the PSST peer mentoring intervention with videoconferencing and text messages
1535946|NCT02699983|Behavioral|Behavioral Dietary Intervention|Undergo SparkPeople program
1535947|NCT02699983|Behavioral|Exercise Intervention|Undergo SparkPeople program
1535948|NCT02699983|Device|Monitoring Device|Wear health monitoring device
1535949|NCT02699983|Procedure|Psychosocial Assessment and Care|Undergo SparkPeople program
1535950|NCT02699983|Other|Quality-of-Life Assessment|Ancillary studies
1535951|NCT02699983|Other|Questionnaire Administration|Correlative studies
1535952|NCT02699957|Procedure|Left Atrial Appendage Occlusion|Patients undergoing percutaneous/epicardial intervention for left atrial appendage occlusion.
1535953|NCT02699944|Device|ECG Vest Optimization|As part of a standard and clinically indicated CRT optimization procedure utilize an ECG Vest as one modality for collecting information to determine best device programming.
1535954|NCT02699931|Device|Electric3D|Oral-B 3D with orthodontic head
1535955|NCT02699931|Device|Manual|Oral-B orthodontic
1535956|NCT02699918|Procedure|nocturnal oximetry|nocturnal oximetry for screening of sleep apnea syndrome. Patients with abnormal nocturnal oximetry will be further explored by polysomnography.
1535957|NCT02699905|Other|phlebotomy|phlebotomy
1535958|NCT02699892|Drug|Rituximab|Rituximab will be administered at the discretion of treating physician according to approved label. Protocol does not specify/enforce the criteria for initiation of treatment with rituximab and procedure of the infusion of rituximab.
1535959|NCT02699879|Drug|Pirfenidone|Pirfenidone will be administered according to the physician discretion as part of standard care.
1535960|NCT02699866|Device|BLT Implant Ø 2.9 mm|Placement of Straumann BLT implants Ø 2.9 mm in central and lateral incisors in the mandible and lateral incisors in the maxilla for single tooth replacement followed by prosthetic loading.
1535961|NCT02699853|Other|Questionnaire Administration|Ancillary studies
1535962|NCT02699853|Procedure|Radical Cystectomy|Undergo RRC
1535963|NCT02699853|Procedure|Radical Cystectomy|Undergo ORC
1535964|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
1535965|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
1535966|NCT02699840|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be provided as part of this study
1535967|NCT02699827|Drug|Levobupivacaine hydrochloride|Patients will receive epidural 20 ml levobupivacaine hydrochloride 0.5%
1535968|NCT02699827|Drug|Magnesium sulphate|Patients will receive epidural 5 ml magnesium sulphate 10%
1535969|NCT02699827|Drug|Saline 0.9%|Patients will receive epidural 5 ml saline 0.9%
1535970|NCT02699814|Behavioral|H3 Services|A community-based integrated care model to improve the prevention, early detection and treatment of child mental health problems
1535971|NCT02699801|Drug|propofol|propofol for post-sternal closure sedation
1535972|NCT02699801|Drug|Dexmedetomidine|dexmedetomidine for post-sternal closure sedation
1535973|NCT02699788|Device|Multifunction Cardiogram|
1535974|NCT02699775|Other|Motion Analysis|Motion analysis is used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
1535975|NCT02699762|Other|self rehabilitation of upper limb in experimental group|The patients in the self-rehabilitation group will be taught the self-rehabilitation program by a physiotherapist who is not involved in the patient follow-up. They will receive a log book which will be used to evaluate compliance and tolerance to the program. They will be instructed to carry out the exercises 7 days per week for the whole duration of the study and to record which exercises they carried out and for how long, after each exercise session.
1535977|NCT02699723|Drug|Arsenic Trioxide|Given PO
1535978|NCT02699723|Drug|Itraconazole|Given PO
1535979|NCT02699723|Other|Laboratory Biomarker Analysis|Correlative studies
1535980|NCT02699710|Drug|Folic Acid|Folic acid will be administered orally as tablet at a single dose of 5 mg.
1535981|NCT02699710|Drug|GDC-0853|GDC-0853 will be administered orally as tablet or capsule at a dose of 200 mg.
1535982|NCT02699710|Drug|Methotrexate|Methotrexate will be administered orally as tablet at a single dose of 7.5 mg.
1535983|NCT02699710|Drug|Rabeprazole|Rabeprazole will be administered orally as tablet at a dose of 20 mg.
1535984|NCT02699697|Radiation|External Beam Radiation Therapy|Undergo EBRT
1535985|NCT02699697|Radiation|Palliative Radiation Therapy|Undergo EBRT
1535986|NCT02699697|Other|Quality-of-Life Assessment|Ancillary studies
1535987|NCT02699697|Other|Questionnaire Administration|Ancillary studies
1535988|NCT02699684|Device|Lotrafilcon B contact lenses with EOBO-41|Lotrafilcon B contact lenses packaged with copolymer 845 and EOBO-41
1535989|NCT02699684|Device|Lotrafilcon B contact lenses|Lotrafilcon B contact lenses packaged with copolymer 845
1535990|NCT02699684|Device|Hydrogen peroxide-based lens care solution|Commercially-available hydrogen peroxide-based lens care solution for cleaning, disinfecting, and storing silicone hydrogel soft contact lenses
1535991|NCT02699684|Device|Saline solution for rinsing contact lenses|Commercially-available saline solution used as needed
1535992|NCT02699684|Device|Saline solution for rinsing contact lens case|Commercially-available solution used as needed
1535993|NCT02699671|Device|Bioresorbable Vascular Scaffold|
1535994|NCT02699658|Drug|Levofloxacin|
1996010|NCT02590133|Drug|Recombinant Human Endostatin Injection (Endostar)|15mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
1996011|NCT02590133|Drug|Fluorouracil (5-Fu)|200mg/m2/d, continuous intravenous infusion in 2ml/h for 30 days each cycle, 60 days as one cycle, 6 cycles in total
1535997|NCT02699619|Device|Pinloc|3 hook pins interlocked in plate.
1535998|NCT02699619|Device|2 Hansson pins|2 isolated hook pins.(Without plate)
1536000|NCT02699593|Device|Test Contact Lens|
1536001|NCT02699593|Device|Control Contact Lens|
1536002|NCT02699580|Device|lateral rectus recession with biodegradable collagen implant|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done. After lateral rectus recession, no degradable collagen implant was placed in the area, where lateral rectus was original inserted. One eye was randomly selected for the comparison.
1536003|NCT02699580|Procedure|Lateral rectus recession without biodegradable collagen implantation|Exotropia was treated with bilateral lateral rectus recession procedure. Lateral rectus recession was done in the other eye without placing biodegradable collagen implantation.
1536004|NCT02699567|Other|No intervention|
1536005|NCT02699554|Procedure|Single-event multilevel surgery|
1536006|NCT02699541|Behavioral|Diabetes Self-Management Education|"This study will implement an individualized DSME program based on Information-Motivation-Behavioral (IMB) skills theory. IMB behavioral change theory assumption proposes that health-related behavior information, motivation and behavioural skills are primary determinants of promoting health behavior.
Researcher will use a previously validated educational toolkit (PRIDE) and will be delivered using motivational interviewing techniques through several sessions for each participant. Two face-to-face sessions (one at the beginning and one at the end of the 3 month period) and one phone call per week or per fortnight."
1536007|NCT02699528|Drug|methylphenidate|The drug will be prescribed as indicated for attention deficit disorder
1536008|NCT02699515|Drug|MSB0011359C|Subjects with metastatic or locally advanced solid tumors will receive intravenous infusion of MSB0011359C over 1 hour once every two weeks for up to 12 months until confirmed progressive disease (PD), unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
1536009|NCT02699502|Other|matching an appropriate drug therapy to patients with osteoporotic hip fractures|The process involves reviewing patients characteristics virtually and finding the right drug for them while they are still in the hospital. After matching an appropriate drug, getting it through regulatory authorities to the family physician
1536010|NCT02699489|Procedure|Laparoscopic donor nephrectomy|Laparoscopic donor nephrectomy performed via a standard 4-port distribution. Control of the hilar vessels is performed using extra-large Hem-o-Lok clips (Weck- Covidien, Research Triangle Park, NC) and graft extraction is performed via a pre-prepared Pfannenstiel incision
1536011|NCT02699489|Procedure|Open donor nephrectomy|Open donor nephrectomy performed via a supracostal incision above the 11th rib and an extra-pleural extra-peritoneal approach was adopted
1536012|NCT02699476|Behavioral|Psycho-Social Therapy|
1536013|NCT02699476|Device|Cognitive Behavioral Computer Training|
1536014|NCT02699476|Behavioral|Interactive Trainer-Subject Sessions|
1536015|NCT02699476|Device|Active Control Games|
1536016|NCT02699463|Device|Continous Positive Airway Pressure|CPAP refers to the application of positive airway pressure through a mask and tubing to splint a patients throat open at night. CPAP is considered standard treatment for OSA
1536017|NCT02699463|Other|Control Group|Standard sleep hygiene counseling as per published guidelines
1536018|NCT02699450|Drug|RO6867461|RO6867461 will be administered by IVT injection in the study eye.
1536019|NCT02699450|Drug|Ranibizumab|Ranibizumab will be administered by IVT injection in the study eye.
1536020|NCT02699437|Other|Testing for antiphospholipid antibodies|Blood samples will be tested for anticardiolipin antibodies and lupus anticoagulant
1536021|NCT02699424|Radiation|External radiation therapy|
1996012|NCT02590133|Drug|Nedaplatin|80mg/m2/d, intravenous drip on d1 and d28 each cycle, 60 days as one cycle, 6 cycles in total
1536024|NCT02699398|Behavioral|Domiciliary VR-based motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
1536025|NCT02699398|Behavioral|Domiciliary occupational therapy for motor rehabilitation|3 weeks, 1 to 3 sessions a day, 20min per sessions, of physical therapy using a VR gaming system.
1536026|NCT02699385|Other|Oral Rehydration Therapy|Each participants will initiate ORT in the physician's office on Day 1.
1536027|NCT02699385|Drug|Domperidone|Each participants will receive Domperidone 0.25 milligram per killogram (mg/kg) of body weight of oral suspension thrice daily for up to 7 days.
1536028|NCT02699385|Drug|Placebo|Each participants will receive placebo oral suspension thrice daily for up to 7 days.
1536029|NCT02699372|Drug|Placebo|
1536030|NCT02699372|Drug|RO6889450|
1536031|NCT02699359|Device|HS-1000 recording|
1536032|NCT02699346|Device|HS-1000 recording|
1536033|NCT02699320|Other|Complications|Not involved
1536034|NCT02699307|Behavioral|Counseling|OT led counseling
1536035|NCT02699294|Other|Manual pressure release|Subjects will be positioned supine on a treatment plinth and will be encouraged to relax as much as possible before pressure is applied. A slow pressure to myofascial latent trigger point will be applied directly over the marked pectoralis minor muscle myofascial latent trigger point site until a moderate but tolerable pain value of 7 out of 10 (0= no pain, 10= severe pain) is reported. Constant pressure will be sustained for 90 seconds if the subjects report that the pain is decreased to a value of 3, the pressure will be increased to restore perceived pain to the value of 7. Then, tissue resistance (barrier) in pectoralis minor muscle will be controlled.
1536036|NCT02699294|Other|Contract-relax PNF stretch|Subjects will be in a sitting position with hands being clasped behind the head. The pectoralis minor muscle will be passively and slowly stretched until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Passive stretch will be sustained for 10 seconds followed by 6 seconds of maximal voluntary isometric contraction of the pectoralis minor muscle. Then, subjects will be instructed to relax for further 4 seconds. Subjects will maintain newly active stretched position of pectoralis minor muscle for 10 seconds with a strong but tolerable stretch discomfort intensity level of 4 out of 10. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
1536037|NCT02699294|Other|Z-stretch|Subjects will be positioned supine with knee bent on a treatment plinth, and the legs will be rotated to the opposite direction of the arm to be stretched placing a stabilizing distal tension on the ribs. Then, the subjects will be slowly brought the arm in a circular motion overhead pausing at the points of tightness, maintaining close contact to the treatment table until a strong but tolerable stretch discomfort intensity level of 4 out of 10 (0= no pain, 10= severe pain) is reported. Self-stretch of pectoralis minor muscle, including myofascial latent trigger points will be sustained for 30 seconds. The procedure will be repeated four times with 30 seconds of rest between two successive trials.
1536038|NCT02699281|Drug|ultra-micronized palmitoylethanolamide|ultra-micronized palmitoylethanolamide 600 mg twice a day
1536039|NCT02699281|Drug|Placebo|um-PEA like placebo twice a day
1536040|NCT02699268|Other|Lung function measurement|The infants will be exposed to lung function measurements performed by a new metod (Volusense Pediatrics) and a validated method (EcoMedics Exhalyzer D). The two Methods will be compared. This is not an intervential study, but a study aiming to validate a New Method versus an old method
1536041|NCT02699242|Device|Simulator (ORSIM) training|The simulator/intervention group will undergo training on the virtual reality bronchoscopic simulator (ORSIM) for 60 minutes before the subjects perform the 2nd Fiber optic intubation
1536042|NCT02699216|Device|Nova Oculus™|Transpalpebral micro-current electrical stimulation treatment for 3 consecutive days followed by a short wash-out period of 2 days.
1536043|NCT02699203|Behavioral|High-carbohydrate meal|Participants will consume a high-carbohydrate low fat meal. The macronutrients content will be 55% carbohydrate, 25% protein and 20% fat providing 400-500 kcal. Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
1536044|NCT02699203|Behavioral|Low-carbohydrate meal|Participants will consume a low-carbohydrate high fat meal. The macronutrients content will be 10% carbohydrate, 25% protein and 65% fat and will provide 400-500 kcal (matched to the high carbohydrate meal). Between interventions there will be at least a 48-hours washout, where participants are encouraged to return to their baseline dietary habits.
1536045|NCT02699190|Other|Whole Genome Sequencing (WGS)|Whole genome sequencing (WGS), widely regarded as the most comprehensive method for analyzing the genome, will be performed in Illumina's CLIA/CAP-certified Clinical Services Laboratory.
1536046|NCT02699190|Other|Standard Clinical Care and Diagnostic Approaches|Any diagnostic testing other than whole genome sequencing (WGS) that may be ordered in the context of a participant's routine clinical care, including scheduled and unscheduled hospital and/or outpatient visits clinic visits.
1536047|NCT02699177|Device|CBF measurements|CBF measurements
1536048|NCT02699164|Device|DRX 9000, Axiom Worldwide, Tampa, Florida|non-surgical spinal decompression therapy consist 18 traction cycles. Traction force applied herniation levels according to Magnetic Resonance Imaging (MRI).
1536049|NCT02699164|Other|physiotherapy|electrotherapy was used. electrotherapy consisted of 20 minutes of hot-pack, 20 minutes of TENS and 5 minutes of ultrasound.
1536050|NCT02699164|Other|spinal stabilization exercise|spinal stabilization exercises started elementary exercises. According to patient tolerance, exercise program reestablished.
1536051|NCT02699151|Drug|any drug|Any drug used for the treatment of SVT (e.g. heparin, low-molecular heparin, non-steroidal anti-inflammatory drug, fondaparinux, vitamin K antagonist)
1536052|NCT02699151|Procedure|any procedure/surgery|Any procedure used for the treatment of SVT(e.g. sclerotherapy, endovenous thermotherapy, crossectomy, stripping, thrombectomy, phlebectomy)
1536053|NCT02699151|Other|Any non-pharmacological treatment of SVT|Any non-pharmacological treatment of SVT (including watchful waiting)
1536054|NCT02699138|Drug|Trazodone|100mg of trazodone to be administered orally once.
1536055|NCT02699138|Drug|Placebo|Compounded sugar pill
1536056|NCT02699138|Device|Epiglottic catheter|Catheter that can be placed through the nose to a position behind the tongue to monitor for upper airway obstruction and to measure changes in pressure below the obstruction.
1536057|NCT02699125|Drug|Guanfacine|Guanfacine 1mg for 2 weeks followed by guanfacine 2mg for 4 weeks.
1536058|NCT02699125|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks
1536059|NCT02699112|Other|Parasternal EMG (EMGpara) and Transthoracic Echocardiography|OHS patients recruited will have EMGpara and Transthoracic Echocardiography at admission and when established on NIV at 3 months.
1536064|NCT02699086|Drug|PDC-1421 Capsule|
1536065|NCT02699086|Drug|placebo|
1536066|NCT02699073|Drug|regorafenib|"160mg once daily during 3 weeks followed by 1 week off therapy.
Regorafenib will be taken until disease progression according to the CHOI and RECIST1.1 criteria, death or inacceptable toxicity."
1536067|NCT02699060|Procedure|Upper gastrointestinal endoscopy with biopsy and collection of refluxate|The procedure should be performed on an empty stomach standard technique of anesthesia;10% lidocaine solution). The examination includes analysis of esophageal mucosa, expression of inflammatory changes, location, size, number of mucosal defects (erosions, ulcers, strictures, hemorrhages), as well as the appearance of the gastric and duodenal mucosa. . The modified Savary-Miller classification of esophagitis will be used to characterize changes in the esophageal mucosa. For morphological research and monocyte/macrophage phenotype assessment biopsy sampling of distal esophagus will be performed.
1536068|NCT02699060|Procedure|24-h esophageal pH-impedance test with manometry-control of pH-transducer|"Procedure of pH impedancemetry includes intranasal introduction of a probe into oesophagus and connection of the probe with the recording device and 24-hour wearing of the probe.
Installation of the probe is carried out on an empty stomach. 24-h pH-impedance monitoring will be done in both distal oesophagus and in the stomach according to standard of practice. Esophageal pH sensor will be positioned 5 cm above the manometrically located border of the lower esophageal sphincter. Measurement with a second pH sensor in the stomach, 10cm below the lower esophageal sphincter in order to monitor intragastric acidity will be done as a standard routine procedure.
Standard measuring parameters will be collected: percent of time when pH is less than 4, total number of reflux episodes, number of acid and alkaline reflux episodes, duration of longest reflux episode."
1536069|NCT02699047|Dietary Supplement|Encapsuled fish oil|Fish oil extracted from sardine, mackerel and anchovy. Nutritional information per capsule: Kcal: 13; protein: 0.35g; Total Fats: 1.25g; Saturated fat: 0g; polyunsaturated fat: 0.75g; EPA: 0.5g; DHA: 0.25g; Cholesterol: 0g. The supplement was provided in gelatinous capsule with antioxidant (tocopherols).
1536070|NCT02699047|Dietary Supplement|Encapsulated Olive oil|Extra virgin olive oil. Nutritional information per capsule: Kcal: 10; protein: 0.35g; Total Fats: 1g; Saturated fat: 0.1 g; monounsaturated fat: 0.75g; polyunsaturated fat: 0.1g; EPA: 0g; DHA: 0g; oleic acid: 0.65g; Cholesterol: 0g. The supplement was provided in gelatinous capsule without antioxidants.
1536071|NCT02699034|Procedure|ablation for typical atrial flutter|
1536072|NCT02699034|Device|Vision-MR ablation catheter|
1536073|NCT02699008|Drug|Clopidogrel|Antiplatelet agent
1536074|NCT02699008|Drug|Ticagrelor|New P2Y12 receptor inhibitor antiplatelet agent
1536075|NCT02698995|Drug|Dexamethasone|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
1536076|NCT02698995|Drug|Ropivacaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
1536077|NCT02698995|Drug|Paracetamol|After the block regression, at the first analgetic request the patients received the same analgesia protocol
1536078|NCT02698995|Drug|Morphine|After the block regression, at the first analgetic request the patients received the same analgesia protocol
1536079|NCT02698995|Drug|Lidocaine|One hour before surgery the patients received single shot VIB block with the mixture according to the group allocation
1536080|NCT02698982|Device|Depth of anesthesia monitoring (BIS, Covidien USA) and Continus non invasive blood pressure monitoring (Clearsight, Edwards LifeScience, USA)|
1536081|NCT02698982|Procedure|moderate risk surgery|
1536082|NCT02698969|Drug|Sugammadex|
1536083|NCT02698969|Device|Diaphragm Ultrasonography|Prior to induction of anesthesia each enrolled patients, ultrasonography diaphragm evaluation will be performed using an ESAOTE ultrasound machine (ESAOTE MyLab, Genova, Italy) by assessing the TF and amplitude of excursion.
1536084|NCT02698969|Drug|Neostigmine|
1536085|NCT02698969|Drug|Atropine|
1536086|NCT02698969|Device|Neurumuscual monitoring|Neuromuscular monitoring assesses muscle recovery after deep neuromuscular block through trainf of four and post tetanic count method
1536087|NCT02698969|Drug|Rocuronium|Rocuronium will be administered 0.6 mg*kg-1 to reach neuromuscular block at the induction of general anesthesia and 0.15 mg*kg-1 when PTC elicits more than 5 twitches in order to maintain a deep neuromuscular block
1536088|NCT02698969|Drug|Fentanyl|Fentanest will be administered 2 mcg*kg-1 at the induction of general anesthesia and titrated 0.5 mcg*kg-1 every 30 minutes
1536089|NCT02698969|Drug|Propofol|Propofol will be administered 2 mg*kg-1 at the induction of general anesthesia
1536090|NCT02698969|Drug|Sevoflurane|Sevoflurane will be administered at 1.0 MAC in an air/oxygen mixture
1536091|NCT02698956|Device|TAVI (Transcatheter Aortic Valve Implantation)|Edwards SAPIEN 3 Transcatheter Heart Valve (S3 THV) and Edwards Commander Delivery system (transfemoral) and Certitude Delivery system (transapical/transaortic). The Edwards S3 THV is indicated for use in patients with severe, symptomatic, calcific aortic stenosis with STS Score ≥ 8 or Logistic EuroSCORE ≥15
1536092|NCT02698943|Procedure|Phacoemulsification|Phacoemulsification for cataract extraction with Envista MX-60 implantation
1536101|NCT02698904|Behavioral|Guided Relaxation Technique|
1536102|NCT02698904|Other|Documentary Movie|
1536103|NCT02698891|Drug|Paclitaxel|
1536104|NCT02698891|Drug|Neulasta|
1536105|NCT02698891|Drug|Cyclophosphamide|
1536106|NCT02698891|Drug|Doxorubicin|
1536107|NCT02698878|Dietary Supplement|lupin protein|19g of lupin crunchy every day for the whole duration of the intervention phase (60 days)
1536108|NCT02698878|Other|Neuromuscular electrical stimulation|Individual neuromuscular electrical stimulation training had to be performed twice a day (morning and evening) over the whole duration of the intervention phase (60 days). Subjects were asked to continuously increase the intensity until a maximum intensity of 100mA per training.
1536109|NCT02698878|Device|HEPHAISTOS unloading orthotic device|Orthotic device which unloads the muscles of the lower leg. Subjects had to wear the device for the whole duration of the intervention phase (60 days).
1536110|NCT02698852|Device|BuMA Supreme|Stent platform: cobalt-chromium alloy
1536111|NCT02698839|Device|BuMA Supreme|Stent platform: cobalt-chromium alloy
1536112|NCT02698839|Device|BuMA™|Stent platform: stainless steel
1536113|NCT02698826|Other|Protocol for rapid FiO2 optimization|"We plan to test a protocol for FiO2 optimization for mechanically ventilated post-cardiac arrest subjects, with a therapeutic goal of partial pressure of arterial oxygen (PaO2) of 60-99 mmHg, based on the PaO2 range that was associated with the lowest risk of poor outcome in our previously published work. We also use PaO2 (measured by arterial blood gas [ABG] analysis) as the ultimate goal rather than arterial oxygen saturation (SaO2) measured by pulse oximetry because an SaO2 value <100% on pulse oximetry monitoring does not always exclude supranormal PaO2. The protocol in this application begins with very rapid reduction of FiO2 as much as possible according to SaO2 values, and when FiO2 is maximally reduced by SaO2 an ABG is measured, followed by finer adjustment of FiO2 to achieve a PaO2 60-99 mmHg. The protocol not only prescribes each downward titration of FiO2 but it also includes detailed limbs for upward titration of FiO2 to account for potential overshoot in FiO2 reduction."
1536114|NCT02698813|Biological|umbilical cord mesenchymal stem cells and hyaluronic acid|
1536115|NCT02698813|Drug|hyaluronic acid|
1536116|NCT02698800|Device|Blue blocking (BB) lenses|Participants will wear blue blocking lenses each night for 1 week for 2 hours preceding bedtime.
1536117|NCT02698800|Device|Clear lenses|Participants will wear clear lenses each night for 1 week for 2 hours preceding bedtime.
1536118|NCT02697851|Drug|Microgynon 30®|
1536119|NCT02697851|Drug|Evotaz®|
1536120|NCT02698761|Other|Comprehensive Care Plan|"Care Plan
Patient Controlled Analgesia (PCA). PCA will be initiated and managed at the discretion of the Pain Management team.
Other Medications. All medications will be given during daytime hours, if possible.
Pain Psychology.
Physical Therapy. Patient is expected to spend time out of bed by Day 2 participating in light activity.
Sleep Hygiene. Patient sleeps between the hours of 10 PM and 5 AM daily. Window blinds open by 8 AM. Patient must be awake and ready to participate in therapy by 9 AM.
Extracurricular. TV, phone, computer, and video games only between hours of 4-9 PM (computer okay outside of hours only for school work).
Other. Patient will eat meals during regular daytime hours (e.g. breakfast consumed before 9 am) and shower daily."
1536121|NCT02698748|Drug|Chloroquine|Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).
1536122|NCT02698748|Drug|Placebo|Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
1536123|NCT02698735|Drug|Gentamicin|
1536124|NCT02698735|Drug|Placebo|
1536125|NCT02698722|Other|End-stage renal disease treatment options|This group will receive the intervention which is a 11.5 minute video about dialysis and non-dialytic therapies.
1536399|NCT02696772|Other|Energy intake|
1536126|NCT02698709|Other|Analysis of anterior and posterior corneal surfaces|Corneal data obtained from a Scheimpflug-based topographer were converted to astigmatic vectors in accordance to the method proposed by Thibos
1536127|NCT02698696|Other|ECo program|
1536128|NCT02698696|Other|CRT program|
1536129|NCT02698696|Other|Supportive psychotherapy|
1536130|NCT02698683|Other|lymphocyte count|lymphocyte count
1536131|NCT02698670|Device|Rhythmia mapping system|A 3-D Cardiac Mapping system
1536132|NCT02698670|Device|IntellaMap Orion mapping catheter|A diagnostic basket mapping catheter
1536133|NCT02698657|Drug|ASP5094|Intravenous (IV)
1536134|NCT02698657|Drug|Placebo|Intravenous (IV)
1536135|NCT02698644|Drug|Isoamyl-2-cyanoacrylate|Isoamyl-2-cyanoacrylate will be injected inside fallopian tube hysteroscopically through ureteric catheter
1536136|NCT02698631|Procedure|Conventional AF ablation|"Conventional AF ablation will be carried out according to the standard procedure. Atrial anatomical MRI information will be integrated into the navigation system. Ablation procedure will be carried out with a Smart Touch® catheter (temperature 45 °C, 40W or 30W for anterior or posterior wall, respectively).
Both in first and re-do procedures, procedure endpoint will be electrical isolation of all pulmonary veins."
1536137|NCT02698631|Procedure|LGE-MRI guided AF ablation|"Post-processed LGE-MRI will be used to identify left atrial fibrotic patches and lesions surrounding pulmonary veins (re-do procedures). Both MRI atrial anatomical and fibrosis information will be integrated into the navigation system. Ablation procedures will be carried out with a SmartTouch® catheter (temperature 45°C, 40W or 30W for anterior or posterior wall, respectively).
Procedural end-point for first ablation procedures will be isolation of all pulmonary veins, and encirclement and isolation of all atrial fibrotic areas.
In re-do procedures, all left atrial fibrosis patches will be encircled and isolated and, for electrically non-isolated pulmonary veins, all anatomical gaps in lesions surrounding pulmonary veins (as identified in LGE-MRI) will be closed."
1536138|NCT02698618|Procedure|Diagnostic|"Pre-PCI and treatment:
At hospital admission: all consecutive patients referred for coronary angiography in stable ischemic heart disease will undergo a complete physical examination, Electrocardiogram (ECG) and laboratory blood testing including cardiac troponin and kinase mioband. Subjects will be investigated to confirm or diagnose existing diabetic or pre-diabetic status.
At the time of diagnostic catheterization After informed consent, diabetic or pre-diabetic patients with at least one stenosis with a Fractional Flow Reserve value (FFR) ≤ 0.80 fulfilling all the inclusion/exclusion criteria will be included in the trial.At the same time, a multimodal physiology assessment, including Coronary Flow Reserve (CFR) and Index of Microcirculatory Resistance (IMR) will be measured."
1536139|NCT02698618|Drug|Randomization|Randomization: patients will be randomly assigned (with 1:1 ratio) to receive either Clopidogrel or Ticagrelor before their clinically-indicated Percutaneous Coronary Intervention (PCI). Either a loading dose of Ticagrelor 180mg followed by a dose of 90mg b.i.d. (during 48 hours) or a loading dose of Clopidogrel 600mg followed by a daily dose (during at least 48 hours) of 75mg will be administered according to their randomization. Additionally the groups will be balanced according to obesity prevalence [Body Mass Index (BMI) ≥30 kg/m2] with the implementation of a dedicated randomization list.
1536140|NCT02698618|Procedure|PCI|"Pre-PCI: multimodal physiological evaluation: FFR, CFR, IMR will be repeated
PCI: For all the patients undergoing PCI, the use of unfractioned heparin (UHF) will be allowed at the time of PCI; UFH be administered with a target on Activated Clotting Time (ACT) of 200-250 s. The PCI procedures will be performed by standard technique using only second generation Drug Eluting Stents (DES). In all cases, balloon pre-dilatation will be performed before stent implantation using a semi-compliant balloon with a diameter lower than a 75% of the distal reference diameter of the vessel to avoid confounders Post-dilation will be performed according to clinical practice although it will be not mandatory.
Post-PCI: After stent implantation/s, multimodal physiological evaluation will be re-performed (FFR, CFR, IMR)."
1536141|NCT02698605|Device|Usability test study of the MirrorPath|"The study was conducted by research assistants. Each subject received one assessment that last lasted 30 minutes. The subjects were not paid for participation. In that, no randomization or masking were performed. Prior to the experiment part of the study, the subjects provided basic biographical information. We then explained the experimental process and demonstrated the operation of the device.
A novel rehabilitation device, the MirrorPath, designed for the upper limb rehabilitation of patients with hemiplegic stroke. The MirrorPath that was 1180x440x300mm in size and had a shell was constructed of acrylonitrile butadiene styrene (ABS). The control module featured an on/off switch, a knob for adjusting the speed, and an emergency cutoff switch."
1536142|NCT02698592|Device|CelsiusTMDS® 8 mm catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with CelsiusTMDS® 8 mm catheter, until complete isthmic block is achieved.
1536143|NCT02698592|Device|Thermocool® 3.5 mm catheter of irrigated tip|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® 3.5 mm catheter of irrigated tip, until complete isthmic block is achieved.
1536144|NCT02698592|Device|Thermocool® SF catheter|After demonstrating cavo-tricuspidal isthmic dependant atrial flutter with a duodecapolar catheter, ablation with continuous tissue lesion will be performed with Thermocool® SF catheter, until complete isthmic block is achieved.
1536145|NCT02698579|Other|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
1536146|NCT02698566|Drug|Ranibizumab|Patients will receive single ITV injection of ranibizumab 0.5 mg delivered via PFS on Day 1.
1536147|NCT02698553|Drug|Bupropion HCl XL tablet 150mg|The 150 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
1536148|NCT02698553|Drug|Bupropion HCl XL tablet 300mg|The 300 mg of tablet will be given to subject once daily orally. Subject will be instructed to swallow whole tablet with 240 ml of water, without crushed, divided or chewed.
1536149|NCT02698540|Other|Nutritional Supplement|High calorie, high protein peptide based
1536150|NCT02698527|Drug|Non-Buffered Lidocaine|Active comparator
1536151|NCT02698527|Drug|Buffered Lidocaine|Experimental, additIon of Sodium Bicarbonate to Lidocaine
1536342|NCT02697110|Behavioral|Edutainment based intervention|Edutainment intervention package
1536152|NCT02698514|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
1536153|NCT02698514|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing standardized nociceptive stimulus (long-lasting tetanic stimulus of the ulnar nerve; 30 s, 50 mA, 50 Hz, square-wave).
1536154|NCT02698501|Drug|MEDI9929|MEDI9929 700mg (3 doses in total, 4-week intervals), administered intravenously
1536155|NCT02698501|Drug|Placebo|Placebo (3 doses in total, 4-week intervals), administered intravenously
1536156|NCT02698488|Procedure|Morphology|
1536157|NCT02698488|Procedure|Morphology and Mass Spectroscopy|
1536158|NCT02698475|Drug|Ustekinumab 0.75 mg/kg|Participants weighing less than (<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
1536159|NCT02698475|Drug|Ustekinumab 45 mg|Participants weighing greater than or equal to (>=) 60 kg to less than or equal to (<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.
1536160|NCT02698475|Drug|Ustekinumab 90 mg|Participants weighing >100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
1536161|NCT02698462|Other|Family history questionnaire|All invitees receive an invitation to complete a FIT (FOB-Gold) and a validated, online family history questionnaire. Answers from the questionnaire are compared with the Dutch criteria for referral for genetic testing and/or surveillance colonoscopies for persons at a potential familial risk for CRC. Invitees are invited to perform both tests, but if they only perform one this will be assessed. Participants with a positive FIT (cut-off value 275 ng/ml) and/or a positive family history and a diagnosis of familial CRC by a clinical geneticist will be referred for colonoscopy.
1536162|NCT02698449|Procedure|transcranial direct current stimulation|intensity provided will be 2 milliampere during 20 minutes using 2 electrodes (7x5cm). Anode electrode will be located on the right prefrontal dorsolateral area; cathode electrode will be located on the left supraorbital area.
1536163|NCT02698449|Procedure|Specific cognitive rehabilitation|Specific cognitive rehabilitation will be personalized regarding the cognitive complaint and will include a training part and an ecological part.
1536164|NCT02698449|Procedure|Nonspecific cognitive rehabilitation|Nonspecific cognitive rehabilitation will be focused on representation of body in space.
1536165|NCT02698449|Procedure|transcranial direct current stimulation sham|the same operation that transcranial direct current stimulating but it is a sham surgery
1536166|NCT02698449|Radiation|functional Magnetic Resonance Imaging n-back task|the n-back cognitive task was developed : 3 runs will be provided (0-back, 1-back and 2-back), each will be composed of 8 activation blocks and 8 resting blocks alternatively presented.
1996019|NCT02588729|Other|Pregnant+ app for smartphone|The Pregnant+app for smartphone with information about a healthy diet, physical activity and management of gestational diabetes mellitus.
1996020|NCT02586688|Device|Active NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
1536169|NCT02698423|Device|Cobas HPV DNA Test|Women will receive a home-sent sample for HPV self-testing
1536170|NCT02698423|Other|Papanicolau test|Women will be invited to come in for a physician-performed Pap test
1536172|NCT02698371|Device|G1-Control: Futurabond®DC-SE|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G1 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
1536173|NCT02698371|Device|G2-Control: Futurabond®DC pre-etching|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G2 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
1536174|NCT02698371|Device|G3: Futurabond® U - ER|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G3 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
1536212|NCT02698072|Other|Therapeutic exercise|20-25 minutes aerobic exercise, 20-25 minutes strength exercise and 10-15 minutes stretch exercise.
1536213|NCT02698072|Device|Dry needling|Dry needling needle AGUPUNT®
1536175|NCT02698371|Device|G4: Futurabond® U - SE|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G4 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
1536176|NCT02698371|Device|G5: Adhese® Universal - ER|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G5 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
1536177|NCT02698371|Device|G6: Adhese® Universal - SE|1st Appointment-Intervention: Initial intra-oral/cavity surface and tooth digital photography; Teeth anaesthesia with 3% mepivacaine (Scandinibsa, Sintra Business Park, Portugal); Operatory field isolation with cotton rolls and retraction floss (Ultradent). All cavities cleaned with pumice and water in a rubber cup, followed by rinsing and drying. Selection composite colour by shade guide; Adhesive interventions according to G6 arm assignment. Adhesive systems will be used as SingleDose mode. Composite restorations (AdmiraFusion Universal nano-hybrid composite) with incremental filling technique (two increments maximum), light-cured (LED Unit) with an intensity of 1000mW/cm2, during 40 seconds. Restorations will be finished immediately with diamond disks (OptiDisc® medium 40μm; Kerr) and burns. Polishing performed with diamond-impregnated silicone polishers (Dimanto, Voco, CuxHaven) during 10 seconds. Intra-oral digital photography of the restoration.
1536178|NCT02698358|Device|Epic stent (Boston Scientific)|
1536179|NCT02698345|Device|drug-eluting balloon (In.PACT Admiral, Medtronic)|
1536180|NCT02698332|Device|Algorithm for UTI|The algorithm consists of one sheet of laminated paper with instruction in how to diagnose UTI
1536181|NCT02698319|Behavioral|Copenhagen Triage Algorithm|The Copenhagen Triage Algorithm is a new triage method for faster triage in the ED
1536182|NCT02698306|Drug|Dexamethasone|Dexamethasone
1536183|NCT02698306|Drug|Diclofenac Sodium|Diclofenac Sodium
1536184|NCT02698293|Drug|Gliolan|orally, 40 mg/kg
1536185|NCT02698280|Drug|Bevacizumab|Bevacizumab is administered intravenously at 5mg/kg every 3 weeks.
1536186|NCT02698280|Drug|Nimustine|Nimustine is administered intravenously at 90mg/m^2 to 110mg/m^2 every 6 weeks.
1536187|NCT02698267|Drug|BIIB074|Administered as specified in the treatment arm
1536188|NCT02698267|Drug|Itraconazole|200 mg twice daily [BID] on Day 8 and once daily (QD) from Day 9 to Day 15 inclusive
1536191|NCT02698241|Device|Diagnostic & Medication Management|Single Arm Study. Subjects will be managed using integrated diagnostics.
1536192|NCT02698228|Drug|Bupivacaine (femoral nerve block)|0.5% bupivacaine
1536193|NCT02698228|Drug|Morphine|Intravenous injection of 0.1mg/kg of morphine
1536194|NCT02698228|Device|Ultrasound|
1536195|NCT02698215|Drug|Varenicline|Varenicline 1 mg twice daily
1536196|NCT02698215|Drug|Varenicline plus Naltrexone|Varenicline 1 mg twice daily plus Naltrexone 50 mg once daily
1536197|NCT02698202|Device|Digital Breast Tomosynthesis|twice screening examination: standard 2D mammography + Digital Breast Tomosynthesis
1536198|NCT02698189|Drug|MK-8628 Dose A|Administered as an oral capsule continuously for 21 days per cycle
1536199|NCT02698189|Drug|MK-8628 Dose B|Administered as an oral capsule continuously for 21 days per cycle
1536200|NCT02698176|Drug|MK-8628 Dose 1|Administered as an oral capsule in a fasted state
1536201|NCT02698176|Drug|MK-8628 Dose 2|Administered as an oral capsule in a fasted state
1536202|NCT02698176|Drug|MK-8628 Dose 3|Administered as an oral capsule in a fasted state
1536203|NCT02698176|Drug|MK-8628 NMC Cohort Dose|Administered as an oral capsule in a fasted state
1536206|NCT02698150|Device|HERMES tablet|Tablet, sensors and wearables for daily collection of clinical data
1536207|NCT02698124|Drug|Decitabine|
1536209|NCT02698098|Drug|Methadone|
1536210|NCT02698085|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means of a set of metallic hooks ending a spatula with bevelled edges that help to treat the muscles and conjunctive tissues and trying to improve mobility between mobility between muscle planes.
1536211|NCT02698085|Other|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula but without effect in the muscle because no penetrate in deep tissue
1536214|NCT02698072|Device|Sham dry needling|Sham dry needling DONGBANG-ACUPRIME®
1536215|NCT02698059|Device|iNAP® Sleep Therapy System (iNAP)|The iNAP Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
1536216|NCT02698046|Dietary Supplement|Ferrous sulfate|200mg of ferrous sulfate three times a day for 4 months
1536217|NCT02698046|Dietary Supplement|Placebo starch|200mg of placebo starch three times a day for 4 months
1536220|NCT02698020|Procedure|Room-air|Provision of room-air
1536221|NCT02698007|Device|Laryngeal Mask Airway (LMA)|Fiberoptic bronchoscopy with the use of LMA
1536224|NCT02697981|Behavioral|nutrition counseling|nutrition counseling and guidance.
1536225|NCT02697968|Device|Electroacupuncture|
1536226|NCT02697955|Drug|Bupivacaine-epinephrine|50 mg bupivacaine and 50 μg adrenalin
1536227|NCT02697955|Other|Placebo|9 mg sodium chloride pr. ml (0,9 %)
1536228|NCT02697942|Other|cognitive training|The investigators will provide participants with tablets to play brain games through Lumosity.
1536229|NCT02697942|Other|exercise training|The investigators will provide participants with foot peddlers.
1536230|NCT02697929|Drug|sugammadex|
1536231|NCT02697929|Drug|Neostigmine|
1536232|NCT02697916|Drug|aspirin|81mg of aspirin daily vs. 325mg of aspirin daily
1536233|NCT02697903|Dietary Supplement|Natural Pomegranate Juice|Supplements (1500ml) of pomegrenate juice (POMj) were taken three times daily in the 48h which proceed the first tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Experimental: 9 elite weightlifter
1536234|NCT02697903|Dietary Supplement|Placebo Juice|Supplements (1500ml) of Placebo juice (PLA) were taken three times daily in the 48h which proceed the second tested training sessions (i.e. 250ml × 6 times with 8-h intervals between it). Moreover, during this tested sessions, subject consumed an additional 500ml of POMj. Arm-specific: Placebo Comparator: 9 elite weightlifter
1536235|NCT02697890|Device|FDBA (MinerOss®) + Mucograft® seal|Collagen matrix membrane for soft-tissue regeneration
1536236|NCT02697890|Device|FDBA (MinerOss®) + Collagen Sponge (HeliPLUG®)|Standard of Care
1536237|NCT02697877|Drug|Regadenoson|
1536238|NCT02697864|Drug|tafamidis|
1536239|NCT02697838|Drug|Apatinib|Apatinib (850 mg qd p.o.) plus paclitaxel (80mg/m2, i.v. d1,d8, d15, q28d)until disease progression or intolerable toxicity
1536240|NCT02697825|Procedure|Schiotz tonometer for Intraocular Pressure|Both Values will be corelated
1536241|NCT02697812|Procedure|slow sternal retraction|the sternal retraction (which always need to be performed for coronary artery bypass graft surgery) will be achieved over 15 min instead of the usual 30 sec
1536242|NCT02697799|Behavioral|High-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a high-level recruitment strategy
1536243|NCT02697799|Behavioral|Mid-level recruitment strategy consent form|Patients will be exposed to pre-consent messaging and a consent form that includes supplemental information describing a mid-level recruitment strategy
1536244|NCT02697786|Device|Transcranial doppler|Prolonged de airing to decrease the number of MES
1536248|NCT02697760|Radiation|thallium-201|Thallium (Tl-201) myocardial single photon emission tomography, dynamic imaging
1536249|NCT02697747|Other|Education|Educational intervention in the use of ultrasound to identify landmarks
1536252|NCT02697721|Behavioral|Powerful Tools for Caregivers|Powerful Tools for Caregivers is a 6-week psychoeducational program. Each week the caregivers will attend a 90-minute workshop in a group setting. These sessions will be co-led by two trained and certified leaders who follow the scripted program. In addition to providing education about caregiving and the importance of self-care, the classes will help caregivers develop self-care tools to manage personal stress and improve communication skills.
1536253|NCT02697721|Other|Control with delayed intervention|Control with delayed intervention
1536254|NCT02697708|Dietary Supplement|Potassium (control diet)|See arm/group description.
1536255|NCT02697708|Dietary Supplement|Potassium (supplement diet)|See arm/group description.
1536256|NCT02697708|Dietary Supplement|Potato Diet|See arm/group description.
1536258|NCT02697695|Other|Laboratory Examination|Laboratory Examination before, 1 month, 3 month, 6 month and up to 12 month after LSK, LRNYGB, LOLGB
1536259|NCT02697682|Biological|injection with the stromal vascular fraction (SVF) of adipose tissue|Description of the active treatment The active treatment is an intra-articular injection with the stromal vascular fraction (SVF) harvested from the patient's own abdominal subcutaneous fatty tissue. SVF is harvested using the Lipogems system.
1536260|NCT02697669|Other|18F-FDG PET|Imaging
1536261|NCT02697656|Behavioral|IPS|Individualized job support provided by an employment specialist
1536262|NCT02697656|Behavioral|Self-help|Self-help resources on obtaining employment and coping with chronic pain
1536263|NCT02697656|Behavioral|Treatment as usual|Transdisciplinary treatment at the pain clinic. This includes medical, psychological and physiotherapy treatment.
1536264|NCT02697643|Behavioral|BHCDS-based recommendations|
1536265|NCT02697643|Behavioral|Non-tailored recommendations|
1536266|NCT02697630|Drug|Pembrolizumab|200 mg administered intravenously (IV) every third week until progression or unacceptable toxicity for a maximum of 24 months
1536267|NCT02697630|Drug|Entinostat|5 mg by mouth (PO) once weekly until progression or unacceptable toxicity for a maximum of 24 months
1536268|NCT02697617|Drug|Pioglitazone|Pioglitazone
1536269|NCT02697617|Drug|Placebo|Placebo
1536270|NCT02697591|Drug|INCAGN01876|Initial cohort dose of INCAGN01876 monotherapy at the protocol-defined starting dose, with subsequent cohort escalations based on protocol-specific criteria. The recommended dose will be taken forward into expansion cohorts.
1536271|NCT02697565|Behavioral|Healthy Caregivers- Healthy Children Toolkit|The treatment arm will receive the train-the-trainer model (utilizing Quality Counts coaches) to deliver the evidence- based HC2 toolkit.
1536272|NCT02697565|Behavioral|Safety Curriculum|Centers randomized to the control arm will receive an attention control consisting of three visits from 'Safety Sam,' a character and safety curriculum that was fully developed and implemented in phase I of HC2. The same delivery model (train-the-trainers utilizing Quality Counts coaches) will be implemented.
1536273|NCT02697552|Drug|HBI-8000|Oral doses of 30mg, 40mg, 50mg twice weekly [BIW].
1536274|NCT02697539|Other|AmF/SnF2|AmF/SnF2 dentifrice used twice daily for 2 minutes for 12 weeks
1536275|NCT02697539|Other|mHA|microcrystalline zinc-hydroxyapatite (mHA) dentifrice dentifrice used twice daily for 2 minutes for 12 weeks.
1536276|NCT02697526|Other|Terumo|
1536277|NCT02697526|Other|Tensoplast|
1536278|NCT02697513|Behavioral|simple infection management protocol|Implementation of a simple management protocol to improve care of patients with acute infection. Implementation will be assisted by a 1.5-day focused training program.
1536279|NCT02697487|Other|No treatment|This is an observational study with no intervention.
1536280|NCT02697474|Biological|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
1536281|NCT02697474|Biological|Euvax B®: Hepatitis B vaccine|0.5 mL, Intramuscular
1536282|NCT02697461|Other|Intrinsic Foot Strengthening|"Intrinsic foot strengthening is a commonly used intervention in clinic used to increase foot stability both in prevention of and in treatment of foot and ankle injury. Subjects allocated to the strengthening program will be educated in commonly used short foot exercises and toe yoga maneuvers that target the intrinsic muscles of the foot. No equipment will be required to perform the exercises."
1536283|NCT02697461|Other|Joint Mobilization|Joint mobilization is a commonly used clinical intervention used to decrease pain and increase joint range of motion. In the treatment groups who present with joint hypomobility, a forefoot inversion maneuver with a dorsally applied pressure in the lateral midfoot and rearfoot stabilized will be applied at the barrier before the physiologic end range of motion. A second mobilization will be performed at the distal segment of the 1st Tarsometatarsal joint. These mobilizations will be performed by a board certified orthopaedic physical therapist with 14-yrs of practice experience. No equipment will be required to perform the joint mobilization.
1536284|NCT02697448|Drug|propofol|Participant receives propofol as anesthetic for cardiac ablation.
1536285|NCT02697448|Drug|sevoflurane|Participant receives sevoflurane as anesthetic for cardiac ablations.
1536286|NCT02697435|Other|Patient-Centered Care|Patient-centered care will be directed by geriatricians who have been trained to assess and treat 11 conditions that commonly affect chronic low back pain. Treatments may involve behavioral components, physical therapy, or medical treatments such as cortisone shots, depending on the patient's needs.
1536287|NCT02697435|Other|Imaging-Directed Care|Imaging-Directed Care will allow patients to follow-up their initial imaging with whatever course they (and/or their doctor) chose, should they chose to follow any course at all.
1536288|NCT02697422|Other|Community-based peer health coach intervention|The focus of the peer health coach intervention will be to deliver brief health messages, discuss goal setting, and action planning around health behavior changes shown to decrease CVD risk (for instance, healthy diet, regular to moderate-intensity physical activity, and quitting smoking).
1536289|NCT02697409|Behavioral|Education Against Tobacco intervention|
1536295|NCT02697370|Drug|Pharmacokinetic based dosage change|Pharmacokinetic based dosing of factor VIII prophylaxis treatment compared to standard prophylactic regimens based on weight.Prophylaxis is prescribed according to routine clinical practice with prophylaxis prescribed on alternate days to maintain predicted target trough of ≥1.5 IU/dL based on sparse blood sampling and Bayesian pharmacokinetic estimation
1536296|NCT02697357|Behavioral|Psychosocial Instruments|
1536297|NCT02697357|Behavioral|Emotion Regulation Therapy for Cancer Caregivers (ERT-C)|
1536298|NCT02697344|Drug|Dexamethasone|Given PO
1536299|NCT02697344|Other|Laboratory Biomarker Analysis|Correlative studies
1536303|NCT02697331|Drug|Progesterone|"women will receive progesterone capsules containing 100mg of progesterone per tablet . it will be used by the patient as one tablet per vagina twice per day .
women will be showed how to use tablets . medication will be started at 20 weeks and stopped at the end of 34 weeks"
1536304|NCT02697331|Other|Placebo|"omen will receive placebo tablets twice a day . it will be used by the patient as one tablet per vagina twice per day .
women will be showed how to use tablets . medication will be started at 20 weeks and stopped at the end of 34 weeks"
1536305|NCT02697318|Drug|Timolol maleate 0.5% ophthalmic solution|
1536306|NCT02697305|Dietary Supplement|IV BCAA|in total dose of 0,4 g/kg in a 2 h intravenous infusion
1536307|NCT02697305|Dietary Supplement|ORAL BCAA|single dose of 0.4g/kg administered over 30s washed down with 500mL of tap water
1536308|NCT02697305|Other|ORAL Placebo|single dose of 0.4 g/kg administered over 30 s washed down with 500mL of tap water
1536309|NCT02697292|Drug|Intravenous Immunoglobulin|GAMUNEX-C is the brand name for Intravenous Immunoglobulin, and is clear a ready-to-use sterile solution of human immune globulin protein for intravenous administration.
1536310|NCT02697292|Drug|Placebo/Normal Saline|Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents.
1536311|NCT02697279|Procedure|Traditional Incision and Drainage.|Control Group- Standard treatment of a simple cutaneous abscess with traditional I&D technique with or without packing utilizing a standard I&D kit.
1536312|NCT02697279|Procedure|Loop drainage|Study Group- Treatment of a simple cutaneous abscess with the loop drainage technique utilizing an standard I&D kit and the cuff of a sterile glove for a loop device.
1536313|NCT02697266|Other|No intervention|This is an observational study.
1536314|NCT02697253|Drug|Exendin 9-39|Infusion of exendin 9-39 at the rate of 600 pmol/kg/min, infusion time 60 minutes. An average of 12.1 ml will be infused in a forearm vein during an oral glucose (50 g) preload.
1536315|NCT02697253|Drug|Placebo|Infusion of 0.9% saline solution (placebo infusion) for 60 minutes. An average of 12.1 ml will be infused in a forearm vein during an oral glucose (50 g) preload.
1536316|NCT02697240|Drug|Intravenous citrulline|Intravenous citrulline at a bolus dose of 20 mg/kg over 5 minutes and then continuous at a rate of 7 mg/kg/hour for the next 23 hours for the first 7 participants, and depending on safety and pharmacokinetic profile, increase or decrease the continuous rate to 9 or 5 mg/kg/hour for the next 7 participants.
1536317|NCT02697227|Behavioral|Questionnaires|Questionnaires completed at Baseline, at Study Visits, and at Follow Up Visit.
1536318|NCT02697227|Behavioral|CO Level Testing|CO level measured at Baseline, Visit 1, Visit 9, and at Visit 10. Participants asked to blow air through a CO-measuring device.
1536319|NCT02697227|Behavioral|Behavior Activation Treatment (BAT)|Smokers assigned to the BATS treatment complete 8, 45-minute individual treatment sessions. Treatment consists of 15 minutes of Standard Cessation (SC) strategies as well as 30 minutes of Behavioral Activation (BA) strategies. The BA strategies focus on encouraging the smoker to structure a variety of reinforcing activities to promote a more rewarding smoke-free lifestyle through daily activity monitoring, assessment of values and life goals to facilitate choice of rewarding activities, scheduling of specific activities related to quit preparation and abstinence, and weekly homework assignments.
1536320|NCT02697227|Behavioral|Standard Cessation (SC)|Smokers assigned to the SC condition receive 8, 45-minute individual behavioral treatment sessions. Sessions initially consist of 15 minutes of behavioral treatment strategies for smoking cessation. Treatment involves preparation for quitting, identification of high risk situations for smoking, development of coping skills and direct support before and after the quit date, motivational intervention 91 for keeping or resetting a quit date, management of withdrawal symptoms, stress management, relaxation, relapse prevention, and medication compliance.
1536321|NCT02697227|Drug|Nicotine Patch|Participants receive 8 weeks of 21 mg NRT patch therapy. Therapy initiated on the scheduled quit day (just prior to Visit 4). Patch dispensation occurs at visit 3 and visit 8.
1536322|NCT02697227|Behavioral|Cotinine Level Testing|Saliva collected to check Cotinine level at Visits 1,9, and 10.
1536323|NCT02697227|Procedure|Lab Session|"Participants take part in a lab session at or before Visit 1 to test brain activity. Participants asked to watch a series of slides.
During the lab session, participant's brain electrical activity checked with an electroencephalogram (EEG).
Participant to complete computer tasks, including questionnaires that measure emotions and attention level.
Lab session may last up to 2 hours total."
1996021|NCT02586688|Device|Sham NeuroStar® Transcranial Magnetic Stimulation (TMS)|Compare active NeuroStar® coil with sham NeuroStar® coil.
1996022|NCT02586688|Device|Open Label Active NeuroStar® TMS|Open label NeuroStar® coil.
1536328|NCT02697201|Drug|Intralipid|0.55 ml/kg/h
1536329|NCT02697201|Drug|Saline|0.55 ml/kg/h for
1536330|NCT02697188|Drug|Testosterone undecanoate|Single-day dose as QD or BID for 3 of 5 crossover periods
1536331|NCT02697188|Drug|Testosterone enanthate|Single-day dose for 2 of 5 crossover periods
1536332|NCT02697175|Device|Live Video-Colposcopy|The colposcopy will be shown in real time on a flat screen
1536333|NCT02697175|Other|No Live Video-Colposcopy|The TV will be shut off during colposcopy
1536334|NCT02697162|Device|Antiseptic-coated catheter|Antiseptic-coated hydrophilic intermittent urinary catheter with octenidine chloride
1536335|NCT02697162|Device|Hydrophilic catheter|Hydrophilic intermittent urinary catheter
1536336|NCT02697162|Drug|Octenidine chloride|Antiseptic
1536337|NCT02697149|Radiation|nonradiation-to-endoscopist endoscopic retrograde cholangiopancreatography|All patients received magnetic resonance cholangiopancreatography before the procedure. Characteristics of lesions (e.g. common bile duct stones, stenosis) in detail was identified. During the procedure, the endoscopist was not exposed to radiation. If fluoroscopy was needed, after contrast injection (sometimes not necessary), the endoscopist went outside of the operation room and observed the X-ray image by remote control of the fluoroscopy machine.
1536338|NCT02697149|Radiation|standard endoscopic retrograde cholangiopancreatography|Patients received standard endoscopic retrograde cholangiopancreatography. Fluoroscopy was normally used when necessary.
1536339|NCT02697136|Drug|CER-001|Recombinant human apoA-I/phospholipid complexes
1536340|NCT02697136|Drug|Placebo|0.9% Sodium Chloride Injection, USP
1536344|NCT02697071|Drug|Ketamine|Patients in this arm will receive 0.2mg/kg ketamine intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
1536345|NCT02697071|Drug|Normal Saline|Patients will receive normal saline intravenously, pain scores will be collected after 30 minutes. At that time rescue medication will also be offered. Pain scores will continued to be recorded until 60 minutes have passed since drug administration.
1536348|NCT02697045|Drug|Aripiprazole 400mg LAI|
1536349|NCT02697032|Drug|Bicalutamide|150mg
1536350|NCT02697032|Procedure|FDHT PET|PET scan
1536351|NCT02697019|Behavioral|Internet-delivered Emotion Regulation Individual Therapy for Adolescents|
1536352|NCT02697006|Drug|i-cor Synchronized Cardiac Assist Device|The i-cor Synchronized Cardiac Assist Device delivers pulsatile cardiac assist synchronized to the ECG during diastole and provides enhanced oxygenation through a membrane oxygenator.
1536353|NCT02696993|Drug|Nivolumab|"Phase I Starting Dose: 3 mg/kg by vein every 2 weeks.
Phase II Starting Dose: Maximum tolerated dose from Phase I, given by vein every two weeks."
1536354|NCT02696993|Drug|Ipilimumab|Phase I and Phase II: Ipilimumab 1 mg/kg by vein every 6 weeks.
1536355|NCT02696993|Radiation|Stereotactic Radiosurgery (SRS)|"Phase I and Phase II:
Stereotactic Radiosurgery (SRS) performed once, at dosage prescribed by treating physician."
1536356|NCT02696993|Radiation|Whole Brain Radiation Therapy (WBRT)|Phase I and Phase II: Whole Brain Radiation Therapy (WBRT) delivered to the whole brain 5 days a week. Participants treated to a total dose of 30 Gy in 10 fractions.
1536357|NCT02696993|Behavioral|Neurocognitive Exam|Neurocognitive exam completed at baseline and 1 month after radiation treatment.
1536358|NCT02696980|Device|Positive Expiratory Pressure|Patient will exhale against positive expiratory pressure 0 mm or 10 mm while inhaling methacholine
1536361|NCT02696954|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: 6-10 weeks
1536362|NCT02696954|Drug|Amodiaquine|Amodiaquine on Day 0, 1 and 2 Washout period: 6-10 weeks
1536363|NCT02696954|Drug|Artemether-lumefantrine|Artemether-lumefantrine on Day 0, 1 and 2 Washout period: 6-10 weeks
1536364|NCT02696954|Drug|Artemether-lumefantrine + Amodiaquine|Artemether-lumefantrine + Amodiaquine on Day 0, 1 and 2 Washout period: 6-10 weeks
1536365|NCT02696954|Drug|Primaquine|Primaquine on Day 0 Washout period: 1-5 weeks
1536366|NCT02696954|Drug|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: 6-10 weeks
1536367|NCT02696954|Drug|Artemether-lumefantrine + Amodiaquine + Primaquine|Artemether-lumefantrine Day 0, 1 and 2 + Amodiaquine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: 6-10 weeks
1536368|NCT02696954|Drug|Artemether-lumefantrine + Primaquine|Artemether-lumefantrine on Day 0, 1 and 2 + Primaquine on Day 0 Washout period: 6-10 weeks
1536369|NCT02696941|Drug|Metformin|Metformin 500mg once daily and titrated weekly to a dose of 1000mg twice daily for 3 months
1536370|NCT02696941|Drug|SGLT2 inhibitor|SGLT2 inhibitor has been recommended to be started as part of routine clinical care
1536371|NCT02696928|Drug|Artemeter-Lumefantrine and MB (combination therapy)|AL first 3 days MB next 14 days
1536372|NCT02696928|Drug|Artemeter-Lumefantrine (combination therapy)|AL first 3 days
1536373|NCT02696928|Drug|Artemeter-Lumefantrine and Primaquine (combination therapy)|AL first 3 days PQ next 14 days
1536374|NCT02696915|Drug|Placebo|Patients received ultrasound guided fascial iliaca compartment blockade using normal saline 0.9%, 40 ml
1536375|NCT02696915|Drug|Bupivacaine|Patients received ultrasound guided fascial iliaca compartment blockade using bupivacaine 0.25%, 40 ml
1536376|NCT02696915|Device|Ultrasound guided fascia iliaca compartment block|Ultrasound guided fascia iliaca compartment block
1536377|NCT02696915|Drug|Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms)|Intrathecal hyperbaric bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms
1536380|NCT02696889|Procedure|ROSE Protocol|Laparoscopy followed by injection of BMSC fraction in right ovary
1536381|NCT02696876|Device|Arthroscopic synovial brushing|The specific and novel surgical procedure that will be carried out here is synovial membrane brushing using a novel device that has been shown to release MSCs from the synovium in vitro. This technique will be carried out in the setting of therapeutic microfracture for cartilage defects.
1536382|NCT02696876|Procedure|Microfracture|Microfracture or marrow-stimulation is a surgical procedure to repair small isolated cartilage defects by recruiting bone marrow mesenchymal stromal cells by creating small holes ('micro fractures') in the sub-chondral bone. These cells are entrapped in the ensuing blood clot and contribute to partial repair of the cartilage.
1536383|NCT02696863|Behavioral|questionnaire|
1536384|NCT02696850|Drug|Budesonide|Participants will undergo 4-week treatment course that includes budesonide powder added to saline rinse.
1536385|NCT02696850|Drug|Saline alone|Participants will undergo 4-week treatment course that includes lactose (placebo) powder added to saline rinse.
1536386|NCT02696837|Device|ETT|
1536387|NCT02696837|Device|Proseal LMA|
1536388|NCT02696837|Drug|Rocuronium|
1536389|NCT02696837|Other|No Muscle Relaxant|
1536390|NCT02696837|Drug|Rocuronium|
1536391|NCT02696824|Behavioral|Cognitive Behavioral Therapy for Adherence and Depression|"This treatment involves integrating CBT for depression with CBT for adherence following our Life-Steps approach."
1536394|NCT02696798|Drug|Ixekizumab|Administered SC
1536400|NCT02696759|Other|Blood & Fecal Collection|Prior to first dose of chemotherapy: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package; (c) Questionnaire on health related quality of life. During chemotherapy: Questionnaires on health related quality of life and regarding any treatment side effects. Questionnaires will be completed every 2 weeks during standard office visits. After chemotherapy, prior to surgery: (a) Blood sample for research; (b) Fecal sample for research using a kit provided by the research staff for home collection of the fecal sample. The kit may be brought back to the clinic or mailed in a discreet package.
1536401|NCT02696746|Other|Observation|No intervention
1536402|NCT02696733|Device|Ultrasound|Ultrasound-guided obturator nerve localization
1536403|NCT02696733|Drug|lidocaine 2%|local anesthetic used to block the obturator nerve
1536404|NCT02696733|Drug|0.9% Natrium Chloratum with a 2nd generation cephalosporin|
1536405|NCT02696720|Drug|Lidocaine|
1536406|NCT02696720|Other|Sham|
1536407|NCT02696707|Procedure|LVEF 3 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 3 months
1536408|NCT02696707|Procedure|LVEF 4 month|cardiac evaluation (by either transthoracic echocardiography or MUGA) every 4 months
1536409|NCT02696694|Other|Progesterone 25-75|Impact of serum progesterone concentrations [25-75] on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
1536410|NCT02696694|Other|Progesterone <25, >75|Impact of serum progesterone concentrations (<25, >75) on the day of embryo transfer in egg donation cycles under hormonal replacement therapy
1536411|NCT02696681|Behavioral|Cognitive Behavioral Therapy|Integrating CBT for mental health and substance issues concern with CBT for health behavior change
1536412|NCT02696668|Other|modified FaME|Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors. The components of the FaME programme include specific falls management strategies, such as bone loading, gait, dynamic posture, balance, reaction and co-ordination training, functional floor activities to improve coping skills and confidence.
1536413|NCT02696668|Other|Multisensory|"Group based exercise classes one hour weekly for 16 weeks. Each exercise class will have 8-10 participants and two instructors.Participants will receive an initial assessment by the research physiotherapists to determine the most appropriate interventions for each participant. Interventions used will include:
Limits of stability training with eyes open / eyes closed
Self induced movement strategies with eyes open / eyes closed
Gaze stability exercises in sitting / standing / walking
Sensory integration
Habituation exercises"
1536414|NCT02696655|Behavioral|Behavioural intervention|Behavioural intervention administered by healthcare professionals targetting multiple lifestyle behaviours
1536416|NCT02696629|Procedure|upper airway surgery|Uvulopalatopharyngoplasty, concomitant transpalatal advancement pharyngoplasty, nasal surgery or multi-level upper airway surgery
1536417|NCT02696629|Device|Continues positive airway pressure|Participants who are treated with continues positive airway pressure during sleep.
1536418|NCT02696629|Behavioral|education and follow up|Patients education and follow up:The impact of weight loss, sleep position, alcohol avoidance, risk factor modification and medication effects and follow-up are provided for patients' education.
1536419|NCT02696616|Drug|BI 655088|
1536420|NCT02696616|Drug|Placebo|
1536428|NCT02696590|Dietary Supplement|Vitamin D3|two forms of vitamin D3 (Oral versus injection) were compared in MS and healthy groups.
1536429|NCT02696577|Drug|Low dose aspirin|
1536430|NCT02696577|Drug|Omega 3|
1536431|NCT02696564|Drug|Losartan|50mg once per day for two weeks,followed by 100mg once per day for 46 weeks if increased dose tolerated
1536432|NCT02696564|Drug|Placebo|one capsule per day for two weeks, followed by two capsules per day for 46 weeks
1536433|NCT02696551|Other|Medical education|
1536434|NCT02696538|Other|Functional Gait Assessment|Balance assessment
1536435|NCT02696538|Other|mini-Balance Evaluation Systems Test|Balance assessment
1536436|NCT02696538|Other|Berg Balance Scale|Balance assessment
1536437|NCT02696512|Drug|Polypharmacy using FDA-approved products|Battery of medications provided through a 12-week schedule including: Minocycline, Lamotrigine, Flumazenil, Modafinil, Bromocriptine, Donepezil, Methylphenidate, Methyl B12, Methylfolate, Rasagiline, Amantadine, Naltrexone and Levodopa/carbidopa.
1536438|NCT02696512|Device|Median Nerve Stimulation (MNS)|40 cycle/second (gamma range) asymmetric, 2 ms wavebands with 300 µs bursts at 20 milliamps bilaterally (randomized left arm and right arm sequencing algorithm) applied 20 seconds on and 40 seconds off for 8 hours per day.
1536439|NCT02696512|Dietary Supplement|Nutraceutical Supplementation|Battery of nutraceuticals provided through a 12-week schedule including: Acidophilus, Alpha-Lipoic Acid, Acetyl L-Carnitine,
1536440|NCT02696512|Other|Standard of Care|Standard of Care treatment
1536441|NCT02696499|Drug|PA101B|40 mg PA101B administered via inhalation twice daily for 7 weeks
1536442|NCT02696499|Drug|Placebo|Matching placebo administered via inhalation twice daily for 7 weeks
1536443|NCT02696486|Behavioral|Exercise Training|Study subjects will receive medically supervised aerobic and resistance exercise training for 1 hour per session, 3 times per week for 6 weeks at the Cardiac Rehab center and then transition to home or YMCA partnership based exercise with staff follow-up contact for an additional 3 weeks.
1536444|NCT02696473|Dietary Supplement|Carrot|
1536445|NCT02696460|Procedure|N2O/O2 analgesia|Analgesia for ulcer debridement procedure is provided by the inhalation of N2O/O2 gas premix.
1536446|NCT02696460|Procedure|Lidocaine/Prilocaine analgesia|Analgesia for ulcer debridement procedure is provided by topically administered lidocaine/prilocaine cream.
1536447|NCT02696447|Biological|Biomarkers assays|D-Dimer assays, C-reactive protein, blood platelets assays
1536451|NCT02696408|Device|Laser treatment|"Patients randomized to the experimental arm receive in addition to mouthwash, preventive treatment of mucositis by LLLT performed by nurses consisting of daily scanning the entire oral cavity for 2 minutes with a power of 250 mW, starting with conditioning and ongoing until the onset of mucositis of grade 1.
If the mucositis is localised, preventive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), preventive laser is stopped for curative laser only."
1536452|NCT02696408|Device|Placebo|"Patients randomized to the Placebo arm receive in addition to mouthwash fictive laser treatment performed by nurses until the onset of mucositis of grade 1.
If the mucositis is localised, fictive laser will be kept on the healthy zones, and curative laser will be performed on painful zone. If the mucositis is general (more than 1 site), fictive laser is stopped for curative laser only."
1536453|NCT02696395|Device|DePuy Tri-Lock® femoral stem + Deltamotion® acetabular component|
1536454|NCT02696395|Device|DePuy Corail® femoral stem + Deltamotion® acetabular component|
1536455|NCT02696382|Behavioral|Progressive High Intensity Therapy (PHIT)|"Participants in the Progressive High Intensity Therapy (PHIT) group will receive high intensity physical therapy following discharge from acute hospitalization. The activities of training will include progressive resistance training, multi-planar motor control and gait exercises, and high intensity activities of daily living training. Like the Usual Care group, the PHIT participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
1536456|NCT02696382|Behavioral|Usual Care (UC)|"Participants in the Usual Care group will receive standard physical therapy following discharge from acute hospitalization. The activities of therapy will include basic strength training, single-planar motor control and gait exercises, and activities of daily living training. Participants will receive 12 intervention visits over 4 weeks (3 visits per week). Participants will also receive a standardized home exercise program."
1536457|NCT02696369|Drug|2% lidocaine HCl with epinephrine 1:200,000|
1536458|NCT02696369|Drug|2% lidocaine HCl with epinephrine 1:80,000|
1536459|NCT02696356|Biological|GRN-1201|GRN-1201 is a vaccine comprised of 4 peptides
1536460|NCT02696343|Device|NTrainer|pulsed orocutaneous stimulation paired with tube feedings
1536461|NCT02696343|Device|SHAM blind pacifier|regular green Soothie pacifier paired with tube feedings
1536462|NCT02696330|Drug|clopidogrel|clopidogrel 75mg tablets with 300mg loading dose followed by 75mg oral tablets daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
1536463|NCT02696330|Drug|enoxaparin|enoxaparin 40 mg by subcutaneous injection once daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
1536464|NCT02696330|Drug|placebo|starch tablets with no active drug material is given daily starting from day of hCG trigger till assessment of pregnancy by ultrasound
1536467|NCT02696304|Other|Adipose tissu repartition|absorptiometry,
1536468|NCT02696304|Other|Visceral and liver adipose tissue repartition|MRI,spectroscopy,
1536469|NCT02696304|Other|Preadipocyte quantification and adipose tissue inflamation|biopsy
1536470|NCT02696304|Other|Inflamation blood markers quantification|blood drawn,
1536471|NCT02696291|Drug|UV-4B 30 mg oral solution|UV-4B 30 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
1536472|NCT02696291|Drug|UV-4B 75 mg oral solution|UV-4B 75 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
1536473|NCT02696291|Drug|UV-4B 150 mg oral solution|UV-4B 150 mg oral solution administered TID (every 8 ± 0.5 hours) for 7 days
1536474|NCT02696291|Drug|UV-4B X mg (dose to be determined) oral solution|UV-4B X mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
1536475|NCT02696291|Drug|UV-4B Y mg (dose to be determined) oral solution|UV-4B Y mg (dose to be determined) oral solution administered TID (every 8 ± 0.5 hours) for 7 days
1536476|NCT02696291|Drug|Placebo|Placebo oral solution administered TID (every 8 ± 0.5 hours) for 7 days
1536477|NCT02696278|Other|Lesson about vegetables|During the introductory period, children will receive a lesson about vegetables 3 days a week for 3 weeks.
1536478|NCT02696278|Other|Vegetables|During the introductory period, children will be served vegetables 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive vegetables everyday for 3 weeks during snack time at their daycare center.
1536479|NCT02696278|Other|Hummus|During the introductory period, children will be served hummus, depending on their group assignment, 3 days a week for 3 weeks during snack time at their daycare center. During the intervention period, children will receive hummus, depending on their group assignment, everyday for 3 weeks during snack time at their daycare center.
1536480|NCT02696265|Procedure|CFAE guided ablation|CFAE/spatiotemporal dispersions mapping and ablation during AF aimed at restoring sinus rhythm during ablation. Pulmonal vein isolation will be checked before and after ablation using a mapping catheter.
1536481|NCT02696265|Procedure|PVI guided ablation|Wide antral pulmonary vein isolation during mapping catheter control of pulmonary vein signals
1536482|NCT02696239|Device|V-lock suture|
1536483|NCT02696239|Device|Vicryl Suture|
1536484|NCT02696239|Device|Lapra-Ty II|
1536489|NCT02696213|Other|Systematic, Comprehensive, One to One Training (SCOOT)|An occupational therapist trained by the principal investigator will perform 1.5 hour SCOOT sessions with participants one to two times a week over a period of 6 weeks. SCOOT will provide instruction and practice for performing scooter skills (i.e., instruction on driving, basic and advanced scooter skills) that are embedded in self-selected activities that participants want to perform using their scooters.
1536490|NCT02696213|Other|Six Week Delay|Participants will begin the SCOOT intervention after a six week delay.
1536491|NCT02696200|Device|Q Collar|The device is fitted to the neck to provide a comfortable and precise jugular compression that potentially mitigates cerebral slosh. The device will be worn inside the collar of an athletic compression shirt.
1536492|NCT02696187|Behavioral|KOLwebben|KOL-webben will be introduced to all people with COPD during their ordinary visits to the primary care center during a 3 months period. The introduction to KOL-webben will be tailored to each person's needs and include 1) registration of the patient at KOL-webben 2) showing and discussing specific content on KOL-webben (e.g. movies with exercises if the person needs exercise training) chosen to meet the needs of the individual 3) giving a card (A5 format) with address to KOL-webben, user information and references to chosen content on KOL-webben. All patients will also receive a pedometer.
1536493|NCT02696174|Other|HMI|A defined priced package of primary care services, including investigation and treatment such as procedures and medication, available at a selected clinic for 6 months
1536494|NCT02696161|Other|platelet rich plasma|Ultrasound-guided 3cc PRP injection between proximal carpal tunnel and median nerve.
1536495|NCT02696161|Other|5% dextrose|Ultrasound-guided 3cc 5% dextrose injection between proximal carpal tunnel and median nerve.
1536496|NCT02696148|Drug|liraglutide|For subcutaneous (s.c., under the skin) injection once daily.
1536497|NCT02696148|Drug|placebo|For subcutaneous (s.c., under the skin) injection once daily.
1536500|NCT02696109|Behavioral|Treatment As Usual|Participants in the TAU arm will be assigned to standard care at our partnering mental health agency. These clients are free to attend one-on-one counseling or any other services available at the clinic or elsewhere to address mental health challenges.
1536501|NCT02696109|Behavioral|Cornerstone|Participants in the experimental arm will be assigned a Transition Facilitator, a clinician with whom the client will meet one-on-one, and will be asked to attend once-a-week groups with other transition age youth. The groups will focus on issues relevant to successful transition to independent adulthood including stress and anger management and healthy relationships.
1536502|NCT02696096|Other|FMRI|all participants will complete 2 FMRIs
1536503|NCT02696096|Drug|Suboxone|all participants will be prescribed Suboxone for 4 months during their study participation
1536505|NCT02696070|Device|Provant Therapy System|
1536506|NCT02696057|Other|manual technics|soft tissue technics, joint mobilization and muscle energy technics were applied three sessions per week, totally six week.
1536507|NCT02696057|Other|Exercise|spinal stabilization exercise applied three sessions per week, totally six week.
1536536|NCT02695810|Behavioral|Exercise|Interval training, 5 times per week, 30 min per session
1536537|NCT02695797|Other|IVIG|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
1536538|NCT02695797|Drug|Prednisolone|IVIG (400mg/kg/day for 5 days) with oral prednisolone (60mg for 5days, than decrease by 10 mg every 2 day)
1536508|NCT02696044|Drug|triheptanoin|Participants will begin a 2 week dose titration period to achieve study drug treatment comprising of 1-4 grams per kilogram of body weight (g/kg) daily depending on age. The age-related target dose will be mixed with food or formula and administered orally or by gastronomy tube. The total daily dose can be divided into 4 equal doses taken 4 times daily. Participants will maintain the age dependent dose treatment at the 1-4 g/kg daily for four months.
1536509|NCT02696031|Drug|Secukinumab|Induction: 4x 150 mg Secukinumab s.c. weekly Maintenance: 150 mg Secukinumab s.c. monthly
1536510|NCT02696031|Drug|Placebo|Induction: 4x placebo s.c. weekly Maintenance: placebo s.c. monthly
1536511|NCT02696031|Drug|Secukinumab|150 mg Secukinumab s.c. monthly
1536512|NCT02696018|Device|Ultrasonography|Ultrasonographic assessment of the diaphragm function
1536513|NCT02696005|Other|Exercise- Based Cardiac Rehabilitation Programme|Exercise- Based Cardiac Rehabilitation Programme for patients suffering from Heart Failure.
1536516|NCT02695966|Procedure|Whipples Surgery|Whipples Surgery
1536517|NCT02695940|Drug|LEO 124249 ointment 30 mg/g|
1536518|NCT02695940|Other|LEO 124249 ointment vehicle|
1536519|NCT02695927|Device|Computer rehabilitation glasses|
1536520|NCT02695914|Drug|Compound Qingre Granule|A kind of Chinese patent medicine, which is developed by Dr.Shuwen Zhang and Dr.Baoen Wang from Beijing Friendship Hospital.
1536521|NCT02695901|Drug|Chlorhexidine gluconate 0.12% (PerioGard®)|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing Chlorhexidine gluconate (0.12%). Plaque indices will be recorded at baseline, day 4, and day 7.
1536522|NCT02695901|Drug|Nanoparticle solution of M. alternifolia oil (0.3%).|At baseline, subjects will receive a professional prophylaxis and will be instructed to withdrawal oral hygiene methods for 3 days. At day 4, 2 contra-lateral quadrants will be randomly chosen to receive a professional prophylaxis, being controls for plaque-covered surfaces. Subjects will then start to rinse twice daily with 15 ml mouthrinse containing a nanoparticle solution of M. alternifolia oil (0.3%). Plaque indices will be recorded at baseline, day 4, and day 7.
1536523|NCT02695888|Behavioral|Risky Driving Prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
1536524|NCT02695888|Behavioral|Teen Healthy Living|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
1536525|NCT02695875|Procedure|Aquatic therapy|"Pool material is contributed by Maria José Jove Foundation. The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
1536526|NCT02695875|Procedure|Land-based therapy|"The material is contributed by Faculty of Physiotherapy at University of A Coruña.
The exercises that will be made during treatment, are designed and developed to improve core muscles and, in this way, improve postural balance."
1536527|NCT02695862|Drug|Terlipressin|
1536528|NCT02695836|Other|Initial face-to-face dissemination workshop|Managers and directors of care will receive a printed report (tailored to their facility) on their facility's performance and performance of each unit (microsystem) within that facility. The workshop will include a presentation of the feedback reports with a particular focus on the core set of actionable context targets (Formal Interactions, Evaluation, Social Capital, Organizational Slack (OS) - Time) in the face-to-face workshops. Following the presentation, participants will discuss their reports in facilitated, round-table group discussions to a) help with interpretation of the results overall, b) draw attention to elements of context that are modifiable, c) encourage microsystem teams to work on improving the more modifiable areas
1536529|NCT02695836|Other|Face-to-face goal setting workshop|Sessions will build on the dissemination workshops and will be held three months after. Feedback reports on Formal Interactions, Evaluation, Social Capital, and Organizational Slack (OS) - Time will be discussed. Small group activities will take place including: a) reflecting on context data, b) performance goal setting using the 'tell and sell' method, which capitalizes on the workshop leaders' perceived expertise about what goals are achievable, c) establishing a series of proximal learning goals that will provide teams with explicit strategies for attaining performance goals set in (b). An action plan and instructions for reporting back at the Virtual Support Workshop will be provided.
1536530|NCT02695836|Other|Virtual support workshops|On virtual support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges.
1536531|NCT02695836|Other|Face-to-face support workshops|On face-to-face support workshop will be held six months after the feedback and goal setting workshop, and a second one another six months later. Groups will a) report on their progress in the proximal learning goals and strategies used toward their performance goals, b) discuss challenges they may be encountering, and c) receive support from the research team in addressing these challenges. Workshops will be attended by all participating teams from a region, to maximize opportunities for teams to learn from one another and trouble-shoot together with the support of workshop leaders.
1536532|NCT02695836|Other|On-demand email and telephone support|Participants can contact the research team if needed with requests for support in defining or implementing improvement strategies or dealing with barriers towards improvement.
1536533|NCT02695823|Device|Ultrasound|"Ultrasound measurements of the optic nerve sheath diameter and intracranial Doppler, at 4 time points during surgery (incision, anhepatic phase + 30 min, declamping + 5 min, declamping + 30 min), and at day 1 and day 5 after surgery, to detect presence of intracranial hypertension.
Search of any neurological complication during the 5 postoperative days."
1536534|NCT02695810|Drug|Dapagliflozin|10 mg per day as monotherapy for 13 weeks
1536535|NCT02695810|Drug|Metformin|2 x 850 mg per day as monotherapy for 13 weeks
1537250|NCT02689921|Drug|Exemestane|Aromatase inhibitor
1536539|NCT02695784|Dietary Supplement|Probiotic Continuation|This arm will continue to receive probiotics beyond 34 weeks corrected gestation until two months after discharge
1536540|NCT02695771|Drug|Mitomycin C|Cancer chemotherapeutic agent
1536541|NCT02695771|Drug|Gemcitabine|Cancer chemotherapeutic agent
1536542|NCT02695758|Procedure|Interscalene brachial plexus block|
1536543|NCT02695758|Procedure|bupivacaine extended-release liposome injection|
1536544|NCT02695745|Drug|V116517 aqueous suspension|300 mg (approximately 100 mL) aqueous suspension taken orally x 1 dose
1536545|NCT02695745|Drug|Celecoxib capsules|400 mg (2 capsules of 200 mg each) taken orally x 1 dose
1536546|NCT02695745|Drug|Placebo|Placebo for V116517 aqueous suspension taken orally x 1 dose and/or placebo for celecoxib, 2 capsules taken orally x 1 dose
1536547|NCT02695745|Drug|Capsaicin|1% administered topically
1536548|NCT02695732|Drug|Carvedilol|Carvedilol is started at a dose of 6.25 mg/d, and titrated to a maximum dose of 12.5 mg/d.Doses are increased every 7 days until ABPsys is not less than 95 mm Hg and HR is not less than 55 bpm.
1536549|NCT02695732|Device|endoscopy|Patients receiving endoscopic therapy (either endoscopic ligation or cyanoacrylate injection) every 4 weeks until eradication of varices.
1536550|NCT02695719|Drug|Lubiprostone|Lubiprostone capsules
1536551|NCT02695719|Drug|Placebo|Lubiprostone placebo-matching capsules
1536552|NCT02695706|Device|Laboratoires Mercurochrome Reparador|Developed for the treatment of damaged or fragile skin.
1536553|NCT02695693|Behavioral|TeachTown|TeachTown is an online program for students with autism that uses an applied behavior analysis framework to provide intervention in academic and pre-academic areas
1536554|NCT02695693|Behavioral|Discrete Trial Training|Discrete trial training is a one-on-one didactic behavioral intervention in which the teacher or therapist uses specific behavioral methods based on principles of operant conditioning, to help students gain skills
1536555|NCT02695693|Behavioral|Pivotal Response Training|Pivotal response training is a one-on-one child-lead behavioral intervention in which the teacher or therapist uses specific behavioral methods, leveraging the students interests, to help students gain skills
1536556|NCT02695693|Behavioral|Teaching in Functional Routines|Functional routines are sets of chained behaviors that students are taught that help them complete and manage specific activities in the classroom
1536557|NCT02695654|Drug|Levobupivacaine|14 ml of 0,25 % Levobupivacaine
1536558|NCT02695654|Drug|Clonidine|Clonidine 100 mcg
1536559|NCT02695641|Drug|1.25mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 1.25mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
1536560|NCT02695641|Drug|2.50mg bevacizumab|Bevacizumab is a monoclonal antibody against VEGF-A. 2.50mg in 50ml 0.9% Sodium Chloride will be administered once as an intravenous infusion over 30 minutes.
1536561|NCT02695628|Drug|18F-Fluoromisonidazole|Undergo [18F] FMISO PET/CT
1536562|NCT02695628|Procedure|Arterial Embolization|Undergo transcatheter arterial embolization
1536563|NCT02695628|Diagnostic Test|Computed Tomography|Undergo [18F] FMISO PET/CT
1536564|NCT02695628|Diagnostic Test|Positron Emission Tomography|Undergo [18F] FMISO PET/CT
1536565|NCT02695602|Procedure|Microdebrider-Assisted Inferior Turbinoplasty (MAIT)|
1536566|NCT02695602|Procedure|Submucous Resection with non powered instrument|
1536567|NCT02695576|Procedure|Lumbar Fusion Surgery|Interbody fusion with fixation
1536568|NCT02695576|Other|Physiotherapy|Examination by physiotherapist, motivation of the patient, training in body awareness, physical activity/Qigong, training in water, outdoor pole work, circle training, stabilization training, massage, stretching, lessons and practice in ergonomics.
1536569|NCT02695576|Other|Cognitive behavioral therapy|Individual and group lessons performed by psychologists.
1536570|NCT02695563|Drug|Lactoferrin|
1536571|NCT02695550|Drug|CT-707|
1536573|NCT02695524|Other|Strengthening exercises|
1536574|NCT02695524|Other|Neuromuscular exercises|
1536575|NCT02695511|Other|Caloric restriction|25% caloric restriction below baseline energy requirement
1536576|NCT02695498|Other|Mindfulness Based Stress Reduction|"MBSR is a standardized course in mindfulness mediation and yoga. The participants will meet weekly for 8 weeks for 2.5 hours, plus a mindfulness retreat day (approximately 6 hours) after the 6th class [9 total classes.] Mindfulness is cultivated through meditation, body scan (sequential attention to parts of the body), and mindful movement (bodily awareness during gentle stretching, based on yoga). The instructor also gives information about stress and stress relief."
1536577|NCT02695498|Other|Migraine/stress Education|The participants will be educated about migraine pathophysiology, headache triggers, stress, gentle stretches, and daily migraine readings.
1536578|NCT02695485|Procedure|innervated sensate flap|sensory reconstruction via digital nerve repair with the donor nerve of the flap
1536579|NCT02695472|Drug|80 Milligrams NSI-189|Orally Administered
1536580|NCT02695472|Drug|Placebo|Orally administered
1536581|NCT02695472|Drug|40 Milligrams NSI-189|Orally Administered
1536582|NCT02695459|Drug|cisplatinum and everolimus|Cisplatinum : 75 mg/m2 days 1,iv Everolimus : 7.5 mg daily: days 1-21 orally
1536583|NCT02695446|Drug|Minocycline|Oral extended release minocycline
1536584|NCT02695433|Dietary Supplement|Active|Active Treatment Diet Plan
1536585|NCT02695433|Dietary Supplement|Control|Control Diet Plan
1536586|NCT02695420|Drug|25 mg Omecamtiv Mecarbil|Drug: Omecamtiv Mecarbil Subjects will receive Omecamtiv Mecarbil 25 mg BID
1536587|NCT02695420|Drug|Placebo|Drug: n/a Subjects will receive Placebo BID
1536588|NCT02695420|Drug|37.5 mg Omecamtiv Mecarbil|Drug: Omecamtiv Mecarbil Subjects will receive Omecamtiv Mecarbil 25 mg BID up to week 4 or week 8 and 25 mg or 37.5 mg BID after week 4 or week 8, based on week 2 PK
1536589|NCT02695420|Drug|50 mg Omecamtiv Mecarbil|Drug: Omecamtiv Mecarbil Subjects will receive Omecamtiv Mecarbil 25 mg BID up to week 4 or week 8 and 25 mg or 50 mg BID after week 4 or week 8, based on week 2 PK
1536590|NCT02695407|Other|3 days cannulation|assessment of artery stenosis after 3 days of artery cannulation
1536591|NCT02695407|Other|5 days cannulation|assessment of artery stenosis after 5 days of artery cannulation
1536592|NCT02695381|Drug|Etodolac-lidocaine topical patch|Once daily
1536593|NCT02695381|Drug|Placebo|Once daily
1536594|NCT02695368|Device|Air cleaner with plasma-filter turned on|The air-cleaner sterilizes the air particles through a plasma chamber. Air in the operating theatre is pumped through the chamber (80 - 380 m3/Hr) and by using a small current it transforms the gas in the vicinity of the electrode into plasma and eradicates any bacteria that pass through.
1536595|NCT02695368|Device|Air-cleaner with plasma-filter turned off|
1536596|NCT02695368|Device|Air-cleaner with plasma-filter turned on or turned off|
1536597|NCT02695355|Drug|Methylphenidate (MPH)|Test 1: No medication. Registration of ERPs and behavioral data during an attention task. Test 2: Test repeated on a single dose of MPH. Outcome measure: Classification as responders or non-responders after a four weeks medication trial, based on rating scales from parents and Teachers.
1536598|NCT02695342|Behavioral|Home balance exercise program|
1536599|NCT02695329|Device|KneeAlign 2|Patients suffering non-severe varus deformity Osteoarthritis will be enrolled and randomly assigned into one of two treatment groups. Patients in investigational group will be treated with total knee arthroplasty and the accelerometer-based navigational device. Patients in control group will be treated with total knee arthroplasty with conventional instrumentation.
1536600|NCT02695316|Other|Focus Group Discussion in native Language|Group Interview with semi-structured key question, moderated in the native language of the participants. Interpreters translate the discussion for the Researcher analogically and adapt it culturally. The discussions are audio-recorded, summarized, translated and transcribed into German.
1536601|NCT02695316|Other|Focus Group Discussion|Group Interview with semi-structured key question, audio-recorded and ad verbatim transcription
1536602|NCT02695316|Other|One-to-one Interview|One-to-one Interview with semi-structured key question, audio-recorded and ad verbatim transcription.
1536603|NCT02695316|Other|Retrospective Quantitative Analysis|Retrospective Quantitative Analysis of questionnaires (Telephone Interpreting Protocols)
1536604|NCT02695303|Drug|Coppertone (BAY 987516)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1536605|NCT02695290|Drug|Afatinib|
1536606|NCT02695277|Device|AtriCure Bipolar System|
1536607|NCT02695277|Device|Standard Endocardial Ablation with Catheter|
1536608|NCT02695277|Device|AtriClip® PRO LAA Exclusion System|
1536609|NCT02695277|Device|Endocardial Ablation with Catheter|
1536610|NCT02695277|Device|Repeated Endocardial ablation(s)|
1536611|NCT02695264|Device|HS-1000 recording|
1536612|NCT02695251|Other|low AGE meal|Patients will receive a low AGE (eggs) meal
1536613|NCT02695251|Other|High AGE meal|Patients will receive a high (mixed nuggets) AGE (eggs) meal
1536614|NCT02695238|Procedure|Prophylactic Manual Rotation of persistent occipital posterior presentation|prophylactic manual rotation of persistent occipital posterior presentation on operative delivery will be performed in the experimental group
1536615|NCT02695225|Behavioral|Lay-led tobacco abstinence|Lay-led tobacco abstinence: Each intervention visit, which lasts an average of 30 minutes, will be delivered face-to-face in a mutually agreed upon convenient location (e.g. participant's home, county extension office). All behavioral and pharmacological intervention strategies will be delivered by the lay educator, with supervision by the county nurse (assigned by county with no overlap between conditions). As recommended by the USPHS guideline, all participants will set a 'quit date' and receive identical behavioral and pharmacological treatment throughout the intervention.
1536616|NCT02695225|Behavioral|Lay-led promotion of Ohio Quit Line|Lay-led promotion of Ohio Quit Line (control condition): Each participant will be given print information about the Ohio Tobacco QUIT LINE (1-800-QUIT-NOW) and encouraged to call for proactive telephone counseling and free NRT. Proactive telephone counseling and NRT administration will be provided by a QUIT LINE counselor, using their standard protocol.
1536617|NCT02695212|Drug|Apremilast|"Investigational Product: Apremilast
Doses: Period A:
10mg Per day, day #1, 10mg Twice Per day, day #2 10mg qAM, 20mg qHS day #3 20mg Twice per day, day #4 20mg qAM, 30 mg qHS day #5 30mg Twice per day, day #6
Period B:
30mg Twice per day, day #7 through week #24
Period C:
Week 28 (4 weeks off therapy), for final evaluation Mode of Administration: Oral"
1536618|NCT02695199|Procedure|Laparoscopic varicocelectomy|Traditional laparoscopic varicocelectomy assisted by laparoscopic Doppler ultrasound
1536619|NCT02695199|Procedure|Microscopic Subinguinal varicocelectomy|Infertile patients with clinically palpable varicoceles were selected to receive microscopic Subinguinal varicocelectomy
1536620|NCT02695186|Procedure|Gastroscopy|Gastroscopy and biopsies, as well as blood sample collection
1536621|NCT02695160|Biological|SB-FIX|Single dose of each of the 3 components of SB-FIX: ZFN1, ZFN2 and cDNA Donor.
1536622|NCT02695147|Procedure|TAVI|
1536623|NCT02695134|Other|Healing Touch|Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and energy centers which control the flow of energy to the physical body.
1536624|NCT02695108|Other|classical approach for neck pain|Patients with mechanical neck pain were instructed to do cervical exercise
1536625|NCT02695108|Other|scapular exercise on neck pain|Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
1536626|NCT02695069|Procedure|Random Placenta Margin Incision|A random hysterotomy incision is done in the placenta margin. To precisely determine the placental location and the edge of the placenta, preoperative ultrasonography is used in determining the optimal place for the uterine incision.
1536627|NCT02695043|Behavioral|RRTBIMS|TBI patients discharged from Bellevue inpatient rehabilitation and enrolled in the Rusk Rehabilitation Traumatic Brain Injury Model System (RRTBIMS)
1536628|NCT02695043|Behavioral|Multimedia Multicultural Educational Program for TBI (MMEPT)|
1536629|NCT02695030|Device|Low Profile Visualized Intraluminal Support Device|LVIS device is intended for use with bare platinum embolic coils for the treatment of unruptured, wide neck, intracranial, saccular aneurysms.
1536630|NCT02695017|Device|Iso inertial|
1536631|NCT02695017|Device|Conventional machine|
1536632|NCT02695004|Drug|DKF-310|
1536633|NCT02695004|Drug|Placebo|
1536634|NCT02694991|Other|Osteopathic Manipulative Treatment|The thoracic wall is gently manipulated in conscious subjects in a supine position in order to facilitate greater diaphragmatic excursion. The thorax is palpated by applying a low pressure load directly on the skin in the direction of resistance, without any sliding over the skin or forcing of the subcutaneous tissue until it begins to yield and there is a sensation of softening. Sterile procedures are used when touching the patients near the surgical site. The treatment consists of a fixed and preordained sequence of three sessions, beginning with the costal arch on the diaphragm and then moving to the sternal area and, finally, the region of the thoracic outlet. The first two phases are performed from the right side, and the third from the head of the bed.
1536635|NCT02694978|Drug|Ferumoxytol|
1536636|NCT02694978|Drug|Ferric carboxymaltose|
1536637|NCT02694965|Other|observational|
1536638|NCT02694952|Biological|FAV-Africa|Polyspecific antivenom immunoglobulin F(ab)'2 fragments of equine origin manufactured by Sanofi Pasteur, S.A., Lyon, France. Per undiluted 1 ml, the multivalent serum contains ≥25 times the LD50 for mice exposed to venom of Bitis gabonica, Bitis arietans, Echis leucogaster, Echis ocellatus, Naja haje, Dendroaspis polylepis, Dendroaspis viridis, and Dendroaspis jamesoni, as well as ≥20 times the LD50 for mice exposed to venom of Naja melanoleuca and Naja nigricollis.
1536639|NCT02694952|Biological|EchiTabPlus-ICP|Polyspecific antivenom immunoglobulin of equine origin manufactured by the Clodomiro Picado Institute, San Jose, Costa Rica. Each 10 ml of undiluted antivenom contains enough antibody fragments to neutralize 30 mg of Echis ocellatus venom, 20 mg of Bitis arietans venom and 5 mg of Naga nigricollis venom.
1536640|NCT02694939|Behavioral|STAND (Behavior Therapy + Motivational Interviewing)|Parent-teen collaborative skills based behavior therapy targeting Executive functioning and Delay Aversion in Teens
1536641|NCT02694939|Behavioral|Usual Care|Community Therapists free to deliver any therapy they feel is indicated.
1536642|NCT02694926|Other|Education|During a session of 90 minutes duration, patients are educated in basic knowledge on adrenal insufficiency including the correct behaviour in emergency settings.
1536643|NCT02694913|Other|Non Interventional|This is a non therapeutic, pilot study.
1536644|NCT02694900|Other|Manually chest compressions|Chest compressions performed manually without any device
1536645|NCT02694900|Device|Cardiopump|Chest compressions performed with Cardiopump
1536646|NCT02694900|Device|LifeLine ARM|Chest compressions performed using mechanical chest compressions system LifeLine ARM
1536647|NCT02694874|Drug|Rosiglitazone|This is the experimental drug, rosiglitazone, being tested against placebo to assess its efficacy as an adjunctive treatment for severe malaria
1536648|NCT02694874|Drug|Placebo|This is the placebo control
1536649|NCT02694848|Drug|Salvianolate injection|Traditional Chinese medicine injection，a kind of innovative drugs developed by Shanghai institute of materia medica, Chinese academy of sciences after 13 years of research and development.the content of magnesium acetate was 80%, and the other 20% were magnesium acetate.It has the function of promoting blood circulation,removing blood stasis and blood stasis,and is used for treating coronary heart disease with stable angina pectoris.
1536650|NCT02694848|Drug|Aspirin|Molecular chemical formula: C9H8O4,molecular structure type: CH3COOC6H4COOH. It has the role of anti thrombosis In vivo, and it can inhibit the release of the platelet reaction, inhibit platelet aggregation, which is related to the reduction of TXA2 generation. Clinically itused to prevent the onset of cardiovascular and cerebrovascular diseases.
1536651|NCT02694822|Drug|AGEN1884|anti-CTLA-4 antibody
1536652|NCT02694809|Drug|Conjugated Estrogens/Bazedoxifene|Given PO
1536653|NCT02694809|Other|Cytology Specimen Collection Procedure|Correlative studies
1536654|NCT02694809|Other|Laboratory Biomarker Analysis|Correlative studies
1536655|NCT02694809|Other|Pharmacological Study|Correlative studies
1536656|NCT02694809|Other|Placebo|Given PO
1536657|NCT02694809|Procedure|Quality-of-Life Assessment|Ancillary studies
1536658|NCT02694809|Other|Questionnaire Administration|Ancillary studies
1536659|NCT02694796|Behavioral|Physical activity program after a balneotherapy|workshop during the balneotherapy associated to an automated program of physical activity after the end of the balneotherapy available during 12 months
1536662|NCT02694770|Biological|Neihulizumab Treatment|Monoclonal antibody
1536663|NCT02694770|Biological|Conventional Treatment|2nd line therapy for aGvHD at the discretion of attending physician, including but not limited to biologics such as ATG, TNF-alpha inhibitors, pentostatin, sirolimus, mycophenolate mofetil and extracorporeal photopheresis.
1536664|NCT02694757|Device|Ostom-i device|The Ostom-i alert (OIA) is a discrete novel device which clips onto any ostomy bag from edge to edge and measures the horizontal tension between the edges over time, as a result of stool volume in the ostomy. It is an FDA approved medical device.
1536666|NCT02694731|Behavioral|Mobile application intervention (Device: Smartphone)|Consists of the app described in the arm description.
1536667|NCT02694718|Drug|Capecitabine|Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m^2 bid orally on Days 1-14, and at a dose of 825mg/m^2 bid on Days 22-35 and 43-56.
1536668|NCT02694718|Drug|Oxaliplatin|Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m^2/d intravenously on Day 1 and 50mg/m^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.
1536669|NCT02694705|Device|Continuous Positive Airway Pressure (CPAP)|CPAP provided by a portable Draeger Oxylog® 3000 plus ventilator
1536670|NCT02694705|Device|Bag-Valve-Mask (BVM)|Preoxygenation provided by BVM device, oxygen flow rate 15 l/min
1536671|NCT02694705|Device|Non-rebreather Mask (NRM)|Preoxygenation provided by NRM, oxygen flow rate 15 l/min
1536672|NCT02694692|Procedure|Vaccinations at 2, 6, 12 and 18 month|Participants will be invited back to IWK Health Centre at time points that correspond to their 2, 6, 12 and 18 month vaccinations and will receive their vaccinations according to Nova Scotia schedule.
1536705|NCT02694393|Drug|sodium nitrite|inhalation of 46 or 80 mg of sodium nitrite by electronic nebulization
1537251|NCT02689921|Drug|Letrozole|Aromatase inhibitor
1536673|NCT02694692|Behavioral|Neurodevelopment assessment at 18 corrected age|During the 18 month follow-up visit, the infants will also undergo neurodevelopmental assessment. Trained medical assessors also blind to original study group assignment will examine the child using the BSID-III Cognitive and Motor Sections. Participants will also be contacted at the infants 18 month corrected postnatal age for the BSIDIII. Parents will be asked to complete the Early Childhood Behaviour Questionnaire and the Brief Infant Toddler Social Emotional Assessment.
1536675|NCT02694666|Other|Controlled whole-body vibration training|The intervention is an 8-week program
1536678|NCT02694640|Behavioral|Reach Plus|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will no longer receive calls from RTR coaches and will be encouraged to use the heart rate monitors and pedometers during exercise. Participants will continue to complete their exercise logs and receive feedback reports from study staff."
1536679|NCT02694640|Behavioral|Reach Plus Phone|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, these participants will have the opportunity to continue to receive support calls from their coach. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
1536680|NCT02694640|Behavioral|Reach Plus Message|"In Months 1-3, participants in this group will receive the previously tested telephone counseling for exercise. RTR volunteers or coaches will be asked to contact participants by telephone weekly over 3 months (12 calls). In months 4-9, participants will receive messages by email or text to motivate, prompt and reinforce continued exercise. Participants will also continue to complete their exercise logs and receive feedback reports from study staff."
1536681|NCT02694627|Behavioral|MenCare+/Bandebereho fathers'/couples' group education|MenCare+/Bandebereho is a 3 year project to engage men in maternal, newborn and child health (MNCH) and in sexual and reproductive health in Rwanda. A core component of the project is fathers'/couples' group education. The target participants are first-time parents or parents of young children living in 16 rural and semi-urban sectors selected by the implementing partner in collaboration with local authorities. The MenCare+/Bandebereho fathers'/couples' group education engages men in 15 weekly sessions of group discussion, critical reflection and interactive activities led by a trained facilitator using a curriculum developed by RWAMREC and Promundo and approved by the Rwandan Ministry of Health, adapted from the Program P Manual. Men's partners participate in 6-8 sessions. The sessions focus on men's role in MNCH, family planning, sharing household responsibilities, intimate partner violence, conflict resolution, family budgeting, and gender equality.
1536682|NCT02694614|Behavioral|smartphone-assisted dietary coaching|
1536684|NCT02694588|Drug|Infliximab|HD-endoscopy, CLE, endoscopic ultrasound after application of TNF alpha antibody
1536685|NCT02694588|Drug|Vedolizumab|HD-endoscopy, CLE, endoscopic ultrasound after application of Anti-Integrin antibody
1536687|NCT02694549|Device|CaveoVasc|
1536688|NCT02694536|Drug|Erlotinib|Participants will receive erlotinib tablets as 100 milligrams (mg) orally (PO) once daily.
1536689|NCT02694536|Drug|Gemcitabine|Participants will receive gemcitabine as 1000 milligrams per meter-squared (mg/m^2) via intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 36, and 43 of the first 8-week cycle, and thereafter on Days 1, 8, and 15 of every 4-week cycle.
1536690|NCT02694523|Drug|ABBV-066|
1536691|NCT02694523|Biological|adalimumab|
1536692|NCT02694523|Drug|placebo for ABBV-066|Matching placebo for blinding purposes
1536693|NCT02694523|Biological|placebo for adalimumab|Matching placebo for blinding purposes
1536694|NCT02694510|Other|Light-protection of TPN solutions|TPN bags and infusion sets in the Light-protected group will be covered by aluminum foils to protect the inside TPN solution from exposure to ambient or photo-therapy lights in the NICU. Protection will be made throughout the study period until the infant reaches full feeding and TPN is discontinued.
1536695|NCT02694497|Other|Chlamydia care as usual|
1536696|NCT02694484|Other|Blood and stool samples|Blood sample at Day 1 and blood and stool sample at the next visit
1536697|NCT02694471|Behavioral|physical inactivity or bed rest with supervised recovery|All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
1536698|NCT02694458|Other|Early vancomycin monitoring and bayesian dosage adjustment|Measure of vancomycin serum concentration at the 3rd hour of treatment and adjustment of vancomycin dosage at the 6th hour of treatment using a bayesian approach. Then measure of vancomycin serum concentration at the 24th hour of treatment.
1536699|NCT02694458|Other|usual vancomycin dose and monitoring strategy|Vancomycin serum concentration will be measured at the 24th hour of treatment.
1536700|NCT02694445|Other|observation|The study is non-interventional.
1536701|NCT02694432|Behavioral|GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support.
1536702|NCT02694432|Behavioral|Minding GOALS|16 weeks of online support to improve blood pressure using traditional behavioral lifestyle approaches and medication adherence support, coupled with a mind-body-behavior program to further enhance improvements in blood pressure.
1536703|NCT02694419|Device|Doppler evaluation|Endometrial volume, endometrial and subendometrial vascularity indices are measured by 3D power Doppler
1536704|NCT02694406|Device|MRI perfusion|contrast-enhanced MR imaging including perfusion weighted imaging (PWI)
1536706|NCT02694367|Other|Investigate the MAP kinase signaling pathways through ERK and p-ERK proteins|
1536707|NCT02694354|Drug|BI 685509|
1536708|NCT02694354|Drug|Placebo|
1536709|NCT02694341|Procedure|Abdominal traction stitch|Abdominal traction stitch to prevent prolapse of the Bakri balloon. A suture is tied through the uterine end shaft hole of the Bakri balloon. The other end of the suture is placed through the uterine wall. The balloon is positioned in the lower segment.The abdominal traction stitch is held by forceps and fixed, with cephalad traction applied continuously to the balloon, preventing balloon prolapse.The abdominal traction stitch is fixed by an umbilical cord clamp on the abdominal wall, preventing the suture from receding into the abdominal cavity, and, thus, maintaining the correct position of the balloon and preventing prolapse. Removal of the balloon is easy, with no resistance; the suture does not hinder balloon removal. At the time of balloon removal, the suture that was placed through the abdominal wall will traverse the intra-abdominal and intrauterine cavities, and should be kept clean.
1536710|NCT02694341|Device|Bakri Balloon|
1536711|NCT02694328|Drug|ALKS 3831|Daily dosing
1536712|NCT02694328|Drug|Olanzapine|Daily dosing
1536713|NCT02694315|Other|Bishop score|calculation of modified Bishop score in numbers by digital vaginal examination
1536714|NCT02694315|Other|cervical length|measuring cervical length by trans-vaginal ultrasound
1536715|NCT02694302|Device|Walkbot|Walkbot(robot assisted gait training) 30 minutes and conventional physical therapy 30 minutes each per day to be administered 5 times a week for 3 weeks.
1536716|NCT02694302|Device|Conventional physical therapy|Conventional physical therapy 30 minutes to be administered twice a day, 5 times a week for 3 weeks.
1536717|NCT02694289|Drug|Metformin|Treatment/continuation of metformin therapy during admission
1536718|NCT02694289|Drug|Subcutaneous (sliding scale) Insulin|Discontinue Metformin and be placed on subcutaneous sliding scale insulin during admission
1536719|NCT02694276|Behavioral|Internet-based cognitive behavior therapy|The CBT treatment lasts for 10 weeks and includes the following: Education on the role of anxiety on cardiac function and the effects of symptom preoccupation and avoidance QoL and depression in AF, creating a vicious cycle; exposure to physical sensations that are similar to AF symptoms (e.g.,palpitations due to physical activity or stress) to reduce fear of these symptoms; exposure to situations or activities previously avoided and abolishment of behaviors that fruitlessly aim to prevent triggering of AF episodes or to control symptoms; and behavioral activation aiming to increase social and physical activity and reduce depressive symptoms. Therapist support is provided at least once weekly through the platform developed for the purpose. Therapists are trained CBT-psychologists.
1536725|NCT02694250|Device|DTRAX® Cervical Cage with DTRAX Bone Screw|DTRAX Cervical Cage is an intervertebral fusion device that provides mechanical support to the spine. DTRAX Cervical Cage is intended to be used in cervical spine fusion surgery. DTRAX Bone Screw is indicated for use in arthrodesis and provides supplemental fixation. .
1536726|NCT02694237|Behavioral|Model|Each participant will receive an informed consent discussion with the aid of an anatomic knee model.
1536727|NCT02694237|Behavioral|Knee Anatomy Video|Each participant will hear a scripted informed consent discussion while they watch a knee anatomy video orated by an interviewer.
1536728|NCT02694237|Behavioral|Verbal|Each participant will receive a verbal informed consent discussion without a visual aid.
1536733|NCT02694211|Behavioral|ProMES|Productivity measurement and enhancement system (ProMES) is a participatory intervention for productivity enhancement. Core strategies of this method could be addressing known work stressors such as absence of influence and control, insufficient interaction with coworkers, unclear and conflicting tasks, insufficient participation in decision-making and insufficient feedback
1536734|NCT02694198|Other|fetal fibronectin measurement|All patients will be put in the dorsal lithotomy position.Using a proper light source and sterile gloves, a sterile speculum free of lubricants will be placed into the vagina before vaginal examination by senior resident and the special Dacron swab from the FFN kit will be used to collect a sample of secretions from the posterior fornix. The sample should be obtained prior to collection of any vaginal wet preparations, before any cervical manipulation or cervical cultures, and if enough amount of fluid (about 2 ml) is not found, vagina will be washed with 2 ml of normal saline.The swab will be placed in sterile plastic containers which will be stored until assayed quantitatively with an Enzyme-Linked Immuno Sorbant Assay.
1536757|NCT02694003|Behavioral|BNBD-NDD Intervention|The intervention comprises 5 sessions, consisting of educational materials followed by interactive activities, designed to facilitate the successful application of the behavioural strategies. Clinicians and caregivers share tips and recommendations about implementing the strategies, providing modelling and emotional/social support, through supplemental videos. Caregivers complete daily internet sleep diaries that track sleep-related variables and patterns, associations between changes in caregivers' behaviour and children's sleep, and associations between changes in children's sleep and their daytime functioning. At the end of each session, caregivers receive a personalized plan for the week, linking relevant session strategies to caregivers' goals for their children's sleep.
1536735|NCT02694185|Other|Caplan IVR|This intervention will consist of: proactive real-time adherence monitoring of patients and targeting of individuals only when they have exhibited non-adherence behavior (i.e., if patients have not refilled their medication more than 4 or 7 days after it was due to be refilled). The intervention will employ a tailored, escalating-intensity approach which begins with some combination of personalized short messaging service (SMS) text messages and interactive voice response (IVR) telephone technology, depending on patient preference. Patients failing SMS and then IVR by not refilling their medication (or declining SMS and failing IVR) escalate to a trained research interventionalist (typically, a clinical pharmacist). The interventionalist will contact the patient and address adherence barriers based on the dimensions outlined by the World Health Organization (WHO) that are specific to each patient.
1536736|NCT02694172|Other|Fiber rich cereal bars|Two cereals per day and per subject for 4 weeks
1536737|NCT02694146|Drug|Platelet rich plasma|Platelet rich plasma (PRP) is a platelet concentrated obtained from autologous blood centrifugation. This concentration technique provides larger amounts of biologically active molecules, mainly growth factors that are responsible for tissue repair. PRP (platelet rich plasma) contains a higher concentration of platelets from baseline (150,000-350,000 / ul).
1536738|NCT02694146|Drug|Hylan G-F 20|Hylan G-F 20 is a viscous, sterile and non-pyrogenic elasto fluid containing hylan. Hylans are byproducts from hyaluronate (hyaluronic acid sodium salt), consisting of repeating disaccharides of N-acetylglucosamine and sodium glucuronate. Hylan G-F 20 replaces and supplements the synovial fluid. It is effective at any stage of the joint pathology.
1536739|NCT02694133|Procedure|Smart Phone Based Assistive Speech Therapeutic System|use the mobile device, which with the camera and speaker, for patients to practice the naming training at home, and assess the speech ability every 2-4weeks by speech therapist via telerehabilitation platform. Concise Chinese Aphasia Test (CCAT) will be used as the assessment tool for evaluation speech ability and functional ability.
1536740|NCT02694133|Procedure|Mobile phone-based tele rehabilitation program|Mobile phone-based tele rehabilitation program
1536741|NCT02694107|Other|Proprioceptive exercises|
1536742|NCT02694107|Other|Control|
1536743|NCT02694094|Dietary Supplement|Modified Atkins or Ketogenic Diet|Biochemical and vascular parameters will be compared from adults who have been on ketogenic diet therapy for > 12 months to adults naive to ketogenic diet therapy. In addition, adults naive to diet therapy who subsequently begin diet therapy will have these same parameters followed over time.
1536744|NCT02694081|Procedure|Uncut Roux-en-Y Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
1536745|NCT02694081|Procedure|Billroth II Reconstruction|All surgical procedures will be performed by the single surgery team ,which is leaded by professor Wang Quan. Uncut Roux-en-Y construction will be used in this group.
1536746|NCT02694068|Other|Peritoneal Equilibrium Test|These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.
1536747|NCT02694068|Other|4 hour dwell of 2.5/4.25% dextrose solution|If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
1536748|NCT02694055|Other|Proactive Community Case Management|CHWs will be trained and deployed to conduct daily active case finding home visits door-to-door for at least two hours each day, with the goal of visiting each household at least two times each month. At these active case finding home visits, CHWs will screen each household of sick children and will offer home pregnancy testing and family planning services to reproductive aged women. For patients they identify, they will offer counselling, diagnostic services, care, accompaniment, and referral according to a CCM service delivery package.
1536749|NCT02694055|Other|Integrated Community Case Management|CHWs will be trained offer counselling, diagnostic services, care, accompaniment, and referral according to a CCM service delivery package to patients that visit them at their work post.
1536750|NCT02694055|Other|Removal of point-of-care user fees|User fees will be removed across the catchment areas for both study and control villages. No fees will be charged for care by CHWs or at all primary care centres.
1536751|NCT02694055|Other|Infrastructure improvements at primary health centre|Targeted infrastructure improvements to rehabilitate, expand and equip the capacity of the seven government primary care centres in the study area. Each health center will be equipped with solar power.
1536752|NCT02694055|Other|Training of primary health centre staff|"Health center staff will receive targeted training in
Integrated management of childhood illness
Diagnosis and treatment of simple and severe cases of malaria
Helping babies breathe
Managing post-partum haemorrhage
Gestational dating using frontal height, last menstrual period and ultrasound
Family planning counselling and administration of long-acting contraceptives
Pharmacy stock management
Health center management"
1536753|NCT02694042|Behavioral|Mission is Remission®|A web-based teaching a support program for adolescents living with inflammatory bowel disease (IBD).
1536754|NCT02694029|Device|Active Breathing Coordinator (ABC)|The ABC system has a digital spirometer that records real time breathing.
1536755|NCT02694029|Device|VisionRT|A technology for implementing the deep inspiration breath-hold technique is real-time surface photogrammetry.
1536756|NCT02694016|Procedure|Remote ischemic preconditioning|A blood pressure cuff is placed around the right leg on the level of the thigh. Randomization is performed after this, using sealed envelopes with covariate balancing for age and sex. Regardless of the outcome of the randomization the cuff is left in place so as not to give any indication of which group the patient belongs to. If the patient is randomized into the remote ischemic preconditioning group (RIPC) then four (4) cycles of five (5) minute inflation are given after induction. Each cycle is followed by a five (5) minute interval of reperfusion. Cuff pressure should be 200mgHg at least (RRsyt + 100mmgHg) during the inflation periods.
1536758|NCT02693990|Radiation|Intensity Modulated Proton Therapy (IMPT)|Radiation Therapy - Intensity Modulated Proton Therapy (IMPT)
1536839|NCT02693392|Drug|Oral hypoglycemic agents (pre-specified) [Metformin, Sulfonylurea]|"Patients receiving either of the following oral hypoglycemic agents
Sulfonylurea based oral hypoglycemic agents
Metformin based oral hypoglycemic agents
Metformin plus Sulfonylurea based oral hypoglycemic agents"
1536759|NCT02693977|Procedure|Sleep Endoscopy|Sleep endoscopy will be performed prior to the adenotonsillectomy, under the same general anesthetic. The endoscopy will be performed using a flexible fiber optic endoscope which will be advanced trans nasally into the pharynx down to the level of the hypopharynx. We will take note of any obvious septal deviation or nasal obstruction as well as adenoid hypertrophy, and dynamic collapse at the level of the velum, oropharynx/lateral walls, tongue base, epiglottis, and supraglottis. Relatively fixed structures such as the nasal airway and adenoids should require 1 minute to fully assess. The endoscope will then be held for 2 minutes of observation above each subsequent site of potential dynamic airway collapse (the velum, oropharynx/lateral walls, tongue base, epiglottis/supraglottis).
1536760|NCT02693964|Other|Bone density and carotid ultrasound|All participants will be asked for relevant medical, personal, family and diabetes history, treatment and complications, and history of falls and fractures and will undergo measurement of bone density, carotid ultrasound and a blood draw.
1536761|NCT02693951|Drug|Cefotiam|Prophylactic use of antibiotics group: Half an hour before endoscopic treatment, cefotiam 2.0g intravenous
1536762|NCT02693938|Device|Follicular Euglycemic clamp|Follicular Euglycemic clamp during follicular phase
1536763|NCT02693938|Device|Luteal Euglycemic clamp|Luteal Euglycemic clamp during luteal phase
1536764|NCT02693912|Procedure|Bronchoscopy|Bronchoscopy will be implemented under sedation in both groups.
1536765|NCT02693899|Other|Non Interventional study|The samples of the study were made in conjunction with blood tests done routinely, no additional venipuncture is provided by the study. Flt3L plasma concentration will be measured at different time monitoring of patients according to their pathology (Acute lymphoblastic leukemia or acute myeloid leukemia). The exact number of samples will vary for each patient depending on the course of the illness, it is expected up to 15 blood tubes 9mL.
1536766|NCT02693886|Other|doctor experience|
1536767|NCT02693873|Behavioral|GLA:D Canada (education and neuromuscular exercise program)|"EDUCATION: 2 sessions cover OA topics (e.g. diagnosis, causes, risk factors, symptoms, treatment). Education also aims to strengthen beliefs in the value of exercise to control and improve pain and encourage exercise adherence after the program.
EXERCISE: 12 sessions (twice weekly, each about 1-hour) are supervised by therapist(s) with individual progression of exercises when good neuromuscular functioning is demonstrated. Exercises are performed using both legs and focus on sensorimotor control, functional stability, and muscular strength. Exercises involve a 10-minute cycle warm-up followed by a 4-station circuit (i.e. 2 exercises per station with 3 progressive levels of difficulty performed in 2 to 3 sets with 10 to 15 repetitions)."
1536768|NCT02693860|Drug|huJ591|Antibody is derived from a hybridoma originally produced in the Weill Medical College Laboratory of Urological Oncology. Treatment with 100 mg of HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute.
1536769|NCT02693860|Drug|89Zr−J591|Drug product is manufactured by the radiochemistry staff of Citigroup Biomedical Imaging Center (CBIC) research core facility. Radiolabeling of DFO−huJ591 with 89Zr is achieved by the addition of 89Zr−oxalate to the DFO−huJ591 in ammonium acetate buffer.
1536772|NCT02693821|Drug|Gabapentin|gabapentin 300 mg per day, orally during 30 days
1536773|NCT02693821|Other|Placebo|Placebo 300 mg per day, orally during 30 days
1536774|NCT02693808|Procedure|Autologous fat injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
1536775|NCT02693808|Procedure|Hyaluronic acid injection|Injection in one side with autologous fat and the other side with hyaluronic acid.
1536776|NCT02693795|Other|Baduanjin exercise|"A detailed description of a standardized Baduanjin exercise protocol complied with the Health Qigong Baduanjin Standard enacted by the General Administration of Sports in 2003."
1536777|NCT02693795|Other|aerobic exercise|Participants allocated to the usual exercise control group receive a closely supervised, group-format aerobic exercise program located on cardiac rehabilitation centre lasting 3 month. The program is consistent with the current recommended guidelines of moderate intensity exercises for MI.
1536778|NCT02693782|Dietary Supplement|Placebo|15 g/day maltodextrin in 3 portions of 5 g.
1536779|NCT02693782|Dietary Supplement|Fibre supplement|15 g/day Wheat Bran Extract in 3 portions of 5 g.
1536780|NCT02693769|Drug|fluticasone propionate/formoterol fumarate breath actuated inhaler|
1536781|NCT02693769|Drug|Indacaterol maleate / glycopyrronium bromide capsules|
1536782|NCT02693756|Other|Motor imagery|"The motor imagery intervention is a non-pharmacological and non-invasive treatment often used in sport, music, or physical rehabilitation (Schuster, Hilfiker et al. 2011). Proposed tasks to be imagined by the participants are for example:
Imagine you are walking on ice. During the first steps, you are slipping quite often, but as you walk on, your steps become more stable and you walk without problems over the ice. Try to imagine how you react when you slip on ice, how you try not to fall and to continue to walk normally The motor imagery intervention will be performed independently by the study participants at home without supervision three times a week for three weeks."
1536783|NCT02693743|Device|repetitive transcranial magnetic stimulation (rTMS)|A Neurostar TMS Therapy System and Neurostar XPLOR coil system (Neuronetics, Malvern, Pennsylvania) will be used to deliver stimulation.
1536784|NCT02693717|Drug|Pemetrexed|500 mg/m2 by vein on Day 1 of each 21-day cycle.
1536785|NCT02693717|Dietary Supplement|Folic Acid|5 daily doses of Folic Acid 400 µg by mouth taken during the 7-day period preceding the first dose of Pemetrexed; and dosing should continue during the full course of therapy and for 3 weeks after the last dose of Pemetrexed.
1536786|NCT02693717|Dietary Supplement|Vitamin B12|1000 μg administered as an intramuscular injection approximately 1 to 2 weeks prior to first dose of Pemetrexed and repeated approximately every 9 weeks until 3 weeks after the last dose of study therapy.
1536787|NCT02693717|Drug|Dexamethasone|4 mg of oral or equivalent by mouth given twice daily taken on the day before, the day of, and the day after each dose of Pemetrexed.
1536838|NCT02693405|Other|quality of life|measures of quality of life with questionnaires
1536914|NCT02692703|Drug|ABT-493/ABT-530|Tablet
1536915|NCT02692690|Device|Stimulette r4x|
1536917|NCT02692664|Device|Endovascular aorto-iliac repair|
1536788|NCT02693704|Device|Hearing Aids|The only intervention consists in applying a specific processing on some recorded speech signals, and comparing the performance obtained with such processed samples with ones that have not been processed. The applied processing is a binaural spatialization method that consists in filtering an original audio signal to get a left and right versions (for the two ears). The binaural rendering gives the impression that the speech signal (and thus the speaker) is located in a desired position in the environment.
1536789|NCT02693691|Device|CardioMEMS HF System|Pulmonary Artery Pressure Monitoring
1536790|NCT02693678|Other|Massage|
1536791|NCT02693678|Device|DIathermy|
1536792|NCT02693678|Device|Sham diathermy|
1536793|NCT02693665|Behavioral|FAmily CEntered Advance Care Planning for Teens with Cancer|3 session weekly intervention: 1) survey completed by adolescent and family (surrogate decision maker) separately with facilitator; 2) Respecting Choices structured interview about patient's representation of illness, goals of care, hopes, treatment preferences; 3) completion of an advance directive.
1536794|NCT02693652|Biological|CVI-HBV-002|"Investigational product: CVI-HBV-002
Dose: 20ug or 40ug
Frequency: 3 or 6 times
Vaccination schedule: 0, 1, 2 months or 0, 1, 2, 3, 4, 5 months
Administration route: Intramuscular injection"
1536795|NCT02693626|Behavioral|intensive cessation message|intensive mobile phone-based text message interventions ('Happy Quit') for smoking cessation for 12 weeks with 24 week follow up.
1536796|NCT02693613|Drug|ASP1517|Oral
1536797|NCT02693613|Drug|Kremezin®|Oral
1536798|NCT02693600|Procedure|Ligamentoplasty with partial trapeziectomy|
1536799|NCT02693600|Procedure|Ligamentoplasty with total trapeziectomy|
1536800|NCT02693587|Drug|Misodel and Angusta|
1536805|NCT02693535|Drug|Erlotinib|drug
1536806|NCT02693535|Drug|Axitinib|drug
1536807|NCT02693535|Drug|Bosutinib|drug
1536808|NCT02693535|Drug|Crizotinib|drug
1536809|NCT02693535|Drug|Palbociclib|drug
1536810|NCT02693535|Drug|Sunitinib|drug
1536811|NCT02693535|Drug|Temsirolimus|drug
1536812|NCT02693535|Drug|Trastuzumab and Pertuzumab|drug
1536813|NCT02693535|Drug|Vemurafenib and Cobimetinib|drug
1536814|NCT02693535|Drug|Vismodegib|drug
1536815|NCT02693535|Drug|Cetuximab|drug
1536816|NCT02693535|Drug|Dasatinib|drug
1536817|NCT02693535|Drug|Regorafenib|drug
1536818|NCT02693535|Drug|Olaparib|drug
1536819|NCT02693535|Drug|Pembrolizumab|drug
1536820|NCT02693535|Drug|Nivolumab and Ipilimumab|drug
1536821|NCT02693522|Drug|somatropin|Subcutaneous injection
1536822|NCT02693522|Drug|Eutropin|Subcutaneous injection
1536823|NCT02693509|Other|GWTG Heart Failure program|Evidence based guideline recommended therapies and counseling prior to hospital discharge
1536824|NCT02693496|Other|Installation or registration of smartphone application|Completed the installation and registration of mobile terminal software online
1536825|NCT02693483|Drug|10% povidone iodine|Vaginal cleansing will be done with 3 gauze pieces soaked with 10% povidone iodine in a sterilized bowl and the scrub will be done from the vaginal apex to introitus with attention to the anterior, posterior and lateral vaginal wall
1536826|NCT02693470|Drug|Ustekinumab|50 patients with severe psoriasis received ustekinumab 45mg at 0 and 1 month. There were 50 healthy controls. The levels of circulating CD31 and CD41a positive microparticles are measured. In patients with psoriasis, the investigators measure microparticles in the baseline and 4 months after ustekinumab. For control group, the investigators measure microparticles in the baseline.
1536827|NCT02693457|Procedure|Drain|One randomized knee will be assigned to receive an intra-articular drain procedure following bilateral total knee arthroplasty. The drain will be removed 24 hours post-operatively. The patient will be blinded to fluid output from intra-articular drain.
1536828|NCT02693457|Procedure|No Drain|The contralateral knee will be assigned to a placebo drain procedure following bilateral total knee arthroplasty. This will blind the patient as to which knee contains the functioning intra-articular drain. A non-suction/ non-functional subcutaneous drain will act as the placebo drain. This drain will not output any fluid and will also be removed 24 hours after post-operatively.
1536829|NCT02693444|Drug|Lidocaine|
1536830|NCT02693444|Drug|Saline|
1536831|NCT02693431|Other|Non interventional Study|"Parents and children will be informed at the inclusion visit (V0) that is a normal consultation under the care of the child.
The children included will be followed for 18 months with a maximum of 6 months without meeting art therapy sessions and 12 months with art therapy. The art therapy sessions will be scheduled during the usual consultations conducted as part of the care of children.
At each visit, clinical, paraclinical and external factors of anxiety will be collected and anxiety of parents and children will be measured using specific questionnaires."
1536832|NCT02693418|Drug|Acidform 5 g|Effect of 5 g vaginally administered Acidform on pH over 7 days
1536833|NCT02693418|Drug|Placebo 4 g|Effect of 4 g of vaginally administered HEC placebo gel on pH over 7 days
1536834|NCT02693418|Drug|Acidform 4 g|Effect of 4 g vaginally administered Acidform on pH over 7 days
1536835|NCT02693418|Drug|Acidform 3 g|Effect of 3 g vaginally administered Acidform on pH over 7 days
1536836|NCT02693405|Other|Executive functions|measures of executive functioning with tasks
1536837|NCT02693405|Other|social cognition|measures of socio-cognitive functioning with tasks
1537049|NCT02691494|Drug|Placebo|Placebo for 6-month Treatment
1536840|NCT02693392|Dietary Supplement|Fenugreek Seed extract|Patients recruited in the study arm will receive Capsule Fenfuro 500 milligram twice daily for 12 weeks as add-on intervention to the pre-specified oral hypoglycemic agents therapy
1536841|NCT02693379|Device|D-VIA|"D-VIA images were captured during the cervical examination with a smartphone. Biopsies and cytological samples were taken on all patients and analyzed for gold standard results. Images were shown to off site experts. D-VIA and VIA diagnoses were then compared.
Women who were diagnosed on-site as pathological underwent appropriate treatment at the same consultation. Women who were diagnosed as pathological later by histopathological analyses were asked to return to the clinic for treatment."
1536842|NCT02693366|Biological|Autologous Cell Transplantation|Endovascular infusion of bone marrow derived cells in both renal arteries.
1536843|NCT02693340|Biological|sampling|"• Sampling period(s):
Blood: W0, W6, W14, W30 and W52 and relapse.
Biopsies and fecal: W0, W14 and M52 and relapse."
1536844|NCT02693327|Other|Biological Sample|A one time sample will be collected.
1536845|NCT02693327|Other|Blood Sample|A one time blood sample will be collected.
1536846|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® (5 billion CFU/capsule)|One capsule containing 5 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
1536847|NCT02693314|Dietary Supplement|Jarro-Dophilus EPS® High Potency (25 billion CFU/capsule)|One capsule containing 25 billion CFU of the probiotic mix (Lactobacillus helveticus, Lactobacillus rhamnosus, Lactobacillus casei, Pediococcus acidilactici, Bifidobacteria breve, Bifidobacteria longum, Lactobacillus plantarum and Lactobacillus lactis ssp. lactis) will be taken once a day for a period of 28 days.
1536848|NCT02693314|Dietary Supplement|Placebo|One capsule (containing potato starch, magnesium stearate and ascorbic acid) will be taken once a day for a period of 28 days.
1536849|NCT02693301|Other|Exercise program|
1536850|NCT02693288|Procedure|Local infiltration anesthesia|Local infiltration by the surgeon at the end of surgery of perifracture site. A solution of 10 mL of ropivacaïne 0,75% is injected in the fracture site, tendon's synovial sheaths, subcutaneous tissue and skin.
1536851|NCT02693275|Device|Quotient® System iPad Test|See arm/group description
1536852|NCT02693262|Device|CLS Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
1536853|NCT02693262|Device|Accelerometer Mode on Biotronik CRT-D|Setting changed and monitored. Quality of life evaluated through CPET, 6 Minute Walk Test, and Rand 36 Questionnaire.
1536854|NCT02693236|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
1536855|NCT02693223|Other|GWTG Stroke program|Evidence based recommended therapies and counseling prior to hospital discharge.
1536856|NCT02693210|Drug|Cyclophosphamide|Participants will receive 750 mg infusions of cyclophosphamide on Days 3 and 17
1536857|NCT02693210|Drug|Methotrexate|Participants will receive >= 10 mg/week methotrexate orally up to 24 weeks
1536858|NCT02693210|Other|Placebo Cyclophosphamide|Participants will receive placebo in place of cyclophosphamide on Days 3 and 17
1536859|NCT02693210|Other|Placebo Methotrexate|Participants will receive weekly oral placebo in place of Methotrexate
1536860|NCT02693210|Other|Placebo Rituximab|Participants will receive placebo in place of rituximab on days 1 and 15
1536861|NCT02693210|Drug|Rituximab|Participants will receive 1g infusions of rituximab on Days 1 and 15
1536862|NCT02693197|Drug|T-817MA|A single oral dose of 448 mg
1536863|NCT02693184|Other|Full length Block 2014 Food Frequency Questionnaire|The food and beverage list includes 127 items, plus additional questions to adjust for fat, protein, carbohydrate, sugar, and whole grain content.
1536864|NCT02693184|Other|Revised Calcium, Vitamin D and Protein Screener|The food list includes 29 food items and 5 supplements
1536865|NCT02693171|Drug|Dinutuximab|Unituxin will be administered along with cytokines according to the prescribing information (see FDA-approved Unituxin Package Insert, March 2015; SmPC, August 2015).
1536866|NCT02693145|Other|Anti-Retroviral Treatment and Access to Services (ARTAS)|Anti-Retroviral Treatment and Access to Services (ARTAS) is an individual-level, multi-session, time-limited intervention with the goal of linking recently diagnosed persons with HIV to medical care soon after receiving their positive test result. ARTAS is based on the Strengths-based Case Management (SBCM) model, which is rooted in Social Cognitive Theory (particularly self-efficacy) and Humanistic Psychology. SBCM is a model that encourages the client to identify and use personal strengths; create goals for himself/herself; and establish an effective, working relationship with the Linkage Coordinator (LC).
1536870|NCT02693119|Drug|elamipretide (MTP-131) 1% topical ophthalmic solution|
1536871|NCT02693119|Drug|Vehicle topical ophthalmic solution|
1536873|NCT02693093|Drug|NI-03|
1536874|NCT02693093|Drug|Placebo|
1536875|NCT02693080|Radiation|Computed Tomography Perfusion Imaging|Undergo perfusion CT
1536876|NCT02693080|Other|Laboratory Biomarker Analysis|Correlative studies
1536877|NCT02693067|Drug|Rose bengal disodium|Percutaneous intralesional injection to NET tumor
1536878|NCT02693054|Device|HALO|Laser Treatment
1537050|NCT02691494|Drug|Elagolix|Elagolix for 6-month Treatment
1536879|NCT02693041|Drug|probiotic|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with LGG during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
1536880|NCT02693041|Drug|placebo|Low-risk women, women with prior preeclampsia and women with a prior preterm birth will be randomized to be treated with placebo during pregnancy. Effect on maternal and perinatal outcome as well as the effect of treatment on immunological and inflammatory biomarkers will be evaluated.
1536881|NCT02693028|Drug|Probiotic lozenges|The women participating in the study will take two probiotic lozenges per day (morning and evening) after meals.Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
1536882|NCT02693028|Drug|Placebo lozenges|The women participating in the study will take two placebo lozenges per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
1536883|NCT02693028|Drug|Probiotic capsules|The women participating in the study will take two probiotic capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
1536884|NCT02693028|Drug|Placebo capsules|The women participating in the study will take two placebo capsules per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
1536885|NCT02693028|Drug|Probiotic chewing gum|The women participating in the study will take two probiotic chewing gums per day (morning and evening) after meals. Enrollment will be done in gestational week 28-36. The treatment will last for the rest of pregnancy and six weeks post partum.
1536886|NCT02693002|Drug|Estradiol/Norethindrone acetate|Estradiol/Norethindrone acetate 1mg/0.5 mg
1536887|NCT02693002|Drug|Placebo|inactive ingredient
1536888|NCT02692989|Procedure|Hip fracture surgery and anesthesia|any operative fixation for hip fracture whether under General Anesthesia or Regional anesthesia
1996023|NCT02585973|Drug|AZD1775|AZD1775 given twice daily (BID) for three consecutive days (M-W) concomitantly with standard of care cisplatin and radiation. AZD1775 doses will be escalated in 50 mg increments up to 200 mg BID (M-W) in subsequent cohorts to determine the MTD.
1996024|NCT02585973|Drug|Cisplatin|40 mg/m2 IV infused over 1 hour D1 of each week of radiation
1996025|NCT02585973|Radiation|Intensity Modulated Radiotherapy Treatments|Total dose will be 70 Gy at 2Gy/fx, 35 fractions, M to Fri, for 7 weeks
1536892|NCT02692963|Biological|BCG vaccination|BCG vaccine InterVax
1536893|NCT02692950|Other|Honor My Decisions Advance Care Planning Video|Honor My Decisions is a commercial computer application which allows a person to record a video of his/her advanced care planning and legacy information.
1536894|NCT02692950|Behavioral|Post-video questionnaire|Questions regarding the video process, changes to previous answers and reaction received by others viewing the video
1536895|NCT02692937|Procedure|Neurolysis|
1536896|NCT02692937|Other|Traditional neck-specific exercise program|
1536897|NCT02692859|Biological|Hib conjugate vaccine|Children aged 3-5 months: 3-dose(0,28,56 d);Children aged 6-11 months: 2-dose(0,28 d);Children aged 1-5 years:one dose(0 d), 0.5ml for each dose
1536898|NCT02692833|Other|No intervention|No intervention. This is an observational study of how patients' renal function responds to their surgery. The groups are defined by this response. There is no difference between clinical interventions between the two groups.
1536899|NCT02692820|Dietary Supplement|Probiotic|The probiotic capsule contains the two probiotics Lactobacillus rhamnosus GR-1 (GR-1) and Lactobacillus reuteri RC-14 (RC-14). The product contains freeze-dried bacteria and excipients in a gelatin capsule;
1536900|NCT02692820|Other|Placebo Comparator|The placebo contains excipients alone in a gelatin capsule
1536901|NCT02692807|Procedure|Arthroscopic surgical procedures|See arm/group description of Arthroscopic surgery and sham surgery (HIPARTI). HARP: only arthroscopic surgery
1536902|NCT02692781|Drug|MOD-6031|
1536903|NCT02692781|Other|Placebo control|
1536904|NCT02692768|Other|Live Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive live music relaxation and education for practice using a CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
1536905|NCT02692768|Other|Recorded Music Therapy|Patients in this arm will meet with the music therapist to indicate preferences for one of three guided imagery scenarios to be included in their music-assisted relaxation routine. Patients will then receive explanation for using the recorded routine on CD. Once admitted for surgery, patients will be seen immediately prior to going to the OR in the SDU, immediately following surgery in the PACU, and then within 12-24 hours of surgery on the inpatient floor. Pain and anxiety measures will be gathered at routine follow-up appointments following discharge (2 weeks and 6 months post-operatively).
1536906|NCT02692768|Other|Control|Patients will receive standard of care without any music therapy intervention. These patients will have pain and anxiety measures taken at the same contact points as the music therapy intervention groups.
1536910|NCT02692729|Procedure|transverse supraumbilical|transverse Supraumbilical Incision, in which the skin incision is a straight transverse skin incision slightly higher than the Pfannenstiel (5- 6) cm. from the upper border of the symphysis pubis The high transverse incision facilitated access to the fascia of the rectus abdominalis
1536911|NCT02692729|Procedure|pfannenstiel incision|Pfannenstiel Incision, in which the skin incision is a transverse upward concavity, typically initiated two finger-breadths above the symphysis pubis and extended in the direction of the anterior superior iliac spine below and medial to it about (2 - 3 ) cm.
1536912|NCT02692716|Drug|semaglutide|For oral use once daily.
1536913|NCT02692716|Drug|placebo|For oral use once daily.
1996026|NCT02585154|Procedure|Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|'Classical' high-frequency Deep Brain Stimulation, which is applied irrespective of ongoing brain activity.
1536918|NCT02692651|Drug|Fidaxomicin|Eligible patients randomized to receive open-label Fidaxomicin will receive 200 mg twice daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
1536919|NCT02692651|Drug|Vancomycin|Eligible patients randomized to Vancomycin will receive 125 mg orally four times daily for 10 days or until the end of the duration of concomitant antibiotics exposure, whichever is longer.
1536920|NCT02692638|Procedure|Early laparoscopic enterolysis|The surgeon will make about 3-4 small incisions in the participant's abdomen. A port (nozzle) is inserted into one of the slits, and carbon dioxide gas inflates the abdomen. A laparoscope is inserted through another port. The laparoscope looks like a telescope with a light and camera on the end so the surgeon can see inside the abdomen. Surgical instruments are placed in the other small openings and used to cut the scar tissue in order to relieve the obstruction. After all this has been accomplished, the carbon dioxide is released out of the abdomen through the slits, and then these sites are closed with sutures or staples, or covered with glue-like bandage and steri-strips.
1536921|NCT02692638|Procedure|nonoperative management|Sometimes a bowel obstruction can be treated by suctioning out the contents of the stomach, giving IV fluids, and not letting the patient eat for a few days.
1536922|NCT02692625|Dietary Supplement|(L. reuteri Prodentis®).|The Test group is instructed to consume Probiotic lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every participating child.
1536923|NCT02692625|Dietary Supplement|Placebo lozenges|The control group is instructed to consume placebo lozenges for two months. The counts of salivary mutans streptococci and lactobacilli were evaluated using the CRT test at baseline, one-month, and two- months, from the beginning of the trial for every
1536926|NCT02692586|Device|FlowTriever System|
1536927|NCT02692573|Other|positioning|prone positioning for the initial 5 minutes of life
1536928|NCT02692573|Other|positioning|supine positioning for the initial 5 minutes of life
1536931|NCT02692547|Device|Hybrid-logic closed loop system|All patients get to wear the pump
1536932|NCT02692534|Other|Urine cocaine negative|Preoperative urine cocaine negative
1536933|NCT02692534|Other|Urine cocaine positive|Preoperative urine cocaine positive
1536934|NCT02692521|Dietary Supplement|Human Milk|
1536937|NCT02692469|Procedure|Duodenal Switch|Bariatric procedure
1536938|NCT02692469|Procedure|Duodenal-ileal Bypass with Sleeve Gastrectomy|Bariatric procedure
1536939|NCT02692456|Device|Double needle celiac neurolysis (DNCN)|CT guided celiac neurolysis will be performed using 2 needles inserted on each sides of aorta where patient was positioned in prone position
1536940|NCT02692456|Device|Single needle celiac neurolysis (SNCN)|CT guided celiac neurolysis will be performed through advancing a single needle to justfront of the aorta near the origin of celiac trunk where patient placed in lateral position
1536941|NCT02692443|Device|Magnetic Resonance Imaging|Brain MRI without Contrast
1536942|NCT02692443|Behavioral|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
1536943|NCT02692430|Other|No intervention is studied|
1536944|NCT02692417|Device|Transcutaneous Electrical Nerve Stimulation|Both arms will receive stimulation from the same TENS (transcutaneous electrical nerve stimulation) unit with identical stimulation frequency, but potentially different amplitudes depending on the subject's stimulation threshold.
1536945|NCT02692391|Drug|Indomethacin|Rectal indomethacin will be administered as 100 mg loading doses following by 5 maintenance doses of 50 mg at internals of 8 hours for total of 48 hours.
1536946|NCT02692391|Drug|Placebo|Glycerin placebo suppositories which are identical in shape, size, color, and packaging to rectal indomethacin
1536947|NCT02692378|Drug|sodium bicarbonate 500mg capsules|Defined by active substance and brand names not specified in protocol
1536948|NCT02692365|Procedure|Magnetic Resonance + hemodynamic + infusion of gadolinium|
1536949|NCT02692352|Other|Goal Management Training|Goal Management training, 8 sessions of 2 hours
1536950|NCT02692352|Other|Brain Health Workshop|Brain Health Workshop training, 8 sessions of 2 hours
1536951|NCT02692339|Drug|Lenalidomide|Standard of Care doses for relapsed/refractory multiple myeloma: 25 mg/day lenalidomide 21 of 28 days cycle
1536952|NCT02692339|Drug|Dexamethasone|Standard of Care doses for relapsed/refractory multiple myeloma: dexamethasone 40 mg/day at day 1,8,15,22 at 28 days cycle
1536953|NCT02692326|Procedure|Cyclic parenteral nutrition|Cyclic parenteral nutrition was provided according to a method described by Longhurst et al. Patients were initially cycled of PN for 1 hour per day with increased rate of 1 hour with a maximum time out of PN of 4 hours for preterm babies < 37 weeks GA and 6 hours for term newborns. Glucose was monitored at half the time without PN to detect the hypoglycemia.
1536954|NCT02692313|Drug|Epinephrine|Dose response of epinephrine infusion
1536955|NCT02692313|Other|Saline infusion|Placebo
1536956|NCT02692300|Procedure|EEG-Guided Group|Device: Bispectral Index (BIS) processed electroencephalogram
1536957|NCT02692287|Device|The PPH Butterfly|The PPH Butterfly is a simple, low cost device that has been developed to facilitate less invasive compression of the uterus in a PPH
1536958|NCT02692261|Procedure|Maxillary Sinus Augmentation|Each 0.5 cc Collagenated Heterolog Bone Graft, mixed with two bundles of Hyalossᵀᴹ matrix and a few drops of sterile saline solution
1536959|NCT02692261|Procedure|Maxillary Sinus Augmentation|Control group sinuses filled with heterolog bone graft alone
1536960|NCT02692248|Drug|Ibrutinib|Ibrutinib 560 mg daily for 14 days during induction cycles. Maintenance phase: Continuous cycles until disease progression or unacceptable toxicity (maximum of 2 years).
1536961|NCT02692248|Drug|Rituximab|Rituximab 375 mg/m2 IV day 1 during 4 cycles.
1536962|NCT02692248|Drug|Gemcitabine|Gemcitabine 1000 mg/msq IV (30-minute infusion) on day 1 or 2, 4 cycles every 14 days.
1536963|NCT02692248|Drug|Oxaliplatin|Oxaliplatin 100 mg/msq (3-hour infusion) on day 1 or 2, after Gemcitabine infusion, 4 cycles every 14 days.
1536964|NCT02692248|Drug|Dexamethasone|Dexamethasone 20 mg orally or IV on day 1 and orally on days 2-3, 4 cycles every 14 days.
1536968|NCT02692222|Other|Calculation of PPV and CO with two methods|
1536969|NCT02692209|Device|FFDM Plus DBT|"FFDM + DBT Images
FujiFilm Aspire Cristalle System"
1536970|NCT02692209|Device|FFDM Alone|FFDM Alone Images
1536971|NCT02692196|Device|Real-time fMRI neurofeedback from Turbo Brain voyager (TBV) 3.2|
1536972|NCT02692170|Biological|CVI-HBV-001|"Investigational product: CVI-HBV-001
Dose: 5, 10, 20 or 40ug
Frequency: 3 times
Vaccination schedule: at 0, 1, 6 months
Administration route: Intramuscular injection"
1536973|NCT02692170|Biological|Conventional Hepatitis B vaccine (20 μg)|"Active comparator: Conventional Hepatitis B vaccine (20 μg)
Dose: 20ug
Frequency: 3 times
Vaccination schedule: at 0, 1, 6 months
Administration route: Intramuscular injection"
1536974|NCT02692157|Drug|Placebo|Placebo for Neurokinin 1,3 antagonist
1536975|NCT02692157|Drug|NT-814 50 mg|Neurokinin 1,3 antagonist 50 mg
1536976|NCT02692157|Drug|NT-814 100 mg|Neurokinin 1,3 antagonist 100 mg
1536977|NCT02692157|Drug|NT-814 200 mg|Neurokinin 1,3 antagonist 200 mg
1536978|NCT02692144|Other|Test Cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
1536979|NCT02692105|Radiation|Low dose rate prostate brachytherapy|Permanent implantation of radioactive Iodine-125 seeds under anesthesia with ultrasound guidance
1536980|NCT02692105|Radiation|High Dose Rate prostate brachytherapy|Temporary implantation of radioactive material into the prostate in the form of a stepping source of Iridium 192 that travels through 16-18 needles or catheters strategically placed through the prostate
1536981|NCT02692079|Procedure|T-PRF|Flap Surgery
1536982|NCT02692079|Procedure|Allograft|Flap Surgery
1536983|NCT02692066|Biological|varicella vaccine|
1536984|NCT02692053|Biological|blood sampling|additional blood sampling (volume: 18 mL)
1536985|NCT02692040|Drug|G3215|Gut hormone analogue
1536986|NCT02692040|Drug|Placebo|0.9% saline
1536987|NCT02692027|Other|Same-day ART initiation|"Participants tested HIV-positive during community-based HIV testing and randomized to the intervention group receive post-test counseling and on-the-spot clinical and laboratory assessment. Directly after the positive HIV-test result the study nurse assesses the participant clinically and performs point-of-care laboratory baseline testing. Thereafter, the participant receives a standardized short adherence counselling. After adherence counseling the participant is offered to start ART immediately. Those who decide to start ART during the visit or intend to start within seven days will receive a 30 day ART-supply and an follow-up appointment at the clinic within 12 to 16 days.
In order to reduce travel time and transport cost, participants who are clinically stable, will have their follow-up visits and ART refills more widely spaced with appointments at 6 weeks, 3, 6, (9) and 12 months after ART initiation."
1536988|NCT02692027|Other|Standard of care|"Individuals found HIV-positive during the community-based HIV testing campaigns and randomized to the control arm receive post-test counselling and a referral letter with an appointment at their chosen health facility. On the first visit to the clinic, the participant receives laboratory assessment and a first adherence counselling session. The participant must then return to the clinic to receive his/her laboratory results and to undergo a second adherence counselling session.
Once the participant has started ART, the first and second follow-up visits are scheduled for 14 and 28 days after ART initiation, respectively. Thereafter, follow-up visits are scheduled monthly until 6 months after ART initiation. If the participant is clinically stable, clinical follow-up visits may then be spaced to 3-monthly intervals, but refills of ART must still be collected on a monthly basis."
1536989|NCT02692001|Other|Intervention MealTrain menu|"Nutrition education was incorporated using an interpretive traffic light system menu labeling. Dietitians categorized current menu items as green, yellow and red based on fiber, added sugar, saturated fats, and sodium content. A section entitled Eat like a superhero was created to prime children to consider what their potential role models choose, and incorporates descriptive names, suggest sample breakfast, lunch and dinner meals with photographs of portion sizes. Original cartoon female grapes and male broccoli superhero characters were created to employ promotional techniques specifically to promote fruits and vegetable selection for boys and girls."
1536990|NCT02691988|Other|ICS withdrawal|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.
1536991|NCT02691988|Other|Usual care|Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)
1536992|NCT02691975|Drug|SHR3680|SHR3680 is administrated orally, qd, 28 days as one cycle. Patients may continue SHR3680 until disease progression or unacceptable toxicity.
1536993|NCT02691962|Device|XenMatrix AB|XenMatrix™ AB Surgical Graft is an acellular, sterile, non-pyrogenic porcine dermal matrix packed dry for use in the reconstruction of soft tissue deficiencies. The device surfaces are coated with the antibacterial agents Rifampin and Minocycline in a bioresorbable L-Tyrosine succinate polymer carrier.
1536994|NCT02691949|Drug|Mycophenolate mofetil|mycophenolate mofetil 1# BID-2# BID
1536995|NCT02691936|Device|CO2 fractionated vaginal laser|Intravaginal treatment with fractional microablative CO2 laser at baseline, 6 weeks and 3 months
1536996|NCT02691936|Drug|Estrogens, Conjugated (USP)|Conjugated estrogen cream 0.5g (equivalent of 0.625 mg of conjugated estrogen) daily for two weeks then twice weekly for 24 weeks
1536997|NCT02691923|Drug|Fluorescein|
1536998|NCT02691923|Drug|Fluorescein + ALA|
1536999|NCT02691910|Drug|Chloroquine|10mg/kg on day 0 and 7.5mg/kg on days 1 and 2. Total dose, 25 mg base/kg. Tablet containing 150mg of base.
1537000|NCT02691910|Drug|Primaquine|0.5 mg/kg once a day, for seven days. Total dose, 3.5mg/kg.
1537001|NCT02691897|Drug|Melatonin|Melatonin 3mg once daily at bedtime
1537002|NCT02691897|Drug|Placebo|Placebo 1 tablet once daily at bedtime
1537003|NCT02691884|Procedure|maternal abdominal pressure|The fetal cardiac response of either acceleration, deceleration or no change at all to the fetal heart- will be recorded and later on analyzed in reference to the amount of pressure applied from the 20th minute of CTG and for 5 minutes, using the FSR 400 sensor.
1537004|NCT02691871|Drug|Apatinib (250 mg/d) + Docetaxel (60 mg/m2)|
1537005|NCT02691871|Drug|Apatinib (500 mg/d) + Docetaxel (60 mg/m2)|
1537006|NCT02691871|Drug|Apatinib (750 mg/d) + Docetaxel (60 mg/m2)|
1537007|NCT02691858|Drug|Hydrocortisone|10 mg/kg with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
1537008|NCT02691858|Drug|Saline|100 ml with Resuscitation before attempting pneumatic reduction, single dose with Resuscitation before attempting reduction
1537009|NCT02691845|Behavioral|BA (brief advice)|
1537010|NCT02691845|Behavioral|SHE (supervised and home-based exercise)|
1537011|NCT02691845|Behavioral|HE (health education)|
1537012|NCT02691845|Behavioral|CBEX (cognitive-behavioral sessions focused on increasing and maintaining exercise)|
1537013|NCT02691832|Device|"Dräger double sensor"|"The Dräger Double Sensor is a novel non-invasive device for assessing core body temperature."
1537014|NCT02691819|Device|single stent and embedded balloon angioplasty|
1537015|NCT02691806|Other|experimental protocol|"first day- VO2max test with the following measurements: anaerobic threshold, maximum oxygen consumption, heart rate and breathing indices.
second day- performing the same physical protocol of VO2max test with the measurements: leg muscles activity using a wireless EMG, hemodynamic measurements of oxygen levels in the skin and skin perfusion, the two latest using optic sensors."
1537016|NCT02691793|Drug|Sunitinib|sunitinib 37.5mg QD
1537017|NCT02691780|Drug|Sorafenib|
1537018|NCT02691767|Drug|pazopanib|
1537019|NCT02691754|Other|free paracetamol|General Practitioners can prescribe paracetamol and the patient had to pick up the drug at the local hospital.
1537020|NCT02691728|Drug|LDV/SOF FDC|
1537021|NCT02691715|Procedure|Endometrial saline plus curettage|
1537022|NCT02691715|Procedure|Endometrial curettage|
1537023|NCT02691702|Drug|PF-05251749|Multiple ascending doses of PF-05251749 (50 mg, 150 mg, 450 mg and 900 mg) as extemporaneously prepared solution/suspension administered once daily over 2 weeks
1537024|NCT02691702|Drug|Melatonin|Positive control used to assess the validity of DLMO as pharmacodynamic endpoint.
1537025|NCT02691689|Other|Genetic testing|Genetic testing by DNA sequencing on blood samples after DNA extraction
1537026|NCT02691676|Drug|Plasmalyte|Parenteral administration of Plasmalyte initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
1537027|NCT02691676|Drug|Ringerfundin|Parenteral administration of Ringerfundin initiated immediately after collection of the first blood sample at 166 mL/hour. Thus, all patients received 1000 mL of infusion solution over 6 hours.
1537028|NCT02691663|Dietary Supplement|Oral bicarbonate supplementation|
1537029|NCT02691663|Dietary Supplement|Placebo|
1537030|NCT02691598|Drug|Infusion|Dexmedetomidine Hydrochloride or normal saline 4ug/ml；0.05ml/kg.h infusion for 24hours
1537031|NCT02691585|Other|Music Intervention|A raga will be played for 10 minutes & data collected.
1537032|NCT02691572|Procedure|Spinal anesthesia|Performed at the L3-4 or L4-5 interspace using 27- or 25-gauge spinal needle.
1537033|NCT02691572|Drug|Intrathecal bupivacaine|Bupivacaine 12.5 mg will be administered in the subarachnoid space.
1537034|NCT02691572|Drug|Intrathecal fentanyl|Fentanyl 15 µg will be administered in the subarachnoid space.
1537035|NCT02691572|Procedure|Cesarean delivery|Lower segment cesarean section using the Pfannenstiel incision and exteriorization of the uterus.
1537036|NCT02691572|Procedure|Wound infiltration|30 mL bupivacaine 0.25% will be injected subcutaneously in the surgical wound (15 mL on the upper and lower sides) by the obstetrician before skin suturing.
1537037|NCT02691572|Procedure|Sham procedure|Sham procedure will be performed after surgery by moving the ultrasound probe and pressing a covered spinal needle on both sides of the patients` abdomen.
1537038|NCT02691572|Procedure|Transversus abdominis plane block|Bilateral ultrasound-guided TAP block using 20 mL bupivacaine 0.25% on each side. A 7-12 MHz linear array probe and 22-gauge needle will be used. The probe will be placed transversely above the iliac crest in the anterior axillary line and the needle will be introduced in-plane with the probe from medial to lateral.
1537039|NCT02691572|Drug|Ketorolac|IV ketorolac 30 mg/8 h starting at the end of surgery.
1537040|NCT02691572|Drug|Paracetamol|Oral paracetamol 1 gm/8 h starting 4 h after surgery.
1537041|NCT02691572|Procedure|Fentanyl patient-controlled analgesia|Intravenous fentanyl: bolus dose = 20 µg, lockout interval = 7 min, 4-h dose limit = 200 µg, with no background infusion.
1537042|NCT02691559|Device|Amniotic fluid analysis by blood gas device|Amniotic fluid analysis by blood gas device in maternal inflammation group vs normal pregnancy group
1537043|NCT02691546|Other|blood sample collection|
1537044|NCT02691533|Drug|ω3 PUFA (Polyunsaturated fatty acids) (10% Omegavan 100 ml)|
1537045|NCT02691533|Drug|ω6 PUFA (Polyunsaturated fatty acids) (10% Intralipid 100 ml)|
1537046|NCT02691533|Drug|No Lipid Emulsion/Placebo|
1537047|NCT02691507|Device|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
1537048|NCT02691507|Drug|Experimental Product 1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
1537051|NCT02691494|Drug|Estradiol/Norethindrone Acetate|Elagolix+Estradiol/Norethindrone Acetate for 6-month Treatment
1537052|NCT02691481|Dietary Supplement|Oatmeal breakfast|
1537053|NCT02691481|Dietary Supplement|Glucerna formula|
1537054|NCT02691481|Dietary Supplement|Ultra Glucose Control formula|
1537055|NCT02691468|Device|PVC DLT|PVC DLT is type of double lumen tube that is composed of PVC
1537056|NCT02691468|Device|silicon DLT|silicon DLT is type of double lumen tube that is composed of silicon
1537057|NCT02691455|Device|Baerveldt Glaucoma Implant 350-mm2 / BG101-350|
1537058|NCT02691455|Procedure|Transscleral Diode Laser Cyclophotocoagulation|Recommended setting are 2000 milliwatt (mW) for 2 seconds, 1850 mW for 3 seconds or 1750 mW for 4 second duration, titrating the energy up or down just below where a pop is heard.
1537059|NCT02691455|Device|Ahmed Model FP7 Flexible Plate|
1537060|NCT02691455|Device|Baerveldt Glaucoma Implant 250-mm2 / BG103-250|
1537061|NCT02691442|Drug|Ropivacaine 0.75%|The investigators adminster 5ml of Ropivacaine 0.75% in an ultrasound-guided inter scalene nerve block
1537062|NCT02691442|Drug|Levobupivacaine 0.5%|The investigators adminster 5ml of Levobupivacaine 0.5% in an ultrasound-guided inter scalene nerve block
1537063|NCT02691442|Drug|Levobupivacaine 0.5% + epinephrin 1/200000|The investigators adminster 5ml of Levobupivacaine 0.5% + epinephrin 1/200000 in an ultrasound-guided inter scalene nerve block
1537064|NCT02691429|Other|Acai dye 10%|dye to be used during chromovitrectomy in humans
1537065|NCT02691416|Drug|propofol postconditioning|administrated Target Controlled Infusion(TCI) of propofol (Cp 1.2ug/ml) and decreased sevoflurane with a Bispectral index (BIS) value of 40-60 to maintain anesthesia after clamp removal
1537066|NCT02691416|Drug|sevoflurane|0.5%-2% sevoflurane with BIS 40-60
1537067|NCT02691403|Drug|levo-bupivacaine|
1537068|NCT02691403|Drug|normal saline|
1537069|NCT02691390|Device|dTMS|dTMS to ACC
1537070|NCT02691390|Device|dTMS|SHAM - no stimulation
1537071|NCT02691377|Device|acupuncture group|Acupoints include 11 on the head, two on the upper extremities, and two on the lower extremities. Before performing acupuncture, a small pad will be pasted on each acupoint. All the needles will insert the acupoints through these pads. Then, they will be twirled, lifted and thrust three times to elicit the Deqi sensation. Each session will last 30 minutes.
1537072|NCT02691377|Device|Sham Acupuncture group|The same acupoints with acupuncture group are selected.A placebo needle with a blunt tip will be used to perform sham acupuncture. They will only insert the pad and no skin penetration. The same procedure with acupuncture group will be performed.
1537073|NCT02691364|Procedure|Blood withdrawal|
1537075|NCT02691338|Other|EEG|EEG analysis
1537076|NCT02691338|Other|Routine follow up tests|Routine tests for patients after CVA. This include: neurologic evaluation, Brain CT, Angiography
1537077|NCT02691325|Drug|GSK2269557 ELLIPTA DPI|GSK2269557 ELLIPTA DPI contains GSK2269557 blended with lactose and magnesium stearate. This will be supplied in two strength of 100 mcg per blister.
1537078|NCT02691325|Drug|Placebo ELLIPTA DPI|Placebo ELLIPTA DPI contains lactose.
1537079|NCT02691325|Drug|Activated charcoal|The activated charcoal will be supplied by the clinical site. Charcoal will be administered as a suspension of 5 gram activated charcoal in 40 mL of water. The suspension will be made to drunk, in its entirety.
1537080|NCT02691312|Device|Digital Retinography System|The DRS is a portable non-mydriatic fundus camera in which children place their chin on a chin rest and the camera, after auto-focusing, takes photographs of their retinas. These photographs will be examined by an ophthalmologist (specializing in retinal disease) to assess for evidence of diabetic retinopathy.
1537081|NCT02691299|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
1537082|NCT02691299|Drug|Placebo|Placebo is a capsule in the form of 5mg and 1mg, orally once daily. 3 weeks on/1 week off
1537083|NCT02691273|Behavioral|cellular application treating diabetes using breathing technique|
1537084|NCT02691260|Behavioral|incentives for dietary self-monitoring|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application.
1537085|NCT02691260|Behavioral|incentives for interim weight loss|Participants will receive intermittent financial incentives for losing an expected amount of weight based weight obtained weekly.
1537086|NCT02691260|Behavioral|incentives for both|Participants will receive intermittent financial incentives for recording their dietary intake on a dietary mobile phone application and for losing an expected amount of weight based on weight obtained weekly.
1537087|NCT02691247|Biological|CLBS03 Low Dose|
1537088|NCT02691247|Biological|CLBS03 High Dose|
1537089|NCT02691247|Biological|Placebo|
1537090|NCT02691234|Device|Extracorporeal Shockwave Therapy and debridement|
1537091|NCT02691234|Other|debridement and cleaning|
1537092|NCT02691221|Behavioral|Relief Link Application Daily Tasks|Participants will complete daily mood tracking and completion of a minimum of one stress management activity per day. Relaxation exercises to choose from on the current version of RL are audio files (i.e., no visuals), and consist of: Guided Meditation, Energizing Breath, Guided Visualization for Relaxation, Progressive Relaxation, Mindfulness Meditation Body Scan, and Mindfulness of Breathing.
1537093|NCT02691208|Other|Kinesiotherapy|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes.
1537094|NCT02691208|Other|Acupuncture|Standard therapeutic exercise, pre-defined, based on stretching the neck muscles, shoulder girdle and upper limb exercises for ADM lasting 30 minutes plus 30 minutes of classical acupuncture using predefined points.
1537095|NCT02691195|Drug|Ropivacaine|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.5% ropivacaine 0.4ml/Kg.
1537096|NCT02691195|Drug|0.9% Nacl|patients were received an ultrasound-guided serratus plane block, the serratus plane was injected with 0.9% Nacl 0.4ml/Kg.
1537097|NCT02691182|Drug|SPN-810|
1537252|NCT02689921|Drug|Anastrozole|Aromatase inhibitor
1537102|NCT02691143|Other|TheraBand Kinesiology Tape|One approach to treating musculoskeletal conditions is a elastic therapeutic taping technique designed to target muscles and lymphatic system. Limited research on the efficacy of elastic therapeutic taping (ETT) is available for specific patient populations, including neck pain. ETT it is theorized to impact muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment. In a study by Gonzalez-Iglesias et al. the investigators reported that neck pain and range of motion significantly improved immediately and 24 hours after the application of ETT in acute whiplash patients as compared to a sham taping.
1537103|NCT02691130|Biological|Multimeric 001 (M-001)|Multimeric 001 is a recombinant protein comprising 9 conserved peptides from influenza A and B
1537104|NCT02691130|Biological|H5N1 influenza vaccine|Alum adjuvanted whole virion inactivated H5N1 vaccine produced by FluArt (Hungary)
1537105|NCT02691130|Biological|Saline|0.9% NaCl in double distilled water
1537106|NCT02691117|Drug|garlic concentrate|Topical application of GarlicRich gel on the scalp areas affected with alopecia areata once a day for 6 months
1537107|NCT02691104|Device|SMART COPD app to promote physical activity in COPD. Used in conjunction with a Fitbit Charge|An app which allows users to set physical activity goals, monitors progress towards those goals, and provides feedback to users. Several options for types of physical activity (daily walk, daily step count, and aerobic / strengthening exercises) which can be tailored to the individual user. Designed to be used in consultation with a physiotherapist initially, and then used independently by the individual with COPD. The app will first be used alongside pulmonary rehabilitation (PR), with physiotherapist advice on exercises and setting goals. After PR the individual with COPD will receive weekly contact from a physiotherapist for the first 4 weeks, and then no contact for the second 4 weeks
1537108|NCT02691104|Device|Control|Participants will follow the (usual care) PR programme. They will be asked to wear a blinided (cannot see step count) Fitbit Charge during the time they are on PR and then for 8 weeks afterwards
1537109|NCT02691078|Other|99m Tc - HYNIC -TOC EDDA and 111In - DTPA-octreotide|The patient will undercome an PET/CT exam with 99m Tc - HYNIC -TOC EDDA, after 20 days of wash out, the same patient will undercome the same exam with 111In - DTPA-octreotide in order to compare both radiopharmaceuticals
1537110|NCT02691065|Drug|Integrase Inhibitor|
1537111|NCT02691052|Other|Quality of Life questionnaire|EORTC QLQ-C30 questionnaire
1537113|NCT02691013|Drug|Ramelteon|
1537114|NCT02691013|Drug|Placebo|
1537115|NCT02691000|Device|LiteBook|Light therapy using a Bright White Light Litebook for 1 hour each morning for 8 weeks. This is the experimental intervention.
1537116|NCT02691000|Device|LiteBook|Light therapy using a Dim Red Light Litebook for 1 hour each morning for 8 weeks. This is the control.
1537117|NCT02690987|Drug|Exenatide|"Exenatide is a commercially available GLP-1 receptor agonist. It is a synthetic form of exendin-4, a protein extracted from the saliva of a Gila monster lizard, which exhibits 53% sequence identity to human GLP-1.
The planned intravenous Exenatide infusion dose is expected to be 0.06 pmol/kg/min aiming for maintenance plasma concentrations of ~130-190 pg/mL."
1537118|NCT02690987|Biological|Desacyl ghrelin|"Ghrelin is a 28 amino acid stomach-derived peptide hormone, with the desacyl ghrelin (DAG) form inactive at the GHSR1a receptor. GMP-grade DAG is obtained from Clinalfa (Bachem AG, Bubendorf, Switzerland).
The planned intravenous DAG infusion dose is expected to be 4.0 mcg/kg/hour aiming for maintenance plasma concentrations of ~13-19 ng/mL."
1537119|NCT02690987|Biological|Saline|The placebo visit will involve an intravenous infusion of normal saline.
1537121|NCT02690961|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
1537122|NCT02690961|Drug|placebo multiple doses|
1537123|NCT02690948|Biological|Pembrolizumab|Given IV
1537124|NCT02690948|Drug|Vismodegib|Given PO
1537127|NCT02690922|Drug|Dasatinib|100mg (d1-d84)
1537128|NCT02690922|Drug|prednisone|60mg/m2 d1-24
1537129|NCT02690922|Drug|dexamethasone|10mg/d 3-7days
1537130|NCT02690922|Drug|methotrexate|3g/m2 1day
1537131|NCT02690909|Device|Redy™ Renal Denervation System|Renal Denervation System
1537132|NCT02690896|Behavioral|UCF Caregiver Support Group|The intervention will be a 90 minute group session, once a week, for a period of 6 consecutive weeks. The intervention will teach caregivers specific behavioral techniques for managing care recipients' symptoms in the home environment and encourage caregiver self-care.
1537133|NCT02690896|Behavioral|Community Support Groups|Comparison group members will come from local community support groups, which typically include components of social support and limited psychoeducation, and are relatively unstructured.
1537134|NCT02690883|Drug|Exenatide|Exenatide (Astrazeneca ) 5 μg(initial dose)/10ug(maintenance dose) Subcutaneous injection Bid
1537135|NCT02690883|Drug|Lispro|Lispro (Eli Lilly), the dosage is initiated according to the previous treatment plan and weight of the patients, distribute the dosage to 1:1:1 before 3 meals, titration following PPG <10.0mmol/L.
1537136|NCT02690870|Drug|Tamoxifen|Patients in the tamoxifen group will take 20 mg of tamoxifen oral tablets daily from day 3 of the menses for 5 days.
1537137|NCT02690870|Drug|Clomiphene|Patients in clomiphene group will take 100 mg of CC oral tablets daily from day 3 of the menses for 5 days.
1537138|NCT02690857|Drug|Docosahexaenoic acid|
1537139|NCT02690857|Drug|Sunflower Oil|
1537140|NCT02690844|Drug|Clonazepam mixed with Mucolox®|1mg clonazepam in 5mL Mucolox® will be used TID. Mixture will be swished around mouth for 3 minutes then spat out.
1537253|NCT02689921|Drug|Leuprolide Acetate|Luteinizing Hormone-Releasing Hormone agonist
1537141|NCT02690844|Drug|Mucolox® alone|5mL Mucolox® TID. Mixture swished around mouth for 3 minutes then spat out.
1537142|NCT02690844|Drug|Clonazepam|1mg Clonazepam tablet will be used TID. Tablet dissolved in mouth, swished around and then expectorated.
1537143|NCT02690831|Other|Inspiratory Muscle training (IMT)|Inspiratory Muscle training This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
1537144|NCT02690831|Other|IMT + Manual Therapy and Motor Control Exercise|IMT + Manual Therapy and Motor Control Exercise The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
1537145|NCT02690831|Device|Powerbreathe|
1537147|NCT02690805|Device|MR-compatible scinti-mammography (MRI-SMM) system|
1537148|NCT02690792|Other|NAFLD/NASH - Placebo|Placebo capsules, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
1537149|NCT02690792|Dietary Supplement|NAFLD/NASH - Vitamin E|Vitamin E 200 IU capsule, 2 capsules by mouth each morning and 2 capsules by mouth each evening for 4 months.
1537150|NCT02690779|Other|Educational intervention|2-3 minute video demonstrating video images of adequate and inadequate bowel preps, and reviewing instructions for split dose prep administration.
1537151|NCT02690779|Other|Routine Care Instructions|patients will follow routine care and instructions
1537152|NCT02690766|Behavioral|Standard Behavioral Weight Change Intervention|Participants enrolled in Phase 2 of the study will meet once a month for 75 minutes over the course of 4 months. Within this 75 minutes, they will complete 25 minutes of physical activity with a licensed physical activity instructor that is very experienced with working with this population, review and discuss various topics/lessons that relate to diabetes, nutrition, survivorship and physical activity with the study's interventionist and Group Leader
1537153|NCT02690753|Procedure|A protocol tailored to individual risk factors|
1537154|NCT02690753|Device|The Prevalon® Turn and Position System 2.0|
1537155|NCT02690753|Device|Comfort Shield® barrier cream cloths|
1537156|NCT02690740|Other|(diagnostic) conjunctival provocation test with solution: ALK 100, 1.000, 10.000, 20.000, 50.000 and 100.000 SQ-U/ml|"see information in arm/group descriptions"
1537157|NCT02690727|Drug|RP6530|Single oral dose
1537158|NCT02690714|Biological|Plasminogen (human) intravenous|ProMetic Plasminogen(human) intravenous
1537159|NCT02690701|Biological|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 48 inclusive. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring on days of study visits will be done by the patients (or caregivers) at home.
1537160|NCT02690701|Biological|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3, 4), then after four weeks at Week 8. At Week 12, patients will be switched to receive 300 mg secukinumab once weekly for five weeks (Weeks 12, 13, 14, 15, 16) followed by monthly dosing through Week 48 inclusive. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring on days of study visits will be done by the patients (or caregivers) at home.
1537161|NCT02690688|Device|determination of dynamic preload variables|
1537162|NCT02690675|Dietary Supplement|Iron fortified formula milk|One group received formula milk fortified with 1.2 mg/100 mL and the other group 0.4 mg/100mL between 6 and 12 months of age.
1537163|NCT02690662|Behavioral|Hypocaloric diet|recommendation of daily ingestion of 2500 ml of water and low-calorie diet of 16 Kcal/kg bw/day
1537164|NCT02690649|Other|Health Messaging (Non-Procedural)|Tailored health messaging delivered via the PHR MyChart pertinent to non-valvular atrial fibrillation and anticoagulant use. Messages will be triggered by medication non-adherence information obtained from Surescripts e-prescribing data and use of AdhereTech smart pill bottle.
1537165|NCT02690636|Radiation|radiotherapy|daily fractions, five fractions per week.
1537166|NCT02690623|Other|Pediatric hospitalist program|In-house hospitalists available at all hours
1537167|NCT02690623|Other|General Pediatric Inpatient Services|Inpatient care by general pediatrics faculty
1537168|NCT02690610|Procedure|EBUS TBNA of mediastinal lesions or lymph nodes|Through endo-bronchial ultrasound, a transbronchial needle will be introduced to take biopsies from mediastinal lesions under ultrasonic guidance.
1537169|NCT02690597|Other|Anxiety visual analog scale|Anxiety visual analog scale is a test of evaluation of anxiety done by the patient, this scale do not include number and the patient have to place a coloured marker at the level indicating his anxiety feeling
1537171|NCT02690571|Other|Bronchoscopy|The bronchoscopy procedure was performed six hours after completion of the exposure session, with sampling of endobronchial mucosal biopsies, bronchial wash and bronchoalveolar lavage performed under topical anaesthesia.
1537172|NCT02690558|Drug|pembrolizumab, gemcitabine and cisplatin|neoadjuvant administration of pebrolizumab with gemcitabine and cisplatin prior to cystectomy
1537173|NCT02690545|Biological|ATLCAR.CD30 cells|For Phase Ib two doses will be investigated: 1x10^8 cells/m^2 and 2x10^8 cells/m^2. Phase II patients will receive the dose level decided upon in Phase I.
1537174|NCT02690519|Drug|GLPG1837 dose 1|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
1537175|NCT02690519|Drug|GLPG1837 dose 2|one GLPG1837 tablet in the morning and one GLPG1837 tablet in the evening, for 2 weeks
1537176|NCT02690506|Drug|Placebo|
1537177|NCT02690506|Drug|Pregabalin|
1537246|NCT02689960|Drug|100mg prednisone suppository|vaginal administration of 100mg prednisone suppository (Rectodelt)
1537247|NCT02689947|Device|Restylane Silk|
1537178|NCT02690493|Procedure|Acupuncture|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, three times a week, during twelve sessions.
1537179|NCT02690493|Other|Functional Taping|Elastic taping is positioned directly on the skin (on the back of the fingers, hand, forearm and arm - paretic upper limb), three times a week, during twelve sessions. The patient should keep the taping on the skin for two days.
1537180|NCT02690493|Other|Acupuncture and Functional Taping|Acupuncture needles are inserted in specific acupuncture points on the boby (three points on both forearms and five points on the top of the head) for twenty minutes, then elastic taping is positioned directly on skin (on the back of the fingers, hand, forearm and arm - paretic upper limb). Both procedures are performed three times a week, during twelve sessions.
1537181|NCT02690480|Drug|PD-0332991 (Palbociclib)|"Palbociclib, 125 mg, orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
1537182|NCT02690480|Drug|Fulvestrant|"Fulvestrant 500mg, two 5ml intramuscular injections (one in each buttock), on days 1, 15 (±3 days) of Cycle 1, and then on Day 1 of each subsequent 28 day cycle (±3 days)
Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs first"
1537183|NCT02690480|Drug|Placebo|"Placebo orally once daily from day 1 to day 21 followed by 7 days off treatment on every 28 days cycles.
Patients will continue to receive their assigned treatment until objective disease progression, clinical progression (under investigator criteria), unacceptable toxicity, death or withdrawal of consent, whichever occurs firs"
1537184|NCT02690467|Device|Insupen G34x3,5mm|
1537185|NCT02690467|Device|Insupen G32x4mm|
1537186|NCT02690441|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy conducted individually. 10 weekly sessions, first session lasts 90 minutes, the remaining sessions last 45 minutes.
1537187|NCT02690441|Behavioral|Physical Exercise|Manualised exercise. 15 weekly sessions with instructor, and two weekly unsupervised sessions performed individually.
1537188|NCT02690441|Behavioral|Placebo control|One follow-up telephone call à 15 minutes each week for 15 weeks. Aims to control for therapist contact in physical exercise condition and total duration of treatment.
1537192|NCT02690402|Behavioral|adapted physical activity|The study begins with an evaluation of physical strenght and cognitive and psychometric assessment.Then, a personalized care will be offered in terms of adapted physical activity. The evaluation protocol will be performed again to measure the impact of physical activity three months after the first assessment.
1537193|NCT02690389|Drug|Flumazenil|used alone or with acupuncture
1537194|NCT02690389|Procedure|Acupuncture|used alone or with flumazenil
1537195|NCT02690376|Device|Magnetic Assisted Capsule Endoscopy|Swallowed magnetic capsule for endoscopy purposes
1537198|NCT02690324|Behavioral|cognitive stress (serial 7)|
1537199|NCT02690311|Device|smartphone display|
1537200|NCT02690298|Device|ExSpiron|Non-Invasive respiratory volume monitoring
1537201|NCT02690285|Drug|Dichloroacetate (DCA)|Dichloroacetate (DCA) 25 mg/kg oral solution will be administered daily for 5 days.
1537202|NCT02690285|Other|GSTZ1 haplotyping|One teaspoon of blood is collected by standard phlebotomy. Cheek cells are collected by standard brushing. Samples will be analyzed at two independent laboratories to validate methods for GSTZ1 haplotype analysis.
1537204|NCT02690259|Procedure|Sentinel node procedure|Patients with Endometrial cancer undergo Sentinel node procedure using Indocyanine green
1537205|NCT02690246|Other|questionnaire|a questionnaire based study
1537207|NCT02690220|Device|TiLOOP® PRO A (surgical mesh implant)|The standard operation method for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans-vaginally using the TiLOOP® Application Set to place the mesh arms.
1537209|NCT02690194|Device|Placebo Group|The placebo group will wear headphones and listen to nature sounds.
1537210|NCT02690194|Device|Buddhify Therapy|The experimental group will complete a Buddhify relaxation therapy session, before their injection. This therapy consists of wearing headphones and listening to guided meditation instructions.
1537248|NCT02689934|Dietary Supplement|Lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
1537249|NCT02689934|Dietary Supplement|Placebo lactoflorene colesterolo|1.8 g + 1.8 g once a day per os
1537217|NCT02690168|Behavioral|Fasting|72 hour fasting
1537218|NCT02690155|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
1537219|NCT02690155|Drug|VKA (Vitamin K antagonist)|As prescribed by treating physicians
1537220|NCT02690142|Drug|Placebo|Single dose i.v.
1537221|NCT02690142|Drug|ABY-035 i.v.|Single dose i.v.
1537222|NCT02690142|Drug|ABY-035 s.c.|Single dose s.c.
1537223|NCT02690129|Drug|Vaginal Progesteron|
1537224|NCT02690116|Other|Qigong/Tai Chi Easy|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 12 weeks, with a recommended home practice time of 2 1/2 hours each week.
1537225|NCT02690116|Other|Sham Qigong|Classes will be at two different times of day (to accommodate working and non-working participants). Participants will attend one 60 minute class per week for the 12 weeks, with a recommended home practice time of 2 1/2 hours each week.
1537226|NCT02690116|Other|Educational Support|Class times and at-home readings correspond to dose set for the QG/TCE and SQG class times and home practice. Participants will attend one 60 minute class per week for the 12 weeks, with a recommended home practice time (reading, workbook completion) of 2 1/2 hours each week.
1537227|NCT02690103|Drug|pegylated IFN|Patients are treated with 180µg of pegylated IFN (Pegasys-Roche) subcutaneously weekly for three months.
1537228|NCT02690103|Dietary Supplement|Biobran|Biobran, at a dose of 1g per day, allocated in packets, taken orally with meals for the three months duration of the study. Biobran is a denatured hemicellulose that is obtained by reacting rice bran hemicellulose with multiple carbohydrate hydrolyzing enzymes from Shiitake mushrooms. It is a polysaccharide that contains ß-1, 3-glucans, and activated hemicellulose. Biobran was kindly provided by Daiwa Pharmaceuticals Co. Ltd., Tokyo, Japan.
1537229|NCT02690103|Drug|Ribavirin|Ribavirin is prescribed according to patients body weight (1200 mg for those over 75 kg and 1000 mg for those under 75 kg).
1537230|NCT02690077|Procedure|Family-Centered Cesarean|Procedure involves lowering part of the surgical drape exposing a transparent window through which the mother can watch the birth of her baby; the baby will be placed on her chest immediately after the delivery. Cleaning and evaluation of the baby will be done by a nurse who is standing at the head of the bed.
1537231|NCT02690077|Procedure|Traditional Cesarean|Procedure involves keeping the surgical drape up throughout the entire surgery so that the birthing process will not be visible to the mother, and the baby will be taken to the warmer to be evaluated and cleaned after birth but is available to be laid on the mother's chest at any point upon request.
1537232|NCT02690064|Dietary Supplement|Acute Antioxidant Cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
1537233|NCT02690064|Dietary Supplement|Chronic Antioxidant Cocktail|Flow-Mediated Dilation will be determined at baseline, week 4, week 8, and week 12.
1537234|NCT02690064|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
1537235|NCT02690051|Device|BeSmooth peripheral stent|patients treated with the BeSmooth Peripheral Stent System
1537236|NCT02690038|Drug|Intravenous immunoglobulin (IVIG)|"Baseline Ig < 7g/L group - Intravenous immunoglobulin (IVIG) 0.8 g/kg will be given within 12 hours after randomization.
Baseline Ig > or = 7 g/L group - Intravenous immunoglobulin (IVIG) 0.5 g/kg will be given within 12 hours after randomization"
1537237|NCT02690038|Drug|Normal Saline|"Baseline Ig < 7g/L group - Normal Saline (0.9% NaCl) 8 mL/kg will be given within 12 hours after randomization.
Baseline Ig > or = 7 g/L group - Normal Saline (0.9% NaCl) 5 mL/kg will be given within 12 hours after randomization"
1537238|NCT02690025|Drug|ZP1848|
1537239|NCT02690012|Other|Magnesium Oxide|Magnesium Oxide
1537240|NCT02690012|Other|Magnesium Citrate|Magnesium Citrate
1537241|NCT02689999|Drug|Dexrabeprazole 10 mg Enteric-Coated Tablets|
1537242|NCT02689986|Drug|Bendamustine, Rituximab|Bendamustine, Rituximab
1537254|NCT02689921|Drug|Pertuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
1537255|NCT02689921|Drug|Trastuzumab|Monoclonal antibody (HER2/neu receptor antagonist)
1537256|NCT02689908|Radiation|computed tomography|low dose protocol of thorax ct
1537257|NCT02689895|Other|modified directly administered anti-retroviral therapy (mDAART)|As described before
1537258|NCT02689882|Dietary Supplement|nicotinamide riboside|Nicotinamide riboside dose up-titration: Days 1 and 2: 250 mg by mouth daily; Days 3 and 4: 250 mg by mouth twice daily; Days 5 and 6: 500 mg by mouth twice daily; Days 7 and 8: 1000mg by mouth twice daily; Day 9: single dose of 1000mg by mouth followed by 24 hour pharmacokinetic study.
1537259|NCT02689869|Drug|Ibrutinib|Ibrutinib (PCI-32765; JNJ-54179060) is a first-in-class, potent, orally-administered covalently-binding small molecule inhibitor of Bruton's tyrosine kinase currently being co-developed by Janssen Research & Development, LLC and Pharmacyclics, Inc for the treatment of B-cell malignancies.
1537260|NCT02689869|Drug|GA 101|Obinutuzumab (GA 101) is a first-in-class, potent, intravenously administered type II anti-CD 20 antibody that is developed by Roche AG for the treatment of B-cell malignancies.
1537261|NCT02689856|Drug|Hydrocortisone acetate and lidocaine hydrochloride|Hydrocortisone and lidocaine in combination
1537262|NCT02689856|Drug|Placebo control|Vehicle cream alone
1537263|NCT02689856|Drug|Hydrocortisone acetate|hydrocortisone alone
1537264|NCT02689856|Drug|Lidocaine hydrochloride|lidocaine alone
1537265|NCT02689843|Drug|Cyproterone compound + Spironolactone|Cyproterone compound (Cyproterone Acetate 2mg-Ethinyl estradiol 35mcg) 1 tablet daily + Spironolactone 50 mg twice daily
1537266|NCT02689843|Drug|Metformin|Metformin 500mg three times daily
1537267|NCT02689843|Drug|Pioglitazone|Pioglitazone 30mg once daily
1537268|NCT02689830|Device|Bead Block|Prostate embolization
1537269|NCT02689817|Device|Patch|A bandage applied to the sacrum with pressure offloading characteristics and pressure monitoring components in a low-profile housing.
1537270|NCT02689804|Drug|LNG-EC|FDA-approved emergency contraceptive pill containing levonorgestrel 1.5mg
1537271|NCT02689804|Drug|UPA-EC|FDA-approved emergency contraceptive pill containing ulipristal acetate 30mg
1537272|NCT02689791|Dietary Supplement|Resistant Starch Type 4|single dose 26g fiber given at the breakfast meal
1537273|NCT02689778|Drug|Pirfenidone|Oral pirfenidone 600 mg with breakfast and 1200 mg pirfenidone with dinner for 12 months.
1537274|NCT02689778|Drug|Placebo|Identical tablets without active substance
1537275|NCT02689765|Dietary Supplement|Anthocyanins|Anthocyanins capsules, which comprises different natural Anthocyanins purified from bilberries and blackcurrants
1537276|NCT02689765|Dietary Supplement|Placebo|Placebo capsules is identically packaged.
1537277|NCT02689752|Drug|fruquintinib|fruquintinib suspension, 5mg ( 100mCi), oral, taken once, fast
1537278|NCT02689739|Procedure|venous duplex ultrasound|Venous duplex ultrasound
1537279|NCT02689726|Drug|GTL001+|
1537280|NCT02689726|Drug|Aldara|5% imiquimod cream
1537283|NCT02689700|Other|Blood samples|Taking blood form the umbilical cord (fetal circulation) and from the vein of the corresponding mother.
1537284|NCT02689687|Behavioral|Support partner|Participants will identify a support partner who will be contacted if the participant is non-adherent to their diuretic and/or weighing-in.
1537285|NCT02689687|Behavioral|Engagement incentives|Participants will be entered into a daily lottery, for which their participation is contingent on adhering to their diuretic and to weighing-in on the previous day.
1537286|NCT02689687|Behavioral|Electronic pill bottle|Participant adherence to their diuretic will be monitored on a daily basis and participants will be contacted if they are non-adherent to this medication.
1537287|NCT02689687|Behavioral|Bluetooth scale|Participant adherence to stepping on their scale will be monitored on a daily basis and participants will be contacted if they are non-adherent to weighing-in. Participant weight gain will also be monitored, and if weight gain exceeds a specific threshold, the managing physician will be notified through the electronic medical record system. Managing providers will also be sent a weekly report of weight measurements.
1537288|NCT02689635|Other|Sodium Restricted Diet|Cardiac Diet, as defined by our Hospital Nutritional Services (containing less than 2000 mg sodium per day)
1537289|NCT02689635|Other|Regular Diet|Non-Cardiac Diet, as defined by our Hospital Nutritional Services
1537290|NCT02689622|Other|research of disease-related factors|included in IPSS and IPSS-R, lactate dehydrogenase, ferritin level, transfusion- dependence, molecular markers as genes mutations
1537291|NCT02689622|Other|research of comorbidities|HCT-Comorbidity Index, MDS-Comorbidity Index, Adult Comorbidity Evaluation-27, Cumulative Illness Rating Scale-G
1537292|NCT02689622|Other|physical performance|Activities of Daily Living and physical performance
1537293|NCT02689609|Radiation|Intensity-modulated radiation therapy|All patients will receive intensity-modulated radiation therapy with or without chemotherapy as usual standard of care in our institution.
1537294|NCT02689596|Drug|Oxytocin|
1537295|NCT02689596|Other|Placebo|
1537296|NCT02689583|Biological|Antibiotic selection based on the antibiotic susceptibility testing|The biological intervention focused on the results from the antibiotic susceptibility testing. All patients should used the their susceptibility antibiotics according to antibiotic susceptibility testing of H. pylori. Considering the safety of drug usage, priority antibiotic selection was as follow: Amoxicillin > Clarithromycin > Levofloxacin >Tetracycline > Furazolidone > Metronidazole.
1537345|NCT02689232|Biological|Platelets Concentrate|
1537346|NCT02689232|Biological|Cryo Precitipitate|
1537386|NCT02688972|Other|Control group|The volunteers stayed in rest about 10 minutes
1537297|NCT02689583|Genetic|PPI selection based on the CYP2C19 gene polymorphism|PPI selection should based on the CYP2C19 gene polymorphism of patients. Patients have different metabolizers, such as poor metabolizers (PM), extensive metabolizers (EM) and intermediate metabolizer (IM). Different metabolism of patients should select different PPI or different doses of PPI. For IM and PM, in this study, patients selected the standard dose of Omeprazole. For EM, in this study, patients selected the Esomeprazole with increasing doses 50%-100%.
1537298|NCT02689583|Dietary Supplement|Probiotics usage based on the 16SrRNA sequencing|Different micro-environment in stomach may influence the antibiotic absorption. In this study, some patients could select probiotic as adjuvant therapy according to their micro-environment in stomach by 16SrRNA sequencing.
1537299|NCT02689570|Other|observational|no interventions; observational study
1537300|NCT02689557|Other|plethysmography|Validate the measurement made by electroactive polymer sensors (plethysmography) during walking tests in venous insufficient subjects and healthy subjects by comparing the measurement made by the reference technique by mercury gauge.
1537301|NCT02689544|Other|intervention with static stretching|Members of static stretching group performed three sets of 30 second self hamstring stretch (IT) of both lower limbs, with 30 seconds of rest between sets, totaling 3 minute intervention so.
1537302|NCT02689544|Other|intervention with Dynamic Stretching|Each subject contracting antagonist muscle (quadriceps) to the target muscle (hamstring), performing dynamic movements of hip flexion with the knee extended, repeated every 1 second. They amounted to 3 of 30 repetitions completing approximately three minutes of dynamic stretching for each lower.
1537303|NCT02689544|Other|Control|The control group volunteers no received intervention
1537304|NCT02689518|Drug|Intravitreal aflibercept injection|Intravitreal aflibercept injection 2 mg (0.05 mL) administered every 4 weeks for the first 3 months, followed by 2 mg (0.05 mL) intravitreal injection once every 8 weeks(2 months) with the option to treat monthly based on retreatment criteria for a total duration of 12 months.
1537305|NCT02689505|Drug|BI 836880|
1537306|NCT02689479|Procedure|Positron-Emission Tomography|Dynamic scanning is performed for 60 minutes. Image acquisition is performed in 3D and reconstructed using an iterative OSEM VUEPOINT algorithm
1537307|NCT02689479|Biological|11C-5-HTP|150-400 MBq [11C]5-HTP (approximately 2-5 MBq/kg) is administered manually as an intravenous bolus in a intravenous catheter in the arm prior to PET imaging.
1537308|NCT02689479|Procedure|Magnetic Resonance Imaging|Analysis will focus on adipose tissue distribution and composition in the liver.
1537309|NCT02689479|Procedure|Mixed-Meal Tolerance Test (MMTT)|
1537310|NCT02689479|Procedure|Continuous Glucose Monitoring System® (CGMS)|CGMS involves the subcutaneous (SC) placement of a glucose sensor connected by tubing to a pager-sized monitoring device that stores glucose data. Subjects will have the sensor placed in the clinic and wear it continuously for 72 - 84 hours (Gold) or 72-144 hours (iPro2).
1537311|NCT02689479|Procedure|Glomerular Filtration Rate Testing|
1537312|NCT02689479|Procedure|Blood draw|
1537314|NCT02689440|Drug|Dasatinib|50 mg by mouth once daily.
1537315|NCT02689427|Drug|Enzalutamide|120 mg by mouth every day for 12 study cycles. Each cycle is 7 days (1 week).
1537316|NCT02689427|Drug|Paclitaxel|80 mg/m^2 by vein on Day 1 of each 7 day cycle.
1537317|NCT02689414|Procedure|Remote ischaemic preconditioning|Ischaemia is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 200 mm Hg or to a value that is 20 mm Hg greater than the patient's systolic blood pressure - if the patient's systolic blood pressure is more than 180 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
1537318|NCT02689414|Procedure|Control to RIPC|Venous pressure is achieved by using a blood pressure cuff on an arm by raising the cuff pressure to 10-20 mm Hg. The intervention starts simultaneously with the induction of anaesthesia or a few minutes earlier.
1537319|NCT02689401|Drug|Ferumoxytol|
1537320|NCT02689401|Device|MRI 3T scanner|
1537321|NCT02689388|Procedure|Femoral Nerve Block|Use of femoral nerve block as part of general anesthesia
1537322|NCT02689375|Device|Senza Spinal Cord Stimulation system|Suitable participants will be booked to have spinal cord stimulator trial leads implanted and an external programmable High Frequency battery trial box as a day case
1537323|NCT02689362|Drug|Evogliptin|1 tablet per day
1537324|NCT02689362|Drug|Sitagliptin|1 tablet per day
1537325|NCT02689362|Drug|Placebo Evogliptin|1 tablet per day
1537326|NCT02689362|Drug|Placebo Sitagliptin|1 tablet per day
1537327|NCT02689349|Device|Implantation of Esteem|Subjects meeting indications are implanted with the Esteem Totally Implantable Hearing System
1537328|NCT02689336|Biological|Erlotinib|
1537329|NCT02689336|Drug|Temozolomide|
1537330|NCT02689323|Device|repeated transcranial magnetic stimulation|
1537331|NCT02689310|Other|Leptospermum scoparium honey|
1537332|NCT02689310|Other|Standard of Care Treatment|
1537333|NCT02689297|Other|chlorine dioxide|First week, subjects were instructed to do regular tooth brushing. After that group A was requested to use chlorine dioxide mouthwash two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
1537334|NCT02689297|Other|small toothbrush for tongue cleaning|First week, subjects were instructed to do regular tooth brushing. After that group B was requested to brush their tongue with small toothbrush two time per days for three weeks in addition to tooth brushing and then, one week for combination of tooth brushing, tongue cleaning and mouth washing.
1537335|NCT02689284|Drug|margetuximab in combination with pembrolizumab|Combination treatment is administered once every 21-day cycle
1537336|NCT02689271|Other|MRI|VERDICT diffusion-weighted microstructure imaging sequence
1537337|NCT02689258|Drug|HTX-011B|
1537338|NCT02689258|Drug|Placebo|
1537339|NCT02689258|Drug|HTX-011A|
1537340|NCT02689258|Drug|HTX-002|
1537341|NCT02689258|Drug|Bupivicaine HCl|
1537342|NCT02689245|Drug|Tenofovir|
1537343|NCT02689245|Drug|Fecal Microbiota Transplantation (FMT)|
1537344|NCT02689232|Biological|Fresh Frozen Plasma|
1537350|NCT02689193|Other|Blood sampling|Blood sampling (Volume depending on age, minimum 2.0 ml, maximum 10.9 ml extra)
1537351|NCT02689180|Drug|Placebo|Replacement of furosemide by placebo
1537352|NCT02689180|Drug|Furosemide|Maintenance of furosemide on usual doses
1537353|NCT02689167|Drug|Sunitinib|
1537354|NCT02689154|Device|W8Loss2Go|The participants will proceed through all parts of the app program (problem food withdrawal, snacking control and withdrawal from excessive portions) and receive weekly phone calls from the study coordinator, who will be monitoring app usage and providing motivation. Subjects will return to the EMPOWER clinic for a three month weight check and face-to-face meeting with their mentor. After the study period, participants will again complete the EBQ, and be offered continued enrollment in the EMPOWER clinic or continued home use of the mHealth technology.
1537355|NCT02689141|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
1537356|NCT02689141|Drug|Ofatumumab|"Induction:
Cycle 1: Day 1 300 mg i.v.; Day 8 1000 mg i.v.; Day 15 1000 mg i.v. Cycle 2-6: Day 1 1000 mg i.v.
Maintenance: After the induction ofatumumab iv 1000 mg every three months will be continued.
Cycle 1-8: Day 1 1000 mg i.v."
1537357|NCT02689141|Drug|Ibrutinib|Induction: Cycle 2-6: d1-28: 420 mg p.o. Maintenance: After the induction ibrutinib p.o. 420 mg daily will be continued. Cycle 1-8: d1-84: 420 mg p.o.
1537358|NCT02689115|Other|Genetic relative expression|The genetic expression of NF-KB1 and IKK epsilon were quantified in both groups.
1537359|NCT02689102|Device|Probe based optical techniques|During the diagnostic bronchoscopy, optical biopsy of the mucosa and alveolar compartment will be conducted by two different probe based optical techniques (Confocal Laser Endomicroscopy (Mauna Kea technologies) and Optical Coherence Tomography (St Jude Medical)). After the study measurements a biopsy will be obtained in the same area.
1537360|NCT02689089|Drug|3HP|An interrupted time series study design will be used to determine if the introduction of the 3HP regimen will result in more people completing LTBI treatment compared to the standard of 9 months INH twice weekly.
1537361|NCT02689076|Other|HIE Notification|VA provider notification of non-VA hospitalization or ED visit via electronic health information exchange
1537362|NCT02689076|Other|Care transitions intervention|Post-hospital geriatrics care transitions coordinator provides home visit and telephone support for 30 days after hospital discharge
1537363|NCT02689063|Drug|Maxigesic IV|IV acetaminophen 1000 mg and IV ibuprofen 300 mg /100 mL solution for infusion, 100mL, every 6 hours for 48 hours
1537364|NCT02689063|Drug|IV Acetaminophen|IV Acetaminophen 1000 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
1537365|NCT02689063|Drug|IV Ibuprofen|IV Ibuprofen 300 mg/100 mL solution for infusion, 100mL, every 6 hours for 48 hours
1537366|NCT02689063|Drug|Placebo IV|Placebo IV- 100 mL intravenous saline for infusion, 100mL, every 6 hours for 48 hours
1537367|NCT02689050|Device|Needle based confocal laser endomicroscopy (nCLE)|During the fine needle aspiration of a suspected and a non-suspected lymph node we will obtain needle based CLE (nCLE) images within the lymph node. Fine needle aspirations will be obtained after the optical biopsy measurements. We will compare the results of the optical biopsy with the cytology results, or to histology in case an additional surgery is indicated.
1537368|NCT02689037|Procedure|Percutaneous transluminal angioplasty and stenting|Surgeons will plant stents after vascular angioplasty in target ICAS vessels within 5 days after randomization.
1537369|NCT02689037|Drug|Aspirin plus clopidogrel|aspirin 100mg daily and clopidogrel 75mg daily for 90 days
1537370|NCT02689024|Drug|Bupivacaine|Local anesthetic: amide group ATC code N01BB01
1537371|NCT02689024|Drug|Acetaminophen|Analgesic drug: Acetanilide derivate with analgetic and antipyretic properties ATC code N02BE01
1537372|NCT02689024|Drug|Diclofenac|Non-Steroidal Anti-Inflammatory Drug: Acetic acid derivative ATC code M01AB05 Usual dosage is 50 mg t.i.d. orally or 75 mg b.i.d. intramuscularly. In the Netherlands, intravenous administration is not used.
1537373|NCT02689024|Drug|Ibuprofen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE01 Usual dosage is 400 mg t.i.d. or q.i.d. orally.
1537374|NCT02689024|Drug|Naproxen|Non-Steroidal Anti-Inflammatory Drug: Propionic acid derivative ATC code M01AE02 Usual dosage is initially 500 mg orally, followed by 250 mg b.i.d. or t.i.d.
1537375|NCT02689024|Drug|Dipyrone|Analgesic drug: Pyrazolone derivate with analgetic, antipyretic and antiphlogistic properties ATC N02BB02 Usual dosage is 1000 mg t.i.d. or q.i.d. orally and intravenously
1537376|NCT02689024|Drug|Fentanyl|Opioids: Phenylpiperidine derivative. Short-acting opioid. ATC code N02AB03 Usual dosage is 1 ug/kg intravenously and titrated guided by pain scores and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
1537377|NCT02689024|Drug|Morphine|Opioids: Natural opium alkaloid. Longer-acting opioid. ATC code N02AA01 Usual dosage is 0.1 mg intravenously and titrated guided by pain and possible side effects. Above the age of 60, dosages are usually divided in two in order to prevent adverse events.
1537378|NCT02689024|Drug|Levobupivacaine|Local anesthetic: amide group ATC code N01BB10
1537379|NCT02689024|Drug|Ropivacaine|Local anesthetic: amide group ATC code N01BB09
1537380|NCT02689011|Procedure|Femoral Nerve Block|For patients in Femoral nerve Block Group (Group F), ultrasound guided Femoral nerve block was performed using 0.375% bupivacaine, 20 ml for femoral nerve
1537381|NCT02689011|Procedure|Epidural|Patients in Epidural Group (Group E) were turned in lateral position for epidural catheter placement in lumbar region. Epidural was loaded with 0.25% bupivacaine and infusion of M2 (Bupivacaine 0.1% + Fentanyl 2mcg/ml) was started at 8 - 12 ml per hour.
1537382|NCT02688998|Device|venous access PORT or PICC|Participants will receive a venous access prior to starting chemotherapy
1537385|NCT02688972|Other|cold water immersion|The volunteers stayed immerged up to the iliac crest, in the water with water. The temperature utilized was 10 degree C and the time was 10 minutes
1537387|NCT02688959|Behavioral|Tai Chi|
1537390|NCT02688933|Drug|Insulin glargine (U300) HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
1537391|NCT02688933|Drug|Insulin glargine HOE901|Pharmaceutical form:Solution Route of administration: subcutaneous
1537392|NCT02688933|Drug|Insulin glulisine HMR1964|Pharmaceutical form:Solution Route of administration: subcutaneous
1537393|NCT02688933|Drug|Insulin aspart|Pharmaceutical form:Solution Route of administration: subcutaneous
1537394|NCT02688933|Drug|Insulin lispro|Pharmaceutical form:Solution Route of administration: subcutaneous
1537395|NCT02688920|Procedure|EUS and OCT imaging|Intraluminal imaging using endoscopic ultrasound and endoscopic optical coherence tomography
1537396|NCT02688907|Drug|AZD1775|Dosage and Schedule : AZD1775 175 mg BID per os every 12 hours (x 6 doses, 3 days) administered days 1-3 the first & second weeks every 21 days Patients will continue to receive study treatment as described above, until they demonstrate objective disease progression (determined by RECIST 1.1) or they meet any other discontinuation criteria.
1537397|NCT02688894|Other|No treatment is included in this protocol.|"Tumor tissues (fresh or archival) will be analyzed using NGS-based cancer panel, nanostring CNV, immunohistochemistry and/or FISH.
Specific methods of each molecular tests will be defined with standard laboratory manual developed by pathologists."
1537398|NCT02688881|Drug|sirolimus|Rapamune
1537399|NCT02688868|Device|FirehawkTM 2.25mm|Implantation of the released specification (2.25mm) of FirehawkTM rapamycin target-eluting coronary stent systems
1537400|NCT02688855|Device|Active Combined Magnetic Field OL1000 Bone Growth Stimulator|Active CMF OL1000 Device
1537401|NCT02688855|Device|Sham Combined Magnetic Field OL1000 Bone Growth Stimulator|Sham CMF OL1000
1537402|NCT02688842|Device|Rapamycin target-eluting coronary stent systems (38mm)|
1537403|NCT02688829|Device|Rapamycin target-eluting Coronary Stent System|Implantation of the rapamycin-eluting coronary stent system
1537404|NCT02688816|Device|Xpert HPV|Point-of-care HPV DNA PCR test
1537405|NCT02688816|Device|OncoE6|Point-of-care E6 oncoprotein test
1537406|NCT02688803|Drug|Dose dense AC-P|(doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 175 mg/m2 q2weeks x 4 cycles)
1537407|NCT02688803|Drug|Dose dense AC|Dose dense AC followed by weekly P (doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 q2weeks x 4 cycles followed by paclitaxel 80 mg/m2 weekly x 12 cycles)
1537408|NCT02688803|Drug|FEC-D|FEC-D (5-FU 500 mg/m2 plus epirubicin 100 mg/m2 plus cyclophosphamide 500 mg/m2 q3weeks x 3 cycles followed by docetaxel 100 mg/m2 q3weeks x 3 cycles)
1537409|NCT02688790|Drug|Dalbavancin|
1537410|NCT02688777|Behavioral|Backward Walking Training|Backward Walking Training will occur both on a treadmill and overground. In brief, BWTraining will consist of 20-30 minutes of step training with a Body Weight Support and Treadmill system (BWST), rest periods provided as warranted, with manual assistance provided by trainers, followed by 15 minutes of overground gait training. A 20-30 min period of actual stepping is the goal for the intervention sessions on the treadmill with rest periods as needed. Each training session may last up to 1 hour and 30 minutes including time for warm-up, stretching, and cool down. Participants will be fitted with a harness around their hips and torso, which will be attached to an overhead support system directly above the treadmill. From a stationary position, the treadmill belt will gradually be increased in speed with intervention trainers assisting participant to step backward with their paretic leg, their non-paretic leg (if needed) and at the hips for weight-shift.
1537411|NCT02688764|Drug|PA21 (Velphoro®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), PA21 subjects will receive PA21 at a starting dose based on their age. Dose of PA21 will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.
During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
1537412|NCT02688764|Drug|Calcium Acetate (Phoslyra®)|"During Stage 1 (Open-Label Dose Titration; up to 10 weeks), Phoslyra subjects will receive Phoslyra either at a starting dose based on their weight or, if considered more appropriate by the Investigator, at an equivalent dose of their previous phosphate binder (PB), calcium-based or sevelamer. Dose of Phoslyra will be increased or decreased as required for efficacy (to achieve age specific target serum phosphorus level), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time.
During Stage 2 (Open-Label Safety Extension, 24 week safety extension),subjects will continue on the dose received at the end of Stage 1, unless a dose change is required. Doses may be titrated for efficacy (to achieve age specific target Serum phosphorus levels), provided a subject has been receiving that dose for a minimum of 2 weeks, and for safety or tolerability reasons at any time during Stage 2."
1537413|NCT02688751|Radiation|time-resolved CT Angiography|A multi-phase contrast CT
1537414|NCT02688751|Procedure|Contrast Enhanced Ultrasound|A ultrasound scan with micro bubble contrast injection
1537415|NCT02688738|Drug|Doxycycline|
1537416|NCT02688725|Device|post mastectomy ultrasound|post mastectomy ultrasound
1537417|NCT02688712|Drug|LY2157299|Small molecule inhibitor of transforming growth factor-beta signaling pathway
1537418|NCT02688712|Drug|Capecitabine|Antimetabolite chemotherapy
1537419|NCT02688712|Drug|Fluorouracil|Antimetabolite chemotherapy
1537420|NCT02688712|Procedure|Tumor specific mesorectal excision|Tumor specific mesorectal excision
1538072|NCT02683733|Drug|5-Aminosalicylic acid|Dosage is as instructed by patient's physician
1537422|NCT02688686|Biological|genetically modified dendritic cells + cytokine-induced killer|This Phase I/II Study to evaluate clinical efficacy, safety of genetically modified dendritic cells in combination with cytokine-induced killer cell treament in NSCLC with bone metastases.
1537423|NCT02688673|Biological|adenovirus-transfected autologous DC vaccine plus CIK cells|
1537425|NCT02688647|Drug|KD025|
1537426|NCT02688647|Drug|Standard of Care|Treatment/Drug determined by each subject's prescribing physician
1537427|NCT02688634|Drug|Amoxicillin|Amoxicillin will be given as: 7 days, 20mg/kg orally every 6 hours to a maximum of 1.8g/day for a 7-day period.
1537428|NCT02688621|Behavioral|Internet Only|18 month behavioral weight loss intervention delivered online
1537429|NCT02688621|Behavioral|Internet + Incentives|18 month behavioral weight loss intervention delivered online with the possibility of earning incentives for losing weight and performing weight loss behaviors including monitoring food intake, exercising, and daily weighing
1537430|NCT02688608|Drug|Pembrolizumab|200 mg IV once every 3 weeks
1537431|NCT02688595|Device|Ultrasound|Ultrasound-guided central venous catheterization in internal jugular vein
1537432|NCT02688595|Other|General anesthesia|Scheduled operation under general anesthesia
1537433|NCT02688582|Other|TCI group|Drug: cefepime, Device: Target Controlled Infusion pump connected to Rugloop vII software
1537434|NCT02688569|Behavioral|Cognitive Behavioral Therapy for Chronic Widespread Pain|CBT-CWP in this study involves 4 sessions of one-hour non-drug behavioral intervention. Session 1 involves education about pain and insomnia and the relationship between the two. Participants will also learn sleep hygiene and stimulus control skills. Session 3 involves teaching participants skills to limit non-sleep time in bed and thus increase sleep efficiency. Participants will also learn the relationship between pain and activity. Session 4 involves teaching participants cognitive restructuring and mindfulness skills to manage maladaptive thoughts related to pain and insomnia. Participants will also review the skills they learned and discuss the maintenance of treatment gains.
1537435|NCT02688556|Drug|cyclosporine|
1537436|NCT02688556|Drug|vehicle of OTX-101|
1537437|NCT02688543|Procedure|RF treatment|the genicular nerves are identified with the help of landmarks, ultrasound and nerve stimulation. Once the needle is correctly placed high frequency current is passed through the probe during 90 seconds at 20 V with tip temperature put to 80°C.
1537438|NCT02688543|Radiation|radiofrequency ablation|
1537439|NCT02688543|Device|ultrasound|
1537440|NCT02688530|Drug|IV Saline|
1537441|NCT02688530|Drug|IV Dexamethasone 4mg|
1537442|NCT02688530|Drug|IV Dexamethasone 6mg|
1537443|NCT02688530|Drug|IV Dexamethasone 8mg|
1537444|NCT02688517|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
1537445|NCT02688517|Other|Laboratory Biomarker Analysis|Correlative studies
1537446|NCT02688491|Drug|sunitinib|The investigators randomly assign assay-defined high risk patients of stageIII ccRCC into intervention group and observation group. The intervention group should receive adjuvant targeted therapy while the control group deserve observation.
1537447|NCT02688478|Other|Phthalate|Delivered by inhalation on day 1 of the triad
1537448|NCT02688478|Other|Filtered Air|Delivered by inhalation on day 1 of the triad
1537449|NCT02688478|Other|Allergen|Subject specific allergen is delivered by inhalation on day 1 of the triad
1537450|NCT02688465|Drug|Apomorphine|
1537451|NCT02688452|Dietary Supplement|Control Unmodified Placebo Water|
1537452|NCT02688452|Dietary Supplement|Electrokinetically modified water (EMW)|
1537453|NCT02688452|Dietary Supplement|Electrokinetically modified water (EMW)|
1537454|NCT02688452|Dietary Supplement|Control Unmodified Placebo Water|
1537455|NCT02688439|Other|Sciatic Nerve block|
1537456|NCT02688439|Other|Leg raised 30°|
1537457|NCT02688439|Other|Distal tourniquet placed on the lower part of the leg|
1537458|NCT02688439|Other|Leg in a neutral position|
1537459|NCT02688426|Device|Sham Low-Level Laser Therapy (Sham LLLT)|perform with the machine off
1537460|NCT02688426|Device|6J Low-Level Laser Therapy (6J LLLT)|irradiation will be perform with 6J
1537466|NCT02688387|Drug|FDC (ambrisentan 10 mg-tadalafil 40 mg) single dose|The four FDCs in part 1 will have the following formulation designation: FDC1, FDC2, FDC3 and FDC4. They are film-coated tablets. The dose will be administered orally. Study treatment for Part2 and Part 3 will be amended after Part 1 study
1537467|NCT02688387|Drug|Reference (ambrisentan 10 mg + tadalafil 40 mg given concurrently)|Ambrisentan is a film-coated tablet. Each tablet of ambrisentan contains 10 mg of ambrisentan, approximately 95 mg of lactose (as monohydrate), 0.25 mg of lecithin and 0.11 mg of Allura red AC Aluminium Lake. Tadalafil is also a film-coated tablet. Each tablet of Tadalafil contains 20 mg tadalafil and 233 mg lactose. Both the tablets will be administered orally concurrently.
1537468|NCT02688374|Other|Treatment A: Nicorette 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicorette
1537469|NCT02688374|Other|Treatment B: Nicotinell 2 mg coated mint gum|Participants will be administered with 2 mg coated mint gum of Nicotinell
1537470|NCT02688374|Other|Treatment C: Nicotinell 2 mg coated fruit flavor gum|Participants will be administered with 2 mg coated fruit flavor gum of Nicotinell
1537471|NCT02688361|Drug|Fluimucil® 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Fluimucil® (reference).
1537472|NCT02688361|Drug|Acetylcysteine 2% solution|Participants will be orally administered with 10ml of 2% oral solution of Acetylcysteine (test)
1537473|NCT02688348|Other|Quality-of-Life Assessment|Ancillary studies
1537474|NCT02688348|Other|Questionnaire Administration|Ancillary studies
1537475|NCT02688335|Device|Cloud9|Low-pressure Continuous Positive Airway Pressure (CPAP = 2 - 4 cm H2O).
1537476|NCT02688322|Drug|Sulbactam|2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate 1 h every 12 h. Blood samples (approximately 5 ml) will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 1.5, 2, 3, 4, 5, 6, 8 and 12 h after 7th dose of sulbactam
1537477|NCT02688309|Drug|Ozurdex|Patients from the clinic will be considered for enrollment if they are receiving an intraocular injection of a steroid as part of standard care for macular edema or progressive fibrosis. Clinic patients who are receiving an intraocular injection of steroid (Ozurdex) as part of standard care who agree to participate will have an AC tap just prior to the intraocular injection of steroid and a second AC tap at a follow up visit 6 ± 2 weeks after the steroid injection.
1537478|NCT02688309|Procedure|Surgery|The 60 patients from the operating room will be patients undergoing surgery for one of the following conditions: (1) Proliferative Diabetic Retinopathy, (2) rhegmatogenous retinal detachment with PVR, (3) rhegmatogenous retinal detachment without PVR, (4) macular pucker, (5) macula hole. All patients will be administered an AC (Anterior Chamber) tap just prior to the surgical procedure while in the OR.
1537479|NCT02688309|Procedure|Anterior Chamber (AC) Tap|A paracentesis removing about 0.1 ml of fluid from the front part of the eye (the aqueous chamber) will be performed in the operating room just prior to surgery or in the clinic. In the operating room, the AC tap is done after the eye is anesthetized and cleaned with 5% povidone iodine for the surgery. A 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is removed. The wound is self-sealing and has no effect on the surgery. In the clinic, the AC tap is done after drops of proparacaine and 5% povidone iodine is placed in the eye and a lid speculum is inserted. The patient is seated at a slit lamp and a 30-gauge needle attached to a tuberculin syringe is inserted into the AC and 0.1 ml of aqueous is aspirated and then the needle is removed.
1537480|NCT02688296|Device|Fibulock|Fibulock intramedullary implant will be used to repair fibula fractures
1537481|NCT02688283|Other|Nutrient cluster|Test cluster is an optimized savory cluster made through a proprietary baking process combined with slow digestible carbohydrates and fiber
1537482|NCT02688270|Drug|Vascana (0.9% nitroglycerin cream)|Study drug administered topically
1537483|NCT02688270|Drug|Vehicle (placebo)|Vehicle administered topically
1537484|NCT02688257|Other|MRI|Functional magnetic resonance imaging
1537485|NCT02688257|Other|Ultrasound|Optoacoustic imaging
1537486|NCT02688244|Procedure|Irrigation|Irrigation of the abdominal cavity with at least 300ml of normal saline using the power suction/irrigator
1537487|NCT02688244|Procedure|No irrigation|Suction only, using suction device
1537488|NCT02688231|Other|Task-oriented upper limb training|"Participants in the experimental groups (high-intensity and low-intensity) receive for 8 weeks, 60 min/day, 5 days/week a task-oriented upper limb rehabilitation training at a high or low intensity, respectively, instead of their regular occupational therapy hours provided in the conventional multidisciplinary rehabilitation program.
The task-oriented training involves practicing of functional daily tasks, with the intention to acquire or reacquire a skill. Most functional upper limb tasks require following essential movement components: reaching, moving, positioning, transporting, lifting the upper limb and/or an object and grasping, releasing, stabilizing, manipulating an object.
The Tagtrainer of SymbioTherapy is used to support the independent training of tasks with real objects with different sizes and weights. The Diego of Tyromotion is used in patients who require assistance (gravity support) during the performance of different upper limb tasks."
1537489|NCT02688231|Other|Control intervention|"The participants in the control group receive for 8 weeks the conventional multidisciplinary rehabilitation program (physiotherapy, occupational therapy and speech or cognitive therapy if needed).
The training sessions are scheduled for 60 min/day, 5 days/week for the duration of 8 weeks."
1537490|NCT02688218|Behavioral|Aerobic Exercise|Exercise for three 15 minute periods, with 10 minute rests between each period, and exercise intensity will vary between periods to achieve different energy expenditures, which may be determined based on VO2 measurements.
1537491|NCT02688218|Behavioral|Resistance Exercise|Subjects will perform 5-15 minutes of up to 7 different activities of daily living, followed by 20 minutes of resistance exercise, such as straight leg raises.
1537492|NCT02688205|Other|Cyriax's functional examination|included active range of motion, passive range of motion, resisted test and accessory test for shoulder pain evaluation
1537493|NCT02688205|Device|Ultrasound examination|to evaluate rotator cuff, acromio-clavicular joint, and subdeltoid-subacromial bursa
1537494|NCT02688192|Behavioral|Exercise Intervention|Participate in fitness program
1537495|NCT02688192|Behavioral|Internet-Based Intervention|Engage in private social support messaging and Use the mobile app
1537496|NCT02688192|Device|Monitoring Device|Wear an electronic accelerometer
1537497|NCT02688192|Other|Quality-of-Life Assessment|Ancillary studies
1537498|NCT02688166|Other|Complete Cardiac Magnetic Resonance Imaging (MRI)|Complete Cardiac Magnetic Resonance Imaging (MRI) prior to treatment and then at approximately 1 year after completion of radiation therapy
1537499|NCT02688153|Device|EDWARDS INTUITY|To evaluate cardiac performance characteristics and adverse events rates associated with the EDWARDS INTUITY Valve in patients undergoing AVR & CABG.
1537500|NCT02688153|Device|Stented aortic bioprostheses|In comparison to control valves available on the market.
1537501|NCT02688140|Drug|Arsenic trioxide|
1537502|NCT02688140|Drug|Idarubicin|
1537503|NCT02688140|Drug|Cytarabine|
1537504|NCT02688140|Drug|Tretinoin|
1537505|NCT02688140|Drug|Mitoxantrone|
1537506|NCT02688140|Drug|Mercaptopurine|
1537507|NCT02688140|Drug|Methotrexate|
1537508|NCT02688127|Drug|Tranexamic Acid|tranexamic acid or placebo are given before cesarean section in patient with placenta previa
1537509|NCT02688114|Procedure|Baseline surveillance endoscopy|All study participants will undergo endoscopy with confocal laser endomicroscopy or volumetric laser endomicroscopy and biopsy of the esophageal mucosa and gastric cardia.
1537510|NCT02688114|Procedure|Radiofrequency ablation|All study participants will undergo radiofrequency ablation of Barrett's esophagus
1537511|NCT02688114|Procedure|Follow up endoscopy 1|All study participants will undergo follow up endoscopy 1 week after RFA, which includes endoscopy, confocal laser endomicroscopy, and biopsies.
1537512|NCT02688114|Procedure|Follow up endoscopy 2|All study participants will undergo follow up endoscopy 2 weeks after RFA, which includes endoscopy, confocal laser endomicroscopy, and biopsies.
1537513|NCT02688114|Procedure|Follow up endoscopy 3|All study participants will undergo follow up endoscopy 4 weeks after RFA, which includes endoscopy, confocal laser endomicroscopy, and biopsies.
1537514|NCT02688101|Drug|DpC|iron chelator
1537518|NCT02688062|Biological|NeuroRegen Scaffold with BMMCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
1537519|NCT02688062|Procedure|Surgical intradural decompression and adhesiolysis|Patients with chronic SCI (ASIA grade A) will receive intradural decompression and adhesiolysis surgery and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
1537520|NCT02688049|Biological|NeuroRegen scaffold/mesenchymal stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million mesenchymal stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
1537521|NCT02688049|Biological|NeuroRegen scaffold/neural stem cells transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with 10 million neural stem cells transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
1537522|NCT02688036|Radiation|hypofractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 45Gy/15F of radiotherapy with concurrent chemotherapy will be used in experimental arm.
1537523|NCT02688036|Radiation|conventionally fractionated concurrent chemoradiotherapy|For patients with Limited Disease Small Cell Lung Cancer, 60Gy/30F of radiotherapy with concurrent chemotherapy will be used in the control arm.
1537524|NCT02688023|Drug|oxaliplatin;irinotecan;leucovorin;5-fluorouracil;capecitabine;S-1|The regimen consisted of irinotecan 150mg/m2 administered as an intravenous infusion on day 1, oxaliplatin 85 mg/m2 administered intravenously on day 2, leucovorin 200 mg intravenously on day 2, 5-fluorouracil 500 mg administered by intravenous bolus,followed by 2400 mg/m2 by 44 h continuous intravenous infusion starting on day 2. S-1 (40-60mg orally twice per day for 10 days) or capecitabine (1000mg/m2 orally twice per day for 10 days) can be substituted for intravenous 5-fluorouracil.14 days as a cycle, up to 4 cycles.
1537525|NCT02688010|Behavioral|Noise reduction and cycled light|Reduced noise exposure (sound levels <45 dB) and cycled light (approximately 12 hours of light on and 12 hours of light off).
1537526|NCT02687997|Other|poligraphy|Sleep study
1537527|NCT02687984|Drug|RBP-7000|A single subcutaneous injection with doses of RBP-7000 containing 120 mg risperidone and either a low, high, or intermediate molecular weight PLGH polymer.
1537528|NCT02687971|Drug|Miltefosine|Miltefosine (hexadecylphosphocholine) is an oral drug which has proven to be effective for the treatment of Visceral leishmaniasis (VL) in the Indian sub-continent. It has also been tested for CL, yielding varying results. Miltefosine was approved by FDA in 2014 for the treatment of CL in the New World for lesions due to L. braziliensis, L. panamensis and L. guyanensis only.
1537529|NCT02687958|Drug|Everolimus|Maintenance therapy
1537530|NCT02687945|Procedure|Outpatient physiotherapy|
1537531|NCT02687945|Procedure|Self-guided physiotherapy|
1537532|NCT02687932|Drug|LCZ696|
1537533|NCT02687932|Drug|Valsartan|
1537535|NCT02687906|Drug|Carbavance|Carbavance (meropenem-vaborbactam) for IV injection
1537536|NCT02687893|Behavioral|Aerobic Exercise|Subjects will exercise on a treadmill for 45 minutes twice during the intervention week. Subjects will exercise at a fixed intensity level to a target heart rate (±10%) based on the heart rate achieved at 60% of their VO2max determined at screening. The speed and grade of the treadmill will be adjusted by trained research personnel with a goal of keeping participants within their target heart rate range for the entire 45 minutes.
1537537|NCT02687893|Behavioral|Resistance Exercise|Subjects will participate in resistance exercises for 45 minutes twice during the intervention week. Subjects will perform multiple-joint exercises with slow to moderate lifting velocity, for 1-3 sets per exercise at a weight that can be lifted for 8-12 repetitions (~60-80% of 1-repetition max). The exercises may include leg press, bench press, leg extension, leg flexion and seated row. Subjects will perform the exercises through the full range of motion. Between each set of repetitions, there would be a 2 minute rest period. The duration of the exercise testing would be approximately 45 minutes.
1537538|NCT02687880|Procedure|Testicular biopsy|Subjects will undergo a surgical procedure to harvest their testicular tissue.
1537539|NCT02687867|Drug|Dabigatran (Pradaxa)|As prescribed by treating physicians
1537540|NCT02687867|Drug|Vitamin K antagonist|As prescribed by treating physicians
1537541|NCT02687854|Drug|Apixaban|As prescribed by treating physicians
1537542|NCT02687854|Drug|Vitamin K antagonist|As prescribed by treating physicians
1537543|NCT02687841|Drug|AST-120and pentoxyphylline (PTX)|AST-120 2g 4 times a day for 5 days then AST-120 2g 3 times a day for 5 days pentoxyphylline 400mg QD PO x 10 days.
1537544|NCT02687841|Drug|pentoxyphylline (PTX)|pentoxyphylline 400mg QD PO x 10 days.
1537545|NCT02687815|Drug|vitamin D3 4000 IU|The vitamin D3 will be in oral gel cap form and contain 4000 International Units (IU) of cholecalciferol per gel cap.
1537546|NCT02687815|Drug|Placebo|The placebo is a gel cap that is indistinguishable from the vitamin D3 gel cap.
1537547|NCT02687802|Other|mechanical ventilation|we will measure static resistance, compliance and intrinsic positive end-expiratory pressure (PEEP) and other variables as risk factors for asynchrony occurrence
1537548|NCT02687789|Other|Medical Device: WO3191|application of vaginal suppository WO3191: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
1537549|NCT02687789|Other|Medical Device: Vagisan® Lactic Acid|application of Vagisan® Lactic Acid: 2 days per week (with a treatment-free interval of three days or two days, respectively; e.g. Monday and Friday)
1537550|NCT02687763|Biological|ProQuad|"2) Patients 6 months to 24 months of age who are being considered and/or evaluated for any solid organ transplant within the next five (5) years who are willing:
to receive two doses of ProQuad® at least 30 days but no more than 365 days apart.
to participate in the three (3) antibody titer blood draws."
1537551|NCT02687750|Device|MRI|Investigational device is a dual tuned (fluorine/proton) MRI surface coil designed and produced by Clinical MR solutions
1537552|NCT02687737|Procedure|Electromyography|During the fine wire electromyography (EMG), the participant will be asked to complete breathing exercises at 50% and 75% of their maximum capacity (determined prior to fine wire EMG using manometry) to determine activation and recruitment of genioglossus muscle.
1537553|NCT02687737|Procedure|Maximum expiratory pressure|The participants' maximum expiratory pressure (MEP) will be assessed using a hand-held digital manometer (MP01, Micro Direct Inc.). The subject will be standing and while wearing a nose clip be asked to blow out as hard and fast as they can to determine their MEP. This will be completed a maximum of three times to obtain values within close range of one another.
1537554|NCT02687737|Procedure|Videofluoroscopy|Videofluoroscopy allows for time-synced, frame-by-frame data analysis for the specific measures taken during swallowing tasks.
1537555|NCT02687737|Behavioral|Swallowing Tasks|"These include: an anterior tongue press to the alveolar ridge (behind the front molars), a saliva swallow, a 10 mL barium swallow, a 10 mL barium hard swallow (i.e. swallowing with extra effort), and two breathing exercise trials at 50% MEP and 75% MEP."
1537556|NCT02687724|Drug|Golimumab (GLM)|GLM is a human IgG1κ monoclonal antibody produced by a murine hybridoma cell line with recombinant DNA technology
1537557|NCT02687698|Other|Ketogenic diet|The proposed ketogenic diet will concern a low glucidic diet with 60-70% of lipidic intake and 20-30% of proteins.
1537558|NCT02687685|Other|Skin to skin contact immediate|Immediate SSC (intervention group) At birth, the baby will be dried and placed at the mother's breast where thermoregulation maneuvers will be applied and, once cord clamping has taken place, the baby will be left in SSC with the mother where the immediate neonatal adaptation interventions will take place. Mother and baby will be left in SSC for at least 1 h or until the baby has completed its first lactation properly. Once completed, the baby will be taken to the heat lamp to perform and complete all the newborn mediate adaptation interventions. If the mother expresses the desire to continue in SSC, this will be allowed again after these interventions. During immediate SSC, mother and baby will receive continuous monitoring by the health staff.
1537559|NCT02687685|Other|skin to skin contact early|Early SSC group (control group) At birth, the baby will be dried and placed on the abdomen and chest of their mother where thermoregulation maneuvers are applied once cord clamping has been completed. At this time, the baby will placed under the radiant heat lamp in order to complete all newborn adaptation interventions. Once stable, the mother and the baby will proceed with the initiation of SSC for at least 1 h or until the baby has completed the first lactation adequately; SSC will be allowed to continue if the mother expresses a desire to do so. During SSC, the mother and baby will receive monitoring by health personnel. All adaptation interventions, mediate and immediate, in the newborn will take place under the radiant heat lamp during the first postnatal hour.
1537560|NCT02687672|Biological|Stem Cell Transplantation|Transplantation of autologous stem cells
1537561|NCT02687659|Device|TEMIS system|Wearing TEMIS system over the day during one week
1537562|NCT02687646|Drug|Adult Allogeneic Mesenchymal cells from adipose tissue.|"Study treatment consists of Mesenchymal Stem Cell (MSC) derived from donors adipose tissue and expanded in vitro in a specific medium with platelet lysate without addition of animal derived products.
Subjects will receive four sequential IV dose of Mesenchymal stem cells.
Sequential doses:
Day 1: 0.7-1 x 106 MSC / kg Day 4: 0.7-1 x 106 MSC / kg Day 11: 0.7-1 x 106 MSC / kg Day 18: 0.7-1 x 106 MSC / kg"
1537563|NCT02687633|Behavioral|JASPER|JASPER (Joint Attention, Symbolic Play, Engagement, and Regulation) is a treatment approach based on a combination of developmental and behavioral principles developed by Dr. Connie Kasari and Dr. Amanda Gulsrud at UCLA. It targets the foundations of social communication (joint attention, imitation, play) and uses naturalistic strategies to increase the rate and complexity of social communication.
1537564|NCT02687607|Device|WEB Aneurysm Embolization System|
1537565|NCT02687594|Drug|sucroferric oxyhydroxide|The non-interventional design allows the observation of patients in a broad range of settings reflecting routine clinical practice. All decisions on therapeutic or diagnostic procedures, treatments, management of the disease, or resource utilisation will be at the full discretion of the treating physician without interference by a sponsor or study protocol. All treatment decisions will follow the real-life treatment behaviour.
1537566|NCT02687581|Device|IO-therapy Glasses|12-hour of 50% intermittent occlusion therapy on the fellow eye.
1537567|NCT02687581|Device|patch|6-hour of eye patch on the fellow eye
1537568|NCT02687568|Other|EEG monitoring|Value of EEG monitoring as adjunct to standard monitoring
1537569|NCT02687555|Behavioral|Cognitive Bias Modification of Appraisals (CBM-App)|
1537570|NCT02687555|Behavioral|Peripheral Vision Task (control condition)|
1537576|NCT02687529|Device|CST001|
1537607|NCT02687373|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated Plasmodium falciparum sporozoites
1537608|NCT02687373|Other|Normal Saline|0.9% Sodium chloride
1537609|NCT02687360|Device|Active rTMS treatment|In the active treatment, magnetic power output will be delivered to the participants through the coils.
1537577|NCT02687516|Behavioral|Family-based behavioral social facilitation therapy|"Family-based Behavioral Social Facilitation Treatment (FBSFT) is founded on the principles of standard family-based behavioural therapy for obesity. FBSFT targets life-style behaviors (diet, physical activity and sedentary activity) in a family setting. FBSFT includes some cognitive elements that are considered important in relation to behavioural change for instance problem solving and cognitive restructuring. FBSFT has an intensive treatment phase including weekly family meetings with therapists over 17 consecutive weeks. Further monthly or bi-weekly follow-up sessions with a focus on social facilitation and maintenance of healthy habits are recommended. The dietary guidance of FBSFT is based on the Traffic light diet in which foods are organized into GREEN, YELLOW and RED groups. Activity guidance of FBSFT uses the same system: GREEN activities have the highest intensity and should be engaged in most often, YELLOW activities sometimes, and RED activities."
1537578|NCT02687516|Behavioral|TAU - Treatment as usual|"This is the default treatment at the obesity clinic. After initial evaluation by paediatrician, nurse, nutritionist and physiotherapist, a contract is written including weight goal, nutritional plan and activity plan. Follow up monthly in primary Health care and every 3rd month at the obesity clinic."
1537579|NCT02687503|Dietary Supplement|Probiotic|
1537580|NCT02687490|Drug|Abraxane|125 mg/m2, D1, D8, D15
1537581|NCT02687477|Procedure|Pulmonary Arterial Denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
1537582|NCT02687477|Procedure|Sham procedure|patient in the sham group will receive sham procedure
1537583|NCT02687464|Other|Non-operative treatment|"will receive a minimum of 12 hours intravenous antibiotics and then receive oral antibiotics once they have shown clinical improvement (a total course of 10 days of antibiotics (intravenous and oral). They will be discharged home once they meet a standardized set of criteria to be used in all centers.
The choice of antibiotics will vary between centers and will be the antibiotic regimen that is current standard of care in that center allowing each center to maintain current protocols will improve study feasibility and increase generalization of the results."
1537584|NCT02687464|Procedure|Appendectomy|"will undergo laparoscopic appendectomy within 18 hours of randomization and will receive intravenous antibiotics per each site's standard care, from the time of randomization and post-operatively according to a defined and standardized treatment regimen based on consensus for this trial.
Children with a visibly normal appendix or non-perforated acute appendicitis will receive no further antibiotics; children with perforated appendicitis will continue to receive intravenous antibiotics for a minimum of 3 days, and then per local practice. The type of antibiotics used in each center will be identical to those used in the non-operative treatment group and are not specified by the study."
1537585|NCT02687451|Drug|Oxymorphone HCl|Oral liquid and injection; dose to be determined by Independent Data Monitoring Committee (IDMC).
1537586|NCT02687451|Drug|Placebo|Placebo Comparator for the double-blinded, placebo-controlled multiple-dose phase.
1537587|NCT02687438|Device|Steroid-releasing sinus implant|PROPEL (Intersect ENT, Menlo Park, CA) containing 370mcg of mometasone furoate designed for gradual release over 30 days
1537588|NCT02687438|Other|Post-op standard of care|post-op standard of care including debridement, irrigation, and/or topical steroids
1537589|NCT02687425|Drug|Pioglitazone|15mg/day,po
1537590|NCT02687425|Drug|imatinib mesylate|400mg/day,po
1537591|NCT02687412|Procedure|pre-operative assessment, counseling and education|pre-operative assessment, counseling and FT management education
1537592|NCT02687412|Procedure|Preoperative nutritional drink up to 4 h prior to surgery|Preoperative nutritional drink up to 4 h prior to surgery mechanical bowl preparation should not be used
1537593|NCT02687412|Procedure|only oral intestinal cleaner 12 h pre-operation|patients are not received mechanical bowel preparation, only oral intestinal cleaner 12 h pre-operation can be accepted, but no need of liquid stool
1537594|NCT02687412|Procedure|preoperative treatment with carbohydrates|preoperative treatment with carbohydrates (patients without diabetes).
1537595|NCT02687412|Procedure|fast solid|fast solid food before 6 h and liquid food Intake of clear fluids 2 h before anaesthesia;
1537596|NCT02687412|Procedure|avoiding hypothermia|avoiding hypothermia, keeping the intra-operative lowtemperature at 36 ±0.5 degree centigrade; antiemetics at end of anaesthesia.
1537597|NCT02687412|Procedure|Postoperative glycaemic control|Postoperative glycaemic control;
1537598|NCT02687412|Procedure|postoperative nausea and vomiting (PONV) control;|
1537599|NCT02687412|Procedure|early postoperative diet|early postoperative diet(3-6 h after surgery, patients resumed a liquid diet, 12 h after surgery patients began to take solid diet).
1537600|NCT02687412|Procedure|pre-operative fasting at least 8h|
1537601|NCT02687412|Procedure|Oral bowel preparations|Oral bowel preparations or mechanical bowl until liquid stool
1537602|NCT02687412|Procedure|intra-operative lowtemperature at 34.7 ±0.6 degree centigrade|keeping the intra-operative lowtemperature at 34.7 ±0.6 degree centigrade
1537603|NCT02687412|Procedure|began to take solid diet after anal exhaust|6 h after surgery, patients resumed a liquid diet, patients began to take solid diet after anal exhaust
1537604|NCT02687399|Other|placebo|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the placebo group will receive placebo for inyection sprayed on the exposed tissues of the knee.
1537605|NCT02687399|Biological|TT-173|After prosthesis cementation and just before knee suture and tourniquet liberation, the patients randomized in the treatment group will receive TT-173 for inyection sprayed on the exposed tissues of the knee.
1537790|NCT02685839|Device|Intelligent POWER Rehabilitation Cluster Machine|
1537610|NCT02687360|Device|Sham rTMS treatment|The sham coil setting is designed to mimic the auditory artifact and the scalp sensations evoked by the real coil, and to produce activation of facial muscles similar to the effect of a real H coil, without stimulating the brain itself.
1537611|NCT02687347|Drug|oral methadone|Oral methadone is the study drug
1537612|NCT02687347|Drug|oral morphine|Oral morphine is the active comparator. It is not a placebo intervention
1537613|NCT02687334|Drug|100% Oxygen|We will investigate the changes of cerebral oxygenation during anesthesia induction of standard general anesthesia with 100% oxygen
1537614|NCT02687321|Other|Determination of CA 125 and HE4, Computed tomography|Blood sample collection to determinate tumor marker found in blood elevated by the presence of cancer recurrence.In case of one or both of tumor markers are elevated, computed tomography examination with intravenous contrast agent of chest and abdomen is performed to detect the recurrence of the disease.
1537615|NCT02687308|Procedure|1 Retrograde radical prostatectomy RRP|This open surgical technique described by Patrick Walsh involves prostatic dissection made from prostatic apex to the bladder neck, so the retrograde direction, the posterior layer of Denonvilliers' fascia is always included with the specimen, and urethrovesical anastomosis usually performed with multifilament interrupted suture
1537616|NCT02687308|Procedure|2 Anterograde radical prostatectomy RRP2A|This open surgical techniques performing radical retropubic prostatectomy using the same technique of minimally invasive surgery, antegrade way, from bladder neck to the apex, with careful bladder neck dissection and preservation, incremental or not careful nervesparing procedures and urethrovesical anastomosis performed by monofilament running suture, described by the Pasadena consensus for the procedure assisted by robot.
1537617|NCT02687295|Dietary Supplement|Thylakoids|
1537618|NCT02687295|Other|Control|
1537619|NCT02687282|Other|Evaluate upper airway changes|Evaluate upper airway changes at several point of time before and after cesarean delivery
1537620|NCT02687269|Drug|Ranolazine|Patients in this arm receive Ranolazine at a dose of 375 mg twice daily in the three days before surgery
1537621|NCT02687269|Drug|Placebo|Patients receive Placebo twice daily in the three days before surgery
1537622|NCT02687256|Device|Extended Wear infusion set|For two of the 4 weeks the Extended Wear insulin infusion set will be used.
1537623|NCT02687256|Device|Standard Infusion set|For two of the 4 weeks the Standard infusion set will be used
1537624|NCT02687243|Device|Interactive Virtual Application|Online application via tablet
1537625|NCT02687230|Drug|MVT-2163|MVT-2163 is administered intravenously as a PET imaging agent
1537626|NCT02687230|Drug|MVT-5873|MVT-5873 is administered intravenously as a non-radioactive blocking agent prior to administration of MVT-2163
1537627|NCT02687217|Drug|oxygen|"Hyperoxygenation ≥50% of oxygen by mask(non-rebreathing) was given through out the surgery.
Received 6L/min of oxygen through venturimask upto 2 hours in post operative period.
Hyperoxygenation refers to provision of ≥50% of oxygen by mask(non-rebreathing) through out the surgery."
1537628|NCT02687204|Drug|Twice daily enoxaparin prophylaxis|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
1537629|NCT02687204|Drug|Real time dose adjustment|Patients will have peak and trough steady state anti-Xa levels drawn. For patients with out of range peak levels, real time enoxaparin dose adjustment using a clinical protocol will be performed. Repeat steady state levels will be checked.
1537631|NCT02687178|Drug|Canrenone 50 vs canrenone 100 mg|
1537632|NCT02687165|Drug|Milnacipran and D-cycloserine|Milnacipran augmented by D-cycloserine
1537633|NCT02687152|Other|N-hydroxy-nor-L-arginine|
1537634|NCT02687139|Drug|18F-DCFPyL|
1537635|NCT02687139|Procedure|PET/CT|Positron Emission Tomography - Computed Tomography (PET/CT)
1537636|NCT02687126|Device|Central Venous Catheterization|Ultrasound guided internal jugular venous catheterization
1537637|NCT02687113|Device|CT/US fusion|Fusion of pre-RFA cross-sectional imaging (CT or MRI) and real-time USG using registration function of USG device.
1537638|NCT02687100|Drug|Beclomethasone|beclometasone, 0.8 mg of saline to a volume of 8 mL, three times through the line for suctioning above the cuff: a) after positioning the tube; b) at the arrival in the cardiac intensive care unit; c) just prior to start respiratory weaning
1537639|NCT02687100|Drug|Placebo|patients will receive 8 mL of saline without any drug
1537640|NCT02687087|Device|Visco-ease|19.6 mg/mL of LMS-611
1537641|NCT02687087|Device|Placebo|Physiological Saline
1537642|NCT02687074|Device|HFNC|patients treated with high flow nasal cannula
1537643|NCT02687074|Device|NIV|patients treated with noninvasive ventilation
1537644|NCT02687048|Behavioral|Otago Exercise program|The Otago exercise program (OEP) is an evidence-based falls prevention home-based program. The participants will be instructed by a physiotherapy to do muscle strengthening and balance exercises (to be done 3x/week). The physiotherapist will progress these exercises during 5 home visits to each participant.
1537645|NCT02687048|Behavioral|Mindful meditation|Mindful meditation aims to reorient the individual to the present and broaden self awareness by promoting attention to internal experiences such as bodily sensations, thoughts, emotions, sights or sounds. The participants will be instructed in mindful meditation during 6 hour-long education sessions and will be expected to practice with audio meditations 30 minutes 5 times per week.
1537646|NCT02687035|Device|TAVR with SAPIEN S3 valve|Transcatheter aortic valve replacement
1537647|NCT02687022|Device|Peramis aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
1537648|NCT02687022|Device|iDesign aberrometry|A non-invasive photographic scan sequence acquired in under 10 seconds
1537649|NCT02687009|Drug|Niclosamide|Niclosamide will be taken orally in the morning of each day from day 1-7 prior to surgery for resection of primary tumor. Niclosamide tablets must be chewed well prior to swallowing.
1537650|NCT02686996|Dietary Supplement|carnosine|Carnosine capsules (2g) twice per day for 14 weeks
1537651|NCT02686996|Other|Placebo|Placebo (methylcellulose) capsules for control group identical to intervention capsules and dose
1537652|NCT02686983|Drug|Betamethasone and local anesthetic|Infiltration of the greater occipital nerve .
1537653|NCT02686944|Biological|Intuvax (suspension for intratumoral injection) (ilixadencel)|Therapeutic vaccine: allogeneic, proinflammatory dendritic cells
1537654|NCT02686918|Other|Advanced Practice Nurse consultation|
1537655|NCT02686905|Dietary Supplement|Chewable Multivitamin with Iron|Take daily: Chewable Multivitamin with Iron. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
1537656|NCT02686905|Dietary Supplement|PatchMD Vitamin D3/Calcium Patch|Wear daily: PatchMD Vitamin D3/Calcium patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
1537657|NCT02686905|Dietary Supplement|PatchMD Multivitamin Patch|Wear daily: PatchMD Multivitamin patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
1537658|NCT02686905|Dietary Supplement|PatchMD B12 Energy Plus Patch|Wear daily: PatchMD B12 Energy Plus patch. The patch can be worn immediately after surgery in order to prevent deficiencies, and we hope to show that this supplementation method can also promote lean muscle mass retention. In addition, due to the malabsorptive properties of bariatric surgery, we hope to show that patients will be more likely to completely absorb the micronutrient via transdermal application than through oral intake.
1537659|NCT02686905|Dietary Supplement|Chewable Calcium|Take daily: Chewable Calcium. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
1537660|NCT02686905|Dietary Supplement|Quick Dissolve B12|Take daily: Quick Dissolve B12. The chewable vitamins, vitamin chew, or vitamin rapid/quick-melts can be consumed after surgery when cleared by the surgeon.
1537661|NCT02686879|Device|Multifocal contact lenses|
1537662|NCT02686879|Device|Single vision contact lenses|
1537663|NCT02686866|Device|bioelectrical impedance analysis (Bodystat, Quadscan 4000)|
1537664|NCT02686866|Device|dual-energy X-ray absorptiometry (Hologic, Delphi QDR)|
1537665|NCT02686866|Device|hand grip strength|
1537666|NCT02686853|Drug|Liposomal amphotericin B|
1537667|NCT02686840|Drug|sublingual misoprostol|"All patients will receive three doses of sublingual misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.
Two doses of misoprostol 800 mcg each (four tablets of 200 mcg per dose).
Paracetamol, eight hourly, will be provided as analgesic or antipyretic.
A specimen bottle to collect the POC if passed out.
Two pairs of disposable gloves.
Pre-filled histopathological examination form to be sent to the laboratory together with the products of conception"
1537668|NCT02686840|Drug|vaginal misoprostol|"All patients will receive three doses of vaginal misoprostol every four hours The first dose of misoprostol 800 mcg will be administrated at the hospital. Then the patient will be observed for 1 hour for any immediate adverse reaction Clear instructions about the method and timing of second dose will be given upon sending home.
Paracetamol, eight hourly, will be provided as analgesic or antipyretic"
1537669|NCT02686827|Drug|Paricalcitol|Vitamin D3 analogue
1537670|NCT02686827|Drug|Placebo (for paricalcitol)|Injection fluid to mimic paricalcitol injection
1537672|NCT02686788|Drug|TMP001|600mg TMP001 as gelatine capsules á 200mg taken orally twice per day for a duration of 24 weeks
1537673|NCT02686775|Behavioral|Patient coach|
1537674|NCT02686775|Behavioral|Standard care|
1537675|NCT02686762|Drug|Emricasan (5 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (5 mg) twice a day.
1537676|NCT02686762|Drug|Emricasan (50 mg)|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with emricasan (50 mg) twice a day.
1537677|NCT02686762|Drug|Placebo|Subjects with Non-alcoholic Steatohepatitis (NASH) Fibrosis will be administered orally with a matching placebo twice a day.
1537678|NCT02686749|Device|Catheter Ablation|"During ablation, a doctor inserts a catheter through blood vessels into the heart. The doctor looks at the electrical activity of the heart. The catheter is used to determine which areas of the heart are causing AF. After the area is identified, the doctor uses a special machine delivers energy through the catheter to tiny areas of the heart muscle that is causing AF. This energy causes a scar in the tissue which disconnects the pathway of the AF."
1537679|NCT02686749|Drug|FDA approved anti arrhythmic drug|Anti arrhythmic drug medical treatment will be based on treating physicians discretion following standard clinical guidelines
1537680|NCT02686736|Behavioral|Internet-based educational intervention|The intervention will include four educational sessions about risky sexual behaviors and its prevention. The intervention will last one month (one session per week) followed by a three-month follow-up. Teens will be allowed to access to a weekly session at any time and as often as he/she likes.
1537682|NCT02686710|Drug|Sevoflurane|
1537683|NCT02686710|Drug|Propofol|
1537684|NCT02686697|Drug|L-Carnosine|
1537685|NCT02686697|Drug|Placebo|
1537686|NCT02686697|Behavioral|Cognitive Training|Cognitive Training for 2 weeks
1537687|NCT02686684|Drug|Dimethyl fumarate|
1537688|NCT02686671|Other|Shoulder clinical examination testing|Shoulder clinical examination including resistive shoulder abduction with and without a humeral traction (Pull Test). Functional status will be measured using the Shoulder Pain and Disability Index (SPADI).
1537689|NCT02686658|Drug|Zimura®|
1537690|NCT02686658|Drug|Sham|
1537691|NCT02686645|Biological|Fecal Microbiota|The fecal microbiota will be by retention enema administered through a rectal tube.
1537692|NCT02686645|Drug|vancomycin|All subjects will be pre-treated with vancomycin 125 mg po qid X 7 days prior to the fecal microbiota.
1537693|NCT02686645|Drug|Loperamide|The subject will take 4 mg of loperamide after the morning bowel prep (approximately 1 hour prior to the procedure) and 2 mg again after the procedure.
1537694|NCT02686645|Drug|metronidazole|If unable to tolerate vancomycin, then it will be substituted with metronidazole 500 mg po tid X 7 days prior to the fecal microbiota.
1537695|NCT02686632|Behavioral|Palatal brushing|Brushing the palate as part of regular oral hygiene habits (behavior) among complete denture wearers.
1537696|NCT02686619|Drug|Cyclosporine|Cyclosporine tablets orally once daily at dose level adapted to maintain concentration at 2 hours after administration (C2): 1000-1500 nanogram per milliliter (ng/mL) during Day 0 to Week 4, and 800-1200 ng/mL during Week 4 to Week 52. For Mycophenoate Mofetil + Sirolimus treatment arm, at Week 12, dose of cyclosporine will be reduced by 50% for 3 days, followed by 1/4 of the dose for 3 days, and then cyclosporine will be stopped.
1537697|NCT02686619|Drug|Daclizumab|Daclizumab 2 milligram (mg) per kilogram (kg) will be administered as intravenous infusion over 15 minute on Day 0 (during the 24 hours preceding renal transplantation) and at a dose of 1 mg/kg on Day14.
1537698|NCT02686619|Drug|Mycophenoate Mofetil|Mycophenoate mofetil 1 gram (g) (2*500mg tablets or 4*250mg capsules) will be given twice daily (daily dose of 2 g) orally for 12 months.
1537699|NCT02686619|Drug|Prednisolone|Prednisolone 250 mg intravenously on Day 0, followed by 0.5 mg/kg orally daily (maximum 40 mg daily) from Day 1 to Day 7, then 0.25 mg/kg orally daily (maximum 20 mg daily), then dose will be stepwise reduced by 2.5 mg per week to reach to a dose level of 10 mg daily and continued up to 6 months and finally drug will be discontinued after 8 months.
1537700|NCT02686619|Drug|Sirolimus|Sirolimus tablets will be given orally from week 12 to week 52, starting with loading dose of 10 mg daily for 2 days followed by 6 mg daily to adapt to trough concentrations of 8-15 ng/mL from week 12 to week 39, and 5-10 ng/mL from week 39 to week 52.
1537701|NCT02686606|Dietary Supplement|Vital 1.5|Oral nutritional supplement
1537702|NCT02686606|Dietary Supplement|Ensure Plus|Oral nutritional supplement
1537703|NCT02686606|Dietary Supplement|elemental 028|Oral nutritional supplement
1537704|NCT02686606|Other|water|water
1537705|NCT02686593|Drug|Clofarabine, AraC, mitoxantrone (CLAM)|The combination of clofarabine, cytarabine (Ara-C) and mitoxantrone will be used in patients with AML in first relapse or after failure of first salvage
1537706|NCT02686580|Biological|Collagen paste|Permacol cross-linked collagen paste, 2.5-3.5 mls to be injected into the MRI defined fistula tracts 7-10 days following drainage of the anorectal abscess.
1537707|NCT02686567|Procedure|with TDT|a transanal drainage tube insert from the anus after laparoscopic anterior resection and double-stapling technique anastomosis were finished. And it will be retaind for 5-7days
1537708|NCT02686567|Procedure|without TDT|After laparoscopic anterior resection and double-stapling technique anastomosis were finished, none additional proceduce was done.
1537709|NCT02686554|Other|Neuropsychological assessment|The patients perform tests to assess their cognitive abilities
1537710|NCT02686541|Device|Atherectomy followed by Drug Eluting Balloon (DEB)|"Patient will undergo an intervention under anaesthesia. After pre-arthrectomy Intravascular ultrasound (IVUS) of the affected arterial segment, patient will undergo treatment with Arthrectomy, followed by post-arthrectomy IVUS analysis.
Following arthrectomy, the affected vessel will be treated by supplementary Ranger Drug Eluting Balloon (DEB).
During post-procedure, patients will be started on dual antiplatelets for 3 month post intervention followed by Aspirin for life unless contraindicated. Clinical follow-up, duplex ultrasound (to assess for re-stenosis) and Ankle Brachial Pressure Index (ABPI) will be performed at 1-month, 6-month and 12-month. Assessment of the symptoms, pulse, and clinical patency will be performed at each visit."
1537711|NCT02686528|Other|Hip Precautions|Hip precautions are functional limitations of the hip replacement prescribed to patients for the first six weeks after surgery and are no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
1537712|NCT02686528|Other|No Hip Precautions|Patients will not be prescribed hip precautions in the first 6 weeks after surgery. The hip precautions that will no longer be prescribed are: no hip flexion past 90º, no crossing the legs, and no twisting at the waist.
1537713|NCT02686515|Device|single-task balance training|The framework of progressive balance exercises in the single-task training will include body stability tasks (Stance activities), transitional activities (Sit to stand and walk), and body transfer tasks (Gait activities). These exercises target various systems for balance control, such as stability limits (standing with changes in base of support and weight shifting), sensory orientation (standing on compliant surfaces with eyes open and eyes closed), postural responses (reactions to balance perturbation, sit to stand and walk), and gait (treadmill walking with increasing speed).
1537714|NCT02686515|Device|dual-task balance training|Three cognitive tasks will be used for dual-task training while standing and walking: auditory discrimination tasks, verbal fluency tasks, and calculation tasks. In addition, motor tasks such as carrying a bag, holding a glass of water, alternating hand movement, carrying a tray with glasses, or getting keys out of a pocket will also be included as added tasks.
1537715|NCT02686502|Behavioral|Lifestyle|As part of the intervention Mode 2 and 3 subjects will use various mobile health applications including heart rate monitor, global positioning system, diet diary, and weight, sleep and mood monitors. They will also be offered music streaming service for e.g. motivation and relaxation.
1537791|NCT02685839|Other|general physical therapy|
1537792|NCT02685826|Drug|Durvalumab|
1537718|NCT02686476|Drug|Empagliflozin|group I (n = 50): T2DM patients receiving standard care for T2DM (metformin, sulfonylurea, DPP-4 inhibitor or insulin, in any combination) plus 10 mg of Empagliflozin per day
1537719|NCT02686463|Procedure|Laparoscopy|Laparoscopy is an operation performed in the abdomen or pelvis through small incisions (usually 0.5-1.5 cm) with the aid of a camera. It can either be used to inspect and diagnose a condition or to perform surgery.
1537720|NCT02686463|Procedure|Laparotomy|A laparotomy is a surgical procedure involving a large incision through the abdominal wall to gain access into the abdominal cavity. It is also known as a celiotomy.
1537722|NCT02686411|Behavioral|Participant Questionnaires|"Participants complete 2 questionnaires about satisfaction and impression of care received in the PCU, how much distress experienced in past week, and level of comfort with being transferred to the PCU. Questionnaires take about 15 minutes to complete.
Two (2) weekdays after completion of first set of questionnaires, 2 questionnaires completed about overall satisfaction and impression of care received in the PCU, and how much distress experienced in the past few days. One (1) questionnaire asks comparison of care received with the palliative care consult, to the care received in the PCU. These questionnaires should also take about 15 minutes to complete."
1537723|NCT02686411|Behavioral|Caregiver Questionnaires|"Caregiver completes questionnaire about their demographic information. It should take about 5-10 minutes to complete.
Caregiver then completes 2 questionnaires about their overall satisfaction and impression of care their family member or friend received in the PCU, how much distress experienced in past week, and level of comfort felt with family member/friend being transferred to the PCU. These questionnaires should take about 15 minutes to complete.
Two (2) weekdays after completion of first set of questionnaires, same questionnaires completed about overall satisfaction and impression of care their family member or friend received in the PCU and how much distress experienced in the past few days. One (1) questionnaire asks caregiver to compare the care their family member or friend received with the palliative care consult, to the care their family member/friend received in the PCU. These questionnaires should take also about 15 minutes to complete."
1537724|NCT02686398|Biological|Fluad|
1537725|NCT02686398|Biological|Agrippal|
1537726|NCT02686385|Drug|Prednisolone|
1537727|NCT02686385|Drug|N-Acetylcysteine|NAC (N-Acetylcysteine) dosing-Loading dose: 150 mg/kg IV; mix in 200 mL of 5% dextrose in water (D5W) and infuse over 1 h Dose 2: 50 mg/kg IV in 500 mL D5W over 4 h Dose 3: 100 mg/kg IV in 1000 mL D5W over 16 h
1537728|NCT02686372|Other|Biological: HBV antigen specific TCR redirected T cell|Subjects will receive escalating doses of HBV antigen specific TCR redirected T cell infusion.
1537729|NCT02686359|Biological|sample|
1537730|NCT02686346|Drug|Brentuximab Vedotin|"Phase I:
Cohort K: BV on Day 1: 1.2 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K+1: BV on Day 1: 1.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4) Cohort K-1: BV on Day 1: 0.8 mg/kg (cycle 1-3) and 1.8 mg/kg (cycle 4)
Phase II:
BV on Day 1: at the Maximal Tolerated Dose (MTD) defined at Phase I"
1537731|NCT02686346|Drug|Etoposide|100 mg/m² Days 1-2-3 of Cycles 1-2-3
1537732|NCT02686346|Drug|Carboplatine|max 800mg Day 2 of Cycles 1-2-3
1537733|NCT02686346|Drug|Ifosfamide|5 g/m² Day 2 of Cycles 1-2-3
1537734|NCT02686333|Other|Meditation|10-15 minutes of individually conducted medication practices (silent meditations, guided meditations, body scans, gentle arm movement exercises).
1537735|NCT02686307|Procedure|ICD Implant|Implantation of an implantable cardioverter/defibrillator
1537736|NCT02686294|Drug|HL151|Test drug : HL151. 1T, once a day oral administration, for 4 days
1537737|NCT02686294|Drug|TALION tab.|Reference drug : TALION tab. 1T, twice a day oral administration, for 4 days
1537738|NCT02686281|Drug|GMC-252-L-Lysine|
1537739|NCT02686281|Other|Placebo|
1537740|NCT02686255|Other|complete blood count|complete blood count during follow up in the heart institute
1537741|NCT02686242|Procedure|spinal anesthesia|bupivacaine injected by spinal puncture
1537742|NCT02686242|Procedure|general anesthesia|general anesthesia with intubation
1537743|NCT02686229|Other|no interventions|
1537744|NCT02686216|Drug|F-18 THK-5351|Totally 24 subjects age 20-90 including 12 healthy cognitively intact subjects and 12 probably AD patients with NINCDS-ADRDA criteria. For disease subjects, caregiver should be able to report activities of daily living and their mental status. Patient should be able to give informed consent or have a caregiver give consent with subject assent.
1537745|NCT02686203|Device|B-Cure Laser Pro and needles|"Treatment will consist of acupuncture applied by a combination of B-Cure Laser Pro, an approved handheld, portable device emitting low level laser, and needles using two to four acupoints (The Investigational Therapy).
The Investigational Therapy will be administered by a treating therapist designated by the Sponsor who is experienced in employing the treatment"
1537746|NCT02686190|Other|Luxtherapy|
1537747|NCT02686177|Drug|Liraglutide|
1537748|NCT02686177|Drug|Metformin or sulfonylurea|
1537749|NCT02686164|Drug|Lenvatinib|Lenvatinib 24 mg (as one 4 mg and two 10 mg capsules) will be administered orally once daily with 240 mL (8 fluid oz) of water each morning, starting on Cycle 1 Day 1, in 28-day cycles.
1537750|NCT02686164|Drug|Midazolam|Midazolam syrup 4 mg will be administered orally after an overnight fast on Cycle 1 Day -3 and concurrently with lenvatinib on Day 1 and Day 14 of Cycle 1. Participants will have to remain fasting for 2 hours after each dose of midazolam.
1537751|NCT02686151|Drug|Letrozole|used after oocyte retrieval
1537752|NCT02686151|Drug|Polygeline|used after oocyte retrieval
1537753|NCT02686151|Drug|Sodium Chloride|used after oocyte retrieval
1537754|NCT02686151|Drug|dexamethasone|used after oocyte retrieval
1537755|NCT02686138|Drug|Tenapanor|
1537756|NCT02686138|Drug|Placebo|
1537757|NCT02686125|Device|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their dystonia symptoms will be offered participation in this registry.
1537758|NCT02686099|Device|SternaLock 360|Sternal closure with SternaLock 360
1537759|NCT02686099|Device|Wire Cerclage|Sternal closure with standard wire cerclage
1537760|NCT02686086|Device|vibrating mesh nebuliser|The Aerogen Solo vibrating mesh nebuliser is an approved 13 485 class II medical device (CE marked) nebuliser licenced for the delivery of physician-prescribed medications for inhalation which are approved for use with a general purpose nebuliser. It has been shown in previous laboratory and clinical studies to have superior drug delivery to standard jet nebulisers.
1537761|NCT02686086|Device|Standard hospital jet nebuliser|"The standard hospital jet nebuliser refers to the nebuliser in clinical use currently throughout Beaumont Hospital and used for the administration of nebulised medications"
1537762|NCT02686086|Drug|Combined salbutamol 2.5 mg and ipratropium 0.5mg nebule|All patients admitted to hospital with an exacerbation of COPD are administered nebulised bronchodilators (salbutamol 2.5mg/ipratropium 0.5mg combination) as standard of care
1537763|NCT02686060|Device|0.2 micron positively charged PALL Corporation filters and 1.2 micro IV in-line filters used for lipid administration|
1537764|NCT02686047|Device|HYAJOINT Plus|The patients in the HYAJOINT Plus group received one intraarticular injection of 3 ml HYAJOINT Plus (2% microbial fermented HA, 20 mg/ml).
1537765|NCT02686047|Device|Synvisc-One|The Synvisc-One group received one injection of 6 ml Synvisc-One (0.8% avian derived HA, 8 mg/ml).
1537771|NCT02686008|Drug|Olaparib|Patients will receive olaparib administered at 300 mg bid x 14 days orally
1537772|NCT02685995|Device|VectorFlow TDC|TDC insertion, either VectorFlow or Palindrome, will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
1537773|NCT02685995|Device|Palindrome TDC|TDC insertion, either VectorFlow or Palindrome, will be in accordance with its FDA-approved indication under moderate sedation or general anesthesia with local anesthesia using 1% lidocaine in per institutional protocol. Following TDC insertion, the catheter may be used immediately. The goal of HD is typically to achieve a target effective blood flow of 300mL/min within the first 3 hemodialysis sessions. The dialysis records from each of the first three HD sessions will be reviewed by the study coordinator for (A) Blood flow rate (QB), (B) Arterial and venous lumen pressures, (C) Kt/V, and (D) Urea reduction ratio (URR). Additionally, need and use of thrombolytic infusion (ie t-PA) (other than single dose injection) to restore or improve patency and/or need for catheter exchange.
1537775|NCT02685969|Procedure|18F-Flutemetamol & 18F-FDG|Characterization of cerebral amyloid deposition with 18F-Flutemetamol PET and glucose metabolism 18F-FDG PET.
1537776|NCT02685956|Device|Vela Sentosa SA HSV1/2 Qualitative PCR Test|medical device test using Vela Sentosa SA HSV1/2 Qualitative PCR Test
1537777|NCT02685943|Behavioral|Psychotherapy|
1537778|NCT02685930|Behavioral|Antibiotic de-escalation by ICU stewardship team with decreased exposure to broad spectrum antibiotics and shorter duration of therapy|ICU stewardship team will provide recommendations to the ICU team regarding antibiotic de-escalation and duration of therapy in attempts of improving antibiotic stewardship practices without compromising patient outcomes.Recommendations will be based on patient showing clinical improvement combined with microbial culture data.
1537779|NCT02685917|Procedure|Microfracture without Collagen Augmentation|Cartifill applied for collagen augmentation
1537780|NCT02685917|Procedure|Microfracture with Collagen Augmentation|Cartifill applied for collagen augmentation
1537781|NCT02685904|Biological|ENIA11|
1537782|NCT02685904|Biological|Placebo|
1537783|NCT02685891|Other|Playing tones during deep sleep|Playing tones time locked to slow waves (Duration:50ms, volume: 50dB)
1537784|NCT02685891|Other|sham condition|in the sham condition, no tones will be played
1537785|NCT02685865|Device|FCSEM Stent|Hot Axios Fully covered self-expandable metal stent - Boston Scientific
1537786|NCT02685865|Device|Plastic Stent|7 French 4 cm double pigtail plastic stent - Cook 7 French 4 cm double pigtail plastic stent - Boston Scientific
1537787|NCT02685852|Drug|Exenatide|Exenatide at a dose of 5 mcg
1537788|NCT02685852|Drug|Acarbose|Acarbose at a dose of 25 mg
1537789|NCT02685852|Drug|Placebo|Placebo
1537795|NCT02685787|Behavioral|Psychosocial Intervention|The caregiver in the intervention arm will meet the counselors six times. The first and the last sessions will be attended by the caregiver only whereas the remaining four sessions will be attended by the caregiver and other family members. Interventions will be tailored for the caregivers based upon: 1) depression and anxiety; 2) burden; 3) self care and health-related behavior; 4) social support; and 5) behavioral symptoms. The design and management of the structured intervention will follow a published counseling caregiver manual, based on the experiences matured at New York University. Every session will be documented.
1537796|NCT02685787|Behavioral|Educational Intervention on AD|"The caregiver enrolled in this arm:1) will not receive counseling or support; 2) will participate to group sessions; 3) the six hours sessions will divulge information on AD using a slide-show. Each session will focus on the following topic: (a) diagnosis and treatment b) cognitive deficit management, c) behavioral disturbance management, d) daily living management, e) non-pharmacological treatment, f) legal issues and available health and social services.
Additionally, contrary to other arm, caregivers will not receive any telephone calls after the end of the educational sessions."
1537797|NCT02685774|Drug|Duvie Tab. 0.5mg, Glucophage XR Tab. 500mg|Duvie Tab. 0.5mg 1T, Glucophage XR Tab. 500mg 2T oral administration
1537798|NCT02685774|Drug|CKD-395 0.25/500mg|CKD-395 0.25/500mg 2T oral administration
1537799|NCT02685761|Procedure|Midline Vertical|Cesarean section performed using a midline vertical skin incision, located between the umbilicus and pubis
1537800|NCT02685761|Procedure|High Transverse|Cesarean section performed using a transverse skin incision located above the pannus
1537801|NCT02685748|Drug|Aspirin|1000 mg pd in two doses
1537802|NCT02685748|Drug|Placebo|two pills twice a day (instead of aspirin and pantoprazole)
1537803|NCT02685748|Drug|Pantoprazole|Pantoprazole 40 mg/pd in two doses, for gastric protection
1537804|NCT02685735|Drug|Gabapentin|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
1537805|NCT02685735|Drug|Placebo|Drug treatment will begin 2 weeks prior to surgery and continue 3 weeks afterwards. Subjects randomized to gabapentin will receive 900 mg/day for the first week, 1800 mg/day for the next 3 weeks, and 900 mg/day for the last week.
1537806|NCT02685722|Biological|UC-MSCs Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,Observation of UC-MSCs Gel group patients efficacy, safety and tolerability of selective parameter.
1537807|NCT02685722|Other|Gel group|This study for a six-month trials,Randomized, open, and parallel comparison before and after its own,Stage test includes screening stage, stochastic screening of more than a month difficult to heal wounds 20 people.By generating a random number of principle,observed and compared Gel group patients may be no efficacy.
1537808|NCT02685709|Drug|Octreotide capsules|Octreotide capsules 40mg/day, 60mg/day, 80mg/day
1537809|NCT02685709|Drug|Injectable Somatostatin Analogs (octreotide or lanreotide)|Octreotide - 10, 20, 30mg. Lanreotide 60,90, 120mg.
1537810|NCT02685709|Drug|Cabergoline|Cabergoline - 3.5mg/week
1537811|NCT02685696|Device|Alexis O Retractor|A newly developed abdominal wall retractor for Caesarean Section is the Alexis O Ring which is formed of 2 rings and a interconnecting plastic polyurethane sheath where the flexible inner ring is placed into the abdomen and where the rigid outer ring is rolled to create tension on the plastic sheath providing 360° abdominal wound retraction with simultaneously a tamponade effect whilst covering the abdominal wound during the Caesarean Section and delivery of the baby.
1537812|NCT02685696|Device|Metal Retractor|The traditional self-retaining metal Collins Caesarean Wound Retractor.
1537813|NCT02685683|Drug|GED-0301|During Induction period patient will receive mongersen 160 mg daily for 12 weeks. This study also offers subjects the option to continue with maintenance treatment at the discretion of the Investigator, beginning after the Week 12 Visit with alternating no IP for 4 weeks, followed by mongersen (GED-0301) 160 mg QD for 4 weeks, up through the Week 52 Visit during the Maintenance Period. At Week 52, subjects who have achieved an endoscopic improvement of >50% from baseline based on the SES-CD, as assessed by the central reader, and clinical improvement (HBI <7), will have the option to continue receiving treatment for an additional year, up through Year 2 (ie, the Week 100 Visit).
1537814|NCT02685670|Biological|anti-CD19 CAR-T|Ex vivo-expanded autologous T cells modified to express CD19 CAR
1537815|NCT02685670|Drug|Fludarabine|
1537816|NCT02685670|Drug|Cyclophosphamide|
1537817|NCT02685657|Drug|Drug: Selumetinib|
1537818|NCT02685657|Drug|Doxorubicin|
1537819|NCT02685657|Drug|Cyclophosphamide|
1537820|NCT02685657|Drug|Docetaxel|
1537821|NCT02685644|Procedure|Laparoscopic removal of cysts|Women with endometrioma lesions will undergo laparoscopic removal. Cysts will be enucleated with blunt dissection of the cyst capsule and following traction, counter traction maneuver. Bipolar coagulation will be used sparsely and suturing will be the predominant choice for achieving bleeding control.
1537822|NCT02685631|Other|Yttrium-90 Resin Microspheres|Data collection into the RESIN registry
1537823|NCT02685618|Drug|Iloprost|
1537824|NCT02685618|Drug|Saline|
1537825|NCT02685618|Device|Phillips M1006B, offset by -10mmHg|Administration of blood pressure module M1006B: offset by -10 mmHg
1537826|NCT02685618|Device|Philips M1006B, No offset|Administration of blood pressure module M1006B: No offset
1537827|NCT02685605|Procedure|Standard surgery (neuronavigation-guided)|
1537828|NCT02685605|Radiation|Intraoperative radiotherapy|Dose to applicator surface: 20-30 Gy; Carl Zeiss INTRABEAM System. IORT with a surface dose of 30 Gy is recommended.Should the proximity to any risk structure not allow to apply 30 Gy, a dose reduction by up to 10 Gy (resulting in a surface dose of 20 Gy) is allowed.
1537829|NCT02685605|Radiation|Radiochemotherapy|EBRT to 60 Gy plus 75 mg/m2/d temozolomide
1537830|NCT02685605|Drug|Temozolomide|Adjuvant chemotherapy with 150-200 mg/m2/d temozolomide per cycle (5/28 days).
1537831|NCT02685592|Drug|5-aminolevulinic acid nanoemulsion|A 1 millimeter thick layer of 5-aminolevulinic acid nanoemulsion light sensitizing gel is applied on the skin and let to absorb 3 hours before illumination.
1538786|NCT02678286|Drug|Intravenous Placebo|
1537832|NCT02685579|Other|Treatment of Obstructive Sleep Apnea-CPAP/BiPAP etc./Diet/surgery/life style changes|
1537833|NCT02685566|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
1537834|NCT02685566|Device|FFDM|FujiFilm Aspire Cristalle System
1537835|NCT02685553|Device|NIR|Laparoscopic use of NIR
1537836|NCT02685514|Device|HIFU Graves|The HIFU treatment technique will be applied to the recruited participants
1537837|NCT02685501|Other|no intervention|
1537839|NCT02685475|Drug|Axillary Brachial Plexus Blocks|All patients received ultrasound-guided axillary brachial plexus block (ABPBs) with the mixture of 10 mL lidocaine 2% and 20 mL bupivacaine 0.5%.
1537840|NCT02685462|Drug|Rosuvastatin|
1537841|NCT02685462|Drug|Atorvastatin|
1537842|NCT02685462|Drug|Simvastatin|
1537843|NCT02685462|Drug|Digoxin|
1537844|NCT02685462|Drug|Caffeine|
1537845|NCT02685449|Drug|Insulin glulisine|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
1537846|NCT02685449|Drug|Insulin aspart|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
1537847|NCT02685449|Drug|Insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
1537849|NCT02685423|Behavioral|Binocular deprivation 10 days|Research participants will be asked to live 10 days in an experimentally-controlled dark environment.
1537850|NCT02685423|Behavioral|Vision training|Subjects will play a video game on their VR headset for 24 minutes per day, followed by 20 minutes of binocular experience with a brightness-reducing filter over the non-amblyopic eye.
1537851|NCT02685410|Other|One Night Stan Prototype|The One Night Stan prototype, will be a social network game with the goal of risk reduction and HIV/STI prevention in young black women.
1537852|NCT02685397|Drug|Leuprolide Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
1537853|NCT02685397|Drug|Goserelin Acetate|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
1537854|NCT02685397|Drug|Triptorelin|Luteinizing hormone releasing hormone (LHRH) agonist administered by subcutaneous injection. Only one of the LHRH agonists described here will be administered during the course of treatment.
1537855|NCT02685397|Drug|Enzalutamide|Anti-androgen medication for the treatment of metastatic castration-resistant prostate cancer. 160 mg (four 40 mg capsules) taken as a single oral daily dose, with or without food, until disease progression.
1537856|NCT02685397|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) is a treatment modality in radiation oncology that delivers a very high dose of radiation to the tumour target with high precision using a single or a small number of fractions.
1537857|NCT02685384|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
1537858|NCT02685371|Behavioral|Breathing|Subjects will have to breath 1- Spontaneously 2- to produce a negative pressure of -15 to -30 cm of water and 3- to produce a negative pressure more than -30 cm of water.
1537859|NCT02685358|Behavioral|Clinician-Supported PTSD Coach|Clinician-supported PTSD Coach is primary care-based treatment. In this treatment a primary care mental health clinician guides patients in using the PTSD Coach mobile app to learn about PTSD symptoms, treatment options, and strategies to cope with common PTSD-related concerns. It consists of 4 brief sessions over 8 weeks.
1537860|NCT02685358|Behavioral|Primary Care Mental Health Integrated Care as Usual|Existing primary care mental health integrated treatment will serve as the comparison condition
1537861|NCT02685345|Drug|DS-8500a 25 mg|
1537862|NCT02685345|Drug|DS-8500a 75 mg|
1537863|NCT02685345|Drug|placebo|
1537864|NCT02685332|Radiation|Stereotactic Radiation|Stereotactic Body Partial Breast irradiation Cohort 1: 22.5 Gy Cohort 2: 25 Gy Cohort 3: 27.5 Gy Cohort 4: 30 Gy
1537865|NCT02685319|Procedure|muscle biopsy|a muscle sample will be taken from the mid-thigh (Vastus Lateralis) and analyzed
1537866|NCT02685306|Biological|Bavituximab|12 weekly doses of bavituximab given on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
1537867|NCT02685306|Drug|Taxane|12 weekly doses of taxane on Days 1, 8,15,22,29, 36, 43, 50, 57, 64, 71, 78
1537868|NCT02685293|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)
1537869|NCT02685293|Drug|Placebo MDI|Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol
1537870|NCT02685280|Device|Medtronic Restore Advanced 37713|Rechargeable neurostimulators are implanted when the non-rechargeable neurostimulators are end-of-life.
1537871|NCT02685267|Drug|Docetaxel|
1537872|NCT02685267|Drug|Enzalutamide|
1537873|NCT02685267|Drug|Prednisone|
1537874|NCT02685254|Behavioral|Structural skills training group|Weekly 2-hours sessions for 14 weeks follow the Norwegian translation of the Swedish version of the ADHD skills training manual/workbook (Hesslinger 2010; Hirvikoski 2011; Morgensterns 2015) which is based on an adaption of Marsha Linehan's dialectical behavior therapy (DBT) for borderline personality disorder into a group-based skills training program for adults with ADHD (Hesslinger 2002; Philipsen 2007). The groups embrace 7 - 10 participants, and two group leaders trained in group therapy, cognitive-behavioral treatment or DBT. Each session contains an initial short repetition and feedback on the previous session, followed by review of the homework during the first hour. After a break, a new topic with exercises and homework for the following week is introduced.
1537875|NCT02685254|Other|Treatment as usual|Treatment as usual includes clinical management and/or medication, and or supportive counselling by physician or nurse
1537876|NCT02685228|Drug|Decitabine|decitabine 5mg/m2,d1-d5;
1537877|NCT02685228|Drug|Gemcitabine|gemcitabine 1.0g/m2, d8,d15,d22
1537879|NCT02685189|Other|Previous exposure to stannsoporfin|No intervention in this protocol
1537880|NCT02685176|Device|Charcoal Heater (STK Heatpac, Emergco Tech Solutions, B.C.)|A heater (STK Heatpac) will be used in the active warming arms of the study.
1537881|NCT02685176|Other|No heat|No active heating provided post cooling
1537882|NCT02685163|Other|Antioxidant ice-cream|Narutal Antioxidant ice-cream
1537883|NCT02685163|Other|Control Ice-cream|Natural Control Ice-cream
1537884|NCT02685150|Device|Endoscopic Tri-Modal Imaging|Endoscope that combines white light imaging (WLI) with autofluorescence imaging (AFI) and narrow band imaging (NBI).
1537885|NCT02685150|Drug|Omeprazole|Omeprazole is one kind of proton-pump inhibitors. All participants undergo standard proton-pump inhibitor (PPI) tests for two weeks with Omeprazole, 20mg twice a day.
1537886|NCT02685150|Other|Analysis of gastric juice|Analysis of gastric juice including routine, biochemical and microbiological analysis.
1537887|NCT02685137|Drug|stannsoporfin|Intramuscular injection of stannsoporfin to treat jaundice.
1537888|NCT02685137|Other|Sham Injection|nothing
1537889|NCT02685124|Dietary Supplement|Orange juice|Three days before the start of the study, all participants will restrict their diet avoiding citrus fruits (orange, tangerine, lemon) and its derivatives (washout period), red fruits and vegetables (strawberry, red lettuce, red grape, tomate). The day before the sample collection will be provided a controlled dinner. A fasting for 8 hours will be required before blood and urine collection. All participants will divided into three groups: I (Cara Cara), II (Bahia), III (Isocaloric control drink). They will consume 250 ml of each drink twice daily for 7 consecutive days, with a washout period of 7 days among each intervention.
1537890|NCT02685111|Drug|Filgrastim|Filgrastim (Gracinᵀᴹ) is administered at the D3, D5, D7, D9, and D11 of each cycle. A dose of 5 μg/kg/day filgrastim is administered S.C. either as a bolus injection or as a continuous injection. Administer into the outer upper arm, abdomen (except within 2 inches of navel), front middle thigh, or the upper outer buttocks area.
1537891|NCT02685111|Drug|Peg-filgrastim|Pegfilgrastim (Neulastaᵀᴹ) is administered at the D2 of each cycle. A dose of 6mg once a cycle is administered S.C., 24 (± 2) hours after completion of chemotherapy.
1537892|NCT02685098|Biological|Allogeneic bone marrow derived mesenchymal stem cells|Injection of HLA-A2 and/or gender mismatched allogeneic MSCs into the anterior tibialis muscle (ATM) of patients scheduled for semi-elective BKA 3-21 days before surgery.
1537893|NCT02685085|Drug|Misoprostol ( Prostaglandin E2)|
1537894|NCT02685085|Device|Foley's catheter|
1537895|NCT02685072|Drug|Progesterone (200 mgs BID)|TNP + Progesterone
1537896|NCT02685072|Drug|Placebo|TNP + Placebo
1537897|NCT02685059|Drug|MEDI4736 (Anti PD-L1)|"MEDI4736 1.5g total i.v. every 4 weeks
As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:
MEDI4736 in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by
MEDI4736 in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
1537898|NCT02685059|Drug|Placebo|"Placebo i.v. every 4 weeks
As monotherapy for the first two weeks (0.75g absolute) (part 1) followed by:
Placebo in combination with nab-paclitaxel 125 mg/m² every week for 12 weeks (part 2) followed by
MEDI4736/Placebo in combination with epirubicin 90mg/m² plus cyclophosphamide 600 mg/m² every 2 weeks for 4 cycles (part 3)."
1537899|NCT02685059|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
1537900|NCT02685059|Drug|Epirubicin|Epirubicin 90 mg/m² 2-weekly for 8 weeks
1537901|NCT02685059|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m² 2-weekly for 8 weeks
1537902|NCT02685046|Drug|Imatinib|Subjects will be treated with the medicinal product imatinib, which will be administered orally in tablets of 400mg, once per day, during two weeks prior to tumor resection.
1537903|NCT02685033|Drug|Dalbavancin|
1537904|NCT02685033|Drug|Comparator|
1537908|NCT02685007|Other|Tachosil|TachoSil is a collagen matrix that is coated with human fibrinogen and human thrombin.
1537909|NCT02684994|Behavioral|Cognitive Processing Therapy|Cognitive-processing therapy is a well-supported treatment for reactions following traumatic events. It includes 12 individual psychotherapy sessions and consists of 4 components: education about trauma responses, experiencing emotions related to the assault, development of skills for examining the truth of thoughts, and examination of beliefs in areas commonly influenced by the trauma.
1537910|NCT02684968|Procedure|Colorectal surgery|
1537911|NCT02684955|Device|Cerebral spectroscopy|Cerebral spectroscopy (near-infrared spectroscopy - NIRS) allows to measure with a noninvasive method the local oxygen saturation of the prefrontal cortex (rSO2), reflecting the balance between need and supply of brain oxygenation.
1537912|NCT02684955|Device|Pupillometry|The quantitative measurement of the pupillary light reaction has been described to predict neurological outcome
1537913|NCT02684942|Drug|Meperidine|Injection meperidine 1 mg/kg with diazepam 0.1 mg/kg.to intravenous 5 minutes before inserting the applicator and then when the patients had pain score greater or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
1537914|NCT02684942|Drug|Fentanyl|Injection meperidine 1 mg/kg to intravenous 5 minute before insertion the applicator and then when the patients had pain score greater than or equal to 4. All patients received supplement oxygen cannula 3 LPM continuously monitored for saturation, pulse and monitored every 5 minutes for blood pressure.
1537915|NCT02684929|Dietary Supplement|branched chain amino acids|15 (women) or 20 (men) grams of BCAA daily for 3 months
1537916|NCT02684916|Procedure|Chiropractic treatment|"The child receives chiropractic manipulation treatment in the neck and in the spine and pelvis according to individual needs. They also receive a written list of general advice regarding lifestyle and habits.
The parents and the child are unaware of group allocation."
1537917|NCT02684916|Procedure|Placebo|Non-therapeutic placebo treatment: a broad non-specific contact outside the spinal column is taken on subject's scapula and gluteal region lying in a side posture position, on the scapulae in a prone position and on trapezius muscles in a sitting position. In those positions the chiropractor pushes in a non-intentional and non- therapeutic directional line with a low-amplitude, low velocity push maneuver. All contacts are performed without soft tissue pre-tension and gentle contact, to insure that no joint cavitation occurs. To obtain a noise that many people associate with a chiropractic spinal adjustment, a de-activated Activator Instrument is used on the arm of the chiropractor to give a click-sound. General advice on lifestyle and habits is handed out to the placebo group as well.
1537919|NCT02684877|Other|Questionnaire|
1537920|NCT02684864|Other|Non-interventional|
1537921|NCT02684851|Drug|Tranexamic Acid|Tranexamic acid: anti-fibrinolytic agents
1537922|NCT02684851|Drug|Placebo|Placebo
1537923|NCT02684825|Device|Reveal LINQTM- LNQ11 Internal Loop Recorder plus standard cardiac monitoring|Reveal LINQTM- LNQ11 continuously monitors cardiac electric activity for up to three years.
1537924|NCT02684812|Drug|Tranexamic Acid|Treatment until aneurysm treatment or maximum dosage of 4 gram
1537925|NCT02684799|Drug|Cenicriviroc|
1537926|NCT02684799|Drug|Omeprazole|
1537927|NCT02684799|Drug|Famotidine|
1537928|NCT02684786|Drug|reserpine|Patients with qualifying hemodynamics from prior right heart catheterization will receive open label reserpine, 0.05 mg by mouth daily for two weeks, then 0.10 mg by mouth daily for two weeks, and then have repeat non-invasive assessments of status
1537929|NCT02684786|Procedure|stellate ganglion block|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
1537930|NCT02684786|Drug|lidocaine|Patients with suspected group 2 pulmonary hypertension by clinical and non-invasive assessments and are scheduled to undergo clinically indicated right heart catheterization will have pulmonary artery pressures measured. If qualifying severity of group 2 pulmonary hypertension is present, after clinically indicated assessment of inhaled nitric oxide, their baseline hemodynamics will be allowed to re-equilibrate over 10 minutes, and then ultrasound guided left stellate ganglion block with lidocaine will be performed, and hemodynamics reassessed 10 minutes afterward
1537931|NCT02684773|Procedure|Conventional Hemodialysis|The intervention involves 3 hemodialysis sessions/week that consists of 4 hours/session
1537932|NCT02684773|Procedure|In-centre Nocturnal Hemodialysis|The intervention involves 3 hemodialysis sessions/week administered overnight (8 hours/session) in-hospital
1537933|NCT02684760|Drug|PF-06651600|PF-06651600 will be administered as a tablet and extemporaneously prepared solution in each cohort.
1537934|NCT02684747|Other|Autologous Transfusion|Participants will receive autologous transfusion on Day 21
1537935|NCT02684747|Other|Control - Normal Saline (Placebo)|Participants will receive saline on Day 21
1537936|NCT02684721|Other|8-week home-based exercise programme|8-week home-based exercise programme is assigned to patients in exercise group following discharge. This includes 3 follow-up telephone calls by physiotherapist.
1537937|NCT02684708|Drug|cyclophosphamide, vincristine, prednisone, dacarbazine|28-day chemotherapy cycle
1537938|NCT02684708|Drug|cyclo, vcr, pred, dacarb,etop and doxo|21-day chemotherapy cycle
1537939|NCT02684695|Other|MRI scan (adolescent spine protocol)|MRI scan of the lumbar spine and sacroiliac joints
1537940|NCT02684695|Other|MRI scan (whole body protocol)|MRI scan of multiple joints ('whole body')
1537941|NCT02684682|Behavioral|Frequency of mechanical control of plaque (12h)|Performing oral hygiene 12 in 12 hours, with tooth brush and interdental device.
1537942|NCT02684682|Behavioral|Frequency of mechanical control of plaque (24h)|Performing oral hygiene 24 in 24 hours, , with tooth brush and interdental device.
1537943|NCT02684682|Behavioral|Frequency of mechanical control of plaque (48h)|Performing oral hygiene 48 in 48 hours, , with tooth brush and interdental device.
1537944|NCT02684669|Drug|Naloxone|active drug infusion
1537945|NCT02684669|Drug|Normal saline|placebo comparator
1537946|NCT02684656|Procedure|Hemodialysis|Hemodialysis >/=4h
1537947|NCT02684656|Procedure|Hemodiafiltration|Hemodiafiltration >/=4h, > 20l convection
1537948|NCT02684643|Other|enhanced individualised therapy|additional dialysis dosage, modification of medication and prescribed dietary plan
1537949|NCT02684643|Other|non-enhanced individualised therapy|modified medication, prescribed dietary plan and regular three times/week dialysis dosage
1537950|NCT02684643|Other|regular intervention|Phosphate binders and calcitriol would be prescribed according to the guidelines. Phosphate binders included in the study are calcium acetate, calcium carbonate or sevelamer. Dosage is based on patients serum phosphate and calcium level. Calcitriol prescribed in the study is Rocaltrol and the dosage is based on PTH, serum phosphate and calcium level. Patients' diet habit will not be altered.
1537951|NCT02684630|Device|Trima Accel System|Platelet Apheresis Procedure
1537952|NCT02684617|Biological|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 of infusion Cycles 1-35
1537953|NCT02684617|Drug|dinaciclib|dinaciclib 7 mg/m^2 administered as an IV infusion on Day 1 of infusion Cycle 1, dinaciclib 10 mg/m^2 administered as an IV infusion on Day 8 of infusion Cycle 1, dinaciclib 14 mg/m^2 administered as an IV infusion on Days 1 and 8 of infusion Cycles 2-35
1537954|NCT02684591|Drug|Aramchol|Aramchol, a conjugate of Cholic acid and Arachidic acid, is a first in class member of a novel family of synthetic Fatty-Acid / Bile-Acid Conjugates (FABACs). FABACs are composed of endogenic compounds, orally administrated with potentially good safety and tolerability parameters
1537955|NCT02684591|Drug|Placebo|Placebo
1537956|NCT02684578|Drug|Metformin|
1537957|NCT02684565|Dietary Supplement|BCAA High Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
1537958|NCT02684565|Dietary Supplement|BCAA Low Protein supplement|Subjects will be randomly assigned to take high BCAA or low-BCAA protein a day for 4 weeks, then switch to BCAA or low-BCAA protein for 4 weeks after a 2-week washout.
1537959|NCT02684552|Device|Non invasive ventilation|Training on treadmill with Non invasive ventilation
1537960|NCT02684552|Device|Oxygen|Training on treadmill with oxygen
1537961|NCT02684539|Device|tilt table Erigo®|tilting table with onset of syncope
1537962|NCT02684526|Procedure|Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using the Eovist contrast agent. This MRI scan takes approximately 45minutes to 1 hour to complete.
1537963|NCT02684526|Procedure|Non Eovist Contrast|Subjects will undergo an MRI (magnetic resonance imaging) scan using a contrast agent other than Eovist. This MRI scan takes approximately 45minutes to 1 hour to complete.
1537964|NCT02684513|Dietary Supplement|Oral Carbohydrate Beverage|The oral carbohydrate beverage will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
1537965|NCT02684513|Dietary Supplement|Rehydration beverage|The rehydration beverage group will be consume in a 710 mL amount the evening prior to surgery and then a 355 mL amount the morning of surgery.
1537966|NCT02684500|Device|Ultrasound|Study measurements of the diameter and doppler flow velocity of the superior mesenteric artery (SMA) for a aneurysmal subarachnoid hemorrhage using abdominal ultrasound.
1537967|NCT02684487|Drug|vitamin D3|Patients will be given 400,000 IU of vitamin D3 within 24 hours of severe sepsis onset followed by weekly doses of 25,000 IU until 90 days or death, whichever comes first.
1537968|NCT02684487|Drug|Placebo|Patients will be given placebo within 24 hours of severe sepsis onset followed by weekly doses of placebo until 90 days or death, whichever comes first.
1537969|NCT02684474|Biological|HBOC-201|Intravenous administration of a hemoglobin based oxygen carrier (HBOC) in patients with life-threatening anemia, for whom allogeneic blood transfusion is not an option.
1537970|NCT02684461|Drug|Pembrolizumab|"Receive Pembrolizumab 200 mg on day 1 every 21 days for four cycles.
Receive nab-paclitaxel 100 mg/m2 on day 1 and day 8 every 21 days for four cycles."
1537971|NCT02684448|Procedure|Inguinal Hernia Repair|Inguinal (unilateral or bilateral) hernia repair
1537972|NCT02684435|Drug|Perflutren lipid microsphere|Dosing per approved package label
1537973|NCT02684422|Other|Intervention N/A. Observational study|There are no interventions to the subjects other than collection of an expectorated sputum since this is an observational study; There are no study groups.See details per detailed study description.
1537974|NCT02684409|Drug|PROT-CL-NP101-015.01|
1537975|NCT02684396|Drug|TAK-648|TAK-648 Solution
1537976|NCT02684396|Drug|TAK-648 Placebo|TAK-648 placebo-matching solution
1537977|NCT02684383|Biological|rDEN3∆30|10^3 plaque-forming units (PFUs); administered by subcutaneous injection in the deltoid region of the upper arm
1537978|NCT02684383|Biological|Placebo|Administered by subcutaneous injection in the deltoid region of the upper arm
1537979|NCT02684370|Drug|ABBV-066|
1537980|NCT02684370|Drug|ustekinumab|
1537981|NCT02684370|Drug|placebo to ABBV-066|
1537982|NCT02684370|Drug|placebo to ustekinumab|
1537983|NCT02684357|Drug|ABBV-066|
1537984|NCT02684357|Drug|ustekinumab|
1537985|NCT02684357|Drug|placebo for ABBV-066|
1537986|NCT02684357|Drug|placebo for ustekinumab|
1537987|NCT02684344|Drug|Tamsulosin|Tamsulosin may have prophylactic properties against post-operative urinary retention
1537988|NCT02684344|Other|Education|Education about signs and symptoms of urinary retention
1537989|NCT02684331|Other|Cardiac Magnetic Resonance Imaging (CMR)|An extensive explorative CMR protocol, including time/volume curves of LV and LA, rest and stress perfusion (with Adenosin) and time/volume curve of LA after chronotropic stress with Glycopyrrolate, further flow measurements and T1 mapping.
1537990|NCT02684331|Other|Echocardiography|Standard measurements and strain.
1537991|NCT02684331|Other|Bood samples|HbA1c, Glucose, Hgb, Creatinin, Sodium, Potassium, Total cholesterol, LDL cholesterol, HDL cholesterol, Free fatty acids, ALAT, Urinary albumin, NT-proBNP, ANP, suPAR, Copeptin, Proendothelin, proCNP, Soluble ST2, Galectin-3
1537992|NCT02684318|Drug|PM01183 + olaparib|
1537993|NCT02684305|Drug|Administration of Propess|"History taking and physical examination including cervical length
Eligibility assessment
Explanation regarding the study protocol
Signed informed consent (at VAS<3)
Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.
Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
1537994|NCT02684305|Device|balloon|"History taking and physical examination including cervical length
Eligibility assessment
Explanation regarding the study protocol
Signed informed consent (at VAS<3)
Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.
Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
1537995|NCT02684305|Drug|Intravenous oxytocin infusion|"History taking and physical examination including cervical length
Eligibility assessment
Explanation regarding the study protocol
Signed informed consent (at VAS<3)
Women agreeing to continued induction of labor 24 hours after insertion of Propess, will be randomized using sealed envelopes to the subsequent method of induction of labor (additional vaginal insert vs. oxytocin infusion with intracervical balloon insertion with 60ml saline). Treatment will be given according to the pre-existing and approved departmental protocol. The protocol for oxytocin infusion is 4 units of Pitocin in 10 cc 0.9% NaCl, infused at a rate of 0.4 ml/hour. Infusion rate will be increased every 20 minutes until 3-4 contractions every 10 minutes are produced.
Follow up on all women will be performed from the time of second agent induction until discharge from hospital postpartum."
1537999|NCT02684266|Drug|SHR6390|SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD
1538000|NCT02684253|Drug|Nivolumab|
1538001|NCT02684253|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
1538002|NCT02684240|Drug|Nitazoxanide|nitazoxanide 1000 mg orally twice daily with food for 14 days
1538003|NCT02684240|Other|Control|The control arm will receive WHO standard therapy for tuberculosis with isoniazid, rifampin, pyrazinamide, and ethambutol
1538007|NCT02684214|Behavioral|Prevention Plus +|Families will receive 6 monthly newsletters and meet with a BHC at the clinic for 30 minutes during months 1, 3, and 5. Child height and weight will be taken. Families will receive feedback about growth and the weight status of their child. The session materials will be reviewed and behavioral parenting strategies will be encouraged to aid with changing two dietary and two leisure-time activity (energy balance) behaviors of the child. The caretaker will also change the same energy balance behaviors as the child, as adult caretakers can then model healthy behaviors. The caretaker and child will be encouraged to change and self-monitor energy balance behaviors with the use of the picture-based diaries. During months 2, 4, and 6, BHCs will complete a 20-minute phone call with the caretaker. Caretakers will be asked to measure the height and weight of their child, calculate BMI and plot it on the BMI-for-age growth chart prior to the call. The BHC will provide feedback.
1538008|NCT02684214|Behavioral|Prevention Plus -|This condition will be identical to PP+ except that caretakers will not receive any energy balance behavior goals. Additionally, the caretaker will not self-monitor energy balance behaviors. The focus will be on all other behavioral parenting strategies to assist the child with making changes in the targeted behaviors.
1538009|NCT02684201|Device|Boston Scientific Stimulator Lead|A Boston Scientific PMA P030017 spinal cord stimulator lead will be placed in the cervical epidural space of ten upper-limb amputees and steered laterally towards the dorsal spinal roots under fluoroscopic guidance.
1538011|NCT02684175|Device|Remote CI Counseling|The remote setup includes a 500 series teleconference audio and video live set-up. The teleconference set-up will be situated on a telemedicine cart and placed within the sound-proof booth at the testing site (UK ENT practice in Morehead, KY). The audiologist will deliver the session remotely.
1538012|NCT02684175|Other|In-Person CI Counseling|The standard face-to-face counseling that will occur between the participant and audiologist is the standard of care. No technology will be used. The audiologist will deliver the session face-to-face with the participant in the same room (standard practice).
1538013|NCT02684162|Drug|SGI-110|"Minimal Residual Disease (MRD) Group Starting Dose: 40 mg/m2 subcutaneously daily, Days 1 to 5.
Relapsed (REL) Group Starting Dose: 60 mg/m2 subcutaneously daily, Days 1 to 5."
1538014|NCT02684162|Procedure|Donor Lymphocyte Infusion|On Day 6 of Cycles 2, 4, and 6, participants receive a donor lymphocyte infusion by vein over about 10-30 minutes.
1538015|NCT02684149|Procedure|relational touch|
1538016|NCT02684136|Drug|suvorexant|suvorexant 20 mg taken before sleep
1538017|NCT02684136|Drug|placebo|placebo taken before sleep
1538018|NCT02684123|Drug|Apremilast|Subjects will get drug or placebo
1538019|NCT02684123|Drug|Placebo|
1538020|NCT02684097|Drug|Tralokinumab|All groups will receive study drug every two weeks for 24 weeks.
1538021|NCT02684097|Drug|Placebo|Matching placebo given every two weeks for 24 weeks
1538022|NCT02684084|Drug|Ozurdex|OZURDEX® (DEX implant; Allergan Inc. Irvine, CA, USA) is a sustained-release biodegradable implant approved for treatment of Macular Edema secondary to central retinal vein occlusion as well as noninfectious uveitis affecting the posterior segment
1538023|NCT02684084|Drug|Lucentis|LUCENTIS® (0.5 mg ranibizumab or RBZ, an anti-neovascular VEGF-A inhibitor, Novartis Pharmaceuticals Canada Inc.) was the first approved medical treatment for DME
1538024|NCT02684071|Drug|Intra thecal methotrexate|IT methotrexate via Ommaya reservoir with concomitant systemic topotecan and cyclophosphamide
1538025|NCT02684071|Drug|topotecan|To be administered in conjunction with methotrexate
1538026|NCT02684071|Drug|cyclophosphamide|To be administered in conjunction with methotrexate and topotecan
1539403|NCT02673866|Drug|pregabalin|pregabalin
1538033|NCT02684019|Drug|Dexmedetomidine|added to propofol sedation
1538034|NCT02684019|Drug|Magnesium Sulphate|added to propofol sedation
1538038|NCT02683993|Device|Lumenis Pulse 120H holmium laser system and 200 DFL ball tip fiber|The Lumenis Pulse P120H will be utilized in high and low frequencies according to subjects group allocation.
1538039|NCT02683980|Device|Lumenis Pulse P120H and Xpeeda side firing fiber|
1538040|NCT02683967|Procedure|acupuncture|patients received a Delphi acupuncture at least 3 times during their fertility treatment cycle.
1538043|NCT02683928|Biological|GBR 830|
1538044|NCT02683928|Biological|Placebo|
1538045|NCT02683915|Procedure|Therapeutic hypothermia|Infants in cooled group will be fitted a cooling cap (Olympic Medical Cool Care System, Olympic Medical) around the head for 72 h. infants will be nursed under a radiant overhead heater, which is servo-controlled to the infant's abdominal skin temperature and adjusted to maintain the rectal temperature at 33.5-34.5ºC. At the end of the 72 h cooling period, the infants will be slowly rewarmed at no more than 0•5ºC /h until their temperature become within normal temperature range (36.5-37.5ºC).
1538046|NCT02683902|Device|Active tDCS|The anode electrode will be placed over F4 position and the cathode electrode over F3, right and left respectively (using EEG 10/20 system). The electric current will be ramped up until it reaches 2 milliampere (mA), and subjects will be stimulated for 20 min.
1538047|NCT02683902|Behavioral|Hypocaloric diet|A hypocaloric dietary prescription and individual counseling from a dietician in order to reduce 3% of their initial weight over 4-week treatment.
1538048|NCT02683902|Device|Sham tDCS|The electrodes will be placed at the same positions as in active stimulation; however, the device will be turned off after 30 s of stimulation.
1538049|NCT02683889|Drug|Acthar|patients will receive acthar 80 units twice a week for 6 months and will measure recurrence of FSGS
1538050|NCT02683863|Drug|BG00012 (DMF) (Tecfidera®.)|Subjects will take DMF 120 mg BID for the first 4 weeks of treatment followed by DMF 240 mg BID for 24 weeks.
1538051|NCT02683850|Dietary Supplement|Omega-3 SPM™ softgel|This four week, prospective, non-randomized, open-label study is assessing the impact on quality of life from taking an Omega-3 SPM™ softgel supplement in adults with pain symptoms at screening of 4 or higher on the PROMIS-43 Profile - Pain Intensity subscale.
1538052|NCT02683837|Drug|Remifentanil|
1538053|NCT02683837|Device|Pupillometry|Pupillary diameter measured every 5 minutes
1538054|NCT02683837|Drug|Sevoflurane|Administered to maintain a Bispectral Index between 40 and 60
1538055|NCT02683824|Procedure|Computed Tomography|Undergo [18F] FP-R01-MG-F2 PET/CT scan
1538056|NCT02683824|Other|Laboratory Biomarker Analysis|Correlative studies
1538057|NCT02683824|Procedure|Positron Emission Tomography|Undergo [18F] FP-R01-MG-F2 PET/CT scan
1538058|NCT02683824|Drug|[18F]FP-R01-MG-F2|
1538059|NCT02683824|Drug|[18F]-FDG|
1538060|NCT02683811|Behavioral|Diario della Salute (DDS-2)|The updated version of Diario della Salute program (DDS-2) includes: 1) teachers' manual, 2) a booklet for teens telling the story of four same-age students (e.g. experimenting with risky behaviours, conflicting feelings and thoughts, need for independence and control, etc.), 3) a booklet for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflicts, parental control and supervision, family communication, etc.).
1538061|NCT02683798|Dietary Supplement|Continuous energy restriction|1 x formula food (202-209kcal) meal replacement per day
1538062|NCT02683798|Dietary Supplement|Intermittent energy restriction|4 x formula food (202-209kcal) total diet replacement per day, on 2 days per week
1538065|NCT02683759|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|"Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
Starting dose: 50 mg BID of Bioenhanced Curcumin Increase dose to 100 mg BID after two (2) weeks if there is no response to the drug"
1538066|NCT02683759|Drug|5-Aminosalicyclic acid|Dosage is as instructed by patient's physician
1538067|NCT02683746|Drug|Lyophilized albiglutide DCC pen injector|A fixed-dose, fully disposable pen injector system with a prefilled dual chamber glass cartridge (DCC) containing lyophilized albiglutide (30mg or 50mg) delivering an injection volume of 0.5mL.
1538068|NCT02683746|Drug|Lyophilized albiglutide DCC pen injector matching placebo|A fixed-dose, fully disposable pen injector system with a prefilled DCC containing matching placebo delivering an injection volume of 0.5mL
1538069|NCT02683746|Drug|Albiglutide liquid auto-injector|A fixed-dose, single use, disposable auto-injector containing albiglutide liquid (30mg or 50mg) in a prefilled glass syringe. The auto-injector delivers the albiglutide liquid in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
1538070|NCT02683746|Drug|Albiglutide liquid auto-injector matching placebo|A fixed-dose, single use, disposable auto-injector containing matching placebo in a prefilled glass syringe. The auto-injector delivers the matching placebo in an injection volume of 0.6 mL for the 30mg dose and 1.0 mL for the 50mg dose.
1538071|NCT02683733|Dietary Supplement|Bio-enhanced Curcumin Soft Gelatin Capsule|Each capsule is a bio-enhanced modification of curcumin (diferuloylmethane), which is a derivative of curcuma longa (rhizome extract)
1538073|NCT02683720|Dietary Supplement|ONS|randomized clinical trial involving different ONS strategies
1538074|NCT02683707|Other|Removal of Fentanyl from peri-procedural analgesia|Removal of Fentanyl from peri-procedural analgesia (which is otherwise routinely given for PCI)
1538075|NCT02683707|Drug|Fentanyl|IV peri-procedural analgesia
1538076|NCT02683707|Drug|Lidocaine|Local Anesthetic
1538077|NCT02683707|Drug|Midazolam|IV sedation
1538079|NCT02683668|Device|Handihaler-Tiotropium 18 mcg untrained|We are looking at the untrained used of Handihaler
1538080|NCT02683668|Device|Handihaler-Tiotropium 18 mcg trained|We are looking at the trained use of Handihaler after 14 days treatment
1538081|NCT02683668|Device|Respimat-Tiotropium 5 mcg trained|we are looking at the trained use of Respimat after 14 days treatment
1538082|NCT02683655|Drug|Apatinib|Apatinib 500mg qd p.o.
1538083|NCT02683655|Drug|Apatinib|Apatinib 750mg qd p.o.
1538084|NCT02683629|Biological|NTCELL Implantation|NTCELL Implantation
1538085|NCT02683629|Other|Sham Surgery|Sham Surgery
1538086|NCT02683616|Device|CPAP|Continuous Positive Airway Pressure in cases of moderate/severe OSA
1538087|NCT02683603|Drug|"AS colistin and imipenem"|colimycin (colistin) powder (1 million units (MU) by flakon) by AS route in addition to imipenem
1538088|NCT02683603|Drug|"IV colistin  and imipenem ."|colimycin (colistin) powder (1 MU by flakon) by intravenous route in addition to imipenem
1538089|NCT02683603|Drug|AS colimycin (colistin)|nebulisation of colimycin (colistin) for 30 minutes 3 times per day during at least 14 days. Nebulisation was made via an ultrasonic vibrating plates nebulizer (Aeroneb Pro® Aerogen Nektar Corporation, Galway, Ireland).
1538090|NCT02683603|Drug|IV colimycin (colistin)|intravenous colimycin (colistin) : 9 MU during 60 minutes followed by 4.5 million units 2 times per day
1538091|NCT02683603|Drug|AS colistin and imipenem|IV imipenem 1 g three times per day.
1538092|NCT02683603|Drug|IV colistin and imipenem|IV imipenem 1 g three times per day
1538093|NCT02683590|Device|Ceramic Implant|The replacement of the sternum by a ceramic implant
1538095|NCT02683564|Drug|BOW015|monoclonal antibody against TNF-alpha
1538096|NCT02683564|Drug|Remicade|monoclonal antibody against TNF-alpha
1538097|NCT02683551|Procedure|Sutureless Thyroidectomy|Thyroidectomy performed with energy based devices and no use of ligation. Used device is not altered for this study. Device which will be used is decided according to current availability in the operating room. Non of the personnel in the operating room including surgical team knows if the patient was enrolled or not in this study.
1538098|NCT02683538|Device|Separable cluster electrode (Octopus®)|Patients undergo RFA under ultrasound guidance, and separable cluster electrodes are used for RFA in monopolar switching mode, using multiple overlapping technique to create larger ablative zones.
1538099|NCT02683525|Drug|Sitagliptin|600 mg ever 12 hours by mouth will be given starting the day before transplant through day +14 after transplant
1538100|NCT02683512|Other|No intervention|This is an observational study that consists of data abstraction.
1538101|NCT02683499|Procedure|Ultrasonic tips|These tips are going to be used to give the final shape of the prepared surfaces before taking the impression for the construction of the veneers.
1538102|NCT02683486|Device|Intelligent oxygen therapy (an auto-titrating oxygen system)|This device is an auto-titrating oxygen system. The system is programmed to maintain a specific target SpO2 by automatically adjusting the oxygen flow rate. The system can deliver flow rates of 0-5 litres/minute.
1538103|NCT02683486|Device|Long-term oxygen therapy|This is the patients usual long-term oxygen therapy
1538104|NCT02683460|Procedure|Patella resurfacing|
1538105|NCT02683460|Procedure|Patella retention|
1538107|NCT02683434|Device|Kinesio Taping application|Therapeutic taping application applied to skin affecting muscle, fascia, circulation, ligaments, tendons and joints.
1538108|NCT02683421|Drug|tilmanocept|
1538109|NCT02683408|Other|placebo|inactive placebo
1538110|NCT02683408|Dietary Supplement|diosmiplex|diosmiplex is an FDA regulated medical food product
1538112|NCT02683382|Device|Moisturizing Eye Product in Liquid Formula|Moisturizing Eye Product in Liquid Formula for dry eyes and skin around the eyes
1538113|NCT02683369|Dietary Supplement|Blood Builder®/Iron Response®|"The low-dose iron dietary supplement is a tablet that contains vitamins and minerals selected to help maintain healthy red blood cells and iron levels in the blood. The supplement ingredients aim to generate a supplement by taking a food which contains the naturally occurring, complex matrix of proteins, lipids, carbohydrates and all other elements associated with the vitamin or mineral of interest. These natural food sources are used to generate tablets that maintain the vitamin and mineral potency found in the original food source as well as the associated elements that naturally accompany it.
One tablet will be taken once a day offering a total daily serving of:
15 mg of Vitamin C
400 mcg of Folate
30 mcg Vitamin of B-12
26 mg of Iron
125 mg of Beet Root"
1538191|NCT02682771|Device|PowerBreathe|Exercises with inspiratory load has the aim to trainning inspiratory muscle in strength and endurance, thus, could help to prevent postoperative complications.
1538299|NCT02681913|Drug|Adenosine|This group receives intermittent warm blood cardioplegia enriched with adenosine
1538116|NCT02683330|Behavioral|Mindfulness-based intervention (MBI)|MBI consists of 8 sessions and will cover becoming aware of emotions, thoughts and physical sensations, decentering and acceptance. Recordings of the body scan, a sitting meditation and a mindful movement meditation will be provided for daily home practice. Special care will be taken to address safety in the context of PD, and to adapt meditations to the physical limitations of PD.
1538117|NCT02683317|Dietary Supplement|docosahexaenoic acid|Docosahexaenoic acid is a dietary supplement derived from algae.
1538118|NCT02683317|Dietary Supplement|sunflower oil|Sunflower similar to the excipient used in experimental group
1538119|NCT02683304|Biological|Plasma S100B levels at inclusion|Patients will have blood drawn to measure plasma S100B levels at inclusion.
1538120|NCT02683304|Device|Magnetic resonance imaging|If not performed under emergency conditions, patients will have an MRI on days 2-4.
1538121|NCT02683291|Drug|sirolimus|
1538122|NCT02683291|Drug|tacrolimus|
1538123|NCT02683291|Drug|mycophenolate|
1538124|NCT02683291|Drug|Prednisone|Prednisone 30mg/day
1538125|NCT02683291|Drug|Basiliximab|Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %
1538126|NCT02683291|Drug|Thymoglobulin|Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %
1538127|NCT02683278|Behavioral|Cognitive-behavioral|Seven sessions of group-based treatment targeting skills to improve dysfunctional pain-related thoughts and behaviors
1538128|NCT02683278|Behavioral|Mindfulness-acceptance|Seven sessions of group-based treatment targeting skills to improve mindful awareness and acceptance of pain and stress, and increase positive emotional experiences
1538129|NCT02683278|Other|Pain Education|Seven sessions of group-based education to provide information regarding managing a chronic pain condition, but with no exercises to promote skill development
1538130|NCT02683265|Drug|Aptensio XR|Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
1538131|NCT02683265|Drug|Placebo|Placebo capsules
1538132|NCT02683252|Other|T1 mapping and MR perfusion acquisition|One T1 mapping acquisition with variable flip angles will be performed before contrast injection. One perfusion 3D FSPGR sequence will be acquired after contrast injection
1538133|NCT02683239|Drug|Fasinumab|Participants will receive sub-cutaneous (SC) injections of fasinumab
1538134|NCT02683239|Drug|Placebo|Participants will receive sub-cutaneous (SC) injections of matching placebo
1538135|NCT02683226|Drug|Vipdomet|
1538136|NCT02683226|Drug|Incresync|
1538137|NCT02683213|Drug|Fluoxetine|Fluoxetine 20mg once daily for 6 months.
1538138|NCT02683213|Drug|Placebo|Matching placebo.
1538139|NCT02683200|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
1538140|NCT02683200|Radiation|Stereotactic Body Radiation Therapy|Undergo MRI-guided Tri-60Co teletherapy SBRT
1538141|NCT02683187|Drug|Active Comparator: Sitagliptin|Subjects will receive sitagliptin prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
1538142|NCT02683187|Drug|Placebo Comparator - No Sitagliptin|Subjects will receive Placebo (instead of sitagliptin) prior to the start of the experiment involving 1/2 of the subjects receiving Exendin-9 (a GLP-1 receptor blocker) first over 60 minutes ; followed by a bolus arginine (5g) infusion after 30 minutes into the Ex-9 infusion, with blood draws over the next 30 minutes. Followed by a 60 minute washout and the procedure is repeated , this time with saline instead of Ex-9 (these procedures are reversed - saline first then Ex-9 - half of the time).
1538148|NCT02683148|Drug|DHEA|
1538149|NCT02683148|Other|FACT-67 validated survey|"Baseline, Cycle 1 Day 15, and Day 1 of each cycle beginning with Cycle 2
7 questions with answers ranging from 0=Not At All to 4 = Very Much."
1538150|NCT02683135|Behavioral|High-carbohydrate diet|Participants will engage in 4 days of high-carbohydrate low fat diet as recommended by the Canadian Diabetes Association. The macronutrients content will go as follow: 55% carbohydrate, 25% protein and 20% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
1538151|NCT02683135|Behavioral|Low-carbohydrate diet|Participants will engage in 4 days of low-carbohydrate high-fat diet. The macronutrients content will go as follow: 10% carbohydrate, 25% protein and 65% fat. Breakfast, lunch and dinner will be provided to the participants as part of an isoenergetic diet. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
1538416|NCT02681042|Device|SentreHeart Lariat®|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
1538152|NCT02683135|Behavioral|Low-carbohydrate diet with post-meal walking|Participants will follow the same diet as in the low-carbohydrate diet arm but also perform 15 minutes of walking beginning ~15 minutes after breakfast, lunch and dinner. Approximately 70 kcal (individualized) will be added to main meals to account for exercise energy expenditure. Between interventions there will be at least a one-week washout, where participants are encouraged to return to their baseline dietary habits.
1538153|NCT02683109|Drug|FDC of tiotropium + olodaterol|Fixed Dose Combination of tiotropium + olodaterol
1538154|NCT02683109|Drug|Placebo|
1538155|NCT02683109|Drug|Tiotropium|
1538156|NCT02683109|Drug|Olodaterol|
1538157|NCT02683096|Other|Observation|Viable Infants with a failed hearing screen or a diagnosis of SGA who are born at either St. John's Hospital or MMC at ≥ 28 weeks gestation.
1538158|NCT02683083|Biological|[131I]-SGMIB Anti-HER2 VHH1|
1538159|NCT02683070|Procedure|Bilateral pudendal nerve block|Bilateral pudendal nerve block with 30ml of 0.33% ropivacaine (15ml for each side) after the completion of surgery before extubation
1538160|NCT02683070|Drug|Intravenous tramadol|Intravenous tramadol of 1.5mg/kg after the completion of surgery before extubation
1538161|NCT02683057|Other|International Physical Activity Questionnaire (IPAQ)|all candidates for sperm donors clinic IVI IVI Bilbao and Valencia were will provide the international physical activity questionnaire (IPAQ) attached to analyze the total physical activity. This will be self-completed questionnaire beforeSperm donation. (Appendix 1) Age, snuff, weight, BMI, alcohol, drug use and the type of sport that practices will be analyzed: Additionally a tab for each donor collecting the existence of associated factors be drawn. (Appendix 2)
1538162|NCT02683044|Procedure|Low-Intensity Extracorporeal Shock Wave Therapy (Li-ESWT)|Sessions of shocks to the body of the penis
1538163|NCT02683031|Other|Ca2+ ionophore|Ca2+ ionophore is a chemical agent used to perform oocyte activation after ICSI. It showed effective treatment to get better fertilization, pregnancy, and healthy livebirth in cases with total or partial fertilization failure.
1538164|NCT02683018|Drug|Smoked Cannabis High CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (15.76% CBD; 3.11% THC) over the course of a 2-3 hour session.
1538165|NCT02683018|Drug|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the Marijuana Research Laboratory 3-5 weekdays per week for 4 weeks to be administered 1-2 cannabis cigarettes (0.01% THC; 0.00% CBD) over the course of a 2-3 hour session.
1538166|NCT02683005|Drug|ledipasvir/sofosbuvir|Hepatitis C treatment with ledipasvir and sofosbuvir will be initiated during pregnancy at approximately 24 weeks of gestation.
1538167|NCT02682992|Device|Low Level Laser Therapy|Patients will receive LLLT three times per week concurrently with chemoradiotherapy. LLLT may be delivered either immediately prior to or after the patient's daily fraction of radiotherapy. Patients will be treated extra-orally with a THOR® LED cluster for one minute along the buccal mucosa on each side and intraorally for one minute to the tongue and soft palate. During each LLLT treatment session a thorough oral exam will be performed to identify any areas of mucositis. If the patient should develop intraoral lesions they will be targeted directly with the intraoral probe for one minute to each site of mucositis. The laser settings to be used are as follows: frequency 2.5 Hz; wavelength 660 nm; and power 75 mW, for an energy of 4.5 J.
1538168|NCT02682979|Other|Medical files analysis|Retrospective analysis of the medical files according to medical, social and geriatric criteria.
1538169|NCT02682966|Radiation|Coronary Computed Tomography Angiography|Coronary Computed Tomography Angiography will be performed in all participants
1538170|NCT02682953|Drug|Neupogen|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
1538171|NCT02682953|Procedure|Hyperbaric oxygen therapy|Exposure to oxygen at 2.4 atmospheres absolute for 90 minutes/day for 3 to 5 days
1538172|NCT02682953|Drug|Plerixafor|Pharmacological agents often used for stem cell mobilization will be utilized in this study.
1538173|NCT02682940|Device|Vigilant Diabetes Management Application|Subjects will download the Vigilant Diabetes Management Application and use it in conjunction with a study supplied wireless blood glucose meter. They will check blood glucose values at least three times a day and receive summaries and notifications from Vigilant regarding periods of risk and blood glucose patterns.
1538174|NCT02682927|Drug|ZX008 (Fenfluramine Hydrochloride)|ZX008 drug product is an oral aqueous solution of fenfluramine hydrochloride buffered to pH 5. The product is sugar free and is intended to be compatible with a ketogenic diet.
1538175|NCT02682927|Drug|Matching Placebo|Placebo solution for ZX008. The product is sugar free and is intended to be compatible with a ketogenic diet.
1538176|NCT02682901|Drug|Cycloset|Cycloset 1.6 -3.2 mg/day
1538177|NCT02682901|Drug|Placebo|Non-active placebo for cycloset
1538178|NCT02682888|Behavioral|trait anxiety scale|splitting subjects into 2 groups according to scores of the trait anxiety scale
1538179|NCT02682888|Drug|Oxytocin|intranasal administration of oxytocin
1538180|NCT02682888|Drug|Placebo|intranasal administration of placebo
1538184|NCT02682823|Device|AI-1000 G2|Tocilizumab will be administered using the AI-1000 G2.
1538185|NCT02682823|Drug|Tocilizumab|Participants will receive three doses of SC tocilizumab using the AI-1000 G2 device at Visits 1, 2, and 3. The dose will remain at 162 milligrams (mg) unless changes are required per protocol for safety or efficacy reasons.
1538186|NCT02682810|Device|DNA PCR HIV diagnostic test|standard of care
1538187|NCT02682810|Device|Alere Q|POC diagnostic Alere Q qualitative test (along with a DBS drawn for confirmatory DNA PCR)
1538188|NCT02682784|Drug|Oxytocin|Nasal spray based on naturally occurring hormone, oxytocin.
1538189|NCT02682784|Drug|Placebo|
1538190|NCT02682771|Device|Bilevel positive airway pressure|The use of positive airway pressure airway seeking in the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume
1538192|NCT02682771|Procedure|Conventional Respiratory Physiotherapy (CRP)|CRP consisted of diaphragmatic respiratory exercises, deep inhalation exercises, inhalations fragmented two to three times and respiratory exercises associated with shoulder flexion movements and extension of the upper limbs. One series of 10 repetitions was carried out for each exercise. Walking sessions and preventive exercises for deep vein thrombosis were carried out
1538193|NCT02682758|Drug|Xenon|Wash-in of xenon for maintenance of anaesthesia
1538194|NCT02682745|Drug|HL151|Test drug l : HL151, 1T, single oral administration on an empty stomach, Test drug ll : HL151, 1T, single oral administration after meal
1538195|NCT02682745|Drug|TALION tab.|Reference drug: TALION tab, 1T, every 12 hours, oral administration
1538196|NCT02682732|Procedure|FDG-PET/CT guided bone marrow sampling|(Fluorodeoxyglucose positron-emission tomography) FDG-PET/CT guided bone marrow sampling will be used to obtain two different samples from avid and dim bone marrow areas.
1538197|NCT02682719|Drug|LCZ696|
1538198|NCT02682719|Drug|Valsartan|
1538199|NCT02682719|Other|Placebo to LCZ696|
1538200|NCT02682719|Other|Placebo to Valsartan|
1538201|NCT02682693|Drug|Denosumab|Denosumab 120 mg every 4 weeks for 6 cycles
1538202|NCT02682693|Drug|nab-Paclitaxel|nab-paclitaxel 125 mg/m² weekly for 12 weeks or at day 1,8 q22 for 4 cycles (12 weeks)
1538203|NCT02682693|Drug|Epirubicin|Epirubicin 90 mg/m² every 2 or 3 weeks for 4 times
1538204|NCT02682693|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m² every 2 or 3 weeks for 4 times
1538205|NCT02682693|Drug|Carboplatin|Carboplatin AUC 2 weekly in parallel to nab-Paclitaxel
1538206|NCT02682693|Drug|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all chemotherapy cycles
1538207|NCT02682693|Drug|Pertuzumab|Pertuzumab 420 (840) mg every 3 weeks simultaneously to all chemotherapy cycles
1538208|NCT02682680|Drug|Colesevelam|Colesevelam 3.75 g daily for 24 weeks
1538209|NCT02682680|Drug|Ezetimibe|Ezetimibe 10 mg daily for 24 weeks
1538210|NCT02682654|Device|Dr. Scholl's Prototype Ankle Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
1538211|NCT02682654|Device|Dr. Scholl's Prototype Knee Brace|Subjects will be instructed to wear the assigned Ankle/Knee brace for 8 ± 2 hours per day, for a minimun of 5 days out of a 7-day/1 week wear period.
1538212|NCT02682641|Drug|IBRUTINIB|Ibrutinib 560 mg daily po for 28 days (cycle one). Continuous cycles until disease progression or unacceptable toxicity.
1538213|NCT02682641|Drug|Rituximab|Rituximab 375 mg/m2 iv day 1,8, 15 and 22 (cycle 1, 4 doses). Rituximab 375 mg/m2 iv, day one of every other cycle for 4 doses (cycle 3, 5, 7 and 9).
1538214|NCT02682628|Drug|Coppertone (BAY987517)|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application.
1538215|NCT02682602|Device|DePuy Synthes total hip arthroplasty|
1538216|NCT02682602|Radiation|Computer tomography|Computer tomography (CT) scan of the hip for creation of bone models.
1538217|NCT02682602|Radiation|Fluoroscopy surveillance|Fluoroscopy evaluation of the hip during gait (level walking), chair rise, and ramp ascent and descent activities. Sound/vibration data will be collected simultaneously via non-invasive sensors attached to the hip joint.
1538218|NCT02682589|Procedure|Open surgery|A traditional midline incision is made through the abdominal wall and a colectomy with CME is performed.
1538219|NCT02682589|Procedure|Laparoscopic surgery|3-5 small incisions are made through the abdominal wall for the placement of trocars and the abdominal cavity is insufflated with carbon dioxide to allow access, visualization and operation. A 6-8cm auxiliary incision is made for specimen extraction and anastomosis. Conversion may occur due to technical difficulties or intraoperative complications, which is defined when completion of the dissection of the mesocolon is performed through a traditional open abdominal approach. Patients undergo conversion to laparotomy will be excluded from this study.
1538220|NCT02682576|Procedure|Brachial artery ultrasound imaging|
1538221|NCT02682563|Drug|Dapagliflozin 10mg QD|Dapagliflozin 10mg once daily for 12 weeks
1538222|NCT02682563|Drug|Gliclazide 30mg QD|Gliclazide30mg once daily for 12 weeks
1538223|NCT02682550|Procedure|blood drawing|blood drawing
1538224|NCT02682524|Drug|Pelubiprofen CR 45mg tab.|
1538225|NCT02682524|Drug|Aceclofenac 100mg tab.|
1538226|NCT02682511|Drug|Oral Ifetroban|Subjects will be treated with oral ifetroban or placebo daily for 365 days
1538227|NCT02682511|Drug|Oral Placebo|Subjects will be treated with oral ifetroban or placebo daily for 365 days
1538228|NCT02682498|Drug|(Bupivacaine Liposome Injectable Suspension)|Instead of injecting the standard joint injection for a case of total knee arthroplasty, Exparel-lipsomal bupivacaine will be administered at the end of the surgery.
1538229|NCT02682498|Drug|Standard Preparation|A standard joint injection of 100ml (Clonidine 80 mcg, Epinephrine 0.5mg, Ketorolac 30mg, Ropivacaine 246.25mg, and Sodium Chloride 0.9% 48.45 ml) will be injected into the soft tissues around the joint after surgery.
1538230|NCT02682485|Drug|Cipro, metronidazole, neomycin combo|During endoscopies after imaging, the anastomosis will be lavaged with an antibiotic solution composed of metronidazole, ciprofloxacin and neomycin
1538231|NCT02682485|Procedure|Serial Endoscopic Surveillance|Patients will undergo serial endoscopic surveillance consisting of three endoscopies: one intra-operative endoscopy (POD0) and two post-operative endoscopies (POD3-7, POD12-28). During endoscopies, the anastomosis will be lavaged with saline, the fluid will be collected by suction and images will be taken.
1538232|NCT02682485|Drug|Saline|During endoscopies after imaging, the anastomosis will be lavaged with a placebo direct topical saline solution
1538233|NCT02682472|Other|SettleIN - Adjustment to care programme|A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
1538234|NCT02682459|Drug|Lisinopril|
1538263|NCT02682225|Drug|Intravenous racemic ketamine|Participants will receive 0.5 mg/kg racemic ketamine, intranasally, on Day 2 in sequence 1, on Day 1 in sequence 2, on Day 1 of Period 1 in Sequence 4, on Day 1 of Period 2 in Sequence 5, on Day 1 of Period 3 in Sequence 3, and on Day 1 of Period 4 in Sequence 6.
1538264|NCT02682225|Drug|Esketamine 112 mg|Participants will receive 112 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 6, on Day 1 of Period 2 in Sequence 3, on Day 1 of Period 3 in Sequence 5, and on Day 1 of Period 4 in Sequence 4.
1538235|NCT02682446|Drug|H pylori eradication|The regimen of H. pylori eradication was like that: 1-week conventional proton pump inhibitor (PPI) based triple therapy (lansoprazole 40 mg b.i.d., clarithromycin 500 mg b.i.d., and amoxicillin 1 g b.i.d. for a week) after confirmation of H. pylori infection. If the participants who initially failed to respond to the first eradication, they recommended to underwent second-line eradication therapy with the regimen of 7-day bismuth containing quadruple regimen [lansoprazole 40 mg b.i.d., tripotassium dicitrate bismuthate (Denol; Greencross Co., Seoul, Korea) 300 mg q.i.d. (three tablets 30 min before meals and one tablet 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d. for 1 week]
1538236|NCT02682433|Device|diagnostic hysteroscopy|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
1538237|NCT02682433|Device|diagnostic sonar test|Women who were routinely referred to perform diagnostic hysteroscopy. As part of the procedure, clear liquid is inserted into the uterine cavity. After the hysteroscopy, abdominal and vaginal sonar will be performed, and the findings will be recorded and will be compared. Immediately after completion of the office hysteroscopy, two-dimensional and three-dimensional sonar to demonstrate the uterine cavity and its walls will be performed while using the liquid which is left in the uterine cavity. It is important to note that no additional invasive operation will be performed beyond what is necessary to perform hysteroscopy. It should be emphasized that the sonar test will be performed immediately and in the same position as the hysteroscopy test. All procedures will be performed in women clinics or day hospitalization. It should be noted that the medical examinations will not be performed unless there are medical reasons.
1538238|NCT02682420|Device|everlinQ endoAVF System|
1538239|NCT02682407|Biological|OMS721|Biological: OMS721
1538240|NCT02682407|Other|Vehicle (D5W)|5% Dextrose in water
1538241|NCT02682381|Drug|Teduglutide 0.05mg/kg|0.05 mg/kg
1538242|NCT02682381|Drug|Teduglutide 0.025 mg/kg|0.025 mg/kg
1538243|NCT02682381|Other|Standard of Care|Observational cohort for the 24-week treatment period and 4 week follow-up.
1538244|NCT02682368|Device|Bedside performed Ultrasound Scan by the surgeon|Bedside performed Ultrasound Scan performed by the surgeon and then compared to radiologist reports and/or surgery
1538245|NCT02682368|Other|Radiology report|Radiologist report compared to the surgeon's report
1538246|NCT02682368|Procedure|Intra-operative findings|Intra-operative findings compared to the bedside USS
1538247|NCT02682342|Other|75 g glucose solution|This is the same as the standard oral glucose challenge dose and route given clinically
1538248|NCT02682329|Other|Hydrogen Peroxide and Carbamide Peroxide|Carbamide Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP 10% at home and HP 40% at office
1538249|NCT02682329|Other|Hydrogen Peroxide and Hydrogen Peroxide|Hydrogen Peroxide + Hydrogen Peroxide were administered to each patient on this group. HP at home and HP at office
1538250|NCT02682316|Other|dry gauze|
1538251|NCT02682316|Device|The Prevena Incision Management System|
1538252|NCT02682303|Device|Elastic Bandage (Idealplast C®)|"Elastic bandage
One anchor strip is applied around the ankle with no tension applied to the tape to avoid restricting blood flow. A supporting stirrup strap is applied from the inside of the ankle, under the heel with no tension up to this point. As the tape is passed up the outside of the ankle tension is applied to the tape with the foot in slight dorsiflexion and secured to the anchor strap (black arrow).
For heel lock, a second strip is applied on the outside of the ankle, taken across the front of the ankle and just above the bony part on the inside of the ankle and back towards the heel (red arrow). Then taken around and under the heel back the way you have just come and around the front of the ankle (orange arrow). The tape then passes above the bony part of the ankle on the outside and diagonally towards the heel, across to the inside of the ankle then around the top to finish"
1538253|NCT02682303|Device|Pretape cramer® (non standarized tape)|"Pretape cramer® was used.
The individual is in supine position keeping the foot and ankle in a neutral position.
The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
This is the only intervention carried out in this group."
1538255|NCT02682277|Device|polygucosamine|2 times daily 2 polyglucosamine tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
1538256|NCT02682277|Other|placebo|2 times daily 2 placebo tablets with the two main meals with 10 % reduction of caloric intake with no increase of physical activity.
1538257|NCT02682264|Drug|CB-03-01 cream, 1%|CB-03-01 (cortexolone 17α-propionate) is a steroidal antiandrogen that is being developed as a 1% cream for the topical treatment of acne vulgaris.
1538258|NCT02682251|Other|PHR Messaging|PHR messaging of data pertinent to chronic resynchronization therapy and heart failure management (i.e. percentage LV pacing).
1538259|NCT02682238|Drug|BBI-4000, 15%|
1538260|NCT02682238|Other|Vehicle gel|
1538261|NCT02682225|Drug|Intravenous placebo|Participants will receive placebo, 40-minute, intravenous infusion on Day 1 of Sequence 1, on Day 2 of Sequence 2, on Day 1 of Period 1 in Sequence 3, 5 and 6, on Day 1 of Period 2 in Sequence 3, 4 and 6, on Day 1 of Period 3 in Sequence 4, 5 and 6, and on Day 1 of Period 4 in Sequence 3, 4 and 5.
1538262|NCT02682225|Drug|Intranasal placebo|Participants will receive placebo, intranasally, on Day 1 or Day 2 in Sequence 1 and 2, on Day 1 of Period 1 in Sequence 3 and 4, on Day 1 of Period 2 in Sequence 4 and 5, on Day 1 of Period 3 in Sequence 3 and 6 and on Day 1 of Period 4 in Sequence 5 and 6.
1538265|NCT02682225|Drug|Esketamine 84 mg|Participants will receive 84 mg of Esketamine, intranasally, on Day 1 of Period 1 in Sequence 5, on Day 1 of Period 2 in Sequence 6, on Day 1 of Period 3 in Sequence 4, and on Day 1 of Period 4 in Sequence 3.
1538266|NCT02682212|Other|Physiotherapy intervention|Compare the effect of early physiotherapy intervention (pelvic floor muscle training, PFMT) with standard care on pelvic floor dysfunction symptoms, quality of life (QoL) and (pelvic floor muscle (PFM) strength, for women who answered the questionnaire positively for 1) urinary incontinence, 2) other dysfunction of the pelvic floor.
1538267|NCT02682186|Drug|Ropivacaine after dilution with sodium chloride 0.9%|"After the anesthesic induction, the interventional team composed by at least a senior anaesthesiologist and a nurse anesthestic, will survey the patient and perform the Pecs blocks, whereas the anesthetic team is outside the room.
Realization of Pecs blocks 1 and 2 : the patient is in supine position with placing the upper limb in abduction position, a 100 mm needle is inserted under ultrasound using a linear US probe of high frequency after sheathing.
In the other group, sterilization, sheating and US are performed but the needle is not inserted."
1538268|NCT02682173|Other|MR Abdomen|
1538269|NCT02682160|Other|use of Protein Assistant|The patient has to complete a dietary record every 2 weeks during 2 months (month 2 and 3 after surgery). The aim is to intake 60g per day. If the aim is not reached, Protein assistant suggests qualitative and/or quantitative solutions.
1538272|NCT02682134|Drug|xylocaine|First group were given xylocaine
1538273|NCT02682134|Drug|Dexamethasone|Second group were given Dexamethasone
1538274|NCT02682134|Drug|Xylocaine and Dexamethasone|Third group were given both Xylocaine and Dexamethasone
1538275|NCT02682121|Drug|Metformin|Metformin 850 mg twice daily
1538276|NCT02682121|Drug|Placebo|Placebo twice daily
1538277|NCT02682108|Device|Diffusion-weighted magnetic resonance imaging (DW-MRI)|Magnetic resonance (MR) imaging examination of liver will be performed on a 3.0T Achieva MR scanner (Philips Medical Systems, The Netherlands). Diffusion-weighted imaging (DWI) will be performed using a single-shot echo-planar imaging during a single end expiratory breath-hold. A single observer placed circular regions of interest around 2.30 cm2 to measure mean signal intensity (SI) in the right hepatic lobe and the spleen for each b value, avoiding areas of artifact, vessels, and focal lesions. A monoexponential fit will be performed to calculate liver and spleen apparent diffusion coefficient (ADC) on the basis of ln(SI) as a function of b value, using all b values. Normalized liver ADC will be calculated as the ratio of liver ADC to spleen ADC.
1538278|NCT02682082|Procedure|Endoscopic ultrasound-guided celiax plexus neurolysis|Endoscopic ultrasound-guided celiax plexus neurolysis
1538279|NCT02682082|Drug|Bupivacaine|Endoscopic ultrasound-guided celiax plexus neurolysis w/wo Bupivacaine
1538280|NCT02682069|Device|MolecuLight i:X Imaging Device|The intended use of the device is to assist clinicians during care and management of patients with chronic wounds by screening for the presence of potentially harmful bacteria levels. The device will be used as part of the current clinical wound assessment process which may include examination for characteristic signs and symptoms of infection. The device can capture and document either an image or video of the chronic wound where the presence of florescent bacteria appears under violet light illumination. This information can be used to guide a clinician to inspect, sample, debride or further evaluate areas within or around a wound where fluorescent bacteria are present.
1538281|NCT02682056|Device|Microneedle patch|The hydrogel microneedle patch will collect interstitial fluid to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
1538282|NCT02682056|Device|Intravenous (IV) catheter|The intravenous (IV) catheter will collect venous blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
1538283|NCT02682056|Device|Lancet|The lancet will collect capillary blood to be tested for glucose level. Participants will have fasting glucose levels measured four times, on an hourly basis, during the study visit.
1538284|NCT02682043|Device|Toy car|"The intervention is the provision of an electric toy car. This toy car will be modified to meet the postural and hand control preference of each child participant.
The child will have the toy car for an 8 week trial period. Parents and child will be instructed in the safe use of the toy car, given written guidelines, and encouraged to use frequently.
Parents will keep a log of what days they use the toy car, where and for how long."
1538285|NCT02682030|Device|High Frequency Chest Compression Device (HFCC)|A vest designed to help clear the airway of mucus and other secretions through mechanical knocking of the chest area.
1538286|NCT02682030|Device|Cough Assist|A device that aids patients to clear mucus and secretions that they would otherwise be unable to clear with coughing.
1538287|NCT02682017|Other|Pork meat from pigs feed with a standard feed.|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week.
1538288|NCT02682017|Other|Pork meat from pigs fed a feed with a Laminarin/fucoidan mix|4 week intervention with 700g (raw weight) of pork meat (3x pork burgers (125g raw weight each) + pork mince (325 g raw weight) per week from pigs fed animal feed supplemented (5.37 kg/tonne of feed) with spray-dried laminarin and fucoidan (seaweed).
1538289|NCT02682004|Other|leptin, serotonin and adiponectin level|
1538290|NCT02682004|Other|leptin,serotonin, adiponectin level|
1538291|NCT02681991|Drug|Renamezin capsule|
1538292|NCT02681978|Drug|Ivabradine|Ivabradine 5 mg twice daily
1538293|NCT02681978|Drug|Standard medical therapy|Standard medical therapy for patients with coronary artery disease undergoing percutaneous coronary interventions
1538294|NCT02681965|Behavioral|LEAN book/videos|The intervention focuses on achieving long lasting lifestyle changes to achieve weight loss and maintenance. Women randomized to the weight loss program will receive the LEAN book, as well as a CD and flash drive with the LEAN videos (and internet link), a pedometer and the Log Book for recording their food intake and physical activity.
1538295|NCT02681952|Drug|Renamezin capsule|
1538296|NCT02681952|Drug|Kremezin granule|
1538297|NCT02681939|Drug|Tulsi(Ocimum sanctum Linn.) capsules|
1538298|NCT02681926|Procedure|VISITAG|Paroxysmal atrial Fibrillation (PAF) ablation with contact force technology
1539912|NCT02669693|Dietary Supplement|bread without olives|
1538300|NCT02681900|Behavioral|Self-affirmation manipulation task|Participants in the self-affirmation condition indicate their most important value, give three examples of why this value is important to them and one example of something they had done to demonstrate its importance.
1538301|NCT02681900|Behavioral|Control task|People in the control condition indicate their least important value, three examples of why that value could be important to someone else, and describe something that person could do to show its importance.
1538302|NCT02681887|Drug|Melatonin|Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
1538303|NCT02681887|Drug|Placebo|placebo tablet identical to circadian
1538304|NCT02681874|Behavioral|SSC Program|The Smart and Secure Children (SSC) program is a 10-week manualized intervention that uses a written validated curriculum. The program is group-based and co-led by peer leaders (Parent Leaders). Parent Leaders facilitate conversations on the SSC program content by sharing real life application, experiences, and solutions.
1538305|NCT02681874|Behavioral|Written Handouts|The handouts are a part of the SSC program that include didactic curriculum content and instruct parents to write goals and document goal progress.
1538306|NCT02681861|Drug|ASP6294 Intravenous|Intravenous (IV)
1538307|NCT02681861|Drug|ASP6294 Subcutaneous|Subcutaneous (SC)
1538308|NCT02681861|Drug|Placebo Intravenous|Intravenous (IV)
1538309|NCT02681861|Drug|Placebo Subcutaneous|Subcutaneous (SC)
1538310|NCT02681848|Drug|Varenicline|Smoking cessation medication
1538311|NCT02681848|Drug|Nicotine replacement therapy|
1538312|NCT02681835|Device|C-MAC laryngoscope|Intubation performed using C-MAC laryngoscope
1538313|NCT02681835|Device|Macintosh laryngoscope|Intubation performed using laryngoscope with Macintosh blade
1538314|NCT02681809|Drug|ocriplasmin 0.0625mg|Up to 3 intravitreal injections of ocriplasmin 0.0625mg approximately 1 month apart
1538315|NCT02681809|Drug|ocriplasmin 0.125mg|Up to 3 intravitreal injections of ocriplasmin 0.125mg approximately 1 month apart
1538316|NCT02681809|Drug|Sham injection|3 sham injections approximately 1 month apart. No actual injections. No medication is used.
1538317|NCT02681796|Drug|Bupivacaine|
1538318|NCT02681783|Drug|aflibercept|
1538319|NCT02681757|Device|triple antibiotic ointment dressing|used for control group under soft cast
1538320|NCT02681757|Device|Mepitel Ag|used for variable/experimental group under soft cast
1538321|NCT02681744|Behavioral|Resistance Training|24-weeks of progressive strength training
1538322|NCT02681718|Behavioral|Community health worker education|Diabetes self-management education by community health workers
1538323|NCT02681718|Behavioral|Cell phone text messaging|Diabetes self-management education through cell phone text messaging
1538324|NCT02681705|Drug|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
1538325|NCT02681705|Radiation|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (Temozolomide).
1538326|NCT02681692|Device|Magnetic endoscopic imaging system|In the first part,patients would be randomly assigned to have colonoscopy examination performed by one inexperienced colonoscopist (having performed less than 200 procedures) with the assistance of magnetic scope navigation system In the second part colonoscopist would be randomized to perform conventional colonoscopy on a colon model with an MEI view while the force measurement device being used to collect data of colon force variation meanwhile. No patients would be involved in this part. All force variation data would be recorded by a image storage device.
1538327|NCT02681679|Drug|0.1% bromfenac ophthalmic solution|
1538328|NCT02681679|Procedure|femtosecond laser cataract surgery|
1538329|NCT02681666|Dietary Supplement|Dietary intervention|Sessions will be spent with patients discussing the FODMAPs (fermentable oligosaccharides, disaccharides, monosaccharides, and polyols) diet and how to use this diet to treat their Irritable Bowel Syndrome.
1538330|NCT02681666|Behavioral|Irritable Bowel Syndrome eating awareness training|A type of meditation about their eating habits.
1538331|NCT02681653|Drug|Atorvastatin|Atorvastatin or placebo given for 7 days to patients of septic shock admitted to ICU
1538332|NCT02681653|Drug|Placebo|Equally matched placebo for 7 days to patients of septic shock admitted to ICU
1538333|NCT02681640|Other|68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE105
1538334|NCT02681640|Device|Positron Emission Tomography PET/CT|Following injection of 68Ga-NOTA-AE105 the patients will be subjected to Positron Emission Tomography PET/CT
1538335|NCT02681627|Other|Endometrial scratch|If patient randomised to intervention arm, will have speculum examination followed by endometrial scratch with a wallace catheter
1538336|NCT02681627|Other|Touching the cervix|If patient is randomised to the control arm, she will have speculum examination followed by cleaning of the cervix with a cotton tip dipped in saline
1538337|NCT02681614|Device|Uronav guided biopsy|All biopsies will be completed in the outpatient setting in the ambulatory operating room prior to routine prostate brachytherapy under general anesthesia. Patients will be prepped in a dorsal lithotomy position with insertion of a Foley catheter. The perineum will be shaved as needed, and cleansed with antiseptic solution, and the scrotum will be elevated with a towel roll to expose the perineum.
1538338|NCT02681614|Device|Magnetic resonance imaging|An MRI (magnetic resonance imaging) is a scan that uses radio waves and a strong magnetic field to provide images of internal organs and tissues. This is not part of the study but will have been done per standard treatment. An MRI will occur at the screening visit and last visit of the study.
1538377|NCT02681276|Procedure|Irrigation with 3% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
1538417|NCT02681029|Procedure|Blastocyte Transferring|Intra-uterine transferring of blastocyst from thawed cleavage embryo in infertile women.
1539913|NCT02669693|Dietary Supplement|bread with olives|
1538339|NCT02681601|Dietary Supplement|Nutrawell Powder|"The NutraWell nutrition powder will be provided by and distributed from New Health Nutraceuticals (Irvine, California - USA). Nutrawell is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.
OmegaRich Contains high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.
Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
1538340|NCT02681601|Other|Diet Only|Subjects will be evaluated by a registered dietitian and randomized to diet prescription (55% carbohydrate, 30% fat and 15% protein)
1538341|NCT02681601|Dietary Supplement|OmegaRich fish oil supplement|"OmegaRich is manufactured New Health Enterprises, Inc. The supplement sample will be stored at room temperature in the UCLA Center for Human Nutrition research unit.
OmegaRich Contains: high concentration and high purity of natural omega-3 polyunsaturated fatty acids: Eicosapenatenoic acid (EPA) and docosahexaenoic acid (DHA) from deep water fish.
Enriched with natural vitamin E: d- tocopherol Triglyceride form (TG-form) of the raw fish oil ingredients. Each fish oil capsule contains 55% EPA and DHA with 330 mg EPA and 220 mg DHA."
1538342|NCT02681588|Procedure|Obstetric management|Screening for gestational diabetes at 32 weeks of gestation, determination of fasting glucose during late pregnancy ; blood samples on arrival at the delivery room ; drawing blood from the umbilical cord after section; skinfold measurement of the newborn within 72 hours of life.
1538343|NCT02681575|Behavioral|Cog-Fun - A|Meta-cognitive functional intervention for improved self management in adults with ADHD
1538344|NCT02681562|Drug|olaparib|
1538345|NCT02681549|Drug|Pembrolizumab plus Bevacizumab|Pembrolizumab will be administered on day 1 of every cycle until disease progression or withdrawal from study. Bevacizumab will be administered in addition to pembrolizumab on day 1 of cycles 1, 2, 3, and 4. Three weeks constitutes one cycle.
1538346|NCT02681536|Drug|Triptorelin|
1538347|NCT02681536|Drug|Combined oral contraceptive pills|
1538348|NCT02681536|Drug|HMG|
1538349|NCT02681523|Drug|Eribulin|
1538351|NCT02681484|Behavioral|Anthroposophic speech therapy|"Anthroposophic speech therapy uses sound-combinations like KLSFM or OM and hexameter verse in German, spoken by the therapist and imitated by the patients, to expand and decelerate respiration. The intervention is conducted by the same qualified therapist for one patient in different days but during the same daytime for 30 minutes in upright position and walking."
1538352|NCT02681471|Other|5% Mannitol|Traditional monopolar TURP was performed by using and irrigation fluid containing 5% mannitol ( Resectisol Eczacibasi-Baxter).
1538353|NCT02681471|Other|0,9% Sodium chloride|Bipolar TURP was carried out by using a 24 Fr TURis (OLYMPUS) resectoscope and irrigation fluid containing 0,9 % sodium chloride.
1538354|NCT02681471|Device|monopolar resectoscope|
1538355|NCT02681471|Device|bipolar resectoscope TURis|
1538356|NCT02681458|Other|Direct Examination|It was an observational study and subjects received their routine treatment.
1538357|NCT02681445|Device|Breath Collection|breath will be collected from patients in breath bag for analysis for observational study.
1538358|NCT02681432|Drug|HIPEC|Cytoreductive surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) with Paclitaxel (175 mg/m2) for 60 minutes at 42-43 degrees.
1538359|NCT02681432|Procedure|No HIPEC|Cytoreductive surgery without HIPEC
1538360|NCT02681419|Procedure|Needle fenestration|This technique creates fenestrations along a nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
1538361|NCT02681419|Procedure|Suture wick|This technique places a single 10-vicryl suture wick through the nonvalved glaucoma implant (e.g. Baerveldt Glaucoma Implant) anterior to the ligature
1538364|NCT02681393|Behavioral|Brochure and Telephone Support|Participants will receive both the Aerobic Exercise After Stroke educational brochure and 4 weekly motivational telephone support calls.
1538365|NCT02681393|Behavioral|Brochure|Participants will receive both the Aerobic Exercise After Stroke educational brochure.
1538366|NCT02681380|Other|Relation learning|Seven session are planned. Each will be supervised by a senior, trained to supervised Balint group.
1538367|NCT02681380|Other|Control group|No session will be planned for the participants.
1538369|NCT02681354|Other|Biorescue training|
1538370|NCT02681328|Other|Afirma GEC|Afirma GEC molecular test on collected thyroid tissue
1538371|NCT02681328|Other|ThyroSeq v.2|ThyroSeq v.2 molecular test on collected thyroid tissue
1538372|NCT02681315|Device|HHHFNC 6 liter minute|Infants allocated to HHHFNC at 6 L/min. will be extubated to a HHHFNC flow of 6 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
1538373|NCT02681315|Device|HHHFNC 3 liters/min|Infants allocated to HHHFNC at 3 L/min. will be extubated to a HHHFNC flow of 3 L/min. Eligible infants will be enrolled while receiving mechanical ventilation. The timing of extubation will be determined by the clinical team and all infants will start caffeine prior to extubation.
1538374|NCT02681302|Drug|Ipilimumab|1 mg/kg; 6 doses Weeks 1, 4, 7, 10, 16, 22
1538375|NCT02681302|Drug|Nivolumab|3 mg/kg; 12 doses Weeks 1, 4, 7, 10, 12, 14, 16, 18, 20, 22, 24, 26
1538376|NCT02681289|Other|Early goal directed neuromotor therapy|Early goal directed neuromotor therapy (NGDT) is referred to as 'task-oriented' and is built on contemporary system theories of motor control. The development and learning of new skills occur in an interaction between the child, the task to be performed and the particular environment in which the activity takes place.
1538418|NCT02681029|Procedure|Embryo Transferring|Inta-uterine transferring of thawed cleavage embryo transfer in infertile women.
1538378|NCT02681276|Procedure|Irrigation with 0.5% NaOCl|All the operators are informed to perform the endodontic treatment the way they normally do. The only variation during treatment was the concentration of the sodium hypochlorite solution for irrigation of the root canal.
1538380|NCT02681250|Procedure|Titanium-zirconium|Titanium-zirconium implants will be installed according to the protocol earlier described in the detailed description.
1538381|NCT02681250|Procedure|Titanium|Titanium implants will be installed according to the protocol earlier described in the detailed description.
1538382|NCT02681237|Drug|Cediranib|Small-molecule inhibitor of several tyrosine kinases including VEGFR-1, VEGFR-2, VEGFR-3 and c-kit.
1538383|NCT02681237|Drug|Olaparib|Poly (ADP-ribose) polymerase (PARP) inhibitor.
1538384|NCT02681224|Other|TR987 Gel with Silon Bandage|Novel healing gel with occlusive dressing
1538385|NCT02681224|Other|TR987 without Silon Bandage|Novel healing gel without occlusive dressing
1538386|NCT02681224|Other|Placebo Gel with Silon Bandage|Placebo gel with occlusive dressing
1538387|NCT02681224|Other|Placebo Gel without Silon Bandage|Placebo Gel without occlusive dressing
1538388|NCT02681211|Other|Auricular Acupuncture|ASP (acupuncture semi-permanent) gold needles will be placed in the efficacious ear points with a maximum of 3 needles in each ear.
1538389|NCT02681211|Drug|Ketorolac 0.5mg/kg, max 30mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:
Ketorolac 0.5mg/kg, max 30mg
Metoclopramide 0.1 mg/kg, max 10mg
Diphenhydramine 1mg/kg, max 50mg
Normal saline fluid bolus 20mL/kg, max 1000mL"
1538390|NCT02681211|Drug|Metoclopramide 0.1 mg/kg, max 10mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:
Ketorolac 0.5mg/kg, max 30mg
Metoclopramide 0.1 mg/kg, max 10mg
Diphenhydramine 1mg/kg, max 50mg
Normal saline fluid bolus 20mL/kg, max 1000mL"
1538391|NCT02681211|Drug|Diphenhydramine 1mg/kg, max 50mg|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:
Ketorolac 0.5mg/kg, max 30mg
Metoclopramide 0.1 mg/kg, max 10mg
Diphenhydramine 1mg/kg, max 50mg
Normal saline fluid bolus 20mL/kg, max 1000mL"
1538392|NCT02681211|Drug|Normal saline fluid bolus 20mL/kg, max 1000mL|"If assigned to receive intravenous medications and fluid the subject will be treated with the ED standard of care medications which include:
Ketorolac 0.5mg/kg, max 30mg
Metoclopramide 0.1 mg/kg, max 10mg
Diphenhydramine 1mg/kg, max 50mg
Normal saline fluid bolus 20mL/kg, max 1000mL"
1538395|NCT02681185|Other|Virtual Care|"Virtual Care consists of the following services and resources:
Have a virtual consult through online methods or telephone with one of the study endocrinologists
Be encouraged to report blood sugar readings every 2 weeks to their endocrinologist for regular follow-up and feedback via online methods
Be given access to a website with modules that attempt to replicate the information learned in a diabetes teaching clinic
Be given access to a certified diabetes educator through online methods or telephone. This will cover any other information that cannot be personalized on the teaching website, such as specific diet advice and social support."
1538396|NCT02681185|Other|Standard of Care|Standard of care offered in the patient's community. May involve in-person education at a diabetes centre and consultation with a healthcare professional.
1538399|NCT02681146|Other|Multimodal intervention|Educational advice + physiotherapist treatment
1538400|NCT02681133|Other|Epidemiological study Survey|
1538401|NCT02681120|Procedure|Biopsy|
1538402|NCT02681120|Procedure|Blood draw|
1538403|NCT02681120|Procedure|Mammogram|
1538404|NCT02681120|Procedure|MRI|
1538405|NCT02681107|Radiation|APBI 27Gy in 5 fractions|Patients will be treated with 3-D conformal, external beam, partial breast RT to deliver 27 Gy in 5 daily fractions using 3-5 beams on a linear accelerator. The target PTV will be the CT-visible seroma plus a 1cm margin to form the CTV (minus 5mm from skin and excluding chest wall) and a further 7mm to form the PTV. Real time review will ensure compliance with target and normal tissues dose constraints in this multi-institutional study. Any (or no) systemic therapy is permitted.
1538406|NCT02681094|Drug|Dapagliflozin|5mg, orally, Green, plain, diamond-shaped, film-coated tablet
1538407|NCT02681094|Drug|Placebo for Dapagliflozin|Does not contain active ingredient, orally, Green, plain, diamond-shaped, film-coated tablet
1538408|NCT02681094|Drug|Saxagliptin|5mg, orally, Plain, yellow, biconvex, round, film-coated tablet
1538409|NCT02681094|Drug|Placebo for Saxagliptin|Does not contain active ingredient, orally, Plain, yellow, biconvex, round, film-coated tablet
1538413|NCT02681068|Other|Fecal microbiota transplantation (FMT)|Fecal microbiota transplantation (FMT) for patients with Clostridium difficile associated diarrhea
1538414|NCT02681055|Drug|MN-001|MN-001 is a novel, orally bioavailable small molecule compound which demonstrates anti-inflammatory activity
1538415|NCT02681042|Procedure|Left atrial appendage closure|The SentreHeart Lariat® device (that is approved for soft tissue ligation) will be used to ligate or close the left atrial appendage as a stand-alone procedure at the participating centers.
1538442|NCT02680886|Device|Novosyn® Quick|Skin closure
1538419|NCT02681016|Device|"DES Calypso"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
1538420|NCT02681016|Device|"DES Xience Prime"|A standard endovascular procedure is carried out under local anesthesia and under fluoroscopic control. Stenosis of coronary artery is passed by the hydrophilic coronary wire. Then balloon angioplasty of target lesion (if required) is provided. After the angiographic control coronary stent is implanted. After coronary wire removing control angiographic study is provided. Medical therapy includes aspirin(acid acetylsalicylic) 125 - 300 mg/d and plavix(clopidogrel) in dose 300-600 mg prescription before the procedure and heparin (heparin sodium) injection during the procedure(5000 U iv). After the procedure aspirin(acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix(clopidogrel) in dose 75/d should be prescribed within 12 months.
1538421|NCT02681016|Procedure|Coronary angioplasty|
1538422|NCT02680990|Behavioral|Band Together|Band Together is a strength training program utilizing resistance bands with progressively increasing resistance, ranging from 3 to 35 pounds. Sessions are to be completed 3 times a week and involve 3 sets of 6 exercises: 1. chair stands, 2. chest press, 3. shoulder press, 4. arm curls, 5. pulls, and 6. calf raises. In addition, Band Together participants will be asked to work up to a walking goal of 10,000 additional steps per week.
1538423|NCT02680990|Other|Exercise Education|Education will consist of counseling by the healthcare provider with supplemental handouts from the American College of Sports Medicine and the National Institute on Aging/ National Institutes of Health.
1538424|NCT02680977|Other|MP-Equivalent|Mucuna pruriens powder at equivalent dosage than LD+DDCI. The dose of MP is calculated to obtain a 5-fold Levodopa dose than LD+DDCI.
1538425|NCT02680977|Other|MP-Low|Mucuna pruriens powder at low dosage. The dose of MP is calculated to obtain a 3.5-fold Levodopa content than LD+DDCI
1538426|NCT02680977|Other|MP+DDCI|Mucuna pruriens powder plus Benserazide. The dosage of MP is calculated to obtain the same Levodopa content than LD+DDCI. Benserazide is given as 1:4 ratio with Levodopa.
1538427|NCT02680977|Drug|LD+DDCI|Levodopa plus Benserazide
1538428|NCT02680977|Drug|LD-DDCI|Levodopa without any DDCI
1538429|NCT02680977|Other|Placebo|Groundnuts powder
1538430|NCT02680951|Drug|Dasatinib|Administered orally on a once daily schedule based on the dose level assigned to the patient at enrollment (60, 80, or 100mg/m2/day). Patients may adjust the time they take dasatinib as long as they take the drug approximately every 24 hours
1538431|NCT02680951|Drug|Fludarabine|"30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 1 to 5, total 5 doses
Participants with body weight less than 12Kg, the fludarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
1538432|NCT02680951|Drug|Cytarabine|"2000 mg/m2/dose intravenous infusion over 1 to 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 1 to 5, total 5 doses
Participants with body weight less than 12Kg, the cytarabine dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
1538433|NCT02680951|Drug|Idarubicin|"8mg/m2/dose intravenous infusion over 15 minutes, once daily, on days 3 to 5, total 3 doses
Participants with body weight less than 12Kg, the idarubicin dose will be corrected as follows: [weight (Kg) x dose (per m2)] divided by 30"
1538434|NCT02680951|Drug|Intrathecal (IT) cytarabine|"Given intrathecally to all participants on day 1 of course 1 and 2. Omit on day 1 of course 1 if participant received IT therapy within 7 days prior to study enrollment. Intrathecal chemotherapy may be given during the end of course 1 disease evaluation (spinal fluid and bone marrow aspiration) and may be repeated every 7 days with bone marrow evaluations per institutional preference.
Cytarabine dose defined by age:
30 mg for patients age 1 - 1.99
50 mg for patients age 2 - 2.99
70 mg for patients ≥3 years of age
The participant may receive intrathecal triple therapy (ITT) if persistent blasts are present in the cerebral spinal fluid (CSF) based on the treating physician's clinical judgment."
1538435|NCT02680938|Drug|oxytocin|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.
- The two groups will be compared in the following terms:
The duration of the third stage of labor by stopwatch.
Hemoglobin (Hb) difference before and 12 h after delivery.
The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
1538436|NCT02680938|Drug|saline|"For each participant, the duration of the third stage of labor (the time period between the delivery of the fetus and the delivery of the placenta) will be recorded.
- The two groups will be compared in the following terms:
The duration of the third stage of labor by stopwatch.
Hemoglobin (Hb) difference before and 12 h after delivery.
The need for manual delivery of the placenta. Manual removal of the placenta will be commonly carried out under general sedation in the operating room, if the placenta will not be delivered 30 min after fetal delivery."
1538437|NCT02680925|Procedure|lung protective ventilation|TV 4 ml/kg during one lung ventilation and 6 ml/kg during two-lung ventilation with PEEP of 6 cmH2O
1538438|NCT02680925|Procedure|Conventional ventilation|TV 8 ml/kg during one lung ventilation and 10 ml/kg during two-lung ventilation without PEEP
1538439|NCT02680912|Device|Warm needle acupuncture|There will be 4-6 points used per knee, therefore 8-12 needles per treatment. Two points will be used as the core treatment ST 35 dubi, Ex-LE 5 xiyan. Four other acu-points can also be used from the following: Ahshi painful points local to the knee (locus dolendi), ST 36 zusanli, GB 34 yanglingquan, Sp 9 yinlingquan, ST34 liangqiu, Sp 10 xuehai, GB 33 yangxiguan, LR 7 xiguan, LR 8 ququan, heding Ex-LE 2 In addition to the acupuncture needles the warm needle acupuncture group will receive moxibustion on up to 4 points. Smokeless moxa will be used.
1538440|NCT02680912|Device|Needle acupuncture|The point selection protocol will be exactly the same as the experimental group
1538441|NCT02680899|Behavioral|Curricular Intervention|The intervention is a novel grades 7 and 8 InSciEd Out curriculum in mental health and addiction called My Mind, My Body.
1538443|NCT02680873|Other|SASI bypass|he operation was done under general anesthesia. The technique commences with the devascularization of the greater curvature of the stomach with the harmonic scalpel.junction. The stomach is then tubularized over a 36 French calibration tube, with a linear stapler charged with a green cartridge, commencing 6 cm proximal to the pylorus. The ileocecal junction is identified and 250 cm is measured upwards. The selected loop is ascended antecolic without division of the greater omentum, and a stapled isoperistaltic side-to-side to the anterior wall of the antrum of the stomach just cranial 3 cm away from the pylorus with a linear stapler charged with a green cartridge.
1538447|NCT02680821|Procedure|ALL reconstruction (Anterolateral ligament)|
1538448|NCT02680821|Procedure|ACL revision (Anterior cruciate ligament )|
1538449|NCT02680808|Drug|Midazolam with F901318|Pharmacokinetics of midazolam with F901318
1538453|NCT02680782|Drug|X4P-001|100 mg capsules, administered orally for 10 days either as 200 mg BID or 400 mg QD. Subjects will be randomized to determine if they will receive the drug QD or BID in the first dosing period.
1538454|NCT02680769|Dietary Supplement|300 mg of citrate Mg|This group will take an oral supplementation of 300 mg of citrate magnesium
1538455|NCT02680769|Other|Placebo|This group will take a placebo
1538458|NCT02680743|Other|Education of parents to pursue prompt hearing screening.|Parents of patients will be counseled on the risks of hearing loss with a positive screen.
1538459|NCT02680730|Behavioral|Listening Project Protocol|The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
1538460|NCT02680717|Drug|Clobetasol|ointment, twice daily (alternating weeks)
1538461|NCT02680717|Drug|Calcipotriene|ointment, twice daily
1538462|NCT02680717|Drug|Tacrolimus|ointment, 0.1%, twice daily
1538463|NCT02680704|Other|PEEP titrated mechanical ventilation|Enrolled patients will receive a sequential, step-wise increase in positive end-expired pressure from 5 cmH2O to 15 cmH2O. Intracranial pressure, transpulmonary pressure, vitals, and mechanical ventilator data will be measured at each increment. PEEP will be increased by increments of 5 cmH2O. The mode of mechanical ventilation (pressure or volume control), inspiratory time and fraction of inspired oxygen (FIO2) will be determined by the critical care team caring for the patient. In the event that PEEP is set > 5 cmH2O, measurements will be obtained from that starting point and increased to a maximum of 15 cmH2O. The physiologic measurements will be obtained at regular intervals (within 5 minutes at each PEEP level) throughout the PEEP titration period.
1538464|NCT02680691|Other|Robot, then conventional training|Robot assisted gait training from the baseline, then conventional gait training at 4 weeks after baseline
1538465|NCT02680691|Other|Conventional, then robot training|Conventional gait training from the baseline, then robot assisted gait training at 4 weeks after baseline
1538466|NCT02680678|Other|Colloid Preload|preload infusion
1538467|NCT02680678|Other|colloid co-load|co-load infusion
1538468|NCT02680678|Other|Crystalloid preload|preload infusion
1538469|NCT02680678|Other|Crystalloid Co-load|co-load infusion
1538470|NCT02680639|Device|BiPAP Synchrony ventilator|The BiPAP Synchrony ventilator will be used to determine Expiratory Positive Airway Pressure (EPAP). The ventilator will be used with varying pressure supports and oscillations depending on what arm of the study the participant is in.
1538471|NCT02680626|Drug|Magnesium Sulfate|Given via transversus abdominis plane block
1538472|NCT02680626|Drug|Ropivacaine|Given via transversus abdominis plane block
1538473|NCT02680613|Behavioral|Motivational SMS|Behaviour change messages delivered via SMS developed with the theoretical guidance of the Health Belief Model.
1538474|NCT02680613|Behavioral|Travel Voucher|A code for return public transportation to closest cervical cancer screening clinic included in the research.
1538475|NCT02680600|Drug|Cefepime dosing|Patients will received cefepime administered per standard-of-care as a 30 min intravenous infusion. Dosing will be based on local guidelines (the Sanford guide to antimicrobial therapy 2012-2013) using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine formula to estimate glomerular filtration rate (GFR).
1538476|NCT02680600|Other|Blood sampling|Blood will be sampled immediately prior to dose administration (time = 0 at the start of the 30 min infusion), at 0.5, 1, 3, 5 hours post-start of infusion and just before the subsequent dose. From day two onwards, samples will be taken at the end of the infusion and just before the next dose. For the quantification of cefepime, a validated solid phase extraction-liquid chromatography electrospray-tandem mass spectrometry method will be used.
1538477|NCT02680600|Other|Urine sampling|Timed urine collections were taken during one dosing interval (8 hours in a three times daily regimen) every day.
1538614|NCT02679573|Drug|Moxifloxacin|Antibacterial Agent, 400 mg IV, Q24H for at least 3 doses with potential to switch to 400 mg oral over-encapsulated tablet, Q24H for up to 10 doses total
1538615|NCT02679573|Drug|Linezolid|Antibacterial Agent, at local investigator discretion, subjects in the moxifloxacin arm with confirmed MRSA can switch to linezolid 600 mg IV Q12H for all remaining doses
1538478|NCT02680600|Other|Determination of renal markers|Creatinine (modified Jaffe method) and urea in serum will be determined using an Architect c16000 analyzer (Abbott, Chicago, IL, USA). Cystatin C will be determined using a particle-enhanced immunonephelometric assay (N Latex Cystatin C, Siemens Healthcare Diagnostics, Marburg, Germany) by use of a BN II nephelometer (Siemens Healthcare Diagnostics). This assay has a calibration traceable to the first certified reference material for cystatin C in human serum (ERM-DA471/IFCC). Kidney injury molecule-1 (KIM-1) in urine and uromodulin in serum will be determined using commercially available ELISA assays: Quantikine ELISA Human TIM-1/KIM-1/HAVCR (R&D Systems, Minneapolis, MN, USA) and Uromodulin ELISA (Euroimmun, Luebeck, Germany), respectively.
1538479|NCT02680600|Other|Population pharmacokinetic modeling|The cefepime concentration versus time data will be fitted using the FOCE-I estimation algorithm in NONMEM® (Version 7.3; GloboMax LLC, Hanover, MD, USA). R® (R foundation for statistical computing, Vienna, Austria) will be used to graphically assess the model's goodness-of-fit and to evaluate the model's predictive capabilities. As a measure of prediction error, the absolute prediction error (APE) will be used. In short, the measured cefepime concentrations for each individual i at time point j were compared against the population predicted cefepime concentrations, i.e. the predictions for each individual without taking into account the between-subject variability (PRED in NONMEM). The distribution of APEs will be summarized by the median and 90% percentile.
1538480|NCT02680600|Other|Covariate screening|Renal function will be assessed by four serum based kidney markers (serum creatinine, cystatin C, urea and uromodulin) and two urinary markers (measured creatinine clearance (CrCl) and KIM-1, both on timed urine collections). Serum creatinine and cystatin C will also be used to calculate the eGFR based on CKD-EPI formulas.
1538481|NCT02680600|Other|Monte Carlo simulations|Based on the final covariate model, a Monte Carlo-based simulation study will be performed to evaluate the Sanford dose recommendations for ICU patients.
1538482|NCT02680587|Radiation|SBRT|SBRT (1-5 fractions) will be administered.
1538483|NCT02680587|Drug|DCFPyL-PET/MRI or -PT/CT|Estimate the proportion of DCFPyL-PET/MRI or -PET/CT positive sites that are positive for new or progressive metastatic disease by bone scan at 6-months from SBRT and vice versa
1538484|NCT02680587|Other|Observational (no SBRT)|These patient will not receive SBRT. They will be observed.
1538485|NCT02680574|Drug|vadadustat|oral tablet
1538486|NCT02680574|Drug|darbepoetin alfa|Subcutaneous
1538487|NCT02680561|Drug|Fluticasone Propionate MDPI|
1538488|NCT02680561|Drug|Fluticasone Propionate/Salmeterol MDPI|
1538489|NCT02680561|Drug|Fluticasone propionate/salmeterol|
1538490|NCT02680548|Drug|0.9% saline|
1538491|NCT02680548|Drug|0.25% bupivacaine hydrochloride injectable suspension USP|
1538492|NCT02680548|Drug|4mg/cc methylprednisolone acetate injectable suspension USP|
1538494|NCT02680522|Other|Exercise|exercise training with virtual reality in videogame
1538495|NCT02680509|Procedure|Sympathicotomy R3|sympathicotomy R3 consists of transecting the sympathetic chain at the third costal level, cranial of the ganglia, leaving the ganglia themselves untouched
1538499|NCT02680470|Device|Virtual observed therapy|Virtual Observation of participants taking their medication
1538500|NCT02680457|Drug|Insulin Degludec|10 IU SC every 24 hours for 6 days
1538501|NCT02680457|Drug|Insulin Glargine|10 IU SC every 24 hours for 6 days
1538502|NCT02680444|Behavioral|Self-Administered Mindful-Reappraisal Exercise|Combining the practice of mindful acceptance of negative events combined with a reappraisal of the event by examining its positive aspects.
1538503|NCT02680444|Behavioral|Self-Administered Reappraisal-Only Exercise|A reappraisal of daily negative events by examining the positive aspects.
1538504|NCT02680444|Behavioral|Self-Administered Event Recall Exercise|Recall a negative event that took place that day.
1538505|NCT02680431|Other|Blood sample|10 mL venous blood sample for analysis of plasma
1538506|NCT02680418|Drug|FDL169|
1538507|NCT02680405|Procedure|Skin Biopsy|Full thickness skin biopsies will be collected from each subject used for proteomic and genomic analysis of associated biomarker levels.
1538508|NCT02680405|Procedure|Skin tape stripping|Skin tape stripping used for proteomic and genomic analysis of associated biomarker levels.
1538509|NCT02680405|Procedure|Blood draw|Whole blood and serum testing used for proteomic and genomic analysis of associated biomarker levels.
1538510|NCT02680392|Procedure|Pulsed and Continuous Radiofrequency|"Preoperative pulsed radiofrequency of the saphenous nerve and Continuous radiofrequency of the genicular nerves of the knee joint.
The saphenous nerve will be approached at the adductor canal and it will be treated with Pulsed RF for 4 minutes at 42 Celsius degrees. Ropivacaine 0.5% 10ml with Dexamethasone 10mg will be injected after the RF.
The Genicular terminal branches of the sciatic and femoral nerves will be treated with Continuous RF for 3 min at 80 Celsius degrees and then with 2 ml of Ropivacaine 0.5% and 10 mg of Methylprednisolone to each nerve (5 in total) A sham catheter in the mid-thigh will be placed for patients in the RF group, infusing Normal Saline 0.9% and simulating a Continuous Adductor Canal Block. To blind the investigator to the type of treatment for the postoperative assessment , every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution."
1538570|NCT02679937|Other|Nutrition Education|Two, 50 minute educational videos address basic concepts of healthy nutrition and weight management reviewing topics such as macro and micronutrients, the virtue of whole grains, fruit, vegetables and superfoods, the dangers of dehydration and vitamin deficiency. The role of poor eating habits, lack of exercise and cultural and technological issues in America's obesity epidemic is examined. A basic understanding of energy balance is conveyed. The role of nutritional supplements is addressed.
1538737|NCT02678572|Procedure|Melphalan|Melphalan (3 mg/kg IBW) with PHP
1538511|NCT02680392|Drug|Continuous Adductor Canal Block|"The patients in the Adductor canal group, will have a catheter for peripheral nerve block inserted under strict asepsis in the adductor canal under ultrasound guidance, and will receive for postoperative analgesia a 48-h continuous infusion of Ropivacaine 0.2% at 8 ml/hour The patients will receive, intraoperatively 10 mg of Dexamethasone i.v.
To blind the investigator who will do the postoperative assessment to the type of treatment, every solution bag will be prepared by the Pharmacy of the Hospital, covered with a plastic envelope and labeled as Study Solution. It will be always possible to crack the code and find out to which group the patient belongs"
1538512|NCT02680379|Drug|Minocycline, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of minocycline 50mg daily for 4 weeks, minocycline 100mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40mg for the following 12 weeks.
1538513|NCT02680379|Drug|Lovastatin, then Minocycline/Lovastatin|Participants of this group will take 1 tablet of lovastatin 20 mg daily for 4 weeks, lovastatin 40 mg for the following 4 weeks and finally a combined treatment of minocycline 100 mg and lovastatin 40 mg for the following 12 weeks.
1538514|NCT02680366|Device|collagen/ABMNC scaffold|The patients will receive a bone marrow puncture to collect bone marrow cells which are used to isolation of ABMNCs. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. Then, the collagen/ABMNCs scaffold was covered on a Foley catheter balloon and placed into the uterine cavity. The catheter balloon was kept for 24 hours and then removed. Oral antibiotics were given to prevent infection in the second and third days after operation. 72 hours after the surgery, a vaginal speculum examinations will be done in order to make patients unknown about their arms. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
1538515|NCT02680366|Device|Foley catheter balloon|The patients will receive a sham bone marrow puncture which just has a local anesthesia and collects no bone marrow cells to isolation. After that, hysteroscopic adhesiolysis will be done according to the patient's uterine adhesion. And then, a Foley catheter balloon will be placed into the uterine cavity and kept for 72 hours before it is removed. Oral antibiotics were given to prevent infection in the second and third days after operation. Estrogen will be administrated for 3 cycles to support the endometrial regeneration after the surgery. The clinical follow up will be done at 1, 3 and 6 months after the procedure.
1538516|NCT02680353|Procedure|Bilateral superficial cervical plexus block|A kind of anesthetic nerve block type performed to block the nerve function temporarily by administrating local anesthetics through the trajectory of the nerve.
1538517|NCT02680340|Procedure|Total Hip Arthroplasty|Patients who had a primary THA between 2002 and 2005
1538518|NCT02680314|Drug|Misoprostol|Misoprostol, a prostaglandin, binds to myometrial cells to cause strong myometrial contractions leading to expulsion of tissue. This agent also causes cervical ripening with softening and dilation of the cervix.
1538521|NCT02680288|Drug|Lorcaserin, 10 mg|Oral type 2C serotonergic agonist, low-dose
1538522|NCT02680288|Drug|Lorcaserin, 20 mg|Oral type 2C serotonergic agonist, high-dose
1538523|NCT02680288|Other|Oral Placebo|Oral inert treatment
1538524|NCT02680275|Drug|Dead Sea Peloid Gel|intravaginally
1538525|NCT02680262|Behavioral|HPV self-sampling kit mailed directly|Women in intervention group 1 will be mailed a modified second reminder, a leaflet entitled Information about HPV self-sampling, and a self-sampling kit. The leaflet provides information about HPV and cervical cancer including benefits and harms about HPV self-sampling compared to regular screening. The kit includes a brush device (Evelyn Brush, Rovers Medical Devices B.V, Oss, Netherlands) to collect a cervico-vaginal sample for subsequent hrHPV testing, written and drawn instructions on how to obtain and mail the sample, and a pre-stamped return envelope addressed to the Department of Pathology, Randers Regional Hospital performing the hrHPV testing.
1538526|NCT02680262|Behavioral|HPV self-sampling kit on demand|"Women in intervention group 2 receive the same material as arm 1, except for the kit, which will only be mailed to the women on demand. Additionally, the leaflet for this group contains information on how to order the kit.
The modified second reminder in both intervention groups informs of the opportunity to collect a self-sample if wanted, but also about the opportunity to have a conventional specimen taken at a general practitioner (usual procedure)."
1538527|NCT02680262|Behavioral|Second reminder|The standard second reminder informs women about the ongoing opportunity to have a conventional cervical sample taken by a general practitioner. (control group)
1538528|NCT02680249|Drug|CTP-656|
1538529|NCT02680236|Other|Art Therapy Group|"Patients fulfilling the inclusion criteria will be made an appointment with the art therapist for the Initial Assessment session. They will be given the following Reflect Interview session Final interview session An analgesic use form will be given to the patient to take home to note their actual analgesic use
At the end of each of these art therapy sessions, patients will be given a Brief Pain Inventory form (BPI) with a stamped addressed envelope. This is to be completed twenty four hours after the appointment and returned by post."
1538530|NCT02680223|Device|Precision tinted lenses|Tinted lens for patient with reading difficulty or visual stress
1538531|NCT02680223|Device|Non-beneficial tinted lenses|Tinted lenses that are unlikely to help reading difficulty or visual stress
1538532|NCT02680210|Other|Questionnaires and cognitive measures|
1538533|NCT02680197|Drug|CHF5259 or Placebo administration|Administration of 2 puffs of treatment in the morning and in the evening during a 4 week period. Each patient will be allocated to 3 out of the 5 possible treatments.
1538571|NCT02679924|Device|Hyaluronic Acid filler|The objective of this study is to determine the efficacy and safety of Restylane® Silk Hyaluronic Acid filler microinjections when used in a grid-like injection pattern for the correction of fine lines to the cheeks.
1538572|NCT02679924|Other|Sham Comparator|Micro-injections of normal saline for correction of mid to low cheek fine lines and wrinkles.
1538573|NCT02679911|Drug|Loceryl Nail Lacquer|Topical over the entire toenail plate of all affected toenails, once weekly in the evening (at bed time) after filing down the affected toenails.
1538534|NCT02680184|Drug|CMP-001|"The study is designed as two parts: Part 1 CMP-001 in combination with pembrolizumab which is comprised of two phases (1): Dose Escalation Phase (2) Dose Expansion Phase and Part 2: Monotherapy CMP-001 The study will evaluate two schedules of CMP-001 given intratumorally, designated as Schedule A or B.
Schedule A: CMP-001 will be administered once a week for 7 weeks (total of 7 doses). Thereafter it will be administered once every 3 weeks until the subject is discontinued.
Schedule B: CMP-001 will be administered once a week for 2 weeks, then once every 3 weeks for 5 additional doses (total of 7 doses). Thereafter it will be administered once every 3 weeks until the subject is discontinued.
Part 1 Dose Expansion and Part 2 Monotherapy will be conducted under Schedule A only."
1538535|NCT02680184|Drug|Pembrolizumab|"The study is designed as two parts: Part 1 CMP-001 in combination with pembrolizumab which is comprised of two phases (1): Dose Escalation Phase (2) Dose Expansion Phase and Part 2: Monotherapy CMP-001 The study will evaluate two schedules of CMP-001 given intratumorally, designated as Schedule A or B.
Schedule A: CMP-001 will be administered once a week for 7 weeks (total of 7 doses). Thereafter it will be administered once every 3 weeks until the subject is discontinued.
Schedule B: CMP-001 will be administered once a week for 2 weeks, then once every 3 weeks for 5 additional doses (total of 7 doses). Thereafter it will be administered once every 3 weeks until the subject is discontinued.
Part 1 Dose Expansion and Part 2 Monotherapy will be conducted under Schedule A only."
1538536|NCT02680171|Behavioral|Prism Goggles|Patients in the experimental condition will wear prism goggles while completing a computerized aiming task. This prisms will shift the patients' vision 10 degrees rightward, causing a recalibration of visuo-motor information. Prism adaptation will be carried out over several days.
1538537|NCT02680171|Other|Non-Shifting Goggles|Non-shifting goggles are worn instead of prism goggles, while completing the same computerized aiming task as those assigned to the prism adaptation.
1538538|NCT02680158|Device|Oculeve Intranasal Lacrimal Neurostimulator|Active Neurostimulation device
1538539|NCT02680158|Device|Extranasal|The active device applied extranasally
1538540|NCT02680158|Device|Sham|Sham device applied intranasally
1538541|NCT02680145|Device|Preoperative Pessary Use|Pessary use for 1-4 weeks prior to surgical prolapse repair
1538542|NCT02680132|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
1538543|NCT02680132|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
1538544|NCT02680119|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA.|oral, crossover
1538545|NCT02680119|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, crossover
1538546|NCT02680106|Device|SPINNER|The SPINNER device is aimed at the DSW from a distance of 20 cm and activated for 1 minute. A nano-fibrous dressing is thus created.
1538547|NCT02680106|Device|JELONET|The patient's DSW will be dressed by JELONET
1538548|NCT02680093|Other|Cervical length in pregnant women.|"Pregnant Women beyond the date of birth. will be followed while coming to routine monitoring. physiological parameter of cervical length will be measured as the differential predictor to determine their due date. the cervical length will be measured as part of routine gynecologic examination to women who come for routine over due date follow up.
additional medical data will be collected from the patient medical record.- demographic data, and all the routine prenatal medical care the women will receive up to the delivery.and delivery out comes."
1538549|NCT02680080|Drug|Moxifloxacin|a single 400 mg tablet of Moxifloxacin
1538550|NCT02680080|Dietary Supplement|Grapefruit group|one liter of fresh pink-grapefruit juice
1538551|NCT02680067|Drug|Indocyanine Green|A trained physician will inject 0.1 ml of Indocyanine Green into the web spaces of the hands in both upper extremities. Subjects may have up to five study visits to confirm feasibility, safety, and reproducibility.
1538552|NCT02680067|Device|MultiSpectral Imaging System|Once the Indocyanine Green is injected, the contrast is expected to fluoresce underneath the MultiSpectral Imaging System. Multispectral video and still images will be recorded at the study visits.
1538553|NCT02680054|Drug|Insulin, Asp(B28)-|This insulin dose is sometimes given for fat and protein content of food in children using insulin pumps, in prolonged boluses. The investigators are replicating this in children using multiple insulin injections at various times related to the meal
1538554|NCT02680041|Drug|18F-fluciclovine PET CT|Subjects will undergo a fluciclovine F18 PET/CT scan in addition to standard of care monitoring. The results of this scan may influence further treatment
1538555|NCT02680028|Device|targon pft nail|
1538556|NCT02680015|Behavioral|PEERS|Social-behavioral intervention designed to help individuals with Autism Spectrum Disorder make and keep friends.
1538557|NCT02680002|Biological|7.5 mcg H5N1 (stored as monobulk)|
1538558|NCT02680002|Biological|15 mcg H5N1 (stored as monobulk)|
1538559|NCT02680002|Biological|90 mcg H5N1 (stored as monobulk)|
1538560|NCT02680002|Biological|90 mcg H5N1 (stored in vials)|
1538561|NCT02680002|Other|MF59|
1538562|NCT02680002|Other|MF59 (stored as monobulk)|
1538563|NCT02679989|Behavioral|Intermittent Energy Restriction|Dietary advice to follow 5:2 diet supported by physical activity advice and motivational group support sessions
1538564|NCT02679989|Behavioral|Continuous Energy Restriction|Dietary advice to follow daily energy restricted diet supported by physical activity advice and motivational group support sessions
1538565|NCT02679976|Device|etafilcon A|Marketed Multifocal Contact Lens
1538566|NCT02679963|Drug|Olaparib|
1538567|NCT02679963|Drug|Placebo|
1538568|NCT02679950|Genetic|Next generation genome sequencing|DNA will be extracted from each sample and assayed.
1538569|NCT02679937|Behavioral|Fit4Duty|Small (<9) participant-driven groups meet weekly for 6, 1 hour sessions. Participants design small, gradual healthy lifestyle change plans with added verbal, written, and behavioral exercises designed to elicit dissonance regarding engaging in unhealthy eating and sedentary practices. Participants are asked to voluntarily discuss the health, interpersonal and societal costs of obesity, an unhealthy diet, and sedentary behavior, as well as the benefits of leanness, a healthy diet, and regular physical activity.
1538574|NCT02679911|Drug|Ciclopirox Nail Lacquer|Topical over the entire toenail plate of all affected toenails and surrounding skin, once daily in the evening (at bed time) after removing the free toenail edge and diseased toenails if needed
1538740|NCT02678572|Drug|Ipilimumab|Ipilimumab is to administered at 3 mg/kg IV over 90 minutes every 3 weeks for a total of 4 treatments.
1538575|NCT02679898|Other|Unloaded-Whole Body Vibration (WBVT)|The unloaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
1538576|NCT02679898|Other|Loaded-Whole Body Vibration (WBVT)|The loaded-WBVT intervention consists of four leg exercises performed dynamically over a vibrating platform 3 times/week for 6 weeks. Importantly, an external load was applied to a weight vest to account for the necessary weight to perform a specific number of repetitions (progressed from 15-8 repetitions maximum during the 6 weeks). Dynamic movements were performed with controlled movements starting from an upright position into a 90 and 120 degree knee angle, wide-stance squat, and maximal heel elevation. The training volume increased progressively by increasing the intensity of the vibration (30-35 Hz; low-high amplitude), duration of exercise (30-60 sec), number of sets per exercise (2-8), and total during of training session, while decreasing the rest periods (60-30 sec).
1538577|NCT02679859|Other|BNP guided medical therapy optimisation|
1538578|NCT02679846|Other|Standardized protocol|The standardized protocol of AEDs withdrawal will be implemented and applied to all inpatients
1538579|NCT02679833|Dietary Supplement|Placebo|Toothpaste not containing the vitamin.
1538580|NCT02679833|Dietary Supplement|Cyanocobalamin|Toothpaste containing100 µg cyanocobalamin/g.
1538581|NCT02679820|Device|Copper T intrauterine device|
1538582|NCT02679807|Biological|Bifidobacterium animalis subsp. lactis Bl-04|
1538583|NCT02679807|Other|sucrose|
1538584|NCT02679794|Behavioral|Egg consumption|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil with 100g (2 large eggs) of whole eggs
1538585|NCT02679794|Behavioral|Control|Subjects will consume a carefully portioned sautéed vegetables and 3g canola oil.
1538586|NCT02679781|Drug|oral midazolam|administration of 0.5mg/kg oral midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
1538587|NCT02679781|Drug|nasal midazolam|administration of 0.2mg/kg nasal midazolam. During dental treatment 50% nitrous oxide/ 50% oxygen will be administered via nasal hood.
1538588|NCT02679768|Behavioral|Circadian Reinforcement Therapy|Electronical monitoring plus psychoeducation on zeitgeber and sleep to learn how to create a stabile sleep-wake cycle
1538591|NCT02679742|Dietary Supplement|β-hydroxymethylbutyrate|β-hydroxymethylbutyrate 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
1538592|NCT02679742|Dietary Supplement|Placebo|Maltodextrin 3 grams once a day combined with a resistance training program (3 progressive resistance training sessions per week) during 12 weeks
1538597|NCT02679703|Device|High voltage|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns
1538598|NCT02679703|Device|Neuromuscular transcutaneous electrical stimulation (TENS)|Electrical stimulation treatments will be made in donor areas (scalp and thigh) in patients burns.
1538599|NCT02679703|Other|Control Group|The control group will not have electrical stimulation however, will be evaluated with digital digital imaging, thermography imaging, skin hardness and subjective pain and healing scales
1538602|NCT02679677|Device|Whole Body Vibration|The principle of the Galileo vibration platform is a side alternating motion similar to a childrens seesaw. Both the amplitude of movement and the frequency of movement may be altered. Frequency may be controlled on the device and settings range from 5Hz to 30Hz. Amplitude of movement is set by spreading one's legs further apart from the midline. Control arm participants remain fixed at 5Hz through the 6 week training period, while intervention arm participants steadily increase their frequency to a maximum of 28Hz.
1538603|NCT02679664|Drug|Rosuvastatin|20 mg tablet of rosuvastatin
1538604|NCT02679651|Other|Ultrasound of the foot|An ultrasound will be used to determine the thickness of the fat pad
1538605|NCT02679651|Other|Pedobarograph Measurements|This non-invasive device measures the force and pressure of the foot while standing and walking.
1538606|NCT02679651|Other|Manchester Foot Pain and Disability Index|This is a patient completed questionnaire that assesses level of function from the past month specific to foot pain.
1538607|NCT02679638|Other|Factors and perceptions questionnaire|A detailed questionnaire inquiring about demand factors, supply factors and perceptions affecting patients' treatment choices in 5 key decision points: participation role in the decision making process, hospital choice, treatment regimen choice, surgical extent and surgeon choice.
1538608|NCT02679638|Other|Qualitative interview|Depth interviews with 20 breast cancer patients, 2 spouses and 3 staff members.
1538609|NCT02679625|Device|Ultrasound and NICOM|All patients enrolled will have all three ultrasound-based modalities for fluid responsiveness performed, as well as have NICOM data to serve as the comparison standard.
1538610|NCT02679599|Other|B-MOBILE-CARDIAC smartphone application|
1538611|NCT02679599|Behavioral|Cardiac rehabilitation as usual|
1538612|NCT02679586|Device|Diffusion weighted MRI|
1538613|NCT02679573|Drug|Delafloxacin|Antibacterial agent, 300 mg IV, Q12H for at least 6 doses with potential to switch to 450 mg oral tablet, Q12H for up to 20 doses total
1538616|NCT02679560|Drug|Liposomal Bupivacaine|A fascia iliaca compartment block using liposomal bupivacaine will require less total opioid administration compared to a fascia iliaca block using 0.2% ropivacaine
1538617|NCT02679560|Drug|Ropivacaine HCL|Ropivacaine HCL is a member of the amino amide class of local anesthetics. Naropin injection is a sterile, isotonic solution that contains the enantiomerically pure drug substance, sodium chloride for isotonicity and water for injection. It is administered parenterally.
1538618|NCT02679547|Other|Breastfeeding|All of the participants and patients will have a questionnaire about their breastfeeding
1538619|NCT02679534|Other|hand massage|
1538620|NCT02679534|Other|hand holding|
1538621|NCT02679534|Other|application of unscented hypoallergenic cream|
1538622|NCT02679534|Other|environmental adjustments|
1538623|NCT02679521|Device|ESWT|"Radial extracorporeal shock wave therapy (rESWT) was performed by the principal investigator with a Swiss DolorClast device (EMS Electro Medical Systems Corporation; Dallas, Texas, USA).
The Swiss DolorClast device obtained Pre-Market Approval (PMA) by FDA as Class III orthopedic lithotripsy device to treat heel pain associated with chronic proximal plantar fasciitis on May 8, 2007 (PMA # P050004), and was re-classified as Class III Generator, Shock Wave, For Pain Relief (Product Code NBN) in the Spring 2009. The present study started on October 3, 2007.
Each patient received two sessions of rESWT one week apart, with 2,000 impulses per session (air pressure of the device set at 3.5 bar; impulses applied with the 15 mm applicator at frequency of 8 Hz)."
1538624|NCT02679521|Device|Placebo|Placebo treatment was performed identically as rESWT but with a clasp on the heel that prevented transmission of the impulses from the applicator to the skin at the treatment site.
1538625|NCT02679508|Drug|Vonoprazan|Vonoprazan fumarate 10 mg or 20 mg capsules
1538626|NCT02679508|Drug|Lansoprazole|Lansoprazole 15 mg or 30 mg capsules
1538627|NCT02679495|Behavioral|Active measures of lifestyle modification|
1538628|NCT02679469|Drug|nalmefene hydrochloride 10 mg|
1538629|NCT02679456|Drug|SCY-078|
1538630|NCT02679456|Drug|Fluconazole|
1538631|NCT02679443|Dietary Supplement|Folate and B12|Vitamin (folate and B12) supplementation started simultaneously with initiation of chemotherapy (within 24 hours of initiation of chemotherapy). The only difference from the delayed (no-intervention) arm is the timing of initiation of vitamin supplementation. Dose and mode of administration of vitamin B12 and folate supplementation remain similar in both arms.
1538632|NCT02679430|Device|Prostate Arterial Embolization|The purpose of this study is to demonstrate the safety and efficacy of the device, Embosphere Microspheres, in prostatic arterial embolization (PAE). PAE, is now an accepted form of treatment for BPH outside of the United States, however few studies have been performed demonstrating safety and efficacy in the US. Embosphere Microsphere is a device that may be used to reduce blood flow to targeted organs. With this research, we would like to show that Embosphere Microsphere may be used for patients with benign hyperplasia of prostate (BPH to reduce blood flow to the prostate gland. This current study is designed to understand the rate of improved BPH symptoms.
1538633|NCT02679417|Behavioral|exercise|12 weeks of aerobic or resistant exercise
1538634|NCT02679378|Device|ClearSight™ System|comparing ClearSight system to histopathological to determine negative-margins in breast conserving surgery.
1538635|NCT02679365|Procedure|lower segment cesarean section and double lock closure of rectus sheath|
1538636|NCT02679365|Procedure|lower segment cesarean section and continuous non-locking closure of rectus sheath|
1538637|NCT02679352|Device|SMR Stemless|Total anatomic or reverse shoulder arthroplasty
1538638|NCT02679339|Drug|CNTX-2022 (lidocaine gel, 40%)|
1538639|NCT02679339|Drug|Placebo|
1538640|NCT02679326|Device|Therapeutic ultrasound|
1538641|NCT02679313|Device|Phoropter|Each subject will be tested on 3 separate occasions using either the manual phoropter (American Optical 11625), electronic phoropter (Topcon CV-5000) or the wearable adaptive refractor (VisionFit). Oculomotor measurements, i.e., heterophoria, vergence ranges, AC/A and accommodative findings will be measured at each session using the different devices. Each session will be separated by a minimum of 24 hours and a maximum of 14 days.
1538642|NCT02679300|Other|Virtual reality exercise group|
1538643|NCT02679300|Other|Conventional exercise group (control group)|
1538644|NCT02679287|Device|CLC|The CLC will be deployed with different functionalities at different stages of the trial, resulting in variation in what the subject will be responsible for and what the system will drive.
1538647|NCT02679261|Drug|Atorvastatin|Oral administration atorvastatin 20 mg per day
1538648|NCT02679261|Drug|Placebo|Oral administration placebo
1538649|NCT02679248|Dietary Supplement|Neo40 Daily®|
1538650|NCT02679248|Dietary Supplement|Placebo|
1538651|NCT02679235|Drug|Triheptanoin|The target daily dose of triheptanoin will be 1 g/kg/d, or approximately 70 g/d during 28±2 days. It will be divided into four daily doses, one of which will be consumed at each meal and one with an evening snack.
1538652|NCT02679222|Dietary Supplement|Supplementation|coconut oil and MCT oils (60-40, tricaprylin and triheptanoate)
1538653|NCT02679209|Biological|Bone allograft|it is a type of bone graft from human cadavers.
1538654|NCT02679209|Biological|Amnion chorion membrane|A bioresorbable allograft membrane for guided tissue regeneration from amnion and chorion parts of the placenta from pregnant females for guided tissue regeneration.
1538655|NCT02679196|Drug|KA2237|PI3 Kinase p110β/δ inhibitor
1538656|NCT02679183|Dietary Supplement|Medically-Graded Honey|Honey added to the baby formula once a day for 2 weeks.
1538657|NCT02679183|Other|Premature Milk Formula|Enteral feeds were provided to subjects of all groups using premature milk formula as per routine nutritional management in the neonatal intensive care unit.
1538659|NCT02679144|Drug|Difluoromethylornithine (DFMO)|Subjects will receive 730 Days of oral difluoromethylornithine (DFMO) at a dose of 500 to 1000 mg/m2 BID on each day of study.
1538781|NCT02678312|Drug|Enalapril|Enalapril will be open label in Part 1 and double blind in Part 2
1538661|NCT02679118|Device|Sentire|The device, at predetermined time points, will draw a small amount of gas from the abdomen. Upon obtaining the samples, the machine will analyze the sample for evidence of bowel gas. After each sample, the device will be purged prior to the acquisition of the next gas sample. The results of the analysis of the gas samples will be recorded for future analysis.
1538662|NCT02679105|Drug|ALK Alutard birch or 5-grasses|3 injections with 4-5 weeks interval.
1538663|NCT02679105|Drug|ALK diluent|0,3% human albumin
1538664|NCT02679092|Drug|Misoprostol|400 mcg buccal 60-90 minutes prior to procedure
1538665|NCT02679092|Drug|Mifepristone|200 mg PO on the day prior to D&E
1538666|NCT02679092|Device|Hygroscopic cervical dilators|osmotic cervical dilators inserted through the internal os
1538669|NCT02679066|Device|Sugar-tong splint|Plaster immobilization including the elbow
1538670|NCT02679066|Device|Short forearm cast|Fiberglass immobilization with elbow free
1538671|NCT02679053|Behavioral|Aerobic exercise|
1538672|NCT02679053|Behavioral|Placebo control|
1538673|NCT02679040|Procedure|Immediate mammary reconstruction|Chemotherapy administration then radiotherapy and then surgery : mastectomy and immediate mammary reconstruction.
1538674|NCT02679040|Drug|Chemotherapy|Chemotherapy treatment
1538675|NCT02679040|Radiation|Radiation therapy|Radiation therapy
1538676|NCT02679027|Other|Protrude tongue maximally and upward (PTMU)|The horizontal line was passing through the mid points of the distance between subnasale to stomion (upper lip height). Patients were asked to protrude tongue maximally and upward (PTMU).
1538677|NCT02679027|Other|Protrude tongue maximally and downward (PTMD)|The horizontal line was passing through the mid points of the distance between stomion to mentum (mandible height). Patients were asked to protrude tongue maximally and downward (PTMD).
1538678|NCT02679014|Drug|Placebo|With the exception of the mornings of Days 7 and 21, placebo capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, placebo will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
1538679|NCT02679014|Drug|RO5459072|With the exception of the mornings of Days 7 and 21, RO5459072 capsules will be taken orally with a glass of still water in the morning and evening under fed conditions. On the mornings of Days 7 and 21, RO5459072 will be administered under fasted conditions (overnight fast of at least 8 hours before dosing).
1538680|NCT02679001|Drug|TNF inhibitor/TCZ|Participants with RA receiving TNF-inhibitor or TCZ according to standard of care and in line with the current SPC/local labeling will be observed.
1538681|NCT02678988|Device|AI-1000 G2|The device will contain TCZ (180 milligrams per milliliter [mg/mL]) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS and assembled in the AI (AI-1000 G2).
1538682|NCT02678988|Device|PFS-NSD|The device will contain TCZ (180 mg/mL) SC formulation single dose of 0.9 mL that corresponds to 162 mg TCZ administered via PFS-NSD.
1538683|NCT02678988|Drug|Tocilizumab|Participants will receive two single doses of 162 mg tocilizumab SC on Day 1 (Period 1) and Day 43 (Period 2), with a washout period of 6 weeks between the periods.
1538684|NCT02678975|Drug|Disulfiram|Disulfiram 400 mg daily
1538685|NCT02678975|Dietary Supplement|Copper|nutritional supplement with copper, 2 mg daily
1538686|NCT02678975|Drug|Alkylating Agents|Alkylating antineoplastic agent
1538687|NCT02678962|Device|SN6AD1|Bilateral cataract surgery with implantation of SN6AD1 multifocal IOLs
1538688|NCT02678962|Device|SBL-3|Bilateral cataract surgery with implantation of SBL-3 multifocal IOLs
1538689|NCT02678962|Device|LS-313 MF30|Bilateral cataract surgery with implantation of LS-313 MF30 multifocal IOLs
1538690|NCT02678962|Device|AT LISA tri 839 MP|Bilateral cataract surgery with implantation of AT LISA tri 839 MP multifocal IOLs
1538691|NCT02678962|Device|ART|Bilateral cataract surgery with implantation of ART toric multifocal IOLs
1538692|NCT02678962|Device|LS-313 MF30T|Bilateral cataract surgery with implantation of LS-313 MF30T toric multifocal IOLs
1538693|NCT02678949|Drug|Inhaled Fluticasone 50 mcg/twice day|After 7 days washout period, patients with mild asthma (group 2) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone 50 mcg/twice a day, for a period of 4 weeks. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
1538694|NCT02678949|Drug|Inhaled Fluticasone 100 mcg/twice day|After 7 days washout period, patients with moderate asthma (group 3) will come to visit 2 where carried out a baseline spirometry and MBW test, subsequently will indicate them start treatment with inhaled fluticasone of 100 mcg/twice a day, for 4 weeks period. At the end of the 4 weeks of treatment patients will come to Visit 3 and perform again spirometry and MBW test.
1538695|NCT02678949|Drug|Inhaled Albuterol|The patients in Group 2 and group 3 performing a baseline spirometry and MBW test, after which one dose of 400 mcg of inhaled albuterol will be administered. Twenty minutes after inhaling the dose of albuterol, spirometry and MBW test will be measured again in both groups.
1538696|NCT02678936|Biological|PRP|Application of platelet-rich plasma during surgery
1538697|NCT02678923|Drug|MDCO-216|
1538698|NCT02678923|Drug|Placebo|
1538699|NCT02678910|Procedure|Ovarian Cryopreservation|The ovarian tissue will be removed at a UK Healthcare facility and evaluated for gross disease by a pathologist, embryologist, andrologist or REI physician. The ovarian cortex will be dissected from the medulla and cut into strips in culture/holding media, washed to remove blood cells, and cryopreserved. Cryopreservation will be performed using modifications of the techniques described by Gosden et al. (1994) or will be vitrified using a modification of the techniques of Kuwayama et al., 2007.
1538738|NCT02678572|Procedure|TACE|Transarterial chemoembolization is a procedure in which the blood supply to a tumor is blocked (embolized) and chemotherapy is administered directly into the tumor.
1538739|NCT02678572|Drug|Dacarbazine|Dacarbazine is to be administered at 250 mg/m2 of body surface area/day given IV for 5 days, with treatment repeated every 3 weeks.
1538782|NCT02678312|Drug|Placebo of LCZ696|
1538783|NCT02678312|Drug|Placebo of Enalapril|
1538700|NCT02678897|Drug|Oxynorm|"We compare different routes of administration (PCA an oral/intramuscular use of oxynorm) in patients undergoing medical termination of pregnancy. Patients are randomized in two groups (for extra pain medication)
If analgesia is inadequate oxycodon (OxyNorm®) (10 mg (less than 80 kg) - 15 mg (over 80 kg) po. In an hour oxycodon 5-10 mg more po if needed. Intramuscular or intravenous administration if needed.
Patient controlled analgesia (PCA pain pump): Oxycodon dose is 3.0 mg (3 ml) and lock-out time 8 min. Maximum four doses in hour. Dose can be lowered or augmented 0,5 mg at time between 2.0-4.0 mg and maximal number of doses can be up to 5."
1538701|NCT02678884|Drug|18-F FDG|All patients enrolled in this study will receive 2 PET Scans: One prior to Radiation, and one during Radiation.
1538702|NCT02678871|Device|Lotus Heart valve system|Patients meeting clinical and anatomical pre-requisites will undergo TAVI with the LOTUS heart valve system
1538703|NCT02678871|Device|WATCHMAN|LAA closure with the WATCHMAN device
1538704|NCT02678858|Behavioral|Integrated Social Cognitive and Behavioral Skills Therapy|The Integrated Social Cognitive and Behavioral Skills Therapy (ISST) is a newly developed treatment program. It is based on the Training of Affect Recognition (Wölwer et al. 2005) and common social skills trainings, which are combined in an integrated rather than a sequenced manner. ISST uses both repeated practice and strategy-based training, and consists of 12 individual sessions, 5 group sessions and 1 individual final session over a period of 6 months.
1538705|NCT02678858|Behavioral|Neurocognitive Remediation Therapy|The Neurocognitive Remediation Program (NCRT) is based on a neurocognitive training already used as active control condition in our earlier studies (Wölwer et al. 2005, Klingberg et al. 2011). The present version of NCRT is matched in dose, mode and scheme of application to the ISST, but differs from the ISST regarding targeted cognitive domains and preferred training strategy (predominantly drill and practice based). The NCRT provides the same amount of group interaction and companionship as well as the same amount of guided community activity as in the ISST, but is structured in such a way that interactional behavior is secondary (e.g. by competition-like tasks rather than cooperative tasks). Thus therapeutic attention and commitment are held constant across study conditions.
1538706|NCT02678845|Other|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
1538707|NCT02678819|Device|Digital cognitive aid|Digital cognitive aid during anesthesia and intensive care crises.
1538708|NCT02678806|Radiation|Postoperative radiotherapy|
1538709|NCT02678793|Drug|CNTX-4975|
1538710|NCT02678780|Drug|Lenvatinib|
1538712|NCT02678754|Other|No intervention required, purely observational|
1538713|NCT02678741|Drug|TLPLDC Vaccine|Tumor Lysate, Particle Loaded, Dendritic Cell Vaccine
1538714|NCT02678728|Drug|Dexmedetomidine|1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia for 24hrs
1538715|NCT02678728|Drug|normal saline|IV loading and infusion of same volume of normal saline after induction of anesthesia for 24hrs
1538721|NCT02678689|Drug|BMN190 recombinant human tripeptidyl peptidase-1 (rhTPP1)|
1538722|NCT02678689|Device|Intraventricular access device|Surgical implantation of an MRI compatible ICV access device in the lateral ventricle of the right hemisphere is required for administration of study drug.
1538723|NCT02678676|Other|No Intervention|Participants who previously received Pioglitazone in the PROactive study (NCT00174993).
1538724|NCT02678676|Other|No Intervention|Participants who previously received pioglitazone-matching placebo in the PROactive study (NCT00174993).
1538725|NCT02678663|Procedure|Injection-assisted Cold Snare Polypectomy|Resection of a polyp after blue-tinted saline injection using a cold snare (without application of electrocautery)
1538726|NCT02678663|Procedure|Endoscopic Mucosal Resection|Resection of a polyp after blue-tinted saline injection using snare electrocautery
1538727|NCT02678650|Drug|volatile anesthetics(isoflurane)|volatile anesthetics wash-in / wash-out operation
1538728|NCT02678650|Drug|propofol intravenous anesthesia|propofol infusion 3-5μg / kg / h
1538729|NCT02678637|Other|MRI and muscle dynamometer|
1538730|NCT02678624|Other|Treatment according to the Collabri model|The Collabri Model is a complex intervention and consists of a number of treatment modalities. The Collabri Model includes the following elements: A multi-professional approach to treatment including a care manager, scheduled monitoring and review, enhanced inter-professional communication and a structured treatment plan. It further integrates: Recruitment of staff with psychiatric experience, training of general practitioner and care manager, use of instruments for detection and follow-up, education and treatment of the patient, supervision from a psychiatric specialist, guided self-help, patient- and relative involvement and a stepped care approach to treatment where treatment is always commenced on the least invasive and least resource-demanding level.
1538731|NCT02678611|Dietary Supplement|Basis 250|
1538732|NCT02678611|Dietary Supplement|Basis 500|
1538733|NCT02678611|Dietary Supplement|Placebo|
1538734|NCT02678598|Drug|Micafungin|Intravenous
1538735|NCT02678585|Drug|Nalbuphine|53 patients received intravenous regional lidocaine plus nalbuphine
1538736|NCT02678585|Drug|Lidocaine|53 patients received intravenous regional lidocaine
1538741|NCT02678572|Drug|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg as an IV infusion over 30 minutes every 3 weeks until disease progression or unacceptable toxicity.
1538742|NCT02678559|Other|tee measurement|
1538743|NCT02678559|Other|flotrac measurement|
1538744|NCT02678559|Other|clearsight measurement|
1538745|NCT02678546|Other|Other|case review of diagnosed disease
1538746|NCT02678533|Drug|G-CSF|D1 to D4 : Injection of 12 µg/kg of G-CSF twice a day . D5 : injection of 12 µg/kg of G-CSF (once/ twice a day according to cytapheresis's realization)
1538747|NCT02678533|Drug|Plerixafor|D5 : injection of 24mg/kg of plerixafor once a day until cytapheresis has be done (maximum of 4 days)
1538748|NCT02678520|Radiation|3-D Conformal Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using 3-D Conformal Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.
The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
1538749|NCT02678520|Radiation|Intensity Modulated Radiation Therapy|"Radiation delivered after surgery to remove the prostate, using Intensity Modulated Radiation Therapy. Radiation will be delivered to prostatic fossa / surgical bed including any suspected regions of microscopic disease such as positive margins, extracapsular extension and/or seminal vesicle involvement.
The total dose of radiation will be 6600 centigray (cGy) at 200 cGy/fraction (fx) given once daily ."
1538750|NCT02678520|Drug|Casodex, Zoladex , Lupron|"Hormonal Therapy (6 Months): Required for High Risk Groups, and as per Standard of Care for Low Risk Groups.
Hormonal therapy protocol regimen for the high risk adjuvant and salvage groups will consist of Casodex (50 mg/day po for 6 months) and Zoladex (10.8 mg subcutaneously once every 3 months x 2) or Lupron (22.5 mg given intramuscularly once every 3 months x 2 injections or 7.5 mg IM q once monthly x 6) to start on day 1 of the clinical trial.
Hormonal therapy will typically begin 2 months prior to radiation and continue for a total of 6 months."
1538751|NCT02678507|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
1538752|NCT02678494|Other|Neurofeedback training|
1538753|NCT02678481|Device|MR-guided in-bore prostate biopsy|2 targeted biopsy cores from each prostate lesion detected at multiparametric MR imaging
1538754|NCT02678481|Device|TRUS-guided prostate biopsy|24-28 systematic biopsy core (saturation scheme)
1538755|NCT02678455|Biological|TV005 vaccine|Delivered by subcutaneous injection; contains 10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31, and 10^3 PFU of rDEN4Δ30.
1538756|NCT02678455|Biological|Placebo|Delivered by subcutaneous injection
1538757|NCT02678442|Device|Fine Needle Biopsy (FNB)|The Shark Core FNB is an FDA approved device for sampling of submucosal lesions, mediastinal masses, lymph nodes and intraperitoneal masses. FNB will be performed by 22 gauge for pancreas head and by 19 gauge for all the other sites.
1538758|NCT02678442|Device|Fine Needle Aspiration (FNA)|Fine needle aspiration is a type of biopsy procedure. In fine needle aspiration, a thin needle is inserted into an area of abnormal-appearing tissue or body fluid, and histological material is obtained. FNA will be performed with a standard 25g needle in the usual fashion using back and forth passes for 30 seconds.
1538759|NCT02678429|Device|Change DBS programming|Patient will change thier settings to move from one group to the other to trial the other DBS settings
1538765|NCT02678403|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
1538766|NCT02678403|Device|SHAM Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve stimulation (TENS) is the use of electric current produced by a device to stimulate the nerves that only induces sensory stimulation (without muscle contraction) and is classically used in the treatment of pain.
1538767|NCT02678390|Dietary Supplement|MCT supplement|30 g of MCT per day for five days with two evaluation of the glucose/ketone/lipid metabolism (4-hour visit with repeated blood sampling) at the beginning and at the end of the sudy.
1538768|NCT02678390|Dietary Supplement|MCT supplement + physical exercise|30 g of MCT per day in combination with 30 minutes of aerobic exercise (70% to 80% HRMax) per day for five days with two evaluation of the glucose/ketone/lipid metabolism (4-hour visit with repeated blood sampling) at the beginning and at the end of the sudy.
1538769|NCT02678377|Drug|OnabotulinumtoxinA (Botox ®) Injections|OnabotulinumtoxinA (Botox ®) is a neurotoxin, which inhibits acetylcholine release and temporarily relaxes the bladder muscle to inhibit urgency incontinence.
1538770|NCT02678377|Drug|Saline Injections|Saline will be injected into the bladder so that investigators are masked to subject randomization.
1538771|NCT02678364|Dietary Supplement|Control eggs|Control eggs containing no additional vitamin D beyond norm
1538772|NCT02678364|Dietary Supplement|Vitamin D3 eggs|Vitamin D3-biofortified eggs
1538773|NCT02678364|Dietary Supplement|25-Hydroxyvitamin D3 eggs|25-Hydroxyvitamin D3-biofortified eggs
1538774|NCT02678351|Drug|gallium Ga 68-PSMA|Undergo gallium Ga 68-PSMA PET/MRI
1538775|NCT02678351|Procedure|Magnetic Resonance Imaging|Undergo gallium Ga 68-PSMA PET/MRI
1538776|NCT02678351|Procedure|Positron Emission Tomography|Undergo gallium Ga 68-PSMA PET/MRI
1538777|NCT02678338|Drug|Hu5F9-G4|
1538778|NCT02678325|Other|Standardized high protein enteral nutrition|A double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration on muscle breakdown and mortality.
1538779|NCT02678325|Other|Standardized normal protein enteral nutrition|double-blind randomized controlled clinical trial of critically ill patients to explore values of high enteral protein administration (compared to normal enteral protein administration) on muscle breakdown and mortality.
1538780|NCT02678312|Drug|LCZ696|LCZ696: 3.125 mg granules (packaged in capsules containing 4 or 10 granules), 50 mg, 100 mg, 200 mg dosage strengths
1538784|NCT02678299|Drug|PREBEN|
1538785|NCT02678286|Drug|N1539|
1538787|NCT02678273|Other|Intervention group|The Family Medicine Clinic will be the patient centred medical home to manage their complex care needs. A common electronic record will be created for information sharing between care partners. The Integrated Clinical Care Service will provide inpatient care for admitted residents, with emphasis on comprehensive discharge planning and hand-over of care. Patients at high risk of destabilization will receive an early review in outpatient clinic. Home or bed bound residents will be managed by SGH Home Care. The Care Closer to Home comprises a case manager and nursing aides to put in place health, personal and social services e.g. medication management, home help services. The Senior Activity Centre will encourage the elderly to remain integrated in society through community outreach programmes and social recreational activities. A community virtual ward will connect these care providers and weekly meetings to discuss care plans for the frail and sick residents
1538788|NCT02678260|Drug|PDR001|PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2 to PD-1.
1538789|NCT02678247|Device|Northwestern University Flexible Sub-Ischial Vacuum Socket|NU-FlexSIV sockets have lower proximal trim lines, do not impinge on the pelvis, are highly flexible so as to allow better comfort during sitting and when muscles move within the socket during activity, and are held securely to the residual limb by suction from a vacuum pump and from compression exerted by the deliberately undersized liner and socket.
1538790|NCT02678247|Device|Ischial Containment Socket|Ischial Containment (IC) sockets are more rigid and have a narrower medio-lateral dimension than anterior-posterior dimension. The socket encapsulates the ischium, ischial ramus and greater trochanter, limiting hip range of motion and comfort.
1538791|NCT02678234|Drug|Paracetamol, phenylephrine HCl, and vitamin C|One sachet is provided for each participant randomized to the Theraflu Aktiv powder for oral solution
1538792|NCT02678221|Drug|Sildenafil citrate|
1538793|NCT02678221|Drug|Aspirin|
1538794|NCT02678208|Drug|Tranexamic Acid|
1538795|NCT02678208|Drug|5% glucose|
1538796|NCT02678195|Drug|Amoxicillin|Oral amoxicillin dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
1538797|NCT02678195|Drug|Placebo|Placebo dispersible tablets (DT), 250 mg tablets, given according to age band, two times daily
1538798|NCT02678182|Drug|Capecitabine|1250 mg/m2/day, 21 day cycle
1538799|NCT02678182|Drug|MEDI4736|IV treatment on days 1&15 of 28 day cycle
1538800|NCT02678182|Drug|Trastuzumab|6mg/kg on day 1 cycle every 21 days
1538801|NCT02678169|Device|Penumbra Aspiration System|Penumbra Aspiration System using the ADAPT technique for recanalization of an occlusion large vessel in the brain
1538802|NCT02678156|Device|Lyoplant Onlay|
1538810|NCT02678130|Device|InterFuse T|Transforaminal Lumbar Interbody fusion (TLIF)
1538811|NCT02678130|Device|Standard of Care TLIF (Stryker AVS Unilif)|Transforaminal Lumbar Interbody Fusion (TLIF)
1538812|NCT02678117|Drug|Pregabalin & Placebo|
1538813|NCT02678117|Drug|Magnesium sulphate & Placebo|
1538814|NCT02678117|Drug|Pregabalin & Magnesium sulphate|
1538815|NCT02678117|Drug|Placebo|
1538816|NCT02678104|Procedure|Tooth extraction|Tooth removal
1538817|NCT02678104|Drug|Chlorhexidine mouth wash|Chlorhexidine mouth wash
1538818|NCT02678104|Drug|Intra-alveolar application of Manuka Honey|Intra-alveolar application of Manuka Honey directly after extraction.
1538819|NCT02678091|Device|Ultrasound exam with Doppler|Ultrasound exam of the orbit
1538820|NCT02678078|Procedure|Analyzing biopsy samples|Analyzing biopsy samples that is preformed as part of the patient treatment.
1538821|NCT02678065|Device|InPact Admiral DEB|
1538822|NCT02678052|Drug|Vedolizumab|Vedolizumab exposure
1538823|NCT02678052|Biological|Other Biological Agent|Other Biological Agent exposure
1538824|NCT02678039|Device|Fluoroscopy|Device: Fluoroscopy Patients lie prone on X-ray compatible operating table and an X-ray device obtains X-ray images of epidural catheter placement. An epidural catheter is placed with local anesthesia as a needle that is advanced into the epidural space. A catheter is then placed through the needle to the desired location and the needle is removed. After the catheter is placed, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr
1538825|NCT02678039|Procedure|Traditional|An epidural catheter is placed before surgery with the patient sitting at bedside. The catheter is placed with local anesthesia using indirect indicators of proper placement: depth of needle insertion and ability to inject solution through the needle ('loss of resistance'). After needle placement in the epidural space, an epidural catheter is threaded through the needle 3-4 cm and the needle removed. After catheter is placement, a test dose of 1.5% lidocaine with 5ug/cc epinephrine is injected into the catheter to exclude intravascular placement. Following this, a continuous infusion of 1/8% bupivacaine is started at 4ml/hr. After surgery, the bupivacaine infusion may be adjusted with bolus injections of 2ml and/or increase in the infusion rate by 2ml/hr up to a maximum of 14ml/hr.
1538826|NCT02678026|Device|Cervical pessary|Cervical pessary is a medical device used to treat an incompetent (or insufficient) cervix (cervix starts to shorten and open too early). Early in the pregnancy a round silicone pessary is placed at the opening to the cervix to close it, and then remove late in the pregnancy when the risk of a preterm birth has passed.
1538827|NCT02678013|Procedure|RFA|Radiofrequency ablation(RFA)for small recurrent HCC
1538828|NCT02678013|Procedure|RFA+highly-purified CTL|Radiofrequency ablation(RFA) plus highly-purified CTL for small recurrent HCC
1538829|NCT02678000|Drug|LHW090|LHW090 is orally administered
1538830|NCT02678000|Drug|Placebo|Matching placebo of LHW090
1538831|NCT02677987|Device|Intervention systematic light exposure|
1538832|NCT02677987|Device|Comparison systematic light exposure|
1538833|NCT02677974|Device|On-X Aortic Heart Valve replacement|Aortic valve replacement with low dose warfarin
1538834|NCT02677961|Other|Observation|
1538835|NCT02677948|Drug|Pacritinib|
1538836|NCT02677948|Drug|Ibrutinib|
1538837|NCT02677935|Other|Community education programs|
1538841|NCT02677909|Device|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|Will place device on admission to SICU. Measure bowel sounds and await bowel function
1538842|NCT02677896|Drug|Enzalutamide|Oral
1538843|NCT02677896|Drug|Placebo|Oral
1538844|NCT02677883|Other|Manometry-guided thoracentesis|Arm I will undergo a standard of care therapeutic thoracentesis procedure, and in addition include pleural pressure monitoring (via an FDA-approved digital manometer) which is also standard of care but left at the discretion of physicians as per expert recommendations. In this group, the procedure will be stopped when the patient develops symptoms or when all the fluid has been removed, and will also be stopped if the pressure begins to fall quickly in the fluid collection.
1538845|NCT02677883|Other|Symptom-guided thoracentesis|Arm II will undergo a standard of care therapeutic thoracentesis procedure. In this group, the procedure but will be stopped when the patient develops symptoms or when all the fluid has been removed.
1538846|NCT02677870|Drug|saproterin dihydrochloride|The drug will be given as described in the arm/group descriptions.
1538847|NCT02677870|Other|Diet treatment|Patients will maintain a stable, Phe restricted diet (including formula) that is consistent with their diet at the time of enrollment. This will be monitored by food diaries kept for 3 days of each week.
1538848|NCT02677857|Behavioral|Common intervention components for Lifestyle|Participants in these conditions will receive standard care and one of the Lifestyle conditions. There are several components that will be identical for both Lifestyle conditions. These components include treatment structure, dietary goals, and cognitive behavioral strategies.
1538852|NCT02677805|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1mL i.m injections into the glabellar area
1538853|NCT02677805|Drug|Placebo|injection, sodium chloride 0.9% divided in five 0.1 mL i.m. injections into the glabellar area
1538854|NCT02677792|Behavioral|Behavioral Family Intervention (BFI)|Participating families will receive standard medical care through the Wellness and Weight Clinic, as well as the BFI. The BFI is based on family systems (Minuchin et al., 1975) and social-cognitive (Bandura, 1998) theories. Each dyad will participate in simultaneous, but separate, 75-minute parent and child groups over a 3 month period. The groups will start off meeting every week for 8 weeks and then bi-weekly for 1 month. Thus, dyads will attend a total of 10 group meetings over the 3 month period (12.5 hours of total treatment contact).
1538855|NCT02677779|Procedure|CO2 laser|Single session of CO2 laser debridement
1538856|NCT02677779|Procedure|traditional surgery|Single session of traditional debridement
1538859|NCT02677753|Radiation|Fluoroscopy|
1538860|NCT02677740|Device|Inhibitory rTMS (1 Hz)|Participants receive rTMS at a rate of 1 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% resting motor threshold (RMT) for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the inhibitory rTMS intervention. One week before the MRI/MRS acquisitions, neurophysiological parameters are also measured before and between 20 and 40 minutes after the inhibitory rTMS intervention.
1538861|NCT02677740|Device|Excitatory rTMS (5 Hz)|Participants receive rTMS at a rate of 5 Hz, applied with a 70-mm figure-eight TMS coil connected to a stimulator, over the motor cortex hotspot contralateral to the dominant arm for 20 minutes at an intensity of 90% RMT for a total of 600 TMS pulses. The total number of stimuli applied is well within the published safety guidelines for use of rTMS. rTMS is applied outside the scanner, whereas functional connectivity and neurochemistry are measured with MRI and MRS, respectively, at 7 Tesla. The MRI/MRS data are collected right before and immediately after the excitatory rTMS intervention. One week before the MRI/MRS acquisitions, neurophysiological parameters are also measured before and between 20 and 40 minutes after the excitatory rTMS intervention.
1538862|NCT02677727|Other|EORTC QLQ-CIPN20|EORTC QLQ-CIPN20 is a 20-item chemotherapy-induced peripheral neuropathy-specific questionnaire which includes three scales assessing sensory (9 items: #31-36, 39, 40, 48), motor (8 items: #37, 38, 41-45, 49), and autonomic (3 items: #46, 47, 50) symptoms and functioning with each item measured on a 1-4 scale (1 - not at all; 4 - very much).
1538864|NCT02677701|Drug|azithromycin|500mg tablet over-encapsulated to match placebo
1538865|NCT02677701|Drug|placebo (for azithromycin)|
1538866|NCT02677701|Drug|inhaled tobramycin|clinically prescribed inhaled tobramycin used by subjects participating in the study
1538867|NCT02677688|Biological|Autologous EBV specific CTL infusion|
1538869|NCT02677662|Other|Diesel Exhaust|Dilute diesel exhaust
1538870|NCT02677662|Other|Filtered air|Filtered air
1538871|NCT02677649|Other|cranberry|the effect of cranberry on the gut microbiota
1538872|NCT02677649|Other|placebo|the effect of placebo on the gut microbiota
1538873|NCT02677636|Drug|MSRD-100|MSRD-100 is a topical gel.
1538874|NCT02677636|Drug|Vehicle|Vehicle is a topical gel without the active ingredients in MSRD-100
1538875|NCT02677623|Drug|Pyridium|
1538876|NCT02677623|Drug|Sodium Fluorescein|
1538877|NCT02677623|Drug|Mannitol|
1538878|NCT02677623|Other|Normal Saline|
1538879|NCT02677610|Drug|MSRD-100|MSRD-100 is a topical gel.
1538880|NCT02677610|Drug|Vehicle|Vehicle is a topical gel without the active ingredient in MSRD-100
1538881|NCT02677597|Drug|Cisplatin Combined With S-1|
1538882|NCT02677597|Drug|Cisplatin Combined With Paclitaxel|
1538883|NCT02677584|Drug|Prophylactic caffeine citrate|Prophylactic caffeine (group1) will be defined as caffeine prescribed for preterm infant within the first 72 hours of life prior to manifest apnea . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base) .
1538884|NCT02677584|Drug|Therapeutic caffeine citrate|Therapeutic caffeine ( group 2 ) will be defined as caffeine prescribed for manifest apnea within or after the first 72 hours of life . patients will be randomly assigned to receive caffeine in loading dose 20 mg/kg (equivalent for 10 mg/kg caffeine base) and maintenance dose 10 mg/kg/day (equivalent for 5 mg/kg caffeine base).
1538885|NCT02677571|Procedure|Paravertebral Thoracic block|
1538886|NCT02677571|Procedure|Pectorals nerve block|
1538887|NCT02677571|Drug|Levobupivacaine 0.25%|
1538888|NCT02677571|Drug|Morphine|
1538889|NCT02677558|Other|Transthoracic Echocardiography|Obese term pregnant women and term pregnant women of normal weight are both undergoing transthoracic echocardiography assessment to establish differences in cardiac function in pregnancy caused by obesity.
1538890|NCT02677545|Drug|Ticagrelor|
1538891|NCT02677545|Drug|Clopidogrel|
1538892|NCT02677545|Drug|Aspirin|
1538893|NCT02677532|Drug|Paracetamol|1 g every 8 hours
1538894|NCT02677532|Drug|Levobupivacaine wound infiltration|Wound infiltration with 10 ml levobupivacaine 0.5%
1538895|NCT02677532|Drug|Levobupivacaine epidural bolus|Epidural bolus of 10 ml 0.25% levobupivacaine
1538896|NCT02677532|Drug|Sufentanil epidural bolus|Epidural bolus of 0.15 mcg/kg sufentanil
1538897|NCT02677532|Drug|Morphine|Intravenous slow bolus of 10 mg morphine
1538898|NCT02677532|Device|Epidural catheter placement|Thoracic epidural catheter placement in the T7-T8 or T8-T9 intervertebral space
1538899|NCT02677532|Device|Wound infusion catheters placement|Pre-peritoneal placement of two catheters for wound infusion
1538900|NCT02677532|Drug|Levobupivacaine plus sufentanil epidural infusion|Epidural infusion of levobupivacaine 0.12% plus sufentanil 0.4 mcg/ml at 4 ml/h for 48 h
1538901|NCT02677532|Drug|Levobupivacaine wound infusion|Wound infusion with levobupivacaine 0.25% at 4 ml/h for 48 h
1538902|NCT02677519|Drug|Aptensio XR|Orally-administered extended release formulation of methylphenidate; once daily dosing
1538903|NCT02677506|Procedure|Supraclavicular|Brachial plexus block with supraclavicular approach
1538904|NCT02677506|Procedure|Infraclavicular|Brachial plexus block with infraclavicular approach
1538905|NCT02677493|Biological|IL-YANG Quadrivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
1538906|NCT02677493|Biological|IL-YANG Flu Vaccine Prefilled Syringe|A single 0.5mL dose administrated as an intramuscular injection.
1538907|NCT02677493|Biological|IL-YANG Trivalent Influenza Vaccine|A single 0.5mL dose administrated as an intramuscular injection.
1538908|NCT02677480|Dietary Supplement|Test group, probiotic tablets and gel|Effect of probiotic tablets and gel on acidogenic bacteria
1538909|NCT02677480|Dietary Supplement|Placebo group, placebo tablets and gel|Effect of placebo tablets and gel on acidogenic bacteria
1538910|NCT02677467|Biological|Blood-pressure variability|Day to Night Blood pressure variability
1538911|NCT02677454|Device|Flash Glucose Monitor|
1538912|NCT02677441|Procedure|Conservative management|Specific standardized rehabilitation protocol under Cote et al (2010)
1538913|NCT02677441|Procedure|Surgery|Coracoclavicular and acromioclavicular fixation as described ly Lädermann et al (2011), followed by specific standardized rehabilitation protocol under Cote et al (2010).
1538916|NCT02677415|Other|Intravenous anesthetics|
1538917|NCT02677415|Other|local anesthesia|
1538918|NCT02677415|Other|Controlled ventilation|
1538919|NCT02677415|Other|Spontaneous breathing|
1538920|NCT02677402|Other|immersion|
1538921|NCT02677389|Other|Educational Intervention|Receive educational material regarding physical activity and standardized emails with wellness tips and information on stress management
1538922|NCT02677389|Other|Internet-Based Intervention|Receive email and technical or how-to support from study coordinator
1538923|NCT02677389|Device|Monitoring Device|Wear a Fitbit web-integrated physical activity tracker
1538924|NCT02677389|Other|Quality-of-Life Assessment|Ancillary studies
1538925|NCT02677389|Other|Questionnaire Administration|Ancillary studies
1538926|NCT02677376|Other|18F-Sodium Fluoride (NaF)|NaF is a tracer (dye) that will show changes to the cancer in bones. By using this tracer with PET/CT imaging, our ability to evaluate and measure changes in bone lesions could be greatly improved. Participants will have a NaF PET/CT scan within 14 days prior to starting enzalutamide. All subjects will undergo a secon NaF PET/CT scan after taking enzalutamide for 12 weeks. The NaF PET/CT obtained at week 12 will be compared to the first NaF PET/CT to identify a bone tumor that is responding (shrinking) and a bone tumor that is not responding (not shrinking).
1538927|NCT02677363|Other|Resistance Exercise|Participants 60 and above aged (both females and males) will perform one hour of resistance exercise twice weekly for 8 weeks.
1538928|NCT02677350|Drug|Allogeneic Bone Marrow derived Human Mesenchymal Stem Cells (hMSCs)|Peri-fistula injections
1538929|NCT02677337|Other|chart abstraction|chart abstraction will be conducted pre and post education intervention to assess efficacy of education at point of care
1538930|NCT02677337|Other|Educational Program|
1538931|NCT02677324|Drug|ABT199|Oral BCL-2 antagonist
1538934|NCT02677298|Drug|Botulinum Toxin A|Injection, 20 Units divided in five 0.1 mL i.m. injections into the glabellar area.
1538935|NCT02677298|Drug|Placebo|Injection, sodium chloride 0.9 mg divided in five 0.1mL i.m. injections into glabellar area
1538936|NCT02677285|Other|Different type of wound|
1538937|NCT02677272|Other|Appropriateness of NH resident's transfer to ED|
1538938|NCT02677259|Drug|17-beta estradiol|
1538939|NCT02677259|Drug|Micronized progesterone|
1538940|NCT02677246|Drug|Denosumab|"Denosumab, one sub-cutaneous infusion, given within 2 weeks after engraftment defined as neutrophils > 0,5x10(9)/L and chimerism ≥ 10% of donor origin.
Before starting Denosumab several requirements have to be met: 1) Calcemia and Phosphatemia in the normal ranges, 2) adequate Calcium and Vitamin D intakes according to age.
Biological activity of Denosumab measured by CTX blood level, expected to last for 4 to 6 months after one infusion.
Possibility of subsequent infusions at the same dose level, every 5 to 6 months, for patient remaining on corticotherapy, provided no DLT occurred and provided CTX blood level decreased under the required threshold, after the previous infusions of Denosumab"
1538942|NCT02677207|Drug|JNJ-39393406|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
1538943|NCT02677207|Drug|Placebo|JNJ-39393406 100 mg capsules or placebo daily for the first week and 200 mg daily for the rest of the trial
1538944|NCT02677194|Device|LED|There are 7 mini-zones of 1,5x1,5 cm at the level of forearm, one of them is allocated to control ( only laser). Dermabrasion by fractional laser CO2 ablative, evaluation of the pain on every zone by VAS post-act. Exposition to LED (630nm, 830nm and 590 nm). Water loss measure and colorimetry before and after laser and after the exposition to LED. Clinical evaluation of local tolerance post-laser and post-LED + standardized photographs.
1538945|NCT02677194|Other|Control device|Device without any LED exposition
1538946|NCT02677181|Drug|ATG|rabbit ATG（Sanofi）
1538947|NCT02677181|Drug|CsA|cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
1538948|NCT02677181|Drug|mycophenolate mofetil|From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
1538949|NCT02677181|Drug|Methotrexate|short-term methotrexate
1538956|NCT02677142|Behavioral|Structured social skills training program, SSIP|Detailed, session by session, in the manual written for this purpose. It addresses six major social skills, one per session, starting with easier skills (Social Initiation and Friendship Making, Cooperation) and moving towards more complex skills (Managing Teasing and Bullying, Conflict Resolution, Empathy, and Assertion).
1538957|NCT02677142|Behavioral|CG - social skills activities|Sessions will not be designed around a specific social skill and activities and games will not have a specific focus. CG sessions will be conducted by facilitators who will receive the standard training for volunteers and will work under the supervision of one of the investigators at each site.
1538958|NCT02677129|Other|home-based exercise intervention|Endurance training (moderate intensity; walking), 3-5 times per week Patients will receive exercise counselling how to realize the planned intervention home-based. Further, they will be asked to fill out an exercise log. The study team will periodically review adherence to the intervention and identify problems.
1538964|NCT02677103|Device|radial extracorporeal shock wave therapy|he RSWT was delivered at 2 Hz with 2000 shock waves and the energy level of 0.26mJ/mm2 in calcific tendinitis of shoulder.
1538965|NCT02677103|Procedure|ultrasound-guided needle puncture|After injecting 3cc 1% Xylocain in the subcutaneous tissue, muscle layer and subdeltoid bursa, multiple back-and-forth puncture about 10-20 times (depending on the size of the plaques) within the calcific plaques will be performed.
1539404|NCT02673840|Drug|Ketotifen|2 mg of Ketotifen, twice a day for a total of ten (10) doses
1538966|NCT02677103|Procedure|RSWT and USNP|each subject will receive radial shock wave therapy after ultrasound-guided needle puncture, as described in the previous paragraphs.
1538967|NCT02677090|Drug|Placebo (including Maltodextrin)|
1538968|NCT02677090|Drug|Dose 1 - Promitor®|
1538969|NCT02677090|Drug|Dose 2 - Promitor®|
1538970|NCT02677090|Drug|Dose 3 - Promitor®|
1538971|NCT02677077|Drug|natalizumab|Participants with RRMS receiving commercial natalizumab in Belgium and Czech Republic
1538972|NCT02677064|Other|assessments|Thus, a prospective observational study in which all newly diagnosed or newly relapsed acute leukemia patients would be registered close to the beginning of induction or re-induction therapy would allow us to follow patients throughout their journey and identify prospectively the reasons why patients did not proceed to HCT when deemed appropriate and eligible.
1538973|NCT02677051|Drug|Sulforaphane|Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.
1538974|NCT02677051|Drug|Placebo|
1538975|NCT02677038|Drug|Olaparib|300 mg by mouth twice daily in a 28 day cycle.
1538976|NCT02677025|Behavioral|Young Women's Health CoOp (YWHC)|Participants in this group will participate in two workshops of the young woman-focused intervention about HIV/STIs (sexually transmitted infections), sexual behaviors, alcohol and other drug use, violence, communication skills, and other issues. Participants will develop personalized risk reduction action plans at the end of each workshop session.
1538977|NCT02677025|Behavioral|HIV Counseling/Testing|Participants will be tested for HIV and if positive will receive counseling in accordance with national standards.
1538978|NCT02677012|Procedure|REVOLVE™ Tissue Process|Tissue is washed with a medical solution and spun at low speed to clean the fatty tissue and separate the fat tissue from other substances before it is transplanted.
1538979|NCT02677012|Procedure|PureGraft™ Tissue Process|System of filters used to wash fatty tissue with a medical solution and separate out unwanted substances before it is transplanted.
1538980|NCT02677012|Procedure|Coleman Technique Tissue Process Group|Fatty tissue is placed in a centrifuge. Tissue spun at high speed in order to separate the different substances in the tissue. Once the spinning is done, fat cells collected and transplanted.
1538981|NCT02676999|Procedure|Implantation of a Scheker total distal radioulnar joint prosthesis|
1538982|NCT02676986|Drug|Enzalutamide|Anti-androgen
1538983|NCT02676986|Drug|Exemestane|Hormonal therapy (Licenced)
1538984|NCT02676973|Procedure|Open, Robotic, or Laparoscopic|Sacral Colpopexy is a surgery performed either through an incision in the abdomen or through several small incisions with the help of a laparoscope (a slender tube) or robot. The surgery is done with a permanent synthetic (man-made) mesh. The mesh is sutured (stitched) to the vagina and sacrum (tail bone) and is used as reinforcement. It provides additional support to weakened tissues and/or muscles.
1538985|NCT02676973|Procedure|Transvaginal Native Tissue Repair|Transvaginal Native Tissue Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done using both permanent and absorbable sutures (stitches), to support weakened tissue and/or muscles, and attach the top of the vagina to ligaments in the pelvis (either to the sacrospinous ligament or uterosacral ligament).
1538986|NCT02676973|Procedure|Uphold™ LITE or Elevate™-AA|Transvaginal Mesh Repair is a surgery performed with an incision through the vagina (transvaginal). The surgery is done with a permanent synthetic (man-made) mesh. The mesh is attached to ligaments in the pelvis and is used to reinforce natural tissue and/or muscles, which are no longer able to provide support to the vagina.
1538987|NCT02676960|Other|MRI without sedation|
1538988|NCT02676947|Drug|Tocilizumab|
1538989|NCT02676934|Device|End tidal control module in Aisys anesthesia workstation|THE USE OF AUTOMATED CONTROL OF END TIDAL SEVOFLURANE CONCENTRATION TO MAINTAIN ANESTHESIA DURING DONOR HEPATECTOMY
1538991|NCT02676895|Biological|S. sonnei vaccine 25 μg|Two injections of the study vaccine will be administered 28 days apart.
1538992|NCT02676895|Biological|S. sonnei vaccine 100 μg|Two injections of the study vaccine will be administered 28 days apart
1538993|NCT02676895|Biological|Menveo|One injection of Menveo will be administered in subjects in Group C
1538994|NCT02676895|Biological|Boostrix|One injection of Boostrix will be administered in subjects in Group C
1538995|NCT02676882|Dietary Supplement|EnBrace HR|Prescription folate prenatal supplement with other dietary ingredients; one multiphasic soft gelatin capsule 1x/day for 12 week study
1538996|NCT02676869|Drug|IMP321|Single subcutaneous injections of 1 mg (cohort 1), 6 mg (cohort 2) or 30 mg (cohort 3) of IMP321 administered every 2 weeks
1538997|NCT02676869|Drug|Pembrolizumab|Administered according to the approved label.
1539002|NCT02676843|Drug|18F-AV-1451|A single injection of up to 10 millicuries of 18F-AV-1451 will be administered to subjects, followed by a 20-minute PET scan.
1539003|NCT02676830|Drug|K-312 100 mg|Single oral dose
1539004|NCT02676830|Drug|K-312 100 ug C14 IV|microtracer dose containing ≤37 kBq (1000 nCi) [14C] given as a 5-ml IV push over 2 minutes
1539034|NCT02676622|Drug|Low-dose IL-2 administration|"IL-2 Subcutaneous injections will start once ANC is > 500/µL and patient is afebrile (start IL-2 will be approximately day +20)for 6 weeks of treatment.
Once patient or parent has learnt the administration and patient is tolerating it well, then the rest of the treatment can be administered at home after discharge with weekly follow up visits."
1539005|NCT02676804|Other|High-intensity, aerobic exercise.|"Aerobic exercise will blend unsupervised moderate and supervised high intensity exercise. It will consist of walking/jogging modalities, dependent on the subject's level of bradykinesia, paced by the subject's level of perceived exertion. The exercise protocol will be designed to target an total of at least 150 minutes of cardio exercise per week.
Exercise training will be performed 5 times per week for 6 weeks, consisting of 3 supervised high intensity sessions and 2 at home moderate intensity sessions. High intensity sessions will be performed on a treadmill at an intensity rating of ~ 15 and 17 on a rating of perceived exertion (RPE) scale of 6 to 20. The moderate intensity exercise will target an RPE of ~10 - 12 and participants will be asked to complete this on their own."
1539006|NCT02676791|Drug|Povidone-Iodine|A standard nasogastric tube will be inserted into all patients after induction of general anesthesia. After surgical dissection, the esophagus / stomach will be cut at the desired level leaving the tip of the nasogastric tube proximal to the esophageal carcinoma. Then, 50ml of a 11% povidone-iodine solution (Betaisodona®, Mundipharma) will be introduced into the esophagus via the nasogastric tube and evacuated with a suction device (washout). The nasogastric tube will then be removed for completion of esophageal resection and beginning of reconstruction.
1539007|NCT02676778|Drug|E7777|
1539008|NCT02676765|Drug|Allergen|1 allergen extract tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
1539009|NCT02676765|Drug|Placebo|1 placebo tablet, placed under the tongue until dissolved, taken daily; do not swallow for 1 minute after placing tablet; do not eat or drink for 5 minutes after placing tablet
1539010|NCT02676752|Procedure|Medical Examination|Evaluation of secondary lymphedema and fibrosis (LEF) status
1539011|NCT02676752|Other|Questionnaire Administration|Completion of questionnaires
1539012|NCT02676752|Procedure|Shear Wave Elastography|Undergo ultrasound shear wave elastrography
1539013|NCT02676739|Drug|Adderall XR|
1539014|NCT02676726|Procedure|Extraperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
1539015|NCT02676726|Procedure|Transperitoneal Laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
1539016|NCT02676713|Drug|pre-ovulation Decoction|HuoXueXiaoYi Decoction(Bupleurum 10g, Cyperus 10g, Salvia miltiorrhiza 20g, Red peony 10g,etc)has activating blood and absorbing clots effect, can inhibit the growth of ectopic endometrium, promote follicular growth, maturity, improve ovulation and the receptivity of endometrium.
1539017|NCT02676713|Drug|post-ovulation Decoction|"BuShenZhuYun Decoction(Bupleurum 10g,Poria 15g, Atractylodes 15g,Ligustrum 15g,etc) has dredging liver and nourishing kidney effect, can improve the function of corpus luteum.
All are made into granules."
1539018|NCT02676713|Drug|pre-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
1539019|NCT02676713|Drug|post-ovulation Decoction(placebo)|Composition of maltodextrin, lactose, edible pigment, taste masking agent.
1539020|NCT02676700|Behavioral|Pelvic floor muscle training and Kaatsu|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT and Kaatsu training as home training
1539021|NCT02676700|Behavioral|Pelvic floor muscle training|The intervention includes three outpatient visits (weeks 0, 6 and 12) and between visits the participants perform PFMT as home training
1539022|NCT02676687|Procedure|total resection|Removing the parenchyma until signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
1539023|NCT02676687|Procedure|supratotal resection|Extended removing the parenchyma at least 1cm beyond signal abnormalities on FLAIR-weighted MR / enhanced-weighted MR in adults with glioma
1539024|NCT02676674|Drug|Vitamin D3|Subjects with vitamin D deficiency will be given 100,000 units of topical vitamin D on days 0,7, and 14. Vitamin D levels will be checked on days 7, 14, and 21.
1539025|NCT02676648|Behavioral|Multicomponent online program|The core program includes information developed in earlier research with individuals with type 2 diabetes, now modified for online delivery: very low-carbohydrate diet taught with lectures on video, handouts, quizzes, and surveys. We also teach participants about the importance of physical activity and adequate sleep, in addition to psychological skills (positive affect, mindful eating) intending to help with intervention adherence.
1539026|NCT02676648|Behavioral|Breath meter|We will send participants a breath meter to test ketones in their breath, to assess dietary adherence.
1539027|NCT02676648|Behavioral|Text messages|We will send participants text messages, to support intervention adherence.
1539028|NCT02676648|Behavioral|Diet-appropriate foods and cookbooks|We will send participants diet-appropriate foods and cookbooks, to support intervention adherence.
1539029|NCT02676635|Behavioral|Ergonomics training and/or Safety Voice training|"Ergonomics training will focus on ergonomic principles specific to masonry such as goals of ergonomics, common musculoskeletal disorders among masons, modifiable work factors and risk factors, hazard analysis, hierarchy of controls, and current ergonomic solutions for masonry. Safety Voice training will focus on development of skills such as self-direction, self-control, accountability, responsibility, communication strategies, and leadership that can help them to develop a safety voice about safety in general, and ergonomics specifically."
1539030|NCT02676622|Drug|mobilization of stem cells to prepare for Leukapheresis|"Cyclophosphomide 2 g/m2 x 2 consecutive days.
Filgrastim (G-csf) 10 mcg/kg SC will start 5 days after the last dose of CY and will end the day before the last leukapharesis."
1539031|NCT02676622|Other|Leukapheresis- Collection of stem cells|"Placement of an Apheresis Catheter on the day of collection of stem cells.
Leukapheresis will be performed on a continuous flow separator machine to target 3-8 x 106 CD34+ cells/kg body weight."
1539032|NCT02676622|Drug|Preparative regimen 4-6 weeks after Leukapheresis|"Prior to starting medicines, a central venous line will be placed (arm or chest)
Cyclophosphamide iv: 50 mg/kg iv over 2 hours
Mesna iv (uro-protectant): 36 mg/kg iv over 12 hours
r-ATG (Thymoglobulin, Genzyme): 2.5 mg/kg/dose iv over 6 hours on days -3,-2,-1"
1539033|NCT02676622|Other|Stem Cell Transplant|"Infusion of the(cryopreserved and thawed)peripheral blood stem cells (PBSC)occurs on Day 0.
Day +5: start Filgrastim (G-csf) subcutaneous injections
Hospitalization in isolation room for 4-5 weeks"
1539035|NCT02676609|Device|Automated carbohydrate and meal insulin dose computing|Use of smart phone application will compute carbohydrate amount and meal insulin dose according to individual meal insulin/carbohydrate ratio.
1539036|NCT02676596|Drug|K-312 10 mg QD|
1539037|NCT02676596|Drug|K-312 25 mg QD|
1539038|NCT02676596|Drug|K-312 50 mg QD|
1539039|NCT02676596|Drug|K-312 100 mg QD|
1539040|NCT02676596|Drug|K-312 200 mg QD|
1539041|NCT02676596|Drug|K-312 400 mg QD|
1539042|NCT02676596|Other|Placebo|
1539043|NCT02676583|Procedure|Tonsillectomy|Closure or not closure of tonsil fossa
1539044|NCT02676557|Device|Exposed to the high pressure during the surgery|
1539045|NCT02676544|Device|Embosphere microspheres|This is a clinical trial assessing the feasibly and safety of prostate artery embolization (PAE) for benign prostatic hypertrophy (BPH) resulting in severe lower urinary tract symptoms (LUTS) in patients with gland size ≥90 grams who are TURP ineligible or non-operative candidates with Embosphere microspheres.
1539046|NCT02676531|Other|Exercise|Walking meditation exercise program
1539048|NCT02676505|Behavioral|Coached pushing group|It includes 217 patients who are admitted in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward. They are coached by the nurse to use closed-glottis and pushing three to four times during each contraction immediately when cervical dilation reached 10 cm and to continue pushing using this method with each contraction until birth. The nurse counts to 10 during each pushing effort to assist the woman in holding her breath for at least 10 seconds.
1539049|NCT02676505|Behavioral|uncoached pushing group|It includes 217 patients who are admitted early in active stage of labor (cervical dilatation 4cm at least) to labor delivery ward at 10-cm cervical dilation where they remain until they feel the urge to push or the second stage had lasted 2 hours (whichever came first)., they are encouraged to bear down with contractions without holding their breath (open-glottis) for no more than 6-8 seconds and continue bearing down no more than three times with each contraction until birth. .
1539050|NCT02676492|Other|Actigraphy to measure sleep duration and efficiency|Actigraphy watch to be worn on participants' wrist for 14 days and nights
1539051|NCT02676492|Other|'Sleepsuite' novel cognitive learning tasks|Novel iPad-administered learning tasks, to be completed one evening and the next morning during actigraphy monitoring period.
1539052|NCT02676479|Device|Uterine Lavage Group|"The PI places the Lavage Catheter per instructions for use
Use of a tenaculum or cervical stitch is required
Use of saline to wash the cervix is required
Use of abdominal ultrasound guidance with a full bladder is required The PI records if there was clinically significant fluid loss through the cervix."
1539053|NCT02676466|Dietary Supplement|Omega-3 fish oil|The Omega-3 fish oil will be provided in 700 mg gelcaps. The starting dose will be 1.4 g/day of fish oil and continue until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), we increase the dose to 2.8 g/day.
1539054|NCT02676466|Drug|Losartan|The Losartan will be provided in 25 mg and 50 mg capsules. The starting dose will be 25 mg/day, if tolerated, then stepped up to 50 mg/day. If there are no safety concerns, a continuation of 50 mg/day will be provided until the 6 month visit. If the average of IL-6 measured at 3- and 6-month visits does not decrease by >40% vs. baseline (average of screening visits 1 and 2), an increase to the dose of 100 mg/day.
1539055|NCT02676466|Other|Placebo|The corn oil placebo gel caps will be identical in shape, color, taste and weight as the Omega-3 fish oil.
1539056|NCT02676466|Other|Placebo|The placebo cellulose based capsules will be identical in shape, color, taste and weight as the losartan capsules.
1539057|NCT02676453|Other|Intervention|Dental hygienist support
1539058|NCT02676440|Other|Treatment|F13/T38
1539059|NCT02676440|Other|Comparitor|M26
1539060|NCT02676427|Procedure|passive leg raising|passive leg raising under echocardiographic monitoring with intravascular doppler in place
1539061|NCT02676414|Behavioral|Interactive hypertension education program of the DHL©|
1539062|NCT02676401|Drug|MT-3995 Low|
1539063|NCT02676401|Drug|MT-3995 Middle|
1539064|NCT02676401|Drug|MT-3995 High|
1539065|NCT02676388|Procedure|Freeze-dried, Capsulized FMT|
1539066|NCT02676388|Procedure|Fresh FMT|
1539067|NCT02676375|Drug|Combination Bupropion + NRTs|
1539068|NCT02676375|Other|Extended Treatment|
1539069|NCT02676375|Other|Home Visits & Calls|
1539070|NCT02676375|Drug|Monotherapy|
1539071|NCT02676362|Other|Gingival crevicular fluid collection with filter paper|Gingival Crevicular Fluid Dynamics
1539076|NCT02676336|Dietary Supplement|Violet™ Molecular Iodine (I2)|
1539077|NCT02676336|Other|Placebo|
1539078|NCT02676323|Drug|Panobinostat|Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.
1539079|NCT02676323|Drug|Fludarabine|Fludarabine will be given intravenously (IV), 30 mg/m^2/dose over 30 minutes, daily for 5 days (days 8-12).
1539080|NCT02676323|Drug|Cytarabine|Cytarabine will be given IV, 2 gram/m^2/dose over 4 hours, daily for 5 days (days 8-12).
1539081|NCT02676323|Drug|Intrathecal Triples|Given intrathecally (IT).
1539082|NCT02676323|Drug|Leucovorin|Leucovorin (5 mg/m^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
1539083|NCT02676310|Drug|Bimatoprost|
1539084|NCT02676297|Drug|tiotropium|four inhalations
1539085|NCT02676284|Device|Durolane SJ|single dose injection
1539128|NCT02675959|Drug|Defibrotide|defibrotide will be given prophylactically prior to AlloSCT to determine if it decreases the incidence of SOS in this high risk population, and determine that it is safe and feasible to give along with myeloimmunoablative therapy and allogeneic transplant.
1539086|NCT02676271|Procedure|Proximal varus derotational osteotomy|The purpose of surgery was to relocate the protruded, deformed femoral head from its lateral position back to the acetabulum to achieve containment. Surgery was preceded by a hip arthrography with dynamic examination to find the suitable containment position and plan the correct osteotomy angles accordingly. A sub trochanteric osteotomy was performed then after in an open or closed wedge form, with fixation in an angle that gave best coverage.
1539087|NCT02676258|Device|Si-Hy (olifilcon B)|Wear Si-Hy silicone hydrgel soft contact lens for 3 months
1539088|NCT02676258|Device|Vistakon (narafilcon A)|Wear Vistakon soft contact lens for 3 months
1539089|NCT02676245|Behavioral|Viewing Newborn Screening movie|NBS Movie and printed brochure were viewed by the participants
1539090|NCT02676245|Behavioral|Viewing Residual Dried Blood Spot movie|DBS Movie and and printed brochure were viewed by the participants
1539091|NCT02676232|Behavioral|DARWeb|Psychosocial Intervention from the cognitive-behavioral model, including different but related units for parents and children with recurrent abdominal pain.
1539092|NCT02676219|Other|RS01|Oral Care product containing sodium monofluorophosphate and sodium fluoride
1539093|NCT02676219|Other|Water|
1539094|NCT02676206|Other|Classical music|Classical music will be played over the headphones
1539095|NCT02676193|Behavioral|Effect of Packaging on Smoking Perceptions and Behavior|The intervention is the use of the assigned pack design.
1539096|NCT02676180|Other|Group|
1539097|NCT02676167|Behavioral|PrEP Intervention|
1539098|NCT02676154|Drug|Fesoterodine|4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.
1539099|NCT02676141|Other|Manual Therapy|The treatment the patients receive is not specifically set up for the study. Participants will already be seeing a practitioner before the participants are included in the study.
1539100|NCT02676128|Behavioral|Twine Collaborative Care Application|This application features a 24-hour medication clock that displays ART dosing schedule and allows participants to record the doses taken. It also features an interactive health coaching feature which will be used to provide support, encouragement, and resources to participants.
1539101|NCT02676128|Behavioral|Information-Motivation-Behavioral Skills Model of ART Adherence|Combines brief motivational interviewing, cognitive behavior therapy, and problem-solving skills to help participants formulate and follow ART adherence goals.
1539102|NCT02676115|Other|Standard Post Operative Skin Care|Control group subjects will receive the standard post-operative skin care which are steri-strips covered with gauze, and this will be removed at the first visit. No additional skin dressings will be used in the control group.
1539103|NCT02676115|Other|Medipore Tape|"One layer of Medipore tape will be placed across the incision.
Patients will be instructed on how to change the tape, and will be encouraged to change the tape as often as once per week for hygiene.
When patients return to the office for their regularly scheduled visit, the Medipore tape will be changed and a picture of the scar will be taken."
1539104|NCT02676102|Behavioral|Control Group|Generic Video about organ donation
1539105|NCT02676102|Behavioral|Targeted Intervention|an educational video produced in partnership with the community of black men including customers, employees, and owners of BOBs. Video production was informed by entertainment education models and produced with experts including an Academy Award winning filmmaker.
1539106|NCT02676102|Behavioral|Tailored Intervention|Videos with content individualized to participant's pre-intervention Organ Donation Belief Index (ODBI).
1539107|NCT02676089|Drug|CHF 5993 200/6/12.5 µg|
1539108|NCT02676089|Drug|CHF 1535 200/6 µg|
1539109|NCT02676089|Drug|CHF 1535 200/6 µg + Tiotropium Respimat 2.5 µg|
1539110|NCT02676076|Drug|CHF 5993 100/6/12.5 µg|
1539111|NCT02676076|Drug|CHF 1535 100/6 µg|
1539115|NCT02676037|Device|foot pressure plate form|
1539116|NCT02676024|Device|Knowledge-based cognitive aid|"Trained on the use of a knowledge-based cognitive aid for pediatric cardiac arrests. Will be used by a dedicated team member (cognitive aid reader)."
1539117|NCT02676024|Device|Cognitive aids with roles defined (CARD)|"Trained on the use of the cognitive aids with roles defined (CARD) system for pediatric cardiac arrests. Participants are given large identification cards to be worn, which enable the code leader to quickly recognize the individuals' purpose at the code. The card identifies specific tasks associated with the role, ensuring that the participant knows exactly what their task is. Will not have a dedicated team member during the scenario (cognitive aid reader)."
1539118|NCT02676024|Device|Integrated cognitive aids|"Trained on the use of the cognitive aids with roles defined (CARD) system and also in the use of a protocol-based cognitive aid for pediatric cardiac arrests which will be used by a dedicated cognitive aid reader."
1539119|NCT02676011|Drug|IM atropine|Atropine (0.01 mg/kg) (1 ml) IM 30 minutes before induction of anesthesia
1539120|NCT02676011|Drug|IV atropine|Atropine (0.01 mg/kg) intravenously (10 ml) 3 minutes before induction of anesthesia
1539121|NCT02676011|Drug|Atropine mixed with second dose succinylcholine|Atropine (0.01 mg/kg) added to the second dose succinylcholine (1mg/kg) prepared to 5 ml syringe with normal saline
1539122|NCT02676011|Drug|IM normal saline|1 ml normal saline IM 30 minutes before induction of anesthesia
1539123|NCT02676011|Drug|IV normal saline|IV 10 ml normal saline 3 minutes before induction of anesthesia
1539124|NCT02676011|Drug|Normal saline mixed with second dose succinylcholine|Second dose succinylcholine (1 mg/kg) prepared to 5 ml syringe with normal saline
1539125|NCT02675998|Drug|Tenapanor|
1539126|NCT02675998|Drug|Placebo|
1539127|NCT02675985|Other|Physical Therapy|Early Intensive Physical therapy in the ICU
1539130|NCT02675933|Behavioral|Questionnaire|There will be a single page document, a patient-centered questionnaire, distributed to parents of study participants who have been randomized to the intervention arm.
1539131|NCT02675920|Drug|non-ionic monomer iodinated CT contrast media|patients underwent contrast-enhanced CT using aforementioned CT contrast media (non-ionic monomer iodinated CT contrast media)
1539132|NCT02675907|Drug|N1539|
1539133|NCT02675907|Drug|Intravenous Placebo|
1539134|NCT02675894|Device|cooled-wet electrode|RFA is performed using three cooled-wet electrodes in switching bipolar mode. The electrode is anticipated to reduce tissue resistance by releasing small amount of saline during the procedure, which may lead larger ablative volume by delivering more RF energy.
1539135|NCT02675894|Device|separable clustered electrode|RFA is performed using separable clustered electrode in switching monopolar mode.
1539136|NCT02675881|Device|DSM|Monopolar RFA using dual switching mode (DSM)
1539137|NCT02675881|Device|separable clustered electrode|A separable clustered electrode is similar to a clustered electrode, although it differs from a conventional clustered electrode in that each individual electrode is separable.
1539138|NCT02675868|Drug|Norepinephrine|Noradrenaline is an endogenous catecholamine with sympathomimetic effects. It has mainly α-adrenergic receptor selectivity but also β-effects in higher concentrations. It will be administered at 0.05 μg/kg/min, a clinical relevant dose on the low end of the scale.
1539139|NCT02675868|Drug|Phenylephrine|Phenylephrine is a selective α-adrenergic receptor agonist. It will be administered at 0.5 μg/kg/min, based on its relative vasopressor potency in comparison with noradrenaline.
1539140|NCT02675868|Drug|Vasopressins|Vasopressin is 8-arginine-vasopressin, a synthetic analogue of endogenous nonapeptide hormone. It exerts its action via V1 receptors (ubiquitous vasoconstriction) and V2 receptors (renal water resorption). It will be administered at 0.04 IU/min, a clinically relevant dose.
1539141|NCT02675868|Drug|Placebo|NaCl 0.9% infusion
1539142|NCT02675855|Other|GrafixPRIME®|Human tissue, Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
1539143|NCT02675855|Procedure|Dressing Application|Wound cover, Application of a non-adherent dressing, a moisture retentive dressing, and a secondary dressing.
1539144|NCT02675855|Device|Off-loading (walking boot)|Patients will be fitted for an off-loading device (walking boot) and agree to comply with use of the device during the course of the study
1539145|NCT02675842|Drug|Smoked Cannabis High CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes (15.76% CBD; 3.11% -9-THC) over the course of 2-3 hours.
1539146|NCT02675842|Drug|Smoked Placebo Cannabis Low CBD/low THC|Participants will visit the research laboratory 3-5 days a week over 6 weeks to be administered 1-2 Cannabis cigarettes Cannabis (0.0% CBD/ 0.01% -9-THC) over the course of 2-3 hours.
1539147|NCT02675829|Drug|ado-trastuzumab emtansine|Ado-trastuzumab emtansine is administered intravenously at 3.6 mg/kg every 21 days (unless dose reduction and/or dose delays are required) until disease progression or unacceptable toxicity.
1539148|NCT02675816|Device|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System. This is a permanent, implantable therapy device, which consists of three implantable components: an implantable pulse generator (IPG), a stimulation lead, and a sensing lead. In addition, the patient receives a handheld remote to activate the therapy
1539149|NCT02675803|Biological|VAY736|VAY736 treatment
1539150|NCT02675803|Biological|VAY736 placebo|VAY736 placebo
1539151|NCT02675790|Drug|Moderate Dose Hydroxyurea|Hydroxyurea therapy at 20 mg/kg/day for primary stroke prevention.
1539152|NCT02675790|Drug|Low Dose Hydroxyurea|Hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for primary stroke prevention.
1539154|NCT02675764|Other|Vibration|peripheral vibration at the wrist skin at an imperceptible level
1539155|NCT02675764|Other|Placebo (for vibration)|No peripheral vibration at the wrist skin
1539156|NCT02675764|Behavioral|therapy|standardized hand therapy program
1539157|NCT02675751|Device|STAR S4 IR laser with iDesign|Surgeons will perform wavefront-guided PRK for the treatment of myopic refractive errors based upon measurements obtained with the iDesign System using the STAR S4 IR laser.
1539158|NCT02675738|Other|good clinical practice|
1539159|NCT02675725|Device|Measurement of sublingual microcirculation with Cytocam-IDF camera|"The normal treatment of a post-cardiac surgery patient is fluid bolus by indication. This indications are hypotension, hyperlactataemia, tachycardia or decreased urine production. This fluid bolus is 250 ml crystalloids in 15 minutes.
When this fluid bolus will be given, the investigators will observe the sublingual microcirculation and measure the red blood cell velocity and total vessel density on one spot for 20 minutes."
1539160|NCT02675712|Other|African drumming|Rhythmic beating or tapping of a variety of percussion instruments, which often occurs within a group setting
1539203|NCT02675348|Dietary Supplement|Dietary Supplement: whey Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of whey protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
1539209|NCT02675309|Drug|MT-8554|
1996027|NCT02585154|Procedure|closed-loop Deep Brain Stimulation applied through custom built external stimulator (Little et al., 2013, 2015)|Deep Brain Stimulation, which is applied depending on ongoing brain activity.
1996028|NCT02585154|Procedure|Deep Brain Stimulation off|Deep Brain Stimulation is turned off.
1996029|NCT02585154|Device|STN-LFP and EEG recordings|Simultaneous recordings of local field potentials from subthalamic nucleus and electroencephalography
1996030|NCT02584985|Procedure|ETAP|Primary transanal endoscopic approach, secondary transabdominal laparoscopic approach
1996031|NCT02584985|Procedure|Standard Transabdominal Laparoscopic Proctectomy|Primary transabdominal laparoscopic approach
1996032|NCT02585024|Drug|Cytisine|
1996033|NCT02584569|Drug|TAK-915|TAK-915 oral suspension
1539161|NCT02675699|Behavioral|Optimisation + HENRY|"HENRY HENRY is an 8-week childhood obesity prevention programme delivered in Children's Centres in the UK by trained practitioners, aiming to provide parents with skills and knowledge to support healthy lifestyles in preschool children and their families. The programme aims to build parents' skills, knowledge and confidence to change old habits and provide healthier nutrition.
OPTIMISATION A tailored 'Optimisation' intervention has being developed to support local authorities and Children's Centres to promote HENRY implementation, based on an ethnography of Children Centres, including interviews with staff and other stakeholders and input from parents. Development was underpinned by strong theories of behaviour change and will be guided by the intervention planning framework; the Behaviour Change wheel using a systematic approach. Strategies have been developed to improve parent motivation to enrol on to HENRY and promote parent self-efficacy to continue to attend."
1539162|NCT02675699|Behavioral|HENRY as standard|Local Authorities / Children's Centres that are assigned to the control group will continue with standard HENRY practice. Current HENRY QA practice involves the review of process data by HENRY central office with provision of written and oral feedback. This will continue in both trial arms and will be monitored.
1539163|NCT02675686|Procedure|amniocentesis|amniotic fluid sample by amniocentesis
1539164|NCT02675673|Procedure|GJ-Tube|Insertion of a GJ tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
1539165|NCT02675673|Procedure|G-Tube|Insertion of a G-tube either prior to the start of radiotherapy or within the first 2 weeks after the first dosage.
1539166|NCT02675660|Dietary Supplement|L-Homoarginine|125 mg L-homoarginine once daily
1539167|NCT02675660|Drug|Placebo|placebo capsules once daily
1539168|NCT02675647|Drug|Heparin, IV route, based on patients body weights (UI/kg)|
1539169|NCT02675647|Procedure|Cardiopulmonary bypass|
1539170|NCT02675647|Drug|Protamin administration|
1539174|NCT02675621|Other|Phenolic Beverage|
1539175|NCT02675608|Biological|Influenza Virus Vaccine|On the first visit, subjects are vaccinated with the 2015-2016 seasonal flu vaccine.
1539176|NCT02675582|Other|Herbal Beverage|Intervention involves consuming one beverage at the beginning of each visit during the incomplete block design sequence
1539177|NCT02675569|Procedure|Catheter|A method of vascular access for hemodialysis that all participants will have in place prior to randomization.
1539178|NCT02675569|Procedure|Fistula|A type of vascular access strategy for hemodialysis which involves connecting the artery and the veins in the participant's arm.
1539179|NCT02675556|Drug|Allo-hMSCs|a single administration of allogeneic Human Mesenchymal Stem Cell (hMSCs): 100 x 10^6 (100 million) allo-hMSCs of cells
1539180|NCT02675556|Drug|Placebo|a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A
1539181|NCT02675543|Device|Vitreous Tamponade with Silicone Oil|
1539182|NCT02675530|Drug|ketamine|"For healthy volunteer arm of study, NMDA antagonist ketamine will be administered. 0.23 mg/kg over 1 minute, followed by 0.58 mg/kg/hour for 30 minutes, followed by 0.29 mg/kg/hour for 50 minutes.
No drug administration for patients with schizophrenia"
1539183|NCT02675517|Drug|Spiolto Respimat|Tiotropium bromide + Olodaterol
1539184|NCT02675504|Other|Placing a scale self-assessment of fear|Children spend a self-assessment scale of fear
1539187|NCT02675465|Drug|ATB200|
1539188|NCT02675465|Drug|AT2221|
1539189|NCT02675452|Drug|AMG 176|Study Drug
1539190|NCT02675439|Drug|ADU-S100|
1539193|NCT02675413|Drug|Dimethyl Fumarate|Open-label
1539194|NCT02675400|Drug|Vyvanse|Half of the participants (fathers) will be randomized to receive Vyvanse.
1539195|NCT02675400|Behavioral|Behavioral Parent Training|Half of the fathers will receive behavioral parent training.
1539196|NCT02675400|Drug|Methylphenidate|If Vyvanse is not well tolerated, methylphenidate can be prescribed.
1539197|NCT02675387|Device|Buzzy|Two minute application of a hand held vibrating device (Buzzy, MMJ labs, Atlanta GA, USA) before the administration of anesthesia
1539198|NCT02675387|Drug|2%Lidocaine|1.8ml of 2%Lidocaine HCl to be administered via a 21mm needle (30 Guage)
1539199|NCT02675374|Drug|dexchlorpheniramine (Polaramine®) injection|5 minutes before CPB, patients will receive 10 mg (2 ml) of Polaramine®
1539200|NCT02675374|Drug|Placebo injection|5 minutes before CPB, patients will receive 2 ml of normal saline
1539201|NCT02675361|Behavioral|Transition program|Participants will be part of a transition program with eight key components: 1. A transition coordinator; 2. Education on congenital heart disease (CHD), treatments, health behavior, dealing with school, friends; 3. Telephone availability; 4. Information about the Grown-Up Congenital Heart Disease (GUCH) program: 5. Guidance of parents; 6. Meeting with peers: 7. A person-centered transition plan; and 8. Transfer to Grown-Up Congenital Heart Disease clinic. The intervention will be implemented by specialized nurses at the outpatient clinic of pediatric cardiology. Overall, 60 to 90 minutes per patient are spent over the 2.5 years.
1539202|NCT02675348|Dietary Supplement|Dietary Supplement: Beef Protein|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of beef protein supplement after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
1539204|NCT02675348|Dietary Supplement|Dietary Supplement: CHO|Participants will combine a 10-week periodized and controlled endurance programme with the ingestion of maltdextrin after training. Measurements pre and post intervention will be endurance performance (vo2max) and blood markers: haemoglobin; red blood cell; erythrocyte; haematocrit; mean corpuscular volume, transferrin; neutrophils; lymphocyte; monocytes
1539212|NCT02675283|Device|Simtomax|Patients will undertake a finger prick point of care test, Simtomax, at the pharmacy. A sample of 25 μl of capillary venous blood is required which can be obtained through a simple finger prick technique. The sample is then applied to the test device, followed by the application of 5 drops of the provided buffer solution. The result can be read after 10 minutes. Positive results are indicated by the presence of a solid red line, with a single line for a combined IgA and IgG DGP positivity, and a single line for the presence of total IgA. An in-built control line ensures a correctly functioning test.
1539216|NCT02675257|Behavioral|Diabetes-related affective problems analysis|Analysis of diabetes-related affective problems with regard to suboptimal glycaemic control
1539217|NCT02675257|Behavioral|Goal setting towards improvement of glycaemic control|Discussing and setting goals regarding improvements of suboptimal glycaemic control, depressive symptoms and diabetes distress
1539218|NCT02675257|Behavioral|Diabetes-specific problem-solving therapy|Diabetes-specific problem-solving therapy with main focus on suboptimal glycaemic control, depressive symptoms and diabetes distress
1539219|NCT02675257|Behavioral|Interventions to increase diabetes treatment motivation|Interventions to increase diabetes treatment motivation in order to achieve improvements of glycaemic control as well as recovery from affective problems
1539220|NCT02675257|Behavioral|Activation of personal and social resources|Activation of personal and social resources with a view to diabetes control and affective problems
1539221|NCT02675257|Behavioral|Reduction of barriers to self-care/glycaemic control|Definition and reduction of barriers to adequate diabetes self-care behaviour as well as good glycaemic control
1539222|NCT02675257|Behavioral|Cognitive restructuring of diabetes-related problems|Cognitive restructuring of diabetes-related problems such as suboptimal glycaemic control and diabetes-related affective problems
1539223|NCT02675257|Behavioral|Goal definition regarding self-care/glycaemia/well-being|Goal definition and agreement regarding diabetes self-care behaviour, optimal glycaemic control and activities supporting well-being and recovery from affective symptoms
1539224|NCT02675257|Behavioral|Health care and specific topics (e. g. blood pressure)|Education on health care and specific topics (e. g. blood pressure)
1539225|NCT02675257|Behavioral|Healthy foods, cooking recommendations, recipes|Education on healthy and unhealthy foods, cooking and recipes
1539226|NCT02675257|Behavioral|Sports, activities and exercise|Education on sports, activities and exercise
1539227|NCT02675257|Behavioral|Foot care: exercises, care & control, injuries, neuropathy|Education on foot care: exercises, care and control, injuries, and diabetic neuropathy
1539228|NCT02675257|Behavioral|Diabetes complications|Education on diabetes complications
1539229|NCT02675257|Behavioral|Social aspects of living with diabetes|Education on social aspects of living with diabetes
1539230|NCT02675244|Procedure|TV Annuloplasty|TV Annuloplasty will be performed using standard surgical techniques
1539231|NCT02675244|Procedure|MVS|MVS will be performed using standard surgical techniques
1539236|NCT02675218|Other|Patients with rheumatoid arthritis|Doppler effect at 3 months after Abatacept treatment initiation.
1539237|NCT02675205|Drug|Clopidogrel|clopidogrel: efficacy and safety in cerebral aneurysm stenting
1539238|NCT02675205|Drug|Ticagrelor|ticagrelor:efficacy and safety in cerebral aneurysm stenting
1539239|NCT02675205|Drug|aspirin|
1539241|NCT02675179|Device|EOS|Pelvimetry will be performed with the new EOS technique of diagnosis to measure the diameter of the basin.
1539242|NCT02675179|Device|Spiral CT pelvimetry|Pelvimetry will be performed with the spiral CT technique. It is the technique usually used.
1539244|NCT02675153|Drug|Sirolimus|Sirolimus 2mg daily will be given to subjects by oral for six months.
1539245|NCT02675153|Drug|5-ASA, Prednisone, Azathioprine or Remicade|5-ASA, Prednisone, Azathioprine and Remicade are traditional treatments according to associated guidelines
1539246|NCT02675140|Drug|ZENTEL|Children in Group 2 (n=62) received 400 mg single-dose albendazole (helmintic treatment)
1539247|NCT02675140|Drug|ZENTEL and Vitamin A Soft Capsules|Children in Group 3 (n=60) received a 200,000 IU vitamin A capsule combined with 400 mg single-dose albendazole once initially
1539248|NCT02675127|Drug|Daktavira|1 tablet contains 60 mg Daclatasvir
1539249|NCT02675127|Drug|Daklinza|1 tablet contains 60 mg Daclatasvir
1539252|NCT02675101|Other|Whole Nuts|Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
1539405|NCT02673840|Drug|Placebo|Identical tablets containing 0 mg of Ketotifen, twice a day for a total of ten (10) doses
1540342|NCT02666625|Procedure|saliva samples|
1539253|NCT02675101|Other|Olestra: Fat Free Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
1539254|NCT02675101|Other|Vegetable Oil: Original Pringles|Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
1539255|NCT02675088|Radiation|high-dose TRT|every day, Monday-Friday, for a total of 3 weeks, 45 Gy/ 3 Gy/ 15 f
1539256|NCT02675088|Radiation|standard-dose TRT|every day, Monday-Friday, for a total of 2 weeks, 30 Gy/ 3 Gy/ 10 f
1539257|NCT02675049|Drug|0.9% saline|0.9% saline intranasally 45 min before surgery using a computer-generated random number table.
1539258|NCT02675049|Drug|dexmedetomidine 1µg.kg-1|dexmedetomidine 1µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
1539259|NCT02675049|Drug|dexmedetomidine 1.5µg.kg-1|Dexmedetomidine 1.5µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
1539260|NCT02675049|Drug|Dexmedetomidine 2µg.kg-1|dexmedetomidine 2µg.kg-1 intranasally 45 min before surgery using a computer-generated random number table.
1539261|NCT02675036|Procedure|Tooth extraction|
1539262|NCT02675023|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
1539263|NCT02675010|Other|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY|ENDOSCOPIC GASTRIC BIOPSIES FROM ANTRUM AND BODY
1539265|NCT02674984|Drug|BB-12 with LGG|Multistrain probiotic
1539266|NCT02674984|Drug|Placebo|
1539267|NCT02674971|Behavioral|Common components of intervention|12-week standard lifestyle intervention for obesity, which consists of weekly meetings. Each meeting will last 60 minutes, with participants attending group meetings specific for their condition. In all meetings, participants will be weighed, homework assignments will be verbally reviewed, and a behavioral lesson will be presented. Basic behavioral lessons, will be similar to those that have been successfully used in the Diabetes Prevention Program (DPP) and Look AHEAD. Topics to be covered in the meetings will focus on the dietary prescriptions and dietary information for each condition, the physical activity goal, energy balance, and behavioral strategies. Each session will conclude with reminding participants of their dietary and physical activity goals, and having participants self-monitor these behaviors every day and implement the behavioral strategies discussed in the session.
1539268|NCT02674958|Drug|Aspirin|Aspirin 325mg bolus followed by 162mg daily until day 7 post alcohol septal ablation
1539269|NCT02674945|Device|Wireless Activity tracker: Fitbit|Patients will wear a Fitbit flex
1539270|NCT02674932|Behavioral|Identifying and Using Signature Strengths|The purpose of the intervention is to identify and focus on one's morally valued strengths and utilize them (i.e. incorporate them into coping skills) to overcome challenges. The study team member and patient will discuss each top strength and ways to use them as coping skills. The patient will identify 2-4 coping mechanisms per strength, and will write his/her strengths and self-identified coping skills on index cards.
1539271|NCT02674932|Behavioral|Identifying and Writing Down Coping Skills|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify at least six coping skills and write them down on index cards.
1539272|NCT02674932|Behavioral|Treatment as Usual|The study team member and patient will discuss the importance of having coping skills to deal with stressful and difficult situations. The patient will then identify coping skills that could be helpful (but will not write them down).
1539273|NCT02674919|Other|Nordic Hamstring|
1539274|NCT02674919|Other|Control|
1539275|NCT02674906|Drug|ACD-A|use of ACD-A as anticoagulant after blood salvage during cardiac surgery
1539276|NCT02674906|Drug|Heparin|use of heparin as anticoagulant after blood salvage during cardiac surgery
1539277|NCT02674893|Drug|Liraglutide|
1539278|NCT02674893|Other|Observation alone|
1539279|NCT02674880|Drug|HMW-HA|Aerolized administration b.i.d.
1539280|NCT02674880|Other|Placebo|Standard therapy
1539281|NCT02674867|Other|Blood draw|
1539282|NCT02674854|Drug|PG324 Ophthalmic Solution|1 drop daily (evening) both eyes
1539283|NCT02674854|Drug|Netarsudil (AR-13324) ophthalmic solution|1 drop daily (evening) both eyes
1539284|NCT02674854|Drug|Latanoprost ophthalmic solution|1 drop daily (evening) both eyes
1539285|NCT02674841|Other|Feedback on TUT|Access to live visual and auditory feedback on TUT and pulling force from an application on an iPad.
1539286|NCT02674841|Other|No feedback on TUT|Access only to live visual feedback on pulling force from an application on an iPad.
1539287|NCT02674841|Other|Exercise|3 exercises (knee extension, hip abduction and hip extension) using an elastic band with 3 sets of 10 repetitions at 10-12 RM 3 times a week for 6 weeks.
1539324|NCT02674503|Behavioral|Walking|MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. MP patients will begin with assisted sitting, then standing, progressing to weight shifting and stepping in place, and then to walking as tolerated. The level of mobility recommended to the MP patient by the Walker will be dependent on the individual patient and will incorporate the activities patients were deemed able to do independent of cueing or assistance during each walking session.
1539446|NCT02673528|Procedure|Laparoscopic appendectomy|Two types of laparoscopic surgery were performed. Total laparoscopic appendectomy or laparoscopic assisted appendectomy
1539288|NCT02674828|Behavioral|Reinforcement for meeting targeted physical activity goals|Participants in this condition will receive reinforcement for meeting targeted physical activity goals. These subjects will receive the same treatment as standard treatment group, including incentives for uploading/synching and discussions of ADA recommendations of managing diabetes in the context of physical activity. The only difference between conditions is that participants in this condition will earn tangible reinforcement for walking the target number of steps per day (6,000 per day in week 1, 8,000 per day in week 2 and 10,000 per day in weeks 3-12). At each upload, participants will earn incentives for each day on which they met the step goals. In addition, for each 7-day period in which they meet goals on at least 5 days, they will earn bonuses.
1539289|NCT02674828|Other|Standard of Care|Participants in the standard of care group will be told to wear Fitbit daily for 12 weeks. They will be instructed to upload or synch it >2x/week, on set days, e.g., Mon and Thurs, for the next 6 weeks and then weekly in the last 6 weeks. They will receive incentives for each upload, plus a bonus for each week in which data are registered for all 7 days in the week as scheduled. They will be encouraged to review Fitbit steps daily and on each upload/synch day. After each upload, research staff will congratulate patients via email or text for days on which they met goals, and encourage meeting goals in the upcoming week.
1539290|NCT02674815|Other|High Intensity Interval Training Exercise programme|High intensity interval training (HIIT) requires participants to exercise at high levels of VO2peak (≥80% VO2peak). Participants exercise for short periods (e.g. 15-30 seconds) followed by periods of rest (active or passive) and typically continue this pattern for a set time period or until exhaustion.
1539291|NCT02674789|Behavioral|Exercise protocol|70% VO2max bike ergometer test for 90 minutes
1539292|NCT02674776|Drug|HuZhen Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
1539293|NCT02674776|Drug|Placebo Capsule|Patients should take 4 tablet once and 3 times per day for 3 days.
1539294|NCT02674763|Drug|IMGN779|
1539295|NCT02674750|Drug|CUDC-907|
1539296|NCT02674737|Drug|dexmedetomidine, tramadol and flurbiprofen|
1539297|NCT02674737|Drug|tramadol and flurbiprofen|
1539298|NCT02674724|Other|Gym Group|"Patients from Gym Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period.
The initial load is established as 60% of one-repetition maximum strength test (1RM) applied for each exercise at the beginning of program. Patients will be encouraged to perform 3 sets of 8 to 12 repetitions. All subjects will be instructed to rest for 30-60 second intervals between sets."
1539299|NCT02674724|Other|Free Weights Group|Patients from Free Weights Group will perform a strengthening program of 45 minutes sessions, twice a week in a 12-week period. The program aim to recruit the same muscles requested in Gym Group. Investigators will apply six different exercises with patients lying supine,standing in stance, sitting and in four points kneeling. All exercises aim to strengthen abdominal muscles, trunk extensors, gluteus, quadriceps and scapula adductors. Patients will perform 3 sets of 8 to 12 repetitions, the load will be offered with dumbbells, elastics with different resistances and anklets.
1539300|NCT02674724|Other|Control Group|All three groups will be instructed to perform stretching exercises of trunk, leg and shoulder muscles, according to an illustrated booklet. Only the Control Group patients will be instructed to perform stretching exercises at home in the same 12-week period.
1539301|NCT02674711|Behavioral|Educational Video|The content of the education focus on providing a historical perspective for opioid prescription from the time when the risk of dependence was highly underestimated. The video discusses the current evidence for the effect of opioid medications in non-cancer non-acute pain. It also discusses some of the dangers of long-term opioid usage. The video is 11 and ½ minutes long.
1539302|NCT02674698|Other|Access to the CNH Dashboard Step 1|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
1539303|NCT02674698|Other|Access to the CNH Dashboard Step 2|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
1539304|NCT02674698|Other|Access to the CNH Dashboard Step 3|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
1539305|NCT02674698|Other|Access to the CNH Dashboard Step 4|VA Integrated Service Networks will be provided education on nursing home quality and access to the CNH Dashboard
1539306|NCT02674672|Device|VenaTech® (VenaTech Retrievable Filter)|
1539307|NCT02674659|Behavioral|resistance training|resistance training consists of lower and upper extremities exercises. We focus on biceps and hamstring to be trained. One session will be held for around 15 minutes.
1539308|NCT02674659|Behavioral|aerobic training|aerobic exercise consists of warming up session, treadmill exercise (around 20-30 minutes), and wrap-up session (for all session about 1 hour)
1539309|NCT02674646|Radiation|Radiotherapy|Radiation as indicated by the cancer diagnosis
1539310|NCT02674646|Device|Needle Acupuncture|Needle Acupuncture according to Traditional Chinese Medicine (TCM)
1539311|NCT02674633|Device|EVO|videogame-like digital therapy
1539312|NCT02674620|Other|Aerobic Exercise|Patients are treated with progressive exercise
1539314|NCT02674581|Drug|Oral BMS-663068 (pro-drug)|Oral BMS-663068 (pro-drug), metabolized to active BMS-626529
1539315|NCT02674568|Drug|Rovalpituzumab tesirine|Rovalpituzumab tesirine is a DLL3 targeted antibody drug conjugate (ADC).
1539316|NCT02674555|Drug|radio-labeled naquotinib|Oral administration
1539317|NCT02674555|Drug|naquotinib|Oral administration
1539318|NCT02674542|Other|In-depth interviews|"Future family planning intentions and beliefs
Family planning experiences and beliefs:
Feasibility and acceptability of birth spacing promotion for women who experienced a still birth or early neonatal demise"
1539319|NCT02674542|Other|Focus Group|"Future family planning intentions and beliefs
Family planning experiences and beliefs:
Feasibility and acceptability of birth spacing promotion for women who have experienced a stillbirth or early neonatal demise"
1539320|NCT02674529|Drug|Escitalopram|Selective Serotonin Reuptake Inhibitor (SSRI)
1539321|NCT02674529|Drug|Placebo|Placebo
1539322|NCT02674516|Device|Transcranial direct current stimulation|
1539323|NCT02674516|Device|Sham transcranial direct current stimulation|
1539399|NCT02673879|Other|Pericardiocentesis with Alteplase|Complete percutaneous pericardial drainage facilitated by intrapericardial alteplase
1539325|NCT02674503|Behavioral|Friendly visit|"UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive."
1539326|NCT02674490|Device|A-tDCS (1 mA)|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. A-tDCS stimulation will be active only in the first 20 minutes of the 45-minute treatment session.
1539327|NCT02674490|Behavioral|SALT|Computer-delivered naming treatment requires matching word (heard and seen being produced by the speaker) with pictures depicting common objects. It is run on a laptop computer with headphones and 2 large response buttons. During treatment, a picture appears on the laptop screen for 2 seconds. Then, a video of the speaker's face below the nose is presented on the screen saying a word that either matches or does not match the picture. The participant is instructed to press a green response button if the word matches the picture and press the red response button if the word does not match the picture.
1539328|NCT02674490|Device|Sham|1 mA of A-tDCS stimulation is induced between two 5 cm x 5 cm saline soaked sponges where one sponge (anode: A-tDCS) is placed on the scalp over the targeted cortical region. Ramping up of the current to 1 mA occurs over 10-15 seconds to allow participants to habituate to the tingling sensation. Then, the current will be ramped back down to 0 mA in the sham condition. Termination of the stimulation after the ramping up process is generally undetectable, and the brief duration of stimulation yields no functional effects.
1539329|NCT02674477|Device|Therapeutic Education System (TES)|The TES program is made of modules about ways to prevent substance use, such as how to refuse drugs and alcohol, how to cope with thoughts about using, and how to make the best possible decisions for a person's mental health. Each module takes less than 30 minutes to complete. Modules may contain videos or other interactive media. At the end of each module, there are questions about the material.
1539330|NCT02674477|Other|Treatment as Usual (TAU)|Participants will received standard treatment during and after hospitalization.
1539331|NCT02674464|Behavioral|Provider Audit-Feedback|
1539332|NCT02674464|Behavioral|Provider Audit-Feedback, Stratified by race, ethnicity, payor status|
1539333|NCT02674464|Behavioral|Blood Pressure Measurement Standardization|
1539334|NCT02674464|Behavioral|System Level Leadership Intervention|
1539335|NCT02674464|Behavioral|Collaborative Care Team Intervention|
1539336|NCT02674464|Behavioral|Community Health Worker|"As a stepped up component of the Collaborative Care Team Intervention for patients needing support in overcoming a variety of social determinants"
1539337|NCT02674464|Behavioral|Specialist Care|"As a stepped up component of the Collaborative Care Team Intervention for patients with complex medical conditions and/or patients that may not typically have access to specialist care"
1539338|NCT02674451|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation to 200 mmHG for three 5-minute periods each separated by 5 minute intervals within 1 hour of planned coronary angiography.
1539339|NCT02674438|Other|Risk stratification and transitional care intervention|"Intervention consists of 2 components:
Risk stratification: Determination of risk using the EHMRG 7-day and 30-day risk scores, where decision to admit, observe, or discharge the patient will be guided by the result of the risk scores
Transitional care: Follow-up care in the RAPID-HF transitional care clinic begins at 48 hours after emergency department or hospital discharge. Care provided by cardiologist + nurse for up to 30 days after emergency department or hospital discharge."
1539340|NCT02674425|Device|Dark Adaptometer|
1539341|NCT02674412|Drug|Buspirone|
1539342|NCT02674412|Dietary Supplement|Placebo|Placebo Pill Manufactured by the Investigational Pharmacy at Cleveland Clinic
1539343|NCT02674399|Drug|JointStem|
1539344|NCT02674399|Drug|Synvisc-One|
1539346|NCT02674360|Behavioral|SDM Training|
1539347|NCT02674347|Drug|3 g or 6 g Zidebactam|IV for over a duration of 60 minutes
1539348|NCT02674347|Drug|Placebo|IV matching the Investigational drug
1539349|NCT02674334|Device|NIRS|Near infrared spectroscopy (NIRS) monitor allows anesthesiologist to treat cerebral desaturations according to NIRS results while maintaining Mean Arterial Pressure (MAP) at least 60mmHG or at least 80% of baseline
1539350|NCT02674334|Device|NIRS monitored not treated|Near infrared spectroscopy (NIRS) monitored but anesthesiologist blinded to NIRS information and treatment is standard of care.
1539351|NCT02674321|Drug|SD-809|
1539352|NCT02674308|Drug|Vedolizumab|
1539353|NCT02674308|Other|Other Biologic Agents|Other biologic agents include: Adalimumab, Certolizumab pegol, Golimumab, and Infliximab
1539354|NCT02674295|Drug|Esketamine 50 mg|50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)
1539355|NCT02674295|Drug|Esketamine 20 mg|20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
1539356|NCT02674282|Procedure|ACL reconstruction|ACL reconstruction with hamstrings autograft.
1539357|NCT02674269|Drug|300 IU of BotuGelTM (60ml)|One intravesical instillation of 300 IU of botox in 60 ml of TC-3 gel
1539358|NCT02674269|Drug|400 IU of BotuGelTM (60ml)|One intravesical instillation of 400 IU of botox in 60 ml of TC-3 gel
1539359|NCT02674269|Device|TC-3 Gel|Intravesical instillation of 60 ml TC-3 gel
1539360|NCT02674256|Drug|CRH|100µg CRH powder for injection (CRH ferring®, Ferring, Aalst, Belgium) and 1 mL of NaCl 0.9% will be put together, then the solution will be injected intravenously over the course of 1 minute
1539361|NCT02674256|Other|Placebo|1 mL of NaCl 0.9% will be injected intravenously over the course of one minute
1539362|NCT02674243|Drug|Iodopovidone solution|In this group, iodopovidone solution will be used as pleurodesis substance
1539363|NCT02674243|Drug|Talc|In this group, Talc will be used as pleurodesis substance
1539364|NCT02674217|Procedure|Hematopoietic stem cell transplantation|autologous transplant using non-frozen peripheral blood stem cells
1539400|NCT02673879|Other|Conventional Pericardiocentesis|Conventional pericardiocentesis when indicated
1539365|NCT02674204|Drug|Atorvastatin|Atorvastatin calcium, a synthetic lipid-lowering agent, is an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase. This enzyme catalyzes the conversion of HMG-CoA to mevalonate, an early and rate-limiting step in cholesterol biosynthesis.
1539366|NCT02674204|Drug|Placebo|A substance that has no therapeutic effect, and will be used as a control in testing the study agent.
1539367|NCT02674191|Device|mini-plates supported molar intrusion|(Stryker, Leibinger, GmbH& Co., Freiburg, Germany) for molar intrusion using miniplates to treat hyperdivergent adolescence
1539368|NCT02674191|Procedure|Application of ULTRACARE benzocaine 20%,|topical anesthesia (Ultradent Products, Inc)
1539369|NCT02674191|Procedure|Administration of , Mepivacaine-l|local anesthesia
1539370|NCT02674191|Procedure|BETADINE povidone-iodine 10%|a local disinfectant
1539371|NCT02674191|Drug|(150g Clindamycin/tds) for 1 week|Postoperative antibiotic
1539372|NCT02674191|Drug|(Cataflam 25mg), are prescribed post-operatively|an analgesic
1539373|NCT02674178|Procedure|Invitro fertilization|"All participants underwent long protocol. Daily SC injection of Triptorelin 0.1 mg started at day 21 of the cycle prior to stimulation cycle and continued till the day of hCG injection. Gn stimulation started in a starting dose of 150-300 IU/day depending on patients age and previous gonadotropin response. then the dose was adjusted according to ovarian response monitored by serum E2 and ultrasound evaluation. All patients were followed up by Transvaginal ultrasound scan daily or on alternate days
Triggering by HCG 10000 IU IM when at least 2 follicles reached a mean diameter of 18 mm [18]
Ovum pick-up (OPU) was done 34-36 hours after hCG injection Transfer of cleaving embryos was done on day 3 after oocyte retrieval"
1539374|NCT02674165|Behavioral|HART|Skills based sexual education intervention plus PTSD awareness
1539375|NCT02674152|Drug|BI 836880|
1539376|NCT02674139|Device|Copper T 380A IUD|intrauterine contraceptive device T-shaped loaded with cupper
1539377|NCT02674126|Behavioral|Control group|Patients in the control group listened to a blank CD connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
1539378|NCT02674126|Behavioral|Maternal sound group|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period till extubation in intensive care unit
1539379|NCT02674113|Drug|regional anesthesia bupivacaine|a single shot fascia iliaca block using bupivacaine prior to hip arthroscopy
1539380|NCT02674113|Drug|regional anesthesia placebo|subcutaneous injection procedure using a normal saline placebo (0.9% sodium chloride in water)
1539381|NCT02674100|Other|Registry|
1539382|NCT02674074|Device|infrared thermography|measurement of corneal temperature by infrared thermography before and after cold provocation
1539383|NCT02674061|Biological|pembrolizumab|IV infusion
1539384|NCT02674048|Other|Metvix|
1539385|NCT02674035|Procedure|Correction of diastasis of the rectus abdominis muscles|Thirty women with similar abdominal deformities, who had had at least one pregnancy, were randomized into three groups to undergo abdominoplasty. Plication of the anterior rectus sheath was performed in two layers with 2-0 monofilament nylon suture (control group) or in a single layer with either a continuous 2-0 monofilament nylon suture (group I) or using a continuous barbed suture (group II). Operative time was recorded. All patients underwent ultrasound examination preoperatively and at 3 weeks and 6 months postoperatively to monitor for diastasis recurrence. The force required to bring the anterior rectus sheath to the midline was measured at the supraumbilical and infraumbilical levels.
1539386|NCT02674022|Dietary Supplement|Prenatal supplement|Treatment with a standard and optimized prenatal supplement, dependent on laboratory evaluations of participants.
1539387|NCT02674009|Drug|Vismodegib|Participants with laBCC will receive a dosing of Vismodegib in accordance with local clinical practice and local labeling.
1539390|NCT02673983|Procedure|Endoscopic full-thickness biopsy|
1539391|NCT02673957|Other|Blood pressure cuff protocol|4 cycles of pneumatic blood pressure cuff inflation to 200mmHg for 5 minutes followed by 5 minutes of deflation. Each subsequent cycles commences as soon as the previous cycle is completed.
1539392|NCT02673944|Device|Peritron+|Peritron+ will be connected to a standard urodynamic analyzer system to measure vesical pressure
1539393|NCT02673931|Drug|Byetta (Lilly, Exenatide)|See description of arms
1539394|NCT02673931|Drug|Conoxia (AGA, oxygen)|See description arms
1539395|NCT02673931|Drug|20% Human Albumin|
1539396|NCT02673918|Other|Home-based upper-body rehabilitation with online support|"Participants will be given written educational material, in which the physiotherapist marks the exercises specifically recommended for the individual patient. In addition, participants will get a personal password giving access to the BRECOR website for 12 weeks. The website contains professionally filmed videos of upper-body rehabilitation exercises (joint mobility and muscle strength) and instructions in scar tissue massage and manual lymph drainage. Furthermore, mindfulness sessions and additional information about prevention and early detection of late effects after breast cancer treatment are available on the website.
On average, participants will complete three rehabilitation exercises 5-7 times weekly with an anticipated duration of approximately 20 minutes."
1539397|NCT02673905|Other|Tissue Engineered Product|Implantation of tissue engineered products
1539401|NCT02673866|Drug|DS-1971a|
1539402|NCT02673866|Drug|placebo|
1539406|NCT02673827|Other|Progressive muscle relaxation|Intervention group: 20 patients with relapsing-remitting multiple sclerosis receive five sessions of Progressive Muscle Relaxation under the supervision of a researcher in neurology clinic. Before and after each session of the Progressive Muscle Relaxation They will be measured heart rate, respiratory rate and blood pressure. Participants will be guided to realize the Progressive Muscle Relaxation daily for 8 weeks, the time of day you feel more comfortable. the same receive education and training as the technical as well as a audio and a leaflet with the description the stages of the Progressive Muscle Relaxation. Control group: 20 patients with relapsing-remitting multiple sclerosis only receive traditional treatment.
1539407|NCT02673814|Biological|durvalumab|
1539408|NCT02673814|Biological|bavituximab|
1539409|NCT02673801|Other|Orthopedic assessment in the outpatient clinic|Orthopedic assessment based on clinic evaluation, patient symptoms and radiographic evaluation
1539410|NCT02673788|Other|observation without intervention in this follow up study|observation without intervention in this follow up study
1539411|NCT02673775|Other|Clean Air|Subjects will have the clean air exposure first, followed by the ozone exposure
1539412|NCT02673775|Other|Ozone|Subjects will have the ozone exposure first, followed by the clean air exposure
1539413|NCT02673749|Drug|RP-G28|Study drug taken orally
1539414|NCT02673749|Other|Placebo|Placebo taken orally
1539416|NCT02673723|Drug|Docozine|dezocine（Dez A：0.05 mg/kg，Dez B：0.1 mg/kg and Dez C：0.15 mg/kg, diluted to 5 ml respectively) is given for 10 seconds after surface anesthesia
1539417|NCT02673723|Drug|Saline|The same amount of saline is given for 10 seconds after surface anesthesia
1539418|NCT02673710|Other|No intervention|Besides participant reported outcomes and a muscle strength test no interventions are administered, all treatment decisions are at the discretion of the physician and will be in line with local clinical practice and labeling
1539419|NCT02673697|Device|Perceval valve|Sutureless Aortic Biological Valve
1539420|NCT02673697|Device|other stented biological valve|Any biological stented valves available on the market (Edwards, Medtronic, St.Jude, LivaNova, Labcor)
1539421|NCT02673684|Device|Experimental NSS|5-Day Active electro auricular device that delivers electrical impulses that stimulate the neurovascular bundles in the ear.
1539422|NCT02673684|Device|Sham NSS|(5 minute active) Electro Auricular Device that delivers electrical impulses to neurovascular bundles in the ear.
1539423|NCT02673671|Device|GTech Gutcheck Myoelectric recording device|A patch is placed on the abdomen of the patient to record myoelectric activity.
1539424|NCT02673658|Behavioral|Motor + problem solving|Developmental motor tasks incorporating cognitive concepts such as object permanence
1539425|NCT02673658|Behavioral|body weight support training|Mobility tasks to change positions or move the body with assistance to initiate movement
1539426|NCT02673645|Other|SAGA Innovations|An intensive math tutoring program.
1539427|NCT02673632|Drug|Merional ®|Using the long protocol of controlled ovarian hyperstimulation (COH). Down regulation by (Decapeptyl ®, Ferring) 0.1mg subcutaneously once daily starting from day 18 of the preceding cycle, human menopausal gonadotrophin (hMG) (Merional ®, IBSA) 75 IU starting from cycle day two after confirmation of down regulation (thin endometrium, number of follicular activity, E2 < 50 pg/mL). hMG dose is optimized according to age, BMI, antral follicles count (AFC), the local protocol, FSH level and previous response. Usually PCO patients start by 150 IU.
1539428|NCT02673619|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colourless solution, free from visible particulates, for topical application. Each subject total daily dose will be calculated as per study reference manual (SRM) using subject's hand area. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects.
1539429|NCT02673619|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application.This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. A single dose of study treatment will be based on the size of the subject's hand in order to provide coverage of approximately 2µL/ cm^2
1539430|NCT02673606|Drug|Estradiol|
1539431|NCT02673606|Drug|Placebo|
1539432|NCT02673593|Drug|DS102|
1539433|NCT02673593|Drug|Placebo|
1539434|NCT02673580|Other|Open Access telePRO|"In open access, contacts to the outpatient clinic are initiated solely by the patient. Contacts may be in the form of a PRO assessment like in standard telePRO, but at a time decided by the patient via the Danish National Health website Sundhed.dk."
1539435|NCT02673580|Other|Standard telePRO|Standard care: fixed interval telePRO follow-up. Patients receive a questionnaire with individually pre-specified intervals.
1539436|NCT02673567|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
1539437|NCT02673567|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
1539438|NCT02673567|Drug|TEV-48125 - 3|Subcutaneous administration Dose Regimen 3
1539439|NCT02673567|Drug|Placebo|Matching Placebo
1539440|NCT02673554|Drug|GIP Bolus|bolus injections of synthetic human GIP (50 pmol/kg body weight) administered 30 and 120 min after commencing the hyperglycemic clamp
1539441|NCT02673554|Drug|GIP Clamp|hyperglycemic clamp with the continuous intravenous infusion of 2 pmol.kg-1.min-1 synthetic human GIP between 30 and 180 min
1539442|NCT02673554|Procedure|Oral glucose tolerance test (OGTT)|an oral glucose challenge (75 g)
1539443|NCT02673554|Procedure|hyperglycemic clamp|a hyperglycemic clamp (capillary venous glucose concentration ~ 8.5 mmol/l)
1539444|NCT02673541|Device|AXIOS™ stent|Arm 1 will undergo EUS-guided cystogastrostomy/enterostomy and placement of the AXIOS™ stent 10-15mm (saddled diameter; choice at the discretion of the treating gastroenterologist) though the tract into the collection cavity, and correct positioning of the inner flange confirmed by EUS prior to deploying within the stomach or duodenum.
1539445|NCT02673541|Device|Double Pigtail Stents|Arm 2 will undergo EUS-guided cystogastrostomy/enterostomy and placement of multiple double pigtail stents (i.e. ≥2) through the tract into the collection cavity.
1540000|NCT02669043|Drug|Ketamine|Intravenous ketamine 0.5mg/kg over 40 minutes
1539447|NCT02673515|Behavioral|Alternate day fasting|Subjects are requested to fast every other day. Calorie free fluids are allowed.
1539448|NCT02673502|Dietary Supplement|simple carbohydrate drink|Patients will ingest 400 ml of the simple carbohydrate drink consisting of commercial orange juice without pulp which contains 50 grams fructose/galactose 2 hours before surgery.
1539449|NCT02673502|Dietary Supplement|complex carbohydrate drink|Patients will ingest 400 ml of the complex carbohydrate drink containing 50 grams of maltodextrin powder in water ( orange food color and artificial orange flavor have been added to the drink) 2 hours before surgery
1539450|NCT02673489|Drug|DCV|
1539451|NCT02673489|Drug|SOF|
1539452|NCT02673489|Drug|RBV|
1539455|NCT02673463|Drug|Spironolactone|25 mg once daily
1539456|NCT02673463|Drug|Placebo|Visually identical to spironolactone, once daily
1539457|NCT02673437|Other|This is a non-interventional study|This is a non-interventional study
1539458|NCT02673424|Procedure|FFR-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the FFR-guided strategy arm
* Criteria for revascularization: The FFR ≤ 0.80 will be targeted for PCI"
1539459|NCT02673424|Procedure|IVUS-guided stenting|"The percutaneous coronaryintervention using drug-eluting stent will be indicated according to following criteria in the IVUS-guided strategy arm
* Criteria for revascularization: Minimum lumen area (MLA) ≤ 3mm2 or (MLA ≤ 4mm2 AND Plaque burden >70%)"
1539460|NCT02673411|Device|ultrasound shear wave elastography|ultrasound shear wave elastography is performed in GE ultrasound scanner according to guidelines of ultrasound elastography.
1539461|NCT02673398|Other|Comprehensive Geriatric Assessment|Ancillary studies
1539462|NCT02673398|Other|Laboratory Biomarker Analysis|Correlative studies
1539463|NCT02673398|Drug|Neratinib|Given PO
1539464|NCT02673398|Other|Pharmacological Study|Correlative studies
1539465|NCT02673385|Other|Brazelton scale|
1539466|NCT02673372|Drug|Morphine|intravenous Morphine given at 0.1 mg/kg as intravenous infusion (10 min) with a maximum dose of 10 mg. The device is the Care Fusion Alaris PC.
1539467|NCT02673372|Drug|Ketamine|Ketamine administered in sub-dissociative doses 0.3 mg/kg as a intravenous infusion (10 min). The device is the Care Fusion Alaris PC.
1539468|NCT02673359|Drug|Progesterone|Vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) will be given in a dose of 400 mg/day
1539469|NCT02673359|Procedure|Cervical cerclage|Cervical cerclage will be performed by transvaginal placement of purse-string stitch suture at the cervicovaginal junction, without mobilization of the urinary bladder (McDonald cervical cerclage)
1539470|NCT02673333|Drug|Pembrolizumab|
1539471|NCT02673320|Procedure|Early surgery within 48 hours|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, early surgery is then realised within 48 hours. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
1539472|NCT02673320|Procedure|Delayed surgery at 15 days|After completion of the clinical and radiological diagnosis of post-traumatic spinal cord contusion on narrow spinal canal, the patient was hospitalized. After obtaining the signed consent form, the patient was included in the protocol. After anesthetic consultation determining the feasibility or not of surgery and in the absence of other vital injury or involving life-threatening, delayed surgery is then realised at 15 days. The surgical technique is a conventional cervical spinal decompression surgery. Surgery by way posterior surgery, by laminectomy in case of significant spinal stenosis greater than or equal to 3 floors will be preferred. In other cases, the type of surgery will be at the discretion of the surgeon. Then, the follow-up visits are D7, M3, Y1 and Y2.
1539473|NCT02673307|Behavioral|1 chewing gum over 45 minutes|
1539474|NCT02673294|Other|balance virtual rehabilitation|
1539475|NCT02673281|Other|Walnut shake|walnut shake will be administered for 5 days as a morning snack instead of a typical breakfast
1539476|NCT02673281|Other|Placebo shake|placebo shake will be administered for 5 days as a morning snack instead of a typical breakfast
1539479|NCT02673255|Biological|Tetanus and Diphtheria (Td) Vaccine|
1539480|NCT02673242|Device|Threshold IMT Philips Respironics|Inspiratory muscle training
1539481|NCT02673229|Drug|Collagenase Santyl|A sterile, enzymatic debriding agent which contains 250 collagenase units per gram of white petrolatum, United States Pharmacopeia (USP).
1539482|NCT02673229|Drug|Bacitracin|One gram is equal to 500 bacitracin units; one unit of bacitracin is equivalent to 0.026 milligrams.
1539483|NCT02673216|Other|No intervention|
1539548|NCT02672644|Device|Emervel Deep|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Deep (severe NLFs; WSRS = 4/4).
1539486|NCT02673177|Procedure|robot-assisted total mesorectal excision|The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery. This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.
1539487|NCT02673177|Procedure|laparoscopic total mesorectal excision|Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
1539488|NCT02673164|Biological|CSCC_ASC|The stem cells will be injected directly into the myocardium using the NOGA XP system (BDS, US)
1539489|NCT02673151|Procedure|Computed Tomography|Undergo 68Ga-PSMA PET/CT
1539490|NCT02673151|Drug|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)-HBED-CC|Given IV
1539491|NCT02673151|Other|Laboratory Biomarker Analysis|Correlative studies
1539492|NCT02673151|Procedure|Positron Emission Tomography|Undergo 68Ga-PSMA PET/CT
1539493|NCT02673138|Drug|canagliflozin|basal interruption with canagliflozin
1539494|NCT02673138|Other|basal interruption without canagliflozin|basal interruption
1539495|NCT02673125|Genetic|MitoGrade|MitoGrade refers to the mitochondrial DNA assessment in embryos.
1539496|NCT02673112|Behavioral|Subthreshold exercise (STEP) with mobile health coaching|Aerobic exercise program performed below the HR threshold that causes symptoms and administered by an RA using mobile health coaching
1539497|NCT02673112|Behavioral|Light stretching (LS)|Brief daily stretching routine.
1539498|NCT02673099|Procedure|HDF online|Hemodialysis by the HDF online method
1539499|NCT02673086|Other|coracoid approach|Coracoid approach for ultrasound guided infraclavicular brachial plexus block
1539500|NCT02673086|Other|retroclavicular approach|retroclavicular approach for ultrasound guided infraclavicular brachial plexus block
1539501|NCT02673073|Other|Patient's diary|"Patients in the intervention arm will be educated to measure body weight, blood pressure, and heart rate every morning after using toilet. Number of remaining pills of the previous day is for the assessment of drug compliance. Degree of pitting edema is graded from 0 (no edema), 1 (mild), 2 (moderate), 3 (severe) and, degree of dyspnea is graded from 0, 1, 2, 3, corresponding to NYHA class I, II, III, and IV, respectively.
Patients are instructed to visit or call the HF-outpatient clinic, when they have (i) body weight gain more than 1 kg/day or 2kg in 7 days;(ii) aggravation of pitting edema by one degree; (iii) aggravation of dyspnea by one grade."
1539502|NCT02673073|Other|Patient's education|All patients will receive patient's information/education booklet on the heart failure including life style modification.
1539503|NCT02673060|Drug|MBC-11|0.5 mg/kg-10 mg/kg , IV (in the vein) on day 1-5 of each 28 day cycle. Number of cycles: 2, in case of partial metabolic reaction or stable metabolic reaction - up to 4.
1539504|NCT02673047|Biological|botulinum toxin Type A|Botulinum toxin Type A (Botox®) injection as prescribed as standard of care in clinical practice.
1539505|NCT02673021|Procedure|Microwave ablation|Microwave tumor ablation is a procedure that uses heat made by an electric current to destroy a tumor (ablation). With imaging equipment, such as ultrasound or CT (computed tomography), and a small incision made in the skin, the tumor is located and treated with radiofrequency energy. The cells that are killed by the microwave ablation are typically not removed but are eventually replaced by fibrosis and scar tissue.
1539508|NCT02672995|Radiation|Fractionated stereotactic radiosurgery|"Fractionated stereotactic radiosurgery:
Group 1: tumors 1.5~2.5 cm in diameter Dose level 1: 21 Gy in 3 fractions Dose level 2: 24 Gy in 3 fractions Dose level 3: 27 Gy in 3 fractions Group 2: tumors 2.5~3.5 cm in diameter Dose level 1: 18 Gy in 3 fractions Dose level 2: 21 Gy in 3 fractions Dose level 3: 24 Gy in 3 fractions Three fractions will be given in one week with at least 1 day break."
1539509|NCT02672995|Drug|bevacizumab|"Concurrent bevacizumab:
Bevacizumab 7.5 mg/kg will be given one day before the first fraction of radiosurgery and 2 weeks after the first dose of bevacizumab."
1539510|NCT02672982|Other|NUTPSY treatment|The psychosocial component of the new combined treatment involves seven weekly counselling sessions with mothers focused on feeding, emotional attachment, stages of child development, stimulation, emotional responsiveness and interaction, and on concerns/strategies of child care and parenting.
1539511|NCT02672982|Other|NUT treatment|Only the standard nutritional treatment in the form of Ready-to-use Therapeutic Food (RUTF) is administered.
1539512|NCT02672969|Device|RapidVac Smoke Evacuator|"The intervention group, using the smoke evacuation (RapidVac Smoke Evacuator) in each OR, the data collection for the amount of surgical smoke and bio-aerosols' particles will be collected during pre-surgery and during surgery (every 30 mins).
Before using the smoke evacuation, the amount of surgical smoke and bio-aerosols' particles in the surgical field and OR environment will be measured by AeroTraxTM Handheld Airborne Particle Counter. This record includes the amount and size of smoke and bio-aerosol particles in each area such as anesthetic area (anesthesiologist physicians and nurses area); instrument preparation area (circulating nurses area) and surgical area (surgeons and scrub nurses areas)."
1539513|NCT02672956|Procedure|Ten mm trocar|
1539514|NCT02672943|Behavioral|Rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks rehabilitation training, should accept MRI and Clinical assessments.
1539515|NCT02672943|Other|non-rehabilitation treatment|The walking exercise will be aerobic with a Borg rating perceived exertion around 11-14 scales. Before and after the 12 weeks non-rehabilitation training, should accept MRI and Clinical assessments.
1539516|NCT02672930|Device|Electrocardiogram (ECG)|ECG and vital parameters were obtained before and after recommended standard calcium gluconate therapy for hyperkalemia
1539517|NCT02672917|Biological|MVT-5873|MVT-5873 is administered weekly by IV infusion. Dose will be increased during the study in order to define the MTD
1539518|NCT02672904|Device|CO2 laser|surgical removal of carcinoma from the vocal cords with CO2 laser
1539519|NCT02672904|Device|KTP laser|surgical removal of carcinoma from the vocal cords with KTP laser
1539547|NCT02672644|Device|Emervel Classic|Subjects requiring bilateral correction of NLFs and meeting eligibility criteria will be enrolled and treated with Emervel Classic (moderate NLFs; WSRS = 3/3)
1540343|NCT02666625|Procedure|blood samples|
1539520|NCT02672891|Device|condom balloon catheter|"The condom balloon catheters were inserted into the uterine cavity digitally or with forceps .Tight vaginal pack was inserted or cervical stitch was done to prevent displacement of the balloon catheter.
(2)-Insertion at Cesarean Section: The catheter was inserted through the uterine incision (pushing the tip to the fundus and the drainage port through the cervix into the vagina) or transvaginally and inﬂated after the uterine incision was closed."
1539521|NCT02672878|Device|Bioresorbable vascular scaffold|
1539523|NCT02672852|Drug|ABBV-066|ABBV-066 administered by subcutaneous injection
1539524|NCT02672852|Drug|Placebo|Placebo for ABBV-066 administered by subcutaneous injection
1539525|NCT02672839|Drug|LGD-6972 Solution|15 mg of LGD-6972
1539526|NCT02672839|Drug|LGD-6972 Capsules|15 mg LGD-6972
1539527|NCT02672826|Procedure|Adipose tissue surgery|Adipose tissue (gluteo-femoral and abdominal) will be obtained from women programmed for surgery in which the estrogenic status as well as adipose tissue mass profile will be evaluated
1539528|NCT02672813|Procedure|Pectoral nerve I and II block|Under Ultrasound guidance, Pectoral nerve I and II block is given for every breast surgery by using 10 and 20 ml of 0.25% Ropivacaine respectively
1539529|NCT02672800|Behavioral|the Reclaiming Yourself tool|This tool is a behavioural writing intervention, intended to facilitate bereavement for spousal caregivers of persons with dementia
1539530|NCT02672787|Behavioral|ED-based behavioral intervention|Data collection, antihypertensive adherence assay, antihypertensive interview and EHR review, barrier identification, personalized goal setting, communication with PCP, and reminder messages/engagement messages.
1539531|NCT02672787|Behavioral|ED usual care plus education|Data collection, antihypertensive adherence assay, antihypertensive interview, EHR review, and usual care education.
1539532|NCT02672774|Procedure|Magnification endoscopy with narrow band imaging|Magnification endoscopy with narrow band imaging is an optically enhanced endoscopic imaging technique used for better characterization of lesions as compared to white light endoscopy alone. With only a push of a button optical filters are applied to reduce the illuminating light to 415 nm (blue) and 540 nm (green) wavelengths, which are selectively absorbed by haemoglobin. As a result the superficial vascular networks are highlighted and morphological changes in capillary patterns can be described for different gastrointestinal lesions.
1539533|NCT02672774|Device|Probe based confocal laser endomicroscopy|Confocal laser endomicroscopy enables in vivo microscopic analysis during ongoing endoscopy and has shown good accuracy for predicting the histopathological diagnosis in lesions of both the upper and lower GI tract. During the examination fluorescein is administered intravenously as a contrast agent, highlighting the vessels and surrounding epithelial structures. The probe based confocal laser endomicroscopy system can be easily integrated into the imaging protocol as it uses flexible catheter probes that can be passed through the working channels of the endoscopes once the area of interest has been identified.
1539534|NCT02672761|Behavioral|MBSR meditation|"Adopted from buddhism for western societies by Jon Kabat-Zinn, MBSR has been described as a group program that focuses upon the progressive acquisition of mindful awareness, of mindfulness. The MBSR program is an eight-week workshop taught by certified trainers that entails weekly group meetings, homework, and instruction in three formal techniques: sitting mindfulness meditation, body scanning and simple yoga postures. Sitting meditation includes concentration on the breathing while not adhering to the flow of thoughts or emotions as well as the development of empathy and loving kindness for all persons. Body scanning is the first prolonged formal mindfulness technique taught during the first four weeks of the workshop, and entails quietly lying on one's back and focusing one's attention on various regions of the body, starting with the toes and moving up slowly to the top of the head."
1539535|NCT02672761|Behavioral|MBT training|"A specific memory brain training stimulates by a validated program according to Kawashima from the Industry University Research Project the according areas in the prefrontal lobe for calculation, logical reflection, optic/episodes and memory. The computerized program adopts to the difficulty level of the trainee. Selected were trainings for the categories working/semantic and episodic/optical memory and logic/calculation adjusted to the individual's selection from all categories but various themes (like sports, cars etc.)."
1539536|NCT02672761|Behavioral|Wellness|"The Brain Light Wellness chair is assessed for the stress reduction in industry and public Enterprises. In a European study 97% of subjects reported a stress reduction, improved well-being, performance and increased vitality, less fatigue and petulance. The chair 3D-Float-plus system comprises of a massage chair in sitting to lying position, a headset with earphones a lighted glasses for visual and audio Stimulation. One standardized session of 45 min duration was chosen for the study that combined a short massage period with a relaxation trance session."
1539537|NCT02672761|Behavioral|Control|The waiting period for the MBSR training to start simply should include no changes in lifestyle, recreational activity or intellectual training
1539538|NCT02672748|Other|Garden|Two years of financial and technical home gardening support for new gardeners
1539539|NCT02672735|Other|Corrective Exercise Programming|Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
1539540|NCT02672722|Drug|Definity|During kidney ultrasound, Definity microbubbles will be injected into the vein to see how blood flows through the kidneys
1539541|NCT02672722|Other|Exercise|
1539542|NCT02672722|Other|Kidney Ultrasound|This done before and after exercise with the help of Definity to see changes in kidney blood flow
1539543|NCT02672709|Drug|apixaban|
1539544|NCT02672696|Device|FluoroMap 3D|Use of the 3D reconstruction software developed by the manufacturer of the Gamma Nail (e.g. Stryker Inc.) along with the standard fluoroscopy
1539545|NCT02672670|Behavioral|Experimental: Intervention group---coping-oriented supportive programme|
1539546|NCT02672670|Behavioral|Active Comparator: Comparison group---a didactic talk (usual care)|
1539630|NCT02671968|Device|Continuous Glucose Monitoring System|
1539552|NCT02672605|Other|Pennsylvania State Abortion Consent|Measuring the level of stigma felt pre- or post-exposure to the abortion consent language.
1539553|NCT02672592|Drug|Anakinra|Anakinra 100mg s.c. bid
1539554|NCT02672592|Drug|Sodium Chloride 0.9%|Sodium Chloride 0.9% s.c. bid
1539555|NCT02672566|Drug|Enoxaparin|Enoxaparin will be delivered to the patients every day at the dose of 4 000 Ui.
1539556|NCT02672566|Other|Usual care|Patients will all benefit from the classic cares, delivered to all pregnant patients.
1539557|NCT02672553|Device|EDWARDS INTUITY Valve System, Model 8300A|To evaluate cardiac perfor-mance characteristics and ad-verse events rates associated with the EDWARDS INTUITY Valve in patients undergoing MIS-AVR.
1539558|NCT02672553|Device|Stented Aortic Bioprostheses|In comparison to control valves available on the market under-going FS-AVR
1539559|NCT02672540|Drug|SANGUINATE 320 mg/kg|Two-hour infusion of SANGUINATE on Day 1 and Day 2
1539560|NCT02672540|Drug|Normal Saline|Two-hour infusion of Normal Saline and Day 1 and Day 2
1539561|NCT02672527|Drug|Trabectedin|
1539562|NCT02672527|Drug|Dexamethasone|
1539563|NCT02672514|Device|Minimally invasive extracorporeal circulation (MiECC)|Minimally invasive extracorporeal circulation (MiECC) is an extracorporeal circulation systems used for cardiopulmonary bypass.
1539564|NCT02672514|Device|Conventional extracorporeal circulation (CECC)|Conventional extracorporeal circulation (CECC) is an extracorporeal circulation system used for cardiopulmonary bypass.
1539565|NCT02672501|Drug|anti-CD19-CAR-T cells|a 2nd CAR, CD19 as target protein, 4-1BB as co- stimulator, and optimized the spatial conformation by a suitable hinge & transmembrane domain sequences
1539566|NCT02672488|Drug|Sorafenib|Standard treatment for advanced HCC
1539567|NCT02672488|Drug|Metformin|To evaluate the safety and efficacy of the combined treatment of Metformin and Sorafenib for advanced HCC
1539571|NCT02672462|Device|Radio frequency renal denervation system (Golden Leaf GL-06E15A)|
1539572|NCT02672449|Radiation|Carbon Ions Boost Followed by Pelvic Photon Radiotherapy|The patients will be enrolled either at the Centro Nazionale di Adroterapia Oncologica (CNAO), Pavia, Italy, at the Division of Radiation Oncology of the European Institute of Oncology (IEO), Milan, Italy, or at the Fondazione IRCCS Istituto Nazionale Tumori (INT), Milan, Italy. The treatment will include a boost phase on the whole prostate with carbon ions performed at CNAO followed by a pelvic photon RT, with IMRT performed with conventional fractionation of 1.8 Gy per fraction up to 45 Gy to the pelvic lymph nodes, prostate and seminal vesicles. The total dose prescribed to the prostate boost with carbon ions will be of 16.6 GyE in 4 fractions (4.15 GyE/fraction).
1539573|NCT02672436|Drug|ENERGI-F703|Standard of care and ENERGI-F703 are applied for treatment of diabetic foot ulcers.
1539574|NCT02672436|Drug|ENERGI-F703 matched vehicle|Standard of care and ENERGI-F703 matched vehicle are applied for treatment of diabetic foot ulcers.
1539577|NCT02672397|Behavioral|Additional Epidural Education|All women allocated to receive additional epidural educational will be given a language appropriate pamphlet and video on neuraxial anesthesia. The video and pamphlet will be in the subject's primary language. After the subject watches the educational video they will be given an opportunity to go through the pamphlet with the research assistant and ask any questions they may have. For Spanish-speaking subjects this will occur through a telephone interpreter. The obstetric anesthesia providers and obstetricians caring for the subject will be absent for the educational video and post-video conversation.
1539579|NCT02672371|Device|Active eMNS|Each session will consist of right eMNS stimulation that will last 20-minutes. The frequency of stimulation will be random assigned using random frequency interval. The electrodes that will be used will be standard transcutaneous electrodes. The electrodes will be placed on the wrist.
1539580|NCT02672371|Device|Sham eMNS|Each session of sham eMNS will be the same as active, except the device will be turned off. Similar parameters will be used (for 20 minutes and same electrode placement), except no stimulation will be delivered.
1539581|NCT02672358|Drug|Dabrafenib|Oral Dabrafenib 150 mg BID
1539582|NCT02672358|Drug|Trametinib|Oral Trametinib 2 mg QD
1539583|NCT02672345|Drug|Sevoflurane|The Sevoflurane Group will receive between 0.7 and 1.5% of sevoflurane CAM only during CPB period. While Not Sevoflurane Group will receive only intravenous anesthetic agents.
1539584|NCT02672332|Drug|SB204 4%|Once daily
1539585|NCT02672332|Drug|Placebo (vehicle)|Placebo comparator
1539586|NCT02672319|Procedure|EUS-guided glue injection|Experimental: EUS-guided glue injection Gastroesophageal varices > 3mm in diameter will be treated with EUS guided cyanoacrylate injection for variceal obturation in standard fashion. A conventional 19G needle (19G-Echotip needle, Cook Medical, USA) will be advanced into the target varix under real-time EUS guidance. Cyanoacrylate injection (Histoacryl, B. Braun Surgical, Germany) will be performed according to established protocol. Each aliquot of cyanoacrylate injection will consist of 0.5ml of Histoacryl + 0.7ml of lipiodol. 1 - 3 aliquots of cyanoacrylate injection may be given depending on the number of varices needed to be treated. EUS with colour Doppler will be used to monitor obliteration of blood flow in varices during and after cyanoacrylate injection.
1540344|NCT02666612|Procedure|Blood samples|
1539587|NCT02672306|Biological|UCMSCs|Biological: Human UCMSCs 20 million cells per subject (0.5×10^6 UCMSCs per kg) intravenous injection Infusion number: 8 (Once every two weeks)
1539588|NCT02672306|Biological|Placebo|Subjects with Alzheimer's Disease placebo comparator (normal saline) intravenous injection Infusion number: 8 (Once every two weeks)
1539589|NCT02672293|Drug|Phoslax|Oral sodium phosphate solution (monobasic sodium phosphate 2.4 g and dibasic sodium phosphate 0.9g / 5 mL).
1539590|NCT02672280|Device|Medical Collagen Membrane with MSC|
1539591|NCT02672280|Device|Medical Collagen Membrane|
1539592|NCT02672267|Biological|Stem cells|human Allogeneic Low Oxygen mesenchymal stem cells; Ischemia tolerant
1539593|NCT02672267|Other|Placebo|Lactated Ringer's Solution
1539594|NCT02672254|Radiation|Samples with 2 treatments|Study the concomitant effects between chemo- and radiotherapy by means of cellular techniques.
1539595|NCT02672241|Drug|Nimotuzumab|Nimotuzumab given during radiotherapy, is administered via intravenous drip with a dosage of 150mg/m2, weekly, for 6 consecutive weeks. After radiotherapy and evaluation, disease progression-free patients will continue to receive Nimotuzumab treatment biweekly until disease relapse or progression.
1539596|NCT02672241|Drug|Temozolomide|Temozolomide is applied to these patients as a chemotherapy drug with a dosage of 75mg/m2, daily. The chemotherapy and radiation are combined as temozolomide is taken 1 hour prior to every fraction of radiotherapy. In 4 weeks after the completion of radiotherapy, temozolomide is given for 8 cycles (dosage: the 1st cycle, 150mg/m2, daily × 5 days, 4 weeks a cycle; the 2-8th cycle, 200mg/m2, daily × 5 days, 4 weeks a cycle and repeated again).
1539597|NCT02672228|Device|MalariaSense device|All participants enrolled in the study will be assessed for malaria using the intervention device called MalariaSense technology
1539598|NCT02672215|Behavioral|Start to stand|web-based computer-tailored intervention including personalized feedback and tips on how to reduce and/or interrupt workplace sitting
1539599|NCT02672215|Behavioral|generic advice|general, non-tailored web-based generic advice with tips
1539600|NCT02672202|Drug|Duloxetine|"60 mg/d - twice before surgery and once a day for post operative days 3-7
30 mg/d - once a day for post operative days 1-2"
1539601|NCT02672202|Drug|Pregabalin|"75 mg/d - twice a day for post operative days 1-2
150 mg/d - twice a day for post operative days 3-7 300 mg/d - twice before surgery"
1539602|NCT02672202|Drug|Placebo|"non-active - twice before surgery
non-active - twice a day for post operative days 1-7"
1539603|NCT02672189|Behavioral|EVA-Online|Internet-based cognitive behavioral therapy
1539604|NCT02672176|Behavioral|Usual Care|This program is a well-established program within the UC Davis Health System, providing care coordination to individuals with chronic conditions. Patients can self-refer or are referred by their providers for this service. The role of the care coordinator is to assess needs of the patient and coordinate healthcare referrals and appointments for the patient, facilitate communication among members of the healthcare team, identify health goals in collaboration with the patient and assist them in meeting those goals if requested by the patient. Contact is variable and conducted on a case by case basis.
1539605|NCT02672176|Behavioral|P2E2T2 Program|The P2E2T2 intervention group will receive Nurse Health Coaching using MI, an approach designed to elicit and support behavioral changes and improve self-efficacy (18-21). Nurses delivering the intervention will have completed the Health Science Institutes Registered Health Coach (RHC) training program (www.healthsciences.org). The intervention protocol is as follows:
1539606|NCT02672163|Procedure|CABG surgery|Elective CABG surgery
1539607|NCT02672163|Procedure|AADC therapy|Atrial appendage derived cells are placed on the site of a infarct scar with matrix sheet
1539608|NCT02672150|Behavioral|Core|
1539609|NCT02672150|Behavioral|Enhanced|
1539610|NCT02672137|Behavioral|knowledge translation|knowledge translation that include: Community of practice, local gap analysis, opinion leaders, targeted interventions, performance feedback, reminders and local formation of ACS teams.
1539611|NCT02672111|Drug|CAM2038 (buprenorphine FluidCrystal® once-weekly injection depot)|
1539612|NCT02672111|Drug|CAM2038 (buprenorphine FluidCrystal® once-monthly injection depot)|
1539613|NCT02672098|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
1539614|NCT02672098|Drug|Carboplatin|"Carboplatin, delivered as HIPEC, will be administered at the time of surgery. Subjects will receive a single cycle of hyperthermic intraperitoneal chemotherapy.
a single dose of carboplatin (800 mg/m2) will be administered in normal saline via intraperitoneal hyperthermic perfusion using the closed-abdomen technique. HIPEC will be continued for 90 minutes in the hyperthermic phase (41°C-43°C)."
1539615|NCT02672085|Procedure|PRP infiltraiton|Two time with 1 month interval, PRP will be extracted from own blood's patients with Regenlab® extraction kit, and injected into supraspinatus interstitial lesion.
1539616|NCT02672085|Procedure|Needling|Two time with 1 month interval, saline water will be injected into supraspinatus interstitial lesion.
1539620|NCT02672059|Other|Observation|No intervention
1539621|NCT02672046|Other|Assessment at the Clinic of Sports Injuries|Assessment at the Clinic of Sports Injuries as well as a new algorithm (using patient-reported symptoms will be applied
1539622|NCT02672033|Radiation|Hypofractionated Radiation Therapy|Undergo accelerated hypofractionated IMRT
1539623|NCT02672033|Radiation|Intensity-Modulated Radiation Therapy|Undergo accelerated hypofractionated IMRT
1539624|NCT02672033|Other|Laboratory Biomarker Analysis|Correlative studies
1539625|NCT02672033|Procedure|Therapeutic Conventional Surgery|Undergo pleurectomy/decortication
1539626|NCT02672020|Biological|omics identity card|
1539627|NCT02672007|Device|SensiumVitals|The patients will have their respiratory rates, heart rates and temperature (axilla) measured continuously by the SensiumVitals patch.
1539628|NCT02671994|Other|G8 screening|
1539629|NCT02671994|Other|Geriatric assessment|
1539631|NCT02671955|Drug|JNJ-61610588|Participants will receive intravenous infusions of JNJ-61610588 until disease progression.
1539632|NCT02671942|Drug|Roflumilast|
1539633|NCT02671942|Drug|Placebo|
1539636|NCT02671916|Behavioral|questionnaire|Investigation on all study patients, no Intervention, no groups
1539637|NCT02671903|Device|Pacemaker: AV optimised, His pacing.|Direct His bundle pacing: a Medtronic Select Secure 3830 pacing lead will be positioned at the His bundle. If selective direct His bundle pacing cannot be achieved then non-selective His bundle pacing will be accepted. AV delay optimisation: will be performed using acute non-invasive blood pressure acquired using the Finometer device (Finapres Medical systems, Netherlands).
1539638|NCT02671890|Drug|Disulfiram|Given PO
1539639|NCT02671890|Drug|Gemcitabine Hydrochloride|Given IV
1539640|NCT02671890|Other|Laboratory Biomarker Analysis|Correlative studies
1539641|NCT02671890|Other|Placebo|Given PO
1539642|NCT02671877|Procedure|Transnasal fiberoscopy|Minimally invasive exploration ot the upper airways, performed in an awake or minimally sedated patient.
1539643|NCT02671864|Other|1: incretin-based therapy|
1539644|NCT02671864|Other|2: other antidiabetic|
1539645|NCT02671851|Drug|Thoracic paravertebral blocks (TPVBs)|Patients received bilateral single injection ultrasound-guided TPVBs with 20mL bupivacaine 0.375% at the level of T3-T4 as an adjunct to GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
1539646|NCT02671851|Drug|IV metamizole sodium, paracetamol|Patients received only standardized GA, intraoperative fentanyl and postoperative tramadol, metamizole sodium and paracetamol were used.
1539647|NCT02671838|Behavioral|Musculoskeletal ultrasound program|Using a musculoskeletal ultrasound program to help improve medication adherence
1539648|NCT02671825|Drug|PUR0200|PUR0200 dry powder inhalation
1539649|NCT02671825|Drug|Reference Product|Dry Powder Inhalation Reference Product
1539650|NCT02671799|Device|VenTouch System Implant|The VenTouch System is intended for use in the treatment of functional MR (FMR) in adults who are symptomatic despite optimal medical management. It is intended for subjects with FMR with essentially normal leaflet anatomy and motion, with mitral valve regurgitation attributable mainly to annular dilatation with or without papillary muscle displacement. It is not intended to treat structural defects/degeneration of the mitral valve. The VenTouch System is used to reshape the base of the heart to bring the mitral valve leaflets into better coaptation. By doing so, it brings the mitral valve leaflets closer, allowing proper closure of the valve, and reducing or eliminating MR. There is provision of support to the ventricular myocardium below the annulus as well as the annulus, so the VenTouch System may allow long-term ventricular remodeling with positive impact on the functionality of the mitral valve.
1539651|NCT02671786|Other|MAHAN RUTF & MAHAN Vit-Min mix|MAHAN RUTF dishes are locally prepared by local tribal women and each packet of RUTF provides 500-550 calories & 15-17 gms of proteins.
1539652|NCT02671773|Drug|Inhaled corticosteroid dose/type|
1539656|NCT02671747|Behavioral|Mind Over Matter; Healthy Bowels, Healthy Bladder|3 workshop sessions over a one-month period using self-efficacy and health behavior change to improve incontinence symptoms and promote care-seeking if symptoms do not improve sufficiently
1539657|NCT02671734|Behavioral|video|Short (2 minute 43 second), animated videos were designed addressing nature of the procedure, risks, benefits, and alternatives for upper and lower endoscopy respectively using PowToon (www.powtoon.com). Sixth grade language was used throughout the video. Videos were shown to youth and their parents on an iPad.
1539658|NCT02671721|Other|Maximal Compliance|PEEP will be set at the maximum static respiratory system compliance during a descending PEEP titration curve.
1539659|NCT02671721|Device|AVEA smartCath Nasogastric Pressure Monitoring Tube|We will use transpulmonary pressure values obtained using an naso/orogastric tube during the operative procedure to titrate PEEP intraoperatively.
1539665|NCT02671682|Procedure|Immunoadsorption|
1539666|NCT02671682|Procedure|Plasmapheresis|
1539667|NCT02671669|Behavioral|Usual Care|Discharge packet of Heart Healthy instructions, with self-report health status, quality of life and psychosocial questionnaires, as well as other educational handouts, exit interview to review exercise progress, receive referrals to additional medical services they might need after discharge from the program, with physician.
1539668|NCT02671669|Behavioral|Movn application (MVN)|"Intervention participants will receive the same discharge packet as the UC group along with their exit interview and will receive the following:
Participant individualized Heart Healthy instructions for post-cardiac rehabilitation will be integrated into the MVN application including daily medication reminders, physical activity prompts, educational materials, and patient-reported outcome assessment of behavior and psychosocial status.
Text messages will be used on an ad hoc basis to provide positive feedback to the participant; two-way messaging between the participant and the research coordinator will be available to provide opportunities to answer specific questions."
1539669|NCT02671656|Device|Uricemia|serum uric acid levels is measured once from venous blood samples in the biochemistry laboratory using standard automated colorimetric methods
1539741|NCT02671071|Behavioral|Quality of Life Questionnaire (QLQ)|The European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire-Cervical cancer module (EORTC QLQ-CX24) will be applied to all patients at 0, 3, 6, 12, 24, 36 months.
1540001|NCT02669030|Drug|suvorexant|an FDA-approved sleep aid
1539670|NCT02671630|Other|A community-based computerized cognitive training program|The computer training games included: 1) a phonological loop to train the participants to choose correct song from a list of different songs which can be categorized as people, nature, and musical instrument. The difficulty level progressed from choosing one from two to choosing one from three songs; 2) a visual-spatial sketchpad to train the participants to remember and find the same graphs including vegetable, fruits, daily necessity, and numbers. The difficulty level progressed from finding one pair to three pairs of similar graphs; 3) a central executive system to train the participants to execute dual tasks including conducting dual memory, calculating while listening to music, making phone calls, and matching medication at correct time.
1539671|NCT02671617|Other|High intensity interval training (HIIT)|Preoperative HIIT protocol.
1539672|NCT02671591|Behavioral|MI-PrEP|This is a one-hour motivational interviewing-based, one-to-one session that will help YBMSM think more about going on PrEP and it will help YBMSM think more about using condoms consistently and correctly with every sex partner.
1539673|NCT02671591|Behavioral|control condition|This is a behavioral program designed to provide men with condoms and lubricants that make sex feel good even though it is fully protected by latex condoms
1539674|NCT02671578|Drug|Nitrous Oxide|The N2O/O2 equipment was composed by two flow meters with an anti-hypoxia system valve, 70% N2O maximum disposal and 30 L/min O2 valve to immediate oxygen dispensation. Masks were individually selected, being 100% O2 (6 L/min) dispensed until respiratory rate stabilization. N2O was incremented at 10% each 2 minutes (70% max, if necessary) until some of the following signals were noticed: silence, relax/comfort report, decreased eyelid movements, decreased spontaneous body movements, warm sensation, tingling sensation or numbness at feet, hands or oral region, and slightly euphoric sensation.
1539675|NCT02671565|Drug|Hyaluronic Acid injections|
1539676|NCT02671552|Drug|Perflutren Protein-Type A Microspheres|Given IV
1539677|NCT02671552|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo contrast-enhanced ultrasound imaging
1539678|NCT02671539|Genetic|rAAV2.REP1|single subretinal injection
1539679|NCT02671526|Other|Computerized plasticity-based adaptive cognitive training|
1539680|NCT02671513|Drug|SHR6390|SHR6390 either 50mg,75mg,100mg,125mg,150mg,175mg given orally, QD
1539681|NCT02671500|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
1539682|NCT02671487|Behavioral|Mind-Body Skills Groups|Mind-Body Skills groups consist of small groups of about 8-10 participants who learn and practice meditation, guided imagery, breathing techniques, autogenic training, biofeedback, genograms, and self-expression through words, drawings, and movement.
1539683|NCT02671474|Other|4-dimensional volume-rendered computed tomography|
1539684|NCT02671461|Drug|BMS-986141|
1539685|NCT02671461|Drug|Aspirin|
1539686|NCT02671461|Other|Placebo|
1539687|NCT02671448|Behavioral|Home monitoring teleconsult visits|A tablet will be provided to both the patient and the caregiver during the homecare portion of the study. The tablet will remain at the home, to be used by the patient and the caregiver during daily homecare visits to complete instruments/surveys and video diary recording sessions.
1539688|NCT02671448|Behavioral|Patient Reported Outcomes (PRO)|Distress Thermometer, MSK-Modified M.D. Anderson Symptom Inventory (MDASI) Instrument, FACT-G Instrument, FACT-BMT Instrument
1539689|NCT02671448|Behavioral|Caregiver Reported Outcomes instruments|Distress Thermometer, Caregiver Reaction Assessment (CRA) Instrument, The Caregiver Quality of Life Index-Cancer (CQOLC) Scale, Satisfaction Questionnaire, Video Diary Entries
1539690|NCT02671435|Drug|Intervention|Biological: Durvalumab Biological: IPH2201
1539691|NCT02671409|Other|Neural Mobilization (exercise)|Initially patients will be informed about the procedures. After the guidelines, the hip and knee are palpated to start the joint angles. Then, the knee joint is positioned in extension and remained so throughout the treatment. In addition, the hip joint is bent until the moment that will be perceived a minimum strength of the muscles of the posterior region of thigh and leg (discarding muscle stretching). Neural mobilization is started at the time when the ankle joint will be manipulated in dorsiflexion at a frequency of approximately 20 oscillations per minute, with a pause of 25 seconds of rest. In the last two minutes of therapy, we will include cervical flexion, in order to intend the neuraxis, keeping artuculares amplitudes.
1539692|NCT02671396|Behavioral|Virtual reality based intervention|Virtual reality based balance training
1539693|NCT02671396|Behavioral|Conventional intervention|Conventional balance training
1539694|NCT02671383|Drug|Darunavir|Darunavir/ritonavir 400/100mg (DRV/r) once daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
1539695|NCT02671383|Drug|Lopinavir|Lopinavir/ritonavir 400/100mg (LPV/r) twice daily plus nucleoside/nucleotide reverse transcriptase inhibitors.
1539696|NCT02671370|Other|Measurement of the range of motion of the cervical spine|There is no intervention. Only measurements and interviews are taken.
1539697|NCT02671357|Procedure|ERAMIP|Minimally invasive pancreaticoduodenectomy with stented pancreatic-gastrostomy & Roux-en-Y reconstruction of the biliary limb of the hepatico-jejunostomy onto the efferent limb of the gastro-enterostomy (RY-GES)
1539698|NCT02671344|Other|Determination of gene profiles using arrays semen|Determination of gene profiles characterizing the set of mRNA and functional interpretation of the resulting list of genes.
1539699|NCT02671331|Procedure|Loop duodenal switch|The loop duodenal switch (L-DS) is a single anastomosis duodeno-intestinal bypass. In this simplified version of a BPD-DS, a sleeve gastrectomy is followed by a single anastomosis of the duodenum to the ileum in a loop fashion. The proposed benefits of this are to reproduce the excellent weight loss seen after a BPD-DS (an accepted and utilized bariatric procedure in the USA) but with the potential for reduced complications. With one anastomoses in the L-DS over two in the BPD-DS there is a theoretical lower probability of leaks, strictures, reduced anesthesia with shorter operative times, and decreased risk of internal hernia.
1539700|NCT02671318|Drug|Drug conversion to sirolimus|Drug conversion to sirolimus: mycophenolate or azathioprine conversion to sirolimus, in a regimen with tacrolimus and prednisone.
1539701|NCT02671318|Drug|Maintenance of the current regimen|Maintenance of the current regimen: mycophenolate or azathioprine maintenance, in a regimen with tacrolimus and prednisone.
1539704|NCT02671292|Behavioral|Interpersonal Psychotherapy|IPT-WG involves one initial 1.5-hour individual session, and 12 weekly 90-minute group sessions. The IPT-WG group sessions follow 3 phases (initial, middle, and termination) and use the interpersonal inventory to identify interpersonal problems that might be contributing to or exacerbated by LOC eating. A framework of common problem areas is used to teach interpersonal problem-solving and communication skills and educate youth about risk factors for excessive weight gain and warning signs such as eating in response to negative affect as opposed to hunger, or feeling a sense of LOC while eating.
1539705|NCT02671292|Other|Health Education|"The HE group is based upon the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each session is 90 minutes). Additionally, individuals will attend a pre-group individual meeting with the group leaders to review family health history.The curriculum includes focus on various health topics, including alcohol, drug and tobacco use, depression and suicide, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence. Session content will be largely identical for boys and girls, with the exception of gender-specific videos and articles (e.g., on body image), which will be tailored for each sex."
1539706|NCT02671279|Dietary Supplement|Low calorie diet|6 days of low calorie diet, estimated kcal 400-600/day.
1539707|NCT02671266|Drug|Oxytocin|Oxytocin nasal sprays will be self-administered in the presence of a study nurse. The dose is 24 IU (3 puffs per nostril, 4 IU per puff) of Syntocinon nasal spray.
1539708|NCT02671266|Drug|Placebo|Placebo nasal sprays will be self-administered in the presence of a study nurse. The sprays will contain all of the same ingredients as the Syntocinon spray minus the active oxytocin ingredient.
1539709|NCT02671253|Procedure|Myomectomy|The patient series consists of consecutive patients scheduled for elective laparotomic, traditional laparoscopic or robotic assisted laparoscopic myomectomy. The surgical method is selected based on clinician´s preference.
1539710|NCT02671227|Drug|intrathecal Mg sulfate.|intrathecal Mg sulfate 50 mg.
1539711|NCT02671227|Drug|intrathecal bupivacaine 15 mg.|intrathecal bupivacaine 15 mg.
1539712|NCT02671214|Other|Control|100 g high fibre flour
1539713|NCT02671214|Other|Active 2|98 g high fibre flour + 2 g guar gum
1539714|NCT02671214|Other|Active 3|88 g high fibre flour + 2 g guar gum + 10 g legume flour
1539715|NCT02671214|Other|Active 4|83 g high fibre flour + 2 g guar gum + 15 g legume flour
1539716|NCT02671214|Other|Active 5|96 g high fibre flour + 4 g guar gum
1539717|NCT02671214|Other|Active 6|86 g high fibre flour + 4 g guar gum + 10 g legume flour
1539718|NCT02671214|Other|Active 7|81 g high fibre flour + 4 g guar gum + 15 g legume flour
1539719|NCT02671214|Other|Active 8|94 g high fibre flour + 6 g guar gum
1539720|NCT02671214|Other|Active 9|98 g high fibre flour + 2 g konjac mannan
1539721|NCT02671214|Other|Active 10|96 g high fibre flour + 4 g konjac mannan
1539722|NCT02671214|Other|Active 11|100 g low fibre flour
1539723|NCT02671214|Other|Active 1|85 g high fibre flour + 15 g legume flour
1539725|NCT02671188|Drug|GSK3050002|The 3 mL glass vial contains white to off-white lyophilized powder which requires reconstitution with sterile water for injection.Prepared as 100 milligrams per milliliter (mg/mL) solution; lower concentrations prepared by dilution with 0.9% weight by volume (w/v) sodium chloride Injection for infusion.
1539726|NCT02671188|Drug|Placebo|Normal saline (0.9% sodium chloride) will be used as placebo.
1539727|NCT02671175|Drug|dihydroartemisinin-piperaquine|Children in both arms will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
1539728|NCT02671175|Drug|dihydroartemisinin-piperaquine placebo|Children will receive standard in-hospital care for severe anaemia (blood transfusion, often combined with quinine or artesunate IV/IM). All children will then receive a 3-day course of AL (whether they initially had malaria or not), which will be started in-hospital as soon as they are able to take oral medication, and will be completed at home after discharge. At 2 weeks after enrolment surviving children will be randomized to receive either a standard 3-day courses of dihydroartemisinin-piperaquine (Eurartesim®, Sigma Tau, Italy) or an identical placebo regimen at 2, 6 and 10 weeks after enrolment.
1539729|NCT02671162|Drug|Wheat|3 times a day each time 2 capsules before eating meal for 8 weeks.
1539730|NCT02671162|Drug|Fumaria|3 times a day each time 2 capsules before eating meal for 8 weeks.
1539731|NCT02671149|Dietary Supplement|Water|Participants will receive two cups of 150ml plain water
1539734|NCT02671123|Procedure|Coronary PCI with OCT with Co Registration|Co-Registration is an online tool used to take measurements during a stent procedure ( PCI-percutaneous coronary intervention) as part of the OCT ( Optical Coherence Tomography intravascular system. Co Registration software may provide additional imaging details during stent implantation when using OCT.
1539735|NCT02671123|Procedure|Coronary PCI with OCT without Co Registration|Coronary PCI will be performed using OCT ( Optical Coherence Tomography intravascular system) guidance without the Co Registration software tool enabled.
1539736|NCT02671110|Behavioral|Transforming Your Life|See Transforming Your Life Arm
1539737|NCT02671110|Behavioral|Diabetes Prevention Program|See Diabetes Prevention Program Arm
1539738|NCT02671097|Drug|Rosuvastatin|5 mg tablet single dose on Day 01 in Period 1 and on Day 08 in Period 2.
1539739|NCT02671097|Drug|BAY1841788 (ODM-201)|600 mg single dose, administered as 2 x 300 mg tablets on Day 01 in Period 2; 600 mg BID multiple dose, administered as 2 x 300 mg tablets on Day 04 to Day 08 in Period 2.
1539740|NCT02671084|Drug|sevoflurane|
1539742|NCT02671058|Drug|Cortenema|Hydrocortisone Administered as a Liquid Enema
1540002|NCT02669030|Drug|Placebo|
1540003|NCT02669017|Drug|ADCT-402|intravenous infusion
1539743|NCT02671058|Drug|Hydrocortisone Acetate|Hydrocortisone Acetate Administered as a Suppository with the Sephure® Rectal Suppository Applicator
1539744|NCT02671045|Genetic|Genomic profile by FoundationOne|Proprietary comprehensive genomic profile.
1539745|NCT02671045|Genetic|Genomic profile by other methods|Genomic profiling by other testing methods.
1539746|NCT02671032|Device|Nucleus CI532 cochlear implant|
1539747|NCT02671019|Behavioral|Guide to better alcohol habits|A treatment for harmful alcohol use based on Motivational Interviewing, Cognitive Behavioral Treatment and Relapse prevention, focusing on: Motivation to change harmful alcohol use, defining a goal for the treatment, self-control strategies, risk situations, planning alternative behaviors and relapse prevention.
1539748|NCT02671006|Other|Basophil patterns|The Basophil patterns (CUBIC) will be compared between patients with urticaria and controls without Chronic Urticaria.
1539749|NCT02670993|Behavioral|Singing sessions.|Patients will be in singing work groups, and will participate to these sessions during 12 weeks, with one session per week of 2 hours.
1539750|NCT02670993|Behavioral|Painting sessions.|Patients will be in painting groups, they will participate to this work session during 12 weeks, with one session of 2 hours per week.
1539751|NCT02670980|Device|Intelligent Retinal Implant System|
1539752|NCT02670967|Dietary Supplement|Soluble Fibre|
1539753|NCT02670954|Drug|Dexmedetomidine, tramadol and flurbiprofen|
1539754|NCT02670954|Drug|tramadol and flurbiprofen|
1539759|NCT02670928|Behavioral|Lifestyle intervention|This study is aimed to achieve of long-term weight loss in T2DM patients by use of comprehensive lifestyle changes study, providing patients with structured diet, exercise plan, group behavioral support and group education. Additionally the study is designed to establish that reduction of the body weight leads to the improvement of glycemic and lipid metabolism, and can also reduce blood pressure level. The study is also directed to show that lifestyle changes study in T2DM patients can lead to decreasing of hospitalization rate and healthcare consumption. In order to demonstrate a change from standard of care, data will be collected from a parallel cohort from the same centers.
1539763|NCT02670902|Behavioral|Critical Time Intervention-Residential (CTI-R)|CTI-R is a 9-month, time-limited intervention that aims to produce an enduring impact by effectively linking individuals to both professional services (substance abuse and health and mental health providers) and social supports (e.g., family and friends) and by providing emotional and practical support. Participants in the CTI-R condition will also receive usual discharge services from the residential substance abuse treatment program.
1539764|NCT02670902|Behavioral|Enhanced Usual Discharge Services-Residential|The enhanced usual discharge condition encompasses the regular discharge services offered at the residential treatment program, as well as three telephone recovery check-up calls post-discharge.
1539765|NCT02670889|Drug|Acetohydroxamic Acid|
1539766|NCT02670889|Drug|Isotopic Intravenous [13C]-Urea|Used to trace 13CO2 and 13C-urea in the blood.
1539767|NCT02670876|Behavioral|Anti-bullying intervention|"The title of each session were as follows :
Introduction of intervention and setting rules, building rapport
Understanding school bullying (The definition of school bullying and proper coping strategies)
Empathy of others ( Practice of understanding victims of school bullying)
Impulse control 1 (Understanding my anger patterns, finding one's true feelings behind that anger)
Impulse control 2 (Finding irrational thoughts that lead to anger and correction of them)
Conflict management (Understanding one's pattern of dealing with conflicts, finding effective strategies)
Communication skills enhancement
Increasing self esteem"
1539768|NCT02670863|Other|Experimental Infant Formula|Standard bovine milk-based term infant formula supplemented with a prebiotic, fed ad libitum
1539769|NCT02670863|Other|Standard Infant Formula|Standard bovine milk-based term infant formula, fed ad libitum
1539770|NCT02670850|Other|Family Caregiver Intervention Program|Family Caregiver Intervention Program included three components: introduction of mild cognitive impairment, maintain and improve cognitive function, and health management.
1539771|NCT02670837|Device|Cellutome Epidermal Harvesting System|
1539772|NCT02670824|Drug|CN-105|Single and multiple intravenous (IV) doses of CN-105
1539773|NCT02670824|Drug|Placebo|Normal Saline
1539774|NCT02670811|Dietary Supplement|Fermented milk|150 mL daily of fermented milk with Lactococcus lactis NRRL-B50571
1539775|NCT02670811|Dietary Supplement|Acidified milk|150 mL daily of artificially acidified milk
1539776|NCT02670798|Procedure|Thromboelastography laboratory testing|Laboratory test that monitors clotting properties of blood
1539777|NCT02670785|Drug|Estradiol Vaginal Capsule (EVC)|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
1539778|NCT02670785|Drug|Placebo|Administered intravaginally once daily for 2 weeks and then once weekly for 4 weeks
1539779|NCT02670772|Drug|Stavudine|Stavudine 20mg twice daily for 96 weeks + Placebo 300mg once daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
1539780|NCT02670772|Drug|Tenofovir Disoproxil Fumarate|TDF 300mg once daily + Placebo 20mg twice daily for 96 weeks + Lamivudine 150mg twice daily for 96 weeks + Efavirenz 600mg once daily for 96 weeks
1539783|NCT02670733|Procedure|Positive end-expiratory pressure|Positive end-expiratory pressure will be applied at 5 cmH2O and 15 cmH2O
1539784|NCT02670720|Drug|avoralstat|
1539785|NCT02670707|Drug|Cytarabine|Cytarabine 100 mg/m^2/day IV for five consecutive days. This five-day cycle will be repeated every 21 days for a total of four cycles for all patients regardless of response. Each new cycle may not begin until absolute neutrophil count (ANC) is ≥ 750/mcL and platelet count is ≥ 75,000/mcL.
1539786|NCT02670707|Drug|Vinblastine/prednisone|"Vinblastine 6 mg/m^2/dose IV push weekly
Prednisone (or prednisolone) 20 mg/m2/dose by mouth twice a day"
1539787|NCT02670681|Behavioral|Aerobic Exercise Training|8 week of aerobic exercise training in different intensities.
1539788|NCT02670668|Other|Mutation analysis|
1539789|NCT02670655|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
1539790|NCT02670655|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
1539791|NCT02670655|Drug|MAL application|Immediately after AFL treatment, an approximately 1-mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue.
1539792|NCT02670655|Device|Iontophoresis application|In Group A, ionotophoresis was performed on MAL-applied sites. We used iontophoresis (vitaliont II®, ITC Inc, Korea) with a patch. The active electrode was the anode, and 0.50-mA/cm2 current was applied to each AK lesion for 10 min.
1539793|NCT02670655|Device|irradiation with red light-emitting diode lamp|After incubation for 2 (Group A and B) or 3 hours (Group C), the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
1539794|NCT02670642|Drug|Esomeprazole|Proton pump inhibitor
1539803|NCT02670603|Drug|EVONAIL® solution|
1539804|NCT02670590|Behavioral|diet|diet
1539805|NCT02670564|Genetic|Pharmacogenomics|"Blood samples (2x5ml EDTA tubes) should be collected just before the start of the conditioning regimen from every patient regardless of therapeutic arm by every centre and stored ≤-20°C Patient should be in remission (MRD negative) for this sampling, otherwise the sample should be taken using a mouth swab/saliva (not intravenously).
For second transplant patients, please provide DNA taken before first transplant or a fresh saliva samples."
1539806|NCT02670564|Other|Busulfan plasma level measurements|"Bu PK analysis after the first dose of IV Bu (+potential subsequent ones).
Blood sampling:
->For Bu 4 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 15 min (Time 2), 30 min (Time 3), 1 hour (Time 4) and 4 hour (Time 5) after the end of infusion
->For Bu 1 X/d: Before the first Bu dose (Time 0), then straight after the end of infusion (Time 1), then at 1 hour (Time 2), 3 hour (Time 3), 5 hour (Time 4), 7 hour (Time 5) and 11 hour (Time 6) after the end of infusion.
For centers not performing BU TDM, perform Dried Blood Sampling (DBS) analysis:
-> 0.5ml blood sample should be collected and 5µl spotted onto DBS cards in duplicate. Dry them max 5 hours and then keep in a sealed envelope and store at -80°C, as below"
1539807|NCT02670551|Drug|cariprazine|
1539808|NCT02670551|Drug|placebo|
1539809|NCT02670538|Drug|cariprazine|
1539810|NCT02670538|Drug|placebo|
1539811|NCT02670525|Genetic|Leukemia Profiling|Genetic profiling of leukemia cells will be performed and analyzed by an expert panel. Matched targeted therapy recommendation based on profiling results will be made if available. The recommendation, if available, will be communicated to the primary oncologist.
1539812|NCT02670512|Device|Telehome Monitoring|
1539813|NCT02670499|Device|CPM|Used to aid in recovery from TKR
1539814|NCT02670499|Device|GAPFLEX|Used to aid in the recovery of TKR
1539815|NCT02670486|Other|Audiovisual stimulus|Water fountain and a video (including scenes of some common triggers for OAB) played on continuous loop throughout the test on a laptop
1539816|NCT02670473|Device|fanfilcon A (test)|contact lens
1539817|NCT02670460|Device|LIVE Catheter|Placement of a temporary LIVE Catheter central venous pacing device in the left subclavian vein to pace the phrenic nerves and allow recruitment of the diaphragm muscle.
1539819|NCT02670434|Drug|NK-104-CR|NK-104-CR 8 mg daily for 52 weeks
1539820|NCT02670434|Drug|Placebo|Placebo daily for 12 weeks
1539821|NCT02670434|Drug|Livalo|Livalo® IR daily from week 12 to week 52
1539868|NCT02670070|Drug|gemigliptin 50mg, rosuvastatin 20mg|gemigliptin/rosuvastatin 50/20mg
1539869|NCT02670057|Procedure|Transnasal SPG block|
1539822|NCT02670421|Behavioral|Face to Face Heart SMART Program|The Heart SMART stress management program survey consists of Perceived Stress Scale (PSS), Brief Resilience Scale (BRS), Patient Health Questionnaire (PHQ - 9) and Generalized Anxiety Disorder (GAD - 7), followed by email communication every three weeks.
1539823|NCT02670421|Behavioral|On-line Heart SMART Program|The Heart SMART stress management program survey consists of PSS (Perceived Stress Scale), BRS (Brief Resilience Scale), PHQ-9 (Patient Health Questionnaire) and GAD-7 (Generalized Anxiety Disorder) taken on-line in twelve, 10 minutes sessions.
1539824|NCT02670421|Behavioral|Mayo Clinic Guide to Stress Free Living|All subjects will be provided with a copy of the book entitled Mayo Clinic Guide to Stress Free Living and encouraged to read it over the twelve week study period.
1539826|NCT02670395|Drug|JNJ-54416076|JNJ-54416076 suspension will be administered orally.
1539827|NCT02670395|Drug|Placebo|Placebo solution will be administered orally.
1539828|NCT02670382|Dietary Supplement|EPA|10 week supplementation
1539829|NCT02670382|Dietary Supplement|DHA|10 week supplementation
1539830|NCT02670382|Dietary Supplement|sunflower oil|10 week supplementation
1539832|NCT02670356|Dietary Supplement|Fish oil|two 750 mg/capsules/day
1539833|NCT02670356|Dietary Supplement|Krill oil|one 300 mg capsule/day
1539835|NCT02670330|Drug|Zorblisa (SD-101-6.0) cream|applied topically once a day to the entire body for 1440 days (48 months).
1539836|NCT02670317|Drug|Obinutuzumab|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
1539837|NCT02670317|Drug|Ibrutinib|Patients will receive a maximum of 6 courses of G-CHOP-21 followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
1539838|NCT02670317|Drug|CHOP|Patients will receive a maximum of 6 courses of CHOP-21 in combination with Obinutuzumab (G) followed by 2 doses of Obinutuzumab in combination with Ibrutinib.
1539841|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
1539842|NCT02670291|Device|MagPro Cool-B65A/P, Magventure|combined active and sham coil
1539843|NCT02670265|Dietary Supplement|Olimel Peri 2.5% ®|During hospital stay patients received 1 l Olimel peri 2.5 %® containing 700 kcal (25.3 g protein, 30.0 g fat and 75.0 g glucose) daily by intravenous route.
1539844|NCT02670265|Dietary Supplement|Isotonic fluid (E153)|Controls received 1l of isotonic fluid daily by intravenous route.
1539848|NCT02670239|Procedure|normothermic ex vivo lung perfusion|
1539850|NCT02670213|Drug|recombinant factor XIII|No treatment given.Patients will be treated according to routine clinical practice at the discretion of the treating physician.
1539851|NCT02670200|Behavioral|cognitive behavior therapy|treatment technique to help people to overcome psychological distress and mental diseases
1539852|NCT02670187|Biological|GLS-5300|
1539853|NCT02670174|Other|Traditional training|
1539854|NCT02670174|Other|Separate kinetic chain training|
1539855|NCT02670174|Other|Integrated kinetic chain training|
1539856|NCT02670161|Drug|Listed for each disorder below, up to three drugs per disorder (too many characters to list in this field; see Intervention Description)|brain tumors (lamotrigine, levetiracetam, valproic acid), epilepsy (lamotrigine, levetiracetam, valproic acid), mild cognitive impairment (donepezil, rivastigmine, memantine), migraine (amitriptyline, propranolol, topiramate), migraine (sumatriptan, rizatriptan, zolmitriptan), mild traumatic brain injury (omega-3 fatty acids, education only), multiple sclerosis (ACTH, methylprednisolone), neuropathy (duloxetine, pregabalin, amitryptiline), Parkinson's disease (pramipexole, ropinerole, rotigotine), restless legs syndrome (pramipexole, ropinerole, rotigotine), stroke (aspirin, clopidogrel).
1539857|NCT02670148|Procedure|Chiropractic manipulative therapy|We will set an a priori treatment schedule of 8 visits at a frequency of 2 visits per week over a 4 week period. CC participants will receive chiropractic manipulative therapy (CMT). CMT procedures can be broadly divided into two types, thrust and non-thrust. Thrust CMT is a high-velocity low-amplitude procedure characterized by a single, short duration thrust (ranging from 100 to 500 ms) of low amplitude force applied to a target joint that often results in an audible sound, or cavitation. Non-thrust CMT employs low-velocity and often repeated joint movements of varying amplitude. In the event that no CMT treatment is clinically indicated, treatment will not be provided.
1539858|NCT02670135|Drug|Triclosan Containing Toothpaste|Active formula containing 0.3% triclosan in a1450 ppm sodium fluoride/silica base
1539859|NCT02670135|Drug|Triclosan Free Toothpaste|Control toothpaste with no triclosan ingredients in a 1450 ppm sodium fluoride/silica base - matching placebo
1539860|NCT02670122|Device|DEB-TACE|Selective and ultraselective transcatheter intraarterial administration up to 3ml of well calibrated 100µ drug eluting microspheres with up to 150 mg of doxorubicin.
1539861|NCT02670109|Drug|Carmustine|300mg/m2, IV, in 3 hours, during day -4
1539862|NCT02670109|Drug|Cyclophosphamide|80mg/kg, IV, in 2 hours, during two days -2, -3
1539863|NCT02670109|Drug|Carboplatin|1400/m2, IV, in 1 hour, during day -3
1539864|NCT02670109|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Transfusion, in 3 hours, during day 0
1539865|NCT02670096|Drug|Acetazolamide|Two single dose administrations of acetazolamide (once before daytime testing, and once before nighttime testing)
1539873|NCT02670031|Other|Cardiovascular Magnetic Resonance|For the evaluation of left ventricular volumes, function and mass. This is also for the assessment of myocardial fibrosis based on delayed enhancement imaging technique.
1539874|NCT02670031|Other|Echocardiogram|For the assessment of diastolic and systolic function as well as valvular and cardiac function. Ventricular-arterial coupling will also be performed.
1539875|NCT02670031|Other|Electrocardiogram|To examine specific function of the heart.
1539876|NCT02670031|Device|Ambulatory Blood Pressure Monitoring|A 24-hour test.
1539877|NCT02670018|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg * 2 tablets, for 1 day
1539878|NCT02670018|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 25mg/metformin HCl extended release 1000mg * 2 tablets, for 1day
1539879|NCT02669992|Procedure|Stapled or Hand-sewn anastomosis|Randomization between stapled or hand-sewn anastomosis
1539880|NCT02669992|Procedure|Mesh or suture stoma site closure|Randomization between suture or Mesh closure of the stoma site
1539881|NCT02669979|Other|Intervention|Professional oral care
1539882|NCT02669966|Procedure|Kidney transplantation|Once the donor and recipient candidates have met inclusion criteria and cleared study-specific as well as standard of care screening, they will proceed to live-donor kidney transplantation and subsequent post-transplant monitoring
1539883|NCT02669953|Drug|Aflibercept|
1539884|NCT02669940|Drug|ABBVIE REGIMEN ± RBV|tablet
1539885|NCT02669927|Other|Observational|
1539886|NCT02669914|Drug|MEDI4736|
1539887|NCT02669901|Behavioral|Naloxone Auto-Injector|Naloxone auto-injector is the only product FDA approved and labeled for use by family members or caregivers for emergency therapy and rescue wherever opioids are present. Bystanders of patient are able to provide naloxone when drug overdose occurs.
1539888|NCT02669888|Drug|Indigo naturalis ointment|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
1539889|NCT02669888|Drug|Placebo|Every 10 x 10 cm area of lesion requires 0.5 g of ointment, applied twice daily (morning and evening, separated by approximately 12±2 hours) for 6 weeks.
1539890|NCT02669875|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
1539891|NCT02669875|Drug|Placebo|Placebo solution (20mM sodium acetate pH5) diluted in 5% v/v glucose solution
1539892|NCT02669862|Drug|A-101 Solution 40|
1539893|NCT02669862|Drug|A-101 Solution 45|
1539894|NCT02669862|Drug|Vehicle Solution|
1539897|NCT02669836|Procedure|Posterior fossa decompression|Planned areas of bone removal from the suboccipital region of the skull and cervical l1 lamina. Then, the constricting epidural band at the level of the foramen magnum is resected.
1539898|NCT02669836|Procedure|Dural Augmentation|The dura is opened sharply, exposing the cerebellar tonsils, brainstem, and upper spinal cord. After microsurgical dissection, the dura is sewn closed with a dural graft.
1539899|NCT02669823|Other|None, treatment as actual best practice|
1539900|NCT02669810|Drug|PROTHERACYTES|ProtheraCytes endocardiac injections performed with the HELIX and Morph catheters
1539901|NCT02669810|Device|Standard of Care (Percutaneous Transluminal Coronary Angioplasty and stent(s) implantation)|
1539904|NCT02669784|Drug|Contrast (Omnipaque)|The patient will be administered a low dose of intravenous contrast (Omnipaque) based on the area of the body being scanned (chest versus chest and abdomen versus chest, abdomen and pelvis). This will be compared to the patient's prior examination performed with 100 mL of intravenous contrast.
1539905|NCT02669771|Drug|enzalutamide|oral
1539906|NCT02669758|Drug|ALKS 3831|Daily dosing
1539907|NCT02669732|Drug|DS-8500a|tablets
1539908|NCT02669732|Drug|placebo|tablets
1539909|NCT02669719|Biological|chemotherapy followed dendritic cells|Pemetrexed and carboplatin would be administered on day 1 of each 3-week cycle.Patients will start with dendritic cells treatment on Day 15 of pemetrexed and carboplatin chemotherapy from Cycle 3 provided that both leukapheresis and the production of dendritic cells are successful.
1539910|NCT02669719|Drug|pemetrexed and carboplatin|Chemotherapy with 4-6 cycles of pemetrexed and carboplatin as first-line induction chemotherapy followed by pemetrexed as maintenance therapy.
1539911|NCT02669706|Drug|Pentamidine|Pentamidine is an antimicrobial medication given for prevention and treatment of Pneumocystis pneumonia (PJP) caused by Pneumocystis jirovecii
1539914|NCT02669680|Drug|G-CSF|G-CSF subcutaneously, 5 μg/kg daily on day 0-4, then every 3rd day over 26 days (days 7, 10, 13, 16, 19, 22, 25) = 12 doses
1539915|NCT02669680|Other|Standard therapy|
1539916|NCT02669667|Drug|MEDI9314|single dose of MEDI9314
1539917|NCT02669667|Drug|placebo|single dose of placebo
1539918|NCT02669654|Other|Day-care management of Severe Pneumonia|Day-care management of Severe Pneumonia
1539919|NCT02669641|Dietary Supplement|Combination Silimarin, Phyllanthus niruri and Choline|Combination of one capsule: Phyllanthus niruri (225 mg), Silybum marianum (150 mg), Choline (60 mg) The dose: 3 capsules per day.
1539920|NCT02669628|Procedure|Surgical technique|Laparoscopic surgery
1539921|NCT02669628|Procedure|Alcohol sclerotherapy|US-guided sclerotherapy
1539922|NCT02669615|Drug|Melphalan HCl for injection (propylene glycol free)|During the study period, patients will receive 200 mg/m2 of Melphalan HCl for injection (propylene glycol free) as a one-time infusion on day 2.
1539923|NCT02669589|Drug|Heparin|
1539924|NCT02669589|Drug|Citrate|
1539927|NCT02669563|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
1539928|NCT02669563|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
1539929|NCT02669563|Drug|[13N]ammonia|IV injection of [13N]ammonia
1539930|NCT02669563|Drug|[11C]HED|IV injection of [11C]HED
1539931|NCT02669550|Device|Fiberoptic bronchoscope|In case of FOB, the FOB was inserted into oral cavity, and the epiglottis and glottis were identified by the FOB. The anterior of FOB was inserted deep into tracheal after the glottis was exposed sufficiently then the tracheal tube was pushed into the trachea via the FOB
1539932|NCT02669550|Device|Disposcope endoscope|In the DE group, the operator gripped the chin and lower incisors of patients with the fingers and thumb to open the mouth adequately wide and grasped the wire body, which was enclosed within the endotracheal tube, by the other hand and held it parallel to,then inserted into oral cavity
1539933|NCT02669537|Device|GoPro Camera|The gopro camera will be used to record the procedure which will be reviewed by the resident prior to performing a second procedure of the same type.
1539934|NCT02669524|Drug|LY2409021|
1539935|NCT02669524|Drug|LY2409021 placebo|
1539936|NCT02669524|Procedure|OGTT|
1539937|NCT02669524|Procedure|IIGI|
1539938|NCT02669524|Procedure|Standardised liquid meal|
1539939|NCT02669511|Drug|PQR309|Oral PQR309, 80mg or 60mg daily or intermittent dosing
1539940|NCT02669498|Procedure|Routine fallopian tube removal|Fallopian tubes are removed by dissection of the Mesosalpinx.
1539941|NCT02669485|Drug|indocyanine green|Injection of indocyanine green and using fluorescence imaging to assess perfusion of bowel before bowel transection and anastomosis
1539942|NCT02669485|Device|Fluorescence imaging|
1539943|NCT02669472|Other|Environmental Intervention|Intervention sites received regularly-scheduled, discount, fresh F&V markets for one year during the first two weeks of each month. The markets brought between 50-70 different produce items, including culturally desired ethnic produce. Markets at the senior and disabled housing complexes were held indoors as were markets at family housing complexes during inclement weather. In good weather, markets were held outside at the family complexes using a mobile retrofitted car trailer. The produce items were set up in racks on three sides of the trailer and shoppers entered through the rear door. FTY markets accepted cash, debit/credit cards and EBT cards (SNAP). Each market lasted two hours and the produce was sold at prices 15%-25% lower than local retail supermarket prices.
1539944|NCT02669472|Behavioral|Educational Intervention|Each household in the housing site received a reusable shopping bag that contained a binder with: an overview page, sleeves to store 12 newsletters, three DVDs and 48 recipe cards. The 20-minute DVDs included cooking demonstrations, tips and testimonials. A two-page, full-color newsletter was delivered each household each month. It had information about a particular F&V in season as well as other tips and recipes. Two 6-week long educational and motivational campaigns were also offered: ''Just Add 2', and 'Color Your Plate'. Both campaigns included full-color campaign booklets, goal-setting activities, educational and motivational content, and F&V trackers with incentives/prizes for completing and turning in the trackers. All materials were provided in English and Spanish.
1539945|NCT02669472|Behavioral|Control|We contracted with the Greater Providence YMCA to bring to provide physical activity and stress reduction programming. Two, six-week campaigns followed the same format and timing of the intervention group campaigns. Campaigns participants received a free, 6-week membership to the YMCA. The 'Take 10!' campaign aimed to increase participants' daily physical activity by 10 minutes per day until they reached the goal of at least 30-60 minutes per day. The second campaign was 'Stress Less' aimed to help participants reduce the amount of stress that they experienced by including relaxation activity into their daily routine.
1539946|NCT02669459|Drug|Imiquimod|12,5 mg imiquimod three times per week during 16 weeks
1539947|NCT02669459|Procedure|LLETZ|surgical treatment for CIN, current gold standard
1539948|NCT02669446|Device|Medical devices|
1539949|NCT02669446|Device|traditional household remedy|
1539950|NCT02669433|Drug|RVT-101 35 mg|once daily, oral, 35-mg tablets
1539951|NCT02669433|Drug|RVT-101 70 mg|once daily, oral, 35-mg tablets
1539952|NCT02669433|Drug|Placebo|once daily, oral, matching tablets
1539953|NCT02669420|Procedure|termination of second trimester pregnancy|Intra uterine extra amniotic (200 μg ) versus Vaginal (200 μg) Misoprostol for Second Trimester Pregnancy Termination. Randomized controlled trial
1539954|NCT02669407|Procedure|splanchnic nerve anesthesia with a local anesthetic|regional nerve block of the splanchnic nerve
1539955|NCT02669407|Drug|regional nerve block with a local anesthetic (Lidocaine)|
1539956|NCT02669394|Behavioral|Resistance exercise training|Twelve months of twice-weekly resistance training program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
1540004|NCT02669004|Drug|Intermittent bolus epidural morphine|morphine given with patient- controlled intermittent bolus epidural, 50 µg/kg in 10 mL bolus, lockout time 1 hour, no infusion
1539957|NCT02669394|Behavioral|Control: stretching and relaxation program|Twelve months of twice-weekly stretching and relaxation program that includes stretches, deep breathing and relaxation techniques, general core control exercises, and general posture and health education. Each session will be 60 minutes.
1539959|NCT02669368|Drug|Magnesium Sulfate|Patients in each group receive Magnesium sulfate 30 mg/kg in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
1539960|NCT02669368|Drug|Saline|Patients in each group receive 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
1539961|NCT02669368|Drug|Standard dose Rocuronium|0.6 mg/kg of Rocuronium given with induction of anesthesia
1539962|NCT02669368|Drug|Low dose Rocuronium|0.45 mg/kg of Rocuronium given with induction of anesthesia
1539963|NCT02669342|Device|Radiance™ Clear Sharklet® Silicone Foley Catheter|
1539964|NCT02669342|Device|Silicone Foley Catheter|
1539965|NCT02669329|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
1539966|NCT02669303|Drug|platelet-rich plasma group|"Once randomized to platelet-rich plasma arm, the study subject will have 30cc of blood drawn and centrifuged using the Recover(TM) Platelet Separation Kit (Biomet Biologics, Warsaw, Indiana, USA). The extracted platelet-rich plasma part will be re-injected into the subacromial space of the subject's affected shoulder."
1539967|NCT02669303|Drug|Methylprednisolone group|Once randomized to Methylprednisolone arm, the study subject will have an injection with 2ml of Methylprednisolone (40mg/ml methylprednisolone acetate injectable suspension) (Pharmacia Upjohn, Kalamazoo, Michigan, USA) with 2ml of lidocaine hydrochloride 2% (Hameln Pharmaceuticals Ltd, Gloucester, UK) into the subacromial space of their affected shoulder.
1539968|NCT02669290|Other|Guided|LV lead placement will be guided by left ventricular systolic function information from MUGA
1539969|NCT02669290|Other|Non-guided|LV lead placement will be conventional posterolateral placement
1539970|NCT02669277|Drug|IVIG prepared by minipool technology|Drug: To demonstrate the efficacy of new product IVIG prepared by minipool technology as assessed by Bleeding Score and platelet count at 3 days, 1 week, 2 weeks and 4 weeks.
1539971|NCT02669277|Drug|standard IVIG product|to compare efficacy and safety with the minipool IVIG
1539972|NCT02669264|Drug|ADCT-402|intravenous infusion
1539974|NCT02669238|Device|Nexplanon®|Subcutaneous implant (Nexplanon®) containing etonogestrel 68 mg
1539975|NCT02669238|Drug|Minidril®/Leeloo®|continuous per os administration of oestroprogestative treatment. 1 pill a day First line: Minidril® (Levonogestrel 0.15 mg / Ethinylestradiol 0.03 mg) Second line: Leeloo® (Levonogestrel 0.1 mg / Ethinylestradiol 0.02 mg)
1539977|NCT02669199|Biological|MSCs|The main purpose of this test is to assess the umbilical cord MSCs between source sample sweat gland cells wound transplanted effectiveness and safety for the treatment of large area skin lesions of the subjects
1539978|NCT02669186|Drug|Bupivacaine + Fentanyl|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain fentanyl + bupivacaine titrated to appropriate surgical conditions and post-operative pain control.
1539979|NCT02669186|Drug|Bupivacaine|General endotracheal anesthesia augmented with an epidural. The epidural solution intraoperatively and post-operatively will contain bupivacaine titrated to appropriate surgical conditions and post-operative pain control
1539980|NCT02669173|Drug|Capecitabine|Drug given orally. Dose to be determined by phase 1 dose escalation, cycle length 28 days. Treatment until progression
1539981|NCT02669173|Drug|Bevacizumab|Drug given by IV, 10 mg/kg days 1, 15 every 28 days, until progression.
1539982|NCT02669160|Device|PC Innowalk|
1539983|NCT02669160|Device|Conventional passive stander|
1539984|NCT02669134|Other|Device programming|"SonRtip bipolar atrial lead and LivaNova (Sorin) CRT-D implantation with device programming: SonR CRT Optimization programmed AV+VV"
1539985|NCT02669121|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|NoV: 15 µg of GI.1 norovirus VLP and 50 µg GII.4 norovirus VLP, adjuvanted with 500 µg aluminum as Al(OH)3, administered as 0.5 mL intramuscularly (IM)
1539986|NCT02669121|Biological|NoV vaccine placebo|NoV vaccine placebo-matching solution [saline (0.9% sodium chloride)] administered as 0.5 mL intramuscularly (IM)
1539987|NCT02669108|Device|PET/ MRI of the Testis|PET/MRI of the testis will be performed upon the patient achieving azoospermia (following the vasectomy), or 25 ejaculations and following proven azoospermia (via standard of care semen analysis).
1539988|NCT02669095|Device|Investigational Contact Lenses (Test)|
1539989|NCT02669095|Device|Marketed Contact Lenses (Control)|
1539990|NCT02669082|Drug|Ramelteon|Ramelteon tablets
1539991|NCT02669069|Device|PS1|Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are synchronous with the tones.
1539992|NCT02669069|Device|PS2|Participants in this arm shall be given an audio stimulus which comprises of a sequence of tones, mixed with a broadband noise that is spectrally modified to compensate for any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
1539993|NCT02669069|Device|PS3|Participants in this arm shall be given an audio stimulus which comprises of a sequence of single-frequency tones mixed with a broadband noise with the frequency characteristics of both chosen outside the region of any hearing loss. Electrical pulses in the somatosensory stimulation are uncorrelated and asynchronous with the tones.
1539994|NCT02669056|Other|5-HT measurement|
1539995|NCT02669056|Other|cerebral MRI|
1539996|NCT02669056|Other|Video recording|
1539997|NCT02669056|Other|EEG|
1539998|NCT02669056|Other|growth curves|
1539999|NCT02669056|Other|ASQ questionnaire|
1540005|NCT02669004|Drug|continuous epidural morphine|morphine given with patient- controlled continuous epidural, initial setting loading morphine 0.02mg/kg in 8mL, was maintained 0.01 mg/kg continuous infusion 4mL, 0.05 mg/kg 2mL bolus dose. 30 minute lock-out interval. 4 hour limit was 4 mg/kg.
1540006|NCT02668978|Device|Hemopatch™ Sealing Hemostat|Hemopatch™ application over lung resection areas
1540007|NCT02668978|Procedure|Standard surgical technique|Lung resuturing or restapling
1540008|NCT02668965|Procedure|Intrauterine hCG (pregnyl)|
1540009|NCT02668952|Drug|0.9% Normal Saline (0.9% Sodium Chloride) injection|
1540010|NCT02668952|Drug|Isolyte S injection|
1540011|NCT02668926|Drug|Lisdexamfetamine, d-amphetamine, Placebo|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
1540012|NCT02668926|Drug|d-amphetamine, Placebo, Lisdexamfetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
1540013|NCT02668926|Drug|Placebo, Lisdexamfetamine, d-amphetamine|Elvanse (Lisdexamfetamine): 100mg p.o, single dose; d-Amphetamine: 40.3mg p.o, single dose; Placebo: Capsules containing mannitol looking identical to lisdexamphetamine and d-Amphetamine.
1540014|NCT02668913|Other|Diagnostic analysis|Molecular profiling
1540015|NCT02668900|Behavioral|Decision Support|The decision support intervention includes a patient decision and a decision coaching session. The patient decision aid includes a summary about the ICD's function, and the risks and benefits (including probabilities) associated with the option of replacing or not replacing the ICD. The decision coaching session will be led by a trained, non-directive decision coach who will provide support that aims to develop patients' skills in thinking about the options, assess their values associated with each option, and prepare them to discuss the decision in a consultation with their physician. The final decision, whether to replace or not replace the ICD, will be made with their treating physician (e.g., cardiologist, electrophysiologist).
1540016|NCT02668887|Behavioral|Quality of Life, status of employment|
1540017|NCT02668874|Other|Isolite® technique|The Isolite technique utilizes a flexible plastic dental adapter to separate the cheek and tongue prior to sealant application.
1540018|NCT02668874|Other|Cotton Roll technique|A cotton roll is placed between the cheek and tongue prior to sealant application
1540019|NCT02668861|Drug|Vitamin D|Vitamin D 4000IU/day for 8 weeks
1540020|NCT02668861|Drug|Budesonide Nasal Spray|Budesonide Nasal Spray 128ug/d for 8 week
1540021|NCT02668861|Other|placebo|placebo for 8 weeks
1540022|NCT02668848|Dietary Supplement|water|If USG>1.02, patients will be advised to drink water via oral or tubal feeding with a dose of 5cc/kg body weight , maximum 300cc, and repeat the same amount of water after dinner in the same day.
1540023|NCT02668835|Device|Non intervention-Monitoring device|Fox Insight self-monitoring android app and smartwatch Participants will be asked to wear a smartwatch with accelerometers, during day and night, for a period of 2 weeks. Additionally, a self-monitoring app on a smartphone is used, where the participant reports when they take any medication and performs a focused attention task to encourage resting tremor.
1540024|NCT02668835|Genetic|Non intervention-Genetic testing|
1540028|NCT02668809|Other|oral health assessment|A baseline oral health assessment of both residents and direct care workers will be conducted before interventions are initiated. Data will be entered directly into a spreadsheet format using the chairside software program to be developed as part of this proposal.
1540029|NCT02668809|Other|Questionnaires|Age, sex, race, nutrition (mini-nutri), quality of life (SF-36), OHIP-14, GOHAI, sources of payment for the NF residency, comorbid conditions (e.g., constipation, arthritis), weight, medications, cognitive status (mini-mental) , dry mouth sensation, x-ray documented pneumonia;
1540030|NCT02668809|Other|Clinical Exam|Dentate status, dental/denture plaque index, DMFS (including root surfaces), gingival bleeding index, plaque index, presence of oral lesions, verification of mouth dryness;
1540031|NCT02668809|Other|Microbiological sampling|Samples will be collected by swabbing patients intra-oral tissues. Samples will be separately collected from dentures and oral tissues for edentulous patients, also using swabs. All samples will be suspended in saline solution.
1540032|NCT02668809|Other|Monitoring Adherence|Adherence to the protocol will be evaluated through unannounced observations at the NF by study personnel twice per month. Adherence is determined by direct observation of the DCW administering the intervention.
1540033|NCT02668809|Other|Varnish application|"1% chlorhexidine varnish application group will receive the educational program described above. In addition, residents who need supervision or are unable to perform oral hygiene procedures will receive 1% chlorhexidine varnish application monthly by the dental hygienist. No additional time commitment will be necessary.The direct care workers will NOT receive any varnish."
1540034|NCT02668809|Other|Consent|Both the residents and primary care workers will be asked to participate on the study, and the investigators will provide information and collect signed informed consents primarily during two in person visits to each nursing facilities.
1540035|NCT02668809|Other|Educational Program|Cognitively capable residents will receive instruction on how to perform their own oral hygiene accordingly to their own needs; and 2) Direct care workers will receive instruction on how to perform oral hygiene for dependent residents or supervise the oral hygiene routines of independent patients. For both 1) and 2) above, dental hygienists will provide a short, standardized presentation and hands-on demonstration.
1540036|NCT02668796|Drug|Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
1540037|NCT02668796|Drug|Vagifem® (Estradiol Vaginal Tablets) 10 mcg (Novo Nordisk)|apply using the given applicator
1540038|NCT02668796|Drug|Placebo of Estradiol Vaginal Tablets 10 mcg (Glenmark)|apply using the given applicator
1540044|NCT02668757|Behavioral|HeartHab application intervention|The intervention patients will use the HeartHab application on a smartphone. During the study, the patients will use the HeartHab application for 4-6 weeks.
1540045|NCT02668744|Behavioral|Intervention|The intervention consists of building edible gardens at each the eight participating and eligible schools. Educators will be provided to lead 18 gardening, nutrition and cooking lessons throughout the school year intervention to all 3-5th grade students. Nine gardening, nutrition, and cooking classes will be taught to parents every month. Garden Leadership Coalitions (GLCs), made up of parents, teachers and school staff, will be formed and training/resources provided to help with adoption of the program. Training and resources will be provided to the GLCs and teachers in the 2nd year to assist with sustainability.
1540046|NCT02668718|Radiation|Adjuvant radiotherapy|The radiation therapy will be given in 37 fractions of 1.8 Gy per day, five days per week. The total dose of radiation will be 66.6 Gy.
1540047|NCT02668705|Other|Embodied Conversational Agent|A computer generated character that can administer informed consent to a potential research subject.
1540050|NCT02668679|Procedure|Sedation of children during gastroscopy with and without the presence of dream doctor|children and their parents with and without the presence of DD upon arrival to the Gastroenterology institute and throughout the induction of sedation, gastroscopy and recovery.
1540051|NCT02668679|Device|evaluation of stress with PPI and GSR|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of PPI and GSR
1540052|NCT02668679|Biological|blood specimens for stress hormones|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of stress hormones.
1540053|NCT02668679|Other|Physiological indices for evaluation of stress|evaluation of stress in children undergoing gastroscopy with sedation with and without the presence of a dream doctor by measurement of blood pressure, pulse, saturation and body temperature.
1540054|NCT02668666|Drug|Palbociclib|Palbociclib 125 mg will be administered orally once daily on days D1-D21 of each 28-day cycle. Subjects will not take palbociclib on D22-D28.
1540055|NCT02668666|Drug|Tamoxifen|Tamoxifen 20 mg will be administered orally once daily for every day of the 28-day cycle (i.e., continuously).
1540056|NCT02668653|Drug|Chemotherapy|
1540057|NCT02668653|Drug|Quizartinib|
1540058|NCT02668653|Drug|Placebo|
1540059|NCT02668627|Procedure|Endovascular treatment|Endovascular mechanical thrombectomy or endovascular delivery of thrombolytic agent
1540060|NCT02668614|Device|WR-22 model microwave sensor|
1540061|NCT02668588|Drug|extended release of octreotide|1 intramuscular injection of extended release of octreotide 30 mg
1540062|NCT02668588|Drug|extended release of placebo|1 intramuscular injection of extended release of placebo
1540063|NCT02668575|Behavioral|Supportive Care Intervention|Patients in the intervention arm of the study will see a SC specialist during regularly-scheduled CF clinic visits; per usual care, these visits should occur on a quarterly basis. Using a structured intervention manual, these visits will span 30-60 minutes each. Each visit will have a specific focus, such as: 1) comprehensive palliative care assessment; 2) symptom assessment and self-management; 3) advance care planning; and, 4) coping and resilience. Patients requiring follow up with SC before the next CF appointment will receive telephone follow up or an extra SC visit at the discretion of the SC provider.
1540064|NCT02668562|Procedure|Early CABG (Day 2-3 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
1540065|NCT02668562|Procedure|Delayed CABG (Day 5-7 after ticagrelor discontinuation)|Timing for CABG after ticagrelor discontinuation
1540066|NCT02668549|Other|DB review for Doctor/Pharmacy Shopping Behavior|Database review to evaluate of doctor/pharmacy shopping behaviors
1540067|NCT02668536|Drug|Standard Sunscreen|Areas will be treated with a standard preparation, consisting of padimate O (7%) and oxybenzone (3%) will be used as the control sunscreen.
1540068|NCT02668536|Device|BNP|Additional areas will be treated with empty bioadhesive nanoparticles (BNPs).
1540069|NCT02668523|Device|Raindrop Near Vision Inlay|To improve the near and intermediate vision in subjects who have previously undergone cataract surgery (pseudophakic subjects)
1540070|NCT02668510|Biological|platelet rich plasma|immediately following shockwave therapy the injection of PRP derived from subjects own blood using Arthex double syringe system will be injected at the origin of the plantar fascia at the calcaneous
1540071|NCT02668510|Drug|Normal saline|placebo injection of normal saline immediately following shockwave therapy
1540072|NCT02668497|Drug|Botulinum Toxin Type A|
1540073|NCT02668484|Device|repositionable valve prosthesis|repositionable valve prosthesis implanted via trans-femoral and trans-catheter route
1540074|NCT02668484|Device|balloon-expandable valve prosthesis|balloon-expandable valve prosthesis implanted via trans-femoral and trans-catheter route
1540075|NCT02668471|Procedure|Ultrasound|ultrasound at radial site and measure the size and depth of radial artery and perform radial artery cannulation
1540076|NCT02668471|Procedure|traditional method|Radial artery catheters will be placed by the palpation technique only.
1540079|NCT02668445|Other|Standard meal containing low or high carbohydrate content|
1540080|NCT02668432|Drug|Amiodarone|Patients will receive a 150 mg IV bolus amiodarone dose, followed by a 1 mg/min continuous infusion for six hours, then 0.5 mg/min. Conversion to PO amiodarone will be based on patient hemodynamic stability and physician/pharmacist discretion. The total loading dose will be calculated based on all IV and PO amiodarone administered within 7 days from initiation of amiodarone. All doses will be compared in total PO equivalents (accounting for 50% bioavailability of PO vs IV amiodarone). Randomization may be overridden by the attending or fellow physician if the patient's severity of illness warrants. Discontinuation of amiodarone in the full-load group will be at the discretion of the physician/pharmacists, after the pre-determined randomization loading dose has been provided.
1540081|NCT02668419|Device|Neuromuscular Electrical Stimulator|"Quadriceps and calf muscles of both legs were simultaneously stimulated using self adhesive surface rectangular electrodes. During all session period, the patients were maintained in the supine Fowler 45º position. Stimulation parameters were set up as follows: biphasic current of 40 Hz, 400-µs pulse duration, mode on-time 10s and off-time 20s and maximal amplitude of 60 mA. The stimulation intensity was progressively increased according to the patient tolerance until a muscular contraction was observed. Stimulation was performed twice a day; the session duration was 60 min."
1540082|NCT02668419|Other|Physical Therapy Session|each session consisted of breathing exercises and global active exercises of the upper and lower limbs in bed. The treatment was applied twice a day during the hospitalization period. The protocol was interrupted if the patient had signs or symptoms suggestive of poor tolerance to exercise: 1) cyanosis, pallor, dizziness, nausea or pre-syncope; 2) chest pain; 3) bradycardia; 4) a drop in systolic blood pressure >15 mmHg in comparison to baseline; 5) an excessive rise in systolic blood pressure defined as >200 mmHg; 6) a rise in diastolic blood pressure during exercise >110 mmHg; 7) fatigue rated ≥6/10 on the perceived exertion Borg scale (PEB); and/or 8) electrocardiographic signs of cardiac ischemia or ventricular arrhythmias.
1540083|NCT02668406|Other|Venous blood sampling (2 timepoints) (Phase A and B)|8.5ml at Day 1 + 8.5ml at Day 5
1540084|NCT02668406|Other|Venous blood sampling (1 timepoint) (Phase A and B)|8.5ml at Day 1
1540085|NCT02668406|Other|Voided urine sampling (first sample) (Phase A)|At least 20ml upon confirmation of being part of one of the 3 study groups
1540086|NCT02668406|Other|Voided urine sampling (second sample) (Phase A)|At least 20ml during routine hospital stay or routine follow-up visit
1540087|NCT02668393|Drug|Docetaxel|
1540088|NCT02668393|Drug|Nintedanib|Low Dose
1540089|NCT02668393|Drug|Nintedanib|Medium dose
1540090|NCT02668393|Drug|Nintedanib|High dose
1540091|NCT02668393|Drug|Nintedanib|Continuous high dose
1540092|NCT02668367|Drug|BTA-C585 oral capsules|BTA-C585; Multiple ascending doses from 100 mg to 600 mg
1540093|NCT02668367|Drug|BTA-C585 matching placebo|Multiple ascending doses to match 100 mg to 600 mg BTA-C585 capsules
1540095|NCT02668328|Behavioral|Social Cognitive Theory Tailored Behavioral Intervention|The intervention will enhance self-efficacy
1540096|NCT02668315|Biological|Transplantation of cord blood expanded with UM171|Myeloablative or submyeloablative conditioning regimen followed by an expanded cord blood transplant
1540097|NCT02668302|Device|Steroid-releasing sinus implant|PROPEL (Intersect ENT, Menlo Park, CA) containing 370μg of mometasone furoate designed for gradual release over 30 days
1540098|NCT02668302|Other|Post-op standard of care|post-op standard of care including debridement, irrigation, and/or topical steroids
1540099|NCT02668289|Other|consent|At the initial screening examination, each subject will receive an informed consent form. Prior to signing the informed consent, one of the investigators or qualified staff will thoroughly discuss participation in the study with each subject, allocating time for questions and answers.
1540100|NCT02668289|Other|Screening|At the initial screening examination, complete medical and dental history will be obtained to verify eligibility.
1540101|NCT02668289|Other|Xray|each subject will undergo site-specific oral radiographic exam (new periapical radiographs will be obtained if needed) to evaluate potential study sites.
1540102|NCT02668289|Other|PVS Impressions|PVS impressions of the arch of interest will be obtained in order perform volumetric analysis of the area of interest.
1540103|NCT02668289|Other|Photographs|Intraoral photographs will also be taken and subsequent study visits will be planned.
1540104|NCT02668289|Other|CBCT|The patient will then be sent to the Department of Radiology at the College of Dentistry for a baseline CBCT and follow-up at 14 week CBCT. These CBCT's will be utilized to evaluate the hard tissue volume in comparison to the clinical volume of soft tissue.
1540105|NCT02668289|Other|Anesthesia|After appropriate local anesthetic is administered and anesthesia is achieved, the buccal tissue thickness will be measured and recorded.
1540106|NCT02668289|Procedure|Extraction|After the pre-extraction baseline measurements are recorded and adequate anesthesia is confirmed, minimally invasive extraction procedures will be initiated. All extractions will be performed by residents in the UI CoD Periodontics advanced education program.
1540107|NCT02668289|Other|Clinical measurements|Measuring soft tissue dimensions, bone thickness prior to and immediately after extraction and then after appropriate healing time frames.
1540108|NCT02668276|Other|Standard NCCN counseling|
1540109|NCT02668276|Other|Standard NCCN counseling and Oncotype DX results|
1540110|NCT02668263|Procedure|Surgery alone|Surgery
1540111|NCT02668263|Procedure|Surgery and Drain(s)|Drains inserted as per standard practice
1540112|NCT02668263|Procedure|Surgery and Quilting Sutures|Quilting sutures to mastectomy flaps
1540117|NCT02668224|Device|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
1540118|NCT02668224|Other|Usual activities|The patients will perform their usual activities, to allow the comparison with a vibration programme. They will not have a specific training.
1540119|NCT02668211|Device|PROFEMUR Preserve Classic Femoral Components|
1540120|NCT02668198|Device|Olympus CF190 Colonoscope High definition white light|Standard endoscopic imaging technique
1540121|NCT02668198|Device|Olympus CF190 Colonoscope White light with near focus|Near focus mode is used to closely examine the area of prior EMR site.
1540122|NCT02668198|Device|Olympus CF190 Colonoscope Narrow band imaging|Narrow band imaging is utilized to examine the area of prior EMR.
1540123|NCT02668198|Device|Olympus CF190 Colonoscope Narrow band imaging with near focus|NBI with near focus to help closely examine for any residual polyp at the prior site of resection.
1540124|NCT02668185|Drug|NK3R antagonist - AZD4901|Neurokinin 3 receptor antagonist
1540125|NCT02668185|Drug|Placebo|Placebo
1540126|NCT02668172|Drug|Pasireotide LAR 60 mg|as mono-therapy or in combination with pegvisomant
1540127|NCT02668172|Drug|Pegvisomant|only in combination with pasireotide LAR
1540128|NCT02668159|Dietary Supplement|Fish peptide supplement|6 capsules of fish peptide supplement (3g/each) administered prior to one of the OGTT
1540129|NCT02668159|Dietary Supplement|Vitamin D supplement|1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
1540130|NCT02668159|Dietary Supplement|Fish peptide + Vitamin D3 supplements|6 capsules of fish peptide (3g/each) + 1 tablet of vitamin D3 (1000 UI) administered prior to one of the OGTT
1540131|NCT02668159|Dietary Supplement|Placebo|7 tablets of placebos administered prior to one the OGTT
1540132|NCT02668146|Drug|Perampanel|Study drug will be administered to study subjects
1540133|NCT02668146|Drug|Placebo|Placebo will be administered to study subjects
1540134|NCT02668133|Dietary Supplement|the nutritional supplement to be used in this trial is a SQ-LNS|Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day
1540135|NCT02668133|Dietary Supplement|lipid-based nutrient supplement (SQ-LNS) with phytase|• Small quantity lipid nutrient supplement (SQ-LNS) containing 6 mg iron and 8 mg zinc per 20 g sachet (per day). Exogenous phytase (projected concentration ~500 FTU/20 g SQ-LNS) added during manufacturing
1540136|NCT02668133|Dietary Supplement|0.9 mg isotopically enriched 67Zn,0.30 mg isotopically enriched 70Zn, 0.60 mg non-enriched zinc|delivered orally in sugar solution
1540137|NCT02668133|Dietary Supplement|1 mg isotopically enriched 68Zn|administered intravenously
1540138|NCT02668107|Other|Hammock positioning|Babies in the intervention group (IG), will be positioned supine in a hammock(hammock positioning) in the incubator, with the appropriate postural adjustments.
1540139|NCT02668094|Drug|Lidocaine|
1540140|NCT02668094|Drug|Pregabalin|
1540141|NCT02668094|Drug|propofol|
1540142|NCT02668081|Procedure|Endoscopic papillary balloon dilation|treatment of endoscopic papillary balloon dilation
1540143|NCT02668081|Procedure|Endoscopic sphincterotomy|treatment of endoscopic sphincterotomy
1540144|NCT02668068|Procedure|large volume whole-lung lavage (WLL)|Generally 1000 ~ 2000ml each time, 14 ~ 10 times totally, each side of the lung to 20 ~ 15 liters, until the lavage fluid from the black into a colorless clear clarification
1540145|NCT02668068|Biological|clinical grade umbilical cord mesenchymal stem cells|10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after whole-lung lavage
1540146|NCT02668055|Biological|TB4|Computing area was in proportion to the slow-release Tb4 collagen and chitosan porous sponge scaffolds skin substitute cells stick in the wound surface
1540147|NCT02668042|Biological|liveness tissue skin|liveness tissue skin safety and effectiveness for the treatment of difficult to heal wounds
1540150|NCT02668016|Drug|Atorvastatin|Atorvastatin 20mg tablets taken orally once daily for one month.
1540151|NCT02668016|Other|Placebo|Placebo tablets taken orally once daily for one month
1540152|NCT02668003|Behavioral|Cognitive Behavioural Therapy|The CBT intervention, delivered by telephone, will consist of an initial assessment, 6 weekly sessions, and then booster sessions at 3 and 6 months. The intervention will be delivered by trained and accredited therapists. Participants will be supported by a self-management CBT manual. There will be a patient-centred assessment by the therapist for problem identification, risk assessment and development of a shared formulation of the current health problem. The sessions will involve education about musculoskeletal pain, somatic symptoms and specific CBT techniques such as pacing of activity, behavioural activation, diary keeping, identifying and challenging negative and unhelpful thinking patterns and the development of a longer term management plan.
1540153|NCT02667990|Other|orthopaedic stilettoe|stilettos with orthopaedic in-sole buildt into the shoe
1540154|NCT02667990|Other|standard stiletto|standard stiletto without insole
1540155|NCT02667990|Other|comfy trainer|comfy trainer
1540156|NCT02667977|Other|0.9 Normal Saline|Use of 0.9 Normal Saline for maintenance IV fluids
1540157|NCT02667977|Other|0.45 Normal Saline|Use of 0.45 Normal Saline for maintenance IV fluids
1540158|NCT02667964|Other|spiroergometry|Spiroergometry on a bicycle ergometer
1540160|NCT02667938|Drug|HCP1303 capsule 5/0.2mg|
1540161|NCT02667938|Drug|HCP1303 capsule 5/0.4mg|
1540162|NCT02667938|Drug|HGP1201|
1540163|NCT02667938|Drug|HCP1303 capsule 5/0.2mg placebo|
1540164|NCT02667938|Drug|HCP1303 capsule 5/0.4mg placebo|
1540165|NCT02667938|Drug|HGP1201 placebo|
1540166|NCT02667925|Drug|Intraperitoneal cisplatin with nanocis|Patients will receive an intraperitoneal chemotherapy combined to a radiotracer in order to assess the intraperitoneal distribution of the chemotherapy
1540379|NCT02666378|Other|Echocardiogram (ECHO)|
1540167|NCT02667912|Procedure|Distal renal denervation|Percutaneous endovascular intervention when catheter-based electrode is used for stepwise radiofrequency energy delivery to inner surface of segmental branches renal artery in a number of points equally distributed along the length and circumference of the vessels in order to ablate renal plexus accompanying the artery in its course from aorta to the kidney
1540168|NCT02667912|Procedure|Conventional renal denervation|Percutaneous endovascular intervention when catheter-based electrode is used for stepwise radiofrequency energy delivery to inner surface of the main trunk of renal artery in a number of points equally distributed along its length and circumference in order to ablate renal plexus accompanying the artery in its course from aorta to the kidney
1540169|NCT02667899|Device|deep brain stimulation|Deep brain stimulation means stimulate the brain with DBS.
1540170|NCT02667899|Device|transcranial magnetic stimulation|Transcranial magnetic stimulation means stimulate the brain with magnetic stimulation.
1540171|NCT02667899|Other|Routine treatment|Means without above additional treatment.
1540172|NCT02667886|Drug|X4P-001|Continuous, oral, once-daily dosing
1540173|NCT02667886|Drug|axitinib|Continuous, oral, twice-daily dosing
1540174|NCT02667873|Drug|SL-801|
1540175|NCT02667860|Procedure|Intracorporeal anastomosis.|Iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Echelon Endopatch and closure of the defect with running suture or another firing of Echelon Endopatch. The surgical specimen will be retrieved through a Pfannenstiel incision.
1540176|NCT02667860|Procedure|Extracorporeal anastomosis|A transverse incision in the right upper quadrant will be performed. An iso or anti-peristaltic side-to-side ileo-colonic anastomosis with Proximate Linear Cutter device and Proximate Stapler.
1540177|NCT02667860|Device|Echelon Endopatch|Use of an Echelon Endopatch Powered Device to perform an ileocolonic side-to-side anastomosis.
1540178|NCT02667860|Device|Proximate Linear Cutter|Use of a Proximate Linear Cutter device to perform a side-to-side ileo-colonic anastomosis.Use of a Proximate stapler to the closure of the defect associated with the creation of the side-to-side ileo-colonic anastomosis.
1540179|NCT02667834|Behavioral|Social Cognition and Interaction Training (SCIT)|A randomized, controled trial of social cognition and interaction training ( SCIT) for patients with schizophrenia Spectrum disorders
1540180|NCT02667834|Behavioral|therapeutic education program (ETP)|usual treatment ,30 hours with therapist, only discussion between patients
1540182|NCT02667808|Other|Focus Group|Subjects will participate in four to eight group discussions aimed to evaluate fertility intentions, family planning, and sexual health behaviors. Discussions will be 1-2 hours in length. Groups will be conducted among men and women.
1540183|NCT02667808|Other|Questionnaire|Participants will complete a questionnaire assessing reproductive health knowledge, attitudes and practices related to family planning, and fertility and sexual health. The questionnaire will take no longer than 30 minutes to complete.
1540184|NCT02667795|Other|Monitored walking based exercise|
1540185|NCT02667782|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Recruited subjects that are randomly allocated into the MBSR group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on stress reduction. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
1540186|NCT02667782|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|Recruited subjects that are randomly allocated into the MBCT group will have an intensive face-to-face (F-T-F) teaching-learning program that is focused on cognitive therapy. After that, there will be some regular telephone follow-ups for a closed group of 10-15 participants. Subjects would receive four consecutive weekly F-T-F sessions, then a weekly telephone follow-up for three months in combination with an F-T-F session once a month. The Interventionist will be an experienced mindfulness therapist who is qualified to deliver both MBSR and MBCT.
1540187|NCT02667769|Other|Fasting day|A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose <55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
1540188|NCT02667756|Other|Non-interventional|
1540189|NCT02667743|Drug|Paclitaxel Micelles for Injection|
1540190|NCT02667743|Drug|Paclitaxel Injection|
1540191|NCT02667743|Drug|Cisplatin|
1540192|NCT02667730|Drug|Acetaminophen|Acetaminophen 500 mg four times daily for 7 days
1540193|NCT02667730|Drug|Naproxen|naproxen 500mg twice daily for 7 days
1540194|NCT02667730|Drug|Celecoxib|celecoxib 100mg twice daily
1540195|NCT02667730|Other|physiotherapy only|physiotherapy only (no drug)
1540196|NCT02667717|Behavioral|Mirror therapy|The intervention is a mirror therapy. The mirror therapy consists in performing some movements with a mirror, the hand that is painful is hidden and the image of the healthy hand is reflected in the mirror. Patients looking at this image seems to see their painful hand moving.
1540197|NCT02667717|Behavioral|Usual care|Patients will have the usual care as an intervention.
1540198|NCT02667704|Drug|Bosentan|
1540199|NCT02667704|Drug|Nintedanib|
1540200|NCT02667691|Dietary Supplement|SODB Dimpless|Subjects are supplemented with SODB, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
1540201|NCT02667691|Dietary Supplement|Placebo|Subjects are supplemented with placebo, daily over 3 Months. Each volunteer was seen for the 4 visits: - visit of pre-inclusion, - visit V1, so-called inclusion visit, - visit V2 at 1,5 months and - visit V3 at 3 months
1540202|NCT02667691|Other|caloric restriction|Caloric recommendation reduced by 20%
1540203|NCT02667678|Biological|Cohort HIVOL, patients infected by HIV|Researchers will take blood and urinary samples from the patients of the HIVOL cohort, to look at the renal clearance. The aim of this study is to check the renal function of the patients infected by HIV.
1540204|NCT02667652|Procedure|short biliarypancreatic limb|biliarypancreatic limb:50cm;roux limb:150cm.
1540205|NCT02667652|Procedure|long biliarypancreatic limb|biliarypancreatic limb:100cm;roux limb:100cm.
1540206|NCT02667639|Biological|RPH-104|
1540207|NCT02667639|Other|Sodium chloride Sterile Injection 0.9% w/v|
1540210|NCT02667613|Other|HABIT-ILE|Hand and arm bimanual intensive therapy including lower extremities
1540211|NCT02667613|Other|Control|Usual customary care
1540216|NCT02667574|Drug|ERIVEDGE|
1540217|NCT02667561|Drug|Testosterone gel 1% 2.2 mg|Application of 220 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
1540218|NCT02667561|Drug|Testosterone gel 1% 4.4 mg|Application of 440 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
1540219|NCT02667561|Drug|Testosterone gel 1% 8.8 mg|Application of 880 mg of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
1540220|NCT02667561|Drug|Placebo of Testosterone Gel 1%|Application of approximately 550 mg of Placebo of Testosterone Gel 1% in pubic region, once daily, for 28 consecutive days.
1540221|NCT02667548|Procedure|PCI|percutaneous coronary intervention
1540222|NCT02667535|Drug|Isosorbide Mononitrate|"Healthy volunteers will receive 2g (2.0%) of investigational product at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product once daily, for 7 consecutive days.
Participants with anal fissure will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, at a single dose, and will undergo a washout period of 7 days; subsequently, they will receive 2g of investigational product, either at 0.5%, 1.0% or 2.0%, once daily, for 7 consecutive days."
1540223|NCT02667522|Behavioral|Parent Child Interaction Therapy (PCIT)|PCIT includes 12-16 sessions across two phases: the first focused on enhancing positive parenting during child-directed interactions, and the second focused on reducing harsh parenting during parent-directed interactions. Parents receive feedback and coaching on their interactions with the child during sessions.
1540224|NCT02667496|Drug|Sargramostim GZ402664|Pharmaceutical form:solution Route of administration: subcutaneous
1540225|NCT02667496|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
1540226|NCT02667496|Drug|Florbetapir F18|Pharmaceutical form:solution Route of administration: intravenous
1540227|NCT02667483|Drug|DS-5141b|DS-5141b, Subcutaneous injection
1540228|NCT02667470|Drug|Solifenacin|Oral
1540230|NCT02667444|Drug|SB204 4%|Once daily
1540231|NCT02667444|Drug|Placebo|Placebo comparator
1540232|NCT02667418|Drug|Fidaxomicin|200 mg PO twice daily for 10 days
1540233|NCT02667418|Drug|Vancomycin with Taper/Pulse|125 mg PO four times daily for 10 days, followed by 125 mg once daily x 7 days, then once every other day x 7 days, then once every 3rd day x 7 days
1540234|NCT02667418|Drug|Vancomycin|125 mg PO for times daily for 10 days
1540235|NCT02667405|Procedure|Hot Pack|Patients have a hot pack and 2 layers of towel wrapped around the wrist and forearm for 15 minutes
1540236|NCT02667405|Procedure|Whirlpool|Patients immerse their arm, from elbow to hand, in a whirlpool bath of 104 degrees Fahrenheit for 15 minutes
1540237|NCT02667392|Procedure|Gait Training with Biofeedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.
Biofeedback Group: Biofeedback (external-focus feedback) will be provided as an adjuvant to therapist-provided feedback during the intervention. Participants will be instructed that a tone will sound when they push off with their (paretic) leg to swing it forward when the participant-specific pre-programmed threshold is exceeded."
1540238|NCT02667392|Procedure|Gait Training with Verbal Feedback|"Intervention (12, 60-minute sessions, 3X/week for four weeks) will occur in an outpatient research setting. Participants will be supervised by a licensed physical therapist and wear a gait belt during all activities. The therapist will choose from a standardized bank of gait activities, suitable to each participant's ability level. The goal for total walking time for each session will be 50 minutes: 5, 10-minute bouts with a 2-minute rest between bouts. This is the typical length and intensity of outpatient rehabilitation sessions for ambulatory patients discharged from inpatient rehabilitation.
Verbal Feedback Group: Therapist-provided internal-focus feedback (directed towards components of body movement) will be used to instruct participants on achieving and/or maintaining appropriate movement patterns that contribute to propulsion generation."
1540532|NCT02665195|Behavioral|questionnaire|
1540239|NCT02667379|Other|Diagnostic skin testing|14 Skin prick tests on each volar forearm with cat dander samples.
1540240|NCT02667366|Behavioral|Tel-PT|
1540241|NCT02667366|Behavioral|TAU and text messages|
1540242|NCT02667353|Procedure|ECT|ECT was administered twice a week with a constant-current brief-pulse device (Thymatron, System IV). Motor and electroencephalographic seizures were monitored to ensure adequate duration and quality. Subjects were all treated with right unilateral (RUL) ECT with stimulus intensity 6 times the initial seizure threshold (ST), as determined by empirical dose titration at the first treatment, until remission (Montgomery-Åsberg Depression Rating Scale (MADRS) (27) < 10 in two consecutive ratings with a week interval). Subjects who failed to respond right unilateral ECT after the sixth treatment were switched to bitemporal ECT (1.5x seizure threshold).
1540243|NCT02667353|Drug|Etomidate|Anesthesia was achieved with intravenous administration of etomidate (0.2mg/kg).
1540244|NCT02667353|Drug|Succinylcholine|Anesthesia was achieved with intravenous administration of succinylcholine (1mg/kg).
1540245|NCT02667340|Dietary Supplement|Superstarch|0.7 g Superstarch or placebo per kg body mass in two ingestions (before game & at halftime)
1540246|NCT02667340|Other|Placebo|0.7 g glucose per kg body mass in two ingestions (before game & at halftime)
1540247|NCT02667327|Drug|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
1540248|NCT02667327|Other|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
1540249|NCT02667314|Behavioral|Jigsaw puzzles|Solving jigsaw puzzles 6 times per week for at least 1 hour over a period of 5 weeks.
1540250|NCT02667314|Behavioral|Cognitive health counseling|Cognitive health counseling regarding modifiable risk and protective factors of cognitive decline and dementia at baseline and three telephone calls during a 5-week period for expert monitoring.
1540251|NCT02667301|Device|EMG recording|1.3X0.4 mm, sterile subdermal monopolar needle electrodes along with the same type of reference needle electrodes were inserted mTVP and mLVP muscles submucosally through the soft palate trans orally. The point of insertion for mTVP was one mm inferior and lateral of the pterygoid hamulus which is palpable at the posterior-medial of the upper alveolus. The active electrode was fully inserted horizontally into the superior belly of mTVP on the tested side. The reference electrode for mTVP was inserted into the palatine aponeurosis at one centimeter apart from the active electrode. The point of insertion for the mLVP active electrode was one centimeter medial and five mm inferior to the hamulus pterygoideus. Reference electrode of mLVP was inserted into one cm apart of medial side of the passive electrode of the mTVP at palatine aponeurosis.
1540252|NCT02667301|Device|Tympanic Cavity Air Exchange Test|Tympanic cavity air exchange test is done by placing a sensitive pressure sensor in the ear canal and another pressure sensor on one of the nostrils. Patient is asked to to obstruct the other nostril with his/her index finger while holding the probe in place securely and asked to swallow the water during the next ten seconds. Both ear canal and nasal pressure values were simultaneously recorded on tympanic cavity air exchange sensor computer for subsequent analyses. The swallowing action triggers the ET opening and causes a momentary increase of pressure in the nasal cavity. ET opening moves the tympanic membrane which is sensed by the sensors.
1540253|NCT02667301|Device|Tympanometer test|Patient is subjected to tympanometry test on the specific ear and information is recorded.
1540257|NCT02667262|Other|Algorithm to identify patients experiencing opioid abuse/addiction|
1540258|NCT02667249|Other|clinical pathway|implementation of a standardized clinical pathway
1540261|NCT02667223|Biological|Cohort 1: bococizumab 150 mg + rHuPH20|bococizumab 150 mg + rHuPH20 administered SC to healthy volunteers
1540262|NCT02667223|Biological|Cohort 2: bococizumab 300 mg|bococizumab 300 mg administered SC to healthy volunteers
1540263|NCT02667223|Biological|Cohort 3: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to healthy volunteers
1540264|NCT02667223|Biological|Cohort 5: bococizumab 450 mg + rHuPH20|bococizumab 450 mg + rHuPH20 administered SC to healthy volunteers
1540265|NCT02667223|Biological|Cohort 4: bococizumab 300 mg + rHuPH20|bococizumab 300 mg + rHuPH20 administered SC to subjects with hypercholesterolemia receiving a statin
1540266|NCT02667210|Other|Medical Record Review|Medical Record Review of Behaviors Suggestive of Misuse, Diversion, Abuse and/or Addiction
1540267|NCT02667197|Other|Algorithm to determine overdose from opioid abuse|
1540268|NCT02667184|Dietary Supplement|Low FODMAP Oral Nutrition Supplement|
1540269|NCT02667171|Behavioral|Supervised COPD Rehabilitation (control group)|"The control group receives standardized conventional supervised COPD rehabilitation (CCR) in groups. Rehabilitation contains exercise training and education sessions twice a week for a duration of 8-12 weeks. The CCR will last 60-120 minutes each session (50% exercise and 50% education).
Physical Exercises in CCR consist endurance based at Borg dyspnea 4-7 for 20-30 minutes and resistance training for upper and lower limb at 50-80% of one repetition maximum of 2-3 sets. Educations sessions consist information a dialogue regarding, life with COPD, participants topics, Medication, daily activity, Nutrition, Smoking cessation, Respiratory and relaxation exercises."
1540270|NCT02667171|Behavioral|Online COPD rehabilitation (experimental)|"Supervised Online COPD rehabilitation, delivered in groups through a computer screen in patients own home. Rehabilitation contains exercise training and education sessions three times per week for a duration of 10 weeks. Each session lasts for 60minutes (60% exercise 40% education). Physical exercises consist high repetitive time-based muscle endurance training, including 5-7 upper and lower limb exercises, performed with a volume of four sets per exercise equivalent to 50-80% of one repetition. Self-rated Borg CR-10 score equivalent from moderate to very strong shortness of breath in active phases.
Educations consists same information as for the control group."
1540271|NCT02667158|Other|Survey to Eval Relation between Shopping and Misuse, Abuse|A Survey Study to Evaluate the Relation Between Doctor/Pharmacy Shopping and Outcomes Suggestive of Misuse, Abuse and/or Diversion
1540272|NCT02667145|Other|Self care program focusing on the assistive device|self-heed program focusing on the assistive device will consist of four weekly meetings lasting approximately 90 minutes. it will be stimulated the self-heed through knowledge of pathology and guidelines of protection articulate, and will be supplied, and trained the use of assistive devices to improve the performance of volunteers in their daily activities. Assistive devices are devices, not attached to the body, which help people with limited movements and restrictions on participation in the activities of everyday life. Example: thickening of tableware, tin openers. These volunteers will be evaluated in three stages: 1-initial assessment 2-after completion of the program and 90 days after the initial assessment. The questionnaires that will be used are: EVA; SACRAH; COPM; WHOQOL-Bref.
1540273|NCT02667119|Behavioral|Prolonged Exposure with Contingency Management|"Prolonged Exposure therapy for posttraumatic stress disorder includes psychoeducation, breathing retraining, in vivo exposure, and imaginal exposure.
Contingency Management for substance abuse disorders: participants will have the chance to win prizes for each negative urine drug screen/breathalyzer provided."
1540274|NCT02667119|Behavioral|Standard Care|Standard care will consist of treatment as usual in a community-based substance use treatment center.
1540275|NCT02667106|Drug|RX0041-2|Pharmacokinetic study
1540276|NCT02667080|Other|2-7 days of Sexual abstinence|2-7 days of Sexual abstinence
1540277|NCT02667080|Other|2 hours of sexual abstinence|2 hours of sexual abstinence
1540278|NCT02667067|Device|Simplify Disc|Simplify Disc at one level in the cervical spine.
1540279|NCT02667067|Device|Anterior Cervical Discectomy & Fusion|"This study will utilize a non-concurrent historical control with subject-level data on a parallel group design. The historical control group will be formed from the randomized ACDF arm (N=133) of the recently completed Kineflex®|C Disc trial."
1540280|NCT02667054|Drug|RX0041 4%|Anesthetic
1540281|NCT02667054|Drug|Placebo|Placebo Comparator
1540282|NCT02667054|Drug|RX0041 8%|Anesthetic
1540283|NCT02667041|Device|NeuroQore rTMS Device|
1540284|NCT02667028|Procedure|PCI|percutaneous coronary intervention
1540285|NCT02667015|Behavioral|Psychotherapy (Anxiety Sensitivity Intervention)|3 week, 6-session psychotherapy targeting anxiety sensitivity
1540286|NCT02667002|Procedure|Bilateral Abdominal Sacral Hysteropexy|The mesh will be fixed right and left side of sacrum.
1540287|NCT02667002|Procedure|Conventional abdominal Sacral Hysteropexy|The mesh will be fixed only right side of sacrum
1540288|NCT02667002|Other|Nulliparous women with no uterovaginal prolapsed|This will be control group which consistent patients with no uterovaginal prolapse.
1540289|NCT02666989|Drug|placebo|2 placebo pills twice a day
1540290|NCT02666976|Drug|Ilaprazole|Patients who were diagnosed clinically as NERD and were treated with ilaprazole 20mg once daily for 4 weeks. Biopsies were obtained from 3cm above the EG junction before and after treatment. GERD Q questionnaire, histologic findings (basal cell hyperplasia, papillary elongation, dilated intercellular spaces, intraepithelial eosinophils and intraepithelial T lymphocyte) and inflammatory biomarkers (TNF-α, IL-8, IL-1β, TRPV1 and MCP-1) were accessed.
1540291|NCT02666963|Drug|RTA 901 Capsules, 10 or 40 mg|
1540292|NCT02666963|Drug|Placebo|
1540299|NCT02666924|Dietary Supplement|Chinese-canadian specific cooking classes|Series of four, four-hour cooking classes, occurring monthly for four months. Each of the cooking classes in the series will have diabetes self-management learning objectives: food choices, meal planning and preparation, portion control, self-monitoring of blood glucose levels and physical activity.
1540300|NCT02666924|Other|Diabetes educational classes|Series of two, four-hour diabetes education classes, occurring weekly for two weeks. Each class is run by a registered dietitian and nurse, trained as clinical diabetes educators, as per standards of the canadian diabetes association. Classes include focused teaching of the background of diabetes, dietary recommendations for diabetes, lifestyle recommendations for diabetes, medications for diabetes, and general standard of living recommended for diabetes mellitus type 2.
1540301|NCT02666911|Procedure|4D Ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
1540302|NCT02666911|Procedure|2D ultrasound|Each subject will be imaged lying supine on imaging table with affected arm outstretched on Plexiglass board. An ultrasound scanner equipped with 15L8 linear array transducer will be set to depth of 20-25 mm with a 15MHz image acquisition frequency (for longitudinal and transverse imaging) and the same ultrasound machine equipped with 4D transducer will be used. Ultrasound evaluation will be performed by a sonographer trained in the pertinent image acquisition procedures. The image acquisition frame rate will be maintained at 70Hz, and the image compression will be set to low.
1540303|NCT02666898|Drug|GA101|"Part 1 :6 cycles
Obinutuzumab/GA101:
First cycle:
D1: 100mg, D2: 900mg D8 and D15: 1000 mg i.v
Cycle 2 to 6 (every 28 days) :
D1 of every cycle: 1000 mg i.v PART 2 4 cycles
-patients have BM MRD >10-4 or PR: Cycle 1 to 4 Obitinuzumab/GA101: 1000 mg i.v on day 1"
1540304|NCT02666898|Drug|Ibrutinib|"Part 1 :6 cycles
Cycle 2 to 6 (every 28 days) :Ibrutinib:
D3 Month 1 to Day 30 Month 15: 420mg daily PO PART 2:4 cycles
patients in CR with BM MRD < 10-4 : Ibrutinib alone 420mg daily
patients with BM MRD >10-4 whatever responses or PR :Cycle 1 to 4 Ibrutinib 420mg daily with Cyclophosphamide and Fludarabine"
1540305|NCT02666898|Drug|Cyclophosphamide|"PART 2 :
patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days Cyclophosphamide : 250 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and fludarabine"
1540306|NCT02666898|Drug|Fludarabine|"PART 2 :
patients with BM MRD >10-4 or PR (except PD and SD), receive : 4 cycles of FC+GA101 every 28 days : Fludarabine : 40 mg/m² per os, D2 to D4 in association with GA101, ibrutinib and cyclophosphamide"
1540307|NCT02666885|Radiation|Integration of PET/MRI in radiotherapy|Integration of pretherapeutical PET/MRI in adjuvant radiotherapy
1540309|NCT02666859|Device|Virtual Reality|During this intervention, the subjects will be immersed in a virtual reality system called the Computer Assisted Rehabilitation Environment (CAREN) system to complete the tasks.
1540310|NCT02666846|Drug|Ibuprofen|Single topical dose per 1.76 cm2 test site of: 22 microliters (μL) (20 ± l mg)* of TIB200 Gel (ibuprofen 10% w/w) (Test Gel) or 22 μL (20 ± l mg)* of matching placebo TIB200 Gel (placebo gel) or 22 μL (20 ± l mg)* of Nurofen Maximum Strength Gel (ibuprofen 10% w/w) (reference gel).
1540311|NCT02666846|Drug|Diclofenac|Subjects were randomised to receive 22 uL (20 ± l mg) DCF100 Gel (diclofenac 2% w/w) / DCF100 Gel (diclofenac 4% w/w) / Matching Placebo DCF100 Gel / Voltarol® 12 Hour Emulgel® P 2.32% Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.
1540312|NCT02666846|Drug|Methyl-salicylate / Menthol|Subjects were randomised to receive 22 uL (20 ± l mg) SPR300 Gel / Matching Placebo SPR300 Gel. The gels were administered topically on two test sites on the lower back of the subject, each 1.76cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.
1540313|NCT02666846|Drug|Placebo|The placebo gels were administered topically on two test sites on the lower back of the subject, each 1.76 cm2 in size. The two test sites were UVB irradiated on the previous day, between 22 and 26 hours (24 ± 2 hours) before dosing.
1540314|NCT02666833|Device|Polarization Enhanced Reflectance and Fluorescence System|Subjects will receive preoperative imaging of their skin cancer with the PERFIS optical imaging device.
1540315|NCT02666820|Procedure|Large balloon dilatation|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 12, 15, 18 or 20 mm CRE-balloon was passed over guide wire and position across the papilla. The balloon was gradually inflated to the largest size of the bile duct stone and/or the bile duct diameter. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
1540316|NCT02666820|Procedure|Mechanical lithotripsy|After biliary sphincterotomy was performed with full extension to the full length of transverse fold. A 3x6 cm Trapezoid Rx retrieval stone basket was used to capture the stone and crushing of stones was done when simple stone extraction failed to remove the stone. The stone fragments were then retrieved with a basket and/ or a retrieval balloon. When complete stone removal was unsuccessful , crossing over treatment was considered at the discretion of the endoscopists.
1540317|NCT02666807|Dietary Supplement|Ginger|Ginger 500 mg capsules (2000 mg per day) by mouth twice daily (BID) for 10 weeks
1540318|NCT02666807|Dietary Supplement|placebo|Placebo matching with ginger 0 mg capsules by mouth twice daily (BID) for 10 weeks
1540319|NCT02666794|Drug|Epidural bupivacaine with vasoconstrictor 0.125%|10 ml
1540320|NCT02666794|Drug|Epidural sufentanil|10 mcg
1540321|NCT02666794|Procedure|Placement of the epidural catheter|Placement of the epidural catheter
1540322|NCT02666794|Drug|Intrathecal hyperbaric bupivacaine solution 0.5%|2.5 mg
1540323|NCT02666794|Drug|Intrathecal morphine|60 mcg
1540324|NCT02666794|Procedure|Placement of an epidural catheter to the catheter through technical needle|Placement of an epidural catheter to the catheter through technical needle
1540325|NCT02666794|Drug|Intrathecal sufentanil|5 mcg
1540326|NCT02666781|Other|ApneaLink Plus, BIA Device and a 3-D accelerometer device|The study is only observational. No interventions will be performed. ApneaLink Plus will be used to diagnose Obstructive Sleep Apnea in potential candidates and grade its severity on Postoperative night 2 in participants. A BIA Device will be used to detect segmental fluid shifts. A 3-D accelerometer will be used to detect head and neck position.
1540327|NCT02666768|Drug|Interferon gamma-1b|gamma interferon-1b dose escalation over first 4 weeks of study to 100 mcg SC 3 times weekly
1540328|NCT02666742|Drug|Apixaban|Apixaban is a blood thinning drug, also called an anticoagulant. Apixaban is approved by the U.S. Food and Drug Administration (FDA) for the treatment of deep vein thrombosis and pulmonary embolism, which are blood clots in the veins or lungs.
1540329|NCT02666742|Drug|Aspirin|Aspirin works by reducing substances in the body that cause pain, fever, and inflammation. Aspirin is used to treat pain, and reduce fever or inflammation.
1540330|NCT02666729|Procedure|AF Ablation with contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will be made aware of contact force data when performing procedure.
1540331|NCT02666729|Procedure|AF Ablation without contact force information|Ablation procedure will be done using TactiCath Quartz ablation catheter which can measure the amount of contact force being used. Researcher will not be made aware of contact force data when performing procedure.
1540332|NCT02666716|Drug|fluconazole|Dose according to summary of product characteristics (SPC) or local protocols
1540333|NCT02666703|Device|CytoSorb|CytoSorb is a first-in-class extracorporeal cytokine adsorber, now approved in the European Union, and broadly indicated for use in any clinical situation where cytokines are elevated.
1540334|NCT02666703|Drug|Methylprednisolone|
1540335|NCT02666690|Device|CEUS (Contrast-enhanced ultrasound)|Each patient will be performed 2 contrast echocardiography (a pre-prandial - a post-prandial) before the antiangiogenic treatment, at D15 and D30.
1540336|NCT02666664|Drug|ETC-1002|ETC-1002 180 mg tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
1540337|NCT02666664|Drug|Placebo|Matching placebo tablets taken orally, once per day. Patients remain on ongoing statin therapy (not study provided)
1540338|NCT02666651|Drug|Tolvaptan|Tolvaptan is dispensed during hospitalization according to its product monograph and clinician discretion. It will be discontinued once serum sodium is normalized, or in the case of a drug related adverse event or hospital discharge.
1540339|NCT02666651|Other|No intervention|There is no intervention planned for the Control group. Aggregate administrative regional data describing patient outcomes from the local health authority will be used as a comparator.
1540345|NCT02666599|Radiation|18F-FDG PET/CT|"A 18F-FDG PET/CT will be done. A dose of 19 µSv/MBq will be received by the patient. Surgery will be conducted within 3 hours after the I.V. injection of 18F-FDG according to the standard procedure applied in the visceral surgery department. During the surgery, emission of β+ from the lesion (s) seen durint the PET/CT will be detected with the probe.
Resected pieces will be analysed histologically."
1540353|NCT02666560|Device|Auditory Cueing|Auditory cueing set at different frequency rates
1540354|NCT02666547|Radiation|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images acquired on all body . For glioma, images acquired centred on the skull
1540355|NCT02666547|Radiation|18F-FDG PET/CT|3.5 MBq/kg 18F-FDG will be administered i.v. and images acquired on all body
1540356|NCT02666547|Radiation|18F-FET PET/CT|200 MBq 18F-FET will be administered i.v. and images acquired centred on the skull
1540357|NCT02666534|Drug|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
1540358|NCT02666534|Device|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
1540359|NCT02666534|Drug|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
1540360|NCT02666534|Device|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
1540363|NCT02666495|Other|Psychological Therapy - Schema Therapy|Psychological treatment using individual Schema-Mode Therapy for Anorexia Nervosa (iST-AN). A 60 session protocol will be used over an 18 month period, moving flexibly through five phases of treatment, guided by the psychological formulation: phase 1 - assessment, engagement & stabilisation; phase 2 - developing trust & understanding; phase 3 - developing awareness & acceptance; phase 4 - testing change & strengthening the healthy mode; phase 5 - consolidating change. A follow-up period of 6 months, with 5 further monthly sessions, will promote self-efficacy and further consolidate change. A total treatment package of 65 sessions will be offered, over 24 months.
1540364|NCT02666482|Behavioral|Stop Smoking SF Web App - baseline|Smoking cessation web app in Spanish and English. Accessible online at no charge.
1540365|NCT02666469|Other|Hyperbaric Oxygen Therapy (HBOT) and Exercise Program|HBOT provided with 100% oxygen at 2.0 ATA and rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
1540366|NCT02666469|Other|Exercise Program|Rehabilitation program consisting of GRASP (60 min) and mental imagery (30 min)
1540367|NCT02666469|Device|Hyperbaric Multiplace Chamber|Patients will receive treatment in a multiplace Hyperbaric Chamber
1540368|NCT02666456|Other|QST, Questionnaires|Assessment of sensory phenotype by QST and questionnaires
1540369|NCT02666443|Drug|Control intervention (no dexamethasone)|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 50 mL normal saline.
1540370|NCT02666443|Drug|Peri-neural Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL dexamethasone 1% (1 mg dexamethasone), and an intravenous solution of 50 mL normal saline.
1540371|NCT02666443|Drug|Intravenous Dexamethasone 1 mg|Patients receive a supraclavicular brachial plexus block with 30 mL of solution containing 0.5% bupivacaine, 1:400,000 epinephrine, 0.1 mL normal saline, and an intravenous solution of 49.9 mL normal saline with 0.1mL dexamethasone 1%
1540372|NCT02666430|Drug|Mylan's insulin glargine|
1540373|NCT02666430|Drug|Lantus®|
1540374|NCT02666417|Dietary Supplement|Fortified maize porridge (MNP+iron)|Maize porridge will be home-fortified with the MNP + iron. Maize porridge for the test meal will be fortified with labelled iron compounds
1540375|NCT02666417|Dietary Supplement|Fortified maize porridge (MNP+iron+GOS)|Maize porridge will be home-fortified with the MNP + iron + GOS. Maize porridge for the test meal will be fortified with labelled iron compounds
1540376|NCT02666404|Other|Measurement|We will perform those new measurements and assessments for guidance of fluid resuscitation at 0, 6, 24, 48, and 72 hours after shock diagnosis and concomitant fulfillment of eligibility requirements
1540377|NCT02666391|Biological|umbilical cord mesenchymal stem cells|
1540378|NCT02666378|Other|Cardiac Magnetic Resonance Imaging (CMR)|
1540380|NCT02666365|Procedure|Bolus infusion of Cefazolin|Subjects in the bolus infusion arm of the study will receive bolus infusions of cefazolin throughout the surgical procedure
1540381|NCT02666365|Procedure|Continuous infusion of Cefazolin|Subjects in the continuous infusion arm of the study will receive a continuous infusion of the cefazolin throughout the surgical procedure
1540382|NCT02666352|Drug|uprifosbuvir|uprifosbuvir 150 mg oral tablets
1540383|NCT02666352|Drug|ruzasvir|ruzasvir 10 mg oral capsules
1540384|NCT02666339|Other|Usual care|Usual care : drug therapy, nurse and physician consultations.
1540385|NCT02666339|Behavioral|Hortitherapy|2 hortitherapy sessions/week during 4 weeks, added at the usual care.
1540386|NCT02666326|Procedure|Accelerated, combined biomarker rule-out strategy for MI|Blood sample is acquired while the patient is in the ambulance. This is brought to hospital and handed over to the laboratory personnel for acute analysis for copeptin level. At arrival to hospital, a second blood sample is acquired and analyzed for high-sensitive cardiac troponin-T(hs-cTnT). Answers of these analyzes are in-hand with-in 60 minutes. If copeptin in the pre-hospital blood sample is <9,8 pmol/L (95% percentile) AND hs-cTnT in the in-hospital blood sample is <14ng/L (99% percentile), then myocardial infarction can be ruled out, and depending of clinical presentation, the patient can be discharged.
1540387|NCT02666313|Behavioral|Exercise|"The physiotherapist will select exercises which are appropriate to that participant. Participants will complete online exercise diaries which are reviewed remotely by the physiotherapist. Depending on progress, exercises can be progressed, added or removed from the patient's individualised programme.
Participants will be encouraged to undertake their exercise programme, according to evidence base guidelines, five days/week for 30 minutes/day. Participants will receive weekly phone calls for the first two weeks of the programme. Thereafter, every two weeks the physiotherapist will review the exercise diary of each participant and remotely alter the participant's exercise programme as appropriate, by changing any combination of exercises, level of difficulty or number of repetitions."
1540389|NCT02666287|Drug|BAT/FF|BAT/FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose and its physical appearance is dry white powder. Second strip contains 100 mcg per blister of FF blended with lactose and its physical appearance is dry white powder.
1540390|NCT02666287|Drug|BAT|BAT is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 300 mcg per blister of BAT blended with lactose appear as dry white powder. Second strip contains lactose which appear as a dry white powder.
1540391|NCT02666287|Drug|FF|FF is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose which appear as dry white powder.
1540392|NCT02666287|Drug|FF (MgSt)|FF magnesium stearate is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 100 mcg per blister of FF blended with lactose appear as dry white powder and second strip contains lactose with magnesium stearate which appear as dry white powder.
1540393|NCT02666287|Drug|FF/Vilanterol|FF/Vilanterol is available in DPI form and will be administered via the ELLIPTA inhaler. Each first strip contains 25 mcg per blister of vilanterol blended with lactose and magnesium stearate appear as dry white powder and second strip contains 100 mcg per blister of FF blended with lactose which appear as dry white powder.
1540394|NCT02666235|Procedure|Remote ischaemic conditioning|Intermittent inflation of an arm blood pressure cuff for 5 minute periods at 200 mmHg separated by a 5 minute rest interval, repeated successively on 4 occasions over a 40 minute period. The intervention will take place on the ward with the patient obscured from the clinical team by a drawn curtain. The clinical team and researchers will be masked to the intervention type.
1540395|NCT02666235|Procedure|Arm cuff placement, no inflation;|Sham procedure involving arm cuff placement, no inflation: A blood pressure cuff will be placed on the arm for 40 minutes. The cuff will not be inflated. The patient will be in bed behind a curtain on the cardiology ward. The curtain will obscure the patient from the attending cardiology team. The clinical team and researchers will be masked to the intervention type.
1540396|NCT02666222|Device|The Esteem Hearing Implant|The Esteem® Hearing Implant is designed to improve hearing in subjects suffering from moderate to severe hearing loss that is sensorineural in origin. The Esteem® has been approved by FDA for the US market under Pre-Market Approval P090018 and this study fulfills the requirement for one of the Post Approval Studies.
1540397|NCT02666209|Drug|Ulocuplumab|CXCR4 inhibitor given weekly on a 28 day cycle intravenously
1540398|NCT02666209|Drug|Lenalidomide|immunomodulatory agent given days 1-21 of a 28 day cycle orally in subjects not receiving bortezomib
1540399|NCT02666209|Drug|Bortezomib|proteasome inhibitor given at physician discretion in subjects not receiving lenalidomide
1540400|NCT02666209|Drug|Dexamethasone|steroid given at physician discretion on a 28 day cycles
1540401|NCT02666196|Drug|DAA-I|
1540402|NCT02666196|Drug|Placebo|
1540403|NCT02666183|Behavioral|Video-C|use videoconferencing to provide personalized information aimed at enhancing self -efficacy and providing emotional support for distant caregivers of patients with advanced cancers
1540404|NCT02666183|Behavioral|Nurse Coaching|structured conversations with registered nurses aimed at providing emotional support
1540405|NCT02666183|Behavioral|Web-Only|Access to a website with caregiving resources, resources for distant care givers, and cancer information
1540406|NCT02666170|Drug|Alpha-lipoic acid|
1540407|NCT02666157|Drug|Dabigatran etexilate|this drug is administered twice per day for the entire study period
1540408|NCT02666157|Drug|Rivaroxaban|this drug is administered once per day for the entire study period
1540409|NCT02666157|Drug|Apixaban|this drug is administered twice per day for the entire study period
1540410|NCT02666144|Device|Spectralis OCT|Measurement of structural parameters of the optic nerve head (ONH), in particular, the neuroretinal rim of the ONH, and the peripapillary retinal nerve fiber layer.
1540411|NCT02666131|Drug|Granexin gel|Granexin gel contains active pharmaceutical ingredient, aCT1 peptide, for topical application to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
1540533|NCT02665182|Behavioral|Up-positioning of the testes|Patients in the experimental arm are asked to elevate their testes during the treatment.
1540412|NCT02666131|Drug|Vehicle gel|The vehicle gel formulation is hydroxyethyl cellulose that does not contain the active aCT1 peptide. Vehicle gel will be applied topically to diabetic foot ulcers once a week for up to 12 weeks or until wound closure, whichever comes first.
1540413|NCT02666118|Procedure|Preemptive Interscalene Block - Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
1540414|NCT02666118|Procedure|Postoperative Interscalene Block- Single Shot|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
1540415|NCT02666118|Procedure|Preemptive Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the induction of anesthesia, but prior to the start of surgery. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
1540416|NCT02666118|Procedure|Postoperative Interscalene Block - Catheter|Interscalene brachial plexus blockade will be performed by the anesthesia team under ultrasound-guidance utilizing 1 ml/kg (to a maximum volume of 20 mls) of 0.2% ropivacaine without epinephrine. A continuous peripheral nerve catheter will then be placed under ultrasound-guidance for continuous infusion postoperatively. Regional anesthesia will be performed following the completion of surgery with the patient still under general anesthesia. Anesthesia team members determined to be proficient in regional blockade, having performed a minimum of ten successful interscalene brachial plexus blocks previously, will be performing the regional blockade.
1540417|NCT02666105|Drug|Exemestane|One 25 mg tablet once daily for a minimum of 6 weeks
1540418|NCT02666092|Other|Questionnaire|Questionnaire on domestic exposure to fish, and, for patients with fish allergy, on the characteristics of clinical manifestations)
1540419|NCT02666092|Biological|Detection of anti-Anisakis and anti-fish antibodies|Anti-fish IgE will be detected using ImmunoCAP. Anti-Anisakis antibodies will be detected using ImmunoCAP (IgE), immunoelectrophoresis (precipitins) and Western Blot.
1540420|NCT02666079|Device|LightPath™ Imaging System.|Intra-operative use of the LightPath™ Imaging System.
1540421|NCT02666053|Drug|BMS-663068|BMS-663068
1540422|NCT02666040|Device|ULTRAPRO® meshes|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
1540423|NCT02666040|Device|"Prolene® meshes"|The inguinal hernia repair has to be performed with the Lichtenstein technique, with standardized prosthesis fixation and no use of plug.
1540424|NCT02666040|Procedure|Detecting the mode of admission to hospital|Ordinary admission or day surgery
1540425|NCT02666040|Procedure|Duration of surgery|Time operating room
1540426|NCT02666040|Procedure|Anesthesia volume and type used|Anesthesias used: infiltration, followed by spinal, general, epidural.
1540427|NCT02666027|Device|Fluid Intravenous Alert (FIVA) 'on'|Fluid Intravenous Alert (FIVA) 'on' - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada (Figure 1). It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
1540428|NCT02666027|Device|Fluid Intravenous Alert (FIVA) 'off'|The FIVA will be turned off. - The FIVA™ (EngenuityMED, Halifax, Canada) is a small, handheld, battery operated, device class I medical device in Canada. It is designed to alarm and alert the physician to change the IV bag when the fluid level in the chamber of the IV set is low. It also functions to stop the fluid flow through the gravity-fed tubing system when the alarm is triggered, preventing air from entering the IV tubing. We hypothesize that the FIVA would decrease the incidence of unnoticed dry IV bags during surgery, particularly when the operating room lights are dimmed and would therefore decrease the risks associated with undetected dry IV bags.
1540429|NCT02666014|Drug|Neuromuscular reversal by Sugammadex|Reversal of neuromuscular blockade
1540430|NCT02666014|Drug|Neuromuscular reversal by Neostigmine|Reversal of neuromuscular blockade
1540431|NCT02666014|Drug|Atropine sulfate-diphenoxylate hydrochloride combination|As an adjuvant drug to balance muscarinic side effects of Neostigmine, when Neostigmine is administered.
1540432|NCT02666001|Drug|BMS-663068|BMS-663068
1540433|NCT02666001|Drug|Methadone|Methadone
1540434|NCT02666001|Drug|Buprenorphine and Norbuprenorphine|Buprenorphine and Norbuprenorphine
1540435|NCT02665988|Device|tDCS|Prior to initiating the real tDCS trial and to reduce the likelihood of irritation associated with electrical stimulation, a low dose (1/8 of an inch) topical lidocaine (4%) cream will be applied to the skin where the tDCS the sponge-coated, surface electrodes soaked in saline solution will be placed. Neurotargeting tDCS-explorer software, Version 2.3 will be used to locate the left and right DLPFC, where anodal stimulation of the left DLPFC and cathodal stimulation of the right DLPFC will be received. Real tDCS will be applied during 20-minute periods over the course of 10 sessions. After each session, vitamin-E will be applied to the skin where the electrodes had been placed to reduce likelihood of skin irritation.
1540534|NCT02665169|Behavioral|Supervised physical exercise|Supervised physical exercises in Taiji and weight training. Free use and access into municipal recreation and training facilities for one year.
1540749|NCT02663726|Behavioral|Written advice|Written advice about physical activity
1540436|NCT02665988|Device|Sham tDCS|Participants randomized to sham tDCS will undergo the same procedures as those in the real tDCS sample, including the same pre-treatment lidocaine 4% cream, localization of electrode placement, actual placement of electrodes, turning on the tDCS device in sham setting but will not receive actual stimulation during the 20 minutes of each session, as well as post-treatment vitamin E.
1540437|NCT02665975|Behavioral|CBT-based internet-intervention for tinnitus|Tinnitus e-learning programme
1540438|NCT02665975|Behavioral|Face-to-face clinical tinnitus care|Hospital tinnitus counselling
1540439|NCT02665962|Other|Perioperative Caloric Restriction Program|
1540440|NCT02665936|Drug|Levobupivacaine|Levobupivacaine will be given epidurally and the duration of analgesia will be calculated
1540441|NCT02665936|Drug|Dexamethasone and levobupivacaine|dexamethasone 4 mg epidurally with levobupivacaine and duration of analgesia is measured
1540442|NCT02665936|Drug|Levobupivacaine and Dexamethasone|dexamethasone 8 mg epidurally with levobupivacaine and duration of analgesia is measured
1540443|NCT02665923|Other|Gastric ultrasound|Ultrasound of abdomen to assess antral volume
1540444|NCT02665910|Drug|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
1540445|NCT02665910|Drug|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
1540446|NCT02665884|Other|Intraocular Pressure Measurement|Diurnal fluctuations of intraocular pressure will be measured and compared
1540447|NCT02665871|Biological|one dose of Influenza Vaccine|
1540448|NCT02665871|Biological|one dose of Influenza Vaccine|
1540449|NCT02665871|Biological|placebo|
1540450|NCT02665871|Biological|placebo|
1540451|NCT02665858|Other|OCT Imaging|
1540454|NCT02665832|Drug|DWJ1351|
1540455|NCT02665832|Drug|Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)|
1540456|NCT02665819|Other|Pediatric cancer women survivors|Women will incur a blood taking to obtain fertility indication.
1540457|NCT02665806|Drug|Ciclesonide|intranasal ciclesonide spray 200 µg once daily
1540458|NCT02665806|Drug|Fluticasone|fluticasone propionate aqueous nasal spray 200 µg twice a day
1540459|NCT02665793|Other|DBPCFC to peanut cookie|
1540460|NCT02665793|Other|Single-dose DBPCFC to peanut flour|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
1540461|NCT02665793|Other|Single-dose DBPCFC to peanut butter|Single-dose DBPCFC to peanut in a water-continuous matrix, at a cumulative dose one dosing level below that individual's threshold (established at the baseline challenge). If no reaction is seen, participants will be given the next dosing level.
1540462|NCT02665780|Procedure|Periodontal debridement|teeth cleaning
1540463|NCT02665780|Other|Cetylpyridium chloride|mouthrinse
1540464|NCT02665767|Device|Smartphone-based Telesonography|The 30 participating examiners were randomly divided into two groups. In phase one, group A performed ultrasonography under onsite mentoring and group B performed the same procedure under remote mentoring. Each examiner was randomly assigned one expert and three SPs for phase one. Four weeks later, they were partnered with the same expert and SPs to whom they had been assigned in phase one and performed the procedure under the other type of mentoring (phase two). The examination order of the SPs was randomly assigned by choosing a number between one and six (1: A-B-C, 2: A-C-B, 3: B-A-C, 4: B-C-A, 5: C-A-B, 6: C-B-A) in each phase.
1540468|NCT02665741|Device|Olympus transparent cap|distal colonscope attachment
1540469|NCT02665741|Device|Medivators Endocuff|distal colonscope attachment
1540470|NCT02665741|Device|Control|No distal colonoscope attachments
1540471|NCT02665728|Drug|BLI400 Laxative|
1540472|NCT02665715|Other|Low carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 30% Protein 30% Fat 40%
1540473|NCT02665715|Other|Standard carbohydrate meals|Meal macronutritional energy composition: Carbohydrate 55% Protein 15% Fat 30%
1540474|NCT02665702|Drug|NVB|25mg/m2 ，D1，8
1540475|NCT02665702|Drug|DDP|75mg/m2 ，D1 or 25mg/m2 D1-3
1540476|NCT02665702|Drug|Endostar|15mg/d，d1-d7 civ
1540477|NCT02665689|Drug|ranibizumab|Ranibizumab injections will be given for diabetic macular edema. In the experimental arm insulin injections and antihypertensiva will be applied.
1540478|NCT02665663|Device|medical device|
1540479|NCT02665650|Biological|AFM13|
1540480|NCT02665650|Biological|Pembrolizumab|
1540481|NCT02665637|Drug|Trastuzumab|Each patient may receive single dose by intravenous infusion
1540482|NCT02665624|Drug|Senna and stewed apricot juice|comparison of bowel cleansing and patient comfort.
1540483|NCT02665624|Drug|Senna alone|comparison of bowel cleansing and patient comfort.
1540484|NCT02665611|Behavioral|intervention for improvement of adherence|intervention for improvement of adherence
1540485|NCT02665611|Behavioral|treatment as usual|The control group will be treated according to the usual stadard of care.
1540486|NCT02665585|Procedure|Carotid stenting procedure by carotid stent implantation|Carotid stenting procedure by carotid stent implantation
1540535|NCT02665169|Other|Health counselling|Health counselling, fall prevention strategies at home, information concerning municipal recreational services available.
1540487|NCT02665572|Behavioral|bladder recycling|Bladder recycling will be done by the patient after proper education. It will be started by the instillation of the sterile water in the bladder in amount equal to the estimated bladder capacity. Then the amount will be gradually increased till the patient can withstand filling the bladder with 300 cc of sterile water for 2 hours.
1540488|NCT02665533|Drug|Dexamethasone|Dexamethasone 8 mg
1540489|NCT02665533|Drug|Diclofenac Sodium associated with Codeine|Diclofenac Sodium 50 mg associated with Codeine 50 mg
1540490|NCT02665520|Procedure|liposuction for retrieval of own stem cells from fat cells|
1540491|NCT02665507|Device|GaAlAs 808nm laser|Hand held superpulsed GaAlAs 808 nm LLLI
1540492|NCT02665507|Device|Sham|Hand held laser that emits no LLLI
1540493|NCT02665481|Behavioral|MBSR|
1540494|NCT02665481|Behavioral|Exercise|
1540495|NCT02665481|Behavioral|Health Education|
1540499|NCT02665442|Device|Esophageal Stylet - EsoSure|The Esophageal Stylet is a thin rigid tube, which will be inserted inside a commonly used nasogastric tube placed inside the esophagus during the ablation. We will use this stylet to move the esophagus away from the site of the ablation about 1-2 centimeters.
1540500|NCT02665429|Behavioral|Individual prescribing data profile and self-assessment|Prior to receiving his or her individual data profile, each provider in the intervention group will be asked to identify his or her self-assessment of his or her own opioid prescribing practices. Immediately after providing self-perception data, providers will be provided with their true profile data with a visual display of where they fall within the distribution of their peers. All peer data are de-identified.
1540501|NCT02665416|Drug|RO7009789|RO7009789 will be provided as concentrate for solution to be administered via SC injection or IV infusion.
1540502|NCT02665416|Drug|Vanucizumab|Vanucizumab will be provided as solution to be administered via IV infusion.
1540503|NCT02665403|Other|Play intervention|participants received around 30 minutes of hospital play interventions each day, conducted by hospital play specialists. Such interventions consisted of structured and non-structured activities. All these activities were given at the patients' bedside, with or without parental supervision, either once or spreading over an hour, depending on the ward routine.
1540504|NCT02665403|Other|control|Children received standard medical and nursing care, such as vital signs observation, pharmacological treatment and wound and pain management as a control treatment
1540505|NCT02665390|Procedure|Percutaneous cryoablation|Percutaneous cryoablation
1540506|NCT02665377|Drug|ANP|
1540510|NCT02665351|Drug|Peramivir|The two regimens of Peramivir were compared
1540511|NCT02665338|Device|Transcranial Magnetic Stimulation|
1540512|NCT02665325|Drug|TSH-suppressive therapy|Thyroidectomy according to the China thyroid association guidelines for the Management of thyroid nodule and thyroid cancer; followed by TSH-suppressive therapy 6 /12 months.
1540513|NCT02665286|Drug|Orphenadrine|Orphenadrine 100mg PO BID x 7 days
1540514|NCT02665286|Drug|Methocarbamol|Methocarbamol 750mg 1-2 tabs po TID x 7 days
1540515|NCT02665286|Drug|Naproxen|Naproxen 500mg PO BID x 7 days
1540516|NCT02665286|Drug|Placebo|1/2 of placebo packages will be dosed to match methocarbamol: 1-2 tabs po TID x 7days 1/2 of placebo packages will be dosed to match orphenadrine: 1 tab PO BID x 7 days
1540517|NCT02665273|Procedure|Greater occipital nerve block|Bilateral greater occipital nerve block
1540518|NCT02665273|Procedure|Sham|0.5 cc of 0.5% bupivacaine injected intradermally
1540519|NCT02665260|Drug|Cantharidin|cantharidin 0.7% topical liquid
1540520|NCT02665260|Drug|Placebo|Placebo topical liquid
1540521|NCT02665260|Device|Gauze occlusion bandage|Gauze occlusion bandage with adhesive tape
1540522|NCT02665247|Behavioral|C-SIP|In session I, information about sleep and the effects of lack of sleep will be presented. Participants will also be presented with advice and tips on how to improve sleep. Session II will focus on assisting participants overcome any barriers they faced in applying the advice they received in session I; participants will also receive additional information on sleep and sleep-related techniques.
1540523|NCT02665247|Other|Dream discussion|Participants assigned to the control group will attend sessions in which information on sleep is presented in the form of dream discussions.
1540524|NCT02665234|Drug|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
1540525|NCT02665234|Drug|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
1540528|NCT02665208|Other|Treatment As Usual (TAU)|informational pamphlets and information from 1800 quit line + prescription for nicotine replacement therapy (NRT) based on on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
1540529|NCT02665208|Drug|Nicotine Replacement Therapies|a prescription for a nicotine replacement therapy (NRT) (i.e. nicotine replacement patches based on the quantity of baseline self-reported smoking, or nicotine replacement gum (2mg)
1540530|NCT02665208|Behavioral|Text Message Intervention (TMI)|
1540531|NCT02665195|Other|saliva specimen|
1540536|NCT02665156|Procedure|Intracorporeal stapled neobladder using robotic staplers|"Robot assisted radical cystecomy. Separate packages extended pelvic lymph node dissection up to aortic bifurcation. Totally intracorporeal orthotopic ileal neobladder with about 45 cm of ileum according to Vescica Ileal Padovana."
1540537|NCT02665143|Drug|nintedanib and AML induction|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. In the phase I part, all patients will receive the combination with Nintedanib 200mg bid begun at day 8 and continued until end of cycle. If a significant incidence of dose limiting toxicities is demonstrated, Nintedanib will be given at a lower dose level (150mg bid).
1540538|NCT02665143|Drug|AML induction (placebo)|The AML induction regimen combines Idarubicin 12mg/m2/d day 1 to 3 and Cytarabine 0.667g/m2/d CIV day 1 to 3. Nintedanib or placebo will be added at day 8 and continued until end of cycle.
1540539|NCT02665130|Other|Tai-chi plus Indacaterol|Participants perform Tai-chi exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
1540540|NCT02665130|Other|Pulmonary rehabilitation plus Indacaterol|Participants perform conventional exercise 5 days/week and take indacaterol 150ug/day for 24 weeks
1540541|NCT02665117|Drug|Potassium Magnesium Citrate (KMgCit)|KMgCit will be administer for 4 months with chlorthalidone.
1540542|NCT02665117|Drug|Potassium Chloride (KCl)|KCl will be administer for 4 months with chlorthalidone.
1540543|NCT02665117|Drug|Chlorthalidone|Chlorthalidone will be administered for 2-3 weeks. Then either KCL or KMgCit will be added to Chlorthalidone and the combination will be taken for 4 months.
1540544|NCT02665104|Device|transcranial Doppler (TCD) and INVOS monitor|Bilateral transcranial Doppler measurements of the blood flow velocity within the middle cerebral arteries: 1. before local anesthesia, 2. after the onset of local anesthetic, but before skin incision, 3. intraoperatively before clamping the internal carotid artery, 4. one minute after clamping the internal carotid artery, 5. five minutes after clamping the internal carotid artery, 6. fifteen minutes after clamping the internal carotid artery, 7. directly after the restoration of blood flow in the internal carotid artery, 8. postoperatively, 4-6 hours after the intervention.
1540545|NCT02665091|Behavioral|Peer Education Program|
1540546|NCT02665078|Other|Thoracoscopic Ultrasound|We will evaluate the resected specimen using the XLTF-UC180 in the operating room (OR) to determine the localization rate of the targets. Ultrasound measurement and images will be compared to the actual size of the tumor and pathological morphology using HE slides of lung tumor to determine the correlation between those variables. The tumor depth from the lung surface will be also collected to clarify the maximum depth to which the ultrasound can visualize.
1540554|NCT02665052|Device|Home-Based BATRAC plus TTT|Home-based BATRAC training will consist of 60 minutes of training at home (45 minutes using the BATRAC and 15 minutes of TTT) using the BATRAC training will include high intensity bilateral reaching and rest periods using the BATRAC followed by 15 minutes of video guided transition to task training (TTT). These videos will be linked from the VA MyHealtheVet site to study specific Youtube videos of the study therapist demonstrating the exercise. Asynchronous communication between the therapist and participant will be completed using the MyHealtheVet secure messaging system.
1540555|NCT02665052|Device|Lab-based BATRAC plus TTT|Lab-based BATRAC will consist of 60 minutes of training in the lab (45 minutes using BATRAC and 15 minutes of TTT). BATRAC training will include high intensity bilateral reaching and retrieving actions (pushing handles away and pulling them back) on a constrained linear track to promote maximum arm extension. This training will be followed by 15 minutes of transition to task training (TTT) with supervision and support as needed by the therapist.
1540556|NCT02665052|Behavioral|Delayed Entry Usual Care|Participants randomized to this group will initially serve as a control for the first 6 weeks of the study and not receive any study interventions except the protocol study evaluations in the same time intervals as those receiving active interventions and weekly phone calls to record general activity level.
1540557|NCT02665039|Drug|Vinflunine|"Vinflunine will be given intravenously once every 21 days, starting at a dose of:
280 mg/m2 in patients with GFR 40-60 ml/min
250 mg/m2 in patients aged >80 years and/or GFR 30-40 ml/min"
1540558|NCT02665039|Drug|Gemcitabine|Gemcitabine will be given intravenously on day 1 and day 8 of every 21 day cycle, starting at a dose of 1000 mg/m2
1540559|NCT02665039|Drug|Carboplatin|Carboplatin will be given intravenously once every 21 days, starting at a dose of AUC 4.5
1540560|NCT02665026|Procedure|stoma closure at different times|Early closure: stoma closure in 12 weeks after surgery for rectal cancer; Late group: stoma closure in 24 weeks after surgery for rectal cancer
1540561|NCT02665013|Behavioral|Tailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the tailored intervention arm will receive vaccine information tailored specific to her concerns and values at each intervention point.
1540562|NCT02665013|Behavioral|Untailored|Pregnant women will be recruited to the study. The intervention will be delivered to participants prior to the child's 2 month well child visit, when the child is between 4 and 6 months of age, and when the child is 10-12 months of age. The first intervention occurs at enrollment in the study. Participants in the untailored arm will receive vaccine information at each intervention time point, but it will not be tailored to her specific concerns.
1540563|NCT02665000|Procedure|Structured training programme|Participants will undergo 5-days training sessions
1540564|NCT02664987|Other|Patients receiving cancer pain treatment|
1540743|NCT02663778|Behavioral|Task Specific timing and coordination training|stepping and walking patterns to improve timing and coordination of gait
1540750|NCT02663713|Drug|Ticagrelor|Ticagrelor 60mg twice daily
1540565|NCT02664974|Dietary Supplement|Enteral nutrition|"Home Enteral Nutrition was planned to cover the basal energy requirement calculated with Harris Benedict Formula, it was administrated preferentially during nocturnal hours as an integration of oral diet.
Enteral Nutrition included any standard polymeric formula providing 1-1.5 Kcal/mL with carbohydrates 50%-60%, lipids 25%-35% and protein 12%-20%.
Home Enteral Nutrition can be withdrawn in the treated group, after 2 months from discharge, whenever a weight gain ≥ 5% is reported, and oral alimentation is regular and adequate."
1540566|NCT02664974|Other|Dietary counseling|"Specific nutritional advices including total energy and protein requirements were provided to patients and oral high-calorie supplements were prescribed whenever necessary.
Home Enteral Nutrition can be started in patients of the control group, not before two months from discharge, if a further weight loss ≥ than 5% is reported."
1540567|NCT02664961|Drug|TRC105|Subjects will begin by receiving TRC105 weekly. Subjects who achieve a complete response on single agent TRC105 may transition to every two week dosing.
1540568|NCT02664961|Drug|Bevacizumab|Bevacizumab will be dosed every two weeks.
1540569|NCT02664948|Procedure|Early geriatric follow-up after discharge|Multidisciplinary assessement and intervention by physician, nurse and physiotherapist
1540570|NCT02664935|Drug|AZD4547|FGFR Inhibitor
1540571|NCT02664935|Drug|AZD2014|MTORC1/2 Inhibitor
1540572|NCT02664935|Drug|Palbociclib|CDK4/6 Inhibitor
1540573|NCT02664935|Drug|Crizotinib|ALK/MET/ROS1 Inhibitor
1540574|NCT02664935|Drug|Selumetinib|MEK Inhibitor
1540575|NCT02664935|Drug|Docetaxel|Taxane, anti-mitotic cytotoxic chemotherapy
1540576|NCT02664935|Drug|AZD5363|AKT Inhibitor
1540577|NCT02664935|Drug|AZD9291|EGFRm+ T790M+ Inhibitor
1540578|NCT02664935|Drug|MEDI4736|Anti-PDL1
1540579|NCT02664922|Drug|Propofol|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
1 of 2 sedation groups for VT ablation and afib procedures."
1540580|NCT02664922|Drug|Ketamine|"1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
1 of 2 sedation groups for VT ablation and afib procedures."
1540581|NCT02664922|Drug|Remifentanil|1 of 3 sedation groups for SVT, RVOT/PVC ablation, and aflutter procedures.
1540582|NCT02664922|Drug|Sevoflurane|1 general anesthesia group for VT ablations and afib procedures.
1540583|NCT02664909|Drug|Tranexamic Acid|
1540584|NCT02664909|Drug|Placebo (saline)|
1540585|NCT02664896|Other|Knee Osteoarthritis|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, knee measurements, blood draw, and knee radiographs.
1540586|NCT02664896|Other|Healthy Control|Questionnaire completion, strength testing, gait testing, pressure-pain threshold testing, proprioception testing, and knee measurements.
1540587|NCT02664883|Procedure|Computed Tomography|Correlative studies
1540588|NCT02664883|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and urine samples
1540589|NCT02664883|Other|Laboratory Biomarker Analysis|Correlative studies
1540590|NCT02664883|Procedure|Magnetic Resonance Imaging|Correlative studies
1540591|NCT02664870|Procedure|Arthroscopy|Arthroscopic Surgery on the hip, shoulder, or knee
1540592|NCT02664870|Procedure|Arthroplasty|Total hip, shoulder, or knee arthroplasty
1540593|NCT02664857|Drug|Vitamin D|Group D will take 600 IU vitamin D per orally during 12 weeks. At first day and end of the 12 weeks serum vitamin D level will analyse with laboratory testing
1540594|NCT02664857|Drug|Placebo|Group P will not take orally during 12 weeks. This group will only observe by researchers.
1540595|NCT02664844|Behavioral|Physical activity|
1540596|NCT02664805|Drug|LEO 124249 ointment|Ointment
1540597|NCT02664805|Drug|LEO 124249 ointment vehicle|Ointment vehicle
1540598|NCT02664792|Other|Use of [18f]FDG - PET/CT for the diagnosis and staging of non-small cell lung carcinoma|
1540599|NCT02664779|Other|Arrhythmia diagnosis with the 10 steps method|
1540600|NCT02664779|Other|Arrhythmia diagnosis with the 6 steps method|
1540601|NCT02664779|Other|Arrhythmia diagnosis with the 4 steps method|
1540602|NCT02664766|Behavioral|Exercise training program|Supervised 8-week exercise training program. Aerobic exercise (walking, jogging) of increasing duration at 50-60% HRR, at least two sessions per week. Participants will be recording their daily alcohol consumption. Participants will also undergo three trials of acute exercise (before, at the 4th week and at the 8th week of exercise training) in order to investigate whether exercise training can lead to changes in acute responses to exercise. Each trial involves 30 min of exercise on a cycle ergometer at 50-60% HRR.
1540605|NCT02664740|Drug|Topical anti-Staphylococcus bacteriophage therapy|Patients randomized to the experimental arm will receive sterile compress dressings impregnated with a phage solution of 10^7 PFU/ml on days 0, 7 and 14 (unless the wound is already healed, i.e. phage solutions are not applied to healed wounds).
1540606|NCT02664740|Drug|Topical placebo corresponding to anti-Staphylococcus bacteriophage therapy|Patients randomized to the placebo arm will receive sterile compress dressings impregnated with a placebo solution on days 0, 7 and 14 (unless the wound is already healed, i.e. placebo solutions are not applied to healed wounds).
1540744|NCT02663778|Behavioral|Physical activity behavioral intervention|Intervention to encourage participants to be more physically active
1540751|NCT02663713|Drug|Clopidogrel|Clopidogrel 75 mg once daily
1540607|NCT02664727|Behavioral|The effects of acute exercise in heavy drinkers|A group of heavy drinkers and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 50-60% of HRR. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
1540608|NCT02664727|Behavioral|The effects of acute exercise in alcoholic patients|A group of alcoholic patients (10-14 days after detoxification) and a group of healthy controls (individuals without alcohol use disorders) will cycle on a cycle ergometer for 30 min at 55-60% of HRmax. Before and immediately after exercise blood will be drawn and psychological and physiological parameters will be measured.
1540609|NCT02664714|Other|PFMT|Participating volunteers of all groups will receive guidance about the anatomy and function of the pelvic floor muscles (PFM) and how to perform a properly contraction: as strong as possible and eliminating at the most the contraction of the gluteus, abdominals and adductors. For all groups it will be used the same protocol which was developed for this study, with progression parameters of the PFMT based on the recommendations for the strength training of the American College of Sports Medicine (VICKI, 2001).
1540610|NCT02664701|Other|Baseline evaluation with a psychiatrist|Baseline data and questionnaires are established.
1540611|NCT02664701|Other|Individual supportive therapy|6 sessions of individual supportive therapy with a psychologist, 1 session per week for 6 weeks
1540612|NCT02664701|Other|Cognitive behavioural group therapy|6 sessions of cognitive behavioural group therapy with a psychologist, 1 session per week for 6 weeks
1540613|NCT02664701|Other|Evaluations with a psychiatrist|Evaluation withs a psychiatrist in the 10 days following the end of psychotherapy, then at 3, 6, 9, and 12 months.
1540614|NCT02664688|Other|Lumbar stabilization exercises|"The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)"
1540615|NCT02664688|Other|Flexor exercises|The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
1540616|NCT02664675|Procedure|Crown lengthening|After a local anesthesia, gingival tissue is removed around the teeth to extend the length of the crown for aesthetic or prosthetic matter.
1540617|NCT02664675|Procedure|Open Flap Debridement|"After local anesthesia, intra-sulcular incisions are done and a flap is released to access to the intra-bony defect.
Granulation tissue is removed and carefully laid aside for further analysis. Interrupted sutures are done to close the flap."
1540618|NCT02664662|Other|tailored education|Tailored rehabilitated education is which fit for each breast cancer patients after surgery in clinic. We design three of tailored books for experimental group. Each patients will be tailored by three principles. First, the educated times and hours are depended on patients physical function and learning ability. Second, the material is depended on each patient's life experience. Finally, the educated content is depended on patient's operation method.
1540619|NCT02664649|Drug|Apixaban|"Investigational Product is open label apixaban 5 mg tablets taken orally two times a day for 12 months. Subjects with 2 or more of the following characteristics will take apixaban 2.5 mg tablets orally twice daily: age ≥80 years, body weight <60 kg, serum creatinine ≥1.5 mg/dL [133 μMol/L].
- Also, subjects with severe renal insufficiency [calculated Creatinine Clearance (Cr.Cl.) (Cockroft-Gault) between 15-29 ml/min] will take apixaban 2.5 mg tablets orally twice daily"
1540620|NCT02664649|Drug|Standard of care|VKA or Antiplatelet therapy
1540621|NCT02664636|Procedure|Physiotherapy|"Physiotherapy regimen (days 0 to 60): orthopedic maintenance, work on trunk balance, sensorimotor techniques for restoration of motor skills, exercises for standing balance and walking. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. They occur as daily sessions during the first two weeks and then two sessions / day.
This is part of routine care."
1540622|NCT02664636|Procedure|Occupational therapy|"Occupational Therapy (days 0 to 60): Orthopaedic maintenance, exercises for sitting and standing balance, sensorimotor techniques for the restoration of motor skills, grip exercises. Sessions last 30 to 60 minutes depending on the fatigue of the subject and the level of recovery. 1 session is performed per day.
This is part of routine care."
1540623|NCT02664636|Procedure|Functional near-infrared spectroscopy|During the therapy protocol, cortical activation measures using the fNIRS method will be conducted every 15 days (at Day0, Day 15, Day 30, Day 45 and Day 60 for 5 sessions in total) at the technical platform of the Grau du Roi physical therapy centre, during the completion of a standardized motor task (maintaining a level of force) using the healthy upper limb and the paretic upper limb.
1540624|NCT02664623|Procedure|Individual dietary consultations|Individual dietary consultations with a dietician will be held at inclusion, month 1 and month 3. Consults consist of a personal interview where the dietician delivers comprehensive information to the patient on how to optimize calcium intake and reduce the risk of fractures; the dietician questions the subject on his/her diet and reassesses the quality and quantity of calcium intake during the 3 days preceding the consultation through a survey calculation software based on data from CIQUAL.
1540625|NCT02664623|Procedure|Dietary advice sheet|"At the beginning neurological consult, patients will be delivered a dietary advice sheet called Grio."
1540626|NCT02664610|Behavioral|Text Messaging|hypertensive participants will be randomized to receive tailored, motivational text messages
1540627|NCT02664597|Procedure|ADNEXMR Scoring System|Patients will undergo a pelvic MR imaging (1.5T or 3T) as routinely performed, including morphological sequences (T2, T1 with and without fat suppression and T1 after dynamic gadolinium injection) and functional sequences (perfusion and diffusion-weighted sequences). Prospectively, a senior radiologist analyzes the different MR criteria to characterize adnexal masses. The reader will classify the mass using ADNEXMR SCORING system and the patient will be managed according to the score
1540628|NCT02664597|Other|Standard strategy|In control group, the complex adnexal mass will be managed according to the standard strategy and treatment plan routinely used by the multidisciplinary team.
1541221|NCT02660281|Drug|Melphalan|Melphalan
1540629|NCT02664571|Device|Pet scan with FBB|"Patients will have a pet scan with Florbetaben (NEURACEQ : FBB). All other care corresponds to routine care.
Florbetaben is used during pet scans to visualize beta amyloid plaques and cannot be a separate intervention in and of itself."
1540630|NCT02664571|Device|MRI scan|Subjects will have an MRI scan at inclusion.
1540631|NCT02664571|Biological|APO E genotyping|Subjects will have APO (apolipoprotein) E genotyping if not already known.
1540632|NCT02664558|Drug|ubenimex|
1540633|NCT02664558|Other|placebo|
1540634|NCT02664545|Device|BEAR Scaffold|A sponge, or scaffold, which is surgically placed between the torn ligament ends and sutures are used to repair the torn anterior cruciate ligament.
1540635|NCT02664545|Procedure|Tendon Graft|A graft of tendon (either two hamstring tendons from the back of the knee or bone-patellar tendon-bone graft from the front of the knee)
1540636|NCT02664532|Other|Miller group|Miller blade was used for laryngoscopy
1540637|NCT02664532|Other|Macintosh group|Macintosh blade was used for laryngoscopy
1540638|NCT02664519|Behavioral|Forearm exercise training|Subjects will be asked to squeeze a tennis ball repeatedly for at least 30 min/day for 28 days at an approximate rate of 20 squeezes/min.
1540639|NCT02664506|Behavioral|Word repetition after a time delay.|This is a behavioral intervention, Word repetition after a time delay. Individuals listen to words and repeat them after 5 or 10 seconds.
1540640|NCT02664493|Drug|Methylprednisolone|Steroid pulse therapy : Methylprednisolone 0.5 g daily for 3 days, followed by a tapered dose of 60 mg per day for a period of five days.
1540641|NCT02664480|Other|Salivary alpha-Amylases|Investigators will collect Salivary alpha-Amylases before and after ovulation
1540642|NCT02664467|Device|Philips EnergyUp EnergyLight HF3419/01|Bright light therapy (10'000 lux) for 60 minutes after wake-up
1540643|NCT02664467|Device|Philips EnergyUp EnergyLight HF3419/01|Placebo dim light (500 lux) for 60 minutes after wake-up
1540644|NCT02664454|Other|health care organization|"Nurse-led or GP-led Geriatric assessment combined with an educational seminar focused on GA and personalized care-plan as well as a dedicated hotline for general practitioners seeking a geriatric advice
Interactive educational seminar Primary care"
1540645|NCT02664441|Drug|Exenatide|Weekly injections of active drug.
1540646|NCT02664441|Drug|placebo|Weekly placebo injections
1540647|NCT02664428|Dietary Supplement|PreBIOil|A daily dose of about 90 gram will be given for 8 weeks
1540648|NCT02664428|Dietary Supplement|Control|A daily dose of about 90 gram will be given for 8 weeks
1540651|NCT02664389|Genetic|Genetic analysis|Sequencing of 200 selected genes in the different study populations
1540652|NCT02664376|Other|Sarcopenia detection|"The assessment of sarcopenia is performed according to the recommendations of the EWGSOP (European Working Group on Sarcopenia in Older people). Three measurements are made:
Muscle mass measurement by dual energy X-ray absorptiometry (DEXA).
Walking speed measurement
Hand grip test
A diagnosis of sarcopenia is established if the walking speed is inferior to 0.8 m/sec, the muscular strength is low and the muscular mass is low.
Data regarding the geriatric characteristics of this sarcopenic population will be collected."
1540653|NCT02664363|Biological|EGFRvIII CAR T cells|The name of the drug is CAR gene-modified T cells or abbreviated as EGFRvIII CARs. The class of action is a biological and the mechanism of action is cytotoxicity. The drug substance is autologous T cells transduced with a retroviral vector encoding for a chimeric antigen receptor (CAR) directed against the tumor specific antigen, EGFRvIII. EGFRvIII CARs are genetically engineered T cells that have been taken from patients with GBM ex vivo to express a CAR recognizing the GBM tumor-specific antigen EGFRvIII, which is expressed on a subset of GBMs but not in normal human tissues with the aim of mediating regression of their tumors. Patients' CARs will be radiolabeled with 111In for correlative studies in the expanded cohort.
1540654|NCT02664350|Genetic|CYP2D6|Gentic testing for CYP2D6 metabolic pathway will be performed at baseline.
1540655|NCT02664350|Behavioral|Brief Pain Inventory-Short Form (BPI-SF)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
1540656|NCT02664350|Behavioral|M.D. Anderson Symptom Inventory (MDASI)|This questionnaire will be completed at baseline and weeks 2, 4, 6 and 8.
1540657|NCT02664350|Genetic|OPRM1|Genetic testing of the OPRM1 will be performed after week 8.
1540658|NCT02664337|Other|Decision tool|A survey will be created for each condition that reflects the most important aspects of the corresponding treatment process.
1540659|NCT02664337|Other|Standard treatment information|Participants will receive information pertaining to one of the 11 specified musculoskeletal conditions. This information will reflect information commonly distributed to patients seeking to make a decision concerning treatment for their condition.
1540660|NCT02664311|Device|Jet Ventilation|Patients are randomized to receive either jet or conventional ventilation during this study
1540661|NCT02664311|Device|Conventional ventilation|Conventional ventilator - control arm
1540664|NCT02664272|Procedure|Total Hip Arthroplasty|
1540665|NCT02664259|Procedure|VBN|VBN is carried out by a VBN software（DirectPath;Olympus,Japan) which can automatically create virtual bronchoscopic images.
1540666|NCT02664259|Procedure|EBUS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm.
1540667|NCT02664259|Procedure|X-ray|The radiograph fluoroscopy is performed when the probe is confirmed to reach the lesion by EBUS image ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
1540668|NCT02664246|Device|percutaneous coronary intervention|
1540747|NCT02663739|Device|Zenith® TXD|Zenith® TXD Dissection Stent Graft System for treatment of patients with aortic dissection of the descending thoracic aorta
1540748|NCT02663726|Other|Yoga|10 weekly 75-min sessions of specialised yoga
1540669|NCT02664233|Behavioral|Mobile and connected health|Patients will use a smart phone and a fitness tracker for self-monitoring of diet and physical activity for 3 months; 3) Smart phones will provide feedback with graphical presentation of self-monitored information to patients; 4) Patient self-monitored information will be integrated into Chronicle Diabetes, so that educators will be able to view this information and give feedback in a follow-up visit.
1540672|NCT02664207|Procedure|Open Fetal Repair of Myelomeningocele|Fetal repair of myelomeningocele in women with additional medical factors that would have excluded them from this treatment under the MOMs trial inclusion/exclusion criteria
1540673|NCT02664194|Device|Proteus® Cooling System|Intravascular hypothermia as an adjunctive method to primary percutaneous coronary intervention, adjunct hypothermia methods and parameters, using Proteus® Cooling System.
1540674|NCT02664194|Procedure|Primary Percutaneous Coronary Intervention|Primary percutaneous coronary intervention
1540675|NCT02664181|Drug|Nivolumab|Nivolumab will be given at 3mg/kg by IV every two weeks until progression
1540676|NCT02664181|Drug|oral decitabine|oral decitabine ~0.2 mg/kg 60 minutes after the THU, twice weekly on consecutive days.
1540677|NCT02664181|Drug|Tetrahydrouridine|Oral THU ~10 mg/kg twice weekly on consecutive days
1540678|NCT02664168|Device|Aquacel Ag Surgical Dressing|
1540679|NCT02664168|Device|Single-Use Negative Pressure Wound Therapy (PICO)|
1540684|NCT02664142|Procedure|BIS Group|BIS monitoring will be used in the BIS Group patients. The BIS value will be known to the anaesthetist, who will be able to act accordingly.
1540685|NCT02664142|Procedure|Non-BIS Group|BIS monitoring will be used in the Non-BIS Group patients. The BIS value will NOT be known to the anaesthetist and will be observed by a trained co-investigator, with subsequent evaluation.
1540686|NCT02664142|Drug|Anaesthetics|Anaesthetics will be administered in both experimental groups, in order to maintain the required general anaesthesia.
1540687|NCT02664129|Other|Video self-observation|Patients will watch the video of them in acute decompensation phase then they will be asked about their emotions, their understanding and awareness of mental illness
1540688|NCT02664129|Other|Non Self video observation|Patients will not watch the video of them in acute decompensation phase.
1540689|NCT02664116|Drug|Diclofenac postassium powder for oral solution and placebo injection|Diclofenac postassium powder for oral solution 50 mg in 1 ounce water orally, single dose and placebo normal saline 2ml intramuscular injection, single dose
1540690|NCT02664116|Drug|Ketorolac intramuscular injection and placebo oral solution|ketorolac 60 mg in 2 ml intramuscular injection, single dose and placebo oral solution, 1 ounce, single dose
1540691|NCT02664103|Drug|Fixed-dose combination of capecitabine and cyclophosphamide SAR439281|Pharmaceutical form:Tablet Route of administration: Oral
1540692|NCT02664077|Drug|Regorafenib|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
1540693|NCT02664077|Drug|Placebo|3 tablets once a day by mouth for 21 consecutive days of 28 day cycle for 26 cycles
1540694|NCT02664064|Behavioral|Prevent|Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
1540695|NCT02664051|Drug|Nalcrom|"Drug: disodium cromoglycate 100mg 4x2 daily
Other Names:
• Nalcrom"
1540696|NCT02664051|Drug|placebo|100mg 4x2 daily mannitol
1540698|NCT02664025|Procedure|vaginal examination simulator|
1540699|NCT02664012|Other|Own Brand Menthol Cigarette|combustible menthol cigarette brand style smoked most frequently by subject
1540700|NCT02664012|Other|Electronic Menthol Cigarette #1|VUSE® Digital Vapor Cigarette (menthol flavor, 14 mg nicotine)
1540701|NCT02664012|Other|Electronic Menthol Cigarette #2|VUSE® Digital Vapor Cigarette (menthol flavor, 29 mg nicotine)
1540702|NCT02664012|Other|Electronic Menthol Cigarette #3|VUSE® Digital Vapor Cigarette (menthol flavor, 36 mg nicotine)
1540703|NCT02664012|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
1540704|NCT02663999|Drug|diazepam nasal spray|diazepam nasal spray at two dose levels (DL). One dose of diazepam nasal spray is administered as two intranasal sprays; one in each nostril using a nasal spray device.
1540705|NCT02663986|Behavioral|Organizational Skills Training (OST) Intervention|
1540706|NCT02663960|Other|fixed citrate doses protocol|fixed doses of anticoagulant citrate dextrose solution to meet a circuit citrate concentration of 4 mmol/l.
1540707|NCT02663960|Other|adjusted citrate doses protocol|the starting infusion rate of anticoagulant citrate dextrose solution be set 2.5 % of blood flow and then be adjusted to obtain postfilter ionized calcium levels of less than 0.40 mmol/l.
1540708|NCT02663947|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 7.5-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Three measurements are taken for each optic nerve in the transverse plane, with the probe being horizontal. The final ONSD is the mean of these measurements.
1989883|NCT02337348|Other|Optical coherence tomography|Preintervention imaging
1989884|NCT02337348|Radiation|Coronary angiography|Conventional coronary intervention
1540709|NCT02663934|Behavioral|Exercise|The resistance exercise training component will follow aerobic exercise and will consist of 4 upper and 3 lower body routines. A combination of guided-motion machines and free weights will be used. Voluntary maximum strength will be measured during the first 4 sessions on each exercise station. The program will initially consist of 1-2 sets of each exercise while lifting a weight that causes muscle fatigue after 8-10 repetitions. The trainer will monitor each participant's exercise response, and when the participant can comfortably lift the weight for 12 repetitions on any exercise, the weight will be increased to cause the muscle group to fatigue after 8 repetitions. This progressive 8-12 repetition cycle is repeated for each exercise over 26 weeks.
1540710|NCT02663934|Behavioral|Stretching and Social Interaction|Participants will receive instructions on stretching, range of motion, limbering, and toning. Activities will focus on flexibility enhancement. Along with the stretching and flexibility, this group will have a social interaction component. They will have discussions and interact with trainers and coordinators during all their sessions. These participants will be supervised by the same trainer and will receive the same amount of attention and class interaction as participants in the EXS program.
1540711|NCT02663921|Other|Part A: Baseline-Week 2|"The study doctor will shine 2 different light bulbs (one a regular or incandescent bulb and the other an LED light bulb) on 12 different areas of patients skin approximately 6 square centimeters in size (less than 1 square inch or the size of your thumb nail). Each light bulb will be exposed to your skin for approximately 20 - 35 minutes. After exposure, the study doctor will perform skin assessments at 3 time points:
Immediately after the light exposure;
30 minutes after light exposure; and
1 hour after light exposure."
1540712|NCT02663921|Other|Part B: Week 4-Week 12|"The study doctor will perform the same 4 skin assessments used in Part A at each visit to assess potential changes in your skin: Digital Photography
Visual Clinical Assessment
Spectroscopy
Colorimetry"
1540715|NCT02663895|Drug|Oral treprostinil|Treprostinil 0.125 mg TID orally, which will be increased by 0.125 mg TID every 3 to 4 days as tolerated
1540716|NCT02663882|Behavioral|self control practice - smoking related task|participants will be asked to practice a smoking-related self control task for 7 days: they will be asked to resist smoking when they have cravings as much as possible during the day
1540717|NCT02663882|Behavioral|self control practice - non-smoking related task|participants will be asked to practice a non-smoking-related self control task for 7 days: they will be asked to keep a straight posture as much as possible during the day
1540718|NCT02663856|Other|observational|Self assessment of ageing transition using a frailty index through MySAwH app
1540719|NCT02663843|Device|i-gel airway|Fibreoptic intubation via i-gel airway device
1540720|NCT02663843|Device|air-Q airway|Fibreoptic intubation via air-Q airway device
1540721|NCT02663830|Drug|Sildenafil & clomiphene citrate|105 Patients will receive 25 mg sildenafil citrate 6hourly orally (day 6 to the end of the cycle), and clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
1540722|NCT02663830|Drug|clomiphene only|105 Patients will receive clomiphene citrate 100 mg/day (day 2 to 6) orally by the patient, for induction of ovulation
1540723|NCT02663817|Device|CT Scan|
1989889|NCT02335411|Biological|pembrolizumab|
1540726|NCT02662686|Other|Transfer according to morphological criteria|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to morphological criteria (control group).
1540727|NCT02662686|Other|Transfer according to the MitoScore results|Embryos will be analyzed by PGS and mitochondrial score on day 3 or day 5/6 biopsy and transferred on day 5/6, according to the MitoScore results (experimental group).
1540728|NCT02662673|Device|Focal High Intensity Focused Ultrasound (HIFU) treatment|Focal High Intensity Focused Ultrasound (HIFU) treatment for localized prostate cancer (maximum two foci). HIFU treatment is using high energy ultrasound focused at the focal point to achieve precise tissue destruction. This mini-invasive therapy is using an endo-rectal approach to deliver the treatment, using a probe composed of a combined imaging and treatment transducer. The treatment is monitored by real-time ultrasound. The treatment planning is performed by the urologist, contouring the area to be treated (MRI target + security margins around the tumor) and the treatment phase is automatically performed by the robotic device.
1540729|NCT02662660|Drug|Port-sites infiltration:Bupivacaine0.25%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
1540730|NCT02662660|Drug|Epidural analgesia:Levobupivacaine0,125%|Port-sites infiltration will be performed with 10 ml of Bupivacaine 0.25%, applying 2 ml under the aponeurotic layer in each port.
1540731|NCT02662660|Drug|Metamizole and Acetaminophen iv|Associated Intravenous analgesia include Metamizole 2g/8h and Acetaminophen 1g/8h, alternating every 4 hours.
1540732|NCT02662647|Drug|Decitabine 20 mg/m²/day for 5 days|
1540733|NCT02662634|Biological|AGS-003-LNG|autologous dendritic cell immunotherapy
1540734|NCT02662634|Drug|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
1540735|NCT02662634|Drug|Abraxane|Paclitaxel destroys cancer cells by preventing the normal breakdown of microtubules during cell division.
1540736|NCT02662634|Drug|Alimta|By inhibiting the formation of precursor purine and pyrimidine nucleotides, pemetrexed prevents the formation of DNA and RNA, which are required for the growth and survival of both normal cells and cancer cell
1540737|NCT02662634|Drug|Cisplatin|Binds to and causes crosslinking of DNA, which ultimately triggers apoptosis
1540738|NCT02662634|Drug|Taxol|Mechanism of action involves interference with the normal breakdown of microtubules during cell division.
1540739|NCT02662634|Radiation|Radiation Therapy|Causes DNA strand breaks.
1540740|NCT02663778|Behavioral|Strength training|weight lifting to increase muscle strength
1540741|NCT02663778|Behavioral|Endurance training|treadmill walking to increase endurance
1540742|NCT02663778|Behavioral|Flexibility training|stretches to improve flexibility
1989890|NCT02335411|Drug|cisplatin|
1989891|NCT02335411|Drug|5-FU|
1989892|NCT02335411|Drug|capecitabine|
1540752|NCT02663700|Drug|Artesunate|Four tablets of 50mg each, totaling 200mg will be given in a single calendar day
1540753|NCT02663700|Biological|PfSPZ|PfSPZ is a candidate vaccine, it consists of a suspension of purified, live-attenuated cryopreserved Pf sporozoites in a cryoprotectant.
1540754|NCT02663700|Other|Placebo|Placebo
1540755|NCT02663687|Drug|Recombinant human C1 esterase inhibitor|Subjects will receive escalating doses I-IV as both IV and SC injections
1540756|NCT02663687|Drug|Placebo|Subjects will receive matching placebo
1540757|NCT02663687|Drug|SHP623|SHP623
1540758|NCT02663687|Drug|Placebo|Placebo
1540759|NCT02663674|Drug|Fluconazole|Fluconazole is a synthetic triazole antifungal agent.
1540760|NCT02663674|Other|Placebo|standard of care
1540761|NCT02663661|Procedure|Metabolic Challenge Admission|A ten hour clinical test involving drinking a liquid mixed meal followed four hours later by the induction of hypoglycemia with intravenous insulin administration.
1540762|NCT02663661|Other|CGM home test|A home study starting immediately after the clinical test during which participants will wear a continuous glucose monitor (CGM) for one week.
1540763|NCT02663635|Device|Safe'N'Sound|
1540764|NCT02663622|Drug|CD24Fc|
1540765|NCT02663622|Drug|Methotrexate|
1540766|NCT02663622|Drug|Tacrolimus|
1540767|NCT02663622|Other|Placebo|
1540768|NCT02663609|Other|No intervention|No treatment (intervention) was administered.
1540769|NCT02663596|Drug|Vancomycin|Patient requiring CRRT and vancomycin that provide consent will be given vancomycin as a continuous infusion by mixing the vancomycin into the CRRT solution(s)
1540770|NCT02663583|Behavioral|Symptom Questionnaires|"Intensity-Modulated Proton Therapy or( IMPT) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, every week during IMPT, at 3 months, and at 6 months.
TransOral Robotic Surgery (TORS) Group: Symptom questionnaires about symptoms of cancer and how they affect life at work and at home, diet, and speech completed at baseline, after TORS, at 3 months, and at 6 months."
1540771|NCT02663583|Behavioral|Dysphagia Inventory Questionnaire|"Intensity-Modulated Proton Therapy or( IMPT) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, every week during IMPT, at 3 months, and at 6 months.
TransOral Robotic Surgery (TORS) Group: Dysphagia Inventory questionnaire about how difficult it is to swallow completed at baseline, after TORS, at 3 months, and at 6 months."
1540772|NCT02663583|Behavioral|Activity Bands|Activity bands given to participant at baseline. Participant wears the band 24 hours a day for 1 week leading up to all study visits.
1540773|NCT02663570|Drug|Melatonin|
1540774|NCT02663544|Other|Limited dairy diet|Consumption of no dairy foods other than 3 servings per week of nonfat milk for 12 weeks
1540775|NCT02663544|Other|Low-fat dairy diet|Consumption of 3.3 servings per day of low-fat milk, yogurt, and cheese for 12 weeks
1540776|NCT02663544|Other|Full-fat dairy diet|Consumption of 3.3 servings per day of full-fat milk, yogurt, and cheese for 12 weeks
1540777|NCT02663531|Device|DVA|
1540778|NCT02663531|Device|FDOCT|
1540779|NCT02663531|Device|Pattern ERG|
1540780|NCT02663531|Device|Optical Coherence Tomography|
1540781|NCT02663518|Drug|TTI-621|Monotherapy
1540782|NCT02663518|Drug|TTI-621 plus Rituximab|Combination therapy
1540783|NCT02663518|Drug|TTI-621 plus Nivolumab|Combination therapy
1540784|NCT02663505|Procedure|Patients receiving the surgery planned for them|No intervention will be performed apart from the surgery planned for each patient. Different aspects of data i.e. patient-centered and surgery-centered will be collected.
1540785|NCT02663492|Device|TEAS|The patients will be treated by their assigned acupuncture stimulation in 7 days. The surface electrical stimulation devices and application parameter are: G6805-II pulse acupuncture treatment instrument from Shanghai Medical Technology Company, Ltd (Shanghai, China); sparse-dense wave stimulation (sparse wave 30Hz; dense wave 100Hz) with an intensity of 6-15 V; and the corresponding parts of the body experienced a slight quiver, with a duration 20 minutes each time.
1540786|NCT02663492|Drug|Sanguisorba officinalis L.|Sanguisorba officinalis L., a Leukogenic medication, named Diyu Shengbai Pian (Chengdu Diao Tianfu Pharmaceutical Group Co., Ltd., China) will be taken 0.4g each time by 3 times per day.
1540787|NCT02663479|Dietary Supplement|Cardiopressin|
1540788|NCT02663479|Dietary Supplement|Placebo|
1540789|NCT02663466|Procedure|erroneous off-midline closures|All patients with pilonidal sinus recurrent disease following Limberg flap reconstruction in the recurrent group were examined by the authors in each study center and high resolution close-up photos of the patients' sacrococcygeal area were taken. These photos were then sent to all authors to asses and reach a collective decision to classify the erroneous off-midline closure technique and precisely measuring the distance between the flap border and the midline in the cleft. Same evaluation method was applied to the patients in nonrecurrent group. Following the completion of the assessments, all digital data of the patients were permanently deleted.
1540790|NCT02663453|Drug|multicomponent lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
1540791|NCT02663453|Drug|pure soybean oil lipid emulsion|Lipids were first administered at a dose of 1gm/kg/day within 24 hours after birth for both groups; lipid dosage was increased by an increment of 0.5 gm/kg/day until the maximal dose of 3.5 gm/kg/day was reached.
1540792|NCT02663440|Radiation|Hypofractionated IMRT|Hypofractionated IMRT
1540793|NCT02663440|Biological|Granulocyte-macrophage Colony-stimulating Factor|Granulocyte-macrophage Colony-stimulating Factor
1540794|NCT02663440|Drug|Temozolomide|Temozolomide
1540795|NCT02663427|Device|serological examination and gastroscope|
1540796|NCT02663414|Device|Atlas Knee System|The Atlas Knee System is an approved device (CE Marked) and is an extra-capsular knee implant specifically designed to treat patients with uni-compartmental, medial knee osteoarthritis (OA).
1540797|NCT02663401|Behavioral|Front-of-pack labelling 5-CNL|Introduction of the 5-CNL Front-of-pack nutrition label on shelf display tags for every food and beverage sold in the cafeteria
1540798|NCT02663388|Procedure|gastric bypass, sleeve, gastric banding|
1540993|NCT02661841|Other|LI-Guided Therapy|Preemptive treatment according to LI monitoring
1540799|NCT02663375|Device|ACURATE TA™ Transapical Aortic Bioprosthesis|ACURATE TA™ Transapical Aortic Bioprosthesis is intended for subjects with severe symptomatic aortic stenosis and are considered high risk for surgical conventional Aortic Valve Replacement.
1989893|NCT02334527|Drug|Palbociclib|125 mg capsule will be taken once per day orally and continuously for 3 weeks followed by 1 week off.
1540801|NCT02663349|Behavioral|Social Cognition and Intervention Training|A manualized group therapy that teaches social cognitive skills.
1540802|NCT02663349|Behavioral|Computer Skills|Computer Application course
1540803|NCT02663336|Other|Comparison ABPM with OBPM|No interventions
1540804|NCT02663323|Device|MeRes100 Sirolimus Eluting Bioresorbable Vascular Scaffold System|
1540805|NCT02663310|Procedure|Surgery|Surgery treatment of the injured vertebra(e), internal fixation of the vertebral column, and bilateral laminectomy for epidural decompression were followed directly by neurosurgical management, including separation of the arachnoid adhesion to restore cerebrospinal fluid flow and debridement of the spinal cord necrotic tissue with concomitant intramedullary decompression.
1540806|NCT02663310|Procedure|Rehabilitation|The patients need to do intensive rehabilitation everyday. （1）The limb comprehensive training is Kunming Locomotor exercise, 60 minutes twice per day.(2)The exercise therapy includes sit-ups by 30 times, twice per day; half bridge exercise by 10 times, twice per day; backward flight movement by 10 times, twice per day; sling exercise training by 30 minutes, twice per day; and postural transfer functional training by 10 minutes, twice per day. (3)The balance training include ball toss training by 10 minutes, twice per day; and balance board training by 10 minutes, twice per day. (4)The wheelchair training will be taken 20 minutes each, twice per day. (5)The isokinetic training needs to perform 20 minutes each, twice per day.
1540807|NCT02663297|Drug|ATLCAR.CD30 cells|"Three dose levels will be evaluated:
Group One, 2x10^7 cells/m^2
Group Two, 1x10^8 cells/m^2
Group Three, 2x10^8 cells/m^2;
Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc."
1540808|NCT02663284|Drug|Ropivacaine 0.5%|Ropivacaine is used to performed the perineural block
1540809|NCT02663271|Drug|Bevacizumab|Bevacizumab will be given at 10mg/kg IV every 2 weeks.
1540810|NCT02663271|Device|Optune|Optune will be worn continuously for 12 months. Optune is programmed by Novocure to deliver 200 kHz TTFields in two sequential, perpendicular field directions at a maximal intensity of 707mARMS. There will be no adjustments made to the device by investigators or patients/caregivers.
1540811|NCT02663271|Other|Brain MRI|Brain MRI will be done at screening and every 8 weeks.
1540812|NCT02663271|Other|Quality of Life Questionnaires|The quality of life questionnaires will be performed within 14 days of treatment and every 4 weeks.
1540813|NCT02663258|Drug|Pembrolizumab|
1540814|NCT02663245|Other|Intervention 1|"Diabetes specific consultation
Basic training in clinical guidelines
Platform of communication for professionals
Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hours training programme to update and review the training of month 0.
7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.
Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
1540815|NCT02663245|Other|Intervention 2|"7-hour training programme in group coaching for primary care professionals with a theoretical and practical approach.
Training update to review and evaluate actual cases where the coaching strategy has been applied 2-hour training programme to update and review the training of month 0.
Basic training in clinical guidelines.
Platform of communication for professionals.
Intervention based on text messaging to patients to remind them of strategies that promote behaviour change in relation to diabetes."
1540816|NCT02663219|Behavioral|Intervention|The intervention arm will provide a Case Manager (CM) intervention package designed to enhance linkage to care, antiretroviral treatment (ART) initiation, treatment adherence and retention in care.
1540817|NCT02663206|Procedure|peroral endoscopic myotomy|peroral endoscopic myotomy
1540818|NCT02663206|Procedure|Botulinum toxin injection|endoscopic Botulinum toxin (BTX) injection at lower esophagus
1540819|NCT02663193|Other|No Intervention|Participants who are receiving enzalutamide or abiraterone acetate in combination with prednisone in a clinical practice setting will be observed for tolerability and quality of life.
1540820|NCT02663180|Behavioral|Educational program|Educational strategies: 2 Lecture about depression 30 minutes supported by group discussion, brochures and display of posters with mental-health slogans on depression in the schools.
1540821|NCT02663180|Behavioral|Video contact|Contact strategies: Investigators will show a video of a young male who had been diagnosed with depression. The video presented information that was moderately disconfirming of prior stereotypes by balancing the individual's difficulties resulting from Depression, with his ability to live a normal life.
1540822|NCT02663167|Behavioral|Internet-delivered Cognitive Behavioral Therapy|The treatment consists of a standard cognitive behavioral therapy for obsessive-compulsive disorder. The treatment is delivered through an Internet platform. The child and his/her parent(s) work through the treatment with regular therapist contact several times per week.
1540823|NCT02663154|Drug|Aromatherapy inhaler|Inhalation of commercial essential oil preparation (QueaseEASE) delivered in the commercial inhaler package in postanesthetic care unit after surgery in paediatric patients complaining of nausea
1540824|NCT02663154|Drug|Saline inhaler|Inhaler is similar in design and function as the intervention inhaler only with saline rather than essential oils. Inhaler provided by the manufacturer QueaseEASE (Soothing Scents, Inc, Enterprise, AL)
1540825|NCT02663141|Drug|Losartan|
1540826|NCT02663141|Drug|Intravitreal bevacizumab|
1540827|NCT02663141|Drug|Placebo|
1540828|NCT02663128|Drug|Lanabecestat|Administered orally
1540829|NCT02663115|Other|Biopsy of the diaphragmatic muscle|
1540830|NCT02663115|Other|Skeletal muscle biopsy|
1540831|NCT02663102|Other|Data collection|Safety monitoring and evaluation: ‒ Recording of all AEs during the study period using diary cards, follow-up contact via telephone or email. ‒ Recording of SAEs throughout the study period for each subject.
1540832|NCT02663089|Drug|[14C]-GSK961081 solution for IV infusion|Subjects will receive 10 mL of solution equivalent to 4 mcg of [14C]-GSK961081 (approximately 6.2 kilobecquerel [kBq]) intravenously as a single dose over 1 hour.
1540833|NCT02663089|Drug|[14C]-GSK961081 oral solution|Subjects will receive 10 mL of solution equivalent to 200 mcg of [14C]-GSK961081 (approximately 311 kBq) orally as a single dose with up to 250 mL of water.
1540834|NCT02663089|Drug|GSK961081 dry powder for inhalation|Subjects will receive single dose of 4 actuations of 300 mcg GSK961081 per actuation (1200 mcg GSK961081 total) as inhalation immediately after the start of infusion.
1540835|NCT02663063|Device|SSP treatment|SSP treatment 5 times a week
1540836|NCT02663050|Other|Kinesio taping|Patients will be taped for four days , ıt will start at the begining of the Dysmenorrhea
1540837|NCT02663050|Drug|NSAID's|twice a daily
1540838|NCT02663024|Biological|idursulfase beta|IV, weekly infusion for 24 weeks
1540839|NCT02663024|Biological|idursulfase|0.5 mg/kg, iv, weekly infusion for 24 weeks
1540840|NCT02663011|Other|Language Evaluation-Preschool Language Scale Corrected edition(PLS-C), Lin|"To assess age and gender effect in the language error type (semantics, syntax and pragmatics)of developmental delay preschool aged children, a standardize tool Preschool Language Scale Corrected edition(PLS-C), Lin was adopted for evaluation."
1540841|NCT02662985|Drug|AIN457 (secukinumab)|"Is a recombinant monoclonal antibody which neutralizes the activity of IL-17A, and has been shown to be effective in treating patients with moderate-to-severe plaque psoriasis.
Secukinumab 150 mg provided in 1 mL pre filled syringes (PFS) for s.c. injection. The 300 mg dose will be administered as 2 × PFS injections."
1540842|NCT02662985|Drug|Placebo|Secukinumab placebo provided in a 1 mL PFS for s.c. injection.
1540843|NCT02662972|Drug|Botulinum Toxin Type A|
1540844|NCT02662959|Drug|Irinotecan|180 mg/m2, IV (in the vein) on day 1 of each 14 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1540845|NCT02662946|Procedure|ICG- angiography|Angiography with ICG prior to and after anastomosis. Extension of colon resection based on ICG angiography results
1540846|NCT02662946|Procedure|No angiography|Extension of resection based on subjective measures
1540847|NCT02662933|Other|Bedside assessment|"The study intervention consists of a bedside functional assessment to be administered to eligible, consented subjects who are hospitalized with a new diagnosis of AML or are undergoing workup for suspected AML diagnosis. All subjects will be enrolled within 5 days of admission to the hospital for known or suspected AML or within 5 days of new confirmed diagnosis of AML obtained during a hospitalization for other indications. All measures will be performed by a trained examiner during a face to face interview.
Bedside assessment measures will be repeated once for subjects who complete induction chemotherapy within 2-8 weeks post discharge from initial hospitalization."
1540848|NCT02662920|Other|No Intervention|
1540849|NCT02662907|Procedure|Barium Swallow|Participants receive modified barium swallow at baseline and after 8 weeks of using the EMST device
1540850|NCT02662907|Behavioral|Questionnaires|Questionnaires completed about symptoms and quality of life at baseline, after 8 weeks of using the EMST device, and 12 months after completing the study.
1540851|NCT02662907|Device|Expiratory Muscle Strength Training (EMST) Device|Participant uses the EMST device at home on a 5-5-5 schedule (5 repetitions, 5 sets, 5 days per week) for 8 weeks.
1540852|NCT02662907|Device|Digital Manometer|Digital manometer used to test how forcefully participant is able to exhale and cough at baseline, and one time each week for 8 weeks while using the EMST device.
1540853|NCT02662907|Behavioral|Neurocognitive Exams|Participants given neurocognitive exams at baseline.
1540854|NCT02662907|Drug|Barium|Participants receive barium prior to modified barium swallow at baseline and after 8 weeks of using the EMST device.
1540855|NCT02662894|Drug|Valsartan 160mg + Rosuvastatin 20mg|1 tablet, oral, a day
1540856|NCT02662894|Drug|Valsartan 320mg + Rosuvastatin 20mg|1 tablet, oral, a day
1540857|NCT02662894|Drug|Diovan® 160mg + Crestor® 20mg|Take together 1 tablet of Diovan (160mg) plus 1 tablet of Crestor (20mg), oral, once daily.
1540858|NCT02662894|Drug|Diovan® 320mg + Crestor® 20mg|Take together 1 tablet of Diovan (320mg) plus 1 tablet of Crestor (20mg), oral, once daily.
1540859|NCT02662881|Device|PerFuse Percutaneous Decompression System|Core decompression with PerFuse
1540860|NCT02662881|Device|BioCUE Platelet Concentration System|PRP injection through the PerFuse cannula into core decompression site
1540861|NCT02662855|Other|WHO-recommended therapies|symptomatic and supportive treatments according to the WHO manual
1540862|NCT02662855|Drug|Favipiravir|oral administration of Favipiravir tablets
1540863|NCT02662842|Device|FlowSmart Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
1540864|NCT02662842|Device|Current Infusion Set|Use of set for subcutaneous insulin infusion, with set change every three days.
1540865|NCT02662829|Behavioral|Community-based intervention|
1540866|NCT02662829|Other|Standard of care|
1540867|NCT02662816|Device|Proton magnetic resonance spectroscopy (1H MRS)|
1540868|NCT02662816|Other|a protein rich breakfast at home|
1540869|NCT02662816|Other|a protein rich lunch at the Clinical Investigation Center|
1540870|NCT02662803|Other|high-intensive aerobe exercise|Aerobe bicycle ergometer training within 77-95% of maximum oxygen consumption; duration of each training session: 20 minutes; frequency of training: 6 sessions within 12 days
1540871|NCT02662803|Other|low-intensive aerobe exercise|Aerobe training below 70% of maximum oxygen consumption (including light stretching and simple exercises adapted from yoga figures); duration of training session: 20 minutes; frequency of training: 6 sessions within 12 days
1540872|NCT02662790|Other|Doppler|
1540873|NCT02662777|Device|Eso-SPONGE® vacuum treatment|
1540874|NCT02662764|Drug|Zalviso™ 15 mcg|Zalviso™ (sufentanil sublingual tablet system) 15 mcg. Tablets to be self-administered by the patient as needed for pain, no more than every 20 minutes, for up to 72 hours
1540875|NCT02662751|Other|Routine Imaging Assessment|"Patients will have the usual post-stroke/TIA imaging assessment according to routine procedures in each participating center. The latter most often begin with an angiography of the supra-aortic trunks but may also include a range of other imaging exams depending on the patient's condition.
Routine Imaging Assessment refers to an imaging strategy and not a specific device. The devices used depend on what is available in participating centres and the routine choices made by those centers."
1540916|NCT02662374|Drug|.02% Chlorohexidine Gluconate|5ml of the drug in mouthwash form to be swished four times a day
1540876|NCT02662751|Device|LDWBA first (CT scan)|"Patients randomized to this arm will start their post-stroke/TIA imaging assessment by a low-dose, whole-body angiography (LDWBA). The latter can be followed by routine imaging assessments if required.
LDWBA: This is a low dose scanner protocol comprising a CT acquisition and an iodine contrast medium injection. The acquisition includes a propeller during the arterial phase of the contrast agent injection in the cervical and thoracic levels with cardiac gaiting (ECG gating to reduce cardiac motion artifacts), continuing with pelvic abdominal arterial acquisition. The second propeller is made on the abdomen and pelvis at the portal time of injection. The reconstruction will be carried out in pulmonary, mediastinal and bone windows. The dose will be calculated for each patient."
1540877|NCT02662738|Dietary Supplement|Natural fruit extract|
1540878|NCT02662738|Other|Placebo|
1540879|NCT02662738|Other|Glucose solution|
1540880|NCT02662725|Drug|IPILIMUMAB|
1540881|NCT02662725|Radiation|Stereotactic radiosurgery|
1540882|NCT02662621|Other|blood samples|
1540883|NCT02662621|Other|Urine samples|
1540884|NCT02662608|Drug|Brontictuzumab|1.5 mg/Kg intravenously every three weeks.
1540885|NCT02662595|Other|SMS reminder message|
1540886|NCT02662595|Other|Voice call + SMS message|
1540887|NCT02662582|Drug|CK-2127107|Oral
1540888|NCT02662582|Drug|Placebo|Oral
1540889|NCT02662569|Biological|Evolocumab (AMG 145)|Subjects will receive evolocumab (AMG 145) every 2 weeks or monthly subcutaneously
1540890|NCT02662569|Drug|Atorvastatin|All subjects will receive atorvastatin 20 mg po daily
1540891|NCT02662569|Other|Placebo|Subjects will receive placebo subcutaneously every 2 weeks or every month
1540892|NCT02662556|Drug|sufentanil sublingual tablet 30 mcg|sufentanil sublingual tablet 30 mcg as needed for pain management, but no more frequently than every 60 minutes, for up to 12 hours.
1540893|NCT02662530|Drug|Botulinum Toxin Type A|A serotype of botulinum toxin type A (BoNT-A) that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections solely determined either by visual/clinical or by biomechanical analysis of dystonic movements for cervical dystonia therapy in neck and shoulder muscles every 12 weeks over 30 weeks. BoNT-A dose will range from 50-300 U.
1540894|NCT02662504|Device|photodynamic therapy (PDT)|"Intra-operative (intrapleural) photodynamic therapy (PDT): briefly, each patient will receive porfimer sodium (PHOTOFRIN®) (2 mg/kg) 24 hours before eP/D (IV injection on 3-5 minutes). Cutaneous light precautions will be instituted immediately and for the next 4 weeks.
After complete macroscopic resection of the tumour, the thoracic surgeon and his team will set isoprobes (7 at least) in the pleural cavity to monitor by a dosimetry device the correct illumination of the cavity with a visible red light (wavelength of 630 nm; laser source). PDT-related postoperative considerations include light precautions, intensive focus on perioperative nutrition, and a greater than normal fluid requirement in the immediate postoperative period."
1540895|NCT02662504|Procedure|thoracic surgery Pleurectomy / extended Decortication|extended P/D is intended to remove any macroscopic tumor including the parietal and visceral pleura when the diaphragm and / or the pericardium was resected
1540896|NCT02662504|Drug|Adjuvant chemotherapy|Chemotherapy should begin up to three months after surgery. It consists of pemetrexed 500 mg / m2 followed 30 minutes later by cisplatin 75 mg / m2 (in the usual manner from the center to the chemotherapy) on day 1 (J1) of each cycle every 3 weeks, for up to 6 cycles.
1540897|NCT02662491|Dietary Supplement|Vitamin D and calcium|
1540898|NCT02662491|Dietary Supplement|Vitamin D|
1540899|NCT02662491|Dietary Supplement|Calcium|
1540900|NCT02662491|Dietary Supplement|Placebo|
1540901|NCT02662478|Procedure|Laparoscopic Surgery|Mid-point between the xiphoid and umbilicus was used to the entrance site of the telescope. Open trocar insertion was used in patients with history of open upper abdominal surgery; otherwise Veress needle established CO2 insufflations. The number, size and entry points of the other trocars were tailored according to the tumor location and size. In general, 2 to 4 additional trocars were used. All specimens were taken out of the abdomen through a suprapubic transverse incision in a sterile bag. Resection technique was determined by the size, number, location of the lesion, and surgical anatomy of the stomach. Lymph node dissection was not done as it is unnecessary.
1540902|NCT02662465|Procedure|Laser|Patients who develop oral mucositis even after the prevention, will be divided into three groups for laser sessions with the purpose of treatment of oral mucositis. The group assignment obeyed severity of oral mucositis.
1540903|NCT02662452|Drug|GLPG2222 single dose|single ascending doses, oral suspension
1540904|NCT02662452|Drug|Placebo single dose|single doses, oral suspension, matching placebo
1540905|NCT02662452|Drug|GLPG2222 multiple doses|multiple ascending doses, daily for 14 days, oral suspension
1540906|NCT02662452|Drug|Placebo multiple doses|multiple doses, daily for 14 days, oral suspension, matching placebo
1540907|NCT02662439|Device|Body Composition Monitor (BCM)|In the experimental group, the diuretic therapy adjusted according to the result of the BCM analysis.
1540908|NCT02662426|Drug|Lingdancao granules|4 packs per time (3g/pack), three times per day
1540909|NCT02662426|Drug|analogous oseltamivir phosphate capsule|1 capsule per time, twice per day
1540910|NCT02662426|Drug|Oseltamivir phosphate capsule|1 capsule per time (75mg), twice per day
1540911|NCT02662426|Drug|analogous Lingdancao granules|4 packs per time, three times per day
1540912|NCT02662413|Other|Validation of Asthma Control Questionnaire|This is an observational study so there is no planned intervention.
1540913|NCT02662400|Biological|MNCs|200 - 300 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months
1540914|NCT02662387|Device|External nasal dilator (END)|Applying External nasal dilator as adjuvant to high flow oxygen
1540915|NCT02662387|Other|High flow nasal cannula (HFNC)|Non-invasive positive pressure ventilation
1540917|NCT02662374|Drug|3% Sodium Bicarbonate|5ml of the drug in the form of a prepared solution to be swished four times a day
1540918|NCT02662374|Drug|Nystatin 10000U/ml|5ml of the drug in mouthwash form to be swished and swallowed four times a day
1540919|NCT02662374|Device|Extra Soft Toothbrush|To be moistened with 0.9% normal Saline and used twice daily to remove dental plaque
1540920|NCT02662374|Drug|Supersaturated Calcium Phosphate|5ml of the solution to be swished four times a day
1540921|NCT02662348|Drug|Recombinant Human Interleukin-2|Given SC
1540922|NCT02662348|Drug|HER2Bi-Armed T Cells|Given IV
1540923|NCT02662335|Other|Computer-Assisted Cognitive Training|Participate in Cogmed computerized working memory training
1540924|NCT02662335|Other|Questionnaire Administration|Ancillary studies
1540925|NCT02662335|Procedure|Standard Follow-Up Care|Undergo standard follow-up care
1540926|NCT02662322|Other|Hypnotic communication|hypnotic communication during peripheral intravenous catheterization
1540927|NCT02662322|Other|negative connotation communication|negative connotation communication during peripheral intravenous catheterization
1540928|NCT02662322|Other|neutral connotation communication|neutral connotation communication during peripheral intravenous catheterization
1540929|NCT02662322|Other|peripheral intravenous catheterization|peripheral intravenous catheterization
1540930|NCT02662309|Drug|MPDL3280A|Intravenous infusion
1540931|NCT02662296|Drug|Ibrutinib|Given PO
1540932|NCT02662296|Drug|Idelalisib|Given PO
1540933|NCT02662283|Drug|Prednisolone|Oral take prednisolone (0.5 mg/kg, qd) for 8 weeks
1540934|NCT02662283|Drug|Reh-acteoside|Oral take and reh-acteoside (0.4g bid) for 8 weeks
1540935|NCT02662257|Drug|Sevoflurane|"Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the bispectral index (BIS) value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
Towards the end of surgery, sevoflurane inhalational concentration will be decreased and fentanyl/sufentanil will be administered when necessary. Sevoflurane inhalation will be stopped at the end of surgery."
1540936|NCT02662257|Drug|Propofol|"Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Analgesia will be supplemented with remifentanil (administered by continuous infusion), sufentanil (administered by intermittent injection/continuous infusion), or fentanyl (administered by intermittent injection).
Towards the end of surgery, propofol infusion rate will be decreased and fentanyl/sufentanil will be administered when necessary. Propofol infusion will be stopped at the end of surgery."
1540937|NCT02662244|Device|Nd:YAG laser|Long-Pulsed 1064 NM ND:Yag Laser Treatment Of Basal Cell Carcinoma
1540938|NCT02662231|Procedure|Emergency, or elective gastrointestinal resection|Gastrointestinal resection is defined as complete transection and removal of a segment of the oesophagus, stomach, small bowel, colon or rectum, including cholecystectomy, and appendicectomy.
1540939|NCT02662205|Other|Psychotherapy Group|Traditional process group
1540940|NCT02662205|Other|Yoga class|Yin yoga class
1540941|NCT02662205|Other|Yoga Therapy Group|Yoga psychotherapy group integrating yoga and process dialogue
1540942|NCT02662192|Other|Exercise + health education+ auditory rehabilitation|comparison of 3/4 of an hour balance, resistance and strength training, 1 hour health education, 1 hour auditory rehabilitation
1540943|NCT02662192|Other|auditory rehabilitation alone|10 weeks of one hour per week of group auditory rehabilitation
1540944|NCT02662179|Other|Quality of life evaluation|Assess the quality of life ('SF-36' questionnaire) of patients 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
1540945|NCT02662179|Other|Functional decline assessment|Assess functional decline ('Katz ADL' Score and 'Lawton IADL' Score) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
1540946|NCT02662179|Other|Physical decline assessment|Assess physical decline (walking speed and prehension force) 3 and 6 months after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
1540947|NCT02662179|Other|Cognitive decline assessment|Assess cognitive decline 3 and 6 months ('MMSE 30' questionnaire) after oncologic treatment. Since a diagnosis of frailness will have been established before the oncologic treatment, a correlation between the decline and the 'frail' categorization according to the Fried criteria can be established or denied.
1540948|NCT02662166|Device|MR imaging|3 T MRI of the urinary bladder
1540949|NCT02662153|Other|Database review to evaluate opioid overdose and death|Database review to evaluate opioid overdose and death
1540950|NCT02662140|Behavioral|Mobile Health Applictaion|"Component 1: Delivering homework via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW.
Component 2: Focuses on targeting factors putative related to poor HW implementation within the Do process"
1540951|NCT02662127|Device|SIGVARIS® Class 2 - RAL: 23-32.|Below knee graduated elastic compression stocking
1540952|NCT02662114|Other|No treatment given|Information will be collected from the medical records (paper/electronic) of each patient at several outpatient clinics to describe the two periods of medical history: before and after the initiation date of Tresiba®. For each patient, data will be collected, to describe a minimum of 6 months to a maximum of 12 months in each period; thus, the study will collect information on 12 to 24 months of medical history for each patient.
1540953|NCT02662101|Device|Exsalt SD7, Exsalt T7 Wound Dressing|
1540990|NCT02661854|Biological|MM09 Mannosylated 50.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
1540955|NCT02662075|Device|E-cigarette/tobacco Smoking Exposure|Subjects will be asked to smoke an e-cigarette containing the equivalence of nicotine in one tobacco cigarette (15 puffs) in the presence of research staff. Each puff will be timed at 4 seconds and there should be a 20-30 seconds interpuff interval as previously recommended.
1540956|NCT02662062|Drug|Pembrolizumab|200 mg/m2, IV (in the vein) on day 1 every three weeks (Weeks 1, 3, 7, 10, 13, 16 and 19). until progression or unacceptable toxicity develops.
1540957|NCT02662062|Drug|Cisplatin|35 mg/m2, IV (in the vein) every week for six weeks.
1540958|NCT02662062|Radiation|Radiotherapy|2.00Gy once daily for 32 fractions, 5 fractions/week over six weeks and two days (a total of 64Gy).
1540959|NCT02662036|Drug|Bupivicaine HCL|
1540960|NCT02662036|Drug|Liposomal bupivacaine|
1540961|NCT02662023|Drug|perineural ropivacaine administration|
1540962|NCT02661997|Behavioral|Tai Chi Intervention|All components of the program derive from the classical Yang Tai Chi 108 postures, which has been shown to be a moderate intensity exercise. Each Tai Chi session will last 60 minutes, twice a week for 12 weeks. In the first session, the Tai Chi instructors will explain exercise theory and procedures of Tai Chi. In subsequent sessions, subjects will practice Tai Chi under the instruction of one of the Tai Chi instructors. Every session will include the following components: (1) warm up and a review of Tai Chi principles; (2) meditation with Tai Chi movement; (3) breathing techniques; and (4) relaxation. The investigators will instruct patients to practice at least 30 minutes a day at home throughout the intervention period and will provide them with training materials for home practice.
1540963|NCT02661997|Behavioral|Wellness Intervention|The investigators will utilize a wellness education program for the control group because this approach has been successfully used in other Tai Chi studies from the investigators' team. Participants in the Wellness condition will also attend two 60-minute sessions per week for 12 weeks. The Wellness condition will correspond to the VA Whole Health Program to emphasize wellness across various domains (e.g., physical, emotional, and spiritual lives.) Each session will include a video clip as well as a brief mindfulness exercise that corresponds with the material being presented. The project coordinator for this study will provide the didactic lessons.
1540964|NCT02661971|Drug|Docetaxel|Docetaxel 50 mg/m², d1
1540965|NCT02661971|Drug|Oxaliplatin|Oxaliplatin 85 mg/m², d1
1540966|NCT02661971|Drug|Calciumfolinat|Leucovorin 200 mg/m², d1
1540967|NCT02661971|Drug|5-Fluorouracil|5-FU 2600 mg/m², d1
1540968|NCT02661971|Biological|Ramucirumab|Ramucirumab 8mg/kg, d1
1540969|NCT02661958|Drug|S6G5T-3|once a day topical cream
1540970|NCT02661958|Drug|S6G5T-1|once a day topical cream
1540971|NCT02661958|Drug|S6G5T-5|once a day topical cream
1540972|NCT02661958|Drug|S6G5T-6|once a day topical cream
1540973|NCT02661958|Drug|S6G5T-7|once a day topical cream
1540974|NCT02661958|Drug|S6G5T-8|once a day topical cream
1540975|NCT02661945|Device|Near focus with narrow band imaging|
1540976|NCT02661932|Drug|Letrozole|"Patients start ovarian stimulation protocol according to their menstrual cycle phase at enrollment (standard or random start). Ovarian stimulation includes gonadotropins administration in a GnRH antagonist protocol Standard Protocol: letrozole is orally administered 2 tablets per day (2,5mgx2/d) from cycle day 2 throughout the ovarian stimulation with gonadotropins protocol until ovulation triggering. GnRH antagonist is administered as soon as at least one follicle reaches 14 mm.
Random start protocol: letrozole is administered throughout the stimulation together with gonadotropins and GnRH antagonist, until ovulation triggering.
Oocytes are collected 36h after ovulation triggering. All patients receive GnRH antagonist after oocyte retrieval for 3-7 days or until chemotherapy starts, to induce luteolysis."
1540977|NCT02661919|Device|Emfit mattress sensor|Patients who are being monitored in the Epilepsy Monitoring Unit will have an Emfit mattress sensor placed under their mattress and the effectiveness of the alarm system will be tested.
1540978|NCT02661906|Other|SKY yoga|Sudarshan Kriya Yoga is a rhythmic breathing exercise with slow and fast breath at a particular pace.It is recommended for stress management as yoga is a mind body control tool. SKY is having effect on multiple organ thus causing the positive effect.
1540979|NCT02661893|Drug|JNJ-42847922|A single oral dose of 40 milligram (mg) (=2*20 mg) dose of JNJ42847922 on Day 1, Day 5 and Day 12.
1540980|NCT02661893|Drug|Rifampin|Oral dose of rifampin 600 mg (2*300 mg) on Day 5 and once daily dosing of rifampin with an oral dose of rifampin 600 mg (2*300 mg) on Days 5 to 12.
1540981|NCT02661880|Behavioral|preferred music|listening to preferred music choices
1540982|NCT02661867|Behavioral|delivery|delivery either vaginal or by cesarean section
1540983|NCT02661854|Biological|MM09 Mannosylated 5.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
1540984|NCT02661854|Biological|MM09 Mannosylated 10.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
1540985|NCT02661854|Biological|MM09 Mannosylated 30.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
1540986|NCT02661854|Biological|MM09 Mannosylated 50.000 subcutaneous|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 50.000 MTU (Mannosylated Therapeutic Units)/ml subcutaneous
1540987|NCT02661854|Biological|MM09 Mannosylated 5.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 5.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
1540988|NCT02661854|Biological|MM09 Mannosylated 10.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 10.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
1540989|NCT02661854|Biological|MM09 Mannosylated 30.000 sublingual|Mixture of the following mites: Dermatophagoides pteronyssinus and Dermatophagoides farinae, allergen extract with a concentration of 30.000 MTU (Mannosylated Therapeutic Units)/ml sublingual
1540991|NCT02661854|Biological|Subcutaneous placebo|Comparison between placebo and active group
1540992|NCT02661854|Biological|Sublingual placebo|Comparison between placebo and active group
1540994|NCT02661841|Other|Heart Failure Guidelines|Treatment according to clinical signs
1540997|NCT02661815|Drug|Paclitaxel|Please see arm/group description.
1540998|NCT02661815|Drug|Ricolinostat|Please see arm/group description.
1540999|NCT02661815|Drug|Bevacizumab|Please see arm/group description.
1541000|NCT02661802|Other|Oxygen Supplementation|Oxygen delivery was continuous by mask at 40%
1541001|NCT02661789|Drug|Goserelin 3.6 mg implant|Pharmacologically induced biphasic sex-steroid hormone fluctuation
1541002|NCT02661789|Drug|Placebo|Injection of saline
1541003|NCT02661750|Drug|Bowel Preparation|"Standard 1/2 Dose: 153 g MiraLAX + 32 oz Gatorade 2 liters, 2 liters NuLYTELY, 1 liter MoviPrep, 16 oz (1 bottle) SuPREP, 10 oz (1 bottle) MagCitrate.
Standard Full Dose: 306 g MiraLAX + 64 oz Gatorade, 4 liters NuLYTELY, 2 liters MoviPrep, 32 oz (2 bottles) SuPREP, 20 oz (2 bottles) MagCitrate.
Step 1: 51 g MiraLAX* noon the day-prior; Full dose - 51 g MiraLAX 6 PM day-prior; 1/2 dose 4 hours before the colonoscopy.
Step 2: 1/2 dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
Step 3: Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
Step 4: 1/2 dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy.
Step 5: Full dose 6 PM 2 days-prior; Full dose noon the day-prior; Full dose 6 PM the day-prior; 1/2 dose 4 hours before the colonoscopy."
1541004|NCT02661737|Device|YVOIRE volumes|
1541005|NCT02661724|Behavioral|TCBR-Pain|The interactive TCBR-Pain uses programmed learning, skill development and behavioral practice to engage persons with burn pain in self-management of pain and related problems. The TCB-Pain program includes 7 lessons addressing key dimensions of pain management for persons with burn injury. Each session is about 20 minutes and focuses on burn injury recovery and life style education. Sessions begin with a brief self-assessment and in later sessions, the participant is given graphical feedback on their progress. The lessons are narrated and include closed captioning, are animated, and include branching to provide personalized content.
1541006|NCT02661711|Drug|Aflibercept|"2mg of 40mg/ml of Eylea Solution administered via intravitreal injection every four weeks for three months (loading dose), followed by a treat and extend protocol up to 12 months. Extension from monthly to 6, 8, 10 and 12 week follow up will occur where there is no reduction in macula oedema compared with the previous visit.
Number of cycles; minimum of 5 injections and maximum of 13 injections per study eye."
1541007|NCT02661698|Dietary Supplement|Omega-3 oil: DHA enriched|3 x 1 g capsules containing a SMEDDS formulation of an DHA-enriched oil: 50% DHA + 15% EPA totalling 900 mg DHA and 270 mg of EPA
1541008|NCT02661698|Dietary Supplement|Placebo|3 x 1 g capsules Placebo: olive oil
1541009|NCT02661698|Dietary Supplement|Omega-3 oil: EPA enriched|3 x 1 g capsules containing a SMEDDS formulation of an EPA-enriched oil: 50% EPA + 20% DHA totalling 900 mg EPA and 360 mg of DHA
1541010|NCT02661685|Other|autologous IKDC-like cells|Subject received autologous IKDC-like cells every 14 days
1541011|NCT02661672|Device|Apollo MIES|surgery with use of the Apollo System.
1541012|NCT02661659|Biological|Multipeptide vaccine S-588210|
1541014|NCT02661633|Device|BrainScope Battery|The BrainScope Battery consists of 3 components to collect brain electrical activity, a cognitive assessment and a balance/sway measurement.
1541015|NCT02661633|Device|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
1541016|NCT02661620|Device|REDAPT Revision Femoral System modular stem|Medical record review for retrospective information and observational prospective data collection of standard of care items at 5 years and 10 years post operatively plus a 7 year post op telephone call to assess stem status and adverse events.
1541017|NCT02661607|Procedure|Point of care echocardiography|Point of echocardiography is performed after routine placement of central venous catheterization and compared with routine chest radiography
1541018|NCT02661607|Device|Central venous catheter placement|Central venous catheter placement is performed as per local guidelines in critically ill patients
1541019|NCT02661607|Procedure|Chest radiography|Routine chest radiography is performed after central venous catheter placement in critically ill patients
1541024|NCT02661581|Behavioral|Peer Support|The intervention is lifestyle change. First, the peer leaders will be trained how to conduct diabetes self-management education and support sessions. During the first 3 months, all the participants will attend the diabetes self-management education sessions. The participants in the intervention arm will also receive diabetes self-management support sessions as well. In the end of the first 3 months, the intervention group participants will receive weekly support sessions for 9 months.
1541025|NCT02661555|Other|Aerobic exercise|
1541026|NCT02661542|Drug|FF-10502-01|
1541068|NCT02661269|Device|Bio-impedance measurements.|measuring resistance and reactance with the BIVA method.
1541222|NCT02660281|Procedure|Stem Cell Infusion|Stem cell infusion
1541031|NCT02661503|Drug|Bleomycin|
1541032|NCT02661503|Drug|Etoposide|
1541033|NCT02661503|Drug|Doxorubicin|
1541034|NCT02661503|Drug|Cyclophosphamide|
1541035|NCT02661503|Drug|Vincristine|
1541036|NCT02661503|Drug|Procarbazine|
1541037|NCT02661503|Drug|Prednisone|
1541038|NCT02661503|Drug|Brentuximab Vedotin|
1541039|NCT02661503|Drug|Dacarbazine|
1541040|NCT02661503|Drug|Dexamethasone|
1541041|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide, without MPL for IM injection
1541042|NCT02661490|Drug|0.9% sodium chloride (saline)|norovirus bivalent placebo-matching vaccine
1541043|NCT02661490|Biological|Norovirus GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with MPL and aluminum hydroxide for IM injection
1541044|NCT02661477|Drug|pegylated interferon alfa 2|
1541045|NCT02661477|Other|Placebo|0,9% natrium chlorine solution
1541048|NCT02661451|Device|SAPIEN 3 THV|
1541049|NCT02661451|Biological|Optimal Heart Failure Therapy|
1541050|NCT02661438|Drug|Placebo to Ciprofloxacin DPI (BAYQ3939)|Placebo to Ciprofloxacin DPI, 3 doses during test session, 1 additional dose for patients during device training
1541051|NCT02661425|Other|EnteraGam|Serum-derived bovine immunoglobulin/protein isolate (SBI) is the nutritional ingredient in EnteraGam. SBI contains a minimum of 50% immunoglobulin. The protein isolate is a light-colored powder. Each packet contains SBI (5.0 g) and the following inactive ingredients: dextrose (5.0 g) and a trace amount of sunflower lecithin.
1541052|NCT02661386|Device|Motility Procedure|The use of esophageal manometry device during general anesthesia
1541053|NCT02661373|Drug|SJ733|SJ733 is an oral, novel inhibitor of Plasmodium Falciparum plasma membrane protein PFATP4. It will be administered as a single oral dose.
1541054|NCT02661360|Behavioral|Swaddling Intervention for Preterm Infants|Procedure for swaddling includes folding one corner of the blanket down two thirds of the way down the blanket in order to make the blanket into a triangular shape. The infant will be positioned with shoulders at the fold of the blanket. The infant will be positioned with the blanket so that elbows, hips, and knees flexed with hands near the face by wrapping one side of the blanket across the chest holding the hands in place, pulling the bottom corner up toward the infant's face, and securing the blanket with the last corner pulled across the infant's chest again and around their back. The blanket will be tight enough to keep extremities in place but one finger will be able to be placed between the infant and the blanket.
1541055|NCT02661360|Behavioral|Unswaddled Control|Procedure for control is blanket loosely draped across the infant without providing containment and without touching the anterior surface of the infant.
1541056|NCT02661347|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
1541057|NCT02661347|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive brain stimulation in which sub-threshold transcranial electric current (in the range of 0.4-2 mA) is applied via two conductive saline soaked electrodes placed on the scalp using a Soterix Medical 1x1 line tDCS Model 1300 low-intensity stimulator.
1541058|NCT02661334|Dietary Supplement|Creatine Monohydrate|Creatine monohydrate is a very common supplement used by enthusiasts, athletes, and the general populace
1541059|NCT02661334|Dietary Supplement|Rice Flour|rice flour powder matched for color, appearance, taste, and solubility
1541060|NCT02661321|Other|No intervention was used in this study, this was an observational study|
1541061|NCT02661308|Device|Litebook|
1541062|NCT02661295|Drug|Ferric Citrate|Study participants will receive ferric citrate at a starting dose of 2 tablets with each meal if serum phosphorus levels are ≥ 6.0 mg/dL calcium levels are in the normal range, Tsat ≥ 20 and < 50% and ferritin ≥ 200 and < 500 ng/ml after a 2 week wash out period.
1541063|NCT02661282|Drug|Temozolomide|"100 mg/m2/day by mouth 1 time a day on Days 1 - 21 of Cycles 1 - 4.
Group 1, continues taking Temozolomide on Days 1 - 21 of Cycles 5 and beyond.
Group 2, takes Temozolomide on Days 1 - 5 of Cycles 5 and beyond."
1541064|NCT02661282|Biological|T Cell Infusion|CMV-specific T cell infusion by vein on Day 22 for 4 cycles. Escalating doses of CMV-specific T cells are: 5 x10^6 in cycle 1, 1 x10^7 in cycle 2, 5 x10^7 in cycle 3 and 1 x10^8 in cycle 4.
1541065|NCT02661282|Procedure|Surgery|Recurrent Glioblastoma + Surgery Group: Participants undergo surgery to remove the tumor on Day 30 of Cycle 1.
1541066|NCT02661282|Behavioral|Phone Calls|Study staff calls participant on the following schedule: about 30 days after last study drug/cell dose, every 8 weeks, if participant stops study drug/cells because of intolerable side effects, every 3 months if participant stops study drug/cells because disease gets worse.
1541067|NCT02661269|Device|Videomicroscopy of the sublingual microcirculation|Measuring total vessel density with the Cytocam-IDF camera.
1541069|NCT02661256|Device|NCPAP|Does NCPAP induce dysphagia in neonates? Each baby will be evaluated for dysphagia (using fluoroscopy) while on NCPAP and off NCPAP.
1541070|NCT02661256|Dietary Supplement|Varibar® Thin Liquid Barium Sulfate for Suspension|Liquid barium is used as a contrast material to allow visualization of swallowed boluses under fluoroscopy.
1541071|NCT02661243|Device|Biohorizons Laser-lok bonelevel dental implants|Insertion of Biohorizons Laser-lok bonelevel dental implants to replace missing (pre)molars or to stabilize a denture
1541072|NCT02661230|Device|COGNIPLUS|"Run 1 Video game: Phasic Alertness (Alert S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.
Run 2 Video game: Intrinsic Alertness (Alert S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.
Run 3 Video game: Visual modality (Select S1) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest.
Run 4 Video game: Acoustic / Stimulus Combinations (Select S2) Instruction phase 2 minutes, 2 x 3 minutes of rest, followed by 5 x 60 sec of video game activity, alternating with 60 sec of rest."
1541074|NCT02661204|Device|Automated breast ultrasound examination (ABUS)|Automated breast ultrasound examination
1541075|NCT02661191|Drug|oral cholecalciferol|Inhaled corticosteroids and long-acting beta-agonists, salbutamol
1541076|NCT02661178|Drug|emodepside (BAY 44-4400)|
1541077|NCT02661178|Drug|placebo|
1541078|NCT02661152|Drug|Nimorazole|Hypoxia gene profile is expected to discriminate between HNSCC responders and non-responders to hypoxic modification with nimorazole during radiotherapy. In DAHANCA 30 expected non-responders are randomized to +/- nimorazole during radiotherapy (non-inferiority study). Thus, similar efficacy of radiotherapy is expected in these groups. More hypoxic tumours receive nimorazole after DAHANCA standards.
1541079|NCT02661126|Drug|MK-3682B|FDC oral tablet containing 225 mg MK-3682 + 50 mg grazoprevir + 30 mg ruzasvir.
1541080|NCT02661113|Drug|Dasatinib|Phase I dose of 100 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
1541081|NCT02661113|Radiation|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
1541082|NCT02661113|Drug|TMZ (Temozolomide)|75 mg/m^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles.
1541083|NCT02661100|Drug|Pembrolizumab|200mg/kg by IV infusion on Day 1 of each 3 week cycle. Given until disease progression
1541084|NCT02661100|Biological|CDX-1401|1mg given subcutaneously on day 1 of each 3 week cycle. Given for 4 cycles
1541085|NCT02661100|Biological|Poly-ICLC|2mg given subcutaneously on day 1 and 2 of each 3 week cycle. Given for 4 cycles
1541086|NCT02661087|Procedure|Hysteroscopic resection with bipolar energy|
1541087|NCT02661087|Procedure|Hysteroscopic resection with monopolar energy|
1541088|NCT02661074|Other|Questionnaire|"A questionnaire will be completed in order to collect data on:
Potential allergic manifestations after fish contact: asthma, allergic rhinitis, conjunctivitis, chronic or acute urticaria, dermatitis/eczema, or severe allergic manifestations (angioedema, bronchospasm, anaphylaxis),
Occupational and/or domestic exposure to fish."
1541089|NCT02661061|Drug|Ketamine|A sub-anaesthetic dose of ketamine will be administered in four infusions, each two weeks apart.
1541090|NCT02661061|Drug|Midazolam|A sub-anaesthetic dose of midazolam will be administered in four infusions, each two weeks apart.
1541091|NCT02661048|Device|CyberHeart System|The CyberHeart system uses proprietary software to assist the cardiologist to contour ablation targets. Standard radiosurgical techniques are then used to accomplish ablation
1541092|NCT02661035|Drug|Allopurinol|300 mg/day (for peds -150 mg/m^2/day), day -6 and continue through day 0 or longer if clinically indicated
1541093|NCT02661035|Drug|Fludarabine|30 mg/m^2 IV over 1 hour, day -6, -5, -4, -3 and -2
1541094|NCT02661035|Drug|Cyclophosphamide|50 mg/kg IV over 2 hours, day -6
1541095|NCT02661035|Drug|ATG|Only for patients with an unrelated donor (URD) and NO multi-agent chemotherapy 3 months prior to transplant. ATG will be administered IV every 12 hours for 6 doses on days -6, -5, and -4 according to institutional guidelines. Methylprednisolone 1 mg/kg IV administered immediately prior to each dose of ATG (6 doses).
1541096|NCT02661035|Radiation|TBI|All patients who have had previous radiation therapy or TBI will be seen by Radiation Oncology prior to entrance on the protocol for approval for additional 200 cGy of TBI. TBI may be delivered by local guidelines provided the effective dose is equivalent to what is recommended in the TBI Guidelines. The dose of TBI will be 200 cGy given in a single fraction on day -1.
1541097|NCT02661035|Drug|Tacrolimus|"All patients will receive tacrolimus therapy beginning on day -3. Initial dosing of tacrolimus will be 0.03 - 0.05 mg/kg/day IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if ≥ 40 kg, twice daily or per current institutional guidelines.
An attempt will be made to maintain a trough level of 5-10 ng/mL and subsequent dose modifications will be provided by the pharmacist.
Once the patient can tolerate oral medications and has a reasonable oral intake, tacrolimus will be converted to an oral form based on the current IV dose providing normal renal and hepatic function and no major drug interactions.
The timing of the tacrolimus taper will be at the discretion of the treating physician, but in general:
Taper begins at day +100 +/- 10 days, if the patient is stably engrafted and has no active GVHD.
Taper to zero by reducing dose by approximately 10% a week (rounded to nearest pill size), with a goal to discontinue by month 6 post-HCT."
1541098|NCT02661035|Drug|MMF|"3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. In obese patients (>125% IBW) 15 mg/kg every 12 hours may be considered. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3. MMF dosing will be monitored and altered as clinically appropriate based on institutional guidelines. Patients will be eligible for MMF dosing and pharmacokinetics studies.
MMF will stop at day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC) ≥ 0.5 x 109 /L]). If no donor engraftment, MMF will continue as long as clinically indicated."
1541099|NCT02661035|Biological|Peripheral Blood Stem Cells|On day 0, patients will receive an allogeneic transplant using PBSC which are CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
1541100|NCT02661035|Biological|Related or Unrelated Bone Marrow Cells|On day 0, a target dose of 3 x 10^8 nucleated cells/kg recipient weight will be collected. The graft will be infused over 15-60 minutes after premedication with acetaminophen 650 mg PO and diphenhydramine 25 mg PO/IV with doses adjusted for pediatric patients.
1541101|NCT02661022|Drug|SL-401/ Pomalidomide/ Dexamethasone|
1541102|NCT02660983|Drug|Donepezil hydrochloride|
1541103|NCT02660983|Drug|Donepezil matching placebo|
1541104|NCT02660970|Other|Acupressure|Children will have to wear a 'seasickness-band', which has the effect of acupressure
1541105|NCT02660970|Other|Placebo-band|Children will have to wear a 'placebo-wristband'
1541106|NCT02660970|Drug|Iberogast|Children will have to take Iberogast drops
1541107|NCT02660970|Other|Placebo-drops|Children will have to take placebo-drops
1541110|NCT02660944|Drug|RSLV-132|RNase-Fc fusion protein
1541111|NCT02660944|Drug|Placebo|Saline placebo
1541112|NCT02660931|Other|AKI Risk Notification|When a patient's calculated acute kidney injury risk exceeds the threshold value, the electronic medical record will notify the provider of the risk and that appropriate screening (BMP including serum creatinine) may be indicated.
1541113|NCT02660918|Drug|Bupivacaine|Paracervical injection of 20 mL 0.25% Bupivacaine at the completion of the procedure
1541114|NCT02660918|Other|Normal Saline|Equal volume injection of normal saline with the same paracervical technique
1541115|NCT02660905|Drug|E/C/F/TAF;|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
1541116|NCT02660905|Drug|Ledipasvir-Sofosbuvir|Evaluation of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Switch followed by Ledipasvir-Sofosbuvir Antiviral HCV Therapy
1541117|NCT02660892|Dietary Supplement|Protein intake|"Oral consumption of eight hourly experimental meals
4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil
4 isotopically labeled experimental meals."
1541118|NCT02660879|Other|Written Document Educational Resource|A 2 page document with pictures discussing how to use an inhaler properly.
1541119|NCT02660879|Other|Online Video Education|Education which included step-by-step instruction on how to use their inhalers correctly as well as a webcam element that allowed users to see themselves practice their inhalers along with actors on screen.
1541120|NCT02660866|Drug|Placebo + background APT + SMT|Placebo drug therapy combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
1541121|NCT02660866|Drug|Vorapaxar 2.08 mg/d + background APT + SMT.|Vorapaxar 2.08 mg/d combined with standard medical therapy combined with Antiplatelet therapy (Aspirin therapy)
1541122|NCT02660840|Drug|0.5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
1541123|NCT02660840|Drug|1 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
1541124|NCT02660840|Drug|5 mg Flupentixol film-coated tablet (test treatment)|single oral dose, fasted state, day 1 in period 1 or 2
1541125|NCT02660840|Drug|0.5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
1541126|NCT02660840|Drug|1 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
1541127|NCT02660840|Drug|5 mg Flupentixol coated tablet (reference treatment)|single oral dose, fasted state, day 1 in period 1 or 2
1541128|NCT02660827|Device|Insulin Pump|Closed Loop Algorithm
1541129|NCT02660814|Other|Non-surgical periodontal treatment|"SRP under local anaesthesia, in a total of 2-3 clinical visits.
Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
1541130|NCT02660814|Other|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
1541131|NCT02660801|Procedure|Spinal manipulation|A high-velocity and low-amplitude thrust delivered posteroanteriorly to a thoracic vertebra
1541132|NCT02660801|Procedure|Spinal mobilization|Three repetitions of a low-velocity and low-amplitude nonthrust movement delivered posteroanteriorly to a thoracic vertebra
1541133|NCT02660788|Other|Standard Reminder Postcard|
1541134|NCT02660788|Other|Family Physician Reminder Letter|
1541135|NCT02660775|Behavioral|schizophrenia|"The battery (ClaCoS) is composed by 6 tests and several scores will be recorded for each:
for emotion perception : Facial emotions recognition task (TREF)
for theory of mind : Movie for the assessment of social cognition ( MASC-VF)
for attributional bias : Ambiguous Intentions Hostility Questionnaire ( AIHQ)
for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )
for empathy :Questionnaire of cognitive and affective empathy ( QCAE) for people with schizophrenia
for self assessment : Self - assessment of social cognition (ACSo)"
1541136|NCT02660775|Behavioral|Autism|"The battery (ClaCoS ) is composed by 6 tests and several scores will be recorded for each:
for emotion perception : Facial emotions recognition task(TREF ): total score, score per emotion, detection levels
for theory of mind : Movie for the assessment of social cognition (MASC ) :total score, error type
for attributional bias : Ambiguous Intentions Hostility Questionnaire (AIHQ) :hostility score, attribution score, aggression score
for social perception and knowledge : interpretation score - with and without index, comprehension score ( PerSo )
for empathy : Empathy quotient (EQ)
for self assessment : Self - assessment of social cognition ( ACSo ): total score and scores per processes"
1541137|NCT02660775|Behavioral|Healthy controls|only social cognitive measures
1541138|NCT02660762|Drug|Vincristine|induction therapy I：1.4 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 1)：1.4 mg/m2 IV d1, 8, 15, 22； Maintenance therapy: 1.4 mg/m2 intravenously every 3 months for a total of 2.5 years
1541139|NCT02660762|Drug|Daunorubicin|induction therapy I：60 mg/m2 IV d1, 8, 15, 22； consolidation therapy(Cycle 3)：25 mg/m2 IV d1, 8, 15, 22；
1541140|NCT02660762|Drug|Pegaspargase|induction therapy I: 2500U/m2,im,d8,22 Intensification therapy:2500U/m2 im, d2,23 consolidation therapy(Cycle 2，4)：2500U/m2 im, d1
1541141|NCT02660762|Drug|Prednisone|induction therapy I：60 mg/m2 PO d1-28; Maintenance therapy:prednisone 60 mg/m2 orally for 5 days every 3 months for a total of 2.5 years
1541142|NCT02660762|Drug|Intrathecal Methotrexate|induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
1541143|NCT02660762|Drug|Cyclophosphamide|induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29
1541144|NCT02660762|Drug|Cytarabine|induction therapy II:75 mg/m2 IV d1-4, 8-11, 15-18, 22-25 consolidation therapy(Cycle 1，2，4)：75 mg/m2 intravenously on days 1 to 5 consolidation therapy(Cycle 3):75 mg/m2 intravenously on days 31 to 34 and 38 to 41
1541145|NCT02660762|Drug|6-Mercaptopurine|induction therapy II:60 mg/m2 PO d1-28 Maintenance therapy:75 mg/m2 orally each day for a total of 2.5 years
1541146|NCT02660762|Drug|Methotrexate|Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
1541147|NCT02660762|Drug|Etoposide|consolidation therapy(Cycle 1，2，4)：100 mg/m2 intravenously on days 1 to 5
1541148|NCT02660762|Drug|dexamethasone|consolidation therapy(Cycle 1)：10mg/m2 orally on days 1 to 28
1541149|NCT02660762|Drug|thioguanine|consolidation therapy(Cycle 3): 60 mg/m2 orally on days 29 to 42
1541150|NCT02660762|Drug|intrathecal cytarabine|50 mg intrathecal cytarabine was given on 4 occasions 3 months apart during maintenance therapy.
1541151|NCT02660736|Drug|Albiglutide Liquid Auto-injector|Albiglutide liquid is provided as a fixed-dose, disposable auto-injector containing albiglutide liquid (50 mg). The auto-injector delivers the study treatment in an injection volume of 1.0 mL for the 50 mg dose
1541152|NCT02660736|Drug|Albiglutide Lyophilized DCC Pen Injector|Albiglutide is supplied as prefilled DCC Pen Injector. Each DCC contains lyophilized albiglutide 50 mg. When the injector pen product is reconstituted a neutral, isotonic solution is produced. The pen delivers albiglutide in an injection volume of 0.5 mL
1541153|NCT02660736|Drug|Placebo Liquid Auto-injector|Liquid albiglutide matching placebo is provided as a fixed-dose, disposable autoinjector containing placebo liquid. The auto-injector delivers the placebo in an injection volume of 1.0 mL for the 50 mg placebo dose.
1541154|NCT02660736|Drug|Placebo Lyophilized DCC Pen injector|Placebo is supplied as prefilled DCC Pen Injector. Each DCC contains matching placebo. When the injector pen product is reconstituted a neutral, isotonic placebo solution is produced. The pen delivers the placebo in an injection volume of 0.5 mL.
1541155|NCT02660723|Other|Healthy Volunteers|A catheter will be introduced in the arm vein and 14 ml of blood will be drawn in one 4 ml dry tube, one 5 ml heparinized tube for cell count and 5 1 ml TruCulture tubes.
1541156|NCT02660710|Drug|R-CHOP|maximum of 6-8 cycles of R-CHOP over 18-24 weeks
1541157|NCT02660697|Procedure|Extraction site development|In the test group, extraction sockets presenting EDS Type 3-4 buccal bony dehiscences were treated by a novel minimally invasive tunnelised modified GBR approach (XSD).
1541158|NCT02660684|Drug|Prograf|Injection or oral
1541159|NCT02660684|Drug|Methotrexate|Injection
1541160|NCT02660684|Drug|Cyclosporine|Injection or oral
1541161|NCT02660671|Behavioral|Email outreach|Subjects will receive an email describing the importance of colorectal cancer screening and that s/he has been selected to participate in this VIP concierge service.
1541162|NCT02660671|Behavioral|Active choice|S/he will receive the ability to pre-commit and choose from 3 different appointment slots by clicking directly on the email.
1541163|NCT02660671|Behavioral|Financial incentive|The participant will receive the offering of $100 if s/he follows through with screening colonoscopy.
1541164|NCT02660658|Drug|Intrathecal dexmedetomidine|The dose of intrathecal DEX given to the next patient will be guided by modified Dixon's up-and-down method using 1.5 mg as a step size, which assumed to be of clinical importance
1541165|NCT02660645|Drug|Hexaminolevulinate hydrochloride (HCL)|Instillation in bladder
1541166|NCT02660645|Device|Karl Storz D-Light C Photodynamic Diagnostic (PDD) system|Cystoscopy procedure
1541167|NCT02660632|Other|Thoracic epidural analgesia (TEA)|Epidural catheter will be inserted at T9-T11. Then, epidural analgesia will be activated with administering bolus of 10 mls 0.25% bupivacaine in conjunction with100 mcg fentanyl to establish a block. This will be followed by an infusion of 0.125% bupivacaine in conjunction with 2 mcg/ ml fentanyl at a rate of 10 mls /hour and then titrated to effect for up to 48 hour postoperative
1541168|NCT02660632|Other|Rectus sheath catheter block|Following insertion of bilateral rectus sheath catheters, 20 ml of 0.25% bupivacaine will be injected through each one. Then continuous infusion pumps will be connected to the catheters and set to deliver boluses of 20 mL of 0.25% bupivacaine, with a 4-hour lockout for up to 48 h postoperatively.
1541169|NCT02660619|Other|Psychiatric Research Interview for Substance and Mental Disorders (PRISM-5-Op)|
1541170|NCT02660606|Other|Prescription Opioid Misuse and Abuse Questionnaire (POMAQ)|
1541171|NCT02660593|Dietary Supplement|SanGrow Decoction|SanGrow Decoction is perpared according to the principle of Chinese medicine to treat thirsty and maransis.
1541172|NCT02660580|Drug|MSB11022|MSB11022 will be administered at a dose of 80 milligram (mg) subcutaneously at Week 1, followed by 40 mg every other week starting 1 week after the initial dose up to and including Week 14. At week 16, subjects with a (PASI) 50 response will remain on study for up to 52 weeks.
1541173|NCT02660580|Drug|Humira®|Humira® will be administered at a dose of 80 mg subcutaneously at Week 1, followed by 40 mg every other week starting 1 week after the initial dose up to and including Week 14. At week 16, subjects with a (PASI) 50 response will remain on study for up to 52 weeks; subjects initially randomized to Humira® will be re-randomized (1:1) to MSB11022 or Humira® treatment for weeks 16-52.
1541217|NCT02660281|Drug|Fludarabine|Fludarabine
1541218|NCT02660281|Drug|Pre-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given prior to the stem cell infusion
1541219|NCT02660281|Drug|Pre-Stem Cell Infusion Mesna|Mesna given prior to the stem cell infusion
1541175|NCT02660554|Other|Polymerase Chain Reaction (PCR)|Respiratory samples called bronchoalveolar lavage (BAL) gathered from subjects in the PCR arm will be tested for the presence of MRSA using the Cepheid Xpert® Assay. Xpert® is a qualitative in vitro test designed for rapid detection and differentiation of Staphylococcus aureus (SA) and methicillin resistant Staphylococcus aureus (MRSA) using PCR amplification. MRSA is identified by the mecA gene and staphylococcal cassette chromosome mec (SCCmec). Xpert® Assay is approved by the Federal Drug Administration to detect MRSA in soft tissue samples. Once the PCR is completed, the results will be relayed to the treating physician, and antibiotic therapy (vancomycin or linezolid) will be started or stopped based on the study protocol. All BAL samples will be sent for routine bacterial cultures.
1541176|NCT02660541|Device|Betafoam|Comparison between 2 medical devices
1541177|NCT02660541|Device|Allevyn Silver Dressing|Comparison between 2 medical devices
1541178|NCT02660528|Drug|Tocilizumab|Subcutaneous tocilizumab
1541179|NCT02660515|Procedure|Additional wrist arthroscopy|
1541180|NCT02660515|Procedure|ORIF|
1541181|NCT02660502|Drug|Biochaperone insulin lispro 0.1 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.1 U/kg
1541182|NCT02660502|Drug|Biochaperone insulin lispro 0.2 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.2 U/kg
1541183|NCT02660502|Drug|Biochaperone insulin lispro 0.4 U/kg|Injection of a single dose of BioChaperone insulin lispro at the dose of 0.4 U/kg
1541184|NCT02660502|Drug|Humalog®|Injection of a single dose of Humalog® at the dose of 0.2 U/kg
1541185|NCT02660489|Drug|OC459|
1541186|NCT02660489|Drug|Placebo|
1541187|NCT02660489|Other|Rhinovirus|Inoculation with rhinovirus serotype 16
1541188|NCT02660463|Other|"Registration of the diagnosis CTEPH"|Registration of risk factors for thromboembolic events
1541189|NCT02660450|Other|Prescription for Workload|Prescription from 65% VO2max for 5 min of exercise
1541190|NCT02660450|Other|Prescription for Heart Rate|Prescription from 60 - 65% Maximum Heart Rate for 5 min of exercise
1541191|NCT02660450|Other|Prescription Self Selected|Prescription Self Selected from Perceived exertion at 3 - 4 (moderate) for 5 min of exercise
1541192|NCT02660437|Other|Pulmonary Rehabilitation program|Patients will attend a comprehensive 3-week PR program (12sessions/ 60min·day) including high intensive interval exercise equivalent to 100% of peak work rate (WRpeak) with 30sec work periods interspersed with 30sec rest periods for 30min and light resistance training (3muscle groups/ 4sets each/10repetitions; ~30min).
1541193|NCT02660424|Drug|VX-150|
1541194|NCT02660424|Drug|Placebo|
1541195|NCT02660411|Drug|Sevoflurane|Sevoflurane will be administered by inhalation for anesthesia maintenance. The concentration of inhaled sevoflurane will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Sevoflurane inhalational concentration will be decreased towards the end of surgery. Sevoflurane inhalation will be stopped at the end of surgery.
1541196|NCT02660411|Drug|Propofol|Propofol will be administered by intravenous infusion for anesthesia maintenance. The infusion rate of propofol will be adjusted to maintain the BIS value between 40 and 60, with or without 50% nitrous oxide. Propofol infusion rate will be decreased towards the end of surgery. Propofol infusion will be stopped at the end of surgery.
1541197|NCT02660398|Procedure|Standardized NMBD Management|The intervention phase will introduce a standardized research protocol that spells out NMBD management, including how muscle relaxant should be administered and monitored, and how reversal with neostigmine should be done.
1541198|NCT02660385|Behavioral|Cognitive Behavioral Therapy for Insomnia|This behavioral intervention includes strategies for modifying thoughts, cognitions and behaviors regarding sleep provided by a therapist in a group format.
1541199|NCT02660385|Behavioral|Self-Management Education for Heart Failure|This is an educational education designed to teach patients about self-management their heart failure. It includes information on medications, lifestyle, cardiac devices, diet, and when to seek assistance from a health care provider.
1541200|NCT02660372|Drug|Imonogas|Simethicone 120 mg in gel capsules
1541201|NCT02660372|Drug|Espumisan|Simethicone 40 mg in gel capsules
1541206|NCT02660346|Drug|Daptomycin|Control Arm Treatment if used as monotherapy. Study Arm Treatment if used in combination with ceftaroline.
1541207|NCT02660346|Drug|Vancomycin|Control Arm Treatment
1541208|NCT02660346|Drug|Ceftaroline|Study Arm Treatment
1541209|NCT02660333|Dietary Supplement|Placebo|Maltodextrin - 12g/day
1541210|NCT02660333|Dietary Supplement|Prebiotic|Fructooligosaccharide - 12g/day
1541211|NCT02660333|Dietary Supplement|Synbiotic|Fructooligosaccharide + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019 - 12g/day
1541212|NCT02660320|Device|Dermabrasion|Preparing the graft bed before epidermal cell suspension The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
1541213|NCT02660320|Device|Laser placebo|The epidermis can be removed using ablative CO2 or Erbium laser. We will assess the efficacy of using instead micro-needles to create micro-holes that will allow the melanocytes to reach the lower layers of the epidermis and thus repigment the lesional skin.
1541214|NCT02660307|Other|PROGRESS group|
1541215|NCT02660294|Biological|platlet rich plasma|Platelet-rich plasma (PRP) is prepared from fresh whole blood which is collected from a peripheral vein, stored in acid citrate dextrose solution A (ACD-A) anticoagulant and processed to increase platelets by separating various components of blood
1541216|NCT02660281|Radiation|Total Body Irradiation 1200 cGy|1200 cGy TBI in 8 fractions
1541223|NCT02660281|Drug|Post-Stem Cell Infusion Cyclophosphamide|Cyclophosphamide given after the stem cell infusion
1541224|NCT02660281|Drug|Post-Stem Cell Infusion Mesna|Mesna given after the Stem Cell Infusion
1541225|NCT02660281|Drug|Thiotepa|Thiotepa
1541226|NCT02660268|Other|Clinical Pathway|Implementation of a Clinical Pathway for Medical and Surgical Management of Hip Prosthesis Infections
1541227|NCT02660255|Drug|Cannabidiol|Formulation: 100mg/ml CBD (Epidiolex) Solution
1541228|NCT02660242|Drug|G-Pen Mini™ (glucagon injection)|Glucagon (150 µg) 15 minutes before the start of exercise (SQ-abdomen).
1541229|NCT02660242|Other|Glucose Tabs|Dextrose tabs orally (20 grams) 15 minutes before the start of exercise and at 30 minutes of exercise (total 40 grams).
1541230|NCT02660242|Other|Basal Insulin Reduction|Basal insulin reduction to 50% one hour before the start of exercise.
1541233|NCT02660203|Procedure|Forced expiration|"Amongst chest physiotherapy technics, forced expiration is one of the passive procedures used in pediatrics.
The patient is positioned on ipsilateral decubitus and the physiotherapist is behind the patient, placing one hand on the patient abdomen and the other on the patient lateral chest. During expiration, the abdominal hand apply a pressure directed posteriorly and superiorly for the patient. Simultaneously, the thoracic hand apply a pressure posteriorly and inferiorly for the patient. The session's duration is 15 minutes after what the physiotherapist replace the patient in dorsal decubitus.Two sessions a day will be performed"
1541234|NCT02660190|Drug|hexaminoavolunate|
1541235|NCT02660190|Procedure|WL cystoscopy|
1541236|NCT02660177|Drug|Metamizole|metamizole IV administration
1541237|NCT02660164|Device|Nautilus BrainPulse Recording|Comparison of Nautilus BrainPulse recordings in subjects who have a concussive event (Cohort A) to Nautilus BrainPulse recording in subjects who do not experience a concussive events (Cohort B or matched subjects to Cohort A). Recordings are obtained over a 2 week period every 2 to 3 days (at least 5 recordings per subject).
1541238|NCT02660151|Device|Hyper-CL™ lens|
1541239|NCT02660151|Device|Regular soft contact lens|
1541240|NCT02660151|Drug|Salt solution|
1541247|NCT02660099|Behavioral|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet platform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks. Both parents and adolescents are involved in treatment. Parents will also receive three lectures on 1, Autism spectrum disorder, 2, CBT and functional analysis and 3, Parental strategies
1541248|NCT02660086|Behavioral|Personalized nutrition feedback|Automated personalized feedback about cafeteria food purchases (weekly); social norms and small financial incentives to promote healthy purchases (monthly)
1541249|NCT02660073|Device|NMES+FES|12 weeks of electrically evoked resistance training followed by 12 weeks of functional electrical stimulation cycling.
1541250|NCT02660073|Device|Control+FES|12 weeks of passive movement followed by 12 weeks of functional electrical stimulation cycling.
1541251|NCT02660060|Drug|Pramipexole Dexa Medica|Pramipexole 0.25 tablets produced by PT Dexa Medica for PT Ferron Par Pharmaceuticals as the test drug.
1541252|NCT02660060|Drug|Pramipexole Boehringer Ingelheim Pharma|Pramipexole 0.25 tablets produced by Boehringer Ingelheim Pharma GmbH & Co.KG for Boehringer Ingelheim International GmbH as the reference drug.
1541253|NCT02660047|Drug|Liraglutide|"Drug: Liraglutide
Preparation and labelling of Investigational Medicinal Product:
Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.
Drug accountability:
Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
1541254|NCT02660047|Drug|Liraglutide - Placebo|"Drug: Liraglutide - Placebo
Preparation and labelling of Investigational Medicinal Product:
Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.
Drug accountability:
Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
1541255|NCT02660034|Biological|BGB-A317|
1541256|NCT02660034|Drug|BGB-290|
1541257|NCT02660008|Drug|ZP4207|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of ZP4207 administered s.c. to hypoglycemic Type 1 diabetic patients
1541258|NCT02660008|Drug|GlucaGen|Parallel trial in Group 1 and cross-over trial in Groups 2-4 with single doses of GlucaGen administered s.c. to hypoglycemic Type 1 diabetic patients
1541259|NCT02659995|Other|No intervention|No interventions will be performed on these patients.
1541265|NCT02659917|Other|Glass ionomer|Application of preventive agent
1541266|NCT02659917|Other|Glass ionomer cement|Application of preventive agent
1541267|NCT02659917|Other|-Glass ionomer-|Atraumatic Restorative Treatment
1541268|NCT02659917|Other|-Glass ionomer cement-|Atraumatic Restorative Treatment
1541269|NCT02659904|Other|Less than 2 mm remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
1541270|NCT02659904|Other|2 mm or more remaining palatal tissue thickness|The greater palatine and incisive nerves were blocked with 2% lidocaine, 1:100,000 epinephrine injection. After preparation of the recipient bed, free gingival graft was harvested using a handle with knife at palatal donor side with acrylic stent guidance.
1541271|NCT02659891|Biological|IVIg|
1541272|NCT02659891|Other|Placebo|
1541273|NCT02659878|Procedure|bleeding, intraventricular and/ or intracerebral hemorrhage.|Patient's age, sex, comorbidities, medications, the exact time point of bleeding, the circumstances of bleeding neurological and cardiological status are recorded, laboratory tests, Transcranial Color Doppler (TCCD), echocardiography and chest X-ray examinations are carried out within 24 hours after the patient is being admitted to the ICU.
1541274|NCT02659865|Drug|Placebo|Administered orally
1541275|NCT02659865|Drug|LY3039478 original formulation|Administered orally
1541276|NCT02659865|Drug|LY3039478 new formulation|Administered orally
1541277|NCT02659852|Procedure|side by side|Stenting generally begins with selective guidewire cannulation into the left and right intrahepatic bile ducts. Self-expandable metallic stent(SEMS) deployment is the conventional method and parallel SEMS can be inserted. SEMS deployment can be performed serially or simultaneously.
1541278|NCT02659852|Procedure|stent in stent|After first SEMS deployment, contralateral placement of a second SEMS through the mesh of the first deployed stent was done and it looks like a Y configuration.
1541279|NCT02659839|Other|Cancer patients admitted to the ICU|There will be no change in the standard ICU treatment.
1541287|NCT02659813|Device|Orthodontic archwire|Archwire used to align teeth in an orthodontic fixed brace
1541288|NCT02659800|Other|Laboratory Biomarker Analysis|Correlative studies
1541289|NCT02659800|Biological|Glycosylated Recombinant Human Interleukin-7|Given IV
1541290|NCT02659800|Other|Placebo|Given IV
1541291|NCT02659787|Drug|0.2mg Buprenorphine|Sublingual buprenorphine tablets (0.2mg)
1541292|NCT02659787|Drug|Placebo|Placebo
1541293|NCT02659787|Drug|0.4mg Buprenorphine|Sublingual buprenorphine tablets (0.4mg)
1541294|NCT02659774|Behavioral|workshop (Motivational intervention)|Through intensive workshop which includes motivation of quitting enhancement, stress management, smoking triggers, cravings and relapse, to provide smoking cessation intervention
1541295|NCT02659774|Behavioral|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking
1541296|NCT02659774|Behavioral|Face to Face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
1541297|NCT02659774|Behavioral|Phone counseling|Use motivational interview strategies through telephone counseling to provide smoking cessation intervention
1541298|NCT02659774|Behavioral|SMS|Use motivational interview strategies through telephone messages to provide smoking cessation intervention
1541299|NCT02659774|Behavioral|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting
1541301|NCT02659748|Dietary Supplement|Milk Fat|Three daily servings of whole yogurt (3.25% fat).
1541302|NCT02659748|Dietary Supplement|Control Fat|Three daily servings of fat-free yogurt supplemented with a control fat.
1541303|NCT02659735|Drug|JNJ-63623872 300 milligram (mg)|Participants will receive 600 milligram (mg) JNJ-63623872 formulated as the 300 mg oral tablet on Day 1.
1541304|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #1 on Day 1.
1541305|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #2 on Day 1.
1541306|NCT02659735|Drug|JNJ-63623872 600 mg|Participants will receive 600 mg JNJ-63623872 formulated as 600 mg oral concept formulation #3 on Day 1.
1541307|NCT02659722|Device|InterFuse|TRansforaminal or Posterior placement of an InterFuse S and/or T device, in combination with approved posterior fixation
1541308|NCT02659709|Device|Smartphone Application|Smartphone Application designed to educate glaucoma patients about disease, testing, and treatments with reminders for taking medications.
1541309|NCT02659683|Drug|Nexium 40 mg DR Capsules of AstraZeneca LP, USA|oral, cross over
1541310|NCT02659683|Drug|Torrent's Esomeprazole Magnesium DR Capsules 40 mg|oral, cross over
1541311|NCT02659670|Other|internet survey|The internet survey will ask them how often they have used their medication that week, as well as giving them treatment tips and reminders about rosacea triggers. They will be asked a variety of questions during the weekly internet survey- such as the amount of erythema they currently have (measured by VAS scale), how much burning and stinging they have, how often they have used the medication and where did they apply the medication, as well as any additional side effects they may be having from the medication.
1541312|NCT02659670|Drug|brimonidine topical gel 0.33%|All subjects will receive standard-of-care brimonidine topical gel 0.33%
1541313|NCT02659657|Drug|Interleukin-2|Interleukin-2 (IL-2), 0.4×10E+6/M2/d, 3 times a week (separated by at least 1 day between injections) until day +90 (+/- 7 days)
1541314|NCT02659644|Drug|Oral L-citrulline|There will be a total of 16 patients divided into 4 equal cohorts. The first 4 cohorts will be started on a 7 day oral regimen of twice daily L-citrulline. They will return to clinic on day #7 to evaluate nitric oxide metabolite levels and pharmacokinetic (PK) profile of citrulline. After PK analysis, the next cohort of patients will be given a higher or lower dose based on their weight and also based safety and tolerability. Of note, a PK analysis will be performed for each 4 patient cohort prior to starting citrulline for the subsequent cohort. Assessment for adverse events will be done at specified times throughout the study duration via both phone and clinic encounters.
1541317|NCT02659605|Procedure|Delayed cord clamping above the perineum|After delivery, the infant will be placed on the mother's abdomen and the cord will be clamped 30-45 seconds after delivery of the infant.
1541318|NCT02659605|Procedure|Delayed cord clamping below the perineum|The infant will be held below the perineum, and the cord clamped and cut 60-75 seconds after delivery of the infant.
1541319|NCT02659592|Procedure|transplantation of ovarian tissue|operation(mini laparotomy) for transplantation of frozen- thawed ovarian tissue
1541320|NCT02659579|Behavioral|The Reader Organisation's Shared Reading Programme|In The Reader Organisation's Shared Reading Programme, parents and children will attend weekly shared book reading sessions for 8 weeks which focus predominately on how to read interactively with children.
1541321|NCT02659579|Behavioral|Shared Reading control|Parents and children will attend a weekly shared reading group at a library for 8 weeks
1541322|NCT02659553|Procedure|steatosis|Liver Transplantation with graft steatosis
1541323|NCT02659540|Drug|Ipilimumab|
1541324|NCT02659540|Drug|Nivolumab|
1541325|NCT02659540|Radiation|Radiotherapy|
1541326|NCT02659527|Drug|68Ga- PSMA-HBED-CC|Patients will receive a dual-tracer PET/MRI scan. FEC and 68Ga-PSMA-HBED-CC, for tissue metabolism and surface marker expressions, as specific PET-tracers as well as multiparametric MRI methods (T2w, DCE, DWI) are used.
1541327|NCT02659527|Device|Biograph mMR, Siemens|All PET-MRI examinations will be performed using a hybrid PET-MRI system (Biograph mMR, Siemens, Germany) capable of simultaneous data acquisition. The system consists of an MRI-compatible state-of the art PET detector integrated in a 3.0-T whole-body MRI scanner.
1541328|NCT02659514|Drug|Poziotinib|Supplied as oral tablets, administered for 14 consecutive days of each cycle
1541329|NCT02659501|Drug|Liposomal bupivacaine|Liposomal Bupivacaine is an aqueous suspension of multivesicular liposomes containing bupivacaine. After injection into soft tissue, bupivacaine is slowly released from the multivesicular liposomes, extending this drug's duration of action.
1541330|NCT02659501|Drug|Bupivacaine with epinephrine|Bupivacaine, like other local anesthetics reduces the flow of sodium in and out of nerves. This decreases the initiation and transfer of nerve signals in the area in which the drug is injected. This leads first to a loss of sensation of pain, temperature, touch, and deep pressure. This drug is the current standard of care for local, postoperative local anesthesia following breast reconstruction. Epinephrine, a vasoconstrictor, is included in bupivacaine formulations to improve the duration of local anesthesia.
1541331|NCT02659501|Drug|Morphine sulfate|Morphine is an opiate pain medication administered intravenously for severe, breakthrough post-operative pain.
1541332|NCT02659501|Drug|Hydrocodone/acetaminophen|Hydrocodone acetaminophen is a combination of an opiate pain medication (hydrocodone) and a non-steroidal anti-inflammatory drug (acetaminophen) given orally to patients for moderate post-operative pain.
1541333|NCT02659501|Drug|Diazepam|Diazepam is a benzodiazepine medication that is administered orally to treat muscle spasms in patient's following expander and implant-based breast reconstruction.
1541334|NCT02659488|Drug|Lisdexamfetamine|20 healthy controls and 20 women subjects with BED agreeing to a 12-week, open-label trial of LDX and fMRI assessments immediately before and after the 12 weeks of LDX treatment will be recruited
1541335|NCT02659475|Drug|PHEN/TPM ER (Qsymia®)|PHEN/TPM ER (Qsymia®)
1541336|NCT02659462|Other|Cardio Pulmonary Exercise Testing|Cardio Pulmonary Exercise Testing
1541337|NCT02659449|Device|made to measure compression gloves|Patients achieve tests with compression glove
1541338|NCT02659449|Device|Compression bandaging|Patients achieve tests with compression bandaging
1541339|NCT02659449|Other|Free Hands|Patients achieve tests without device
1541340|NCT02659436|Other|Verbal-linguistic CBT|Participants will receive 4 sessions of individual therapy focused on traditional cognitive restructuring and exposure therapy.
1541341|NCT02659436|Other|Imagery-based CBT|Participants will receive 4 sessions of individual therapy focused on imagery-based cognitive work and behavioural experiments.
1541342|NCT02659423|Behavioral|BIC 1|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
1541343|NCT02659423|Behavioral|BIC 2|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
1541344|NCT02659423|Behavioral|BIC 3|BIC cluster creation will include policy, implementation and degree of community coverage, specific title mandatory, and exclusively online training.
1541345|NCT02659410|Other|Heat stress (21)|4h exposure to heat (WBGT of 21°C), no solvent
1541346|NCT02659410|Other|Heat stress (25)|4h exposure to heat (WBGT of 25°C), no solvent
1541347|NCT02659410|Other|Heat stress (30)|4h exposure to heat (WBGT of 30°C), no solvent
1541348|NCT02659410|Other|Heat Stress (21) +TOL|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV)
1541349|NCT02659410|Other|Heat stress (25) + TOL|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV)
1541350|NCT02659410|Other|Heat stress (21) + TOL|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV)
1541351|NCT02659410|Other|Heat stress (21) + ACE|4h exposure to heat (WBGT of 21°C) + Acetone (concentration = TLV)
1541352|NCT02659410|Other|Heat stress (25) + ACE|4h exposure to heat (WBGT of 25°C) + Acetone (concentration = TLV)
1541353|NCT02659410|Other|Heat stress (30) + ACE|4h exposure to heat (WBGT of 30°C) + Acetone (concentration = TLV)
1541354|NCT02659410|Other|Heat stress (21) + DCM|4h exposure to heat (WBGT of 21°C) + Dichloromethane (concentration = TLV)
1541355|NCT02659410|Other|Heat stress (25) + DCM|4h exposure to heat (WBGT of 25°C) + Dichloromethane (concentration = TLV)
1541356|NCT02659410|Other|Heat stress (30) + DCM|4h exposure to heat (WBGT of 30°C) + Dichloromethane (concentration = TLV)
1541357|NCT02659410|Other|Heat stress (21) + TOL (dermal)|4h exposure to heat (WBGT of 21°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
1541358|NCT02659410|Other|Heat stress (25) + TOL (dermal)|4h exposure to heat (WBGT of 25°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
1541359|NCT02659410|Other|Heat stress (30) + TOL (dermal)|4h exposure to heat (WBGT of 30°C) + Toluene (concentration = TLV), participants breath normal air through a mask for evaluation of dermal absorption.
1541360|NCT02659397|Drug|ETC-1002|Blinded ETC-1002 180 mg tablet once daily for 4 weeks (Weeks 1 to 4)
1541361|NCT02659397|Drug|Atorvastatin|Atorvastatin 80 mg tablet once daily for 8 weeks (Weeks -4 to 4)
1541362|NCT02659397|Drug|Placebo|Blinded ETC-1002-matched placebo tablet once daily for 4 weeks (Weeks 1 to 4)
1541363|NCT02659384|Drug|Bevacizumab|
1541364|NCT02659384|Drug|atezolizumab|
1541365|NCT02659384|Drug|acetylsalicylic acid|
1541366|NCT02659384|Drug|placebo|
1541367|NCT02659371|Dietary Supplement|Low energy diet|
1541368|NCT02659358|Device|Fitbit Charge HR®|A wrist worn biosensor, the Fitbit Charge HR® has sensor capability, good battery life, water resistant, Bluetooth capabilities, and provides accessible data.
1541369|NCT02659345|Behavioral|Emotions Thermometer|The Emotions Thermometer, was chosen to assess patients' mood, anxiety level, and pain scale for this study. For patient ease, the study team chose to utilize a scale of 1-10 for all subjective measurements to be obtained from patients (mood and anxiety level). The study team included the thermometer image to mirror the NCCN Guidelines Version Distress Management Screening tool, for measuring distress and mood level. This screening tool has been shown to be effective in assessing patient distress and mood in oncology patients with ease of use in patients and utility in providers.
1541370|NCT02659345|Behavioral|Art Therapy|Each participant will participate in a private art therapy session with the Art Therapist for 50 minutes. The participant will have a choice of materials to work with, including painting, drawing, clay, and collage materials. The session will conclude with processing of the art and supportive counseling.
1541371|NCT02659332|Device|TURBT|Diode laser (400μm fiber, 6-12W, laser pulse 1ms and intervals of 1 ms)
1541372|NCT02659319|Behavioral|Family Lifestyle (FL)|12-week Family Food & Lifestyle intervention, aimed at improving family nutritional intake, activity levels, weight perception, and parental monitoring of child eating. Material is delivered in psychoeducational groups in the children's schools.
1541373|NCT02659319|Behavioral|Family Dynamics (FD)|The Family Dynamics intervention focuses on positive parenting (i.e., emotion coaching, praise, limit setting) and on child emotion regulation and positive problem solving. Material is delivered in psychoeducational groups in the children's schools.
1541374|NCT02659319|Behavioral|Peer Group (PG)|Peer Group intervention conducted throughout one semester of the school year that includes 12 sessions of a guidance-type curriculum during class time sensitizing children to the importance of social inclusion of all children
1541375|NCT02659306|Drug|Metformin|Metformin hydrochloride is a white to off-white crystalline compound formulated as tablets for oral consumption; tablets contain 500 mg, 850 mg, or 1000 mg of metformin hydrochloride. Only 500 mg and 850 mg tablets will be used for this study.
1541376|NCT02659293|Drug|Lenalidomide|
1541377|NCT02659293|Drug|Carfilzomib|
1541378|NCT02659293|Drug|Dexamethasone|
1541379|NCT02659280|Other|Adjunct Therapy|"Store and Forward Tele-heath"
1541380|NCT02659280|Other|Standard of Care|Standard of Care Outpatient Physical Therapy
1541381|NCT02659267|Behavioral|Interventions Group|VAMOS is a lifestyle promotion strategy, designed to promote physical activity and healthy eating habits. The intervention is composed by a weekly meeting, 12-week, in group, lasting about 60 min. In each weekly meeting, were discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the VAMOS strategy are based in behavior changes theories. The participants of this group received educational material and, in the middle of the program, they received a pedometer to aid in motivation and in the self-monitoring physical activity.
1541382|NCT02659254|Device|Sirolimus Target Eluting Bioresorbable Vascular Scaffold|Implantation of the Sirolimus Target Eluting Bioresorbable Vascular Scaffold
1541383|NCT02659241|Drug|AZD1775|Starting the day of laparoscopic surgery, AZD1775 175 mg tablets taken by mouth 2 times each day on Days 1 - 3 of a 28-day study cycle. Depending on when tumor reduction surgery is scheduled, participant may be able to continue taking the study drug on Days 8 - 10, 15 - 17, and 22 - 24.
1541384|NCT02659228|Device|EEG recording|EEG recording with anesthetic (DIPRIVAN)
1541385|NCT02659228|Drug|Anesthetics, Intravenous|The participant will receive an intravenous infusion of propofol (DIPRIVAN Injectable Emulsion USP 1%, AstraZeneca).
1541386|NCT02659215|Device|Hyalofast|Implantation of Hyalofast scaffold with autologous bone marrow aspirate concentrate via arthroscopy/mini-arthrotomy.
1541387|NCT02659215|Procedure|Microfracture|Microfracture is a well-established arthroscopic surgical technique for cartilage repair which involves several systematic steps, including debridement to a stable cartilage margin, careful removal of the calcified cartilage layer, and homogeneous placement of microfracture penetrations within the cartilage defect, with resultant complete defect fill by a well-anchored clot
1541388|NCT02659202|Device|Precision Spinal Cord Stimulator System|The precision system will consist of a pulse generator that will not be implanted, temporary percutaneous leads, surgical paddle leads and lead extensions, each packaged as a separate kit.
1541389|NCT02659176|Procedure|Transperineal repair with PIS|Repair of anterior rectocele via transperineal approach followed by limited internal sphincterotomy at 6 o'clock.
1541390|NCT02659176|Procedure|Transperineal repair without PIS|Repair of anterior rectocele via transperineal approach without performing limited internal sphincterotomy
1541391|NCT02659163|Behavioral|mHealth wristband|A wristband containing several sensors worn by participants to collect daily objective patient-generated health behavior data on physical activity, sleep, and screen time
1541392|NCT02659163|Behavioral|mHealth scale|A wireless scale used by participants to measure and record daily weight.
1541393|NCT02659163|Behavioral|EMA|Self-reported information on sugar sweetened beverage consumption collected via mobile messaging
1541394|NCT02659163|Behavioral|mHealth app|A mobile application that houses study data and provides two-way messaging between the study team and study participants.
1541395|NCT02659163|Behavioral|Health Behavior Feedback|Provide feedback on patient-generated health behaviors data, along with standard of care recommendations, for self-guided
1541396|NCT02659163|Behavioral|Integrated closed-loop feedback system|Daily feedback and weekly e-report cards on patient-generated longitudinal health behaviors along with clinical recommendations via mobile messaging
1541397|NCT02659150|Drug|tocilizumab|subjects will be treated with 162mg of weekly subcutaneous tocilizumab in an open-label manner, this will be done addition to MTX or monotherapy. On subsequent weeks after the first dose of tocilizumab, subjects will be instructed to inject the full amount of syringe according to the directions provided in the Instructions For Use (IFU).
1541398|NCT02659137|Other|HV measurement|Electrophysiology (EP) study during the TAVI procedure
1541399|NCT02659124|Device|AmnioFix plus Standard of Care|Patients will receive the standard of care alone on half of their face, and AmnioFix in addition to the standard of care on the other half of their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
1541400|NCT02659124|Procedure|Standard of Care|Patients will receive the standard of care dressing only, on their face. The standard of care after ablative resurfacing is conservative wound care which may include flexible wound care dressings and/or emollients.
1541401|NCT02659111|Other|High Intensive Functional Exercise (HIFE)|Patients invited to high-intensity physical exercise, HIFE by a physiotherapist with special competence in neurology at one of the two centers, or by a general physiotherapist where the patient lives. Goal Attainment Scaling is performed. The training will be given twice a week for one hour during 12 weeks . At least 18 of 24 training session in a four month period of time will be required. A training manual will be distributed to each training physiotherapist. The patients will also be encouraged to do additional training and they will receive standardized written physical training advice
1541402|NCT02659111|Other|Physical training advice|Patients randomized to written advice for physical training will be given a leaflet with instructions how to train by there own.The physiotherapist responsible for evaluating sets goals together with the patient according to Goal Attainment Scaling.
1541572|NCT02658045|Device|Oxitone oximeter|Oxygen saturation will be measured by Oxitone oximeter
1541403|NCT02659098|Drug|CNTO 2476 6.0 x 10^4 cells|Participants will receive a single subretinal administration of CNTO 2476 6.0 x 10^4 cells in 50 microliter (mcL) given by subretinal Delivery System.
1541404|NCT02659098|Drug|CNTO 2476 3.0 x 10^5 cells|Participants will receive a single subretinal administration of CNTO 2476 3.0 x 10^5 cells in 50 microliter (mcL) given by subretinal Delivery System.
1541405|NCT02659098|Procedure|Sham-Surgical Procedure|Participants will receive a modified sham surgical procedure.
1541406|NCT02659098|Device|Subretinal Delivery System|Participants will receive CNTO 2476 by using the Delivery System.
1541407|NCT02659085|Drug|Ketamine IV Infusion|Patients randomized to the experimental treatment receive intravenous infusions of racemic ketamine (0.5 mg/kg), delivered over a period of forty minutes thrice weekly (Monday, Wednesday, Friday) under supervision.
1541408|NCT02659085|Procedure|ECT|ECT given in line with standard procedures (including anesthesia, muscle relaxation and oxygenation) thrice weekly.
1541409|NCT02659059|Biological|Nivolumab|Specified Dose on Specified Days
1541410|NCT02659059|Biological|Ipilimumab|Specified Dose on Specified Days
1541411|NCT02659059|Drug|Platinum Doublet Chemotherapy|Specified Dose on Specified Days
1541412|NCT02659033|Drug|ceftriaxone|ceftriaxone (1 gram per day)
1541413|NCT02659033|Drug|Cefotaxime|cefotaxime (1 gram every 8 hours)
1541418|NCT02659007|Other|yoga|8 weeks of yoga, twice a week. sitting, standing, and floor postures with meditation and breath work
1541419|NCT02658994|Behavioral|Thinking Healthy Program Peer Delivered Plus|
1541420|NCT02658994|Other|Enhanced Usual Care|
1541421|NCT02658981|Biological|Anti-LAG-3 Monoclonal Antibody BMS 986016|Given IV
1541422|NCT02658981|Biological|Anti-PD-1|Given IV
1541423|NCT02658981|Other|Pharmacological Study|Correlative Studies
1541424|NCT02658981|Other|Laboratory Biomarker Analysis|Correlative Studies
1541425|NCT02658981|Biological|Anti-CD137|Given IV
1541426|NCT02658968|Drug|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin® (lutetium (177Lu)-lilotomab satetraxetan), single injection with lilotomab pre-dosing.
1541427|NCT02658955|Procedure|Short stitch|Surgeons will receive instructions to change the technique of abdominal wall closure
1541428|NCT02658942|Procedure|Ureteroscopy|In Group A patients, Karl Storz Flex-X 7.5, FURS with a 365 µm laser fiber.
1541429|NCT02658942|Procedure|Shockwave lithotripsy|In Group B patients, a Siemens Lithostar Lithotriptor
1541430|NCT02658929|Biological|bb2121|
1541431|NCT02658916|Drug|BIIB092|Same dose as corresponding CN002003 study panel.
1541432|NCT02658903|Device|Oxys Catheter|The study catheter is inserted over the urethra in the bladder as a foley catheter. The study foley catheter delivers electromagnetic therapy.
1541433|NCT02658903|Device|Covidien Mona-Therm Foley catheter|The control arm catheter is inserted over the urethra in the bladder. The control catheter is a Mona-Therm catheter from Covidien.
1541437|NCT02658877|Drug|Omalizumab|Omalizumab will be dosed according to dosing and U.S. administration guidelines for omalizumab. Omalizumab will be dosed every 2-4 weeks based on the patient's pre treatment serum IgE level (IU/mL) and initial visit body weight (kg). Omalizumab will be delivered as a subcutaneous injection. Standard safety precautions for dosing will be observed, including clinical observation after dosing, and provision of an epinephrine pen. Maintenance asthma treatment will remain unchanged.
1541438|NCT02658877|Drug|Placebo|Saline with a volume of injection frequency indicated based on the patient's serum IgE and body weight, delivered subcutaneously and supplied by Novartis Pharma.
1541439|NCT02658864|Drug|lafutidine|comparison of different doses, sex and medication conditions
1541440|NCT02658851|Device|J-Plasma|Bovie Medical Corporation's J-Plasma® helium based plasma technology is a hemostatic tool for the cutting, coagulation, and ablation of soft tissue.
1541441|NCT02658838|Drug|Ticagrelor|Patients were treated with full amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
1541442|NCT02658838|Drug|full amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
1541443|NCT02658838|Drug|half amount low molecular weight heparin|Patients were treated with half amount low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
1541444|NCT02658838|Drug|No low molecular weight heparin|Patients were treated with no low molecular weight heparin randomly after PCI,All patients are treated with ticagrelor one year.
1541445|NCT02658825|Drug|JNJ-63623872 2400 milligram (mg)|Participants will receive JNJ-63623872 2400 mg tablet orally once on Day 1 of Panel 1.
1541446|NCT02658825|Drug|JNJ-63623872 3000 mg|Participants will receive JNJ-63623872 3000 mg tablet orally once on Day 1 of Panel 1.
1541447|NCT02658825|Drug|JNJ-63623872|Participants will receive JNJ-63623872 dose selected in Panel 1 tablet orally once on Day 1 of Panel 2.
1541448|NCT02658825|Drug|Moxifloxacin|Participants will receive moxifloxacin 400 mg capsule orally once on Day 1 of Panel 2.
1541449|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 2400 mg)|Participants will receive placebo (matching with JNJ-63623872 2400 mg) tablet orally once on Day 1 of Panel 1.
1541450|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 3000 mg)|Participants will receive placebo (matching with JNJ-63623872 3000 mg) tablet orally once on Day 1 of Panel 1 and 2.
1541451|NCT02658825|Drug|Placebo (Matching with JNJ-63623872 Dose)|Participants will receive placebo (matching with JNJ-63623872 dose) tablet orally once on Day 1 of Panel 2.
1541452|NCT02658825|Drug|Placebo (Matching with Moxifloxacin)|Participants will receive placebo (matching with Moxifloxacin) tablet orally once on Day 1 of Panel 2.
1541453|NCT02658812|Drug|Talimogene Laherparepvec (T-VEC)|"Talimogene laherparepvec given via intra-tumoral injection at visible locally recurrent breast cancer site and skin metastases at an initial dose of 10^6 PFU/mL .
Second talimogene laherparepvec dose administered 10^8 PFU/mL on Day 22, and talimogene laherparepvec administered every 2 weeks after the second course with same dose with the maximum dose of 4.0 mL for each course."
1541454|NCT02658812|Other|Photographs|Photographs taken of lesions on chest at baseline, at Cycle 2, Cycles 4, 8, and 10 if the doctor thinks it is needed, Day 1 of Cycle 5, Day 1 of Cycle 7, and then every odd numbered cycle after that.
1541455|NCT02658812|Behavioral|Follow-Up Visit/Phone Call|About 30 days after end-of-treatment visit and then every 3 months after that for up to 1 year, participant has follow-up visit or phone call from study staff.
1541456|NCT02658799|Drug|cataflam (diclofenac potassium)|Cataflam (diclofenac potassium, 50 mg) b.i.d. after a meal for 6 months in a cyclic regimen. Administration of diclofenac potassium was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly.
1541457|NCT02658799|Drug|placebo|"Placebo gel caps (containing inactive filler of starch flour and carboxymethylcellulose) b.i.d. after a meal for 6 months in a cyclic regimen.
Administration of placebo was undertaken from baseline to 2 months, no drug (diclofenac potassium or placebo) was administered from 2 to 4 months, then diclofenac potassium or placebo therapy was reinstituted (b.i.d.) from 4 to 6 months. To promote compliance, each patient was recalled monthly."
1541458|NCT02658773|Drug|lidocaine-Prilocaine cream|
1541459|NCT02658773|Drug|placebo cream|
1541460|NCT02658760|Drug|Dexmedetomidine|dexmedetomidine plus placebo
1541461|NCT02658760|Drug|Bupivacaine|dexmedetomidine and Bupivacaine
1541462|NCT02658747|Other|No intervention|No intervention administered in this study
1541464|NCT02658721|Drug|Lidocaine|
1541465|NCT02658721|Drug|lidocaine+adjunct tramadol|IVRA was performed with 3 mg/kg lidocaine (10% Lidocaine) plus 50 mg tramadol, which were administered after diluting with saline to 40 mL. While performing IVRA, 30 mL saline was simultaneously administered to the systemic circulation
1541466|NCT02658721|Drug|lidocaine+systemic tramadol|IVRA was performed with 3 mg/kg lidocaine, which was diluted with saline to 40 mL. While performing IVRA, 50 mg tramadol diluted with saline to 30 mL was simultaneously administered to the systemic circulation
1541467|NCT02658721|Drug|Fentanyl|If the patient had a VAS score of >4 and if required, 1 μg/kg fentanyl was administered for analgesia and the dosage and time were recorded.
1541468|NCT02658721|Drug|Atropine|"The patients received premedication 45 min before the surgery with intramuscular 0.01 mg/kg atropine.
In case of bradycardia (HR <50/min), 0.5 mg intravenous atropine was administered."
1541469|NCT02658721|Drug|Midazolam|The patients received premedication 45 min before the surgery with intramuscular 0.07 mg/kg midazolam
1541470|NCT02658721|Drug|Diclofenac sodium|The patients with a VAS score of >4 were administered with 75 mg diclofenac sodium via intramuscular route.
1541471|NCT02658721|Drug|Ephedrine|In the event of hypotension (systolic arterial pressure <90 mmHg or a decrease of more than 50 mmHg from the normal value) during the surgery, 5 mg intravenous ephedrine was administered.
1541472|NCT02658721|Drug|Ondansetron|Intravenous 4 mg ondansetron was administered for nausea and vomiting.
1541473|NCT02658708|Other|Bright blue-green light using light visor cap|
1541474|NCT02658708|Other|Dim red light using light visor cap|
1541475|NCT02658708|Other|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire|-Consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life
1541476|NCT02658708|Other|Epworth Sleepiness Scale|-Consists of 8 common daily activities with a 4-point rating scale (0=would never doze to 3=a high chance of dozing) measuring usual daytime sleepiness over a recent time period
1541477|NCT02658708|Other|Pittsburgh Sleep Quality Index|-Contains 19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance
1541478|NCT02658708|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|-Consists of 8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances
1541479|NCT02658708|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|-Consists of 8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue.
1541480|NCT02658708|Diagnostic Test|Digital foot candle datalogging light meter (Extech Instrument, Model SDL400)|-The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck.
1541481|NCT02658708|Diagnostic Test|Polysomnography (Easy Ambulatory 2 Cadwell, Kennewick, WA)|-A standard sleep montage of electroencephalography following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed
1541482|NCT02658708|Other|Horne-Ostberg Morningness-Eveningness Questionnaire|
1541483|NCT02658708|Other|Daily Fatigue and Sleep Log|"Two visual analog scales (VAS) for diurnal fatigue and daytime sleepiness
Two 0-10 point rating scales (average and worst fatigue levels in 24 hours)"
1541484|NCT02658682|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
1541485|NCT02658682|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
1541488|NCT02658656|Device|ReWalk 6.0|Exoskeletal Assisted Walking Device
1541571|NCT02658045|Device|Standard Oximeter|Oxygen saturation will be measured by standard oximeter
1541491|NCT02658630|Device|Robot + TTT exercise|The intervention will be completed 3x/week for 12 weeks. The training progression will be sequential with 4 weeks completed on the wrist robot, followed by 4 weeks on the shoulder-elbow robot and completing with 4 weeks alternating sessions on the wrist and shoulder-elbow robot. Participants will perform robot training for 45 minutes with each robot followed by 15 minutes of TTT practice to complete their 60 minute intervention session.
1541492|NCT02658604|Other|Home medication review by a pharmacist|Patients will receive a home visit from a pharmacist, including a medication review and the identification and addressing of drug therapy problems through patient education, the provision of pharmacologic and/or non-pharmacologic advice, or the adaptation of therapy or communication of recommendations to prescribers. All activities are within the current scope of practice for pharmacists in Ontario. A detailed assessment of the patient's medication inventory and organization/storage practices will be conducted, followed by a medication cabinet cleanup to help the patient organize their medications and discard any expired or discontinued medications. A list of inappropriate medications found in the home will be documented, detailing the reasons why they are inappropriate and if/how the patient is currently using these medications. With patient consent, inappropriate medications will be removed from the home and returned to the pharmacy for safe disposal.
1541493|NCT02658591|Dietary Supplement|Crackers with added faba bean protein concentrate|Protein concentrate treatment
1541494|NCT02658591|Dietary Supplement|Crackers with added faba bean protein isolate|Protein isolate treatment
1541495|NCT02658591|Dietary Supplement|Crackers with added faba bean starch|Starch treatment
1541496|NCT02658591|Dietary Supplement|Crackers with added faba bean flour|Flour treatment
1541497|NCT02658591|Dietary Supplement|Crackers with no faba bean fraction|Control treatment
1541499|NCT02658565|Procedure|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
1541500|NCT02658552|Device|Echopulse|Echopulse is a real-time US-guided High-intensity focused ultrasound (HIFU) system, the HIFU session is a noninvasive procedure that involves application of a focused high-energy ultrasound beam for thermal tissue ablation inside the targeted zone, with minimal effect on the surrounding tissue
1541501|NCT02658526|Behavioral|anesthesia - surgery|
1541502|NCT02658513|Other|Lancet blood sampling|Blood samples will be obtained using a finger-prick (lancet) technique.
1541503|NCT02658513|Other|Standard intravenous blood sampling|Blood samples will be obtained using a standard intravenous technique.
1541504|NCT02658500|Dietary Supplement|Infant Formula|
1541505|NCT02658500|Dietary Supplement|breast milk|
1541506|NCT02658487|Drug|Cytarabine|Given IV
1541507|NCT02658487|Drug|Vosaroxin|Given IV
1541508|NCT02658474|Behavioral|Acceptance and Commitment Therapy|Group based Acceptance and Commitment Therapy
1541509|NCT02658461|Drug|Trastuzumab|Trastuzumab will be given on Day 1 of each 3-week cycle for a total of 18 cycles. Dosage will be according to the local labeling: 600 milligrams (mg) SC or 6 milligrams per kilogram (mg/kg) via IV infusion. For those assigned to the IV arm or if IV treatment is delayed >1 week, an initial loading/reloading dose of 8 mg/kg will be given instead. Due to the observational nature of this study, trastuzumab is not an investigational product but will be supplied in the MO22982 trial. Each route/device (SC single-use injection device, SC vial/syringe, IV infusion) will be observed in at least 12 episodes of care.
1541510|NCT02658448|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 3 mg
1541511|NCT02658435|Drug|Tafenoquine 150 mg|Tablet contains TQ as tafenoquine succinate. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
1541512|NCT02658435|Drug|Matched placebo 150mg|It is the matched Placebo tablet. The 2 tablets (2 tablets of 150mg) of dark pink, capsule-shaped, film coated will be administered orally with 240ml of water.
1541513|NCT02658422|Drug|Test Montelukast|Test Montelukast (GW483100) is available as round, biconvex, pink 10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water.
1541514|NCT02658422|Drug|Reference Montelukast|Reference Montelukast (innovator product) is available as pale beige, rounded square shaped,10 mg film-coated tablet (containing montelukast sodium equivalent to 10 mg of montelukast) and is administered as a single dose with 240 mL of water. Singular is the innovator product used for this study, which is a trade name owned by Merck Sharp and Dohme Corporation.
1541515|NCT02658409|Biological|GC3106(quadrivalent cell-culture based influenza vaccine)|GC3106(quadrivalent),0.5ml, intramuscular, a single dosing at Day 1
1541516|NCT02658409|Biological|Fluarix™tetra Syringe Inj.(quadrivalent influenza vaccine)|Fluarix™tetra Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
1541517|NCT02658396|Drug|GO-203-2C|
1541518|NCT02658396|Drug|Bortezomib|
1541519|NCT02658383|Other|Cleaner cookstove received after visit 2|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 2).
1541520|NCT02658383|Other|Cleaner cookstove received after visit 4|The participants will change from a traditional wood burning cookstove to a cleaner burning (wood) cookstove called the JUSTA (after visit 4).
1541521|NCT02658370|Device|animated home-based exercises (Wii-fit)|
1541522|NCT02658370|Procedure|conventional home-based exercise program|
1541523|NCT02658357|Drug|Risperidone Implant|
1541524|NCT02658344|Biological|JOINTSTEM|Jointstem (Autologous Adipose Tissue derived MSCs 1x10^8cells/3ml), 1 time injection
1541525|NCT02658344|Drug|Saline solution|Saline solution (Sodium chloride 9mg/ml), 1 time injection
1541526|NCT02658292|Drug|Naftifine hydrochloride foam, 3%|Apply NAFT900 foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
1541965|NCT02655250|Other|Microbiome|
1541527|NCT02658292|Drug|Vehicle|Apply vehicle foam twice daily to the affected area(s) plus half-inch around each affected area for 4 weeks
1541528|NCT02658279|Drug|Pembrolizumab|
1541529|NCT02658266|Behavioral|Home based resistance training|The participants in the intervention group will receive an individualized resistance training program. The individual adjustments in load will will be made from the results of the muscle function and muscle strength tests. The resistance training will be home based and performed 3 times per week 10-12 reps 2 sets 12 weeks. Increment of load will be performed continuously according to rating of perceived exertion.
1541530|NCT02658253|Biological|PRIMVAC|3 different dosages of VAR2CSA protein (20µg - 50µg and 100µg)
1541531|NCT02658253|Biological|GLA-SE|2.56 µg of GLA content
1541532|NCT02658253|Biological|Alhydrogel|0.85 mg og Aluminium content
1541533|NCT02658253|Biological|Placebo|0.9% Na cl
1541534|NCT02658240|Drug|Ropivacaine|Ropivacaine 300 mg and 0.5 mg epinephrine diluted to 60 mL
1541535|NCT02658240|Drug|Epinephrine|0.5 mg epinephrine
1541544|NCT02658188|Drug|ASP8825|Oral
1541545|NCT02658175|Drug|Volanesorsen|300 mg volanesorsen
1541546|NCT02658162|Drug|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
1541547|NCT02658162|Drug|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
1541548|NCT02658149|Drug|Ropivacaine with NaCl|50 mL (40 mL of 0.2% Ropivicaine and 10 mL of 0.9% NaCl) are administered into the psoas compartment
1541549|NCT02658149|Drug|Epinephrine|"0.15 mg Epinephrine are injected as part of the drug cocktail"
1541550|NCT02658149|Drug|Morphine|"4 mg Morphine are injected as part of the drug cocktail"
1541551|NCT02658149|Drug|Ketorolac Tromethamine|"30 mg morphine are injected as part of the drug cocktail"
1541552|NCT02658149|Drug|Ropivacaine|"30 mL 0.5% Ropivicaine are injected as part of the drug cocktail"
1541553|NCT02658136|Other|Cardiac Computed tomography|
1541554|NCT02658123|Other|Pre-operative education (standard of care)|
1541555|NCT02658123|Other|Home health care visits (standard of care)|
1541556|NCT02658123|Other|Follow-up post-operative visits|
1541557|NCT02658123|Other|Patient Data Collection Form|-Form that contains date, area to record number of pouches, and if home health care visit took place.
1541558|NCT02658123|Other|Healthcare Utilization Form|"Form for patient to record if they visited an emergency room or urgent care or if they were hospitalized
Form allows patient to record reason for visit and date of visit"
1541559|NCT02658123|Other|The City of Hope QOL Survey for Ostomy Patients|"Consists of 47 questions asking various physical, psychological, sexual, work-related, and demographic questions.
Additional 34 questions on how the ostomy affects quality of life. Answers range from 0=not at all to 10=severe problem."
1541560|NCT02658123|Other|Phone call with CWOCN or PA|
1541561|NCT02658110|Dietary Supplement|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to 200ml water and served as a beverage
1541562|NCT02658110|Other|Mixed Macronutrient Breakfast Meal|A standardised mixed-macronutrient breakfast served to all participants. The macronutrient distribution of the breakfast is 13% protein, 70% carbohydrate, 17% fat (1958 kJ; 468 kcal total)
1541563|NCT02658110|Other|Mixed Macronutrient Lunch Meal|A standardised mixed-macronutrient lunch served to all participants. The macronutrient distribution of the lunch is 14% protein, 51% carbohydrate, 35% fat (3506 kJ; 838 kcal total)
1541564|NCT02658097|Drug|Pembrolizumab|200mg Pembrolizumab by IV infusion
1541565|NCT02658097|Radiation|Single Fraction Radiation Therapy|8Gy radiation therapy will be given in a single fraction on the first day of treatment
1541568|NCT02658058|Other|Landmark technique|The site of needle insertion will be determined via manual palpation. A line joining the superior aspect of the iliac crests posteriorly (Tuffier's line') will be used as a surface landmark for the L4 vertebral body. The midline will be established by palpation of the tips of the spinous processes, and the site of needle insertion will be marked on the patient's skin. The interspace that appears widest, based on manual palpation, will be chosen for the first attempt. If the first attempt is unsuccessful, further attempts can be made at the same interspace or another interspace.
1541569|NCT02658058|Other|Ultrasound-guided paramedian technique|The transducer will be applied in the parasagittal plane and the intervertebral levels will be identified by counting upwards from the sacrum (continuous hyperechoic line). The probe will then be angled obliquely to obtain a PSO view. The locations of the interlaminar spaces will be identified by visualizing the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body. The angulation at which the ligamentum flavum-dura mater complex and posterior vertebral body are best visualized will be considered the optimal angle for needle insertion and clearly communicated to the operator. The interlaminar space will be centered on the ultrasound screen and a skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe.
1541570|NCT02658058|Other|Ultrasound-guided midline technique|The transducer will be applied in the parasagittal plane, and after identification of the intervertebral levels, the probe will be rotated 90 degree to obtain the TM view. The transducer is moved in a cephalad-caudad direction between the spinous processes of L2 and L5 vertebra. The probe will be tilted slightly up and down to ensure a sufficient echogenic window at the selected intervertebral space. A skin marker will be used to make a mark on the patient's back at the middle of the ultrasound probe. The angle at which the ligamentum flavum-dura mater complex and the posterior aspect of the vertebral body are best visualized will be noted
1541573|NCT02658032|Behavioral|personalized cessation care|Individuals randomized to this condition will receive standard care (i.e., 5 counseling sessions and nicotine patch(NRT)) and 4 personalized videos with 5 packages of personalized print materials
1541574|NCT02658032|Behavioral|bio feedback|Individuals randomized to this group will be provided with a personalized graph of their biomarker data from baseline, 6 and 8 weeks at the 8-week and 3-month study visits.
1541575|NCT02658032|Other|standard care|
1541576|NCT02658019|Drug|Pembrolizumab|Patients will be treated in three-week cycles, with intravenous (IV) administration of 200 mg of pembrolizumab on day 1 of each 3-week cycle.
1541577|NCT02658019|Procedure|Peripheral Blood Sample (optional)|Peripheral blood sample, if available, for biomarkers collected at during screening, every 12 weeks while on treatment, and at the end of treatment visit.
1541578|NCT02658019|Genetic|Tumor Tissue Collection (optional)|Tissue sample (archival or newly obtained), if available, collected during screening.
1541579|NCT02658006|Procedure|Cardiac surgery|All cardiac surgery procedures
1541580|NCT02657993|Behavioral|Hypnosis|"The hypnosis intervention involves three parts. First, participants will receive three, face-to-face hypnosis sessions delivered by doctoral-level psychology professionals. The sessions are based on materials developed by experienced psychologists in the Integrative Behavioral Medicine Program at the Icahn School of Medicine at Mount Sinai. Second, participants will be taught how to use hypnosis themselves (self-hypnosis) to help manage their pain. Third, participants will receive a hypnosis recording to listen to in-between sessions and throughout the course of the study. At home hypnosis practice will be recommended.
Participants will be asked to complete questionnaires over a period of 12 months."
1541581|NCT02657993|Behavioral|Attention Control|"The attention control intervention involves three face-to-face meetings with a doctoral-level psychology professional. During these sessions, participants will be asked to discuss with the interventionist their experience of taking aromatase inhibitors and associated musculoskeletal pain. The interventionist will not lead the patient in imagery, relaxation, evaluation of thought processes, or even simple discussion. Rather interventionists will allow the patient to direct the flow of the conversation and will provide support and empathy. Interventionist contact time in AC sessions will be identical to that in the hypnosis group. Overall, the attention control intervention will control for professional attention.
Participants will be asked to complete questionnaires over a period of 12 months."
1541582|NCT02657980|Device|Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 30 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
1541583|NCT02657980|Device|Sham-Yband(YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
1541586|NCT02657941|Behavioral|Motivational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education
Session 1: General information on the risk of weight gain and the means of prevention, motivational balance on the practice of physical activity, developing a personal goal, information about the sports center Session 2: brainstorming and card game on Food Hygiene Session 3: Find situations at risk of snacking and consider alternative lines"
1541587|NCT02657941|Behavioral|educational group|"Three weekly sessions of one hour, co-managed by two nurses specialized in psycho-education
Session 1: General information on the risk of weight gain and means of prevention, video on physical activity, discussions with therapists, information about the sports center Session 2: Video on Food Hygiene, discussions with therapists Session 3: Return on basic concepts covered in the first 2 sessions"
1541588|NCT02657928|Other|Laboratory Biomarker Analysis|Correlative studies
1541589|NCT02657928|Drug|Letrozole|Given PO
1541590|NCT02657928|Drug|Ribociclib|Given PO
1541591|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail|
1541592|NCT02657902|Procedure|Fractures were treated with a Gamma 3 intramedullary nail + U-Blade|
1541593|NCT02657889|Drug|niraparib|
1541594|NCT02657889|Biological|pembrolizumab|
1541595|NCT02657876|Biological|ExpressGraft-C9T1 Skin Tissue|ExpressGraft-C9T1 skin tissue is provided as a suturable, biologically-active, circular skin tissue with a fully-stratified epithelial compartment comprised of human keratinocytes (NIKSC9T1) and a dermal compartment containing fibroblasts
1541596|NCT02657863|Procedure|Urine collection and blood draw|
1541597|NCT02657850|Other|non- head and neck self reporting|non- head and neck patient self reports dysphagia symptoms
1541598|NCT02657850|Other|head neck self reporting|head and neck patient self reports dysphagia symptoms
1541599|NCT02657850|Other|provider reporting|provider reports on head and neck cancer patients' dysphagia symptoms
1541600|NCT02657824|Other|dyspneic patients|measuring mitral valve and septal distance in acute dyspneic patients for estimating left ventricular ejection fraction
1541601|NCT02657811|Device|Miri, Benchtop Multi-room incubator|Bench Incubation - Morphologic Assessment These embryos will undergo multiple evaluations using light microscopy and traditional morphologic assessment.
1541602|NCT02657811|Device|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic/Morphokinetic Assessment These embryos will remain in the TLI and undergo both morphologic and morphokinetic evaluation and grading according to a hierarchical multivariable model. They will not be removed from incubation for the duration of culture.
1541603|NCT02657811|Device|Miri TL, Time-Lapse incubator|Time Lapse Incubation - Morphologic Assessment These embryos will remain in the TLI and undergo only traditional morphologic assessment according to accepted criteria with no additional imaging. They will also not be removed from incubation for the duration of culture. The time points and evaluated parameters will be identical to those in arm 1 of the study.
1541604|NCT02657785|Drug|R-IDARAM plus intrathecal chemotherapy|R-IDARAM comprised of rituximab 375 mg/m2 (day 1), idarubicin 10 mg/m2(day 2 and 3); dexamethasone 100 mg/m2 (12 h.infusion in day 2, 3 and 4); cytarabine 1 g/m2 (1 h. infusion in day 2 and 3); methotrexate 2 g/m2 (6 h. infusion in day 4 with folinic acid rescue). Intrathecal Immunochemotherapy comprised of rituximab 10mg, MTX 15mg, dexamethasone 5mg and Ara-c 50mg once a week.
1541605|NCT02657759|Dietary Supplement|CARDICHOL|
1541606|NCT02657759|Dietary Supplement|PLACEBO|
1541966|NCT02655237|Drug|TAK-385 40 mg|TAK-385 40 mg tablets + Leuprorelin acetate placebo injection
1541607|NCT02657746|Other|multi-component interventions|The multi-component interventions (MCI) is comprised of all the following five components: 1) home health education (HHE) by government community health workers (CHWs), plus 2) blood pressure (BP) monitoring and stepped-up referral to a trained general practitioner (GP) using a checklist, plus 3) training public and private providers in management of hypertension and using a checklist, plus 4) designating hypertension triage counter and hypertension care coordinators in government clinics, plus 5) a financing model to compensate for additional health services and provide subsides to low income individuals with poorly controlled hypertension.
1541608|NCT02657733|Device|Radical-7|"Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time.
Radical-7- measures respiratory rate according to acoustic respiratory rate (RRa)."
1541609|NCT02657733|Device|Nellcor™ Bedside Respiratory Patient Monitoring System|"Comparison between 3 different monitors that measure repiratory rate. The participant is connected to 3 monitors at the same time.
Nellcor™ Bedside Respiratory Patient Monitoring System - measures respiratory rate according to oximetry respiration rate (RRoxi)."
1541610|NCT02657733|Device|Capnostream 20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream 20p- measures respiratory rate according to Capnography (RRetco2).
1541611|NCT02657720|Device|Radical 7|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Radical 7 measures respiratory rate according to acoustic respiratory rate (RRa).
1541612|NCT02657720|Device|Capnostream20p|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. Capnostream20p measures respiratory rate using capnography (RRetCO2).
1541613|NCT02657720|Device|PTAF2|Comparison between 3 different monitors that measure respiratory rate. The participant is connected to 3 monitors at the same time. PTAF2 measures respiratory rate using flow pressure (RRflow).
1541614|NCT02657707|Device|Roadsaver™ Carotid Artery Stent Device|The Roadsaver™ carotid artery stent system is indicated for use in patients with significant atherosclerotic disease of the carotid arteries.
1541615|NCT02657707|Device|Nanoparasol® Embolic Protection System|The Nanoparasol® embolic protection system is indicated for use with a guidewire to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in carotid arteries.
1541616|NCT02657694|Drug|Sofosbuvir+Ledipasvir|DAA medication treatment
1541617|NCT02657694|Drug|Sofosbuvir+Daclatasvir|DAA medication treatment
1541618|NCT02657694|Drug|Sofosbuvir+Velpatasvir|DAA medication treatment
1541619|NCT02657681|Device|tSMS|Transcranial static magnetic field stimulation (tSMS) is a non-invasive brain stimulation (NIBS) technique that decreases cortical excitability. Static magnetic fields suitable for tSMS are obtained with commercially available neodymium magnets. We will use a cylindrical neodymium magnet of 45 mm diameter and 30 mm of thickness, with a weight of 360 g (MAG45r; Neurek SL, Toledo, Spain), which will be applied with south polarity to the motor cortex, over the representational field of hand area contralateral to the more affected side of the body.
1541620|NCT02657681|Device|sham|A non-magnetic metal cylinder, with the same size, weight and appearance of the magnet, will be used for sham stimulation (MAG45s; Neurek SL, Toledo, Spain).
1541621|NCT02657668|Behavioral|Emotion Focused Therapy|EFT was conducted in eight sessions (without pretest and posttest sessions) according to Greenberg's manual (22) in a clinic of gastrointestinal patients. According to Greenberg manual, EFT consists of three steps: 1) emotional awareness 2) accessing healthy emotions 3) skills of emotional intelligence. There were five individuals in the posttest (because of being absent more than three sessions or not participating in the posttest).
1541622|NCT02657655|Device|Kinesia 360|Kinesia 360 includes a mobile app and wireless motion sensors worn on the patient's wrist and ankle to quantify tremor, dyskinesias, and mobility throughout the day as he or she goes about normal activities. The app includes electronic diaries enable patients to rate their symptoms and log when medications are taken. Data is transferred to a cloud server where motor symptom reports are generated for clinician review.
1541623|NCT02657629|Other|Continuous Feeding Regimen|Nocturnal continuous enteral feedings given from 8pm-8am with intermittent bolus feedings every 3 hours between 11am and 5pm. Continuous feedings given via gavage (nasogastric tube, orogastric tube or gastrostomy tube) and intermittent bolus feeds via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
1541624|NCT02657629|Other|Intermittent Bolus Feeding Regimen|Intermittent bolus enteral feedings given after 3 hours for entire 24 hours period. Feedings given via gavage or nipple. Total caloric intake maintained at 120-130 kcal/kg/d.
1541625|NCT02657616|Drug|vitamin-k-antagonists|
1541626|NCT02657616|Drug|Novel oral anticoagulants|
1541631|NCT02657577|Other|There is no intervention|There is no intervention
1541632|NCT02657564|Drug|Polyethylene glycol (PEG)|Participants receive blood tests for serum creatinine and electrolytes (Ca, P, Cl, Mg, Na, K) before and after taking polythylene glycol.
1541633|NCT02657551|Drug|Regorafenib|Regorafenib is a small molecule inhibitor of multiple membrane-bound and intracellular kinases involved in normal cellular functions and in pathologic processes.
1541634|NCT02657538|Other|Non invasive caries treatment|If the active comparator does not detect cavitation, fluoride varnish is applied on the test surface.
1541635|NCT02657538|Other|Invasive caries treatment|If the active comparator does detect cavitation, a composite restauration is placed
1541636|NCT02657538|Device|Near-infrared light transillumination device (DIAGNOcam, KaVo, Biberach, Germany)|
1541637|NCT02657538|Other|Visual examination and bitewing (BW) radiography|established diagnostic methods
1541638|NCT02657512|Drug|rivaroxaban|rivaroxaban 40 mg/day (1 day)
1541639|NCT02657512|Drug|rivaroxaban and activated charcoal|rivaroxaban 40 mg/day (1 day) and 50 g of activated charcoal 2 or 5 or 8 hours after rivaroxaban administration (1 day)
1541640|NCT02657499|Other|Medicaid Expansion|There will be no direct intervention, but rather an observation of change based on whether a state expanded Medicaid or not
1541641|NCT02657486|Drug|BGJ398|
1541642|NCT02657473|Drug|tobramycin inhalation solution|
1541643|NCT02657473|Drug|Saline 0.9% inhalation solution|
1541644|NCT02657460|Biological|tumor derived microparticles|The main difference between the two treatment groups is the biological coat, which is tumor derived microparticles.
1541645|NCT02657460|Drug|cisplatin|cisplatin is a traditional drug for lung cancer
1541646|NCT02657447|Drug|Betalutin with lilotomab dose 1|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 1
1541647|NCT02657447|Drug|Betalutin with lilotomab dose 2|15 MBq/kg b.w. Betalutin (lutetium (177Lu) lilotomab satetraxetan) single injection, with lilotomab pre-dosing, dose 2
1541648|NCT02657434|Drug|Atezolizumab|Participants will receive IV infusion of 1200 mg atezolizumab on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
1541649|NCT02657434|Drug|Carboplatin|Participants will receive IV infusion of carboplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period with doses calculated using Calvart formula.
1541650|NCT02657434|Drug|Cisplatin|Participants will receive IV infusion of 75 mg/m^2 cisplatin on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period.
1541651|NCT02657434|Drug|Pemetrexed|Participants will receive IV infusion of 500 mg/m^2 pemetrexed on Day 1 q3w for 4 or 6 cycles (Cycle length=21 days) in induction dosing period and until disease progression on Day 1 q3w in the maintenance dosing period.
1541652|NCT02657421|Procedure|Oblique Lateral Interbody Fusion|The oblique lateral interbody fusion (OLIF) procedures at L2-L5 (OLIF25™) and L5-S1 (OLIF51™) is a minimally invasive surgical option for degenerative lumbar disease. This approach allows for psoas-preserving access to the lumbar spine and minimizes the need to reposition the patient during surgery for accessing additional spinal levels for the interbody fusion portion of the procedure
1541653|NCT02657408|Drug|BI 1026706|
1541654|NCT02657408|Drug|Placebo|
1541655|NCT02657395|Device|PriMatrix|Use of PriMatrix under a coronal positioned flap to obtain root coverage.
1541656|NCT02657382|Behavioral|Heart Rate Variability (HRV) Biofeedback (BF)|Heart Rate Variability (HRV) biofeedback involves deep breathing, mindfulness (focusing on one's emotions and thoughts) and cognitive therapy (identifying and changing unhelpful or inaccurate thinking and distressing emotional responses). It is a 6-week training with one hour sessions with a certified biofeedback coach once per week. A handheld personal stress reliever device will be provided to the patients to practice at home for 20 minutes a day.
1541657|NCT02657382|Other|Mental Stress Protocol|Mental stress will consist of a 3-min math serial subtraction paradigm.The participants will be asked to serially subtract 7 from number specified by the researcher. For participants who have difficulty with this task, easier serial subtraction will be provided for. Throughout the task, to increase stressfulness and titrate difficulty, the participant will be prompted for faster performance and the starting number from which they were subtracting will be periodically changed. Finally, to add an evaluation component, participants will be given negative feedback during the test.
1541658|NCT02657369|Drug|Lenvatinib 24 mg|
1541659|NCT02657356|Drug|Placebo capsules|
1541660|NCT02657356|Drug|Bardoxolone methyl capsules|
1541661|NCT02657343|Drug|Ribociclib|
1541662|NCT02657343|Drug|T-DM1|
1541663|NCT02657343|Drug|Trastuzumab|
1541664|NCT02657330|Drug|SBP-101|Subcutaneous drug, escalating dose cohorts
1541665|NCT02657317|Behavioral|FORT-A|FORT-A is based on a functional restoration paradigm of pain management in which treatment is interdisciplinary and designed to achieve a functional goal (often specified by the patient; e.g., doing more with family, returning to work). FORT-A includes intensive functional rehabilitation, group-based pain management intervention, and individual interventions tailored to the patient's specific needs (e.g., biofeedback for stress, individual psychotherapy for mood or trauma symptoms).
1541666|NCT02657317|Other|VA Treatment as Usual|VA TAU includes referrals for specialty intervention, rehabilitation, and behavioral health intervention within the VA medical system. Some participants may be referred for care outside of the VA system. The South Texas Veterans Health Care System offers a wide range of pain management services.
1541669|NCT02657291|Drug|Ropivacaine|Local anesthetic
1541670|NCT02657291|Device|Ultrasound|Ultrasound guided block
1541671|NCT02657278|Procedure|Arterial Revascularization surgery or Endovascular procedure|Symptoms limited Cardiopulmonary Exercise Test (CPET) performed before and four weeks after surgical or endovascular correction of peripheral arterial disease
1541672|NCT02657265|Device|SpineJack system|Spine fracture management for traumatic vertebral compression fracture
1541673|NCT02657265|Device|Conservative management|Surgical corset according to measurement's impression, rigid corset with sternal support
1541676|NCT02657239|Behavioral|MOVE UP|Weight management behavioral program
1541679|NCT02657200|Other|survey|questionnaire assessing the knowlegde, attitude and practices regarding spontaneous abortion
1541680|NCT02657187|Device|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Inbody, Seoul, Korea) after fast for eight hours.
1542076|NCT02654275|Other|Proprioceptive Intervention|
1541681|NCT02657187|Drug|Rocuronium|The individual dose method was used for the determination of the dose response of rocuronium. After induction of anesthesia, four groups of 40 patients each received randomly one of the four doses of rocuronium ( 0.24, 0.32, 0.40, 0.48mg/muscle mass(kg))
1541684|NCT02657161|Biological|RABIPUR®|Biological rabies vaccine
1541685|NCT02657161|Biological|PIKA rabies vaccine|Biological rabies vaccine
1541686|NCT02657161|Biological|PIKA rabies vaccine with an accelerated regimen|Biological rabies vaccine
1541687|NCT02657148|Drug|Nexplanon (etonogestrel contraceptive implant)|Nexplanon is a single, radiopaque, rod-shaped implant, containing 68 mg etonogestrel indicated for postpartum contraceptive use by women to prevent pregnancy. Nexplanon is designed to be effective for 3 years.
1541688|NCT02657148|Drug|Standard postpartum contraceptive care|Condoms, Depo Provera (DMPA) or progestin-only pills initiated at any time after delivery, Nexplanon insertion at > 4 weeks after delivery, combined hormonal contraception (e. g. pills, patch, ring) initiated at any time > 4 weeks after delivery or levonorgestrel-intrauterine system or copper IUD insertion any time > 6 weeks after delivery.
1541689|NCT02657135|Behavioral|Cognitive/Neuropsychological Testing|These tests will be used to determine how the participant will continue with future procedures, and depending on results, may involve the participant returning to complete subsequent testing.
1541690|NCT02657135|Other|Vestibular/Ocular-Motor Testing|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI and will include dizziness, balance, ocular-motor coordination, and reflexes.
1541691|NCT02657135|Other|Cervical (Neck) Evaluation|These assessments will involve a series of tests and questionnaires that focus on physical symptoms of TBI including neck mobility and pain levels.
1541692|NCT02657135|Other|Sleep Evaluation|These evaluations will focus on assessing insomnia (duration, frequency, daytime consequences), combat exposure, and the presence and severity of trauma history.
1541693|NCT02657135|Other|HDFT MRI|This MRI aims at providing qualitative and quantitative assessments of the nature, location, and extent of white matter injury.
1541694|NCT02657135|Other|MR Spectroscopy (MRS)|This is a noninvasive diagnostic test for measuring biochemical changes in the brain.
1541695|NCT02657135|Other|MEG (Magnetoencephalography)|This is a non-invasive neurophysiological technique that measures the magnetic fields generated by neuronal activity of the brain.
1541696|NCT02657122|Drug|TD-1473 for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
1541697|NCT02657122|Drug|Placebo for SAD|SAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 5 dose ascending cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally as a single dose.
1541698|NCT02657122|Drug|TD-1473 for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
1541699|NCT02657122|Drug|Placebo for MAD|MAD: Healthy subjects meeting eligibility criteria will be sequentially randomized to each dose cohort (up to 4 cohorts) to receive either TD-1473 or placebo. The study drug (TD-1473 or placebo) will be administered orally for a total of 14 days of dosing.
1541700|NCT02657109|Other|physical therapy procedure|physiotherapy exercises conducted in early way for the rehabilitation of patients in the postoperative period of cardiac valve replacement.
1541701|NCT02657096|Procedure|Hybenx treatment (device)|In the maxillary quadrant assigned to SRP + hybenx treatment, hybenx was applied, after SRP, on the gingiva with a 30-second incubation period and then thoroughly rinsed away through abundant irrigation with a sterile saline solution.
1541702|NCT02657096|Procedure|Scaling and Root Planing (SRP)|The contra-lateral quadrants were treated as conventional Scaling and Root Planing (SRP) alone.
1541703|NCT02657083|Device|DreaMed Substance Administration Device|"2 exercise days under DreaMed MD-AID control with afternoon exercise (in the time between 16:30 and 19:30).
New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.
The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.
The DreaMed MD-AID uses a vendor-supplied and self-developed (communication module) communication application programming interface (API) in order to retrieve glucose / insulin data from the Paradigm Veo and set insulin treatment according to the algorithm decision."
1541704|NCT02657083|Device|Sensor Augmented Pump (SAP)|"2 exercise days under Sensor Augmented Pump with afternoon exercise (in the time between 16:30 and 19:30).
New infusion set and two continuous glucose sensors (one for back-up) will be inserted in the subcutaneous tissue of the arm and then calibrated the day before each visit from 3 to 6.
The continuous glucose sensor continuously will measure interstitial glucose levels and these values will be sent by the Minilink™ via wireless, low-powered, radio frequency to the Paradigm Veo every 5 minutes for up to 6 days.
During the exercise the group will turn off the insulin pump and lower their basal insulin for 20% for the next 4 hours after the exercise"
1541705|NCT02657070|Behavioral|Reinforcement-Induced Movement Therapy (RIMT)|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS) with augmented visuomotor feedback
1541777|NCT02656498|Drug|[18F]THK-5351|Imaging for evaluating the accumulation of abnormal tau protein in the brain
1541706|NCT02657070|Behavioral|VR-based motor rehabilitation in RGS without augmented feedback|6 weeks, 1 session a day, 30min per sessions, of physical therapy using a VR rehabilitation gaming system (RGS)
1541707|NCT02657057|Device|PTNS|The needle and electrode are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
1541708|NCT02657057|Device|TENS SNS|Electrodes are connected to a low voltage (9 V) electrical stimulator (URO stim2). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot.
1541709|NCT02657044|Procedure|EMR|
1541710|NCT02657044|Procedure|ESD|
1541716|NCT02657018|Device|MOBIGAME|Mobile phone based game-like software application and platform (MOBIGAME) that includes individualized and structured exercise regimens (endurance, strength, balance and flexibility) that are based on the user's individual fitness evaluation (through established fitness tests) and incorporated into the story line of a gardening simulation game.
1541717|NCT02657018|Other|Control|One-time standard lifestyle counseling including the promotion of baseline activities of daily life as well as a structured exercise plan including strength and endurance exercises with moderately increasing intensity and duration that is to be implemented autonomously.
1541719|NCT02656992|Device|Inspiratory muscle training group|
1541720|NCT02656979|Drug|Latanoprost|Between measurements on day 1 and day 2, the subjects will receive a drop of latanoprost which is an IOP lowering drug once daily in one eye.
1541721|NCT02656966|Device|Auricular acupuncture|"Five ear acupuncture points: MA-IC, MA-TF1, MA-SC, MA-AT1 and MA-TG will be needled bilaterally in patients, who will wish to receive AA. Indwelling fixed New Pyonex needles (length: 1.5 mm, diameter: 0.22 mm; Seirin Corp., Shizuoka City, Japan) will be used for AA."
1541722|NCT02656953|Device|VDU lenses (Zeiss® Officelens Plus)|The treatment group (n=22) was given progressive VDU glasses (Zeiss® Officelens Plus), specially designed for VDU work. The participants were asked to wear their new glasses for six months during computer work.
1541723|NCT02656953|Device|Progressive lenses (Zeiss® Multifocal Precision Plus)|The comparison group (n=18) was given progressive glasses (Zeiss® Multifocal Precision Plus). The participants were asked to wear their new glasses for six months during computer work.
1541724|NCT02656940|Dietary Supplement|Group 1 - diet rich in n-3 and n-6 PUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
1541725|NCT02656940|Dietary Supplement|Group 2 - diet rich in MUFA|In order to achieve the desired intake of unsaturated FA, the group received individual portions of vegetable oils in the form of sachets, which were consumed for lunch and dinner, besides gelatin capsules, for 60 days.
1541726|NCT02656940|Dietary Supplement|Group 3 - Placebo group|Placebo group was instructed to keep their eating habits and consuming placebo for 60 days.
1541727|NCT02656927|Behavioral|Yoga Condition|
1541728|NCT02656914|Drug|Guaifenesin and Ibuprofen and Loratadine|Take 10 mL every 12 hours (2x/day), oral route.
1541729|NCT02656914|Drug|Resfenol®|Take 10 mL, each 6h, oral route.
1541730|NCT02656901|Device|auto total endovenous anesthesia|a closed-loop controller guided by the BIS steering the infusion pumps (Alaris Medical UK Ldt, Hants, Uk) as already approved by ClinicalTrials.gov Identifier: NCT00392158
1541731|NCT02656901|Device|Manual Desflurane anesthesia|General anesthesia will be maintained with desflurane (Baxter D-Vapor Desflurane Vaporiser) to obtain a BIS value as close as possible to 50 and between 40
1541732|NCT02656901|Device|Manual Sevoflurane anesthesia|General anesthesia will be maintained with sevoflurane ( Baxter Vapour 2000 Sevoflurane Vapouriser) to obtain a BIS value as close as possible to 50 and between 40 and 60.
1541733|NCT02656901|Device|Manual total endovenous anesthesia|In ManualTIVA group, the anesthesia will be maintained with propofol (Injectomat TIVA Agilia, Fresenius Kabi, Bad Hamburg, Germany) to obtain a BIS value as close as possible to 50 and between 40 and 60.
1541734|NCT02656888|Drug|Guaifenesin and ibuprofen and Loratadine|For children 2 to 6 years old: take 2,5 mL every 12 hours (2x/day), oral route. For children 6 to 12 years old: take 5 mL every 12 hours (2x/day), oral route.
1541735|NCT02656888|Drug|Nasaliv®|For body weight below 30 kg: According to the weight, doses of 3 to 7.5 mL, each 6h; For body weight above 30 kg: take 10 ml, each 6h.
1541736|NCT02656875|Drug|TRV130|
1541737|NCT02656862|Other|No intervention|
1541738|NCT02656849|Drug|BAY 1000394|
1541739|NCT02656836|Other|Home tonometry, diagnostic study|Evaluating intraocular pressure
1541740|NCT02656823|Device|ANKYLOS C/X 6.6 mm|
1541741|NCT02656810|Drug|Teriparatide|Single subcutaneous injection
1541743|NCT02656784|Behavioral|Cognitive Therapy|Trial-Based Cognitive Therapy (TBCT) is a three-level, three-phase, case formulation approach. TBCT's foundation is in cognitive therapy (CT); however, it has a unique approach to conceptualization and techniques that make it a distinct intervention in modifying patients' core beliefs, especially those about the self. All the individuals will be submitted to MRI.
1541744|NCT02656784|Behavioral|Behavioral Therapy|The Behavioral therapy employs the technique of Exposure and Response Prevention ( ERP ).The technique involves directly exposing patients to recall stimulation of obsessive thoughts and prevent them from performing the compulsive rituals. All the individuals will be submitted to MRI.
1541745|NCT02656771|Device|Echo Bi-Metric|The insertion of the Echo® Bi-Metric® THA stem
1541778|NCT02656485|Drug|B244|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
1541746|NCT02656758|Behavioral|intensive Executive function training|Children diagnosis of attention deficit hyperactivity disorder are randomized to the experimental condition(Executive Function training) or waiting group experimental:participants will receive 12 sessions of intensive executive function training weekly no intervention :waiting participants will not be treated with intensive executive function training and keep waiting for 12 weeks for comparison
1541747|NCT02656745|Device|Mobile Smoking Cessation Solution|"The intervention regimen is almost entirely user-directed; users will download the application on their iPhones & engage with it throughout their quit journey. They will be asked to complete missions, daily activities to help prepare them to quit and keep them off cigarettes. When they have a craving, a series of options are available to ease the craving and resist the urge to smoke. Daily and Weekly Check-Ins are scheduled by the user to gather information about their smoking habits, help them learn about their addiction, and ultimately to overcome it. Ideally, the user will open and use the program several times a day. Participants who continue with the study through its completion will spend a total of 8 weeks using this smoking cessation mobile program."
1541748|NCT02656732|Biological|amnion chorion allograft membrane|Biologic Amnion chorion allograft membrane derived from placenta of a donor pregnant subject.
1541749|NCT02656732|Procedure|coronally advanced flap with the subepithelial connective tissue graft|coronally advanced flap with the placement of subepithelial connective tissue graft harvested from the palate
1541750|NCT02656719|Device|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
1541751|NCT02656719|Device|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
1541752|NCT02656706|Drug|Ipilumumab|
1541753|NCT02656706|Drug|Nivolumab|
1541754|NCT02656693|Behavioral|Online weight management program|Patients who are enrolled in one of the two arms using the online weight management program (BMIQ) will complete structured educational sessions, follow specific calorie goals and meal plans, participate in self-monitoring activities (i.e., regular tracking of weight, diet, and physical activity), and interact with other features of the program.
1541755|NCT02656693|Behavioral|Population health management support|Patients will receive weight-related population health management support from their primary care practice; their online weight management program data will be monitored by the population health manager, who will conduct outreach with patients at designated points according to the protocol.
1541761|NCT02656654|Other|Whole-body compression|
1541762|NCT02656641|Behavioral|Continuous Client Feedback|Clients complete rating scales before each therapy session. The therapist then views these results and discusses treatment progress with the client during the session.
1541763|NCT02656641|Behavioral|Continuous Self Feedback|Clients complete rating scales before each therapy session. Progress is not reviewed with the therapist.
1541764|NCT02656628|Device|Dynamic Locking Screw 3.7mm and 5.0mm|Treatment with DLS and locked plate constructs (small or large fragments)
1541765|NCT02656615|Drug|abiraterone acetate|Abiraterone acetate 1000 mg once daily and Prednisone 2x5 mg daily (continuously as per prescription label).
1541766|NCT02656602|Other|Computer Assisted Instruction|The computer assisted instruction consisted of a platform using video mimicking the patient journey with voice-over supported by photo's, 3D animation and instructive texts. The video was presented in short clips, maximal 45 seconds, to maintain the focus of patient. Patient interaction was ascertained by mandatory mouse-click after each item in the CAI. All elements of informed consent for colonoscopy (risks, alternatives) were included.
1541767|NCT02656589|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 2500mg/m2 daily for 3 months (Day 1 to 14 of a 21-day cycle)
1541768|NCT02656589|Drug|Trastuzumab|patients will receive herceptin intravenous infusion at a dose of 6mg on day 1 of each cycle
1541769|NCT02656576|Procedure|Tonsil Biopsy|Biopsies were obtained during endoscopy of Aero-Digestive Tract Superior under general anesthesia.
1541770|NCT02656576|Procedure|Smear|The smears are made in consultation a fortnight before performing endoscopic examination. They are carried out after a local anesthetic spray in order to optimize the number of cells collected.
1541771|NCT02656563|Radiation|Radium 223 Dichloride (Xofigo®)|Radium 223 Dichloride (Xofigo®) monthly for six months
1541772|NCT02656550|Procedure|Uterine Transplant|Transplant of a uterus from either a living donor or a deceased donor.,
1541773|NCT02656537|Device|EnSite™ HD Grid Catheter mapping system|
1541774|NCT02656524|Drug|Regorafenib (Stivarga, BAY73-4506)|Product is used in accordance with SmPC
1542118|NCT02654067|Procedure|photograph|photograph of airway
1541779|NCT02656485|Drug|Placebo|10 pumps (1.4 ml) of spray must be applied BID twice a day to the entire face for 14 days
1541780|NCT02656472|Drug|Tranexamic acid|"TXA Loading dose: 31 mg/kg diluted to 2 ml/kg NS (in syringe)
31 x _______kg = _______ mg TXA (max: 930mg)
2 x _______ kg = _______ ml NS (max: 60 ml)
TXA infusion: 14 mg/kg hour = 1 ml/kg/hour (6 hour bag) (Max rate of infusion = 30ml/hr)
14 x ______ kg = _____mg x 6 = ______ mg TXA (max: 2,520mg)
1 x ______ kg = _______ml x 6 = ______ ml NS (max: 180ml)
TXA second bolus in 1 ml/kg NS
< 16 kg: TXA 45 mg in 1 ml/kg NS = _______ml NS
16-30 kg: TXA 90 mg in 1 ml/kg NS = _______ml NS
> 30 kg: TXA 120 mg 1 ml/kg NS = _______ml NS (max 30ml)"
1541781|NCT02656472|Drug|Epsilon Aminocaproic Acid|"Aminocaproic acid Loading dose: 75 mg/kg diluted to 2 ml/kg NS
75 x _______kg = _______ mg EACA (max: 2,250mg)
2x _______ kg = _______ ml NS (max 60ml)
Aminocaproic acid infusion: 75 mg/kg hour = 1 ml/kg/hour (6 hour bag)
75 x ______ kg = _____mg x 6 = ______ mg EACA (max: 13,500 mg)
1 x ______ kg = _______ml x 6 = ______ ml NS (max: 180ml)
Aminocaproic acid second bolus: 75 mg/kg in 1ml/kg NS
75 x _______kg = _______ mg EACA (max: 2,250mg)
1 x _______ kg = _______ ml NS (max 30 ml)"
1541782|NCT02656459|Other|11-gene set|This trial is NOT interventional. The 11-gene set / Sepsis MetaScore will be tested post-hoc.
1541783|NCT02656446|Device|Accuro Handheld Ultrasound|Use of an Accuro Handheld Ultrasound to identify lumbar interspaces, midline, and depth to epidural space
1541784|NCT02656446|Device|Standard Ultrasound Machine|Use of standard ultrasound as gold standard to identify lumbar interspaces, midline, and depth to epidural space
1541785|NCT02656433|Device|Transcranial Random Noise Stimulation|A special Helmet supply weak electrical currents in the head
1541786|NCT02656433|Other|Physiotherapy|Standard of care physiotherapy aimed to the motor impairment the subject presents
1541787|NCT02656420|Drug|Broccoli Sprout Powder|Maximum, half and one-fifth doses of broccoli sprout-derived beverage compared to placebo.
1541788|NCT02656407|Device|Ultrasound device|Ultrasensitive Doppler acquisition obtained with the Aixplorer ultrasound device
1541789|NCT02656394|Drug|GL101|Topical Gel
1541790|NCT02656394|Drug|Placebo|Placebo topical gel
1541791|NCT02656368|Device|SEBORRHEAMEDIS Face Cream|SEBORRHEAMEDIS Face Cream is a barrier-based, non-steroidal cream. The cream includes plant extracts The cream was designed to manage the symptoms of facial Seborrheic dermatitis symptoms such as erythema, scaling and pruritus.
1541792|NCT02656355|Other|Weight shift training and APA feedback|Use COP trajectory to train weight shift on force plate. To give APA visual feedback for subjects after weight shift training.
1541793|NCT02656355|Other|Weight shift training without APA feedback|Use COP trajectory to train weight shift on force plate.
1541794|NCT02656342|Drug|D-Cycloserine|Predicted to enhance stabilization of the effects of concentrated exposure treatment
1541795|NCT02656342|Drug|Placebo|Predicted to have no enhancing effect
1541796|NCT02656329|Drug|Iobenguane I -123 Injection|Iobenguane I-123 Injection, AdreView. All patients will be scheduled for an Iobenguane I-123 Injection, AdreView scan.
1541797|NCT02656329|Device|Implantable Cardioverter Defibrillator|In the Iobenguane I-123 Injection group, patient with H/M ratio less or equal to 1.6 will undergo ICD device implantation, while those with H/M ratio greater than or equal to 1.6 will not. All patients allocated to the SoC (control) group will undergo ICD implantation.
1541798|NCT02656329|Drug|Thyroid blocking|Patients will receive a thyroid blocking agent before the Iobenguane I-123 Injection, AdreView, scan unless medically not indicated, according to local practice.
1541799|NCT02656316|Device|Active tDCS|In this group subjects will receive 20 min of treatment.
1541800|NCT02656316|Device|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
1541801|NCT02656303|Biological|ublituximab|ublituximab IV infusion
1541802|NCT02656303|Drug|TGR-1202|TGR-1202 oral daily dose
1541803|NCT02656290|Device|Model 11000A in pulmonary position|Edwards Aortic Bioprosthesis Model 11000A in the pulmonary position
1541804|NCT02656277|Other|Decision Tool|
1541805|NCT02656277|Other|Information on Shoulder Dislocation|
1541811|NCT02656212|Drug|epicatechin|30 mg (+)-epicatechin, taken orally, one pill/day in the morning
1541812|NCT02656212|Drug|Placebo|Placebo pill, taken orally, one pill/day in the morning
1541813|NCT02656199|Procedure|Diaphragm Ultrasound|Once on a pressure support weaning trial, enrolled subjects will have an ultrasound of their right hemidiaphragm performed on three levels of pressure support: 15/5 10/5 and 5/5
1541814|NCT02656186|Dietary Supplement|Pre-intervention|First 2-weeks : keeping routine dietary habit
1541815|NCT02656186|Dietary Supplement|Liquid nutritional supplement|Pre-intervention period was followed by an intervention period, during which consumed twice-daily 200 mL cartons of oral liquid nutritional supplementation (total 400 mL daily, containing 16 g protein, 12 g fat and 60 g carbohydrate and providing 400 kcal)
1541816|NCT02656173|Drug|Mirabegron|Oral
1541817|NCT02656173|Drug|Placebo|Oral
1541818|NCT02656160|Drug|Placebo|Placebo 3 hrs before sleep
1541819|NCT02656160|Drug|Dalfampridine|Dalfampridine 10 mg extended release 3 hrs before sleep
1541820|NCT02656147|Biological|Anti-CD19-CAR γδT|Cells extracted, followed by induction chemotherapy before Anti-CD19-CAR γδT infusion (dose escalation.)
1541821|NCT02656134|Procedure|Duodenoscopy and enteroscopy|All patients will undergo duodenoscopy and classified according to Spigelman. Patients classified as Spigelman III and IV will undergo enteroscopy.
1541822|NCT02656134|Genetic|Molecular analysis.|DNA analysis
1541823|NCT02656121|Drug|Vitamin D|One-Alpha Capsules 0.25 microgram One-Alpha Capsules 0.5 microgram One-Alpha Capsules 1 microgram
1541824|NCT02656121|Drug|placebo|placebo instead of vitamin D
1541825|NCT02656108|Procedure|Ommited controlled cord traction|No controlled cord traction and no fundal pressure. placenta will be allowed to deliver physiologically
1541826|NCT02656108|Procedure|controlled cord traction|active management of third stage of labor in the form of uterine massage with controlled cord traction
1541827|NCT02656095|Drug|Heparin|Participants will be given IV heparin in order to release lipoprotein lipase from capillary endothelial cells. Blood will be drawn 10-15 minutes post-heparin administration and run through assay to determine lipoprotein lipase levels.
1541832|NCT02656043|Drug|XPF-005|Comparison of active treatment XPF-005 topical gel against Placebo (XPF-005 Vehicle Gel) applied to face for acne vulgaris.
1541833|NCT02656043|Drug|Placebo|
1541834|NCT02656030|Other|semispinalis cervicis resisted exercise|semispinalis cervicis resisted exercise, 2 time per week, 6 weeks duration
1541835|NCT02656030|Other|cranio-cervical flexion exercise|cranio-cervical flexion exercise, 2 time per week, 6 weeks duration
1541836|NCT02656030|Other|usual care|usual care, 2 time per week, 6 weeks duration
1541837|NCT02656017|Drug|Metformin|Monitoring of tolerability and symptoms.
1541838|NCT02656017|Other|Placebo|Monitoring of tolerability and symptoms.
1541839|NCT02656004|Other|Essential Eucalyptus Oil|Using a disposable face mask was inhale for ten minutes 0.25 ml of essential oil of eucalyptus measured through adjustable Pipettor 100/1000μl. Inhalation of the substance occurred immediately after the 20 minute rest period in the session Essential Oil of Eucalyptus.
1541840|NCT02656004|Other|Control Session|In the control session the procedure was the same. Using a disposable face mask was inhale for ten minutes fresh air. Inhalation of the fresh air occurred immediately after the 20 minute rest period in the session Control.
1541841|NCT02655991|Behavioral|Telephone Case Monitoring|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy) augmented by up to six fortnightly telephone monitoring and support calls from a case manager during the first three months of treatment.
1541842|NCT02655991|Behavioral|Treatment as Usual|Outpatient mental health treatment as usual (normal case management, psychotherapy and/or pharmacotherapy).
1541843|NCT02655978|Other|Magnetic Resonance Imaging|
1541844|NCT02655965|Drug|Ropivacaine|Ropivacaine 3.5 mg/ml
1541845|NCT02655965|Drug|Clonidine|Clonidine 5µg/ml
1541846|NCT02655965|Drug|Sodium Chloride|Sodium Chloride 0.9 %
1541847|NCT02655952|Drug|Foxy-5|
1541848|NCT02655939|Dietary Supplement|Reflex Plus|Collagen Hydrolysate: 5g ,Rosehip aqueous extract 0.55g,
1541849|NCT02655939|Dietary Supplement|Placebo|Fructose,Orange flavor and sucralose
1541850|NCT02655926|Procedure|Deep Brain Stimulation|Participants undergo implantation of bilateral electrodes at both the VS/VC and STN sites through a single burr hole under general anaesthesia. High-resolution MRI scans are used to calculate target coordinates and to verify accurate electrode location post-surgery. Each STN electrode have 4 electrical contacts at its distal tip (with a 0.5mm separation) and each VS/VC electrode have 4 electrical contacts at its distal tip (with a 1.5mm separation) to allow fine tuning of the exact site for stimulation delivery. Two non-rechargeable batteries (Activa PC) are connected to the electrodes and positioned under the skin of the right and left chest wall so that they correspond to the same set of electrodes for each patient: one for the 2 STN electrodes and one for the 2 VC/VS electrodes.
1541851|NCT02655913|Drug|vitamin C|Vitamin C infusion, as an alternative anticancer therapy, has been used for many years. In the last 10 years, an increasing number of studies have indicated that VitC in pharmacological concentration can selectively kill cancer cells. Phase I clinical trial showed that VitC(1.5g/kg, 90-120mins, 3 times a week) infusion is safe without significant adverse reactions. A phase II clinical trial indicated that large dose of vitC infusion can reduce toxic side effects from chemo drugs when it was used synergy with chemotherapy.
1541852|NCT02655913|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
1541853|NCT02655913|Other|Supportive care|Supportive care focuses on helping patients get relief from symptoms such as nausea, pain, fatigue, or shortness of breath,etc.
1541854|NCT02655900|Other|Pelvic Floor Ultrasound|Transperineal Ultrasound (3D TPUS) and Endovaginal Ultrasound (3D EVUS)
1541855|NCT02655874|Biological|Influenza vaccine|Administered at day 1
1541856|NCT02655874|Biological|Influenza vaccine|Administered at day 180
1541857|NCT02655874|Biological|Tetanus-diphtheria-pertussis vaccine|Administered at day 180
1541858|NCT02655861|Other|Observation|
1541859|NCT02655848|Procedure|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair using suture anchors
1541860|NCT02655848|Procedure|LHB Tenodesis|Arthroscopic tenotomy and subsequent fixation of long head biceps proximal in the biceps groove
1541861|NCT02655848|Procedure|LHB Tenotomy|Arthroscopic tenotomy of long head biceps
1541862|NCT02655835|Behavioral|Internet Mindfulness Meditation|
1541863|NCT02655835|Behavioral|Access|
1541864|NCT02655822|Drug|CPI-444|100 mg orally twice daily for the first 14 days of each 28-day cycle.
1541865|NCT02655822|Drug|CPI-444|100 mg orally twice daily for 28 days of each 28-day cycle.
1541866|NCT02655822|Drug|CPI-444|200 mg orally once daily for the first 14 days of each 28-day cycle.
1541867|NCT02655822|Drug|CPI-444 + atezolizumab|CPI-444 orally in combination with atezolizumab intravenously.
1541868|NCT02655809|Radiation|Fluoroscopic examination|
1541869|NCT02655796|Device|OAK|The OAK device evaluates the fall risk through exercises assessing mobility, equilibrium and postural reaction.
1541870|NCT02655783|Other|5% dextrose|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution + 5% dextrose
1541871|NCT02655783|Other|normal saline|women with an elective induction of labor receive IV hydratation (250 ml/h) with a normal saline solution
1541872|NCT02655770|Drug|Liraglutide|
1541873|NCT02655770|Drug|Placebo|
1541874|NCT02655757|Drug|Sitagliptin|5 mg, 1 tablet per day for 12 months
1541875|NCT02655757|Drug|Placebo|Placebo,1 tablet per day for 12 months
1541876|NCT02655744|Radiation|Standard treatment protocol with combined chemoradiation|
1541877|NCT02655731|Device|PVI with HeartLight|Catheter ablation
1541878|NCT02655718|Other|Patients with ACS|Cardiovascular magnetic resonance (CMR) imaging with contrast (Gadovist) in regime inversion recovery time, regime T-2 weighted images , T1-weighted images.
1541879|NCT02655718|Device|MRI|
1541880|NCT02655705|Drug|Cyclosporine A|Male 200 mg/day, Female 150 mg/day for 16 weeks
1541881|NCT02655705|Drug|Methotrexate|Initial dose with 10 mg/week, increasing 2.5 mg every 2 weeks up to 15 mg/week maintenance dose
1541882|NCT02655692|Drug|Ketamine|FDA approved anesthetic medication with rapid acting antidepressant effects.
1541883|NCT02655692|Drug|Placebo|This is a saline placebo/non-active solution.
1541884|NCT02655679|Drug|VTP-38543|VTP-38543 administered topically every 12 hours
1541885|NCT02655679|Drug|Vehicle|Vehicle matching VTP-38543 administered topically every 12 hours
1541886|NCT02655653|Drug|Epsilon-aminocaproic acid administered|Following anesthetic induction, Epsilon-aminocaproic acid was administered as a bolus loading dose of 150 mg/ kg followed by a maintenance infusion of 15 mg/ kg /hr. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
1541887|NCT02655653|Drug|Tranexamic Acid administered|Following anesthetic induction, Tranexamic Acid was administered as a bolus dose of 30 mg /kg followed by a 16 mg/ kg/hour maintenance infusion. Maintenance infusion of both drugs was discontinued when the patient arrived in the cardiac surgical intensive care unit. In addition to routine blood sampling ( standard of care in our hospital), patients had thromboelastogram(TEG) and D-dimer levels drawn at the following time points: post incision but prior to initial antifibrinolytic load, immediately following the antifibrinolytic loading dose, and post-protamine reversal of heparin.
1541888|NCT02655640|Other|Questionnaires|Questionnaires will be provided to patients
1541889|NCT02655627|Other|Internet based exercise training|
1541890|NCT02655627|Other|group exercise training|
1541891|NCT02655627|Other|Physical activity counselling via a brochure|
1541892|NCT02655614|Drug|GDC-0134|GDC-0134 capsule will be administered orally at various doses, depending on the cohort and treatment period.
1541893|NCT02655614|Drug|Placebo|Placebo matching to GDC-0134
1541894|NCT02655614|Drug|Rabeprazole|Rabeprazole 20 mg twice daily orally
1541895|NCT02655614|Drug|Midazolam|2mg of liquid formulation of midazolam orally
1541896|NCT02655614|Drug|Caffeine|100 mg tablet or solution of caffeine orally
1541897|NCT02655601|Drug|BMX-001|
1541898|NCT02655601|Radiation|Radiation Therapy|
1541899|NCT02655601|Drug|Temozolomide|
1541900|NCT02655588|Behavioral|Interactive Media-Based Problems Solving Treatment|
1541901|NCT02655575|Behavioral|BI + VR + CBT|Brief intervention (information and advice) + group-based vestibular rehabilitation combined with cognitive behavioral therapy
1541902|NCT02655575|Behavioral|BI + phone calls|Brief intervention (information and advice). Patients are followed-up by phone calls
1541903|NCT02655562|Drug|Montelukast|"Patients in biomarker treatment arm and FENO≥25ppb were given Montelukast Sodium Tablets (p.o., 10mg, qd) . Patients in biomarker reatment arm and FENO＜25ppb were given placebo (p.o., 10mg, qd).
Patients in standard treatment arm and FENO≥25ppb were given placebo (p.o., 10mg, qd). Patients in standard treatment arm and FENO＜25ppb were given Montelukast Sodium Tablets (p.o., 10mg, q.d.).All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients."
1541904|NCT02655549|Biological|Px563L, RPA563, or placebo|Two intramuscular injections
1541905|NCT02655536|Drug|Bevacizumab plus erlotinib|Bevacizumab will be administered at a dose of 15 mg/kg on day 1 of every 3 weeks cycle by IV infusion erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
1541906|NCT02655536|Drug|Erlotinib|erlotinib will be give at 150mg orally every day for 21 days of every 3 weeks cycle
1541907|NCT02655523|Drug|Triamcinolone|1 mL of 40 mg of Triamcinolone
1541908|NCT02655523|Drug|Dexamethasone|1 mL of 4mg of Dexamethasone
1541909|NCT02655523|Drug|Normal Saline|1 mL of preservative free normal saline
1541910|NCT02655523|Drug|Bupivacaine|2 mL of 0.5% bupivacaine
1541911|NCT02655510|Drug|F-652|Participants will receive 10 μg/kg, 30 μg/kg or 45 μg/kg of F-652 on Day 1 and Day 7 via slow intravenous infusion. Three patients will receive 10 μg/kg of F-652. Pharmacokinetic testing will be completed on these subjects. If evaluations demonstrate safety and efficacy signals, the next 3 patients will receive 30 μg/kg. If pharmacokinetic testing demonstrates safety and efficacy signals, the next 3 patients will receive 45 μg/kg.
1541912|NCT02655497|Behavioral|Cognitive training|
1541913|NCT02655497|Behavioral|Psychosocial education|
1541914|NCT02655484|Device|"BiPAP® Vision® ventilator（Ventilator, Philips Respironics™ BiPAP® Vision® ）"|See details from arm descriptions.
1541915|NCT02655471|Drug|"Raltegravir and Zidovudine"|Through measure of pro-viral load and clinical score, we evaluate about safety and efficacy of combination of Raltegravir 400 mg BID and zidovudine 300 mg BID in patients with recent onset of Tropical Spastic paraparesis due HTLV-1 during 48 weeks
1541916|NCT02655458|Drug|Elotuzumab|"The following must also be administered before any elotuzumab:
Dexamethasone 8 mg IV (on the day of elotuzumab infusion 45-90 mins prior to the start of infusion), the following 30 - 90 minutes prior to start of infusion: H1 blocker: diphenhydramine (25 - 50 mg po or IV) or equivalent, H2 blocker: ranitidine (50 mg IV) or equivalent (adjusted for renal failure as indicated), acetaminophen (650 - 1000 mg po)."
1541961|NCT02655276|Other|microencapsulated Glycine|100 mg microencapsulated Glycine (Bidicin® from Biotiki® ) t.i.d.
1541917|NCT02655458|Drug|Lenalidomide|On the days of elotuzumab administration, the dose of lenalidomide is to be administered at least 2 hours after completion of elotuzumab dosing. Aspirin 81 mg PO daily will also be prescribed for DVT prophylaxis.
1541918|NCT02655458|Other|autologous PBMC reconstitution|Autologous peripheral blood mononuclear cell collection and reconstitution. PBMC will be collected from patients by standard apheresis procedures. Up to 25 ml of autologous plasma will also be recovered for dilution of cryopreserved products (if necessary). For reconstitution, Patients will be pre-medicated as per each institution's standard protocols prior to reinfusion of PBMC products. Patient ID will be checked and verified by nursing staff and the products will be re-infused by continuous intravenous infusion pump. Patient vital signs will be monitored every 15 minutes for the duration of the procedure as per standard reinfusion protocol.
1541919|NCT02655458|Other|ASCT|"Autologous peripheral blood stem cell transplantation. (stem cells from the patient's own marrow are harvested, stored and then returned to the body (engrafted). To be done as part of standard of care."
1541923|NCT02655432|Device|Spot photoscreener|Screening of vision problem through an automated device
1541924|NCT02655432|Procedure|Ophthalmologic evaluation|Screening of vision problem through an ophthalmologic evaluation
1541925|NCT02655432|Procedure|Cyclopleged refraction|Screening of refractive problems through a cyclopleged optometric refraction
1541928|NCT02655406|Other|Class 2 compression stockings|
1541929|NCT02655393|Dietary Supplement|AMAZ-02|
1541930|NCT02655380|Drug|Ketamine 1|Anesthesia induction is performed with 1 mg ketamine.
1541931|NCT02655380|Drug|Ketamine 2|Anesthesia induction is performed with 2 mg ketamine.
1541932|NCT02655380|Drug|Remifentanil|After anesthesia induction with ketamine, predetermined remifentanil using Dixon's up and dowm method is administered.
1541933|NCT02655367|Other|Flaked oats|Test meal consisting of 264g porridge made with flaked oats
1541934|NCT02655367|Other|Milled oats|Test meal consisting of 264g porridge made with milled oats
1541935|NCT02655354|Behavioral|Motivational Interviewing|
1541936|NCT02655354|Behavioral|Cognitive Behavioral Therapy Elements|
1541937|NCT02655354|Behavioral|Care Management|
1541938|NCT02655354|Drug|Fluoxetine|Anti-depressant
1541939|NCT02655354|Drug|Fluvoxamine|Anti-depressant
1541940|NCT02655354|Drug|Paroxetine|Anti-depressant
1541941|NCT02655354|Drug|Setraline|Anti-depressant
1541942|NCT02655354|Drug|Citalopram|Anti-depressant
1541943|NCT02655354|Drug|Venlafaxine|Anti-depressant
1541944|NCT02655354|Drug|Duloxetine|Anti-depressant
1541945|NCT02655354|Drug|Mirtazapine|Anti-depressant
1541946|NCT02655354|Drug|Diphenhydramine|Sleep medication
1541947|NCT02655354|Drug|Trazodone|Sleep medication
1541948|NCT02655354|Drug|Prazosin|Sleep medication
1541949|NCT02655341|Device|Body Composition Monitoring|using Fresenius device; two measurements before and after coronary intervention;
1541950|NCT02655341|Procedure|Coronarography|Preprocedural coronary arteriography is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the left coronary stem, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording.
1541951|NCT02655341|Procedure|Primary Percutaneous Coronary Intervention|An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
1541952|NCT02655341|Procedure|Renal Angiography|After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. This procedure is performed in the same time with primary PCI
1541953|NCT02655328|Other|blood sample|blood sample
1541954|NCT02655328|Other|urine sample|urine sample
1541955|NCT02655315|Drug|Deferiprone|15 mg / kg twice daily morning and evening (30mg / kg per day).The treatment lasts nine months.
1541956|NCT02655315|Drug|Placebo|the placebo twice daily morning and evening. The treatment lasts nine months
1541957|NCT02655302|Other|Sample collecting|Collect sputum, blood and nasopharyngeal swab during the exacerbation and at steady state 8 to 16 weeks later.
1541958|NCT02655302|Other|Lung function measure|Measure lung function and follow it during 4 years
1541962|NCT02655276|Other|Placebo tablets|Placebo t.i.d. from Biotiki® in a crossover-design.
1541967|NCT02655237|Drug|Leuprorelin 1.88 mg|TAK-385 placebo tablets + Leuprorelin acetate 1.88 mg injection
1541968|NCT02655237|Drug|Leuprorelin 3.75 mg|TAK-385 placebo tablets + Leuprorelin acetate 3.75 mg injection
1541969|NCT02655224|Drug|TAK-385 40 mg|TAK-385 placebo tablets + TAK-385 40 mg tablets
1541970|NCT02655224|Drug|TAK-385 placebo|TAK-385 placebo tablets + TAK-385 placebo tablets
1541971|NCT02655211|Procedure|CO2 laser treatment|Surgical treatment using fractionated ablative carbon dioxide laser (CO2)
1541972|NCT02655211|Procedure|PDL laser treatment|Surgical treatment using flashlamp-excited pulsed dye laser (PDL)
1541973|NCT02655211|Other|Usual care|Usual care (i.e., non-surgical) therapy (compression garments, massage, physical therapy, silicone gel sheeting)
1541975|NCT02655172|Other|cognitive tasks + PANSS+ IQ|Patients will perform different tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield,1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale (Kay et al., 1987) + the experimental task (affordance task with graspable device)
1541976|NCT02655172|Other|cognitive tasks|Healthy volunteers will perform only Edinburgh laterality questionnaire (Oldfield, 1971) + the experimental task (affordance task with graspable device).
1541977|NCT02655146|Drug|triptorelin 0.1|a single dose of decapeptyl 0.1 s.c. on the 3rd day of embryo transfer with routine luteal phase support.
1541978|NCT02655146|Drug|E2|Patients will be on the Progynova tablets 4-10mg daily at least 14 days.
1541979|NCT02655146|Drug|Progesterone|After ultrasound and hormorne tests, progesterone 100mg intramuscular injection is allocated with Progynova.
1541980|NCT02655146|Drug|triptorelin 3.75mg|as a pretreatment of E2 in some subjects with a fail history of hormonal artificially endometrium preparing.
1541981|NCT02655133|Drug|Pentaglobin®|Immunoglobulins that will be used are IgM enriched and will be infused at 5 ml/Kg/day for 3 days.
1541982|NCT02655133|Drug|Physiologic solution|Physiologic solution will be infused and will be infused at 5 ml/Kg/day for 3 days.
1541983|NCT02655120|Procedure|Drilling|
1541984|NCT02655120|Biological|Bone Marrow +BMP7|
1541985|NCT02655081|Dietary Supplement|high arginine nutritional supplement (Nestle's Impact AR)|Preoperative High-Arginine Nutritional Supplement Prior to Radical Cystectomy
1541986|NCT02655068|Other|PET/CT|"Patients who undergo primary radiotherapy will have their first study imaging surveillance at 6 months (+/- 30 days) post radiotherapy. The Positron Emission Tomography - Computed Tomography (PET/CT)surveillance will continue at 9,12,18,24 months.
During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).
The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings."
1541987|NCT02655068|Other|Computed Tomography (CT)|"Patients who undergo primary surgery will have their first study imaging surveillance at 3 months (+/- 30 days) post-surgery. CT surveillance will continue at 6,9,12,18,24 months.
During years 3-5, or long term follow up, surveillance with history and physical examination will occur every 6 months (+/- 30 days).
The last protocol-specified imaging will occur at 24 months; during long term follow-up imaging will be conducted per the judgment of the treating physicians, as indicated by the history and physical examination findings"
1541988|NCT02655055|Procedure|high frequency voluntary apheresis blood donation|
1541989|NCT02655029|Drug|Perindopril/Indapamide/Amlodipine fixed dose combination|Dose selection is based on investigators management.
1541990|NCT02655016|Drug|Niraparib|Niraparib vs Placebo 2:1 ratio
1541991|NCT02655016|Drug|Placebo|
1541992|NCT02655003|Other|TIME|
1541993|NCT02655003|Other|Education-only intervention|The staff and physicians in the control nursing homes will receive a 2 hours education session about dementia and neuropsychiatric symptoms
1541998|NCT02654964|Drug|Combination Drug Therapy|"Up to 3 of 73 possible interventions from the drug classes listed below will be selected based on their potency against CSCs, potential for synergy without cross-reactive toxicities, drug safety profiles, pharmacokinetics, and drug-drug interactions. Those patients that have GBM that has recurred (as defined by RANO (45)), and for whom HTS was successfully completed, will be eligible to continue to the treatment component of the study to receive the drug cocktail comprised from the following drug classes:
Antineoplastic Anti-infective Antiemetic Antihyperlipidemic Anti-inflammatory Antihistamine Antihypertensive Antidepressant Cardiotonic Alcohol antagonist Diuretic Antipsychotic NMDA receptor antagonist Antidiabetic Immunosuppressant Anticonvulsant Antimethemoglobinemic Sclerosing agent"
1541999|NCT02654951|Other|Visual Feedback|"The visual feedback condition will use a monitor to display two cursors (empty circles) that will represent the participant's hands, and the circles will fill with red ink as the user starts to compensate outside a normal error band. The amount of red ink will increase proportionally to the magnitude of trunk compensation.
The goal of the participants will be to move their hands/cursors towards a target, while keeping the cursors as empty as possible."
1542000|NCT02654951|Other|Force Feedback|"A monitor will display the same cursors as in the visual feedback condition, however, the cursors will be completely empty and will not fill with color.
The force feedback cues will be provided as resistance to move the robots' handles. These cues will be applied when the user moves outside a normal error band. In addition, the magnitude of the cue will be proportional to the magnitude of trunk compensation.
The goal of the participants will be to move their hands/cursors towards a target, while moving the robots with the least resistance possible."
1542119|NCT02654054|Drug|Placebo|Placebo for 6-month Treatment
1542120|NCT02654054|Drug|Elagolix|Elagolix for 6-month Treatment
1542001|NCT02654938|Drug|Mobilan (M-VM3)|Mobilan (M-VM3), innovative experimental drug based on non-replicate adenoviral delivery system consisting genomic vector coding TLR5-receptor and its ligand 502s.
1542002|NCT02654938|Drug|Placebo|5% infusion solution of dextrose
1542003|NCT02654925|Procedure|Adipose Tissue Biopsy|
1542004|NCT02654912|Drug|Reactive Focal Drug Administration|This is the experimental arm and is described by a reactive response to passively detected index case of malaria. The reactive response consists of treating all individuals within a defined radius of each RDT-confirmed incident malaria case with dihydroartemisinin-piperaquine (DHAP).
1542005|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as a liquid dosage formulation
1542006|NCT02654899|Other|Placebo|Placebo
1542007|NCT02654899|Drug|PF-06815345|PF-06815345 will be administered as either solid dosage formulation or liquid dosage formulation
1542008|NCT02654886|Other|Resistance Exercise Training|"Resistance Exercise Training: knee extension and elbow flexion each 3 times per week 3 sets each session; 10 reps/set for 6 months
Respiratory muscle strength training: 25 repetitions -twice daily, 6 days/week for 6 months"
1542009|NCT02654860|Drug|Paracetamol 3%|Investigate the efficacy and safety of a single intrathecal injection of paracetamol,for post-operative analgesia of hip replacement surgery
1542010|NCT02654860|Drug|Placebo injection containing Saline solution 0.9%|Injection containing sterile solution of Saline Solution 0.9 %. Study part 2 will be placebo-controlled. Each patient will be allocated to a treatment arm (one of the three paracetamol doses or placebo) according to a computer-generated randomisation list.
1542011|NCT02654860|Drug|Hyperbaric Bupivacaine HCl 0.5%|NIMP, spinal anaesthetic before the surgical procedure
1542012|NCT02654847|Drug|Norepinephrine|
1542013|NCT02654847|Drug|Normal Saline|0.9% sodium chloride solution, used as a diluent.
1542014|NCT02654834|Other|Exposure to nitrous oxide or other volatile anesthetics|No intervention, but routine work-place exposure to volatile anesthetics
1542015|NCT02654821|Biological|TCR transduced T-cells|Eligible patients will undergo leukapheresis to isolate autologous T cells. These T cells will be transduced with a retroviral vector encoding the 1D3 HM CysTCR, and subsequently expanded during short-term ex vivo culture. Following pre-treatment with nonmyeloablative chemotherapy, patients will receive the adoptive transfer of autologous, TCR transduced T cells.
1542016|NCT02654821|Procedure|Biopsy|During screening, after treatment and at time of regression/progression a biopsy will be taken for translational research.
1542017|NCT02654821|Procedure|Blood taking|During screening, after the infusion with T-cells, after treatment and at time of regression/progression blood will be taken for translational research.
1542018|NCT02654808|Device|AirSeal trocar|"The AirSeal® trocar is a valveless trocar that has been designed to replace the trap door and silicone valve of standard trocars with a curtain of forced CO2 gas (Fig. 1)1. With the AirSeal® trocar, escaping gas is collected at the proximal end of the trocar, filtered, and redirected into the peritoneal cavity to maintain the pressure differential. The result is an invisible barrier that instantaneously responds to changes in intra-abdominal pressure, either by allowing more CO2 inflow with pressure drops or by serving as a pressure relief valve during pressure spikes."
1542019|NCT02654808|Device|Standard trocar|"A standard insufflation trocar delivers CO2 into the abdominal cavity to create workspace and uses either a trap door or silicone valve to prevent the egress of CO2 during laparoscopy in order to maintain intra-abdominal pressures. The standard trocars are not equipped to respond to changes in the intra-abdominal pressures in order to trigger an increase or decrease in the flow rate of CO2 gas."
1542020|NCT02654795|Radiation|computed tomography|CT angiography will be performed with a dual-source CT scanner using prospective ECG gating, with detector collimation of 128x0.6 mm, a gantry rotation time of 280 ms, tube voltage of 100-120 kV, tube current of 280-380 mAs depending on the patient's body mass.
1542021|NCT02654782|Drug|Lactated Ringer's|Crystalloid fluid given for hemodynamic resuscitation based off of individual patient needs.
1542022|NCT02654782|Drug|5% Human Albumin|Colloid given for hemodynamic resuscitation based off of individual patient needs.
1542023|NCT02654769|Drug|Ingenol Mebutate (Picato®)|Brand product
1542024|NCT02654769|Drug|Generic Ingenol Mebutate|Generic formulated to have the same therapeutic effect of the brand
1542025|NCT02654769|Drug|Vehicle Foam|It does not contain active ingredient. A placebo to test the sensitivity of the active treatments.
1542026|NCT02654743|Dietary Supplement|Sulforaphane|Children with ASD will receive Sulforaphane in this study
1542027|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
1542028|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
1542029|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient|G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
1542030|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
1542031|NCT02654730|Drug|Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal|G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
1542032|NCT02654717|Drug|DFD-07 Cream|
1542033|NCT02654717|Drug|Placebo Cream|
1542121|NCT02654054|Drug|Elagolix + Estradiol/Norethindrone Acetate|Elagolix + Estradiol/Norethindrone Acetate for 6-month Treatment
1542034|NCT02654704|Biological|Pneumococcal Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard Pneumococcal Polysaccharide Vaccine (PPSV23) as approved by the FDA.
1542035|NCT02654678|Drug|Enalapril Orodispersible Minitablet|Weight-dependent long-term treatment scheme with enalapril ODMTs of 0.25 and/or 1 mg strength
1542036|NCT02654665|Behavioral|Lifestyle modification|Diet and exercise designed for 5-7% weight loss over 6 months
1542037|NCT02654665|Drug|Liraglutide|GLP-1 agonist
1542040|NCT02654639|Drug|TAS-102 and Bevacizumab|TAS-102 Twice a day by mouth day 1-5 and 8-12 and Bevacizumab by intravenous infusion once every 14 days
1542041|NCT02654626|Drug|KBP-7072|Drug Intervention
1542042|NCT02654626|Other|Placebo|
1542043|NCT02654613|Other|Quality Improvement Model of Care|"QI addresses the how of program implementation. Technically, QI improves process performance by developing a common simplified view of the components and linkages of integrated care, real-time data feed-back to track system performance, understanding the psychology of system change, and crucially, the iterative testing and incorporation of ideas for performance improvement from the front-line practitioners, managers, and customers in the local context."
1542044|NCT02654587|Drug|OSE2101|
1542045|NCT02654587|Drug|Docetaxel|
1542046|NCT02654587|Drug|Pemetrexed|
1542047|NCT02654574|Other|IADL administration by phone|The administration of IADL questionnaire by phone consists of a collection of answers given by the caregiver during the interview with the research nurse, trained for this procedure. This method of procurement will be standardized with a listing support for the phone interview to obtain the same conditions for collection of data from a caregiver to another. Questions will be asked in the same order than the questionnaire collected with the reference procedure i.e. face-to-face interview at the Memory Clinic. The IADL questionnaires in paper format used during the ace-to-face interview and by phone will be identical.
1542048|NCT02654561|Drug|Heparin Sodium|A bottle solution of Heparin Sodium(2ml:12500IU) is added to 50ml saline and administered i.v. continuously for 24 hours, which last 7 days or until the death or discharge. The same amount of 0.9% saline as the heparin group will be administered in the placebo group.
1542049|NCT02654561|Drug|Saline|For all the severe sepsis or septic shock patients, normal saline will be administered for fluid resuscitation according to the Guideline of Survival Sepsis Campaign.
1542050|NCT02654548|Other|Sebutape|Women who consent to the study will have a sebutape attached to their and their babies foreheads to measure the levels of androgens.
1542051|NCT02654535|Other|Dietary tree nuts & peanuts|An intervention in which tree nuts and/or peanuts are included in the diet
1542052|NCT02654522|Drug|Hylenex|1-3 hours post injection, the 8 HA injection sites (4 per forearm) per subject will then receive a randomized amount of Hylenex recombinant (0U, 30U, 60U or 75U).
1542054|NCT02654496|Other|Meal challenge|Participants will receive a liquid nutritional supplement. Before and after administration, biological variables of interest will be collected.
1542055|NCT02654483|Drug|VPD-737|VPD-737 inhibits the receptor neurokinin-1.
1542056|NCT02654483|Drug|Placebo|Matching tablets to VPD-737 tablets without active drug
1542057|NCT02654470|Device|Watchman FLX|Patients who are receiving the Watchman FLX device
1542058|NCT02654457|Procedure|Women with Breast Cancer|IVD Study
1542059|NCT02654431|Procedure|Breast Cancer patient|Samples
1542060|NCT02654431|Procedure|Cancer patients|Samples
1542061|NCT02654418|Procedure|Endoscopic Mucosal Resection of large colon polyps (greater than or equal to 20 mm in size)|
1542062|NCT02654405|Dietary Supplement|Sodium Butyrate|6.57 gms of sodium butyrate per day for 12 weeks
1542063|NCT02654405|Other|Placebo|placebo capsules containing approximately 9 mg of sodium butyrate/day
1542064|NCT02654392|Dietary Supplement|corn syrup|This group will receive an iso-energetic corn syrup supplement everyday for 5 weeks
1542065|NCT02654392|Dietary Supplement|Polyunsaturated fatty acid|This groups will receive 4 capsules/70kg body mass (Pureform Omega® capsules made from Fax, Sunflower, Coconut, Evening Primrose, & Pumpkin oils) every day for 5 weeks
1542066|NCT02654379|Biological|Rituximab|Rituximab use in non-oncology indications
1542067|NCT02654366|Behavioral|Risk Reduction Group|"The Risk Reduction and Treatment Readiness skills component includes six modules: 1) BNEP services and substance abuse treatment; 2) nature of chemical dependence (severity/chronicity and medical aspects); 3) infectious diseases (HIV and Hepatitis C virus (HCV) information); 4) injection drug use risk reduction (effective equipment cleaning and drug-splitting techniques); 5) sex risk reduction (reducing high-risk behaviors and effective condom use); and 6) overdose prevention.
The Community Outreach skills component is devoted to discussing the benefits of recovery-focused social support, and directing BNEP registrants and their CSPs to participate in activities together (as determined in the group session) at least 1 time per week to work toward expanding the scope of drug-free social support."
1542068|NCT02654353|Procedure|Ablation|In both arms, patients will undergo an ablation procedure for persistent atrial fibrillation. The sequence of ablation steps are different between both arms.
1542069|NCT02654327|Device|VV-ECCO2R to enable lower tidal volume mechanical ventilation|In the intervention arm a dual lumen catheter will be inserted into a central vein. VV-ECCO2R is commenced and managed as per study manual. Tidal volumes are then reduced on mechanical ventilation to enable lower tidal volume ventilation. Lower tidal volume facilitated by VV-ECCO2R will continue for a least 2 days up to a maximum of 7 days
1542070|NCT02654314|Drug|Melatonin|
1542071|NCT02654301|Dietary Supplement|Test 1|sucrose : xylose = 10:1, sucrose 50 g + xylose 5 g + deionized water 95 g
1542072|NCT02654301|Dietary Supplement|Test 2|sucrose : xylose = 15:1, sucrose 50 g + xylose 3.33 g + deionized water 96.67 g
1542073|NCT02654301|Dietary Supplement|Test 3|sucrose : xylose = 20:1, sucrose 50 g + xylose 2.5 g + deionized water 97.5 g
1542074|NCT02654301|Dietary Supplement|Control|sucrose 50 g + deionized water 100 g
1542075|NCT02654288|Other|gemcitabine-based chemotherapy|
1542077|NCT02654249|Device|Transanal hemorrhoidal dearterialization + mucopexy (THD).|Using an anoscope combined with a Doppler transducer the hemorrhoidal arteries are identified and ligated to decrease the blood flow to the hemorrhoidal plexus. In order to reduce hemorroidal prolapse a mucopexy is performed.
1542078|NCT02654249|Procedure|Ligasure™ hemorrhoidectomy|Excisional hemorroidectomy performed with Ligasure™
1542079|NCT02654249|Device|THD anoscope and doppler|An dedicated anoscope with an incorporated doppler probe sold by THD Lab S.p.A will be used for the THD procedure
1542080|NCT02654249|Device|Ligasure Vessel Sealing|A curved, small jaw, open sealer/divider sold by Covidien/medtronic will be used for the Ligasure™ hemorrhoidectomy
1542081|NCT02654236|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 4 weeks.
1542082|NCT02654236|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 4 weeks.
1542083|NCT02654223|Biological|MG56 Mannosylated 60 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 60 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
1542084|NCT02654223|Biological|MG56 Mannosylated 100 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 100 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
1542085|NCT02654223|Biological|MG56 Mannosylated 300 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 300 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
1542086|NCT02654223|Biological|MG56 Mannosylated 500 subcutaneous|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 MTU(Mannosylated Therapeutic Units)/ml subcutaneous
1542087|NCT02654223|Biological|MG56 Mannosylated 60 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 60 MTU(Mannosylated Therapeutic Units)/ml sublingual
1542088|NCT02654223|Biological|MG56 Mannosylated 100 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 100 MTU(Mannosylated Therapeutic Units)/ml sublingual
1542089|NCT02654223|Biological|MG56 Mannosylated 300 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 300 MTU(Mannosylated Therapeutic Units)/ml sublingual
1542090|NCT02654223|Biological|MG56 Mannosylated 500 sublingual|Mixture of the following pollens: Phleum pratense, Dactylis glomerata, allergen extract with a concentration of 500 MTU(Mannosylated Therapeutic Units)/ml sublingual
1542091|NCT02654223|Biological|Subcutaneous placebo|Comparison between placebo and active group
1542092|NCT02654223|Biological|Sublingual placebo|Comparison between placebo and active group
1542093|NCT02654210|Other|No Intervention|No Intervention
1542094|NCT02654184|Procedure|supine position|Anesthesia induction with sevoflurane for the patient while he is in supine position.
1542095|NCT02654184|Procedure|Right lateral position|Anesthesia induction with sevoflurane for the patient while he is in right lateral position.
1542096|NCT02654171|Drug|AK0529|AK0529 is a novel compound being developed for the treatment of RSV infection. The enteric coated drug pellets with sugar core can be administered orally with apple sauce/purée or yoghurt, or by flushing with 10% dextrose water via a nasogastric or other feeding tube, or upon a glucose wafer.
1542097|NCT02654171|Drug|Placebo|The placebo was made with the same smell and appearance as AK0529 but without the active ingredients. The placebo supplements are composed primarily of microcrystaline cellulose pellet.
1542098|NCT02654158|Drug|Low-dose of Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day
1~3 years old: 10mL each time and three times a day
4~6 years old: 10mL each time and four times a day
7~12 years old: 10mL each time and five times a day"
1542099|NCT02654158|Drug|High-dose of Fuganlin Oral Liquid|"less than 1 years old: 10mL each time and three times a day
1~3 years old: 20mL each time and three times a day
4~6 years old: 20mL each time and four times a day
7~12 years old: 20mL each time and five times a day"
1542106|NCT02654119|Drug|Cyclophosphamide|Given IV
1542107|NCT02654119|Other|Laboratory Biomarker Analysis|Correlative studies
1542108|NCT02654119|Drug|Paclitaxel|Given IV
1542109|NCT02654119|Biological|Trastuzumab|Given IV
1542110|NCT02654106|Radiation|Fractionated Stereotactic Radiotherapy|The regular fraction modes were as follows: a. lesions≥3 cm：52Gy/4Gy/13f or 52.5Gy/3.5Gy/15f; b. lesions＜2cm：36Gy/12Gy/3f or 24Gy/24Gy/1f; for lesions located in function areas, it would be adjusted to 40Gy/8Gy/5f; c. lesions 2-3cm：40-48Gy/8-10Gy/6-4f; d. lesions located in brainstem：50-60Gy/2.5-3Gy/20f.
1542111|NCT02654106|Drug|Temozolomide|concomitant TMZ: 75mg/m2 adjuvant TMZ: 150mg/m2*5d, q28d, 6cycles
1542112|NCT02654093|Drug|Cholecalciferol|
1542113|NCT02654093|Drug|Raloxifene|
1542114|NCT02654093|Drug|Cholecalciferol and Raloxifene co-administration|
1542115|NCT02654080|Biological|HIV-1 nef/tat/vif, env pDNA vaccine|1500 mcg to be administered as 0.5 mL intramuscular (IM) in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device
1542116|NCT02654080|Biological|rVSV HIV envC vaccine|1 × 10^7 PFU to be administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)
1542117|NCT02654080|Biological|Placebo|"Sodium Chloride for Injection, USP 0.9%;
At Months 0, 1, and 3: administered as 0.5 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated) using the Ichor Medical Systems TDS EP device.
At Months 6 and 9: administered as 1 mL IM in the deltoid of the non-dominant arm (unless medically contraindicated)."
1542122|NCT02654041|Drug|Combined T3 and Methimazole treatment|Oral administration of T3 and Methimazole
1542123|NCT02654028|Procedure|Autotransfusion|These group of patients will receive autotransfusion before liver resection.
1542124|NCT02654028|Other|Control group|These group of patients will not receive autotransfusion before or after liver resection.
1542127|NCT02654002|Drug|GS-9674|GS-9674 tablets administered orally
1542128|NCT02654002|Drug|Placebo|GS-9674 placebo tablets administered orally
1542129|NCT02653989|Biological|MDV9300|MDV9300 will be administered at a dose of 200 mg by intravenous (IV) infusion every 2 weeks until treatment discontinuation criteria are met.
1542130|NCT02653976|Drug|SP-02L (darinaparsin for injection)|Darinaparsin 300 mg/m2 once daily for 5 consecutive days every 21 days
1542131|NCT02653963|Drug|Adjunctival Triamcinolone|Intraoperative Periplate 10 mg Triamcinolone Injection during AGV Implantation
1542132|NCT02653950|Procedure|Endoscopic septoplasty|Endoscopic surgery; septoplasty with or without middle turbenectomy
1542133|NCT02653950|Procedure|Traditional septoplasty|septoplasty under direct vision
1542134|NCT02653937|Drug|Tsumura's shigyakusan|"Shigyakusan appears in the early 3rd Century. Four herbal crude medicines included are the following:
Root of Bupleurum falcatum L Unripe fruit of Citrus aurantium Linne var. daidai Makino, Citrus aurantium Linne, or Citrus natsu-daidai Hayata (Rutaceae) Root of Paeonia lactiflora Pall Root and stolon of Glycyrrhiza uralensis Fisher or Glycyrrhiza glabra Linne"
1542135|NCT02653924|Other|silk suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
1542136|NCT02653924|Other|vicryl suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
1542137|NCT02653924|Other|nylon suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
1542138|NCT02653924|Other|polypropylene suture|each treatment will include 4 types of suture (as described above). all subjects will receive the same types of sutures. treatment plan is NOT influenced by the suture material used.
1542141|NCT02653898|Drug|DHA-PIP|Administered monthly (weight-based) on days 1-3, during months 1, 2, and 3 in the MMP arm and also as a first line agent for P.v malaria recurrence in both MMP and FSAT treatment arms
1542142|NCT02653898|Drug|Primaquine|22.5 mg weekly for 12 weeks in the MMP arm; low dose primaquine (15mg) for transmission blocking of P. falciparum or 14 days of primaquine (15mg) in G6PD normal volunteers or 8 weeks of low dose primaquine (45mg) in G6PD-deficient volunteers for radical cure of P. vivax
1542143|NCT02653898|Drug|Artesunate + Mefloquine|Weight based; first line agent for P.f malaria infection diagnosed at monthly follow ups, administered on days 1-3 in subjects with malaria recurrence
1542144|NCT02653898|Drug|Permethrin (Insecticide treated uniform)|40% Permethrin IDA kit, applied once to the uniforms for volunteers assigned to ITU arm
1542145|NCT02653885|Other|Red red cell distribution width|Results from hemogram
1542150|NCT02653846|Procedure|RT-2D-SWE measurement|measurement of liver and spleen stiffness by ultrasound real-time 2D shear wave elastography (SWE™)
1542151|NCT02653846|Procedure|HVPG measurement|assessment of portal hypertension assessed by hepatic venous pressure gradient measurement
1542152|NCT02653833|Drug|Tadalafil 20 MG|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
1542153|NCT02653833|Other|beetroot juice extract|Blood flow to the forearm is visualized via an ultrasound technique at rest and with graded exercise. The experiment is then repeated shortly after the subject takes the study agent, beetroot juice extract.
1542154|NCT02653820|Other|Reflexology|
1542155|NCT02653807|Other|mobilization with movement|manual therapy intervention
1542156|NCT02653807|Other|osteopathic mobilization|manual therapy intervention
1542163|NCT02653755|Device|Prosigna|Transcriptional profile of 50 genes used for risk stratification.
1542164|NCT02653742|Drug|Ketorolac|Ketorolac 1mg/kg sublingual is administered after induction of general anesthesia.
1542165|NCT02653742|Drug|Fentanyl|Fentanyl 2mg/kg intranasal is administered after induction of general anesthesia
1542166|NCT02653729|Behavioral|cognitive behaviour therapy|
1542167|NCT02653729|Drug|Espidone|
1542168|NCT02653729|Drug|Olepra|
1542169|NCT02653729|Drug|Donu|
1542170|NCT02653716|Behavioral|New Orleans Intervention Method|An attachment based assessment, then a tailored intervention aimed at maximising the chances of the maltreated child being returned to the birth family
1542171|NCT02653716|Behavioral|Case Management|A social work assessment of family functioning that makes future recommendations regarding the future placement of a maltreated child.
1542172|NCT02653703|Other|Topical L-menthol 40%|Naturally occurring local anaesthetic, counterirritant and TPRM8-agonist. CAS Number: 2216-51-5
1542173|NCT02653703|Other|Vehicle, topical ethanol 96%|Organic solvent CAS Number: 64-17-5
1542174|NCT02653677|Other|intake of the specific kind of bread|To determine the glycemic and insulinemic responses (area-under the curve, AUCs), the satiety rate and the AUCs of free fatty acids (FFA), triglycerides and ghrelin after the ingestion of four types of breads, each containing 50g of available carbohydrates
1542175|NCT02653664|Behavioral|PsychoEducation|Condition #1
1542176|NCT02653664|Behavioral|Self-Hypnosis Training|Condition #2
1542177|NCT02653664|Behavioral|Mindfulness Meditation|Condition #3
1542178|NCT02653651|Drug|Ketamine|Ketamine infused at 0.1 mg/kg/hour
1542179|NCT02653651|Drug|Lidocaine|Lidocaine infused at 1 mg/kg/hour
1542180|NCT02653651|Drug|Placebo|An equal volume of saline
1542183|NCT02653625|Drug|Cenicriviroc 150 mg|One tablet of CVC 150 mg once daily taken with food in the morning
1542184|NCT02653612|Drug|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
1542185|NCT02653599|Drug|TTP273|
1542186|NCT02653599|Drug|Placebo|
1542187|NCT02653586|Other|"program In Favor of Resilience Self"|A prevention program aiming at improve self-resilience ,self-esteem and body image, contains nine interactive activities, based on a cognitive dissonance method.
1542188|NCT02653573|Behavioral|Coaching|Self-management education
1542189|NCT02653560|Drug|Potassium chloride powder|
1542190|NCT02653560|Drug|Potassium magnesium Citrate (KMgCit)|
1542191|NCT02653560|Drug|Potassium citrate powder|
1542192|NCT02653560|Drug|Placebo|
1542193|NCT02653547|Other|standard multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
1542194|NCT02653547|Other|high-frequency multisite four weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients continue treatment after two weeks for further two weeks of treatment (20 treatment days).
1542195|NCT02653547|Other|standard multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
1542196|NCT02653547|Other|high-frequency multisite two weeks|Repetitive transcranial magnetic stimulation (Magventure): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 20 Hz rTMS over right temporoparietal cortex (110% motor threshold). Patients discontinue treatment after two weeks (10 treatment days).
1542197|NCT02653534|Behavioral|Kangaroo Mother Care|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
1542199|NCT02653508|Behavioral|Diet and Activity|During all the following meetings, before the initiation of the training sessions, 10 to 15 minutes were devoted to an interactive discussion with participants on food pyramid, food choices, food labels, food preparation and cooking, eating habits, regular meals, controlling environments that stimulate overeating. All adolescents participated in a three-day per week training programme (45 minutes per training session). Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills.
1542200|NCT02653508|Behavioral|Activity|All adolescents participated in a three-day per week training programme (45 minutes per training session). Training was directed by a professional teacher of physical education in a public training centre. The training program was designed according to the type and intensity of exercise that school children normally perform. Many activities were delivered as games in order to encourage enthusiasm and participation. Endurance type activities accounted for most of the time spent in training (about 50% team sports and 50% running games), with attention to coordination and flexibility skills. In order to encourage adolescents' behaviour change, they were instructed to add an extra 30-45 minutes of walking or other sport activity of their preference at least once a week and to reduce inactivity
1542201|NCT02653495|Biological|Influenza vaccine|Influenza vaccine administered intramuscularly (IM), 1 time only, on visit 3
1542202|NCT02653482|Drug|Dapagliflozin|
1542203|NCT02653482|Drug|Dapagliflozin matching placebo|
1542271|NCT02653066|Other|HealtheRx++|Participant receives $5 bill when they returned signed PRR consent form.
1542204|NCT02653469|Other|Augmented ventilation|When the patient's PPV is within grey zone, patient's tidal volume is maintained with augmented tidal volume of 12 ml/kg (from normal ventilation of 8ml/kg) for 2min duration.
1542205|NCT02653469|Other|Fluid loading|We record the stroke volume index (SVI) values before and after volume expansion with 6ml/kg of balanced crystalloid
1542206|NCT02653456|Device|RA-308 Excimer Laser and DABRA Catheter|See information already included in arm description
1542207|NCT02653443|Biological|Autologous apheresis Platelet Components, prepared with the INTERCEPT Blood System for Platelets.|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with INTERCEPT treated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
1542208|NCT02653443|Biological|Autologous apheresis Conventional untreated Platelet Components|Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
1542209|NCT02653430|Procedure|Sleeve gastrectomy|"After complete exams such as EKG，UCG，spirometry and other basic exams,estimate the condition of patient whether he(she) can tolerate a surgical operation.Then we operate theSleeve gastrectomy laparoscopically by a group of experienced surgeons."
1542210|NCT02653417|Drug|RAD1901|RAD1901
1542211|NCT02653417|Other|Placebo|Placebo
1542212|NCT02653404|Other|IGRA test (QTF-GIT)|blood sample for QFT-GIT will be taken together with other routine blood samples
1542215|NCT02653378|Behavioral|DIET|25% Energy Depletion by Diet only for 3 Days
1542216|NCT02653378|Behavioral|EX|25% Energy Depletion by Exercise only for 3 Days
1542217|NCT02653365|Device|Non-invasive ventilation|Noninvasive ventilation (NIV) was performed with a noninvasive ventilator (BiPAP Synchrony®, Respironics Inc., Murrysville, PA, USA).
1542218|NCT02653352|Behavioral|Lifestyle modification|The centre of the campaign was to encourage the exchange of sugar-sweetened beverages for water. Ten one-hour sessions of activities facilitated by four trained research assistants were assigned for each class. The activities required 20-30 min and teachers were encouraged to reiterate the message during their lesson. Classroom quizzes and games using water v. sugar-sweetened carbonated beverages as the theme, as well as song and drawing competitions, were promoted. In addition, a musician using a tambourine helped each class to collectively develop songs related to drinking water and reducing the consumption of sugar-sweetened carbonated beverages. This musical activity was conducted during three one-hour sessions.
1542219|NCT02653339|Drug|Qufeng Shengshi Fang and Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.
The experimental group patients are treated with Qufeng by oral, 200ml two times a day and Loratadine by oral,10mg QD"
1542220|NCT02653339|Drug|Loratadine|"The patients with allergic rhinitis are divided into two groups, one is experimental group, and the other is control group.
The control group patients are treated with Loratadine by oral, 10mg QD"
1542221|NCT02653326|Device|Telerehabilitation Monitors|After completing a 12-session physical therapy programme and the aforementioned co-interventions, patients will receive a telerehabilitation strategy comprised by electrocardiographic monitoring and a smartphone application aimed at detecting adverse events during exercise activities. These devices will also inform patients and healthcare providers regarding the adequacy of their physical activities in terms of cardiovascular outcomes and the observed changes during treatment.
1542222|NCT02653326|Procedure|Physical Therapy|Physical therapy will be provided in form of twelve 90-minute sessions. Exercises will be tailored to patient needs, but a common goal of reaching an oxygen consumption of 80-90% will be used for every participant.
1542223|NCT02653326|Behavioral|Nutritional Counseling|Nutritional counseling will be provided in 60-minute group sessions for included participants. A nutritionist will provide education in terms of healthy eating and risk factor modification.
1542224|NCT02653326|Other|Depression Screening|Participants will be screened for depression using the Hospital Anxiety and Depression scale, which has been validated for Spanish-speaking countries. If depression is confirmed, pharmacologic treatment and/or psychotherapy will be prescribed at the discretion of the attending physician.
1542225|NCT02653326|Drug|Treatment of Comorbidities|Whenever needed, treatment of comorbid conditions, such as hypertension, diabetes or dyslipidemia, will be provided for study participants.
1542226|NCT02653313|Drug|Parvovirus H-1 (H-1PV)|"Parvovirus H-1 administered at three increasing dose levels , according to the following schedule: i) 4 daily intravenous infusions of 10% of the total dose over 2 hours on 4 consecutive days, ii) direct injection of 60% of the total dose into a hepatic metastasis of the pancreatic cancer.
The total dose levels are: 1E09, 5E09 and 1E10 pfu."
1542227|NCT02653300|Biological|Oral Insulin|all patients will receive treatment regimen of a soft gel capsule of ORMD-0801.
1542228|NCT02653287|Behavioral|Experimental|The experimental intervention includes 4 individual coaching sessions (initial 1 hour in-person and remaining 10-15 minutes per telephone) designed to identify barriers and supports for physical activity and nutrition using motivational interviewing. They occur shortly after randomization, 1.5, 3, and 6 months. Daily participants monitor their physical activity via the Fitbit Flex and their dietary behavior on a paper diary. Participants receive 6 consecutive monthly group sessions, beginning shortly after randomization focusing on the following topics: introduction to physical activity; fruits/vegetables; motivation; lifestyle physical activity; healthy diet; and enhancing your environment. The 1 hour sessions are interactive so participants can share information and support each other.
1542269|NCT02653079|Other|Blood Draw and Questionaire|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw from patients at several time points during and after low dose radiation therapy.
1542777|NCT02649218|Biological|QGE031|QGE031
1542229|NCT02653287|Other|Control|The control group will receive 6 group educational sessions focusing on SLE disease management. Topics include: what is lupus, laboratory tests, medications, taking charge of your health care and managing stress (2 sessions). Sessions will be didactic followed by a brief question and answer period and last about 1 hour. A nurse practitioner will be responsible for conducting the group sessions. Control arm participants receive 4 individual phone calls checking in with participants regarding questions about the study or from the group sessions, each lasting about 10-15 minutes. They occur shortly before first group session, then at 1.5, 3, and 6 months.
1542230|NCT02653274|Other|Breakfast porridge|220 kcal breakfast porridge served with 240 mL glass of water
1542231|NCT02653261|Drug|Tranexamic Acid|Tranexamic acid (TXA) is a synthetic analog of serin than reversibly inhibits fibrinolysis by blocking lysine union sites in the plasmin and plasminogen activator molecules. TXA: bolus of 10 mg/kg thirty minutes before resection followed by infusion of 1 mg/kg/h intraoperatively and for 24 h postoperatively
1542232|NCT02653261|Drug|Placebo|An equal volume of saline
1542233|NCT02653248|Radiation|Stereotactic Body Radiation Therapy|Patients will receive 5 fractions of SBRT radiation, treated every other day. No more than three fractions per week. Total dose will depend on cohort. Cohort 1: 40Gy, Cohort 2: 45 Gy, Cohort 3: 50 Gy.
1542234|NCT02653235|Biological|Salmonella typhi vaccination|
1542235|NCT02653235|Biological|Placebo|
1542236|NCT02653222|Procedure|Renal sympathicolysis|
1542237|NCT02653222|Procedure|Ambulatory Blood Pressure Monitoring|1 month before and after surgery the patient will have an ABPM over 24h
1542238|NCT02653222|Radiation|Magnetic Resonance Angiography|1 month before and after surgery the patient will have a MRA
1542239|NCT02653222|Biological|Blood test|complete blood count, blood platelets, coagulation profile, irregular agglutinins search
1542240|NCT02653209|Drug|Sitagliptin - DPP4i|DPP4 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
1542241|NCT02653209|Drug|Canagliflozin - SGLT2i|SGLT2 inhibitor 100mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
1542242|NCT02653209|Drug|Pioglitazone - TZD|Thiazolidinedione 30mg supplied as over-encapsulated hard capsule shell to be taken orally, once a day for 16 weeks in addition to existing prescribed oral diabetes therapy.
1542243|NCT02653196|Procedure|Allogeneic hematopoietic stem cell transplant following thiotepa-based marrow ablative chemotherapy|Allogeneic hematopoietic stem cell transplant (HSCT) following thiotepa-based marrow ablative chemotherapy (MAC) for children with high-grade and/or recurrent neuro-epithelial and other solid tumors.
1542244|NCT02653196|Drug|Keratinocyte Growth Factor|KGF 60 mcg/kg IV: 6 doses
1542245|NCT02653196|Drug|Alemtuzumab|Alemtuzumab 12 mg/m2 IV: 2 doses (not given if matched related donor is 10/10 HLA matched sibling donor)
1542246|NCT02653196|Drug|Thiotepa|Thiotepa 300 mg/m2 IV: 3 doses
1542247|NCT02653196|Drug|Etoposide|Etoposide 100 mg/m2 IV: 3 doses
1542248|NCT02653196|Drug|Fludarabine|Fludarabine 30 mg/m2 IV: 3 doses
1542249|NCT02653196|Drug|Melphalan|Melphalan 70 mg/m2 IV: Day 2 doses
1542250|NCT02653196|Drug|Tacrolimus|Tacrolimus 0.05 mg/kg/day IV (Cyclosporine may be substituted for Tacrolimus): Start Day -2, begin taper on Day +100, discontinue on Day +180
1542251|NCT02653196|Drug|Cyclosporine A|Cyclosporine A dosed as follows: Age ≤ 6 years: 6 mg/kg/day IV in divided doses (e.g. 2 mg/kg every 8 hours) OR Age > 6 years: 3 mg/kg/day IV in divided doses (1.5 mg/kg every 12 hours): Start Day -2, begin taper on Day +100, discontinue on Day +180
1542252|NCT02653196|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg every 8 hours oral or IV: Start Day 0 (4-6 hours post stem cell infusion) to Day +40, then taper weekly until discontinuation on Day +90
1542255|NCT02653170|Other|SCM|"One intervention (SCM) is provided. Stroke Case Managers (SCMs) will conduct 2 home visits; the first within 72-96 hours and the other after 30-days of returning home. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted if needed. Home visit activities include:
Biopsychosocial assessment of patient and caregiver needs.
Set up appointments.
Assist scheduling appointments with primary care physician and other medical providers.
Promote medication adherence through medication tool kits, pill organizers and other aids.
Facilitate patient and caregiver engagement and activation.
Facilitate access to social and community services."
1542256|NCT02653170|Other|SCM and VSSP|"SCM: Stroke Case Managers (SCMs) will conduct home visits at 72-96 hours and after 30-days. SCMs will conduct weekly follow-up phone calls. Additional home visits are permitted as needed. Activities include:
Biopsychosocial assessment of patient and caregiver needs.
Set up appointments.
Assist scheduling appointments with primary care physician and other medical providers.
Promote medication adherence through medication tool kits, pill organizers and other aids.
Facilitate patient and caregiver engagement and activation.
Facilitate access to social and community services.
VSSP: Access and training on the Virtual Stroke Support Portal, an online information and support website which includes:
Contact list of care team members.
Access to hospital patient portal.
Stroke education materials, resources, and guidelines.
Access to Michigan 2-1-1 services.
Medication information and adherence tools.
Patient and Caregiver support networks."
1542257|NCT02653157|Other|MDR-GNB|
1542258|NCT02653144|Drug|Ropivacaine,Dexmedetomidine,Dexamethasone|pre-operative single shot interscalene nerve block under ultrasound guidance and peripheral nerve stimulation in patients undergoing ambulatory shoulder surgery
1542259|NCT02653131|Drug|Dipeptidyl peptidase-4 inhibitor|
1542262|NCT02653105|Biological|OLFM4|patient have an additional blood test every 6 months for dosing OLFM4
1542263|NCT02653092|Drug|Insulin|
1542264|NCT02653092|Drug|Intralipid|
1542265|NCT02653092|Drug|Dextrose|
1542266|NCT02653092|Drug|Heparin|
1542267|NCT02653092|Drug|GnRH|
1542268|NCT02653092|Procedure|Hyperinsulinemic Euglycemic Clamp|
1542270|NCT02653066|Other|HealtheRx+|Participant receives $5 bill with incentive check and blank consent form
1542272|NCT02653040|Other|Dynamic lighting|"Intervention is rooms with light settings imitating natural light conditions with white light at day and low-lux no-blue light at night:
07am-10am: white light, increasing intensity 10am-07pm: white light, full intensity 07pm-11pm: no blue wavelength, low intensity 11pm-07am: no blue wavelength, very low intensity"
1542273|NCT02653027|Drug|Lumacaftor-ivacaftor|Subjects who are planning on starting the combination therapy (lumacaftor-ivacaftor) will participate in OGTTs before and after starting the medication.
1542274|NCT02653027|Other|OGTT|A subject is given an oral glucose load and insulin and glucose measurements are taken at specified time periods.
1542275|NCT02653014|Drug|KBP-5074|
1542276|NCT02653001|Other|Stool sample collection|Collection of complete stool sample
1542277|NCT02652988|Other|Active-tDCS|Active home-based tDCS applied at home.
1542278|NCT02652988|Other|Sham-tDCS|Sham home-based tDCS applied at home.
1542279|NCT02652975|Procedure|Venous occlusion plethysmography|To characterize endothelial function in vivo the effect of vasodilatating substances is measured in the forearm circuit. The substances is administered via a thin catheter placed in the Brachial artery near the elbow in local anesthesia. Once the vessels dilate, the blood flow in the forearm will increase and the flow change is a measure of the vasodilatory capacity of that substance. The change is measured with classical venous occlusion plethysmography. The method described is established at Aarhus University Hospital and has been used for several decades to illustrate the effect of vasoactive drugs on the human circulation, meaning it is a proven and well documented method.
1542280|NCT02652975|Procedure|SphygmoCor|"Applanation tonometry (pulse wave velocity and central blood pressure/arterial stiffness): The central blood pressure and the augmentation index is estimated from the shape of the radial pulse wave measured with a tonometer.
Pulse wave velocity (PWV) is calculated from the average difference between the pulse pressure wave measured with a tonometer and the R in an ECG recorded simultaneously."
1542281|NCT02652975|Procedure|24hour blood pressure|24 hour blood pressure measurement
1542282|NCT02652975|Procedure|DEXA scan|Measurements of body composition: Total body fat and fat free mass is measured by Dual Energy X-ray Absorptiometry (DEXA).
1542283|NCT02652975|Biological|Laboratory blood samples|"Fasting blood tests are drawn from an antecubital placed catheter (albumin, ALAT/ASAT, alkaline phosphatase, bilirubin, gammaglutamyl transferase, coagulation factors, red and white blood cells, creatinin, potassium, sodium, fasting lipids, fasting glucose, hemoglobin A1C, insulin, sex hormones, von Willebrand factor, low grade inflammation markers, DNA and RNA for later analyses, including relevant coding genes).
Further more urine samples to determine possible systemic impact of cardiovascular disease.
We will create a biobank containing urine and blood samples from participants for future research, provided that the participant gives her permission.
Responsibility for the biobank lies with the project responsible physician, Anders Bonde Jensen."
1542284|NCT02652962|Device|Gelesis200|3 capsules each containing 0.70 g
1542285|NCT02652962|Other|Placebo|3 capsules each containing 0.57 g of a mixture of microcrystalline cellulose and maltodextrin in a ratio of approximately 50 ± 10%
1542286|NCT02652949|Device|Valiant Evo Thoracic Stent Graft|
1542287|NCT02652936|Drug|AF-130|AF-130 oral capsules (50 mg) administered as a single dose or once daily for 7 days
1542288|NCT02652936|Drug|Placebo comparator|AF-130 matching placebo capsule
1542290|NCT02652910|Drug|CD19.CAR-T cells|Retroviral vector-transduced autologous T cells to express CD19-specific CARs
1542291|NCT02652897|Procedure|Exposure to glioma resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
1542292|NCT02652897|Procedure|Exposure to colon resection surgery|The following blood samples will be drawn for hemostasis evaluation: 1. Conventional clotting tests, 2. Rotational thromboelastometry (ROTEM), including EXTEM and FIBTEM; 3. Platelet function as assessed by PFA-200 for; and 4. Platelet function as assessed by ara-tem, adp-tem and trap-tem. All the analyses will be performed before (within a period 24-h before surgery) and after (within of the following periods: 2 h, 24 h and 48 h after surgery).
1542293|NCT02652884|Drug|phosphate and betamethasone acetate, 2 mL.|single dose of intramuscular depot corticosteroid
1542294|NCT02652884|Drug|saline 0.9% NaCl|single dose of intramuscular placebo
1542295|NCT02652871|Drug|LY2510924|"Dose Escalation Phase: Starting dose level of LY2510924 is 10 mg subcutaneously each day of a 28 day cycle. Dose escalated in successive cohorts of patients.
Dose Expansion Phase: LY2510924 given at the maximum tolerated dose (MTD) from Dose Escalation Phase."
1542296|NCT02652871|Drug|Idarubicin|"Dose Escalation Phase: Idarubicin 12 mg/m2 by vein given on Days 8 and 9 of a 28 day cycle. In patients > 60 years of age Idarubicin given for 2 days.
Dose Expansion Phase: Idarubicin 8 mg/m2 by vein for 2 days."
1542297|NCT02652871|Drug|Cytarabine|"Dose Escalation Phase: Cytarabine 1.5 gm/m2 by vein daily for 4 days (age < 60 years). In patients > 60 years of age Cytarabine given for 3 days only.
Dose Expansion Phase: Cytarabine 0.75 gm/m2 by vein for 3 days."
1542298|NCT02652858|Procedure|Non-invasive blood pressure oscillometer (NIBP) implementation|Implementation of two additional NIBP on humeral and femoral sites.
1542299|NCT02652845|Behavioral|Wellness Engagement Program|This intervention is an evidence based and community informed program designed to stimulate physical activity and increase healthy food choices among participants. The intervention includes weekly lessons, personal support in the form of biweekly check in calls with a peer support coach and weekly physical activity and nutrition classes.
1542300|NCT02652832|Device|non invasive brain stimulation|non invasive brain stimulation
1542301|NCT02652819|Drug|FG-4592|
1542302|NCT02652819|Drug|Placebo|
1542303|NCT02652806|Drug|FG-4592|
1542304|NCT02652806|Drug|Epoetin Alfa|
1542305|NCT02652793|Drug|Boosted atazanavir|Atanazir 300 mg once dailly boosted with 100 mg of ritonavir once dailly
1542306|NCT02652793|Drug|Lamivudine|Lamivudine 300 mg once dailly
1542455|NCT02651857|Device|Fuse® Colonoscope|Endoscopic diagnostic procedures for lower GI tract
1542307|NCT02652780|Genetic|GS010|"Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.
GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Subjects will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
1542308|NCT02652780|Other|Sham Intravitreal Injection|"Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.
Sham-treated Eyes: One eye of each subject will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
1542309|NCT02652767|Genetic|GS010|"Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.
GS010-treated Eyes: GS010 is a recombinant adeno-associated viral vector serotype 2 (rAAV2/2) containing the wild-type ND4 gene (rAAV2/2-ND4). Subjects will receive a single dose of GS010 in one of their randomly selected eyes, via intravitreal injection containing 9E10 viral genomes in 90μL balanced salt solution (BSS) plus 0.001% Pluronic F68®."
1542310|NCT02652767|Other|Sham Intravitreal Injection|"Both eyes of each subject will receive standard antiseptic preparation, administration of topical local ocular anesthetic agents and will undergo pupillary dilation. Administration of an intra-ocular pressure lowering agent will precede treatment for every subject.
Sham-treated Eyes: One eye of each subject will undergo sham injection. Sham Intravitreal injection will be performed by applying pressure to the eye at the location of a typical intravitreal injection procedure using the blunt end of a syringe without a needle."
1542311|NCT02652754|Drug|Granexin® gel|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
1542312|NCT02652741|Drug|Enalapril Orodispersible Minitablet|8-weeks treatment, open, uncontrolled, PK/PD, acceptability and palatability assessments and safety assessments after Enalapril intake in form of 0.25 mg or 1 mg ODMTs
1542313|NCT02652728|Drug|Enalapril Orodispersible Minitablet|Weight-dependent dose titration and long-term treatment scheme with enalapril ODMTs of 0.25 mg and 1 mg strength
1542314|NCT02652715|Other|Laboratory Biomarker Analysis|Correlative studies
1542315|NCT02652715|Other|Quality-of-Life Assessment|Ancillary studies
1542316|NCT02652715|Other|Questionnaire Administration|Ancillary studies
1542317|NCT02652715|Dietary Supplement|Salvia hispanica Seed|Given PO
1542318|NCT02652702|Procedure|circular stapler-assisted colostomy|procedure:circular stapler-assisted colostomy device:circular stapler
1542319|NCT02652702|Procedure|conventional hand-stitching colostomy|procedure:hand-stitching colostomy
1542320|NCT02652689|Radiation|Diagnostic ultrasound radiation|Recording Doppler ultrasound signals from the right chest wall
1542321|NCT02652676|Procedure|Reversible Pulmonary Artery Banding|A sternotomy incision is used for application of the rPAB. Tightening is under echocardiographic control until the inter-ventricular septum becomes a midline structure. Myocardial function is augmented with inotropic and vasodilator agents that are weaned after 2-4 weeks. The infant is separated from mechanical ventilation within the first week, and enteric feeding is resumed. The infant is discharged on oral medications, with follow-ups. Band enlargement is in stages as a balloon catheter-based procedure if a finding of increasing right ventricular dilation, onset or worsening tricuspid valve regurgitation, or a gradual late increase in plasma B-type natriuretic peptide (BNP) levels, opting for a mild residual right ventricle-main pulmonary artery pressure gradient of 15-30 mmHg.
1542322|NCT02652676|Device|GORE-TEX DualMesh EMERGE PLUS Biomaterial|The study is being conducted to evaluate the procedure, not the materials being used. The study uses the patch as materials to create the band around the pulmonary artery which is currently done routinely off label. The patch is approved as a cardiovascular patch. FDA 501(k) K032168.
1542323|NCT02652650|Drug|Ethinylestradiol|Participants will receive 35 microgram (mcg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
1542324|NCT02652650|Drug|Norethindrone|Participants will receive 1 milligram (mg) alone once daily (qd) for 21 days on Days 1 to 21 (Cycle I: lead-in) during first OC cycle; Days 29 to 49 (Cycle II: OC alone, reference) during the second OC cycle and Days 57 to 77 during third OC cycle.
1542325|NCT02652650|Drug|JNJ-63623872|Participants will receive 600 mg twice daily (bid) for 5 days on Days 73 to 77 (Cycle III: OC plus JNJ-63623872, test) during third OC cycle under fed conditions.
1542326|NCT02652637|Drug|neomycin, metronidazole, polyethylene glycol (PEG)|
1542327|NCT02652624|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily with food
1542328|NCT02652624|Drug|E/C/F/TDF|150/150/200/300 mg FDC administered orally once daily with food
1542329|NCT02652624|Drug|ATV|ATV 300 mg capsules administered orally once daily with food
1542330|NCT02652624|Drug|RTV|RTV 100 mg tablets administered orally once daily with food
1542331|NCT02652624|Drug|FTC/TDF|200/300 mg tablet administered orally once daily with food
1542332|NCT02652624|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
1542333|NCT02652611|Procedure|SI Screw Removal Surgery|
1542334|NCT02652611|Procedure|Non-screw removal treatment (non-operative management)|
1542335|NCT02652598|Drug|Tolcapone|
1542336|NCT02652585|Drug|Naltrexone|
1542337|NCT02652585|Drug|Placebo|capsule filled with micro crystalline cellulose, manufactured to mimic naltrexone capsule
1542338|NCT02652572|Drug|Granexin|Granexin® gel will be dispensed directly from a 5 gram laminate tube and will be spread and smoothed directly over the wound surface in full contact with the wound bed to obtain an even, uniform layer on Day 0 (baseline), Day 3, and Day 7.
1542456|NCT02651857|Device|Fuse® Gastroscope|Endoscopic diagnostic procedures for upper GI tract
1542348|NCT02652533|Device|Ultrasound Shear Wave Elastography|The investigators have recently published a very small study in neonates/infants with suspected BA showing that US liver shear wave speed (i.e. - liver stiffness) can differentiate BA from other causes of cholestasis, potentially with a very high degree of accuracy. Additional research is needed to confirm these very preliminary results and determine if liver shear wave speed measurements either before or after (including longitudinally) Kasai can predict key outcomes.
1542349|NCT02652520|Procedure|HEMO2Life® use in organ preservation solution|The surgeon decides whether the local transplant kidney may be part of the study and whether it should be stored in static cold storage or machine perfusion. The transplant kidney will be perfused in situ before procurement with the Belzer UW® cold storage solution furnish by the BridgetoLife company. HEMO2Life® will then be added to preservation solution.
1542350|NCT02652507|Drug|Dexmedetomidine|2 mc/kg/h over ten minutes followed by a continuous infusion of 2 mcg/kg/h
1542351|NCT02652507|Drug|Ketamine|Bolus dose 2 mg/kg after first set of research images are obtained
1542352|NCT02652481|Device|ImageReady MR Conditional Defibrillation System|"ImageReady MR Conditional Defibrillation System Components:
Device Name Device Model Number Pulse Generators Phase I and II Phase II Only * CRT-D (IS1/DF4/IS4) VR ICD (DF4) DR ICD (IS1/DF4) ORIGEN™ MINI ICD ORIGEN EL ICD ORIGEN X4 CRT INOGEN™ MINI ICD INOGEN EL ICD INOGEN X4 CRT DYNAGEN™ MINI ICD DYNAGEN EL ICD DYNAGEN X4 CRT-D AUTOGEN ™ MINI ICD* AUTOGEN EL ICD* AUTOGEN X4 CRT-D* Right Atrial Leads and Accessories FINELINE™ II Sterox FINELINE II Sterox EZ Suture Sleeves for FINELINE II Leads INGEVITY™ MRI* Suture Sleeve for INGEVITY MRI* IS-1 Lead Port Plug 7145 Right Ventricular Leads and Accessories RELIANCE 4-FRONT™ (DF4)* Suture Sleeve for RELIANCE 4-FRONT leads*; ENDOTAK RELIANCE™ (DF4) Left Ventricular Leads and Accessories ACUITY™ X4 (IS4) Suture Sleeve for ACUITY X4 leads
* May only be used internationally outside the US"
1542353|NCT02652468|Drug|Fludarabine Phosphate|Fludarabine will be administered by IV over approximately 30 minutes for 4 days.
1542354|NCT02652468|Drug|Mesna|Given IV over 24 hours starting prior to cyclophosphamide
1542355|NCT02652468|Drug|Cyclophosphamide|Given IV for 2 days
1542356|NCT02652468|Radiation|Total nodal irradiation|Undergo total lymphoid irradiation
1542357|NCT02652468|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
1542358|NCT02652468|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo TCR alpha-beta/DC19-depleted hematopoietic stem cell transplant
1542359|NCT02652468|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo TCR alpha-beta/CD19-depleted hematopoietic stem cell transplant
1542360|NCT02652468|Drug|Mycophenolate Mofetil|Given PO
1542361|NCT02652468|Drug|Tacrolimus|Given PO or IV ONLY if graft cell content is over 1 x 10^5 cells/kg ideal BW of the patient
1542362|NCT02652468|Biological|Rituximab|Given IV ONLY if graft B cell content exceeds 1 x 10^5 cells/kg ideal BW of the patient
1542363|NCT02652455|Drug|Nivolumab|Participants entering the study after the first 6 participants only: Treatment with nivolumab prior to removal of tumor sample for TIL growth. About 2 weeks after their tumor sample has been taken, these participants may receive additional infusions of nivolumab.
1542364|NCT02652455|Procedure|Surgery to Remove Tumor for Growth of TIL|All participants: Tumor sample taken for growth of TILs. Growing the TILs takes about 4-8 weeks.
1542365|NCT02652455|Drug|CD137|All participants: Anti-CD137 agonistic antibody as an agent to augment T cell proliferation in vitro. The growth of the TIL will be accelerated by the use of CD137 activating antibody in the laboratory.
1542366|NCT02652455|Drug|Cyclophosphamide|All participants: Lymphodepleting chemotherapy intravenously, beginning 3 to 6 weeks after tumor collection for TIL growth.
1542367|NCT02652455|Drug|Fludarabine|All participants: Lymphodepleting chemotherapy intravenously, beginning after first 2 days of cyclophosphamide.
1542368|NCT02652455|Biological|TIL Infusion|After completing one week of lymphodepleting chemotherapy, all participants will be admitted back into the hospital for IV infusion of the TIL cells.
1542369|NCT02652455|Drug|Interleukin-2|After TIL infusion, in-patient high dose IL-2 treatment.
1542528|NCT02651311|Other|intermediate cervical plexus block|ultrasound guided intermediate cervical plexus block with 0.25% ropivacaine 0.2 ml/kg
1542529|NCT02651311|Drug|Fentanyl|fentanyl 0.5 µg/kg in postanesthetic care unit when more or equal to FLACC scale 4.
1542373|NCT02652429|Drug|Inhaled Nitric Oxide|
1542374|NCT02652416|Drug|BI 1026706|oral administration
1542375|NCT02652416|Drug|Placebo|placebo
1542376|NCT02652403|Device|Complete conventional dentures|"The typical operations of conventional technique will be carried out dentures fabrication and clinical appointments and laboratory steps will be necessary until denture insertion:
Preliminary impression using irreversible hydrocolloid in a stock trays; Individual acrylic resin trays fabrication; Functional impressions using Zinc oxide-eugenol paste and low fusion compound in a individual acrylic resin trays; Maxillary occlusion rims fabrication; Maxillary occlusion rims fabrication adjustments, Centric relation records and transference of the maxillary occlusion rims positions to semiadjustable articulators using a facebow; Setting of teeth in wax; Complete denture wax try-in; Insertion, instructions and postinsertion appointments."
1542377|NCT02652403|Device|Complete simplified dentures|For a complete simplified denture fabrication, individual acrylic resin trays fabrication and functional impressions steps will be deleted, and the facebow for transference of the maxillary occlusion rims positions to semiadjustable articulators will be replaced by the table Camper.
1542378|NCT02652390|Drug|Methylprednisolone 80 mg|2 mL methylprednisolone (40 mg/mL) + 1 mL lidocaine
1542379|NCT02652390|Drug|Methylprednisolone 40 mg|1 mL methylprednisolone (40 mg/mL) + 1 mL saline + 1 mL lidocaine
1542380|NCT02652390|Other|Saline|2 mL saline + 1 mL lidocaine
1542381|NCT02652377|Drug|EDP-494|10, 100 and 200 mg capsules
1542382|NCT02652377|Drug|Placebo|placebo to match EDP-494
1542383|NCT02652351|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intravenous infusion or Hepatic artery intervention, and repeated every week for four times.
1542384|NCT02652338|Dietary Supplement|MNC-01|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
1542385|NCT02652338|Dietary Supplement|Placebo|twice daily 2 tablets with appr. 200 ml still water or tap water; duration: 6 weeks
1542386|NCT02652325|Drug|Saline|
1542387|NCT02652325|Drug|Povidone-Iodine|
1542388|NCT02652325|Drug|5% Povidone-Iodine USP swabs|
1542389|NCT02652312|Drug|Dexmedetomidine|A maintenance dose of Dexmedetomidine infusion at 0.5 mcg/kg/hour made to 20 mL with normal saline will be administered
1542390|NCT02652312|Drug|Placebo|A maintenance dose of 20 mL with normal saline will be administered at a rate similar to that of dexmedetomidine
1542391|NCT02652312|Procedure|Ondansetron|0.15 mg/kg intravenous (IV) will be given as a pre-medication
1542392|NCT02652312|Procedure|fentanyl|1.5 μg/kg intraoperative
1542393|NCT02652312|Procedure|propofol|10 mg every 5 seconds until the BIS level dropped below 60 for induction of anesthesia
1542394|NCT02652312|Procedure|Atracurium|0.5 mg/kg IV for endotracheal intubation
1542395|NCT02652312|Procedure|diclofenac sodium|1 mg/kg for postoperative analgesia
1542396|NCT02652312|Procedure|desflurane|1 MAC concentration (expired fraction of 6.0 vol%) for maintenance of anesthesia
1542397|NCT02652299|Biological|Synovial biopsy|Synovial tissue for analysis and biobank.
1542398|NCT02652286|Device|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in VATS lobectomy in humans
1542399|NCT02652273|Drug|Abatacept|Abatacept 125mg/ml
1542405|NCT02652247|Procedure|molecular analysis of exhaled breath condensate|
1542406|NCT02652247|Procedure|molecular analysis of mini-bronchoalveolar lavage (BAL) aspirate|
1542407|NCT02652247|Procedure|molecular analysis of bronchoalveolar lavage (BAL) aspirate|
1542408|NCT02652234|Drug|Endostar|Endostar, ih, QD，day 1 of cycle 1; Endostar, ih, QD，day 2-15 of cycle 3;
1542409|NCT02652234|Drug|Chemotherapy|
1542410|NCT02652221|Device|Acoustic Radiation Force Imaging|ARFI US is a novel technique, recently FDA approved for use in children and adults, which provides an alternative method for quantifying liver stiffness.
1542411|NCT02652208|Behavioral|Online decision aid|The Healthwise online shared decision point for Stable Chest Discomfort
1542412|NCT02652208|Behavioral|Video decision aid|The Health Dialog DVD and booklet decision aid for Stable Chest Discomfort
1542413|NCT02652195|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril, delivered prior to scanning session.
1542414|NCT02652195|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff, delivered prior to scanning session.
1542415|NCT02652169|Drug|PRF mixed with amikacin and teicoplanin|PRF, mixed with amikacin and teicoplanin is applied to the chronic ulcer
1542416|NCT02652169|Drug|PRF mixed with PHMB plus Macrogolol|PRF, mixed with Lavasorb is applied to the chronic ulcer
1542417|NCT02652169|Drug|PRF plus normal saline|PRF as a monosubstance plus sodium chloride 0.9% is applied to the chronic ulcer
1542418|NCT02652169|Other|Silver gauze|Acticoat 7 silver wound dressing is applied to the chronic ulcer
1542419|NCT02652156|Drug|Bupivacaine|60 ml Bupivacaine 0.25% will be drawn via 60 ml Syringe. The syringe will be connected and a 10ml flush syringe containing 10ml 0.9% Normal Saline (NS) will be connected to the end of an IV extension set via a 3-way stopcock and Luer lock connections. The Bupivacaine 0.25% syringe will be connected to the stopcock. The distal end of the IV connection will be connected to the injection needle. The entire setup will be flushed with 0.9% NS via flush syringe. The TAP space will also be located under ultrasound guidance and verified by using the 0.9% NS flush syringe. Once in the TAP space, 30 ml Bupivacaine 0.25% will be injected into the TAP space. This dose will be decreased to 25 ml for patients under 70 kg. The process will be repeated on the opposite side TAP block.
1542420|NCT02652156|Drug|Exparel®|20 ml Exparel (266 mg) will be drawn into a 20 ml syringe. A 20 ml Bupivacaine 0.25% syringe and the syringe containing the Exparel solution will be connected to the end of an IV extension set via a 3-way stopcock. The IV connection will be connected to the injection needle. The setup will be flushed with the Bupivacaine syringe. The TAP space will be located under ultrasound guidance. 133mg of Exparel will be injected into the TAP space. After injection, the syringe will be exchanged for the Bupivacaine syringe and 20ml Bupivacaine injected into the space. The process will be repeated on the opposite side TAP block.
1542421|NCT02652156|Drug|Ropivacaine|40 ml Bupivacaine 0.25% will be drawn via two 20ml Syringes. A Bupivacaine 20ml syringe will be connected to an IV extension via a 3-way stopcock and Luer lock. The IV will be connected to an injection tuohy needle and flushed with NS. The TAP space will be located using ultrasound guidance. 15 ml Bupivacaine 0.25% will be injected. A catheter will be threaded through the tuohy needle into the TAP space. 5ml Bupivacaine 0.25% will then be injected. The catheter will be secured via standard technique. The process will be repeated for the opposite side. Patients will receive a filled ON-Q system. The ON-Q system contains Ropivacaine 0.2%. The pump will run at 7 ml/hr. per side.
1542422|NCT02652143|Device|AneVivo (Medical device for in vivo culture of embryos)|
1542423|NCT02652143|Other|comparator for embryo culture in vitro|
1542424|NCT02652091|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Applied via the BETACONNECT device. Dose as prescribed by physician.
1542425|NCT02652091|Device|BETACONNECT device|Used to apply Betaseron.
1542426|NCT02652078|Device|Extracorporeal shockwave therapy|Ultrasonic shockwaves targeted at calf muscle bulk using the Piezowave 2 device (Richard Wolf, Knittlingen, Germany)
1542427|NCT02652065|Other|Acetylcholine iontophoresis|Acetylcholine will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
1542428|NCT02652065|Other|Sodium Nitroprussiate iontophoresis|Sodium Nitroprussiate will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
1542429|NCT02652065|Other|ppi water iontophoresis|ppi water will be locally delivered to patients by iontophoresis successively on healthy skin and on psoriasis plaque (order determined by randomization).
1542430|NCT02652065|Other|Laser Doppler recording|Skin blood flow will be recorded by laser Doppler during 2 minutes before iontophoresis, and during 30 minutes following iontophoretic delivery of vasodilators.
1542434|NCT02652039|Other|Questionnaires|Questionnaires
1542435|NCT02652026|Procedure|Nonsurgical periodontal treatment|Full mouth debridement, which consisted of scaling and root planing (SRP), was done in a single visit using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France) and Gracey curretes (Hu- Friedy, Chicago, USA).
1542436|NCT02652026|Procedure|Dental Prophylaxis|Removal superficial plaque using an ultrasonic scaler (SATELEC P5 Newtron XS, Acteon, Merignac, France)
1542437|NCT02652013|Other|cognitive evaluation|
1542438|NCT02652000|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis.
1542440|NCT02651974|Behavioral|Control condition|Patients will be mailed a control invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
1542441|NCT02651974|Behavioral|Cost condition|Patients will be mailed a cost condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
1542442|NCT02651974|Behavioral|Cost/Future condition|Patients will be mailed a cost/future condition invitation letter to complete a home fecal immunochemical test (FIT) for colorectal cancer screening.
1542443|NCT02651961|Procedure|Exchange of total hip or knee arthroplasty on same time|Removal of the index implants, extensive debridement, reimplantation of a new prosthesis
1542444|NCT02651961|Procedure|Exchange of total hip or knee arthroplasty in two time|Removal of the index implants in first time, extensive debridement, reimplantation of a new prosthesis in seconde time
1542445|NCT02651948|Procedure|Transperineal, MRI-guided, prostate biopsy|
1542446|NCT02651948|Procedure|Transrectal prostate biopsy (TRB):|
1542447|NCT02651935|Device|Hamilton G5 Mechanical ventilator|Invasive mechanical ventilation and weaning strategy
1542448|NCT02651909|Other|blood sampling|blood sampling for TEG analysis, Thrombin time, thrombin generation, PT with neoplastine, ecarin chromogenic assay, anti-factor Xa (rivaroxaban assay
1542449|NCT02651896|Radiation|HypoIGRT|"Hypofractionated intensity modulated and image guided radiotherapy 60 Gy in 20 fractions over four weeks for the prostate gland to all groups.
For intermediate and high risk group: seminal vesicle will be included: 48 Gy in 20 fractions over 4 weeks (proximal third to half on physicians description).
Image guidance with cone beam CT will be mandatory before every treatment fraction."
1542450|NCT02651883|Behavioral|Screening invitation (with education)|The participant will be provided with brief education about the importance and effectiveness of cervical cancer screening, and invited to schedule an appointment for a free in-clinic screening
1542451|NCT02651883|Behavioral|Self-collection for HPV testing|Participant is provided with a kit to take a self-collected sample at home and return it by mail for HPV testing. Results are provided to participant by phone.
1542452|NCT02651870|Drug|Candesartan 16mg|
1542453|NCT02651870|Drug|Amlodipine 5mg|
1542454|NCT02651870|Drug|Amlodipine 10mg|
1542457|NCT02651844|Drug|Mifepristone|"At the time a patient enters the protocol, 14 pills will be given to the personnel responsible of giving the patient the medicine at her home (This was a special requirement from the Argentine Authorities).
Patients and personnel will sign the form each then she gets the medication and after that the signed form will be kept at the CRF file."
1542458|NCT02651831|Other|Focus groups and individual interviews|Focus groups conducted to explore general experiences, insights and concerns of those receiving ICM therapies. Individual semi-structured interviews to provide in-depth data on the themes identified in the focus groups.
1542459|NCT02651831|Other|Questionnaire|Health related quality of life questionnaire (FACT-ICM) to be completed by patients
1542460|NCT02651818|Procedure|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
1542461|NCT02651805|Device|Mechanical Insufflation-Exsufflation|Mechanical Insufflator-Exsufflator (MI-E): 6 assisted cough with expiratory pressure of -40cmH2O and inspiratory pressure defined by the therapist as the maximum pressure defined as comfortable; inspiratory time 3s and expiratory time 4s, using a manual cycle. Patients will be instructed to cough during exsufflation phase, with exception of Chronic obstructive pulmonary disease patients which will be instructed to exhale slowly. An oral-nasal mask will be used as interface, but in patients with tracheotomy, the device will be connected to it. A trained physiotherapist will conduct the therapy. During the night and weekends, patients will not start this therapy, however, if they have already started the therapy in MI-E group, or if they have already finished the period of follow-up they will be able to request this therapy, which will be provided by hospital staff . The equipment (Cough Assist®, Respironics, Phillips), will be available in the ward for the interventions.
1542462|NCT02651805|Other|Usual Care|The patients will receive the treatment according to the hospital protocol to deal with hypersecretive patients (suctioning that can be preceded by respiratory physiotherapy and nebulisation). A trained member of the nurse staff or a physiotherapist will be responsible for providing the therapy. A member of the research team will collect in the patients' records all the therapies provided by the staff to control hypersecretions.
1542463|NCT02651792|Drug|ketamine- propofol|1 mg x kg(-1) ketamine + 1.2 mg x kg(-1) propofol.
1542464|NCT02651792|Drug|pethidine- propofol|1.1 mg x kg(-1) pethidine + 1.2 mg x kg(-1) propofol for sedation induction
1542465|NCT02651779|Procedure|Open reduction and internal plate fixation|
1542466|NCT02651779|Other|Closed reduction and plasterimmobilisation|
1542467|NCT02651766|Procedure|Cupping massage|Using suction on the skin by means of glass cups, and moving the cups after applying massage oil on the skin
1542468|NCT02651753|Drug|Lipitor + Lipidil supra|Reference Drug: Lipitor + Lipidil supra
1542469|NCT02651753|Drug|CKD-337|Test Drug: CKD-337
1542472|NCT02651727|Drug|Part B, Cohort 1- VS-4718, nab-paclitaxel, gemcitabine|IV treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 BID continuously starting on Day 1 of Cycle 1
1542473|NCT02651727|Drug|Part B, Cohort 2- VS4718, nab-paclitaxel, gemcitabine|IV treatment for the first 2 cycles, followed by IV treatment and oral VS-4718 BID continuously starting on Day 1 of Cycle 3
1542474|NCT02651727|Drug|Part A- VS-4718, nab-paclitaxel, gemcitabine|Part A- intravenous (IV) treatment in 28-day cycles (nab-paclitaxel 125 mg/m2 over 30 minutes on Days 1, 8, and 15 and gemcitabine at 1000 mg/m2 over 30 minutes on Days 1, 8, and 15) and oral VS 4718 twice-daily (BID) continuously starting on Cycle 1 Day 2. The starting dose of VS-4718 will be 200 mg BID.
1542475|NCT02651714|Drug|Tradipitant|
1542476|NCT02651714|Drug|Placebo|
1542477|NCT02651701|Procedure|MR-PET|whole body MR-PET with dedicated liver+rectal protocol
1542478|NCT02651688|Drug|Placebo|
1542479|NCT02651688|Drug|12.5 mg Enclomiphene Citrate|
1542480|NCT02651688|Drug|25 mg Enclomiphene Citrate|
1542482|NCT02651662|Drug|REGN2810|
1542483|NCT02651662|Drug|REGN1979|
1542484|NCT02651649|Device|Continuous Positive Airway Pressure (CPAP)|FGR diagnosed parturients who are diagnosed with OSA will be prescribed CPAP as per standard of care.
1542485|NCT02651636|Drug|myo-inositol,alpha-lipoic acid and folic acid|
1542486|NCT02651623|Drug|Sertraline|Multiple doses of sertraline for 14 days
1542487|NCT02651623|Drug|Moxifloxacin|A single dose of 400 mg Moxifloxacin
1542488|NCT02651623|Drug|Drug - Placebo|Placebo administered for 14 days
1542489|NCT02651610|Biological|Bavituximab|Biological: bavituximab
1542490|NCT02651610|Drug|Taxane|Drug: Taxane Other names: Paclitaxel. Taxotere, Taxotere, Docecad, Taxol
1542491|NCT02651597|Other|Oatmeal|
1542492|NCT02651584|Drug|CAM2038 subcutaneous injection|
1542493|NCT02651584|Drug|SL BPN tablets|
1542494|NCT02651584|Drug|placebo subcutaneous (SC) injections|
1542495|NCT02651584|Drug|SL placebo tablets|
1542496|NCT02651558|Device|CSEM BP system 2015-MD-0022|"At the onset of general anesthesia:
continuous measurements of radial arterial blood pressure values (arterial catheter, via a commercial PHILIPS IntelliVue MP50 monitor)
continuous estimates of optical blood pressure values (optical blood pressure system, via Swissmedic approved measuring device 2015-MD-0022 developed by CSEM)
will be recorded."
1542497|NCT02651532|Device|Confocal Laser Endomicroscopy|During colonoscopic withdrawal, the colonic mucosa will be observed with white light and be evaluated on the different segments of the colon with the confocal laser endomicroscopy technology in order to search for microscopic inflammation signs (altered crypt architecture, fluorescein leaks and dilated and prominent branching vessels)
1542498|NCT02651519|Drug|0.25% ropivacaine hydrochloride|stellate-ganglion block with 0.25% ropivacaine hydrochloride
1542499|NCT02651519|Drug|saline|stellate-ganglion block with saline
1542530|NCT02651311|Drug|Ibuprofen|ibuprofen in ward when more or equal to FLACC scale 4.
1542531|NCT02651298|Device|Fractional Co2-laser|laser treatment
1542532|NCT02651285|Other|G-CSF medium|incubation of IVF embryos with a specific medium containing G-CSF
1542500|NCT02651506|Procedure|Electromagnetic Navigation Bronchoscopy|• Participants randomized to the intervention arm will undergo biopsy using the superDimension®InReach™ System. Participants will undergo ENB guided biopsy under general anesthesia or local anesthesia. The procedure will be performed by a thoracic surgeon in the operating room or endoscopy suite. Following electromagnetic mapping, bronchoscopy and biopsy will be performed. Fiducial markings will be placed when necessary.
1542501|NCT02651506|Procedure|Transthoracic Needle Biopsy|• Patients randomized to the control arm (TTNB) will undergo lung biopsy using standard transthoracic needle biopsy technique. The procedure will be performed under local anesthesia with computed tomography guidance by an interventional radiologist. In this procedure, a CT-image is used to locate the area for biopsy. Once identified, the radiologist applies a local anesthetic and inserts an aspiration needle between the ribs, through normal lung tissue, leading into the biopsy area. The sampled lung tissue is then sent for pathological analysis.
1542502|NCT02651493|Device|photographs|computer based program to analyze photographs (computer-aided diagnosis (CAD) software)
1542503|NCT02651480|Dietary Supplement|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
1542504|NCT02651480|Dietary Supplement|Control Group|Unrestricted diet with no instruction.
1542505|NCT02651467|Other|Experimental Oral Rinse 1 (1.5% w/w KOX, 0ppm F, pH 7.0)|1.5% w/w KOX, 0ppm F, pH 7.0
1542506|NCT02651467|Other|Experimental Oral Rinse 2 (2.0% w/w KOX, 45ppm F, pH 4.5)|2.0% w/w KOX, 45ppm F, pH 4.5
1542507|NCT02651467|Other|Placebo Oral Rinse (0% w/w KOX 0ppm F, pH 4.5 )|0% w/w KOX 0ppm F, pH 4.5
1542508|NCT02651454|Drug|Daesiho-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
1542509|NCT02651454|Drug|Jowiseungcheung-tang|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: Hanzung Pharmaceutical. co. Ltd.
1542510|NCT02651454|Drug|Placebo|Usage: 6g, three times a day, each taken before or between meals for 12 weeks Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
1542511|NCT02651441|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day1 and day8, repeat every 3 weeks.
1542512|NCT02651441|Drug|Cisplatin|Cisplatin 25mg/m2 IV on day 1,2 and 3, repeat every 3 weeks.
1542513|NCT02651441|Biological|D-CIK|8×10^9 D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
1542514|NCT02651428|Drug|Neutrolin|Neutrolin® or heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
1542515|NCT02651428|Drug|Heparin|Neutrolin® or heparin will be instilled into central venous HD catheters at the discontinuation of all dialysis sessions and will be withdrawn prior to the initiation of the next dialysis session
1542516|NCT02651415|Drug|Regorafenib|"Stivarga® will be used as per the marketed indication (on label), Coversyl will be used off-label and as such a Clinical Trial Application will be filed with Health Canada.
Regorafenib will be administered 160 mg daily for 21 days of a 28 day cycle. Regorafenib will be administered with low fat breakfast, one hour after perindopril. A low fat breakfast as defined by the Stivarga ® (regorafenib) Product Monograph is one that is <30% fat, ~300-550 calories."
1542517|NCT02651415|Drug|Perindopril|COVERSYL® (perindopril erbumine) 4 mg will be administered daily for 21 days of a 28 day cycle. Perindopril will be administered orally, first thing in the morning on an empty stomach.
1542518|NCT02651402|Behavioral|FRIENDS for Life|Friends for Life (FRIENDS): FRIENDS, a GCBT program, is an effective program for the prevention and treatment of anxiety disorders in children evidenced by a meta-analysis on school-based interventions for at-risk and clinically anxious youth. FRIENDS was developed based on the view that anxiety is a tripartite construct involving physiological, cognitive, and behavioral components. Core Intervention components: Experts in CBT for childhood anxiety disorders have identified 5 essential components: psychoeducation, somatic management skills training, cognitive restructuring, exposure methods, and contingency management. The FRIENDS protocol consists of 10 weekly sessions and two booster sessions. We included the booster sessions in the regular protocol for a total of 12 sessions.
1542519|NCT02651402|Behavioral|Adapted FRIENDS|Adapted Friends (aFRIENDS): We conducted planned adaptations to the FRIENDS protocol based on our collective experience with the protocol and qualitative data (focus group and interviews). We followed procedures developed by Lee and colleagues, including surveying service providers and trainers regarding the appropriateness of FRIENDS for the target population. Changes were made to the language (idioms, metaphors, words), cultural fit (cultural values), methods (session length, number of sessions), activities (in-session practices), which resulted in additions and substitutions in these areas while maintaining the 5 essential components of the treatment. aFRIENDS is a briefer (8-session) and more engaging and culturally-sensitive protocol than FRIENDS.
1542520|NCT02651402|Behavioral|Train-the-Trainer|Train the Trainer (TT): agency supervisors are trained to conduct effective supervision (one initial training and 2 booster sessions), and then go on to train intervention therapists.
1542521|NCT02651402|Behavioral|Train-the-Trainer Plus|Train the Trainer Plus (TT+): a modified train-the-trainer approach by which supervisors receive training plus extended on-going consultation on conducting effective supervision with intervention therapists.
1542522|NCT02651376|Combination Product|Conventional plus AAIT|Participants received conventional (anti-opportunistic infections and ART) treatment and taken i.v., at a roud (3 times) of 2-3*10E8 MNCs/kg body at baseline, week 1 and 2.
1542523|NCT02651350|Drug|Methylprednisolone|Participants will receive methylprednisolone,48mg/d for the 1st week,32mg/d for the 2nd week,24mg/d for the next two weeks, followed by 16mg/d for 32 weeks and reduction in doses of methylprednisolone by 4 mg per 4 weeks until drug withdrawal.Participants will also receive standard treatment including reduced glutathione, glycyrrhizin, ademetionine, alprostadil, or ursodeoxycholic acid (UDCA) in the first 12 weeks.The total treatment duration will be 48 weeks. Follow-up duration is 24 weeks.
1542524|NCT02651350|Drug|Standard Treatment|Participants will only receive standard treatment,namely,routine liver protection drugs including reduced glutathione, glycyrrhizin, ademetionine, alprostadil,or ursodeoxycholic acid (UDCA) from week 0 through week 12 study visit. Participants will then be followed until week 72.
1542525|NCT02651337|Device|Cerebrospinal Fluid (CSF) Drainage|Placement of Alivio in line flusher during CSF drainage
1542526|NCT02651324|Drug|Ketamine|
1542527|NCT02651324|Other|Placebo|
1542533|NCT02651285|Other|Control|incubation of IVF embryos with a medium without G-CSF
1542534|NCT02651272|Drug|macitentan|10mg macitentan tablets
1542535|NCT02651259|Drug|Rifapentine (RPT)|900 mg of RPT
1542536|NCT02651259|Drug|Isoniazid (INH)|900 mg of INH
1542537|NCT02651259|Dietary Supplement|Pyridoxine (vitamin B6)|25 mg to 100 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
1542538|NCT02651246|Other|data collection|
1542539|NCT02651233|Other|ADRCs therapy|Patients are submitted to manual liposuction and extraction of ADRCS is done with closed system. All patients were candidates for subcutaneous transplantation of autologous cell enriched adipose tissue for different indications.
1542540|NCT02651220|Drug|Epiduo® Forte Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
1542541|NCT02651220|Drug|Adapalene and Benzoyl Peroxide Gel|Adapalene and Benzoyl Peroxide Gel, 0.3%/2.5% w/w
1542542|NCT02651220|Drug|placebo gel|vehicle used as placebo
1542543|NCT02651207|Other|Questionnaire based study looking at pain scores felt by patients either having a lidocaine injection or ethyl chloride spray prior to insertion of a contraceptive implant|
1542545|NCT02651181|Device|HLCL- Hybrid Logic Closed Loop System|All subjects wearing the HLCL System and using it with the closed loop algorithm
1542546|NCT02651168|Biological|aflibercept|EYLEA (aflibercept, solution for intravitreal injection) is a recombinant fusion protein consisting of portions of human Vascular Endothelial Growth Factor (VEGF) receptor 1 and 2 extracellular domains fused to the Fc portion of human IgG1 and formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is produced in Chinese hamster ovary (CHO) K1 cells by recombinant DNA technology.
1542547|NCT02651155|Drug|Lubiprostone|Lubiprostone capsules
1542548|NCT02651155|Drug|Placebo|Lubiprostone placebo-matching capsules
1542549|NCT02651142|Procedure|Patients receive SLNB|Patients receive sentinel lymph node biopsy
1542550|NCT02651129|Other|Noise measurement|We will be measuring noise levels in the operating room
1542555|NCT02651090|Drug|Sonazoid|Comparison of Sonazoid enhanced ultrasound to non enhanced CT
1542556|NCT02651064|Other|HIP|
1542557|NCT02651051|Dietary Supplement|Whey Protein|20 g whey protein isolate (Arla Foods Ingredients Group) added to breakfast meal
1542558|NCT02651051|Other|High Fat Breakfast Meal|A standardised high fat breakfast served to all participants. The macronutrient distribution of the breakfast is 12% protein, 3% carbohydrate, 85% fat (1771 kJ; 423 kcal total)
1542559|NCT02651038|Drug|Micafungin|Measurement of PK
1542560|NCT02651025|Other|Resistance Exercise Program|"During the first week of training will be conducted two sets of 10 repetitions, and from the second week of training until the twelfth will be performed three sets of 10 repetitions. The work rate will set to the tolerance of each patient as established by his/her inability to maintain Borg ratings for dyspnea and effort (10-point category-ratio Borg scale) scores between 4 and 6."
1542561|NCT02651012|Drug|sarecycline|1.5 mg/kg/day sarecycline or placebo tablets for duration of 12 week study
1542562|NCT02651012|Drug|Placebo|1 tablet taken daily for duration of 12 week study
1542563|NCT02650999|Drug|Pembrolizumab|200mg intravenously (IV)
1542564|NCT02650986|Drug|Cyclophosphamide|Given IV
1542565|NCT02650986|Other|Laboratory Biomarker Analysis|Correlative studies
1542566|NCT02650986|Biological|NY-ESO-1 Reactive TCR Retroviral Vector Transduced Autologous PBL|Given IV
1542567|NCT02650986|Biological|TGFbDNRII-transduced Autologous Tumor Infiltrating Lymphocytes|Given IV
1542568|NCT02650973|Drug|CHS-1701|
1542569|NCT02650973|Drug|Pegfilgrastim|
1542572|NCT02650934|Procedure|Percutanous coronary intervention|
1542573|NCT02650921|Device|Restylane Lyft with Lidocaine|An injectable gel of Hyaluronic Acid and Lidocaine
1542574|NCT02650895|Biological|CD24Fc|Recombinant fusion protein consisting of the extracellular domain of mature human CD24 linked to the human immunoglobulin G1 (IgG1) Fc domain
1542575|NCT02650895|Drug|Saline|0.9% sodium chloride
1542576|NCT02650882|Procedure|Device POWERbreathe|
1542577|NCT02650869|Dietary Supplement|Probiotics|probiotics at a dose of 3x109 CFU/day. (Cap TS6 probiotic + contain Bifidobacterium spp., Lactobacillus at 6x109 CFU = 6 billion CFU manufactured by TENSALL BIO-TECH CO.LTD.Taiwan, distributed by Century Health Care, Bangladesh)
1542578|NCT02650869|Dietary Supplement|Breast milk|Normal breast milk will be given as part of standard care
1542579|NCT02650856|Drug|Group 1 Tranexamic Acid|2 gr of tranexamic acid will be applied on the surgical site.
1542580|NCT02650856|Biological|Group 2 Platelet rich plasma|16ml of platelet rich plasma will be applied of the surgical site
1542581|NCT02650843|Other|DAT SPECT imaging|
1542582|NCT02650817|Drug|RAD1901|RAD1901, a novel selective ER degrader (SERD)
1542585|NCT02650791|Drug|Tranexamic Acid|
1542586|NCT02650778|Procedure|Breast ultrasound|automated whole breast ultrasound
1542587|NCT02650765|Other|Indications for head CT imaging after acute head injury|Indications for head CT imaging after acute head injury as per the Scandinavian guidelines for initial management of minimal, mild and moderate head injuries in adults.
1542588|NCT02650752|Drug|Lapatinib in Tandem With Capecitabine|
1542589|NCT02650739|Procedure|Macular hole surgery|Vitrectomy with internal limiting membrane removal and gas tamponade
1542590|NCT02650726|Dietary Supplement|Anthocyanin|anthocyanin 320 mg daily for 24 weeks
1542591|NCT02650726|Other|Placebo|placebo 320mg daily for 24 weeks
1542594|NCT02650700|Radiation|spleen radiation|In Experimental arm, combine spleen radiation with chemotherapy. In Chemotherapy alone arm, the subjects should also receive spleen radiation once there is a severe CIT (≧grade III) during chemotherapy after radomization.
1542595|NCT02650687|Procedure|Processed EEG|In the operating room. Processed EEG will be measured using the Bispectral Index (BIS) monitor which is standard of care.
1542596|NCT02650674|Other|Product A: NP-0148|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
1542597|NCT02650674|Other|Glucose solution|Glucose solution providing 50 g of available carbohydrates in 250 ml of water. This will be performed 3 times
1542598|NCT02650674|Other|Product B: NP-0149|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
1542599|NCT02650674|Other|Product C: NP-0150|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
1542600|NCT02650674|Other|Product D: NP-0151|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
1542601|NCT02650674|Other|Product E: NP-0152|Portions of cereal product calculated to provide 50 g of available carbohydrates will be served with 250 mL water.
1542602|NCT02650661|Behavioral|Online health management program|"Web-based health management program designed according to SMASH strategy, which includes (i) Assessment, (ii) Acceptance, (iii) Preparation for change, (iv) Commitment, (v) Planning, (vi) Promoting environment, (vii) Execution, (viii) Feedback and Maintenance, and (ix) Core perspectives, for 6 months.
The program consists of four areas: self-assessment, self-planning, self-learning, and self-monitoring. The learning session includes SMASH strategies and 10 Rules for Highly Effective Health Behavior."
1542603|NCT02650661|Behavioral|Health coaching|Personalized tele-coaching for 6 months by health coaches who were trained by the Smart Management and Coaching for Health (SMACH) program
1542604|NCT02650661|Behavioral|Workshop|Total three sessions are to be held at 3-, 5-, and 7-month after the initiation of the enrollment. Each session includes 30-minute health education, 1-hour health management strategy workshop, and 30-minute team coaching.
1542605|NCT02650661|Behavioral|Standard health educational booklet|"Standard health educational booklets about 10 Rules for Highly Effective Health Behavior that are organized according to the Trans-theoretical Model (TTM).
Booklets are provided at 0-, 2-, and 4-month after the enrollment."
1542606|NCT02650648|Drug|cyclophosphamide|chemotherapy with intravenous (IV) cyclophosphamide 50mg/kg/day (for patients with body weight<70kg) or 1500mg/m^2/day (for patients with body weight ≥70kg) for two days (days -6 and -5).
1542607|NCT02650648|Biological|NK cells|Day 0: NK cell infusion. NK cells are resuspended in Normasol at a concentration no less than 5 x 10^6cells/mL. The patient is pre-medicated as per standard cell product infusion. The cell product is infused through a central venous catheter. Patients will be evaluated clinically by vital signs pre- and approximately 30 minutes post infusion of NK cells and thereafter at approximately 1 hour intervals for 4 hours.
1542608|NCT02650648|Biological|hu3F8|On Days -1, +1, +5, +7 and +9 hu3F8 is administered at 1.68 mg/kg/day and infused over ~0.5 hr
1542609|NCT02650648|Drug|rIL-2|On day 0, daily from +2 through +4, day +6, and day +8, rIL-2 is administered subcutaneously at 6 x 10^5 U/m^2/day.
1542610|NCT02650635|Drug|Cyclophosphamide|Given IV
1542611|NCT02650635|Other|Laboratory Biomarker Analysis|Correlative studies
1542612|NCT02650635|Biological|Pegfilgrastim|Given SC
1542613|NCT02650635|Other|Pharmacological Study|Correlative studies
1542614|NCT02650635|Drug|TLR8 Agonist VTX-2337|Given SC
1542615|NCT02650622|Procedure|Skin Biopsy|Skin biopsy will only be performed on the proband children in the cohort 3. A small piece of skin (less than 1/8'') will be removed using a local anesthetic cream and a punch, which will then be used for culture of skin cells and other laboratory tests on metabolic function.
1542616|NCT02650609|Drug|Methylprednisolone|
1542617|NCT02650609|Drug|Placebo|
1542618|NCT02650596|Drug|GLP-1|Liraglutide were taken daily for 3 months
1542619|NCT02650596|Drug|Placebo|Placebo were taken daily for 3 months
1542620|NCT02650583|Other|Educational Intervention|Receive Enhancing Connections Program
1542621|NCT02650583|Other|Questionnaire Administration|Ancillary studies
1542623|NCT02650544|Drug|Mirtazapine|Patients in mirtazapine arm will be orally administered mirtazapine as an anti-depression therapy; along with palliative chemotherapy.
1542624|NCT02650544|Drug|Placebo|Patients in placebo arm will be orally administered placebo; along with palliative chemotherapy.
1542625|NCT02650518|Other|Short-course Antibiotics|3 days of amoxicillin/clavulanate, ciprofloxacin, or cotrimoxazole.
1542626|NCT02650518|Device|Catheter Change|Urinary catheter change once randomization is complete.
1542627|NCT02650505|Drug|LEO 43204|
1542628|NCT02650505|Drug|LEO 43204 Vehicle|
1542629|NCT02650492|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherpy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
1542630|NCT02650479|Drug|Exenatide|6 hour IV infusion (double infusion of 0.1250 mcg/kg/hour for 30 min followed by infusion rate (1X) of 0.0625 mcg/kg/hour for 5.5 hours).
1542631|NCT02650479|Drug|Placebo|6 hour IV infusion.
1542632|NCT02650479|Drug|Moxifloxacin|400 mg oral dose moxifloxacin within 1 min of start of infusion of exenatide
1542633|NCT02650479|Drug|Palonosetron|0.25 mg administered IV within 30 minutes prior to initiating the infusion of exenatide
1542704|NCT02649790|Drug|KPT-8602|
1542634|NCT02650466|Device|Nanopulse System|The Nanopulse System consists of an electrical pulse generator, a handpiece, and a detachable applicator tip at the end of the handpiece that interfaces with the treatment area on the skin. The detachable applicator tip delivers the pulses to the skin through five 3 mm long needle electrodes (27 gauge). The applied electric field, is limited to the space enclosed by the 4 outer electrodes in the applicator tip. An inert, water based gel is applied to the skin and the applicator tip before making contact between subject and applicator tip to ensure that there are no air gaps present between the electrodes through which electrical arcing could occur while pulses are being delivered to the subject. The Applicator Tips are designed for single patient use, and are sterilized prior to first use and between treatment sessions using a standard steam autoclave.
1542635|NCT02650453|Procedure|Deep venous reconstruction|PTA & stenting with/without endophlebectomy and/or arteriovenous fistula creation
1542636|NCT02650440|Procedure|Novel Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Novel (discrete) robot-assisted LT-BWST used progressive decrease in speed. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject.
1542637|NCT02650440|Procedure|Standard Protocol|All subjects performed robot-assissted LT-BWST 5 times a week for 6 weeks (30 minutes of training and 15 minutes of setup). Standard (rhythmic) robot-assisted LT-BWST used progressively increased speed each week. Both groups started the robot-assisted LT-BWST at the same speed of 1.4km/h. The body weight support started approximately at 40% of body weight for both groups and rapidly decreased each week. The guidance force was also progressively decreased for both groups so that the exoskeleton provided the least possible assistance to the subject
1542638|NCT02650427|Drug|Sitagliptin|100mg or 200mg or 600mg, daily for 3 weeks ± 7 days
1542639|NCT02650414|Biological|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB|
1542640|NCT02650401|Drug|Entrectinib|TRKA/B/C, ROS1, and ALK inhibitor
1542641|NCT02650388|Behavioral|Cognitive fuction, quality of life|To test the above score in patients undergoing TAVI
1542642|NCT02650375|Drug|Metatinib Tromethamine|Patients receive Metatinib orally 200mg once daily (QD) or 100mg twice daily (BID) until disease progression or unacceptable toxicity occurred.
1542645|NCT02650336|Drug|contrast|a substance used to enhance the contrast of structures or fluids within the body in medical imaging. It is commonly used to enhance the visibility of blood vessels and the gastrointestinal tract
1542646|NCT02650310|Device|Thermostable device|Investigators place the catheter with the loaded embryos into a plastic device at 37ºC in order to maintain the temperature
1542647|NCT02650297|Other|combined decongestive therapy|Patients in the intervention group received treatment with combined decongestive therapy and pneumatic compression pump. Patients in the control group received no treatment for lymphedema but were placed on the waiting list for combined decongestive therapy and pneumatic compression pump as soon as possible after the 8 weeks follow-up period.
1542648|NCT02650297|Device|pneumatic compression pump|Intermittent pneumatic pump or pressure therapy is not as a part of CDT, but it can be used as an adjunct method. This device intermittently and according to a specific program is air filled and emptied. The device leads the lymphatic fluid from distal to the proximal part of extremities and then to the trunk
1542649|NCT02650284|Device|Stryker Triathlon Primary Total Knee System|Total Knee Replacement
1542650|NCT02650284|Device|Restoris MCK Multicompartmental Knee System|Bicompartmental Knee Replacement
1542651|NCT02650271|Drug|Entecavir|Patients will be received entecavir (10 mg/d) after 3 days of liver resection.
1542652|NCT02650271|Drug|Lamivudine|Patients will be received lamivudine (100 mg/d) after 3 days of liver resection.
1542653|NCT02650245|Dietary Supplement|EAS Myoplex Protein Drink + 10gm lactulose|
1542654|NCT02650232|Device|SOMNOtouch device (Somnomedics)|In each arm, we will evaluate the capacity of SOMNOtouch to measure the baroreflex sensitivity compared to Finapre Nova (reference)
1542655|NCT02650232|Procedure|Orthostatic test|"For each arm we will proceed to an orthostatic test day one and day two with :
10 minutes in supine position
10 minutes in sitting position
5 minutes in standing position
5 minutes in supine position"
1542656|NCT02650232|Device|Finapres Nova device (FMS system)|
1542657|NCT02650219|Genetic|genetic analyses|
1542658|NCT02650206|Drug|Victoza (liraglutide) with dietician monitoring|Victoza (liraglutide), an FDA-approved medication, is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Subjects with this intervention will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
1542659|NCT02650206|Other|Placebo with dietician monitoring|Subjects will not receive the study drug, but will be followed by the MD and dietician throughout the study to monitor progress through 4 week period of weight maintenance and 8 week period of weight loss.
1542662|NCT02650167|Biological|Colostrum feeding|
1542663|NCT02650167|Biological|formula for preterm infants|
1542705|NCT02649764|Drug|Fludarabine|Induction and Consolidation Phase Dose of Fludarabine: 30 mg/m2 by vein over 2 hours for 4 days.
1542667|NCT02650102|Drug|Risperidone|a kind of antipsychotics
1542668|NCT02650102|Drug|Olanzapine|a kind of antipsychotics
1542669|NCT02650102|Drug|Quetiapine|a kind of antipsychotics
1542670|NCT02650102|Drug|Aripiprazole|a kind of antipsychotics
1542671|NCT02650102|Drug|Ziprasidone|a kind of antipsychotics
1542672|NCT02650089|Other|Resistance Exercise Low intensity|The 40% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
1542673|NCT02650089|Other|Resistance Exercise High intensity|The 80% one maximum repetition resistance exercise session lasted 40 minutes. Three circuits with 7 exercises, 16 repetitions were performed for each exercise, with an interval of 60 seconds between exercises and 120 seconds between circuits. The duration of repetition in the exercises was 3 seconds - 1 second in the concentric phase and 2 seconds in the eccentric phase of the movement.
1542674|NCT02650089|Other|Control|In the control session, the participants remained seated in a comfortable chair in the same environment of the resistance exercise sessions.
1542675|NCT02650076|Drug|SK-1405|
1542676|NCT02650063|Drug|DE-117|
1542677|NCT02650050|Radiation|Micropulsed laser photocoagulation|Micropulsed laser photocoagulation after 3 anti-VEGF injections
1542678|NCT02650037|Procedure|Air Test|The Air Test simply consisted in breathing room air for 5 min on arrival into the postoperative anesthesia care unit while measuring peripheral oxygen saturation by Pulse oximetry
1542681|NCT02650011|Other|Acute deterioration of liver function|development of new ascites within 4 weeks or re-emergence of ascites who have previous well controlled ascites (greater than or equal to grade 2 or 3; International ascites club criteria) development of hepatic encephalopathy development of gastrointestinal hemorrhage development of jaundice (serum bilirubin greater than or equal to 3mg/dl) development of bacterial infection
1542682|NCT02649998|Drug|Furosemide|Furosemide is the most commonly used medication for treatment of heart failure. It causes a direct vasodilator effect shortly after administration, followed by diuresis induction. However, furosemide also activates both the sympathetic and the renin angiotensin systems, causing a rise in peripheral resistance.
1542683|NCT02649998|Drug|Isosorbide Dinitrate|Isosorbide dinitrate is a vasodilator which is also well-known for treating acute decompensated heart failure. It induces acute venodilatation at low dose and arteries dilation when gradually increasing the dose. The effect peaks 5 min after administration.
1542684|NCT02649985|Drug|[F-18]PBR06|PET radiopharmaceutical
1542685|NCT02649972|Drug|Cobimetinib|Patients in this study will receive single-agent Cobimetinib 60mg oral daily for days 1-21 of each 28 day cycle. The rationale for single agent therapy, is the evidence for robust and sustained response to BRAF inhibitor monotherapy in histiocytic disorders harboring the BRAFV600E mutation.
1542686|NCT02649959|Drug|CM-AT|Single unit does powder of active substance (CM-AT) administered 3 times per day
1542687|NCT02649933|Device|Watch PAT 200|screening of OSA with Watch PAT 200
1542688|NCT02649920|Device|Cervical ripening balloon|
1542689|NCT02649920|Drug|Dinoprostone|
1542690|NCT02649907|Dietary Supplement|nutritional stimulation via different testmeals|nutritional stimulation of hormonal response through different testmeals
1542691|NCT02649907|Other|Nutritional counseling|nutritional counseling for healthy eating behaviour
1542692|NCT02649907|Dietary Supplement|formula diet|formula diet to help weight loss
1542693|NCT02649894|Device|Indwelling Pleural Catheter|
1542694|NCT02649881|Procedure|The heart subject will undergo OCT|
1542701|NCT02649842|Device|TECNIS Toric Models ZCT450, ZCT525 or ZCT600|Approved toric intraocular lens
1542702|NCT02649829|Biological|dendritic cell vaccination plus chemotherapy|"A. Chemoimmunotherapy:
four 3-weekly cycles of platinum/pemetrexed; on day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as intravenous (IV) infusion over 10 minutes followed 30 minutes later by cisplatin 75 mg/m2 as IV over approximately 2 hours.
four intradermal vaccinations with 8-10 x 10e6 autologous WT1 mRNA-loaded DCs; at day 14+/- 3 days after the start of each chemotherapy cycle.
B. Surgery: pleurectomy/decortication; in case of resectable disease, 4-6 weeks after start of the last chemotherapy cycle."
1542703|NCT02649803|Behavioral|asthma APP|Subjects diagnosed as pediatric asthma at Shanghai Children's Medical Center will be consecutively screened and eligible patients will be recruited (enrolment visit, V1). The subject will be assigned to the nearest community hospital or Shanghai Children's Medical Center, whichever is nearer to the subject's home, for their future onsite visits (V2-V5). The patient's caregiver will be instructed to install the asthma APP at their smart phone and learn how to use this APP.
1542706|NCT02649764|Drug|Cytarabine|Induction and Consolidation Phase Dose of Cytarabine: 1.0 gram/m2 continuous infusion daily for 4 days.
1542707|NCT02649764|Drug|LY2606368|"Induction Phase Starting Dose of LY2606368: 20 mg/m2 by vein daily for 3 days (days 1, 3, 4).
Consolidation Phase Starting Dose of LY2606368: Maximum tolerated dose (MTD) from Induction Phase."
1542708|NCT02649751|Drug|Roscovitine|Roscovitine is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors that preferentially inhibit multiple enzyme targets including CDK2, CDK7 and CDK9. Seliciclib is a 2,6,9-substituted purine analog.
1542709|NCT02649751|Drug|Placebo|The placebo treatment is lactose capsule.
1542710|NCT02649738|Procedure|Corneal tissue inlay|A mid-stomal pocket will be made into the cornea with a femtosecond laser (Intralase). A small disc of preserved corneal tissue will then be placed into the pocket
1542711|NCT02649725|Behavioral|patient's satisfaction|Questionnaire based measurement.
1542712|NCT02649712|Device|biliary stent|Self-expandable biliary nitinol alloys stent
1542713|NCT02649699|Other|3D MRI Scans|Patients will receive additional MRI scans before commencing their radiation treatment, at 3-4 months, 6 months and 12 months post RT as well as at recurrence or suspected recurrence.
1542716|NCT02649673|Drug|LCL161|
1542717|NCT02649673|Drug|Topotecan|
1542718|NCT02649647|Procedure|Conventional resection|The conventional technique requests an excision of at least 10 cm of bowel proximal to the tumor, and the sigmoid colon is anastomosed to the rectum or anus.
1542719|NCT02649647|Procedure|Proximally extended resection|The modified technique requests an excision of the whole sigmoid colon and rectum proximal to the tumor, and the descending colon is anastomosed to the rectum or anus.
1542720|NCT02649634|Behavioral|Motivational Interviewing|The semi-structured MI protocol was a 45-60 minute intervention based on general MI principles and guidelines, MI strategies specific to health care practice, and MI principles for obesity treatment. The MI protocol included the following components: (1) eliciting concerns about weight; (2) exploring ambivalence; (3) assessing importance and confidence for change; (4) writing a decisional balance; (5) bolstering self-efficacy; (6) looking towards the future; and (8) eliciting ideas for possible changes participant could make to work towards weight loss. Although there was slight variation, the protocol for both MI sessions consisted of similar components.
1542721|NCT02649634|Behavioral|Attention Control|The attention control interview was a semi-structured interview ascertaining information relevant to health history, weight history, diet history, dietary and physical activity habits. The majority of questions for the control interviews were drawn from the Behavioural Weight Loss Program intake application. It was designed to be structurally equivalent to the MI session in terms of length of session, timing of sessions, and treatment modality. The goal of the attention-control interview was to provide a pseudo-intervention that controlled for factors common to attending treatment (e.g., attending treatment sessions, having personal contact with a therapist, discussing weight-related issues).
1542722|NCT02649621|Biological|Amniotic Membrane Extract Eye Drop (AMEED)|Use of use Amniotic Membrane Extract Eye Drop (AMEED) on in vivo cultured limbal stem cells in the treatment of unilateral corneal stem cell damage.
1542723|NCT02649608|Drug|Lu AE04621|Low dose of Lu AE04621 on Day 1 followed by a medium dose of Lu AE04621 on Day 2, and a a high dose of Lu AE04621 on Day 3. If deemed appropriate the dosing period may be extended to 4 days. Oral solution, single dose
1542724|NCT02649595|Other|Red Cross Respite care|See detailed description.
1542725|NCT02649582|Biological|Dendritic cell vaccine plus temozolomide chemotherapy|"When eligible after total or subtotal resection (as assessed by neurosurgeon and post-operative brain MRI):
Leukocyte apheresis ± 1 week before chemoradiation (for DC vaccine production)
Chemoradiation (standard treatment): 2 Gy once daily 5 days/week for 6 weeks with 75 mg/m² temozolomide daily from the first until the last day of radiotherapy (no longer than 49 days in total)
Induction immunotherapy: intradermal vaccination with autologous WT1 mRNA-loaded DCs weekly for 3 weeks, starting 1 week after radiotherapy
Chemo-immunotherapy: 150-200 mg/m²/d temozolomide days 1-5 every 28 days (max. 12 months) starting 1 week after induction immunotherapy + DC on day 21 of every 28-day cycle"
1542726|NCT02649569|Device|Monitoring Device|Wear activity monitor
1542727|NCT02649569|Other|Quality-of-Life Assessment|Complete the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30
1542728|NCT02649556|Other|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks.
1542729|NCT02649556|Other|CC|"Ad libitum use of CC in an ambulatory setting for 26 weeks.
The subject's own preferred brands of CC (no brand restriction) continue to be used as the reference product."
1542730|NCT02649543|Procedure|Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. Subcutaneous tissue was approximated with Polyglycolic Acid 3-0, and the skin is sutured using Polypropylene 2-0.
1542731|NCT02649543|Procedure|Vacuum Assisted Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia is closed with a continuous Polyglycolic Acid 0 suture. The VAC® system is then used, with change of dressings every 48 hrs. The wound is closed using Polypropylene 2-0 only after healthy granulation tissue and no signs of infection are present.
1542732|NCT02649543|Procedure|Delayed Primary Closure|A double antibiotic scheme with a cephalosporin and metronidazole is used as prophylaxis, and the fascia was closed with a continuous Polyglycolic Acid 0 suture. The wound is left open for at least 7 days, after which closure with Polypropylene 2-0 takes place if considered suitable by a board certified surgeon.
1542733|NCT02649530|Drug|WNT974|
1542734|NCT02649517|Procedure|Endomyocardial biopsy|Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
1542735|NCT02649504|Drug|Rituximab|Rituximab will be given at the standard dose of 375mg/m2 on days 1, 8, 15, 22 of the study
1542736|NCT02649504|Drug|Dexamethasone|Dexamethasone will be given at dose 40 mg/day on days 1-4, 15-18, and 29-32 (+/- 3 days) of the study.
1542737|NCT02649504|Drug|Mycophenolate mofetil|Patients allocated to the active drug arm will be given Mycophenolate mofetil starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
1542738|NCT02649504|Drug|Placebo|Patients allocated to the placebo arm will be given placebo starting on day 33, 500 mg twice daily for the first week and then escalation to 1000 mg twice daily for 24 weeks.
1542739|NCT02649491|Other|Cohort Observation|Study participation will be offered to women, newly diagnosed with a gynecological malignancy who are due to be treated with pelvic radiotherapy.
1542740|NCT02649478|Drug|Fluticasone / Salmeterol|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Vectura LOMI inhaler device
1542741|NCT02649478|Drug|Placebo|
1542742|NCT02649478|Drug|Advair Diskus 100/50|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate administered via the Diskus inhaler device)
1542743|NCT02649465|Drug|Tofogliflozin|The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks
1542744|NCT02649465|Drug|Glimepiride|Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
1542745|NCT02649452|Other|vibration|vibration will be given using whole body vibration machine. The subject will place both palms on top of the vibration platform with their knee supported on the ground. They need to apply as much pressure on the vibration platform by using their body weight. The whole body vibration machine will be set at the frequency of 30 Hz and the amplitude of 5 mm. They need to hold that position for 1 minute for 3 sets with 1 minute rest in between. The researcher will immediately stop this if the subjects feel dizziness and discomfort
1542750|NCT02649413|Drug|Prednisone|Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
1542751|NCT02649387|Drug|Ibrutinib|Given PO
1542752|NCT02649387|Other|Laboratory Biomarker Analysis|Correlative studies
1542753|NCT02649374|Behavioral|Dietary, Exercise and lifestyle modifications|Women without GDM will receive advise on diet, exercise and lifestyle modifications similar to what is advised to women with GDM
1542754|NCT02649361|Drug|Anlotinib|Anlotinib p.o. qd
1542755|NCT02649361|Drug|Placebo|Placebo p.o. qd
1542756|NCT02649348|Other|prehabilitation|Gastric Cancer Patients With Metabolic Syndrome will do preoperative exercise and to bind abdominal binder over 5 days before operation.
1542757|NCT02649335|Drug|Propranolol|Propranolol will be started at a dose of 40 mg and will be titrated based on pulse rate with target of 55-60 beats per minute or 20-25% reduction in heart rate and maximum tolerated dose.If any patients develop intolerable side effects, they will be withdrawn from the study
1542758|NCT02649335|Procedure|Endoscopic variceal ligation (EVL)|Patients in EVL group will undergo regular sessions of UGIE with EVL till variceal eradication every 2- 4 weekly followed by 3 monthly for initial 6 months and 6 monthly in rest of the study period. If any patient develop acute variceal hemorrhage on follow up , will be treated inpatient with standard medical therapy(SMT) .
1542759|NCT02649322|Device|J-Tip|"After sterile preparation, the J-tip injector will be placed on the skin at the selected site of the regional block needle introduction. Firm pressure will be placed with the J-tip injector on the site for the chosen block, the safety ring slid down, the trigger pressed and the tip held firmly on the skin for three seconds. One quarter of a milliliter of one percent lidocaine will be injected with the characteristic pop and hissing sounds inherent to the J-tip injector."
1542760|NCT02649322|Device|Syringe and 25 gauge needle|The same initial timeout and sterile prep procedure will be followed for the use of local syringe and 25 gauge needle injection of 1% lidocaine ninety seconds prior to introduction of the regional block needle.
1542761|NCT02649309|Procedure|RIPre|Preconditioning 200 mmHg x 5 minutes before procedure
1542762|NCT02649309|Procedure|Sham-Pre|Sham 10 mmHg x 5 minutes before procedure
1542763|NCT02649309|Procedure|RIPost|Postconditioning 200 mmHg x 5 minutes after procedure
1542764|NCT02649309|Procedure|Sham-Post|Sham 10 mmHg x 5 minutes after procedure
1542765|NCT02649296|Other|Skanlab bodywave|The intervention will be done twice a week
1542766|NCT02649283|Device|OrbiSymm device|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, with the OrbiSymm device, that requires reduction of at least 150grams.
1542767|NCT02649283|Procedure|Breast symmetrisation|Breast symmetrisation following unilateral mastectomy and referred to contralateral symmetrisation procedure, without the OrbiSymm System, that requires reduction of at least 150grams.
1542768|NCT02649270|Biological|T1h|Given T1h for different groups by vein to evaluate safety and tolerability;Collecting blood samples for pharmacokinetics and pharmacodynamics after administration.
1542769|NCT02649257|Procedure|cataract surgery|
1542770|NCT02649257|Device|intraocular lens (MC 6125 AS)|
1542771|NCT02649257|Device|capsular tension ring (CTR 13/11)|
1542772|NCT02649244|Behavioral|The Family Caregiver Training Program|The intervention consisted of a two-hour PowerPoint® presentation throughout three modules (i.e., communication, eating/feeding, and nutrition; transferring and toileting; and dressing, bathing, and grooming). Each module was followed by a hands-on demonstration and practice session, including how to properly position and feed an adult, transfer from a seated position to another seated position, and a case study on modifications and assistance to provide during dressing and grooming.
1542773|NCT02649231|Drug|Ketamine|0.8 mg/kg ketamine
1542774|NCT02649231|Drug|Placebo|0.9% saline
1542775|NCT02649231|Behavioral|Psychological Therapy|Manualised relapse prevention based CBT
1542776|NCT02649231|Behavioral|Alcohol Education|Simple education about alcohol effects
1542778|NCT02649205|Other|Observational study: Supplemented protein-restricted diet|Observational study: Supplemented protein-restricted diet
1542779|NCT02649192|Biological|Influenza virus vaccine|Children will have the first influenza virus vaccine dose (dose 1) administered on day 0 of the trial, and the second dose (dose 2) administered 28 days later.
1542780|NCT02649192|Dietary Supplement|Vitamins A and D|The chewable gummy contains either Vitamin A (20,000 International Units) and Vitamin D3 (2,000 International Units), which should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
1542781|NCT02649192|Other|Placebo|The chewable gummy matched placebo will be formulated with gelatin base and tangerine oil and match the Vitamin A and D in shape, taste, texture, and appearance. Gummies should be fully chewed under supervision of study staff with documentation in the participant's research record and eMAR (electronic medical administration record). The chewable gummy should be administered prior to receiving influenza virus vaccination.
1542782|NCT02649179|Drug|Ropivacaine|All wounds were infiltrated with 0.75% ropivacaine 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
1542783|NCT02649179|Drug|0.9% saline|All wounds were infiltrated with 0.9% saline 14ml at port sites before wound closure(6ml for epigastric port ,6ml for umbilical port ,and 4ml for working port) . The study drugs will be applied to the skin, subcutis, fascia, and parietal peritoneum through the port sites at the end of surgery.
1542786|NCT02649153|Drug|smoked plum|Patients will receive smoked plum (3 piece each time, three times per day) starting in the first day after resection until flatus
1542787|NCT02649153|Drug|gum chewing|Patients will receive gum chewing (three times per day) in the first day after resection until flatus.
1542788|NCT02649140|Dietary Supplement|Vinegar group|Each participant in vinegar group drink 15ml vinegar(Ninghuafu,Sanxi,China)after dinner at noon and evening respectively for a period of four weeks.
1542789|NCT02649127|Behavioral|imaginal therapy|imaginal exercise of Prolonged Exposure therapy
1542790|NCT02649127|Behavioral|exercise|aerobic training at a frequency of a minimum of 3 sessions per week, at vigorous intensity [i. e., >60% of oxygen uptake reserve (VO2R)], and a time of 20-25 minutes each bout of training
1542791|NCT02649127|Behavioral|self-care|meeting with a nurse to review and discuss publically available written materials that outline approaches for dealing with posttraumatic stress symptoms
1542792|NCT02649114|Behavioral|Cognitive-Behavioural Therapy|
1542793|NCT02649114|Behavioral|Compassion-Focused Therapy|
1542794|NCT02649101|Drug|Thalidomide|Thalidomide tablet 100mg qn po.
1542795|NCT02649101|Drug|Physician's choice chemotherapy|Investigators will declare no constraint of regimens.
1542796|NCT02649088|Device|Microscan|It allows to look at sublingual microcirculation
1542797|NCT02649088|Device|NIRS from Hutchinson|It allows to monitor tissue oxygen saturation
1542798|NCT02649075|Other|Serum-derived Bovine Immunoglobulin / Protein Isolate|Serum-derived bovine immunoglobulin protein isolate (SBI) is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients. Two packets (each packet contains 5 g of SBI) BID.
1542799|NCT02649075|Other|Placebo|Matching placebo with control hydrolyzed gelatin protein. Two packets BID.
1542800|NCT02649062|Biological|NGM282|
1542801|NCT02649062|Other|Placebo|
1542802|NCT02649049|Other|there is no intervention|
1542803|NCT02649010|Device|Enlite 3 Sensor|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the arm and used with the 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 12 months.
1542804|NCT02648997|Drug|Nivolumab|
1542805|NCT02648984|Other|The intervention is performing an exercise test|Patients and controls will undergo a bicycle stress echocardiography and a cardiopulmonary exercise test
1542806|NCT02648971|Procedure|Single Portal Knee Arthroscopy|Patients in Group 1 will undergo knee arthroscopy using a single portal.
1542807|NCT02648971|Procedure|Two Portal Knee Arthroscopy|Patients in Group 2 will undergo knee arthroscopy using two portals.
1542808|NCT02648958|Drug|Dexmedetomidine|The dexmedetomidine group received the dexmedetomidine infusion at a rate of 0.4mg/kg/h after a loading dose of 0.5mg/kg for 10 minutes.
1542809|NCT02648958|Drug|normal saline|The control group received the normal saline infusion
1542909|NCT02648308|Behavioral|Obesity Management Workshop|Workshop provided to first year medical residents to improve confidence and skill when conducting weight management visits with patients
1542911|NCT02648282|Drug|Cyclophosphamide|200 mg/m2 is to be administered as a 30 minute IV infusion one day prior to GVAX for a total of 8 doses.
1542810|NCT02648945|Other|Exercise|first, Verbal Memory task was completed by each participant. Participant then started walking on the treadmill at either a speed of 3.0 mph (4.8 km/h) for sedentary individuals or 3.5 mph (5.6 km/h) for active individuals with grade 0% (Hanson, 1984). This was followed by an increase in grade of 2% for every 2 mins with the speed remaining constant until targeted HR was reached. A heart rate (HR) monitor (POLAR®) was used to measure HR throughout the test and rating of perceived exertion (RPE) was done at the end of every 2 min stage. Exercise was stopped as soon as participant reaches targeted HR or requests to stop because of fatigue or any discomfort. Participant was then given time to cool down until HR reached or fell below 120 bpm and was allowed to take a break for approximately 1 min before proceeding with the second set of Verbal Memory Task. Upon completing the memory test, the participant was allowed to leave
1542811|NCT02648932|Biological|Haplo-Cord Transplant|For conditioning regimens, haplo-identical grafts will be selected by the Miltenyi Device
1542812|NCT02648932|Procedure|Matched Unrelated Donor Transplant|
1542813|NCT02648919|Drug|Noni extract|Intervention will be administered on an outpatient basis.Six bottles containing 60 capsules will be dispensed to all participants upon enrollment. Then 12 bottles (at 30-day visit) and 18 bottles (at 3, 6 and 9 month visits) will be dispensed to all participants.
1542814|NCT02648906|Drug|Choline alfoscerate|
1542815|NCT02648906|Drug|Placebo|
1542816|NCT02648893|Other|Multiple biofortified food crops basket (MBFC-Exp)|Four biofortified food crops will be consumed by children (and potentially their lactating mothers) three times per day, six days per week, for 9 months.
1542817|NCT02648893|Other|Commercially available four food crops (MBFC-C)|The Commercially available food crops arm will consume four commercially available food crops three times per day, six days per week, for 9 months.
1542818|NCT02648880|Behavioral|Exercise program|"Individual exercise sessions in this program implement a whole body approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises. Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors. Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation."
1542819|NCT02648880|Other|Standard Care|The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition. These services are provided by their oncology team.
1542820|NCT02648867|Device|Continuous Maternal Feedback|The PushCoach device consists of a modification of the standard fetal scalp electrode and a separate apparatus designed to detect movement of the fetal head by detecting movement of an FSE. The PushCoach will be attached to the patient by an adhesive pad over the sacrum and extend between the patient's legs approximately 2-3 inches from the vaginal introitus. It assesses the movement of the FSE attached to the fetal scalp during pushing. The amount of fetal movement will be measured and recorded. The PushCoach device is connected to a laptop computer which will provide optical and auditory feedback to the patient about descent of the fetal head with maternal expulsive efforts.
1542821|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (fasting condition)
1542822|NCT02648854|Drug|CKD-395 0.5(Lobeglitazone)/1000(Metformin)mg 1T|administered CKD-395 0.5/1000mg 1T to oral (High fat meal fed condition)
1542823|NCT02648841|Radiation|Adjuvant Concurrent Chemo-radiotherapy|Adjuvant concurrent chemo-radiotherapy will be given to the patients in the Experimental group after 4-6 cycles of SOX chemotherapy. Total dose of 45Gy is delivered by IMRT Radiotherapy technique. The concurrent chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral.
1542824|NCT02648841|Drug|Adjuvant chemotherapy for active comparator group|8 cycles of SOX adjuvant chemotherapy will be given to the patients in the active comparator group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
1542825|NCT02648841|Drug|Adjuvant chemotherapy for experimental group|6 cycles of SOX adjuvant chemotherapy will be given to the patients in the experimental group. The SOX chemotherapy regimen is as follow: S-1 40-60mg Bid, Oral, D1-14, Q21D; Oxaliplatin 130mg/m2, ivgtt, D1, Q21d.
1542826|NCT02648828|Other|Clinical deterioration|Patients at risk of clinical deterioration
1542827|NCT02648815|Procedure|Percutaneous catheter drainage|Depending on the operator experience, tandem trocar technique or Seldinger technique can be used. If the Seldinger technique is used, then the catheter tract should be sequentially dilated over a guidewire. Access routes that avoid crossing the bowel and other intervening organs, or major mesenteric, peripancreatic, or retroperitoneal blood vessels are selected to minimize the risk of bacterial contamination and hemorrhage. Successful percutaneous treatment of necrotic collections of the pancreas depends on several important factors. Catheters often need to remain in place for several weeks and sometimes months; hence, close follow-up is required.
1542828|NCT02648815|Procedure|Abdominal paracentesis evacuation|Evacuation of peritoneal ascitic fluid using percutaneous catheters
1542831|NCT02648776|Drug|Exposure to sedative-hypnotic drugs|These patients will have been prescribed a sedative-hypnotic drug for at least one week prior to enrollment.
1542832|NCT02648750|Behavioral|Bridges self-management programme|The Bridges self-management programme is based on self-efficacy principles. It includes a Bridges stroke workbook consisting of stroke survivors' experiences and strategies, with space to record and reflect on personal goals and achievements, which the practitioner will work through with the participant. The practitioner will also used strategies based on key principles of self-management during interactions with patients.
1542833|NCT02648737|Behavioral|Cognitive Behavioural Therapy (CBT)|Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch & Craske, 2009; Craske, 2010).
1542834|NCT02648737|Other|Clinical monitoring|Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
1542836|NCT02648711|Drug|CRLX101|infusion CRLX101 weekly
1542837|NCT02648711|Drug|Bevacizumab|infusion weekly CRLX101 + bevacizumab biweekly
1542838|NCT02648711|Drug|mFOLFOX6|infusion weekly CRLX101 for 3 or every 4 weeks and in combination with bi-weekly mFOLFOX6
1542839|NCT02648698|Drug|antibiotics|Levofloxacin Tab and Tinidazole Tab are combined in the experimental group
1542840|NCT02648698|Drug|placebo|Vitamin c is used as a placebo
1542841|NCT02648672|Drug|BPN14770|BPN14770 is an investigational new drug being developed for the treatment of Alzheimer's disease and other cognitive disorders. BPN14770 is a small molecule, subtype selective, negative allosteric modulator of phosphodiesterase 4D.
1542842|NCT02648672|Drug|Placebo|
1542843|NCT02648659|Drug|Ilaprazole|Ilaprazole 10mg 1tablet qid(4 times/day)
1542844|NCT02648659|Drug|Amoxicillin|Amoxicillin 500mg 1capsule qid(4times/day)
1542845|NCT02648659|Drug|Clarithromycin|Clarithromycin 500mg 1tablet bid(2times/day)
1542846|NCT02648659|Drug|Metronidazole|Metronidazole 250mg 2tablets tid(3times/day)
1542848|NCT02648633|Radiation|Stereotactic Radiosurgery|Subjects will receive a single large dose of radiation to one or more lesions.
1542849|NCT02648633|Drug|Nivolumab|3 mg/kg of nivolumab will be administered through IV infusion every two weeks following stereotactic radiosurgery.
1542850|NCT02648633|Drug|Valproate|Subjects will begin regimen of valproate prior to radiosurgery and continue to receive therapy concurrently with nivolumab. Subjects will receive valproate daily with a target serum level of 75-100 μg/ml.
1542851|NCT02648620|Device|SurVeil Drug Coated Balloon|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
1542852|NCT02648620|Procedure|Angioplasty|Angioplasty procedure with the SurModics SurVeil Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (Paclitaxel-coated PTA Catheter)
1542854|NCT02648594|Device|Hook wire CT guided|The intervention consist to place a CT-guided hook wire in lung patient
1542855|NCT02648581|Drug|Subcutaneous Ustekinumab|Injections of ustekinumab at 90 mg at week 0, week 4 and week 16. Patients in treatment failure at week 24 will terminate the study. Responder patients at week 24 will receive additional 2 injections of ustekinumab at week 28 and week 40 with a final evaluation at week 52.
1542856|NCT02648568|Behavioral|Hypnosis plus relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles followed by an induction of hypnosis based on the preferential channel of each patient and, during trance, recommendation to assimilter the bed room and bed to a safe place
1542857|NCT02648568|Behavioral|Relaxation|The patient will have 20 min of Jacobson 's type relaxation, with sequential contraction and relaxation of limb muscles
1542858|NCT02648555|Behavioral|Daily walking|Participants will be instructed to walk briskly for >40 minutes, 7 days a week.
1542859|NCT02648555|Behavioral|Dietary recommendations|"Participants will be instructed to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting at least one week before embryo transfer and continuing until delivery. They will be also recommended to avoid high-glycemic index meals (high-carbohydrate, low-fiber), such as snacks, candies, fiber-free juices, coconut water, and sugar-sweetened beverages, particularly carbonated soft drinks and sport drinks.
Patients suffering from nausea usually do not tolerate solid food. As a result, fiber-free juices and sugar-sweetened beverages account of most of their caloric intake, which may cause non-adherence to the protocol. Women with nausea or vomiting will be treated with ondansetron."
1542860|NCT02648542|Other|Compensatory auditory stimulation|Compensating for peripheral hearing loss by adjusting sound levels based on individual audiogram.
1542861|NCT02648542|Device|transcranial direct current stimulation|Low-current electrical brain stimulation
1542862|NCT02648542|Other|Combined CAS and tDCS|Combined auditory and electrical stimulation
1542863|NCT02648542|Other|Sham stimulation|Sham stimulation
1542864|NCT02648529|Procedure|MRI|"Patients are investigated with the following sequences:
High-resolution 3D T1-weighted anatomical MRI.
DTI with 48 directions (to examine white matter)"
1542865|NCT02648529|Procedure|functional MRI (fMRI)|"fMRI investigations will be focused on :
language: investigation on possible atypical language networks in children with epilepsy. The fMRI task is a silent verb generation.
Social cognition: investigations on social cognition skills
Memory :
Declarative memory: investigations on the pattern of activations in the brain associated with successful memory formation and changes from childhood to adolescence
Working memory: A verbal and a spatial working memory task has been chosen, and is an adaptation of two published cross-sectional studies of working memory from Gabrieli and Sowell groups."
1542866|NCT02648529|Behavioral|neuropsychological assessment|Patients undergo a repeated annual neuropsychological assessment over the five years of their participation in the project.
1542867|NCT02648516|Combination Product|Conventional plus AAIT|Participants will receive ART and taken i.v., at a dose of 2-3*10E8 MNCs/kg body at baseline, week 1 and 3.
1542868|NCT02648503|Drug|Deep neuromuscular block|Using rocuronium and reversal with sugammadex
1542869|NCT02648503|Drug|Moderate neuromuscular block|Using rocuronium and reversal with neostigmine (1 to 2 mg) and atropine (0.5 to 1 mg)
1542870|NCT02648490|Drug|HLX07|recombinant human anti-EGFR monoclonal antibody against cancers
1542871|NCT02648490|Drug|Acetaminophen|Acetaminophen 500 mg PO 30 minutes before the infusion of HLX07.
1542872|NCT02648490|Drug|dexamethasone|dexamethasone 10 mg intravenous infusion for 10 minutes before the infusion of HLX07.
1542873|NCT02648490|Drug|diphenhydramine|diphenhydramine 30 mg intravenous infusion for 10 minutes before the infusion of HLX07.
1542874|NCT02648490|Drug|5-HT3 inhibitor|If the patient experience grade 2 or 3 nausea and vomiting during the first infusion of HLX07, the addition of 5-HT3 inhibitor may be included in the premedication before subsequent infusions.
1542875|NCT02648477|Drug|Anastrozole|Given PO
1542876|NCT02648477|Drug|Doxorubicin Hydrochloride|Given IV
1542877|NCT02648477|Drug|Exemestane|Given PO
1542878|NCT02648477|Other|Laboratory Biomarker Analysis|Correlative studies
1542879|NCT02648477|Drug|Letrozole|Given PO
1542880|NCT02648477|Biological|Pembrolizumab|Given IV
1542881|NCT02648464|Drug|Hydroxychloroquine|
1542882|NCT02648464|Drug|Placebo|
1542883|NCT02648451|Dietary Supplement|AYMES ROME|AYMES Rome is a powder, designed to be mixed with 250 ml water to make up a juice style ONS. When made up AYMES Rome provides 300 kcal (1 kcal / ml) and 10.7 g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
1542884|NCT02648438|Drug|AZD7594 Solution for infusion (150 μg intravenous formulation)|Solution for infusion 0.01 mg/ml; AZD7594 150 μg IV
1542885|NCT02648438|Drug|AZD7594 Oral suspension (1200 μg oral formulation)|0.1 - 10 mg/g oral solution; AZD7594 1200 μg oral
1542886|NCT02648438|Drug|AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)|Inhalation powder, hard capsules 400 μg Monodose inhaler; AZD7594 400 μg by dry powder inhaler (DPI) Device 1 (Monodose inhaler)
1542887|NCT02648438|Drug|AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)|Inhalation powder, multiple-dose dry powder inhaler (DPI) 400 μg; AZD7594 400 μg by DPI Device 2 (multiple-dose DPI)
1542888|NCT02648438|Drug|AZD7594 Pressurized inhalation suspension (400 μg) by pMDI|Inhalation suspension 200 μg; AZD7594 400 μg by pressurized metered-dose inhaler (pMDI); 2 puffs x 200 μg = 400 μg
1542889|NCT02648425|Drug|ASLAN001|ASLAN001 400mg BID daily; ASLAN001 500mg BID daily; or ASLAN001 300mg BID daily
1542890|NCT02648425|Drug|cisplatin + capecitabine|Cisplatin 80 mg/m2 IV infusion and capecitabine 1,000 mg/m2 orally BID for 14 days every 3 weeks
1542891|NCT02648425|Drug|cisplatin + 5-fluorouracil (or+ Leucovorin)|"Cisplatin 80 mg/m2 IV infusion and 5-fluorouracil 800 mg/m2/day IV infusion for 5 days every 3 weeks;
Or
Cisplatin 35 mg/m2 24-hour infusion for day 1 and day 8, 5-fluorouracil 2,000 mg/m2 and Leucovorin 300mg/m2 24-hour infusion for day 1, day 8 and day 15 every 4 weeks."
1542892|NCT02648412|Drug|ketamine|bolus 1 mg/kg
1542893|NCT02648412|Procedure|Tetanic stimulations of incremental intensities|10-20-30-40-60 milliamps on the patient's left forearm
1542894|NCT02648399|Procedure|surgery：BCND（bilateral central lymph node dissection）|
1542895|NCT02648399|Procedure|surgery：UCND（unilateral central lymph node dissection）|
1542896|NCT02648386|Procedure|Laparoscopic surgery|Completely resected rectal tumor.
1542897|NCT02648386|Device|NeuroRegen scaffold transplantation|After completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold to the nerve.
1542898|NCT02648386|Biological|NeuroRegen scaffold/BMMCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million bone marrow mononuclear cells to the nerve.
1542899|NCT02648386|Biological|NeuroRegen scaffold/HUC-MSCs transplantation|Completely resected rectal tumor, exposed pelvic autonomic nerves, and then transplanted NeuroRegen scaffold loaded with 5 million human umbilical cord mesenchymal cells to the nerve.
1542900|NCT02648373|Behavioral|Patient Education|An educational video was watched based on Consumer Reports Choosing Wisely patient education supporting the recommendation that imaging is not helpful early for low back pain and the best strategy is to remain as active as possible. Key themes were discussed with a physical therapist and the patient's questions were answered.
1542901|NCT02648373|Other|Control|Patients receive no additional intervention. They will begin physical therapy and receive care at the therapist's discretion.
1542902|NCT02648360|Behavioral|Text Messaging|The content of the program will be delivered via 3 weekly text messages over a 4 month period of time.
1542903|NCT02648347|Drug|vadadustat|oral tablet
1542904|NCT02648347|Drug|darbepoetin alfa|Subcutaneous
1542905|NCT02648334|Device|IN.PACT drug coated balloon|
1542906|NCT02648334|Device|Lutonix drug coated balloon|
1542907|NCT02648321|Behavioral|Motivational Interviewing|Motivational Interviewing is a patient-centered, tailored counselling intervention for exercise, through which patients' motives to change are identified. Personal ideas and ambivalence are explored. The discrepancies between the present behavior and the patient's own future goals are amplified. The patient's intrinsic motivation for change is increased through the process.
1542908|NCT02648321|Behavioral|Health Education|General education about healthy lifestyle and diet.
1542912|NCT02648282|Drug|GVAX|2.5E8 cells of each cell line (Panc 6.03/Panc 10.05) for a total of 5E8 cells is to be administered one day after CY and pembrolizumab for a total of eight doses.
1542913|NCT02648282|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion one day prior to the GVAX pancreas vaccine for a total of 8 doses.
1542914|NCT02648282|Radiation|SBRT|Patients will receive SBRT (6.6 Gy for 5 days) with the second dose of combined immunotherapy (CY/Pembrolizumab/GVAX).
1542915|NCT02648269|Drug|SEL-110|
1542916|NCT02648269|Biological|SEL-212|
1542917|NCT02648269|Biological|SEL-037|
1542918|NCT02648256|Other|Polymerase Chain Reaction on Oropharyngeal rinse|
1542919|NCT02648243|Behavioral|Structured intervention at discharge and tailored follow up post discharge|"At discharge, pharmacist-delivered personalized intervention would include the following (30-60 minutes session): The pharmacist will perform medication reconciliation and will check the appropriateness and accuracy of discharge medications. - Other potential interventions that could be done by the pharmacist include in addition to medication initiation: dose and/or frequency optimization, changing ACEI with ARB if necessary, changing to another statin if needed, identification of inappropriate or duplicated therapy, etc.
The pharmacist will ensure that a follow-up plan for medication monitoring after discharge is communicated to the patient. The pharmacist will also provide a tailored and thorough counseling to the patient. In addition to the pharmacist delivered intervention at discharge (as described above), the study pharmacist will schedule 2 follow-up sessions (30-60 minutes each session) with the patients at 4 weeks of discharge and at 8 weeks of discharge."
1542920|NCT02648230|Device|St. Jude Medical Pressure Wire|FFR measurement will be obtained with a PW with the FFR measurement obtained by using a MC within the same subject across the same target lesion at the same time
1542921|NCT02648230|Device|ACIST Navvus Microcatheter|FFR measurement will be obtained with a MC with the FFR measurement obtained by using a PW within the same subject across the same target lesion at the same time
1542924|NCT02648204|Drug|semaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
1542925|NCT02648204|Drug|Dulaglutide|Administered subcutaneously (s.c., under the skin) once-weekly.
1542928|NCT02648178|Device|HALO|HALO manufactures e-cigarettes which will be distributed to patients. Two products, the G6 and tank model will be used.
1542929|NCT02648165|Behavioral|Attention Bias Modification|Computer based Attention Bias Modification
1542930|NCT02648165|Behavioral|Sham Attention Bias Modification|Computer based Sham Attention Bias Modification
1542931|NCT02648165|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy delivered in a group therapy setting
1542932|NCT02648152|Device|Osteoarthritis|Total Hip Arthroplasty
1542933|NCT02648139|Drug|Dentifrice|3x/day for 7 days.
1542934|NCT02648126|Procedure|Pure Red Cell Aplasia diagnostic confirmation|"Patients who meet the appropriate criteria in the selection period will be subject to Pure Red Cell Aplasia diagnostic confirmation by collecting 20 mL of blood in dialysis units.
The samples will be processed, aliquoted and transported to Bio-Manguinhos, where depart periodically (according to the volume of samples) to the reference laboratory Sce Immunologie et d'Hématologie biologiques Hôpital Saint Antoine, where the dosage of antibody will be held anti epoetin alfa"
1542935|NCT02648113|Procedure|Restrictive transfusion|Transfusions are withheld unless Hb is <= 8 g/dL, with a target Hb of 8 to 10 g /dL
1542936|NCT02648113|Procedure|Liberal transfusion|transfusions are allowed as soon as Hb <= 10 g/dL with a target of 11 g /dL
1542937|NCT02648113|Biological|red blood transfusion|
1542938|NCT02648100|Other|biomarker study|
1542939|NCT02648087|Device|With and without SDB|Screening of sleep-disordered breathing (SDB)
1542940|NCT02648074|Procedure|Bronchial challenge with allergen|Bronchial challenge is performed with D. pteronyssinus allergen.
1542941|NCT02648074|Other|Co-culture formation|Eosinophil and linear bronchial smooth muscle cell co-culture formation. Airway smooth muscle cell proliferation, eosinophil adhesion to the bronchial smooth muscle cells, the role of eosinophil integrins in the airway remodelling process is assessed in individual formed co-culture
1542944|NCT02648035|Biological|Tocilizumab|Subcutaneous Tocilizumab according to approved label.
1542945|NCT02648022|Behavioral|Brief mental health interventions and case management|The mental health practitioner (MHP) provided brief interventions and follow up sessions designed to reduce the risk factors that are barriers to successful antiviral treatment (substance use, depression, PTSD. Second, MHP provided ongoing case management services to these patients, with an emphasis on navigating the complex HCV care process, preparation for antiviral treatment, and managing the treatment process (adherence, side effects, etc). Third, the MHP also activated the patient and facilitate the medication management of depression and other psychiatric disorders when possible by collaborating with the prescribing HCV physicians.
1542946|NCT02648009|Drug|Hyperpolarized (13) Pyruvate Injection|MRI with Hyperpolarized Pyruvate (13) Injection
1542947|NCT02647996|Procedure|MRI: functional (resting state) and structural (DTI)|One hour brain MRI recording without active task for the patient, no sedation
1542948|NCT02647983|Drug|Hyperpolarized Pyruvate (13C) Injection|Hyperpolarized Pyruvate (13C) Injection is a MRI contrast agent.
1542949|NCT02647970|Behavioral|PUFA‒Cys/Met diet|Provision of food and supplements that are rich in polyunsaturated fatty acids (PUFA, n-3 and n-6) and low in the amino acids cysteine (Cys) and methionine (Met).
1542950|NCT02647970|Behavioral|SFA+Cys/Met diet|Provision of food and supplements that are rich in saturated fatty acids (SFA) and the amino acids cysteine (Cys) and methionine (Met).
1542951|NCT02647957|Procedure|Code Stroke|Apply a protocol called Code Stroke that involves the entire care chain from emergency teams outpatient specialists of Neurology, Internal Medicine, Radiology or Intensitivos Care, among other hospital areas.
1542954|NCT02647931|Behavioral|Voice therapy for Muscle Tension Dysphagia|Voice therapy for Muscle Tension Dysphagia
1542955|NCT02647918|Drug|Sotagliflozin|Single dose
1542956|NCT02647918|Drug|Sotagliflozin|2 single doses
1542957|NCT02647905|Device|Continuous Glucose Monitoring System|Accuracy and safety assessment of a continuous glucose monitoring device
1542958|NCT02647892|Drug|lidocaine|local anesthesia
1542959|NCT02647892|Drug|sodium bicarbonate|additional drug added to lidocaine
1542960|NCT02647866|Drug|KHK4083|IV Infusion
1542961|NCT02647866|Drug|Placebo|IV Infusion
1542962|NCT02647853|Drug|TAT4 Gel concentration A|
1542963|NCT02647853|Drug|TAT4 Gel concentration B|
1542964|NCT02647853|Drug|Placebo|
1542965|NCT02647840|Behavioral|voice therapy|voice therapy based on Estill Voice Model The study will provide primarily direct intervention, i.e. working directly on the voice with voice exercises based on the Estill model of voice. This will be structured and hierarchical. Participants will work through the content one-to-one with the voice specialist SLT at their level and pace, to suit their specific vocal needs, again reflecting current clinical practice. Participants may need fewer or more than four sessions to gain the required skills. Should patients need more than six session of voice therapy to recover their voice fully, final assessment for the study purposes will be taken at session 6, and voice therapy will continue as required.
1542966|NCT02647827|Other|Lifestyle management|All women will receive lifestyle management instructions at the baseline visit, before randomization. The lifestyle management involves one initial counselling session in connection with the baseline visit, which includes information about the importance of weight management, healthy diet and physical activity.
1542967|NCT02647827|Device|Acupuncture|Disposable, single-use, sterilized CE marked needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50 mm will be inserted to a depth of 15-40 mm in segmental acupuncture points located in abdominal and leg muscles, with innervations corresponding to the ovaries and the pancreas. Two sets of acupuncture points will be alternated every second treatment.
1542968|NCT02647827|Drug|Metformin|Oral metformin 500 mg three times daily, in total 1500 mg per day. To reduce gastrointestinal side-effects of metformin, the dose will be slowly escalated starting with 500 mg daily during the first week, increasing to 500 mg twice per day during the second the week, and 500 mg three times daily, morning, lunch and dinner from the third week in total 16 weeks including the 3 weeks step-up phase (i.e. 4 months).
1542969|NCT02647814|Behavioral|Salud al Día|A pilot randomized controlled trial comparing the effectiveness of a parent support intervention consisting of periodic text messages and educational support (video, collateral materials),and usual care on the healthcare engagement of LEP Latino parents during their child's first year and to examine its impact on healthcare utilization and primary care quality.
1542970|NCT02647801|Behavioral|Mindfulness intervention|"Mindfulness is practiced with a weekly computer based guided breathing meditation in which one's own breath has to be counted repetitively from 1 to 9. Participants have to press a specific button for breaths 1 to 8 and then press another button for breath 9 on a keyboard. During this practice they put on headphones and listen to a voice that guides them through breathing meditation. A click sound will occur if breath is miscounted (Levinson et al., 2014). After each computer based breathing meditation the experimenter and participants exchange meditation experiences and views. After the first mindfulness training participants in the experimental group are also able to practice mindfulness at home by listening to audio files on the mobile phone (bodyscan or breathing meditation)."
1542971|NCT02647788|Drug|Acetaminophen/Ibuprofen|After hand surgery, take Acetaminophen 650 mg/Ibuprofen 400 mg every 6 hours as needed for pain until postoperative clinic visit
1542972|NCT02647788|Drug|Acetaminophen/Codeine|After hand surgery, take Acetaminophen 300mg/Codeine 30 mg every 6 hours as needed for pain until postoperative clinic visit
1542973|NCT02647775|Procedure|multi-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
1542974|NCT02647775|Procedure|single-port VATS|Patients with thoracic surgical diseases who underwent VATS will be recruited into this study to investigate the postoperative pain , physiologic and immunologic impacts of two different approaches for minimally invasive thoracic surgery.
1542975|NCT02647762|Drug|CF101 1 mg|CF101 tablets, 1mg BID for 12 weeks
1542976|NCT02647762|Drug|CF101 2 mg|CF101 tablets, 2 mg BID for 12 weeks
1542977|NCT02647762|Drug|Placebo|Placebo tablets, 1mg BID for 12 weeks
1542978|NCT02647762|Drug|MTX|MTX 5 mg tablets, given once weekly at 10 mg/week (2 tablets) for the first 2 weeks, then 15 mg/week (3 tablets) for the next 2 weeks, then 20 mg/week (4 tablets) thereafter, for 12 weeks.
1542979|NCT02647749|Device|Cardioinsight® mapping system|
1542980|NCT02647749|Other|Conventional method without non-invasive mapping|
1542981|NCT02647736|Other|Hypertonic saline infusion|
1542982|NCT02647723|Dietary Supplement|DHA|2 dietary supplement gel capsules providing 450 mg of DHA twice daily by oral intake for 24 weeks
1542983|NCT02647723|Dietary Supplement|Sugar pill|2 dietary supplement gel capsules providing 450 mg of soybean oil twice daily by oral intake for 24 weeks
1542984|NCT02647710|Behavioral|PHAT Life Intervention|HIV Prevention behavioral health intervention
1542985|NCT02647710|Behavioral|Health Promotion Control|Behavioral health intervention control
1542986|NCT02647697|Drug|Radiprodil oral|"Active Substance: Radiprodil
Pharmaceutical Form: dry granules for oral suspension
Concentration: 30 mg
Route of Administration: oral use"
1542987|NCT02647684|Behavioral|Self-Directed Triple P|10 Week Triple P Self directed workbook
1542988|NCT02647671|Drug|Aquamin®|90 days of Aquamin
1542989|NCT02647671|Drug|Calcium Carbonate|90 days of Calcium Carbonate
1542990|NCT02647671|Drug|Placebo|90 days of placebo
1542991|NCT02647658|Behavioral|GBC+PIPT|PCP care is enhanced with a prompt referral to physical therapy (PT) that includes psychologically informed coaching directed towards education and reduced fear of movement
1542992|NCT02647658|Behavioral|GBC|Management decisions are made between PCPs and patients with the guidance of best evidence but with no specific directives
1542993|NCT02647645|Device|Transcranial direct current stimulation|Direct current stimulation
1542994|NCT02647632|Drug|Grazoprevir/Elbasvir|
1542995|NCT02647632|Drug|Sofosbuvir|
1542996|NCT02647632|Drug|Ribavirin|
1542997|NCT02647619|Drug|Xiapex|Injection of collagenase of primary dupytren cord
1542998|NCT02647619|Procedure|Needle aponeurotomy|26 G needle multiple perforation tecqnique with local anesthetic
1542999|NCT02647606|Procedure|MILS|MILS(Manual in-line stabilization) will be applied during intubation. With MILS, different kinds of laryngoscope will be evaluated in a simulated difficult airway.
1543000|NCT02647606|Device|McGrath videolaryngoscope|McGrath videolaryngoscope will be used for intubation
1543001|NCT02647606|Device|Pentax AWS videolaryngoscope|Pentax AWS videolaryngoscope will be used for intubation
1543002|NCT02647606|Device|Macintosh laryngoscope|Macintosh laryngoscope will be used for intubation
1543003|NCT02647567|Other|Caffeine Intake|The experimental group ingest 500 mg of caffeine before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
1543004|NCT02647567|Other|Placebo Intake|The control group ingest 500 mg of placebo before (60 min) aerobic exercise (procedure double blind), and perform a battery of neuropsychological and psychomotor tests. 1 min and 30 min after the exercise the subjects perform a new battery of neuropsychological and psychomotor tests.
1543005|NCT02647554|Drug|ulinastatin|ulinastatin 400,000 IU every 8 hours for 10 days
1543006|NCT02647554|Drug|Placebo|matching placebo every 8 hours for 10 days
1543007|NCT02647541|Dietary Supplement|Nutritional intervention|Consultation with a dietitian, nutritional recommendations to achieve the expected energy expenditure, with or without supplementation with enriched formulas.
1543008|NCT02647528|Device|Chromogenix Regenlite Transform Treatment|Pulse Dyed Laser - 7mm spot size 3-3.6 J/cm2
1543009|NCT02647528|Device|Chromogenix Regenlite Transform Placebo|Pulse Dyed Laser - 7mm spot size 0 J/cm2
1543011|NCT02647502|Other|Diet|Diet, standardized to the 50th percentile for macronutrients, will be provided at varied calorie levels as described.
1543017|NCT02647476|Dietary Supplement|Immunomodulating nutrition (Reconvan)|protein rich, isocaloric, no-residue diet including arginine, glutamines and omega-3 fatty acids - Reconvan, Fresenius Kabi
1543018|NCT02647476|Dietary Supplement|Standard nutrition (Peptisorb)|oligopeptide, low-fat, isocaloric, non-residue diet
1543019|NCT02647463|Behavioral|Attachment and Biobehavioral Catch-up (ABC)|
1543020|NCT02647450|Other|GIANT Completed patient|Patients identified in the GIANT clinic and who fulfill the inclusion criteria will be sent a 9 page questionnaire. Upon receipt the questionnaire will be sent to the patient's GP for validation.
1543021|NCT02647437|Drug|Levetiracetam|
1543022|NCT02647437|Drug|Placebo|
1543023|NCT02647424|Drug|Letrozole|Letrozole 2.5 mg daily from Day 2 to 6
1543024|NCT02647424|Drug|Clomiphene|After one month of washout period, clomiphene 50 mg daily from day 2 to day 6 given
1543025|NCT02647398|Behavioral|Vigorous aerobic training|Supervised vigorous aerobic training
1543026|NCT02647385|Drug|Block with lidocaine for SAM and PEC I block|"Patients could be submitted to general anesthesia or general anesthesia associated with SAM and PEC I block with lidocaine before mastectomy.
Interventions: include pain assessment, inflammatory response and opioid consumption."
1543027|NCT02647372|Procedure|Subthalamic nucleus|Surgery will be performed in 15 patients with DBS target to the subthalamic nucleus
1543028|NCT02647372|Procedure|Globus pallidus|Surgery will be performed in 15 patients with DBS target to the globus pallidus nucleus
1543029|NCT02647359|Drug|Ataluren|
1543030|NCT02647359|Drug|Placebo|
1543031|NCT02647346|Device|Daily use of podimetrics smart-foot mat|
1543032|NCT02647333|Dietary Supplement|Omega-3 Fatty Acid|Experimental: Omega-3 fatty acid In the intervention period the participants will receive a daily supplement of omega-3 fatty acids for 8 weeks, where the dosage are 3 and 4 g/day for women and men, respectively. The omega-3 supplement is a hydrolyzed and reesterified TAG fish oil, containing 33 area percent eicosapentaenoic acid and 22 area percent docosahexaenoic acid.
1543033|NCT02647333|Dietary Supplement|Omega-6 Fatty Acid|Experimental: Omega-6 fatty acid In the intervention period the participants will receive a daily supplement of omega-6 fatty acid for 8 weeks, where the dosage are 20 and 27 g/day for women and men, respectively. The omega-6 supplement is a high-quality organic, cold pressed and filtered safflower oil, containing 68-83% linoleic acid, 5-15% saturated fatty acid, 8-21% oleic acid, 0,0-0,5% ALA and maximum 2% other fatty acids.
1543034|NCT02647320|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg
1543035|NCT02647320|Drug|DS-8500a 25mg|DS-8500a 25mg
1543036|NCT02647320|Drug|placebo|placebo to match both sitagliptin and DS-8500a
1543037|NCT02647307|Drug|DS-1040b|Single 12-hour intravenous infusion of DS-1040b (20 mg)
1543038|NCT02647294|Dietary Supplement|Maxicor|Patients with NAFLD will be randomly allocated to receive or n-3 PUFA (3,6 g/day, oral treatment) or placebo (1:1).
1543039|NCT02647294|Other|Placebo|Patients with NAFLD will be randomly allocated to receive or placebo or n-3 PUFA for 12 months (1:1).
1543042|NCT02647268|Drug|Oxytocin|Oxytocin, 10-5M solution
1543043|NCT02647268|Drug|Magnesium Sulphate|Magnesium sulphate, 3.5mM solution
1543044|NCT02647255|Procedure|Plasma Exchange (PE)|PE treatment>7 within 3weeks; Volume exchanged: 60ml/kg/course; Replacement fluid: 5% Albumin or fresh frozen plasma; PE was performed by dialysis machine (IQ-21, Asahi Japan) and plasma separator (OP- 08W, Asahi Japan)
1543045|NCT02647255|Drug|Methylprednisolone pulse|methylprednisolone 7-15mg/kg/d 3 times, Qd. or Qod
1543046|NCT02647242|Behavioral|Auto rehabilitation program of gait with Beat Health device.|The auto-rehabilitation program will consist in an outside walk, during 5 sessions of 30 minutes per week during 4 weeks with the beatHealth device, delivering the optimal rythmic auditory cueing. The device will associate an Android smartphone, hold at the belt, connected by bluetooth to a headphone and to two sensors strapped to the ankles. The patient will transfer the data collected by BeatHealth to a secured website and will complete the agenda
1543047|NCT02647229|Other|Isosmotic bowel cleansing preparation|Isosmotic Preps contain polyethylene glycol (PEG) and are osmotically balanced, high-volume, nonabsorbable, and nonfermentable electrolyte solutions.
1543048|NCT02647229|Other|Colonic Hyrdrotherapy|FDA approved method of colon cleansing using constant warm water lavage with a contained temperature and pressure controlled device administered by a trained technician
1543049|NCT02647216|Behavioral|Mindfulness Based Cognitive Therapy|Weekly MBCT sessions consist of: a) mindfulness practice including breath-focused sitting meditation, body scanning, and mindful stretching; b) review of previous weeks' homework and an overview of the current week's homework; c) barriers to completing the homework. Homework includes: a) practicing the mindfulness exercise reviewed in class using the CDs provided to each participant (guided practice of the relevant exercise); b) maintaining a calendar of pleasant events; c) mindfully engaging in activities of daily living; and d) logging practice efforts in a daily log.
1543050|NCT02647216|Behavioral|Treatment as Usual|Subjects randomized to the Treatment as Usual group will be advised to seek help from their family doctor or other sources as they normally would if they encountered symptomatic deterioration or other difficulties over the course of the study.
1543051|NCT02647203|Drug|Self-administered fluoridated dentifrices|Elderly participants will be instructed to self administer toothpastes, twice per day. Toothpastes will be provided.
1543052|NCT02647190|Drug|Erwinia Chrysanthemi asparaginase|
1543053|NCT02647177|Other|Pancreatic Cyst Aspiration|10 CC of pancreatic cyst aspiration
1543054|NCT02647151|Drug|METHYLAMINOLEVULINATE HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.
skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
1543055|NCT02647151|Drug|AMINOLEVULINIC ACID HYDROCHLORIDE|"This is an intrapatient randomized clinical trial. All patients participating in the trial will receive both, experimental and control treatment, randomization will be used to determine side (right or left for treatment). Three visits will be scheduled. In the first visit epidemiological data will be collected , Actinic Keratoses are counted and drawn in a transparent template and also a photograph of each side. In that first visit treatment the PDT will be also performed, the degree of fluorescence, the pain and the degree of immediate local reaction will be measured.
skin after PDT. In the second visit, to be held at 2 or 3 days, the delayed local reaction degree will be assessed. And in the third visit, held a month of PDT the clinical response and patient satisfaction will be assessed."
1543056|NCT02647138|Device|Marpac White Noise|The investigators will place a Marpac white noise machine in the patients room.
1543057|NCT02647125|Drug|Huachansu|Huachansu 20 ml/m2/d, intervenous infusion, once a day, 5 times per week, during the period of radiation.
1543058|NCT02647125|Radiation|thoracic radiation|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
1543059|NCT02647112|Other|Bladder EpiCheck|Urine test for the monitoring of bladder cancer recurrence
1543060|NCT02647099|Drug|Acetylsalicylic acid|
1543061|NCT02647099|Drug|Placebo|
1543062|NCT02647086|Drug|Dupilumab|
1543063|NCT02647086|Drug|Midazolam|Cytochrome P450 substrate
1543064|NCT02647086|Drug|Omeprazole|Cytochrome P450 substrate
1543065|NCT02647086|Drug|Warfarin|Cytochrome P450 substrate
1543066|NCT02647086|Drug|Caffeine|Cytochrome P450 substrate
1543067|NCT02647086|Drug|Metoprolol|Cytochrome P450 substrate
1543068|NCT02647073|Device|Canary 01 Mobile Vital Signs Monitoring Device|The prototype has several main components, including several commercially available sensors to measure heart rate, respiration, and motion data, an enclosed case containing circuitry for processing and transmitting data, and a mobile phone/system interface to store and transmit data.
1543069|NCT02647047|Procedure|Spinal analgesia|Administration of morphine 0.2 mg in subarachnoid space.
1543070|NCT02647047|Procedure|Epidural analgesia|Bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL + sufentanil 50 mcg/mL 1 mL in epidural space
1543071|NCT02647047|Procedure|Transversus Abdominis Plane block|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally
1543072|NCT02647047|Procedure|Surgical wound infiltration|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
1543073|NCT02647047|Drug|Acetaminophen|Administration of 1000 mg of acetaminophen 40 minutes before ending of surgery followed by intravenous administration of 1000 mg every 8 hours
1543074|NCT02647047|Drug|Ketorolac|Administration of a non-steroidal antinflammatory drug (ketorolac 30 mg) as a rescue therapy
1543075|NCT02647047|Drug|Ropivacaine|Epidural bolus of ropivacaine 0.2% 4-6 mL followed by continuous epidural infusion of ropivacaine 0.2% 99 mL
1543076|NCT02647047|Drug|Sufentanil|Epidural continuous epidural infusion of sufentanil 50 mcg/mL 1 mL
1543077|NCT02647047|Drug|Ropivacaine|Administration of ropivacaine 0.375% 20 mL in the plane between the internal oblique and the transversus abdominis muscles, bilaterally to obtain the transversus abdominis plane block
1543078|NCT02647047|Drug|Ropivacaine|Infiltration of the surgical wound with ropivacaine 0.75% 10- 20 mL
1543079|NCT02647034|Other|no intervention|no intervention
1543080|NCT02647021|Behavioral|Therapeutic Exercise|A specialized therapeutic exercise program to address neck and shoulder dysfunction due to spinal accessory nerve damage.
1543081|NCT02647021|Behavioral|Therapeutic + Lower Body Exercise|A combined therapeutic exercise program (as per the comparison arm) plus the addition of lower body resistance exercise
1543082|NCT02647008|Device|TENS|Transcutaneous electrical nerve stimulation (TENS) is a nonpharmacological intervention that activates a complex neuronal network to reduce pain by activating descending inhibitory systems in the central nervous system to reduce hyperalgesia.These small battery powered devices deliver alternating current via cutaneous electrodes positioned near the painful area.
1543083|NCT02646995|Dietary Supplement|modified lipid formulation|Tested oils will be used in liquid form and encapsulated in soft gelatin capsules.
1543084|NCT02646995|Dietary Supplement|Fish oil|Fish oil will be used in liquid form and encapsulated in soft gelatin capsules.
1543085|NCT02646982|Drug|Placebo|A matched placebo will be given once daily for 12 months.
1543086|NCT02646982|Drug|Candesartan|Candesartan will be started at 8 mg orally, once daily. The dose will be increased in 2 week increments to 16 mg and 32 mg orally, once a day, as long as SBP>110 mm Hg, DBP>40 mm Hg and there are no reported symptoms of hypotension (dizziness or weakness). Candesartan will be given for a total of 12 months.
1543087|NCT02646969|Dietary Supplement|Formula regimen 1|
1543088|NCT02646969|Dietary Supplement|Formula regimen 2|
1543089|NCT02646956|Other|sweeteners|Participants tasted a variety of nutritive and nonnutritive sweeteners
1543090|NCT02646930|Procedure|Endometrial biopsy|Endometrial biopsy in women undergoing first IVF cycle
1543091|NCT02646917|Device|SkinPen|Treatment of acne scars on the face and/or back at needle depth settings ranging between 0.25 mm to 2.0 mm, depending on severity and location of scarring.
1543094|NCT02646891|Biological|Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 15 mcg|
1543095|NCT02646891|Biological|Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 30 mcg|
1543096|NCT02646891|Biological|Placebo|
1543097|NCT02646891|Biological|Trivalent P2VP8 Subunit Rotavirus Vaccine (TV P2VP8) 90 mcg|
1543098|NCT02646878|Device|Harmony 1 Sensor|Use of Harmony 1 Sensor for 10 days when inserted in the arm and abdomen and used with the Guardian Mobile in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least 6 months.
1543099|NCT02646865|Behavioral|Self-Compassion Enhanced Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol with additional self-compassion exercises integrated into the treatment
1543100|NCT02646865|Behavioral|Cognitive-Behavioral Therapy|12 group sessions of CBT for social anxiety based on Heimberg & Becker's (2002) protocol
1543101|NCT02646852|Drug|DFP-13318|
1543103|NCT02646826|Other|Placebo|Subjects are treated with Placebo tablets
1543104|NCT02646826|Drug|Paxerol - Dose Level 1|Subjects are treated with the first dose level of Paxerol
1543105|NCT02646826|Drug|Paxerol - Dose Level 2|Subjects are treated with the second dose level of Paxerol
1543106|NCT02646826|Drug|Paxerol - Dose Level 3|Subjects are treated with the third dose level of Paxerol
1543107|NCT02646813|Procedure|Intraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed intraluminally
1543108|NCT02646813|Procedure|Extraluminal Placement|Pt. will have Arndt Endobronchial Blocker placed extraluminally
1543109|NCT02646800|Drug|Micafungin|Injection
1543110|NCT02646787|Behavioral|Active Virtual Reality|The subject is actively engaged in using virtual reality during a painful burn wound care session.
1543111|NCT02646787|Behavioral|Passive Virtual Reality|The subject is passively engaged in using virtual reality during a painful burn wound care session.
1543112|NCT02646774|Drug|Micafungin|Injection
1543113|NCT02646761|Device|InterACTION|InterACTION guided home exercise program paired with standard of care physical therapy
1543114|NCT02646761|Other|Standard of Care Physical Therapy|Physical therapy rehabilitation program
1543115|NCT02646748|Drug|Pembrolizumab|Pembrolizumab 200 mg IV Q3W.
1543116|NCT02646748|Drug|itacitinib|Itacitinib tablets administered orally once daily.
1543117|NCT02646748|Drug|INCB050465|INCB050465 tablets administered orally once daily.
1543118|NCT02646735|Drug|Fulvestrant 500 mg|Fulvestrant 500mg will be given monthly.
1543119|NCT02646735|Drug|Exemestane 25 mg|Exemestane 25mg will be given once daily.
1543120|NCT02646709|Drug|Rocuronium|Low dose rocuronium (0.3 mg/kg) will be injected after induction of anesthesia with ketamine.
1543121|NCT02646709|Drug|ketamine 1|ketamine 1 mg/kg will be injected for induction of anesthesia
1543122|NCT02646709|Drug|ketamine 1.5|ketamine 1.5 mg/kg will be injected for induction of anesthesia
1543123|NCT02646709|Drug|ketamine 2|ketamine 2 mg/kg will be injected for induction of anesthesia
1543124|NCT02646696|Other|Sensory Challenge Protocol|Measurement of electrodermal activity in response to sensation
1543125|NCT02646683|Drug|vedolizumab|
1543126|NCT02646670|Drug|Ranibizumab|- In the first group will be held three applications of intravitreal ranibizumab 0.1 ml, with one application every month and follow up with Optical Coherence Tomography
1543127|NCT02646670|Drug|Aflibercept|- In the second group will be held three applications of Intravitreal Aflibercept 0.1 ml, with one application each month followed by monitoring with Optical Coherence Tomography
1543128|NCT02646670|Drug|Ranibizumab and Aflibercept|- The third group will be held two applications of Ranibizumab 0.1 ml interspersed with one application of Aflibercept 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
1543129|NCT02646670|Drug|Aflibercept and ranibizumab|- In the fourth group will be held two applications of 0.1 ml Aflibercept interspersed with one application of Ranibizumab 0.1 ml in the second month and subsequent evaluation with Optical Coherence Tomography
1543130|NCT02646657|Drug|Vedolizumab 300 mg|Open-label VEDOLIZUMAB 300 mg at week 0,2,6, 14, 22, 30, 38, 46
1543131|NCT02646644|Other|Metastasized intestinal NET|This is an observational study
1543132|NCT02646631|Other|Usual Care|Participants assigned to this treatment will receive the usual care as determined by their physician
1543133|NCT02646631|Behavioral|Management of Risks in Epilepsy (MORE)|MORE is a smartphone application which participants use to record information on a daily basis about seizures (severity, type), medications, and mood and stress levels. It also includes a camera-based application which uses a pill scanner and photo to record the identity and quantity (dose) of medications just prior to them being taken. Also included in the app are medication reminders, educational video clips, and self-management tips.
1543134|NCT02646631|Behavioral|Telephone-based motivational interviewing (MORE+MI)|Participants will receive a total of 4 motivational interviewing sessions over the phone. These sessions last approximately 20 minutes each and build on the educational materials already provided within the MORE app.
1543135|NCT02646631|Other|Educational Materials|Printed educational materials on the management of epilepsy
1543139|NCT02646605|Other|depression screening|Patient Health Questionnaire
1543140|NCT02646592|Drug|Alfentanil|Bolus of alfentanil 10 µg/kg 5 minutes before skin incision
1543141|NCT02646592|Drug|sevoflurane or propofol|
1543142|NCT02646579|Procedure|Spinal and Peripheral Dry Needling|Participants will be positioned lying flat and the relevant spinal level will be treated using a Seirin L- type 50 mm needle. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
1543143|NCT02646579|Procedure|Peripheral Dry Needling|Participants will be positioned lying flat and the relevant peripheral points will be treated using a Seirin L- type 50 mm needle. The peripheral treatment site(s) will be determined by the physical therapist's palpation of active or latent trigger points or tender points. The needle will be inserted to a depth no greater than three-quarters length of the needle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
1543144|NCT02646566|Drug|APD421|
1543145|NCT02646566|Drug|Placebo|
1543146|NCT02646553|Other|Children refered to the obesity clinic|Compere if urine cortisol is as good as saliva cortisol as a screening for hypercortisolism in children.
1543147|NCT02646540|Drug|Tolvaptan 30 mg + IV Diuretics|Participants will receive oral daily tolvaptan 30 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
1543148|NCT02646540|Drug|Metolazone 5 mg + IV Diuretics|Participants will receive oral daily metolazone 5 mg concomitantly with their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
1543149|NCT02646540|Drug|2.5 times the Diuretics Dose|Participants will receive two and a half (2.5) times their standard dose of intravenous (IV) diuretics for the duration of their hospitalization.
1543150|NCT02646527|Behavioral|Dignity Therapy|Dignity Therapy (DT) is a brief psychotherapeutic intervention developed by Chochinov (2012) which has been shown to enhance the end of life experience in people with life-limiting conditions. DT focuses on helping patients with terminal illnesses to go over things that are most meaningful to them and document their legacy. Dignity Therapy+ (DT+) involves patient and partner/family asking questions about their most important achievements, roles and other important aspects of life. DT+ encourages patients saying things to loved ones that have remained unsaid. DT+ consists of 3 sessions (1. introduction (30'); 2. main session (60'), 3. final session (30')) and will be conducted by a trained therapist. All therapy session will be audio-taped, transcribed verbatim by the study coordinator, edited by the therapist and returned to the patient or the patient and partner/family as a 'generativity document'.
1543151|NCT02646514|Device|Radiofrequency ablation with stenting|"Side viewing endoscope or PTCS scope can be used for all procedures. Cholangiogram is performed to confirm the stricture location, length and diameter. And then, RF catheter (ELRA®) is advanced over a guide wire at the level of the biliary stricture and ablation at 7-10 watts for a time period of 60-120s according to the length is conducted.
After performance of RFA, metal stents are inserted to ensure adequate decompression and bile drainage."
1543152|NCT02646514|Device|stenting|Metal stents are inserted to ensure adequate decompression and bile drainage. The diameter and stent lengths can be changed according to the lesion.
1543153|NCT02646501|Drug|Antiarrhythmic drug|
1543154|NCT02646501|Procedure|percutaneous stellate ganglion block (PSGB)|
1543171|NCT02646475|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels as well as a role in the regulation of insulin action.
1543172|NCT02646475|Drug|Saline|Normal saline will be used as a placebo comparator.
1543173|NCT02646449|Drug|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
1543174|NCT02646449|Drug|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
1543175|NCT02646436|Other|HD treatment|Patients with absolute contraindication to the PD method will be treated with HD. HD will be performed after implantation of central venous catheter using Seldinger technique by nephrology team.
1543176|NCT02646436|Other|PD treatment|Patients without absolute contraindication to the PD method will be treated with PD. PD will be performed after implantation of peritoneal catheter using Seldinger technique by nephrology team.
1543177|NCT02646423|Behavioral|Prior CD Decision App|The Prior CD Decision App begins with an explanation that its goal is to help the user better understand the two approaches to delivery she is eligible for (trial of labor after cesarean (TOLAC) and elective repeat cesarean delivery (ERCD)), and that its goal is to help her engage with her provide in making an informed, shared decision regarding which approach to undergo. It includes four sections: a calculator to estimate the likelihood of having a vaginal delivery if she undergoes TOLAC, a series of information pages that include graphical presentations of the chances of various potential outcomes of the two options, a series of values clarification exercises to help the user think through what's important to her, and a summary print out for her to keep.
1543178|NCT02646410|Other|FPD+NDOT|
1543179|NCT02646410|Other|FPD+DOT|
1543180|NCT02646410|Other|DDD+NDOT|Door to door delivery + non directly observed treatment
1543181|NCT02646410|Other|DDD+DOT|Door to door delivery + directly observed treatment
1543182|NCT02646397|Drug|Fosinopril|Fosinopril is an angiotensin-converting enzyme inhibitor.
1543183|NCT02646397|Drug|Benidipine|Benidipine is a dihydropyridine-derived calcium channel blocker.
1543184|NCT02646397|Drug|Hydrochlorothiazide|Hydrochlorothiazide is a diuretic medication.
1543185|NCT02646384|Procedure|Ovarian tissue cryopreservation|Ovarian tissue will be removed
1543186|NCT02646371|Biological|Flexyn2a|2 doses of 10 μg of Flexyn2a will be injected intramuscularly 4 weeks apart
1543187|NCT02646371|Biological|Placebo|2 doses of TBS solution will be injected intramuscularly 4 weeks apart
1543188|NCT02646358|Drug|Vepoloxamer|
1543189|NCT02646345|Procedure|Surgical checklist|Use of the World Health Organization Surgical checklist
1543190|NCT02646332|Drug|(dexlan+amox+clar+metr)+(dexlan+amox)|a 7-day quadruple regimen with dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with dexlansoprazole MR 60 mg once daily and amoxicillin 1 g twice daily
1543191|NCT02646332|Drug|dexlan+clarith+amox+metro|dexlansoprazole MR 60 mg once daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily for 14 days
1543192|NCT02646319|Other|Laboratory Biomarker Analysis|Correlative studies
1543193|NCT02646319|Drug|Nanoparticle Albumin-Bound Rapamycin|Given IV
1543194|NCT02646319|Other|Quality-of-Life Assessment|Ancillary studies
1543195|NCT02646306|Other|shoulder proprioceptive rehabilitation tool|"Using of this tool to measure which is the average error in reaching back in both healthy subjects and subjects with shoulder impingement syndrome starting from the assumption that the shoulder, through the articulation scapulothoracic, helps to determine direction and distance during the reaching of an object."
1543196|NCT02646280|Other|Massage therapy|Massage therapy as a treatment option to induce a relaxation and a reduction of pain and stress in patients affected by chronic low back pain.
1543197|NCT02646280|Other|Neurocognitive rehabilitation|Provided through the association of motor imagery and the words of the physiotherapist with the aim of increasing the effectiveness of massage in reducing pain.
1543198|NCT02646267|Drug|standard intensity warfarin|target international normalised ratio(INR) was 2.1-3.0
1543199|NCT02646267|Drug|low intensity warfarin|target international normalised ratio(INR) was 1.7-2.2
1543200|NCT02646267|Drug|dabigatran etexilate|110mg, twice a day, oral
1543201|NCT02646254|Other|blood cardioplegia|
1543202|NCT02646254|Other|del nido cardioplegia|
1543203|NCT02646241|Procedure|unroofing biopsy|Unroofing biopsy menas that the mucosa is resected with endoscopic mucosal resection and biopsies are done repeatedly for the exposed tumor with a conventional forcep. It will be performed for the patients with a suspected upper gastrointestinal subepithelial tumor after EUS-FNB. After unroofing biopsy, the final histopathological result will be used to determine diagnostic accuracy.
1543204|NCT02646241|Procedure|EUS-FNB(endoscopic ultrasonography guided fine needle biopsy)|EUS-FNB will be performed for the same patients who have a gastrointestinal subepithelail tumor before unroofing biopsy. EUS-FNB is called when the tissue is obtained by puncutre of a tumor, the tissue whithin the lumen of the fine needle being detached by rotatin, and the needle withdrawn. The pathological result will be also used to compare diagnostic accuracy between EUS-FNB & unroofing biopsy.
1543205|NCT02646228|Other|molecular profiling, patient derived cells|"molecular profiling,patient derived cells sample and experimental methods-Blood sample,tumor tissue or primary cultures of human effusions.
Malignant ascites, pleural effusions, or pericardial effusions will be collected from patients with metastatic cancer."
1543206|NCT02646215|Device|Threshold inspiratory muscle training|Inspiratory muscle training
1543207|NCT02646202|Procedure|Sclerotherapy|Injection of varices
1543208|NCT02646202|Procedure|Band ligation|endoscopic banding of varices
1543209|NCT02646202|Procedure|Scleroligation|intra variceal endoscopic sclerotherapy combined with band ligation.
1543210|NCT02646189|Drug|REP 2139-Ca|REP 2139-Ca is administered weekly at 250 or 500mg doses by slow IV infusion.
1543211|NCT02646189|Drug|Zadaxin|Zadaxin is administered twice weekly (1.6mg) by subcutaneous injection
1543212|NCT02646189|Drug|Pegasys|Pegasys in administered once weekly by subcutaneous injection with dose escalation to 180ug / week.
1543213|NCT02646176|Behavioral|Inpatient rehabilitation|Inpatient rehabilitation includes activities and interventions provided by occupational, physical, therapeutic recreation and speech therapists, and psychologists.
1543214|NCT02646163|Drug|REP 2055|"(First two patients) REP 2055 is administered once weekly by slow IV infusion in dose escalation from 100 to 1200mg until a grade 3 adverse event is observed not to exceed 40 weeks of dosing.
(Subsequent patients) 400mg of REP 2055 is administered by slow IV infusion. First week of infusion to include daily dosing followed by twice weekly dosing for 40 weeks."
1543215|NCT02646150|Procedure|Magnetic Resonance Perfusion Imaging|
1543216|NCT02646137|Procedure|Transarterial chemoembolization (TACE)|TACE exploits the preferential hepatic arterial supply of liver tumors for targeted delivery of chemotherapeutic agents followed by embolization or reduction in arterial flow using various types of particles
1543217|NCT02646137|Procedure|Radiofrequency ablation combined with TACE|Radiofrequency ablation (RFA) is an alternative therapy for HCC and liver metastases that can destroy a tumor by inducing thermal injury to the tissue through electromagnetic energy deposition
1543218|NCT02646137|Procedure|Microwave ablation combined with TACE|Microwave ablation (MWA) is an appealing alternative therapy for HCC in which a microwave antenna is placed directly into the tumor, emitting an electromagnetic wave which agitates water molecules in the surrounding tissue, producing friction and heat, thereby inducing cell death via coagulation necrosis
1543219|NCT02646124|Drug|Naproxen|Naproxen 500mg po BID #20
1543220|NCT02646124|Drug|Placebo|28 placebo capsules
1543221|NCT02646124|Drug|Diazepam|Diazepam 5mg capsules, 1-2 tabs po BID, #28
1543222|NCT02646111|Drug|12 weeks without Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir (25/150/100 mg dose) once daily and Dasabuvir 250 mg twice daily.
1543223|NCT02646111|Drug|12 weeks with Ribavirin|12 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
1543224|NCT02646111|Drug|24 weeks with Ribavirin|24 weeks Triple Therapy: Ombitasvir, Paritaprevir, Ritonavir 25/150/100 mg dose once daily + Dasabuvir 250 mg twice daily + weight adjusted Ribavirin, daily dose: 1,000 mg weight <75 kg, 1,200 mg weight> 75 kg.
1543225|NCT02646098|Procedure|CD34+ cell selection|CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
1543226|NCT02646085|Drug|C11 Methionine positron emission tomography|diagnostic positron emission tomography imaging after intravenous injection of C11 Methionine
1543227|NCT02646072|Drug|Ketorolac tromethamine ophthalmic solution 0.45%|Indicated for the treatment of pain and inflammation following cataract surgery.
1543228|NCT02646059|Other|Text message|Text messages would be sent via the messaging platform of Guangzhou Blood Center. The feedback of sending status (received, failed to receive, or unknown) would be marked on every number. Four to six months follow-up, blood donation rate would be checked.
1543229|NCT02646059|Other|Telephone|Status (response, no answer, line issue, wrong number or refused to be interviewed) of every donor in this groups would be marked. Four to six months follow-up, blood donation rate would be checked.
1543230|NCT02646046|Behavioral|Combi lone-CPR|When study participants meet the arrest victim (simulated), they start chest compression and call for help to EMS at the same time, then continue the chest compression and 2 breath alternatively until the EMS arrival
1543231|NCT02646046|Behavioral|Conventional lone-CPR|When study participants meet the arrest victim (simulated), they first call for help to EMS and then start chest compression and 2 breath alternatively until the EMS arrival
1543232|NCT02646020|Drug|Aprepitant and placebo|aprepitant 125mg d1, 80mg d3 and d5, along with placebo 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
1543233|NCT02646020|Drug|desloratadine and placebo|placebo 125mg d1, 80mg d3 and d5, along with desloratadine 5mg d1-d28; until pruritus recurrence or discontinuation of EGFR-TKI or safely issues (SAE etc.)
1543234|NCT02646007|Biological|BM-MSC transplantation|Transplantation of bone marrow derived mesenchymal stem/ stromal cells in combination with bone decompression surgery in Kienböck's disease.
1543235|NCT02645994|Device|Target Controlled Infusion|Used to control intravenous propofol delivery with target plasma concentratioins changed manually
1543236|NCT02645994|Device|Closed Loop Anesthesia Delivery System|Used to deliver propofol automatically titrated to achieve a target BIS 50, and maintain it between 40 and 60.
1543237|NCT02645981|Drug|Donafenib|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects
1543238|NCT02645981|Drug|Sorafenib|Control
1543239|NCT02645942|Dietary Supplement|L-carnitine|L-carnitine 1400 mg daily for 8 weeks
1543240|NCT02645942|Dietary Supplement|Placebo|Placebo daily for 8 weeks
1543241|NCT02645929|Behavioral|Interpersonal Psychotherapy (IPT)|IPT is a 14 week psychotherapy for PTSD. SSRF is a brief interview to assess emotional understanding of one's symptoms.
1543242|NCT02645916|Drug|Danggui-Sayuk-Ga-Osuyu-Saenggang-tang|Usage: 3g, three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
1543243|NCT02645916|Drug|Placebo: corn starch|Usage: 3g three times a day, each taken before or between meals Manufacturing company: HANPOONG PHARM & FOODS Co. Ltd.
1543244|NCT02645903|Drug|Transversus Abdominis Plane Block|Cases to whom used bupivacaine with ultrasound guided transversus abdominis plane block was applied after standard general anesthesia were determined as Group 1
1543245|NCT02645903|Drug|standard general anesthesia|Cases to whom applied alone standard general anesthesia were determined as Group 2
1543246|NCT02645890|Drug|CKD-397|Arm A:Tamsulosin/ Tadalafil Fixed dose combination
1543247|NCT02645890|Drug|TD+TM|Arm B: Tamsulosin/ Tadalafil Coadministration
1543280|NCT02645630|Other|Sham Cervical Manipulation|The sham procedure will simulate C3/C4 manipulation in both sides without any therapeutic thrust
1543281|NCT02645617|Drug|Varnish|Topical application to the teeth
1543248|NCT02645877|Procedure|Prehospital care|The common cause of pre-hospital care demands were Abdominal Problems, Allergies/Envenomation, Animal Bites, Assault/Sexual, Back Pain, Breathing Problems, Burns/Explosions, Carbon Monoxide/Inhalation/Radiation/Hazardous Material, Cardiac or Respiratory Arrest, Chest Pain, Choking, Convulsions/Seizures, Diabetic Problems, Drowning/Diving/Scuba Accident, Electrocution/Lightning, Eye Problems/Injuries, Falls, Headache, Heart Problems, Heat/Cold Exposure, Hemorrhage/Lacerations, Inaccessible Incident/Entrapments, Overdose/Poisoning, Pregnancy/Childbirth/Miscarriage, Psychiatric/Suicide Attempt, Sick Person, Stabbing/Gunshot/Penetrating Trauma, Stroke, Traffic Injuries, Traumatic Injuries, Unconscious/Fainting, Unknown Problems, Inter-Facility Transfer/Palliative Care, Flu-Like Symptoms, etc.
1543249|NCT02645864|Drug|Apatinib|250mg p.o. qd in first cohort (3 subjects). 250mg p.o. bid in second cohort (3 subjects) 250mg p.o. tid in third cohort (3 subjects)
1543250|NCT02645864|Drug|Irinotecan|150mg/m^2 i.v. q2w
1543251|NCT02645851|Drug|fluid bolus|Administration of the fluid bolus if deemed clinically necessary, OR if deemed clinically necessary AND PLR-induced SV or PP changes ≥10%, depending of the Arm the patient is assigned to
1543252|NCT02645851|Device|PiCCO system (Pulsion, Germany)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Stroke Volume changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced stroke volume change is over 10%; in case stroke volume change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
1543253|NCT02645851|Device|Vascular pressure transducers (Edwards Life Science, USA)|During the intervention period (from inclusion to the 120th hour), every time a fluid bolus is deemed necessary, fluid responsiveness will be assessed by Pulse Pressure changes obtained at 1 min of a Passive Leg Raising (PLR) test (fluid will be given if PLR-induced Pulse Pressure change is over 10%; in case Pulse Pressure change is below 10%, fluid will not be given and need for fluid reassessed after a short period of time, as in usual care)
1543254|NCT02645851|Other|Passive Leg Raising test|Passive elevation of the legs of the patient, and lying down of the trunk (if patient is in the semi-recumbent position), preferably using electric bed. If not available, elevation of the legs by an assistant to a 45 degrees angle. Effects of Passive Leg Raising on Pulse Pressure or on Stroke Volume are used to assess fluid responsiveness in patients suffering from shock states.
1543255|NCT02645838|Behavioral|Motivational interviewing|1. Structural motivational interviewing for one section (about 20 mins)，provided by family physician;2. Follow-up telephone call，provided by family physician.
1543256|NCT02645799|Drug|LABR-312|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
1543257|NCT02645799|Drug|Saline (placebo)|administered intravenously at the time of percutaneous coronary intervention (PCI) with a drug eluting stent
1543258|NCT02645773|Device|non-ablative laser|non-abaltive laser pre, immediate and post wounding
1543259|NCT02645760|Other|Core stabilization exercise|7-weeks of core stabilization exercise
1543260|NCT02645760|Other|Conventional treatment|7-weeks of conventional treatment include therapeutic ultrasound and hot pack
1543261|NCT02645747|Drug|aflibercept (Eylea, Bay 86-5321)|Eylea (intravitreal aflibercept) is an anti-Vascular Endothelial Growth Factor (VEGF) drug indicated for neovascular age-related macular degeneration (AMD), visual impairment due to diabetic macular edema (DME) and visual impairment due to macular edema (ME) secondary to central or branched retinal vein occlusion (RVO). RVO, both branch and central, is the second most common type of retinal vascular disorders after diabetic retinal disease. Central retinal vein occlusion (CRVO) is characterized by an obstruction of the central retinal vein combined with variable amounts of retinal arterial insufficiency.
1543262|NCT02645734|Drug|bevacizumab|1.25 mg of bevacizumab is injected
1543263|NCT02645734|Drug|ziv-aflibercept 1.25 mg|1.25 mg of ziv-aflibercept is injected
1543264|NCT02645734|Drug|ziv-aflibercept 2.5mg|2.5 mg of ziv-aflibercept is injected
1543265|NCT02645721|Behavioral|Extended self-help program with guidance|See arm description for Experimental
1543266|NCT02645721|Behavioral|Briefer Self-help program, no guidance|See arm description for Active Comparator
1543267|NCT02645721|Behavioral|Waiting list: Extended self-help program with choice of guidance intensity|See arm description for Waiting list.
1543268|NCT02645708|Procedure|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
1543269|NCT02645708|Procedure|EPVL after RIRS|Patients in Group 2 undergo EPVL after RIRS
1543270|NCT02645695|Device|routine pulmonary rehabilitation|received routine pulmonary rehabilitation consisted of position giving technique (left lateral, supine, right lateral), chest wall percussion, postural drainage and airway aspiration at every 3 hours.
1543271|NCT02645695|Device|chest wall vibration technique|administered chest wall vibration technique in addition to the routine pulmonary rehabilitation method for 72 hours. Chest vibration method was applied with 7-10 hz frequency given by a ped wrapped around the thorax and pulmonary rehabilitation with 3 mmHg pressure four times a day with 15-minute periods (TheVest® Model 205).
1543272|NCT02645682|Device|anti-infection CVC|
1543273|NCT02645682|Device|normal CVC|
1543274|NCT02645669|Procedure|Study site|The probiotic is in the form of a lyophilized powder containing approximately 5 billion colony forming units (CFU) of the Saccharomyces boulardii. At the time of administration, the probiotic mixture was mixed with fructooligosaccharide in the ratio of 4:1 to induce growth and activity in S boulardii. This was applied after scaling and root planing.
1543275|NCT02645669|Procedure|Control site|Only Scaling and Root planing was done.
1543276|NCT02645656|Drug|Curcumin Arm|Curcumin gel will be applied in sites with Oral Submucous Fibrosis at designated time intervals
1543277|NCT02645643|Other|Education of medical humanities|The medical students in the intervention group would gain education about the medical humanities, but not the control group.
1543278|NCT02645630|Other|Right Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the right articular pillar of C3, on the right articular pillar of C4 with the patient in supine, with left rotation and right side-bending.
1543279|NCT02645630|Other|Left Cervical Manipulation|We will use a high-velocity, mid-range, left rotational force to the left articular pillar of C3, on the left articular pillar of C4 with the patient in supine, with right rotation and left side-bending.
1543282|NCT02645591|Procedure|Robotic Assisted Laparoscopic Radical Prostatectomy (RARP)|Participants receive Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP).
1543283|NCT02645591|Biological|AmnioFix®|Dehydrated human amnion/chorion membrane (dHACM) wrapped around the nerve bundles at the end of Nerve Sparing robotic assisted laparoscopic radical prostatectomy (RARP) surgery.
1543284|NCT02645591|Behavioral|Questionnaire|Questionnaire completed about erectile function before surgery, and at 6 weeks, 3 months, 6 months, and 12 months after surgery.
1543285|NCT02645578|Device|Right median nerve stimulation|Right median nerve electrical stimulation (RMNS) is administered via a pair of lubricated one-inch square rubber surface electrodes pasted on the volar aspect of the right distal forearm over the median nerve. An electrical neuromuscular stimulator supplied trains of asymmetric biphasic pluses at an amplitude of 20 milliamps with a pulse width of 300 microseconds at 40 Hz for 20 sec/min. The RMNS treatment continues 8 hours per day for two weeks.
1543286|NCT02645565|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent used for the treatment of lupus nephritis.
1543287|NCT02645565|Drug|Azathioprine|azathioprine will be given at 2 mg/kg.
1543288|NCT02645565|Drug|Methylprednisolone|Each treatment arm shall receive 1 gm methylprednisolone pulse for 3 days followed by prednisolone 1 mg/kg for 4 weeks and tapered 5 mg every 2 weekly ,to maintain 7.5 mg dose daily
1543289|NCT02645552|Drug|Tranexamic Acid|Tranexamic acid 1 gram in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
1543290|NCT02645552|Other|Sodium chloride|Sodium Chloride solution (0.9%) 1 ml (gram) in 100 ml saline, by intravenous drip over 10 minutes, once patient admitted to the trial on the spot of TBI
1543291|NCT02644434|Procedure|Conventional Strategy|"Jailed wire technique: Both MV and SB are wired. The MV is stented with wire protection in SB. The SB is not further treated unless there is threatened SB closure, severe ostial pinching of SB (>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A. If one of these criteria exists, the SB would be rewired and a kissing balloon inflation is undertaken.
Provisional two-stent strategy: Lesion preparation and MV stenting are the same as the jailed wire technique. Provisional T stenting of the SB could be undertaken if one of the following criteria exists after SB rewiring and a kissing balloon inflation is undertaken: threatened SB closure, severe ostial pinching of SB (>90%), TIMI flow grade decrease in SB, or SB dissection greater than type A."
1543292|NCT02644434|Procedure|Intentional strategy|"Jailed balloon technique: The technique has been detailed in previous studies. A monorail balloon that is angiographically sized to approximate the Side Branch (SB) vessel diameter is advanced into the SB. If there is TIMI flow grade decrease in the SB after MV stenting, the SB balloon is inflated to simulate attempt to reopen the SB. The procedure would be completed with the standard kissing balloon technique no matter there is SB compromise or not.
Elective two-stent strategy: Patients in this subgroup would undergo crush procedure or any other elective two-stent strategy which stenting SB before MV stenting."
1543293|NCT02644421|Drug|VVZ-149|
1543294|NCT02644421|Drug|Lidocaine|
1543295|NCT02644421|Drug|Placebo|
1543296|NCT02644408|Drug|Megestrol（Yining）|Megestrol（Yining）: 160mg/d, po,7 weeks in total, one week before chemoradiotherapy and one week after chemoradiotherapy.
1543297|NCT02644408|Radiation|radiotherapy|radiotherapy (radiation): 50Gy in total，2 Gy/d，5d/w.
1543298|NCT02644408|Other|chemotherapy|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total or capecitabine(Aibin) plus Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V. or cisplatin: 75mg/m2 d1，29 5-Fu：750mg/m2CIV24h d1-4，d29-32. The 3 regimens were Randomly distributed to patients.
1543299|NCT02644395|Drug|Chlorthalidone|Drug
1543300|NCT02644395|Drug|Amlodipine|Drug
1543301|NCT02644382|Other|qualitative data collection|qualitative data collection
1543302|NCT02644369|Biological|Pembrolizumab|Pembrolizumab is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
1543303|NCT02644356|Behavioral|Online CE/CME course|Educational modules of a proposed online CE/CME course, module topics consisting of acupuncture, massage, and music-related interventions
1543304|NCT02643251|Drug|Clonidine Hydrochloride Topical Gel, 0.1%|Clonidine Gel is supplied as an aqueous gel formulation for topical use.
1543305|NCT02643251|Drug|Clonidine Hydrochloride Gel Comparator|Clonidine Gel Comparator is supplied as an aqueous gel formulation for topical use.
1543306|NCT02643238|Device|BrainPort|This system is a novel, bionic, non-invasive, vision bypass system that conveys environment images from a spectacle-frame-mounted video-camera to the brain via an electro-tactile tongue array. The electro-tactile stimulation delivered by the tongue-array placed on the tongue allows users to interpret the images of objects in their camera's visual field
1543307|NCT02645526|Other|Woolen cap|
1543308|NCT02645513|Behavioral|Malaria text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria
1543309|NCT02645513|Behavioral|Malaria, pneumonia, and diarrhea text message reminders to health workers|Text message reminders contain key details from national case management guidelines on diagnosis and treatment of malaria, pneumonia, and diarrhea
1543310|NCT02645513|Behavioral|Control|No text message reminders
1543311|NCT02645500|Behavioral|Holistic health training and physical exercise messages|The physical activity message arm includes a training workshop in relation to holistic health, and daily physical activity messages.
1543312|NCT02645500|Behavioral|Holistic Health Training with healthy diet messages|The healthy diet message arm includes a training workshop in relation to holistic health, and daily healthy diet messages.
1543313|NCT02645487|Radiation|Stereotactic Radiosurgery|Radiation, Stereotactic Radiosurgery Size <= 1cm: 24 Gray (Gy); + 3 Gy incremental escalation up to 30 Gy >1-2cm: 21 Gy; + 3 Gy incremental escalation up to 27 Gy >2-3cm: 18 Gy; + 3 Gy incremental escalation up to 24 Gy >3-4cm: 15 Gy; + 3 Gy incremental escalation up to 21 Gy
1543314|NCT02645474|Procedure|PECS block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 30 ml) is infiltrated in between the fasciae of serratus and minor pectoralis muscles under ultrasound guidance.
1543315|NCT02645474|Procedure|Paravertebral block with ropivacaine|Local anesthetic (ropivacaine 0.5%, total volume 20 ml) is infiltrated in the paravertebral block at T4 level under ultrasound guidance.
1543316|NCT02645474|Drug|Ropivacaine|Amidic local anesthetic standardly used for nerve block and infiltration
1543319|NCT02645448|Other|Resistance Exercise|"Control Session
Resistance exercise at different intensities (40%1RM or 80%1RM)
Duration of effect"
1543320|NCT02645435|Procedure|hip replacement|Total hip replacement
1543321|NCT02645409|Drug|OTL38|OTL38 is a folate analog conjugated with a fluorescent dye that emits light in the near infrared spectrum. This longer wavelength allows for deeper penetration of the fluorescent light through tissues with the potential to better image tumors beneath adipose tissue or deeper into organ parenchyma.
1543322|NCT02645409|Device|Intraoperative fluorescence imaging system|
1543323|NCT02645383|Device|PASCAL laser|A novel semi-automatic and multi-shot photocoagulator called as PASCAL (Pattern scan laser, Opti-Medica Corp., Santa Clara, California, USA) was introduced with a reduction in pulse duration of each laser spot from typical 100 ms down to 10-30 millisecond. Compared with the conventional laser, shorter pulses have been shown to significantly reduce the risk of damage to the adjacent retinal tissues. One eye was treated with PASCAL laser, the other was treated with conventional laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, PASCAL laser was performed in the first eyes in half of the patients (14 patients) randomly.
1543324|NCT02645383|Device|Conventional laser|Maintaining of good glycemic regulation and performing panretinal laser photocoagulation (PRP) with conventional laser device (ELLEX Integre, Adailade, Australia) when it is indicated are evidence based effective methods for proliferative diabetic retinopathy.One eye was treated with conventional laser, the other was treated with PASCAL laser with 30 minutes resting intervals. To avoid a bias about orientation or becoming accustomed to laser procedure, conventional laser was performed in the first eyes in half of the patients (14 patients) randomly.
1543325|NCT02645370|Drug|Danzhen|
1543326|NCT02645370|Drug|Topiramate|
1543327|NCT02645357|Other|computer reminders on clinical practice|on-screen, point-of-care computer reminders on clinical practice.
1543328|NCT02645357|Other|Control group|control group
1543329|NCT02645344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
1543330|NCT02645344|Behavioral|Sensory Cueing (SC)|
1543331|NCT02645344|Behavioral|Conventional Rehabilitation|
1543332|NCT02645331|Behavioral|Remind-to-move|
1543333|NCT02645331|Behavioral|Modified constraint induced movement therapy|
1543334|NCT02645331|Behavioral|Conventional rehabilitation|
1543335|NCT02645305|Biological|Adipose derived stem cells|Adipose derived stem cells that are isolated from adipose tissue are mesenchymal stem cells with high immune modulation capacity. Therefore, they can effectively modulate the immune system.
1543336|NCT02645292|Device|1 mile walk using treadmill|Walk for 1 mile on treadmill (American Motion Fitness, 8800D) at self selected speed as fast as participant can without any inclination.
1543337|NCT02645292|Device|Stair Climbing|Climb 14 flights of stairs at self selected speed. No double step at a time and running allowed.
1543338|NCT02645279|Other|oral 30% glucose|30% glucose solution was administered orally through a teat. 1 mL 30% glucose solution was added following placement of the teat into the mouth of the newborn. After suckling of 0.5-1 mL glucose solution, the motionless and sleepiness of newborn was evaluated. If the target conditions was not achieved, 0.5-1 mL increments of glucose was added until the newborn kept motionless or asleep.
1543339|NCT02645279|Drug|IV midazolam|IV 0.1 mg/kg midazolam was administered.MRI was routinely performed and the newborns who did not keep motionless or asleep and had motion artefacts were sedated with intravenous 0.5 mg/kg propofol.
1543340|NCT02645266|Drug|aflibercept|
1543346|NCT02645240|Drug|Heparin injection|Intravenous heparin injection in patients with acute mesenteric ischemia and evaluating their response within 24 hours
1543347|NCT02645227|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by OFD for treating bone defect
1543348|NCT02645227|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by OFD with PRF placement into the bone defect
1543349|NCT02645227|Procedure|OFD with PRF and 1.2% Rosuvastatin|Oral prophylaxis followed by OFD with PRF and 1.2% Rosuvastatin placement into the bone defect
1543350|NCT02645214|Other|Non-antiseptic scrubs|
1543351|NCT02645214|Other|Antiseptic scrubs|
1543352|NCT02645201|Dietary Supplement|Gastrus|to compare Gastrus 4x108 tbl twice a day to placebo tbl
1543353|NCT02645201|Other|Placebo|to compare Gastrus 4x108 tbl twice a day to placebo tbl
1543354|NCT02645188|Other|Cueing|Verbal and tactile cueing to enhance gluteus maximus recruitment
1543355|NCT02645175|Dietary Supplement|TW1025|20ml, 3 times per day (daily dose: 60 ml)
1543356|NCT02645175|Dietary Supplement|Placebo|20ml, 3 times per day (daily dose: 60 ml)
1543357|NCT02645162|Behavioral|Community-based Preschool|"Preschool sessions in community-based preschool
Run by trained community youth leaders from the same village."
1543358|NCT02645149|Drug|Standard therapy or clinical trial|Patients with BRAF V600 and NRAS mutations detected by standard of care tumour testing will be treated with standard approved therapies or on clinical trials.
1543404|NCT02644941|Biological|Human Acellular Vessel (HAV)|Surgical implantation of the HAV and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
1543479|NCT02644447|Biological|HUC-MSCs Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs.
1543359|NCT02645149|Drug|Matched targeted therapy|Patients with tumour found to be BRAF and NRAS wild type will have tumour tested further using the extended molecular testing platform designed for this project. Patients will first receive standard therapy(ies) for BRAF / NRAS wild type melanoma until disease progression or intolerable drug toxicities. Followed by a targeted therapy matched to the genetic aberration detected in their tumour as listed above.
1543360|NCT02645149|Drug|Trametinib and / or supportive care|Patients with BRAF and NRAS wild type tumour for whom there is no actionable genetic aberration in tumour tissue following extended molecular testing, may receive trametinib (if not already administered as part of standard care) and/or supportive care.
1543361|NCT02645136|Other|Pilates|Pilates exercises
1543362|NCT02645136|Other|PFMT and AES|conventional pelvic floor muscle exercises combined with anal electrical stimulation Device: electrical stimulation (Dualpex 961 Uro®)
1543363|NCT02645136|Other|Control|
1543364|NCT02645123|Device|TENS|Enraf-Nonius Sonopuls 692
1543365|NCT02645123|Procedure|spinal mobilization|passive physiological intervertebral movements and passive accessory posteroanterior mobilization
1543366|NCT02645123|Procedure|swedish type massage|petrissage, effleurage, tapotement
1543367|NCT02645123|Procedure|static hamstring stretch|static hamstring stretching
1543368|NCT02645123|Procedure|sham treatment|touching of the skin overlying the lumbar area
1543369|NCT02645110|Device|MC Hand Soap|Washing hand with soap in comparison to hand washing with water alone
1543370|NCT02645110|Device|Tap water|Washing hand with water alone in comparison to hand washing with soap
1543371|NCT02645097|Procedure|Saphenous Nerve Block|A nerve block will be performed by the anesthesiologist. The location of the nerve block will be per randomization envelope (proximal vs. distal) and performed just prior to foot or ankle surgical procedures that require a saphenous nerve block
1543372|NCT02645084|Other|Offering an online risk assessment questionnaire|Offering an online risk assessment questionnaire to CRC patients, to facilitate the detection of colorectal cancer patients with hereditary or familial colorectal cancer
1543373|NCT02645071|Behavioral|Physical Activity|A brief education program in reducing sedentary behavior and promoting physical exercise with family would be conducted. Assessments will be conducted in two different time points, before training session (T1), immediately following training (T2) and two weeks after training (T3) to evaluate the effectiveness of training program.
1543374|NCT02645058|Procedure|RIRS|Treatment by ureterorenoscopy (RIRS) and laser lithotripsy
1543375|NCT02645058|Procedure|ESWL|Treatment by extracorporeal shock waves lithotripsy
1543376|NCT02645058|Device|Rigid and flexible ureteroscope|
1543377|NCT02645058|Device|Lithotripter|
1543378|NCT02645058|Device|Holmium laser|
1543379|NCT02645058|Device|Basket for fragment removal|
1543380|NCT02645058|Procedure|General or spinal anesthesia|
1543381|NCT02645058|Drug|Intravenous pain medication|If required by the patient
1543382|NCT02645058|Device|X-ray|To focus the stone
1543383|NCT02645058|Device|Ultrasound|To focus the stone
1543384|NCT02645032|Biological|Vi-DT|Manufacturer: SK Chemicals Co., Ltd. Ingredient: Purified Vi-polysaccharide conjugated to diphtheria toxoid Dose: 0.5 mL/Vial
1543385|NCT02645032|Biological|Typhim Vi®|Manufacturer: Sanofi Pasteur Ingredient: Purified Vi-polysaccharide Appearance: colourless liquid Dose: 0.5mL/vial
1543386|NCT02645032|Biological|VAXIGRIP®|Dose: Single injection, participants 6-35 months of age will receive 0.25 ml (half a dose), participants 36 months of age and older will receive 0.5ml (full dose)
1543388|NCT02645006|Behavioral|3 session workshop|The intervention group will attend a three session workshop, will learn to recognize their risk factors for fall, will be encouraged to adopt a healthy diet (vitamin D consumption), modify home hazards , and increase physical activity (a strength and balance program at home and a group walking route). After a monthly telephone follow-up they are invited to attend a recall session, were they realize the change in the strength and balance tests results.
1543389|NCT02645006|Behavioral|1 session workshop|The control group will attend a single workshop session summarizing the major points of prevention of falls ( risk factors of fall, healthy diet and vitamin D consumption, home hazards, physical activity). After a monthly telephone follow-up they are invited to attend the three session workshop for further prevention.
1543390|NCT02644993|Radiation|Proton therapy|
1543391|NCT02644980|Drug|Propofol|The initiate drug concentration of propofol is set to 1.0 μg/ml, increasing 0.3 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
1543392|NCT02644980|Drug|Etomidate|The initiate drug concentration of etomidate is set to 0.2 μg/ml, increasing 0.1 μg/ml every minutes until the BIS(Bispectral index ) reaches 40~60.
1543393|NCT02644980|Device|Bispectral Index Monitor|BIS monitored from beginning of anesthesia induction to the end of the surgery.
1543394|NCT02644980|Drug|Induction of anesthesia|Midazolam 0.03 mg/kg injection vein，Sufentanyl 0.5~1 μg/kg, target controlled infusion of etomidate or propofol,after the consciousness of patients is lost, rocuronium 0.6mg/kg is given.
1543395|NCT02644980|Drug|Maintenance of anesthesia|After the intubation, target controlled infusion(TCI) of etomidate or propofol is maintained,rocuronium 0.15mg/kg and sufentanil is given when needed. When the operation is over, the TCI is stopped.
1543396|NCT02644980|Other|Tracheal Intubation|After the induction of anesthesia, Tracheal intubation is performed.
1543397|NCT02644967|Drug|IMO-2125|Drug: IMO-2125 Intratumoral injection administered as 9 doses on Weeks 1, 2, 3, 5, 8, 11, 17, 23, and 29.
1543398|NCT02644967|Drug|Ipilimumab|4 doses administered intravenously at a dose of 3 mg/kg over 90 minutes on Weeks 2, 5, 8, and 11.
1543399|NCT02644967|Drug|Pembrolizumab|Drug: Pembrolizumab Administered intravenously at a dose of 200 mg over 30 minutes every 3 weeks beginning on Week 2.
1543400|NCT02644954|Drug|Metformin|Metformin 850 mg twice daily given in the intervention arm to patients of moderate psoriasis
1543401|NCT02644954|Drug|Placebo|Placebo drug twice daily given in the intervention arm to patients of moderate psoriasis
1543402|NCT02644954|Drug|Topical Coal tar|Topical coal tar to be applied once daily
1543403|NCT02644954|Drug|Topical calcipotriol|Topical calcipotriol to be applied once daily
1543405|NCT02644941|Device|ePTFE graft|Surgical implantation of a commercially available ePTFE graft and subsequent use of the implanted vascular conduit for hemodialysis vascular access.
1543406|NCT02644915|Drug|Edaravone|Edaravone 30mg dissolved in 0.9%NaCl 100ml will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.The number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded.The participation of each patient is scheduled for 1 month.
1543407|NCT02644915|Drug|0.9%%NaCl solution|"100ml 0.9%%NaCl solution,but without edaravone ,will be treated at 10 minutes before kidney reperfusion , ending in 30 minutes.
Standard anaesthesia and standard cure are given for all patients. During the operation we maintain the target blood pressure by keeping Central Venous Pressure(CVP)> 6 mmHg"
1543408|NCT02644902|Other|Avatar assisted cascade training|Training of health workers in THP through tablets including avatar characters , and cascaded supervision model.
1543409|NCT02644902|Other|Specialist led training in THP|Training and supervision of lady health workers by specialists as in original THP
1543410|NCT02644876|Drug|Penehyclidine inhalation|Penehyclidine inhalation will be administered by inhalation (penehyclidine hydrochloride 0.5 mg/0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
1543411|NCT02644876|Drug|Placebo inhalation|Placebo inhalation will be administered by inhalation (water for injection 0.5 ml, mixed with normal saline 5.5 ml) once every 12 hours from the night before surgery till the second day after surgery. The total number of inhalation is seven times. Study drug inhalation is performed with the high-flow oxygen-driven method for the non-intubated patients or with the atomizing inhalation device of ventilator for the intubated patients.
1543412|NCT02644863|Drug|Paclitaxel|Paclitaxel 175mg/m2 IV over 2 hours,day 1; Repeat every 3 weeks;regimen for 3 cycles
1543413|NCT02644863|Biological|DC-CIK|Antigen-sensitized DC-CIK 8×10^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
1543414|NCT02644863|Drug|Cisplatin|Cisplatin 30mg/m2 IV on 1-3 days, Repeat every 3 weeks;regimen for 3 cycles
1543415|NCT02644837|Device|Insertion of Ambu AuraGain laryngeal mask airway and Igel|Insertion of Ambu AuraGain and iGel laryngeal mask airways in accordance with manufacturer instruction
1543416|NCT02644837|Device|Fibreoptic assessment with Ambu A-scope|Passage of Ambu a-scope fibrescope down shaft of laryngeal mask airway and assessment of alignment with glottis in relation to amount of glottis that is easily visualised
1543417|NCT02644837|Device|Ability to insert nasogastric tube|Passage of nasogastric tube down the gastric drainage channel of the device in accordance with manufacturer guidance
1543418|NCT02644837|Device|Measurement of OLP|Measurement of OLP by closing the adjustable pressure limiting valve against a constant fresh gas flow rate of 3 litres/minute
1543419|NCT02644837|Device|Ability to perform positive pressure ventilation|The ability to deliver 6 mls/kg volumes breaths by means of positive pressure ventilation will be assessed
1543420|NCT02644837|Device|Assessment of ease of insertion|Ease of insertion will be subjectively assessed by operator in relation to presence and nature of resistance to insertion of the device
1543421|NCT02644837|Device|Record number of manipulations|The number of manipulations/adjustments will be recorded for the second device only for the remainder of the device use during surgery until the patient wakes.
1543422|NCT02644837|Device|Assessment of device related trauma|Observation and assessment of any trauma caused by the insertion of the first device used
1543423|NCT02644824|Device|Biventricular Pacing (BiVp)|BiVp shortens QRS duration and synchronizes ventricular contraction; thereby decreasing wall stress and increasing CI and BP. In contrast to inotropes, BiVp does not increase myocardial VO2. Resynchronizing myocardial contraction normalizes glucose metabolism, myocardial perfusion and distribution of proteins essential to myocardial contraction and relaxation such as calcium-handling phospholamban. Overall, BiVp improves pump function, increases CI, improves myocardial perfusion and reduces VO2, improving hemodynamics.
1543424|NCT02644811|Drug|Topical anesthesia (buccal and palatal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
1543425|NCT02644811|Drug|Local anesthesia (buccal and palatal)|Injection of 1,5 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
1543426|NCT02644811|Procedure|Extraction of the maxillary first premolars|Careful extraction of the maxillary first premolars after mobilization.
1543427|NCT02644811|Drug|Topical anesthesia (buccal)|Saliva is removed with a sterile swab followed by application of 5% Lidocaine gel (APL, Sweden) on the gingiva.
1543428|NCT02644811|Drug|Local anesthesia (buccal)|Injection of 0.3 ml Xylocaine Dental Adrenaline (Lidocaine hydrochloride 20 mg/ml, adrenaline 12.5 µg/ml, Dentsply Pharmaceutical, Weybridge, Surrey, UK).
1543429|NCT02644811|Device|Molarblock|Molarblock is a Stainless steel ligature connecting the maxillary second premolar with the maxillary first and second molar.
1543430|NCT02644811|Device|Spider Screw K1 short neck|The Spider Screw K1 (Health Development Company, Sarcedo, Italy) is a self-drilling and self-tapping screw. Short neck screws (SCR-1508 and SCR-1510) with a diameter of 1.5 mm and length 8 or 10 mm are used.
1543431|NCT02644798|Other|Gene polymorphism|Samples of gene polymorphism in ARDS patients and patients with ARDS risk factors
1543432|NCT02644785|Drug|protamine|Protamine infusion exposures
1543433|NCT02644759|Biological|Stem Cell Transplantation|Interventional radiology-mediated transplantation of purified, autologous stem cells into pancreatic artery and capillaries, and intravenous injection of autologous, immunomodulated mononuclear cells.
1543471|NCT02644499|Drug|Prednisolone|Low dose prednisolone (weeks 1-2: 15 mg/day, weeks 2-4: 10 mg/day, weeks 4-6: 5 mg/day and weeks 6-8: 2.5 mg/day then stop)
1543472|NCT02644499|Drug|Folic Acid|Folic acid is to be given to all patients receiving methotrexate at a dose of 5 mg twice a week.
1543473|NCT02644486|Drug|High dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 4.8g/d+Irbesartan 300mg/d
1543474|NCT02644486|Drug|Low dosage Sevelamer Carbonate + Irbesartan|Sevelamer Carbonate 2.4g/d+Irbesartan 300mg/d
1543475|NCT02644486|Drug|Irbesartan|Irbesartan 300mg/d
1543476|NCT02644473|Drug|Tranexamic Acid|
1543434|NCT02644746|Device|acupuncture|Shenshu (BL23), Dachangshu (BL25), Weizhong (BL40), Chengshan (BL57), Taixi (KI3) acupoints will be used. For bilateral Dachangshu (BL 25), the needle will be inserted vertically at approximately 40-70 mm until participants got a electric shock feeling downward to calves, then the needle should be elevated up 2 mm, without rotating or lifting. For other four acupoints (BL23, BL40, BL57, KI3), they will be inserted 10 to 15 mm in depth with three times light amplitude rotation and lift to induce a sensation of soreness. The manipulations will be performed 3 times in total during 1 session (every 10 min). There are 24 treatment sessions after baseline, 3 times a week, and the patients will undergo a 30-min treatment each session.
1543435|NCT02644746|Device|placebo needle|Acupuncturists will use blunt tip needles (Huatuo, Suzhou, China) that cannot penetrate skin and stimulate deep tissues, and the thrusting and twisting motions will be used by acupuncturists to simulate the treatment and blind the patients. Each placebo needle consists of four parts: needle handle, needle body, blunt tip and adhesive pad. The chosen of acupoints, treatment duration, and frequency of sessions will be the same as the acupuncture group. To guarantee blinding, the investigators will make appointments with each participant on alternate days to prevent crosstalk among groups.
1543436|NCT02644733|Procedure|head of bed elevation 30 degree|the intraabdominal pressure will be measured by nasogastric tube when the head of bed elevated to 30 degree
1543437|NCT02644733|Procedure|urinary catheter|the intraabdominal pressure will be measured by urinary catheter when the patient in supine position
1543438|NCT02644720|Procedure|multifocal intraocular lens implantation|In this group, the surgery was performed with cataract extraction and multifocal intraocular lens (IOL) (Tecnis ZMB00). The standard technique in all patients consisted of sutureless phacomulsifacation using the Legacy 2000 Series and Infinity phacoemulsification machine (Alcon Laboratories Inc., Fort Worth, Texas, USA), with clear corneal incisions up to 3.2 mm and 5.0 to 5.5 mm capsulorhexis. Surgery in the fellow eye was performed 1 month later in each patient.
1543439|NCT02644720|Procedure|monofocal intraocular lens implantation|In the group, the surgery was performed with cataract extraction and monofocal intraocular lens (IOL) (Tecnis ZCB). The surgery technique was same as the multifocal intraocular lens group
1543440|NCT02644720|Drug|Dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery
1543441|NCT02644720|Device|multifocal intraocular lens (IOL) (Tecnis ZMB00)|
1543442|NCT02644720|Device|monofocal intraocular lens (IOL) (Tecnis ZCB)|
1543443|NCT02644707|Dietary Supplement|L-selenomethionine|The group will be randomized to receive organic selenium in the form of L-selenomethionine at the dose of 200mcg daily (intervention group) for 6 months
1543444|NCT02644707|Other|Placebo|The group will be randomized to receive placebo (control group) for 6 months
1543445|NCT02644694|Drug|Dexamethasone Phosphate Ophthalmic Solution|Experimental: Dexamethasone Phosphate Ophthalmic Solution (40 mg/mL) delivered via the EyeGate II Drug Delivery System
1543446|NCT02644681|Procedure|Aortic Aneurysm, Thoracic surgery|
1543447|NCT02644668|Drug|CK-2127107 150 mg|
1543448|NCT02644668|Drug|Placebo|
1543449|NCT02644668|Drug|CK-2127107 450 mg|
1543450|NCT02644655|Biological|CD19-specific chimeric antigen receptor|Cyclophosphamide 500 mg - 2000 mg/m2 (day 2) with or without Fludarabine 30 mg/m2 /day, 4 days (day 6, 5, 4, 3); nCAR19-T transfusion：day 0(5×105/kg，1×106/kg，3×106/kg).
1543451|NCT02644642|Other|disconnection technique|Before lung isolation, the ventilator stays switched-off until the carbon dioxide on the capnogram reached to zero. Then, inflate the balloon either on the double lumen tube or on the bronchial blocker.
1543457|NCT02644603|Procedure|Enhanced Recovery After Surgery|"Before operation:
Preoperative optimization of organ function, No preoperative bowel preparation, Prohibit eating 6h, drinking water 2h before operation, Oral rehydration before operation.
In operation:
Optimized combined anesthesia, Minimal invasive operations, Normothermia, Minimal use of tubes and drains.
After operation:
Postoperative analgesia and antiemetic, Early mobilization, Oral nutrition, Early and scheduled mobilization."
1543458|NCT02644590|Drug|Melatonin|Detailed in arm description
1543459|NCT02644577|Drug|Metformin|
1543460|NCT02644577|Other|Starch|
1543462|NCT02644551|Drug|CELEXT07|
1543463|NCT02644551|Drug|Penlac|
1543464|NCT02644551|Other|vehicle solution|
1543465|NCT02644538|Drug|PegIFN alfa-2a|chronic hepatitis B patients who treated with nucleot(s)ides (including lamivudine, adefovir, entecavir, tenofovir) arrived HBV DNA <1000copies/ml, and HBsAg<3000IU/ml, then change the treatment to original nucleot(s)ides add on PegIFN alfa-2a, the combined treatment is for 48 weeks, and follow up for 24 weeks
1543468|NCT02644499|Drug|Methotrexate|Methotrexate, a structural analogue of folic acid, can be administered orally or parenterally to treat a variety of rheumatic dise
1543469|NCT02644499|Drug|Leflunomide|Leflunomide inhibits pyrimidine synthesis, resulting in blockade of T-cell proliferation. Leflunomide is used in patients with moderate to severe active rheumatoid arthritis with early or late disease
1543470|NCT02644499|Drug|Hydroxychloroquine|Hydroxychloroquine (HCQ) is a well-tolerated DMARD that is commonly used in combination therapy regimens for RA. HCQ is more commonly used than chloroquine.
1543477|NCT02644473|Drug|Normal saline|Control
1543480|NCT02644447|Biological|HUC-MSCs with Injectable Collagen Scaffold Transplantation|The patients with POF that will undergo bilateral ovaries injection of 10 million allogeneic HUC-MSCs with injectable collagen scaffold.
1543481|NCT02644330|Procedure|transthoracic device closure|minimally invasive transthoracic device closure
1543482|NCT02644330|Procedure|surgical repair|surgical repair with cardiopulmonary bypass
1543483|NCT02644317|Device|Modified shoe inserts|For experimental arm: wear modified shoe inserts and shoes for balance test.
1543484|NCT02644304|Drug|Clomiphene citrate|50 mg tablet twice daily from the second day of menses to the sixth day
1543485|NCT02644304|Drug|Cabergoline|Cabergoline 0.25 mg (half tablet) every 3 days (4 doses).
1543486|NCT02644304|Other|Placebo|placebo(half tablet) every 3 days (4 doses).
1543487|NCT02644291|Drug|Mebendazole|chewable mebendazole tablets that can also be crushed and mixed with food or drink to be taken daily with meals
1543488|NCT02644278|Drug|VX-984|oral administration
1543489|NCT02644278|Drug|IV pegylated liposomal doxorubicin (PLD)|
1543490|NCT02644252|Drug|Day 1: Cisplatin 75 mg/m2|
1543491|NCT02644252|Drug|Day 1: Vinorelbine 25 mg/m2|
1543492|NCT02644252|Drug|Day 8: Capsule vinorelbine 50 mg/m2|
1543493|NCT02644252|Drug|Day 1: Carboplatin AUC=5|
1543494|NCT02644252|Drug|Day 1: Vinorelbine 30 mg/m2|
1543495|NCT02644252|Drug|Day 8: Capsule vinorelbine 60 mg/m2|
1543496|NCT02644252|Dietary Supplement|Tocotrienol 300 mg x 3 daily until progression|
1543497|NCT02644252|Drug|Placebo 1 capsule x 3 daily until progression|
1543498|NCT02644239|Dietary Supplement|ketogenic diet|Ketogenic diet with high fat (90%)
1543499|NCT02644226|Other|Sevoflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using sevoflurane as maintenance agents.
1543500|NCT02644226|Other|Desflurane|The investigators retrospectively reviewed and analyzed the electrical medical records of consecutive children aged 1 to 15 years who underwent general anesthesia under supraglottic airways using desflurane as maintenance agents.
1543501|NCT02644213|Other|protocol of using CAREN and MOTEK systems|"The subjects will perform randomly 3 experimental days (at least weak between one to another):
simulated road march using a virtual reality environment without additional load
simulated road march using a virtual reality environment which combines cognitive load during the road march. Cognitive tasks for example: navigation, identification and remembering cars/aircraft.
without physical or cognitive load (without march, waiting between performance evaluations) as control."
1543502|NCT02644200|Device|Gelatin tannate|
1543503|NCT02644187|Device|BF-RhodoLED|Infrared light, with total dose of 37J/cm2.
1543504|NCT02644187|Device|Aktilite CL128|Infrared light, with total dose of 37J/cm2.
1543505|NCT02644187|Drug|BF200-ALA/5-aminolevulinic acid|Prodrug applied to whole treatment area previous to illumination with either light source.
1543506|NCT02644174|Procedure|Bariatric Surgery|
1543507|NCT02644161|Procedure|Dense cranial electroacupuncture stimulation|"DCEAS is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.
Six pairs of acupoints are used: Baihui (GV20, +) and Yintang (EX-HN3, -), left Sishencong (EX-HN1, -) and Toulinqi (GB15, +), right Sishencong (EX-HN1, -) and Toulinqi (GB15, +), bilateral Shuaigu (GB8, L+, R-), bilateral Taiyang (EX-HN5, L+, R-), and bilateral Touwei (ST8, L+, R-).
Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz, 100 µs)."
1543508|NCT02644161|Procedure|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Qu-Chi (LI11), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).
Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation at 15 min. No electrical stimulation is delivered."
1543509|NCT02644161|Drug|Antidepressant|Patients will continue their existing antidepressant therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
1543510|NCT02644161|Other|Rehabilitation|Patients will continue their existing rehabilitation therapy as usual. Treatment regimens may be further adjusted during 8 weeks of study, depending upon physicians' discretion.
1543511|NCT02644161|Procedure|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (BI7, L+, R-), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (BI7) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
1543512|NCT02644148|Procedure|Conventional Roux-en-Y Gastrojejunostomy|Conventional Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
1543513|NCT02644148|Procedure|Uncut Roux-en-Y Gastrojejunostomy|Uncut Roux-en-Y Gastrojejunostomy after laparoscopic distal gastrectomy for early gastric cancer patients
1543517|NCT02644109|Dietary Supplement|Phytosterol|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.
Days 7 & 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.
Days 15 & 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
1543641|NCT02643147|Drug|CA125 guided strategy|Initial dose of intravenous furosemide ≥120 mg/day or 2.5 times the dose the patient was taking at home.
1543518|NCT02644109|Dietary Supplement|Placebo|"Day 1: Anthropometry, laboratory test, dietary intake (24 hour recall and food frequency questionnaire) and presence of symptoms and side effects will be determined, a logbook will be provided to record product consumption, symptoms, medications and side effects. Then will be randomly assigned to one of the groups.
Days 7 & 21: 24 hour recall, review of symptoms, side effects and adherence as registered in the logbook.
Days 15 & 30: Anthropometry, vital signs, venous blood sample, review of symptoms, side effects and adherence to intervention as registered on logbook, dietary intake (24-hour recall), delivery of monetary compensation proportional to the study days will be given before being discharged."
1543519|NCT02644096|Other|counselling and support after discharge from hospital|patients were contacted by telephone 2 times after discharge from surgery by a specialist nurse, who followed an interview guide due to nursing-rehabilitation after THR
1543520|NCT02644083|Drug|Dimethyl fumarate|
1543521|NCT02644070|Device|alveolar bone preservation with mp3|graft with corticocancellous porcine bone and collagen (MP3, Osteobiol, Coazze, Italy)
1543522|NCT02644070|Device|alveolar bone preservation with apatos|graft with cortical porcine bone (Apatos, Osteobiol, Coazze, Italy )
1543523|NCT02644070|Device|stabilization with membrane|socket stabilization with a collagen membrane (Evolution, Osteobiol, Coazze, Italy)
1543524|NCT02644057|Drug|Milrinone|Patients who meet the inclusion criteria for the study will receive milrinone and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
1543525|NCT02644057|Drug|Dobutamine|Patients who meet the inclusion criteria for the study will receive dobutamine and patients will be monitored for improvement of the renal function objectively with measures such as Blood urea nitrogen, creatinine , daily urine output and changes in weight
1543526|NCT02644044|Drug|Intrathecal methotrexate|12.5 mg of methotrexate diluted to a concentration of up to 4 mg/mL in 0.9 percent sodium chloride with 4 mg Dexamethasone via lumbar puncture needle.
1543527|NCT02644031|Procedure|mtwo rotary system|post-treatment pain after using mtwo rotary system
1543528|NCT02644031|Procedure|safe-sider rotary system|post-treatment pain after using safe-sider rotary system
1543529|NCT02644031|Procedure|hand files|post-treatment pain after using hand files
1543530|NCT02644018|Drug|Imidazolyl ethanamide pentandioic acid|
1543531|NCT02644018|Drug|placebo|
1543532|NCT02644005|Device|Smart Vent Control|Smart Vent Control (SVC) was designed to automatically control the following ventilator settings: mechanical breathing frequency, inspiratory pressure, pressure support, inspiratory time, trigger sensitivity. SVC adjusts the ventilator settings with the aim to keep a patient stable in a target zone (TZ). Numerous predefined TZs exist that can be set according to the current therapeutic situation. All TZs are adoptable by the user for each individual patient and consist of upper and lower limits for tidal volume and for the partial pressure of end-tidal carbon dioxide (PetCO2). Based on these limits, the system classifies the current quality of ventilation, called Classification of Ventilation, and derives new ventilator settings accordingly. SVC is available as a software option on Zeus Infinity Empowered anesthesia machines (Drägerwerk AG & Co. KGAa, Lübeck, Germany) and is approved as a medical product according to 93/42/European Economic Community.
1543533|NCT02643992|Other|DOAC concentration measurement|
1543534|NCT02643979|Drug|Ketofol|50mg of Ketamine mixed with 100mg of Propofol
1543535|NCT02643979|Drug|Propofol|100mg of Propofol
1543536|NCT02643979|Drug|Saline|1mL of saline
1543537|NCT02643966|Device|Whole breast ultrasound|Breast cancer screening with whole breast ultrasound
1543538|NCT02643953|Behavioral|Incentives|1) provision of incentives to encourage women to attend primary health care and use family planning, antenatal, delivery and postnatal services; 2) conditional cash transfers to promote uptake of services; 3) targeted community health education and advocacy activities; 4) community maternal audit/accountability activities, with community-led activities aimed at promoting utilization of services
1543539|NCT02643953|Behavioral|Community|1) outreach services by PHCs; 6) PHC strengthening including training of health providers; and 2) training and kitting of community health rangers who will be trained to follow up women at home to ensure that they do not default but that they continue to use PHC services until delivery.
1543540|NCT02643927|Behavioral|standard 8-weeks MBSR|A 8 weekly sessions of 120 min based on the standard protocol of Kabat Zinn was performed. The adapted program did not include a one-day retreat in silence, but one session in silence plus extra kindly awareness (compassion-based) and value-based exercises. Home practice was not systematically assessed, but recommended to be of 45min per day, most of the days. It was administered by a trained (3-y experience) and certified MBSR teacher (MMPD).
1543541|NCT02643927|Behavioral|4-week shortened MBSR|This protocol was made up of 4 sessions of 120 mn administered by the same trained MBSR programme therapist to avoid variables associated to the therapist. The rationale behind the shortened version of MBSR was to keep the core content and practices of the program, in fewer sessions: raisin exercise (experiential concept of mindfulness); and main anchors of attention (breathing, body sensations, body movements).
1543542|NCT02643914|Drug|Nicotine|
1543543|NCT02643914|Device|MR Compatible Nicotine Delivery Device|
1543544|NCT02643901|Biological|GW003|single SC injection
1543545|NCT02643875|Device|Orthokeratology|It is a kind of rigid permeable lens.
1543547|NCT02643849|Device|The Spanner Temporary Prostatic Stent|
1543548|NCT02643836|Device|PEMF|The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
1543549|NCT02643823|Biological|hUC-MSC + DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease. Combinated with a single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
1543550|NCT02643823|Drug|DMARDs|Patients will be treated by conventional drugs (DMARDs) for alleviating disease.
1543644|NCT02643134|Device|External Physical Vibration Lithecbole|Multi-dimensional physical harmonic vibration inertial guidance technology
1543551|NCT02643810|Other|Exercise training|Patients to be randomized to the 'interval training group' or 'continuous training group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
1543552|NCT02643797|Behavioral|Medical Assistant Health Coaching|One-on-one behavioral health screening and tailored intervention by the MA health coach with patients who have type 2 diabetes.
1543553|NCT02643784|Drug|Rosuvastatin|"Randomized Treatment Period (Day 1 through Day 14): 20 mg once daily for 14 days.
Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
1543554|NCT02643784|Other|Control|"Randomized Treatment Period (Day 1 through Day 14):
No treatment of rosuvastatin for control group. Follow up Period (Day 15 through Day 90) Subjects in both groups who enter the follow up period will receive rosuvastatin 10mg/day."
1543555|NCT02643771|Procedure|Full Mouth Scaling and Root Planing|This procedure was performed as described by Quirynen et al. 2005 with some modifications
1543556|NCT02643758|Device|Bifocal soft contact lenses|
1543557|NCT02643745|Procedure|Nephrology Intervention|"pre-operative study:
Kidney function: creatinine, Glomerular filtration rate (GFR) and presence albuminuria or proteinuria. Assessment whether there is a functional component added.
Discard presence of renal disease: renovascular disease, glomerular disease, toxic, etc.
optimise the patient' s overall condition with a pre-operative strategy:
Obesity control
Control protein, caloric, salt intake
Stop smoking
Good glycemic control
Start ACEI/ARA II (enalapril, ramipril, valsartan, losartan) if there is proteinuria
Start additional antihypertensive drug if required (amlodipine, manidipine, doxazosine, enalapril, ramipril, valsartan, losartan, hidralazine, bisoprolol)
Start hypolipemic treatment if required (atorvastatine, simvastatine, ezetimibe)
Start hyperuricemia treatment if required (alopurinol, febuxostate)
Start AAS, clopidogrel if it is necessary (prophylaxis)
Phosphate control
Anemia control
Metabolic acidosis correction"
1543558|NCT02643732|Drug|Methylphenidate (overencapsulated)|10mg (1 capsule) methylphenidate (standard release) twice daily, increased to 20mg (2 capsules) twice daily after 2 weeks. The drug can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
1543559|NCT02643732|Drug|Placebo (Over-encapsulated tablet)|Identical capsules (over-encapsulated placebo tablets), administered initially one capsule twice daily, increased to 2 capsules after 2 weeks. As with the methylphenidate arm, the dose can be down-titrated in the event of side effects, although re-uptitration is not allowed even if the side effects resolve on the lower dose.
1543560|NCT02643719|Behavioral|Relaxation Therapy|Between 30-60 minutes after the standard of care medication administration (metoclopramide, magnesium, prochlorperazine, ketorolac, or steroids at discretion of treating physician), patient receives training in relaxation therapy.
1543561|NCT02643719|Drug|Topiramate|"Preventive medication prescriptions given to the patient along with written instructions and information about side effects:
Topiramate 25mg tabs (with a plan to increase to 100mg)"
1543562|NCT02643719|Drug|Standard of Care|Standard discharge instruction sheet plus standard of care medication as prescribed by treating physician. The clinical team will be instructed to address post-discharge care as appropriate
1543563|NCT02643719|Drug|Abortive Medication (Naproxen and Sumatriptan)|All participants will receive abortive medication for acute treatment of their migraine. Preferred medications are Naproxen (500mg) and Sumatriptan (100mg)
1543564|NCT02643693|Other|P3L|"Ad libitum use for a maximum of three hours.
P3L delivers on average 80 µg of nicotine per puff under Health Canada Intense smoking regime."
1543565|NCT02643693|Other|VUSE|"Ad libitum use for a maximum of three hours.
VUSE delivers on average 80 µg of nicotine per puff based on the CORESTA e-cigarette recommended smoking regime."
1543566|NCT02643693|Other|CC|Ad libitum use of the subject's own brand of non-menthol CC for a maximum of three hours.
1543567|NCT02643680|Device|The novel biocellulose wound dressing|The novel biocellulose dressing will used as a primary dressing at one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
1543568|NCT02643680|Device|Bactigras|Bactigras will used as a primary dressing at another one half of the donor site. Then,the wound will be covered with 2 layers of gauze (secondary dressing) and 1 layer of bandage.The primary dressing will be unchanged until the wound healing (the day that the dressing detaches by itself with no exudate and air contacted pain) except signs of infection. The secondary dressing will be changed when excessive fluid appears.
1543569|NCT02643667|Drug|Ibrutinib|
1543570|NCT02643654|Drug|MABp1|This is a sterile injectable liquid formulation of 50 mg/mL MABp1 in a stabilizing isotonic buffer (pH 6.4). Each 10-mL serum vial contains 6 ml of the formulation, and is sealed with a 20-mm grey bromobutyl stopper and flip-off aluminum seal
1543571|NCT02643654|Drug|Placebo|The placebo dosage form is a sterile isotonic formulation buffer at pH 6.2-6.5. Each 10-ml Type I borosilicate glass serum vial contains 6mL of the formulation buffer, and is sealed with a 20-mm Daikyo Flurotec butyl rubber stopper and flip-off aluminum seal.
1543572|NCT02643641|Biological|BM32|BM32 is a mixture of 4 different recombinant proteins directed at the major grass pollen allergens, adsorbed on aluminum hydroxide
1543573|NCT02643641|Biological|Placebo|Placebo contains aluminum hydroxide only
1543574|NCT02643628|Procedure|Microneedling|
1543575|NCT02643628|Device|Microneedling followed by Bellafill treatment|
1543576|NCT02643615|Device|VEP under TIVA|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
1543577|NCT02643615|Device|VEP under balanced anesth.|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
1543642|NCT02643147|Drug|Conventional Strategy|The dosage of loop diuretics is done according to the presence of symptoms and signs of systemic congestion and current recommendations
1543578|NCT02643615|Drug|Propofol|Propofol will be administered for anesthesia maintenance in patients randomized to the TIVA arm of the study. In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
1543579|NCT02643615|Drug|Desflurane|Balanced general anesthesia with desflurane will be administered for anesthesia maintenance in patients randomized to the balanced general anesthesia arm of the study, In order to record the VEPs, standard half-inch sub-dermal needle electrodes will be inserted subcutaneously around the visual area and the SightSaverTM visual stimulator will be placed to monitor VEP during surgery.
1543580|NCT02643602|Other|Hydration with bicarbonate in addition to theophylline|0.154-molar sodium bicarbonate; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
1543581|NCT02643602|Other|Hydration with sodium chloride in addition to theophylline|0.9% sodium chloride; 3 ml per kg bodyweight (maximum 330 ml) one hour before contrast exposure; additionally 200 mg theophylline as a short infusion; after contrast application hydration with another 1 ml per kg bodyweight per hour (maximum 110 ml per hour) for 6 hours
1543582|NCT02643589|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
1543586|NCT02643563|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% is used for low-volume ultrasound-guided interscalene brachial plexus block.
1543587|NCT02643563|Drug|Ropivacaine 1%|Ropivicaine 1% is used for low-volume ultrasound-guided interscalene brachial plexus block.
1543588|NCT02643563|Drug|Bupivacaine 0.5% + epinephrine 1:200,000|Bupivacaine 0.5% + epinephrine 1:200,000 is used for low-volume ultrasound-guided interscalene brachial plexus block.
1543589|NCT02643550|Biological|IPH2201|Five dose levels of Monalizumab will be tested in the dose escalation part: 0.4, 1, 2, 4 and 10 mg/kg every 2 weeks.The patients will then receive the recommended dose for phase 2.
1543590|NCT02643550|Biological|CETUXIMAB|The first dose of Cetuximab will be 400 mg/m2 IV.All subsequent doses will be 250 mg/m2
1543591|NCT02643524|Behavioral|Nutrition and Exercise Counseling|Patients are prescribed CAM boot and provided nutritional and upper body exercise counseling at the time the CAM boot is dispensed. Patients will be given a diary to complete their daily meal intake (optional), seated upper body physical exercise guidelines and asked to perform them three days per week and each exercise three times per session if able. They will be asked to record number of hours CAM boot is worn daily in the Patient Diary, if one is utilized. Albumin lab test will be drawn and their height and weight measured.
1543592|NCT02643524|Behavioral|Control|Patients are prescribed CAM boot. No nutritional or exercise guidelines will be provided. Patients will be given a diary to complete their daily meal intake and physician exercise (if any) and number of hours CAM boot is worn daily. Albumin lab test will be drawn and their height and weight measured.
1543593|NCT02643511|Radiation|Transperineal template guided mapping biopsy, multiparametric MRI, Hemiablative Focal Brachytherapy|A re-staging transperineal template guided mapping prostate biopsy as currently performed at participating institutions. Hemiablative Focal brachytherapy will be performed . The affected half of the prostate will be targeted with the prescription dose and receive 145 Gy of Iodine-125 (I-125). A postimplant dosimetry will be performed 30 days after procedure. The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then 4 weeks, 6 months, 12 months, 20 months, 24 months, 32 months and 36 months after treatment. A second transperineal biopsy will be performed 36 months after the implant.
1543594|NCT02643498|Radiation|Stereotactic Body Radiotherapy (SBRT)|
1543595|NCT02643485|Procedure|Forefoot surgery|Forefoot surgery (Chevron, Scarf, Lapidus, Arthrodesis)
1543596|NCT02643472|Behavioral|Parent Navigator|Parents will be contacted by the parent navigator within 2 business days after discharge to assess how the family is coping, answer questions, and provide necessary resources. Navigators will be in touch with families monthly and according to the parent's needs. They will assist the parent in making and keeping appointments, answer questions about insurance coverage, medical equipment and supplies, and serve as a liaison between parent and healthcare providers. However, the specific PN intervention for each family will be based on each family's needs and therefore may differ.
1543597|NCT02643472|Behavioral|Care Notebook|A care notebook will be provided to all parents at discharge. The notebook was created to provide resources and serve as an organizer for appointments for parents of NICU graduates. It was based on peer to peer feedback from former NICU parents, in addition, to community resources developed by current Parent Navigator Program at Children's National Health System.
1543598|NCT02643459|Behavioral|suPAR measurement|The biomarker suPAR will be measured on all patients included in the study. Before the study period the doctors will receive information on suPAR. We want to study if the information provided by suPAR is useful in emergency medicine. Interventions depends on the clinical issue, as suPAR is an unspecific marker of disease. Usually a elevated suPAR level could result in more investigation e.g. diagnostic procedures or follow up, while a low suPAR could result in faster discharge.
1543599|NCT02643446|Biological|IPV|IPV will be vaccinated at 2 months of age act as the first dose of poliovirus vaccine in the study group1 to group 4,group8 to group 11. IPV will be given at 3 month of age act as second vaccine in group 8,9,12
1543643|NCT02643134|Procedure|extracorporeal shockwave lithotripsy|Patients in Group 1 undergo extracorporeal shockwave lithotripsy(ESWL).
1543600|NCT02643446|Biological|OPV|"OPV will be vaccinated at 3 and 4 months of age, act as the second and third dose of poliovirus vaccine in the study group 1 to group 4,group 10 to group 11.
OPV will be vaccinated at 2, 3 and 4 months of age act as the full three primary immunization doses of polio virus vaccine in the study group 5 to group 7."
1543601|NCT02643433|Biological|Measles-Rubella combined vaccine(MR)|0.5ml for each dose,be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
1543602|NCT02643433|Biological|Japanese Encephalitis alive vaccine(JE)|0.5ml for each dose be administered by single use syringe subcutaneously in the lower part of the deltoid area of lateral arm.
1543603|NCT02643420|Drug|SPI-2012|Supplied in prefilled single-use syringes for subcutaneous injection, administered on Day 2 of each cycle.
1543604|NCT02643420|Drug|Pegfilgrastim|Single-dose subcutaneous injection administered on Day 2 of each cycle.
1543605|NCT02643407|Drug|Docetaxel|60mg/m2
1543606|NCT02643407|Drug|Nedaplatin|80mg/m2
1543607|NCT02643407|Drug|Cisplatin|75mg/m2
1543608|NCT02643394|Drug|Oral Acetaminophen|1000mg oral acetaminophen + 400mg oral celecoxib given within one hour of incision
1543609|NCT02643394|Drug|Intravenous acetaminophen|400mg oral celecoxib given within one hour of incision + 1000mg IV acetaminophen within one hour prior to anesthetic emergence.
1543614|NCT02643368|Biological|mOPV2 at 6 and 7 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 7 weeks of age
1543615|NCT02643368|Biological|mOPV2 at 6 and 8 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 8 weeks of age
1543616|NCT02643368|Biological|mOPV2 at 6 and 10 weeks of age|Participants assigned to this intervention will receive a dose of monovalent oral type 2 polio vaccine (mOPV2) at 6 and 10 weeks of age
1543617|NCT02643368|Biological|IPV at 6 weeks of age|Participants assigned to this intervention will receive a dose of inactivated polio vaccine (IPV) 6 weeks of age
1543618|NCT02643355|Drug|Olanzapine|
1543619|NCT02643355|Drug|Clonidine|
1543620|NCT02643342|Device|Orthokeratology|
1543621|NCT02643329|Drug|BF-Gliclazide Tablet 80mg|BF-Gliclazide Tablet is a generic product manufactured by Bright Future Pharmaceuticals Factory O/B Bright Future Pharmaceutical Laboratories Limited
1543622|NCT02643329|Drug|Diamicron 80mg Tablet|Diamicron 80mg Tablet is manufactured by Les Laboratoires Servier Industrie, France
1543623|NCT02643316|Drug|Same day 4 L preparation (Polyethylene Glycol)|Receive 1 gallon (4 L) of Polyethylene Glycol preparation on the morning of the colonoscopy.
1543624|NCT02643316|Drug|Split dose 4 L preparation (Polyethylene Glycol)|Receive the split-dose regimen. Will take half (2 L) the preparation the evening before colonoscopy and half (2 L) on the morning of the procedure.
1543628|NCT02643290|Device|Peak Scoliosis Bracing System|Brace is fit to adult scoliosis patients for 2-4 hours a day and tracked for six months.
1543629|NCT02643277|Behavioral|Mobile phone text messaging|The intervention will be text messages delivered by an automated text messaging manager. The message content will be designed to induce lifestyle modification (diet and physical activity) and will be motivational, based on the content which has been proven to be effective in reducing progression to diabetes in people with pre-diabetes. Other text messages will aim to improve drug compliance and disease monitoring, based on our pilot studies in India. The control arm will receive conventional management, according to local guidelines in the Indian centers, which in all cases are compatible with those of the International Diabetes Federation.
1543630|NCT02643277|Other|Conventional care|Conventional care is comprised of a one-to-one interview by a trained research personnel on diet and exercise advice at baseline and during every visit. The goals were to reduce portion size (total calories) and, to avoid simple sugars and refined carbohydrates, reduce total fat intake, restrict use of saturated fat, include more fibre rich food-(e.g., whole grains, legumes, vegetables, and fruits).
1543631|NCT02643264|Other|rTMS 10 Hz targeting the insula|Participants will receive a total of 15 sessions of rTMS targeting the insula bilaterally, Stimulation will be delivered at an intensity of 120% of the motor threshold (MT), with a frequency of 10 Hz, delivered as 50 trains of 30 pulses delivered in each train of 3 seconds duration, with a 20 seconds inter-train interval, for a total of 1500 pulses delivered over app. 20 min. On the very first two sessions stimulations will be given at lower strength for adaptation, starting at 100% for the first and 110% for the second session
1543632|NCT02643264|Other|Sham rTMS|Sham stimulation with the same regimen as active treatment
1543633|NCT02643212|Drug|Rivaroxaban|
1543634|NCT02643212|Drug|Placebo|
1543635|NCT02643186|Drug|preoperative vaginal misoprostol|preoperative vaginal misoprostol 400 micrograms 1 hour before surgery
1543636|NCT02643186|Procedure|bilateral uterine artery ligation|bilateral ascending uterine artery ligation at the level of uterine isthmus with 2/0 vicryl sutures
1543640|NCT02643147|Drug|CA125 guided strategy|Initial dose of intravenous furosemide ≤80 mg / day regardless of prior dose of loop diuretics who were receiving.
1543645|NCT02643121|Other|therapy sepsis|Treatment of sepsis varies depending on the site and cause of the initial infection, the organs affected and the extent of any damage
1543646|NCT02643108|Procedure|Lateral episiotomy|When the woman is randomized to episiotomy, lateral episiotomy is performed with scissors on the left or right side of the vaginal opening. Origin of incision is 1.5 - 2.0 cm from the midline/posterior forchette and is cut 3.0 cm or more towards the ischial tuberosity at an angle of 60 degrees from the midline.
1543647|NCT02643095|Device|scleral contact lens|Scleral contact lens
1543648|NCT02643082|Drug|GFF MDI (PT003) 14.4/9.6μg|Glycopyrronium and Formoterol Fumarate
1543649|NCT02643082|Drug|Placebo MDI|Comparator: Placebo MDI which contains no active ingredients
1543650|NCT02643069|Other|Intervention Geriatric Program|The investigators will implemented programs to detected and manage care for older patients in four settings: Emergency room, oncology department, surgery departments making major surgery and Cardiology. The core intervention will consist of the following elements: comprehensive geriatric assessment, coordination with primary ans social care, integrated and continued care, access to rehabilitation facilities, management of drug treatment avoiding polypharmacy and stressing adherence.
1543651|NCT02643056|Drug|Panitumumab|IV administration every 2 weeks
1543652|NCT02643043|Other|Biospecimen Collection|Subjects consent to provide access to archival tumor tissue and whole blood samples for genetic analysis. Subjects also consent to the indefinite use of their specimens and linked clinical information for ongoing or future research related to metastatic urothelial cancer.
1543653|NCT02643030|Behavioral|hypercapnia|Tidal volume (6 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 45mmHg
1543654|NCT02643030|Behavioral|normocapnia|Tidal volume (10 ml/kg) and respiratory rate is adjusted to achieve the objective values of ETCO2 35mmHg
1543655|NCT02643017|Drug|Dexmedetomidine|Administration of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
1543656|NCT02643017|Drug|normal saline|Administration of same amount of dexmedetomidine at a rate 0.6 ug/kg/hr during surgery.
1543657|NCT02643004|Device|Senofilcon A|contact lens
1543658|NCT02643004|Device|Stenfilcon A|contact lens
1543659|NCT02642991|Device|Study Test contact lens|
1543660|NCT02642991|Device|comfilcon A contact lens|
1543661|NCT02642978|Procedure|RSRCLM|The Da Vinci Surgical System may help to overcome some of the difficulties of laparoscopy for complicated abdominal surgery. The aim of this study was to present an innovative technique that is robot-assisted, simultaneous radical resection of both colorectal cancer and liver metastasis (RSRCLM).
1543662|NCT02642978|Procedure|Open|Traditional open simultaneous radical resection of both colorectal cancer and liver metastasis
1543663|NCT02642965|Drug|Cytarabine|Given IT or IV
1543664|NCT02642965|Biological|Filgrastim|Given SC or IV
1543665|NCT02642965|Drug|Fludarabine Phosphate|Given IV
1543666|NCT02642965|Other|Laboratory Biomarker Analysis|Correlative studies
1543667|NCT02642965|Drug|Liposomal Cytarabine-Daunorubicin CPX-351|Given IV
1543668|NCT02642965|Other|Pharmacological Study|Correlative studies
1543669|NCT02642952|Other|non-invasive methods|To measure central hemodynamics and arterial stiffness by non-invasive methods using SphygmocoR (Atcor Medical, Sydney, Australia) before and after the procedure.
1543670|NCT02642939|Drug|Mifepristone|Mifepristone is an antagonist of the GR-II (glucocorticoid) receptor, yet has little affinity for the GR-I (mineralocorticoid) receptor. Mifepristone is also a potent antagonist at the progesterone receptor, and may block the androgen receptor to a limited degree.
1543671|NCT02642926|Procedure|Monopolar current|Hysteroscopic surgical treatment of menorrhagia by use of monopolar current
1543672|NCT02642926|Procedure|Bipolar current|Hysteroscopic surgical treatment of menorrhagia by use of bipolar current
1543675|NCT02642900|Procedure|Photodynamic Therapy|evaluate the effectiveness of photodynamic therapy (PDT) in the treatment of denture stomatitis in complete denture wearers.
1543676|NCT02642900|Drug|Nystatin 100.000 units|Control group treated with nystatin
1543677|NCT02642887|Procedure|mTA + SCTG|These recession defects will be covered by modified tunnel approach; using a full thickness flap till the level of mucogingival junction then, partial thickness flap will be applied in the vestibular mucosa. SCTG will be harvested from the palate, put on the root surface then covered by the mTA and sutured.
1543678|NCT02642874|Drug|Methocarbamol|Methocarbamol twice daily
1543679|NCT02642874|Drug|Calcium Carbonate|Calcium carbonate twice daily
1543680|NCT02642861|Drug|Cyclobenzaprine|cyclobenzaprine administration for 2 weeks
1543681|NCT02642861|Drug|Calcium Carbonate|Calcium carbonate for 2 weeks
1543682|NCT02642848|Procedure|HTO with microfracture|High tibial osteotomy(HTO) with micro fracture on femoral condyle is an common treatment for the correction of malalignment of the knee treating osteoarthritis. Device: Tomofix
1543683|NCT02642848|Procedure|Transplantation of bone marrow stem cell|Transplantation of autologous bone marrow cell concentrate using BMAC collecting from iliac bone. Bone marrow cell cell 6cc
1543684|NCT02642848|Procedure|Transplantation of adipose derived stem cell|Transplantation of autologous adipose-derived stromal vascular fraction using LipoSculptor collecting from abdominal fat tissue. Adipose derived stem cell from abdominal fat tissue 3cc
1543692|NCT02642796|Device|transcutaneous electric nerve stimulation|"The TENS device will be applied for treatment periods of 30-40 minutes. The electrodes will be connected to the TENS device are stimulated in modulation mode and the parameters will be adjusted as pulse width of 60 μs,frequency of 120 Hz and the stimulation intensity as high as the subject could tolerate.
Electrodes will be placed on either lumbar and sciatic nerve tracing unilaterally or on either side or parallel to the surgical wound."
1543693|NCT02642783|Behavioral|Descriptive analysis|subjects were asked to assess the sensory profile by tasting the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
1543694|NCT02642783|Behavioral|acceptability test|subjects were asked to assess the acceptability of the laxative bowel cleansing solutions, namely: Moviprep, picoprep, fortrans and isinova
1543695|NCT02642770|Device|Transesophageal echocardiography|2D LV Speckle tracking strain and 3D LVEF measurements
1543696|NCT02642757|Behavioral|AUDIT brief intervention|Intervention will be provided following the Chilean ministry of health implementation manual on the AUDIT associated brief intervention. The pamphlet on alcohol use will be provided to participants.
1543697|NCT02642757|Other|Pamphlet on alcohol use|Only the pamphlet on alcohol use will be provided (the same received by participants on the intervention group). This is not an active intervention based on the current literature.
1543698|NCT02642744|Other|Nursing care model|Subjects will be randomized into either the attending nursing model of care vs the standard nursing model
1543699|NCT02642718|Drug|Ketorolac Tromethamine|In the operating room, the anesthesiologist administered ketorolac (30 mg) in 50 mL of 0.9 % saline intravenously to patients in the ketorolac group 30 minutes before surgical incision (a single dose).
1543700|NCT02642718|Other|Placebo|In the operating room, the anesthesiologist administered 50 mL of 0.9 % saline intravenously to patients in the control group 30 minutes before surgical incision
1543701|NCT02642705|Other|High intensity interval training N|Exercise training and ambient air breathing
1543702|NCT02642705|Other|High intensity interval training H|Exercise training and hypoxic breathing
1543703|NCT02642705|Other|Constant load exercise training N|Exercise training and ambient air breathing
1543704|NCT02642705|Other|Constant load exercise training H|Exercise training and hypoxic breathing
1543705|NCT02642705|Other|Hypoxic conditioning at rest|Hypoxic breathing at rest
1543706|NCT02642705|Other|Normoxic conditioning at rest|Normoxic breathing at rest (placebo)
1543707|NCT02642692|Procedure|Patellar Tendon graft|Acl reconstruction with patellar tendon graft
1543708|NCT02642692|Procedure|Hamstring Graft|Acl reconstruction with hamstring graft
1543710|NCT02642666|Behavioral|Children's Yoga|"Trained children's yoga instructors will guide the children through 30 minute yoga classes (in-person and on the yoga video), using a manualized curriculum from If I Was a Bird Yoga ™ with child centered themes. Each class will have a similar structure, set of poses, and breathing exercises, but the theme of the class will change every two weeks. The themes for the classes are ocean yoga adventure, jungle yoga adventure and outer space yoga adventure. The study participants will spend two weeks practicing the same theme at home and at school before moving on to the next theme."
1543711|NCT02642653|Drug|Lovastatin|Once per day dosing
1543712|NCT02642653|Other|Placebo|Once per day dosing
1543713|NCT02642640|Dietary Supplement|melatonin|5 mg of melatonin per os.
1543714|NCT02642640|Drug|placebo|
1543715|NCT02642627|Device|Bellafill|
1543716|NCT02642614|Drug|BI 1026706|
1543717|NCT02642614|Drug|Placebo|
1543718|NCT02642614|Drug|Placebo|For blinding purposes
1543719|NCT02642601|Drug|Indomethacin(KAHIRA PHARMA&CHEM,IND,CO.CAIRO-EGYPT)|one dose of indomethacin 100 mg rectal suppository 1- 2 hours before embryo transfer
1543720|NCT02642588|Dietary Supplement|energy gel|energy gel: gelatinous edible containing carbohydrates typically used during endurance races
1543722|NCT02642549|Behavioral|Girls for Health|"The G4H '1000 Hours' Bridge Program will offer English, science and math training, career workshops, opportunity to 'shadow' a health provider, a mentored safe space club to facilitate economic empowerment, training on gender equity and human rights, and communication/leadership skills. Cash transfers for vacations will be provided to support participation. Girls who receive 5 credits on their SSCE exams and pass the health training institute (HTI) entrance exam are eligible for admission. A Foundational Science Training (FST) program will be provided to the '1000 Hours' participants who gain admission to a HTI to strengthen their ability to the pass the HTI weeding exams. The FST will focus on English, math and science training, and safe spaces for social support development."
1543723|NCT02642536|Behavioral|MH MOVE|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms to be used during 10 phone based clinician led CBT sessions
1543724|NCT02642536|Behavioral|Enhanced Usual Care|provides the standard MOVE! weight management program plus a workbook containing education for management of depression, anxiety and PTSD symptoms but not phone calls are provided.
1543725|NCT02642523|Drug|Nesiritide|Subjects will receive an intravenous infusion of recombinant human b-type natriuretic peptide (BNP) (Nesiritide) over 2 hours at 2 doses: 0.003 ug/kg/min for 1 hour, followed by 0.01 ug/kg/min for 1 hour. Nesiritide (Johnson and Johnson) is FDA-approved for the treatment of heart failure. Study investigators received approval from the FDA for an IND exemption for nesiritide in this study. While receiving the BNP infusion, subjects will also receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
1543726|NCT02642523|Drug|Insulin|The hyperinsulinemic-euglycemic insulin clamp, which will last between 2-2.5 hours, involves continuous intravenous infusions of human regular insulin and of dextrose solution. Simultaneously, subjects receive an intravenous infusion of normal (0.9%) saline over 2 hours. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
1543727|NCT02642523|Other|Saline|Subjects will receive an intravenous infusion of normal (0.9%) saline over 2 hours at a rate of 0.25 ml/kg/min. Subjects will receive a standardized high-salt diet for at least 6 days prior to this study visit.
1543728|NCT02642510|Other|Structured Education DVD + Verbal Teaching|"The structured education DVD is a 15-minute DVD presentation of information about unit routines and activities; leukemia/lymphoma; treatment modalities and procedures; treatment of side effects; and participant and family members activities of importance to prevent infection and promote well-being during cancer treatment.
Participants will also receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects."
1543729|NCT02642510|Other|Verbal Teaching|Participants will receive verbal educational teaching by their assigned nursing staff regarding information about leukemia and lymphoma, common treatments, and side effects.
1543730|NCT02642497|Drug|intra-wound instillation of ketamine|intra-wound instillation of ketamine (1 mg/ kg) and normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
1543731|NCT02642497|Drug|intra-wound instillation of normal saline|intra-wound instillation of normal saline in a total volume of 10 ml dispersed evenly throughout the wound; given after hemostasis and before wound closure
1543732|NCT02642497|Drug|systemic administration of ketamine|intra-muscular administration of ketamine (1 mg/ kg), given before wound closure.
1543733|NCT02642484|Drug|Gabapentin|Gapapentin twice daily
1543734|NCT02642484|Drug|Calcium Carbonate|calcium carbonate twice daily
1543735|NCT02642471|Procedure|no systematic pelvic lymphadnectomy|systematic pelvic lymphadnectomy is omitted in surgical treatment
1543736|NCT02642445|Device|Renal Sympathetic Denervation|We applied a ablation catheter for discrete radiofrequency ablations of 8 W or less and lasting up to 2 min each to obtain up to four-six ablations separated both longitudinally and rotationally from the adventitia
1543738|NCT02642419|Drug|Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel)|"Rivaroxaban will be orally administered after a meal at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min (regardless of time)
Antiplatelet will be selected from aspirin or thienopyridine derivatives (clopidogrel or prasugrel)
Aspirin will be orally administered once a day at a dose of 81 mg or 100 mg
Clopidogrel will be orally administered once a day after a meal at a dose of 75 mg. The dose will be reduced to 50mg once a day depending on age, body weight or clinical findings.
Prasugrel will be orally administered once a day at a dose of 3.75 mg. If the body weight is 50kg or less a reduced dose(2.5 mg once a day) will be considered depending on the age, renal function or other bleeding and thrombotic risk."
1543739|NCT02642419|Drug|Rivaroxaban|Rivaroxaban will be orally administered at a dose of 15 mg if the creatinine clearance (CLcr) is 50 mL/min or more and at a dose of 10 mg if the CLcr is 15-49 mL/min.
1543740|NCT02642406|Procedure|Blood sampling|A blood sample will be taken during a routine blood draw before the application of any nab-Paclitaxel.
1543743|NCT02642380|Drug|Dexamethasone (4 cycles)|dexamethasone 40mg daily for 4 consecutive days every 14 days for 4 courses
1543744|NCT02642380|Drug|Dexamethasone (1 cycle)|dexamethasone 40mg daily for 4 consecutive days
1543745|NCT02642367|Device|McGrath videolaryngoscope|without use of stylet
1543746|NCT02642367|Device|McGrath videolaryngoscope with Intubating stylet (Mallinckrodt)|use of stylet
1543747|NCT02642367|Drug|rocuronium|tracehal intubation was performed 2 min after rocuronium injection with McGrath videolaryngoscope
1543748|NCT02642354|Device|Study Test contact lens|
1543749|NCT02642354|Device|comfilcon A contact lens|
1543750|NCT02642341|Device|Study Test contact lens|
1543751|NCT02642341|Device|comfilcon A contact lens|
1543752|NCT02642328|Other|HIIT Training|Circuit of high intensity interval training (HIIT) with Strength and Power Exercises for 4 minutes (20 sec of stimulus / 10 sec rest)
1543753|NCT02642328|Other|Control|Continuous aerobic exercise at 65% of VO2Max
1543754|NCT02642315|Drug|Horizant|"Phase1: During phase 1 therapy, Horizant will be added on as an adjunct to all subjects taking part in the study along with stable dose of their current dopaminergic (DA) agent and both medication will be continued for a total period of 90 days from day 0 to day 90. Subjects will be evaluated for three visits (days 30, 60 and 90) during Phase I.
Phase 2: At the 90th day follow-up visit, with initiation of phase 2 therapy, all subjects will be tapered off (by 50% reduction in dose each week) of their current dopaminergic agents while maintaining the same dose of Horizant and will be on Horizant monotherapy. All subjects will be evaluated for additional three clinic visits (days 120, 180, 360)."
1543755|NCT02642302|Behavioral|HIIT With 60 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 60 seconds rest on VO2Max and aerobic/ anaerobic performance
1543756|NCT02642302|Behavioral|HIIT With120 sec Rest|30 sessions of High intensity interval training (all out) with 30 seconds of stimulous with 120 seconds rest on VO2Max and aerobic/ anaerobic performance
1543757|NCT02642302|Behavioral|Control|Continuous exercise at 50-55% VO2Max with similar total work of interval training
1543758|NCT02642289|Dietary Supplement|Lactobacillus acidophilus|"Probiotic 5000, a commercial probiotic product provided by the company Complementos Fitonutricionales, S.L."
1543759|NCT02642289|Dietary Supplement|Lactobacillus Rhamnosus GG ®|"Ergyphilus confort, a commercial probiotic product provided by the nutritional supplements lab Laboratorios Nutergia"
1543760|NCT02642289|Other|Placebo|Innocuous substance
1543761|NCT02642276|Other|Exercise training|Patients to be randomized to the 'maximal walking group' or 'submaximal group' will undergo exercise training sessions 3 times per week for a period of 12 weeks.
1543762|NCT02642263|Drug|Carbetocin|Postpartum uterotonic drug
1543763|NCT02642250|Drug|Metronidazole|The data will be recorded for physical examination including gender , age, height, weight, temperature, heart rate ,respiratory rate and blood pressure of the subject, number of stool per day, stool with or without mucus or mixed with blood along with abdominal cramps, dehydration, nausea, vomiting and related clinical information will be carefully recorded. Statistical tools and tabulated results will be used to identify the similarities and differences in safety, efficacy and tolerability of treatment.
1543764|NCT02642250|Drug|Entoban|To evaluate the safety and efficacy of coded herbal formulation (Entoban) through randomized clinical study and compared with Metronidazole DS for treatment of gastrointestinal infections for improving the health of the community with due regard to the prevalence of disease and the feasibility of using alternative treatments.
1543765|NCT02642237|Biological|Fluenz|intranasal inoculation with Fluenz
1543766|NCT02642237|Other|placebo|
1543767|NCT02642237|Other|LPS|
1544012|NCT02640430|Device|standard treatment|20 minutes, twice a day for 10 sessions
1543768|NCT02642224|Behavioral|Social Work Case Management|The National Network of Hospital Violence Intervention (NNHVI) suggests that intervening when gunshot victims are receiving treatment in hospital trauma services may be effective in linking high-risk individuals to appropriate case management services, and that this service linkage may lower the risk of further violence. Our adaptation of the NNHVI model will focus on the social networks of gunshot victims as well as the victims themselves. Intervention efforts will range from job training and mentoring to relocation to different communities.
1543769|NCT02642211|Procedure|cataract surgery|Eyes (one eye per patient) randomized to either phacoemulsification and intraocular lens insertion or small incision cataract surgery and intraocular lens insertion
1543771|NCT02642185|Procedure|Microwave ablation|CT-guided percutaneous ablation of 1-5, <31mm in diameter, colorectal liver metastases, performed with any generic microwave ablation system cleared for clinical use
1543772|NCT02642185|Procedure|Resection|Open or laparoscopic resection of liver metastases using standard of care surgical procedures
1543773|NCT02642172|Dietary Supplement|ITF (Inulin/OFS 75/25)|Participants will consume 16 g/day ITF
1543774|NCT02642172|Dietary Supplement|Placebo|Participants will consume 16 g/day maltodextrin
1543775|NCT02642159|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1543776|NCT02642159|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1543777|NCT02642159|Drug|statins|Pharmaceutical form:tablet Route of administration: oral
1543778|NCT02642159|Drug|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
1543779|NCT02642159|Drug|fenofibrate|Pharmaceutical form:tablet Route of administration: oral
1543780|NCT02642159|Drug|nicotinic acid|Pharmaceutical form:tablet Route of administration: oral
1543781|NCT02642159|Drug|omega-3 fatty acids|Pharmaceutical form:tablet Route of administration: oral
1543782|NCT02642146|Drug|Calcium Channel Blockers|
1543783|NCT02642146|Drug|Phosphodiesterase Inhibitors|
1543784|NCT02642146|Drug|Endothelin receptor blocker|
1543785|NCT02642146|Drug|Prostanoids|
1543786|NCT02642146|Drug|Other vasodilator|
1543787|NCT02642133|Procedure|Lingual Frenotomy and/or maxillary labial frenectomy|The procedure is performed with a 1064nm InGaAsP semiconductor diode laser which is a soft tissue laser with variable pulsed wave and wattage settings. The procedure was performed at 0.7-0.8 pulsed watts, 200 microseconds on and 100 microseconds off (actual wattage: 0.47 to 0.53 W) using a 300 micron laser fiber. The tongue is elevated using a grooved director while the laser tip is applied to the frenulum. If present, the anterior frenulum is divided until the submucosal portion of the tie is identified (this is the posterior tongue-tie). A small window in the central mucosa is made and the lateral mucosal walls of the posterior tongue-tie are released, taking care to not disturb the fascia of the underlying genioglossus muscle.
1543788|NCT02642120|Device|"Dental device Laboraide"|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
1543789|NCT02642107|Radiation|Elective neck irradiation|Whole neck irradiation is given in the positive neck. Elective neck irradiation of Level II,III,Va lymph node area is given in negative neck, and Level IV,Vb and Supraclavicular fossa lymph node area were not irradiated in negative neck.
1543790|NCT02642107|Radiation|Whole neck irradiation|Whole neck irradiation is given regardless of negative neck or positive neck
1543792|NCT02642055|Behavioral|Neuro+ Attention Training|Attention training program with Neuro+ software
1543793|NCT02642055|Other|Treatment as Usual|Continuation of current ADHD treatment
1543797|NCT02642029|Device|Excitatory TMS|Single session of intermittent theta-burst stimulation (600 pulses in blocks of 2s, separated by 8s of pause) to cerebellar vermis.
1543798|NCT02642029|Device|Inhibitory TMS|Single session of continuous theta-burst stimulation of 600 pulses to cerebellar vermis.
1543799|NCT02642029|Device|Sham TMS|Single session, using the exact same procedures as the active arms but with a sham coil, which is designed to induce the same nonspecific sensory effects of TMS (auditory and somatosensory activation) without inducing the neuromodulatory magnetic fields.
1543800|NCT02642016|Biological|CDX-0158 (formerly known as KTN-0158)|Single agent CDX-0158 until unacceptable toxicity or progressive disease
1543801|NCT02642003|Drug|Granulocyte Colony Stimulating Factor|
1543802|NCT02641990|Drug|ITCA 650 20/60 mcg/day, ITCA placebo|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days, followed by ITCA osmotic mini pump delivering placebo and Levora® for 28 days
1543803|NCT02641990|Drug|ITCA placebo, ITCA 650 20/60 mcg/day|ITCA osmotic mini pump delivering placebo and Levora® for 28 days, followed by Levora® and ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day and Levora® for 28 days
1543804|NCT02641951|Other|Stellate ganglionic block|Ultrasound guided stellate ganglionic block
1543805|NCT02641951|Other|Pecs II block|Ultrasound guided Pecs II block
1543806|NCT02641938|Drug|Dexmedetomidine|Dexmedetomidine group :1ug/kg IV loading over 20 minutes followed by 0.5ug/kg/hr IV infusion after induction of anesthesia until the completion of the surgery
1543807|NCT02641938|Drug|Normal Saline|Control group :IV loading and infusion of same volume of normal saline after induction of anesthesia until the completion of the surgery
1543808|NCT02641925|Procedure|Omentum preserving|The minimum volume of omentum (within 3cm from gastroepiploic vessel) will be removed during gastrectomy with lymph node dissection.
1543809|NCT02641925|Procedure|Total omentectomy|Whole omentum will be removed during gastrectomy with lymph node dissection.
1544013|NCT02640430|Device|Free Aspire|20 minutes, twice a day for 10 sessions
1543810|NCT02641912|Other|Biotene mouthwash|During supervised product use: Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. No rinsing with water immediately after product usage is permitted. At Home use:Participants will rinse with 15 mls of mouthwash for 30 seconds and spit out. A maximum of two doses can be used per day.
1543811|NCT02641912|Other|Mineral Water|"During supervised product use:Participants will take a dose (drink) of one measured sip of 15mls of water.
At Home use: Participants can sip (drink) water as often as required. Participants will be consuming their own water for home use."
1543812|NCT02641899|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20 mcg/day for 14 days, followed by ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day.
1543813|NCT02641899|Drug|Acetaminophen|Oral acetaminophen 1000 mg on Day 1 and Day 27
1543814|NCT02641899|Drug|Atorvastatin|Oral atorvastatin 40 mg on Day 2 and Day 28
1543815|NCT02641899|Drug|Lisinopril|Oral lisinopril 20 mg on Day 2 and Day 28
1543816|NCT02641899|Drug|Warfarin|Oral warfarin 25 mg on Day 2 and Day 28
1543817|NCT02641899|Drug|Digoxin|Oral digoxin 0.5 mg on Day 2 and Day 28
1543818|NCT02641886|Drug|Jian Pi Yi Shen Hua Tan Granules|Jianpi Yishen Huatan Granules contain Herba cistanche，Fructus Alpinia Oxyphyllae，Rhodiola rosea, Polygala tenuifolia willd and Coptis chinensis.Jianpi Yishen Huatan Granules dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of treatment cycles: one
1543819|NCT02641886|Other|the placebo group|Treat with the placebo which contain 5% of prescription of Jian Pi Yi Shen Hua Tan Granules and 95% dextrin.The placebo dissolved in water of 100 ml ,po, bid of each 90-days cycle. Number of cycles: one
1543820|NCT02641873|Drug|BBI608|240 mg twice daily (480 mg total daily dose)
1543821|NCT02641873|Drug|5-FU|400 mg/m2 bolus will be administered intravenously immediately following irinotecan/levofolinate infusion, followed by 1200 mg/m2/day (total 2400 mg/m2) continuous infusion per cycle(14 days).
1543822|NCT02641873|Drug|Irinotecan|180 mg/m2 together with levofolinate will be administered intravenously per cycle(14 days).
1543823|NCT02641873|Drug|Levofolinate|200 mg/m2 together with Irinotecan will be administered intravenously per cycle(14 days).
1543824|NCT02641873|Drug|Bevacizumab|5 mg/kg will be administered intravenously following irinotecan/levofolinate infusion per cycle(14 days).
1543825|NCT02641860|Biological|Mesenchymal progenitor cells|Biological: Allogenic Adipose tissue-derived mesenchymal progentior cells administrated for intra-articular use
1543826|NCT02641847|Drug|docetaxel|
1543827|NCT02641847|Drug|doxorubicin or epirubicin|
1543828|NCT02641847|Drug|cyclophosphamide|
1543829|NCT02641847|Drug|gemcitabine|
1543830|NCT02641847|Drug|cisplatin|
1543831|NCT02641834|Other|Vegetarian diet|7-days dietary profile with an isocaloric Vegetarian diet for 3 months
1543832|NCT02641834|Other|Mediterranean diet|7-days dietary profile with an isocaloric Mediterranean diet for 3 months
1543833|NCT02641821|Drug|Nifedipine GITS|
1543834|NCT02641808|Other|follicular flushing|Depending on randomisation the follicle is not flushed (group A) or flushed adapted to follicule size (16mm 2ml, 18mm 3ml, and 20mm 4ml etc.) up to five times with (e.g.flushing media with heparin (SynVitro® Flush, Origio, Berlin, Germany). The flushings are collected each in a separate collecting tube (group B). The analysis of the collected oocytes is performed in the IVF lab.
1543835|NCT02641808|Other|no follicular flushing|
1543836|NCT02641795|Device|Minimally invasive robotic cochlear implantation|
1543837|NCT02641782|Drug|antibody ch14.18|17.5mg/m²d 10-20h i.v, d4-7 in cycles 1,3,5 and d8-11 in cycles 2,4.
1543838|NCT02641782|Drug|GM-CSF|250µg/m²xd, d1-14 s.c. or i.v (2h) in cycles 1,3,5
1543839|NCT02641782|Drug|IL-2 i.v.|3.0 mio U/m²xd d1-4 continuous infusion i.v. and 4.5 mio U/m²xd d8-11 continuous infusion i.v. in cycles 2,4
1543840|NCT02641782|Drug|IL-2 s.c.|0.06 mio U/m² i.v. test dosis for 30min. i.v. at least 2h before first subcutaneous (s.c.) application. 6 mio U/m²xd d1-5 and 8-12 s.c. in cycles 2,4
1543841|NCT02641782|Drug|Retinoic acid|160mg/m²xd b.i.d.oral d 11-24 in cycles 1,3,5,6 and d15-28 in cycles 2,4
1543842|NCT02641769|Biological|Stem Cell Transplantation|intervention with transplantation of autologous purified stem cells
1543843|NCT02641756|Other|treatment interruption after in depth sampling under CART|The participants will undergo in depth sampling under CART to characterise the HIV reservoir in different anatomical compartments. Subsequently an experimental viral rebound, by a brief therapy stop, will help us identify the clinically relevant viral reservoir by doing phylogenetic analysis on the rebounding virus and on the virus found in the different compartments under CART.
1543844|NCT02641743|Dietary Supplement|Inslow|carbohydrate adjusted liquid food using palatinose as the major carbohydrate (>50%)
1543845|NCT02641743|Dietary Supplement|standard balanced formula|
1543846|NCT02641730|Drug|Guselkumab|Participants will receive two or one syringe of guselkumab 100 mg subcutaneously at Week 0, 4, 12 and every 8 weeks thereafter through Week 60 in group 1 or 2. Group 3a or 3b participants will receive two or one syringe of guselkumab 100 mg at Week 16, 20 and every 8 weeks thereafter through Week 60.
1543847|NCT02641730|Drug|Placebo|Participants in group 1 will receive placebo at Week 16. Participants in group 2 will receive placebo at Week 0, 4, 12, 16, 20 and every 8 weeks thereafter through Week 60. Participants in group 3 will receive placebo at Week 0, 4, 12, then at Week 16, 20 and every 8 weeks thereafter through Week 60 for group 3b.
1543848|NCT02641717|Other|vaginal swab|
1543849|NCT02641704|Behavioral|Multidisciplinary program|Coordinated multidisciplinary program
1543850|NCT02641691|Radiation|Radiation|
1543851|NCT02641691|Drug|Oxaliplatin|
1543852|NCT02641691|Drug|Leucovorin|
1543853|NCT02641691|Drug|Fluorouracil|
1543854|NCT02641678|Device|Implantation of cardiac monitor|In patients with kryptogenic stroke, a cardiac monitor was implanted to detect atrial fibrillation
1543855|NCT02641665|Procedure|Cardiac valve surgery|Aortic or mitral valve replacement/repair performed in isolation of in addition to coronary artery bypass graft(s).
1543856|NCT02641652|Drug|Sertraline|25 mg once daily for first 7 days, then 50 mg once daily for the rest of the trial
1543857|NCT02641652|Drug|Placebo|1/2 tablet once daily for first 7 days, then 1 tablet once daily for the rest of the trial
1544014|NCT02640417|Drug|Nucleotides + B12|Oral treatment with either Nucleotides + Vitamin B12
1543858|NCT02641639|Drug|Fosbretabulin tromethamine|CA4P is a synthetic phosphorylated prodrug of CA4, a naturally occurring derivative of the South African willow tree, combretum caffrum. CA4P targets pre-existing tumor vasculature, resulting in an acute, reversible reduction in TBF that leads to central necrosis within tumors.
1543859|NCT02641639|Drug|Placebo|Saline for infusion
1543860|NCT02641626|Procedure|Urgent Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
1543861|NCT02641626|Procedure|Deferred Coronary Angiography|Diagnostic test for the evaluation of the coronary vasculature.
1543862|NCT02641613|Procedure|retroclavicular block|retroclavicular block for forearm or hand surgery
1543863|NCT02641613|Procedure|supraclavicular block|supraclavicular block for forearm or hand surgery
1543866|NCT02641587|Other|CHTP 1.2|Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.
1543867|NCT02641587|Other|CC|Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.
1543868|NCT02641574|Other|compare complication|
1543873|NCT02641548|Device|Sock of silicone|
1543874|NCT02641548|Other|Heel cream|
1543875|NCT02641535|Other|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously
experiment days (2 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (35 deg. centigrade & 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
1543876|NCT02641535|Device|BC membrane protective garment|
1543877|NCT02641535|Device|NBC mask|
1543878|NCT02641522|Drug|Siltuximab|Single infusion of siltuximab (11 mg/kg)
1543879|NCT02641509|Device|NBI during polypectomy|NBI to perform the polipectomy
1543880|NCT02641509|Device|no NBI during polypectomy|no NBI to perform the polypectomy
1543881|NCT02641496|Behavioral|CBT-OSA|Participants will
1543882|NCT02641496|Behavioral|Sleep Education|Participants will
1543883|NCT02641483|Other|Electrical Rectal Stimulation|Electrical stimulation of the rectum will be applied to activate sensory afferent neurons of the rectum and evoke a recto-colonic reflex to improve colonic motility. This intervention will compared to individuals' usual mechanical intervention of digital rectal stimulation.
1543884|NCT02641470|Dietary Supplement|DA9301 (Vaccinium uliginosum extract)|
1543885|NCT02641470|Dietary Supplement|Placebo|
1543886|NCT02641457|Drug|Aflibercept|12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
1543887|NCT02641457|Drug|Ranibizumab|12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
1543888|NCT02641444|Procedure|Blood plasma collection|Approximately 3mL of blood will be taken from each subject just prior to the colonoscopy.
1543889|NCT02641444|Procedure|Cervical and Vaginal Biopsy|2 biopsies each will be collected from the vaginal wall and the cervix
1543890|NCT02641444|Procedure|Colonoscopy with Ileal and Rectal Biopsy|10 biopsies each will be collected from the rectum and terminal ileum from each subject during the colonoscopy.
1543891|NCT02641431|Procedure|mapping/ablation|Mapping/ablation procedures will be performed under general anesthesia. After femoral venous access and percutaneous epicardial access, a multipolar catheter will be positioned at the right ventricle apex. High-density endocardial and epicardial electroanatomical maps will be performed using the CARTO3 system to define areas of delayed fragmented prolonged potentials during stable sinus rhythm and during spontaneous or ajmaline-induced type 1 BrS ECG pattern. Ajmaline (1mg/Kg in 5 minutes) will be used for the provocative test. Complete endo and epicardial maps will be obtained to ensure reconstruction of a 3-dimensional geometry of the cardiac chambers and to identify areas of abnormal electrograms as characterized by prolonged fragmented ventricular signals
1543892|NCT02641431|Drug|Ajmaline|Epicardial mapping will be performed before and after ajmaline (1mg/Kg in 5 minutes).
1543893|NCT02641431|Procedure|ablation|Radiofrequency will be delivered on areas of the abnormal electrograms using an externally irrigated 3.5-mm tip ablation catheter.
1543894|NCT02641431|Procedure|mapping|A re-map focusing on the targeted area will be obtained after ablation. Re-mapping and ajmaline reinfusion will be used to confirm the elimination of all the abnormal electrogram and BrS-ECG pattern disappearance.
1543895|NCT02641418|Other|Supervised exercise programme|supervised exercise programme
1543896|NCT02641405|Device|Equistasi|Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.
1543897|NCT02641405|Device|Inactive Equistasi|Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
1543898|NCT02641392|Drug|GED-0301|Mongersen
1543899|NCT02641392|Other|Placebo|Placebo
1543900|NCT02641379|Drug|Peginterferon alfa-2a|PEG-IFN is available as 180 microgram (mcg) per 0.5 mL, prefilled syringe and pen for single dose sc. injection\n
1543901|NCT02641379|Drug|Ribavirin|Ribavirin is available as 200 mg tablets
1543905|NCT02641353|Drug|Apremilast|30 mg tablet
1543906|NCT02641353|Drug|Apremilast Oral Suspension|30 mg oral suspension
1543907|NCT02641340|Drug|Fentanyl Sublingual Spray|Fentanyl delivered at low, medium and high doses by sublingual spray (FSS)
1543908|NCT02641340|Drug|Fentanyl Citrate IV|Fentanyl Citrate 50 mcg, delivered intravenously
1543909|NCT02641327|Device|EarlySense (Passive monitoring)|Passive contact-free monitoring
1543910|NCT02641314|Drug|metronomic therapy|"Propranolol 0.5 mg/kgxd p.o. day 1,
mg/kgxd p.o. day 2,
mg/kgxd p.o. day 3-365 (maximum total daily dose: 120 mg) divided in 2 doses per day
Celecoxib 400 mg/m2xd p.o.; day 1-365 (maximum total daily dose: 800 mg) divided in 2 doses per day
Cyclophosphamide cycle 1, day1: loading dose: 500 mg/m2 intravenous 1-h-infusion, single dose day 2-365 25 mg/m2xd p.o (maximum total daily dose: 50 mg) as single daily dose
Vinblastine 3 mg/m2xd i.v. (maximum total daily dose: 6 mg) administered day 1 and 15 (every two weeks) as single daily dose
Etoposide 25 mg/m2xd p.o.; day 1-21 weeks 1-3, 9-11, 17-19, 25-27 (maximum total daily dose: 50 mg) as single daily dose"
1543911|NCT02641301|Drug|Sustained release morphine sulfate, 30 mg|A single oral administration of a capsule of sustained release morphine sulfate, 30 mg, on one day.
1543912|NCT02641288|Drug|Ropivacaine irrigation|Using a standard irrigation device (no specific device is being used), 300 mg total of ropivacaine in 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure. Under direct visualization, the solution is delivered over the oesophageal hiatus, over both anastomoses and in both subdiaphragmatic spaces.
1543913|NCT02641288|Drug|Normal saline irrigation|Using a standard irrigation device (no specific device is being used), 200ml normal saline will be instilled into the abdomen after surgical dissection, just before abdominal wall closure.
1543914|NCT02641275|Other|Structured self-management-training|Structured self-management-training (incl. systemic analysis, coaching, teaching) in 4 sessions
1543915|NCT02641249|Device|Vibration|A device providing vibrations is placed on the subject and vibration is turned on and off in a 6 hour on/off sequence. Heart rate, respiratory pauses and oxygen saturation are compared during vibration (intervention) and without vibration (no intervention) in the same subject.
1543916|NCT02641236|Drug|Vancomycin-polymyxin B|
1543917|NCT02641223|Device|spinal cord stimulator|Pt asked to wear FitBit device prior to and after spinal cord stimulator placement.
1543918|NCT02641210|Procedure|Periodontal Treatment|Periodontal Treatment using Gracey curettes and ultrasonic device.
1543919|NCT02641210|Drug|Albendazole|All participants took Albendazole 400 mg before the intervention.
1543920|NCT02641197|Device|AngioDefender|"Repeatability will be assessed by repeat AngioDefender (AD) testing of the same subject 1 hour apart, using the same AD device and operator.
Reproducibility will be assessed by comparing FMD scores obtained for the same subject, but using different AD devices and operators."
1543921|NCT02641171|Other|Lack of intervention|This is an observational/validation study and there is no intervention involved.
1543922|NCT02641158|Other|Control Group|"After screening HCV antibody positive, participants will receive an appointment and reminder card to return for their HCV RNA results. If HCV RNA positive, study staff will attempt to make an appointment for the participant's next step in the HCV continuum. If a participant attends the next step visit, the participant would be subject to whatever is the local standard of care at that clinic/agency from that point forward."
1543923|NCT02641158|Behavioral|Care Facilitation Group|"The same will occur for intervention participants, yet an HCV care facilitator will motivate them to return for their HCV RNA results; appointment reminders will be made prior to the next step visit; follow-up contact will be made for missed appointments; and the HCV care facilitator will coordinate and link the participant to available community resources (e.g., mental health, housing agencies) by scheduling appointments, arranging transportation, and helping to complete any clinic registration (or other) paperwork that agencies may require to access services."
1543924|NCT02641145|Radiation|F-18 florbetapir/C-11 acetate PET|F-18 florbetapir PET scan, C-11 acetate PET scan
1543925|NCT02641145|Device|MRI|Cardiac MRI with gadolinium contrast.
1543926|NCT02641145|Radiation|N-13 ammonia PET|N-13 ammonia PET scan following supine bicycle stress.
1543927|NCT02641132|Drug|Mitomycin C 0.02%|Pterygium excision with application of mitomycin C
1543928|NCT02641132|Procedure|Pterygium surgery|Two different procedures- excision of the head and the body and excision of the head only
1543929|NCT02641106|Other|Video Directly Observed Therapy|Video Directly Observed Therapy (VDOT) is a novel means of remotely observing patients ingesting medications using videos sent from a smartphone. VDOT was developed and found to be feasible and acceptable for monitoring daily treatment of active TB in San Diego, CA and Tijuana, B.C., Mexico (R21-AI088326; PI: R. Garfein). Patients are taught how to use the VDOT recording app, record medication ingestion, and contact their physician when side effects occur. Participants are trained at the time of their first LTBI treatment dose to ensure participants know how to record videos. All remaining 11 weekly doses are taken and recorded wherever the participant chooses. Clinic staff monitor videos as they arrive using a password protected website and document each medication dose that is taken.
1543930|NCT02641106|Other|In-Person DOT|Clinic-based, in-person DOT is the standard of care for monitoring adherence for patients taking the 12-dose isoniazid/rifapentine treatment for LTBI. Participants visit the clinic once weekly until all 12 doses are taken or 16 weeks pass, whichever comes first.
1543937|NCT02641067|Drug|Doravirine|Following an overnight fast, a single coated tablet of 100 mg doravirine will be administered orally
1543938|NCT02641054|Drug|CVXL-0107|
1543939|NCT02641054|Drug|Placebo|
1543940|NCT02641054|Drug|Levodopa|
1543941|NCT02641041|Biological|BIIB033|single or multiple dose
1543942|NCT02641041|Other|Placebo|single or multiple dose
1543943|NCT02641028|Drug|CERC-501|CERC-501
1543944|NCT02641028|Drug|Placebo|Placebo
1543945|NCT02641002|Drug|CC-90002|Monoclonal Ab to CD47
1543946|NCT02640989|Biological|Seasonal trivalent influenza vaccine, Anflu®|Seasonal trivalent influenza vaccine manufactured by Sinovac Co., Ltd.
1543947|NCT02640989|Biological|Seasonal trivalent influenza vaccine, VAXIGRIP|Seasonal trivalent influenza vaccine manufactured by PasteurSanofi Pasteur
1543948|NCT02640989|Biological|Seasonal trivalent influenza vaccine, Fluarix|Seasonal trivalent influenza vaccine manufactured by GlaxoSmithKline Biologicals
1543949|NCT02640976|Drug|Human menopausal gonadotrophin (HMG)|[Merional® 75 IU ampoules, IBSA institut]
1543950|NCT02640976|Drug|GnRH antagonist Cetrorelix|[Cetrotide® 0.25 mg syringes, Merck Serono]
1543951|NCT02640976|Drug|Human chorionic gonadotrophin (hCG)|[Choriomon® 5000 IU ampoules, IBSA institut]
1543952|NCT02640963|Other|Exercise|to determine the feasibility of the GrACE (Group Aged Care Exercise) programme in RAC, with the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength.
1543953|NCT02640963|Other|Control|to compare with the GrACE (Group Aged Care Exercise) programme in RAC, as well as the secondary objective of measuring the programme benefits on gait speed, sit to stand and handgrip strength against the intervention group
1543954|NCT02640950|Device|NeuroStar TMS|Transcranial Magnetic Stimulation
1543955|NCT02640924|Radiation|Proton radiotherapy|
1543956|NCT02640924|Procedure|Radiofrequency Ablation|
1543957|NCT02640898|Radiation|docetaxel-based chemoradiotherapy|experimental:Patients with Zubrod performance status (PS) of 0-2 received up to 2 21-day cycles of pre- and post-radiation chemotherapy (docetaxel 37.5 mg/m2 on days 1 and 8, cisplatin 25 mg/m2 on days 1-3, and a continuous infusion of fluorouracil (FU) 750 mg/m2 on days 1-5), respectively. CCRT between pre- and post-radiation chemotherapy was initiated on day 43 and consisted of 3-dimensional conformal intensity-modulated radiation therapy (45 Gy) plus concurrent docetaxel 20 mg/m2 weekly for 6 weeks;
1543958|NCT02640898|Radiation|FU-based chemoradiotherapy|The adjuvant treatment consisted of 425mg/m2 of bolus fluorouracil(5-FU) per day, 20 mg/m2 of leucovorin (LV), per day, for 5 days, followed by 45Gy of radiation with current 5-FU ( 400mg/m2 ) and LV (20mg/m2) as an intravenous bolus on each of of the first four days and the last three days of irradiation. One month after the completion of radiotherapy, two 5-day cycles of 5-FU and FV chemotherapy were given one month apart.
1543959|NCT02640885|Device|Foley's cather ballon|
1543960|NCT02640846|Drug|Levosimendan|Levosimendan will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
1543961|NCT02640846|Drug|Milrinone|Corotrope will be given and after 30 minutes of treatment the cardiac function will be assessed with echocardiography and systemic hemodynamics.
1543962|NCT02640833|Drug|Duvelisib|Duvelisib will be taken continuously. This is a defining dose study, therefore the dose of Duvelisib may change.
1543963|NCT02640833|Drug|Venetoclax|Venetoclax will be taken continuously. This is a defining dose study, therefore the dose of Venetoclax will change.
1543964|NCT02640820|Drug|Sensitizing DPCP Ointment|Sensitization
1543965|NCT02640820|Drug|Treatment DPCP Ointment|Treatment
1543966|NCT02640807|Drug|Interleukin-7|IM (intra-muscular) administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR (International Normalized Ratio) >2.5 or platelet count < 35,000
1543967|NCT02640807|Drug|Placebo|IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count < 35,000
1543968|NCT02640794|Drug|Clopidogrel|Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months.
1543969|NCT02640794|Drug|Aspirin|Aspirin/acetylsalicylic acid (80-325 mg/d). Aspirin/acetylsalicylic acid therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
1543970|NCT02640781|Device|self-expandable metal stent insertion|Stent insertion was performed by experienced endoscopists under fluoroscopy and by using through-the-scope methods. After the obstructing tumor was identified by endoscopy, a guidewire was introduced through the stricture under endoscopic and fluoroscopic controls. Then, the self-expandable colorectal stent delivery catheter was advanced through the working channel of the endoscope over the guidewire until the stent was positioned across the stricture. Upon releasing the stent delivery catheter, stent deployment was initiated proximally and progressed distally. Simple abdominal radiography was performed during and after the procedures to confirm proper stent placement and expansion.
1543971|NCT02640768|Other|educational training|implementation of a structured educational program for physicians and nurses
1544011|NCT02640443|Drug|Sulfamethoxazole|60 mg sulfamethoxazole per kg bodyweight (maximal of 3g) divided in 2 doses per day during 3 weeks
1543978|NCT02640716|Behavioral|multi-domain internet-based adaptive training program|The cognitive training will be a multi-domain adaptive training program, including processing speed, attention, long-term memory, working memory, flexibility, calculation, and problem solving. Specific training paradigms include a time perception task, visual search task, attention blink, delayed mapping task, attention span task, Go-No go task, Stroop task, task switching, and name-face match task, among others. To maintain task difficulty, the tasks will be grouped based on the task difficulty in each domain. Furthermore, each task will have various difficulty levels.
1543979|NCT02640716|Behavioral|placebo program|For the control group, tasks for processing speed and attention are included. Importantly, a fixed, primary difficulty level for all participants in the control group is set.
1543981|NCT02640690|Behavioral|Trauma Sensitive Yoga Intervention|(10) 1-hour sessions of trauma sensitive yoga
1543982|NCT02640690|Behavioral|Cognitive Processing Therapy-Cognitive Only|(12) 1.5 hour sessions of cognitive processing therapy
1543983|NCT02640677|Biological|4CMenB|This study is strictly observational; Administration of BEXSERO, the schedule of office visits and all treatment regimens will be determined by the treating health care provider in the context of routine clinical care.
1543986|NCT02640651|Device|DC-Stimulator (PLUS version)|transcranial direct current stimulation
1543987|NCT02640638|Behavioral|CenteringPregnancy|8-12 pregnant women whose due dates are in the same month will receive ten 2-hour group prenatal care sessions according to the standard curriculum provided by the Centering Healthcare Institute.
1543988|NCT02640625|Dietary Supplement|Probiotic compound|Lactobacillus rhamnosus GG, Lactobacillus acidophilus, Lactobacillus bulgaricus, Bifidobacterium animalis subsp. lactis, and Streptococcus thermophilus.
1543990|NCT02640599|Other|Vestibular Rehabilitation + Aerobic Exercise|Subjects in the experimental group will undergo traditional Vestibular Rehabilitation as well as participate in an aerobic exercise training program.
1543991|NCT02640599|Other|Vestibular Rehabilitation|The control group will receive standard care which includes participation in vestibular physical therapy treatments 1-2 times per week.
1543992|NCT02640586|Device|three MR examination|Three MR examinations: first MRI taken within 1 week before preoperative chemo-radiotherapy; second MRI taken between 14-16days after the initiation of radio-chemotherapy; third MRI taken 7-9 weeks after the completion of preoperative chemo-radiotherapy.
1543993|NCT02640573|Drug|Hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the AdultsQLTM 3.0 Sickle Cell Disease Module after 6 months at MTD, compared to entrance scores
1543994|NCT02640560|Other|Food allergy questionnaire|The Parents of the cases children will compile a questionnaire including questions about general information on the family, on life and food habits, on indoor environment, on health status, on clinical aspects of the allergy, on the access to diagnostic and treatment resources
1543995|NCT02640560|Other|Control Questionnaire|The Parents of the control children will compile a questionnaire including questions about general information on the family, on life and food habits and on indoor environment.
1543996|NCT02640534|Drug|Enzalutamide|Enzalutamide 160 mg od until disease progression
1543997|NCT02640534|Drug|Metformin|850 mg bid until disease progression
1543998|NCT02640521|Behavioral|Chart Reminders & New York State Quit line referral system|Investigators at New York University Medical School, Bellevue and Lincoln Hospital will work closely to (1) develop chart reminders appropriate for each of their clinics (2) to prompt providers to ask about in home smoking at every medical visit and (3) to establish a New York Quit line referral system in the pediatric practice, including clearly defined roles and responsibilities for each step. The New York State Quit line service includes proactive telephone calls with mailings of self-help material, free nicotine replacement therapy for those who qualify, and referrals to local treatment programs, ensuring that health literacy levels of materials is maximized, amending the training curriculum for providers as necessary, and modifying patient education materials that are part of the provider tool kit to focus on the negative impact of secondhand smoke.
1543999|NCT02640508|Drug|Eribulin|Will be given by I.V. at 1.4 mg/m2 on day 1 and day 8.
1544000|NCT02640508|Drug|Lenvatinib|Will be taken orally at 20-24 mg daily in each 21 day cycle.
1544001|NCT02640495|Drug|Intravenous Artesunate as part of standard medical practice|Intravenous Artesunate 2.4 mg/kg
1544004|NCT02640469|Other|Chlorhexidine with water rinse|"This procedure will be followed for both the right and left hands and arms:
scrub each side of finger, in between fingers and back and front of hands for 2 minutes, followed by scrubbing of arms, keeping hands higher than arms at all times, wash each side of the arms from wrist to elbow for 1 minute"
1544005|NCT02640469|Other|Chlorhexidine without water rinse|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm.
1544006|NCT02640469|Other|Chlorhexidine + sterillium hand rub|Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, Scrub each side of finger, in between fingers and back and front of hands for 2 minutes, proceed to scrub the arms, keeping the hand higher than the arm at all times, wash each side of the arms from wrist to elbow for 1 minute, and repeat the process on the other arm. Rinse hands and arms by passing through water in one direction, dry hands, and rub 5 mL of alcohol into the palm of the hands, forearms and elbows. Ensure that the whole skin area on both arms is covered.
1544007|NCT02640456|Biological|Bacteriology|Tonsillar surface swabs, tonsillar tissues, and pus aspirates.
1544008|NCT02640456|Procedure|Type of surgery|Surgical approach and complications.
1544009|NCT02640456|Biological|Biochemistry|Amylase concentration i pus aspirates.
1544010|NCT02640456|Biological|Serology|Levels of antibodies against selected bacteria (F. necrophorum, F. nucleatum, and Group A streptococci) in acute and convalescent sera.
1544015|NCT02640417|Drug|B Vitamins|Oral treatment with vitamins B1, B6, and B12
1544018|NCT02640391|Other|colonoscopy|
1544019|NCT02640378|Other|NO intervention|This study was a cross-sectional study. It had no intervention.
1544020|NCT02640365|Drug|MM-398|unresectable Advanced non-colorectal cancer
1544021|NCT02640365|Drug|Irinotecan|unresectable metastatic colorectal cancer
1544022|NCT02640365|Drug|Leucovorin (LV)|unresectable metastatic colorectal cancer
1544023|NCT02640365|Drug|5-fluorouracile (5-FU)|unresectable metastatic colorectal cancer
1544024|NCT02640365|Drug|bevacizumab|unresectable metastatic colorectal cancer
1544025|NCT02640365|Drug|MM-398|unresectable metastatic colorectal cancer
1544026|NCT02640352|Dietary Supplement|Probi Defendum|
1544027|NCT02640352|Dietary Supplement|Placebo|
1544028|NCT02640326|Other|No Foley Urinary Catheter|
1544029|NCT02640326|Other|Standard of care Foley urinary catheter insertion|
1544030|NCT02640313|Drug|18F-choline PET-MR imaging|Dynamic and static 18F-choline PET-MR imaging
1544031|NCT02640300|Drug|Clozapine|Switching to clozapine with immediate or gradual antipsychotic discontinuation
1544032|NCT02640287|Biological|Blood or bone marrow samples|
1544033|NCT02640274|Behavioral|Nurse-led counselling programme|The intervention is an individual nurse-led counselling programme in addition to usual care. The intervention includes 3 outpatient clinic visits (at weeks 2, 14 and 26) and two telephone calls (at weeks 4 and 16) by a cardiovascular nurse during the first 6 months early discharged. The counselling focuses on cardiac risk reduction behaviour based on guidelines issued by European Society of Cardiology and self-management support.
1544034|NCT02640274|Other|Usual care|
1544035|NCT02640248|Device|Cuff ETT|
1544038|NCT02640222|Drug|VKA|
1544039|NCT02640222|Drug|Apixaban|
1544040|NCT02640222|Drug|dabigatran|
1544041|NCT02640222|Drug|rivaroxaban|
1544042|NCT02640209|Biological|CART 19|The target dose range administered in this study is 1-5x108 CART-19 cells administered via split dosing: 10% on Day 1 (1-5x107 CART19), 30% on Day 1 (3x107-1.5x108 CART19), 60% on Day 2 (6x107-3x108 CART19).
1544043|NCT02640196|Device|Macintosh|The participants intubated the easy airway simulator with a double lumen tube using the Macintosh laryngoscope followed with intubating the difficult airway simulator
1544044|NCT02640196|Device|GlideScope|The participants intubated the easy airway simulator with a double lumen tube using the GlideScope followed with intubating the difficult airway simulator
1544045|NCT02640196|Device|Airtraq|The participants intubated the easy airway simulator with a double lumen tube using the Airtraq followed with intubating the difficult airway simulator
1544046|NCT02640196|Device|King Vision|The participants intubated the easy airway simulator with a double lumen tube using the King Vision followed with intubating the difficult airway simulator
1544047|NCT02640183|Drug|EMLA|
1544048|NCT02640183|Other|Placebo|
1544049|NCT02640170|Other|Registry|
1544050|NCT02640157|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
1544051|NCT02640157|Drug|Sofosbuvir|Tablet
1544052|NCT02640157|Drug|Daclatasvir|Tablet
1544053|NCT02640144|Drug|Sodium Hyaluronate 1%|Intra articular knee injection following arthroscopy
1544054|NCT02640144|Drug|Placebo|Intra articular knee injection following knee arthroscopy. Serves as a placebo. This is the actual buffer of the ARTHREASE injection.
1544055|NCT02640131|Behavioral|Biomedical Component|Bio-medical: The bio-medical component includes an appointment with urologist pre-operatively and 5 follow-up appointments. Patients/partners are provided instruction on the use of pro-erectile agents/devices.
1544056|NCT02640131|Behavioral|Psychosocial Component|Psychosocial: aims to support maintenance of intimacy, pro-erectile therapy use, and regular satisfying sexual activity. At each time point, participants receive standardized sexual health counselor (SexHC) counseling and manualized support.
1544057|NCT02640131|Behavioral|Attention Control|Couples will attend 30-minute clinic consultations with an Urologist and a Survivorship Counsellor (SurvC) at 3-4, 7-8, and 12-13 months post radical prostatectomy (RP). Couples will receive a Kegel Exercise booklet and receive appointment-specific chapters of the Challenging Prostate Cancer: Nutrition, Exercise, and You (CPC) manual (a patient self-help manual written by the Princess Margaret Prostate Centre team). The core topics discussed during the counselling sessions include: preparation for immediate post-RP recovery, Kegel exercises, nutrition and prostate cancer (PC), exercise and PC, and maintaining healthy lifestyle change.
1544058|NCT02640118|Drug|Lixisenatide|single injection of 20 µg lixisenatide subcutaneously
1544059|NCT02640118|Drug|Lixisenatide-Placebo|
1544060|NCT02640118|Other|Standardized liquid meal|standardized liquid meal (200 ml containing 1,650 kJ (394 kcal): carbohydrate 50%, protein 15%, fat 35%, consisting of glucose (48.4 g + 1.6 g [U-13C6]-glucose), rapeseed oil (14.1 g), whey protein (15.2 g) and 1.5 g paracetamol).
1544061|NCT02640105|Other|Neurological clinical examination|Diagnostic and description of cluster headache
1544062|NCT02640105|Other|Psychological clinical examination|Scale and questionnaires
1544063|NCT02640105|Other|Questionnaires|Psychopathological and cognitive questionnaires
1544064|NCT02640105|Other|Blood sample|Blood sample for DNA collection
1544065|NCT02640105|Other|Endothelial function measurement|Endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
1544067|NCT02640079|Behavioral|Cognitive behavioral therapy|
1544068|NCT02640066|Other|acupuncture|
1544073|NCT02640040|Device|llizarov external fixation device|llizarov external fixation device was applied to fix the tibia.
1544074|NCT02640040|Device|intramedullary rod fixation|retrograde intramedullary rod was applied to stabilize the tibia.
1544075|NCT02640040|Procedure|surgery|combined surgery for enrolled patients with CPT: sleeve resection of the pathological soft tissues, retrograde intramedullary rodding, packaged lilac bone autograft,and llizarov external fixation device installation.
1544076|NCT02640027|Procedure|Cast removal at home using a telemedicine tool|Instead of receiving follow up treatment in a clinical setting, patients randomized to the arm of the study requiring telemedicine will receive some of their follow up care at home.
1544077|NCT02640014|Dietary Supplement|Milk|Milk Oral immunotherapy
1544078|NCT02639975|Drug|PBF-677|once daily oral administration
1544079|NCT02639975|Drug|Placebo|once daily oral administration
1544080|NCT02639962|Radiation|Cardiac CT|Cardiac CT before the CAG, and follow up after 2 month and 12 month
1544081|NCT02639949|Behavioral|Cognitive-behavioral adherence promotion program|A culturally sensitive group cognitive behavioral therapy combined with adherence promotion.
1544082|NCT02639949|Behavioral|Standard Care|
1544083|NCT02639923|Procedure|Drawing of 7ml peripheral blood|puncture peripheral vein
1544087|NCT02639897|Other|Direct Laryngoscopy|Tracheal intubation with direct laryngoscopy using Macintosh laryngoscope blade
1544088|NCT02637791|Device|Virtual glove|The intervention (the virtual glove) consists of a hand-mounted power unit, with four infra- red light emitting diodes (LEDs) mounted on the user's finger tips. The LEDs are tracked using one or two Nintendo Wii motes mounted by the computer screen on which the games are displayed to translate the location of the user's hand, fingers and thumb in 3D space. Three games have been produced especially for the project with the help of therapists and stroke patients. In order to play them, users have to perform the movements of reach to grasp, grasp and release, pronation and supination that are necessary to effect many activities of daily living.
1544089|NCT02637778|Dietary Supplement|Cardioprotective diet|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.
1544090|NCT02637778|Dietary Supplement|Cardioprotective diet + 3 g EPA + DHA/d|The 'cardioprotective diet' is characterized by (i) adequate energy intake, (ii) intake of carbohydrates, protein, fat according to the guidelines of the German Society of Nutrition (DGE e. V.), (iii) desirable intake of saturated fatty acids (SFA, 7 En%), monounsaturated fatty acids (MUFA, > 10 En%), polyunsaturated fatty acids (PUFA, approx. 10 En%) and in particular n-3 LC-PUFA, (iv) encouraged consumption of vegetables, fruits, cereals, (v) salt and sugar reduction, (vi) avoiding of highly processed, calorie-dense, nutrient-poor food as well as (vii) encouraged physical activity.The participants will consume additional n-3 LC-PUFA (3 g EPA+DHA/d)
1544091|NCT02637765|Behavioral|Increased Physical Activity|Patients will receive a program of increased physical activity starting from 5000 steps/day up to 12000 steps/day after 8 weeks and an 8-week recreational program of brisk walking/running (3 times a week).
1544092|NCT02637752|Behavioral|Lifestyle counseling or nutrition/physical counselling|A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
1544093|NCT02637739|Device|hysteroscope|Women of PUL with β-hCG > 1000 IU/L or abnormal β-hCG trend (increase < 66% or decrease < 15%) were offered HSC.
1544094|NCT02637726|Drug|Propofol : TCI Schnider|Target controlled infusion using schnider model for propofol
1544095|NCT02637726|Drug|Propofol : TCI Kataria|Target controlled infusion using Kataria model for propofol
1544096|NCT02637726|Drug|Propofol : TIVA|Total intravenous anesthesia without use of a pharmokinetic model
1544097|NCT02637726|Device|EEG Monitoring|Maintaining a bispectral index between 45 and 55
1544098|NCT02637726|Drug|Remifentanil|Remifentanil at discretion of the anesthesiologist
1544099|NCT02637713|Procedure|Radiofrequency energy to the LES|Stretta is an FDA approved device that delivers Radiofrequency energy delivery to the lower esophageal sphincter it is approved for the management of GRED.
1544100|NCT02637700|Drug|Intravenous Immunoglobulin|Comparison between intravenous immunoglobulin and placebo (saline 0.9%).
1544101|NCT02637700|Drug|Placebo|Comparison between placebo (saline 0.9%) and intravenous immunoglobulin.
1544103|NCT02637674|Procedure|Uterus Transplant|
1544104|NCT02637661|Other|earlobe crease positive|
1544105|NCT02637661|Other|earlobe crease negative|
1544106|NCT02639858|Drug|Docetaxel-PM|Docetaxel PM 75mg/m2 IV infusion
1544107|NCT02639832|Device|LiquidBiopsy®, NK VueTM|The LiquidBiopsy® device will test for cells with tumor cell markers in blood. The genetic sequence of DNA recovered samples will be studied. Using NK VueTM researchers will test for NK cell activity.
1544108|NCT02639819|Drug|ɛ-Aminocaproic Acid|Intervention: intravenous ε-Aminocaproic Acid within 3 hours of symptom onset
1544109|NCT02639806|Drug|Sevoflurane|
1544110|NCT02639806|Drug|Lidocaine|
1544146|NCT02639611|Other|No Acupuncture Treatment|no acupuncture treatment for 6 weeks, but offered acupuncture at the end of the 6 week study period.
1544111|NCT02639793|Procedure|catheter ablation|Three different catheter ablation techniques will be used aimed at isolating the pulmonary veins from left atrium.The endpoint is defined as absence or dissociation of all pulmonary vein potentials as confirmed by the circular mapping catheter after a waiting period of 30 minutes after the last ablation. The use of adenosine or isoproterenol to detect concealed pulmonary vein conduction is voluntary.
1544112|NCT02639780|Other|protein expression pattern of packed red blood cells|the proteome of packed red blood cells will be assessed at predefined time points
1544113|NCT02639767|Drug|Pemetrexed/Cisplatin|Dose escalation of pemetrexed and cisplatin will follow the dose levels. The escalation will not exceed 500 mg/m^2 for pemetrexed in combination with 75 mg/m^2 of cisplatin even if the maximum tolerated dose is not identified. Each treatment cycle of chemotherapy will be 21 days. Patients will receive up to 2 cycles of chemotherapy during the radiation, and be followed for any DLT during the radiation therapy and for 12 weeks afterwards.
1544114|NCT02639767|Radiation|Pleural Intensity Modulated Radiation Therapy|Pleura intensity modulated radiation therapy (IMRT) will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions. The prescription radiation dose may anywhere between 45 and 50.4 Gy in 25 fractions if necessary to meet the normal tissue dose constraints.
1544115|NCT02639767|Device|MRI|A pre-treatment MRI before chemo-RT will be acquired and will be used for target delineation. A three month post-treatment MRI will be acquired with the same protocol to assess the response from concurrent chemo-RT.
1544116|NCT02639754|Behavioral|Social Network Leader Endorsement|Leaders of social networks will attend a multi-session intervention during which they will be trained to deliver messages endorsing frequent HIV testing, compliance with medical guidelines, and adherence to medical treatment regimens to friends. Additionally, these leaders will be trained on how to deliver effective messages.
1544117|NCT02639754|Behavioral|HIV Counseling|At the baseline session, participants in this condition will receive counseling about the benefits and availability of HIV care and the importance of frequent HIV testing.
1544118|NCT02639741|Drug|Melatonin|Preoperative melatonin tablet will be given and postoperative pain scores will be evaluated
1544119|NCT02639741|Drug|Vitamin C|Preoperative vitamin C tablet will be given and postoperative pain scores will be evaluated
1544120|NCT02639741|Other|Placebo|Preoperative placebo tablet will be given and postoperative pain scores will be evaluated
1544121|NCT02639728|Other|Regular Coffee|Regular coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
1544122|NCT02639728|Other|Decaffeinated coffee|Decaffeinated coffee will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
1544123|NCT02639728|Other|Warm water|Warm water will be given a 4oz cup three times daily and will be instructed to consume all of its liquid contents.
1544125|NCT02639689|Device|WALKAIDE|"A clinical evaluation will be conducted at T0 with achievement of the following tests without orthosis and with the usual orthosis if applicable: he will be made a stimulation test of common peroneal nerve and settings Walkaide® device.
Subjects will be reconvened at T1, one to four weeks after the initial assessment to ensure the stability of walking speed. We will perform the following tests without orthosis and with the usual orthosis if applicable. The final evaluation (T2) will be 28 days after the start of the port of the device."
1544126|NCT02639676|Other|Diffusion Lung Capacity (DLCO), Vascular Challenge, Video Imaging, Specimen Collections|
1544127|NCT02639663|Device|dental device|"Leboride
Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups
Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.
Control group: participants will not receive any device for breastfeeding pain control
Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
1544128|NCT02639650|Drug|Etoposide|etoposide 100mg/m2 ivgtt started at the first day of cycle, two weeks a cycle
1544129|NCT02639650|Drug|actinomycin D|actinomycin D 500ug ivgtt, started at the first day of cycle, two weeks a cycle
1544130|NCT02639650|Drug|methotrexate|methotrexate 100mg/m2, 200mg/m2, ivgtt, tetrahydrofolic acid （FA) 15mg q12h*4(24h after methotrexate injection),started at the first day of cycle, two weeks a cycle
1544131|NCT02639650|Drug|vincristine|vincristine 1mg/m2 started at the 8th day of cycle, two weeks a cycle
1544132|NCT02639650|Drug|cyclophosphamide|cyclophosphamide 600mg/m2, started at the 8th day of cycle, two weeks a cycle
1544133|NCT02639650|Drug|Paclitaxel|paclitaxel 135mg/m2, started at the first day of cycle, two weeks a cycle
1544134|NCT02639650|Drug|Cisplatin|cisplatin 50mg/m2, started at the first day of cycle, two weeks a cycle
1544135|NCT02639650|Drug|Carboplatin|carboplatin area under curve (AUC)=4-5, started at the first day of cycle, two weeks a cycle,as a substitute drug for cisplatin
1544141|NCT02639624|Drug|Low bicarbonate dialysate First|
1544142|NCT02639624|Drug|Normal bicarbonate dialysate First|
1544143|NCT02639624|Drug|Normal bicarbonate dialysate|
1544144|NCT02639624|Drug|Low bicarbonate dialysate|
1544145|NCT02639611|Other|Immediate Post Operative Acupuncture Treatment|acupuncture treatment immediately after surgery (twice a week for 6 weeks)
1544149|NCT02639585|Drug|Daclinza and Sunvepra|direct acting antiviral agent against to hepatitis C virus
1544150|NCT02639572|Biological|Siloss® bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing. Randomization was employed.
1544151|NCT02639572|Biological|Hydroxyapatitie Bone graft|The osseous defect was debrided of granulation tissue and the root surface was planed to remove plaque and calculus, until a smooth hard consistency was found. The defect's architecture was confirmed by direct observation and classified based on number of bony walls present. In patients selected for test group, in addition to open flap debridement (OFD), Siloss® bone replacement graft was utilized to fill the defects to the most coronal level of the osseous walls. The required amount of composite alloplast (Siloss®) was dispensed into a sterile dappen dish and mixed with patients own blood and carried to the defect site with an amalgam carrier. The mucoperiosteal flaps were repositioned and secured in place using interrupted sutures. The surgical procedure in control site included open flap debridement followed by placement of hydroxyapatite graft (G-graft®, Saharanpur, UP, India). The surgical area was protected and covered using a periodontal dressing.Randomization was employed.
1544152|NCT02639559|Drug|BL-8040|
1544153|NCT02639559|Procedure|Leukapheresis|
1544154|NCT02639559|Procedure|Hematopoietic cell transplant|
1544155|NCT02639546|Drug|Cobimetinib|Cobimetinib tablet or suspension will be administered as per the schedule described in arm description.
1544156|NCT02639533|Drug|Pregabalin|Pregabalin 150 mg PO, single dose.
1544157|NCT02639533|Other|Placebo|Pill of same physical characteristics as the one used for the intervention, containing starch only. Administered PO in single dose.
1544158|NCT02639520|Drug|Canephron® N|2 tablets 3 times a day for 7 days
1544159|NCT02639520|Drug|Fosfomycin trometamol|1 sachet of 8 g of granules; one single dose on Day 1
1544160|NCT02639520|Drug|Canephron® N-placebo|2 tablets 3 times a day for 7 days
1544161|NCT02639520|Drug|Fosfomycin trometamol-placebo|1 sachet of 8 g of granules; one single dose on Day 1
1544162|NCT02639507|Procedure|Vitrectomy|
1544164|NCT02639481|Behavioral|Standard physiotherapy|Classical standard physiotherapy, including measures to verticalize patients by means of orthesis, classical tilt tables, or castings
1544165|NCT02639481|Device|Erigo®Pro group without FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES ist not used.
1544166|NCT02639481|Device|Erigo®Pro group with FES|Use of the Erigo®Pro device to verticalize patients to above 60° while performing robotic stepping leg movements. FES is applied during then whole treatment session, providing electrical stimulation to the muscles of the upper and lower leg, synchronous to the robotic stepping movements
1544167|NCT02639468|Device|Stroke Volume estimation using electrical impedance tomography|
1544168|NCT02639455|Behavioral|Exercise|Participants will exercise 4 days per week, 20 minutes per session for 5 weeks (a total of 400 minutes). Exercise will be independent (with the goal of 85% of max effort for at least 2 minutes each session) and consist of running, jumping jacks, sit ups, push ups, or burpees depending on the participant's comfort and skill.
1544169|NCT02639442|Device|ClearRing™|
1544170|NCT02639429|Drug|Vaginal Misoprostol|
1544171|NCT02639429|Device|Foley Balloon + Vaginal Misoprostol|
1544172|NCT02639416|Dietary Supplement|Polymeric formula|Polymeric formulae are recommended in the management of inflammatory bowel disease in children
1544173|NCT02639416|Dietary Supplement|Elemental formula|Elemental formulae are recommended in cow's milk and other food intolerances in children.
1544174|NCT02639416|Other|Standard management|Standard management with F-100 and/or RUTF
1544175|NCT02639403|Radiation|Conformal three-dimensional Radiotherapy|Conformal three-dimensional RT was planned (3D-RT) using the Oncentra-Masterplan treatment planning system (Nucletron B.V., Veenendaal, Netherland). Short course RT (total, 25 Gy; 5 fraction in 5 days) will be delivered with an isocentric four-field box technique.
1544176|NCT02639390|Device|Robotic Therapy|Subjects will be placed in the robot and practice common upper extremity tasks involving grasping, manipulating and moving objects.
1544177|NCT02639390|Other|Conventional Therapy|An occupational therapist will provide one-on-one individualized programs focused on arm function. Treatment will focus on practice of specific tasks, such as reach, grasp, transport and release of various objects between different targets. Progression is done by varying the shape, size and weight of objects, altering the end range of the target or increasing the speed of movement.
1544178|NCT02639377|Drug|Chlorhexidine gluconate|
1544179|NCT02639377|Drug|Placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
1544180|NCT02639364|Device|Nellcor Puritan Bennett 840 ventilator system|Puritan Bennett 840 ventilator can provide the VCV,PCV,Bi-level Airway Pressure Ventilation-airway Pressure Release Ventilation(BILEVER-APRV) mode.
1544181|NCT02639351|Biological|MenC-CRM conjugate vaccine with 12.5 ug LHD153R|Intramuscular (IM) vaccination of 1 dose of 0.5 mL
1544182|NCT02639351|Biological|MenC-CRM conjugate vaccine with 25 ug LHD153R|IM vaccination of 1 dose of 0.5 mL
1544183|NCT02639351|Biological|MenC-CRM conjugate vaccine with 50 ug LHD153R|IM vaccination of 1 dose of 0.5 mL
1544184|NCT02639351|Biological|MenC-CRM conjugate vaccine with 100 ug LHD153R|IM vaccination of 1 dose of 0.5 mL
1544185|NCT02639351|Biological|MenC-CRM conjugate vaccine|IM vaccination of 1 dose of 0.5 mL
1544195|NCT02639234|Biological|Vigil™|Upon completion of nivolumab infusion, subjects will receive Vigil™, 1.0 x 10^7cells via intradermal injection on Day 1 every 14 days for a minimum of 4 and a maximum of 12 doses depending on quantity of Vigil™ manufactured from surgical specimens.
1544196|NCT02639234|Drug|Nivolumab|Prior to Vigil™, subjects will receive nivolumab 3 mg/kg by intravenous infusion over 60 minutes on Day 1 every 14 days. If nivolumab is administered beyond 12 months it will be administered off study.
1544197|NCT02639221|Drug|PXT002331|
1544198|NCT02639208|Other|PatientsLikeMe (PLM)|
1544199|NCT02639195|Other|Treatment|Retrospective chart review of patients treated with manual therapy.
1544203|NCT02639156|Dietary Supplement|AYMES LONDON|AYMES LONDON is a powder, designed to be mixed with 75ml whole milk to make a dessert style ONS. When made-up, AYMES LONDON provides 303kcal (2.2kcal/ml) and 11.2g protein. It is not designed to be used as a sole source of nutrition. It is a Food for Special Medical Purposes (FSMP) and must therefore be used under medical supervision.
1544204|NCT02639143|Drug|ticagrelor|
1544205|NCT02639143|Drug|Clopidogrel|
1544206|NCT02639130|Drug|Exendin [9-39]|Exendin [9-39] at 350 and 500 pmol/kg/min for infusion as challenge agent
1544207|NCT02639130|Drug|Placebo|Placebo infusion as challenge agent
1544208|NCT02639117|Drug|Vismodegib|Vismodegib 150 mgs po qd for 3 months
1544209|NCT02639104|Radiation|Radiography|"Obtaining patients lateral spot cervical spine radiography and will measure;
The segmental angle will be measured from C2-C7 inferior endplates on the lateral radiography
If there is a segmental kyphosis (for example kyphotic angle in C4-5 level), the segmental cobb angle will be measured in the level of the main kyphosis
The segmental cobb angle will be measured between C2-C4 inferior endplates and C4-C7 inferior endplates"
1544210|NCT02639104|Other|Electromyography|"Serratus anterior needle electromyography:
The needle can be inserted into the muscle superficially to the fourth to sixth rib in the medial or posterior axillary line. The usual nerve latency time is between 2.6-4 ms."
1544214|NCT02639078|Drug|TD-0714|One time dosing in capsule formulation
1544215|NCT02639078|Drug|Placebo Comparator|One time dosing in capsule formulation
1544216|NCT02639065|Drug|Durvalumab|1500 mg IV every 4 weeks (1 cycle) for a maximum 13 doses (12 months), or until unacceptable toxicities or disease recurrence.
1544217|NCT02639052|Drug|Botox|10 units of Botox will be intradermally injected into one 4x4cm area on the volar forearm on 1st study visit.
1544218|NCT02639052|Drug|Saline|10 units of the Saline vehicle will be intradermally injected into one 4x4cm area on the contralateral volar forearm on the 1st study visit.
1544219|NCT02639039|Drug|Cortisone Injection|Exact location and technique of injection within the region of the involved greater trochanter will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but CI is the only treatment.
1544220|NCT02639039|Procedure|Trigger Point Dry Needling|Exact location of needle insertion, technique and number of penetrations within the region of the involved posterolateral hip will be determined by the provider. The number of f/u visits within 6 wks following initiation of treatment will be determined by the provider, but TDN is the only treatment.
1544221|NCT02639026|Radiation|Radiotherapy|two schedules of radiotherapy (8 Gy x 3 fractions and 17 Gy x 1 fraction)
1544222|NCT02639026|Drug|MEDI4736|20 mg/kg MEDI4736 every 4 weeks for 4 doses, followed by 10 mg/kg MEDI4736 monotherapy every 2 weeks for 18 doses
1544223|NCT02639026|Drug|Tremelimumab|1 mg/kg every 4 weeks for 4 doses
1544224|NCT02639013|Procedure|transducer technique|the nurses will receive the intervention ( the transducer method) to measure intraabdominal pressure intraabdominal hypertension and how to measure intraabdominal pressure in the third section
1544225|NCT02639000|Procedure|Embryo transfer|Embryo transfer of maximum of 2 embryos at cleavage or blastocyst stage
1544226|NCT02638987|Device|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
1544227|NCT02638974|Other|Medical Skin Camouflage|Medical skin camouflage is a prescription preparation designed to cover scars and other skin conditions
1544228|NCT02638961|Other|IMT|Patients allocated to IMT arm will receive standard medical treatment and will be instructed to train at home twice daily, for 20 minutes each session, and during 12 weeks using a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them will be instructed by a respiratory therapist and educated to maintain a diaphragmatic breathing during the training period. The subjects start breathing at a resistance equal to 25-30% of their maximal inspiratory pressure (MIP) for 1 week. The respiratory therapist examines the patients at weekly intervals by checking the diary card and measuring their MIP each time. The resistance is modified each session according to their 25-30% of their MIP measured.
1544384|NCT02637960|Drug|Placebo|One daily dose of placebo (matched to fedovapagon) for 12 weeks
1544229|NCT02638961|Other|FES|Patients allocated to FES arm will receive standard medical treatment and will be trained in a FES program of both legs by a physiotherapist for 45 minutes a day, 2 days per week for a total of 12 weeks. Eight adhesive electrodes are positioned on the skin over the quadriceps and gastrocnemius muscles of both legs. The stimulator is configured to deliver a direct electrical current at 25 Hz for 5 seconds followed by a 5-second rest. The intensity of the stimulation is adjusted to achieve a visible muscle contraction without discomfort.
1544230|NCT02638961|Other|Standard treatment|Patients allocated to this arm will not receive any physical therapy, only standard medical treatment. They will be checked weekly by a physiotherapist who measures their maximal inspiratory mouth pressure each time.
1544235|NCT02638922|Drug|Estradiol|Estradiol containing compounds administered orally in a non-randomized manner.
1544237|NCT02638896|Drug|etanercept (Half-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will be randomized to one of the three treatment arms. In the dose reduction arm, patients will receive etanercept 50 mg subcutaneous injections every other weeks .
1544238|NCT02638896|Drug|etanercept (Full-Dose)|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will be randomized to one of the three treatment arms. In the dose maintenance arm, patients will receive etanercept 50 mg subcutaneous injections every weeks.
1544239|NCT02638896|Drug|Sulfasalazine|AS patients who satisfied the criteria for disease remission (ASDAS<1.3) will take sulfasalazine (2g/d) from week12 to week48.
1544240|NCT02638896|Drug|Celecoxib|Celecoxib (0.4g/d) will be the background therapy.
1544241|NCT02637648|Drug|Sodium Oxybate|parallel Group administration
1544242|NCT02637648|Drug|Placebo|parallel Group administration
1544243|NCT02637635|Procedure|Autologous fat transplantation|100 ml of autologous fat will be injected to the reconstruction area 3 month prior the breast reconstruction with expander prosthesis.
1544244|NCT02637635|Procedure|Expander prosthesis|breast reconstruction with expander prosthesis.
1544249|NCT02637596|Procedure|Radiofrequency ablation|After laparotomy, intraoperative IOUS quided RFA of primary tumor was performed.
1544250|NCT02637583|Drug|PCV13|Intramuscular injection of 13-valent pneumococcal conjugate vaccine once
1544251|NCT02637583|Drug|PPV23|Intramuscular injection of 23-valent pneumococcal polysaccharide vaccine once
1544252|NCT02637570|Dietary Supplement|Hibiscus tea|
1544253|NCT02637570|Dietary Supplement|green tea|
1544254|NCT02637570|Dietary Supplement|placebo (dextrose)|
1544255|NCT02638870|Drug|Amitriptyline|This was a prospective, observational study conducted at Samsung Medical Center, Seoul, Korea. Enrolled IBS patients underwent colonoscopy and colonoscopy-related pain score was evaluated. After colonoscopy, all patients received 5 mg amitriptyline once daily at bedtime for the first week and 10 mg for the subsequent 3 weeks. After the intervention period of 4 weeks, the treatment response was determined.
1544256|NCT02638857|Procedure|TACE|lipiodol 10-20ml,MMC 8～10mg,EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm2 hepatic arterial infusion.Each cycle received one TACE treatment on day 13,34,55.
1544257|NCT02638857|Biological|Dendritic Cell|DC suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
1544258|NCT02638857|Drug|lipiodol|lipiodol 10-20ml,hepatic arterial infusion
1544259|NCT02638857|Drug|Mitomycin (MMC)|MMC 8～10mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2, hepatic arterial infusion.
1544260|NCT02638857|Drug|Epirubicin(EADM)|EADM20～40mg. According to tumor area of maximum diameter,0.1～0.2ml/cm※2 hepatic arterial infusion.
1544261|NCT02638857|Biological|Precision Multiple Antigen T Cell|PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
1544262|NCT02638831|Drug|Ketorolac Tromethamine|Ketorolac tromethamine gel 2% for external application. Column of gel about 3-5 cm is applied on the area of maximum pain three times a day for 10 days
1544263|NCT02638831|Drug|Ketoprofen|Ketoprofen gel 2.5% for external application Column of gel (3-5 cm) is applied with a thin layer on the skin in the area of maximum pain 3 times a day for 10 days
1544264|NCT02638818|Procedure|minimally invasive pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
1544548|NCT02636478|Other|questionnaire for travel habits|questionnaire has been used to collect information about travelling
1544265|NCT02638818|Procedure|traditional pancreaticoduodenectomy|Surgical technique (minimally invasive versus open) will be at the discretion of the operating surgeon. Patients will not be randomized to a treatment arm.
1544268|NCT02638792|Behavioral|Internet-based exposure therapy (I-ET)|"The internet-based exposure therapy (I-ET) group receives a ten-week Internet-based CBT treatment, which is an extended version of the self-help book Sluta älta och grubbla med kognitiv beteendeterapi (How to quit worrying and ruminating with Cognitive behavior therapy) by licensed psychologist Olle Wadström (2007). The main focus of the book is to expose to the frightening word/image and refrain from using neutralizing thoughts. This is supposed to lead to the extinction of upsetting words/images."
1544269|NCT02638792|Behavioral|Internet-based stress management therapy|The I-SMT group receives a ten-week Internet-based CBT treatment focused on stress and how to manage stressful situations. This protocol is based on current evidence based recommendations for worry and has shown to be effective when delivered via the internet for irritable bowel syndrome and hypochondric worries.
1544270|NCT02638779|Biological|Blood sampling|Specific Blood sampling will be performed in patients and healthy volunteers
1544271|NCT02638766|Drug|regorafenib|Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days
1544272|NCT02638753|Other|education|Patients will be educated about pain neurophysiology.
1544273|NCT02638753|Other|education combined with hypnosis|Patients will be educated about pain neurophysiology combined with hypnosis.
1544274|NCT02638740|Procedure|SCALING AND ROOT PLANING (SRP)|Scaling and root planning done with ultrasonic scalar with reinforcement of oral hygiene measures and follow up for 90 days.
1544275|NCT02638740|Procedure|MUSTARD OIL AND SALT MASSAGE WITH SRP|Scaling and root planing was done with ultrasonic scalar. It was followed by gum massaging with 0.32gm salt in 5ml mustard oil for 5min, twice daily for 90 days.
1544276|NCT02638727|Drug|L-Citrulline|This group treat with L-Citrulline (3 grams per day)
1544277|NCT02638727|Drug|placebo|This group treat with placebo dayley
1544278|NCT02638714|Biological|Stem Cells|Intervention: Transplantation of autologous purified stem cells
1544279|NCT02638701|Drug|Infliximab|
1544280|NCT02638688|Other|ultrasound|
1544281|NCT02638675|Behavioral|Wellness program|All participants have access to Change4Life, a web-based health education and behaviour change program. Individuals are rewarded with very modest incentives (uncertain chance; less than 1 in 100 chance of earning) when they complete learning modules or health tasks.
1544282|NCT02638675|Device|Accelerometer|All participants will be asked to wear the StepsCount Piezo accelerometer, which tracks steps and bout minutes of MVPA per day, synchronize the device to the Change4Life program, and reach daily step count goals for 24 weeks.
1544283|NCT02638675|Behavioral|Incentive|During the first 12 weeks, participants will be eligible to earn $1 in vouchers (e.g., grocery, cinema) when daily goals are reached. The total amount available over the 3-month intervention period will be $90 (9,000 points). During weeks 13 to 24, participants will not receive daily reward points for completing step count goals.
1544284|NCT02638662|Other|Observational|Questionnaires are completed such as self-evaluation questionnaire (STAI), Beck Depression Inventory, FertiQol International and Daily stress questionnaire
1544285|NCT02638649|Procedure|Lung ultrasound|At each call, the paramedic will initially evaluate the patient clinically conducting a standard history and physical exam. The paramedic will then use the portable U/S machine to look for the presence of either unilateral or bilateral B-lines indicating possible pneumonia (in the case of unilateral B-lines) or pulmonary edema (in the case of bilateral B-lines). The paramedic will then document the presence or absence of B-lines for each lung on the prehospital study sheet. The paramedic will then use the U/S to evaluate for the presence of pleural effusions, lung sliding and pericardial effusion.
1544286|NCT02638649|Device|ultrasound|
1544287|NCT02638636|Behavioral|Internet-based exposure therapy|The treatment is a 10 week long cognitive behavior therapy. It is based mainly on the principles of exposure; i.e. the participant is instructed to approach situations they have avoided in order to reduce or avoid pain or other aversive experiences until they feel less discomfort and extended behavior repertoire in presence of pain and aversive inner experiences Other interventions include psychoeducation, mindfulness and acceptance strategies and are employed in order to facilitate exposure.
1544290|NCT02638610|Device|Cochet-Bonnet aesthesiometer|"The eyelid's sensation will be assessed at 6 points of the eyelid using the Cochet-Bonnet aesthesiometer (Luneau Ophtalmologie, Paris, France). Measurements will take place before surgery, and two weeks, three months and six months after surgery.
This instrument contains a 6 centimeters long, retractable, flexible monofilament. For any given length, when applied perpendicularly to a test surface, the filament will exert a precise pressure before visibly bending. The filament's length inversely corresponds to the pressure exerted by the aesthesiometer such that the shorter the filament length, the more pressure it exerts on the test surface."
1544291|NCT02638597|Drug|Gemfibrozil|FDA Approved Drug(s)/Biologic(s) (study use is not an FDA-approved use)
1544292|NCT02638597|Behavioral|smoking cessation counseling|smoking cessation counseling
1544293|NCT02638584|Drug|Ilaprazole|Ilaprazole 10mg 2tablets once a day(1 times / day), before breakfast
1544294|NCT02638584|Drug|Rabeprazole|Rabeprazole 20mg 1tablets once a day(1 times / day), before breakfast
1544295|NCT02638571|Other|enhanced education on pulse use in complementary foods|Enhanced Nutrition education with sessions and counseling by health extension workers
1544296|NCT02638558|Other|written + oral explanation|
1544297|NCT02638558|Other|written explanation|
1544298|NCT02638545|Drug|Dexmedetomidine|Sedation with propofol and remifentanyl will be replaced by a sedation with dexmedetomidine and remifentanyl
1544376|NCT02638012|Other|Packing|If bleeding is not controlled after up to two Floseal applications, the gel and clots will be removed with suction, and the patient will be treated with a standard packing treatment (standard of care).
1544377|NCT02637999|Drug|Myrcludex B|
1544378|NCT02637999|Drug|PEG IFN alfa-2a|
1544299|NCT02638532|Procedure|Foot Fat Pad Grafting|Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
1544304|NCT02638506|Drug|Fentanyl|All patients will receive a 1.5 mcg⁄kg dose of fentanyl. This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
1544305|NCT02638506|Other|Salinex|All patients will receive an equivalent volume of similar looking placebo to fentanyl (1.5 mcg/kg dose). This will be administered intranasally via a mucosal atomiser device (MAD) using 50 mcg/mL solution with a 2 mL syringe
1544306|NCT02638480|Device|KneeMD|KneeMD is a subject-controlled knee rehabilita¬tion device that helps subjects who have undergone total knee replacements or other major knee surger¬ies improve range of motion and stretch in extension.
1544307|NCT02638467|Drug|Bosutinib|Subjects will receive 400mg of bosutinib once daily from day +30 after transplant, by mouth with food, preferably in the morning. Bosutinib will also be administered from day at least -45 to day -15 to assess the sensitivity of patient CML to this TKI.
1544308|NCT02638467|Procedure|Bone Marrow Transplant|"Samples of the unrelated stem cell graft shall be characterised with respect to the number of CD34 positive cells per kg body weight of the recipient.
The number of transplanted CD34 positive cells per kg body weight (BW) of the recipient shall be recorded in the Case Report Form (CRF). If the transplant was cryopreserved the number of viable CD34 positive cells has to be determined after thawing and documented.
The goal is to transplant > 3 x 106 CD34+ cells/kg BW recipient from bone marrow or > 3 x 108 nucleated cells/kg BW recipient from bone marrow"
1544309|NCT02638467|Drug|Bone Marrow cells|
1544311|NCT02638441|Other|hospital anxiety and depression scale|Detection of infertility effect on emotional status
1544312|NCT02638428|Procedure|CancerSCAN™|Targeted deep sequencing
1544313|NCT02638428|Drug|Ifosfamide|
1544314|NCT02638428|Drug|Carboplatin|
1544315|NCT02638428|Drug|Etoposide|
1544316|NCT02638428|Drug|Fludarabine|
1544317|NCT02638428|Drug|Cytarabine|
1544318|NCT02638428|Drug|Pazopanib|
1544319|NCT02638428|Drug|Sorafenib|
1544320|NCT02638428|Drug|Axitinib|
1544321|NCT02638428|Drug|Crizotinib|
1544322|NCT02638428|Drug|Dasatinib|
1544323|NCT02638428|Drug|Erlotinib|
1544324|NCT02638428|Drug|Everolimus|
1544325|NCT02638428|Drug|Imatinib|
1544326|NCT02638428|Drug|Ruxolitinib|
1544327|NCT02638428|Drug|Vandetanib|
1544328|NCT02638428|Drug|Vemurafenib|
1544329|NCT02638428|Drug|Trastuzumab|
1544330|NCT02638415|Procedure|HVPG-guided therapy|"Patients with an HVPG over 20mmHg will be suggested to receive transjugular intrahepatic portocaval shunt (TIPS) or surgical shunt operation.
Patients with an HVPG between 16 and 20mmHg can choose either endoscopic treatment or TIPS according their willingness and indication.
Patients with an HVPG below 16mmHg will be treated by endoscopy plus Carvedilol, until endoscopic treatment fails."
1544331|NCT02638415|Other|routine therapy|Patients start treatment without HVPG measurement and receive endoscopic therapy plus Carvedilol.
1544332|NCT02638415|Drug|Carvedilol|Patients in HVPG group with HVPG below 16mmHg and all patients in non-HVPG group will take Carvedilol 12.5mg/d if they have no contraindications.
1544333|NCT02638389|Drug|Sirolimus|evaluate the efficacy and safety of sirolimus in these patients
1544334|NCT02638376|Radiation|0.1% Riboflavin ophthalmic solution (KXL System With vibeX Rapid)|"KC Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off.
PLEc Eyes will be irradiated at 30mW/cm2 for 4 minutes continuous or 8 minutes pulse treatment: 1 second on 1 second off."
1544335|NCT02638376|Procedure|simultaneous KXL and topography-guided transepithelial photorefractive keratectomy(PRK)|"The (Partial, Spherically Corrected) Topography-guided Transepithelial PRK Technique. Is performed with WaveLight® EX 500 excimer laser (Alcon Laboratories Inc, Ft Worth, Texas) customized platform.
This software utilizes topographic data from the linked topography device (Topolyzer; Wave- Light GmbH, Erlangen, Germany). The image of the planned surgery is generated by the laser software.
The topography-guided PRK is used to normalize the cornea by reducing irregular astigmatism while treating part of the refractive error. The maximum ablation depth of stromal ablation is set at 50um.
A 6.5-mm, 50-μm phototherapeutic keratectomy (PTK) was performed to remove the corneal epithelium. Partial topography- guided PRK laser treatment was applied. A cellulose sponge soaked in mitomycin C (MMC) 0.02% solution was applied over the ablated tissue for 20 seconds followed by irrigation with 10 mL of chilled balanced salt solution."
1544379|NCT02637986|Dietary Supplement|Urex Plus - containing L. rhamnosus GR-1 and L. reuteri RC-14|2 capsules will be given per day
1544380|NCT02637986|Other|Placebo - capsule with no active ingredient|2 capsules will be given per day
1544381|NCT02637973|Drug|Empagliflozin|25 mg once daily
1544336|NCT02638363|Behavioral|Cognitive behavioral therapy|The participants will receive 12-16 sessions of manualized group-based CBT with a maximum of 8 participants in each group. The therapists are trained psychiatrists, psychologists, or nurses under supervision. The treatment manuals are developed by mental health professionals in the Capital Region of Denmark. The treatment program includes traditional CBT components (e.g., psychoeducation, identification of thoughts and feelings, exposure, cognitive restructuring, and relapse prevention).
1544337|NCT02638350|Device|Strategy with lung ultrasound|"Each patient admitted for suspicion of acute lung edema will be treated according to the protocol of the emergency department.
Another doctor will independently do a lung ultrasound and measurement of the inferior vena cava. The ultrasound results are not made available to the doctor in charge of the patient.
At the end of the study, all the files will be analyzed by a independent committee, blinded ultrasound results for the final diagnosis of acute pulmonary edema."
1544338|NCT02638337|Drug|Ospemifene|60 mg tablet
1544339|NCT02638337|Drug|Placebo|Tablet identical to the ospemifene tablet without drug
1544340|NCT02638324|Device|Renal nervous denervation|The heart failure patients will undergo renal nervous denervation if they have not properly responded to medication and biventricular pacing therapy.
1544341|NCT02638298|Device|Prevana Dressing|negative pressure wound therapy (NPWT) dressing
1544342|NCT02638298|Other|Standard Dry Gauze Dressing|Standard Dry Gauze Dressing
1544343|NCT02638285|Drug|LH|
1544344|NCT02638285|Drug|HCG|
1544345|NCT02638285|Drug|Clomiphene|
1544346|NCT02638272|Procedure|no debridement|It is a spinal surgery performed with isolated posterior instrumentation without debridement.
1544347|NCT02638259|Drug|GP2015|Enbrel comparator
1544348|NCT02638246|Behavioral|Internet-delivered, Incentive-based intervention + Motivational Interviewing|Blood glucose monitoring was verified by videos uploaded to a secure server. Participants in the experimental group received incentives for adherence whereas participants in the control group received adherence independent of adherence.
1544349|NCT02638246|Behavioral|Internet-delivered, non-contingent incentives + Motivational Interviewing|
1544350|NCT02638233|Drug|Sofosbuvir 400mg / Ledipasvir 90 mg (FDC)|
1544351|NCT02638207|Drug|NewGam|In the Dose-evaluation Phase, all patients will receive a loading dose of 2.0 g/kg Newgam (administered over two consecutive days), followed by seven infusions of the maintenance dose the patient has been randomized to (0.5, 1.0 or 2.0 g/kg NewGam), also administered over two consecutive days every 3 weeks (±4 days). If a patient is randomized to receive the low or medium NewGam dose, the same volume with the same infusion rate as would have been applied in case the patient would have been randomized to 2.0 g/kg NewGam will be used, thus supplemented with an authorized 0.9% w/v isotonic sodium chloride solution as appropriate and detailed in the following infusion bag split to maintain the blinding
1544352|NCT02638194|Other|Active smoking of Tobacco Hookah for 2 hours|
1544353|NCT02638194|Other|Exposure to tobacco hookah second hand smoke|
1544354|NCT02638194|Other|Visit a win bar|Participants will visit a wine bar for food and/or drinks
1544355|NCT02638181|Procedure|trabeculectomy|
1544356|NCT02638168|Drug|Immediate Release Methylphenidate|The medication assessment procedure will be a double-blind, within-subject evaluation of placebo and matching evening dose of IR MPH rounded to the nearest 2.5mg increment with a max IR MPH dose of 0.3mg/kg. Expected evening dose range will be from 2.5mg to 20mg with most participants receiving between 5 to 15mg per evening dose. Dose will be determined based on current dose of their morning extended release stimulant
1544357|NCT02638168|Drug|Placebo|inert placebo ingredient
1544358|NCT02638142|Drug|Continuous Furosemide Infusion|Intravenous continuous Furosemide infusion
1544359|NCT02638142|Drug|Intermittent Furosemide Infusion|Intravenous bolus intermittent Furosemide Infusion
1544360|NCT02638129|Drug|Naltrexone HCl/Bupropion HCl ER|Naltrexone HCl 8 mg/bupropion HCl 90 mg ER combination tablets
1544361|NCT02638129|Drug|Placebo|Naltrexone HCl/bupropion HCl placebo-matching tablets
1544362|NCT02638116|Drug|Ibrutinib|Ibrutinib will be administered at a dose of 560 milligram (mg) orally (4 x 140 mg capsules) on Day 1 and Day 7.
1544363|NCT02638116|Drug|Omeprazole|Omeprazole will be administered at dose of 40 mg tablets orally once daily from Day 3 to Day 7.
1544364|NCT02638103|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
1544365|NCT02638103|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
1544366|NCT02638103|Drug|Placebo|Matching Placebo
1544367|NCT02638090|Drug|Vorinostat|Administered per treatment arm guidelines.
1544368|NCT02638090|Drug|Pembrolizumab|Administered per treatment arm guidelines.
1544369|NCT02638064|Procedure|Surgiflo injection|Curettage of sinus cavity then injection of surgiflo material
1544370|NCT02638051|Device|Modulated Electro-Hyperthermia (mEHT)|MEHT is a descendant of hyperthermia initially based on nano-thermal but not temperature-dependent effects of electromagnetic fields and special fractal modulation, whose effect could 3-4 times exceed the effect of the overall heating (macroscopic temperature elevation). MEHT does not require hyperthermia-range temperatures and could be performed safely without invasive thermal control. EHY-2000 local machine is used for mEHT in the trial.
1544371|NCT02638051|Dietary Supplement|TCM Herbal Decoction (Shi Pi)|Shi Pi Decoction can warm Yang, invigorate the spleen, promote Qi circulation to induce diuresis and treat Foot-Taiyin meridian in Gu Zhang.
1544372|NCT02638051|Drug|IPCI (CDDP+5FU)|Intraperitoneal chemoinfusion of CDDP (30-60 mg) and 5-fluorouracil (500-600 mg/sqm).
1544373|NCT02638038|Drug|INT131|INT- 131
1544374|NCT02638025|Device|OCT|Anterior Segment Spectral-domain Optical Coherence Tomography
1544375|NCT02638012|Drug|Floseal|Topical lidocaine spray (2%) is then administered using 1-2 sprays in the affected nasal cavity via the nostril that is to have Floseal® applied. Once the bleeding has stopped following application of the Floseal® a 50 cc syringe with sterile saline will be used to irrigate the treated nasal cavity to remove any excess Floseal® product as per manufacturer recommendations. This is done with the patient's head tilted downwards at a 30 degree angle so that the irrigation and excess product is removed from the nasal cavity. Once the irrigation is complete, the nasal cavity is inspected for evidence of continued bleeding.
1544382|NCT02637973|Drug|Placebo|once daily
1544383|NCT02637960|Drug|Fedovapagon 2 mg|One daily dose of 2 mg fedovapagon for 12 weeks
1544385|NCT02637947|Device|catheter ablation using magnetic navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of Stereotaxis's Niobe ES System with the NaviStar RMT ThermoCool catheter or other magnetically compatible catheters.
1544386|NCT02637947|Device|catheter ablation using manual navigation|elimination of cardiac arrhythmias through heating and destroying heart tissue with faulty electrical pathways through the use of the NaviStar ThermoCool catheter or other manually navigated catheters.
1544387|NCT02637934|Drug|[18F]FluorThanatrace|
1544388|NCT02637934|Radiation|PET/CT imaging sessions|
1544389|NCT02637921|Other|Hypoxia|21 days confinement in normobaric hypoxic (FiO2 = 14%)
1544390|NCT02637921|Other|Ambulatory|Participants hava a standardized activity level throughout the intervention
1544391|NCT02637921|Other|Normoxia|21 days confinement in normobaric normoxic (FiO2 = 21%) environment
1544392|NCT02637921|Other|Bed Rest|Participants remain on supine bed rest throughout the intervention
1544393|NCT02637921|Other|Standardised nutritional intake|Macronutrient, salt and dietary energy intake will be standardized per kg body weight for each participant
1544394|NCT02637908|Behavioral|Mindfulness training|6-weeks of group-based mindfulness training for parents
1544397|NCT02637882|Other|Ear plug|The patients will receive the first intervention (ear plug) in the third night (N3) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale.
1544398|NCT02637882|Other|Eye mask|The patients will receive the second intervention (eye mask) in the second night (N2) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
1544399|NCT02637882|Other|Mixed intervention (ear plug and eye mask)|The patients will receive the intervention (eye mask and ear plug) in the first night (N1) from 9 pm to 6 am.and the patient will complete the sleep questionnaire sheet and delirium scale
1544400|NCT02637869|Other|Alternative Payment Model|Oregon developed an Alternative Payment Methodology (APM). Under this APM pilot participating CHCs will receive a prospective payment system (PPS) payment as a capitated equivalent in a per-member-per-month rate for all of their Medicaid patients
1544402|NCT02637843|Device|Slender Sheath|Comparing outcomes for two different sheaths used during radial CAG/PCI
1544403|NCT02637830|Other|Application of fluoride varnish (22600 ppm F, Duraphat) at the begining of the study|
1544404|NCT02637830|Other|Application of fluoride toothpaste (1500 ppm F, Crest) twice a day for 3 days of the study|
1544405|NCT02637830|Other|Application of placebo toothpaste (0 ppm F, Ice Fresh) twice a day for 3 days of the study|
1544409|NCT02637557|Drug|IW-3718|
1544410|NCT02637557|Drug|Matching Placebo|
1544411|NCT02637544|Other|acupuncture|classical acupuncture therapy
1544412|NCT02637531|Drug|IPI-549|IPI-549 daily dose administered orally in 28-day cycles (Part A/BC/D/D-Annex/E)
1544413|NCT02637531|Drug|Nivolumab|Nivolumab (240 mg, Q2W) administered intravenously (IV) in 28-day cycles (Part C/D-Annex/E).
1544414|NCT02637518|Other|Assessment of frailty tools in elderly people|Assessment of the tools as screening/diagnosis instruments in older adults attended in Primary Care. To build the integration of tools in algorithms to be used in each setting of care and along the settings to permit an integrated care in different conditions (isolated assessment or sequential assessment)
1544415|NCT02637505|Procedure|Arthroscopic microfracture (MF)|Arthroscopy With microfracture procedure
1544416|NCT02637505|Procedure|Arthroscopic debridement (AD)|Arthroscopy With debridement procedure
1544417|NCT02637492|Other|Collection of clinical signs and symptoms|Collection of clinical signs and symptoms used for developing a Clinical prediction rule of critical lower limb ischaemia (diagnosed by haemodynamic methods: ankle pressure, toe pressure-laser Doppler or photo-plethysmography, transcutaneous oxygen pressure) in patients with peripheral occlusive arterial disease
1544418|NCT02637479|Device|GammaKnife®|
1544419|NCT02637479|Device|18F-2-fluoro-2-deoxy-D-glucose - positron emission tomography (FDG-PET)|
1544420|NCT02637479|Device|MRI|
1544421|NCT02637466|Drug|Vortioxetine|
1544422|NCT02637453|Procedure|CPVI|patients with circumferential pulmonary vein isolation （CPVI）
1544423|NCT02637453|Procedure|CPVI+ALA|patients with circumferential pulmonary vein isolation（CPVI）and additional linear ablation perpendicular to the PV ostium （ALA）
1544424|NCT02637440|Procedure|FFR guided PCI|Patients undergo Fractional Flow measurement (FFR) followed by PCI, if the FFR is less than 0.8
1544425|NCT02637440|Procedure|Angio guided PCI|Patients receive PCI without FFR measurement
1544426|NCT02637427|Biological|Fresh frozen plasma transfusion|Pre-procedure fresh frozen plasma transfusion (15 cc per Kg to a maximum of 5 units)
1544427|NCT02637414|Behavioral|Flourishing App Program|This intervention is based on relaxation, well-being promotion, meditation practices and positive psychology principles. The program is being evaluated in a classroom format into another project and was adapted for this project in the application format for mobile devices. It will last for 8 weeks, with trainings of 15 to 25 minutes, four times a week.
1544428|NCT02637401|Behavioral|Dialectical Behaviour Therapy|
1544429|NCT02637388|Dietary Supplement|Oatwell28 Oatwell Original Powder|
1544430|NCT02637388|Dietary Supplement|Control Breakfast|Isocaloric breakfast without added beta-glucans
1544431|NCT02637375|Drug|Ganetespib|
1544432|NCT02637375|Drug|Paclitaxel|
1544433|NCT02637375|Drug|Doxorubicin|
1544434|NCT02637375|Drug|Cyclophosphamide|
1544435|NCT02637362|Procedure|Ankle block|Ultrasound guided ankle block of the tibial, superficial peroneal and deep peroneal nerves will be performed using a standardised technique
1544811|NCT02634489|Drug|Solifenacin Succinate|Oral
1544436|NCT02637362|Procedure|Sham ankle block|In the supine position with the hip and knee flexed, and the hip externally rotated, the skin from medial malleolus to Achilles tendon will be prepared with chlorhexidine 0.5% solution and allowed to dry. An ultrasound probe (linear array HFL25, Sonosite, Hitchin, UK) will be placed on a line from medial malleolus to achilles tendon to identify the posterior tibial artery and tibial nerve. A Stimuplex A50 needle (B-Braun) will be placed against the skin at the point at which the practitioner would normally have performed insertion of the needle. It will remain there for a total of 30 seconds and then will be removed.
1544437|NCT02637362|Procedure|Metatarsal block|A metatarsal block will be performed using a standardised technique
1544438|NCT02637362|Procedure|Sham metatarsal block|In the supine position, after the surgical incision has been sutured, a 25G standard bevel needle will be placed against the skin at the points at which the practitioner would normally have performed insertions of the needle. It will remain there for a total of 30 seconds and then be removed.
1544439|NCT02637349|Behavioral|POST Intervention|POST Intervention group will receive a tailored survivorship care plan (SCP) at the end of their active treatment. The SCP will be discussed with them. Patient will be asked about satisfaction with the end of treatment session.
1544440|NCT02637349|Behavioral|POST Treatment as Usual|The POST control group may receive a survivorship care plan (SCP) as part of treatment as usual though it is not a usual procedure. They will be asked about their satisfaction with the end of treatment session.
1544441|NCT02637336|Device|Acupuncture|Acupuncture in point 6 of the pericardium channel (neiguan) bilaterally
1544442|NCT02637336|Device|Aerobic exercise|aerobic exercise of moderate intensity
1544443|NCT02637336|Device|Aromatherapy|inhalation of eucalyptus essential oil
1544446|NCT02637310|Drug|N02RS1 1200mg|1200mg/day, Three times a day orally, 2 tablets once, 7 days
1544447|NCT02637310|Drug|Placebo|1200mg/day, Three times a day orally, 2 tablets once, 7 days
1544448|NCT02637297|Procedure|Hypnotherapy|Undergo hypnotherapy
1544449|NCT02637297|Other|Questionnaire Administration|Ancillary studies
1544450|NCT02637284|Drug|Bepecin|"Phase 1a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-02 containing 1 mg of Bepecin to study safety and pharmacokinetics.
Phase 1b: All subjects will take 3 tablets of PCO-02 containing 1 mg of Bepecin every 8 hours during two weeks, to study safety and pharmacokinetics."
1544451|NCT02637284|Drug|Placebo|"Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.
Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group."
1544452|NCT02637271|Other|Low calorie total meal replacement|Participants will be provided instruction in the appropriate use of the meal replacement product. The participants will be directed to refrain from all items of food for a period of 21 days except for the meal replacement products and vitamin supplements provided by the investigators (1120 kcal/day). Optifast™ 800 total meal replacement shakes will be provided to the participants for the 21 day intervention period.
1544453|NCT02637271|Other|Low calorie typical diet|Participants will be directed to use portion control to maintain a calorie level no greater than 1120 kcal per day. The participants will be directed to continue to consume food and beverage items that are representative of their typical diet (with the exception of reduced portions). Participants will be provided resources to assist them in determining caloric content of foods eaten.
1544454|NCT02637258|Other|Ultrasonographic Measurements of Optic Nerve Sheath Diameter|Bedside Ultrasonographic Measurements of Optic Nerve Sheath Diameter
1544455|NCT02637245|Other|No intervention|No intervention
1544456|NCT02637232|Other|Mirvaso® / Onreltea TM|
1544457|NCT02637206|Drug|GSK2894512 Cream|GSK2894512 cream supplied will be white to off-white cream packaged in 28-gram laminate tubes of 2 concentrations: 0.5% and 1%, to be applied topically.
1544458|NCT02637206|Drug|Vehicle Cream|Vehicle Cream (placebo cream without active ingredient) supplied will be white to off-white cream packaged in 28-gram laminate tubes, to be applied topically.
1544459|NCT02637206|Drug|Empty Patch|Empty patches without any ingredients will be used as negative control.
1544460|NCT02637193|Drug|Venlafaxine|Multiple doses of Venlafaxine for 14 days plus 3 days of down titration
1544461|NCT02637193|Drug|Moxifloxacin|400 mg single dose moxifloxacin
1544462|NCT02637193|Drug|Drug - placebo|Placebo administered for 16 days
1544463|NCT02637180|Drug|anti-osteoporotic medication|check previous information
1544464|NCT02637167|Drug|Rifaximin|Rifaximin has negligible intestinal absorption after oral administration, giving it a good safety profile. Unlike systemically available antibiotics, this antimicrobial allows localized enteric targeting of bacteria and is associated with a minimal risk of systemic toxicity or side effects.
1544465|NCT02637167|Drug|Saccharomyces boulardii|The same advantage described above to Rifaximin applies to S. Boulardii, which might be therapeutically sufficient with the advantage of being less disruptive to the instestinal microbiota than broad-spectrum antibiotics.
1544466|NCT02637154|Behavioral|Motivational Interviewing|Motivational Interviewing method
1544467|NCT02637154|Behavioral|Standard Education|Standard Education material will be used
1544468|NCT02637141|Biological|AMG 714|A fully human anti-IL-15 monoclonal antibody
1544469|NCT02637141|Biological|Placebo|Placebo comparator
1544470|NCT02637128|Drug|artemether-lumefantrine (AL)|Dispersible formulation of artemether-lumefantrine (Coartem-D™; 20mg artemether/120mg lumefantrine per tablet, Novartis, Switzerland) administered twice a day for 3 days according to manufacturer recommended dosing for weight
1544471|NCT02637128|Drug|artesunate-amodiaquine (ASAQ)|Co-formulated artesunate-amodiaquine (25mg artesunate/67.5mg amodiaquine and 50mg artesunate/135mg amodiaquine tablets) administered once a day for 3 days, according to manufacturer recommended dosing for weight
1544472|NCT02637115|Dietary Supplement|Placebo|Consumption of one dose-sachet per day. This dose-sachet contains a placebo (PBS/Glycerol)
1544473|NCT02637115|Dietary Supplement|Live Akk 9|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (one billion per dose-sachet)
1544474|NCT02637115|Dietary Supplement|Live Akk 10|Consumption of one dose-sachet per day. This dose-sachet contains Live Akkermansia muciniphila (ten billion per dose-sachet)
1544475|NCT02637115|Dietary Supplement|Killed Akk|Consumption of one dose-sachet per day. This dose-sachet contains heat-killed Akkermansia muciniphila
1544476|NCT02637102|Other|Not applicable - observational study|
1544477|NCT02637076|Drug|Xyrem|single 3.0 gram dose
1544478|NCT02637063|Behavioral|BlipHub mobile-web app|Mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
1544479|NCT02637063|Behavioral|BlipHub mobile-web app + health coaching|Telephonic coach-supported mobile web app to promote blood-pressure-reducing diet, physical activity and weight loss.
1544480|NCT02637063|Other|Usual care|No intervention beyond participants' own medical care.
1544488|NCT02636972|Drug|OCPs|"Participants in the contraceptive pill groups can use any one of the following contraceptive pills:
Oestradiol valerate and dienogest, drospirenone and ethinyl estradiol , ethinyloestradiol and levonorgestrel, cyproterone and ethinyl estradiol, ethinylestradiol and norethisterone, Nomegestrol Acetate and Oestradiol and Ethinyl Estra"
1544489|NCT02636959|Other|saline irrigation|HVSI (NeilMed® Sinus Rinse™) versus LVSI (Salinex®) in the early post-operative management in patients with chronic rhinosinusitis. Both are a saline rinse spray.
1544490|NCT02636946|Drug|Bimatoprost SR|Bimatoprost sustained-release (SR) Dose A administered on Day 4, Weeks 16 and 32.
1544491|NCT02636946|Drug|Sham Bimatoprost SR|Sham Bimatoprost SR administered on Day 4, Weeks 16 and 32.
1544492|NCT02636946|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
1544493|NCT02636946|Procedure|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
1544494|NCT02636933|Other|Lung Function Assessment|Lung Function Assessment
1544495|NCT02636920|Other|Therapeutic Education to the Patient (TEP)|"Educational Diagnosis, asking what patient has, what he knows, what he is doing, what he would like to do.
Therapeutic Contract, to define objectives to reach at the end of educational path, integrating new knowledges and replacing wrong cognitive-behavior models with new schemes.
Educational Therapeutic Intervention, with individual or group methodologies (Role Playing, Brain Storming) and a disease diary in which patients could describe symptoms, therapies, behaviors and benefits.
Assessing of the knowledges acquired by patients."
1544496|NCT02636907|Drug|BI 695501 Autoinjector|
1544497|NCT02636907|Drug|BI 695501 Prefilled syringe|
1544498|NCT02636894|Device|Restylane Silk|
1544499|NCT02636881|Procedure|Autologous Chondrocyte Implantation|Implantation of the patients own cartilage cells in a chondral defect of the knee
1544500|NCT02636881|Procedure|Arthroscopic Debridement|Arthroscopic diagnosis and debridement of the lesion, without cartilage therapy. Removal of lose bodies etc.
1544501|NCT02636868|Drug|Lucinactant delivered via investigational delivery device|Lucinactant for inhalation refers to the active investigational agent lucinactant in combination with the investigational delivery device (drug-device combination product)
1544502|NCT02636868|Drug|nCPAP|Nasal CPAP
1544503|NCT02636842|Drug|Aripiprazole Lauroxil|Intramuscular (IM) injection, single dose
1544504|NCT02636829|Other|QALCIMUM questionnaire|All patients will fill out the QALCIMUM questionnaire.
1544505|NCT02636829|Other|Determination of calcium intake by a dietician interview|"All patients will have an interview with a dietician who performs a food survey serving as a reference (gold standard) and based on data from CIQUAL *.
* CIQUAL Data: Nutritional food composition table available on the website of the ANSES (National Agency for Sanitary Security of Food, Environment and Labour), published by the Observatory of the Nutritional Quality of Foods. This table includes 1500 sheets of 58 nutritional components. The data is integrated into the software (DATAMEAL) for calculating the ingesta parameters at the Nîmes University Hospital."
1544507|NCT02636803|Drug|oxfendazole|group receives a single dose of oxfendazole at 6 or 30 mg/kg or three 6 mg/kg doses
1544508|NCT02636803|Drug|albendazole|group receives one 400 mg dose of albendazole
1544509|NCT02636790|Procedure|Surgery wait time|VCH CRS patients need a waitlist system that promotes wellness and ensures care that focuses on quality - this can be achieved with a prioritized waitlist based on quality of life improvement and decreased healthcare expenditure.
1544510|NCT02636777|Other|no intervention|Patients will be allowed to continue their usual treatment as recommended by their care team.
1544511|NCT02636764|Other|exercise|exercises designed with the objective of strengthening the musculature: flexor and extensor of the knee; extensor, abductor, lateral rotator of the hip.
1544512|NCT02636764|Device|interferential current|The basic principle of Interferential Therapy (IFT) is to utilise the significant physiological effects of low frequency (<250pps) electrical stimulation of nerves without the associated painful and somewhat unpleasant side effects sometimes associated with low frequency stimulation
1544513|NCT02636764|Device|short-wave diathermy|Is a modality that produces deep heating via conversion of electromagnetic energy to thermal energy
1544514|NCT02636764|Device|Low level laser therapy|Laser treatment in which the energy output is low enough so that the temperature of the treated tissue does not rise above 98.6°F (36.5° C) or normal body temperature.
1544515|NCT02636764|Device|Ultrasound therapy|Ultrasound (US) is a form of mechanical energy, not electrical energy and therefore strictly speaking, not really electrotherapy at all but does fall into the Electro Physical Agents grouping.
1544516|NCT02636751|Behavioral|12-week prehabilitation program|stretching, strengthening, proprioceptive exercises of the lower limb and cardiovascular training using low-impact activities
1544517|NCT02636751|Device|Walking aid adjustment|Walking aid adjustment
1544518|NCT02636751|Behavioral|Information about pain control|General information about pain control, such as ice application and medication usage
1544519|NCT02636738|Device|Vela XL thulium laser, laser fiber and accessories.|The VelaTM XL Laser is a continuous wave thulium laser that uses an optimized 1.94μm wavelength. This powerful, highly precise laser is designed for hemostatic cutting or ablation of soft and hard tissue
1544520|NCT02636725|Drug|Axitinib|Twice daily dosing of axitinib alone for the first 7 days, followed by concurrent axitinib administered twice daily at 5 mg PO twice daily, plus intravenous administration of pembrolizumab every 21 days. Intrapatient dose escalation of axitinib will be performed following an initial safety lead-in of 5 patients.
1544521|NCT02636725|Drug|Pembrolizumab|Pembrolizumab 200 mg flat dose shall be administered via intravenous (IV) infusion, once every 21 days, on day 8 and day 29 of the first cycle, and days 1 and 22 of the following cycles.
1544522|NCT02636725|Procedure|Blood Draw|Peripheral blood draws for correlative studies characterizing T-cells in peripheral blood will be performed at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
1544523|NCT02636725|Procedure|Tumor Specimen Collection|Tumor specimen collection via core needle biopsy for correlative studies characterizing T-cells in tumor tissue will occur at three timepoints: 1) pre-treatment, 2) on-treatment on cycle 3 day 1, and 3) off-study.
1544525|NCT02636699|Biological|Viaskin Peanut 250mcg|Peanut extract cutaneous patch
1544526|NCT02636699|Biological|Placebo|Cutaneous patch containing an inactive deposit manufactured to mimic peanut extract
1544527|NCT02636686|Drug|Drisapersen|Subjects will receive 6 mg/kg of drisapersen by subcutaneous injection once weekly. If subjects have experienced an intolerable injection site reaction(s), in consultation with the investigator, the subject may be allowed intermittent injections (8 weeks on/4 weeks off) or weekly intravenous infusions of 3 or 6 mg/kg
1544528|NCT02636673|Procedure|Sigmoid Resection|
1544529|NCT02636647|Biological|Fecal transplant|
1544530|NCT02636634|Other|imaging|
1544531|NCT02636621|Device|Brazilian Dental Appliance|Brazilian Dental Appliance is an oral appliance worn only during sleep that supports the jaw in a forward position to help maintain an open upper airway.
1544532|NCT02636621|Other|Placebo|The placebo consists in a protective dental plate worn only during sleep that do not interfere in the size of the upper airway.
1544533|NCT02636595|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
1544534|NCT02636582|Other|Laboratory Biomarker Analysis|Correlative studies
1544535|NCT02636582|Drug|Nelipepimut-S Plus GM-CSF Vaccine|Given ID
1544536|NCT02636582|Biological|Sargramostim|Given ID
1544539|NCT02636556|Radiation|concurrent chemoradiation|The patients receive chemotherapy concurrent with Radiotherapy. The prescription dose is 60Gy in 30 fractions in 6 weeks.The chemotherapy regimen is cisplatin (25mg/m2,iv drip,d1-3) and etoposide (75mg/m2,iv drip,d1-3),q4w*4.
1544540|NCT02636543|Other|Questionnaire after the reading of letter B.|Oral questionnaire after the reading of letter B.
1544541|NCT02636543|Other|Questionnaire after the reading of letters A and B|Oral questionnaire after the reading of letters A and B during individual interview.
1544542|NCT02636530|Behavioral|Ground Reaction Forces|6 month exercise program that loads the body via gravitational forces.
1544543|NCT02636530|Behavioral|Joint Reaction Forces|6 month exercise program that loads the body via loading the joints.
1544544|NCT02636517|Biological|Fecal Microbiota Transplant|Fecal Microbiota transplant via colonoscopy, considered both a biologic and a drug
1544545|NCT02636504|Device|Laser Doppler Flowmetry|Pulp vitality of teeth is tested with three pulp vitality testing including laser Doppler flowmetry, cold testing, and electric pulp testing.
1544546|NCT02636491|Device|MD-Logic-Automated Insulin Delivery System|"Subjects will undergo 60 hours at home under MD-Logic control and continuing with their regular routine life. At evening of the first intervention day patients will switch to MD-Logic control. Patients will be asked to connect study sensor and pump to the computer using the MD-Logic software. After the activation of the MD-Logic system, basal insulin dosing and correction boluses will be fully automated and controlled by the MD-Logic system except to meal boluses. Patients will be encouraged to measure capillary blood glucose at least 4 times a day, before each meal and before bed time. After the third night the patient will turn the closed-loop controller OFF, this will automatically save the log file. The patient will return to his regular insulin treatment."
1544547|NCT02636491|Device|MiniMed Paradigm® Veo™ System|Subjects use 60 hours at home their conventional insulin pump and continuing with their regular Routine life. During this therapy the Insulin pump operating separately and are not controlled by the MD-Logic System.
1544812|NCT02634489|Drug|EC905|Oral
1996147|NCT02554435|Device|EAM|The monitor provides the participant feedback on their daily steps, active time, idle time, burned calories, and distance traveled through the mobile application (app). Participants can review all of their feedback while in the intervention. If the participants chose, they are also able to monitor their sleep and dietary intake. The app also provides health tips and daily challenges. The participants will also have the opportunity to interact with other participants through the social features of the app.
1996148|NCT02554435|Behavioral|5 A's counseling|Brief counseling to encourage behavioral change. The counseling is intended to be administered by a health care provider. The component of the counseling are assess, advise, agree, assist, and arrange.
1996149|NCT02554435|Device|Pedometer|The pedometer provides the participant feedback on their daily steps, activity time, distance traveled, and calories burned. Participants can review the feedback for the past 7 days.
1996150|NCT02554474|Behavioral|Education, Fitbit/FitViz, physiotherapist counselling.|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
1996151|NCT02554474|Behavioral|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
1996152|NCT02552407|Device|Manual Aspiration Thrombectomy|Thrombus aspiration
1544549|NCT02636465|Other|flight simulationin obese healthy adults or obese patients with or without COPD, OHS|
1544550|NCT02636452|Other|cardiopulmonary exercise test|
1544551|NCT02636439|Behavioral|dietary, aerobic and resistance training|hypocaloric diet individual exercise prescription for aerobic training individual exercise prescription for resistance training.
1544552|NCT02636439|Behavioral|dietary, and aerobic exercise|hypocaloric diet individual prescription for aerobic training.
1544553|NCT02636426|Drug|sorafenib|In new dosing schedule of sorafenib is investigated in this study: high-dose, pulsatile sorafenib
1544554|NCT02636413|Drug|gaxilose|After gaxilose administration, urine collection, cuantification (firstly from 0 to 4 hours, and total urine from 0 to 5 hours), and xilose cuantification afterwards.
1544555|NCT02636413|Dietary Supplement|lactose|After lactose administration, expired hydrogen measurement at pre-specified intervals.
1544557|NCT02636387|Drug|Desmopressin|Two desmopressin 0.2 mg tablets at bedtime for 14 days and if <50 % improvement then increase to three 0.2 mg tablets at bedtime for 14 days
1544558|NCT02636387|Drug|Placebo|Sugar pill manufactured to mimic 0.2 pill of desmopressin. Take two pills at bedtime, if no improvement in 14 days then will take 3 pills at bedtime for an additional 14 days
1544559|NCT02636374|Behavioral|Guided Imagery|A fifteen minute recording of gentle music together with soft talking to guide relaxation.
1544560|NCT02636361|Drug|LY900014|Administered subcutaneously (SC)
1544561|NCT02636361|Drug|Insulin lispro|Administered SC
1544562|NCT02636348|Dietary Supplement|Calcium/Vitamin D|2000 mg calcium and 1000 IU vitamin D administered daily as 8 pills or 2 fortified snack bars.
1544563|NCT02636348|Dietary Supplement|Placebo|Administered daily as 8 placebo pills or 2 unfortified snack bars.
1544564|NCT02636335|Device|Phillips Energy Light HF3319|Exposure to Light administered with Phillips Energy Light HF3319.
1544574|NCT02636296|Other|Pilates|The Pilates program was conducted twice weekly, 60 minutes/session, for twelve consecutive weeks by a certified Pilates Instructor.
1544575|NCT02636296|Other|Control|The control group did not receive the Pilates training program and were instructed to maintain their currently activities during the twelve-week follow-up period.
1544578|NCT02636270|Drug|Increlex|Treat PAPP-A2 deficient patients with Increlex
1544581|NCT02636244|Drug|SHAPE Gel|
1544582|NCT02636231|Drug|Endostatins|Endostar (Endostatins) is to give from the first day of IMRT, 201mg, civ d1-14, q3w for two cycles.
1544583|NCT02636231|Radiation|IMRT|IMRT is to give GTV 60Gy in 27 fractions.
1544584|NCT02636218|Drug|Ketamine|500 ml of ketamine (0.2 mg/ml) infused at 5 ug/kg/min for 4 hours.
1544585|NCT02636218|Drug|0.9% NaCl|500 ml of 0.9% NaCl infused at 5 ug/kg/min for 4 hours.
1544586|NCT02636205|Device|Armeo therapy|Participants will receive 18 sessionsx30 mins of ArmeoSpring therapy over 6weeks.
1544587|NCT02636192|Drug|No Intervention|This is an observational study and participants did not receive any intervention in this study.
1544588|NCT02636179|Other|Comparative epidemiological survey|The method used to select the control group will be the random sampling of eligible schools. It will be defined according to the place of schooling of the historic cohort of children. The children will be matched as close as possible based on sex, age, school class and type of school (public/private).
1544592|NCT02636153|Other|normal diet|Diet containing 1500mg of phosphorus
1544593|NCT02636153|Other|restricted phosphate diet|Diet containing 500mg of phosphorus
1544594|NCT02636140|Other|Light|A brief, 1 minute exposure to light of varying color and intensity. The combination of color and intensity will be the same in all participants, but the order in which they are received is randomized.
1544595|NCT02636127|Other|blood samples|"one blood sample will be done for dosage and role of Fractalkine in the serum.
- Functional study of the interactions between T cells and NK cells and / endothelial cells (HMVEC): immuno mediated endothelial cytotoxicity, endothelial activation and microparticles release by the HMVEC, endothelial progenitor cells analysis and evaluation of the endothelial lysis by fluorescence release."
1544596|NCT02636114|Procedure|scaling and root planing|Scaling and root planing at baseline , checked clinical parameter and serum renal function markers at baseline and 1 month after therapy
1544597|NCT02636101|Drug|Calcipotriol/betamethasone dipropionate gel|Topical treatment of psoriasis plaques located on the body
1544598|NCT02636088|Drug|Cetuximab|
1544600|NCT02636036|Biological|enadenotucirev|
1544601|NCT02636036|Biological|nivolumab|
1544602|NCT02636023|Device|SPhENo-Cardiograph|SPhENo-Cardiograph
1544603|NCT02636010|Drug|Pembrolizumab|
1544604|NCT02635997|Drug|antiresorptive therapy|
1544605|NCT02635984|Drug|Olanzapine|Olanzapine 10mg by mouth once daily on all chemotherapy days and for three days post-chemotherapy
1544606|NCT02635984|Drug|Placebo|Placebo tablet taken by mouth once daily on chemotherapy days and for 3 days post chemotherapy
1544607|NCT02635971|Procedure|Transcatheter arterial infusion|
1544608|NCT02635971|Procedure|Intravenous chemotherapy|
1544609|NCT02635971|Drug|Gemcitabine|
1544610|NCT02635971|Drug|Oxaliplatin|
1544611|NCT02635945|Drug|PBF-680|
1544612|NCT02635945|Drug|Placebo|
1544613|NCT02635932|Device|Day Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the daily life activities.
1544614|NCT02635932|Device|Night Splint|A thermoplastic splint was confected for each participant to stabilize the trapeziometacarpal joint, maintaining the pulp of the distal phalange of the index finger free for gripping with the other fingers and leaving the thumb in a functional position. In this group the slint was used during the night.
1544615|NCT02635919|Device|mSMART|A smartphone application that targets medication adherence in substance users, providing information and reminders and tracking medication usage and factors interfering with adherence.
1544616|NCT02635906|Other|2 hours|BED REST FOR TWO HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
1544617|NCT02635906|Other|4 hours|BED REST FOR FOUR HOURS AFTER CORONARY ARTERIOGRAPHY OR CORONARY ANGIOPLASTY
1544618|NCT02635893|Drug|D-Cycloserine|100 mg of Seromycin by mouth will be administered
1544619|NCT02635893|Drug|Placebo|placebo pill will be administered instead of medication by mouth
1544620|NCT02635893|Other|Training|walking around a designated track at different speeds both forward and backward
1544621|NCT02635893|Other|Stimulation|magnetic stimulation and electrical stimulation may be applied
1544622|NCT02635893|Other|Placebo Stimulation|this is a fake stimulation that is administered but will be unknow to the subject.
1544623|NCT02635880|Device|Investigational Enlighten Device|Up to 3 laser treatments, spaced 4 to 6 weeks apart
1544624|NCT02635867|Drug|Resin-modified calcium silicate - TheraCal LC|
1544625|NCT02635867|Drug|Calcium hydroxide - Dycal|
1544626|NCT02635867|Drug|Resin-based dentin bonding agent|
1544629|NCT02635841|Drug|Deferiprone|Deferiprone oral solution (80 mg/mL)
1544630|NCT02635828|Drug|Palonosetron 0.075 mg IV|At induction of anesthesia, palonosetron 0.075 mg IV was given as PONV prophylaxis.
1544631|NCT02635828|Drug|Dexamethasone 10 mg IV|At induction of anesthesia, dexamethasone 10 mg IV was given as PONV prophylaxis.
1544632|NCT02635828|Drug|Promethazine 25 mg IV|At induction of anesthesia, promethazine 25 mg was given as PONV prophylaxis.
1544633|NCT02635815|Procedure|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy using the Pentax video endoscope EG 3440
1544634|NCT02635802|Drug|Remifentanil|"a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time ＞1min,then 5μg/kg·h pumping if the operation can not be done in 5 minutes.
Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after the loading.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5 μg/kg·h every 2-5min."
1544707|NCT02635256|Radiation|Hypofractionated Radiosurgery|"Image-guided stereotactic Linac based RT preferable with dedicated radiosurgery system such as CyberKnife"
1544635|NCT02635802|Drug|Lidocaine|lidocaine 100-400mg,local anesthesia.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after local anesthesia.We should maintain the CPOT≤2 and RASS 0～2.
1544636|NCT02635802|Drug|Remifentanil+Lidocaine|a loading dose 1.0-2.0μg/kg remifentanil,intravenous injection slowly,time ＞1min,then 5μg/kg·h remifentanil pumping immediately if the operation can not be done in 5 minutes.then local anesthesia with lidocaine 100-400mg.Critical-Care Observation Tool(CPOT) and Richmond Agitation-Sedation Scale(RASS) are assessed before and after anesthesia.We should maintain the CPOT≤2 and RASS 0～2,if it is not up to the standard,increasing the pumping rate 0.5μg/kg·h every 2-5min.
1544637|NCT02635802|Drug|Midazolam|midazolam is an adjuvant drug.we should maintain the CPOT≤2 and RASS 0～2,if lidocaine is already used up to 400mg or the pumping rate of remifentanil is already 7.5μg/kg·h,then we should use midazolam 3mg, intravenous injection slowly.
1544638|NCT02635789|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 12 weeks
1544639|NCT02635789|Drug|Placebo gel|NPC-12G gel placebo is administered topically twice a day for 12 weeks
1544640|NCT02635776|Biological|AR101 powder provided in capsules & sachets|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
1544641|NCT02635776|Biological|Placebo powder provided in capsules & sachets|Study product formulated to contain only inactive ingredients for use as defined in the protocol
1544642|NCT02635763|Procedure|Femoral nerve and the lateral cutaneous nerve block|Femoral nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide;the lateral cutaneous nerve block was performed using 0.5% ropivacaine (5ml) under ultrasound guide
1544643|NCT02635763|Procedure|Lumbar plexus and sacral plexus nerve block|Lumbar plexus block was performed using 0.5% ropivacaine (25ml) under ultrasound guide; sacral plexus nerve block was performed using 0.5% ropivacaine (15ml) under ultrasound guide
1544644|NCT02635750|Drug|BI 409306|
1544645|NCT02635750|Drug|Donepezil low dose|
1544646|NCT02635750|Drug|Donepezil high dose|
1544647|NCT02635737|Device|Sentimark|Placement of a metallic clip with paramagnetic properties for tumour localisation
1544648|NCT02635724|Drug|Peramivir|
1544649|NCT02635711|Behavioral|Adapted Taekwondo training|Adapted Taekwondo training for beginners
1544650|NCT02635711|Behavioral|Control|Daily jogging
1544651|NCT02635698|Other|Optifast|medically-supervised weight management program
1544652|NCT02635698|Other|Food-Based|low-energy, low-fat diet
1544655|NCT02635659|Other|Encapsulated nutrients|
1544656|NCT02635659|Other|Placebo|
1544659|NCT02635633|Device|continuous thetaburst stimulation|On 4 consecutive days patients receive 5 cTBS trains with a 10min intertrain-interval. One cTBS train consists of 600 pulses delivered in bursts at theta frequency (200ms) during 40s. Each burst comprises 3 pulses at 50Hz. Focal stimulation occurs over the epileptogenic focus (EF), perpendicular to the local gyral geometry, using online neuronavigation. Stimulation intensity is set relative to the resting motor threshold (rMT) determined at baseline (80% rMT). Stimulation intensity is further adjusted to the coil-cortex distance at the EF with the following formula: adjusted MT% (AdjMT) = rMT + 2,7*(DEF-DM1) [DEF = distance over EF; DM1 = distance over M1]. If rMT exceeds the capacity of the stimulator output, stimulation intensity is 100% of maximal stimulator output (MSO).
1544660|NCT02635607|Drug|Follitropin Beta|Patients will start stimulation with a daily s.c. injection of 150IU follitropin beta on menstrual cycle day 3. A modification of the rFSH dose will be allowed from stimulation day 6 onward in case that a high ovarian response occurs at the discretion of the investigator.
1544661|NCT02635607|Drug|Ganirelix|Ganirelix 0.25mg daily s.c. will start after 4 days of rFSH stimulation
1544662|NCT02635607|Drug|Ganirelix|Ganirelix 0.25mg daily s.c. will start when at least one of the following criteria are fulfilled: (i) the presence of at least one follicle measuring≥12 mm; (ii) serum E2 levels＞600 pg/ml; and (iii) serum LH levels＞10 IU/l.
1544663|NCT02635607|Drug|rhCG|An amount of 250ug rhCG will be administered to induce final oocyte maturation as soon as at least three follicles of ≥17 mm were observed
1544664|NCT02635607|Drug|triptorelin|0.2mg triptorelin will replace rHCG to trigger in case of high risk of overstimulation
1544665|NCT02635594|Dietary Supplement|L-Carnitine|1000mg of L-Carnitine provided as 1475mg Carnipure® tartrate
1544666|NCT02635594|Other|Placebo|1000mg cellulose + 475mg L-tartaric acid
1544667|NCT02635581|Device|Delta TT acetabular cup|
1544668|NCT02635568|Other|Cannabis Use|Observational Study
1544669|NCT02635555|Drug|Phenylephrine|100 mcg of phenylephrine or 5 mg ephedrine given as deemed necessary for treating episodes of hypotension.
1544670|NCT02635542|Drug|Succinylcholine|Succinylcholine will be used to facilitate endotracheal intubation for general anesthesia in the operating room. No additional neuromuscular blockade will be provided during general anesthesia.
1544671|NCT02635542|Drug|Cisatracurium|Cisatracurium will be used to maintain neuromuscular blockade during general anesthesia.
1544708|NCT02635243|Drug|SAR438544|"Pharmaceutical form:solution
Route of administration: subcutaneous"
1544674|NCT02635516|Device|Near-Infrared Phototherapy|"The In Light Wellness Systems Near-Infrared Phototherapy Device (manufactured by In Light Wellness Systems, Inc.) contains alternating rows of 402 red (640 nm) and infrared (880 nm) light-emitting diodes embedded in 2 neoprene pads. One pad circles the skull, providing 720 Joules/min, and the other pad covers the top of the head, providing 360 joules/min. For each treatment session, the A setting on the 3-port controller is utilized, which runs approximately 6.7 min of 73 Hz, 587 Hz, and 1175 Hz in an automated sequential manner. No other interventions were utilized."
1544675|NCT02635503|Procedure|transrectal specimen extraction|After mobilization of bowel and dissection of lymph nodes, a cross clamp was placed distal to the tumor. Distal rectum was transected after fully disinfecting rectal lumen by 10% povidone-iodine. An anvil head attached to circular stapling device was put into abdominal cavity through rectal stump, and put into colon lumen through a longitudinal incision, then the proximal colon was transected in close proximity to the upper pole of incision by a linear stapling device. During specimen extraction though the rectum, a disposable sterile protective cover was used to avoid cancer cell exfoliation and implantation. The rectal opening was reclosed by a linear stapler. End-to-end colorectal anastomosis was performed with a circular stapler using the double-stapling technique.
1544676|NCT02635503|Procedure|Conventional laparoscopic surgery|High ligation of inferior mesenteric vessel , mobilization of bowel, and dissection of lymph nodes were performed laparoscopically, and total mesorectal excision with nerve-sparing technique was followed for rectal cancer. Conventional laparoscopic-assisted surgery (CLS), a small incision with a 3-7cm length was made in hypogastrium, transection of rectum was completed through abdominal incision, then the specimen was removed and the bowel was prepared for anastomosis. The anastomosis for all rectal cancer and most of sigmoid colon cancer was performed by a double-stapling technique following open resection.
1544677|NCT02635477|Behavioral|Intervention|Behavioral: actigraphy device, adaptive step count algorithm
1544678|NCT02635477|Behavioral|Control|Behavioral: actigraphy device, step count measurement only
1544679|NCT02635464|Biological|hUC-MSCs+Injectable collagen scaffold+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) in collagen scaffold injecting in the infarct region.
1544680|NCT02635464|Biological|hUC-MSCs+CABG|Patients underwent Coronary Artery Bypass Surgery (CABG) with 10^8 allogeneic human umbilical cord mesenchymal stem cells (hUC-MSCs) injecting in the infarct region.
1544681|NCT02635464|Procedure|CABG|Patients underwent CABG alone.
1544684|NCT02635425|Procedure|7 eggs collection|vaginal US
1544685|NCT02635425|Procedure|Full eggs collection|vaginal US
1544686|NCT02635412|Other|Scheduled timing of delivery|
1544687|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy)|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
1544688|NCT02635399|Procedure|PPPD (pylorus-preserving pancreaticoduodenectomy) with DJ-pexy|pylorus-preserving pancreaticoduodenectomy is done in a conventional method. Additional DJ-pexy is performed for experimental group. DJ-pexy is performed by anchoring DJ site to transverse colon so that DJ is fixed to its original position.
1544689|NCT02635386|Drug|Exenatide once weekly (EQW )|2 mg SC injection every 7 days
1544690|NCT02635386|Drug|Dapagliflozin (DAPA)|One pill (10 mg) by mouth daily (QD) in am
1544691|NCT02635386|Drug|EQW plus DAPA|2 mg SC injection every 7 days One pill (10 mg) by mouth QD in am
1544692|NCT02635386|Drug|Dapagliflozin plus Glucophage (MET ER)|DAPA/MET ER-5 mg /1000 mg - 1 pill by mouth in am with food for 4 weeks DAPA/MET ER-10 mg /2000 mg - 2 pills in am by mouth with food -final dose
1544693|NCT02635386|Drug|Phentermine /Topiramate (PHEN/ TRP) ER|PHEN 3.75/TRP ER 23mg - 1 pill by mouth once daily in am for 2 weeks. After 2 weeks, PHEN 7.5mg/TRP ER 46mg- 1 pill by mouth once daily in am
1544694|NCT02635360|Drug|Pembrolizumab|200 mg of study drug is given through intravenous (IV) administration once every 21 days for 3 months.
1544695|NCT02635360|Radiation|Brachytherapy|Radiation is done for standard clinical care purposes.
1544696|NCT02635360|Drug|Cisplatin|40 mg of chemotherapy drug will be given weekly for 5-6 weeks.
1544697|NCT02635347|Procedure|Remote Ischemic Conditioning (RIC)|Each RIC intervention will comprise three cycles of 5 minutes of inflation followed by 5 minutes of deflation of a pneumatic tourniquet placed in mid-thigh.
1544698|NCT02635347|Device|Pneumatic tourniquet|Portable Tourniquet System(PTSii, Delfi Medical Innovations, Inc.) used to perform RIC interventions.
1544699|NCT02635334|Drug|Montelukast 10 mg orally|
1544700|NCT02635334|Other|Placebo|
1544701|NCT02635308|Behavioral|"Unilaterally Biased Resistance Training / MOVE"|High-intensity resistance training including: whole body movement patterns, unilaterally biased lower extremity strength training, task-oriented balance tasks
1544702|NCT02635295|Behavioral|Mobile cooperation during the clinical practicum|"The intervention include (1) use of mobile application in nursing student - nurse teacher (NT) cooperation during the 5 weeks clinical practicum and (2) training at the beginning of the clinical practicum in the functions of the mobile application by the researcher.
Students in the intervention group use mobile application for documentation of the terms of hours, learning diaries, objectives as well as mid-point and end-evaluation during the clinical practicum. NT and students have direct access to documents in the mobile application and to wireless communication regardless of time and place. The actions in the mobile application are automatically saved and shared between student and the NT."
1544703|NCT02635282|Drug|intranasal ketamine|
1544704|NCT02635282|Drug|intranasal fentanyl|
1544705|NCT02635282|Drug|intranasal midazolam|
1544706|NCT02635269|Other|Sugar|10 minutes before exercising, the subjects are given a bolus of glucose solution 0.2 g/kg in a cubital vein catheter and a constant infusion of 10% glucose solution is started (100ml/h). The infusion continues throughout the exercise period.
1544709|NCT02635243|Drug|r-glucagon|"Pharmaceutical form:solution
Route of administration: subcutaneous"
1544710|NCT02635243|Drug|insulin|"Pharmaceutical form:solution
Route of administration: intravenous"
1544711|NCT02635230|Drug|Combination of chronic oral anticoagulation and a P2Y12 inhibitor with or without aspirin.|
1544712|NCT02635217|Device|Carbon dioxide insufflation|using an automated carbon dioxide insufflator the gas will be infused on demand during the endoscopies
1544713|NCT02635217|Device|room air insufflation|using standard care room air will be infused on demand
1544714|NCT02635217|Procedure|EGD (Esophagogastroduodenoscopy) before Colonoscopy|the order of endoscopies will be randomized as well
1544715|NCT02635217|Procedure|Colonoscopy before EGD (Esophagogastroduodenoscopy)|
1544716|NCT02635204|Drug|DFD06 Cream|Twice daily topical application for 14 days.
1544717|NCT02635204|Drug|Vehicle Cream|Twice daily topical application for 14 days.
1544718|NCT02635191|Drug|Tailored Group|All the patients who enrolled in this arm will be received endoscopy followed by biopsy for antimicrobial susceptibility testing and cytochrome P450 isoenzyme 2C19 genotype. 10 days tailored therapy will be given including one Proton Pump Inhibitor ( Rabeprazole0.4-0.5mg/kg.d,bid. or Esomeprazole0.8-1.0mg/kg.d,bid) and two antibiotics (Amoxicillin30-50mg/kg.d bid, Clarithromycin15-20mg/kg.d bid, Metronidazole15-20mg/kg.d bid ) based on the cytochrome P450 isoenzyme 2C19 genotype and the antimicrobial susceptibility.
1544719|NCT02635191|Drug|Standard group|All the patients who enrolled in this arm will be treated by Omeprazole(0.8-1.0mg/kg.d,bid), Amoxicillin (30-50mg/kg.d bid)and Clarithromycin (15-20mg/kg.d bid) .
1544720|NCT02635178|Other|Cognitive Anxiety Sensitivity Treatment|Cognitive Anxiety Sensitivity Treatment (CAST) is a computerized treatment designed to model the educational and behavioral techniques used in anxiety treatments. The psychoeducational component focuses on the nature of stress and its effects. CAST was designed to dispel myths concerning the immediate dangers of stress on cognitive processes. Individuals are taught that psychological arousal from stress is not dangerous and they may have developed a conditioned fear to these sensations, as indicated by their elevated levels of AS cognitive concerns. In addition to the psychoeducation, interoceptive exposure exercises will be introduced to correct the conditioned fear response. The program will demonstrate exercises that elicit sensations consistent with AS cognitive concerns.
1544721|NCT02635178|Other|Physical Health Education Training|The Physical Health Education Training (PHET) control condition was designed to control for the effects of general education provided in the CAST condition. Participants will be presented with information regarding the importance and benefits of maintaining a healthy lifestyle. The program will discuss diet, alcohol and water consumption, exercise, sexual health, and sleep. PHET will instruct the participant how to monitor their daily health habits in order to achieve a healthy lifestyle. PHET will take approximately 45 minutes to complete. Based on the findings of Schmidt and colleagues (in press), this intervention does not appear to exert a strong effect on AS.
1544722|NCT02635165|Device|Thoracic osteosyntheses with Stracos|
1544723|NCT02635152|Behavioral|Interpretation Bias Modification|Eight 10-25 minute sessions of interpretation modification to reduce negative interpretation biases related to appearance.
1544724|NCT02635152|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR).
1544725|NCT02635139|Behavioral|Breakfast skipping|18h fasting period in the morning
1544726|NCT02635139|Behavioral|Dinner skipping|18h fasting period in the evening
1544727|NCT02635113|Device|Gait Synchronized Vibration System|A wearable vibratory shoe that delivers stimulus to the soles that is synchronized with step resulting in improved gait.The shoe consists of two externally mounted vibration units (tactors). The vibration units allow for variation of both frequency and amplitude of stimulation independently. Using the pressure sensors and timing data, gait velocity, cadence, swing time, stance phase and double support time will be analyzed to assess features of their gait performance during the Dynamic Gait Index with and without vibratory stimuli.
1544728|NCT02635100|Device|CPAP machine with MNT algorithm|"The multinight (MNT) algorithm will be evaluated on patients with Obstructive Sleep Apnea (OSA) over multiple nights while using CPAP in the home for a total of 45 days. In particular the main goal is to assess the behavior of the two main stages of the algorithm:
Fast Track (FT) stage. Assesses if the algorithm reliably and timely reaches approximate therapeutic pressure levels.
Slow Titration (ST) stage.Assesses if data samples are appropriately collected in a pressure range so that the therapeutic pressure can be inferred according to the algorithm proposed.
Five days with standard auto titration.
MNT algorithm : 7 days (maximum) with Fast Track mode, 27 days (maximum) in Slow Titration mode. After PMNT is found, the device remains at PMNT for 5 sessions. Total approximately 45 days."
1544729|NCT02635087|Device|miRNA tool|patients to be assessed by the miRNA tool. MicroRNA tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miR-21-5p)+(0.086×status of miR-20a-5p)+(0.240×status of miR-103a-3p)+(0.095×status of miR-106b-5p)- (0.238×status of miR-143-5p)-(0.237×status of miR-215),low expression status equals 0 and high expression status equals 1.Then we determine the patients who with a score higher than 1 as exposed patient.
1544730|NCT02635074|Drug|Cytarabine|Given IV
1544731|NCT02635074|Drug|Ibrutinib|Given PO
1544732|NCT02635074|Drug|Idarubicin|Given IV
1544733|NCT02635061|Drug|ACY-241|
1544734|NCT02635061|Drug|Nivolumab|
1544735|NCT02635061|Drug|Ipilimumab|
1544736|NCT02635048|Procedure|Mini Percutaneous Nephrolithotomy|patients undergo PNCL with 18Fr nephrostomy tract
1544737|NCT02635048|Procedure|Percutaneous Nephrolithotomy|patients undergo PNCL with 24Fr nephrostomy tract
1544738|NCT02635035|Drug|Lisdexamfetamine|Vyvanse (Lisdexamfetamine Dimesylate) manufactured by Shire, is a Drug Enforcement Administration (DEA) class two,sympathomimetic amine, used for the treatment of attention-deficit hyperactivity disorder. The initial adult dosage is 30mg with allowed adjustments in increments of 10mg or 20mg at weekly intervals. Subjects are initiated on these doses and then they were titrated up by 20mg with a maximum dose of 70mg.
1544739|NCT02635035|Drug|Placebo|Placebo looks just like Vyvanse but has no active ingredients, like a sugar pill.
1544740|NCT02635009|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo PCI using 3DCRT
1544741|NCT02635009|Other|Cognitive Assessment|Ancillary studies
1544742|NCT02635009|Radiation|Intensity-Modulated Radiation Therapy|Undergo PCI with HA using IMRT
1544743|NCT02635009|Other|Laboratory Biomarker Analysis|Correlative studies
1544744|NCT02635009|Other|Quality-of-Life Assessment|Ancillary studies
1544745|NCT02634983|Drug|QVA149|QVA149 110/50 μg o.d. capsules for inhalation, supplied in blisters via the Concept 1 inhalation device, a single dose dry powder inhaler.
1544746|NCT02634983|Drug|Placebo|Matching placebo
1544747|NCT02634970|Drug|Ranibizumab|0.5 mg, intravitreal injection
1544748|NCT02634957|Behavioral|absolute voice rest|absolute voice rest is the complete elimination of any vocalization (no sounds, speaking or whispering)
1544749|NCT02634944|Diagnostic Test|Vestibular Ocular Motor Screening Tool (VOMS)|Vestibular Ocular Motor Screening Tool (VOMS)
1544750|NCT02634931|Drug|NPC-12G gel|NPC-12G gel is administered topically twice a day for 52 weeks or longer
1544751|NCT02634918|Other|ultrasound|ultrasound will be performed in hemophilia boys with a history of 20 joint bleeds- Group I, less than 2 joint bleeds into a joint -Group II and no joint bleeds- Group III
1544752|NCT02634905|Other|Individual session therapeutic education|within 2 weeks after inclusion (week 0)
1544753|NCT02634905|Other|Phone Call|
1544754|NCT02634892|Device|PRO-TECT|Patient will be placed on ROHO SOFFLEX2 mattress with has been modified with gel cushions in the sacral region for heal dissipation by standard closed system cooling pad
1544755|NCT02634879|Behavioral|Incentive Change|
1544756|NCT02634853|Drug|1% Tavilermide Ophthalmic Solution|1% Tavilermide BID Dosing
1544757|NCT02634853|Drug|Placebo Ophthalmic Solution|Vehicle Ophthalmic Solution
1544758|NCT02634840|Procedure|bilateral sagittal split osteotomy|surgical technique to split the mandibular ramus through three osteotomy lines on the medial-cranial, buccal-caudal and anterior surface to facilitate a split of the posterior border of the mandible without injury of the inferior alveolar nerve
1544759|NCT02634827|Drug|Decitabine|Given IV
1544760|NCT02634827|Other|Laboratory Biomarker Analysis|Correlative studies
1544761|NCT02634827|Drug|Midostaurin|Given PO
1544762|NCT02634814|Device|Transcutaneous Electrical Nerve Stimulation|TENS is FDA approved for the purposes in which we will be applying the modality (21CFR882.5890; http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/cfrsearch.cfm?fr=882.5890, these TENS Units have been acquired by the PI, who is a licensed Allied Health Professional in the state of North Carolina).
1544763|NCT02634814|Other|Therapeutic Exercise|Ten sessions of TE will be provided under the supervision of a licensed Physical Therapist. Each TE Session will last 45 minutes and include open and closed chain lower extremity muscle strengthening exercises. The exercise will be progressed using the Daily Adjusted Progressive Resistive Exercise Program. The intervention will consist of 10 45-minute sessions.
1544764|NCT02634814|Device|Sham Transcutaneous Electrical Nerve Stimulation|"Sham TENS+TE patients will receive a Select System TENS unit (EMPI, Inc., St. Paul, MN) specifically configured to cease TENS current output 20 seconds after the participants initiation. For blinding purposes, patients will be told that they should feel a brief stimulation (~20 seconds) that will become sub-sensory in nature. The participants will wear the Sham TENS for 8 hours per day."
1544765|NCT02634801|Drug|Fumaric Acid Esters|Administered orally
1544766|NCT02634801|Drug|Methotrexate|Administered orally
1544767|NCT02634801|Drug|Ixekizumab|Administered SC
1544768|NCT02634788|Drug|Buprenorphine|Buprenorphine sublingual spray delivered via single 100 μL spray
1544769|NCT02634788|Drug|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
1544770|NCT02634775|Other|Change in treatment strategy|Start on dialysis, transplantation, change of PD prescription, change of HD prescription
1544776|NCT02634710|Radiation|Hypofractionated Radiation Therapy|Treatments will have a minimum of a 48-hour interfraction interval. Treatments will be completed over 20 days maximum.
1544777|NCT02634697|Behavioral|Relaxation Response Resiliency Program|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga
1544780|NCT02634671|Other|schizophrenia|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in schizophrenia with a control group using an experimental paradigm based on electroencephalography (EEG)
1544781|NCT02634671|Other|the 22q11 deletion syndrome|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
1544782|NCT02634671|Other|control group|The present study aims to identify the mechanisms underlying the deficit in facial emotion recognition reported both in the schizophrenia and 22q11.2 deletion syndrome with a control group using an experimental paradigm based on electroencephalography (EEG)
1544783|NCT02634658|Other|Muscle Ultrasound|Ultrasound will be performed using a linear-array transducer with standardized gain and varying depth based on the amount of overlying soft tissue and muscle size. The subjects will be examined in the supine position with extended limbs and relaxed muscles. We will perform bilateral scans of the biceps, anterior forearm, and anterior thigh at standardized sites. For muscle echogenicity measurements, we will scan the same muscles at the same points.
1544784|NCT02634658|Other|Nerve Conduction Study|Nerve Conduction Studies will be performed using a Nicolet EDX using standard procedures. Repetitive stimulation of the median motor nerve are performed in all subjects. Bilateral sural, radial and median sensory nerves will be analyzed. We will only perform surface, not subdermal sensory recordings. The bilateral peroneal, tibial and median motor responses will be recorded over extensor digitorum brevis, abductor hallucis brevis, and abductor pollicis brevis muscles. The peroneal motor nerve will be stimulated at the fibular head and lateral popliteal fossa, recording from the tibialis anterior muscle. The compound motor action potential (CMAP) responses will be elicited from standard distal and proximal sites.
1544785|NCT02634658|Other|Electromyography|EMG studies will be performed using standard precautions. Insertional activity, spontaneous activity, motor unit potential (MUP) morphology and recruitment/activation pattern will be recorded from some combination of the deltoid, triceps, biceps, first dorsal interosseous, abductor pollicis brevis, iliopsoas, vastus medialis, and tibialis anterior muscles. The specific muscles studied for each patient will vary according to the patient's level of consciousness and ability to activate the muscles either voluntarily or during spontaneous limb movement. If possible, we will try to examine 3 unilateral upper extremity and 3 unilateral lower extremity muscles. If a patient is not able to volitionally participate in EMG testing (by contracting their muscles on command), we will analyze insertional/spontaneous activity and potentially morphology/recruitment (e.g. stroking the sole of the foot to stimulate contraction of the tibialis anterior).
1544786|NCT02634645|Procedure|Endoscopic eradication therapies (EET)|Endoscopic eradication therapies (EET) includes endoscopic mucosal resection (EMR), which describes the process by which the area most likely to harbor highest grade of dysplasia/neoplasia is removed; radiofrequency ablation (RFA), which describes the process by which Barrett's segments are removed via burning/ablation; and cryotherapy.
1544787|NCT02634645|Procedure|Esophagectomy|The esophagus is surgically removed
1544788|NCT02634645|Drug|Chemotherapy|Chemical substances are used to treat cancer
1544789|NCT02634645|Radiation|Radiation|Cancer cells are destroyed by radiation therapy.
1544790|NCT02634632|Behavioral|Choosing to write advance directives|
1544791|NCT02634619|Procedure|Ventral buccal mucosa onlay urethroplasty|Ventral buccal graft onlay involves a midline perineal incision and retraction of the bulbospongiosum muscle downward to expose the ventral urethral surface. The corpus spongiosum is incised longitudinally to expose the urethral lumen and the incision is extended proximal and distal to the established stricture. The buccal mucosa graft is harvested and trimmed to the length and width of the urethrotomy and the graft is sutured at the proximal and distal apices and a running suture at the lateral margins to establish a tight anastomosis. Ventral placement allows for limited urethral mobilization and easy access, but there is concern about higher likelihood of diverticulum formation and development of other associated complications - such as post void dribbling and ejaculatory dysfunction.
1544792|NCT02634619|Procedure|Dorsal buccal mucosa onlay urethroplasty|Dorsal buccal onlay also involves a midline perineal incision. The bulbo-cavernosum and corpora cavernosum are dissected from the bulbar urethra allowing for complete mobilization of the urethra. The urethra is rotated 180 degrees to allow for dorsal access and an incision is made on the dorsal urethra proximal and distal to the stricture location. The buccal graft is harvested and trimmed to the appropriate size of the urethrotomy and spread on the overlying tunica albuginea of the corporal bodies. The urethra is rotated back to allow for suturing of the left mucosal margin to the left margin of the buccal graft and corporal bodies, essentially covering the entire urethral plate. Dorsal placement has potential for a more stable vascular bed for graft sustainability and less spongiosal bleeding, but requires a greater urethral mobilization and longer operative times.
1544793|NCT02634606|Drug|Gamma Delta Tocotrienols - Low Dose|250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
1544794|NCT02634606|Drug|Gamma Delta Tocotrienols - High Dose|250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
1544795|NCT02634606|Drug|Sugar Pill|250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
1544796|NCT02634593|Behavioral|Low glycemic load snacks|Intervention to replace standard night-time food and drinks with lower glycemic load options
1544797|NCT02634580|Biological|Evolocumab|Subjects will receive Evolocumab (AMG 145) subcutaneous monthly and Ezetimibe matching placebo pill daily by mouth.
1544798|NCT02634580|Drug|Ezetimibe|Subjects will receive Ezetimibe pill daily by mouth and Evolocumab matching placebo subcutaneous monthly.
1544799|NCT02634580|Biological|Evolocumab|Subjects will receive Evolocumab (AMG 145) subcutaneous every two weeks and Ezetimibe matching placebo pill daily by mouth.
1544800|NCT02634580|Drug|Ezetimibe|Subjects will receive Evolocumab (AMG 145) every two weeks and Ezetimibe matching placebo pill daily by mouth.
1544801|NCT02634567|Behavioral|Cogmed Working Memory Training (CWMT)|The CWMT (Cogmed) method consists of 25 training sessions done online. Each participant assigned to the training group will complete eight exercises for five weeks with five sessions every week. Each session consists of a selection of various tasks that target the different aspects of attention/working memory. Participants will engage in weekly discussions over the phone for about 1 hour with an assigned Cogmed coach who will provide support and encouragement over the 5 weeks.
1544802|NCT02634541|Drug|Adalimumab|Biologic drug
1544803|NCT02634541|Other|PET/CT imaging|PET/CT imaging
1544804|NCT02634528|Drug|Julphar Insulin N (human isophane insulin)|investigational insulin: Julphar N (human isophane insulin), biosimilar
1544805|NCT02634528|Drug|Huminsulin® Basal (NPH, human isophane insulin)|marketed reference product: Huminsulin® Basal (NPH, human isophane insulin)
1544806|NCT02634515|Drug|Julphar Insulin R (soluble human insulin, biosimilar)|investigational insulin, Julphar Insulin R (soluble human insulin)
1544807|NCT02634515|Drug|Huminsulin® Normal (soluble human insulin, reference)|marketed product, Huminsulin® Normal (soluble human insulin
1544808|NCT02634502|Procedure|radiofrequency ablation|
1544809|NCT02634502|Drug|S-1|
1544810|NCT02634489|Drug|Tamsulosin HCl|Oral
1544813|NCT02634476|Behavioral|Alcohol approach/avoidance task|The approach-bias modification is a computerised alcohol approach/avoidance task (alcohol-AAT) in which participants are instructed to respond with an approach movement (pulling a joystick) to pictures in landscape orientation and an avoidance movement (pushing a joystick) to pictures in portrait orientation. The size of the image is increased and decreased by pulling and pushing the joystick respectively, generating a sensation of approach or avoidance. Pictures include images of 20 alcoholic and 20 non-alcoholic drinks presented in a fixed orientation such that participants are in effect instructed to respond to pictures of alcohol by making an avoidance movement (pushing the joystick) and to pictures of non-alcoholic soft drinks by making an approach movement (pulling the joystick).
1544814|NCT02634476|Behavioral|Sham approach/avoidance task|The computerised training for the sham condition is the same as for the experimental condition, except that in the sham approach/avoidance task, both landscape and portrait pictures all contain neutral (non-alcohol related).
1544815|NCT02634463|Drug|Aripiprazole|No study agent will be administered as a part of this study. Participants must be on Aripiprazole 5 milligram (mg) (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (300-400 mg once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for development of antipsychotic immunoassays.
1544816|NCT02634463|Other|Olanzapine|No study agent will be administered as a part of this study. Participants must be on Olanzapine 5 mg (minimum dose) to 30 mg (maximum dose), orally, daily or long-acting injectable versions (150-405 mg once every 2-4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
1544817|NCT02634463|Drug|Paliperidone|No study agent will be administered as a part of this study. Participants must be on Paliperidone 3 mg (minimum dose) to 12 mg (maximum dose), orally, daily or long-acting injectable versions (25-150 mg equivalent [eq.] once every 4 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
1544818|NCT02634463|Drug|Risperidone|No study agent will be administered as a part of this study. Participants must be on Risperidone 1 mg (minimum dose) to 8 mg (maximum dose), orally, daily or long-acting injectable versions (12.5-50 mg once every 2 weeks), as part of the treatment for a psychiatric illness to be eligible for enrollment in this study. Whole Blood and Plasma Samples will be collected for Development of the antipsychotic immunoassays.
1544819|NCT02634450|Device|Alere q|
1544820|NCT02634437|Drug|Ulipristal acetate|
1544821|NCT02634424|Device|MyPKFiT|Adjustment of the treatment dose using a decision support software according to the PK values
1544822|NCT02634411|Drug|8 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).
Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 8 days."
1544823|NCT02634411|Drug|15 days of effective antibiotic treatment|"Antibiotics used for usual care in PA-VAP treatment : Penicillins, Cephalosporins, Monobactams, Carbapenems, Fluoroquinolones, Aminoglycosides (list not exhaustive).
Antibiotic treatment should be started just after realization of bacteriological sampling, and then converted into a narrow-spectrum therapy, based on culture results, for a total duration of effective antibiotic therapy against pseudomona aeruginosa of 15 days."
1544824|NCT02634385|Procedure|Renal Artery Embolization|Patients will be receiving embolization prior to planned partial nephrectomy.
1544825|NCT02634385|Procedure|Partial Nephrectomy (Surgical Resection)|Patients will be undergoing planned partial nephrectomy post embolization.
1544826|NCT02634372|Behavioral|EMDR therapy|EMDR: We designed a specific EMDR Bipolar Protocol which consists of a detailed interview with respect to traumatic events, the treatment of those with the EMDR standard protocol, and five new specific bipolar adapted EMDR protocols focusing on adherence, insight, de-idealisation of manic symptoms, prodromal symptoms and moodstabilization.
1544827|NCT02634372|Behavioral|Supportive Therapy|Supportive therapy: Therapists adopt a client-centred focus, meaning that whatever problems the patient presents will be dealt with by providing emotional support and general advise. If no specific topic is mentioned by the patient, information about bipolar disorder and medication will be delivered by the therapist without referring to written or any other material.
1544828|NCT02634359|Device|EarlySense home device|Passive contact-free monitoring at home measuring HR, RR and movements Arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
1544829|NCT02634359|Procedure|Vaginal ultrasound|Vaginal ultrasound for the purpose of determining follicle size Arms:IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
1544830|NCT02634359|Procedure|Blood Test|Hormonal profile blood tests arms: IVF Treatments- Frozen Embryo transfer IVF Treatments- Clinical Evaluation No IVF
1544831|NCT02634346|Drug|ALK3831|Daily dosing
1544832|NCT02634346|Drug|Olanzapine|Daily dosing
1544833|NCT02634346|Drug|Placebo|Daily dosing
1544838|NCT02634320|Drug|Aripiprazole Lauroxil|Monthly IM injection
1544839|NCT02634307|Drug|ALKS 8700|Capsules taken twice daily
1544882|NCT02634034|Drug|B: Pitavastatin IR 4 mg|Pitavastatin IR 4 mg (Immediate Release single 4-mg tablet)
1544840|NCT02634294|Drug|Peg interferon alfa-2b|Eligible patients were treated with pegylated interferon alpha-2b (Peg Intron®; Schering-Plough (Brinny) Company, Innishannon, County Cork, Ireland) 1~1.5ug/kg qw, until occurrence of grade II or higher grade of acute graft versus host disease, or no response to treatment after 8 doses of treatments.
1544843|NCT02634268|Behavioral|Lifestyle Intervention|Behavioral lifestyle intervention focused on healthy eating and physical activity
1544850|NCT02634242|Other|Si-Wu-Tang (SWT)|The purpose of the current study was to check the physiological improvement of SWT on liver and skin and also the antioxidation in healthy adults.
1544851|NCT02634242|Other|placebo|The purpose of the current study was to check the physiological improvement of placebo on liver and skin and also the antioxidation in healthy adults.
1544852|NCT02634229|Genetic|blood sample|
1544853|NCT02634216|Dietary Supplement|Capros|250 mg BID
1544854|NCT02634203|Procedure|Balloon Pulmonary Angioplasty (BPA)|Balloon pulmonary angioplasty (BPA) will be done via femoral vein. 2 sessions will be performed during the same hospitalization following by additional sessions at an interval of 2-3 weeks until a mean PAP< 30 mmHg is achieved A pulmonary angiography and a right heart catheterization will be performed at each BPA session
1544855|NCT02634203|Drug|Riociguat|The starting dose will be 1 mg three times daily as recommended. The dose will be titrated every 2 weeks according to the peripheral systolic pressure. Dose should be increased by 0.5 mg three times daily every two weeks to a maximum of 2.5 mg three times daily, if systolic blood pressure is ≥95 mmHg and the patient has no signs or symptoms of hypotension.
1544856|NCT02634190|Other|Thinprep® LBC|liquid based cytology
1544857|NCT02634190|Other|APTIMA® HPV Assay|in vitro diagnostic test
1544858|NCT02634190|Other|HR HC2® HPV DNA|in vitro diagnostic test
1544859|NCT02634190|Other|Colposcopy|Colposcopy
1544860|NCT02634177|Genetic|Assay-guided treatment (AGT)|The assay provides information to guide pharmacotherapeutic decisions personalized to a patient's genetic profile, to maximize improvement in symptomatology and minimize treatment failure and treatment intolerability.
1544861|NCT02634177|Other|Treatment-as-usual (TAU)|Subjects are treated-as-usual without the aid of the assay.
1544862|NCT02634164|Dietary Supplement|Leucine Supplement|For this visit participants will ingest a powdered form of Leucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution
1544863|NCT02634164|Dietary Supplement|Isoleucine Supplement|For this visit participants will ingest a powdered form of Isoleucine in the amount of 0.3g/kg of lean body mass weight with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
1544864|NCT02634164|Dietary Supplement|Leucine Supplement combined with Isoleucine Supplement|For this visit participants will ingest a powdered form of Leucine and Isoleucine in the amount of 0.3g/kg of lean body mass weight (equal in total dosage to other treatments) with water (150 mL) with additional water if needed to ensure dose is fully consumed. The amino acid solution will be ingested 30 min prior to 75 g glucose solution.
1544865|NCT02634151|Drug|Gemcabene 600 mg|2-300 mg tablets, 1 placebo tablet, QD, 84 days
1544866|NCT02634151|Drug|Placebo|Placebo, 3 tabs QD, 84 days
1544867|NCT02634138|Device|Revitive IX|A foot plate Neuromuscular Electrical Stimulation Device
1544868|NCT02633020|Biological|AMG 714|A fully human anti-IL-15 monoclonal antibody
1544869|NCT02633020|Biological|Placebo|
1544870|NCT02633007|Drug|CVT-301 (levodopa inhalation powder)|Capsules containing l-dopa, designed to deliver ldopa to the lung using the CVT-301 inhaler. CVT-301 will be administered 3 times, 4 hours apart, and 1 hour following the administration of carbidopa.
1544871|NCT02633007|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
1544872|NCT02633007|Other|Placebo|Placebo of CVT-301 is administered in the same way as the investigational product, except that it does not contain l-dopa.
1544873|NCT02634099|Device|blood measurement|Hemoglobin measurement
1544874|NCT02634099|Device|pulse co-oxymeter (SpHb)|non invasive method of hemoglobin measurement
1544875|NCT02634099|Device|hemoCue|non invasive method of hemoglobin measurement
1544876|NCT02634073|Drug|Lamivudine|It is a clear, colorless to pale yellow solution with the odour of fruit. It will be provided in a 240 mL bottle with the strength of 10 mg/mL Lamivudine 300 mg (30 mL of solution) will be administered orally to the participants
1544877|NCT02634073|Drug|Sorbitol|It is a clear, colorless, odourless solution. It will be available in 3 dosage levels viz;. 3.2 g (low dose), 10.2 g (medium dose) and 13.4 g (high dose) sorbitol total dose.
1544879|NCT02634047|Device|conventional technique|transesophageal echocardiography probe was inserted using a traditional blind insertion technique.
1544880|NCT02634047|Device|videolaryngoscope technique|transesophageal echocardiography probe was advanced into esophagus under direct vision using videolaryngoscope
1544881|NCT02634034|Drug|A: NK-104-CR 8 mg|NK-104-CR 8 mg (Controlled Release single 8-mg tablet)
1544883|NCT02634034|Drug|C: Pitavastatin IR 8 mg|Pitavastatin IR 8 mg (Immediate Release two 4-mg tablets)
1544884|NCT02634021|Drug|dexmedetomidine group|intravenous loading of dexmedetomidine for 1 mcg/kg
1544885|NCT02634021|Drug|midazolam group|intravenous loading of midazolam for 0.1 mg/kg
1544886|NCT02634008|Drug|Paritaprevir/ritonavir/ombitasvir|
1544887|NCT02634008|Drug|Dasabuvir|
1544888|NCT02634008|Drug|Ribavirin|
1544889|NCT02634008|Drug|Glecaprevir/pibrentasvir|
1544890|NCT02633995|Procedure|spinal anaesthesia|regional anesthesia will be induced with a total of 10 mg of 0.5% hyperbaric bupivacaine and 25 µg fentanyl (total volume 2.5 ml) at the L3-4 interspace in the sitting position then the patient will be returned immediately to the supine position with left lateral tilt.
1544891|NCT02633969|Drug|Indomethacin Capsules low dose|
1544892|NCT02633969|Drug|Indomethacin Capsules high dose|
1544893|NCT02633956|Drug|Obeticholic Acid|Once a day (QD) by mouth (PO)
1544894|NCT02633956|Drug|Atorvastatin|"Initiate treatment with Atorvastatin at 4 Week Visit with a dose of 10 mg once daily (QD) by mouth (PO).
Increase Atorvastatin to 20 mg once daily (QD) by mouth (PO) at Week 8 Visit if 10 mg daily is tolerated.
Atorvastatin may be titrated up or down at 12 week visit as clinically indicated."
1544895|NCT02633956|Drug|Placebo|Once a day (QD) by mouth (PO)
1544896|NCT02633943|Other|Safety and efficacy assessments|Vector copy number (VCN) measurement, safety evaluations, disease-specific assessments, and assessments to monitor for long-term complications of autologous transplant
1544897|NCT02633930|Drug|Berberine|: given for 14 days at a dose of berberine 100 mg 3 tablets TID, lansoprazole 30 mg BID, amoxicillin 500 mg 2 capsules BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID
1544898|NCT02633930|Drug|clarithromycin|Clarithromycin-containing quadruple therapy group 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, lansoprazole 30mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID.
1544899|NCT02633930|Drug|Bismuth|Bismuth:given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID or given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, lansoprazole30 mg BID, amoxicillin 500 mg 2 capsules BID, and berberine 100 mg 3 tablet TID
1544900|NCT02633930|Drug|Lansoprazole|Lansoprazole 30mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID given to berberine-containing quadruple therapy group or clarithromycin-containing quadruple therapy group
1544901|NCT02633930|Drug|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus lansoprazole 30mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 3 tablets TID as a dose given for clarithromycin-containing quadruple therapy or berberine-containing quadruple therapy.
1544902|NCT02633917|Behavioral|Motor control exercises|exercises to strength the lumbar musculature and control the posture
1544903|NCT02633917|Behavioral|Standard exercises|general exercises
1544904|NCT02633904|Procedure|Osteotomy|Femoral osteotomy are applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
1544905|NCT02633904|Procedure|Non-osteotomy|Femoral osteotomy are not applied in the open treatment of Developmental Dislocation of the Hip （DDH）.
1544906|NCT02633891|Behavioral|Balance exercise|tailored balance exercise program
1544907|NCT02633891|Behavioral|Standard care|general health education and fall prevention classes
1544908|NCT02633878|Drug|Chinese herbal medicine granules|
1544909|NCT02633878|Drug|Micronized progesterone|
1544910|NCT02633878|Drug|Chinese herbal medicine granules placebo|
1544911|NCT02633878|Drug|Micronized progesterone placebo|
1544912|NCT02633852|Drug|Aflibercept|
1544913|NCT02633839|Drug|CVT-301|Levodopa inhalation powder, will be supplied in capsules containing levodopa (l-dopa), designed to deliver to the lung using the CVT-301 inhaler.
1544914|NCT02633839|Drug|Carbidopa|Administered orally according to the carbidopa dosing schedule.
1544915|NCT02633813|Drug|Naftifine hydrochloride 2%|Topical application for two weeks
1544916|NCT02633813|Drug|Placebo|Topical application for two weeks
1544917|NCT02633813|Drug|Naftin® 2% (Naftifine hydrochloride 2%)|Topical application for two weeks
1544923|NCT02633787|Biological|Meningococcal (Groups A, C, Y, and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|No vaccine will be administered in this trial
1544924|NCT02633774|Drug|Propafenone|AAD(antiarrhythmic drug)
1544925|NCT02633774|Drug|Apixaban|anti-coagulation
1544926|NCT02633761|Drug|Mifepristone|200mg mifepristone followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
1544927|NCT02633761|Drug|Placebo|placebo followed in 24 hours by 200mcg buccal misoprostol every 3 hours.
1544928|NCT02633761|Drug|Misoprostol 200mcg|Buccal misoprostol 200mcg
1544929|NCT02633748|Behavioral|Mindfulness-Based Cancer Survivorship|Mindfulness-Based Cancer Survivorship (MBCS) is a four-week standardized mindfulness program, adapted for cancer survivors from Mindfulness-Based Stress Reduction (MBSR). MBCS teaches formal mindfulness practice (meditation) and informal mindfulness during daily activities. Mindfulness has been shown to help stress, fatigue, sleep complaints, and other symptoms but has not been extensively studied in cancer survivors.
1544930|NCT02633735|Behavioral|appy-cds|See description under arm/group section
1544931|NCT02633722|Behavioral|Lifestyle intervention B|Time limiting feeding from 8-5pm (TRFb)
1544932|NCT02633722|Behavioral|Lifestyle Intervention D|Time limiting feeding (12-9pm)
1544933|NCT02633709|Drug|Itraconazole|Itraconazole will be administered as an oral 200 mg dose twice daily from Day 1 to Day 8 in Part 3.
1544934|NCT02633709|Other|Placebo|In Part 1 of the study matching oral placebo will be administered once on Day 1.
1544935|NCT02633709|Drug|RO7034067|Single ascending oral doses of RO7034067 will be administered on Day 1 of Part 1. In Part 2 a single dose of RO7034067 will be once administered under fasted and once under fed conditions. In Part 3 a single dose of RO7034067 will be once administered alone (Period 1) and once concomitantly to itraconazole (Period 2).
1544936|NCT02633696|Drug|silybin phosphatidylcholine|
1544937|NCT02633696|Drug|Legalón SIL|
1544938|NCT02633683|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
1544939|NCT02633670|Device|Hemopatch|
1544940|NCT02633670|Device|No Hemopatch|
1544941|NCT02633657|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
1544942|NCT02633644|Device|Harmony System|Percutaneous neuromodulation of the aortic wall
1544943|NCT02633618|Biological|Analgecine|Extraction from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
1544944|NCT02633618|Biological|Neurotropin|a natural bio-product obtained from rabbit skin extract through vaccinia virus inoculation inflammation as an antigen immune reaction.
1544945|NCT02633605|Device|First Sense Medical®|
1544946|NCT02633592|Other|HRARM|Patients and healthy volunteers are investigated in the seated and lying position during HRAM
1544947|NCT02633592|Other|MRI Defecography|Patients and healthy volunteers are investigated in the supine and left lateral position in the MRI
1544948|NCT02633579|Drug|erythromycin lactobionate|intravenous administration of erythromycin
1544949|NCT02633579|Drug|Atropine|intravenous administration of atropine
1544950|NCT02633579|Drug|Erythromycin with atropine|intravenous administration of erythromycin with saline
1544951|NCT02633579|Drug|Saline|intravenous administration of saline
1544953|NCT02633553|Radiation|adjuvant radiotherapy|50Gy/25Fx
1544954|NCT02633540|Radiation|IMRT Radiation|Radiation to Larynx
1544955|NCT02633527|Drug|Placebo|
1544956|NCT02633527|Drug|SPN-812 ER, Low Dose|
1544957|NCT02633527|Drug|SPN-812 ER, Low-Medium Dose|
1544958|NCT02633527|Drug|SPN-812 ER, High-Medium Dose|
1544959|NCT02633527|Drug|SPN-812 ER, High Dose|
1544960|NCT02633514|Drug|Cisplatin|25mg/m2,iv gtt,d1-3
1544961|NCT02633514|Drug|Etoposide|75mg/m2,iv gtt,d1-3
1544962|NCT02633514|Radiation|radiotherapy|60Gy/30Fx
1544963|NCT02633501|Drug|P03277|Single intravenous (IV) bolus injection at a rate of 2 mL/second
1544964|NCT02633501|Drug|Gadobenate dimeglumine|Single intravenous (IV) bolus injection at a rate of 2 mL/second
1544965|NCT02633501|Device|MRI|
1544966|NCT02633488|Drug|Placebos|A 12 week single blind placebos
1544967|NCT02633488|Drug|metformin|A 12 week single blind metformin
1544968|NCT02633475|Genetic|IL-10 polymorphism|The IL-10 genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
1544969|NCT02633462|Procedure|scaling and root planing , Myo-inositol|scaling and root planing along with Myo-inositol supplementation (1 gm twice a day)
1544970|NCT02633462|Drug|Myo-inositol|only provided treatment with Myo-inositol supplementation (1 gm twice a day)
1544971|NCT02633449|Behavioral|cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy, six patients, two therapists, duration: 60 minutes, two sessions per week for a total of six weeks
1544972|NCT02633449|Device|tDCS|transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, 1-2 mA, anode over electrode position F3, cathode over F4
1544973|NCT02633449|Device|sham-tDCS|sham transcranial direct current stimulation during cognitive behavioral therapy with delayed onset after 10 minutes for 30 minutes, anode over electrode position F3, cathode over F4
1544974|NCT02633436|Other|SLC1A5 expression|To observe the expression of SLC1A5 by immunohistochemistry and WesternBlot analysis.
1544975|NCT02633423|Procedure|No ventilation during CPB|No ventilation will be provided during CPB. Patients will be deconnected from ventilator. Lungs will completely collapse.
1544976|NCT02633423|Procedure|Ventilation with CPAP during CPB|A continuous Positive Airway Pressure (CPAP) will be applied during CPB, with an airway pressure of 5 cmH2O.
1544977|NCT02633423|Procedure|Ventilation with low tidal volume during CPB|Ventilation will be provided with 5 acts per minute, with a tidal volume of 2-3 ml/kg of IBW and a PEEP of 5 cmH2O.
1544978|NCT02633410|Procedure|Femoral tunnel creation|Arthroscopic surgery approach used to create tunnel in femur into which graft is positioned
1544981|NCT02633384|Other|SMOFlipid|Exclusive total parenteral nutrition using a new generation intravenous lipid emulsion composed of 30% LCT n-6 (soybean oil), 30% MCT (coconut oil), 25% monounsaturated fatty acids (olive oil), 15% LCT n-3 (fish oil) and α-tocopherol
1544982|NCT02633384|Other|Lipofundin|Exclusive total parenteral nutrition using a current intravenous lipid emulsion composed of 50% LCT (soybean oil) and 50% MCT (coconut oil)
1544983|NCT02633371|Drug|Oxybutynin 3% gel|
1544984|NCT02633358|Device|Therapeutic hypothermia|Therapeutic hypothermia
1544985|NCT02633345|Dietary Supplement|Probiotic tablets|Tablets with both Lactobacillus rhamnosus PB01 and Lactobacillus curvatus P2-2. Two tablets a day for four weeks
1544986|NCT02633345|Dietary Supplement|Placebo|Placebo tablets
1544987|NCT02633319|Behavioral|Skilful Parenting|Skilful Parenting is a 2-week group-based parenting intervention delivered by Investing in Children and Our Societies to caregivers who are members of farmer groups in participating villages. It reinforces positive parenting practices, empowering parents to address the challenges that they face in bringing up their children. The intervention helps create parent peer groups to share ideas, support, information, and resources in the community. The intervention involves weekly sessions with farmer groups, awareness raising amongst local authorities and communities, and the establishment of parent peer groups. Topics consist of the following issues related to parenting: roles and responsibilities; family relations; communication; values; positive discipline; child protection; and family budgeting.
1545029|NCT02633046|Drug|Acthar 80 U 3x/week|Acthar 80 U 3x/week
1544988|NCT02633319|Other|Agrics|Agrics provides smallholder farmers, organized in farmer groups, with access to farm inputs on a credit basis, and agricultural extension and advisory services to improve farming techniques and improve market connections. These services include an intensive intervention during planting season and then ongoing support after the initial 3-month intervention.
1544991|NCT02633267|Behavioral|Vocational Services as usual plus Cognitive Behavioral Therapy (CBT)|Teaches thought restructuring and exposure therapy to socially anxious job seekers delivered by vocational service professionals
1544992|NCT02633267|Behavioral|Usual Vocational Services|Vocational services delivered by vocational professionals at vocational service center (e.g., resume assistance, job leads)
1544993|NCT02633254|Device|Magnetic Resonance guided High Intensity Focused Ultrasound|Targeted vessel ablation of type 3 uterine fibroids with magnetic resonance guided high intensity focused ultrasound
1544994|NCT02633241|Drug|Dexmedetomidine-Propofol|First, the investigators will administer dexmedetomidine 1mcg/kg over 5 minutes. Next, the investigators will begin an infusion at 1mcg/kg/hour. At the 5 minute point, propofol will be given (2mg/kg bolus followed by 100mcg/kg/min infusion). The attending clinician will determine whether or not the child is in an adequate state to begin the MRI scan. If the sedative effect of the dexmedetomidine-propofol does not produce a sufficiently sedated state within 10 minutes, a repeat bolus of propofol 2mg/kg will be administered. The dose of Dexmedetomidine will not be changed. The dose will be repeated if the child is not adequately sedated in 2 more minutes. At this time infusion rate of propofol will be increased to 200 mcg/kg/minute. If the child is not sedated in 5 more minutes, the outcome will be recorded as a technique failure and sedation will continue at the discretion of the anesthesiologist.
1544995|NCT02633228|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of Oculentis® MplusX® multifocal intraocular lenses with an addition of +2.0 D in the distance-dominant eye and +3.0 D in the fellow eye.
1544996|NCT02633215|Device|S88 Dual Output Stimulator by Grass Technologies|Peripheral nerve stimulation of Erb's point, radial and median nerves paired with task-oriented therapy
1544997|NCT02633202|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
1544998|NCT02633202|Drug|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
1544999|NCT02633189|Drug|Erlotinib|given orally 150 mg daily
1545000|NCT02633189|Drug|Bevacizumab|15 mg/kg intravenously every 21 days.
1545001|NCT02633176|Drug|Cetuximab|400 mg/m^2 intravenously on day 1,then 250 mg/m^2 intravenously every week of each 21 day cycle for 6 cycles of induction chemotherapy.250 mg/m^2 intravenously every week concurrent with radiotherapy.
1545002|NCT02633176|Drug|Cisplatin|75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.30 mg/m^2 intravenously every week concurrent with radiotherapy.
1545003|NCT02633176|Drug|Docetaxel|75mg/m^2 intravenously on day 1 of each 21 day cycle for 6 cycles of induction chemotherapy.
1545004|NCT02633176|Drug|Capecitabine|1000mg/m^2 orally twice a day, days 1 to 14 of each 21 day cycle for at least 2 years or until progression following concurrent chemoradiation.
1545005|NCT02633176|Radiation|Radiotherapy|60-66 Gy if complete response or 66-70 Gy if partial response following induction chemotherapy.
1545006|NCT02633163|Drug|Low Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells (MSCs) 1 x 10^6 cells/kg in Plasma-Lyte A solution. All participants will receive the infusion at the Baseline (Day 0) visit. All participants will continue on their standard-of-care therapy during the trial.
1545007|NCT02633163|Drug|High Dose Mesenchymal Stem Cells (MSCs)|Participants will receive a single IV infusion of Mesenchymal Stem Cells MSCs 5 x 10^6 cells/kg in Plasma-Lyte A solution.
1545008|NCT02633163|Drug|Placebo Infusion|Participants will receive a placebo infusion that does not contain any mesenchymal stem cells.The placebo infusion will consist of Plasma-Lyte A, which is the same vehicle used to deliver the MSCs in the experimental groups.
1545009|NCT02633150|Other|Supplementation with red grapes polyphenol|
1545010|NCT02633137|Drug|Lenalidomide|
1545011|NCT02633137|Drug|R-CHOP|"Rituximab 375 mg/m^2 IVPB with premedications Day 1
Cyclophosphamide 750 mg/m^2 IVPB Day 1
Doxorubicin 50 mg/m^2 IVP Day 1
Vincristine 1.4 mg/m^2 IVP (capped at 2 mg) Day 1
Prednisone 100 mg PO Daily on Days 1-5 or 2-6"
1545012|NCT02633137|Drug|high-dose cytarabine (HIDAC)|
1545013|NCT02633124|Device|Edelvaiss Multiline NEO|Use of Edelvaiss Multiline NEO to infuse the parenteral nutrition and drugs during the study period
1545014|NCT02633124|Device|Standard Infusion Set|Use of Standard Infusion Set to infuse the parenteral nutrition and drugs during the study period
1545015|NCT02633111|Other|collected at pre-treatment tumor biopsy|to identify the tumor-specific clonotype
1545016|NCT02633111|Other|Peripheral blood tests|for MRD analysis at 3, 6, 9, 12, 15, 18, 21, and at relapse (+/- 1 month).
1545017|NCT02633111|Device|PET/CT|at 3, 6, 9, 15, 18, 21 and at relapse(+/- 1 month)
1545021|NCT02633072|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AMO® Tecnis® multifocal intraocular lenses with an addition of +2.75 D in the distance-dominant eye and +3.25 D in the fellow eye.
1545022|NCT02633059|Drug|Dexamethasone|Given PO
1545023|NCT02633059|Drug|Idasanutlin|Given PO
1545024|NCT02633059|Drug|Ixazomib Citrate|Given PO
1545025|NCT02633059|Other|Laboratory Biomarker Analysis|Correlative studies
1545026|NCT02633059|Other|Pharmacological Study|Correlative studies
1545027|NCT02633046|Drug|Acthar 80 U 2x/week|Acthar 80 U 2x/week
1545028|NCT02633046|Other|Placebo 80 U 2x/week|Placebo 80 U 2x/week
1545030|NCT02633033|Drug|H.P. Acthar® Gel (repository corticotropin injection)|
1545031|NCT02632994|Drug|LY2503029|Administered orally.
1545032|NCT02632981|Other|nonsurgical periodontal treatment|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
1545033|NCT02632981|Other|Gingival crevicular fluid and saliva collection|GCF collection with filter paper (Periopaper) using the intracrevicular method. Patients' mouths were rinsed with distilled water, and unstimulated salivary samples were collected by patients expectorating into disposable tubes.
1545035|NCT02632955|Drug|Drug Eluting Balloon|After pre dilation of the lesion with regular angioplasty balloon, drug coated balloon Lutonix(R) by Bard Inc. will be introduced over the lesion as quickly as possible. Lutonix is a paclitaxel coated balloon which delivers the drug locally. The diameter of the drug coated balloon will be same as the diameter of the largest balloon used for pre dilation. Drug coated balloon will be inflated not exceeding the rated burst pressure. The minimum inflation time will be 1 minute.
1545036|NCT02632955|Procedure|Regular angioplasty|After predilation of the lesion with regular balloon, the same balloon will be reintroduced without the drug to be inflated for a minimum of 1 minute. This angioplasty will not deliver any local drug.
1545037|NCT02632942|Procedure|HAQ criteria|"Obliteration of accessory vein which satisfy the HAQ criteria as below:
60% or greater diameter of the main AVF
50% diameter of AVF with at least one more av>40% in diameter.
50% in diameter and divides into branches of same size.
av likely to interfere with cannulation on physical examination.
>30% in diameter and associated with stenosis at site of origin."
1545038|NCT02632942|Procedure|Current Recommendation|Obliteration of accessory vein which satisfy current recommendations defined as the diameter greater than 25% of the AVF diameter.
1545039|NCT02632916|Drug|Zoledronic Acid|Intravenous zoledronic acid 0.025mg/kg at baseline and 6 months
1545040|NCT02632916|Drug|Denosumab|Subcutaneous denosumab 1.0mg/kg at baseline and 6 months
1545041|NCT02632903|Drug|Zoledronic acid|
1545042|NCT02632877|Drug|Pirfenidone with MODD|Patients with diabetic foot ulcer will be treated three times a day with a smooth layer (standar finger tip unit 0.5g for an area of 100 to 120 square centimeters) of KitosCell Q (Pirfenidone with MODD) in form of gel and the wound will be covered with a bandage.
1545043|NCT02632877|Drug|Ketanserin|Patients will be administered ketanserin twice a day usign the standar finger tip unit (0.5g for an area of 100 to 120 square centimeters) and the wound will be covered with a bandage. This arm is a control for evolution of diabetic foot ulcer.
1545044|NCT02632864|Radiation|Proton arm|Proton beam therapy
1545045|NCT02632838|Device|iHealth BP7-Wireless Blood Pressure Wrist Monitor,|The mHealth group will ask to use iHealth BP7-Wireless Blood Pressure Wrist Monitor at home. This monitor is a fully automatic wrist cuff blood pressure monitor that uses the oscillometric principle to measure blood pressure and pulse rate. The monitor works with mobile devices to test, track and share vital blood pressure data. The Bluetooth sync system allows the monitor to send BP measures and pulse rate to patients' mobile devices. The free iHealth app automatically keeps a history of BP data and gives patient the option to share their blood pressure data with their provider. In addition to keep the data on the mobile device, patient also receive a free and secure cloud account. Vital data on the cloud allows patients to access from any computer and to share with their provider.
1545046|NCT02632825|Device|Nasal High Flow|Nasal High Flow Therapy
1545047|NCT02632812|Drug|Rebamipide effervescent granules|Rebamipide effervescent granules 100mg (oral), twice daily for 7 days
1545048|NCT02632812|Drug|Placebo effervescent granules|Placebo effervescent granules (oral), twice daily for 7 days
1545049|NCT02632812|Drug|Naproxen tablet|Naproxen tablet 550mg (tablet), twice daily for 7 days
1545050|NCT02632799|Device|NHF small cannula|NHF 8 l/min by Airvo 2 by small cannula
1545051|NCT02632799|Device|NHF big cannula|NHF 8 l/min by Airvo 2 by large cannula
1545052|NCT02632799|Device|CPAP|Nsal CPAP 5cm H2o by face mask
1545053|NCT02632786|Drug|NEOD001|NEOD001 is a monoclonal antibody directed at soluble and insoluble light chain aggregates
1545054|NCT02632786|Drug|Placebo|Saline Bag
1545055|NCT02632773|Behavioral|Responsive Intervention|Mothers assigned to the responsive experimental condition will learn how to talk about what is in their child's focus of attention and to respond to all child communicative attempts by either: (a) assigning a presumed meaning to preverbal communication or vocalizations or (b) by repeating the child's verbal communication and adding words.
1545056|NCT02632773|Behavioral|Directive Intervention|Mothers assigned to the directive experimental condition will learn how to: (a) set up a prompting trial through management of toys or by responding to a child request, (b) recruit the child's attention, (c) provide a discriminative stimulus (cue), (d) wait for the child's response for 5 seconds, (e) reinforce the child for correct production of the target or provide additional prompts after incorrect productions. Parents will perform one prompting trial per minute for a total of 20 trials per parent session.
1545057|NCT02632760|Drug|Ferric carboxymaltose|treatment for Iron deficient anaemia
1545058|NCT02632760|Drug|Placebo|placebo - no active drug
1545062|NCT02632734|Device|CoreBone Cone device|coral derived devices in the form of Cones are placed in extraction sites for preservation of bone during 6month and more.
1545063|NCT02632734|Device|CoreBone 500 device|coral derived devices in the form of particulate (CoreBone 500) are placed in extraction sites for preservation of bone. Follow up during 6month and more.
1545066|NCT02632708|Drug|AG-120|
1545067|NCT02632708|Drug|AG-221|
1545068|NCT02632708|Drug|cytarabine|
1545069|NCT02632708|Drug|daunorubicin|
1545070|NCT02632708|Drug|idarubicin|
1545071|NCT02632708|Drug|mitoxantrone|
1545072|NCT02632708|Drug|etoposide|
1545073|NCT02632695|Device|FOOTFIT|Individuals with venous leg ulcers will be instructed on physical activity movements for their lower legs to be performed over six weeks while wearing a foot based activity monitor (accelerometer) that will send them motivational messages and progress reports. For those in the FOOTFIT Plus group, individuals will have the option to communicate with their wound care provider via text messages, emails or phone calls.
1545074|NCT02632669|Radiation|Hemi gland focal LDR brachytherapy|The treatment is limited to the hemigland that has been diagnosed with unilateral low to intermediate risk prostate cancer by means of pre - treatment staging with mpMRI and transperineal template biopsy. The affected hemigland will be treated with iodine 125 to a prescription dose of 145Gy. Patients will be assessed at baseline and subsequently at 6 weeks,3,6,9,12,18,24 months after treatment with PSA and EN2 measurements and validated questionnaires relating to erectile, urinary, and bowel function and general health related quality of life. mpMRI and transperineal template biopsy will be performed 24 months after treatment.
1545075|NCT02632656|Other|Monitoring on heart failure therapy|This is a prospective observational study where participants will have serial blood collection on medical therapy for heart failure.
1545076|NCT02632643|Behavioral|Sensorimotor education with a view to obtaining an optimal FWS further to the relaxation of the masticatory, lingual and labial system. Learning of mandibular micro-movements in 5 directions.|
1545077|NCT02632630|Drug|Amino Acids w/Electrolytes in Dextrose|Patients will receive peripheral parenteral nutrition to a maximum of 2L/day (with a minimum rate of 45mL/hour and a maximum rate of 85mL/hour) of pre-packaged Peri-OLIMEL 2.5% E. The PPN will be administered in place of their maintenance crystalloid solution, and will be adjusted or stopped as clinically indicated by the attending medical team., for up to 5 days of hospitalization or until discharge, whichever is sooner.
1545078|NCT02632630|Dietary Supplement|Ensure product|Patients will receive one package of Ensure two times daily in hospital. At discharge, patients randomized to receive Ensure will be provided with 28 packages of Ensure with instructions to attempt to consume 1 package per day.
1545079|NCT02632630|Drug|Crystalloid solutions|Standard care intravenous maintenance fluid administration for up to 5 days of hospitalization or until discharge, whichever is sooner.
1545080|NCT02632630|Dietary Supplement|Oral nutritional supplementation|Standard of care oral nutritional supplementation is determined by the clinician. A dietitian may also be involved.
1545081|NCT02632617|Other|Computed tomographic angiography|Preoperative examination is needed in patients with valvular disease. The invasive coronary angiography is used for patients in ICA group, while the computed tomographic angiography is used as a gatekeeper and invasive coronary angiography is selectively used for patients in CTA group.
1545082|NCT02632604|Behavioral|Computerized cognitive training|40 hours of a computerized cognitive training, given 1 hour daily
1545083|NCT02632604|Behavioral|Computer games|
1545084|NCT02632578|Biological|2015 Fluvax® vaccine, BioCSL (a licensed influenza vaccine)|Subjects received licensed influenza vaccine (Fluvax®), 1ml intramuscular injection.
1545085|NCT02632565|Drug|Lidocaine|
1545086|NCT02632565|Drug|Saline|
1545087|NCT02632552|Behavioral|Technology-assisted care transition intervention|In-patient virtual nurse on-screen touchscreen and outpatient virtual nurse follow-up by texting
1545088|NCT02632552|Behavioral|Active attention control|In-patient brief animated power-point style didactic onscreen tutorial covering the core pillars of care transitions
1545089|NCT02632539|Procedure|Manual air-impingement operation|A method which we invented to clear subglottic secretion
1545090|NCT02632539|Procedure|subglottic secretion drainage|The conventional method which we use subglottic secretion drainage to clear subglottic secretion
1545095|NCT02632513|Device|Proultra PiezoFlow (Dentsply Tulsa Dental Specialties)|In continuous ultrasonic irrigation group, Proultra PiezoFlow (Dentsply Tulsa Dental Specialties, Tulsa,OK) was used for the activation of the irrigating solution according to manufacturer's recommendations.
1545097|NCT02632487|Behavioral|Exercise|Center-based walking + balance, stretching, and light resistance
1545098|NCT02632487|Behavioral|Non-Exercise Physical Activity (NEPA)|Behavioral counseling paired with technology intervention to monitor physical activity
1545099|NCT02632474|Drug|Tenofovir(TDF)+Lamivudine(3TC)+Efavirenz(EFV)|The first 2 weeks, TDF (300 mg) + 3-TC (300 mg) + EFV (400 mg); week 3, TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg ); week 4, TDF (150 mg) + 3-TC (300 mg) + EFV (400 mg).From week5, if the HIV viral load decreased as expected or no rebound, use TDF (200 mg) + 3-TC (300 mg) + EFV (400 mg) until study complete; if the viral load increases, switch to the standard treatment regimen: TDF (300 mg) + 3-TC (300 mg) + EFV (600 mg).
1545100|NCT02632461|Behavioral|Podcasts|Participants will receive twice weekly podcasts that will cover topics related to weight loss.
1545101|NCT02632461|Behavioral|Mobile Diet Application|Participants will use a mobile application on their smartphone to track their diet.
1545102|NCT02632461|Behavioral|Bite Counter|Participants will use a wrist-worn Bite Counter to track the number of bites in their diet per day.
1545103|NCT02632448|Drug|LY2880070|Capsules
1545104|NCT02632448|Drug|Gemcitabine|250 to 600 milligrams per square meter of body surface area (mg/m2)
1545105|NCT02632435|Device|PICC|Participants will be randomized to a PICC for vascular access during chemotherapy.
1545106|NCT02632435|Device|PORT|Participants will be randomized to a PORT for vascular access during chemotherapy
1545107|NCT02632422|Other|Daily acute intermittent hypoxia (dAIH)|Each participant will be exposed to 10 sessions of daily acute intermittent hypoxia (dAIH) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute hypoxia (FIO2=0.09±0.02, i.e. 9% O2). Participants will receive 5 consecutive days of daily acute intermittent hypoxia (dAIH).
1545183|NCT02631863|Drug|Aminolaevulinic acid|Aminolaevulinic acid with illumination
1545184|NCT02631863|Drug|Placebo|Placebo with illumination
1545108|NCT02632422|Other|dSHAM|Each participant will be exposed to 10 sessions of daily room air (dSHAM) via air generators. The generator will fill reservoir bags attached to a non-rebreathing facemask. Each session will consist of 15 episodes of 1.5 minute normoxia (FIO2=0.21±0.02) . Participants will receive 5 consecutive days of daily room air (dSHAM).
1545109|NCT02632422|Other|Walking|"Participants will participate in 10 days of walking practice sessions. Walking practice sessions will immediately follow (within 60 minutes) the breathing intervention during training visits and will last for 60 minutes.
Walking practice will incorporate 5 walking-related tasks:
walking balance (e.g., walking on different surfaces)
skilled walking tasks (e.g., negotiating obstacles)
walking with secondary task (e.g., walking and carrying object)
endurance
speed"
1545112|NCT02632396|Drug|Ixazomib|Given PO
1545113|NCT02632383|Device|Young with Diabetes - app|"The mHealth app Young with Diabetes containes 8 main functions:
Contact your health care provider (ask questions, set the agenda for the next clinical visit)
My Department (hotline numbers, videos about the new adult department, pictures of my diabetes team)
Chatroom
Counting Carbohydrates (information and tips about carbs, introduction to apps to count carbs, quiz)
Knowledge-section (Text, links, tips and videos (animations and videoselfies) about What is diabetes?, Alcohol etc.)
Tips packages (Receive a tip about alcohol, drivers license etc.)
To parents (Text, links, tips and videoselfies to parents about what it is like to be young with diabetes and what they can do to support)
Reminder"
1545114|NCT02632370|Drug|Gliolan|single dose of oral 5-ALA (20mg/kg bodyweight) at 3 hours (range 2-5 hours) given preoperatively
1545115|NCT02632370|Procedure|Fluorescence-Guided Surgery|performed utilizing blue light. At least 3-5 fluorescent tissue samples will be taken.
1545116|NCT02632357|Other|Spinal Manipulation|
1545117|NCT02632344|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks on day 1 of each cycle after all procedures/assessments have been completed.
1545118|NCT02632331|Drug|ASP8825|Oral
1545119|NCT02632318|Device|Light|30 minutes of dawn simulation
1545120|NCT02632305|Drug|nab-paclitaxel in combination with gemcitabine + cisplatin|Patients with unresectable BTC will be treated with the triple combination of nab-paclitaxel in combination with gemcitabine + cisplatin
1545121|NCT02632292|Device|Absorb GT1|Bioresorbable vascular scaffold
1545122|NCT02632292|Device|Promus|Everolimus-eluting stent
1545123|NCT02632279|Dietary Supplement|Tryptophan (TRP) depletion|TRP depletion will be accomplished by administering a TRP-low amino acid protein drink containing 100 g of gelatin powder. The protein mixture consists of 18 amino acids. According to Dutch law, TRP is considered a food supplement and is not registered as a medicine.
1545124|NCT02632279|Dietary Supplement|Placebo|The placebo treatment will consist of an identical amino acid protein drink containing 100 g of gelatin powder to which 1.21g TRP is added.
1545125|NCT02632279|Device|Stimulator ON|Participants will be tested while their stimulator is turned ON
1545126|NCT02632279|Device|Stimulator OFF|Participans will be tested while their stimulator is turned OFF
1545127|NCT02632266|Dietary Supplement|Powder HMF|powder human milk fortifier
1545128|NCT02632266|Dietary Supplement|Liquid HMF|Liquid human milk fortifier
1545129|NCT02632253|Procedure|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-70% of peak heart rate). The total duration of the HIIT training is 38 min. The HIIT group will perform two supervised HIIT trainings and one self monitored MICE training per week.
1545130|NCT02632253|Other|MICE|MICE is also performed on a cycle ergometer at an intensity of 70-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform two supervised and one self monitored MICE training per week.
1545131|NCT02632240|Other|Surgery:The tunnel technique for covering gingival recession|The surgery starts with the sulcular incisions in the region of recessions, which enable access for the supraperiosteal preparation. The procedure is extended into the mucosal tissue using the tunneling knives. The partial-thickness flap is performed at the buccal site. Only the papillary regions are fully detached with the periosteum. The graft is placed into the tunnel and stabilized with absorbable sutures.The mobilized mucous flap is advanced coronally and stabilized with non-absorbable suspensory sutures.
1545132|NCT02632227|Procedure|TFU(transfontanel ultrasound)|The respiratory variation of the carotid artery blood flow peak velocity was measured using TFU before and after the fluid administration (10ml/kg for 20 min.)
1545133|NCT02632214|Other|fMRI measure|
1545134|NCT02632201|Biological|PIK-HER2|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-HER2 cell suspension (1-6×109 PIK-HER2 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
1545135|NCT02632201|Biological|DC-PMAT|DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
1545136|NCT02632188|Procedure|Postoperative routine treatment|Postoperative routine treatment according to the hospitals local routines
1545137|NCT02632188|Biological|DC-PMAT treatment|Postoperative routine treatment according to the hospitals local routines; DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×109 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63.
1545139|NCT02632162|Other|screening|Screening for sleep disordered breathing with the ApnoeLink Air device
1545140|NCT02632149|Device|PINS Vagus Nerve Stimulator|
1546360|NCT02624245|Other|Conventional Physical Therapy|
1545141|NCT02632136|Drug|TAP Block Group|Transversus Abdominus Plane (TAP) block: Bupivacaine (30 ml of 0.25%)is injected between internal oblique and transveralis facia. The location of needle and the bleb that is formed after the injection is inspected under diect laparoscopic vision.
1545142|NCT02632136|Drug|Peri-Portal Block Group|15 ml of 0.5% Bupivacaine is injected in the skin and subcutaneous tissue before inserting the ports. 7 ml out of it is injected at sub-umblical port and 4 ml each a the site of other two ports.
1545148|NCT02632097|Procedure|Lichtenstein Hernioplasty with Histoacryl|"Procedure/Surgery: Lichtenstein Hernioplasty with Histoacryl:
0.5 ml of cyanoacrylate glue is used for mesh fixation"
1545149|NCT02632097|Procedure|Lichtenstein Hernioplasty with Sutures|Procedure/Surgery: Lichtenstein Hernioplasty with Sutures: non-absorbable suture (polypropylene 2/0) is used for mesh fixation Other Name: prolene 2-0
1545150|NCT02632071|Drug|ACY-1215|An orally active, selective HDAC6 inhibitor. Assigned dosing 80 mg, 120 mg, 180 mg, 240 mg PO, once daily Days 1-21 in a 28-day cycle
1545151|NCT02632071|Drug|Nab-paclitaxel|"Taxanes are among the most widely used chemotherapy agents in the treatment of breast cancer.
100 mg/m2 30 minute IV infusion Days 1, 8, and 15 in a 28-day cycle"
1545152|NCT02632058|Other|Cognitive Behavioral Therapy|
1545153|NCT02632045|Drug|LEE-011|600 mg capsule (3x 200 mg capsules)
1545154|NCT02632045|Drug|Fulvestrant|500 mg injection
1545155|NCT02632045|Drug|Placebo|600 mg capsule (3x 200 mg capsules)
1545157|NCT02632019|Drug|Gemcitabine|Gemcitabine 1000mg/m2, Physiological saline 100ml:IV (in the vein) once a week with a total of six times.
1545158|NCT02632019|Biological|Dendritic cell-precision T cell for neo-antigen combined with gemcitabine treatment|"Gemcitabine: Gemcitabine 1000mg/m2, Physiological saline 100ml: IV (in the vein) once a week with a total of six times before 60 days prior to the start of drawing blood. DC-PNAT: DC cell suspension (1×107 DC+ physiological saline + 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion, 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62.
PNAT cell suspension (1-6×109 PNAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion, 3 cycles, each cycle received one infusions on day 21, 42, 63."
1545159|NCT02632006|Biological|PIK-PD-1 cells|"DC cell suspension (1×10*7 DC+ physiological saline
+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PIK-PD-1 cell suspension (1-6×10*9 PIK-PD-1 + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
1545160|NCT02632006|Biological|DC-PMAT|"DC cell suspension (1×10*7 DC+ physiological saline
+ 0.25% human serum albumin) 1ml for each infusion, subcutaneous injection for each infusion 3 cycles, each cycle received two infusions on day 19, 20; 40, 41; 61, 62. PMAT cell suspension (1-6×10*9 PMAT + physiological saline + 0.25% human serum albumin) 300ml for each infusion, IV (in the vein) for each infusion 3 cycles, each cycle received one infusions on day 21, 42, 63."
1545161|NCT02631993|Radiation|Photochemotherapy|Oral 8-Methoxypsoralene (8-MOP), (0.4-0.8 mg/kg), are given 1.5-2 hours before phototherapy. Ultraviolet light type A (UVA, 320−400 nm) is administered in a Waldmann UV1000 supine unit through 26 100-W fluorescent PUVA lamps (Waldmann F85), if needed, UVA is given in a half body unit with 15 100-W PUVA-lamps (Waldmann F85), (Waldmann UV3003K), (Waldmann, Villingen-Schwenningen, Germany). Eye protection is applied during 24 h after oral 8-MOP and the genital area are shielded in males during therapy.The UVA is initiated at 0.2−1.5 J/cm2 and is amplified by 0.25-0.5 J/cm2 after two treatments if photo toxicity is absent. PUVA is given to the patients 3−5 times each week.
1545162|NCT02631980|Drug|IV iron|Intravenous iron 15 mg/kg (max 1000 mg) in 250 ml 0.9% saline
1545163|NCT02631980|Drug|IV placebo|Intravenous 0.9% saline (250 ml)
1545164|NCT02631967|Procedure|Kono anastomosis|Kono anastomosis
1545165|NCT02631967|Procedure|Stapled side-to-side anastomosis|Stapled side-to-side anastomosis
1545166|NCT02631954|Drug|Vorico Injection 200mg(Voriconazole)|Vorico Injection 200mg(Voriconazole) to administered intravenously once
1545167|NCT02631954|Drug|Vfend®(Voriconazole) IV 200mg|Vfend®(Voriconazole) IV 200mg to administered intravenously once
1545168|NCT02631941|Drug|Z7200|
1545169|NCT02631941|Drug|Symbicort Turbohaler|
1545170|NCT02631941|Drug|Z7200 with charcoal|
1545171|NCT02631941|Drug|Symbicort Turbohaler with charcoal|
1545172|NCT02631941|Drug|Symbicort Turbohaler replicate|
1545173|NCT02631928|Drug|human biphasic insulin|investigational insulin, biosimilar human insulin suspension of 30% normal insulin and 70% basal protamined insulin
1545174|NCT02631928|Drug|human biphasic insulin, reference|marketed product, human insulin suspension of 30% normal insulin and 70% basal (NPH) insulin
1545175|NCT02631902|Behavioral|Exercise|Community-based exercise program with 3 weekly exercise sessions
1545176|NCT02631902|Behavioral|Dietary intervention|Community-based dietary intervention program
1545177|NCT02631889|Device|Transcollation technology|The use transcollation technology for dissection during lung surgery
1545178|NCT02631889|Device|Traditional electrocautery|The use of traditional Electrocautery for dissection during Lung Surgery
1545185|NCT02631850|Behavioral|Traditional CI Therapy|Intensive in-person therapy for upper extremity hemiparesis.
1545186|NCT02631850|Behavioral|Gaming CI Therapy|Intensive remote (via video game) therapy for upper extremity hemiparesis.
1545187|NCT02631850|Behavioral|Gaming CI Therapy with Additional Contact via Video Conference|Intensive remote (via video game) therapy for upper extremity hemiparesis with additional therapist contact via video conference.
1545188|NCT02631850|Behavioral|Traditional Occupational Therapy/Physical Therapy|Traditional in-person therapy focusing on the rehabilitation of the upper extremity.
1545189|NCT02631837|Procedure|vNOTES hysterectomy|Surgical removal of the uterus by Natural Orifice Transluminal Endoscopic Surgery using a colpotomy
1545190|NCT02631837|Procedure|LSC hysterectomy|Surgical removal of the uterus by transabdominal laparoscopy
1545191|NCT02631824|Procedure|open reduction and internal fixation|Open reduction and internal fixation using an intramedullary nail
1545192|NCT02631824|Device|TFNA|Trochanteric Femoral Nail Advance
1545193|NCT02631824|Device|Augmentation (Cement)|Cement placement (3-6ml) through the cephalic blade under fluoroscopic vision. Cement contains 40% zirconuim dioxide, 15% hydroxiapatite, 45% polymethyl methacrylate (PMMA).
1545194|NCT02631811|Other|Supportive /palliative care intervention|patients will be seen by palliative care team at least once a month until the 12th week, more if needed. The symptom and suffering will be assessed by a multidisciplinary palliative specialist team of physician, nurse and psychologist. Physical, psychological, social and existential suffering will be addressed.
1545195|NCT02631798|Dietary Supplement|Food grade dye mucosal staining|mucosal staining with food grade dye
1545196|NCT02631785|Other|Cognitive Behavioral Therapy|"Psychologists will deliver the COPING CAT treatment for reducing anxiety symptoms. It is a manualized treatment that was extensively used before. The treatment will include 10- 14 sessions, mostly individual but also two parents meetings. All the treatments will occur in the Department of Psychology in Haifa University as a part of a clinical trial. The treatment will take place in a room that was designed for this purpose fully equipped with cameras, microphone and double sided mirror. All sessions will be audio and video recorded and will be closely monitored by the PI. To increase protocol adherence and verify the adequacy of the treatment delivered, all clinicians will complete routine forms with the content of each session."
1545197|NCT02631772|Drug|Sofosbuvir/Ledipasvir x 8 weeks|
1545198|NCT02631772|Drug|Sofosbuvir/Ledipasvir x 12 weeks|
1545199|NCT02631772|Drug|Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks|
1545200|NCT02631759|Drug|Lévétiracetam|"Levetiracetam will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .
The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.
The decay phase takes place in two phases:
A phase of 7 days of levetiracetam 250 mg every 12 hours ( morning and evening)
Then a phase of 7 days of levetiracetam 250 mg every 24 hours (evening)."
1545201|NCT02631759|Drug|Placebo|"Placebo (NaCl 0,9%) will be administered at 500mg / 12h through IV started within 24 hours after enrollment in the study for at least 48 hours and for up to 5 days, then a per os administration will be made out as soon as oral will be possible, at a dose of 500mg / 12h (1g / day in two divided doses ) .
The total duration of treatment will be 1 month and 15 days taking into account the processing taking decay phase.
The decay phase takes place in two phases:
A phase of 7 days of placebo 250 mg every 12 hours ( morning and evening)
Then a phase of 7 days of placebo 250 mg every 24 hours (evening)."
1545202|NCT02631746|Other|Laboratory Biomarker Analysis|Correlative studies
1545203|NCT02631746|Biological|Nivolumab|Given IV
1545204|NCT02631746|Other|Pharmacogenomic Study|Correlative studies
1545210|NCT02631720|Procedure|Blood Draw|
1545211|NCT02631720|Procedure|Bronchoscopy|
1545213|NCT02631694|Drug|Propranolol|Intake of propranolol pill (40 milligram)
1545214|NCT02631694|Drug|Placebo|Intake of placebo pill (40 milligram)
1545215|NCT02631694|Other|Carbon dioxide|Inhalation of 35% carbon dioxide
1545216|NCT02631694|Other|Compressed air|Inhalation of air
1545217|NCT02631681|Behavioral|Group based exercise|Supervised group based combined aerobic and resistance training for 12 weeks as part of our normal clinical practice.
1545218|NCT02631668|Drug|ferrous succinate and vitamin C|As experimental group, when patients take the tablets of ferrous succinate, they also take vitamin C at the same time
1545219|NCT02631668|Drug|ferrous succinate|As active comparator, patients take the tablets of ferrous succinate with normal dosage in clinical practice
1545220|NCT02631668|Drug|ferrous succinate|As another active comparator, patients take the tablets of ferrous succinate with double dosage
1545221|NCT02631655|Other|impact of device 18F-FDOPA PET on treatment decisions|Imagery device: impact of 18F-FDOPA PET imaging on treatment decisions for patients with high-grade gliomas with an uncertain diagnosis.
1545222|NCT02631642|Drug|HMPL-689|selective PI3Kδ inhibitor
1545223|NCT02631642|Drug|HMPL-689 placebo|placebo of HMPL-689
1545224|NCT02631629|Other|Non-fortified foods|The non-fortified placebo foods are eggs, cheese, yoghurt and crisp bread (without vitamin D added).
1545225|NCT02631629|Other|Fortified foods|The fortified intervention foods are eggs, cheese, yoghurt and crisp bread (with about 20 mcg/day).
1545226|NCT02631616|Drug|Somatostatin|Monthly injections of Somatostatin
1545227|NCT02631603|Drug|Placebo|Administer Placebo as anti-inflammatory
1545228|NCT02631603|Drug|Prednisolone|Administer Prednisolone as anti-inflammatory
1545229|NCT02631590|Drug|Cisplatin|Cisplatin administered once as intravenous (IV) infusion over 60 minutes. Treatment is on Days 1 and 8 every 21 days.
1545230|NCT02631590|Drug|Gemcitabine|Gemcitabine administered as 30-min IV infusion. Treatment is on Days 1 and 8 every 21 days.
1545231|NCT02631590|Drug|Copanlisib|Experimental Drug: Copanlisib administered as an IV over 60-minutes beginning 1 hour after completing gemcitabine infusion. Treatment is on Days 1 and 8 every 21 days.
1545232|NCT02631577|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ]|Atezolizumab will be administered at a flat dose of 840 mg on Days 1 and 15 of Cycles 2 to 6, given in 28-day cycles as induction treatment and 840 mg on Days 1 and 2 of each month, given as maintenance treatment.
1545233|NCT02631577|Drug|Lenalidomide|Lenalidomide will be administered orally once daily on Days 1 to 21 of Cycles 1 to 6 (28-day cycles) during induction treatment and on Days 1 to 21 of each month during maintenance treatment. Lenalidomide will be administered at a dose of 15 or 20 mg (dose may be de-escalated to 10 mg) during induction treatment and at 10 mg during maintenance treatment. During the expansion phase, lenalidomide will be administered at the RP2D during induction treatment and at 10 mg during maintenance treatment.
1545234|NCT02631577|Drug|Obinutuzumab|Obinutuzumab will be administered by intravenous infusion at an absolute (flat) dose of 1000 mg on Days 1, 8, and 15 of the first cycle and on Day 1 of each subsequent cycle during induction treatment, and on Day 1 of every other month (i.e., every 2 months) during maintenance treatment.
1545235|NCT02631551|Drug|GSP 301 NS|2 spray in each nostril twice daily for 14 days
1545236|NCT02631551|Drug|GOM NS|2 spray in each nostril twice daily for 14 days
1545237|NCT02631551|Drug|GMM-2 NS|2 spray in each nostril twice daily for 14 days
1545238|NCT02631551|Drug|GSP 301 Placebo NS|2 spray in each nostril twice daily for 14 days
1545243|NCT02631525|Drug|Desflurane|Balanced anesthesia with remifentanil and desflurane guided by bispectral monitoring
1545244|NCT02631525|Drug|Propofol|Total intravenous anesthesia based on propofol
1545245|NCT02631512|Device|Woulgan Gel|Primary dressing gel to be applied to the wound bed, and to be covered with a secondary bandage.
1545246|NCT02631512|Device|Intrasite Hydrogel|Primary dressing hydrogel to be applied to the wound bed, and to be covered with a secondary bandage
1545247|NCT02631499|Procedure|TACE|TACE is performed 4-6 weeks after hepatectomy. Epirubicin and lipiodol are used in TACE.
1545248|NCT02631499|Drug|Epirubicin|Epirubicin is a chemotherapy drug used in TACE
1545249|NCT02631499|Drug|lipiodol|lipiodol is a kind of embolization material used in TACE
1545251|NCT02631473|Drug|50mg NANO-efavirenz|OD
1545252|NCT02631473|Drug|400mg NANO-Lopinavir|BID
1545253|NCT02631473|Drug|200mg NANO-Lopinavir|BID
1545254|NCT02631473|Drug|100mg Ritonavir|BID
1545255|NCT02631473|Drug|300mg NANO-Efavirenz|OD
1545256|NCT02631473|Drug|600mg Sustiva|OD
1545257|NCT02631473|Drug|200mg NANO-Efavirenz|OD
1545258|NCT02631473|Drug|Kaletra® (lopinavir 400mg/ritonavir 100mg)|BID
1545259|NCT02631473|Drug|+/- 200mg NANO-Lopinavir|BID
1545260|NCT02631473|Drug|+/- 200mg ritonavir NORVIR|BID
1545261|NCT02631473|Drug|400mg Sustiva|
1545262|NCT02631460|Drug|S1 80-120 mg/d|d1, every 3 weeks
1545263|NCT02631460|Drug|pemetrexed 500 mg/m2|d1, every 3 weeks
1545264|NCT02631460|Drug|carboplatin AUC=5|d1, every 3 weeks
1545265|NCT02631447|Drug|LGX818|LGX818 450 mg p.o. od
1545266|NCT02631447|Drug|MEK162|MEK162 45 mg p.o. bid
1545267|NCT02631447|Drug|Nivolumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
1545268|NCT02631447|Drug|Ipilimumab|Nivolumab 1 mg/kg solution IV combined with ipilimumab 3 mg/kg solution IV every 3 weeks for 4 doses then nivolumab 3 mg/kg solution IV every 2 weeks
1545269|NCT02631434|Procedure|sit-to-stand test|
1545270|NCT02631434|Procedure|six-minutes walking test|
1545271|NCT02631421|Procedure|Blood Sampling|
1545272|NCT02631421|Other|Cardiac MRI|
1545273|NCT02631408|Drug|Vancomycin|Locally, intrawound applied vancomycin powder
1545274|NCT02631395|Other|Exercise|Three teams participated in a seven--month, three--times--a--week shoulder--muscle strength--training program while three teams participated in a comparable handball training program but did not conduct any specific upper--body strength training.
1545275|NCT02631395|Other|Control group|The three teams in the Control Group trained as normal throughout the season and participated in a comparable handball training program, but did not conduct any specific upper--body strength training
1545276|NCT02631382|Procedure|wet cupping|"In double cupping (traditional technique): Cupping (suction) then scarification then cupping (suction).
In single cupping (Asian): puncture using auto lancet then cupping (suction). In both techniques 4 out of 6 acupoints (BL23, BL24, BL25 bilateral) will be selected."
1545277|NCT02631369|Device|Heidelberg Spectralis OCT device|
1545278|NCT02631356|Drug|Ringer's lactate solution|
1545279|NCT02631356|Drug|Succinylated gelatin|
1545280|NCT02631343|Behavioral|KMC|Promotion of, and support for lactation management and skin to skin care as soon as possible after birth by study ANM supported by study ASHA in addition to routine visits by government health workers
1545281|NCT02631343|Other|Essential newborn care|
1545282|NCT02631330|Other|Multicomponent physical activity|Balance, muscle strength and aerobic capacity will be increased in intensity according Training Intervention in a Controlled Population of Frail Elderly (EMTIFE) study NCT02331459
1545283|NCT02631317|Behavioral|Advance hospital notification by EMS|Advance hospital notification by EMS
1545284|NCT02631317|Behavioral|stroke team notification|stroke team notification
1545285|NCT02631317|Behavioral|key performance indicators feedback form|"a key performance indicators real-time feedback form as continuing quality improvement"
1545286|NCT02631317|Behavioral|standard informed consent procedures|standard informed consent procedures with public poster of thrombolysis
1545287|NCT02631317|Behavioral|performance of thrombolysis at CT-room|performance of thrombolysis at CT-room or emergency room
1545288|NCT02631304|Procedure|Elective cardiac surgery|Coronary artery bypass graft (CABG), valve surgery, combined CABG-valve surgery
1545289|NCT02631291|Behavioral|Behavioral self-monitoring|Behavioral self-monitoring will teach older adults to pay attention to their daily lifestyle practices and the conditions in which they occur. Behavioral self-monitoring is crucial for detecting change early, thereby preventing complications (mental illness symptom burden) that are associated with disruptions in healthy lifestyle practices. The steps of behavioral self-monitoring include: (1) selecting a goal, (2) paying attention to some aspect of behavior, and (3) recording some details of that behavior in a diary.
1545290|NCT02631291|Behavioral|Behavioral self-monitoring + Motivational interviewing|Participants will receive the same Behavioral self-monitoring intervention; participants in this condition will interact with a 'lifestyle coach' about their recorded behaviors, weekly. The lifestyle coach will use motivational interviewing to enhance older adults' confidence and intrinsic motivation to engage in healthy lifestyle practices.
1545291|NCT02631278|Device|Intraoperative radiofrequency ablation|Intra-operative Radiofrequency ablation will be carried out and followed by surgical removal of the treated leiomyoma.
1545292|NCT02631265|Other|Exercise 1|Participants will be admitted at IRCM at 14:00. At 15:30, participant's insulin basal rate will be reduced by 80% and participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
1545293|NCT02631265|Other|Exercise 2|Participants will be admitted at IRCM at 14:00. At 15:10, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
1545294|NCT02631265|Other|Exercise 3|Participants will be admitted at IRCM at 14:00. At 14:50, participant's insulin basal rate will be reduced by 80%. At 15:30, participants will perform a 45-minute exercise on the ergocycle at 60% of VO2 peak (moderate intensity). At 16:15, the participant's usual insulin basal rate will be set in the insulin pump and a standardized snack (30g CHO) will be served. At 16:45, the participant will be discharged and will be asked to eat a standardized dinner at home (60g CHO for females and 80g CHO for males).
1545295|NCT02631252|Drug|Hydroxychloroquine|Doses ranging from 600-1400mg daily in divided twice daily doses and administered orally.
1545296|NCT02631252|Drug|Mitoxantrone|Dose: 10mg/m2 IVPB in 50ml NS
1545297|NCT02631252|Drug|Etoposide|Dose: 100 mg/m2 administered intravenously in 500 ml of 0.9% sodium chloride
1545298|NCT02631239|Drug|Methotrexate|1g/m2/d IV *1d
1545299|NCT02631239|Drug|Etoposide|200mg/d PO *3d
1545300|NCT02631239|Drug|Dexamethasone|40mg/d PO *3d
1545301|NCT02631239|Drug|Pegaspargase|2500IU/m2/d IM *1d
1545302|NCT02631239|Radiation|Radiotherapy|50-56Gy
1545303|NCT02631200|Behavioral|Advance care plan|Participants will be offered the opportunity to complete an ACP by a nurse trained as an ACP facilitator, who will discuss the process with them using standard materials. At least 48 hours later, they will complete an ACP document with the help of the ACP facilitator, working together with trained expert patients who will provide peer support at the time of ACP completion and subsequently by telephone, assisted where necessary by the ACP facilitator.
1545304|NCT02631187|Device|Bielefeld balloon|Balloon Eustachian tuboplasty = dilatation of the cartilaginous Eustachian tube with a balloon catheter device performed with endoscopic control under general anaesthetic
1545305|NCT02631174|Drug|Antithrombin III|We are comparing neonates and infants on ECMP or CPB receiving ATIII, the dose of which is calculated to account for circuit volume, and compared with those not accounting for circuit volume
1545306|NCT02631161|Other|Equia Forte|Restoration of cavities with a Glasshybrid material (Equia Forte)
1545307|NCT02631161|Other|Filtek Supreme XT/Clearfil SE Bond|Restoration of cavities with a composite resin based material after placing an adhesive
1545308|NCT02631148|Drug|Melatonin|2mg controlled release melatonin tablet
1545309|NCT02631148|Drug|Placebo|placebo tablet identical to circadin
1545314|NCT02631122|Procedure|Supraclavicular vs Retroclavicular Nerve Block|An ultrasound guided supraclavicular or retroclavicular nerve block with 30 ml of 0.5% mepivicaine will be performed on patients scheduled for lower arm surgery
1545315|NCT02631109|Drug|Pegaspargase|2000U/m2 day5
1545316|NCT02631109|Drug|doxorubicin|25mg/m2 day1
1545317|NCT02631109|Drug|etoposide|100 mg/m2 was administered once on the first day of every week
1545318|NCT02631109|Drug|methylprednisolone|15 mg/kg days 1 to 3, 0.75 mg/kg days 4 to 7
1545319|NCT02631096|Drug|ARB-001467|An IV infusion of ARB-001467 once a month for three months.
1545320|NCT02631096|Other|Placebo|An IV infusion of placebo once a month for three months.
1545321|NCT02631083|Other|Breakfast, lunch, snack and dinner|These meals (cereal, rice and bread meals) will be tested in subjects for their glycaemic response (CGMS) and substrate utilization (calorimeter)
1545322|NCT02631070|Drug|Luspatercept|
1545323|NCT02631070|Other|Placebo|
1545363|NCT02630797|Dietary Supplement|Blueberry Medium|Food products will be provided daily for 50 days which contain dried blueberry powder equivalent to a total of 1.5 cups fresh blueberries
1545328|NCT02631031|Drug|Valsartan|single oral dose of 160 mg valsartan under fasting conditions
1545329|NCT02631018|Behavioral|Standard Weight Loss Intervention|18 session, group-based, 6-month, standard behavioral weight loss intervention
1545330|NCT02631018|Behavioral|Physical Activity Enhanced Weight Loss Intervention|18 session, group-based, 6-month, physical activity enhanced behavioral weight loss intervention
1545331|NCT02631005|Other|"Walk With Ease"|Six-week walking program
1545333|NCT02630979|Behavioral|Measuring satisfaction, knowledge and bias|Questionnaire based assessment.
1545338|NCT02630927|Drug|AG-519|AG519 will be tested.
1545339|NCT02630927|Drug|Placebo|Placebo will be tested.
1545340|NCT02630914|Device|The AtriCure Synergy Ablation System|The AtriCure Synergy Ablation System will be used on all patients for AF ablation.
1545341|NCT02630901|Drug|PRX003|
1545342|NCT02630901|Other|Placebo|
1545343|NCT02630888|Drug|Memantine|Memantine association in the treatment of young patients with Bipolar I Disorder, partial responders or non-responders to the combination of (quetiapine + lithium) or (quetiapine + aripiprazole) from the ARIQUELI study.
1545344|NCT02630888|Drug|Placebo|Patients randomized to this group will receive a unit dosage identical to that contains 15 mg of memantine during the first week (V0); all have the dose of the placebo (similar to memantine) increased on the second week (V1) in two divided doses of a unit dosage identical to that contains 15 mg of memantine
1545345|NCT02630875|Drug|A4250|A4250
1545346|NCT02630862|Drug|Aspirin|Aspirin is a standard and guidelines supported therapy for patients undergoing carotid endoarterectomy as secondary prevention measure of cardiovascular risk
1545347|NCT02630862|Drug|aspirin plus dipyridamole|the combination of aspirin plus dipyridamole is approved to lower the risk of stroke in people who have had a transient ischemic attack or stroke
1545348|NCT02630849|Procedure|intercostal muscle flap and pericostal no-compression suture|intercostal muscle flap and pericostal no-compression suture of the intercostal space
1545349|NCT02630849|Procedure|Standard suture technique of the intercostal space|Standard suture technique of the intercostal space associated with an intrapleural intercostal nerve block
1545350|NCT02630836|Drug|XCEL-MT-OSTEO-BETA|XCEL-MT-OSTEO-BETA followed by endomedullary nailing
1545351|NCT02630836|Procedure|Surgical treatment|Isolated endomedullary nailing
1545352|NCT02630823|Drug|MK-3475|
1545353|NCT02630823|Procedure|Surgical resection (standard of care)|
1545354|NCT02630823|Drug|Paclitaxel (standard of care)|
1545355|NCT02630823|Drug|Carboplatin (standard of care)|
1545356|NCT02630823|Radiation|Radiation (standard of care)|
1545357|NCT02630823|Procedure|Endometrial biopsy|
1545358|NCT02630823|Procedure|Peripheral blood draw|
1545359|NCT02630810|Other|Early oral hydration|starting oral hydration 1 hour following Cesarean Section using 100 ml clear water
1545360|NCT02630810|Other|Delayed oral hydration|starting oral hydration 6 hours following Cesarean Section using 100 ml clear water
1545361|NCT02630797|Dietary Supplement|Blueberry Baseline|Before the beginning of the study eligible participants will receive a radioactive tracer, Ca-41, by iv infusion. 150 days will be required for equilibration in the body i.e. elimination of the tracer from soft tissue and deposition in the bone. After equilibration, a baseline phase of 50 days will occur during which no blueberry products will be consumed in addition to usual dietary intake
1545362|NCT02630797|Dietary Supplement|Blueberry low|Food products will be provided daily for 50 days which contain dried blueberry powder equivalent to a total of 0.75 cups fresh blueberries
1545435|NCT02630329|Procedure|Laparoscopic adnexectomy|Surgical removal of one or both adnexa by transabdominal laparoscopy
1996155|NCT02552108|Behavioral|Behavioural experiments for intolerance of uncertainty (BE-IU)|
1996156|NCT02551822|Device|sacral neuromodulator|The Implanted Pulse Generator will be set via randomization to continuous vs cycling stimulation.
1996157|NCT02551718|Other|Chemosensitivity Assay|Lab test in which leukemia cells obtained from blood or bone marrow are tested for sensitivity to 115 drugs individually and in certain combinations
1996158|NCT02551718|Other|Cytology Specimen Collection Procedure|Undergo blood or bone marrow collection
1996159|NCT02551718|Genetic|Gene Expression Analysis|Analysis of leukemia cell genes to identify possible drug targets
1996160|NCT02551718|Genetic|Genetic Variation Analysis|Analysis of leukemia cell genes to identify possible drug targets
1996161|NCT02551718|Drug|In Vitro Sensitivity-Directed Chemotherapy|"Receive personalized chemotherapy with one or more of the following drugs:
Afatinib Arsenic trioxide Axitinib Azacitidine Bexarotene Bortezomib Bosutinib Busulfan Cabazitaxel Cabozantinib Carfilzomib Ceritinib Cladribine Clofarabine Crizotinib Cytarabine HCl Dabrafenib Dasatinib Daunorubicin HCl Decitabine Erlotinib Etoposide Everolimus Fludarabine Gefitinib Gemcitabine HCl Hydroxyurea Imatinib Irinotecan Lapatinib Lomustine Melphalan Mercaptopurine Methotrexate Mitoxantrone Nelarabine Nilotinib Paclitaxel Pazopanib Pentostatin Ponatinib Pralatrexate Rapamycin Regorafenib Romidepsin Ruxolitinib Sorafenib Sunitinib Temsirolimus Thioguanine Topotecan HCl Trametinib Tretinoin"
1996162|NCT02551289|Other|Gluten free diet|Patients will follow a gluten free diet
1545364|NCT02630797|Dietary Supplement|Blueberry High|Food products will be provided daily for 50 days which contain dried blueberry powder equivalent to a total of 3 cups blueberries
1545365|NCT02630784|Procedure|Non-Invasive Ventilation with Homecare ventilator|
1545366|NCT02630784|Procedure|Non-Invasive Ventilation with ICU ventilator|
1545367|NCT02630771|Procedure|Pressure pain threshold|Pressure algometry over thenar eminence, bilateral masseter muscles measured at baseline and during conditioned pain modulation
1545368|NCT02630758|Behavioral|Mindfulness-based Yoga|See study arm description.
1545369|NCT02630758|Behavioral|Walking Control Condition|See study arm description.
1545370|NCT02630745|Procedure|Immediate periodontal surgery|Treatment involves immediate surgical periodontal therapy in form of open flap debridement after non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in concurrent endodontic periodontal lesions with communication .
1545371|NCT02630745|Procedure|Delayed periodontal surgery|Treatment involves surgical periodontal therapy after 3 months of non surgical endodontic treatment and obturation with gutta-percha and zinc oxide eugenol (ZOE) sealer. in the form of open flap debridement in concurrent endodontic periodontal lesions with communication .
1545372|NCT02630732|Behavioral|Brain school|2 sessions of education provided by a therapist. The first session one day before surgery, the other two days after surgery. Education contains physiology of the central nerve system and the pain system. Information about acute pain, chronic pain and central sensitisation.
1545373|NCT02630732|Behavioral|Back school|Two education sessions ( one day before surgery and two days after surgery) with information about the biomechanics of the lumbar spine, physiology of the spine and ergonomics.
1545376|NCT02630706|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg oral tablet taken once daily
1545377|NCT02630706|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg (5-mg and 10-mg tables) oral taken once daily
1545378|NCT02630706|Drug|Placebo matching ertugliflozin|Placebo matching ertugliflozin (5-mg and/or 10-mg tablet) oral taken once daily
1545379|NCT02630706|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin <1500 at screening are up-titrated to >= 1500 daily.
1545380|NCT02630706|Drug|Glimepiride|Glycemic rescue therapy with open-label glimepiride will be initiated in participants with glucose values exceeding protocol-specified values. Dosing and titration of open-label glimepiride rescue therapy will be at the Investigator's discretion.
1545381|NCT02630693|Drug|Palbociclib 100mg|100mg PO daily
1545382|NCT02630693|Drug|Palbociclib 125mg|125mg PO daily 3 weeks out of 4
1545383|NCT02630693|Drug|Fulvestrant or Tamoxifen or Aromatase Inhibitor|given at the standard doses/schedules
1545384|NCT02630680|Drug|Eziclen®/Izinova®|
1545385|NCT02630667|Other|SLOW Carbohydrate|Treatment consists of a carbohydrate blend designed to elicit a slow postprandial glycemic response
1545386|NCT02630667|Other|MEDIUM Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a medium/moderate postprandial glycemic response
1545387|NCT02630667|Other|FAST Carbohydrate|Treatment consists of only one carbohydrate source designed to elicit a fast postprandial glycemic response
1545389|NCT02630641|Drug|Gonadotropin-releasing Hormone (GnRH) agonist therapy|This is a non-interventional study. Thus, investigators are free to choose GnRH agonist therapy product, and modalities of administration in accordance with local Summary of Product Characteristics.
1545390|NCT02630628|Drug|Tacrolimus|Dosage: start at 2mg twice a day, then taper as per protocol
1545391|NCT02630628|Drug|Mycophenolate mofetil|Dosage: start at 1g twice a day, then taper as per protocol
1545393|NCT02630602|Dietary Supplement|Functional goat cheese|60 g per day during 12 weeks
1545394|NCT02630602|Dietary Supplement|Control cheese|60 g per day during 12 weeks
1545395|NCT02630589|Device|Auditory brainstem implant|The ABI will be implanted by the neurosurgeon. The implant is fixed in a bed drilled in the parietal-temporal cortex, and the ABI electrode array is inserted into the lateral recess of the fourth ventricle and placed on the cochlear nucleus. Access to the cochlear nucleus will be made via retrosigmoid transcranial approach.
1545396|NCT02630576|Device|Neuromuscular stimulation|Single twitch and train-of-four stimulation protocols will be performed at the randomised side with growing current intensity
1545397|NCT02630563|Drug|Corticosteroids|Corticosteroids will be administered as per center practice. The choice of corticosteroid drug will also be based on center practice.
1545398|NCT02630563|Drug|Cyclosporine|Cyclosporine will be administered as per center practice.
1545399|NCT02630563|Drug|mycophenolate mofetil|Part 1: Mycophenolate mofetil will be administered as per center practice. Part 2: Mycophenolate mofetil will be administered as per dose determined in Part 1.
1545400|NCT02630550|Device|Cheetah NICOM|The Cheetah NICOM will be installed on all patients to evaluate the validity of its measurements.
1545401|NCT02630550|Device|Transesophageal echocardiography (TEE)|TEE will serve as gold standard measurements for the evaluation of the Cheetah NICOM.
1545402|NCT02630524|Behavioral|eHealth Behavioral Lifestyle Intervention Device: Telecoach|Participants will receive weekly/biweekly coaching sessions with a telecoach and use eHealth platform to log food and exercise, review daily goals, and find strategies for reaching goals.
1545403|NCT02630511|Drug|Mannitol|
1545404|NCT02630511|Drug|Methacholine|
1545405|NCT02630511|Drug|Placebo|
1545406|NCT02630511|Other|Rest|
1545407|NCT02630511|Other|Exercise|
1545408|NCT02630498|Procedure|Brachial plexus block|Patients receiving brachial plexus block for hand/arm surgery
1545468|NCT02630108|Drug|EADM|EADM is a chemotherapy drug used in transarterial chemoembolization (TACE).Dosage: EADM 30-60 mg per patient,depending on the situation of the patient.
1545409|NCT02630485|Behavioral|Graceful Lifestyle Changes|Participants will be educated in small groups of 8-10. A wellness booklet designed by physicians and researchers at Grace Fertility Centre will be provided.The target diet for our study is 45% carbohydrates and 55 grams of glycemic load. Participants will keep a 3-day food diary at baseline, 4, 8 and 12 weeks. Secondly, participants will be provided a pedometer and a goal to reach 10,000 steps a day. The third aspect of the program will be to decrease overall stress through mindfulness. Educational sessions will be held to teach the relaxation response and meditation techniques such as breathing and grounding exercises. Participants will be required to meditate for at least 20 minutes each day and record this.
1545410|NCT02630485|Dietary Supplement|Myo-inositol|Myo-inositol will be consumed in juice or water every morning (6 grams) for 12 weeks.
1545411|NCT02630485|Drug|Letrozole|Letrozole will be administered to patients. The initial dose will be 5 mg daily for five days and the dose can be increased by 2.5 mg to a total daily dose of 7.5 mg if necessary depending on ovulatory response, as in clinical practice. This treatment regimen will continue for three cycles (approximately the same period of time as the treatment group) or until pregnancy is achieved.
1545418|NCT02630446|Other|in-home respite care program|During the respite care period, lasting at least five days, a trained or experienced care worker for persons with dementia takes over all caregiving tasks while the informal caregiver is absent. The care worker thus temporary moves into the house of the person with dementia. The care worker also writes down his/her observations in a diary as well as daily experiences and strategies on how to manage the difficult behaviors the caregivers listed before. So additionally to the provision of respite, this program also includes caregiver support and psycho-education. This support enables the caregiver to validate theirs perceptions, to learn how to deal with difficult behaviors and to feel understood by somebody.
1545419|NCT02630433|Procedure|Index cholecystectomy|Cholecystectomy performed within 48 hours after inclusion, before discharge after admission for acute biliary pancreatitis.
1545420|NCT02630433|Procedure|Scheduled cholecystectomy|Cholecystectomy performed as a scheduled procedure 6 weeks after the first admission.
1545422|NCT02630407|Biological|viscosupplementation|A single 3 ml hyaluronic acid (HA) injection (viscosupplementation) performed the day after ACL reconstruction, after drainage removal
1545423|NCT02630407|Other|Placebo group|A single 3 ml saline injection performed the day after ACL reconstruction, after drainage removal
1545424|NCT02630394|Drug|Azithromycin|
1545426|NCT02630368|Drug|Cyclophosphamide and JX-594 dose escalation|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as designated by assigned dose-level, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
1545427|NCT02630368|Drug|Cyclophosphamide and JX-594|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off. JX-594 will be administered, as the dose recommended in the experimental phase I dose escalating study, intraveinously, on Days 8 and 22 of cycle 1, and on days 8 of each subsequent cycles. One cycle consits of 28 days.
1545428|NCT02630368|Drug|Cyclophosphamide|Metronomic cyclophosphamide will be administered orally, 50 mg twice daily, one week on/one week off.
1545429|NCT02630355|Other|Remote Ischaemic Preconditioning|Inflation of blood pressure cuff in lower limb
1545430|NCT02630342|Behavioral|Mock MRI scanner|Using a mock scanner for preparation for MRI
1545431|NCT02630342|Behavioral|Preparation materials|links to online videos about MRI, audio files with scanner noises, and a childrens book about MRI scan.
1545432|NCT02630342|Behavioral|Child Life Specialist preparation|Child Life Therapist will coordinate the prepartion of the child
1545433|NCT02630342|Behavioral|Review Preparation Materials|Review of preparation materials at the hospital with member of research team
1545434|NCT02630329|Procedure|vNOTES adnexectomy|Surgical removal of one or both adnexa by a natural orifice transluminal endoscopic surgical technique using a colpotomy (transvaginal incision)
1545438|NCT02630303|Device|LED-RL Phototherapy|"The maximum recommended starting dose (MSRD) (160 J/cm2) will be administered to Group 1's LED-RL phototherapy randomized subjects and the LED-RL dose will be escalated in subsequent groups using the classical method for dose escalation as described by Spilker: starting with dose (X) increased by an equal amount (in this instance: X=160 J/cm2, 2X=320 J/cm2, 3X=480 J/cm2, 4X=640 J/cm2). Common expected procedure side effects are mild and temporary, including warmth, redness (erythema) and swelling (edema). The maximally tolerated dose (MTD) is defined as the dose level below the dose producing unacceptable but reversible toxicity and is considered the upper limit of subject tolerance.
All subjects will receive total of nine LED-RL phototherapy, three times per week for three consecutive weeks."
1545439|NCT02630303|Device|Mock Therapy|"Mock therapy will be administered to mock therapy randomized subjects using the mock therapy unit and only generates warmth and does not emit LED-RL.
All subjects will receive total of nine mock therapy procedures, three times per week for three consecutive weeks."
1545440|NCT02630290|Drug|Ropivacaine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine
1545441|NCT02630290|Drug|Ropivacaine + Dexmedetomidine|Ultrasound-guided supraclavicular brachial plexus block with 0.5% ropivacaine plus low-dose (30 microg) dexmedetomidine
1545442|NCT02630277|Drug|Aflibercept|Intravitreal Aflibercept Injection 2.0 mg
1545443|NCT02630264|Drug|Endostatins|"Specification: 1mL/division, 1×1012 VP/1.0mL
E10A preparation:
Thaw frozen E10A stored at -20°C vials at room temperature until E10A is liquid.
Swirl gently. Do NOT shake.
Method of administration
E10A was diluted with 0.9% sodium chloride to appropriate dose according to the longest diameter of the target lesion.
After local anesthesia, we penetrated the syringe under normal skin subcutaneously 5 mm into the tumor or vertically into the lymph node under direct visualization and withdrew it to confirm the absence of blood.
Applied local compression for 10 minutes and pasted a sterile sticker on the injection site to avoid bleeding."
1545444|NCT02630264|Drug|Paclitaxel injection|"Specification:
30mg/5mL,
Usage:
160mg/m2 on day 3, according to instruction."
1545445|NCT02630264|Drug|Cisplatin injection|"Specification:
20mg
Usage:
Cisplatin 25mg/ m2 on day 3, 4, and 5,according to instruction."
1545446|NCT02630251|Drug|GSK2820151|GSK2820151 is provided as capsules containing 1 mg, 5 mg, 10 mg, 50 mg, or 100 mg of GSK2820151 as free base equivalent to be administered orally. The dosing regimen is as follows: Week 1 - once daily on days 1, 3, 4, and 5; Week 2 - once daily on days 1, 2, 3, 4, 5; and Weeks 3 and beyond - once daily continuously.
1545447|NCT02630238|Dietary Supplement|Branched-Chain Amino Acid Supplementation|All participants will partake in the same diet & exercise regime but this group will also be placed on a BCAA intake level of 0.342g/kg of BCAA per day
1545448|NCT02630238|Other|Placebo|All participants will partake in the same diet & exercise regime but this group will receive an isocaloric placebo in form of carbohydrate solution
1545449|NCT02630238|Other|Exercise|Exercise will take place in a class based, circuit training setting run by a certified personal trainer composed of both aerobic and lifting exercises
1545450|NCT02630238|Other|Diet|Each participants will be placed on a daily energy deficit of 500 calories for the 8 week study period.
1545451|NCT02630225|Behavioral|Critical Time Intervention|"The Critical Time Intervention approach strengthens an individual's long-term ties to services, family and friends as well as provides emotional and practical support to individuals during the critical time of transition back to the community. CTI contains three phases:
Phase 1 - The Support Specialist gets to know the individual, assesses the individual's need and implements a transition plan intended to link the individual to services and supports in the community.
Phase 2 -- The Support Specialist monitors and adjusts the systems of support that were developed in Phase 1.
Phase 3 -- The Support Specialist helps the individual develop and implement a plan to achieve long-term goals and finalizes the transfer of responsibilities to caregivers and community providers."
1545452|NCT02630225|Other|Treatment as Usual|"Services provided by HMC physicians and staff that are part of standard care for patients with firearm-related injuries. This care could include:
All necessary medical care and scheduled follow-ups with subspecialty services
Evaluation by social work with referral to appropriate community services
Screening for alcohol use
Discharge planning services
Financial counseling"
1545453|NCT02630225|Behavioral|Motivational Interviewing|A brief intervention to elicit the goals and needs of participants. As needed, this will included referrals to community resources.
1545454|NCT02630225|Other|Multi-Agency Attention|Intervention cases will receive attention from a multidisciplinary team of professionals. This team will help the study Support Specialist identify service recommendations and provide case management guidance.
1545455|NCT02630199|Drug|AZD6738|The starting dose of 40 mg AZD6738 OD will be escalated to reach a maximum tolerated dose in patients with advanced solid malignancies, as defined by dose-limiting toxicity.
1545456|NCT02630199|Drug|Paclitaxel|Paclitaxel 80mg/m2 on days 1,8, and 15 every 4 weeks
1545457|NCT02630186|Drug|Rociletinib|A novel, potent, covalent (irreversible) small molecule, tyrosine kinase inhibitor (TKI) administered orally (PO) to patients with EGFRm NSCLC.
1545458|NCT02630186|Drug|MPDL3280A|A human IgG1 monoclonal antibody administered intravenously (IV)
1545459|NCT02630173|Procedure|Scaling and root planing|Scaling and root planing was done in both the groups
1545460|NCT02630173|Other|Endodontic treatment|In non vital teethRoot canal treatment was completed in two visits. 3% Naocle was used as irritant and calcium hydroxide was used as intracanal medicament .Obturation was done with gutta percha.
1545461|NCT02630160|Drug|Bupivacaine hydrochloride|Intraarticular infusion with bupivacaine
1545462|NCT02630160|Other|Physiological Saline|Intraarticular infusion physiological serum
1545463|NCT02630147|Other|Vanilla scent|"A 12-hour continuous recording for monitoring hemoglobin oxygen saturation, electrocardiogram and respiratory movements will be performed while the infant is exposed to vanilla scent (from vanilla solution on the infant's pyjamas).
In addition, a 3-hour polysomnography will be done in a sub-sample on the morning following the night recording with vanilla solution."
1545464|NCT02630134|Other|These patients receive the Baeta device and take it home|
1545465|NCT02630121|Drug|Oxymetazoline Hydrochloride|Proportion of the subjects with 50% reduction in AHI.
1545466|NCT02630121|Drug|Placebo|Proportion of the subjects with 50% reduction in AHI.
1545467|NCT02630108|Procedure|Thermal Ablation|Thermal ablation in this trial includes radiofrequency ablation and microwave ablation, one of them can be chosen to be performed.
1545469|NCT02630108|Drug|Ultra-fluid lipiodol|Ultra-fluid lipiodol is a kind of embolization material used in TACE. Standard: 38% ultra-fluid lipiodol .
1545470|NCT02630108|Other|Gelatin sponge articles|Gelatin sponge articles embolization material used in TACE. Standard: 350-560 um in diameter.
1545471|NCT02630095|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3, and during the of perioperative period of Endoscopic treatment changing to use Nadroparin Calcium 4100IU／d，subcutaneous.
1545472|NCT02630095|Device|Doppler ultrasound and CT|all patient will take Doppler ultrasound examination every 3 months ；Abdominal CT will be done every 6 months。
1545473|NCT02630082|Procedure|Circumcision|
1545474|NCT02630082|Procedure|Flexible sigmoidoscopy|
1545478|NCT02630043|Drug|Tolcapone|Tolcapone is an oral agent that will be administered every day of each 21-day cycle during Cycle 1 and in combination with oxaliplatin during cycles 2-5 given IV on Day 1 of each 21-day cycle.
1545479|NCT02630043|Drug|Oxaliplatin|Oxaliplatin will be given starting in Cycle 2 at 100 mg/m2 IV on Day 1 of each 21-day cycle
1545481|NCT02630017|Drug|methylphenidate|double-blind, counter-balanced administration
1545482|NCT02630017|Drug|Placebo|double-blind, counter-balanced administration
1545483|NCT02630004|Drug|Melatonin oral gel 3%|
1545484|NCT02630004|Drug|Placebo oral gel|
1545485|NCT02629991|Drug|Intranasal Oxytocin (IN-OXT)|Each subject will receive a dose of 16 IU BID (32 IU a day), and will be instructed to inhale 2 puffs per nostril (4 IU each) twice a day.
1545486|NCT02629991|Drug|Matched Placebo|Each subject will receive a dose of 16 IU BID (32 IU a day), and will be instructed to inhale 2 puffs per nostril (4 IU each) twice a day.
1545487|NCT02629978|Procedure|CT-guided percutaneous radiofrequency ablation|Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.
1545488|NCT02629965|Drug|tiotropium|fixed dose combination
1545489|NCT02629965|Drug|olodaterol|fixed dose combination
1545490|NCT02629965|Drug|tiotropium|
1545491|NCT02629952|Other|Blueberry Tea|Blueberry Tea
1545492|NCT02629939|Behavioral|course for learning CPR|
1545493|NCT02629926|Other|GH Replacement (NutropinAq®)|GH Replacement continued.
1545494|NCT02629926|Other|No additional treatment|GH Replacement not continued.
1545495|NCT02629913|Device|mementor somnium|
1545496|NCT02629913|Other|wait list|delayed access to mementor somnium
1545497|NCT02629900|Behavioral|Time restricted feeding|Participants will consume their daily calories only between 12:00 and 20:00 for 4 weeks
1545498|NCT02629887|Device|Non-inflatable supraglottic airway|at delivery if resuscitation is required infant randomized to NI-SGA or face mask as the interface for positive pressure ventilation.
1545499|NCT02629887|Device|Face Mask|at delivery - standard airway management per Neonatal Resuscitation Program utilizing face mask.
1545500|NCT02629887|Device|T-Piece Resuscitator|T-Piece Resuscitator for providing postivie pressure ventilation via face mask or non-inflatable supraglottic airway
1545501|NCT02629874|Drug|EA-230|at t=0 30, 90 or 180 mg/kg EA-230 will be administered intravenously over 2 hours.
1545502|NCT02629874|Drug|Endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
1545503|NCT02629874|Drug|Placebo|
1545504|NCT02629861|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
1545505|NCT02629861|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
1545506|NCT02629861|Drug|Placebo|Matching Placebo
1545507|NCT02629848|Drug|Motesanib|Motesanib (AMG 706) 5 x 25 mg tablets
1545508|NCT02629848|Drug|Placebo|Motesanib placebo-matching tablets
1545509|NCT02629848|Drug|Paclitaxel|Paclitaxel IV
1545510|NCT02629848|Drug|Carboplatin|Carboplatin IV
1545511|NCT02629835|Other|intravenous 8 mg dexamethasone and perineural 0.8 ml of saline solution|
1545512|NCT02629835|Other|intravenous 0,8 ml of saline solution and perineural 8 mg of dexamethasone|
1545514|NCT02629809|Drug|Obinutuzumab|100 mg on Day 1, 900 mg on Day 2, 1000 mg on Day 8, and 15 of Cycle 1, and 1000 mg on Day 1 of Cycles 2-3. Obinutuzumab given by vein.
1545515|NCT02629809|Drug|Fludarabine|25 mg by vein on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2-3.
1545516|NCT02629809|Drug|Cyclophosphamide|250 mg by vein Days 2-4 of Cycle 1, and Days 1-3 of Cycles 2-3.
1545517|NCT02629809|Drug|Ibrutinib|420 mg by mouth every day during Cycles 1-3.
1545518|NCT02629809|Drug|Allopurinol|300 mg by mouth daily on Days 1-7 of Cycle 1.
1545519|NCT02629809|Drug|Valacyclovir|500 mg by mouth every day while on Ibrutinib and 3 months after last dose.
1545520|NCT02629796|Other|CIDP treated (IVIG)|usual treatment with intravenous immunoglobulin
1545521|NCT02629783|Other|Psychomotor therapy|1 treatment of approximately 45 minutes the first 5 weeks after randomization. The treatment will focus on teaching the patients about body awareness and handling of there shoulder problems in daily living.
1545522|NCT02629783|Other|Physiotherapy|Patients are, in secondary care setting, given 3-5 basic physiotherapy exercises for there shoulder pain, targeting rotator cuff muscles and scapula thoracic muscles. Furthermore they are given advice on seeking further physiotherapy guidance in private setting.
1546361|NCT02624219|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
1545523|NCT02629783|Drug|corticosteroid injection|At baseline, patients with signs of inflammation in the subacromial bursa, can receive a ultrasound guided corticosteroid injection in the bursa
1545524|NCT02629770|Drug|usual antibiotic treatment|pharmacological studies in patients treated with usual antibiotics, for different types of joint and bone infections
1545525|NCT02629757|Drug|β-elemene|β-elemene 600mg/d,ivdrip,d1-14,every 28 days for 1 cycle, totally 6 cycles
1545526|NCT02629744|Drug|Etrolizumab|Single SC dose of etrolizumab at 105 milligrams (mg) on Day 1.
1545527|NCT02629744|Device|Prefilled Auto-injector (Rotaject)|Participants self-administered etrolizumabSC injection using a prefilled auto-injector.
1545528|NCT02629731|Device|custom orthoses with varying degrees of hindfoot posting|The base orthotic design will be altered for one foot (most symptomatic in the case of patients or randomly chosen for controls) to give variations from 5-degree lateral hindfoot posting to 10-degree medial in 2.5-degree increments.
1545529|NCT02629718|Drug|NACT (Paclitaxel + Cisplatin or carboplatin)|Paclitaxel 150mg/m2 over 3 hours + Cisplatin 70mg/m2 or carboplatin AUC = 6, repeat per 21 days, 3 cycles.
1545530|NCT02629718|Procedure|radical surgery|Radical hysterectomy (Piver Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
1545531|NCT02629705|Dietary Supplement|Carrageenan|Carrageenan 250 mg bid supplemented to a standard food
1545532|NCT02629705|Dietary Supplement|Placebo|Placebo (Mannitol/Aerosil) bid supplemented to a standard food
1545533|NCT02629692|Drug|K0706|Oral administration
1545534|NCT02629692|Drug|Placebo|Oral administration
1545535|NCT02629679|Behavioral|Regular scholastic system and organized sports|This group will consist of children involved in regular school system who at the same time participate in organized sport in sport-clubs
1545536|NCT02629679|Behavioral|Regular scholastic system|The group will consist of children who are regularly in school, but not being involved in organized sport activities
1545537|NCT02629666|Behavioral|ERS and/or Self-management Strategies|
1545538|NCT02629653|Device|endovascular cooling (Zoll system)|The Zoll IVTM is an endovascular cooling system that consists of a control module (either CoolGard 3000 or Thermogard XP), a CoolGard start-up kit, and an ICY catheter (either IC-3585 AE or IC-3585).
1545539|NCT02629640|Other|Medical history questionnaire|Epidemiological review of past medical/dental history; residential history; occupational history; family history of neurodegenerative disease.
1545540|NCT02629640|Other|Clinical assessment and review|History of current illness; neurological examination including general appearance, full cognitive assessment and physical examination; MRI research brain scan.
1545541|NCT02629640|Other|Participant follow-up|Hospital patient management system; regular telephone contact with patient/representative.
1545542|NCT02629640|Other|Blood sample|Codon-129 genotyping; storage for future research.
1545543|NCT02629640|Other|Post mortem examination|Brain tissue donation to the Edinburgh Brain and Tissue Bank for research,including investigations for evidence of prion disease.
1545544|NCT02629627|Drug|Conjugated linoleic acid/Leucine + metformin|Conjugated linoleic acid/Leucine capsules, 825mg time daily with the first bite of eat meal + Metformin in a dosis of 500mg per day (with the first bite of the second meal) during 8 weeks.
1545545|NCT02629627|Drug|Metformin + Pacebo of ACL/Leucine|ACL/Leucine in a dosis of 2,475mg per 24hrs (1,650mg or 2 capsules with the first meal and 825 mg or 1 capsule with the second meal) plus homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
1545546|NCT02629627|Drug|Placebo of ACL/Leucine plus Placebo of Metformin|Homologate placebo of ACL/Leucine (linseed oil capsules) in a dosis of 3600 mg each 24 hrs (2 capsules of 2400 mg with the first meal and 1200 mg or 1 capsule with the second meal) plus homologate placebo of metformin (calcinated magnesia capsules) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks.
1545547|NCT02629627|Drug|ACL/Leucine + Placebo of Metformin|ACL/Leucine in a dosis of 2,475mg per 24hrs (1,650mg or 2 capsules with the first meal and 825 mg or 1 capsule with the second meal) plus homologate placebo of metformin (calcinated magnesia) in a dosis of 500 mg per day (with the first bite of the second meal) during 8 weeks
1545548|NCT02629601|Behavioral|Active Rewards|Vitality standard active rewards wellness program for physical activity promotion
1545549|NCT02629601|Behavioral|Lottery 1|Participants have 1 in 3 chance of winning 3 times the reward and 1 in 100 chance of winning 40 times the reward
1545550|NCT02629601|Behavioral|Lottery 2|Participants have 1 in 2 chance of winning 2 times the reward and 1 in 200 chance of winning 80 times the reward
1545551|NCT02629601|Behavioral|Broadcasting winners|Participants are told how many individuals won the lottery during that week.
1545552|NCT02629601|Behavioral|Active Rewards Doubled|Vitality standard active rewards wellness program for physical activity promotion with double the magnitude of incentives
1545554|NCT02629575|Device|stenting with the Coroflex ISAR sirolimus-eluting stent|coronary stenting
1545556|NCT02629549|Drug|OTL38|Infusion of OTL38 prior to surgery
1545557|NCT02629536|Drug|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet|N-acetyl cysteine 600 mg, VitE 250 IU, VitC 500 mg tablet
1545558|NCT02629523|Drug|Afatinib|Treatment efficacy of afatinib will be assessed in patients with lung cancer harboring EGFR mutations which were detected from circulating tumor DNA.
1545559|NCT02629510|Drug|Tachosil|
1545560|NCT02629497|Dietary Supplement|Primrose oil|T2DM patients and matched controls subjects will be given Primrose oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
1545561|NCT02629497|Dietary Supplement|Fish Oil|T2DM patients and matched controls subjects will be given Fish oil for 2 months, followed by 2-week washout. Blood will be drawn at the beginning, during, and following treatments and platelet function will be assessed.
1545562|NCT02629484|Other|Focused cardiac ultrasound|focused cardiac ultrasound is a goal-focused transthoracic echocardiography examination of the heart, aimed to improve the diagnostic accuracy of clinical assessment
1545563|NCT02629471|Behavioral|response time due to light flash pulses|light flash pulses effect on response time to random targets appearance
1545564|NCT02629458|Procedure|Treatment by Surgical resection|
1545565|NCT02629458|Procedure|Stereotactic Ablative Radiotherapy (SABR)|
1545566|NCT02629445|Device|Cardiac Resynchronisation Defibrillator|Defibrillation testing of cardiac defibrilator
1545567|NCT02629419|Drug|Amphotericin B|Lipid crystal nano-particle formulation of amphotericin B
1545568|NCT02629406|Other|Hypoxia|Intermittent hypoxia which consist of five hypoxic periods (13% O2 inspired fraction of oxygen) each lasting 6 min, with five normoxic intervals of same duration
1545569|NCT02629393|Drug|ALXN1101|
1545570|NCT02629380|Biological|hyaluronic acid|A single injection of 3 ml hyaluronic acid to be performed under arthroscopic view at the end of meniscectomy
1545571|NCT02629380|Procedure|meniscectomy alone|The patients randomized in this group will receive arthroscopic meniscectomy alone
1545572|NCT02629367|Drug|Vorapaxar|
1545573|NCT02629367|Drug|Asprin|
1545574|NCT02629367|Drug|Clopidogrel|
1545575|NCT02629354|Drug|Ibuprofen|
1545576|NCT02629354|Drug|Caffeine|
1545577|NCT02629354|Drug|Ibuprofen|
1545578|NCT02629341|Dietary Supplement|Functional yogurt powder|"Once daily during 24 weeks, 150g of yogurt powder enriched with:
Calcium (mg) 501 D3 Vitamin (Colecalciferol) (μg(UI)) 6(240) K Vitamin (μg) 80 C Vitamin (mg) 100 Zinc (mg) 10,39 Magnesium (mg) 250,5 L-Leucin (g) 1 Lactobacillus plantarum 3547 (ufc) 1x10e10"
1545579|NCT02629341|Dietary Supplement|Control yogurt powder|Once daily during 24 weeks, 150g of yogurt powder not enriched, isocaloric and with an equal macronutrient composition than the functional yogurt
1545580|NCT02629328|Device|CardioCel|Treatment with CardioCel implant
1545581|NCT02629315|Other|Carnoy's solution|
1545582|NCT02629315|Other|10% neutral buffered formaldehyde|
1545585|NCT02629289|Drug|HSP-130|
1545586|NCT02629289|Drug|US-approved Neulasta|
1545587|NCT02629289|Drug|EU-approved Neulasta|
1545588|NCT02629276|Other|neurodynamic testing|
1545589|NCT02629263|Dietary Supplement|Viscous Fiber|Meta- analysis of Randomized Controlled Trials
1545590|NCT02629250|Procedure|SV maximization|When SpO2 ≥92%, mean arterial pressure (MAP) 65-100 mmHg, HR <100 bpm, Hb >8mg/dL and temperature ≥36℃, the patients will receive a 250 ml Ringer's lactate solution in 5 min as a fluid challenge for stroke volume (SV) maximization. The fluid challenge will repeat until the SV failed to increase by a factor of 10%. A reassessment on the SV maximization will be taken every 30 minutes and to restart algorithm when increased SV >10% or blood loss >250ml. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
1545591|NCT02629250|Procedure|supernormal DO2|Goal directed fluid therapy is administrated as group SV maximization. Then DO2I will be assessed. If at this stage the DO2I can not be greater than 600 mL/m2 (supernormal oxygen delivery goal), then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia.
1545592|NCT02629237|Other|Multifaceted education|Subjects will be asked to watch a 5-10 min education film and participate in a 10-15 min counseling session with a trained doctor/nurse before glaucoma surgery,and at 1 week and 2 week after surgery.
1545593|NCT02629224|Drug|ASP8825|Oral
1545594|NCT02629211|Device|NaviAid™ AB|NaviAid™ AB Procedure
1545599|NCT02629146|Drug|Midazolam|
1545600|NCT02629146|Drug|Fentanyl|
1545601|NCT02629146|Drug|Isotonic saline|
1545602|NCT02629133|Behavioral|SHE Program|The SHE program will be specifically tailored, innovative and relevant to diverse, racial, and ethnic sheltered, battered women in a number of ways including the images and content used in the intervention. It will also be tailored to participants' alcohol or substance use status, and be designed to reach participants across levels of motivation for change. The content of SHE will be theory-driven, consistent with the motivational interviewing model of behavior, and consistent with the literature on effective interventions that address IPV and substance use.
1545607|NCT02629094|Drug|Inspra /Eplerenone|Eplerenone is provided as 25- or 50-mg tablets that are to be taken orally. Eplerenone can be taken with or without food. Subjects will be dosed at 25 mg daily for 1 week, and then 50 mg daily for 23 weeks. The total duration of dosing for each subject is 24 weeks.
1545608|NCT02629081|Other|Controls & Cases|All interventions are standard of care and both controls and cases will be treated the same. IEE results from controls and cases will be compared.
1545699|NCT02628444|Biological|NaCl + CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0 (placebo), 6 and 12 months (CYD), respectively
1545610|NCT02629055|Other|Respiratory EMG|Titration of non-invasive ventilation on surface respiratory muscle activity
1545611|NCT02629042|Procedure|Partial endodontic treatment under local and/or locoregional anesthesia|The reference management consists in local and locoregional anesthesia of the molar and partial endodontic treatment. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
1545612|NCT02629042|Drug|prednisolone|The evaluated intervention consists in per-os administration of prednisolone (1 mg / kg) during the emergency visit followed-up by one morning dose by day during three days. At the end of the emergency visit, all the patients, whatever their randomization group, will be given two types of antalgics and will be recommended to take them only if they have pain. Seventy-two hours after, all the patients, whatever their randomization will have endodontic treatment under local and locoregional anesthesia.
1545613|NCT02629029|Procedure|Pre-op CTA with IV contrast|Preoperative mapping of perforators by computed tomography angiography (CTA) could prove valuable in head and neck free flap transfer and shorten the operation time significantly. This modality could provide useful information for H&N cancer reconstruction in difficult cases, especially in patients with large or through-and-through defects that might need multiple perforators in flap design. In addition, near-infrared (NIR) fluorescence imaging using indocyanine green (ICG) angiography can provide robust, intraoperative, objective data to optimize the free flap skin paddle design while potentially minimizing patient morbidity.
1545614|NCT02629029|Device|Computed tomography angiography (CTA)|
1545615|NCT02629016|Other|Mindfulness|
1545616|NCT02629016|Other|Wellness|
1545617|NCT02629003|Drug|[11C]Cimbi-36|
1545618|NCT02629003|Drug|[11C]Cimbi-36-5|
1545619|NCT02628990|Other|1.6 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols
1545620|NCT02628990|Other|2 g plant stanols|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols
1545621|NCT02628990|Other|1.6 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 1.6 g plant stanols and camelina oil
1545622|NCT02628990|Other|2 g plant stanols and camelina oil|Lipid-lowering effect of Yoghurt Drink with 2 g plant stanols and camelina oil
1545623|NCT02628990|Other|Placebo|Lipid-lowering effect of Placebo Yoghurt Drink
1545624|NCT02628977|Behavioral|Peer Based Sleep Health Education and Social Support|Participants randomly assigned to the intervention arm will receive Obstructive Sleep Apnea education and social support from a trained Peer Educator.
1545625|NCT02628977|Behavioral|Attention Control Group|Participants assigned to this arm of the study will receive standard sleep literature, providing information about OSA and access to available sleep services.
1545626|NCT02628964|Device|e-cigarettes|Participants and research assistants will be blind to the allocation of nicotine or placebo e-cigarettes as there are no difference in appearance or odor of the mist emitted from the e-cigarettes with and without nicotine containing cartridges.
1545627|NCT02628951|Drug|Ramucirumab|Ramucirumab injection for intravenous (I.V.) use, supplied in single-use 500-mg/50-mL vials containing 10 mg/mL of product in histidine buffer, administered as an I.V. infusion after dilution at 8 mg/kg every 2 weeks in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
1545628|NCT02628951|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m2 on Days 1, 8 and 15 of a 28-day cycle in the absence of disease progression, toxicity requiring cessation, or withdrawal for any other reason.
1545629|NCT02628938|Other|Miswak extract mouth wash|50% Miswak extract mouth wash (5ml) twice a day for 7 days
1545630|NCT02628938|Other|Miswak stick|Miswak stick twice a day for 7 days
1545631|NCT02628938|Other|Chlorohexidine gluconate|5 ml of 0.2% Chlorohexidine gluconate mouth wash Oraxine ® twice a day for 7 days
1545632|NCT02628925|Device|Nu-DESC DK|Nu-DESC DK as a screening tool is presented to the medical staff and they have to evaluate the tool an evaluate the screening tool on a evaluation form and rates on a 6 step Likert scale.
1545633|NCT02628912|Other|blood draw|
1545634|NCT02628912|Behavioral|study questionnaire|
1545635|NCT02628912|Other|cardiopulmonary exercise testing (CPET)|
1545636|NCT02628912|Other|DXA (dual-energy x-ray absorptiometry) scan|
1545637|NCT02628899|Device|Transfemoral TAVR|
1545638|NCT02628899|Device|SAVR|
1545639|NCT02628886|Biological|13-valent pneumococcal conjugate vaccine [Prevenar13®] plus tetanus toxoid|pregnant women will be given intramuscular PCV 13 vaccine between 28-34 weeks
1545640|NCT02628886|Biological|placebo 0.9% sodium chloride plus tetanus toxoid|pregnant women will be given intramuscular saline injection between 28-34 weeks
1545641|NCT02628886|Other|tetanus toxoid|new born babies will be given PCV13 vaccine at birth
1545642|NCT02628873|Device|HyCoSy|Saline infused sonogram in which air bubbles are delivered via the FemVue saline air device in order to evaluate the patency (openness) of the fallopian tubes
1545643|NCT02628860|Drug|Ferinject (Ferric Carboxymaltose)|"Ferinject® to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50 Kg .
Study drug may be administered as IV drip infusion or IV undiluted bolus injection."
1545644|NCT02628847|Drug|sildenafil citrate|
1545645|NCT02628847|Drug|Placebo|
1545697|NCT02628457|Procedure|arthroscopic rotator cuff repair|arthroscopic rotator cuff repair done in all patients to check whether, surgery itself changes the appearance of muscle atrophy in the supraspinatus in all patients irrespective of size of preoperative tendon retraction
1545698|NCT02628444|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months, respectively
1545646|NCT02628834|Other|Fascial mobilization|The patient will lie on prone position with knee extension and therapist put the patient's plantar surface to her femoral region. Achilles, tibialis posterior, perenous longus and brevis distal tendons, gastrocnemius proximal tendons, hamstring's distal tendons will be mobilized at first stage. The second stage of fascia mobilization included the deep fascial mobilization of posterior crural muscle trunks. After that, the skin also will be gently mobilized. During fascial mobilization, once the spastic muscles relaxation will appeared, the ankle will move to dorsiflexion gradually. FM will carry out for 15 minutes for each foot.
1545647|NCT02628834|Other|Stretching Exercise|Patients will receive also stretching exercises consisted of 30 s stretching and 10 s resting periods and will carry out for 15 minutes for each foot at second day after the first evaluation.
1545648|NCT02628821|Other|Preterm Infants treated with non-invasive ventilation.|
1545649|NCT02628795|Behavioral|PRT + FM|Supervised progressive resistance training + functional mobility training (PRT+FM) 3 days per week for 16 weeks post-surgery.
1545650|NCT02628795|Other|Usual Care|Post-surgical usual care activities including any prescribed physical therapy
1545651|NCT02628782|Device|InSeal's Vascular Closure Device|
1545652|NCT02628769|Drug|Solithromycin|
1545653|NCT02628769|Drug|Placebo|
1545654|NCT02628756|Procedure|Endometrial injury|Office hysteroscopy (Karl Storz, Tuttlingen, Germany)
1545655|NCT02628743|Drug|Olesoxime|Participants will receive homogeneous suspension of olesoxime.
1545656|NCT02628730|Device|PVI using ThermoCool® SmartTouch® Catheter|PVI using RFA, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), guided by Ablation Index.
1545657|NCT02628730|Device|RFA ablation data comparison|Ablation data from previous ablations, using ThermoCool® SmartTouch® Catheter (Biosense Webster Inc., CA, US), that members of this group had in the past, will be compared with those of the Active Comparator Group.
1545658|NCT02628704|Drug|Selinexor|The fixed dose of selinexor is 60 mg (three 20 mg tablets)
1545659|NCT02628704|Drug|Placebo (for selinexor)|sugar tablet manufactured to mimic selinexor tablet
1545660|NCT02628704|Drug|carfilzomib|Administered as an IV infusion on Days 1, 2, 8, 9, 15 and 16 of each 4-week cycle for Cycles 1-13 and then on Days 1, 2, 15, and 16 for Cycles ≥ 14.
1545661|NCT02628704|Drug|Dexamethasone|Fixed oral dose of 20 mg will be given twice weekly (Days 1, 2, 8, 9, 15, 16, 22 and 23) in each cycle.
1545662|NCT02628691|Other|Liver fibrosis progression|A history taking and physical examination focused on hepatic disease and blood sampling for basic hematologic and hepatic function parameters will be performed. Patients will also be referred every year for ultrasound and transient elastography measurements and sampling for some additional liver function tests and measurement of HCV-RNA viral load.
1545663|NCT02628678|Dietary Supplement|FOS|
1545664|NCT02628665|Drug|photosensitizer(photofrin)|photosensitizer(photofrin): 2mg/kg
1545665|NCT02628665|Device|630 nm laser irradiation (DIOMED)|630 nm laser irradiation (DIOMED): The diseased tissue with laser irradiation in 1200 seconds.
1545666|NCT02628652|Dietary Supplement|GOS|
1545667|NCT02628652|Dietary Supplement|GLOS|
1545668|NCT02628652|Dietary Supplement|FOS|
1545669|NCT02628639|Device|high-density electroencephalography|
1545670|NCT02628626|Drug|Colesevelam|Patients who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
1545671|NCT02628626|Drug|Clonidine|Patients who satisfy symptom criteria in Phase 2 will be randomized in a 1:1 ratio to receive either a combination of colesevelam (1.875 gm twice daily) and clonidine (0.1 mg oral twice daily) or an identical placebo for 4 weeks.
1545672|NCT02628626|Other|Placebo|Placebo will be identical in appearance to the active drug.
1545673|NCT02628613|Drug|Vinorelbine plus Epirubicin|Evaluate the efficiency and safety of Vinorelbine plus Epirubicin for neoadjuvant chemotherapy in locally advanced HER-2(-) breast cancer with TEKT4 variation
1545674|NCT02628613|Drug|Paclitaxel plus Carboplatin|standard neoadjuvant chemotherapy
1545675|NCT02628600|Drug|Liposomal Amikacin for Inhalation|
1545676|NCT02628587|Drug|Generic clopidogrel|"Comparison of different brands of clopidogrel:
*Clopidogrel (generic) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
1545677|NCT02628587|Drug|Patent clopidogrel|"Comparison of different brands of clopidogrel:
*Clopidogrel (Plavix) 300mg orally single dose on day 0. Later, clopidogrel 75mg orally single dose on days 1, 2 and 3."
1545678|NCT02628574|Drug|TRX518|comparison of different (ascending) doses of TRX518 given via IV fusion
1545679|NCT02628561|Device|Transcranial direct current stimulation|
1545680|NCT02628561|Behavioral|Constraint-Induced Movement Therapy|
1545681|NCT02628548|Behavioral|Cognitive training program|8 week cognitive training program
1545682|NCT02628535|Biological|MGD009|B7-H3 x CD3 DART protein
1545683|NCT02628522|Other|ADRCs therapy|Patients with chronic anal fissures will receive one treatment of local injections of fat enriched with adipose derived regenerative cells starting from December 2014.
1545684|NCT02628522|Device|Celution|Adipose derived regenerative cell isolation
1545685|NCT02628522|Device|Tulip cannulas|Lipoaspiration
1545686|NCT02628522|Other|20mL Lidocaine 2% and Epinephrine 1:100 000|Infiltration prior to liposuction
1545687|NCT02628509|Device|cardiac devices|patients receiving mechanical circulatory support or undergoing trans aortic valve replacement
1545688|NCT02628496|Drug|Fluorescein injection, USP 10%|-2.5 ml intravenous 10 minutes before procedure
1545689|NCT02628496|Device|Confocal laser microlaryngoscopy|
1545690|NCT02628496|Procedure|Biopsy (standard of care)|
1545691|NCT02628496|Procedure|KTP laser photoablation (standard of care)|
1545692|NCT02628483|Dietary Supplement|Fish Oil|1000mg fish oil per capsule (325mg EPA + 225mg DHA)
1545693|NCT02628483|Dietary Supplement|Fish Oil|1000mg fish oil per capsule (300mg EPA + 200mg DHA)
1545694|NCT02628470|Procedure|cervical manipulation|cervical high-velocity low-amplitude thrust manipulation
1545695|NCT02628470|Procedure|cervical control exercises|Exercises of flexion, extension and rotation of the cervical spine
1545696|NCT02628470|Procedure|Oscillatory mobilization technique|Joint mobilization technique type III according Maitland
1545700|NCT02628444|Biological|NaCl + CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0 and Month 6 (placebo), 12 months (CYD), respectively
1545701|NCT02628431|Device|Elfi tech monitor|
1545702|NCT02628418|Other|General Rehabilitation|All patients underwent basic rehabilitation following the guidelines according to the Bobath concept. Mobilization performed by physiotherapist of the lower and upper limbs through passive and/or active manoeuvres, gait training, standing and functional exercises and speech rehabilitation.
1545703|NCT02628418|Device|Specific hand rehabilitation by Gloreha device|"Each training session consisted of six parts:
A sequence of digital joint flexion/extension exercises, from the thumb to the fifth finger (7 min);
7 min of a number sequence (counting from one to five);
A sequence of thumb-finger opposition movements from the 2nd to the 5th finger (7 min)
A sequence of wave-like finger movements (7 min)
A sequence of fist opening/closing (7 min)
A sequence of flexion-extension of the fingers alternated with flexion-extension of the thumb (5 min)."
1545704|NCT02628418|Other|Specific hand rehabilitation performed by physiotherapist|"The activities were:
Flexion-extension of the fingers (10 min);
Thumb opposition with the other fingers keeping the forearm in supine position (10 min);
Adduction and abduction of the fingers (10 min);
Global movement of the hand consisting in reaching for a 0.5l bottle of water, taking hold of it, pouring water into a glass, and then putting the bottle down and letting go of it (10 min)."
1545705|NCT02628405|Drug|Carboplatin|Given IV
1545706|NCT02628405|Drug|Etoposide|Given IV
1545707|NCT02628405|Drug|Ifosfamide|Given IV
1545708|NCT02628405|Other|Laboratory Biomarker Analysis|Correlative studies
1545709|NCT02628405|Drug|Lenalidomide|Given PO
1545710|NCT02628405|Biological|Rituximab|Given IV
1545711|NCT02628392|Drug|DS-8500a|DS-8500a tablets 25mg, 50mg, 75mg
1545712|NCT02628392|Drug|Sitagliptin|capsules
1545713|NCT02628392|Drug|placebo|matching DS-8500a tablets and sitagliptin capsules
1545714|NCT02628366|Other|Personalized Dialysate Temperature|Dialysis centres randomized to the intervention will provide temperature-reduced personalized hemodialysis. A nurse will set the temperature of the dialysate to 0.5°C below each patient's body temperature measured just before starting the dialysis treatment. We are aware that some dialysis machines (e.g. Fresenius 5008) are only able to modify dialysate temperature by 0.5°C increments. For centres with those machines, the temperature should be lowered by a minimum of 0.5°C and a maximum of 0.9°C.
1545715|NCT02628353|Dietary Supplement|placebo|1 capsule of placebo product (100 mg carboxymetylcellulose) in one visit
1545716|NCT02628353|Dietary Supplement|phenolic compound|1 capsule of phenolic compound product (100mg phenolic compound + 100 mg carboxymetylcellulose) in one visit
1545717|NCT02628340|Other|Ex-vivo analysis|
1545718|NCT02628301|Dietary Supplement|Hypercaloric diet|Hypercaloric diet consisting of 60% excess calories based on resting energy expenditure (REE). Calories will be provided in the form of snacks in between the ad libitum meals. A subsequent hypocaloric diet will consist of 1.0x resting energy expenditure.
1545719|NCT02628301|Other|Normocaloric diet|Normocaloric diet
1545720|NCT02628288|Device|Coronary Bifurcation PCI|In one group, the coronary bifurcation lesion will be treated (Coronary bifurcation PCI) with the Axxess device + Absorb BVS. In the other group, the coronary bifurcation lesions will be treated(Coronary bifurcation PCI) by modified T stenting using Absorb BVS.
1545721|NCT02628275|Behavioral|Moderate to vigorous physical activity|55-90% maximum heart rate for 150min/week (current recommendations)
1545722|NCT02628275|Behavioral|Light physical activity|40-55% maximum heart rate for 150min/week
1545723|NCT02628262|Procedure|Vitrectomy with internal limiting membrane removal and gas tamponade|Vitrectomy with internal limiting membrane removal and gas tamponade
1545729|NCT02628236|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
1545730|NCT02628236|Device|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
1545731|NCT02628223|Procedure|Selective Laser Trabeculoplasty|The procedure uses light energy provided by a neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
1545732|NCT02628223|Device|Neodymium:Yttrium Aluminum Garnet (YAG) laser|The procedure uses a 400 μm spot size of light energy provided by a low-energy, Q-switched, frequency-doubled (532 nm) neodymium (Nd):Yttrium Aluminum Garnet (YAG) laser with a short pulse duration of 3 nanoseconds that is directed into the iridocorneal angle via a goniolens viewed through a standard slit lamp.
1545734|NCT02628197|Dietary Supplement|calcium (500mg) and vitamin D (250I.U.)|calcium (500mg) and vitamin D (250I.U.) was given twice a day for 6 months
1545735|NCT02628197|Procedure|Scaling and root planing|scaling and root planing was done in the test group along with calcium (500mg) and vitamin D (250I.U.)
1545736|NCT02628184|Other|Maternity Services Development Programme|The Maternity Services Development Programme was implemented to improve care for local families (service users) involved with maternity services. The aim was to improve care during the early stages of a family's development and to establish foundations for long-term well-being. One aspect of the programme worked to improve the delivery of care by facilitating collaboration and joint-planning between service providers. The programme uses local city Children's Centres to co-locate services (different agencies or professionals who are working within the same locality). The aim of co-location was to promote stronger collaboration between maternity services and other service provider agencies to develop stronger partnerships, and to help identify those who are (or who may become) vulnerable.
1545773|NCT02627898|Drug|placebo|Placebo capsules, 400mg 1 time daily with the first bite of eat meal
1547488|NCT02615912|Other|Sodium lauryl sulfate (Sigma Aldrich) 1.0%|
1545737|NCT02628171|Other|Base Diet|Participants will receive a controlled diet with 0 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
1545738|NCT02628171|Other|Base Diet with Cashew Nuts|Participants will receive a controlled diet with 42 g/d of cashew nuts. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet.
1545739|NCT02628158|Procedure|Vitrectomy with internal limiting membrane removal|Vitrectomy with removal of epiretinal membrane and internal limiting membrane
1545740|NCT02628145|Behavioral|Resistance Training Intervention|The RTI group will participate in a periodized RT program on 3 non-consecutive days/week using NSCA and ACSM guidelines and will be designed by a team member who is a NSCA certified strength and conditioning specialist. This program will consist of a full-body, nonlinear periodized program: a training method that has frequent variations in program variables. Intensity variations intensity are based on training phase. E.g., the first portion of 12-week cycle has more moderate and light days as participants adapt to the program. Weeks 1-4 will consist of primarily RT machine exercises and few unilateral and multi-joint light free weight exercise. Weeks 5-8 will incorporate more free-weight exercises that are multi-joint. Weeks 9-12 will incorporate more complex multi-joint movements.
1545741|NCT02628145|Behavioral|Active Control Group|The CON group will meet three times weekly for approximately 12 weeks for light physical activity and stretching.
1545742|NCT02628132|Drug|Paclitaxel|Paclitaxel will be given weekly for 6 cycles
1545743|NCT02628132|Drug|Durvalumab|Durvalumab will be given q2 wks concurrently with paclitaxel.
1545744|NCT02628119|Procedure|Intra-procedural access flow|"Intra-procedure access flow technique:
Room temperature saline is injected into the vascular access blood stream during angioplasty via ReoCath(tm) 6 French antegrade or retrograde flow catheters. When the saline is injected into the access, an injection thermistor located close to the proximal end of the catheter records the temperature of the injected saline. A second thermistor located close to the distal tip of the catheter then records the thermodilution within the access and the HVT100 endovascular flow meter calculates and displays intragraft blood flow in ml/min."
1545745|NCT02628119|Procedure|Standard Angioplasty|Intervention based on 2 Dimensional fluoroscopy views
1545746|NCT02628106|Drug|Lipo-PGE1|all patients received 10 ug lipo-PGE1 intravenously once daily for consecutive 14 days
1545747|NCT02628093|Device|THUNDERBEAT|Tissue dissection and vessels ligation
1545748|NCT02628093|Device|LIGASURE|Tissue dissection and vessels ligation
1545749|NCT02628080|Drug|Atovaquone|Atovaquone has an EU marketing authorisation (held by Glaxo Wellcome UK Ltd) and is indicated for acute treatment of mild to moderate Pneumocystis pneumonia (PCP). It is also used in combination with proguanil for malaria prophylaxis.
1545751|NCT02628054|Biological|Typhoid Vaccine|Typhoid Vaccine injection given 7 days apart
1545752|NCT02628054|Biological|Placebo|Saline injection given 7 days apart
1545753|NCT02628041|Radiation|Permanent Iodine-125 seed implant|"Permanent Iodine seed implant is performed under general or epidural anesthesia with the patient is positioned in the lithotomy position.
A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, the prostates is scanned and the dosimetry is generated. Catheters are inserted in the prostate and the seeds are injected using the Nucletron automatic after loader according to the dosimetry plan.
The catheters are removed at the end of the procedure."
1545754|NCT02628041|Radiation|High-Dose-rate Prostate Brachytherapy|"High-Dose-Rate Prostate brachytherapy is performed under general or epidural anesthesia, the patient is positioned in the lithotomy position.
A Foley catheter is inserted in the bladder. Under transrectal ultrasound guidance, catheters are inserted in the prostate to assure adequate coverage. The patient is returned in dorsal decubitus and a CT scan or Ultrasound scan is performed. A inverse-planning dosimetry plan is generated to deliver 19 Gy to the target volume. The patient is treated and then the implant is removed and anesthesia is reversed."
1545755|NCT02628028|Drug|LY3337641|Administered orally
1545756|NCT02628028|Drug|Placebo|Administered orally
1545757|NCT02628002|Device|Antigravity treadmill (Alter-G)|Test arm subjects will exercise according to the Bruce protocol unweighted to 75% of their body weight with additional unweighting to 50% during the test if unable to reach target at 75% weight. Once these subjects have reached their target heart rate on the Bruce protocol, patients will receive the Tc-99m injection as per standard clinical protocol and maintain target heart rate for 1 minute following the injection.
1545758|NCT02628002|Device|Conventional treadmill/regadenoson|Subjects randomized to the control arm will proceed with the clinical standard regadenoson pharmacological stress SPECT study with adjunctive low-intensity walk on conventional treadmill during regadenoson and Tc-99m injections if tolerated. If they are unable to tolerate any treadmill exercise, they will receive regadenoson and Tc-99m injections at rest. Study patients will have stable systemic blood pressure with readings equal to or greater than 90 mmHg systolic. Other inclusion and exclusion criteria are described in detail below.
1545759|NCT02627989|Drug|Diflucortolone valerate (Nerisona)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
1545760|NCT02627989|Drug|Diflucortolone valerate (Texmeten)|Potency Class II (classified as Very Strong class in Japan) topical corticosteroids
1545761|NCT02627976|Device|Compression vest, Thuasne|Wearing a compression 4 days/weel with a minumum of 6 hours per day
1545762|NCT02627963|Drug|tivozanib hydrochloride|tivozanib hydrochloride
1545763|NCT02627963|Drug|Sorafenib|tivozanib hydrochloride
1545764|NCT02627950|Drug|Morphinhydrochloricum|5 mg morphine intravenously
1545765|NCT02627950|Drug|Metoclopramide|10 mg MCP intravenously
1545766|NCT02627950|Drug|Ticagrelor|180 mg ticagrelor orally
1545767|NCT02627950|Drug|Isotonic sodium chloride|10 ml NaCl 0.9% intravenously
1545768|NCT02627911|Device|Diabeloop System|Insulin delivery
1545769|NCT02627911|Device|Continuous Glucose Monitoring|
1545770|NCT02627911|Device|Accelerometer and heart rate monitor|Monitoring and measurement of physical activity
1545771|NCT02627911|Dietary Supplement|Meals|Calibrated meals for all patients and outstanding dinners for patients being in outstanding meals situation (Centers : Grenoble, Toulouse, Montpellier)
1545772|NCT02627898|Drug|green tea extract|Green tea extract capsules, 400mg 1 time daily with the first bite of eat meal
1545774|NCT02627885|Behavioral|Internet-based CBT|Through the use of CBT material at an Internet-platform, we aim for behavioral changes in the subjects to improve everyday level of functioning and quality of life.
1545775|NCT02627885|Other|SMT|Standard Medical Treatment includes pharmacological management and other typical medical interventions for the patient group but no behavioural interventions
1545776|NCT02627859|Device|Durolane SJ|1ml single intra-articular injection in ankle
1545777|NCT02627846|Device|Endovenous Laser Ablation|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. The EVLA fibre is introduced into the vein using the Seldinger technique and its tip will be positioned under duplex ultrasound (DUS). Then tumescent anaesthetic, made of a solution of 100ml of 1% Lidocaine with 1:200,000 epinephrine in 900ml of 0.9% Sodium Chloride and buffered to pH 7.4 with 10ml of 8.4% Sodium Bicarbonate, will be infiltrated around the target axial vein under DUS using a spinal needle and a peristaltic pump. Following deployment of appropriate laser safety precautions, the laser energy will be delivered via the fibre. The wavelength used is 1470nm, with NeverTouch Gold-Tip fibre, at 10W power. This laser light energy is converted into heat inducing a permanent, non-thrombotic occlusion.
1545778|NCT02627846|Device|Mechanochemical Ablation|1% Lidocaine with 1:200,000 epinephrine will be used for skin infiltration. MOCA is performed by a device called ClariVein® (Vascular Insights, UK) which is a long thin catheter that is passed up inside the vein, with a rotating wire that protrudes at an angle from the end when deployed. This is motorised via an electric motor in the handle and rotates at approximately 3500 revolutions per minute. In addition, liquid sclerotherapy is injected at the handle end by a syringe. This sclerotherapy liquid emerges from the end of the catheter and is present in the area of the rotating tip. The sclerosant will be Sodium Tetradecyl Sulphate (STS), marketed as Fibrovein. Concentration of 1.5% Fibrovein will be used, and maximum of 12ml.
1545779|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|It is used as local anaesthetic given via subcutaneous injection, so that the skin is numb prior to the introduction of either endovenous laser ablation or mechenochemical ablation catheter. Typically 1-2ml is required.
1545780|NCT02627846|Drug|Lidocaine with 1:200,000 epinephrine solution|100ml of 1% lidocaine with 1:200,000 epinephrine is diluted into 900ml of 0.9% Sodium Chloride to make the tumescent anaesthetic solution, which is required when using endovenous laser ablation.
1545781|NCT02627846|Drug|Sodium Bicarbonate|10ml of 8.4% Sodium Bicarbonate is added into the tumescent anaesthetic solution, to buffer the pH to 7.4. Tumescent anaesthetic solution is required when using endovenous laser ablation.
1545782|NCT02627846|Drug|Sodium Tetradecyl Sulphate|1.5% of Sodium Tetradecyl Sulphate, marketed as Fibrovein, will be used with the mechanochemical ablation device (ClariVein®). This is a sclerosing agent with Manufacturer Authorisation, and it will be used unmodified. Intravenous injection causes intima inflammation and thrombus formation. This usually occludes the injected vein.
1545783|NCT02627833|Other|observation|Record lung function, Lung clearance index, inflammatory status
1545784|NCT02627820|Drug|Isis 420915/GSK 299872|Open label study in comparison to historic control.
1545785|NCT02627807|Radiation|IMRT using individualized CTV|Intensity modulated radiotherapy (IMRT) using individualized CTV based on disease extension risk atlas and computer-aided delineation is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
1545786|NCT02627807|Radiation|IMRT using traditional CTV|Intensity modulated radiotherapy(IMRT) using traditional CTV is given as 2.13 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 70.29 Gy to the primary tumor.
1545787|NCT02627807|Drug|Gemcitabine and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who participate in another randomized trial (NCT01872962) at the same time receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before radiotherapy.
1545788|NCT02627807|Drug|Docetaxel and cisplatin (induction chemotherapy)|Induction chemotherapy is optional for patients with T2-4N0-3M0 NPC. Patients who haven't participated in other trials receive docetaxel (75 mg/m² d1) and cisplatin (75mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles before radiotherapy.
1545789|NCT02627807|Drug|Cisplatin 100mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC. Patients who participate another clinical trial (NCT01872962) at the same time receive cisplatin (100mg/m² d1) every 3 weeks for 3 cycles concurrently with radiotherapy.
1545790|NCT02627807|Drug|Cisplatin 80mg/m² concurrent chemotherapy|Cisplatin concurrent chemotherapy is required for patients with T2-4N0-3M0 NPC.Patients who haven't participated in other trials receive cisplatin (80mg/m²,total dose average to d1-d3) every 3 weeks for 3 cycles concurrently with radiotherapy.
1545793|NCT02627768|Drug|No Intervention|Participants who have a confirmed diagnosis of Psoriatic Arthritis (PsA) and are starting ustekinumab or a tumor necrosis factor alpha inhibitor (TNFi) as a first, second, or third line of biological disease-modifying antirheumatic drugs (bDMARD) therapy will be observed.
1545794|NCT02627755|Device|aScope®|we use the aScope® as a flexible and dirigible guide to facilitate the passage of the endotracheal tube through the vocal cords.
1545795|NCT02627755|Device|Glidescope®|use of Glidescope® in conventional manner to facilitate endotracheal intubation
1545796|NCT02627742|Device|MetaNeb® System|The treatment protocol used for Respiratory Care during the CHANGE IN PRACTICE period of the Study will be that prescribed by the patient's health care team in the routine standard care of each patient. With the exception of standard airway clearance and lung expansion procedures, other components of the patients respiratory care regimen will remain the same as during the standard therapy period, however the CHANGE IN PRACTICE will incorporate the use/treatment with The MetaNeb® System as an alternative to usual airway clearance and lung expansion procedures. Use of The MetaNeb® System will follow the labeling of the device.
1545797|NCT02627729|Device|Linear cutter-Circular stapler|a 5 to 6 cm-long colonic pouch will be created with a 80 mm linear cutting-closing stapler. The anastomosis of j-pouch will be routinely strengthened with 3:0 vicryl sutures. Then, a pouch to anal anastomosis will be performed
1545798|NCT02627729|Device|Circular stapler|a 5 to 6 cm-long colonic segment will be left at the distal part and a side-to-end anastomosis will be performed.
1545799|NCT02627716|Procedure|SOS Plan|"It is a customised procedure that involves a meeting (crisis planning meeting) with the patient, their various medical and social referrers and any other person who they may have desired to invite.
The booklet outlines four avenues to consider:
Contact details / contact person
Treatment and current follow-ups
Medical care in the event of a crisis
Practical aid in the event of a crisis
Updating the SOS Plan every 6 months in the absence of hospitalisation or after each relapse that leads to an unscheduled psychiatric hospitalisation lasting more than two weeks."
1545800|NCT02627703|Other|Oncotype DX|The Oncotype DX® assay is a multi-gene reverse-transcriptase-polymerase-chain-reaction (RT-PCR) test that analyzes the expression of 21 genes, and quantifies the 10 year distant breast cancer recurrence risk in patients with stage I and II, lymph node negative, estrogen receptor positive disease who plan to be treated with tamoxifen for 5 years.
1545801|NCT02627690|Other|islet transplanted|islet transplantation
1545802|NCT02627690|Other|non islet transplanted|no islet transplantation (for a non nephrolgic reason)
1545803|NCT02627677|Drug|ponatinib 30 mg QD|ponatinib 30 mg, taken orally once daily
1545804|NCT02627677|Drug|ponatinib 15 mg QD|ponatinib 15 mg, taken orally once daily
1545805|NCT02627677|Drug|nilotinib 400 mg BID|nilotinib 400 mg, taken orally twice daily
1545806|NCT02627664|Other|observational study|natural history of non dopaminergic signs
1545807|NCT02627651|Other|cognitive and motor assignments|walking on treadmill, performing cognitive assignment; and performing the cognitive assignment while walking .
1545808|NCT02627638|Other|Ostheopathic treatment|Once their clinical data were collected and their symptoms were assessed, all the enrolled patients had an osteopathic session a week during two weeks. After those sessions, they had an interview (scheduled between D11 and D14) with a psychologist
1545809|NCT02627625|Drug|Tiotropium|4 inhalations
1545810|NCT02627612|Behavioral|Pro Vetus|Volunteer mentors (a mix of Veterans and non-Veterans) in the civilian community work with transitioning Veterans for approximately four months within five transition domains (1. Employment/Education, 2. Housing, 3. Family and Legal, 4. Social/Community/ Physical Fitness and 5. Medical Care).
1545811|NCT02627612|Behavioral|Team Red, White, and Blue (TM RWB)|TM RWB is a 501(c)(3) non-profit, Veteran support organization found in 2010. Its mission is to enrich the lives of America's Veterans by connecting them to their community through physical and social activity. Central to TM RWB's mission is that inspiring Veterans to become physically active will create opportunities to establish authentic connections to other Veterans, active duty military, and civilians as well as improve the chances for continued successful integration. Enrollment in TM RWB takes place by simply signing up online and providing a name, email address, and zip code (teamrwb.org). TM RWB is not designed as a mental health intervention.
1545812|NCT02627599|Device|Breath Responsive Variable Bolus Oxygen Conserving Device|Mini Electronic Oxygen Conserving Device
1545813|NCT02627586|Other|HIIT|High-intensity interval training (HIIT) is performed on a cycle ergometer. It consists of a 10 min warm-up followed by 4 min intervals in Zone III (at 90-95% of peak heart rate), with each interval separated by 3 min of active pauses in zone I (at 50-60% of peak heart rate). The total duration of the HIIT training is 38 min.
1545814|NCT02627586|Other|MICE|MICE is also performed on a cycle ergometer at an intensity of 50-80% of peak VO2 or 60-75% of peak heart rate for 47 min (in order for the two training protocols to be isocaloric). The control group will perform MICE training three times per week.
1545815|NCT02627573|Procedure|Unrelated allogeneic stem cell transplantation|
1545816|NCT02627573|Drug|Busulfan|
1545817|NCT02627573|Drug|Fludarabine monophosphate|
1545818|NCT02627573|Drug|Tacrolimus|
1545819|NCT02627573|Drug|Mycophenolate mofetil|
1545820|NCT02627573|Drug|Cyclophosphamide|
1545821|NCT02627573|Drug|Thymoglobulin|
1545822|NCT02627560|Drug|Tranexamic Acid|moisten the surgical wound surface with 20 ml tranexamic acid 25 mg/ml
1545823|NCT02627560|Drug|saline|moisten the surgical wound surface with 20 ml placebo (0.9% saline)
1545824|NCT02627547|Behavioral|Normal training|5-10 hours of endurance training each week
1545825|NCT02627547|Behavioral|De-training|No training
1545826|NCT02627534|Procedure|Ultrasonic debridement|All periodontal pockets received ultrasonic debridement (Cavitron, Dentsply) with specific inserts (UI25KSF10S, Hu-Friedy). All diseased sites were instrumented in one session by an experienced periodontist.
1545827|NCT02627534|Procedure|Antimicrobial photodynamic therapy|After ultrasonic debridement, one randomly selected periodontal pocket received an additional aPDT performed by a trained operator (NMRBA). One pocket with probing depth ≥ 5mm in each patient was randomly selected to aPDT. After washing the pocket with saline solution, the photosensitizer (methylene blue 10mg/ml) was applied to the bottom of the pocket in a coronal direction. Following this, the pocket was exposed to a diode laser light with a fibre optic application for 1 min (Thera Lase DMC - Brazil), with wavelength of 660nm, power of 60mW and fluency of 129J/cm2.
1545828|NCT02627521|Procedure|PRU guided CABG|Coronary Artery Bypass Surgery
1545829|NCT02627521|Procedure|CABG per standard of care|Coronary Artery Bypass Surgery
1545830|NCT02627521|Device|VerifyNow assay|Platelet reactivity Units by VerifyNow assay
1545831|NCT02627521|Drug|Ticagrelor|Ticagrelor administration prior to randomization
1545832|NCT02627508|Drug|Pregnenolone|orally administered Pregnenolone capsules
1545833|NCT02627508|Drug|Placebo|orally administered placebo capsules
1545834|NCT02627495|Device|transcranial Direct Current Stimulation (tDCS): (Soterix ©)|Subjects will undergo tDCS stimulation. We will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated limb (or for bilateral amputees contralateral to the most painful side). The subject will undergo stimulation for 20 minutes. The subject will have 5 sessions of stimulation during a 1 week time period.
1545876|NCT02627222|Other|Pro-vitamin A biofortified cassava|Pro-vitamin A biofortified cassava is the product of international conventional breeding programs (non-GMO) in order to increase the pro-vitamin A content of cassava for improved nutritional intake
1545877|NCT02627222|Other|White cassava|Conventional white cassava
1545835|NCT02627482|Device|Fetal heart rate monitor (Monica AN24)|"The AN24 is a portable, battery powered device, developed in the UK and designed to monitor passively an unborn baby in the antenatal period. The device is CE marked and is attached via a cable assembly which in turn attaches to five standard disposable electrodes placed on the abdomen of a pregnant woman. It is intended for ambulatory use in either the home or hospital environment.
The AN24 has had rigorous checks in the UK and has been used in many European countries. No hazards have been identified that could compromise the safety of, or cause harm to the fetus or the mother. The only potential issue identified is a local reaction under the electrodes. Nonetheless, the electrodes used are the standard disposable ECG electrodes, used routinely for adult ECG measurements."
1545836|NCT02627469|Behavioral|Extended professional oral hygiene care|Weekly professional oral hygiene performed by dental hygienists
1545837|NCT02627469|Device|Electric toothbrush (Oral-B Professional Care 7000)|Weekly professional oral hygiene performed by dental hygienists
1545838|NCT02627469|Device|1100 ppm sodium fluoride dentifrice (Zendium Classic)|Weekly professional oral hygiene performed by dental hygienists
1545842|NCT02627443|Drug|ATR Kinase Inhibitor VX-970|Given IV
1545843|NCT02627443|Drug|Carboplatin|Given IV
1545844|NCT02627443|Drug|Gemcitabine Hydrochloride|Given IV
1545845|NCT02627443|Other|Laboratory Biomarker Analysis|Correlative studies
1545846|NCT02627443|Other|Pharmacological Study|Correlative studies
1545847|NCT02627430|Drug|Hsp90 Inhibitor AT13387|Given IV
1545848|NCT02627430|Other|Laboratory Biomarker Analysis|Correlative studies
1545849|NCT02627430|Other|Pharmacological Study|Correlative studies
1545850|NCT02627430|Drug|Talazoparib|Given PO
1545851|NCT02627417|Drug|Dapsone (Disulone®)|Experimental group will receive dapsone at a fixed dose of 100 mg per day for a total of 12 months unless they fail to respond to the treatment.
1545852|NCT02627417|Drug|"Prednisone (Cortancyl®) alone followed by monitoring and standard of care"|Patients randomized in the control arm will be treated only prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks. After this 3 weeks period, patients from arm B will be left without treatment and monitored.
1545853|NCT02627417|Drug|Prednisone (Cortancyl®)|Experimental group will receive prednisone at a daily dose of 1 mg per kg for 2 weeks and then tapered and stopped over a week for a total of 3 consecutive weeks.
1545854|NCT02627404|Other|Blood sample|A blood sample is taken at inclusion of patients in the study to perform DNA analysis
1545855|NCT02627404|Device|actometer|To evaluate the quality of sleep, questionnaires are completed and patients wear an actometer for 21 days. They will also complete a sleep diary
1545856|NCT02627391|Other|Early surgical aortic valve replacement|
1545857|NCT02627391|Other|Delayed Surgical aortic valve replacement|
1545858|NCT02627378|Other|Extracorporeal Membrane Oxygenation|Patients received veno-venous Extracorporeal Membrane Oxygenation (ECMO) support
1545859|NCT02627378|Other|Non Extracorporeal Membrane Oxygenation|Patients received no Extracorporeal Membrane Oxygenation (ECMO) support
1996163|NCT02549755|Drug|11C-Acetate|"The 11C-Acetate radiopharmaceutical will be administered intravenously at a dose of 20-40 mCi (0.74-1.5 GBq).
There will be a total of three 11C-acetate radiopharmaceutical administrations for each patient"
1545862|NCT02627326|Procedure|open flap debridement|periodontal surgery in the form of open flap debridement was done in both the groups
1545863|NCT02627313|Device|GammaPod Tumour Bed Boost|Single fraction Tumour Bed boost of 8Gy in 1 Fraction
1545864|NCT02627300|Drug|Octanorm 16.5%|
1545865|NCT02627287|Device|FlexPen®|For subcutaneously (s.c. under the skin) injection.
1545866|NCT02627287|Device|DV3316 pen-injector|For subcutaneously (s.c. under the skin) injection.
1545867|NCT02627287|Drug|placebo|For subcutaneously (s.c. under the skin) injection
1545869|NCT02627261|Biological|blood samples and bone marrow aspirates will be collected|Serial analysis will be performed at different time point in order to evaluate the presence or absence of residual disease after different treatment steps (before treatment, after induction, after intensification, after consolidation)
1545870|NCT02627248|Drug|Huaier Granule|20g tid, orally
1545871|NCT02627248|Drug|Epirubicin|70 mg/m² ivdrip, d1 for both TEC and ET regimes
1545872|NCT02627248|Drug|Docetaxel|75 mg/m² ivdrip, d2 for both TEC and ET regimes
1545873|NCT02627248|Drug|Cyclophosphamide|600 mg/m² ivdrip, d2 for TEC regimes
1996164|NCT02549885|Other|PNF contract-relax|Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
1996165|NCT02549885|Other|Static stretching|Static stretching of neck muscles.
1545878|NCT02627209|Other|spectrophotometric assay|measurement of enzyme activity in the serum
1545879|NCT02627209|Other|radial immunodiffusion|measurement of the precipitated ring diameters showing enzyme activity in the serum
1545881|NCT02627183|Procedure|Catheter ablation|Subjects undergoing catheter ablation for the first time for atrial fibrillation as part of their regular care (regardless of involvement in this study).
1545882|NCT02627183|Behavioral|Exercise training|Subjects participating in supervised exercise classes for up to 60 minutes in length 2 times/week as part of their involvement in another study (NCT02602457).
1545883|NCT02627170|Device|dynamic Scheimpflug analyzer (corneal visualization Scheimpflug technology [Corvis ST], OCULUS, Wetzlar, Germany)|
1545884|NCT02627157|Device|Dynamic Scheimpflug Analyzer|Measurements of Corneal Biomechanical Properties Using a Dynamic Scheimpflug Analyzer
1545885|NCT02627144|Drug|Bevacizumab|Bevacizumab will be administered at the recommended dose of 10 mg/kg of body weight once every 2 weeks as an intravenous infusion until disease progression.
1545886|NCT02627144|Drug|Interferon alpha-2a|Interferon alpha-2a will be administered at the recommended starting dose of 9 MIU 3 times a week until disease progression.
1545887|NCT02627131|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
1545888|NCT02627118|Device|FRESENIUS OPTIFLUX 160NR|BLOOD SAMPLING BEFORE AND AFTER 2 MONTHS OF DIALYSIS WITH THE FRESENIUS OPTIFLUX F160NR DIALYZER
1545889|NCT02627118|Device|NIPRO ELISIO-15H|BLOOD SAMPLING BEFORE AND AFTER 2 MONTHS OF DIALYSIS WITH THE NIPRO ELISIO-15H DIALYZER
1545892|NCT02627092|Other|Copper linen exposure|Subjects will use hospital linens (top sheet, bottom sheet, pillow case, gown) made with copper to see if this helps reduce infections during their hospital stay.
1545893|NCT02627079|Other|Daily SMS text messaging|
1545894|NCT02627066|Behavioral|Volume Control|Persistent reduction in post-dialysis weight and dietary sodium restriction
1545895|NCT02627066|Behavioral|Volume Control + Exercise|Volume reduction intervention and comprehensive exercise counseling
1545896|NCT02627053|Drug|rivaroxaban|
1545897|NCT02627040|Device|InterTan Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an InterTan Intertrochanteric Nail
1545898|NCT02627040|Device|Gamma 3 Intertrochanteric Nail|Cephalomedullary fixation of intertrochanteric fracture with an Gamma 3 Intertrochanteric Nail
1545899|NCT02627027|Drug|Duvie Tab. 0.5mg, Glucodaun OR Tab. 750mg|oral administration
1545900|NCT02627027|Drug|CKD-395 0.25/750mg|oral administration
1545901|NCT02627014|Other|Manual therapy|"6 treatments: 2 treatments for week
1 treatment = 30 minutes"
1545902|NCT02627014|Other|Home physical therapy|once a day: 15 minutes
1545903|NCT02627014|Other|Manual therapy in cervical region|"6 treatments: 2 treatments for week
1 treatment = 30 minutes"
1545904|NCT02627014|Other|Home physical therapy in cervical region|once a day: 15 minutes
1545905|NCT02627001|Device|NuMask Intraoral Airway Device|NuMask Intraoral Airway Device
1545906|NCT02627001|Device|Bag Valve Mask|Conventional bag valve mask
1545907|NCT02626988|Behavioral|Promotion of a biodiverse diet|Nutrition education combined with Agriculture Capacity building focused on a key set of nutritious crops. Component (C) 1 - Participatory Identification of Intervention Approach (PIIA); C2 - Local stakeholder consultation; C3 - Sensitisation of community; C4 - Formation of Diversity club. Club will receive capacity building from a Village health worker. The following topics will be covered species selected for promotion: 1. Where to locally source inputs and expected price, 2. How/when to prepare plots using organic inputs, 3. Planting and best-practice management practices, 4. Seed saving and storage and 4. Active Cooking demonstrations and Nutrition Education and counselling including Diversified cooking practices
1545908|NCT02626962|Drug|ipilimumab|Ipilimumab every 3 weeks for a total of four doses (Cycles 1 and 2)
1545909|NCT02626962|Drug|Nivolumab|Nivolumab every 3 weeks for a total of four doses (Cycles 1 and 2) followed by Nivolumab every 2 weeks
1545910|NCT02626949|Behavioral|MBSR Course|Formal mindfulness meditation methods taught in the MBSR course include: Body Scan Meditation (a supine meditation), Gentle Hatha Yoga (practiced with mindful awareness of the body), Sitting Meditation (mindfulness of breath, body, feelings, thoughts, and emotions), and Walking Meditation. Informal Mindfulness Meditation Practices (mindfulness in everyday life) include: 1) awareness of pleasant and unpleasant events, and, 2) deliberate awareness of routine activities and events such as eating, weather, walking, and interpersonal communication. Daily home assignments include a minimum of 30 minutes daily formal mindfulness practices and 5-15 minutes informal practice, 6 days per week for the entire duration of the course. Course sessions will consist of discussions oriented around weekly homework assignments, including an exploration of obstacles, and development of self-regulatory skills and capacities.
1545911|NCT02626949|Behavioral|HEP Course|HEP is an active control that matches MBSR in non-specific factors, such as the amount of time participants interact, but does not include mindfulness practice as an active component. HEP instructors will be selected from experts in the areas covered: music, nutrition education, and, functional movement. The study's RC will coordinate HEP sessions and monitor attendance. Following the 8-week HEP protocol, subjects will meet monthly in 1.5-hour educational sessions to match the booster sessions of MBSR participants.
1545912|NCT02626936|Other|Dual-hormone closed-loop|Interventions will be undertaken one to 5 days after sensor insertion. Subjects will be admitted at the research center at 7:00 am. Subject's pump will be substituted with the study pump and an additional pump containing glucagon will be installed. At 7:00, CLS will be initiated. At 9:00, a standardized breakfast (75g CHO) will be served. Study subjects will consume the same meal on the two intervention days. During the intervention, patients will be allowed to do sedentary activities. Patients will allowed to consume caffeine during the intervention, but will have to replicate their caffeine consumption on both interventions.The intervention day will end at 13:00.
1545913|NCT02626936|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
1547489|NCT02615912|Other|Water (control)|
1545914|NCT02626936|Drug|Glucagon|Glucagon (Eli Lilly) will be used during dual-hormone closed-loop strategy.
1545915|NCT02626936|Device|Dexcom G4 Platinum glucose sensor|
1545916|NCT02626936|Device|Accu Chek Combo insulin pump|
1545920|NCT02626884|Drug|Ibrutinib|
1545921|NCT02626858|Device|extra treatment planning CT-scan|Beside the standard post-operative CT-scan, an extra pre-operative CT-scan is performed.
1545922|NCT02626845|Drug|Rituximab|Standard of care induction with Rituximab: 375mg/m2 weekly x 4 weeks. Once randomized, the rituximab dose will be 1000mg IV every 4 months x 2.
1545923|NCT02626845|Other|Placebo|Will be given at two time-points (week 16 and week 32) to subjects in the Placebo Arm.
1545924|NCT02626832|Other|Procedural|All subjects receive intravenous hypertonic saline and serial blood samples are drawn for AVP concentrations
1545925|NCT02626819|Behavioral|MOVE! Toward Your Goals|Patients will take an online tool accessing weight management and lifestyle behaviors, and will meet with a health coach regularly to establish SMART goals to help them in their weight loss journey. The goals may be supported by the patients' PACT members
1545926|NCT02626819|Behavioral|Enhanced Usual Care|"Patients will be given information on healthy living messages that were created by the VA, and given more information on specific messages they are interested in from the health coaches, but will not receive official coaching. These messages are the current standard of care at the VA for obesity counseling."
1545927|NCT02626780|Device|GID SVF-2|Comparison of the number and thickness of hair before and after treatment of autologous adipose-derived SVF.
1545928|NCT02626767|Other|Novel high-intensity interval exercise training|Please see information already included in the 'intervention' arm description.
1545929|NCT02626754|Drug|Sunitinib malate|Sunitinib 50mg will be given for 2 consecutive weeks then followed by one week of rest.
1545930|NCT02626741|Dietary Supplement|meal replacement group|The participants will receive SlimWell 60 grams per meal for 2 meals per day plus life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
1545931|NCT02626741|Behavioral|control group|The participants will receive only life style modification including educational sessions of exercise, dietary intake, food record. The duration is 3 months.
1545932|NCT02626728|Procedure|laparoscopic assisted transanal surgery (TAMIS)|all patients included recieve laparoscopic assisted transanal minimally invasive surgery
1545933|NCT02626715|Drug|Reduced-Intensity Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Droxia (hydroxyurea) - drug class: antimetabolite Fludara (fludarabine) - drug class: antimetabolite Alkeran (melphalan) - drug class: alkylating agent Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent
1545934|NCT02626715|Drug|Myeloablative Conditioning Regimen|Campath (alemtuzumab) - drug class: monoclonal antibody Thiotepa (triethylenethiophosphoramide) - drug class: cytotoxic agent Fludara (fludarabine) - drug class: antimetabolite Busulfex (busulfan) - drug class: alkylating agent
1545935|NCT02626702|Other|Observational|Excess blood from subjects will be analyzed to explore the relationship between Immune Modulators and IVF outcomes.
1545936|NCT02626689|Other|Quality of Life (QOL) questionnaires|Monitoring of FACT-AN, SF-36V2, TransQol, and NTD PRO assessments,
1545937|NCT02626689|Other|Healthcare Resource Utilization|Monitoring and reviewing HealthCare Resource Utilization information.
1545938|NCT02626676|Other|Educational Programme|Educational Programme consists of lectures and group dynamics about nutrition during hemodialysis sessions.
1545939|NCT02626650|Other|Symptom elicitiation|Survey procedure, people check or uncheck symptoms they have or haven't experienced. We randomly assign participants to only one of these symptom elicitation procedures.
1545940|NCT02626637|Other|Physical activity coaching|Children and adolescents will receive the study intervention, which includes exercise coaching and prescription, that is be incorporated into the standard care they receive from the nurse practitioners during their outpatient visits.
1545943|NCT02626598|Device|Blended Belotero|Belotero blended with 0.1 cc of 1% lidocaine with epinephrine per 1.0 cc Belotero will be injected to etched in fine facial lines
1545944|NCT02626585|Procedure|Postrhinoplasty taping|Postrhinoplasty taping is commonly applied by rhinoplasty surgeons. Following rhinoplasty the nose is generally taped and a (thermoplastic) nasal cast is applied on top of this to make sure the final form of the nose is protected. Postoperatively, this cast is removed at some point. After this, some of the surgeons prefer to tape the nose with nasal tapes such as Micropore (3M) etc. Postrhinoplasty taping is the term used for this. The nose is (generally) taped horizontally with 1/2 inch wide tapes. This is done superiorly from radix to inferiorly to nasal tip. The idea is to compress the nose and to cover it. The duration of postrhinoplasty taping differs according to the preference of the surgeon and the patient
1545945|NCT02626572|Drug|S47445 5mg|S47445 5 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
1545946|NCT02626572|Drug|S47445 15mg|S47445 15 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
1545947|NCT02626572|Drug|S47445 50mg|S47445 50 mg tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
1545948|NCT02626572|Drug|Placebo|Placebo tablets taken orally once a day during breakfast, starting the day after inclusion visit and ending the day of the W024 visit (main period) or starting the day after inclusion visit and ending the day of the W052 visit (period including main period and optional extension period).
1545949|NCT02626559|Drug|liposomal bupivacaine/plain bupivacaine peri-articular injection|Injection of a mixture of liposomal and plain bupivacaine around the knee during total knee arthroplasty.
1545950|NCT02626546|Procedure|Major surgical procedure|observation of postoperative outcomes
1545951|NCT02626533|Procedure|Total Knee Arthroplasty|Patients will undergo total unilateral knee arthroplasty for osteoarthritis.
1545952|NCT02626520|Drug|Gemcitabine and nanoparticle albumin bound paclitaxel|Gemcitabine and nab-paclitaxel given every 14 days x 4 cycles
1545953|NCT02626520|Drug|5-fluorouracil and irinotecan|FOLFIRI.3 given every 14 days x 4 cycles
1545954|NCT02626520|Radiation|Preoperative chemoradiation|Pre-operative chemoradiation to 40 Gy in 20 fractions
1545955|NCT02626520|Procedure|Definitive resection|Definitive surgical resection of primary tumor
1545956|NCT02626507|Drug|Gedatolisib|adenosine triphosphate (ATP) competitive, highly selective and potent inhibitor of pan-class I isoform phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3-K)
1545957|NCT02626507|Drug|Faslodex|Faslodex® (Fulvestrant) is a potent anti-estrogen drug that binds and degrades estrogen receptors (ERs).
1545958|NCT02626507|Drug|Palbociclib|Palbociclib (Ibrance®) is an orally active highly selective reversible inhibitor of cyclin-dependent kinase (CDK) 4 and CDK 6.
1545959|NCT02626507|Drug|Zoladex|Zoladex is used to render menopause in pre-menopausal subjects, given once every 28 days starting at least 14 days prior to treatment.
1545960|NCT02626494|Drug|N-Acetylcystein|n-AC will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of n-AC over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of n-AC 5 days after the screening assessment (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of n-AC capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
1545961|NCT02626494|Drug|Placebo|14 days before or after, placebo will be administered analogously as described with n-AC. Placebo will be given according to a double-blind, placebo-controlled cross-over design. Subjects receive 3 doses of placebo over 2 consecutive days (total dose=4800mg; individual doses=2x1200mg, 1x2400mg). Subjects will take 2 first doses (à 1200mg) of placebo 1 day before scanning (one in the morning, one in the evening), and the last dose (2400mg) 1h prior to scanning, with 12 hours dosing intervals in between. Preparation and blinding of placebo capsules will be performed by the Kantonsapotheke Zürich according to the guidelines of Good Manufacturing Practice.
1545962|NCT02626481|Drug|Daratumumab|patients treated with Daratumumab (16 mg/kg) and Dexamethasone (40 or 20 mg regarding age of patient)
1545963|NCT02626481|Drug|Dexamethasone|patients treated with Dexamethasone (40 or 20 mg regarding age of patient)
1545972|NCT02626442|Other|Exercise|6 month group exercise class
1545973|NCT02626429|Dietary Supplement|Amino acid intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
1545974|NCT02626416|Device|LenZOC (mobile application)|The transparency of the visual axial at the anterior segment is observed through a dilated pupil. Image of the eye of a patient taken with LenZOC is calibrated with a standardized white and black bar adhered to the patient's eyelid. Calibrated images are dimmed as graysalegrayscale. The intensity and progress of visual axial opacification (VAO) is quantified as absolute area and relative area (calculated as: absolute area of VAO/ absolute area of dilated pupil).
1545975|NCT02626403|Device|Anodal tDCS|Patients will receive anodal tDCS during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised) and an EEG. The anodes will be placed over F3, F4, CP5, and CP6 in order to stimulation the fronto-parietal cortex bilaterally.
1545976|NCT02626403|Device|Sham tDCS|Identical to anodal tDCS, except that the stimulation will be stopped after 15 seconds.
1545977|NCT02626390|Other|Frequent instructions/feedback and an Internal Focus of Attention|
1545978|NCT02626390|Other|Minimal instructions/feedback and an External Focus of Attention|
1546114|NCT02625506|Drug|Levobupivacaine|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine
1547751|NCT02613988|Device|Dynamic susceptibility contrast MRI|
1545981|NCT02626364|Drug|crenolanib|single-agent crenolanib at 100 mg PO TID
1545982|NCT02626351|Other|Quality Improvement|In a stepped wedge fashion all 7 PHC clinics will receive QI one by one (exception: the two smallest clinics will be rolled into one step). Each step is of 2 months' duration. The study will commence with baseline data collection across all clinics, before the first randomised clinic receives the QI intervention. The QI intervention involves the following activities at each clinic: [1] Situational Analysis: assessment of clinic needs and gaps in processes that influence the specified study endpoints; [2] Intensive Intervention Phase (2 months): the clinic QI team (healthcare facility staff) with support of CRH QI mentors maps clinic processes and establishes priorities for process improvements through identification of bottlenecks, root-causes and commence plan-do-study-act (PDSA) cycles; [3] Maintenance Phase (duration varies for each clinic based on stepped wedge study design): clinic processes are further improved through iterative PDSA cycles; [4] Follow up.
1545983|NCT02626351|Other|Baseline data collection (active comparator)|Endpoint data collection only
1545984|NCT02626338|Drug|Crenolanib|
1545985|NCT02626338|Drug|Mitoxantrone|
1545986|NCT02626338|Drug|Cytarabine|
1545987|NCT02626338|Drug|Etoposide|
1545988|NCT02626338|Drug|Fludarabine|
1545989|NCT02626338|Drug|G-CSF|
1545990|NCT02626338|Drug|Idarubicin|
1545991|NCT02626325|Other|High-carbohydrate or High-monounsaturated fat diets|
1545992|NCT02626312|Radiation|Radiation Therapy|Participant receives radiation therapy up to 5 days a week for a total of either 15 or 25 doses, based on decision of physician.
1545993|NCT02626312|Drug|Chemotherapy|Participant may receive chemotherapy while on study based on decision of physician.
1545994|NCT02626312|Behavioral|Questionnaire|Symptom questionnaire completed at baseline, weekly during radiation treatment, and at follow up.
1545998|NCT02626286|Other|HIV quarterly global care|
1545999|NCT02626273|Radiation|weight loss|
1546000|NCT02626260|Other|adhesive strip|Adhesive strip with a standard adhesive base
1546001|NCT02626247|Dietary Supplement|Vitamin A +Long chain PUFA|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
1546002|NCT02626247|Other|Placebo|3 capsules per day, two capsules at breakfast and one capsule at lunch, with a glass of water.
1546003|NCT02626234|Drug|INC280|
1546004|NCT02626234|Drug|digoxin|
1546005|NCT02626234|Drug|rosuvastatin|
1546006|NCT02626221|Other|Non Interventional Study|Non Interventional Study
1546007|NCT02626208|Device|Nestorone®/Estradiol Contraceptive Vaginal Ring|Three arms of contraceptive vaginal rings contain a fixed dose (200 mcg/day) of Nestorone® and escalating doses (75 µg/d, 100 µg/d, or 200 µg/d /day) of estradiol
1546008|NCT02626195|Dietary Supplement|nutritional support program|"Nutritional support program is briefly described below.
Interval: 5-10 days Contents: admission is required
Calories: 30-35Kg, via enteral or parenteral
Protein: 1.2-1.5g/Kg
Lipid : 1-1.5g/Kg
Mineral and vitamins supply
Blood glucose control
Daily monitoring by dietician and specialized nurse"
1546009|NCT02626182|Drug|sildenafil|active sildenafil
1546010|NCT02626182|Drug|placebo|sugar pill that looks like sildenafil tablets
1546011|NCT02626169|Drug|Clopidogrel|Clopidogrel 75 mg once a day by mouth for 30 days
1546012|NCT02626169|Drug|Ticagrelor|Ticagrelor 90 mg twice daily by mouth for 30 days
1546013|NCT02626156|Device|Cooling gel pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cooling gel pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
1546014|NCT02626156|Device|Cooling cotton pack|Individuals will self monitor skin temperature of skin over a recently health venous leg or diabetic foot ulcer with a dermal thermometer. A cotton filled pack will be applied to skin of recently healed venous leg or diabetic foot ulcers for 30 minutes 3 times a week for six months. If the temperature of this skin site increases and stays elevated 2°F above the usual temperature of that site, the individual will cool the skin 5 consecutive days and will continue to monitor skin temperature.
1546015|NCT02626143|Other|Investigational nutrient-rich whey protein formula|
1546016|NCT02626143|Other|Cow's milk based formula|
1546017|NCT02626130|Drug|Tremelimumab|Participants receive a course of 2 preoperative doses of Tremelimumab. Tremelimumab administered intravenously at a dose of 10 mg/kg. Participants receive first dose at Week 1, second dose at Week 5. After surgery participants receive one dose of Tremelimumab every 4 weeks for 3 doses and every 12 weeks after that until progression .
1546018|NCT02626130|Procedure|Cryoablation|Participants have cryoablation procedure about 2-6 days before first dose of Tremelimumab. Study doctor inserts cryoprobe needle and an ultrasound device used to help guide cryoprobe until it reaches the cancerous area. When in place, cryoprobe used to freeze the cancerous area.
1546019|NCT02626130|Behavioral|Long-Term Follow-Up|Participant contacted by study staff about every 6 months. Participant contacted by phone call or e-mail. Phone call should last about 5 minutes.
1546115|NCT02625506|Drug|Levobupivacaine and Tramadol|Ultrasound guided Pecs block will be performed using 20 ml of levobupivacaine in conjunction with tramadol
1546022|NCT02626104|Dietary Supplement|Bovine lactoferrin|The children will be randomly assigned to receive 100 mg of bovine lactoferrin twice a day orally for the whole period of antibiotic therapy.
1546023|NCT02626104|Dietary Supplement|Maltodextrin|The children will be randomly assigned to receive 100 mg of placebo - maltodextrin twice a day orally for the whole period of antibiotic therapy.
1546024|NCT02626091|Procedure|Left-sided colonic resection|"During interventions, anastomosis perfusion will be estimated (outcomes: visual appreciation of the surgeon, ICG fluorescence-based enhanced reality and series of peri-operative samplings) in order to validate the accuracy of ICG fluorescence-based enhanced reality technique.
In any case, the resection will be performed according to the surgeon's appreciation."
1546025|NCT02626078|Other|observation and interview of residents|Residents will be observed during lunch to evaluate their behavior, verbal interactions between residents. The food intake during 24 hours will be evaluated also. In an interview after lunch, the appreciation of the meal by residents will be assessed by a questionnaire and the score of the nutritional state will be defined.
1546026|NCT02626065|Biological|blood sampling|Blood samples (44mL) will be taken before starting treatment with Nivolumab and at week 2, week 12, week 54 or at relapse (before week 54)
1546027|NCT02626065|Drug|Nivolumab|injection of Nivolumab every two weeks from day 0 and until relapse, toxicity motivating withdrawal or temporary suspension of treatment or up to 54 weeks.
1546028|NCT02626052|Behavioral|Dizziness Handicap Inventory|A standardized questionnaire used to quantify symptoms of dizziness.
1546029|NCT02626052|Behavioral|Global Rating of Change|A standardized questionnaire used to review the overall outcome of the participants condition with physical therapy.
1546030|NCT02626052|Behavioral|Patient Acceptable Symptom State|A standardized questionnaire used to determine whether meaningful progress has been made
1546031|NCT02626052|Procedure|Spontaneous Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
1546032|NCT02626052|Procedure|Gazehold Nystagmus Test|An observational test procedure used to identify involuntary eye movements caused by inner ear and/or brain dysfunction. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
1546033|NCT02626052|Procedure|Primary Vibration Test|A test used to identify asymmetry that may be present in the vestibular system through 60-100 MHz vibration applied to the mastoid bone. A WAHL massager is used to stimulate the inner ear by vibrating the mastoid bone. The test is performed both in room light and with fixation blocked with a Micromedical Technologies infrared lens.
1546034|NCT02626026|Drug|GS-4059|GS-4059 capsules administered orally
1546035|NCT02626026|Drug|Placebo|GS-4059 placebo administered orally
1546036|NCT02626000|Drug|Talimogene laherparepvec in combination with pembrolizumab|Talimogene laherparepvec will be administered in combination with pembrolizumab starting on day 1. Talimogene laherparepvec: 10^6 PFU/mL followed 3 weeks (+ 3 days) later by 10^8 PFU/mL every 3 weeks (± 3 days). Pembrolizumab: 200 mg will be administered intravenously every 3 weeks (± 3 days). The second dose of pembrolizumab will be administered 3 weeks (+ 3 days) after the initial dose. Subjects will be followed up for serious adverse events until 90 (+ 7) days after the cessation of all study treatment or 30 (+7) days following cessation of treatment if the subject initiates new anticancer therapy (whichever is earlier)
1546037|NCT02625987|Procedure|Continuous intradermic stitch|Appendectomy wound closure with an intradermic Polyglactina 910 stitch
1546038|NCT02625987|Procedure|Separated stitches|Appendectomy wound closure with a separated stitches.
1546042|NCT02625948|Drug|Tranexamic Acid|
1546043|NCT02625922|Drug|Serelaxin|Serelaxin will be administered as a continuous i.v. infusion according to a weight-range adjusted dosing regimen
1546044|NCT02625922|Drug|Placebo|Matching placebo i.v infusion
1546045|NCT02625909|Drug|SOF/VEL for 6 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm A (6 weeks short treatment duration).
1546046|NCT02625909|Drug|SOF/VEL for 12 weeks|Open-label SOF/VEL 400mg/100mg once daily to be given to participants randomised to Arm B (12 weeks standard treatment duration).
1546079|NCT02625688|Other|Cord milking|If cord milking will be the allocated intervention, the recruiter will supervise the midwife, or obstetrician preforming the procedure, and count out loud the number of times the cord has been milked. During vaginal deliveries midwifes will be asked to maintain the infant at least 10 cm above the uterus until the cord is clamped. In case of caesarian sections the baby will be placed on the mother's laps and swaddled in sterile towels to prevent heat loss.
1546116|NCT02625493|Other|Questionnaire|Questionnaire containing a Best-worst Scaling scenario
1546117|NCT02625480|Biological|KTE-C19|
1546047|NCT02625896|Behavioral|Intervention|Standard skydive from 4 000 m above mean sea level (AMSL) following standard safety recommendations and procedures including, if necessary, standard reserve parachute activation procedures. If necessary for safety, participants are asked to immediately leave the study at will. At 1 500 m AMSL, the participant is asked to begin to slow down the fall rate by increasing the body surface area to the relative wind. At no lower than 1 200 m AMSL, the participant is asked to deploy the main parachute. At main parachute deployment, while maintaining a stable body position with shoulders level to the horizon and unaltered heading, the participant is asked to increase the pitch angle of the long body axis attitude, raising the head, shoulders, and upper body up from the flat belly-to-relative-wind plane to a head-high body position, using any free fall technique the participant is comfortable with - as long as there is NO RISK for an unintentional backflip.
1546048|NCT02625883|Other|Interview|Interview by validated Quality-of-life-questionnaire
1546049|NCT02625870|Drug|Omega-3-Acid Ethyl Esters 90 Soft Capsules|Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
1546050|NCT02625870|Drug|Corn Oil|Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
1546051|NCT02625857|Biological|JNJ-64041809 (Cohort 1A and 1B)|JNJ-64041809 will be administered IV at a lower dose in Cohort 1A (1x10^8 colony forming units [CFU]) and at a higher dose in Cohort 1B (1x10^9 CFU).
1546052|NCT02625857|Biological|JNJ-64041809 (Cohort 2A and 2B)|JNJ-64041809 will be administered intravenously (IV) once every 21 days at the recommended dose as determined in Cohort 1A or 1B.
1546053|NCT02625844|Other|No intervention|No intervention administered in this study.
1546054|NCT02625831|Other|Biological analysis|"Biological analysis :
ficolin-3
anti-ficolin 3 antibodies
anti-C1q antibodies"
1546055|NCT02625805|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises. Additional EEG monitoring will be performed during performance of a computerized test using MindWave Headset.
1546056|NCT02625805|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
1546057|NCT02625805|Drug|Methylphenidate|Methylphenidate will be administered to each of the study participants in both groups in one of the two days on the study selected randomly.
1546058|NCT02625792|Drug|Endo-Clot(TM)|After patients treated with ESD, Hemostatic power was applied on the post-resection surface by Endo-Clot™ system. And treated with proton pump inhibitor as usual.
1546059|NCT02625779|Drug|Valproate and Placebo|
1546060|NCT02625779|Drug|Valproate and Cytidine-containing Drug|
1546061|NCT02625779|Drug|Valproate and Creatine-containing Drug|
1546062|NCT02625766|Procedure|LC fracture surgical fixation|
1546063|NCT02625766|Procedure|LC fracture non-operative management|
1546064|NCT02625753|Drug|Codeine|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
1546065|NCT02625753|Drug|paracetamol|Patients submitted to photorefractive keratectomy received codeine 50mg plus paracetamol 500mg every 6h for 72h after the procedure
1546066|NCT02625753|Drug|placebo|Patients submmitted to photorefractive keratectomy received placebo, in the form of a pill of similar appearance to the comparator, every 6h for 72h after the
1546067|NCT02625740|Device|Local exposition of target lesion to high intensity, low-frequency ultrasound|Target lesion was exposed to 60 seconds of high intensity, low-frequency ultrasound generated by the Genesis™ system ( CardioProlific Inc., Hayward, CA). The ultrasound catheter is removed after the exposition.
1546068|NCT02625740|Device|drug eluting ballon angioplasty|Target lesion was treated with an angioplasty, performed using the INPACT Admiral drug eluting ballon (Medtronic)
1546069|NCT02625740|Device|Flow occlusion with an angioplasty balloon|Inflation of a 2 cm long balloon catheter Admiral (Medtronic) , located distally to the treatment area, in order to obtain a flow cessation
1546070|NCT02625740|Drug|Local Paclitaxel infusion|Paclitaxel in a mixture with contrast medium at 1.0 µg/mm³ concentration was delivered to the treatment area for 60 seconds. The column of the Paclitaxel mixture filling the vessel was observed under the fluoroscopy and sustained during 60 seconds. The Paclitaxel /contrast medium mixture was then aspired with a 50 cc syringe and the distal balloon was deflated.
1546071|NCT02625740|Procedure|Angiographic control|A final angiographic control was performed with injection of 10 cc of contrast medium and compared with the pre-procedural one.
1546072|NCT02625727|Other|hyaluronic acid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
1546073|NCT02625727|Other|hyaluronic acid combined corticosteroid|compare the therapeutic effects of hyaluronic acid injection and hyaluronic acid combined corticosteroid injection to patients with knee osteoarthritis
1546074|NCT02625714|Drug|Renexin®|Cilostazol 100mg/ginko biloba leaf extract 80mg, Immediate release, bid
1546075|NCT02625714|Drug|SID142|Cilostazol 200mg/ginko biloba leaf extract 160mg, Controlled release, qd
1546076|NCT02625701|Procedure|Goal-directed therapy|Optimize CO with additional fluid according to dynamic indices (PPV, SVV, Stroke volume)
1546077|NCT02625701|Procedure|Restrictive fluid therapy|Keep normovolemia with basal crystalloids infusion (3-6 ml/kg/h) and compensate additional fluid losses with colloids or crystalloids.
1546078|NCT02625688|Other|Delayed cord clamping|We have decided to delay cord clamping in the intervention group to 3 minutes and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
1546112|NCT02625519|Drug|Urinary follicle-stimulating hormone|Ovarian stimulation with highly purified urinary follicle-stimulating hormone
1546113|NCT02625519|Drug|Recombinant follicle-stimulating hormone|Controled ovarian stimulation with recombinant follicle-stimulating hormone
1546080|NCT02625688|Other|Early cord clamping|We have decided to clamp the cord in the early intervention group at 30 seconds and place the baby 10 cm above the placental, as it seems most efficient based on the available literature. At all births (spontaneous vaginal deliveries and caesarian sections) a member of the recruitment team will be present. He will inform the midwife or obstetrician about the allocated intervention and measure the time from the delivery of the shoulders to the cord clamping.
1546081|NCT02625675|Other|Ultrasound scan|
1546082|NCT02625636|Drug|SAR438544|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1546083|NCT02625636|Drug|placebo|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1546084|NCT02625636|Drug|r-glucagon|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1546085|NCT02625623|Drug|Avelumab|Avelumab will be administered as a 1-hour intravenous (IV) infusion at 10 milligram per kilogram (mg/kg) once every 2-week treatment cycle until confirmed progressive disease or unacceptable toxicity along with best supportive care (BSC).
1546086|NCT02625623|Drug|Irinotecan|Irinotecan will be administered at a dose of 150 mg/m ^2 on Day 1 and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
1546087|NCT02625623|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m^2 on Day 1, 8, and 15 of a 4-week treatment cycle until disease progression or unacceptable toxicities along with BSC.
1546088|NCT02625623|Other|Best Supportive Care (BSC)|BSC is defined as treatment administered with the intent to maximize Quality of life without a specific antineoplastic regimen and is based on investigator's discretion. BSC will be administered once every 3 weeks.
1546089|NCT02625610|Drug|Avelumab|Maintenance Phase: Intravenous (IV) infusion (10 mg/kg over 1 hour) once every 2 weeks.
1546090|NCT02625610|Drug|Oxaliplatin|"Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
Maintenance Phase: Subjects will continue the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
1546091|NCT02625610|Drug|5-Fluorouracil|"Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m^2 IV push on Day 1 and 2400 mg/m^2 IV continuous infusion over 48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
Maintenance Phase: Subjects will continue the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
1546092|NCT02625610|Drug|Leucovorin|"Induction Phase: Leucovorin will be administered at a dose of 200 mg/m^2 IV (or) Leucovorin 400 mg/m^2 IV on Day 1 on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
Maintenance Phase: Subjects will continue the same regimen of chemotherapy as they received during the Induction Phase until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
1546093|NCT02625610|Drug|Capecitabine|"Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
Maintenance Phase: Subjects will continue the same regimen of chemotherapy as they received during the Induction Phase every 3 weeks until disease progression, significant clinical deterioration, unacceptable toxicity, or discontinuation."
1546094|NCT02625610|Other|Best supportive care|Treatment administered with the intent to maximize Quality of Life (QoL) without a specific antineoplastic regimen. These may include for example antibiotics, analgesics, antiemetics, thoracentesis, paracentesis, blood transfusions, nutritional support (including jejunostomy), and focal external-beam radiation for control of pain, cough, dyspnea, or bleeding. Best supportive care will be administered per institutional guidelines and subjects will visit the clinic every 3 weeks.
1546095|NCT02625610|Drug|Oxaliplatin|Induction Phase: Oxaliplatin will be administered at a dose of 85 mg per square meter (mg/m^2) as a continuous intravenous (IV) infusion on Day 1 along with leucovorin followed by 5-Fluorouracil every 2 weeks up to 12 weeks (or) Oxaliplatin at 130 mg/m^2 IV on Day 1 along with capecitabine twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks up to 12 weeks.
1546096|NCT02625610|Drug|5-Fluorouracil|Induction Phase: 5-Fluorouracil will be administered at a dose of 2600 mg/m^2 IV continuous infusion over 24 hours on Day 1 (or) 5-FU at 400 mg/m^2 IV push on Day 1 and 2400 mg/m^2 IV continuous infusion over 48 hours (Days 1 and 2) along with oxaliplatin and leucovorin every 2 weeks up to 12 weeks.
1546097|NCT02625610|Drug|Leucovorin|Induction Phase: Leucovorin will be administered at a dose of 200 mg/m^2 IV (or) Leucovorin 400 mg/m^2 IV on Day 1 on Day 1 along with oxaliplatin and 5-FU every 2 weeks up to 12 weeks.
1546098|NCT02625610|Drug|Capecitabine|Induction Phase: Capecitabine will be administered at a dose of 1000 mg/m^2 twice daily for 2 weeks followed by a 1-week rest period given every 3 weeks along with oxaliplatin up to 12 weeks.
1546099|NCT02625597|Device|Cotton Pellet|
1546100|NCT02625597|Device|Polytetrafluoroethylene Tape|
1546101|NCT02625597|Device|Synthetic Foam|
1546102|NCT02625597|Device|Polyvinylsiloxane|
1546103|NCT02625584|Behavioral|Reading Together - Pausing for Reading|
1546104|NCT02625584|Behavioral|Reading Together - Dialogic Reading|
1546105|NCT02625584|Behavioral|Reading Together - Shared Reading Control|
1546106|NCT02625571|Behavioral|Phase-based treatment of sexual behavior problems of children|
1546107|NCT02625558|Drug|Riociguat|Patients will initiated on 0.5 mg tid and titrated every 2 weeks to a maximum of 2.5 mg three times a day
1546108|NCT02625558|Drug|Placebo|Placebo given three times a day
1546109|NCT02625545|Device|UroLift System procedure|Minimally invasive procedure for treatment of lower urinary tract symptoms (LUTS) due to BPH
1546110|NCT02625532|Procedure|Follicular phase|Controlled ovarian stimulation starts on day 2-3 of the menstrual cycle with recombinant recombinant FSH + LH, adding cetrorelix when the follicles reach 14 mm size and ovarian maturation with triptorelin acetate
1546111|NCT02625532|Procedure|Luteal phase|Controlled ovarian stimulation is started between 3rd and 5th day after the first LH positive urine test, adding cetrorelix when follicles reached 14 mm size and ovarian maturation with triptorelin acetate
1546118|NCT02625467|Procedure|Penetrating keratoplasty|Conventional Penetrating keratoplasty technique
1546119|NCT02625467|Procedure|Pachymetry and Excimer laser assisted lamellar keratoplasty|Ablation profile focusing on topography and pachymetry with Schwind Amaris excimer laser
1546120|NCT02625467|Drug|Treatment posterior to surgery|Fluoroquinolone topical antibiotic (Moxifloxacin, Vigamox) and topical steroid (Prednisolone Acetate Ophthalmic Suspension, Pred Forte)
1546121|NCT02625454|Drug|Intravenous Acetaminophen|1000 mg Acetaminophen q 6 hours, given intravenously
1546122|NCT02625454|Drug|Oral Acetaminophen|1000 mg Acetaminophen q 6 hours given orally
1546123|NCT02625441|Drug|Pertuzumab|Pertuzumab 420 mg i.v. 3-weekly for 3 cycles
1546124|NCT02625441|Drug|Trastuzumab|Trastuzumab 6 mg/kg, i.v., 3-weekly for for a total duration of one year
1546126|NCT02625415|Device|Vitamin B6 cream|Topical Vitamin B6 cream
1546127|NCT02625415|Device|Placebo Vitamin B6 cream|Placebo Vitamin B6 cream
1546130|NCT02625389|Drug|Lipiodol® Ultra Fluid with surgical glues|Lipiodol® Ultra Fluid and surgical glue mixture may vary from 20 to 80% and should be administered via selective arterial catheterization only.
1546131|NCT02625376|Dietary Supplement|Resvega|Dietary supplementation with Resvega BD
1546132|NCT02625376|Dietary Supplement|Trans-Resveratrol|Dietary supplementation with resveratrol 250 mg BD
1546133|NCT02625376|Dietary Supplement|placebo|Dietary supplementation with a placebo BD
1546134|NCT02625363|Other|Glucose Ref - Std|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
1546135|NCT02625363|Other|Glucose Ref and 450 ml water|First, fasting blood glucose was measured. Then, subjects consumed the glucose sample in 5-10 minutes. Subjects given additional 150 ml water at 45, 75, and 105 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120
1546136|NCT02625363|Other|White Bread with 250 ml water|First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
1546137|NCT02625363|Other|White Bread and 700 ml water|"Sample consumed with 250 ml water immediately after meal consumption, and additional 150 ml water at 45, 75, and 105 minutes.
First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
1546138|NCT02625363|Other|White Bread with 125 ml water (twice)|"Sample consumed with 125 ml water immediately after meal consumption, and additional 125 ml water after 60 minutes
First, fasting blood glucose was measured. Then, subjects consumed the samples in 10-15 minutes and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'"
1546139|NCT02625350|Other|Instant noodle without soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle without soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
1546140|NCT02625350|Other|Instant noodle with soup|First, fasting blood glucose was measured. Then, subjects consumed the sample (instant noodle with soup) and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
1546141|NCT02625350|Other|Glucose reference|First, fasting blood glucose was measured. Then, subjects consumed the glucose reference and blood sugar level were measured at 0', 15', 30', 45', 60', 90', and 120'
1546142|NCT02625337|Drug|Pembrolizumab|
1546143|NCT02625337|Drug|Dabrafenib|
1546144|NCT02625337|Drug|Trametinib|
1546145|NCT02625337|Procedure|Biopsy|Biopsies will be taken during screening, before randomization, at week 8 (only arm 2-4) after 12 weeks, at week 18 and if PD.
1546146|NCT02625337|Procedure|Blood taking|Blood will be taken for PBMCs during screening (twice), before randomization, at weeks 12 at week 18 and if PD.
1546147|NCT02625324|Device|Valiant Evo Thoracic Stent Graft System|Procedure: thoracic endovascular aneurysm repair (TEVAR)
1546148|NCT02625311|Procedure|surgery method using CR TKP|Operation through minimal invasive surgery or standard open surgery
1546149|NCT02625298|Device|ProRoot MTA|Apical thirds of the root canals obturated with ProRoot MTA (Dentsply Tulsa Dental Specialties, Tulsa, OK USA).
1546150|NCT02625298|Device|MTA+ Cerkamed|Apical thirds of the root canals obturated with MTA + (Cerkamed, Stalowa Wola, Poland).
1546151|NCT02625272|Procedure|HALS-CME with no touch isolation|the novel hand-assisted laparoscopic surgery (HALS) with complete mesocolic excision (CME) and no touch isolation for right colon cancer
1546155|NCT02625246|Biological|hMSCs|intravenous infusion of bone marrow-derived allogeneic stem cells
1546156|NCT02625233|Device|senofilcon C|
1546157|NCT02625233|Device|comfilcon A|
1546158|NCT02625220|Device|Prototype toric lens senofilcon A|Investigational prototype
1546159|NCT02625207|Drug|Maraviroc (Part 1)|300 mg twice daily x 5 days
1546160|NCT02625207|Drug|Maraviroc (Part 2)|150 mg once daily x 10 days
1546161|NCT02625207|Drug|Darunavir/cobicistat (Part 2)|800/150 mg once daily x 10 days
1546162|NCT02625194|Drug|Oxygen|Oxygen is supplied through suction port during bronchoscope-guided intubation.
1546163|NCT02625181|Procedure|Automated recommendation at the start of the case|The first notification is the main notification that informs the anesthesia providers at the start of anesthesia of the risk score for that individual patient and the recommended number of prophylactic interventions. The notification occurs within the anesthesia information management system (AIMS)
1546164|NCT02625181|Procedure|Automated notification at the start of surgery|The second notification within the AIMS will notify the anesthesia providers at the start of surgery when no prophylaxis has been given while three or more interventions were recommended.
1546165|NCT02625181|Procedure|Preoperative recommendations: by email|A recommendation on PONV prophylaxis to anesthesia providers through email at the Vanderbilt University Medical Center.
1546166|NCT02625181|Procedure|Automated notification at the end of surgery|A notification will remind anesthesia providers at the closing of surgery how many prophylactic interventions are required to adhere to the recommended number of interventions.
1546167|NCT02625181|Device|Anesthesia Information Management System (AIMS)|The anesthesia electronic record keeping system
1546168|NCT02625181|Device|Perioperative Data Warehouse (PDW)|The data warehouse that is used to gather perioperative data and create user reports. In this instance the PDW will be used to send the preoperative emails.
1546169|NCT02625181|Procedure|General anesthesia|Any anesthetic drugs that are used to induce general anesthesia above the level of sedation.
1546170|NCT02625181|Procedure|Elective surgery|Surgical procedures that are scheduled and not an emergency.
1546171|NCT02625181|Drug|Propofol|Anesthetic drug used to maintain general anesthesia
1546172|NCT02625181|Drug|Sevoflurane|Anesthetic drug used to maintain general anesthesia
1546173|NCT02625181|Drug|Isoflurane|Anesthetic drug used to maintain general anesthesia
1546174|NCT02625181|Drug|Desflurane|Anesthetic drug used to maintain general anesthesia
1546175|NCT02625181|Drug|Scopolamine|Prophylactic antiemetic
1546176|NCT02625181|Drug|Droperidol|Prophylactic antiemetic & rescue antiemetic
1546177|NCT02625181|Drug|Haloperidol|Prophylactic antiemetic & rescue antiemetic
1546178|NCT02625181|Drug|Dexamethasone|Prophylactic antiemetic & rescue antiemetic
1546179|NCT02625181|Drug|Promethazine|Prophylactic antiemetic & rescue antiemetic
1546180|NCT02625181|Drug|Meclizine|Prophylactic antiemetic & rescue antiemetic
1546181|NCT02625181|Drug|Aprepitant|Prophylactic antiemetic & rescue antiemetic
1546182|NCT02625181|Drug|Metoclopramide|Rescue antiemetic
1546183|NCT02625181|Drug|Fentanyl|Analgesic drug / Opioid
1546184|NCT02625181|Drug|Sufentanil|Analgesic drug / Opioid
1546185|NCT02625181|Drug|Alfentanil|Analgesic drug / Opioid
1546186|NCT02625181|Drug|Remifentanil|Analgesic drug / Opioid
1546187|NCT02625181|Drug|Morphine|Analgesic drug / Opioid
1546188|NCT02625181|Drug|Meperidine|Analgesic drug / Opioid
1546189|NCT02625181|Drug|Hydromorphone|Analgesic drug / Opioid
1546190|NCT02625181|Drug|Methadone|Analgesic drug / Opioid
1546191|NCT02625181|Drug|Oxycodone|Analgesic drug / Opioid
1546192|NCT02625181|Drug|Oxymorphone|Analgesic drug / Opioid
1546193|NCT02625181|Drug|Hydrocodone|Analgesic drug / Opioid
1546194|NCT02625181|Drug|Ketamine|Analgetic / Analgesic drug
1546195|NCT02625181|Drug|Ondansetron|Prophylactic antiemetic & rescue antiemetic
1546196|NCT02625181|Drug|Granisetron|Prophylactic antiemetic & rescue antiemetic
1546197|NCT02625181|Drug|Dolasetron mesylate|Prophylactic antiemetic & rescue antiemetic
1546198|NCT02625181|Drug|Palonosetron|Prophylactic antiemetic & rescue antiemetic
1546199|NCT02625181|Drug|Tropisetron|Prophylactic antiemetic & rescue antiemetic
1546200|NCT02625181|Drug|Ramosetron|Prophylactic antiemetic & rescue antiemetic
1546201|NCT02625168|Drug|Afatinib|Afatinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
1546202|NCT02625168|Drug|Erlotinib|Erlotinib from study recruitment until disease progression, intolerable side effects as judged by investigators or patient withdrawal
1546203|NCT02625155|Other|Urine diagnostic testing as SOC, drug regimen changes per SOC|
1546204|NCT02625155|Other|Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results|
1546205|NCT02625142|Other|Family-centered rounds checklist tool|A printed checklist containing 9 key tasks associated with effective delivery of family-centered rounds. A previously-identified member of each rounding team was responsible for holding the printed checklist during morning rounds. Team members were trained the in the use of this checklist prior to the post-intervention period, and a brief refresher training was conducted mid-way through the period.
1546206|NCT02625129|Other|Pharmacist-provided travel care|Subjects will receive a pre-travel consultation from a pharmacist with specialty training in travel medicine, and with authorization to prescribe medications and vaccines and administer injections
1546207|NCT02625103|Procedure|Blood sampling|blood samples for s-clozapine and s-desmethyl-clozapine analysis are collected at 10, 11, 12, 13 and 14 hours post evening-clozapine-administration
1546208|NCT02625103|Drug|Clozapine|Registration of the exact time of drug administration. Also postponement of any morning clozapine administration until ended blood sampling.
1546209|NCT02625090|Drug|UCB0942|"Active Substance: UCB0942
Pharmaceutical form: Film-coated tablet
Concentration: 25 mg, 100 mg or 200 mg
Route of Administration: oral"
1546210|NCT02625077|Procedure|Laparoscopic gastroesophageal valvuloplasty|
1546211|NCT02625077|Procedure|Laparoscopic Toupet fundoplication|
1546212|NCT02625064|Other|Blood samples collection before treatment|
1546213|NCT02625064|Other|Blood samples collection after treatment|
1546214|NCT02625064|Other|laboratory biomarker proteomic analysis|
1546215|NCT02625051|Procedure|Ureteroscopy|Under general anesthesia, the patient is placed in the lithotomy position. All procedures are performed under direct videoscopic and fluoroscopic guidance. Fluoroscopic screening is utilized using a mobile multidirectional C-arm fluoroscopy unit. A safety guide-wire is then placed into renal pelvis, followed by a ureteral access sheath to maintain low intra-renal pressure, and to facilitate the procedures. Using flexible ureteroscope, renal or proximal ureteral stone is identified and fragmented with a holmium laser. Basket extraction of residual fragments is done until visual complete clearance of stone fragments is achieved.
1546216|NCT02625051|Procedure|Percutaneous nephrolithotomy|Under general anesthesia, an open-ended 5 french ureteral exchange catheter is placed into the ipsilateral ureter under cystoscopic guidance. The patient is then safely turned and secured in the prone position. Percutaneous renal access is obtained under ultrasonographic or fluoroscopic guidance. Either a 24 or 30 french sheath is advanced in the kidney and nephroscopy is performed with a rigid offset nephroscope. Stone fragmentation is accomplished using a dual CyberWand lithotripter or holmium laser lithotripsy. Flexible nephroscopy is performed to look for possible residual fragments and basket extraction is done for complete clearance of stone.
1546264|NCT02624778|Biological|LY3002813|Administered IV
1546265|NCT02624778|Drug|Placebo|Administered IV
1546217|NCT02625051|Device|Ureteral stent (double-J stent)|After ureteroscopy (URS) is done and stone clearance is achieved, a 4.6 french ureteral stent is routinely placed at the end of the procedure to drain the kidney for 1-3 weeks.
1546218|NCT02625051|Device|Percutaneous nephrostomy tube|At the end of the percutaneous nephrolithotomy (PNL) procedure, a 10 french Cope loop percutaneous nephrostomy tube is placed in all patients to drain the kidney for 1-2 days.
1546219|NCT02625038|Device|EUDAMED CIV-14-03-011940|
1546220|NCT02625025|Procedure|Low pression pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.
Intra-abdominal pressure will be maintained at 8 mm Hg during pneumoperitoneum creation and insertion of trocars."
1546221|NCT02625025|Procedure|Standard Pression Pneumoperitoneum|"Pneumoperitoneum will be obtained by infusing carbon dioxide to distend the peritoneal cavity.
Intra-abdominal pressure will be maintained at 12 mm Hg during pneumoperitoneum creation and insertion of trocars."
1546222|NCT02625025|Procedure|Single Port Access Laparoscopy|Laparoscopy surgery with use of only one incision of 2 cm in the umbilicus in order to threat benign adnexal pathology
1546223|NCT02624999|Biological|AlloVax™|AlloVax™ combines an anti-tumor effect of mini-transplant procedures with patient specific tumor antigens
1546224|NCT02624999|Drug|Cisplatin|Subjects in the chemotherapy arm will receive up to 6 cycles of cisplatin on day 0 of the 3-week cycle at dose of 80-100 mg/m2 IV and 1000 mg/m2 IV 5FU on days 1-4 of the cycle
1546228|NCT02624973|Drug|Neoadjuvant tamoxifen + goserelin (premenopausal women)|
1546229|NCT02624973|Drug|Neoadjuvant letrozole (postmenopausal women)|
1546230|NCT02624973|Drug|Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)|
1546231|NCT02624973|Drug|Neoadjuvant docetaxel + cyclophosphamide|
1546232|NCT02624973|Drug|Neoadjuvant docetaxel|
1546233|NCT02624973|Drug|Neoadjuvant docetaxel + trastuzumab + pertuzumab|
1546234|NCT02624973|Drug|Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab|
1546235|NCT02624973|Drug|Neoadjuvant olaparib|
1546236|NCT02624973|Drug|Neoadjuvant olaparib + carboplatin (if lack of response to olaparib alone)|
1546237|NCT02624973|Procedure|Breast conserving surgery or mastectomy + SNB/axillary dissection|After response to neoadjuvant treatment
1546238|NCT02624973|Radiation|Postoperative radiotherapy breast/chest wall + regional lymph nodes|
1546239|NCT02624973|Drug|Adjuvant trastuzumab|
1546240|NCT02624973|Drug|Adjuvant letrozole (postmenopausal women)|
1546241|NCT02624973|Drug|Adjuvant tamoxifen + goserelin (premenopausal women)|
1546242|NCT02624973|Drug|Adjuvant palbociclib (if palbociclib given neoadjuvant)|
1546243|NCT02624973|Drug|Adjuvant Epirubicin+ Cyclophosphamide|
1546244|NCT02624960|Device|Accucinch Implant|Percutaneous implantation of the Accucinch Implant in the mitral subannular space
1546245|NCT02624947|Biological|RSV F vaccine with adjuvant|
1546246|NCT02624947|Biological|Formulation buffer|
1546247|NCT02624921|Other|There was no intervention.|Participants were transported one day to a urban setting, one day to a green space, one day to a beach. No intervention was done.
1546248|NCT02624908|Drug|canagliflozin|Subjects randomized to active drug will receive canagliflozin 100 mg . If study drug well tolerated, dose will be increased to 300 mg canagliflozin at Visit 4.
1546249|NCT02624908|Drug|placebo|Subjects randomized to placebo will receive 100 mg placebo pill . If study drug well tolerated, dose will be increased to 300 mg placebo pill at Visit 4.
1546250|NCT02624882|Procedure|Positive rapid GAS test|"If TDR positive, the child will be treated with antibiotics alone:
Amoxicillin 50mg / kg / day in 2 divided doses for 10 days (maximum dose 3 g / day in 2 divided doses) Or if allergic to penicillins and in the absence of cross-known allergy to cephalosporins
Cefpodoxime 8mg / kg / day in 2 divided doses for 10 days (maximum dose 400mg / day in 2 divided doses) J10 A control visit will review all the children included in the study. If the surgeon deems it necessary, the patient will be reviewed in consultation up to three months."
1546251|NCT02624882|Procedure|Negative rapid GAS test|Usual care
1546253|NCT02624856|Drug|Liposomal bupivacaine|Liposomal bupivacaine (EXPAREL®) 133 mg in 10 mL for quadriceps sparing femoral nerve block and 133 mg in 20 mL for posterior knee compartment periarticular injection.
1546254|NCT02624856|Drug|Bupivacaine plus dexamethasone|Bupivacaine HCl 0.5% 10 mL plus dexamethasone 2 mg for quadriceps sparing femoral nerve block and bupivacaine HCl 0.25% plus dexamethasone 2 mg for posterior knee compartment periarticular injection
1546255|NCT02624843|Drug|Benzyl Alcohol Lotion 5%|White topical lotion
1546256|NCT02624843|Drug|Ulesfia (benzyl alcohol lotion) 5%|White topical lotion
1546257|NCT02624843|Drug|Placebo|White topical lotion
1546258|NCT02624830|Drug|Sulfonylurea|See Arm description.
1546259|NCT02624817|Drug|Sulfonylurea|See Arm description.
1546260|NCT02624804|Genetic|Stem Cell Educator Therapy|"Patients will receive apheresis and then have their own blood returned to them with the educated stem cells"
1546261|NCT02624791|Device|1-DAY ACUVUE® MOIST contact lenses|spherical contact lenses worn during simulated driving tests
1546262|NCT02624791|Device|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses|toric contact lenses worn during simulated driving tests
1546263|NCT02624791|Other|No contact lenses|simulated driving tests
1546266|NCT02624765|Drug|Digoxin (monotherapy)|Digoxin: oral or intravenous loading dose 0.5 mg q 12 h (total 4 doses over 48 hours) Oral maintenance dose: 0.25 mg-1mg/day
1546267|NCT02624765|Drug|Sotalol (monotherapy)|Sotalol: 80 mg TID (TID mg/day)
1546268|NCT02624765|Drug|Flecainide (monotherapy)|Flecainide: 100 mg TID (300 mg/day)
1546269|NCT02624765|Drug|Digoxin (dual therapy)|Digoxin: oral or intravenous loading dose 0.5 mg q 8 h (total 4 doses over 32 hours) Oral maintenance dose: 0.25 mg-1mg/day
1546270|NCT02624765|Drug|Sotalol (dual therapy)|Sotalol: 160 mg BID (320 mg/day)
1546271|NCT02624765|Drug|Flecainide (dual therapy)|Flecainide: 100 mg TID (300 mg/day)
1546272|NCT02624752|Dietary Supplement|Ensure|Comparison of enhanced oral nutrition supplementation versus standard of care
1546273|NCT02623647|Radiation|stereotactic body radiotherapy SBRT|40 Gy in 3 fractions to the prostate gland delivered with stereotactic body radiotherapy
1546274|NCT02623634|Behavioral|Position, waveform|different positions and waveform
1546275|NCT02623621|Drug|chemotherapy plus bevacizumab|Every chemotherapy regimen combined with bevacizumab is allowed
1546276|NCT02623608|Other|Reference breakfast|A high fat, high calorie breakfast
1546277|NCT02623608|Other|Active Ingredient 1|A high fat, high calorie breakfast including the Active Ingredient 1
1546278|NCT02623608|Other|Active Ingredient 2|A high fat, high calorie breakfast including the Active Ingredient 2
1546279|NCT02623608|Other|Active Ingredient 3|A high fat, high calorie breakfast including the Active Ingredient 3
1546280|NCT02623608|Other|Active Ingredient 4|A high fat, high calorie breakfast including the Active Ingredient 4
1546281|NCT02623595|Radiation|Stereotactic body radiotherapy|A type of radiation therapy
1546282|NCT02623595|Drug|rhGM-CSF|Immune modulating agents
1546285|NCT02623569|Drug|Ivabradine|Not Provided
1546286|NCT02623569|Drug|Atenolol|Not Provided
1546287|NCT02624726|Drug|5 Fluorouracil|5 Fluorouracil: 400mg/m2, bolus infusion in <5min followed by 5 Fluorouracil: 2400mg/m2, i.v in 46 hours continuous infusion (cycle repeated every two weeks)
1546288|NCT02624726|Drug|Leucovorin|Leucovorin: 400mg/m2, i.v in 2 hours infusion (cycle repeated every two weeks)
1546289|NCT02624726|Drug|Irinotecan|Irinotecan: 180mg/m2, i.v in 90min infusion (cycle repeated every two weeks)
1546290|NCT02624726|Drug|Aflibercept|Aflibercept: 4mg/kg i.v in 1 hour infusion (cycle repeated every two weeks)
1546292|NCT02624700|Drug|Pemetrexed|Treatment schedule is administered on day 1 of each 14-day cycle by Intravenous infusion over 10 minutes with a dose of 500 mg/m2. If necessary, the duration of the pemetrexed infusion may be extended to a maximum of 20 minutes.
1546293|NCT02624700|Drug|Sorafenib|Treatment schedule is administered twice daily by mouth on an empty stomach on days 1-5 of each 14-day cycle with a dose of 400 mg. Instruct patient to take sorafenib on an empty stomach (ie, at least 1 hour before or 2 hours after eating) starting the morning of each pemetrexed dose. If a sorafenib dose is missed, the patient will be instructed to omit the dose and to not take more than 2 doses of sorafenib on the same day to make up for doses that were missed on the previous day.
1546294|NCT02624687|Behavioral|Decreasing Sedentary Behavior|
1546295|NCT02624687|Other|No intervention|
1546296|NCT02624674|Device|Multi-spectral Imaging Device (MSID)|
1546297|NCT02624661|Drug|Glycerol|
1546298|NCT02624648|Behavioral|The Female Sexual Function Index (FSFI)|The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function
1546299|NCT02624648|Behavioral|The Female Intervention Efficacy Index (FIEI)|The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function
1546300|NCT02624648|Behavioral|The Beck Depression Inventory II|The Beck Depression Inventory II will be used to evaluate or ward off depression
1546301|NCT02624648|Drug|Lepidium Meyenii Walp|They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
1546302|NCT02624648|Drug|Placebo|They will receive a capsule of Placebo twice a day for 120 days
1546303|NCT02624635|Other|Manual Therapy|The scheme established for that intervention is as follows: joint manipulation passive ankle and foot, myofascial release technique (gastrocnemius, soleus muscle and plantar fascia), neural mobilization (nerve tibial) and stretching the plantar region and sural triceps, following the recommendations described by Mcpoil et al. (2008).
1546304|NCT02624635|Other|Manual Therapy and Hip Strengthening|It will be done the same treatment performed in group 1 plus the strengthening of the muscles of the hip (iliac muscle, psoas, gluteus maximus, gluteus medius and gluteus minimus) and the treatment schedule established for this intervention is the use of exercises with progressive resistance. Will be performed 3 sets of 10 reps with 30 seconds rest between each set, according to the guidelines of the American College of Sports Medicine (ACSM, 2014). The home exercises consist of repeating the same procedures performed for supervised strengthening. The calculation of the ideal individual load will be carried by Brzycki formula, i.e. one repetition maximum (1RM) = weight ÷ [1.0278 - (0.0278 x number of repetitions)] as was used by (Shirazi et al., 2007).
1546305|NCT02624622|Procedure|Chlorhexidine application to cord by mother|
1546306|NCT02624622|Procedure|Chlorhexidine application by CHW|
1546307|NCT02624609|Other|Control without pomegranate juice|Control meal of 109 g white bread and 200 ml water (containing the same amount and type of sugars naturally present in pomegranate juice) to which the response of the test meal with pomegranate juice will be compared to.
1546308|NCT02624609|Other|Test with pomegranate juice|The test meal will contain 109 g white bread and 200 ml of pomegranate juice whose response will be compared to that of the control meal.
1546309|NCT02624596|Drug|Ketamine|OCD patients in this arm will receive 0.5mg/kg of ketamine - one single infusion
1546310|NCT02624596|Drug|Midazolam|OCD patients in this arm will receive 0.045mg/kg of midazolam - one single infusion
1546313|NCT02624544|Drug|esomeprazole|esomex 40 mg twice daily
1546314|NCT02624544|Drug|desonide|topical corticosteroid desonid 0,1% b.i.d
1546315|NCT02624531|Drug|Taxane|NACT and Fertility-sparing Treatment Strategy
1546316|NCT02624531|Procedure|radical trachelectomy|NACT and Fertility-sparing Treatment Strategy
1546317|NCT02624518|Drug|Gallium Ga 68-labeled GRPR Antagonist BAY86-7548|Imaging with PET/MRI
1546318|NCT02624518|Procedure|Magnetic Resonance Imaging|Imaging with 68Ga-RM2 PET/MRI
1546319|NCT02624518|Procedure|Positron Emission Tomography|Imaging with 68Ga-RM2 PET/MRI
1546320|NCT02624505|Drug|90 mcg Reference Product|Drug: 90 mcg Reference Product
1546321|NCT02624505|Drug|180 mcg Reference Product|Drug: 180 mcg of Reference Product
1546322|NCT02624505|Drug|90 mcg Test Product|Drug: 90 mcg of Test Product
1546323|NCT02624505|Drug|Placebo|Placebo Product
1546324|NCT02624492|Drug|BI 836826|
1546325|NCT02624492|Drug|GemOx|
1546326|NCT02624492|Drug|Rituximab|
1546327|NCT02624492|Drug|GemOx|
1546328|NCT02624479|Drug|Sodium thiosulfate|oral administration of thiosulfate
1546329|NCT02624466|Other|CKD progress|CKD progress
1546330|NCT02624453|Drug|Fluconazole|Pre-emptive fluconazole therapy at 800mg/day for two weeks, then 400mg/day for eight weeks, and then 200mg/day thereafter till CD4 count goes beyond 200cells/ml
1546331|NCT02624453|Drug|Antiretroviral therapy|First line anti-retroviral therapy according to Cameroon national guidelines for the management of HIV/AIDS
1546332|NCT02624440|Drug|Standard myeloma treatment|The choice of myeloma standard treatment is at the discretion of the treating investigator guided by the national Danish guidelines for treatment of multiple myeloma
1546333|NCT02624440|Drug|Clarithromycin|P.o. clarithromycin 250 mg twice daily
1546334|NCT02624440|Drug|Sulfamethoxazole/trimethoprim|P.o. sulfamethoxazole/trimethoprim 400/80 mg twice daily
1546335|NCT02624440|Drug|Observation|Observation without prophylactic antibiotic
1546336|NCT02624427|Device|Measurement of intraocular pressure (IOP)|Measurement of IOP with the following devices: (1) Goldmann tonometer, (2) Dynamic Contour tonometer, and (3) Corvis ST tonometer
1546337|NCT02624414|Device|PillCam® COLON 2 Capsule Endoscopy|
1546338|NCT02624401|Drug|Dexmedetomidine|Intravenous infusion
1546339|NCT02624401|Drug|Propofol|Intravenous infusion
1546340|NCT02624401|Drug|S-ketamine|Intravenous infusion
1546341|NCT02624401|Drug|Sevoflurane|Inhalation
1546342|NCT02624401|Drug|Placebo|Intravenous infusion of saline (Ringer's Acetate)
1546343|NCT02624388|Drug|Genistein|Estrogen-like compound (isoflavone) derived from soybeans
1546344|NCT02624388|Drug|Placebo|Pill that contains no medicine
1546345|NCT02624375|Drug|Zoster Vaccine Live|
1546349|NCT02624349|Drug|Quadravalent human papillomavirus vaccine|Vaccine will be administered to all transplant recipients. Controls will be recruited based on previous documented receipt of vaccine
1546350|NCT02624336|Other|DTC1|15ml DTC1 twice a day, rinse for 30sec refrain from eating or drinking for 30min
1546351|NCT02624336|Other|Oradex|15ml Chlorhexidine gluconate 0.12% (w/v) twice a day, rinse for 30sec refrain from eating or drinking for 30min
1546352|NCT02624336|Other|Distilled water|15ml distilled water twice a day, rinse for 30sec refrain from eating or drinking for 30min
1546353|NCT02624323|Procedure|Real-time ultrasound-guided central vein catheterization.|
1546354|NCT02624310|Drug|Droxidopa (L-DOPS)|Patients will be given their initial 100 mg of L-DOPS (visit 2a). The dose of L-DOPS will be increased in escalation in the following visits. Each day the dose will be increased 100 mg. The escalating doses of L-DOPS will be 200 mg (visit 2b), 300 mg (visit 2c), 400 mg (visit 2d), 500 mg (visit 2e) and 600 mg (visit 2f). Following this titration step, L-DOPS will be withdrawn from the subjects for a minimum of two weeks, when the subject will return for visit 3.Visit 3a,b,c,d,e,f: Carbidopa open-label dose titration. This titration step will be similar than L-DOPS titration. Carbidopa starting dose will be 100 mg (visit 3a) and will be increased 100 mg each visit up to a maximum of 600 mg (visit 3f). Following carbidopa titration step, patients will be withdrawn from the drug for minimum of two weeks, then the subject will return for the next titration step (visit 4).
1546355|NCT02624310|Drug|Placebo|
1546356|NCT02624297|Other|Aerobic exercise training|The patients will be submitted to four months of aerobic exercise training, three time a week.
1546357|NCT02624284|Device|transcranial direct current stimulation (tDCS)|"Active tDCS: A neuroConn DC-Stimulator Plus will apply a constant direct current (1.0 mA to 2.0 mA via 5x7 electrode) to the left dorsal lateral prefrontal cortex. Each participant will receive anodal stimulation for a period of 20 minutes. For anodal stimulation over the left DLPFC, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area (international EEG 10/20 system).
Sham tDCS: During sham tDCS, a 1.0 mA to 2.0 mA current will be delivered for approximately 30 seconds before being extinguished over a course of seconds. Again, the anodal electrode will be placed over the left F3 and the cathodal electrode over the right supraorbital area. Most participants cannot distinguish between real and sham tDCS."
1546358|NCT02624271|Other|blood samples analysis|Analyze blood samples with GastroPanel test to detect gastric precancerous lesions.
1546359|NCT02624258|Biological|CD19 RNA redirected autologous T-cells (RNA CART19 cells)|Subjects will be treated with IV administration of RNA anti-CD19 CAR T cells for a total of six doses over 3 weeks. The first dose will be administered 1-4 days after infusion of cyclophosphamide 30mg/kg.
1546362|NCT02624219|Drug|MF59 adjuvant|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion.
1546363|NCT02624219|Biological|Monovalent Influenza A/H5N8 vaccine|Monovalent inactivated influenza A/H5N8 virus vaccine for IM injection. prepared from influenza virus propagated in chicken egg fluid using seed virus prepared from the candidate vaccine virus (CVV), influenza virus A/gyrfalcon/Washington/41088-6/2014(H5N8)-PR8-IDCDC-RG43A (abbreviated as IDCDC-RG43A).
1546364|NCT02624206|Dietary Supplement|Juice A|Subjects to be given juice daily for 3 weeks.
1546365|NCT02624206|Dietary Supplement|Juice B|Subjects to be given juice daily for 3 weeks.
1546366|NCT02624193|Behavioral|MBSR Program|Mindfulness-based stress reduction, as described previously.
1546367|NCT02624193|Behavioral|HT Program|Health education curriculum, as described previously
1546368|NCT02624180|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
1546369|NCT02624180|Drug|Placebo|A substance containing no medication
1546370|NCT02624167|Drug|NW-3509A|Patients will be given oral doses of 15, 20 and 25 mg BID of NW-3509A
1546371|NCT02624167|Drug|Placebo|Patients will be given oral dose of matching Placebo
1546372|NCT02624154|Procedure|pancreatectomy|Remove the pancreatic neuroendocrine tumor by surgery
1546373|NCT02624141|Drug|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 grams per deciliter (g/dL) versus baseline.
1546374|NCT02624128|Drug|Valproic Acid|Treatment will be administered orally starting at day -14, with 500 mg slow releasing tablet at evening. Thereafter, the dose will be increased also using 300 mg tablets until reaching 1500 mg on day -1. The titration strategy is to reach a target VPA serum level of 50-100 μg/ml.
1546375|NCT02624128|Drug|Cisplatin|administered intravenously at dose of 75 mg/m2 given every three weeks for 6 cycles
1546376|NCT02624128|Drug|Cetuximab|administered intravenously at induction dose of 400 mg/m2 followed by maintenance doses of 250 mg/m2 given weekly
1546377|NCT02624102|Behavioral|Trial based cognitive therapy|Patients with MDD, in use of antidepressants plus Trial Based Cognitive Therapy
1546378|NCT02624102|Behavioral|Behavioral Activation|Patients with MDD, in use of antidepressants plus Behavioral Activation
1546379|NCT02624102|Drug|Antidepressants|Patients with MDD, in use of antidepressants (fluoxetine, citalopram, escitalopram, bupropion, etc.) without psychotherapy.
1546380|NCT02624089|Drug|Ropivacaine|Ropivicaine will be administered via in-line nebulization using the Aeroneb Pro™ system
1546381|NCT02624089|Drug|Normal saline|Normal saline will be administered via in-line nebulization using the Aeroneb Pro™ system
1546382|NCT02624076|Other|Acupuncture|semi-fixed protocol will be used including four local core points; conception vessel (CV) 3, CV 6, and stomach (ST) 29 bilaterally and four in the leg/feet; spleen (SP) 6, and SP 9 bilaterally. The core points CV 3, CV 6, ST 29, SP 6, and SP 9 are thereafter connected to electrical stimulator (Hwoto, China) and stimulated with low-frequency, 2Hz, 0.5 ms
1546383|NCT02624076|Other|expectant management|one initial counselling session, an information leaflet on timed intercourse, access to a telephone helpline for queries and ad hoc support on demand from the fertility clinic over a period of 4 months post randomization.
1546384|NCT02624063|Drug|Daclatasvir + Sofosbuvir|Sofosbuvir 400 mg tablet + Daclatasvir 60 mg tablet oral dosing once daily for 12 weeks
1546385|NCT02624063|Drug|Simeprevir + Sofosbuvir|Sofosbuvir 400 mg tablet + Simeprevir 150 mg tablet oral dosing once daily for 12 weeks
1546386|NCT02624050|Drug|Methohexital|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
1546387|NCT02624050|Drug|Propofol|Both drugs of interest are standard of care for use as general anesthetics. The purpose of the study is the determine the susceptibility of both drugs to inducing a hypotensive event.
1546389|NCT02624011|Behavioral|7 days of habitual physical activity followed by 7 days of reduced physical activity|Young, active participants will undergo a 7 day period of habitual physical activity followed by a 7 day period of step reduction and exercise cessation.
1546390|NCT02623998|Drug|insulin glargine|Dose is titrated to achieve fasting normoglycemia
1546391|NCT02623998|Drug|sitagliptin/metformin|Dose is titrated to 50/1000 mg bid or maximal tolerated dose
1546392|NCT02623998|Behavioral|lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
1546393|NCT02623985|Device|Sofia|Patients who presented with sore throat will be performed throat swab and sent for Sofia for rapid test.
1546394|NCT02623985|Device|QuickVue|Patients who presented with sore throat will be performed throat swab and sent for QuickVue for rapid test.
1546395|NCT02623985|Device|Throat swab culture|Patients who presented with sore throat will be performed throat swab and sent for throat swab culture for gold standard.
1546396|NCT02623972|Drug|Eribulin|administered IV for 4 cycles
1546397|NCT02623972|Drug|Adriamycin|administered IV with cyclophosphamide for 4 cycles
1546398|NCT02623972|Drug|Cyclophosphamide|administered IV with adriamycin for 4 cycles
1546399|NCT02623959|Behavioral|Questionnaires|Symptom and quality of life questionnaires completed at baseline and at 10 - 14 days after receiving Saline or Doxycycline.
1546400|NCT02623959|Drug|Fentanyl Patch|Participant given a Fentanyl patch, 12 mcg/hour, which should be worn at follow up visit 5 days after IPC placement.
1546401|NCT02623959|Drug|Fentanyl (IV)|Fentanyl 50 mcg given by vein prior to catheter draining.
1546402|NCT02623959|Other|Saline|Catheter is drained then Saline placed in the catheter. Catheter is capped for 1 hour and then drained again.
1546403|NCT02623959|Drug|Doxycycline|Catheter is drained then Doxycycline 500 mg placed in the catheter. Catheter is capped for 1 hour and then drained again.
1546404|NCT02623959|Behavioral|Phone Calls|After the IPC is removed, participant is called one time each month by study staff to check on their status.
1549214|NCT02603809|Drug|Lisinopril|20 mg capsules orally o.d. for 8 weeks
1546405|NCT02623933|Radiation|MRI assisted focal boost with HDR monotherapy|Prior to brachytherapy treatment, a multiparametric MRI will be obtained for identification of the dominant intraprostatic lesion (DIL) and fused with the preplanning transrectal ultrasound. A total of 19 Gy will be prescribed to the prostate, organ at risk limits will be observed and up to 22.5 Gy can be delivered to the DIL
1546406|NCT02623920|Drug|Brentuximab|Brentuximab vedotin IV over 30 minutes on day 1.Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
1546407|NCT02623920|Drug|Bendamustine|Bendamustine IV over 30-60 minutes on days 1-2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
1546408|NCT02623920|Drug|Rituximab|Rituximab IV on day 2. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
1546409|NCT02623881|Device|Cervical pessary|Arabin (cervical pessary) will be inserted at 16-22 weeks and removed at 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
1546410|NCT02623881|Drug|Vaginal progesterone|Vaginal progesterone (Cyclogest 400 mg) once a day will be used, from 16-22 to 36 weeks of pregnancy or in case of premature rupture of membranes, signs of preterm labour or patient severe discomfort
1546411|NCT02623868|Drug|CKD-519 50mg 2Tabs.|after taking Standard meal, CKD-519 50mg 2Tabs. administration.
1546412|NCT02623868|Drug|CKD-519 100mg 1Tab.|after taking Standard meal, CKD-519 100mg 1Tab. administration.
1546413|NCT02623868|Drug|CKD-519 100mg 1Cap.|after taking Standard meal, CKD-519 100mg 1Cap. administration.
1546414|NCT02623855|Behavioral|Family outings|Participants will be invited to three weekly outings to local parks, case management and support in getting to nature. Participants will be offered transportation to the outings and s meal at local nature destinations. Programming at the park will include a picnic and walk with nature exploration, and will be facilitated by park and clinic staff.
1546415|NCT02623855|Behavioral|Park prescription|Participants will receive a map of local parks, and the recommendation to be physically active outdoors three days a week in nature.
1546416|NCT02623855|Device|Pedometry|Participants will record their daily pedometry.
1546417|NCT02623855|Behavioral|Case Management|Participants will receive a phone call to list potential barriers to participating in nature outings, and will talk through solutions with an investigator. Participants will be offered assistance with transportation if necessary.
1546418|NCT02623842|Device|Tonederm® (Radiofrequency non ablative)|The application of RF was performed by physical therapist trained in the technique of radio frequency through the Tonederm® brand device with capacitive transfer method using non-ablative handle with electrode in the region of the external urethral meatro and coupling electrode placed on the participant's back. For application, the participants were in gynecological position. The session had an average duration of 20 minutes. The temperature was measured by an infrared thermometer when it reached 41graus radiofrequency was maintained for 2 minutes.
1546419|NCT02623829|Drug|Botulinum Toxin|50 units of botulinum toxin diluted in 1ml of normal saline will be administered.
1546420|NCT02623829|Drug|Saline|1ml of normal saline will be administered
1546421|NCT02623816|Drug|Optimal Dosing of Omeprazole|Omeprazole 20 mg
1546422|NCT02623803|Drug|Lidocaine|
1546423|NCT02623803|Drug|Placebo D5W|
1546424|NCT02623790|Other|Test meal (butter)|Subjects will eat one meal test containing 33g of lipids from butter (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
1546425|NCT02623790|Other|Test meal (cheddar cheese)|Subjects will eat one meal test containing 33g of lipids from cheddar cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
1546426|NCT02623790|Other|Test meal (cream cheese)|Subjects will eat one meal test containing 33g of lipids from cream cheese (percent of total caloric intake: 15.0% from proteins; 53.0% from carbohydrates; 32.0% from fat).
1546427|NCT02623777|Dietary Supplement|Arabinoxylan oligosaccharides|Arabinoxylan oligosaccharides administered
1546428|NCT02623777|Dietary Supplement|Short chain fatty acids|Short chain fatty acids administered
1546431|NCT02623738|Drug|Placebo ophthalmic solution|
1546432|NCT02623738|Drug|DE-117 ophthalmic solution low|
1546433|NCT02623738|Drug|DE-117 ophthalmic solution high|
1546434|NCT02623738|Drug|Latanoprost ophthalmic solution 0.005%|
1546435|NCT02623725|Biological|CYD Dengue Vaccine (5-dose formulation)|0.5 mL, Subcutaneous
1546436|NCT02623725|Biological|Placebo, NaCl 0.9%|0.5 mL, Subcutaneous
1546437|NCT02623712|Other|More Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density)
1546438|NCT02623712|Other|Less Frequent Surveillance Strategy|Chest CT scans to be repeated at 3, 6, 12 and/or 24 months, depending on patient risk factors and nodule size and attenuation (density). Overall, participants in the less frequent arm are expected to undergo 30% fewer surveillance imaging tests.
1546439|NCT02623699|Drug|BIIB067|Part A and B
1546440|NCT02623699|Other|Placebo|Part A and B
1546441|NCT02623686|Other|Aroma Therapy Massage and Inhalation Patch|
1546442|NCT02623673|Drug|simultaneous treatment with intravitreal injection of bevacizumab 1.25mg and intravitreal implant of dexamethasone 0.7mg.|
1546443|NCT02623660|Device|ODIN1|"Shortly after surgery, electrodes will be applied to the lower extremity in such a way that the current will flow from the ankle through the knee replacement and pass through the thigh. The frequency of the treatments will vary over the period of time from post-op recovery to end of rehab.
All treatments are applying current that consists of different combinations of intensities within the micro to nano ampere ranges."
1546444|NCT02623660|Other|Standard Care|Anti-thrombotic medication. Elevation and ice. Pain medications as needed. Dressings changes. Topical antibiotics. Progressive physical therapy.
1546445|NCT02623660|Device|Diagnostic Device Testing|Diagnostic interventions include: the Perometer which scans the lower extremity and determines its volume to a high degree of accuracy; the Impedimed Bioimpedance Spectroscopy (BIS) device that measures intra and intercellular fluid movement; the Microfet muscle force testing device that provides a digital output of the number of pounds exerted by the quadriceps upon extension; the Acumar digital digital Inclinometer that accurately measures the ROM of the knee; and the K.I.S.S. wound measuring system to measure rate of incision healing.
1546448|NCT02623543|Device|OrthoK|
1546449|NCT02623530|Other|Educational intervention|"Control Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through the Methodology of PBL without the support MEAPC.
Experimental Group: An educational intervention focusing on first aid for the development of skills and dispositions of critical thinking. For this group will be taught the contents of first aid through Methodology PBL, supported by the MEAPC."
1546450|NCT02623504|Drug|Carbamazepine|200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
1546451|NCT02623504|Drug|Placebo|Dosage to match active treatment by mouth twice daily in the morning and in the evening.
1546452|NCT02623491|Drug|JNJ-55375515|Participants will receive JNJ-55375515 at a starting dose of 0.75 milligrams (mg) and maximum escalated dose will be 200 mg.
1546453|NCT02623491|Drug|Placebo|Participants will receive matching placebo.
1546454|NCT02623478|Drug|Insulin Lispro|Administered subcutaneously (SC)
1546455|NCT02623465|Drug|Insulin Lispro|Administered subcutaneously (SC)
1546456|NCT02623452|Drug|Insulin Lispro|Administered subcutaneously (SC)
1546457|NCT02623439|Drug|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant|Cyclophosphamide 50 mg/kg IV Days 3 and 4 post transplant
1546458|NCT02623426|Drug|Dexamethasone intravitreal implant 0.7 mg|Standard preparation as described for intravitreal injections.
1546459|NCT02623426|Drug|Intravitreal Methotrexate 400 µg|"Intravitreal Methotrexate 400 µg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
Use of frozen methotrexate preparations are permitted if used within 45 days of preparation and freezing and within 8 hours after thawing"
1546460|NCT02623426|Drug|Intravitreal Ranibizumab 0.5 mg|Intravitreal Ranibizumab 0.5 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to the injection.
1546461|NCT02623387|Procedure|Ultrasound guided paravertebral block|Paravertebral blocks is a regional anaesthetic technique in which thoracic spinal nerves are inhibited for post operative analgesia in patients undergoing breast surgery. The site of injection can be determined using anatomical landmarks (standard) or using ultrasound guidance.
1546462|NCT02623374|Behavioral|self-help CBT intervention (SHCBT)|See 'Arms' section
1546466|NCT02623335|Other|QPL (question prompt list) brochure|The QPL intervention includes the QPL intervention brochure, plus a letter from the surgeon encouraging its use during the upcoming office visit. Intervention materials will be mailed in advance of the patient's appointment with an enrolled surgeon.
1546467|NCT02623322|Drug|MHAA4549A|MHAA4549A will be administered as a single dose by IV administration.
1546468|NCT02623322|Drug|Placebo|Placebo will be administered as a single dose by IV administration.
1546469|NCT02623309|Procedure|Allogeneic (Allo) hematopoietic stem cell transplantation|
1546470|NCT02623296|Drug|GLPG1205|Once daily administration of 2 GLPG1205 capsules from Day 1 to Day 13
1546471|NCT02623296|Drug|Placebo|Once daily administration of 2 matching placebo capsules from Day 1 to Day 13
1546472|NCT02623296|Drug|Cocktail of CYP450 substrates|Single administration on Day 13 of cocktail of CYP450 substrates: warfarin tablet, omeprazole capsule and caffeine oral solution
1546473|NCT02623283|Other|No intervention given|Participants will have a full dental examination but no operative intervention
1546474|NCT02623270|Device|Noninvasive Ventilator, V60 (Philips)|The noninvasive ventilator will be set to deliver 10 breaths per minute with a pressure setting of 8 cm H2O during exhalation and 20 cm H2O during inspiration. The inspired oxygen fraction given by the ventilator will be set at the maximum level (100% oxygen).
1546475|NCT02623270|Device|Manual Bag|Oxygen will flow through the standard breathing circuit with the fresh gas flow rate set at 10 L/min and the patient will be ventilated. The anesthesia provider will manually bag mask ventilate the patient until the anesthesiologist feels comfortable that the patient can be ventilated appropriately.
1546476|NCT02623257|Other|mutation detection|
1546477|NCT02623257|Other|ARMS|
1546478|NCT02623257|Genetic|ctDNA analysis|
1546479|NCT02623244|Procedure|Laparoscopic oophorocystectomy or oophorectomy|
1546480|NCT02623231|Drug|Escitalopram|Group number 1 will include 50 patients, who will receive Escitalopram at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
1546481|NCT02623231|Drug|placebo|group # 2 Will include 50 patients , who will receive placebo at a dose of 10 mg for a week exceeding 20 mg immediately after diagnosis for 3 months
1546523|NCT02622906|Drug|Placebo|Vehicule injection per month during 6 months
1546484|NCT02623205|Drug|Escitalopram|Participants randomized to the escitalopram group will be given the medication for 8 weeks, after which they will be given the option to continue for 4 more weeks if they are close to remission.
1546485|NCT02623205|Drug|Placebo|To reduce the burden of the patients on placebo, the placebo trial will have a target of 8 weeks. To provide an opportunity for placebo non-responders to receive active drug and to aid in recruitment, we will provide 8-12 weeks of SSRI treatment to placebo non-responders.
1546486|NCT02623192|Other|Patients who have performed the ARDS pulmonary function test|
1546487|NCT02623179|Other|culture versus Molecular diagnostics|Treatment based on the results of the FH C & S testing - Odd Numbers on randomization table
1546488|NCT02623153|Drug|Oxaliplatin|oxaliplatin 130 mg/m2
1546489|NCT02623153|Drug|capecitabine|capecitabine of 1000 mg/m2
1546490|NCT02623153|Drug|S1|S1 of 40 mg/m2
1546491|NCT02623153|Drug|Docetaxel|docetaxel 40 mg/m2
1546492|NCT02623140|Device|Biofreedom|PCI with Biofreedom stent
1546493|NCT02623140|Device|Orsiro|PCI with Orsiro stent
1546494|NCT02623127|Drug|Sunitinib|
1546495|NCT02623114|Drug|methylphenidate|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
1546496|NCT02623114|Drug|atomoxetine|The patients received a fixed dose of medication for 2 weeks. The dose was increased according to the clinician's judgment. The patients came to the hospital at week 2,4,6,8,16,24wks, 9, 12,15,18,21,24 months
1546497|NCT02623101|Device|Reflectance confocal microscopy|Non-invasive imaging of the lesion
1546498|NCT02623101|Procedure|Punch biopsy|Obtaining a skin sample of the suspicious lesion under local anesthetics
1546499|NCT02623101|Procedure|Surgical excision|Excision of the basal cell carcinoma lesion under local anesthetics
1546500|NCT02623088|Other|PAP Therapies (CPAP)|Patients with sleep apnea syndrome treated by PAP Therapies (CPAP) after diagnosis and followed 5-7 years.
1546501|NCT02623075|Biological|Influenza vaccine|Blood samples will be collected at research study visits at 0 and 30 days (+/- 2 days) post-IIV4 (influenza vaccine). Collection will be as follows: 45-50 ml blood at each visit (not to exceed more than three visits over a two month period).
1546502|NCT02623062|Drug|Compound Sodium Alginate Oral Suspension sachet|Contents of 2 sachets taken four times daily for 7 days
1546503|NCT02623062|Drug|Matched placebo|Contents of 2 sachets taken four times daily for 7 days
1546504|NCT02623049|Other|New oral anticoagulant pharmacodynamic analysis (blood level assesment)|
1546505|NCT02623036|Drug|Equivalent dose enalapril|Chronotherapy with enalapril.
1546506|NCT02623036|Drug|Equivalent dose lisinopril|Chronotherapy with lisinopril
1546507|NCT02623023|Drug|Combigan|brimonidine/timolol fixed combination (Combigan®, Allergan; Dublin, IRL)
1546508|NCT02623023|Other|Refresh tears|This is a placebo group. Refresh tears®, Allergan; Dublin, IRL, is a lubricant eye drop that keeps they eye hydrated
1546509|NCT02623010|Drug|Imbruvica|Bruton's Tyrosine Kinase Inhibitor Ibrutinib as maintenance treatment in elderly patients with primary CNS lymphoma following first line chemotherapy treatment
1546513|NCT02622984|Behavioral|RBIRT|Intervention group will receive the telehealth or remote behavior intervention and referral for substance use (RBIRT). Other group will receive treatment as usual which is SBIRT.
1546514|NCT02622984|Behavioral|SBIRT|"Face to face standard intervention considered treatment as usual."
1546515|NCT02622971|Other|PBMT|Effects of phototherapy isolated and/or combined with cryotherapy in post-exercise skeletal muscle recovery.
1546516|NCT02622971|Other|Cryotherapy|Effects of cryotherapy isolated and/or combined with phototherapy in post-exercise skeletal muscle recovery.
1546519|NCT02622945|Device|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain not affected by the lesion(perilesional areas, right hemisphere or cerebellum). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
1546520|NCT02622945|Device|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
1546521|NCT02622932|Drug|Anlotinib and 14C-labeled Anlotinib|oral
1546522|NCT02622906|Drug|Pasireotide|60 mg per month of the Pasireotide during 6 months
1546524|NCT02622893|Drug|Transperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
1546525|NCT02622893|Drug|Retroperitoneal laparoscopic nephrectomy|After the surgery: 10 ml 0.25% bupivacaine through epidural catheters before extubation and continuous infusion of 0,1% bupivacaine and 1 µg/ml fentanyl 5 ml/h with patient-controlled boluses of an additional 4 ml, with a lockout time of 20 min and 4-h limit of 30 ml by a patient controlled epidural analgesia (PCEA) device
1546526|NCT02622880|Dietary Supplement|immunomodulatory supplement|Experimental Group (immunomodulatory supplement STUDY)
1546527|NCT02622880|Dietary Supplement|IMPACT|IMPACT (Nestle Healthcare Nutrition, Minnesota USA) an `immune-enhancing` feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
1546528|NCT02622867|Other|Lactobacillus plantarum 3547|During one period of parallel study (12 weeks) volunteers consumed 1 capsule/daily with Lactobacillus plantarum 3547 immediately after finishing their meal.
1546529|NCT02622867|Dietary Supplement|Maltodextrin|During one period of parallel study (12 weeks), volunteers will consume 1 daily capsule of maltodextrin immediately after finishing their meal.
1546532|NCT02622841|Procedure|BLEND|Stereotactic bodyradiotherapy and surgical stabilization within 48 hours.
1546534|NCT02622802|Drug|paracetamol|In an ex vivo placenta perfusion study, placental tissue is exposed to paracetamol
1546535|NCT02622802|Drug|Erythromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to erythromycin
1546536|NCT02622802|Drug|Azithromycin|In an ex vivo placenta perfusion study, placental tissue is exposed to azithromycin
1546537|NCT02622789|Other|Pilates Exercises|Pilates method based stability exercise intervention
1546538|NCT02622776|Other|Vaginal DNA Collection|Vaginal self-swab, 6hr tampon collection and response to an acceptability questionnaire
1546539|NCT02622763|Biological|Tolerogenic Dendritic Cells|Intralesional administration
1546540|NCT02622750|Procedure|triple-branched stent graft|place the triple-branched stent graft into the aortic arch, descending aorta ,the left subclavian artery, the left common carotid artery, and the innominate artery.
1546541|NCT02622750|Procedure|four-branched Dacron graft|"The stent elephant trunk was inserted into the true lumen of the distal aorta in a bound, compressed state after the distal aorta was transected between the origin of the left subclavian artery and the left carotid artery. The distal aorta incorporating the stent graft was firmly attached to the distal end of the four-branched Dacron graft using the open aortic procedure. After the anastomosis was completed, blood perfusion of the lower body was started via the perfusion limb of the four-branched Dacron graft."
1546542|NCT02622737|Other|Functional training|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a functional training and 5 minutes of respiratory exercises.
1546543|NCT02622737|Device|Stationary bike|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Stationary Bike exercise and 5 minutes of respiratory exercises.
1546544|NCT02622737|Device|Exergaming|Three times per week, with 50 minutes per session, during 8 weeks of training activities involving 10 minutes of muscle stretching, 5 minutes of warm-up exercise, 30 minutes of a Virtual Reality exercise (performed by Xbox360 with KinectTM sensor) and 5 minutes of respiratory exercises.
1546545|NCT02622724|Drug|Interferon beta-1a|Investigational drug
1546546|NCT02622724|Drug|Placebo|Placebo for investigational drug
1546547|NCT02622711|Behavioral|DI|Participants will be offered an individualized dietary counselling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
1546548|NCT02622711|Behavioral|PAI|Participants will be offered an individualized physical activity counseling according to their lifestyle habits to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
1546549|NCT02622711|Behavioral|PADI|Participants will be offered an individualized dietary and physical activity counseling to reduce weight consisting of face-to face contacts, group meetings, motivational phone calls and information pamphlets.
1546550|NCT02622711|Behavioral|LII|Participants will be considered as control group. They will receive a general healthy counselling providing materials and guidelines available for the general public.
1546551|NCT02622698|Dietary Supplement|Prostat AWC|Prostat AWC- patients received protein supplementation after surgery
1546552|NCT02622698|Other|Placebo|Placebo- Patients did not take any protein supplementation after surgery
1546553|NCT02622685|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, multiple administration
1546554|NCT02622685|Drug|DWP10292 Placebo|Placebo tablets, oral administration, multiple administrations
1546555|NCT02622685|Drug|Ursodeoxycholic acid (UDCA)|Drug: Ursodeoxycholic acid (UDCA) tablets, oral administration, multiple administration
1546556|NCT02622685|Drug|UDCA Placebo|Placebo tablets, oral administration, multiple administrations
1546557|NCT02622672|Dietary Supplement|water-soluble ubiquinol|100 mg/d
1546558|NCT02622672|Dietary Supplement|Placebo|glycerin.soy-lecithin, and water
1546559|NCT02622659|Drug|Fuganlin Oral Liquid|"less than 1 years old: 5mL each time and three times a day
1~3 years old: 10mL each time and three times a day
4~6 years old: 10mL each time and four times a day
7~12 years old: 10mL each time and five times a day"
1546647|NCT02621970|Drug|Cisplatin 1|Cisplatin 25 mg/m2, D1-3
1546648|NCT02621970|Drug|Cisplatin 2|Cisplatin 100 mg/m2, D1
1546560|NCT02622659|Drug|Xiaoer Jiebiao Oral Liquid|"1~2 years old: 5mL each time and twice a day
3~5 years old: 5mL each time and three times a day
6~14 years old: 10mL each time and twice a day"
1546561|NCT02622646|Drug|Recombinant VIII factor|"Identify and analyze cause(s) of poor bleeding control in patients on prophylaxis treatment and study the clinical impact of a personalized pilot program with a 1 year follow up to act on the specific causes.
Describe PK parameters in patients on prophylaxis treatment with Advate®
Analyze differences in PK parameters in non-controlled vs well controlled patients
Identify causes of poor clinical outcome in non-controlled patients. Patients' individual variables that influence bleeding risk will be studied (individual PK, bleeding pattern, joint status, physical activity, life style and patient's adherence).
Study the improvement in clinical outcomes (ABR and Joint status) of a 1 year Personalized Prophylaxis Program that acts specifically on the previously identified causes of bleeding in non-controlled patients (named: short half-life, high bleeding pattern, joint damage, high risk physical activity, active life style and poor patient's adherence)."
1546562|NCT02622633|Device|Epidural Electrode|Epidural electrode of high frequency (50Hz) stimulation in the dorsolateral prefrontal cortex.
1546563|NCT02622607|Drug|Zoledronic acid|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride)
1546564|NCT02622594|Drug|Aminolevulinic Acid (ALA)|
1546565|NCT02622594|Device|Environ Cosmetic Roller|
1546566|NCT02622594|Device|BLU-U IIlluminator|
1546567|NCT02622581|Other|data collection|Baseline (demographic, clinical, tumor) characteristics, details on biomarker testing, including re-testing, treatment decision making, all systemic anticancer therapies including details, key data on radiotherapies, surgeries and specified supportive therapies, outcome (response, progression, survival), course of disease. Data will be documented at baseline and updated at least every three months.
1546568|NCT02622568|Drug|Veregen only|Topical application of Veregen 15% ointment on affected areas twice daily
1546569|NCT02622568|Procedure|Cryotherapy and Veregen|Cryotherapy followed by topical application of Veregen 15% ointment on affected areas twice daily
1546570|NCT02622555|Drug|Mirabegron|Patients with overactive bladder eligible for drug treatment who fulfill the EMA prescription guidelines receive mirabegron 50 mg extended release once daily according to clinical routine
1546571|NCT02622542|Device|BMT+TEVAR|These FDA-approved devices will be used for performing TEVAR in the patients randomized to this arm, in addition to the medical therapy to control blood pressure (BMT)
1546572|NCT02622542|Other|BMT|Optimal medical therapy will be administered to the patients randomized to this arm, involving but not limited to, beta-blockers, etc., to control the blood pressure and pain for stabilizing the patient upon presentation.
1546574|NCT02622516|Other|Intervention Group (IG)|"Therapeutic approaches to this proposal are intended to promote muscle relaxation to increase range of motion and analgesia of neck and shoulder girdle region, as well as the fascial release these regions with the intervention of cervical global pompage, exercises for body mobility for upper limb and trunk in the positions supine, lateral and dorsal, sitting and standing and gradually followed by proprioceptive exercises to the lower limbs and trunk in sitting and standing positions with aid devices such as foams, pool baguettes, balance boards, Swiss balls, steps, trampolines and BOSU ( BOSU® Home Balance Trainer ).
The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
1546575|NCT02622516|Other|Control Group (CG)|"The exercises consist of eye movements in different directions, slow and fast; head movements in different planes, with open and closed eyes, slow and fast; and body exercises such as lifting and sit, walk open and closed eyes, up and down ramps and stairs, as well as some activities and ball games.
The exercises will be held in individual treatments lasting sixty minutes with a frequency of once a week for all group members."
1546576|NCT02622503|Drug|Rituximab|This is an observational study. Patients with rheumatoid arthritis and having received treatment previously will be assessed for the treatment responses.
1546577|NCT02622490|Other|two test meals with two different macronutrient compositions|Either a high or a low carb meal either as one large or as 5 small meals. ie a crossover trial with one arm
1546578|NCT02622477|Drug|Pirfenidone|This is an observational study. Pirfenidone is available as an 267 mg capsule for oral administration.
1546579|NCT02622464|Other|micro injection of SVF in vocal cords|
1546580|NCT02622451|Behavioral|Teen Intervene|Teen Intervene (TI) is an early intervention program for 12-19 year olds who display early stages of alcohol or drug use. TI uses motivational interviewing, goal setting, and skill training to foster the internal development of responsible decision-making with the goal of choosing attitudes and behaviors that are healthier alternatives to drug use behaviors.
1546581|NCT02622451|Behavioral|Everyday Parenting|Everyday Parenting is a family-focused intervention that works with parents to provide environmental scaffolding necessary to help teens gradually internalize decision-making skills that reinforce and promote healthy lifestyle alternatives.
1546582|NCT02622438|Other|Followed with an initial assessment, six months and followed annually for 3 years corresponding to the usual follow-up of the patient.|
1546583|NCT02622425|Dietary Supplement|Placebo|maltodextrin
1546584|NCT02622425|Dietary Supplement|PD01|Carotenoid-producing Bacillus strain PD01
1546585|NCT02622412|Other|Multi-professional breathlessness service (MBS)|Patients visit the MBS twice. At week 1, delivered by palliative care specialists and respiratory disease specialists, patients receive an detailed assessment of breathlessness, relevant symptoms beyond breathlessness, psychosocial issues and carer burden. Recommendations are provided, and reviewed at the concluding visit in week 6 with palliative care specialists. In between these visits, weekly physiotherapy sessions focus on positioning, breathing techniques, exercise as well as pacing and fatigue management. Further support from the multi-professional expert team is given as needed.
1546586|NCT02622412|Other|Delayed MBS Intervention|Patients will wait 8 weeks for start of intervention and will receive standard care in the meantime with access to respiratory medicine, general practitioners and palliative care services as needed. Standard care includes support by their general practitioners and disease orientated treatment (e.g. anti-obstructive treatment, oxygen supply if indicated, chemotherapy).
1546649|NCT02621970|Drug|Docetaxel|Docetaxel 60mg/m2, D1
1552281|NCT02582073|Biological|Placebo (1.0ml)|
1546587|NCT02622399|Behavioral|Project NOW|This intervention aims to reduce social isolation and promote engagement in health promoting enrichment and activities, by embedding a community health worker-assisted forum in a community-driven mobile communications through a private, secure, and confidential platform supported by txtwire. The principal innovation is harnessing both the behavioral change utility of a mobile health application and the social support potential of an online social network the investigators can deliver more timely and dynamic reinforcement to caregivers and social support more in rhythm with the pace of community events and stressors.
1546588|NCT02622386|Drug|Riboflavin|Riboflavin (Vitamin B2) 400 mg capsule taken daily for 12 weeks.
1546589|NCT02622386|Other|Placebo|Matching placebo capsule taken daily for 12 weeks.
1546590|NCT02622373|Device|PEA POD Infant Body Composition System|The non-invasive device used in this study to measure a baby's body composition is a called a Pea Pod. The Pea Pod is a quick, safe, non-invasive and reliable bedside procedure used to measure changes in infant body composition.
1546591|NCT02622334|Drug|Latanoprost|Latanoprost is a ophthalmic solution, available in dose strength as 0.005%.
1546592|NCT02622334|Drug|Placebo|Matching placebo formulation will be administered in Part A.
1546593|NCT02622334|Drug|RO5093151|RO5093151 is a ophthalmic solution, available in dose strengths as 0.1%, 0.5% and 1%.
1546596|NCT02622308|Device|FlowOx™|FlowOx™ uses intermittent negative and atmospheric pressure, and is intended for use as an adjunct non-invasive therapy for the treatment of reduced peripheral circulation. Negative pressure cycles are created by alternating between removing air and venting the vacuum-chamber to atmospheric pressure. The vacuum cycle is controlled by the Control Unit (Pump). FlowOx™ is designed to assists wound healing indirectly by improving blood flow to the affected limb and augmenting the wound healing effect of the contact dressings and any associated medication. Treatment is planned to be applied while the participants are seated and it does not interfere with other activities normally enjoyed while seated. Treatment is recommended for one to two hours per session aiming to improve blood flow in the affected area and thus the clinical outcomes.
1546597|NCT02622295|Behavioral|Single-session high-frequency active-resisted stance|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit high muscle forces.
1546598|NCT02622295|Behavioral|Single-session low-frequency active-resisted stance|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit low muscle forces.
1546599|NCT02622295|Behavioral|High-frequency active-resisted stance training|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit high muscle forces. Subjects will train for 16 weeks.
1546600|NCT02622295|Behavioral|Low-frequency active-resisted stance training|In a standing frame or standing wheelchair, the quadriceps and hamstrings will be electrically activated to elicit low muscle forces. Subjects will train for 16 weeks.
1546601|NCT02622282|Other|Text Messages|Text messages will be sent one time per day. Text messages will include messages to motivate and inform participants on the importance of walking.
1546602|NCT02622282|Other|Phone Calls|Participants may receive a telephone call every two weeks for one month followed by once per month for two months.
1546603|NCT02622282|Other|Handout|Handout includes information specific to participant's condition and ways to promote an active lifestyle.
1546604|NCT02622269|Device|Patient-regulated compression device|Compression of the abdomen with a patient-regulated compression device
1546605|NCT02622269|Device|Standard compression device|Compression of the abdomen with the standard compression device
1546606|NCT02622256|Behavioral|Health System: HTN Intervention|Interested participants can enroll online via a Twitter link. Patients will consent to having their electronic health records accessed to validate clinical data. Participants will complete short surveys. The project Twitter account would follow tweeters with high impact CV messages and tweet daily high impact and accurate CV health messages (identified in aim 3). Participants will follow the study team & may receive daily private heart health messages via Twitter. This would allow participants to see CV health messages posted in the words and context of patients that may be similar to them, participate in online CV health discussions, and access CV health networks that they may not otherwise know about. Participants will also tweet heart health messages weekly.
1546607|NCT02622243|Drug|Tiotropium|long acting muscarinic antagonist
1546608|NCT02622243|Drug|glycopyrronium|long acting muscarinic antagonist
1546609|NCT02622243|Device|Respimat|inhaler device used to deliver active tiotropium or placebo
1546610|NCT02622243|Device|Breezehaler|inhaler device used to deliver active glycopyrronium or placebo
1546611|NCT02622230|Drug|Mianhuahua Flavonoids Tablets|"Tolerability Study:
Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(seven dose groups:0.3g-5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)
Pharmacokinetic Study:
Period I:Single oral administration,dose-escalation of Mianhuahua Flavonoids Tablets(six dose groups: 0.9g, 1.8g, 2.7g, 3.6g, 4.5g, 5.4g) Period II:Repeated oral administration of Mianhuahua Flavonoids Tablets (group 1:MTD（maximum tolerated dose）/1.5g, TID, group 2:depending on the adverse drug reaction,1.8g/1.2g, TID)"
1546612|NCT02622230|Drug|Placebo|Placebo to match with experimental groups
1546613|NCT02622217|Behavioral|Sleep deprivation|
1546614|NCT02622204|Procedure|high tibial osteotomy|open wedge high tibial osteotomy
1546615|NCT02622191|Device|Spectral domain Optical Coherence Tomography|Participants of the study, both Glaucoma patients and controls with normal eyes will be tested with spectral domain Optical Coherence Tomography.
1546650|NCT02621970|Drug|Xeloda|Xeloda 2000mg/m2, D1-14 in concurrent chemotherapy and Xeloda 2500mg/m2, D1-14 in adjuvant chemotherapy
1546651|NCT02621970|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
1546693|NCT02621684|Other|Godin Leisure-Time Exercise Questionnaire (GLTEQ)|-4 item query of usual leisure time exercise habits
1546616|NCT02622178|Device|Optical Coherence Tomography|Optical coherence tomography (OCT) is a noninvasive imaging modality that provides micrometer-scale resolution.It has been revolutionized in recent years by exploitation of Fourier domain (FD) techniques, which have a significant sensitivity advantage over traditional time domain (TD) OCT. In spectral-domain (SD-OCT) the reference mirror is stationary, and OCT signal is acquired using a spectrometer as detector or by varying the wavelength of the light source.
1546617|NCT02622178|Device|Diopsys Visual evoked potential (VEP)|The viewing distance shall be set to 1 m, yielding a total display viewing angle of 15.5 degrees. The square black/white checkerboard pattern reversal stimulus has a height and width of 27 cm with a red circular ring used as a fixation target. The diameter of this target is approximately 1.5 cm with a ring thickness of 1.5 mm. The target ring shall be centered on the stimulus. Two pattern contrasts shall be used in the study, based on earlier studies that suggested that differential contrast stimulation could affect the NOVA-DN VEP protocol wave forms. The first pattern shall have a Michelson contrast of 15%. The second pattern shall have a Michelson contrast of 85%. These two patterns are referred to as Lc (Low contrast) and Hc (High contrast) respectively.
1546618|NCT02622165|Behavioral|The REWARD serious game intervention|The REWARD intervention is based on the dual process model incorporating strategies to influence both the automatic pathway (i.e., operant learning theory) and the conscious pathway (i.e., a focus on certain determinants). The central idea of the intervention will be that participants will earn credits in the game when scanning healthy (rather than unhealthy) snacks which will influence the advancement of the players in the game. This credit system will be related to the dietary quality index of the consumed snacks.
1546619|NCT02622152|Procedure|Right lateral position (2 hours)|Repositioning the patients for two-hours period on the right lateral position
1546620|NCT02622152|Procedure|Left lateral position (30 minutes)|Repositioning the patients for 30 minutes period on the left lateral position
1546621|NCT02622152|Procedure|Supine position (30 minutes)|Repositioning the patients for 30 minutes period on the supine position
1546622|NCT02622152|Procedure|Left lateral position (2 hours)|Repositioning the patients for two-hours period on the left lateral position
1546623|NCT02622152|Procedure|Supine position (2 hours)|Repositioning the patients for two-hours period on supine position
1546624|NCT02622139|Device|Multispectral Optoacoustic Tomography (MSOT)|MSOT for the evaluation of disease activity in IBD patients
1546625|NCT02622126|Drug|hydroxyethyl starch (6% 130/0.4)|preloaded prior to spinal anesthesia with 500 mL hydroxyethyl starch (6%130/0.4) (Voluven).
1546626|NCT02622126|Drug|Hyperbaric bupivacaine|Sub arachnoid 10-12 mg hyperbaric bupivacaine
1546627|NCT02622126|Drug|Morphine|Sub arachnoid 200 meg morphine
1546628|NCT02622126|Drug|Isotonic 0.9 sodium chloride (NaCl) solution|10 ml/kg of isotonic 0.9 sodium chloride (NaCl) solutions will be used as co loading during the duration of the operation
1546629|NCT02622126|Drug|Ephedrine|If severe hypotension (fall of > 20% of mean arterial pressure from baseline) occurred, vasopressors, 6 mg ephedrine (per dose) will be used.
1546630|NCT02622126|Drug|Atropine|Bradycardia (fall of >30% of heart rate from baseline or <50 beats /minute and when associated with hypotension) will treated with 0.5 mg of atropine intravenous.
1546631|NCT02622113|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 36 weeks
1546632|NCT02622100|Device|Bioresorbable Vascular Scaffold|
1546633|NCT02622087|Behavioral|One-Session-Treatment|There are a total of five steps, each to be repeated until the participant experiences a reduction of at least 50% in their anxiety. Step 1 is catching a spider with a glass and postcard. Step 2 is touching a spider from behind with the dominant index finger. Step 3 is letting a spider walk on the participant's hands. Step 4 is allowing a spider to walk on the participant's legs and body. Steps 1-4 are repeated with larger spiders, and then the two biggest spiders will walk on the participants' hands simultaneously. Step 5 is using a chopstick to guide a huntsman spider over their gloved hand. Treatment ends when all steps are completed, or if the maximum 3 hour time limit has been reached, or if the participant indicates that they do not want to continue.
1546640|NCT02622048|Behavioral|Triple P Positive Parenting Programme|10 week self-directed (guided) parenting intervention promoting self-belief, parenting confidence/self-efficacy and problem solving skills.
1546641|NCT02622022|Drug|Morphine hydrochloride|
1546642|NCT02622009|Procedure|BRONCHOSCOPIC PROCEDURE|After the routine bronchoscopic inspection of the tracheobronchial tree, the investigators performed BAL from subsegmental bronchi and bronchial biopsies (3-4 per patient) from non infiltrated carina
1546643|NCT02621996|Device|hammock|PN who will be positioned in hammock inside the incubator will be with the high trunk to about the 30th, and will be used a roll of restraint in the neck by keeping a slight lordosis to avoid suffocation risks. In two days of placement, should remain about 8 hours in the hammock, being removed during cleaning procedures, diet and medical evaluation and then immediately replaced in the hammock. The alternation of decubitus (right side, supine and left lateral) should be performed whenever the child is manipulated for these procedures.
1546644|NCT02621996|Device|containment nest|"In the control group, the position will follow the routine procedure of the Hospital Barão de Lucena, consisting of the use of restraint nests U, made with rolled sheet placed on the mattress of the incubator and covered by another sheet. The control group incubators will also be inclined at 30 ° as routine service. During the 8 position, switching the supine will also be held, side left and side right after the baby handling to cleaning procedures, diet and medical evaluation."
1546645|NCT02621983|Behavioral|Aerobic Exercise|Subjects with a diagnosis of SCZ will complete aerobic exercises consisting of spin classes 3 times a week on a stationary bicycle ergometer. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
1546646|NCT02621983|Behavioral|Balance and Stretching|Subjects with a diagnosis of SCZ will complete a balance and stretching program consisting of progressive whole body stretching and toning exercises. Exercise time will progress from an initial 20 minutes per session to a maximum of 45 minutes by increasing 5 minutes each week for 12 weeks.
1546652|NCT02621957|Drug|GDC-0810|During Period 2 subjects will be administered an oral 600 mg dose GDC-0810 daily beginning on Day 5 for 4 consecutive days (from Days 5 to 8, inclusive).
1546653|NCT02621957|Drug|Pravastatin|Subjects will receive a single oral dose of 10 mg pravastatin on Day 1 in Period 1 and Day 7 in Period 2.
1546654|NCT02621944|Drug|Melatonin|Participants 1-10 will receive a 0.5 mg/kg enteral dose of Melatonin. Participants 11-20 will receive Melatonin dose of 3 mg/kg enteral. Participants 21-30 will receive Melatonin dose of 5 mg/kg enterally.
1546655|NCT02621944|Other|Magnetic Resonance Imaging|All participants will receive an MRI between 7-12 days of age.
1546656|NCT02621944|Other|Pharmacokinetics|All participants will receive pharmacokinetics to test the amount of melatonin in the blood.
1546657|NCT02621944|Behavioral|Neurological Outcome Assessment|All participants will receive the Bayley-III Scores and Subsets for neurological outcome assessments.
1546658|NCT02621944|Behavioral|Generalized Motor Assessment|All participants will receive the GMA assessment.
1546659|NCT02621931|Drug|TEV-48125 - 1|Subcutaneous administration Dose Regimen 1
1546660|NCT02621931|Drug|TEV-48125 - 2|Subcutaneous administration Dose Regimen 2
1546661|NCT02621931|Drug|Placebo|Matching Placebo
1546662|NCT02621918|Other|Progressive resistance training|
1546663|NCT02621918|Other|Aerobic training|
1546664|NCT02621918|Other|Placebo training|
1546665|NCT02621905|Drug|Sporanox|At least 2 capsules twice a day for 3 weeks
1546666|NCT02621905|Drug|Lozanoc|At least 2 capsules twice a day for 3 weeks
1546667|NCT02621892|Drug|Tenapanor|
1546668|NCT02621892|Drug|Placebo|
1546669|NCT02621879|Procedure|Bilateral Gluteal Advancement Flap|Dissection of both gluteus maximus muscles from their origin in the sacrum, advancement of both muscles is conducted to the midline after creating release incisions in their fascia.
1546670|NCT02621866|Device|Ultraviolet A radiation|Twice daily with 10 Joules/cm2. Half body (one side) with Waldmann 100L phototherapy lamp fitted with UVA bulbs (main emission 320-410nm)
1546671|NCT02621866|Device|Sham irradiation|As active, but lamps to be shielded with Amber 81 museum film which prevents transmission of <500nm, but permits visible light to pass.
1546672|NCT02621853|Device|Raman spectroscopy of the liver|Liver will be illuminated by the Raman spectroscope optic probe in order to assess fat content
1546673|NCT02621840|Behavioral|Mandatory On-Site Pre-Admission Testing|
1546674|NCT02621827|Other|Oral dose of stable isotope labeled 25(OH)D3|At each measurement, women are given an oral dose of stable isotope labelled 25(OH)D3. Blood and urine samples are collected at baseline and on day 21 post-dose. Additional blood samples are collected post-dose on days 6,9,24,27 and 30.
1546675|NCT02621814|Dietary Supplement|Friso|Formula feeding on demand for 3 months
1546676|NCT02621814|Dietary Supplement|Wyeth|Formula feeding on demand for 3 months
1546677|NCT02621801|Behavioral|Stress Management and Resiliency Training for Residents (SMART-R)|The Stress Management and Resiliency Training Program for residents (SMART-R) is a six-hour intervention delivered over 2 or 3 sessions that teaches residents mind-body skills to reduce stress and enhance coping strategies.
1546678|NCT02621788|Behavioral|Stress Management and Resiliency Training for Residents (SMART-R)|The SMART-R is a mind-body Educational Program for residents that is aimed at reducing the impact of stress and enhancing coping strategies through skill building exercises. The intervention consists of 3, 2 hour sessions over the course of 12 months.
1546679|NCT02621775|Behavioral|Computer-based stress management program|The program includes 5 one hour weekly sessions that patient follow from a web site accessible from a computer in our unit. He benefits from a minimal contact with a medical member of staff before and after every session. The duration of each session is about one hour. To avoid internet connexion problem between session it is supplied to the patient, from the first session an USB key (Universal Serial Bus) containing videos, audio files, self help book, portfolio in the form of e-guide, log book with the program of the exercises to be realized between two session of the five sessions program. The patient is encouraged to practice a twenty-minutes daily exercises five or six days per week.
1546680|NCT02621775|Behavioral|Stress management in face-to-face|The program includes 5 forty-five minutes weekly session with a therapist (psychologist graduate of a master of cognitive and emotional therapy with a minimal of one year of practice in CBT and CBSM (Cognitive-Behavioral Stress Management ). Information, exercises and homework assignments are delivered by the therapist without self help support.
1546681|NCT02621775|Other|Waiting list|The patients are followed by their General Practitioners without change in treatment .
1546682|NCT02621762|Device|Magnesium|Magnesium in dialysate increased
1546683|NCT02621762|Device|Bicarbonate|Bicarbonate in dialysate increased
1546684|NCT02621749|Device|Renal replacement therapy|Patients receive renal replacement therapy according to institutional standards
1546685|NCT02621736|Other|blood sampling|At 4 visits capillary blood sampling for copeptin measurement will be performed with each child.
1546687|NCT02621697|Other|Cognitive motor training|Initially an intervention consisting of double duty activities (motor-cognitive) and the control group will be subjected to a conventional treatment based on stretching and strengthening will be held.
1546688|NCT02621697|Other|kinesiotherapeutic conventional treatment|Standardized global stretching and strengthening with squat exercise, plantar flexion in foot and elbow flexion supporting body weight in the hands arranged on the wall
1546689|NCT02621684|Other|Community Health Activities Model Program for Seniors (CHAMPS)|"Physical activity questionnaire for older adults
Asks about activities in the past 4 weeks
41 questions and asks to notate how long the activity took"
1546690|NCT02621684|Other|Lifetime Total Physical Activity Questionnaire|"Questions about leisure time (27) and household activities (5)
Mark if participated in the activity during the past year, ages 51-65, 35-50, 23-34, and onset of puberty through 21 years"
1546691|NCT02621684|Other|Expanded Prostate Cancer Index Composite (EPIC)|"Measures urinary and sexual function before and after prostate cancer treatment
7 questions about urinary function
9 questions about sexual function"
1546692|NCT02621684|Other|International Physical Activity Prevalence Study Environmental Module|-The 17-item Physical Activity Neighborhood Environment Scale can be used to assess the environmental factors for walking and bicycling in various neighborhoods.
1546694|NCT02621684|Other|Questionnaire regarding behavior/lifestyle changes since diagnosis|
1546695|NCT02621684|Other|12 week Walking Program|
1546696|NCT02621684|Other|12 week Resistance Training Program|
1546697|NCT02621671|Behavioral|Cognitive interview|
1546698|NCT02621671|Other|Survey|
1546699|NCT02621658|Other|Clear Liquid Diet|Patients will be allowed to consume clear soft drinks like ginger ales, Sprite®, 7-Up®, Gatorade®, Kool Aid®. They can also have strained fruit juices like apple, white grape juice and lemonade, and water, tea and coffee without milk or non-dairy creamer. Patient in this arm will also be allowed to have low-sodium chicken or beef broth , in addition to non-red hard candies, Jell-O®, and popsicles.
1546700|NCT02621658|Other|Full Liquid Diet|Patients will be allowed to consume a Full Liquid Diet, including nutritional supplements(Ensure®, Boost®, Glucerna®), strained cereals(like cream of wheat or strained oatmeal) and vegetables, purred fruit without seeds or pulp, milk, plain ice cream or yogurt, sherbet, coffee with cream, and tea.
1546701|NCT02621645|Procedure|Early selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using an 18 Gauge to 20 Gauge needle
1546702|NCT02621645|Procedure|Late selective reduction of TRAP mass|Ultrasound-guided intrafetal ablation using a 17 Gauge to 20 Gauge needle OR fetoscopic laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber. The treating physician can decide which technique will be used for the selective reduction.
1546703|NCT02621645|Device|Ultrasound-guided intrafetal ablation using a 18 to 20 Gauge needle|
1546704|NCT02621645|Device|Ultrasound-guided intrafetal ablation using a 17 to 20 Gauge needle|
1546705|NCT02621645|Device|Laser coagulation of the cord or anastomising vessels through a 17 Gauge to 7 French trocar, with a 1-1,3 mm fetoscope and a 400 µm laser fiber|
1546706|NCT02621632|Device|(Socknleg)To done of a novel compression system|To done a novel compression system.
1546707|NCT02621619|Drug|IV acetaminophen + 0.5 mg IV hydromorphone|1 gram (100 ml) IV acetaminophen in addition to 0.5 mg IV hydromorphone
1546708|NCT02621619|Drug|Normal saline + 0.5 mg IV hydromorphone|100 cc normal saline placebo in addition to 0.5 mg IV hydromorphone
1546709|NCT02621619|Drug|0.5 mg IV hydromorphone|Both groups (intervention and placebo) will receive 0.5 mg IV hydromorphone
1546710|NCT02621606|Drug|[11C]MK-6884|IV bolus dose of ~370 MBq [11C]MK-6884
1546711|NCT02621593|Device|M22-IPL|The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filters that will be used for this evaluation are filters blocking wavelengths of 560 and 595 nm.
1546712|NCT02621580|Device|Pan-Retinal Photocoagulation|"Diabetic retinopathy does not usually impair sight until the development of long-term complications, including proliferative retinopathy, a condition in which abnormal new blood vessels may rupture and bleed inside the eye. When this advanced stage of retinopathy occurs, pan-retinal photocoagulation is usually recommended.
During this procedure, a special laser is used to make tiny burns that seal the retina and stop vessels from growing and leaking. Hundreds of tiny spots of laser are placed in the retina to reduce the risk of vitreous haemorrhage and retinal detachment."
1546713|NCT02621567|Device|Bright Light Therapy Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps emit light of intensity 10,000 lux.
1546714|NCT02621567|Device|Modified Dim Lamp|TRAVelite Desk Lamp manufactured by Northern Light Technologies, located in Montreal, Quebec. The light is emitted from a lamp. The florescent tubes in the box are covered with a diffusing screen to ensure even distribution of light and protection from ultraviolet light. These lamps also have a stand which enables users to place the box horizontally or vertically on most surfaces. These lamps have been modified to emit light of intensity 500 lux.
1546715|NCT02621554|Dietary Supplement|resveratrol supplementation|6 months of resveratrol supplementation
1546716|NCT02621554|Dietary Supplement|Placebo|6 months of placebo intake
1546717|NCT02621541|Device|PET/CT|
1546718|NCT02621528|Device|CeraFlex|The Lifetech CeraFlex™ study is a triple-arm study.
1546719|NCT02621515|Drug|Nivolumab|All patients in this phase 2 trial will receive treatment with nivolumab, a monoclonal antibody against the PD1-receptor on T cells. Dosing will be based on patients' weight (3 mg/kg). It will be administered in an intravenous infusion every 2 weeks and for a maximum of 2 years.
1546720|NCT02621502|Dietary Supplement|Quinoa variety 1|"On the intervention day, the volunteers will consume the Quinoa Variety 1.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
1546721|NCT02621502|Dietary Supplement|Quinoa variety 2|"On the intervention day, the volunteers will consume the Quinoa Variety 2.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
1546722|NCT02621502|Dietary Supplement|Quinoa variety 3|"On the intervention day, the volunteers will consume the Quinoa Variety 3.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
1546723|NCT02621502|Dietary Supplement|Quinoa variety 4|"On the intervention day, the volunteers will consume the Quinoa Variety 4.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
1546775|NCT02621177|Biological|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
1546724|NCT02621502|Dietary Supplement|Anhydrous Glucose|"On the intervention day, the volunteers will consume the control product.
Then during minutes 0, 15, 30, 45, 60, 90, 120, 180, 240 and 260 two types of methodologies were conducted:
In minutes 0, 15, 30, 45, 60, 90 and 120, blood samples were collected.
In minutes 0, 15, 30, 60, 90, 120, 180, 240 and 260, volunteers completed the Visual analogue scale questionnaire."
1546725|NCT02621489|Drug|Bydureon|2 mg Once Weekly
1546726|NCT02621489|Drug|Humulin kwickpen|Humulin kwickpen 10U QD at bedtime
1546727|NCT02621489|Drug|Metformin|Metformin 1g BID
1546728|NCT02621476|Behavioral|Standardized intervention|Standardized intervention to encourage mail order use and provide easily accessible information on how to access the service
1546729|NCT02621476|Behavioral|Personalized intervention|personalized intervention that includes components of the standardized intervention as well as additional information tailored to patient-specific characteristics
1546730|NCT02621476|Behavioral|Usual care|Usual care
1546732|NCT02621450|Biological|standart dialysis|dialysate sodium consentration 140 mEq
1546733|NCT02621450|Biological|low sodium dialysis|dialysate sodium consentration will be reducer from 140 mEq to 137 mEq
1546738|NCT02621411|Drug|Substance use|Patients are found use of substances by preoperative screen
1546739|NCT02621398|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT or IMRT
1546740|NCT02621398|Drug|Carboplatin|Given IV
1546741|NCT02621398|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D-CRT or IMRT
1546742|NCT02621398|Other|Laboratory Biomarker Analysis|Correlative studies
1546743|NCT02621398|Drug|Paclitaxel|Given IV
1546744|NCT02621398|Biological|Pembrolizumab|Given IV
1546745|NCT02621385|Drug|tradipitant|test agent
1546746|NCT02621385|Drug|Midazolam|substrate for drug-drug interaction assessment
1546747|NCT02621372|Other|platelet count|Correlation of esophageal varices with platelet count
1546748|NCT02621359|Drug|Nitazoxanide|Nitazoxanide 500 mg twice daily
1546749|NCT02621359|Drug|Levofloxacin|Levofloxacin 500 mg once daily
1546750|NCT02621359|Drug|Doxycyclin|Doxycyclin 100 mg twice daily
1546751|NCT02621359|Drug|Omeprazole|Omeprazole 40 mg twice daily
1546752|NCT02621346|Behavioral|Imagery|Prior to exercising participants will be given an imagery script. Afterwards, participants will imagine completing the leg press.
1546753|NCT02621346|Behavioral|Muscle Maintenance|Participants complete the leg press exercises at an intensity that promotes muscle maintenance but not muscle growth
1546754|NCT02621346|Behavioral|Bicep Curls|Control group participants will complete a bicep exercise at a maintenance training intensity.
1546755|NCT02621333|Biological|CIK|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1. After 3 or 4 days of chemotherapy, about 5×109 autologous cytokine-induced killer cells are transfused into the vein of patients in one hour.
1546756|NCT02621333|Drug|chemotherapy|platinum combined doublets: Paclitaxel 175mg/m2 D1, or Docetaxel75mg/m2 D1, or Pemetrexed Disodium 500mg/m2，D1；combined cisplatin 25mg/m2，D1-3 or carboplatin AUC=5, D1.
1546757|NCT02621320|Dietary Supplement|Vitamin D|Vitamin D3 (Vi-De 3®. WILD) 6000IU daily over a period of 12 weeks.
1546758|NCT02621320|Dietary Supplement|Placebo|alcohol-based solution 1.3ml daily over a period of 12 weeks.
1546759|NCT02621307|Dietary Supplement|Salba|
1546760|NCT02621307|Dietary Supplement|Flax|
1546761|NCT02621307|Dietary Supplement|Control|
1546762|NCT02621294|Other|Measuring protein requirement|a repeated measures design will be used on each athlete receiving eight graded intakes of protein on separate days in the form of AA in random order ranging from 0.2 to 3.5 g/(kg/d). Three baseline samples of breath and urine will be collected at 60, 45 and 30 min before the stable isotope is given orally. During a period of 150 to 270 min. after stable isotope ingestion, 5 breath and urine samples (every 30 min) will be collected to determine an isotopic plateau in breath and urine. The rate of release of 13CO2 from the oxidation of L-[1-13C] phenylalanine (F 13CO2) in breath will be measured and a breakpoint analysis will determine total protein requirement
1546763|NCT02621281|Device|Kidney Transporter machines|Kidney Transporter gently pumps the special cold solution through the kidney which outside the body.
1546764|NCT02621281|Device|cold storage|The kidneys procurement from the donor will be cold stored using some cold preservation solution.
1546765|NCT02621268|Drug|Indocyanine Green|Infusion of ICG 24 hours prior to surgery
1546766|NCT02621255|Drug|Sevoflurane|Anesthesia type of performed for patient which has femur fracture.
1546767|NCT02621255|Drug|Bupivacaine|Anesthesia type of performed for patient which has femur fracture.
1546768|NCT02621242|Procedure|Upper endoscopy|Upper endoscopy with biopsies
1546769|NCT02621242|Procedure|Anoscopy|Anoscopy with biopsies
1546770|NCT02621242|Drug|Truvada|Truvada (tenofovir/emtricitabine) daily as HIV pre-exposure prophylaxis. This medication will not be provided by the study.
1546771|NCT02621229|Behavioral|High calorie refeeding|beginning with 2000 kcal and advanced 200 kcal/d
1546772|NCT02621229|Behavioral|Low calorie refeeding|beginning at 1400 kcal/d and advanced 200 kcal every other day
1546773|NCT02621190|Drug|cabazitaxel|25mg/m2 q3w
1546774|NCT02621177|Biological|NBP607|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
1546776|NCT02621164|Biological|NBP607-QIV|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
1546777|NCT02621164|Biological|Agrippal S1|For subjects 6 months to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 18 years of age, single intramuscular dose (0.25mL/0.5 mL)
1546778|NCT02621151|Biological|Pembrolizumab|
1546779|NCT02621151|Procedure|Transurethral Resection of Bladder Tumor|
1546780|NCT02621151|Drug|Gemcitabine|
1546781|NCT02621151|Radiation|External Beam Radiation Therapy|
1546782|NCT02621125|Dietary Supplement|Fertilix|daily supplementation
1546783|NCT02621125|Other|Placebo|Placebo
1546784|NCT02621112|Biological|Intradermal HBVv with imiquimod|Intradermal hepatitis B vaccine with imiquimod pretreatment
1546785|NCT02621112|Biological|Intradermal HBVv with aqueous cream|Intradermal hepatitis B vaccine with aqueous cream pretreatment
1546786|NCT02621112|Biological|Intramuscular HBVv with aqueous cream|Intramuscular hepatitis B vaccine with aqueous cream pretreatment
1546787|NCT02621099|Device|Hybrid optical-gamma imaging|Acquisition of images using the camera as additional steps to the standard SLNB procedures.
1546788|NCT02621086|Dietary Supplement|Cellodextrin|Gastrointestinal tolerability of single ascending doses of Cellodextrins
1546789|NCT02621073|Drug|VeraFlo with Prontosan|VeraFlo device with Prontosan instillation (n=10).
1546790|NCT02621073|Device|V.A.C Ulta System|V.A.C. Ulta Negative Pressure Wound Therapy System without instillation (n=10).
1546791|NCT02621060|Drug|Placebo|Placebo: 1200 mg per day for three months
1546792|NCT02621060|Drug|Chlorogenic acid|Chologenic acid: 1200 mg per day for three months
1546793|NCT02621047|Drug|Alectinib|Participants will receive alectinib at a single oral dose of no more than 300 mg on Day 1.
1546794|NCT02621034|Procedure|Control|K-file hand instrumentation
1546795|NCT02621034|Procedure|Reciproc|reciprocating rotary instrument
1546796|NCT02621034|Procedure|One shape|full rotation protocol
1546802|NCT02621008|Other|Stress Reduction& Healthy living|Utilizing a stress reduction app (Serenita) and lifestyle intervention App (NewMe) and obtaining the NewMe guideline for healthy living, plus obtaining periodic messages regarding healthy living.
1546803|NCT02620995|Drug|sildenafil citrate|the hypertensive patients with erectile dysfunction will be treated with sildenafil citrate (100 mg daily) or placebo (crossover design)
1546804|NCT02620995|Other|comparator group|Normotensive individuals age-matched to the hypertensive patients will receive only a single dose of sildenafil citrate (100 mg) - acute protocol. Penile and systemic microvascular function will be evaluated before and one hour after sildenafil administration.
1546805|NCT02620982|Device|ARIES (Extracorporal Shock Wave Application)|The treatment protocol includes 1 treatment per week for 6 weeks and an application of 5000 shockwaves per session in 5 treatment areas with 1000 SW each at energy level 4-5 (energy flux density (0.051-0.062 mJ/mm²), while moving the applicator along the penile shaft within the treatment areas. The maximum energy applied during this treatment would be 23.35J.
1546806|NCT02620969|Other|Blood and dialysate sampling|Blood and dialysate sampling
1546807|NCT02620956|Other|nebulizing with heliox and oxygen|Mesh Nebulizer with heliox and oxygen. In order to determine the sequence of the gas associated with the inhaled a randomization was performed, sequence 1- first oxygen and second heliox (80:20) or sequence 2- first heliox (80:20) and secondy oxygen.
1546808|NCT02620930|Device|All market approved CRT-D or ICD systems endowed with the APNEA Scan algorithm|
1546809|NCT02620904|Drug|Mifepristone|
1546810|NCT02620904|Drug|placebo|
1546811|NCT02620891|Device|helium oxygen mixture|
1546814|NCT02620865|Biological|Aldesleukin|Given SC
1546815|NCT02620865|Biological|Antibody Therapy|Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
1546816|NCT02620865|Drug|Fluorouracil|Given IV
1546817|NCT02620865|Drug|Gemcitabine Hydrochloride|Given IV
1546818|NCT02620865|Drug|Irinotecan Hydrochloride|Given IV
1546819|NCT02620865|Other|Laboratory Biomarker Analysis|Correlative studies
1546820|NCT02620865|Drug|Leucovorin Calcium|Given IV
1546821|NCT02620865|Drug|Oxaliplatin|Given IV
1546822|NCT02620865|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1546823|NCT02620865|Biological|Sargramostim|Given SC
1546824|NCT02620852|Other|Complete a health questionnaire|Complete a health history questionnaire.
1546825|NCT02620852|Genetic|Provide a saliva sample for genetic testing|Provide a saliva sample for testing of 9 genes and a panel of single nucleotide polymorphisms (SNPs) that influence breast cancer risk
1546826|NCT02620852|Other|Screening advice based on a comprehensive risk assessment|Receive a screening schedule recommendation
1546827|NCT02620852|Other|Screening advice based on a basic risk assessment|Receive a screening schedule recommendation
1546828|NCT02620839|Drug|Alpelisib|
1546829|NCT02620839|Drug|Cisplatin|
1547425|NCT02616315|Drug|Naltrexone HCl/Bupropion HCl|Naltrexone HCl 8 mg/bupropion HCl 90 mg tablets
1996173|NCT02548754|Device|Salustim tragus stimulation device|
1996174|NCT02546544|Drug|Linsitinib|
1996175|NCT02546674|Drug|Nilotinib|Nilotinib will be prescribed by the investigator according to the patient's medical need.
1546830|NCT02620826|Procedure|Indirect pulp therapy|Decayed dentin is lined with a resin-modified glass ionomer (Vitrebond Plus)
1546831|NCT02620826|Procedure|Pulpotomy|A cervical pulpotomy is done and the radicular pulp is lined with Mineral Trioxide Aggregate
1546832|NCT02620813|Drug|Tretinoin|Subjects will apply 0.5% tretinoin cream nightly to their face for a total of 12 weeks.
1546833|NCT02620813|Drug|Isotretinoin|Subjects will take isotretinoin as prescribed by their dermatologist.
1546843|NCT02620761|Drug|Fenoldopam|Randomized to receive Fenoldopam or 0.9%NS
1546844|NCT02620761|Drug|0.9%NS|Randomized to receive Fenoldopam or 0.9%NS
1546845|NCT02620748|Drug|Tranexamic Acid|
1546846|NCT02620748|Other|Saline Solution|
1546847|NCT02620735|Device|Fit bit Device|Use of the fit bit flex for the duration of the study. Measures steps and sleep. Health Coaching
1546848|NCT02620735|Behavioral|Exercise Only|12 week exercise program
1546849|NCT02620735|Behavioral|Connected Wellness HealthCoach Software|Use of the app on Smart-phones and an online platform. Measures the following factors: Mood, Pain, energy,exercise not picked up by Fit bit.
1546850|NCT02620735|Behavioral|Health Coaching|10 over the phone health coaching sessions.
1546851|NCT02620722|Device|Personalized Tourniquet Instrument|Measure the limb occlusion pressure in each patient using the new technique with the personalized tourniquet instrument.
1546852|NCT02620722|Device|Handheld Doppler ultrasound|Measure the limb occlusion pressure in each patient using the gold-standard technique with the Doppler ultrasound.
1546854|NCT02620696|Drug|netazepide|
1546856|NCT02620670|Behavioral|Physical activity of moderate intensity for 3 days|The intervencion consist in a moderate-intensity physical activity exercise is a heart rate between 60 and 70% of maximum heart beats per minute for at least 30 minutes for three days
1546857|NCT02620657|Other|Non interventional study|Non interventional study
1546858|NCT02620644|Device|OCT Retinal GCC|measuring of the retinal ganglion cell complex (GCC) thickness and the central foveal thickness (CFT) using the RTVue® SD-OCT (Optovue, Inc.)
1546861|NCT02620618|Drug|Intravitreal Infliximab|ocular safety and efficacy in treating inflammation in uveitis patients with Behcets Disease
1546862|NCT02620605|Drug|Late Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily at day of HCG trigger and continued for 8days
1546863|NCT02620605|Drug|Early Cabergoline 0.5mg|Cabergoline 0.5mg will be administrated once daily when E2 is more than 4000pg/ml and /or more than 18 follicles of 11mm diameter or more are encountered at any day of the controlled ovarian hyper-stimulation and before HCG trigger to be continued for 8days after HCG trigger.
1546864|NCT02620592|Drug|ZYDPLA1 tablet|The oral dose of ZYDPLA1 tablet administered with 240 ± 10 mL of water at ambient temperature.
1546865|NCT02620592|Drug|Placebo tablet|The oral dose of placebo tablet administered with 240 ± 10 mL of water at ambient temperature.
1546866|NCT02620579|Drug|Propranolol LA (60 mg)|Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.
1546867|NCT02620579|Drug|Placebo|Placebo capsules will be prepared by the University of Florida Investigational Drug Service to be visually indistinguishable from the active medication and delivered orally. Placebo administration will be done in the same fashion as propranolol - administered on Days 1 (before exercise induced muscle injury) and the Days 2-4 after the exercise induced muscle injury.
1546868|NCT02620579|Behavioral|Shoulder Anatomy Education|Shoulder anatomy education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of participant understanding shoulder anatomy and injury while reviewing: a) structure and arthrokinematics of the shoulder joint; b) muscle anatomy of the shoulder with emphasis on the rotator cuff; and c) potential shoulder pain generators from the exercise-induced injury. This education component will be devoid of information related to pain signaling and cognitive restructuring that characterizes Pain Processing Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
1546931|NCT02620137|Drug|Multicentrum® (Pfizer, Spain) 3 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 3 months
1552282|NCT02582073|Biological|Grass MATA MPL (0.5ml) 5100SU|
1546869|NCT02620579|Behavioral|Pain Processing Education|Pain processing education modules will be administered Days 2-4 (after exercised induced muscle injury) following exercise enhance injury with the goal of better understanding of pain processing and psycho-education. This information will encourage shoulder activation by: a) reducing the threat of muscle injury; b) encouraging normal use of the shoulder and arm; and c) addressing specific concerns expressed by the subject (e.g. pain with shoulder motion is a sign of re-injury). This education component will be devoid of detailed information on shoulder anatomy, movement, and injury that characterizes the Shoulder Anatomy Education modules. These education modules will be scripted and structured so they are provided in a standardized manner for all subjects.
1546872|NCT02620553|Drug|Human Insulin|There is a study drug dose increase once during the study. The dose increase will occur 6 months after entering into the study. A total of 6 children will be included at each dose (3 children will not have received insulin prior to entering the study and 3 children will have received a lower dose of insulin for 6 months). Further dose increases or more frequent dose increases in individual children will not be performed during Pre-POINT. Escalation will occur in both treatment and placebo group so that participants and study investigators will remain blinded to treatment throughout the study. First dose (2.5 mg oral insulin/day) Second dose (7.5 mg oral insulin/day) Third dose (22.5 mg oral insulin/day) Fourth dose (67.5 mg oral insulin/day)
1546873|NCT02620553|Other|Oral Placebo|Oral Placebo is given orally daily
1546874|NCT02620540|Device|Accuracy of an algorithm and the Broselow Tape|Computer based comparison of the two devices based on collected patient data
1546875|NCT02620514|Behavioral|Education and Reminders|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will be provided education materials, and will receive scheduled educational reminder phone calls and text messages at 2,6,12, and 24 weeks from the baseline assessment.
1546876|NCT02620514|Behavioral|Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence.Participants will undergo one scheduled visit with a nurse practitioner or physician for education about inflammatory bowel disease (IBD) after the baseline assessment.
1546877|NCT02620514|Behavioral|Medication Educational Visit|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will undergo one scheduled visit with a nurse practitioner or physician to discuss medication side effects and medication inadequacy after the baseline assessment.
1546878|NCT02620514|Behavioral|Financial Support|Participants with inflammatory bowel disease (IBD) will complete health-literacy surveys to assess medication adherence. Participants will receive information about patient assistance programs, copay cards, and a scheduled meeting with a social worker or financial advisor.
1546879|NCT02620501|Drug|Lidocaine|topical lidocaine
1546880|NCT02620501|Drug|Placebo|0.45% Normal Saline
1546881|NCT02620488|Behavioral|Guided Imagery|Brief guided imagery session with a trained clinician focused on relaxation and pleasant imagery.
1546882|NCT02620475|Device|SutureSafe|SutureSafe dressing are designed to apply a constant gentle inward pressure on the incision to reduce separating tension on newly formed incisions, stabilizing the healing environment.
1546883|NCT02620462|Device|Wearable sensor-based exercise training|The device provides real-time visual feedback of joint movement during balance exercise
1546884|NCT02620449|Other|Diet|Participants will be fed a low-additive diet as the primary intervention
1546885|NCT02620436|Other|Core Mother Shelter Model|"Infrastructure, Supplies, Equipment: All MHs will have: latrines, lockable cupboards, doors, windows, lighting, mattresses, mosquito nets, cooking space and utensils, and a bathing site.
Policies, Management, Finances:. The policies, management, and financial structures will follow the same general principles, but will be site-specific to account for cultural variation.
Linkages with Health Facilities: Each MH will be operationally linked to the health facility and 1) ensure daily check-ins by a health facility staff; 2) ensure every pregnant woman has someone able to contact a staff if she is incapacitated; and 3) will orient women to procedures upon arrival. Clinical services will be conducted at the health facility."
1546893|NCT02620410|Device|Axonics Sacral Neuromodulation (SNM) System|The implantable components of the Axonics Sacral Neuromodulation (SNM) System consist of an IPG and tined lead. Additional components include a clinician programmer, surgical tool kit, recharging kit, and patient remote control.
1546894|NCT02620384|Drug|Placebo|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first placebo dose is given within six hours of admininstration of first dose of intravenous diuretic. The second placebo dose is given at 24-hours after the first dose.
1546895|NCT02620384|Drug|Metolazone|All patients will receive standard heart failure therapy, including but not restricted to diuretics, digoxin, angiotensin converting enzyme inhibitors or angiotensin II receptor blockers, beta blockers, aldosterone antagonists, hydralazine, and/or nitrates, at the discretion of the treating physician. After informed consent is obtained, patients will be randomized 1:1 to the treatment arm or placebo arm. The first dose of metolazone is given within six hours of admininstration of first dose of intravenous diuretic The second dose of metolazone is given 24-hours after the first dose.
1546896|NCT02620371|Procedure|modified pectoral block|"Modified Pecs block was performed under general anesthesia, and 15 min. before skin incision. We performed the modified Pecs block or the  Pecs II block by using a two needle approach instead of one. The first puncture is a Pecs I block with 10 ml of local anesthetic injected between the two pectoralis muscles, and the second puncture injects 20 ml of local anesthetic between the Pectoralis minor muscle and the serratus muscle. This breaks through the 'axillary door' and will reach the long thoracic nerve and reliably at least two intercostal nerves.
We used A high frequency linear US probe is used for this block. a broadband linear array probe, with an imaging depth of 3-4cm. starting from the lateral third of the clavicle and moving distally and laterally to the mid axillary line."
1546897|NCT02620358|Other|T Tube for 120 minuts|Spontaneous Breathing Trial using T Tube for 120 minutes.
1546898|NCT02620358|Other|Pressure Support Ventilation of 8 cmH2O for 30 minutes|Spontaneous Breathing Trial using Pressure Support Ventilation of 8 cmH2O for 30 minutes
1546899|NCT02620345|Drug|Dydrogesterone M ( case 1 )|"Dydrogesterone Multivitamin nature
Fibroids / Women Pregnancy ( discovered fibroids during pregnancy ) Dydrogesterone Multivitamin nature.
1tablet/24 hours/day (to 4 weeks after postpartum)"
1546900|NCT02620345|Drug|Dydrogesterone M ( case 2 )|"Dydrogesterone Multivitamin nature
Fibroids/ Women of Reproductive age ( discovered fibroids )
1tablet/24 hours/day ( from discovered fibroids through 6 months)"
1546901|NCT02620332|Drug|MultiPepT1De injection|A mix of peptides
1546902|NCT02620332|Other|Placebo|Water for injection
1546903|NCT02620319|Device|SX-ELLA Stent DV Tracheal (DV Stent)|The trachea is intubated with a rigid bronchoscope while participants are placed under total intravenous anesthesia and jet ventilation. The delivery apparatus containing the stent is introduced through a rigid tube to the desired depth under visual control. Then the stent is deployed and its position is determined and, if necessary, stent is repositioned using rigid forceps. In-stent balloon dilation is carried out. If needed, thoracic surgeon can secure the stent in place via external (percutaneous) fixation: one suture is passed through the stent, the tracheal wall, soft tissues, and skin; the suture is then knotted on the skin of the neck. The suture is removed two to three weeks after implantation.
1546904|NCT02620306|Drug|Fimsartan 60mg~120mg|Standard BP control group (SBP < 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
1546905|NCT02620306|Drug|Fimsartan 60mg~120mg|Strict BP control group (SBP < 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
1546906|NCT02620306|Drug|Losartan 50mg~100mg|Standard BP control group (SBP < 140 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
1546907|NCT02620306|Drug|Losartan 50mg~100mg|Strict BP control group (SBP < 130 mmHg). In case of patients with blood pressure that cannot be controlled to the targeted level at each visit during the entire clinical study period, the dose of study drug is increased or other antihypertensive drugs are administered concomitantly.
1546908|NCT02620293|Device|Eczema Repair Emollient|An Emollient
1546909|NCT02620280|Drug|Carboplatin|Carboplatin AUC 2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
1546910|NCT02620280|Drug|Abraxane|Abraxane, 125 mg/m2 will be given i.v. on day 1 and day 8 q 3 weeks for a total of 8 cycles
1546911|NCT02620280|Drug|MPDL3280A|MPDL3280A, 1200 mg. will be given i.v. infusion on day 1 q 3 weeks for a total of 8 cycles
1546912|NCT02620280|Procedure|Surgery|Breast cancer surgery (breast and axilla) either conservative or radical not later than 6 weeks
1546913|NCT02620280|Drug|Anthra|AC or EC (adriamycin or epirubicin and cyclophosphamide) or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles to be delivered after surgery
1546914|NCT02620267|Device|tDCS Stimulation|Subjects will receive tDCS stimulation over the auditory cortex for 20 min. For anodal stimulation the anode electrodes will be placed over the auditory cortex. For cathodal stimulation, the cathode electrodes will be placed over the auditory cortex. For sham stimulation, the anode electrodes will be placed over the auditory cortex and current turned on for 30 sec before being turned off to simulate the sensation of active stimulation.
1546915|NCT02620241|Other|sitting position|
1546916|NCT02620228|Device|BIP Biopsy System|BIP Biopsy system is essentially similar as traditional biopsy systems but it enables real-time bioimpedance measurement from the tip of the biopsy needle.
1546917|NCT02620215|Device|Cervical Ripening Balloon|Cook® Cervical Ripening Balloon with Stylet Order number G19891 Reference Part Number J-CRBS-184000 Catheter (Fr) 18.0 Length (cm) 40 Balloon Volume (mL) 80
1546918|NCT02620215|Drug|Prostin|Prostin E2 vaginal tablets contain the active ingredient dinoprostone, which is a naturally occuring female hormone also known as prostaglandin E2. Prostaglandins are involved in naturally starting labour. Dose of Prostin is 3 mg vaginally.
1546919|NCT02620189|Drug|Anti-TNF Biologics Therapy|
1546921|NCT02620163|Drug|telmisartan/amlodipine 40/5mg|
1546922|NCT02620163|Drug|YH22162 40/5/12.5 mg|
1546923|NCT02620163|Drug|telmisartan/amlodipine 80/5mg|
1546924|NCT02620163|Drug|YH22162 80/5/25 mg|
1546925|NCT02620163|Drug|telmisartan/amlodipine 40/5mg placebo|
1546926|NCT02620163|Drug|YH22162 40/5/12.5 mg placebo|
1546927|NCT02620163|Drug|telmisartan/amlodipine 80/5mg placebo|
1546928|NCT02620163|Drug|YH22162 80/5/25 mg placebo|
1546929|NCT02620150|Drug|Escitalopram|10 week trial
1546930|NCT02620150|Other|Placebo|10 week trial
1546932|NCT02620137|Drug|Multicentrum® (Pfizer, Spain) 12 months|The multivitamin supplement (Multicentrum® (Pfizer, Spain) 1 tablet/day) will be maintained during 12 months
1546933|NCT02620124|Drug|Natural cycle: Triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in additon to standard micronized progesterone 400 mg vaginally
1546934|NCT02620124|Drug|Hormone replacement cycle and triptorelin acetate 0.1 mg|A single dose of triptorelin acetate 0.1 s.c. was giwen when the age of the transferred embryo was six days in addition to standard Estradiol and progesterone support
1546935|NCT02620111|Dietary Supplement|Whey protein high in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
1546936|NCT02620111|Dietary Supplement|Whey protein normal in leucin|This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
1546937|NCT02620098|Other|Size Matters Handwriting Program|The Size Matters Handwriting Program (Moskowitz, 2009) (SMHP) program incorporates principles grounded in motor learning theory, cognitive theory, and motivation theory. Children learn the importance of letter size by learning size 1 (capital and tall letters), size 2 (small letters) and size 3 letters (those that dive below the baseline) at different stages (Moskowitz, 2009). The intervention group received a total of 30 sessions of the SMHP, completed twice weekly over a 16 week period. Sessions lasted 30 minutes, and were led by an occupational therapist with training in the Size Matters Handwriting Program. All interventions were provided within the existing support classrooms. Each child had their own SMHP workbook.
1546938|NCT02620085|Procedure|blood sampling|blood sampling
1546939|NCT02620072|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 67.5 mg or placebo for the following 9 months of the treatment period. Follow-up will continue for 24 months after the last administration of treatment.
1546940|NCT02620072|Other|Placebo|Total of 12 months intervention period; daily administration of insulin or placebo capsules containing filling substance (microcrystalline cellulose). Follow-up will continue for 24 months after the last administration of treatment.
1546941|NCT02620059|Behavioral|Lifestyle Intervention|The investigators will provide information on healthy eating and physical activity. They will give pedometers to the participants to monitor their daily steps in order to increase it till 10000 steps/day.
1546943|NCT02620033|Behavioral|Yoga therapy|
1546944|NCT02620020|Drug|Fasinumab|
1546945|NCT02620020|Drug|placebo|
1546946|NCT02620007|Drug|Ciprofloxacin|oral Ciprofloxacin 500 mg bis in die (bid) for 12 weeks
1546947|NCT02620007|Drug|Rifaximin|oral Rifaximin 800 mg bid for 12 weeks
1546948|NCT02620007|Drug|Ciprofloxacin Placebo|a placebo of Ciprofloxacin bid for 12 weeks
1546949|NCT02620007|Drug|Rifaximin Placebo|a placebo of Rifaximin bid for 12 weeks
1546950|NCT02619994|Drug|Linezolid|
1546951|NCT02619994|Drug|Delamanid|
1546952|NCT02619994|Drug|Levofloxacin|
1546953|NCT02619994|Drug|Pyrazinamide|
1546954|NCT02619994|Drug|Locally-used WHO-approved MDR-TB regimen in Korea|
1546955|NCT02619981|Procedure|Restorative procedure|A restorative dental procedure requiring maxillary buccal infiltration anesthesia, and not exceeding 30 minutes of working time
1546956|NCT02619981|Drug|Maxillary infiltration anesthesia with 2%Lidocaine|1.8ml of 2% Lidocaine with adrenaline administered using a 27 gauge 21mm needle
1546957|NCT02619968|Other|experimental group|Will be held isometric and isotonic concentric to the flexor muscles of the elbow and wrist using tennis ball, halter and handgrip added to partial occlusion of blood flow to tourniquet application. The Application of the tourniquet will be held in conjunction with exercises for the experimental group.
1546958|NCT02619955|Other|samples with DNA|
1546959|NCT02619942|Procedure|D2 radical operation|In D2 radical operation group(D2), the lymph node dissection is based on ligating the supplying vessels close to the right-side of superior mesenteric vein and clean up the surrounding lymph node and adipose tissue.
1546960|NCT02619942|Procedure|Complete mesocolic excision (CME)|In complete mesocolic excision group (CME), the dissecting extent includes the lymphatic and fat tissues surrounding the root of ascending mesocolon, which situated on the surface of superior mesenteric vein, and the root of right half of transverse mesocolon, which situated on the surface of pancreas neck.
1546961|NCT02619929|Drug|Vinorelbine oral|
1546962|NCT02619916|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 60 minutes
1546963|NCT02619916|Behavioral|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 60 minutes.
1546964|NCT02619903|Procedure|Dental cleaning|Dental scaling and cleaning to remove dental plaque as well as removing the tongue biofilm.
1546965|NCT02619890|Other|Brain Glioma Registry|
1546966|NCT02619877|Biological|ALLO-ASC-DFU|Application of ALLO-ASC-DFU sheet to diabetic foot ulcer
1546967|NCT02619877|Other|Standard therapy|Standard therapy conducted for patients with diabetic foot ulcer
1546969|NCT02619851|Biological|ALLO-ASC-DFU|Dressing for Second Deep degree Burn injury
1546970|NCT02619851|Device|Conventional Therapy|Typical therapy conducted for burn injury patients
1546971|NCT02619838|Device|Aptus CCS 5.0 or/and 7.0 screws|Fusion of the talonavicular joint, the subtalar joint, and the calcaneal-cuboid joint with a Aptus CCS screws. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
1546972|NCT02619825|Device|Echography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and measurement of all echocardiographic parameters estimated in children with a clinical ultrasound Machine
1546973|NCT02619825|Device|Elastography|cardiac ultrasound, in two stages, with an estimate of the stiffness of the myocardium ShearWave Elastography (Aixplorer®) and
1547163|NCT02618330|Device|retainer|24 h wearing whether 0.75-mm-thick or 1.00-mm-thick film retainer
1546974|NCT02619812|Other|Serum-derived bovine immunoglobulin/protein isolate (SBI)|SBI 10 grams (The subject will take a total of 4 packets of SBI; taken as two packets of SBI twice a day mixed with water or blended with certain foods)
1546975|NCT02619812|Drug|Colesevelam|Colesevelam 1.875 g (The subject will take a total of 12 capsules of Welchol 1.875g per day; taken as 6 capsules twice a day by mouth).
1546976|NCT02619812|Other|Double Placebo|Double placebo twice per day (The subject will take a total of 4 packets of placebo and 12 capsules daily taken as 6 capsules twice a day by mouth and two packets of placebo twice a day mixed with water or blended with certain foods).
1546977|NCT02619799|Drug|intrathecal magnesium sulphate,|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
1546978|NCT02619799|Drug|Intrathecal midazolam|comparision of effects of intrathecal magnesium sulphate with intrathecal midazolam when administered along with epidural 0.75% Ropivacaine
1546979|NCT02619786|Drug|Inhaled colistin|75 mg of colistin activity, inhaled per dose, every 12 hours
1546980|NCT02619773|Procedure|mupirocin ointment|Mupirocin ointment will be applied after skin closure. A standard island dressing will be placed over the incision.
1546981|NCT02619760|Drug|1-month DAPT|1-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
1546982|NCT02619760|Drug|12-month DAPT|12-month dual antiplatelet therapy (DAPT) composed of aspirin and P2Y12 receptor antagonists
1546983|NCT02619747|Drug|Compound Sodium Alginate Oral Suspension sachet|
1546984|NCT02619747|Drug|Matched placebo|
1546985|NCT02619734|Biological|Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be administered by intramuscular injection into and around the leg ulcer. The number of injected cells will be from 5x108 to 1x109 total number of cells on Study Day 1.
1546986|NCT02619721|Device|PINS SNS|
1546987|NCT02619708|Behavioral|Immersive Preoperative Experience|The video will include a simulated patient encounter (with actors not real patients) showcasing the preoperative experience of the patient, including getting checked in, meeting the nurses, surgeons, and the anesthesiologists. The technology used will allow the immersion of the patient in the preoperative environment. Patients will be able to look around and explore the spaces they will visit on the day of their operation.
1546988|NCT02619695|Drug|Fastjel|2.5% ketoprofen gel (Fastjel) has been administer as 2 gr in 5 cm area.
1546989|NCT02619682|Drug|Ixazomib Citrate|Given PO
1546990|NCT02619682|Other|Laboratory Biomarker Analysis|Correlative studies
1546991|NCT02619682|Drug|Lenalidomide|Given PO
1546992|NCT02619669|Drug|TAK-228|Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin (mTOR). TAK-228 (formerly INK128 or MLN0128) targets 2 distinct multiprotein complexes, mTORC1 and mTORC2. TAK-228 selectively and potently inhibits mTOR kinase (IC50 = 1.1 nM), inhibits mTORC1/2 signaling, and prevents cellular proliferation.
1546993|NCT02619669|Drug|Letrozole|An aromatase inhibitor that has a greater inhibitory effect on Ki67 (marker of cell proliferation).
1546994|NCT02619656|Procedure|CO2 insufflation|Patients were randomized to insufflation with CO2.
1546995|NCT02619656|Procedure|Ambient air insufflation|Patients were randomized to insufflation with ambient air.
1546996|NCT02619643|Device|Transcranial Magnetic Stimulation (Magstim)|
1546997|NCT02619630|Drug|nelarabine|"Nelarabine 1500 mg/m2/d (IV 2h) : D1, D3, D5 Cyclophosphamide 150 mg/m2/d (IV 3h) : D1, D3 etoposide (VP-16) 75 mg/m2/d (IV 1h) : D1, D3 granulocyte-colony stimulating factor 5 µg/kg/d (SC) : D7 until neutrophil >1 Giga/Liter
for a maximum of 5 blocks"
1546998|NCT02619617|Drug|SOM230|The study will evaluate SOM230 vs Placebo
1546999|NCT02619617|Drug|Placebo|The study will evaluate SOM230 vs Placebo
1547000|NCT02619604|Other|Education Intervention|Education interventions will be delivered sporadically within the 6-month window between the time the clinician completes the pre-survey and when he/she completes the post-survey. Interventions consist of e-brief publications, teleconferences with project faculty, and evidence based resources.
1547001|NCT02619591|Other|Ultrasound Imaging|views of a hemithorax was obtained using the Zonare Ultrasound machine.
1547002|NCT02619578|Other|TEAS|According to the theory of traditional Chinese medicine, bilateral Baihui (GV20), Yingtang (EX-HN3), Zusanli (ST36) and Neiguan (PC6) were chosen as the acupuncture points. These acupoints were identified according to the traditional anatomic localization . Gel electrodes were applied to the skin after it had been cleaned with ethyl alcohol. The acupoints were then stimulated electrically with an intensity of 12-15 mA and dense-disperse frequency of 2/100 Hz for 30 min, using the Hwato electronic acupuncture treatment instrument (model No. SDZ-V, Suzhou Medical Appliances Co., Ltd, Suzhou, China). The intensity was adjusted to maintain a slight twitching of local muscles according to individual maximum tolerance, indicating a satisfactory of De-Qi phenomenon and thus adequate stimulation.
1547003|NCT02619578|Other|Con|The patients in the Con group had the electrodes applied at the same acupoints, but received no stimulation.
1547004|NCT02619578|Drug|propofol, remifentanil, vecuronium|Anesthesia was induced i.v. with propofol (2 mg kg-1) and remifentanil (1 μg kg-1) using a target-controlled infusion (TCI) system. After loss of consciousness, vecuronium (0.1 mg kg-1) was administered i.v.
1547005|NCT02619578|Other|mechanical ventilation|Patients' lungs were mechanically ventilated in a volume-controlled mode with a tidal volume of 8ml kg-1 body weight during the operation.
1547006|NCT02619565|Other|blood samples|blood samples at Day 0 and also if there is an evolution of the disease
1547007|NCT02619552|Drug|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
1547008|NCT02619552|Drug|Anti-TNF|All participants in this arm receive an anti-TNF for the treatment of perianal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
1547426|NCT02616302|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, 30 mg, and 60 mg capsules
1547009|NCT02619552|Drug|Steroids|All participants in this arm receive steroids for the treatment of luminal CD. They are required to undergo study visits at baseline, 2 months, and 6 months in addition to any other routine visits. Sexual function, body image, disease activity, quality of life, and depression scores will be measured at baseline and at each study visit during the 6-month study.
1547010|NCT02619539|Procedure|plasma fibrinogen measurement|plasma fibrinogen measurement
1547011|NCT02619526|Drug|Nebivolol|Nebivolol 10mg, once a day
1547012|NCT02619526|Drug|Carvedilol|Carvedilol 25mg, twice a day
1547013|NCT02619513|Drug|Dexmedetomidine|Group GTD received thoracic continuous paravertebral nerve block with dexmedetomidine (0.5μg/kg) added to ropivacaine before anesthesia induction, and used continuous thoracic paravertebral nerve block patient-controlled analgesia(with dexmedetomidine 100μg）.
1547014|NCT02619513|Drug|Ropivacaine|Group GE\GT\GTD respectively received continuous nerve blocks and postoperative analgesia combined with ropivacaine.
1547015|NCT02619513|Device|Mindray M7 series|Ultrasound real-time guidance have been used in continuous thoracic paravertebral blocks in group GT and group GTD.
1547016|NCT02619500|Other|Home Exercise Program|A standardized home exercise program will be given to subjects that will include active range of motion of the cervical and thoracic spine and deep cervical flexion endurance exercises.
1547017|NCT02619500|Other|Patient advice, encouragement, and education|Therapists will provide each subject with advice and education pertaining to their condition as well as encouragement towards reducing pain and disability.
1547018|NCT02619500|Other|Thrust Manipulation|High velocity low amplitude (HVLA) thrust performed at or near the end range of a targeted segment in both the cervical and thoracic spine
1547019|NCT02619500|Other|Non-thrust Mobilizations|Repetitive and rhythmic accessory passive movements applied with either small or large amplitude at a targeted segment to both the cervical and thoracic spine
1547020|NCT02619487|Other|text message to parent only|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
1547021|NCT02619487|Other|text message to parent and adolescent|A weekly text message of an educational or motivational nature and related to Type 1 Diabetes will be sent for a duration of one year
1547022|NCT02619474|Other|Whiteboard|"On morning rounds, the child's management will be discussed with the family and the day's plan for treatment and investigations will be written on the whiteboard.
The second step will be to review and update the whiteboard at the end of the day. Anything that has been left out or uncompleted will be highlighted and brought up on the following morning's rounds. Next, the nurse will ask the family to write down any questions.
Lastly, on the afternoon before a child's discharge, the nurse will take particular care to make sure the parents write down all of their concerns prior to going home. These specific questions concerning discharge planning will be addressed in detail at rounds the following morning."
1547023|NCT02619461|Other|Exercise|Exercise at 70%VO2max on a recumbent bicycle for 30 minutes to investigate the effects of exercise at high intensities on appetite and biomarkers of appetite and inflammation.
1547024|NCT02619448|Drug|Carboplatin|chemotherapy
1547025|NCT02619448|Drug|Paclitaxel|chemotherapy
1547026|NCT02619448|Radiation|70 Gy in 20 fractions over 4 weeks|accelerated hypofractionated RT
1547027|NCT02619435|Drug|regorafenib|Patients will receive regorafenib orally 160 mg once daily for the first 3 weeks of each 4-week cycle.
1547028|NCT02619422|Other|Intensive cardiac rehabilitation program in less time|2 weeks, 5 days a week, and reinforcement sessions at 3, 6 and 9 months
1547029|NCT02619409|Drug|Bupivacaine Only|The bupivacaine only group will receive bupivacaine 0.5% 3cc plus sterile saline 0.1cc.
1547030|NCT02619409|Drug|EPI25|The EPI25 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.025cc, and sterile saline 0.075cc.
1547031|NCT02619409|Drug|EPI50 group|The EPI50 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.05cc, and sterile saline 0.05cc
1547032|NCT02619409|Drug|EPI75 group|The EPI75 group will receive bupivacaine 0.5% 3cc, epinephrine 1:1000 0.075cc, and sterile saline 0.025%.
1547033|NCT02619409|Drug|EPI100 group|The EPI100 group will receive bupivacaine 0.5% 3cc, and epinephrine 1:1000 0.1cc.
1547034|NCT02619396|Procedure|Combination 1 of RF power and LSI on LA posterior wall|20 W RF power and target LSI = 4 on LA posterior wall
1547035|NCT02619396|Procedure|Combination 2 of RF power and LSI on LA posterior wall|40 W RF power and target LSI = 4 on LA posterior wall
1547036|NCT02619396|Procedure|Combination 3 of RF power and LSI on LA posterior wall|20 W RF power and target LSI = 5 on LA posterior wall
1547037|NCT02619396|Procedure|Combination 4 of RF power and LSI on LA posterior wall|40 W RF power and target LSI = 5 on LA posterior wall
1547038|NCT02619383|Device|Hyperbaric oxygen therapy|The treatment comprised 40 daily hyperbaric sessions, 5 days a week, in a multiplace hyperbaric chamber (HAUX-Life-Support GmbH). Each session consisted of 90 minutes of exposure to 100% oxygen at 2 ATA with 5 minutes air breaks every 30 minutes and 1 meter per minute compression and decompression.
1547039|NCT02619370|Behavioral|Conversation card game|
1547040|NCT02619370|Behavioral|Active Control|
1547041|NCT02619357|Device|SenseWear Armband Gecko|Subjects will wear SenseWear Armband Gecko up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
1547042|NCT02619357|Device|SenseWear Armband MF|Subjects will wear SenseWear Armband MF up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
1547043|NCT02619357|Device|Actigraph GT9x wristband and waistband|Subjects will wear Actigraph GT9x wristband and waistband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
1547044|NCT02619357|Device|Garmin Vivofit 2 wristband|Subjects will wear Garmin Vivofit 2 wristband up to 24 hours per day for 2 days while performing usual activities of daily living, strength exercises, laboratory-based, and field-based exercise tests
1547045|NCT02619357|Device|SOMNOwatch plus EEG 6 sleep monitor|In a subset of subjects, this device will be worn as a comparator for monitoring sleep quality and duration.
1547046|NCT02619357|Other|Strength exercises|Subjects will perform strength exercises using elastic bands of varying resistance
1547490|NCT02615899|Other|Matched: Targeted (specific) balance exercise interventions|
1547047|NCT02619357|Other|Field-based exercise tests|Subjects will perform an Incremental Shuttle Walk Test (ISWT) and each individual component of a Short Physical Performance Battery (SPPB).
1547048|NCT02619357|Other|Laboratory-based exercise tests|Subjects will perform an incremental, symptom-limited cardiopulmonary exercise test on a cycle ergometer and will walk at various speeds on a treadmill
1547049|NCT02619331|Procedure|Allergy test reading|Reading of allergy skin tests (in response to allergen extracts or histamine or negative control) by HSL-DI versus direct observer evaluation (CWFM)
1547050|NCT02619318|Behavioral|Balancing Everyday Life (BEL)|
1547051|NCT02619318|Behavioral|Care as usual (generally standard occupational therapy)|
1547052|NCT02619305|Other|Social network tie|Participants will be social network ties of women receiving a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
1547053|NCT02619292|Behavioral|Mindful Movement Program|Mindfulness is turning one's awareness to the present moment. Movement-dance therapy is the expression of thoughts or feelings through body movement, under the supervision of a licensed professional.
1547054|NCT02619279|Other|Livelihood intervention|Participants' mothers will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
1547055|NCT02619266|Other|Acupuncture|Acupuncture is the practice of inserting thin needles into specific points to improve health and well-being.
1547056|NCT02619266|Other|Sham Acupuncture|Sham acupuncture is used as a control in scientific studies that test the efficacy of acupuncture in the treatment of various illness or disorders.
1547057|NCT02619266|Drug|Megestrol Acetate|Megestrol Acetate 160mg tablet
1547058|NCT02619266|Drug|Placebo(Megestrol Acetate)|Starch pill manufactured to mimic Megestrol Acetate 160mg tablet
1547059|NCT02619253|Drug|Pembrolizumab|
1547060|NCT02619253|Drug|Vorinostat|
1547061|NCT02619240|Procedure|bronchoscopy|performance of bronchoscopy with BAL
1547062|NCT02619227|Other|Livelihood intervention|Participants will receive a livelihood intervention package consisting of a orientation and training and a loan package of chickens and associated implements to create poultry microenterprises.
1547063|NCT02619214|Drug|30% of oxygen concentration.|30% oxygen concentration during one hour of general anesthesia.
1547064|NCT02619214|Drug|60% of oxygen concentration.|60% oxygen concentration during one hour of general anesthesia.
1547065|NCT02619201|Drug|Ondansetron|An intravenous dose of ondansetron ( 0.15mg /kg / doses ) .
1547066|NCT02619201|Drug|metoclopramide|An intravenous dose of metoclopramide ( 0.15mg /kg / doses ) .
1547067|NCT02619188|Other|PUQE-form inclusion|PUQE-form encompassing last 24 hours completion
1547068|NCT02619188|Other|Nutritional form inclusion|Food-list form encompassing last 24 hours completion
1547069|NCT02619188|Other|Blood sampling inclusion|Measurement of biochemical nutrition marker(s); Prealbumin
1547070|NCT02619188|Other|Intervention at discharge|PUQE-form, nutritional form and Blood sampling
1547071|NCT02619175|Device|BalanceTutor|
1547072|NCT02619175|Device|posturograph|
1547073|NCT02619162|Drug|Nintedanib|Tablets of 100 mg. or 150 mg.
1547074|NCT02619162|Drug|Letrozole|Tablet of 2.5 mg.
1547075|NCT02619149|Drug|Piperacillin-tazobactam combination product|Piperacillin-Tazobactam (extended-spectrum, beta-lactamase inhibitor) iv peroperatively as prophylaxis
1547076|NCT02619149|Drug|Saline solution|Saline iv as placebo control
1547077|NCT02619136|Procedure|Transfusion|Red Blood Cell Transfusion
1547078|NCT02619123|Other|Tailored screening according to breast density|Different interval of mammography screening according to breast density
1547079|NCT02619123|Other|Annual invitation to mammography|Annual interval mammography screening according to international guidelines for women younger than 50 years old
1547080|NCT02619110|Other|backward walking treadmill training|subjects accepted 30 minutes backward walking treadmill training. a week for four weeks.
1547081|NCT02619110|Other|conventional physical therapy|subjects accepted 30 minutes traditional physical therapy three times a week for four weeks
1547082|NCT02619097|Drug|Pegol-sihematide injection|single dose
1547083|NCT02619084|Procedure|STN DBS|Bilateral STN DBS
1547084|NCT02619071|Procedure|Tumor sampling|Bone marrow aspirate, blood sampling
1547085|NCT02619071|Biological|Constiutional DNA sampling|Buccal swab or Hair follicles
1547086|NCT02619058|Biological|NKT cells|autologous natural killer T cell
1547087|NCT02619045|Other|Telephone follow-up nursing device|"Telephone follow-up nursing device involving:
telephone appointments made by a dedicated nurse and set up at key stage of treatment (1 phone call per week during chemotherapy cycles),
specific questionnaire used by the nurse at each phone call (toxicity, general care, quality of life...),
actions taken for the patient following each phone call (consultation with a doctor, patient hospitalization, sending of a prescription, coordination with the city medical caregiver);"
1547088|NCT02619032|Drug|Remifentanil|Intraoperative continuous infusion of remifenatanil. Remifentanil infusion was interrupted upon completion of surgical intervention.
1547089|NCT02619032|Drug|Fentanyl|Fentanyl 50 μg iv bolus at the induction of anesthesia and before the start of surgery.
1547090|NCT02619019|Drug|Dexamethasone|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 8 mg of dexamethasone intrathecally
1547091|NCT02619019|Drug|Pethidine|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 0.2 mg/kg of pethidine intrathecally
1547092|NCT02619019|Drug|Normal saline|Patients will receive 8 mg of hyperbaric bupivacaine 0.5%, plus 2 ml normal saline intrathecally
1547093|NCT02619006|Other|Delayed Cord Clamping or Cord Milking|Healthy term infants who were previously randomized or assigned at birth to the intervention group known as delayed cord clamping. The cord was clamped and cut at or beyond 300 seconds (5 mins). Cord milking (cord milked x 5) was used as a proxy for delayed cord clamping when there was a clinical situation of concern.
1547094|NCT02618993|Procedure|Realization of the V3 block in maxillofacial surgeries|bilateral mandibular block in maxillofacial surgeries
1547229|NCT02617797|Device|Radiofrequency OFF|Will be used to put off radio frequency will be heated glycerin to occur masking for the patient.
1547095|NCT02618980|Other|endoscopic hemostasis|At endoscopy, stigmata of hemorrhage (SRH) will be treated by dual endoscopic local therapy (combining at least two of the following treatments: epinephrine injection, coaptive thermocoagulation, hemoclip therapy, argon plasma coagulation, bipolar coagulation).
1547096|NCT02618967|Biological|AMG 570|6 dose levels of AMG 570 administered as single dose subcutaneous in healthy volunteers.
1547097|NCT02618967|Biological|AMG 570 Matching Placebo|6 dose levels of Placebo administered as single dose subcutaneous in healthy volunteers.
1547098|NCT02618954|Other|Articular ultrasound|(Device : Ultrasound) : Articular ultrasound of the Disease Activity Score (DAS) 28 articular joint
1547099|NCT02618941|Biological|AFFITOPE® PD01A|s.c. injection
1547104|NCT02618902|Biological|tolerogenic dendritic cells (tolDC)|dose-escalation
1547105|NCT02618889|Behavioral|CBT|All participating subjects will start a 12-week CBT treatment program. These consist of weekly 1-hour CBT sessions led by a cognitive therapist. Assessments will be repeated at week 16. All PsyD subjects will undergo a 15-minute, structured diagnostic interview (Mini International Neuropsychiatric Interview (MINI)) developed to screen for axis I DSM-IV and ICD-10 psychiatric disorders. We will also use two clinician-rated instruments to assess comorbid psychopathology in PsyD patients, the 17-item Hamilton Depression Rating Scale (HAM-D), to evaluate for depressed mood, vegetative and cognitive symptoms of depression; and the 14-item Hamilton Anxiety Rating Scale (HAM-A) to evaluate psychic and somatic anxiety. These scales will be administered as part of a structured interview.
1547106|NCT02618876|Drug|Nalbuphine plus Bupivacaine|Addition of caudal Nalbuphine to the standard Bupivacaine
1547107|NCT02618876|Drug|Bupivacaine|Caudal Bupivacaine is the standard of care will be considered as a control
1547108|NCT02618863|Device|Cricoid pressure|Applying cricoid pressure and testing its effectiveness using gastric tube . in addition , by using the cricometer , the CP 50 is defined and compared in both gender
1547109|NCT02618850|Procedure|PET/CT|PET/CT scan at baseline and 10-14 days after day 1 of first cycle chemotherapy
1547110|NCT02618850|Drug|first-line chemotherapy|as prescribed by oncologist
1547111|NCT02618837|Procedure|Downstream strategy|"At diagnosis:
Subjects receive a loading dose of aspirin (150-300mg). Administration of clopidogrel is allowed only for patients already receiving clopidogrel
Pre-procedure:
Until PCI is performed, all subjects will be maintained at a minimum of 75mg of aspirin (Subjects with clopidogrel may be maintained at a minimum of 75mg of clopidogrel)
Peri- and post-procedure:
For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; choice based upon clinical judgement.
In this case, subject will be randomized in a 1:1 fashion to prasugrel vs ticagrelor
At the time of PCI, the loading doses required (according to randomization):
Ticagrelor 180mg, maintained at 90mg b.i.d. for at least 12 months
Prasugrel 60mg, maintained at a minimum of 75mg of aspirin for at least 12 months plus 10mg of prasugrel* daily for at least 12 months
If subject is >75 years old or <60 kg, daily dose of prasugrel should be 5mg"
1547112|NCT02618837|Procedure|Upstream strategy|"At the time of diagnosis:
Subjects randomized in this arm must receive a loading dose of aspirin (150-300 mg) and ticagrelor (180 mg) at admission as soon as possible.
Pre-procedure:
All subjects will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, until coronary angiography is performed.
Peri- and post-procedure:
For all the patients undergoing PCI, both the use of unfractioned heparin and of bivalirudin will be allowed at the time of PCI; the choice of the anticoagulant at the time of PCI will be based upon clinical judgement.
All subjects randomized to the upstream strategy arm will be maintained at a minimum of 90 mg of ticagrelor b.i.d. and a minimum of 75 mg of aspirin, for at least 12 months. If the subject develops hypersensitivity or intolerance to ticagrelor, clopidogrel may be used as a substitute at a dose in accordance with standard hospital practice (to be documented in the eCRF)."
1547113|NCT02618824|Drug|Histidine Tryptophan Ketoglutarate Solution|Hearts will be arrested with Histidine Tryptophan Ketoglutarate (HTK) solution during cardiac operation. After aortic cross clamp 50-60 ml/kg HTK will be administered
1547114|NCT02618824|Other|Terminal Warm Blood Cardioplegia|Terminal warm blood cardioplegia (TWBC) contains 20% HTK solution and 80% blood from cardiopulmonary bypass machine. Before aortic cross clamp removal 10-15 ml/kg TWBC will be administered with temperature 34-36 oCelcius
1547115|NCT02618785|Procedure|hysterosalpingography|Starting procedure by using largest appropriate speculum for maximum cervical exposure. Cleanse the cervix with povidone iodine. A tenaculum was applied to the anterior cervix to help for stabilization and counter-traction. Then insert a sterile Rubin's cannula into the cervix uteri. A scout radiograph of the pelvis was obtained with the catheter in place before contrast material was instilled. After that the water soluble contrast media was slowly instilled through the cannula appropriate volume range 10-15 ml., with fluoroscopic images obtained intermittently to evaluate the uterus, fallopian tubes and tubal patency
1547116|NCT02618772|Drug|Midazolam|Intranasal administration of midazolam at dose of 0.4mg/kg (max 10 mg) one time 10 minutes prior to laceration repair
1547117|NCT02618772|Drug|Saline|Intranasal administration of saline at a dose of 0.08ml/kg (max 2ml) one time prior to laceration repair as a placebo
1547118|NCT02618759|Drug|DSXS|active treatment
1547119|NCT02618759|Drug|Placebo|placebo treatment
1547120|NCT02618746|Other|Telerehabilitation|
1547121|NCT02618746|Other|Hospital based Rehabilitation|
1547122|NCT02618733|Drug|Ticagrelor|90mg, twice a day
1547123|NCT02618733|Drug|Clopidogrel|75mg, once a day
1547124|NCT02618720|Drug|ornidazole|
1547125|NCT02618720|Drug|Placebo|
1547126|NCT02618707|Other|Lactate|Lactate samples will drawn at specific time points within 5 time intervals: before CPB after induction, during cooling on CPB, during rewarming on CPB, immediately after CPB in the operating room, and after admission to the post-operative intensive care unit.
1547230|NCT02617784|Drug|Oseltamivir|Oseltamivir will be given as marketed oral suspension, 30 mg after HD or CAPD treatment.
1547491|NCT02615899|Other|Mismatched: Untargeted (non-specific) balance exercise interventions|
1547127|NCT02618694|Procedure|Posterior retroperitoneoscopic adrenalectomy|Patient is in prone, half Jack-knife position, and hips and knees are fixed in 75-90°. A 15 mm trocar incision just below the tip 12th rib. Prepare a small retroperitoneal space with finger and insert two 5 mm trocars about 5 cm lateral and medial to the first trocar with digital guidance. Medial trocar will be inserted upward. Lateral one will be lateral and below the 11th rib. Dissect inferior to diaphragm and retraction of the kidney downward. Mobilize the adrenal gland. At right side, start medial and caudally. Control the adrenl arteries crossing the IVC posteriorly. Prepare adrenal vein posterolaterally. Control between two clips. Continue gland dissection laterally and cranially. At left side, prepare the adrenal vein between the gland and diaphragm medial to the upper pole of the kidney. Dissect medial, lateral and cranially. Retrieve the mass through middle incision. Insert a drain and close skin incisions (Walz M. K., 2005).
1547128|NCT02618694|Procedure|Transperitoneal laparoscopic adrenalectomy|On right side, patient is on supine position. Put a trocar at umbilicus for the camera. Put 4 trocars 1-2 cm subcostal from subxiphoid (10-12 mm) for liver retractor, to far lateral (5 mm) and two 10 mm trocars inbetween. Retract liver, incise the retroperitoneum, and identify right adrenal gland between upper pole of the kidney and IVC. Dissect gland from the kidney than laterally and posteriorly from the diaphragm. Expose, apply clips to, and divide the adrenal vein. On left side, patient is on lateral decubitus. Put a trocar at umbilicus for the camera, 4 trocars 1-2 cm subcostal from the midline to the far most lateral possible (the last is 5 mm the rest are 10 mm). Mobilize colon flexure and expose the kidney. Separate kidney from the pancreas and spleen. Mobilize the tumor, starting by posterior surface, superior border then from the renal surface. Divide the adrenal vein. Retrieve the mass (Suzuki, Tsuru, & Ihara, 2012; Linos, 2005; George & Kavoussi, 2010).
1547129|NCT02618668|Drug|Ketamine / Propofol Admixture|propofol-ketamine 3:1 mixture(%1 15 ml propofol + 1 ml 50mg/ml ketamine+4 ml saline in a 20-ml syringe which resulted in0.25 mg.ml-1 ketamine and 0.75 mg.ml-1 propofol
1547130|NCT02618668|Drug|Propofol|2 mg/kg I.V
1547131|NCT02618655|Other|diagnostic methods|explore several laboratory diagnostic methods to find out which will be more helpful for making an accurate diagnosis in the early period of TBDs.
1547132|NCT02618642|Radiation|Piler light phototherapy|"Piler light + red filter: phototherapy, 10 treatment sessions,10 minutes for one session Piler light + blue filter: phototherapy, 10 treatment sessions,10 minutes for one session Piler light without a filter: phototherapy, 10 treatment sessions, 10 minutes for one session
Piler light + red filter: 10 people Piler light + blue filter: 10 people Piler light without a filter: 10 people"
1547133|NCT02618629|Drug|14C-Z-215|Single oral dose of 20mg Z-215 and 14C-Z-215 solution
1547134|NCT02618616|Drug|ZPL-3893787|
1547135|NCT02618616|Drug|Placebo|
1547136|NCT02618603|Drug|Botulinum toxin A|
1547137|NCT02618603|Drug|Triamcinolone Acetonide|
1547140|NCT02618564|Drug|Sennosides|Each group will be assigned different doses of sennosides and varying times of administration
1547141|NCT02618551|Procedure|Bronchial thermoplasty for treatment of severe asthma|"Three sessions of bronchial thermoplasty are needed to treat patients. There will be 3 to 4 weeks between each procedure.
Bronchial thermoplasty procedure is performed under general anesthesia. The medical device used in this research to achieve the thermoplasty is the Alair system (class IIb medical device ; Boston scientific)
A confocal endomicroscopy will be conducted at the first and final session of thermoplasty. This examination involves analyzing and recording the structure of bronchi microscopy through a small catheter placed on the bronchus. Photographs of the bronchi will be realized."
1547142|NCT02618525|Other|Supraorbital pressure|Supraorbital pressure is applied by applying pressure over the notch on the inner aspect of eyebrow.
1547143|NCT02618525|Other|Jaw thrust maneuver|Jaw thrust is performed by placing the index and middle fingers to physically pull the posterior aspects of the mandible upwards while their thumbs push down on the chin to open the mouth.
1547145|NCT02618499|Drug|Timing of administration of post partum Oxytocin|10 IU of oxytocin given IV at different times after birth
1547146|NCT02618486|Procedure|Non surgical periodontal therapy|NSPT includes oral hygiene education, scaling root planing and mouth wash
1547147|NCT02618473|Other|non-seloken|regarding the guidelines patients receive seloken before the cardiac CT scan to lower the heart rate during the scan. The intervention in this study is to avoid the medication with seloken before the scan, and to investigate if the use of a new motion correction scan algorithm can compensate for the absence of the seloken.
1547148|NCT02618460|Device|Non contrast-enhanced magnetic resonance imaging|
1547149|NCT02618447|Device|4Dimensional Phase Contrast Magnetic Resonance Angiography|4D PC MRA is a new non-contrast MRA technique that can measure flow of blood within vessels of interest over time.
1547150|NCT02618447|Procedure|Portal vein embolization|
1547151|NCT02618434|Drug|SPN-810|
1547152|NCT02618434|Drug|Placebo|
1547153|NCT02618408|Drug|SPN-810|
1547154|NCT02618408|Drug|Placebo|
1547155|NCT02618395|Drug|SPARC001A|
1547156|NCT02618395|Drug|SPARC001B|
1547157|NCT02618395|Drug|Reference001 - Hydrocodone|Hydrocodone-acetaminophen
1547158|NCT02618382|Drug|Tranexamic Acid|1300mg tranexamic acid by mouth once before surgery and then three times a day for up to three days or until they are discharged from the hospital, whichever comes first
1547159|NCT02618369|Device|MR-Guided High Intensity Focused Ultrasound|Target treatment of bone lesion using High Intensity Focused Ultrasound
1547160|NCT02618356|Drug|Raltitrexed and S-1|"Raltitrexed 3mg/m2 intravenously guttae, d1 and S-1,bid,po,d1-d14,every three weeks for a cycle.
BSA (body surface area) S-1 dosage <1.25 m2 80 mg/d
1.25m2 — <1.5 m2 100 mg/d
1.5 m2 120 mg/d"
1547161|NCT02618343|Drug|IPA|IPA Aromatherapy for the experimental arm
1547162|NCT02618343|Drug|Ondansetron|Zofran will be administered to the Control arm. This is the drug historically administered by prehospital personnel.
1552283|NCT02582073|Biological|Grass MATA MPL (1.0ml) 10200SU|
1547164|NCT02618317|Drug|Heparin Lock Solution|Just after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
1547165|NCT02618317|Drug|Trissodium Citrate 30%|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
1547166|NCT02618317|Drug|Minocycline-EDTA 30 mg/ml - 3 mg/ml|ust after the insertion (since first the hemodialysis session), long-term Central Venous Catheter of CKD 5D patients on high-efficiency hemodialysis have been locked during 15 weeks (100 days) with appropriate lock solution.
1547167|NCT02618304|Drug|Treatment of Meibomian gland dysfunction|artificial tears, 3% Diquafosol Tetrasodium eye drops, steroid eye drops, squeezing of meibomian glands, cleansing of eyelids.
1547168|NCT02618291|Other|Active Geriatric Evaluation (AGE tool)|Yearly administration of the brief assessment tool (BAT). Once the presence of one or more geriatric syndromes is suspected using the brief assessment tool, a management strategy is proposed. It is divided in two distinct steps: 1) perform additional tests to confirm or exclude the diagnosis and 2) to propose specific management attitudes. All proposed attitudes are based on literature review and geriatrician expertise. The FP remains free to follow the proposed attitudes.
1547169|NCT02618291|Other|Usual care|"No specific intervention will be provided to the patients, except what family practitioners (FPs) usually do. In this regard, it is possible that some FPs might use structured interventions similar to the AGE tool. This will be neither encouraged nor discouraged. FPs in the usual care arm will be asked to perform one BAT after 2 years of follow-up, at the final patient visit."
1547170|NCT02618278|Other|Physiotherapy|The aims of physiotherapy are to promote physical and psychological health for the patient, and in doing so promote and improve function. In light of the evidence to suggest spontaneous resorption of the disc fragment occurs, physiotherapy provides support and guidance for the patient to manage their symptoms whilst resorption takes place. The physiotherapy regimen will be tailored to the individuals' requirements. It will be goal orientated, and assessed using a biopsychosocial approach based on 7 different elements; neurological dysfunction, motor control of movement of the lumbar spine and pelvis, movement restriction in the lumbar spine and pelvis, psychological barriers to recovery, advice and education, functional-based exercise and pain.
1547171|NCT02618265|Procedure|Mobile terminal|multiple strategy including mobile terminal based compliance managment, platelet reactivity modified drug adjustment
1547172|NCT02618265|Procedure|traditional management|aspirin or clopidogrel monotherapy or double treatment for
1547173|NCT02618265|Procedure|website platform management|second prevention based on website platform management
1547174|NCT02618252|Device|Zonare|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
1547175|NCT02618252|Device|Veinviewer|Patients with difficulty IV access are randomized to receive either intervention with ultrasound machine (Zonare ZS3 machine) or the Veinviewer Flex machine.
1547176|NCT02618239|Dietary Supplement|Bimuno Galacto-oligo-saccharide|
1547177|NCT02618226|Device|Optic nerve ultrasound|Measurement of ONSD with concomitant invasive ICP measurement will be performed at enrollment and at least daily for a total of 7 days. Additional measurements of ONSD may be performed at any time following any decline in Glasgow Coma Scale (GCS) score by 2+ points during the 7 day period.
1547178|NCT02618213|Device|Optiflow Junior|Humified air are dispensed through the system. Airflow, FiO2 (Fraction of inspired oxygen) , SpO2 (peripheral capillary Oxygen saturation) and respiratory rate are noted each hour. Progression of condition might lead to change of system og mechanical ventilation. poor tolerance might lead to change of system
1547179|NCT02618213|Device|Continous Positive Airway Pressure|Humified air are dispensed throug the system. Airflow, FiO2, SpO2 and respiratory rate are noted each hour. Progression of condition might lead to change of system or mechanical ventilation. Poor tolerance might lead to change of system.
1547180|NCT02618200|Device|3D prostate ultrasound|
1547181|NCT02618187|Drug|Eubacterial Spores, Purified Suspension, Encapsulated|
1547182|NCT02618187|Drug|Placebo|
1547183|NCT02618187|Drug|Placebo Pre-Treat|
1547184|NCT02618187|Drug|Vancomycin Pre-Treat|
1547185|NCT02618174|Behavioral|Neutral Control Condition|Message about age of University of Birmingham
1547186|NCT02618174|Behavioral|Food-based Control Condition|Message about variety of vegetables in the world
1547187|NCT02618174|Behavioral|Health Condition|Message about the health benefits of eating vegetables
1547188|NCT02618174|Behavioral|Descriptive Social Norm|Message suggesting most people eat plenty of vegetables
1547189|NCT02618174|Behavioral|Liking Social Norm|Message suggesting most people like eating vegetables
1547190|NCT02618161|Radiation|HDR Brachytherapy|HDR Brachytherapy, a single dose of 15 Gy delivered to prostate
1547191|NCT02618161|Radiation|External beam Radiotherapy|External beam Radiotherapy, a dose of 46 Gy in 23 fractions delivered to prostate
1547192|NCT02618148|Drug|ESTROGEN HERBALS 21|"Applies to the following strengths:
17β-estradiol 1.5mg/24 hours x 21 days, stop drinking for 7 days. Progesterone 5 mg/24 hours x 10 days, stop drinking for 7 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
1547193|NCT02618148|Drug|ESTROGEN HERBALS 28|"Applies to the following strengths:
17β-estradiol 1.5mg/24 hours x 28 days. Garlic oil 30mg/24 hours x 28 days. Enzyme nattokinase 300 FU x 24 hours x 28 days."
1547194|NCT02618135|Other|Intervention Group|Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology.
1547231|NCT02617771|Drug|Vitamin D3|from October to March, a Vitamin D oral supplementation (400 UI/die up to 12 month or 600 UI/die beyond 1 year
1547232|NCT02617758|Drug|Fentanyl|Participants will receive single application of DURAGESIC fentanyl transdermal system 100 µg/h dose in one of the treatment periods.
1547195|NCT02618135|Other|Control Group|"Participants will wait for 8 weeks before training intervention begins.
Each participant will first need to master a simple concentration task before moving on to play a series of training tasks. An eye gaze tracker connected to the computer will detect the location of eye gaze on the computer screen. The game progresses according to how well the participant can focus their eye gaze on correct objects and sustain their attention. Each task employs the BCI system, and is controlled by the child's concentration. As the child attends to activities on a computer screen, their EEG waves will be recorded simultaneously via the EEG sensors through Bluetooth technology."
1547196|NCT02618109|Biological|Collection of blood samples|Collection of blood samples
1547200|NCT02618083|Device|color Doppler ultrasound|pre-operative blood flow velocity measurement with a color Doppler ultrasound device
1547201|NCT02618070|Other|Yogurt|
1547202|NCT02618057|Drug|Prednisolone|PO prednisolone, 1 mg/kg/day, for 5 days
1547203|NCT02618057|Drug|Levofloxacin|Levofloxacin, 10mg/kg/day, IV, for 5days
1547204|NCT02618031|Procedure|Endovascular Treatment (EVT)|EVT is an endovascular procedure in which a catheter is inserted into an artery and directed to the site of the blocked blood vessel in the brain. The clot is removed using a mechanical device with or without an injection of tPA directly at the site of the clot.
1547205|NCT02618018|Procedure|AT TORBI 709M|Cataract surgery with AT TORBI 709M 4-haptic toric IOL
1547206|NCT02618005|Dietary Supplement|Probiotic capsule|Continuously take five capsules containing freeze-dried LcS on ISS for four weeks, from four weeks before the return (R-4W) to one day before the return (R-1d)
1547207|NCT02617979|Other|SAFECARE at Home customized lessons|
1547208|NCT02617953|Device|Active rTMS(A)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.
auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
1547209|NCT02617953|Device|Active rTMS(B)|"repetitive transcranial magnetic stimulation:1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex , each consisting of 4 days of rTMS treatment.
auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
1547210|NCT02617953|Device|Sham condition(C)|"The sham stimulation looks and sounds like the active coil, but diverts the magnetic field away from the patient.
auditory ERP,continuous resting EEG and MRI are measured pre-treatment rTMS and auditory ERP,continuous resting EEG are measured two weeks after rTMS treatment. Tinnitus subjects were asked to perform an interval duration paried pulse task before and after the rTMS train."
1547211|NCT02617940|Other|fissure sealant|"Surfaces allocated to this group will be treated with resin-based sealant (FluroShield®, Dentsply, United States of America) according to the manufacturer's instructions.
Initially, local anesthesia and rubber dam adaptation will be performed. Then, 37% phosphoric acid will be applied on the surface for 30 seconds, followed by spray of water/air for at least 15 seconds. The sealant will be dispensed on the occlusal surface and light cured for 20 seconds (Optilight Max, Gnatus, Brazil)."
1547212|NCT02617940|Other|oral hygiene orientation|Surfaces allocated to this group will be treated with sterile water application, as a placebo, without anesthesia and rubber dam. The active treatment in this group will be only oral hygiene orientations.
1547213|NCT02617914|Procedure|individualized PEEP treatment, Invasive mechanical ventilation, ECMO,|
1547215|NCT02617888|Radiation|CCTA ~ BREAST SHIELDS|Breast shield placement (randomized) among women.
1547216|NCT02617875|Other|conventional EMS physician|A physically present conventional EMS physician on scene, will treat the patients according to the standard operating procedures.
1547217|NCT02617875|Other|tele-EMS physician|The patients will be treated by the paramedics, which are concurrently instructed by the tele-EMS physicians of the tele consultation center according to the software-based guideline conform algorithms for diagnosis and treatment.
1547218|NCT02617862|Procedure|Examination under anaesthetic (EUA)|The EUA is scheduled as part of the routine clinical management of children with various ophthalmic conditions.
1547219|NCT02617862|Device|RetCam|The RetCam is a pediatric wide-field retinal camera that has been the mainstay for pediatric ophthalmic imaging since 1997. Imaging using the RetCam (during the EUA) is conducted as part of routine clinical magagement.
1547220|NCT02617862|Device|COSMOS|The COSMOS images will be captured (during the EUA) after the RetCam images. The COSMOS is designed to be used in the same way as the RetCam, but to produce higher quality images.
1547221|NCT02617849|Drug|Pembrolizumab|200 mg IV every 3 weeks
1547222|NCT02617849|Drug|Carboplatin|AUC=6, every 3 weeks x 4
1547223|NCT02617849|Drug|Paclitaxel|175 mg/m2, every 3 weeks x 4
1547224|NCT02617823|Procedure|lateral position|patients placed on their left side after epidural catheter insertion
1547225|NCT02617810|Drug|JNJ-42847922|Participants will receive JNJ-42847922 20 milligram (mg) tablet orally once daily from Day 1 to Day 9.
1547226|NCT02617810|Drug|Midazolam|Participants will receive midazolam 4 milligram (mg) syrup orally once on Day 1 during treatment A and on Day 7 during treatment B.
1547227|NCT02617810|Drug|Warfarin|Participants will receive warfarin 25 milligram (mg) tablet orally once on Day 3 during treatment A and on Day 9 during treatment B.
1547228|NCT02617797|Device|Radiofrequecy|The radiofrequency is a noninvasive technique that will be applied to the external urethral meatus region.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes.It will use a digital thermometer with infrared to mention the temperature should reach 39 ° C and maintain this temperature for 2 minutes
1547233|NCT02617758|Drug|Fentanyl|Participants will receive single application of Fentanyl transdermal system (JNJ-35685-AAA-G021) 100 microgram per hour (µg/h) dose in one of the treatment periods.
1547234|NCT02617745|Other|Platelet level determination|evaluate the predictive value of a biological test performed in the radio-chemotherapy phase in patients suffering from glioblastoma. For this the platelet level will be determined each wek during the radiotherapy phase and each cycle during the chemotherapy phase
1547235|NCT02617732|Drug|Tianqi capsule|"The patients with type 2 diabetes are divided into two groups, one is experimental group, and the other is placebo group.
The experimental group patients are treated with Tianqi capsule by oral, 5 pills three times a day"
1547236|NCT02617732|Drug|placebo|"The patients with type 2 diabetes are divided into two groups, one is experimental group, the other is placebo group.
The placebo group patients are treated with placebo by oral, 5 pills three times a day"
1547237|NCT02617706|Device|Epiflo|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
1547238|NCT02617693|Dietary Supplement|No treatment given|Evaluation of lifestyle intervention combining behavioural change councelling and utilisation of E-health platform
1547239|NCT02617680|Drug|desflurane - oxygen in air|The manufacturer recommended age-corrected end-tidal concentrations of desflurane in air should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
1547240|NCT02617680|Drug|desflurane - oxygen in nitric oxide|The manufacturer recommended age-corrected end-tidal concentrations of desflurane with nitric oxide - oxygen should be set and achieved initially. Individual EEtC of desflurane will be defined according to entropy parameters and maintained in the targeted range of static and response entropy 40-50
1547241|NCT02617667|Drug|Cyclosporine A|topical ocular, eye drops
1547242|NCT02617667|Drug|Placebo|topical ocular, eye drops
1547245|NCT02617641|Behavioral|TAVIEenM@RCHE|The intervention goal is to increase up to 150 minutes per week of moderate-intensity physical activity through walking. The intervention is underpinned by Strengths-Based Nursing Care that specifies nursing values, and by Self-Determination Theory that specifies variables to tailor the intervention. The four intervention strategies are: 1) Providing information and feedback, 2) Exploring reasons to build motivation, 3) Exploring strengths to build confidence (self-efficacy), and 4) Developing an action plan to maintain motivation and confidence (self-efficacy). The TAVIE system platform is designed to provide a fully automated, easy to navigate website, and the main mode of delivery is video clips of a 'virtual nurse' who presents the tailored intervention content.
1547246|NCT02617641|Behavioral|Publicly available websites|"Le Programme de marche (Institut de Cardiologie de Montréal)
L'activité physique (Institut de Cardiologie de Montréal)
L'activité physique (Fondation des maladies du cœur et de l'AVC)
Directives canadiennes en matiére d'activité physique à l'intention des adultes âgés de 65 ans et plus (Société Canadienne de Physiologie de l'exercice)
Directives canadiennes en matière d'activité physique à l'intention des personnes âgées de 65 et plus (ParticipACTION)"
1547247|NCT02617628|Drug|extended release naltrexone|Extended Release Naltrexone is currently marketed in the US for use in adults with alcohol dependence. It will be administered in this study at the currently marketed dose of 380 mgs. Subjects will be randomized to receive one injection of 380 mg of extended release naltrexone, at baseline, before they leave the prison, or either 380 mg of extended release naltrexone after they are released from prison. Both groups will receive three additional monthly doses of 380 mgs while enrolled in intensive outpatient treatment for six months. Subjects will also receive weekly psychosocial counseling.
1547248|NCT02617615|Drug|MB-110|MB-110 is a novel, potent, and selective HCV inhibitor against the NS5A protein. In the preclinical studies, MB-110 demonstrated picomolar EC50s towards various genotypes and favorable pharmacokinetic properties to support the once daily dosing regimen.
1547249|NCT02617615|Drug|Placebo|It will be identical in appearance and similar in weight to the MB-110 hard-gel capsule.
1547250|NCT02617602|Procedure|Goal directed therapy|"Based on transpulmonary thermodilution data, the following interventions will be implemented:
Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;
cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:
decreased heart rate (HR): dobutamine, dopamine;
normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine."
1547251|NCT02617602|Other|Control|
1547256|NCT02617550|Drug|Vericiguat (BAY1021189)|Vericiguat up-titration from 2.5 mg to 10 mg in an interval of 14 +/- 3 days: 2.5 mg vericiguat for 14 +/-3 days given as 2 x 1.25 mg tablets followed by 5 mg vericiguat for 14 +/-3 days given as 1 x 5 mg tablet followed by 10 mg vericiguat for 14 +/-3 days given as 2 x 5 mg tablets
1547257|NCT02617550|Drug|Placebo|Placebo for 14 +/-3 days given as 1 or 2 tablets [o.d.].
1547258|NCT02617550|Drug|Nitroglycerin|0.4 mg nitroglycerin spray administered at 2.5 hours before treatment (vericiguat [trough] or placebo) on day 12, day 26 and day 40 at 4 hours after treatment (vericiguat [peak] or placebo) on day 13, day 27 and day 41
1547259|NCT02617537|Drug|EE20/DRSP(YAZ,BAY86-5300)|0.02 mg EE (β-CDC)/3 mg DRSP for 24 days and placebo tablets for 4 days per 28-day intake cycle
1547260|NCT02617537|Drug|Placebo|Matching placebo tablets for 28 days per 28-day intake cycle
1547261|NCT02617524|Device|Valve Medical Dedicated Sheath version 00|The Valve Medical Dedicated Sheath is intended to be used as an introducer sheath during BAV procedures
1547262|NCT02617511|Dietary Supplement|Omega-3 Supplementation|
1547263|NCT02617511|Dietary Supplement|Placebo|
1547264|NCT02617498|Device|harmonic scalpel|parenchymal liver transection was performed either by harmonic scalpel after demarcation of line of transection by intraoperative US and doppler.
1547265|NCT02617498|Device|spray mode diathermy|parenchymal liver transection was performed either by spray mode diathermy after demarcation of line of transection by intraoperative US and doppler.
1547266|NCT02617485|Drug|Rituximab|375 mg/m2 IV on day 1 of each 21 days chemotherapy cycle. Number of Cycles: 8.
1547267|NCT02617485|Drug|Doxorubicin|50 mg of doxorubicin per square meter administrated IV on day 1 of each chemotherapy cycle
1547268|NCT02617485|Drug|Vincristine|1.4 mg of vincristine per square meter, up to a maximal dose of 2 mg, administrated IV on day 1 of each chemotherapy cycle
1547269|NCT02617485|Drug|Cyclophosphamide|750 mg of cyclophosphamide per square meter of body-surface area administrated IV on day 1 of each chemotherapy cycle
1547270|NCT02617485|Drug|prednisone|100 mg of prednisone administrated PO per day for five days, day 1-5 of each chemotherapy cycle
1547271|NCT02617472|Device|Pelvic floor exerciser|Daily exercise using the study device
1547272|NCT02617459|Drug|Levobetaxolol eye drops|one drop per time; twice daily
1547273|NCT02617459|Drug|Betaxolol eye drops|one drop per time; twice daily
1547274|NCT02617446|Drug|placebo|
1547275|NCT02617446|Drug|Istaroxime|
1547276|NCT02617433|Device|Inbody|Participant measure muscle mass by bioelectrical impedance analysis (Inbody 720, Seoul, Korea) after fast for eight hours. After measurement, patient is induced anesthesia. Rocuronium dose is 12mg for male, and 9mg for female.
1547277|NCT02617420|Device|Propeller Health Monitoring Device|
1547278|NCT02617407|Other|Livionex®|Dental Plaque, Gingivitis and Oral Microbiome Control
1547279|NCT02617407|Other|PreviDent® 5000 plus|Dental Plaque, Gingivitis and Oral Microbiome Control
1547280|NCT02617394|Other|Diaphragm scanning - traditional method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows. The second (post-block) diaphragm scan will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration.
1547281|NCT02617394|Other|Diaphragm scanning - novel method first|The first (pre-block) diaphragm scan with ultrasound will be done on both sides using a novel method in which lung sliding is used as a guide to identify the diaphragm and quantify diaphragm thickening upon respiration. The second (post-block) diaphragm scan will be done will be done on both sides using the liver (right side) and spleen (left side) as acoustic windows.
1547282|NCT02617381|Other|questionnaire|assessing the sensitivity and specificity of a simple structured questionnaire
1547283|NCT02617355|Device|Prototype surgical magnetic drape|New prototype surgical magnetic drape made with bottom-isolated ferrite magnets applied to the patient's thorax
1547284|NCT02617355|Device|Green Covidien Magnetic Drape|Green Covidien Magnetic Drape applied to the patient's thorax
1547285|NCT02617355|Device|Jac-Cell Medic Reusable Magnetic Pad|Jaa-Cell Medic Reusable Magnetic Pad applied to the patient's thorax
1547286|NCT02617355|Device|"DeRoyal Magnetic Pad size 20 x 16"|"Magnetic Instrument Pad #25-002, size 20 x 16, DeRoyal Industries Inc applied to the patient's thorax"
1547287|NCT02617355|Device|"DeRoyal Magnetic Pad size 10 x 16"|"Magnetic Instrument Pad #25-001, size 10 x 16, DeRoyal Industries Inc applied to the patient's thorax"
1547288|NCT02617342|Behavioral|Robot-mediated Intervention|The intervention follows the curriculum developed by RoboKind to target and improve upon social interactions through core vocabulary and modeling.
1547289|NCT02617329|Other|Extracorporeal shock wave therapy (ESWT)|The Extracorporeal shock wave therapy (ESWT) was applied on upper trapezius and levator scapulae following parameters 1.5 bar, per intervention 2000 impulse, once a week for three weeks for the experimental group
1547290|NCT02617329|Other|cervical flexion|Education have 8 movement home program for flexion, extension, side bending, rotation in neutral position, and rotation in a position of full cervical flexion.
1547291|NCT02617316|Other|Barefoot|barefoot running test was 20 minutes.
1547292|NCT02617316|Other|In shoes|In shoes test was 20 minutes.
1547293|NCT02617303|Procedure|OTAGO's exercises|The intervention is based on OTAGO's program, consisting of a set of aerobic exercises affecting gait, balance, stability and are adapted for older people to support them both in groups and individually. The program lasts 3 months and is followed by a loyalty phase to consolidate the exercise program. Falls and fractures will be monitored quarterly for 15 months.
1547294|NCT02617303|Procedure|COMMON PRACTICE|Normal medical treatment will be provided by family physicians and nurses.
1547295|NCT02617290|Drug|Ticagrelor|Ticagrelor Loading dose of 180mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 90mg bid.
1547296|NCT02617290|Drug|Clopidogrel|Clopidogrel Loading dose of 300 or 600mg given after angiography and before PCI , followed by a 30 days treatment with the maintenance dose of 75mg per day.
1547299|NCT02617264|Procedure|SPOT|Injecting the ink (SPOT) to the axillary lymph node prior the surgery. During the surgery the lymph nodes will be tasted to diagnose the marked node.
1547300|NCT02617251|Other|No intervention|
1547301|NCT02617238|Other|Cardiovascular risk management based on PWV|"Arterial stiffness will be measured through the determination of the carotid-femoral pulse wave velocity (PWV).
In the PWV group, PWV will be measured at baseline, and then every 6 months. PWV measurement will guide the intensification of treatment. Measurements will be immediately available to the physician in charge of the patient, in order to adapt treatment. The therapeutic strategy is based both on the normalisation of BP and then on the BP-independent reduction in PWV, using commercially available antihypertensive medications.
In the conventional group, PWV will be measured at baseline, after 2 years, and at the end of the study. PWV values will be masked to the physician"
1547375|NCT02616692|Drug|Hepatocellular Cancer (HCC) treatments including oral anti-cancer therapy [Nexavar (Sorafenib, BAY43-9006)]|Oral anti-cancer therapy (Sorafenib, an multiple kinase inhibitor), repeated transarterial chemoembolization (TACE) procedures, and hepatic arterial infusion chemotherapy (HAIC)
1547480|NCT02615951|Other|blood sampling|Blood sample retrieval for biological and genetic analysis and comparison
1547302|NCT02617225|Behavioral|DHaAL Intervention|"This group handwashing program is for rural elementary schools to institutionalize the practice of handwashing before mid-day meal consumption and after use of toilets by harnessing the theory of social peer pressure.
DHaAL intervention consists of: (1) capacity building of school teachers to implement group handwashing; (2) installing group handwashing station; (3) generating demand among students to wash hands in group; and (4) establishing systems to sustain handwashing infrastructure and behaviors."
1547303|NCT02617225|Behavioral|DHaAL + CFSS Intervention|In addition to support under DHaAL, several intervention schools receive a more holistic and participatory support that focuses on health, safety, nutrition status, and psychological wellbeing of the children, and thus can also influence handwashing practices (and other WASH facilities). CFSS provides capacity building support and establishes systems to improve school environment, learning outcome, teachers capacity, and physical education for children.
1547304|NCT02617212|Procedure|Implant surgery|The volunteers will receive one or two dental implant(s) placed by a surgical procedure, under local anesthesia and careful soft and hard tissue handling. After implant insertion, the volunteers will be randomly assigned to one arm.
1547305|NCT02617212|Device|Three abutment dis-/reconnections.|At the active comparator arm, each implant will receive a titanium healing abutment during the surgery, according to manufacturer's recommendations. Three dis-/reconnections of abutments will be performed after the soft tissue healing period: the first, after 8 weeks, for adjustment of the emergence profile by healing abutment changing; the second, 10 weeks after surgery, for intra-oral prosthetic abutment selection; and the third, 12 weeks after surgery, for the prosthetic abutment definitive connection with the manufacturer recommended torque.
1547306|NCT02617212|Device|No abutment dis-/reconnections.|Each experimental arm implant will receive its definitive prosthetic abutment at the surgical procedure. The manufacturer recommended torque will be applied so that no disconnection of the abutment will occur during and after completion of the treatment. The abutment will receive healing caps, which shall remain in position until the end of 12 weeks after surgery.
1547307|NCT02617199|Drug|Epidural anesthesia|Epidural anesthesia placed at L1-L2 Epidural infusion of ropivacaine 0.2% + 3-4 mcg/ml fentanyl + saline 0.9% (100 ML) 3-5ml/ hr during 120 hours
1547308|NCT02617199|Drug|intravenous analgesia|ketorolac 1mg/kg every 8 hours or metamizol 15 mg/kg every 8 hrs and intravenous opioids (buprenorphine 3 mcg / kg or tramadol 1mg/ kg in continuos infusion
1547309|NCT02617186|Procedure|Video-assisted thoracoscopic surgery|patients randomized to this arm will receive video-assisted thoracic surgery (VATS)
1547310|NCT02617186|Procedure|Robotic thoracic surgery|patients randomized to this arm will receive robotic thoracic surgery (RTS) with the da Vinci Robot
1547311|NCT02617173|Device|Micro 400 Matrix Therapy Products|Positive electrical current with a low amplitude bellow sensation level situated on the scrotum.
1547312|NCT02617160|Device|MD-Logic Pump Advisor|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
1547313|NCT02617160|Other|Control Group|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team in accordance to the regular practice
1547314|NCT02617134|Biological|anti-MUC1 CAR-T cells|
1547315|NCT02617121|Drug|Gabapentin|oral gabapentin 300 mg 1 hour before induction of anesthesia
1547316|NCT02617121|Drug|Ramosetron|ramosetron 0.3 mg iv at end of surgery
1547317|NCT02617121|Drug|Gabapentin and Ramosetron|oral gabapentin 300 mg 1 hour before induction of anesthesia and ramosetron 0.3 mg iv at end of surgery
1547318|NCT02617108|Device|Foley balloon|a Foley balloon with 4 ml of normal saline solution will be placed into the uterine cavity at the end of the operation for five days.
1547319|NCT02617095|Device|T2762|One drop in each eye 3 to 6 times daily
1547320|NCT02617095|Device|Optive|One drop in each eye 3 to 6 times daily
1547321|NCT02617082|Radiation|partial breast irradiation|The prescription dose is 40.5Gy in 15 fractions in 3 weeks.
1547322|NCT02617069|Biological|botulinum toxin injection|
1547323|NCT02617069|Biological|0.9% normal saline injection|
1547324|NCT02617069|Device|Implantable loop recorder|
1547325|NCT02617043|Radiation|hypofractionated whole breast irradiation with simultaneously integrated boost|deliver 40Gy/15Fx to whole breast with 48Gy/15fx simultaneously integrated to tumor bed
1547326|NCT02617017|Drug|Buspirone|Capsules of buspirone will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
1547327|NCT02617017|Drug|Placebo|Capsules of placebo will be administered orally once a day for 2 weeks (10mg, morning), BID for 2 further weeks (20 mg, morning and evening), TID between weeks 5 and 12 (third intake at noon)
1547328|NCT02616991|Procedure|computed tomography venography|systematically performing computed tomography venography in addition to thoracic computed tomography angiography
1547329|NCT02616965|Drug|Romidepsin|Romidepsin at the dosage 10mg/m2 or 14mg/m2 will be given ONCE 14 days prior to cycle one and then on days 1,8,15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
1547330|NCT02616965|Drug|Brentuximab vedotin|Brentuximab vedotin at the dosage 0.9mg/kg or 1.2 mg/kg will be given on days 1 and 15 in each cycle. Each cycle is 28 days and treatment will continue up to 16 cycles
1547331|NCT02616952|Dietary Supplement|Chinese herbal therapy|Participants take a Chinese herbal decoction, Yiqi Suoquan Tang, 200ml orally twice a day for 12 weeks. The Yiqi Suoquan Tang are composed of Radix Astragali 30 g, Radix Codonopsis pilosula 10g, Radix Angelica sinensis 10g, Radix Atractylodis Macrocephalae 10g, Fructus Alpiniae Oxyphyllae 10g, Radix Lindera aggregata 6g, Rhizoma Dioscoreae 10g, pericarpium citri reticulatae 10g, Rhizoma Cimicifuga 10g, Radix Bupleuri 10g, Fructus Rubi 15g, and Semen raphani 10g. All the decoctions are provided by the Department of Pharmacy, Guang'anmen Hospital, China Academy of Chinese Medical Sciences, and are packed in opaque plastic bags with 200 ml for each one.
1547481|NCT02615938|Drug|Hydroxychloroquine sulfate|Apply drug to modify lysosomal pH
1547482|NCT02615938|Other|Placebo|Apply Placebo not to modify lysosomal pH
1547332|NCT02616952|Behavioral|Pelvic floor muscle training|In intensive exercises, participants are taught how to identify the muscles: 1) identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; 2) identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; 3) contract levator ani with a position of sitting, lying, and standing; 4) contract anal sphincter with a position of sitting, lying, and standing. Once the participants can identify the muscles, they are asked to do a set consists of 10 contractions, each lasting 5 seconds, with a 5 seconds break between contractions. Then they need to do same procedure 3 times daily as the home exercises.
1547333|NCT02616939|Other|Cardiac CT scanning (with the SpotLight CT)|Cardiac CT scanning
1547334|NCT02616926|Procedure|Hepatic resection|Anatomical surgical resection of the liver including the tumor. Make sure the resection margin is negative during the process.
1547335|NCT02616926|Procedure|TACE|TACE will be performed according to the standard procedure of TACE and will be repeated every four months if needed
1547336|NCT02616926|Procedure|RFA|RFA will be performed 1 week after TACE.
1547337|NCT02616913|Other|R,R-monatin|Each subject consumes test article R,R-monatin (150 mg) in one of 3 treatment periods
1547338|NCT02616913|Other|Moxifloxacin|Each subject consumes moxifloxacin (400 mg; positive control) in one of 3 treatment periods
1547339|NCT02616913|Other|Placebo|Each subject consumes placebo in one of 3 treatment periods
1547340|NCT02616900|Device|eSight Eyewear|primary intervention
1547341|NCT02616887|Radiation|Single dose SBRT and VMAT technique|One fraction of 18 Gy delivered in one day with VMAT and Flattening filter-free (FFF) beams.
1547342|NCT02616874|Drug|MVA.HIVconsv vaccine|Dose: 2x10e8 pfu, Interval: weeks 0 and 9.
1547343|NCT02616874|Drug|Romidepsin|Dose: 5mg/m2 over 4hours, Interval: weeks 3, 4 and 5
1547344|NCT02616861|Drug|IW-1973|IW-1973 Tablet
1547345|NCT02616861|Drug|Matching Placebo Tablet|Matching placebo tablet
1547346|NCT02616848|Drug|Everolimus|
1547347|NCT02616848|Drug|Eribulin|
1547348|NCT02616835|Device|theta-burst TMS|This protocol involves short periods of pulse delivery in combination with long periods of silent intervals.
1547349|NCT02616835|Device|sham theta-burst TMS|This protocol delivers theta-burst pulses from a sham device (i.e. at same speed and timeframe but without the magnetic output)
1547350|NCT02616822|Dietary Supplement|Trans-resveratrol|Used for trans-resveratrol substance 300 mg single dose
1547351|NCT02616822|Other|Placebo|Used for placebo substance single dose
1547352|NCT02616809|Other|Maintaining posture and energy expenditure|Participants will sit continuously for 8-hrs during a simulated office environment
1547353|NCT02616809|Other|Increasing energy expenditure|Participants will cycle slowly while seated in prescribed hourly intervals. This condition will increase energy expenditure while keeping a sitting posture
1547354|NCT02616809|Other|Changing posture|Participants will transition from sitting to standing in prescribed hourly intervals. This condition will change posture (sit to stand) while maintaining low energy expenditure
1547355|NCT02616809|Other|Increasing energy expenditure and changing posture|Participants will transition from sitting to a walking workstation in prescribed hourly intervals. This condition will both increase energy expenditure and change posture.
1547356|NCT02616796|Behavioral|Social gaze training|Appropriate social gaze behavior will be shaped using the principles of Applied Behavior Analysis.
1547357|NCT02616783|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily
1547358|NCT02616783|Drug|TDF|TDF 300 mg tablet administered orally once daily
1547359|NCT02616783|Drug|FTC|FTC 200 mg capsule administered orally once daily
1547360|NCT02616783|Drug|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
1547361|NCT02616783|Drug|3TC|3TC tablet administered orally
1547362|NCT02616783|Drug|Third agent|"Third agent may include one of the following regimens: lopinavir+ritonavir (LPV/r; Kaletra®), atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®), ATV + cobicistat (COBI;Tybost®) (or ATV/COBI FDC), DRV + RTV, darunavir (DRV; Prezista®) + COBI (or DRV/COBI FDC), fosamprenavir (FPV; Lexiva®) + RTV , saquinavir (SQV; Invirase®; Fortovase®) + RTV, efavirenz (EFV;Sustiva®), rilpivirine (RPV;Edurant®), nevirapine (NVP;Viramune®), etravirine (ETR;Intelence®), raltegravir (RAL; Isentress®), elvitegravir (EVG) + COBI, or dolutegravir (DTG;Tivicay®)
Drug classes:
Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV, and SQV
Pharmacokinetic enhancer: COBI
Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR
Integrase inhibitors: RAL and DTG"
1547363|NCT02616770|Drug|S1226 (4%)|3 ml Peflubron nebulized, with Medical Gas containing 4% carbon Dioxide, for 2 minutes as a single dose.
1547364|NCT02616770|Drug|Saline (for 4%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
1547365|NCT02616770|Drug|S1226(8%)|3 ml Peflubron nebulized, with Medical Gas containing 8% carbon Dioxide for, 2 minutes as a single dose.
1547366|NCT02616770|Drug|Saline (for 8%)|3ml saline nebulized, with Medical Air, for 2 minutes as a single dose
1547367|NCT02616770|Drug|S1226(12%)|3 ml Peflubron nebulized, with Medical Gas containing 12% carbon Dioxide, for 2 minutes as a single dose.
1547368|NCT02616770|Drug|Saline (for 12%)|3ml saline nebulized with Medical Air for 2 minutes as a single dose
1547369|NCT02616757|Device|Sunlight Omnisense Quantitative Ultrasound|Ultrasound
1547370|NCT02616744|Drug|Ibandronic acid|150 mg per month oral ibandronate
1547371|NCT02616744|Drug|Placebo|1 oral capsule of placebo per month
1547372|NCT02616731|Drug|Tranexamic Acid|use tranexamic acid oral tablets 500 mg two tablets every six hour with the onset of the first day of menstrual cycle till the end of bleeding then The amount of menstrual flow will be calculated by the PBAC
1547373|NCT02616731|Drug|Diosmin|use diosmin oral tablets 500 mg t.d.s (three times daily) with the onset of the first day of menstrual cycle till the end of bleeding.then The amount of menstrual flow will be calculated by the PBAC
1547374|NCT02616718|Radiation|Repeated computed tomography scan of abdomen|Repeated computed tomography scan of abdomen within two weeks prior to surgery or 28-32 weeks after initial scan
1547423|NCT02616328|Other|No intervention|No intervention administered in this study
1547424|NCT02616315|Drug|Naltrexone HCl/Bupropion HCl Placebo|Naltrexone/bupropion placebo-matching tablets
1547378|NCT02616653|Procedure|L3-L4 location: Palpation method confirmed by US|An anesthesiologist will locate the L3-L4 space using the palpation method (Tuffier's line). An investigator trained in US imaging will proceed to the US exam of the spine specifically aiming to identify the L3-L4 intervertebral space. The investigator will note if the same level was identified and if not, which one was according to the US exam.
1547379|NCT02616640|Drug|Durvalumab|
1547380|NCT02616640|Drug|Pomalidomide|
1547381|NCT02616640|Drug|Dexamethasone|
1547382|NCT02616614|Drug|Onexton|Topical gel for treating acne
1547383|NCT02616614|Drug|Clindamycin/benzoyl peroxide gel|Generic Clindamycin/benzoyl peroxide gel for treating acne
1547384|NCT02616614|Drug|Placebo|Vehicle gel used as a placebo
1547385|NCT02616601|Drug|Carac Cream|Active drug product (brand) applied to face or scalp once daily for 2 weeks
1547386|NCT02616601|Drug|Generic Fluorouracil Cream|Active drug product (generic) applied to face or scalp once daily for 2 weeks
1547387|NCT02616601|Drug|Placebo|Apply product to face or scalp once daily for 2 weeks
1547388|NCT02616588|Behavioral|Veteran Patient Navigator and Social Work Intervention|Each study participant will receive a veteran patient navigator intervention which consists of five study visits consisting of advance care planning, pain/symptom management, and education about hospice and palliative care. When clinically indicated, patients will be referred to a social work intervention providing psychosocial care and support.
1547391|NCT02616549|Behavioral|Sudarshan Kriya Yoga|A manual-based yoga program featuring a yoga-breathing meditation technique
1547392|NCT02616536|Other|Teaching methods|the two teaching methods will be given to two groups of students and their knowledge gain will be analysed
1547393|NCT02616523|Drug|Dexmedetomidine|The participants will be given infusion of dexmedetomidine 0,5 mcg/kg/h intravenously.
1547394|NCT02616523|Drug|Lidocaine|The participants will be given infusion of lidocaine 1,5 mg/kg/h intravenously.
1547395|NCT02616523|Other|placebo|The participants will be given infusion of normal saline intravenously.
1547396|NCT02616523|Drug|Fentanyl|Fentanyl 2 mcg/kg will be given to all participants for the intubation and during the operation when ANI value drops below 50.
1547397|NCT02616510|Procedure|cardiovascular screening|cardiovascular screening: serum, urine, ECG, carotid intima media thickness (IMT), cardiac ultrasound
1547398|NCT02616497|Drug|Aspirin|COX-1 inhibitor
1547399|NCT02616497|Drug|Triflusal|COX-1 inhibitor
1547403|NCT02616471|Dietary Supplement|High-fat cheese|
1547404|NCT02616471|Dietary Supplement|Low-fat cheese|
1547405|NCT02616471|Dietary Supplement|No-cheese/carbohydrate|
1547406|NCT02616458|Other|ear pain counseling|The Ear Pain counseling materials reviewed concepts such as how to recognize ear pain and safely provide pain relief, and how to recognize danger signs that require urgent medical attention. Families were also encouraged to schedule an appointment in the CHC for a possible ear infection rather than going to the emergency department or urgent care facility after hours.
1547407|NCT02616458|Other|language power counseling|The Language Power materials explained the importance of frequent conversations between parents and children and of using encouraging rather than discouraging comments and the PRA reviewed age-appropriate activities in the Learning Games book, and the importance of daily reading using the provided children's book as an example.
1547408|NCT02616445|Drug|UE2343|"UE2343
10mg, 20, 35mg
twice daily for 9 days"
1547409|NCT02616445|Drug|Placebo|"10mg, 20, 35mg
twice daily for 9 days"
1547410|NCT02616445|Drug|Placebo|"Cross-over study
single dose administered twice (on day 1 and day 8)
study duration 17 days"
1547411|NCT02616445|Drug|UE2343|"Cross-over study
UE2343
single dose administered twice (on day 1 and day 8)
study duration 17 days"
1547412|NCT02616445|Drug|UE2343|"UE2343
twice daily for 3 days
single dose on day 4"
1547413|NCT02616432|Device|Tomosynthesis|Three-dimensional imaging of both breasts in standard CC and MLO views
1547414|NCT02616419|Device|Buzzy® device|Just before the needle-related procedure, the Buzzy®, combining an ice pack and vibration integrated to a plastic bee, will be applied 5 cm above the needle insertion site and will be maintained in place throughout the painful procedure.
1547415|NCT02616419|Drug|Maxilene® (Lidocaine liposomal 4%)|Maxilene® topical anaesthetic cream will be applied 30 minutes before the needle-related procedure at the insertion site.
1547417|NCT02616393|Drug|Tesevatinib|
1547418|NCT02616367|Drug|liposomal bupivacaine Periarticular injection|Liposomal bupivacaine used for a periarticular injection in the knee
1547419|NCT02616367|Drug|Ropivacaine Periarticular Injection|Periarticular Injection for the knee with ropivacaine
1547420|NCT02616354|Drug|Imipenem|Patients in group I received a dose of imipenem/cilastatin 1g each every 8 hours or 0.5g every 6 hours optimized two-step infusion therapy (rapid first-step infusion in 30 min and slow second-step infusion above 1.5 hours)
1547421|NCT02616341|Behavioral|Team ERP (T-ERP) Intervention|
1547422|NCT02616341|Behavioral|Treatment as Usual (TAU)|
1547427|NCT02616289|Other|Topical emollient (Sun Flower seed oil)|3 g of oil per kg of infant's weight at study entry of Sunflower Seed oil (SSO) will be applied three times per day at regularly spaced intervals (8-hour intervals) for 10 days. Oil will not be applied to the face (to avoid the possibility of any accidental aspiration or ingestion), ears or under the hairline. Care will be taken to not injure the skin during the massage treatment. The child's anal area will be washed prior to application to avoid the spread fecal flora from the anal region (to which the oil will be applied to last). Prior to bathing the child a minimum of 3-4 hours should have elapsed following the application of the SSO. The amount of oil required will be calculated based on the child's weight and the required amount weighed out each time.
1547428|NCT02616276|Other|Control breakfast|It consists of 350 ml of water at room temperature.
1547429|NCT02616276|Other|High glycemic index breakfast|It consists of 350 ml of water at room temperature, 200 ml of grape juice (with 136.28 kcal), 40 g of white bread (2 slices of 52.2 kcal each) and 29 g of strawberry jam (with 127.52 kcal); providing a total of 368.2 kcal.
1547430|NCT02616276|Other|Low glycemic index breakfast|It consists of 350 ml of water at room temperature, a 150 g apple (with 81.12 kcal), a 125 g low-fat natural yogurt (with 56.10 kcal), 3 shelled walnuts (with 38.94 kcal per unit) and 17.5 g of 72% black chocolate (with 102 kcal); supplying a total of 356.04 kcal.
1547431|NCT02616263|Other|Foot exercise|
1547432|NCT02616263|Other|Shoulder exercise|
1547437|NCT02616237|Behavioral|Lifestyle Intervention|East-meets-West Lifestyle Intervention elements include nutrition and exercise from the Western perspective, food therapy and acupressure from the Traditional Chinese Medicine perspective, self-monitoring, and motivational videos of successful stories from working colleagues. The group participants in the Facebook are encouraged to post their health behaviors and questions, self-monitor, pledge for weight loss, seek social support and interact with health partners and other participants.
1547438|NCT02616224|Other|No intervention|No intervention was administered in this study.
1547439|NCT02616198|Other|EquiaFil G-coat|The old restorations or new caries were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing 10 sec. in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
1547440|NCT02616198|Other|EquiaFil Fuji Varnish|The old restorations or carious lesions were removed with anaesthetic solutions when necessary, a matrix was applied for two surface cavities and the restoration was performed with EquiaFil in bulk after mixing in the mixing machine. After 2min 30 sec, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers of Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
1547441|NCT02616198|Other|Riva SC G-coat|The old restorations or carious lesions were removed and a sectional matrix was applied for two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. The glass ionomer was packed with hand instruments in the cavities and 2min after the first setting the restoration was contoured and the occlusion adjusted.Then the surface was coated with G-coat resin and light cured for 10 sec. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
1547442|NCT02616198|Other|Riva SC Fuji Varnish|The caries lesions were removed with diamond and stainless steel burs, a sectional matrix was applied for restoring two surface cavities and the restoration was performed with Riva SC in bulk after mixing 10 sec. in the mixing machine. After the first setting of 2min, the restoration was contoured and the occlusion adjusted.Then the surface was coated in 2 layers with Fuji Varnish. The restorations were controlled by 2 independent examiners at baseline, 6-12-18 months and 6 years according to the United State Public Health Service criteria.
1547443|NCT02616185|Biological|PF-06755992|PF-06755992 will be administered on Day 1 of each cycle. Two dose levels will be evaluated.
1547444|NCT02616185|Biological|PF-06755990|PF-06755990 will be administered using a device on Day 29, 57 and 85 of each cycle.
1547445|NCT02616185|Device|TDS-IM Electroporation Device|TDS-IM electroporation device and associated supplies will be used for PF-06755990 administration
1547446|NCT02616185|Biological|Tremelimumab|PF-06753388 will be administered every 28 days.
1547447|NCT02616185|Drug|Sunitinib|Sunitinib will be taken daily. Up to three dose levels may be evaluated to determine the MTD when given in combination with the PrCa VBIR.
1547448|NCT02616185|Biological|PF-06801591|PF-06801591 will be administered every 28 days.
1547449|NCT02616172|Genetic|Autologous Bone Marrow Infusion|The subjects autologous bone marrow cells harvested at Florida Hospital will be infused intravenously by gravity
1547450|NCT02616159|Other|Oatmeal|
1547453|NCT02616133|Other|chart abstraction|abstraction of breast cancer patients with de-identified data
1547483|NCT02615925|Other|Psychiatry Consultation|Psychiatry Consultation
1547484|NCT02615912|Other|PEG-40 Hydrogenated Castor Oil (Tagat CH40, Evonik) 1.5%|
1547485|NCT02615912|Other|Lauryl glucoside (Plantacare® 1200UP, BASF) 1.5%|
1547486|NCT02615912|Other|Sorbitan palmitate (SPANTM 40 (powder), Croda) 1.5%|
1547487|NCT02615912|Other|Silwet* DA-63 (Momentive) 1.5%|
1547456|NCT02616107|Other|Managing Cancer Care: A Caregiver's Guide|"MCC-CG is a set of 7 printed modules including information about caregiver-nominated SM topics, conversation starters to facilitate communication with patients and providers, and links to caregiver resources. The modules are as follows:
Becoming a Cancer Caregiver [role, changes, challenges, adjusting, self-care]
Basics of Cancer Caregiving [physical, functional, emotional, social, & spiritual support; treatment timeline worksheet]
Caregiver's Role in Managing Patient Care [who/what is involved; health care professionals worksheet]
Managing Cancer Symptoms and Side Effects [common symptoms/side effects; maintaining health; nutrition & exercise; medication management worksheet]
Care Options: [information on curative, palliative and hospice care]
Talking About Goals of Care [information on goals of care conversations]
Managing Transitions [defining transitions, transition examples, helping yourself and patient to manage transitions; transitions worksheet]"
1547457|NCT02616107|Other|Symptom Management Toolkit|Along with an overview of symptom management, the Toolkit provides concise information on commonly experienced symptoms, including fatigue, alopecia, cognitive dysfunction, nausea and vomiting, and sleep problems, among others. Each chapter uses a question-and-answer format to cover the topics of who is most likely to experience the symptom, when and why the symptom may occur, how the symptom can be managed, and when to call a provider. Drs. Schulman-Green and McCorkle have previously tested the Symptom Toolkit in an attention-control group.
1547460|NCT02616081|Other|Clean Intermittent Catheterization|Clean intermittent self catheterization is a standard of care.
1547461|NCT02616081|Other|Indwelling Catheter|Indwelling catheterization is a standard of care.
1547462|NCT02616081|Other|Bladder Surgery|Bladder surgery is a standard of care.
1547463|NCT02616068|Drug|Transdermal Patch|Transdermal patch 100 mg once a day for 7 days
1547464|NCT02616068|Drug|Loxoprofen sodium|Loxoprofen sodium 60 mg per tablet by mouth, every 8 hours for 7 days
1547465|NCT02616068|Drug|Placebo (for loxoprofen sodium)|Placebo (for loxoprofen sodium 60 mg per tablet) by mouth, every 8 hours for 7 days
1547466|NCT02616068|Drug|Placebo (for transdermal patch)|Placebo (for transdermal patch 100 mg) once a day for 7 days
1547467|NCT02616055|Drug|tesevatinib|
1547468|NCT02616042|Other|Centella asiatica and bamboo salt|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica and bamboo salt is compared with control dentifrice.
1547469|NCT02616042|Other|Centella asiatica|Participants uses three types of dentifrices for four days after each wash-out period of 10 days. Dentifrice with Centella asiatica is compared with control dentifrice.
1547470|NCT02616029|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablets administered orally once daily
1547471|NCT02616016|Device|MRI Guided High Intensity Focused Ultrasound|Target treatment of bone metastases using High Intensity Focused Ultrasound
1547472|NCT02616003|Drug|Liraglutide|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
1547473|NCT02616003|Other|Aminosteril hepa 8%|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
1547474|NCT02616003|Dietary Supplement|Caloric diet with 800 kcal|Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)
1547475|NCT02615990|Device|Erigo Pro|Verticalization table with two integrated robotic devices for leg movement and cyclic loading
1547476|NCT02615990|Other|Standard Physical Therapy|Patients receive standard physical therapy.
1547477|NCT02615977|Behavioral|Zooming Joystick Task|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).
Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
1547478|NCT02615977|Behavioral|Zooming Joystick Task (Placebo)|"Subjects are instructed to use the joystick to pull all pictures (alcoholic and non-alcoholic beverages) towards them that appear in the portrait format, while pictures in a landscape format are pushed away. Half of the pictures are alcohol-related and the other half is not. The assignment of stimuli (alcohol versus neutral) to the picture format (portrait versus landscape) is manipulated (see 'Study Arm' descriptions).
Arousal and valence of the alcohol and non-alcohol pictures is rated as previously described. The investigators will apply six sessions of ZJT training, as this number has been proven sufficient for reducing relapse rates."
1547479|NCT02615964|Radiation|Nova Flow Procedure|Evaluation of the diagnosis, and stratification of the severity of Raynaud's disorder in patients with scleroderma based on clinical and imaging data will allow creation of more precise diagnostic criteria as well as disease classification which may guide treatment practices. The study results will likely have no immediate benefit to the patients participating in the study, however may have a future impact diagnosis, stratification and ultimately treatment of patients with Raynaud's disorder. In addition, data collected in this study may provide insight into disease process and leading to future research endeavors.
1547492|NCT02615886|Other|Observational Control|Participants will be observed and not provided any dietary supplementation.
1547493|NCT02615886|Dietary Supplement|Rice bran|Dietary rice bran consumed daily and amounts increase throughout the 6 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 2 g/day, 9 months: 3g/day, 10 months: 4g/day, 11 months: 5g/day).
1547494|NCT02615873|Drug|Accordion Pill™ Carbidopa/Levodopa|Accordion Pill™ Carbidopa/Levodopa Capsule 50/400mg , b.i.d or t.i.d or Accordion Pill™ Carbidopa/Levodopa Capsule 50/500mg , b.i.d or t.i.d
1547495|NCT02615860|Other|Topical 85% trichloroacetic acid (TCA)|In the experimental intervention arm, all visible lesions are treated with 85% TCA by dipping the wooden stick end of a cotton swab into a cup containing TCA. The stick end is saturated with TCA and is inserted through the anoscope and directed to the lesion under HRA guidance. TCA is applied to the lesion repeatedly until the lesion changes to a dense white colour. Each TCA application session is followed by another appointment four weeks later, where the clinician re-evaluates the lesions of the patient and determines whether a next TCA application is necessary up to a maximum of four times
1547496|NCT02615860|Procedure|Surgical electrocautery (ECA)|In the control arm, HRA-guided ECA, is performed every 4 weeks up to a maximum of four times. All visible lesions are ablated at every visit. Bleeding from small vessels can be stopped by ECA. Patients undergo local anaesthesia if necessary
1547497|NCT02615847|Drug|Memantinhydrochlorid|"Memantin Mepha® Lactabs (memantinehydrochlorid) will be provided as 5 mg, 10 mg, 15 mg and 20 mg tablets, packed in blister.
The study drug will be taken once a day per os, during 12 month."
1547498|NCT02615834|Procedure|Gentle chest pressure|Gentle pressure on the patient's right chest will be applied to achieve 12 breaths per minute.
1547499|NCT02615821|Behavioral|Mental Contrasting|n the mental contrasting activity participants will be asked by the researcher to consider the best outcome associated with engaging in physical activity, as well as the obstacles they may encounter while completing the activity. The first question will ask participants to name the most positive outcome of realizing their goal (e.g., feeling more awake during classes; weight loss). The second question will ask participants to name the most critical obstacle (e.g., feeling tired; rain) to reaching their goal.
1547500|NCT02615808|Other|Oxygen saturation data visualization|The data visualization contains current and recent (over last 4, 8 or 12 hours) pulse oximetry readings and trends as well as the monitor alarm limits and most recently recorded supplemental oxygen content and flow.
1547501|NCT02615795|Device|Tele Monitoring, using Tunstall monitoring device|Monitoring of symptoms and physiological parameters at home, using Tunstall Healthcare telemedicine equipment. Patients perform physiological measurement. In addition, they correspond to a standardized questionnaire regarding disease specific symptoms. Data is assessed by the medical staff the same day. If the data indicates worsening in the patient's condition, the patient is contacted by phone. The assessment of the patient is made either on the specialist nurse level, or at a conference between the specialist nurse and a senior pulmonary doctor. There is no call center service.
1547502|NCT02615782|Drug|CKD-397|CKD-397 1T single oral administration under fasting condition or fed condition(high fat meals)
1547503|NCT02615769|Behavioral|focused information of spirometry in the invitation|Focused information of spirometry in the invitation to the preventive health check compose the intervention in this trial.
1547504|NCT02615769|Behavioral|standard invitation|The active comparator will receive a standard invitation to the preventive health checks. The preventive health checks in the active comparator group and the intervention group are identical.
1547505|NCT02615756|Behavioral|Exercise|
1547508|NCT02615730|Drug|GSK2636771|Increasing dose levels of GSK2636771 (300 mg or 400 mg once daily)
1547509|NCT02615730|Drug|Paclitaxel|fixed dose of paclitaxel (80 mg/m2 on Days 1, 8 and 15 of a 28-day treatment cycle)
1547510|NCT02615717|Behavioral|Attention Bias Modification|comparison of treatment versus control
1547516|NCT02615678|Device|Acupuncture|Acupuncture twice a week for 6 weeks then one treatment a week for 4 weeks. Total 16 treatments in 10 weeks.
1547517|NCT02615665|Procedure|Hepatic resection|Removal of a part of the liver during surgery
1547518|NCT02615652|Other|no intervention|no intervention, observational study
1547519|NCT02615639|Biological|HPDC-T cells & Entecavir|experimental groups will be given HPDC-T cells & Entecavir. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and entecavir 0.5mg tablet every night by mouth
1547520|NCT02615639|Drug|Entecavir|0.5mg tablet every night by mouth
1547521|NCT02615639|Drug|HPDC-T cells & IFN-a-2a|experimental groups will be given HPDC-T cells & IFN-a-2a. HPDC-T cells will be given for 24 weeks on the basis of anti-HBV therapy ,and IFN-a-2a 180ug subcutaneous injection every week
1547522|NCT02615639|Drug|IFN-a-2a|IFN-a-2a 180ug subcutaneous injection every week
1547523|NCT02615639|Drug|HPDC-T cells & Telbivudine|experimental groups will be given HPDC-T cells & Telbivudine. HPDC-T cells will be given for 24weeks on the basis of anti-HBV therapy ,and Telbivudine 600mg tablet every day by mouth
1547524|NCT02615639|Drug|Telbivudine|Telbivudine 600mg tablet every day by mouth
1547525|NCT02615626|Procedure|Non-surgical Periodontal Treatment.|Non-surgical periodontal therapy is an anti-infective therapy which includes both mechanical and chemotherapeutic approaches to minimize or eliminate microbial biofilm, the primary etiology of gingivitis and periodontitis
1547526|NCT02615613|Other|Low Acceptability Meal|
1547527|NCT02615613|Other|High acceptability meal|
1547528|NCT02615600|Device|lf-tRNS|Low-frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): <100Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4
1547529|NCT02615587|Drug|Standard of care in AF in Denmark|As used in clinical practice, analysed as per drug class, not separate drugs.
1547530|NCT02615574|Biological|αDC1 vaccine|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
1547531|NCT02615574|Drug|CKM|Subjects will receive one cycle of CKM alone followed by three cycles of vaccine + CKM.
1547532|NCT02615561|Device|Bepanthen Itch Relief Cream: Phoenix 2 (Bepanthen Sensiderm, BAY207543)|2-3 times daily using multiples of Finger Tip Units (FTUs) depending on size of the area of the flares
1547533|NCT02615561|Other|New cosmetic Bepanthen product: Pumpkin (BAY207543)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
1547534|NCT02615561|Other|Stelatopia (cosmetic comparator)|Twice daily on the whole body; about 10 FTUs (i.e. 5g) per application depending on age of subject
1547535|NCT02615548|Other|community-based exercise class|This intervention will be held in a community centre, twice per week, for 36 weeks.The participants will have an educational session regarding importance of regular exercise.The class will consist of evidence-based exercises such as: sustained, high effort exercises, resistance exercises, and endurance training.Two trainers with specific for Parkinson Disease training will lead the class.
1547536|NCT02615548|Other|self-directed physical activity|Participants from this group will have an educational session regarding importance of regular exercises for Parkinson Disease and will be asked to stay as active as possible.Both groups will be asked to fill out physical activity diary.
1547537|NCT02615535|Device|EEG neurofeedback-assisted meditation|meditation with auditory feedback regarding EEG status
1547538|NCT02615535|Device|Non-EEG feedback-assisted meditation|meditation without auditory feedback regarding EEG status
1547539|NCT02615522|Device|BPK-S Integration|
1547540|NCT02615496|Behavioral|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Survey to measure physician awareness and understanding of the key messages in the educational materials: the prescriber guide and video.
1547541|NCT02615496|Behavioral|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|"Survey to measure patient awareness and understanding of the key messages in the educational materials: the patient booklet Your guide to EYLEA, patient information leaflet, and audio CD."
1547542|NCT02615483|Other|Web-based platform|"The WP is based on a conducted literature review and results form a previous study conducted in the regional context of the study. Information on the WP is animated based on the current literature stating that educative animation video optimises patients' acquisition of knowledge. The intention is to offer the patients the advantages in gaining knowledge in familiar surroundings and at a pace matching their needs and wishes.
The WP contains animated and written information mirroring the course of treatment, frequently asked questions and answers, it contains animated training support, a diary in order to keep track of training and development of pain and finally a social feature, a web-café."
1547543|NCT02615470|Behavioral|Enhanced immunization delivery model|Webinar and online training will be delivered to intervention pharmacist-technician pairs to discuss strategies that can be used to enhance immunization delivery model and how to integrate the new model into their routine practice. This intervention also includes feedback from immunization experts for the period of 6 months.
1547544|NCT02615470|Other|Immunization update|Basic immunization update online webinar will summarize changes in immunization schedules.
1547545|NCT02615457|Drug|Huaier Granule|Huaier Granule was given orally, 20 g tid for 5 years.
1547546|NCT02615444|Dietary Supplement|Beta-glucan enriched oatcake|5 oatcakes enriched with oat beta-glucan will be consumed daily for six weeks
1547547|NCT02615444|Dietary Supplement|Isocaloric control|6.5 wheat based control snacks without beta-glucan will be consumed daily for six weeks
1547548|NCT02615431|Other|MitraClip Intervention|
1547549|NCT02615418|Device|NIBS system for evaluation and treatment utilizing non invasive brain stimulation|
1547550|NCT02615405|Dietary Supplement|EPA|A daily treatment of 5 identical capsules of EPA (3.5 g/d) for Studies 1 & 2.
1547551|NCT02615405|Dietary Supplement|DHA|A daily treatment of 5 identical capsules of DHA (1.75 g/d) for Studies 1 & 2.
1547552|NCT02615405|Dietary Supplement|Placebo|A daily treatment of 5 identical capsules of placebo (high oleic oil) in single or divided administration for Study 1.
1547553|NCT02615392|Behavioral|Park Prescription|Please refer to the information included in the arm description.
1547554|NCT02615379|Device|EPIFLO|Transdermal continuous oxygen therapy is oxygen delivery to the wound site directly. Ogenix makes a small portable oxygen concentrator (Trade Name: EPIFLO) that makes continuous transdermal delivery of oxygen possible. It is a 3 ounce oxygen generator that continuously delivers 3 ml of pure oxygen to the wound site.
1547555|NCT02615366|Drug|Tranexamic Acid|
1547556|NCT02615366|Drug|Placebo|
1547557|NCT02615353|Behavioral|Intensive Lifestyle Intervention|6-months of lifestyle education
1547558|NCT02615353|Other|Usual Care Control|Medical visit and dietary counseling
1547752|NCT02613975|Device|positonal device|positional device detects prone positional and will vibrate to cause patient to lie laterally
1547561|NCT02615327|Dietary Supplement|Polydextrose|8g of Polydextrose
1547562|NCT02615327|Dietary Supplement|Polydextrose|12 g of Polydextrose
1547563|NCT02615327|Dietary Supplement|Polydextrose|16 g of Polydextrose
1547564|NCT02615327|Dietary Supplement|Placebo|0 g of Polydextrose
1547565|NCT02615314|Procedure|Particle re-positioning maneuver|Patients with posterior canal BPPV (PC-BPPV) were treated with Epley maneuver. Patients with superior canal (SC-BPPV) were treated with Li or reverse Epley maneuver. Patients with lateral canal (LC) apogeotropic or geotropic nystagmus were treated with Barbeque, Semont's or Gufoni maneuvers. If geotropic or ageotropic type nystagmus is equal intensity on both sides. The involved side was determined according to the patient sense of disturbance or lying down positioning test. If the patient has involvement of both sides according to Dix-Hallpike maneuver. Therapeutic maneuver was applied to the more severe side. All patients were re-evaluated at maximum 7 days.
1547566|NCT02615301|Dietary Supplement|Tailor-made salmon with high levels of vitamin D3 and K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
1547567|NCT02615301|Dietary Supplement|Tailor-made salmon with low levels of vitamin D3 and high K1|The aims were to investigate how intake of tailor-made salmon with low levels of vitamin D3 and high K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
1547568|NCT02615301|Dietary Supplement|Tailor-made salmon with high levels of vitamin D3 and low K1|The aims were to investigate how intake of tailor-made salmon with high levels of vitamin D3 and low K1 affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
1547569|NCT02615301|Dietary Supplement|Supplement with vitamin D and Calcium|The aims were to investigate how supplement with vitamin D and Calcium affected bone biomarkers, nutritional status (vitamin D, omega-3), as well as body composition and bone mineral density.
1547570|NCT02615288|Dietary Supplement|Vitamin D3|
1547571|NCT02615275|Device|SECA mBCA|Body composition assessed at baseline, weekly throughout RT during clinic visits, and after completion of treatment at the 10-12 week follow up.
1547572|NCT02615275|Procedure|X-Ray Imaging|Computed tomography (CT) or positron emission tomography (PET) scan performed at baseline, every week during radiation treatment (about 6-7 weeks), and at 10-12 weeks after completion of radiation therapy.
1547573|NCT02615275|Behavioral|Questionnaire|Symptom questionnaire completed at baseline, every week during radiation treatment (about 6-7 weeks), and at 10-12 weeks after completion of radiation therapy.
1547574|NCT02615275|Radiation|Radiation Therapy|Radiation treatment administered per treating physician for 6-7 weeks. Total prescribed dose is 60-70 Gy in 30-35 fx at 2.0-2.2 Gy/fx prescribed to the PTV. Radiation planned and delivered using intensity modulated radiation therapy (IMRT), volumetric arc therapy (VMAT), and/or three-dimensional conformal radiation therapy (3DCRT).
1547575|NCT02615262|Drug|Dexamethasone|
1547576|NCT02615262|Drug|Placebo|0.9% Sodium Chloride
1547577|NCT02615249|Biological|Metal Allergen Epicutaneous Patch|48 hour application of metal allergen patch to diagnose contact dermatitis
1547578|NCT02615236|Device|perineal ultrasound|transvaginal probe will be used to scan the perineum immediately after vaginal delivery in primiparous women
1547579|NCT02615236|Procedure|Clinical diagnosis|diagnosis of OASIS clinically
1547580|NCT02615223|Procedure|cryoablation|Cryoablation therapy
1547581|NCT02615223|Drug|Bicalutamide|bicalutamide
1547582|NCT02615223|Drug|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
1547583|NCT02615210|Device|SOC-directed biopsies using the SpyGlass System|The cholangioscopy procedure with the SpyGlass System is performed by a single operator with the SpyScope Access and Delivery Catheter positioned just below the operating channel of the duodenoscope. SpyBite Biopsy Forceps guided by the SpyScope Catheter are introduced and endoscopic-guided biopsy is taken at the level of the stricture. Target lesions will be identified under direct visualization using the SOC system, and 6-8 bites will be performed with the SpyBite forceps. Once SOC-directed biopsies are obtained, the SOC system will be withdrawn into the working channel of the duodenoscope and removed Patient will be contacted monthly to determine if they have undergone any additional procedures and to record potential adverse events.
1547586|NCT02615184|Drug|Dexlansoprazole|
1547587|NCT02615184|Drug|Placebo|Dexlansoprazole placebo-matching capsules
1547591|NCT02615158|Behavioral|Maternal Physical Activity and Nutrition|At each session, mothers will identify a dietary goal for the next session (e.g., reduce soda intake). They will learn to track and evaluate their progress, setting new goals or modifying existing ones as necessary. Mothers will be given pedometers and shown how to keep a pedometer tracking chart. As with dietary choice, our objective is to have the mothers identify personal goals and strategies to achieve those goals, so they are more likely to continue to engage in physical activity after the intervention ends.
1547592|NCT02615158|Behavioral|Parenting|Behavior and Development Related to Diet and Physical Activity. The toddler parenting intervention will include modules on toddler behavior and development. We will devote sessions to topics involving parenting toddlers, limit setting, and child development.
1547593|NCT02615158|Behavioral|Child Safety|The intervention will focus on child safety issues, including car seat safety, fire safety, fall prevention, and poison prevention. Participants will set weekly child safety goals.
1547594|NCT02615132|Behavioral|iPad|Using iPad speech therapy apps on patients with post-stroke communication deficits
1547595|NCT02615119|Drug|Isoproterenol|Intravenous infusions of isoproterenol, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
1547596|NCT02615119|Drug|Normal saline|Intravenous infusions of normal saline, delivered in a randomized double blinded order, in each participant from each group. Participants will rate the experience of heartbeat and breathing sensations as well as anxiety induced by the infusion.
1547597|NCT02615106|Drug|Endostar|7.5 mg/m2/day, day 1-14
1547598|NCT02615106|Radiation|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor|21.6Gy/12Fx to the tumor bed and 36Gy/20Fx to the tumor
1547599|NCT02615080|Drug|CRD007|
1547600|NCT02615080|Drug|Placebo|
1547601|NCT02615067|Drug|99mTc-MIP-1404 Injection|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
1547602|NCT02615054|Device|2D Echocardiogram|All patients will undergo a two-dimensional echocardiogram with speckle tracking strain analysis within the MSK echocardiography laboratory.
1547603|NCT02615054|Device|Cardiopulmonary exercise testing and post-CPET cardiac function|To determine VO2peak, an electronic motorized treadmill test with 12-lead ECG monitoring (Mac ® 5000, GE Healthcare) will be performed by certified exercise physiologists.
1547604|NCT02615041|Drug|Meropenem|1 g in 100 ml of normal saline solution and administered via bolus injection Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 hh after 3rd dose of meropenem
1547605|NCT02615041|Drug|Meropenem|"1 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.
Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and
1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
1547606|NCT02615041|Drug|Meropenem|"2 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 3 h every 8 h.
Blood samples (approximately 5 ml)will be obtained by direct venepuncture at the following time: before (time zero) and 10 and 30 min and 1, 1.5, 2, 2.5, 3.5, 4, 4.5, 5, 6, and 8 h after the 3rd dose of meropenem."
1547607|NCT02615028|Other|Closed eyes double-leg stance|Closed eyes double-leg stance: Body relaxed with both arms naturally placed beside thighs, eyes closed for 40 seconds.
1547608|NCT02615015|Other|Blood draw|
1547609|NCT02615002|Drug|Piromelatine|
1547610|NCT02615002|Drug|Placebo|
1547611|NCT02614989|Procedure|MRI guided focused ultrasound thalamotomy|MRI guided focused ultrasound thalamotomy
1547612|NCT02614976|Device|Padding|"Padding webrill (Covidian) TM 6"
1547613|NCT02614963|Drug|Clostridium Butyricum|Irritable bowel syndrome patients treated with Clostridium Butyricum
1547614|NCT02614963|Drug|placebo|Irritable bowel syndrome patients treated with placebo
1547615|NCT02614950|Other|Treatment interruption|
1547616|NCT02614937|Drug|ranibizumab|0.5 mg IVT ranibizumab
1547617|NCT02614937|Drug|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution BID
1547618|NCT02614924|Device|Flexible fibreoptic scope|Patient intubated using fibreoptic scope
1547619|NCT02614924|Device|Pentax AWS videolaryngoscope|Patient intubated using Pentax AWS videolaryngoscope
1547620|NCT02614911|Other|Biological sampling|Biological sampling including blood, feces, biopsies...
1547621|NCT02614898|Other|Clinical assessments and laboratory tests.|Clinical assessments and laboratory tests required at a minimum monthly. Frequency is increased at enrollment and any time there is a change in Soliris® regimen. Treatment for aHUS is observational and remains at the discretion of the treating physician.
1547622|NCT02614885|Device|Radiofrequency Ablation|
1547623|NCT02614872|Drug|GLASSIA® and Institution standard of care (SOC)|Alpha-1 Antitrypsin (AAT) [GLASSIA®] add-on pharmacotherapy and Institution standard of care (SOC)
1547624|NCT02614859|Drug|Bicalutamide|Bicalutamide 50 mg daily beginning at cycle 3 to cycle 8
1547625|NCT02614859|Drug|Metformin and Bicalutamide|Metformin 1000mg twice a day Bicalutamide 50 mg daily beginning at cycle 3
1547626|NCT02614846|Drug|Hetrombopag Olamine|
1547630|NCT02614820|Procedure|Remote Ischemic Preconditioning Training Apparatus|
1547742|NCT02614027|Other|Evaluation of changes in fat by DXA while on current therapy|Comparison of changes in fat (visceral and subcutaneous) by dual X-ray absorptiometry since therapy initiation
1547743|NCT02614014|Behavioral|Cognitive-behavior interventional program|
1547631|NCT02614807|Dietary Supplement|Nepro|The intervention is a dietary protein supplement. In the elderly hypertensive patient (assuming body weight of 70 kg) with mild to moderate hyponatremia free water excess is around 2.5 L. One bottle of Nepro/day will generate about 120 mosm to be excreted via urine. Given limited and mostly fixed urinary dilution and concentration between 300 and 800 mosm/L in the elderly and very elderly, one bottle of Nepro a day will result in an extra 400 ml of urine for a net loss of 163 ml of free water. Thus over the period of 2 to 4 weeks the calculated free water excess should be completely eliminated.
1547636|NCT02614768|Device|Glucose Sensor|"The investigational intervention is CGM monitoring using four different CGM systems. Three of the four CGM devices which are used will be CGM systems which have received CE certification (Dexcom G4 Platinum, Medtronic MiniMed 640G system, Abbott FreeStyle Libre Flash). The SPIDIMAN sensor will be used for the first time in human subjects, does not yet have received CE certification and will be given an identifying label in addition to being labelled for investigative use only."
1547637|NCT02614742|Drug|SFX-01|An intervention releasing sulforaphane.
1547638|NCT02614742|Drug|Placebo|Placebo otherwise identical to Active product
1547643|NCT02614716|Drug|LY3090106|Administered SC
1547644|NCT02614716|Drug|Placebo|Administered SC
1547645|NCT02614703|Drug|Chromoendoscopy using Acetic Acid 2.5%|Spraying esophageal mucosa during random biopsies for Barrett's esophagus
1547646|NCT02614703|Other|Standard random esophageal biopsies|Random esophageal biopsies performed as per protocol
1547650|NCT02614664|Device|NIRS|Cerebral oxygenation monitor which is standard of care for this surgery.
1547651|NCT02614651|Procedure|Find visual comfort threshold related to light intensity|"In this testing session, the patient's visual comfort threshold related to light intensity will be determined. Test sessions are kept under 45 minutes.
The subject is sitting in front of a keyboard and a computer screen. He/she is invited to recognize letters successively displayed in the center of the screen, this center is marked with a black cross. Each letter appearance is preceded by a beep. The subject must click on the space bar on the keyboard as soon as he/she recognizes the letter, then gives his/her answer orally."
1547652|NCT02614651|Procedure|Find the size of the visual field|For these tests, the subject is seated at a table, 1.5m from a wall. It features a computer keyboard. It projects an image on the wall, using to a video projector. An image moving towards a target (along 16 different trajectories) is used to evaluate the size of the visual field.
1547653|NCT02614651|Procedure|Effectiveness of brightness control|"During this testing session, the investigators seek to evaluate the effectiveness of the algorithms used to control the brightness.
The subject is in a room with four different computers. The subject is asked to identify the objects displayed on different computer monitors in the room: he/she must press a key on the keyboard when he/she detects an object and state aloud the nature of the object."
1547744|NCT02614001|Device|Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA|Patient will be trained daily, total 30 minutes or 15 minutes twice per day, at least 5 times a week, for 10 weeks
1547745|NCT02614001|Other|post-stroke rehabilitation program|
1547746|NCT02613988|Radiation|Radiation|
1547654|NCT02614651|Procedure|Performance of color correction|"During this session, the investigators try to assess the performance for the color vision correction (saturation and hue).
The subject, while wearing the virtual reality glasses + camera performs a test (twice) that requires matching colored dots (i.e. a Farnsworth test) under controlled light conditions."
1547655|NCT02614651|Device|Vuzix Wrap 1200DX virtural reality glasses|The other interventions are performed with the use of virtual reality glasses, specifically the Vuzix Wrap 1200DX. In case of technical difficulties, the latter can be swapped with the Oculus Rift model or another model. The associated webcameras are from Logitech, and the exact model used can vary and does not carry any importance for this research.
1547656|NCT02614638|Other|One month of department-wide observation|A pharmacy technician will be present full time in the care unit from Monday to Friday between 8:30 and 17h for 1 month for observational purposes only. During this phase, the pharmacy technician observes the current practices of preparation and administration of medication by nurses. He / she will collect medication errors and other observational data.
1547657|NCT02614638|Other|Pharm Tech participates in department|Following a 1 month wash-out period, a pharmacy technician will again be present full time (in practice, two technicians will relay each other) in the care unit from Monday to Friday between 8:30 and 17h for 1 month. He/she will actively take part in drug care activities in the department: management of product pathways, verification of injectable preparation, advice, etc. Medication errors and other observational data will be collected.
1547658|NCT02614612|Drug|Itacitinib (200 mg)|
1547659|NCT02614612|Drug|Itacitinib (300 mg)|
1547660|NCT02614612|Drug|prednisone or methylprednisolone (corticosteroids)|All subjects will receive prednisone 2.5 mg/kg per day PO (or methylprednisolone 2 mg/kg IV daily) on Days 1 through 5. Subjects will be tapered as tolerated beginning on Day 6 to no less than 0.25 mg/kg per day PO (or methylprednisolone 0.2 mg/kg per day) by Day 28. After Day 28, corticosteroids should be tapered according to institutional guidelines to attain ≤ prednisone 0.2 mg/kg per day (or ≤ methylprednisolone 0.16 mg/kg per day) by Day 56.
1547661|NCT02614599|Drug|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
1547662|NCT02614599|Dietary Supplement|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
1547663|NCT02614586|Drug|TAK-058|TAK-058 oral solution.
1547664|NCT02614586|Drug|Ondansetron|Ondansetron capsule.
1547665|NCT02614586|Drug|TAK-058 Placebo|TAK-058 placebo-matching, solution.
1547666|NCT02614586|Drug|Ondansetron Placebo|Ondansetron placebo-matching, capsule.
1547667|NCT02614573|Device|CoagucheckXSR Capillary INR measures|"We will be using the CoagucheckXSR device for capillary INR measures performed by nurses every 7 days during the 6 months of the study, plus after related intercurrent events.
If capillary INR is <2 or >3 (with a tolerance of 1.9 to 3.1 given the margin of measurement inaccuracy of the coagulometer), then a classic venous measure is performed. If both tests agree, adaptation of treatment as indicated. If slightly discordant results, then the INR values are considered discordant and the decision to adjust the treatment dose and the next monitoring date for venous INR is made based on the value of the venous INR, according to the predefined protocol. If clinically significant discordance (> 0.3), a venous INR is reperformed within 24 hours and if the discrepancy persists, dose adjustment is made according to the venous INR and the predefined protocol.
If capillary INR is > 4, then verification by venous measure and refer to general practitioner."
1547668|NCT02614560|Drug|Fludarabine|30 mg/m2/day intravenously, 5 to 2 days before the transplant (total dose of 120 mg/m2)
1547669|NCT02614560|Drug|Melphalan|Melphalan 140 mg/m2 intravenously, 2 days before the transplant
1547670|NCT02614560|Drug|vadastuximab talirine|Pre-allo (before stem cell transplant) given 14 days before the stem cell transplant
1547671|NCT02614560|Drug|vadastuximab talirine|Post-allo (after stem cell transplant) given on Day 1 of each cycle
1547672|NCT02614547|Drug|SAGE-547|
1547673|NCT02614547|Drug|Placebo|
1547674|NCT02614534|Drug|MITOMYCIN-C 40 mg|
1547675|NCT02614521|Other|pulmonary veins ablation's successful outcome|Assessment of predictive factors in patients with successful outcome of pulmonary veins ablations and suffer from paroxysmal atrial fibrillation.
1547676|NCT02614508|Drug|Buparlisib|Given PO
1547677|NCT02614508|Drug|Ibrutinib|Given PO
1547678|NCT02614508|Biological|Ofatumumab|Given IV
1547679|NCT02614495|Drug|Sulfatinib|Patients receive oral Sulfatinib at a dose of 300mg/d within 1 hour after breakfast (once-daily dosing continuously, every 28-day treatment cycle)
1547680|NCT02614482|Drug|Fesoterodine|Administer medication to patients with overactive bladder
1547681|NCT02614469|Drug|Inosine|Inosine, 1000 mg
1547682|NCT02614456|Drug|interferon-gamma and nivolumab|
1547683|NCT02614443|Other|Space from Depression|Delivered through the online SilverCloud platform, the program for the treatment of depression employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
1547684|NCT02614443|Other|Space from Anxiety|Delivered through the online SilverCloud platform, the program for the treatment of anxiety employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
1547685|NCT02614443|Other|Space from Stress|Delivered through the online SilverCloud platform, the program for the treatment of stress employs several innovative engagement strategies for improving the user experience. These are divided into several categories: personal, interactive, supportive, and social.
1547686|NCT02614430|Other|Vocational training|The intervention consists of a physical training program, individual motivational talks and guidance on labor market-oriented topics. Each program is customised to the patient's physical resources and conditions where. The framework for the intervention of physical activity 1 hours 3 times weekly with concurrent motivational talks for an overall maximum duration of 9 weeks. Based on an assessment of the patient is instructed about pain management, ergonomics, conflict management, diet, lifestyle, behavior modification, stress symptoms and preventive home training.
1547747|NCT02613988|Device|3 Tesla magnetic resonance imaging|
1547748|NCT02613988|Device|Chemical exchange saturation transfer MRI|
1547749|NCT02613988|Device|Diffusion weighted MRI|
1547687|NCT02614417|Other|Polysomnography|One night polysomnography performed using standard techniques and scored in accordance with American Academy of Sleep Medicine standards. Polysomnography monitors sleep by electroencephalography (F4-A1, C4-M1, O2-M1 F3-M2, C3-M2, O1-A2), electro-myography (submental and tibialis anterior muscles), electro-oculography, nasal flow, respiratory effort, pulse oximetry and transcutaneous carbon dioxide partial pressure.
1547688|NCT02614404|Drug|Imatinib|Experimental drug
1547689|NCT02614404|Drug|Dihydroartemisinin-piperaquine|Standard of care
1547690|NCT02614391|Other|Active distraction using a tablet|Playing a videogame using a computer tablet
1547691|NCT02614391|Other|Passive distraction|A nurses singing a song, reading a book, blowing bubbles and playing a puppet show
1547692|NCT02614378|Procedure|air insufflation|modulated air insufflation of the ear canal
1547693|NCT02614378|Procedure|placebo|no air will be introduced in the ear canal
1547694|NCT02614365|Behavioral|Aerobic exercise|Cardiovascular fitness
1547695|NCT02614365|Behavioral|Stretch exercise|Muscle stretch
1547696|NCT02614352|Drug|Atorvastatin + Candesartan|
1547697|NCT02614352|Drug|AG1502|
1547698|NCT02614339|Drug|metformin|The patients of this group are treated according to NCCN guideline for stage III colorectal cancer and receive an additional prescription metformin. Metformin will be prescribed 1g/day (500mg, 2 table/day, or 1000mg, 1 table/day). After adjustment period for 1month, patients who do not have side effects will be taken metformin for additional 35 months (total 36months including the adjustment period).
1547699|NCT02614339|Drug|control|The patients of this group are treated according to NCCN guideline for stage III colorectal cancer.
1547700|NCT02614326|Behavioral|Autobiographical Memory Flexibility (MemFlex) training|As in experimental arm description
1547701|NCT02614326|Behavioral|Psychoeducation|As in experimental arm description
1547702|NCT02614313|Procedure|Open breath test with fructose|Open randomised fructose 35g during breath test
1547703|NCT02614313|Procedure|Breath test with sweet placebo (Assugrin)|Double-blind randomised breath-testing with sweet placebo (Assugrin)
1547704|NCT02614313|Procedure|Breath test with neutral placebo (still water)|Double-blind randomised breath-testing with neutral placebo
1547705|NCT02614313|Procedure|Blinded breath test with fructose|Double-blind randomised fructose 35g during breath test
1547706|NCT02614300|Other|Pulmonary Rehabilitation and Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 1h15min
1547707|NCT02614300|Other|Pulmonary Rehabilitation|The patient will come 3 times per week during 12 weeks Each session 45min
1547708|NCT02614300|Other|Chest Physiotherapy|The patient will come 3 times per week during 12 weeks Each session 30min
1547709|NCT02614287|Drug|LY2951742|Administered SC
1547711|NCT02614261|Drug|LY2951742|Administered SC
1547712|NCT02614261|Drug|Placebo|Administered SC
1547713|NCT02614248|Other|Organic, Unrefined Coconut Oil|
1547714|NCT02614248|Other|Medline Remedy Phytoplex Z-Guard Skin Protectant|
1547715|NCT02614235|Device|Pocket-ECG III system|Continuous cardiac telemetry until diagnosis or a maximum of two months
1547716|NCT02614222|Device|Peripheral Nerve Blocks with CAIG|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
1547717|NCT02614209|Device|In Vitro diagnostic tests|Prospective blood collection
1547718|NCT02614196|Drug|LY2951742|Administered SC
1547719|NCT02614196|Drug|Placebo|Administered SC
1547720|NCT02614183|Drug|LY2951742|Administered SC
1547721|NCT02614183|Drug|Placebo|Administered SC
1547722|NCT02614170|Other|Prospective Blood Draw|This is prospective collection blood and urine study. This is not a treatment trial or device trial.
1547723|NCT02614157|Procedure|LLND|advanced rectal cancer patients whose lymph nodes are suspiciously enlarged after neoadjuvant chemoradiation will undergo lateral lymph node dissection (LLND) and total mesorectal excision (TME)
1547724|NCT02614157|Device|labeled line|
1547725|NCT02614131|Drug|LY2599666|Administered SC
1547726|NCT02614131|Drug|Solanezumab|Administered IV
1547727|NCT02614131|Drug|Placebo SC|Administered SC
1547728|NCT02614131|Drug|Placebo IV|Administered IV
1547729|NCT02614118|Drug|Ketorolac tromethamine|10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment
1547730|NCT02614118|Drug|Acetaminophen|1000 mg oral Acetaminophen along with10 mg oral Ketorolac tromethamine 45 minutes before root canal treatment.
1547731|NCT02614118|Drug|Placebo|placebo 45 minutes before root canal treatment
1547732|NCT02614105|Procedure|Pelvic floor muscle training|16 weeks of group-based exercise
1547733|NCT02614105|Procedure|Cough-suppression therapy|Group and individual sessions of respiratory physiotherapy with focus on techniques to suppress cough
1547734|NCT02614105|Other|Control|Brief information only
1547735|NCT02614092|Behavioral|Water-based Activity + Cognitive Training|This is an 8 month long two phase intervention. The first phase consists of 6 months of thrice weekly pool based physical activity occurring at the Palo Alto VA Health Care System. After completion of the 6 month long water based physical activity, participants transition to a ten session cognitive training program at the Palo Alto VA. The cognitive training classes are approximately two hours in length and will be spread over ten sessions across 4 weeks.
1547736|NCT02614079|Device|DSSEP|Collision testing after the placement of SCS leads
1547737|NCT02614066|Biological|KTE-C19|
1547738|NCT02614053|Device|Masimo Radical-7™ Pulse CO-Oximeter|a device collecting data regarding PVI, PI & spHB
1547739|NCT02614040|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
1547740|NCT02614040|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
1547741|NCT02614027|Other|Evaluation of metabolic syndrome|Evaluation and analytical determinations of the different components of the syndrome
1547750|NCT02613988|Device|Dynamic contrast enhancement MRI|
1547753|NCT02613962|Procedure|biopsy or surgical resection of tumor and blood sampling|
1547754|NCT02613949|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
1547755|NCT02613936|Device|Anodal tDCS|Anodal tDCS lowers neuronal membrane potentials, leading to increased probability of depolarization from incoming stimuli.
1547756|NCT02613936|Behavioral|Cognitive training|Cognitive training involves solving executive function tasks on a computer.
1547757|NCT02613923|Behavioral|GO! To Sleep|Controlled sleep intervention. Provide online education and reminder emails on improving sleep behavior
1547758|NCT02613923|Behavioral|Sleep information|Participants will receive weekly emails on the health benefits of sleep for 6 weeks
1547759|NCT02613923|Procedure|Blood Draw|blood sample measured for stress and sleep markers
1547760|NCT02613923|Other|Pittsburgh Sleep Quality Index (PSQI)|Assessment of sleep quality. This is a continuous measure from 0 (best) to 21 (worst). Sleep duration will be obtained directly from responses.
1547761|NCT02613923|Other|Insomnia Severity Index (ISI)|
1547762|NCT02613923|Other|SF-12 quality of life survey|
1547763|NCT02613910|Drug|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided as a liquid concentrate in a prefilled glass syringe with staked needle, stopper, and plunger containing 0.4 millilitre (mL) (20 mg) drug product of 50 mg/mL concentration
1547764|NCT02613910|Drug|Acetaminophen/paracetamol|Acetaminophen/paracetamol will be supplied by study centre as 1 gram tablet, caplet, capsule or liquid for oral administration
1547765|NCT02613910|Drug|Antihistamine (cetirizine or equivalent)|Antihistamine (cetirizine or equivalent) will be supplied by study center as 10 mg tablet, caplet, capsule or liquid for oral administration
1547766|NCT02613910|Drug|Prednisone/Prednisolone|Prednisone/Prednisolone will be supplied from the dose range 2.5, 5, 7.5, 10, 12.5, 15, 17.5, 20, 25, 30, 40, 50, 60, 80, 100, 120, 140, 160, 180, 200, 220 and 240 mg for oral administration
1547767|NCT02613897|Drug|Saxagliptin|Saxagliptin (Onglyza™) is approved by the US FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. The 5 mg dose will be used for this study as it is the dose that is routinely used in the clinic. In addition, this dose is used in the pivotal studies in the saxagliptin/dapagliflozin clinical program.
1547768|NCT02613897|Drug|Dapagliflozin|Dapagliflozin (Farxiga) is approved by the FDA as an adjunct to diet and exercise to improve glycemic control in adults with T2DM. Dapagliflozin (Farxiga) is also approved in the EU as an adjunct to diet and exercise to improve glycemic control in patients with T2DM for whom metformin use is considered inappropriate due to intolerance, and in combination with other glucose-lowering medicinal products when these, in combination with diet and exercise do not provide adequate glycemic control. The 10 mg dose was chosen for this study because it has been extensively studied in Phase 3 trials and has demonstrated a favorable benefit-risk profile. In addition, this dose is the most commonly used dose in most countries.
1547769|NCT02613897|Drug|Placebo|Placebo
1547770|NCT02613884|Drug|Treatment|
1547771|NCT02613871|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
1547772|NCT02613845|Other|no intervention|
1547773|NCT02613832|Other|EPAP|The EPAP will be applied with a Spring Load Valve Resistor (Vital Signs, Totowa, NJ, USA), adjusted with a pressure of 10 cmH2O. The Spring Load Valve Resistor will be connected to the expiratory branch of the T-tube. Duration of intervention: 5 minutes.
1547774|NCT02613832|Other|Breath Stacking|The BS will be performed by a T-tube with a one-way inspiratory valve and the expiratory branch occluded. The expiratory occlusion is maintain until observed the presence of a plateau in the impedance plethysmogram by EIT, which corresponds to the absence of inspired air displacement or when a maximum time of 40 seconds was attained. Durantion of intervention:Three BS interventions will be performed at one minute intervals between them.
1547775|NCT02613819|Radiation|SABR|"Renal cell carcinoma (RCC) is conventionally considered radioresistant to fully fractionated EBRT. In an effort to overcome the perceived radioresistance of RCC, severely hypofractionated External beam radiation therapy (EBRT) in the form of stereotactic radiotherapy will be used in the management of renal cell carcinoma with radiotherapy."
1547776|NCT02613806|Drug|Dexmeditomidine|Dexmeditomidine 0.2 ug/kg·h will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
1547777|NCT02613806|Drug|normal saline|Isovolumetric normal saline will be administered to participants by intravenous infusion at the beginning of the surgery,and continued till end of surgery.
1547778|NCT02613780|Procedure|Crosslinking|corneal collagen crosslinking with riboflavin
1547779|NCT02613780|Procedure|Photorefractive keratectomy|
1547780|NCT02613780|Device|iDesign® Advanced WaveScan Studio|Used to map wavefront aberration in planning photorefractive keratectomy
1547781|NCT02613767|Other|Protein meal|Ingestion of protein
1547782|NCT02613767|Other|L-[ring 13C6]Phenylalanine infusion|experimental method for determining protein synthesis rates
1547785|NCT02613741|Other|Lifestyle-based physical activity|Obese subjects will undergo a randomized physical activity-based weight reduction program (12 weeks). The lifestyle intervention will be determined based on an initial evaluation of each subjects' energy expenditure (by indirect calorimetry). Caloric intake will be set to elicit the loss of 1 to 1.5 lbs/week. The subjects and the family will meet with a dietitian once/week for 12 weeks. The intervention group will undergo an aerobic exercise program 3 times/week. The duration of exercise will be progressively increased from 20 to 45 minutes/session. The subjects will keep daily record of exercise activity and food intake. Interventions will be monitored during the subjects' weekly visit with the research group and they will be given counseling to stick to the intervention program.
1547786|NCT02613728|Behavioral|Accelerated Recovery Plan|
1547787|NCT02613728|Behavioral|Early Discharge|
1547788|NCT02613728|Other|Telemedicine|
1547789|NCT02613728|Behavioral|Standard Enhanced Care|
1547790|NCT02613715|Dietary Supplement|Blackberry juice with 12% ethanol|
1547791|NCT02613715|Dietary Supplement|Blackberry juice|
1547792|NCT02613702|Procedure|Free Gingival Graft|Surgical technique (autologous graft): Free gingival graft technique, harvested from palate.
1547863|NCT02613117|Device|Potassium Oxalate Gel|Self applied
1547793|NCT02613702|Procedure|Original Free Gingival Graft technique|Surgical technique (autologous graft): Original technique of free gingival graft, positioned at the inferior incisors area at the donor area
1547794|NCT02613702|Procedure|Modified Free Gingival Graft technique|Surgical technique (autologous graft): Free gingival graft. positioned at the inferior incisors area and covered by a flap at the donor area
1547795|NCT02613689|Behavioral|Scheduled Gradual Reduction (SGR)|Participants in this group will group will receive the Scheduled Gradual Reduction (SGR) smokeless tobacco cessation reduction intervention via text message over a period of four weeks. Participants will initially report their smokeless tobacco use according to their usual habit, and over the course of the intervention be directed via text message precise times to start and stop each instance of smokeless tobacco use, gradually reducing the occurrences of use. In addition, this group will also receive the support messages that are sent to the control group.
1547796|NCT02613689|Behavioral|Text Messages|Participants in this group will receive text messages about smokeless tobacco cessation in the form of counseling messages at various times throughout the day over a period of four weeks.
1547797|NCT02613676|Device|Transcutaneous bilirubin screening|Transcutaneous bilirubin screening before hospital discharge and assessment of risk category according to the Bhutani nomogram
1547798|NCT02613676|Other|Standard care (Visual inspection)|Participants in this group will be assessed for jaundice by visual inspection. Blood draw for TsB will be drawn only if the participant is visibly jaundiced.
1547799|NCT02613663|Procedure|Immediate implants with nanobone graft|Extraction of unrestorable tooth replaced with immediate implant and use nanobone graft to fill the gap.
1547800|NCT02613663|Procedure|immediate implants with autogenous bone graft|Extraction of unrestorable tooth replaced with immediate implant and use autogenous bone graft to fill the gap.
1547801|NCT02613650|Drug|MEK162 and mFOLFIRI|"MEK162 in combination with mFOLFIRI in a 14 day cycle
MEK162 will be given single agent 6 day lead in and then will be given in combination with mFOLFIRI
mFOLFIRI Administered Day 1 of each cycle Irinotecan 180mg/m2 iv over 90 minutes on day 1 5-fluoruracil 1200mg/m2 continuous infusion for 48 hours (2400mg/m2 in 48 hours)
Followed by MEK162 - Taken twice daily orally on Days 1-12 of each cycle
Level -1: mFOLFIRI at 80% + MEK162 30 mg twice daily 1 week on and 1 week off Level 1: mFOLFIRI + MEK162 30 mg twice daily Level 2: mFOLFIRI + MEK162 45 mg twice daily"
1547802|NCT02613637|Other|Registry|
1547803|NCT02613598|Drug|Bortezomib|
1547804|NCT02613598|Drug|Ruxolitinib|
1547805|NCT02613585|Other|Permethrin Impregnated Clothing|Uniforms and work clothing treated with permethrin according to proprietary process used by Insect Shield, Inc.
1547806|NCT02613572|Drug|alpha lipoic acid|
1547807|NCT02613572|Drug|Placebo|
1547808|NCT02613559|Biological|TK001|Intravitreal Injection
1547809|NCT02613546|Behavioral|Cognitive behavioral therapy (CBT)|"The study group will undergo 10 sessions of guidelines and cognitive behavioral therapy (CBT) about an hour long, once a week. Of these:
evaluation session;
sessions of psychoeducation about the CBT model
5 sessions of cognitive restructuring 2 sessions of preventing relapse"
1547810|NCT02613546|Behavioral|Control therapy|The control group will be subjected to 10 weekly sessions (1 time per week) approximately one hour guidelines.
1547811|NCT02613533|Other|Intra-ocular pressure measurement (IOP)|Subjects will be given 10ml/kg of water over 15 min prior to LPI surgery and IOP is tested every 15 min before and after surgical procedure
1547812|NCT02613520|Biological|PfSPZ Vaccine|Metabolically active, non-replicating, radiation attenuated, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Vaccine)
1547813|NCT02613520|Other|Normal Saline|0.9% Sodium chloride
1547814|NCT02613520|Biological|PfSPZ Challenge (for CHMI)|live, infectious, aseptic, purified, cryopreserved NF54 P. falciparum (Pf) sporozoites (PfSPZ Challenge) Controlled human malaria infection (CHMI) by direct venous inoculation of 3,200 PfSPZ Challenge
1547817|NCT02613494|Drug|Hyoscine|300 micrograms twice daily, increasing to 300 micrograms three times daily
1547818|NCT02613494|Drug|Glycopyrrolate|1 milligram twice daily, increasing to 1 milligram three times daily
1547819|NCT02613494|Other|Placebo|Placebo twice daily, increasing to placebo three times daily
1547820|NCT02613481|Drug|Poly-L-Lactic Acid (Sculptra) injection|1 vial of of poly-l-lactic acid (Sculptra) reconstituted in the usual sterile fashion with 7cc of sterile water and 2cc of Lidocaine without epinephrine. The contents of the vial will be injected as deemed appropriate by the certified injector and agreed upon by the study subject.
1547821|NCT02613468|Other|collection of periodontal records|"Clinic attachment level
Probing depth
Gingival index
Plaque index
Bleeding on probing were performed in all groups. These measurements were performed at the end of each trimester."
1547822|NCT02613468|Other|pregnancy parameters|Parameters such as number of pregnancies, previous low birth weight, prenatal care, genital tract infection, use of antibiotics, smoking, tooth brushing habit and birth weight were evaluated.
1547823|NCT02613468|Other|Initial Periodontal Therapy|Initial Periodontal Therapy is completed ( Supragingival and subgingival calculus elimination, root planning, polishing etc.) This treatment is considered to be the safest time for pregnant mothers was performed in 2 trimester.
1547824|NCT02613455|Procedure|extracorporeal shock wave therapy|Following clearance, patients will be booked for ESWT in the operating room either WRNMMC or Kimbrough Ambulatory Care Center (KACC), depending on availability. Under conscious sedation, patients will receive 2000 shocks at 18-24kV, which is the standard dose utilized by our clinic in treatment of this condition. The range is necessary to account for differing size of the soft tissue envelope depending on patient habitus. The final dose utilized will be at the surgeon's discretion.
1547825|NCT02613455|Drug|Kenalog (triamcinolone)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
1547864|NCT02613117|Device|Potassium Oxalate Liquid|Professionally Applied
1547865|NCT02613117|Drug|Stannous fluoride paste|SnF2 Paste
1547826|NCT02613455|Drug|lidocaine 1% (lidocaine HCl 20mg)|patients will receive an intratendinous injection in the common tendon origin of the extensor/supinators at the lateral epicondyle by an attending orthopaedic hand surgeon. The injection will contain 1cc of Kenalog-40 (triamcinolone 40mg) + 2cc lidocaine 1% (lidocaine HCl 20mg). This is the standard dose for lateral epicondylitis used routinely in the WRNMMC orthopaedic clinic.
1547827|NCT02613429|Behavioral|identification of the airway by from the cranial end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the thyroid cartilage and from there moving distally
1547828|NCT02613429|Behavioral|identification of the airway from the distal end|The airway is identified with inspection and imaging technique (ultrasound) by placing the ultrasound transducer over the distal trachea and moving cranially
1547829|NCT02613416|Drug|Denosumab|monthly subcutaneous injections
1547832|NCT02613390|Procedure|Magnetic Resonance Imaging (MRI)|MRI images of the spine taken of anesthetized participant in the operative prone position.
1547833|NCT02613390|Behavioral|Questionnaires|Pain and symptom questionnaires completed at baseline and at follow up.
1547834|NCT02613377|Other|Blood transfusion|
1547835|NCT02613364|Behavioral|Behavioral Intervention|Undergo yoga intervention
1547836|NCT02613364|Other|Cognitive Intervention|Undergo CBT-I intervention
1547837|NCT02613364|Other|Educational Intervention|Receive health education
1547838|NCT02613364|Other|Laboratory Biomarker Analysis|Correlative studies
1547839|NCT02613364|Device|Monitoring Device|Correlative studies
1547840|NCT02613364|Other|Quality-of-Life Assessment|Ancillary studies
1547841|NCT02613351|Device|scooting|three-wheeled scooter (Monark 662, Monark Exercise AB Sweden) comprised of a single front wheel that provides steering and two rear wheels that create a wide base of support.
1547842|NCT02613338|Device|DePuy Attune posterior stabilizing fixed bearing knee system|Individuals implanted with the DePuy Attune posterior stabilizing fixed bearing knee system at least three months post-operative.
1547843|NCT02613325|Device|Functional photoacoustic microscopy|-Hybrid imaging technique that detects absorbed diffusive protons ultrasonically through the photoacoustic effect.
1547844|NCT02613325|Procedure|Standard of care surgical excision|
1547845|NCT02613325|Device|Single cell photoacoustic microscopy|
1547846|NCT02613286|Procedure|Extrafascial Hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
1547847|NCT02613286|Procedure|Modified radical hysterectomy|Hysterectomy plus Pelvic Lymph-Node Dissection
1547850|NCT02613260|Behavioral|FIT Outreach|This arm will consist of priming patients with a postcard and a possibly a phone call two weeks prior to them being mailed a FIT kit. The FIT kits will be mailed to the patients with a letter from their clinic's care team informing them why they should complete the FIT and wordless instructions to help them complete the FIT. Two weeks after the FIT kit is mailed the patients that have not returned the kit will receive up to two reminder calls. During the phone calls the outreach workers will use health coaching techniques to encourage patients to complete the FIT. All written materials have been translated into English and Chinese and during phone calls patients will be spoken to in the language that they are most comfortable using.
1547851|NCT02613247|Device|Hylan G-F 20|Intra-articular injection of 6 mL Hylan G-F 20
1547852|NCT02613234|Device|cathode tDCS|"At the first randomized controlled stage, the experimental group will undergo five daily sessions of active brain-wave intervention by cathode tDCS (20min, 1mA) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.
At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
1547853|NCT02613234|Device|Sham cathode tDCS|"At the first randomized controlled stage, the control group will undergo five daily sessions of sham brain-wave intervention by cathode tDCS (20min, 1mA, the stimulator will be turned off after 5s) targeting the epileptogenic focus, which is confirmed by 128-channel EEG and BESA dipole localization method.
At the second open-label extension stage, all the patients will undergo five daily sessions of active intervention (20min, 1mA)."
1547854|NCT02613221|Drug|panitumumab, TAS-102|panitumumab: 6 mg/kg, every 2 weeks TAS-102: 35 mg/m², given orally twice a day in a 28-day) in 2-week cycle of 5 days of treatment followed by a 2-day rest period, and then a 14-day rest period.
1547855|NCT02613208|Drug|Bevacizumab|Bevacizumab will be administered as per local clinical practice and local labeling.
1547856|NCT02613208|Drug|Paclitaxel|Paclitaxel will be administered as per local clinical practice and local labeling.
1547857|NCT02613195|Drug|Hydrogen-Rich Celsior Solution|Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
1547859|NCT02613169|Drug|Isoniazid|HIV-exposed uninfected infants will be randomized to receive either INH or no INH daily for 12 months for the prevention of Mycobacterium tuberculosis (MTB) infection.
1547860|NCT02613156|Procedure|laparoscopic resection|The surgical instruments used for the laparoscopic group included conventional laparoscopic instruments (three 5 mm trocars, two 10 mm trocars, and two damage-free laparoscopic clamps), the STORZ high-resolution laparoscopic operating system (Germany), the GEN300 ultrasonic scalpel system (Johnson & Johnson, USA), a laparoscopic linear cutter stapler (Johnson & Johnson, USA), a laparoscopic ultrasound device, LigaSure, bipolar coagulation, titanium laparoscopic clips, and absorbable hemostatic gauze.
1547861|NCT02613130|Drug|Stannous fluoride toothpaste|
1547862|NCT02613130|Drug|Potassium nitrate toothpaste|
1547942|NCT02612649|Drug|Ramosetron|Oral
1547866|NCT02613104|Other|emotion recognition modification - sad>happy|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than sad. The intervention is completed three times.
1547867|NCT02613104|Other|emotion recognition modification - sad>happy control|Participants must choose whether each face is happy or sad. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or sad. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
1547868|NCT02613104|Other|emotion recognition modification - angry>happy|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the intervention, the participant receives feedback on their emotion choices designed to train them to identify two additional morphs as happy, rather than angry. The intervention is completed three times.
1547869|NCT02613104|Other|emotion recognition modification - angry>happy control|Participants must choose whether each face is happy or angry. Based on these responses, an algorithm then estimates each participant's balance point, the threshold point on the morph sequence at which they are equally likely to label the face as happy or angry. During the placebo intervention, the participant receives feedback on their emotion choices designed to reinforce their initial emotion choices. The placebo intervention is completed three times.
1547870|NCT02613091|Drug|Clemastine fumarate|4mg 2x day clemastine fumarate orally.
1547871|NCT02613078|Behavioral|Gut-Directed Hypnotherapy|Hypnotherapy protocol is based on the Manchester protocol for gut-directed hypnotherapy and was adapted for children and adolescents. It consists of elements aiming at relaxation and suggestions for control and relief from pain and discomfort. The hypnotherapy will be provided using a CD. Children of the hypnotherapy condition will be instructed to practice with their CD on a daily basis (20 min each day, at least 4 times/week) during 4 weeks
1547872|NCT02613078|Dietary Supplement|Nutritional Supplement|SymbioLact® B a preparation of Bifidobacterium lactis and vitamin B7, Biotin. Number of living organisms in one dose is at least 1 x 10^9 cfu. SymbioLact® B will be used in the dose recommended in the pediatric patient information sheet - one dose of SymbioLact® B diluted in water or tee once a day together with a main meal during 4 weeks
1547873|NCT02613078|Behavioral|Self-Monitoring|Use of symptom diary that questions about main bowel complains (including pain or discomfort) during the day. Applied on a daily basis (about 2 min in the evening)
1547874|NCT02613065|Dietary Supplement|Consumption of NOW Foods eggwhite protein shake|Consumption of NOW Foods egg white protein shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
1547875|NCT02613065|Dietary Supplement|Consumption of NOW Foods maltodextrin shake|Consumption of NOW Foods maltodextrin shake at beginning of 3 daily meals that in total, is approximately 20% of caloric needs.
1547876|NCT02613052|Drug|normal saline|10 mL of normal saline agitated prior to IV administration
1547877|NCT02613052|Drug|human albumin|10 mL of 5% albumin agitated prior to IV administration
1547878|NCT02613052|Drug|human albumin and propofol|7 mL of 5% albumin mixed with 3 mL of propofol (10 mg/mL) agitated together prior to IV administration
1547880|NCT02613026|Drug|Pirarubicin|
1547881|NCT02613026|Drug|Docetaxel|
1547882|NCT02613026|Drug|Cyclophosphamide|
1547883|NCT02613013|Device|neodymium:yttrium-aluminum- garnet laser|a neodymium:yttrium-aluminum- garnet laser was used to perform the LPI
1547884|NCT02613013|Device|frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser|a frequency-doubled Q-switched neodymium:yttrium-aluminum-garnet 532-nm laser was used to perform the LPIP
1547885|NCT02613013|Drug|Pilocarpine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
1547886|NCT02613013|Procedure|LPIP plus LPI|LPIP was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia will be administered. Twenty to 30 spots of 250-300 mW power with 300-500 microns of size and duration of 400-500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. Effective iris contraction was considered as a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain. LPI was performed after LPIP procedure.
1547887|NCT02613013|Drug|Proparacaine|30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered
1547888|NCT02613013|Procedure|LPI|LPI was performed with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA). 30 minutes prior to the procedure, a drop of 2% pilocarpine will be instilled into the eye every 15 minutes, Topical anaesthesia (Proparacaine) will be administered. The treatment site was selected in the superior nasal iris or in a crypt, where present. Treatment was initiated with a pulse of 3-5mJ, the power was increased until patency was achieved, the opening of iris >0.1mm. and patency was determined by direct visualization of the posterior chamber.
1547889|NCT02613000|Other|No intervention|
1547890|NCT02612987|Behavioral|Internet-based Cognitive Behaviour Therapy (iCBT)|
1547891|NCT02612974|Biological|Hirudinaria granulosa, qurse mafasil|compare the efficacy of both groups
1547892|NCT02612961|Other|3mL of normal saline from the pink sodium chloride bullet|
1547893|NCT02612961|Other|Sham Comparator of 3mL normal saline|
1547894|NCT02612948|Drug|Quetiapine|escalating dose to prevent delerium.
1552284|NCT02582073|Biological|Grass MATA MPL (1.0ml) 18200SU|
1547895|NCT02612935|Device|Lumosity|Lumosity offers a suite of online games focused on stimulating cognitive domains of attention, memory, cognitive flexibility, problem solving, and speed of processing. The Lumosity program may be well suited for cognitive remediation in individuals with MS.
1547896|NCT02612922|Drug|Nitazoxanide|Nitazoxanide 600 mg administered orally twice daily for five days
1547897|NCT02612922|Drug|Placebo|Placebo administered orally twice daily for five days
1547898|NCT02612909|Biological|A/H5N1 vaccine|Monovalent A/H5N1 influenza vaccine (MIV), whole virion inactivated, purified by sucrose gradient on ultracentrifuge. The vaccine will be produced in eggs, inactivated with formaldehyde, and formulated with aluminum hydroxide 0.6 mg/0.5 mL with no preservative.
1547899|NCT02612909|Biological|Placebo Comparator|Placebo (PBS) will be manufactured by IVAC. PBS, pH 7.2, will also be in 0.5 mL single-dose vials. Every vial contain : Nacl 4.500mg;Na2HPO4.2H2O: 0.685 mg; NaH2PO4.2H2O:0.186 mg and Water For Injection (qs):0.5 mL
1547900|NCT02612896|Drug|Mass drug administration, praziquantel 10mg/kg|see previous, in elimination study arm only
1547901|NCT02612896|Behavioral|Health education|in all study arms, using village meetings, posters, pamphlets.
1547902|NCT02612870|Device|Sienna+ retro|Sentinel node marking with Sienna+ retro-mamillary 1 day before surgery
1547903|NCT02612870|Device|Sienna+ peri|Sentinel node marking with Sienna+ peri-tumorally 1 day before surgery
1547904|NCT02612870|Device|Sienna+ retro 4-6|Sentinel node marking with Sienna+ retro-mamillary 4-6 days before surgery
1547905|NCT02612870|Device|Sienna+ peri 4-6|Sentinel node marking with Sienna+ peri-tumorally 4-6 days before surgery
1547906|NCT02612870|Device|Technetium 1|Sentinel node marking with Technetium 1 day before surgery
1547910|NCT02612844|Drug|NNC0143-0406|Subject will receive one single dose only Subcutanesously (s.c., under the skin)
1547911|NCT02612844|Drug|insulin aspart|Subject will receive one single dose only. Subcutanesously (s.c., under the skin)
1547912|NCT02612831|Procedure|Early bariatric surgery|
1547913|NCT02612831|Procedure|Delayed bariatric surgery|
1547914|NCT02612818|Device|Coelioscopy|
1547915|NCT02612805|Other|Aerobic training|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
1547916|NCT02612805|Other|Combined training|"Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Method of training: Aerobic more resistance training.
Aerobic component (between 30 and 40 minutes of the sessions): Method: Aerobic continuous in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: 85% to 100% of the anaerobic threshold during the intervention.
Resistance component (Between 10 and 20 minutes of the sessions): Method: Multiple sets (2 to 4 sets of 30 to 15 seconds) in aquatic environment; Modality: Hydrogymnastics; Weekly frequency: 3; Intensity: Maximum execution speed."
1547917|NCT02612805|Other|Training placebo|Total duration of exercise sessions: 56 minutes (3 minutes of warming - 50 minutes of main part - 3 minutes of stretching); Activities performed in main part: Stretching and relaxation in aquatic environment.
1547918|NCT02612792|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
1547919|NCT02612792|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
1547920|NCT02612792|Procedure|OFD with Platelet rich fibrin (PRF)+1.2% Atorvastatin (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1.2% Atorvastatin gel placement
1547921|NCT02612779|Drug|Elotuzumab|
1547922|NCT02612779|Drug|Pomalidomide|
1547923|NCT02612779|Drug|Dexamethasone|
1547924|NCT02612779|Drug|Nivolumab|
1547925|NCT02612766|Dietary Supplement|Pure, uncontaminated oats|
1547926|NCT02612753|Procedure|improvement of language for aphasics patients|Aphasics patients receive active stimulation during SLT
1547927|NCT02612753|Device|Sham tDCS|Aphasics patients control receive sham stimulation during SLT
1547928|NCT02612753|Device|tDCs|
1547929|NCT02612740|Procedure|Deproteinized bovine bone|cyst removal followed by heterologous bone grafting
1547930|NCT02612740|Device|granules of deproteinized bovine bone (Bio-Oss)|
1547931|NCT02612727|Device|Window tinting film for filtered sunlight phototherapy|Six hours of filtered sunlight phototherapy for 1 to 10 days.
1547932|NCT02612727|Device|conventional phototherapy|Conventional phototherapy unit will be used for infants randomized to this arm for1-10 days
1547933|NCT02612714|Drug|Rosuvastatin|All parameters were measured before statin treatment, after 6 months of statin treatment and 6 months after discontinuing statin treatment. Scores of the sexual health inventory for men (SHIM) were also evaluated.
1547934|NCT02612701|Other|Cigarettes|Subjects will smoke a standard cigarette (yield: tar 12 mg, nicotine 1 mg)
1547935|NCT02612701|Other|E-cigarettes (nicotine free e-liquid)|Subjects will smoke nicotine free e-liquid with an e-cigarette.
1547936|NCT02612701|Other|E-cigarettes (low nicotine e-liquid)|Subjects will smoke low nicotine (4-6 mg/mL) e-liquid with an e-cigarette.
1547937|NCT02612701|Other|E-cigarettes (high nicotine e-liquid)|Subjects will smoke low nicotine (18-24 mg/mL) e-liquid with an e-cigarette.
1547938|NCT02612688|Behavioral|ACP Video Program|The ACP Video Program consists of five videos that address ACP decisions: (1) General Goals of Care, (2) Goals of Care for Advanced Dementia, (3) Hospice, (4) Hospitalization, and (5) ACP for Healthy Patients. NH staff will offer videos to patients at these clinical triggers: (1) Within 7 days of admission or readmission; (2) Every 6 months for long-stay patients; (3) When there is a significant change in clinical status; (4) When a treatment decision arises for which there is a specific video; and (5) Special circumstances when goals of care are being considered (e.g., family visiting).
1547939|NCT02612675|Other|ONS|
1547943|NCT02612636|Other|ear plug|The patients will receive the intervention (ear plug) in the third night (N3) from 9 pm to 6 am.
1547944|NCT02612636|Other|eye mask|The patients will receive the intervention (eye mask) in the second night (N2) from 9 pm to 6 am.
1547945|NCT02612623|Drug|Gefapixant|
1547946|NCT02612623|Drug|Placebo (for gefapixant)|
1547947|NCT02612610|Drug|Gefapixant|
1547948|NCT02612610|Drug|Placebo (for gefapixant)|
1547949|NCT02612597|Other|Bedrest|
1547950|NCT02612597|Other|Exercise Training|
1547951|NCT02612584|Device|Pinhole Soft Contact Lens apply for presbyopia|
1547952|NCT02612558|Drug|Fostamatinib 150 mg bid|Fostamatinib 150 mg bid. The dose of Fostamatinib may be reduced at any time to as low as 100 mg PO once daily (qd) if dose limiting adverse events are observed
1547955|NCT02612532|Device|ReCIVA breath sampler|Device developed for standardised collection of breath samples http://www.owlstonenanotech.com/medical/products/reciva
1547956|NCT02612519|Device|Alfapump|Implantation of Alfapump
1547957|NCT02612519|Device|TIPS|Implantation of TIPS
1547958|NCT02612506|Drug|Hepalatide|There are seven cohorts as follows 0.21mg, 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. Dose of 0.21mg is a pilot trial with no placebo. At each dose level, healthy volunteers will be received treatment drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
1547959|NCT02612506|Drug|Placebo|There are six cohorts as follows 0.525mg, 2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. At each dose level, healthy volunteers will be received control drug by abdominal subcutaneous injection at the first day and monitored for 8 days.
1547960|NCT02612493|Other|Obese patients with type I diabetes|Postsurgical follow - up in obese patients with type I diabetes
1547961|NCT02612480|Drug|ticagrelor|7 day treatment of ticagrelor 2dd90mg after a loading dose of 180mg
1547962|NCT02612480|Drug|Clopidogrel|7 day treatment of clopidogrel 1d75mg after a loading dose of 300mg
1547963|NCT02612480|Drug|Acetylsalicylic acid lysinate|7 day treatment of acetylsalicyclic acid 1d80mg after a loading dose of 160mg
1547964|NCT02612480|Drug|Placebo|7 day treatment with placebo
1547965|NCT02612467|Other|Stratified care|"Patients are stratified according to the SBT subgroups (low, medium and high risk) and the appropriate matched intervention will be delivered accordingly.
Low risk: Reassuring information. Onwards referral, investigation or further treatment is not recommended Medium risk: In addition to reassuring information patients receive evidence based individualised treatment focusing on restoring function (targeting back pain, leg pain, co-morbid pain and disability) High risk : In addition to medium risk treatment patients will receive individualised psychologically informed physiotherapy aiming to reduce pain and disability."
1547966|NCT02612467|Other|Current care|Treatment based on clinical judgement, clinical need and patient preferences. No access to guidance tools.
1547967|NCT02612454|Drug|Dupilumab|
1547968|NCT02612441|Device|real Acupuncture Needles|Acupuncture needles
1547969|NCT02612441|Device|sham Acupuncture Needles|sham Acupuncture Needles
1547970|NCT02612428|Biological|ELAD System|An extracorporeal human hepatic cell-based liver treatment
1547971|NCT02612428|Other|Standard of Care (Control)|Standard medical treatment as defined by the protocol
1547972|NCT02612415|Device|Treatment strategy: Non-invasive respiratory support delivered via high flow nasal cannula|A heated, humidified, HFNC device will be used to deliver a gas flow rate of 2 L/kg/min for the duration that the patient needs non-invasive respiratory support
1547973|NCT02612415|Device|Treatment strategy: Non-invasive respiratory support delivered via continuous positive airway pressure|CPAP will be provided using a set expiratory pressure of 6-8 cm water (H2O) pressure for the duration that the infant needs non-invasive respiratory support
1547974|NCT02612402|Device|messages generated by learning algorithm|THIS INTERVENTION HAS BEEN INCLUDED IN THE LEARNING ALGORITHM ARM The app measures physical activity by the phone accelerometer and sends SMS messages to encourage activity. An automatic learning algorithm for encouraging physical activity learns the patterns of response for each patient and chooses the best messages for the patient to encourage activity.
1547975|NCT02612402|Device|constant weekly message reminding patient to exercise|THIS INTERVENTION HAS BEEN INCLUDED IN THE CONTROL ARM The app measures physical activity by the phone accelerometer and sends a constant SMS messages to remind the patient to exercise.
1547976|NCT02612389|Other|Meditative Movement taught via DVD|Gentle movement with attention to posture and breathing with emphasis on interoceptive awareness and self regulation.
1547977|NCT02612363|Drug|Dexmedetomidine for sedation|"Dexmedetomidine or control drug for sedation
Analgesia
Propofol at lowest dosage.
Dose range: 0.1- 0.7 u/kg/hour
Target RASS score of -2 to +1
Supplemental other sedatives at lowest effective dose"
1547978|NCT02612350|Genetic|ctDNA Analysis for the Detection of Genetic Mutations|Cell-free DNA (cfDNA) is isolated from a blood plasma sample and tested for the presence of 96 specific well-described mutations in 9 cancer driver genes. The presence of more than 2 copies of a mutation may indicate the presence of a malignancy. Follow up with the subject's physician would be needed for an examination and any additional testing that the physician wants to perform to further assess for the development of cancer.
1547979|NCT02612337|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
1547980|NCT02612337|Drug|Placebo|Single intratympanic injection of placebo
1547981|NCT02612324|Behavioral|Pono Choices|Medically accurate teen pregnancy and STI prevention education delivered through a place-based framework integrating Hawaiian cultural activities that draw upon both historical and local references.
1547982|NCT02612324|Behavioral|Business as Usual|Teen pregnancy and STI prevention education left to the discretion of the school.
1547987|NCT02612298|Drug|Arotinolol Hydrochloride|Arotinolol Hydrochloride, oral, 5-15mg, bid for 12 weeks.
1549376|NCT02602613|Device|AMEND Mitral Valve Repair System|Annuloplasty ring applied in a transcatheter method
1547988|NCT02612298|Drug|Metoprolol succinate sustained-release tablet|Metoprolol succinate sustained-release tablet,oral, 23.75-71.25mg, qd for 12 weeks.
1547989|NCT02612285|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total 11 doses) out of a 28-day treatment cycle
1547990|NCT02612272|Drug|Ketorolac|intra-articular ketorolac
1547991|NCT02612272|Drug|Betamethasone|intra-articular betamethasone
1547994|NCT02612246|Drug|GLPG1972 single ascending doses|single dose, oral solution
1547995|NCT02612246|Drug|Placebo single dose|single dose, oral solution, matching placebo
1547996|NCT02612246|Drug|GLPG1972 multiple ascending doses|multiple doses, daily for 14 days, oral solution
1547997|NCT02612246|Drug|Placebo multiple doses|multiple doses, daily for 14 days, oral solution
1547998|NCT02612233|Drug|Pregabalin or Duloxetine or Placebo|This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
1548001|NCT02612207|Device|Bilirubin Binding Capacity by hematofluorometry|
1548002|NCT02612194|Drug|Crizotinib|All arms will receive crizotinib.
1548003|NCT02612181|Drug|Dexmedetomidine for dexmedetomidine group|The effect of dex and placebo for sedation on microcirculation
1548004|NCT02612168|Device|Melanoma Image Analysis Algorithm (MIAA)|The images will be analysed by MIAA (Melanoma Image Analysis Algorithm). The MIAA result for PLs that are biopsied will be compared to the diagnosis made from the biopsy. The MIAA result for PLs not biopsied will be compared to clinician diagnosis.
1548005|NCT02612155|Biological|Infusion of autologous cord blood|Infants who meet study enrollment criteria will receive up to 2 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells.
1548006|NCT02612155|Biological|Placebo|Infants who meet study enrollment criteria will receive up to 2 placebo infusions composed of an equivalent volume (volume of product that would have been administered if the infant randomized to the intervention arm) of packed red blood cells (PRBCs) from the red cell compartment of the separated cord blood unit.
1548007|NCT02612142|Behavioral|physical exercise|endurance-training or stretching (sham exercise)
1548008|NCT02612129|Drug|arimoclomol|
1548009|NCT02612129|Drug|Placebo|
1548010|NCT02612116|Drug|Pulverized ticagrelor sublingually|Pulverized ticagrelor (180 mg) administered sublingually
1548011|NCT02612116|Drug|Pulverized ticagrelor orally|Pulverized ticagrelor (180 mg) administered orally
1548012|NCT02612116|Drug|Integral ticagrelor|Integral ticagrelor (180 mg) administered orally
1548013|NCT02612090|Dietary Supplement|Active Treatment Beverage|Strawberry
1548014|NCT02612090|Dietary Supplement|Placebo Treatment Beverage|Placebo
1548015|NCT02612077|Other|Observational Chemotherapy|No intervention - Observational standard practice chemotherapy
1548016|NCT02612077|Drug|Concomitant Bevacizumab|No intervention - Observational concomitant bevacizumab
1548017|NCT02612064|Device|Stannous Fluoride dentifice|Experimental dentifrice containing 0.454% w/w stannous fluoride (1100ppm)
1548018|NCT02612064|Other|Sodium Monofluorophosphate dentifrice|Dentifrice containing 0.76% sodium monofluorophosphate (1000ppm fluoride)
1548019|NCT02612051|Drug|GSK3008348 Nebuliser solution|Nebuliser solution formulated at 5000 mcg/mL with 5% mannitol, citric acid, sodium citrate and water for injection, pH adjusted using Hydrochloric acid or Sodium hydroxide to the target pH 5.4 +/- 0.4. 4 ml of diluted dose of appropriate concentration will be administered by nebulisation.
1548020|NCT02612051|Drug|Placebo Nebuliser solution|5% mannitol nebuliser solution. 4 ml of solution will be administered by nebulisation
1548021|NCT02612051|Radiation|GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion|Formulated in 0.9% saline. The maximum amount of radioactivity injected during each PET scan will be 150 Megabecquerel (MBq) and maximum mass of [18F]-FBA-A20FMDV2 administered across all three administrations will be 100 mcg. Intravenous bolus infusion of 20 ml will be administered over about 30 seconds.
1548022|NCT02612038|Device|Expiratory resistance|Generic expiratory resistance will be added to the patient's respiratory circuit
1548023|NCT02612038|Device|Sham expiratory resistance|Sham expiratory resistance will be added to the patient's respiratory circuit
1548024|NCT02612025|Behavioral|Exercise Training|Exercise training during intensive medical treatment. Training mainly composed of endurance and resistance exercises. 3 to 5 times per week for six weeks.
1548025|NCT02612012|Radiation|axillary radiotherapy|Whole breast irradiation and axillary level I-II areas radiotherapy. The prescription dose is 50Gy in 25 fractions in 5 weeks. Tumor bed boost is necessary with 10Gy in 5 fractions in one week.
1548026|NCT02611999|Behavioral|Single median price information|Physicians in this Arm received a single median price in the electronic medical record at the time of ordering in addition to the paper memo.
1548027|NCT02611999|Behavioral|Paired inside/outside price information|Physicians in this Arm received two prices (the inside and outside price) in the electronic medical record at the time of ordering in addition to the paper memo.
1548028|NCT02611986|Device|the McGrath MAC|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
1548029|NCT02611986|Device|the Macintosh Laryngoscope|in a randomised order we evaluate the success rate with the first attempt of the tracheal tube into the trachea.
1548030|NCT02611973|Other|Aspirin therapy interruption|Stop the treatment by aspirin 100mg/d in the experimental arm.
1548031|NCT02611973|Other|Usual treatment by aspirin 100 mg/d in the active comparator arm|HU+ aspirin maintenance
1550650|NCT02593487|Drug|Rosuvastatin 10mg/d group|rosuvastatin 10mg tablet,q.d. for 12 weeks.
1548032|NCT02611973|Other|No interruption of aspirin in the Observational arm|patient with Contre indication to aspirin or required antithrombotic therapy
1548033|NCT02611973|Drug|Hydroxyurea treatment (HU)|HU maintenance
1548034|NCT02611960|Biological|Pembrolizumab|IV infusion
1548035|NCT02611960|Drug|Capecitabine|oral tablet
1548036|NCT02611960|Drug|Gemcitabine|IV infusion
1548037|NCT02611960|Drug|Docetaxel|IV infusion
1548038|NCT02611947|Radiation|Low-dose chest CT scans|"Supine chest CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)
35 quality ref mAs with care-dose ON 120 kV Pitch 1.4 Rotation time 0.33 s Acquired images 64 x 0.6 mm"
1548039|NCT02611934|Procedure|Mild Therapeutic Hypothermia (MHT)|The induction with ice packs and infusion of 0.9% sodium chloride (NaCl) at the temperature of 4˚C. MHT will be maintained with a MTH-dedicated catheter introduced into the inferior vena cava through the femoral vein during PCI. MTH will be maintained for at least 12 hours at target temperature of 33˚C. The rewarming phase will be conducted in an actively controlled manner (0.3˚C per hour). The patient's core temperature will be independently measured in the urinary bladder as well as in the lower one third of the oesophagus using a dedicated catheter and tube. All patients treated with MTH will be mechanically ventilated with a concomitant continuous intravenous infusion of propofol and fentanyl for sedation and analgesia.
1548040|NCT02611921|Drug|Ketamine|Ketamine will be compounded into a mucosal atomization device and self-administered or administered with assistance of a caregiver/study coordinator
1548041|NCT02611921|Drug|Placebo|Placebo will delivered as an atomized saline spray which will be self-administered or administered with assistance of a caregiver/study coordinator
1548042|NCT02611908|Drug|ibrutinib|Cohort 1 420 mg PO daily Cohort 2 560 mg PO daily Cohort 3 700 mg PO daily Cohort 4 840 mg PO daily
1548043|NCT02611908|Drug|obinutuzumab|obinutuzumab 100 mg IV on day 1, 900mg IV on day 2, 1000mg IV day 8, 15, 28 then q 28 days for a total of 8 doses.
1548044|NCT02611895|Biological|HIV DNA|Quantitate the amount of HIV DNA harbored in the cytoplasm of peripheral blood CD4+ T cells
1548045|NCT02611882|Drug|Ga-68 labeled HBED-CC PSMA PET imaging|Patients will be imaged using Ga-68-HBED-CC-PSMA PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol.
1548046|NCT02611869|Procedure|Cryoballoon|Pulmonary vein isolation by cryoablation using a 2nd generation cryoballoon catheter
1548047|NCT02611869|Procedure|RF ablation|Pulmonary vein isolation by radiofrequency current ablation using a touch-force-sensing irrigated catheter
1548048|NCT02611843|Behavioral|Peer-Supported Web CBT|
1548049|NCT02611843|Behavioral|Self-Managed Web CBT|
1548057|NCT02611804|Drug|Diclofenac sodium|
1548058|NCT02611804|Drug|Diclofenac sodium|
1548059|NCT02611804|Drug|Placebo|
1548062|NCT02611778|Biological|ranibizumab|
1548063|NCT02611765|Drug|Benzathine penicillin G intramuscular 7.2 million units|Three doses of intramuscular 2.4 million units of benzathine penicillin G administered weekly (a total of 7.2 million units).
1548064|NCT02611765|Drug|Benzathine penicillin G intramuscular 2.4 million units|A single dose of intramuscular 2.4 million units of benzathine penicillin G
1548065|NCT02611752|Drug|CAM2038|CAM2038 subcutaneous injection
1548066|NCT02611739|Device|Medi-Port|Treatment
1548067|NCT02611739|Device|Medi-Port|Control
1548068|NCT02611726|Other|Acupuncture|Acupuncture
1548069|NCT02611700|Drug|Nimotuzumab|400mg,day1,weekly,until disease progression or toxicity
1548070|NCT02611700|Drug|Paclitaxel|175mg/m^2,for 3 hour(Peripherally Inserted Central Catheter,PICC),day1,21 days for a cycle ,until disease progression or toxicity，maximum duration is 6 cycles.
1548071|NCT02611700|Drug|Cisplatin|60mg/m^2,day1，21 days for a cycle ,until disease progression or toxicity,maximum duration is 6 cycles.
1548072|NCT02611700|Drug|Placebo|400mg,day1,weekly,until disease progression or toxicity
1548073|NCT02611687|Drug|pitolisant|Tablet
1548074|NCT02611687|Drug|Placebo|Tablet
1548075|NCT02611661|Device|PET/MRI|
1548076|NCT02611661|Radiation|Percutaneous microwave ablation|
1548077|NCT02611661|Radiation|Stereotactic body radiotherapy|
1548078|NCT02611648|Other|Double HLD|Standard high level disinfectant (metricide ortho-phthalaldehyde) with an additional exposure time to disinfect
1548079|NCT02611648|Other|HLD/ETO|Standard high level disinfectant (metricide ortho-phthalaldehyde) followed by ethylene oxide
1548080|NCT02611635|Drug|VKA: Warfarin (Waran)|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1996183|NCT02542605|Drug|AMG 334|AMG 334 Investigational Product
1996184|NCT02542605|Drug|Placebo|Placebo Comparator
1996185|NCT02542605|Drug|PACAP-38 Challenge Agent|PACAP-38 challenge agent
1548081|NCT02611635|Drug|NOAC: Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1548082|NCT02611635|Drug|NOAC: Dabigatran etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1548083|NCT02611635|Drug|NOAC: Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1548084|NCT02611635|Drug|NOAC: Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1548085|NCT02611635|Drug|NOAC: Lixiana|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1548086|NCT02611622|Behavioral|LUMA ENT™|
1548087|NCT02611622|Other|Survey|Demographic and Patient Satisfaction Survey
1548088|NCT02611609|Biological|MultiStem|
1548089|NCT02611609|Biological|MultiStem|
1548090|NCT02611609|Biological|Placebo|
1548091|NCT02611596|Drug|Ranolazine|24 weeks of the assigned medication
1548092|NCT02611596|Drug|Placebo|Placebo for 24 weeks
1548093|NCT02611583|Device|TENS|Transcutaneous Electrical Nerve Stimulation
1548094|NCT02611557|Procedure|Manual lymphatic drainage therapy|Patients will undergo a 50 min manual lymphatic drainage (MLD) therapy session by a certified lymphedema therapist. MLD therapy is performed routinely for standard of care in these patients and consists of light massage to facilitate lymphatic fluid mobility.
1548095|NCT02611544|Behavioral|Acceptance and Commitment Therapy|6-week ACT intervention group (n=33)
1548096|NCT02611544|Behavioral|Survivorship Education|6-week survivorship education group (SE; n=32)
1548097|NCT02611544|Behavioral|Enhanced Usual Care|enhanced usual care (EUC; n=26)
1548098|NCT02611531|Behavioral|Video Module Education (VME)|Participants will complete inhaler education on a tablet device
1548099|NCT02611531|Behavioral|Teach-To-Goal (TTG)|Participants will complete intensive in-person inhaler education
1548100|NCT02611518|Drug|Rosuvastatin|Rosuvastatin will be administered as a single oral 10 milligram (mg) dose on Day 1 and Day 14.
1548101|NCT02611518|Drug|JNJ-54861911|JNJ-54861911 will be administered at a dose of 25 mg once daily from Day 8 to Day 17 (in panel 1), Day 8 to 16 (in panel 2).
1548102|NCT02611518|Drug|Metformin|Metformin will be administered as a single oral 500 mg on Day 1 and Day 14.
1548103|NCT02611505|Drug|Esketamine|Esketamine 28 mg will be self-administered by participants as intranasal spray at 0 hour (h) on Day 1.
1548104|NCT02611492|Drug|Nilotinib|400 mg/12h per os D1 to D28 cycles 1-4 300 mg/12h per os D1-D14 interphase
1548105|NCT02611492|Drug|Methotrexate|1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
1548106|NCT02611492|Drug|Aracytine (Ara C)|Age<45 years: 3 mg/m2/12h D2, D3 cycles 2 and 4 Age>=45 years: 1.5 mg/m2/12h D2, D3 cycles 2 and 4
1548107|NCT02611492|Drug|Granulocyte Colony-Stimulating Factor (G-CSF)|5µg/kg/d (SC) D6 until neutrophils > 1 G/L D15 cycles 1 and 3; D6 cycles 2 and 4
1548108|NCT02611492|Drug|Depomedrol|40 mg + methotrexate 15 mg + Aracytine (AraC) 40mg IT cycle 1: D1, D8, D15 IT cycles 2 and 4: D9 IT cycle 3: D1
1548109|NCT02611492|Drug|Dexamethasone|40 mg per os, D1-D2, D8-D9, D15-D16, D22-D23, cycles 1 and 3
1548110|NCT02611492|Drug|Vincristine|2 mg total dose IV, D1 D8 D15 D22 cycles 1 and 3
1548111|NCT02611492|Drug|Imatinib|300 mg/12h per os in post-SCT maintenance therapy for during at least 2 years
1548112|NCT02611492|Drug|6 Mercaptopurine (6MP)|60 mg/m2 per os, D1 to D14, interphase
1996186|NCT02540889|Behavioral|Auditory comprehension therapy.|100 hours of Auditory comprehension therapy embedded within a computer game.
1996187|NCT02541903|Drug|Gilotrif|Patients will take a single oral dose of Gilotrif each day starting at 40 mg. Dose escalation and reductions can occur.
1996188|NCT02541565|Drug|Cyclophosphamide|Given IV
1548116|NCT02611453|Other|"Air contrast cholangiography using carbon dioxide gas"|Carbon dioxide (CO2) will be injected into the biliary tree (which is already exposed to CO2 during routine ERCP) and images will be obtained by using fluoroscopy and digital subtraction imaging (a specific setting on certain fluoroscopy tables).
1548117|NCT02611440|Behavioral|Pharmaceutical care|"Initial interview with pharmacist (at the hospital discharge): Evaluation aimed to identify barriers to adherence to drug treatment followed by an information session on the disease, the benefit of drugs and the importance of diet and lifestyle habits. Pharmacist advices focused on how to take medication and how to manage adverse events will be provided.
Telephone interviews with hospital clinical pharmacist - patient (at M3 M6 and M9): The objective is to review with the patient its medication-taking routine and its potential difficulties, to motivate adherence to treatment and lifestyle/dietary rules, to give advices about therapeutics and how to take medication.
HCP contacts CP to determine the prescription refill. Final interview with HCP pharmacist (at M12): The objective is to take stock with the patient about its taking drug load."
1996189|NCT02541565|Drug|Doxorubicin Hydrochloride|Given IV
1548120|NCT02611414|Device|anodal tDCS|tDCS anodal stimulation over M1 area applied for 20 minutes at five consecutive days.
1548121|NCT02611414|Device|Sham tDCS|tDCS sham stimulation over M1 applied for 20 minutes (with current turned off at 30 seconds) at five consecutive days.
1548122|NCT02611401|Behavioral|Mindfulness|"The MBI is based on MBSR protocol but in order to maximize the clinical utility in people with MS suffering from depressive symptoms, we will tailor mindfulness intervention on the needs of this specific population. We will apply a modified MBSR protocol integrated with techniques from Sensorimotor Psychotherapy.
The MBI comprises an 8-week group program. Participants will took part in a 3 hour single weekly sessions, and there will be also an additional all-day session of 7 hours. Each session will cover specific exercises and topics within the context of mindfulness practice and training. Participants will be required to carry out daily 45-min homework assignments, which consist on mindfulness exercises and mindfulness applications in everyday life."
1548123|NCT02611401|Behavioral|Psychoeducation|"The control group is designed to control for the nonspecific elements of the MBI treatment. It will be based on a psycho-educational framework and will include some relaxation techniques. In each session is discussed a MS-related topic. Relaxation and gentle stretching exercises will be proposed at the end of each session. Homework and the material (photocopies, slides, etc.) discussed in group sessions is left to each participant to encourage participants to practice exercises between sessions.
This intervention will follow the same structure and weekly format of the MBI intervention. The only difference will be the absence of an all-day session."
1548124|NCT02611388|Device|TEAS (transcutaneous electrical acupoint stimulation)|2/10HZ Electric stimulation was given through electrode attached to specific acupoints
1548125|NCT02611388|Device|TEAS (transcutaneous electrical acupoint stimulation)|10/50HZ Electric stimulation was given through electrode attached to specific acupoints
1548126|NCT02611388|Device|fake stimulation|Patients were only attached electrodes without electric current
1548127|NCT02611375|Device|transcranial direct current stimulation|High-definition transcranial direct current stimulation is applied over the hand area of the primary motor cortex (M1). Parameters= 2mA for 20 minutes. Functional task practice will be completed concurrently with tDCS and for approximate 40 minutes after the stimulation stops.
1548128|NCT02611375|Device|peripheral nerve somatosensory stimulation|"Electrical stimulation will be applied to the median nerve of the primary hand being trained at parameters that elicit a sensory but not motor response (called peripheral nerve somatosensory stimulation). Stimulation parameters are 100Hz with a 250uS pulse width. Stimulation intensity will vary between 1-10mA per participant. Stimulation will be applied for 1 hour and functional task practice will be completed concurrent with the stimulation."
1548129|NCT02611375|Other|sham transcranial direct current stimulation|During sham transcranial direct current stimulation (tDCS), a sham tDCS device will be used along with functional task practice. The sham tDCS unit will be used for the first 20 minutes of FTP, followed by an additional 40 minutes of FTP.
1548130|NCT02611362|Behavioral|IMB Gaming Intervention|
1548131|NCT02611336|Drug|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
1548132|NCT02611323|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 1000 mg via IV infusion on Day 1 of every other month (starting from Month 2) for up to 24 months, until disease progression or unacceptable toxicity.
1548133|NCT02611323|Drug|Rituximab|Participants will receive a fixed dose of rituximab, 375 milligrams per square meter (mg/m^2) via IV infusion to be given on Day 1 of Cycles 1 to 6. Cycle length will be 21 days. For eligible participants, post-induction treatment may be given at a dose of 375 mg/m^2 via IV infusion on Day 1 of every other month (starting from Month 2) for up to 8 months, until disease progression or unacceptable toxicity.
1548134|NCT02611323|Drug|Polatuzumab Vedotin|Participants will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) (for FL), and 1.8 mg/kg (for DLBCL) on Day 1 of each 21-day cycle for up to 18 weeks during induction treatment. Polatuzumab vedotin will not be given during the post-induction period.
1548135|NCT02611323|Drug|Venetoclax|Participants will receive venetoclax film-coated tablets at doses of 200, 400, 600, or 800 mg (for FL), and 400, 600, or 800 mg (for DLBCL) on Days 1 to 21 of each 21-day cycle. Post-induction venetoclax may continue for up to 8 months, until disease progression or unacceptable toxicity.
1548137|NCT02611297|Procedure|Cryoprobe|
1548138|NCT02611284|Procedure|LISA|All infants were supported with nCPAP while breathing spontaneously during instillation. A 5Frenchgamma sterilized multi-access catheter specifically designed to deliver surfactants for Neonates was placed 1-2 cm below the vocal cords by direct laryngoscopy without the use of a Magill forceps. Beractant was used as exogenous natural surfactant, (100mg/kg; 4ml/kg) and administered in two aliquots during 1-3 minutes. Positive pressure inflations were given by a mask and bag only if the infant was apneic or bradycardia develops despite the interruption of the procedure. The surfactant administration catheter was removed after surfactant instillation and nCPAP support was maintained. A second dose of surfactant was administered during the first 3 days of life if more than 40% of FiO2 was needed while on nCPAP with at least 6 cm H2O pressure.
1548166|NCT02611154|Drug|Testosterone|Participants will self-administer 11 mg 3x daily, for 5 consecutive days for 4 weeks.
1548201|NCT02610881|Dietary Supplement|Micronutrient Powders (MNP)|"One sachet of micronutrient powder will be mixed into food to be taken once daily for a total of one month. One sachet of micronutrient powders includes the following:
Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin Base"
1548202|NCT02610881|Behavioral|Iron Plus Strategy Counseling|Mothers of participants will receive counseling on the benefits of regular iron intake, side effects associated with IFA administration, and the preservation of the IFA bottle and MNP sachets.
1548139|NCT02611284|Procedure|INSURE|"The INSURE technique was performed using Beractant (4ml/kg) after endotracheal intubation. A multi-access catheter for Neonates/Pediatrics designed to deliver surfactants (KimVentTrach Care Technology ®, United Kingdom) was pre-connected to the endotracheal tube and used for surfactant administration without having to disconnect the ventilator. While surfactant was administered all infants were connected to pressure support ventilation modality (PSV) combined with volume guarantee (VG), Dräger ventilator). A tidal volume of 4ml/kg was initially adjusted.
After surfactant administration, all infants were to be extubated, in accordance with our institutional extubation guidelines, if FiO2< 0.35; for a target Oxygen Saturation (SpO2) of >90%, and if a consistent respiratory effort was present. Extubation was supported with nCPAP in all patients."
1548140|NCT02611271|Other|Monitoring of antibiotic drug removal|No study specific intervention will be performed
1548141|NCT02611258|Drug|Tadalafil|Tadalafil 20 mg to be taken orally once daily, for 5 months
1548142|NCT02611245|Drug|Indocyanine green|This group of patients accepted intravenous injection from 0.5mg / kg to 5mg / kg ICG within 4 to 24 hours before surgery. All patients under general anesthesia to accept conventional thoracoscopy or thoracotomy. After entering the chest using fluorescence thoracoscopy system to collect the fluorescence and white-light images and record the video. After following the routine preoperative planning surgery, the researchers will carefully assess the possibility of the benign and malignant nodules and to communicate with the families of patients. If the patient's family expressed their willingness to dissect the nodules, the researchers will remove this extra pulmonary nodules. Resected specimens will send to routine pathological confirmation compared with the fluorescence results.
1548145|NCT02611219|Other|General Health Module-Baseline Adolescent-Self Report (13-18 years)|"38 question questionnaire
Answers range from 1=all of the time to 5=none of the time"
1548146|NCT02611219|Other|General Health Module-Follow Up Adolescent-Self Report (13-18 years)|"38 question questionnaire about child
Answers range from 1=all of the time to 5=none of the time"
1548147|NCT02611219|Other|General Health Module-Baseline Parent Report-Adolescent (13-18 years)|"38 question questionnaire about child
49 question questionnaire about parent
Answers range from 1-all of the time to 5=none of the time"
1548148|NCT02611219|Other|General Health Module-Follow Up Parent Report-Adolescent (13-18 years)|"38 question questionnaire about child
49 question questionnaire about parent
Answers range from 1-all of the time to 5=none of the time"
1548149|NCT02611219|Other|General Health Module-Baseline Parent Report-School Age (5-12 years)|"34 question questionnaire about child
49 question questionnaire about parent
Answers range from 1-all of the time to 5=none of the time"
1548150|NCT02611219|Other|General Health Module-Follow Up Parent Report-School Age (5-12 years)|"34 question questionnaire about child
49 question questionnaire about parent
Answers range from 1-all of the time to 5=none of the time"
1548151|NCT02611219|Other|Demographic Data Form|-16 questions about demographics such as household income, race, and gender
1548152|NCT02611219|Other|SCT Daily Activity Log|"Uses Fitbit Flex
Log that lists time in 15 minute increments and allows for checking when out of bed and describing the activity that occurred while out of bed"
1548153|NCT02611219|Other|The Functional Independence Measure for Children|"18-item, 7-level ordinal scale instrument that measures a child's consistent performance in essential daily functional skills. Three main domains (selfcare, mobility, and cognition) are assessed by interviewing or by observing a child's performance of a task to criterion standards
Categorized into 2 main functional streams: Dependent (ie, requires helper: scores 1-5) and Independent (ie, requires no helper: scores 6-7). Scores 1 (total assistance) and 2 (maximal assistance) belongs to the Complete Dependence category. Scores 3 (moderate assistance), 4 (minimal contact assistance), and 5 (supervision or set-up) belongs to the Modified Dependence category. Scores 6 (modified independence) and 7 (complete independence) belongs to the Independent category."
1548154|NCT02611219|Other|Manual Muscle Testing|"-Isometric muscle strength is tested in specific positions, usually with the muscle at an optimal working length. Using a break test, the test giver overpowers the muscle being tested to determine the muscle grade."
1548155|NCT02611219|Other|3-Minute Step Test|"Using an aerobic step, the participant walks up and down for a given amount of time with the heart rate being checked before and after
Using the difference in heart rate and a shortness of breath scale, this test is able to give an estimate of aerobic tolerance"
1548156|NCT02611219|Other|HSCT Module-Follow Up Adolescent-Self Report (13-18 years)|"7 question questionnaire about child
Answers range from 1=all of the time to 5=none of the time"
1548157|NCT02611219|Other|HSCT Module-Follow Child-Self Report (5-12 years)|"10 question questionnaire about child
Answers range from 1=all of the time to 5=none of the time"
1548158|NCT02611219|Other|HSCT Module-Follow Up Parent Report-adolescent (13-18 years)|"7 question questionnaire about child
49 question questionnaire about parent
Answers range from 1=all of the time to 5=none of the time"
1548159|NCT02611219|Other|HSCT Module-Follow Up Parent Report-School Age (5-12 years)|"7 question questionnaire about child
49 question questionnaire about parent
Answers range from 1=all of the time to 5=none of the time"
1548160|NCT02611206|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS applies a pulsatile magnetic field to the scalp which painlessly induces electrical currents to the brain. Typically, rTMS is applied to the dorsolateral prefrontal cortex (DLPFC), a brain region that is hypoactive in depression. Whereas standard rTMS stimulates superficial (1cm depth) cortical areas, recent advances in rTMS coil technology support stimulation of deeper (5 cm depth) limbic structures that are also relevant to depression.
1548161|NCT02611193|Procedure|Manipulative treatment|Manipulative treatment as described by the GBMOIM (Grupo Barcelona de Medicina Ortopédica y Manual) will be perform with extension of the transverse carpal ligament maneuver and fascia release maneuver
1548162|NCT02611193|Procedure|Simulated manipulative treatment|Simulated Manipulative Treatment
1548163|NCT02611180|Procedure|Skin punch biopsy|
1548164|NCT02611180|Procedure|Peripheral blood draw|
1548240|NCT02610530|Other|Medical Treatment|Conventional Non-Surgical Treatment for Glycemic Control group consisted of patients who did not undergo any kind of surgery, and are on medical treatment for type 2 diabetes.
1548167|NCT02611141|Procedure|Retromolar laryngoscopy and scoring of the visualisation of the vocal cords according to Cormack & Lehane|"To facilitate the insertion of the straight blade laryngoscope (Miller #4) the head of the patient will be turned to the left side. The blade will be inserted and then pushed laterally rightwards until the retromolar space will be finally reached. Thereafter the epiglottis will be lifted up in order to achieve the best direct view to the vocal cords and scored according to Cormack & Lehane .
This score will be assessed at least 2 minutes after muscle relaxation:
Once without a backward, upward, rightwards pressure maneuver (=BURB) and immediately thereafter (i.e. 5-10 seconds later):
If 100% visualization of the vocal cords is not possible a BURP maneuver will be performed and the scored again.
Intubation will then be performed by the conventional method using a Macintosh blade #3. In the case that intubation with the conventional method is not successful the retromolar technique will be used."
1548168|NCT02611128|Other|Phenotype/genotype assessment|The investigators will perform careful phenotyping in addition to hormonal assessments and assessments of DENND1A
1548169|NCT02611102|Dietary Supplement|MCT oil + Butter in Coffee|2 tablespoons medium-chain triglyceride oil + 2 tablespoons butter added to 2-4 cups of coffee similar to their usual intake prior to 1200 daily over a 4 week period after a 2 week run-in phase during which the doses of butter and MCT oil will be titrated up (1 Tbsp. of each butter + MCT x 5 days, 2 Tbsp. butter + 1 Tbsp. MCT x 5 days, then 2 Tbsp. of each x 4 days) followed by 6 weeks of washout without treatment.
1548170|NCT02611089|Procedure|Tissue biopsy|Sampling of tissue as described.
1548171|NCT02611076|Behavioral|Stop Smoking for Good Intervention in Spanish (SS-SP)|Assessments will occur at six-month intervals, through 24 months.
1548172|NCT02611076|Behavioral|Usual care (UC)|Assessments will occur at six-month intervals, through 24 months.
1548173|NCT02611063|Drug|fostamatinib|100mg qd, 150mg qd, or 100mg bid
1548174|NCT02611050|Behavioral|The Multi-vessel Coronary Artery Disease Option Grid|The Multi-vessel Coronary Artery Disease Option Grid is a patient decision aid used during the clinical visit. It is one page and contains a table a patient's frequently asked questions and the respective information for each treatment strategy. The Multi-vessel Coronary Artery Disease Option Grid was developed using patient and provider feedback and has been field-tested in clinic by cardiologists and surgeons.
1548175|NCT02611050|Behavioral|Usual Care|In usual care clinicians will discuss the patient diagnosis and treatment options typical to routine care for that clinician.
1548176|NCT02611037|Drug|Cisplatin|The recommended dose of cisplatin for transarterial chemoperfusion in this study is 35 mg/m^2 body surface area (BSA). During the lead in phase of the study, 3 patients will be treated with regular doses of cisplatin.
1548177|NCT02611037|Drug|Methotrexate|The recommended dose of methotrexate for transarterial chemoperfusion in this study is 100 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with 50% reduced dose of methotrexate (50 mg/m^2).
1548178|NCT02611037|Drug|Gemcitabine|The recommended dose of gemcitabine for transarterial chemoperfusion in this study is 1000 mg/m^2 BSA. During the lead in phase of the study, 3 patients will be treated with regular doses of gemcitabine.
1548179|NCT02611037|Other|Lung Cancer Symptom Scale for Mesothelioma Questionnaire|Quality of life will be assessed using the modified version of the Lung Cancer Symptom Scale for Mesothelioma questionnaire.
1548180|NCT02611024|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) 4mg vials
1548181|NCT02611024|Drug|Irinotecan|irinotecan 40 mg, 100 mg or 300 mg vials
1548182|NCT02611011|Device|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
1548183|NCT02610985|Device|3-D laparoscopy|3-D laparoscopy
1548184|NCT02610985|Device|2-D laparoscopy|2-D laparoscopy
1548185|NCT02610972|Device|Congo Red test GV-005|Congo Red test GV-005 test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
1548186|NCT02610959|Other|Intervention group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
1548187|NCT02610959|Other|Control group|The overall aim of the present project is to investigate if intake of cod in pregnancy has impact on infant development up to 12 month.
1548188|NCT02610946|Behavioral|Electronic application|Electronic application (app) based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
1548189|NCT02610946|Behavioral|Paper-based|Paper-based intervention to improve adolescent compliance with transplant care and readiness to transition to adult care.
1548190|NCT02610933|Drug|rivaroxaban|replacement of vitamin K antagonist by rivaroxaban
1548191|NCT02610933|Dietary Supplement|Vitamin K2|Vitamin K2 supplementation
1548192|NCT02610920|Procedure|Iron-tracer guided axillary ultrasound and biopsy|After ultrasound identifying sentinel lymph nodes, no more than two nodes will be core-needle biopsied and sent to pathology department for analysis of cancer involvement. The biopsied node(s) will be marked for later identification for the surgeons during the regularly scheduled intraoperative sentinel lymph node biopsy (standard of care).
1548193|NCT02610920|Drug|Iron tracer|All participants will receive a 30mg injection of subcutaneous iron sucrose into the breast followed by an axillary ultrasound looking for lymph nodes with enhanced reflexivity.
1548194|NCT02610907|Other|Buffer|The sleeve contains phosphate buffered saline buffer
1548195|NCT02610907|Other|Own output|The sleeve contains the subject own ileal effluent
1548196|NCT02610907|Other|simulated output|The sleeve contains simulated output
1548197|NCT02610894|Other|As usual with the Postoperative Care at Home mHealth application (PoCAH)|MHealth app, Postop Care at Home, is a theory based, patient-centered, and tailored self-management program delivered via mHealth technology (application on iPad mini) to orthopaedic ambulatory surgery patients.
1548198|NCT02610894|Other|As usual standard discharge and care instructions|As usual standard discharge and care instructions are provided via iPad mini to orthopaedic ambulatory surgery patients.
1548199|NCT02610894|Device|iPad mini|
1548200|NCT02610881|Dietary Supplement|Iron and Folic Acid (IFA)|1 mg of IFA syrup (containing 20 mg of elemental iron and 100 mcg of folic acid) will be taken twice per week for one month.
1548352|NCT02609685|Other|Active Surveillance|Subjects will be actively observed for disease progression (condition worsens) instead of receiving immediate surgery, considered standard of care.
1548204|NCT02610855|Procedure|Spinal Fusion Surgery|Participants with severe scoliosis curves requiring spinal fusion surgery.
1548205|NCT02610855|Other|Bracing|Participants with scoliosis curves that require brace treatment for at least the next year. Braces include monitors to record hours of brace wear, as is current standard of care.
1548206|NCT02610855|Device|Tri-axial Accelerometers|Four monitors are place on the participant (waist, thigh, both ankles), attached with straps. Periods of static and dynamic activity are measured based on accelerations in three orthogonal directions for 4 day's time while participating in regular daily activities.
1548207|NCT02610855|Other|Shear Wave Elastography (SWUE)|SWUE is an ultrasound technique for noninvasively evaluating the mechanical properties (stiffness) of skeletal muscle tissue. A commercial ultrasound scanner (Aixplorer from Supersonic Imagine, France) with 2D real time SWUE will be used. The Aixplorer uses ultrasonic push beams to produce shear waves in tissue. The shear wave propagation speed is inherently related to tissue mechanical properties and is used to create a quantitative 2D elastogram of the tissue.
1996190|NCT02541565|Other|Laboratory Biomarker Analysis|Correlative studies
1548209|NCT02610829|Dietary Supplement|Gamma tocopherol|3 doses of 1400 mg gamma tocopherol (2 capsules, each is 700mg), at 12 hour intervals
1548210|NCT02610816|Other|elimination diet therapy|"1FED: milk elimination 4FED: milk, egg, wheat, and soy elimination
Other Names:
1FED
4FED"
1548211|NCT02610816|Drug|Flovent (fluticasone propionate)|"Drug: Flovent
Flovent (fluticasone propionate): swallowed glucocorticoid
Other Names:
•fluticasone propionate"
1996191|NCT02541565|Biological|Pembrolizumab|Given IV
1996192|NCT02541565|Drug|Prednisone|Given PO
1548214|NCT02610764|Procedure|Blood Test for CTC evaluation|
1548215|NCT02610738|Behavioral|Junior KICk-OFF education programme|The Junior KICk-OFF course is an age appropriate eduction course which aims to improve the understanding and knowledge of children with type 1 diabetes. It has been designed with school teachers and educationalists to meet the learning needs of children aged 4-11yrs
1548216|NCT02610725|Other|Hatha yoga|Participants will be shown a 30 minute video of a yoga class that they will be invited to follow along with.
1548217|NCT02610712|Drug|Ketamine|
1548218|NCT02610699|Other|Conventional otoscope|The conventional analogue otoscope will be used to provide a two-dimensional view of the ear canal. Clinicians will use this for one month periods for a total of 3 months.
1548219|NCT02610699|Other|Smartphone otoscope|The smartphone otoscope is a pocket size smartphone attachment that uses technology and light source of a smartphone to capture reproducible images of the middle ear and tympanic membrane. Images and videos can be transmitted via real-time communication software from the device to another smartphone. Clinicians will use this for one month periods for a total of 3 months.
1548220|NCT02610686|Drug|Chloroquine|efficacy of chloroquine for the treatment of Plasmodium vivax infections
1548221|NCT02610673|Device|WiCS-LV System|Implant of left ventricular receiver-electrode and ultrasound transmitter.
1548222|NCT02610647|Drug|Wrist anesthesia|Prior to the tapping test, regional anesthesia is performed in the form of sensory blocks distal to the wrist: injection of ropivacaine 7.5mg / ml is carried out successively in contact with three nerves (ulnar, median and radial) with a volume of 2 ml for nerve, for a total of 45mg.
1548223|NCT02610647|Other|Blinding mask|Patients will don a mask that prevents them from seeing during the tapping test.
1548224|NCT02610647|Other|Anti-noise helmet|Patients will don a helmet that prevents them from hearing during the tapping test.
1548225|NCT02610647|Other|Tapping test|"Subjects will be placed at a table in a sitting position where they will perform a rhythmic finger tapping test. The seat height is adjusted so that the front dominant arm rests comfortably on the table. Subjects will be equipped with headphones to receive auditory signals during a first synchronized phase of tapping.
After the last auditory signal, participants will continue the tapping task by themselves as directed: after the metronome stops,continue tapping the prescribed tempo as accurately and consistently as possible throughout the test. The movements of the index finger will be measured by a single-axis accelerometer (15 × 15 mm) attached to the nail."
1548226|NCT02610621|Procedure|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
1548227|NCT02610608|Other|ovarian stimulation|evaluation of clincal practice regarding prevention of arterial and venous thrombosis following ovarian stimulation
1548228|NCT02610595|Drug|Jianpixiaozhong particles and Wuse Dietotherapy|Jianpixiaozhong particles: Three packs once,bid po; Wuse Dietotherapy: one packs once,bid po
1548229|NCT02610582|Drug|rAAV.hCNGA3|Single subretinal injection of rAAV.hCNGA3
1548230|NCT02610569|Device|standard endoscopy|standard endoscopy will be either colonoscopy or rectosigmoidoscopy
1548231|NCT02610569|Device|PillCamCOLON (C2)|PillCamCOLON (C2) is a colon video-capsule
1548232|NCT02610556|Drug|Cisplatin 2|Cisplatin 100 mg/m2, D1 every 3 weeks for 3 cycles
1548233|NCT02610556|Drug|Docetaxel|Docetaxel 60 mg/m2, D1 every 3 weeks for 3 cycles
1548234|NCT02610556|Drug|Cisplatin 1|Cisplatin 25 mg/m2, D1-3 every 3 weeks for 3 cycles
1548235|NCT02610556|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
1548238|NCT02610530|Procedure|Sleeve Gastrectomy with Ileal Transposition|Type 2 diabetic patients who underwent ileal transposition surgery within the last 2 years.
1548239|NCT02610530|Procedure|Sleeve Gastrectomy with Transit Bipartition|Type 2 diabetic patients who underwent transit bipartition surgery within the last 2 years.
1552285|NCT02582073|Biological|Grass MATA (0.5ml) 5100SU|
1996193|NCT02541565|Biological|Rituximab|Given IV
1996194|NCT02541565|Drug|Vincristine Sulfate|Given IV
1996195|NCT02541955|Drug|Acthar|Injections will be self administered
1996196|NCT02539875|Behavioral|AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices|Use AWARD and brief leaflet/ Referral leaflet and active referral/ Smoking cessation booklet and general advices interventions to achieve smoking abstinence
1548241|NCT02610517|Behavioral|Provider Training|All providers will receive an online survey about alcohol pharmacotherapy, and an on-site training on alcohol pharmacotherapy will be offered at UAB and UW. The training will cover the most commonly prescribed alcohol pharmacotherapy. Some medications (ex: Zofran) have been used clinically for alcohol pharmacotherapy but have not yet received FDA approval for this indication. Research has shown these medications are beneficial as alcohol pharmacotherapy and are more frequently used by doctors due to the more favorable side effects. Providers in this study will use their clinical judgment in prescribing alcohol medications per their normal standard of care and using any new information gained from the alcohol pharmacotherapy training.
1548242|NCT02610517|Behavioral|Patient Intervention|Eligible participants will be screened using the Audit and Mini instruments that are routinely asked during regular clinic visits. Once a participant consents, they will be shown 2 computerized brief interventions (CBIs) - one after enrollment (visit 1) and one 3-6 months after enrollment (visit 2). Participants will interact with the touch-screen computer via Peedy the Parrot, a three dimensional animated character. The intervention emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. At the end of both visits, patients will complete a patient satisfaction survey with questions related to ease of use of CBI and satisfaction with program content. Providers will have the opportunity to prescribe pharmacotherapy at visit 1 and 2.
1548243|NCT02610504|Device|Durolane|single injection of 3ml
1548244|NCT02610491|Dietary Supplement|Hesperidin|Citrus peel extract
1548245|NCT02610491|Dietary Supplement|Placebo|Cellulose
1548248|NCT02610452|Other|Clown therapy|"The clowns intervene by twos: a game takes place.
The game requires the active presence of a number of potential players in the room (patient, family, caregivers) and takes into account body position, emotional state, the general atmosphere.
The clowns initiate a game proposal: provisional staging of clown characters based on imagination/improvisation which engages a physicality and a basic emotional state.
The original game proposal is adjusted according to mutual empathy with those present.
The game is developed on the model of theatrical improvisation: an original creation that has scenic quality comparable to that of a complete representation. Improvisation time varies depending on the condition of the person, his/her desire to participate, choosing the main theme.
The final stage of the game is preparing all actors for separation: restitution of roles, revisiting the paths traveled."
1548252|NCT02610400|Combination Product|RACD|"Active malaria surveillance using rapid diagnostic test in households around passively-detected index case. RDT-positive subjects are treated per national policy, under which combination medication artemether-lumefantrine is first-line, using dosing (mg artemether / mg lumefantrine):
(i) 5-14kg patient: 20/120mg twice (8 hr apart) on day 1, 20/120mg twice (12 hr apart) on each of days 2 and 3 then stop (ii) 15-24kg patient: 40/240mg twice (8 hrs apart) on day 1, 40/240mg twice (12 hrs apart) on each of days 2 and 3 then stop (iii) 25-34kg patient: 60/360mg twice (8 hrs apart) on day 1, 60/360mg twice (12 hrs apart) on each of days 2 and 3 then stop (iv) > 34kg patient: 80/480mg twice (8 hrs apart) on day 1, 80/480mg twice (12 hrs apart) on each of days 2 and 3, then stop"
1548253|NCT02610400|Combination Product|RAVC|Focal, targeted indoor spraying with long-lasting insecticide pirimiphos-methyl or Actellic 300 CS, a World Health Organization (WHO)-approved organophosphate. Safety measures: (i) seeking advance permission to spray; (ii) temporarily removing items (utensils, water, food, pets) from the building during spray; (iii) covering all unremovable items; (iv) asking inhabitants to temporarily relocate outdoors during spray; (v) advising children remain outdoors until floors washed; and (vi) avoiding of spraying of any rooms that contain inhabitants, animals, or incorrectly removed/covered items. Actellic will be applied according to National Vector-borne Disease Control Program (NVDCP) indoor residual spraying (IRS) guidelines, using a Hudson X-pert sprayer (Hudson Manufacturing Co., Chicago, USA) at 40 mL/m-sq.
1548254|NCT02610400|Combination Product|TPE|"Presumptive treatment, using the medication A-L, of the inhabitants of households surrounding a passively-detected index case, without incorporating a diagnostic test step. The investigators will administer A-L with dosing as follows (mg artemether / mg lumefantrine):
(i) 5-14kg patient: 20/120mg twice (8 hours apart) on day 1, 20/120mg twice (12 hours apart) on each of days 2 and 3, then stop (ii) 15-24kg patient: 40/240mg twice (8 hours apart) on day 1, 40/240mg twice (12 hours apart) on each of days 2 and 3, then stop (iii) 25-34kg patient: 60/360mg twice (8 hours apart) on day 1, 60/360mg twice (12 hours apart) on each of days 2 and 3, then stop (iv) > 34kg patient: 80/480mg twice (8 hours apart) on day 1, 80/480mg twice (12 hours apart) on each of days 2 and 3, then stop"
1548255|NCT02610387|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation for 20 minutes plus balance training for 20 minutes for 5 consecutive days.
1548256|NCT02610387|Device|Sham tDCS|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation plus balance training for 20 minutes for 5 consecutive days.
1548257|NCT02610374|Other|Agrarian Diet|A diet higher in carbohydrates and lower in fats and sugars
1548258|NCT02610374|Other|Western-type Diet|A diet higher in fats and lower in carbohydrates
1548259|NCT02610361|Drug|BGB-283|In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
1548260|NCT02610348|Biological|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
1548261|NCT02610348|Biological|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|Original Vaccine in Study A3L12 (NCT00401531). No vaccination will be administered as part of this study
1548473|NCT02608944|Drug|O-15 labeled radioactive water|O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
1548262|NCT02610335|Other|Control group (C)|"kyphosis reeducation on Huber platform during 2 weeks,
patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),
flexibility exercises, stretching exercises and abdominal muscles exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),
exercises on cycle ergometer or walking on treadmill : to continue at home."
1548263|NCT02610335|Other|Test group|"spinal mobility reeducation on Huber platform during 2 weeks,
patient education : on physiopathology of the lumbar spinal stenosis and treatments as well as healthy lifestyle and prevention (plans of anatomy, plastic column, slides of medical imaging),
flexibility exercises and mobilization exercises : to continue at home (the exercises will be reported on a book that will be given to the patient),
exercises on cycle ergometer or walking on treadmill : to continue at home."
1548264|NCT02610322|Behavioral|Whole soy replacement diet|Participants who are allocated to Whole soy group will receive a 30~40 min counseling session by an experienced nutritionist on: 1) conventional lifestyle education on metabolic syndrome (MetS); 2) The benefits of whole soy diet; 2) Practical techniques to incorporate of 4 servings of whole soy foods (equivalent to 25g soy protein) into their daily diet and reduce high saturated fat and cholesterol rich animal foods based on their prior 7-day dietary record during run-in; (3) Participants will also receive a pamphlet and an 30 min DVD which will provide practical cooking recipes with both illustration and demonstration on how to prepare whole soy foods/diet in an easy and fun way to replace fatty animal meat and dairy products
1548265|NCT02610322|Behavioral|usual diet|Participants who are assigned to the usual diet group (control group) will receive a 5~10 min conventional lifestyle education on MetS by a research staff in which the general recommendation for macronutrient composition of the control diet will be 50-60% of energy as carbohydrate, 15-20% of energy as protein, and <30% of energy as total fat.
1548266|NCT02610309|Behavioral|Family-Based Crisis Intervention|This intensive ED-based intervention with suicidal adolescents and their families includes cognitive behavioral skill building, psychoeducation, enhancing therapeutic readiness, safety planning, and co-creation of a joint crisis narrative.
1548267|NCT02610296|Drug|QPI-1002|IV injection
1548268|NCT02610296|Other|Placebo|isotonic saline
1548269|NCT02610283|Drug|QPI-1002|IV injection
1548270|NCT02610283|Drug|Placebo|isotonic saline
1548271|NCT02610270|Dietary Supplement|2 Gums|760 mg DHA
1548272|NCT02610270|Dietary Supplement|3 Gums|1140 mg DHA
1548273|NCT02610257|Device|Mechanical stimulus (vibration) applied on the forearm|"Local vibration will be applied using a custom-made vibratory system (named Vibrators) consisted of small vibratory devices (constructed using DC micro motors (Faulhaber® - Switzerland) bearing an eccentric load, enclosure on a PVC involucre). Vibrators measure 4.5cm x 2cm x 2cm and weight 27-31g each. Vibrators were custom-made especially for this study and therefore do not have a trade name.
Vibrators will be positioned either on the extensor carpi radialis brevis (ECRB) muscle belly or on the olecranon region. Devices will be kept in place using regular elbow elastic supports."
1548274|NCT02610244|Other|Modified Cogmed Training|Comparison of outcome measures between treatment-as-usual group and Modified Cogmed Training group after 10 weeks and 3 months follow up.
1548275|NCT02610231|Drug|Istradefylline 20 mg or 40 mg|Istradefylline 20 or 40 mg
1548277|NCT02610205|Other|caring touch|The caring touch was adjusted to suit each participant and lasted for 20-60 minutes, once a week, for a maximum of eight treatment sessions altogether. The tactile massage, a soft tissue massage, without applying direct pressure or stretching to the muscles. The massage can be described as slow, gentle, structured, circulating movements with the palm of the therapist's hand, during which natural oil, or oil with the fragrance of lavender, was applied. The healing touch was based on an established procedure, during which the therapist applied a light pressure to the feet, ankles, knees, hips, stomach, heart area, arms, throat, forehead and scalp. The participant was fully dressed during the healing touch, as the therapist used her/his hand in different positions on the participant's body.
1548278|NCT02610192|Device|nSTRIDE Autologous Protein Solution (APS) Kit|Intra-articular injection of APS
1548279|NCT02610179|Dietary Supplement|Standard Glucola GCT|Participants will be screened with the standard method of consumption of the glucola beverage followed by a 1 hour venous blood draw.
1548280|NCT02610179|Dietary Supplement|Twizzlers challenge|Participants will consume the Twizzlers equivalent (10 strawberry flavored Twizzlers) and have their venous blood glucose checked in 1 hour.
1548281|NCT02610166|Behavioral|Game|"In addition to standard medical care, children in the experimental group will receive the Match-3 game. The game will be designed for short individual gameplay sessions (as little as a few seconds), once to three times a day, over the course of 8 weeks, involving no more than 15 minutes per day in anticipated screen time. There is no way to lose the game. Through a structured series of daily interactions, the player will learn strategies and develop decision-making abilities that will assist with management of their own JIA. The Match 3 concept (similar to the game, Bejeweled) will require the player to successfully match the treatment strategy to the JIA symptom."
1548282|NCT02610166|Other|Usual Care|Children in usual care group receive standard medical care.
1548315|NCT02609932|Drug|Administration of drug (Interferon-gamma 1-b) subcutaneously|SD = group who has received a single dose of IFN-gamma (10, 25, 50, and 100 mcg/m2) given once with subsequent analysis of effects (serum IL-10, Neuropterin, and IFN levels as well as neutrophil Nox2 activity and gene expression by Affimetrics Chip analysis). One month is allowed between doses. SS = administration of four doses (50 mcg/m2) of IFN-gamma given on Monday, Wednesday Friday schedule with neutrophil or monocyte function studies performed before the first and after the fourth dose to determine steady state effects.
1548545|NCT02608411|Drug|ARQ197|
1548284|NCT02610140|Drug|Anetumab ravtansine (BAY 94-9343)|Starting dose: 6.5 mg/kg administered as IV infusion over 1 h every 3 weeks until disease progression or treatment withdrawal for any reason. Dose reductions are permitted.
1548285|NCT02610140|Drug|Vinorelbine|Starting dose: 30mg/m² administered as an IV infusion over 6 to 10 min every week until disease progression or treatment withdrawal for any reason. Dose reductions are permitted per standard practise.
1548286|NCT02610127|Biological|OBIZUR|Treating physician will determine treatment regimen, frequency of laboratory and clinical assessments, according to routine clinical practice.
1548287|NCT02610114|Other|Z-Score and computer algorithm|In addition to the routine Z-score for zygote selection, if needed, the photographs of the zygotes already taken for quality and safety reasons are analysed using the new computer algorithm. Within a few minutes it generates a score, determining the quality of the cells. The two best cells upon Z-score result and new computer algorithm result are selected for first transfer.
1548288|NCT02610114|Other|Z-Score|After fertilisation pronuclei and nucleoli can be seen inside the cells by microscope. Routinely, the alignment of nucleoli can be used generating a score, the Z-score 1-4, established by Scott. Two zygotes getting the best Z-score are selected for cell culture and the cells that develop to embryo stage are used for first transfer.
1548289|NCT02610101|Other|Traditional SCD Diet|Traditional SCD includes removal of all processed foods as well as all grains, sweetners except for honey and all diary except for yogurt fermented for over 24hrs and some hard cheeses
1548290|NCT02610101|Other|Modified SCD Diet|Food components of the traditional SCD with the addition of rice and oats.
1548291|NCT02610101|Other|Whole foods diet|A whole foods diet with removal of processed foods. Removal of corn, wheat, sugar and milk are also apart of this dietary regime.
1548294|NCT02610075|Drug|AZD1775|All patients will receive intervention with AZD1775 orally. Patients will continue to receive treatment with AZD1775 until disease progression, intolerable toxicity, or discontinuation criteria are met.
1548295|NCT02610062|Drug|AGS67E|Intravenous (IV) infusion
1548296|NCT02610049|Behavioral|Cognitive Processing therapy|8 sessions of standard CPT from CPT manual developed by Dr. S Resick, Monson & Chard (11/2010)
1548297|NCT02610049|Behavioral|Art + CPT|8 sessions of individual therapy of mixes techniques Art + CPT 8 sessions of standard CPT (same 8 as in control group) from manual developed by Dr.s Resick, Monson & Chard (11/2010)
1548298|NCT02610049|Behavioral|CPT + Art Therapy|Subjects to complete 8 sessions of standard Cognitive Processing Therapy from manual developed by Dr. S. Resick, Monson & Chard (1/2010) CPT + Art Therapy of mixed individual techniques
1548299|NCT02610023|Other|Questionnaire Administration|Complete the Willett FFQ, the Fred Hutchinson FFQ, and the CCAT
1548300|NCT02610023|Other|Laboratory Biomarker Analysis|Correlative studies
1548301|NCT02610023|Device|Spectroscopy|Undergo resonance Raman spectroscopy
1548302|NCT02610010|Drug|Cisplatin|Cisplatin 100 mg/m² every 3 weeks for 3 cycles during radiotherapy.
1548303|NCT02610010|Radiation|Intensity-modulated radiotherapy|Intensity-modulated radiotherapy
1548304|NCT02609997|Procedure|Phacomulsification lens removal cataract surgery with single-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with single-piece IOL.During Phacoemulsification.
1548305|NCT02609997|Procedure|Phacomulsification lens removal cataract surgery with three-piece Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with three-piece IOL.During Phacoemulsification.
1548306|NCT02609997|Drug|Subconjunctival dexamethasone|All patients received subconjunctival dexamethasone (2 mg) during surgery. Topical anesthesia, consisting of a single drop of 0.5% proparacaine (Alcaine, Alcon Laboratories), was administered three times at intervals of 5 minutes prior to surgery
1548307|NCT02609997|Device|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells
1548308|NCT02609997|Drug|proparacaine|0.5% proparacaine (Alcaine, Alcon Laboratories)
1548309|NCT02609984|Biological|CMB305|CMB305 is a sequential combination of two investigational study agents, LV305 and G305, with each agent given at different times over several weeks or months.
1548310|NCT02609984|Biological|atezolizumab|Atezolizumab is known as a checkpoint inhibitor (CPI) or immune checkpoint controller. It is a programmed cell death ligand 1 (PD-L1) inhibitor also known as MPDL3280A.
1548311|NCT02609971|Other|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
1548312|NCT02609958|Drug|Varlitinib|"varlitinib tablets with:
starting dose: 300mg BID
target dose: 400mg BID
dose modification by investigator allowed between 200mg BID to 500mg BID"
1548313|NCT02609945|Drug|zolmitriptan|Oral Tablet and Nasal Spray
1548314|NCT02609945|Drug|CVT-427 (zolmitriptan inhalation powder),|Capsules containing zolmitriptan; dose levels equivalent to estimated fine particle dose (i.e., lung-delivered) zolmitriptan.
1548349|NCT02609698|Device|Coroflex ISAR|This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
1548350|NCT02609698|Drug|3 months DAPT|
1548351|NCT02609698|Drug|6 months DAPT|
1549692|NCT02600520|Drug|SRP with placebo gel LDD|After SRP, placebo gel was delivered subgingivally into the pocket
1996200|NCT02538497|Behavioral|The Newborn Behavioral Observation (NBO)|"The Newborn Behavioral Observation (NBO) is a flexible parental guidance methodology which takes between 20 and 40 minutes to administer. It consists of 18 neurobehavioral observations which give a profile of the infant´s behavioral repertoire along the dimensions: attentional-interactional, autonomic, motor and state organization.
The intervention group will receive 3 NBO consultations: 1) Routine care plus the NBO at the hospital within two days post-delivery; 2) Routine home visit plus the NBO by a public health nurse when the infant is 7-10 days old; and 3) NBO at the well-baby clinic when the infant is about 4 weeks old."
1996201|NCT02538497|Behavioral|Routine care|The control group will receive routine care. Between 7 and 10 days after birth a public health nurse routinely visits the family at home. Six weeks after birth, the mother and the infant visit the well-baby clinic
1548317|NCT02609906|Device|PhilosTM with augmentation (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.
Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the angle stable plate fixation system PhilosTM with augmentation (Depuy-Synthes)."
1548318|NCT02609906|Device|MultiLoc®-Nail (Depuy-Synthes)|"All fractures will initially be immobilised by a Gilchrist-bandage. This is the same procedure as for patients who do not attend this or any other trial and will be performed by the doctor on-duty in the emergency room. Patients will be admitted to the trauma ward after that. On the same day or at the latest on day after this patients will be informed about the current investigation, screened, included and randomized by one of the study doctors to our trial after written consent will be obtained as described above.
Operative treatment is exclusively performed by the below mentioned study doctors. This group will be treated by the multiplanar proximal humeral nail MultiLoc® (Depuy-Synthes)."
1548319|NCT02609893|Other|modified directly observed therapy (mDOT)|
1548320|NCT02609893|Other|unobserved dosing|
1548321|NCT02609893|Other|Motivational Interviewing-based counseling|Motivational Interviewing-based risk reduction and medication adherence counseling
1548322|NCT02609880|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is used to optimize sleep, pain, and mood in women with gynecologic cancers and will be provided 2 hours once a week for six weeks.
1548323|NCT02609880|Behavioral|Psychoeducation|Psychoeducation is used to provide information, resources, and non-specific support related to adapting well to cancer. Sessions will be provided 2 hours once a week for 6 weeks.
1548325|NCT02609854|Device|Sustained Acoustic Medicine (SAM)|Long-duration, low-intensity therapeutic ultrasound device that is self-applied and wearable, delivering treatment up to 4 hours per day.
1548326|NCT02609854|Device|Sham Device|Inactive ultrasound device
1548327|NCT02609841|Device|Cardiac rhythm remote monitoring system|Non-invasive wearable remote cardiac rhythm monitoring system used throughout 12 days of study.
1548331|NCT02609802|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
1548332|NCT02609802|Drug|Desflurane|Anesthesia was maintained with desflurane in patients undergoing arthroscopic shoulder surgery under general anesthesia and interscalene brachial plexus block.
1548333|NCT02609789|Drug|JNJ-55920839|JNJ-55920839 will be administered as either IV infusion or subcutaneous injection.
1548334|NCT02609789|Drug|Placebo|0.9 percent (%) normal saline.
1548337|NCT02609750|Other|Structured care & workplace intervention|In addition to structured care a workplace intervention named Convergence Dialogue Meetings (CDM) are carried out. CDM is a three step structured dialogue and meeting model supporting the patient, health care professionals and employer to summarize concrete suggestions to support sustainable work ability and a return to work if sick listed.
1548338|NCT02609750|Other|Treatment as Usual|Patients will follow the primary health care's standard time schedule and procedures as of ordinary care and the rehabilitation guarantee. For each patient all treatment measures are recorded in a manual, regarding number of treatments, time used per treatment and type of treatment.
1548339|NCT02609737|Device|PET/CT Imaging|
1548340|NCT02609737|Radiation|68Ga-DOTA-JR11|
1548341|NCT02609737|Radiation|177Lu-DOTA-JR11|
1548342|NCT02609724|Other|Information|During intensive phase: a leaflet with information about the lymphatic system and lymphoedema, clinical evaluation and conservative treatment of lymphoedema During maintenance phase: two informational sessions about self-management and about compression sleeves and other compression material
1548343|NCT02609724|Other|Skin care|The skin is hydrated during the session. If wounds are present, the wound is cared.
1548344|NCT02609724|Other|Compression therapy|During intensive phase: application of multi-layer, multi-component bandages During maintenance phase: wearing custom-made compression garment
1548345|NCT02609724|Other|Fluoroscopy-guided MLD|Fluoroscopy-guided MLD is applied on patient-specific lymphatic system (known from lymphofluoroscopy) by applying cleaning techniques on lymph nodes, resorption techniques to stimulate resorption of lymph by lymph capillaries and gliding technique to stimulate transport of lymph through lymph collectors
1548346|NCT02609724|Other|Traditional MLD|Traditional MLD is applied without knowledge of the patient-specific lymphatic architecture. During MLD no cream or oil is used. A pressure with the hands up to 40 mmHg is applied. Drainage is performed at the level of the jugular and occipital region and the belly (in the depth). Draining techniques are applied on the retroclavicular lymph nodes, axillary lymph nodes, humeral lymph nodes and cubital lymph nodes. At the level of the hand, arm, shoulder and trunk, hand movements are applied to stimulate lymphatic transport through the lymph collectors. The therapist's hands perform 'pumping-movements' while stretching the skin.
1548347|NCT02609724|Other|Placebo MLD|During placebo MLD a superficial massage with massage cream is performed on the patient's contralateral arm and on the belly.
1548348|NCT02609711|Drug|Candesartan cilexetil|
1548358|NCT02609646|Drug|Linezolid|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
1548359|NCT02609646|Drug|Meropenem|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
1548360|NCT02609646|Drug|Piperacillin-tazobactam combination product|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
1548361|NCT02609646|Drug|Vancomycin|Drug choice is performed according to standard clinical practice, that will not be modified by the participation in the study. As a consequence, assignment of patients to groups is not protocol based, but it is defined by standard clinical choices.
1548362|NCT02609633|Device|Accu-Chek Connect DMS|SMBG will be performed during the 6-month study using the Accu-Chek(R) Aviva Connect monitoring device, and corresponding Smartphone app and online tracking tool.
1548363|NCT02609633|Device|DMS|SMBG will be performed during the 6-month study according to usual care, using the participant's current DMS (other than Accu-Chek(R) Connect DMS).
1548364|NCT02609620|Device|Peristaltic Feeding Tube|
1548365|NCT02609620|Device|ConvaTec Levin Duodenal Tube|
1548372|NCT02609555|Procedure|TEM perineal rectopexy|perineal rectopexy using polyprolene mesh assisted by TEM technique and special proctoscope postanal repair in two layers to narrow the postanal space anal cerclage with absorbable sutures
1548373|NCT02609542|Other|Eye Tracking|Eye tracker will allows the recording of various information concerning eye fixation (number, duration, location) and saccadic eye movement (speed, range, number, duration) in order to determine the interplay between linguistic and visual information processing during tests performance
1548374|NCT02609529|Other|Medical Food|Serum-derived bovine immunoglobulin protein isolate will be supplied by EnteraHealth. The product is manufactured in accordance with Good Manufacturing Practice (GMP) and U.S. Food and Drug Administration (FDA) guidelines for medical food ingredients (21 CFR Part 110). Serum-derived bovine immunoglobulin protein isolate (SBI) is generally recognized as safe (GRAS). The FDA has reviewed the safety dossier for SBI as a medical food product.
1548375|NCT02609529|Other|Placebo|
1548376|NCT02609516|Other|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
1548377|NCT02609503|Drug|Pembrolizumab|Pembrolizamab, 200 mg IV during cycle visits every 3-weeks for up to 6 cycles, or until toxicities are no longer tolerable
1548378|NCT02609503|Radiation|Intensity Modulated Radiation Therapy|Eligible participants will receive Intensity Modulated Radiation Therapy daily x 7 weeks
1548379|NCT02609490|Drug|Azilsartan tablets|20mg/tablet
1548380|NCT02609490|Drug|Azilsartan placebo tablets|placebo tablet
1548381|NCT02609490|Drug|Olmesartan medoxomil tablets|20mg/tablet
1548382|NCT02609490|Drug|olmesartan medoxomil placebo tablets|placebo tablet
1548383|NCT02609477|Drug|Istradefylline|Istradefylline 40, 80, 160 mg
1548384|NCT02609477|Drug|Phentermine 45 mg|Phentermine 45 or 90 mg
1548385|NCT02609477|Other|Placebo|Placebo
1548386|NCT02609464|Device|Interrupted Knotted Sutures|
1548387|NCT02609464|Device|STRATAFIX Symmetric PDS PLUS Knotless Tissue Control Devices|
1548388|NCT02609451|Procedure|Ileostomy closure|Ileostomy closure at a different time point
1548389|NCT02609438|Behavioral|Short breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take a 1-minute active break every 30 minutes during the workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
1548390|NCT02609438|Behavioral|Long breaks|Following baseline testing, participants will attend a 30-minute individual orientation session, during which they will complete a planning worksheet with a research assistant. They will identify specific strategies they will use to accomplish the pre-specified goal (i.e., to take two 15-minute activity breaks during each workday). They will also identify potential barriers they will face and devise strategies for overcoming them. The intervention will officially start the Monday after the orientation session and will last for 8 weeks. Participants will receive a weekly email containing tips related to reducing sitting time at work. All participants will complete daily activity logs indicating the time and duration of all breaks from sitting across the 8-week intervention.
1548391|NCT02609425|Device|Stratafix PGA Suture|Subject leak Stricture rates post procedure
1548392|NCT02609412|Other|Static compression of LMTRP|Static compression of most sensitive Triggerpoint with a foam roller (Blackroll Inc., Germany).
1548393|NCT02609412|Other|Dynamic self-myofascial release of calf|Dynamic self-massage of the calf with a foam roller (Blackroll Inc., Germany).
1548394|NCT02609412|Device|Placebo laser acupuncture of LMTRP|Used device: Laserneedle System (Laserneedle Systems GmbH, Glienicke/Nordbahn, Germany). Electrodes positioned on skin but device remains switched off.
1548395|NCT02609399|Drug|Oseltamivir|Oral
1548396|NCT02609399|Drug|Peramivir|"IV
Note: Should a patient remain in the hospital after 5 days of treatment, and the patient is symptomatically better, treatment will stop. If the patient remains hospitalized after 5 days of treatment and has not improved, the treating physician will continue to have an option to continue use of peramivir daily for another 5 day course."
1548402|NCT02609373|Behavioral|Sleep intervention|"Session 1: Intervener & participant review 2-week sleep diary and actigraph data. Provide individualized sleep hygiene prescription.
Session 2: Review sleep diary; calculate sleep efficiency; identify adjustments needed.
Session 3: Review sleep-related vs. stress-related symptoms. Develop plan for sleep-related symptoms and discuss Sleep Restriction with Relaxation Exercises. Session 4: Reinforce progress and make corrections as required. If Sleep Restriction is not working, Stimulus Control is introduced.
Session 5-10: Provide reinforcement, assess adherence, answer questions, and offer encouragement and monitoring, including alterations as required.
Booster sessions: At 8 & 10 months: reinforcement, question answering, encouragement and monitoring."
1548403|NCT02609360|Other|Priming of ECMO circuit with 0.9% NaCl|0.9% NaCl as priming crystalloid solution
1548404|NCT02609360|Other|Priming of ECMO circuit with Ringer Lactate|Ringer Lactate as priming crystalloid solution
1548405|NCT02609360|Other|Priming of ECMO circuit with Balanced Solution|Balanced Solution as priming crystalloid solution
1548406|NCT02609347|Other|Manual Therapy Group|The manual therapy intervention will be based on the typed of fracture the patient sustained, and their limitations in joint mobility.
1548407|NCT02609347|Other|Control Group|The sham intervention will consist of soft tissue mobilization and Grade I mobilization at the proximal tib/fib joint.
1548408|NCT02609334|Drug|CRD007|One single dose given 3 hours prior to Mannitol challenge
1548409|NCT02609334|Other|Placebo|One single dose given 3 hours prior to Mannitol challenge
1548410|NCT02609321|Procedure|Thoracic Paravertebral Block|Thoracic paravertebral block at T3 level with bupivacaine 0.5%, dosis 1.5mg/Kg
1548411|NCT02609321|Procedure|Surgical Wound Infiltration|Surgical wound infiltration on the skin and subcutaneous tissue in surgical area with bipivacaine 0.5%, dosis 1.5mg/kg
1548414|NCT02609295|Dietary Supplement|Placebo|1.2 g (two capsules) of medium-chain triglyceride (MCT) oil
1548415|NCT02609295|Dietary Supplement|ALA group|1.2 g (two capsules) of perilla oil
1548416|NCT02609282|Behavioral|Hourly prompts to stand delivered by Microsoft Outlook|
1548417|NCT02609269|Other|Decipher Prostate Cancer Classifier|The Decipher Prostate Cancer Classifier (Decipher Test) is a genomic test that predicts the probability of high-grade disease, metastasis and prostate cancer specific mortality for men with prostate cancer and is commercially available through GenomeDx Biosciences' CLIA & CAP certified laboratory in San Diego, CA
1548418|NCT02609269|Other|Decipher Genomics Resource Information Database (GRID)|The Decipher GRID (GRID) is the world's largest research use only (RUO), clinically annotated urologic cancer genomic expression database, built up over 8 years of US and international research conducted using the Decipher® (Decipher) test platform. The GRID currently consists of genomic data comprised of 1.4M data points per patient from more than 20,000 prostate and bladder cancer patients, including those from published retrospective clinical studies that have been annotated with comprehensive treatment and outcomes data. It is anticipated that the GRID will also contain data from several other types of cancer in the future.
1548419|NCT02609256|Procedure|Stereotactic infarct tissue aspiration|The patient posed supine position to expose local skin and puncture point was located at 6.5 cm behind the hairline of the lesion side, and 5.0 cm lateral of midline. After routine skin preparation and disinfection, 5% lidocaine 2-5 ml was injected for local anesthesia. The skin was cut to expose periosteum by a scalpel. After skull was vertically drilled through with a 6mm diameter hole, a sterile tube with a needle in tube was put about 8 cm into centrum semiovale. The needle was put out and about 50ml necrosis brain tissue was aspirated by a 20 ml syringe. The tube was fixed into the skin about 2 cm after subcutaneous tunnel, and connected to the drainage bag. Surgical area was sterilized and wrapped by sterile gauze bandage.
1548420|NCT02609256|Other|Medical therapy|osmotic therapy with mannitol and glycerol fructose，anti-platelet treatment, statins, and other symptomatic treatments such as controlling blood pressure, blood sugar, and infection, and tracheal intubation or incision, etc
1548421|NCT02609243|Behavioral|dietary consulting|dietary consulting implies specific dietary advice based on pre-interventional self-report regarding food intake; consulting focuses on nutrient content, calory intake, weight loss; with regard to randomisation consulting intensity and content varies
1548422|NCT02609230|Drug|ONC-201|
1548423|NCT02609217|Other|Questionnaires and interviews|
1548424|NCT02609204|Device|Diopsys NOVA|Every participant will have both eyes tested by the Diopsys NOVA machine using the Pattern Electroretinogram (PERG) and Flash Electroretinogram (FERG) modules.
1549693|NCT02600507|Drug|ITI-007|
1549694|NCT02600507|Drug|Placebo|
1548428|NCT02609178|Procedure|FGP|To execute FGP technique, the occlusal surface of the interim should be back cut to leave at least 1mm occlusal space. Then apply the recording resin. Ask the subjects to close the mouth to maximum intercuspal position then perform right lateral, left lateral and protrusive movements in succession ending in maximum intercuspation position. Excessive resin then should be trimmed off and Bausch articulating paper would be used to mark the intercuspal contacts. Zinc oxide is then applied to check eccentric occlusion, trimmed off resin if there're interferences. Then the interim would be used as a copy to design the occlusal surface of the crown. (CAD/CAM)
1548429|NCT02609178|Procedure|AVR|the crowns in this group would be designed by setting virtual articulator to average mode (CAD/CAM)
1548430|NCT02609165|Drug|rhNGF 180 µg/ml eye drops solution|eye drops
1548431|NCT02609165|Drug|vehicle eye drops|placebo
1548432|NCT02609152|Drug|Continuous perfusion of esmolol|In the experimental arm of the study, a continuous perfusion of esmolol will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. At H4, the doctor in charge is free to gradually continue or stop the infusion.
1548433|NCT02609152|Drug|Continuous perfusion of saline|In the control arm of the study, a continuous infusion of normal saline will be performed. This infusion starts at 5 ml / h with an increase of 5 ml / hr every 10 minutes to obtain a 15% decrease in heart rate. The infusion will be reduced by 5 ml / h every 5 minutes if the cardiac rate is less than 90 beats per minute and stopped if it is less than 70 beats per minute. A H4, the doctor in charge is free to gradually continue or stop the infusion.
1548434|NCT02609139|Drug|PF-06650833|Up to 400mg modified release tablets administered under fasted conditions
1548435|NCT02609139|Drug|PF-06650833|100mg modified release tablet administered under fasted conditions
1548436|NCT02609139|Drug|PF-06650833|20mg modified release tablet administered under fasted conditions
1548437|NCT02609139|Drug|PF-06650833|Up to 400mg modified release tablets administered with high fat meal food intake
1548438|NCT02609139|Drug|PF-06650833|100mg modified released tablet administered with high fat meal food intake
1548439|NCT02609139|Drug|PF-06650833|20 mg modified release tablet administered with high fat meal food intake
1548440|NCT02609126|Drug|EP-104IAR|Single, ultrasound-guided injection of EP-104IAR into the knee
1548441|NCT02609126|Drug|Vehicle|Single, ultrasound-guided injection of vehicle placebo into the knee
1548442|NCT02609113|Device|Strong Magnetic Wristband|
1548443|NCT02609113|Device|Weaker Magnetic Wristband|
1548444|NCT02609100|Procedure|Video Capsule Endoscopy|Video Capsule Endoscopy allows for imaging of the small intestine between the distant duodeno-jejunal junction, which is beyond the reach of upper GI endoscopy and the terminal ileum and is similarly beyond the reach of colonoscopy. It is of greatest use in identifying points of bleeding and ulcers.
1548445|NCT02609100|Procedure|Colonoscopy|The colonoscopy helps find ulcers, tumors, and areas of inflammation or bleeding in the large intestine.
1548446|NCT02609100|Device|1.0 X 2.5 cm 'pill' containing a camera|
1548447|NCT02609087|Drug|Sevoflurane|
1548448|NCT02609087|Drug|Propofol|
1548449|NCT02609074|Procedure|Minimally invasive internal fixation surgeries|
1548450|NCT02609074|Device|CPC/rhBMP-2 micro-scaffolds|
1548451|NCT02609074|Device|CPC paste|
1548452|NCT02609061|Procedure|Open flap debridement (OFD)|Open flap debridement (OFD) alone
1548453|NCT02609061|Procedure|OFD with Platelet rich fibrin (PRF)|Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement
1548454|NCT02609061|Procedure|OFD with Platelet rich fibrin (PRF)+1% Alendronate (Drug) in gel form|Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate gel placement
1548455|NCT02609048|Drug|Placebo Comparator|Placebo Capsule (2 taken once daily)
1548456|NCT02609048|Drug|Experimental: MBX-8025 50 mg|MBX-8025 50 mg capsule (1 taken once daily)
1548457|NCT02609048|Drug|Experimental: MBX-8025 200 mg|MBX-8025 100 mg capsules (2 taken once daily)
1548458|NCT02609035|Behavioral|Telephonic prompt|
1548459|NCT02609022|Biological|CV-MG01|"3 consecutive subcutaneous injections of CV-MG01. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
Two dose levels: low and high dose."
1548460|NCT02609022|Biological|Placebo|3 consecutive subcutaneous injections of placebo. The three injections are planned for each patient on Days 1, 29 (+/- 3 days) and 85 (+/- 7 days), respectively.
1548461|NCT02609009|Other|Spinal Manipulation Therapy|Intervention will consist of Diversified type adjustments. Patients will be assigned to the nearest participating chiropractic clinic and will have a complete standardized examination on their first visit. Patient will then receive a maximum of 12 treatments (3x per week for a period of 4 weeks).
1548462|NCT02609009|Other|Usual Medical Care|Usual interventions generally consist in the administration of medications (NSAIDs or ibuprofen), physical therapy or exercises. If recommended, physical therapy will be provided by the hospital physical therapy services. Physical therapy might include treatments such as massage, different electrotherapy, postural repositioning, exercises, etc
1548463|NCT02608996|Drug|Nesiritide|This intervention is designed to determine the optimal dose range of BNP for treatment of patients with uncontrolled hypertension
1548464|NCT02608996|Drug|Placebo|For comparison to elucidate the true effect of nesiritide
1548465|NCT02608983|Dietary Supplement|Agar H1CC2013|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2013 as part of normal diet for 28 days
1548466|NCT02608983|Dietary Supplement|Agar H1CC2012|Following a 28-day washout one 250ml drink / day containing 8g of agar H1CC2012 as part of normal diet for 28 days
1548467|NCT02608983|Dietary Supplement|Maltodextrin|Following a 28-day washout one 250ml drink / day containing 8g of maltodextrin as part of normal diet for 28 days
1548468|NCT02608970|Drug|BMS-986177|
1548469|NCT02608970|Other|Placebo|
1548470|NCT02608957|Device|Latella Knee Implant System|
1548471|NCT02608944|Drug|Adenosine|Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
1548472|NCT02608944|Drug|Regadenoson|Regadenoson: 0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
1549695|NCT02600494|Drug|ITI-007|
1548474|NCT02608944|Device|MRI|Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
1548475|NCT02608944|Device|PET Imaging|Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day.
1548476|NCT02608931|Drug|Dronabinol|
1548477|NCT02608931|Other|Placebo|placebo
1548478|NCT02608918|Drug|BMS-955176|
1548479|NCT02608905|Drug|Dapagliflozin|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
1548480|NCT02608905|Drug|Placebo|Patients with Type 2 diabetes will be randomized to receive dapagliflozin 5 mg daily for 2 weeks followed by10 mg daily for 10 weeks by mouth or matching placebo for 12 weeks. All subjects will receive measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, monocyte inflammation, as well as ultrasound assessment of flow-mediated dilatation (FMD) of the brachial artery at baseline and after 12 weeks of drug treatment with either dapagliflozin or placebo.
1548481|NCT02608892|Behavioral|BSweet2Babies video|Mothers (and partners if possible) will view the brief BSweet2Babies video on electronic notebooks in French or English, as per parent/s' preference.
1548486|NCT02608866|Radiation|SF-SSRS|Spine stereotactic radiosurgery/ablative radiotherapy (SSRS) with 16 Gy in single fraction to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc).
1548487|NCT02608866|Radiation|MF-SSRS|SSRS with 24 Gy in three fractions to the defined target volume using intensity modulated radiotherapy or volumetric modulated arc therapy (VMAT or RapidArc). Treatment should be given on every other day. Treatment on the consecutive days to the same target volume is not allowed.
1548488|NCT02608853|Other|No treatment given|No treatment is actively administered. Patients are treated according to routine clinical practice at the discretion of their treating physicians.
1548489|NCT02608840|Other|Auditory stimulation during sleep|The intervention is a brain computer interface program which measures brain electroencephalogram to identify slow waves and time the sounds. Barely audible sounds are delivered through headphones and played during sleep (specifically, during slow wave sleep).
1548490|NCT02608840|Other|Sham Intervention|The brain electroencephalogram is measured and headphones are worn, but sounds are not played during sleep.
1548491|NCT02608827|Device|Resperate®-InterCure Ltda|The device-guided breathing - Resperate®-InterCure Ltda, uses sound to guide and therefore reduce the respiration rate in individuals.
1548492|NCT02608827|Other|Music group (GC)|The patients in this arm will hear slow music - Music group (GC).
1548493|NCT02608814|Procedure|Pleural biopsy sampling|6 - 8 pleural biopsy samples will be taken before the insertion of the chest drain. These samples will be sent to microbiology for examination.
1548494|NCT02608814|Other|Ultrasound|
1548495|NCT02608788|Drug|S.L.®|"1.5mg/ml Benzydamine hydrochloride, S.L.® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
1548496|NCT02608788|Drug|Difflam Forte ®|"3.0mg/ml Benzydamine hydrochloride ,  Difflam Forte ® spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
1548497|NCT02608788|Drug|Acular®|"5％ Ketorolac Tromethamine ,  Acular®  spray by mouth . Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff."
1548498|NCT02608788|Drug|placebo|Distilled water spray by mouth. Before intubation, each endotracheal tube cuff was scattered 10 times of spray by physicians that might cover 20 cm long of the cuff.
1548499|NCT02608775|Device|Metrodoloris Medical System|Application of a skin electrode
1548500|NCT02608775|Device|Aisys® care station, Acertys|Standard photoplethysmography
1548502|NCT02608749|Behavioral|Integrated care (IC)|Integraded care (IC) Weekly professional led exercise program for 90 mins with reinforcemen on osteoporosis related educations and caremangements from study educational booklet and CD rom for 3-month. The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
1548503|NCT02608749|Behavioral|Lower extremity exercise (LEE)|Lower extremity exercise (LEE) group subjects were invited to BB site to receive 2 sessions of 45-mintute training using isotonic strength training machines on major muslce groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist.
1548504|NCT02608749|Behavioral|Home care (HC)|Home care (HC) group subjects were invited to LK site. For examining whether the exercise video could help elderly people to maintain their exercise and improve their muscle strength or not, the investigators provided exercise video to subjects, and encouraged them to play this exercise at least 2 hours for one week.
1549696|NCT02600494|Drug|Placebo|
1553107|NCT02576353|Drug|Fentanyl|Fentanyl Sublingual Spray (FSS)
1548505|NCT02608736|Drug|Valproic Acid|Half of the participants will receive valproic acid orally for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in placebo arm.
1548506|NCT02608736|Drug|Placebo|The other half of the participants will receive placebo for three months. Saliva and blood will be sampled in the study entry. The participants will be followed with blood tests every month for three cycles. After the third cycle, saliva and blood will be sampled once more. Finally, histone acetylation and DNMT expression will be studied comparing the samples collected in different timelines and comparing them to saliva collected in valproic acid arm.
1548507|NCT02608723|Device|Standard shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
1548508|NCT02608723|Device|Austere shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
1548509|NCT02608723|Device|Sophisticated shock waves device|3 sessions were applied: one per week. Energy flux density 0,18 mJ/mm2. Frequency: 8 Hz. 2500 shockwaves/session. The shock waves emitted to the 3 devices are identical; the only difference is the external image of the device.
1548513|NCT02608697|Drug|CAT-2054|
1548514|NCT02608697|Drug|Placebo|
1548515|NCT02608697|Drug|Atorvastatin|
1548516|NCT02608684|Drug|Pembrolizumab|Pembrolizumab IV solution
1548517|NCT02608684|Drug|Gemcitabine|Gemcitabine IV solution
1548518|NCT02608684|Drug|Cisplatin|Cisplatin IV solution
1548519|NCT02608671|Procedure|Skin adhesive tape|
1548520|NCT02608658|Other|Medical food, EnteraGam (Serum-Derived Bovine Immunoglobulin)|"Visit 1, screening (Day 0): At this visit, the investigators of the study will:
Obtain demographic information, as will past medical history and medications.
Perform a physical examination.
Collect samples for labs
Administer the Chronic Liver Disease Questionnaire (CLDQ)
Perform a lactulose breath test
From Day 0 to 8 weeks: subjects will take the medical food twice daily
Visit 2, Week 4 (Day 28 +/- 3): At this visit, the investigators of the study will:
Perform a physical examination
Collect and record returned investigational product
Dispense investigational product and instruct again regarding use
Record any adverse events
Visit 3, Week 8 (Day 56 +/- 3): At this visit, the investigators of the study will:
Perform a physical examination.
Collect samples for labs
Administer the Chronic Liver Disease Questionnaire (CLDQ)
Perform a lactulose breath test"
1548521|NCT02608632|Device|Renal denervation guided by HFS|
1548522|NCT02608632|Device|Renal denervation as standard procedure|
1548523|NCT02608619|Radiation|F-choline PET Scan|
1548524|NCT02608619|Device|FDG-PET|
1548525|NCT02608619|Procedure|biopsy|
1548526|NCT02608606|Drug|Tacrolimus|compared oral administration versus sublingual administration of tacrolimus.
1548527|NCT02608593|Procedure|Strattice|Implant based reconstruction with strattice cover of part or all of implant
1548528|NCT02608580|Other|Survey|
1548531|NCT02608541|Other|rib fracture fixation|Use of MatrixRib, where indicated, according to departmental protocol
1548532|NCT02608528|Radiation|[18F]fluoroglucose(FDG)|
1548533|NCT02608502|Biological|RSV-F Vaccine|
1548534|NCT02608502|Biological|Phosphate Buffer Placebo|
1548535|NCT02608489|Drug|Diquafosol (Diquas)|Diquafosol group used diquafosol 6 times a day during study period.
1548536|NCT02608489|Drug|Sodium Hyaluronate (Hyalein)|Hyaluronate group used sodium hyaluronate 6 times a day during study period.
1548539|NCT02608463|Device|Transcranial Magnetic Stimulation|Subjects will undergo daily repetitive transcranial magnetic stimulation (rTMS), defined as Monday through Friday, for a total of 10 consecutive sessions. rTMS will be applied using the NeuroStar TMS Therapy System through a figure-8 coil connected to a magnetic stimulator, which provides a biphasic pulse. The coil is applied to the primary motor cortex, M1, contralateral to the painful side. The optimal stimulus site, motor hot spot, will be determined according to visual detection of muscle twitches, and a resting motor threshold is defined as the minimal intensity necessary to induce at least one visible muscle twitch. An rTMS session consists of 10 trains at 90% intensity of resting motor threshold (one train, 100 pulses at 10 Hz; intertrain interval, 50s).
1548542|NCT02608437|Drug|SGI-110|SGI-110: start at 30 mg/m2 s.c. on W0, 3, 6, 9 Day 1 - 5 q21 days. Dose level -1: 15 mg/m2; dose level +1: 45 mg/m2
1548543|NCT02608437|Drug|Ipilimumab|ipilimumab: 3 mg/Kg i.v. over 90 minutes on W1, 4, 7 and 10 for a total of 4 cycles.
1548544|NCT02608424|Device|Foot Mechanical Stimulation (Gondola®, CE marking n° 0476)|The feet mechanical stimulation will be performed by Gondola (Gondola®, CE marking n° 0476).
1548546|NCT02608398|Other|no intervention|NO intervention by the research group - this is an observational study. urine samples simply collected as children lose weight on their diet and exercise camp
1548547|NCT02608385|Drug|Stereotactic body radiotherapy|
1548548|NCT02608385|Drug|Pembrolizumab|
1548549|NCT02608372|Other|LD|Participants ingested 5 g of Laminaria digitata followed by 30 g of corn starch mixed with 200 mL of water.
1548550|NCT02608372|Other|UP|Participants ingested 5 g of Undaria pinnatifida followed by 30 g of corn starch mixed with 200 mL of water.
1548551|NCT02608372|Other|CTR|Participants ingested 30 g of corn starch and 1 g of pea protein powder mixed with 200 mL of water.
1548552|NCT02608359|Drug|Abiraterone Acetate|This is an observational study and participants will not receive any intervention as a part of this study. All prospective participants who will be prescribed abiraterone acetate tablets 250 milligram (mg) treatment based on independent clinical judgment and as per locally approved prescribing information will be enrolled in the PMS. Participants will be exclusively observed for safety.
1548553|NCT02608346|Procedure|Blood sampling|"Patients will have a blood draw at each visit to the hospital,
with a maximum of 1 blood draw every 3 months, in absence of any abnormal clinical/radiological exam
with a maximum of 1 blood draw every week, in case of abnormal clinical/radiological exam that requires further investigation"
1548554|NCT02608333|Behavioral|ESDM-12|"ESDM is a comprehensive relational, developmental and behavioral intervention. It's described in a manual for professional (Rogers et al, 2010).
Children receive ESDM 12H per week by trained therapist. Therapist work in collaboration with parents (at home) and preschool or nursery."
1548555|NCT02608333|Behavioral|control group|"heteregenous as usual community intervention"
1548556|NCT02608320|Drug|Duragesic (Fentanyl Transdermal System [TDS] Small Patches)|Duragesic 12.5 mcg/h (Treatment A) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
1548557|NCT02608320|Drug|New JNJ-35685-AAA-G016 (Fentanyl TDS -Small Patches)|New JNJ-35685-AAA-G016 12.5 mcg/h (Treatment B) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
1548558|NCT02608320|Drug|Aged JNJ-35685-AAA-G016 (Fentanyl TDS Small Patches)|Aged JNJ-35685-AAA-G016 12.5 mcg/h (Treatment C) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
1548559|NCT02608320|Drug|Duragesic (Fentanyl TDS Large Patches)|Duragesic 100 mcg/h (Treatment D) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours, applied to the paraspinal region of the back for 72 hours.
1548560|NCT02608320|Drug|New JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|New JNJ-35685-AAA-G021 100 mcg/h (Treatment E) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
1548561|NCT02608320|Drug|Aged JNJ-35685-AAA-G021 (Fentanyl TDS Large Patches)|Aged JNJ-35685-AAA-G021 100 mcg/h (Treatment F) in either period 1, 2 or 3 as per treatment sequence, applied to the paraspinal region of the back for 72 hours.
1548562|NCT02608294|Device|Kinesio Taping|The patient is placed on a stretcher, his ankle positioned in plantar flexion and inversion, a measure was held between Point A and B with a tape measure, right after the KT was removed from the paper and cut to the same extent. The KT was pulled to its maximum limit and measured with a tape for a second evaluator. This measure found after the maximum tensile strain represented 100% and a rule of three was applied in order to find the 35% voltage for muscle activation. After finding the measure of 35% strain in centimeters, the evaluator cut KT this measurement and the same was discarded. Finally the tape was positioned at Point A; pulled up to Point B; and fixed. This procedure was carried out with the ankle positioned in plantar flexion and inversion.
1548563|NCT02608294|Device|Kinesio Taping Sham|The sham group received the tape applied without tension. The patient was positioned supine; the ankle was placed in a neutral position (90 degrees); and measured between Point A and Point B with a tape measure placed on the skin was performed. Once registered this measure in centimeters the evaluator cut the KT with the same measure, but without the presence of paper attached to it to ensure that there was no tension, because the KT needs a minimum voltage to be applied on paper. After measured and cut the KT, it was applied to the patient in the supine position with the ankle positioned at 90 degrees with no traction.
1548564|NCT02608281|Device|CONTRAST ENHANCED DUAL ENERGY (CEDEM)|The CEDEM application requires the intravenous injection of iodide contrast agents. For each projection view (CC, MLO) a low and a high energy x-ray image will be acquired after Iodine based contrast medium administration. Patient will undergo CE MRI procedure.
1548565|NCT02608268|Drug|MBG453|anti human TIM-3 monoclonal antibody
1548566|NCT02608268|Drug|PDR001|anti-human PD-1 monoclonal antibody
1548567|NCT02608255|Other|blood samples|
1548568|NCT02608242|Drug|YH22189|
1548569|NCT02608242|Drug|Twynsta 80/10mg|
1548570|NCT02608242|Drug|Crestor 20mg|
1548571|NCT02608229|Drug|BVD-523|
1548572|NCT02608229|Drug|Nab-paclitaxel|
1548573|NCT02608229|Drug|Gemcitabine|
1548574|NCT02608229|Procedure|Tumor biopsy|
1548575|NCT02608216|Drug|[18F]FLT|[18F]FLT PET/CT scan, imaging tracer
1548576|NCT02608216|Device|PET/CT|[18F]FLT PET/CT scan
1548577|NCT02608216|Drug|ribociclib|therapeutic
1548578|NCT02608216|Drug|paclitaxel|therapeutic
1548579|NCT02608203|Drug|[68Ga]-DOTANOC PET/CT|
1548580|NCT02608190|Behavioral|Working memory training|See protocol
1548581|NCT02608177|Drug|Linagliptin|Receives 4 weeks of study drug linagliptin
1548582|NCT02608177|Drug|Glipizide|Receives 4 weeks of study drug glipizide
1548583|NCT02608164|Dietary Supplement|3000IU(75μg) vitamin D3|
1548584|NCT02608151|Other|massage with oil|Application or not of an oil consisting of 4 vegetable oils (40% sunflower oil, 3% grape seed oil, 1.5% coriander oil, and 57% of rapeseed oil) during the massage. This oil was chosen due to its composition of essential fatty acids (60%) including: linoleic acid (omega 6,25g 100 g)), linolenic acid (omega 3 5.3g to 100 g) and tocopherol (vitamin E) .
1548585|NCT02608151|Other|massage without oil|
1548586|NCT02608138|Other|Iodine status among portuguese school children|
1548587|NCT02608125|Drug|PRN1371|Oral PRN1371
1548588|NCT02608112|Drug|Methotrexate|Administered as per investigator's discretion. Investigator could also suggest any other csDMARDs instead of methotrexate.
1548589|NCT02608112|Drug|Tocilizumab|Tocilizumab treatment will be administered SC at the discretion of the investigator in accordance with local clinical practice and local labelling.
1548590|NCT02608099|Drug|Interrupted apixaban|Apixaban dose is administered on the evening prior to the procedure; apixaban dose is held on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
1548591|NCT02608099|Drug|Uninterrupted apixaban|Intervention description: Apixaban dose is administered on the evening prior to the procedure; apixaban dose is administered on the morning of the procedure; apixaban dose is administered on the evening after the procedure if there were no peri-procedural complications that necessitated withholding anticoagulation for longer duration.
1548592|NCT02608086|Behavioral|Psychoeducation|"Participants in Control Group will be delivered a flyer named What can I do facing a crisis?, containing information about normal reactions to crisis, what to do to return to normal life and which are the signals of an initial trauma."
1548593|NCT02608086|Behavioral|Psychological First Aid|"Psychology students (PFA Providers) will intervene according to an adapted protocol based on the WHO PFA Operation Guide 2012. Protocol for this study contemplates 4 steps: 1. Active Listening 2. Relaxing and Breathing Techniques 3. Help in prioritizing needs 4. Help in contacting network and services. Moreover, participants in this group will receive a brochure with full contact information of public network, and a flyer named What can I do facing a crisis?."
1548594|NCT02608073|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 BID on Days 1 to 14 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
1548595|NCT02608073|Drug|Cisplatin|Participants will receive cisplatin, 100 mg/m^2 via IV infusion on Day 1 of each 21-day cycle, for up to 8 treatment cycles (24 weeks).
1548596|NCT02608060|Drug|Epoetin Beta|Dosage at Initiation: Subcutaneous injection of 30000 IU administered once a week. Dosage could be increased to 30000 IU twice a week or 60000 IU once a week after 4 weeks if a blood transfusion was required or hemoglobin level did not increase by at least 0.5 g/dL versus baseline.
1548600|NCT02608008|Device|Data analysis|data parameters Analysis
1548601|NCT02607995|Behavioral|Behavioral standardized manual-based multidisciplinary routine care|Behavioral standardized manual-based multidisciplinary routine care (lifestyle intervention). Six sessions offered over the course of three to six months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media will be covered.
1548605|NCT02607969|Other|Home program|Parents will be educated about the home program which consisted of positioning the neck and head, sleep in alternating head positions and in side-laying to increase head shape symmetry and place infants, when awake and under supervision, regularly in the prone position a day to stimulate normal motor development (tummy time), decreasing the time spent in car seat at supine position. Environmental settings also were given to challenge the baby look through from the side no flattening to room, place colorful and sonorous toys or mirror on the opposite of the flattening side, and stimulate active rotation by communicating with baby from this side. Handling strategies, stretching and strengthening exercises will given for CMT
1548606|NCT02607956|Drug|DTG|50 mg tablets administered orally, once daily, without regard to food
1548607|NCT02607956|Drug|F/TAF|200/25 mg tablets administered orally, once daily, without regard to food
1548608|NCT02607956|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally, once daily, without regard to food
1548609|NCT02607956|Drug|DTG Placebo|Tablets administered orally, once daily, without regard to food
1548610|NCT02607956|Drug|F/TAF Placebo|Tablets administered orally, once daily, without regard to food
1548611|NCT02607956|Drug|B/F/TAF Placebo|Tablets administered orally, once daily, without regard to food
1548612|NCT02607943|Drug|Insulin Glargine|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
1548613|NCT02607943|Drug|Regular Insulin|Insulin Glargine Versus Regular Insulin Based Regimens in Glycemic Control
1548614|NCT02607930|Drug|ABC/DTG/3TC|600/50/300 mg tablets administered orally, once daily, without regard to food
1548615|NCT02607930|Drug|B/F/TAF|50/200/25 mg tablets administered orally, once daily, without regard to food
1548616|NCT02607930|Drug|ABC/DTG/3TC Placebo|Tablets administered orally, once daily, without regard to food
1548617|NCT02607930|Drug|B/F/TAF Placebo|Tablets administered orally, once daily, without regard to food
1548618|NCT02607917|Other|Mass Media plus clinic intervention.|
1548619|NCT02607917|Other|Media|
1548626|NCT02607852|Device|iPads|The current study will help determine if using Burn Outcomes Questionnaire and 17- item Pediatric Symptom Checklist (PSC-17) feedback data, collected on iPads or online, over the course of patient treatment will be useful for the physicians and ultimately impact the recovery of the patient.
1548627|NCT02607839|Biological|glucose or normal saline|20% glucose solution or normal saline, intravenous infusion
1548628|NCT02607826|Procedure|Starvation|Short-term starvation for a timeframe beginning 24h prior to chemotherapy administration, lasting until 6h after administration
1548629|NCT02607813|Drug|LXH254|pan-RAF inhibitor
1548630|NCT02607813|Drug|PDR001|Biological: PDR001 anti-PD1 antibody
1548633|NCT02607787|Behavioral|Exercise|The exercise programme aims to gradually increase participants physical activity levels so that they start achieving the recommended levels of at least 150 minutes moderate intensity aerobic activity per week and strengthening exercise for all major muscle groups at least twice per week.
1548634|NCT02607787|Other|Control|The control group will receive usual care whilst attending for the same 4 visits as the intervention group and have the same outcome measures tested. They will however receive the intervention information on their last visit.
1548635|NCT02607774|Drug|Midazolam|midazolam administered to all patients Days -7, 1 and 35.
1548636|NCT02607774|Drug|AIN457|secukinumab administered at Weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24
1548637|NCT02607761|Other|Video|Video-Audio Media
1548638|NCT02607748|Other|18F-NaF PET and coronary CTA imaging|
1548642|NCT02607709|Procedure|Lymphadenectomy in conjugation with nephroureterectomy|"Lymphadenectomy (intervention group only):
Lymphadenectomy performs in four fractions on the right side and two fractions on the left side according to Dissection template (Appendix 1). Renal hilar nodes are included in fraction 1 and 3, respectively."
1548643|NCT02607709|Procedure|Nephroureterectomy without lymphadenectomy|Removing the kidney, ureter and bladder cuff
1548644|NCT02607696|Drug|Zolpidem Hemitartarate|
1548648|NCT02607670|Drug|TAT4 Gel|
1548649|NCT02607670|Drug|Matching placebo|
1548650|NCT02607657|Drug|Eplerenone 25 mg|
1548651|NCT02607657|Drug|Eplerenone 50 mg|
1548652|NCT02607657|Drug|Eplerenone 100 mg|
1548653|NCT02607657|Drug|Eplerenone 50 mg twice a day|
1548654|NCT02607657|Drug|Eplerenone 25 mg twice a day|
1548655|NCT02607644|Device|Laryngeal Mask Airway (LMA)|Laryngeal Mask Airway (LMA) for Control group
1548656|NCT02607644|Device|Laryngeal Tube (LT)|Laryngeal Tube (LT) for Intervention group
1548657|NCT02607631|Drug|Pembrolizumab|treated with Pembrolizumab 200 mg every 3 weeks
1548658|NCT02607618|Drug|Iclaprim|Experimental treatment
1548659|NCT02607618|Drug|Vancomycin|Active comparator
1548662|NCT02607579|Drug|Exparel|
1548663|NCT02607579|Drug|Ropivacaine|
1548664|NCT02607566|Behavioral|Yoga|
1548665|NCT02607566|Behavioral|Walking Program|twice weekly walking program, 60 minutes for 12 weeks
1548666|NCT02607553|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle until disease progression
1548667|NCT02607540|Other|2 cycles cisplatin-5-fluorouracil|2 cycles cisplatin-5-fluorouracil(PF 2 cycles): cisplatin: 75mg/m2 d1，29; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32.
1548668|NCT02607540|Other|4 cycles cisplatin-5-fluorouracil|4 cycles cisplatin-5-fluoroura(PF 4 cycles): cilcisplatin: 75mg/m2 d1，29, 57, 85; 5-fluorouracil：750mg/m2 CIV24h d1-4，d29-32, d57-60, d85-88.
1548669|NCT02607540|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
1548670|NCT02607527|Device|Mitral Valve IRIS Ring|implantation of mitral implant surgically or mini thoracotomy
1548671|NCT02607514|Behavioral|hyperthermic yoga|heated yoga, 90-minutes
1548672|NCT02607501|Device|Implant eCLIPs|Implant eCLIPs at target bifurcation aneurysm
1548673|NCT02607488|Drug|Placebo|"Participants will receive an intravenous bolus of 0.1 mL/kg of saline 0.9% solution followed by a continuous infusion 0.1 mL/kg/h of Saline 0.9% which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]"
1548674|NCT02607488|Drug|Lidocaine 1%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1% solution which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]"
1548675|NCT02607488|Drug|Lidocaine 1.5%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 1.5% solution which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]"
1548676|NCT02607488|Drug|Lidocaine 2%|"Participants will receive an intravenous bolus of 0.1 mL/kg of lidocaine 1.5% solution followed by a continuous infusion 0.1 mL/kg/h of lidocaine 2% solution which will be continued for 24 hours after surgery.
All medications in the study protocol will be based on the dosing body weight [ideal body weight (IBW) + 0.4 × (actual body weight−IBW)]"
1548677|NCT02607475|Device|Robotic telesonography (MELODY Patient System, AdEchoTech)|Robotic telesonography using the MELODY Patient System (AdEchoTech) in conjunction with the SonixTablet ultrasound system (BK Ultrasound, formerly Ultrasonix).
1548678|NCT02607475|Device|Conventional sonography (EPIQ 5, Philips or LOGIQ E9, GE Healthcare)|Conventional sonography using EPIQ 5 (Philips) or LOGIQ E9 (GE Healthcare) ultrasound systems.
1548679|NCT02607462|Biological|PRP|
1548680|NCT02607462|Other|Placebo|
1548681|NCT02607449|Drug|FS-1|FS-1 is a liquid solution for internal intake and bears antimicrobial and antibacterial activities.
1548682|NCT02607449|Drug|Placebo|Placebo without any active pharmaceutical ingredients
1548683|NCT02607436|Drug|Sarpogrelate|Sarpogrelate
1548684|NCT02607436|Drug|Aspirin|Aspirin
1548692|NCT02607410|Drug|sitagliptin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
1548693|NCT02607410|Drug|NPH insulin|patients with type 2 diabetes,inadequately controlled with metformin plus glyburide, HbA1c between 6.6 to 10%, will be randomized to the addition of sitagliptin (Sitagliptin Group) or of bedtime NPH insulin (NPH Group) during one year
1548694|NCT02607384|Behavioral|Eyeglass wearing|Children found to require eyeglasses will be given two pairs free of charge
1548695|NCT02607384|Behavioral|Orthoptic exercises|Children found to have convergence insufficiency will be prescribed orthoptic exercises
1548696|NCT02607384|Other|Specialist referral|Children found to any other eye condition will be referred to a pediatric eye care specialist
1548697|NCT02607371|Other|VKAs|VKA have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1548698|NCT02607371|Other|NOACs including Rivaroxaban (Xarelto, BAY59-7939)|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1548699|NCT02607371|Other|Edoxaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1548700|NCT02607371|Other|Apixaban|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1548701|NCT02607371|Other|Dabigatran-etexilate|NOAC have been prescribed in the customary manner in accordance with the terms of the marketing authorization; decision to prescribe these agents has been made at least 3 months prior to study inclusion; assignment of a patient to a particular therapeutic strategy is only made retrospectively (treatment decision falls within current practice and the prescription of the medicines is separated from the decision to include the patient in the study)
1548702|NCT02607358|Other|blood sampling for HOTPR-testing|All subjects are tested for responderstatus using the VerifyNow System
1548703|NCT02607345|Dietary Supplement|Zusto|25gr
1548704|NCT02607345|Dietary Supplement|Glucomedics®|25gr
1548705|NCT02607332|Drug|Paclitaxel|
1548706|NCT02607319|Drug|Bemiparin sodium|Bemiparin sodium 3,500 IU will be started on the evening of the same day of embryo transfer and until the day of pregnancy test. If the test is positive, Bemiparin will be discontinued by the end of the 12th week of gestation.
1548710|NCT02607293|Drug|Gonal-f®|Recombinant human follicle stimulating hormone (r-FSH) will be administered subcutaneously (SC) for about 10 to 20 days along with the ART regimen as routinely practiced by Investigators and according to licensed summary of product characteristics (SmPC label) for the ovarian stimulation.
1548711|NCT02607293|Drug|Long GnRH agonist|As a part of the ART regimen GnRH-agonist will be administered for about 14 to 20 days until down regulation is satisfied as judged by investigator.
1548712|NCT02607293|Drug|GnRH antagonist|As a part of ART regimen GnRH-antagonist will be initiated and regimen will be as routinely practiced by Investigators and according to licensed SmPC label.
1548713|NCT02607280|Drug|DS-5565|DS-5565 15 mg (for moderate renal impairment) or 7,5 mg (for severe renal impairment), oral administration, Treatment period; 2-weeks titration and 12-weeks fixed dose
1548714|NCT02607267|Other|LSG and LRYGB|The role of the Edmonton Obesity Staging System in predicting post-operative outcome and 30-day mortality after metabolic surgery (LSG and LRYGB)
1548715|NCT02607254|Drug|Pregabalin|This enriched enrollment randomized withdrawal study comprises 4 phases: a screening and selection phase, a washout period from previous pain medication for enriched enrollment, an 8 week single blind pregabalin treatment phase; and a 4 week randomized withdrawal phase.
1553108|NCT02576353|Drug|Fentanyl Citrate|Fentanyl Citrate IV (FCIV)
1548716|NCT02607254|Drug|Placebo|After finishing the first phase of treatment with Pregabalin for 8 weeks, patients who report significant improvement in their pain will be randomized to either receive placebo or Pregabalin.
1548717|NCT02607241|Device|OCT-guided BRS implantation|Implantation of a BRS using OCT to measure vessel size, choose BRS size and length and assess implantation results and the need of further postdilations
1548718|NCT02607241|Device|FFR-guided DCB-only PCI|PCI performed under FFR guidance using following algorithm: (1) predilation followed by angiographic assessment of residual stenosis and dissections; (2) evaluate suitability for DCB-only, which is deemed feasible if the FFR > 0.8, residual diameter stenosis < 40% and no flow-limiting dissections are observed; (3) DCB dilation and (4) assessment of final results using FFR and QCA measurements. Provisional stenting is allowed only if the final PCI results are not acceptable (flow-limiting dissection, residual stenosis > 40% or FFR < 0.8).
1548721|NCT02607215|Drug|Vinorelbine|25 mg/m2, D1, D8
1548722|NCT02607215|Drug|DDP|75 mg/m2, D1
1548723|NCT02607202|Drug|nab-paclitaxel|
1548724|NCT02607202|Drug|Carboplatin|
1548725|NCT02607202|Drug|Gemcitabine|
1548726|NCT02607176|Drug|Heweizhixie capsule|3 #, Tid, Oral for 3 days
1548727|NCT02607163|Drug|dexmedetomidine|Immediately after the induction of anesthesia, patients in the dexmedetomidine group received dexmedetomidine continuous intravenous (IV) infusion of 0.4 mcg/kg/h until 24 hours after surgery.
1548728|NCT02607163|Drug|saline|same infusion rate (received equal volume of normal saline), IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery.
1548729|NCT02607150|Other|Cerebral Oxygenation Changes|Monitor cerebral oxygenation changes in patients receiving blood transfusions who are undergoing spinal fusion surgery.
1548730|NCT02607137|Behavioral|Health Education|Information on healthy living style in relation to physical activity
1548731|NCT02607124|Drug|Ribociclib|
1548732|NCT02607111|Drug|Dalteparin|
1548733|NCT02607072|Drug|Acetylsalicylic acid (ASA)/aspirin 200 mg daily|
1548734|NCT02607072|Drug|Acetylsalicylic acid (ASA)/aspirin 100 mg daily|
1548735|NCT02607072|Drug|Placebo|
1548736|NCT02607059|Other|Registry|
1548737|NCT02607046|Other|Exercise training|The exercise program includes supervised treadmill walking and home-based walking exercise.
1548738|NCT02607046|Other|NMES|This intervention consists of using neuromuscular electrical stimulation (NMES) as a form of passive exercise for muscles in the legs.
1548739|NCT02607033|Other|Exercise|Individuals will be asked to walk 3 times a week on a treadmill (initially starting at 15 minutes and progressing up to 40 minutes) and participate in a short weight training program focused on increasing strength in the legs.
1548740|NCT02607033|Other|Weight Loss|Individuals will be asked to meet with a registered dietitian once a week to discuss strategies to reduce daily caloric intake to gradually reduce body weight over 6 months.
1548741|NCT02607020|Other|Physical exercises in an self-management setting|"Workout sessions will be based on the principle of self-management, without direct supervision of a therapist. Sessions will include:
1. Twenty minutes of aerobic exercises 1.2. Five to ten minutes of stretching exercises. 2.3. Fifteen to twenty minutes of resistance exercises to improve muscle strength of lower limbs. The targeted muscles will be the hip flexors, the knee extensors and flexors, and the foot extensors and plantar flexors. These exercises will comply with the recommendations of the American College of Sports Medicine (ACSM, 2011). Patients will be asked to perform muscle contractions against the gravity (about 15 repeats). There will be on average 5 to 6 series per session. Several muscle groups of the lower limbs will be trained during the same session."
1548742|NCT02607020|Other|Relaxation|The relaxation sessions of the control group will be carried out with the help of soothing music. Patients will receive a Compact Disc (CD) of soothing music at the inclusion. Patients will also have an electronic training logbook that will be reviewed each week by a therapist. They will have a phone contact with the therapist every two weeks, to discuss about the treatment and adapt it if necessary. They will also have a reminder session every four weeks.
1548743|NCT02607007|Other|2% M.F. Milk|
1548744|NCT02607007|Other|White Bread|
1548745|NCT02607007|Other|Strawberry Jam|
1548746|NCT02607007|Other|31% M.F. Cheddar Cheese|
1548747|NCT02607007|Other|2% M.F. Plain Greek yogurt|
1548748|NCT02607007|Other|Soy Beverage|
1548749|NCT02607007|Other|Water|
1548750|NCT02606994|Drug|Oral Defense Toothpaste|Brush with a Oral Defense Toothpaste three times per day during the study
1548751|NCT02606994|Drug|Crest Toothpaste|Brush with Crest Toothpaste three times per day during the study
1548752|NCT02606994|Drug|Magic Mouth Rinse|Participants using Crest Toothpaste who require additional pain intervention for their oral mucositis will be provided Magic Mouth Rinse
1548753|NCT02606981|Device|Water chlorination by the Flogenic|The chlorine doser delivers a constant amount of chlorine into water as it flows into a holding tank. The water is then piped to public and private taps.
1548754|NCT02606981|Device|Active control, vitamin C dosing into water|The control group will receive a vitamin C dosing device that looks identical to the intervention chlorine doser installed in the holding tank that feeds their shared water access point.
1548755|NCT02606955|Device|BIA DW|All patients undergo a Clinical DW assessment. Then, they undergo a HD session in which BIA DW (injection of 800 microAmpere at 50 kilohertz alternating sinusoidal current with a standard tetrapolar technique) is determined. BIA DW is determined by performing the REsistance Stabilization Test (REST).
1548756|NCT02606942|Other|Questionnaires, physical exam, US of the knee|Function and pain questioners, physical findings and sonographic study of the knee joint
1548757|NCT02606916|Radiation|SMART|Once-daily simultaneous modulated accelerated radiotherapy(64Gy/30f )
1548758|NCT02606916|Drug|DDP|DDP(25 mg/m2.qw) for six weeks.
1548759|NCT02606916|Drug|S-1|S-1(40 mg/m2.Bid .po) on D1-14，D22-35 during radiotherapy
1549907|NCT02598934|Drug|Ibandronate|Participants will receive oral ibandronate, 150 mg once weekly, for approximately 6 months.
1548762|NCT02606890|Other|MRI|Stroke patients routinely undergo MRI at Charite Campus Benjamin Franklin. Type of MRI stroke pattern is evaluated with regard to presence or detection of (new) atrial fibrillation.
1548763|NCT02606877|Drug|nintedanib|
1548764|NCT02606877|Drug|pirfenidone|
1548765|NCT02606864|Drug|Nifurtimox (BAYa2502)|Oral Intake of 4 x 30 mg nifurtimox tablets
1548766|NCT02606838|Device|Styx Lancing Device|Untrained Persons With Diabetes used the Styx Lancing Device with 28 and 30 Gauge lancets to obtain fingerstick and Alternate Site palm capillary blood. Study Staff tested the capillary blood using Contour NEXT Blood Glucose Meters (BGMs) and recorded the results. Meter results could be numeric, non-numeric (ie, error messages), or not obtained at all.
1548768|NCT02606812|Dietary Supplement|Traditional-food|Intake of ethnic local food
1548769|NCT02606799|Device|CytoSorb cytokine elimination|Hemoperfusion using continuous veno-venous hemofiltration (citrate regional anticoagulation) with CytoSorb cytokine elimination over a period of 48h immediately following admission to the intensive care unit
1548770|NCT02606786|Other|Lumbopelvic stabilization exercises|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine.
1548771|NCT02606773|Drug|Ascorbic Acid|Ascorbic acid in different ways and doses
1548772|NCT02606760|Drug|P-3073|
1548773|NCT02606760|Drug|Vehicle of P-3073|
1548774|NCT02606734|Device|Coronary Angiography|The DyeVert System will be used during coronary angiographic procedures which include: diagnostic only, diagnostic + PCI or PCI only cases.
1548776|NCT02606682|Drug|NPT200-11|Single doses of NPT200-11capsules, orally administered
1548777|NCT02606682|Drug|Placebo|Single doses of microcrystalline cellulose capsules, orally administered
1548778|NCT02606669|Dietary Supplement|Meal Replacement|Using a Meal Replacement product, supplemented by protein powder and multivitamin
1548782|NCT02606630|Drug|ABT-555|ABT-555 will be administered on Visit 4 in Part 2 only
1548783|NCT02606617|Drug|Mosapride|Mosapride(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
1548784|NCT02606617|Drug|Placebo|Placebo(5mg, 3/d), antidiabetic drug except DPP-IV inhibitor and GLP-1 receptor activator.
1548785|NCT02606604|Device|RT 300: Lower Extremity Cycling|Individuals will be randomly assigned to either the FES cycling or cycling only group and will perform lower extremity cycling. Individuals will participate in an interval training cycling program 3 times per week for 8 weeks.
1548789|NCT02606578|Other|Questionnaires|"The study team will collect information from your medical record regarding: demographics, operation, nutritional status, laboratory values, testing results, complications, hospital data, cost, length of stay, past medical history and clinical outcomes.
At your clinical follow-up visits (~4 weeks, 6 months, and 12 months post operation), a study coordinator will meet with you to assess for adverse events and to have you complete research questionnaires. Alternatively, the study coordinator may call you to assess for adverse events and ask if we can mail you the research questionnaires to complete and mail back.
You will also be asked to complete the research questionnaires a minimum of once a year for your lifetime: A study coordinator will call you and ask if we can mail you questionnaires to complete and mail back."
1548790|NCT02606565|Biological|Intervention arm: 4% chlorhexidine|See previous description
1548791|NCT02606552|Drug|Dabigatrain plus aspirin|Dabigatran (Pradaxa®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with atrial fibrillation. Aspirin is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop clopidogrel (maintain dabigatran + aspirin) at 3 months after PCI.
1548792|NCT02606552|Drug|Dabigatrain plus clopidogrel|Clopidogrel is indicated for the prevention of stent thrombosis and myocardial infarction in patients treated with drug-eluting stents. Patients will be randomized to stop aspirin (maintain dabigatran + clopidogrel) at 3 months after PCI.
1548793|NCT02606552|Device|Amplazter Cardiac Plug (ACP)|Patients allocated to the intervention group should be received percutaneous closure of the LAA by use of the ACP device (St. Jude Medical, St Paul, MN, USA).
1548794|NCT02606539|Procedure|Total abdominal hysterectomy and methotrexate|After written consent laparotomy will be done then pelvic examination for extra uterine spread, palpation of liver, omentum for any gross lesions and then hystrectomt bilateral salpigooophrectomy will be done) plus single course methotrexate(anti folate chemotheraputic agent, vial form given by intramuscular injection) 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG (the cycle may be repeated until normalization of B-HCG)
1548795|NCT02606539|Drug|Methotrexate plus folinic acid alone|methotrxate 1mg/kg every other day alternating with calcium folinate 0.1 mg/kg for 4 doses each cycle then measuring B-HCG and cycle repeated until normalization of B-HCG
1548796|NCT02606526|Biological|BCG at birth|See previous description
1548797|NCT02606526|Biological|Control arm: Delayed BCG|See previous description
1548798|NCT02606513|Other|MR Urography; CT Urography|
1548872|NCT02605928|Device|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is an injection needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with synovial fluid.
1548800|NCT02606461|Drug|Selinexor|Selinexor 60mg
1548801|NCT02606461|Drug|Placebo|
1548802|NCT02606448|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
1548803|NCT02606448|Procedure|Femoral nerve block|Pre-operative femoral nerve block
1548804|NCT02606448|Drug|Ropivicaine|Ropivicaine was used in all femoral nerve blocks
1548805|NCT02606435|Procedure|percutaneous coronary intervention (PCI)|percutaneous coronary intervention (PCI) by stent implantation
1548806|NCT02606435|Device|thrombus aspiration|thrombus aspiration with export catheter
1548807|NCT02606422|Device|Active tDCS plus Speech-Language Therapy|Stimulation will be delivered by a battery-driven constant current stimulator. The electrical current will be administered to a pre-specified region of the brain (inferior frontal gyrus). The stimulation will be delivered at an intensity of 2mA (estimated current density 0.04 mA/cm2; estimated total charge 0.048C/cm2) in a ramp-like fashion for a maximum of 20 minutes. Speech-language therapy will be oral and written naming.
1548808|NCT02606422|Device|Sham plus Speech-Language Therapy|Speech-Language therapy will be administered during sham stimulation. Current will be administered in a ramp-line fashion but after the ramping the intensity will drop to 0 mA. Speech-language therapy will be oral and written naming.
1548809|NCT02606409|Drug|Dexmedetomidine|Dexmedetomidine sedation at a starting dose of 0.2-7.0 µg/kg/hour.
1548810|NCT02606409|Drug|Propofol|Propofol sedation at a starting dose of 10-70 µg/kg/hour.
1548811|NCT02606396|Procedure|Cryotherapy|Cryotherapy employs thermal ablation to treat esophageal cancer and BE. Ablation is achieved by intracellular disruption and ischemia that is produced by freeze-thaw cycles using liquid nitrogen or carbon dioxide
1548812|NCT02606396|Procedure|Esophagogastroduodenoscopy (EGD)|EGD is a diagnostic procedure that allows the physician to diagnose and treat problems in the upper gastrointestinal (UGI) tract. The doctor uses a long, flexible, lighted tube called an endoscope.
1548813|NCT02606396|Procedure|Endoscopic ultrasound (EUS)|EUS is a procedure that allows a doctor to obtain images and information about the digestive tract and the surrounding tissue and organs, including the lungs. Ultrasound testing uses sound waves to make a picture of internal organs.
1548814|NCT02606383|Drug|Dapaconazole|
1548815|NCT02606383|Drug|Ketoconazole|
1548816|NCT02606370|Other|Unstable shoe|Wearing Unstable shoes during 1 month
1548817|NCT02606357|Drug|INSULIN GLARGINE|"Pharmaceutical form:Solution
Route of administration: Subcutaneous"
1548818|NCT02606344|Other|Mico-finance based intervention|
1548819|NCT02606331|Procedure|Piezosurgery|Corticotomy cuts will be performed by this technique.
1548820|NCT02606331|Radiation|ER:YAG laser|Corticotomy cuts will be performed by this technique.
1548821|NCT02606318|Other|Adjusted the challenge-skill balance|In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
1548822|NCT02606318|Other|Non-adjusted the challenge-skill balance|The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
1548823|NCT02606305|Drug|IMGN853|
1548824|NCT02606305|Drug|Bevacizumab|
1548825|NCT02606305|Drug|Carboplatin|
1548826|NCT02606305|Drug|Pegylated Liposomal Doxorubicin|
1548827|NCT02606305|Drug|Pembrolizumab|
1548828|NCT02606292|Procedure|Photoacoustic endoscopy|
1548829|NCT02606292|Procedure|Endoscopic ultrasound (standard of care)|
1548830|NCT02606292|Procedure|Endoscopic surgery (standard of care)|
1548833|NCT02606266|Drug|Valganciclovir|Oral valganciclovir (Rovalcyte 50 mg/ml, powder for oral suspension) at a dose of 16 mg/kg 2 times/day (max 900 mg/d) for 6 weeks.
1548834|NCT02606253|Drug|tolvaptan|Tolvaptan (Samsca) is a vasopressin 2 receptor antagonist that works in the collecting duct of the nephron to cause diuresis.
1548835|NCT02606253|Drug|Chlorothiazide|Chlorothiazide (Diuril) is an intravenous thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
1548836|NCT02606253|Drug|Metolazone|Metolazone (Zaroxolyn) is an oral thiazide diuretic that works in the distal convoluted tubule of the nephron to cause diuresis.
1548837|NCT02606240|Device|CO2 removal with PRISMALUNG in ARDS|Observational study of patients with mild to moderate Acute Respiratory Distress Syndrome (ARDS) submitted to Extracorporeal CO2 removal (ECCO2R) with the PRISMALUNG device to allow ultraprotective mechanical ventilation with tidal volume reduction (from 6 to 4 ml/kg, predicted body weight) and plateau pressure reduction from 28-30 to 23-25 cmH2O.
1548838|NCT02606227|Behavioral|Financial incentive|Vouchers
1548839|NCT02606227|Other|No financial incentive|No financial intervention
1548840|NCT02606214|Drug|TBA-354|
1548841|NCT02606214|Drug|TBA-354 Placebo|
1548873|NCT02605915|Drug|Atezolizumab|Atezolizumab 1200 milligrams (mg) or 840 mg (Cohort 1E only) flat dose administered via intravenous (IV) infusion on Day 1 of every 21-day cycle.
1548842|NCT02606201|Other|Peri sphincter injection Autologous myofibers|"The first step of the procedure consists to harvest a muscle fragment from the lower part of the rectus abdominis muscle of the abdomen approached by a short incision. Injectable myofiber cores will be prepared by hydrodissection of the muscle biopsy.
All myofibers cores will be suspended in autologous serum prepared by centrifugation before the incision.
During the second step of the procedure, the myofibers will be injected percutaneously into the peri-sphincter region under endoscopic and radiographic control."
1548843|NCT02606188|Device|Modified High-flow nasal cannula|Modified High-flow nasal cannula
1548844|NCT02606188|Device|nasal cannula|Conventional oxygen therap
1548845|NCT02606175|Other|Taking questionnaires and tests|"At predefined timepoints:
2 tests for health literacy: New Vital Sign-Dutch version (NVS-D) and Functional, Communicative and Critical Health Literacy (FCCHL)
1 test for medication adherence: BAASIS
1 questionnaire about demographic factors (weight, income, sex, age, financial situation,...)
1 test about medication knowledge"
1548846|NCT02606149|Behavioral|Truthful information on chemotherapy risks|One of two trained oncologist will meet the patient and inform him following an interview-guideline
1548847|NCT02606149|Behavioral|Standard of information|
1548849|NCT02606123|Drug|EPI-506|"Patients will receive EPI-506 as an oral softgel capsule.
Part 1:
Approximately six dose levels of EPI-506 will be studied, beginning at 80 mg/day. During the Single-Dose Period, patients will first receive a dose of EPI-506 in the fasted state followed by 2 days of washout, and then patients will receive a second dose of EPI-506 in the fed state followed by 2 days of washout. Patients will then enter the Multiple Dosing and Long-term Dosing Period where they will receive once or twice daily dosing in a fed or fasted state until they meet discontinuation criteria.
Part 2:
The dose in Part 2 will be determined in Part 1 of the study. Patients will receive the Part 2 dose daily until they meet discontinuation criteria."
1548850|NCT02606097|Drug|regorafenib|
1548852|NCT02606071|Device|CRT-D|HF patients treated in clinical practice with a CRT-D device
1548853|NCT02606058|Procedure|Deferred cord clamping|Deferred cord clamping (for 60 seconds or more with the baby held below or at the level of the placenta)
1548854|NCT02606045|Drug|recombinant von Willebrand factor|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
1548855|NCT02606045|Drug|tranexamic acid|"Group I will receive Arm A recombinant von Willebrand factor 40 IU/kg intravenously (IV) infusion on day 1 of each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5 of each of two menstrual cycles, Cycles 3 and 4.
Group II will receive Arm B, TA 650 mg 2 tablets orally (po) three times daily on days 1-5, for each of two menstrual cycles, Cycles 1 and 2. They will then be crossed over to Arm A, rVWF 40 IU/kg intravenously (IV) infusion on day 1 on each of two menstrual cycles, Cycles 3 and 4."
1548856|NCT02606032|Drug|Metronidazole|active comparator
1548857|NCT02606032|Drug|Doxycycline|active comparator
1548858|NCT02606032|Drug|Terbinafine|active comparator
1548859|NCT02606032|Drug|Placebo|identical placebos to all antibiotics
1548860|NCT02606006|Behavioral|Canine Animal-Assisted Therapy|Canine Animal-Assisted Therapy is the inclusion of a certified therapy canine in the standard of care physical therapy session, such as for walking, fetching balls, standing/petting, etc.
1548861|NCT02606006|Behavioral|Standard of Care Physical Therapy|This intervention is the standard of care physical therapy currently offered. No canine is present.
1548862|NCT02605993|Biological|Study Drug- ALXN1210|"Cohort 1: ascending dose escalation to therapeutic dose level
At Day 477, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen, as follows:
≥ 40 to < 60 kg: 3000 mg every 8 weeks
≥ 60 to < 100 kg: 3300 mg every 8 weeks
≥ 100 kg: 3600 mg every 8 weeks"
1548863|NCT02605993|Biological|Study Drug- ALXN1210|"Cohort 2: ascending dose escalation to therapeutic dose level
At Day 463, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen, as follows:
≥ 40 to < 60 kg: 3000 mg every 8 weeks
≥ 60 to < 100 kg: 3300 mg every 8 weeks
≥ 100 kg: 3600 mg every 8 weeks"
1548864|NCT02605993|Biological|Study Drug- ALXN1210|"Cohort 3: ascending dose escalation to therapeutic dose level
At Day 477, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen, as follows:
≥ 40 to < 60 kg: 3000 mg every 8 weeks
≥ 60 to < 100 kg: 3300 mg every 8 weeks
≥ 100 kg: 3600 mg every 8 weeks"
1548865|NCT02605993|Biological|Study Drug- ALXN1210|Cohort 4: ascending dose escalation to therapeutic dose level
1548866|NCT02605980|Behavioral|Sedentary time|
1548867|NCT02605967|Drug|PDR001|PDR001 is a humanized anti-PD-1 IgG4 antibody which blocks the binding of PD1 to its ligands PD-L1 and PD-L2.
1548868|NCT02605967|Drug|Investigator choice of chemotherapy|commonly used chemotherapy as per investigator's choice
1548869|NCT02605954|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablets administered orally once daily
1548870|NCT02605954|Drug|ABC/3TC|ABC/3TC (600/300 mg) tablets administered orally once daily
1548871|NCT02605954|Drug|Third Antiretroviral Agent|"Third antiretroviral agents could include one of the following:
ATV+cobicistat (COBI; Tybost®) or ATV/COBI FDC
DRV+COBI or DRV/COBI FDC
darunavir (DRV; Prezista®) + RTV
lopinavir/ritonavir (LPV/r; Kaletra®)
atazanavir (ATV; Reyataz®) + ritonavir (RTV; Norvir®)
efavirenz (EFV; Sustiva®)
etravirine (ETR; Intelence®)
nevirapine (NVP; Viramune®)
rilpivirine (RPV; Edurant®)
dolutegravir (DTG; Tivicay®)
raltegravir (RAL; Isentress®)
fosamprenavir (FPV; Lexiva®) + RTV
saquinavir (SQV; Invirase®) + RTV
ATV (no booster)
Drug classes:
Protease inhibitors (PI): LPV/r, ATV, RTV, ATV, DRV, FPV and SQV
Pharmacokinetic enhancer: COBI
Non-nucleoside reverse transcriptase inhibitors (NNRTI): EFV, RPV, NVP, and ETR
Integrase inhibitors: RAL and DTG"
1548874|NCT02605915|Drug|Carboplatin|Carboplatin will be administered at an initial target of area under the curve (AUC) of 6 milligrams per milliliter*min (mg/mL*min) via an IV infusion on Day 1 of every 21-days for 6 cycles.
1548875|NCT02605915|Drug|Docetaxel|Docetaxel 75 mg/m^2 administered via IV infusion on Day 1 every 21-days for 6 cycles.
1548876|NCT02605915|Drug|Pertuzumab|Pertuzumab 840 mg loading dose then 420 mg administered via IV infusion on Day 1 of every 21-day cycle.
1548877|NCT02605915|Drug|Trastuzumab|Trastuzumab 8 milligram per kilogram (mg/kg) loading dose, then 6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle.
1548878|NCT02605915|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg administered via IV infusion on Day 1 of every 21-day cycle. Dose de-escalation may occur for trastuzumab emtansine, from the full trastuzumab emtansine dose at 3.6 mg/kg on Day 1 of every 21-day cycle, potentially to 3.0 mg/kg (Cohort 1C) or 2.4 mg/kg q3w (Cohort 1D).
1548879|NCT02605915|Drug|Doxorubicin|Doxorubicin will be administered at 60 mg/m^2 every 2 weeks as an IV bolus over 3 to 5 minutes or as an infusion over 15 to 30 minutes.
1548880|NCT02605915|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 600 mg/m^2 on Day 1 of each 21 day cycle as an IV bolus over 3 to 5 minutes or as an infusion, in accordance with local policy.
1548881|NCT02605902|Behavioral|(i)Comprehensive Behavioral Intervention for Tics|
1548882|NCT02605902|Behavioral|internet-delivered psychoeducation and relaxation training|
1548883|NCT02605889|Other|Laser acupuncture|Laser acupuncture
1548884|NCT02605876|Device|Whole body vibration|
1548885|NCT02605876|Device|Local muscle vibration|
1548886|NCT02605863|Drug|Enzalutamide|160 mg by mouth daily for 12 months
1548887|NCT02605850|Other|Water|All subjects will consume ground beef patty meal with water at the baseline visit.
1548888|NCT02605850|Dietary Supplement|Pomegranate Juice|Pomegranate Juice will be taken 1/day for 4 weeks.
1548889|NCT02605850|Dietary Supplement|Pomegranate extract|Pomegranate extract will be taken 1/day for 4 weeks.
1548890|NCT02605837|Drug|OBS|Oral Budesonide Suspension 10 mL of 0.2 mg/mL every morning and at bedtime
1548891|NCT02605837|Drug|Placebo|Identical presentation of the experimental drug administered orallys as specified
1548892|NCT02605824|Drug|n-acetylcystine|NAC is a mucolytic drug.
1548893|NCT02605824|Drug|0.9% saline|Normal saline is a placebo agent.
1548894|NCT02605811|Drug|temozolomide|
1548895|NCT02605811|Radiation|prophylaxis cranial radiotherapy|2
1548896|NCT02605798|Drug|Elbanovir|1 tablet contains 400 mg sofosbuvir
1548897|NCT02605798|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
1548898|NCT02605798|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
1548900|NCT02605772|Drug|Acarbose|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
1548901|NCT02605772|Drug|Metformin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
1548902|NCT02605772|Drug|Saxagliptin|group1:metformin 1.5g + Saxagliptin 5mg group2:acarbose 300mg + Saxagliptin 5mg
1548903|NCT02605759|Device|CryoBalloon Focal Ablation System|Positioned within the esophagus at the target location, the Balloon is simultaneously inflated and cooled with nitrous oxide. The nitrous oxide cools the inner Balloon surface. The Balloon remains stationary during the delivery of the nitrous oxide for the Cryoablation of Dysplastic Squamous Tissue in Patients with Esophageal Squamous Cell Dysplasia
1548904|NCT02605746|Drug|ceritinib 750mg|
1548907|NCT02605720|Drug|Dihydroartemisinin-piperaquine|DHA/PPQ dose 2.1/17.1 mg/Kg daily for 3 days (PNG National Malaria Treatment Protocol) monthly for 3 months
1548908|NCT02605707|Drug|Intravenous stem cell transplantation|Intravenous injection of autologous endothelial progenitor cells transplantation
1548909|NCT02605694|Drug|Duvelisib|25 mg will be administered orally twice daily (BID) during 21-day cycles (Cycles 1-6) followed by 28-day cycles (Cycle 7 and beyond) until disease progression or unacceptable toxicity
1548910|NCT02605694|Drug|Rituximab|375 mg/m2 will be administered as an intravenous (IV) infusion on Day 1 of Cycles 1-6 (21-day cycles).
1548911|NCT02605694|Drug|R-CHOP|"IV infusion on Day 1 of Cycles 1-6 (21-day cycles)
Cyclophosphamide (750 mg/m2)
Doxorubicin hydrochloride (50 mg/m2)
Vincristine sulfate (1.4 mg/m2) (2 mg maximum)
Rituximab (375 mg/m2)"
1548912|NCT02605694|Drug|Prednisone|100 mg orally on Days 1-5 of Cycles 1-6 (21-day cycles)
1548913|NCT02605681|Other|Therapy for sepsis|Conventional therapy to treat sepsis
1548914|NCT02605668|Behavioral|Intensified psychological intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 6 weeks (2 sessions per week/week 1 and 2, 3 sessions per week/week 3 und 4, 1 session per week/week 5 and 6)
1548915|NCT02605668|Behavioral|Standard intervention|12 sessions of Cognitive Behavioral Therapy a 100 minutes, over the course of 10 weeks (2 sessions per week/week 1 and 2, 1 session per week/week 3 to 10)
1548916|NCT02605655|Drug|AMP-1915|A traditional Chinese Formula extract from Astragalus, Radix Puerariae and Cortex Mori is mixed into instant noodles. Patients are treated with AMP-1915 as meal.
1548917|NCT02605655|Other|Placebo|Instant noodles without drug
1548919|NCT02605629|Other|CG428|The experimental group will receive CG428. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
1548920|NCT02605629|Other|Placebo|The placebo group will received placebo which excluded active ingredients. For each application, the patient should shake the bottle before spraying 10-12 times directly to the dry scalp whole area, with the nozzle, and then gently massage the whole scalp with fingertips in order to spread the lotion evenly until it has completely penetrated the scalp. Hairs should not be washed or shampooed within 1 hour following study treatment administration. Each dose should be spaced out by minimum 4 hours.
1549102|NCT02604485|Drug|Cohort 3|XOMA 358 single dose level C administered by an intravenous infusion
1548921|NCT02605616|Drug|AZ compound|AZ compound 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
1548922|NCT02605616|Other|Placebo|Placebo 800 mg/day for 12 weeks (plus or minus 1 week) in two divided doses morning (400 mg) and evening (400 mg).
1548923|NCT02605590|Drug|AIR DNase|
1548924|NCT02605590|Drug|Placebo|
1548925|NCT02605577|Procedure|new systemic nutrition management protocol|a new established systemic nutrition management protocol
1548926|NCT02605564|Other|Gluten Free Diet|Gluten Free Diet
1548927|NCT02605564|Other|Placebo|Placebo No intervention, standard T1DM diet
1548928|NCT02605551|Procedure|Osteopathic Manipulative Therapy|"All OMT techniques will be performed by osteopathic physicians who will have received training specific to this protocol prior to study initiation. All used techniques will be slow moving and gentle to augment rest and relaxation, promote autonomic balance, and release fascial contractures. The techniques that will be used in this protocol are:
OM Occipitomastoid release technique
Sub-Occipital Release Technique
Rib Raising Technique
Rotatory stimulation of posterior Chapman's Reflexes
Lymphatic Pumps and Effleurage: (Pedal Pump of Dalrymple)"
1548929|NCT02605551|Behavioral|Lifestyle Modification|Patients will be counseled on healthy behaviors such as regular exercise, weight loss, and a healthy diet
1548930|NCT02605538|Biological|Vaccination with vaccine against hepatitis A and B|Vaccination against hepatitis A and B
1548933|NCT02605512|Other|Subclinical cardiac lesions and biomarkers|Functional myocardial dysfunction based on 2D-speckle tracking echocardiography, Anatomical coronary lesions based on Coronary computed tomography angiography, a panel of circulating biomarkers based on blood samples and plasma
1548934|NCT02605499|Other|UV-C light disinfection|UV-C light disinfection will be used in hospital patient rooms as an adjunct to routine daily and discharge cleaning.
1548937|NCT02605473|Drug|Decitabine|Starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
1548938|NCT02605473|Drug|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
1548939|NCT02605460|Drug|Busulfan|12mg/kg, ORAL, divided in 4 days, 3mg/kg/day ORAL, during days -7, -6, -5 y -4.
1548940|NCT02605460|Drug|Cyclophosphamide|80mg/kg, Intravenous (IV), divided in 2 days, 40mg/kg/day IV, during days -3 y -2.
1548941|NCT02605460|Drug|CXCR4 Antagonist|24mg, Subcutaneous (SC), in one day, 24mg/day SC, during day -4.
1548942|NCT02605460|Procedure|Hematopoietic Stem Cell Transplantation|Peripheral blood HSC (autologous HSCT) or Bone Marrow HSC (allogeneic HSCT) transfusion, day 0
1548943|NCT02605447|Drug|3 months of dual antiplatelet therapy (DAPT)|3 months of P2Y12 inhibitor (clopidogrel, prasugrel or ticagrelor) plus 15-months of aspirin
1548944|NCT02605447|Device|SYNERGY Stent System|SYNERGY Everolimus-Eluting Platinum Chromium Coronary Stent System
1548945|NCT02605434|Drug|Accordion Pill™ Carbidopa/Levodopa|AP-CD/LD capsule containing 50 mg carbidopa with 400 mg or 500 mg levodopa administered orally twice or 3 times a day
1548946|NCT02605434|Drug|Sinemet®|Sinemet® tables containing carbidopa and levodopa 25/100 mg will be administered orally at least 4 times a day according to patients need
1548947|NCT02605434|Drug|Placebo -AP-CD/LD|Placebo for AP-CD/LD capsule
1548948|NCT02605434|Drug|Placebo- Sinemet|Placebo for Sinemet tables
1548949|NCT02605421|Drug|Thiotepa|Thiotepa by IV once daily for 3 doses on Days -7, -6 and -5. Given as part of Consolidation Course #1 along with Cyclophosphamide.
1548950|NCT02605421|Drug|Cyclophosphamide|Cyclophosphamide by IV once daily for 4 doses on Days -5, -4, -3 and -2. Given as part of Consolidation Course #1 along with Thiotepa.
1548951|NCT02605421|Drug|Melphalan|Melphalan by IV once daily for 3 doses on Days -7, -6, and -5. Given as part of Consolidation Course #2 along with Etoposide and Carboplatin.
1548952|NCT02605421|Drug|Etoposide|Etoposide by IV once daily for 4 doses on Days -7, -6, -5 and -4. Given as part of Consolidation Course #2 along with Melphalan and Carboplatin.
1548953|NCT02605421|Drug|Carboplatin|Carboplatin by IV once daily for 4 doses on Days -7, -6, -5 and -4. Given as part of Consolidation Course #2 along with Etoposide and Melphalan.
1548954|NCT02605421|Biological|Autologous Stem Cell Infusion|On Day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
1548955|NCT02605421|Biological|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF SQ or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir ANC > 2000/μL for 3 consecutive days.
1548956|NCT02605408|Device|LenSx® laser system|Femtosecond laser system used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
1548957|NCT02605408|Procedure|Phacoemulsification|Removal of the cataractous lens
1548960|NCT02605382|Drug|Chlorhexidine gluconate|
1548961|NCT02605382|Drug|placebo|Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
1548962|NCT02605369|Behavioral|Intervention arm: An integrated package|See description in previous column
1548963|NCT02605356|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|
1548964|NCT02605356|Drug|Placebo|
1548965|NCT02605356|Drug|Bortezomib|
1548966|NCT02605356|Drug|Dexamethasone|
1548967|NCT02605343|Other|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
1548968|NCT02605330|Procedure|Fibrinogen plasma level|At 12 different time points investigators plan to measure the plasma fibrinogen level with conventional coagulation tests (Clauss fibrinogen) and with ROTEM.
1548969|NCT02605317|Other|WhatsApp|Consultations used WhatsApp Messenger
1549908|NCT02598921|Radiation|three dimensional ultrasound|
1548972|NCT02605291|Other|Diet with a different macronutrient content A|A diet with altered macronutrient content will be provided to participants on days 4-6 of experimental arm 1.
1548973|NCT02605291|Other|Diet with a different macronutrient content B|A diet with a different macronutrient content compared to arm 1 will be provided to participants on days 4-6 of experimental arm 2.
1548974|NCT02605291|Other|Diet with a different macronutrient content C|A diet with a different macronutrient content compared to arms 1 and 2 will be provided to participants on days 4-6 of experimental arm 3.
1548975|NCT02605291|Other|Interval treadmill running exercise|Participants will perform interval treadmill running exercise on days 4 and 5 of all experimental arms.
1548976|NCT02605291|Other|Steady state treadmill running exercise|Participants will perform steady state treadmill running exercise on day 7 of all experimental arms.
1548977|NCT02605278|Other|Clinical program for pain and depression|Already described
1548978|NCT02605278|Other|Control|Care as usual
1548979|NCT02605265|Radiation|Radiation|Pelvic Radiation: 50Gy/25Fx
1548980|NCT02605265|Drug|Capecitabine|
1548981|NCT02605265|Drug|Irinotecan|
1548982|NCT02605265|Drug|Oxaliplatin|
1548983|NCT02605252|Drug|Peginterferon alfa-2b|peginterferon alfa-2b 80 micrograms/week for 48 weeks
1548984|NCT02605239|Drug|Bleaching teeth|bleaching teeth with carbamide peroxide 10% for 3 weeks
1548985|NCT02605226|Procedure|Cryoablation therapy|Cryoablation therapy
1548986|NCT02605226|Radiation|External beam radiation therapy|External beam radiation therapy
1548987|NCT02605226|Drug|bicalutamide|bicalutamide
1548988|NCT02605226|Drug|luteinizing-hormone releasing-hormone (LHRH) agonist|luteinizing-hormone releasing-hormone (LHRH) agonist
1548989|NCT02605213|Drug|Vancomycin|Vancomycin for treatment of primary sclerosing cholangitis
1548990|NCT02605213|Drug|Placebo|Placebo for control Group of primary sclerosing vhlangitis
1548991|NCT02605200|Behavioral|Psychologist Support|Participants will complete several psychological questionnaires that are intended to cover a broad spectrum of physical, mental, and emotional aspects of the health of participants; the Behavior Assessment System for Children (BASC) ,the Children Depression Inventory (CDI 2), the Pediatric Quality of Life Inventory Transplant Module (PedsQL), and the Wechsler Abbreviated Scale of Intelligence II (WASI-II). Data gathered from this testing will be used to guide the provision of psychological care to address psychosocial challenges inherent to the care of children with transplant related diabetes.
1548992|NCT02605200|Behavioral|Pediatric Certified Diabetes Educators (CDEs) Support|Pediatric Certified Diabetes Educators (CDEs) are specially trained to teach diabetes self-management to children and their families. Participants who are diagnosed with diabetes will receive individualized support from a CDE in conjunction with their routine transplant care.
1548993|NCT02605187|Other|No choice given|Patients are randomized to getting a choice or not getting a choice. If they do not get a choice, they receive standard dose.
1548994|NCT02605187|Other|Choice given|Patients are randomized to getting a choice or not getting a choice. If they do get a choice, they will receive the protocol they select.
1548995|NCT02605187|Drug|Ibuprofen|Ibuprofen 600mg po q6h
1548996|NCT02605187|Drug|Acetaminophen|Acetaminophen 650mg po q6h
1548997|NCT02605187|Drug|Gabapentin|Gabapentin 600mg po one time within 1 hour of delivery
1548998|NCT02605187|Drug|Morphine (low)|Intrathecal morphine dose 50mcg
1548999|NCT02605187|Drug|Morphine (med)|Intrathecal morphine dose 150mcg
1549000|NCT02605187|Drug|Morphine (high)|Intrathecal morphine 300mcg
1549001|NCT02605174|Drug|Lasmiditan 50 mg|One tablet lasmiditan 50 mg plus one placebo tablet (matching one of the lasmiditan doses)
1549002|NCT02605174|Drug|Lasmiditan 100 mg|One tablet lasmiditan 100 mg plus one placebo tablet (matching one of the lasmiditan doses)
1549003|NCT02605174|Drug|Lasmiditan 200 mg|One tablet lasmiditan 200 mg plus one placebo tablet (matching one of the lasmiditan doses)
1549004|NCT02605174|Drug|Placebo|Two placebo tablets to match lasmiditan doses.
1549005|NCT02605148|Dietary Supplement|Gluten free diet|Gluten free diet during 18 months.
1549006|NCT02605148|Dietary Supplement|Omega 3 fatty acid|Omega 3 fatty acid
1549007|NCT02605148|Dietary Supplement|Vitamin D|Vitamin D 800 U/day
1549008|NCT02605148|Dietary Supplement|Probiotics|Probiotics
1549009|NCT02605135|Device|Continued Pessary Use|Pessary Fitting
1549010|NCT02605122|Drug|Solithromycin|
1549011|NCT02605122|Drug|Standard of Care|Age- and weight-based dosing as appropriate.
1549012|NCT02605109|Other|Risk of MERS infection|HCPs, patients and layperson to closely or indirectly contact a case-patients
1549013|NCT02605096|Procedure|MRI|Magnetic Resonance Imaging Scan
1549014|NCT02605096|Procedure|X-ray|X-ray exam (conventional radiography)
1549015|NCT02605083|Drug|eFT508|Will be given orally once or twice daily. Each treatment cycle = 21 days.
1549016|NCT02605070|Drug|Bravelle|"Bravelle will be provided to all patients in the treatment group by the principal investigator (PI) or another member of the research team.
From week nine on, the patients will undergo a physical examination on three different occasions to assess the appearance of any adverse reactions during treatment. It will be up to the patient to communicate the appearance of signs or symptoms which could be associated with the use of the drug.
At week 12 the patient will be scheduled for another visit to perform a semen study and to measure new hormone levels. To this end, a blood test will be carried out (FSH, LH, estradiol, total testosterone, SHBG, and albumin to calculate the amount of bioavailable testosterone). A semen sample will also be obtained to carry out a spermiogram according to WHO guidelines; part of this sample will be used for epigenetic analysis."
1549017|NCT02605057|Drug|LEO 80185 gel|
1549018|NCT02605057|Drug|Dovobet(r) Ointment|
1549019|NCT02605044|Drug|Masitinib (AB1010)|
1549020|NCT02605044|Drug|FOLFIRI|
1549021|NCT02604992|Drug|Treatment A|Dronabinol oral solution, under fed conditions
1549022|NCT02604992|Drug|Treatment B|Dronabinol oral capsule, under fed conditions
1549023|NCT02604992|Drug|Treatment C|Dronabinol oral capsule, under fasted conditions
1549024|NCT02604966|Drug|Artesunate (AS) group|Oral treatment with AS at 4mg/kg/day for 3 days followed by three days of DHA - PPQ in order to insure total parasite clearance. Randomization is done by blocks of ten.
1549025|NCT02604966|Drug|DHA - PPQ group|Oral treatment with 3-day course of DHA - PPQ. Randomization is done by blocks of ten.
1549026|NCT02604953|Device|Short Duration Transient Visual Evoked Potential (SDtVEP)|Visual evoked potentials (VEPs) are able to detect the disruption of electrical signals at any point along the visual pathway, from the retinal ganglion cells (RGCs) to the primary visual cortex. As an objective measure of visual function, the VEP may have an advantage over traditional visual field tests, by reducing confounded factors such as age, fatigue, and mental status
1549027|NCT02604953|Device|Pattern electroretinogram (PERG)|The pattern electroretinogram (PERG) is another important test, which is aimed for evaluating early damage to retinal ganglion cells (RGC). In PERG the retinal response is tested by pattern stimuli in the visual field
1549028|NCT02604940|Drug|Dexmedetomidine|1mcg/kg IV dexmedetomidine over 10 minutes from 60ml syringe in OR upon notification of surgical closure
1549029|NCT02604940|Drug|Normal Saline|60ml Saline delivered over 10 minutes in OR upon notification of surgical closure.
1549030|NCT02604927|Dietary Supplement|Beta-alanine|
1549031|NCT02604927|Dietary Supplement|Dextrose|
1549032|NCT02604914|Drug|ND0612|Subcutaneous solution
1549033|NCT02604914|Drug|LCIG|Intrajejunal Gel
1549034|NCT02604901|Behavioral|Screening and Brief Intervention (BI)|Rite Aid® pharmacists screened patients at the time of the initial fill with the Adherence Estimator™ and using the screening results, provided the behavioral intervention, Brief Intervention using motivational interviewing principles based on POLAR*S (BI). BI was considered an active intervention method.
1549035|NCT02604901|Behavioral|Pill Box (PB)|Rite Aid® pharmacists provided patients with a Pill Box (PB) and information about their medications. However, pharmacists did not use motivational interviewing principles for engaging patients in direct interventions to modify behavior. PB was considered a passive intervention method.
1549036|NCT02604888|Other|MEXIS/M6S Patent - lotion against alopecia|For greatest problems 20 drops on the scalp per day for 6 months. For minor problems 10 drops on the scalp three times per week for 6 months.
1549037|NCT02604875|Other|observation|blood sampling during 24 hours
1549039|NCT02604849|Drug|Neomycin|
1549040|NCT02604849|Drug|Streptomycin|
1549041|NCT02604849|Drug|Gentamicins|
1549042|NCT02604836|Drug|Ibandronate|Film-coated oral ibandronate tablet (150 mg) once-monthly
1549043|NCT02604823|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a will be administered at a dose of 180 mcg subcutaneously once weekly for 48 weeks.
1549044|NCT02604810|Biological|IGIV-C 10%|IGIV-C 10% infusions every 3 to 4 weeks based on previous IgG regimen
1549045|NCT02604810|Biological|IGSC 20%|IGSC 20% weekly infusions with dose calculated based on previous IgG regimen
1549046|NCT02604797|Drug|Nalbuphine|patient-controlled intravenous analgesia
1549047|NCT02604797|Drug|Sufentanil|patient-controlled intravenous analgesia
1549048|NCT02604797|Drug|flurbiprofen axetil|patient-controlled intravenous analgesia
1549049|NCT02604797|Drug|ramosetron|patient-controlled intravenous analgesia
1549050|NCT02604784|Drug|Pressurized IntraPeritoneal Air-flow Chemotherapy (PIPAC)|An open access with a midline 5-6 cm incision is performed and a single-port platform is positioned. A 12 mm Hg CO2 pneumoperitoneum is inflated. Ascites is removed if present and the amount documented. PC extent is evaluated according to Peritoneal Cancer Index (PCI) and peritoneal biopsies are taken. A nebulizer (MIP, Regr Medizintechnik, Rottweil, Germany) is connected to an intravenous high-pressure injector and inserted into the peritoneal cavity; the tightness of the abdomen has to be documented with a CO2 zero-flow. The laparoscopic camera and the nebulizer are maintained in position by a self-retaining retractor (Thompson). A pressurized aerosol containing drugs is delivered. The capnoperitoneum is then maintained for 30 minutes at 37°C. At the end, the aerosol is exsufflated through two sequential micro-particle filters into the air-waste system of the hospital.
1549052|NCT02604732|Procedure|Laparoscopic inguinal hernia repair|
1549053|NCT02604719|Drug|Tranexamic Acid and Ethamsylate|The intervention will be the intravenous administration of 10 ml blinded vial of the study drugs (either 1 gmTranexamic acid and 1 gm Ethamsylate or placebo according to randomization group) slowly (over 30-60 sec ) in the 2 minutes after birth and the routine prophylactic oxytocin and after the cord has been clamped , all generally by the anesthesiologist or obstetrician then a pad will be placed under women buttocks then weighting the pads to allow objective measurement of blood loss.
1549054|NCT02604706|Device|NADA Acupuncture|NADA-acupuncture was delivered in three phases: (1) one treatment each day during the first of a total of five weeks; (2) three treatments each week during the following two weeks; (3) two treatments each week during the two remaining weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. NADA-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
1549103|NCT02604485|Drug|Cohort 4|XOMA 358 single dose level D administered by an intravenous infusion
1549104|NCT02604472|Other|CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received platinum-based/non-platinum based concurrent chemoradiotherapy.
1549055|NCT02604706|Device|LP acupuncture|The LP-acupuncture was delivered in two phases: (1) three treatments each week during the two first weeks; (2) two treatments each week for two weeks. each session consisted of approximately 40 minutes with acupuncture at five ear points called Sympathetic, Shen Men, Kidney, Liver and Lung, which are believed to be the best points for substance abuse patients. Acupuncture was administered to both ears using stainless steel needles. LP-acupuncture were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
1549056|NCT02604706|Behavioral|Relaxation|Relaxation consisted of listening to soft music in a quiet room with dampened light and was delivered to match the amount and phases of the LP-acupuncture. Relaxation were given as a supplement to treatment as usual consisting of Motivational Interview, pharmacological treatment, and control of drug use with urine tests.
1549057|NCT02604693|Other|Nothing|No interventions will be administered.
1549058|NCT02604680|Drug|BLI1100-1|BLI1100-1 Topical gel
1549059|NCT02604680|Drug|BLI1100-2|BLI1100-2 Topical gel
1549060|NCT02604680|Drug|BLI1100-3|BLI1100-3 Topical gel
1549061|NCT02604680|Drug|BLI1100-4|BLI1100-4 Topical gel
1549062|NCT02604680|Drug|Placebo|Placebo - Topical gel
1549063|NCT02604667|Other|Blood tests|"Study participants will undergo a single, peripheral blood draw. Blood specimens will be used to perform hematological biomarker testing and leukocyte RNA gene expression analysis.
Hematological biomarker testing will be performed to better elucidate the mechanisms of ischemic stroke in cancer patients and will include markers of coagulation, platelet function, and endothelial integrity. This analysis will occur at MSKCC.
Leukocyte RNA gene expression analysis will be performed to evaluate whether patients with cancer and stroke more often have cardioembolic mechanisms than patients with stroke and no cancer. This analysis will occur at the University of California, Davis where investigators have previously shown that differential RNA expression patterns can predict stroke subtypes."
1549064|NCT02604667|Other|Transcranial Doppler Microemboli Detection Study|Study participants will undergo a single Transcranial Doppler Microemboli Detection Study at NYPH/WCMC or MSKCC within two weeks of enrollment. Both middle cerebral arteries will be insonated for 30 minutes by a trained technician or stroke neurologist certified in neurosonology using a fixed headset to assess for the rate and laterality of microemboli.
1549065|NCT02604654|Drug|Yiqitongluo granule|administered after dissolved
1549066|NCT02604641|Dietary Supplement|Placebo group|Subjects will take 5 mL of placebo syrup (0 mg CoQ10/day) once per day for 12 weeks.
1549067|NCT02604641|Dietary Supplement|Quvital LD group|Subjects will take 5 mL of LD syrup (50 mg CoQ10/day) once per day for 12 weeks.
1549068|NCT02604641|Dietary Supplement|Quvital HD group|Subjects will take 5 mL of LD syrup (150 mg CoQ10/day) once per day for 12 weeks.
1549069|NCT02604628|Behavioral|Antibiotic Stewardship Intervention|The Antibiotic Stewardship Intervention will consist of education, motivating opinion leaders, adapting a pragmatic disease severity classification and prospective audit and feedback.
1549070|NCT02604615|Drug|Capecitabine(Aibin)|capecitabine(Aibin):625mg/m2,bid d1-5; q1w, po,5 or 10 weeks in total
1549071|NCT02604615|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,I.V. or Oxaliplatin(Aiheng):65mg/m2,d1,8,22,29,43,50,64,71,I.V.
1549072|NCT02604615|Radiation|Radiotherapy|concurrent radiotherapy:50Gy in total,2 Gy/d,5d/w,Until disease progression or unacceptable toxicity
1549073|NCT02604602|Other|blood exam|laboratory test
1549074|NCT02604589|Drug|hydromorphone hydrochloride|Patient-controlled narcotic analgesia pump
1549075|NCT02604589|Procedure|Infusion catheter placement|Placement of continuous infusion catheter and elastomeric pump into extrathoracic paraspinous space
1549076|NCT02604589|Drug|bupivicaine 0.25%|Low Dose analgesia
1549077|NCT02604589|Drug|bupivicaine 0.5%|High dose analgesia
1549078|NCT02604576|Drug|FDC Bromopride 10 mg and Simethicone 80 mg|Fixed-dose combination of Bromopride 10 mg and Simethicone 80 mg
1549079|NCT02604576|Drug|Bromopride 10 mg|Bromopride 10 mg
1549080|NCT02604563|Procedure|Cognitive Assessment|
1549081|NCT02604563|Procedure|Timed Up and Go|-A timed test where the participant will stand up from a chair and walk to a spot 10 feet away.
1549082|NCT02604563|Procedure|Activities of Daily Living Questionnaire|-10 items about daily functional status
1549083|NCT02604563|Procedure|Instrumental Activities of Daily Living, subscale of the OARS|-7 items about daily functional status
1549084|NCT02604563|Procedure|Karnofsky Self-reported Performance Rating Scale|-1 item about daily functional status
1549085|NCT02604563|Procedure|Number of Falls|-1 item about daily functional status
1549086|NCT02604563|Procedure|Physical Health Section, subscale of the OARS|-13 items about comorbidity
1549087|NCT02604563|Procedure|MOS Social Activity Survey|-4 items about social activity
1549088|NCT02604563|Procedure|Body Mass Index & Unintentional Weight Loss|-2 items about nutrition
1549089|NCT02604563|Genetic|Peripheral Blood Draw|
1549090|NCT02604563|Genetic|Buccal Swab|-Participants will rinse their mouths 2 times with water for 20-30 seconds and discard the expectorated sample. One side of the inner cheek (buccal mucosa) will then be scraped with a cotton swab 20 times (alternatively, the tongue will be brushed 20 times with a toothbrush)
1549091|NCT02604550|Drug|Ropivacaine 0.5%|Ropivacaine 0.5% will be administered to the femoral nerve or adductor canal.
1549092|NCT02604550|Drug|Percocet 7.5/325|Percocet 7.5/325 will taken as needed up to every four hours.
1549093|NCT02604550|Drug|Naprosyn 500 mg|Naprosyn 500 mg will be taken twice daily.
1549096|NCT02604524|Device|Closed-Loop Control|Subjects will use the CLC during 5 nights/6 days at a ski camp.
1549097|NCT02604524|Other|Sensor Augmented Pump Therapy|Subjects using their personal pumps with study CGM.
1549098|NCT02604511|Drug|Ibrutinib|
1549099|NCT02604498|Drug|Nemonoxacin|Single dose 500mg oral
1549100|NCT02604485|Drug|Cohort 1|XOMA 358 single dose level A administered by an intravenous infusion
1549101|NCT02604485|Drug|Cohort 2|XOMA 358 single dose level B administered by an intravenous infusion
1549909|NCT02598921|Device|Office hysteroscopy|
1549105|NCT02604472|Other|IC+CCRT|Locoregionally advanced nasopharyngeal carcinoma patients received induction chemotherapy and platinum-based/non-platinum based concurrent chemoradiotherapy.
1549106|NCT02604459|Device|cerebral oximeter (Fore-Sight)|The cerebral oximeter will be monitored in the optimized care group and cerebral oxygenation will be maintained at 60% or higher.
1549107|NCT02604459|Device|depth of anesthesia monitor (BIS)|The depth of anesthesia will be maintained between 40 and 60 in the optimized care group.
1549108|NCT02604459|Procedure|BP management|The systolic blood pressure will be maintained within 20% of preoperative levels in the optimized care group.
1549109|NCT02604459|Procedure|General anesthesia|General anesthesia will be used in both groups
1549110|NCT02604459|Drug|propofol|propofol per protocol
1549111|NCT02604459|Drug|fentanyl|fentanyl per protocol
1549112|NCT02604459|Drug|sevoflurane|maintenance of anesthesia with inhaled sevoflurane
1549113|NCT02604446|Drug|Tapentadol|
1549114|NCT02604446|Drug|Oxycodone|
1549115|NCT02604446|Drug|Placebo|
1549116|NCT02604446|Drug|usual pain treatment|premedication of Dexamethasone, Paracetamol, Vimovo; postoperative Paracetamol and Vimovo
1549117|NCT02604433|Drug|Luspatercept|Subjects will start with luspatercept at 1 mg/kg dose level.
1549118|NCT02604433|Other|Placebo|Placebo, Subcutaneous, every 21 days.
1549119|NCT02604420|Drug|eculizumab|
1549120|NCT02604407|Drug|SHP465 12.5mg capsules (one capsule daily)|one capsule daily
1549121|NCT02604407|Other|Placebo|Matching placebo capsule that appears identical in size, weight, shape, and color (one capsule daily)
1549122|NCT02604407|Drug|SHP465 12.5mg, 25mg, or 37.5mg capsules (one capsule daily)|One capsule daily
1549123|NCT02604394|Procedure|Rheolytic Thrombectomy|"RT will be performed with the The AngioJet rheolytic thrombectomy system (Medrad Interventional/Possis, Minneapolis, Minnesota).
The RT system includes three units: disposable catheter, disposable pump set and a reusable drive unit:
The single-use catheter has two lumens; one allows for the in-flow of high velocity saline jets through the catheter tip, and the other allows for the evacuation of thrombotic debris and passage of a guidewire.
The disposable pump connects to a bag of heparinized saline.
The drive unit pumps pressurized heparinized saline at 10,000 psi at the tip of the catheter,"
1549124|NCT02604394|Procedure|Conventional PCI|In patients in the conventional PCI group, antegrade flow in the culprit vessel will be established with conventional PCI with preference of direct stenting and use of manual thrombus aspiration when deemed necessary by the operator.
1549125|NCT02604381|Dietary Supplement|Glucosamine Sulfate Potassium Chloride/Standardized Ginkgo Biloba Extract|
1549126|NCT02604381|Other|Placebo|
1549127|NCT02604368|Drug|SC411|Soft gelatin capsule
1549128|NCT02604368|Drug|Placebo|Soft gelatin capsule
1549129|NCT02604355|Other|Matching Placebo|Oral dosing with placebo capsules to match RO7020322.
1549130|NCT02604355|Drug|RO7020322|Adaptive oral dosing with RO7020322 capsules, starting at 1 mg daily, with ascending or adjusted dosing based on the results of previous dosing.
1549131|NCT02604342|Drug|Alectinib|Participants will receive oral alectinib at a dose of 600 mg twice daily, taken with food until disease progression, unacceptable toxicity, withdrawal of consent or death.
1549132|NCT02604342|Drug|Docetaxel|Participants will receive docetaxel at a dose of 75 mg/m^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
1549133|NCT02604342|Drug|Pemetrexed|Participants will receive pemetrexed at a dose of 500 mg/m^2 of body surface area intravenously every 3 weeks, until disease progression, unacceptable toxicity, withdrawal of consent or death.
1549134|NCT02604329|Device|"Oncolase Digi therapy laser diode"|"The athermic phototherapy laser diode will be used by scanning the entire oral mucosa, including cheek and lip mucosa, gums, palate, tongue and floor of the mouth. It will be applied uniformly every two days as long as the grade of mucositis is 2 or more, with a fluence of 4J/cm², under two wavelengths (635 nm and 815 nm).
Cheeks will be scanned extra-orally with laser fiber during 50 seconds, at the fluence of 4J/cm², associating two wavelengths : infra-red (815 nm, 3850mW) and red (635 nm, 150mW).
Intra-orally, the fiber will be used to scan each area of mucositis during 30 seconds per area of 2 cm2, at 1cm from the mucosa; the power at 635 nm will be 150 milliwatts and 150 milliwatts at 815 nm."
1549135|NCT02604316|Other|Arabinoxylan|10 days of weight loss diet calculated as 100% RMR + 15g Arabinoxylan (Medium Chain Naxus, BioActor b.v., Netherlands) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40% carbohydrate.
1549136|NCT02604316|Other|Beta- Glucan|10 days of weight loss diet calculated as 100% RMR + 6g β-glucan (Viscofibre, Naturex SA, France) per day in incremental dose 25% according energy requirement, 30% protein, 30% fat, 40%
1549137|NCT02604303|Other|No Intervention|No intervention; prospective observational study
1549138|NCT02604290|Device|Kinesio Taping method|"The tape is applied depending on the physical examination:
Muscular technique is placed along paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied in the direction of paravertebral muscle fibers; the base is placed up or down if the mobilisation direction is up or down respectively.
Space technique is placed horizontally over the painful spinal segmental level if back pain in flexion or extension improves when skin/fascial mobilisation is applied approaching to a central point.
Fascia technique is placed horizontally over the painful area in paravertebral muscles if back pain in flexion or extension improves when skin/fascial mobilisation is applied transverse to the paravertebral muscle fibers."
1549139|NCT02604290|Device|Kinesio Taping sham|The tape is applied with 0% tension, horizontally over two non-tender to palpation spinal segmental levels. The patient is kept in neutral position.
1549140|NCT02604277|Behavioral|Interpersonal and Social Rhythm Therapy (ISRT)|Interpersonal and Social Rhythm Therapy (ISRT) will be given once a week over a six week period for 55-60 minutes. ISRT emphasizes identifying and maintaining a regular routine in daily life. It includes addressing sleep and solving interpersonal concerns and conflicts by focusing on daily routine.
1549208|NCT02603835|Device|SSO2 Therapy|Delivery of SSO2 Therapy for 60 minutes selectively into the left main coronary artery (LMCA) using the TherOx DownStream System along with a single use disposable device called the TherOx DownStream Cartridge and a commercially available, qualified SSO2 delivery catheter
1549209|NCT02603822|Dietary Supplement|12C mannitol|12C mannitol 100 mg
1549141|NCT02604277|Behavioral|Bipolar-Specific Cognitive Behavioral Therapy (CBT)|Bipolar-Specific Cognitive Behavioral Therapy (CBT) will be given once a week over a six week period for 55-60 minutes.The therapy is directly focused on eliminating or managing specific problems experienced by people with Bipolar Disorder. As part of this intervention, participant's maladaptive thoughts, behaviors and emotions are identified followed by learning how to challenge negative thoughts and reframing into positive, more adaptive thoughts. Additionally, the intervention involves enhancing the participant's coping skills and the ability to view a situation more objectively.
1549142|NCT02604277|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) will be given once a week over a six week period for 55-60 minutes. MSBR is a structured intervention that utilizes mindfulness meditation to reduce suffering associated with physical and psychiatric illnesses. MBSR is nonreligious in nature and aims to encourage an enhanced awareness of moment-to-moment experience of noticeable mental processes.
1549143|NCT02604277|Behavioral|Psycho-education & Understanding Bipolar Medications Therapy|Psycho-education & Understanding Bipolar Medications Therapy will be given once a week over a six week period for 55-60 minutes. Psycho-education & Understanding Bipolar Medications Therapy aims to provide psycho-education about Bipolar Depression as well as provide a platform for participants to address concerns about managing their illness. Issues such as managing symptoms, reducing relapses and hospitalizations as well as maintaining gains will be discussed
1549144|NCT02604264|Device|ClearGuard HD end cap|The ClearGuard HD End Cap elutes chlorhexidine acetate into the hemodialysis catheter hub
1549145|NCT02604251|Device|KLOX BioPhotonic WoundGel System|Patients will then be re-randomized to one of the three comparisons: treatment starting on day 7 post-surgery, treatment starting on Day 21 post-surgery, or two consecutive treatments applied once weekly.
1549146|NCT02604251|Device|Silicone sheets|Treatment of the surgical wounds with silicone sheets.
1549147|NCT02604238|Drug|Alteplase|Enoxaparin (1mg) 100UI aXa/kg/sc [LMWH], 15 -30 minutes prior to administration of intravenous (iv) bolus loading dose of 10 mg in 1 min, followed by iv infusion of 40 mg within two hours (for patients weighing <50 kg, a loading dose of bolus of 0.5 mg in 1 min, followed by iv infusion of 40 mg in two hours); the infusion will be adjusted to maintain the value of aPTT between 50-70 seconds (1.5 to 2.5 times the reference value).
1549150|NCT02604212|Drug|ARC-520|
1549151|NCT02604212|Other|Placebo|
1549152|NCT02604199|Drug|ARC-520 Injection|
1549153|NCT02604199|Other|Placebo|
1549154|NCT02604186|Other|Botulinum Toxin Injections|Each patient in the treatment group will receive 400 units of botulinum toxin. 100 units will be injected at adductors at each leg and 100 units will be applied in each triceps surae bilaterally.
1549155|NCT02604186|Other|Placebo Injections|Each patient in the placebo group will receive sterile sodium chloride injections at adductors and triceps surae muscles bilaterally.
1549161|NCT02604147|Device|Inspiratory pressure-threshold muscle training device.|The participants who will be allocated in this simulated intervention group will have to do a simulated inspiratory muscle training protocol through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with a load of 15% of maximal inspiratory pressure without progression. In each session will be requested to the volunteers make 30 slow breaths, which will be constantly supervised by the researchers.
1549162|NCT02604147|Device|nspiratory pressure-threshold muscle training device.|The participants who will be allocated in this intervention group will have to make a inspiratory muscle training protocol with progressive loads through the inspiratory muscle exerciser POWERbreathe, model Sports Plus Heavy Resistance (POWERbreathe; HAB International Ltd., Warwickshire, United Kingdom) for 12 weeks five times at week and twice daily, with an initial load of 50% of maximal inspiratory pressure, progressing to 60% after the fourth week, and 70% after the octave week. In each session will be requested to volunteers who performed 30 maximal and prolonged inspiration, maintaining the diaphragmatic breathing, which will be constantly supervised by the researchers.
1549163|NCT02604134|Procedure|Prophylaxis|A dental prophylaxis is a cleaning procedure performed to thoroughly clean the teeth. Prophylaxis is an important dental treatment for halting the progression of periodontal disease and gingivitis.
1549164|NCT02604134|Drug|Fluoride varnish|Fluoride varnish is a highly concentrated form of fluoride which is applied to the tooth's surface, by a dentist, dental hygienist or other health care professional, as a type of topical fluoride therapy.
1549165|NCT02604134|Drug|Silver Nitrate|a small amount will be applied to the tooth via a cotton applicator. Silver nitrate is a colorless, odorless, transparent solution used as an escharotic, dehydrating and sclerosing agent.
1549166|NCT02604121|Device|Orcellex® Rovers brush|transepithelial brushing
1549167|NCT02604108|Behavioral|Physical Exercise|"The Physical Exercise arm includes a training workshop and electronic health messages related to positive psychology and physical activity for all participants in physical exercise group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.
The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
1549210|NCT02603822|Drug|Indomethacin|Subjects will receive six 25 mg capsules of Indomethacin (immediate release). The subjects will take 3 capsules 8 hours before the timing of visit 5 (before fasting), and 3 additional capsules 30 minutes before visit 5.
1549211|NCT02603822|Dietary Supplement|13C mannitol|13C mannitol 100 mg
1549168|NCT02604108|Behavioral|Healthy Diet|"The Healthy Diet arm includes a training workshop and electronic health messages related to positive psychology and health diet for all participants in healthy diet group. Skills on program design and implementation will be conducted for those participants, who will design and implement community-based family intervention to the public.
The training workshop includes: (i) 2-day core session and half day booster session for trainers; and (ii) 1-day core session and half day booster session for ambassadors"
1549169|NCT02604095|Dietary Supplement|melatonin|Take one tablet (containing melatonin 3mg, calcium 52mg, vitamin B6 5mg) at bedtime everyday for 12 weeks.
1549170|NCT02604082|Other|Vibrocompression (VB)|Vibrocompression is a physical therapy technique, that aims to clear the airways of patients on mechanical ventilation (MV)
1549171|NCT02604082|Other|Hyperinflation (HMV)|Hyperinflation technique with mechanical ventilator which aims to clear the airways of patients on mechanical ventilation
1549172|NCT02604082|Other|HMV+VB|Association between Vibrocompression and Hyperinflation with mechanical ventilator
1549173|NCT02604069|Device|Continuous Glucose Monitor|
1549174|NCT02604056|Behavioral|Audit + Feedback|Online Audit + Feedback practice reports detailing prescribing performance for this class of medication for each prescriber in the nursing home. (Details: http://www.hqontario.ca/Quality-Improvement/Practice-Reports/Primary-Care)
1549175|NCT02604056|Behavioral|Audit + Feedback + Educational Outreach|"The Educational Outreach program will be delivered by academic detailers, health professionals (often nurses or pharmacists) who have received specific intensive training to support prescribing providers in a particular environment, in this case long-term care homes, to make the best or appropriate clinical decisions as possible. It is defined as: an innovative method of service-oriented educational outreach for front-line clinicians. It combines the interactive, one-on-one communication approach of industry detailers with the evidence-based, non-commercial information of academia. The Educational Outreach will be delivered in addition to online Audit + Feedback practice reports, which detail prescribing performance for this class of medication for each prescriber in the nursing home."
1549176|NCT02604043|Device|supraglottic impendence/pH probe|After endotracheal intubation, the impedence/pH probe will be placed under indirect visualization using a McGrath MAC video laryngoscope directly above the vocal cords. The sensor will remain in place for the duration of the surgery or for 24 hours in ICU patients. At that time, the device will be manually removed by a member of the study staff.
1549177|NCT02604043|Device|accelerometer monitoring|Patient position will be continuously monitored with the accelerometer for the duration of the pH monitoring period.
1549178|NCT02604030|Other|Upper limb function|Physical therapy program will be done in two steps, with 8 sessions each one (twice a week for four weeks). First, 8 sessions of passive mobilization in glenohumeral joint and scapular, scar massage, lymphatic drainage, stretching exercises will be completed. Second, 8 sessions of upper limb strengthening and stretching exercises for upper limb. Each session will be completed in 1 hour (twice a week) during two months.
1549179|NCT02604017|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
1549180|NCT02604004|Drug|Epivir ® tablet 150-mg single dose (drug reference)|Bioequivalence lamivudine 150 mg tablets fasting condition
1549181|NCT02604004|Drug|Lamivudine 150-mg tablet single dose (drug test)|Bioequivalence lamivudine 150 mg tablets fasting condition
1549182|NCT02603991|Procedure|PINS Vagus Nerve Stimulator|The stimulators are implanted in the body,with the stimulation of the IPG
1549183|NCT02603991|Drug|Levetiracetam|The best anti-epileptic drugs to patients who participate in this study，Levetiracetam，
1549184|NCT02603978|Behavioral|BASICS|A 2-hour group intervention focused on reducing alcohol use with the use of motivational interviewing
1549185|NCT02603978|Behavioral|Bystander and Social Norms|A 2-hour group intervention focused on increasing healthy sexual behaviors and prosocial bystander behavior
1549186|NCT02603978|Behavioral|Combined BASICS and Bystander|A 2-session, 4-hour group that consists of both BASICS and the Bystander intervention
1549187|NCT02603965|Radiation|Copper Cu 64 TP3805|Given IV
1549188|NCT02603965|Procedure|Positron Emission Tomography|Undergo Cu-64-TP3805 PET(Positron Emission Tomography)/CT
1549189|NCT02603965|Procedure|Computed Tomography|Undergo Cu-64-TP3805 PET/CT (Computed Tomography)
1549190|NCT02603965|Procedure|Radical Prostatectomy|Undergo radical prostatectomy
1549191|NCT02603965|Other|Laboratory Biomarker Analysis|Correlative studies
1549192|NCT02603952|Drug|Oseltamivir|Commercially supplied capsule.
1549193|NCT02603952|Drug|MEDI8852|MEDI8852 is a human IgG1 kappa monoclonal antibody (mAb) administered via infusion.
1549194|NCT02603952|Drug|Placebo|Salt-water solution containing no active ingredients.
1549195|NCT02603939|Procedure|Joint replacement surgery|We are assessing pain responses in participants with osteoarthritis before an after joint replacement surgery
1549196|NCT02603926|Drug|Allopregnanolone|
1549197|NCT02603900|Drug|ropivacaine|15 ml 0.5% Ropivicaine for primary adductor canal block under ultrasound guidance and 0.2% Ropivicaine infusion 10 ml/hr.
1549198|NCT02603900|Drug|bupivacaine|20 ml bupivacaine ( Marcaine 0.25% with epinephrine 1:200000, Hospira Inc. Lake Forest, IL) diluted with 40 ml of normal saline injected intraoperatively into the knee joint before closure.
1549199|NCT02603900|Device|Sham Adductor Canal Catheter|Sham catheter placement via ultrasound-guided adductor canal block and 10ml/hr saline via OnQ Pump via continuous catheter in adductor canal.
1549200|NCT02603900|Device|Adductor Canal Catheter|Catheter placed in adductor canal via ultrasound guidance and continuous infusion via OnQ pump.
1549202|NCT02603874|Device|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
1549203|NCT02603861|Drug|LY3154207|LY3154207 administered orally.
1549204|NCT02603861|Drug|Placebo|Placebo administered orally.
1549205|NCT02603861|Drug|Modafinil|Modafinil administered orally.
1549206|NCT02603848|Drug|Ibuprofen|(10mg/kg; maximum 600 mg) every six hours as needed
1549207|NCT02603848|Drug|Morphine|0.2 mg/ kg morphine suspension (maximum 10mg) every four hours as needed
1549212|NCT02603822|Dietary Supplement|Lactulose|lactulose 1 g
1549213|NCT02603809|Drug|ERA|ERA Dose 1, Dose 2, Dose 3, and Dose 4 administered as capsules orally once a day (o.d.) for 8 weeks
1549215|NCT02603809|Other|Placebo|Placebo matching ERA and placebo matching lisinopril capsules will be administered concomitantly orally o.d. for 8 weeks
1549216|NCT02603796|Other|3D Scan of nares|3D scan of subjects nose prior to implementation of ncpap and upon discontinuation of ncpap.
1549217|NCT02603783|Other|Capsaicin|capsaicin 1,5 mg
1549218|NCT02603783|Other|Placebo|0,9% saline 75 ml
1549219|NCT02603770|Drug|XueZhiKang|
1549220|NCT02603770|Drug|Lovastatin|
1549222|NCT02603744|Biological|Intraovarian injection of Adipose derived Stromal cells (ADSCs)|Intra-ovarian injection of Adipose derived mesenchymal stem cells.
1549223|NCT02603718|Other|Rehabilitation treatment|
1549224|NCT02603705|Drug|Oxycodone extended-release|
1549225|NCT02603692|Other|PROMIS-QOL|PROMIS questionnaires completed every 3 months for up to 2 years.
1549226|NCT02603679|Drug|Paclitaxel|Any brand of paclitaxel may be used, excluding nab-paclitaxel
1549227|NCT02603679|Drug|Tamoxifen + Palbociclib|Any brand of tamoxifen may be used
1549228|NCT02603679|Drug|Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
1549229|NCT02603679|Drug|Goserelin + Aromatase Inhibitor + Palbociclib|Any brand of letrozole, anastrozole or exemestane may be used
1549230|NCT02603666|Device|Fibroscan|Ultrasound by specific wavelength developed for elastography, repeated measures according to the manufacturer's instructions.
1549231|NCT02603653|Device|Virtual radial task in 3D|The virtual radial task is a labyrinth in 3D with twelve ways. The primary aim of our study is the evaluation of persistent cognitive impairments (hippocampal memory) according to the responses of participants after instructions to choose the right way in the labyrinth.
1549232|NCT02603640|Device|MRI scanning|
1549233|NCT02603614|Drug|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
1549234|NCT02603614|Drug|Placebo|Placebo control
1549235|NCT02603601|Behavioral|Mind-body lifestyle intervention|
1549236|NCT02603601|Behavioral|Standard lifestyle intervention|
1549237|NCT02603588|Procedure|active sphenopalatine ganglion acupuncture|"The acupuncture point was selected in the sphenopalatine ganglion (unilateral side). The acupuncture needle was inserted from the lower border of the zygomatic arch, slightly posterior to the suture protuberance between the zygomatic process and temporal process. The needle was rotated until the participant felt de-qi sensations."
1549238|NCT02603588|Procedure|sham sphenopalatine ganglion acupuncture|The acupuncture point was selected same to the sphenopalatine ganglion. But the needle was inserted at the selected acupuncture site to a depth of only 2-3cm, and the procedure of rotating, twirling and thrusting the needle was repeated, in order to blind the subject to the sham treatment.
1549239|NCT02603575|Drug|caspofungin|70mg ivdrip the first day, then 50mg ivdrip qd
1549240|NCT02603575|Drug|corticosteroids|40mg ivdrip q12h for 5 days 40mg ivdrip qd for 5 days 20mg po for 11 days
1549241|NCT02603575|Drug|Sulfanilamides|1.92g q8h
1549242|NCT02603562|Biological|ATYR1940|ATYR1940 will be administered as an IV infusion at doses of 0.3, 1.0, and 3.0 mg/kg using intrapatient dose escalation. The dose level in this study will not exceed 3.0 mg/kg
1549243|NCT02603562|Biological|Placebo|An initial IV infusion of placebo will be supplied as normal saline, and administered over a 30-minute period at Week 1.
1549244|NCT02603549|Other|Pituitary panel will be drawn pre-op and post-op for all patients.|
1549245|NCT02603536|Other|WelTel|An evidence-based, text messaging solution for improving patient adherence.
1549246|NCT02603523|Behavioral|Senior Dance|The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
1549247|NCT02603510|Drug|SAR342434|"Pharmaceutical form:solution
Route of administration: subcutaneous"
1549248|NCT02603510|Drug|insulin lispro|"Pharmaceutical form:solution
Route of administration: subcutaneous"
1549249|NCT02603497|Drug|ASP015K|oral
1549250|NCT02603471|Other|Informational group|A pamphlet will be provided to the participants with information about ART adherence, HIV and relapse prevention.
1549251|NCT02603471|Behavioral|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
1549252|NCT02603458|Drug|NRX-1074|Participants will receive two IV NRX-1074 infusions 1 week apart, each lasting 1 minute.
1549253|NCT02603458|Drug|Placebo|Patients will receive two IV placebo infusions 1 week apart, each lasting 1 minute.
1550062|NCT02597894|Procedure|Biopsy of Prostate|Undergo biopsy
1549263|NCT02603406|Drug|erythropoietin|
1549264|NCT02603393|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI
1549265|NCT02603393|Drug|Tiotropium|Tiotropium will be supplied as commercially available blisters, delivered via HandiHaler®
1549266|NCT02603393|Drug|Salmeterol/fluticasone|Salmeterol/fluticasone propionate dry inhalation powder delivered via Accuhaler™
1549267|NCT02603380|Other|No intervention|This is an observational study. No intervention will be given.
1549268|NCT02603367|Other|Communication Intervention|Undergo communication coaching
1549269|NCT02603367|Other|Educational Intervention|Receive COMFORT communication curriculum
1549270|NCT02603367|Other|Psychosocial Support for Caregiver|Undergo communication coaching
1549271|NCT02603367|Other|Questionnaire Administration|Complete questionnaires
1549272|NCT02603354|Drug|peroxide gel tooth bleaching 6%|gel of hygrogen peroxide for teeth bleaching in a low concentration (6%)
1549273|NCT02603341|Radiation|Photon|Photon Therapy:once a day, 5 days a week, for 5 to 7 weeks
1549274|NCT02603341|Radiation|Proton|Proton Therapy: once a day, 5 days a week, for 5 to 7 weeks
1549275|NCT02603328|Drug|Atorvastatin|40-80 mg OD
1549276|NCT02603328|Other|Placebo|inactive
1549277|NCT02603315|Other|marker CD74 and vascular endothelial growth factor VEGF|correlate the result of vascularity test done on paraffin blocks on both types of malignant pleural mesothelioma patients diagnosed and receive treatment and evaluated after treatment
1549278|NCT02603302|Radiation|Dose Escalation Radiotherapy|RT (3D conformal RT) 45 Gy to the whole pelvis + boost 14.4 Gy to the GTV Chemotherapy with 5-FU
1549279|NCT02603302|Procedure|Delayed surgery|Surgery after 8 weeks with TME (total mesorectal excision)
1549280|NCT02603289|Device|Invisalign|
1549281|NCT02603276|Dietary Supplement|Plant sterols|Plant sterols 800 mg/dose, 1 liquid stick per day, for 8 weeks
1549282|NCT02603276|Dietary Supplement|Red Yeast Rice|Red Yeast Rice titrated in 5 mg monacolin K per daily dose, 1 liquid stick per day, for 8 weeks
1549283|NCT02603276|Dietary Supplement|Red Yeast Rice plus Plant sterols|Red Yeast Rice titrated in 5 mg monacolin K per daily dose plus Plant sterols 800 mg/dose, together in 1 liquid stick per day, for 8 weeks
1549284|NCT02603263|Other|Social Norms Poster|"A poster containing a social norms message: Most people here choose to eat vegetables with their lunch"
1549285|NCT02603237|Other|Glucose tolerance test|Standardized oral glucose tolerance test (75 g oral glucose) and blood collection before and 2hrs after the glucose load
1549286|NCT02603237|Other|Fat tolerance test|Oral fat tolerance will be provided to fasting participants and blood samples will be collected before and 4 hrs after the fat load.
1549287|NCT02603224|Drug|MRG-201|Intradermal injection of single ascending doses and multiple ascending doses in healthy volunteers.
1549288|NCT02603224|Drug|Placebo|Intradermal injection of placebo at a second site in healthy volunteers. Each subject will serve as their own control.
1549290|NCT02603198|Drug|mepivacaine chloridrato epinephrine|local anesthesia for tooth removal
1549291|NCT02603198|Drug|mepivacaine chloridrato levonordefrin|local anesthesia for tooth removal
1549294|NCT02603172|Drug|GSK3039294|GSK3039294 will be provided as white, opaque capsules. A single capsule or multiple capsules (20 mg to 200 mg), depending on the dosage required, will be taken orally with water.
1549295|NCT02603159|Drug|Capecitabine(Aibin)|Capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 or 10 weeks in total
1549296|NCT02603159|Radiation|radiotherapy|Concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
1549297|NCT02603146|Drug|Hydroxychloroquine|As described. Dosing will be based upon Screening IBW.
1549298|NCT02603146|Drug|HCQ Placebo|As described. Dosing will be based upon Screening IBW.
1549299|NCT02603133|Behavioral|WISER 1|Introduces prevalence of burnout, evidence of enhancing resilience and overview of the next 5 modules. In addition, this module provides a structured opportunity to learn about and express gratitude toward others through a guided gratitude letter writing exercise and sending several grateful text messages over two weeks. Through expressing gratitude, we learn more about our vital connections to others, often in surprising and meaningful ways, and we see improvements in resilience, sleep quality and depression.
1549300|NCT02603133|Behavioral|WISER 2|This module introduces a structured opportunity to cultivate positive experiences by reflecting on them for a couple of minutes within two hours of sleep onset (daily email/SMS sent to each participant for 2 weeks). By savoring good moments from earlier that day just before sleep onset, we see improvements in resilience, sleep quality, relationships, work-life balance, and depression. Participants also benefit from electronically sharing the nightly Three Good Things with their colleagues.
1549301|NCT02603133|Behavioral|WISER 3|"This module provides a structured opportunity to learn about and experience the benefits of awe and wonder through a series of visually and conceptually stunning images, followed by an exercise to recount in detail one of their own experiences of awe and a daily moment of awe log. When we experience awe, our sense of time expands, we are kinder to others, and we prefer experiences over material things. By cultivating awe we see improvements in life satisfaction, kindness, and sense that we have more time to do the important things in life."
1549302|NCT02603133|Behavioral|WISER 4|This module uses a strengths-finder tool to examine what you do well, and sends daily email prompts to elicit how participants will be deliberate about using their strengths in new and more frequent ways to address their challenges. When you use your strengths personally and professionally, you feel engaged and invigorated, and you feel like what you are doing has more meaning to you personally. By deliberately choosing to do what we already do well, we see improvements in engagement, happiness, resilience and depression.
1550063|NCT02597894|Other|Laboratory Biomarker Analysis|Correlative studies
1549303|NCT02603133|Behavioral|WISER 5|This module encourages participants to commit a random act of kindness. This intervention reliably produces improvements in happiness, resilience and depression.
1549304|NCT02603133|Behavioral|WISER 6|This module pulls together the previous modules as strategies for enhancing resilience and builds to demonstrate the latest research on dealing with difficult colleagues, how long a nap should be if you are tired vs. well rested, and how to take advantage of sleep hygiene research findings.
1549305|NCT02603120|Drug|ABC/DTG/3TC|600/50/300 mg FDC tablets administered orally once daily without regard to food
1549306|NCT02603120|Drug|B/F/TAF|50/200/25 mg FDC tablets administered orally once daily without regard to food
1549307|NCT02603120|Drug|ABC/DTG/3TC Placebo|Tablets administered orally once daily without regard to food
1549308|NCT02603120|Drug|B/F/TAF Placebo|Tablets administered orally once daily without regard to food
1549309|NCT02603107|Drug|RTV|100 mg capsule coadministered orally with ATV or DRV once daily with food
1549310|NCT02603107|Drug|ATV|300 mg capsule administered orally once daily with food
1549311|NCT02603107|Drug|DRV|800 mg tablet administered orally once daily with food
1549312|NCT02603107|Drug|COBI|150 mg tablet coadministered orally with ATV or DRV once daily with food
1549313|NCT02603107|Drug|ATV/co|300/150 mg FDC tablet administered orally once daily with food
1549314|NCT02603107|Drug|DRV/co|800/150 mg FDC tablet administered orally once daily with food
1549315|NCT02603107|Drug|FTC/TDF|200/300 mg FDC tablet administered orally once daily without regard to food
1549316|NCT02603107|Drug|ABC/3TC|600/300 mg tablet administered orally once daily with or without regard to food
1549317|NCT02603107|Drug|B/F/TAF|50/200/25 mg FDC tablet administered orally once daily without regard to food
1549318|NCT02603094|Procedure|clear fluid ingestion|drinking of clear fluid in preoperative period
1549319|NCT02603081|Drug|SPI-1005|Ebselen is a small molecule mimic and inducer of glutathione peroxidase (GPx). GPx reduces reactive oxygen species by the binding of free radicals to its selenium moiety. Ebselen has strong anti-inflammatory characteristics.
1549320|NCT02603068|Drug|Oral treprostinil|Oral treprostinil will be administered as TID dosing for up to 16 Weeks.
1549321|NCT02603055|Biological|30μg/0.5ml Hepatitis E vaccine|three doses, 30μg/0.5ml per dose
1549322|NCT02603055|Biological|30μg/0.5ml Recombinant Hepatitis E vaccine|30μg/0.5ml Hepatitis E vaccine developed by Xiamen innovax biotech Co.,Ltd.,three doses, 30μg/0.5ml per dose
1549323|NCT02603029|Other|Placebo cream|Subjects will use placebo cream twice per day for 12 weeks on one half of the face and of the gluteal area.
1549324|NCT02603029|Other|Belinal cream|Subjects will use Belinal cream twice per day for 12 weeks on the other half of the face and of the gluteal area.
1549325|NCT02603016|Drug|GLSE compound|
1549326|NCT02603016|Drug|Maitake mushroom extract compound|
1549327|NCT02603016|Drug|Ginseng compound|
1549328|NCT02603003|Drug|JinFuKang|po.tid.30ml
1549329|NCT02603003|Drug|Cisplatin|According to the individual patient's condition
1549330|NCT02603003|Drug|Pemetrexed|According to the individual patient's condition
1549331|NCT02602990|Device|SQUID™|
1549332|NCT02602977|Other|Multiple-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.
1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.
Multiple-dose RIPC consists of a daily dose of 1 RIPC as described above for 7 consecutive days."
1549333|NCT02602977|Other|Single-dose Remote Ischemic Preconditioning|"A blood-pressure cuff with handheld rubber inflation balloon and manometer is placed on the non-dominant arm of the subject. The cuff will be placed proximally from the elbow with the most proximal part of the cuff placed in the armpit. The cuff will be inflated to 250 mmHg after which a 5 minute countdown is started. After 5 minutes the pressure is released and the 5 minute countdown for reperfusion is started. This concludes one cycle out of a total of four.
1 RIPC-dose consists of 4 cycles of 5 minute ischemia followed by 5 minute reperfusion as described above.
Single-dose RIPC consists of 1 dose of RIPC as described above"
1549334|NCT02602977|Biological|LPS infusion|To achieve a controlled inflammatory state, 30 subjects (multiple-dose RIPC group [n=10], single-dose RIPC group [n=10] and control group [n=10]) will receive LPS intravenously. The LPS at a dose of 2 ng/kg iv will be injected in 1 minute.
1549335|NCT02602964|Other|Deep neuromsucular block|Deep or standard neuromuscular block
1549338|NCT02602938|Drug|Aspirin|Take aspirin (100mg) orally once a day for 2 months
1549339|NCT02602925|Other|Dose decrease|Treatment strategy change: dose decrease based on PASI and DLQI
1549340|NCT02602925|Other|Usual care|Usual care
1549341|NCT02602912|Device|Injeq Bioimpedance Probe (BIP) Needle|Injeq Bioimpedance Probe (BIP) Needle is a spinal needle that has bioimpedance measurement capability. It consists of traditional needle cannulae and removable bioimpedance probe which enables the measurement of bioimpedance. The needle is connected to measurement device and tissue identifying algorithm. Bioimpedance is measured during the operation and the algorithm detects when the needle tip is in contact with cerebrospinal fluid.
1549342|NCT02602899|Procedure|PINS'Deep Brain Stimulator device|deep brain stimulation of the PINS'IPG function to anterior nucleus of the thalamus is off in a short time
1549343|NCT02602886|Behavioral|Exposure and Response Prevention Therapy|The treatment includes both therapist-supervised and self-controlled exposure and ritual prevention exercises. 2 sessions per week, up to 15 sessions in total. Session time is 90 minutes. The majority of in-session time is spent conducting in vivo exposures. When engaging in E/RP tasks, patients are instructed to refrain from ritual engagement. Between-session homework is given the patient practicing the within-session E/RP task up to 90 minutes each day. Clinicians supplement E/RP with other cognitive-behavioral interventions including motivational strategies for resistant patients, Socratic dialogue, and behavioral experiments to test the validity of erroneous cognitions.
1549344|NCT02602873|Other|therapeutic drug monitoring|with therapeutic drug monitoring , dose of tacrolimus can be adjusted by therapeutic drug monitoring.
1549349|NCT02602847|Biological|cccDNA assay on liver biopsy|cccDNA assay will be performed on liver biopsies at different times : During transplantation : Liver biopsy of explant and graft and virological biology Between M1 to M3 after transplantation : Liver biopsy between 1 to 3 months after transplantation M12 : Liver biopsy 12 months after transplantation
1549350|NCT02602834|Other|interval training|4 intervals with high intensity on treadmill, and approximately 3 minutes rest between intervals.
1549351|NCT02602834|Other|moderate exercise|30 minutes (moderate intensity) aerobic exercise on treadmill without rest.
1549352|NCT02602795|Behavioral|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to help participants develop target adaptive responses to negative affect and other negative internal stimuli related to opioid detoxification.
1549353|NCT02602795|Behavioral|Information Motivation Behavioral Model|This intervention is based on the Information Motivation Behavior model for HIV/STI risk reduction and is tailored to more directly address HIV/STI risk among opioid dependent patients.
1549354|NCT02602769|Procedure|Body composition|The investigators will measure body composition by Dual energy X-ray absorptiometry, a non-invasive procedure with minimal radiation and provides body composition including fat - and fat-free body mass.
1549355|NCT02602769|Behavioral|Energy intake|The investigators will obtain dietary intake over 3-days by using food-intake questionnaire and diet recall.
1549356|NCT02602769|Procedure|Resting energy expenditure|This will be measured by Indirect calorimetry. Indirect calorimetry is a non-invasive, 30-minute test during which a clear plastic hood will be placed over the subject's head to measure oxygen consumption and carbon dioxide production.
1549357|NCT02602769|Procedure|Total energy expenditure|This will be measured by standard technique of doubly labeled water. The subjects receive a one-time dose of doubly labeled water (DLW) based on their weight for measurement of total energy expenditure. We will also collect baseline and 4-hour post-dose urine sample. Subjects will receive instructions in collecting daily urine samples for measurement of energy expenditure in labeled containers for the next 7 -days at home.
1549358|NCT02602769|Other|Mixed meal tolerance test|Subjects will consume 6 cc/kg (maximum 360 cc) of a liquid mixed meal (t=0), (Boost High Protein; Mead Johnson Nutritionals; 45% carbohydrate, 15% protein, and 40% fat) within a 10-min window. Blood samples will be obtained at t= -15, 0, 15, 30, 60, 90, 120, and 180 min. Leptin will be measured at t=-15 and 0 min. Postprandial samples will be assayed for active ghrelin.
1549359|NCT02602756|Radiation|Protontherapy|Proton-therapy consists in four consecutive sessions. The experimental arm consists in eight sessions. Irradiation is administered over two weeks, delivering a total dose of 60 Cobalt Gris Equivalent (CGE is the physical Gray dose multiplied by a biological factor of relative efficiency of 1.1 for protons compared to photons).
1549360|NCT02602743|Drug|Remifentanyl|0,25 µg/kg remifentanyl will be administered for induction in 1 minute. Then 0,1 µg/kg/h remifentanyl infusion will be started.
1549361|NCT02602743|Drug|Propofol|1 mg/kg propofol will be administered for induction and then 1 mg/kg/h propofol infusion will be started.
1549362|NCT02602743|Drug|Ketamine|2 mg/kg ketamine will be administered for induction in 1 minute.
1549363|NCT02602730|Behavioral|Break the Chain|Internet-based smoking cessation intervention designed for general population smokers with targeted materials for pregnant women. The program included a digital coaching component delivered via email at specific points as the user progresses through his/her quit process. Program content is based on Department of Health and Human Services Clinical Practice Guidelines for Treating Tobacco Use and Dependence.
1549364|NCT02602730|Behavioral|Clearing the Air|PDF version of smoking cessation booklet from National Cancer Institute.
1549365|NCT02602717|Other|lymph nodes cyto-punction|
1549366|NCT02602704|Drug|Bazedoxifene|Bazedoxifene 20mg/day (Viviant) for 48 weeks
1549367|NCT02602704|Drug|Calcium/Vit D|Elemental calcium 1200mg daily and vitamin D 800 IU daily (Caltrate D 400 * 2/day) for 48 weeks
1549368|NCT02602691|Other|AlloMap®|
1549369|NCT02602691|Procedure|Endomyocardial biopsies|
1549370|NCT02602678|Procedure|Supine then Prone position|One hour in supine position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash-out) and one hour in prone position with CPAP (+7 cmH2O)
1549371|NCT02602678|Procedure|Prone then supine position|One hour in prone position with CPAP (+7 cmH2O) then 15 min in supine position in spontaneous ventilation (wash out ) and one hour in supine position with CPAP (+7 cmH2O)
1549372|NCT02602665|Procedure|Shallow catheter tip placement|for shallow placement tip of catheter placed 1 vertebral body above to even with the carina
1549373|NCT02602665|Procedure|Deep catheter tip placement|deep placement catheter tip is placed 1.5 to 2.5 vertebral bodies below the carina
1549375|NCT02602639|Device|Functional electrical stimulation rowing (Odstock 4 channel neuromuscular stimulator with Concept 2 Rower)|Participants will strengthen their quadriceps and hamstrings using electrical stimulation for up to 12 weeks (using an Odstock 4 channel neuromuscular stimulator). Then participants will use a seated rower (Concept 2 Rower, fitted with a backrest that allows those with spinal cord injury to engage in rowing) in conjunction with the electrical stimulation for 12-24 weeks.
1549377|NCT02602600|Drug|Liraglutide|"Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.
Weight maintenance diet for 2 weeks"
1549378|NCT02602587|Biological|Blood sample|additional samples of blood in acts planned in the prognostic or follow-up protocols.
1549379|NCT02602587|Biological|Bone marrow sample|additional bone marrow sample in acts planned in the prognostic or follow-up protocols.
1549380|NCT02602574|Other|heparinized peripheral venous blood and urine sample.|All patients will be taken heparinized peripheral venous blood and urine sample
1549381|NCT02602561|Dietary Supplement|HMB|
1549382|NCT02602561|Dietary Supplement|Placebo|
1549383|NCT02602548|Other|Culture|Specimens will be obtained and sent to the lab for cultures.
1549384|NCT02602535|Behavioral|Mindfulness-Oriented Recovery Enhancement|Mindfulness-Oriented Recovery Enhancement (MORE) is a group behavioral intervention that unites mindfulness training, cognitive reappraisal, and positive psychological principles into an integrative intervention strategy targeting mechanisms of pain and opioid misuse.
1549385|NCT02602535|Behavioral|Support Group|A conventional support group will allow participants to express emotions, share experiences, and receive social support under the guidance of a skilled therapist.
1549386|NCT02602522|Drug|Shandong Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Shandong Danshen-Jiang-Fu Granule is Laiwu District in Shandong province.
1549387|NCT02602522|Drug|Sichuan Danshen-Jiang-Fu Granule|Danshen-Jiang-Fu Granule is prepared from 4 kinds of Chinese herbs including Danshen (Salvia Miltiorrhiza), Paojiang (Roasted Ginger), Xiangfu(Rhizoma Cyperi), Wuyao(Lindera Aggregata). The producing area of Danshen in Sichuan Danshen-Jiang-Fu Granule is Zhongjiang District in Sichuan province.
1549388|NCT02602509|Drug|Celecoxib|
1549389|NCT02602509|Drug|Rifampicin|
1549390|NCT02602509|Drug|Pyrazinamide|
1549391|NCT02602496|Other|Fruits and Vegetables|5 servings of fruits or vegetables
1549392|NCT02602496|Other|Whole Grain|3 servings of whole grain
1549393|NCT02602496|Other|Control|3 servings of refined grain
1549394|NCT02602496|Other|Whole Grain + Fruits and Vegetables|3 servings of whole grain and 5 servings of fruits or vegetables
1549395|NCT02602483|Drug|Ibuprofen|
1549396|NCT02602483|Drug|Magnesium|
1549397|NCT02602483|Drug|Ascorbic Acid|
1549398|NCT02602483|Drug|Placebo|
1549399|NCT02602470|Drug|Azelaic Acid Gel including: Finacea (Azelaic Acid Gel 15%, BAY39-6251)|Azelaic Acid Gel 15%, Azelaic Acid Gel 15% w/Cleanser & Moisturizing
1549400|NCT02602470|Drug|Azelaic Acid Cream|Azelaic Acid Cream 20%
1549401|NCT02602470|Drug|Metronidazole gel|Metronidazole Gel 1%, Metronidazole Gel 1% w/ Cleanser, Metronidazole Gel 0.75%, Metronidazole Gel 0.75% w/ Cleanser
1549402|NCT02602470|Drug|Metronidazole cream|Metronidazole Cream 1%, Metronidazole Cream 0.75%, Metronidazole Cream 0.75% w/ Cleanser
1549403|NCT02602470|Drug|Metronidazole Emulsion|Metronidazole Emulsion 0.75%
1549404|NCT02602470|Drug|Metronidazole Lotion|Metronidazole Lotion 0,75%
1549405|NCT02602470|Drug|Brimonidine Tartrate Gel|Brimonidine Tartrate Gel 0.33%
1549406|NCT02602457|Behavioral|moderate-intensity continuous exercise training|Participants will complete supervised exercise sessions. Moderate-intensity continuous exercise training will follow cardiovascular rehabilitation guidelines. Participants will attend on-site moderate-intensity continuous exercise training two times weekly for 12 weeks.
1549407|NCT02602457|Behavioral|high-intensity interval training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks.
1549408|NCT02602444|Drug|ticagrelor|180 mg loading dose
1549409|NCT02602431|Device|Extra-oral laser irradiation|Irradiation will be employed extra oral by infra-red wave laser, 660nm, 100mW, and 107J/cm2 in four points of Masseter muscle for 30 seconds in each
1549410|NCT02602431|Device|Intra-oral laser irradiation|Irradiation will be employed intra oral by red wave laser, 660nm, 100mW, and 107J/cm2 in four points for 30 seconds in each : 1. Superficial face of dental socket, 2. Lingual face; 3. buccal face and 4. Retromolar region
1549411|NCT02602431|Device|Extra-oral placebo|Laser point will be placed over the same extra-oral points for 30 seconds in each point without irradiation on
1549412|NCT02602431|Device|Intra-oral Placebo|Laser point will be placed over the same intra-oral points for 30 seconds in each point without irradiation on
1549413|NCT02602418|Other|Adaptive WM CogMed Training|"12 different computerized visual and spatial Working Memory tasks will be presented at each sessoin. Each session will involve 8 of the 12 tasks, and each subject is required to complete 25 training sessions, 30-40 minutes per day, 4-5 days per week over a 5-8 week period (minimum 20 sessions). The tasks will become more difficult in an adaptive manner, which is hypothesized as optimal for learning and training effects."
1549414|NCT02602418|Other|Nonadaptive WM CogMed Training|"The same 12 computerized visual and spatial working memory tasks will be presented, but at a fixed (non-adaptive) and low difficulty level. 5 sessions per week x 5 weeks fora total of 25 sessions (minimum 20 sessions)."
1549415|NCT02602392|Behavioral|Lungtropolis|A game-based website for children with asthma aged 5-10 to teach basic self-management skills and a comprehensive adjunct informational website for parents
1549416|NCT02602392|Behavioral|Asthma educational booklet|Text-based asthma education booklet for parents and children in PDF format
1549417|NCT02602379|Other|Tetanic stimulation|Standard Tetanic stimulation will be used as the stimulus to evaluate responses of the intraoperative pain indexes (ANI and NoL) at different concentration of i.v. remifentanil during anesthesia.
1549418|NCT02602366|Other|HEC Placebo Gel|
1549419|NCT02602366|Other|Placebo Vaginal Insert|
1549420|NCT02602366|Other|Placebo Vaginal Film|
1549421|NCT02602366|Other|Placebo Intravaginal ring (IVR)|
1549422|NCT02602353|Drug|Loxoprofen Pain Patch|One Loxoprofen Pain Patch (active NSAID) applied once daily for 3 days
1549423|NCT02602353|Drug|Placebo Patch|One Placebo Patch applied daily for 3 days
1549424|NCT02602353|Drug|No Treatment|No Treatment for 3 days
1549425|NCT02602340|Behavioral|Behavioral Activation therapy|Behavioral Activation therapy
1550168|NCT02597062|Drug|Cyclophosphamide|
1549426|NCT02602327|Drug|Tas-102|Oral nucleoside antitumor agent consisting of α,α,α-trifluorothymidine (FTD) and 5-chloro-6-(2-iminopyrrolidin-1-yl) methyl-2,4 (1H,3H)-pyrimidinedione hydro chloride (TPI) at a molar ratio of 1:0.5.
1549427|NCT02602327|Device|SIR-Sphere|20-60mm resin microspheres containing Yttrium-90 (90Y, Y90) radioisotope
1549430|NCT02602301|Drug|Oxytocin|different oxytocin diluents and effect on fetal bilirubin&sodium levels.
1549437|NCT02602275|Drug|Neurexan®|There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the experimantal arm participants will receive verum on DAY1/PERIOD 1 and will receive placebo on DAY2/PERIOD 2.
1549438|NCT02602275|Other|Placebo|There are two experimental conditions; in one condition participants receive Neurexan® and the second condition they receive Placebo for oral administration (three tablets) in a cross over design. In the comparator arm participants will receive placebo on DAY1/PERIOD 1 and will receive verum on DAY2/PERIOD 2.
1549439|NCT02602262|Other|HIV-infected deceased donor organ|HIV-infected deceased donor organ transplant
1549440|NCT02602249|Biological|MUC1-gene-DC-CTL|MUC1-gene-DC-CTL will be used against tumor cells.
1549441|NCT02602249|Biological|MUC1-peptide-DC-CTL|MUC1-peptide-DC-CTL will be used against tumor cells.
1549442|NCT02602236|Device|AOS-C2000-B|1 base plate for 2 or 3 days and 1 to 4 collection special pouch per day
1549443|NCT02602223|Device|Placing Amnion chorion membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol ACM (BioXclude, Snoasis Medical, Colorado, U.S.A were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
1549444|NCT02602223|Device|Placing d-PTFE membrane over grafted site|Selected teeth were extracted with minimal trauma to hard and soft tissues. The extraction sites were evaluated to verify presence of intact socket walls. Sockets were thoroughly debrided and a combination of demineralized freeze-dried bone and mineralized freeze-dried bone allograft from a single lot number (Maxxeus, Ohio, U.S.A) was placed in the sockets. Per randomization protocol d-PTFE membranes (Cytoplast, Osteogenics Medical, Texas, U.S.A) were tucked into the buccal and lingual flaps, which were minimally elevated (2-3mm) and d-PTFE sutures (Osteogenics Medical, Texas, U.S.A) were used to keep membrane in place. Primary closure was not attempted and membranes were intentionally left exposed
1549445|NCT02602210|Drug|Hydrocortisone|IV bolus of 100 mg hydrocortisone in 50ml NaCl 0.9% (sodium chloride); followed by continuous IV infusion of 200 mg hydrocortisone in 50 ml NaCl 0.9% at a rate of 2 ml/h until the start of day 4.Reduction of infusion rate with 0.5 ml/h/day.
1549446|NCT02602210|Drug|NaCL 0.9%|IV bolus of 50 ml NaCL 0.9%; followed by continuous IV infusion of NaCL 0.9%
1549447|NCT02602197|Drug|Paracetamol|After anesthetic induction, the first I.V bolus injections of 1 gr paracetamol (total amount of 100 ml) were given during 15 minutes and then repeated every 6 h until 24 h postoperative period.
1549448|NCT02602197|Drug|Dexketoprofen|After anesthetic induction, the first I.V bolus injections of 50 mg Dexketoprofen (premixed with 0.9 % sodium chloride to total amount of 100 ml) were given during 15 minutes and then repeated every 8 h until 24 h postoperative period.
1549449|NCT02602184|Drug|AR/101|
1549450|NCT02602184|Drug|Placebo|
1549452|NCT02602158|Dietary Supplement|Octanoic acid (1-13C, 99%)|"13C-marker will be mixed with emulsions. 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability Lipid emulsion 1: acid stable, particle size 0.6 µm
Optional study pending interim analysis:
Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
1549453|NCT02602158|Dietary Supplement|TRIOCTANOIN (1,1,1-13C3, 99%)|"13C-marker will be mixed with emulsions 2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability
Lipid emulsion 1: acid stable, particle size 0.6 µm
Optional study pending interim analysis:
Lipid emulsion 4: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm"
1549454|NCT02602145|Other|follow-up CTA|All patients will receive PAD stents as their normal standard of care determined by their treating physician. If the patient would decide to enroll in the study, we will perform a standard post-operative contrast-enhanced CTA of the lower extremities at 6 months after stenting.
1549455|NCT02602132|Procedure|Clamping|To clamp before the removal of short-term indwelling urethral catheters
1549456|NCT02602119|Drug|OTL38|Infusion of OTL38 prior to surgery
1549457|NCT02602106|Behavioral|Aquatic activities intervention|Women were suggested to exercise regularly through aquatic activities. A professional in physical exercise and sports designed and conducted the aquatic exercise program.
1549491|NCT02601794|Behavioral|App-based Mindfulness Training|A commercially available mindfulness training app delivered to smartphone or tablet.
1549492|NCT02601781|Procedure|Primary percutaneous coronary intervention (PPCI)|Primary percutaneous coronary intervention (PPCI) aims to recanalize an occluded coronary artery causing ST-elevation myocardial infarction (STEMI).
1549458|NCT02602093|Procedure|Transforaminal Endoscopic Discectomy|Local anaesthesia is to be administered. Verification of the site to be performed by an image intensifier and depending upon the patient's posture, a line is to be drawn from the center of the herniation. The needle is to be set and position checked. After the needle has reached the correct position, a guidewire is inserted. Following that, a series of conical rods are introduced, subsequently a drill is introduced through the cannula. After drilling, the instruments are removed, but the guidewire is to remain in place. The endoscope with the working channels are introduced via an 8mm cannula. Following removal of the hernia, the cannula and endoscope are removed. The patient is to be treated on an outpatient basis.
1549459|NCT02602093|Procedure|Open Microdiscectomy|General or spinal anaesthesia is to be administered. Verification is to be performed using a Carm and the patient is to be positioned prone or in the salaam position. A paramedian incision is to be performed and the level is to be indicated. Loupe or microscope magnification is to be used. Laminotomy as well as foraminotomy is to be performed, if necessary. The amount of degenerative disc material to be removed is at the discretion of the attending surgeon. Post-operative policy will be followed and it is expected that the duration of recovery in the hospital may vary from 2-7 days, but the patient will be discharged as soon as medically responsible.
1549460|NCT02602067|Radiation|131I-Tenatumomab|I131anti-Tenascin monoclonal antibody administered to be targeted on neoplasms expressing Tenascin-C
1549461|NCT02602054|Procedure|Surgical treatment|Standard left thoracotomy
1549462|NCT02602054|Drug|Control group|"- Indomethacin:
Administer 1 full cycle (3 doses) / (1 dose every 12 hours) in the first fourteen days of life:
Preterm infants less than 48 hours of life: first dose 0.2 mg/kg, second dose 0.1 mg/kg and third dose 0.1 mg/kg Preterm infants more than 48 hours of life: first dose 0.2 mg/kg, second dose 0.2 mg/kg and third dose 0.2 mg/kg And preterm infants more than 7 days of life: first dose 0.2 mg/kg, second dose 0.25 mg/kg and third dose 0.25 mg/kg - Ibuprofen:
Administer 1 full cycle (3 doses) / (1 dose every 24 hours) in the first fourteen days of life of preterm infants:
First dose 10 mg/kg Second dose 05 mg/kg Third dose 05 mg/kg
- Acetaminophen
Administer 1 full cycle, in the first fourteen days of life in preterm infants:
Acetaminophen 15 mg/kg every 6 hours for 3 days"
1549463|NCT02602041|Other|Literature search and semi-structured interview|We will do a literature search and perform semi-structured interviews with cancer patients and their partners in order to explore knowledge, attitudes, barriers and facilitators regarding health behavior change following cancer treatment.
1549464|NCT02602028|Drug|colchicine|to compare once daily dosage schema of colchicine and twice daily dosage schema of colchicine
1549465|NCT02602002|Drug|Remifentanil|IV
1549466|NCT02602002|Drug|Placebo|Placebo
1549467|NCT02601989|Drug|Tadalafil|
1549468|NCT02601989|Drug|Placebo|Per oral intake of placebo for six weeks
1549469|NCT02601976|Drug|Peginterferon alfa-2a|PegInterferon alfa-2a 180mcg 20kDa administered subcutaneously once weekly for 24 weeks in genotype 3 and for 48 weeks in genotype 1 patients.
1549470|NCT02601976|Drug|Ribavirin|Ribavirin administered orally in a divided daily dose according to body weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1549471|NCT02601963|Drug|FMX-103 1.5%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
1549472|NCT02601963|Drug|FMX-103 3%|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
1549473|NCT02601963|Drug|Vehicle foam (0%)|The investigational product is FMX-103 minocycline foam. Two concentrations of the investigational product, 1.5% and 3%, will be studied compared to vehicle in patients with moderate-to-severe papulopustular rosacea. The foam will be applied once daily to the face for the 12-week treatment duration of the study.
1549474|NCT02601950|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene
1549475|NCT02601937|Drug|Tazemetostat|Tazemetostat (EPZ-6438) is a selective small molecule inhibitor of the histone-lysine methyltransferase EZH2 gene.
1549476|NCT02601924|Drug|20% Benzocain (Master-Dent, Monroe, NC)|Two topical anesthetic gel groups will receive anesthetic gel at the site of injection with massage on treating tooth.
1549477|NCT02601924|Other|Topical pressure massage|Two topical pressure massage groups will receive topical placebo gel with pressure massage at the site of injection.
1549478|NCT02601911|Drug|Ketorolac Tromethamine|10 mg Ketorolac tromethamine is applied 45 minutes before the injection.
1549479|NCT02601911|Drug|Acetaminophen|10 mg Ketorolac tromethamine/ 1000mg Acetaminophen application before injection.
1549480|NCT02601911|Other|Placebo|This group receive the caplet including placebo 45 minutes before the injection.
1549481|NCT02601898|Device|Lipoic acid|Vaginal capsules (medical device) containing 10 mg of lipoic acid (1 per day)
1549482|NCT02601898|Drug|Progesterone|Vaginal capsules (drug) containing 200 mg of progesterone (2 per day)
1549483|NCT02601885|Drug|ABT-555|Intravenous Infusion
1549484|NCT02601885|Other|Placebo|Intravenous Infusion
1549485|NCT02601859|Drug|Lithium Carbonate|
1549486|NCT02601846|Other|No intervention|This is an observational study, without any specific intervention.
1549487|NCT02601833|Device|Silver Diamine Fluoride|No caries removal will take place. The tooth will be dried and Silver Diamine Fluoride will be placed on the carious dentin until saturated. Excess will be blotted dry with a cotton pellet.
1549488|NCT02601833|Procedure|Conventional Caries Management|These children will receive restorative dental care in alignment with the American Academy of Pediatric Dentistry guidelines, within the confines of the Mott Children's Health Center clinic. This treatment typically includes administration of local anesthesia, placement of rubber dam, caries removal with rotary and hand instruments, and placement of a final restoration.
1549489|NCT02601807|Device|ActiPatch (active)|Active version of the ActiPatch pulsed shortwave therapy device. Emits shortwave radiofrequency pulsed energy.
1549490|NCT02601807|Device|ActiPatch (placebo)|Placebo version of the ActiPatch pulsed shortwave therapy device. Emits no radiofrequency energy but otherwise appears identical to the active device.
1549493|NCT02601781|Device|Bioresorbable Vascular Scaffold (BVS ABSORB)|BVS Use during Primary PCI following a pre-specified implantation strategy (eventual thrombectomy, intravascular imaging, lesion pre-dilatation, BVS implantation and BVS post-dilatation).
1549494|NCT02601768|Device|Transcatheter closure of ASD II|Transcatheter closure of ASD II performed in our center.
1549495|NCT02601755|Behavioral|iCanCope app and website|"In addition to standard medical care, adolescents and young adults in the experimental group will receive access to the iCanCope with Pain smartphone app and website for 8 weeks. The app consists of daily pain symptom tracking (pain intensity, sleep, mood, physical activity, and fatigue), goal setting, in-the moment coping strategies, as well as a social community component. The website provides chronic pain-specific education, self-management strategies, and resources."
1549496|NCT02601755|Behavioral|Attention control group|"The control group is designed to control for the potential effects on outcomes of time, attention, smartphone and computer use during the intervention. In addition to standard medical care, adolescents and young adults in the attention control group will receive access to the iCanCope with Pain smartphone app (control version, with limited functionality), and a pain resource website without access to self-management strategies."
1549497|NCT02601742|Other|Zinc group|Pedialyte diarrhea oral electrolyte solution, 330 ml per day for 7 days
1549498|NCT02601742|Other|Placebo group|Pedialyte oral electrolyte solution, 330 ml per day for 7 days
1549499|NCT02601716|Biological|PfSPZ Vaccine|Aseptic, purified, cryopreserved, radiation-attenuated, Plasmodium falciparum (Pf) sporozoites
1549500|NCT02601716|Biological|CHMI (7G8)|CHMI is conducted by exposure to the bites of five mosquitoes infected with heterologous (7G8) Pf parasites.
1549501|NCT02601716|Biological|CHMI (NF135.C10)|CHMI is conducted by exposure to the bites of three to five mosquitoes infected with heterologous (NF135.C10) Pf parasites.
1549502|NCT02601703|Drug|Tacrolimus Ointment 0.1%|apply thin layer of ointment to affected area
1549503|NCT02601703|Drug|Protopic® ointment, 0.1%|apply thin layer of ointment to affected area
1549504|NCT02601703|Drug|Placebo of Tacrolimus Ointment|apply thin layer of ointment to affected area
1549505|NCT02601690|Other|Blood Sampling|
1549506|NCT02601677|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral Nucleus accumbens/Anterior Limb of Internal Capsule
1549507|NCT02601677|Drug|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
1549508|NCT02601664|Procedure|Combined Intervention|pre-PCI intracoronary vasodilator administration and glycoprotein IIb/IIIa inhibitor administration, use of an embolization protection device if technically feasible, and complete coverage of the lipid core plaque, if technically feasible
1549509|NCT02601664|Procedure|Conventional PCI|Conventional PCI
1549510|NCT02601651|Drug|Lidocaine|Lignocaine group will receive an intravenous (IV) bolus 1.5 mg/kg at induction followed by continuous infusion of 2 mg/kg/hr until the tracheal extubation.
1549511|NCT02601651|Drug|Normal saline|Normal saline group will receive an intravenous normal saline bolus at induction followed by continuous infusion of normal saline until the tracheal extubation
1549512|NCT02601638|Other|Demographics and Health History Questionnaire|
1549513|NCT02601638|Other|Pre-Class Laryngectomy Survey|
1549514|NCT02601638|Behavioral|Counseling session with speech pathologist|
1549515|NCT02601638|Behavioral|Total Laryngectomy Preoperative Education Class|
1549516|NCT02601638|Other|Day of Hospital Discharge Laryngectomy Survey|
1549517|NCT02601638|Other|Day of Discharge Practicum|
1549518|NCT02601638|Other|Laryngectomy Education Study Exit Survey|
1549525|NCT02601612|Biological|D46cpΔM2-2 vaccine|Delivered as nose drops
1549526|NCT02601612|Biological|Placebo|Delivered as nose drops
1549527|NCT02601599|Behavioral|Motivational interviewing|"The medical student will deliver a brief (approximately 15 minute) consultation with the patient that is based on principles of social cognitive theory and motivational interviewing. The goals of this consultation will be to enhance the patient's motivation and self-efficacy regarding quitting, and collaboratively elicit a plan to stay quit after discharge. Patients will be offered the opportunity to receive a consultation from the attending physician to determine eligibility for pharmacotherapy (via a chart sticker).
Each student will counsel 1-3 smokers each over the 8-month academic period, with student training and intervention staggered over this time. Students will also re-contact the smoker at 1-week post-discharge via telephone or personal follow-up, to provide further support."
1549528|NCT02601586|Drug|PR Oxycodone|PR Oxycodone
1549529|NCT02601586|Drug|Levodopa|Levodopa
1549530|NCT02601586|Drug|Oxycodone Placebo|Placebo of PR Oxycodone
1549531|NCT02601586|Drug|Levodopa placebo|
1549536|NCT02601560|Biological|MEDI6012|MEDI6012
1549537|NCT02601560|Biological|Placebo|
1549577|NCT02601157|Device|CX-ISAR|Patients with significant coronary lesions will be treated with this contemporary stent platform. This stent platform has a thin-strut cobalt-chromiun alloy backbone, no polymer, microporous surface.
1550169|NCT02597062|Drug|Dexamethasone|
1549538|NCT02601547|Device|PET-FDG brain imaging and NPT|PET-FDG brain imaging and NPT should be performed at T0, at Tf (within 1 month after chemotherapy termination), T+12. Several PET parameters should be calculated: minimal SUV (Standard Uptake Value), maximum SUV, and mean SUV for each of 20 cortical and sub-cortical territories.
1549539|NCT02601534|Behavioral|3 zero exercise|Two interactive sessions and monthly mobile messages related to 3 zero exercise
1549540|NCT02601534|Behavioral|Healthy diet|Two interactive sessions and monthly mobile messages related to healthy diet
1549541|NCT02601521|Behavioral|Internal tobacco coach|"The internal coaching program will provide cognitive-behavioral counseling and medication adherence support for smokers who are ready to quit in the next 3 months It consists of:
Telephone counseling by the Tobacco Coach (8 calls over 12 weeks). supplemented by automated phone calls using interactive voice response. At each IVR contact, smokers can request a call back from the Tobacco Coach. Smokers who are not quit after 3 months can restart into the 12-week counseling program.
The Tobacco Coach will assist smokers in choosing pharmacotherapy and in obtaining a prescription from the smoker's physician.
Support and monitoring for 12 months using automated phone calls. If relapse occurs, the smoker will have the option to return to the active 12-week program."
1549542|NCT02601521|Behavioral|External tobacco coach|Referral to Massachusetts Smokers Helpline (telephone quitline operated by the Massachusetts Tobacco Control Program) for proactive telephone counseling.
1549543|NCT02601508|Drug|Rocuronium|Continuous infusion of rocuronium for PTC 1 + Sugammadex
1549544|NCT02601508|Drug|cis-atracurium|Intermittent injection of cis-atracurium for TOF 1 + Pyridostigmine & Glycopyrrolate
1549545|NCT02601495|Behavioral|Women in a court diversion program|Women in Recovery (WIR) is an intensive outpatient alternative for eligible women facing long prison sentences for non-violent, drug-related offenses in Oklahoma.
1549546|NCT02601482|Behavioral|CON|
1549547|NCT02601482|Behavioral|IW-60|
1549548|NCT02601482|Behavioral|IW-45|
1549549|NCT02601469|Drug|DSXS|twice daily for 28 days
1549550|NCT02601443|Device|Cervical Pessary|
1549552|NCT02601417|Other|Ignoring result of bile culture|Patients in the trial arm will do bile cultures which will not be considered when choosing antibiotics.
1549553|NCT02601404|Device|Bioresorbable scaffold (BRS)|The implantation procedure of an Absorb™ is similar to a metallic stent.
1549554|NCT02601391|Behavioral|Adapting STEPPS within forensic inpatient services.|This study will focus upon delivering the STEPPs-HI group within Forensic Healthcare Inpatient Services.
1549555|NCT02601378|Drug|LXS196|
1549556|NCT02601365|Drug|inhaled GM-CSF (sargramostim)|GM-CSF will be administered over 4h via a nebulizer
1549557|NCT02601339|Procedure|ETV/CPC|endoscopic third ventriculostomy (ETV) combined with choroid plexus cauterization (CPC) is a surgical procedure to treat infant hydrocephalus
1549558|NCT02601339|Procedure|VP shunt|ventriculoperitoneal (VP) shunting is a surgical procedure to treat infant hydrocephalus
1549559|NCT02601326|Procedure|Laparoscopic ventral mesh Rectopexy|Laparoscopic fixation of rectum to sacral promontory using mesh
1549560|NCT02601326|Procedure|Delorme's procedure|Transanal excision of rectal mucosa and plication of muscle layer
1549561|NCT02601313|Biological|KTE-C19|
1549562|NCT02601300|Drug|GED-0301|
1549563|NCT02601287|Biological|Botulinum Toxin Type A|Botulinum Toxin Type A into detrusor muscle on Day 1
1549564|NCT02601274|Drug|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
1549565|NCT02601261|Other|At the first day of hospitalization the field investigator will submit to pregnant women in a pathological condition five questionnaires|"Some of these questionnaires will have to be completed every day and others every other day:
The Internet questionnaire is divided in two parts. The first one investigates the use of internet at home and it will be administered only once, the second part will investigate the internet use at the hospital, in the case the women have a personal smartphone, tablet or personal computer (they are the owners) and it will be administered every other days.
The questionnaire is aimed to understand the quality of life (EQ-5D) will be administered only once, at the beginning of the hospitalization.
The STAI questionnaire is divided in to parts, the first part aims to determinate the state anxiety and it will be administered every other day, while the second part will discuss the anxiety itself, and has to completed only once.
The short questionnaire on critical events occurring during the day,
The short questionnaire with obstetric anamnesis."
1549566|NCT02601248|Drug|Theliatinib|Theliatinib is a tablet in the form of 25 mg ,10mg and 100 mg,oral,once daily
1549567|NCT02601235|Drug|Naridrin|Naridrin® : 2 drops in each nostril once daily as prescription
1549568|NCT02601235|Drug|oxymetazoline hydrochloride|2 pumps in each nostril every 12 hours.
1549569|NCT02601222|Drug|Runzao zhiyang capsule|Runzao zhiyang capsule：4 pills each time, 3 times a day, oral. Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
1549570|NCT02601222|Drug|Runzaozhiyang capsule agent simulation|Runzaozhiyang capsule agent simulation：4 pills each time, 3 times a day, oral， Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
1549571|NCT02601222|Drug|Urea cream|Topical application, apply to the affected area and gently rub, 2 times a day.Number of Cycles：4 weeks of treatment, the cured patients were followed up for 8 weeks to evaluate recurrence.
1549574|NCT02601196|Drug|Ulipristal acetate|"Transvaginal US and diagnostic hysteroscopy - to ascertain suitability. A therapeutic course of ulipristal acetate 5 mg per day for 13 weeks. After completion of the treatment protocol - another TVUS, diagnostic hysteroscopy and histological examination of the endometrium - to assess results of UPA treatment.
Another IVF cycle."
1996207|NCT02537418|Drug|durvalumab|
1549650|NCT02600741|Drug|Prochlorperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549578|NCT02601157|Device|Orsiro|Patients with significant coronary lesions will be treated with this contemporary stent platform. This stent platform has a thin-strut cobalt-chromiun alloy backbone, abluminal coatings with biodegradable polymer.
1549579|NCT02601157|Drug|3-months DAPT|Contrast to the conventional 1-year DAPT, patients in this group will be followed with 3-months DAPT schedule after the stenting
1549580|NCT02601157|Drug|1-year DAPT|Patients in this group will be followed with the conventional 1-year DAPT schedule after the stenting
1549581|NCT02601144|Device|Deep Brain Stimulation|Deep Brain Stimulation
1549582|NCT02601131|Biological|Platelet transfusion|
1549583|NCT02601118|Other|Micro Expression Training Tool|The Micro Expression Training Tool (METT) and the Subtle Expression Training Tool (SETT) to help improve the non-verbal communication skills
1996208|NCT02537418|Drug|tremelimumab|
1549586|NCT02601092|Procedure|Mini Gastric Bypass|"The mini gastric bypass procedure was first developed by Dr Robert Rutledge from the USA in 1997, as a modification of the standard Billroth II procedure. A mini gastric bypass creates a long narrow tube of the stomach along its right border (the lesser curvature). A loop of the small gut is brought up and hooked to this tube at about 180 cm from the start of the intestine.
No drugs or devices will be used."
1549587|NCT02601092|Procedure|Roux-en-Y Gastric Bypass|"This variant is the most commonly employed gastric bypass technique, and is by far the most commonly performed bariatric procedure in the United States. The small intestine is divided approximately 45 cm (18 in) below the lower stomach outlet and is re-arranged into a Y-configuration, enabling outflow of food from the small upper stomach pouch via a Roux limb. In the proximal version, the Y-intersection is formed near the upper (proximal) end of the small intestine. The Roux limb is constructed using 80-150 cm (31-59 in) of the small intestine, preserving the rest (and the majority) of it for absorbing nutrients.
No drugs or devices will be used."
1549588|NCT02601079|Device|Endodrill Biopsy|Testing a new device for taking tissue biopsies in the GI tract. The investigators will use the Endodrill instrument in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the Endodrill instrument can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
1549589|NCT02601079|Device|Conventional Biopsy forceps|Using a conventional biopsy forceps for taking tissue biopsies in the GI tract. The investigators will use conventional biopsy forceps in order to sample high quality biopsies from tumor tissue in the distal esophagus and cardia. The investigators will also investigate to what extent the conventional biopsy forceps can generate biopsies with the correct diagnosis and also evaluate the possibility for genetic studies of the harvested tumor tissue.
1549590|NCT02601066|Device|Electrophysiological Study and ECG holter monitor|Electrophysiological Study and ECG holter monitor implantation
1549591|NCT02601053|Other|Dull movie|A dull movie (duration approximately 90 minutes)
1549592|NCT02601053|Other|Scary (horrifying) movie|A scary movie (duration approximately 90 minutes)
1549593|NCT02601053|Other|Heart rate measurement|Heart rate measurement using a actiheart device
1549594|NCT02601040|Biological|Attenuated Hepatitis A Vaccine, H2 Strain|6.50 lgCCID50/ml in babies aged 18-35 months\6.50 lgCCID50/ml in children aged 3-16 years \6.50 lgCCID50/ml in adults aged 17 up to 65 years old
1549595|NCT02601040|Biological|Inactivated Hepatitis A Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months \320EU/Vial in children aged 3-16 years \640EU/Vial in adults aged 17 up to 65 years old\boost at month 6\two-dose
1549596|NCT02601040|Biological|Group A Meningococcal Polysaccharide vaccine|30µg Group A Meningococcal Polysaccharide vaccine in subjects aged 18 months-65 years old
1549597|NCT02601027|Procedure|TAP block|
1549598|NCT02601027|Other|saline infusion|
1549599|NCT02601027|Drug|bupivacaine infusion|
1549600|NCT02601027|Drug|acetominophen|
1549601|NCT02601027|Drug|Hydromorphone|
1549602|NCT02601027|Drug|Oxycodone|
1549603|NCT02601027|Drug|Ondansetron|
1549604|NCT02601014|Biological|Ipilimumab|Given IV
1549605|NCT02601014|Other|Laboratory Biomarker Analysis|Correlative studies
1549606|NCT02601014|Biological|Nivolumab|Given IV
1549607|NCT02601001|Drug|AMG 423|Omecamtiv mecarbil at 25 mg and 37.5 mg
1549608|NCT02601001|Drug|AMG 423|Omecamtiv mercabil at 25 mg and 50 mg
1549609|NCT02601001|Drug|Placebo|Placebo Comparator
1549610|NCT02600988|Drug|1000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
1549611|NCT02600988|Drug|5000IU/day of Vitamine D|Administration of a specified dose of Vitamine D
1549612|NCT02600975|Biological|R21 with ASO1B|R21 with ASO1B
1549616|NCT02600936|Device|vein stent placement|Venous outflow obstruction will be treated by the placement of a stent to keep the vein open. This procedure is a minimally invasive endovascular treatment.
1549617|NCT02600923|Drug|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1).
1549618|NCT02600923|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
1549619|NCT02600897|Drug|Lenalidomide|All participants will receive lenalidomide oral capsules at doses of 10, 15, or 20 milligrams (mg) on Days 1 to 21 of each 28-day cycle for up to 6 Cycles in dose escalation phase followed by post-induction treatment at a dose of 10 mg once daily on Days 1 to 21 of each subsequent 28-day cycle. Post-induction lenalidomide may continue for up to 12 months until disease progression or unacceptable toxicity for participants with R/R FL and up to 6 months until disease progression or unacceptable toxicity for participants with R/R DLBCL.
1549620|NCT02600897|Drug|Obinutuzumab|Participants will receive a fixed dose of obinutuzumab, 1000 mg via intravenous (IV) infusion to be given on Days 1, 8 and 15 of Cycle 1 and on Day 1 of Cycles 2 to 6 followed by post-induction treatment at a dose of 1000 mg via IV infusion on Day 1 of every other month for up to 24 months until disease progression or unacceptable toxicity.
1549621|NCT02600897|Drug|Polatuzumab Vedotin|Participants with R/R FL will receive polatuzumab vedotin via IV infusion at doses of 1.4 or 1.8 milligrams per kilogram (mg/kg) on Day 1 of each 28-day cycle for up to 6 months during induction treatment. Participants wit R/R DLBCL will receive polatuzumab vedotin via IV infusion at dose 1.8 mg/kg on Day 1 of each 28-day cycle for up to 6 months during induction treatment.
1549622|NCT02600897|Drug|Rituximab|Participants will receive a fixed dose of rituximab, 375 mg/m^2 via intravenous (IV) infusion to be given on Days 1 of Cycle 1 to 6 followed by post-induction treatment at a dose of 375 mg/m^2 via IV infusion on Day 1 of every other month for up to 6 months, until disease progression or unacceptable toxicity.
1549623|NCT02600884|Behavioral|Families Talking Together Plus (FTT+HPV)|Intervention parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the experimental intervention includes parent child sexual health communication and HPV vaccination navigation.
1549624|NCT02600884|Behavioral|Brief motivational interviewing (BMI)|Control parents will attend a 1-hour intervention session and receive program materials to use with youth at home and 2 booster phone calls post intervention. Content of the control intervention includes obesity prevention strategies using motivational interviewing.
1549625|NCT02600871|Drug|Provodine|
1549626|NCT02600871|Procedure|Incision and Drainage|
1549627|NCT02600858|Behavioral|Upper limb feeding training|"Participants will spoon two raw kidney beans at a time from a center proximal start cup to three distal target cups positioned 16 cm away at 45°, 90° and 135° around the start cup as fast as possible using their non-dominant hand. Spooning two beans between the start cup and a target cup is considered one repetition; each trial will consist of 15 repetitions. Participants will perform 50 trials per day for 3 consecutive days."
1996209|NCT02536170|Drug|L-arginine|L-arginine will be dispensed intravenously (IV) in the standard dose of 100 mg/kg three times a day until discharge from the emergency department (ED) or hospital.
1549629|NCT02600832|Behavioral|AABM Training|The investigators will use a training version of the Alcohol Approach-Avoidance Task (AAT), in which patients are asked to respond to the format of presented pictures, irrespective of the pictures' content. Pushing a presented picture away will decrease picture size, whereas pulling a picture closer will increase size. There are 2 categories of pictures; 20 different alcoholic and 20 different non-alcoholic beverages. Training effect is achieved by presenting alcohol pictures in push format only and non-alcoholic drinks in pull format only. Two hundred training trials are presented per session.
1549630|NCT02600832|Behavioral|Sham Training|Sham training is identical to AABM training, except pictures are presented randomly in both formats.
1996210|NCT02536170|Drug|L-arginine Loading Dose|One loading dose of L-arginine will be dispensed intravenously (IV) at 200 mg/kg
1549632|NCT02600806|Drug|Azithromycin|Patients are given oral azithromycin when procalcitonin levels are < 0.5 ng/ml
1549633|NCT02600806|Drug|Levofloxacin|Patients are given oral levofloxacin when procalcitonin levels are >= 0.5 ng/ml.
1549634|NCT02600793|Drug|Ceftaroline|Following Ceftaroline single IV dose, 3 blood and cerbrospinal fluid samples will be collected
1549635|NCT02600780|Drug|Febuxostat|Comparison of two anti-hyperuricemic molecules
1549636|NCT02600780|Drug|Allopurinol|Comparison of two anti-hyperuricemic molecules
1996211|NCT02536170|Other|Placebo|Placebo of intravenous (IV) normal saline 1-2 ml/kg three times a day until discharge from the emergency department (ED) or hospital.
1549638|NCT02600754|Behavioral|IT-PST|5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)
1549639|NCT02600754|Behavioral|IT-SCM|5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
1549640|NCT02600741|Other|Caregiver psycho-education and skills training|Caregivers will receive up to 16 sessions of study-provided caregiver psycho-education and skills training sessions they are able to attend within a 6-month period.
1549641|NCT02600741|Other|Caregiver support available at the study site|Caregivers will receive whatever caregiver support that is customarily available at the study site, if any.
1549642|NCT02600741|Drug|Paliperidone palmitate|Patients enrolled in this study will continue to receive routine treatment of paliperidone palmitate, as directed by their treating physician.
1549643|NCT02600741|Drug|Chlorpromazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549644|NCT02600741|Drug|Droperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549645|NCT02600741|Drug|Fluphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549646|NCT02600741|Drug|Haloperidol|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549647|NCT02600741|Drug|Loxapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549648|NCT02600741|Drug|Perphenazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549649|NCT02600741|Drug|Pimozide|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1550170|NCT02597049|Drug|Dulaglutide|Administered SC
1549651|NCT02600741|Drug|Thiothixene|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549652|NCT02600741|Drug|Thioridazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549653|NCT02600741|Drug|Trifluoperazine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549654|NCT02600741|Drug|Aripiprazole|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549655|NCT02600741|Drug|Asenapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549656|NCT02600741|Drug|Clozapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549657|NCT02600741|Drug|Iloperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549658|NCT02600741|Drug|Olanzapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549659|NCT02600741|Drug|Paliperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549660|NCT02600741|Drug|Quetiapine|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549661|NCT02600741|Drug|Risperidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549662|NCT02600741|Drug|Ziprasidone|Patients enrolled in this study will continue to receive routine treatment of oral antipsychotics, as directed by their treating physician.
1549663|NCT02600728|Behavioral|Experimental Training|"The ET consisted of 3 phases being that the first one (Phase 1) was done only in the first session.
Phase 1: patients received a short and simple explanation about the deficiency in automatic movement resulting from PD. Following explanation, the patient memorized a sequence of declarative cues. Phase 2: the patient organized a sequence of cues using cards illustrating the subcomponent movements (key movement) involved in taking steps.
Phase 3: the patient had to train using declarative cues as a gait performance aid through 8 sets follow the instruction Walk in your ordinary speed. Use the key movements and going to saying each of them while you make them. The declarative cues had to be evoked verbally by the patients themselves, during gait, triggering the corresponding movement."
1549664|NCT02600728|Behavioral|Control Training|"The CT consisted of 3 phases, being the first one (Phase 1) was done only in the first session of training, and the other two (Phase 2 and 3) were repeated at each of the 8 sessions.
Phase 1: Patients received a short and simple explanation about the deficiency in automatic movement resulting from PD.
Phase 2: Patients received a general verbal attentional instruction of pay attention to your steps and try to walk as better as you can, before starting the walk.
Phase 3: motor training of gait, where the patient had to perform 8 sets, following the instruction Walk in your ordinary speed, paying attention to your steps in the identical trajectories of ET. Additional instructions or cues were not provided."
1549670|NCT02600702|Other|Siriraj knee exercise|Siriraj knee exercise, 12 position of exercise protocol
1549671|NCT02600702|Other|Physical modalities|
1549672|NCT02600689|Behavioral|Physical exercise training|
1549673|NCT02600689|Behavioral|Cognitive exercise training|
1549674|NCT02600676|Device|Transcutaneous Electric Nerve Stimulation (TENS) - active|TENS is a non-invasive method using surface electrodes. Except a few cases with local skin irritation in the area where the electrodes are applied, there is no evidence of side effects of TENS treatment.
1549675|NCT02600676|Device|Transcutaneous Electric Nerve Stimulation (TENS) - placebo|
1549676|NCT02600650|Dietary Supplement|Testosterone boosting supplement|Proprietary formulation of Testosterone boosting supplement administered daily
1549677|NCT02600650|Dietary Supplement|Placebo Comparator|Daily administration of Placebo Comparator
1549678|NCT02600637|Behavioral|MBSR|Mindfulness-based Stress Reduction is an 8-week course designed to teach a number of mindfulness techniques to help improve stress- and depression-related symptoms.
1549679|NCT02600637|Behavioral|Brain Health class|An 8-week course on brain health will be administered to participants as an active control group.
1549680|NCT02600611|Drug|iclaprim|Experimental treatment
1549681|NCT02600611|Drug|vancomycin|Active comparator
1549682|NCT02600598|Drug|LEO 43204 Gel, 0.037%|
1549683|NCT02600598|Drug|LEO 43204 Gel, 0.037%|
1996212|NCT02535936|Procedure|3Tesla MRI with DTI-MRI and rsfcMRI under general anesthesia|2 post-operative MRI's at 2 months and 12 months
1549686|NCT02600572|Other|Isometric exercises|Subjects will perform one session of isometric exercises at the end of Day 1
1549687|NCT02600572|Other|Eccentric exercises|Subjects will perform one session of eccentric exercises at the end of Day 2
1549688|NCT02600559|Drug|OTO-201 (ciprofloxacin)|
1549689|NCT02600533|Procedure|Video viewing group|First, participants will complete a brief electronic survey measuring their opinions on clinical trials. Next, participants in the video viewing group will watch the 10-minute DVD video on tablet devices using headphones in the clinic. Participants in this groups will be informed that a team member will call him/her in approximately 1 week to ask him/her the (same) questions about clinical research.
1549690|NCT02600520|Drug|SRP with RSV gel LDD|After SRP, 1.2% Rosuvastatin (RSV) gel was delivered subgingivally into the pocket
1549691|NCT02600520|Drug|SRP with ATV gel LDD|After SRP, 1.2% Atorvastatin (ATV) gel was delivered subgingivally into the pocket
1996215|NCT02535585|Device|knotted anchors (SutureTak biocomposite 3.0 mm)|Arthroscopic repair of the labral lesion with knotted anchors (SutureTak biocomposite 3.0 mm).
1996216|NCT02535585|Device|knotless anchors (PushLock biocomposite 2.9 mm knotless)|Arthroscopic repair of the labral lesion with knotless anchors (PushLock biocomposite 2.9 mm knotless)
1549697|NCT02600481|Procedure|low-pressure pneumoperitoneum|Using low-pressure(between 7-10 mm Hg ) pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
1549698|NCT02600481|Procedure|standard-pressure pneumoperitoneum|Using standard-pressure (between 12-16 mm Hg )pneumoperitoneum to complete robot-assisted surgeries,such as radical prostatectomy or cystectomy.
1549699|NCT02600468|Drug|Orencia|
1549700|NCT02600455|Drug|Orencia|
1549701|NCT02600442|Other|non interventional study|
1549702|NCT02600429|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into affected eye(s), five times a day for 4 weeks.
1549703|NCT02600429|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
1549704|NCT02600416|Other|AV port reversal|Reversal of the AV port at 1h Reversal of the AV port to start position at 7h
1549708|NCT02600390|Biological|SANGUINATE|A two-hour infusion provided once a week over a 4-week or 6-week period.
1549709|NCT02600377|Other|Vegetarian diet|Diets that omit all animal products (vegan diet) or all animal products with the exception of eggs and/or dairy products (vegetarian)
1549710|NCT02600351|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
1549711|NCT02600351|Drug|RBV|RBV tablets administered orally in a divided daily dose according to weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1549712|NCT02600338|Other|Legumes|beans, peas, chickpeas, lentils, soybeans, lupins, peanuts in whole or flour form
1549713|NCT02600325|Drug|Grazoprevir/Elbasvir 100mg/50mg|Grazoprevir/Elbasvir 100mg/50mg
1549714|NCT02600312|Device|oXiris|oXiris CRRT filter which adsorbs cytokines, toxins.
1549715|NCT02600299|Behavioral|Psychoeducation group|On the basis of previous studies that evaluated PEG interventions for women with breast cancer, a structured program based on the Cognitive Behavioral Therapy (CBT) principles was developed. Patients in the PEG group will be involved in three sessions of psychoeducation. The PEG program is designed to cover the various aspects outlined by the IOM on quality cancer survivorship.
1549716|NCT02600299|Behavioral|Usual Care|Usual Care
1549717|NCT02600286|Drug|EllaOne|"5 mg/per os of EllaOne every day through 12 months.
10 mg/per os of EllaOne every day through 12 months.
EllaOne placebo/per os every day through 12 months."
1549718|NCT02600286|Drug|EllaOne placebo|"5 mg/per os of EllaOne every day through 12 months.
10 mg/per os of EllaOne every day through 12 months.
EllaOne placebo/per os every day through 12 months."
1549719|NCT02600273|Other|Usual brand cigarettes|Usual brand cigarettes
1549720|NCT02600273|Other|Lower nicotine content cigarettes|SPECTRUM research cigarettes
1549721|NCT02600273|Other|Electronic cigarettes 1|Electronic cigarette with 0 g/mL e-liquid
1549722|NCT02600273|Other|Electronic cigarettes 2|Electronic cigarette with 18 g/mL e-liquid
1549725|NCT02600247|Drug|Duloxetine|"Experimental: Duloxetine group
Phase I (preemptive): 1day before operation (30mg for 1 day)
Phase II (maintenance): 6weeks after operation (30mg for 6 weeks) plus routine pain control (celecoxib, pregabalin, acetaminophen/tramadol, oxycodone)
Other Name: cymbalta Drug: Celebrex, Lyrica, Ultracet, Ircodon
Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week
Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
1549726|NCT02600247|Drug|celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone|"Preemptive analgesia : celebrex 200mg 1C#1, Lyrica 150mg 1C#1 (preoperation. 2 hours), Patient controlled analgesia (postoperation 28 hours) During admission : celebrex 200mg#1, Ircodon 5mg 2T#2, Ultracet 2T#2 (Postoperation 1 week) Discharge medication: celebrex 200mg 1C#1 x 5Weeks, Ultracet 2T#2 x 1 week
Other name : celecoxib, Pregabalin, acetaminophen/tramadol, oxycodone"
1549727|NCT02600234|Device|Inter-Atrial Shunt Device|An implantable device placed in the interatrial septum
1549728|NCT02600234|Other|Intracardiac Echo|Patients randomized to the control arm will undergo intra cardiac echocardiography, with examination of the atrial septum and left atrial appendage.
1549729|NCT02600208|Biological|CliniMACs|Depletion of Alpha Beta T cells in the PBSC graft
1549730|NCT02600195|Behavioral|Evidence-based Practice for Improving Quality (EPIQ) method|The intervention NICUs (n = 12) will receive training in the Evidence-based Practice for Improving Quality (EPIQ) method and then develop, implement, and document evidence-based practice changes to reduce hospital-acquired infection. Compliance with practice changes and neonatal outcomes will be monitored. NICUs will receive quarterly feedback on their progress, as well as access to implementation support.
1549731|NCT02600182|Device|Bilevel Positive Airway Pressure|Bilevel positive airway pressure twice per day during the hospital stay.
1549732|NCT02600169|Drug|Pemprolizumab|All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.
1549733|NCT02600156|Procedure|Focal laser ablation of the prostate|MR guided laser ablation of the focal prostatic lesion which has been identified by MRI and biopsy prior to ablation.
1549734|NCT02600130|Biological|Longeveron Mesenchymal Stem Cells|via peripheral intravenous infusion
1549735|NCT02600130|Biological|Placebo|via peripheral intravenous infusion
1549736|NCT02600117|Drug|Tenofovir disoproxil fumarate|300 mg, oral, once a day
1550171|NCT02597049|Drug|Placebo|Administered SC
1549737|NCT02600104|Device|PicoWayTM|The PicoWayTM base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier
1549739|NCT02600078|Device|AMS Monitor App|Participants will complete a novel coordination task performed on an android phone.
1549740|NCT02600078|Other|Lake Louise Score|Participants will complete a questionnaire to assess acclimatization to hypoxia.
1549741|NCT02600078|Other|Balance Error Scoring System|Participants will complete a series of static stance positions to evaluate their ability to maintain balance.
1549742|NCT02600078|Other|Heart Rate & Pulse Oxygen Saturation|Participants will have their heart rate and pulse oxygen saturation continuously monitored throughout the entire exposure.
1549743|NCT02600065|Other|Blood draw and MRI|The study is observational. The treatment-plan of the underlying disease remained unchanged. Blood draw and MRI from patients at several time points during and after radio(chemo)therapy.
1549744|NCT02600052|Other|PNF|RESPIRATORY PATTERN PROPRIOCEPTIVE NEUROMUSCULAR FACILITATION
1549745|NCT02600052|Device|treadmill|AEROBIC TRAINING
1549746|NCT02600039|Other|ELTGOL|Individuals will be placed in the lateral decubitus position and instructed to perform slow expirations with an open glottis through a nozzle attached to the mouth from the residual functional capacity to residual volume. Concurrently, a trained and subsequently positioned relative to the voluntary physical therapist will perform a manual compression of the abdominal region dependent and the rib cage to enhance contralateral lung deflation. This intervention is performed so that the time is homogeneous between each repetition interval of one minute between each set. To this end, three sets of ten repetitions will be performed on each lateral decubitus (left and right)
1549747|NCT02600039|Device|Acapella|Participant should be comfortably seated and with his elbows on a table. The mouthpiece is attached properly to not allow leaks. The resistance load will be one in which the individual is able to maintain uninterrupted expiration of 3 seconds. Then the patient will be instructed to inhale slowly and deeply, with lung volumes between the residual volume and total lung capacity. The air exhaled by Acapella is directed toward an orifice which opens and closes periodically, promoting oscillations in the air stream throughout the expiratory phase. The expiration is always performed to the VR, and without performing the active contraction of the abdominal muscles. Still prompted an inspiratory pause of 2 seconds for the end of the inspiratory phase. This procedure will be performed in 4 sets of 5 minutes with interval of 1 minute between the series.
1549748|NCT02600026|Device|DriveCam|Video event monitoring device
1549749|NCT02600026|Behavioral|Feedback|Video feedback intervention
1549750|NCT02600000|Radiation|Myocardial scintigraphy|Myocardial scintigraphy with Iodo123-Metaiodobenzylguanidine (MIBG) to assess the Sympathetic myocardial activity
1549751|NCT02600000|Device|Cardiopulmonary test|Assessment of maximal functional capacity
1549752|NCT02600000|Device|AVD-Glittre Test|Determining an accurate cutoff point for assessing the functional capacity. Evaluation of submaximal functional capacity after inspiratory muscle training.
1549753|NCT02600000|Device|Diaphragm ultrasound|Evaluation of thickness and diaphragmatic mobility
1549754|NCT02599987|Device|POWERbreathe® Classic Light|Inspiratory Muscle Training
1549755|NCT02599961|Drug|UX007|UX007 is a liquid intended for oral (PO) administration.
1549756|NCT02599948|Other|no intervention|
1549757|NCT02599935|Dietary Supplement|Hypercaloric beverages|Nutritional supplement: Hypercaloric beverages
1549758|NCT02599935|Other|standard treatment|No other than standard treatment
1549759|NCT02599935|Other|educational structured counseling|Nutritional counseling leaded to patient and caregivers
1549763|NCT02599883|Radiation|Low-Dose Computed Tomography|Low-Dose Computed Tomography will be administered to COPD patients as part of COPD phenotypization.
1549764|NCT02599870|Genetic|NeuroIDgenetix Test Panel|The NeuroIDgenetix Test Panel is used to make recommendations on post-operative pain medication therapy that may be impacted by the genetic background of the patient.
1549765|NCT02599857|Device|CONCOR smartphone application|
1549766|NCT02599844|Drug|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
1549767|NCT02599844|Procedure|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
1549768|NCT02599844|Procedure|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
1549769|NCT02599844|Procedure|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
1549770|NCT02599844|Drug|Gadolinium|Magnevist Gadolinium (GD)-diethylene-triamine-pentaacetic acid-bis-oleate (0.07 to 0.14 mL/kg) will be used to determine GFR.
1550172|NCT02597036|Drug|LY3127804|Administered IV
1549771|NCT02599831|Device|Electrical pudendal nerve stimulation|Four sacrococcygeal points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the root of the penis (perineum) or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the root of the penis (perineum). After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
1549772|NCT02599831|Device|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
1549773|NCT02599831|Device|Transanal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
1549774|NCT02599818|Behavioral|NavSTAR|Participants in the NavSTAR program will work with a team of case workers who will provide motivational intervention and proactive barrier resolution services using patient navigation
1549775|NCT02599805|Device|Natrox™ Oxygen Delivery System (ODS)|Natrox™ ODS will be applied to the subject's diabetic ulcer and attached to the active Natrox™ Oxygen Generator using the tubing provided or regular dressing will be used. The Natrox™ oxygen delivery system (ODS) is a device designed to overcome a number of problems associated with previous methods of oxygen therapy by delivering continuous oxygen to the ulcer bed through a dressing.
1549776|NCT02599792|Drug|CTP-656|
1549777|NCT02599792|Drug|Placebo for CTP-656|
1549778|NCT02599792|Drug|Kalydeco|
1549779|NCT02599779|Drug|Pembrolizumab|200mg given intravenously over 30 minutes day 1 of every 3 week cycle until progression as per immune related response criteria
1549780|NCT02599779|Radiation|Stereotactic Body Radiation Therapy|Dose and duration dependent on body site. In Arm A: SBRT given at the time of progression on pembrolizumab. In Arm B: SBRT given before the 2nd course of pembrolizumab.
1549781|NCT02599766|Other|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
1549782|NCT02599766|Other|standard therapy|standard physiotherapy, standard speech therapy and standard occupational therapy
1549783|NCT02599753|Drug|18-FDTBZ|"During this study, participants will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.
The proposed dose for this study is based on the investigators' phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
1549784|NCT02599740|Other|Natural fruit extract|Natural fruit extract consumed with rice
1549785|NCT02599740|Other|Assumed active|Assumed key active consumed with rice
1549786|NCT02599740|Other|Placebo|Rice only
1549787|NCT02599727|Other|Isometric exercises|subjects will perform specific isometric exercises for 10-20 minutes, three times a week throughout the enrollment period
1549788|NCT02599727|Other|No exercise|Subjects will go on with their life without any specific isometric exercise regimen during the enrollment period
1549794|NCT02599701|Drug|Gabapentin|A single dose Gabapentin 300mg at bedtime.
1549795|NCT02599701|Drug|Placebo|A single placebo dose with the same physical characteristics of the active intervention.
1549796|NCT02599688|Other|None in this study|No intervention in this study.
1549797|NCT02599675|Dietary Supplement|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
1549798|NCT02599675|Dietary Supplement|Placebo|Olive oil, encapsuled
1549799|NCT02599662|Radiation|10 Gy Low-KV IORT|: intraoperative low-kV IORT will be delivered as a single dose of 10 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
1549800|NCT02599662|Radiation|15 Gy Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 15 Gy at 2 millimeter depth. Doses will be escalated in increments of 5 Gy until completion of 20 Gy dose level or the DLT is reached and MTD is realized.
1549801|NCT02599662|Radiation|20 GY Low-KV IORT|intraoperative low-kV IORT will be delivered as a single dose of 20 Gy at 2 millimeter depth. Patients will be accrued to this group until the DLT is reached and MTD is realized.
1549802|NCT02599649|Drug|Lirilumab|3 mg/kg by vein every 4 weeks.
1549803|NCT02599649|Drug|Nivolumab|3 mg/kg by vein on Days 7 and 21 of a 28 day cycle.
1549804|NCT02599649|Drug|Azacitidine|75 mg/m^2 by vein for 7 days of a 28 day cycle.
1549805|NCT02599636|Other|None intervention|Investigators will study the usual medical assistance
1549806|NCT02599623|Procedure|Local Anesthesia|Patients in LA group received the local infiltration technique. A mixture of 2% lidocaine 20ml and 0.9%NS 30ml was used as the local anesthetic. Patients required extra analgesia during the surgery were given 20-40mg parecoxib sodium intravenously. Conversion to GA was performed if LA was intolerant for patient, which was evaluated by both anesthetists and surgeons.
1549807|NCT02599623|Procedure|General Anesthesia|In group GA, anesthesia was induced with propofol 2mg/kg and fentanyl 0.1-0.2mg intravenously. Inhalation anesthesia was given at the same time with a mixture of oxygen and isoflurane 1-2% through an intubation.
1549808|NCT02599610|Other|Digital vaginal examination|Patients will be subject to digital vaginal examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
1550173|NCT02597036|Drug|Ramucirumab|Administered IV
1550174|NCT02597036|Drug|Paclitaxel|Administered IV
1549809|NCT02599610|Device|Transperineal ultrasound examination|Patients will be subject to transperineal ultrasound examinations every four hours during latent phase of first stage, hourly during active phase of first stage and as needed during second stage.
1549810|NCT02599597|Behavioral|Therapist-assisted iCBT|13 week long individualized prevention program containing, physical activation, sleep management, tailored cognitive behavioral therapy for individual problems.
1549811|NCT02599597|Behavioral|Monthly screening with feedback|Participants are screened with a depression inventory each month and receives feedback from a therapist on the results
1549812|NCT02599584|Behavioral|precritical staff|free pre critical scenario team staff
1549813|NCT02599571|Other|Very low nicotine content cigarettes|
1549814|NCT02599571|Other|Conventional nicotine content cigarettes|
1549815|NCT02599558|Device|Cytosponge|Patients undergoing the six food elimination diet will be monitored through the diet with swallowing the cytosponge. This is a ten minute procedure in the office. The cytosponge will be sent to the lab for histology reading of the eosinophilic count.
1549816|NCT02599558|Other|Diet|Investigators will reintroduce 1 of the six food for two weeks, then another for two weeks. Participant will return for the cytosponge procedure which will help the Investigator to direct which foods will be add or removed for the next two to four weeks. This will be repeated until all six foods have been reintroduced back into the participants diet.
1549817|NCT02599558|Other|Phone call|The study coordinator will call the participant two weeks after the participate has added in one of the six foods as directed by the Investigator, completing a short questionnaire (esophageal eosinophilic Activity Index Pro) EEsAI Pro.
1549818|NCT02599558|Other|EEsAI Pro|This is a short questionnaire to assess the participants swallowing. This will be completed at baseline, two weeks after a food has been added to the diet and at the final visit.
1549819|NCT02599532|Drug|apixaban|Study subjects will be given a single-dose of apixaban 10 mg.
1549820|NCT02599493|Drug|Rifampicin|Patients will be randomly assigned to low dosage (10 mg/kg/j) rifampicin group or high dosage (20 mg/kg/j) rifampicin group. Rifampicin treatment will be prescribed in association with another antibiotic chosen by investigator according to the antibiogram results. Association with fluoroquinolones is the first choice combination, if it is possible. The global antibiotic treatment duration depends on the investigator's choice.
1549821|NCT02599480|Drug|mirabegron|50 mg daily during 12 months
1549822|NCT02599480|Procedure|Echocardiography|Echocardiography
1549823|NCT02599480|Procedure|Cardiac MRI|Cardiac MRI
1549824|NCT02599480|Procedure|Maximal exercise capacity|Maximal exercise capacity
1549825|NCT02599480|Procedure|Blood sampling|Blood sampling for study assessments and future exploratory studies.
1549826|NCT02599480|Procedure|Endothelial function measurement|EndoPAT assessment
1549827|NCT02599480|Radiation|18FDG-PET|PET scanning for beige/brown fat activation
1549828|NCT02599467|Other|ULNT 1 and EMG recording|While the ULNT 1 was performing, EMG muscle activity form biceps brachii and triceps brachii were recorded. The maneuver was stopped to measure abduction, external rotation and elbow flexion range of motion (ROM) with a goniometer. Three measurements were performed: measure 1) when the first sense of tightness perceived by the subject appeared; measure 2) when evoked muscle activity increased on EMG record; measure 3) when sense of final resistance perceived by the investigator appeared. Considering the increase of symptoms with contralateral or decrease of symptoms with ipsilateral cervical side bending as mandatory positivity criterion.
1549829|NCT02599454|Drug|Atezolizumab|Into the vein Day 1 every 3 weeks for 6 cycles
1549830|NCT02599454|Radiation|Stereotactic Body Radiation Therapy|Radiation therapy will be performed to 50 Gy over 4 fractions of 12/5 Gy each for peripherally located tumors and 50 Gy over 5 fractions of 10 Gy each for centrally located tumors
1549831|NCT02599415|Device|TL01 light treatment|Patients received treatment in TL01 cabinet three sessions weekly according to a standard escalating protocol based on minimal erythema dose. Standard dose ranges between 0.55 and 3.13J/cm2.
1549834|NCT02599389|Device|Drug-coated balloons|
1549835|NCT02599389|Device|Excimer Laser|
1549836|NCT02599376|Device|LiDCOrapid|Cardiac output will be non invasively monitored by using 2 cuffs on fingers.
1549837|NCT02599363|Drug|Ribociclib (LEE011)|
1549838|NCT02599363|Drug|Paclitaxel|
1549839|NCT02599337|Drug|Nexavar|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.
Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
1549840|NCT02599337|Drug|Sorafenib|"Single oral dose (1 x 200 mg) sorafenib or Nexavar in each period. No food were allowed from at least 10 hours before dosing until at least 4 hours after dosing.
Except for water given with study medication, no fluids were allowed from 1 hour before dosing until 1 hour post-dose."
1549841|NCT02599324|Drug|ibrutinib|
1549842|NCT02599324|Drug|everolimus|
1549843|NCT02599324|Drug|docetaxel|
1549844|NCT02599324|Drug|paclitaxel|
1549845|NCT02599324|Drug|cetuximab|
1549846|NCT02599311|Device|transvaginal synthetic mesh|transvaginal synthetic mesh
1549847|NCT02599311|Drug|Tolterodine|Tolterodine tartrate can improve patients' LUTS.
1549848|NCT02599298|Device|Continuous Positive Airway Therapy|
1549849|NCT02599298|Behavioral|Sleep-Study Guided Multidisciplinary Therapy|
1549850|NCT02599285|Device|Fixation|Fixation of the posterior malleolus with lag-screws or plate-fixation. If syndesmosis is intra-operatively stable, no syndesmotic positioning screws will be placed.
1549851|NCT02599285|Device|NO Fixation|Posterior malleolus will not be fixated. Syndesmotic positioning screws will be placed.
1549852|NCT02599272|Other|Rice with tomatoes and peeled aubergine (no spice)|Dose 0
1549853|NCT02599272|Other|Rice with vegetables and low spice|Dose 1, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, peeled aubergine, onion, ginger and garlic
1549854|NCT02599272|Other|Rice with vegetables and high spice|Dose 2, Rice with mixed spices (turmeric, coriander, cumin, gooseberry cayenne pepper, cinnamon, clove), tomatoes, onion, ginger and garlic
1549855|NCT02599259|Device|Monitored (M+)|Patients assigned to the intervention arm will use the AiCure Platform to monitor ingestion of all prescribed doses of oral anticoagulants. If a patient misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by the Study Coordinator or AiCure study team.
1549856|NCT02599233|Other|Telephone conctact at 3 months|Patients will be contacted at 3 months post-surgery for pain questionnaires.
1549857|NCT02599233|Other|In hospital pain evaluation|Patients will evaluate their pain levels via a verbal numerical scale on days 1(or-1), 2, 3, 4, 5, 6 & 7.
1549858|NCT02599233|Other|In hospital questionnaires|Patients are required to fill out the HADS and PCS questionnaires between on day -1 or +1.
1549859|NCT02599207|Biological|sibling umbilical cord blood|All subjects will receive a single infusion of allogeneic sibling cord blood. The first six subjects will receive cord blood cells from an HLA-matched sibling. The following 9 subjects will receive cord blood cells from an HLA-mismatched (≥3/6 match) or matched sibling. Six of the 15 subjects must be treated with haplo-identical sibling CB. Duration of study participation will be six months from the time of CB infusion.
1549860|NCT02599194|Procedure|Computed Tomography|
1549861|NCT02599194|Drug|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given IV
1549862|NCT02599194|Procedure|Positron Emission Tomography|
1549863|NCT02599194|Procedure|Magnetic Resonance Imaging|
1549864|NCT02599181|Other|propanol-biphenol: Kodan|WITH-group, the skin is disinfected with an aerosolized alcoholic solutionpropanol-biphenol: Kodan, Schülke & Mayr, Zurich, Switzerland.
1549865|NCT02599168|Drug|Propofol|
1549866|NCT02599168|Drug|Dexmedetomidine|
1549867|NCT02599168|Drug|Placebo (normal saline)|
1549868|NCT02599155|Drug|Crystalloid|normal saline administration for volume expansion in hypovolemic status
1549869|NCT02599155|Drug|Colloid|HES 130/0.4 administration for volume expansion in hypovolemic status
1549870|NCT02599142|Device|Group A: Closed-face shell|As for arm description
1549871|NCT02599142|Device|Group B: Open-face shell|As for arm description
1549872|NCT02599129|Drug|Secukinumab|subcutaneous secukinumab (300 mg) at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including Week 20.
1549873|NCT02599129|Drug|Placebo|￼subcutaneous placebo at weeks 0, 1, 2, 3, 4 and every 4 weeks thereafter up to and including week 20.
1549874|NCT02599116|Other|Bio-specimen collection|Collection of bio-specimens (fecal sample) at 3 different time points One pre-operative collection, Two post-operative collections
1549875|NCT02599116|Other|Questionnaire|Completion of lifestyle and food questionnaires (2) at each bio-specimen collection timepoint
1549876|NCT02599103|Other|Fat-free milkshake|participants drinks a fat-free milk shakes
1549877|NCT02599103|Other|Olive oil|participants drinks the milk shakes prepared from 60g of olive oil
1549878|NCT02599103|Other|Soybean oil|participants drinks the milk shakes prepared from 60g of soybean oil
1549879|NCT02599103|Other|Fried soybean oil|participants drinks the milk shakes prepared from 60g of fried soybean oil
1549880|NCT02599103|Other|Palm oil|participants drinks the milk shakes prepared from 60g of palm oil
1549881|NCT02599103|Other|Fried palm oil|participants drinks the milk shakes prepared from 60g of fried palm oil
1549882|NCT02599103|Other|Camellia oil|participants drinks the milk shakes prepared from 60g of camellia oil
1549883|NCT02599103|Other|Fried camellia oil|participants drinks the milk shakes prepared from 60g of fried camellia oil
1549884|NCT02599103|Other|Tallow|participants drinks the milk shakes prepared from 60g of tallow
1549885|NCT02599103|Other|Fried tallow|participants drinks the milk shakes prepared from 60g of fried tallow
1549886|NCT02599090|Drug|Temozolomide|"Groups 1 & 2: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.
Groups 3 & 4: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
1549887|NCT02599090|Radiation|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
1549888|NCT02599090|Drug|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.
Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
1549889|NCT02599077|Drug|Dienogest|patients assigned to this treatment receive 2 milligrams per day
1549890|NCT02599077|Drug|Levonorgestrel|patients assigned to this treatment receive (0.10 mg levonorgestrel + ethinyl estradiol - 0.02 milligrams daily)
1549891|NCT02599064|Drug|RXI-109|RXI-109 dosed intravitreally to subjects with NVAMD
1549892|NCT02599051|Device|Mini-arc|We will place a single incision sling at the time of surgery for stress urinary incontinence
1549893|NCT02599051|Device|Monarc|We will place a transobturator sling at the time of surgery for stress urinary incontinence
1549894|NCT02599038|Dietary Supplement|Serine supplementation|Serine supplementation (200 mg/kg/day)
1549895|NCT02599025|Device|Innowalk cycling system|Innowalk is a unique, motorized medical device
1549896|NCT02599025|Device|APT cycling system|APT is used as a rehabilitative device that cycles the feet automatically or by the individual
1549897|NCT02599012|Drug|Ferinject®|intravenous Ferinject 1000mg injection
1549898|NCT02598999|Drug|ALX-009|Solution for inhalation administered through nebulization
1549899|NCT02598999|Drug|OSCN-|Solution for inhalation administered through nebulization
1549900|NCT02598999|Drug|bLF|Solution for inhalation administered through nebulization
1549901|NCT02598999|Drug|Placebo|Solution for inhalation administered through nebulization, Sodium Chloride 0.9%
1549902|NCT02598986|Dietary Supplement|Macronutrient supplementation|adding of phosphorus, potassium and magnesium
1549903|NCT02598973|Behavioral|Exercise|Aerobic walking
1549906|NCT02598947|Other|Manual therapy|Exercise and manual therapy
1549910|NCT02598908|Diagnostic Test|Quality control - enzyme activity|A blood sample will be collected from patients and staff donors, no more than twice per year.
1549911|NCT02598895|Drug|Carboplatin|Given IV
1549912|NCT02598895|Drug|Docetaxel|Given IV
1549913|NCT02598895|Other|Laboratory Biomarker Analysis|Correlative studies
1549916|NCT02598869|Drug|Triamcinolone Acetonide|injection of triamcinolone acetonide
1549917|NCT02598856|Drug|Intranasal (IN) naloxone 1x|Administered as 100 μl 14.0 mg/ml (1.4 mg naloxone) by Aptar Unitdose device as one puff in one nostril
1549918|NCT02598856|Drug|Intranasal (IN) naloxone 2|Administered as 2x 100 μl 14 mg/ml (2.8 mg naloxone) by Aptar Unitdose device as two puffs within the same nostril with 3 minutes interval
1549919|NCT02598856|Drug|Intravenous (IV) naloxone|Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
1549920|NCT02598856|Drug|Intramuscular (IM) naloxone|Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
1549921|NCT02598843|Other|Standard treatment protocol|"Cast Protocol 4 weeks in Full Equinus cast - Non Weight Bearing (NWB) with axillary crutches; 4 weeks in Semi-Equinus cast NWB with axillary crutches; 2 weeks in neutral cast - Full Weight Bearing (FWB) 2 weeks FWB out of cast, with 1cm heel raise
Followed by course of physiotherapy"
1549922|NCT02598843|Other|Accelerated Rehabilitation|"4 weeks in Ossur Rebound walking boot with 3cm heel raise, worn continuously including in bed. Weight bearing as tolerated (WBAT)/FWB - crutches for balance.
2 weeks in Rebound walking boot with 1.5cm heel raise (WBAT/FWB - crutches for balance.
2 weeks in Rebound walking boot with foot in neutral with immediate but gradual weaning out off boot. At 8 weeks, remove boot completely and allow FWB out of boot.
Physiotherapy, commenced 4 weeks after initiation of treatment, involves: NWB early active plantar/dorsiflexion to neutral and active inversion/eversion below neutral. At 8 weeks after initiation of treatment, physiotherapy is expanded to include slow dorsiflexion stretching, graduated resistance exercises (open and closed kinetic chain) and proprioception and gait retraining."
1549923|NCT02598830|Dietary Supplement|Vitamin D3|Vitamin D3 dissolved in olive oil, encapsuled
1549924|NCT02598830|Dietary Supplement|Placebo|Olive oil, encapsuled
1549925|NCT02598817|Other|Standard Infant Formula|Standard Infant Formula containing High Sn-2
1549926|NCT02598804|Other|5 educational workshop|
1549927|NCT02598804|Other|written information booklet|
1549931|NCT02598778|Drug|Chlorhexidine gluconate (.12%)|30 second oral rinse of 10mL of solution
1549932|NCT02598778|Drug|Sodium Fluoride (.05%)|30 second oral rinse of 10mL of solution
1549933|NCT02598778|Other|Coconut Oil|30 second oral rinse of 10mL of solution
1549934|NCT02598778|Other|Deionized water|30 second oral rinse of 10mL of solution
1549935|NCT02598765|Procedure|Standard Trabeculectomy|Fornix-based trabeculectomy with a 3x4 mm scleral flap.
1549936|NCT02598765|Procedure|Microtrabeculectomy|Fornix-based trabeculectomy with a 2x2 mm scleral flap.
1549937|NCT02598752|Other|Symptom-limited cardiopulmonary exercise test (CPET)|
1549938|NCT02598752|Other|Resting assessment of cardiac function by echocardiography|
1549939|NCT02598752|Other|Post-exercise assessment of cardiac function by echocardiography|
1549940|NCT02598752|Other|Flow-mediated dilation|
1549941|NCT02598752|Other|Pulmonary function|
1549942|NCT02598752|Other|Vascular function (regional arterial stiffness and endothelial function)|
1549943|NCT02598752|Other|Muscle cross sectional area|
1549944|NCT02598752|Behavioral|Patient-reported outcomes questionnaire|
1549945|NCT02598739|Other|Resistance exercise|"Underwent resistance exercise twice a week, for twelve weeks. The IG patients performed resistance exercises for the following muscles group: upper limbs, lower limbs and trunk.
It was carried out two exercises for major muscle groups and one exercise for small muscles. The exercises were divided in 3 sets of 12 repetitions for each muscle group. The intensity of the exercises were 60% of one-maximum repetition (1RM).
The exercise program involved pectoral exercises: crucifix and seat supine; biceps: alternated screw; triceps: triceps pulley; back: standing handsaw and pulled ahead; quadriceps: leg extensor and finally gluteo: standing hips extension."
1549946|NCT02598739|Other|Waiting list for the exercises|
1549947|NCT02598726|Drug|Curcumin|Given PO
1549948|NCT02598726|Other|Laboratory Biomarker Analysis|Correlative studies
1549949|NCT02598726|Dietary Supplement|Piperine Extract (Standardized)|Given PO
1549950|NCT02598726|Other|Quality-of-Life Assessment|Ancillary studies
1549951|NCT02598713|Drug|Aspiration Marker|Instillation of Quinine suspended in sterile water in the retropharyngeal space of intubated ICU admitted patients for two consecutive days.
1549952|NCT02598687|Drug|TH-302|TH-302 day 4 (pre-treatment) and weekly during chemo-radiotherapy (CRT)
1549953|NCT02598687|Other|HX4 scan|HX 4 scan day 1 and day 8
1549954|NCT02598687|Drug|Carboplatin|2mg/ml/min
1549955|NCT02598687|Drug|Paclitaxel|50 mg/m2
1549956|NCT02598687|Radiation|Radiotherapy|23 x 1.8 Gy
1549957|NCT02598687|Procedure|surgery|minimally invasive transhiatal approach including a one-field node dissection or transthoracic approach with a two-field lymph node dissection
1549958|NCT02598674|Drug|Iodohippurate|An injection of non-radioactive iodohippurate (0.07 mL/kg) will be administered to determine renal plasma flow (RPF)
1549959|NCT02598674|Procedure|24 hour ambulatory Blood Pressure|Ambulatory blood pressure (BP) monitoring will be performed using a commercially available device (TIBA Ambulo 2400) for 24 hours with measurements every 30 minutes while awake and every hour during sleep.
1549960|NCT02598674|Procedure|Peripheral Arterial Tonometry|The peripheral arterial tonometry (PAT) device measures changes in the cutaneous circulation that correlate with flow-mediated dilatation.
1549961|NCT02598674|Procedure|Pulse Wave Velocity|Carotid-femoral and carotid-radial pulse wave velocities (PWV), validated markers of individual cardiovascular risk, will be determined by applanation tonometry using SphygmoCorVx technology (AtCor Medical). PWV is an index of the overall stiffness of a vascular segment between measurement sites 59. Thus, while carotid-femoral PWV is an index of the overall stiffness of proximal (central) arteries, the overall stiffness of peripheral arteries contributes relatively more to carotid-radial PWV.
1549962|NCT02598674|Drug|Gadolinium|Dotarem Gadolinium (GD)- Gadoterate Meglumine (0.07 to 0.14 mL/kg) will be used to determine GFR.
1549965|NCT02598648|Other|FXR|FXR could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. FXR were measured in neonate with ALI、ARDS and control
1549966|NCT02598648|Other|RIPK3|FXR(farnesoid-X-receptor) could elevate the transcription of RIPK3, a key protein in necroptosis, and play important role in bile aicd induced alveolar epithelial cell(AEC) necroptosis. RIPK3 were measured in neonate with ALI、ARDS and control.
1549967|NCT02598635|Drug|Cholecalciferol|Patients on peritoneal dialysis and 25-(OH) levels <20 ng/mL will received one capsule of cholecalciferol (4800 U) once a day for 16 weeks.
1549968|NCT02598635|Drug|Placebo|An oral placebo capsule matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for 16 weeks.
1549969|NCT02598622|Drug|Acetylcarnitine|Acetylcarnitine is taken 2 times a day for days 1 through 21.
1549970|NCT02598622|Drug|Placebo|Placebo is taken 2 times a day for days 1 through 21.
1549971|NCT02598609|Behavioral|Education program for NICU caregivers|"standardized educational program : learning how to retrospectively analyze causes of a medical error in the NICU in order to prevent it (compulsory)
implementation of a central line maintenance bundle and checklist, of a central line insertion bundle and checklist and of a daily goals bundle and checklist. (compulsory)
multicenter sharing of strategies to prevent adverse events in the NICU"
1549972|NCT02598596|Biological|Pegloticase|Subjects will receive one of 3 different loading doses (8, 12, or 16 mg) on Study Day 1, and then receive 8 mg on Weeks 2 and 3, followed by 8 mg every 2 weeks through Week 17 for a total of 10 doses.
1549975|NCT02598570|Drug|duvelisib|Duvelisib will be administered orally as a fixed dose in 28-day cycles.
1549982|NCT02598544|Other|adipose tissue sampling|adipose tissue (subcutaneous and visceral adipose tissue) sampling during abdominal surgery and phenotype determination
1549983|NCT02598518|Behavioral|Integrating Combined Therapies|Individual Integrating Combined Therapies, approximately 10 sessions, one session per week
1549984|NCT02598518|Behavioral|Standard Care|Standard Care, individual or group therapy, approximately 9 hours per week for 3 months.
1549985|NCT02598505|Drug|Indacaterol|
1549986|NCT02598505|Drug|Placebo|
1549987|NCT02598492|Other|arterial blood gas|Just record clinical lab data
1549988|NCT02598479|Other|IPTLD and nutrition therapy|The measurement of Quality of Life in patients who choose to use Insulin Potentiation Low Dose Therapy and Nutritional Therapy in the treatment of cancer
1549989|NCT02598466|Drug|Abatacept|
1549990|NCT02598453|Drug|Ibandronate|Either 150 mg oral tablet once monthly or 3 mg IV injection once every 3 months
1549991|NCT02598440|Drug|Alendronate|Participants wil receive once-weekly oral alendronate (70 mg tablet)
1549992|NCT02598440|Drug|Ibandronate|Participants wil receive once-monthly oral ibandronate (150 mg tablet)
1549993|NCT02598427|Drug|Pertuzumab|Pertuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
1549994|NCT02598427|Drug|Trastuzumab|Trastuzumab will be administered intrathecally via a lumber puncture. The dosing cohorts are described above in the arm description.
1549995|NCT02598414|Procedure|Near-infrared ICG fluorescence imaging|Patient will have their bowel anastomosis assessed intraoperatively by near-infrared technology after indocyanine green has been injected intravenously at a concentration of 2.5 mg/ml. This procedure will be repeated twice during surgery, the first time before and the second time after the anastomosis has been done. The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
1549996|NCT02598414|Procedure|Traditional bowel anastomosis|Traditional bowel anastomosis will be performed without ICG fluorescence imaging.
1549997|NCT02598414|Device|FireFly™|The microvascularization at the anastomosis site will be assessed using a robotic fluorescence imaging device (FireFly™).
1549998|NCT02598401|Other|observation|Observational study with no intervention
1549999|NCT02598388|Biological|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles).
1550000|NCT02598388|Biological|MVA-BN-Filo|One 0.5 mL IM injection of (1x10*8 infectious units).
1550001|NCT02598388|Biological|Placebo|One 0.5 mL IM injection of 0.9 percent (%) saline.
1550002|NCT02598375|Other|Feeding intolerance|In this study ; it is aimed to show the value of IFABP regarding the identifying the feeding intolerance and early detection of enteral feeding intolerance
1550003|NCT02598362|Drug|ciprofloxacin|Serum and urine concentrations after ciprofloxacin administration. pharmacokinetic testing after ciprofloxacin administration
1550004|NCT02598349|Radiation|Proton Radiation|Proton Radiation 40.50 Gy relative biological effectiveness (RBE) in 18 fractions to gross disease and elective nodal volume followed by a 22.50 Gy (RBE) in 10 fraction boost to gross disease. Total dose 63 Gy (RBE) in 28 fractions over 6 weeks.
1550005|NCT02598349|Drug|Capecitabine|Concomitant oral chemotherapy, capecitabine 1000mg by mouth twice daily, 5 days a week (M-F) on radiation days only.
1550006|NCT02598349|Procedure|Surgical resection|Surgery between 8 and 16 weeks of radiotherapy completion if radiographic studies suggest operability.
1550007|NCT02598349|Behavioral|FACT-Hep questionnaire|The FACT-Hep questionnaire is specific to those with gastrointestinal cancers focusing on hepatobiliary and pancreatic cancer.
1550008|NCT02598336|Device|Structured Light Plethysmography|Non contact device that uses light to record displacement of the anterior thorax and abdomen region
1550009|NCT02598336|Device|Pneumotachograph Spirometry|Device that measures airflow at the mouth using a mouthpiece
1550010|NCT02598323|Device|ultrasound|
1550011|NCT02598310|Drug|nab-paclitaxel|nab-paclitaxel 260mg/m2 q3w
1550012|NCT02598310|Drug|Trastuzumab|trastuzumab 6 mg/kg (8 mg/kg as the loading dose)
1550013|NCT02598297|Drug|Ruxolitinib|Tablet for oral use
1550014|NCT02598297|Drug|Ruxolitinib Placebo|Matching placebo tablet for oral use
1550015|NCT02598284|Other|Point of Care|Practice facilitators will work with practices to implement strategies to improve ABCS care during the patient encounter. Some examples of these types of quality improvement initiatives are electronic reminders and clinical decision support to prescribe aspirin or a statin at the time of a visit, improving how your practice collects blood pressure measures to increase clinicians' willingness to act on readings, or electronic reminders for nursing staff that there is no lipid panel in record and have a standing order to act on this.
1550016|NCT02598284|Other|Population Management|"Practice Facilitators will work with practices to both implement Point of Care strategies as well as population management strategies. These practices will use their EHR and/or receive training to use the popHealth software package, which works with data from the EHR, to generate lists of high-risk patients that need outreach for one of the ABCS domains (such as conducting outreach to patients who are not on aspirin who would benefit from this therapy).
Practices in this arm will receive the opportunity to link to community resources such as pharmacists who could assist patients with medication management or tobacco quit lines through the HealtheRx program."
1550017|NCT02598258|Other|Sauna and cold water bath|Subjects will first spend 10 minutes in a dry sauna at 85 degrees celtius. Immediately after, subjects will be immersed in a cold water bath (ICool , Australia) at a temperature of 5 degrees celtius for approximately one minute. Blood pressure , ecg , gaz exchange and thoracic impedance will be measured during sauna and cold water bath.
1550018|NCT02598245|Device|TOT 8/4|placement of transobturator sling according to the TOT 8/4 technique
1550019|NCT02598245|Device|TOT 6/3|placement of transobturator sling according to the TOT 6/3 technique
1550020|NCT02598232|Device|1,414nm Nd:YAG Laser System|It has high absorption coefficient in water and a short pulse width.
1550021|NCT02598219|Drug|Pre-operative SN mapping with Nanocis|"Preparation : four 1ml syringe are prepared per patient, each containing a total activity 10 MBq if the injection is planned the same day of surgery and in the operative theater OR each containing a total activity 30MBq if the injection is performed the day before the surgery.
Intracervical injection is performed by the surgeon, no more than 3-24 hours before surgery : 4 submucous injections with the filtered radiocolloid at 3, 6, 9 and 12 o'clock positions. Each injection if performed at 2 mm of depth for a total activity of 40 MBq or a total activity of 120 MBq is the surgery is planned the day after the injection.
Sentinel Node detection by planar scintigraphy at 1 and 3h (if no detection at 1 hour), or by SPECT-CT imaging if available."
1550022|NCT02598219|Drug|Intra-operative SN mapping with patent V blue dye|"Patent blue V dye are diluted with saline sterile solution to obtain 4ml of 50%. Four 1ml syringe, each containing a 50% patent blue dye solution, are prepared per patient.
Intracervical injection is performed by the surgeon. after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible.
SN are detected by direct visualization of blue colored lymphatics and node"
1550023|NCT02598219|Drug|Intra-operative SN mapping with indocyanin green|"1: Infracyanine powder is diluted in aqueous sterile water to obtain 4ml with a concentration of 1.25 mg/mL. Four 1ml syringe, each containing a 1.25 mg/mL Infracyanine dye solution, are prepared per patient.
2- Intracervical injection is performed by the surgeon, after anesthesis induction and incising the skin,under laparoscopic / laparotomy control to detect intraperitoneal injection of the tracer. Sub-mucous injections are performed with 50% diluted dye at 3 and 9 o'clock positions. At each positions : 1ml is injected deep into the stroma of the cervix (1cm), another 1ml is injected superficially (at 2mm depth). The time between the injection of the dye and the search for the SN must be as shortest as possible
3- SN detection by near-infrared fluorescence imaging"
1550024|NCT02598219|Procedure|Full bilateral laparoscopic lymphadenectomy and Hysterectomy|"Bilateral pelvic lymphadenectomy (intermediate risk endometrioid)
Or Ilio-infrarenal paraaortic lymphadenectomy (high risk endometrioid)
Or Pelvic + paraaortic lymphadenectomies (high risk non endometrioid)"
1550025|NCT02598219|Procedure|Current initial staging protocols|Current French initial staging protocols
1550026|NCT02598206|Drug|PF-04136309|"Treatment A (n=18): a single dose of 1000 mg PF 04136309 will be administered in a fasted state as 8 × 125 mg Tablets.
Treatment B (n=18): a single dose of 1000 mg PF-04136309 will be administered with a high fat breakfast as 8 × 125 mg Tablets."
1550027|NCT02598193|Drug|Nintedanib|Participants with IPF will receive nintedanib at the 200-300 mg/day dose up to 24 weeks.
1550028|NCT02598193|Drug|Pirfenidone|Participants with IPF will receive pirfenidone at 1602-2403 mg/day dose up to 24 weeks.
1550029|NCT02598180|Device|VergenixTM Flowable Gel|The VergenixTM Flowable Gel is supplied as powder contained in a syringe that will be hydrated with saline.
1550030|NCT02598141|Biological|Biological sampling grinding|One half of the biological material collected during the intervetion (according to standard procedures) will be ground using the Ultra Turrax technique before proceeding with culturing.
1550031|NCT02598141|Biological|Biological sampling with standard procedures|One half of the biological material collected during the intervetion (according to standard procedures) will be treated according to standard techniques before proceeding with culturing.
1550032|NCT02598128|Device|RELiZORB|Peptamen 1.5 received Period A and Period B (washout only). Impact Peptide 1.5 received Period B (Days 1 and 9 only) and Period C.
1550033|NCT02598128|Device|Placebo|Sham device
1550034|NCT02598115|Other|Collaborative Pharmaceutical Care|The pharmacist performs collaborative pharmaceutical care in the ward: reconciliation of drug treatments and revision of drug prescriptions indicated on the admission drug prescription. He/she emits pharmaceutical interventions recorded on the standardized support provided by the French Society of Clinical Pharmacy. The pharmaceutical interventions are discussed during a collaborative interview.
1550035|NCT02598102|Drug|Diclofenac sodium|Diclofenac for pain relief
1550036|NCT02598102|Drug|Placebo|Placebo for comparison
1550037|NCT02598089|Biological|Trivalent Seasonal Influenza Vaccine|The seasonal trivalent influenza vaccine produced by IVAC uses embryonated chicken eggs. This is a split virion, inactivated vaccine, collected in a linear sucrose density gradient solution using a continuous flow centrifuge (Alfa Wassermann, West Caldwell, NJ) and inactivated with formaldehyde.
1550038|NCT02598089|Biological|Placebo Comparator|Placebo (PBS) will be manufactured by IVAC. PBS, pH 7.2, will also be in 0.5 mL single-dose vials. Every vial contain : Nacl 4.500mg;Na2HPO4.2H2O: 0.685 mg; NaH2PO4.2H2O:0.186 mg and Water For Injection (qs):0.5 mL
1550039|NCT02598076|Behavioral|motivational interviewing|Motivational interviews will include the classical 4 steps of MI: 1) engagement (in which the patient's goals and interests are elicited and the therapeutic alliance is established); 2) focusing (in which the specific subjects of discussion and intervention are negotiated); 3) strengthening motivation (in which the patients' reasons for healthcare intervention are made explicit, discussed, and reinforced); and 4) planning (in which actions for healthcare intervention are planned out based on the patients' own goals and interests). MI will be performed by the study author who is a board certified neurologist and who has formal training and certification in motivational interviewing.
1550040|NCT02598076|Behavioral|standard psychotherapy|Standard cognitive behavioral therapy based psychotherapy for the treatment of PNES
1550041|NCT02598063|Drug|Adefovir dipivoxil|ADV will be administered orally at a dose of 10 mg QD for 72 weeks.
1550042|NCT02598063|Drug|Lamivudine|Lamivudine tablets will be administered orally at a dose of 10 mg QD for 12 weeks.
1550043|NCT02598063|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a injection will be administered at a dose of 180 mcg QW for 48 weeks.
1550044|NCT02598050|Other|Mini Cog|Cognitive screen
1550046|NCT02598024|Behavioral|Narrative Exposure Therapy|In Narrative Exposure Therapy the patient constructs a narration of his or her life, focusing on the detailed context of the traumatic experiences as well as on the important elements of the emotional networks and how they go together. This process allows the majority of persons to recognise that the fear/trauma structure results from past experiences and that its activation is just a memory. They thus lose the emotional response to the recollection of the traumatic events, which consequently leads to a remission of PTSD symptoms. Thus, they gain access to 'lost' past memories and develop a sense of coherence, control, and integration. Revised Narrative Exposure Therapy (NET-R, Zang et al, 2013) is a 4-session treatment delivered within a week.
1550047|NCT02598024|Behavioral|Control Focused Behavioural Treatment|The Control-focused Behavioural Treatment (CFBT, Başoğlu et al 2005) for earthquake survivors was designed after 1999 Turkey earthquake as an intervention to facilitate natural recovery processes by restoring sense of control over anxiety, fear, or distress. Its underlying principle is to reduce helplessness responses by encouraging behaviours that are likely to enhance sense of control over stressor events and life in general. Its primary aim is to reverse traumatic stress processes by increasing anxiety or distress tolerance. In earthquake survivors, CFBT involves a single session in most cases and an additional few sessions in cases that do not respond to the initial session.
1550048|NCT02598011|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
1550049|NCT02598011|Drug|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
1550050|NCT02597998|Drug|14C-BI 409306|
1550053|NCT02597972|Device|Fracture repair|
1550054|NCT02597972|Device|Fracture repair with joint replacement|
1550055|NCT02597946|Drug|afatinib|
1550056|NCT02597946|Drug|paclitaxel|
1550059|NCT02597907|Drug|aprepitant|aprepitant 80 mg is given to all patients before surgery
1550060|NCT02597907|Drug|palonosetron|palonosetron 0.075 mg is given to patients in the aprepitant plus palonosetron group after induction of general anesthesia
1550061|NCT02597907|Drug|Ramosetron|ramosetron 0.3 mg is given to patients in the aprepitant plus ramosetron group after induction of general anesthesia
1550064|NCT02597868|Drug|Capecitabine|Capecitabine is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment.
1550065|NCT02597868|Procedure|endocrine therapy|endocrine therapy is be given as a sequential treatment in Metastatic breast cancer patients who are got benefit in chemo treatment,the medicine will be confirmed by the patient's past-treatment.
1550066|NCT02597855|Drug|Aflibercept|Total 4 times of intravitreal aflibercept injection was performed
1550067|NCT02597855|Drug|Indocyanine green angiography (intraveonus indocyanine green dye)|At initial visit, indocyanine green angiography was performed. After 1 month of third Aflibercept injection, indocyanine green angiography was performed to evaluate polyp closure.
1550068|NCT02597842|Device|TEAS (transcutaneous electrical acupoint stimulation)|Electric stimulation was given through electrode attached to specific acupoints
1550069|NCT02597829|Drug|Certolizumab Pegol|Subcutaneous Injection
1550070|NCT02597816|Radiation|Three dimensional ultrasound|
1550071|NCT02597803|Drug|RGN-259|A preservative-free, sterile eye drop solution containing Tβ4 for direct instillation into each eye, four times a day (QID) for 28 days
1550072|NCT02597803|Drug|Placebo|It is composed of the same excipients as RGN-259 but does not contain Tβ4
1550073|NCT02597777|Other|Acetyl Hexapeptide-8|Acetyl-Hexapeptide-8 peptide solution will be diluted to a final concentration of 10% using Cetaphil facial lotion base
1550074|NCT02597777|Other|Placebo vehicle|Water will be diluted to a final concentration of 10% using Cetaphil facial lotion base.
1550075|NCT02597764|Behavioral|Diaphragmatic Breathing|
1550076|NCT02597764|Behavioral|Standard Urotherapy|
1550077|NCT02597751|Behavioral|Cognitive Orientation to Occupational Performance (CO-OP)|"CO-OP is a cognitive approach to solving functional motor problems (Polatajko et al., 2001b). Therapists teach children a global problem solving strategy (Goal-Plan-Do-Check) as a framework for developing specific strategies for overcoming motor problems; these strategies are determined after a dynamic performance analysis by the therapist to determine where the breakdown is in performing the task. Occupational therapists will see children once weekly for one hour over 10 weeks as per published protocol (Polatajko et al., 2001b), plus two assessment sessions. Children will select three functional motor goals to be addressed over the course of treatment, rating their performance and satisfaction of these goals pre- and post-intervention."
1550078|NCT02597738|Other|Fresh tissue biopsy and blood collection|Fresh tissue biopsy and research blood work samples will be collected for one year.
1550079|NCT02597738|Other|Blood Sample Collection|A one time blood sample will be collected.
1550082|NCT02597699|Drug|Ultiva ® associated with a lethal reference agent, Xylocaine ® in Procedure of foeticide|Arm 2: Ultiva ® associated with a lethal reference agent, Xylocaine ® in Procedure of foeticide Arm 1 :Sufentanil ® associated with Xylocaine ® in Procedure of foeticide
1550083|NCT02597686|Behavioral|SD-PB training|
1550084|NCT02597673|Other|Home Exercise Program (HEP)|All participants will receive a standard home-based exercise rehabilitation protocol for PFPS. HEP teaches muscle strengthening exercises and self-management strategies to prevent recurrence. This program includes sessions with the study coordinator. A handout and given a demonstration of the daily exercises to be performed at home and weekly communication from the study coordinator regarding compliance with the exercises.
1550085|NCT02597673|Device|NMES|To ensure consistent interventions across participants, a specified percentage of baseline maximal voluntary contraction (% MVC) will be used to determine the intensity of the training contraction. The electrical amplitude to obtain the desired intensity will be determined for each participant. Participants will train at 20-30% of MVC during weeks 1-3, 30-40% of MVC during weeks 3-6, and 40-50% of MVC during weeks 6-9. Incremental increases will be made at the 3 and 6 week clinic visits. Individualized instructions for adjusting the amplitude dial settings, with a return demonstration, will be used to maintain the appropriate percentage of MVC. During the home training sessions, participants will adjust the amplitude required to achieve the desired goal, as tolerated.
1550086|NCT02597673|Device|TENS|The TENS protocol consists of 20-minutes of TENS stimulation while concurrently performing the HEP. The TENS with HEP and HEP alone will be alternated for 9 weeks. The Active device delivers a pre-set program of pulsed electrostimulation using a patented asymmetrical simple modulated pulse (SMP) waveform. SMP delivers a group of pulses as a repeating 12-second cycle.
1550091|NCT02597647|Biological|LAIV|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of LAIV.
1550092|NCT02597647|Other|Saline|Subjects underwent nasal swabs, nasopharyngeal saline wash, and nasal brushings pre, and 1-2 weeks and 4-6 weeks following intranasal administration of saline nasal spray.
1550093|NCT02597634|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
1550380|NCT02595593|Device|Rib Fixation System|This intervention involves a surgical procedure to affix rib plates to broken ribs
1550094|NCT02597634|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
1550095|NCT02597621|Other|no intervention|no intervention
1550096|NCT02597608|Behavioral|CLP: Livelihoods|Capital for purchase of income generating asset, physical infrastructure (plinths, latrines, tubewells), livelihood maintenance stipend, monthly asset maintenance cost stipend, agricultural livelihood training, non-agricultural livelihood training, financial training, health and nutrition training.
1550097|NCT02597608|Dietary Supplement|CLP: Nutrition|Counseling on breastfeeding and complementary feeding; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children 7-23 months dosage of 120 sachets per year; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester; identification and referral of acute malnutrition; facilitation of government campaigns on nutrition.
1550098|NCT02597608|Behavioral|Shiree: Livelihoods|Financial training; input support for livelihoods (cropping, livestock, poultry, fishing, bamboo working, small businesses, tailoring etc.); capacity building (mobilising Self Help Groups, facilitating community based organizations (CBOs), skills transfer); innovation support (market linkage and access to value chains); credit and savings groups; support in mobilizing communities to advocate for their needs.
1550099|NCT02597608|Dietary Supplement|Shiree: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
1550100|NCT02597608|Behavioral|UPPR: Livelihoods|Monetary support for communities to improve infrastructure (drains, footpaths, latrines and water dwells, access to roads and markets); financing for apprenticeships; grants for small businesses; education grants for girls; grants for urban food production activities; financial training; establishment of savings and credit groups; support for communities in advocating for their needs; microcredit; improving access to health facilities; improving housing conditions; provision of plinths.
1550101|NCT02597608|Dietary Supplement|UPPR: Nutrition|Counseling on breastfeeding, complementary feeding, and sanitation; community discussions including adolescent girls on early and forced marriage; five components micronutrients (iron 12.5 mg, folic acid 0.16 mg, zinc 5 mg, vitamin A 0.3 mg, vitamin C 30 mg) for children aged 7-23 months; 180 iron and folic acid tablets (60 mg iron and 400 mg folic acid) tablets to each pregnant woman after first trimester and up to 180 for each breastfeeding woman per year, as well as 104 tablets to each adolescent girl; deworming treatment for children aged 1-5 years, adolescent girls, pregnant women after first trimester.
1550102|NCT02597608|Other|UPPR: Control|No interventions provided.
1550103|NCT02597595|Other|spirulina|oral spirulina (tablet=500mg) will be given to patients for 3 months in a dose of 250 mg/kg/day (maximum 4 gm)
1550104|NCT02597582|Procedure|Neck dissection|The Small Jaw® handpiece (Small Jaw® with ForceTriad®; Covidien, Colorado, USA) was not only used as a dissection forceps but also served as a ligation device.
1550105|NCT02597569|Behavioral|CO-OP KT Exposure|"Patient participants who receive therapy from clinicians who have received CO-OP KT training will belong to the CO-OP KT Exposure group. Patient participants will not receive treatment that is different from the treatment being offered to patients who do not enroll in the study.
The CO-OP KT intervention is directed at the inpatient rehabilitation team. They will be trained in Cognitive Orientation to daily Occupational Performance (CO-OP) and will also receive multi-faceted knowledge translation (KT) support."
1550106|NCT02597556|Drug|Albendazole|A single 400mg dose of Albendazole administered at 0, 3, 6, 9, and 12 months.
1550107|NCT02597556|Drug|Placebo|Matching placebo tablet administered at 0, 3, 6, and 9 months. At month 12, all participants will receive a single dose of 400mg Albendazole.
1550108|NCT02597543|Drug|Regadenoson|For use in stress myocardial perfusion imaging.
1550109|NCT02597543|Drug|Gadolinium|For use in both perfusion imaging and late gadolinium enhancement.
1550110|NCT02597543|Procedure|Cardiac MRI|Cardiac MRI will be the imaging modality for perfusion imaging, late gadolinium enhancement and obtaining mean T1 segmental values of the heart.
1550111|NCT02597530|Device|TEAS|According to ancient Chinese medical books, acupoints LI4,PC6 and ST36 are chosen and identified.TEAS in long-term group will be administered 30 minutes prior to anesthesia and continued until the end of the surgery. In short-term group,TEAS will be administered 30 minutes prior to anesthesia and ended at time of anesthesia.In sham group,electrodes will be pasted 30 minutes before anesthesia but without electrical stimulation.All patients will remove electrodes on surgery over.
1550112|NCT02597517|Device|Digital chromoendoscopy and magnification|After the gastric body mucosal evaluation with white light endoscopy, the Optical Enhancement chromoendoscopy and magnification will be used for a more detailed evaluation of the subepithelial capillary network, the collecting venules and mucosal pits
1550113|NCT02597504|Other|Pen and paper neuropsychological test|Will be administered for Construct Validity to determine agreement with Quick Test
1550114|NCT02597504|Device|Quick Test|Quick Test, computerized test will be administered to all subjects.
1550115|NCT02597491|Behavioral|TLC monthly|Tobacco longitudinal care monthly
1550116|NCT02597491|Behavioral|TLC quarterly|Tobacco longitudinal care quarterly
1550117|NCT02597491|Behavioral|MTM|Medication management therapy
1550118|NCT02597491|Behavioral|4 week assessment|4 week assessment
1550119|NCT02597491|Behavioral|8 week assessment|8 week assessment
1550120|NCT02597478|Drug|Fentanyl Sublingual Spray|"Low-dose Fentanyl Goup: 15-25% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test.
High-Dose Fentanyl Group: 35-45% of the morphine equivalent daily dose (MEDD) sprayed into mouth and under tongue one hour after first Shuttle Walk Test."
1550381|NCT02595580|Device|Glucopred|
1550651|NCT02593487|Drug|Rosuvastatin 20mg/d group|rosuvastatin 20mg tablet,q.d. for 12 weeks.
1550121|NCT02597478|Procedure|Shuttle Walk Test|Participants walk back and forth between 2 cones in an indoor hallway for up to 12 minutes. After one hour Fentanyl Spray delivered, then second walk test performed.
1550122|NCT02597478|Behavioral|Questionnaires|Questionnaire completed about any breathing problems or other symptoms participant may be having at baseline. End of study questionnaire asks which dose level of study drug participant thinks they received. Participant also completes a questionnaire about how study drug may have helped them and how satisfied they are with the study. It should take about 5 minutes to complete the questionnaire.
1550123|NCT02597478|Behavioral|Mental Ability Tests|After each walk test, participant completes 4 tests of their mental abilities. It should take 15 minutes total to complete these tests.
1550124|NCT02597478|Behavioral|Phone Call|Thirty days study visit participant called by study staff. This call should last about 10 minutes.
1550125|NCT02597465|Drug|SPARC1507|The administered dose is calculated based on the BSA calculated for the subject on Day 1 of the Cycle
1550126|NCT02597465|Drug|Reference1507|Investigators choice including chemotherapy or supportive therapy
1550127|NCT02597452|Device|intelligent Breast Exam, iBE|A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.
1550128|NCT02597439|Drug|Omega-3 fatty acids|
1550129|NCT02597439|Other|Placebo|
1550130|NCT02597413|Procedure|Catheterization|Women in this group will be systematically catheterized before leaving the delivery room.
1550131|NCT02597400|Drug|Metformin|"Metformin500 mg BID on Days 1-2, only the morning dose on Day 3. Metformin will be taken 30 minutes prior to meals;
Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals"
1550132|NCT02597400|Drug|HMS5552|"Metformin 500 mg BID and HMS5552 50 mg BID on Days 4-7, only the morning dose on Day 8. Metformin and HMS5552 will be taken 30 minutes prior to meals;
HMS5552 50 mg BID on Days 9 -12, only the morning dose on Day 13. HMS5552 will be taken 30 minutes prior to meals."
1550133|NCT02597387|Drug|Mitoxantrone HCL Liposome Injection|
1550134|NCT02597374|Device|EEG|A 45 mn EEG will be performed in each participants during action and action observation of each hand.
1550135|NCT02597361|Drug|Irbesartan|Irbesartan: 150 or 300 mg o.d. The up-titration of irbesartan from 150 mg to 300 mg o.d. occur during the first 8 weeks following randomization
1550136|NCT02597361|Drug|Placebo|Placebo o.d. to match 150mg or 300mg irbesartan tablets
1550137|NCT02597348|Procedure|Liver Transplantation|The patient of the arm LT+C are treated by experimental liver transplantation preceding the Non experimental standard chemotherapy (according to usual practices) .
1550138|NCT02597335|Radiation|Spectro-MRI|Spectro-MRI for D-2HG detection
1550139|NCT02597335|Other|Dosage of free circulating plasmatic DNA|
1550140|NCT02597335|Other|Dosage of D-2HG in the urine|
1550141|NCT02597322|Drug|AXITINIB|Axitinib is an oral, potent, and selective inhibitor of vascular endothelial growth factor (VEGF) receptors 1, 2, 3 It will be supplied as 1 mg and 5 mg film coated tablets for oral administration in light protecting bottles of 60 tablets.
1550142|NCT02597309|Drug|Canagliflozin|
1550143|NCT02597283|Device|Biguard sirolimus-eluting bifurcation stent system|PCI with Biguard sirolimus-eluting bifurcation stent system
1550144|NCT02597283|Device|Sirolimus-eluting stent system|PCI with sirolimus-eluting stent system
1550145|NCT02597257|Drug|Lidocaine HCl|lidocaine continuous infusion
1550146|NCT02597257|Drug|Normal saline|Normal saline continuous infusion
1550147|NCT02597244|Device|Percutaneous Extraforaminotomy|percutaneous dissecting of the lumbar extraforaminal and foraminal region with BS extraforamonotomy kit(BioSpine Co.,Ltd, Seoul, South Korea) under fluoroscopy
1550148|NCT02597231|Dietary Supplement|Melatonin|Melatonin is the dietary supplement we are using in delirium prevention.
1550149|NCT02597231|Other|Placebo|Patients in this group will receive a matching placebo pill.
1550150|NCT02597205|Behavioral|physician-facing app and patient-facing messages|A physician-facing app was designed to help physicians with recruiting and managing patients and with evidence-based medications prescription. Messages were also developed to send to patients to improve their medical adherence and modify lifestyle.
1550151|NCT02597192|Other|probiotic oral hygiene products with Bacillus (PIP, Chrisal)|products with Bacillus probiotics
1550152|NCT02597192|Other|oral hygiene products without Bacillus|products without Bacillus
1550153|NCT02597166|Drug|Ledipasvir/Sofosbuvir|Each tablet of Harvoni contains 90 mg ledipasvir and 400 mg sofosbuvir.
1550154|NCT02597153|Drug|Mitoxantrone HCL Liposome Injection|
1550155|NCT02597140|Drug|lidocaine|Patients in lidocaine group will be received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous infusion of 2 mg/kg/hr lidocaine.
1550156|NCT02597140|Drug|normal saline|Patients in control group will be received an intravenous bolus injection of 1.5 mg/kg normal saline followed by a continuous infusion of 2 mg/kg/hr normal saline.
1550157|NCT02597140|Drug|propofol|Propofol will be administered using target controlled infusion during monitored anesthesia care to adjust 60 to 80 of bispectral index.
1550158|NCT02597127|Drug|ALN-PCSSC|ALN-PCSSC is a small interfering RNA that inhibits PCSK9 synthesis and is given as subcutaneous injections
1550159|NCT02597114|Drug|AGT-181|intravenous infusion over 3-4 hours
1550160|NCT02597101|Drug|Metformin|background drug
1550161|NCT02597101|Drug|saxagliptin|background drug
1550162|NCT02597101|Drug|AZD9668|study drug
1550163|NCT02597101|Drug|placebo|placebo for AZD9668 to be added to background drugs
1550164|NCT02597088|Other|Laboratory studies of the effect of human milk handling using a rage surface area bottle (study device)|Using laboratory studies of the effect of storage and heating on expressed human milk, the investigators will compare milk handled in regular bottle and bottle warmer and milk handled using the study device (large surface area bottle)
1550165|NCT02597075|Other|standard therapy + physical activity program|
1550166|NCT02597075|Other|standard therapy|
1550167|NCT02597062|Drug|Carfilzomib|
1550177|NCT02597010|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
1550178|NCT02597010|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
1550180|NCT02596984|Drug|Caspofungin|Either preemptive, empirical or curative prescription of Caspofungin by one of the ICUs' attending physician. Caspofungin will be administered according to the international recommendation
1550181|NCT02596971|Drug|Atezolizumab|Atezo-G-Benda: Atezolizumab 840 milligrams (mg) intravenously (IV) on Days 1 and 15 of Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-6, during induction treatment, followed by 840 mg IV on Days 1 and 2 of each month, starting with Month 1. Atezo-R-CHOP: Atezolizumab 1200 mg IV on Day 1 Cycles 2-8, during induction treatment, followed by 1200 mg IV on Day 1 of Cycles 9-25.
1550182|NCT02596971|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 milligrams per square meter (mg/m^2) IV on Days 1 and 2 of Cycles 1-6, during induction treatment.
1550183|NCT02596971|Drug|Cyclophosphamide|Cyclophosphamide will be administered at a dose of 750 mg/m^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
1550184|NCT02596971|Drug|Doxorubicin|Doxorubicin will be administered at a dose of 50 mg/m^2 IV on Day 1 of Cycle 1-6/8, during induction treatment.
1550185|NCT02596971|Drug|Obinutuzumab|Atezo-G-Benda: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6, during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1, during maintenance treatment. Atezo-G-CHOP: Obinutuzumab will be administered at a dose of 1000 mg IV on Days 1, 8, and 15 of Cycle 1 and 1000 mg IV on Day 1 of Cycles 2-6 during induction treatment, followed by 1000 mg IV on Day 1 of every other month, starting with Month 1 during maintenance treatment.
1550186|NCT02596971|Drug|Prednisone|Prednisone will be administered at a dose of 40 mg/m^2 orally on Days 1-5 of Cycle 1-6/8, during induction treatment. Prednisolone may be given if prednisone is unavailable. The 40 mg/m^2 dose of prednisone on Day 1 will be replaced by oral corticosteroids given as premedication on Day 1 of Cycle 1 (and subsequent cycles).
1550187|NCT02596971|Drug|Vincristine|Vincristine will be administered at a dose of 1.4 mg/m^2 (maximum 2 mg) IV on Day 1 of Cycle 1-6/8, during induction treatment.
1550188|NCT02596971|Drug|Rituximab|Atezo-R-CHOP: Participants with previously untreated DLBCL will receive rituximab at a dose of 375 mg/m^2 IV on Day 1 of Cycle 1-8, during induction treatment.
1550189|NCT02596958|Drug|Bevacizumab|Six 3-weeks cycle of IV bevacizumab will be administered for approximately 7 months.
1550190|NCT02596945|Drug|Methoxy polyethylene glycol epoetin beta|Methoxy polyethylene glycol epoetin beta is prescribed as per physician's discretion in accordance with the Summary of Product Characteristics (SmPC).
1550191|NCT02596932|Other|Standard Protocol for intrapartum glucose management|Tight glucose control protocol: Goal maternal blood glucose 70-100, q 1 hour blood glucose checks, insulin treatment started with single maternal blood glucose level > 100mg/dL
1550192|NCT02596932|Other|Experimental Protocol for intrapartum glucose management|Less Tight: Goal maternal blood glucose 70-120, q 4 hour blood glucose checks (unless symptomatic), insulin treatment started with single maternal blood glucose > 120 mg/dL
1550193|NCT02596919|Other|photography|photography of meibomian glands
1550194|NCT02596906|Device|tDCS|Prior to the reasoning training, participants will undergo tDCS. Participants will receive 20 minutes of tDCS using 2mA or less targeting the inferior frontal gyrus prior to each of their 8 reasoning training sessions for a total of 160 total combined minutes. This time does not include set up time which should take no more than 5 minutes. A brief engaging film is shown to participants during the 20 minute session.
1550195|NCT02596906|Behavioral|Brain Training Program|The Brain training program includes 8 1-hour sessions conducted over 4 weeks. The goal of these treatment sessions is to provide strategies to improve brain function. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
1550196|NCT02596906|Device|Sham tDCS|For the sham tDCS group, the device will be turned off after 30s. The only reported sensations from tDCS is an itching or a tingling when the device turns on but disappears quickly. Thus, those receiving sham tDCS will be unaware that the device has turned off, and will experience an initial tingling similar to that received in the tDCS group.
1550197|NCT02596893|Drug|GED-0301|
1550198|NCT02596893|Drug|Placebo|
1550199|NCT02596880|Drug|Sofosbuvir|400 mg, included in a combination pill (Sovodak) with 60 mg daclatasvir
1550200|NCT02596880|Drug|Daclatasvir|60 mg, included in a combination pill (Sovodak) with 400 mg sofosbuvir
1550201|NCT02596880|Drug|Ribavirin|1000 mg/day if <75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
1550204|NCT02596828|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).
Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
1550205|NCT02596828|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
1550206|NCT02596828|Drug|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
1550207|NCT02596828|Drug|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
1550208|NCT02596815|Procedure|Median Nerve Neural Mobilization|Nonsurgical noninvasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
1550209|NCT02596815|Device|Goniometer|
1550210|NCT02596802|Device|FETO therapy|Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
1550211|NCT02596789|Device|"TMS Magpro®, Magventure Inc device"|
1550212|NCT02596776|Procedure|Fat biopsy|up to 16 biopsy samples will be taken from each subject
1550213|NCT02596776|Drug|Propranolol and fat biopsy|subset of subjects will receive propranolol and have fat biopsy performed
1550214|NCT02596776|Other|heavy water and fat biopsy|subset of subjects will be given heavy water and have fat biopsy performed
1550215|NCT02596763|Drug|Baclofen|Patient receiving an off-label baclofen treatment for alcohol use disorder for less than 1 month.
1550219|NCT02596737|Behavioral|wittyFit concept|
1550220|NCT02596724|Other|Genomic and/or molecular testing of blood or tissue|Genomic and/or molecular testing of blood or tissue
1550221|NCT02596711|Drug|Nicotine Patch|Participants receive 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches.
1550222|NCT02596711|Behavioral|Questionnaires|Questionnaires regarding tobacco and alcohol use, culture, religion, and sense of control completed at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
1550223|NCT02596711|Other|Carbon Monoxide (CO) Test|Carbon monoxide (CO) test given at baseline, at weeks 2 and 6, and at 3 and 6 months after baseline.
1550224|NCT02596711|Behavioral|Health Education and Handouts|Participants receive general health education and handouts.
1550225|NCT02596711|Behavioral|Culturally Tailored Reading Materials|Participants given reading materials that highlight how aspects of their culture relate to health, smoking and quitting.
1550226|NCT02596711|Behavioral|Counseling Sessions|Participants attend 3 counseling sessions during the study.
1550227|NCT02596685|Procedure|Bronchoscopy|Undergo bronchoscopy
1550228|NCT02596685|Other|Electronic Cigarette|Given nicotine-free and flavor-free electronic cigarettes
1550229|NCT02596685|Other|Laboratory Biomarker Analysis|Correlative studies
1550230|NCT02596685|Other|Questionnaire Administration|Ancillary studies
1550231|NCT02596672|Behavioral|The friendly walking group|A 12 week peer led walking group for adults and older adults (> 55 years) living in independent living communities in Northern Ireland. Designed to increase physical activity levels of inactive older adults and measure sustained changes in physical behaviour 6 months after the intervention ends.
1550232|NCT02596659|Procedure|Radial extracorporeal shock wave therapy (rESWT)|Each participant in the experimental group received rESWT for 3 sessions, consisting of 2000 impulses for each session, and one session per week over 3 weeks (a total of 6000 shock waves were given). The pneumatic pressure was set at the maximum level tolerable for each patient. The frequency of pulses was set at 10 Hz.
1550233|NCT02596659|Procedure|sham shockwave therapy|Sham shockwave therapy were given by the same physiatrist using the same machine as the experimental group, with the same rESWT protocol (3 sessions, 2000 impulses for each session, one session per week over 3 weeks) and the same frequency (10 Hz) of impulses, but the pneumatic pressure was set at 0.1 bar, with a similar sound to the regular rESWT but without actual energy conduction.
1550234|NCT02596659|Procedure|Physical therapy|The physical therapy program was performed 3 times a week over the same 3 weeks as rESWT, and consisted of 5 minutes of ultrasound diathermy, 15 minutes of transcutaneous electrical nerve stimulation (TENS), and 10 minutes of therapeutic exercise, including wrist common extensor stretching and self-massage.
1550235|NCT02596646|Procedure|Early Precut|Early precut was performed during ERCP with difficult biliary cannulation
1550236|NCT02596646|Procedure|Prolonged cannulation attempts|Prolonged cannulation attempts was performed during ERCP with difficult biliary cannulation
1550237|NCT02596633|Behavioral|Telephone-support Acceptance and Commitment Therapy (ACT)|Telephone-support Acceptance and Commitment Therapy (ACT): ACT self-help book and 8 telephone support calls
1550238|NCT02596620|Drug|Nexium|Esomeprazole (Nexium)(40 mg) 1 tablet twice daily for 10 days in both arms
1550239|NCT02596620|Drug|Amolin|Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for the first 5 days in the Sequential arm; Amoxicillin (Amolin)(500 mg) 2 tablets twice daily for 10 days for triple therapy arm
1550240|NCT02596620|Drug|Cravit|Levofloxacin(Cravit)(500 mg) 1 tablet once dialy for the last 5 days in the sequential arm and 1 tablets once daily for 10 days in the triple therapy arm
1550241|NCT02596620|Drug|Flagyl|Metronidazole (Flagyl)(250 mg) 2 # tid for the last 5 days in the sequential arm
1550741|NCT02592863|Drug|Placebo|Patients will take placebo 3 times per day for 12 weeks
1550242|NCT02596594|Device|fetal nutrition port system, (PakuMed Company, Essen, Germany)|Under local anesthesia a subcutaneous pouch for the port capsule was prepared using a pair of scissors. The umbilical vein was punctured with a 18 gauge needle under ultrasound control and the catheter was inserted into the umbilical vein. Note the amniotic cavity remained intact. A 25 gauge port needle was used to enter the port system. The treatment course included daily infusions of AA solution (Fresenius Kabi, Bad Homburg, Germany) with a 10% glucose solution. The investigators limited the volume of the intraumbilical infusion to 10% of the estimated feto-placental blood volume per day. On average, the AA/glucose-infusion was below 50 ml/kg.
1550243|NCT02596581|Other|non-surgical periodontal treatment|scaling and root planing were performed
1550244|NCT02596568|Device|transcranial direct current stimulation (tDCS)|tDCS is a type of brain stimulation that uses low current applied directly over the scalp to increase, or decrease cortical activity under the stimulating electrodes. tDCS applied bi-frontally using Chattanooga Ionto™ Iontophoresis System - Phoresor. A square wave will be delivered at 0.75 Hz for five blocks of five minutes each with one minute inter-train interval. Stimulation will be applied following 8 epochs of consecutive stage 2 or deeper sleep.
1550245|NCT02596568|Other|Sham|tDCS device connected and tested, but not turned on during the night. This has been found to be an effective sham in other studies using this technique.
1550246|NCT02596555|Drug|Dabigatran|Low molecular weight heparin for 72 hours followed by 6 months of dabigatran
1550247|NCT02596542|Other|Water immersion|Different temperatures of cold water immersion will be assessed
1550248|NCT02596529|Device|Fixation|Fixation of the posterior malleolus with lag-screws or platefixation (usually by Drittelrohr plate).
1550249|NCT02596529|Other|NO Fixation|NO Fixation of the posterior malleolus.
1550256|NCT02596477|Drug|Vepoloxamer|
1550257|NCT02596477|Other|5% dextrose in water|
1550258|NCT02596451|Drug|Diclofenac Sodium gel, 1%|
1550259|NCT02596451|Drug|Voltaren® Gel|
1550260|NCT02596451|Drug|Placebo|
1550262|NCT02596425|Procedure|40 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 40 cmH2O at the end of surgery.
1550263|NCT02596425|Procedure|60 cmH2O|The intervention was five manual inflations of the lungs with positive pressure ventilation of 60 cmH2O at the end of surgery.
1550264|NCT02596425|Procedure|Passive deflation|In the controls, CO2 was removed by the traditional passive deflation of abdominal cavity.
1550265|NCT02596412|Other|use the module with augmented reality (Mini-Docs) on tablet during TB injection|Provision of a tablet with a module using augmented reality (Mini-Docs) during TB injections in addition to the commonly used drug technology
1550266|NCT02596399|Drug|DSTA4637S|Participants will receive DSTA4637S intravenously on Day 1.
1550267|NCT02596399|Drug|Placebo|Participants will receive placebo matched to DSTA4637S intravenously on Day 1.
1550268|NCT02596386|Procedure|sialometry|potassium evaluation
1550269|NCT02596386|Procedure|blood test|potassium evaluation
1550270|NCT02596373|Drug|Mitoxantrone Hydrochloride Liposome Injection|
1550271|NCT02596360|Drug|Pulmodexane® 30mg|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
1550272|NCT02596360|Drug|lactose|The study design is divided in two study sequences and each subject participates in the two study sequences and receive the two treatments (dextromethorphan and placebo).
1550273|NCT02596347|Procedure|Blood draw|We will draw 4 heparin tubes for peripheral blood mononuclear cells (PBMC)
1550274|NCT02596347|Procedure|bronchoscopy|CBD subjects will undergo a bronchoscopy with lavage. This is the passage of a think flexible tube through the nose into the windpipe then into the bronchial tubes. Sterile saltwater solution is through the flexible tube then immediately removed.
1550275|NCT02596334|Drug|dolutegravir 50mg +abacavir 600mg +lamivudine 300mg|
1550276|NCT02596334|Drug|dolutegravir|
1550279|NCT02596308|Biological|Plague vaccine|Plague vaccine is comrised by native fraction 1 capsule (F1) and recombine virulence-associated (V) antigens.
1550376|NCT02595645|Genetic|Polypectomy and NGS|NGS of 38 cancer-related genes, systems biological analyses, correlation genetics to pathology and clinical data
1550280|NCT02596282|Procedure|Neonatal circumcision under topical anesthesia|"The standard procedure for neonatal circumcision is as follows: combined analgesia was topical 2.5% lidocaine and 2.5% prilocaine <1 gm applied 60 minutes and 40mg acetaminophen suppository 30 minutes prior to surgery. Infants were given a 24% sucrose solution pacifier if needed. Infants under 2 weeks of age received subcutaneous Vitamin K 1 mg. The perineum cleaned, and the penis swabbed with povidone iodine. Hemostats were applied at 3 and 9 o'clock positions and the glans pushed down. Traction was applied before placing the Mogen clamp, the clamp was closed for 5 minutes and the foreskin removed with a scalpel.
Petroleum jelly (e.g., Vaseline) was applied to the glans and the wound covered with sterile gauze. Infants were observed for one hour. Mothers were instructed in wound care."
1550281|NCT02596269|Drug|Nefopam|120 mg of nefopam is included in the i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time was set, without any background continuous infusion. After the end of surgery, and if the goal VRS score was achieved at PACU, PCA device was turned on and the patient was encouraged to use the pre-set bolus dose, until 24h after the end of surgery.
1550282|NCT02596269|Drug|Saline|i.v. PCA with with 100 ml solution containing 1250 µg fentanyl. a bolus of 1 ml with an 8-min lockout time
1550283|NCT02596256|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
1550284|NCT02596256|Drug|Docetaxel|Docetaxel (60 mg/m2 qd d1 q3w i.v.) until disease progression or intolerable toxicity
1550285|NCT02596243|Biological|GX-188E|1mg of GX-188E administered IM using EP device at day 0, week 4 and week 12.
1550286|NCT02596243|Biological|Placebo|0.5mL of Placebo administered IM using EP device at day 0, week 4 and week 12.
1550287|NCT02596217|Drug|ABBV-066|SC injection
1550288|NCT02596217|Drug|ABBV-066|IV infusion
1550289|NCT02596217|Drug|Placebo|SC injection (stage 1)
1550290|NCT02596217|Drug|Placebo|IV infusion (stage 2)
1550291|NCT02596204|Other|Weekly Review|Subjects will wear a FitBit activity monitor and continue to use their insulin pump. Fitbit, pump and sensor (if applicable) data will be uploaded at least weekly. For subjects in the weekly review group, research staff (CDE, NP and/or MD) will review uploaded blood glucose, pump, and available sensor, activity and sleep data on a weekly basis. If glucose patterns are identified which suggest a change to diabetes management (ie insulin dose changes), the family will be contacted by text, email or telephone to review glucose patterns and to review staff recommendations.
1550292|NCT02596204|Device|FitBit|All subjects will wear a FitBit activity monitor.
1550293|NCT02596191|Other|Clinical evaluation|
1550294|NCT02596191|Other|electrophysiological record|
1550295|NCT02596191|Other|Muscle MRI|
1550296|NCT02596191|Other|blood samples analysis|
1550298|NCT02596165|Device|Pulse wave analysis measurement with Schiller BR-102 Plus PWA device|Measurement of central and peripheral blood pressure and central arterial stiffness simultaneously with the Schiller BR-102 Plus PWA device
1550299|NCT02596152|Other|mini-trampoline|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
1550300|NCT02596152|Other|Nordic Walking|Intervention period lasts 12 weeks, training is group instructed, twice weekly. Training sessions are one hour each. The training intensity of the two interventional arms is comparable. The training progression is defined in advance.
1550301|NCT02596139|Other|No Interventions|
1550302|NCT02596126|Drug|Cardiovascular Polypill|"Cardiovascular Polypill contains Aspirin, Atorvastatin and Ramipril.
Participants will receive one of the following cardiovascular polypill:
(A) Aspirin 100 mg, Atorvastatin 40mg, and Ramipril (2.5 mg, or 5 mg, or 10mg).
or
(B) Aspirin 100 mg, Atorvastatin 20mg, and Ramipril (2.5 mg, or 5 mg, or 10mg)."
1550303|NCT02596126|Drug|Treatment Prevention for Secondary CV|ESC Guideline (2013 guideline on management of stable coronary disease) recommended pharmacological treatment for event prevention.
1550304|NCT02596100|Drug|Betrixaban|
1550305|NCT02596087|Other|Problem List Suggestion|Sites will configure their EHR systems so that alerts for these conditions will be triggered for providers in the intervention arm if the patient does not have the condition on her/his problem list. each alert will be actionable and allow the provider to add the problem to her or his patient's problem list with a single click. The provider will also be able to override the rule of the patient does not have the condition (in which case the alert will not be displayed again unless new information that would trigger the alert is added to the patient's record), or defer the alert until later.
1550306|NCT02596074|Drug|Omiganan (CLS001) topical gel|
1550307|NCT02596074|Drug|Vehicle topical gel|
1550308|NCT02596061|Behavioral|Deposit Contract|Contracts prompt patients to put money they have earned at stake on a commitment to remain smoke-free for a longer period of time.
1550309|NCT02596061|Other|Incentives|Patients receive incentives for completing smoking cessation activities.
1550310|NCT02596048|Other|Iomeron|Iomeron or Imeron which is a iomeprol injection, hereafter referred to as iomeprol is an injectable solution of iomeprol, a non-ionic hydrosoluble iodinated compound used as a medical imaging contrast agent for radiological examinations.
1550377|NCT02595632|Other|No intervention|
1550378|NCT02595619|Device|RRT plus ECCO2R|Patients with acute kidney injury will be treated with Renal replacement therapy associated to extracorporeal carbon dioxide removal in a single treatment
1550379|NCT02595606|Drug|0.3% Sodium Hyaluronate|five times per day for the intervention of eye drop
1550317|NCT02595996|Drug|Propranolol|escalating doses of propranolol from 1mg/kg/day to 2mg/kg/day to 3mg/kg/day
1550318|NCT02595983|Drug|Revusiran (ALN-TTRSC)|500mg Revusiran by subcutaneous (sc) injection
1550333|NCT02595892|Drug|ATR Kinase Inhibitor VX-970|Given IV
1550334|NCT02595892|Drug|Gemcitabine Hydrochloride|Given IV
1550335|NCT02595892|Other|Laboratory Biomarker Analysis|Correlative studies
1550346|NCT02595853|Other|Non interventional study|All upper gastro-intestinal bleeding need endoscopic hemostasis. Endoscopic hemostasis conventional methods are injection of saline with epinephrine, placement of hemoclips and thermic or plasma coagulation. Hemospray™ will be sprayed onto bleeding lesions seen in endoscopy after failure of conventional methods or in salvage therapy at the discretion of endoscopists. Retrospective analysis of prospectively cellected data.
1550347|NCT02595840|Other|Collection of tumor and blood specimen|
1550348|NCT02595827|Other|Conditional Advice|Caretakers are told to return in 2-3 only (Conditional Advice) if the child's symptoms continue.
1550349|NCT02595801|Other|Surgery in early childhood|Surgical interventions in early childhood (prior to completion of Early Development Instrument)
1550350|NCT02595788|Other|Change from supine to prone position|Change from supine to prone position
1550351|NCT02595775|Other|Individualized A/F report|Individualized A/F report containing 9 colonoscopy quality measures.
1550352|NCT02595775|Other|A/F report plus a high intensity intervention|E.g. Master class in colonoscopy
1550353|NCT02595775|Other|A/F report plus a low intensity intervention|E.g. Access to a video/presentation on good colonoscopy technique followed by a post presentation assessment.
1550354|NCT02595775|Other|A/F report alone|
1550355|NCT02595749|Drug|Oxytocin|
1550356|NCT02595749|Drug|Placebo|
1550357|NCT02595736|Drug|Placebo (SC)|Administered SC
1550358|NCT02595736|Drug|LY3200327 (SC)|Administered SC
1550359|NCT02595736|Drug|LY3200327 (IV)|Administered IV
1550360|NCT02595736|Drug|Placebo (IV)|Administered IV
1550361|NCT02595723|Drug|Phenytoin|Phenytoin is in a class of medications called anticonvulsants. It works by decreasing abnormal electrical activity in the brain.
1550362|NCT02595723|Drug|Megestrol Acetate|Megestrol Acetate is a frequently prescribed medication that is used to stimulate appetite in HIV patients. It is also used for cancer patients and in the elderly, particularly nursing home patients who may be at risk for cognitive impairment or delirium.
1550363|NCT02595723|Drug|Placebo|Inactive ingredient matching the active medication in appearance
1550364|NCT02595710|Other|skin punch biopsy collection|Four-mm skin biopsies from non-lesional skin will be acquired from the patients, processed using our published techniques with Bartonella biomarkers, and imaged using confocal microscopy.
1550365|NCT02595710|Other|Blood collection|Blood will be tested for presence of Bartonella DNA and Bartonella antibodies using the Alpha Proteobacterium Growth Medium (BAPGM) multi-platform testing, including liquid culture, enriched agar plating and molecular techniques.Blood smears will be analyzed for presence of intra-erythrocytic Bartonella spp. by immunostaining.
1550366|NCT02595710|Other|Urine sample collection|Urine samples will be collected and analyzed for Bartonella spp specific microRNAs.
1550367|NCT02595697|Behavioral|J-EMT for Toddlers with Autism|Children assigned to the J-EMT group will receive a total of 48, 1-hour direct intervention sessions over six months that will include teaching their parents to implement J-EMT procedures across daily activities.
1550368|NCT02595684|Drug|Tadalafil|Tadalafil capsules: 5 mg, one per day, at night, during 28 days.
1550369|NCT02595684|Drug|Placebo|Calcined magnesia capsules: one per day, at night, during 28 days.
1550370|NCT02595671|Other|Digital Super Coach|Receive Digital Super Coach during 12 weeks
1550371|NCT02595671|Other|Conventional face to face PA & dietitian|Receive 7 face-to-face contacts (dietary and physical activity advice)
1550372|NCT02595671|Other|Digital Super Coach + minimal coaching|Receive 3 face-to-face contacts (dietary and physical activity advice)
1550373|NCT02595671|Other|Waiting Group|Receive Digital Super Coach during 12 weeks, after 12 weeks of no treatment
1550374|NCT02595658|Dietary Supplement|Meal composition|
1550375|NCT02595658|Drug|Rapid-Acting Insulin Dose|
1550382|NCT02595567|Device|Indwelling tunneled pleural catheter (ITPC)|ITPCs have been shown to successfully and safely control dyspnea in patients with malignant pleural effusions. Compared to the large amount of published data regarding the use of indwelling tunneled pleural catheters in malignant effusions, there is a paucity of data regarding the use of ITPC in liver disease for the treatment of hepatic hydrothorax.
1550383|NCT02595554|Radiation|Concurrent chemoirradiation|External beam radiation therapy (EBRT) with concurrent weekly platinum chemotherapy followed by brachytherapy
1550384|NCT02595554|Drug|Paclitaxel|New adjuvant chemotherapy 3 cycles with Paclitaxel 150mg/m2 over 3 hours and Cisplatin
1550385|NCT02595554|Procedure|Radical Surgery|Radical hysterectomy (Type III or Type IV hysterectomy) plus bilateral pelvic lymph node dissection and para-aortic lymph node dissection or sampling
1550386|NCT02595554|Drug|Cisplatin|New adjuvant chemotherapy 3 cycles with Paclitaxel and Cisplatin 70mg/m2
1550387|NCT02595541|Drug|milrinone|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study.
1550388|NCT02595541|Drug|Sildenafil|IV milrinone (0.75 mcg/kg) loading dose over one hour started during re-warming of the patient (before weaning from CPB) and followed by a maintenance dose of 0.75 mcg/kg/minutes till the end of the study. After baseline measurements, sildenafil (1mg/kg) administered in ICU via a nasogastric tube, to be repeated every 4 hours via a nasogastric tube or orally. Sildnafil is presented in tablet form which was dissolved in water to make a concentration of 1 mg/ml.
1550389|NCT02595528|Drug|AGN-199201 ophthalmic solution|1 drop of AGN-199201 ophthalmic solution Doses A, B, C in the eye.
1550390|NCT02595528|Drug|AGN-190584 ophthalmic solution|1 drop AGN-190584 ophthalmic solution doses A, B and C in the eye.
1550391|NCT02595528|Drug|AGN-190584 vehicle|Vehicle to AGN-190584
1550392|NCT02595528|Drug|AGN-199201 + AGN-190584 Combination|1 drop AGN-199201 and AGN-190584 fixed combination ophthalmic solution in the eye.
1550393|NCT02595528|Drug|AGN-199201 vehicle|Vehicle to AGN-199201
1550394|NCT02595515|Other|Chiropractic treatment|Procedure: chiropractic treatment.
1550395|NCT02595515|Other|Visit without active treatment|Procedure: Visit without active treatment. The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether the treatment is delivered or not.
1550396|NCT02595502|Device|JJVC Marketed Contact Lens (Test)|
1550397|NCT02595502|Device|Competitor Marketed Contact Lens (Control)|
1550398|NCT02595489|Dietary Supplement|vitamin D3|Daily oral supplement provided by study investigators
1550399|NCT02595476|Drug|Remifentanil|
1550400|NCT02595476|Drug|propofol|
1550401|NCT02595476|Device|TCI|
1550402|NCT02595476|Procedure|Tetanic stimulation|
1550403|NCT02595476|Device|Algiscan|Pupillometry
1550404|NCT02595463|Drug|Lidocaine|Intraoperative dose of intravenous lidocaine followed by an infusion until discharge from the initial recovery period.
1550405|NCT02595463|Drug|Saline|Intraoperative dose of saline followed by an infusion until discharge from the initial recovery period.
1550406|NCT02595450|Drug|Erlotinib|Participants with locally advanced or metastatic non-small cell lung cancer will be treated with erlotinib according to the product label. This non-interventional study will not affect by any means the treatment, medical care or monitoring of the participant, since it reports retrospective data, which already exist in the participants' medical files.
1550407|NCT02595437|Drug|Triferic|
1550408|NCT02595424|Drug|Capecitabine|Given PO
1550409|NCT02595424|Drug|Carboplatin|Given IV
1550410|NCT02595424|Drug|Cisplatin|Given IV
1550411|NCT02595424|Drug|Etoposide|Given IV
1550412|NCT02595424|Other|Laboratory Biomarker Analysis|Correlative studies
1550413|NCT02595424|Drug|Temozolomide|Given PO
1550414|NCT02595398|Drug|4mg CLS-TA Suprachoriodal Injection|CLS-TA, 40 mg/mL (4 mg in 100 µL), will be administered as a single injection at 2 timepoints
1550415|NCT02595398|Drug|Sham Procedure|Sham procedure will be administered at 2 timepoints
1550416|NCT02595385|Device|Cell Salvage|Reinfusion of shed blood during the operation
1550417|NCT02595385|Procedure|Retrograde Autologous Prime|Removal of fluid from the bypass circuit
1550418|NCT02595372|Drug|Omeprazole|
1550419|NCT02595359|Drug|Moxifloxacin|Moxifloxacin intracameral
1550420|NCT02595346|Drug|Hydroxychloroquine|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.
glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.
oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
1550421|NCT02595346|Drug|placebo|"endothelial function is assessed by measuring the flow mediated dilatation of humeral artery in response to ischemia. the dilatation is evaluated by echotracking.
glycocalyx thickness is measured by the study of sublingual microcirculation with SDF imaging.
oxydative, inflammatory and coagulation parameters is assessed on plasma samples."
1550422|NCT02595333|Drug|Group SF1|primary cesarean section+postoperative analgesia with sufentanil plus flurbiprofen axetil group
1550423|NCT02595333|Drug|Group S1|sufentanil was administered for analgesia in primary cesarean section
1550424|NCT02595333|Drug|Group SF2|sufentanil and flurbiprofen was administered for analgesia in repeated cesarean section
1550425|NCT02595333|Drug|Group S2|sufentanil was administered for analgesia in repeated cesarean section
1550426|NCT02595320|Drug|Capecitabine|"Capecitabine will be given to participants in Arm A at 1500 mg PO BID for 7 days, followed by a 7 day rest (7-7).
Capecitabine will be given to participants in group B at 1250 mg/m2 OR 1000 mg/m2 PO BID for 14 days, followed by a 7 day rest (14-7)."
1550427|NCT02595307|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
1550428|NCT02595294|Procedure|Cervical Lateral Glide neural mobilization|Non-surgical non-invasive Cervical Lateral Glide neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The correct linear alignment of patient's cervical spine was determined through the baseline use of a Universal Goniometer Device in each application of Cervical Lateral Glide neural mobilization.
1550430|NCT02595268|Drug|Pitavastatin|Participants will receive single oral dose of pitavastatin 1 milligram (mg) on Day 1 and Day 9.
1550431|NCT02595268|Drug|JNJ-63623872|Participants will receive JNJ-63623872 600 mg twice daily on Days 4 through 12.
1550432|NCT02595255|Other|No intervention|No intervention
1550433|NCT02595242|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 will be infused intravenously once 1-2 minutes in 20-30 ml saline on the first day during a treatment phase of 3 weeks.
1550434|NCT02595242|Drug|Vincristine|Vincristine 0.3-0.5 mg/ml will be infused intravenously once about 5 minutes in saline on the first day during a treatment phase of 3 weeks.
1550435|NCT02595242|Drug|Prednisone|Prednisone 100 mg/d will be taken orally on the first 1-5 day during a treatment phase of 3 weeks.
1550436|NCT02595229|Procedure|Pronator quadratus repair|Suturing of the pronator quadratus muscle
1550437|NCT02595216|Device|Profound System|The Profound system is indicated for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis, and the percutaneous treatment of submental laxity
1550438|NCT02595203|Drug|[14C-pos 1]-Debio 1450 BES Solution|A solution containing Debio 1450 bis ethanolamine salt (BES) radiolabelled with carbon-14 (14C) at position 1
1550439|NCT02595203|Drug|[14C-pos 25]-Debio 1450 BES Solution|A solution containing Debio 1450 BES radiolabelled with carbon-14 (14C) at position 25
1550440|NCT02595190|Procedure|sacral canal cyst microscopic tamponade|sacral canal cyst microscopic tamponade treatment
1550441|NCT02595190|Drug|gabapentin + tramadol|dose range：gabapentin 400-1200mg tid, tramadol 100-200mg bid
1550442|NCT02595190|Device|resting state functional magnetic resonance imaging (rfMRI)|First time:2 days before Surgery or Drug use; Second time:3 months after Surgery or Drug use; Third time:1 year after Surgery or Drug use
1550443|NCT02595177|Procedure|Cataract surgery with intraocular lens implantation.|Phacoemulsification under topical anesthesia with intraocular lens implantation.
1550444|NCT02595151|Device|CLE|The CLE procedure did not differ from that of conventional colonoscopy, except for the additional storage of pCLE images and videos in the gastric antrum.
1550445|NCT02595138|Drug|Zoledronic acid|
1550446|NCT02595125|Device|IUD|copper IUD or levonogestrel IUD insert by the conventional technique or by direct technique
1550447|NCT02595112|Other|Staphylococcus aureus carriage|Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery
1550448|NCT02595099|Other|Mindfulness training|group-based training programme, 2.5 hours delivered weekly for 8 weeks
1550449|NCT02595086|Procedure|Laparoscopic PPG|Laparoscopy assisted pylorus-preserving gastrectomy with D1+ lymphadenectomy (exclude lymph node station No. 5) in Japanese classification.
1550450|NCT02595086|Procedure|Laparoscopic DG|Laparoscopic distal gastrectomy with D1+ lymphadenectomy in Japanese classification.
1550451|NCT02595073|Drug|DSXS|Active treatment
1550452|NCT02595073|Drug|Placebo|Placebo treatment
1550453|NCT02595060|Drug|inhaled molgramostim (rhGM-CSF)|
1550454|NCT02595060|Drug|inhaled placebo|formulated as the active substance without molgramostim
1550455|NCT02595047|Procedure|tissue/ organ prefabrication|tissue/ organ is prefabricated in vivo independent of exogenous factors for replacement/ reconstruction purposes
1550456|NCT02595034|Drug|Clindamycin and Benzoyl Peroxide Gel 1%5%|Clindamycin and Benzoyl Peroxide Gel 1%5% (Taro Pharmaceuticals Inc.)
1550457|NCT02595034|Drug|BenzaClin® Topical Gel|BenzaClin® (clindamycin 1%/benzoyl peroxide 5%) Topical Gel (Sanofi Aventis, U.S.)
1550458|NCT02595034|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
1550459|NCT02595021|Procedure|Total or Subtotal Colectomy|Resect all or most parts of the colon: with total or subtotal colectomy as a part of optimal cytoreductive surgery(residual disease <=0.5cm)
1550460|NCT02595021|Procedure|Other Bowel Resection|Resect part of the colon or small intestine: with other types of bowel resection as a part of optimal cytoreductive surgery(residual disease <=0.5cm)
1550461|NCT02595008|Drug|DSXS|Active treatment
1550462|NCT02594995|Drug|NBP|
1550463|NCT02594982|Other|intervention bundle (sedation, pain, mobilization and sleep)|"Sedation: Sedation after target RASS Pain: Implementing a pain guideline and CPOT for pain assessment. Mobilization: Implementing a guideline on early mobilization and a daily prescribed mobilization level.
Sleep: Implementing a daily quite time and changing procedures to minimize noise during the night"
1550464|NCT02594969|Other|Bleach Bath and Moisturizers|All subjects will have one forearm in a bleach bath and the other forearm in a water bath for 10 minutes. Following the bath, skin barrier function will be evaluated. Secondly, moisturizers will be applied to the arms and the skin barrier will be evaluated overtime.
1550465|NCT02594956|Device|no nasogastric tube|
1550466|NCT02594956|Device|nasogastric tube|
1550467|NCT02594943|Device|Boston Scientific Large Capacity with needle Biopsy|The investigators will use a conventional biopsy forceps for taking tissue biopsies in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the conventional biopsy forceps from the tumor tissue.
1550468|NCT02594943|Device|Endodrill 1A (BIBBInstruments, Lund, Sweden)|The investigators will use the Endodrill, a new device for endoscopic tissue sampling in the GI tract. In a randomized order 4 out of total 8 biopsies will be taken with the Endodrill instrument from the tumor tissue.
1550469|NCT02594930|Procedure|synovial biopsy of total knee arthroplasty|synovial biopsies are taken via two different techniques in the same patient to allow direct comparison of results
1550470|NCT02594904|Drug|Yinzhihuang Oral Liquid|All the four groups will be given same treatment as being described in arm description.
1550471|NCT02594891|Device|endoscopic retrograde biliary drainage|A 8.5 F plastic stent with proximal flap （XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
1550472|NCT02594891|Device|endoscopic nasobiliary drainage|A nose bile duct（XinChang medical instrument co., LTD,Shanghai, China) will be inserted into common bile duct with standard procedure.
1550473|NCT02594878|Drug|Pamidronatdinatrium|
1550474|NCT02594878|Other|Natrium chloride 9mg/ml|
1550475|NCT02594865|Dietary Supplement|Glucerna|Glucerna ® 1.5 kcal (Abbott, USA), the standard enteral formula used at our ICU and the investigational enteral feeding.
1550476|NCT02594865|Dietary Supplement|Fresubin|Fresubin ® Energy Fibre (Fresenius, UK), the control enteral feeding.
1550477|NCT02594852|Device|+ laser|Use of laser in the treatment
1550478|NCT02594839|Drug|Bone marrow mesenchymal stem cells|Bone marrow will be harvested in healthy donors followed by separation and cultivation of MSCs. Before infusion cells will be suspended in 400 mL saline
1550479|NCT02594839|Drug|Placebo|intravenous infusion of 400 mL saline
1550480|NCT02594826|Behavioral|Culturally appropriate intervention|Church-based educational intervention combined with navigation assistance
1550481|NCT02594826|Behavioral|General health education control|General health and cancer education
1550482|NCT02594813|Procedure|Biopsy or cold snare polypectomy|
1550483|NCT02594800|Drug|Rosuvastatin|standard or intensive dose rosuvastatin therapy based on other routine medication for stroke for 52 weeks.
1550484|NCT02594787|Dietary Supplement|Phosphorus|
1550485|NCT02594787|Dietary Supplement|Placebo|
1550486|NCT02594774|Other|Manipulative osteopathy|Osteopathic treatment (BMT) which works on the influence on the pressure distribution in the (especially abdominal) body cavities and consequently on the viscera contained therein, proper arterial supply and venous and limphatic drainage.
1550487|NCT02594761|Biological|Hercules|Powder Concentrate for Intravenous Infusion, 150 mg/vial
1550488|NCT02594761|Biological|Herceptin EU|Powder for Concentrate for Solution for Infusion, 150 mg/vial
1550489|NCT02594761|Biological|Herceptin US|Intravenous Infusion, 440 mg/vial
1550490|NCT02594748|Behavioral|Self-management education|The intervention group will receive diabetes self-management education based on the idea of extended theory of planned behavior .
1550491|NCT02594748|Behavioral|Routine care|They will attend the routine lecture in hospital sit and listen, usually 1-2 times during one week in hospital
1550493|NCT02594722|Device|FES-cycling|Patients performed an endurance tests with functional electrical stimulation during 30 minutes with an oxygen uptake measure.
1550494|NCT02594722|Device|Classic cycloergometer|Patients performed an endurance tests on classic ergometer during 30 minutes with a sham electrical stimulation with an oxygen uptake measure.
1550495|NCT02594709|Radiation|Multisession Radiosurgery|Patients will undergo multisession radiosurgery as clinical practice.
1550496|NCT02594696|Other|Proactive Psychiatry Consultation (PPC)|"The psychiatrist conducts a tailored, cancer-specific assessment to optimize psychiatric symptoms and collaborates with the oncologist to develop and modify the cancer treatment plan.
The case manager, a social worker, engages with the patient to promote self-management, identify and address barriers to care, and bridge communication with oncology and mental health.
The psychiatrist and case manager proactively monitor symptoms and the process of cancer care, remain in regular contact with the patient and communicate with the oncology team at least every 4 weeks
The psychiatrist and case manager are available for consultation across care settings (outpatient, inpatient, home).
Recommendations are documented in the medical record and communicated directly to the oncology team"
1550497|NCT02594670|Other|DU20 and HT7 combination|acupoints combination includes Baihui (DU20) and Shenmen(HT7),which was considered as the optimal clinical efficay among various combinations of acupoints.
1550498|NCT02594670|Other|DU20 and SP6 combination|acupoints combination of Baihui (DU20) and Sanyinjiao (SP6), which should have some clinical efficay among various combinations of acupoints.
1550499|NCT02594670|Other|DU20 and SA combination|Combination of Baihui (DU20) and a Sham acupoint (SA), which should have least clinical efficacy among these three types of acupoints combinations.
1550500|NCT02594657|Procedure|pedal rate on 50 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
1550501|NCT02594657|Procedure|pedal rate on 80 RPM|All measurements are performed in two pedalling situations. The two frequencies used will be 50 and 80 RPM. For each subject the running order (50 and 80, 80 and 50) is randomly determined
1550502|NCT02594644|Device|Microneedle Roller|The study device (MR200, Clinical Resolutions Laboratory, Inc.) is a disposable roller equipped with stainless steel needles that are 200 micrometers in length.
1550503|NCT02594644|Drug|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
1550504|NCT02594644|Radiation|Blue Light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA
1550505|NCT02594631|Procedure|ESWL|Patients in this arm will receive ESWL for treatment of acute calcular urinary retention
1550506|NCT02594631|Procedure|Endoscopic treatment|Patients in this arm will receive endoscopic treatment of acute calcular urinary retention
1550507|NCT02594605|Device|Platelet Rich Fibrin|Platelet rich fibrin increases the growth factors. So it was applied for treatment of periodontal bone loss.
1550508|NCT02594605|Device|Conventional Flap Surgery|Only Conventional Flap Surgery treatment the bone loss limitedly.
1550509|NCT02594592|Other|questionaire|Arm: Experimental :questionaire medium risk, and high risk.(more than one positive answer about questionaire) Arm:Active Comparator: questionaire low risk (none of positive answer about questionaire)
1550510|NCT02594579|Drug|Vitamin D3|Vitamin D3 100,000 u per day on day 1,3 then 50,000 u/day on day 5,7,9,12 and continue 50,000 u 3 times/ week for 4 weeks
1550511|NCT02594579|Drug|Placebo|Placebo on day 1,3,5,7,9,12 then 3 times/ week for 4 weeks
1550512|NCT02594566|Drug|CyMVectin|CyMVectin will be delivered by unilateral intramuscular (IM) injection at Day 0, Day 28(+4 days), and Day 56 (+4 days) in alternating arms. Each dose of CyMVectin will be administered in a 1.0-mL volume
1550561|NCT02594137|Procedure|Without watertight duraplasty|After standard craniectomy and dural opening, provided there is no brain contusions or hematomas requiring surgical evacuation, no watertight duraplasty is performed. The dura is left opened and the brain parenchyma is covered with Surgicel. Usual closure is then performed.
1554203|NCT02568683|Drug|VCR|VCR administered intravenously
1550513|NCT02594553|Behavioral|GP-parent information-exchange tool|The booklet incorporates already existing information about fever, alarm symptoms, advices use of medication and specific infectious diseases that frequently occur in childhood in combination with fever such as upper respiratory tract infections, and otitis media. The difference with these existing sources of information is the fact that they until now, were not incorporated into one booklet which can be physically handed over to parents.
1550514|NCT02594540|Device|Mechanical Peripheral Stimulation (GONDOLA)|
1550520|NCT02594462|Drug|etonogestrel-releasing implant contraceptive|The etonogestrel implant will be inserted until the fifth day of the menstrual cycle . Anthropometric measurements will be performed , blood pressure measurement , application of pain questionnaire for the last three months, and collection of fasting blood in our clinic . After these measures , the ENG implant will be applied per researcher trained for such a procedure , following the recommendations outlined by the manufacturer. Women are instructed to return after 3, 6, 9, 12 months, fasting 8h , when they will be measured anthropometric measurements , blood collection, and delivery of pain questionnaires and standard of menstrual bleeding.
1550521|NCT02594449|Drug|Benzalkonium Chloride Solution|To compare pharmacodynamics among the different concentrations of BCS and NS
1550522|NCT02594436|Drug|Ingenol mebutate|Non-Interventional study enrolling patients already planned to be treated with ingenol mebutate according to approved labelling
1550523|NCT02594423|Device|Fine Needle Diathermy|Fine needle diathermy is a surgical procedure that is used in the treatment of corneal NV. It is a safe and effective method for corneal vessels occlusion.
1550524|NCT02594423|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal antibody that binds to isoforms of VEGF-A .
1550525|NCT02594410|Device|stent|patients receiving renal artery stenting for renal artery atherosclerosis
1550526|NCT02594410|Drug|Aspirine|100mg Qd
1550527|NCT02594410|Drug|Clopidogrel|75mg Qd
1550528|NCT02594410|Drug|Lercanidipine|10-20mg Qd
1550529|NCT02594397|Other|acupoints combination 1|
1550530|NCT02594397|Other|acupoints combination 2|
1550531|NCT02594397|Other|sham acupoints combination|
1550532|NCT02594384|Drug|LAM-002A|25 mg capsules
1550533|NCT02594371|Drug|Oraxol|
1550534|NCT02594371|Drug|IV paclitaxel|
1550535|NCT02594358|Drug|Caffeine|20 MG OR 40 MG ONCE DAILY ALONG WITH PATCHING
1550536|NCT02594345|Other|in vitro study|Exosomes will be mixed with healthy volunteers' blood in vitro
1550537|NCT02594332|Drug|Mepolizumab|100 mg SC every 4 weeks for 13 injections
1550538|NCT02594332|Drug|Placebo|
1550539|NCT02594319|Behavioral|Monetary incentives|
1550540|NCT02594319|Behavioral|Self monitoring|
1550541|NCT02594306|Device|Emotional pictures stimulation system|Emotional pictures stimulation system is component of neutral and drug-related images.
1550542|NCT02594306|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral NAc/ALIC
1550543|NCT02594306|Procedure|adjacent contact stimulation|The electrode of deep brain stimulation has four contacts.We stimulate one contact,and record the local field potential of other contacts.
1550544|NCT02594306|Procedure|microelectrode|We put the microelectrodes into bilateral nucleus accumbens and anterior limb of the internal capsule,to record the waveform of bilateral NAc/ALIC.
1550545|NCT02594293|Drug|PegIFN alfa-2a|180 μg/ 0.5 ml ,hypodermic injection once a week
1550547|NCT02594254|Drug|C16G2 Gel|Antimicrobial peptide
1550548|NCT02594254|Other|Placebo|Placebo
1550549|NCT02594241|Drug|Methyl-Prednisolone|Single-shot 125 mg infusion given immediately after induction of anesthesia.
1550550|NCT02594241|Drug|Physiological saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
1550551|NCT02594228|Behavioral|Whey Protein and exercise training|Six meals per day four of which were whole food and two of whey protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
1550552|NCT02594228|Behavioral|Food Protein and exercise training|Six meals per day all of which were whole food protein for an overall percentage of macronutrient intake of 25% protein and 4 days per week of exercise training
1550555|NCT02594176|Device|FLEXISEQ®|applicable gel
1550556|NCT02594176|Device|Placebo|applicable gel
1550560|NCT02594150|Other|Financial Incentive|Financial incentives provide small immediate and tangible rewards that are aligned with the abstract long-term rewards of cancer prevention.
1550562|NCT02594124|Drug|nusinersen|Administered by intrathecal (IT) injection
1550563|NCT02594111|Drug|Colchicine vs Placebo|Colchicine vs Placebo 1.8 mg PO over 1 hour
1550564|NCT02594098|Drug|Secukinumab|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
1550565|NCT02594098|Drug|Placebo|At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.
1550566|NCT02594085|Other|Patch 1|Patch 1 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 1 contains the subjects own feces. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
1550567|NCT02594085|Other|Patch 2|Patch 2 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve Patch 2 contains the subjects own feces and filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
1550568|NCT02594085|Other|Patch 3|Patch 3 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 3 contains simulated output. The Patch is placed over the adhesive strip to invesitgate the impact of output on the adhesive strip
1550569|NCT02594085|Other|Patch 4|Patch 4 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 4 contains simulated output with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
1550570|NCT02594085|Other|patch 5|Patch 5 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 5 contains buffer. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
1550571|NCT02594085|Other|Patch 6|Patch 6 describes a test system which contains an adhesive strip and an adhesive patch with a sleeve. The sleeve of Patch 6 contains buffer with filler. The Patch is placed over the adhesive strip to investigate the impact of output on the adhesive strip
1550575|NCT02594059|Other|endothelial function|measure of reactive hyperemia-peripheral artery tone index
1550576|NCT02594046|Other|stem cell component extract|The Allogeneic Human adipose derived stem cell component extract
1550577|NCT02594033|Drug|insulin aspart|All subjects make three intervention visits with at least 5 days between individual intervention visits. At each intervention visit the subject receives one insulin aspart injection with only one type of needle.
1550578|NCT02594020|Procedure|air abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
1550579|NCT02594020|Procedure|sono abrasion|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
1550580|NCT02594020|Procedure|dental bur|already used intervention to prepare micro cavities of the dental to be treated by a photopolymerizable resin
1550581|NCT02594007|Device|SEEQ|Mobile cardiac telemetry system worn externally for a total of 28 days.
1550582|NCT02594007|Device|Cardiocom|Patient-based interface tool that includes a blood pressure cuff and blue-tooth enabled scale for daily recordings. The patient will also answer a series of behavioral and symptomatic questions daily through 30 days.
1550583|NCT02594007|Device|DocView|Patient-based interface tool that analyzes state of wellness. The patient will answer a series of questions daily through day 30.
1550584|NCT02593994|Device|Onyx Drug Eluting Stent group|
1550585|NCT02593981|Dietary Supplement|Fruit/Honey drink|2 canisters of powder containing fruit/honey mix to be mixed with water and ingested twice a day for 28 days
1550586|NCT02593981|Dietary Supplement|Placebo|2 canisters of Placebo powder containing non-active ingredient to be mixed with water and ingested twice a day for 28 days
1550587|NCT02593968|Drug|Recombinant Human Interferon a-2b Gel|
1550588|NCT02593968|Drug|Placebo|
1550589|NCT02593955|Behavioral|PD exercise|Supervised high intensity exercise 3x/week for 16 weeks
1550590|NCT02593955|Behavioral|Sleep Hygiene|Sleep medicine physician will provide discuss sleep habits with participants, provide tips for improving sleep hygiene, and provide reading materials.
1550591|NCT02593942|Drug|Remifentanil|0.1-0.5 mcg/kg/min infusion
1550592|NCT02593942|Drug|Propofol|75-200 mcg/kg/min infusion
1550593|NCT02593929|Drug|ruxolitinib|
1550594|NCT02593903|Drug|Septra|
1550595|NCT02593890|Device|THEYA Recovery Range|Post-operative Lingerie made from viscose derived bamboo
1550596|NCT02593877|Device|VHA algorithm|Analysis of more than 2,200 trauma subjects has enabled the definition of clinically-relevant VHA thresholds (i.e. ROTEM® and TEG® parameters) and patterns by which it is possible to rapidly identify coagulopathic patients and anticipate the need for massive transfusion. These threshold parameters have been defined and applied to the generation of an evidence-based targeted treatment algorithm (i.e. the Intervention)
1550597|NCT02593864|Device|Variable-Stiffness Shoe|A load-modifying variable-stiffness shoe previously shown to reduce joint loading
1550598|NCT02593851|Drug|JNJ-53718678|JNJ-53718678 oral solution will be administered once or twice daily for 7 days.
1550599|NCT02593851|Drug|Placebo|Placebo oral solution will be administered once or twice daily for 7 days.
1550643|NCT02593539|Drug|GSK2269557 DPI 500 mcg|Subjects will receive 2 inhalations of GSK2269557 500 mcg in DPI (total dose: 1000 mcg) to be taken every day before breakfast (with the exception of days when the subjects have a planned visit to the study clinic. On those days, they will be dosed at the clinic). The subject should hold their breath for 10 seconds before exhaling. Inhalations should be taken approximately 30 seconds apart.
1550646|NCT02593513|Device|Daifert|
1550647|NCT02593513|Procedure|Control Group|Control - Morphological Assessment
1550603|NCT02593812|Behavioral|Stepping training|Participants will step rapidly to one of four cued targets. Each trial will consist of 24 steps. Participants will perform 6 blocks of 6 trials per day for 3 consecutive days.
1550604|NCT02593799|Procedure|Endoscopy|Upper gastrointestinal endoscopy to evaluate the presence of any grade varices and high-risk varices.
1550606|NCT02593773|Drug|Interferon γ-1b|Approximately 90 subjects will receive subcutaneous (SC) doses of ACTIMMUNE® three times a week (TIW) for a total of 26 weeks. The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By week 13, all subjects are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related AEs.
1550607|NCT02593760|Other|Placebo|Placebo will be administered PO QD for up to 48 weeks.
1550608|NCT02593760|Drug|Ruxolitinib|Ruxolitinib will be administered PO BID at a starting dose depending on the participants's baseline platelet count for up to 48 weeks.
1550609|NCT02593760|Drug|Vismodegib|Vismodegib will be administered at a dose of 150 mg PO QD for up to 48 weeks.
1550610|NCT02593747|Drug|Loratadine oral solution|Subjects received a single oral dose of 10 mg loratadine oral solution/syrup 1 mg/mL (GPLA formula, test formulation) under fasted condition in any intervention period.
1550611|NCT02593747|Drug|Loratadine (Claritin peach syrup)|Subjects received a single oral dose of 10 mg loratadine claritin peach syrup 1 mg/mL (ANNA formula, reference formulation) under fasted condition in any intervention period.
1550612|NCT02593734|Drug|olanzapine|oral antipsychotic drug therapy
1550613|NCT02593734|Drug|risperidone|oral antipsychotic drug therapy
1550614|NCT02593734|Drug|amitryptaline|oral antidepressant drug therapy
1550615|NCT02593734|Drug|fluoxetine|oral drug therapy for depression
1550616|NCT02593721|Procedure|Median Nerve Neural Mobilization|Non-surgical non-invasive Median Nerve neural mobilization procedure was applied by a physical therapist continuously during 2 minutes in 5 different occasions with 1 minute of rest between each 2 minute application of the Neural Mobilization technique. The intervention was applied during a period of 6 weeks. The maximum level of elbow extension movement degree without the reproduction of symptoms during the application of the Median Nerve Neural mobilization treatment was determined through the baseline use of a Universal Goniometer Device.
1550617|NCT02593721|Drug|Ibuprofen|The active comparator group received an oral Ibuprofen treatment. The starting dose was of 400 mg/day and it was increased to a maximum of 1200 mg/day divided in 3 oral intakes every 8 hours depending on patient tolerance.The intervention was applied during a period of 6 weeks.
1550618|NCT02593708|Drug|Neratinib|
1550619|NCT02593708|Drug|Paclitaxel|
1550620|NCT02593708|Drug|Pertuzumab|
1550621|NCT02593708|Drug|Trastuzumab|
1550622|NCT02593695|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
1550623|NCT02593695|Other|Fluoxetine|Fluoxetine is one of selective serotonin reuptake inhibitors(SSRIs).
1550624|NCT02593682|Drug|suvorexant|
1550625|NCT02593682|Drug|placebo|
1550626|NCT02593669|Procedure|Phacomulsification lens removal cataract surgery with neutral Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with neutral IOL.implantation
1550627|NCT02593669|Procedure|Phacomulsification lens removal cataract surgery with blue-blocking Intraocular lens(IOL) implantation|The phacoemulsification lens removal cataract surgery is performed with blue-blocking IOL.implantation.
1550628|NCT02593669|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
1550629|NCT02593669|Drug|Viscoelastic materials|viscoelastic materials are used to protect corneal endothelial cells.
1550630|NCT02593656|Behavioral|High Protein|Protein-pacing throughout the day and exercise training for 12 weeks
1550631|NCT02593656|Behavioral|Normal Protein|Normal protein intake throughout the day and exercise training for 12 weeks
1550632|NCT02593643|Drug|Ketamine|
1550633|NCT02593643|Drug|Midazolam|
1550634|NCT02593643|Other|Treatment as usual (TAU)|TAU includes any current treatment a patient is receiving from their primary care practitioner. In the major depressive disorder (MDD) group, TAU may include a newly initiated or longstanding antidepressant. In the bipolar depression (BD) group, TAU may include a mood stabilizer such as lithium or valproate that is a first or second line agent as per Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines (Yatham et al., 2013).
1550636|NCT02593617|Other|Addiction Profile Index|
1550637|NCT02593617|Other|Alcohol Use Disorders Identification Test|
1550638|NCT02593617|Other|Barratt Impulsiveness Scale|
1550639|NCT02593617|Other|Zuckerman Sensation Seeking Scale|
1550640|NCT02593617|Other|Energy Drink Consumption Questionnaire|
1550641|NCT02593565|Other|Online questionnaires|Women will be asked to complete questionnaires during their pregnancy and a postpartum questionnaire.
1550648|NCT02593500|Drug|Budesonida Pulmictan® 200 µg|
1550649|NCT02593500|Drug|Budesonide 200 µg|
1550652|NCT02593474|Drug|Naltrexone|Outpatient detoxification and induction onto long-acting naltrexone followed by an additional second injection of long-acting naltrexone and and additional third if desired.
1550653|NCT02593461|Device|Daifert|
1550654|NCT02593461|Other|Control Group|
1550655|NCT02593448|Procedure|NIRS during VOT|"Near infrared spectroscopy with INVOS oximeter during vascular occlusion test (VOT) on following timepoints:
30 minutes after anaesthesia induction,
directly after the sternotomy,
during CPB - 20 minutes after aortic cross-clamping ,
40 minutes after aortic cross-clamping,
20 minutes after the release of the aortic cross-clamp,
45 minutes after weaning of CPB."
1550656|NCT02593448|Procedure|General anaesthesia with propofol use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.
Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.
Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.
Maintenance of anaesthesia in 'Propofol' group will be accomplished using continuous intravenous infusion of propofol 2-4 mg kg/h.
Propofol infusion rate will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with Bispectral Index (BIS), with a target range of 40-60."
1550657|NCT02593448|Procedure|General anaesthesia with sevoflurane use|"Premedication: lorazepam 50 μg kg-1, omeprazole 40 mg, and metoprolol 12.5 mg one hour before transport to the operating theatre.
Anaesthesia induction: 0.2 mg fentanyl, 0.3 mg/kg, etomidate, and vecuronium bromide 0.1 mg/kg for muscle relaxation, followed by a continuous infusion at the rate of 0.05 mg/kg/h until the sternum closure.
Intraoperative analgesia: fentanyl in fractions, up to the total dose of 20-30 μg/kg.
Sevoflurane concentration in exhaled gas will be adjusted according to patient's haemodynamic parameters and the level of anaesthesia, as assessed with BIS, with a target range of 40-60."
1550658|NCT02593435|Genetic|NGS test|"To record the characteristic QC parameters and evaluate the detection performance of Next-Generation Sequencing (NGS), including coverage depth and sequence similarity, then be used to evaluate the quality of base recognition and alignment.
To know mutation characteristic spectrum of BRCA1/2."
1550659|NCT02593422|Behavioral|Writing about ovarian cancer|Participants will be asked to write about their experiences with ovarian cancer
1550660|NCT02593409|Drug|TDF/FTC|All participants receive pre-exposure prophylaxis in the form of a daily tablet containing 300 mg of tenofovir disoproxil fumarate and 200 mg emtricitabine (Truvada®, Gilead) for one year, with an optional extension for 6 months.
1550661|NCT02593396|Drug|Bupropion hydrochloride sustained-release|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)The study drug will be repacked in the standard capsules by the research assistant who is not involved in the assessment of the study. The study drug and placebo will be packaged in sets of 11 (1 tablet per day for 3 days, followed by 2 tablets per day for 4 days.) for the first week. Subsequently, the study drug and placebo will be packaged in sets of 14 (2 tablets per day for 7 days.).
1550662|NCT02593396|Drug|placebo|Up to 70 eligible patients will be randomly assigned to Bupropion Hydrochloride Sustained-Release or placebo treatment groups in a 1:1 ratio using a computer-generated table of random numbers through the use of the Randomization.com program. Subjects will be randomized to to Bupropion Hydrochloride Sustained-Release 150mg b.d. (n = 35) or placebo b.d (n = 35)
1550663|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 1% Clindamycin Hydrochloride
1550664|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.1% Adapalene + 2% Clindamycin Hydrochloride
1550665|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 0.5% Clindamycin Hydrochloride
1550666|NCT02593383|Drug|Adapalene + Clindamycin Hydrochloride|0.05% Adapalene + 1% Clindamycin Hydrochloride
1550667|NCT02593383|Drug|Placebo|
1550668|NCT02593370|Drug|Lidocaine-epinephrine added gadoterate meglumine|
1550669|NCT02593357|Device|COPD patients|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (EndoPAT®)
1550670|NCT02593344|Device|Endopat|measure of peripheral endothelial function by the reactive hyperemia-peripheral artery tone index with a specific device (Endopat)
1550671|NCT02593331|Drug|BFKB8488A|Participants will receive either a single escalated dose of BFKB8488A administered SC or a single dose of BFKB8488A administered IV on Day 1.
1550672|NCT02593331|Other|Placebo|Participants will receive a single dose of placebo on Day 1.
1550673|NCT02593318|Drug|Oxaloacetate (OAA)|Pills to be taken orally in 500mg or 1000mg doses two times per day depending on the part of the study
1550676|NCT02593292|Behavioral|PROSPERO|"The intervention is carried out in 3 steps:
At the start of the pregnancy: a number of process steps are defined for a patient's pathway adapted to medical, obstetric and social risk factors.
During pregnancy: city based doctors and midwives work together with their hospital peers enabling patients to participate through the reporting via a medical information system
The entrance in the delivery room: patients are classified as low or high risk for greater vigilance from midwives."
1550677|NCT02593292|Other|control|At the start of the pregnancy, medical, obstetric and social risk factors are checked in the same way than the PROSPERO group. An adapted patient pathway was defined by a Clinical Research Assistant but unreachable from patients, midwifes and physicians. The electronic patient care reporting information system will be disabled and midwifes cannot create the classification checklist for low or high risk delivery.
1550678|NCT02593279|Genetic|asthma with proximal airways obstruction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, igE analysis, tomodensitometric test.
1550705|NCT02593123|Biological|Filgrastim|G-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-30 cohort will receive filgrastim (G-CSF) 5 mcg/kg/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
1550679|NCT02593279|Genetic|asthma with small airways dysfunction phenotype profile description with clinical, biological, morphologic and genetic elements.|symptoms, medical history, date of start, date of aggravation, comorbidities, increased factors related to asthma, blood eosinophils, blood periostin, allergologic patch test, IgE analysis, tomodensitometric test.
1550680|NCT02593266|Behavioral|Preventive Intervention Program (PIP) for depression|"Manualized intervention designed by Beardslee and colleagues (Beardslee et al., 2003) It is a program based on cognitive behavioural therapy, narrative therapy and systemic therapy. It is divided in 7 modules which are imparted weekly in the family home by 2 'preventionists' (therapists trained to deliver the intervention)
Module 1: Depression and family
Module 2: Psychoeducation about depression
Module 3:The child's perspective on their parent's depression
Module 4: Skills development
Module 5: Preparation for the family session
Module 6: Family session
Module 7: Revision and future planning
Follow-up"
1550681|NCT02593253|Other|Audit and Feedback Bundle|The intervention arm teams will receive the new audit and feedback bundle, which includes access to the electronic dashboard and weekly feedback rounds in which they review their performance on several inpatient quality metrics via the dashboard.
1550682|NCT02593253|Other|Bi-weekly audit and feedback emails|The control arm will undergo audit and feedback per the current system, which is biweekly feedback emails with performance on selected quality measures.
1550683|NCT02593240|Behavioral|The iDiet® with Food|Intensive iDiet group behavioral weight loss program delivered in-person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Ten participants per worksite per iDiet intervention arm will be randomized to receive commercial dried food products (partial supply) from Yevo Intl., which are designed to help with weight control and health.
1550684|NCT02593240|Behavioral|The iDiet® with Voucher|Intensive iDiet group behavioral weight loss program delivered in-person at the worksite or by videoconference and with support of the program's web platform. This intervention will be delivered by trained group leaders and will initially include weekly 1-hour support and education meetings of 20 participants/group with a message board for group communication and individual communication with the group leader. Over time support will be provided online rather than in live meetings. The intervention involves a weight loss behavioral program with particular emphasis on hunger reduction and craving control for both weight loss and prevention of weight regain. Ten participants per worksite per iDiet intervention arm will be randomized to receive gift cards monthly for the first 6 months to purchase foods at their local grocery store (partial costs).
1550685|NCT02593240|Behavioral|Human Performance Institute©|Human Performance Institute© (HPI) training workshop: Is comprised of a comprehensive individual development training program that focuses on the concept of energy management. The primary aim of this program is to help individuals develop attitudes, habits, and behaviors that increase their levels of daily energy, life satisfaction, and overall functioning. The course is delivered at an off-site location over 2.5 days, by 3 coaches, in a group format of 25 - 32 participants (with employees from more than one worksite per group).
1550686|NCT02593227|Biological|Low dose FRα vaccine|165ug per peptide ID injection
1550687|NCT02593227|Drug|Cyclophosphamide|IV infusion over 1 hour
1550688|NCT02593227|Biological|High dose FRα vaccine|500ug per peptide ID injection
1550689|NCT02593214|Device|Wondaleaf®|Use of Wondaleaf® during sexual intercourse with husband for 5 times in a month period
1550690|NCT02593201|Drug|Extended antibiotics (cefazolin or ceftazidime)|To continue with the existing effective antibiotic therapy for one extra week
1550691|NCT02593201|Drug|Usual antibiotics (cefazolin or ceftazidime)|Usual duration of effective antibiotic therapy therapy
1550693|NCT02593175|Drug|Panitumumab|One week before Cycle 1 participants receive a single dose of Panitumumab by vein. On Day 1, 8, and 15 of each 21 day cycle, participants receive Panitumumab 2.5 mg/kg by vein.
1550694|NCT02593175|Drug|Paclitaxel|On Day 1, 8, and 15 of each 21 day cycle, participants receive Paclitaxel 80mg/m2 by vein.
1550695|NCT02593175|Procedure|Biopsy|About 1 week after the first Panitumumab dose, participants have an image-guided core biopsy and/or a fine needle aspiration (FNA) to remove breast tissue.
1550696|NCT02593175|Drug|Carboplatin|On Day 1 of each 21 day cycle Carboplatin AUC 4 received by vein.
1550697|NCT02593162|Drug|Faldaprevir|
1550698|NCT02593162|Drug|TD-6450|
1550699|NCT02593162|Drug|Ribavirin|
1550700|NCT02593149|Device|ClearGuard HD End Cap|The ClearGuard HD end cap elutes chlorhexidine acetate into the hemodialysis hub
1550701|NCT02593136|Dietary Supplement|Home Fortification Product (HFP)|"The home fortification product (HFP) is a sachet containing multiple vitamins and nutrients as follows:
Iron (Ferrous Fumarate) 12.5 mg Zinc (Zinc Gluconate) 5 mg Folic Acid 0.160 mg Vitamin-A (Vit-A Acetate) 0.30 mg Vitamin-C (Ascorbic Acid) 30 mg Vitamin-B12 0.9 mcg Iodine 90 mcg Maltodextrin (Base)"
1550702|NCT02593136|Other|Infant and Young Child Feeding (IYCF) Practices Counseling|Infant and Young Child Feeding (IYCF) Practices Counseling provides direction on breast milk and milk feeding, food variety, and frequency for caregivers of children aged 6 to 18 months. Participants will be visited at least monthly by a field line worker for IYCF counseling and educational materials distribution.
1550703|NCT02593123|Drug|mycophenolate mofetil|Given PO, by mouth, orally or IV, intravenous medication administration.
1550704|NCT02593123|Biological|Sargramostim|"GM-CSF beginning post-transplant day 4 and continuing until hematopoietic reconstitution. Patients in the MMF-15 cohort will receive sargramostim (GM-CSF) 250 mcg/m2/day beginning on post-transplant day 4 and continuing until neutrophil engraftment.
Patients receiving GM-CSF will also receive inhaled corticosteroids, fluticasone (Flovent) 2 puffs twice daily, starting on post-transplant day 4 and stopping after cessation of GM-CSF, to diminish the risk of pneumonitis.
Note: At investigator discretion, patients in the MMF-15 cohort who have preexisting pulmonary risk factors, will be permitted to receive G-CSF."
1550740|NCT02592863|Drug|Pentoxifylline|Patients will take Trental (Pentoxifylline) 3 times per day for 12 weeks
1550706|NCT02593110|Behavioral|Supervised Treadmill Exercise Therapy|Participants randomized to the exercise intervention will receive supervised treadmill exercise three times weekly for six months.
1550707|NCT02593110|Drug|Telmisartan|Participants randomized to the telmisartan arm of the study will take 40 mg of telmisartan daily. Participants will have their dose increased to up to 80 mg as tolerated.
1550708|NCT02593110|Other|"No exercise control group"|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months.
1550709|NCT02593110|Drug|Placebo|
1550712|NCT02593084|Behavioral|Higher Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using multi-joint movements involving both upper and lower extremities (e.g squats). Participants will perform 3-5 sets of 3-6 repetitions at Rating of Perceived Exertion 8/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
1550713|NCT02593084|Behavioral|Lower Intensity Resistance Training|Bi-weekly resistance training for 12 weeks using single-joint movements involving both upper and lower extremities (e.g leg extension). Participants will perform 3-5 sets of 8-10 repetitions at Rating of Perceived Exertion 5/10. The intervention will be administered by a Physical Therapist or trained fitness professional.
1550714|NCT02593071|Biological|RSV-F Vaccine|
1550715|NCT02593071|Biological|Phosphate Buffer Placebo|
1550716|NCT02593058|Behavioral|Positive Emotions Program for Schizophrenia|Each session of PEPS includes relaxation-meditation exercise, review of homework task given during the previous session, exercises to challenge defeatist beliefs. According to the session's theme, participants learn skills to improve their anticipation or maintenance of pleasure such as savoring a pleasant experience, expressing emotions by increasing behavioral expression, capitalizing on positive moments, and anticipating pleasant moments. A simple homework task is assigned to be done between each session. The pedagogical concept underpinning the program was built according to Kolb and Kolb's model of experiential learning. The program uses a collaborative, egalitarian approach.
1550717|NCT02593058|Behavioral|Treatment As Usual|TAU consists of psychiatric management by a clinical team composed of at least one psychiatrist and a social worker and/or a psychiatric nurse with additional access to community treatment or hospital admission. Treatment involves antipsychotic medication, regular office-based or community contact with the clinical team for treatment monitoring, and socialization groups, therapy, and psychoeducational groups. No attempts have been made to standardize this treatment as TAU is tailored to the patient's specific needs.
1550718|NCT02593045|Biological|IPH4102|
1550720|NCT02593019|Drug|AZD1775|"AZD1775 175 mg BID per os every 12 hours (6 doses) administered days 1-3 the first week and then days 1-3 the 2nd week of 21 day cycle.
Tumour evaluation using RECIST 1.1 will be conducted at screening (within 28 days prior to first dose) and every 6 weeks relative to the date of first dose, up to week 42, then every 9 weeks until objective disease progression (within a window of +/- 7 days of the scheduled date)."
1550721|NCT02592993|Device|PicoWay device|The PicoWay base unit using a single, free-running, flashlamp-pumped alexandrite laser as a pump source for both the oscillator and the amplifier.
1550722|NCT02592980|Genetic|Pharmacogenetic anticoagulation|The investigators use a algorithm pharmacogenetic for adjust only the first dose in the study.
1550723|NCT02592980|Drug|Traditional anticoagulation|The physician will adjust the dose according to current INR value based on guidelines.
1550726|NCT02592954|Drug|Jojoba oil with broccoli sprout extract|500nmol of broccoli sprout extract in 1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
1550727|NCT02592954|Drug|Jojoba oil (placebo)|1ml of jojoba oil will be applied to the same arm every night under saran wrap for 1 week
1550728|NCT02592941|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
1550729|NCT02592928|Other|Inclusion of Spirometry into the Electronic Health Records|Inclusion of the Forced Spirometry into the Electronic Health Records
1550730|NCT02592915|Drug|Clonidine hydrochloride|Single bolus of clonidine hydrochloride 0.3µg/kg (max 150 µg/kg) administered IV after induction and obtaining a stable anaesthetic level
1550731|NCT02592915|Other|Single bolus of physiologic sodium chloride serum administered IV after induction and obtaining a stable anaesthetic level|
1550732|NCT02592902|Procedure|Surgical collection of histology specimen|Collection of a histology specimen from the vocal cords and rear laryngeal commissure
1550733|NCT02592902|Procedure|Performance of immunohistochemical analysis|Immunohistochemical analysis - presence of pepsin, HPV 6 and 11, HSV 2 and chlamydia trachomasis
1550734|NCT02592889|Device|MITRACLIP|MITRAL VALVE REPAIR WITH THE MITRACLIP SYSTEM
1550742|NCT02592850|Other|osteopathic manipulative treatment|"This intervention will not be protocol-based but the treating D.O. will compulsory have to include the evaluation (and possible treatment) of temporo-mandibular joint disorders and cervical dysfunctions (semi-structured treatment). Specifically, OMT will focus on correcting those osteopathic dysfunctions found during the initial evaluation; both structural (including myofascial release and HVLA), visceral and craniosacral techniques will be administered as appropriate.
Duration: 45 minutes. Administered once a week for four weeks."
1550743|NCT02592850|Other|sham|"In this intervention, the operator will be restricted to the assessment of the cranial rhythmic impulse (CRI), temporo-mandibular joint disorders and cervical dysfunctions, spending a similar amount of time to that being spent on OMT-treated patients. Any found osteopathic dysfunction will not be corrected.
Duration: 45 minutes. Administered once a week for four weeks."
1550744|NCT02592837|Device|Flexible 19G EBUS-TBNA needle|
1550745|NCT02592837|Device|21G EBUS-TBNA needle|
1550748|NCT02592811|Procedure|ERCP|Common bile duct cannulation with a cannulation catheter
1550749|NCT02592811|Procedure|Endoscopic Sphincterotomy|Endoscopic large sphincterotomy
1550750|NCT02592811|Device|Large Balloon Dilatation of Oddi Sphincter|Large Balloon Dilatation : with the HERCULES, Cook 12, 15, 18 or 20 mm of diameter (adapted to stone diameter)
1550751|NCT02592811|Procedure|Stone extraction|After dilatation, extraction of stones is done with dormia basket or extraction balloon and if not possible a mechanical lithotripsy is performed
1550755|NCT02592785|Drug|BAY1163877|"Cohort 1: Single dose 600 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose.
Cohort 2: Single dose 800 mg on day 1, no drug on day 2 and then twice daily administration of the same dose for the remaining 19 days of cycle 1. From cycle 2 onwards all subjects are continuously treated for 21 days per cycle with twice daily administration of the same dose."
1550756|NCT02592772|Other|Reduced Nicotine Non-Menthol (RNC)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield without menthol.
1550757|NCT02592772|Other|Reduced Nicotine Menthol (RNC-Men)|Switch from own brand of cigarette to an investigational tobacco product with a reduced nicotine content of 0.07mg nicotine yield with menthol.
1550758|NCT02592772|Other|Conventional Nicotine Non-Menthol (CN)|Switch from own brand of cigarette to an investigational tobacco product which contains conventional nicotine yield.
1550759|NCT02592759|Device|Smart Glove Treatment|Smart glove is digital motion-based treatment device for stroke rehabilitation. The stroke patients wear this glove and hand motion is displayed on the computer monitor. They play games with this glove and are motivated to rehabilitation treatment because of fun.
1550760|NCT02592746|Drug|Palbociclib|Palbociclib 125mg, orally once daily on D1 to D21 followed by 7days off
1550761|NCT02592746|Drug|Exemestane|Exemestane 25mg, orally once daily
1550762|NCT02592746|Drug|Leuprolide Acetate|GnRH agonist 3.75mg SC q 4weeks
1550763|NCT02592746|Drug|Capecitabine|Capecitabine 1,250mg/m2 bid orally form day1 to day 14 q 3weeks
1550764|NCT02592733|Device|CYDAR|CYDAR is an automated image mask that is cloud based adn delivered to operating theatres over a secure network. It fuses preoperative images with intraoperative images to provide more accurate image guidance for the surgeon.
1550765|NCT02592720|Drug|cocktail|Intracoronary cocktail injection before fractional flow reserve (FFR) measurement. Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
1550766|NCT02592720|Device|FFR|Percutaneous Coronary Intervention (PCI) strategy is decided by FFR value in patients with acute coronary syndrome (ACS).
1550767|NCT02592720|Device|QCA guided group|Percutaneous Coronary Intervention (PCI) strategy is decided by QCA value in patients with acute coronary syndrome (ACS).
1550768|NCT02592707|Drug|177Lu-OPS201|177Lu-OPS201 will be administered in 3 cycles at intervals of 8 weeks
1550769|NCT02592694|Drug|cocktail|Cocktail (tirofiban, bivalirudin, tenecteplase) will be given in addition to thrombus aspiration
1550770|NCT02592694|Device|thrombus aspiration|manual thrombus aspiration
1550771|NCT02592681|Procedure|verum acupuncture|"Participants will receive real needle insertion. Sterile needles will be used on all acupoints. The depth of insertion will vary from 15 mm to 20 mm depending on the exact locations. An initial manual stimulation will be given at insertion by rotation methods to produce a specific sensation described as de-qi in TCM. Then the needles will be left in the acupoint for 20 min, with a manual rotation at 4-8 Hz and an amplitude of approximately 0.5-2 rotations at a ten-min interval to maintain the sensation of de-qi. Primary acupoints used in the verum acupuncture group will be: LR3 (Taichong), LI4 (Hegu), SP6 (Sanyinjiao), GB20 (Fengchi). Extra acupoints will be selected based on TCM pattern are GB41 (Zulinqi), SP10 (Xuehai), KI3 (Taixi), or LR2 (Xingjian)."
1550772|NCT02592681|Procedure|acupressure|"The acupoints and the number of the sessions will be exactly the same as for the verum acupuncture group. Acupressure will be applied on all the corresponding acupoints described in the acupuncture group. Finger pressure will be applied to each acupoint for eight seconds followed by two-seconds rest, repeated for 3 min. The strength of the pressure depends on individual participant's sensation of de-qi. Duration of each session will be 15 min."
1550849|NCT02592239|Device|Functional brain MRI|Functional brain MRI before and after test meal ingestion
1550850|NCT02592239|Dietary Supplement|A warm ham and cheese sandwich and a 200 ml fruit juice|
1550851|NCT02592226|Procedure|Anesthesia: alveolar recruitment maneuver|
1550852|NCT02592226|Procedure|Anesthesia: standardized|
1550773|NCT02592681|Procedure|control acupuncture|The number, duration, and frequency of the sessions will be the same as for the verum acupuncture group. Sterile needles will be used on acupoints that have no therapeutic effect on either menstruation or migraines, based on the acupuncture text books and acupuncture research literature. The points chosen will be: LR7 (Xiguan), GB35 (Yangjiao), LI12 (Zhouliao), M-BW-1 (Dingchuan). The depth of needle insertion will be as superficial as 3 mm, and without manual rotation, in order to minimize stimulation of the needle.
1550774|NCT02592668|Device|Epidural Stimulator|Subjects will be implanted with an epidural stimulator onto the dorsal aspect of the lumbosacral spinal cord dura mater. Patients will undergo a structured program of daily physical rehabilitation, treadmill step training, and epidural stimulation to recover motor, sensory, and autonomic function.
1550775|NCT02592655|Device|Pneumatic Tourniquet|Automated pneumatic tourniquet, applied to middle upper thigh.
1550776|NCT02592655|Device|One Windlass Tourniquet|One Windlass Tourniquet 3.8 cm (1.5 inch) wide. A Special Operations Forces Tactical Tourniquet Wide (SOFTT-W) will be used for the windlass tourniquet. One windlass tourniquet will be applied to the middle upper thigh.
1550777|NCT02592655|Device|Two Windlass Tourniquets|Two Windlass Tourniquets will be applied by applying a second 3.8 cm (1.5 inch) wide windlass tourniquet immediately proximal to the first windlass tourniquet.
1550778|NCT02592655|Device|Tourniquet Tape 5 cm|Tourniquet Tape is 5 cm (2 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
1550779|NCT02592655|Device|Tourniquet Tape 10 cm|Tourniquet Tape is 10 cm (4 inch) in width. Tourniquet Tape is a highly elastic transparent occlusive material that can create circumferential pressure when stretched and wrapped around a limb. The tape should be stretched and overlapped by at least half the width as it is applied. The final wrap should be applied without tension.
1550780|NCT02592642|Behavioral|Self-management Program, Workbook, Video, Pedometer|Participants will attend 12 sessions over a six week period. The following therapies will be provided by licensed chiropractors: instruction on self-management strategies, cognitive behavioural techniques; exercise instruction, manual therapy. An instructional workbook and video will provide education and instruction on how to perform exercises, and reinforce instructions received during the sessions. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
1550781|NCT02592642|Behavioral|Instructional Workbook, Video, and Pedometer|Participants will attend one session with a chiropractor at the beginning of the six week treatment period. The chiropractor will provide and explain the instructional workbook and video. The workbook and video will provide education and instruction on how to perform exercises all aimed at improving overall fitness in the back and lower extremity and facilitate lumbar flexion. An exercise diary will outline the frequency and intensity of the exercises. All exercises will be performed twice per day at home with the number, intensity, and frequency increasing weekly. Participants will receive a pedometer and record the maximum number of continuous walking steps and time (minutes) to stop walking due to neurogenic symptoms weekly.
1550782|NCT02592642|Device|Para-spinal TENS|Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal musculature from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine (NeuroTrac TENS from Verity Medical Ltd U.K.) which will be worn by the subject concealed within a waist pouch. The TENS will be programmed for a frequency of 65-100 Hz modulated over 3-second intervals with a pulse width of 100-200 usec, and turned on 2 minutes before the start and during the SPWT. Current intensity will be set to the level of comfort of the patient, approximately 3 milliamps in pilot experiments, and below the level causing muscle twitch.
1550783|NCT02592642|Device|Para-spinal Placebo TENS|Group b: Participants randomized to this subgroup will have disposable self-adhesive electrical pads (Blue Sensor P, Ambu A/S, Denmark) applied over the para-spinal muscular from L3 to S1 by a licensed chiropractor. The electrical pad electrodes will be connected to a TENS machine [NeuroTrac TENS from Verity Medical Ltd (U.K.)] which will be worn by the subject concealed within a waist pouch. The TENS will be programmed using a transient placebo frequency and intensity (45) i.e. the unit will be active for the first 30 seconds then ramping down to zero stimulus over 15 seconds and worn from 2 minutes before the start and during the Self-Paced Walk Test (SPWT).
1550784|NCT02592642|Device|Prototype Spinal Stenosis Belt|Participants randomized to this subgroup will be fitted with the prototype spinal stenosis belt by a licensed chiropractor. The belt is designed as garment that will snugly fit over the sacrum and pelvic girdle with a pump that place pressure over the sacrum aimed at reducing lordosis.
1550785|NCT02592642|Device|Sham Spinal Stenosis Belt|Participants randomized to this subgroup will have a standard lumbar support belt (Tensor Adjustable Back Brace from 3M, 207744) fitted around the lumbar spine above the iliac crest comfortably according the manufacturer's instructions for wear. We speculate that the placement of the stenosis belt around the lumbar spine should not have any impact on the lumbar lordosis.
1550786|NCT02592629|Drug|lidocaine|used with Kenalog in shoulder injection and as topical anesthetic as subcutaneous injection
1550787|NCT02592629|Drug|ethyl chloride|topical spray
1550788|NCT02592629|Drug|Kenalog|used with lidocaine in shoulder injection
1550789|NCT02592616|Behavioral|CON|No exercise intervention.
1550790|NCT02592616|Behavioral|CW|One hour of continuous walking on a treadmill.
1550791|NCT02592616|Behavioral|IW|One hour of interval (repeated cycles of 3 minutes of fast and 3 minutes of slow) walking on treadmill.
1550792|NCT02592603|Device|Endocuff-assisted Colonoscopy|Colonic examination with Endocuff-assisted Colonoscopy
1550815|NCT02592447|Other|Therapy for Targeted Therapy-related Fatigue (TTF)|Cognitive Behavior Therapy for Targeted Therapy-related Fatigue (CBT-TTF) group will receive cognitive behavior therapy to help manage fatigue via FaceTime on an iPad, which will be provided to participants. Participants will meet with a trained therapist who will outline their therapy plan and will be taught how to use the iPad for upcoming therapy sessions. The sessions will initially be held weekly, but the therapist may schedule sessions at 1-, 2-, or 3-week intervals during the 18 week study period. The final session will be conducted either in-person at Moffitt or via FaceTime.
1550793|NCT02592590|Behavioral|Group A|"This condition receives three study components:
The base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, quiz questions), activity tracking, and graphical feedback.
The guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription.
The points-based feedback module. For each action in the app (e.g., setting goals, achieving goals, viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser)."
1550794|NCT02592590|Behavioral|Group B|"This condition receives two study components:
The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.
The second is the guided goal-setting module within the app that utilizes participant activity preferences and experiences, as well as performance within the program to guide the setting of high-quality short and long-term physical activity goals. These goals form the basis of the physical activity prescription."
1550795|NCT02592590|Behavioral|Group C|"This condition receives two study components:
The first is the base-level of the smartphone app, which contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback.
The second is the points-based feedback module. For each action in the app (e.g., viewing weekly videos, answering quiz questions, tracking activity), a number of program points is awarded. These are weighted by task difficulty, and accumulate to earn levels. Levels accumulate to earn badges depicting an avatar becoming increasingly healthy and active. Badges accumulate to earn titles (e.g., expert exerciser). As the intervention is goal drive, these participants will also receive printed goal setting worksheets."
1550796|NCT02592590|Behavioral|Group D|This condition receives only the base-level smartphone app. This contains health-related educational content (i.e., weekly videos, additional resources, brief quiz questions), behavioral tracking, and instantaneous graphical feedback. As the intervention is goal drive, these participants will also receive printed goal setting worksheets.
1550798|NCT02592564|Behavioral|Internet-delivered cognitive behavior therapy|Internet-delivered cognitive behavior therapy for social anxiety disorder. Similar to previous studies in our research group, the treatment will be delivered during 9 weeks. Each week the participant will be introduced to a module containing text material and homework assignments. The participants will receive feedback via text by a clinical psychologist once a week.
1550802|NCT02592538|Device|radiofrequency ablation|All patients underwent biliary sphincterotomy. Cholangiogram was performed to confirm stricture location, length and diameter. The Habib Endo HPB (Hepatobiliary) probe (EMcision, HitchinHerts, UK) was then advanced over a wire at the level of the biliary stricture and ablation using ERBE generator set at 7-10 watts for a time period of 90-120 s was conducted. A 1- to 2-min resting period after energy delivery was allowed before moving the catheter along the length of the stricture to ablate the rest of the stricture.
1550803|NCT02592538|Drug|S-1|In the RFA plus S-1 group, treatment with S-1 began within 1 month after RFA. Based on the patient's body surface area, S-1 was administered as follows: when the level of total bilirubin was less than 2 mg/dl. Based on the body surface area, S-1 was administered if <1.25 m2, 80 mg/day; if 1.25-1.5 m2, 100 mg/day; if≥1.5 m2, 120 mg/day. S-1 was administered orally twice daily for 14 days, followed by 7 days without treatment.
1550804|NCT02592538|Device|Stent|Plastic stent(s) were placed after RFA depending on the location of the malignant obstruction
1550806|NCT02592512|Other|NIV-NAVA|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
1550807|NCT02592512|Other|NIV-PS/PC|Cross-over study where participants are randomized to start with either NIV-NAVA or NIV-PS/PC for 4 hours, followed by another 4 hours with the other arm.
1550808|NCT02592499|Device|HM III|
1550809|NCT02592499|Other|OMM, optimal medical management|Patients randomized to OMM will be treated according to international guidelines. All patients should receive a beta blocker, an ACE-inhibitor or an Angiotension II receptor blocker, and a mineralocorticoid receptor antagonist if tolerated and at optimally titrated doses according to guidelines. Loop diuretics should also be used as needed to control fluid retention. Other drugs that may relieve symptoms and improve prognosis can be used (incl ivabradin, digoxin, hydralazine,isosorbiddinitrate, anticoagulant agents). Patients that have an indication for implantable cardioverter defibrillator (ICD) and/or cardiac resynchronization therapy (CRT) should receive such therapy. Surgical interventions that may be indicated for specific underlying or contributing causes of heart failure.
1550812|NCT02592473|Device|Embozene Microspheres|Minimally invasive intra-arterial administration of particle embolics into prostate arteries under fluoroscopy and cone-beam CT imaging guidance.
1550847|NCT02592252|Behavioral|Participatory gender training|10 sessions of participatory gender training
1550848|NCT02592252|Other|Microfinance|Microfinance loan
1550816|NCT02592447|Other|Wait-List Control Condition (WLC)|Participants randomized to Wait-List Control Condition will continue to receive care under direction of their Moffitt Cancer Center (MCC) physician. Physicians will be informed by email of patients' participation on the basis of elevated fatigue and their randomization to WLC. Chart review and a patient self-report form will be used at baseline and follow-up assessments to determine what, if any, services or interventions participants received in the preceding 18 weeks that might address fatigue.
1550819|NCT02592421|Drug|Dapagliflozin|SGLT2 inhibitor (dapagliflozin)
1550820|NCT02592421|Drug|Placebo|Placebo Comparator
1550821|NCT02592408|Drug|ASP|3 days of artesunate sulfadoxine/pyrimethamine on days 0-2
1550822|NCT02592408|Drug|SDPQ|single dose primaquine on day 2
1550823|NCT02592408|Drug|14DPQ|14 day primaquine starting on day 2
1550824|NCT02592408|Drug|14DPQ on Day 42|14 day primaquine starting on day 42
1550827|NCT02592382|Dietary Supplement|Xylitol spray|xylitol nasal spray will be administered to this arm three times daily for two months
1550828|NCT02592382|Other|Isotonic saline spray|saline nasal spray will be administered to this arm three times daily for two months
1550829|NCT02592369|Device|Medtronic CoreValve™ Evolut R™ System|The Evolut R System is intended for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a heart team, to be at high or extreme risk for open heart surgery. The Evolut R TAV treats aortic stenosis by displacing and functionally replacing the dysfunctional native valve with a bioprosthetic valve delivered on a catheter while the heart is still beating, thus avoiding the risks of cardiopulmonary bypass. Its intended performance is to relieve aortic valve stenosis without inducing significant regurgitation, thereby restoring effective aortic valve function.
1550830|NCT02592356|Other|Strength and Balance Tests|"Participants have basic tests of their physical strength and balance. Participant's hand grip strength measured. Participant asked to rise from a chair without using their arms to push off, and they will complete a 6-minute walk test.
Tests performed at baseline, and at months 3, 6, and 12."
1550831|NCT02592356|Procedure|Dual-Energy X-Ray Absorptiometry (DXA) Scan|DXA full body scan performed at baseline, and at months 3, 6, and 12.
1550832|NCT02592356|Behavioral|Questionnaires|"Questionnaires completed about any pain or other symptoms participant may have had; about any gastrointestinal (GI) side effects they may be having before starting chemotherapy; about the amount of physical exercise and activity they get; and about their food intake over the last 24 hours.
Questionnaires completed at baseline, once a week during months 1, 2, and at months 3, 4, 5, 6, and 12."
1550833|NCT02592356|Drug|Cabozantinib|After the baseline visit, participant starts receiving either Cabozantinib or Lenvatinib according to the treatment plan from their doctor.
1550834|NCT02592356|Other|Body Measurements and Weight|Participant's weight, height, hip and waist circumference measurements done at baseline and repeated at every study visit
1550835|NCT02592356|Drug|Lenvatinib|After the baseline visit, participant starts receiving either Cabozantinib or Lenvatinib according to the treatment plan from their doctor.
1550836|NCT02592343|Biological|Lyophilized Fecal Microbiota Transplantation|
1550837|NCT02592330|Biological|CALEC|Cultivated autologous limbal epithelial cell (CALEC) therapy utilizes a bio-engineered composite of ex vivo expanded autologous corneal epithelial cells and an FDA-approved amniotic membrane (AmnioGraft®, Bio-Tissue, Inc.) to reconstruct the ocular surface. A small biopsy (2-3 mm2) from the patient's contralateral eye serves as a source epithelial (stem) cells that are expanded on the amniotic membrane in culture and the resulting product is surgically transplanted onto the cornea after excision of the fibrovascular pannus.
1550838|NCT02592330|Procedure|CLAU|Donor tissue is obtained from the fellow eye (limbal autograft) with the goal of transplantation of a new source of epithelium for a diseased ocular surface after the removal of the recipient's scarred and diseased epithelium.
1550839|NCT02592317|Drug|JNJ 56021927|JNJ 56021927 will be adminitered once daily orally in a dose of 240 mg from Study Day 15 up to disease progression, unacceptable toxicity, withdrawal of consent, lost to follow-up, the participant is no longer receiving clinical benefit in the opinion of the Investigator, the start of subsequent anticancer therapy, or the Sponsor ends the study.
1550840|NCT02592317|Drug|Drug Cocktail|Drug cocktail comprise of midazolam (2 mg), warfarin (10 mg), vitamin K (10 mg), omeprazole (40 mg), and fexofenadine (30 mg) will be administerd on Study Day 1 and 43.
1550841|NCT02592317|Drug|Pioglitazone|Pioglitazone 15 mg will be administered orally on Study Day 8 and 50.
1550842|NCT02592317|Drug|Rosuvastatin|Rosuvastatin 15 mg will be administered orally on Study Day 9 and 51.
1550843|NCT02592304|Device|Dual energy computed tomography|one extra scanning with a dual energy ct.
1550844|NCT02592291|Device|MHealth|The Mhealth system consists of a suite of apps to support participants manage their self-care and the clinician portal. Participants will use the system for 1 year.
1550845|NCT02592278|Drug|Fluoride Varnish|Application of fluoride varnish every 3 and 6 months.
1550846|NCT02592278|Drug|Control Group|Twice a day brush with fluoride toothpaste.
1550853|NCT02592213|Procedure|Cell-assisted lipotransfer|Stromal vascular fraction, autologous. Isolated using Celution System (Cytori)
1550854|NCT02592200|Dietary Supplement|Lactobacillus gasseri DSM 27123|109 CFU (divided in two doses) per day for 28 days
1550855|NCT02592200|Dietary Supplement|Placebo|Two doses per day for 28 days
1550856|NCT02592187|Behavioral|ReMemory-MCI|
1550857|NCT02592187|Behavioral|Active control training|
1550858|NCT02592174|Other|Health related quality of life and social and demographic informations|At the inclusion visit with a self-assessment questionnaire
1550859|NCT02592174|Other|Neurocognitive assessment|At the neurocognitive visit, with standard test as CONSTANCES cohort
1550860|NCT02592174|Radiation|cerebral images sub-study|Standard magnetic resonance imaging
1550861|NCT02592161|Drug|Experimental|"Test drug : Granules, Chung A Won 3g (Eucommiaceae, Psoralea corylifolia, Walnut, Ginger) Three times a day, oral administration for 24weeks
Reference drug : Granules, Placebo 3g (Lactose hydrate, Corn starch, Caramel pigment)
Three times a day, oral administration for 24weeks"
1550862|NCT02592135|Other|hsTnT level|hsTnT and NTproBNP levels at baseline and baseline plus 3 hours.
1550863|NCT02592122|Drug|Salbutamol Aerosol|
1550864|NCT02592122|Drug|No drugs|
1550865|NCT02592109|Behavioral|Enhanced Counseling using CFR based on Linear Programming|
1550866|NCT02592096|Drug|0.1% Pazufloxacin Mesilate Ear Drops|
1550867|NCT02592096|Drug|0.3% Pazufloxacin Mesilate Ear Drops|
1550868|NCT02592096|Drug|0.5% Pazufloxacin Mesilate Ear Drops|
1550869|NCT02592096|Drug|Pazufloxacin mesilate injection|
1550870|NCT02592083|Drug|Tamoxifen or Aromatase Inhibitor or Aromatase Inhibitor + goserelin|
1550871|NCT02592083|Drug|Palbociclib|
1550872|NCT02592070|Behavioral|Walking|Participants will walk on the treadmill for 30 minutes at a moderate intensity.
1550873|NCT02592057|Drug|SOF|SOF tablets administered orally once daily based on approved prescribing information
1550874|NCT02592044|Procedure|peripheral venous cannulation|The 18 gauge venous cannula will be inserted in a peripheral vein on the back of right hand of the patient.
1550875|NCT02592044|Procedure|Aromatherapy with lavender essential oil|The two drops of lavender essential oil will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
1550876|NCT02592044|Procedure|Placebo|The two drops of water will be dropped into the gauze and the patient will inhale it for 5 minutes and during venous cannulation.
1550877|NCT02592031|Drug|XM17|300 IU corresponds to an injection volume of 0.5 mL.
1550878|NCT02592031|Drug|Gonal-f®|300 IU corresponds to an injection volume of 0.5 mL.
1550879|NCT02592031|Drug|Zoladex®|3.6 mg
1550880|NCT02592018|Drug|Secukinumab|Secukinumab 300mg SQ at weeks 0, 1, 2, 3, 4, and every 4 weeks thereafter until week 48. Skin biopsy procedures will be performed at weeks 0, 2, 4, and 12.
1550881|NCT02592005|Other|amount of fine dust and other environmental exposure|this study compares levels of exposure to to fine dust PM 2.5 by individual measurement both at home and at work
1550882|NCT02591992|Other|Cardiac CT as the first diagnostic modality in suspected CAD|Performation of non-invasive cardiac CT angiogram
1550883|NCT02591992|Other|Invasive coronary angiography as indicated by the guidelines|Patient undergoes invasive coronary angiography
1550884|NCT02591953|Procedure|Ultrasound-guidance|Using ultrasound-guidance to perform a corticosteroid injection
1550885|NCT02591953|Procedure|Landmark-guidance|Using landmark-guidance to perform a corticosteroid injection
1550886|NCT02591953|Drug|Methylprednisolone|Corticosteroid used in injection (40 mg)
1550887|NCT02591953|Drug|Lidocaine 1%|Anesthesic used in injection
1550888|NCT02591940|Procedure|Surgery or Treatment by Heart Catheter|
1550889|NCT02591927|Drug|Glucose-Insulin-Potassium|Rackley's GIK formula by continuous I.V. infusion at 1.5 ml/Kg/hour for 12 hours (about 100 ml/hour for a 70 kg patient).
1550890|NCT02591927|Drug|Glucose 5%|Glucose 5% (Placebo) by continuous I.V. infusion at 1.5ml/kg/hour for 12 hours (about 100 ml/hour for 70 Kg patient)
1550891|NCT02591914|Drug|Fovista™|Anti-PDGF-B pegylated aptamer
1550892|NCT02591914|Drug|Lucentis®|Anti-VEGF
1550893|NCT02591914|Drug|Avastin®|Anti-VEGF
1550894|NCT02591914|Drug|Eylea®|Anti-VEGF
1550895|NCT02591901|Drug|Uro vaxom|Prevention of recurrent lower urinary tract infections
1550896|NCT02591901|Other|Placebo comparator|Placebo comparator
1550897|NCT02591888|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of normal saline injected.
1550898|NCT02591888|Drug|Liposomal bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have the 30ml of dilutional liposomal bupivacaine injected.
1550899|NCT02591862|Drug|Coversin|Patients enrolled in this protocol will initially be treated with an ablating dose of Coversin and daily repeat maintenance doses calculated according to body weight, the ablating dose to be 0.57mg/kg. Thereafter the daily repeat dose will be titrated according to clinical response and complement inhibition determined by CH50 ELISA. The initial repeat dose will be 25% of the ablating dose and this will be adjusted up or down if necessary once steady state is reached (5 days).
1550900|NCT02591849|Dietary Supplement|Glucagon-like peptide-1 (GLP-1)|
1550901|NCT02591849|Other|Isotonic saline|
1550902|NCT02591849|Other|Hyperglycemic clamp|
1550903|NCT02591836|Drug|Gemcabene|Gemcabene
1550904|NCT02591836|Drug|Atorvastatin|Atorvastatin
1550905|NCT02591836|Drug|Placebo|
1550906|NCT02591810|Procedure|Serial casting/splinting|Serial Casting involves applying and removing a series of lightweight casts made of fiberglass. The wrist is monitored as healing occurs.
1550907|NCT02591810|Procedure|Percutaneous fixation|Injury is treated by the percutaneous placement of Kirschner wires to promote healing. This is an invasive procedure, involving the placement of Kirschner wires to stabilize the wrist.
1550908|NCT02591810|Procedure|Foveal repair|Injury is treated by open anatomic foveal repair of the ligaments. This is a surgical procedure.
1550909|NCT02591797|Procedure|inferior alveolar and lingual nerve block procedure|"The needle is inserted laterally to the pterygomandibular pit at its deepest point without noticing any resistance. In children the positioning of the syringe must be perpendicular, between the canine and the first molar on the opposite side and puncture is performed slightly below the occlusal plane. It was initially deposited 2/3 anesthetic carpule solution and then the needle is slightly recede depositing there the remaining third of anesthetic solution.
The application of anesthesia shall be in accordance with the following guidelines:
Topical Anesthetic: Benzocaine 20% (Hurricaine, Clarben Laboratories SA, Madrid, Spain).
Dental Needle: short needles (21mm/30g) (Octoplus, Clarben Laboratories SA, Madrid, Spain)
anesthetic: lidocaine hydrochloride 2% with epinephrine 1: 100,000 (2% XILOCAINE, Dentsply, Spain).
Syringe: carpule syringe-conventional harpoon with suction system."
1550910|NCT02591784|Drug|Nimotuzumab|the nimotuzumab treatment; 200mg/w,weekly,5-6 weeks.
1550911|NCT02591784|Radiation|Radiotherapy|the Radiotherapy treatment;95%PTV A dose of 50-60Gy will be administered in 25-30 fractions ( 2 Gy /fraction)
1550912|NCT02591771|Drug|adrenaline|i.v. adrenaline infusion as an early and fast haemodynamic stabilizer, associated with a tight tissue perfusion monitoring, in the context of a stepwise progression in the treatment of cardiogenic shock, including ventricular mechanical support
1550913|NCT02591758|Device|Hexoskin Vest|The Hexoskin vest will be used at home to monitor the patient before and after the coronary angiography, during a treadmill test and during a home cardiac rehabilitation program.
1550914|NCT02591758|Behavioral|Cardiac rehabilitation program|A 6 sessions home cardiac rehabilitation program will be prescribed to the patient 2 to 4 weeks after the coronary angiogram. Those sessions will take place under Hexoskin surveillance. One session will take place at our specialized institution and six sessions will take place at home over the time span of two to three weeks.
1550915|NCT02591758|Other|Anxiety assessment as determined by the GAD-7|Anxiety assessment using the General Anxiety Disorder (GAD-7) scale, at the end of the study, to see if the Hexoskin relieved the anxiety patients can feel at home when exercising after a percutaneous coronary intervention.
1550916|NCT02591758|Other|Angina assessment with the angina diary, the SAQ and the SF-36|
1550917|NCT02591758|Other|Exercise stress test|Using the RAMP protocol before and after the coronary intervention, under Hexoskin surveillance.
1550918|NCT02591758|Other|Holter monitoring|24-hour Holter monitoring before and after the coronary angiogram with simultaneous Hexoskin reading.
1550919|NCT02591745|Procedure|Fetal intervention|Type of fetal conditions requiring intervention and medications administered to fetuses undergoing varying types of fetal intervention will be documeted in this database.
1550920|NCT02591719|Device|MagPro magnetic stimulator (HF rTMS)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the true coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
1550921|NCT02591719|Device|MagPro magnetic stimulator (sham)|Most activated area from fNIRS findings: Perilesional Broca's area. Use the sham coil. High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
1550922|NCT02591719|Device|MagPro magnetic stimulator (LF rTMS)|"Most activated area from fNIRS findings: Contralesional homologs of Broca's area.
Use the true coil. Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session"
1550923|NCT02591706|Device|MIS Implants|The implantation procedure will be carried out according to a standard surgical protocol, and according the manufacture protocol. Patient will be randomly assigned to one of the two groups after flap opening. The implant stability will be measured using the wench key and recorded in N/cm. The implants will be covered with healing abutments for trans-gingival healing for a period of 4 months. The area will be sutured with thin nylon sutures for a primary passive fit closure. Immediately after the surgery the patient will perform a CBCT of the treated area with a cotton roll on the buccal side in order to be able to evaluate the buccal soft tissue thickness.
1550924|NCT02591693|Behavioral|Caregiver training|Occupational therapy training focuses on improving confidence to manage practical aspects of care in areas of daily life important to patient and caregiver, in which caregiver reports or anticipates low levels of confidence.
1550925|NCT02591680|Other|Neuromuscular training|
1550926|NCT02591680|Other|Muscle strengthening|
1550927|NCT02591680|Device|Sensorimotor|
1550928|NCT02591667|Procedure|Upfront staging laparoscopy + peritoneal biopsy|Upfront staging laparoscopy with biopsy of peritoneal tumor deposits, assessment of peritoneal cancer index and resectability.
1550929|NCT02591667|Drug|Neoadjuvant chemotherapy with FOLFOXIRI + bevacizumab|"Patients will receive 4 cycles of FOLFOXIRI + bevacizumab; the last cycle will be given w/o bevacizumab
Dosage: Bevacizumab: 5 mg/kg via 30 min. IV infusion, day 1; Oxaliplatin: 85 mg/m2 via 2-hour IV infusion, day 1; Irinotecan: 165 mg/m2 via 1-hour IV infusion, day 1; Leucovorin: 200 mg/m2 via 2-hour IV infusion, day 1; 5-Fluorouracil: 3200 mg/m2 via 48-hour IV infusion, day 1;"
1550930|NCT02591667|Procedure|Surgical re-exploration|Three to 5 weeks after completion of FOLFOXIRI + bevacizumab chemotherapy, patients will undergo surgical re-exploration with the intent to perform a complete surgical cytoreduction. Further chemotherapy according to the currently available treatment guidelines, including intraperitoneal hyperthermic chemotherapy in patients where complete surgical cytoreduction has been achieved, may be given at the discretion of the investigator. Systemic chemotherapy may be started beginning 4 weeks post-surgery and after complete wound healing.
1550933|NCT02591641|Device|Anti-shear mattress overlay|A commercial full-length LiquiCell® anti-shear mattress overlay (ASMO) was placed on the standard ambulance stretcher mattress.
1550934|NCT02591641|Other|Standard of Care|Standard ambulance stretcher mattress
1550936|NCT02591615|Drug|MK-3475|Dose frequency of Q3W, Day 1 of each cycle
1550937|NCT02591615|Drug|Carboplatin|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
1550938|NCT02591615|Drug|Paclitaxel|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
1550939|NCT02591615|Drug|Pemetrexed|Dose frequency of Q3W, Day 1 of each cycle (standard Chemotherapy)
1550940|NCT02591602|Other|Teleradiology Service|Teleradiology Service at home or in nursing homes
1550941|NCT02591589|Other|Normoxic oxygenation|FiO2 set at 0.35 to maintain PaO2 > 70 mmHg or oxygen saturation greater than or equal to 92%.
1550942|NCT02591589|Other|Hyperoxic oxygenation|FiO2 set at 1.0 throughout the procedure
1550943|NCT02591563|Other|procedures|Throat swab, nasopharyngeal swab, tympanocentesis (if acute otitis media occurs)
1550944|NCT02591537|Device|OxyGenesys Dissolved Oxygen Dressing|1/2 of the abdominal wounds will be covered with Oxygenesys Dissolved Dressing.
1550945|NCT02591524|Other|Bronchoalveolar and Nasal Lavage|A previously scheduled flexible bronchoscopy via the nasal route on the date of baseline visit combined with a nasal lavage and another nasal lavage after 6 month
1550946|NCT02591511|Device|smart phone and pad|The mobile include the smart phone and pad, that can download the APP from internet.
1550947|NCT02591511|Other|stroke education handbook|
1550948|NCT02591498|Behavioral|Computerized cognitive training|
1550949|NCT02591485|Behavioral|Attention Control Training|In the ACT, participants perform six computerized attention training sessions, 10 minutes per training session over six weeks. In each session the dot-probe task is administered. This task is consisted of 160 trials. Each trial began with a centrally-presented fixation cross that then replaced by a pair of words presented. Following that, a target probe appeared in the location previously occupied by one of the words, and participants are requested to discriminate the probe type via button press. Targets appear with equal probability at the location of threat and neutral stimuli, in order to modify the fluctuations in attention allocation.
1550960|NCT02591459|Other|Using the app to assist routine anticipation|Using the app to assist routine anticipation for autistic children in Android mobile devices
1550961|NCT02591433|Other|Tobacco Cessation Counseling|Undergo JeffQuit group therapy
1550962|NCT02591433|Other|Support Group Therapy|Undergo JeffQuit group therapy
1550963|NCT02591433|Other|Quality-of-Life Assessment|Ancillary studies
1550964|NCT02591420|Biological|VRC01|40 mg/kg of VRC01 will be administered as an intravenous infusion over 60 minutes using a volumetric pump
1550965|NCT02591420|Biological|Placebo for VRC01|Administered as an intravenous infusion over 60 minutes using a volumetric pump
1551028|NCT02590965|Drug|Placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/1 week off
1550966|NCT02591420|Drug|Antiretroviral therapy (ART) (regimen will vary within countries and by patient)|ART is provided by the study sites and consists of country guideline-recommended first line once-daily oral combination therapy: either efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg or efavirenz 600 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg. This initial ART regimen may be adjusted or switched to an alternate regimen as clinically indicated for regimen intolerance or failure.
1550967|NCT02591407|Procedure|TAP Block|This is a one time injection of Exparel in the plane between the internal oblique and transversus abdominis muscles
1550968|NCT02591407|Procedure|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion
1550969|NCT02591394|Behavioral|STEP Clinic|Patients will visit with STEP clinic staff (including a stroke nurse practitioner or stroke doctor) to receive personalized goals, stroke education (including diet and exercise), instructions to self-monitor using blood pressure cuff, and prescription medications Patient will be scheduled for additional clinic follow-up or be contacted for telephone follow-up for management of your blood pressure. Questionnaires will be administered to determine medication adherence and persistence (following instructions for prescribed medication), disability, depression, cognition, self-efficacy, and sleep apnea. The care plan determined by the STEP clinic will be shared with the patient's primary care provider.
1550970|NCT02591394|Behavioral|Usual Care|"Patients will complete questionnaires related to medical history and health behaviors prior to initial visit.
After being seen by the stroke neurologist, patients may be scheduled to return to the stroke clinic according the doctor's recommendations.
Recommendations for blood pressure and risk factor monitoring will be sent to primary care providers."
1550971|NCT02591381|Procedure|Artificial Urinary Sphincter Placement|The AUS is the gold standard for treatment of severe stress urinary incontinence, particularly in patients following surgical resection of the prostate for prostate cancer. AUSs are small devices that prevent urinary flow via compression of the urethra, thus mimicking the native urinary sphincter.
1550972|NCT02591368|Procedure|Ligament reconstruction tendon interposition|In this procedure the trapezium is removed and one of the patient's own tendons (or portion of the tendon), usually the flexor carpi radialis or abductor pollicis longus, is passed through a drill hole in the thumb metacarpal and is used to suspend the first metacarpal base.
1550973|NCT02591368|Procedure|Suspensionplasty with one-suture construct|In this procedure the trapezium is removed and an Arthrex mini tightrope system using Fiberwire suture is drilled across the first metacarpal to the second metacarpal and is used to suspend the first metacarpal base instead of a tendon.
1550974|NCT02591368|Procedure|Suspensionplasty with two-suture construct|In this procedure the trapezium is removed and two Arthrex mini tightrope systems using Fiberwire sutures are drilled across the first metacarpal to the second metacarpal and are used to suspend the first metacarpal base instead of a tendon.
1550977|NCT02591329|Behavioral|Mail-out hard copy materials (education plus self-regulatory strategies examples)|
1550978|NCT02591329|Behavioral|Standard Care|
1550979|NCT02591316|Other|no intervention|
1550980|NCT02591303|Other|Stress reactions measurement during stressful and neutral driving sessions|Stress effects will be measured during 3 driving sessions (training without events on Day 17, with neutral events on Day 18, with stressful events on Day19), through nighttime PSG and questionnaires.
1550982|NCT02591277|Drug|Harvoni|Harvoni (90/400 mg) FDC tablet administered orally once daily
1550983|NCT02591264|Other|Blood sample|Blood sample drawn from participants for analysis of neutrophil peptide level
1550984|NCT02591251|Drug|Povidone-iodine solution|
1550985|NCT02591251|Drug|Normal saline solution|
1550986|NCT02591238|Other|non-smoker oral placebo|Participants oral placebo last 2 weeks.
1550987|NCT02591238|Drug|non-smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
1550988|NCT02591238|Other|smoker oral placebo|Participants oral placebo last 2 weeks.
1550989|NCT02591238|Drug|smoker oral melatonin|Participants oral melatonin 3 mg/day last 2 weeks.
1550990|NCT02591225|Drug|Dabigatranetexilate|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
1550991|NCT02591225|Drug|Phenprocoumon|After inclusion of the subjects with LA thrombus, they are treated according to the randomization either with Dabigatran (150 mg bid) or Phenprocoumon (INR adjusted once) for the treatment period of 12 months.
1550992|NCT02591212|Behavioral|Green Dot|Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.
1550993|NCT02591212|Behavioral|Wellness Initiatives for Student Empowerment|Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
1550994|NCT02591199|Drug|URG101|
1550995|NCT02591199|Drug|Placebo|
1550996|NCT02591199|Drug|Lidocaine|
1550997|NCT02591199|Drug|Heparin|
1550999|NCT02591173|Drug|Angiotensin-(1-7)|This is a biologically active endogenous angiotensin peptide. It may play an important role in the regulation of blood pressure by dilating blood vessels.
1551000|NCT02591173|Drug|Saline|Normal saline will be used as the placebo comparator.
1551001|NCT02591160|Procedure|HCTZ cessation|Patients will stop taking their HCTZ for 3 months
1551002|NCT02591147|Drug|Silver Diamine Fluoride 38%|Group 1 (SDF group) subjects will receive the application of silver diamine fluoride (38% SDF solution) in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
1551003|NCT02591147|Drug|Group 2 (Placebo)|Group 2 (Placebo) subjects will receive application of sterile water in addition to 5% Fluoride varnish to each approximal incipiency, using super floss, for a duration of 3 minutes under rubber dam isolation.
1551004|NCT02591134|Other|Non Nutritive Sweetened Beverages|Non-nutritive sweeteners (NNS) beverages encompass a range of carbonated and still drinks with added artificial sweeteners. Participants will be provided with a list of permitted beverages and are expected to consume at least two portions (330ml) per day.
1551005|NCT02591134|Other|Control|Water beverages provided in 330ml portions to be consumed twice per day over the duration of the trial
1551006|NCT02591108|Device|Neuromuscular Block Aid|Neuromuscular Block Aid, is a quantitative mechansim for collecting the the train-of-four and can be kept in an electronic medical record, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
1551007|NCT02591108|Device|Standard of Care: Microstim Plus|A peripheral nerve stimulator, also known as a train-of-four monitor, is used to assess neuromuscular transmission when neuromuscular blocking agents (NMBAs) are given to block musculoskeletal activity. By assessing the depth of neuromuscular blockade, peripheral nerve stimulation/monitoring can ensure proper medication dosing and thus decrease the incidence of side effects. Peripheral nerve stimulation is most commonly used for ongoing monitoring in the intensive care unit (ICU).
1551008|NCT02591095|Drug|ABT-263|
1551009|NCT02591082|Device|RenovoCath™ R120 Catheter|The RenovoCath™ RC120 Catheter will be used to isolate segments of arteries supplying blood to the pancreas. The two balloons on the catheter will be positioned and inflated to temporarily stop blood flow while medication is infused through the catheter between the balloons.
1551010|NCT02591069|Device|stimulation device|All patients included in the study will undergo baseline assessment of all measures before surgery (implantation of a vagus nerve stimulation device). A second baseline assessment will take place after surgery, before the beginning of the stimulation. Stimulation intensity will start at 0.25mA and increase progressively by 0.25mA each week until reaching 1mA. Then, intensity will be set at 1.5mA (recommended by manufacturer) and will stay to this level until the end of the trial. Experimenters will keep the right to modify these parameters depending on patients' reaction to the treatment.
1551011|NCT02591056|Device|Erchonia® Verju™ Laser|There are 12 procedure administrations with the Erchonia® Verju™ Laser across 6 weeks: 2 procedures per week. For each procedure administration, the Erchonia Verju is applied to the midsection for 30 minutes: 15 minutes to the front and 15 minutes to the back. All subjects receive the active Erchonia Verju Laser treatment for all 12 procedure administrations.
1551012|NCT02591056|Device|Green PRESS 8|There are 12 procedure administrations with the Green PRESS 8 across 6 weeks: 2 procedures per week. For each procedure administration, the Green PRESS 8 is applied to the midsection for 30 minutes. All subjects receive the active Green PRESS 8 treatment for all 12 procedure administrations. Each Green PRESS 8 procedure administration occurs right after each procedure administration with the Erchonia Verju Laser.
1551013|NCT02591043|Procedure|Outcome after surgery|Functional outcome after surgical treatment of pelvic ring fractures Measurements: TUG-test score, ADLs index, maximal pain (VAS 1-10) at rest and experienced during TUG-test. One-year mortality, signs of healing, dislocation or other complications on anterior-posterior radiographs of the pelvis, living situation before and after the injury (at home/institutional placement)
1551014|NCT02591030|Drug|GEMCIS|"At D1 and D8 of each cycle, i.e. every 21 days for 6 months:
Cisplatin 25 mg/m² over 1 hour at D1 and D8
Gemcitabine 1000 mg/m² over 30 minutes at D1 and D8."
1551015|NCT02591030|Drug|mFolfirinox|"At D1 of each cycle, i.e. every 15 days for 6 months:
Oxiplatin: 85 mg/m² (IP/120 minutes)
Irinotecan: 180 mg/m² (IV/90 minutes)
Folinic acid: 400 mg/m² (or 200 mg/m² if Elvorine [calcium levofolinate]) (IV/2 hours), via a Y connector at the same time as irinotecan
5-FU: 2400 mg/m² (IV over 46 hours) without 5FU bolus at D1"
1551016|NCT02591017|Drug|Morphine|
1551017|NCT02591017|Drug|Ketamine|
1551018|NCT02591017|Drug|Placebo|
1551019|NCT02591017|Drug|Chitosan|
1551020|NCT02591004|Drug|Magesium sulphate|*Experimental: Group A: Magesium sulphate 4 gm intravenous (I.V) loading dose over 30 mins & 1 gm/ hour maintenance dose for 24 hours, or till labor occurs ( whichever occurs first)
1551021|NCT02591004|Drug|Nifedipine|*Active Comparator: Group B Nifedipine wil be given in a loading dose of 40 mg in the 1st hour (10mg will be given every 15 min), then a maintenance dose of 60mg /24 hours, divided in 3 doses
1551022|NCT02591004|Radiation|Doppler on fetal middle cerebral artery|both group A and group B: ultrasound doppler to measure the mean pulsility index (PI) and resistance index (PI) of the middle cerebral artery in the fetus twice, once before giving them the drug, and the other after 4 hours of starting the loading dose.
1551023|NCT02590991|Other|Prebiotics|To study the long term effect of supplementation in early life
1551024|NCT02590991|Other|Prebiotics & Probiotics|To study the long term effect of supplementation in early life
1551025|NCT02590978|Procedure|Early cholecystectomy|Cholecystectomy + intraoperative cholangiography within the first 72 hours of admission.
1551026|NCT02590978|Procedure|Control (Delayed cholecystectomy)|Standard care arm. Cholecystectomy + intraoperative cholangiography is delayed until normalization of laboratory values, abdominal pain resolves and oral intake is restored.
1551027|NCT02590965|Drug|Fruquintinib|After checking eligibility criteria, subjects will be randomized into Fruquintinib plus best supportive care group (treatment group) or placebo plus best supportive care group (control group) in a ration of 2:1.
1551029|NCT02590952|Drug|Epitinib|The starting daily dose is 20 mg. Dose escalation will follow daily dose of 40 mg,80 mg, 120 mg, 160 mg, 200 mg, and 250 mg. A 3+3 design applies to this study. Patients will continue taking Epitinib until they experience intolerable adverse events or their diseases are confirmed to be progressed.
1551030|NCT02590939|Device|CEFALY Active|Active external trigeminal nerve stimulation
1551031|NCT02590939|Device|CEFALY Placebo|Placebo external trigeminal nerve stimulation
1551032|NCT02590926|Procedure|Fractional Flow Reserve, Myocardial|The ratio of maximum blood flow to the myocardium with coronary stenosis present, to the maximum equivalent blood flow without stenosis.
1551033|NCT02590913|Dietary Supplement|fructose|75g fructose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
1551034|NCT02590913|Dietary Supplement|glucose|75g glucose is dissolved in 300 ml water.After overnight fasting, 300ml of solution at 0830 within 5 minutes is taken by volunteers
1551035|NCT02590900|Drug|intravenous paracetamol (acetaminophen)|paracetamol disposition in young women, exploring the impact of covariates (pregnancy, postpartum, oral contraceptives) in this population.
1551036|NCT02590887|Other|Drink manufactured from lupine peptides|Comparison of blood levels of immune, oxidative stress, biochemical markers and haemogram before and after (15, 28 and 42 days) drinking the beverage.
1551037|NCT02590874|Drug|Duloxetine|Duloxetine 30 mg per day for 2 weeks. Duloxetine 60 mg per day for 4 months. Duloxetine 30 mg per day for 2 weeks.
1551038|NCT02590874|Drug|Placebo|Placebo 30 mg per day for 2 weeks. Placebo 60 mg per day for 4 months. Placebo 30 mg per day for 2 weeks.
1551039|NCT02590861|Procedure|Dental implant|All participants will receive the same intervention, this is a single group study.
1551040|NCT02590848|Dietary Supplement|Walnut intake|Nutritional intervention: 30g walnut kernels per day
1551041|NCT02590835|Procedure|Orthodontic procedures (for both groups : Control group and Test group)|Damon self-ligating systems (Ormco, Orange, Calif) were used for all patients. The patients were allowed to choose between clear or metal brackets. The bonding method was standardized and applied according to the manufacturer's instructions. After bracket bonding, 0.014-in copper-nickel-titanium Damon arch forms were placed. The subjects were recalled every two weeks, and the archwires were changed only when full bracket engagement was achieved. The sequence of archwires was as follows: 0.018-in, 0.014x0.025-in and 0.018x0.025-in copper nickel-titanium archwires for alignment; and 0.019x0.025-in stainless steel archwires for fine-tuning. Following the alignment steps, impressions were taken, and blinded orthodontic consultants validated appliance removal or provided advice regarding further adjustments. Alginate impressions were taken after the removal of the appliances, and both fixed and removable retainers were placed.
1551042|NCT02590835|Procedure|Piezo-assisted orthodontics (only the Test group)|The piezocisionTM surgery was performed one week after orthodontic appliance placement . The patients received local anesthesia in both arches, and vertical interproximal micro-incisions were created below each interdental papilla. In cases of root proximity (i.e., less than 2 mm of interdental bone), this procedure was not applied. These incisions were kept to a minimum (varying from 5 mm to 8 mm). Next, using a vertical piezoelectric device, 5-mm long and 3-mm deep corticotomies were made, and no subsequent sutures were required needed (figure 1). The patients were advised to take analgesics (paracetamol) only if necessary and to record their daily intakes for one week. Anti-inflammatories were prohibited to avoid interference with the RAP. Careful tooth brushing and the use of a mouthwash (chlorhexidine 0.2% Perio-Aid, Dentaid Benelux, Houten, Netherlands) were recommended for 7 days.
1551043|NCT02590822|Dietary Supplement|Cambridge Weight Plan|"Group receives a total meal replacement diet from Cambridge Weight Plan containing 810 kcal/day (40% protein, 50% carbohydrate, 10% fat). As 3 or 4 mini-meals daily in flavoured formula food packets made up with water, milk or non-dairy alternative; or as snack bars based on preference. Supplemented with up to three portions of non-starchy vegetables and 2 litres of water, or other non-calorific drinks, per day. Participants to abstain from alcohol for study duration. The diet will be stopped, and a maintenance diet re-introduced once 50% excess body weight has been lost, or by 12 weeks, whichever comes first.
The TDR will be undertaken alongside health behaviour coaching and relapse prevention through weekly, where possible, contact (telephone or face-to-face) with a qualified dietician or equivalent.
Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
1551044|NCT02590822|Other|Supervised Exercise Sessions|"The exercise group will attend supervised exercise sessions at the Leicester-Loughborough Diet, Lifestyle and Physical Activity (LLP) BRU or at the Leicester Diabetes Centre. The exercise program will typically consist of a thrice weekly, 60 minute session of moderate intensity aerobic exercise, in line with prevailing guidelines. An initial assessment of cardiorespiratory fitness will be performed, and exercise intensity titrated to aim for a workload of approximately 60% of the patient's VO2 max.
Due to the potential risk of hypoglycaemia and symptomatic hypotension; medication at enrolment will need to be adjusted initially and throughout the study."
1551045|NCT02590809|Drug|Treatment BX1514M|X mg x 3 /day of BX1514M for 15 days. Dosage will be then adapted, depending on symptoms release and walk distance test results for another 15 days period.
1551046|NCT02590809|Drug|Placebo|Placebo will be given for 30 days
1551047|NCT02590809|Other|Walk distance test|Walk distance test during 6 minutes
1551048|NCT02590809|Other|Exercise echocardiography|
1551049|NCT02590796|Other|No intervention given to participants|This is an observational study. Participants will receive no intervention.
1551050|NCT02590783|Procedure|experimental intervention surgery|Patients are placed supine on the carbon table. Screw paths are planned on a spiral CT scan from the sacrum on transversal slices, two Kirschner-wires 2.5 mm in diameter are introduced into the iliac bone through a stab incision and advanced into the ilio-sacral joint, through the lateral part of sacrum into the first and second sacral body, through the contralateral lateral part of the sacrum and exiting the contralateral iliac bone through the sacra-iliac joint with aid of CT-guidance. Over the Kirschner-wires 7.0 mm cannulated screws are introduced and the Kirschner-wires withdrawn. Several low-dose computer tomography scans are performed to secure the correct position. Total radiation dose is 300 mille gray square centimetres (mGycm).
1551374|NCT02588391|Behavioral|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving match the child's skill level.
1551051|NCT02590783|Procedure|control intervention|Mobilization guided by our physiotherapists. Full weight bearing is allowed. Analgetic treatment with metamizol, ibuprofen or paracetamol to the attending physicians discretion under regular surveillance laboratory values and/ or morphine or methadone. Patients will be treated with an individually based approach, if necessary involving our anesthesiologic pain service. Thrombo-embolic prophylaxis with a low molecular weight heparin or rivaroxaban for 6 weeks unless there is an indication for oral anticoagulation. All patients will be followed up by the Geriatric Fracture Center considering osteoporosis, fall prophylaxis, malnutrition and delirium. For the duration of the study the patients will not receive Parathyroid Hormone Substitution or Phosphonates.
1551052|NCT02590770|Behavioral|attention modification|participants will receive gaze-continent feedback according to their viewing patterns
1551053|NCT02590770|Other|Placebo|participants will receive non-gaze-continent feedback unrelated to their viewing patterns
1551056|NCT02590744|Behavioral|eye patch|cover the sick eye with eye patch preoperatively for 3 hours
1551057|NCT02590744|Behavioral|non-eye patch|do not cover the sick eye with eye patch preoperatively
1551058|NCT02590718|Procedure|optimized postoperative management|lying without the pillow for half an hour after lumbar puncture
1551059|NCT02590705|Drug|Lidocaine|surface anesthesia with lidocaine
1551060|NCT02590692|Biological|CPCB-RPE1|Patients will receive one CPCB-RPE1 implant of approximately 100,000 differentiated RPE cells attached to a small parylene membrane. The density of cells on the membrane represents the approximate density of RPE cells in the human eye. The membrane size was chosen to cover a substantial portion of the macular region of the retina.
1551061|NCT02590679|Device|Venues-P Valve|a Novel Self-Expanding Percutaneous Stent-Valve in the Native Right Ventricular Outflow Tract
1551062|NCT02590666|Procedure|Bipolar Polypectomy|Polyps resection with bipolar electrode
1551063|NCT02590666|Procedure|Mechanical Polypectomy|Polyps resection with microscissors or graspers
1551064|NCT02590666|Device|Bipolar electrode|Bipolar electrode used to performs polypectomy
1551065|NCT02590666|Device|Microscissors or graspers|Mechanical instruments used to performs polypectomy
1551066|NCT02590653|Drug|Atorvastatin|Lipid-lowering therapy
1551067|NCT02590640|Device|Repetitive transcranial magnetic stimulation, MagStim Rapid2|"This study plans to learn more about the way an experimental technique called transcranial magnetic stimulation (TMS) affects a specific part of the brain, called the insula. Some research suggests that this part of the brain plays an important role in craving. The investigators plan to study the effects of TMS using standard surveys and magnetic resonance imaging (MRI) of subjects' brain."
1551068|NCT02590640|Device|Sham repetitive transcranial magnetic stimulation|Sham repetitive transcranial magnetic stimulation will be applied to the insula in smokers.
1551069|NCT02590627|Drug|Artemether-lumefantrine|Artemether-lumefantrine
1551070|NCT02590627|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine
1551071|NCT02590614|Dietary Supplement|800 IU Vitamin D|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the intervention group.
1551072|NCT02590614|Dietary Supplement|Placebo|Among the cross-sectional study participants, a subset is randomly selected and matched based on genetic ancestry, and randomized to the placebo group
1551073|NCT02590601|Drug|Bromocriptine|
1551074|NCT02590601|Other|Guideline-driven medical therapy (GDMT)|
1551075|NCT02590588|Drug|Idelalisib|Idelalisib daily until unacceptable toxicity or disease progression.
1551076|NCT02590575|Device|Extracorporeal CO2 removal with the Prismalung(R) gas exchanger on the Prismaflex(R) renal replacement platform|"With ongoing continuous hemofiltration and mechanical ventilation additional membrane gas exchange device (Prismalung®) in the renal replacement circulation; measurements of the effects on PaCO2 under varying blood and sweep gas flows
Afterwards, reduction of the tidal volume (VT) / plateau pressure until reaching the initial PaCO2value"
1551077|NCT02590562|Other|Routine clinical practice|
1551078|NCT02590549|Procedure|Corneal Collagen Crosslinking|"Sterile riboflavin solution 0.1% was then continuously injected for 3 minutes into the corneal pocket via a standard 0.3-mm cannula through the incision tunnel.
Standard surface UVA irradiation (370 nm, 3 mW/cm2) was then applied at a 5-cm distance for 30 minutes.
After UVA irradiation, a flexible MyoRing intracorneal implant was inserted into the corneal pocket,"
1551079|NCT02590549|Device|Ufalink|UVA irradiation with wave length 370 nm, 3 mW/cm2 is provided with UFalink, device,Russian Federation
1551080|NCT02590536|Drug|Sildenafil citrate|"In patients with Fetal Growth Restriction (FGR)and abnormal umbilical artery Doppler, will be randomly assigned and divided to 2 groups which will be treated with sildenafil citrate either placebo.
This study will compare the change in Resistance Index (RI) and the Pulsatility Index (PI) of the umbilical artery and fetal middle cerebral artery, for patients who receive 25 mg of oral sildenafil citrate 8 hourly starting at diagnosis of FGR until delivery against those who will receive placebo of the same color and shape of sildenafil citrate tablet."
1551081|NCT02590536|Drug|placebo|
1551082|NCT02590523|Drug|Vancomycin|Intracameral vancomycin injection during cataract surgery
1551083|NCT02590523|Drug|Moxifloxacin|Intracameral moxifloxacin injection during cataract surgery
1551084|NCT02590523|Drug|Placebo|Intracameral placebo injection with BSS during cataract surgery
1551085|NCT02590510|Drug|methotrexate|The quantity of methotrexate is different in the two groups.
1551086|NCT02590497|Procedure|Diffusion Weighted Imaging|Undergo diffusion weighted MRI
1551087|NCT02590497|Drug|Gadolinium|Undergo gadolinium-enhanced MRI
1551088|NCT02590497|Other|Laboratory Biomarker Analysis|Tissue genetic analysis
1551089|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo gadolinium-enhanced MRI
1551090|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo 3D volumetric T1-weighted sequence
1551091|NCT02590497|Procedure|Magnetic Resonance Imaging|Undergo FLAIR sequence
1551092|NCT02590497|Procedure|Perfusion Magnetic Resonance Imaging|Undergo perfusion MRI
1551093|NCT02590484|Procedure|The cervix as a natural tamponade (cervical inversion)|Suturing an inverted lip(s) of the cervix over the bleeding placental bed to control the bleeding.
1551094|NCT02590471|Procedure|Angioplasty with stenting of the femoral artery|"A standard endovascular exposure is carried out under local anesthesia and a lesioned arterial segment is visualized. Stenosis or artery occlusion is passed by the hydrophilic guide. During the occlusion transluminal or subintimal artery recanalization (most frequently mixed) is conduced. Then balloon angioplasty of stenosis or occlusion are carried out. After the angiographic control if necessary stent (balloon extpandable or self-expanding) of all the extension is mounted.
Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
1551095|NCT02590471|Procedure|Angioplasty with stenting of the femoral artery, supplemented by fasciotomy in Hunter's channel|"Standard endovascular stenting of femoral artery. The exposure is carried out to the distal part of superficial femoral artery when it lives Hunter's canal and the first portion of popliteal artery. Intermuscular vastoadductoria sept is dissected and the following arteries are ligated and dissected: а. superior medialis genus, а. superior lateralis genus.
Medical therapy includes aspirin (acid acetylsalicylic) prescription before the procedure (160 - 300 mg/d), beginning from minimum per day and heparin (heparin sodium) injection during the procedure (5000 U iv). After the procedure aspirin (acid acetylsalicylic) in dose 100 mg/d within long period should be prescribed in all the patients, and plavix (clopidogrel) in dose 75/d should be prescribed within 3 months."
1551096|NCT02590458|Procedure|Short Breast MRI (SBMRI)|One day after routine MRI, short breast MRI (SBMRI) with contrast performed. Scan will take about 10 minutes to complete.
1551097|NCT02590458|Behavioral|Questionnaire|After SBMRI, participant completes a questionnaire about their comfort level and experience of the research scan. It should take about 10 minutes to complete the questionnaire.
1551098|NCT02590445|Device|deep brain stimulation system|
1551099|NCT02590432|Drug|Linaclotide 290 micrograms|IBS-C patients only
1551100|NCT02590432|Drug|Linaclotide 145 micrograms|IBS-C and CIC patients
1551101|NCT02590432|Drug|Linaclotide 72 micrograms|Patients who meet criteria for dose adjustment during the Open-label Treatment Period may be offered a treatment paradigm including possible doses of 290 µg or 145 µg or 72 µg for IBS-C patients, or 145 µg or 72 µg for CIC patients.
1551102|NCT02590419|Device|BrightMatter™ products|"BrightMatter™ Plan (BMP): BMP is a software that enables surgeons to plan their neurosurgery preoperatively. BMP automatically generates whole brain tractography and highly accurate fusion of anatomical MRI and DTI images.
BrightMatter™ Bridge (BMB):BMB involves offering SMI's MRI expertise to ensure a smooth workflow in neuroimaging including DTI to ensure optimized protocols are used to acquire the DTI images. Once the images are acquired, they are evaluated for their quality in real time using a quality control (QC) algorithm. The QC allows quality assessment of DTI images at the time-of-scan allowing for immediate correction while the patient is still there and reduces the need for patient re-scan.
BrightMatter™ Guide (BMG): BMG is a neuro-navigation system that utilizes the DTI information and the trajectory planned by the surgeon in BMP pre-operatively, but bringing it into the operating room intraoperatively."
1551105|NCT02590393|Combination Product|E-cigarettes|Participants will be asked to switch from cigarette use to use of e-cigarettes for eight weeks.
1551106|NCT02590380|Device|MESA Rail Deformity System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the MESA Rail Deformity System.
1551107|NCT02590380|Device|DePuy Synthes USS II System|The spinal deformity will be correction via a standard of care procedure performed by the principal investigator. The correction will be fixated with the DePuy Synthes USS II system.
1551108|NCT02590367|Drug|FOLFOX regimen|"FOLFOX regimens are combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (different dose like FOLFOX4/FOLFOX6) via ambulatory pump administered for a period of 46 to 48 hours.
XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks."
1551109|NCT02590367|Drug|HD6610 Granule|the HD6610 Granule will be given 2 times a day.
1551110|NCT02590367|Drug|HD6610 Granule placebo|the HD6610 Granule placebo will be given 2 times a day.
1551111|NCT02590354|Other|ART interruption|
1551112|NCT02590315|Other|Invitation for breast screening and random allocation|Invitation for breast screening; Women who consent to take part in the trial will be randomised to DBT or DM.
1551113|NCT02590315|Device|DBT|Combo-mode DBT. DBT participants will have an additional radiation exposure for breast tomosynthesis.
1551114|NCT02590315|Device|Conventional digital mammography.|Conventional digital mammography.
1551115|NCT02590302|Other|Implementation Phase|"Core Components of the implementation intervention include:
Hospital and CMHA project commitment
Site champion teams (from hospital and CMHA)
Memorandum of Agreement between Hospital and CMHA
Pre-intervention site visits
Education sessions
Posters/reminders
Instructional videos (HEADS ED video)
Completed pathway implementation includes EDMHCP site-customization and committee approvals, consequent planning and agreements among ED-CMHA partners, delivery of at least two educational workshops, and EDMHCP availability in the ED. An 8-month period for EDMHCP implementation, with negotiated interim target dates was set for each site."
1551116|NCT02590289|Drug|BBI-5000|BBI-5000 low dose, middle dose, or high doses
1551117|NCT02590276|Behavioral|characterization|
1551491|NCT02587533|Other|Hyperoxia without dopamine|Nearly complete hemoglobin oxygen saturation.
1551121|NCT02590250|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
1551122|NCT02590237|Device|Ambu KingVision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu KingVision Video Laryngoscope with a size 1 aBlade. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
1551123|NCT02590237|Device|Miller Direct Laryngoscopy|At time of tracheal intubation, the subject will be intubated using a Miller blade laryngoscope. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded. Information on time to glottic view, time to removal of the blade, and time of first capnography upstroke (successful intubation) will be recorded. Other parameters measured will be information on subsequent attempts, ease of tracheal tube insertion, and hemodynamic responses for 5 minutes.
1551124|NCT02590224|Drug|Ferrous bis-glycinate|
1551125|NCT02590224|Drug|Ferrous glycine sulphate|
1551126|NCT02590211|Behavioral|cognitive, emotional and clinical assessment|Cognitive and emotional assessment: Posner paradigm applied to emotional information (attention and emotional perception abilities), the modified Wisconsin Card Sorting Test (mental flexibility), the Hayling Sentence Completion Task (verbal inhibition), the Go - No Go test (motor inhibition) and the expressive suppression method (facial expression inhibition) Clinical assessment: gambling course and habits, description and role of the avatar, level of cognitive distortions, control attribution (locus of control), social phobia, motivation for gambling, impulsivity, co-addictions, coping and gambling related-damage
1551127|NCT02590198|Other|ANAES algorithm|care as recommended by ANAES, with ANAES algorithm
1551128|NCT02590198|Other|PCT algorithm|care based on PCT algorithm
1551129|NCT02590185|Drug|cocktail probe drugs|"For the assessment of drug-metabolizing enzyme activity, the patients will be given the cocktail probe drugs, by oral route, one time during the study:
A capsule of omeprazole ABBOTT® 10mg
10 mg of an oral liquid formulation of Dextrométhorphane bromhydrate (Drill Pierre FABRE MEDICAMENT® 5mg/5mL, syrup)
1 mg of an injectable solution of Midazolam for oral administration (Midazolam Panpharma® 1mg/mL, injectable solution)
A tablet of fexofenadine Zentiva® 120mg"
1551130|NCT02590159|Device|BONGO NASAL EPAP|The BONGO NASAL EPAP device consists of two nasal inserts (a connected pair), each containing an actuated valve, with a patient attachment mechanism. The device works by providing an inhalation port that offers minimal inhale resistance during inhalation, but is closed by the actuated valve so that exhalation occurs against a fixed orifice. This mechanism provides increased EPAP upon exhalation.
1551131|NCT02590146|Behavioral|Non-pharmacologic pain control adjuncts|
1551136|NCT02590107|Dietary Supplement|Boost Plus|Receive nutritional supplementation twice daily to provide 28g of protein
1551137|NCT02590107|Dietary Supplement|Pro-Stat 101|Receive nutritional supplementation twice daily to provide 30g of protein
1551138|NCT02590107|Dietary Supplement|Milkshake|Receive alternate nutritional supplementation once daily to provide 28g protein
1551139|NCT02590107|Other|daily food diaries|Participants will be given a food intake form, clipboard, and pen to record specific foods, as well as amounts of foods that are consumed from outside sources. In addition, the specific food items that each participant consumes will be recorded by the participant on his or her meal tickets which are included with each meal tray
1551140|NCT02590094|Drug|Intravitreal bevacizumab|Intravitreal bevacizumab is given preoperatively at various time intervals and doses
1551141|NCT02590081|Drug|Dextrose 5%|
1551142|NCT02590081|Drug|normal saline|
1551143|NCT02590068|Drug|Zoster vaccine live|Single Zostavax vaccine, 0.65 ml dose, administered subcutaneously
1551144|NCT02590055|Drug|gemcitabine/docetaxel combination|
1551145|NCT02590042|Biological|ADSC-SVF-002|"ADSC-SVF with the following identity:
Less than or equal to 10% each CD34 and CD45 positive cells At least 70% each CD90, CD73 and CD105 positive cells Viability of at least 85% Mean Florescence Intensity of less than or equal to 100 C12FDG 0-5-2.5x10^6 cells/g of liposuctioned (hydrated fat)"
1551146|NCT02590029|Behavioral|Mindfulness|The 15 minute mindfulness session is a scripted mindfulness exercise that incorporates mindfulness principles of intentionally paying attention to present-moment experience in a non-judgmental fashion.
1551147|NCT02590029|Behavioral|Suggestion|The 15 minute suggestion session is a scripted suggestion exercise that incorporates imagery and suggestions for changes in cognition, emotion, and body sensations.
1551148|NCT02590029|Behavioral|Psychoeducation|The 15 minute psychoeducation session is a supportive session in which behavioral coping strategies for pain management are discussed.
1551149|NCT02590016|Drug|Insulin, Aspart|Insulin aspart Novorapid® Penfill 40 IU/0,4 ml is diluted into 1000ml of 0,9 % sodium chloride (NaCl). Infusion is started at rate 48 ml/l, which equates insulin dosing at rate of 2 IU/h. Glucose infusion is started simultaneously. 5 ml of potassium chloride (KCl) is added to 500 ml of 10 % Glucose solution. Infusion rate is 100 ml/h giving glucose infusion rate of 10 g/l. Plasma glucose level is measured every 1-2 hours and infusion rate of insulin is increased by 6ml/h if plasma glucose is more than 7,5 mmol/l and decreased by 6 mmol/h if plasma glucose is below 4 mmol/l.
1551152|NCT02589990|Behavioral|Strength training|see arm description
1551153|NCT02589977|Drug|regadenoson|evaluation of myocardial blood flow, interstitial fibrosis and oxidative metabolism in HFpEF, compared to hypertensive and normal participants
1551199|NCT02589678|Biological|MMR Vaccine|A live attenuated virus vaccine against measles, mumps and rubella (0.5 ml) will be administered intramuscularly.
1551154|NCT02589964|Dietary Supplement|Florajen-3|The probiotic treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
1551155|NCT02589964|Other|Placebo|The placebo treatment is the experimental aspect of the study. Treatment will be initiated within 48 hours of the first antibiotic and will be administered twice a day for 20 days.
1551156|NCT02589951|Other|admission to non-psychiatric service|
1551157|NCT02589938|Other|Standard Oral Hygiene|Oral hygiene care provided per individual institutions standard of care.
1551158|NCT02589938|Other|Standard Oral Hygiene + True Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 true acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
1551159|NCT02589938|Other|Standard Oral Hygiene + Sham Acupuncture|Oral hygiene care provided per individual institutions standard of care. 14 sham acupoint sites will be selected and applied to each participant for 20 minutes at each session. There will be 2 sessions a week for 8 weeks.
1551160|NCT02589925|Device|Vercise deep brain stimulation|implantation of a Vercise neurostimulation system
1551161|NCT02589925|Procedure|subthalamic nucleus (STN) stimulation|bilateral high-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
1551162|NCT02589925|Procedure|NBM stimulation|bilateral low-frequency neurostimulation of the subthalamic nucleus using a Vercise neurostimulation system
1551163|NCT02589925|Procedure|sham stimulation|ineffective neurostimulation by setting 0mA output at the Vercise neurostimulation system
1551164|NCT02589912|Device|Nucleus Profile ABI541 Auditory Brainstem Implant|
1551165|NCT02589899|Other|Needle placement in different tissue types|Bioimpedance will be measured for needle positions in different tissue types
1551166|NCT02589886|Other|Education and self-help internet intervention|The intervention is a newly developed website which consists of information about the mechanism and treatment of functional motor disorders. Furthermore self-help elements like exercises to perform at home and rehabilitation advice are added. The intervention is unguided.
1551167|NCT02589873|Behavioral|In-Person Diabetes Prevention Program|Lifestyle intervention program involving group-based educational sessions, diet and physical activity tracking, and weekly weigh ins. Participants complete the intervention over 12 months.
1551168|NCT02589873|Behavioral|Online Diabetes Prevention Program|Lifestyle intervention program involving web-based educational videos, diet and physical activity tracking, and recording weight. Participants complete the intervention over 12 months.
1551169|NCT02589860|Other|Melphalan kinetic study|Concentration of Melphalan in plasma samples
1551170|NCT02589860|Genetic|Oral bacterial study|DNA from oral buccal mucosal cells will be sequenced for bacterial composition
1551171|NCT02589860|Genetic|Gene expression study|RNA from oral buccal mucosal cells will be analyzed to compare gene expression
1551172|NCT02589847|Biological|RBX2660|suspension of intestinal microbes
1551173|NCT02589834|Other|Quran group|
1551174|NCT02589821|Drug|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
1551175|NCT02589821|Other|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
1551176|NCT02589808|Device|Echocardiography|Pocket ultrasound device.
1551177|NCT02589795|Biological|DNA-C CN54ENV|DNA plasmid containing the Clade C gp140 envelope gene from HIV-1 isolate CN54
1551178|NCT02589795|Biological|CN54gp140|Recombinant protein expressed from the Clade C gp140 envelope gene from HIV-1 isolate CN54
1551179|NCT02589795|Device|Trigrid Delivery System - Intramuscular|Electroporation
1551180|NCT02589795|Device|Trigrid Delivery System - Intradermal|Electroporation
1551181|NCT02589782|Drug|Bedaquiline|
1551182|NCT02589782|Drug|Pretomanid|
1551183|NCT02589782|Drug|Moxifloxacin|
1551184|NCT02589782|Drug|Linezolid|
1551185|NCT02589782|Drug|Clofazimine|
1551186|NCT02589782|Drug|Locally accepted standard of care which is consistent with the WHO recommendations for the treatment of M/XDR-TB.|
1551187|NCT02589769|Other|unsaturated fat for saturated fat|Substituting unsaturated fat for saturated fat
1551188|NCT02589769|Other|saturated fat|a control diet with whole fat dairy and meat with saturated fats that are not fat reduced
1551189|NCT02589756|Other|The fatty fish group|At inclusion demographic information recorded, including length of breastfeeding for women. Thereafter, participants will start with a run-in period of two weeks where they will be asked not to consume salmon, mackerel, sardines or other fatty fish or nuts providing a dietary baseline. At baseline, subjects will be randomized to a fish, nuts or control group. The fish group will be asked to consume three to four portions weekly. The fish will be eaten at the main meal and in sandwiches for a total of 600 grams weekly for 6 months. This group will avoid eating nuts. The nut group will consume equal amount of energy (~1400 kcal ) for weekly use for 6 months. This group will avoid eating fatty fish. The control group will consume their usual diet, but asked to avoid fatty fish and nuts.
1551190|NCT02589756|Other|The nut group|At baseline (conditions for baseline are the same in all three groups) the nut group will consume equal amount of energy (~1400 kcal ~100 grams walnuts, ~50 grams hazelnuts and ~50 grams almonds/week).The nuts will be provided free of charge for the six months. This group will avoid eating fatty fish.
1551191|NCT02589756|Other|The control group|After the baseline the control group will consume their usual diet, asked to avoid fatty fish and nuts.
1551192|NCT02589743|Device|Sealant|Application of preventive agent
1551193|NCT02589743|Device|Adhesive and Sealant|Application of preventive agent and technique for control moisture
1551194|NCT02589730|Device|Welltang App|This App is a large platform of individualized diabetic management
1551195|NCT02589717|Drug|Atezolizumab [TECENTRIQ]|Atezolizumab 1200 mg will be administered by IV infusion q3w. Initial IV infusion will be given over 60 minutes and subsequent infusions will be given over 30 minutes.
1551196|NCT02589691|Drug|Rocuronium|
1551197|NCT02589691|Other|Sodium chloride 0.9%|
1551198|NCT02589678|Biological|Tdap - IPV Vaccine|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, combined with inactivated poliomyelitis vaccine (0.5 ml) will be administered intramuscularly.
1551202|NCT02589652|Drug|Pegylated interferon alfa-2a|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 8 weeks and followed by PegIFN alfa-2a 180ug subcutaneous injection weekly for 40 weeks
1551203|NCT02589652|Drug|Pegylated interferon alfa-2a plus Entecavir|ETV 0.5mg oral daily plus PegIFN alfa-2a 180ug subcutaneous injection weekly for 48 weeks
1551204|NCT02589652|Drug|Entecavir|ETV 0.5mg oral daily for 48 weeks
1551205|NCT02589639|Drug|Empagliflozin|
1551206|NCT02589639|Drug|Placebo|
1551207|NCT02589639|Drug|Placebo|For blinding purposes
1551208|NCT02589626|Drug|empagliflozin 10mg|
1551209|NCT02589626|Drug|empagliflozin 25 mg|
1551210|NCT02589626|Drug|Placebo|For blinding purposes
1551211|NCT02589613|Dietary Supplement|tap water|300ml tap water via nasogastric tube
1551212|NCT02589613|Dietary Supplement|Glucose|300ml tap water with 75g Glucose via nasogastric tube
1551213|NCT02589613|Dietary Supplement|Fructose|300ml tap water with 25g Fructose via nasogastric tube
1551214|NCT02589600|Drug|Zoledronic acid|Annual intravenous 5.0 mg
1551215|NCT02589600|Dietary Supplement|vitamin D|800 IU daily
1551216|NCT02589600|Dietary Supplement|calcium|approximately 1200 mg (dietary and supplement)
1551217|NCT02589600|Other|Saline|Annual intravenous saline placebo
1551218|NCT02589587|Procedure|sleeve gastrectomy|Sleeve gastrectomy is an established form of bariatric (weight reducing) surgery, where the greater curvature of the stomach is removed.
1551219|NCT02589587|Other|no intervention|lean control group
1551220|NCT02589574|Other|electronic text message|"Besides the reminder of the free vaccination, the messages included information that vaccination reduces the personal risk of influenza illness. It also reduces the risk to infect patients and family members. It is also the social expectation on and professional as well as personal responsibility of nurses in protecting own selves and their patients from contacting influenza.
it is a safe vaccine. The reminders are developed with reference to promotion messages from Hospital Authority."
1551221|NCT02589561|Device|Remote fitting|remote fitting of hearing aids
1551222|NCT02589561|Device|Face to face fitting|face to face fitting of hearing aids
1551229|NCT02589509|Behavioral|Direct-attention training using web-based BrainHQ|"BrainHQ (by Posit Science Corp.) computerized attention training using the following modules: Divided attention, Target tracker, Double Decision, Mixed Signals, and Freeze Frame."
1551230|NCT02589509|Behavioral|Goal Management Training (GMT)|A compensatory metacognitive strategy-based intervention program that teaches strategies for improving attentional control and problem solving.
1551231|NCT02589496|Drug|pembrolizumab|200 mg every 3 weeks
1551232|NCT02589483|Procedure|The rectal anastomosis will be reinforced with HemoPatch.|Associated with the making of the anastomosis stapled or hand sewed, the device HemoPatch will be wrapped all the way around the anastomotic circumference.
1551233|NCT02589483|Device|Hemopatch|The rectal anastomosis reinforced with Hemopatch
1551234|NCT02589470|Other|COMETE|Patients of COMETE group will attend 12 individual sessions of cognitive rehabilitation, which are not systematic in usual treatment, and will receive memory exercises via internet to continue cognitive exercizes at home.
1551235|NCT02589457|Drug|CKD-390|Tenofovir Disoproxil Aspartate 1T PO
1551236|NCT02589457|Drug|Viread® tablet|Tenofovir Disoproxil Fumarate 1T PO
1551237|NCT02589444|Dietary Supplement|High-Dose Vitamin D3|50,000 IU of oral vitamin D3 once a week (the standard of care for repletion of vitamin D status by the Cystic fibrosis Foundation)
1551238|NCT02589444|Other|Stool Sample|Participants will be asked to provide a stool sample in a collection container for analysis of stool microbiota. This will be done upon enrollment (baseline) and at 3 month follow-up.
1551239|NCT02589444|Other|Sputum Sample|"Participants will be asked to collect their sputum (the thick mucus or phlegm that is expelled from the lower respiratory tract through coughing) into a kit.
This will be done upon enrollment (baseline) and at 3 month follow-up."
1551240|NCT02589444|Other|Sham Comparator|A placebo capsule taken once a week (manufactured by the same company that makes the Vitamin D supplement).
1551241|NCT02589444|Procedure|Blood draw|Participants will be asked to provide 30 ml of blood collected via a blood draw to measure 25 (OH)D serum concentration and other nutrient markers related to vitamin D including Parathyroid hormone, fibroblast growth factor-23, vitamin D binding protein and markers of immune system/inflammation. This will be done at baseline and at 3 months follow up.
1551242|NCT02589418|Procedure|Acupuncture|Needle insertion and manipulation at 4 acupuncture points (bilateral LI4, right ST6 and ST7).
1551243|NCT02589418|Procedure|Sham-Acupuncture|Needle insertion and manipulation at 4 non-acupoints
1551244|NCT02589418|Procedure|No Acupuncture|Control intervention: No needle insertion and manipulation
1551248|NCT02589392|Other|Cetaphil® Restoraderm® moisturizer + Cetaphil® Restoraderm® body wash|
1551249|NCT02589392|Other|Cetaphil® Restoraderm® body wash|
1551250|NCT02589379|Procedure|Pancreatic Resection|Endoscopic ultrasound elastography, intraoperative ultrasound elastography and magnet resonance imaging to asses pancreatic stiffness prior to pancreatic resection
1551251|NCT02589366|Drug|Lymphoseek plus Vital Blue Dye|intrapatient comparison of Lymphoseek with Vital Blue Dye in detecting lymph node metastases
1551252|NCT02589353|Drug|Acarbose|Acarbose solution will be swabbed on the tip of the tongue to inhibit salivary alpha amylase activity; each swab will contain ~484 microgram acarbose; total maximum exposure of each subject to acarbose will be ~14-30 mg each session (1-20 sessions)
1551253|NCT02589340|Drug|Buspirone|
1551254|NCT02589340|Drug|Placebo|Sugar Pill
1551255|NCT02589327|Other|Exercise Intervention|The intervention will consist of 3 weeks of whole body circuit training (resistance training) where participants in the intervention group will perform 7 different exercises. The circuit will consist of 10 repetitions per exercise of 7 exercises: leg press, bent-over row, bench press, squats, dumbbell jump squats with raises, dead-lifts and weighted abdominal crunches, with approximately 30 sec of rest in between each exercise (based on the estimated time needed to move from one position to the next). Each participant will move through the circuit 3 times, with 2 to 3 minutes of rest between each round. Intensity will be 6-7 of RPE at the first set, and 9-10 at the third set.
1551256|NCT02589314|Device|Mechanical periodontal therapy|
1551257|NCT02589314|Procedure|nonsurgical periodontal therapy|
1551258|NCT02589301|Biological|Pegfilgrastim|
1551259|NCT02589288|Procedure|Continuous Infusion of ropivacaine 0.2%|Postoperative continuous infusion of Ropivacaine 0,2% at 6 ml/h and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
1551260|NCT02589288|Procedure|Automatic Intermittent Bolus of ropivacaine 0.2%|Postoperative Automatic Intermittent Bolus of 6 ml Ropivacaine 0,2% every hour and 4 ml PCA bolus, lockout 20 minutes via electronic infusion pump (Micrel device, Greece).
1551261|NCT02589275|Drug|TNX-102 SL Tablet 2.8 mg|TNX-102 SL 2.8 mg tablet taken daily at bedtime
1551262|NCT02589262|Drug|AUT00206|
1551263|NCT02589249|Dietary Supplement|AyuFlex|Active product
1551264|NCT02589249|Dietary Supplement|Placebo|Placebo
1551265|NCT02589236|Drug|Cavosonstat|GSNOR inhibitor
1551266|NCT02589236|Drug|Placebo|Control sample with only capsule excipients and fillers
1551267|NCT02589223|Other|Multisensory Stimulation|Subjects assigned to the multisensory stimulation group will receive the multisensory stimulation protocol designed for the study, which will include a variety of techniques designed to awaken the individual. Stimulus provided may include: visual activities (i.e. presenting the individual with objects/pictures to look at), auditory information (i.e. playing music or speaking), tactile stimuli (i.e. touching the individual with materials of different textures), taste and smell stimuli (i.e. offering items for the individual to taste or smell).
1551268|NCT02589223|Other|Control|Intervention sessions will occur 3 times per week, for approximately 30 minutes per session for a total of 4 weeks. During each session, subjects will be played a pre-recorded reading of complex material for 30 minutes, in order to assist with control/blinding.
1551269|NCT02589210|Other|EpiFix Mesh|Weekly application of EpiFix Mesh and standard of care (moist wound therapy and offloading)
1551270|NCT02589197|Device|Group 1 (Medial-Pivot)|EVOLUTION® Total Knee Arthroplasty Medial Pivot system with CS inserts
1551271|NCT02589197|Device|Group 2 (Posterior-Stabilized)|Zimmer® NexGen® Total Knee Arthroplasty system with PS inserts
1551272|NCT02589184|Other|Hypergravity|the rubber bands attached to the waist belt are tighten to simulate extra gravity during every exercise the subject performs while standing
1551273|NCT02589184|Other|isometric load|at the end of the therapy session the subject will perform 2 sets of one minute each of a 33% squat under load
1551274|NCT02589184|Other|normal gravity|the rubber bands attached to the waist belt are NOT tighten so the subject performs the exercises in normal gravity
1551275|NCT02589171|Device|Neo Close Abdominal Closure|Neo Close Abdominal Closure
1551276|NCT02589171|Device|Carter Thomason Device|Carter Thomason Device
1551277|NCT02589158|Drug|Evotaz|All participants will be administered Evotaz®) (atazanavir 300mg + cobicistat 150mg) once daily for 10 days
1551278|NCT02589158|Drug|Rezolsta|All participants will be administered Rezolsta® (darunavir 800mg + cobicistat 150mg) once daily for 10 days.
1551279|NCT02589145|Drug|Lenalidomide|"Dose Escalation Phase Starting dose of Lenalidomide: 50 mg by mouth on Days -9 to -2.
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Phase I."
1551280|NCT02589145|Drug|Vorinostat|1000 mg by mouth on Days -9 to -2.
1551281|NCT02589145|Drug|Gemcitabine|Gemcitabine administered as a loading dose of 75 mg/m2 by vein on Day -8 and 2775 mg by vein on Day -3.
1551282|NCT02589145|Drug|Busulfan|"Busulfan test dose administered by vein either as outpatient before admission, or as inpatient on day -10. The test dose of 32 mg/m2 based on actual body weight. Doses of days -6 and -5 subsequently adjusted to target an AUC of 4,000 microMol.min-1."
1551283|NCT02589145|Drug|Melphalan|60 mg/m2 by vein on days -3 and -2.
1551284|NCT02589145|Drug|Rituximab|Patients with CD20+ tumors receive Rituximab 375 mg/m2 by vein on day -9 in the AM as an inpatient.
1551285|NCT02589145|Drug|Dexamethasone|8 mg by vein twice a day from Day -8 AM to Day -2 PM.
1551286|NCT02589145|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -8.
1551287|NCT02589145|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed started on Day -8.
1551288|NCT02589145|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1
1551289|NCT02589145|Drug|Enoxaparin|40 mg subcutaneously daily from admission until platelet count drops below 50,000/mm3.
1551290|NCT02589145|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
1551291|NCT02589145|Drug|Palifermin|Palifermin per departmental standard of care with 3 doses to be administered prior to starting chemotherapy and 3 doses starting on day 0.
1551292|NCT02589132|Other|Mobile-Thrive application|Families receive standard of care plus the Mobile-Thrive application
1551294|NCT02589106|Device|Anisotropic Textile Braces|The period of the wear trial is 12-18 months in time for each subject. Wear instructions (23 hrs per day) and wash instructions will be provided to the subjects before the wear trial. Evaluation tests based on health in consideration of the use of the anisotropic textile brace (heart and pulmonary function testing and sensory level measurements) will be carried out at the beginning of the wear trial. Clinical, radiography, self-report and follow-up after completion of the study
1551367|NCT02588456|Biological|CART22 cells|CART22 cells transduced with a lentiviral vector to express anti-CD22 scFv TCRz:41BB administered by IV infusion.
1551368|NCT02588443|Drug|RO70097890|
1551369|NCT02588443|Drug|nab-paclitaxel|
1551370|NCT02588443|Drug|gemcitabine|
1551296|NCT02589080|Behavioral|Non-invasive sensory feedback|"A non-invasive simple sensory feedback system, which provides the user of a prosthetic hand with sensory feedback on the arm stump. It is mediated by air in a closed loop system connecting silicone pads on the prosthetic hand with pads on the amputation stump. The silicone pads in a tactile display on the amputation stump expand when their corresponding sensor-bulb in the prosthesis is touched, evoking an experience of real touch. Most amputees experience phantom limb sensations and/or phantom limb pain, as well as residual limb stump pain. There is often a map of the phantom hand on the amputation stump, where pressure on specific skin areas result in evoked sensation from specific fingers in the amputated phantom hand. This map is the target for the sensory feedback."
1551297|NCT02589067|Drug|Chlorhexidine gluconate|Oral rinse of either 0.12% Chlorhexidine Gluconate oral rinse to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
1551298|NCT02589067|Drug|Saline Placebo|Placebo saline oral rinse to to test the safety/efficacy of 0.12% Chlorhexidine Gluconate oral rinse in decolonizing the oropharynx of children colonized with S. aureus.
1551299|NCT02589054|Other|Monitoring|
1551300|NCT02589041|Procedure|intraneural sciatic nerve injection|"A popliteal intraneural sciatic nerve block will be performed under ultrasound guidance. Minimal effective volume will be evaluated performing a randomization based on the Up-and-down methodology.
A baseline and postoperative electrophysiological study will assess the presence of any neurological complication."
1551301|NCT02589041|Drug|Ropivacaine 1%|
1551302|NCT02589028|Dietary Supplement|premeal protein-enriched bar intake|Premeal protein bar is provided 30 minutes before breakfast. Participants have to eat protein bar with in 5 minutes with 150ml of water.
1551303|NCT02589028|Other|breakfast follows by protein bar|Participants have to eat provided breakfast within 30 minutes. It is recommended for participants to eat protein bar shortly after finishing breakfast within 5 minutes.
1551304|NCT02589002|Other|Sucralose|
1551305|NCT02588976|Device|Sonoclot Analyzer|Blood coagulation test during cardiac surgery: Measurement of activated clotting time during cardiac surgery by Sonoclot Analyzer
1551306|NCT02588963|Other|Health education session|It was created an education health session regarding the prevention of respiratory infections of children, according to caregivers needs. This session have a theoretical component, addressing especially modifiable risk factors of respiratory infections in children, and a practical component where caregivers can learn and practice nasal clearance techniques, demonstrated by the physiotherapist.
1551307|NCT02588963|Other|Nasal clearance Protocol|Nasal clearance protocol consists on the application of physiological serum in the nostrils of the child, followed by the stimulation of nasal inspiration in order to remove mucus from the nose and nasopharynx. The protocol is applied for 3 consecutive days, according to established criteria suggested by Postiaux.
1551308|NCT02588963|Other|Control|Children proceeded to their normal activities at the daycare; Caregivers did not attend to education health session.
1551309|NCT02588950|Drug|U-500R|Administered SC
1551310|NCT02588937|Drug|EntecaBell ODT. 0.5mg|
1551311|NCT02588937|Drug|Baraclude Tab. 0.5mg|
1551312|NCT02588924|Other|Second University of Naples|enrollment of patients with Parkinson's disease; collection of blood samples; measuring out the concentrations of copper, iron and manganese in biological fluids (blood, serum) of patients with Parkinson's disease and of subjects of the control group and assess possible correlations between changes in the content of metals and the pathology.
1551313|NCT02588924|Other|Neuromed IRCCS|enrollment of patients with Parkinson's disease; collection of blood samples;
1551314|NCT02588911|Procedure|Conventional Surgery|Cranial ligation of the great saphenous vein and branches of the sapheno-femoral junction and stripping of the great saphenous vein
1551315|NCT02588911|Procedure|Radiofrequency Ablation|Catheter-based ablation of the great saphenous vein
1551316|NCT02588898|Device|Blood collection and electrophysiological tests|Blood collected using a conventional method. Electrophysiology was tested after nerve Stimulation. Medical history and symptoms were collected after a standardized interview.
1551317|NCT02588885|Behavioral|Trauma-sensitive Care|"Psychological intervention
education
empowerment
desensitization
relaxation tools
Physical therapy intervention
techniques to address muscular tension
empowerment
comfort
encouragement of trauma-related coping skills"
1551318|NCT02588872|Biological|Platelet-rich Plasma (PRP)|
1551319|NCT02588872|Biological|Hyaluronic Acid|
1551320|NCT02588846|Device|Combined real-time use of 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'|This intervention uses the simultaneous combined use of two technologies: 'Multi-Leaf Collimator Adaptation' and 'kV Intrafraction Monitoring'. kV Intrafraction Monitoring (KIM) measures the motion of tissues targeted for radiotherapy in real time using kV imaging.The multi-leaf collimator (MLC) reshapes the radiation beam to maximise dose to the target tissue and minimise dose to the surrounding healthy tissue. Combining KIM and MLC allows the shaped radiation beam to follow the moving target (the prostate) while remaining fixed on a stationary target (lymph nodes) that are also being treated at the same time.
1551321|NCT02588833|Drug|APL-2|
1551322|NCT02588820|Drug|Antiretroviral Therapy (Experimental)|"Initial ART until HLA-B5701 results became available (48 hours):
Tenofovir 245 mg once a day
Emtricitabine 200 mg once a day
Dolutegravir 50 mg once a day
Darunavir 800 mg once a day
Ritonavir 100 mg once a day
Maraviroc 150 mg twice a day
Three months continuation treatment (after HLA-B5701 confirmed as negative):
Dolutegravir 50 mg once a day.
Abacavir 600 mg once a day
Lamivudine 300 mg once a day
Darunavir 800 mg once a day
Ritonavir 100 mg once a day
Maraviroc 150 mg twice a day The whole treatment schedule comprises 7 pills per day (in a single dose), except for maraviroc, which will be given twice daily.
Nine months continuation treatment (till complete 12 months treatment):
Abacavir, 600mg once a day
Lamivudine, 300 mg once a day
Dolutegravir, 50 mg once a day"
1551323|NCT02588807|Drug|Spirit1|Spirit 1 is a combination of phospholipids and anti-oxidant medicinal plants
1551324|NCT02588794|Device|CytoSorb 300 ml device (3804606CE01)|additional cytokine adsorber
1551325|NCT02588781|Drug|Pemetrexed|Alimta 500mg/m2 + NS 100ml IV infusion for 10mins Every 3weeks
1551371|NCT02588417|Drug|Dexamethasone|4mg dexamethasone intrathecally plus levobupivacaine 2.5 mg
1551372|NCT02588417|Drug|Levobupivacaine|levobupivacaine 2.5 mg
1551373|NCT02588404|Drug|LHRH therapy|These patients will be treated with LHRH agonist as standard therapy.
1551326|NCT02588768|Device|Photobiomodulation therapy (Phototherapy)|PBMT was applied employing MR4 Laser Therapy Systems manufactured by Multi Radiance Medical, Solon - OH, USA. The cluster emitter contains 12 diodes with four super-pulsed laser diodes (905 nm, 0.3125 mW average power, and 12.5 W peak power for each diode), four red LED diodes (640 nm, 15 mW average power for each diode), and four infrared LEDs diodes (875 nm, 17.5 mW average power for each diode). It was applied in direct contact with the skin to 9 sites on extensor muscles of the knee, 6 sites on knee flexors of the knee, and 2 sites on the calf of both lower limbs. To ensure blinding, the device emitted the same sounds and regardless of the programmed mode (active or placebo).
1551327|NCT02588755|Procedure|TACE+Tegafur|Tegafur: 40mg bid for 3 continuous months in 4 months. TACE: 4 or 8 weeks after resection.
1551328|NCT02588755|Procedure|TACE|TACE alone
1551329|NCT02588742|Dietary Supplement|Melatonin|Patients in the melatonin group are given 5mg of melatonin at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
1551330|NCT02588742|Dietary Supplement|Placebo|Patients in the control group are given placebo at 8 pm the day before surgery, POD#0, POD#1, POD#2, POD#3, POD#4, and POD#5.
1551332|NCT02588716|Drug|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 50ml of NaCl over 30 mins, then 2mg in 50ml of NaCl infusion (8ml/h), throughout the operation then gradually withdrawn over 4 hours.
1551333|NCT02588716|Drug|normal saline|50ml of normal saline over 30 mins, then 50ml of normal saline infusion (8ml/h), throughout the operation then gradually withdrawn over 4 hours.
1551334|NCT02588703|Behavioral|Cognitive Behavioral Therapy|Coping Skills Treatment
1551335|NCT02588703|Behavioral|Usual Care|Existing DUI program group counseling
1551336|NCT02588690|Procedure|Fingerstick cholesterol test|A finger stick draws approximately four drops of blood. The total cholesterol (TC), High Density Lipoprotein Cholesterol (HDL-C), Triglycerides, Low Density Cholesterol (LDL-C), and Glucose tests are done.
1551337|NCT02588690|Other|Atherosclerosis Cardiovascular Disease Risk assessment|"This Risk Estimator enables estimation of 10-year and lifetime risks for atherosclerotic cardiovascular disease (ASCVD), defined as coronary death or nonfatal myocardial infarction, or fatal or nonfatal stroke, based on the Pooled Cohort Equations and lifetime risk prediction tools. The Risk Estimator is intended for use in those without ASCVD with a LDL-cholesterol <190 mg/dL.
The information required to estimate ASCVD risk includes age, sex, race, total cholesterol, HDL cholesterol, systolic blood pressure, blood pressure lowering medication use, diabetes status, and smoking status."
1551338|NCT02588690|Procedure|Blood pressure measurement|Blood pressure measurement
1551339|NCT02588677|Drug|Masitinib (AB1010)|4.5 mg/kg/day, 3 mg/kg/day
1551340|NCT02588677|Drug|Riluzole|
1551341|NCT02588677|Drug|Placebo|
1551342|NCT02588664|Other|COMPASS Intervention|"A Post-Acute Coordinator (PAC) will visit each patient prior to discharge from the hospital.
Patient will receive a follow-up telephone call two days after having been discharged.
7-14 days after discharge, the patient will attend post-acute stroke clinic visit and receive an assessment from an Advanced Practice Provider (APP), a brief patient-reported functional assessment to generate an individualized Care Plan, and referrals from an APP. The patient's primary caregiver will be assessed to ensure caregiver availability and ability to support the patient and the caregiver's ability to cope with the new challenges of caregiving.
Patient will receive a call at 30 and 60 days post-discharge for follow-up of functional status, recovery, risk factor management and their access or utilization of recommended services."
1551343|NCT02588651|Drug|Brentuximab vedotin|study drug given intravenously to determine efficacy in study diseases
1551344|NCT02588625|Drug|BMS-986020|
1551345|NCT02588625|Other|Placebo|
1551347|NCT02588599|Device|Erchonia LUNULA|Active low level laser light therapy
1551348|NCT02588586|Drug|3BNC117|3BNC117 infusions
1551349|NCT02588586|Other|Antiretroviral Treatment Interruption|Antiretroviral therapy will be discontinued 2 days after the third 3BNC117 infusion, at week 24, and resumed at week 36.
1551352|NCT02588547|Drug|Granisetron|IV granisetron 1 mg before spinal anethesia
1551353|NCT02588547|Drug|Granisetron|IV granisetron 0.7 mg before spinal anethesia
1551354|NCT02588547|Drug|pethidine|IV Pethidine 25 mg before spinal anethesia
1551355|NCT02588547|Drug|Sodium chloride|IV 2 ml 0.9 sodium chloride before spinal anethesia
1551356|NCT02588534|Device|etanercept (ENBREL®) via auto-injector device|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via an auto-injector device manufactured by Scandinavian Health Limited (SHL)
1551357|NCT02588534|Other|Etanercept (ENBREL®) via Manual injection|single 50 mg subcutaneous dose of liquid etanercept (ENBREL®) in a 1.0 ml pre-filled syringe administered via manual injection (reference treatment) to compare to the auto-injection
1551360|NCT02588508|Procedure|Warm packs|: The warm packs are held in the mother's perineum during birth. The warm packs are changed as needed to maintain warmth.
1551361|NCT02588508|Procedure|Perineal massage|"The perineal massage will be gently held in the longitudinal direction of the muscle fibers, with movements of the thumb and forefinger, like count coins."
1551362|NCT02588495|Other|Food intake|Either drinking a cup of clear liquid, or having a cup of coffee and a muffin
1551363|NCT02588482|Device|high-density electroencephalography|Auditory stimulations during electroencephalography recording
1551364|NCT02588482|Device|Conventional electroencephalography|Auditory stimulations during electroencephalography recording
1551365|NCT02588469|Other|Interventional group|"Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.
To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA."
1551366|NCT02588469|Other|Control group|Standard obesity care with physical activity program
1551375|NCT02588391|Behavioral|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving are set to a consistent level.
1551376|NCT02588391|Behavioral|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem-solving either match the child's level or are set to a consistent level depending on which version the child has already completed.
1551377|NCT02588378|Procedure|multi-modal cSLO imaging|
1551378|NCT02588365|Behavioral|Brain Training (Active)|Online computer games targeting attention, EF, and problem-solving
1551379|NCT02588365|Behavioral|Brain Training (Passive)|Online computer games targeting attention, EF, and problem solving
1551380|NCT02588365|Behavioral|Brain Training (Active or Passive)|Online computer games targeting attention, EF, and problem solving
1551381|NCT02588352|Dietary Supplement|Salt tablet|Subjects will be given salt tablets and instructed to take 4 grams of sale three times a day (total of 12 grams of salt/day) for one week
1551385|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 1|Mometasone furoate drug formulation (MFF) 1 will be administered by suspension-based nasal spray.
1551386|NCT02588326|Drug|Mometasone furoate drug formulation (MFF) 2|Mometasone furoate drug formulation (MFF) 2 will be administered by suspension-based nasal spray.
1551387|NCT02588313|Dietary Supplement|Mango fruit powder|Investigation of long-term effects of CarelessTM on microcirculation in healthy volunteers - a randomized, double-blind, placebo-controlled study with parallel design
1551388|NCT02588300|Procedure|Drug induced sleep endoscopy|Titration of propofol using a target controlled Infusion pump and description of the upper airway according to the VOTE classification
1551389|NCT02588287|Other|Blood draws for tenofovir PK, renal function|
1551390|NCT02588274|Device|Acupuncture|Acupuncture is one of the oldest standardized neuromodulatory therapies. The method of acupuncture treatment involves the insertion of needles in acupuncture points according to a system of channels and meridians. The needles are stimulated by manual manipulation, electrical stimulation or heat. The general theory of acupuncture is based on the premise that there are patterns of energy flow through the body that are essential for health. Disruptions of this flow are believed to be responsible for disease. Acupuncture may correct imbalances of flow at identifiable points close to the skin.
1551391|NCT02588274|Device|placebo needle|Placebo needle is a type of control without skin penetration based on the application of placebo needles with blunt needle tips.
1551395|NCT02588248|Drug|Peppermint Oil|
1551396|NCT02588248|Other|Placebo|
1551397|NCT02588235|Drug|Ezetimibe and Atorvastatin|atorvastatin (20 mg/day）plus ezetimibe（10 mg/day）
1551398|NCT02588235|Drug|Atorvastatin|atorvastatin (20 mg/day）
1551399|NCT02588209|Behavioral|Strategic Memory Advanced Reasoning Training|SMART teaches strategies to improve the ability to process information.
1551400|NCT02588209|Behavioral|Brain Health Workshop|Brain Health Workshop provides information about brain health in a seminar format. Topics include: sleep, nutrition, and exercise.
1551401|NCT02588196|Drug|Dexamethasone acetate|
1551402|NCT02588183|Device|ArticFont Advance ST Cryoenergy Balloon Catheter|PV isolation using the ArticFont Advance ST Cryoenergy Balloon Catheter
1551403|NCT02588170|Drug|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle
1551404|NCT02588170|Other|Placebo|Placebo 300 mg once a day (QD) will be orally administrated on a 28-day cycle
1551405|NCT02588157|Device|Macintosh|Direct laryngoscopy
1551406|NCT02588157|Device|Glidescope|Glidescope videolaryngoscope
1551407|NCT02588157|Device|McGrath MAC X-Blade|McGrath MAC X-Blade videolaryngoscope
1551408|NCT02588144|Procedure|[standard STN]|High frequency deep brain stimulation with variable (best individual) stimulation on subthalamic contacts
1551409|NCT02588144|Procedure|[STN+SNr]|high frequency deep brain stimulation of combined (best individual) subthalamic and nigral stimulation
1551410|NCT02588131|Drug|tremelimumab plus MEDI4736|tremelimumab1 mg/kg i.v over 60 minutes plus MEDI 4736 20 mg/kg i.v every four weeks for 4 doses, then MEDI4736 20 mg/kg IV every four weeks for additional 9 doses.
1551411|NCT02588118|Drug|propofol|Propofol 3 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 2 min (t2). Patients will be monitored using bispectral index monitoring for propofol and TOF-Watch neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
1551412|NCT02588118|Drug|Cisatracurium|Propofol 3 mg/kg (t0) followed by cisatracurium 0.1 mg/kg 2 min (t2). Patients will be monitored using bispectral index monitoring for propofol and TOF-Watch neuromuscular monitoring for cisatracurium. Serial arterial blood samples (5 ml) were withdrawn in EDTA-tubes before cisatracurium administration, 1, 3, 5, 7, 10, 13, 16, 19, 22, 25, 30, 60 and 90 min following administration. Blood samples were assayed in duplicate using high performance liquid chromatograph for Pharmacokinetic analysis.
1551413|NCT02588105|Drug|AZD0156|All patients will receive AZD0156 as a monotherapy or in combination to assess safety and tolerability.
1551414|NCT02588105|Drug|Olaparib|Module 1 combination with olaparib
1551415|NCT02588092|Drug|ADCT-301|intravenous infusion
1551416|NCT02588079|Behavioral|Internet-based cognitive behavioral therapy|
1551417|NCT02588066|Procedure|Ligamentum teres/falciform-plasty|Ligamentum teres/falciform-plasty around the gastroduodenal artery stump during pancreatoduodenectomy
1551418|NCT02588040|Biological|Leukocyte- and Platelet-Rich Plasma (L-PRP)|The Recover L-PRP Mini Platelet Separation Kit aids in the separation of the patient's own blood components by density through the use of a Biomet Biologics centrifuge.
1551419|NCT02588027|Drug|Ibuprofen|Patients will be randomized using a computer generated number to received either ibuprofen (400mg by mouth every eight hours as needed) versus placebo for post-operative pain control in addition to opiate medication (hydrocodone/acetaminophen). Study doctors or research staff will be given randomly generated treatment allocations within sealed opaque envelopes. Once the patient is screened/qualified in surgery, the envelope will be opened and the patient randomized to the allocated treatment regimen. Patients will be given a two week supply (42 pills total) of either ibuprofen or placebo on the day of surgery upon discharge from the surgery center by a research coordinator.
1551420|NCT02588027|Drug|Placebo|Pharmacy formulated placebo
1551421|NCT02588014|Other|Magnetoencephalography|Magnetoencephalography is a non-invasive technique for investigating human brain activity. It allows the measurement of ongoing brain activity on a millisecond-by-millisecond basis, and it shows where in the brain activity is produced.
1551423|NCT02587988|Drug|HCP1302|
1551424|NCT02587988|Drug|HGP0904|
1551425|NCT02587988|Drug|Placebo (for HCP1302)|
1551426|NCT02587988|Drug|Placebo (for HGP0904)|
1551427|NCT02587975|Drug|Evogliptin|10 mg
1551428|NCT02587962|Drug|Birinapant|Birinapant IV on Days 1 and 8 of each 21-Day Cycle. The following escalating doses of birinapant to be studied: 5.6, 11, 17, and 22 mg/m2
1551429|NCT02587962|Drug|Pembrolizumab|200 mg pembrolizumab IV on Day 1 of each 21-Day Cycle
1551430|NCT02587936|Other|Collaborative Model of Primary care and Subspecialty care|Pieces will access Electronic Health Record for all patients receiving care at the participating sites to detect patients with a triad of chronic kidney disease, diabetes and hypertension, facilitate management and monitor outcomes. To maximize successful implementation of care, a Practice Facilitator will be at each site with standardized role training using a curriculum based on the Agency for Healthcare Research and Quality (AHRQ) Practice Facilitation Handbook. Specific interventions are maintaining BP less than 140/90 mmHg, use of angiotensin-converting-enzyme inhibitor (ACEI) or angiotensin receptor blocker (ARB), treatment with statins, aiming for glycosylated Hemoglobin (HgA1C) at the recommended target, and avoiding nephrotoxic medications. Additional interventions include chronic kidney disease education for Primary Care Providers (PCP) and patients using National Kidney Disease Education Program (NKDEP) materials.
1551431|NCT02587910|Dietary Supplement|Melanole for GERD treatment|Melanole is given orally as 2 capsules TID 5 minutes before each meal
1551432|NCT02587910|Dietary Supplement|Placebo|Placebo is given orally as 2 capsules TID 5 minutes before each meal
1551433|NCT02587897|Other|Academic Coursework|Didactic training provided by the university through coursework and laboratory training that meets requirements of the accreditation standards provided by the professional society associated with each professional degree granting program.
1551434|NCT02587897|Other|Work-Related Hand Activities|Exposure to intensive training in the use of dental scaling tools as part of laboratory courses, as well as fieldwork and residency training during the academic degree program.
1551435|NCT02587884|Procedure|TACE|Patients will treated by TACE in 4 or 8 weeks after operation.
1551436|NCT02587871|Drug|Cytarabine|Given IV
1551437|NCT02587871|Other|Laboratory Biomarker Analysis|Correlative studies
1551438|NCT02587871|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo microtransplant
1551439|NCT02587871|Biological|Therapeutic Allogeneic Lymphocytes|Undergo microtransplant
1551440|NCT02587871|Biological|G-CSF mobilized peripheral blood cells|microtransplantation
1551441|NCT02587845|Drug|Tranexamic Acid (IV)|IV tranexamic acid group were administered intravenous 10 mg/kg dose of TXA after closing the ITB.
1551442|NCT02587845|Drug|Tranexamic Acid (Topical)|Topical tranexamic acid group were administered 2.0 g TXA in 100 ml of normal saline into the hemovac line after closing the ITB.
1551443|NCT02587832|Device|HHHFNC|Tri-Anim Vaptherm the Precision Flow, which is a self contained unit that provides flow rates up to or 8 LPM (Infants) of blended oxygen that is heated and humidified
1551444|NCT02587832|Device|NCPAP|Bubble CPAP System.
1551445|NCT02587819|Drug|Treatment with BSCT|"The study product BSCT (anti-nf-P2X7) 10% Ointment was anti-nf-P2X7 (highly purified sheep IgG) in an ointment formulation for topical administration. The formulation contained 10% weight by weight of the active pharmaceutical ingredient in an anhydrous ointment base.
Fifty (50) to 100 mg of product (an amount the size of a small pea) was applied topically twice a day for 28 days to a 25 cm2 area of skin containing a single BCC lesion. The product was to be applied in the morning and in the evening after washing."
1551446|NCT02587806|Biological|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
1551447|NCT02587806|Other|Liberation therapy|
1551448|NCT02587793|Other|not interventional study|
1551449|NCT02587767|Device|577-MPL|All treatments were provided by a single practitioner with the 577-nm yellow laser system(Supra 577nm LaserSystem) in 577-MPL arm. The individual power for the patient was titrated at a normal area of near the affected area in micropulse model.The power titration was started at 700 milliwatt(mW) and then gradually increased until a just visible burn was seen. When this threshold was reached, the power was reduced by 50%, using a 100-μm spot diameter and a 200-ms duration with 5 % duty cycle.
1551490|NCT02587533|Other|Hypoxia with dopamine|Target hemoglobin oxygen saturation (SpO2) 80%. Dopamine dose 3 µg/kg/min.
1551450|NCT02587767|Device|HD-PDT|5 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will been performed in HD-PDT arm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds.
1551451|NCT02587754|Device|Acupuncture|10 sessions of acupuncture, twice a week over 5 weeks.
1551452|NCT02587741|Drug|Metformin|start with metformin，from 500mg bid,if metformin reach the biggest dosage，added gliclazide modified release tablets，afterthat，add acarbose
1551453|NCT02587741|Drug|Lantus|started with insulin glargine 0.2 u/kg subcutaneous injection ，add dosage if glucose dose not reach the target.after that,you can add oral drugs（like oral drug group）
1551454|NCT02587741|Drug|Novomix30|started with premixed insulin subcutaneous injection(0.4-0.6 u/kg divided into half before breakfast and dinner),and add dosage if glucose dose not reach the target.after that,you can add oral drugs ,as Group Oral Drugs
1551455|NCT02587728|Procedure|Blood Draw|Samples to be obtained from all subjects will include 70cc samples of heparinized whole blood. Blood specimens will be obtained specifically for the purposes of this study, and will be collected at intervals required for clinical purposes to minimize the need for additional blood draws of study participants.
1551456|NCT02587715|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
1551457|NCT02587715|Other|Liberation therapy|
1551458|NCT02587702|Other|β-Palmitate Content|
1551459|NCT02587702|Other|Placebo|
1551460|NCT02587702|Other|β-Palmitate Content Naturely in Human Milk|
1551461|NCT02587689|Biological|anti-MUC1 CAR T Cells|
1551462|NCT02587676|Other|Evatouch Super|The deterioration of RDLs may differ between in vitro conditions and the conditions encountered in denture wearers. We conducted an in vivo study to investigate how resilient denture liners (RDLs) changed in hardness when embedded in complete maxillary dentures worn by patients for one month in a clinical setting. We hypothesized that the hardness one month after application of the RDLs would be affected by the age, the condition of the saliva, the occlusal force, type of denture used, the patients habits related to smoking, drinking, wearing dentures while sleeping, and using a denture cleanser.
1551463|NCT02587663|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo bilateral breast contrast enhanced MRI
1551464|NCT02587663|Procedure|Mammography|Undergo bilateral mammography
1551465|NCT02587663|Procedure|Therapeutic Conventional Surgery|Undergo breast conserving surgery
1551466|NCT02587663|Procedure|Ultrasonography|Undergo bilateral whole-breast ultrasound
1551467|NCT02587663|Procedure|Ultrasonography|Undergo targeted breast ultrasound
1551468|NCT02587663|Other|Gadolinium|Contrast agent used in MRI
1551469|NCT02587650|Drug|INC280|
1551470|NCT02587650|Drug|Ceritinib|
1551471|NCT02587650|Drug|Regorafenib|
1551472|NCT02587650|Drug|Entrectinib|
1551473|NCT02587637|Device|Dorsal Root Ganglion Stimulation|
1551474|NCT02587624|Procedure|catheter ablation|Intervention: All patients undergo magnetically guided pulmonary vein antral isolation and mapping for fibrotic areas. Procedural endpoint: bidirectional PV block. Additional substrate modification on decision of the operator.
1551475|NCT02587611|Other|Elemental liquid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg [13C]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
1551476|NCT02587611|Other|Standard semi-solid diet|This is a randomized, crossover trial. Two types of test meals (200 kcal/200 mL of either the elemental diet or the semi-solid diet) are labeled with 100 mg [13C]sodium acetate and administered within 5 min in healthy subjects or within 15 min in gastrostomy-fed patients.
1551477|NCT02587598|Drug|INCB053914|"Initial cohort dose of INCB053914 at the protocol-specified starting dose in two treatment groups in dose escalation, with subsequent expansion in up to five cohorts based on protocol-specific criteria.
INCB053914 tablets to be administered by mouth."
1551478|NCT02587598|Drug|INCB053914|Initial cohort dose of INCB053914 at the protocol-specified starting dose. INCB053914 tablets to be administered by mouth.
1551479|NCT02587598|Drug|I-DAC (Intermediate dose cytarabine)|Cytarabine dose will be 1 g/m^2. Cytarabine will be administered as an intravenous (IV) infusion.
1551480|NCT02587598|Drug|Azacitidine|Azacitidine dose will be 75 mg/m^2. Azacitidine will be administered either sub-cutaneously (SC) or intravenously (IV).
1551481|NCT02587598|Drug|Ruxolitinib|Starting dose of ruxolitinib will be the dose the subject was on at study entry Ruxolitinib will be administered by mouth.
1551482|NCT02587585|Behavioral|Feedback against tailored target|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. In the active group, the watch will summate activity movement in two hour epochs and the target for the day for that epoch is the activity in the same epoch 24 hours earlier, plus 5%. During an epoch the patient is shown progress towards the target at at the end of an epoch, they will see their final process towards target for that epoch.
1551483|NCT02587585|Behavioral|No feedback|Participants will wear a smart watch every weekday for nine hours during in-patient rehabilitation to monitor activity levels while receiving their usual care. However the watch face will simply show which epoch a person is in. The watch will collect the activity in exactly the same way over the day.
1551484|NCT02587572|Biological|Peripheral Intravenous (IV) infusion of LMSCs|Peripheral Intravenous (IV) infusion of LMSCs
1551485|NCT02587559|Procedure|physical therapy|application of manual therapy techniques to upper extremity along with therapeutic exercise procedures to the axioscapular and rotator cuff musculature
1551486|NCT02587546|Procedure|laryngeal carcinoma|treatment of laryngeal carcinoma using thulium contact laser
1551487|NCT02587546|Procedure|bilateral vocal cord paralysis|treatment of bilateral vocal cord paralysis using thulium contact laser
1551488|NCT02587546|Procedure|subglottic stenosis|treatment of subglottic stenosis using thulium contact laser
1551489|NCT02587533|Other|Hypoxia without dopamine|Target hemoglobin oxygen saturation (SpO2) 80%.
1551492|NCT02587533|Other|Hyperoxia with dopamine|Nearly complete hemoglobin oxygen saturation. Dopamine dose 3 µg/kg/min.
1551493|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed Formulation 1|0.5 mL, Intramuscular
1551494|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 2|0.5 mL, Intramuscular
1551495|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 3|0.5 mL, Intramuscular
1551496|NCT02587520|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed, Formulation 4|0.5 mL, Intramuscular
1551497|NCT02587520|Biological|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid, and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
1551498|NCT02587520|Biological|Licensed Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine|0.5 mL, Intramuscular
1551499|NCT02587507|Other|Orange juice|Individuals will consume the HFHC meal with 500mL of orange juice.
1551500|NCT02587507|Other|Water|Individuals will consume the HFHC meal with 500mL of water.
1551501|NCT02587507|Other|Water with glucose|Individuals will consume the HFHC meal with 500mL of water with glucose.
1551502|NCT02587494|Procedure|Cardiac catheterization|Cardiac catheterization / coronary angiography is a diagnostic procedure used to define the coronary anatomy and presence of obstructive coronary lesions or culprit lesions. According to the findings, it may lead to percutaneous coronary intervention (PCI) using stents
1551503|NCT02587468|Dietary Supplement|Juice Plus+(R)|before-after comparison of plasma phenolics
1551504|NCT02587455|Drug|Pembrolizumab|Pembrolizumab - Trial Treatment
1551505|NCT02587455|Radiation|Radiotherapy|Radiotherapy - Standard Treatment
1551506|NCT02587442|Drug|RadProtect®|This study will evaluate RadProtect® at sequential, escalating dose levels. Once administration is given, study subjects will be followed during 24 hours of hospitalization according to the final injection timing. All subjects will need to return to the hospital for monitoring at 7+2 days after dosing, and follow-up visits by telephone at Day 3, Day 14+2, and Day 28+2 days will need to be conducted.
1551507|NCT02587429|Behavioral|Patient education|
1551508|NCT02587416|Drug|Gemcabene 300 mg|1x300 mg gemcabene tablets orally once daily (QD) for 11 days
1551509|NCT02587416|Drug|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 11 days
1551510|NCT02587416|Drug|Atorvastatin|2x40 mg Atorvastatin tablets orally once daily (QD)
1551513|NCT02587390|Drug|Gemcabene 900 mg|3x300 mg Gemcabene tablets orally once daily (QD) for 15 days
1551514|NCT02587390|Drug|Simvastatin 80 mg|2x40 mg Simvastatin tablets orally once daily (QD) for 15 days
1551515|NCT02587377|Other|Non Standard of Care blood samples collection|According to Belgian Law of 07MAY2004, if non standard of care interventions are performed as per protocol, the study must be classified as Interventional Study.
1551516|NCT02587364|Drug|Gemcabene 50 mg|Gemcabene 50 mg once daily (QD)
1551517|NCT02587364|Drug|Gemcabene 150 mg|Gemcabene 150 mg once daily (QD)
1551518|NCT02587364|Drug|Gemcabene 450 mg|Gemcabene 450 mg once daily (QD)
1551519|NCT02587364|Drug|Gemcabene 750/600 mg|Gemcabene 750/600 mg once daily (QD)
1551520|NCT02587364|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
1551521|NCT02587364|Drug|Placebo|Placebo once daily (QD)
1551522|NCT02587351|Drug|Metoprolol succinate|Extended release Metoprolol succinate
1551523|NCT02587351|Other|Placebo|Matching placebo
1551524|NCT02587338|Device|Verum tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 2000 microampere left anadal, right cathodal
1551525|NCT02587338|Device|Sham tDCS|Neuropsychological (Working memory) training for 30 minutes, 6 sessions tDCS during training with 0 microampere
1551526|NCT02587325|Drug|ABI-009, nab-rapamycin, albumin-bound rapamycin|ABI-009
1551527|NCT02587312|Other|Very low nicotine content cigarettes|
1551528|NCT02587312|Other|Standard nicotine content cigarettes|
1551529|NCT02587286|Other|Gather app|Participants in the intervention group will receive the Gather Health software free for the duration of the study. Their medication and BG testing goals will be entered into the system and they will receive automated reminders. Their data will be regularly reviewed by study staff and feedback provided.
1551530|NCT02587273|Drug|Fentanyl|In this study there will be no administration of an investigational product per study protocol. The dosage of fentanyl will be according to the ICU's established procedures and the treating physician's judgment. The specific dose of fentanyl given to each patient will differ extensively. By routine, the ICU's in our hospital usually dose the fentanyl infusion as 0,5 - 6 μg/kg/hrs (kg = Ideal Body Weight). The intervention in this study will be a per protocol cessation in administration of fentanyl over a 6 hours period. Arterial blood samples, urine samples, pre and post filter samples and samples from dialysate will be collected during this 6 hours. If the patient needs opioid analgesia during the period, alternative opioid analgesia will be given.
1551531|NCT02587260|Drug|Ticagrelor|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
1551532|NCT02587260|Drug|Prasugrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
1551533|NCT02587260|Drug|Clopidogrel|Comparison of ticagrelor with respect to prasugrel and clopidogrel in a different sequence
1551534|NCT02587247|Drug|TF2 antibody/68Ga-IMP-288|
1551535|NCT02587234|Device|peripheral nerve stimulation|Non-invasive stimulation of median, ulnar and radial nerves
1551536|NCT02587221|Biological|MF59-adjuvanted Quadrivalent Influenza Vaccine|1 dose approximately 0.5 mL of aQIV
1551537|NCT02587221|Biological|Non-Influenza Comparator vaccine|1 dose approximately 0.5 mL dose of Non-influenza comparator vaccine
1551538|NCT02587208|Device|Plastibell|In the Plastibell group, the size of the device is chosen according to the lateral-lateral diameter of the glans. A dorsal slit incision is made and then the foreskin is pulled up and the Plastibell device placed between the prepuce and the glans. A non-absorbable string was tightly tied around the device and the distal prepuce is removed.
1551539|NCT02587208|Procedure|conventional sleeve|In the sleeve dissection group, a double incision technique on both outer and inner layers of the foreskin is employed. Hemostasis is achieved by bipolar diathermy, and cut edges are sutured with 5/0 rapide vicryl.
1551540|NCT02587195|Drug|Teriflunomide|
1551541|NCT02587182|Device|Deep Dry needling|The muscles were repeatedly perforated by rapidly inserting and partially withdrawing the needle from the myofascial trigger point, eliciting local twitch responses in some insertions
1551542|NCT02587169|Drug|Nilotinib-adriamycin|The nilotinib-adriamycin combination will be given in 4 cycles of 21 days. In each cycle, nilotinib will be administered at fixed dose of 400 mg/12h orally during 6 consecutive days (1-6) and endovenous adriamycin (20 minutes) on day 5 at three levels (in phase I, dosage of 60 mg/m2, 65 mg/m2, and 75 mg/m2 will be tested to determine the recommended dose for phase II).
1551543|NCT02587156|Dietary Supplement|Meal serving at high dietary protein|Participants are habituated to a high level of dietary protein intake for 21 days.
1551544|NCT02587156|Dietary Supplement|Meal serving at low dietary protein|Participants are habituated to a low level of dietary protein intake for 21 days.
1551545|NCT02587156|Dietary Supplement|Meal serving|To investigate impact of habituated protein level
1551548|NCT02587130|Drug|Ketamine|ketamine administered in bolus by subcutaneous injection
1551549|NCT02587117|Drug|lycopene|Each capsule contain 2 mg lycopene. Each patient was received two capsules of lycopene (total dose was 4 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
1551550|NCT02587117|Drug|Prednisolone|Each capsule contain 20 mg prednisolone. Each patient was received two capsules of prednisolone (total dose was 40 mg) single dose in morning for 2 months. Follow-up was done at base line, 2nd, 4th, 6th and 8th weeks of the therapy.
1551551|NCT02587104|Other|EpiFix|Weekly application of EpiFix and standard of care (moist wound therapy and offloading)
1551552|NCT02587091|Behavioral|Portable obstetric ultrasound|This intervention was advertised at the cluster level
1551553|NCT02587078|Drug|Volulyte|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
1551554|NCT02587078|Drug|Jonosteril|Patients who meet the inclusion criteria (at Screening, see below for definition) will be randomized immediately in a ratio of 1:1 to either intravenous Volulyte® or Jonosteril® for fluid resuscitation (on RAND). Fluid resuscitation with study drug will be started immediately in order to reach initial hemodynamic stabilization.
1551555|NCT02587065|Drug|peginterferon beta-1a|125 mcg administered subcutaneously (SC) every 2 weeks.
1551556|NCT02587052|Drug|Generic tacrolimus|Generic tacrolimus
1551557|NCT02587052|Drug|Prograf|Prograf, the original tacrolimus
1551558|NCT02587039|Procedure|Remote ischemic pre-conditioning|Remote ischemic preconditioning is exposure to a brief period ischemia to an area or limb that is not involved in surgery. This intervention is believed to reduce the incidence of cerebral (brain) ischemia during cardiac surgery.
1551559|NCT02587039|Behavioral|Delirium Assessment|The Delirium assessment consist of a validated psychiatric screening tool called the Confusion Assessment Method. We will use this tool to determine if patients have any confusion after surgery.
1551560|NCT02587026|Other|Blood sample collection|
1551561|NCT02587026|Other|Tumor tissue sample collection|
1551562|NCT02587013|Procedure|Type A of uterine repair: In situ|The uterine incision is closed with the uterus within the abdominal cavity
1551563|NCT02587013|Procedure|Type B of uterine repair: Exteriorization|The uterine incision is repaired with the exteriorization of the uterus
1551564|NCT02587000|Drug|Ulipristal acetate|
1551565|NCT02587000|Drug|Placebo|
1551566|NCT02586987|Drug|Selumetinib|Selumetinib oral
1551567|NCT02586987|Drug|MEDI4736|MEDI4736 IV
1551568|NCT02586987|Drug|Tremelimumab|Tremelimumab, IV
1551569|NCT02586974|Device|Humigard|warmed and humidified CO2 insufflation
1551570|NCT02586961|Drug|0.9% saline solution|"Placebo:
Nebulized 0.9% saline solution"
1551571|NCT02586961|Drug|oral betamethasone placebo|placebo of oral betamethasone: equivalent of 1 mg/kg at inclusion followed by five once-daily doses
1551572|NCT02586961|Drug|adrenaline|Catecholamine nebulized adrenaline (3 ml of 1:1000 solution)
1551573|NCT02586961|Drug|oral betamethasone|Mineralocorticoid: a short course of oral betamethasone: 1.0 mg/kg at inclusion, followed by five once-daily doses (0.6 mg/kg)
1551574|NCT02586948|Device|extracorporeal CO2 removal (Hemolung device)|ECCO2R in severe exacerbation of COPD patients, requiring invasive mechanical ventilation with persistent respiratory acidosis and dynamic hyperinflation
1551575|NCT02586935|Drug|Tideglusib|Administered orally after dispersion in approximately 100 ml of water at dose levels of 400 to 1000 mg
1551576|NCT02586935|Other|Placebo|Administered orally after dispersion in approximately 100 ml of water
1551577|NCT02586922|Device|Three-dimensional (3D) ultrasonography|A longitudinal section of fetal chest will be obtained that clearly depicts the lung. A 3D window will be activated . After complete electronic sweep and assurance of absence of fetal or maternal movements to avoid motion artifacts, 3D multi-planar view will be then obtained
1551578|NCT02586909|Drug|RVT-101 35 mg tablets|once daily, oral tablets
1551612|NCT02586649|Drug|Tiotropium Bromide|Tiotropium bromide is an anticholinergic used to study bronchodilatation and improvement of pulmonary function in tetraplegic patients
1551613|NCT02586649|Drug|Placebo|Placebo is a non-active inhalation capsule .
1551614|NCT02586636|Drug|Metformin|Metformin is given alongside omeprazole / placebo. Started at low dose and titrated gradually over four weeks according to the individual's tolerance of metformin. We anticipate that their tolerance of metformin will be reduced by loss of function variants in OCT1, and by concurrent use of OCT1 inhibiting drugs (in our study this is omeprazole).
1551737|NCT02585869|Drug|Gemcabene 150 mg|Blinded capsules and tablets, 150 mg, once daily, 84 days
1551581|NCT02586883|Other|bronchial ddp test|bronchial ddp test during endoscopy, nasal smear, bronchial smear
1551582|NCT02586870|Device|Intravascular Ultrasound|
1551583|NCT02586857|Drug|ACP-196|
1551584|NCT02586831|Drug|Anti-Thymocyte Globulin (ATG)|Concomitant Drug Administration
1551585|NCT02586831|Drug|Placebo|Drug Administration
1551586|NCT02586831|Drug|Pegylated GCSF|Concomitant Drug Administration
1551587|NCT02586831|Drug|Interleukin 2|Concomitant Drug Administration
1551588|NCT02586831|Drug|Etanercept|Concomitant Drug Administration
1551589|NCT02586831|Drug|Exenatide|Concomitant Drug Administration
1551590|NCT02586818|Procedure|SOC fingerstick|sample collection
1551591|NCT02586818|Procedure|Venous blood draw|sample collection
1551592|NCT02586805|Drug|DX-2930 - 300mg/2wk|300 mg DX-2930 administered every 2 weeks by subcutaneous injection.
1551593|NCT02586805|Drug|DX-2930 - 300mg/4wk|300 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
1551594|NCT02586805|Drug|DX-2930 - 150mg/4wk|150 mg DX-2930 administered every 4 weeks by subcutaneous injection. To maintain the study blind, subjects will be given placebo injections every other 2 weeks when they are not receiving drug.
1551595|NCT02586805|Drug|Placebo|Placebo administered every 2 weeks by subcutaneous injection.
1551596|NCT02586792|Biological|Monovalent influenza A/H7N9 virus vaccine|Monovalent influenza A/H7N9 virus vaccine.
1551597|NCT02586779|Other|whatsApp|whatsApp application will be used for consultations.
1551598|NCT02586779|Other|without whatsApp|whatsApp application will be not used for consultations.
1551599|NCT02586766|Behavioral|Project Sync|A 30 minute private on-on-one brief motivational interviewing intervention given during emergency department care. The goal of the intervention was to reduce and prevention youth violence using techniques to change behavior in a respectful, non-confrontational, and non-judgmental manner. This one-on one counseling approach emphasizes individual choice and responsibility and differentiates between future goals/values and current behavior
1551600|NCT02586753|Other|Paclitaxel plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy, PT regime (paclitaxel and cisplatine ) Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PT regimen (cisplatin of 20 mg/m2/d, d1-3; PTX(paclitaxel)of 135mg/m2/d, d1) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.
Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
1551601|NCT02586753|Other|S1 plus Cisplatin with radiotherapy|"we want to compare which regime is better with radiotherapy,SP regime (Tegafur Gimeracil Oteracil Potassium Capsule and cisplatine).
Chemotherapy: Patients will be concurrently administered with irradiation every 3 weeks with PS regimen (cisplatin of 20 mg/m2/d, d1-3; S1(Tegafur Gimeracil Oteracil Potassium Capsule)of 50mg/m2/d, d1-14) for 4 cycles. For the first 2-cycles of chemotherapy they will be concurrently given with irradiation and the remained 2 cycles, after irradiation.
Radiotherapy:Patients will be conducted CT simulation, and Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator."
1551602|NCT02586740|Procedure|Pulmonary artery rehabilitation|
1551603|NCT02586727|Drug|aflibercept|This study will consist of 2 simultaneous treatment arms of aflibercept: A six week dosing regimen arm and a treat and extend (TAE) dosing regimen arm, total duration 54 weeks. In the TAE arm the patients will receive an intravitreal aflibercept injection first visit, again at the second visit at 6 weeks, and then begin treat and extend from second injection forward.
1551604|NCT02586714|Other|No intervention|Observation only
1551605|NCT02586701|Other|Prehabilitation Plus|Supervised exercise program and home-based exercise program.
1551640|NCT02586454|Drug|ropivacaine|
1551615|NCT02586636|Drug|Omeprazole|Given as concurrent treatment in one of the two treatment periods. Omeprazole treatment dose is fixed at 20mg twice daily for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
1551616|NCT02586636|Drug|Placebo|Given as concurrent treatment in one of the two treatment periods. Placebo treatment dose is fixed at one tablet twice daily (to match the dosing pattern of omeprazole) for four weeks duration. Omeprazole, in our study, is used as an OCT1 inhibitor, and we hypothesise that this will reduce an individual's maximum tolerated dose of metformin during concurrent treatment. This will be compared to the other treatment period in which concurrent treatment is a placebo, and therefore, the maximum tolerated dose of metformin would not be affected.
1551617|NCT02586623|Drug|Droxidopa capsules|100, 200 or 300 mg
1551618|NCT02586623|Drug|Placebo capsules|
1551619|NCT02586610|Drug|Pembrolizumab|Pembrolizumab 200 mg IV Days 1, 22 and 43
1551620|NCT02586610|Drug|Capecitabine|Capecitabine 825 mg/m2 PO twice a day (daily total 1650 mg/m2) on 5 consecutive days / week M-F given on the radiation days for 28 days
1551621|NCT02586610|Radiation|Radiation Therapy|Radiation 50.4 GY in daily fractions of 1.8 Gy over a 6 week interval (excludes weekends)
1551622|NCT02586597|Device|Transcranial magnetic stimulation & median nerve stimulation|"Paired associative stimulation (PAS) is a new technique where one pairs a peripheral stimulation with centrally applied transcranial magnetic stimulation (TMS), and produces plasticity, as measured by TMS MEP's. Currently PAS is performed with median nerve stimulation.
PA25: The interval between median nerve stimulation and TMS was chosen to be 25 ms, which is called PAS25. 240 paired TMS and median nerve stimulation at a frequency of 0.2 Hz over 20 min.
PAS10: 240 paired TMS and median nerve stimulation with interval of 10 min second at a frequency of 0.2 Hz over 20 min.
PAS100: 240 paired TMS and median nerve stimulation with interval of 100 min second at a frequency of 0.2 Hz over 20 min."
1551623|NCT02586571|Behavioral|Breastfeeding|Breastfeeding at 5.5 months of age (exclusive or partial)
1551624|NCT02586558|Other|Experimental Infant formula|Ready-to-feed infant formula to be fed ad libitum
1551625|NCT02586558|Other|Reference group|Ready-to-feed infant formula to be fed ad libitum
1551626|NCT02586545|Other|Shared care|
1551627|NCT02586519|Device|SurroSense Rx System|"The SurroSense Rx system (Orpyx Medical Technologies Inc., Calgary, AB) is a smart insole system designed to aid in the prevention of plantar pressure ulceration and re-ulceration, and the treatment of active ulcers in neuropathic patients. It comprises two pressure-sensing inserts and a smartwatch display device. The device alerts the user when safe pressure and time thresholds have been exceeded so that on-demand offloading can occur."
1551630|NCT02586493|Drug|Placebo|Subjects will receive 1 inhalation once-daily until visit 2.
1551631|NCT02586493|Other|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
1551633|NCT02586467|Behavioral|Gain-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.)
1551634|NCT02586467|Behavioral|Loss-Framed|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium).
1551635|NCT02586467|Behavioral|Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Self-Regulatory Efficacy message condition will receive information pertaining to how to include milk and milk products within their diet. This information will come in the form of recipes, meal planning, food combining etc.
1551636|NCT02586467|Behavioral|Gain-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Gain-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential benefits of consuming milk and milk products (i.e., high protein content, stronger hair and nail etc.) and information pertaining to how to include milk and milk products within their diet.
1551637|NCT02586467|Behavioral|Loss-Framed + Self-Regulatory Efficacy|Participants will be randomised to one of five message conditions. Each condition will receive a total of four emailed messages on four consecutive days (i.e., 1 message per day). Participants in the Loss-Framed message + Self-Regulatory Efficacy condition will receive message content that highlights the potential losses of not consuming milk and milk products (i.e., lack of essential nutrients, less calcium) and information pertaining to how to include milk and milk products within their diet.
1551638|NCT02586454|Procedure|Transmuscular quadratus lumborum block|
1551639|NCT02586454|Drug|morphine|
1551641|NCT02586441|Device|Electroencephalography|Raw EEG signals were acquired at a sampling rate of 128Hz using a BIS-VISTATM monitor and was measured during all anesthetic period.
1551642|NCT02586441|Drug|Propofol|intravenous 1% propofol (1.5-2.5 mg/kg)
1551643|NCT02586441|Drug|Rocuronium bromide|intravenous rocuronium bromide (0.6 mg/kg)
1551644|NCT02586428|Other|what patients elect noninvasive prenatal testing (NIPT)|what percentages of patients elect noninvasive prenatal testing (NIPT), amniocentesis, or no testing before and after genetic counseling.
1551645|NCT02586415|Procedure|Endovascular Thrombectomy|Patients will be treated with thrombectomy devices (stent-retrievers) and/or suction thrombectomy systems currently cleared by the FDA for thrombus removal in patients experiencing an acute stroke following the published instructions for use for these devices. These devices will be used between 6 and 16 hours following symptom onset in DEFUSE 3 based on an FDA IDE. The devices which will be used are the Trevo Retriever, the Solitaire Revascularization Device and the Penumbra system thrombectomy system.
1551646|NCT02586415|Device|Trevo Retriever|Trevo Retriever is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
1551647|NCT02586415|Device|Solitaire™ FR Revascularization Device|Solitaire™ FR Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
1551648|NCT02586415|Device|Penumbra thrombectomy system|"Penumbra thrombectomy system is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure. The Penumbra System includes:
• Penumbra Aspiration Pump (1115V) Penumbra System 054 Penumbra System MAX Penumbra System 110 Aspiration Tubing Penumbra System [026, 032, 041] Penumbra System Separator Flex [026, 032, 041, 054] Penumbra Pump MAX Penumbra System Reperfusion Catheter ACE64 & ACE68"
1551649|NCT02586415|Device|Covidien MindFrame Capture Revascularization Device|Covidien MindFrame Capture Revascularization Device is one of the interventional devices that is approved for use in DEFUSE 3 during the endovascular thrombectomy procedure. The device choice is at the discretion of the physician performing the procedure.
1551650|NCT02586402|Drug|pegol-Sihematide|
1551651|NCT02586402|Drug|Epoetin Alfa|
1551652|NCT02586376|Device|0J LLLT|Sham Low-Level Laser Therapy (Sham LLLT): perform with the machine off.
1551653|NCT02586376|Device|4J LLLT|4J Low-Level Laser Therapy (4J LLLT) irradiation will be perform with 4J.
1551654|NCT02586376|Device|6J LLLT|6J Low-Level Laser Therapy (6J LLLT) irradiation will be perform with 6J.
1551655|NCT02586376|Device|8J LLLT|8J Low-Level Laser Therapy (8J LLLT) irradiation will be perform with 8J.
1551656|NCT02586363|Drug|Baraclude Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
1551657|NCT02586363|Drug|Cavir Tab. 0.5mg, fasting|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
1551658|NCT02586363|Drug|Cavir Tab. 0.5mg, high fatty meal|After drug administration, Blood sampling for Pharmacokinetics (Entecavir concentration)
1551659|NCT02586350|Drug|Anlotinib|
1551660|NCT02586350|Drug|Placebo|Placebo p.o. qd
1551661|NCT02586337|Drug|Anlotinib|Anlotinib p.o. qd
1551662|NCT02586337|Drug|Placebo|Placebo p.o. qd
1551663|NCT02586324|Biological|global medium|
1551664|NCT02586324|Biological|SSM|
1551665|NCT02586311|Drug|CKD-330 16/5mg|Once a day, 8 weeks
1551666|NCT02586311|Drug|Amlodipine 5mg Placebo|Once a day, 8 weeks
1551667|NCT02586311|Drug|CKD-330 16/5mg Placebo|Once a day, 8 weeks
1551668|NCT02586311|Drug|Amlodipine 5mg|Once a day, 8 weeks
1551669|NCT02586298|Other|Autologous mitochondria with ICSI|Autologous mitochondria during the intracytoplasmic sperm injection (ICSI) process will be added to this randomized group of oocytes.
1551670|NCT02586298|Other|STANDARD ICSI PROCEDURE|STANDARD ICSI PROCEDURE
1551671|NCT02586285|Drug|S-Adenosyl Methionine|500mg-1000mg,iv,qd
1551672|NCT02586272|Device|Daifert|
1551673|NCT02586272|Procedure|Control Group|
1551674|NCT02586259|Drug|budesonide MMX®|
1551675|NCT02586246|Drug|CDP870|Self-injection
1551678|NCT02586207|Drug|pembrolizumab (MK-3475)|200mg IV on days -7(loading dose), 15, 36, 57, 78, 99, 120, 141.
1551679|NCT02586207|Drug|Cisplatin|Cisplatin 40 mg/m2 IV on days 1, 8, 15, 22, 29, 36
1551680|NCT02586207|Radiation|Radiation|70 Gy fractionated over 35 days
1551681|NCT02586194|Drug|ASP015K|Oral
1551682|NCT02586181|Dietary Supplement|Vitamin D and Calcium|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate
1200 IE Vitamin D3 plus 800 mg Calcium Carbonate
Arm: Experimental: Vitamin D, Calcium, Vitamins B9, B6, B12
1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
1551683|NCT02586181|Dietary Supplement|Vitamin D, Calcium, Vitamins B9, B6, B12|"a combination of dietary supplement including all 1200 IE Vitamin D3 plus 800 mg Calcium Carbonate plus 0,5mg Folic acid, 50 mg B6, 0,5 mg B12"
1551684|NCT02586168|Drug|Gemcabene 900 mg|Gemcabene 900 mg once daily (QD)
1551685|NCT02586168|Drug|Placebo|Placebo
1551686|NCT02586155|Drug|RVX000222|100 mg capsule
1551687|NCT02586155|Drug|Placebo (for RVX000222)|Capsule manufactured to mimic RVX000222 100 mg capsule
1551688|NCT02586155|Drug|atorvastatin|High-Intensity Statin
1551689|NCT02586155|Drug|rosuvastatin|High-Intensity Statin
1551690|NCT02586142|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by ultrasounds guidance.
1551691|NCT02586142|Other|Stretching exercise|After accepting Botulinum toxin type A injection, participants will be arranged to receive stretch exercise in Kaohsiung Chang Gung Memorial Hospital 3 times per week, for 3 month.
1551692|NCT02586129|Drug|YH14755|20/1500mg, QD
1551693|NCT02586129|Drug|Metformin|1500mg, QD
1551694|NCT02586129|Drug|Rosuvastatin|20mg, QD
1551697|NCT02586103|Device|MRI simulation|It is not a working MRI machine but sounds and feels just like the real machine.
1551698|NCT02586090|Behavioral|Parents as Coaches|PAC (modeled after NIH-funded NOURISH) focuses on parenting strategies to support and facilitate their child's weight management via family-based change. Each visit includes group psychoeducation and discussion, focused on parenting strategies to facilitate healthy weight management in their child(ren). Topics include focus such as role modeling, strategies for healthy lifestyle changes, and how to be a coach to your teen.
1551699|NCT02586090|Behavioral|Parent Weight Loss|In PWL parents will be given a weight loss goal of 1-2 lbs/week, as well as specific calorie and fat prescriptions, PA goals, and instructions to self-monitor key information. Parents will receive training in core behavioral weight loss strategies (e.g., goal setting, stimulus control) and techniques to help them achieve these goals and will also receive personalized feedback throughout the program
1551700|NCT02586077|Drug|Exparel|
1551701|NCT02586064|Behavioral|Interpersonal Therapy for PTSD|Relationally focused treatment that focuses on relationship problems that may be caused or maintained by PTSD symptoms. Consists of 12 individual weekly sessions of 45 to 50 minutes. Includes psycho-education, assessing which relationships (or lack of) are causing problems for the Veteran, and addressing the problem areas identified through specific strategies (e.g. communication analysis, decision analysis, role play). Final 2 sessions focus on consolidating what has been learned, what issues remain, identifying types of relationship triggers that could reactivate symptoms, and addressing feelings about termination.
1551702|NCT02586064|Behavioral|Prolonged Exposure|Aim is to allow Veterans to re-experience traumatic events experienced during military service in a safe and supportive environment, and to re-engage in activities they have been avoiding. 12 individual weekly sessions of 90 minutes. Consists of psychoeducation, breathing retraining, imaginal exposure (repeated imaginal recall of the trauma including sensory details, and associated thoughts and feelings experienced during the trauma), and with trauma, and in vivo exposure (systematically confronting feared and avoided places and activities).
1551705|NCT02586038|Drug|MLN9708|
1551706|NCT02586038|Drug|Dexamethasone|
1551707|NCT02586038|Drug|Cyclophosphamide|
1551708|NCT02586038|Drug|Bendamustine|
1551709|NCT02586038|Drug|Thalidomide|
1551716|NCT02586012|Drug|rFVIII|Recombinant FVIII concentrate is an FDA approved, and both efficacious and safe, therapy for the treatment and prevention of bleeding in hemophilia A. The rFVIII infusion dose will be calculated as follows: [(weight in kg x desired FVIII increase of 100 IU/dL)/(2)].
1551717|NCT02585999|Device|Xulane Contraceptive Patch|Extended use (12 weeks) of contraceptive patch
1551718|NCT02585986|Dietary Supplement|Probiotic|daily intake of 1 capsule probiotic
1551719|NCT02585986|Dietary Supplement|Placebo|daily intake of 1 capsule containing placebo
1551726|NCT02585947|Drug|Tenofovir|Anti-HBc positive patients with Non-Hodgkin's lymphoma planned to receive rituximab based chemotherapy will be randomized to either Group A or Group B in a 1:1 ratio and will be monitored every 12 weeks from the start of treatment for up to 72 weeks after the end of chemotherapy (EOC).
1551727|NCT02585934|Drug|RVT-101|once daily, oral, 35 mg tablets
1551728|NCT02585934|Drug|Placebo|once daily, oral, pill manufactured to match RVT-101 35 mg tablet
1551729|NCT02585921|Behavioral|Video Interventions|Participants will watch 2 5-minute videos and then discuss them as a group.
1551730|NCT02585921|Behavioral|Donation Discussion Education|Participants will learn techniques for introducing and discussing organ donation with parents and guardians.
1551731|NCT02585908|Biological|CIK|CIK cells will be used against tumor cells.
1551732|NCT02585908|Biological|γδ T|γδ T cells will be used against tumor cells.
1551733|NCT02585908|Biological|CIK and γδ T|CIK and γδ T cells will be used against tumor cells.
1551734|NCT02585895|Biological|Evolocumab|Administered by subcutaneous injection once every 2 weeks
1551735|NCT02585895|Procedure|Low-density Lipoprotein Cholesterol (LDL-C) Apheresis|Participants received apheresis for LDL-C according the their physician's prescription and local custom.
1551736|NCT02585882|Other|Fluoride table salt|
1551738|NCT02585869|Drug|Gemcabene 300 mg|Blinded capsules and tablets, 300 mg, once daily, 84 days
1551739|NCT02585869|Drug|Gemcabene 600 mg|Blinded capsules and tablets, 600 mg, once daily, 84 days
1551740|NCT02585869|Drug|Gemcabene 900 mg|Blinded capsules and tablets, 900 mg, once daily, 84 days
1551741|NCT02585869|Drug|Placebo|Blinded capsule and tablets, once daily, 84 days
1551742|NCT02585856|Device|PDT|"Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.
PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length)."
1551743|NCT02585856|Device|stent|Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
1551744|NCT02585843|Drug|Spironolactone 100mg|2 capsules of study medication consist of 100mg, PO (oral) for 7 days
1551745|NCT02585843|Drug|Spironolactone 25mg|25mg/day of spironolactone
1551746|NCT02585817|Device|Remote CIED Management|Information Technology
1551747|NCT02585804|Drug|Dapagliflozin|Oral tablet, 10mg, PO, 8 weeks
1551748|NCT02585791|Other|Propylene Glycol|inhaled Propylene Glycol (PG) by vaporing
1551749|NCT02585791|Other|vegetable glycerin|inhaled vegetable glycerin (VG) by vaporing
1551750|NCT02585791|Other|PG+VG|inhaled PG+VG by vaporing
1551751|NCT02585778|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1551752|NCT02585778|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1551753|NCT02585778|Drug|insulin|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1551754|NCT02585778|Drug|insulin|Pharmaceutical form:powder Route of administration: inhalation
1551755|NCT02585778|Drug|statin|Pharmaceutical form:tablet Route of administration: oral
1551756|NCT02585778|Drug|lipid modifying therapy|Pharmaceutical form:tablet Route of administration: oral
1551757|NCT02585765|Drug|Pioglitazone|8 weeks of daily pioglitazone (30 mg/d).
1551758|NCT02585765|Drug|Placebo|8 weeks of daily placebo capsules.
1551759|NCT02584660|Drug|Rivaroxaban|Participants will receive Rivaroxaban 15 milligram (mg) twice daily up to Days 21 by orally and Rivaroxaban 20 mg once daily up to Days 90 by orally.
1551760|NCT02584660|Drug|Standard-of-care|Standard-of-care as per local protocol and defined by the medical team caring for the participant.
1551761|NCT02584647|Drug|PLX3397|PLX3397 is a selective inhibitor of FMS, as well as the ligand interleukin 34, KIT, and oncogenic Flt3 activity intended for oral administration.
1551762|NCT02584647|Drug|Sirolimus|"Sirolimus is a macrocyclic lactone that binds to tacrolimus (FK506) binding protein 12 and inhibits mammalian target of rapamycin (mTOR) resulting in cell-cycle arrest and apoptosis.
Sirolimus is currently approved as an immunosuppressive agent for organ transplantation and more recently, as a component of cardiac arterial stents because of its potent antiproliferative effects on fibroblasts responsible for restenosis after such a procedure (26) Sirolimus is commonly administered orally on a daily basis, in doses ranging from 2 to 40 mg/day."
1551766|NCT02584621|Behavioral|Check Yourself App with Feedback|
1551767|NCT02585739|Genetic|blood sample|
1551768|NCT02585726|Device|SP-402 VenaSeal™ Closure System|A medical device kit consisting of seven delivery tools and the proprietary VenaSeal™ Adhesive (Medtronic Cardiovascular, Santa Rosa, CA). The device is used to treat venous reflux in lower extremity superficial truncal veins.
1551774|NCT02585687|Device|liver Perfusion MRI|
1551775|NCT02585674|Drug|Insulin glargine (U300)|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1551776|NCT02585674|Device|MyStar DoseCoach|Glucose meter
1551777|NCT02585661|Dietary Supplement|Dairy product fortified with enriched Fe-54 salt (1)|2.5mg of Fe per 100g of product
1551778|NCT02585661|Dietary Supplement|Dairy product fortified with enriched Fe-57 salt (2)|2.5mg of Fe per 100g of product
1551779|NCT02585648|Device|Thealoz Duo Gel and Thealoz Duo eye drops|Thealoz Duo gel at night (1 drop before going to bed) + Thealoz Duo eye drops during the day (4 to 6 drops per day)
1551780|NCT02585648|Device|Thealoz Duo eye drops|Thealoz Duo eye drops during the day (4 to 6 drops per day)
1551781|NCT02585622|Biological|Mesenchymal Stromal Cells|Cells will be administered intravenously at 3 different doses (80, 160, or 240 x 10^6, fixed dose) over 10-20 minutes. Volume total of fluid infused: 40 ml
1551782|NCT02585622|Other|Placebo|Volume total of fluid infused: 40 ml
1551783|NCT02585596|Drug|YH23537 1000mg/day|YH23537 500mg 2 tab
1551784|NCT02585596|Drug|YH23537 2000mg/day|YH23537 500mg 4 tab
1551785|NCT02585596|Drug|YH23537 3000mg/day|YH23537 500mg 6 tab
1551786|NCT02585596|Drug|placebo|YH23537 500mg tab placebo
1551787|NCT02585583|Radiation|Thalamotomy|VoA-Vop complex of the thalamous or VIM nucleus will be targeted. 100 Gy, 120 Gy, 130 Gy, 140 Gy will be the foreseen prescription dose. CyberKnife will be always used to perform the procedure.
1551788|NCT02585570|Drug|Phenylephrine|Patients is received phenylephrine 1.0 mcg/kg/min or 0.5 mcg/kg/min for 5 minutes before being placed in the beach chair position.
1551789|NCT02585557|Other|Primary Care Practice Support|The intervention consists of practice facilitation, academic detailing, and regional learning collaboratives.
1551790|NCT02585544|Procedure|day-care surgery|day-care surgery
1551791|NCT02585531|Drug|Hypertonic Saline 3%|"The treatment will be administered in the following order :
First day: 3 treatments of nebulized HS 3% 3ml of treatment with interval 20 minutes Second to fourth day: One treatment of nebulized HS 3% 3ml every 24 hours ."
1551792|NCT02585531|Drug|Epinephrine and Dexamethasone|"The treatment will be administered in the following order :
First day: One treatment of nebulized dexamethasone 4mg (1ml of dexamethasone 8mg/2ml) + 3ml NS, followed by two treatments of nebulized epinephrine (3 ml of epinephrine in a 1:1000 solution per treatment) with interval 20 minutes Second to fourth day: One treatment of nebulized dexamethasone 4 mg (1ml of dexamethasone 8mg/2ml) + 3ml Normal saline 0.9%, every 24 hours."
1551793|NCT02585505|Procedure|stem cells|stem cell will be injected
1551794|NCT02585492|Other|Head-of-bed elevated 15°|Head-of-bed elevated 15° during 2 hours after delivery.
1551795|NCT02585492|Other|Head-of-bed elevated 45°|Head-of-bed elevated 45° during 2 hours after delivery.
1551796|NCT02585479|Drug|Pirarubicin|"Pirarubicin 30mg/m2 intravenously
Pirarubicin17mg/m2 are infused through the right and left hepatic arteries"
1551797|NCT02585479|Drug|Oxaliplatin|"Oxaliplatin 100 mg/m2 intravenously
Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries"
1551798|NCT02585479|Drug|Lipiodol|Lipiodol 5-10ml infused through the right and left hepatic arteries
1551799|NCT02585479|Device|Gelfoam|Hepatic artery embolization with Gelfoam.
1551800|NCT02585453|Device|Thealoz Duo Gel|Manufacturer: Laboratoires Thea, France
1551801|NCT02585453|Device|Hylo-Gel|Manufacturer: Ursapharm, Saarbrücken, Germany
1551802|NCT02585453|Device|Systane Gel Drops|Manufacturer: Alcon Pharma GmbH, Fort Worth, TX, USA
1551803|NCT02585440|Drug|CMX157|Oral tablet
1551804|NCT02585440|Drug|placebo|Oral tablet
1551805|NCT02585427|Dietary Supplement|low glycemic index rice, high glycemic index rice, butter, olive oil and grapeseed oil|
1551806|NCT02585401|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|The physician questionnaire will contain primarily closed-ended questions (e.g., multiple choice, true/false), with few free-text response fields, eliciting responses measuring physician knowledge and understanding of the key information in the Eylea vial preparation instruction card, the intravitreal injection procedure video, and the product monograph.
1551807|NCT02585388|Drug|Vinorelbine|Vinorelbine metronomic at 50 mg (1 tablet at 20 mg and 1 tablet at 30mg),per oral, 3 times per week. One dose level reduction is authorized at 30 mg per day.when stopping over 3 consecutive weeks due to toxicity, treatment should be permanently discontinued
1551808|NCT02585388|Drug|Letrozole|Lestrozole at 2,5 mg every day , per oral
1551809|NCT02585388|Drug|Anastrozole|Anastrozole at 1 mg every day, per oral
1551810|NCT02585375|Drug|Preservative-free latanoprost 50µg/ml|
1551811|NCT02585375|Drug|Preserved latanoprost 0.005%|
1551812|NCT02585362|Behavioral|physical exercise|The standardized Training program will be performed twice a week in the Kantonsspital Winterthur and once a week in a home based setting
1551813|NCT02585362|Behavioral|nutrition counseling|At least 3 times, participants will receive nutrition counseling to improve energy- and protein intake
1551814|NCT02585362|Dietary Supplement|whey protein supplement|On workout days study participants will consume twice a day 15 g of the supplement powder with approximately 150 ml water. On the remaining days participants consume the supplement once a day.
1551815|NCT02585336|Behavioral|Brief intervention|An interviewer provides health information, elicits motivation to reduce SSB consumption, and helps participants make implementation plans. Booster phone calls occur at 1 week after the intervention visit, and at 2 weeks and 24 weeks following the date on which SSBs sales ended at the participant's work location.
1551816|NCT02585323|Behavioral|Education session, Fitbit/FitViz, PT counselling|Participants will receive a brief education session, use a physical activity tracker Fitbit Flex with paired with a FitViz app, and remote counseling by a PT. Intervention will be received immediately.
1551817|NCT02585323|Behavioral|Same intervention with a 3 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 3 month delay.
1551818|NCT02585310|Other|Packed red blood cell transfusion|Record number of PRBC transfusion during perioperative period.
1551819|NCT02585297|Other|no intervention|
1551820|NCT02585271|Device|Transanal decompression tube|22 Fr transanal decompression tube
1551821|NCT02585271|Device|Stent|self-expandable colorectal nitinol alloys stent
1551822|NCT02585258|Drug|Prednisolone|capsules 5 mg / day
1551823|NCT02585258|Other|Placebo|capsules 1 / day
1551824|NCT02585232|Behavioral|Counseling (C)|The counseling component incorporates elements of existing manualized interventions that have been tailored for this population and follow a cognitive behavioral therapy framework. Counseling sessions will be completed for 8-10 domains of potential distress (grief, hostility, sexual intimacy, etc.).
1551825|NCT02585232|Behavioral|Care Consultation (CC)|"Care Consultation (CC): is an established telephone-based, empowerment intervention that uses coaching and emotional support to mobilize family caregivers and individuals with dementia through psychoeducation, resource referral, psychosocial support, and encouragement of informal and formal service use utilization. A computerized clinical tool called the Care Consultation Information System (CCIS) guides the care consultant through a standardized delivery of protocol components. Rather than a strong focus on assessment, this intervention is designed to quickly identify areas of unmet need through brief trigger questions called the initial assessment, which then immediately shapes development of concrete action plans."
1551909|NCT02584738|Drug|Methylprednisolone or Prednisolone|Begin with intravenous methylprednisolone or oral prednisolone 2 mg/kg/day for each treatment
1551831|NCT02585193|Behavioral|Weight Watchers Intervention|All participants are enrolled in this single arm of the study. All participants receive the Weight Watchers intervention which consists of weekly group intervention/support meetings in which weight loss behaviors (diet, physical activity) are discussed.
1551832|NCT02585180|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
1551833|NCT02585180|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
1551834|NCT02585167|Procedure|operation|the fistula will be excised after dividing the sphincter and primary reconstruction will be performed with absorbable sutures, closing the internal opening and leaving the external opening unclosed for drainage.
1551835|NCT02585167|Device|VAAFT|Karl Storz Video Equipment is used. The fistula tract will be visualized from the external to the internal opening, closing the internal opening with absorbable sutures, then brushing and cauterization of the tract(s) leaving the external opening unclosed for drainage.
1551840|NCT02585141|Device|MEDIPLAST® (aspiration)|The aspiration drainage will be with a large caliber needle (MEDIPLAST® 13 G, 2,5 x 110 mm) and a syringe of 20 ml. The cavity must be emptied for pus and irrigated by repeated injection and aspiration of saline until clear fluid is obtained.
1551841|NCT02585141|Procedure|incision|Incision drainage will be undertaken as standardized de-roofing of the abscess and debridement. Wound packing and dressing will not be used, just sitz bath or ordinary hygiene until wound healing.
1551842|NCT02585141|Drug|Clindamycin|Postoperative broad spectrum oral antibiotics covering both aerobes and anaerobes bacteria will be given for seven days of Clindamycin 300 mg tablets x 3 a day
1551843|NCT02585128|Other|Delirium assessment|During the first post-procedural five days all patients will be evaluated on a daily basis for delirium occurrence by the CAM (Confusion Assessment Method) or CAM - ICU (Confusion Assessment Method - Intensive Care Unit)
1551844|NCT02585128|Other|MMSE (Mini Mental State Examination)|
1551845|NCT02585128|Other|Barthel index|
1551846|NCT02585128|Other|HADS (Hospital Anxiety and Depression Scale)|
1551847|NCT02585128|Other|MNA-SF (Mini Nutritional Assessment - Short Form)|
1551848|NCT02585128|Device|NIRS (Near-Infrared Spectroscopy)|Regional cerebral oxygen saturation monitoring during TAVI procedure
1551849|NCT02585128|Other|CIRS (Cumulative Illness Rating Scale)|
1551850|NCT02585102|Other|Recommended Vegetable Intake|Subjects will consume vegetables in amounts recommended by the Dietary Guidelines for Americans
1551851|NCT02585102|Other|Usual Vegetable Intake|Subjects will consume vegetables in their usual amount
1551852|NCT02585089|Other|Spanish cured-pork ham|"Dry-cured ham with reduced salt will be used in order to decrease the sodium intake that could affect blood pressure too. Such ham contains 25% lower salt than similar products on the market (3,7g vs 4,5g/100g).
Volunteers will receive 80g of cured pork ham daily for 28 consecutive days. They can eat the interventional product at any time of the day."
1551853|NCT02585089|Other|Cooked pork ham|Volunteers will receive 100g of cooked pork ham daily for 28 consecutive days. They can eat the product (placebo product) at any time of the day.
1551854|NCT02585076|Other|Standard of care|As prescribed by treated physician
1551855|NCT02585037|Other|Kinesio Taping® bandage|"The Kinesio Taping® bandage will be applied in an I format in the wrist flexor muscles of a dominant and non-dominant limb in G1 and G2 groups."
1551856|NCT02585037|Other|Dynamometer Jamar® pressure|The Jamar® dynamometer will be adjusted to the second position for measurement of maximal voluntary strength of handgrip. A muscle contraction period of three seconds will be performed in order to record handgrip strength.
1551857|NCT02585037|Other|Placebo|For the control group (G3) the Kinesio Taping® bandage will be placed from the lateral extremity to the medial axis.
1551859|NCT02585011|Drug|Ropivacaine|
1551860|NCT02585011|Drug|Epinephrine|
1551861|NCT02585011|Drug|Saline|
1551910|NCT02584725|Drug|Tranexamic Acid|Comparison of 3 different doses of the drug
1551911|NCT02584712|Other|Combined Exercise Training|This intervention consisted in 4 weeks of strength, flexibility and aerobic exercises made at the hospital and at home.
1551912|NCT02584699|Radiation|Stereotactic Ablative Radiotherapy (SABR)|Six Gy irradiation per fraction times 12 fractionations, resulting a total dose of 72Gy
1996217|NCT02534493|Device|Carpal Tunnel Tissue Manipulation Device (CTMD)|This piece of rigid, shaped, biocompatible plastic (polypropylene) rated for skin contact and a strong but safe hypoallergenic biocompatible medical adhesive which bonds the skin over the carpal tunnel to the plastic piece for a duration of 2-14 hours.
1996218|NCT02533908|Drug|Fentanyl intranasal|fentanyl is applied intranasally with a MAD (mucosal atomization device) prior to the application of nitrous oxide 70% analgosedation
1996219|NCT02533908|Drug|NaCl 0.9% intranasal|Placebo is applied intranasally with a MAD (mucosal atomization device) Prior to the application of nitrous oxide 70% analgosedation
1996220|NCT02531971|Drug|Intravenous fentanyl citrate|100 micrograms (2 millilitres) via intravenous injection
1996221|NCT02531971|Drug|Duragesic®|TDDS dosage is 25 micrograms/hour
1996222|NCT02531971|Drug|Mylan generic fentanyl|TDDS dosage is 25 micrograms/hour
1551862|NCT02584998|Other|Mailed-FIT|The FIT is analyzed at the Philadelphia VAMC by an auto-analyzer system that provides quantitative results corresponding to the concentration of hemoglobin in the collected sample. Specimens will be analyzed according to manufacturer's instructions to minimize potential degradation of hemoglobin. Results are provided as positive if the hemoglobin concentration is 100ng/dL. The machine records (but does not report) the quantitative results of the hemoglobin concentration in the sample, which we will seek to obtain from the laboratory for future studies.
1551863|NCT02584998|Other|Screening invitation-reminder|These patients will continue to receive UC. They will in addition receive an invitation letter with all of the information about CRC testing in the mail-FIT arm
1551866|NCT02584972|Other|no intervention required|no intervention required
1551867|NCT02584959|Drug|C1 esterase inhibitor [human] liquid|C1 Esterase Inhibitor [Human] Liquid administered Subcutaneously as specified on specified days
1551868|NCT02584959|Drug|Placebo|Placebo
1551869|NCT02584946|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa).
1551870|NCT02584933|Drug|ceritinib|hard gelatin capsule or hard tablet for oral use up to 750 mg
1551871|NCT02584920|Drug|HLX01|
1551872|NCT02584920|Drug|Rituximab|
1551873|NCT02584907|Other|High Fat Enteral Nutrition|Diet in high fat group will be 20% from protein, 45% from fat and 35% from carbohydrate
1551874|NCT02584894|Device|rTMS 1Hz|trauma exposure + repeated transcranial magnetic stimulation at 1Hz
1551875|NCT02584894|Device|rTMS 10Hz|trauma exposure + repeated transcranial magnetic stimulation at 10Hz
1551876|NCT02584894|Behavioral|psychoneurological assessment|psychoneurological assessment
1551877|NCT02584894|Device|conductivity meter|electrodermal conductance measure
1551878|NCT02584894|Device|electrocardiogram|heart rate measure
1551879|NCT02584881|Other|safe opioid prescription protocol|When indicated a prescription for naloxone will be given to patients discharged with prescription opioids from the trauma services. All patients will receive information on safe opioid use and storage and methods for pain management.
1551880|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution|Peri-operative fluid replacement therapy (max 40ml/kg/day)
1551881|NCT02584868|Drug|Hydroxyethyl starch 130/0.4 in 0.9% sodium chloride|Peri-operative fluid replacement therapy (max 40ml/kg/day)
1551882|NCT02584855|Drug|Ixekizumab|Administered SC
1551883|NCT02584855|Drug|Placebo|Administered SC
1551884|NCT02584829|Drug|Avelumab|Given IV
1551885|NCT02584829|Other|Laboratory Biomarker Analysis|Correlative studies
1551886|NCT02584829|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
1551887|NCT02584829|Radiation|Radiation Therapy|Undergo radiation therapy
1551888|NCT02584829|Biological|Recombinant Interferon Beta|Given via intra-tumor injection
1551889|NCT02584816|Biological|BRV-PV Lot A + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
1551890|NCT02584816|Biological|BRV-PV Lot B + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
1551891|NCT02584816|Biological|BRV-PV Lot C + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week
1551892|NCT02584816|Biological|ROTARIX + DPT-HepB-Hib + OPV|Dose 1: 6-8 weeks, Dose 2: 10 week, Dose 3: 14 week (Third dose-Placebo)
1551893|NCT02584803|Radiation|Ultrasound|"Evaluating the feasibility and efficacy of IVC ultrasound imaging through the RUQ and subxiphoid view in term parturients.
Patient Acceptability of procedure
Patient Comfort:
Ease of exam for the examiner"
1996223|NCT02530723|Other|power training|Resistance training machines with CAM devices will be used for training.
1551896|NCT02584764|Behavioral|Cognitive behavior therapy|
1551897|NCT02584764|Behavioral|Internet support|
1551898|NCT02584751|Drug|Omeprazole|Omeprazole is a commonly prescribed anti-reflux medication. If a SCI patient has GERD, they will be prescribed with 40mg omeprazole twice daily for two months
1551899|NCT02584751|Device|24 Hour pH Monitor|Monitors the acidity and levels of pH in the esophagus for 24hours and helps diagnose people with GERD
1551900|NCT02584751|Procedure|Pulmonary Function Examination|Assess pulmonary function such as lung volumes, spirometry, and max inspiration/expiration pressures.
1551901|NCT02584751|Procedure|Exhaled Nitric Oxide|Used to measure inflammation markers for airway resistance.
1551902|NCT02584751|Procedure|Exhaled Breath Concentrate (EBC)|EBC will be used to measure airway inflammation via specific markers, such as 8-isoprostane. This marker, if elevated, has been identified as an indicator for asthma inflammation.
1551903|NCT02584751|Procedure|Bernstein's Acid Clearance Test|Bernstein test is a clinical test for the diagnosis of chest pain in association with gastric acid exposure
1551904|NCT02584751|Procedure|Esophageal Motility|Esophageal Motility will be used to measure a subject's ability to swallow a bolus (i.e. saline solution) and record pressure changes throughout the esophagus during the swallow. This will also be used to identify anatomical landmarks, such as lower esophageal sphincter, which are necessary for proper placement of 24hr pH catheter.
1551905|NCT02584738|Drug|Nebulized Magnesium Sulfate|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic MgSO4 (150 mg) per dose every 20 minutes during the first hour.
will be continued with nebulized standard treatment every hour for 4 hours."
1551906|NCT02584738|Drug|Nebulized isotonic saline|"Nebulized salbutamol and ipratropium bromide mixed with 2.5 ml of isotonic saline per dose every 20 minutes during the first hour.
will be continued with nebulized standard treatment every hour for 4 hours."
1551907|NCT02584738|Drug|Nebulized Salbutamol|Nebulized salbutamol 2.5mg (2-5 years) or 5 mg (≥6 years)
1551908|NCT02584738|Drug|Ipratropium bromide|Nebulized ipratropium bromide 250 mcg
1552032|NCT02583828|Drug|Letrozole 2.5 mg|
1996224|NCT02528942|Radiation|Radiation therapy|Radiation therapy will be given to study patients.
1996225|NCT02528214|Drug|Dupilumab SAR231893 (REGN668)|Pharmaceutical form:solution Route of administration: subcutaneous
1996226|NCT02528214|Drug|Placebo|Pharmaceutical form:solution Route of administration: subcutaneous
1996227|NCT02528214|Drug|asthma controller therapies (including prednisone/prednisolone)|Pharmaceutical form:aerosol, capsules, tablets Route of administration: inhaled, oral
1551913|NCT02584686|Drug|Botulinum Toxin Type A|The treatment group will be injected intracavernously with a trimix solution (20 ug alprostadil + 1 mg phentolamine + 30 mg papaverine) for colour Doppler assessment, followed next day by 50 units of BTX-A.
1551914|NCT02584686|Drug|Normal Saline|The control group, 12 patients, will be injected with a trimix solution during penile colour Doppler assessment followed next day with a normal saline injection.
1551915|NCT02584673|Device|Computer Assisted Instrument Guidance (CAIG), which supplements existing ultrasound capabilities.|The Clear Guide ONE is a Computer Assisted Instrument Guidance (CAIG) device which supplements existing ultrasound capabilities. The participants randomly selected (out of 100 patients) for use of the Clear Guide ONE (test group) will receive ultrasound guidance as well as CAIG from the MDs performing the procedure.
1551916|NCT02584608|Drug|ACTIMMUNE|
1551917|NCT02584595|Device|ICD/CRT-D with NIPS or EP Study|ICD/CRT-D implanted patients are tested for inducible MMVT during electrophysiology (EP) Study or Non-Invasive Programmed Stimulation (NIPS) Study
1551918|NCT02584582|Drug|Liraglutide|
1551919|NCT02584582|Drug|Exenatide|
1551920|NCT02584582|Procedure|Liquid meal test|
1551921|NCT02584582|Other|No drug (Baseline day)|
1551923|NCT02584556|Drug|systemic chemotherapy|Pirarubicin(Brand Name:Pirarubicin - Main Luck Pharmaceutical, China) 30mg/m2 intravenously on Day 1 and Oxaliplatin(Brand Name: Eloxatin) 100 mg/m2 intravenously on Day 2 every 3 weeks starting 4-6 weeks after hepatic resection.
1551924|NCT02584556|Drug|Transcatheter Arterial Chemoembolization|Lipiodol 5-10ml,Pirarubicin17mg/m2 and Oxaliplatin 30mg/m2 are infused through the right and left hepatic arteries,followed by embolization using gelatin sponge particles(Gelfoam; Guangzhou) starting 4-6 weeks after hepatic resection.
1551925|NCT02584543|Biological|HEV vaccine|
1551926|NCT02584543|Biological|HBV vaccine|
1551927|NCT02584530|Procedure|Ultrasound guidance for PICC line placement|Apply ultrasound guidance for PICC line placement and positioning in newborns
1551928|NCT02584504|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1551929|NCT02584504|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1551930|NCT02584504|Drug|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
1551931|NCT02584504|Drug|fenofibrate|Pharmaceutical form:tablet Route of administration: oral
1551932|NCT02584504|Drug|bezafibrate|Pharmaceutical form:tablet Route of administration: oral
1551933|NCT02584504|Drug|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
1551934|NCT02584491|Behavioral|Functional gait-related training|The motor learning (ML)-based functional gait-related training program is designed to improve advanced gross motor skills and athleticism. It will involve 45-min sessions twice to three times weekly over 6 weeks for a total of 16 active sessions. A maximum of 7 weeks will be permitted. Each session will consist of 35-min of active training along with a 10-min active warm-up/cool-down that incorporates ML. Scheduling flexibility will promote adherence, with a minimum one day between sessions to provide opportunity for rest. Children will be given a 3- to 5-min mental motor imagery script to practice on days when they do not have active training sessions. The total number of sessions (combined active/imagery) will be five per week.
1551935|NCT02584478|Drug|AL3818|Taken daily from Day 8 to Day 21 (14 days). Administered orally.
1551936|NCT02584478|Drug|Carboplatin|AUC 5/6 on Day 1 of each 21-Day cycles
1551937|NCT02584478|Drug|Paclitaxel|175mg/m2 IV over 3 hours on Day 1 of each 21-Day cycle
1551938|NCT02584465|Drug|Tamoxifen|Tamoxifen: 40 mg/day
1551939|NCT02584465|Drug|Regorafenib|Stivarga; 120mg/day
1551940|NCT02584452|Drug|Mepivacaine|20cc of 2% mepivacaine <20 minutes prior to in room time.
1551941|NCT02584452|Procedure|adductor canal continuous nerve catheter|Placement of ultrasound guided adductor canal continuous nerve catheter
1551942|NCT02584452|Drug|Normal Saline as bolus followed by bupivacaine|normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through adductor canal catheter at 8cc/h
1551943|NCT02584452|Procedure|adductor canal nerve block|ultrasound guided adductor canal nerve block
1551944|NCT02584452|Drug|ropivacaine and dexamethasone|10cc of 0.5% ropivacaine + 2 mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve
1551945|NCT02584452|Drug|Propofol|Anesthesia induction will include a propofol bolus.
1551946|NCT02584452|Drug|Fentanyl|Intraoperative opioid should be limited to no more than 150mcg of fentanyl.
1551947|NCT02584439|Drug|ivabradine|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
1551948|NCT02584439|Drug|lactose capsule (placebo)|It is a cross over study with two arms : either ivabradine-placebo or placebo-ivabradine. The capsules containing the placebo or ivabradine are completely identical.
1551949|NCT02584426|Device|Ultrasonic Distribution of Cefazolin|
1551950|NCT02584413|Device|Magnetic resonance imaging|
1551951|NCT02584413|Drug|Gadolinium contrast|
1551952|NCT02584400|Drug|Injection with the hypoxia tracer [18F]HX4,|The [18F]HX4 PET scan will be performed, by administrating 444 MBq (12 mCi) [18F]HX4 via a bolus IV injection.
1551954|NCT02584374|Other|Venography with balloon occlusion test|First, regular venography of the venous iliac tract will be performed. Second, a 16mm diameter balloon will be inflated in the common iliac vein and venography will be repeated.
1996229|NCT02527798|Drug|Furosemide Cohort 1|furosemide 1 mg/kg q 24 hours IV or 2 mg/kg q 24 hours enterally Cohorts will be enrolled sequentially after a safety review.
1551957|NCT02584348|Device|Gastric ultrasound|Preoperative qualitative ultrasound assessment of gastric contents will be performed for each children admitted for emergency surgery
1551958|NCT02584335|Drug|"Lidocaine solution (A)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.
The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is A, the nurse will receive the syringes number 2 and 3 containing lidocaine solution to apply (blinded to the nurse, the patient and the doctor).
Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
1551959|NCT02584335|Drug|"Saline solution (B)"|"Each of 26 patients will be evaluated during 6 consecutive wound treatments. The nurse will receive 3 syringes for each procedure, the syringe 1 always contains saline solution (blinded to the patient and to the nurse) to register the basal pain; the other two syringes are identical (number 2 and 3) and contain the study drug: lidocaine solution or saline solution.
The investigators randomise the patients depending on the administration sequence (ABABAB or BABABA). When the procedure is B, the nurse will receive the syringes number 2 and 3 containing saline solution to apply (blinded to the nurse, the patient and the doctor).
Note: The investigators consider important apply both treatments (lidocaine solution and saline solution) alternatively to avoid the bias that could might fall a cause of wound evolution (to heal or to get worse). And it is important that the same patient receives both treatments to decrease the subjective component in pain perception."
1551960|NCT02584322|Other|Enhanced Recovery pathway|The enhanced recovery pathway consists of postoperative medical orders including nursing care, investigations and tests, and other peri-operative orders. The enhanced recovery pathway is standardized for all patients, and can be discontinued at any time when clinical judgment mandates (i.e. patient has a severe complication).
1551961|NCT02584309|Drug|Dexrazoxane|
1551962|NCT02584309|Drug|Doxorubicin|
1551963|NCT02584309|Drug|Olaratumab|
1551964|NCT02584296|Behavioral|BSMA|Biobehavioral self-management approach (BSMA) intervention is aligned with information-motivation-behavioral skills (IMB) model and is guided physical activity (PA). Collects demographic, medical, disease, treatment data, blood specimens and the battery of measures. Includes PA self-assessment, 6 minute walk test(6MWT) and chair squat test (CST) with Physical Therapist (PT); provides PA handouts based on American Cancer Society (ACS) guidelines, discusses known benefits, beliefs and goals of PA (IMB health behavior motivation); assess/discuss perceived barriers to PA. PT or Exercise physiologist (EP) works with subject on various exercises (both strength and aerobic, ~30 minutes; IMB behavioral skills);PT or EP reviews exercises, subject practices, and provides a BSMA program (including strength/aerobic training) for subject to begin upon discharge. Subject keeps journal of PA and wears accelerometer (TAA) to record PA levels. 3-weeks at home study nurse calls subjects each week.
1551965|NCT02584283|Procedure|Dual hypothermic oxygenated perfusion|Dual hypothermic oxygenated perfusion using the Liver Assist
1551966|NCT02584283|Device|Liver Assist®|The Liver Assist® is the device used to give the intervention dual hypothermic perfusion.
1551967|NCT02584283|Procedure|Perfusion fluid|The perfusion fluid is Belzer machine perfusion solution University of Wisconsin (Bridge-to-Life, Ltd., Northbrook, IL).
1551968|NCT02584283|Drug|Glutathione|Glutathione in a dosage of 3 mmol/ is added to the perfusion fluid according to the intention of use of the perfusion fluid.
1551969|NCT02584270|Device|Palatal Augmentation Prosthesis (PAP)|The palatal augmentation prosthesis improves speech and swallowing function through reshaping the palatal contours in order to obtain contact of the tongue to the hard palate during function. It is intended to be fabricated after adequate healing in patients with adequate motivation for improvements in their speech and swallowing. Regular wear and associated articulation therapy are necessary for this therapy to be effective.
1551970|NCT02584270|Other|Articulation Therapy|Subjects will receive the standard of care speech and articulation therapy regardless of which arm they are matched.
1551971|NCT02584257|Other|methacholine chloride|
1551972|NCT02584257|Drug|Placebo dose|
1551973|NCT02584257|Drug|90 mcg Reference Product|
1551974|NCT02584257|Drug|180 mcg of Reference product|
1551975|NCT02584257|Drug|90 mcg of Test product|
1551976|NCT02584257|Drug|180 mcg of Test product|
1551977|NCT02584244|Drug|LUM015|
1551978|NCT02584244|Device|LUM 2.6 Imaging Device|
1551979|NCT02584231|Drug|desmopressin|One time dosing of desmopressin oral lyophilisate formulation. The dose is age-dependant: >6 months and < 2years: 60µg; ≥2 years and <4 years: 120µg PO and ≥4 years and <8 years: 240 µg PO. There will be blood sampling and urine sampling for PK and PD/safety
1551980|NCT02584218|Procedure|Non-invasive resin based caries sealing|The dentists use resin based sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
1551981|NCT02584218|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Pediatric Dentistry and Orthodontics, Federal University of Rio de Janeiro, Brazil
1551982|NCT02584205|Device|Powerbreathe|"In this intervention we will use an equipment called powerbreathe classic light. It provides us to choose resistance levels with an adjustable load setting range: 1 to 9 and it's ideal for beginners. In this research we will use it on the intervention group to improve the strength of inspiratory muscle training and evaluate the results in the functional capacity of the subjects with obstructive sleep apnea."
1551983|NCT02584192|Behavioral|entailing an early home-based CR program|enter the early outpatient phase of CR program. The progressive exercise training of this phase was performed without supervision after their discharge. The CR program consisted of a five-minute warm-up period (stretching), a twenty-minute aerobic exercise (walking or trotting, gymnastics), and a five-minute cooling-down period (stretching)
1551984|NCT02584192|Other|enter the usual care program|enter the usual care program, including the importance of carrying out physical activity, which was performed during inpatient care.
1551985|NCT02584179|Device|Biparametric MRI before biopsy|ALL subjects will have a Biparametric MRI before biopsy
1551986|NCT02584166|Behavioral|multifaceted program|This program present two steps : a first step to revise protocols related to the management of cases (between M5 and M8) and a second step after M8 et M 26, with morbimortality conferences organized every trimester to analyze management with the staff.
1551987|NCT02584153|Drug|Fibrin Sealant|TISSEEL® fibrin sealant (Baxter Biosurgery, Deerfield, IL)
1551988|NCT02584153|Drug|Silver Microparticles|Product Code: AG-M-04M-P.200M (American Elements, Los Angeles, CA)
1551989|NCT02584140|Behavioral|Text Messaging/Counseling|All participants assigned to the iTAB intervention will receive daily dosing reminders that will be sent for the first 6 weeks and then continue with reminders for the duration of the study.
1551990|NCT02584140|Behavioral|Text Messaging/Counseling|All participants assigned to the counseling intervention will receive sexual health and medication adherence counseling at each study visit. Participants with suboptimal adherence (TFV-DP levels of <1050 fmol/punch (representing fewer than mean 6-7 daily doses per week)) will trigger a targeted iNSC session. Participants with two TFV-DP levels of <1050 fmol/punch will trigger PrEP Steps, a higher intensity adherence counseling intervention consisting of four 50-minute counseling sessions and 2 booster counseling sessions.
1551991|NCT02584127|Behavioral|high reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with high reinforcement.
1551992|NCT02584127|Behavioral|low reinforcement cessation program|Six-step, self-administered, internet smoking cessation program with low reinforcement.
1551993|NCT02584114|Behavioral|Peak app for memory training|
1551994|NCT02584114|Behavioral|Non-memory training group|
1551995|NCT02584101|Behavioral|ACT|ACT therapy administered in 3 sessions over a 4 week period
1551996|NCT02584101|Behavioral|Enhanced Treatment as Usual|2 group discussion sessions over a 4 week period
1551997|NCT02584088|Other|Ultrasound|The appearance of the post ablative endometrium on transvaginal ultrasound at 2, 6, and 12 months.
1551998|NCT02584075|Drug|Byetta (Exenatide)|Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
1551999|NCT02584075|Drug|Glucophage ( Metformin Hydrochloride)|Metformin 500mg Tid
1552000|NCT02584062|Procedure|no-touch fluid-air exchange|
1552001|NCT02584062|Procedure|vitrectomy metrectomy and internal membrane peeling and gas tamponed|
1552002|NCT02584049|Other|Osteopathy|3 sessions of osteopathy during 60 minutes each
1552003|NCT02584049|Other|Sham osteopathy|3 sessions of sham osteopathy during 60 minutes each
1552004|NCT02584036|Biological|Vaccine administration by a pharmacist|Administration, number and types, of vaccine(s) by a pharmacist
1552005|NCT02584036|Behavioral|Unmet vaccination needs identified and met|Identification of unmet vaccination needs and having those needs met
1552006|NCT02584036|Behavioral|Vaccination forecast review and patient education|Pharmacist review of the vaccination forecast and patient education on his/her vaccine needs
1552007|NCT02584023|Device|Lung ultrasound|Lung ultrasound on both hemithorax in supine position
1552008|NCT02584010|Other|Silicon-based aerosol|Apply twice a day over the postoperative scar
1552009|NCT02584010|Other|Silicon-based gel|Apply twice a day over the postoperative scar
1552010|NCT02583997|Procedure|Suturing of lower alveoli|After extraction of wisdom teeth, the lower alveoli are sutured closed.
1552011|NCT02583997|Procedure|Non suturing of lower alveoli|After extraction of wisdom teeth, no alveoli are sutured closed.
1552012|NCT02583984|Procedure|Thoracic Surgery with Lung Resection|General anesthesia and lung separation Thoracic surgery with lung resection, such as lobectomy, segmentectomy
1552013|NCT02583984|Procedure|Thoracic Surgery without Lung Resection|General anesthesia and lung separation Thoracic surgery without lung resection, such as esophageal surgery, mediastinal surgery
1552014|NCT02583958|Device|Urgo 3103166|URGO 310 3166 dressing should be changed as often as required (let to the Investigator's convenience). The dressing change frequency is based on the exudate level and the clinical progress of the wound (up to 7 days).
1552015|NCT02583958|Device|Aquacel Extra|Aquacel Extra hydrofibre dressing can be left in place up to 7 days, where clinically indicated.
1552016|NCT02583945|Procedure|kidney treatment bundle (KDIGO)|Application of the measures of the kidney treatment bundle.
1552017|NCT02583932|Drug|Meaning-Making intervention (MMi)|The MMi is a brief, individualized and manualized therapeutic approach based on post-trauma literature and designed to facilitate a search for meaning following a cancer diagnosis.
1552018|NCT02583932|Behavioral|Empathic Visitor|They will provide the basic ingredients for fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing.
1552019|NCT02583919|Drug|ISIS-GCGRRx- Dose Level 1|once weekly dosing for 26 weeks
1552020|NCT02583919|Drug|ISIS-GCGRRx- Dose Level 2|once weekly dosing for 26 weeks
1552021|NCT02583919|Drug|Placebo|once weekly dosing for 26 weeks
1552022|NCT02583906|Device|CPAP|Treatment with CPAP for six months in the CPAP arm.
1552023|NCT02583893|Drug|Sirolimus|Given PO
1552024|NCT02583893|Drug|Mitoxantrone|Given IV
1552025|NCT02583893|Drug|Etoposide|Given IV
1552026|NCT02583893|Drug|Cytarabine|Given IV
1552028|NCT02583854|Device|RY-STOP hemostasis device|
1552029|NCT02583854|Device|TR-Band, Terumo|
1552030|NCT02583841|Procedure|Scaling and root planing|scaling and root planing as an intervention was done in patients of the test group
1552031|NCT02583828|Drug|Cyclophosphamide 50mg|
1552033|NCT02583802|Drug|Ear pills|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks. After 4 weeks after a washout period, two groups of cross accept the next phase of treatment.
1552034|NCT02583802|Drug|Shengmai capsule|The clinical design of this study was a randomized crossover trial. This experiment research is divided into two stages, each stage is 8 weeks.
1552035|NCT02583789|Drug|oral treprostinil|Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
1552036|NCT02583789|Drug|Placebo|Placebo is a sugar pill manufactured to resemble UT-15C. Change in the Raynaud's Condition Score from baseline (2-week run in), comparing treprostinil treatment phase vs. placebo phase
1552037|NCT02583776|Device|Unblinded - CGM|Data from device will be readable and alarms on
1552038|NCT02583776|Device|Blinded - CGM|Data from device will be blinded and alarms off
1552039|NCT02583763|Other|Echocardiography|During the ultrasound examinations standardized, moving sequences of the heart will be saved. Analyzes are performed off-line and analyzed by vector velocity imaging software.
1552040|NCT02583763|Procedure|Blood sample|The investigators will take a blood sample from the umbilical cord at birth and again at 7 years of age.
1552041|NCT02583750|Behavioral|OGTT after deprived sleep first|Participants slept 1-3 hours less than their normal amount for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept as much as they wanted for three nights.
1552042|NCT02583750|Behavioral|OGTT after sufficient sleep first|Participants slept as much as they wanted for three nights, and then came to the lab for the oral glucose tolerance testing after a 12 hour overnight fast. The second oral glucose tolerance test was after they slept 1-3 hours less than normal for three nights.
1552043|NCT02583737|Procedure|freeze bone allograft|sinus lifting filling procedure employing freeze bone allograft from tissue bone bank.
1552044|NCT02583737|Procedure|lyophilized bone allograft|sinus lifting filling procedure employing lyophilized bone allograft from tissue bone bank.
1552046|NCT02583698|Drug|Carvedilol|
1552047|NCT02583698|Drug|Placebo|
1552048|NCT02583685|Drug|PR4 + LDV/SOF + ASV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
1552049|NCT02583685|Drug|PR4 + LDV/SOF + SMV 4 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
1552050|NCT02583685|Drug|PR4 + LDV/SOF + ASV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
1552051|NCT02583685|Drug|PR4 + LDV/SOF + SMV 6 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
1552052|NCT02583685|Drug|PR4 + LDV/SOF + ASV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
1552053|NCT02583685|Drug|PR4 + LDV/SOF + SMV 8 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
1552054|NCT02583685|Drug|PR4 + LDV/SOF + ASV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Asunaprevir (ASV) 200mg administered orally twice daily.
1552055|NCT02583685|Drug|PR4 + LDV/SOF + SMV 12 wk|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection; Ribavirin (RBV) administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg); Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
1552056|NCT02583672|Drug|N-acetylcysteine|1800mg NAC twice daily (3600mg/day) orally for approximately 90 days.
1996230|NCT02527798|Drug|Furosemide Cohort 2|furosemide 1 mg/kg q 6 hours IV or 2 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
1996231|NCT02527798|Drug|Furosemide Cohort 3|furosemide 2 mg/kg q 6 hours IV or 4 mg/kg q 6 hours enterally Cohorts will be enrolled sequentially after a safety review.
1552059|NCT02583620|Genetic|blood sample|A blood test is realized on the subject
1552060|NCT02583607|Device|Brava|"The purpose of the study is to examine the efficacy of Brava with fat grafting in woman undergoing mastectomy in the institution.
woman who will agree to participate in the study will be instructed how to wear the Brava, and after 200 hours of using the device they will be operated for fat transfer to the breast in order to reconstruct it."
1552061|NCT02583594|Drug|Acyclovir|Pharmaceutical form:tablet Route of administration: oral
1552062|NCT02583594|Drug|Methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
1552063|NCT02583594|Drug|alemtuzumab GZ402673|Pharmaceutical form:solution for infusion Route of administration: intravenous
1552064|NCT02583594|Drug|alemtuzumab GZ402673|Pharmaceutical form:injection Route of administration: subcutaneous
1552065|NCT02583594|Drug|Paracetamol|Pharmaceutical form:tablet Route of administration: oral
1552066|NCT02583594|Drug|Loratadine|Pharmaceutical form:tablet Route of administration: oral
1552067|NCT02583594|Drug|Ceterizine|Pharmaceutical form:tablet Route of administration: oral
1552068|NCT02583594|Drug|Dexchlorpheniramine|Pharmaceutical form:tablet Route of administration: oral
1552069|NCT02583581|Device|EEG monitoring (MindWave by NeuroSky)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
1552070|NCT02583581|Device|EEG monitoring (EPOC by Emotiv)|EEG evaluation will be conducted for duration of 10 minutes. 5 minutes without auditory stimulation and 5 minutes with auditory stimulation performed using standard headphone or earphones to reduce external noises.
1552071|NCT02583568|Drug|Bevacizumab-800CW|three days prior to surgery bevacizumab-800CW will be administered
1552072|NCT02583555|Behavioral|Interview followed by frequent telephone support|Interview followed by telephone support
1552073|NCT02583542|Drug|AZD2014|AZD2014 is a dual inhibitor of both mTORC1 (rapamycin-sensitive) and mTORC2 (rapamycin insensitive); compared to rapalogues, AZD2014 has a broader range of growth inhibitory activity in preclinical models based on a more profound mTORC1 inhibition and the additional inhibition of mTORC2. AZD2014 is currently in phase 2 studies in renal cell cancers and metastatic breast cancer.
1552074|NCT02583542|Drug|AZD6244|Selumetinib (AZD6244, ARRY-142886) is an orally available, potent, selective, non-ATP competitive inhibitor of MEK1/MEK2 kinases. Selumetinib has demonstrated clinical efficacy in pre-treated KRAS-mutant NSCLC, leading to a significantly improved progression-free survival in combination with docetaxel compared to docetaxel alone.
1552075|NCT02583529|Device|Back Tibial Nerve Electrostimulation|The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
1552076|NCT02583529|Device|Placebo Electrostimulation|The BTNPE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
1552077|NCT02583516|Drug|vemurafenib and cobimetinib|Comparison between different treatment regimens
1552078|NCT02583503|Radiation|Hindfoot alignment view x ray|Diagnostic x rays used to measure leg alignment.
1552079|NCT02583490|Device|spectrum 5000Q ECT device (RUL ECT)|
1552080|NCT02583490|Device|spectrum 5000Q ECT device (RUL LAP ECT)|
1552083|NCT02583464|Drug|Tenofovir disoproxil fumarate and emtricitabine|Two period administration of a formulation containing a combination of emtricitabine 200 mg and tenofovir disoproxil fumarate 300 mg.
1552084|NCT02583451|Drug|Placebo tablet matching lemborexant|Tablet form taken orally at bedtime.
1552085|NCT02583451|Drug|Placebo tablet matching zopiclone|Tablet form taken orally at bedtime.
1552086|NCT02583451|Drug|Zopiclone 7.5 mg|7.5 mg tablet taken orally at bedtime.
1552087|NCT02583451|Drug|Lemborexant 2.5 mg|2.5 tablet taken orally at bedtime.
1552088|NCT02583451|Drug|Lemborexant 5 mg|5 mg tablet taken orally at bedtime.
1552089|NCT02583451|Drug|Lemborexant 10 mg|10 mg tablet taken orally at bedtime.
1552090|NCT02583438|Drug|Saxagliptin (Bristol-Myers Squibb Company)|6-month treatment of Saxagliptin 5mg Qd
1552092|NCT02583412|Biological|Bexsero®|Multicomponent meningococcal B vaccine
1552093|NCT02583412|Biological|Havrix®|Hepatitis A vaccine
1552094|NCT02583399|Drug|Ibuprofen|Ibuprofen, 10 mg/kg
1552095|NCT02583386|Behavioral|Free From Falls fall prevention program|Eight-week education and exercise program, intended to reduce falls in people with Multiple Sclerosis.
1552096|NCT02583386|Device|Electronic Fall Detector|30 participants will be randomly selected to wear an electronic fall detector during the first 10 weeks of study participation. This fall detector will automatically record any falls occurring while worn.
1552097|NCT02583373|Drug|CAL02 Low-dose|Two doses of CAL02 (low-dose) administered 2 times (24 hours apart) as i.v. infusion
1552098|NCT02583373|Drug|CAL02 High-dose|Two doses of CAL02 (high-dose) administered 2 times (24 hours apart) as i.v. infusion
1552099|NCT02583373|Drug|Placebo|Placebo administered administered 2 times (24 hours apart) as i.v. infusion
1552100|NCT02583360|Other|Slower Flow Rate|Use of nipple that has a slower flow rate than used prior to testing. No change in formula prescription
1552101|NCT02583360|Other|Thickened Formula|Use of a predetermined amount of rice cereal to thicken formula. Use of nipple preferred by patient
1552102|NCT02583347|Device|Vivia Home Hemodialysis System|The cohort of interest is those patients performing nocturnal home hemodialysis using the Vivia Home Hemodialysis System for 8 hours, 5 nights per week
1552103|NCT02583334|Device|Verum acupuncture (30# acupuncture needle)|Acupuncture will be applied by inserting acupuncture needle into acupoints (LI4, LI11, LR3, ST36, SP6, GB34)
1552104|NCT02583334|Device|Sham acupuncture|Streitberger device will be applied by onto acupoints (LI4, LI11, LR3, ST36, SP6, GB34). The device will not really insert the blunt needle into skin but let the participants feel like real acupuncture (Lancet 1998; 352: 364-365.).
1552105|NCT02583321|Device|Endotracheal tubes not allowing SSD|In the participating center, a bundle of Ventilator-Associated Pneumonia (VAP) prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
1552106|NCT02583321|Device|Endotracheal tubes allowing SSD|"In the participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
1552107|NCT02583308|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
1552108|NCT02583308|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
1552111|NCT02583282|Other|Doxycycline|500 mg of doxycycline will be dissolved in 50 ml of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
1552112|NCT02583282|Other|Iodopovidine|20 ml of 10% betadine (Microshield, Johnson and Johnson, Solan, India) will be dissolved in 80 mL of normal saline. The combination will then be instilled through the chest tube in the pleural cavity and the chest tube drain will be clamped for 4 hours.
1552113|NCT02583269|Other|Laboratory Biomarker Analysis|Correlative studies
1552114|NCT02583269|Dietary Supplement|Muscadine Grape Skin Extract|Given PO
1552115|NCT02583269|Procedure|Quality-of-Life Assessment|Ancillary studies
1552120|NCT02583243|Behavioral|MET/CBT based individualized counseling|Manualized counseling with the first four week being MET followed by 8 weeks of CBT
1552121|NCT02583243|Drug|Buprenorphine|Target dose in stabilization is 16 mg of buprenorphine to be taken sublingually once daily.
1552123|NCT02583217|Drug|Ketamine|To compare ketamine+propofol versus remifentanyl+propofol to maintain good laryngeal mask insertion conditions
1552124|NCT02583217|Drug|remifentanyl|
1552125|NCT02583217|Drug|propofol|
1552126|NCT02583217|Device|laryngeal mask|
1552127|NCT02583204|Device|Onicolife nail drops|The prescription free, CE (Conformité Européenne) marked product is for local application, and has a novel mode of action involving the modulation of mast cell action with the fatty acid amide, Adelmidrol ®. Mast cells are known to have a key role in the ability of the body to promote healing /repair and control tissue damage caused by chemo and radiotherapy. This includes damage to the nail and/ or nail matrix. OnicoLife ® thus helps to control inflammation and pain whilst antimicrobial action also provides antibacterial and antifungal support.
1552128|NCT02583204|Other|Nail polish|One dark colour of nail polish (deep burgundy/red) will be used in this study since this colour is considered more acceptable to many more women than a pure black coloured nail polish and hence, more likely to ensure compliance. No nail polish containing hardeners will be used since there is some evidence to suggest they can induce nail changes. As dark nail polish can stain the nail plate (and therefore mask any changes in nail pigmentation induced by chemotherapy), one clear base coat, two coats of coloured, and one clear top coat of polish will be required for each application. This standard of application is proposed as a gold standard for the prevention of nail staining and hypersensitivity reactions by an eminent podiatrist (Spalding, 2008).
1552129|NCT02583191|Drug|Rivaroxaban|Rivaroxaban 15 mg twice daily for 21 days, followed by 20 mg once daily over a period of 3 months
1552130|NCT02583191|Drug|low-molecular heparine|"LMWH in therapeutic dosage (1-2× daily s.c.) according to standards of the individual study center, using licensed dosages, e.g.
Enoxaparin 1 mg/kg BW twice daily
Tinzaparin 175 I.E./kg BW once daily
Dalteparin 200 I.E./kg BW once daily"
1552133|NCT02583139|Behavioral|Designed Music Narratives|"Four music narratives for children each comprising an introductory relaxation exercise, a resource-oriented narrative including guided imagery suggestions and relaxing nature scenarios plus especially composed music.
The narrative and music reflect and support each other."
1552134|NCT02583126|Behavioral|Guided Imagery and Music|Modified and resource-oriented form of the Bonny Method of Guided Imagery and Music (BM-GIM)
1552135|NCT02583113|Device|Total and Unicompartment Knee Replacement|Patients who have undergone a primary TKA on one side and primary UKA on the opposite side and are at a minimum of two years post-surgery.
1552136|NCT02583100|Behavioral|Intensive Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial, (2) receive an analysis of their video-recorded operative technique by surgeon peers, (3) directly observe a peer surgeon with lower fistula rate, and (4) develop a personalized action plan with a target for improvement.
1552137|NCT02583100|Behavioral|Routine Feedback|(1) receive feedback regarding their individual fistula rate and those of all other participants in the trial
1552138|NCT02583087|Procedure|endoscopic submucosal dissection|Endoscopic resection of a superficial neoplastic lesion of the esophagus, including the mucosal and the submucosa resected en bloc.
1552139|NCT02583074|Procedure|Stimulation|After surgery, patients in 'Neurostimulation Group' will receive subthalamic nucleus stimulation for 3 months.
1552140|NCT02583074|Procedure|Sham-stimulation|After surgery, patients in 'sham-stimulation Group' will receive subthalamic nucleus sham-stimulation for 3 months.
1552141|NCT02583061|Other|There is no intervention. An exposure of interest is glucose tolerance status in pregnancy|
1552142|NCT02583048|Drug|Bedaquiline|Bedaquiline will be administered as four 100 mg tablets (400 mg) by mouth once a day for 2 weeks, followed by two 100 mg tablets (200 mg) by mouth three times a week for 22 weeks, for all study arms involving the use of this drug.
1552143|NCT02583048|Drug|Delamanid|Delamanid will be administered with food as two 50 mg tablets (100 mg) by mouth twice a day for 24 weeks, for all study arms involving the use of this drug.
1552144|NCT02583048|Drug|Dolutegravir|For HIV-positive participants only: dolutegravir will be administered at a dose of one 50 mg tablet once daily, to be used in combination with two NRTIs until study completion. (NRTIs will not be provided by the study.)
1552145|NCT02583035|Other|Nurse telephone contact|Nurse will contact patient 3 days before consultation
1552146|NCT02583022|Drug|PAC-14028 cream 1.0%|Topical application
1552147|NCT02583022|Drug|PAC-14028 cream vehicle|Topical application
1552148|NCT02583022|Drug|Elidel cream 1%|Topical application
1552149|NCT02583009|Drug|PAC-14028 cream 0.1%|Topical application
1552150|NCT02583009|Drug|PAC-14028 cream 0.3%|Topical application
1552151|NCT02583009|Drug|PAC-14028 cream 1.0%|Topical application
1552152|NCT02583009|Drug|PAC-14028 cream vehicle|Topical application
1552153|NCT02582996|Drug|Acetaminophen+Caffeine+Dihydroergotamine+Metoclopramide.|The subject must manage 02 tablets of Cefalium right after a moderate to severe migraine.
1552154|NCT02582996|Drug|Acetaminophen|The subject must manage 02 tablets of Tylenol right after a moderate to severe migraine.
1552155|NCT02582983|Drug|Enfuvirtide|All participants received enfuvirtide 90 mg SC BID until 4 weeks after commercial availability was established in Thailand.
1552156|NCT02582970|Drug|5-Fluorouracil|Intravenous 5-fluorouracil based chemotherapy will be administered until disease progression or until termination of the study. The chemotherapy regimen will be at the discretion of the prescriber and will not be provided by the sponsor.
1552157|NCT02582970|Drug|Bevacizumab|Bevacizumab will be administered IV 5 mg/kg every 2 weeks until disease progression or until termination of the study.
1552158|NCT02582970|Drug|Irinotecan|Irinotecan will be administered at the discretion of the prescriber until disease progression or until termination of the study.
1552159|NCT02582970|Drug|Oxaliplatin|Oxaliplatin will be administered at the discretion of the prescriber until disease progression or until termination of the study.
1552160|NCT02582957|Other|Sigh breaths|Sigh breaths delivered once every 6 minutes, as part of usual invasive mechanical ventilation.
1552161|NCT02582944|Device|Olympus BF-180 bronchoscope (standard adult)|-Standard of care
1552162|NCT02582944|Device|Veran Spinview Thoracic Navigation System|-Electromagnetic navigation
1552163|NCT02582944|Device|Olympus UM-S20-17S|-Endobronchial ultrasound mini-probe
1552164|NCT02582944|Procedure|Biopsy|
1552165|NCT02582931|Device|MRI-guided SBRT|
1552166|NCT02582931|Behavioral|EORTC QLQ-C30 Questionnaire|30 questions with 28 questions having answers that range from 1 (not at all) to 4 (very much) and the other 2 questions have answers that range from 1 (very poor) to 7 (excellent)
1552167|NCT02582931|Behavioral|EORTC QLQ-OV28 Questionnaire|28 questions having answers that range from 1 (not at all) to 4 (very much)
1552168|NCT02582918|Behavioral|Outreach with patient education and patient navigation services|"Outreach invitations include number to call for more information about scheduling an ultrasound and alpha fetoprotein (AFP) blood test.
Patients receive up to three phone calls 2-4 weeks after invitations and a reminder call 5-7 business days before appointments.
If results are normal, the patient is invited to repeat screening in 6 months.
If suspicious mass on ultrasound or abnormal AFP level, the patient is referred for follow-up testing with triple-phase CT scan or MRI.
If CT/MRI is unremarkable, the patient is referred back for routine screening.
If HCC is confirmed, the patient and their primary care provider will be contacted with the results.
All patients diagnosed with HCC will be seen in the multi-disciplinary HCC clinic."
1552169|NCT02582905|Drug|Placebo|Inactive ingredient matching the active comparators in appearance.
1552170|NCT02582905|Drug|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
1552171|NCT02582905|Drug|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and also in the brain. Pregnenolone produces other neuroactive steroids.
1552172|NCT02582892|Drug|Vit D|20 mg/day
1552174|NCT02582853|Procedure|Lumbar puncture|Lumbar puncture for spinal fluid
1552175|NCT02582853|Procedure|Blood Sample|Blood sample
1552179|NCT02582827|Drug|ABI-011|ABI-011 is a novel, albumin-bound formulation of a potent thiocolchicine analog, IDN 5404, with a mean particle size of approximately 100 nm.
1552180|NCT02582814|Drug|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
1552181|NCT02582814|Drug|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
1552182|NCT02582801|Drug|18F-Alfatide Ⅱ PET/CT|Inject 18F-Alfatide Ⅱ by vein and then perform PET/CT scan after 60 min
1552184|NCT02582775|Drug|Thymoglobulin|0.5 mg/kg IV over 6 hours on day -9 and 2 mg/kg IV over 4 hours on day -8 and day -7 with premeds and solumedrol through day -2
1552185|NCT02582775|Drug|Cyclophosphamide|14.5 mg/kg IV over 1 hour day -6 and -5 50 mg/kg IV over 2 hours with mesna 40 mg/kg IV day +2 and +3
1552186|NCT02582775|Drug|Fludarabine|30 mg/m2 IV over 60 minutes days -6 through day -2
1552187|NCT02582775|Radiation|Total Body Irradiation|See arm description for dosing.
1552188|NCT02582775|Procedure|Bone marrow infusion|Bone marrow infusion on Day 0
1552189|NCT02582775|Drug|Tacrolimus|Day +5 through day +100 with goals of 5-10 ug/L (not used for HLA-identical related donors)
1552190|NCT02582775|Drug|Mycophenolate Mofetil|15 mg/kg IV q8h (based upon actual body weight) with the maximum total daily dose not to exceed 3 grams. Day +5 through day 35
1552191|NCT02582775|Biological|Donor mesenchymal stem cell infusions|Day 60, 100 and 180 (collected during donor BM harvest for graft)
1552192|NCT02582762|Drug|Nail gel|apply nail gel on affected nails twice daily for 2 months
1552193|NCT02582749|Drug|LHRH agonist/antagonist|Treating physician will determine LHRH agonist/antagonist, dosage and route of administration, per package insert, during each 28-day cycle.
1552194|NCT02582749|Drug|Bicalutamide|Bicalutamide, 50 mg Oral (PO) will be administered daily in each 28-day cycle.
1552195|NCT02582749|Radiation|Radium-223 dichloride|Radium-223 dichloride, 50 kBq (1.35 microcurie) per kg body weight intravenous (IV bolus) every 28 days for 6 injections
1552196|NCT02582736|Drug|Olanzapine|Exposure to olanzapine (ATC N05AH03) will be defined as a prescription for olanzapine on the date of cohort entry.
1552197|NCT02582736|Drug|Risperidone|Exposure to risperidone (ATC N05AX08) will be defined will be defined as a prescription for risperidone on the date of cohort entry.
1552198|NCT02582736|Drug|atypical antipsychotics (other)|Exposure to other atypitical antipsychotics (ATC N05AH02, N05AH04, N05AE04, N05AX13, N05AX12) will be defined will be defined as a prescription for an atypical antipsychotic other than olanzapine on the date of cohort entry.
1552199|NCT02582736|Drug|typical antipsychotics|Exposure to typical antipsychotics (M03BB02, N05AA01, N05AF03, N05AF01, N05AB02, N05AG01, N05AD01, N05AA02, N05AH01, N05AC03, N05AB03, N05AG02, N05AC04, N07XX06, N05AB05, N05AB08, N05AC02, N05AF04, N05AB06, N05AF05) will be defined as a prescription for a typical antipsychotic on the date of cohort entry.
1552200|NCT02582723|Other|High protein/high fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
1552201|NCT02582723|Other|High protein/low fat hard cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
1552202|NCT02582723|Other|Low protein/high fat creme cheese|Assess whether the cheeses with high protein content have improved effect on satiety compared to the cheese with low protein content.
1552203|NCT02582710|Dietary Supplement|VASCAZEN|6 weeks treatment with an optimized formulation of omega 3 before the carotid endarterectomy
1552204|NCT02582710|Dietary Supplement|PLACEBO|6 weeks treatment with a placebo before the carotid endarterectomy
1552205|NCT02582697|Drug|Bleomycin (active name: Bleomycin Sulfate)|"Standard Arm: Bleomycin 30,000 international units IV weekly for 3 doses (eg. days 1, 8 and 15 or days 2, 9 and 16 of a 21-day cycle) for 4 cycles.
Accelerated Arm: Bleomycin 30,000 international units IV weekly for 2 doses (eg. days 1 and 8 or days 2 and 9 of a 14-day cycle) for 4 cycles. Followed by Bleomycin 30,000 international units IV weekly for 4 doses."
1552206|NCT02582697|Drug|Etoposide|"Standard Arm: Etoposide 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.
Accelerated Arm: 100 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
1552207|NCT02582697|Drug|Cisplatin|"Standard Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 21-day cycle for 4 cycles.
Accelerated Arm: Cisplatin 20 mg/m2 IV on days 1, 2, 3, 4, 5 of a 14-day cycle for 4 cycles."
1552208|NCT02582697|Drug|Pegylated G-CSF (Pegfilgrastim)|Standard Arm: 6 mg SCI on day 6 of a 21-day cycle for 4 cycles. Accelerated Arm: 6 mg SCI on day 6 of a 14-day cycle for 4 cycles.
1552209|NCT02582697|Drug|Filgrastim|"Standard Arm: 10 mcg/kg/day on day6, until post-nadir absolute neutrophil count ≥ 1.0 x 10^9/L, of a 21-day cycle for 4 cycles.
Accelerated Arm: 10 mcg/kg/day on day 6, until post-nadir absolute neutrophil count ≥ 1.0 x 10^9/L, of a 14-day cycle for 4 cycles."
1552210|NCT02582684|Drug|Dolutegravir|Participants will receive 50 mg of DTG orally daily
1552211|NCT02582684|Drug|Lamivudine|Participants will receive 300 mg of 3TC orally daily.
1552212|NCT02582645|Procedure|open window technique|palatally impacted canine will be exposed and left without traction for a maximum of 9 months
1552213|NCT02582645|Procedure|closed window technique|palatally impacted canine will be exposed, an attachment will be bonded, and then the canine will be covered with palatal tissue; traction of the canine will be initiated within 2 weeks following surgery
1552214|NCT02582632|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet
1552215|NCT02582632|Drug|dasabuvir|Tablet
1552216|NCT02582619|Other|Focus groups, semistructured interviews and Delphi rounds|
1552217|NCT02582606|Other|Regular meal pattern|a 14-day period of eating 6 meal per day
1552218|NCT02582606|Other|Irregular meal pattern|a 14-day period of eating between 3 and 9 meal per day
1552221|NCT02582580|Other|Perineal massage|"Perineal massage should be practiced once a day, from the 34th week of gestation until the beginning of labor. It should obey the following sequence: the pregnant woman must be positioned comfortably and use intimate water based lubricant at her fingertips; start the massage in the outdoor area of the vulva with circular movements of the skin and connective tissue around the vagina and at the central tendon of the perineum, clockwise, clitoris to clitoris; introduce two thumb fingers or index and middle fingers into the vagina at a distance of approximately 4 centimeters; perform internal massaging with laterally semicircles towards the anus for 20 to 30 seconds; put pressure down towards the anus and to each side of the vagina until feeling a slight burning or stretching sensation and hold the position for 2 minutes; massage the lower half of the vaginal introitus in a movement simulating the letter U. All movements should be repeated four times."
1552277|NCT02582099|Drug|Normal saline nasal irrigation|Nasal wash with normal saline solution
1552278|NCT02582086|Other|BOR15001L7|Active cream with 5% 15019L0
1552279|NCT02582086|Other|Placebo|Placebo Cream with 0% 15019L0
1552222|NCT02582580|Device|Vaginal Dilator|Vaginal dilator Epi-No® should be used once a day for 15 minutes, from the 34th week of pregnancy until the beginning of labor. It should be coated with a condom and intimate water based lubricant and then be inserted into the vaginal canal in such way that the balloon stays two centimeters away from the vaginal introitus. The device will be inflated by manual pumping until the tolerable woman's limit. The pregnant woman will be encouraged to daily inflate a greater volume of compressed air into the balloon so that the amount of air is greater than the quantity in the previous day, achieving, day after day, a greater stretching of perivaginal structures, always respecting the individual tolerance limit. The amount of manual pumping imposed to inflate the balloon should be written in an Intervention Diary so that the next use, the pregnant woman will be sure that pumped the device more times than in the previous session.
1552223|NCT02582580|Other|Pelvic floor muscles training|Pregnant women allocated to this group will perform pelvic floor muscles training. The progression of the protocol of this study will occur gradually in view of the peculiarities that involve the pelvic floor in the gestational stage and the ultimate goal is the promotion of an intact perineum after vaginal delivery. The exercises will obey a sequence, according to the gestation week, considering the following factors/parameters: exercise position, number and sustaining period of slow and fast contractions, and relaxation time between contractions. All contractions should be during the expiratory phase of breathing associated with an isometric contraction of the abdominal muscles and at the end of each series of contractions, perform a one minute interval between sets and in that time perform the diaphragmatic breathing exercise to promote overall relaxation. This protocol should be practiced once a day, every day from the 34th week of gestation until the beginning of labor.
1552224|NCT02582567|Other|Exercise intervention|The exercise intervention will be performed in two groups so that each group will have 12-13 participants.The groups will train 3 days/week (60min per session) from the 16th week of gestation until delivery. The exercise intervention group will go through different phases of training: a) Learning phase: which will involve the intervention plan, the goals we want to work, and how we will perform it; b) Movement Learning phase: theoretical and practical sessions with the explanation of movements and ergonomic basic patterns; and c) Physical Fitness Training phase: with training sessions aimed at improving fitness and weight loss, and training sessions focused on a correct pelvic mobilization for the delivery.The intensity will be adapted during the exercise program based on the week of gestation and each pregnant heart rate. The sessions will consist of a mixed work, composed of circuits where both muscular and cardiovascular conditioning will be implemented.
1552225|NCT02582554|Behavioral|NutriSTEP|Provision of nutrition risk screening with NutriSTEP (a nutrition risk screening questionnaire for preschoolers) and nutrition education with NutriSTEP related materials
1552226|NCT02582541|Procedure|SEMS alone|The SEMS (Wallstent, Boston Scientific, USA) would be placed.
1552227|NCT02582541|Procedure|SEMS plus radiofrequency ablation|The RFA catheter has an 8 F bipolar probe and two ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5 cm length. The catheter is compatible with standard side-viewing endoscopes (3.2 mm working channel), and could be passed over 0.035 inch guidewires. Ablation was performed by using an RFA generator (1500 RF generator; RITA Medical Systems, Fremont, Calif) delivering electrical energy at 400 kHz set at 7-10 W for 90-120 seconds. The RFA energy can be delivered repetitively at different tumor sites within one procedure. After the RFA application is completed, SEMS (Wallstent, Boston Scientific, USA) can be deployed.
1552228|NCT02582528|Behavioral|Cognitive remediation treatment|Cognitive remediation treatment consisting of a novel computerized training called My Brain Solutions (MBS)
1552229|NCT02582528|Behavioral|Motivational Interviewing|A client-centered, directive method for enhancing intrinsic motivation to change.
1552232|NCT02582502|Other|Hyperbaric Oxygen|The only intervention given will be 100% oxygen under hyperbaric pressure.
1552233|NCT02582502|Other|Sham Hyperbaric Oxygen|The only intervention given will be a sham hyperbaric oxygen treatment.
1552234|NCT02582489|Biological|Bone Marrow Aspirate Concentrate|Subjects undergoing autologous bone marrow aspirate concentrate will receive an intra-articular injection into the affected knee.
1552235|NCT02582489|Procedure|Standard Meniscectomy|All subjects will undergo either a partial or complete meniscectomy to treat the torn meniscus.
1996232|NCT02527798|Other|Placebo|Sugar water will be administered in a equivalent volume as drug intervention.
1552239|NCT02582437|Other|History for opioid use|
1552240|NCT02582424|Other|PD-L0101|92% EPA+6 mg ATX+50 mg TCT GG BID
1552241|NCT02582424|Other|placebo|placebo
1552242|NCT02582411|Device|Laser Speckle Flowgraphy|A commercially available LSFG (Softcare, Fukutsu, Japan) system will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device. NB, the relative velocity of blood flow, is derived from the pattern of speckle contrast produced by the interference of a laser scattered by blood cells moving in the ocular fundus. Images are acquired continuously at the rate of 30 frames per seconds in a 4-second time period and stored on a personal computer. Heartbeat map of the optic nerve head and the retina/choroid is generated
1552273|NCT02582138|Other|Healthy Aging Lifestyle Education (HALE)|The healthy aging lifestyle education programme will be based on a workshop series. Participants will receive information on a variety of topics of relevance to older adults (e.g., recommended preventive services and screenings at different ages). The programme will also include a short instructor-led programme (5-10 minutes) of upper extremity stretching exercises or some relaxation techniques that will be performed at the end of each workshop.
1996233|NCT02526173|Procedure|RALP using full nerve sparing technique|RALP using full nerve sparing technique
1996234|NCT02526173|Other|dHACM Application|2x12 sheet of dHACM applied to the neurovascular bundle
1996303|NCT02501889|Behavioral|Walnut-rich weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. Walnuts will be provided to participants. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
1552243|NCT02582411|Device|Doppler Optical Coherence Tomography|"A dual-beam bidirectional Doppler OCT system comprises a broadband superluminescent diode (SLD) with a central wavelength of 840 (spectral bandwidth 54 nm) and two CCD cameras with a maximum readout rate of 20 kHz. The system provides a resolution (in tissue) of about 6 and 18 μm in axial and lateral direction, respectively. The sample, i.e. the retinal vessel under study, is illuminated by two probe beams separated by their polarization properties. Light back scattered and backreflected from the sample is spectrally detected by two identical spectrometers and postprocessing, i.e.
calculation the phase shift due moving scatterers within the sample, is carried out by a personal computer with software written in National Instruments LabView. The power of both probe beams incident on the cornea is 650 μW, which is below the ANSI (American National Standard Institute) limits for small source ocular exposure to a laser beam within the measuring time."
1552244|NCT02582398|Other|Light Therapy|One subgroup of SAD patients and healthy controls respectively will receive bright light therapy using an artificial white light source (PhysioLight LD220 by DAVITA®, www.davita.de/shop/lichttherapiegeraete/lichtduschen-tageslicht/physiolight-ld-220.html) with full-spectrum 10.000lux light intensity. The treatment will be applied 30min per day at a distance of about of 50cm, preferably in the morning, during 3 weeks.
1552245|NCT02582398|Other|Placebo Light|The second subgroup of the SAD patients and healthy controls will receive a non-biologically active light source (<400nm or >500nm). Here, the lamp will have largely similar shape and size as compared to the therapeutic device, but the fluorescent tube with the high light intensity will be replaced by an ordinary bulb.
1552246|NCT02582385|Other|in-situ cytokine expression|
1552249|NCT02582359|Drug|MLN9708|Dose of 1.5 mg or 2.3 mg or 3.0 mg taken by mouth on days 2, 5, 9, 12 of each cycle.
1552250|NCT02582359|Drug|Cytarabine|Induction: cytarabine 100 mg/m2/day continuous infusion, days 1-7 Consolidation: cytarabine 2000 mg/m2/day, 3 hour infusion, on days 1-5
1552251|NCT02582359|Drug|Daunorubicin|Daunorubicin 60 mg/m2, IV bolus, on days 1-3 of induction, only.
1552252|NCT02582346|Procedure|MRI acquisition - no contrast agent|No surgery. Volunteers will have an MRI with a 3T clinical system. Installation will be performed according to standard protocols. Different neurography and tractography sequences will be acquired in order to get different contrasts.
1552253|NCT02582333|Other|Observation for clinical and virological changes|Only observation after stopping nucleos(t)ide analogue
1552254|NCT02582320|Drug|Ibrutinib|A longitudinal survey will be carried out by collecting data of patients who received at least 1 dose of Ibrutinib. All patients will be observed for at least 12 months from the treatment start.
1552255|NCT02582307|Drug|Acetaminophen, Analgesics, Non-Narcotic|Oral single dose
1552256|NCT02582307|Drug|Hyoscine butylbromide, Analgesics, Non-Narcotic|Oral single dose
1552258|NCT02582281|Device|intrauterine device TCu 380A|
1552259|NCT02582268|Device|intrauterine device TCu 380A|
1552260|NCT02582268|Radiation|Trans-abdominal sonography|
1552261|NCT02582255|Biological|Sabin mOPV2|"Polio Sabin™ Mono Two (oral) is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2. Magnesium chloride is used as a stabilizer. Polio Sabin™ Mono Two (Oral) contains trace amounts of neomycin sulphate and polymyxin B sulphate.
One dose of vaccine (0.1 mL) is contained in two drops which are delivered from the polyethylene dropper supplied with vaccine."
1552262|NCT02582242|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) thrice daily or twice daily. Subjects will continue with metformin all throughout the trial.
1552263|NCT02582229|Device|Endomina|The intervention will be performed under general anesthesia with tracheal intubation. Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
1552265|NCT02582203|Drug|Ceftaroline|
1552266|NCT02582203|Drug|Vancomycin|
1552267|NCT02582190|Drug|Colchicine group|antiarrhythmic therapy plus colchicine & antiarrhythmic therapy alone.
1552268|NCT02582177|Drug|Ketoconazole + betamethasone dipropionate|Apply on the affected area and around it twice a day
1552269|NCT02582177|Drug|Clotrimazole + Dexamethasone acetate|Apply on the affected area and around it twice a day
1552270|NCT02582164|Device|Duke Biomedical Engineering's Long-working distance OCT|The long-distance SSOCT system designed by Duke University Biomedical Engineering Department allows the user to quickly image an eye at a much greater distance (typically 20-40 cm away but this could be longer or shorter). This could potentially be used while briefly attracting a child's attention to an illuminated image over the imaging lens. With this methodology, young patients would not need to place their eye close to the system and could be rapidly imaged during the short interval while they glance at the image from the correct distance.
1552271|NCT02582151|Device|EV-906 Digital Transcutaneous electrical nerve stimulation (TENS) machine|Percutaneous patch electrodes are used to deliver low level electrical currents.
1552272|NCT02582138|Other|Multicomponent intervention (MCI)|"The multicomponent intervention will include physical activity (PA), nutrition and information and communications technology (ICT). The PA will be of moderate intensity and will include aerobic, strength, flexibility, and balance training. Walking will be the primary mode of PA .
The nutritional intervention will combine individual nutritional assessment and personalised dietary recommendations to achieve:
a daily total energy intake of 25-30 kcal/kg body weight;
an average protein daily intake between 1.0 and 1.2 g/Kg/body weight.
The ICT component will involve the use of an ad hoc technological device to record actimetry data to support the elaboration of a personalised training programme."
1552274|NCT02582125|Drug|ONO-4538|
1552275|NCT02582112|Other|Active Comparator: Warming group|Placebo Comparator: Control group
1552276|NCT02582099|Drug|Gentamicin nasal irrigation|Nasal wash with gentamicin solution
1552280|NCT02582073|Biological|Placebo (0.5ml)|
1552286|NCT02582060|Other|Thromboelastography/Thromboelastometry-Guided Treatment Regimen|The results of the TEG/ROTEM assay (specifically the R time/CT) will be used to determine the prophylaxis treatment regimen.
1552287|NCT02582047|Biological|Influenza vaccination with PPV23|GCflu and Pneumovax-23
1552288|NCT02582047|Biological|Influenza vaccination with PCV13|GCflu and Prevenar-13
1552289|NCT02582034|Radiation|Optimized Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).
Optimized dosimetry arm: the activity to be administered is calculated so as to deliver predictive dosimetry:
An absorbed dose to the tumor of at least ≥ 205 Gy and if possible exceeding 250 Gy or even 300 Gy
A dose at the treated healthy liver < 120 Gy in case of lobar treatment
Dose to the treated healthy liver can exceed 120 Gy in case of segmental treatment and hepatic reserve > 30%
A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments."
1552290|NCT02582034|Radiation|Standard Internal Radiation Therapy|"Injection of yttrium-90 microspheres (TheraSphere®) is performed during the therapeutic angiogram, directly into the hepatic artery (left or right, or even segmental).Standard dosimetry arm: the activity to be administered is calculated so as predictive dosimetry:
An absorbed dose of 120 ± 20 Gy to the treated volume (whatever the tumor absorbed dose)
A pulmonary dose < 30 Gy for one treatment and < 50 Gy in cumulative dose in case of multiple treatments."
1552291|NCT02582021|Procedure|Coronary Angiography|"A coronary angiogram is a procedure that uses x-ray imaging to see the heart's blood vessels; it is a part of Heart (cardiac) catheterization procedure. During a coronary angiogram, a type of dye that's visible by an x-ray machine is injected into the blood vessels of the heart. The x-ray machine rapidly takes a series of images (angiograms).
The Coronary Reactivity test (CRT), heart pressure (Millar) evaluation, and Millar stress testing are performed during the coronary angiography."
1552292|NCT02582021|Procedure|Coronary Reactivity Testing|An angiography procedure specifically designed to examine the blood vessels in the heart and how they respond to different medications.
1552293|NCT02582021|Procedure|Cardiac Magnetic Resonance Imaging|"Noninvasive high resolution imaging test; Optimized magnetic resonance imaging technique for use in the cardiovascular system - use of ECG gating and rapid imaging sequences.
Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. The CMRA is performed as part of the CMRI."
1552294|NCT02582021|Procedure|Cardiac Magnetic Resonance Angiography|Test for validation purposes against gold-standard Angiography. CMRA is a part of the CMRI test. The residual contrast (gadolinium) circulating in the blood stream (following the CMRI prior images) is sufficient for CMRA evaluation.
1552295|NCT02582021|Procedure|Computed Coronary Tomographic Angiography|Noninvasive, imaging method that uses a computed tomography (CT) scanner to look at the structures and blood vessels of the heart.
1552296|NCT02582021|Procedure|Rest-Stress Millar Testing|"Handgrip, mild leg exercise, and brief Valsalva Maneuver will be conducted to characterize cardiac response to stress. They are designed to test how your heart muscle is functioning.
Rest-stress Millar testing is performed during the coronary angiography and Cardiac Magnetic Resonance Imaging."
1552297|NCT02582021|Procedure|Aortic vasorelaxation tests|Non-invasive clinical test. Repeat blood pressure and heart rate per minute will be read for three times; Your pulse wave velocity, pulse wave analysis and central pressure measurements will be recorded.
1552298|NCT02582008|Drug|Bupropion Hydrochloride|Given PO
1552299|NCT02582008|Other|Laboratory Biomarker Analysis|Correlative studies
1552300|NCT02582008|Drug|Nicotine Replacement|Given NRT
1552301|NCT02582008|Other|Quality-of-Life Assessment|Ancillary studies
1552302|NCT02582008|Other|Questionnaire Administration|Ancillary studies
1552303|NCT02582008|Drug|Varenicline|Given PO
1552304|NCT02581995|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|2 mg aflibercept administered every 8 weeks following 5 initial monthly doses Intravitreal (IVT) injection
1552305|NCT02581982|Other|Laboratory Biomarker Analysis|Correlative studies
1552306|NCT02581982|Drug|Paclitaxel|Given IV
1552307|NCT02581982|Biological|Pembrolizumab|Given IV
1552310|NCT02581956|Behavioral|Walking exercise|Walk normally with the duration and frequency at a 30- minute or more daily at least five days per week and gradually increased to a maximum of 60 minutes daily.
1552311|NCT02581956|Behavioral|No walking exercise|no exercise
1552312|NCT02581943|Drug|Carboplatin|Given IV
1552313|NCT02581943|Other|Laboratory Biomarker Analysis|Correlative studies
1552314|NCT02581943|Drug|Paclitaxel|Given IV
1552315|NCT02581943|Biological|Pembrolizumab|Given IV
1552316|NCT02581943|Other|Quality-of-Life Assessment|Ancillary studies
1552317|NCT02581930|Drug|Ibrutinib|Given PO
1552318|NCT02581930|Other|Laboratory Biomarker Analysis|Correlative studies
1552319|NCT02581930|Other|Pharmacogenomic Study|Correlative studies
1552322|NCT02581904|Device|Prevena Care|The Prevena device is a product from KCI and is a sterile sponge that covers the closed incision. The device is placed sterile in the operating room and suction is then applied to the sponge for 5-7 days.
1552323|NCT02581904|Device|Dry gauze dressing care|Initial dry gauze dressing will be placed sterile in the operating room and will be changed daily
1552324|NCT02581891|Drug|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by individualized treatment intervals of between 8 to16 weeks based on protocol-defined anatomical criteria
1552325|NCT02581891|Drug|Eylea (Intravitreal Aflibercept, VEGF Trap-Eye, BAY86-5321)|3 monthly doses followed by five 8-weekly doses (5 x 2Q8), then by individualized treatment intervals of between 8 to 16 weeks based on protocol-defined anatomical criteria
1552404|NCT02581293|Procedure|Group 2 : Only parietal peritoneum will be closed|
1552405|NCT02581293|Procedure|Group 3 : Both of them will be closed|
1552406|NCT02581293|Procedure|Group 4: None of them will be closed|
1552330|NCT02581852|Other|Cross sectional assessment|Assessment of workability, functional disability, frailty, muscle strength, quality of sleep and sexual functioning
1552331|NCT02581839|Drug|Eribulin Mesylate|Most subjects will begin eribulin mesylate at 1.4 mg/m2 administered intravenously over 2 to 5 minutes on Days 1 and 8 of a 21-day cycle.
1552332|NCT02581839|Device|MRI|An MRI will be completed at week 1, week 12 and every 12 weeks after cycles 4+ while on study eribulin mesylate
1552333|NCT02581839|Drug|Pre-Medication: Zofran|Zofran at 8mg orally
1552334|NCT02581839|Drug|Pre-Medication: Decadron|decadron at 8mg orally
1552335|NCT02581826|Drug|Silodosin|α1-adrenoceptor antagonists are distributed not only in the bladder neck, urethra, and prostate, but also in the seminal vesicle and vas deferens. Specifically, the distribution of messenger ribonucleic acid (mRNA) of α1-adrenoceptor antagonists in seminal vesicle and vas deferens is reported to be 75-97%. It is reasonable to use α1-adrenoceptor antagonists with high selectivity for patients with Premature Ejaculation (PE). A new highly selective α1-adrenoceptor antagonists, is strongly associated with dry ejaculation with loss of seminal emission. It had the highest selectivity for the vas deferens compared with other α1-adrenoceptor antagonists.The effectiveness of highly selective α1-adrenoceptor antagonists as a potential therapy for this class of patients was scarcely investigated.
1552336|NCT02581826|Drug|Placebo|No column specified.
1552337|NCT02581813|Behavioral|I.D.E.A.L. for Adolescents Study - Higher Dairy|12 weeks diet and exercise intervention characterized by higher dairy consumption (4 servings per day) and exercise 3 times per week
1552338|NCT02581813|Behavioral|I.D.E.A.L. for Adolescents Study - Lower Dairy|12 weeks diet and exercise intervention characterized by lower dairy consumption (0-1 serving per day) and exercise 3 times per week
1552339|NCT02581800|Other|App group|
1552340|NCT02581787|Biological|Fresolimumab|Given IV
1552341|NCT02581787|Other|Pharmacological Study|Correlative studies
1552342|NCT02581787|Radiation|Stereotactic Body Radiation Therapy|Undergo SABR
1552343|NCT02581774|Other|normal delivery tracking|normal delivery tracking
1552344|NCT02581761|Drug|CYTOTEC|synthetic prostaglandin E1
1552345|NCT02581761|Other|Placebo|no active material
1552346|NCT02581748|Drug|HLX02|
1552347|NCT02581748|Drug|Herceptin|
1552349|NCT02581722|Device|PrePex Device|The PrePex device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures. For contraindicated subjects, a preparation procedure will take place.
1552350|NCT02581709|Behavioral|Countering cognitive impairment|The intervention will include education about cancer-related cognitive impairment, instruction on relaxation techniques, compensatory techniques, goal-setting and lifestyle advice. Each session will last between 90 and 120 minutes, once a week for six weeks. The intervention will be delivered in a group setting, in a non-clinical environment by the investigators.
1552351|NCT02581696|Drug|Lafutidine|Lafutidine 10mg, 1 tablet, bid
1552352|NCT02581696|Drug|Irsogladine maleate|Irsogladine maleate 2mg, 2 tablet, qd
1552353|NCT02581683|Drug|Magnesium Sulfate|Given via adductor canal block
1552354|NCT02581683|Drug|Ropivacaine|Given via adductor canal block
1552355|NCT02581683|Other|Sham|Sham adductor canal block
1552356|NCT02581670|Radiation|stereotactic radiation therapy (SRT)|Lung and liver stereotactic radiation therapy (SRT) in oligometastatic breast cancer patients unsuitable for surgery, using VMAT RapidArc approach
1552357|NCT02581657|Drug|PE0139 Injection|PE0139 Injection
1552358|NCT02581657|Drug|Placebo Injection|Placebo Injection
1552361|NCT02581618|Other|remote ischemic preconditioning|Blood pressure cuff inflation up to 200mmHg in the non-dominant arm before guiding catheter engagement
1552362|NCT02581605|Device|Custom-made 'cutting block'|To improve the accuracy of this operation we propose the use of a custom-made 'cutting block' tailored for each individual patient.
1552363|NCT02581592|Drug|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
1552364|NCT02581579|Dietary Supplement|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis|Nyaditum resae ® 10e5 of heat-killed Mycobacterium manresensis, 1 capsule per day during 14
1552365|NCT02581579|Other|Placebo|Placebo, 1 capsule per day during 14
1552366|NCT02581566|Drug|Intrathecal Dexmedetomidine|Addition of Intathecal Dexmedetomidine plus Intrathecal Bupivacaine
1552367|NCT02581566|Drug|Intraarticular Dexmedetomidine|Addition of Intraarticular Dexmedetomidine plus Intrathecal Bupivacaine
1552368|NCT02581566|Drug|Bupivacaine|Intrathecal Bupivacaine
1552374|NCT02581527|Drug|Rifampicin 1200mg|4FDC + additional rifampicin tablets to = 1200mg
1552375|NCT02581527|Drug|Rifampicin 1800mg|4FDC + additional rifampicin tablets to = 1800mg
1552376|NCT02581527|Drug|4FDC|Standard Fixed dose combination
1552377|NCT02581514|Other|Scheduled exams and diagnosis|Scheduled exams and diagnosis circuit as imposed by the algorithm
1552378|NCT02581501|Drug|GAX - Gemcitabine, Abraxane and Xeloda|GAX represents a novel approach to the development of cancer chemotherapy agents in pancreatic cancer and is based upon extensive laboratory investigations for the induction of apoptosis in pancreatic carcinoma cells. It is our expectation that this combination will induce apoptotic pathways downstream of biochemical mechanisms of resistance and synergistically induce pathways for apoptosis that are non-p53 dependent, which have not been previously explored in chemotherapy trials for this cancer.
1552379|NCT02581488|Biological|Santyl|
1552380|NCT02581488|Other|Product containing silver|Silver product not specified by the protocol; Investigators choose the appropriate silver containing product for each diabetic foot ulcer
1552381|NCT02581475|Procedure|Extending withdrawal time in the proximal colon|
1552382|NCT02581475|Procedure|Segmental examination twice of the proximal colon|
1552383|NCT02581462|Drug|FLOT alone|"Pre-operative therapy:
Docetaxel 50 mg/m², d1, d15, d29, d43
Oxaliplatin 85 mg/m², d1, d15, d29, d43
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
5-FU 2600 mg/m², d1, d15, d29, d43
Surgery is recommended to be scheduled 4 weeks after d43.
Post-operative therapy (start 6 to 8 weeks after surgery):
Docetaxel 50 mg/m², d1, d15, d29, d43
Oxaliplatin 85 mg/m², d1, d15, d29, d43
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
5-FU 2600 mg/m², d1, d15, d29, d43"
1552384|NCT02581462|Biological|FLOT + Herceptin/Pertuzumab|"Pre-operative therapy:
Herceptin 8/6 mg/kg, d1, d22, d43
Pertuzumab 840 mg, d1, d22, d43
Docetaxel 50 mg/m², d1, d15, d29, d43
Oxaliplatin 85 mg/m², d1, d15, d29, d43
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
5-FU 2600 mg/m², d1, d15, d29, d43
Surgery is recommended to be scheduled 4 weeks after d43.
Post-operative therapy (start 6 to 8 weeks after surgery):
Herceptin 8/6 mg/kg, d1, d22, d43
Pertuzumab 840 mg, d1, d22, d43
Docetaxel 50 mg/m², d1, d15, d29, d43
Oxaliplatin 85 mg/m², d1, d15, d29, d43
Leucovorin 200 mg/m², d1, d15, d29, d43 (can be replaced by sodium folinate according to local guidelines)
5-FU 2600 mg/m², d1, d15, d29, d43."
1552385|NCT02581449|Dietary Supplement|omega-3|dietary supplement
1552386|NCT02581449|Other|empty soft gelatin capsules|empty softgels of matched size, shape and color
1552387|NCT02581436|Other|kSORT assay based follow-up|kSORT assay in pre-established days: 14, 45, 90, 180, 365 and 540 of post transplantation follow-up. If kSORT result is positive maintenance immunosuppressive will be increased (tacrolimus trough levels 12-15 ng/mL, Mofetil Mycophenolate 1.5 mg every 24 hours and prednisone 5 mg/day) and graft biopsy will be obtained. Kidney biopsy will be obtained one mo after treatment as well as kSORT assay. If kSORT result is negative, the maintenance immunosuppressor dosages will remain as established in our institutional guidelines. If after a year of follow-up, the kSORT result is negative, immunosuppression will be decreased (Tacrolimus levels 5 - 10 ng/ml and mofetil mycophenolate 500 mg every 12 hours).
1552388|NCT02581436|Other|Standard follow-up|Surveillance will be the usual, includes creatinine determinations and clinical evaluation as often as established in the institutional protocol. A kidney graft biopsy will be obtained in case of dysfunction (increase in serum creatinine >25% above baseline or 0.3 mg/mL above baseline) or as part of our institutional programmed biopsies (months 3 and 12). Treatment will be established in accordance with biopsy results. In all cases of rejection a kidney biopsy will be obtained one month after initiating treatment. In this control group, samples for kSORT analysis will be collected on pre-established dates for the study, but patient treatment will not be contingent on the assay's results; investigators will be blinded to the result in this control patient group.
1552389|NCT02581423|Drug|Capecitabine|Participants will receive oral capecitabine, 1250 miligrams per meter-squared (mg/m^2) twice daily, in 3-week treatment cycles for up to 8 cycles. Treatment will be administered for 2 weeks followed by 1 week of rest without medication.
1552390|NCT02581410|Biological|GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A)|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
1552391|NCT02581397|Drug|Transpulmin suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
1552392|NCT02581397|Drug|Guaiacol suppository|01 suppository in the morning and 01 at night, via rectal, for 03 or 07 days
1552393|NCT02581397|Drug|Transpulmin syrup|7,5ml every 4 hours, orally, for 03 or 07 days
1552394|NCT02581384|Radiation|Stereotactic Body Radiotherapy (SBRT)|
1552395|NCT02581371|Drug|Cerebrolysin infusion|Two 10-day courses of 50 ml of investigational drug + 50 ml of sodium chloride 0.9% iv slowly drip infusions daily, separated with a 7-day interval
1552396|NCT02581371|Other|Placebo infusion|Two 10-day courses of 100 ml of sodium chloride 0.9% iv slowly drip daily, separated with a 7-day interval
1552397|NCT02581358|Other|Scolioscan (Ultrasound imaging system)|To assess the scoliotic patient, a 3D ultrasound imaging system (the Scolioscan) was developed. The system composes of an ultrasound scanner with a linear probe, a frame structure, an electromagnetic spatial sensing device and a dedicated PC program for imaging and data collection, processing, visualization, analysis, and assessment. The spatial sensor was attached to the ultrasound probe for spatial information collection and calibration. The Scolioscan will generate ultrasound images of the spine for quantitative assessment of the curve deformity in terms of Cobb angles.
1552398|NCT02581345|Biological|M923|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
1552399|NCT02581345|Biological|Humira|Recombinant human immunoglobulin G subclass 1 (IgG1) monoclonal antibody specific for human tumor necrosis factor-alpha (TNF-α)
1552400|NCT02581332|Behavioral|Mindfulness Meditation Training|Training will be held in groups of up to five participants. All of the participants within this group will receive up to 6 days (20m/d) of meditation training to be administered over 15 days. This is a paradigm similar to one employed in previous studies.
1552401|NCT02581319|Procedure|Periodontal treatment|Periodontal treatment will consist of scaling and planning root, 4 times in the first month and after that once a month until complete one year. Patients will be clinically evaluated and microbiological collects were made at baseline, 3 months, 6 months and 1 year after periodontal treatment.
1552402|NCT02581306|Other|Exercise session|There is no drug or device intervention in this study. Subjects will exercise at a moderate intensity for 60 minutes and a blood sample will be obtained before and after the exercise session
1552403|NCT02581293|Procedure|Group 1: Only visceral peritoneum will be closed|
1552448|NCT02580955|Device|LEGFLOW DCB|
1552407|NCT02581280|Other|Residual blood|Residual blood samples(1~2 cc) at each sampling time are collected from all subjects while using ECMO for drug concentration assays(LC-MS/MS etc.).
1552408|NCT02581254|Device|Thin Wire Snare|
1552409|NCT02581254|Device|Thick Wire Snare|
1552410|NCT02581241|Device|tilt table|"Participating individuals will be instructed to rest supine for 10 minutes while repeat electrocardiograms are recorded. They will then be instructed to stand up quickly and remain standing still for 10 minutes.
Individuals with inability to stand up quickly will be tested with tilt table test used in our hospital"
1552411|NCT02581228|Device|ML-PrediCare|
1552412|NCT02581215|Drug|mFOLFIRINOX|"mFOLFIRINOX:
Oxaliplatin 85 mg/m2 over 2-4 hours
Irinotecan 165 mg/m2 over 90 minutes
5-FU 2,400 mg/m2 as a 46-hour continuous infusion without the 5-FU bolus to decrease the risk of neutropenia."
1552413|NCT02581215|Drug|Ramucirumab|Ramucirumab administered as an intravenous infusion over 60 minutes (infusion rate should not exceed 25 mg/min), at a fixed dose of 8 mg/kg every 2 weeks.
1552414|NCT02581215|Other|Placebo|Placebo infusion with volume calculated as if it were ramucirumab every 2 weeks.
1552415|NCT02581202|Drug|lopinavir/ritonavir|tablet
1552416|NCT02581202|Drug|Lamivudine|tablet
1552417|NCT02581176|Drug|Apixaban|
1552418|NCT02581150|Procedure|Treatment of Occlusive Arterial Disease|Regarding the intervention, the technique used during the diagnostic and/or therapeutic procedure shall be left to the operator's discretion, except the use of an arterial closure device (ACD). In the ambulatory hospitalisation arm, the ACD use will be mandatory. In the conventional hospitalisation arm, ACD will be used at the discretion of the interventionalist.
1552421|NCT02581124|Drug|JTZ-951|
1552422|NCT02581124|Drug|Lapatinib|
1552423|NCT02581111|Drug|Naloxone|Naloxone 8-mg IV bolus
1552424|NCT02581111|Drug|Normal saline|
1552425|NCT02581098|Other|Tissue Biopsies|4-6 tissue biopsies will be obtained. Each biopsies will be sent for Laser Capture Molecular (LCM) - wound-edge endothelial cell capture, immunohistochemistry studies, to determine if the wound is infected using quantitative bacterial cultures and scanning electron microscopy for biofilm structure detection.
1552426|NCT02581098|Other|Wound Fluid|Fluid will be collected from negative pressure wound vac (if present), filter paper method, or aspiration method. When utilizing the filter paper method, three filter paper discs will be placed over the open wound and covered with an occlusive dressing. When utilizing the aspiration method, subjects will be provided with 1 liter of water to drink, and the wound will be cleaned with sterile water. The wound fluid will then be aspirated from beneath the dressing with a catheter and syringe and transferred into collection tubes. Endothelial cells and levels of circulation of miR-200b will be analyzed from the wound fluid.
1552427|NCT02581085|Dietary Supplement|Tocotrienol|Vitamin E is a dietary supplement. Vitamin E is a fat-soluble vitamin that exists in eight different forms. Each form has its own biological activity, which is the measure of potency or functional use in the body. Vitamin E is a dietary antioxidant that assists in maintaining cell integrity. It is obtained from sunflower, safflower, canola, and olive oils; also from many grains, nuts, fruits as well as fatty parts of meats. The tocotrienol form of natural vitamin E is found in rice and cereals but more abundantly in palm oil. Palm oil is an integral part of daily diet in southeastern Asia
1552428|NCT02581085|Other|Placebo|Control study capsule that includes no study product (Vitamin E - Tocotrienol)
1552429|NCT02581072|Drug|SB204|therapeutic dose of SB204
1552430|NCT02581072|Drug|SB204 8% or 12%|Supratherapeutic dose
1552431|NCT02581072|Drug|Moxifloxacin|
1552432|NCT02581072|Drug|Placebo|
1552433|NCT02581059|Drug|Regorafenib|All subjects will receive regorafenib 160 mg orally once daily for the first 21 days of each 28-day cycle for 2 cycles.
1552434|NCT02581059|Dietary Supplement|Ginseng|Subjects randomized to ginseng will receive 1,000 mg orally twice every day of each 28-day cycle for 2 cycles.
1552435|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 3month of the patients|The surgical timing of phacoemulsification is perform at the age of 3 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
1552436|NCT02581046|Procedure|Phacomulsification lens removal cataract surgery without Intraocular lens(IOL) implantation at the age of 6 month of the patients|The surgical timing of phacoemulsification is perform at the age of 6 month of the patients. During Phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
1552437|NCT02581046|Drug|Subconjunctival dexamethasone and general anesthesia|All patients received subconjunctival dexamethasone (2 mg) during surgery, and all surgeries were performed under general anesthesia.
1552438|NCT02581033|Drug|Nucleoside Analogue therapy|Determinants of sustained virological response after discontinuation of long-term nucleoside analogue therapy in chronic hepatitis B patients.
1552439|NCT02581007|Drug|Fludarabine|fludarabine (30mg/m2) given every day starting on Day -6 through Day -2;
1552440|NCT02581007|Drug|Melphalan|
1552441|NCT02581007|Drug|Cyclophosphamide|cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4.
1552442|NCT02581007|Procedure|peripheral blood stem cell transplant|
1552443|NCT02580994|Drug|Pembrolizumab|IV infusion at the dose of 200 mg on day 1
1552444|NCT02580994|Drug|cis/carboplatin and etoposide|Cisplatin 80 mg/m2 or Carboplatin Area Under the Curve (AUC) 5 IV infusion on day 1 Etoposide 100 mg/m2 IV infusion on day 1, 2 and 3
1552445|NCT02580981|Other|Acute Lymphobastic Leukemia (ALL) Treatment Options|Depending on the genomic testing results, patients with targetable genomic lesions will be enrolled onto available national clinical trials that are sponsored by the NCI National Clinical Trials Network (NCTN) (COG and other adult NCI Cooperative Groups). If no suitable NCTN trial exists, appropriate therapeutic regimens (including currently accepted standards-of-care), alterations in therapy, or treatment with targeted agents to specific genomic lesions will be considered.
1552446|NCT02580968|Device|electro-acupuncture|electro-acupuncture on acupoints according to the traditional syndrome diagnosis.once per day, for 20 days.
1552447|NCT02580968|Drug|flunarizine hydrochloride|flunarizine hydrochloride ，10mg/day，for 20 days。
1552449|NCT02580942|Device|Magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
1552450|NCT02580942|Device|Sham magnetic stickers|36 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22), and sham magnetic stickers on Feishu(BL13), Pishu(BL20) and Shenshu(BL23) once every other day, retention for 4 hours. Patients receive verum acupoint sticking therapy once every other day with a total of 18 sessions in 6 weeks.
1552451|NCT02580942|Drug|Chinese herbal medicine|72 patients receive acupoint sticking treatment of Chinese herbal medicine on Dazhui(GV14) and Tiantu(RN22).
1552452|NCT02580929|Radiation|radiotherapy|radiotherapy before surgery
1552453|NCT02580916|Other|SCQOLIT questionnaire|"Participants will be invited to complete the SCQOLIT and EQ-5D (used for comparison purposes, given its widespread use in other healthcare contexts in the UK) questionnaires [Appendices C & D) at:
baseline (after histological diagnosis of a NMSC is confirmed - both Groups)
3 months - either by postal (Group 1) or face-to-face (Group 2) dependent on whether the patient is returning to the Dermatology clinic for routine follow-up
at 6-9 months in the dermatology clinic if the patient is deemed high risk (squamous cell carcinoma with high risk clinicopathological features as listed by the National British Association Dermatologists Multiprofessional Guidelines for management of SCC) (Group 2 only)"
1552454|NCT02580903|Radiation|Radiology|Only a small subsample will require CT and right heart catherisation
1552455|NCT02580890|Device|tDCS active|Stimulation will be performed with the anode placed over the right DLPFC, and the cathode placed on the left DLPFC. The applied electric current will be 2mA and is going to be applied for 20 minutes. The electrodes have a size of 35cm ² each and will be covered by sponges soaked with saline.
1552456|NCT02580890|Device|tDCS sham|For the sham tDCS, the same setting will be used. However, the current is going to be applied for only 30 seconds, not being able to induce effects on neuronal excitability.
1552457|NCT02580877|Drug|67.5 mg oral insulin crystals daily|human insulin crystals in capsules
1552458|NCT02580877|Drug|500mg oral insulin crystals every other week|human insulin crystals in capsules
1552461|NCT02580838|Drug|OnabotulinumtoxinA|Early OnabotulinumtoxinA group will receive OnabotulinumtoxinA injection when their spasticity develop, late OnabotulinumtoxinA group will have injection at 6 months after emergence of spasticity, the third group will not have OnabotulinumtoxinA intervention.
1552462|NCT02580825|Behavioral|Biofeedback gait retraining|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section). During the meeting, participant will receive biofeedback that will displayed on a computer screen that shows the forces that develop in the knee joint so that the patient can see graphically the forces that develop around the knee joint and will be guided / try to reduce the values of the graph by changing the intensity of his landing on the tracks. In all training the time that the biofeedback is shown will be reduced.
1552463|NCT02580825|Behavioral|Exercise|Each session will include a continuous exercise in which the patient will do walking, walking pace and running (3 minutes each section).
1552464|NCT02580812|Other|Clinical and neuropsychological evaluation procedure|WPPSI, NEPSY, Brief, SDQ, Vineland and SCQ evaluation Clinical examination
1552465|NCT02580786|Behavioral|Breastfeeding peer support|
1552468|NCT02580747|Biological|anti-meso-CAR vector transduced T cells|genetically engineered lymphocyte therapy
1552469|NCT02580734|Dietary Supplement|melatonin|Cross-over randomized clinical trials
1552470|NCT02580721|Device|Dentsply Astra Tech Implant System EV|Dentsply Astra Tech Implant System EV will be placed
1552471|NCT02580708|Drug|Rociletinib|
1552472|NCT02580708|Drug|Trametinib|
1552473|NCT02580695|Biological|umbilical-cord mesenchymal stromal cells|Intra-articular knee injection of UC-MSC 20x10e6 at 0 and 6 months
1552474|NCT02580695|Drug|Hyaluronic Acid|Intra-articular knee injection of Hyaluronic Acid (3ml) at 0 and 6 months
1552475|NCT02580682|Drug|Sanfu herbal patch|The formula of the patch consists of Huang Qi (Astagalus Membranaceus), Fu Zi (Aconiti Lateralis Radix Praeparata), Yan Hu Suo (Rhizoma Corydalis), Xi Xin (Herba As5ari), Bai Jie Zi (Semen Sinapis Albae) and Rou Gui(Cortex Cinnamomi), in a proportion of 2:2:1:1:2:1.
1552476|NCT02580682|Drug|Sanfu moxibustion|Moxibustion is a kind of thermal therapy without any feeling of pain or swell.Moxibustion exerts its therapeutic effect by thermal power and the application of moxa.
1552477|NCT02580682|Drug|Sanfu herbal patch and moxibustion|use Sanfu moxibustion followed by Sanfu herbal patch
1552478|NCT02580669|Other|Neuropsychological assessment|A neuropsychological assessment is done
1552479|NCT02580669|Other|Neurologic consultation|A neurologic consultation is done
1552480|NCT02580669|Other|MRIs (with vasoreactivity testing)|MRIs (with vasoreactivity testing) is done
1552481|NCT02580656|Behavioral|Metacognitive Therapy|MCT helps patients to understand the deleterious and counterproductive effects of responding to negative thoughts and feelings with worry and rumination. Treatment aims to enable patients to exert greater metacognitive control over their worry and rumination. The positive and negative metacognitive beliefs that keep perseverative thinking in place are modified, using verbal and behavioural reattribution and through specifically designed therapeutic methods.
1552482|NCT02580643|Biological|APS|intra-articular injection
1552483|NCT02580630|Behavioral|Reduction in running and jumping|Advocate to avoid running and jumping sports for the first 3 months, thereafter slowly progressing to normal sport activity.
1552484|NCT02580630|Other|Training|Patients are instructed to carry out strengthening exercises for the diseased achilles tendon 3 times a week. Physiotherapist will instruct all patients in these heavy slow resistance exercises. First time one week after the first injection, and then week 3, 6, 10. The patient will register all training on a diary and on an App.
1552485|NCT02580630|Drug|Ultrasound guided injection with Glucocorticosteroid|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml methylprednisolone 40mg/ml. Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
1552486|NCT02580630|Drug|Ultrasound guided injection with local anaestethic|Ultrasound guided injection in Kagers triangle underneath the thickest part of the achilles tendon with 1ml Lidocain 5 mg/ml and 1 ml of intralipid (for blinding). Injection is given every months until the tendon pain is markedly reduced (VAS morning pain: 0-20, and VAS training pain: 0-40, and Global recovery rating scale (-5 to +5) is +3 to +5 ). (max 3 injections).
1552487|NCT02580617|Biological|ALLO-ASC|Infusion for Crohn's disease
1552488|NCT02580604|Drug|Calcium Chloride/Calcium Gluconate|Calcium (as either calcium chloride or calcium gluconate in half normal saline) will be delivered via IV during exercise to keep serum ionized calcium levels above baseline. The clamp is modeled after the hyperglycemic glucose clamp.
1552489|NCT02580604|Drug|Placebo|Saline Infusion
1552490|NCT02580591|Drug|Empagliflozin|
1552491|NCT02580591|Drug|Placebo|For blinding purposes
1552492|NCT02580578|Other|No Intervention|No intervention is administered in this study.
1552493|NCT02580565|Other|telephone interview|Clinical assessment for screening and a phone call for questionnaire administration
1552494|NCT02580552|Drug|MRG-106|Decreasing intratumoral doses
1552495|NCT02580552|Drug|MRG-106|Escalating subcutaneous or intravenous doses with starting dose selected based on MRG-106 tolerability determined in Part A
1552496|NCT02580539|Biological|Group A|Peptide-stimulated T cells 2 x 10^7/m^2
1552497|NCT02580539|Biological|Group B|Peptide-stimulated T cells per dose-escalation protocol
1552498|NCT02580526|Procedure|V-E mask ventilation for one minute|"V-E approach maintains mouth open, creates larger oral cavity and allow positive pressure generated during inspiration to push forwards submandibular region.
When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique. Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
1552499|NCT02580526|Procedure|C-E mask ventilation for one minute|"Using C-E technique, the operator's fingers pressure mouth closed and push posteriorily the soft tissue of submandibular region.
When apnea occurs after anesthesia induction subjects will be ventilated with one of the two techniques randomly, either two-handed C-E facemask ventilation technique or with V-E technique . Ventilation will be carried out using pressure mode ventilation at respiratory rate of 10 breaths per minute. Subject will start with one technique and then cross over to the other technique."
1552500|NCT02580513|Behavioral|Circadian Misalignment|
1552501|NCT02580500|Procedure|epidural catheter|epidural anaesthesia application for spinal catheter will be used
1552502|NCT02580500|Procedure|spinal catheter|spinal anesthesia application for spinal catheter will be used
1552503|NCT02580487|Procedure|appendicectomy|Appendix was removed either laparoscopically or open surgery
1552504|NCT02580474|Drug|Daclatasvir plus Asunaprevir|
1552505|NCT02580461|Behavioral|A 24 week center-based structured exercise and education program|The intervention will consist of a strength and aerobic exercise program. The exercise program will include twice weekly group resistance exercises classes, twice monthly group education classes, and individual activities to achieve 150 weekly minutes of aerobic activity. The resistance exercise and education classes will be run at a gym space at the University of Calgary. The wait-list control participants will be told not to change their activity levels throughout the 12 weeks of the trial. The wait list control participants will be enrolled into the exercise and education intervention once they have completed 12 weeks of wait-list control. A 12 week maintenance exercise program will be offered to all participants who finish the 12 week exercise and education program. The maintenance exercise program will consist of once weekly resistance group based exercise classes and individual activities to achieve 150 weekly minutes of aerobic physical activity.
1552506|NCT02580448|Drug|Female AR(+) TNBC Enzalutamide Naïve|Seviteronel given daily with evening meal in 28 day cycles
1552507|NCT02580448|Drug|Female ER(+) BC Patients|Seviteronel given daily with evening meal in 28 day cycles
1552508|NCT02580448|Drug|Male ER(+) BC Patients|Seviteronel given daily with evening meal in 28 day cycles
1552509|NCT02580409|Behavioral|Exercise Intervention|Investigators are proposing an innovative rehabilitative care program for older primary care patients at risk for mobility decline. The program targets newly identified risk factors for mobility decline and utilizes mobile health technology to deliver patient centered care more efficiently. Study participants will receive exercise instruction with a licensed physical therapist for an average of 8-10 training sessions, with the possibility of up to 16 sessions. some at home and some in the clinic. The exercise training sessions will focus on improving mobility, balance and ability to get up from a chair with the use of an exercise application (Wellpepper) being used on a study issued iPad.
1552510|NCT02580396|Device|CanADVICE+® (smart phone app)|The main objective of this project is to optimise pharmaceutical counselling services by providing drug related information, in a digital format, to patients with metastatic breast cancer receiving Capecitabine.
1552511|NCT02580383|Procedure|Radiofrequency neurotomy of lumbar medial branch|In above L5, The RF needle was placed to contact with bone as close as possible to the course of the target nerve in parallel. For L5 dorsal rami ablation, the needle was positioned in the groove between the S1 articular process and sacral ala. At each level, the electrodes were adjusted to optimize sensory stimulation at a frequency of 50 Hz and maximize multifidus contraction at 2 Hz. A 75 second 80°C lesion was made using an RF generator.
1552512|NCT02580370|Biological|Botulinum toxin type A|Topical botulinum toxin type A
1552513|NCT02580370|Biological|Placebo comparator|Topical placebo comparator
1552514|NCT02580357|Procedure|Low Level Laser Therapy|Low Level Laser Therapy on the palatal donor site of connective tissue graft.
1552515|NCT02580357|Device|GaAlAs laser|Utilization of GaAlAs laser to irradiation on the palatal donor site.
1552516|NCT02580344|Drug|Ibuprofen|The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days
1552517|NCT02580331|Drug|SRP and placebo|Placement of placebo gel into classII furcation defects after scaling and root planing
1552518|NCT02580331|Drug|SRP and 1% metformin|Placement of 1% metformin gel into classII furcation defects after scaling and root planing
1552519|NCT02580318|Device|breathalyzer|
1552522|NCT02580279|Drug|EGCG|
1552523|NCT02580279|Drug|placebo|
1552524|NCT02580253|Drug|Individualized Chemotherapy|Two drug combination adjuvant chemotherapy based on the Adenosine Triphosphate Tumor Chemosensitivity(Oxaliplatin, Gemcitabine, Irinotecan, Paclitaxel,docetaxel, Fluorouracil,Doxorubicin,Cisplatin)
1552525|NCT02580253|Drug|mFOLFOX6|Oxaliplatin,Fluorouracil
1552526|NCT02580240|Drug|Hydrocortisone|Hydrocortisone was administered 200 mg/d as a continuous infusion for 6d, then tapered off. Once all vasopressors were discontinued, the taper protocol was initiated (half dose for three days, then quarter dose for three days and then stopped).
1552527|NCT02580240|Drug|saline|Vials containing normal saline as placebo were identical to those containing hydrocortisone. Placebo administration procedures were similar.
1552528|NCT02580227|Drug|Tranexamic Acid|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
1552529|NCT02580227|Other|Placebo|All subjects will be given 1g of TXA in 100cc normal saline, or placebo of 100cc normal saline at time of admission, after consent is given.
1552530|NCT02580214|Dietary Supplement|Impact|600 ml of Impact, Nestle for 5 days prior to surgery
1552531|NCT02580201|Biological|Oral Polio Vaccine|"Opvero™ (oral) is a trivalent, live attenuated poliomyelitis virus vaccine containing at least 6.0 log 50% cell culture infective dose (CCID50) of LS c2ab strain of live attenuated polio virus type 1, 5.0 log CCID50 of P712, Ch, 2ab strain of live attenuated polio virus type 2, 5.8 log CCID50 Leon I2aIb strain of polio virus type 3. Excipients: human albumin, HEPES buffer solution, magnesium chloride solution (containing polysorbate 80 and phenol red), hydrochloric acid or sodium hydroxide for pH adjustment.
The vaccine is presented as a suspension for oral administration. One dose of vaccine (0.1 ml) is contained in two drops which are delivered from the dropper supplied with the multidose container."
1552532|NCT02580188|Drug|sugammadex|Maintenance dose of 0.4-0.9 mg/kg/hr rocuronium is continuous infusion during surgery for the maintenance of post tetanic count 1-2 (deep block).
1552533|NCT02580175|Procedure|Blinded evacuation|Ring evacuation was performed in the conventional way without use of ultrasound followed by sharp gentle curettage until complete evacuation.
1552534|NCT02580175|Procedure|Evacuation under ultrasound guidance|Ring evacuation was performed under ultrasound guidance followed by sharp gentle curettage until complete evacuation. The surgery was considered complete when the endometrial cavity appeared as a regular echogenic line.
1552535|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Professionals|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is delivered by PROFESSIONAL interventionists.
1552536|NCT02580162|Behavioral|FBT for Pediatric Weight Management by Peers|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change. This 20 week treatment is adapted from our existing evidence-based interventions and is provided by PEER interventionists.
1552537|NCT02580162|Behavioral|Peer Interventionists|Parents who receive FBT complete 6 weeks of training and then serve as peer interventionists to a new group of families.
1552538|NCT02580149|Drug|Ticagrelor|"Subjects will receive an oral loading dose of 180 mg ticagrelor on study day
1 followed by a maintenance dose of 90 mg twice daily for 14 days (until study day 15)."
1552539|NCT02580149|Drug|Clopidogrel|Subjects will receive a loading dose of 600 mg clopidogrel on the first study day followed by a maintenance dose of 75 mg once daily for 14 days
1552540|NCT02580123|Behavioral|Intervention taught by trained educators|
1552541|NCT02580110|Other|Sucrose|
1552542|NCT02580110|Other|Stevia glycosides|
1552543|NCT02580110|Other|saccharin|
1552544|NCT02580097|Other|MRI|MRI perfusion imaging, including contrast bolus perfusion imaging and arterial spin labeling.
1552545|NCT02580084|Procedure|Hybrid Intervention|"The puncture of the femoral artery general is executed and the introducer 7Fr is set. Further, the hydrophilic conductor executes a recanalization of the Vasa of iliac artery occlusion. if you cannot pass the occlusion retrograde is additional access to antegrade recanalization. Then using hydrophilic conductors, an iliac artery antegrade or retrograde recanalization of the Vasa is made.
Femoral artery arteriotomy. Further execute a direct endarterectomy femoral artery and from the mouth of a hip artery.
arteriotomy of the femoral artery is closed with a vascular patch use (synthetic or biological).
Balloon angioplasty and stenting, iliac artery is done, the controlling angiography Closing maims."
1552546|NCT02580084|Procedure|Aorta femoral Bypass|It is sufficient to identify only the anterior-lateral aorta surface. After heparinization the aorta is clamped above and below the anastomosis. The aorta is dissected along the anterior wall, calcium portions or mural thrombus are removed. Prosthesis is cut obliquely and anastomosis suturing starts with distal angle. Occluded at the prosthetic base jaws, aortic compressor is removed, restoring blood flow in the lower limb. Next stage is tunnel creating for jaws prosthesis conduction on hip. Ureters must remain over the prosthesis, jaw should be above the iliac arteries. After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. Before anastomosis completion the testing jaws and all arteries bloodletting is performed.
1552548|NCT02580058|Biological|avelumab|10 mg/kg will be given as a 1 hour intravenous infusion (IV) every 2 weeks (Q2W) in 4 week cycles
1552549|NCT02580058|Drug|PLD|PLD (Arm B, Arm C) 40 mg/m2 will be given as a 1 hour IV infusion every 4 weeks (Q4W) in 4 week cycles
1552550|NCT02580032|Other|No treatment given|No treatment given.
1552551|NCT02580019|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
1552552|NCT02580006|Drug|EPORON|single dose administration subcutaneously
1552553|NCT02580006|Drug|EPREX|single dose administration subcutaneously
1552554|NCT02579993|Procedure|Pannus and conjunctival dissection|A complete conjunctival peritomy is performed and the fibrovascular pannus and conjunctiva invading the cornea is dissected from the cornea and limbus.
1552555|NCT02579993|Procedure|Human cultivated limbal stem cell transplantation|The amniotic membrane graft cultured with the human limbal stem cell transplantation is placed in the limbic and corneal surface and fixed with fibrin glue. The amniotic membrane is placed with the stroma in contact with the graft and it is sutured.
1552556|NCT02579980|Procedure|DCE and DWI MRI|Dynamic Contrast Enhanced MRI (DCE-MRI) and Diffusion Weighted MRI (DW-MRI): DW-MRI is a technique for quantifying the increase in water diffusion caused by cellular necrosis or apoptosis in tumors within days of therapy. DCE-MRI is frequently used in preclinical and early clinical trial assessment of anti-angiogenic and vascular disrupting compounds, also within hours of therapeutic intervention.
1552557|NCT02579980|Procedure|Surgery|Standard of care procedure for sarcoma patients
1552558|NCT02579980|Device|MRI|Standard of care procedure for sarcoma patients
1552566|NCT02579954|Behavioral|Rehabilitation|
1552567|NCT02579941|Procedure|Blood sampling (pregnant)|"5.4 ml of venous blood will be taken during the delivery or the caesarian procedure, in addition to the standard of care blood sampling.
This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
1552568|NCT02579941|Procedure|Blood sampling (non pregnant)|"5.4 ml of venous blood will be taken.
This blood vial will be sent to the coagulation laboratory and all tests will be performed in vitro. The blood sample will be split in several aliquots. In each blood sample, fibrinolysis will be activated by the plasminogen tissular activator (tPA - concentration: 1066 UtPA/ml). Tranexamic acid will be added at increasing concentrations (2.5 microg/ml up to 40 microg/ml) to each sample and coagulation will be measured by two different tests: EXTEM and NATEM."
1552569|NCT02579928|Drug|Ketamine|A single dose of 0.5mg/kg of Ketamine will be administered Intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
1552570|NCT02579928|Drug|Midazolam|A single dose of 0.045mg/kg of Midazolam will be administered intravenously during 40 minutes in the Hospital Research Unit of YNHH. The subject will be monitored continuously during the procedure, and every hour for three hours after the infusion.
1552571|NCT02579915|Behavioral|FaceAnxiety|Computerized treatment targeting mental habits and primary care linkage.
1552572|NCT02579915|Behavioral|Symptom Tracking|Weekly self-assessment with validated questionnaires and primary care linkage
1552573|NCT02579902|Dietary Supplement|Vitamin D3 (Cholecalciferol)|50000 IU Vitamin D3 (Cholecalciferol) will be given as one gelcaps every 2 weeks for a period of 6 months.
1552574|NCT02579902|Dietary Supplement|placebo|placebo will be given in identical gelcaps once every 2 weeks for a period of 6 months.
1552575|NCT02579889|Device|DDD+CLS|Device will be programmed in a dual-chamber DDD pacing mode with the Closed Loop Stimulation (CLS) function ON
1552576|NCT02579889|Device|DDD(R)|Device will be programmed in a dual-chamber DDD(R) pacing mode with the Closed Loop Stimulation (CLS) function OFF
1552579|NCT02579863|Drug|lenalidomide|25 mg administered orally (PO) on Days 1 to 21 of each treatment cycle
1552580|NCT02579863|Drug|dexamethasone|40 mg administered orally (PO) on Days 1, 8, 15, and 22 of each treatment cycle
1552581|NCT02579863|Biological|pembrolizumab|200 mg administered as an intravenous (IV) infusion on Day 1 every 3 weeks
1552582|NCT02579850|Drug|CHF 5993 + Ultibro matched placebo|Active medication treatment CHF 5993 and Ultibro matched placebo administered twice a day
1552583|NCT02579850|Drug|Ultibro + CHF 5993 matched placebo|Active medication treatment Ultibro and CHF 5993 matched placebo administered twice a day
1552584|NCT02579850|Procedure|Central spirometry|Central spirometry to assess forced expiratory volume at one second and forced vital capacity
1552585|NCT02579850|Other|COPD assessment test|COPD assessment test (CAT) at visit 1
1552586|NCT02579850|Procedure|Local laboratory Assessments|ECG + Standard Haematology and Biochemistry
1552587|NCT02579850|Other|Saint George's Respiratory Questionnaire|Saint George's Respiratory Questionnaire
1552588|NCT02579850|Other|EXACT-pro questionnaire|daily from randomization (Visit 2) to end of study (Visit 7)
1552589|NCT02579837|Device|Optos 200Tx|non-mydriatic ultra-widefield (UWF) retinal imaging device
1552590|NCT02579837|Device|Zeiss Cirrus|optical coherence tomographer (OCT)
1552591|NCT02579824|Drug|DS-3032b|Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
1552592|NCT02579811|Drug|Axitinib|The intent is to maximize sustained dose intensity of axitinib based on individual tolerability using dose modification criteria
1552593|NCT02579798|Device|PEEP (positive end-expiratory pressure)|
1552594|NCT02579785|Behavioral|Mhealth intervention|A series of ten automated interactive voice messages will be delivered to the participant's mobile phone over a period of 4 months. Messages will be targeted to the method of contraception the participant is using (no-method, condoms, pills, injectable, implant, copper coil). Messages will support uptake of contraception among no-method users. Messages will support existing users to continue their method and to use it correctly and will also encourage participants who are not happy with their method to switch to a different method. All messages will end with five options: Press 1 to repeat the message, press 2 to listen to recorded information about methods of contraception, press 3 to speak to a counsellor, press 4 to tell me you're fine, press 5 to stop receiving these messages.
1552595|NCT02579772|Drug|N-acetylcysteine|Pharmacological treatment with N-acetylcysteine (NAC): 3 pills of 600 mg of NAC/day orally for 4 days prior to experimental procedures and 1 pill of 600 mg of NAC orally on the day of the experiment.
1552596|NCT02579772|Drug|Placebo|Placebo: 3 placebo pills/day orally for 4 days prior to experimental procedures and 1 placebo pill orally on the day of the experiment.
1552597|NCT02579759|Drug|PXT3003 dose 1|Liquid oral solution, 5 ml twice a day, morning and evening with food
1552598|NCT02579759|Drug|PXT3003 dose 2|Liquid oral solution, 5 ml twice a day, morning and evening with food
1552599|NCT02579759|Drug|placebo|Liquid oral solution, 5 ml twice a day, morning and evening with food
1552600|NCT02579746|Behavioral|DASHNa-CC|The 8-week DASHNa-CC intervention incorporated Dietary Approach to Stop Hypertension (DASH) diet, sodium reduction with the food therapy of Traditional Chinese Medicine, and included an intervention manual, two sessions of classroom instruction delivered in Mandarin, and a 20-minute telephone follow-up.
1552601|NCT02579746|Behavioral|usual care|education booklet, encouragement of physician visit, use of public health resources if needed
1552602|NCT02579733|Drug|Azathioprine|
1552603|NCT02579733|Drug|Placebo|
1552604|NCT02579707|Drug|AG120|AG120 in fed and fasted conditions. Part 2- AG120 single dose exposure
1552605|NCT02579694|Device|Acumed Scapholunate Intercarpal Screw|Evaluation of provisional fixation to allow biologic healing of the scapholunate interval
1552606|NCT02579681|Drug|dimethyl fumarate|dimethyl fumarate administered as per the arm description
1552607|NCT02579668|Other|Language Therapy|
1552612|NCT02579629|Drug|Ropivacaine 0.1%|Ropivacaine 0.1% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.1% ropivacaine followed by an infusion of 8ml/hr of 0.1% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.1% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.1% ropivacaine for 72 hours post-operatively.
1552613|NCT02579629|Drug|Ropivacaine 0.2%|Ropivacaine 0.2% is a local anaesthetic drug and will be administered as a single bolus dose of 8ml of 0.2% ropivacaine followed by an infusion of 8ml/hr of 0.2% ropivacaine using the On-Q® elastomeric pump. The bolus dose of 8ml of 0.2% ropivacaine will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr of 0.2% ropivacaine for 72 hours post-operatively.
1552614|NCT02579629|Drug|Normal saline|Normal saline will be administered as a single bolus dose of 8ml of normal saline followed by an infusion of normal saline using the On-Q® elastomeric pump. The bolus dose of 8ml of normal saline will be administered via a multiport, silver-impregnated catheter (6-10cm) placed above the rectus muscle parallel to the fascial incision, using a preloaded syringe. The infusion will be delivered by the On-Q® elastomeric pump pre-set to deliver 8ml/hr normal saline for 72 hours post-operatively.
1552615|NCT02579629|Device|On-Q ® elastomeric pump|The On-Q® elastomeric pump automatically and continuously delivers a regulated flow of 0.1% or 0.2% ropivacaine or normal saline locally to the surgical site for 72 hours post-operatively. The infusion will be delivered by pre-setting the On-Q® elastomeric pump to deliver at the rate of 8ml/hr for 72 hours post-operatively.
1552616|NCT02579616|Drug|Lenvatinib|Lenvatinib will be administered orally once daily in 28-day cycles. Participants will be treated until disease progression, unacceptable toxicity, withdrawal of consent, participant's choice, etc.
1552617|NCT02579603|Drug|Nintedanib|Nintedanib 150mg bid
1552618|NCT02579603|Drug|Pirfenidone|
1552619|NCT02579590|Drug|Depot Medroxyprogesterone Acetate 150 mg|"the DMPA user where they are using Depot Medroxyprogesterone Acetate 150 mg (DMPA; Phrmcia) injection every 3 month"
1552620|NCT02579590|Drug|Implanon( 68 mg etonogestrel implant)|where they are using etonogestrel 68 mg implant (Implanon; Organon)
1552621|NCT02579590|Drug|Cerazette pills (75 micrograms desogestrel)|where they are using desogestrel 75 micrograms (Cerazette; Organon), one pill every day for 28 days without pill-free interval.
1553109|NCT02576340|Drug|otilonium bromide|otilonium bromide was administered before the procedure
1552622|NCT02579577|Other|Observation|Observation of clinic appointments and ward rounds if the child is admitted to hospital during the study period.
1552623|NCT02579577|Other|Interviews|Semi-structured interviews will be conducted approximately 3 times during the study period with each participant.
1552624|NCT02579577|Other|Medical notes review|The child's electronic medical record will be accessed periodically to identify any planned appointments or periods of hospitalisation and their medical notes will also be reviewed at the end of the study.
1552625|NCT02579564|Drug|Gemcitabine|
1552626|NCT02579564|Drug|Vinorelbine|
1552627|NCT02579564|Drug|Paclitaxel|
1552628|NCT02579564|Drug|Pemetrexed|
1552629|NCT02579564|Drug|Oncorine|
1552630|NCT02579564|Drug|Endostar|
1552631|NCT02579564|Drug|Cisplatin|
1552632|NCT02579551|Procedure|Therapeutic Conventional Surgery|Undergo surgical excision
1552633|NCT02579525|Other|Hemodynamical treatment TTP|Based on capillary refilling time, peripheral temperature, mottling, diuresis, MAP safety limit monitoring
1552634|NCT02579525|Other|Hemodynamical treatment MCG|Based on MAP, CVP, urine output monitoring
1552635|NCT02579512|Other|Extra-corporeal ECG signal analysis|The NIA algorithm is similar to the traditional 12-lead ECG equipment. By analyzing patient data, NIA algorithm provides more detailed results compared to traditional 12-lead ECG. Patients with suspected coronary artery disease are conventionally diagnosed and treated by cardiac catheterization. However, cardiac catheterization is invasive procedure. Unless clinical diagnosis is evident before cardiac catheterization, a treadmill exercise test, a nuclear medicine myocardial perfusion test, or a multi-direction coronary CT angiogram is usually performed to increase the accuracy of diagnosis. But these examinations are not accessible to all patients, and are time-consuming and costly.
1552636|NCT02579499|Drug|fixed high potent statin therapy|Patients assigned fixed high-potent statin group will be received high-intensity statin therapy (atorvastatin 40mg or rosuvastatin 20mg) regardless of their baseline LDL-C levels, and maintain high-intensity statin therapy regardless of their follow-up LDL-C level.
1552637|NCT02579499|Drug|targeted LDL-C goal statin|"Statin naïve patients: Patients will be received moderate intensity statin therapy (atorvastatin 20mg or rosuvastatin 10mg)
Patients already received statin therapy
Baseline LDL-C <70mg: same intensity of statin therapy
Baseline LDL-C≥70mg: uptiltrated statin therapy Patients will be tiltrated statin intensity guided by follow-up LDL-C level ( Attained LDL-C < 50mg/dL : down regulated intensity statin therapy, 50mg/dL ≤ Attained LDL-C < 70g/dL: maintain current intensity statin therapy, Attained LDL-C ≥ 70mg/dL: up regulated intensity statin therapy)"
1552638|NCT02579473|Drug|SER-214|SER-214 is a poly(2-ethyl-oxazoline) (POZ) polymer conjugate of the potent dopamine agonist rotigotine that is designed to provide continuous drug delivery following a single weekly injection
1552639|NCT02579460|Other|Cessation of Acid Suppressing Medications|Acid suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations are performed while the participant is not on acid-suppressing medications.
1552640|NCT02579434|Drug|Midazolam I.V.|Midazolam I.V. 1mg/ml
1552641|NCT02579421|Drug|Progesterone|generic progesterone
1552642|NCT02579421|Drug|placebo|placebo
1552643|NCT02579395|Behavioral|Collaborative implementation Intentions|With spouse/romantic partner
1552644|NCT02579395|Behavioral|Individual implementation Intentions|Without spouse/romantic partner
1552645|NCT02579395|Behavioral|Control|
1552646|NCT02579382|Drug|TDF|300 mg tablets administered orally once daily
1552647|NCT02579382|Drug|Vesatolimod|Tablets administered orally once a week (every 7 days) for 12 doses
1552648|NCT02579382|Drug|Placebo|Placebo administered orally once a week (every 7 days) for 12 doses
1552649|NCT02579369|Other|Allogeneic mesenchymal stem cells|Dressing for Dystrophic Epidermolysis Bullosa wound.
1552650|NCT02579369|Device|Polyurethene Film|Dressing for Dystrophic Epidermolysis Bullosa wound.
1552651|NCT02579356|Drug|Telmisartan|
1552652|NCT02579356|Drug|Atorvastatin|
1552653|NCT02579343|Device|Auricular Acupuncture|Auricular acupuncture is a form of acupuncture which utilizes the surface of the external ear to identify points of inflammation in the body. It does this, in this case, by utilizing the Pointer Excel II probe which can pick up a change in electrical conductivity on the surface of the ear, which reflects an internal point of inflammation or stress. Once the point of inflammation is identified, the Pointer Excel II is equipped with a sensor that it will not only illuminate by way of a small light on the front of the probe will also identify the point of inflammation by way of an auditory signal. Once the point of inflammation is identified auricular acupuncture will treat that point with a micro-current of electricity for several seconds.
1552654|NCT02579343|Drug|Sham Auricular Acupuncture + Lexapro|Participants will be treated with the SSRI Lexapro 10 mg daily which will be increased to 20 mg daily at week 2. Participants will be treated twice weekly during their follow-up visits with sham auricular acupuncture (No micro-current).
1552655|NCT02579330|Device|Coloshield|Coloshield is designed to occlude the rectum during surgery thus enabling the possibility for rectal washout and maintaining a clear operating field. The rod-shaped Instrument contains two silicon balloons which are inflated by means of a catheter. Several holes at the section in between the two balloons are connected to another catheter, which enable negative pressure to be established. By insufflation of the two balloons and establishment of a negative pressure between the balloons by means of connection to a closed drainage bottle the colon is occluded for the duration of surgery.
1552656|NCT02579330|Other|Control|In the control group no device is introduced but a rectal washout with 500ml of Saline solution in performed.
1552657|NCT02579317|Behavioral|Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
1552658|NCT02579317|Behavioral|Non-Resonance Breathing|Breathing is paced with a pre-installed iPhone app that includes a visual pacer.
1552659|NCT02579304|Procedure|transbronchial lung cryobiopsy|bronchoscopic sampling
1552660|NCT02579291|Other|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
1552661|NCT02579291|Other|Bobath|Patients will receive different neuromodulatory interventions based on the Bobath concept with the aim to decrease spasticity on the lower extremity
1552662|NCT02579278|Other|Blood sample (mrEMVI positive patient)|Two blood samples are taken from each patient with mrEMVI positive tumours post chemoradiotherapy. One pre-surgery and one during surgery from a peripheral vein.
1552663|NCT02579278|Other|Blood sample (mrEMVI negative patient)|
1552664|NCT02579265|Drug|Smoflipid 20% (investigational lipid for parenteral nutrition)|"Dose: The targeted maximal lipid dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the lipid dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.
Investigational or control drug will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.
The lipid emulsions will be infused into a central or peripheral vein."
1552665|NCT02579265|Drug|Intralipid® 20%|"Dose: The targeted maximal lipid dose is 3.0 g/kg/day. In patients already receiving parenteral nutrition (PN) before starting study treatment, the lipid dose will either stay at 3.0 g/kg/day or be increased by 1.0 g/kg/day steps to a maximum of 3.0 g/kg/day.
Investigational or control drug will be infused over 20 - 24 hours, as per hospital policy, at a weight based infusion rate.
The lipid emulsions will be infused into a central or peripheral vein."
1552666|NCT02579252|Biological|AADvac1|
1552667|NCT02579252|Drug|Placebo|
1552668|NCT02579239|Biological|ATYR1940|Intrapatient dose escalation of intravenous ATYR1940 administered twice weekly at doses of 0.3, 1.0, or 3.0 mg/kg for up to 12 weeks.
1552669|NCT02579239|Biological|Placebo|Patients will receive an initial infusion of placebo at Week 1, supplied as normal saline and administered via IV infusion over a 30-minute period.
1552672|NCT02579213|Other|observational study done only in women candidate for amniocentesis|As a part of routine test in women with obstetrical indication for amniocentesis, we take 30 cc of amniotic fluid. only additional 3 ml of the amniotic fluid are needed for examination by electronic sensors.
1552673|NCT02579200|Device|POWERbreathe®KHA (IMT group)|2 training sessions/day consisting of 30 breaths (~50% maximal inspiratory pressure; Pi,max), 7 days/week (once/week supervised at research center), for 8 weeks using an electronic tapered flow resistive loading (TFRL) device (POWERbreathe®KH2, HaB International Ltd., Southam, UK). Measurements of PImax will be performed every week and training loads will be increased continuously to maintain the actual ~50% Pimax values.
1552674|NCT02579200|Device|POWERbreathe®KH2 (sham group)|2 training sessions/day of 30 breaths at an inspiratory load of no more than 10% of their initial Pi,max (POWERbreathe®KH2, HaB International Ltd., Southam, UK). This training load will not be changed during the entire study period.
1552675|NCT02579187|Procedure|tooth extraction|The study tooth will be removed
1552676|NCT02579187|Radiation|CBCT scan|a CBCT scan limited to the dental arch that includes the study side will be obtained
1552677|NCT02579187|Drug|Anesthesia|all subjects will receive local infiltrative anesthesia, prior to extraction of the tooth
1552678|NCT02579187|Other|clinical measurements|After tooth extraction, clinical measurements of the site will be obtained and recorded (keratinized mucosa width, horizontal ridge width, facial and lingual bone thickness
1552679|NCT02579187|Drug|Biodegradable sponge (type I bovine collagen)|control group subjects will receive a biodegradable sponge (type I bovine collagen) to stabilize the clot
1552680|NCT02579187|Drug|10µg of pSil-miR200c|subjects in the experimental group will receive a 10µg of pSil-miR200c plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
1552681|NCT02579187|Procedure|cross mattress suture|The site will be stabilized with a simplet external, cross mattress suture
1552682|NCT02579187|Drug|10µg of PMIS miR200a plasmids|subjects in the experimental group will receive a 10µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
1552683|NCT02579187|Drug|5µg of pSil-miR200c and 5µg of PMIS miR200a|subjects in the experimental group will receive a 5µg of pSil-miR200c and 5µg of PMIS miR200a plasmids in a biodegradable sponge (type I bovine collagen) to stabilize the clot
1552684|NCT02579187|Procedure|Blood|Subjects will have venipuncture performed to obtain a small blood sample (approx. 2 ml) to assess for miR-200c and PMIS-miR-200a expression and liver function (AST, ALT, bilirubin levels)
1552685|NCT02579187|Other|Photos/videos|subjects will have photos and/or videos of the extraction site and/or implant taken at each visit.
1552686|NCT02579187|Procedure|Wound fluid|a small sample of wound fluid will be obtained from the extraction site in a minimally invasive manner using a paper point at 1, 2, 3 & 4 weeks post extraction
1552687|NCT02579187|Procedure|saliva|approximately 2 mls of saliva will be obtained in a minimally invasive manner at the time of extraction and at 14 weeks post extraction.
1552688|NCT02579187|Radiation|periapical xray|periapical xrays will be obtained at screening, 16 weeks and at 12 month followup time point
1552689|NCT02579187|Other|PVS impression|PVS impressions will be taken to plan the implant placement surgery. This will be done at the screening visit and also at 14 weeks post extraction.
1552690|NCT02579174|Device|Medacta GMK Sphere|
1552691|NCT02579161|Drug|cephalosporins|Looking at the same drugs and doses the variable is the timeframe of the medication
1552692|NCT02579161|Drug|aminoglycoside|
1552693|NCT02579161|Drug|metronidazole|
1552694|NCT02579161|Drug|Clindamycin|
1552695|NCT02579161|Drug|aminoglycoside/ sulbactam|If allergies to above medicines
1552696|NCT02579161|Drug|Fluoroquinolones|
1552697|NCT02579148|Biological|HUCMSC injection|The subjects will receive intracavernous injection of HUCMSC.`
1552698|NCT02579148|Biological|collagen scaffolds/HUCMSC injection|The subjects will receive intracavernous injection of the mixture of collagen scaffolds and HUCMSC respectively.`
1552699|NCT02579135|Behavioral|Safer Sex|Interactive web-based intervention with five modules: motivation, knowledge, attitudes/norms, self-efficacy, and sexual communication skills.
1552700|NCT02579135|Behavioral|Growth Mindsets|Interactive web-based intervention with five modules: mindsets introduction, growth mindsets of intelligence, growth mindsets of self-control, growth mindsets of people, and integrative summary.
1552701|NCT02579109|Other|memory test|
1552708|NCT02579070|Device|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet.
1552711|NCT02579044|Drug|Everolimus and lonafarnib|
1552712|NCT02579031|Device|Orsiro|Novel biodegradable-polymer sirolimus-eluting stent used during primary percutaneous coronary intervention
1552713|NCT02579031|Device|Xience|Durable-polymer everolimus-eluting stent used during primary percutaneous coronary intervention
1552714|NCT02579018|Behavioral|One hour supervised exercise session|All participants will participate in a one hour supervised exercise session. Participants will wear a physical activity monitor during the assessment for continuous monitoring of heart rate. Short, intense bouts of exercise will be interspersed with rest periods.
1552715|NCT02579005|Biological|Patients with a living donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The dose of external radiation will be 15 Gy divided in 3 fractions, from Day -3. Cyclophosphamide, 250 mg/m2 will be given on Day -2. Donors will receive 5 daily doses of GCSF, 10 µg/kg, by subcutaneous injection from Day -4. PBMC will be collected through apheresis on Day 0. A dose of 5 x 10exp7 CD3 cells/kg will be administered. The infused volume will be adjusted to contain this T cell dose.
1552716|NCT02579005|Biological|Patients with a UCB donor|The day of allogeneic cell infusion will be referred to as Day 0 and the n-th day before that, as Day -n. The UCB unit should have at least 4 of 6 HLA compatibility and at least 3 x 10exp6 TNC per kg patient weight. The dose of external radiation will be 15 Gy, divided in 3 fractions, starting on Day -3. Cyclophosphamide, 250 mg/m2 intravenously, will be given on Day -2.
1552717|NCT02578992|Procedure|Head-lift position|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
1552718|NCT02578992|Device|7cm high pillow|A 7 cm high pillow was set beneath the patients' head with head in neutral position for intubation.
1552719|NCT02578979|Device|Electrocardiogram|Patients will receive electrocardiogram for detecting atrial fibrillation - a 5-day routine ECG.
1552720|NCT02578979|Device|Holter|Patients will receive electrocardiogram for detecting atrial fibrillation - a 24-h Holter.
1552721|NCT02578966|Behavioral|Motivational Interview|
1552722|NCT02578966|Other|Traditional health education|
1552723|NCT02578953|Drug|Dutasteride-Test product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by GSK, Poznan.
1552724|NCT02578953|Drug|Dutasteride-Reference product|Dutasteride Capsules are oblong, opaque, dull-yellow, gelatin capsules. The capsules contain 0.5 mg dutasteride for oral administration. The capsules also contain Butylated Hydroxytoluene, Mono-di-glycerides of Caprylic/Capric Acid (MDC), Gelatin, Glycerin, Concentrated Glycerin, Titanium Dioxide, Iron Oxide Yellow as ingredients. This product will be manufactured by Catalent, Beinheim.
1552725|NCT02578940|Radiation|Fluciclovine 18 F|Radioligand for PET CT scanning
1552726|NCT02578927|Dietary Supplement|GT+Ex|In this session the volunteers ingested capsules with 2g of powder green tea before exercise
1552727|NCT02578927|Dietary Supplement|PL+Ex|In this session the volunteers ingested capsules with 2g of placebo before exercise
1552728|NCT02578927|Dietary Supplement|Green Tea|In this investigation the volunteers ingested capsules with 2g of powder green tea before the rest similar to the exercise time
1552729|NCT02578914|Drug|NS2 Ophthalmic Drops (0.5%)|
1552730|NCT02578914|Drug|NS2 Ophthalmic Drops Vehicle (0.0%)|
1552731|NCT02578901|Drug|Tranexamic Acid|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, TXA 1.0 gram will be administered. When given PO, TXA 1.3 grams will be administered
1552732|NCT02578901|Drug|Placebo|Doses will be given intravenous (IV) or orally (PO) per the discretion of the treating investigator. Doses are administered every 8 hours. When given IV, Normal Saline will be administered. When given PO, placebo pills will be administered
1552733|NCT02578888|Other|Palliative Therapy|Palliative Therapy
1552734|NCT02578888|Other|Palliative Therapy + idiographic|Ancillary studies
1552735|NCT02578862|Drug|Propofol|
1552736|NCT02578862|Drug|Sevoflurane|
1552737|NCT02578849|Drug|L-DOPA|Patients and healthy controls are recruited to participate in [11C]yohimbine scans before and after L-DOPA challenge.
1552738|NCT02578836|Procedure|Fogel Gastroplasty|The subject will be placed under general anesthesia. The procedure will last approximately 1-2 hours. CO2 will be used rather than air for the insufflation that is required during the procedure to minimize abdominal distention. The physician will place an interrupted suture pattern in a manner which partitions the greater curvature of the stomach from the Angle of His to the level of the incisura, creating a tube-like passage for gastric volume reduction. Afterwards, the remaining gastric volume will be reduced using a circumferential running stitch.The device that will be used to place the stitches is the OverStitch system FDA approved for tissue apposition
1552739|NCT02578823|Device|Arctic Sun®|Core temperature is maintained to 36℃ for 3 days by using the skin attached pad(Arcticgel™) and targeted temperature management(Arctic Sun®).
1552740|NCT02578823|Device|Arcticgel™|
1552741|NCT02578823|Procedure|Conventional antipyretic treatment|Conventional antipyretic treatment for fever includes using of antipyretics, ice packs, circulating fan, and tepid bathing, etc.
1552742|NCT02578797|Drug|Apalutamide|Study drug will be administered orally at a dose level of 240 mg daily (4 x 60 mg tablets) in treatment cycles of 28 days.
1552743|NCT02578784|Device|Angioplasty with drug-coated balloon|"Angioplasty with drug-coated balloon Elutax (Aachen Resonance, Germany)"
1552744|NCT02578784|Device|Angioplasty with plain old balloon|"Angioplasty with plain old balloon Sterling (BostonScientific, Switzerland)"
1552745|NCT02578771|Drug|ZuraPrep with 70% IPA|Apply topically
1552746|NCT02578771|Drug|ZuraPrep without 70% IPA|Apply topically. 0% IPA
1552747|NCT02578771|Drug|ChloraPrep CHG/IPA Teal Tint|Apply topically
1552748|NCT02578771|Other|Normal Saline|Apply topically
1552752|NCT02578745|Device|Prophylactic NPWT (PICO system)|The PICO NPWT system is a small, lightweight (~126 grams), portable suction device consisting of an electric motor-driven vacuum pump connected to a proprietary super-absorbent adhesive dressing. It is supplied as a pump with two sterile dressing kits and two batteries. Different dressing sizes are available for transverse and vertical incisions ranging from 10 to 40 cm. The PICO pump maintains negative pressure of -80 mmHg (+/-20 mmHg) to the wound surface.
1552753|NCT02578745|Other|Standard Dressing|Standard wound dressing consists of routine postoperative wound dressing consisting of layers of gauze and adhesive tape.
1552754|NCT02578732|Drug|FOLFOXA|FOLFOXA is a combination treatment including: Abraxane, Oxaliplatin, Leucovorin and 5-FU
1552755|NCT02578719|Drug|bupivacaine|marcaine %0.5 20 ml flacon
1552756|NCT02578719|Drug|saline|%0.9 sodium chloride
1552760|NCT02578680|Biological|Pembrolizumab 200 mg|IV infusion
1552761|NCT02578680|Drug|Cisplatin|IV infusion
1552762|NCT02578680|Drug|Carboplatin|IV infusion
1552763|NCT02578680|Drug|Pemetrexed|IV infusion
1552764|NCT02578680|Dietary Supplement|Folic acid 350-1000 μg|Orally; at least 5 doses of folic acid must be taken during the 7 days preceding the first dose of pemetrexed, and folic acid dosing must continue during the full course of therapy and for 21 days after the last dose of pemetrexed.
1552765|NCT02578680|Dietary Supplement|Vitamin B12 1000 μg|Intramuscular injection in the week preceding the first dose of pemetrexed and once every 3 cycles thereafter. Subsequent vitamin B12 injections may be given the same day as pemetrexed administration.
1552766|NCT02578680|Drug|Dexamethsone 4 mg|For prophylaxis; orally twice per day (or equivalent). Taken the day before, day of, and day after pemetrexed administration.
1552767|NCT02578680|Drug|Saline solution|IV infusion
1552768|NCT02578667|Device|Gorbly Compression Device|The compression device provides a way to displace critical structures along the path from skin to target, retract excess body wall tissue, and provide mechanical stabilization in a repeatable and sustainable fashion.
1552769|NCT02578654|Other|Strategies to improve HIV care engagement|"Additional HIV care team daily inpatient round and three telephone calls to remind the upcoming clinic appointment. These interventions are specifically added on routine care during the post-intervention period. The routine care does not include the additional round and the three telephone calls and is assessed during the pre-intervention period."
1552770|NCT02578641|Biological|autologous EBV specific Cytotoxic T Lymphocytes|The CTL line will be prepared by co-cultivation of the irradiated EBV-LCL with patient PBMC. A proportion of peripheral blood will be used to generate EBV specific CTLs.
1552771|NCT02578641|Drug|combination IV gemcitabine and IV carboplatin (AUC2)|4 cycles for Arm A and 6 cycles for Arm B
1552772|NCT02578628|Other|Patient Engagement|The patient engagement system monitors routine clinical laboratory test results and sends messages to patients and providers when action is indicated, such as when tests are overdue or results require extra clinical attention. Patients receive first class letters directing them to call their provider. Providers receive fax or electronic messages directing them to reach out to the patient to arrange follow-up care.
1552773|NCT02578615|Other|physiotherapy|physiotherapeutic intervention according to the principles of the Spiraldynamik® concept
1552774|NCT02578602|Drug|Gadoxetate Disodium|Given IV
1552775|NCT02578602|Device|Magnetic Resonance Imaging|Undergo MRI with gadoxetate disodium
1552777|NCT02578550|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide fixed-dose combination (FDC)|A single tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg will be administered.
1552778|NCT02578550|Drug|Emtricitabine/tenofovir alafenamide FDC|A single tablet containing FTC 200 mg and TAF 10 mg will be administered.
1552779|NCT02578550|Drug|Darunavir|A single tablet containing darunavir 800 mg will be administered.
1552780|NCT02578550|Drug|Cobicistat|A single table containing cobistat 150 mg will be administered.
1552783|NCT02578524|Other|Survey|
1552784|NCT02578511|Drug|Ixazomib|Patients who have been on stable doses of 6 - MP, vincristine, and methotrexate for a minimum of eight weeks and have at least six months remaining of maintenance are eligible to receive Ixazomib, which will be administered on days 1, 8 and 15.
1552785|NCT02578498|Dietary Supplement|High carbohydrate intake|Carbohydrate intake < 50 gram
1552786|NCT02578498|Dietary Supplement|Low carbohydrate intake|Carbohydrate intake > 250 gram
1552787|NCT02578485|Device|AVideogame|Participants active video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
1552788|NCT02578485|Device|SVideogame|Participants sedentary video game played by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
1552789|NCT02578485|Device|EMIntensity|Participants performed walking on a treadmill at moderate intensity by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
1552790|NCT02578485|Device|EISVideogame|Participants performed walking on a treadmill in intensity similar to the game by a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
1552791|NCT02578485|Device|Control|participants remained at rest for a period of 60 minutes, then remain at rest for the evaluation of post-exercise blood pressure for an additional period of 60 minutes.
1552792|NCT02578472|Drug|JNJ-42847922|JNJ-42847922 will be administered as 40 milligram oral capsule (2 capsule*20 mg) in one of the treatment periods.
1552793|NCT02578472|Drug|Zolpidem|Zolpidem will be administered as 1 capsule containing 10 mg in one of the treatment periods.
1552794|NCT02578472|Drug|Placebo|Matching Placebo will be administered orally.
1552795|NCT02578459|Device|Intrathecal Drug Delivery System|The Prometra Pump is a battery-operated, implantable, programmable infusion pump that dispenses pain medication into the intrathecal space through an implanted infusion catheter.
1552796|NCT02578459|Other|Conventional Medical Management|Treatment with conventional medical management will include using standard systemic pain medications such as narcotics, nonsteroidal anti-inflammatory drugs (NSAIDs), and neuropathic medications (examples: gabapentin, Lyrica, Cymbalta) that are typically used to treat pancreatic cancer pain.
1552797|NCT02578446|Device|Uncemented Triathlon Tritanium CR Total Knee System|Primary Total Knee Replacement
1552798|NCT02578446|Device|Cemented Triathlon CR Total Knee System|Primary Total Knee Replacement
1552799|NCT02578433|Behavioral|Mindful Self Compassion|Mindful Self Compassion (MSC) training has its primary focus on developing a friendly relationship with oneself by meditation,conversation with the group and the trainer, informal practice and homework assignments. These relationship is founded on mindfulness; therefore the participants will learn a way concentrate on the present moment. The orginal MSC training by Neff and Germer is well established, this intervention will be a shortened form of the original version and will last for the whole visit of the clinical patients in rehabilitation
1552800|NCT02578433|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation by Jacobson is a well known relaxation technique where participants learn to recognize the difference between tension and relaxation by tensing and subsequently relaxing the muscles. The trainingw ill last the wohole stay and the control group will also do homework assignments.
1552801|NCT02578420|Other|open-label placebo|"Placebo Cream, openly described as Placebo"
1552802|NCT02578420|Other|deceptive placebo|"Placebo Cream, described as Voltaren, containing Diclofenac"
1552803|NCT02578407|Other|accommodative/vergence therapy|12 weekly accommodative/vergence therapies
1552804|NCT02578394|Drug|Anakinra 100mg and Placebo Depo-Medrone|Anakinra 100mg injection S/C Day 1 to Day 5 and Placebo Depo-Medrone (Lipofundin 3mL) I/M Day 1. Anakinra is an interleukin-1 receptor antagonist. Placebo for Depo-Medrone placebo is Lipofundin MCT/LCT 10%.
1552805|NCT02578394|Drug|Depo-Medrone 120mg and Placebo (Anakinra)|Depo-Medrone 120mg in 3mL. Placebo for Anakinra supplied from manufacturer. 120mg Depo-Medrone I/M Day 1 and Placebo Anakinra 100mg injection S/C Day 1 to Day 5.
1552806|NCT02578381|Device|Boston Scientific Pressure Wire|St Jude Medical Pressure Wire
1552807|NCT02578381|Device|Validation of Boston Scientific pressure wire|
1552808|NCT02578368|Drug|5-Fluorouracil|2600 mg/m², d1 i.v., every 2 weeks
1552809|NCT02578368|Drug|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
1552810|NCT02578368|Drug|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
1552811|NCT02578368|Drug|Docetaxel|50mg/m², d1, i.v., every 2 weeks
1552812|NCT02578368|Drug|Trastuzumab|4 mg/kg BW (6 mg loading dose at 1st administration), i.v. for 1 h, d1, i.v., every two weeks
1552813|NCT02578368|Drug|sodium folinate|can be used to replace leucovorin (calcium folinate)
1552814|NCT02578368|Procedure|Surgery|Aim of surgical resection is a complete (R0) resection of the primary tumor and the metastases or a complete macroscopic cytoreduction of the metastases.
1552815|NCT02578342|Device|MRI|Functional Magnetic Resonance Imaging technique measures brain activity by detecting associated changes in blood oxygenation level dependency
1553380|NCT02574520|Drug|SABER®-Bupivacaine|
1552816|NCT02578329|Behavioral|Intensively advised Mediterranean diet|Mediterranean Diet: fatty fish 3 times/week; legumes 2-3 times/week; vegetables twice/day; fresh fruits twice/day; 30 to 45g olive oil/day; 1-2 glasses red wine/day; less than 150g red meat/week
1552817|NCT02578329|Behavioral|usual low-fat dietary advice|usual low-fat dietary advice for cardiovascular disease
1552818|NCT02578316|Drug|Lenvatinib|"Study phase dosing: participants received an initial single dose of radiolabelled 14C-lenvatinib oral patient dosing solution containing 24 mg of lenvatinib as anhydrous free base and radioactivity of 3.7 millibecquerel (MBq) on Day 1.
Extension phase dosing: 24 mg of 14C-lenvatinib: 2 x 10mg, and 4 x 1mg or 1 x 4mg tablets once-daily, continuously in each 28-day cycle during extension phase."
1552819|NCT02578303|Other|Vascular flow measurement by PC-MRI|participants will undergo vascular flow measurement by PC-MRI at intra and extracranial levels
1552820|NCT02578290|Other|Clinical Decision Support (CDS)|"A best practices alert (BPA) pop-up screen providing CDS will appear at physician sign-off for all scans scored 1-3, and scans scored 4-6 for which an alternative scan scored 7-9 exists.
This screen will show the appropriateness score of the original scan order, and will display any alternative scans that are scored 7-9 for the same indications and patient characteristics. It will also display a link to relevant ACR documentation relevant to the selected scan and indication.
Any time the pop-up alert appears, a checkbox removing the selected scan from unsigned orders will be checked by default."
1552821|NCT02578277|Drug|Cocktail of CYP (cytochrome P450) and transporter probe substrates|
1552822|NCT02578277|Drug|BMS-955176|
1552823|NCT02578277|Drug|BMS-955176 plus the cocktail of CYP and transporter probe substrates|
1552824|NCT02578251|Drug|Paracetamol|
1552825|NCT02578251|Drug|Pethidine|
1552827|NCT02578212|Other|Placebo|
1552828|NCT02578199|Behavioral|motivational interviewing and nutrition|Motivational Interviewing and Nutritional Counseling
1552829|NCT02578186|Drug|Diphenhydramine Hydrochloride|30 mL at bedtime
1552830|NCT02578186|Drug|Placebo|30 mL at bedtime
1552831|NCT02578173|Device|AVERT PLUS|
1552832|NCT02578160|Procedure|inferior alveolar and lingual nerve block procedure|inferior alveolar and lingual nerve block
1552833|NCT02578147|Behavioral|Mighty Girls|
1552834|NCT02578147|Behavioral|Game Girls|
1552835|NCT02578134|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the symptomatic insertion of the plantar fascia
1552836|NCT02578134|Other|Sham US-guided percutaneous electrolysis|The acupuncture needle will be inserted into the symptomatic plantar fascia but no galvanic electrical current will be applied, the equipment will be turn off. Patients will be blinded to the application of galvanic electrical current.
1552837|NCT02578121|Drug|Ixazomib|4.0 mg will be given on days 1, 8 and 15 of a 28 day cycle
1552838|NCT02578121|Drug|Pomalidomide|4.0 mg will be given on days 1-21 of a 28 day cycle
1552839|NCT02578121|Drug|Dexamethasone|20 mg will be given on days 1, 8, 15 and 22 of a 28 day cycle
1552840|NCT02578108|Procedure|genicular nerve diagnostic block with lidocaine (local anesthetic)|sensory denervation of the knee joint
1552841|NCT02578108|Procedure|genicular nerve radiofrequency ablation|Ablation of the genicular nerves of the knee by radiofrequency energy
1552842|NCT02578095|Drug|VK5211|Capsule
1552843|NCT02578095|Drug|Placebo for VK5211|Capsule
1552844|NCT02578082|Drug|TD-4208|A single inhaled dose of TD 4208 (175 mcg)
1552845|NCT02578069|Device|NOVA Intracranial Sirolimus Eluting Stent System|A sirolimus eluting intracranial stent system with polylactic-co-glycolic acid (PLGA) biodegradable drug carrier and electro-grated polybutyl methacrylate (PBMA) base coating. The stent platform is made of 316L stainless steel.
1552846|NCT02578069|Device|Apollo Intracranial Stent System|A 316L stainless steel balloon-expandable intracranial stent system
1552847|NCT02578056|Device|Midurethral sling|Anti-urinary incontinence procedure, in a prophylactic way.
1552848|NCT02578056|Procedure|Genital prolapse surgery|Surgical correction of genital prolapse
1552849|NCT02578043|Drug|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%|Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75% (Taro Pharmaceuticals Inc.)
1552850|NCT02578043|Drug|Onexton™ Gel|Onexton™ Gel (Clindamycin and Benzoyl Peroxide Gel 1.2%/3.75%) (Valeant Pharmaceuticals LLC)
1552851|NCT02578043|Drug|Placebo|Placebo (vehicle of the test product) (Taro Pharmaceuticals Inc.)
1552852|NCT02578030|Drug|SHP465 12.5mg|
1552853|NCT02578030|Drug|SHP465 25mg|
1552854|NCT02578017|Behavioral|Mobile DOT|Mobile DOT is a multi-dimensional tool that uses automated reminders, adherence feedback messages, incentives, and video observation of medication administration.
1552855|NCT02578004|Other|biochemical and molecular analysis|
1552856|NCT02577991|Drug|Decadron|10 mg of intraoperative intravenous decadron with gel foam sponge placed on cervical plate
1552857|NCT02577991|Drug|Triamcinolone|40 mg of triamcinolone on gel foam sponge dabbed on the anterior cervical plate
1552858|NCT02577978|Device|Medacta GMK posterior stabilized prosthesis|
1552859|NCT02577978|Device|Medacta GMK Sphere prosthesis|
1552860|NCT02577965|Procedure|Percutaneous Coronary Intervention|Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up
1552861|NCT02577965|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System|Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
1552862|NCT02577939|Behavioral|Interval Exercise Training (IET)|This is a single arm study. All patients receive the intervention of 6 weeks of pre-transplant IET, pre- and post-tests, and data collection via FitBit accelerometer and weekly surveys.
1552863|NCT02577926|Drug|Ruxolitinib|Ruxolitinib is a JAK1/2-specific tyrosine kinase inhibitor (TKI) which has been approved for the treatment of symptomatic myelofibrosis. The compound was shown to be superior to hydroxyurea in reducing splenomegaly and constitutional symptoms.
1552942|NCT02577406|Drug|Low-dose cytarabine (LDAC)|continuous 28-day cycles of cytarabine 20 mg SC twice a day (BID) for 10 days, plus BSC
1552864|NCT02577926|Drug|BAT|BAT is at the choice of the investigator (monotherapy with i.e. hydroxyurea, anagrelide, interferon, busulfan, immunomodulators etc).
1552865|NCT02577900|Device|Acticoat absorbent|Apply Acticoat absorbent daily onto diabetic foot ulcer in 12-week study interval
1552866|NCT02577900|Device|Honey gel sheet|Apply Honey gel sheet daily onto diabetic foot ulcer in 12-week study interval
1552867|NCT02577900|Device|Jelonet|Apply Jelonet daily onto diabetic foot ulcer in 12-week study interval
1552869|NCT02577861|Procedure|Biopsy from donor eye|Corneal biopsy from undamaged limbus
1552870|NCT02577861|Procedure|Implant of Holoclar|Implant of Holoclar into the eye to be treated after scraping of the fibrovascular pannus
1552871|NCT02577861|Procedure|Ophtalmologic examination|"The following assessments are performed:
Epithelial defects assessment by fluorescein staining; superficial corneal neo-vascularization assessment; Best-Corrected Visual Acuity; ocular tonometry; slit lamp examination (both corneal endothelium and anterior chamber); conjunctival inflammation (both bulbar and limbal) assessment; corneal sensitivity and involvement assessment; Schirmer's test type I; evaluation of the following symptoms: pain, burning, photophobia."
1552872|NCT02577861|Procedure|Blood sample collection|Standard haematology, biochemistry and Infectious profile (Virology) are assessed
1552873|NCT02577861|Procedure|Digital pictures|At least 4 digital corneal slit lamp photos without fluorescein and at least 4 digital corneal slit lamp photos with fluorescein are taken using digital camera
1552874|NCT02577861|Procedure|ECG|A 12-lead ECG measurement in single recording at screening for safety reason and before each transplantation.
1552875|NCT02577861|Behavioral|Questionnaires|Quality of Life assessment through the NEI VFQ 25and EQ-5D-3L questionnaire (EQ-5D-Y in paediatric population)
1552876|NCT02577861|Procedure|Physical examination and vital signs|A complete physical examination and vital signs (Systolic and Diastolic Blood Pressure (SBP, DBP) and Pulse Rate (PR) must be assessed at each visit (but not at pre-screening and at visit 6)
1552877|NCT02577848|Drug|GLP-1|GLP-1 were taken daily for 7 days
1552878|NCT02577848|Drug|Placebo|Placebo were taken daily for 7 days
1552879|NCT02577835|Device|Ambulatory blood pressure monitoring|Ambulatory blood pressure monitoring with arterial stiffness evaluation at 6-12 month intervals.
1552880|NCT02577822|Device|Taperloc standard length stem|
1552881|NCT02577822|Device|Taperloc short length stem|
1552882|NCT02577809|Drug|Morphine100|100mcg added to the spinal anaesthetic
1552883|NCT02577809|Drug|Morphine50|50mcg added to the spinal anaesthetic
1552884|NCT02577809|Drug|Fentanyl|25mcg Fentanyl added to the spinal anaesthetic
1552885|NCT02577809|Drug|Hyperbaric Bupivicaine|1.8ml 0.5% spinal bupivicaine with dextrose
1552886|NCT02577809|Drug|Indomethacin|100mg Indomethacin suppository
1552887|NCT02577783|Drug|Chemotherapy with PDD regimen|doxorubicin hydrochloride iposome (duomeisu) plus bortizomib (velcade) and dexamethasone (disaimisong)
1552888|NCT02577783|Drug|Chemotherapy with PAD regimen|doxorubicin (duoroubixing) plus bortizomib (velcade) and dexamethasone (disaimisong)
1552889|NCT02577770|Device|acupuncture|therapeutic acupuncture treatment with actual needles
1552890|NCT02577770|Dietary Supplement|200mg caffeine|8g coffee, po
1552891|NCT02577770|Dietary Supplement|400mg caffeine|16g coffee, po
1552892|NCT02577770|Dietary Supplement|Decaffeinated|decaffeinated coffee, po
1552893|NCT02577757|Device|MRI|MRI
1552894|NCT02577744|Other|Noninvasive Ventilation|Noninvasive ventilation for 15 minutes with EPAP set at 10 cmH2O and IPAP adjusted to maintain a tidal volume of 6 ml / kg ideal weight.
1552895|NCT02577744|Other|Expiratory Positive Air Pressure|EPAP through facial mask with valve spring load for 15 minutes set at 10 cmH2O.
1552896|NCT02577731|Other|Bone marrow collection|Bone marrow will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
1552897|NCT02577731|Other|Muscle tissue collection|Muscle tissue will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
1552898|NCT02577731|Other|Blood collection|Blood sample collection will be collected from the patient at time of orthopedic repair in the operating room. A second sample may be collected if the patient is required to return to the operating room for further repair of orthopedic injury.
1552899|NCT02577731|Other|Clinical data collection|Clinical data collection will encompass demographic information, past and present medical records, laboratory, microbiology, and all other test results, x-ray, CT, MRI, US and all other imaging test results, records about any medication received during admission, records of physical exam during admission, records of all vital signs and hemodynamic monitoring during admission, records of any procedure or intervention during admission, records of any procedure or intervention during hospital admission, condition at the discharge and discharge facility.
1552901|NCT02577705|Behavioral|Self Empowerment Groups|The Self Empowerment Groups (SEG) curriculum draws key components from the S.E.L.F. tool within Sanctuary, focusing the four domains: creating personal, emotional, moral and physical safety (S), processing and managing emotions (E), recognizing loss and letting go (L), and developing goals for a sense of future (F). S.E.L.F. establishes a common language that all people who have experienced adversity can use to organize their lives and work towards building stable foundations to support their goals and invest in their potential.
1552902|NCT02577705|Behavioral|Financial Empowerment|The Financial Empowerment curriculum developed for this study consisted of interactive exercises, worksheets, and journal assignments that fostered understanding and practice of banking, building credit and debt management, making the most of one's money, and setting financial goals for oneself and one's family. Content focused on identifying and harnessing the internal and external resources that participants can leverage to begin taking steps towards financial self-sufficiency.
1553012|NCT02576977|Drug|Dexamethasone|dexamethasone 40 mg tablets
1553381|NCT02574520|Drug|Bupivacaine HCl|
1552903|NCT02577705|Behavioral|Matched Savings|Participants were assisted with opening a savings accounts at a local non-profit federal credit union (with 1:1 matches of up to twenty dollars per month) over the course of 12 months.
1552904|NCT02577692|Other|Oxygen|breathing oxygen
1552905|NCT02577692|Other|Ambient|breathing ambient air
1552906|NCT02577666|Behavioral|Ecologically Based Therapy|6 months of community reinforcement approach and case management, 3 months of rental assistance for housing
1552907|NCT02577666|Behavioral|Housing Only|receives 3 months of project supported rental assistance
1552908|NCT02577666|Behavioral|Treatment as Usual|receives services as normally offered within the community
1552909|NCT02577653|Other|Posturographic evaluation|Subjects will undergo CDP testing using the modified Clinical Testing of Sensory Integration in Balance (mCTSIB) protocol. Subsequently, subjects will be asked to stand first on the right leg and then on the left leg with eyes open. Finally, subjects will be asked to perform 10 repetition of the squatting movement, with the operator pacing them (telling them when to start and when to stop the movements).
1552910|NCT02577640|Dietary Supplement|Soy bread|Soy breads will be produced using a sponge-dough process. Finished dough will be formed, panned, and proofed in proofing cabinet (~95% RH) at 40ºC for 60 minutes. Proofed loaves will be baked for 50 minutes at 150ºC in a convection oven (jet air oven, model: JA14, Doyon, Liniere, Quebec, Canada). Breads will be considered done at an internal temperature of 95 ± 5ºC.
1552911|NCT02577627|Device|PrediCare|
1552912|NCT02577614|Drug|FEIBA|Administration of FEIBA after cardiopulmonary bypass
1552913|NCT02577614|Drug|Normal Saline|Administration of placebo after cardiopulmonary bypass
1552914|NCT02577601|Drug|Ulipristal Acetate|
1552915|NCT02577601|Drug|Levonorgestrel (LNG)/Ethinyl estradiol birth control pill|
1552916|NCT02577588|Biological|re-activated T cells|autologous reactivated T cells against p53
1552917|NCT02577575|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
1552918|NCT02577575|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
1552919|NCT02577562|Device|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
1552920|NCT02577549|Behavioral|Diet & Exercise|Participants will attend exercise and diet classes.
1552921|NCT02577549|Behavioral|Attention Control|Participants will attend healthy living classes and receive health newsletters and phone calls/emails/texts.
1552922|NCT02577536|Other|No Interventions|No Interventions will be conducted under this study.
1552923|NCT02577523|Drug|ND0612 (Levodopa/Carbidopa solution)|
1552924|NCT02577510|Drug|Nerve Injection- Nerve Stimulator|For the neurostimulation nerve injection technique, the initial puncture site will be located medial to the anterosuperior iliac spine, just caudal to the inguinal ligament [7]. The 22-gauge insulated needle will be connected to a stimulator set at a current of 1.5 mA, a pulse width of 300 ms and a frequency of 2 Hz. A paresthesia referred to the lateral aspect of the thigh at a minimal stimulatory threshold of 0.6 mA (0.3ms) will be sought prior to the injection of local anesthetic [7]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
1552925|NCT02577510|Drug|Nerve Injection - Ultrasound|For the ultrasound nerve injection group, after skin disinfection, the inguinal region of patients will be scanned using a high-frequency (6 to 13 MHz) linear array transducer covered with a sterile plastic cover. An ultrasound image showing the inguinal ligament and anterior superior iliac spine (ASIS) will be obtained. Using an out-of-plane technique, a 22-gauge nerve block needle will be inserted 1-2 cm medial to ASIS. The needle will be advanced until its tip rests under the inguinal ligament, immediately ventral to the iliopsoas muscle [6]. A total of 5cc of 2%Xylocaine will be injected for the nerve injection/anesthesia.
1552926|NCT02577497|Drug|beclomethasone|
1552927|NCT02577497|Drug|fluticasone|
1552928|NCT02577484|Device|RXi System|"Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
Measurement of FFR requires simultaneously monitoring the blood pressures proximal and distal to a lesion. The RXi system includes a single use catheter (Navvus) with a pressure sensor for acquisition of the distal pressure. The proximal pressure is acquired by the guide catheter via an interface to the hospital hemodynamic monitor.
The Navvus catheter interfaces to the RXi system console which includes embedded software, a user interface touch screen and associated electronics."
1552929|NCT02577484|Device|Pressure Wire|Provide hemodynamic information for the diagnosis and treatment of coronary and peripheral artery disease. The system is intended for use in catheterization and related cardiovascular specialty laboratories to compute and display fractional flow reserve or FFR.
1552930|NCT02577458|Drug|CM082|CM082 tablets taken orally once a day on 28-day cycles
1552931|NCT02577458|Drug|Everolimus|Everolimus tablets taken orally once a day on 28-day cycles
1552932|NCT02577432|Drug|fentanyl|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
1552933|NCT02577432|Drug|fentanyl|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
1552934|NCT02577432|Drug|Hyperbaric bupivacaine|Give 25 micro grams fentanyl intrathecal with one syringe. Then immediately give 10 mg hyperbaric bupivacaine intrathecally with an other syringe.
1552935|NCT02577432|Drug|hyperbaric bupivacaine|Mix 25 micro grams fentanyl with 10 mg hyperbaric bupivacaine in one syringe. Give them intrathecally.
1552936|NCT02577419|Other|Target Fortification|
1552937|NCT02577419|Other|Higher Initial Concentration|
1552938|NCT02577419|Other|Portagen Formula|
1552939|NCT02577406|Drug|AG-221|Continuous 28-day cycles of AG 221 100 mg orally (PO) once a day (QD) for 28 days
1552940|NCT02577406|Other|BSC|Best supportive care includes, hydroxyurea for leukocytosis and/or differentiation-like syndrome, anti-infectives, analgesics, antiemetics, antipyretics, transfusions and nutritional support
1552941|NCT02577406|Drug|Azacitidine|continuous 28-day cycles of azacitidine 75 mg/m2/day SC for 7 days, plus BSC
1552943|NCT02577406|Drug|Intermediate-dose cytarabine (IDAC)|28-day cycles of cytarabine 0.5 to 1.5 g/m2/day IV for 3 to 6 days, per standard institutional practice, plus BSC; only BSC given after IDAC therapy concludes per standard institutional practice
1552944|NCT02577393|Drug|EGCG|EGCG (purity≥95% by high pressure liquid chromatography; from Ningbo HEP Biotech Co., Ltd) is dissolved in 0.9% saline solution three times a day. A new batch is made up each time. For esophageal application, repeated swallowing of 10 ml of the EGCG solution is indispensable to assure the prolonged presence of drug the esophageal walls. We choose a dose of 440 lmol/L as the recommended concentration for this study by referring to our previous phase I study. Immediately at the beginning of radiotherapy, the EGCG solution is given until two weeks after radiotherapy completed. Steroids, non-steroidal anti-inflammatory drugs, narcotics, local anesthetics, or other antibiotic/antifungal therapy are not given unless esophagitis progressed to grade 4.
1552945|NCT02577393|Drug|placebo|The placebo is 0.9% saline solution. Patients are also given three times daily and swallow 10ml solution which are same as the EGCG group.
1552946|NCT02577380|Behavioral|IPV/GBV HTC|Participants will be interviewed after receiving their services.
1552947|NCT02577367|Drug|Levothyroxine|Administer Levothyroxine
1552948|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Subject Appropriate Stimulation)|ReActiv8 implanted and configured to deliver stimulation at a Subject-appropriate level and subjects instructed to deliver stimulation in two 30-minute sessions per day.
1552949|NCT02577354|Device|ReActiv8 Implantable Stimulation System (Low Stimulation)|ReActiv8 implanted and configured to deliver low stimulation, and subjects instructed to deliver stimulation in two 30-minute sessions per day.
1552950|NCT02577341|Drug|Nimotuzumab|Patients received five cycles of weekly nimotuzumab (200mg, IV) in combined with chemoradiotherapy.
1552951|NCT02577341|Drug|docetaxel and cisplatin|Patients received five cycles of weekly docetaxel and cisplatin, each of 1 day's duration,concurrent with chest radiotherapy
1552952|NCT02577341|Radiation|daily RT (65Gy in 25 fractions) to the chest|Patients received daily RT (65Gy in 25 fractions) to the chest
1552953|NCT02577341|Drug|placebo|
1552954|NCT02577315|Drug|Empagliflozin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
1552955|NCT02577315|Drug|Metformin|Test Therapy - fixed dose combination of 2 tablets of 12.5 mg Empagliflozin and 500 mg Metformin
1552956|NCT02577315|Drug|Empagliflozin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
1552957|NCT02577315|Drug|Metformin|Reference Therapy - free combination of 1 tablets of 25 mg Empagliflozin and 1000 mg Metformin
1552958|NCT02577302|Device|CAN-Stim - StimGuard Protect CAN-Stim System|CAN-Stim subjects will be implanted unilaterally (implantation side is up to the investigators discretion) with the StimGuard CAN-Stim System. Subjects will be educated on the use of the transmitter and programmer. Therapy will be delivered for a minimum of 8 hours per day for 12 weeks. Subjects who are considered a responder at the 13-week follow-up, will continue therapy and followed for a total of 12 months.
1552959|NCT02577302|Device|PTNS - Uroplasty PTNS System|PTNS subjects will receive in-office PTNS therapy using the Uroplasty device. Unilateral percutaneous stimulation will be performed in the standard fashion for a total of 12 weeks. Primary objectives will be measured at the 13-week follow-up. At this point study participants who received the in-office PTNS therapy may choose to receive a CAN-Stim device at least 8 weeks after their last PTNS session.
1552960|NCT02577289|Procedure|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation ( Nano crystalline hydroxyapatite)|• The sinus cavity will be augmented with bone graft ( Nano crystalline hydroxyapatite)
1552961|NCT02577289|Procedure|Evaluation of bone quantity in open sinus lift technique with simultaneous implantation (PRF)|platelet rich fibrin (PRF) as sole grafting material in created space (PRF)
1552962|NCT02577276|Device|Tele-motion rehabilitation system|Tele-motion rehabilitation system: Interventions include functional therapeutic exercise and real-time feedback. Clinicians remotely monitor subjects' motor performance using Microsoft Kinect 3D sensor tracking system in their home to record their upper limb and trunk movements as they participate in a variety of functional tasks and motor activities, which are directed by their interaction with a monitor screen in their home using uniquely adapted software to integrate key rehabilitation intervention principles.
1552963|NCT02577263|Other|Quality of life assessment|Quality of life and chemotherapy induced neurotoxicity evaluation
1552964|NCT02577250|Drug|Ketamine|Six infusions of 0.5 mg/Kg of ketamine hydrochloride solution over 2 weeks.
1552965|NCT02577237|Behavioral|In-person education sessions|The intervention will be delivered by a radiation oncology nurse. Each of the four in-person sessions consists of approximately 30 minutes of educational content/simulation that addresses a specific caregiving topic and any issues or concerns that the caregiver may be experiencing.
1552966|NCT02577237|Behavioral|NCI Booklet|Radiation Oncology Nurse will hand participant the NCI booklet
1552967|NCT02577237|Other|Survey|written, qualitative assessments of areas including depression and anxiety, caregiver self-efficacy, care-giver self efficacy for head and neck cancer, health-related quality of life, patient performance status, demographics, and medical history.
1552968|NCT02577237|Other|Interview|A structured series of open-ended questions will be used during a telephone interview with participants at four weeks post radiation treatment.
1552969|NCT02577224|Other|Patient-initiated treatment|Please see Intervention Arm
1552970|NCT02577211|Dietary Supplement|Hipocaloric enteral nutrition|15 kcal/Kg of body weight
1552971|NCT02577211|Dietary Supplement|Normocaloric enteral nutrition|25 kcal/kg of body weight
1552972|NCT02577198|Other|Medilogy Decision Support System (MediDSS)|Italian translation of Evidence-Based Medicine electronic Decision Support (EBMeDS), a set of rules (scripts) based on Evidence Based Medicine guidelines and applied to structured health data. MediDSS further includes knowledge from Swedish, Finnish, INteraction X-referencing (SFINX), a drug-drug interaction database containing concise evidence-based information of about 18,000 drug interactions and adverse events. MediDSS is integrated with local reminders.
1552973|NCT02577185|Drug|Botulinum Toxin Type A|
1552974|NCT02577185|Drug|Sodium chloride 9 mg/ml|
1552975|NCT02577172|Behavioral|Exercise group|The intervention will be conducted during chemotherapy and tailored for each patient. The program will include 1) weight bearing aerobic exercises to maintain the oxygen transport and thereby reduce the decline in VO2max during chemotherapy and 2) strength training exercises to maintain muscle mass and muscle strength. The intervention will last for 9 or 12 weeks, depending on the number of BEP/EP cycles received. The program will consist of two-three one-hour exercise sessions per week, of which most supervised by a personal trainer. The intensity of each exercise sessions will varies from easy (warm-up: 60-70 % of peak heart rate) to moderate/high (between aerobic intervals 60-70% of peak heart rate and during aerobic intervals 85-95 %).
1552976|NCT02577172|Behavioral|Control group|The control group will receive one individual lifestyle counseling session during the first chemotherapy cycle and can perform all activities that they have planned to do during chemotherapy.
1552977|NCT02577159|Drug|Dapagliflozin|Dapagliflozin is orally administered for 8 weeks in the dose of 5mg per day by adding the conventional treatment if there is no serious event included in termination criteria. If the effect for improving diabetes is insufficient, it is allowed to raise its dose up to 10mg/day.
1552978|NCT02577146|Device|renal and bladder ultrasound with ureteral jet assessment|The number of jets from each ureteral orifice will be tabulated over time so that ureteral jet frequency, defined as number of jets per minute, can be calculated. Patients will be categorized into three groups. Group I- no ureteral jets on the symptomatic side; Group II- continuous low-level ureteral jet on the symptomatic side; Group III- ureteral jets similar to nonsymptomatic side.
1552979|NCT02577133|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM 17938 1,000,000,000 CFU per day (5 drops) for 28 days
1552980|NCT02577133|Dietary Supplement|Placebo|The placebo consisted of an identical bottle with distilled water
1552981|NCT02577120|Device|Epiceram Skin Barrier Function|Epiceram is a non-sterile, viscous, lipid-rich emulsion
1552982|NCT02577120|Biological|Vaseline Petroleum Jelly|A skin protectant used for temporarily protecting minor cuts, scraps, burns, and helps to protect and help relieve chapped or cracked skin and lips.
1552983|NCT02577120|Biological|Ceramiseal|Topical serum designed to fortify delicate skin with essential lipids. The proprietary blend of naturally occurring lipids contained in Ceramiseal are designed to improve the barrier function of your skin's outer layer; thereby restoring critical moisture balance and improving physical appearance and function.
1552986|NCT02577094|Drug|90Y-DOTA-Epratuzumab IgG/Epratuzumab IgG|2 injections of 90Y-DOTA- hLL2 IgG- hLL2 IgG at day -21 and day -14. (The 2 drugs are mixted in the same infusion)
1552987|NCT02577094|Drug|Busulfan|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
1552988|NCT02577094|Biological|allogeneic stem cell transplantation.|At Day 0
1552989|NCT02577094|Drug|Fludarabine|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
1552990|NCT02577094|Biological|Thymoglobulines|Between the last injection of 90Y-DOTA- hLL2 IgG/hLL2 IgG (J-14) and the allogeneic stem cell transplantation
1552991|NCT02577081|Other|CAT scan (CT scan)|all patients will pass a CAT scan of ths pelvis and the 2 femurs. No other interventions are required.
1552992|NCT02577068|Drug|Nefopam|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
1552993|NCT02577068|Drug|Propacetamol|Patients undergoing thyroidectomy receive medications depending on the group allocation 30minutes prior to the surgery end; Nefopam 20mg, Propacetamol 2g, and Nefopam 20mg+Propacetamol 2g. In addition, patients will take the same medication every six hours during POD 1.
1552994|NCT02577055|Procedure|Poly-myomectomy|Surgical ablation of all fibroids
1552995|NCT02577055|Procedure|embolisation|Embolisation of the peri-myoma vascular network, with non-resorbable particles of >500 µm diameter, using an ultra thin catheter introduced through the vascular network up to the uterine arteries under radioscopic control.
1552996|NCT02577042|Drug|Raltegravir|Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.
1552997|NCT02577042|Drug|PI-based regimen|Continue with the same PI-based regimen, plus Kivexa or Truvada, for 24 weeks.
1552998|NCT02577042|Drug|Atorvastatin|Atorvastatin, 20mg/day, will be added after 24 weeks of study for 48 weeks
1552999|NCT02577029|Drug|ARC-520|
1553000|NCT02577029|Drug|Entecavir|
1553001|NCT02577029|Biological|Pegylated Interferon alpha 2a|
1553002|NCT02577029|Drug|Tenofovir disoproxil|
1553003|NCT02577016|Drug|Sitagliptin|
1553004|NCT02577016|Drug|Placebo|Placebo to sitagliptin
1553005|NCT02577016|Drug|Ipragliflozin|Background medication
1553006|NCT02577003|Drug|Ipragliflozin|
1553007|NCT02577003|Drug|Placebo|Placebo to ipragliflozin
1553008|NCT02577003|Drug|Sitagliptin|Background medication
1553009|NCT02576990|Biological|Pembrolizumab|IV infusion
1553010|NCT02576977|Biological|Pembrolizumab|pembrolizumab 200 mg IV infusion
1553011|NCT02576977|Drug|Pomalidomide|pomalidomide 4 mg capsules
1553013|NCT02576964|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
1553014|NCT02576964|Drug|Peginterferon alfa-2a|Participants will receive SC peginterferon alfa-2a, 180 mcg every week during each 21-day cycle, for at least 6 cycles (18 weeks). Treatment may continue until disease progression, intolerable toxicity, or consent withdrawal.
1553015|NCT02576951|Drug|LY2951742|Administered SC
1553016|NCT02576951|Drug|Placebo|Administered SC
1553017|NCT02576938|Drug|Baricitinib|Administered orally
1553018|NCT02576938|Drug|Placebo|Administered orally
1553019|NCT02576938|Drug|Triamcinolone (Optional)|Administered topically
1553020|NCT02576925|Other|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Imagery :Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, Biology : blood count, erythrocytes sedimentation rate, C reactive protein Ophthalomogy : visual field, optical coherence tomography, retinography
1553021|NCT02576912|Drug|Active Delta-9-THC|Active Delta-9-THC (0.036 mg/kg) given intravenously.
1553022|NCT02576912|Drug|Active Pregnenolone|A dose given sublingually.
1553023|NCT02576912|Drug|Placebo|A placebo dose given sublingually.
1553024|NCT02576912|Drug|Placebo|Placebo dose given intravenously.
1553025|NCT02576899|Behavioral|Acceptance and Commitment Therapy for PTSD and Tobacco Use|ACT-PT is an acceptance and mindfulness-based smoking cessation treatment for Veterans with PTSD and tobacco dependence. ACT-PT specifically targets smoking cravings related to PTSD symptoms and memories of trauma, in addition to difficulties managing PTSD symptoms. negative affect and nicotine withdrawal symptoms during quit attempts. ACT-PT includes structured intervention components that guide Veterans to replace smoking as a coping strategy for PTSD symptoms and memories with alternative coping strategies (e.g., mindfulness, acceptance). And healthy living activities (e.g., engaging in work, expanding social networks, engaging in physical exercise) that are consistent with Veterans' values.
1553026|NCT02576899|Behavioral|Freedom From Smoking|The American Lung Association's Freedom from Smoking program (FFS) is a commonly used smoking cessation intervention that is used in community treatment programs.
1553027|NCT02576886|Device|Gamma Camera|All images acquired with the General Electric Discovery 530c
1553028|NCT02576886|Procedure|Prone Imaging|
1553029|NCT02576873|Other|Hemodiafiltration|Hemodiafiltration treatments were prescribed to the patients as their long-term renal replacement therapies
1553030|NCT02576860|Drug|Omiganan|Topical gel
1553031|NCT02576860|Drug|Vehicle|Vehicle gel
1553032|NCT02576847|Drug|Omiganan|Topical gel
1553033|NCT02576834|Behavioral|Cognitive Therapy for Suicide Prevention|10 sessions of cognitive therapy for suicide prevention provided, along with optional 9 booster sessions + SAU
1553034|NCT02576834|Other|Services as Usual|Services as usually provided in the community
1553042|NCT02576795|Genetic|BMN 270|
1553043|NCT02576782|Drug|Perineural Dexamethasone and bupivacaine|
1553044|NCT02576782|Drug|Systemic Dexamethasone plus perineural bupivacaine|
1553045|NCT02576782|Drug|intravenous saline plus perineural bupivacaine|
1553046|NCT02576769|Other|No intervention|
1553047|NCT02576743|Device|7 Tesla MRI|MR imaging using a 7 Tesla MR system.
1553048|NCT02576730|Procedure|ORIF|surgery for foot and ankle fractures
1553049|NCT02576717|Drug|RPC1063|
1553050|NCT02576704|Device|semi conductor gamma camera|we use a new mathematic technique from entropy analysis to provide precise, objective, automated quantification of perfusion heterogeneity at stress with camera SPECT. This method may be a non-invasive imaging to assess coronary microvascular dysfunction.
1553051|NCT02576691|Device|percutaneous coronary intervention|
1553052|NCT02576678|Drug|Apremilast|
1553053|NCT02576665|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-fluorocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector
1553054|NCT02576665|Drug|Toca FC|"Toca FC is an extended-release formulation of flucytosine. Toca FC is supplied as 500 mg white, oblong tablets with TOCA FC embossed on one side and 500 embossed on the other side"
1553055|NCT02576652|Other|Tetracycline/Demeclocycline|Standard bone labeling procedures with tetracycline, demeclocycline, or other tetracycline derivative will be performed prior to the prescheduled THR.
1553056|NCT02576639|Drug|CNP520|
1553057|NCT02576639|Drug|Placebo|Matching placebo to CNP520 was supplied in capsules.
1553062|NCT02576613|Other|MPP-S|> 30 weekly sessions of modified psychodynamic psychotherapy in addition to standard treatment
1553063|NCT02576613|Other|TAU|standard medical treatment without structured psychotherapeutic intervention
1553064|NCT02576600|Device|Videopupillometer Algiscan|pupillary diameter measurement every five minutes per-operatively
1553065|NCT02576600|Other|Standard practice|remifentanil administration left to the discretion of the anesthesiologist in charge according to standard practice
1553066|NCT02576600|Drug|Propofol|TCI
1553067|NCT02576600|Drug|Remifentanil|TCI
1553068|NCT02576587|Other|Continuous Positive Airway Pressure|For cases, those found to have moderate sleep apnea (AHI >=15) will be place on CPAP therapy.
1553105|NCT02576366|Drug|Voriconazole|
1553082|NCT02576535|Procedure|Fractionated stereotactic radiosurgery|
1553083|NCT02576535|Device|Leskell gamma unit|FDA approved device
1553084|NCT02576522|Radiation|brain metastatic patients|Surgery followed by hypofractionated intensity modulated radiation therapy (IMRT) using VMAT approach
1553085|NCT02576509|Drug|Nivolumab|
1553086|NCT02576509|Drug|Sorafenib|
1553087|NCT02576496|Drug|EDO-S101|
1553088|NCT02576483|Behavioral|Questionnaire (QoV questionnaire)|Quality of vision and quality of life questionnaire
1553096|NCT02576457|Biological|BMS-936559|
1553097|NCT02576457|Other|Placebo|
1553098|NCT02576444|Drug|AZD2281|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
1553099|NCT02576444|Drug|AZD5363|Patients will be administered AZD5363 at 640 mg twice daily for two days on/five days off (2/7) schedule. Two (2) 200 mg tablets and three (3) 80 mg tablets should be taken twice daily.
1553100|NCT02576444|Drug|AZD1775|The recommended dose will be available no earlier than March 2016.
1553101|NCT02576444|Drug|AZD2014|The recommended dose will be available no earlier than November 2015.
1553102|NCT02576431|Drug|LOXO-101|Oral capsule of LOXO-101 - 100mg BID
1553103|NCT02576418|Other|Partosure TTD test|PartoSure TTD test and CL will be performed on all patients and the test-to-spontaneous-delivery interval will be calculated.
1553104|NCT02576392|Behavioral|Intervention|Intervention consisted of a mailing 2 weeks prior to surgery, another 2 weeks post surgery, and a pharmacist intervention if a refill of opioid medication was requested within 90 days of surgery.
1553110|NCT02576327|Drug|Tropisetron|Tropisetron Hydrochloride Injection 5mg (Day 1-6)
1553111|NCT02576327|Drug|Dexamethasone|Dexamethasone Sodium Phosphate Injection 10mg (Day 1-6)
1553112|NCT02576327|Drug|Aprepitant|Aprepitant 125mg （Day1-2）, 80mg (Day 3-6)
1553113|NCT02576314|Drug|sofosbuvir and daclatasvir|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60 mg tablet administered orally once daily.
1553114|NCT02576314|Drug|ledipasvir/sofosbuvir|"Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed dose combination (FDC) tablet administered orally.
once daily;"
1553115|NCT02576301|Drug|Phase 1 - OXi4503|Determination of MTD of OXi4503
1553116|NCT02576301|Drug|Phase 1 - OXi4503 + cytarabine|Determination of MTD of the combination of OXi4503 + cytarabine
1553117|NCT02576301|Drug|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with AML
1553118|NCT02576301|Drug|Phase 2 - OXi4503 + cytarabine|Safety and efficacy of the combination of OXi4503 + cytarabine in subjects with MDS
1553119|NCT02576288|Drug|Sitagliptin|anti-inflammatory properties
1553120|NCT02576288|Drug|Placebo|No anti-inflammatory properties
1553121|NCT02576275|Drug|Duvelisib|Duvelisib (25 mg BID) administered orally in 28-day continuous treatment cycles
1553122|NCT02576275|Drug|Placebo|Matching placebo (25 mg BID) administered orally in 28-day continuous treatment cycles
1553123|NCT02576275|Drug|Rituximab|IV infusion of rituximab (375 mg/m2) on Day 1 of Cycles 1-6.
1553124|NCT02576275|Drug|Bendamustine|IV infusion of bendamustine (90 mg/m2) on Day 1 and Day 2 of Cycles 1-6.
1553125|NCT02576262|Procedure|TCT，HPV，colposcopic inspection|
1553126|NCT02576249|Drug|Ropivacaine|4cc 0.5% ropivacaine
1553127|NCT02576249|Drug|Normal saline|4cc of sterile normal saline (0.9%)
1553128|NCT02576249|Drug|Methylprednisolone|1cc 40mg methylprednisolone
1553129|NCT02576236|Other|Quadruple concomitant therapy treatment|"Quadruple concomitant therapy treatment:
high dose PPI (Esoméprazole 40 mg X 2 / d- amoxicillin 1gX2 / d - - clarithromycin 500mgX2 / d - metronidazole 500mgX2 / d for 14 days"
1553130|NCT02576236|Other|Triple therapy guided by the result of the molecular resistance test|"Triple therapy guided by the result of the molecular resistance test:
If clarithromycin S : high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d - clarithromycin 500mgX2 / d The total duration of treatment is 14 days.
If clarithromycin R: high dose PPI (Esoméprazole 40mg X 2/ d) - amoxicillin 1gX2 / d- levofloxacin 500mg X2 / d The total duration of treatment is 14 days."
1553131|NCT02576223|Drug|Ropivacaine hydrochloride|Ropivacaine injected perineural at the suprascapular nerve.
1553132|NCT02576223|Drug|Isotonic Saline|Saline injected perineural at the suprascapular nerve.
1553133|NCT02576197|Dietary Supplement|Probiotic|one capsule per day, containing the probiotic along with the patient's customary psoriasis treatment (excluding systemic treatments)
1553134|NCT02576197|Dietary Supplement|Placebo|one capsule per day, containing the placebo, along with the patient's customary psoriasis treatment (excluding systemic treatments)
1553135|NCT02576184|Device|Biologic Mesh|Biologic mesh placed in retromuscular position during ileostoma closure
1553136|NCT02576184|Device|Synthetic Mesh|synthetic mesh placed in retromuscular position during ileostoma closure
1553137|NCT02576171|Behavioral|Group-therapy + ICBT|The group therapy supported ICBT treatment program is a combined web-based and face-to-face intervention that will involve adolescents as well as their parents. The program is founded on and inspired by previously evaluated and evidence-based interventions. Altogether, adolescents go through 12 chapters/sessions, 3 of which are face-to-face group sessions at the research clinic, and 9 of which are web-bases chapters. The program is divided into three different phases, starting with psychoeducation regarding social anxiety and the rationale for a cognitive behavioral intervention. Phase two is the main part of treatment and contains behavioral interventions, mainly exposure and habituation to feared situations and/or stimuli.
1553138|NCT02576158|Procedure|TCT，HPV，colposcopic inspection|
1553139|NCT02576145|Biological|DT|Diphtheria and Tetanus Toxoid (DT) will be administered intramuscularly as a 1/3 dilution (0.33 flocculation units). The participants will be rechallenged with DT 6 months after Day 29 if failed to show >=1.5 fold increase in lymphocyte proliferative response but have a humoral response.
1553140|NCT02576145|Drug|Daclizumab|The fifth dose (1 milligram per kilogram [mg/kg]) of daclizumab will be administered in this study to participants who already received four doses (one dose at 1 mg/kg within 24 hours post-transplant and then every other week for 3 doses).
1553141|NCT02576145|Biological|KLH|KLH will be administered intradermally with a dose of 250 mcg for participants aged 2 to less than 12 years, and 500 mcg for participants aged 12 to 19 years. The participants will be rechallenged with KLH 6 months after Day 29 if failed to show specified increase in lymphocyte proliferative response or humoral response.
1553142|NCT02576119|Drug|BMS-955176, Placebo (Part 1)|The BMS-955176 dose in sentinel Cohort 1 will be 240 mg orally. The BMS-955176 dose in sentinel Cohort 2 will be determined based on the results of data from sentinel Cohort 1.
1553143|NCT02576119|Drug|BMS-955176, Moxifloxacin, Placebo (Part 2)|Subjects will be randomized to 1 of 12 sequences. Each sequence includes combination of different regimens (combination of BMS-955176, placebo and Moxifloxacin).
1553144|NCT02576106|Device|Cryoablation|
1553145|NCT02576093|Drug|0.1% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
1553146|NCT02576093|Drug|0.3% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
1553147|NCT02576093|Drug|1.0% WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
1553148|NCT02576093|Drug|Placebo of WOL071-007|Application of approximately 2 mg cream/cm² skin to a defined surface area. SAD part: Single application to ≤ 100 cm² of non-lesional or lesional skin; MAD part: Multiple application (6 Days) to 2000 cm² of lesional and non-lesional skin.
1553149|NCT02576080|Drug|Imatinib|
1553150|NCT02576080|Other|Surveillance|The Experimental Group will receive the same thoraco-abdominal and pelvic CT scan.
1553151|NCT02576067|Drug|Low dose methotrexate|Study participants will additionally receive 1 mg daily oral folate.
1553152|NCT02576067|Drug|Placebo|
1553154|NCT02576041|Drug|Bilastine|Bilastine tablets once a day for 7+3 days
1553155|NCT02576041|Drug|Placebo|Placebo tablets once a day during 7+3 days run in period
1553156|NCT02576028|Other|Fascial Manipulation® (FM)|Fascial Manipulation® (FM) is a manual therapy that focus on the deep muscular fascia. This technique considers the fascia as a three-dimensional continuum. The mainstay of this manual technique lies in the identification of specific localised areas of the fascia, defined Center of Coordination (CC), where the gliding of the subcutis should be preserved to avoid biomechanical in-coordination of the surrounding muscles. The method is performed by applying a deep friction over the CCs that result more altered at the clinical palpation
1553157|NCT02576028|Other|standard active exercises|two sessions of 45 minutes of active exercises
1553158|NCT02576015|Procedure|peri-operative continuous femoral nerve block with light sedation|this technique will be administered to participants in group L .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block intra-operatively and post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 50-60 with BIS monitoring
1553159|NCT02576015|Procedure|post-operative continuous femoral nerve block|this technique will be administered to participants in group D .The puncture site was identified using ultrasound guidance (2 cm distal to the inguinal ligament, and 1 ～2 cm lateral to the femoral artery).2% lidocaine was used for topical anesthesia, then an insulated needle (Contiplex B Braun, Melsungen, Germany) (20 G*45 mm，short bevel，30°) was connected to the nerve stimulator（Innervator，Fisher &Paykel，New Zealand）.The parameters were as follows: stimulating intensity of 1 mA at a rate of 2 Hz. The needle was advanced at 30°～45° angle to the skin, until quadriceps femoral muscle twitches were elicited. Its position was accepted if contractions were still elicited when an output equal to 0.3 mA.The participants will receive continuous femoral nerve block post-operatively till 3 days post-operatively.The depth of anesthesia will modulated at 30-40 with BIS monitoring
1553160|NCT02576015|Drug|lidocaine|
1553161|NCT02576015|Device|ultrasound|
1553162|NCT02576015|Device|insulated needle (Contiplex B Braun, Melsungen, Germany)|
1553163|NCT02576015|Drug|ropivacaine|
1553164|NCT02576015|Drug|saline|
1553165|NCT02576002|Drug|Assigned pulmonary hypertension medication|As assigned by treating physician; may include following product classes: - Calcium channel blockers/antagonists - Prostanoids (prostaglandins, thromboxanes, prostacyclines) - Endothelin receptor antagonists - PDE-5 inhibitors - SGc stimulators
1553166|NCT02575989|Other|1: control group|Classic - current management of trauma patients by French medical teams
1553167|NCT02575989|Other|2: interventional group|"Intervention Name : monitoring, treatment, control and prevention of hypothermia
Continuous monitoring of body temperature
Ambulance warming (target : 30°C)
Patient warming with dedicated blanket
Infusion fluid warming (and temperature control)"
1553168|NCT02575976|Behavioral|comprehensive CR|In the comprehensive CR arm, 24 sessions education will be offered, of 30 minutes duration beyond the exercises already performed in the cardiac rehabilitation program (The main program is 6 months in duration, with 36 1-hour exercise sessions)
1553169|NCT02575976|Other|exercise-based CR|The main program is 6 months in duration, with 36 1-hour exercise sessions.
1553170|NCT02575976|Other|wait list control|No cardiac rehabilitation.
1553171|NCT02575963|Drug|Cytarabine (Phase 1 only)|Low dose cytarabine administered at 20 mg subcutaneously every 12 hours for the first 10 days (Days 1 to 10) of every cycle. Cycle 1 can last up to 52 days (depending on the schedule of study drug dosing) in order to allow for recovery from Lintuzumab-Ac225. Cycles 2-12 will last 28 days each.
1553172|NCT02575963|Biological|Lintuzumab-Ac225|In Phase 1 the starting dose level was 1.0 μCi/Kg of Lintuzumab-Ac225 and 15 μg/Kg unlabeled HuM195 divided into 2 equal fractionated doses (0.5 μCi/Kg and 7.5 μg /Kg + 0.5 μCi/Kg and 7.5 μg /Kg) with the first fraction administered approximately 4-7 days after 1 cycle of low dose cytarabine and the second fraction administered 4-7 days after the first fraction, followed by up to 11 more cycles. In Phase 2 the dose will be 4.0 μCi/Kg Lintuzumab-Ac225 and 25 μg/Kg unlabeled HuM195 divided into 2 equal fractions with the first fraction given on Day 1 and the second fraction given on Day 5-8.
1553173|NCT02575963|Drug|Furosemide (Phase 1 only)|40 mg by mouth daily one day prior to treatment with Lintuzumab-Ac225 and continuing for 10 days following administration of the 2nd divided dose.
1553174|NCT02575963|Drug|Spironolactone|25 mg by mouth daily, administered 10 days after second dose of 225Ac-HuM195 and continued for 12 months.
1553175|NCT02575950|Drug|LEO43204|
1553176|NCT02575950|Drug|Placebo|
1553177|NCT02575937|Behavioral|low glycemic diet|nutrition education-based low glycemic diet intervention
1553178|NCT02575924|Drug|sequential medium|administration of Quinn's Advantage® Fertilization Medium on day0 administration of Quinn's Advantage® Cleavage Medium from day0 to day3 administration of Quinn's Advantage® Blastocyst Medium from day3 to day7
1553179|NCT02575924|Drug|1-step medium|administration of SAGE 1-Step™ with Human Albumin Solution, from day0 to day7
1553180|NCT02575911|Device|Femtosecond Laser System|Used for the creation of a corneal flap in patients undergoing LASIK surgery
1553181|NCT02575911|Procedure|LASIK surgery|
1553182|NCT02575898|Other|First Session|Creative Practice and Positive Re-enforcement
1553183|NCT02575898|Other|Second Session|Disease Related
1553184|NCT02575898|Behavioral|Third through Sixth Sessions|Life Review and Legacy
1553185|NCT02575885|Other|Electronic Cigarette|Receive different type of ENDS product at each visit
1553186|NCT02575885|Other|Electronic Cigarette|Receive BLU e-cigarette ENDS product
1553187|NCT02575885|Other|Laboratory Biomarker Analysis|Correlative studies
1553188|NCT02575885|Other|Pharmacological Study|Correlative studies
1553189|NCT02575885|Other|Questionnaire Administration|Ancillary studies
1553190|NCT02575872|Behavioral|Exercise Intervention|Participate in physical activity behavioral intervention
1553191|NCT02575859|Drug|adjuvant HIPEC|Closed-abdomen HIPEC with cisplatin (25 mg/m2/l of perfusate) and mitomycin-C (3•3 mg/m2/l of perfusate) at 42•5°C for 60 minutes. Perfusate volume: 4-6 l.
1553192|NCT02575859|Procedure|surgery|Colon resections for primary tumors were performed according to the oncologic principles of adequate lymph-adenectomy. Complete adhesiolysis, resection of falciform hepatic ligament, greater and lesser omentectomy were performed in all patients to ensure optimal perfusion during the HIPEC. Tumor deposits on visceral and parietal surfaces were surgically removed by formal peritonectomy procedures and/or organ resections, as needed.
1553193|NCT02575846|Dietary Supplement|Enteral Intake - Human Milk|Comparing formula and human milk
1553194|NCT02575846|Dietary Supplement|Enteral Intake - Formula|Comparing formula and human milk
1553195|NCT02575833|Drug|AMG 334|Single dose of IV AMG 334
1553196|NCT02575833|Drug|Placebo|Single dose of IV Placebo
1553197|NCT02575820|Procedure|Old red blood cells transfusion|Red blood cells (shelf life > 14 days) transfusion during the operation (total hip replacement arthroplasty)
1553198|NCT02575820|Procedure|New red blood cells transfusion|Red blood cells (shelf life =< 14 days) transfusion during the operation (total hip replacement arthroplasty)
1553199|NCT02575807|Biological|CRS-207|via IV infusion
1553200|NCT02575807|Drug|Epacadostat|PO BID
1553201|NCT02575807|Biological|Pembrolizumab|via IV infusion
1553202|NCT02575794|Drug|Terameprocol|Given PO
1553203|NCT02575794|Other|Pharmacological Study|Correlative studies
1553205|NCT02575768|Other|Adenosine-stress cardiac magnetic resonance imaging|undergoing adenosine-stress cardiac magnetic resonance imaging
1553206|NCT02575755|Drug|Azithromycin plus piperaquine phosphate|
1553207|NCT02575755|Drug|Sulfadoxine-pyrimethamine|
1553208|NCT02575742|Device|3D-Transit system|
1553209|NCT02575729|Drug|betamethasone|Inject betamethasone on the wrist for patient with carpal tunnel syndrome with sonography- guided, directly.
1553210|NCT02575716|Device|Videolaryngoscope|Intubation with McGrath video laryngoscope after muscle relaxant
1553211|NCT02575703|Drug|[¹⁴C]-LY3023414|LY3023414 in solution containing approximately 100 microCi [¹⁴C]-LY3023414
1553212|NCT02575690|Dietary Supplement|Spirulina|Individuals receive 2 g of spirulina daily, for 3 months.
1553213|NCT02575690|Other|Placebo|Individuals receive a placebo daily, for 3 months.
1553214|NCT02575677|Other|oxycodone|oxycodone 0,1/kg up to 10 mg sc.
1553215|NCT02575664|Drug|Buprenorphine|Buprenorphine 5 microg/h/7 days
1553216|NCT02575664|Drug|Placebo|Placebo patch
1553217|NCT02575651|Drug|Fluzoparib|Fluzoparib either at 10,20,40,80,120mg ....., capsule oral.
1553218|NCT02575638|Drug|CZ48|CZ48 is an analog of the topoisomerase I inhibitor Camptothecin (CPT). CPT is a natural extract from the tree Camptotheca acuminata
1553219|NCT02575625|Device|Fibroscan|Three series oh independent measures Measure done with Fibroscan will be preceded by tracking ultrasonography.
1553220|NCT02575625|Biological|Blood test for biological assessment of liver function|Blood test for biological assessment of liver function
1553221|NCT02575625|Device|MRI|Liver MRI
1553222|NCT02575612|Procedure|vacuum-assisted biopsy|Ultrasound guided VAB was used directly prior to breast conserving surgery or mastectomy. It was performed by experienced physicians (> 50 ultrasound guided minimal invasive biopsies per year, > 500 breast ultrasound examination of the breast per year). The needle was placed below or beside the target lesion according to physician's choice. At least six biopsies should be taken; up to 12 according to the physicians choice. After the VAB a clip marker was placed to highlight the position of the biopsy for specimen radiography and pathology.
1553223|NCT02575599|Behavioral|Guided self-determination programme (GSD)|The GSD intervention consist of four e-consultations with structured reflection sheets. Reflection sheets are intended to increase patients' ability to express their views and prepare them for active participation in the care process. Through the web-based platform, the subsequent four e-consultations will allow for communication between patients and nurses. The platform allows the participants to fill in the reflection sheets using their own words and drawings to express their own experiences with self-management as well as to formulate behavioral goals and plans to achieve their goals. It also permits feedback from the nurses on these reflections sheets via secure emails. Each person will be able to access the web-based program from his or her own computers or other electronic devices.
1553226|NCT02575573|Other|Factors influencing resuscitation decisions of patients|
1553227|NCT02575573|Other|Factors leading to not asking patients about resuscitation preference|
1553228|NCT02575560|Other|history data|history data of PFS after 1st line or second line theray
1553229|NCT02575547|Drug|cisplatin and docetaxel|"NC：cisplatin 75 mg/m2 intravenous infusion in day1，docetaxel 75 mg/m2 intravenous infusion in day1，both drugs are given every 3 weeks, two courses.
CCRT: intensity modulation radiation therapy(IMRT) and cisplatin (100mg/m2 on day 1) every three weeks for three\three cycles during radiation therapy(RT).
Dietary supplement: enteral nutrition and parenteral nutrition"
1553230|NCT02575534|Drug|Procainamide|the procainamide will be infused at 12mcg/kg up to a max of 1 gram at a rate of 20mg/min which will take up to 1 hour to infuse
1553470|NCT02573909|Drug|Oxycodone intravenously|Oxycodone intravenously 0,1mg/kg
1553471|NCT02573909|Drug|Oxycodone epidurally|Oxycodone 0,1 mg epidurally
1554204|NCT02568670|Other|clinical signs|to remove the peripheral venous catheter according clinical signs
1553233|NCT02575508|Drug|Fluorouracil|Given IV
1553234|NCT02575508|Drug|Irinotecan Hydrochloride|Given IV
1553235|NCT02575508|Other|Laboratory Biomarker Analysis|Correlative studies
1553236|NCT02575508|Drug|Oxaliplatin|Given IV
1553237|NCT02575508|Drug|pan FGFR Kinase Inhibitor BGJ398|Given IV
1553238|NCT02575508|Other|Pharmacological Study|Correlative studies
1553239|NCT02575495|Drug|7 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 7 days
1553240|NCT02575495|Drug|14 days course of antibiotic treatment|start specific intravenous antibiotic therapy as microbiological susceptibility from urine culture for 14 days
1553241|NCT02575482|Drug|SUVN-D4010|
1553242|NCT02575482|Drug|Placebo|
1553243|NCT02575456|Biological|Ebola Vaccine|
1553244|NCT02575456|Biological|Placebo|control
1553245|NCT02575443|Drug|Rocuronium (MB group)|Count of train-of-four: 1-2 Titration of rocuronium dose
1553246|NCT02575443|Drug|Rocuronium (DB group)|Post-tetanic count: 1-2 Titration of rocuronium dose
1553247|NCT02575430|Other|No treatment: retrospective chart review|
1553248|NCT02575417|Behavioral|Conversation Game|The game consists of 47 question cards that prompt players to identify and articulate their values and beliefs related to dying and end-of-life issues; 20 questions have been selected for this study
1553249|NCT02575404|Drug|GR-MD-02|Patients will receive five doses of GR-MD-02 intravenously over 85 Days.
1553250|NCT02575404|Drug|Pembrolizumab|Patients will receive five 200mg doses of pembrolizumab intravenously over 85 days. After 85 days, patients may continue to receive pembrolizumab every 3 weeks if clinical benefit is noted.
1553251|NCT02575391|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
1553252|NCT02575378|Drug|Metronimic chemotherapy plus Chinese Traditional Medicine|Capecitabine 300mg/m2, twice a day, everyday plus Chinese Traditional Medicine
1553253|NCT02575378|Drug|Metronimic chemotherapy|Capecitabine 300mg/m2, twice a day, everyday
1553254|NCT02575365|Drug|0,5 mg Fingolimod|Treatment will be 0.5 mg p.o fingolimod daily
1553255|NCT02575339|Drug|MLN0128|Phase I Dose Escalation Study Cohort 1 MLN0128 15mg QW; Cohort 2 MLN0128 20mg QW; Cohort 3 MLN0128 30mg QW
1553256|NCT02575339|Drug|MLN0128 (RP2D)|"Phase II Arm A:
MLN0128 administered orally at the recommended phase II dose (RP2D) once weekly."
1553257|NCT02575339|Drug|Sorafenib|"Phase II Arm B:
Sorafenib administered at 400mg PO BID daily"
1553258|NCT02575326|Other|Standard Control|Teens in the control group will receive standard or usual care as provided by their physician.
1553259|NCT02575326|Behavioral|a provider administered, tailored discussion guide|Teens in the intervention group will receive a provider administered, tailored discussion guide based on motivational interviewing techniques.
1553260|NCT02575313|Dietary Supplement|Whole Food Intervention|A combination of honey, glutamine, probiotics, and butter was administered to participants undergoing cancer.
1553261|NCT02575300|Drug|Ibrutinib|Ibrutinib will be administered orally once daily and each cycle will be defined as 4 weeks duration. Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
1553262|NCT02575287|Device|Optical Enhancement|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement (Pentax Video Processor EPK-i7010; HOYA Co. Tokyo, Japan)
1553263|NCT02575287|Device|Optical Enhancement with optical magnification|A endoscopic visualization of the mucosa using the pre-processor filter called Optical enhancement associated with an optical magnification using the scope called magniview (PENTAX Medical EG-2990Zi)
1553264|NCT02575287|Device|Optical magnification without Optical enhancement|A endoscopic visualization of the mucosa using optical magnification without the use of the pre-processor filter called Optical enhancement
1553265|NCT02575274|Procedure|Surgical flaps|Surgical intervention will be performed with full thickness mucoperiostal flaps to obtain access in the bone defects. All groups will receive the same treatment for implant surface decontamination: debridement with plastic curette Implacare Hu-Friedy®, cleaning the surface with chlorhexidine gel 2% during 3 minutes and abundant irrigation with saline solution 0.9%.
1553266|NCT02575261|Biological|CAR-T cell immunotherapy|This CAR-T cell immunotherapy with a novel specific Chimeric antigen receptor aiming at EphA2 antigen.
1553267|NCT02575248|Drug|Dienogest 2mg|Dienogest 2mg is given daily for 3 months then followed by Clomiphene citrate 5 mg induction of ovulation for three months
1553268|NCT02575248|Drug|Clomiphene citrate 5 mg|Clomiphene citrate 5 mg for induction of ovulation for three months
1553269|NCT02575235|Drug|CPC|Two study groups take cetylpyridinium chloride of 1.5mg and 4.5mg daily for four weeks.
1553270|NCT02575235|Drug|placebo|Control group takes the placebo for the same period.
1553271|NCT02575222|Drug|Nivolumab|3 mg/kg, IV (in the vein) on day 1 of each 2-week cycle, for a total of 3 doses prior to nephrectomy.
1553272|NCT02575209|Other|GENDER|
1553273|NCT02575196|Device|Non-invasive cerebral flow monitoring|As soon as possible after ROSC, c-flow monitor will be connected to the patient, recording cerebral flow index for the first 72 hours following ROSC. All other relevant clinical data will be recorded.
1553274|NCT02575183|Drug|Varinecline (Chantix)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive varenicline (Chantix). The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
1553472|NCT02573896|Drug|Ch14.18|17.5 mg/m2/day of Ch.14.18 will be given for 4 consecutive days (days 1-4 of each course) via intravenous infusion over ten hours.
1553275|NCT02575183|Drug|Placebo (for Varenicline)|A randomized double-blind placebo-controlled trial that will evaluate the effect of Varenicline (Chantix), in 2 parallel groups of habitual waterpipe smokers who are willing to quit (n=152). 76 subjects will be randomized to receive a varenicline-matched. The participants, study investigators and personnel who will be interviewing the participants and collecting the clinical data, will be blinded to the assigned treatment.
1553276|NCT02575183|Behavioral|Behavioral Therapy|This intervention is for all study participants and it involves 4 visits to the hospital. Each visit include a 30-min one-on-one individual session with the specialized therapist during which participants will be taught how to manage any withdrawal symptoms they experience, how to anticipate high-risk situations, deal with smoking triggers, achieve and maintain their goal to stop waterpipe smoking.
1553277|NCT02575170|Drug|Amino acid solution|a balanced mixture of 18 pure crystalline amino acids, eight of which are essential amino acids
1553278|NCT02575170|Drug|Ringer's lactate solution|200 ml of Ringer's lactate solution
1553279|NCT02575157|Other|No intervention|No intervention
1553280|NCT02575144|Drug|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle
1553281|NCT02575144|Drug|Lenalidomide|25mg PO daily on days 1-21 of a 28-day cycle for patients with a calculated creatinine clearance of >60 cc/min
1553282|NCT02575144|Drug|Dexamethasone|40mg PO will be given on days 1, 8, 15, 22 of a 28-day cycle
1553283|NCT02575131|Other|whole wheat bread yeast basis|
1553284|NCT02575131|Other|Oatmeal|
1553285|NCT02575131|Other|Cheerios|
1553286|NCT02575131|Other|whole wheat sourdough bread|
1553287|NCT02575131|Other|standard breakfast|
1553288|NCT02575118|Device|Restoration of dental caries with dental composite|
1553289|NCT02575092|Drug|Enalapril Maleate Tablets(as the program-based antihypertension)|
1553290|NCT02575092|Drug|Enalapril Maleate and Folic Acid tablets(as the program-based antihypertension)|
1553291|NCT02575092|Drug|Placebo|
1553292|NCT02575079|Device|Parafilm|Single-use, pre-cut sections of parafilm over the central venous catheter (CVC) hub (if not connected) or around the CVC hub connection (if connected). Parafilm will be maintained on the CVC until it is removed.
1553293|NCT02575066|Radiation|external beam radiotherapy|external beam radiotherapy 25 x 2 Gy
1553294|NCT02575066|Drug|pazopanib|pazopanib QD 800 mg
1553295|NCT02575053|Procedure|assessment of a new latex protocol|"All powdered latex surgical gloves are removed from the operating theatres, recovery room and surroundings starting from 01-07-2015 in order to create a latex safe environment.
Steps 2 and 3 remain unchanged in respect to ASA( American Society of Anesthesiologists) protocol.
Removal of all materials containing latex from the resuscitation carts.
Further requirements in case of latex allergic patients:
Identification of patients with (suspected) latex allergy.
All materials used during the procedure (catheters, drains, monitoring equipment,…) should be checked for latex.
All latex containing materials should be removed from the room and latex free alternatives should be available.
All staff present in the room should use latex free synthetic gloves.
Operating tables and supports should be made of latex free material or should be covered with blankets.
The entire OR staff is thoroughly educated concerning the latex safe protocol."
1553296|NCT02575040|Biological|Fecal microbiota transplantation|Fecal microbiota transplantation to patients with ulcerative colitis and Crohn disease
1553297|NCT02575027|Radiation|Palliative Radiation Therapy|Undergo 4pi palliative radiotherapy
1553298|NCT02575027|Other|Questionnaire Administration|Ancillary studies
1553299|NCT02575027|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo 4pi radiation simulation and planning
1553300|NCT02575014|Drug|Preoperative hyperbaric oxygen|Subjects undergoing preoperative HBOT will be treated with up to 2.4 ATA O2, for a maximum of 90 minutes each day with or without air breaks, as deemed necessary by the investigator, for two days. The two days will be the day of and the day immediately prior to the operation.
1553301|NCT02575001|Behavioral|Psychological background determinations|"For the psychological background determinations a structured interview and questionnaires will be administered:
Child Attachment Interview (CAI)
General/sociodemographic questionnaire with the questions on diabetes management, current health status and the child's development in the infancy
Parenting Stress Index with the 19-item Life Stress Scale (PSI)
Achenbach System of Empirically Based Assessment (CBCL, YSR)
Holmes and Rahe Social readjustment rating scale
Lifetime Incidence of Traumatic Events (LITE) - parent and child reports of child's trauma/loss history (LITE- S/ P)
Experiences in Close Relationships - Relationship Structures questionnaire (ECR-RS)"
1553302|NCT02575001|Genetic|Genetic susceptibility determination|DNA will be isolated from the patients' blood samples and form the control subjects buccal swabs. The genes with expected influence to stress reactivity and mental disorders will be tested.
1553303|NCT02575001|Procedure|Cortisol release test|Synacthen test - will be used with the group of patients with type 1 diabetes to measure HPA axis reactivity
1553304|NCT02575001|Procedure|Saliva cortisol measurement|Saliva cortisol measurement - will be used with the patients before and after the Synacthen test and with the Hashimoto thyroiditis and the healthy control group before and after the Child Attachment Interview
1553305|NCT02574975|Drug|methacholine|Methacholine,inhaled cumulative dosage 2.5mg
1553306|NCT02574975|Drug|adenosine monophosphate|Adenosine monophosphate ,inhaled cumulative dosage 40mg
1553307|NCT02574975|Drug|leukotriene D4|Leukotriene D4,inhaled cumulative dosage 2.4 μg
1553308|NCT02574975|Device|Astograph Jupiter-21 airway reaction testing apparatus|Methacholine bronchial provocation test was performed by using Astograph Jupiter-21 airway reaction testing apparatus
1553309|NCT02574975|Drug|budesonide /formoterol|budesonide 160μg and formoterol 4.5ug,1 inhalation ,twice daily ,for three months in all participants (80 Anticipated)
1553310|NCT02574962|Drug|H.P. Acthar® Gel|
1553311|NCT02574949|Radiation|Radiation: 15 FPS Cine 15 PPS|Radiation 15 FPS Cine 15 PPS
1553312|NCT02574949|Radiation|Radiation: 7.5 low Frame rate|Radiation: Frame rate 7.5 FPS, Cine 15 PPS
1553313|NCT02574949|Radiation|Low Cine|Radiation: Frame rate 7.5 FPS, Cine 10 PPS
1553473|NCT02573896|Biological|NK Cells|The designated dose of NK Cells will be infused on Day 5 by IV drip using a Y infusion set with a filter-less chamber. Cells should not be delivered at a rate faster than 10 ml/kg/hr (as determined by drip rate or syringe push rate), and should not take longer than one hour for total infusion time if possible.
1553314|NCT02574936|Procedure|A new surgical technique|"Description of a new surgical technique in pilonidal sinüs surgery in order to reduce dead space volume.
A flap extending across the cut (Karydakis) is prepared in medial edge of the wound, 1 cm deep and 2 to 3 cm to be towards the interior. Prepared flap is shifted to the medial and sutured to presacral fascia with vicryl 2/0. To reduce the volume of the dead space formed in the lateral, 5 mm skin is excised along the incision in the flap side. Skin is approximated with sutures in the form of intermittent, using 2/0 poliprolen. No drain used"
1553315|NCT02574923|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
1553316|NCT02574910|Drug|Abiraterone acetate|This is a dose escalation study. Up to 3 successive cohorts of 8 subjects each will receive 7 days of 1, 2 or 4 mg/kg/d of abiraterone acetate, until 7/8 subjects have met the desired endpoint.
1553317|NCT02574897|Other|Electronic symptom survey|Standard of care plus daily electronic symptom surveys, the results of which are sent to clinicians electronically.
1553318|NCT02574897|Other|Blinded Electronic Symptom Survey|Standard of care daily clinician interviews with blinded symptom surveys
1553319|NCT02574884|Procedure|Blood sample (act specific of blood withdrawal for the study)|Specific intervention : blood sample (3x7 ml in total)
1553320|NCT02574871|Other|Psychological and biological data collection|Psychological and biological data collection for identification of the chronic stress presence
1553322|NCT02574845|Drug|Rosuvastatin|
1553323|NCT02574845|Drug|Metformin HCl|
1553324|NCT02574845|Drug|Furosemide|
1553326|NCT02574819|Drug|Methylnaltrexone (MNTX)|MNTX nearly 0.15mg/kg administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
1553327|NCT02574819|Drug|Placebo|Placebo administered every other day for 2 weeks. Baseline laxatives and rescue laxative ( enemas/suppositories ) were allowed, but could not be administered within 4 hours of the study drug.
1553328|NCT02574806|Procedure|Blood sample and BNP measurement|Blood sample of umbilical artery from umbilical cord immediately after birth.
1553329|NCT02574793|Device|continuous glucose monitoring|Patients newly diagnosed GH-releasing pituitary adenoma or Cushing Syndrome in our department will be monitored blood glucose by CGMS Gold.
1553330|NCT02574780|Other|complex physical therapy|Compare the standard treatment of lymphedema, by complex physical therapy versus TFC associated with the upper limbs strengthening exercises.
1553331|NCT02574780|Other|Evaluate treatment of lymphedema, with in the quality of life and depression|evaluate through the questionnaires fatigue and quality of life of patients with lymphedema (FACT- F and Inventory BECK)
1553332|NCT02574767|Behavioral|Lifestyle counseling|Obese pregnant women from PHCC randomized to this group will receive Home-based Diet & Physical activity (PA) counseling. Home-based intervention will consider 2 home visits of one hour of duration. During this session dietary educational and behavioral will be discussed with the participants and their families tailoring the contents based on the specific contexts.
1553333|NCT02574767|Dietary Supplement|PUFA Supplementation|Obese pregnant women from PHCC randomized to this group will receive n3LC-PUFAs oral supplementation based on Schizochytrium oil (S-oil) containing 800 mg docosahexaenoic (DHA) acid/day, which will be administered as capsular preparations containing 200 mg DHA/capsule (4 capsules/day).
1553334|NCT02574767|Behavioral|Routine diet & PA|Obese pregnant women from PHCC randomized to this group will receive will receive routine diet & PA counseling (i.e. they will receive the standard education sessions included in the prenatal controls at PHCC but no home-based counseling sessions).
1553335|NCT02574767|Dietary Supplement|PUFA placebo|Obese pregnant women from PHCC randomized to this group will receive capsular preparations containing 50 mg DHA/capsule (4 capsules/day), given that evidence suggests that it would be unethical not to provide DHA during pregnancy. Placebo will be delivered in the same way that the n3LC-PUFA supplementation.
1553336|NCT02574754|Drug|warfarin|warfarin 10 mg PO x 1
1553337|NCT02574741|Behavioral|Behavioral Therapy|Thrice-weekly individually based language JAE-EMT intervention will be provided by a trained therapist and taught to the child and their caregivers. A total of 36 sessions will be provided over 12 weeks, with 2 per week at UCLA, and one session per week in the home.
1553338|NCT02574741|Drug|Aripiprazole|50% of the subjects will be randomized to aripiprazole (active study medication)
1553339|NCT02574741|Drug|Placebo|50% of the subjects will be randomized to placebo (inactive study medication).
1553340|NCT02574728|Drug|Sirolimus|The starting dose for sirolimus is 2 mg/m2 once daily. The dose of sirolimus will be individually adjusted to achieve a target serum trough concentration in the range of 10-15 ng/ml. Sirolimus will be given by mouth every day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
1553341|NCT02574728|Drug|Celecoxib|Celecoxib 100 mg will be given by mouth twice a day for six weeks (every six weeks is called one cycle) for up to two years or 16 cycles.
1553342|NCT02574728|Drug|Etoposide|Etoposide 50 mg/m2 (maximum dose 100 mg) will be given daily by mouth for the first 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
1553343|NCT02574728|Drug|Cyclophosphamide|Cyclophosphamide 2.5 mg/Kg (maximum dose 100 mg) will be given daily by mouth for the second 3 weeks of a 6 week cycle. Six week cycles will be repeated for up to two years or 16 cycles.
1553344|NCT02574715|Drug|Levonorgestrel (Jaydess, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
1553345|NCT02574702|Procedure|application of a contralateral drainage (Penrose ® device)|application of a contralateral drainage (Penrose ®) in surgical wound of primary loop ileostomy closure
1553474|NCT02573896|Drug|Lenalidomide|25 mg/m2/day of Lenalidomide will be given at Dose Level 4, once daily with or without food by mouth on days -6 through +14.
1553346|NCT02574689|Behavioral|HIPP|The physical activity intervention is based on the Social Cognitive Theory and Transtheoretical Model and includes motivation-matched physical activity manuals and individually-tailored computer expert system feedback reports. Tailored reports are based on participants' monthly update survey data and cover: 1) current stage of change; 2) self-efficacy; 3) decisional balance; 4) social support; 5) outcome expectations; 6) enjoyment; 7) progress feedback; 8) normative feedback; 9) self regulation. The computer expert system draws from a bank of 330 messages addressing different levels of psychosocial and environmental factors affecting physical activity.
1553347|NCT02574689|Behavioral|Wellness contact control|"Cancer prevention information on topics other than physical activity (e.g., Add Fruits and Veggies to Your Diet) from the American Cancer Society website (www.cancer.org) are mailed to control participants at the same time points that the HIPP Intervention participants receive their physical activity intervention materials."
1553348|NCT02574676|Other|non-interventional|
1553349|NCT02574663|Drug|TGR-1202|TGR-1202 oral daily dose
1553350|NCT02574663|Drug|nab-paclitaxel + gemcitabine|IV infusion
1553351|NCT02574663|Drug|Oxaliplatin + Folinic acid + Fluorouracil|IV infusion
1553352|NCT02574663|Drug|Oxaliplatin + Folinic acid + Fluorouracil + Bevacizumab|IV Infusion
1553354|NCT02574637|Drug|MEDI2070 High dose|MEDI2070 intravenous (IV)infusion wks 0 & 4 plus placebo SC injection wks 0 & 4, and then subcutaneous (SC) dose of MEDI2070 every 4 wks through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
1553355|NCT02574637|Drug|MEDI2070 High-Med dose|MEDI2070 intravenous (IV) infusion wk 0 plus placebo SC injection wk 0, and then subcutaneous (SC) dose of MEDI2070 wk 4 plus placebo IV infusion wk 4, and then subcutaneous (SC) dose of MEDI2070 every 4 wks from wk 8 through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
1553356|NCT02574637|Drug|MEDI2070 Low-Med dose|Subcutaneous (SC) low-med dose of MEDI2070 wk 0 & wk 4 plus placebo intravenous (IV) infusion wk 0 & wk 4, then subcutaneous (SC) low-med dose of MEDI2070 every 4 wks wk 8 through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
1553357|NCT02574637|Drug|MEDI2070 Low dose|Subcutaneous (SC) low dose of MEDI2070 Wk 0 & Wk 4 plus intravenous (IV) Placebo dose Wk 0 & Wk 4, then subcutaneous (SC) low dose of MEDI2070 every 4 wks wk 8 through week 24. Beginning at wk 28, SC dose of MEDI2070 once every 4 weeks during the Open-label Period.
1553358|NCT02574637|Drug|Placebo|Placebo SC and IV infusion wks 0 & 4 and then SC dose of placebo every 4 weeks wk 8 through wk 24. then SC dose of MEDI2070 once every 4 weeks during Open Label period.
1553359|NCT02574624|Procedure|Intraocular assistance|Intraocular assistance with help of surgical assistants during vitreous surgery (VISIA) in patients who require vitreous surgeries as part of standard of care procedure for conditions like retinal detachments, dislocated intraocular lens and glaucoma patients requiring endophotocoagulation.
1553360|NCT02574611|Drug|Neostigmine|
1553361|NCT02574611|Drug|Glycopyrrolate|
1553362|NCT02574611|Other|Saline (Placebo)|
1553363|NCT02574611|Device|High Resolution Colonic Manometry|
1553364|NCT02574598|Drug|MK-3475|The dosing interval of pembrolizumab can be increased in case of toxicity.
1553365|NCT02574598|Drug|Docetaxel|Use on both arms as standard of care.
1553366|NCT02574585|Biological|Autologous mesenchymal cells transplantation|Two percutaneous injections of mesenchymal stem cells, with a 3-month interval between the injections.
1553367|NCT02574572|Biological|Autologous mesenchymal cells transplantation|All patients will undergo laminectomy and autologous mesenchymal cells injection into the lesion area.
1553378|NCT02574533|Biological|Vigil|Vigil™ 1 x 10e7 cells via intradermal injection on Day 1, 15, 29, 43 and then every 3 weeks thereafter for a minimum of 4 administrations and a maximum of 9 administrations (depending on the quantity of Vigil™ manufactured from surgical specimens)
1553379|NCT02574533|Drug|Pembrolizumab|Pembrolizumab 2mg/kg by intravenous infusion over 30 minute starting on day 43 and every 3 weeks thereafter
1553382|NCT02574507|Behavioral|Couples-Based Behavioral Weight and Symptom Management|Investigators anticipate that the intervention developed in phase I will consist of a total of 12 sessions 90 minutes in length (18 therapy hours) spaced across approximately 5 months. Sessions are spaced to provide participants sufficient time to complete home practice exercises and adequately examine change in weight and maintenance of weight loss. Sessions will be conducted individually for each day. The first 6 sessions will occur weekly and the final 6 sessions will occur biweekly.
1553385|NCT02574468|Drug|Dexamethasone applied on pulp or Dexamethasone did not applied on pulp|on half of cases we put dexamethasone on pulp on other half we did not put dexamethasone on pulp
1553386|NCT02574468|Procedure|DPC or MP|on half of cases we treat teeth with DPC(Direct Pulp Cap) on other half we treat teeth with MP(Miniature Pulpotomy)
1553392|NCT02574442|Device|In Vivo Confocal Microscopy Probe|Participants will have 2 areas on their cervical imaged by the confocal probe.
1553393|NCT02574429|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy is an evidenced-based treatment for PTSD. The investigators are offering CPT group over 13 weeks (12 group sessions & 1 individual session). CPT focuses on challenging beliefs that developed or were reinforced following the trauma(s).
1553394|NCT02574416|Other|There is no intervention|The study is observational and there is no intervention
1553395|NCT02574403|Drug|eculizumab|eculizumab discontinuation
1553399|NCT02574364|Radiation|The application of abdomen CT|A modified incision(MI)was designed based on abdomen CT.Using a MI compare traditional incision(TI) to the patient including cut extended, operating time,cut infection, false-positive rate,rehabilitation and return to work.
1553400|NCT02574364|Other|traditional incision|McBurney incision,Rectus incision,Appendix Transverse incision or Tenderness point incision,it was invaginated at the discretion of the surgeon.
1553401|NCT02574351|Biological|blood draw, breathing test|A blood draw,breathing test will be performed on every participant
1553402|NCT02574338|Device|Foley's Catheter|intracervical extraamniotic Foley's catheter
1553403|NCT02574338|Drug|prostaglandin E1 analogue|intravaginal misoprostol
1553404|NCT02574325|Drug|Placebo|Control
1553405|NCT02574325|Drug|ARI-3037MO|Treatment
1553406|NCT02574312|Device|ATTUNE TKA with ATTUNE RUI|ATTUNE TKA with ATTUNE RUI
1553407|NCT02574312|Device|ATTUNE TKA with ATTUNE SUI|ATTUNE TKA with ATTUNE SUI
1553408|NCT02574299|Other|E-learning|Management of auditory processing disorders with serious game (E-learning)
1553409|NCT02574299|Device|Hearing aids fitting|Symmetrical hearing loss which are fitted with binaural hearing aids for the first time
1553410|NCT02574286|Drug|Velaglucerase alfa|Velaglucerase alfa 60 U/kg every other week (EOW) as a 60-minute intravenous infusion
1553411|NCT02574286|Dietary Supplement|800 International Unit (IU) Vitamin D|800 IU vitamin D orally daily starting at the week 1 visit
1553412|NCT02574273|Behavioral|Secret Agent Society (SAS) Program|The Secret Agent Society (SAS) intervention involves subjects participating in 9 weekly two-hour therapy groups ('Club meetings') with 3 to 6 other children. The SAS intervention includes a number of components to help children apply the skills that they learn in the session to home.
1553413|NCT02574273|Other|Waitlist Group / Treatment As Usual|The wait list control condition includes the treatment participants are already receiving (which may include but is not limited to: individual therapy, group therapy, and/or medication management). Therefore, the wait list control condition consists of treatment which is individually tailored for each participant. Parent and child assessments will be completed at pre and post treatment (Wk 1 and Wk 10) and at 3-month and 6-month follow-up booster visits. The wait-list group will then be given the opportunity to participate in the SAS intervention at their treating clinic.
1553414|NCT02574260|Biological|Talimogene Laherparepvec|Administered by intratumoral injection.
1553421|NCT02574221|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
1553422|NCT02574221|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
1553423|NCT02574208|Procedure|HIV testing by ELISA|HIV testing randomized between ELISA or rapid test
1553424|NCT02574208|Procedure|HIV testing by rapid test|HIV testing randomized between ELISA or rapid test
1553623|NCT02572908|Other|Gluten-free diet|Gluten-free diet excluding even oats and buckwheat. Rice, quinoa, corn and potato allowed as grains/pseudo-grains
1553425|NCT02574182|Radiation|Brain MRI|"Brain MRI (Magnetic Resonance Imaging) brain is a painless test that allows to visualize the different brain structures.
Korvit, device made up of 2 shoes which reproduces the feeling to go. The Korvit® system appears possible to analyze the activated cerebral zones and to thus try to better understand the operation of the brain during walk.
The GAITRite is a carpet for recording the walking operating parameters"
1553426|NCT02574169|Other|alveolar recruitment maneuvers group 1|"Patients are randomized to receive in cross-over 2 ARM: CPAP at first and then eSigh.
The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.
The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.
The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
1553427|NCT02574169|Other|alveolar recruitment maneuvers group 2|"Patients are randomized to receive in cross-over 2 ARM: eSigh at first and then CPAP.
The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.
The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.
The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM."
1553428|NCT02574156|Drug|Insulin|All patients will receive insulin. However, the infusion flow will be different according to the group.
1553429|NCT02574130|Drug|Amikacin|400 mg, nebulizer, every 12 hours, 10 days
1553430|NCT02574130|Drug|Placebo|placebo 4 ml, nebulizer, every 12 hours, 10 days
1553431|NCT02574117|Procedure|flap with corticotomy and bone allograft|A maxillary expansion with quad helix appliance was placed on the posterior teeth with cross bite. A Luebke buccal flap was opened in the area of maxillary 1st premolar, 2nd premolar and first molar with a no. 15 scalpel. Corticotomy procedure was performed using low speed round bur size 3, holes to create a 0.5 mm deep hole penetrating the cortical bone. Multiple holes were performed leaving 1.5 mm distance in between. The defects were covered with demineralized freeze-dried bone allograft and the flap was sutured in its original position with 3-0 black silk suture.
1553432|NCT02574104|Other|Simulate a functional NICU prior to moving patients|Test translation of care paradigms in the new environment a priori. Invest significant time and resources into scenario design, staffing, preparing and orchestration the simulations. 80-160 staff participate in simulations, discover and resolve latent safety threats
1553433|NCT02574091|Drug|1% icotinib hydrochloride cream|Topical administration for twice daily
1553434|NCT02574091|Drug|2% icotinib hydrochloride cream|Topical administration for twice daily.
1553435|NCT02574091|Drug|Placebo|Topical administration for twice daily.
1553447|NCT02574065|Drug|L. reuteri DSM 17938|Effects on crying time in colicky infants with the supplementation of Lactobacillus reuteri DSM 17938
1553448|NCT02574065|Other|The placebo consists of an identical formulation without L. reuteri DSM 17938|
1553449|NCT02574052|Behavioral|participants' food choices|just recorded the participants' food choices in the school cafeteria
1553450|NCT02574052|Behavioral|menu labelling without nutrition education|The investigators provided every participant with a menu labeling without any interpretation and recorded their dietary selections
1553451|NCT02574052|Behavioral|menu labelling with nutrition education|The investigators not only sent a menu labeling to every participant, but also delivered nutrition education to participants by providing them with nutrition and health knowledge through WeChat daily.
1553452|NCT02574039|Dietary Supplement|Oat bran|66g oat bran made up in 350ml skimmed milk
1553453|NCT02574039|Dietary Supplement|refined grain|refined grain product and 350ml skimmed milk
1553454|NCT02574026|Behavioral|Psychomotor tasks|the acquisition of data will be performed in one unique session no drug administration no surgery
1553455|NCT02574013|Device|Endoractor®|Endoscopic sponge for retraction of small intestine
1553456|NCT02574000|Other|ShoulderQ which is a shoulder pain questionnaire|Questions regarding shoulder pain at rest, during movement and at night with visual analogue scales. Factors affecting shoulder pain.
1553457|NCT02574000|Other|Clinical shoulder examination|Shoulder-Hand-Score (measuring pain, oedema, passive range of movement), muscle strength (using Oxford scale and National Institute of Health Stroke Scale (NIHSS) upper limbe motor and shoulder joint palpation (recording subluxation and soft-tissue pain).
1553458|NCT02573987|Drug|Equimolar Mix of Oxygen and Nitrogen Monoxide|an experimental strategy inhalation by means of a breathing mask diffusing MEOPA
1553459|NCT02573987|Drug|Lidocaïn|standart strategy by local injection anesthesy
1553461|NCT02573961|Device|Laser acupuncture|GaAlAs semiconductor diode Laser Phototherapy Device
1553462|NCT02573961|Behavioral|high protein low carbohydrate diet|A tailored high protein/low carbohydrate/low caloric diet
1553463|NCT02573961|Behavioral|low caloric diet|Tailored balanced low caloric diet
1553465|NCT02573935|Drug|Clarithromycin|p.o. clarithromycin 500 mg twice daily for 63 days
1553466|NCT02573935|Drug|Placebo|Placebo tablet twice daily for 63 days
1553467|NCT02573935|Drug|VCD induction therapy|Three courses of VCD (sc bortezomib 1.3 mg/sqm days 1, 4, 8, 11, iv cyclophosphamide 500 mg/sqm on days 1 and 8, and p.o. dexamethasone 40 mg days 1, 2, 4, 5, 8, 9, 11, 12 in each 21-days course)
1553468|NCT02573922|Drug|oxycodone-naloxone|
1553469|NCT02573922|Drug|Oxycodone|
1554205|NCT02568657|Device|Celox group|
1553475|NCT02573883|Device|Fractionated Carbon Dioxide Laser|Vulvar lichen sclerosis will be treated except for the clitoris glans and clitoral hood which will be spared with at least 5mm margin. The procedure will be performed in the outpatient clinic at the National Center for Advanced Pelvic Surgery at MedStar Washington Hospital Center Lafayette Office, 1133 21st St NW, Washington, DC 20036, and include 3 sessions, 4 weeks apart.
1553476|NCT02573883|Drug|Clobetasol Propionate 0.05% ointment|Topical Steroid therapy (Clobetasol propionate .05% ointment nightly for one month then three times weekly for 2 additional months) for a total of three months of treatment.
1553477|NCT02573870|Drug|Batefenterol + Fluticasone Furoate|Batefenterol and Fluticasone Furoate (FF) will be provided as a fixed-dose combination in a dry powder inhaler (DPI), for oral inhalation once every morning, for 42 days. The DPI will consist of 2 strips of 30 blisters each, containing 300 microgram (mcg) batefenterol per blister in one strip and 100 mcg FF per blister in another strip. Both drugs will be available in a micronized form, blended with lactose monohydrate.
1553478|NCT02573870|Drug|Placebo|Placebo will be provided in a DPI, for oral inhalation once every morning, for 42 days. The DPI will consist of 2 matching strips of 30 blisters each, with each blister containing lactose monohydrate and no active pharmaceutical ingredient.
1553479|NCT02573870|Drug|Albuterol|Albuterol inhalation will be provided as an open-label rescue medication to use as needed, to relieve chronic obstructive pulmonary disease (COPD) symptoms.
1553480|NCT02573857|Drug|DSM265|Oral suspension from bulk powder
1553481|NCT02573857|Drug|OZ439|Oral suspension from powder in a bottle
1553482|NCT02573844|Drug|Proklama|
1553483|NCT02573831|Drug|Oxycodone|The patients are given at first oxycodone 0,05 mg/kg and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
1553484|NCT02573831|Drug|Placebo|The patients are given at first placebo and after one hour oxycodone 0,05 mg/kg if their pain in numerical rating scale from 0 to 10 is 5 or more
1553485|NCT02573818|Device|SEDASYS System|propofol sedation with the SEDASYS System
1553486|NCT02573805|Device|Rigiscan test|Rigiscan tests are performed in enrolled subjects for consecutive two nights.
1553487|NCT02573779|Other|Observational - no intervention|This study will observe cohorts of infants who are fed primarily either their own mother's milk or donor milk as part of their routine care. No direct intervention is performed as part of the study.
1553488|NCT02573766|Procedure|Neurofeedback Training|Neurofeedback Group + Sham Neurofeedback Group: Participants participate in sessions for a minimum of 2 treatments a week for a maximum of 10 weeks for a total of 20 sessions.
1553489|NCT02573766|Procedure|Electroencephalogram|"Participants undergo an EEG at baseline, during each neurofeedback session, within 7 days of the conclusion of treatment, and again in one month.
Standard of care group receives EEG at baseline, 1 week after neurofeedback group completes sessions, and again in one month."
1553490|NCT02573766|Behavioral|Pain Scale|Participants in neurofeedback groups asked to rate their pain on a scale of 0 (no pain) to 10 (the worst pain) prior to each session of neurofeedback, and again at the conclusion of the session.
1553491|NCT02573766|Behavioral|Questionnaires|Seven questionnaires regarding symptoms and quality of life completed at baseline, 1 week after neurofeedback sessions, and again in one month.
1553492|NCT02573753|Behavioral|Sleep restriction|
1553493|NCT02573753|Dietary Supplement|Weight gain|
1553494|NCT02573740|Drug|ABT-957|
1553495|NCT02573740|Other|Placebo|
1553496|NCT02573727|Drug|Nor adrenaline + albumin|
1553497|NCT02573727|Drug|Terlipressin + albumin|
1553498|NCT02573714|Drug|Ketamine|Intranasal ketamine (concentration: 50 mg/ml, dose: 1 mg/kg) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
1553499|NCT02573714|Drug|Normal Saline|Intranasal normal saline (placebo: volume-matched with intranasal ketamine) will be given at time zero. Intranasal administration will be performed by placing the needleless syringe gently into the nares with the patient sitting upright. Volumes of ≤ 0.75ml will be nasally inhaled in a single nare, while volumes > 0.75ml will be divided between both nares. Patients who are unable to inhale the medication nasally will receive drip administration of the same volume while recumbent on the bed.
1553500|NCT02573714|Other|Standard Pain Therapy|Typical management strategy for pediatric sickle cell disease vasoocclusive crises including acetaminophen/paracetamol, ibuprofen, oral opioids, and injectable opioids depending on pain severity.
1553501|NCT02573714|Other|Pediatric Quality of Life - Sickle Cell Disease Module|Standardized quality of life assessment performed 2-3 weeks post intranasal medication administration to evaluate pain management and severity of symptoms after discharge from the hospital.
1553502|NCT02573714|Other|Faces Pain Scale - Revised|All patients will answer the FPS-R at 0 minutes (immediately prior to receiving intranasal medication), 30 minutes, 60 minutes, and 120 minutes to assess current pain status.
1553540|NCT02573402|Device|Transcutaneous Tibial Nerve Stimulation|10 sessions over a 2 week period of TTNS for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode, verified with rhythmic flexion of the toes secondary to stimulation of the flexor digitorum and hallicus brevis. Current intensity may vary from patient to patient and will be documented and used in the analysis.
1553506|NCT02573688|Behavioral|Interdisciplinary Therapy|The nutrition intervention will consist of group meetings and prescription of individual diets. Participants will have dietary lessons, with information related to the improvement of food consumption and nutritional quality. Exercise program will be focused on improving activity habits, leading to increased energy expenditure. They will undergo training sessions containing aerobic and resistance training. In Psychological program, participants will be monitored in the support group and, if necessary, individual psychological therapy is recommended. The sessions will discuss common psychological aspects commonly associated with obesity (depression, anxiety, stress, family problems, body image, eating disorders and others). The physiotherapy interventions aim to increase functional capacity.
1553507|NCT02573662|Biological|Blood and Urine sampling|Blood and Urine Sampling
1553508|NCT02573662|Radiation|DXA scan|Scan of Lumbar columna and neck of femur/hip Scan of visceral/subcutaneous fatty tissue
1553509|NCT02573662|Biological|OGTT|Oral Glucose Tolerance Test for Minimal Model analysis for insulin sensitivity and Lipid oxidation
1553510|NCT02573649|Device|Closed-loop Stimulation on first|Closed-loop Stimulation algorithm is turned on in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned off and the patient performs a second head up tilt test.
1553511|NCT02573649|Device|Closed-loop Stimulation off first|Closed-loop Stimulation algorithm is turned off in the device. The patient performs a head up tilt test. After a week Closed-loop Stimulation algorithm is turned on and the patient performs a second head up tilt test.
1553514|NCT02573597|Drug|Bupivacaine|Continuous or bolus administration
1553515|NCT02573597|Drug|Sufentanil|Continuous or bolus administration
1553516|NCT02573571|Other|Development of biomarkers|Blood sampling
1553517|NCT02573558|Drug|Dexmedetomidine|
1553518|NCT02573558|Drug|Propofol|
1553519|NCT02573545|Device|Planning@IFE and Standard@IFE Software|
1553520|NCT02573545|Device|MR Syngo (Numaris/4) software|
1553521|NCT02573519|Radiation|11C Donepezil PET/CT scan|Donepezil binds with high affinity to acetylcholine esterase in the cholinergic synapses. The quantity of density of acetylcholine esterase in the abdominal organs including the intestinal wall are demonstrated by 11C Donepezil PET/CT scan. The PET-signal are measured as Standard-uptake values (SUV) in the internal organs. After 6 hours of fast CT- and PET-scans are performed after injection of iv. contrast and about 500MBq (megabecquerel) [11C]donepezil. The CT scan is used for anatomical location of the internal organs. The scan-field includes the heart and the abdominal organs. Total scan time is about 60 minutes.
1553522|NCT02573519|Device|3D-Transit|"3D-Transit: 3D-Transit for minimal invasive and ambulant describing of regional transit times and contractions pattern of the bowel. The motility and the passage time is measured by 3D-Transit The description of location and rotation of the capsule is dynamic and very precise. It permits precise detailed description of the gastrointestinal contraction pattern and regional passage time. 3D-transit consist of three different parts:
A wireless electromagnetic capsule to be swallowed by the subject
A portable detector plate comprising four sensors worn in a belt around the waist
Specific software for visualizing and analyzing data"
1553523|NCT02573519|Drug|3D-Transit during treatment with Pyridostigmine|3D-Transit and Pyridostigmine: The motility and the passage time is measured by 3D-Transit (as mentioned above) in diabetic patients during administration of Pyridostigmine 60 mg administrated 4 times with 4 hours between each administration. Pyridostigmine is increasing the amount of cholinergic neurotransmitter and is suggested to have a reversible effect on the cholinergic denervation. The mechanism of action of Pyridostigmine in the human body is well-known and the drug is used as a tool to determine if the disturbance in the guts are reversible in diabetic patients.
1553524|NCT02573519|Device|3D-Transit after Malone appendicostomy|3D-Transit (as earlier described) is performed after Malone appendicostomy. The patients are suppose use the antegrade edema technic during the 3D-transit examination.
1553525|NCT02573506|Drug|consolidation chemotherapy of pemetrexed or docetaxel after CCRT|pemetrexed(500mg/㎡) in non-squamous lung cancer or docetaxel(60mg/㎡) in squamous lung cancer
1553526|NCT02573506|Radiation|chest radiation|split-course chest radiation at 51Gy/17f and 15Gy/5f
1553527|NCT02573506|Drug|weekly DP concurrent with chest radiation|weekly docetaxel(25mg/㎡) and nedaplatin(25mg/㎡) concurrent with chest radiation
1553528|NCT02573493|Drug|nab-Paclitaxel|
1553529|NCT02573493|Drug|Cisplatin|
1553530|NCT02573493|Biological|Cetuximab|
1553531|NCT02573493|Radiation|Intensity-Modulated Radiation Therapy|
1553532|NCT02573480|Behavioral|Wraparound care|Wraparound care starts by linking an individual with a support worker who works with them to address risk factors and empower the individual to make positive choices. It not only includes connecting the youth with existing community resources such as education, employment, cultural services and substance counselling, it also helps build problem-solving skills, coping skills, and self-efficacy of the youth and family members. The support worker provides mentorship to the youth. Mentorship both teaches and emulates appropriate behaviours with respect to attitudes and behaviours associated with violence.
1553533|NCT02573467|Drug|Bimagrumab|
1553534|NCT02573467|Drug|Placebo|
1553535|NCT02573454|Behavioral|App assignment|Under-active undergraduates are assigned to use a GPS exercise app that is prosocial (i.e., allows the user to raise money for charities) or personal (does not allow the user to raise money for charities) in nature
1553536|NCT02573441|Behavioral|Jump Math|Jump Math is a workbook based program aimed at improving math skills
1553537|NCT02573441|Behavioral|Cogmed|Cogmed is an online computer program aimed at improving working memory skills
1553538|NCT02573441|Behavioral|Liaison Services|Liaison Services will include working closely with schools to help explain the strengths and weaknesses of a child based on cognitive testing and to help with the implementation of recommendations
1553539|NCT02573415|Procedure|Uterus Transplant|transplant of a deceased donor uterus.
1554206|NCT02568657|Device|Bakri Balloon|
1553541|NCT02573402|Device|Control|10 sessions over a 2 week period of TTNS sham stimulation for 30 minutes. Electrodes will be placed 2 inch by 4 inch according to anatomic landmarks, with the negative electrode behind the internal malleolus and the positive electrode 10cm superior to the negative electrode. Current intensity will be set to zero.
1553542|NCT02573389|Device|Boston Scientific or Cook pancreatic duct stents|Boston Scientific or Cook straight or pigtail pancreatic stents. Stent size depends on duct size (capacity). Pancreatic plastic stents are made primarily of polyethylene materials. Pancreatic stent sizes range from 2 to 25 cm in length and 3F to 11.5F in.
1553543|NCT02573376|Behavioral|Directly Observed Therapy|
1553544|NCT02573376|Behavioral|Wirelessly Observed Therapy|
1553545|NCT02573363|Drug|Cytarabine|Given per standard of care
1553546|NCT02573363|Drug|Mitoxantrone Hydrochloride|Given per standard of care
1553547|NCT02573363|Drug|Selinexor|Given PO
1553548|NCT02573350|Drug|Delamanid|Delamanid was administered orally as 50-mg tablets.
1553549|NCT02573337|Device|Emervel Classic Lidocaine|Treatment of wrinkles and folds
1553550|NCT02573337|Device|Emervel Deep Lidocaine|Treatment of wrinkles and folds
1553551|NCT02573324|Drug|ABT-414|intravenous infusion
1553552|NCT02573324|Radiation|Radiation|
1553553|NCT02573324|Drug|Temozolomide|oral
1553554|NCT02573324|Drug|Placebo for ABT-414|intravenous infusion
1553555|NCT02573311|Drug|tamsulosin hydrochloride|
1553556|NCT02573298|Device|ice|local ice application for 30 minutes
1553557|NCT02573298|Device|cold gas|local cold gas application for 2 minutes
1553558|NCT02573285|Procedure|Simple Aspiration|Aspiration of pneumothorax with a small-bore catheter
1553559|NCT02573285|Procedure|Surgeon Preference|Any standard treatment option may be utilized for the treatment of the pneumothorax, including simple aspiration, chest tube placement, or an operation (VATS).
1553560|NCT02573272|Drug|eslicarbacepine|
1553563|NCT02573246|Behavioral|Cognitive Restructuring|Cognitive restructuring is a cognitive behavioral intervention through which participants learn how to think differently about stressful events in order to feel less emotional arousal. Specifically, participants learn how to distance themselves from the situation, think of the memory as just a memory, or focus on alternative explanations or facets of the situation that are less emotionally upsetting.
1553564|NCT02573246|Device|rTMS|rTMS is a neurostimulation intervention where the participant receives 15 minutes of high frequency (10 HZ) transcranial magnetic stimulation pulses
1553565|NCT02573246|Device|Sham rTMS|Sham rTMS is a placebo intervention aimed to mimic the effects of repetitive transcranial magnetic stimulation with no known direct benefit for the participant.
1553571|NCT02573220|Biological|Cetuximab|Given IV
1553572|NCT02573220|Drug|Fluorouracil|Given IV
1553573|NCT02573220|Drug|Irinotecan Hydrochloride|Given IV
1553574|NCT02573220|Drug|Leucovorin Calcium|Given IV
1553575|NCT02573194|Dietary Supplement|Breakfasts varying in protein source content on appetite|In this randomized, within-subject study, subjects are asked to consume 4 iso-energetic and iso-volumetric puddings as breakfast (20% of estimated energy requirements) with varying distribution of protein sources. The objective is to identify the protein source and the distribution on suppressing appetite.
1553576|NCT02573181|Biological|V114|V114 containing pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F in each 0.5 mL dose
1553577|NCT02573181|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F in each 0.5 mL dose.
1553578|NCT02573168|Genetic|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
1553579|NCT02573168|Genetic|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
1553580|NCT02573168|Other|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
1553592|NCT02573142|Behavioral|Bull City Healthy and Fit|Integrated model of child obesity treatment including clinical care plus community-based program for family-based experiential learning of healthy habits.
1553593|NCT02573142|Behavioral|Healthy Lifestyles Clinic|Clinic-only model of care including clinical care and educational materials
1553594|NCT02573129|Other|Red Meat Restricted|restrict intake of red meat while a Mediterranean diet
1553595|NCT02573129|Other|Red Meat Rich|Mediterranean diet rich in red meat
1553596|NCT02573116|Procedure|scaling and root planing|full-mouth intensive removal of subgingival dental plaque biofilms with the use of scaling and root planing after the administration of local anesthesia
1553597|NCT02573090|Procedure|Non-invasive resin based fissure sealing|The dentists use resin based fissure sealants of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
1553598|NCT02573090|Procedure|Invasive resin based restoration|The dentists use preparation design and resin composites of own choice, and follow their usual clinical procedures based on the instructions from the manufacturer and the guidelines from The Department of Cariology and Endodontics, University of Copenhagen, DK
1553599|NCT02573064|Drug|Colistin|
1553600|NCT02573064|Drug|Tigecycline|
1553601|NCT02573064|Drug|Vancomycin|
1553602|NCT02573051|Drug|Misoprostol|800 µg of misoprostol (Misotac 200 µg Sigma for Pharmaceutical Industries)
1553603|NCT02573051|Drug|Isosorbide mononitrate|40 mg isosorbide mononitrate (Effox 40 mg Minipharma Company)
1553604|NCT02573051|Other|placebo|
1553605|NCT02573038|Drug|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) followed by mandatory injections at week 4, week 8, week 20, week 32 and week 44. During the other visits, an injection can be performed in case of CNV activity (PRN regimen).Therefore, each patient receives between 6 and 13 injections in the whole study.
1553606|NCT02573025|Drug|PEG-IFN alfa-2a BA-free formulation (Test)|Participants will receive single injection of 180 micrograms (mcg) of PEG-IFN alfa-2a BA-free formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
1553607|NCT02573025|Drug|PEG-IFN alfa-2a market formulation (Reference)|Participants will receive single injection of 180 mcg of PEG-IFN alfa-2a market formulation, subcutaneously via prefilled syringe in either period 1 and 2 (each period having 35 days).
1553608|NCT02573012|Drug|Placebo matched to prednisone|Participants will receive placebo matched to prednisone orally for 24 weeks.
1553609|NCT02573012|Drug|Prednisone|Participants will receive prednisone either at a constant dose of 5 mg/day, or 5 mg/day with 1 mg decrements every 4 weeks orally for 24 weeks.
1553610|NCT02573012|Biological|Tocilizumab|Participants will receive tocilizumab at a dose of 162 mg once a week subcutaneously for 24 weeks.
1553611|NCT02572999|Procedure|Not applicable (observational design)|
1553612|NCT02572986|Drug|Permethrin|
1553613|NCT02572973|Other|Acoustic Neuromodulation (ANM)|The purpose of this study is test the safety of the Acoustic Neuromodulation (ANM) treatment and see what effects it has on your child's anxiety symptoms. Observation and anecdotal evidence suggest that this is an effective intervention for anxiety disorders. This is the first research study to test this theory, and could lead to more robust studies in the future. This study intends to assess the efficacy of this type of intervention for children with an anxiety disorder. As this is only a pilot study, the results will also inform the design and execution of future research on this treatment. We hope to add to the growing literature supporting novel treatment approaches for affected individuals.
1553614|NCT02572960|Drug|Valsartan|2 weeks of Valsartan 80 mg per day
1553615|NCT02572960|Drug|Placebo Valsartan|2 weeks of Placebo Valsartan, one tablet per day. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
1553616|NCT02572960|Dietary Supplement|Cholecalciferol|12 weeks of daily cholecalciferol treatment, 70 microgram per day
1553617|NCT02572960|Dietary Supplement|Placebo cholecalciferol|12 weeks of daily Placebo cholecalciferol treatment. Placebo tablets are identical in regards to size and appearance to the experimental intervention tablet.
1553619|NCT02572921|Behavioral|Positive Psychotherapy|"The Positive Psychotherapy Group Treatment was developed by Martin Seligman and Tayyab Rashid (2013) and consists of 14 weekly group sessions of 2 hours. The strictly manualized program includes the following components:
positive orientation and introduction, character strengths, signature strengths, good vs. bad memories, forgiveness, gratitude, satisficing vs. maximising, meaningful life, posttraumatic growth, hope and optimism, positive communication, signature strengths of others, savouring and slowness, altruism and the last session is about the integration of all these components to the full life."
1553620|NCT02572921|Behavioral|Cognitive behavioral therapy|This well-established, cognitive-behavior group therapy was developed by Schaub, Roth and Goldmann (2006) and consists of 12 weekly group sessions of 2 hours. The strictly manualized program includes the following components: education, building up activities, cognitive restructuring, relapse prevention. Moreover, there are 2 sessions added to the standard program: one session concerning savouring and the other one concerning stress reduction. Thus the whole program consists of 14 sessions.
1553621|NCT02572908|Other|Sourdough wheat bread|
1553622|NCT02572908|Other|Regular yeast baked toast bread|
1553624|NCT02572895|Dietary Supplement|Cranberry extract|The aim of this clinical trial is to assess efficacy of an optimal dose of cranberry extract compared to a control dose on mean number of new UTIs for a 6-month period follow-up in women. Participants will be randomly assigned to the optimal dose or control dose treatment at their first visit at the Institute of Nutrition and Functional Foods. This intervention includes three visits at 0, 12 and 24 weeks. At the first visit, women will have to complete questionnaires to provide sociodemographic, medication and natural health products, health antecedents and quality of life information and to document risk factors related to UTIs. A 24-hour recall questionnaire about consumption of PACs will also be completed. A urinary sample analysis and culture as well as a pregnant test will also be performed. Compliance regarding capsules' intake and potential side effects will be documented. The completion of questionnaires and urinary measurements will be repeated at weeks 12 and 24.
1553625|NCT02572882|Dietary Supplement|p-inulin|12 week self-administered treatment phase
1553626|NCT02572869|Other|physical exam|Patients will be examined by the treating physician or his/her designee (Fellow). The examining physician will complete an 11-item clinical examination form about the patient's clinical function. This examination assesses lip competence, tongue movement, oral mucosa, dental state, mouth opening, speech, drooling, diet, appearance, oral sensation, and shoulder movement. Where appropriate, the physician will ask the patient questions regarding items on the questionnaire to ensure the completeness and accuracy of the outcome assessment.
1553627|NCT02572869|Behavioral|questionnaires|"The participating patients will be asked to complete three questionnaires:
(1) The European Organization for Research and Treatment of Cancer (EORTC) Head and Neck questionnaire (EORTC H&N 35) to assess their quality of life as it relates to their mandible function and aesthetic appearance (2) The EORTC QLQ-C30, which assesses overall health-related quality of life (3) The FACE-Q Oncology Module: Mandibulectomy, which contains questions regarding both functional and aesthetic outcomes."
1553628|NCT02572856|Device|Continuous Glucose Monitor (CGM)|Apply Dexcom Gen 4 Professional CGM sensor and calibrate the sensor during preanesthesia visit. Configure CGM so that its measurements are blinded. Setup CGM to make continuous glucose measurements during and after surgery. Calibrate sensor at least every 12 hours. Download CGM measurement data after study and compare measurements against glucose measurements made for clinical care.
1553629|NCT02572843|Drug|MEDI4736 (anti-PD-L1)|fixed dosing 750 mg
1553630|NCT02572830|Behavioral|Delayed Bilateral Eye Movements|Bilateral Eye Movements followed by a 10 min delay after reactivation of fear-memory.
1553631|NCT02572830|Behavioral|Undelayed Bilateral Eye Movement|Bilateral Eye Movements followed by no delay after reactivation of fear-memory. reactivation of the fear memory trace during which the reactivated memory is assumed to be in a labile state.
1553632|NCT02572817|Biological|High-titer anti-influenza plasma|Human plasma (FFP or FP24, 250-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of at least 1:80
1553633|NCT02572817|Biological|Low-titer (control) anti-influenza plasma|Human plasma (FFP or FP24, 250-350 mL per unit or pediatric equivalent) with both an influenza A/H1N1 and A/H3N2 HAI titer of 1:10 or less
1553634|NCT02572804|Device|Epidural|Patients in this group will have an epidural inserted in a standard fashion, prior to the induction of anesthesia. These will be infused with 0.125% Bupivicaine at an initial rate of 5mls/hour, titrated to response. Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
1553635|NCT02572804|Device|Rectus Sheath Catheters|Patients in this group will have surgically inserted rectus sheath catheters (bilaterally), immediately prior to closure of the anterior abdominal wall. These will be infused with 0.125% Bupivicaine at 5mls an hour at a standard rate.Patients will also receive a patient controlled analgesia with hydromorphone 0.2mg/ml, bolus of 200 micrograms with 6 minute lock out (variable in accordance with anesthetic preference).
1553636|NCT02572791|Drug|Chlorhexidine|
1553637|NCT02572791|Drug|Mupirocin|
1553638|NCT02572791|Behavioral|Household cleaning|
1553639|NCT02572778|Procedure|Local biopsy in the tumor|A tumor biopsy of 0.5 cm2 or more will be collected from every patient during surgery or endoscopy after informed consent and if there is enough material after review by the pathologist.
1553640|NCT02572765|Other|PET/CT scan|
1553641|NCT02572752|Drug|Nintedanib|1 soft gelatine capsule, single dose, oral
1553642|NCT02572752|Drug|Nintedanib|Nintedanib, 2 soft gelatine capsules, single dose, oral
1553643|NCT02572752|Drug|Nintedanib|
1553644|NCT02572739|Device|PICCO|measurements based on thermodilution
1553645|NCT02572739|Device|NICCOMO|measurements based on impedance
1553646|NCT02572726|Device|active repeated transcranial magnetic stimulation|ten daily sessions with active 10Hz 20 min-long stimulation over the primary motor cortex
1553647|NCT02572726|Device|'sham' repeated transcranial magnetic stimulation|ten daily sessions with 'sham' 10Hz 20 min-long stimulation over the primary motor cortex
1553648|NCT02572713|Procedure|Biofluid samplings|Biofluid samplings (blood, saliva, and cerebrospinal fluid (CSF)
1553649|NCT02572713|Procedure|Tissue samplings|Tissue samplings (skin, colon, submandibular gland)
1553650|NCT02572713|Drug|DaTSCAN™|
1553651|NCT02572700|Other|Pain and US assessment|All patients will have a baseline visit when treatment is initiated and a follow up visit after 4 months. At each time point, pain mechanisms will be clarified by clinical examination and questionnaires. Besides, ultrasonography of joints and entheses, AMPS test, blood samples, x-ray of hands and feet and interview/additional questionnaires will be applied
1553654|NCT02572674|Other|Experimental follow up|Neuropsychological assessment (intellectual functioning, episodic verbal memory, processing speed, attention, working verbal memory, working visual memory, executive function)
1553655|NCT02572674|Genetic|Genetic sample|Blood samples
1553656|NCT02572661|Radiation|radiation in Squamous Head and Neck Cancer|
1553657|NCT02572648|Other|Brain Imaging (Neuroimaging)|"Magnetic Resonance Imaging (MR) will be acquired on a research dedicated Siemens 3Tesla TIM TRIO MRI scanner with a 32-channel head coil.The MRI scanning protocol will have scans to measure voxelwise and whole-brain measures of grey matter (GM) volumes through a high resolution T1-weighted (T1W) multi-echo magnetization prepared gradient echo (MEMPRAGE) anatomic scan.
Total time in scanner will be approximately 53 minutes."
1553658|NCT02572648|Other|Cognitive Function Assessment|Cognitive function will be assessed using several batteries; the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS), the Controlled Oral Word Association Test (COWA), the Color Trails 1 & 2, the WAIS-III Digit Span and Letter Number Sequence test, the Stroop Test, and the California Computerized Assessment Package Reaction Time test (CALCAP).
1553659|NCT02572635|Biological|PnuBioVax|Three administrations (by intramuscular injection) given 28 days apart to 9 subjects.
1553660|NCT02572635|Biological|Placebo|Placebo administered by intramuscular injection to 3 subjects in each cohort. Three administrations given 28 days apart.
1553661|NCT02572622|Other|non -surgical spinal decompression therapy|it is a kind of traction therapy, it has an special traction design which can provide intermittent traction as to herniation levels.
1553662|NCT02572622|Other|deep friction massage,|deep friction massage is a kind of massage targeting deep muscles for decreasing pain and increasing function
1553663|NCT02572622|Other|electrotherapy|electrotherapy is consist of hot pack, ultrasound and TENS. electrotherapy agents were help decreasing pain, increasing metabolism of tissues.
1553664|NCT02572622|Other|exercise|special lumbar stabilization exercises were applied in advanced protocol.
1553665|NCT02572609|Drug|Ambroxol hydrochloride soft pastille|
1553666|NCT02572609|Drug|Mucosolvan ® adult syrup|
1553667|NCT02572596|Drug|rhTPO|rhTPO was administered 15 000 U/d once daily by subcutaneous injection from day 5-7 after chemotherapy and until the stem cell collection was completed.
1553668|NCT02572596|Drug|CTX|CTX 2.5/m2 for 2 days.
1553669|NCT02572596|Drug|-CSF|10 ug/kg/d of G-CSFwas administered from the WBC was lower than 1×10^9/L following bejing of chemotherapy or no later than day 7after chemotherapy. G-CSF was subcutaneously administered once daily until the stem cell collection was completed.
1553670|NCT02572583|Drug|Liugan Shuangjie Heji|
1553671|NCT02572583|Drug|Shufeng Jiedu Capsule|
1553672|NCT02572583|Drug|Oseltamivir Phosphate Capsule|
1553673|NCT02572570|Device|Filtek Bulk Fill Posterior|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Filtek Bulk Fill Posterior). Procedures will be done using local anesthesia and following ordinary restorative techniques.
1553674|NCT02572570|Device|Filtek Supreme Ultra|Tooth (teeth) affected by dental caries or with an existing defective filling will be restored using the materials listed (Filtek Supreme Ultra). Procedures will be done using local anesthesia and following ordinary restorative techniques.
1553675|NCT02572557|Device|TruFreeze Spray CryoTherapy|TruFreeze Spray CryoTherapy using liquid nitrogen
1553676|NCT02572557|Drug|Liquid nitrogen|TruFreeze Spray CryoTherapy using liquid nitrogen
1553677|NCT02572544|Device|Trayner Pinhole Glasses (Trayner Glasses, Ivybridge Devon, U.K.)|Wearing multiple and single pinhole glasses
1553678|NCT02572531|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge three times daily for 2 weeks
1553679|NCT02572531|Dietary Supplement|Placebo|Ingestion of placebo lozenge three times daily for 2 weeks
1553680|NCT02572505|Drug|Truvada|Female patient will take Truvada and use condoms for each act of intercourse except once at the optimal time for fertility.
1553681|NCT02572492|Drug|Induction with CAR-CY-DEX and conditioning with carfilzomib and highdose melphalan|"All patients entering the study receive four series of CAR-CY-DEX (Cycle 1 with iv carfilzomib 20 mg/sqm on days 1 and 2, and iv carfilzomib 36 mg/sqm on days 8, 9, 15 and 16. Cycle 2 - 4 with iv carfilzomib 36 mg/sqm on days 1, 2, 8, 9, 15 and 16. P.o. cyclophosphamide 300 mg/sqm on days 1, 8 and 15 and p.o. dexamethasone 20 mg on days 1, 2, 8, 9, 15 and 16 in each 28-days series)
Subsequently all patients receive the conditioning regimen:
Iv carfilzomib 27 mg/sqm on day -2 and -1 Iv melphalan 200 mg/sqm on day -2 > 2.0 m CD34+ stem cells/kg body weight on day 0"
1553682|NCT02572492|Drug|Carfilzomib/dexamethasone maintenance|Maintenance therapy two months after salvage HDT with iv carfilzomib 27 mg/sqm every second week and p.o. dexamethasone 20 mg every second week. The maintenance dose of carfilzomib will be escalated to 56 mg/sqm after 4 weeks provided acceptable side effects.
1553683|NCT02572492|Drug|Observation without carfilzomib/dexamethasone maintenance|Observation without carfilzomib/dexamethasone maintenance
1553684|NCT02572466|Other|Hemodialysis|ESRD group received long-term hemodialysis
1553685|NCT02572453|Other|Laboratory Biomarker Analysis|Correlative studies
1553686|NCT02572453|Drug|Onalespib|Given IV
1553687|NCT02572440|Procedure|Sorin XTRA/Sorin Group,|
1553688|NCT02572427|Other|Education for intubation skills|Routine training in neonatal resuscitation, intensive cognitive and hands on training for intubating neonates using manikins in a simulation lab.
1553689|NCT02572427|Other|No added education for intubation skills|Routine training in neonatal resuscitation but no added experience in simulation lab.
1553690|NCT02572414|Behavioral|Men Together Making a Difference Health Promotion Intervention|Men Together Making a Difference Health Promotion Intervention, which included three, 3-hour weekly sessions, implemented in small groups by trained facilitators using scripted manuals, was designed to increase self-efficacy, outcome expectancy, and skills for behaviors tied to cardiovascular disease, diabetes, hypertension, and cancer. It encouraged men to adhere to guidelines for physical activity, 5-a-Day diet, and colon cancer screening. It encouraged at least 30 min of moderate-intensity aerobic activity on 5 days or at least 20 min of vigorous-intensity aerobic activity on 4 days and muscle-strengthening activity on at least 2 days each week. Participants identified their personal barriers to engaging in the recommended behaviors and strategies for surmounting those barriers.
1553691|NCT02572414|Behavioral|Health Awareness Control Intervention|Health Awareness Control Intervention consisted of one 1-hour small-group session led by a trained facilitator. Participants viewed and discussed video clips on physical activity, fruit and vegetable consumption, and colon cancer screening.
1553729|NCT02572115|Behavioral|Akutknappen - used|A caller chooses to bypass the telephone waiting line by pressing the emergency access button
1553730|NCT02572115|Behavioral|Akutknappen - not used|A caller chooses NOT to bypass the telephone waiting line.
1553731|NCT02572102|Dietary Supplement|Energy Drink|Energy Drink, two 16oz containers consumed in 45 minutes
1553732|NCT02572102|Dietary Supplement|Panax Ginseng|Panax Ginseng, lime juice, water and cherry flavoring
1553733|NCT02572102|Other|Placebo|Lime juice, water and cherry flavoring
1553734|NCT02572089|Drug|Naloxone|
1553692|NCT02572401|Behavioral|STAND HIV Risk Reduction Intervention|STAND HIV Risk Reduction Intervention, designed to increase consistent condom use and reduce other sexual risk behaviors, is implemented in small groups over 2 weekly 135-minute sessions. It draws on social cognitive theory, the reasoned action approach, and focus groups, a prospective survey, and an intervention pilot test with African American men. It contains culturally appropriate video clips, interactive activities, brainstorming, role-playing, and discussions designed to affect hypothesized mediators of risk-reducing behavior, including outcome expectancies about the effects of condom use on sexual enjoyment; self-efficacy and skill to have condoms available and to stop to use condoms or refuse unsafe sex even when aroused; and self-efficacy and skill to negotiate condom use.
1553693|NCT02572401|Behavioral|Text Messaging Intervention|Text Messaging Intervention participants receive text messages designed to increase the consistent use of condoms and to reduce other sexual risk behaviors. They receive 3 times a week text messages that ask about their sexual behavior and condom use that day and are asked to respond with either a 1 or 2 numeric response to indicate yes or no. Based on their responses, they receive either an affirming, pro safe-sex text message or a cautionary text against unprotected sex.
1553694|NCT02572388|Biological|R21|
1553695|NCT02572388|Biological|Matrix-M1|
1553696|NCT02572375|Drug|Codeine Phosphate/Guaifenesin ER Tablet|Provide two Codeine Phosphate and Guaifenesin ER Tablet every 12 hours for 6 1/2 days.
1553697|NCT02572375|Drug|Codeine Phosphate/Guaifenesin IR Tablet|Provide one Codeine Phosphate and Guaifenesin IR Tablet every 4 hours for 6 1/2 days
1553698|NCT02572362|Other|No intervention in this retrospective study|No Intervention in this retrospective Analysis. All patients included did receive Radiation therapy Independent of this study
1553699|NCT02572349|Drug|IW-1701|
1553700|NCT02572349|Drug|Matching Placebo|
1553701|NCT02572336|Drug|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
1553702|NCT02572336|Drug|Placebo|Placebo is a THR-18 lookalike, to be administered with tPA.
1553703|NCT02572336|Drug|Tissue Plasminogen Activator (tPA)|tPA is a thrombolytic agent. tPA is not an investigational drug.
1553705|NCT02572310|Device|Simplex High Viscosity Bone Cement|high viscosity bone cement for total knee replacement
1553706|NCT02572297|Other|video-EEG|Registration of seizures during video-EEG
1553707|NCT02572284|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first group of patients to enter the study will receive 5Gy of SBRT per day for 5 days, the second group will receive 6Gy per day for 5 days and the third group will receive 7Gy per day for 5 days. Each treatment will take about 3 minutes and be given as an outpatient at Moffitt Cancer Center.
1553708|NCT02572284|Procedure|Prostatectomy|About 4-6 weeks after SBRT, participants will have a prostatectomy.
1553709|NCT02572284|Other|Quality of Life Questionnaires|Patient assessed health-related quality of life (HRQOL). Quality of Life (QOL) will be assessed using Prostate Symptom Score (IPSS), rectal assessment scale (RAS), sexual health inventory for men (SHIM), and Expanded Prostate Cancer Index Composite (EPIC) patient questionnaires: administered prior to SBRT, and at 2 weeks, 4 weeks, 2 months and then every 3 months up to 18 months post-prostatectomy.
1553710|NCT02572271|Procedure|Rubins Mastopexy|The surgical technique described by Rubin is performed. No other intervention.
1553711|NCT02572271|Procedure|LOPOSAM|The surgical technique LOPOSAM is performed. No other intervention.
1553712|NCT02572258|Other|Nutritional cookie|
1553713|NCT02572245|Device|PF-06410293 PFS|PF-06410293 40 mg administered subcutaneously by Prefilled syringe
1553714|NCT02572245|Device|PF-06410293 PFP|PF-06410293 40 mg administered subcutaneously by prefilled pen
1553715|NCT02572232|Device|Combitube, Easytube, Laryngeal masks|Supraglottic airway device
1553716|NCT02572219|Dietary Supplement|Nutraceutical compound|
1553717|NCT02572219|Dietary Supplement|Placebo|
1553718|NCT02572206|Radiation|PET/SPECT Scan|PET scan will be performed on a mCT scanner.
1553719|NCT02572206|Device|MRI scan|Structural MRI will be obtained to permit co-registration of PET images.
1553720|NCT02572193|Procedure|POEM|To determine the feasibility of same-day discharge following a POEM procedure
1553721|NCT02572180|Behavioral|EMG-based biofeedback training|
1553722|NCT02572180|Behavioral|NIRS-based neurofeedback training|
1553725|NCT02572154|Other|Blood and sperm samples|20 ml of blood and sperm samples for sperm DNA fragmentation exploration
1553726|NCT02572141|Drug|Perioperative chemotherapy with mFOLFOX6 or CAPOX regimens|mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 6 cycles followed by colectomy (3 to 5 weeks after) followed by mFOLFOX6 (6 cycles); CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 4 cycles followed by colectomy (3 to 5 weeks after) followed by CAPOX (4 cycles).
1553727|NCT02572141|Drug|Postoperative chemotherapy with mFOLFOX6 or CAPOX regimens|Colectomy (maximum 4 weeks after randomization) followed by mFOLFOX6 (IV oxaliplatin given over 120 min at a dose of 85 mg/m2 on day 1 followed by IV leucovorin 400 mg/m2 over 2h, IV bolus 5-Fluorouracil 400 mg/m2 and IV infusional 5-Fluorouracil 2400 mg/m2 over 46h every 14 days) for 12 cycles; Colectomy (maximum 4 weeks after randomization) followed by CAPOX (IV oxaliplatin given over 120 min at a dose of 130 mg/m2 on day 1, oral capecitabine 1000 mg/m2 twice daily on days 1 through 14 every 21 days) for 8 cycles
1553728|NCT02572128|Other|Fortified rice|"Study 1: Hot or cold extruded rice fortified test meals fortified with Ferric Pyrophosphate and Zinc oxide will be administered - subjects serve as their own controls.
Study 2: Hot extruded rice or coated rice fortified with Ferric Pyrophosphate and Zinc Oxide will be administered.
Regular rice fortified with Ferrous Sulfate (FeSO4) will act as a control in study 2."
1553735|NCT02572076|Device|Motus Cleansing System|
1553736|NCT02572050|Procedure|Distal Gastrectomy with D2 LND|Robotic Distal Gastrectomy with D2 lymphadenectomy(#7, #8a, #9, #11p, #12a in Japanese Classification) for patient with stage II or III gastric cancer
1553737|NCT02572024|Device|BAT|Baroreflex activation therapy device ON
1553738|NCT02572024|Other|Placebo|Baroreflex activation therapy device OFF
1553739|NCT02572011|Other|Home-based Games Console Balance Training|The balance training intervention involves completing prescribed balance tasks for a minimum of 60 minutes per session, three times a week for 12 weeks (minimum intervention time of 2160 minutes) in their own home. Participants will perform the balance related Wii Fit games that have been suggested previously by professional bodies and amputee therapists (BACPAR Ossur Wii Fit Exercise Recommendations).
1553740|NCT02571998|Drug|Omiganan (CLS001) Topical Gel|
1553741|NCT02571998|Drug|Vehicle Topical Gel|
1553742|NCT02571985|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation System|Zenith® Branch Endovascular Graft-Iliac Bifurcation (Branch Graft) with the ConnectSX™
1553743|NCT02571972|Drug|Dorzolamide-timolol|On enrollment, eligible patients will be started on topical dorzolamide-timolol in the study eye twice daily for the study duration
1553744|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 1 : a dose of amoxicillin and clavulanic acid 1g / 200mg will be intravenously administered
1553745|NCT02571959|Drug|amoxicillin and clavulanic acid|Day 2 : a dose of amoxicillin and clavulanic acid 1g / 125mg will be administered by oral route
1553746|NCT02571946|Radiation|Proton beam therapy|
1553747|NCT02571933|Other|Pre-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised as an assessment of pain prior to standard analgesia dosing.
1553748|NCT02571933|Other|Post-treatment Faces Pain Scale - Revised|Patients will be asked to answer the Faces Pain Scale - Revised 1-2 hours after receiving standard analgesia as an assessment of pain.
1553749|NCT02571933|Other|Cognitive interview|Patients will answer a series of questions pertaining to the pain scale's ease of use, intuitive nature, and cultural appropriateness.
1553750|NCT02571907|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation.
1553751|NCT02571907|Device|Atrium iCAST™|Implantation of Atrium iCAST
1553752|NCT02571907|Device|Zenith® Flex AAA Endovascular Graft|Implantation of the Zenith Flex Endovascular Graft
1553753|NCT02571894|Other|Subclinical cardiotoxicity surveillance and treatment|Intervention arm receives cardiology assessment and intervention.
1553754|NCT02571881|Procedure|Caesarean section|After caesarean section oxycodone or oxycodone-naloxone prolonged release tablet twice a day is started for pain medication
1553755|NCT02571881|Drug|Oxycodone|
1553756|NCT02571881|Drug|oxycodone-naloxone|
1553757|NCT02571868|Device|Optimization CRT-D|
1553758|NCT02571855|Drug|ACT-541468 (hydrochloride salt)|Hard-gelatin capsules (strength: 5 mg and 25 mg)
1553759|NCT02571855|Drug|ACT-541468 (free base)|Soft capsules (strength: 25 mg)
1553760|NCT02571855|Drug|Placebo|Placebo capsules matching the ACT-541468 formulations
1553761|NCT02571842|Drug|Intravenous Rituximab|- 375 mg/m2 rituximab be prescribed 4 consecutive monthly
1553762|NCT02571842|Drug|ACEI/ARB and corticosteroids|"ACEI or ARB will be prescribed as high as tolerable dose.
Prednisolone will be prescribed starting as 0.5 mg/kg/day then taper off to 5 mg/day within 6-8 weeks"
1553763|NCT02571829|Drug|ribociclib|Oral, 600 mg x 1 a day, duration - according to response
1553764|NCT02571816|Drug|ASP2215|oral
1553765|NCT02571803|Behavioral|Dietary And Lifestyle Counseling|The DASH (Dietary Approaches to Stop Hypertension) diet is a dietary pattern of proven effect on arterial blood pressure reduction. It is rich in fruits, vegetables, whole grains, and low-fat dairy foods; includes meat, fish, poultry, nuts, and beans; and is limited in sugar-sweetened foods and beverages, red meat, and added fats. Dietary counseling will be provided during each of 7 control visits within the 12-month time of observation.
1553766|NCT02571803|Other|Optimal Medical Treatment|Optimal Medical Treatment as per 2013 ESC Guidelines on the Management of Stable Coronary Artery Disease.
1553767|NCT02571790|Behavioral|Relaxation optimized virtual reality|
1553768|NCT02571790|Behavioral|Classical relaxation (without Virtual Reality)|
1553769|NCT02571777|Drug|QVM149|
1553770|NCT02571777|Drug|QVM149|
1553771|NCT02571777|Drug|QMF149|
1553772|NCT02571777|Drug|QMF149|
1553773|NCT02571777|Drug|salmeterol/fluticasone|
1553774|NCT02571764|Other|Nutritional Oats Cookie|
1553775|NCT02571751|Device|UNIGEL Silicone Gel-Filled Breast Implant|
1553776|NCT02571738|Biological|CHAM|The treatment indication is for chronic diabetic foot ulcers that can accommodate up to one 5cm x 5cm piece of CHAM
1553777|NCT02571738|Other|Control|Standard of Care
1553778|NCT02571725|Drug|Olaparib|Olaparib starts concomitantly with the first dose of Tremelimumab
1553779|NCT02571725|Drug|Tremelimumab|3 to 6 patients will be treated at 10 mg/kg depending on RLT observed in the first 3 patients. If 0 out of 3 or 1 out of 6 patients experienced a RLT at 10 mg/kg, then this dose will be considered at the recommended phase 2 dose (RP2D). If 2 out of 6 patients experience RLT at this dose within 56 days, then dose reductions as detailed in the Arm description will be carried out.
1553780|NCT02571712|Drug|bimatoprost 0.03% plus timolol 0.5%|1 drop of bimatoprost 0.03% plus timolol 0.5% (GANFORT®) instilled in the affected eye once daily.
1553781|NCT02571699|Other|Subgluteal Nerve Block|ultrasound-guided subgluteal sciatic nerve block.
1553783|NCT02571673|Behavioral|Assessments|Usability outcomes will come from patient surveys and interviews and a nurse practitioner interview in Aim 1: Part 1. In Aim 1: Part 2, patients and their primary care providers will complete online surveys regarding feasibility. Health outcomes and data regarding health care actions will be collected from HN-STAR and the clinic note will be collected to assess feasibility of collecting these metrics in a future trial. Directly after each clinic visit, the NP will complete one brief online survey for each participant.
1553784|NCT02571660|Drug|GINA treatment fot asthma +vit.D low supplementation dose|Dose of 400 IU of vitamin D3 every 24 hours for 1 year + the standard treatment for asthma,
1553785|NCT02571660|Drug|GINA treatment fot asthma +vit.D high supplementation dose|Dose of 1600 IU of vitamin D3 be allocated each 24 hours for 1 year + standard treatment for asthma
1553786|NCT02571647|Other|Non interventional study|"Patients agreeing to participate in the study will have a cognitive assessment and geriatric assessment, carried out according to usual practices and grids clinical gerontology cluster.
They will benefit in addition to a noninvasive screening and risk-free ophthalmic (visual acuity, intraocular pressure, examination of the eyelids and fundus)."
1553787|NCT02571634|Drug|Lazanda|Given pre radiofrequency ablation of the lumbar facet joints to see if patients can remain alert, and it provides relaxation and pain control.
1553788|NCT02571621|Device|Combitube|Intubation with Combitube
1553789|NCT02571608|Drug|Metformin|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
1553790|NCT02571608|Drug|Placebo|The study intervention involves Type II Diabetes Mellitus patient self-administered metformin vs. placebo according to regular dosing schedule and randomization. Both placebo and active drug will be over-encapsulated by pharmacy so that they will be indistinguishable to the personnel involved in the study.
1553791|NCT02571595|Behavioral|Digital cognitive behavioural therapy for insomnia (dCBT-I)|dCBT-I is a computer-based treatment intervention that provides strategies to improve sleep and daytime function (concentration, productivity) in individuals with insomnia
1553793|NCT02571556|Drug|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA|Experimental: Dexamethasone Phosphate Ophthalmic solution (40 mg/mL) delivered by ocular iontophoresis consisting of 4.0 mA-min at 1.5 mA
1553794|NCT02571543|Drug|Ibuprofen|Beginning with 400mg Ibuprofen, 5 times. Depending on the outcome of stage 1 the treatment dose will increase to 800mg, 5 times.
1553795|NCT02571530|Drug|Intra-arterial Cerebral Infusion of Trastuzumab|
1553796|NCT02571517|Drug|Glucocorticoids|Patients assigned to experimental group (group 1) will receive iv methylprednisolone 2 mg/kg/day (divided in two doses) doses and/or oral prednisolone 2,5 mg/kg/day (divided in two doses) during 7 days.
1553797|NCT02571517|Other|Placebo|Patients assigned to control group (group 2) will receive iv/oral glucose 5% solution as placebo, 2 mg/kg/day (divided in two doses) during 7 days.
1553798|NCT02571504|Behavioral|Plasticity-based Adaptive Cognitive Remediation (PACR)|Web-based cognitive training program focused on improving attention and executive function (designed by Posit Science)
1553803|NCT02571478|Behavioral|Marriage Checkup|The MC adapted for primary care consists of three 30-minute appointments with the IBHC. Session 1 consists of discussing the of the couple's relationship history and each partner's primary strengths. Session 2 focuses on each partner's primary concern about the relationship. Session 3 is dedicated to providing feedback for the couple that identifies strengths, areas for possible improvement, and a menu of possible strategies or resources for the couple to consider pursuing.
1553804|NCT02571465|Other|Passive leg raising test and fluid challenge|
1553805|NCT02571452|Behavioral|Brief Behavioral Treatment for Insomnia|Participants will receive 4 weeks of Brief Behavioral Treatment for Insomnia (BBTI). BBTI consists of two in-person sessions, with the two other sessions conducted via telephone. BBTI emphasizes behavioral elements of insomnia treatment. Treatment begins with sleep education and discussion of the biological rhythms that influence sleep cycles. Next, a series of interventions are employed that are derived from sleep restriction and stimulus control techniques.
1553806|NCT02571452|Behavioral|Progressive Muscle Relaxation|Participants will receive 4 weeks of progressive muscle relaxation training (PMRT). PMRT consists of two in-person and two phone sessions. Treatment begins with training on muscle tensing and relaxing, and advances to progressively more efficient tensing-relaxing and passive relaxation exercises. Sessions are employed that teach techniques and problem-solve barriers to the use of PMRT.
1553807|NCT02571439|Procedure|Surgical TAP block|surgeon administered TAP block
1553808|NCT02571439|Procedure|Conventional TAP block|Anesthesiologist administered TAP block
1553809|NCT02571439|Drug|0.5% ropivacaine|20ml of 0.5% ropivacaine is used to perform the TAP block
1553810|NCT02571426|Drug|Sevoflurane|anesthetic agent
1553811|NCT02571426|Drug|propofol|anesthetic agent
1553812|NCT02571413|Other|score before teaching|score the check-point of correct INCS usage before teaching
1553813|NCT02571413|Other|score immediately after teaching|score the check-point of correct INCS usage immediately after teaching
1553814|NCT02571413|Other|score 3 months after teaching|score the check-point of correct INCS usage 3 months after teaching
1553815|NCT02571400|Other|Continued use of opioid analgesics >90 days post-surgery|Exposure of interest: continued use of opioid analgesics >90 days post-surgery
1553816|NCT02571387|Behavioral|Mindfulness-based intervention|
1553817|NCT02571387|Behavioral|Sham meditation|
1553818|NCT02571374|Dietary Supplement|symbiotic group|this group received sachets of symbiotic
1553819|NCT02571374|Dietary Supplement|placebo group|this group received placebo
1553825|NCT02571348|Procedure|micro-osteoperforation|micro-osteoperforation with mini implant at different interval
1553828|NCT02571322|Device|HyperVibe Whole Body Vibration training device|Standing on the HyperVibe platform during WBV training will cause repetitive upward movements of platform to be felt by participant.Thus the participant will feel a whole body vibration, as the name of training implies. Each session will last approximately fifteen minutes.
1553829|NCT02571322|Other|Aerobic Exercise|Aerobic exercise session will last approximately thirty minutes. Starting training intensity will be specific to each participant based on his/her baseline fitness level.
1553830|NCT02571309|Device|Asthmatuner|Asthmatuner is an app for self-management of asthma.
1553831|NCT02571296|Drug|micronized progesterone|Oral
1553832|NCT02571296|Drug|Placebo|Oral
1553833|NCT02571283|Drug|Cocktail|Administered as a single dose injection.
1553834|NCT02571283|Drug|Exparel|Administered 20 minutes+ before additional medications.
1553835|NCT02571283|Drug|Marcaine|Administered 20 minutes or more after Exparel is administered.
1553836|NCT02571270|Other|Combined aerobic and resistance physical training program|
1553837|NCT02571257|Drug|Gemcabene|1-300 mg tablet, QD, 56 days
1553838|NCT02571257|Drug|Gemcabene|3-300 mg tablets, QD, 56 days
1553839|NCT02571257|Drug|Placebo|
1553841|NCT02571231|Device|HFV + and - VG|High frequency ventilation with and without volume guarantuee
1553842|NCT02571218|Device|Substrate+mCPVA|The intervention in the experimental arm includes using a research software (investigational device) to map AF substrate and guide ablation.
1553843|NCT02571218|Device|mCPVA|The intervention in the active comparator arm includes using the commercially available EnSite Velocity mapping and ablation system for modified circumferential pulmonary vein ablation.
1553844|NCT02571205|Drug|Sustanon (testosterone)|Standard incremental regimen of Sustanon
1553847|NCT02571179|Drug|intranasal fentanyl 50 microg dose up to 250 microg|When contraction pain was ≥ 5/10 (numerical rating scale 0= no pain, 10= worst pain), the parturient was given a intranasal fentanyl 50 µg dose. After 15 minutes, if contraction pain was still ≥ 5/10, a second 50 µg intranasal dose was administered. Fentanyl was administered every 15 minute until contraction pain decreased to less than 5/10 or until the maximum fentanyl dose of 250 µg was administered.
1553848|NCT02571166|Biological|HSV529|Live, Replication-defective HSV-2 virus
1553849|NCT02571166|Drug|Valacyclovir|500 mg orally, once daily for 4 weeks
1553850|NCT02571153|Drug|Ketamine 0.4 mg/kg|Intravenous ketamine 0.4 mg/kg after induction of anesthesia
1553851|NCT02571153|Drug|Normal saline|Intravenous normal saline 0.9% 5 mL
1553852|NCT02571153|Drug|Ketamine 0.2 mg/kg|Intravenous ketamine 0.2 mg/kg after induction of anesthesia
1553853|NCT02571140|Drug|Teriparatide|subcutaneous standard injection
1553854|NCT02571140|Drug|Oral PTH (1-34)|Different optimization of API
1553855|NCT02571127|Drug|Hidra1|"Parameters: Vaginal health index (VHI) : The parameter of efficiency : a vaginal moisture ; Will Measured through the VHI : 1 = none / inflamed area ; 2 = no / NOT inflamed surface ; 3 = minimal, 4 = moderate and 5 = normal.
Will be described through the Media and Standard Deviation or median and interquartile rank , as Minimum and Maximum.
Scala: pH tape: It will be measured by its own value. Questionnaire: Sexual Function Index female (FSFI): internationally validated questionnaire with single answers for patient."
1553856|NCT02571114|Dietary Supplement|Saskatoon Berry Frozen Yogurt|Frozen yogurt containing a defined amount of powder prepared from Saskatoon berries (serving size = 25 g available carbohydrate)
1553857|NCT02571114|Dietary Supplement|Frozen Yogurt|Unflavoured frozen yogurt (serving size = 25 g available carbohydrate)
1553858|NCT02571114|Dietary Supplement|Control 1|White bread (serving size = 25 g available carbohydrate)
1553859|NCT02571114|Dietary Supplement|Control 2|White bread (serving size = 25 g available carbohydrate)
1553860|NCT02571101|Drug|CDFR0812-15/25mg|Contains chlomipramine HCl 15mg and sildenafil citrate 25mg.
1553861|NCT02571101|Drug|CDFR0812-15/50mg|Contains chlomipramine HCl 15mg and sildenafil citrate 50mg.
1553862|NCT02571101|Drug|Condencia|Contains chlomipramine HCl 15mg.
1553863|NCT02571101|Drug|CDFR0812-Placebo|Placebo tablet of CDFR0812.
1553864|NCT02571101|Drug|Condencia-Placebo|Placebo tablet of Condencia
1553947|NCT02570542|Drug|carmustine, etoposide, cytarabine, melphalan|Carmustine 300 mg/m2 day -6 Etoposide 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Cytarabine 100 mg/m2 q12hrs x 8 doses day - 5 thru day -2 Melphalan 140 mg/m2 day -1 BEAM dosages may be adjusted per institutional dose adjustments based on body weight.
1553948|NCT02570542|Procedure|Autologous Stem Cell Transplantation|
1553865|NCT02571088|Other|Training Program|Each training session will last 45 min. Exercise will start by a 5-min warm-up cycling period, followed by 30 min of cycling at the power output (W) individually determined before and corresponding to the first lactate threshold corresponding approximately to 2.5 mmol/l . Then patients will cool down for 5 min. Finally, the training sessions will end by 5 min of light stretching. All training sessions will take place at the hospital and will be under the supervision of a physician. Heart rate, oxygen saturation and blood lactate concentrations will be regularly measured. Work rate will be adjusted according to the obtained results. As a safety procedure, blood lactate concentration must not exceed 4 mmol/L during the training sessions. A particular attention will be paid to the hydration of patients. Pain and fatigue will be evaluated everyday by the patients using (100 mm) visual analog scales.
1553867|NCT02571062|Drug|Fexinidazole|
1553870|NCT02571036|Drug|DCC-2618|10 mg and 50 mg formulated tablets
1553871|NCT02571023|Procedure|microscope surgery|
1553872|NCT02571023|Procedure|neuroendoscope surgery|
1553873|NCT02571010|Other|Standard Medical treatment|Standard treatment with drugs and usual rehabilitation
1553874|NCT02571010|Device|Vibrotactile stimulation|Rehabilitation by vibrotactile stimulation at medical center
1553875|NCT02571010|Device|Sham Stimulation with Vibradol device switched off|Sham Rehabilitation at medical center but with Vibradol device switched off
1553876|NCT02570997|Drug|CT1812|Doses will be escalated in the following sequence: 10mg, 30mg, 90mg, 180mg, 360mg, 650mg.
1553877|NCT02570997|Drug|Placebo|Matching placebo administered.
1553880|NCT02570971|Drug|Mannitol|
1553881|NCT02570958|Drug|Indocyanine Green|In the operating room ENB will be used to locate the targeted lung tumor. Once the tumor is located, the surgeon will advance a bronchoscope to the tumor, a needle will be passed through the bronchoscope, and the tumor will be injected with 100-150 micro liters of ICG solution at 0.125mg/mL concentration. The tumor is expected to fluoresce using the da Vinci Firefly robotic camera, giving off a bright green hue. Wedge resection of the fluorescent part of the lung will then be performed. The excised specimen will be sent for immediate pathologist analysis. If the tumor is found within the specimen, and the specimen margins are free of tumor cells, then the procedure will be completed. If the tumor cannot be targeted or visualized, or if the tumor is not found in the pathological specimen, or if the margins of the specimen contain tumor cells, then a formal anatomical lobectomy or segmental resection of the lung will be performed to ensure that the tumor is completely excised.
1553882|NCT02570945|Procedure|Pharmacist-physician intervention to reduce high-risk medication use by elderly inpatients|
1553883|NCT02570932|Biological|Autologous Mesenchymal Bone Marrow Cell|"Suspension in autologous plasma cell of Adult mesenchymal stem cells expanded autologous bone marrow.
Route of administration: Intrathecal in subarachnoid space by lumbar puncture.Total dose of 300 x 106 CME, divided in 3 injections of 100 x 106 CME, with intervals of three months between each administration"
1553884|NCT02570919|Radiation|IGRT 45 Gy in 5 fractions of 9 Gy|Administration of 9 Gy in five consecutive days, to a total dose of 45 Gy radiation
1553885|NCT02570919|Radiation|IGRT 24 Gy single dose|Administration of a single dose of 24 Gy in one session
1553886|NCT02570906|Device|Zephyr BioPatch|Remote patient monitoring devices: BioPatch™ (ZephyrLIFE Hospital System™)
1553887|NCT02570893|Radiation|Adjuvant radiotherapy|Adjuvant radiotherapy (50.4gray/28fraction) followed by 4 cycles of chemotherapy (Paclitaxel and carboplatin) after radical esophagectomy.
1553888|NCT02570893|Radiation|Adjuvant radiotherapy|adjuvant radiotherapy (50.4gray/28fraction) only after radical esophagectomy.
1553889|NCT02570893|Drug|Paclitaxel and carboplatin|
1553890|NCT02570880|Other|glycemic index (glucose-solution, bread samples)|All participants will test 2 breads, prepared with different fermentation times of dough, both breads will be tested in duplicate. Methode: International Organization for Standardization / Final Draft International Standard 26642, Food products — Determination of the glycaemic index (GI) and recommendation for food classification
1553891|NCT02570854|Biological|CSJ137|Starting dose is 0.010 mg/kg and subsequent doses will determined using adaptive Bayesian logistc regression model (adaptive dose escalation strategy). Subjects receive the treatment over 30-60 minutes via intravenous infusion.
1553892|NCT02570854|Drug|Placebo|Subjects will be dosed with a matching placebo (vehicle control) over 30-60 minutes via intravenous infusion.
1553893|NCT02570841|Drug|Topical High dose Capsaicin|Topical High dose Capsaicin exposure within an area of 3x3 cm for 60 minutes
1553894|NCT02570841|Drug|Topical Placebo|Placebo exposure within an area of 3x3 cm for 60 minutes
1553895|NCT02570828|Device|Thermal Imaging|FLIR ONE attachment to an iPhone
1553896|NCT02570815|Drug|indocyanine green|ICG will be prepared as a sterile solution (2.5 mg/10mL) for injection. After vascular ligation, a 6 to 8mL bolus of ICG solution will be injected into the peripheral vein catheter, followed by a 10mL saline solution bolus. The Firefly camera will then be used for the NIF imaging. It is expected that the entire lung, except the segment which was previously isolated from blood supply, will fluoresce within 30-40 seconds, exhibiting a green hue. The surgeon will perform the pulmonary resection and the resected 'dark' lung segment will be immediately evaluated by a pathologist, depending on the pathologist findings the operation may be concluded or the patient will receive a pulmonary lobectomy.
1553897|NCT02570802|Procedure|Ultrasonographic examination|
1553898|NCT02570789|Drug|patients with sunitinib or pazopanib|The treatment with sunitinib or pazopanib should comply with the recommendations written in the Belgian product information and the reimbursement criteria
1553899|NCT02570763|Device|Active tDCS stimulation|
1553900|NCT02570763|Device|Sham tDCS stimulation|
1554007|NCT02570165|Drug|Placebo|Placebo will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip) containing lactose
1554388|NCT02567396|Other|Laboratory Biomarker Analysis|Correlative studies
1553901|NCT02570750|Behavioral|QUESTIONNAIRE ON SMOKING HABITS|"Data on smoking will include the age at which cigarette smoking began and ceased and the average amount smoked daily. Intensity (number of cigarettes smoked per day), duration of smoking (years), and time since cessation (years) will be categorized. Also, the smoking status of the patient prior psoriasis diagnosis will be assessed (smoker or non-smoker and years of smoking prior to psoriasis diagnosis).
Smoking habit evaluation: baseline and changes in smoking habit at 12 and 24-weeks follow-up time points."
1553902|NCT02570724|Drug|"injection of HES  Voluven® "|Injection into the epidural space of 15 to 30 ml Voluven ® at a rate of 1 ml / about 5 seconds.
1553903|NCT02570724|Biological|blood patch|
1553904|NCT02570711|Drug|ACP-196 and Nab-paclitaxel and gemcitabine|
1553905|NCT02570711|Drug|Nab-paclitaxel and gemcitabine|
1553906|NCT02570685|Behavioral|Reflective Interpersonal Gratitude|Participants were given the following instructions in their journal: Writing is a great way to reflect on your daily events, helping to look back and focus on the good things in our lives. There are many things in our lives, big and small, which we might be grateful for. For the next three weeks, 3 times a week (9 days in total), reflect back on your day and think of the people you met and interacted with and are grateful for. Please write down in the space provided a number of positive social interactions over the day or friendships/relationships you are grateful for…..
1553907|NCT02570685|Behavioral|Reflective-Behavioral Gratitude|"Participants were given the following identical instructions as the reflective journal in addition to this At the end of each week, express this gratitude to a friend of your choice face-to-face or through e-mail, facebook, a kind note, tell him/her how much you appreciate something specific that he/she does and reflect on how your friend's reaction and how you feel."
1553908|NCT02570685|Behavioral|Neutral Control Journal|Writing is a great way to reflect on your daily events, helping to look back and reflect on our lives. For the next three weeks, 3 times a week (9 days in total), please write in the spaces provided things that happened during the day.
1553909|NCT02570672|Drug|Metformin|Subjects will be randomized to metformin titrated to 1000mg twice daily as tolerated.
1553910|NCT02570672|Drug|Placebo|Subjects will randomized to placebo will receive placebo
1553911|NCT02570659|Behavioral|Information Video|A 14 minutes intervention video explaining the mechanism of the injury from cross-professional point of view and physiotherapeutic advise
1553912|NCT02570646|Behavioral|QA-DDS|QuitAdvisorDDS is a point-of-care software tool to facilitate implementation of evidence-based tobacco treatment interventions in dental care settings.
1553913|NCT02570633|Other|Extract of ginger|Migraine patients (both genders) will receive capsules of 200 mg of ginger extract (5% gingerols) to be taken three times a day for 12 weeks.
1553914|NCT02570633|Other|Cellulose|Migraine patients (both genders) will receive capsules of 200 mg of placebo (cellulose) to be taken three times a day for 12 weeks.
1553915|NCT02570620|Device|Ultrasonography of the cervix|
1553916|NCT02570607|Biological|BNP dosage|
1553917|NCT02570594|Other|questionary|
1553918|NCT02570581|Other|Jelly with:Paracetamol|"A single dose of each drug will be opened (Paracetamol capsule) or crushed (tablets) in 100 ml of jelly (intervention 1-10) and in 100 ml of apple compote A mix of 6 drugs will be added to 100 ml of jelly (intervention 11) and in 100 ml of apple compote A negative control will consists in 100 ml of plain jelly or apple compote Each participant will receive 24 small transparent plastic glasses (verrines) randomly allocated from number 1 to number 24, each verrine containing 5 ml of the initial 100 ml drug preparation. The participant will be blind to the verrine content.
The participant will taste the verrine content with a 1 ml spoon and spit out each spoonful et rinse his or her mouth with plain water (Evian) between two tests.
The participant will score each verrine numbered 1-24 with a mark ranging from 0 to 10 on the results scoring sheet.
Unblinding will take place immediately after the end of the test. Every volunteer will propose alternative solutions."
1553919|NCT02570581|Other|Jelly with Furosemide|
1553920|NCT02570581|Other|Jelly with Levothyroxine sodium salt|
1553921|NCT02570581|Other|Jelly with Memantine|
1553922|NCT02570581|Other|Jelly with Zopiclone|
1553923|NCT02570581|Other|Jelly with Alprazolam|
1553924|NCT02570581|Other|Jelly with Oxazepam|
1553925|NCT02570581|Other|Jelly with Donepezil|
1553926|NCT02570581|Other|Jelly with Clopidogrel|
1553927|NCT02570581|Other|Jelly with Ramipril|
1553928|NCT02570581|Other|Jelly with Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
1553929|NCT02570581|Other|Plain jelly control|
1553930|NCT02570581|Other|Apple compote Paracetamol|
1553931|NCT02570581|Other|Apple compote Furosemide|
1553932|NCT02570581|Other|Apple compote Levothyroxine sodium salt|
1553933|NCT02570581|Other|Apple compote Memantine|
1553934|NCT02570581|Other|Apple compote Zopiclone|
1553935|NCT02570581|Other|Apple compote Alprazolam|
1553936|NCT02570581|Other|Apple compote Oxazepam|
1553937|NCT02570581|Other|Apple compote Donepezil|
1553938|NCT02570581|Other|Apple compote Clopidogrel|
1553939|NCT02570581|Other|Apple compote Ramipril|
1553940|NCT02570581|Other|Apple compote + Paracetamol + Furosemide + Levothyroxine sodium salt + Memantine + Zopiclone + Alprazolam|
1553941|NCT02570581|Other|Plain apple compote control|
1553942|NCT02570568|Device|Veinlite|Veinlite is a device that emits red light. It provides a non-invasive technique of inserting intra-venous cannula. Placing it onto the skin will cause the outlines of the veins to show up.
1553943|NCT02570568|Device|Pen-torch Transillumination|Pen-torch Transillumination is a non-invasive technique that utilizes 2 pen-torches to provide illumination.The tips of the pen torches are pressed onto the skin, causing the silhouette of the vein to show up
1553944|NCT02570568|Procedure|Conventional Venepuncture|This involves the conventional method of identifying veins suitable for venepuncture, which involves visualization and palpation.
1553945|NCT02570542|Procedure|leukapheresis|
1553946|NCT02570542|Drug|Plerixafor|Following enrollment, patients will be CD34+ stem cell mobilized at the discretion of the treating attending physician with the plerixafor for a maximum of 4 apheresis days, for the achievement of ≥ 7 x106 CD34+ cells/kg.
1554097|NCT02569476|Drug|BGB-3111 and Obinutuzumab|
1554389|NCT02567396|Other|Pharmacological Study|Correlative studies
1553949|NCT02570529|Drug|Albis®|The patients take Albis® 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
1553950|NCT02570529|Drug|Placebo|The patients take placebo 2T orally twice a day during the period between start day of concurrent chemoradiotherapy and 1 month after the treatment. During the period receiving radiation, the patient are prescribed the medication by the 2 weeks, and after radiation, they receive the 1 month's medication.
1553951|NCT02570516|Procedure|Colonoscopy|A double colonoscopy is performed in a back-to-back design using NBI chromoendoscopy then indigo carmine in each patient.
1553952|NCT02570503|Drug|Ropivacaine|Ropivacaine (5mg/ml)-50ml
1553953|NCT02570503|Drug|Ketorolac|ketorolac (30mg/ml)- 1 ml
1553954|NCT02570503|Drug|Clonidine|clonidine (0.1mg/ml)- 0.8ml
1553955|NCT02570503|Drug|Epinephrine|epinephrine (1mg/ml)-1ml
1553956|NCT02570503|Drug|0.9% sodium chloride|Sodium chloride 0.9%- 47.7 ml
1553957|NCT02570490|Drug|sodium fusidate|
1553958|NCT02570490|Drug|linezolid|
1553959|NCT02570477|Procedure|Fecal Microbiota Transplantation|Healthy donor is screened and donates feces. It will then be diluted with sterile saline, blended and filtered. Supernatant will be infused to recipient.
1553960|NCT02570477|Drug|Vancomycin|125mg Vancomycin four times per day
1553961|NCT02570464|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
1553962|NCT02570464|Biological|Blood drawn|Blood drawn is done for patients undergoing elective open infrarenal abdominal aortic aneurysm repair
1553963|NCT02570451|Other|Patient Survey|This survey will assess patients' perspective about the importance of preoperative cognitive screening, information about living situation, information about who accompanied them to the preoperative visit, and level of perceived stress.
1553964|NCT02570451|Other|Mini Cog|The MiniCog is a simple cognitive screening tool that takes just 2-4 min to complete and has little or no education, language, or race bias. This is a well-validated tool to assess mild cognitive impairment.
1553965|NCT02570451|Other|Independent Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for instrumental activities of daily living using standardized scales
1553966|NCT02570451|Other|Activities of Daily Living Score Sheet|Questionnaire used to measure self-reported functional status for basic activities of daily living using standardized scores
1553967|NCT02570451|Other|Geriatric Depression Scale Short Form|Questionnaire used to measure self-reported mood
1553968|NCT02570451|Other|Confusion Assessment Method (CAM)|This well-validated measure of post-operative delirium will be utilized up to 3 days after surgery
1553969|NCT02570451|Other|RAND 36-Item Short Form Health Survey|This measure is a generic, coherent, and easily administered health survey used to assess self-reported quality of life
1553970|NCT02570451|Other|Grip Strength|Measured using the JAMAR dynamometer
1553971|NCT02570425|Device|Training on BF Spiromax followed by SYMBICORT Turbohaler|Training with a placebo comparator: Budesonide Formoterol (BF) Spiromax® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
1553972|NCT02570425|Device|Training on SYMBICORT Turbohaler followed by BF Spiromax|Training with a placebo comparator: SYMBICORT Turbohaler® device using a 6-level system to examine the number of levels required to acquire mastery of device at baseline and maintenance and mastery at 4 and 8 weeks after initial training.
1553973|NCT02570412|Drug|aldoxorubicin|aldoxorubicin administered at 350 mg/m2
1553974|NCT02570399|Radiation|Oligometastatic patients with abdominal-pelvic lymph nodes|Hypofractionated ablative radiation therapy for oligometastatic patients with lymph node metastases
1553977|NCT02570373|Drug|Guselkumab|Participant will receive a single intravenous (IV) infusion of guselkumab at a dose of 10 milligram per kilogram (mg/kg) over 60 minutes on Day 1.
1553978|NCT02570360|Behavioral|exercise|The EX participants will engage in supervised, individual treadmill exercise 3xs/wk at the UW Natatorium. Sessions will consist of a 5-minute warm-up followed by 30 minutes of a moderate to moderately-high intensity exercise and then finish with a 5-minute cool down. Questionnaires will be completed before and after exercise on a weekly basis.
1553979|NCT02570360|Behavioral|treatment-as-usual|The control (standard care) participants will come to the UW-Natatorium on a weekly basis to complete questionnaires.
1553980|NCT02570347|Drug|Co-amoxiclav|Injection Co-amoxiclav 1.2 g intravenously q8h for a minimum of 48-72 hours; switched to oral Co-amoxiclav 625 mg b.i.d. when clinically appropriate.
1553981|NCT02570347|Biological|Tetanus toxoid|Injection Tetanus toxoid 0.5 ml intramuscularly Stat
1553982|NCT02570334|Other|HIV-infected children initiated antiretroviral treatment within the first 7 months of life|All arms will recieve a thourough clinical evaluation : Global motor development (Touwen test), global cognitive development (K-ABC II test), visual (Log Mar Char) and hearing (full ear nose and throat examination) impediments as well as a questionnaire concerning socioeconomic situation, medical history of the child and mother, and HIV treatment and follow up information.
1553983|NCT02570321|Procedure|Bacterial ulcer cross-linking|For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis.
1554390|NCT02567396|Drug|Talazoparib|Given PO
1553984|NCT02570321|Procedure|Bacterial ulcer control|For those bacterial ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for bacterial ulcers. This group will have their eyes irrigated with a balanced salt solution.
1553985|NCT02570321|Procedure|Fungal ulcer cross-linking|"Prior to receiving cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.
For those subjects randomized to receive collagen cross-linking, the procedure will be performed as per the routine at the hospital (UV-X machine; strict aseptic precautions; corneal epithelium debrided and 0.1% riboflavin applied for 30 minutes, then UV-A radiation applied for 30 minutes at 370nm with 3mW/cm2). Corneal cross-linking is a routine procedure performed by Aravind Eye Hospital for infectious keratitis."
1553986|NCT02570321|Procedure|Fungal ulcer control|"Prior to receiving sham cross-linking, topical amphotericin B or topical natamycin antifungal therapy will be started as per routine at the hospital; a loading dose of amphotericin B or natamycin every 5 minutes x 6 will be followed by dosing every 30 minutes. Amphotericin B and natamycin are routinely used therapies for fungal keratitis at Aravind Eye Hospital.
For those fungal ulcer subjects randomized to the control group, they will receive the standard of care topical treatment for fungal ulcers. This group will have their eyes irrigated with a balanced salt solution."
1553988|NCT02570295|Other|Swiss Army Physical Fitness Training|2 x 90 minutes strength training and sport games and 2 x 30 minutes endurance training per week during 18 weeks of basic military training
1553989|NCT02570282|Drug|Placebo|Approximately 50% of the cream is to be applied externally to the clitoris and labia minora and approximately 50% is to be applied intravaginally.
1553990|NCT02570282|Drug|SST-6007|SST-6007 is a white to off-white cream containing 5% (w/w) sildenafil citrate
1553991|NCT02570269|Procedure|AuraGain|Fiberoptic Intubation
1553992|NCT02570269|Procedure|Slotted Guedeltubus|Fiberoptic Intubation
1553993|NCT02570256|Behavioral|Deficit-fields to reduce error|Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.
1553994|NCT02570256|Behavioral|Deficit-fields to expand range of motion|Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).
1553995|NCT02570256|Behavioral|Deficit-fields to improve function|Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
1553996|NCT02570243|Drug|High dose of Unfractionated Heparin|Unfractionated Heparin 100IU/Kg
1553997|NCT02570243|Drug|Standard dose of Unfractionated heparin|Unfractionated heparin 50IU/Kg
1553998|NCT02570230|Other|NSS|NSS infusion
1553999|NCT02570230|Drug|Ketamine|Ketamine 0.2 mg/kg/hr intravenous infusion
1554000|NCT02570217|Device|HHHFNC|infants receive non-invasive respiratory support by mean of HHHFNC
1554001|NCT02570217|Device|NCPAP|infants receive non-invasive respiratory support by mean of NCPAP
1554002|NCT02570204|Behavioral|Self-assessment|Patients enrolled into the study will do a multi-level pregnancy test (MLPT) at enrollment, and will receive one MLPT to do at home one week after taking mifepristone and misoprostol. They will be instructed to call the study site if the at-home MLPT result do not decline, or if they experience any abortion complications.
1554003|NCT02570191|Drug|Peginterferon alfa-2a|180 uG in 0.5 mL solution administered once weekly for 48 weeks
1554004|NCT02570178|Other|balance training|Participants complete 2 sessions per week for 30 minutes each, over a period of three months and are distributed in groups of four individuals carrying out the exercises at once.The groups were led by monitors who had received standardized training. Each participant was barefoot on the balance board, carrying out the different exercises in the balance area of the Wii Fit™ game, according to the indications made on the screen.Eight out of the nine balance exercises were used from the Wii Fit™ game (balance bubble, soccer heading, ski jump, table tilt, ski slalom, penguin slide, snowboard slalom, tightrope walk);.The number of repetitions of each exercise varied depending on the skill of the participants but the total time dedicated to each exercise was the same for all group participants.
1554005|NCT02570165|Drug|Batefenterol|Batefenterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain lactose and the second strip will contain batefenterol blended with lactose with a unit dose strength of 37.5 mcg, 75 mcg, 150 mcg, 300 mcg, or 600 mcg per blister
1554006|NCT02570165|Drug|Umeclidinium/ Vilanterol|Umeclidinium/Vilanterol will be provided as dry white powder for inhalation via a DPI with 30 doses (2 strips with 30 blisters per strip). First strip will contain umeclidinium blended with lactose and magnesium stearate with a unit dose strength of 62.5 mcg per blister and the second strip will contain vilanterol blended with lactose and magnesium stearate with a unit dose strength of 25 mcg per blister
1554253|NCT02568280|Drug|insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
1554008|NCT02570152|Procedure|Blood sample collection|Blood samples will be collected during the Suspected Dengue First Visit. All study subjects with AFI (fever [body temperature ≥ 38°C/≥ 100.4°F] on ≥ 2 consecutive calendar days, measured at least twice, at least 8 hours apart) should be seen at a designated study hospital/clinic by the study physician. The Suspected Dengue First Visit should be scheduled within 7 days from the onset of fever (Days 2-7) and should ideally take place on the second day of fever (Day 2).
1554013|NCT02570113|Device|Peregrine System Infusion Catheter|The Peregrine Catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
1554014|NCT02570100|Procedure|Biological collection|"Collection of blood samples and tumor specimens :
Biological collection before treatment :
1 tumor specimen (under echographic control)
4 blood collections
Biological collection during treatment :
1 tumor specimen after 3 cycles
4 blood collections after 3 and 6 cycles"
1554015|NCT02570087|Procedure|chronic total coronary occlusion percutaneous intervention|Percutaneous intervention of chronic total coronary occlusion with stent implantation
1554016|NCT02570074|Drug|Fosfomycin|Broad spectrum antibiotic
1554017|NCT02570061|Behavioral|telephone|information given at the primary contact by phone, or at a scheduled later time
1554018|NCT02570061|Behavioral|consultation face-to-face|information given at a scheduled consultation at the hospital
1554019|NCT02570048|Device|Mutebutton intervention|Participants are asked to use the MuteButton daily for 30-40 minutes.They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollypop' sensor that sits on the anterior section (tip) of the tongue.
1554020|NCT02570035|Drug|Mirabegron|oral
1554021|NCT02570022|Drug|Liposomal bupivacaine|Local infiltration of liposomal bupivacaine
1554022|NCT02570022|Procedure|Inter-scalene nerve block|Pre-operative inter-scalene nerve block
1554023|NCT02570022|Drug|Ropivacaine|Ropivicaine was used for the inter-scalene nerve block.
1554024|NCT02570009|Behavioral|TEAMS (Talking about Eating, Activity, Mutual Support)|
1554025|NCT02570009|Behavioral|Need Support Training|
1554026|NCT02569996|Drug|Rituximab|Rituximab will be administered at 375 mg/m^2 every 8 weeks for 24 months or until progression, relapse, death, or institution of a new anti-lymphoma treatment.
1554027|NCT02569983|Other|Observational cohort|No intervention - observational study
1554028|NCT02569970|Drug|fluoxetine 20 mg|"Fluoxetine 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.
At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
1554029|NCT02569970|Drug|placebo 20 mg|"Placebo 20 mg per day during 4 weeks prior to video-EEG, then continued during video-EEG.
At the end of video-EEG, and according to patient's decision, treatment was either progressively withdrawn (1 week at 10 mg per day and then 1 week at 5 mg per day), or replaced by fluoxetine 20 mg open-label."
1554033|NCT02569944|Procedure|Bladder stimulation|"Patients included in this arm were stimulated to collect urine with bladder stimulation technique. This technique consists in a tapping movement in the suprapubic area, followed by a circular massage in sacral zone. This sequence lasts one minute and it is repeated five times.
No other procedure, drug or device was done/used in this patients."
1554034|NCT02569944|Procedure|Perineal bag|Patients included in this arm were placed a perineal bag to collect urine sample. No other procedure, drug or device was done/used in this patients.
1554035|NCT02569931|Other|Gait analysis|Participants will be asked to walk on an instrumented treadmill. The study group will undergo gait analysis before surgery and 6 months after surgery. The control group will undergo gait analysis at one visit only.
1554036|NCT02569931|Other|Electromyography|Participants in the study group will undergo electromyography before and 6 months after surgery. Participants in the control group will undergo electromyography at one visit only
1554037|NCT02569931|Procedure|Intra-operative tracking and pressure measurements|Participants in the study group will undergo intra-operative tracking and pressure measurements to see if corrective surgery to stabilise the patella improves tracking and pressure measurements
1554038|NCT02569918|Device|Surface electrical stimulation|"Surface electrical stimulation using the following experimental devices. 1) The CE-approved HASOMED electrical isolated stimulator (Rehastim). 2) Two hand prosthesis: the robotic hand Azzurra (Prensilia, Italy) and the robotic hand Multi-sensory Prosthetic Hand (Wessling robotics, Germany) 3) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject."
1554039|NCT02569905|Drug|parecoxib sodium|parecoxib sodium 40mg
1554040|NCT02569905|Drug|flurbiprofen|flurbiprofen 50mg
1554041|NCT02569905|Drug|saline|normal saline
1554042|NCT02569892|Device|macular laser treatment|Sub-threshold macular laser treatment with Pascal laser Endpoint Management System
1554043|NCT02569892|Device|sham macular laser treatment|Sham macular laser treatment with Pascal laser power setting of zero
1554044|NCT02569879|Other|Pertussis maternal immunization|Retrospective time trend analysis before and after pertussis maternal immunization in Bogota, Colombia.
1554045|NCT02569866|Drug|Cephalexin|Capsules containing cephalexin/500mg
1554046|NCT02569866|Drug|Placebo|Capsules containing placebo/500mg
1554047|NCT02569853|Drug|DFN-11|
1554048|NCT02569853|Other|Placebo|
1554050|NCT02569827|Drug|Celgosivir|Celgosivir 150 mg Q6H for 5 days (total of 20 doses = 3000 mg celgosivir total).
1554051|NCT02569827|Drug|Modipafant 50mg|Modipafant 50 mg Q12H alternating with placebo Q12H for 5 days (total of 10 modipafant doses = 500 mg modipafant)
1554052|NCT02569827|Drug|Placebo|Placebo Q6H for 5 days
1554053|NCT02569827|Drug|Modipafant 100mg|Modipafant 100 mg Q12H alternating with placebo Q12H for 5 days (total of modipafant 10 doses = 1000 mg modipafant)
1554054|NCT02569814|Drug|Fimasartan/Amlodipine/Rosuvastatin|
1554055|NCT02569814|Drug|Fimasartan/Amlodipine|
1554056|NCT02569814|Drug|Rosuvastatin|
1554057|NCT02569801|Drug|Fulvestrant|Fulvestrant at a dose of 500 mg as two intramuscular injections will be administered on Day 1 and Day 15 of Cycle 1, and on Day 1 of each subsequent 28-day cycle.
1554058|NCT02569801|Drug|GDC-0810|GDC-0810 will be administered as tablets at a dose of 600 mg orally once daily.
1554059|NCT02569788|Radiation|CIRT arm|Five dose levels (55GyE, 57.5GyE, 60GyE, 62.5GyE, 65GyE) are planned within the Phase I part. Daily fraction of 2.5 GyE will be delivered for all dose levels. After the recommended dose (RD), i.e., MTD, is determined or if the treatments to 65 GyE are safely delivered, the recommended dose (or 65 GyE) will be the prescribed dose in the Phase II part of the study. Ninty-five percent (95%) of the isodose line should cover the GTV+3~5mm.
1554060|NCT02569775|Biological|Autologous Bone Marrow Mononuclear Cells|Transplantation of Autologous Bone Marrow Mononuclear Cells
1554061|NCT02569762|Dietary Supplement|Sucralose-Aspartame|Sucralose or aspartame
1554062|NCT02569762|Dietary Supplement|Aspartame-Sucralose|Aspartame or sucralose
1554063|NCT02569749|Other|Berlin and Epworth questionaries|
1554064|NCT02569749|Other|Sleep apnea monitoring in those patients in whom a pacemaker with monitoring apnea system has been implanted.|
1554065|NCT02569749|Other|Night polygraph / Polysomnography|
1554066|NCT02569723|Drug|Carbon C 14 Oxaliplatin|Intravenous infusion
1554067|NCT02569723|Drug|Oxaliplatin|Intravenous infusion
1554071|NCT02569697|Other|HEC Placebo gel|
1554072|NCT02569697|Other|Placebo Intravaginal Ring|
1554073|NCT02569697|Other|Placebo Vaginal Film|
1554074|NCT02569697|Other|Placebo Vaginal Insert|
1554075|NCT02569684|Dietary Supplement|Prebiotic fibers: oligofructose and inulin|
1554076|NCT02569684|Dietary Supplement|Maltodextrin|
1554079|NCT02569658|Drug|Tranexamic Acid|
1554080|NCT02569658|Drug|Placebo|
1554081|NCT02569645|Drug|Rosuvastatin|40 mg rosuvastatin orally once per day with or without food, swallowed whole (not chewed, crushed or divided) starting 2 weeks prior to the initiation of radiation therapy and stopped at 4 weeks after the completion of radiation. Total duration of Rosuvastatin is 11 weeks if 25 fractions of radiotherapy are given, or 12 weeks if 30 fractions of radiotherapy are given.
1554083|NCT02569619|Behavioral|Activity Intervention|
1554084|NCT02569619|Behavioral|Healthy Diet Intervention|
1554085|NCT02569593|Dietary Supplement|Iron supplements, more specific Ferrodyn and Vista Ferrum|Ferrodyn is an Fe-chelate supplement. One tablet contains 28 mg elemental iron. Vista Ferrum is an iron(II)sulfate supplement. One tablet also contains 28 mg elemental iron. The volunteers will be asked to take the provided supplement orally with 150 mL of water.
1554086|NCT02569580|Device|Topically|"use the No More medical device as anti lice treatment"
1554087|NCT02569567|Procedure|Smart-Shear Wave(SSW) imaging|"All Smart-Shear Wave(SSW) imaging examinations will be performed by one operator.
The right lobe of the liver is examined through the intercostal view with the patient lying in a supine or semi-decubitus position with the right arm in maximal abduction.
Once the optimal sizes of the regions of interest is chosen, they are fixed for subsequent measurement in each subject. Special attention is paid to avoid any focal lesion, vessels, biliary tracts, or artifacts from nearby lung gas or cardiac movement."
1554088|NCT02569567|Procedure|Transient elastography(TE)|"Using the M probe in patients with BMI <30 kg/m2.
Liver measurement is taken at either the seventh or eighth intercostal space of each subject over the right lobe of the liver. The measuring depth ranges from 2.5 to 6.5 cm below the skin surface.
Examinations are performed by a sonographer blinded to S-shear wave elastography, and biological results."
1554089|NCT02569554|Drug|PF-06463922|each subject will receive 4 single oral doses of 100 mg PF-06463922 (treatment A: tablets without food; treatment B: tablets with food; treatment C: tablets without food with rabeprazole; treatment D: oral solution without food). There will be at least 10 days washout period between consecutive PF-06463922 single dose.
1554090|NCT02569554|Drug|rabeprazole|20 mg daily tablets in the evening for 5 days and Pf-06463922 on the morning of day 6 in treatment C.
1554091|NCT02569541|Drug|sodium fusidate|
1554092|NCT02569515|Drug|Epoetin Beta|Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
1554093|NCT02569502|Drug|enfuvirtide|Participants will receive a total daily dose of 180mg of enfurtide administered twice daily as a subcutaneous injection.
1554094|NCT02569489|Drug|HBI-8000|
1554095|NCT02569489|Drug|Trastuzumab|
1554096|NCT02569489|Drug|Paclitaxel|
1554098|NCT02569463|Drug|Interleukin-2|Recombinant Human Interleukin-2 (RhIL-2) was administered subcutaneously at a dose of 1 million IU every other day for 4 weeks.
1554099|NCT02569450|Behavioral|Surgical outcomes monitoring using Shewhart control chart|"Assistance by a local surgeon responsible for the implementation of intervention within his/her department
Quarterly team meeting to interpret variations in observed outcomes on the control charts
Restitution of surgical outcomes based on wall posters in operating room
Training sessions provided to local surgeon for appropriate control chart utilization"
1554105|NCT02569424|Behavioral|Patient's position|Supine or Trendelenburg strict -20°)
1554106|NCT02569411|Other|Financial Incentive|money
1554110|NCT02569385|Other|Spontaneous breathing trial|
1554112|NCT02569359|Dietary Supplement|shea nut oil extract|
1554113|NCT02569359|Other|Placebo|
1554114|NCT02569346|Drug|Triumeq|Single-dose Triumeq as a whole tablet
1554115|NCT02569346|Drug|Triumeq crushed + breakfast|Single-dose crushed and suspended tablet of Triumeq
1554116|NCT02569346|Drug|Triumeq crushed + drip feed|Drip feed followed by single-dose crushed and suspended tablet of Triumeq
1554117|NCT02569333|Other|Educational video|iPad with educational video highlighting current guidelines for the management of hospitalized patients with ulcerative colitis.
1554118|NCT02569320|Drug|Dexamethasone|Given PO
1554119|NCT02569320|Drug|HDAC Inhibitor AR-42|Given PO
1554120|NCT02569320|Other|Laboratory Biomarker Analysis|Correlative studies
1554121|NCT02569320|Drug|Pomalidomide|Given PO
1554126|NCT02569294|Behavioral|Yoga intervention|Hatha-yoga intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by Hatha-yoga trained teachers. This program was developed previously in Montreal and the following were included at each session: 1) preparatory warm-up synchronized with breathing; 2) selected postures (e.g. forward , backward-, and side-bending asanas in sitting and lying positions); 3) deep relaxation; 4) alternate-nostril breathing or pranayama; and 5) meditation. Each participant received a DVD to encourage at-home practice.
1554127|NCT02569294|Behavioral|Hypnosis intervention|Hypnosis intervention included 6 sessions of 2 hours every 2 weeks. This was led by an anesthesist with experience in oncology and trained in hypnosis. Based on years of consultation with cancer patients, her team created a negotiating approach that fosters shared decision-making through using tasks that are centered on general well-being rather than on the health problem itself. Patients were asked to be actively involved. Several topics are addressed through tasks: eg. adjusting self-expectations. Patients were also required to keep a work-diary that was reviewed at the beginning of each session. At the end of the session, a 15-min hypnosis exercise is conducted. They receive CDs containing the hypnosis exercises and homework assignments.
1554128|NCT02569294|Behavioral|CBT intervention|CBT intervention included 6 weekly 90-min sessions in groups of 3 to 8 participants led by CBT-trained psychologists with experience in psycho-oncology. This program was developed by team leaders and is modelled on the work of Andersen et al. (2008) and Savard (2010). The intervention targets were: 1) breast cancer, meaning of illness, understanding stress and responses to it; 2) impact of treatment on body image; 3) impact of treatment on self-esteem; 4) fear of recurrence; 5) relationships with relatives and health professionals; and 6) life projects, return to daily activities and work. Relaxation training took place at the end of each session and participants performed tasks between sessions.
1554131|NCT02569268|Other|Questionnaires and follow-up|Detecting the vascular functional parameters, questionnaire and follow-up: For 2 years or the occurrence of vascular events end time, including cardiovascular events (acute myocardial infarction, angina, coronary reperfusion therapy), stroke, heart failure, peripheral vascular disease.
1554132|NCT02569255|Procedure|Pulmonary venous ostia isolation|Percutaneous, catheterbased, radiofrequency ablation with left atrial access via atrial septal puncture. Helped by 3D-imaging system (Carto(tm)) and electrical signal guidance the PV ostia together with neighbouring atrial tissue is electrically isolated from the rest of the left atrium.
1554133|NCT02569242|Drug|Nivolumab|
1554134|NCT02569242|Drug|Docetaxel/Paclitaxel|
1554135|NCT02569229|Other|Diagnostics for glucose tolerance with 3 different methods.|"A 7-day course of subcutaneous continuous glucose monitoring system (CGMS).
An oral glucose tolerance test done within the 7 day period of CGMS.
Optionally a intravenous glucose tolerance test done within the 7 day period of CGMS."
1554136|NCT02569216|Device|Electrical Inhibition (EI)|constant direct current 1-20mA transvaginal 10 second bursts only when needed
1554137|NCT02569203|Dietary Supplement|standard enteral nutrition|standard enteral nutrition
1554138|NCT02569203|Dietary Supplement|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan|high-protein enteral nutrition of immune modulating nutrients enriched with β-glucan
1554139|NCT02569203|Dietary Supplement|high-protein enteral nutrition of immune modulating nutrients without β-glucan|high-protein enteral nutrition of immune modulating nutrients without β-glucan
1554141|NCT02569151|Device|HBP & CBP measurement using systo 130 mmHg|
1554142|NCT02569138|Device|Modified Insole|hard and thin shoe insert between the foot sole and base of the footwear
1554143|NCT02569138|Device|Non-Modified Insole|regular shoe insert between the foot sole and base of the footwear
1554144|NCT02569125|Drug|Everolimus|4.5 mg/m² daily
1554145|NCT02569112|Device|Venus Legacy|Venus Legacy is a multi-polar Radio frequency (RF) technology combining pulsed electro magnetic fields (PEMF) and mild suction stimulation (varipulse). RF technology works by exciting fat molecules 2-3 million times per second to achieve desired heating effects on fat. RF has been shown to increase the production new collagen and other cell enhancing biological molecules. PEMF delivered in synergy with RF assists in the creation of FGF-2 (fibroblast growth factors 2), TNF-α (tumour necrosis factor-a) and TGF-β (transforming growth factor-b) increasing fibroblasts. Varipulse technology increases the movement of fluids in the lymphatic system and manually stimulates fibroblasts.
1554146|NCT02569112|Device|CoolSculpt|Cryolipolysis has been developed and commercialized to non-invasively reduce subcutaneous fat. The cryolipolysis technology utilizes the sensitivity of fat cells to cold injury in order to selectively eliminate subcutaneous fat tissue without affecting the skin or other surrounding tissues. Cryolipolysis technology enables a non-invasive alternative for subcutaneous fat reduction through cellular apoptosis.
1554147|NCT02569099|Other|Caregiver training|One hour training of family caregivers on the basic function of the brain and the stroke condition and its management in the home.
1554149|NCT02569073|Drug|Dronabinol|Dronabinol 5 mg, every other night, orally
1554150|NCT02569073|Drug|Placebo|Placebo--no drug
1554151|NCT02569060|Other|Testing and Monitoring of Blood Glucose Levels|Point-of-care testing of HbA1c levels at the food pantry at approximately 3 month intervals
1554152|NCT02569060|Other|Primary care coordination|Referral to a local primary care provider, if none currently exists. Coordination of care with primary care provider.
1554153|NCT02569060|Other|Diabetes-appropriate food packages|Food (perishable and non-perishable) appropriate for diabetes self-management available for pick-up at the food pantry twice monthly.
1554154|NCT02569060|Behavioral|Diabetes self-management education|Education materials drawn from evidence-based practice and adapted from existing diabetes education curricula to be flexible to individual, community, and site variations. The Immediate Intervention Arm receives more robust diabetes self-management education (with group education visits) than the Waitlist Control Arm.
1554155|NCT02569047|Procedure|Atraumatic Restorative Treatment|No local anaesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with Glass Ionomer Cement (GIC).The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed.
1554156|NCT02569047|Procedure|Hall Technique|It employs the cementation of preformed metal crowns (PMC) without the need of any prior teeth preparation or caries removal. No local anesthesia is used neither tooth preparation.Different sizes of PMCs will be tested until the smallest size that perfectly fit the tooth is achieved. The PMC will be loaded with the dental material glass ionomer cement (GIC) and placed. Child will asked to bite firmly on it, until it is fitted. The excess of GIC will be removed with hand instruments and dental floss.
1554157|NCT02569034|Other|Functional Magnetic Resonance Imaging|"Both groups will have the fMRI performed once. The fMRI will be use to to dissociate activity associated with both reward wanting and reward liking using the EEfRT. Learning more about the brain basis of components of anhedonia in both young and older adults is important in the context of previous research showing that risk-taking behavior and reward sensitivity changes with age, enhancing the knowledge of anhedonia."
1554158|NCT02569034|Other|Effort-Expenditure for Rewards Task|"Both groups with have the EEfRT performed once. The EEfRT is an effort-based decision-making task that measures reward wanting, in contrast to commonly used anhedonia questionnaires, which focus on reward liking. This novel task may provide a useful measure of components of anhedonia in older adults and in different patient populations."
1554159|NCT02569021|Device|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.
Current best/optimized DBS setting (considered baseline)
DBS off for 30 minutes as a washout period
Biphasic pulse stimulation mode (assessment at 0.5hr)
Biphasic pulse stimulation mode (assessment at 1hr)
Biphasic pulse stimulation mode (assessment at 2hr)
Biphasic pulse stimulation mode (assessment at 3hr)"
1554160|NCT02569021|Other|Unified Parkinson's Disease Rating Scale|UPDRS is used by neurologists to rate the motor impairment of people with Parkinson's Disease.
1554161|NCT02569021|Other|Tremor Rating Scale|TRS is used by neurologists to rate the severity of a tremor.
1554162|NCT02569021|Device|Kinesia accelerometer|The kinesia accelerometer is used to analyze the tremor and slowness (bradykinesia) of the participants.
1554163|NCT02569021|Device|Trigno wireless system|The Trigno system measure muscle contractions.
1554164|NCT02569021|Other|GaitRite walking assessment.|GaitRite records a patients gait pattern.
1554165|NCT02569008|Drug|Fluid challenge with Compound Sodium Lactate|Infusion of the mentioned dose of Compound sodium Lactate over 5 minutes intravenously.
1554166|NCT02568995|Drug|ropivacaine + ketorolac + adrenaline|A combination of drugs injected locally for postoperative pain management
1554167|NCT02568982|Other|Exams and questionnaires|Blood sample 24hrs urinary cortisol and salivary cortisol, urinary labstick test, EKG, cardiac ultrasound, cardiac CT-scan, arterial and venous US ophthalmology examination spine X-Ray bone densitometry QoL questionnaires (SF-36, QoLCushing, Beck BDI-II)
1554200|NCT02568709|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
1554201|NCT02568709|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
1554202|NCT02568683|Drug|ENTO|ENTO spray dried dispersion tablets administered orally twice daily while in a fasted state
1554168|NCT02568969|Device|Eirus continuous lactate monitor|a triple-lumen central venous catheter (Eirus TLC) functioning as a regular central venous catheter (CVC) with an integrated microdialysis function will be inserted via the left jugular vein for continuous monitoring of lactate and glucose using Eirus intravascular microdialysis system (Maquet Critical Care, Solna, Sweden) after calibration with arterial sample. Eirus TLC will be used for both drug administration and blood sampling and will be removed postoperatively when a central line will no longer be necessary.
1554170|NCT02568917|Procedure|Atraumatic Restorative Treatment - Ketac Molar Easy Mix|Occlusal and occlusal-proximal ART restorations in primary and permanent molars using the high viscosity GIC Ketac Molar Easy mix will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
1554171|NCT02568917|Procedure|Conventional Restoration - Composite Resin (Bulk Fill)|Occlusal and occlusal-proximal composite resin restorations in primary and permanent molars using the Scotchbond Multi-purpose adhesive system and the Filtek Bulk Fill composite resin wil be performed. Local anesthesia can be used if necessary. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
1554172|NCT02568904|Other|Alcohol|every participant will drink vodka at a dose of 2ml/kg bodyweight
1554173|NCT02568891|Dietary Supplement|Probiotic|multispecies probiotic
1554174|NCT02568891|Dietary Supplement|Placebo|matrix
1554175|NCT02568878|Drug|Creatine monohydrate|
1554176|NCT02568865|Other|Physiological Sensors|Wearable biosensors can play an important role in depression diagnosis. For this study, we will use a cost-effective, unobtrusive, and non-stigmatizing sensor to monitor physiological signals (including heart rate (HR), heart rate variability (HRV), electrodermal activity (EDA), physical activity, and temperature).
1554177|NCT02568865|Other|Sleep Monitoring Device|The X4 Device is an internally battery powered FDA-classified Type BF device used for configurable acquisition of physiological signals via EEG.
1554178|NCT02568865|Other|Vocal Monitoring|The participants will be provided with a phone app to leave audio diary recordings.
1554179|NCT02568865|Other|Mobile Phone|A mobile phone and tablet will be used for various purposes, including, recording of socialization, location, and activity patterns of participants and to collect emotional information based on interactive surveys, as well as for forwarding sleep and physiological sensor measurements to a secure server.
1554180|NCT02568852|Procedure|Combined anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
1554181|NCT02568852|Procedure|General anaesthesia|Laparoscopic cholecystectomy under 10 mmHg pressure
1554182|NCT02568839|Drug|docetaxel + trastuzumab sc + pertuzumab|docetaxel 75-100 mg IV + trastuzumab sc 5 ml (600 mg) SC + pertuzumab 840 mg IV starting dose, subsequently 420 mg IV, repeated every 3 weeks, 6 courses
1554183|NCT02568839|Drug|trastuzumab emtansin|trastuzumab emtansine 3.6 mg/kg IV, repeated every 3 weeks, 6 courses
1554184|NCT02568826|Drug|3-glycosyl-3-Odemethylthiocolchicine derivative|IDN 5243 is a new muscle relaxant molecule. This molecule has showed significant anti-inflammatory activity by intraperitoneal route at 10 mg/kg in both carrageenan induced oedema and granuloma tests. IDN 5243 is a new 3-glycosyl-3-Odemethylthiocolchicine derivative endowed with muscle-relaxant, anti-inflammatory and analgesic activities. The primary packaging of test formulation will be a glass vial containing a solution of IDN 5243, 4 mg/ 1 mL. The secondary package will correspond to the patient's kit and will be a box containing ten (10) vials. The box label will be provided with a tear-off label.
1554185|NCT02568813|Behavioral|Multiscore Depression Inventory for Children scale|
1554186|NCT02568800|Drug|Prolonged Cefepime Infusion|Cefepime infusion should last at least 4 hours with the aide of an infusion bomb
1554187|NCT02568800|Drug|Usual Cefepime Infusion|Cefepime infusion occurs directly without the aide of an infusion bomb, lasting roughly thirty minutes
1554188|NCT02568787|Dietary Supplement|rice bran arabinoxylan compound (RBAC)|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
1554189|NCT02568787|Dietary Supplement|Placebo|Take 2 tablets 1 time (1 gram) per day for the 3-month intervention period.
1554190|NCT02568774|Other|Traditional Acupuncture|Treatment is based on the traditional Chinese medicine theory for treating overactive bladder. Qi-transforming function of bladder is regulated by experienced Chinese medicine practitioner.
1554191|NCT02568774|Other|Usual Care|Patients will receive conventional rehabilitation as usual, including standard physiotherapy, bladder training and general advise of fluid intake.
1554192|NCT02568761|Procedure|Injection Snoreplasty|Nonsurgical treatment involving the injection of 1.5 ml of 50% ethanol (1 ml of 99.5% ethanol diluted in 1ml of 2% xylocaine) into the upper palate.
1554193|NCT02568761|Other|Oropharyngeal Exercises|Myofunctional isometric and isotonic exercises of the soft palate, pharyngeal side walls, face and tongue.
1554194|NCT02568748|Biological|CIK|Cytokine -induced killer cells in Egyptian patients with advanced hepatocellular carcinoma as treatment or adjuvant treatment in comparison with traditional treatment.
1554195|NCT02568748|Procedure|TACE|Trans-arterial chemoembolization
1554198|NCT02568722|Other|Standard RRT initiation|"In the absence of kidney function recovery, the initiation of RRT will be permitted if one of the following develops:
serum potassium ≥ 6.0 mmol/L; pH ≤ 7.20 or serum bicarbonate ≤ 12 mmol/L; evidence of severe respiratory failure, based on a PaO2/FiO2 ≤ 200 and clinical perception of volume overload; and/or persistent AKI > 72 hours following the time of randomization."
1554199|NCT02568722|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
1554207|NCT02568644|Dietary Supplement|Extract of ginger|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two capsules of ginger extract (containing 5% of gingerois).
1554208|NCT02568644|Other|Cellulose|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received two placebo capsules (cellulose).
1554209|NCT02568644|Drug|Intravenous ketoprofen|People (both genders) who went to the emergency room of the Hospital Vera Cruz (Belo Horizonte, MG, BR) with a migraine attack received intravenous ketoprofen (100mg).
1554210|NCT02568631|Other|serious game JeStiMulE|The objective of JeStiMulE players will be ending the game after a learning period and two playing periods (with emotional words and idioms, which include three modules each). The session ends when the module is completed, which is approximately one hour per module, or 6 sessions of play.
1554211|NCT02568631|Other|control video game|The patients will play 6 sessions of one hour with the control video game
1554212|NCT02568618|Genetic|Pain Medication DNA Insight (TM) test|The DNA insight test uses saliva to test the metabolism of certain pain and mental health medications to determine if the subject is a poor metabolizer, intermediate metabolizer or ultrarapid metabolizer.
1554213|NCT02568605|Dietary Supplement|Prebiotic fibre|Oligofructose-enriched inulin (Synergy1)
1554214|NCT02568605|Dietary Supplement|Placebo|Maltodextrin
1554215|NCT02568605|Behavioral|Weight Loss|All participants will receive 10 one-on-one sessions with a Registered Dietitian designed to achieve 10% weight loss over 6 months. The sessions will focus on nutrition education and behavior counseling to reduce food intake and improve dietary quality.
1554216|NCT02568592|Dietary Supplement|High Fat|High Fat - Carbohydrate (20%), Fat (65%), Protein (15%)
1554217|NCT02568592|Dietary Supplement|Normal|Normal - Carbohydrate (50%), Fat (35%) and Protein (15%)
1554218|NCT02568592|Dietary Supplement|Normal + Extra Fat|Normal + Extra Fat - Carbohydrate (50%), Fat (65%), Protein (15%). Carbohydrate and protein intake identical in absolute amounts to NORMAL, with an additional 30% extra energy coming from fat.
1554219|NCT02568579|Procedure|blood sample/ stool sample|blood sample to be done when possible with standard of care lab draw. Stool sample to be collected monthly at home.
1554220|NCT02568566|Other|Laboratory Biomarker Analysis|Correlative studies
1554221|NCT02568566|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
1554222|NCT02568553|Biological|Blinatumomab|Given IV
1554223|NCT02568553|Other|Laboratory Biomarker Analysis|Correlative studies
1554224|NCT02568553|Drug|Lenalidomide|Given PO
1554225|NCT02568527|Device|PLGA scaffold|Poly-Lactic-co-Glycolic Acid (50:50) biodegradable, synthetic scaffold
1554226|NCT02568514|Device|Secure text messaging|A smartphone and web application that allows physicians and other health care professionals to communicate to each other by secure text message
1554227|NCT02568501|Behavioral|Daily feedback|Daily feedback on glucose levels from wireless glucometers
1554228|NCT02568501|Behavioral|Financial incentive|Participant receive a $2 daily financial incentive framed as a loss with money allocated upfront and taken away each day of non-adherence to goal
1554229|NCT02568488|Drug|Metformin|850 mg orally twice daily for 6 months
1554231|NCT02568462|Device|AmM APTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
1554232|NCT02568449|Drug|Nintedanib|Given PO
1554233|NCT02568436|Radiation|low level laser therapy|low level laser therapy is intended to accelerate tooth movement
1554234|NCT02568423|Drug|Mirikizumab - IV|Administered IV
1554235|NCT02568423|Drug|Mirikizumab - SC|Administered SC
1554236|NCT02568423|Drug|Placebo - IV|Administered IV
1554237|NCT02568423|Drug|Placebo - SC|Administered SC
1554238|NCT02568410|Procedure|coronary artery bypass grafting using cardiopulmonary bypass|no study intervention. Study cohort will undergo coronary artery bypass grafting using cardiopulmonary bypass according to standard practices at DUMC
1554239|NCT02568397|Drug|Lanabecestat|Administered orally
1554240|NCT02568397|Drug|Dabigatran etexilate|Administered orally
1554241|NCT02568384|Device|Onyx BG Meter / App System|Subjects with diabetes used the Onyx BG Meter / App System at home and assessed software operations, ease of use of the system, and clarity and utility of user instructions.
1554242|NCT02568358|Other|Experimental Intervention: DNA-based testing of BAL fluid|DNA based testing needs 4.5 hours lab time in addition to standard testing
1554243|NCT02568345|Drug|sugammadex ED90|"The first patient received the dose of 2.4 mg/kg and if there was a negative response, the next patient would be allocated to receive the next higher dose of 2.6 mg/kg.
In case that 2.4 mg/kg did produce a positive response, the next patient would be randomized with 10% of probability to receive the next dose of 2.2 mg/kg or 90% probability to receive the same dose of 2.4 mg/kg."
1554244|NCT02568332|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
1554245|NCT02568332|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
1554246|NCT02568319|Drug|LIPO-202|
1554247|NCT02568319|Drug|Placebo|
1554248|NCT02568306|Drug|NNC0165-1562|Administered subcutaneously (s.c., under the skin) single dose [SD] or multiple dose [MD] with daily dosing.
1554249|NCT02568306|Drug|placebo|Administered subcutaneously (s.c., under the skin) single dose [SD]) or multiple dose [MD] with daily dosing.
1554250|NCT02568293|Other|SBCV|SBCV is a single use, sterile product that acts as a localized physical barrier at the vascular wall.
1554251|NCT02568293|Other|Saline|Saline is used as a control.
1554252|NCT02568280|Drug|Faster-acting insulin aspart|Administered subcutaneously (S.C., under the skin).Subjects will be individually dosed.
1554255|NCT02568254|Device|Lens 1 (etafilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
1554256|NCT02568254|Device|Lens 2 (nelfilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
1554257|NCT02568254|Device|Lens 3 (nesofilcon A)|Each lens type will be worn for approximately 2 weeks (12 +/- 2 days).
1554258|NCT02568241|Other|Interferon Alfa-2b|High-risk acute leukemia patients receive prophylactic DLI at day 30-60 after hematopoietic stem cell transplantation,they received interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
1554259|NCT02568228|Dietary Supplement|Krill oil|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
1554260|NCT02568228|Other|Lean and fatty fish|The fish group will be open labeled.
1554261|NCT02568228|Dietary Supplement|Placebo capsules|The krill group and the control group will be double blinded. The krill oil and placebo capsules will be administered in equal amounts and are of equal size and have the same color.
1554262|NCT02568215|Biological|VRC01|Administered by IV infusion; total dose will vary based on participant's weight
1554263|NCT02568215|Biological|Placebo for VRC01|Sodium Chloride for Injection USP, 0.9%; administered by IV infusion
1554264|NCT02568202|Other|No treatment given|"This is an online web-based cross-sectional survey in which participants will complete one of two questionnaires.
There will be no treatment."
1554265|NCT02568189|Device|SonoSite Maxx Series Ultrasound System|Ultrasound imaging is a non-radiating, non invasive modality to assess many areas of the body including vascular fluid status. By placing the probe on the abdomen and looking at the inferior vena cava the clinician can assess a patient's degree of dehydration. We are evaluating the utility of this diagnostic intervention within the clinical management of patients in the pediatric emergency department.
1554266|NCT02568176|Drug|Midazolam|Single oral dose of midazolam 6 mg Day 1 and Day 17.
1554267|NCT02568176|Drug|Esketamine|Intranasal esketamine will be self-administered 5 times during 15 days.
1554268|NCT02568176|Drug|Bupropion|Single oral dose of bupropion 150 mg on Day 1 and 19.
1554269|NCT02568163|Other|Non surgical periodontal treatment|
1554270|NCT02568150|Biological|Single group, open-label|
1554271|NCT02568137|Behavioral|Smart-phone based technology|
1554272|NCT02568124|Drug|Tranexamic Acid|
1554273|NCT02568124|Drug|Placebo|
1554274|NCT02568111|Drug|peginterferon beta-1a|SC administration as prescribed by the physician- initial dose of 63 μg followed by 94 μg dose on day 15 and 125 μg on day 29
1554275|NCT02568111|Drug|brimonidine tartrate|Applied to injection site as specified in the treatment arm. Commercially available Mirvaso (Brimonidine tartrate) gel will be provided by Galderma.
1554276|NCT02568111|Drug|Vehicle Gel|Matched placebo applied to injection site as specified in the treatment arm. Matching vehicle gel will be provided by Galderma.
1554277|NCT02568098|Drug|IVM, IVM and PQ, IVM and DHA-PQP, IVM and DHA-PQP and PQ|Regimen 1: IVM; Regimen 2: IVM and PQ; Regimen 3: IVM and DHA-PQP; Regimen 4: IVM and DHA-PQP and PQ;
1554278|NCT02568098|Drug|PQ and DHA-PQP and PQ|Regimen 5: PQ; Regimen 7: DHA-PQP and PQ
1554279|NCT02568098|Drug|DHA-PQP|Regimen 6: DHA-PQP
1554280|NCT02568085|Device|Arista|Arista™ AH is a medical device intended for application to surgical wound sites as an absorbable hemostat. The device is a fine, dry, sterilized white powder that is biocompatible, non-pyrogenic, and is typically absorbed within 24 to 48 hours.
1554281|NCT02568059|Drug|Sahastara remedy alcoholic extract|comparison of different dose of drug
1554282|NCT02568046|Drug|Sym004|The Investigational Medicinal Product (IMP) is Sym004. Sym004 is a 1:1 mixture of 2 monoclonal Antibodies (mAbs), which bind specifically to 2 non-overlapping epitopes of the Epidermal Growth Factor Receptor (EGFR).
1554283|NCT02568046|Drug|Irinotecan|180 mg/m2 iv, infused over 60-90 minutes
1554284|NCT02568046|Drug|Folinic Acid|400 mg/m2 iv, infused over 120 minutes concurrently with Irinotecan
1554285|NCT02568046|Drug|Fluorouracil|After the Irinotecan and Folinic Acid infusions, Fluorouracil (5-FU) 400 mg/m2 iv bolus, then 2400 mg/m2 5-FU infused over 46 hours
1554286|NCT02568033|Drug|Pemetrexed|
1554287|NCT02568033|Drug|Carboplatin|
1554288|NCT02568033|Drug|Cisplatin|
1554289|NCT02568033|Drug|Docetaxel|
1554290|NCT02568033|Drug|Paclitaxel|
1554291|NCT02568033|Radiation|stereotactic radiosurgery|
1554292|NCT02568020|Drug|keto-amino acids|Ketosteril®( Fresenius Kabi) will be given at a dosage of one tablet/5kg ideal body weight/day, divided into three doses taken during meals.The patients will be followed-up for one year. The patients will come to the hospital every 4 weeks.
1554293|NCT02568007|Drug|Cyproheptadine|
1554294|NCT02567994|Drug|Teneligliptin|Subjects will visit the center on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.
1554295|NCT02567981|Dietary Supplement|21 micronutrient-fortified supplement|21 micronutrient fortified supplement: Dose: 18.75g/day. Contains the following daily amounts per dose: Zinc 9 mg, Copper 300mcg, Iron 12mg, Vitamin D 5 mcg, Folic Acid 160mcg, Vitamin E 5mg, Iodine 90mcg, Calcium 200mg, Vitamin A 250mg, Phosphorus 150 mg, Vitamin C 40mg, Magnesium 40mg, Vitamin B12 0.9mcg, Selenium 17mcg, Thiamine 0.5mg, Manganese 0.17mg, Niacin 6mg, Biotin 8mg, Riboflavin 0.5mg, Vitamin B5 1.8mg, Vitamin B6 0.5 mg. Formula (percentage by weight): Maize 64.08%, Soy Beans 30%, Vitamins and Minerals 5.92%, BHA 0.006%. Energy: 73kcal, Protein 4g, Fat 1g, Dietary Fiber 2g, Carbohydrates 12g.
1554296|NCT02567981|Dietary Supplement|Cereal Fortificado (Fortified Cereal)|"Cereal Fortificado Dose: 45g/day. Contains the following daily amounts per dose: Vitamin A 226.6mcg, Thiamine 0.058mg, Riboflavin 0.202mg, Niacin 2.16mg, Panthotenic acid 3.015mg, Vitamin B6 0.765mg, Folate 27mcg, Vitamin B12 0.9mg, Vitamin C 45mg, Vitamin D 1.8mcg, Vitamin E 3.735mg, Vitamin K 45mcg, iron 3.6mg, Zinc 1.8mg, Iodine 18mcg, potassium 180mg, phosphorus 90 mg, calcium 58.50mg. Percentage weight: 58% corn, 20% soy, Skim dry milk 8%, Sugar 9%, Soy Oil 3%, Vitamins and Minerals 0.2%, calcium phosphate 1.23%, Potassium chloride 0.27%. Energy 184.5 kcal, protein 7.2%, Fat 4.1%, Fiber 1.4%, Ash 4.6%."
1554297|NCT02567981|Dietary Supplement|Ferrous sulphate|"Ferrous sulfate drops children <12 months: 12,5mg elemental iron/day (continuous). Children from 12-23.9months: elemental iron 25mg/day (continuous).
Chidlren from 24 to 59 months: 1ml/day for two months, every 6 months."
1554298|NCT02567981|Dietary Supplement|Vitamin A|Vitamin A Capsules: children <12 months: 100.000 IU/6 months. Children 12-59 months: 200.000 IU/6 months.
1554299|NCT02567968|Drug|Caffeine|Anesthetized volunteers will be allowed to wake after injection of caffeine (15 mg/ kg). The time to wake will be measured.
1554300|NCT02567968|Drug|Placebo Control|Anesthetized volunteers will be allowed to wake after injection of saline (placebo control). The time to wake will be measured.
1554301|NCT02567955|Biological|Gardasil-9 and Gardasil-9|Subjects will receive two standard doses of Gardasil-9 (0.5 ml)
1554302|NCT02567955|Biological|Cervarix and Gardasil-9|Subjects will receive a standard dose of Cervarix (0.5 ml) and a standard dose of Gardasil-9 (0.5 ml)
1554303|NCT02567942|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation
1554304|NCT02567942|Drug|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation
1554305|NCT02567929|Drug|propofol group|Patient will be anesthetized by using propofol infusion during operation.
1554306|NCT02567929|Drug|sevoflurane group|Patient will be anesthetized by using sevoflurane inhalation during operation.
1554307|NCT02567916|Drug|Fresofol|
1554308|NCT02567916|Drug|Propofol|
1554309|NCT02567903|Device|Thigh Tourniquet|Knee arthroscopy with the use of a thigh tourniquet that is inflated to 100-150 mmHg above systolic blood pressure.
1554310|NCT02567903|Procedure|Knee arthroscopy|Knee arthroscopy
1554311|NCT02567890|Behavioral|Internet-based DBI|Participants will go through a four week interactive program that will improve body acceptance. Includes some homework assignments and monitoring.
1554312|NCT02567890|Behavioral|Expressive writing|Participants will be asked to reflect upon issues related to body image.
1554313|NCT02567877|Procedure|thyroidectomy|Patients enrolled in the study will undergo a clinically-indicated thyroidectomy performed as standard of care.
1554314|NCT02567877|Drug|levothyroxine in thyroidectomy patients|Patients will initiate levothyroxine treatment after surgery consistent with standard of care. The drug dosage will be titrated to TSH goal that matches the pre-surgery TSH (+/- 1 mIU/L)
1554315|NCT02567864|Other|Healthy Beat Accupunch exercise program|HBA has three phases and takes 40 minutes to complete.
1554316|NCT02567864|Other|control|participants maintain their daily activities.
1554317|NCT02567851|Drug|Brentuximab Vedotin|Monoclonal antibody drug conjugate
1554318|NCT02567838|Drug|Lidocaine gel|Instillagel (2% lidocaine) was administered rectally prior to probe insertion.
1554319|NCT02567838|Drug|Placebo|Placebo (Aquagel) was administered rectally prior to probe insertion.
1554320|NCT02567825|Procedure|Tympanostomy tube placement|As per routine care, tympanostomy tubes will be inserted under general anesthesia, using a small radial incision in the anteroinferior portion of the tympanic membrane; a Teflon® Armstrong-type tympanostomy tube will be used. Participants will be followed overtime for recurrences of AOM and treated with topical antimicrobials.
1554321|NCT02567825|Procedure|Nonsurgical management|Participants will be followed overtime for recurrences of AOM and treated with systemic antimicrobials.
1554326|NCT02567786|Procedure|Surgery with CPB|
1554327|NCT02567786|Other|Fresh Frozen Plasma|
1554328|NCT02567786|Other|Plasmalyte|
1554329|NCT02567773|Drug|GSK2881078|GSK2881078 hot melt solutions, ranging in concentration from 0.05 mg/g to 50 mg/g, will be prepared by weighing drug substance directly into specific quantities of the hot melt vehicle solution. Subjects will be administered GSK2881078 (dose for Cohort 1: 0.75 mg for females and 1.5 mg for males) hot melt solution within capsule orally with water.
1554330|NCT02567773|Drug|Placebo|Subjects will be administered as hot melt vehicle placebo within capsule orally with water.
1554331|NCT02567773|Drug|Itraconazole|Subjects will be administered as two capsules of itraconazole 100 mg (200 mg) orally with water.
1554332|NCT02567760|Dietary Supplement|MP1|Subjects receive MP1 drink at the dose of 400 mg/day after meal for 8 weeks.
1554333|NCT02567760|Other|Placebo|Subjects receive Placebo drink after meal for 8 weeks.
1554334|NCT02567747|Other|Data collection|Data will be collected retrospectively for cases identified through RIPS*/ DANE** from 2008 until 2014 and through PAI*** from 2009 until 2014. *Registro Individual de Prestación de Servicios de Salud (RIPS) database (Health Service Provider Individual Registration Database), Columbia. **Departamento Administrativo Nacional de Estadística (DANE) database (The National Administrative Department of Statistics database), Columbia. ***Programa Ampliado de Immunizaciones (PAI) database (National Immunization Program database), Columbia.
1554335|NCT02567734|Procedure|CT-guided percutaneous irreversible electroporation|Patients undergo the irreversible electroporation ablation that induce protracted cell death by apoptosis through cell membrane perforation.All these procedures will be performed under the guide of Big bore multislice spiral CT scanning system.
1554336|NCT02567721|Other|Vaccine safety surveillance|Extraction of routinely collected primary care data from nine GP practices and an active surveillance approach in 3 of the 9 GP practices, by using an existing card-based ADR reporting system (MHRA Yellow Card), to estimate proportions of AEIs among seasonal influenza-vaccinated individuals.
1554339|NCT02567695|Drug|GBT440|Test: GBT440 300 mg capsule (high-strength) Reference: GBT440 100 mg capsule (low-strength)
1554340|NCT02567682|Drug|GBT440|GBT440 capsules followed by Caffeine, S-warfarin+vitamin K, Omeprazole, and Midazolam
1554341|NCT02567669|Radiation|standard postoperative radiotherapy for breast cancer|subjects will undergo ct scans to assess muscle mass and questionnaires to assess fatigue at 4 defined time points during and after radiotherapy
1554342|NCT02567656|Drug|RP6530|Tablet starting at 200 mg
1554343|NCT02567643|Radiation|Stereotactic Radiosurgery|
1554344|NCT02567630|Behavioral|Soft Mitt Constraint Therapy for Sensory/Motor Impairment in Cerebral Palsy|The CIMT intervention includes 3 components: (1) placement of a removable soft constraint for ½ each day, with a non-invasive wear monitor (2) demonstration and prescribed home-use of a sensory kit (3) and a reach/grasp tool. The intervention lasts 4 weeks as has been published in older children as well as used in infant trial descriptions.
1554345|NCT02567617|Dietary Supplement|Polyphenols|Capsules with five substances (polyphenols) at a concentration of 3000mg per day
1554346|NCT02567617|Dietary Supplement|Placebo controlled|Starch capsules
1554347|NCT02567604|Behavioral|Focus Groups|at least three focus groups lasting approximately one hour
1554348|NCT02567591|Other|Physical activity|walk (three times per week) and muscle building twice per week with the use of elastic bands. They will include 5 strengthening exercises mobilizing large muscle groups of the lower limbs (abs (if possible for the patient), hamstrings, quadriceps, triceps sural and gluteus maximus).
1554349|NCT02567578|Drug|YH12852 0.1 mg|
1554350|NCT02567578|Drug|YH12852 0.25 mg|
1554351|NCT02567578|Drug|YH12852 0.5 mg|
1554352|NCT02567578|Drug|Placebo|
1554353|NCT02567565|Other|LipiView|tear film lipid layer thickness measured by LipiView interferometer (TearScience Inc, Morrisville, NC)
1554356|NCT02567539|Radiation|IMRT with or without radiosensitive therapy|Re-irradiation with hypofractionated intensity modulated radiation therapy (IMRT), using VMAT RapidArc
1554357|NCT02567539|Drug|Radiosensitive therapy|Radiosensitive therapy with Temozolomide
1554358|NCT02567526|Behavioral|Between-Meal Intervention Group|Non-nursing staff trained as Feeding Assistants were responsible for supplement and snack delivery in the mornings and afternoons between meals supervised by research staff
1554359|NCT02567513|Behavioral|Supplement Intervention|Supplements given twice/day, 5 days/week, for 24 weeks by research staff.
1554360|NCT02567513|Behavioral|Snack Intervention|Snacks given twice/day, 5 days/week for 24 weeks by research staff.
1554361|NCT02567500|Behavioral|Patients with auditory hallucination|"Patients with auditory hallucination (20 for each arm):
Evaluation at time 0 and 6 month after of:
The social cognitive marker (NEPSY II) : theory of mind and affect recognition
The emotional marker:
Differential emotion scale IV (DES IV): emotional individual stability
Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.
Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.
Evaluation of diagnosis with DSM-IV criteria:
MINI-Kids
Psychosis section of Kiddie-SADS"
1554362|NCT02567500|Behavioral|Patients without auditory hallucination|"Patients without auditory hallucination (20 for each arm):
Evaluation at time 0 and 6 month after of:
The social cognitive marker (NEPSY II) : theory of mind and affect recognition
The emotional marker:
Differential emotion scale IV (DES IV): emotional individual stability
Revised Beliefs About Voices Questionnaire (BAVQ-R): a self report measure of patients' beliefs, emotional and behavior about auditory hallucination.
Evaluation of auditory hallucinations persistence with a self report scale using in recruiting criteria.
Evaluation of diagnosis with DSM-IV criteria:
MINI-Kids
Psychosis section of Kiddie-SADS"
1554363|NCT02567487|Drug|Levobupivacaine|Transversus abdominis plane block with levobupivacaine
1554364|NCT02567474|Behavioral|5 A model|self management program based on 5A model
1554369|NCT02567448|Other|Sleep and pulmonary physiologic measurements|Two overnight sleep studies, CT scan of upper airway and chest, pulmonary function test and pharyngeal lavage
1554391|NCT02567383|Radiation|Radiation|5-Gy once a week for a subtotal of 10Gy/2fx a week to gross tumors, followed by 40Gy/20fx/4 weeks, total 50Gy/22fx/5weeks
1554392|NCT02567383|Device|Hyperthermia; Thermotron RF-8|40 minutes within 2hr after irradiation
1554393|NCT02567383|Drug|Cisplatin|20mg/m2 per week for 6 weekly cycles before radiotherapy
1554394|NCT02567383|Drug|Taxotere|10-12mg/m2 per week for 6 weekly cycles before radiotherapy
1554395|NCT02567370|Drug|AMG 581|Active drug
1554396|NCT02567370|Drug|Placebo|Placebo
1554397|NCT02567357|Behavioral|Visual Scheduling|Caregivers will present a visual schedule with pictorial representations of activities/events expected to occur each day will be presented to children at set times of day (tailored for individual's schedules). Ultimately caregivers will aim to ensure that activities occur as per the schedule as far as possible - thus decreasing the child's level of exposure to unexpected changes in routines or plans.
1554398|NCT02567357|Behavioral|signalling change|Caregivers will present a distinct visual-verbal cue card whenever they become aware that a change to the child's routine or plan is about to occur. Thus, the intervention uses a stimulus control approach so that the child learns that presentation of the cue reliably predicts the subsequent occurrence of a change to routine/plan, and the change is therefore more predictable and easier for the child to deal with.
1554399|NCT02567344|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS will be delivered at 110% rMT to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
1554400|NCT02567344|Device|Sham Repetitive Transcranial Magnetic Stimulation|rTMS will be delivered via an electronic sham coil that mimics real rTMS in appearance, sound, and feeling. Pulses will be delivered to the Left DLPFC with 5 seconds on, 10 seconds off for 4000 pulses.
1554401|NCT02567331|Drug|Capecitabine|Participants will receive 1250 mg/m^2 capecitabine administered twice daily as oral tablets for 14 days followed by a 7 day rest period for up to 6 treatment cycles.
1554402|NCT02567318|Device|MRI-scan|Magnetic resonance imaging scan of the brain
1554403|NCT02567305|Other|Markers of NET formation|i.e. Plasma DNA, Histone, MPO, DNase
1554405|NCT02567279|Drug|Denosumab subcutaneous injections|Subcutaneous injection of Denosumab 60 mg, one injection at baseline and another injection at 6 months
1554406|NCT02567279|Drug|Placebo subcutaneous injections|Subcutaneous injection of Placebo, one injection at baseline and another injection at 6 months
1554407|NCT02567266|Behavioral|Unified Protocol for Adolescents (UP-A)|The UP-A is an emotion-focused, transdiagnostic approach for adolescents (ages 12-18) with a primary emotional disorder. It is a developmental adaptation of the Unified Protocol, a transdiagnostic treatment for adults with emotional disorders. Clinicians present all skills in the context of the emotions most salient to presenting concerns and adolescent/caregiver conceptualizations of treatment needs, thereby personalizing treatment. The UP-A is delivered in 8-21 weekly sessions, with clinician flexibility regarding the sequencing and depth with which various sections are presented to clients and caregivers, as well as the emotions targeted during the course of the intervention.
1554408|NCT02567266|Behavioral|Youth Outcomes Questionnaire|"The YOQ consists of parent- and youth-report measures of symptoms and alliance administered weekly on a tablet computer. The YOQ online system then generates reports to provide clinicians with systematic feedback about client progress, flagging critical items that have been endorsed (e.g., suicidality, hallucinations), presenting graphs of ratings over time, and providing empirically-derived alerts when clients are failing to progress or showing deterioration. Clinicians will be trained to use this feedback to modify treatment as needed, share it with families as appropriate, and use it to enhance use of supervision."
1554409|NCT02567266|Behavioral|Treatment as Usual|Clinicians assigned to the TAU condition will be instructed to use whatever treatment methods and outcome monitoring strategies they typically use with adolescents with internalizing disorders.
1554415|NCT02567240|Other|Carbon monoxide-bubbled mediums|Islets will be harvested with carbon monoxide bubbled mediums
1554416|NCT02567227|Other|Cognitive Remediation|This computerized program has successfully been used by seniors in different settings. It trains a number of cognitive processes including attention and Executive Function.The Cognitive Remediation (CREM) training is constructed based on the program's built in baseline cognitive evaluation.
1554417|NCT02567227|Other|Active Control|Computer, multimedia and group based health education programs.
1554418|NCT02567214|Drug|Ultibro®|The intervention in this arm is the Ultibro®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be delivered and the Spiriva will be a placebo. We will measure the exertional dyspnea after 21 days of treatment.
1554419|NCT02567214|Drug|Spiriva®|The intervention in this arm is the Spiriva®. To keep the patients blinded on which treatement they are taking they will use the two devices but in this arm the Ultibro will be a placebo and the Spiriva will be delivered. We will measure the exertional dyspnea after 21 days of treatment.
1554420|NCT02567201|Other|electrophysiological evaluation|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1, 2, 3 : one session maximum by experience
1554460|NCT02566837|Procedure|Ultrasound|ultrasound imaging to guide the intramuscular injections of botulinum toxin : Ultrasound is used to identify the target muscle, and for guiding the insertion of the needle in the muscle. Once the needle is positioned, the botulinum toxin is injected
1554519|NCT02566408|Other|Survey Questions|Complete survey
1554566|NCT02566044|Drug|QBW276|0.3 mg and 1.5 mg strengths
1554421|NCT02567201|Other|electrophysiological evaluation of patients|electrophysiological assessment (experience 1 : passive ; experience 2 : active versus passive ; experience 3 : active, with feedback) Experience 1 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 2 : maximum one session by sensory modality of stimulation (auditory, tactile, or visual) Experience 3 : Stimulation = auditory or visual ; possibility of several sessions if the patient is tired.
1554422|NCT02567188|Other|MIRCERA|
1554423|NCT02567175|Drug|Domperidone|
1554424|NCT02567149|Drug|Cidofovir|Cidofovir
1554425|NCT02567123|Behavioral|Experimental|
1554426|NCT02567097|Behavioral|Self-Incentive|Participants are asked to form plans to quit smoking using various descriptions specified dependent on the arm in which they are randomised.
1554427|NCT02567084|Device|"CERAMENT™ |BONE VOID FILLER"|Implantation of bi-phasic ceramic bone substitute to provide bone generation and bone remodeling in patients with benign bone tumors.
1554428|NCT02567071|Other|perineal impregnated swab|After planned C-section birth, newborns will suck on previously impregnated swab by perineal and vaginal mother secretions.
1554429|NCT02567071|Other|clean swab|After planned C-section birth, newborns will suck on clean swab.
1554430|NCT02567058|Device|Ultrasound exam|"Ultrasound exam with :
2 successions of 3 measures repeated for 2 visits (day 0 and day 21) for group I
1 succession of 3 measures repeated for 4 visits (day 0, day 14, day 45, day 90)for group II
1 succession of 3 measures for group III"
1554431|NCT02567058|Behavioral|IPAQ questionnaire|IPAQ questionnaire
1554432|NCT02567045|Procedure|annual FIT and colonoscopy in case of a positive test|FIT and colonoscopy in case of a positive test. Annual interval (2 rounds), without diet restriction, 1 stool sample. Positive cut-off 10 mcg Hemoglobin/g feces.
1554433|NCT02567045|Procedure|colonoscopy with sedation|One-time Colonoscopy with sedation.
1554434|NCT02567032|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
1554435|NCT02567032|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
1554436|NCT02567019|Other|blood samples|blood samples will be done for patients patients suffering of periodontal diseases and healthy volunteers
1554437|NCT02567006|Behavioral|SMS message|SMS messages will be delivered at 6, 4, and 2 days before the next scheduled date of the primary vaccines for the intervention group
1554438|NCT02567006|Other|Usual care|Health clinic nurse provides regular appointment in the vaccination card with no active reminders
1554444|NCT02566967|Drug|tofacitinib|oral tofacitinib will be taken 2 times daily
1554445|NCT02566954|Other|3D measurement of the lower limb by EOS|"The intervention is to performed an additional radiologic exam by the EOS® system of imaging. This imaging is not usually realized for the patient.
3 dimensional study of lower limbs and feet of children in standing position will be performed using the EOS® system (EOS® Imaging, France)"
1554446|NCT02566941|Device|Gymna Belgium, DUO 400 (Neuromuscular electrical stimulation)|
1554447|NCT02566928|Drug|2% mupirocin ointment|Index patients and consenting household members will complete a decolonization regimen consisting of twice-daily application of mupirocin ointment to the anterior nares with a sterile cotton applicator for five days.
1554448|NCT02566928|Other|Chlorhexidine wash|Index patients and consenting household members will daily daily for five days with chlorhexidine wash.
1554449|NCT02566928|Behavioral|Hygiene protocol|Index patients and consenting household members will be given educational materials and instructed to in the use of hand-washing, surface disinfection, and laundering.
1554450|NCT02566915|Device|CPET submaximal with EPAP|The expiratory positive pressure is applied through silicone mask (RHDSON Vital Signs®, New Jersey, USA) containing one-way valve and a resistance mechanism expiratory positive expiratory pressure generator adjustable 5-20 cm H2O (Spring Loaded) (Vital Signs® , New Jersey, USA). The mask one headgear will be comfortably adjusted to face being used to prevent air leakage, and the pressure level gradually adjusted to the level of 10 cm H2O.
1554451|NCT02566902|Device|T-Piece Nebulizer|Albuterol treatment administered with Hudson RCI® Micro Mist® nebulizer (Teleflex Medical®, Research Triangle Park, NJ)
1554452|NCT02566902|Device|Breath-Enhanced Nebulizer|Albuterol treatment administered with NebuTech® HDN®, Breath-Enhanced High Density Jet Nebulizer (Salter Labs®, Arvin, CA)
1554453|NCT02566902|Drug|Albuterol|One time 5mg nebulized albuterol treatment given with one of two devices over 10 minutes.
1554454|NCT02566902|Procedure|Pre-Treatment Spirometry Measurement|Bedside spirometry measurements taken prior to albuterol therapy using ndd® EasyOne Plus® spirometer.
1554455|NCT02566902|Procedure|Post-Treatment Spirometry Measurement|Bedside spirometry measurements taken after albuterol therapy using ndd® EasyOne Plus® spirometer.
1554457|NCT02566876|Drug|Mixture of three Bifidobacteria|This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 70 children with FD or IBS and will be articulated in 16 weeks as follows. Fifty-nine children (median age 11.2 years, range 5.2-17.9) with IBS and FD were randomized to receive either a mixture of three Bifidobacteria or a placebo for 6 weeks. At the end, after a 2-week-''washout'' period, each patient was switched to the other group and followed for 6 further weeks. At baseline and at follow-up, patients and/or their parents completed a dairy for bowel habit and gastrointestinal symptoms, and a quality of life (QoL) questionnaire.
1554458|NCT02566863|Drug|Dexmedetomidine|1 mcg/kg over 10 minutes, followed by a maintenance infusion titrated to achieve desired clinical effect - Richmond Agitation Scale between 0 and (-) 3. Holter ECG recording before start of infusion and during infusion for 25 minutes.
1554459|NCT02566850|Device|Ekso|powered lower extremity exoskeleton
1554513|NCT02566447|Device|Solana Trichomonas Assay Testing|Specimen collection of urine and/or vaginal swabs for testing
1554520|NCT02566395|Radiation|Radiation|1,200 cGy, delivered in 8 fractions of 150 cGy bid x 4 days
1554461|NCT02566837|Procedure|electrical stimulation|electrical stimulation (reference technique currently recommended over muscle palpation and anatomical landmarks) to guide intramuscular injections of botulinum toxin. Intramuscular injection is carried out in register with the zone where is located the theoretically target muscle. Electrical stimulation (mediated by the tip of the needle) used to verify the correct position of the needle, and reposition it if necessary. Once the needle is correctly positioned, the botulinum toxin is injected.
1554462|NCT02566824|Behavioral|Cognitive Behavioural & Skills Training|This will be administered in groups of 10 participants in 12 sessions each lasting 1.5 hours. Each session will focus on a new topic- Modules will be introduced via role play illustrating the topic, followed by Q&A. Strategies will be introduced to address the problems illustrated. Adolescents will practice using these strategies via planned activities or games. Obstacles to applying the skills in everyday life will be discussed and a physical reminder will be provided for each skill. A homework activity will be assigned to help participants practice the skill during the week. Each session will begin with homework review. Adolescents will also receive individual telephone coaching twice a week during the 12 weeks, which will taper off during the follow-up phase. Parents will also attend their own support group.
1554463|NCT02566824|Behavioral|Supportive Group Therapy|This will be administered in groups of 10 participants in 12 sessions each session lasting 1.5 hours. During the initial session group members will be asked to identify a specific goal to address during the program. Each session will review the previous week's events (challenges and positive accomplishments) and psychoeducation on a topic relating to ADHD (topics will be elicited from group members at the outset of each session). Adolescents will also receive a telephone coaching at the same frequency as the CBT+S group participants. These phone calls will deal with issues a given participant had raised in the preceding session, and the approach will emphasize support and unconditional positive regard. Parents will also attend their own support group.
1554464|NCT02566824|Other|Treatment as Usual - community resources|The treatment as usual group reflects what patients currently receive in the community (mainly medication). Participants will be stabilized on optimal medication (if they choose to be on medication) and referred back to the community for follow-up. Participants are free to seek out any additional interventions that they feel are required. These participants will be evaluated at the same intervals as the two therapy groups. They will receive a follow-up phone call from the study coordinator at two-month intervals in-between evaluation points. If participants indicate during the phone call that they require services, they will be referred to services in the community.
1554465|NCT02566824|Drug|Methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Participants, parents and teachers complete ADHD symptom scales at baseline and before each medication visit. They will also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the participants remain on this dose for the remainder of the study.
1554466|NCT02566811|Procedure|Abdominal surgery|Hysterectomy defined as an extrafascial hysterectomy whereby the cervix is removed completely but no radical dissection of the parametria is required
1554467|NCT02566811|Procedure|Lymphadenectomy|Bilateral pelvic and para-aortic lymph node dissection
1554468|NCT02566798|Drug|Extract of grape and olive|"Patients are taking capsules of OleograpeSEED 3 times a day (1mg/day) in the morning, at noon and in the evening during 7 days.
Blood samples and synovial fluid are performed on D0 and D7"
1554469|NCT02566798|Drug|Lactose|"Patients are taking capsules of placebo 3 times a day in the morning, at noon and in the evening during 7 days.
Blood samples and synovial fluid are performed on D0 and D7"
1554471|NCT02566772|Drug|TAS3681|TAS3681 will be provided as 25 mg and 100 mg tablets to be administered QD orally for 28 days, at least 1 hour before or 2 hours after a meal. Number of cycles: approximately 6 or until discontinuation criteria is met.
1554474|NCT02566746|Device|Chait Trapdoor caecostomie catheter|implantation of the Chait Trapdoor caecostomie catheter
1554475|NCT02566746|Drug|continuation of optimal medical therapy|continuation of treatment with laxative and / or suppositories and / or enemas retrograde
1554476|NCT02566733|Drug|Remiva|Target controlled infusion of remifentanil (generic drug, Remiva™)
1554477|NCT02566733|Drug|Ultiva|Target controlled infusion of remifentanil (brand-named drug, Ultiva™)
1554478|NCT02566720|Drug|Amantadine|Participants will initially receive amantadine at the starting dose of 50mg twice daily either by mouth or feeding tube. The dosage will increase every week by 50mg twice daily (100mg total dose increase) up to the target dose of 200mg twice daily. These are the usual doses and rate of increase that are offered to patients with brain injury.
1554479|NCT02566720|Procedure|MRI Tractography Study|Participants will initially receive a baseline MRI Tractography scan. The size of RAS fiber tracts will be measured prior to initiating treatment and near the time of discharge from the rehabilitation hospital or at approximately ninety-days.
1554480|NCT02566707|Drug|Atazanavir|HIV therapy will be adapted: atazanavir 400mg QD
1554481|NCT02566707|Drug|Dolutegravir|HIV therapy will be adapted: dolutegravir 50mg QD
1554482|NCT02566707|Drug|Lamivudine|HIV therapy will be adapted: lamivudine 300mg QD
1554483|NCT02566694|Procedure|Implant|orthopaedic implant
1554514|NCT02566434|Dietary Supplement|methionine|4 weeks intervention and 2 to 4 weeks washout in healthy volunteers with free methionine at 10 mg/kg body weight/day (=requirement), 25 mg/kg body weight/day, 50 mg/kg body weight/day and 100 mg/kg body weight/day.
1554515|NCT02566421|Other|Laboratory Biomarker Analysis|Correlative studies
1554516|NCT02566421|Other|Quality-of-Life Assessment|Ancillary studies
1554517|NCT02566421|Other|Targeted Therapy|Receive treatment based on genomic sequencing
1554518|NCT02566408|Other|One-on-one interview|Undergo one-on-one interview about KAPs towards PA
1554565|NCT02566044|Other|Placebo|Placebo
1554484|NCT02566681|Biological|MSC construct for Osteonecrosis|"30 days before implanting the construct made with MSC + TP + DBM, bone marrow of patients diagnosed with osteonecrosis of the jaw included in the clinical trial is obtained. The bone marrow will be obtained according to standard practice for Hematologists of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).
Mononuclear bone marrow cells were separated and cultured in GMP conditions (Good Manufacturing Practices). The cells are seeded on tricalcium phosphate and maintained in culture for 14 days.
The day when the implant is performed, the patient is prepared in the operating room. The area where the implant will be placed is cleaned. Mesenchymal cells seeded in tricalcium phosphate are mixed with demineralized bone matrix and It's coagulated with autologous platelet rich plasma and grafting is performed. Finally, the oral mucosa or skin will be sealingly closed by silk sutures."
1554485|NCT02566668|Other|1 year Observational Follow-up|Approximately 12 months after research bronchoscopy, subjects will return for follow-up visit.
1554486|NCT02566655|Biological|Fucosylated MSC for Osteoporosis|"Aproximately 30 days before the infusion of the investigational product, patient bone marrow will be obtained according to standard practice of the Haematology University Hospital Virgen de la Arrixaca (HCUVA).
Mononuclear bone marrow cells will be separated and cultured in GMP conditions to purify and obtain mesenchymal cell established dose range. The infusion day BM-MSCs will be fucosylated and resuspended in saline to a concentration of 5 million cells per 1 mL. Then, the final product will be packaged in syringes for intravenous administration to patients through a peripheral venous access."
1554487|NCT02566642|Other|educational material|pts coming to preadmission testing will view self administered tutorial on the role of anesthesiologist
1554488|NCT02566629|Other|collect faeces from participants|analyze the fecal microbiota community using 16S rDNA detection technique
1554489|NCT02566616|Device|Ulnar Nerve Stimulation|1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
1554490|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation after start of infusion.
1554491|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation after start of infusion.
1554492|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
1554493|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
1554494|NCT02566603|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation after start of infusion.
1554495|NCT02566590|Device|NMES|device is used to stimulate muscle contraction in the legs of the patient. The intervention will be used 3 times a day during bed rest.
1554496|NCT02566590|Dietary Supplement|Protein|supplement will used to enhance muscle anabolism. The intervention will be provided 3 times a day during bed rest.
1554497|NCT02566590|Dietary Supplement|non-protein placebo supplement|supplement will be used as a placebo to control participants. The supplement will be provided 3x a day during bed rest.
1554498|NCT02566577|Biological|Fresh red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from fresh (<10 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
1554499|NCT02566577|Biological|Storage-aged red blood cell (RBC) transfusion|1 or 2 cross-matched, packed red blood cells (RBC) units from storage-aged (>21 days old) blood, as ordered by the attending physician, will be given as an intravenous infusion via a programmable electronic infusion pump (Baxter, Inc) over a period of 1 hour per unit.
1554500|NCT02566577|Device|Electronic infusion pump|A programmable, electronic infusion pump (Baxter, Inc) will be used for intravenous transfusion of units of packed red blood cells (RBC). The pump will be programmed to deliver 1 unit of packed RBC per hour.
1554501|NCT02566564|Drug|Lopain|intra-articular injection
1554502|NCT02566551|Procedure|PAE|Embolization of the prostate with gelatin embolization spheres via microcatheterization of the prostatic arteries.
1554503|NCT02566551|Device|Gelatin microspheres|Gelatin embolization microspheres (300-500 microns) will be used as embolic material for the prostatic artery embolization (PAE) protocol
1554504|NCT02566551|Procedure|TURP|Bipolar transurethral resection of the prostate
1554505|NCT02566551|Device|Bipolar electrosurgery generator|A bipolar electrosurgery generator will be used to perform transurethral resection of the prostate (TURP)
1554506|NCT02566525|Device|CytoSorb|Cytosorb device use during cardiopulmonary bypass
1554510|NCT02566486|Device|Reciprocating system|Different root canal instrumentation systems
1554511|NCT02566486|Device|Rotational system|Different root canal instrumentation systems
1554512|NCT02566460|Other|Resuscitation|First, either crystalloid or colloid could be given to achieve a CVP of 8 to 12 mm Hg. Second, if the mean arterial pressure (MAP) was less than 65 mm Hg, norepinephrine was administrated to maintain MAP ≥65 mm Hg. If the mean arterial pressure was higher than 90 mm Hg, vasodilators were given until it was 90 mm Hg or below. Finally, SCVO2 or lactate clearance will be checked to determine red blood cells transfused or not to achieve a haematocrit of at least 30%. If ScvO2 or lactate clearance remains unmet target value, dobutamine could be used in the treatment.
1554521|NCT02566395|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg IV daily x 2 consecutive days
1554522|NCT02566395|Biological|Donor Lymphocyte Infusion (DLI)|DLI containing 1 x 10E8/kg donor T-cells
1554523|NCT02566395|Biological|Haploidentical Stem Cell Transplantation|2-10 x 10E6/kg donor CD34+ selected cells
1554525|NCT02566369|Drug|CD5789 50μg/g cream|CD5789 50µg/g cream applied once daily for 12 weeks.
1554526|NCT02566369|Drug|Placebo cream|Placebo cream applied once daily for 12 weeks
1554527|NCT02566356|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
1554528|NCT02566356|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
1554529|NCT02566330|Device|EndoBarrier|The device is a 60-cm long, impermeable plastic sleeve that is open at both sides so food can pass through. The sleeve is anchored in the duodenal bulb and extends partially into the jejunum. This way the pancreatic and bile juices will only mix with the food after the sleeve, hereby creating a functional bypass of the duodenum and the proximal jejunum, which causes malabsorption of nutrients.
1554530|NCT02566317|Device|Sit-Stand workstation|Installation of a sit-stand desk at work
1554531|NCT02566317|Behavioral|Move|A multi-level individual, social, environmental, and organizational intervention targeting increases in light-intensity physical activity in the workplace
1554540|NCT02566291|Device|Success|Success rate and time for insertion
1554541|NCT02566278|Other|Upper airway collapsibility (Pcrit)|To measure passive Pcrit, patients sleep with a mask over their nose or nose and mouth, and CPAP is applied using a custom made machine that can rapidly change mask pressures in research setting. The idea is that rapid changes in airway pressure produce a clear step change in airflow that will be observed quickly. In contrast, during clinical titrations, the CPAP machines change pressure much more slowly to help promote patient comfort. Passive Pcrit will be measured using both research and clinical equipment in the same patients and the Pcrit result using clinical CPAP titration equipment will be compared to the gold standard: Pcrit measurement done through research equipment that changes CPAP pressure rapidly.
1554542|NCT02566265|Biological|Fluzone High Dose Vaccine|
1554543|NCT02566265|Biological|Standard of care/Placebo|
1554544|NCT02566252|Drug|PUL-042 Inhalation Solution|PUL-042
1554545|NCT02566252|Drug|Cromolyn Sodium|Pre-treatment
1554546|NCT02566252|Drug|Albuterol sulfate|Pre-treatment
1554547|NCT02566239|Other|Share activity data with care team|Share participant in-home activity data with retirement community care team.
1554548|NCT02566226|Drug|Bupivacaine with normal saline|Isobaric bupivacaine 15 mg + normal saline 0.5 cc
1554549|NCT02566226|Drug|Bupivacaine with intrathecal morphine|Isobaric bupivacaine 15 mg + intrathecal morphine 100 mcg
1554550|NCT02566213|Other|Parabolic flight|
1554551|NCT02566213|Other|Motor skills measurements|"the kinematics measurements of the right hand with a motion analysis system;
the measurements of forces applied by the hand on the object to be grasped and moved with a 6 degree of freedom force sensor;
the measurement of position of the moved object with an inductive position encoder."
1554552|NCT02566187|Drug|Fimasartan/Atorvastatin Combination Tablet|
1554553|NCT02566187|Drug|Fimasartan|
1554554|NCT02566187|Drug|Atorvastatin|
1554557|NCT02566122|Other|measurements|
1554558|NCT02566109|Other|Fast MRI and Questionnaires|"The Self-Reported questionnaires are a collection of well-validated, brief, fee-free instruments assessing key patient reported outcomes related to this study. For this study, we are using the short forms for quality of life. The total administration time for these questionnaires is 5 minutes.
Self-Report questionnaires will be obtained monthly. As part of this study, an additional measurement of ultrasensitive Troponin I will be collected at 2-months, as well as, a Fast MRI and 3D ECHO."
1554559|NCT02566096|Drug|transversus abdominis-plane block with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine|compare the analgesic efficacy of transversus abdominis-plane block with bupivicaine with morphine in patients undergoing major abdominal cancer surgery.
1554560|NCT02566083|Device|non-toric intraocular lens|TECNIS One-piece Monofocal Model ZCB00
1554561|NCT02566083|Device|toric intraocular lens|TECNIS One-piece Toric Models ZCT300 or ZCT400
1554562|NCT02566070|Other|Continuous Gastric Feeding|
1554563|NCT02566070|Other|Bolus Gastric Feeding|
1554564|NCT02566057|Biological|PGx testing guided treatment (PGT)|Genecept Assay (GeneceptTM Assay) will provide information on genotypes of genetic variants that are relevant to psychiatric drug response. The provider can use the information to decide on which psychotropic drugs to use.
1989924|NCT02318927|Device|Deep Brain Stimulation|Deep Brain Stimulation (DBS) of Globus Pallidum plus Pedunculopontine Nucleus, including lead implant and battery placement. Magnetic Resonance Imaging and Computed Tomography (CT) scan will be obtained prior to implant. Measurement of number of Freezing of Gait (FoG) episodes during a FoG test at a lab. Other measures include freezing of gait questionnaire, gait and falls questionnaire, activities/balance confidence scale, Parkinson's disease quality of life questionnaire, Unified Parkinson's Disease Rating Scale physiology collection and sensor testing, adverse event recording, falls diaries, tracking use of assistive devices, gait and balance testing, and neuropsychological, neurosurgical, neurological, and physical exams.
1554567|NCT02566031|Drug|Indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI
1554568|NCT02566031|Drug|Tiotropium|Capsules for inhalation delivered via HandiHaler® device
1554569|NCT02566018|Procedure|treatment/medical device|The new treatment algorithm was applied to all patients with proximal humerus fracture as from May 2013 onwards
1554570|NCT02566018|Procedure|standard|The old treatment algorithm was applied to all patients with proximal humerus fracture up to May 2013.
1554571|NCT02566005|Device|misoprostol|25mcg of misoprostol per vagina every 4hours per the standard hospital protocol. Once the cervix becomes favorable or if the patient is in active labor, or if there is no progress for 24 hours, misoprostol administration will be discontinued. Further management of labor will depend on the labor team. (25mcg tablets are not available commercially; a 100mcg table is cut into fourths by the hospital pharmacist).
1554572|NCT02566005|Device|Foley bulb|a foley bulb will be inserted digitally or by direct visualization with the use of a sterile speculum. The foley will be inserted through the internal os and filled with 60cc of normal saline. The catheter will be taped to the patient's inner thigh under gentle traction. When the foley bulb has fallen out (spontaneous expulsion), further management of labor depends on the labor team. If this does not occur, the catheter will be deflated and removed after 24 hours.
1554573|NCT02565992|Biological|CAVATAK|Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.
1554574|NCT02565992|Drug|Pembrolizumab|Intravenous pembrolizumab at 2 mg/kg solution.
1554577|NCT02565966|Other|Modified Atkins Diet (MAD)|For those in the MAD intervention group, the dietitian trains the patient and family in the preparation and management of this specialized therapy including sick-day guidelines, meal planning, carbohydrate counting and trouble-shooting. Written and verbal education including, but not limited to: recipes, education materials, sample meal plans and carbohydrate counters are provided to the patient during the initial education session. The caregiver/patient is trained in the outpatient setting and the diet is implemented at home with as much email/phone support from the dietician and ketogenic team as the patient needs to successfully maintain the diet. Medications are all changed over to the lowest carbohydrate forms to eliminate excess carbohydrate intake and all patients are started on vitamin supplements to maintain adequate nutrition.
1554578|NCT02565953|Device|Paclitaxel-releasing PTA balloon catheter|
1554579|NCT02565953|Device|PTA balloon catheter|
1554580|NCT02565940|Other|biopsy|
1554581|NCT02565927|Device|Traditional airway stent|process airway stenting
1554582|NCT02565927|Drug|Iodine-125 seeds|process intraluminal brachytherapy
1554583|NCT02565914|Drug|VX-661/ivacaftor|
1554584|NCT02565914|Drug|ivacaftor|
1554585|NCT02565901|Drug|Carboplatin|Given IV
1554586|NCT02565901|Drug|Docetaxel|Given IV
1554587|NCT02565901|Other|Laboratory Biomarker Analysis|Correlative studies
1554588|NCT02565901|Drug|Sirolimus|Given PO
1554589|NCT02565888|Drug|Daclatasvir|
1554590|NCT02565888|Drug|Atazanavir|
1554591|NCT02565888|Drug|Ritonavir|
1554592|NCT02565888|Drug|Cobicistat|
1554593|NCT02565875|Behavioral|SLL Presentation|Educational presentation on the use of a standardized lexicon for communication between surgeon and assistant during laparoscopy
1554594|NCT02565875|Behavioral|Control Presentation|Educational presentation on relevant anatomy related to laparoscopy performed by a gynecologic surgeon.
1554595|NCT02565875|Other|Simulated laparoscopic task|Using a low-fidelity pelvis simulator and laparoscopic instruments, pairs of each arm will be asked to perform a laparoscopic task (maneuver a ball into a nylon surgical bag). Use of SLL will be tabulated and task will be timed.
1554596|NCT02565862|Drug|Daclatasvir|
1554597|NCT02565862|Drug|Metformin|
1554600|NCT02565823|Other|Exercise bout|Participants will exercise for 45min at 75% of VO2peak
1554601|NCT02565810|Drug|Adalimumab PFS and Pen|
1554602|NCT02565797|Device|DabirAIR alternating pressure overlay|DabirAIR alternating pressure overlay is a dynamic support surface that is placed on top a mattress. The DabirAIR overlay provides periodic pressure relief through the alternate inflation and deflation of air cells.
1554603|NCT02565784|Device|Restylane|Facial tissue augmentation
1554604|NCT02565784|Device|Perlane|Facial tissue augmentation
1554605|NCT02565771|Other|Adapted physical activity|The adapted physical activity is done by Education Physique et Gymnastique Volontaire (EPGV) centres.
1554606|NCT02565758|Drug|ABBV-085|Administered as an intravenous infusion in 28-day dosing cycles.
1554607|NCT02565758|Drug|Nivolumab|It is an intravenous infusion administered every 14 days.
1554608|NCT02565758|Drug|Gemcitabine|It is an intravenous infusion administered on day 1, 8 and 15 of a 28-day cycle.
1554609|NCT02565758|Drug|nab-paclitaxel|It is an intravenous infusion administered on day 1, 8 and 15 of a 28-day cycle.
1554610|NCT02565745|Combination Product|Skin dressing|Pre-determined skin areas at risk for PUs (3 or more, depending on the prevaliing body position, prone, supine or Sims') will be covered. Dressings will be changed every 6-7 days unless found wet/contaminated
1554611|NCT02565745|Other|Moisturizing cream|It will be applied twice a day to the same skin areas as the experimental group
1554612|NCT02565732|Biological|Botulinum toxin type A|Botulinum toxin type A, Dose A, Topical
1554613|NCT02565732|Biological|Botulinum toxin type A|Botulinum toxin type A, Dose B, Topical
1554614|NCT02565732|Biological|Placebo comparator|Placebo, Dose C, Topical
1554615|NCT02565719|Drug|REP 2139-Mg|REP 2139-Mg = magnesium chelate complex of REP 2139
1554616|NCT02565719|Drug|Pegasys|immunotherapy
1554617|NCT02565719|Drug|Viread|HBV RT polymerase inhibitor
1554618|NCT02565719|Drug|REP 2165-Mg|REP 2165-Mg = magnesium chelate complex of REP 2165
1554619|NCT02565706|Behavioral|WIC Fresh Start Program|The intervention is an online lesson to promote farmers' market FV purchases and consumption. The lesson comprises three modules, each consisting of 1) behavior change content presented through a video segment featuring WIC participants, and 2) an interactive activity to build targeted knowledge, attitudes, and skills.
1554620|NCT02565706|Behavioral|Existing Online Health Education|Any of seven existing online WIC health education lessons (lessons are available on breastfeeding, being active, fruits and vegetables, calcium, cholesterol, oral health and iron). The lessons consist of an introductory segment presented with online text and graphics. After reading this material, viewers have the option to complete one of four lesson activities. The activities provide opportunities for viewers to read further on the topic and are designed to reinforce key points of the lesson.
1554621|NCT02565693|Drug|Apixaban|
1554622|NCT02565693|Drug|Aspirin|
1554623|NCT02565693|Drug|Carbasalate calcium|
1554624|NCT02565693|Drug|Clopidogrel|
1554625|NCT02565693|Drug|Dipyridamole|
1554626|NCT02565693|Other|No antithrombotic treatment|
1554627|NCT02565680|Drug|placebo|Xyzall 5mg during 5 days + placebo 40mg during 4 days
1554628|NCT02565680|Drug|prednisone|Xyzall 5mg during 5 days + prednisone 40mg during 4 days
1554629|NCT02565667|Device|KOL|KOL staple was used for rectal anastomosis
1554630|NCT02565667|Device|traditional staple|traditional staple was used for rectal anastomosis
1554631|NCT02565641|Drug|Capecitabine|Capecitabine will be administered orally at 830 mg/m^2 BID (equivalent to a total daily dose of 1660 mg/m^2) as intermittent treatment (given days 1 to 21 q4w).
1554632|NCT02565641|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 mg/m^2 once weekly via IV infusion as intermittent treatment (repeated 4-week cycles of 3 weeks treatment and 1 week rest).
1554633|NCT02565628|Drug|PF-06669571|1 milligram (mg) QD for 3 days followed by 3 mg QD for 4 days
1554634|NCT02565628|Drug|Placebo|Placebo
1554636|NCT02565602|Other|Ca-41(isotope tracer)|Ca-41 is given orally in the form of (Ca-41)Cl3 in citrate-buffered solution. Tracer will be used to determine parameters of calcium metabolism based on tracer excretion data.
1554637|NCT02565602|Other|Sr-84 (isotope tracer)|Sr-84 is given orally in the form of (Sr-84)Cl2 in aqueous solution.Tracer will be used to determine parameters of strontium metabolism based on tracer excretion data.
1554638|NCT02565602|Dietary Supplement|Vitamin D|One tablet daily (400IU per tablet)
1554639|NCT02565576|Drug|Placebo|
1554640|NCT02565576|Drug|CFZ533|
1554641|NCT02565563|Other|Eye Movement Desensitisation Reprocessing|The purpose of this study is not to assess the device itself. The new device will seek to measure heart rate variabilty during the administration of the treatment EMDR. It will measure the patients sympathetic nervous systems (anxiety arousal). Previous reseach studies have used Electrocardiography (ECG) and the purpose of this study is to determine whether or not this device will obtain similar findings as ECG has done.
1554642|NCT02565563|Device|HeartMath measuring Heart Rate Variability (HRV)|This small device will be attached to the patients finger to allow their heart rate variability to be measured.
1554643|NCT02565550|Dietary Supplement|low FODMAPs|low FODMAPs means excluding food which contains oligosaccharides.disaccharides,monosaccharides, and polyols
1554644|NCT02565537|Procedure|LASIK|WFG vs. WFO LASIK
1554645|NCT02565524|Other|genetic and phenotypic profile|Genetic and phenotypic profile, clinical and neurocognitive assessment for child with Schizophrenia and autism, their parents and brotherhood
1554650|NCT02565498|Radiation|Preoperative intensity modulated radiation therapy|50 Gy delivered in 25 fractions 4-6 weeks prior to surgical excision
1554651|NCT02565498|Radiation|Postoperative intensity modulated radiation therapy|Surgery followed by 50 Gy delivered in 25 fractions within 6 weeks of surgery for patients with negative margins; for patients with positive margins a boost of 16 Gy in 8 fractions will be added.
1554652|NCT02565485|Drug|Lactated Ringer's|IV Fluid (crystalloid) used for preload prior to epidural adminstration
1554653|NCT02565472|Other|White grape juice|
1554654|NCT02565472|Other|Apple juice|
1554655|NCT02565459|Biological|Mesenchymal Stromal Cells|
1554658|NCT02565433|Other|questionnaire administration|Within 15 days before radiosurgery and then at 3, 6, 9, 12 months after radiosurgery, the patients who have accepted to participate will have to complete these questionnaires : QLQC30, BN20, IADL, HADS, MoCa, Edmonton Symptom Assessment Scale
1554659|NCT02565420|Other|Normal saline|Patients will be administered normal saline for intraoperative fluid management.
1554660|NCT02565420|Other|Lactated Ringer's solution|Patients will be administered Lactated Ringer's solution for intraoperative fluid management.
1554771|NCT02564536|Drug|Pacritinib|-Patients should take pacritinib at approximately the same times every day with a glass of water, with or without food.
1554661|NCT02565407|Behavioral|Proprioceptive training|Training includes a virtual balance board and center-out task. Small vibratory motors placed on forearms provide vibro-tactile movement feedback (VTF). During familiarization participants learn to associate VTF with wrist movement and visual feedback. Vision is occluded after this phase. In the virtual balance board task participants use wrist motion to roll a ball to a target on the board. VTF indicates the desired movement direction and ball velocity. The center-out task involves wrist motion to control a cursor to reach a target. The wrist robot delivers an assistive force towards the target. VTF signals magnitude and direction of the cursor deviating away from the desired path.
1554662|NCT02565407|Behavioral|Usual care|Usual care refers to care that participants receive through their healthcare providers. It may range from no treatment to various sessions of occupational and physical therapy received at in- or outpatient rehabilitation clinics or at home.
1554663|NCT02565394|Other|Micro Break with Dynamic Exercise Activities|Surgeons may elect to activate a web application (video) and perform targeted intraoperative exercises.
1554664|NCT02565381|Drug|Transdermal nicotine patch|"≥10 cigarettes per day: nicotine 21mg/24hr patch daily x 6 weeks, then nicotine 14mg/24hr patch daily x 2 weeks
<10 cigarettes per day: nicotine 14mg/24hr patch daily x 8 weeks"
1554665|NCT02565381|Behavioral|In-person smoking cessation counseling|- One-on-one 15-minute counseling sessions once per week for 8 weeks
1554666|NCT02565381|Behavioral|Contingent financial rewards for smoking abstinence|- Escalating-value financial rewards for smoking abstinence, verified by exhaled carbon monoxide <8ppm
1554667|NCT02565381|Behavioral|Text messages to support smoking abstinence|- 1-5 text messages per day starting up to 2 weeks before the quit date and continuing until 6 weeks after the quit date, delivered by SmokefreeTXT
1554668|NCT02565368|Drug|Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg|single oral administration
1554669|NCT02565368|Drug|CKD-395 0.5/1000mg|single oral administration
1554670|NCT02565355|Other|Dietary Exclusion|The IgG antibody results will be disclosed ONLY to the patients in the lifestyle modification group by phone approximately one week after clinic visit.. 'Dietary Exclusion' will be advised by a dietitian. Patients are advised to eliminate a maximum of two foods as identified by high IgG antibody titres.
1554671|NCT02565355|Other|Standard Treatment|The standard therapy group will receive conventional treatment for Abdominal Pain as per usual practice at the Pediatric GI (PG) Clinic - counseling, reassurance, improving coping strategies and pain relievers as appropriate.
1554672|NCT02565342|Procedure|Interscalene brachial plexus block|
1554673|NCT02565316|Drug|Nepeta menthoides Boiss & Bohse freeze dried extract|
1554674|NCT02565316|Drug|Sertraline|
1554675|NCT02565303|Procedure|Intervertebral space|
1554676|NCT02565303|Drug|Ropivacaine|The initial dose of ropivacaine is chosen as 12 mg in L2-3 group and 15 mg in L3-4 group with the volume of 3 mL in both groups. The testing interval is 0.5 mg with subsequent doses being determined by the outcome of the previous injection in the same group.If the previous response is ineffective, the next patient will receive 0.5 mg more than the last patient. If the response of the previous patient is effective, the next patient decrease 0.5mg.
1554677|NCT02565290|Dietary Supplement|Omega 3|Pregnant women should take 2 capsules of omega 3 (1g), 2 times a day, for 21 days.
1554678|NCT02565290|Dietary Supplement|Soy Oil|Pregnant women should take 2 capsules of placebo 3 - soy oil oil (1g), 2 times a day, for 21 days.
1554679|NCT02565277|Biological|Influenza Vaccine|
1554680|NCT02565277|Drug|Placebo|
1554681|NCT02565264|Other|plasma-derived exosomes|Plasma samples from the participants will be filtered through 0.45 μm and 0.20 μm filters. The samples will be filtered through 0.02 μm filter to trap exosomes with the filter. Saline solution will be loaded from the other side of the 0.02 μm filter to obtain exosome rich buffer. The plasma-derived exosomes will be applied to the participants' ulcers daily for 28 days.
1554682|NCT02565251|Device|Flotrac/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with Flotrac/Ev1000 device in the first two hours
1554683|NCT02565251|Device|Standard ICU monitorisation|Hemodynamic resusucitation guided by the data obtained from ICU standard hemodynamic monitoring (BP, CVP) in the first 2 hours
1554684|NCT02565251|Device|VolumeView/Ev1000|Hemodynamic resusucitation guided by the data obtained from the monitorisation with VolumeView/Ev1000 device in the next four hours
1554685|NCT02565238|Device|BioMonitor 2|Implantation of BioMonitor 2
1554686|NCT02565225|Behavioral|RheumaLive App use|
1554687|NCT02565212|Drug|Montelukast,mometazon froat|
1554688|NCT02565199|Device|rTMS over Premotor Cortex (Contralateral Hemisphere)|"Location of rTMS: premotor cortex
Frequency of rTMS: 0.1 Hz
Time of rTMS: 50 milliseconds before the onset of movement-related EMG
Device: MagStim Super Rapid 2 Transcranial Magnetic Stimulator"
1554689|NCT02565199|Device|rTMS over Premotor Cortex (Ipsilateral Hemisphere)|"Location of rTMS: premotor cortex
Frequency of rTMS: 0.1 Hz
Time of rTMS: 50 milliseconds before the onset of movement-related EMG
Device: Super Rapid 2 Transcranial Magnetic Stimulator"
1554690|NCT02565199|Device|rTMS (Control 1)|"Location of rTMS: premotor cortex
Frequency of rTMS: 0.1 Hz
Time of rTMS: 400 milliseconds after the onset of movement-related EMG
Device: Super Rapid 2 Transcranial Magnetic Stimulator"
1554691|NCT02565199|Device|rTMS (Control 2)|"Location of rTMS: somatosensory cortex
Frequency of rTMS: 0.1 Hz
Time of rTMS: 50 milliseconds before the onset of movement-related EMG
Device: Super Rapid 2 Transcranial Magnetic Stimulator"
1554692|NCT02565199|Device|rTMS (Control 3)|"Location of rTMS: premotor cortex
Frequency of rTMS: 0.1 Hz
Time of rTMS: 50 milliseconds before the onset of movement-related EMG
Device: Super Rapid 2 Transcranial Magnetic Stimulator with Sham Coil"
1554693|NCT02565199|Other|Motor Training|During motor training, participants will quickly extend their hand at a pace of one extension every 5 seconds (0.2Hz) in response to an auditory cue.
1554694|NCT02565186|Drug|lasmiditan 100 mg|oral tablet
1554695|NCT02565186|Drug|lasmiditan 200 mg|oral tablet
1554696|NCT02565173|Drug|trabodenoson 4.5% BID|Trabodenoson 4.5% administered twice per day in both eyes for 12 weeks.
1554697|NCT02565173|Drug|trabodenoson 6.0% QD|Trabodenoson 6.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
1554772|NCT02564536|Drug|Decitabine|-From commercial stock
1555390|NCT02560298|Drug|Fluorouracil|Given IV
1554698|NCT02565173|Drug|trabodenoson 3.0% QD|Trabodenoson 3.0% administered once per day in the morning in both eyes followed by matching placebo administered once per day in the evening in both eyes for 12 weeks.
1554699|NCT02565173|Drug|timolol 0.5% BID|Timolol 0.5% administered twice per day in both eyes for 12 weeks.
1554700|NCT02565173|Drug|placebo BID|Placebo administered twice per day in both eyes for 12 weeks.
1554701|NCT02565160|Procedure|Intra-articular aspiration of Joint|Procedural sampling of the joint for diagnostic purposes
1554702|NCT02565160|Procedure|Joint irrigation washout|Procedural washout for treatment purposes
1554703|NCT02565160|Procedure|Total Joint Arthroplasty|
1554704|NCT02565160|Procedure|Revision Joint Arthroplasty|
1554707|NCT02565134|Drug|PAC-14028 cream 0.1%|Topical application
1554708|NCT02565134|Drug|PAC-14028 cream 0.3%|Topical application
1554709|NCT02565134|Drug|PAC-14028 cream 1.0%|Topical application
1554710|NCT02565134|Drug|PAC-14028 cream vehicle|Topical application
1554711|NCT02565121|Drug|corticosteroids|
1554712|NCT02565121|Behavioral|olfactory stimulation|stimulation with odorants by sniffing 4 different odorants for a total of 5 minutes twice a day during 3 months
1554713|NCT02565108|Drug|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1554714|NCT02565108|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1554715|NCT02565095|Procedure|Stimulation of the carotid baroreceptors with a pressure system|In each decubitus, trains of stimuli 8 (-80, -60, -40, -20, 0, 10, 20 and 40 Torr), with a duration of 500 milliseconds each, will be applied using a positive and negative pressure system placed around the neck of the subject.
1554716|NCT02565082|Other|Blood sampling - healthy volunteers|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
1554717|NCT02565082|Other|Blood sampling - sickle cell patients arm - stable condition|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
1554718|NCT02565082|Other|Blood sampling - sickle cell patients arm- exsanguinotransfusion needed|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once, before and after the exsanguinotransfusion.
1554719|NCT02565082|Other|Blood sampling - sickle cell patients arm - vaso-occlusive crisis.|Four citrate blood sampling tubes (blue cap, 2.7ml) will be taken only once.
1554720|NCT02565069|Device|CartoFinder™ Device with CARTO® 3 System V5 Navigation|Ablation treatment
1554721|NCT02565056|Other|Self help book + telephone support|Self-help book based upon principles of Acceptance and Commitment Therapy
1554722|NCT02565017|Behavioral|Focus groups|After the presentation of the of IBM Watson Oncology at the opening of the focus group, participants will be asked to fill out a de-identified brief 15-item questionnaire to assess participants' first impressions of IBM Watson Oncology. The questionnaire will be self administered, and will take approximately 5 minutes to complete. Completed questionnaires will be collected by a member of the study staff, and the focus group will proceed with introductions. The focus group will be audio recorded from the completion of the introductions and notes will be taken. The focus group guide will address the study aims. At the end of the focus group, participants will complete a 7-item questionnaire to capture simple demographic information including education, income, and health literacy. This questionnaire will take 3-5 minutes to complete.
1554724|NCT02564965|Device|Double Pigtail Plastic Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
1554725|NCT02564965|Device|AXIOS Metal Stent|Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
1554726|NCT02564952|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1554727|NCT02564939|Drug|ramelteon|double-blind RCT
1554728|NCT02564939|Drug|Placebo|double-blind RCT
1554731|NCT02564913|Other|clinical evaluation|
1554733|NCT02564887|Device|Iowa Oral Performance Instrument|the IOPI device is being used to increase tongue strength and endurance
1554734|NCT02564874|Other|Discretionary calorie source|We are assigning participants randomly to either of two different sources of discretionary calories (savory snacks or sugary beverages)
1554735|NCT02564861|Drug|DS-1971a|DS 1971a is supplied as a powder or crystals and will be given as an oral suspension
1554736|NCT02564861|Drug|Placebo|Placebo matching DS-1971a suspension
1554737|NCT02564848|Procedure|Lumpectomy without sentinel node biopsy|Biopsy of the sentinel node is considered standard of care treatment for women with localized breast cancer. The procedure will be eliminated at time of lumpectomy.
1554738|NCT02564835|Other|Yoga|The yoga curriculum in this study is based is based on the Integral Yoga approach that includes branches of yoga associated with cognitive and immune benefits (Hatha, Raja). Within the Integral Yoga approach, physical poses, breathing techniques and mediation practices were chosen to provide benefits to the nervous system, immune system, musculoskeletal system and gastrointestinal system. Poses will be adapted to individual needs. The number of repetitions and/or length of hold will be increased through standard progression.
1555276|NCT02561130|Drug|insulin glargine|Dose is titrated to achieve fasting normoglycemia
1554739|NCT02564835|Other|Physical Activity|The physical activity intervention is based on the Exercise for People Living with Cancer program. The intervention will include nine resistance exercises (e.g. squats) and 8 flexibility exercises (e.g. shoulder stretch) targeted for the whole body as well as a brief warm up and cool down (walking). Exercises will be adapted to individual needs. The number of repetitions and/or length of hold will increase through standard progression.
1554740|NCT02564822|Procedure|Visual Stimulation|volunteers will be invited to sit in a comfortable chair, in a calm and dark room, at 90 cm of distance from computer screen. It will be asked to fix his right eye visual field on a red point at the center of the screen (the left one will be blindfolded). Visual stimuli will be a black and White grid pattern, alternating at a frequency of 3.1 Hz.
1554741|NCT02564809|Behavioral|Fit Brains Training|These hourly classes will consist of cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individuals aim to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
1554742|NCT02564809|Behavioral|Exercise + Fit Brains Training|These classes combine aerobic training and cognitive training. The classes will consist of a 15-minute walk prior to cognitive brain training (Fit Brains by Rosetta Stone) on a mobile device (tablet/iPad). Fit Brains offers 60+ different training games, each targeting one of five cognitive domains - executive functions, memory, concentration/attention, visual-spatial ability, and processing speed. Each game lasts exactly 60 seconds during which individual aims to answer as many questions correctly. The difficulty of the game increases after each correct answer. Each game has three level of difficulty: 1) novice; 2) intermediate; and 3) advanced.
1554743|NCT02564809|Behavioral|Balanced And Tone|These classes will consist of hourly sham training class, hourly classes of sham exercise (e.g., balance, stretching, range of motion), and hourly educational classes.
1554744|NCT02564796|Drug|Epoetin Alfa and Iron|Patients in the treatment group will receive weekly EPO injections and iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization) They will be followed for 14 weeks.
1554745|NCT02564796|Other|Control|Patients in the treatment group will not receive any extra intervention outside of standard of care. They will receive iron supplementation for 6 weeks starting before 8 weeks of age, 1 week after their first procedure (surgery or heart catheterization). They will be followed for 14 weeks.
1554746|NCT02564783|Other|No intervention|No intervention
1554750|NCT02564705|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|
1554751|NCT02564705|Procedure|Posterior Fusion|"Posterolateral Fusion (PLF)
Posterior Lumbar Interbody Fusion (PLIF)
Transforaminal Lumbar Interbody Fusion (TLIF)"
1554752|NCT02564679|Procedure|Laparoscopic Sleeve gastrectomy (LSG)|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.
They are treated with laparoscopic sleeve gastrectomy associated to lifestyle intervention. Concomitantly to surgical intervention, liver biopsy is performed.
At 6 and 12 months after LSG the patients are evaluated with laboratory, clinical and echographic assessment. Moreover, one year after LSG liver biopsy is repeated."
1554753|NCT02564679|Behavioral|Lifestyle Intervention|"These patients (no. 20) are assessed by clinical and psychological evaluation (auxological parameters, blood pressure and personal and family history), blood tests (liver function test's (LFT's), uric acid, lipid and gluco-insulinemic profile with oral glucose tolerance test (OGTT)), abdominal ultrasound at time of enrollment.
They are treated with lifestyle intervention. At 6 and 12 months after enrollment the patients are evaluated with laboratory, clinical and echographic assessment."
1554754|NCT02564666|Other|telephone counseling|regular telephone counseling for compliance and advese event
1554757|NCT02564640|Device|videolaryngoscope|patients intubated by using the videolaryngoscope
1554758|NCT02564640|Device|Macintosh laryngoscope|patients intubated by using the Macintosh laryngoscope
1554759|NCT02564627|Procedure|Self-applied patch|An ambulatory self-applied patch will be placed weekly by the patients for PENS of dermatome T6.
1554760|NCT02564627|Procedure|Conventional procedure|PENS of dermatome T6 will be applied by the MD in the Outpatient Clinic.
1554761|NCT02564627|Dietary Supplement|1200 Kcal/day diet|A 1200 Kcal/day diet will be prescribed.
1554762|NCT02564614|Drug|RO7070179|RO7070179 (13 mg/kg/week) will be administered as 2-hour IV infusion.
1554763|NCT02564601|Behavioral|Piano Training|The intervention focuses upon progressively difficult piano performance exercises (repertoire), technique, and finger dexterity exercises.
1554764|NCT02564601|Behavioral|Computer Cognitive Training|The intervention focuses upon progressively difficult perceptual exercises using the Brain Fitness program plus working memory exercises.
1554765|NCT02564588|Drug|Dasotraline|Dasotraline 4, 6, 8mg flexibly dosed once daily
1554766|NCT02564588|Drug|Placebo|Placebo once daily
1554767|NCT02564575|Biological|HPIV3-EbovZ GP Vaccine|Administered intranasally by a VaxINator device
1554768|NCT02564562|Drug|[14C] PF-06463922|Single oral dose of 100mg PF-06463922 + [14C] PF-06463922
1555391|NCT02560298|Other|Laboratory Biomarker Analysis|Correlative studies
1554773|NCT02564523|Biological|Ad26.ZEBOV|One 0.5 mL intramuscular (IM) injection of (5x10*10 viral particles)
1554774|NCT02564523|Biological|MVA-BN-Filo|One 0.5 mL IM injection of (1x10*8 infectious units)
1554775|NCT02564523|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline
1554776|NCT02564497|Biological|Process E Belatacept|
1554777|NCT02564497|Biological|Process C Belatacept|
1554778|NCT02564471|Drug|Chloroquine|FDA approve dosing schedule
1554779|NCT02564471|Drug|Atovaquone and Proguanil|FDA approve dosing schedule
1554780|NCT02564471|Drug|Doxycycline|FDA approve dosing schedule
1554781|NCT02564471|Biological|Rabies Vaccine|FDA approve dosing schedule
1554782|NCT02564458|Behavioral|Interval Exercise Training/Motivational Accelerometry|During the 5-12 weeks before allogeneic stem cell transplant, the patient will participate in an at home, interval exercise training (IET) program, as well as wear a physical activity tracker, the FitBit Surge, combined with a weekly motivational call, termed Motivational Accelerometry (MA). The combined intervention is referred to as (IET/MA). The first week of the IET program consists of the participants being asked to engage in 30 minutes of aerobic exercise at any intensity for 3-4 days. For weeks two and beyond, patients be asked to undergo 3-4 sessions of IET, consisting of a 5 minute warm-up and five 2-minute intervals, with the goal of reaching 80% MHR, separated by 3 minutes of recovery/light activity in between each interval. Each exercise session is a total of 30 minutes. In addition, each week prior to transplant, the patient will receive a weekly check-in/motivational call from the study staff in order to track progress and motivate the patient to continue participation.
1554783|NCT02564445|Behavioral|Gamification|All participants will be entered with their teammate into a game that includes points and levels
1554784|NCT02564445|Behavioral|Share Data with PCP|Weight and step count data will be shared with the participant's primary care physician
1554785|NCT02564445|Behavioral|Feedback on weight|Participants will use a wireless weight scale to weigh-in at home and receive feedback on weight.
1554786|NCT02564445|Behavioral|Feedback on step counts|Participants will use a smartphone application that uses accelerometers within the phone to track step counts and receive feedback on step counts
1554787|NCT02564419|Device|Medtronic Activa PC+S|Upon consent, the good candidates will undergo surgical screening that includes a full neurological workup and baseline functional assessment. Subjects that demonstrate feasibility for control will undergo surgery for unilateral implantation of the Activa PC+S as well as the implantation of unilateral subdural strip electrodes (Resume II, model 3587A) over the motor cortex. After 24 hour observation in the hospital, subjects will participate in 24 distinct sessions or visits of testing over a 3-6 month period. During these visits, the sensing, decoding of the implanted device (Activa PC+S) as well as the external stimulation components (Bioness H200) and parameters will be tested and benchmarked. Subjects will participate for 24 sessions and continue to participate in the study until the end of life of the device, at which point the subject may elect to undergo an explant at that time.
1554788|NCT02564406|Device|LOW FLOW EXTRACORPOREAL CO2 REMOVAL, PROLUNG ESTOR|
1554789|NCT02564380|Drug|Pembrolizumab|
1554790|NCT02564380|Drug|Placebo|
1554791|NCT02564367|Drug|S-1|"18 cycles S-1, orally administered twice daily D1-14, q 3 wks
S-1 starting dose: 2 x 30 mg/m^2 body surface area (BSA), D1-14, q 3 wks First dose reduction: 2 x 25 mg/m^2 BSA, D1-14, q 3 wks Second dose reduction: 2 x 20 mg/m^2 BSA, D1-14, q 3 wks"
1554792|NCT02564367|Drug|S-1|"9 cycles S-1, orally administered twice daily D1-28, q 6 wks
S-1 starting dose: 2 x 30 mg/ m^2 BSA, D1-28, q 6 wks First dose reduction: 2 x 25 mg/ m^2 BSA, D1-28, q 6 wks Second dose reduction: 2 x 20 mg/ m^2 BSA, D1-28, q 6 wks"
1554793|NCT02564354|Drug|QR-010|Single-stranded RNA antisense oligonucleotide in isoosmolar solution
1554794|NCT02564341|Behavioral|Collaboration with an IT enabled nurse care manager|The nurse care manager at each site will collaborate with intervention physicians to implement key essential elements of guideline driven care, namely opioid treatment agreements, urine drug testing, random pill counts and periodic checking of on-line Prescription Monitoring Programs. The nurse care manager will use an electronic registry to retrieve pain medication information from the electronic medical record (EMR). Registry data will be collected on the patients of the intervention group providers. The nurse care manager will be able to use the registry to generate reports that will allow him/her to monitor those patients who are receiving opioids for chronic pain.
1554795|NCT02564341|Behavioral|Education and academic detailing|All intervention participants will receive a 60 minute group didactic session by a national expert on opioid prescribing for pain. Physicians will receive two academic detailing sessions, and will be given the option of having a third, booster academic detailing session if desired.
1554796|NCT02564341|Behavioral|Facilitated access to a specialist in addictions|The nurse care manager will encourage and arrange referral of challenging patients with potential abuse or dependence to prescription opioids to an addiction specialist.
1554797|NCT02564328|Genetic|Intravenous stem cell transplantation|Intravenous injection of autologous bone marrow mesenchymal stem cell transplantation
1554798|NCT02564315|Drug|Nicotine Mini-Lozenge for 11 Months|Participants receive up to 11 months of Nicotine Mini-Lozenges as part of this treatment (dosing based on their nicotine dependence as measured when they started the study: 4 mg if they smoked within 30 minutes of waking and 2 mg if they smoked more than 30 minutes after waking, as per the package insert), along with instructions for use.
1554799|NCT02564315|Behavioral|Preparation Phase Behavioral Reduction Counseling|Participants randomized to receive this treatment receive manual-based counseling calls and visits over the course of 11 months. The ultimate goal will be smoking that is reduced in amount and location. Case managers and participants will collaboratively identify a set of steps to progressively reduce smoking. The primary vehicles for change are to encourage substitution of the nicotine mini-lozenge for cigarettes and to reduce the contexts in which smoking occurs. Counseling will counter post-lapse demoralization by emphasizing participants' progress, the value of smoking reduction as a transitional goal, and the critical value of ongoing treatment engagement. Evidence of progress in reduction of smoking, and smoking contexts will be used to build self-efficacy.
1554800|NCT02564315|Behavioral|Preparation Phase Recycling Counseling|Participants randomized to receive this treatment condition will be encouraged to commit to a new quit date as soon as they feel ready. In the counseling sessions, participants will be encouraged to discuss reasons for and concerns about quitting as well as barriers to setting a quit date.
1554801|NCT02564315|Behavioral|Preparation Phase Control Treatment|Participants randomly assigned to the Preparation Phase Control Treatment condition will continue to receive the Initial Cessation usual care treatment (8 weeks of nicotine patch; two coaching sessions), but will also be told that they can receive additional treatment at no cost from the Wisconsin Tobacco Quitline (WTQL).
1554802|NCT02564315|Behavioral|Cessation Phase Supportive Counseling|Supportive Counseling will be consistent with the Public Health Service (PHS) Clinical Practice Guideline (Fiore et al., 2008) and will involve encouragement, a focus on short-term goals, discussion of participant values (what the participant feels would be good and healthy for them in the long run) and how these values are congruent with cessation, emphasis on the patient and the counselor being a team, encouragement for the participant to generate a quitting strategy with the message that smokers often have a good sense of what will work for them, and prompts for the participant to explore his/her feelings about quitting and feelings of optimism and concern (i.e., to use the counselor as a sounding board).
1554803|NCT02564315|Behavioral|Cessation Phase Skill Training Counseling|"Skill training Counseling will: 1) carefully assess smoking cue contexts and opportunities to smoke, to identify problems encountered in the prior quit attempt; 2) develop specific plans for avoiding such contexts and identify skills for coping with them; 3) develop plans for negotiating with others who smoke; 4) develop lifestyle changes to reduce future smoking opportunities and contexts; and 5) assign homework and assess execution of assigned skills. Participants will receive coping menus that provide personalized coping/avoidance options and coping reports that assess coping execution over time and troublesome contexts and cues around which counseling will be focused. There will be praise for any progress and a collaborative determination of barriers to skill execution."
1554804|NCT02564315|Behavioral|Cessation Phase Brief Information|Participants randomized to receive Brief Information will receive brief (generic) information about the importance of taking the cessation medication, how to use the medication, information about side effects/safety, and what to do in case of problems, and will also be given encouragement to quit smoking.
1554805|NCT02564315|Drug|Cessation Phase Nicotine Patch + Nicotine Mini-Lozenge|All participants will receive 8-weeks of combination NRT (nicotine patch + nicotine mini-lozenge). Nicotine patch dosing will be based on current cigarettes smoked per day, per package insert: for those who currently smoke >10 cigs/day=4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg nicotine patches, along with nicotine mini-lozenges; for those who currently smoke <=10 cigs/day=6 weeks of 14 mg and 2 weeks of 7 mg nicotine patches along with mini-lozenges. Mini-lozenge dosing will be based on how soon participants currently smoke after waking before their initial quit attempt and will be consistent with the package insert (4 mg for participants who smoke within 30 minutes of waking and 2 mg for participants smoke more than 30 minutes after waking).
1554806|NCT02564302|Device|MUSE Headband|MUSE Headband will help patients with mindfulness.
1554807|NCT02564276|Procedure|Sentinel lymph node biopsy|
1554812|NCT02564237|Biological|StreptAnova™ (Group A streptococcal (GAS) vaccine)|StreptAnova™ vaccine - 30-valent plus Spa group A Streptococcal vaccine
1554813|NCT02564237|Biological|Hepatitis B vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
1554814|NCT02564237|Biological|Hepatitis A vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
1554815|NCT02564237|Biological|Human Papillomavirus vaccine|Participants will indicate which vaccine they wish to receive (Hepatitis B, Hepatitis A, or Human Papillomavirus vaccine) if they are randomized to a comparator prior to randomization.
1554816|NCT02564224|Procedure|Pursestring Wound Closure|Procedure: Pursestring Wound Closure
1554817|NCT02564224|Procedure|Conventional Wound Closure|Procedure: Conventional Wound Closure
1554818|NCT02564224|Device|prolene|
1554819|NCT02564211|Drug|Ipragliflozin|
1554820|NCT02564211|Drug|Sitagliptin|Background medication
1554821|NCT02564198|Drug|Ramucirumab|Administered IV
1554822|NCT02564185|Other|Usual practice|
1554823|NCT02564185|Other|Education program|
1554824|NCT02564172|Device|CMS group|"Conus medullaris stimulation with pentapolar surgical lead includes:
Pentapolar surgical lead implant ((TM)Penta lead from St Judes Medical ANS which is the medical device under study)
Test phase of 10 days according to HAS(Haute Autorité de Santé) recommendation
If test phase positive, the lead is kept and subcutaneous rechargeable generator is implanted.
If test phase negative, the lead is removed.
Optimal medical management : Similarly to patients randomized in active comparator group, patients randomized in experimental group will also be prescribed optimized medical management (treatment for pain relief) under algologist control.
(A decrease of the consumption of pain treatment should be observed if conus medullaris stimulation has a positive effect)."
1554825|NCT02564172|Other|OMM group|"Optimal Medical Management (treatment for pain relief) includes analgesics and/or antidepressant and/or antiepileptics.Usually, drugs for neuropathic pain are prescribed as follows:
at effective dose, and minimal effective dose on the basis of adverse events and contraindications
as alone treatment in first and second line, then combination treatment. All this depends on the patient, on her/his pain, on her/his previous treatment.
Medical treatment prescription will reviewed by algologist at each clinical visit. It is not possible in this indication to establish a standardized treatment.
Non drugs therapies (physiotherapy, psychobehavioral approaches…) will not be forbidden or contra-indicated."
1554826|NCT02564159|Other|Measure of quadriceps diameter and albumin/prealbumin levels|Evaluation of quadriceps diameter on the anterior aspect of the thigh using the mid-distance between the anterior superior iliac spine and the upper pole of the patella ; collection of albumin and prealbumin levels
1554914|NCT02563600|Behavioral|Pre-letter telephone call.|A brief 2-10 min telephone call made to the patient prior to receipt of appointment invitation letter.
1554915|NCT02563600|Behavioral|Post-letter telephone call|A brief 2-10 min telephone call made to the patient after receipt of appointment invitation letter.
1555277|NCT02561130|Drug|metformin|Dose is titrated to 1 g bid or maximal tolerated dose
1554827|NCT02564146|Drug|nab-paclitaxel and gemcitabine|"Induction treatment:
3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Continouous treatment after randomization:
Continuing application of nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity. Duration of each cycle is 28 days nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
1554828|NCT02564146|Drug|gemcitabine mono and nab-paclitaxel and gemcitabine|"Induction treatment:
3 cycles nab-paclitaxel and gemcitabine 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Continouous treatment after randomization:
Alternating application of gemcitabine monotherapy and nab-paclitaxel and gemcitabine treatment cycles until progression or unacceptable toxicity, starting with a treatment cycle of gemcitabine monotherapy.
Duration of each cycle irrespective of treatment cycle with gemcitabine monotherapy or treatment with nab-paclitaxel/gemcitabine is 28 days.
Gemcitabine monotherapy treatment cycle: Gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle.
Nab-paclitaxel and gemcitabine treatment cycle: Nab-paclitaxel 125 mg/m^2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m^2 as a 30-minute IV infusion; D1, D8, D15 of each 28-day cycle."
1554829|NCT02564133|Device|Transthoracic echocardiography|A transthoracic echocardiography is performed to discover a patent foramen ovale
1554830|NCT02564107|Drug|Ibandronate|Participants will receive ibandronate, 50 milligrams (mg) by mouth every morning, for a period of 25 weeks.
1554831|NCT02564094|Drug|Epoetin beta|Participants will receive SC epoetin beta as 30,000 international units (IU) once weekly for 20 weeks.
1554832|NCT02564081|Other|Static Stretching lower limb|
1554833|NCT02564081|Other|Static stretching Cervical|
1554834|NCT02564068|Drug|Oxytocin|"To test that intranasal oxytocin administration blunts the deleterious hypoxia/hypercapnia induced changes in heart rate that occur during nocturnal apnea in patients with OSA, we will examine the changes in heart rate in a group of patients that have recently been diagnosed with OSA. Ten subjects that have recently undergone a standard in the sleep-lab diagnostic polysomnography (per standard of care medical guidelines, and not for research purposes) and have been diagnosed with OSA will be recruited into a study to assess the beneficial effects of oxytocin treatment."
1554835|NCT02564068|Drug|Placebo|Group B is a crossover study, where subjects will be randomized to receive either placebo or active drug on their first visit, and then the opposite intervention on their second visit.
1554842|NCT02564029|Drug|PF-06372865|Single dose
1554843|NCT02564029|Drug|Placebo|Placebo for PF-06372865 and placebo for lorazepam
1554844|NCT02564029|Drug|Lorazepam|2 mg single oral dose
1554845|NCT02564016|Drug|Normal Saline Infusion|Group 2 (treatment) will have an epidural infusion initiated with preservative-free normal saline at a continuous rate of 4ml/hour
1554846|NCT02564016|Other|Capped Epidural|epidural will be capped with no saline infusion.
1554847|NCT02564003|Drug|Oxycodone|oxycodone 0,1 mg/kg iv
1554848|NCT02563990|Procedure|High Pressure Injection|Adductor canal block performed at greater than 20 psi injection pressure
1554849|NCT02563990|Procedure|Low Pressure Injection|Adductor canal block performed at less than 15 psi injection pressure
1554850|NCT02563990|Drug|High Pressure Injection|Ropivacaine 0.2% injection at greater than 20 psi injection pressure
1554851|NCT02563990|Drug|Low Pressure Injection|Ropivacaine 0.2% injection at less than 15 psi injection pressure
1554852|NCT02563977|Device|2 year postop CT scan of the abdomen|CT scan of the abdomen (from the xiphoid process to the symphysis) performed approximately two years after performed DIEP flap breast reconstruction. No contrast used. Low dose of radiation.
1554853|NCT02563951|Drug|GNS Spray 0.5mg|
1554854|NCT02563951|Drug|GNS Spray 1.0mg|
1554855|NCT02563951|Drug|GNS Spray 2.0mg|
1554856|NCT02563951|Drug|Kytril 1mg (IV injection)|
1554857|NCT02563951|Drug|Kytril 1mg (Tablet)|
1554858|NCT02563938|Drug|AK001|Given parenterally.
1554859|NCT02563938|Drug|Placebo|
1554860|NCT02563925|Radiation|Brain radiotherapy or Stereotactic Radiosurgery|
1554861|NCT02563925|Drug|Tremelimumab|
1554862|NCT02563925|Drug|HER2 directed therapy|
1554863|NCT02563912|Other|Handbook|Resuscitation handbook who provides drug dosages for each weight for children. For example, at the page of 15 kg, it is written that the dosage of epinephrin is 1.5 cc of 1: 10 000.
1554864|NCT02563912|Other|Medication chart|Medication chart who provides drug dosages for each weight for children. For example,it is written that the dosage of epinephrin is 0.01 mg/kg.
1555014|NCT02562924|Procedure|Endoscopic sinus surgery|Endoscopic sinus surgery to debride polyps and establish adequate sinus drainage
1554867|NCT02563886|Other|Electrically Assisted Movement Therapy|Electrically Assisted Movement Therapy (EAMT) is an extension of conventional Constraint-Induced Movement Therapy (CIMT) for moderately-to-severely paralyzed patients. During EAMT, patients use a movement controller with the healthy hand, controlling movements generated through neuromuscular electrical stimulation of the paralyzed arm and hand. During each session three types of exercises can be performed: mobilization, games, and training for activities of daily living, all three involving proper shaping of exercise difficulty at therapist discretion. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks.
1554868|NCT02563886|Other|Usual and customary care|Usual and customary care ranges from no treatment to varying amounts of orthotics, home-based and clinic-based occupational therapy, or physiotherapy, but always excludes CIMT and EAMT. Therapy consists in 20 sessions of 45 minutes twice per day over five weeks, whenever possible, to match EAMT amount of therapy.
1554869|NCT02563873|Device|Tailored pacemaker settings|Tailored pacemaker settings, optimised for cardiac contractility: Pacemaker settings, optimised for cardiac contractility as determined by echocardiography, will be programmed
1554870|NCT02563860|Drug|Lovastatin|dose escallating
1554871|NCT02563847|Dietary Supplement|0.52 g L-Tryptophan|
1554872|NCT02563847|Dietary Supplement|1.56 g L-Tryptophan|
1554873|NCT02563847|Dietary Supplement|1.56 g L-Leucine|
1554874|NCT02563847|Dietary Supplement|50 g Xylitol|
1554875|NCT02563847|Dietary Supplement|75 g Erythritol|
1554876|NCT02563847|Dietary Supplement|75 g Glucose|
1554877|NCT02563847|Dietary Supplement|300 mL tap water|
1554878|NCT02563847|Other|50 mg 13C-sodium acetate|
1554879|NCT02563834|Drug|thiapalmitate tracer|Radiolabeled tracer infusion; occurs in all treatment arms
1554880|NCT02563834|Drug|Saline|Saline infusion for control
1554881|NCT02563834|Drug|Insulin|Insulin infusion for insulin/glucose clamp procedure
1554889|NCT02563795|Drug|Bupivacaine|To compare low dose spinal anesthesia with bupivacaine alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
1554890|NCT02563795|Drug|Fentanyl|To compare low dose spinal anesthesia with bupivacaine+ fentanyl alone if it can maintain surgical anesthesia during cesarean section in obese and non-obese pregnants
1554891|NCT02563782|Biological|Sub-retinal transplantation of MA09-hRPE cells|transplantation
1554892|NCT02563782|Drug|tacrolimus and mycophenolate mofetil|Immunosuppressive Agents
1554893|NCT02563782|Drug|Placebo tacrolimus and mycophenolate mofetil|placebo
1554894|NCT02563782|Procedure|Sham Surgery|Sham surgery
1554895|NCT02563769|Drug|Clavulanic acid|
1554896|NCT02563769|Drug|Intravenous cocaine|
1554897|NCT02563769|Drug|Placebo|
1554898|NCT02563756|Procedure|Unicompartmental knee replacement|Participants with a medial gonarthritis are operated with a medial unicompartmental prosthesis
1554899|NCT02563756|Procedure|Total knee replacement|Participants with a medial gonarthritis are operated with a total knee replacement
1554900|NCT02563743|Behavioral|Problem-solving based intervention|The intervention comprises both the employee and the employer, and follows a clear structure comprising problem solving, stepwise activation and relapse prevention. It includes three meetings at the OHS with additional follow-ups.
1554901|NCT02563743|Behavioral|Treatment as usual|Study participants that are randomized into the control group will receive the usual care given at the OHS. This intervention will differ due to differences between the OHS units.
1554902|NCT02563730|Procedure|Lung biopsy|transbronchial lung biopsy. First kryobiopsy, second open biopsy
1554905|NCT02563704|Drug|Artesunate|
1554906|NCT02563704|Drug|Quinine|
1554907|NCT02563691|Radiation|stereotactic radiotherapy|"Patients will receive ADT for a minimum of 1 year. After this, an intermittent hormone therapy approach will be taken.
The prostate (if not previously treated) will be treated to a dose of 35-40 Gy in 5 fractions. All visible nodal metastases will be treated to a dose of 30-35 Gy in 5 fractions. Non-spine bone metastases will be treated to a dose of 30-40 Gy in 5 fractions. Metastases in the brain, spine, lung, liver, and adrenal will be treated according to established SRT policies at the Sunnybrook Odette Cancer Centre. Comprehensive SRT should be delivered within 3 months of starting ADT."
1554908|NCT02563678|Drug|Hyperbaric Oxygen|Hyperbaric oxygen therapy
1554909|NCT02563678|Other|Hyperbaric Air/Oxygen|Breathing air inside a hyperbaric chamber, then breathing oxygen inside a hyperbaric chamber
1554910|NCT02563678|Other|Normobaric oxygen|Breathing 100% oxygen at normal, atmospheric pressure
1554911|NCT02563613|Behavioral|Physical Exercise (PE)|Core session: 2 hours, Booster session: 1 hour
1554912|NCT02563613|Behavioral|Healthy Diet (HD)|Core session: 2 hours, Booster session: 1 hour
1554913|NCT02563613|Other|Wait-list Control (C)|The wait-list control group will receive the intervention at 3 months.
1555015|NCT02562924|Drug|nasal saline spray|saline nasal mist every hour while awake
1554916|NCT02563587|Other|Laughter therapy|Laughter therapy sessions will begin as soon as / after that the complete anesthesia recovery, then we could start with two interventions, each of them in morning and during the afternoon will be held until their discharge lasting 30 minutes per each one, these sessions will be held in the service pediatric hospital by trained personnel in laughter therapy, which will be implemented through hospital clowns.
1554917|NCT02563587|Other|Accompaniment without causing the laughter of children.|The interventions will be carried out by means of reading stories and own stories for the age. These sessions will begin subsequent to the full recovery of the anesthesia, and then two interventions per day, in the morning and evening, with duration of 30 minutes, until the time of his discharge, these sessions will take place in the service of Hospital pediatrics by the resident in charge.
1554918|NCT02563587|Drug|Conventional treatment|Conventional treatment involves handling analgesic with non-steroidal anti-inflammatory drugs (paracetaol, metamizol and ketorolac) as prescribed by the doctor surgeon treating, which starts immediately in the postoperative period.
1554919|NCT02563574|Behavioral|Motivational Interviewing|A type of counseling aimed at reducing consumption of alcohol.
1554920|NCT02563574|Other|Questionnaire assessment|Several different types of questionnaires will be fill out by the participants.
1554921|NCT02563574|Other|Neurocognitive assessments|Several different types of neurocognitive assessment will be performed.
1554922|NCT02563574|Other|Blood specimens|Blood specimens will be used to measure the immunological, virologic, and hepatic status, as well as other biomarkers.
1554923|NCT02563561|Drug|Apaziquone|The first dose of either 4 mg/40 mL apaziquone or placebo will be administered by intravesical administration into the bladder at 60±30 minutes post TURBT (randomization date, Day 1) via an indwelling 100% Silicone Foley catheter. The second dose of either 4 mg/40 mL apaziquone or placebo will administered by intravesical administration via an indwelling catheter on Day 15 (±5 days).
1554924|NCT02563561|Other|Placebo|Matching placebo containing 12 mg FD&C red #40, 15 mg sodium chloride, and 10 mg mannitol is supplied in identical appearing vials.
1554925|NCT02563548|Drug|PEGPEM|PEGPH20 + pembrolizumab
1554926|NCT02563535|Device|DEB|angioplasty with Litos drug eluting balloon
1554927|NCT02563535|Device|PTA|angioplasty with conventional balloon
1554930|NCT02563509|Biological|HIV-specific CD8 cells|Based on HAART, receive HIV-specific CD8 cells transfuion.
1554933|NCT02563483|Behavioral|yoga and compassion meditation program|25 min of physical exercise, holding each pose (stretching exercise) for an average of 1 min and 30 s; 25 min of breathing exercises and 25 min of meditation.
1554934|NCT02563457|Other|periodontal manual treatment|periodontal manual treatment
1554935|NCT02563457|Other|no periodontal manual treatment|blood sampling
1554936|NCT02563444|Device|Ultrasound fusion guiding system - TUS A-500 (Aplio 500)|
1554937|NCT02563431|Device|SYSTAM - SP-ED|"Positioning in bed, wheelchair and standing with classics materials (pillow, holds, sling) on day J0 until J7 or Exit.
Daily passive mobilisation of the upper member by a therapist.
Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers)"
1554938|NCT02563431|Device|Ultrasling ER 15°Donjoy - 4P-ED|"Positioning in bed, wheelchair and standing with specific materials (holds, sling in external rotation and abduction) on day J0 until J7 or Exit.
A training of the patient and members of family on pathology, risk, use of material
Daily passive mobilization of the upper member by a therapist.
Be careful of shoulder's coaptation in care and functional activities (toilet, dressing, transfers) and active patient training for use the other side for support hemiplegic shoulder to prevent diastasis."
1554939|NCT02563418|Device|Eye-tracking|
1554940|NCT02563405|Drug|Doxazosin|Doxazosin was given orally in a dose of 4 mg/day to treat patients in the doxazosin group for 12 weeks.
1554941|NCT02563405|Drug|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
1554942|NCT02563392|Procedure|uterine myomectomy with preventive uterine arteries occlusion|laparoscopic uterine myomectomy with preventive uterine arteries occlusion
1554943|NCT02563392|Procedure|laparoscopic uterine myomectomy without preventive uterine arteries occlusion|laparoscopic uterine myomectomy
1554944|NCT02563366|Other|BM-MSCs|BM-MSCs are from third-party healthy volunteer donors.
1554945|NCT02563366|Other|Saline|Saline is the placebo of MSCs in this study.
1554946|NCT02563353|Other|whole-body vibration|"Whole-body vibration on vibration platforms. 30-40 Hertz, from 2 mm (low) to 4 mm (high) amplitude,
1 minutes x 6 with 1 minute break between. 3 times a week."
1554947|NCT02563353|Drug|teriparatide|Teriparatide, 20 microgram/day. 24 months of treatment.
1554948|NCT02563340|Other|BM-MSCs|BM-MSCs are from third-party healthy donors, and have no HLA alleles similar to renal allograft donors or reacting to positive anti-HLA antibodies in recipients.
1554949|NCT02563340|Other|Desensitization therapy (PP, IVIG, rituximab or Bortezomib)|At least one drug or treatment is applied as desensitization therapy to decrease DSA, reduce B cells or inhibit plasma cells, depending on individual condition.
1554950|NCT02563327|Drug|Rifapentine|A rifamycin with activity against Mycobacterium tuberculosis
1554951|NCT02563327|Drug|Moxifloxacin|A fluoroquinolone
1554952|NCT02563327|Drug|Rifampin|A rifamycin with activity against Mycobacterium tuberculosis
1554953|NCT02563327|Drug|Isoniazid|An anti-tuberculosis agent
1554954|NCT02563327|Drug|Pyrazinamide|An anti-tuberculosis agent
1554955|NCT02563327|Drug|Ethambutol|An anti-tuberculosis agent
1554956|NCT02563327|Dietary Supplement|Pyridoxine|An essential vitamin
1554957|NCT02563314|Device|Non-invasive mechanical ventilation - Normoxia|Maintenance of an oxygen setting allowing normal oxygen saturation during non-invasive mechanical ventilation (SpO2 targeted 96-98%)
1554958|NCT02563314|Device|Non-invasive mechanical ventilation - Controlled hypoxemia|Maintenance of an oxygen setting allowing mild hypoxemia during non-invasive mechanical ventilation (SpO2 targeted 88-92%)
1555105|NCT02562287|Drug|Risperidone|Risperidone, in a flexible dosage
1554959|NCT02563301|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis, laryngoscopy is performed and the patient's trachea is intubated.
1554960|NCT02563288|Drug|Esmolol|effect of esmolol on intraoperative sympathetic control and on extubation conditions.
1554961|NCT02563288|Drug|Dexmedetomidine|effect of dexmedetomidine on intraoperative sympathetic control and on extubation conditions.
1554962|NCT02563275|Other|motion analysis system|
1554963|NCT02563275|Other|parabolic flight|
1554964|NCT02563262|Other|body angles measurements during weightlessness|
1554965|NCT02563249|Other|Parabolic flight|
1554966|NCT02563249|Other|movements of the upper limb, the gripping force, muscle activity and eye-cephalic subject movement measurements|
1554967|NCT02563236|Other|Parabolic flight|
1554968|NCT02563223|Other|Parabolic flight|
1554969|NCT02563223|Device|Subject Loading System|a device that combines a force platform on which the subject jumps and a Subject Loading System (SLS) that pulls the subject downwards.
1554970|NCT02563210|Other|airway resistance measurement|assessment of airway resistance
1554971|NCT02563197|Device|T-326 Inhaler|No drug dosing,three test inhalations through the inhaler device filled with an empty capsule.
1554972|NCT02563184|Biological|Fluzone|
1554973|NCT02563171|Other|non surgical periodontal treatment|"SRP under local anaesthesia, in a total of 2-3 clinical visits.
Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
1554974|NCT02563171|Other|Gingival crevicular fluid collection|GCF collection with filter paper (Periopaper) using the intracrevicular method.
1554975|NCT02563158|Procedure|non-occlusion technique|Hepatectomy is carried out without hepatic inflow control. (non-occlusion technique)
1554976|NCT02563145|Behavioral|Real-time fMRI feedback|feedback about activation patterns in brain regions related with instrumental aggression
1554977|NCT02563145|Behavioral|Treatment as usual|Psychoeducation, general counselling
1554978|NCT02563132|Procedure|Carbon dioxide insufflation|Carbon dioxide insufflation during diagnostic colonoscopy
1554979|NCT02563119|Procedure|Gastric Bypass or Sleeve gastrectomy|
1554980|NCT02563106|Drug|SYN-004|
1554981|NCT02563106|Drug|Placebo|
1554982|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular (IM)
1554983|NCT02563093|Biological|Fluzone Intradermal Quadrivalent vaccine, 2015-2016 formulation|0.1 mL, Intradermal
1554984|NCT02563093|Biological|Fluzone Quadrivalent vaccine, 2015-2016 formulation, No Preservative|0.5 mL, Intramuscular
1554985|NCT02563093|Biological|Fluzone High-Dose vaccine, 2015-2016 formulation|0.5 mL, Intramuscular
1554986|NCT02563067|Drug|QAW039|QAW039 Dose 1 once daily
1554987|NCT02563067|Drug|QAW039|QAW039 Dose 2 once daily
1554988|NCT02563067|Drug|Placebo|Placebo once daily
1554989|NCT02563054|Drug|5-Fluorouracil|Participants will receive 5-FU, 800 milligrams per meter-squared (mg/m^2) per day via IV infusion during Days 1 to 5 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
1554990|NCT02563054|Drug|Capecitabine|Participants will receive oral capecitabine, 1000 mg/m^2 twice daily on Days 1 to 14 of each 3-week cycle, for a total of 6 cycles in combination with cisplatin or upto disease progression.
1554991|NCT02563054|Drug|Cisplatin|Participants will receive cisplastin, 80 mg/m^2 via IV infusion on Day 1 of each 3-week cycle, for a total of 6 cycles or upto disease progression in combination with either capecitabine or 5-FU.
1554992|NCT02563041|Drug|30% TSC|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
1554993|NCT02563041|Drug|Heparin|The patients were randomly assigned to have their catheter locked with either unfractionated sodium heparin 5000 U/mL or 30% trisodium citrate.
1554994|NCT02563028|Device|SightSaver Visual Stimulator|Evoked response photic stimulator
1554995|NCT02563015|Dietary Supplement|cholecalciferol|liquid drops
1554996|NCT02563015|Dietary Supplement|Reference 400|liquid drops
1554997|NCT02563002|Drug|mFOLFOX6|Regimen consists of oxaliplatin 85 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-fluorouracil (5-FU) 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle
1554998|NCT02563002|Drug|FOLFIRI|Regimen consists of irinotecan 180 mg/m^2 IV on Day 1, leucovorin 400 mg/m^2 or levoleucovorin 200 mg/m^2 IV on Day 1, 5-FU 400 mg/m^2 IV bolus on Day 1 and then 1200 mg/m^2/day IV over 2 days for total dose of 2400 mg/m^2 in each 2-week cycle
1554999|NCT02563002|Biological|pembrolizumab|
1555000|NCT02563002|Biological|bevacizumab|
1555001|NCT02563002|Biological|cetuximab|
1555004|NCT02562976|Other|gastric atrophy and intestinal metaplasia|use Japanese endoscopic gastric atrophy classification, Operative Link on Gastritis Assessment (OLGA), Operative Link on Gastric Intestinal Metaplasia Assessment (OLGIM) to evaluate the severity of gastric atrophy and intestinal metaplasia
1555005|NCT02562963|Biological|natural killer T cell|The eligible patients are infused with two doses of (4±0.5)x10^9 NKT cells in one course of treatment.
1555006|NCT02562950|Drug|GLPG1837 500 mg|Each subject will receive multiple oral daily doses of GLPG1837 (250 mg b.i.d. for 11 days) from Days 2 to 12.
1555007|NCT02562950|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 12).
1555008|NCT02562950|Drug|GLPG1837 1000 mg|Each subject will receive multiple oral doses of GLPG1837 (500 mg b.i.d. for 11 days) from Days 2 to 12.
1555009|NCT02562937|Behavioral|text messages related to sedentary behaviour|texts sent twice daily encouraging reduced sedentary behaviour
1555010|NCT02562924|Device|MEDIHONEY®|MEDIHONEY® is a seminatural product with antibacterial and anti-inflammatory properties
1555011|NCT02562924|Drug|Budesonide|Topical steroid
1555012|NCT02562924|Drug|Normal saline sinus rinse|8 oz or 4 oz of normal saline with NeilMed sinus rinse bottle
1555013|NCT02562924|Drug|Prednisone|Post-operatively, 40 mg daily for 7 days
1555016|NCT02562911|Procedure|Data collection|"Clinical examination
Complete pelvic ultrasound abdominal ultrasound
Bone age: X-ray
biological examination
Lung function assessed by the Maximum Volume Expired
Brasfield radiological score (if available)"
1555017|NCT02562898|Drug|Ibrutinib|560, 840, 420, or 280mg, orally once per day - 4 week cycle
1555018|NCT02562898|Drug|Paclitaxel|125mg/m2 IV Day 1, 8, and 15 - 4 week cycle
1555019|NCT02562898|Drug|Gemcitabine|1000mg/m2 IV Day 1, 8, and 15 - 4 week cycle
1555020|NCT02562885|Device|Acoustic pulses|"Acoustic pulses applied during NREM sleep slow waves Up-phase or Down-phase. The acoustic stimulus will be delivered by speakers with a volume of about 50 dB."
1555021|NCT02562872|Drug|DSM265|DSM265 400 mg single oral dose
1555022|NCT02562872|Drug|Placebo|Placebo to match DSM265, single oral dose
1555023|NCT02562872|Biological|Sporozoites|Direct venous inoculation of 3200 cryopreserved Plasmodium falciparum (NF54 strain) sporozoites
1555024|NCT02562872|Biological|Infective mosquito bite|Five single bites by laboratory reared female Anopheles stephensi mosquitoes carrying Plasmodium falciparum
1555025|NCT02562859|Drug|500 mg GLPG1837 as oral suspension|A single dose of 500 mg GLPG1837 administered as oral suspension
1555026|NCT02562859|Drug|500 mg GLPG1837 as oral tablet|A single dose of 500 mg GLPG1837 administered as oral tablet
1555028|NCT02562833|Device|Self-Management and exercise|Self-Management and exercise It is a 3 months intervention where the participants were enrolled two times per week, 90 minutes each session, first 30 minutes were allocated for the self-management component and the remaining 60 minutes for the exercise component. Additionally,participants received glucosamine and chondroitin sulfate supplement.
1555029|NCT02562833|Device|Educational|This group received an educational book with information about OA features, treatment modalities and exercise education with illustration. Additionally, a monthly educational session each with one hour and a half duration, in total 3, where joint protections strategies, OA self-management and exercise contents were transmitted. Additionally,participants received glucosamine and chondroitin sulfate supplement.
1555030|NCT02562820|Procedure|Intravenous infusion|Intravenous infusion of Ketamine
1555031|NCT02562820|Procedure|Intravenous infusion|Intravenous infusion of Normal Saline
1555032|NCT02562807|Drug|TAS-303 18mg single-dose|
1555033|NCT02562807|Drug|Placebo 18mg single-dose|
1555034|NCT02562807|Drug|TAS-303 9mg single-dose|
1555035|NCT02562807|Drug|Placebo 9mg single-dose|
1555036|NCT02562794|Behavioral|Family Strengthening Intervention-Refugees|This study aims to design a preventive intervention for at-risk refugee children and families. The intervention is focused on strengthening core family resources and promoting resilience and healthy parent-child interactions.
1555037|NCT02562781|Drug|Oxygen|Oxygen in sufficient quantity to maintain SpO2 > 98%
1555038|NCT02562781|Other|Air|Supplemental Oxygen in sufficient quantity to maintain SpO2 > 90%
1555039|NCT02562768|Drug|LY3154207|Administered orally
1555040|NCT02562768|Drug|Placebo|Administered orally
1555043|NCT02562742|Drug|SOF|SOF 400 mg tablets administered orally once daily
1555044|NCT02562742|Drug|REB|REB capsules administered orally in a divided daily weight-based dose according to the package insert for the approved Rebetol® labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
1555045|NCT02562729|Procedure|Nerve-Sparing Radical Hysterectomy|Type C1 NSRH Removal indwelling catheter on day 4 after surgery
1555046|NCT02562716|Drug|Fluorouracil|Given IV
1555047|NCT02562716|Drug|Gemcitabine Hydrochloride|Given IV
1555048|NCT02562716|Drug|Irinotecan Hydrochloride|Given IV
1555049|NCT02562716|Drug|Oxaliplatin|Given IV
1555050|NCT02562716|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1555051|NCT02562716|Procedure|Pancreatectomy|Undergo pancreatectomy
1555052|NCT02562703|Device|Transcutaneous Vagus Nerve Stimulation|tVNS will be applied by the external simulator (Monarch). The stimulation will be conducted at a frequency of 120 Hz with pulse duration of 250 microseconds. The current intensity will be individually established and should be equivalent to a slight feeling of not painful paresthesia .The stimulus generates a pulse and asymmetric biphasic waveform. Electrodes (25cm2) will be placed over the mastoid process bilaterally. The study protocol will follow the rational of our previous trials with TNS.
1555053|NCT02562690|Other|Thrombin generation assays, TEG and GTT|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)
1555054|NCT02562677|Device|Transcutaneous Trigeminal Nerve Stimulation|
1555055|NCT02562664|Drug|CC|100 mg clomiphene Citrate (Clomid , global Napi , Egypt) CC tablets taken from day 3 to day 7 of the cycle
1555056|NCT02562664|Drug|Placebo tablets|Placebo tablets taken twice daily continuously for three cycles.
1555057|NCT02562664|Drug|Metformin|wMetformin (Cidophage , Amon , Egypt) 500 mg twice daily continuously for three cycles.
1555060|NCT02562638|Other|Non-fasting|Clear fluids up to 1hour pre-procedure and fasting for solids for up to 4 hours
1555061|NCT02562625|Drug|Pembrolizumab|Powder solution for infusion
1555062|NCT02562625|Radiation|Radiotherapy|24Gy
1555063|NCT02562612|Drug|SM-88|Daily SM-88 in multiple ascending doses over 6 months
1555106|NCT02562287|Drug|Olanzapine|Olanzapine, flexible dosage
1555107|NCT02562287|Drug|Quetiapine|Quetiapine, flexible dosage
1555064|NCT02562599|Drug|raltitrexed-cisplatin|Patients receive raltitrexed-cisplatin neoadjuvant chemotherapy every three weeks for two cycles, then receive raltitrexed -cisplatin concurrent chemoradiotherapy every three weeks for two cycles
1555065|NCT02562599|Radiation|Intensity-modulated radiotherapy (IMRT)|
1555066|NCT02562586|Device|Closed Suction Drainage System|patients undergoing total hip replacement have received a closed suction drainage for 24 hours after the surgical procedure
1555067|NCT02562573|Drug|PBI4050|
1555068|NCT02562560|Behavioral|Neuropsychological tests|
1555069|NCT02562560|Device|Cerebral imaging (MRI, PET-FDG)|
1555070|NCT02562547|Device|Hem-Avert Perianal Stabilizer|The HEM-AVERT® Perianal Stabilizer is an FDA approved Class II device in accordance with FDA regulations 21 CFR 801.109. The HEM-AVERT® Perianal Stabilizer is a non-invasive device used to help provide continuous pressure to the perianal region as a means to help provide support during the labor process.
1555071|NCT02562534|Device|MRI compatible ElectroCardioGraph|MRI with ECG control for personnes with healthy heart or heart diseases
1555072|NCT02562521|Behavioral|Contingency management|Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.
1555073|NCT02562521|Drug|Nicotine replacement therapy|Participants have the option of using nicotine patch in combination with nicotine gum or lozenge
1555074|NCT02562521|Drug|Varenicline|Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative
1555075|NCT02562521|Behavioral|Additional behavioral support|Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
1555076|NCT02562508|Procedure|3 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to the standard 3-dose schedule (0,1,6 months)
1555077|NCT02562508|Procedure|2 doses of HPV 16/18 bivalent vaccine|Participants would receive 60μg of HPV 16/18 bivalent vaccine according to an alternative 2-dose schedule (0,6 months)
1555078|NCT02562495|Device|CT Scan and ultrasonography|Up to three measurements (CT scan and Ultrasonography) of the thickness of quadriceps, will be made concurrently .
1555079|NCT02562482|Biological|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a VLP vaccine that consists of CHIKV VLP composed of E1, E2 and capsid proteins. The vaccine is filled in a single dose glass vial at 40+/- 10mcg/mL.
1555080|NCT02562482|Other|VRC-PBSPLA043-00-VP|VRC-PBSPLA043-00-VP, a sterile phosphate buffered saline (PBS) is the placebo for the CHIKV VLP vaccine
1555081|NCT02562469|Other|ACTIVATE|A home-based computerized brain training intervention for youth.
1555088|NCT02562430|Drug|Welbutrin XL|12.5% of participants will receive Welbutrin XL in phase 1 of the study.
1555089|NCT02562430|Drug|Placebo|87.5% of subjects will be randomized to placebo in phase 1 of the study.
1555090|NCT02562417|Drug|Normal saline|
1555091|NCT02562417|Drug|IV dexamethasone|
1555092|NCT02562391|Device|Surgical ablation of the left atrium (PVI+Box lesions)|
1555093|NCT02562391|Device|Surgical ablation of the left atrium (PVI+Box lesions) and left atrial appendage cutting|
1555094|NCT02562378|Drug|Trastuzumab and non-pegylated liposomal doxorubicin|Trastuzumab 3.6 mg/kg IV on Day 1 every 3 weeks and non-pegylated liposomal doxorubicin (45 mg/m2, 50 mg/m2 and 60 mg/m2) IV
1555095|NCT02562365|Drug|Etoposide, Cyclophosphamide, Carboplatin|CTX 400mg（250mg/m2）+VP-16 100mg (70mg/m2)d1-d3 iv 4w/6cycles , CBP(AUC=5)+CTX 600mg(400mg/m2)d1-d2 iv 8w/6cycles
1555096|NCT02562352|Other|TAPER program|Patients will be randomized to receive the TAPER program at study start or delayed intervention at 6 months.
1555097|NCT02562339|Behavioral|SMART-3RP|8-week group intervention teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
1555098|NCT02562326|Drug|BioChaperone insulin lispro|Injection immediately before the start of the individualised standard meal
1555099|NCT02562326|Drug|Humalog®|Injection immediately before the start of the individualised standard meal
1555100|NCT02562313|Drug|BioChaperone insulin lispro|BioChaperone insulin lispro bolus infusion followed by test meal intake
1555101|NCT02562313|Drug|Humalog®|Humalog® bolus infusion followed by test meal intake
1555102|NCT02562300|Drug|Misoprostol|400 micrograms of sublingual misoprostol were given immediately after delivery of the neonate.
1555103|NCT02562300|Drug|Oxytocin|20 IU oxytocin dissolved in 1 L of Lactated Ringer's or glucose solution) at the rate of 125 ml /h were given immediately after delivery of the neonate.
1555104|NCT02562287|Drug|Clozapine|Flexible dosage, with up-titration according to standard schedules employed for schezophrenia
1555108|NCT02562274|Dietary Supplement|Placebo|Subjects are received placebo treatments once daily for 8 weeks
1555109|NCT02562274|Dietary Supplement|MP 50 mg/day|Subjects are received MP 50 mg/day treatments once daily for 8 weeks
1555110|NCT02562274|Dietary Supplement|MP 1500 mg/day|Subjects are received MP 1500 mg/day treatments once daily for 8 weeks
1555111|NCT02562248|Other|Automated screening for pediatric anxiety|families receiving care at the intervention clinics with concern for disruptive behaviors will be administered the SCARED tool for anxiety in addition to the Vanderbilt tool for ADHD
1555112|NCT02562248|Other|Usual Care|families receiving care at the control clinics with concern for disruptive behaviors will be administered the Vanderbilt tool for ADHD only
1555114|NCT02562222|Procedure|anodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
1555115|NCT02562222|Procedure|cathodal tDCS on M1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
1555116|NCT02562222|Procedure|anodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
1555117|NCT02562222|Procedure|cathodal tDCS on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
1555118|NCT02562222|Procedure|anodal tDCS on M1 and cathodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
1555119|NCT02562222|Procedure|cathodal tDCS on M1 and anodal on V1|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
1555120|NCT02562222|Procedure|sham tDCS|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
1555121|NCT02562209|Dietary Supplement|PACER Diet|Pacer diet to be followed for 8 weeks
1555392|NCT02560298|Drug|Paclitaxel|Given IV
1555122|NCT02562209|Other|Standard weight reducing diet|Standard weight reducing diet to be followed for 8 weeks
1555123|NCT02562196|Device|tdcs|"The direct electric current will be applied by surface electrodes with 35cm² and composed of rubbers conductive electricity and surrounded by sponges soaked in saline solution. The electrodes position will be performed according the 10-20 international system of marking and the different montages will be realized by distinct applications sites.
To stimuli the primary motor cortex the active electrode will be positioned on C3 point and the reference electrode on the contralateral supraorbital region. To visual cortex stimulation, the active electrode will be positioned on the Oz point and the reference on Cz. To duo stimulation, the two electrodes will be considerate actives, stimulating the visual and motor cortex simultaneously. The sham tDCS has already been used in several studies to assess the effect active tDCS and the duration of the current is only 30 seconds."
1555124|NCT02562183|Drug|kallikrein|Using kallikrein
1555125|NCT02562170|Device|TiLoop Bra|
1555126|NCT02562170|Device|Protexa|
1555127|NCT02562157|Device|NOTES gastroenteric anastomosis|
1555128|NCT02562144|Drug|Xylocaine spray|Cutaneous xylocaine spray before intravenous cannulation.
1555129|NCT02562144|Drug|Placebo|Cutaneous placebo before intravenous cannulation.
1555130|NCT02562118|Drug|Lenvatinib + Letrozole|Single agent lenvatinib daily continuously x 2 weeks, followed by letrozole 2.5mg daily + lenvatinib x 12 weeks. Lumpectomy or mastectomy should be considered after completing 14 weeks of pre-operative lenvatinib + letrozole for curative intent in non-metastatic patients and for local control for patients with metastatic disease. If surgery is planned, it should preferably be performed within 2-12 weeks after completing neoadjuvant endocrine therapy, and after toxicities (if any) from the neoadjuvant endocrine therapy have resolved. If the patient is deemed inoperable after 14 weeks of lenvatinib + letrozole, a final biopsy will be obtained, and the patient discontinued from the study and treated as per standard clinical practice by the treating physician.
1555131|NCT02562105|Procedure|Mechanical ventilation|requiring mechanical ventilation at admission to ICU for one day or more during the study period
1555132|NCT02562092|Behavioral|Reducing Risk Behavior|A small survey will be conducted to identify risk factors and assess demographics. Participants will receive psychological support and counseling on reducing risk behavior for one year.
1555133|NCT02562092|Behavioral|Support and Guidance|A small survey will be conducted to identify risk factors and assess demographics. Participants with a positive HIV test will receive standard HIV care, support, and guidance from a psychologist and case manager including an assessment of basic needs (food, clothing, shelter), and counseling on risk taking behaviors for one year.
1555134|NCT02562079|Biological|Blood samples|"biological features of the standard follow-up
2 more blood tube for the biological collection (serum and PBMC)"
1555135|NCT02562079|Biological|Biopsy|Skin biopsies
1555136|NCT02562066|Drug|amifampridine phosphate|Amifampridine phosphate tablets 10 mg will be provided in round, white-scored tablets, and containing amifampridine phosphate formulated to be the equivalent of 10 mg amifampridine base per tablet.
1555137|NCT02562066|Drug|Placebo|A placebo equivalent will be provided as tablets indistinguishable from the amifampridine phosphate tablets. The placebo will be administered consistent with the dose regimen of amifampridine phosphate.
1555138|NCT02562053|Drug|Fluoxetine|Women will receive oral fluoxetine 20 mg daily.
1555139|NCT02562053|Drug|Combined oral contraceptives|women will receive COC containing drospirenone (drospirenone 3mg+Ethinylestradiol 0.03mg; Yasmin® Schering AG, Egypt) daily for 21 days starting from the 3rd day of menstruation
1555140|NCT02562053|Drug|Placebo 1|Women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
1555141|NCT02562053|Drug|Placebo 2|Women will receive a daily oral placebo similar to fluoxetine
1555142|NCT02562040|Procedure|Early Adenotonsillectomy (eAT)|Standard clinical adenotonsillectomy within 4 weeks post randomization in addition to information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
1555143|NCT02562040|Behavioral|Watchful Waiting with Supportive Care (WWSC)|Information about healthy sleep habits for children and appropriate clinical referrals for management of co-morbidities.
1555144|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire C30|"30 quality of life questions for the participant to answer
The first 28 questions have answers that range from 1 (Not at All) to 4 (Very Much)
The final 2 questions answers range from 1 (Very Poor) to 7 (Excellent)
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
1555145|NCT02562027|Behavioral|European Organization for Research and Treatment of Cancer Quality of Life Questionnaire LC-13|"13 quality of life questions for the participant to answer
The answers range from 1 (Not at All) to 4 (Very Much)
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
1555146|NCT02562027|Behavioral|Modified Medical Research Council|"Participants is given 5 grades to choose from ranging from 0 to 4 and participant will choose grade
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
1555147|NCT02562027|Behavioral|EQ-5D|"5 headings with 5 statements and the participant will check the box that best describes how he or she feels that day
The second part shows a scale ranging from 0 (worst health) to 100 (best health) and the participant chooses the best number on the scale
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
1555148|NCT02562027|Behavioral|Center for Epidemiological Studies Depression Scale|"20 quality of life questions for the participant to answer
Answers range from Rarely or none of the time to Most or all of the time
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
1555149|NCT02562027|Behavioral|Medical Outcomes Study Social Support Survey|"19 quality of life questions for the participant to answer
Answers from from 1 (None of the time) to 5 (All of the time)
Collected at baseline, 3 months post-treatment, 6 months post-treatment, 12 months post-treatment, and 24 months post-treatment"
1555150|NCT02562014|Other|Glucose|75g glucose
1555151|NCT02562014|Other|Inulin|75g glucose plus 24g inulin
1555152|NCT02562014|Other|Resistant Starch|75g glucose plus 28.2g resistant starch
1555237|NCT02561403|Behavioral|EVO words video game|Participants will play a word puzzle game for 4 weeks
1555153|NCT02562001|Device|HD tDCS active|active HD-tDCS (Soterix Medical, New York, EUA) during 20 minutes before Lokomat and ARMEO Spring
1555154|NCT02562001|Device|HD tDCS placebo|placebo HD-tDCS (Soterix Medical, New York, EUA) during 20 minutes before Lokomat and ARMEO Spring
1555155|NCT02561988|Drug|BLU-285|
1555156|NCT02561975|Other|Double pulmonary diffusing|"Measure of double pulmonary diffusing will be done as the single-breath test: the patient will be seated and connected to device by an oral tip. Measure begins by a maximal inhalation of a gas mixture (0.28% of CO, 14% of He, 21% of O2,450 ppm of NO/N2 and 40ppm of NO).After, the patient will maintain an apnea of 4 secondes and will breathe out in oral tip until his residual capacity.
With the expired air, some parameters will be assessed:
Alveolar volume (VA)
Membrane ductance (Dm) and pulmonar capillary volume (values adjusted by Haemoglobin)
Values of TLCO, TLCO/VA, TLNO, TLNO/VA Vc, Dm, Vc/VA, Dm/VA, TLNO/TLCO et Dm/Vc"
1555157|NCT02561962|Drug|AMG 224|AMG 224 will be given on Day 1 once every 3 weeks with dose ranging from 30 mg to 300 mg.
1555158|NCT02561949|Behavioral|YRI (Youth Readiness Intervention)|Youth Readiness Intervention (YRI) is an innovative, evidence-based mental health intervention to address co-morbid difficulties with externalizing problems (anger/emotion dysregulation) and internalizing problems (hopelessness/anxiety) among violence-affected youth. YRI methodology draws on evidence-based treatment elements commonly used in both cognitive-behavioral intervention and group interpersonal therapy. YRI has cross-cutting efficacy across a range of mental health conditions common in violence-affected youth. YRI will be delivered in 12 sessions over the course of 3 months.
1555159|NCT02561949|Other|Income generating activity program|Income generating activity programming will be carried out by GOAL in partnership with St. George's foundation through use of their current funding. GOAL focuses on supporting people in need by providing healthcare resources, advocating and advancing child protection practices and policies, and administering livelihood programs to empower them improve their lives in a sustainable manner. The St. George's Foundation's addresses child welfare concerns by actively reaching out to homeless and orphaned children. The program is 4 months in length and consists of skills training, soft skills development (primarily in numeracy and literacy), and a cash transfer of $200.
1555160|NCT02561936|Drug|Rilpivirine Oral Tablet|Rilpivirine formulated as 25 mg oral tablet.
1555161|NCT02561936|Drug|Rilpivirine formulation G007|Rilpivirine G007 formulation as 10*2.5 mg tablets.
1555162|NCT02561936|Drug|Rilpivirine formulation G009-01|Rilpivirine G009-01 formulation as 10*2.5 mg tablets.
1555163|NCT02561936|Drug|Rilpivirine formulation G002|Rilpivirine G002 formulation as 10 g of 2.5 milligram per gram (mg/gm) granules.
1555164|NCT02561936|Dietary Supplement|Standardized Breakfast|It will consist of (or its equivalent) 4 slices of bread, 2 slices of ham and/or cheese, butter, fruit preserve and 1 or 2 cups (up to 480 milliliter [mL]) of decaffeinated coffee or decaffeinated tea with milk and/or sugar, if desired (containing approximately fat: 21 gram (gm), carbohydrates: 67 gm, proteins: 19 gm; calories 533 kilocalorie (kcal) [189 kcal from fat, 268 kcal from carbohydrates, and 76 kcal from proteins]).
1555165|NCT02561923|Drug|Rivaroxaban|A single dose of 20 milligram (mg) of rivaroxaban orally will be administered to participants on Day 1 in part 1 and through day 1 and 3 with a final 20 mg dose administered on the morning of Day 4 in part 2.
1555166|NCT02561923|Drug|Tranexamic acid|1.0 g single dose of tranexamic acid (TXA), intravenously administered (over 10 mins) on Day 4.
1555167|NCT02561923|Drug|Kcentra, a 4-factor PCC|Kcentra, a 4-factor PCC, 50 IU/kg, single dose, intravenously administered (maximum rate of 210 [international units] IU/min) on Day 4.
1555168|NCT02561923|Drug|Saline|Saline [Kcentra saline control or TXA saline control] on Day 4.
1555170|NCT02561897|Drug|Edoxaban|
1555171|NCT02561897|Drug|Warfarin|
1555172|NCT02561884|Drug|Olostar Tab.|
1555173|NCT02561884|Drug|Co-administration of Olmetec and Crestor|
1555174|NCT02561871|Biological|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 and 85 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on day 1 in Group 2.
1555175|NCT02561871|Biological|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 169 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10^11 virus particles [vp]) on day 85 in Group 2.
1555176|NCT02561871|Drug|Placebo|Participants will receive Intramuscular injection of Placebo control on day 169 in Group 2. Intramuscular injection of Placebo control on day 1, 85 and 169 in Group 3.
1555177|NCT02561858|Other|acid load test|
1555178|NCT02561845|Drug|rosuvastatin|5mg, 10mg, 20mg
1555179|NCT02561832|Drug|Olaparib|tablets taken orally twice daily
1555180|NCT02561832|Drug|Carboplatin|intravenous injections on day one of each cycle
1555181|NCT02561832|Drug|Anthracycline|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
1555182|NCT02561832|Drug|Cyclophosphamide|The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
1555185|NCT02561793|Drug|DHEA|Women will receive DHEA 12 weeks before starting IVF/ICSI
1555186|NCT02561793|Drug|Placebo|women will receive a placebo 12 weeks before starting IVF/ICSI
1555187|NCT02561780|Behavioral|Curriculum|A mental health educational resource delivered in the classroom by trained educators
1555188|NCT02561780|Behavioral|eLearning Follow-up|An online mental health education module that students access individually
1555189|NCT02561767|Other|bone marrow-derived mesenchymal stem cells|BM-MSCs is harvested from third-party health volunteer donors.
1555190|NCT02561767|Other|Saline|Saline as placebo of MSCs
1555191|NCT02561767|Drug|Induction therapy (ATG or Basiliximab)|ATG, antithymocyte globulin; Basiliximab, anti-CD25 mAb. Recipients receive ATG or Basiliximab as induction therapy in both MSCs group and control group.
1555192|NCT02561767|Drug|Maintenance therapy (Low-dose CNI + MPA + steroids)|Maintenance immunosuppressive therapy consists of low-dose tacrolimus and mycophenolic acid and steroids. Recipients receive the same maintenance therapy in both MSCs group and control group.
1555193|NCT02561754|Dietary Supplement|Enhanced Stop Light Diet (eSLD)|eSDL includes reduced energy portion controlled meals for 6 months, encouraged consumption of lower energy shakes and 35 fruits and vegetables per week.
1555194|NCT02561754|Dietary Supplement|Conventional Diet (CD)|CD is a nutritionally balanced, reduced energy, high volume, lower fat ( fat=20-30% energy) diet.
1555195|NCT02561754|Behavioral|Face-to-face (FTF)|FTF will meet with a health educator in person and will track progress using pen and paper records for both physical activity and diet.
1555196|NCT02561754|Behavioral|Technology (TECH)|TECH groups will receive the intervention using an iPad with the FaceTimeTM application for video meetings with a health educator and will track progress using the Lose it! application for both physical activity and diet.
1555197|NCT02561754|Other|iPad with FaceTime|TECH groups will receive the intervention using an iPad with the FaceTimeTM to the intervention field.
1555198|NCT02561741|Drug|COV155|COV155 tablets
1555199|NCT02561728|Device|Hangar Helmet|Child will be fitted with the Hangar Helmet
1555200|NCT02561728|Device|P-Pod Helmet|Child will be fitted with the P-Pod Helmet
1555201|NCT02561715|Behavioral|Questionnaires|Pre and post deep brain surgery questionnaires
1555202|NCT02561702|Other|Placebo|240 mg lactose powder in a size 3 capsule taken by mouth 3 times daily for 5-7 days
1555203|NCT02561702|Drug|Mexiletine|150 mg Mexiletine taken by mouth in capsule form 3 times daily for 5-7 days
1555204|NCT02561689|Other|Fissure sealing|"Procedure:
The included teeth of the participating patients will in any case be sealed, but in this study, the operator is not free to choose the material, the material choice is determined by randomisation
Standardized radiographs (bitewings) will be taken before treatment and after 1, 2, 3 years and possibly after 5 years. Baseline radiograph can be taken up to six months before treatment. If using conventional radiography, double-film packs will be used. A maximum of 8/10 bitewings will be taken during the study period of 3/5 years
The occlusal surface is sealed by the dentist or dental hygienist.
Clinical evaluation of the quality of sealants and the need for re-treatments during the follow-up will be performed after 1, 2 and 3 years and possibly after 5 years"
1555205|NCT02561676|Other|Education Program Type 1|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
1555206|NCT02561676|Other|Education Program Type 2|The classes will discuss topics related to health and functioning of people with spinal cord injury. During these classes, participants will be given information by the class instructor and will also participate in discussions and other learning activities with the rest of the group. Participants will be assigned activities to complete at home for about 30 minutes per day that relate to the topics discussed in class.
1555207|NCT02561663|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|egg-white protein hydrolysate
1555208|NCT02561663|Other|Placebo|
1555209|NCT02561650|Drug|COV155|COV155 tablets
1555210|NCT02561637|Behavioral|Case management|
1555211|NCT02561637|Behavioral|Control group|
1555212|NCT02561624|Behavioral|Behaviour change communication via text message|
1555213|NCT02561611|Behavioral|Intervention Group|The content of both intervention components will be covered during a weekly scheduled group meeting (or face-to-face meetings, as needed). The step-counting component of the WMPD intervention will be modeled off the success of The First Step Program (FSP).
1555214|NCT02561585|Drug|LEO 124249|
1555215|NCT02561585|Other|Vehicle|
1555216|NCT02561572|Other|Acupuncture|Yintang point acupuncture
1555217|NCT02561559|Radiation|Lung metastasis from soft-tissue sarcoma|Tretament based on Intensity Modulated Radiation Therapy (IMRT) using Volumetric Modulated Arc Therapy (VMAT)
1555218|NCT02561546|Drug|p53 gene therapy|Trans-catheter embolization (TAE) combined with recombinant adenoviral human p53 gene (rAd-p53) will be given one per month
1555219|NCT02561546|Drug|Trans-catheter embolization|Trans-catheter embolization alone
1555220|NCT02561533|Other|BRAF detection on fine needle aspiration biopsy (FNAB)|
1555221|NCT02561520|Biological|PRP eye drops|Eye drops 4x a day, patients will start this eye drop first.
1555222|NCT02561520|Biological|PPP eye drops|Eye drops 4x a day, patients will start this eye drops after PRP.
1555223|NCT02561507|Behavioral|Survey|
1555224|NCT02561494|Drug|Nefopam|
1555225|NCT02561494|Drug|Saline|
1555226|NCT02561481|Drug|Sulforaphane|See under active arm description
1555227|NCT02561481|Drug|Placebo|See under placebo arm description
1555228|NCT02561468|Drug|Nefopam|
1555229|NCT02561468|Drug|Saline|
1555230|NCT02561455|Drug|gilteritinib|oral
1555231|NCT02561442|Drug|ceftriaxone|
1555232|NCT02561429|Procedure|SPT|SPT of histamine concentration 1, 5 and 10 mg/ml
1555233|NCT02561416|Behavioral|MBSR|Session 1: Recognising the present moment Session 2: Engaging with the breath Session 3: Practice, practice, practice Session 4: Stress and the flow of emotions Session 5: Stress and thoughts: finding another place to stand Session 6: Interpersonal mindfulness / mindful communication. Session 7: Applying mindfulness Session 8: Making mindfulness a part of your life
1555234|NCT02561416|Behavioral|FibroQol|"Session 1: General information. Expectations of the patients. History of the illness. Principal and secondary symptoms in FM. Physiological mechanisms involved in the genesis of pain.
Session 2: Relaxation training-I. Session 3: Diagnosis. Pharmacological and non-pharmacological treatments. Prognosis. Current model of health care in Catalonia. Units specialized in the treatment of FM.
Session 4: Relaxation training-II. Session 5: Strategies to increase self-esteem and regulate emotions. Pain experience and recurrent invalidation. Social support (family and friends).
Session 6: Relaxation training-III Session 7: Benefits of physical exercise in FM. Session 8: Relaxation training-IV."
1555235|NCT02561416|Drug|TAU|In Spain the treatment as usual provided in FMS is mainly pharmacological and adjusted to the symptomatic profile of the patient. Counselling about aerobic exercise adjusted to patients' physical limitations is usually also provided.
1555236|NCT02561403|Behavioral|EVO multitask video game|Participants will play a multitasking game for 4 weeks
1555238|NCT02561390|Procedure|Skin prick test|skin prick test to American cockroach, dog, cat, dust mite and mold allergen extracts are performed
1555239|NCT02561390|Other|specific IgE measurement|measure specific IgE of American cockroach, dog, cat, dust mite and mold
1555240|NCT02561377|Behavioral|resistance training|Resistance training consisted of 6 different resistance exercises per session using elastic string, and each exercise progressed to 2-3 at maximum resistance lifted 8-10 times.
1555241|NCT02561377|Behavioral|aerobic training|Aerobic training consisted of aerobic exercise and progressed from 15-20min/session at 60% maximum heart rate to 45-50min/session at 75% maximum heart rate.
1555242|NCT02561351|Other|FeNO measurement|FeNO was performed repeatedly every 3 months in every cases. exacerbations were recorded each visit
1555243|NCT02561338|Drug|HMS5552|50mgBID/75mgBID/75mgQD/100mgQD
1555244|NCT02561338|Other|placebo|placebo BID/QD
1555245|NCT02561325|Drug|Sodium Bicarbonate and Sodium chloride|
1555246|NCT02561312|Other|Rapid manual partial exchange transfusion|The first four participants will receive peripheral red blood cells via rapid manual partial exchange transfusions every month for 6 months. There is a pre-study washout for 3 months then there is a 3 month test period (data collection) before the participant is transferred to ST treatment.
1555247|NCT02561312|Other|Simple Transfusion|The second group of four participants will receive peripheral red blood cells via simple transfusion every month for 6 months. There is a pre-study washout period for 3 months then there is a 3 month test period (data collection) before the participant is transferred to RMPET treatment.
1555248|NCT02561299|Device|Peripheral Orbital Atherectomy System|Orbital Atherectomy
1555249|NCT02561299|Device|014 Drug Coated Balloon|Drug Coated Balloon
1555250|NCT02561286|Behavioral|BRO HIV Risk Reduction Intervention|BRO HIV Risk Reduction Intervention was designed to strengthen outcome expectancies supporting condom use and other sexual risk reduction strategies and skill and self-efficacy to use condoms and reduce sexual risk behaviors. It consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals. Sessions 1 and 2 included take-home assignments that the participants reviewed at the subsequent session. The delivery of the intervention was tailored to the information that the participants provided during the sessions, including the context in which behaviors occurred and participants' motivation for the behaviors.
1555251|NCT02561286|Behavioral|Health Promotion Intervention|"Health Promotion Intervention was designed to provide a control for Hawthorne effects, reducing the likelihood that the HIV/STI risk-reduction intervention's effects could be attributed to non-specific features, including special attention. It focused on increasing physical activity and fruit-and-vegetable consumption and decreasing fat consumption to reduce the risk of chronic diseases, including heart disease, hypertension, stroke, diabetes, and certain cancers—leading causes of morbidity and mortality among African Americans It also consisted of three 90-min one-on-one individual sessions implemented during 3 consecutive weeks by specially trained facilitators using standardized intervention manuals."
1555252|NCT02561273|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous stem cell transplant
1555253|NCT02561273|Drug|Cyclophosphamide|Given IV
1555254|NCT02561273|Drug|Doxorubicin Hydrochloride|Given IV
1555255|NCT02561273|Drug|Etoposide|Given IV
1555256|NCT02561273|Other|Laboratory Biomarker Analysis|Correlative studies
1555257|NCT02561273|Drug|Lenalidomide|Given PO
1555258|NCT02561273|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
1555259|NCT02561273|Drug|Prednisone|Given PO
1555260|NCT02561273|Drug|Vincristine Sulfate|Given IV
1555263|NCT02561234|Drug|Co-ArgI-PEG|modified human arginase I
1555264|NCT02561221|Behavioral|Lifestyle Counseling|"Trained health coaches will deliver the active intervention - a comprehensive, high-intensity program, as recommended first-line therapy by the 2013 American Heart Association/American College of Cardiology/The Obesity Society Guidelines."
1555265|NCT02561208|Other|mHealth Intervention Group|Women with HPV self-collected tests will receive a mixed intervention which includes counseling through an interactive Apps specifically devised to increase adherence to triage which will be run on a tablet, and SMS text messages (SMS message) to remind them to attend triage. In addition, Heads of CHWs, chiefs of gynecology services and CHWs will receive reminders via e-mails to contact women if after 60 days from the HPV-results HPV+ they have not performed triage.
1555266|NCT02561195|Biological|Clostridium difficile Vaccine|0.5 mL intramuscular injection.
1555267|NCT02561195|Biological|Placebo|0.5 mL intramuscular injection
1555268|NCT02561169|Drug|Oseltamivir|Those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
1555269|NCT02561169|Other|Placebo|Those randomized to the control arm will receive 75mg placebo calcium carbonate pills taken twice daily for five days within 72 hours of symptom onset and will be identical in appearance to oseltamivir. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
1555270|NCT02561156|Drug|TAK-653 Placebo|TAK-653 placebo-matching tablets
1555271|NCT02561156|Drug|TAK-653|TAK-653 tablets
1555272|NCT02561143|Dietary Supplement|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients will be given 100 grams of Improved Atta (to make unleavened bread) everyday for consumption for six months.
1555273|NCT02561143|Dietary Supplement|Wheat flour|Whole wheat flour 100 grams (to make unleavened bread) will be given everyday for consumption for six months to the patients.
1555274|NCT02561143|Behavioral|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), will be encouraged daily during counseling sessions.
1555275|NCT02561143|Other|Nutritional counseling|Dietary counseling for 30 minutes will be imparted to all patients on every hospital visits by the nutritionist. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) will be encouraged in their daily diets.
1555278|NCT02561130|Drug|Forxiga|Dose is titrated to 10 mg po daily or maximal tolerated dose
1555279|NCT02561130|Behavioral|Lifestyle therapy|Lifestyle intervention includes individualized dietary and exercise advice and frequent visits for goal reinforcement, behavior modification and problem-solving
1555280|NCT02561117|Drug|Metronidazole|Administration once daily
1555281|NCT02561104|Procedure|Laser-assisted cataract surgery.|
1555282|NCT02561104|Procedure|Traditional manual phacoemulsification|
1555286|NCT02561078|Drug|Human regular U-500 insulin (CSII)|Administered SC
1555287|NCT02561078|Drug|Human regular U-500 insulin (MDI)|Administered SC
1555288|NCT02561065|Behavioral|Lifestyle intervention|"Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.
The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.
A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday."
1555289|NCT02561039|Drug|Ibandronate|Participants will receive ibandronate, either as a 6-mg IV infusion every 3 to 4 weeks or a 50-mg tablet PO daily, for 4 months.
1555290|NCT02561026|Biological|Frozen plasma|patients randomized to receive frozen plasma transfusions
1555291|NCT02561013|Device|3M™ Coban™ Custom Fit Compression System|"3M Coban™ Fit is a compression system that consists of two components: 1. A Compression Stocking and 2. Coban™ Fit Sleeve.
The stocking provides compression to the foot and improves wearing comfort in the calf area under the sleeve. The compression sleeve is intended to provide the therapeutic compression to the calf, with the initial fitting to be done by a health-care professional. The compression sleeve is customized according to the anatomy of the patient's leg; both components are designed to be used together."
1555292|NCT02561013|Device|Profore|PROFORE is a multi-layer compression bandaging system developed to apply sustained graduated compression for the management of venous leg ulcers and associated conditions. Multi-layer compression bandaging is the first choice in treatment for venous leg ulcers.
1555293|NCT02561000|Drug|PZ-128|
1555294|NCT02561000|Drug|Placebo|
1555295|NCT02560974|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m^2 BID on Days 1 to 15 of a 3-week cycle, for 8 cycles.
1555296|NCT02560974|Drug|Oxaliplatin|Oxaliplatin will be administered as an IV infusion, 130 mg/m^2 on Day 1 of each 3-week cycle for 8 cycles.
1555297|NCT02560961|Other|Kinesio Taping (Kinesio Tex Gold®; color: black)|Kinesio Taping technique described by Kase for activation of the triceps surae on the dominant leg will be employed, with the volunteer in the prone position, maintaining the dominant leg off the cot with hip extension, knee extension and ankle dorsiflexion to maintain the triceps surae in a stretched position. The tape will be applied in a Y shape beginning with the origin of the muscle (femur condyles) without tension (Anchor I), passing over the belly of the muscle (therapeutic region) with 15 to 20% tension and ending near the posterior surface of the heel (Anchor II) without tension.
1555298|NCT02560961|Other|Placebo Taping|Standard white bandaging tape will be applied by the same researcher who placed the tape in Group A. The application will be performed the same way as a kinesio taping.
1555299|NCT02560948|Biological|Placebo solution|4 x 2 injections over 21 days
1555300|NCT02560948|Biological|gpASIT+TM|4 x 2 injections over 21 days
1555301|NCT02560935|Drug|Hydroxyurea (Moderate Dose)|The study intervention will include moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) for 36 months.
1555302|NCT02560935|Drug|Hydroxyurea (Low Dose)|The study intervention will include random allocation to low dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day) for 36 months.
1555303|NCT02560922|Behavioral|Pain Coping Skills Training (CST)|The pain CST intervention includes 11 individual sessions with a study counselor, delivered via telephone to enhance access and reach. The sessions include the following: general information about why pain coping skills training is important, training in specific pain coping skills (such as progressive muscle relaxation, communication, imagery, and activity pacing), and guided practice with each skill. The CST program will also include information about other behaviors important for OA, such as physical activity and weight management.
1555304|NCT02560909|Biological|FLUAD® influenza vaccine|MF59 adjuvant has been used in seasonal influenza vaccine in Canada and Europe for people ≥65 years. MF59 contains squalene, polysorbate 80, and sorbitan trioleate. It is packaged as small microvesicles of 160nm diameter. The complete mechanism of action of MF59 is not well understood but requires activation of the innate immune system; the adjuvant exerts a local inflammatory response increasing the influx of neutrophils and macrophages to the injection site.
1555305|NCT02560909|Biological|FLUVIRAL®|Standard 2015-2016 nonadjuvanted vaccine
1555306|NCT02560870|Drug|Active Comparator:Aloe Vera mouthwash|mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
1555307|NCT02560870|Drug|Active Comparator:Chlorhexidine mouthwash|mouthwash( Chlorhexidine ),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
1555309|NCT02560831|Behavioral|Therapeutic exercise and Pompage|Strengthening exercises for flexors and knee extensors, balance training, knee's pompage twice per week for 12 weeks.
1555310|NCT02560831|Behavioral|Educational lectures|Educational lectures in four meetings for 12 weeks (Control Group)
1555348|NCT02560636|Radiation|Radiotherapy|Radiotherapy - Standard Treatment
1555349|NCT02560623|Device|Sponge capsule|Subjects will swallow sponge capsule and esophageal cells will be collected on deployed sponge.
1555350|NCT02560610|Drug|OC000459|
1555351|NCT02560610|Drug|Placebo|
1555393|NCT02560298|Other|Quality-of-Life Assessment|Ancillary studies
1555313|NCT02560805|Procedure|Microneurography|Skin will be stimulated with a pencil-shaped electrode to find a certain nerve. Once the nerve is found, two tiny sterile wire needles (about the size of acupuncture needles) will be put in the skin. One needle is put just under the skin at a short distance away from the nerve, and the other one into the nerve. The needles are attached to a computer recorder to record the nerve activity. It may take up to one hour to get the needles in the right place. After the tiny needle is in the right place, investigators record nerve activity at rest for about 10 minutes. Then, it will be recorded throughout the rest of the visit (up to 4 hours).
1555314|NCT02560805|Behavioral|Combat virtual reality video clip|Subjects will watch a video clip of combat on a computer screen or wearing video goggles.
1555315|NCT02560805|Procedure|Handgrip Exercise|Subjects will squeeze a hand dynamometer intermittently.
1555316|NCT02560805|Procedure|Cold Pressor Test (CPT)|Subjects' hand will be submerged in cold water (~0-1°C) up to the wrist for 1 minute.
1555317|NCT02560805|Drug|Sodium Nitroprusside (SNP)|Subjects will receive sodium nitroprusside 100 µg, which is bolused through an antecubital intravenous catheter.
1555318|NCT02560805|Drug|Phenylephrine|Subjects will receive phenylephrine 150 µg, which is bolused through an antecubital intravenous catheter 60 seconds after the sodium nitroprusside bolus
1555319|NCT02560805|Drug|Losartan|Subjects will receive Losartan 25 mg once a day orally up to 12 weeks
1555320|NCT02560805|Drug|Atenolol|Subjects will receive Atenolol 25 mg once a day orally up to 12 weeks
1555321|NCT02560792|Behavioral|Positive Affect Condition|"Participants read: Most people exercising at this intensity say that it feels good, and that it makes them feel energized and more positive, and more relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to positive feelings, and what specifically about this exercise might make you, personally, feel good."
1555322|NCT02560792|Behavioral|Negative Affect Condition|"Participants read: Most people exercising at this intensity say that it doesn't feel very good, and that it makes them feel tired and not so positive, and not very relaxed afterwards. Thinking about your exercise prescription, please list the reasons or ways in which you, personally, might expect this exercise to lead to negative feelings, and what specifically about this exercise might make you, personally, feel bad."
1555323|NCT02560792|Behavioral|Control Condition|Participants receive no information about affective response
1555326|NCT02560766|Drug|HORIZANT 300 mg|HORIZANT 300 mg once daily
1555327|NCT02560766|Drug|HORIZANT 600 mg|HORIZANT 600 mg once daily
1555328|NCT02560766|Drug|Placebo|Placebo once daily
1555329|NCT02560753|Drug|T3D-959|The 3mg dosage is supplied as 1mg capsules (three capsules, taken once daily by mouth) The 10mg dosage is supplied as 5mg capsules (two capsules, taken once daily by mouth) The 30mg dosage is supplied as either 5mg or 15mg capsules (six 5mg capsules or two 15mg capsules taken once daily by mouth) The 90mg dosage is supplied as 15mg capsules (six capsules, taken once daily by mouth)
1555330|NCT02560740|Dietary Supplement|PerOx Quench|By 1 week pretreatment of PerOx Quench and following 4 weeks taken to decrease the CIPN incidence.
1555331|NCT02560740|Dietary Supplement|PerOx Quench Placebo|By 1 week pretreatment of Placebo and following 4 weeks taken to record the CIPN incidence.
1555332|NCT02560727|Device|transendoscopic enteral tubing|Investigators designed transendoscopic enteral tubing (TET).The enteral segment of the tube is fixed in the ileocecum with distal segment fixed buttocks. The tube was used for FMT and colonic local administration
1555333|NCT02560727|Device|colonoscope|FMT via colonoscope is the most common approach.
1555334|NCT02560714|Device|SImmetry Sacroiliac Fusion System|"SImmetry
The SImmetry device is commercially available. The implanted devices consist of a range of threaded, self-tapping, cannulated implants designed to transfix the sacrum and ilium, providing stability for intra-articular fusion.
The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
1555335|NCT02560701|Other|Patient Interview|Investigators will conduct in-depth interviews with approximately 40 commercially insured individuals with bipolar disorder or their family caregivers to explore how they navigate deductibles, copayments, and other complex insurance features. Investigators will also determine the health care services that patients most value and assess how they prioritize difficult health care cost tradeoffs.
1555336|NCT02560688|Drug|DS-1040b|20 mg single 12-hour intravenous infusion
1555337|NCT02560688|Drug|Clopidogrel|Clopidogrel (Plavix) administered orally 300 mg loading dose on Day 1 followed by 75 mg daily on Days 2-5
1555338|NCT02560662|Behavioral|Physical activity|"Preoperative intervention - takes place from randomization until surgery (4 weeks +/-2 w):
• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.
Postoperative intervention - takes place from discharge from the hospital until 4 weeks postoperatively:
• 30 minutes of exercise daily added to the existing daily exercise routine. The level of exercise should produce shortness of breath but the patient should be able to talk without much effort.
Participants randomized to intervention will receive a visit to a physiotherapist for personally adjusted information regarding the intervention, later followed up with a telephone call."
1555339|NCT02560649|Drug|Peginterferon alfa-2a plus Entecavir|Peginterferon alfa-2a 180μg /wk plus Entecavir 0.5mg qd for 48 weeks(Arm A and B)
1555340|NCT02560649|Drug|Peginterferon alfa-2a plus Lamivudine|Peginterferon alfa-2a 180μg /wk plus Lamivudine 0.1g qd for 48 weeks(Arm A and B)
1555341|NCT02560649|Drug|Peginterferon alfa-2a plus Adefovir|Peginterferon alfa-2a 180μg /wk plus Adefovir 10mg qd for 48 weeks(Arm A and B)
1555342|NCT02560649|Drug|Peginterferon alfa-2a plus Tenofovir|Peginterferon alfa-2a 180μg /wk plus Tenofovir 300mg qd for 48 weeks(Arm A and B)
1555343|NCT02560649|Drug|Entecavir|Entecavir 0.5mg qd for 24 weeks(Arm C)
1555344|NCT02560649|Drug|Lamivudine|Lamivudine 0.1g qd for 24 weeks(Arm C)
1555345|NCT02560649|Drug|Adefovir|Adefovir 10mg qd for 24 weeks(ArmC)
1555346|NCT02560649|Drug|Tenofovir disoproxil|Tenofovir 300mg qd for 24 weeks(Arm C)
1555347|NCT02560636|Drug|Pembrolizumab|Pembrolizumab - Trial Treatment
1555389|NCT02560298|Drug|Cisplatin|Given IV
1555352|NCT02560597|Procedure|repetitive transcranial magnetic stimulation|"Stimulation over the epileptogenic focus using variable stimulation protocols as described in literature. This protocol may vary case by case, depending on patient characteristics and achieved effect from previous stimulation.
In absence of effect, rTMS is given on 5 consecutive days at most."
1555353|NCT02560584|Drug|Hexaminolevulinate hydrochloride|Instillation in bladder
1555354|NCT02560584|Device|KARL STORZ D-Light C PDD Flexible Videoscope System|Cystoscopy procedure
1555355|NCT02560571|Device|ultrasound|
1555356|NCT02560571|Other|blood test|
1555357|NCT02560558|Drug|Belatacept|Belatacept is an immunosuppressive medication and will be given as an intravenous infusion at a dose of 5 mg/kg at 4-weekly or 8-weekly intervals.
1555358|NCT02560545|Drug|Cannabis oil|Cannabis oil 20% THC
1555359|NCT02560532|Drug|Clazosentan|Concentrated solution for intravenous injection
1555362|NCT02560506|Device|Elastic assisted treadmill walking|Rubber band pulley system that will assist therapists in advancing limbs while gait training. The device is positioned in front of a treadmill and the stretch of the elastic bands when a legs moves backwards on a treadmill is resists the movement and facilitates limb swing when walking.
1555363|NCT02560493|Behavioral|Exergaming Condition|Participants are encouraged to meet the MVPA goal of 60 minutes/day, which will be gradually achieved beginning with 10 minutes/day in Week 1 and reaching 60 minutes/day in Week 6. Three hours each week will be devoted to exergame play, following prescribed exergame routines.
1555364|NCT02560480|Device|magnetic resonance imaging|to diagonose groin injury exactly in magnetic resonance imaging
1555365|NCT02560467|Drug|Echo and myocardial contrast echocardiography perfusion imaging|"Myocardial blood flow will be assessed by myocardial contrast echo. Perfusion at rest and stress will be quantified and compared to patient sx, degree of dysfunction on echo strain imaging, and degree of fibrosis on magnetic resonance imaging (when available) that was ordered as part of routine clinical care.
Myocardial contrast echocardiography will be performed by intravenous administration of ultrasound contrast agent (Definity or Lumason) using FDA-approved dose limits. Vasodilator stress during MCE imaging will be performed using regadenoson at FDA-approved doses."
1555366|NCT02560454|Behavioral|Cogmed|"Cogmed training working memory (unifactorial). Before beginning the program an appointment of one hour will be organized to present the program.
Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.
A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.
Cogmed working memory training CogMed RM® (RoboMemo,Cognitive Medical Systems AB, Stockholm) version for children will be used in this program. Twelve exercises target verbal and visio-spatial working memory. Difficulty is adjusted depending on participant performance`s"
1555367|NCT02560454|Behavioral|Presco|"Presco drive of several cognitive functions (multifactorial). Before beginning the program an appointment of one hour will be organized to present the program.
Participants will train at home during 25 sessions (about 30-45 minutes each) over a maximum of 5-6 weeks.
A coach will call the participant one a week to verify program adherence. The coach will verify participant results on internet before calling.
The program PRESCO® (Program in Cognitive Stimulation and rehabilitation ) comprises 40 exercises targeting: verbal and visio spatial working memory, attention capacities, reasoning, executive functioning , language and mental imagery. Only exercises targeting verbal, visual spatial working memory, and attentional capacities altered in ADHD are used in this present study. Difficulty is adjusted depending on the participant performances."
1555368|NCT02560441|Other|chemotherapy followed by radiotherapy|
1555369|NCT02560441|Other|radiotherapy followed by chemotherapy|
1555370|NCT02560441|Drug|IPGDP regimen chemotherapy|
1555371|NCT02560428|Behavioral|ESCALATES|The investigators collect and analyze qualitative data to identify the most effective combinations of intervention strategies for various practice types, contexts, and organizational characteristics, and to understand why and how those combinations are effective. The investigators also gather de-identified quantitative data that the R18s collected.
1555372|NCT02560415|Device|Experimental|Gaming Open Library for Intervention in Autism at Home plus Treatment as usual
1555373|NCT02560415|Behavioral|Comparator|Treatment as usual
1555374|NCT02560389|Drug|Placebo|Sugar pill packaged to resemble levodopa
1555375|NCT02560389|Drug|Levodopa|EIther 100mg or 200 mg, depending on arm assignment, administered once by mouth.
1555376|NCT02560376|Drug|68Ga-NOTA-exendin-4|68Ga-NOTA-exendin-4 were injected into the patients before the PET/CT scans
1555377|NCT02560363|Drug|AZD9977 immediate release (IR) oral suspension|120 mg (4.8 mL x 25 mg/mL) oral suspension, single dose
1555378|NCT02560363|Drug|AZD9977 extended release (ER) capsules [fast]|120 mg (2 x 60mg capsules) single dose
1555379|NCT02560363|Drug|AZD9977 extended release (ER) capsules [intermediate]|120 mg (2 x 60mg capsules) single dose
1555380|NCT02560363|Drug|AZD9977 extended release (ER) capsules [slow]|120 mg (2 x 60mg capsules) single dose
1555381|NCT02560350|Other|no intervention|no intervention
1555382|NCT02560337|Drug|Cabazitaxel|
1555383|NCT02560337|Drug|Tocotrienol|
1555384|NCT02560324|Drug|Ramelteon|
1555385|NCT02560324|Drug|Placebo|
1555386|NCT02560311|Other|observation|
1555387|NCT02560298|Drug|Capecitabine|
1555388|NCT02560298|Drug|Carboplatin|Given IV
1555394|NCT02560272|Biological|Minhai-HIB|0.5ml, intramuscular
1555395|NCT02560272|Biological|Act-HIB®|0.5ml, intramuscular
1555396|NCT02560259|Other|Physiotherapy|Physiotherapy
1555397|NCT02560259|Other|Conservative treatment|Conservative treatment
1555398|NCT02560233|Other|Contingent RT-fMRI-NF|Subjects are provided with contingent RT-fMRI-NF of brain activity in the target region of interest.
1555399|NCT02560233|Other|Sham RT-fMRI-NF|Subjects are provided with sham RT-fMRI-NF of brain activity of previously recorded subject.
1555400|NCT02560220|Biological|Mitomycin C-induced peripheral blood mononuclear cells (MICs)|MICs are given intravenously 2 or 7 days before kidney transplantation from a living donor
1555401|NCT02560207|Drug|Cefotaxime|To assess the influence of administration route on target attainment cefotaxime is administered via two IV routes.
1555402|NCT02560194|Procedure|Flexible Sigmoidoscopy|Examination of the rectal and distal colon by means of a flexible endoscope
1555403|NCT02560194|Other|Fecal occult blood test|Test for hemoglobin in faeces
1555404|NCT02560181|Radiation|HDR brachytherapy|Whole gland salvage
1555410|NCT02560129|Other|Questionnaires, Physical and Cognitive Function|ICU survivors will be administered a battery of questionnaires. Measurements of physical and cognitive function will also be performed.
1555411|NCT02560103|Other|Transmeridian travel across multiple time zones|
1555412|NCT02560090|Behavioral|Surveys|The following information will be collected: demographics, literacy screener, depression screener, medication adherence, self-efficacy, tobacco use, patient activation, health questionnaire, eating patterns, diabetes self-management assessment, stages of change questionnaire, vitals, and self-care behaviors.
1555413|NCT02560090|Behavioral|Telephonic Nurse Intervention|A nurse will contact patients by phone at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
1555414|NCT02560090|Behavioral|In-person Community Health Worker|An in-person Community Health Worker will contact patients in-person at least weekly for month 1 and at least every other week for months 2 and 3 and will collect the following information: medication adherence, discharge plan adherence, problem solving, diet and physical activity issues and to assess self-management, dietary, and physical activity improvements. In addition the nurse will link participants with resources.
1555415|NCT02560077|Other|placebo|Subject receive the Placebo product (placebo group had same color and smell of treatment groups)
1555416|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 120 mg/day after meal
1555417|NCT02560077|Other|cashew apple juice|Subject received the cashew apple juice at dose of 240 mg/day after meal
1555418|NCT02560064|Procedure|Laparotomy|Small bowel length will measure in laparotomy, regardless of indication.
1555427|NCT02560025|Drug|Alisertib|
1555428|NCT02560025|Drug|Cytarabine|
1555429|NCT02560025|Drug|Idarubicin|
1555430|NCT02560025|Drug|Daunorubicin|Can be used in place of idarubicin
1555431|NCT02560012|Drug|Sunitinib|One 50-mg capsule taken orally once daily, on a schedule of 4 weeks on treatment followed by 2 weeks off
1555432|NCT02560012|Drug|Temsirolimus|25 mg by an IV infusion over 30-60 minutes, once a week
1555433|NCT02560012|Drug|Sorafenib|400 mg (2 tablets) orally twice daily without food
1555434|NCT02560012|Drug|Pazopanib|800 mg orally once a day without food, at least 1 hour before or 2 hours after a meal
1555435|NCT02560012|Drug|Everolimus|10 mg orally once daily with or without food
1555436|NCT02560012|Drug|Axitinib|5 mg orally twice daily
1555437|NCT02559999|Other|Painful tonic stimuli|
1555438|NCT02559999|Other|non-painful stimuli|
1555439|NCT02559986|Other|telephone interview|telephone interview about their care received during the first year of life and associated events
1555440|NCT02559973|Drug|RBP-6000|RBP-6000 uses buprenorphine in the ATRIGEL Delivery System. The single-syringe is prefilled with RBP-6000 containing 300 mg buprenorphine.
1555441|NCT02559973|Drug|SUBOXONE Sublingual Film|Subjects will be dose-stabilized on SUBOXONE sublingual film prior to administration of RBP-6000. SUBOXONE sublingual film will be administered beginning after the subject is experiencing signs and symptoms of withdrawal on Day -8 and continue until Day -1.
1555442|NCT02559960|Drug|Breviscapine Powder-Injection|Patients will be given Breviscapine Powder-Injection according to their disease condition in the real world. The investigator only can record the information on the usage of the drug and the relevant medications without any interventions.
1555443|NCT02559934|Drug|SR-T100 Gel|0.3-0.5 g topical SR-T100 gel (containing 2.3% solamargine in Solanum undatum plant extract)
1555444|NCT02559921|Biological|rhRIG（20 IU/kg）|
1555445|NCT02559921|Biological|rhRIG（40 IU/kg）|
1555446|NCT02559921|Biological|HRIG（20 IU/kg）|
1555447|NCT02559921|Biological|rhRIG（20 IU/kg） and vaccine|
1555448|NCT02559921|Biological|rhRIG（40 IU/kg） and vaccine|
1555449|NCT02559921|Biological|HRIG（20 IU/kg） and vaccine|
1555450|NCT02559921|Biological|placebo and vaccine|
1555451|NCT02559908|Device|Hyaluronic Acid Injectable Gel|Hyaluronic Acid Injectable Gel (VYC-25L) injection into the chin and/or jaw areas (up to 4.0 mLs).
1555452|NCT02559895|Drug|ALD403|
1555453|NCT02559895|Drug|Placebo|
1555454|NCT02559869|Drug|[18F] GE-180|PET Tracer Ligand
1555455|NCT02559856|Drug|Apixaban|
1555456|NCT02559856|Drug|Rivaroxaban|
1555457|NCT02559843|Dietary Supplement|pomegranate juice|
1555458|NCT02559843|Behavioral|lifestyle modification|
1555459|NCT02559830|Genetic|transduced CD34+ hematopoietic stem cell|Autologous hematopoietic stem cells (HSCs) collected from the mobilized peripheral blood and transduced ex vivo with a Lentiviral vector encoding the human ARSA(for MLD)/ABCD1(for ALD) cDNA（complementary DNA）. Dose: ≥ 2x10^6 transduced CD34+ cells/Kg (maximum 20x10^6) at bedside for infusion.
1555460|NCT02559817|Drug|Linaclotide Dose A|
1555461|NCT02559817|Drug|Linaclotide Dose B|
1555462|NCT02559817|Drug|Linaclotide Dose C|
1555463|NCT02559817|Drug|Linaclotide Approved Adult Dose|
1555464|NCT02559817|Drug|Matching Placebo|
1555465|NCT02559804|Other|survival and late effects|survival and late effects
1555466|NCT02559791|Biological|Reslizumab|Reslizumab 3ml/kg once monthly for 4 months
1555467|NCT02559791|Drug|Placebo|Matching placebo once monthly for 2 months
1555468|NCT02559778|Drug|bortezomib|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
1555469|NCT02559778|Drug|crizotinib|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
1555470|NCT02559778|Drug|dasatinib|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
1555471|NCT02559778|Drug|lapatinib|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
1555472|NCT02559778|Drug|sorafenib|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
1555473|NCT02559778|Drug|vorinostat|One of the following drugs will be chosen for each subject based on molecular guided results: bortezomib, crizotinib, dasatinib, lapatinib, sorafenib or vorinostat. This will be followed by consolidation, immunotherapy, and then DFMO for 2 years as maintenance.
1555474|NCT02559778|Drug|DFMO|DFMO will be given for 2 years as maintenance to all subjects completing immunotherapy.
1555475|NCT02559752|Other|NIH Toolbox Cognitive Battery|"For ages 4 to 7 years, the NIH Toolbox Early Childhood Battery will be administered. This test includes the Picture Vocabulary, Flanker Inhibitory Control and Attention, Dimensional Change Card Sort, and Picture Sequence Memory measures to evaluate language, executive function, attention, and episodic memory, respectively.
For patients age 8 years or older, the administered battery will consist of the aforementioned tests in addition to Oral Reading Recognition, Pattern Comparison Processing Speed, and List Sort Working Memory tests. Results will include scores for each individual measure. In addition, each cognition battery provides composite scores, which allow for general interpretation/evaluation of overall cognitive functioning."
1555476|NCT02559752|Device|Proton Beam Radiation Therapy|-Standard of care
1555477|NCT02559726|Procedure|Echocardiography (TEE)|
1555478|NCT02559726|Device|Magnetic resonance imaging (MRI) with gadolinium enhancement|
1555479|NCT02559726|Device|Magnetic resonance imaging (MRI) without gadolinium enhancement|
1555480|NCT02559726|Procedure|3D electrocardiographic mapping (ECM)|
1555481|NCT02559713|Drug|Vedolizumab|Vedolizumab intravenous infusion
1555482|NCT02559700|Behavioral|Brain training programme|An online package of brain training programmes
1555484|NCT02559674|Biological|Gemcitabine|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of gemcitabine given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
1555485|NCT02559674|Biological|Nab-paclitaxel|Intravenous Infusion; Patients will receive two 4-week treatment cycles consisting of nab-paclitaxel given on Day 1, 8, 15, 29, 36, and 43. Eligible patients may receive up to 10 additional treatment cycles.
1555486|NCT02559674|Biological|ALT-803|Subcutaneous Injection; Patients will receive two 4-week cycles consisting of ALT-803 given on Day 2, 9, 16, 30, 37, and 44. Eligible patients may receive up to 10 additional treatment cycles.
1555487|NCT02559661|Other|Training on a virtual simulator in eye surgery|
1555525|NCT02559492|Drug|INCB050465|INCB050465 tablets will be administered orally once daily.
1555526|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 18%-protein diet|
1555488|NCT02559648|Drug|Denosumab|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.
The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
1555489|NCT02559648|Drug|Placebo|"Patients will be randomly assigned, in a 1:1 fashion, to the two therapeutic arms (Group A, Group B, respectively), upon enrollment in the study.
The effect of denosumab on lumbar spine BMD (bone mineral density) in patients with Thalassemia Major and Osteoporosis as compared with control at 12 months will be evaluated."
1555490|NCT02559635|Procedure|Bowel stimulation|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
1555491|NCT02559635|Drug|Nestle Resource|Stimulation will be performed daily on an outpatient basis for the two weeks (ten business days) prior to ileostomy closure by a trained research assistant. The efferent limb of the ileostomy loop will be canalized with an 18 Fr Foley catheter and infused with a solution comprising of 500mL of normal saline mixed with 30g of a thickening-agent (Nestle Resource). It will be prepared in five 100mL syringes and administered slowly over 20 minutes.
1555492|NCT02559622|Drug|Secukinumab|300 mg secukinumab
1555493|NCT02559622|Other|Placebo|Placebo followed by 300 mg secukinumab
1555494|NCT02559622|Other|Placebo|Placebo followed by 150 mg secukinumab
1555495|NCT02559622|Drug|Secukinumab|150 mg secukinumab
1555496|NCT02559609|Behavioral|contingency management for alcohol abstinence|Participants will earn chances to win prizes for each negative breath alcohol recording provided.
1555497|NCT02559609|Behavioral|contingency management for activity completion|Participants will earn chances to win prizes for completing specific job-related activities.
1555498|NCT02559609|Behavioral|activity contracting|Participants will complete job-related activity contracts each week with the goal of obtaining employment.
1555499|NCT02559583|Other|Chronic Lymphocytic Leukemia (CLL)|This is observational study. Participants with Chronic Lymphocytic Leukemia (CLL) will be observed for 1 year.
1555500|NCT02559583|Other|Multiple Myeloma (MM)|This is observational study. Participants with Multiple Myeloma (MM) will be observed for 1 year.
1555501|NCT02559583|Other|Non-Hodgkin's lymphoma (NHL)|This is observational study. Participants with non-Hodgkin's lymphoma (NHL) will be observed for 1 year.
1555502|NCT02559570|Drug|Linaclotide Dose A|
1555503|NCT02559570|Drug|Linaclotide Dose B|
1555504|NCT02559570|Drug|Linaclotide Dose C|
1555505|NCT02559570|Drug|Linaclotide Approved Adult Dose|
1555506|NCT02559570|Drug|Matching Placebo|
1555507|NCT02559557|Other|Educational Intervention|Participate in focus groups
1555508|NCT02559557|Other|Educational Intervention|Undergo Spanish-adapted skills training and homework assignments
1555509|NCT02559557|Other|Quality-of-Life Assessment|Answer questionnaires
1555510|NCT02559557|Other|Questionnaire Administration|Answer questionnaires
1555511|NCT02559544|Radiation|[18F]Fluoroestradiol (FES) PET/CT Imaging|
1555512|NCT02559531|Device|Mobile triage system|A mobile triage system used by EMS providers will be evaluated using standardized clinical vignettes
1555513|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
1555514|NCT02559518|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x5 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the right arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
1555515|NCT02559518|Device|tDCS|Sham ctDCS will be applied using the same electrodes placement and parameter settings of cathodal ctDCS. However, stimulation will last only 30 seconds but volunteers will be with electrodes montage for 20 minutes.
1555516|NCT02559518|Device|rTMS|High frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 10Hz, 110% RMT, 33 trains, 50 stimuli per train, intertrain interval of 25 seconds, 1650 stimuli.
1555517|NCT02559518|Device|rTMS|Low frequency c-rTMS will be applied through a figure-eight coil connected to a magnetic stimulator (Rapid², Magstim, UK) placed over the left cerebellar hemisphere (3 cm lateral to the inion), tangentially to the scalp and pointing upwards. Protocol: 1Hz, 110% RMT, 1000 stimuli (1 train).
1555518|NCT02559518|Device|rTMS|Sham c-rTMS will be performed with low frequency protocol using two coils. The first one - connected to the stimulator (Rapid², Magstim, UK) - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left cerebellar hemisphere.
1555519|NCT02559518|Device|pp-TMS assessment|SICI and ICF will be evaluated through pp-TMS. Subthreshold conditioning stimuli (80% of RMT) and suprathreshold test stimuli (120% of RMT) will be delivered at 2 milliseconds ISI, in order to determine SICI. ICF will be evaluated by MEP average at an ISI of 10 milliseconds. Ten stimuli will be applied at each condition (unconditioned pulse and pairs of stimuli with ISI of 2 and 10 milliseconds). Stimuli order delivery will be pseudo-randomized and SICI and ICF will be expressed as conditioned stimulus percentage regarding an unconditioned stimulus.
1555522|NCT02559492|Drug|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
1555523|NCT02559492|Drug|Epacadostat|Epacadostat tablets will be administered orally, twice daily.
1555524|NCT02559492|Drug|Itacitinib|Itacitinib (INCB039110) tablets will be administered orally once daily in the morning.
1555578|NCT02559115|Device|PET/CT Scan|
1555527|NCT02559479|Behavioral|Weight loss interventional study with a low-calorie 35%-protein diet|
1555528|NCT02559466|Device|Transcranial Magnetic Stimulation (TMS - ) - MagPro®|Class IIa
1555529|NCT02559466|Device|Positon Emission Tomography (PET) - Discovery 710®|Class IB
1555530|NCT02559453|Procedure|Debridement|Removing dead tissue from infected wounds.
1555537|NCT02559427|Other|3-week immediate SPA treatment|a comprehensive program soon after randomization including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
1555538|NCT02559427|Other|3-week late SPA treatment|a comprehensive program after 4.5 months, including sessions of balneotherapy, diet information, exercise training. The most adapted to the concerned pathology and common to all SPA resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massages shower...)
1555539|NCT02559414|Drug|Aspirin|
1555540|NCT02559414|Drug|Clopidogrel|
1555541|NCT02559401|Other|MRI|
1555542|NCT02559401|Other|Neurocognitive battery|
1555545|NCT02559375|Other|Survey|
1555546|NCT02559362|Behavioral|Survey|
1555547|NCT02559349|Other|Stool Collection|
1555548|NCT02559336|Other|Integrated palliative oncology care|Integrated palliative care and oncology care for advanced cancer patients who have an unplanned admission to hospital
1555549|NCT02559323|Other|Survey|
1555550|NCT02559310|Drug|lefamulin|antibacterial agent
1555551|NCT02559310|Drug|Moxifloxacin|antibacterial agent
1555552|NCT02559310|Drug|Linezolid|antibacterial agent
1555553|NCT02559297|Drug|Sevoflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 2% to 2.5% sevoflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of sevoflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
1555554|NCT02559297|Drug|Desflurane|After induction of anesthesia and successful intubation, 2 L/min N2O, 2 L/min O2 , and 6% to 8% desflurane will be given for 10 minutes then total flow will be decreased to 2 L/min. Anesthesia will be maintained using 1-1.5 minimal alveolar concentration (MAC) of desflurane in 50% O2 and 50% N2O. Ventilation will be adjusted to keep end-tidal carbon dioxide 30-35 mmHg (Tidal volume 7-10 mL/kg).
1555555|NCT02559284|Other|A postoperative care after ethmoid sinus surgery|"A comparison of two products used for nasal cavity cleansing, at the rate of 4 washes/day (240mL per wash), as local postoperative care following endoscopic sinus surgery. This surgery, known as an ethmoidectomy, aims to improve sinus ventilation, treat the chronically infected area, and remove polyps that cause nasal obstruction.
Detailed information concerning the purpose of nasal irrigation, as well as how to use and clean the device, will be given to patients upon inclusion.
The nasal washing procedure will be as follow:
Washing both nostrils using 180mL of solution distributed equally on each side to remove crusting and clotting
Gentle blowing of the nose
Rinsing both nostrils with the remaining 60mL of solution distributed equally on each side (no nose-blowing)."
1555556|NCT02559258|Drug|0.1 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1, infused over 30 minutes
1555557|NCT02559258|Drug|0.3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
1555558|NCT02559258|Drug|1.0 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 30 minutes
1555559|NCT02559258|Drug|3 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 60 minutes
1555560|NCT02559258|Drug|10 mg/kg epsi-gam or placebo (6:2)|administered as a single intravenous infusion on Day 1 infused over 120 minutes
1555561|NCT02559245|Other|Descurainia Sophia|
1555562|NCT02559245|Other|Ficus carica|
1555563|NCT02559232|Drug|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
1555564|NCT02559219|Other|Questionniares|
1555565|NCT02559206|Drug|Linaclotide|Oral, once daily
1555566|NCT02559206|Drug|Matching Placebo|Oral, once daily
1555568|NCT02559180|Drug|aflibercept|aflibercept 2mg given intravitreally every month until resolution of fluid in retina and then continued every 2 months for a total of 24 months of treatment
1555569|NCT02559167|Drug|Cannabidiol|The investigators will carry out a double-blind, randomized, controlled trial comparing the effects of 92 days of 400 (only for the first 2 Days starting on the Day 2 of the study) or 800 mg CBD (subjects who report side effects with the 800mg dose will be administered the CBD 400 mg dose for the remainder of the trial) vs. placebo administration on cocaine craving and relapse in 110 cocaine-dependent subjects.
1555570|NCT02559154|Drug|Bortezomib|
1555571|NCT02559154|Drug|Dexamethasone|
1555572|NCT02559154|Drug|Doxorubicin|
1555573|NCT02559154|Drug|Cyclophosphamide|
1555574|NCT02559154|Drug|Mitoxsnteone|
1555575|NCT02559154|Drug|Thalidomide|
1555576|NCT02559141|Drug|Dobutamine|If PPV ≤10%, volume substitution of 500 ml of crystalloids and/or colloids as long as CI was ≥2.5 l/min/m². Maintenance of CI ≥2.5 l/min/m² and MAP ≥65 mmHg was achieved by using dobutamine (10 µg/kg/min) and norepinephrine (0.03 µg/kg/min).
1555577|NCT02559115|Radiation|68Ga-RM2 (RM2)|
1555579|NCT02559102|Drug|Dexmedetomidine sedation|Patients receive dexmedetomidine sedation
1555580|NCT02559102|Drug|General sevoflurane anaesthesia|Patients receive general sevoflurane anaesthesia with endotracheal intubation
1555581|NCT02559102|Procedure|Caudal anaesthesia|single shot caudal anaesthesia
1555582|NCT02559102|Procedure|Inguinal hernia surgery|Infant inguinal hernia repair.
1555583|NCT02559076|Behavioral|Ten Steps leaflet advice for healthy lifestyle|Ten steps leaflet advice for healthy lifestyle
1555584|NCT02559063|Behavioral|Vision-based speed of processing training|computerized cognitive tasks addressing vision-based speed of processing
1555585|NCT02559063|Behavioral|Mental leisure activities|computerized cognitive tasks addressing different aspects of executive function
1555586|NCT02559050|Other|Customized 3D-printed nasal stent|Silicone stent with unconventional shape, 3D-printed based on patient's computed topographical images, to exactly fit newly made nasal cavity.
1555587|NCT02559037|Device|Acupuncture-moxibustion|"Acupuncture is puncture the needle into specific part of the body according to a certain angle, using specific means to cause the De-qi sensation, and maintain a certain amount of time.
Mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin, keeping the spot warm and making it reddened, but not burnt.The temperature maintained at 43 ± 1℃。"
1555588|NCT02559037|Device|Placebo acupuncture-moxibustion|"Placebo acupuncture is puncture the needle into specific part of the body according to a certain angle, without using specific means to cause the De-qi sensation, and maintain a certain amount of time.
Placebo mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin (farther than the real moxibustion), keeping the temperature maintained at 37 ± 1℃。"
1555589|NCT02559024|Drug|MEDI6469|MEDI6469 0.4 mg/kg IV x 3 doses over 5-6 days
1555590|NCT02558998|Other|Survey|
1555591|NCT02558985|Procedure|Casting|Serial casting is used to partially correct the deformity before beginning bracing. A cast can be considered a full-time brace which cannot be removed.
1555596|NCT02558959|Drug|Irinotecan|
1555597|NCT02558959|Drug|Capecitabine|
1555598|NCT02558946|Behavioral|Pelvic Floor Muscle Physical Therapy|The treatment group will receive pelvic floor muscle training through a course of three one-hour sessions with a trained pelvic floor physical therapist in addition to the current standard information from their surgeon. The physical therapy sessions will be conducted at 1-6 weeks preoperative, 1 week postoperative, and 4-6 weeks postoperative and will be coordinated with surgeon appointments to minimize any inconvenience and travel time.
1555599|NCT02558946|Behavioral|Control Group|At the cancer consultation visit, subjects will be educated by the urologist or urology team member regarding surgical and postoperative expectations. At this time, subjects will be provided verbal instruction and written information regarding Kegel exercises. Subjects in the control group may decide the duration and frequency of home exercise performance.
1555600|NCT02558933|Dietary Supplement|Epigallocatechin gallate|Pre and post study, non randomized, controlled and without placebo, to evaluate the efficacy of Epigallocatechin gallate (EGCG). It is a pilot study in a cohort of 40 FAS children, between 7 ans 14 years old. An oral dose of 9 mg/Kg/day will be administered during 1 year, with 6 control visits until 6 months after finishing the treatment.
1555601|NCT02558920|Other|Fructose-containing Sugars|An intervention in which calories from fructose-containing sugars are substituted, added, or subtracted in the diet
1555602|NCT02558907|Other|cognitive evaluation by MMS (Mini-Mental State Examination) and MoCA (Montreal Cognitive Assessment) tests|
1555603|NCT02558894|Drug|MEDI4736 monotherapy|MEDI4736 via IV infusion.
1555604|NCT02558894|Drug|tremelimumab+MEDI4736|tremelimumab+MEDI4736 via IV infusion.
1555605|NCT02558881|Procedure|Virtual colonoscopy|
1555606|NCT02558881|Procedure|Colon capsule|
1555607|NCT02558868|Drug|Oxaliplatin, Irinotecan|
1555608|NCT02558855|Other|Thrust Joint Manipulation of the Lumbar Spine|
1555609|NCT02558855|Other|Non-thrust Joint Manipulation of the Lumbar Spine|
1555649|NCT02558543|Drug|Ringer lactate|
1555650|NCT02558530|Other|Low carbohydrate diet|Isocaloric, carbohydrate restricted diet 14 days
1555651|NCT02558517|Drug|prednisone discontinuation|randomization
1555610|NCT02558842|Other|Education Strategy|"Interview with the patient and their contacts, even during hospitalization, Delivering educational material about TB distribution free; Advise the patient about the BHU nearest their home, where it will follow the treatment of tuberculosis. Provide the address and telephone contact BHU this writing.
During the time of TB treatment, contact the patient to see if it is adhering to treatment and answer questions about the disease and treatment, The contact will be performed weekly for the first month, biweekly for the other months.
During the treatment period, contact BHU to monitor the progress of the case. Monitoring will be terminated: when the patient is discharged after cure of BHU or when the patient is absent for more than 30 days from the last scheduled visit."
1555611|NCT02558829|Drug|Macimorelin|macimorelin acetate, 0.5 mg/kg body weight, drinking solution, single dose
1555612|NCT02558829|Drug|Insulin|Insulin, 0.10 U/kg (0.15 U/kg if BMI > 30 kg/m2), intravenous injection, single dose
1555613|NCT02558816|Drug|Ibrutinib + GA101 +GDC-0199|Step A : 9 patients will receive the combination of Ibrutinib + GA101, as soon as the step A patients are recruited and if no toxicity observed the step B will be initiated, Step B : 24 new patients will receive the combination of Ibrutinib + GA101 + GDC-0199
1555614|NCT02558803|Behavioral|Simple Reminder|A simple reminder prompt in which CHICA will provide an immunization reminder to the physician that the child is eligible for the 2nd or 3rd dose of vaccine.
1555615|NCT02558790|Drug|MMFS-201-301|
1555616|NCT02558777|Other|Multicomponent nurse-led intervention|"Participants in the intervention group received the first intervention in the first 24 hours from admission, and thereafter daily until hospital discharge. The intervention was carried out exclusively by the intervention nurses, and was composed of two main parts, being the first one a risk factor analysis, and the second one the intervention on the risk factors detected (orientation, sensorial deficit, sleep, mobilization, hydration, nutrition, drugs, elimination, oxygenation, pain). Furthermore, the intervention nurses identified the principal caregiver in the first 24 hours from admission, and provided an informative booklet about strategies and recommendations to prevent delirium incidence, including ambient strategies, orientation abilities, and identification of alert signs."
1555617|NCT02558764|Device|portable (pocket) negative pressure wound treatment device|PICO device will be applied to the surgical wounds of kidney transplant patients who are enrolled in the PICO group. These patients will have this device on for 7 days after undergoing kidney transplant surgery.
1555618|NCT02558751|Biological|23-valent pneumococcal polysaccharide vaccine|One standard adult dose of the 23-valent pneumococcal polysaccharide vaccine
1555619|NCT02558751|Biological|13-valent pneumococcal conjugate vaccine|One dose of the 13-valent pneumococcal conjugate vaccine, PCV13, followed 8 weeks later by one dose of the 23-valent pneumococcal polysaccharide vaccine, PPV23.
1555620|NCT02558738|Device|ear spray|
1555621|NCT02558725|Drug|two capsules of aktiferrin F|two capsules of Aktiferrin F or Foliferrin
1996275|NCT02510404|Biological|mCTLs|The investigators have elected to limit this phase I study to PIDD patients with active viral infections unable to be controlled with standard pharmacotherapy, who are therefore likely to benefit from mCTLs treatment. This trial will be performed as dose-escalation study. Patients will be evaluated for matched lines from a bank of third-party mCTLs, derived from CMV seropositive donors. These lines will have been used clinically in prior clinical trials, with safety demonstrated in the post-HSCT setting.
1555623|NCT02558699|Procedure|physician's personal experience|
1555624|NCT02558699|Procedure|Virtual rotor mapping|
1555625|NCT02558686|Other|Eccentric Exercise|Individuals will perform 3 sets of 10 repetitions of eccentric exercise of the infraspinatus muscle after the application of trigger point dry needling
1555626|NCT02558686|Other|Detuned Ultrasound|Individuals will received 10 minutes of detuned ultrasound on the infraspinatus muscle after the application of trigger point dry needling
1555627|NCT02558686|Other|Placebo|Individuals will not perform any action after the application of trigger point dry needling
1555628|NCT02558673|Other|TMAO dietary precursors|
1555629|NCT02558673|Other|Control (or active comparator)|
1555630|NCT02558660|Behavioral|Education|Educational intervention about an existing SNAP healthy food incentive program
1555631|NCT02558660|Behavioral|voucher|$10 voucher to spend on produce at farmers markets
1555632|NCT02558647|Behavioral|CBT for insomnia SHUTi|
1555633|NCT02558647|Behavioral|passive patient education/sleep hygiene|
1555634|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation ON|
1555635|NCT02558634|Device|VIM Thalamic Deep Brain Stimulation OFF|
1555636|NCT02558621|Device|AQrate Robotic Assistance System|Robotic guidance during spinal fusion surgery
1555637|NCT02558608|Procedure|DIPL|dissection of the inferior pulmonary ligament
1555638|NCT02558608|Procedure|WR|wedge resection of the lung bleb
1555639|NCT02558608|Procedure|thoracoscopic surgery|surgery performed by video assisted thoracoscopy
1555640|NCT02558595|Dietary Supplement|Niacinamide|
1555641|NCT02558595|Other|Placebo|Placebo pill that matches niacinamide pill is size, shape and color
1555642|NCT02558582|Behavioral|respiratory and exercise therapy|The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
1555643|NCT02558582|Behavioral|respiratory and exercise therapy with supplemental oxygen|"The PH specific rehabilitation consists of: bicycle ergometer training, respiratory training, dumbbell-training and (mental) gait training.
Patients who are not already under long-term oxygen therapy (LTOT) due to daytime hypoxemia will additionally be randomized to receive standardized supplemental oxygen therapy (SSOT) during training and nights."
1555644|NCT02558569|Drug|Levobupivacaine|L form of bupivacaine with less cardiotoxicity.
1555645|NCT02558569|Other|NSS|Clear intravenous fluid looks alike local anesthetic.
1555646|NCT02558556|Device|Laparoscopic Fluorescence Imaging System (Karl Storz)|The Laparoscopic Fluorescence Imaging System (incl. laparoscope, light source, light cable) will supply the needs for near-infrared fluorescence imaging with ICG. The hypothesis is that this device will help in visualizing the anatomical structures such as the common bile duct, which are hard to visualize in white light due to the surrounding tissues.
1555647|NCT02558556|Other|Indocyanine Green|Indocyanine Green will be injected intravenously as a contrast agent for the use of the Laparoscopic Fluorescence Imaging System.
1555648|NCT02558543|Drug|Stromal Vascular fraction|
1555652|NCT02558504|Procedure|Oesophagectomy|
1555653|NCT02558504|Device|Radiofrequency ablation|
1555654|NCT02558491|Device|Decision Support System|"The purpose of this study is to demonstrate the safety and feasibility of a Decision Support System aimed at reducing glucose variability in T1DM patient using an insulin pump. The system will be deployed on our portable medical application platform (DiAs) and will include the following elements:
An insulin pump treatment parameters optimization routine, using a month of collected CGM/insulin/meal data
An exercise risk warning system, capable of predicting hypoglycemia at the onset of physical activity and advising on mitigating alteration of treatment."
1555655|NCT02558478|Genetic|blood sampling|
1555657|NCT02558452|Drug|Tacrolimus once daily (Advagraf)|Antibody induction by antithymocyte Globulin (ATG) or Basiliximab possible but not mandatory
1555658|NCT02558439|Drug|CNTX-4975|
1555659|NCT02558439|Other|Placebo|
1555660|NCT02558426|Procedure|Venous Surgery|Patients with Varicose Veins will undergo to venous surgery procedure. Samples obtained from patients undergoing surgical removal of varicose veins will be collected and immediately preserved at -80°. Briefly, the venous tissueswill be excised, homogenized with a motor-driven homogenizer and total RNA will be isolated using the Trizol reagent (Invitrogen, Milan, Italy), according to the manufacturer's instructions. The expression of ERα, ERβ and GPER will be quantified by real-time PCR using the Step OneTM sequence detection system (Applied Biosystems Inc., Milan, Italy), following the manufacturer's instructions
1555661|NCT02558413|Drug|BTA-C585 oral capsules|BTA-C585; Single ascending doses from 50 mg to 800 mg
1555662|NCT02558413|Drug|BTA-C585 matching placebo|Single ascending doses to match 50 to 800 mg BTA-C585 capsules
1555663|NCT02558400|Drug|PG324 Ophthalmic Solution|1 drop daily (evening) both eyes
1555664|NCT02558400|Drug|Netarsudil (AR-13324) Ophthalmic Solution|1 drop daily (evening) both eyes
1555665|NCT02558400|Drug|Latanoprost Ophthalmic Solution|1 drop daily (evening) both eyes
1555666|NCT02558387|Drug|BIBF1120|Nintedanib will be given orally at a dose of 200mg twice daily (bid) until progression or unacceptable toxicity.
1555667|NCT02558374|Drug|Netarsudil (AR-13324) Ophthalmic Solution|"1 drop placebo (morning) both eyes
1 drop active (evening) both eyes"
1555668|NCT02558374|Drug|Timolol Maleate Ophthalmic Solution|1 drop twice daily (morning/evening) both eyes
1555669|NCT02558361|Drug|Treatment with Apremilast|Standard dosing with apremilast (Otezla) will be used. [30mg po BID after initial titration]
1555670|NCT02558348|Drug|AL3818|Administered orally
1555671|NCT02558322|Other|Primary medical care|All study participants receive primary care as usual in the respective region
1555672|NCT02558296|Drug|Bexagliflozin|20 mg, tablet
1555673|NCT02558296|Drug|Placebo|20 mg tablet to match active comparator
1555674|NCT02558283|Device|JUVÉDERM® VOLIFT® with Lidocaine|JUVÉDERM® VOLIFT® with lidocaine injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
1555675|NCT02558283|Device|Restylane®|Restylane® injected into the nasolabial fold on Day 1, with optional touch-up injections into the nasolabial fold on Month 1.
1555676|NCT02558270|Drug|Dapagliflozin|
1555677|NCT02558270|Drug|Placebo|
1555678|NCT02558257|Behavioral|Survey|Participants complete palliative care survey within 1 week +/- 4 days of initial consultation via phone survey conducted by Research nurse/assistant.
1555679|NCT02558231|Drug|Macitentan|Used open-label in both arms, 10 mg tablet, 1 tablet u.i.d.
1555680|NCT02558231|Drug|Tadalafil|Used open-label in both arms, 20 mg tablet, 1-2 tablets u.i.d.
1555681|NCT02558231|Drug|Selexipag|Used double-blind in the triple oral treatment arm, 200 microgram tablet, 1-8 tablets b.i.d.
1555682|NCT02558218|Drug|Systane Ultra|Further to standard medication (tobradex quid for 20 days), participants were administered Systane Ultra quid for 2 months
1555683|NCT02558218|Drug|tobradex quid (Standard)|Standard medication (tobradex quid for 20 days)
1555684|NCT02558205|Radiation|CT Liver Perfusion|Imaging study of liver using injection of Iodine contrast agent done using CT imaging
1555685|NCT02558205|Radiation|PET/CT of liver|PET/CT of liver following Y-90 treatment. PET/CT imaging uses positron decay of Y-90 to detect distribution of Y-90 in the liver.
1555686|NCT02558192|Dietary Supplement|Lactobacillus Rhamnosus GG|1 vials q12 for 15 days
1555687|NCT02558192|Dietary Supplement|PLACEBO|1 vials q12 for 15 days
1555688|NCT02558153|Device|DEB, drug eluting balloon|Percutaneous angioplasty performed with a DEB - drug eluting balloon
1555689|NCT02558153|Device|standard PTA|Percutaneous angioplasty performed with a standard balloon
1555692|NCT02558127|Genetic|Asthma patients|Patients with inclusion criteria, following examinations: a study of lung function measurement of the fraction of nitric oxide in exhaled air, induced sputum, sputum, and extraction of peripheral venous blood for Study of genetic variants in the CFTR gene,skin prick test . The number of eosinophils in peripheral blood by automated cell counting and Total IgE by ELISA were measured. Furthermore, the level of asthma control be assessed by validated symptom questionnaire Asthma Control Test, quality of life is determined by the MiniAQLQ questionnaire.
1555693|NCT02558114|Drug|Ribavirin|
1555694|NCT02558101|Behavioral|Control invitation materials|"In the absence of usual care screening invitation materials, the control invitation materials and strategy are based upon the best available materials and methods of existing cancer screening programmes. These are comprised of the following:
a pre-invitation letter notifying patients of the lung health check service and an information booklet mimicking those of existing screening programmes
an invitation letter with a pre-scheduled appointment plus the same information booklet
a reminder re-invitation letter for those who miss their appointment without cancelling"
1555778|NCT02557503|Drug|Oxaliplatin and fluorouracil|Oxaliplatin and fluorouracil by HAIC on with or without concomitant vascular invasion and extrahepatic metastases unresectable advanced primary liver cancer after TACE
1555695|NCT02558101|Behavioral|Intervention invitation materials|The intervention invitation strategy is comprised of the same stages of invitation materials as the control group. The two differences are i) Instead of the information booklet they will received a targeted leaflet, and ii) the invitation and reminder letters will use indirect phrasing to explain that smokers and ex-smokers are being invited. Together, these manipulations aim to deliver a targeted, stepped and low burden approach to information provision prior to the appointment.
1555696|NCT02558088|Drug|Salmeterol|
1555699|NCT02558049|Other|Decision aid|Participants will receive a patient decision aid which outlines the potential benefits and harms of proton pump inhibitor use, as well as the potential benefits and harms of switching to a lower dose of PPI or stopping and using on-demand (only when symptoms occur). The decision aid also allows participants to clarify their values regarding these potential benefits and harms.
1555700|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned the neutral Head and Neck Position
1555701|NCT02558036|Other|C-Mac D-Blade Videolaryngoscope|Using C-Mac D-Blade Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
1555702|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in the neutral Head and Neck Position
1555703|NCT02558036|Other|King Vision Videolaryngoscope|Using the King Vision Videolaryngoscope patients will be positioned in Sniffing Head and Neck Position
1555704|NCT02558023|Drug|Urapidil|"Urapidil (Eupressyl*) : IV One initial iv bolus of 12.5 mg. One or more bolus of 6.25 mg at intervals of 5 minutes if the diastolic pressure remains above 100 mmHg.
The treatment is then continued at 4 mg.h-1 iv via a syringe pump. The maintenance dose needed to maintain MAP between 100 and 120 mmHg is sought by adjustments of ± 2 mg.h-1every 5 minutes.
Maximum dose of 30 mg.h-1."
1555705|NCT02558023|Drug|Nicardipine|"Nicardipine : IV
1 mcg.kg-1.min-1until reduction MAP 15%. Reduction 1/4 of the posology (0.75 mcg.kg -1.min-1). The maintenance dose needed to maintain MAP between 100 and 120 mmHg is then sought by adjustments of ± 0.25 mcg.kg.min-1every 5 minutes.
Maximum dose of 6 mg.h-1"
1555706|NCT02558010|Drug|Methadone|perioperative IV methadone to be given
1555707|NCT02558010|Other|Normal Saline|control arm
1555708|NCT02558010|Drug|Morphine|Both groups will receive morphine via Patient-Controlled Analgesia pump.
1555709|NCT02557997|Other|Blood tube bottom analyses|
1555710|NCT02557984|Drug|Placebo|Placebo Pill
1555711|NCT02557984|Drug|Amisulpride|400 mg Amisulpride
1555712|NCT02557984|Drug|Naltrexone|50 mg Naltrexone
1555713|NCT02557971|Drug|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) as prescribed in clinical practice.
1555714|NCT02557958|Drug|Azithromycin|We hypothesize that in patients with COPD, treatment with azithromycin will show reduced inflammatory markers, transcription factors changes, and lung function changes consistent with reduced inflammation.
1555715|NCT02557958|Drug|Placebo|We hypothesize that in patients with COPD, treatment with placebo will show NO change in inflammatory markers, transcription factor changes and lung function from baseline.
1555716|NCT02557945|Drug|Gabapentin|Subjects will be treated with 400mg pills of gabapentin , titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
1555717|NCT02557945|Drug|Placebo|Subjects will be treated with 400mg pills of placebo, titrating up to 3600mg per day, or 9 tablets (3 tabs tid)
1555718|NCT02557932|Drug|Standard triple therapy|Lansoprazole 30mg, 2 times a day + Clarithromycin 500mg, 2 times a day + Amoxicillin 1000mg, 2 times a day for 7 days
1555719|NCT02557932|Drug|Bismuth quadruple therapy|Lansoprazole 30mg, 2 times a day + Bismuth 300mg, 4 times a day + Tetracycline 500mg, 4 times a day + Metronidazole 500mg, 3 times a day for 10 days
1555720|NCT02557919|Other|Motivational Interviewing Training|1.5 day training on Motivational Interviewing (MI) techniques plus 2 booster sessions to address real experiences using MI with families.
1555721|NCT02557919|Other|Usual Best Practice|.5 day training on tobacco control and emerging products.
1555722|NCT02557906|Procedure|Breast reconstruction - implant and an ADM (SurgiMend)|Skin or nipple sparing mastectomy and immediate breast reconstruction with implants and SurgiMend
1555723|NCT02557906|Procedure|Breast reconstruction- autologous tissue|Skin or nipple sparing mastectomy and immediate breast reconstruction with autologous tissue
1555724|NCT02557906|Procedure|Breast reconstruction- implant + dermal sling/LD flap|Skin or nipple sparing mastectomy and immediate breast reconstruction using an implant and a dermal sling or a latissimus dorsi flap
1555725|NCT02557893|Behavioral|Resistance exercise|Resistance exercise involved 12-weeks of strength training twice per week
1555726|NCT02557893|Other|Education|Bimonthly pregnancy education classes
1555727|NCT02557893|Other|Wait list|Wait list participants were tested on the outcomes during their pregnancy and were eligible to participate in a post-partum supervised exercise program. The wait list participants formed a no treatment control group.
1555728|NCT02557880|Behavioral|Sleep Application Diary|Tool used to document sleep hygiene.
1555729|NCT02557880|Behavioral|Treatment As Usual|Sleep hygiene counseling
1555730|NCT02557867|Drug|Dexmedetomidine|Dexmedetomidine 0.5 μg/kg over 10 minutes and then, 0.5 mcg/kg/h throughout surgery.
1555731|NCT02557854|Drug|Doxorubicin HCl liposomal injection|50mg IV every 4 weeks
1555732|NCT02557854|Device|Philips Sonalleve MR-HIFU Hyperthermia|Hyperthermia to 42C for 30 minutes every 4 weeks
1555824|NCT02557204|Procedure|videolaryngoscope technique|Nasogastric tube was inserted transnasally and advanced into esophagus under direct vision.
1555825|NCT02557191|Other|Observational study|
1555733|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany).The active electrode (anode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
1555734|NCT02557841|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn Plus, Germany). The active electrode (cathode: 5x7 cm²) will be placed over the left cerebellar hemisphere (3 cm lateral to the inion) and the reference (5x7 cm²), over the left arm with current intensity of 2mA, fade in and fade out of 10 seconds, during 20 minutes.
1555735|NCT02557841|Device|tDCS|Sham ctDCS (NeuroConn Plus, Germany) will be applied at the same parameter settings used on cathodal ctDCS however, current duration will be only 30 seconds. Moreover, device automatically turned off without volunteer's perception, but volunteers will be with electrodes montage for 20 minutes.
1555736|NCT02557828|Procedure|arterial line placement|radial arterial cannulation placed via palpation or ultrasound technique
1555737|NCT02557815|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive 10Hz right DLPFC stimulation using Magstim TMS apparatus
1555738|NCT02557802|Biological|Fluenz Tetra|Intranasal spray, 0.2 ml dose
1555739|NCT02557802|Biological|Fluarix Tetra|Intramuscular injection, 0.5 ml dose
1555740|NCT02557789|Drug|Lefamulin|Lefamulin administered iv or orally in the fasted state and orally in the fed state
1555742|NCT02557763|Device|Oxford unicompartmental knee arthroplasty|The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
1555743|NCT02557737|Drug|Botulinum Toxin Type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
1555744|NCT02557724|Procedure|blood samples|liver transplant patients will have (5) 3cc blood samples drawn at specific time points.
1555745|NCT02557724|Procedure|blood samples|liver resection patients will have (3) 3cc. blood samples drawn at specific time points
1555746|NCT02557711|Device|ultrasound elastography, acoustic radiation force impulse|Two physiatrists will perform ultrasound elastography and ARFI for intra-rater and inter-rater reliability evaluation.
1555747|NCT02557698|Other|Balneum oil bath|
1555748|NCT02557685|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Translantation involves administering fecal material from a healthy donor to a sick patient, with relapsing C-difficile infection, to restore missing components of normal intestinal flora. Subjects will receive Fecal Microbiota Translantation via sigmoidoscopy.
1555749|NCT02557672|Drug|Prothrombin complex concentrate (Human)|PCC (Kcentra)
1555750|NCT02557672|Biological|Fresh frozen plasma (FFP)|FFP
1555751|NCT02557659|Device|Zenith Low Profile AAA Endovascular Graft|Treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair
1555752|NCT02557646|Biological|Peginterferon alfa-2a|Participants received pegylated interferon subcutaneous injection in accordance with current guidelines and SPCs.P
1555753|NCT02557646|Drug|Ribavirin|Participants received ribavirin 200 mg film-coated tablet in accordance with current guidelines and SPCs.
1555754|NCT02557633|Biological|Grass MATA MPL 10200|
1555755|NCT02557633|Biological|Grass MATA MPL 18200|
1555756|NCT02557633|Biological|Placebo|
1555757|NCT02557620|Drug|semaglutide|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
1555758|NCT02557620|Drug|placebo|Administered subcutaneously (s.c., under the skin)once daily or once weekly.
1555759|NCT02557607|Device|MRI|An analysis of the three sessions MRI performed systematically within the first 14 days of the start of symptoms revealing the HSA will be
1555760|NCT02557594|Drug|Viread 300mg|single dose administration after 10hr fasting
1555761|NCT02557594|Drug|DA-2802 319mg|single dose administration after 10hr fasting
1555768|NCT02557568|Other|Staphylococcus aureus carriage|Staphylococcus aureus carriage is measured in the nose. Nasal samples were taken by the nursing staff of the ward using nylon flocked swab. Prior taking the sample, swabs were wetted using an additional tube containing a sponge impregnated with normal saline solution.
1555769|NCT02557555|Other|educational information|patients will receive pamphlet on labor analgesia options.
1555770|NCT02557542|Other|One Stop Vein Clinic|Same day diagnosis and treatment
1555771|NCT02557542|Device|Radiofrequency ablation|Venous ablation
1555772|NCT02557542|Device|Endovenous laser ablation|Venous ablation
1555773|NCT02557542|Drug|Foam sclerotherapy (Polidocanol or Sodium Tetradecyl Sulphate)|Venous ablation
1555774|NCT02557529|Behavioral|Progressive Resistance Training|12 weeks supervised resistance training program. Details of the program: 12 weeks, 3 sessions per week, 7 exercises in training machines (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
1555775|NCT02557529|Behavioral|physical activity|Weekly diary of performed physical activity using the Physical Activity Score (PAS) during the 12-weeks intervention
1555776|NCT02557529|Behavioral|Diet diary|Weekly diet diary during the 12-weeks intervention
1555777|NCT02557516|Drug|monalizumab|"During phase 1b, patients receive IPH2201, IV, at the dose of 1, 2, 4 or 10 mg/kg, as a single agent during 4 weeks and thereafter combined with ibrutinib 420 mg, orally, once daily, during 52 weeks.
During phase 2a, patients receive IPH2201, IV, at the dose recommended upon completion of phase 1b portion, combined with ibrutinib 420 mg orally, once daily, from the first cycle, during 52 weeks. In both parts of the trial, the first 4 administrations of IPH2201 (from week 0 to week 6) occur every 2 weeks. From the 5th administration IPH2201 is administered every 4 weeks."
1556148|NCT02554877|Drug|Placebo|oral tablet
1555779|NCT02557490|Drug|oxaliplatin and raltitrexed|"TACE methods: use of epirubicin 20-40mg emulsifier lipiodol embolization target vessel, with gelatin sponge particles or PVA particles or microspheres embolization supplement.
Hepatic arterial chemotherapy: Bi embolization catheter in the hepatic artery or left hepatic artery branch within the right, chemotherapy, for the experimental group (A group): OXA 130mg / m2 artery 0-4 hours pumped Raltitrexed 3mg/m2 4-5 hours pumped into the arteries; the control group (group B)"
1555780|NCT02557477|Dietary Supplement|Omega 3/6 fatty acids|Three Omega 3/6 capsules twice daily
1555781|NCT02557477|Dietary Supplement|Placebo|Three placebo capsules twice daily
1555782|NCT02557464|Behavioral|An eye tracking experiment|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
1555783|NCT02557464|Behavioral|A neuropsychological evaluation|Neuropsychological assessments and eye tracking during reading will be practice twice with an interval of 6 months
1555784|NCT02557451|Other|Surgery|
1555785|NCT02557451|Other|Intravitreal injections of gas|
1555786|NCT02557451|Procedure|injections of an antiangiogenic|
1555787|NCT02557438|Procedure|Roux-en-Y Gastric Bypass|Determination of the kind of surgery will be made by the participant's providers and not by study staff
1555788|NCT02557438|Procedure|Vertical Sleeve Gastrectomy|Determination of the kind of surgery will be made by the participant's providers and not by study staff
1555789|NCT02557425|Other|No intervention in PROTECT|
1555790|NCT02557412|Device|Continuous positive airway pressure|Treatment with nasal CPAP. Treatment begins with an empirical pressure of 8 cmH2O and in a period of three weeks, the pressure is adjusted by automatic titration with AutoSet II (ResMed) device.
1555791|NCT02557412|Behavioral|Intensive lifestyle intervention|Specific alimentary plan (carbohydrates: 40-45%; fats: 25-35% [saturated fats <7% monounsaturated fats up to 20% and polyunsaturated fats <10% ] and proteins: 15-20%) and recommendation to increase daily physical activity, setting a target walking 10,000 steps a day. The patients will be provided with a pedometer and will asked to fill out a form with the steps that they walked each day. At each visit, the distance walked will be reviewed and the target set will be remarked.
1555792|NCT02557412|Other|Conventional treatment|Hygiene and diet recommendations on sleep
1555796|NCT02557386|Drug|Levobupivacaine 5 mL|Levobupivacaine 0.25% 5 mL in adductor canal nerve block
1555797|NCT02557386|Drug|Levobupivacaine 10 mL|Levobupivacaine 0.25% 10 mL in adductor canal nerve block
1555798|NCT02557386|Drug|Levobupivacaine 15 mL|Levobupivacaine 0.25% 15 mL in adductor canal nerve block
1555799|NCT02557386|Drug|Levobupivacaine 20 mL|Levobupivacaine 0.25% 20 mL in adductor canal nerve block
1555800|NCT02557386|Drug|Levobupivacaine 25 mL|Levobupivacaine 0.25% 25 mL in adductor canal nerve block
1555801|NCT02557386|Drug|Levobupivacaine 30 mL|Levobupivacaine 0.25% 30 mL in adductor canal nerve block
1555802|NCT02557373|Dietary Supplement|Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation.
1555803|NCT02557373|Dietary Supplement|Rice Bran + Vitamin A|100,000 IU (oral supplement) on Day 1 of the intervention. No additional Vitamin A supplementation. Dietary rice bran consumed daily and amounts increase throughout the 3 month intervention (6 months of age: 1 g/day rice bran, 7 months: 2 g/day rice bran, 8 months: 3 g/day)
1555804|NCT02557360|Dietary Supplement|S-adenosyl-L-methionine|Patients will be treated with S-adenosyl-L-methionine, tablets 800 mg twice a day (daily dosage 1600 mg) for six months
1555805|NCT02557347|Behavioral|Aggressive fluid management|nursing education, dietary advice, extra hypertonic dialysis cycles
1555806|NCT02557334|Dietary Supplement|Low Dose Strawberry Powder|40 g composed of 13 g freeze dried strawberry powder + 27 g placebo powder
1555807|NCT02557334|Dietary Supplement|High Dose Strawberry Powder|40 g freeze dried strawberry powder
1555808|NCT02557334|Dietary Supplement|Placebo Powder|40 g color and taste matched placebo powder
1555809|NCT02557321|Drug|PV-10|PV-10 will be administered by intralesional injection every 3 weeks at Day 1 (Week 1), Week 4, Week 7, Week 10 and Week 13
1555810|NCT02557321|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks starting at Day 1 (Week 1)
1555812|NCT02557269|Drug|Xylometazoline - intranasal application|Applied as needed up to 5 consecutive days when prominent congestion
1555813|NCT02557269|Drug|Azelastine - intranasal application|Applied as needed when prominent symptom is rhinorrhea
1555814|NCT02557269|Drug|Mometasone furoate - intranasal application|Applied once daily (2 puffs) when no satisfactory therapeutic control from other intranasal treatment
1555815|NCT02557269|Drug|Hydroxyl-propyl-methyl cellulose powder - intranasal application|Applied intranasally immediately after every application other intranasal formulation
1555816|NCT02557269|Other|Placebo - Lactose powder|Applied intranasally immediately after every application other intranasal formulation
1555817|NCT02557269|Drug|Bilastine 20 mg|1 tablet per os - as needed
1555818|NCT02557269|Drug|Prednisolone 5 mg|Per os - if needed (only in case of broncial obstruction)
1555819|NCT02557217|Drug|NP202|Active
1555820|NCT02557217|Other|Placebo|Placebo
1555821|NCT02557204|Procedure|conventional technique|the nasogastric tube will be inserted gently through a selected nostril with the head being maintained in the neutral position.
1555822|NCT02557204|Procedure|head in the lateral position technique|the patient's head will be turned to the right lateral position. Nasogastric tube will be inserted through the right nostril without any maneuvers of the neck.
1555823|NCT02557204|Procedure|endotracheal tube assisted technique|Nasogastric tube will be inserted the trimmed 7.5 mm internal diameter endotracheal tube what cut proximal end with sterile scissors and endotracheal tube will be advanced blindly into the oral cavity to a depth of approximately 18 cm without laryngoscope together the nasogastric tube.
1555826|NCT02557178|Device|COPD Activity Monitor|A custom activity monitor capable.
1555827|NCT02557178|Behavioral|health coaching|Supportive coaching to encourage compliance with prescribed pulmonary rehabilitation.
1555828|NCT02557165|Procedure|Muscle biopsies|Muscle biopsies will allow acces to samples for observational studies. Vastus latetalis: needle biopsy (Bergstrom technique). Diaphragm: open biopsy performed by thoracic surgeon during lung surgery.
1555830|NCT02557139|Drug|KD025 Tablet|
1555831|NCT02557139|Drug|KD025 as drug in capsule|
1555832|NCT02557126|Drug|URC102|
1555833|NCT02557126|Drug|Placebo|
1555834|NCT02557113|Procedure|Vertebroplasty|Fractured Osteoporotic Vertebral Body is Augmented with Injection of Bone Cement
1555835|NCT02557113|Procedure|Cavuplasty|Small Cavity is Created in Fractured Osteoporotic Vertebral Body Prior to Cement Injection
1555839|NCT02557087|Drug|Hyoscine|
1555840|NCT02557087|Drug|Pethidine|
1555841|NCT02557074|Drug|IL2|IL2 1.5MUI/d SC from day 1 to day 5 for the first course of treatment IL2 3MUI/d SC from day 1 to day 5 for the 3 following courses
1555842|NCT02557074|Drug|placebo|NaCl 9% serum SC from day 1 to day 5 for the four courses of treatment
1555843|NCT02557061|Procedure|Colorectal surgery (resection)|Colorectal surgery (resection) is done for patient with colorectal cancer
1555844|NCT02557061|Biological|Blood sampling|Pre-operative blood sampling is done for patient with colorectal cancer
1555847|NCT02557022|Other|GI and/or GL|Randomized controlled trials of equal or more than 12 weeks duration looking at the GI and/or GL of diet as a whole and providing data on body weight
1555848|NCT02556996|Biological|ETEC/rCTB vaccine|Cocktail of five whole-cell, formalin-inactivated ETEC strains (total of 10^11 formalin-killed bacteria per dose) plus recombinant cholera toxin B-subunit (rCTB) (1 mg)
1555849|NCT02556996|Other|Placebo|Heat-killed, nonpathogenic E. coli K-12 bacteria (total of 10^11 heat-killed bacteria per dose)
1555850|NCT02556983|Radiation|CT|Contrast-enhanced CT images of the abdomen and pelvis will be obtained during the portal venous phase using a 256-channel CT system (Philips Healthcare, Cleveland, OH). The target median dose-length product (DLP) is 130 mGy·cm, which corresponded to an effective dose of 2 mSv with a conversion factor of 0.015 mSv·mGy-1·cm-1. The radiation output was automatically adjusted according to the individual patient's body size.
1555851|NCT02556970|Procedure|Single port VATS|Performing video-assisted thorascopic surgery through a single port
1555852|NCT02556970|Drug|Paracetamol|1g intraoperatively
1555853|NCT02556970|Drug|Diclofenac|75mg intraoperatively
1555854|NCT02556970|Device|Camera (5mm diameter 30 degree videothoracoscope)|
1555855|NCT02556970|Device|Forceps grasper|
1555856|NCT02556970|Drug|0.25% Levobupivicaine intercostal nerve block|Multi-level intercostal blocks will be placed subpleurally under thorascopic visualisation.
1555857|NCT02556957|Behavioral|HealthScouts|
1555858|NCT02556957|Other|Standard of Care|
1555859|NCT02556944|Device|Phacoemulsification with multifocal intraocular lens|Phacoemulsification and implantation of a multifocal intraocular lens (IOL) with two different add power (+2.75 diopters (D) or +3.25 D, respectively) in each eye of a patient, contralaterally. They're called mix and matched patients.
1555860|NCT02556931|Drug|Fludarabine|Days -6 through -2: 30 mg/m^2 IV daily
1555861|NCT02556931|Drug|Cyclophosphamide|Days -6 and -5: 14.5 mg/kg IV daily Days 3 and 4: 50 mg/kg IV daily
1555862|NCT02556931|Radiation|Total body irradiation|Day -1: 200 cGy in a single fraction
1555863|NCT02556931|Drug|Tacrolimus|Start on Day 5 through either Day 60 or Day 90 depending on cohort assignment. May be continued through Day 180 depending on GVHD status.
1555864|NCT02556931|Drug|Mycophenolate mofetil|Days 5 through 35: 15 mg/kg PO three times daily (max 3 g/day)
1555865|NCT02556918|Drug|Sitagliptin|Subjects will take one pill daily starting one day prior to surgery until discharge from the hospital. Sitagliptin will be dispensed orally at 100 mg/day for patients with a glomeruler filtration rate (GFR) greater than or equal to 50. Patients with a GFR between 30-49 will receive 50 mg/day.
1555866|NCT02556918|Drug|Placebo|One pill daily starting one day prior to surgery until discharge from the hospital.
1555867|NCT02556918|Drug|Regular Human Insulin|Continuous intravenous insulin given to intensive care unit (ICU) patients with a blood glucose (BG) greater than 180 mg/DL and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol.Intravenous insulin infusion will be continued until the patient is able to eat and/or is transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
1555868|NCT02556918|Drug|Insulin glargine|"Patients that required continuous insulin infusion (CII) at a rate >1U/h will be transitioned to basal insulin (glargine/detemir). Calculate total daily dose (TDD) of insulin from the average CII rate during the last four hours of infusion (example, if the average rate is 2 U/hr., the TDD is 48 U/day) Give 50% of calculated dose as basal (glargine/detemir) insulin every day. Basal insulin will be given approx. 4 hours before discontinuation of CII.
The total daily insulin dose will be adjusted as follow:
Fasting and pre-meal BG between 100-180 mg/dl without hypoglycemia the previous day: no change Fasting and pre-meal BG between >180-240 mg/dl: increase basal dose by 10% every day Fasting and pre-meal BG >241 mg/dl: increase basal dose by 20% every day Fasting and pre-meal BG <100 mg/dl: stop basal"
1555869|NCT02556918|Drug|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin lispro
BG between 221-260 mg/dL; 3-5 units of insulin lispro
BG between 261-300 mg/dL; 4-6 units of insulin lispro
BG between 301-350 mg/dL; 5-7 units of insulin lispro
BG between 351-400 mg/dL; 6-8 units of insulin lispro
BG greater than 400 mg/dL; 7-9 units of insulin lispro"
1555870|NCT02556918|Drug|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) greater than 240 mg/dL will be given. For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin aspart
BG between 221-260 mg/dL; 3-5 units of insulin aspart
BG between 261-300 mg/dL; 4-6 units of insulin aspart
BG between 301-350 mg/dL; 5-7 units of insulin aspart
BG between 351-400 mg/dL; 6-8 units of insulin aspart
BG greater than 400 mg/dL; 7-9 units of insulin aspart"
1555871|NCT02556905|Drug|REVLIMID®|The recommended starting dose of REVLIMID® is 25mg/day with water orally administered as a single 25mg capsule on Days 1-21 of repeated 28-day cycles. Dose can be adjusted upon the clinical laboratory result.
1555872|NCT02556905|Drug|Dexamethasone|The recommended dose of dexamethasone is 40mg/day on Days 1-4, 9-12, and 17-20 of each 28-day cycle for the 4 cycle of therapy and then 40mg/day orally on Days 1-4 every 28 days.
1555873|NCT02556892|Drug|Ibrutinib|Participants will self-administer 420 milligram (mg) oral ibrutinib once daily continuously from Cycle 1 to Cycle 6 and thereafter every 28 days until treatment discontinuation.
1555874|NCT02556879|Biological|Donor specific antibodies|Additional samples for Donor specific antibodies at each visit
1555875|NCT02556879|Biological|Serum bank|Additional samples for serum bank at each visit if possible
1555876|NCT02556879|Biological|DNA bank|Additional sample for DNA bank at inclusion visit if possible
1555877|NCT02556879|Procedure|Liver biopsy|Liver biopsy at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
1555878|NCT02556879|Procedure|Liver ultrasounds and Fibroscan|Liver ultrasounds and Fibroscan at 12 and 24 months after retransplantation (depending the centers : procedure performed in routine or interventional procedure)
1555879|NCT02556866|Drug|rituximab|Prednisone treatment plus rituximab administered by slow intravenous infusion at 375 mg/m2 at D1, D8, D15 and D22.
1555880|NCT02556866|Drug|Prednisone|
1555881|NCT02556866|Drug|Placebo|
1555882|NCT02556853|Device|Determination of tube position by ultrasound.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by ultrasound (Sonoscape S6®). The ultrasound probe will be placed between the 2nd and 3rd intercostal space at the level of the midclavicular line parallel to the line. The probe will be slightly moved or tilted until the pleural line is identified. If lung sliding is identified then the ventilation of the lung will be considered adequate. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
1555883|NCT02556853|Other|Determination of tube position by auscultation.|After placement of the left sided double lumen endotracheal tube, ventilation of both lungs will be verified by auscultation of the upper lung fields. The same procedure will be repeated for each lung alone, after lung separation is applied. Verification of the ultrasound findings will be performed by bronchoscopy (Pentax®). The depth of the tube will be adjusted according to the bronchoscopy findings until correct positioning is established.
1555884|NCT02556840|Other|insulin therapy|
1555885|NCT02556827|Other|Obtaining a blood sample|Total oxidant capacity (TOC), total antioxidant capacity (TAC), oxidative stress index (OSI), paraoxonase-1 (PON-1), aryl esterase (ARES), myeloperoxidase (MPO), tumor necrosis factor-alpha (TNF-α), interleukin-1beta (IL-1β), matrix metalloproteinase-1 (MMP-1) and matrix metalloproteinase-9 (MMP-9) levels in venous blood were measured.
1555886|NCT02556827|Device|Reflectance confocal microscopy|1mm2-sized 10 images were taken from right cheek and forehead; the number of demodex, follicle, the number of mite per follicle, the number of infested follicle and the number of mite per infested follicle were calculated with RCM. And photoaging severity were also assessed by using RCM.
1555887|NCT02556827|Device|Sebumeter|Sebum rate at forehead and right cheek were evaluated with sebumeter
1555888|NCT02556827|Device|Video dermoscopy|Dermoscopic photoaging scale were assessed by using video dermoscopy.
1555889|NCT02556814|Drug|Caffeic acid tablets|Oral administration of caffeic acid tablets 0.3g three times per day for 3 months
1555890|NCT02556814|Drug|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later.
1555891|NCT02556814|Drug|placebo|Oral administration of placebo tablets 0.3g three times per day for 3 months
1555892|NCT02556801|Biological|SUBLIVAC FIX Phleum Prat.|
1555893|NCT02556788|Drug|CD5789 50µg/g Cream|CD5789 50µg/g cream applied once daily during 12 weeks.
1555894|NCT02556788|Drug|Placebo cream|Placebo cream applied once daily during 12 weeks.
1555895|NCT02556775|Biological|A licensed human normal immunoglobulin other than HYQVIA for IV or SC infusion or an alternative treatment|To be determined by the physician
1555896|NCT02556775|Biological|HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase]|
1555897|NCT02556762|Radiation|Radiotherapy with simultaneous modulated accelerated boost|Radiotherapy: 66Gy/30F to the gross tumor and 50Gy/25 to subclinical diseases
1555898|NCT02556762|Radiation|Standard dose radiotherapy|Radiotherapy: 50Gy/25F to both gross tumor and subclinical disease
1555899|NCT02556762|Drug|PF|Chemotherapy: Cisplatin and 5fluorouracil
1555900|NCT02556749|Dietary Supplement|Cranberry Juice Beverage|16 ounces of 54% cranberry juice cocktail
1555901|NCT02556749|Dietary Supplement|Placebo Beverage|Color, calorie, and taste matched beverage without cranberry bioactives
1555902|NCT02556736|Drug|RST-001|RST-001 is a gene therapeutic delivered by intravitreal injection
1555903|NCT02556723|Drug|Intravitreal injections of ziv-aflibercept|All subjects will receive intravitreal injections of ziv-aflibercept under sterile conditions at baseline, 4 weeks, 8 weeks, 12 weeks, 16 weeks, and 20 weeks. No topical or systemic antibiotics will be prescribed (pre- injection or postinjection).
1555904|NCT02556710|Biological|AMPION™|4 mL Ampion Injection
1555905|NCT02556710|Biological|Saline|4 mL Saline Injection
1555906|NCT02556697|Device|Bronchoscopy with in vivo confocal endomicroscopy|A bronchoscopy with in vivo confocal endomicroscopy is done for patients with a suspicion of emphysema or for patients with a suspicion of scleroderma
1555907|NCT02556658|Device|General anesthesia managed by the Smartpilot® View|General anaesthesia managed by the Smartpilot® View device The intervention consists of administering hypnotics and opioids according to effect-site concentrations and interaction model provided by the Smartpilot® View software for the entire duration of general anaesthesia.
1555908|NCT02556658|Device|General anesthesia managed without the Smartpilot® View|General anaesthesia without using the Smartpilot® View device The anesthetic induction will be performed by propofol or sufentanil and atracurium. The maintenance of anesthesia will be directed by desflurane and sufentanil. The dosages of anesthetics are left to the discretion of the doctor and nurse anesthetists in charge of the patient in the operating room.
1555909|NCT02556645|Other|Web-PE Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on gradually confronting distressing trauma-related memories and reminders. Web-PE is an internet-based version of prolonged exposure (PE) for posttraumatic stress disorder (PTSD).
1555910|NCT02556645|Other|Therapist-Delivered Present-Centered Therapy|Ten 60-minute psychotherapy sessions over 8 weeks, focused on identifying and solving day-to-day problems as they are brought up by the participants. PCT is a manualized therapy that has been used as active control condition in several CBT studies. It provides a credible comparison therapy to control for nonspecific therapeutic factors so that observed effects of Web-PE can be attributed to its specific ingredients beyond the benefits of good therapy.
1996286|NCT02506049|Device|S-LPC:Selective Laser Photocoagulation|Under anesthesia (epidural, general anesthesia with intubation, or intravenous sedation with infiltration of a local anesthetic), one treatment with the use of fetoscopy instrument sets for Selective Laser Photocoagulation (S-PLC) to seal the connecting blood vessels, help to normalize blood flow between twins.
1555916|NCT02556619|Behavioral|Early Palliative Care/Symptom Control|"Establish palliative care goals
Determination of Medical Power of Attorney
Discuss/plan code status/advance directives
Document palliative care goals
Symptom Assessment and Control
Pain-treatment with opioid and non-opioid medications
Itching-H2 blockers, steroids
Nutrition-appetite stimulated with Megace, review low sodium diet
Ascites/edema- optimize ascites management with Lasix or Aldactone. In refractory cases intermittent paracentesis can be performed
Nausea- treated with anti-emetics
Jaundice and Body Image- counselling regarding symptoms
End-of-Life Care
Discuss religious preferences
Assess for distress- ensure interaction with Cancer Resource Center
Hospice- charity Hospice options for select patients."
1555917|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.1mg/Kg
1555918|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.25mg/Kg
1555919|NCT02556606|Drug|Ketamine|randomly assigned to a single 40 min infusion of either KET 0.50mg/Kg
1555920|NCT02556606|Drug|Midazolam|single 40 min infusion of MID 0.03mg/Kg
1555921|NCT02556593|Radiation|IMRT|Daily IMRT at 45 Gy in 15 fractions to brain metastases
1555922|NCT02556593|Radiation|WBRT|3DCRT at 30 Gy in 10 fractions to whole brain
1555923|NCT02556593|Drug|erlotinib|erlotinib 150mg daily
1555924|NCT02556580|Drug|Albumin 20%|Intervention: intravenious infusion Drug: albumin
1555925|NCT02556567|Other|Fitbit® Charge Heart Rate (HR) wristband|The Investigators will conduct a proof of concept and feasibility study to explore associations between asthma symptoms and sleep patterns and physical activity over an 8-week intervention period among 20 adolescent patients with persistent asthma.
1555926|NCT02556554|Device|Dexcom G4 or G5 Platinum CGM system|Intervention arm using the Dexcom G4 or G5 Platinum® CGM system during pregnancy
1555927|NCT02556554|Device|Dexcom G4 or G5 Platinum CGM system with Share|Treatment arm using the Dexcom G4 or G5 Platinum® CGM system with Share™
1555928|NCT02556541|Procedure|IV puncture guided by ultrasound|
1555929|NCT02556528|Behavioral|Health Coaching|
1555930|NCT02556515|Procedure|Interpositional arthroplasty (Burton-Pellegrini procedure)|Burton-Pellegrini procedure
1555931|NCT02556515|Procedure|Total joint replacement|Total joint replacement
1555932|NCT02556515|Device|Elektra prosthesis|Elektra prosthesis
1555933|NCT02556502|Device|18F-Florbetaben PET|
1555934|NCT02556476|Procedure|mechanical ventilation|ventilator support for the patients presenting with acute respiratory failure
1555935|NCT02556476|Procedure|neuromuscular blockade|paralysis of the skeletal muscles in order to optimize mechanical ventilation, especially during ARDS
1555936|NCT02556476|Procedure|renal replacement therapy|the procedures used to treat acute kidney injury
1555937|NCT02556476|Procedure|non-invasive ventilation|Procedure used for ventilation support in patients with congestive heart failure, pulmonary edema, COPD and some other conditions.
1555941|NCT02556450|Drug|Spironolacton|Administration of Spironolacton 25 mg per day
1555942|NCT02556437|Drug|HyQvia|Human immunoglobulin 10% with recombinant hyaluronidase for subcutaneous injection
1555943|NCT02556437|Drug|Subcuvia|Human immunoglobulin 16% for subcutaneous injection
1555944|NCT02556424|Drug|Dexamethasone|Intravitreal implant at D0
1555945|NCT02556424|Drug|Triamcinolone|Subconjunctival injection at 4 mm from the limbus at 6 o'clock
1555946|NCT02556411|Drug|LNG-IUS 13,5 mg Levonorgestrel|LNG-IUS
1555947|NCT02556411|Drug|Levonorgestrel 0,10 mg+ ethinylestradiol 0,02 mg|Levonorgestrel 0,10 mg+ethinylestradiol 0,02 mg oral contraceptive pill in continuous regime
1555948|NCT02556398|Behavioral|Sugar Sleuth|"Educational module and use of smart phone app (Sugar Sleuth)"
1555949|NCT02556385|Device|High frequency rTMS|Most activated area from fNIRS findings: Perileisional Broca's area, High frequency rTMS (10Hz), Number of total stimuli: 800, Location: perilesional Broca's area, Intensity: 100% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
1555983|NCT02556125|Device|Diaphragm pacing|Intramuscular diaphragm implantation is achieved by a laparoscopic approach whereby phrenic motor points on the diaphragm are mapped to optimize electrode placement. The electrodes are threaded into the diaphragm muscle and wire leads are externalized and attached to a stimulation controller.
1555950|NCT02556385|Device|Low frequency rTMS|Most activated area from fNIRS findings: Contralesional homologs of Broca's area, Low frequency rTMS (1Hz), Number of total stimuli: 1200, Location: Contralesional homologs of Broca's area (Pars triangularis), Intensity: 90% of resting motor threshold, Coil orientation: tangential to scalp, in combination with speech therapy(35-40min) after each rTMS session, Daily 10 treatment session
1555951|NCT02556372|Drug|JKB-122|Orally administered capsules of JKB-122 which will be taken once daily with dose escalation
1555952|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
1555953|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
1555954|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
1555955|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
1555956|NCT02556346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
1993657|NCT03157713|Behavioral|Goal-Directed Financial Incentives|Patients will receive financial incentives for using a food diary, verified by entries in in the BookFactory Food Diary or another food diary, including internet/app-based diaries ($30 monthly); achieving 75 minutes of physical activity per week in first three months, as verified by a wearable fitness tracker ($20 monthly); achieving 150 minutes of physical activity per week in last three months, as verified by a wearable fitness tracker ($20 monthly); enrollment in a clinic-based or commercial weight loss program ($150 one time); and active participation in clinic-based or commercial weight loss program, as verified by the program ($60 monthly).
1555958|NCT02556320|Drug|anti-epileptic drug|Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
1555959|NCT02556320|Biological|Blood sampling|Blood sampling is done for Patient who initiate anti-epileptic drug (sodium valproate, divalproate sodium, valpromide, lamotrigine, carbamazepine, oxcarbazepine, eslicarbazepine acetate)
1555960|NCT02556307|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
1555961|NCT02556307|Drug|Ribavirin|Ribavirin according to the standard practice in line with current summaries \nof product characteristics (SPCs)/local labeling.
1555962|NCT02556294|Behavioral|Self-acceptance based intervention|The intervention will consist of HIV/STI counseling and testing as well as individual counseling sessions and group sessions. The primary focus of the group sessions are to help foster self-acceptance by the support from the group, as well as learn skills to reduce distress and HIV risk. The primary purpose of the individual sessions is to help develop and implement an individualized plan for HIV risk reduction, and, as needed and available, linkage to other services.
1555963|NCT02556294|Behavioral|HIV/STI counseling and testing|The counseling component is standard of care in India and will focus on HIV/STI risk and how to minimize risk. This is followed by biological testing for HIV and STIs.
1555964|NCT02556281|Biological|Blood sampling|Blood sampling is done for patient with colorectal cancer
1555965|NCT02556268|Drug|Riociguat (Adempas, BAY 63-2521)|0.5 mg, Oral (fasted conditions), 1 single dose
1555966|NCT02556268|Drug|ATRIPLA|600 mg efavirenz, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
1555967|NCT02556268|Drug|COMPLERA|200 mg emtricitabine, 25 mg rilpivirine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
1555968|NCT02556268|Drug|STRIBILD|150 mg elvitegravir, 150 mg cobicistat, 200 mg emtricitabine, and 300 mg tenofovir disoproxil fumarate, i.e. 1 tablet, once daily
1555969|NCT02556268|Drug|TRIUMEQ|600 mg abacavir, 50 mg dolutegravir, and 300 mg lamivudine, i.e. 1 tablet, once daily
1555970|NCT02556268|Drug|Antiretroviral protease inhibitor|Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
1555971|NCT02556255|Device|CathiTM Atherectomy Hybrid Catheter|Percutaneous Transluminal Atherectomy (PTA) catheter for treatment of infrainguinal arteries in patients with Peripheral Artery Disease (PAD)
1555972|NCT02556242|Other|Targeted indoor residual spraying|IRS is carried out in neighbourhoods of cases
1555973|NCT02556242|Other|Generalised Indoor residual spraying|IRS is carried out as normally practiced
1555974|NCT02556229|Drug|Aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated at inclusion (mandatory injection) with reinjection every 4 weeks only in case of CNV activity (PRN regimen) until 52 weeks.Therefore, each patient receives between 1 and 13 injections in the whole study.
1555978|NCT02556177|Procedure|MRI|MRI scanning
1555979|NCT02556164|Procedure|Electroacupuncture|Acupuncture is an alternative medicine methodology that treats patient by various techniques including inserting small, thin needles at specific points of body. Electroacupuncture (EA), like the name implies, combines classical acupuncture and low electric current running through the needles, which are often used to enhance a treatment.
1555980|NCT02556164|Other|Body-worn sensor technology|Three-dimensional acceleration and angular velocity of shanks, thighs and the trunk were measured using wearable sensors each included a triaxial accelerometer and a triaxial gyroscope (LEGSys™ and BalanSens™ - BioSensics, Boston, MA)
1555981|NCT02556151|Procedure|Repetitive magnetic stimulation|Six sessions of weekly therapy with 1, 5 or 15 Hz magnetic stimulations of the lumbar and sacral regions.
1555984|NCT02556112|Behavioral|Group Lifestyle Balance|The content of the GLB program consists of educating participants about the association between high calorie and fat intake with excessive weight, how to determine the fat and calorie content of foods they eat, and how to make changes in their diet to reduce the fat and calorie content. Participants are also given information about increasing activity in their daily routines. In addition, they are given information about negative behaviors that lead to overeating and decreased activity and are taught ways to develop positive behaviors to facilitate weight loss and increased activity. GLB instructors function as lifestyle coaches for class participants. They provide individual feedback and encouragement on documented eating and activity habits. The instructors make themselves available to be contacted by participants outside of class to address participant concerns and issues as needed
1555985|NCT02556112|Behavioral|Better Body Better Life|The BBBL program is an Air Force weight management program.). It was created based on the Adult Learning Model and consists of 5 independent modules that are taught in-person to groups of up to 15-20 individuals. Each module is done in a classroom and is 2 hours long. One module per week is offered. Individuals can attend the modules in any order but they are required to complete a pre-survey and 3-day food record prior to attending their first class
1555986|NCT02556112|Behavioral|Fitness Improvement Program|The FIP is a standardized course that can be accessed on-line through the Advanced Distributed Learning Service (ADLS) and takes approximately 90 minutes to view all of the course material. The on-line FIP can be done all in one sitting or in segments. There is no restriction on the frequency with which the FIP is viewed however, because it is accessed through ADLS, it may be difficult to view at a non-military computer. The FIP consists of an introduction, three core components (nutrition, physical training, and spiritual well-being), and a summary. Each section has a short video presentation. The core components have short quizzes at the end to assess knowledge and the training asks participants to set goals. Participants are then responsible for using the information for their own self-directed program.
1555987|NCT02556099|Drug|Hydroxyurea|drug to be administered
1555988|NCT02556086|Drug|Daclatasvir|
1555989|NCT02556086|Drug|Sofosbuvir|
1555990|NCT02556073|Other|Smartphone action|Smartphone applications (Apps) can provides a platform not only to share health information at the point-of-living, including health assessments, personalized health plans, but also to remind the patients' medication adherence regularly. With the application of modern smartphone-based asthma self management deserves further investigation to improve asthma control.
1555991|NCT02556073|Drug|usual care|fluticasone/salmeterol 125/25 ug/puff, 2 puff bid plus salmeterol as-needed
1555992|NCT02556060|Drug|Lamotrigine|Starting from 25 mg/day in the first week, then titrated up to 200 mg/day for 12 weeks
1555993|NCT02556060|Drug|Placebo|Same dosing schedule as study drug
1555994|NCT02556047|Device|Star Intradermal Safety Device|Star Intradermal Safety Device 1.2mm needle length, Star Intradermal Safety Device 1.5mm needle length, Mantoux technique by N&S
1555995|NCT02556034|Other|Disease evaluation.|Patients will complete a self-evaluation of 28 joint counts for swelling and tenderness and assess their disease activity on a Visual Analog Scale. A 28 joint count and VAS will then be assessed by a nurse and by a rheumatologist. The same rheumatologist will examine all patients and two nurses will each randomly assess half the total enrolled patients. The nurse will be blinded to the patient's joint count and VAS, and similarly, the rheumatologist will be blinded to both the patient and nurse's assessments.
1555996|NCT02556021|Drug|CJ-12420 50mg|CJ-12420 50mg, tablet, once daily, oral administration for up to 4 weeks
1555997|NCT02556021|Drug|CJ-12420 100mg|CJ-12420 100mg, tablet, once daily, oral administration for up to 4 weeks
1555998|NCT02556021|Drug|Placebo|Placebo, tablet, once daily, oral administration for up to 4 weeks
1555999|NCT02556008|Drug|cannabidiol (CBD)|Treatment will begin with 2 mg/kg/day given in two divided doses. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
1556000|NCT02555995|Device|OCT scan (as yet unnamed)|OCT scan (as yet unnamed) of the eye with investigational device; newly developed sparse OCT retina scanner by Artorg Center Bern and Berner Fachhochschule Biel
1556001|NCT02555982|Drug|BOTOX ® 200 Unités|"Patients eligible for inclusion will be randomized to one of the two groups:
Experimental group: 60 patients will receive 2 injections of Btx A (BOTOX - Allergan), one on D0 and one at 12W (into each splenius capitis).
Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis)."
1556002|NCT02555982|Drug|Placebo|Control group: 60 patients will receive 2 injections of placebo, one on D0 and one at 12W (into each splenius capitis).
1556003|NCT02555943|Drug|Ledipasvir/Sofosbuvir|Oral direct anti-HCV agent. Ledipasvir/Sofosbuvir(LDV/SOF) 400mg/90mg fixed-dose combination(FDC) tablet, administered orally once daily.
1556004|NCT02555943|Drug|Sofosbuvir and Daclatasvir|TWO oral direct anti-HCV agent: Sofosbuvir(SOF), 400mg tablet administered orally once daily. Daclatavir(DCV), 60mg tablet administered orally once daily.
1556005|NCT02555943|Drug|Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir|VIEKIRA PAK includes ombitasvir, a hepatitis C virus NS5A inhibitor, paritaprevir, a hepatitis C virus NS3/4A protease inhibitor, ritonavir, a CYP3A inhibitor and dasabuvir, a hepatitis C virus non-nucleoside NS5B palm polymerase inhibitor.
1556006|NCT02555943|Drug|Entecavir|Nucleoside-inhibitor-treatment-naïve with compensated liver disease (greater than or equal to 16 years old): 0.5 mg once daily.
1556007|NCT02555943|Drug|Tenofovir disoproxil|VIREAD is indicated for the treatment of chronic hepatitis B in adults and pediatric patients 12 years of age and older.
1556008|NCT02555930|Other|No Intervention|No intervention - observational only
1556009|NCT02555917|Procedure|anterior cruciate ligament reconstruction|Twenty patients planed to undergo anterior cruciate ligament reconstruction by preserving remnant and other twenty patients undergo anterior cruciate ligament reconstruction by preserving remnant.
1556027|NCT02555839|Drug|Pomalidomide|4mg capsules on Days 1 through 21 of a 28 day cycle
1556028|NCT02555839|Drug|Dexamethasone|40mg by mouth on Days 1, 8, 15, 22 of a 28 day cycle
1556029|NCT02555813|Drug|Abraxane|Abraxane By IV infusion on Days 1, 8, and 15 until progression or toxicity
1556030|NCT02555813|Drug|Gemcitabine|Gemcitabine 1000mg IV infusion on Days 1, 8 and 15 until disease progression or toxicity
1556031|NCT02555800|Drug|Bevacizumab|Patients will receive 3 intralesional injections of bevacizumab (Avastin, Genentech, San Francisco, California) every 3 to 6 weeks in a submucosal plane after surgical debulking. 12.5 mg of bevacizumab diluted in 3mL of 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
1556032|NCT02555800|Drug|Cidofovir|Patients will receive 3 intralesional injections of cidofovir every 3 to 6 weeks a submucosal plane after surgical debulking. 3.5 mL of cidofovir diluted to a concentration of 5 mg/mL in a 9% isotonic sodium chloride solution will be injected intralesionally using a 25 gauge.
1556033|NCT02555800|Other|Placebo|Saline solution
1556034|NCT02555787|Drug|Tacrolimus|oral
1556035|NCT02555774|Behavioral|cognitive training|cognitive training is held 2 times a week for 3 months, 90 minutes per 1 session. It includes cognitive exercise of multiple cognitive domains such as memory, attention, calculation, executive function and visuospatial function.
1556036|NCT02555774|Behavioral|lifestyle modification|education about lifestyle modification is done by investigators at the first day of the trial and the investigators conduct weekly phone call to participants to educate the lifestyle modifications
1556037|NCT02555761|Drug|Alcaftadine Ophthalmic Solution 0.25%|Alcaftadine Ophthalmic Solution 0.25% (Lastacaft®) as prescribed as standard of care in clinical practice.
1556038|NCT02555748|Drug|Pazopanib|
1556039|NCT02555748|Drug|Sunitinib|
1556040|NCT02555735|Drug|Standard of care chemotherapy|FOLFIRINOX or Gemcitabine + nab-paclitaxel
1556041|NCT02555722|Device|fanfilcon A (test)|silicone hydrogel lens
1556042|NCT02555722|Device|enfilcon A (control)|silicone hydrogel lens
1556043|NCT02555709|Drug|VTP-43742|VTP-43742 administered as an oral capsule once daily
1556044|NCT02555709|Drug|Placebo 1|Placebo 1 matching VTP-43742 administered as an oral capsule once daily
1556045|NCT02555709|Drug|Placebo 2|Placebo 2 matching VTP-43742 administered as an oral capsule once daily
1556046|NCT02555696|Drug|nab-paclitaxel|nab-paclitaxel by IV infusion every 3 weeks until progression or toxicity
1556047|NCT02555683|Drug|QAW039|QAW039 Dose 1 once daily
1556048|NCT02555683|Drug|QAW039|QAW039 Dose 2 once daily
1556049|NCT02555683|Drug|Placebo|Placebo once daily
1556050|NCT02555670|Other|BIA|Bioelectrical impedance analysis was performed within 4 days after a CT-scan was made
1556051|NCT02555657|Biological|pembrolizumab|
1556052|NCT02555657|Drug|capecitabine|
1556053|NCT02555657|Drug|eribulin|
1556054|NCT02555657|Drug|gemcitabine|
1556055|NCT02555657|Drug|vinorelbine|
1556056|NCT02555644|Drug|Prexasertib|Administered IV
1556057|NCT02555644|Drug|Cisplatin|Administered IV
1556058|NCT02555644|Drug|Cetuximab|Administered IV
1556059|NCT02555644|Radiation|Intensity Modulated Radiation Therapy|
1556060|NCT02555631|Behavioral|lifestyle|In this pilot study, each subject will receive the lifestyle intervention of the diabetes prevention program, a modified program for men from disadvantaged neighborhoods--a 16 weekly sessions of 1 hour each session
1556061|NCT02555618|Biological|TAK-850|TAK-850 subcutaneous injection
1556062|NCT02555618|Biological|Influenza HA vaccine|Influenza HA vaccine subcutaneous injection
1556099|NCT02555228|Drug|Simethicone|100mg of liquid simethicone is put into 5mls of water and given at least 30 minutes before the gastroscopy.
1556100|NCT02555228|Other|Water|5mls of water is given at least 30 minutes before the gastroscopy.
1556101|NCT02555215|Drug|dimethyl fumarate|administered orally
1556102|NCT02555189|Drug|Enzalutamide|Given PO
1556103|NCT02555189|Drug|Ribociclib|Given PO
1556104|NCT02555176|Dietary Supplement|Dietary intervention|Follow a low-carbohydrate diet
1556105|NCT02555163|Device|HoLERBT|Using holmium laser, the tumour will be removed as one piece from its base working underneath the muscle layer
1556063|NCT02555605|Drug|Dexmedetomidine|Children up to the age of 16 years requiring MRI under deep sedation with at least 3 characteristics of respiratory morbidities were identified as having increased risk for adverse respiratory events. Dexmedetomidine was administered as a first bolus of 1 mcg•kg−1 over 10 min, followed by a continuous infusion at 1.0 mcg•kg−1•h−1. Sedation level was assessed by Ramsay Sedation Scale and it was initially recorded at 1-min interval. If the child failed to achieve a minimum RSS of 5, this bolus was repeated once again and the continuous infusion was subsequently increased to 2 mcg•kg−1•h−1. In addition, propofol 0.5 mg.kg−1 iv. was allowed to be administered, in patients still exhibiting movement that could interfere with image acquisition.
1556064|NCT02555592|Procedure|Primary surgical resection with sequential adjuvant therapy|First, surgery resection of the affected lung with mediastinal lymph node dissection, including sub- and para-aortic lymph node, will be performed. If malignant tumor involvement only in the sub- or para-aortic lymph nodes is identified, adjuvant chemotherapy will be initiated within 8 weeks after surgery. After completion of adjuvant chemotherapy, post-operative radiotherapy will be initiated within 2~4 weeks after adjuvant chemotherapy.
1556065|NCT02555579|Behavioral|Dietary Protein Counting and Free Fruits and Vegetables|Subjects will be educated on new simplified diet approach and phenylalanine levels will be monitored for 1 year, and will be compared to 12 months prior to study enrollment
1556066|NCT02555566|Procedure|Blood sampling|Blood sampling is done for Kidney transplant recipients for evaluation of the polymorphisms and EETs dosage
1556067|NCT02555566|Procedure|flow-mediated distal stimulation of the forearm radial artery by cutaneous heating|Flow-mediated distal stimulation of the forearm radial artery by cutaneous heating for Kidney transplant recipients
1556069|NCT02555540|Biological|Boostrix|Randomised assignment
1556070|NCT02555540|Biological|Placebo (Saline)|Randomised assignment
1556071|NCT02555501|Other|PDT + Low level laser|"Two days before the laser treatment, the side of the oral cavity chosen for the experimental treatment was pigmented with aqueous solution of 0.005% methylene blue. A ball of sterile cotton was soaked in the dye solution and placed in the center of the lesion. Photosensitizer remained in the place for 5 minutes (pre-irradiation period). Then, to activate the dye, the lesion was irradiated with red light (InGaAlP / phosphide and Indium, Gallium and potassium).
From the 3rd to the 10th day was carried out only laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium)."
1556072|NCT02555501|Radiation|Low level laser|Two days before the laser treatment, the lesion of the side of the oral cavity chosen for the control treatment was treated with ball of sterile cotton soaked in distilled water and the laser unit placed on the lesion without activation of the light. From the 3rd to the 10th day was carried out laser therapy. For laser therapy was first used infrared emitter laser unit with active medium AsGaAl (Gallium Arsenide and Aluminium). Then, we used the red emitter, whose active medium was the InGaAlP (phosphide and Indium, Gallium and Potassium).
1556073|NCT02555488|Device|diode laser|MB and diode
1556074|NCT02555488|Device|diode laser|diode laser
1556075|NCT02555488|Drug|Methylene blue|Methylene blue and diode laser was used
1556076|NCT02555475|Other|community based hepatitis C care and treatment|
1556077|NCT02555462|Device|Real-Ear Measurement system integrated in hearing aid fitting software|The subjects individual response of the ear canal gets measured with the help of a probe tube and a following hearing aid fitting.
1556078|NCT02555449|Drug|[¹⁴C]-LY3202626|Administered as solution by mouth
1556079|NCT02555423|Drug|Local anaesthetic - chirocaine|
1556080|NCT02555410|Device|Brain Sentinel Seizure Detection and Warning System|A sEMG based automated seizure detection and warning system worn on the biceps
1556081|NCT02555397|Biological|Ad5-yCD/mutTKSR39rep-hIL12|Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1
1556082|NCT02555384|Other|crowded drawing task|Marking inverted signs on a sheet where symbols are presented close to one another
1556083|NCT02555384|Other|uncrowded drawing task|Marking inverted signs on a sheet where there is a larger distance between symbols
1556088|NCT02555332|Other|75g oral glucose tolerance test (OGTT)|All these women underwent the 75g oral glucose tolerance test (OGTT) at 24-28 weeks of gestation.
1556090|NCT02555306|Drug|DE-122|DE-122 Injectable Solution
1556091|NCT02555293|Drug|XIFAXAN® (Rifaximin)|
1556092|NCT02555280|Device|coflex® Interlaminar Technology|Decompression plus coflex® Interlaminar Technology
1556093|NCT02555280|Procedure|Decompression|Decompression alone
1556094|NCT02555254|Procedure|Low Speed of Rewarming|Speed of rewarming will be at 0.25°C/h with specific temperature controlled external device
1556095|NCT02555254|Procedure|High Speed of Rewarming|Speed of rewarming will be at 0.50°C/h with specific temperature controlled external device
1556096|NCT02555241|Behavioral|Mand Training|The mand training component of treatment will consist of behavioral principles designed to increase the participant's Mean Length of Utterances (MLU) when manding.
1556097|NCT02555241|Behavioral|Matrix|The matrix training component of treatment will consist of behavioral principles designed to teach labeling of noun-verb and color-shape combinations using matrix training.
1556098|NCT02555241|Behavioral|Stimulus Equivalence Training|The stimulus equivalence training component of treatment is designed to examine the emergence of untrained skills following the training of relational skills.
1556147|NCT02554877|Drug|PF-06291874|study drug to be given as an oral tablet at 30, 60 or 100 mg
1556106|NCT02555163|Device|cTURBT|using the conventional electrocautery device with the cutting hot loop the tumor will be removed in pieces
1556107|NCT02555150|Drug|PRC-063|Oral extended-release capsule
1556108|NCT02555150|Drug|lisdexamfetamine dimesylate|Oral capsule
1556109|NCT02555150|Drug|Placebo|Oral placebo capsule
1556110|NCT02555137|Other|'prediction score' and 'rule-out criteria'|The combination of the 'prediction score' and the 'rule-out criteria' constitutes an accurate follow-up after PE aimed at diagnosing CTEPH in early stages.
1556111|NCT02555124|Drug|JNJ-42847922, 5 mg|Participants will receive single oral dose of 5 milligram (mg) of JNJ-42847922 on Day 1, fasted condition.
1556112|NCT02555124|Drug|JNJ-42847922, 20 mg|Participants will receive single oral dose of 20 mg of JNJ-42847922 on Day 1, fasted condition.
1556113|NCT02555124|Drug|JNJ-42847922, 40 mg|Participants will receive single oral dose of 40 mg of JNJ-42847922 on Day 1, fasted condition.
1556114|NCT02555124|Drug|Placebo|Participants will receive placebo on Day 1, fasted condition in Cohort A, Cohort B and Cohort C.
1556115|NCT02555111|Drug|Xarelto|15mg/day oral administration during 2 to 4 years (based on the recruitment date).
1556116|NCT02555085|Biological|BIIB063|Single ascending IV dose
1556117|NCT02555085|Other|Placebo|Single dose
1556118|NCT02555072|Biological|yellow fever vaccine|yellow fever vaccination in naive individuals who leaves in a state where this type of vaccination is not recommendated
1556120|NCT02555046|Procedure|Local Anesthesia|Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
1556121|NCT02555033|Other|Resistance training|traditional resistance training
1556122|NCT02555033|Other|Instability resistance training|training under unstable conditions
1556123|NCT02555020|Dietary Supplement|Allocated to Carbohydrated group|Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
1556124|NCT02555020|Dietary Supplement|Allocated to Placebo group|Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
1556125|NCT02555020|Dietary Supplement|Allocated to MN NPO group,|Patients received NPO from MN.
1556126|NCT02555007|Drug|Vinorelbine|
1556127|NCT02554994|Other|Multifactorial intervention|"There are six components of intervention in this study.
For all participants:
Group exercise
Nutritional supplement(commercial liquid formula will be provided every day).
For selected participants:
Wellness visit in primary care setting, polypharmacy and multi-morbidity every month.
At risk of depression(the people identified as high risk of depression would meet psychiatrist every month).
Domestic safety(If there are possible hazards in participants' home, social worker provide amendments for getting rid of it)."
1556128|NCT02554994|Other|Usual care|"Experienced nurses will visit all participants every month during 6 months of study period, and will conduct an interview and comprehensive geriatric assessments to collect information regarding physical, nutritional, mental, mood condition and health related quality of life.
According to ASPRA cohort schedule, all participants will be assessed by the composite measurement method composed of K-FRAIL frailty scare, Mini-Nutritional Assessment Short Form(MNA-S), the Korean version of Mini-Mental State Examination(K-MMSE), Center for Epidemiological Studies depression(CES-D), EQ-5D 3 level version from EuroQol Research Foundation(EQ-5D 3 level), Short Physical Performance Battery(SPPB), and the Cardiovascular Health Study(CHS)."
1556129|NCT02554981|Drug|Cyclosporine 0.05% Ophthalmic Emulsion|Cyclosporine 0.05% Ophthalmic Emulsion (RESTASIS®) 1 drop instilled in each eye twice a day.
1556130|NCT02554968|Other|Questionnaires|
1556131|NCT02554955|Drug|Daclizumab|Participants will receive IV daclizumab (2 mg/kg within 6 hours after transplantation and 1 mg/kg every 2 weeks) for a total of five doses.
1556132|NCT02554955|Drug|Mycophenolate mofetil|Participants will receive mycophenolate mofetil orally (one dose of 1.5 mg within 12 hours pretransplant, 1.5 mg BID within first week and 1 g/day BID from second week onwards) for 6 months.
1556133|NCT02554955|Drug|Silrolimus|Participants will receive sirolimus orally (3 mg/day) for 6 months.
1556134|NCT02554942|Drug|Epoetin beta|Participants will receive weekly SC injections of epoetin beta beginning at 450 IU/kg, with doses adjusted according to hemoglobin level. Treatment will continue for a total of 16 weeks.
1556135|NCT02554929|Behavioral|Taming Sneaky Fears|Parents receive coping strategies based on CBT in parent group and children receive coping strategies based on CBT in child group.
1556136|NCT02554929|Behavioral|Parent Psycho-education and Child Socialization|Parents receive psycho-education in parent group and children receive socialization skills in child group.
1556137|NCT02554916|Behavioral|Dual-Belt Exercise|The dual-belted exercise treadmill can control the speeds of the right and left legs individually. When asymmetric, the dual-belt treadmill imposes mechanical and sensory perturbations independently to each leg such that the central nervous system (CNS) must solve and adapt to the challenge to maintain walking.
1556138|NCT02554916|Behavioral|Treadmill Exercise|The treadmill exercise will maintain the speed of the right and left leg together while walking.
1556139|NCT02554916|Other|Usual Care|This group will not be assigned to a treadmill but is as a non-exercising control group.
1556140|NCT02554916|Device|Dual-Belt Treadmill|
1556141|NCT02554903|Drug|Macitentan 10mg|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
1556142|NCT02554903|Drug|Placebo sugar pill|2 groups, randomized in a 1:1 ratio by an Interactive Voice/Web Randomization System to macitentan 10 mg or placebo
1556149|NCT02554864|Drug|lidocaine|Local anesthetic
1556150|NCT02554864|Drug|ropivacaine|Local anesthetic
1556151|NCT02554851|Drug|recombinant human Epidermal Growth Factor (rhEGF)|The Heberprot-P® is a parenteral formulation, which is in a lyophilized powder vial presentation containing 75μg of recombinant Epidermal Growth Factor (rhEGF) for local application (intralesional) with the therapeutic potential to promote granulation and wound healing of DFU. The rhEGF is a polypeptide of 53 amino acids and has the ability to stimulate fibroblasts, keratinocytes and vascular endothelial cells proliferation. Then it contributes to its properties in scar tissue formation. The action mechanism is based on the interaction with specific receptors located on specifics cell membranes. The rhEGF was developed through recombinant DNA technology and it has been produced by biotechnological methods in Saccharomyces cerevisiae yeast line.
1556152|NCT02554851|Other|Placebo|This group will receive the standard medication and the placebo drug. The placebo drug has the same formulation, except for the fact that it does not contain the recombinant human Epidermal Growth Factor (rhEGF).
1556153|NCT02554838|Other|Physical activity|Participants receive a weekly individual session of physical activity during 8 consecutive weeks conducted by a licensed physical therapist and focusing on muscle strengthening, flexibility, gait and balance retraining.
1556154|NCT02554838|Other|Home assessment and modification|Two home-based sessions of modification of the home environment by a licensed rehabilitation therapist, in order to increase the aera of mobility, the frequency of moving in this aera and the independence to move.
1556155|NCT02554838|Behavioral|Cognitive behavioral therapy|Participants receive during 8 consecutive weeks a weekly individual sessions of CBT and a booster session one month later conducted by a psychologist specialized in CBT focusing on : functional analysis, education about treatment and anxiety, relaxation training and progressive exposure in imagination then in vivo.
1556156|NCT02554825|Behavioral|Healthy Futures|Healthy Futures is an age-appropriate program that targets change at different social ecological levels—individual, interpersonal, and organizational. The main component is a classroom-based relationship education curriculum, Nu-CULTURE, offered in 6th, 7th, and 8th grade for eight 50-minute sessions each year. A number of supplemental efforts aim to enhance the Nu-CULTURE program and create social supports: 1) virtual classrooms where participating youth are encouraged to visit age-appropriate youth websites; 2) daily interactive parental connection forms linked with Nu-CULTURE, a parent website, and workshops (True Connections); 3) a 10-week after-school program, Rhymin' it Write, encourages youth leadership; 4) a 6-week summer program, Code A, engages youth during out-of-school time after 8th grade.
1556157|NCT02554825|Behavioral|Control|The Control Curriculum offers students in the control group two 50-minute classes each year on general health education topics. Students in the 6th grade receive a class on puberty/reproduction and a class on bullying prevention; students in the 7th grade receive two classes on dating-violence prevention; and students in the 8th grade receive two classes on mental health promotion.
1556162|NCT02554799|Drug|MMV390048 formulation A|MMV390048 formulation A, tablet
1556163|NCT02554799|Drug|MMV390048 formulation B|MMV390048 formulation B, tablet
1556164|NCT02554786|Drug|QMF149|
1556165|NCT02554786|Drug|QMF149|
1556166|NCT02554786|Drug|MF 400|
1556167|NCT02554786|Drug|MF 400|
1556168|NCT02554786|Drug|salmeterol /fluticasone|
1556169|NCT02554773|Drug|ALN-AT3SC|Multiple doses of ALN-AT3SC by subcutaneous (sc) injection
1556170|NCT02554760|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
1556171|NCT02554747|Device|Navigated laser|Aflibercept, Navilas®
1556172|NCT02554747|Device|Conventional laser|Aflibercept, Pascal
1556173|NCT02554734|Drug|levodopa, carbidopa, ODM-104|
1556174|NCT02554734|Drug|levodopa, carbidopa, entacapone|
1556175|NCT02554721|Drug|Cilostazol|
1556176|NCT02554721|Drug|Acetylsalicylic acid|
1556177|NCT02554721|Drug|Clopidogrel|
1556178|NCT02554708|Device|implantation of the pCONus Bifurcation Aneurysm Implant|The device will be introduced through a regular microcatheter. After deployment of the device with the crown positioned in the aneurysm neck the aneurysm will be entered with a microcatheter to perform endovascular coil occlusion. After completion of the coiling procedure the pCONus device will be electrolytically detached from the insertion wire and only the crown and the shaft will remain as a permanent implant.
1556179|NCT02554695|Drug|placebo|subcutaneous saline injection
1556180|NCT02554695|Drug|denosumab|single subcutaneous injection of denosumab 60 mg
1556181|NCT02554682|Behavioral|Sexual Health|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about sexual health, STD prevention, and safe sex practices for teenager.
1556182|NCT02554682|Behavioral|Alcohol Prevention|Psychoeducational workbook, worksheets, tip sheets, and health coaching session about alcohol prevention and safety, underage drinking, and drinking and driving.
1556183|NCT02554682|Behavioral|Teen Driving|Psychoeducational workbook, worksheets, videos, tip sheets, and health coaching session about how parents can help supervise their teens' safe driving practices and how to talk with their teen about important safety topics for teen drivers.
1556184|NCT02554669|Behavioral|postprandial and postabsorptive physical activity on treadmill|
1556185|NCT02554643|Other|Diet|Nutrition intervention, once a week during 12 weeks
1556186|NCT02554643|Other|Soccer|Nutrition intervention, once a week during 12 weeks + Soccer training, 3 x week, during 12 weeks
1556187|NCT02554643|Other|Running|Nutrition intervention, once a week during 12 weeks + Running training, 3 x week, during 12 weeks
1556190|NCT02554578|Other|Multidisciplinary follow-up programme supported by mHealth|"The follow-up programme integrates an online health platform (app and web) to monitor patients remotely, into the multidisciplinary team workflow, in order to improve heart transplant management.
Patients will use the mobile application designed to help them to manage their health issues and facilitate communication with the transplant team.
Data recorded manually by the patient using the mHealth application include pharmacotherapeutic information (medication adherence, barriers to adherence, side effects, interactions, etc.), clinical symptoms and other relevant clinical information (blood pressure, cardiac frequency, exercise, glucose level, diet, mood, etc.).
mHealth will be used by the transplant team as a complementary way of deliver patient care. Analysis of the data collected by the multidisciplinary team may help to prioritise and provide personalized pharmacotherapeutic and medical interventions to patients and their families."
1556191|NCT02554565|Procedure|Tumor biopsy|Tumor biopsy before treatment
1556192|NCT02554565|Procedure|Blood sampling|Blood sample before, during and after treatment
1556193|NCT02554552|Drug|YY1201 2ml|YY1201 2ml
1556194|NCT02554552|Drug|Placebo 2ml|phosphate buffered saline 2ml
1556195|NCT02554552|Drug|YY1201 3ml|YY1201 2ml
1556196|NCT02554552|Drug|Placebo 3ml|phosphate buffered saline 3ml
1556197|NCT02554539|Procedure|Endometrial fluid aspiration|Patient will undergo a biopsy to aspirate endometrial fluid from the uterine cavity
1556198|NCT02554513|Device|EPG Tx|behavioral intervention that incorporates a device that provides visual biofeedback
1556199|NCT02554513|Behavioral|SPT|A treatment hierarchy involving integral stimulation
1556200|NCT02554500|Procedure|Remote Ischemic Preconditioning (by Blood Pressure Cuff)|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
1556201|NCT02554487|Device|AirCurveTM10 CS PACEWAVE Adaptive-Servo-Ventilator (ResMed Ldt., Australia)|Adaptive Servo-Ventilation (ASV) is a ventilator mode used to treat central and obstructive forms of sleep disordered breathing. It is authorized in Switzerland, bears a conformity marking (CE 0123) and it is used according to the approved indications. Stroke patients with an AHI > 20/h assessed within the first night following stroke that are randomized to ASV treatment, starting in the second night after stroke, are part of this group. The other half of patients are randomized to no treatment and patients without sleep disordered breathing (AHI < 5) following stroke serve as a control group
1556204|NCT02554461|Other|advise for exercices given by team staff|"To respond to questions asked:
it is not the investigator who decides on the intervention, but the daily team staff (e.g. trainer, coach, PT,.....). So no predetermined intervention is provided"
1556205|NCT02554448|Other|ISET system|Use ISET system to test the number of CTCs from patients before and during treatment.
1556209|NCT02554422|Device|PalpEar|Palpation of the middle-ear ossicles using the PalpEar device, to measure mobility of the ossicle chain
1556210|NCT02554409|Biological|Quadrivalent Intradermal Influenza Vaccine (QIV)|No Intervention as part of this protocol
1556213|NCT02554383|Drug|Amoxicillin-clavulanate|Amoxicillin-clavulanate (90/6.4 mg/kg/d in 2 divided dosed for 10 days)
1556214|NCT02554383|Drug|Placebo|placebo made to match the study antibiotic given twice a day orally for 10 days
1556215|NCT02554370|Behavioral|Psychoeducational programme|4 sessions of psychoeducation before and 3 after surgery for subthalamic deep brain stimulation
1556216|NCT02554357|Drug|Exparel block in arthroscopic shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
1556217|NCT02554357|Drug|Bupivacaine block in shoulder surgery|The interscalene block will be performed with ultrasound guidance and nerve stimulation.
1556218|NCT02554344|Drug|Curcumin|Patients will receive 500mg of curcumin administered orally, twice a day for 12 weeks.
1556219|NCT02554331|Radiation|FP-CIT single-photon emission computed tomography|FP-CIT radiolabeled is used as a surrogate marker to examine the integrity of the dopaminergic nigrostriatal neurons.
1556220|NCT02554331|Behavioral|neuropsychological evaluation|"Assessment of:
overall cognitive function
executive functions
visuospatial functions
Nonverbal memory
verbal memory
Evaluation of hearing ability of time perception and sensorimotor synchronization from selected tasks the Battery of assessment of auditory sensorimotor and timing abilities
Beck Depression Inventory"
1556221|NCT02554331|Other|Gait recording with sensors|Gait recording with sensors
1556222|NCT02554318|Drug|Rifampicin|
1556223|NCT02554318|Drug|Isoniazid|
1556224|NCT02554318|Drug|Pyrazinamide|
1556225|NCT02554318|Drug|Ethambutol|
1556226|NCT02554318|Dietary Supplement|Fermented soybean|
1556227|NCT02554305|Device|fusion oxygenation system|The fusion oxygenation system is a novel design of the pump oxygenator used in cardiopulmonary bypass, integrating multiple new engineering concepts that have altered its performance profile.
1556228|NCT02554305|Device|Affinity oxygenation system|The affinity oxygenation system is the classical pump oxygenator used in cardiopulmonary bypass surgeries
1556229|NCT02554292|Device|Drug Coated Balloon Angioplasty, Scoring Balloon Dilatation|Percutaneous Coronary Intervention
1556232|NCT02554266|Device|Lutonix 014 Drug Coated Balloon PTA Catheter|Drug Coated Balloon PTA Catheter for Treatment of Below-the-Knee (BTK) Arteries
1556233|NCT02554253|Drug|Ketamine|Ketamine used for induction
1556234|NCT02554253|Drug|Propofol|Propofol for induction
1556235|NCT02554240|Drug|DA-5202 20mg|once a week, intra-articular injection, for 3 weeks
1556236|NCT02554240|Drug|DA-5202 10mg|once a week, intra-articular injection, for 3 weeks
1556237|NCT02554240|Drug|Na Hyaluronate 20mg|once a week, intra-articular injection, for 3 weeks
1556238|NCT02554227|Other|Cytokine Profile|Routine blood collection will be carried out directly before surgery and also during the stationary hospitalization on day 4 and day 10. Additional blood collection will be done after 6 weeks and 3 months during the follow-up.
1556239|NCT02554214|Device|Glafkos drainage device|
1556240|NCT02554201|Device|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. Needles of 0.40 Х 100 mm are inserted perpendicularly to the upper points to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The two lower points are about 1 cm bilateral to the tip of the coccyx. Needles of 0.40 Х 100 or 125 mm are inserted obliquely to the lower points towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally needles.
1556241|NCT02554201|Device|Transvaginal electrical stimulation|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
1556242|NCT02554188|Biological|Seasonal influenza (flu) vaccine|"Seasonal influenza (flu) vaccine
Fluzone Quadrivalent Vaccine (Sanofi Pasteur), for participants ages 50 - 64 years old
Fluzone High-Dose (Sanofi Pasteur), for participants ages 65 years and older"
1556243|NCT02554188|Other|Diet|A 5-day low calorie fasting-mimicking diet
1556244|NCT02554175|Drug|Propofol|Propofol was administered to achieve target propofol Ce
1556245|NCT02554162|Other|Rye products with varying structures|The satiating effect of rye products with various structures will be studied
1556246|NCT02554149|Radiation|Radiological measurement of femoral stem version|particular radiographs( lateral decubitus view) and CT scans
1556247|NCT02554136|Drug|HGP0918|
1556248|NCT02554136|Drug|HGP0816|
1556249|NCT02554136|Drug|HGP0918 + HGP0816|
1556250|NCT02554123|Drug|Vitamin E ointment application|Vitamin E ointment application. Every 12 hours during 7 days.
1556251|NCT02554123|Drug|Vaseline ointment application|Vaseline ointment application. Every 12 hours during 7 days.
1556252|NCT02554110|Device|Stimulator active device|This is a stimulator active device that delivers peripheral nerve stimulation in conjunction with pulse oximetry information.
1556253|NCT02554110|Device|Stimulator sham Device|This is an stimulator sham device that is not providing peripheral nerve stimulation.
1556254|NCT02554097|Procedure|endoscopic sphincterotomy|Sphincterotomy (EST) is performed to remove the common bile duct stone.
1556255|NCT02554097|Procedure|laparoscopic common bile duct exploration|Transductal exploration was carried out to remove the common bile duct stone. Primary closure or a T tube drainage was performed according to the results of transductal surgery.
1556256|NCT02554097|Procedure|laparoscopic transcystic common bile duct exploration|A wide local dissection of Calot's triangle is performed and a 2.8mm, 3-mm or 5-mm flexible choledochoscope according to the diameter of the cystic duct is inserted through the cystic duct into the common bile duct. After the common bile duct stone is removed, the cystic duct was ligated with Hem-o-lok.
1556257|NCT02554097|Procedure|laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed to remove the gallbladder.
1556258|NCT02554084|Device|Optical Coherence Tomography|Digital images of tear film
1556259|NCT02554071|Other|Pharmacist - Smoking Cessation Support|Intervention mirrors clinical practice with smoking cessation counselling -- patients receive smoking cessation product at no cost and pharmacists are paid flat fee for providing counselling
1556260|NCT02554058|Device|Cycling and Mechanical stimulation|Cycling and Mechanical stimulation : 30 minute cycling training, 3 times a week for 8 weeks.
1556263|NCT02554032|Procedure|Axillary artery cannulation|The right axillary artery will be exposed via an infraclavicular incision and a Dacron graft sewn to it in an end to side fashion after 5000 units of IV heparin. Following median sternotomy and full systemic heparinization, CPB will be initiated and the patient cooled. The base of the innominate artery will be clamped, and antegrade cerebral perfusion will be provided via the axillary artery. Following completion of the distal open aortic anastomosis, the clamp on the innominate artery will be removed, CPB via the aorta will be resumed and the patient will be rewarmed. After completion of surgery and weaning from CPB, the axillary artery graft will then be removed, the artery repaired and the skin will be closed.
1556264|NCT02554032|Procedure|Innominate artery cannulation|After median sternotomy, systemic heparinization, cannulation of the ascending aorta and right atrium, CPB and systemic cooling will be initiated. The ascending aorta, proximal arch and the base of the innominate artery will be mobilized. Purse-string sutures are placed on the anterior wall of the proximal innominate artery and a pediatric venous cannula inserted using a J wire and sequential dilatation. Circulatory arrest with ACP is provided by clamping the base of the innominate artery and connecting the afferent limb of the CPB circuit to the innominate cannula. Once the distal aortic anastomosis is completed, ACP is discontinued, and full CPB via the aortic graft is resumed. Rewarming and the remaining surgery are then completed.
1556265|NCT02554019|Biological|BT063|Repeated IV infusions over 12 weeks
1556266|NCT02554019|Biological|Placebo|Repeated IV infusions over 12 weeks
1556392|NCT02553083|Drug|Nexium 40 mg|Nexium 40 mg twice daily for 14 days
1556267|NCT02554006|Behavioral|good clinical practice|education from physician regarding dual antiplatelet therapy as part of the routine discharge process
1556268|NCT02554006|Behavioral|bundle group|visits and materials describing advantages and side effects of dual antiplatelet therapy and their management
1556269|NCT02553993|Device|Wii Fit(30 Mins)|Receive Wi Fit games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
1556270|NCT02553993|Device|Tetrax biofeedback(30 Mins)|Receive Tetrax biofeedback games training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
1556271|NCT02553993|Other|Conventional weight-shifting(30 Mins)|Receive weight-shifting exercise training for 30 minutes. There are 2 sections for 1 week; the intervention period will be 12 weeks.
1556272|NCT02553980|Behavioral|Follow Your Virtual Trainer (FYVT) program|"Participants in intervention group will under the instruction of a web-based computer software termed Virtual Trainer, which interact with their smartphone apps, to conduct a 3-month self-planned PA training program. A serious of online video seminars related to healthy lifestyle advice will be released to the participants among 3 months. After that, 6 months observation will be followed."
1556273|NCT02553980|Other|Daily PA recommendation & healthy lifestyle suggestions|A written advice of daily PA recommendation, and the textual content of the healthy lifestyle seminars will be provided to the participants.
1556274|NCT02553967|Device|Functional MRI|Functional MRI
1556275|NCT02553954|Procedure|Collection of healthy skin tissue|Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
1556276|NCT02553941|Drug|Azacitidine|Given intravenous or subcutaneous
1556277|NCT02553941|Drug|Ibrutinib|Given by mouth once daily
1996287|NCT02503410|Behavioral|Home-based exercises|Subjects will receive a combination of physical therapy and home exercise program during 8 to 12 weeks. Home exercise will be recommended at least two times a week. Usual Care of LBP provided in SRH consists of exercises and manual therapy in various combinations according to the needs of the subject. Subjects will fill out a questionnaire about their pain and how much time they spent doing the home exercises every two weeks.
1556280|NCT02553915|Other|Placebo|Soybean oil placebo
1556281|NCT02553915|Drug|EPA 1 g/day|Omega-3 fatty acid extracted from fish oil, 1 g/day
1556282|NCT02553915|Drug|EPA 2 g/day|Omega-3 fatty acid extracted from fish oil, 2 g/day
1556283|NCT02553915|Drug|EPA 4 g/day|Omega-3 fatty acid extracted from fish oil, 4 g/day
1556284|NCT02553902|Device|Sleep position trainer|
1556285|NCT02553902|Device|Mandibular advancement device|
1556286|NCT02553902|Device|Continuous positive airway pressure|
1556287|NCT02553889|Drug|ISIS 416858|subcutaneous injection
1556288|NCT02553889|Drug|Placebo|subcutaneous injection
1556289|NCT02553863|Procedure|Acupuncture|Acupuncture for 30min [twice weekly for 8 weeks]
1556290|NCT02553863|Procedure|Standard care|Standard care
1556291|NCT02553837|Biological|Hantavax injection|A single 0.5mL dose intramuscular or subcutaneous injection
1556292|NCT02553824|Drug|Phentermine/Topiramate-First|Patients randomly assigned to this Arm will have a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated). Then will have a 2 week washout followed by a crossover to 12 weeks of control medication/ placebo.
1556293|NCT02553824|Drug|Placebo|Patients randomly assigned to this Arm will have begin with 12 weeks of placebo followed by a 2 week washout. They will then crossover to Qsymia and receive a 4 week ramp up period (in which doses will be increased, as tolerated, starting from 3.75 mg/23 mg, 7.5 mg/46 mg ,11.25 mg/69 mg , 15 mg/92 mg taken once daily in the morning. For the final 8 weeks, participants will take the 15mg/92 mg (or highest dose tolerated).
1556294|NCT02553811|Diagnostic Test|accuracy diagnostic|effectiveness of the ultrasonography and electromiography for best performance and diagnostic accuracy in carpal tunnel syndrome
1556295|NCT02553798|Drug|DRM04 Topical Wipes|DRM04 Topical Wipes
1556296|NCT02553785|Device|Revivent TC|
1556299|NCT02553759|Other|Actions observed|Patients observed movements without realize them. After this actions, movements will be imagined by patients
1556300|NCT02553746|Device|Detection of the puncture site by ultrasound scan of the lumbar spine.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by ultrasound scan of the spine. The scanning will be performed as described by Arzola et al. The L3-L4 space will be identified by palpation and identification of the landmarks (Tuffier's line). The ultrasound probe will be placed perpendicular to the long axis of the spine. The spinous process will be identified (bright signal followed by dark triangular area). The probe will be moved to cephalad or caudal to identify the intervertebral space and when the best view of the ligamentum flavum is achieved two marks will be drawn on the skin: one at the center of the upper surface of the probe and one at the center of the right lateral vertical side of the probe. The intersection of the two landmarks will be the puncture site. The distance from the skin to the ligamentum flavum will be measured by the ultrasound caliper.
1556301|NCT02553746|Procedure|Detection of the puncture site by identification of the landmarks.|Neuraxial anesthesia will be performed to the patients after detection of the puncture site by the identification of the landmarks. The L3-L4 space will be identified by palpation of the posterior iliac crests and the ideal intervertebral space will be selected after palpation of the spinous processes.
1556302|NCT02553733|Drug|Beetroot juice|This beverage contains 0.3 g of inorganic nitrate per 70 ml container, and is bottled and supplied by James White Drinks (UK).
1556303|NCT02553733|Drug|Beetroot juice placebo|This beverage is identical in look and taste to the Beet-It organic shot, but has the nitrate removed. It is also bottled and supplied by James White Drinks (UK).
1556304|NCT02553720|Other|exercise in water|The patients will be instructed to perform walking or swimming for 15 minutes, 3 times a week for 3 months in a swimming pool in addition to conventional management
1556305|NCT02553720|Other|conventional management|conventional management
1556306|NCT02553707|Drug|Ibandronate|Participants will receive ibandronate 6 mg IV on Days 1, 2, and 3.
1556393|NCT02553083|Drug|amoxicillin 1.5 gr|amoxicillin 1.5 gr twice daily for 14 days
1556307|NCT02553694|Other|Enhanced education|Investigator created video to help educate subject before the in-laboratory split night polysomnogram. The subject will watch the short video immediately prior to the initiation of the in-laboratory polysomnogram.
1556308|NCT02553694|Other|Usual education|Usual education by American Academy of Sleep Medicine (AASM)- created educational pamphlets
1556309|NCT02553694|Other|Usual follow up|MD will follow up by phone after the in-laboratory split night polysomnogram
1556310|NCT02553694|Other|Enhanced follow up|Sleep center non-MD staff member will follow up by phone after the in-laboratory split night polysomnogram
1556311|NCT02553681|Device|roflufocon D contact lenses|HPT treated rigid contact lenses
1556312|NCT02553681|Device|RGP contact lenses made from roflufocon D|
1556313|NCT02553668|Drug|Oxygen (FiO2 1,0)|Participants will inhale Oxygen (FiO2 1,0) via Facemask for 3 hours.
1556314|NCT02553668|Device|Facemask|
1556315|NCT02553655|Procedure|4x 5min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 millimeters of mercury (mmHg) above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 5min and is followed by 5 minutes of reperfusion/rest. This will be repeated 4 times.
1556316|NCT02553655|Procedure|3x 10min Limb Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 30 mmHg above systolic blood pressure. The loss of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of reperfusion/rest. This will be repeated 3 times.
1556317|NCT02553655|Procedure|3x 10min Sham Preconditioning|A blood pressure cuff is placed over the upper thigh of the participant(s) and inflated to 40 mmHg, sufficient to apply pressure but not affect blood flow. The presence of pedal pulses is confirmed by palpation. The cuff remains inflated for 10min and is followed by 5 minutes of rest. This will be repeated 3 times.
1556320|NCT02553629|Drug|Rocuronium|
1556322|NCT02553603|Drug|Growth Hormone Releasing Hormone (GHRH)|Growth Hormone Releasing Hormone (GHRH) 1mg/day for 10 weeks
1556323|NCT02553603|Drug|Placebo Growth Hormone Releasing Hormone|Placebo GHRH to be given once daily for 10 weeks
1556324|NCT02553564|Other|Checklist driven clinical encounter after hospital discharge|"Within 96 hours of hospital discharge an Nurse Practitioner will perform a checklist guided assessment to preventing rehospitalizations. The assessment consists of the following:
The participants's hospital course will be reviewed and their clinical recovery and stability assessed.
Determination of the participants's estimated dry weight (EDW).
The participants's post discharge medications will be checked, compared to the prehospitalization medication, and discrepancies will be reviewed and corrected.
Blood tests will be ordered for the participants's first return dialysis treatment if medically appropriate after clinical assessment.
Write new dialysis orders.
Dialysis Access- review access and determine any changes required in treatment"
1556325|NCT02553551|Drug|Vitamin C|"During the period of hospitalization, Intake of vitamin C 3000 mg per day via oral route until the day of discharge.
After discharge, no additional vitamin C pill was given."
1556326|NCT02553551|Drug|Placebo|"During the period of hospitalization, Intake of gelatinous capsule three times per day via oral route until the day of discharge.
After discharge, no additional capsule was given."
1556328|NCT02553525|Procedure|Therapeutic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to suppress oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
1556329|NCT02553525|Procedure|Symptogenic Stimulation Patterns|During deep brain stimulation (DBS) electrode implantation or implanted pulse generator (IPG) replacement surgery, different stimulation patterns that are designed to exacerbate oscillatory neural activity at theta- or beta-frequencies will be delivered in randomized order, and the subject will be blinded to the patterns. Neural activity and/or motor symptoms (tremor and/or bradykinesia) will be measured in response to DBS. Measurements will be made during 2- to 8-minute trials, in which stimulation will be off for the first half of the trial, and on for the remaining half. Neural activity and/or motor symptoms will be measured during both the off and on phases. The total amount of time necessary for data collection will be about 45 minutes.
1556330|NCT02553512|Other|Ingestible Sensor and Wearable Sensor|This digital health offering passively acquires and records medication-taking and habits of daily living.
1556331|NCT02553499|Biological|MK-1248|IV on Day 1 of each 21-day cycle
1556332|NCT02553499|Biological|pembrolizumab|IV on Day 1 of each 21-day cycle
1556333|NCT02553486|Other|quality of life evaluation|
1556350|NCT02553447|Dietary Supplement|Cholecalciferol|Given PO
1556351|NCT02553447|Other|Laboratory Biomarker Analysis|Optional correlative studies
1556352|NCT02553434|Device|Pigtail catheter|Insertion of pigtail catheter
1556353|NCT02553421|Device|ivWatch Model 400|The ivWatch Model 400 is placed next to the subject's PIV site. All subjects will receive standard care for their IV sites including the normal routine assessments of the IV site by the bedside registered nurses.
1556354|NCT02553408|Device|FreeStyle Precision Neo-Meter|Participants will receive a free glucose meter (Neo) and test strips from their care providers with education and instructions on how to use the meter to monitor their glucose level. Three months after the start of using the meter, participants will be interviewed on their experiences, likes and dislikes about the meter.
1556355|NCT02553382|Dietary Supplement|Dietary, Herbal|Viscous fibre blend and Salba and American and Korean Red Ginseng capsules
1556356|NCT02553382|Dietary Supplement|Positive Control|Oat bran blend and wheat bran capsules
1556357|NCT02553369|Other|Biological sample collection|A blood sample is collected during a follow up visit for HIV infection.
1556358|NCT02553356|Drug|PT2385|
1556359|NCT02553343|Biological|High-dose quadrivalent influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
1556360|NCT02553343|Biological|High-dose influenza virus vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
1556361|NCT02553343|Biological|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
1556362|NCT02553343|Biological|High-dose trivalent inactivated influenza vaccine|0.5 mL, Intramuscular (IM), injected into the deltoid area
1556363|NCT02553330|Drug|Placebo Cream|
1556364|NCT02553330|Drug|INCB018424 Phosphate Cream|
1556365|NCT02553317|Biological|caplacizumab|
1556366|NCT02553317|Biological|placebo|
1556367|NCT02553291|Behavioral|SystemCHANGE|
1556368|NCT02553291|Behavioral|Control|
1556369|NCT02553278|Device|VelaShape device|Modified VelaShape radiofrequency device for non invasive fat reduction treatment.
1556370|NCT02553278|Device|Contour I V3 device|Contour I V3 device are non invasive for fat reduction.
1556371|NCT02553265|Drug|Carbidopa Low Dose|
1556372|NCT02553265|Other|Placebo|A placebo containing an inert substance, in capsule form that does not contain an active drug ingredient.
1556373|NCT02553265|Drug|Carbidopa High Dose|
1556374|NCT02553252|Other|Sudarshan Kriya Yoga Trauma Relief Program (SKY)|Participants in the SKY group will undergo a 12-week training course in Sudarshan Kriya Yoga (SKY) conducted by certified instructors from the Art of Living Foundation.
1556375|NCT02553239|Device|CoolLoop®|Cryoablation of Atrial Fibrillation Using the CoolLoop Cryoablation System
1556376|NCT02553226|Drug|Oxytocin|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
1556377|NCT02553226|Drug|Placebo|Both arms will initially receive routine treatment with oxytocin according to national guidelines. When active phase of labour is established both arms will have their infusion-set changed for a blinded infusion-set.
1556378|NCT02553213|Other|Laparoscopic sleeve gastrectomy|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
1556379|NCT02553213|Other|Laparoscopic Roux-en-Y gastric bypass|The surgical procedure and aftercare is indicated and performed according to the routine clinical setting of the Hospital. Patients stay 5 days stationary after surgical treatment. They receive a defined easy digestible diet, starting with liquid and mash food.
1556380|NCT02553213|Other|Caloric restriction diet|Patients of the control group do not undergo surgical treatment. They undergo a caloric restriction diet for 5 days. This diet is adapted to the postoperative diet of the patients included in the two other groups.
1556381|NCT02553213|Other|easy digestible diet|
1556382|NCT02553200|Device|BreatheMAX (OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
1556383|NCT02553200|Device|BreatheMAX (OIS and OPEP)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
1556384|NCT02553200|Device|BreatheMAX (unload and non-oscillated)|for 10 breathes/set, 10 sets/day and rest 1 minute between set
1556385|NCT02553187|Drug|Kanglaite Injection|"200 mL, slow IV drip, once daily for 14 consecutive days, subsequent courses repeated after a 7-day interval.
Subjects will be treated for 4 courses (12 weeks)."
1556386|NCT02553161|Drug|Escitalopram|Youth in the MED condition will be given the USFDA approved antidepressant, escitalopram for the treatment of depression or anxiety in youth and follow a standard dose titration schedule of 5 mg/day for 1 week, 10mg/day for 1 week, then with a target dose of 20-30 mg/day by 4 weeks. Titration will be no faster than 5mg/week. This titration guideline was drawn from the escitalopram package insert for pediatric dosing, which states that target doses may be achieved by 4 weeks.
1556387|NCT02553161|Behavioral|Cognitive behavioral Psychotherapy|All participants (No MED and MED) will be assigned a study-trained therapist who will provide hour-long weekly individual cognitive behavioral psychotherapy (CBT) based on current evidence-based practices for the treatment of anxiety and depressive symptoms for youth.
1556388|NCT02553148|Other|Need for children's palliative care|Need for children's palliative care
1556389|NCT02553135|Biological|Injection of AAV2-REP1 (10e11 vg)|Single Group: single arm study
1556390|NCT02553122|Drug|Evicel|Fibrant Sealant to apply on the soft tissue to control intra-operative blood loss
1556391|NCT02553096|Device|ACCESS|The ACCESS system consists of a smartphone, a pulse-oximeter, a spirometer and a forehead thermometer. Questions concerning changes in symptoms, physical limitations and emotions are answered by touch screen on the smartphone, complemented by measurements of the pulse-oximeter, spirometer and thermometer. Based on this information, the system calculates the current risk of an exacerbation and, when applicable, the participant will receive personalized instructions about which actions to take in order to manage the exacerbation. Participants are instructed to use ACCESS in case of symptom worsening.
1556394|NCT02553083|Drug|doxycycline 200 mg|doxycycline 200 mg twice daily for 14 days
1556395|NCT02553083|Drug|Nexium 20 mg|Nexium 20 mg twice a day for 10 days
1556396|NCT02553083|Drug|clarythromicin 500 mg|clarythromicin 500 mg twice a day for 10 days
1556397|NCT02553083|Drug|amoxicillin 1gr|amoxicillin 1gr twice a day for 10 days
1556398|NCT02553070|Other|Survey|Pharmacy students will be asked to participate in a short (5-7 minutes) survey (see below) that contains 21-short cases involving an exposure to a pharmaceutical or non-pharmaceutical agent. All cases involve children less than 19 years of age. Participants will be asked to indicate their year in pharmacy school (1st or 2nd) and their gender (female/male).
1556399|NCT02553057|Device|mechanical ventilation|
1556400|NCT02553044|Dietary Supplement|Cholecalciferol (Vitamin D3)|Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
1556401|NCT02553031|Device|The imaging biomarkers determined by MR-PET|This study will explore the potential value in proper therapeutic decision and clinical outcome prediction by using integrated MR-PET system and advanced MR techniques in patients with colorectal cancer.
1556402|NCT02553018|Drug|Methotrexate|
1556403|NCT02553005|Procedure|Acupuncture|
1556404|NCT02552992|Behavioral|Yoga|
1556405|NCT02552992|Behavioral|Self-Directed Mind-Body Program|
1556406|NCT02552979|Other|atopic patch test|
1556407|NCT02552966|Device|UESAD|Device designed to provide modest cricoid pressure to reduce reflux
1556408|NCT02552953|Drug|CYC065|
1556409|NCT02552940|Drug|Tocilizumab|Participants with RA receive TCZ SC, as per routine clinical practice and are followed for approximately 6 months.
1556410|NCT02552927|Device|Chest shield with aluminum foil (CALF)|
1556411|NCT02552927|Device|SHIELD|
1556412|NCT02552914|Device|Colli-Pee|Participants will be asked to use the colli-pee to collect first-void urine and to send it back to the Institute of Tropical Medicine by regular mail.
1556413|NCT02552901|Drug|0.1 mg/kg ICG Dose|least efficacious dose
1556414|NCT02552901|Drug|0.5 mg/kg ICG dose|per package insert
1556415|NCT02552888|Drug|Immediate release sodium nitrite|Immediate release sodium nitrite 40 mg by mouth twice per day
1556416|NCT02552888|Dietary Supplement|Isoquercetin|Isoquercetin 225 mg by mouth once per day
1556417|NCT02552888|Other|placebos|placebos
1556418|NCT02552875|Other|Tetanic stimulation|50 Hz tetanic stimulation before TOF-twitch stabilization with the aim to eliminate the staircase phenomenon
1556419|NCT02552875|Other|Staircase Stimulation|TOF-twitch stabilization without 50 Hz tetanic stimulation with the aim to verify the staircase phenomenon
1556420|NCT02552862|Drug|Vivomixx®|Vivomixx® is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus DSM 24731, bifidobacteria (B. breve DSM 24732, B. longum DSM 24736, B. infantis DSM 24737) and lactobacilli (L. paracasei DSM 24733, L. acidophilus DSM 24735, L. delbrueckii subsp bulgaricus DSM 24734, L. plantarum DSM 24730). The active agent will be supplied as a 4.4g sachet at a dose of 450 billion live bacteria per sachet with maltose and silicon dioxide as excipients.
1556421|NCT02552862|Drug|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
1556422|NCT02552849|Other|No intervention|
1556423|NCT02552836|Behavioral|Interpersonal Psychotherapy|A 12-week intervention that focuses on resolving interpersonal stressors that are linked to the onset, maintenance or exacerbation of depressive symptoms
1556424|NCT02552836|Behavioral|Supportive Psychotherapy|A 12-week intervention that focuses on non-specific factors that contribute to therapy outcome
1556425|NCT02552823|Other|Group1|
1556426|NCT02552823|Other|Group2|
1556427|NCT02552810|Device|Steam clean|Control group: dental implant abutments underwent cleaning by steam (VAP 1, Zhermark, Cologne, Germany), performed for 5 seconds at 4 megapascal (MPa).
1556428|NCT02552810|Device|Plasma of Argon|Test group: dental implant underwent argon plasma treatment in a plasma reactor (Diener Electronic, Jettingen, Germany). The treatment conditions were 75 W of power and 1 bar of pressure for 12 minutes.
1556429|NCT02552797|Behavioral|Shared Decision Making tool|
1556430|NCT02552784|Behavioral|data assessment of the state of health and quality of life of patients and their families|Study medical determinants, socioeconomic, behavioral, environmental of health, school and professional integration, and short- and medium-term quality of life of all patients residing in France for which the diagnosis of hereditary diseases metabolism with specific diet (MHMRS) was performed during their childhood.
1556431|NCT02552771|Procedure|Mitral repair with leaflet preservation|Placing man-made fibers (sutures) to more securely connect the mitral leaflets to the papillary muscles (muscles located in the ventricle).
1556432|NCT02552771|Procedure|Mitral repair with leaflet resection|Removing one or both of the mitral leaflets that flop or bulge back.
1556433|NCT02552758|Biological|omega-3 fatty acid|omega-3 fatty acid
1556434|NCT02552758|Biological|placebo|placebo
1556435|NCT02552758|Device|positron emission tomography (PET)|
1556436|NCT02552745|Drug|parecoxib sodium|parecoxib sodium was administered postoperatively, when transcatheter arterial embolization finished.
1556437|NCT02552732|Device|NHF with Oxygen using myAIRVO™ 2|NHF will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C.
1556438|NCT02552732|Device|NHF without Oxygen using myAIRVO™ 2|NHF will be set at 25L/min at 37°C. However, all participants are able to lower the delivered temperature to 34°C. Participants can also increase/decrease the flow rate (up to 30L/min or down to 20L/min).
1556439|NCT02552706|Dietary Supplement|probiotics|Administration of mixture probiotics 500mg by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
1556440|NCT02552706|Dietary Supplement|glucose solution|Administration of 1 mL of a 5% glucose solution by mouth, one time or divided into 2-4 times depends on the feeding volume until to 36 weeks post menstrual age.
1556486|NCT02552342|Drug|methylprednisolone|
1556487|NCT02552342|Drug|Normal saline|
1556542|NCT02551913|Behavioral|Control|the adolescents will not receive any specific intervention
1556658|NCT02551159|Drug|5-fluorouracil (5FU)|Chemotherapy Agent
1556441|NCT02552693|Other|Enhanced training, supervision and support|"The intervention includes the following activities:
Conduct of pre-intervention facility audits; Cross-verification of appointment diaries with facility attendance records; Development and implementation of job aids and tools; Provides supplemental training and technical support to focal facility point (FFP) and other staff, and community health workers (CHWs); Improves coordination, supervision and reporting systems at the health facilities."
1556442|NCT02552680|Other|Exercise|Physical Exercise
1556443|NCT02552680|Other|Guideline|Guideline on care and prevention of Work-Related Musculoskeletal Disorders in activities of daily living, especially those relating work activities.
1556444|NCT02552680|Other|Brochure|Manual/brochure containing information about general health
1556445|NCT02552667|Drug|HCP1102+HGP0711Placebo|Coadministration of HCP1102 with HGP0711 Placebo for 4-week
1556446|NCT02552667|Drug|HCP1102Placebo+HGP0711|Coadministration of HCP1102 Placebo with HGP0711 for 4-week
1556447|NCT02552654|Behavioral|Stress Film|Film scene with severe physical and sexual violence.
1556448|NCT02552654|Drug|Hydrocortisone|10mg
1556449|NCT02552654|Drug|Placebo|
1556450|NCT02552641|Other|Food effect|
1556451|NCT02552641|Drug|Esomeprazole|
1556452|NCT02552641|Drug|Amoxicillin|
1556453|NCT02552641|Drug|Clarythromycin|
1556454|NCT02552628|Device|"Medtronic, Activa® PC on"|
1556455|NCT02552628|Device|"Medtronic, Activa® PC off"|
1556462|NCT02552589|Other|Amine fluoride|toothpaste
1556463|NCT02552589|Other|Placebo|toothpaste
1556464|NCT02552576|Biological|Voncento|Human coagulation VWF / coagulation factor VIII (FVIII) complex concentrate
1556465|NCT02552563|Behavioral|Dementia Care Management|The intervention involves two main components. The first component includes individualized dementia care management that involves regular and extended contact between the CG, care manager, and when appropriate, Veteran's primary care provider (PCP). The care manager monitors Veterans' symptoms via CG report, provides psychoeducation and support to CGs, influences adherence to guidelines by providing timely and tailored information to PCPs, and suggests appropriate care strategies and service referrals. The second major component is the Telehealth Education Program (TEP). For this pilot study, the program was modified for use with individual CGs and was formatted so that CGs could select from a menu of up to 7 modules covering various content areas evaluated during the course of the care management assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, long-term planning, etc.).
1556466|NCT02552550|Procedure|Ability to swallow, speak and quality of life|This study will not change the patient's treatment. This will just be an evaluation, before any treatment, his ability to swallow, speak, then his quality of life, as in normal practice, after 3, 6 and 12 months after treatment.
1556467|NCT02552537|Drug|Omeprazole|patients with walnut allergy will be exposed during 5 days before food challenge with Omeprazole
1556468|NCT02552537|Drug|Placebo|patients with walnut allergy will be exposed during 5 days before food challenge with Placebo
1556469|NCT02552524|Device|rTMS active then rTMS placebo|A 20 minute session of rTMS active at the frequency of 10 Hz then, 7 days later, a 20 minute session of rTMS placebo
1556470|NCT02552524|Device|rTMS placebo then rTMS active|A 20 minute session of rTMS placebo then, 7 days later, a 20 minute session of rTMS at the frequency of 10 Hz
1556471|NCT02552498|Procedure|strangulation|The strangulation is applied on the attached gingiva with an angulated manual instrument. The force of the occlusion is standardized by a calibrated spring connecting the head with the handle of the tool. The head is overlaid onto the gingiva covering 10mm long and 1mm width surface. The amount of the applied pressure is 100 gram.
1556472|NCT02552485|Other|No intervention was applied, because it is an observational study|
1556473|NCT02552459|Drug|Sufentanil|sufentanil 150μg， intravenous administration during post-operative 72 hours.
1556474|NCT02552459|Drug|dexmedetomidine 1|dexmedetomidine 0.05μg/kg/h, Continuous intravenous injection for 72 hours after operation
1556475|NCT02552459|Drug|dexmedetomidine 2|dexmedetomidine 0.1μg/kg/h, Continuous intravenous injection for 72 hours after operation
1556476|NCT02552459|Drug|dexmedetomidine 3|dexmedetomidine 0.15μg/kg/h, Continuous intravenous injection for 72 hours after operation recorded in the following 72h.
1556477|NCT02552433|Dietary Supplement|protein intake assessment and optimisation|
1556479|NCT02552394|Drug|huJ591|HuJ591 will be administered as an intravenous infusion at a concentration of 5 mg/mL and rate of <5 mg/minute. Pre-medications prior to J591 infusion with diphenhydramine 25 - 50 mg p.o. or IV and acetaminophen 500 - 650 mg p.o.
1556480|NCT02552381|Other|Fibrin Structure|Modifications of Fibrin Structure in patients who have developed VTE in comparison with patients without VTE.
1556481|NCT02552368|Device|IpsiHand Device|Once a participant has completed (3) EEG Signal Screens and (2) separate set of baseline measurements, the IpsiHand BCI Device is provided to participants to use a minimum of (5) out of (7) days a week for a total duration of 12 weeks. Participants are seen bi-weekly throughout the duration of the trial to assess affected upper extremity and assess functional impact. At the completion of 12 weeks of device use, the participants complete a set of measurements to assess function of the affected upper extremity.
1556482|NCT02552355|Drug|Metformin|Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
1556483|NCT02552355|Drug|Placebo|Daily administration of matching placebo during a 12 week exercise training program.
1556484|NCT02552355|Dietary Supplement|Carbohydrate beverage|Post-exercise consumption of a isocaloric carbohydrate beverage 3 days/week
1556485|NCT02552355|Dietary Supplement|Protein beverage|Post-exercise consumption of a protein beverage 3 days/week
1556488|NCT02552329|Other|Tai Chi exercise|The Tai Chi exercise group will exercise for 50 minutes/session, 3 times /week for 24 consecutive weeks (6 months). Each 50-minute session will include a 10-minute warm up, 30-min exercise, and 10-min cool down, The 10 forms Tai Chi will be used.
1556489|NCT02552316|Device|NB-UVB Phototherapy|
1556490|NCT02552303|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia.
1556491|NCT02552303|Drug|Armodafinil|Active medication
1556492|NCT02552303|Drug|Placebo|Placebo for Nuvigil (armodafinil)
1556493|NCT02552290|Other|Upper Trapezius Stretch|Sustained stretch of upper trapezius muscle
1556494|NCT02552290|Other|Cervicothoracic manipulation|Manipulation to the cervicothoracic spine
1556495|NCT02552290|Other|No intervention|Wait
1556496|NCT02552277|Biological|PDA-002|PDA-002 cells administered intramuscular (IM) on study Days 1, 29, and 57.
1556497|NCT02552277|Drug|Placebo|Subjects will receive placebo administered on study days 1, 29, and 57.
1556498|NCT02552264|Behavioral|Acceptance and Commitment Therapy for the Workplace|Acceptance and Commitment Therapy
1556499|NCT02552251|Biological|Hormonal balance measurements|
1556500|NCT02552251|Biological|metabolic balance measurements|
1556501|NCT02552251|Biological|bone balance measurements|
1556502|NCT02552251|Behavioral|quality of life assessment|
1556503|NCT02552238|Drug|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent will be administered as 2 single 2-mL IV injections during rest and stress echocardiography
1556508|NCT02552199|Other|gravimetric|
1556509|NCT02552186|Other|Caliper measurement|Clinical caliper measurements will be taken and used to calculate the Clinical PI
1556510|NCT02552173|Radiation|The Relationship Between Operative and Radiologic Stem Version|intraopertive surgeon's estimation and postoperative CT scan
1556511|NCT02552147|Drug|Transdermal nicotine|
1556512|NCT02552147|Other|Transdermal placebo|
1556513|NCT02552134|Other|exercise training|
1556514|NCT02552134|Other|recommendation to be active|
1556515|NCT02552121|Drug|Tisotumab vedotin (HuMax-TF-ADC)|
1556517|NCT02552095|Device|Triathlon PKR|
1556518|NCT02552082|Device|Scorpio NRG posterior stabilized (PS)|
1556519|NCT02552069|Device|Tritanium® cup|
1556520|NCT02552056|Other|CAMH training|Training of PHC workers included in the study for 5 days to screen children and adolescents for CAMH conditions, based in the mhGAP curriculum for non-specialist health providers.
1556521|NCT02552043|Other|Nintendo Wii exercise program|The aerobic training protocol was designed to improve muscular strength, body endurance and flexibility (involved activities as: running, up the knees, butt kickers, etc.). The game used has a strap pouch to hold the Nunchuk© controller placed on the thigh that detects the lower body movements, and also features a number of exercise options supervised by a virtual personal trainer
1556522|NCT02552030|Device|cuff device (Omron HBP-1300-E Pro)|Comparison of systolic blood pressure results measured with an oscillometric cuff device (Omron HBP-1300-E Pro) and iPhone 4s
1556523|NCT02552030|Device|iPhone 4s|
1556524|NCT02552017|Device|Endocuff Vision|Endocuff Vision is a new device made of soft plastic material with a unique dynamic shape. It is manufactured by ARC Medical Design Limited and Diagmed in the United Kingdom. It has European Conformity in United Kingdom. The core is made of polypropylene and the 'finger like' projections are made of a thermoplastic elastomer. It comes in four colour coded sizes (purple, blue, green and orange) to fit a range of paediatric and adult colonoscopes. Endocuff Vision is the more updated version of device that has only one proximal row of more rounded finger-like projections. It is mounted at the tip of the colonoscope and held on by friction (pull-off force is a minimum of 10 Newtons).
1556525|NCT02552004|Device|pCLE|Histological examination by pCLE technique preceding the frozen section
1556526|NCT02552004|Drug|IV fluorescein administration|IV Fluorescein (fluorescent contrast agent) administration
1556527|NCT02551991|Drug|nal-IRI|
1556528|NCT02551991|Drug|5 fluorouracil|
1556529|NCT02551991|Drug|Leucovorin|
1556530|NCT02551991|Drug|Oxaliplatin|
1556531|NCT02551991|Drug|nab-paclitaxel|
1556532|NCT02551991|Drug|Gemcitabine|
1556533|NCT02551978|Other|The serious game KOP|The serious game transfers knowledge about nutrition (food pyramid, energy density of foods, which foods contribute to satiety and which not, energy in liquids, self-reflexive diagnostic tool to analyze daily food intake), physical activity (a motion-control to navigate through the game is partly used, relationship between energy expenditure and energy intake) and psychological aspects (relaxation-exercises, what is stress, stress-coping strategies).
1556534|NCT02551965|Other|Phone nursing follow-up|From the day of geriatric cancer patient's consultation, nurses will identify caregiver and will follow them by phone (caregiver) during 6 months
1556535|NCT02551952|Device|MentalPlus®|Validate the MentalPlus® digital game as neuropsychological test of cognitive assessment pre and postoperative on study the internal consistency and validity of content and construct (convergent) MentalPlus® of the evaluated patients. Study the influence of age, gender and level of education of surgical patients in performance for the use of electronic devices (laptop, tablet, mobile) and digital games. Investigate the rehabilitation capacity of cognitive functions after training sessions with MentalPlus® game. Evaluate the effect of training with MentalPlus® game in brain networks involved in executive function, memory and attention by means of fMRI this is a brain imaging study.
1556536|NCT02551939|Procedure|Autologous Fat Grafting|Autologous Fat Grafting
1556537|NCT02551926|Behavioral|mobile text messages|
1556538|NCT02551926|Behavioral|virtual community|
1556543|NCT02551913|Behavioral|Intervention|A theory based sleep hygiene intervention based on the theory planned behavior will be conduced on the adolescent
1556544|NCT02551900|Other|Warm water exercise|Warm water based cycling exercise training program will be based on cycling in warm water (temperature 34◦C ). Warm water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
1556545|NCT02551900|Other|Cold water exercise|Cold water based cycling exercise training will be based on cycling in cold water (temperature 20◦C ). Cold water exercise will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
1556546|NCT02551900|Other|Land based cycling exercise|Land based cycling exercise training will be based on ride a bicycle ergometer (Monark 894e, Sweden). Land based cycling exercise training will be conducted at moderate intensity (60-70% maximum heart rate). The three groups were exercise 15 minutes on the first month, second month will be increased to 20 minutes and the last month will be increased to 30 minutes. The training program will be performed 3 times per week for 12 weeks.
1556547|NCT02551887|Behavioral|Automated Reminder|Automated reminder shown to provider
1556548|NCT02551887|Behavioral|Automated Reminder Plus Script|Provider sees both reminder and script.
1556549|NCT02551874|Drug|Saxagliptin, Onglyza|Tablets, Oral, 5mg , Once daily, 24 weeks
1556550|NCT02551874|Drug|Dapagliflozin, Farxiga|Tablets, Oral, 10mg , Once daily, 24 weeks
1556551|NCT02551874|Drug|Glargine insulin|100 Units/ml solution for injection in a prefilled SoloStar pen
1556552|NCT02551874|Drug|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
1556553|NCT02551861|Drug|Daclatasvir|
1556554|NCT02551861|Drug|Sofosbuvir|
1556555|NCT02551861|Drug|Ribavirin|
1556556|NCT02551848|Drug|Botulinum toxin type A (Xeomin®)|
1556558|NCT02551809|Biological|UB-311|
1556559|NCT02551809|Drug|Placebo|
1556560|NCT02551796|Procedure|lenticule extraction|Four femtosecond incisions will be created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction is released, the flap will be opened using a thin, blunt spatula and the free refractive lenticule will be subsequently grasped with a forceps and extracted, after which the flap will be repositioned carefully.
1556561|NCT02551796|Procedure|laser in situ keratomileusis|During LASIK surgery, the eye will be gently proptosed and a hinged corneal flap will be cut using a microkeratome. The flap will be lifted and the stromal bed will receive a 6 mm diameter and stroma ablation. Finally reposition the flap carefully.
1556562|NCT02551796|Procedure|FS assisted laser in situ keratomileusis|Track distance and spot distance will be 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter will be 8.0 mm, and flap thickness will be set to 105 μm. Side-cut angle and hinge angle will be 90°and 50° respectively. The flaps will be created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system will be used in the subsequent ablation of thstromal bed with a 6.0 mm optical zone. Once the excimer. ablation is completed, the flap will be repositioned in a similar fashion as in routine LASIK.
1556563|NCT02551783|Procedure|Urethroplasty with buccal mucosa graft|A surgery to correct urethral stricture
1556564|NCT02551783|Procedure|Ventral Buccal|Urethroplasty with buccal graft. In this arm the graft is placed on the ventral wall of the urethra.
1556565|NCT02551770|Device|Scaling and root planing with Emdogain|Using minimally invasive surgical procedure (scaling and root planing) with Emdogain application to treat one contra-lateral quadrant in subject's jaw.
1556566|NCT02551770|Device|Scaling and root planing without Emdogain|Using minimally invasive surgical procedure (scaling and root planing) without Emdogain application to treat one contra-lateral quadrant in subject's jaw.
1556567|NCT02551757|Device|Auto-titrating CPAP|Auto-titrating CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with active-CPAP included patient education, desensitization of CPAP through brief periods of daytime use, adjustments of humidity and mask (including addition of a chin strap), decreasing CPAP maximum pressure and use of expiratory pressure relief (CFlex) for patients treated with active-CPAP.
1556568|NCT02551757|Device|Sham-CPAP|Sham-CPAP was initiated after admission to the inpatient rehabilitation unit for the duration of rehabilitation but not exceeding 28 days. A respiratory therapist visited patients nightly to document adherence and address issues arising at night. A sleep technologist also met with patients at least twice weekly to monitor safety and adverse events and make any adjustments to the CPAP mask or machine. Efforts to improve adherence to CPAP for patients treated with sham-CPAP included patient education, desensitization of CPAP through brief periods of daytime use and adjustments of humidity and mask, including addition of a chin strap.
1556569|NCT02551744|Drug|proton pump inhibitor (PPI) group pantoprazole|pantoprazole 40 mg qd for 6 months.
1556570|NCT02551744|Drug|histamine-2 receptor antagonist group famotidine|famotidine 40 mg qd for 6 months.
1556571|NCT02551731|Drug|Cannabidiol Oral Solution|20-40 mg/kg/day BID
1556607|NCT02551510|Procedure|Suture|Skin incision closure with standard subcuticular technique
1556577|NCT02551705|Other|functional Imaging|Brain responses associated with emotional memory will be investigated
1556578|NCT02551692|Drug|Nicotine Patch|Participants will wear 21mg/day patches for days 1-14. After day 14, participants will make a quit attempt continue to wear the 21mg/d patches for 6 weeks, then step down to 14mg/d patches for 2 weeks and finally step down 7mg/d for the last 2 weeks of treatment. Participants will also take a placebo capsule. During days 8-14, participants will undergo 2 cue-exposure sessions.
1556579|NCT02551692|Drug|Varenicline|Varenicline (VAR) will be administered by titrating to steady state levels over a 7 day induction period (.5 mg once daily in Days 1-3; .5 mg twice daily on Days 4-7 and 1 mg twice daily on Days 8-14). Participants will continue on 1mg twice daily until the end of treatment (days 15-84). Participants will also wear a placebo patch. During days 8-14, participants will undergo 2 cue-exposure sessions.
1556580|NCT02551692|Drug|Placebo Nicotine Patch|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.
In the VAR group, participants will wear a placebo patch while taking varenicline."
1556581|NCT02551692|Drug|Placebo Capsule|"In the PLAC group, participants will receive placebo patches and placebo capsules for 14 days prior to quitting smoking. They will then switch to wearing a nicotine patch the morning of their quit day in order to provide them with the minimum standard of care. During days 8-14, participants will undergo 2 cue-exposure sessions.
In the NRT group, participants will take a placebo capsule while wearing nicotine patches."
1556582|NCT02551679|Biological|Angiogenic Cell Precursors|injection of Angiogenic Cell Precursors
1556583|NCT02551679|Other|cell culture medium|injection of cell culture medium
1556584|NCT02551666|Other|Balance recovery training|Participants will practice recovering their balance after a perturbation similar to tripping while walking. Each of these 'balance recovery training' sessions will last approximately 30 minutes, and will be performed 3 times per week for 4 weeks.
1556585|NCT02551666|Other|Tai Chi exercise|Participants will perform Tai Chi exercises (Yang short form) for 30 minutes, 3 times a week for 4 weeks. Each session will be led by an experienced Tai Chi instructor.
1556586|NCT02551653|Drug|[11C]-GSK2256098 500 MBq|[11C]-GSK2256098 injection will be provided as IV infusion, 20 mL, containing up to 5% ethanol in saline.
1556587|NCT02551640|Other|FeatForward App (on study smartphone)|"The FeatForward mobile app will have the following features:
Messaging: Educational messages tailored to user's medical conditions and motivational messages tailored to user's stage of change.
Tracking: Ability to track physical activity, weight, blood pressure, blood glucose and heart rate.
Community: Users in later stages of change able to encourage and motivate one another through groups.
Educational Library: To provide educational tips and health information. Provider Engagement: Ability for physicians to view patient data, and send messages to patients.
Monthly depression assessments: The app will prompt users to complete a monthly voluntary depression assessment.
Social Support: Those using the FeatForward app will also have access to a Facebook group."
1556588|NCT02551627|Dietary Supplement|Test Product|MMN fortified beverage powder.
1556589|NCT02551627|Dietary Supplement|Control|Isocaloric beverage powder without micronutrient fortification.
1556590|NCT02551614|Procedure|Lipopolysaccharide challenge|Lipopolysaccharide solution inhaled using a dosimeter.
1556591|NCT02551614|Procedure|Saline challenge|0.9% sodium chloride solution inhaled using dosimeter.
1556592|NCT02551614|Procedure|Labelled neutrophils and Imaging assessment|Injection of labelled neutrophils and imaging assessments
1556593|NCT02551601|Other|measure subfoveal choroidal thickness|measure subfoveal choroidal thickness using optical coherence tomography
1556594|NCT02551588|Procedure|Valvular aortic stenosis surgery|Dilatation of Valvular aortic stenosis
1556595|NCT02551575|Drug|Treatment of MTX and HCQ|"Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.
Hydroxychloroquine: 200mg, 2 times a day, oral, for 24 weeks. Qingre Huoxue granule placebo: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation placebo: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks."
1556596|NCT02551575|Drug|Treatment of TCM|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.
Methotrexate placebo: 10-15mg per week according to patient's weight, oral, for 24 weeks.
Hydroxychloroquine placebo: 200mg, 3 times a day, oral, for 24 weeks."
1556597|NCT02551575|Drug|Integrative Medicine|"Qingre Huoxue granule: 10g, 2 times a day, oral, for 24 weeks. Qingre Huoxue external preparation: 20g, 1 times a day, external, for 4 weeks, then 10g, 1 times a day, external, for 8 weeks.
Methotrexate: 10-15mg per week according to patient's weight, oral, for 24 weeks.
Hydroxychloroquine: 200mg, 3 times a day, oral, for 24 weeks."
1556598|NCT02551562|Other|NuDerm® System|The Nu-Derm® System (Valeant Pharmaceuticals North America, LLP) is a skin care system that helps correct and reduce visible signs of aging such as age spots, rough skin, erythema, sallowness, and hyperpigmentation.
1556599|NCT02551562|Other|Placebo|Basic skin care regimen
1556600|NCT02551549|Drug|CD101 IV|antifungal
1556601|NCT02551549|Drug|Placebo|Normal saline
1556602|NCT02551536|Drug|Montelukast|
1556603|NCT02551536|Drug|Fexofenadine|group B received FDC tablet of montelukast 10mg and fexofenadine 120 mg O.D
1556604|NCT02551536|Drug|Levocetrizine|group A recieved FDC tablet of montelukast 10 mg and levocetrizine 5mg O.D
1556608|NCT02551510|Device|Experimental: Histoacryl®|Skin incision closure with topic skin adhesive Histoacryl® Flexible (n‐Butyl‐2‐Cyanoacrylate Monomer)
1556610|NCT02551484|Device|Measurements using NIRS|
1556611|NCT02551484|Device|TCPO2 measurements|
1556612|NCT02551484|Other|2-minute walk test|
1556613|NCT02551471|Other|Blinded inter-country reading of pelvic MRI (Magnetic Resonance Imaging)|"This experiment will consist of an inter-country reading of patients' pelvic MRIs, blind to the other country's decision. The MRI shared will be the one based on which the treatment decision will be made. In case of medical contraindication to perform pelvic MRI, the scan will be used to assess the care-decision concordance between both countries."
1556614|NCT02551471|Other|MDT (Multidisciplinary team) meeting observation|"3 per centre with real patient cases and theoretical patient cases (blinded pelvic MRI re-reading)."
1556615|NCT02551471|Other|Semi-structured exploratory interviews and focus group with MDT health professional attendees|Will identify care management systems for PRC-bTME and LRRC patients, explore social representations that direct the formulation of a therapeutic decisions and identify cultural, medical and personal factors
1556616|NCT02551458|Other|Systematic surgery|
1556617|NCT02551458|Other|Surveillance and rescue surgery in cases of resectable loco-regional recurrence|
1556618|NCT02551445|Behavioral|Gradual exposure to food stimuli|Patients with anorexia nervosa will be encouraged to confront their fears and avoidance in relation to food and will be gradually exposed to different food items during the sessions.
1556619|NCT02551432|Drug|pembrolizumab, paclitaxel|pembrolizumab, paclitaxel
1556620|NCT02551419|Dietary Supplement|ketogenic drink|6 months' supplementation with the ketogenic drink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the evening meal.
1556621|NCT02551419|Dietary Supplement|placebo|6 months' supplementation with the palcebodrink . Product will be taken daily - 125 ml will be consumed at the morning meal, and 125 ml at the
1556622|NCT02551406|Device|Capno-oxymetry monitoring|Monitoring of home mechanical ventilation by capno-oximetry
1556623|NCT02551393|Behavioral|Home Blood Presssure Monitoring, Education|Doctors and Nurses in intervention clinic will receive 1 hour briefing + education on the background, scientific basis and detail of the program during lunch time. People from intervention clinics will be invited to attend 2 x 2 hours education group (15-30 subjects / group) ran by clinic nurses and doctors. You will be educated on basic knowledge, management and drug for hypertension in the first session. In the 2nd session, a certified valid Home BP device will be loaned to you for 6-9 months and you will be taught to perform home BP monitoring, record and response to the BP reading accordingly. Upon completion of session 2, you will be arranged for nurse individual follow up after 4-8 weeks to see their progress and monitoring
1556624|NCT02551380|Drug|FOLINORAL|Folinoral (folinic acid) 5mg twice a day (10 mg per day) during 12 weeks
1556625|NCT02551380|Other|Placebo|Placebo 5mg twice a day (10 mg per day) during 12 weeks
1556626|NCT02551367|Drug|Letrozole|2.5 mg will taken from day 2 to day 6 of the cycle , for 3 consecutive cycles
1556627|NCT02551367|Drug|Clomiphene citrate|50 mg twice daily orally from day 2 to day 6 , for 3 consecutive cycles
1556628|NCT02551367|Drug|hcg hormone|10.000 iu im injection when follicle diameter reach 18 mm by transvaginal ultrasound
1556629|NCT02551354|Device|Portable video pupillometer|Portable video pupillometer measures pupil diameter (PD) in patient during obstetrical labor
1556630|NCT02551341|Procedure|higher PEEP ventilation|
1556631|NCT02551328|Drug|sevofluorane|Continuous infusion of sevofluorane
1556632|NCT02551302|Device|Solera™ Medtronic|The control group will receive a monosegmental posterior lumbar spine fusion with an intervertebral cage (PLIF). Solera™ Medtronic
1556633|NCT02551302|Device|CD HORIZON BalanC™ Medtronic|"The intervention group will receive a hybrid system with a PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed with the following devices:
CD HORIZON BalanC™ Medtronic"
1556635|NCT02551276|Drug|Salbutamol|
1556636|NCT02551276|Drug|Placebo|
1556637|NCT02551276|Other|Resistance training|
1556638|NCT02551263|Drug|Eribulin|Eribulin 1.4 mg/m2 will be administered intravenously over 2 to 5 minutes on day 1 and 8 of every 21-day cycle, in a real-world setting.
1556639|NCT02551250|Device|annual noncontrast MRI|liver MRI without contrast agents T2 weighted image, T1 in/out of phase, diffusion weighted images with b-values of 0, 500 mm2/s
1556640|NCT02551250|Device|biannual ultrasonography|liver ultrasonography for HCC screening performed by experienced sonologists
1556641|NCT02551237|Radiation|50 Gy|radiotherapy 50 Gy in 25 fractions of 2 Gy, five times per week, over a period of 5 weeks
1556642|NCT02551237|Drug|Capecitabine|oral capecitabine 800 mg/m2 twice daily from the first day of radiotherapy and given 5 days per week during radiotherapy.
1556643|NCT02551237|Radiation|25 Gy|radiotherapy 25 Gy in 5 fractions of 5 Gy delivered in one week (short-course arm)
1556645|NCT02551211|Procedure|blood drawn|blood drawn
1556646|NCT02551211|Procedure|surgical resection of cancer|
1556647|NCT02551198|Drug|HAPREP®|"Arm1: HAPREP® (2L polyethylene glycol with ascorbic acid; PEG-Asc)
: : PEG-Asc(500mLx2 times q30min)[PM 7-9, the day before colonoscopy] + PEG-Asc(500mLx2 times q30min)[AM 5-7, the day of colonoscopy]"
1556648|NCT02551198|Drug|SUCLEAR®|Arm2: SUCLEAR® (oral sulfate solution; OSS): OSS(1b/177mL)[PM 7-9, the day before colonoscopy] + OSS(1b/177mL)[AM 5-7, the day of colonoscopy]
1556649|NCT02551185|Drug|ACY-241|
1556650|NCT02551172|Drug|HCP1105|Rosuvastatin + Omega-3-acids ethyl esters
1556651|NCT02551172|Drug|HGP0816|Rosuvastatin
1556652|NCT02551172|Drug|Placebo of HCP1105|Soybean Oil
1556653|NCT02551172|Drug|Placebo of HGP0816|Exclusion of Rosuvastatin in HGP0816
1556654|NCT02551159|Biological|MEDI4736|Anti-PD-L1 antibody
1556655|NCT02551159|Biological|Tremelimumab|Anti-CTLA-4 Antibody
1556656|NCT02551159|Biological|MEDI4736+Tremelimumab|
1556657|NCT02551159|Biological|Cetuximab|Monoclonal Antibody
1556659|NCT02551159|Drug|Cisplatin|Chemotherapy agent
1556660|NCT02551159|Drug|Carboplatin|Chemotherapy Agent
1556661|NCT02551146|Device|A Locator with retention elements|Insertion of GC Pilier locator abutments with retention elements
1556662|NCT02551146|Device|B Locator without retention elements|Insertion of GC Pilier locator abutments without retention elements
1556663|NCT02551133|Drug|dexamethasone|1 hour before surgery
1556664|NCT02551107|Device|Measurement of nasal Nitric Oxide level|ECO MEDICS CLD 88 sp Nitric Oxide Analyzer
1556665|NCT02551094|Drug|colchicine|0.5 mg tablet taken once a day
1556666|NCT02551094|Drug|colchicine placebo|sugar pill manufactured to mimic colchicine 0.5 mg tablet
1556667|NCT02551068|Other|60% Oxygen|While participants are exercising, they will be inhaling 60% oxygen through a mask
1556668|NCT02551068|Other|Standard of Care|While participants are exercising, they will be breathing air through a mask that will be titrated to keep oxygen saturation at least 88%, allowing a maximum inhaled oxygen percentage of 40%.
1556669|NCT02551055|Drug|MLN1117|MLN1117 Tablets
1556670|NCT02551055|Drug|TAK-659|TAK-659 Tablets
1556671|NCT02551055|Drug|Alisertib|Alisertib Tablets
1556672|NCT02551055|Drug|Paclitaxel|Paclitaxel intravenous infusion
1556673|NCT02551055|Drug|Docetaxel|Docetaxel intravenous infusion
1556674|NCT02551042|Drug|Fibrogammin®P, coagulation factor XIII concentrate (Human)|IV infusion
1556675|NCT02551042|Drug|0.9% sodium chloride|IV infusion
1556676|NCT02551029|Other|Capsaicin|
1556677|NCT02551029|Other|Placebo|
1556678|NCT02551003|Drug|Autologous cord blood|Autologous cord blood will be collected after birth and administered in divided aliquots during the first 3 days of life. At the same time, babies will referred to neonatal intensive care unit for hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
1556679|NCT02551003|Device|Hypothermia|Hypothermia therapy of cooling to 33.5 ℃ body temperature for 72 hours and standard intensive care.
1556680|NCT02550990|Behavioral|Cognitive training|
1556681|NCT02550990|Behavioral|Aerobic exercise training|
1556682|NCT02550990|Behavioral|Sequential combination of aerobic exercise and cognitive training|
1556683|NCT02550977|Drug|Gestodene/EE Patch (BAY86-5016)|7 day patch containing 0.55 mg ethinyl estradiol and 2.1 gestodene in a 21 day regimen.
1556684|NCT02550964|Procedure|Composite Examination|First, patients will get the baseline ophthalmologic exam and medical evaluation by physicians. As a diagnostic method, the composite examination including fundus photography, fundus autofluorescence, spectral-domain optical coherence tomography, Humphrey visual field test and multifocal electroretinography will be tested once every year.
1556685|NCT02550951|Procedure|lymphangiography|
1556687|NCT02550925|Behavioral|Acceptance and Commitment Therapy (ACT) Group|A 7-session Acceptance and Commitment Therapy (ACT) group intervention
1556688|NCT02550925|Behavioral|Usual Care|Check in with clinical social worker at oncology care site and obtain list of supportive resources
1556689|NCT02550912|Drug|Vitamin D3|vitamin D drops for paediatrics
1556690|NCT02550912|Other|Placebo|glucose syrup with same taste and color to vitamin D3 drops
1556691|NCT02550899|Procedure|Transanal submucosal injection group 1|Transanal submucosal injection using an anoscope using four sites circumferentially above the dentate line at 12, 3, 6 and 9 o'clock using 4 ml polyacrylamide
1556692|NCT02550899|Procedure|Transanal submucosal injection group 2|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 4 ml polyacrylamide
1556693|NCT02550899|Procedure|Transanal submucosal injection group 3|Transanal submucosal injection using an anoscope using three sites circumferentially above the dentate line at 12, 4 and 8 o'clock using 6 ml polyacrylamide
1556694|NCT02550886|Other|Survey|Patients and their caregivers will be asked to complete surveys about their expected and actual time taken off from work. They will also answer questions about the patient's recovery, as well as the patient/caregiver relationship.
1556695|NCT02550873|Biological|PRM-151|PRM 151 10 mg/kg IV infusion over 60 minutes days 1, 3, and 5, then one infusion every 4 weeks
1556696|NCT02550873|Other|placebo|Placebo IV infusion over 60 minutes on days 1, 3, and 5, then one infusion every 4 weeks
1556697|NCT02550860|Drug|soybean oil (SO)-based IVFE (Medialipide)|The soybean oil (SO)-based IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
1556698|NCT02550860|Drug|fish oil (FO)-containing IVFE (Lipidem)|The fish oil (FO)-containing IVFE will be allocated for a 3-month period, allowing sufficient timeframe for epidermal complete renewal.
1556699|NCT02550847|Device|The imaging biomarkers determined by MR-PET|The aim of this study was to evaluate MR/PET with both functional and molecular imaging on the prediction of prognosis in patients with suspected pancreatic cancer.
1556700|NCT02550834|Other|Wheelchair indoors curling training|8x 90 minutes of training and playing indoors curling in 4 weeks
1556701|NCT02550821|Device|Triaxial accelerometer|Participants will use triaxial accelerometer for 7 days
1556702|NCT02550795|Drug|Dexmedetomidine|administration of dexmedetomidine only
1556703|NCT02550795|Drug|Dexmedetomidine and dexamethasone|administration of dexmedetomidine and dexamethasone
1556704|NCT02550795|Drug|Control|administration of normal saline
1556705|NCT02550782|Drug|Bupivacaine|patient- controlled infraclavicular perineural marcaine infusion
1556706|NCT02550782|Drug|Dexmedetomidine|patient- controlled infraclavicular perineural marcaine with dexmedetomidine infusion
1556774|NCT02550288|Behavioral|Diet control/Daily Exercise|Diet and Daily exercise program as per Japan Atherosclerosis Society Guideline 2012 (JAS2012)
1556707|NCT02550769|Procedure|TRANSANAL TOTAL MESORECTAL EXCISION|The technique begins with the TEO equipment and a purse string 1 cm distal to the tumor. The dissection progresses in the posterior part until the laparoscopic TME field is reached. After the section of the rectum and TME transanal dissection, the anvil of the circular mechanical stapler is introduced through the TEO rectoscope. In the laparoscopic field, the mesosigma is sectioned at the point where the colon section is to be performed. The TEO rectoscope is withdrawn, and the bag containing the specimen is removed through the anus. The stapler is inserted. From the laparoscopic field, the strings of the purse are tightened and the purse is closed around the rectal stump with a clip. Then the stapler are joined to perform the anastomosis and a loop ileostomy is placed in the right flank.
1556708|NCT02550769|Procedure|Laparoscopic-LAR|Standard laparoscopic low anterior resection of the rectum with total mesorectal excision and colorectal anastomosis
1556709|NCT02550756|Drug|CTNX-4975|
1556710|NCT02550743|Drug|BYL719|
1556711|NCT02550743|Drug|Capecitabine|
1556712|NCT02550743|Radiation|Radiation|
1556713|NCT02550730|Behavioral|Birth Sisters Best Beginnings for Babies|Birth Sisters Best Beginnings for Babies support during Pregnancy, Labor and Delivery and six weeks postpartum. Participants assigned to the Birth Sister group receive community doula services with consultation from the Medical Legal Partnership when indicated beginning at 24 weeks. Participants receive up to 8 two-hour prenatal home visits; continuous support through labor and birth, and up to 4 two-hour postpartum home visits through 6-8 weeks postpartum.
1556714|NCT02550730|Other|Usual maternity care|Usual prenatal, intrapartum and postpartum maternity care
1556715|NCT02550717|Drug|Acetylsalicylic Acid (Asprin, BAYE4465)|Low-dose ASA for secondary prevention of cardiovascular events
1556716|NCT02550717|Drug|Clopidogrel, Oral Anticoagulants, NSAIDs and SSRIs|Secondary prevention of cardiovascular events
1556717|NCT02550704|Procedure|Colonoscopy with eleven biopsies in the left colon to assess intestinal permeability|Eleven colonic biopsies are taken in the left colon during colonoscopy. Intestinal permeability is assessed by western blot, qPCR and immunofluorescence for claudin, occludin and ZO-1.
1556718|NCT02550691|Procedure|blood sampling|A blood sample will be taken on subject carrying specific genotype
1556719|NCT02550678|Biological|ASN-002|ASN‐002, is made of a suspension of recombinant adenoviral particles carrying a gene coding for the human interferon‐gamma (IFN). Study participants will receive protocol defined dose of ASN-002 as intra-tumoral injections.
1556720|NCT02550678|Drug|5-FU|5-FU is chemotherapeutic agent used to treat various cancers.
1556721|NCT02550665|Drug|donepezil|using different titration method for the first 4 weeks, and after the 4 weeks, 23mg/day orally
1556728|NCT02550613|Device|The imaging biomarkers determined by MR-PET|The purpose of this study is to explore the ability of integrated MRI/PET to detect and evaluate treatment outcome in HCC patients. This study using 18F-FDG PET and functional MRI (DCE-MRI, Diffusion-weighted MRI, MR spectroscopy).
1556729|NCT02550600|Procedure|iLA activve treatment|"iLA activve is aimed at efficient extracorporeal membrane oxygenation with an initial blood flow of ≥2L/min. The length of therapy is at the discretion of the treating physician.
Treating physicians are recommended to use a pre-specified algorithm to optimize the extracorporeal lung assist (choice of cannulas and oxygenator, titration of blood flow and sweep gas flow). Primary/mandatory goals are pO2≥65mmHg, P_peak ≤30cm H2O, TV ≤6ml/kg PBW and pH ≥7.25. Secondary suggested goals are setting the PEEP level within the limits suggested by the ARDSnet low and high PEEP strategy, 35mmHg ≤ pCO2 ≤45mmHg, Delta-pressure (= P_peak - PEEP) ≤15 cm H2O and P_peak ≤25 cm H2O.
iLA activve treatment also requires anticoagulation with un-fractionized heparin (PTT-goal 45s-60s depending on blood flow)."
1556730|NCT02550600|Procedure|Control group|"The controls will be treated according to the recent guideline of the German Sepsis Society and the German Interdisciplinary Association of Intensive Care and Emergency Medicine and good clinical practice including lung-protective ventilation with low tidal volume (LTV), moderate hypercapnia, PEEP according to ARDSnet, adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) and treatment of the underlying disease as applied in the experimental group.
There will be no sham treatment of iLA activve.in the controls. All adjunctive measures (e.g. prone positioning; neuromuscular blockers as appropriate) are also available for the intervention group."
1556731|NCT02550587|Behavioral|satisfaction|anesthesia satisfaction rates
1556732|NCT02550574|Procedure|Wound Closure with 2-octylcyanoacrylate|
1556733|NCT02550574|Procedure|Wound Closure with 5-0 Vicryl Sutures|
1556734|NCT02550561|Device|Posterior Tibial Nerve Stimulation|PTNS (under the brand name Urgent PC) is an FDA-approved device for the treatment of urinary urgency, urinary frequency and urge incontinence. It is often described as a peripheral form of neuromodulation (as opposed to SNM which is central neuromodulation at the level of the nerve root). PTNS involves 12 weeks of weekly 30 minute office-based treatment sessions with a small electrode placed slightly above the ankle in order to stimulate the S2-4 nerve roots.
1556735|NCT02550548|Drug|GIP infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GIP will be infused
1556736|NCT02550548|Drug|GLP-1 infusion|after establishing a hyperglycemic clamp (target: 125 mg/dL) GLP-1 will be infused
1556737|NCT02550548|Drug|Ex-9 infusion|Ex-9 infusion will be initiated at start of hyperglycemic clamp (target: 125 mg/dL)
1556738|NCT02550535|Genetic|Gene-modified WT1 TCR-transduced T cells intravenous infusion|
1556739|NCT02550522|Device|Brain-computer interface (BCI) platform including two implanted remotely powered ElectroCorticoGraph (ECoG) recording devices and an exoskeleton|
1556740|NCT02550509|Device|ultrasound echogenicity|ultrasound echogenicity to patient with stroke
1556741|NCT02550509|Device|elastography|elastography to patient with stoke
1556742|NCT02550496|Device|Dermoscopy|
1556743|NCT02550483|Other|Base diet + high beta-carotene tomato juice|Participants will receive high beta-carotene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
1556744|NCT02550483|Other|Base diet + high lycopene tomato juice|Participants will receive high lycopene tomato juice daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
1556745|NCT02550483|Other|Base diet + placebo beverage|Participants will receive a placebo beverage daily in addition to the base diet. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. The base diet will be low in betacarotene and lycopene (no carrots, sweet potato, tomatoes, and dark greens). During the controlled diet period, participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
1556746|NCT02550470|Device|Carbon Dioxide Absorbents|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.7,8
1556747|NCT02550470|Device|Micropore SpiraLith|lithium hydroxide was studied for use in anesthesia as a possible replacement for calcium absorbents. This agent has been used for CO2 absorption in the military and in aerospace for over 50 years due to its high capacity and efficiency in the removal of CO2. It was however not considered usable by the medical industry due to concerns with its granular form. It has now been demonstrated that LiOH does not interact with commonly used inhalation anesthetic agents and appears to have higher CO2 removal capability.
1556748|NCT02550470|Drug|Sevoflurane|
1556749|NCT02550457|Other|Functional elastic tape tensioned|Application of Kinesio Taping with tension in the erector spine muscles.
1556750|NCT02550457|Other|Functional elastic tape non-tensioned|Application of Kinesio Taping without tension in the erector spine muscles.
1556751|NCT02550457|Other|Rigid Tape|Application of Micropore tape in the erector spine muscles.
1556755|NCT02550418|Drug|Budesonide|
1556756|NCT02550405|Behavioral|Craving behavioral intervention|The CBI was given once a week for 6 weeks, conducted by four therapists. A pair of therapists was randomly assigned to a CBI+ group. Each session included 5 parts in 2.5-3 hours: warming-up exercise, discussion about the homework from the last session, main structured activity, brief summary, and the homework assignment. There were 6 sessions with each focused on a topic: recognize craving and its relationship with IGD; reduce craving through ameliorating the salience of cues and irrational beliefs, withdrawal symptoms and other negative affects; enhance self-monitoring and control for craving through time management training; relieve fulﬁllment of psychological needs through Internet use and attenuate the relation between craving and gaming behaviors through coping skill training
1556757|NCT02550392|Behavioral|Psychoeducation|A time-limited group psychoeducational intervention that will aim to offer educational, psychological and social support.
1556758|NCT02550379|Behavioral|Intervention|Emotion Recognition Training
1556759|NCT02550379|Other|Placebo|Placebo Training
1556760|NCT02550366|Drug|MRI Contrast|MRI Contrast
1556761|NCT02550353|Procedure|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully.
1556762|NCT02550353|Procedure|femtosecond laser-assisted laser in situ keratomileusis|track distance and spot distance were 3.0 μm during flap creation and 1.5 μm during flap side-cutting. The flap diameter was 8.0 mm, and flap thickness was set to 105 μm. Side-cut angle and hinge angle were 90°and 50° respectively. The flaps were created by laser scanning in spirals from the periphery to the center of the pupil. An excimer laser system was used in the subsequent ablation of the stromal bed with a 6.0 mm optical zone. Once the excimer ablation was completed, the flap was repositioned in a similar fashion as in routine LASIK.
1556763|NCT02550340|Other|acute alcohol intake|Smart phone based ECG recording
1556764|NCT02550327|Drug|Nab-paclitaxel|125 mg/m2
1556765|NCT02550327|Drug|Gemcitabine|1000 mg/m2
1556766|NCT02550327|Drug|Cisplatin|25 mg/m2
1556767|NCT02550327|Drug|Anakinra|100 mg
1556768|NCT02550314|Drug|fiblast,gelatin sponge,fibrin glue|
1556769|NCT02550301|Other|Mean Platelet Volume|Ten milliliters (mls) of blood will be drawn from eligible, consented patients at the time of the admission, collected in ethylenediamine tetraacetic acid (EDTA) tubes, and tested for CBC. Platelets have an average life span that can vary from 8-10 days or 10-36 days. To minimize this bias, three additional MPV samples will be collected on day 1, day 7 and day 30 post PCI.
1556770|NCT02550288|Drug|Ezetimibe 10 mg|
1556771|NCT02550288|Drug|Atorvastatin 10 mg|
1556772|NCT02550288|Drug|Placebo for Ezetimibe 10 mg tablet|
1556773|NCT02550288|Drug|Placebo for Atorvastatin 10 mg capsule|
1556775|NCT02550275|Behavioral|neuropsychological test|
1556777|NCT02550262|Drug|Bupivacaine|0.0625% Bupivacaine plus fentanyl 2mcg/ml
1556778|NCT02550262|Drug|Fentanyl|0.0625% Bupivacaine plus fentanyl 2mcg/ml
1556779|NCT02550262|Device|Infusion pump|Infusion pump set to deliver programmed intermittent epidural boluses (PIEB) plus patient-controlled epidural analgesia (PCEA).
1556780|NCT02550249|Drug|Nivolumab|Intravenous administration of nivolumab
1556781|NCT02550223|Procedure|radial artery Catheterization|Insertion of radial artery catheter for sampling and blood pressure measurement
1556782|NCT02550210|Device|Breast Cancer Locator (BCL)|This locator will be constructed pre-operatively, sterilized and provided to the surgeon at the time of procedure. The outline of the breast cancer on the breast surface at the point where the cancer is closest to the skin is built into the locator, so that the surgeon can simply apply the locator to the patient's breast and trace the tumor outline on the skin.
1556783|NCT02550197|Biological|Quadrivalent influenza vaccine (QIV) (split virion, inactivated) Northern Hemisphere (NH) 2015-2016|0.5 mL, Intramuscular
1556784|NCT02550197|Biological|Trivalent influenza vaccine (TIV) (split virion, inactivated) NH 2015-2016 formulation|0.5 mL, Intramuscular
1556785|NCT02550184|Other|Focused ultrasonographic examination.|Focused ultrasonographic examination of the lungs and the heart of patients who fulfill the inclusion criteria and who have given their informed and written consent for participation.
1556786|NCT02550158|Procedure|Educational program EDU-MICI|
1556787|NCT02550145|Drug|Exendin (9-39)|IV infusion of Exendin (9-39) during standardized oral glucose tolerance test (OGTT).
1556788|NCT02550145|Other|Placebo|IV infusion of Placebo (normal saline) during standardized oral glucose tolerance test (OGTT)
1556789|NCT02550132|Procedure|Spinal manipulation|Participants will lie down during the 45-minute experimental session. Vertebral displacements (cm) and muscle response amplitude (RMS value) will be recorded through kinematic markers (on T6, T7 and T8 spinous processes) and surface electromyography electrodes (on the left and right erector spinae at T6 and T8 vertebra level). Each SMT (4 per participant) will be delivered at T7 transverse processes by an apparatus. Responses during the thrust phase (duration equal to twice the time to peak force) and after the thrust (1,5s duration) will be compared between SMTs.
1556790|NCT02550132|Device|Apparatus used to deliver spinal manipulations|An apparatus using a servo-controlled linear actuator motor (Linear Motor Series P01-48x360, LinMot Inc., Switzerland) will be used to deliver spinal manipulations.
1556791|NCT02550119|Drug|Aprepitant|Given PO
1556792|NCT02550119|Drug|Dexamethasone|Given PO or IV
1556793|NCT02550119|Drug|Dolasetron Mesylate|Given PO or IV
1556794|NCT02550119|Drug|Placebo|Given PO
1556798|NCT02550080|Drug|Dapsone|For the HLA-B*1301 positive subjects, dapsone will not be administrated.
1556799|NCT02550080|Genetic|HLA-B*1301|The prospective genetic screening group will be tested before administrating dapsone
1556800|NCT02550067|Drug|DMPA|Women randomized to DMPA, will receive an intramuscular injection of DMPA (medroxyprogesterone acetate sterile aqueous suspension 150 mg per 1 mL) at enrolment. Subsequent injections will be given every 3 months (i.e., at quarterly study visits) at the study site.
1556801|NCT02550067|Drug|LNG|Women randomized to implants will receive LNG implants in the arm, at enrolment from trained clinicians.
1556802|NCT02550067|Drug|Copper IUD|Women randomized to IUDs will receive their IUDs at enrolment. Trained providers will insert T380a copper IUDs using standard insertion techniques.
1556803|NCT02550054|Drug|Epo|Epo is administered 1000 U/kg, iv in 48 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, subcutaneously 400 U/Kg per injection and 3 doses per week until at corrected age of 34 weeks.
1556804|NCT02550054|Drug|Normal saline|Normal saline is administered 5ml, iv at 3 to 6 hours after premature birth, and at 48 hours interval for 3 doses per week. After 6 doses, Subcutaneously 3 doses per week until at corrected age of 34 weeks.
1556805|NCT02550041|Other|T specific response for diagnostic of aspergillus bronchitis|
1556806|NCT02550028|Drug|Oral levetiracetam|Oral load of levetiracetam (50 mg/kg) following identification of EEG confirmed neonatal seizure.
1556807|NCT02550028|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 mg/kg)following EEG confirmation of seizure activity load.
1556808|NCT02550015|Behavioral|High intensity interval training|Uphill treadmill walking
1556809|NCT02550015|Behavioral|General information|Standard care
1556810|NCT02550002|Drug|Aflibercept|Intravitreal injection
1556811|NCT02549989|Drug|LY3023414|Enrolled patients will take LY3023414 200 mg orally twice a day. Each cycle will be 21 days in duration. Patients will receive study treatment until disease progression, intolerable toxicity, elective withdrawal from the study, study completion, or study termination
1556812|NCT02549976|Procedure|Abdominal MRI|Abdominal MRI to realize within 4 months following inclusion
1556813|NCT02549976|Procedure|Upper endoscopy|Upper endoscopy to realize within 4 months following inclusion
1556814|NCT02549976|Procedure|Colonoscopy|Colonoscopy to realize within 4 months following inclusion
1556815|NCT02549976|Procedure|Pelvic MRI|Pelvic MRI to realize within 4 months following inclusion
1556816|NCT02549963|Device|WATCHMAN Left Atrial Appendage Occlusion Device|
1556817|NCT02549963|Drug|Rivaroxaban|
1556818|NCT02549950|Procedure|Peizocorticision|Peizocorticision a non invasive procedure used in/ to accelerate orthodontic tooth movement
1556819|NCT02549950|Procedure|Conventional Orthodontic Mechanics|Full Fixed Orthodontic Appliance with conventional orthodontic Mechanics
1556820|NCT02549937|Drug|sulfatinib|orally once daily (QD) in patients with advanced solid tumor.
1556821|NCT02549924|Drug|Resveratrol|Resveratrol capsules, 500 mg 3 times daily with the first bite of each meal
1556822|NCT02549924|Drug|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
1556879|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 20% HPMC|1 tablet 660 mg administered orally once daily
1556823|NCT02549911|Other|HIPEC,Chemotherapy AND surgery|"HIPEC（RHL-2000B, Madain Medical Devices Co., Ltd., Jilin, China): Taxol (Paclitaxel Injection) 75 mg/m2, twice, within 72 hours after surgical exploration ; oral chemotherapy:S-1(Tegafur,Gimeracil and Oteracil Potassium Capsules): 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
chemotherapy(PS for 3 cycles) : Taxol 150mg/m2,d1, S-1: 80mg/m2, twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
surgery:Secondary surgical exploration:if PCI less than 20,then perform the cytoreductive surgery(resection of primary tumors and metastases )
after the surgery,HIPEC for two cycles,and PS chemotherapy for 3 cycles"
1556830|NCT02549872|Other|This is not an intervention study|This study is based on the retrospective analysis of linked electronic health records.
1556831|NCT02549859|Device|DBS|"Patients will have a randomized double-blind prospective crossover study with usual medication on state under 3 different DBS stimulation frequency condition (60Hz vs 130Hz vs DBS off). Aspiration frequency on modified barium swallowing test and swallowing difficulty on questionnaire, FOG in stand-walk-sit test and questionnaire, and other axial and motor function will be assessed under each DBS condition. Changes in measurements between 60Hz and 130Hz at each visit and under 60Hz between two visits of 8 months apart on average will be analyzed, with swallowing function and FOG as primary, and the rest as secondary outcomes, correcting for potential carryover effect. Changes between other DBS conditions might also be explored in this 2-year study."
1556832|NCT02549846|Drug|Statin|Randomized controlled trial of early versus late statin therapy in patients with ischemic stroke
1556833|NCT02549833|Biological|GBM6-AD and poly-ICLC before and after surgery|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
1556834|NCT02549833|Biological|GBM6-AD and poly-ICLC after surgery only|Subcutaneous vaccination with GBM6-AD lysate protein and poly-ICLC combination
1556835|NCT02549820|Device|GoldBAL2 Detachable Balloon and BALTACCIBDPE100 Delivery Catheter|Fetoscopic Endoluminal Tracheal Occlusion (FETO)
1556836|NCT02549807|Device|Muscle elasticity measure|an ultrasound examination will be conducted on the hemiplegic leg side, while lying on his stomach and on the back. The thickness, elasticity and the angle of the medial gastrocnemius muscle pennation will be measured.
1556837|NCT02549794|Procedure|CT angiography with high concentration contrast agent|Standard concentration of iodine contrast agent for CT
1556838|NCT02549794|Procedure|CT angiography with low concentration contrast agent (320)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
1556839|NCT02549794|Procedure|CT angiography with low concentration contrast agent (270)|Two interventional arms use two different low concentration of iodine contrast agents, which is 320mgI/ml and 270mgI/ml respectively.
1556840|NCT02549781|Other|Go-Nogo test|"In this study, Gambler performing Go-Nogo test. On a computer, various exercises (called Go-Nogo) whose principle is: 2 symbols (for example, a circle and a square) appear in random order on the screen computer. The patient will not press the response button (key on the keyboard) that upon the occurrence of one of the two symbols, in dependence upon the command that it has been given by the psychiatrist, and this as quickly as possible. The patient will successively perform 3 versions of this exercise (with a neutral wallpaper, with neutral/games images or with neutral/games tones). Order of the 3 versions will be determined by randomization."
1556841|NCT02549768|Drug|Dexmedetomidine|At start of anesthesia, bolus of 1 mcg/kg of dexmedetomidine over 10 minutes and then infusion of 0.7 mcg/kg/h during surgery will be administered.
1556842|NCT02549768|Drug|Sodium Chloride 0.9%|Sodium chloride 0.9% with a pump programmed in same way as Dexmedetomidine pump
1556844|NCT02549742|Procedure|Electrochemotherapy|Electroporation by a device, Cliniporator, combined with chemotherapy, Bleomycin.
1556845|NCT02549742|Device|Cliniporator|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz.
1556846|NCT02549742|Drug|Bleomycin|Administered intravenously or injected into the tumour before electroporation.
1556847|NCT02549729|Behavioral|pelvic floor muscle training|Women will be instructed to perform pelvic floor muscle training daily at home 4 sets of 10 maximum perceived voluntary contraction of the pelvic floor muscle sustained for 6 seconds followed by 5 flick voluntary contraction of the pelvic floor muscle. The 4 sets will be performed in 4 different positions (supine, all four, sit and standing). Twice a week they will receive a supervised session using the same protocol described above.
1556848|NCT02549716|Drug|IV acetaminophen|Patients in this group will receive IV acetaminophen and an oral placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
1556849|NCT02549716|Drug|Oral acetaminophen|Patients in this group will receive oral acetaminophen and an IV saline solution placebo every 6 hours for a 14 day period. Blood and CSF samples will be collected from patients throughout the 14 day period.
1556850|NCT02549716|Drug|Oral placebo|Patients who receive IV acetaminophen will also receive an oral placebo with their IV treatments (every 6 hours for a 14 day period).
1556851|NCT02549716|Drug|IV placebo|Patients who receive oral acetaminophen will also receive a saline solution placebo at the same time that they receive the oral acetaminophen treatment (every 6 hours for 14 days).
1556852|NCT02549690|Drug|Testosterone gel|Apply 10mg testosterone gel to the abdomen and rub on with one finger, once a day, in the morning, then allow sites to dry and cover with clothing. Continue the treatment for 6-8 weeks until next IVF treatment.
1556853|NCT02549690|Drug|DHEA|Take DHEA 25mg tablet orally, three times per day. Continue the treatment for 6-8 weeks, until next IVF treatment.
1556854|NCT02549677|Drug|Epirubicin|epirubicin, 90mg per square meter, every 3 weeks, day 1
1556855|NCT02549677|Drug|Docetaxel|docetaxel, 75mg per square meter, every 3 weeks, day 1
1556856|NCT02549677|Drug|cyclophosphamide|cyclophosphamide, 600mg per square meter, every 3 weeks, day 1
1556857|NCT02549651|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb) administered via intravenous infusion
1556858|NCT02549651|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (MAb) administered via intravenous infusion
1556859|NCT02549651|Drug|AZD9150|AZD9150 is an antisense oligonucleotide (ASO) administered via intravenous infusion
1556861|NCT02549625|Biological|Autologous Bone Marrow-derived Mononuclear Cells|
1556862|NCT02549612|Device|Moniri Otovent|Please see arm description.
1556863|NCT02549599|Behavioral|Chat/Text Program|Participants will receive access to the Chat/Text program on the internet via computer or mobile device. The Chat/Text program involves interactive, immediate, and tailored messages (with pre-determined content) delivered by Chat/Text agents via online chat or mobile phone text. At the conclusion of the session, the participants will receive a combination-baseline and follow-up survey.
1556864|NCT02549599|Behavioral|Website Content|Participants will be directed to content and information on the Planned Parenthood website. The website contains information on birth control methods, locations of Planned Parenthood health clinics, and on sexual and reproductive health more broadly.
1556865|NCT02549599|Other|Delayed Treatment|Participants will receive a baseline survey and be routed to the Planned Parenthood website. No subsequent survey will be administered
1556866|NCT02549586|Other|Autologous Hematopoietic Stem Cell Transplant|"Step 1: Participants will receive intravenous chemotherapy and cytokine-based treatment for mobilization of hematopoietic stem cells (HSC) into the circulation, followed by collection using peripheral vein leukopheresis. The HSC graft product will undergo ex vivo purification with CD34 selection using Miltenyil CliniMACS and cryopreserved.
Step 2: Intravenous busulphan, cyclophosphamide and anti-thymocyte globulin will be administered to participants to achieve immune ablation prior to the infusion of the participants' own thawed HSC graft product (HSC transplant). Routine supportive measures will be employed during the recovery from the chemotherapy and HSCT. Participants' immune suppression will be stopped at the time of immunoablative therapy and will be switched to everolimus which will be discontinued at 6 months post HSCT."
1556869|NCT02549560|Device|tDCS|Application of two daily sessions of cerebral stimulation starting from the first day after de surgery, for 4 consecutive days, with each session having 20 minutes, having an 8 hour minimum break between them. Will be applied a direct current stimulus of 2 milliampere (mA) (right anode/left cathode) in the prefrontal right region.
1556870|NCT02549547|Behavioral|Group Medical Visits|"Cohorts will participate in a weekly series of 14 Group Medical Visits (GMVs) co-led by a psychiatrist and an exercise professional. Each two-hour Group Medical Visit will be divided into three sections:
Group check in/out; enter patients weekly step count into database; review and outline the day's group program - 20 minutes
Group discussion, regarding selected physical activity topics including psychiatric issues - 50 minutes
Physical activity component - 50 minutes The 'content' or curriculum of the GMVs will support participant Self-Management/Activation. Research has consistently emphasized the role of positive feedback, social support, reinforcement, goal setting, and motivation for improving person's self-perception to uptake physical activity."
1556874|NCT02549521|Dietary Supplement|Oral magnesium substitution|The elderly was given tablets two times daily with calsium and vitamin D. They were further given magnesium tablets 120 mg two times daily for 28 days.
1556875|NCT02549521|Dietary Supplement|Placebo tablets without magnesium|The elderly was given tablets two times daily with calsium and vitamin D. They were further given placebo without magnesium two times daily for 28 days.
1556876|NCT02549508|Device|SensAwake On|The comfort feature 'SensAwake' will be turned on
1556877|NCT02549508|Device|SensAwake Off|The comfort feature 'SensAwake' will be turned off
1556878|NCT02549482|Other|Respiratory resistor|The volunteers are breathing through the four respiratory resistors (inspiratory, expiratory, combined in- and expiratory and no resistor) in order to increase the intrathoracic pressure svings
1557362|NCT02546141|Other|full-fat milk (UHT)|
1996288|NCT02503410|Behavioral|Interactive gaming home-based exercises|Subjects will receive a combination of physical therapy (during 8 to 12 weeks) and at least two sessions of interactive exercises program at home with the Valedo® System (Hocoma AG). Subjects will fill out a questionnaire about their pain every two weeks during the treatment period.
1996289|NCT02503410|Device|Valedo® System (Hocoma AG)|
1556880|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 30% HPMC|1 tablet 660 mg administered orally once daily
1556881|NCT02549469|Drug|Naproxen Sodium ER (BAY117031), 40% HPMC|1 tablet 660 mg administered orally once daily
1556882|NCT02549469|Drug|Aleve (Naproxen Sodium, BAY117031)|1 tablet 220 mg administered orally three times daily
1556883|NCT02549456|Procedure|natural orifice specimen extraction|Conventional laparoscopic resection of colorectal cancer is done then specimen is extracted through natural orifice (anal or vaginal orifice).
1556884|NCT02549456|Procedure|Laparoendoscopic resection|"Endoscopic phase: Transanal platform is inserted into the rectum, and pneumorectum is established. The lumen is occluded below the level of the tumor. The avascular ''oncologic'' presacral plane is entered posteriorly, and dissection proceeds cephalad in the total mesorectal excision planes. Next, the abdominal cavity is entered at the peritoneal reﬂection. The superior rectal artery is divided. The rectal stump then is reﬂected into the abdominal cavity, and retrograde dissection is performed until the procedure is limited by instrument length.
Laparoscopic phase: Colon mobilization, lymph node dissection, and mesenteric excision are performed laparoscopically. Mobilization of the splenic ﬂexure is done if needed."
1556885|NCT02549443|Dietary Supplement|Amino acids|AA (Travasol Baxter, Deerfield IL) during and after surgery in an amount equivalent to 20% and 35% of the patient's energy expenditure (EE)
1556886|NCT02549430|Drug|Palbociclib|Palbociclib 125 mg/day orally in an ongoing 3:1 schedule (3 weeks on/1 week off)
1556887|NCT02549430|Drug|Anastrozole|Continuation of prior anastrozole 1mg/day orally in a continuous regimen
1556888|NCT02549430|Drug|Letrozole|Continuation of prior letrozole 2.5mg/day orally in a continuous regimen
1556889|NCT02549430|Drug|Exemestane|Continuation of prior exemestane 25mg/day orally in a continuous regimen
1556890|NCT02549430|Drug|Fulvestrant|Continuation of prior fulvestrant 500mg intramuscular injection every 4 weeks in a continuous regimen
1556891|NCT02549417|Drug|KHK7580|Oral administration
1556892|NCT02549404|Drug|KHK7580|Oral administration
1556893|NCT02549391|Drug|KHK7580|Oral administration
1556894|NCT02549391|Drug|KRN1493|Oral administration
1556895|NCT02549378|Device|confocal microscopy|microvessel diameter measured by confocal microscopy
1556896|NCT02549365|Drug|Live attenuated influenza vaccine|Administration of LAIV, with subsequent surveillance (nasal swabbing) during influenza season
1556897|NCT02549365|Procedure|Surveillance (nasal swabbing) during influenza season|
1556898|NCT02549352|Drug|LEO43204 gel|
1556899|NCT02549352|Drug|Vehicle gel|
1556900|NCT02549339|Drug|LEO 43204 gel|
1556901|NCT02549339|Drug|Vehicle gel|
1556902|NCT02549326|Dietary Supplement|vitamin D|
1556903|NCT02549326|Dietary Supplement|Placebo|
1556904|NCT02549313|Procedure|position changes of the head|Registration of blood flow changes induced when the patient's head will be tilted at 0 ° (that is to say flat), 15 ° and 30 ° (the order of actions will be determined by drawing lots). The patient will remain 10 minutes in each of these positions.
1556905|NCT02549300|Other|Connective tissue massage|It is a manual reflex therapy in that it is applied with the therapist's hands which are in contact with the patient's skin. The assessment of the patient and the clinical decision-making that directs treatment is based on a theoretical model that assumes a reflex effect on the autonomic nervous system which is induced by manipulating the fascial layers within and beneath the skin.
1556906|NCT02549287|Behavioral|SafeCare|An evidence-based home visiting program
1556907|NCT02549287|Behavioral|Supportive Case Management|Child welfare services as usual
1556908|NCT02549274|Other|self-rehabilitation + physiotherapy|2 training sessions in self-rehabilitation at the hospital and then a self-rehabilitation / day session + 14 physiotherapy sessions (2 by week)
1556909|NCT02549274|Other|physiotherapy|14 physiotherapy sessions (2 by week)
1556910|NCT02549261|Drug|nimotuzumab|the nimotuzumab treatment: 200mg/w weekly, for 16 weeks. A treatment:nimotuzumab for 3 levels (100mg/w, 200mg/w, 400mg/w, weekly, for 16 weeks).
1556911|NCT02549261|Drug|Cisplatin|Concurrent Chemotherapy,50mg/m2 (d1,d8),4 weeks/cycle, for 2 cycles. the consolidation chemotherapy: Cisplatin: 50mg/m2 (d1,d8)4 weeks/cycle, for 2 cycles.
1556912|NCT02549261|Drug|Etoposide|"Concurrent Chemotherapy, Cisplatin: Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles.
the consolidation chemotherapy:Etoposide: 50mg/m2 (d1-5)，4 weeks/cycle, for 2 cycles."
1556913|NCT02549261|Radiation|radiotherapy|the tolerance trial of treatment A and B of treatment;95％PTV,60-66Gy/30-33/fraction,6-7weeks.
1556914|NCT02549248|Other|BAL|Patients with idiopathic and non idiopathic interstitial lung diseases
1556915|NCT02549248|Other|BW|Patients with idiopathic and non idiopathic interstitial lung diseases
1556916|NCT02549248|Other|EAC|Patients with idiopathic and non idiopathic interstitial lung diseases
1556917|NCT02549248|Other|blood specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
1556918|NCT02549248|Other|Urine specimen|Patients with idiopathic and non idiopathic interstitial lung diseases
1556919|NCT02549235|Other|Ultrasound|Routine ultrasound assessment
1556921|NCT02549209|Drug|Pembrolizumab|Pembrolizumab 200 mg will be administered every 3 weeks for all subjects
1556922|NCT02549209|Drug|Paclitaxel|"For subjects with no prior therapy, paclitaxel will be dosed at 175mg/m2 and be administered as a 3-hour continuous IV infusion.
Subjects with prior XRT/platinum-based chemotherapy must initiate paclitaxel at 135mg/m2 and be administered as a 3-hour continuous IV infusion."
1556923|NCT02549209|Drug|Carboplatin|"For subjects with no prior therapy, carboplatin will be dosed at an AUC of 6 and given as an IV infusion in 250ml of D5W over 30 minutes.
Subjects with prior XRT/platinum-based chemotherapy must initiate carboplatin at an AUC of 5 given as an IV infusion in 250ml of D5W over 30 minutes."
1556924|NCT02549196|Drug|CPC-201|
1556925|NCT02549183|Device|Boston Scientific PRECISION Spinal Cord Stimulator System|Spinal cord stimulation randomly programmed to KHz frequencies; A, B, C and D Kilo Hertz.
1556972|NCT02548832|Drug|Placebo|Placebo capsules, 200 mg 2 times daily with the first bite of each meal
1556929|NCT02549157|Procedure|Pelvic Floor Muscle Training|
1556930|NCT02549144|Dietary Supplement|Low versus high fat/cholesterol diet|The low fat/cholesterol diet had 10% calories from fat and 150-200 mg of cholesterol per day.The high fat/cholesterol diet had 40% calories from fat and 250-300 mg of cholesterol per day.
1556931|NCT02549131|Procedure|Randomizing to Suture or Staple closure of Cesarean section|Randomizing to either surgical subcuticular suture or surgical staples in women of BMI greater than 40 undergoing Cesarean section delivery.
1556932|NCT02549118|Drug|Tenoxicam|
1556933|NCT02549118|Drug|Pethidine|
1556934|NCT02549105|Drug|EMLA CREAM 5 mg|EMLA CREAM APPLICATION FOR WOUND AFTER CS
1556935|NCT02549105|Drug|LIDOCAINE 1 %|LIDOCAINE 1 % INFILTERATION FOR WOUND AND ASSESSMENT OF PAIN IN FIRST 6 HOURS
1996295|NCT02503774|Biological|MEDI9447|Subjects will receive MEDI9447 until disease progression
1556937|NCT02549079|Other|Blood sample|Blood will be taken from all patients meeting the inclusion criteria.
1556938|NCT02549066|Procedure|Increased cardiopulmonary bypass flow|In randomized order, CPB flow will be adjusted to 2,4, 2,7 and 3,0 L/min/m2. After 10 minutes of steady conditions at each level, measurements will be made.
1556939|NCT02549066|Drug|Milrinone|"After weaning from CPB, patients with signs of cardiac failure (as defined below) will be given milrinone (0,04 mg/kg as a loading dose and 0,50 ug/kg/min as subsequent infusion). Measurements of systemic and renal variables will be made before and 30 minutes after the dose.
Indication: Central venous pressure (CVP) ≥ 12 mmHg AND/OR Pulmonary Capillary Wedge Pressure (PCWP) ≥ 16 mmHg AND Cardiac Index (CI) ≤ 2,1 L/min/m2 AND Pulse Pressure Variation (PPV) < 12 %."
1556940|NCT02549053|Procedure|esophagus biopsies (pathologic and healthy zones)|Biopsies were realised in the distal third of esophagus : 4 for Barrett esophagus patients (2 in healthy zone, 2 in pathological zone).
1556941|NCT02549053|Procedure|esophagus biopsies (healthy zones)|Biopsies were realised in the distal third of esophagus :2 for control patients in healthy zone
1556942|NCT02549040|Drug|MK-1439 film coated tablet|A single MK-1439 film coated tablet, administered orally at the start of Period 2
1556943|NCT02549040|Drug|MK-1439 NF|A single MK-1439 NF, administered orally at the start of Periods 1, 3, 4, and 5.
1556944|NCT02549027|Drug|MK-1064|Oral MK-1064 tablets (10 and 50 mg strengths)
1556945|NCT02549027|Drug|MK-6096|Oral MK-6096 tablets (5 mg strength)
1556946|NCT02549027|Drug|Placebo|Oral placebo tablets (matching active MK-1064 tablets, matching active MK-6096 tablets)
1556947|NCT02549014|Drug|MK-1064|Dose for each period administered as oral MK-1064 tablets (1, 10 and 50 mg strengths)
1556948|NCT02549014|Drug|Placebo|Dose for each period administered as oral placebo tablets matching active MK-1064 tablets
1556949|NCT02549001|Drug|P-3058 10%|
1556950|NCT02549001|Drug|vehicle of P-3058 10%|
1556951|NCT02549001|Drug|amorolfine 5%|
1556952|NCT02548988|Other|Neuromuscular Electrical Stimulation|Selective Neuromuscular Electrical Stimulation on VMO
1556953|NCT02548975|Drug|Statin, beta blocker|Patients receiving either statin or beta blockers prior to cardiac surgery.
1556954|NCT02548975|Other|Cardiopulmonary bypass|Patients exposed to cardiopulmonary bypass during cardiac surgery.
1556955|NCT02548962|Drug|Ibrutinib|
1556956|NCT02548962|Drug|Pomalidomide|
1556957|NCT02548962|Drug|Dexamethasone|
1556958|NCT02548962|Drug|Placebo|
1556959|NCT02548936|Drug|Ezetimibe+Simvastatin Drug Combination|The patients in Ezetimibe+Simvastatin Drug Combination group received simvastatin (10mg/day) + ezetimibe (20 mg/day) by oral administration for 12 month.
1556960|NCT02548923|Drug|Dexmedetomidine|comparison to propofol
1556961|NCT02548910|Procedure|Phlebotomy|A central venous catheter will be inserted for every patient to measure central venous pressure, as is the standard of care in elective liver surgery. Strict aseptic technique will be maintained. A total volume of whole blood of 7-10 mL per kg of body weight will be removed, as tolerated. The volume of removed blood will not be replaced by intravenous fluid administration. Collected blood will be transfused back at the end of the liver parenchymal transection, or within 8 hours of collection.
1556962|NCT02548910|Device|Citrated whole blood collection bag|Transfusion Medicine will send the requested number of whole blood collection bags labelled with the patient's name and MRN. These whole blood collection bags are used in standard practice for collection of whole blood.
1556963|NCT02548897|Device|Deep brain stimulation|The programming of DBS settings in all participants with bilateral DBS implants in the globus pallidus internus (GPi) and pedunculopontine nucleus (PPN) will be performed.
1556964|NCT02548897|Other|Electroencephalography|An electroencephalography (EEG) will be performed on all participants to better understand the neurophysiological underpinnings of the symptom.
1556965|NCT02548884|Procedure|Biliary cannulation|
1556966|NCT02548871|Behavioral|Teen Outreach Program|TOP® is a positive youth development and service learning program for youth ages 12 to 17, and its Changing Scenes curriculum is separated into age appropriate levels. The program uses an approach that involves a caring adult, positive self-efficacy, future planning and goal setting and life management skills to to reduce risky sexual behavior and improve school outcomes. TOP® is designed to be delivered in weekly sessions over 9 months and includes community service learning.
1556967|NCT02548858|Procedure|Perineorrhaphy|Those patients who are randomized to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
1556968|NCT02548858|Procedure|No Perineorrhaphy|Those patients who are randomized not to undergo a perineorrhaphy as part of their vaginal or abdominal reconstructive procedure for pelvic organ prolapse.
1556969|NCT02548832|Drug|Berberine|Berberine capsules, 500 mg 3 times daily with the first bite of each meal
1556970|NCT02548832|Drug|Bezafibrate|Bezafibrate capsules, 200 mg 2 times daily with the first bite of each meal
1556971|NCT02548832|Drug|Placebo|Placebo capsules, 500 mg 3 times daily with the first bite of each meal
1556973|NCT02548819|Other|MRI|MR imaging of patients with implanted cardiac devices
1556974|NCT02548806|Drug|Clonidine MBT 50µg|Clonidine MBT 50µg, single dose
1556975|NCT02548806|Drug|Clonidine MBT 100µg|Clonidine MBT 100µg, single dose
1556976|NCT02548806|Drug|Catapres 100μg|Catapres tablet 100μg, single dose
1556977|NCT02548793|Other|Education: CPR Training via Mobile App|Using a mobile app to train users on chest-compression only CPR. Subjects will be encouraged to share the app with family and friends.
1556978|NCT02548793|Other|Education: CPR Training using the CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
1556979|NCT02548780|Device|Chemoembolization|"First, an angiography of the celiac trunk, superior mesenteric artery and hepatic artery will be obtained by using a peripheral arterial approach.
Arterial embolization will be performed through catheterization of intrahepatic arteries, as selectively as possible (tumor feeders, subsegmental, segmental). The size of the microcatheter must be consistent with the size of LifePearl beads used. Microspheres of 200 µm will be be used. They will be loaded with the appropriate dose of doxorubicin injectable solution, mixed with the contrast media and distributed according to the location of the HCC lesions. The endpoint of the procedure will be achieved end when stasis of the feeders is achieved and confirmed with angiography of the whole liver."
1556980|NCT02548780|Other|Pharmacokinetics|Pharmacokinetic analysis will be performed in cohort I and II after the first treatment only. In addition to blood samples taken for biochemistry and haematology analysis, blood will be taken for pharmacokinetic assessment: Whole venous blood samples (6 ml in 2 tubes) will be taken from peripheral blood into ethylenediaminetetraacetic acid (EDTA) tubes prior to and at 5mins, 20mins, 40mins, 1h, 2h, 6h, 24h, 48h and 7 days after the procedure, and if needed (i.e. value at d7 is detectable) at 1 month (for safety assessment visit) either during hospital stay or in the outpatient clinic.
1556981|NCT02548767|Other|high fructose corn syrup|High fructose corn syrup provided as 15% HFCS/85% water (weight/weight) fruit-flavored beverage
1556982|NCT02548767|Other|aspartame|Aspartame provided as 0.04% aspartame/99.96% water (weight/weight), fruit-flavored beverage
1556983|NCT02548767|Other|Energy-balanced diet|Provided in quantities that equal energy requirement. Formulated such that the overall macronutrient intake; including beverage; equal 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
1556984|NCT02548767|Other|Ad libitum diet|Provided in quantities that exceed energy requirement by approximately 25%. Formulated such that the overall macronutrient intake; including beverage; equals approximately 45%/5% energy requirement at complex/simple carbohydrate, 35% energy requirement as fat, 15% energy requirement as protein.
1556986|NCT02548741|Drug|Metformin Hydrochloride (500-mg capsule)|Metformin hydrochloride tablets (500-mg) are manufactured by Heritage Pharma INC. Noha Ashy & David Lee will ground the tablets and put them in capsules to avoid differentiation between treatment and placebo. Using USP 797 compounding standers, Noha Ashy & David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona. New empty capsules (size 0, ½ blue-opaque and ½ white-opaque capsule which will be supplied by Letco Medical) will be provided to the treatment (metformin hydrochloride) arm participants that are similar to the placebo (comparator) capsules in term of color and size to conceal placebo from the investigators and participants.
1556987|NCT02548741|Drug|Calcium carbonate (placebo)|Investigators will use powder of calcium carbonate as filler of placebo capsules. Placebo capsules (size 0,½ blue-opaque and ½white-opaque capsule which will be supplied by Letco Medical),will be provided to the comparator arms' participants that are similar to the metformin hydrochloride capsules in term of color and size to conceal placebo from the investigators and participants.Using USP 797 compounding standers, Noha Ashy & David Lee will package the capsules to conceal it from the participants and other investigators. Compounding will take place at the lab, College of Pharmacy (Darchman building, 2nd floor), University of Arizona.
1556988|NCT02548741|Other|Glucometer (One Touch glucometer), strips and lancets|Investigators will provide glucometer (One Touch glucometer), strips and lancets to the treatment and placebo groups. They will be provided to patients who never had glucometer before enrolling to our study.Also, a logbook will be provided to each participant to record their blood sugar measurements at home.
1556989|NCT02548741|Other|Urine container for 24-hour urine collection|During visit 2 (day 0) and visit 3 (day 42), urine container will be provided to the study participant for 24-hour urine collection. Patient will be instructed to bring the container back to the collaboratory. Investigators will transfer the urine container to Dr.Lau's lab to measure the IMZ concentration/content.
1556990|NCT02548728|Drug|Intranasal Oxytocin Spray|10 insufflations (40IU of oxytocin total) given three times on day of enrollment and then twice daily for 4 days
1556991|NCT02548728|Drug|Placebo|10 insufflations (40IU of placebo, same solution as active treatment minus oxytocin) given three times on day of enrollment and then twice daily for 4 day
1556992|NCT02548715|Drug|Levothyroxine|
1556993|NCT02548715|Drug|Placebo|
1556994|NCT02548702|Behavioral|Fit4Life|Fit4Life is a programme whereby patients with type 2 diabetes are counselled and then allocated to a community-based sport programme based on their interests and perceived barriers to participation
1556995|NCT02548676|Device|Optical angiography based on OCT|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
1556996|NCT02548663|Other|Sport therapy|"Frequency: 60 min three times/week
20 min: aerobic training on bicycle ergometer.
20 min: strength training at 60% of maximal load.
20 min: proprioception and stretching exercises."
1556997|NCT02548663|Other|Osteopathic treatment|Frequency: 60 min weekly
1557033|NCT02548403|Drug|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
1556998|NCT02548650|Drug|Vorapaxar|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
1556999|NCT02548650|Drug|Clopidogrel|Triple therapy with DAPT plus vorapaxar (vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
1557000|NCT02548650|Drug|Aspirin|Triple therapy with DAPT plus vorapaxar(vorapaxar 2.5mg od plus clopidogrel 75 mg od and aspirin 81 mg od) will be administered for 30 days; then patients will stop aspirin and will take dual treatment (vorapaxar 2.5mg od plus clopidogrel 75 mg od ) for other 30 days
1557001|NCT02548637|Procedure|Acupuncture Therapy|The standard textbook of Chinese Acupuncture and Moxibustion is the source for the name and location of the points for this study. A total of 38 points will be used, divided between two acupuncture sessions: 20 points or 37 locations in the supine position; 18 points or 36 locations in the prone position. Other than points governing vessel (GV) 20, conception vessel (CV) 6, CV 10, all points will be performed bilaterally.
1557002|NCT02548624|Device|Zephyr BioPatch|"The ZephyrLIFE Hospital System includes the BioPatch™ device (consisting of the BioModule™ sensor, BioModule™ holder, and snap ECG electrodes), the ECHO radio system, and a software monitoring interface. The BioModule™ sensor is a Class II device, 510(k) cleared by the FDA, and commercially available.
The ZephyrLIFE Hospital System stores, transmits and displays vital sign data including ECG, HR, RR, body orientation, and activity to caregivers via a central station."
1557003|NCT02548611|Drug|Prasugrel|see arm description
1557004|NCT02548611|Drug|Clopidogrel|see arm description
1557005|NCT02548598|Procedure|Endoscopic sinus surgery|This is an observational trial of patients with and without asthma who have concomitant chronic rhinosinusitis requiring endoscopic sinus surgery.
1557006|NCT02548585|Drug|MEDI0382|MEDI0382 administered subcutaneously
1557007|NCT02548585|Drug|Placebo|Placebo administered subcutaneously
1557008|NCT02548572|Device|Transcorneal Electrical Stimulation using Okustim device|"The Okustim® stimulation device is a battery-powered electronic neuro-stimulator, which delivers a weak electrical pulse. This current is delivered to the eyes by the OkuStim® device using the OkuEl® electrodes, which are held in place via the OkuSpex® frame. In this study the treatment level will be held constant at 0.8 mA for all study subjects. After switching on the neuro-stimulator, the subject's retina will be stimulated through specific electrodes (OkuEl, held in position by the OkuSpex) worn on the face with the predetermined intensity and time period (delivered by the OkuStim device)."
1557009|NCT02548559|Drug|Cannabidiol|Cannabidiol; total daily dose of 28.08mg.
1557010|NCT02548546|Device|ECHO|Imaging
1557011|NCT02548546|Device|ECG-gated MRA|Imaging
1557012|NCT02548533|Device|AFXL|Pretreatment at 2.5 mJ/microbeam and 15% density.
1557013|NCT02548533|Drug|AHES|Topical application on AFXL pretreated skin 15 minutes prior to the treatment.
1557014|NCT02548533|Drug|EMLA cream|Topical application 2 hours prior to the treatment.
1557015|NCT02548520|Other|Blood and breastmilk samples|The investigators collected maternal and infants blood samples from birth, and 4 and 9 months forward, including breastmilk from the mothers at all visits
1557016|NCT02548507|Other|observational study, no intervention|
1557017|NCT02548494|Drug|Glargine|The control group will receive all traditional methods of treatment for DKA, including a placebo subcutaneous injection. The study group will receive the same treatment, but will be supplemented with a subcutaneous glargine injection.
1557018|NCT02548494|Drug|IV insulin|The intravenous infusion of insulin at a weight-based fixed rate until ketosis has subsided.
1557019|NCT02548494|Other|Electrolyte Correction|If the potassium level is greater than 6 mEq/L, do not administer potassium supplement. If the potassium level is 4.5-6 mEq/L, administer 10 mEq/h of potassium chloride. If the potassium level is 3-4.5 mEq/L, administer 20 mEq/h of potassium chloride.
1557020|NCT02548494|Other|Correction of Fluid Loss|"Initial correction of fluid loss is either by isotonic sodium chloride solution or by lactated Ringer solution. The recommended schedule for restoring fluids is as follows:
Administer 1-3 L during the first hour.
Administer 1 L during the second hour.
Administer 1 L during the following 2 hours
Administer 1 L every 4 hours, depending on the degree of dehydration and central venous pressure readings"
1557021|NCT02548481|Other|BESTA scale|BESTA scale is administrated at T0, T1 and T2.
1557022|NCT02548468|Drug|Fludarabine|Given IV
1557023|NCT02548468|Radiation|Total-Body Irradiation|Undergo TBI
1557024|NCT02548468|Biological|T Cell-Depleted Donor Lymphocyte Infusion|Undergo donor CD3+ enriched T lymphocyte infusion
1557025|NCT02548468|Drug|Cyclophosphamide|Given IV
1557026|NCT02548468|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSC transplant
1557027|NCT02548468|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
1557028|NCT02548468|Drug|Mycophenolate mofetil|Given IV
1557029|NCT02548468|Drug|Tacrolimus|Given IV
1557030|NCT02548455|Device|Left Ventricular Lead|
1557031|NCT02548416|Procedure|Positive end-expiratory pressure|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium.
As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Positive end-expiratory pressure is set to 6 or 8 cm H20 (8 if BMI>25) in the intervention group.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
1557032|NCT02548416|Procedure|Control group, zero PEEP|"Induction of anaesthesia is performed in a conventional manner using a target controlled infusion of propofol and remifentanil. Intubation of the trachea is facilitated by rocuronium. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg body weight and a respiratory frequency of 10. The fresh gas flow is set to 1 litre/min with an oxygen mixture of 40%, aiming for an inspired oxygen fraction (FiO2) of 30-35%. Zero PEEP is used.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
1557195|NCT02547298|Device|Cystoscopy|
1557034|NCT02548403|Drug|PEG-Asc with simethicone|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure. Two packs (200 mg/10 mL each) of simethicone (400 mg) was mixed with last 500 mL of additional clear fluid.
1557035|NCT02548390|Drug|RXDX-107|Subjects in this study will receive RXDX-107 intravenously at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg/m2 on Day 1 and Day 2 of a 28-day cycle and will escalate until the maximum tolerated dose (MTD) or (RP2D) is determined. An additional schedule of administration of RXDX-107 on Day 1 of a 28 day cycle may be assessed. Cycles will be repeated in four-week (28 day) intervals for up to 6 cycles or until progression of disease, unacceptable toxicity, or another discontinuation criterion is met.
1557036|NCT02548377|Procedure|Remote ischemic preconditioning|
1557037|NCT02548377|Procedure|Sham|
1557038|NCT02548364|Drug|Calcifediol|calcifediol treatment
1557039|NCT02548364|Drug|Placebo|placebo control group
1557040|NCT02548351|Drug|Obeticholic Acid|
1557041|NCT02548351|Drug|Placebo|
1557042|NCT02548338|Procedure|argon plasma coagulation|On the first group we use the regular electric scalpel to perform the surgery , and on the second group we use the argon plasma coagulation scalpel to perform the procedure.
1557043|NCT02548325|Other|Not apply|None. Just registration epidemiology dates
1557044|NCT02548312|Other|Variations of financial competing interest statements|Participants will be randomised to receive 1 of 2 review articles on different topics. For each review there will be 4 groups. Each of the 4 groups will receive an identical version of the review article with the exception of the competing interest statement which will vary depending on group assignment.
1557045|NCT02548299|Other|Nutrition Education|Nutrition classes will be led by a registered dietician.
1557046|NCT02548299|Other|Cooking Lecture|
1557047|NCT02548299|Other|Cooking Demo|
1557048|NCT02548299|Other|Hands-on Cooking|
1557049|NCT02548299|Other|e-Coaching|
1557050|NCT02548286|Drug|Candesartan 8mg|PO, 1day or 22day
1557051|NCT02548286|Drug|Amlodipine 5mg|PO, 1day or 22day
1557052|NCT02548286|Drug|CKD-330 8/5mg|PO, 1day or 22day
1557053|NCT02548260|Device|Syndactyly without compression|three week relative immobilization by syndactyly
1557054|NCT02548260|Device|Syndactyly with compression|three week relative immobilization by syndactyly and compression
1557055|NCT02548260|Device|Rigid splint without compression|three week rigid immobilization by splint
1557056|NCT02548260|Device|Rigid splint with compression|three week rigid immobilization by splint and compression
1557057|NCT02548247|Dietary Supplement|Orafti® Inulin|Dietary fiber
1557058|NCT02548247|Dietary Supplement|Placebo|Maltodextrin
1557061|NCT02548221|Device|transthoracic echocardiogram|Thoracentesis was performed on patients with large-volume pleural effusions, and TTE was utilized to access the change of heart and lung function before and after this medical procedure.
1557062|NCT02548208|Device|Verum focused extracorporeal shockwave|the concentrated shockwave energy per unit area (energy flux density EFD) can vary from 0.06 to 0.09 mJ/mm2. The pulse ratio per point is 200.
1557063|NCT02548208|Device|Sham shock wave|Sham shock wave is performed using the same device as stated above, but using a special applicator that has been isolated with layers of metal and water by the manufacturer, extinguishing the transmitted energy.
1557064|NCT02548195|Drug|oxaliplatin and gemcitabine|oxaliplatin and gemcitabine (GEMOX regimen): day 1: oxaliplatin 85 mg/m2, gemcitabine 1000 mg/m2; day 8: gemcitabine 1000 mg/m2 every three weeks for 6-8 cycles in total.
1557065|NCT02548195|Drug|capecitabine|capecitabine 1250 mg/m2, twice daily for two weeks plus one week rest for 8 cycles in total.
1557066|NCT02548182|Device|smartcare|Fit.life™ wireless physical activity tracker can measure daily physical activity including activity strength and time. It was chosen for its small size, accuracy in the measurement of physical activity, and convenient data upload via Bluetooth on participant mobile phone or wirelessly via a personal computer. Fit.life™ wireless physical activity tracker has been validated for measurement of free-living physical activity in adults [REF]. A smartphone application was customized for the use of the investigators' intervention, different for the 'smart care' group and 'smartcare plus financial incentive' group. The version for the latter group included the feature for the monitoring and feedback of financial incentives.
1557067|NCT02548182|Other|financial incentives|Financial incentives are provided in the form of process-based and outcome-based incentive.(maximum 320,000KRW) Process-based incentives were based on daily physical activity level. Participants in the 'smart care plus financial incentive' arms could earn incentives of up to 10,000 KRW per week according to the following schedule: 1,000 KRW if a participant reached target amount of physical activity in a day / An additional 3,000 KRW if a participant reached target amount of physical activity every day in a week. Outcome-based incentives were based on achievement of weight loss target at each visit. 50,000 KRW if a participant reached weight loss target of 3% from the baseline body weight at visit 2 (4 week)/ 50,000 KRW in weight loss target of 5% from the baseline body weight at visit 3 (8 week) / 100,000 KRW in weight loss target of 7% from the baseline body weight at final visit 4 (12 week)
1557068|NCT02548169|Biological|DC Vaccine + Standard of Care Chemotherapy|"4 doses of DC vaccine at 2 weeks interval, combined with either:
Standard of care neoadjuvant folinic acid, oxaliplatin, irinotecan and 5- Fluorouracil (5FU) (FOLFIRINOX) regimen alone (6 cycles)
FOLRIRINOX regimen followed by 5-FU chemoradiation or Gemcitabine Chemoradiation
Gemcitabine + nab-paclitaxel
The first vaccination will include one intradermal injection of 100 μL at 15 x106 cells/mL in the upper thigh and one subcutaneous injection of 1 mL (15 x 106 cells/mL) .
The participants will receive 3 additional subcutaneous vaccinations, each injection of 1 mL at 15 x 106 cells/mL, at 2 weeks interval, on Day 2 of study weeks 3, 5 and 7.
Participants will receive 2 booster DC vaccinations subcutaneously of 1 mL at 15x106 cells/mL."
1557069|NCT02548156|Other|Test Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
1557070|NCT02548156|Other|Reference Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
1557071|NCT02548156|Other|Comparator Dentifrice|Marketed dentifrice containing 1150ppm fluoride and 5% w/w KNO3
1557072|NCT02548156|Other|Orange Juice|Teeth will be rinsed with orange juice followed by rinsing with de-ionised water in test dentifrice and comparator dentifrice arms.
1557073|NCT02548156|Other|De-ionised water|Teeth will be rinsed with de-ionised water followed by reference dentifrice and followed by rinsing with orange juice in test dentifrice and comparator dentifrice arms.
1557074|NCT02548143|Biological|Coagulation Factor VIIa (Recombinant)|LR769
1557075|NCT02548130|Other|MELD score|introduction of MELD score
1557076|NCT02548117|Drug|Finasteride|Subjects will take 5 mg finasteride orally every day for about 2 years.
1557077|NCT02548104|Other|ACB|Before surgery, Adductor canal block (ACB): 0.25% Bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): Saline 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: Saline 15 ml
1557078|NCT02548104|Other|ACB + AFB|Before the surgery, Adductor canal block (ACB): 0.25% Bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): 0.25% Bupivacaine with 1:200,000 epinephrine 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: Saline 15 ml
1557079|NCT02548104|Other|ACB + iPACK|Before the surgery, Adductor canal block (ACB): 0.25% Bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): Saline 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
1557080|NCT02548104|Other|ACB + AFB+ iPACK|Before the surgery, Adductor canal block (ACB): 0.25% Bupivacaine with 1:200,000 epinephrine 30 ml Anterior Femoral Block (AFB): 0.25% Bupivacaine with 1:200,000 epinephrine 15 ml Interspace between the popliteal artery and the capsule of the knee (iPACK) block: 0.25% Bupivicaine with 1:200,000 epinephrine 15 ml
1996296|NCT02503774|Biological|MEDI4736 and MEDI9447|Subjects will receive MEDI9447 and MEDI4736 until disease progression
1996297|NCT02502929|Behavioral|Enhanced standard care|
1996298|NCT02502929|Behavioral|Lifestyle|
1996299|NCT02502929|Behavioral|Lifestyle Plus Medication Therapy Management|
1557087|NCT02548065|Other|Balneotherapy|"Bath with mineral water named Debole of Vetriolo at 36°C, 15 minutes for 12 consecutive days in bathtubs"
1557088|NCT02548065|Other|Placebo|Bath with Thermal tap water
1557089|NCT02548052|Drug|GSK2981278 0.03%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.03%. Approximately 200 microliters of the GSK2981278 0.03% ointment will be applied topically to the assigned test field once daily.
1557090|NCT02548052|Drug|GSK2981278 0.1%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.1%. Approximately 200 microliters of the GSK2981278 0.1% ointment will be applied topically to the assigned test field once daily.
1557091|NCT02548052|Drug|GSK2981278 0.8%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 0.8%. Approximately 200 microliters of the GSK2981278 0.8% ointment will be applied topically to the assigned test field once daily.
1557092|NCT02548052|Drug|GSK2981278 4%|GSK2981278 will be supplied as a white to off-white ointment containing GSK2981278A drug substance at a concentration of 4%. Approximately 200 microliters of the 4% ointment will be applied topically to the assigned test field once daily.
1557093|NCT02548052|Drug|Vehicle|GSK2981278 vehicle will be supplied as a white to off-white ointment containing no drug substance. Approximately 200 microliters of the vehicle will be applied topically to the assigned test field once daily.
1557094|NCT02548052|Drug|Betamethasone valerate 0.1%|Betamethasone valerate will be supplied as a cream. Approximately 200 microliters of the 0.1% betamethasone valerate cream will be applied topically to the assigned test field once daily.
1557095|NCT02548026|Behavioral|High Eating Frequency (High EF)|Free-living participants complete a 21-day high eating frequency (high EF) Phase in which they consume all daily energy at 8 eating occasions.
1557096|NCT02548026|Behavioral|Low Eating Frequency (Low EF)|Free-living participants complete a 21-day low eating frequency (low EF) Phase in which they consume all daily energy at 3 eating occasions.
1557097|NCT02548013|Other|outpatient management|patients if stable will be discharged to continue treatment at home
1557098|NCT02548013|Other|Inpatient management|patients will continue there treatment in hospital till delivery
1557099|NCT02548000|Other|Resistance training|The resistance training will be compound by 12 exercises for all body muscles, performed three times per week. The intensity of training will be measure by maximum repetitions from 12 until 8 repetitions with 2-3 series. The loads will increase for keep the maximum strength as the capacity of patients. The blood pressure and the casual glycemic will be measure before and after the training in each session. Before to start the exercises, patients will perform a warming on treadmill for 10 minutes and after the training will perform some stretching exercises for muscles groups trained.
1557100|NCT02548000|Other|Stretching control|The stretching session will be composed by stretching and joint mobilization exercises for all body muscles and will happen only one time per week.
1557101|NCT02547987|Drug|Docetaxel/Carboplatin|Docetaxel 75 mg/m2 plus Carboplatin AUC 6 IV (in the vein) on day 1 of each 21-day cycle. Number of Cycles: 6
1557102|NCT02547974|Biological|Formulation 1 (plain) NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
1557271|NCT02546791|Drug|Dasatinib|
1557103|NCT02547974|Biological|Formulation 2 (adjuvanted) NTHi/Mcat vaccine GSK3277513A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
1557104|NCT02547974|Biological|Formulation 3 (adjuvanted) NTHi/Mcat vaccine GSK3339036A|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
1557105|NCT02547974|Drug|Placebo|2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
1557106|NCT02547961|Biological|HER-2-targeting CAR T Cells infusion|HER-2-targeting CAR t cells infusion in breast cancer
1557107|NCT02547948|Biological|CD19-targeting CAR T Cells infusion|CD19-targeting 2nd generation CAR t cells infusion for refractory B cell lymphoma
1557108|NCT02547935|Drug|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks.
1557109|NCT02547935|Drug|Dapagliflozin 10mg+Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
1557110|NCT02547935|Drug|Matching Placebo for Dapagliflozin 10 mg and Saxagliptin 2.5mg|Tablets administered orally once daily for 24 weeks.
1557116|NCT02547896|Drug|Codeine + Diclofenac|The patients will receive codeine and diclofenac as pain relief medicine after the surgery
1557117|NCT02547896|Drug|Diclofenac|The patients will receive only diclofenac
1557118|NCT02547883|Drug|Cessation of statin|The intervention evaluated is the cessation of statin
1557119|NCT02547870|Drug|Rilpivirine (RPV)|Participants will receive one oral tablet of rilpivirine 25 milligram (mg) once on Day 1 of session 1.
1557120|NCT02547870|Drug|Rilpivirine Long-Acting Parenteral Formulation (RPV‐LA)|Participants will receive one intramuscular (IM) injection of rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
1557121|NCT02547870|Drug|Aged RPV‐LA|Participants will receive one intramuscular (IM) injection of aged rilpivirine long-acting parenteral formulation 600 mg once on day 1 of session 2.
1557122|NCT02547857|Other|Pelvic US|To be eligible for inclusion, a woman will have pelvic US completed as part of her ED stay. This is a non-interventional study.
1557123|NCT02547844|Drug|efavirenz + emtricitabina + tenofovir|
1557124|NCT02547844|Drug|rilpivirina + emtricitabina + tenofovir|
1557125|NCT02547831|Other|Observational approach|Patients will be placed under wait and see approach without any specific treatment
1557126|NCT02547818|Drug|ALZT-OP1a|AB polymerization inhibitor
1557127|NCT02547818|Drug|ALZT-OP1b|Anti-inflammatory
1557128|NCT02547818|Other|Placebo ALZT-OP1a|Non-active capsules
1557129|NCT02547818|Other|Placebo ALZT-OP1b|Non-active tablets
1557130|NCT02547805|Drug|ALLN-177|ALLN-177 7,500 units (5 capsules) PO TID with meals
1557131|NCT02547805|Drug|Placebo|Placebo 5 capsules PO TID with meals
1557132|NCT02547792|Biological|Influenza B Oral Vaccine Tablets|Enteric coated tablet for oral delivery
1557133|NCT02547779|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
1557134|NCT02547779|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
1557135|NCT02547766|Drug|Anakinra|Anakinra is an Interleukin-1 receptor antagonist that will be given to the patient via subcutaneous injection for a period of 14 consecutive days.
1557136|NCT02547727|Biological|rabies vaccine|Rabies vaccine is injected according to the protocol then blood would be drawn for rabies neutralizing antibody, OX-40 assay and cytokines assessment on day 0,7,14.
1557137|NCT02547714|Drug|Secukinumab (AIN457)|Secukinumab was supplied as 150 mg doses, provided in 1 mL prefilled syringes.
1557138|NCT02547701|Drug|P-3058|
1557139|NCT02547688|Device|Nasal High Flow|
1557140|NCT02547675|Drug|Rociletinib|Rociletinib will be administered to patients orally
1557141|NCT02547662|Drug|Dexamethasone|Given PO
1557142|NCT02547662|Drug|Ixazomib Citrate|Given PO
1557143|NCT02547662|Other|Laboratory Biomarker Analysis|Correlative studies
1557144|NCT02547662|Drug|Pomalidomide|Given PO
1557145|NCT02547649|Biological|V114 Formulation A|Formulation A of V114 containing pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and 6B (4 mcg) in each 0.5 mL dose
1557146|NCT02547649|Biological|V114 Formulation B|Formulation B of V114 containing pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and 6B (4 mcg) in each 0.5 mL dose
1557147|NCT02547649|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg each), and 6B (4.4 mcg) in each 0.5 mL dose.
1557148|NCT02547636|Other|Observational study|No intervention will be used in this study.
1557149|NCT02547623|Drug|Dexamethasone|depot intracameral
1557150|NCT02547623|Drug|Prednisolone|Prednisolone eye drops 1%
1557151|NCT02547610|Device|The imaging biomarkers determined by MR-PET|Combining PET and MRI, namely MR/PET, has the benefit of evaluating tissue metabolism with PET and at the same time evaluating tissue morphology/functional information with MR.
1557152|NCT02547597|Drug|Carvedilol|
1557153|NCT02547597|Drug|Atenolol|
1557155|NCT02547571|Drug|High volume PEG split-dose|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 2L of the preparation starting at 7:00 PM the day before the procedure at a rate of 240 mL every 10 minutes until completed. The second dose of 2L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the planned procedural time at a rate of 240 mL every 10 minutes until completed.
1557156|NCT02547571|Drug|Low volume PEG split-dose|Bi-PegLyte® will be provided to the subject who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure. After the first bowel movement, or if there is no bowel movement within 6 hours of taking the Bisacodyl tablets, the subject will be asked to drink 1L of the solution at a rate of 240 mL every 10 minutes until the solution is completed. The second dose of 1L of preparation will be taken the morning of the colonoscopy starting 4-5 hours prior to the procedure at a rate of 240 mL every 10 minutes. Use of antacids will not be permitted within one hour of taking bisacodyl.
1557157|NCT02547571|Drug|High volume PEG non split, day before|Colyte® or PegLyte® will be provided to the subject who will be asked to drink 4L of preparation starting at 6:00 PM the day before the procedure, at a rate of 240 mL every 10 minutes until completed.
1557158|NCT02547571|Drug|Low volume PEG non split, same day|Bi-PegLyte® will be provided to the subject, who will be asked to ingest 3 tabs of Bisacodyl 5 mg (total 15 mg) at 2:00 PM the day before the procedure and will drink 2L of preparation the morning of the colonoscopy starting 4 hours prior to the procedure at a rate of 240 mL every 10 minutes, until completed. Use of antacids will not be permitted within one hour of taking Bisacodyl.
1557159|NCT02547571|Other|Clear liquid diet|
1557160|NCT02547571|Other|Low residue diet|
1557161|NCT02547571|Other|Early colonoscopy (stratified)|"Early appointments: 7:30 AM to 10h30 AM"
1557162|NCT02547571|Other|Later colonoscopy (stratified)|"Later appointments: 10:30 AM to 4:30 PM."
1557163|NCT02547558|Procedure|Arterial blood gases|Measured through radial arterial catheter
1557164|NCT02547558|Procedure|Cardiac Output|Measured through bioimpedance: FloTrac pressure transducer (FloTrac sensor; Edwards Lifesciences) using the third-generation (3.01) FloTrac software for continuous CO display.
1557165|NCT02547558|Procedure|Vital signs|As measured in clinical practice
1557166|NCT02547558|Procedure|Exhaled breath|Were recorded using a pneumotachograph (CPX/D; Med Graphics, St. Paul, MN, U.S.A.).
1557167|NCT02547558|Procedure|Spirometry|In a daily calibrated spirometer.
1557168|NCT02547558|Drug|Indacaterol|Indacaterol Breezhaler@ 300 mcg (1 inhalation)
1557169|NCT02547532|Other|collection of sputum|
1557170|NCT02547519|Drug|Oral Insulin|Total of 12 months treatment; dose escalation scheme: daily treatment with 7.5 mg or placebo for 3 months; increasing to daily treatment with 22.5 mg or placebo for the following 3 months; increasing to daily treatment with 67.5 mg or placebo for the last 6 months of the treatment period.
1557171|NCT02547519|Drug|Placebo|Total of 12 months treatment; daily treatment with insulin or placebo capsules containing filling substance (microcrystalline cellulose).
1557172|NCT02547493|Biological|pneumococcal polysaccharide vaccine|Vaccination with Pneumo23 on first day.
1557173|NCT02547493|Biological|pneumococcal conjugate vaccine|Patients are vaccinated with Prevenar13 on the first day, and with Pneumo23 two months later
1557174|NCT02547493|Drug|Abatacept|Abatacept started on frst day
1557175|NCT02547480|Device|TACE with irinotecan loaded LifePearl|Arterial embolization will be performed through lobar infusion and using a microcatheter. LifePearl microspheres of 200 µm will be used as preferred beads. They will be loaded with the appropriate dose of irinotecan hydrochloride injectable solution, mixed with the contrast media and distributed to the targeted lobe. The targeted dose is 100 mg of irinotecan per lobe treated, meaning that when treated unilobarly at baseline the total dose received will be 100 mg ( all in one lobe) and in during bilobar treatment, 200 mg in both lobes.
1557176|NCT02547467|Other|epidemiologic study|There is no intervention as it is a pure observational study for epidemiologic survey.
1557177|NCT02547454|Drug|Methoxy polyethylene glycol-epoetin beta|
1557178|NCT02547441|Drug|Omiganan|Topical gel
1557179|NCT02547441|Drug|Vehicle|Vehicle Gel
1557180|NCT02547428|Drug|CTN SR|Participants will receive CTN SR tablets in a 100-mg dose strength, designed for twice-daily (BID) oral (PO) administration.
1557181|NCT02547428|Drug|Placebo|Participants will receive CTN SR matching placebo tablets, orally twice daily, titrated in the same manner as CTN SR to protect the blind.
1557182|NCT02547415|Other|questionnaires and psychological testing|"Child/adolescent and parents interview and consultation with both a physician and a psychologist for a somatic and pain indicators assessment within an usual setting.
Then, parents and child or adolescent are interviewed separately using different psychological instruments with only a psychologist:
Psychological (cognitive and projective evaluation) : Intellectual Quotient, mental flexibility, projective evaluation with Rorschach and Thematic Apperception Test, parents and children attachment questionnaires
Psychopathological: anxiety and depression questionnaires, psychiatric disorders evaluation, quality of life, life events questionnaires, family functioning interview."
1557183|NCT02547402|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
1557184|NCT02547402|Drug|pravastatin|It is statin medicine used to lower cholesterol and triglycerides in the blood.
1557185|NCT02547402|Drug|Vytorin® (combination of simvastatin and ezetimibe)|It lowers bad cholesterol in the blood, and raises good cholesterol
1557186|NCT02547389|Behavioral|Community support group|
1557187|NCT02547389|Other|Printed material Supported|
1557188|NCT02547363|Drug|LEO 43204 gel|
1557189|NCT02547363|Drug|Vehicle gel|
1557190|NCT02547350|Drug|pharmorubicin or pirarubicin|pharmorubicin 50mg pirarubicin 30mg
1557191|NCT02547324|Radiation|Slump sitting|Patients are asked to sit slumped on the chair as much as possible without leaning forwards, and place you hands below your thighs.
1557192|NCT02547324|Radiation|Forward bending|Patients are asked to stand with both feet placed together, hands behind their heads, and bend forward in this position as much as possible without falling
1557193|NCT02547311|Behavioral|Team Clinic|
1557194|NCT02547298|Procedure|Hydrodistension|Patients who are already scheduled to have a gynecologic, urologic or uro-gynecologic procedure involving cystoscopy if consented will have hydrodistension performed
1557196|NCT02547285|Other|Shoes characteristics|A single parameter of shoe vary for each test (Different insole, heel height, stem length ...)
1557197|NCT02547272|Procedure|Nasal and rectal bacterial samples|Bacterial nasal and rectal samples at admission and one weekly for the presence of S Aureus
1557198|NCT02547259|Procedure|pain words test|"words to painful sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer will need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
1557199|NCT02547259|Procedure|negative words test|"words to negative sense will be shown on a screen, one at a time for 5 seconds. Patient or healthy volunteer need to retain them. Then these same words, mixed with others that patient/healthy volunteer will not learn, will again be displayed on the computer screen one at a time for 5 seconds. Upon the occurrence of a word, patient/healthy volunteer must press the 'L' key if they think they have learned the word or the D key on the keyboard if they feel that they have not learned this word."
1557200|NCT02547246|Device|rTMS session|One session of rTMS at a frequency of 10 Hz during 20 minutes
1557201|NCT02547246|Device|rTMS Placebo (SHAM)|One session of placebo (SHAM) rTMS during 20 minutes
1557202|NCT02547233|Drug|LEO 43204 gel|
1557203|NCT02547233|Drug|Vehicle gel|
1557204|NCT02547220|Biological|Cinryze®|7 doses of study drug over 13 days
1557205|NCT02547220|Drug|Placebo|7 doses of placebo over 13 days
1557206|NCT02547181|Behavioral|Behavioral Modification|Patient will be provided with tensor bandage and instructed on specific behaviors to prevent movement of the injured part of the hand.
1557207|NCT02547181|Behavioral|Splint|fibreglass splint
1557208|NCT02547168|Device|iRhythm ZIO XT patch|The iRhythm ZIO XT patch is an ECG monitor that has to be worn by study participants. It will be used to track any incidence of atrial fibrillation.
1557209|NCT02547155|Procedure|Spinal anesthesia|8-12.5 mg of bupivacaine will be administered for spinal anesthesia
1557210|NCT02547155|Procedure|General anesthesia|propofol induction, in combination with a muscle relaxant and inhalational gas
1557211|NCT02547142|Other|Early Palliative Care|Metastatic esophageal cancer patients that receive early palliative care along with standard oncological care
1557212|NCT02547129|Device|Static Antibiotic Spacers surgical implant|Joint spacer for treatment of joint infection
1557213|NCT02547129|Device|Articulating Antibiotic Spacer surgical implant|Joint spacer for treatment of joint infection
1557214|NCT02547116|Drug|Rifampin|
1557215|NCT02547103|Other|Chlorhexidine gluconate-soaked cloths|
1557216|NCT02547103|Other|Normal saline|
1557217|NCT02547103|Other|mupirocin ointment|
1557218|NCT02547090|Procedure|The use of two attending surgeons during posterior spinal fusion|Patients in the experimental group received posterior spinal fusion with two attending surgeons. Patients in the control group received posterior spinal fusion with one attending surgeon and one first assist, which could be a resident, PA, or nurse.
1557219|NCT02547077|Procedure|Wound Closure with 2-octylcyanoacrylate|
1557220|NCT02547077|Procedure|Wound Closure with 5-0 Fast Absorbing Gut Sutures|
1557221|NCT02547064|Procedure|Glidescope guided intubation|
1557222|NCT02547064|Device|GlideScope®|
1557224|NCT02547038|Drug|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg twice daily, bismuth subcitrate 120 mg four times daily, and tetracycline 500 mg four times daily, and metronidazole 250 mg four times daily for 14 days
1557225|NCT02547038|Drug|(panto+amox+clar+metr)+(panto+amox)|a 7-day quadruple regimen with pantoprazole 40 mg twice daily, amoxicillin 1 g twice daily, clarithromycin 500 mg twice daily, and metronidazole 500 mg twice daily, followed by a 7-day dual regimen with pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily
1557226|NCT02547025|Drug|rabeprazole+3 antibiotics|(rabeprazole 20 mg q.d.s. and three effective antibiotics) for 14 days.
1557227|NCT02547025|Drug|rabeprazole+bismuth+2 antibiotics|(rabeprazole 20 mg q.d.s., bismuth subcitrate 120 mg q.d.s. and all the effective antibiotics) for 14 days.
1557228|NCT02547025|Drug|rabeprazole+amox+tetr+levo|(rabeprazole 20 mg q.d.s, amoxicillin 500 mg q.d.s., tetracycline 500 mg q.d.s. and levofloxacin 500 mg o.d.) for 14 days.
1557231|NCT02546999|Drug|botox|The agent will be given only once at point zero in the time scheme for the project.
1557232|NCT02546999|Drug|placebo|The agent will be given only once at point zero in the time scheme for the project.
1557233|NCT02546986|Drug|CC-486|Each cycle will be 21 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-14 of each 21-day cycle.
1557234|NCT02546986|Drug|Pembrolizumab|Each cycle will be 21 days. Pembrolizumab will be administered as a 30-minute IV infusion on day 1 of each 21-day cycle.
1557235|NCT02546986|Drug|Placebo|Each cycle will be 21 days. Placebo will be administered orally daily on days 1-14 of each 21-day cycle.
1557236|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 4)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 4) as an intramuscular (i.m) injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the DRC). The ExPEC4V doses contain polysaccharide antigen (in microgram [mcg]) from the ExPEC serotypes O1A, O2, O6A, and O25B.
1557237|NCT02546960|Biological|ExPEC4V (4 : 4 : 4 : 8)|Participants will receive single vaccination of ExPEC4V dose (4 : 4 : 4 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the DRC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
1557272|NCT02546778|Device|Dermosux RF|The radio frequency was used for 20 min in the abdomen and flanks, once per week for 7 weeks.
1557273|NCT02546765|Drug|IV acetaminophen & IV propofol|use of IV tylenol and IV propofol for pain and sedation (respectively)
1557238|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 8)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 8) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the DRC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
1557239|NCT02546960|Biological|ExPEC4V (8 : 8 : 8 : 16)|Participants will receive single vaccination of ExPEC4V dose (8 : 8 : 8 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the DRC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
1557240|NCT02546960|Biological|ExPEC4V (16 : 16 : 16 : 16)|Participants will receive single vaccination of ExPEC4V dose (16 : 16 : 16 : 16) as an i.m injection into deltoid muscle in part 1 (age groups >=18 to <50 years and >=50 years) and part 2 (based on review of safety data by the DRC). The ExPEC4V doses contain polysaccharide antigen (in mcg) from the ExPEC serotypes O1A, O2, O6A, and O25B.
1557241|NCT02546960|Drug|Placebo|Participants will receive matching placebo (Tris-buffered saline) to ExPEC4V.
1557242|NCT02546947|Other|Train of four monitoring|with an end point of one or two response at orbicularis oculi to TOF stimulation
1557243|NCT02546934|Drug|ABX, cisplatin|ABX 125 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
1557244|NCT02546934|Drug|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
1557245|NCT02546921|Drug|MOv18 IgE|The allocated dose of MOv18 IgE will be diluted in 250 mL saline and administered by IV infusion once weekly for six weeks.
1557247|NCT02546895|Other|chart review|"The patient charts will be reviewed to determine pretreatment characteristics, treatment-related adverse events, time to progression and overall survival.
Behavioral: Questionnaires Completion of 3 questionnaires 1 week before treatment(radiotherapy or chemotherapy) begins or been hospitalized for surgery the same day, 1 week after the end of treatment(expected average of 8 weeks), and again 3 months after treatment. It may take about 30 minutes to complete the questionnaires each time."
1557248|NCT02546882|Biological|stromal vascular fraction|1million stromal vascular fraction was resuspended in 1 ml saline and transplanted for 1 cm2 area.
1557249|NCT02546882|Drug|saline|1 ml saline was injected for 1 cm2 area.
1557250|NCT02546869|Drug|Lebrikizumab|Lebrikizumab will be administered SC using PFS, q4w up to Week 12.
1557251|NCT02546869|Device|Prefilled Syringes|
1557252|NCT02546856|Other|HF nurse up-titration|"Up-titration of Beta-Blocker (BB) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 European Society of Cardiology (ESC) HF guidelines with cardiologist prescription and support"
1557253|NCT02546856|Other|HF nurse up-titration|"Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support"
1557254|NCT02546856|Other|HF nurse up-titration|"Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support"
1557255|NCT02546856|Other|HF nurse up-titration|"Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines with cardiologist prescription and support"
1557256|NCT02546856|Other|HF cardiologist up-titration|"Up-titration of Beta-Blocker (BB) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines"
1557257|NCT02546856|Other|HF cardiologist up-titration|"Up-titration of Angiotensin Converting Enzyme Inhibitor (ACEI) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines"
1557258|NCT02546856|Other|HF cardiologist up-titration|"Up-titration of Angiotensin II Receptor Blocker (ARB) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines"
1557259|NCT02546856|Other|HF cardiologist up-titration|"Up-titration of Mineralocorticoid Receptor Antagonist (MRA) in Heart Failure  De Novo EF≤ 40% Patients, following a protocol based on 2012 ESC HF guidelines"
1557260|NCT02546843|Drug|Rocuronium|rocuronium 0.6 mg/kg intravenously (1 mg/kg only in a case of a rapid sequence induction)
1557261|NCT02546843|Drug|Cisatracurium|cisatracurium 0.15mg/kg intravenously
1557262|NCT02546843|Drug|Nonspecific Neuromuscular Blockade reversal|neostigmine 0.03 mg/kg and atropine 0.02 mg/kg intravenously
1557263|NCT02546843|Drug|Specific Neuromuscular Blockade reversal|Sugammadex intravenously aimed to reverse the neuromuscular blockade.According to neuromuscular blockade monitoring: at TOF - (train-of-four) 2m g/kg, if TOF 0 and PTC(post-tetanic count) 0-1 4mg/kg of sugammadex will be administered
1557264|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - rocuronium|repeated boluses of rocuronium 0.3 mg/kg will be administered to maintain the muscular blockage - according to TOF 0, PTC 0-1
1557265|NCT02546843|Drug|maintaining the depth of neuromuscular blockade - cisatracurium|repeated boluses of cisatracurium 0.03 mg/kg will be administered to maintain the muscular blockage - according to TOFmaintaining of muscular relaxation TOF 1
1557266|NCT02546830|Device|FreeO2 v2.2 active|"Automatic adjustment of oxygen through the Free O2 device.
FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
1557267|NCT02546830|Device|FreeO2 v2.2 with manual oxygenation|"Manual adjustment of oxygen without the assistance of the FreeO2 device.
Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
1557268|NCT02546804|Procedure|HOT SALT WATER|25ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
1557269|NCT02546804|Procedure|POTASSIUM PERMANGANATE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
1557270|NCT02546804|Procedure|CHLORHEXIDINE|10ml mouthwash will be rinsed for 60sec), twice daily for 60 days The subjects then will be recalled for measuring the data's after 2weeks, 4weeks, 6weeks and 8weeks.
1557274|NCT02546765|Drug|IV acetaminophen & IV dexmedetomidine|use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)
1557275|NCT02546765|Drug|IV propofol & placebo|use of IV propofol for sedation and morphine, the drug of choice for cardiac pain
1557276|NCT02546765|Drug|IV dexmedetomidine & placebo|use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
1557277|NCT02546752|Other|THEO|THEO is interactive patient engagement software that runs on an iPad tablet platform (developed by Noble.MD). THEO is the intervention in this study.
1557278|NCT02546739|Biological|Anti-CD19-CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
1557279|NCT02546726|Behavioral|Heat & Aerobic Training (HEAT)|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise steam-room therapy. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
1557280|NCT02546726|Behavioral|Exercise Only|Participants receive 42 supervised 50-minute, moderately intensive (50-75% max HR) aerobic exercise sessions (3 times per week), followed by 11-20 minutes of post-exercise sitting in the lobby of the fitness facility. Participants are encouraged to exercise on their own (e.g., 1-2 days of aerobic and/or resistance training) but to refrain from unsupervised steam-room sessions or any other form of heat therapy.
1557281|NCT02546713|Other|Abutment with concave subcritical contour|Implants will be restored with abutments with concave configuration of the subcritical contour
1557282|NCT02546713|Other|Abutment with convex subcritical contour|Implants will be restored with abutments with convex configuration of the subcritical contour
1557283|NCT02546700|Drug|Lebrikizumab|Lebrikizumab 125 milligrams (mg) will be administered subcutaneously once in every 4 weeks.
1557284|NCT02546700|Drug|Placebo|Matching placebo will be administered subcutaneously once in every 4 weeks.
1557285|NCT02546687|Other|Venous blood sampling|"The investigators will take 1-2 cc of venous blood from proximal part of stomach before gastric tube creation and in the same time the investigators will take same amount of venous blood from peripheral vein. This blood will be analyzed in the ABL800 FLEX blood gas analyzer as a routine blood analyses that making by anesthesiologist during the operation. This blood sampling the investigators will make again after 15-30 minutes from the same area in proximal stomach (after creation of gastric tube) and peripheral vein just before anastomosis creation. The investigators will measure components of venous blood gases (O2, pH, CO2, lactate) from the area of future anastomosis before construction of gastric tube and just before creation of anastomosis ( after 15-30 minutes), compare the results of this analysis with systemic venous blood."
1557293|NCT02546648|Drug|Tranexamic Acid|
1557294|NCT02546648|Drug|Tranexamic Acid Placebo|
1557295|NCT02546648|Drug|Rosuvastatin or matching placebo|Subjects who are not on a statin will also be randomized to Rosuvastatin or Rosuvastatin placebo. 40mg preoperatively, followed by 20mg postoperatively (4-6 hours after surgical close) and 20mg/day for 30 days postoperatively.
1557296|NCT02546635|Drug|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
1557297|NCT02546635|Drug|AX-024.HCl|AX-024.HCl will be administered as per the protocol defined frequency and dose level
1557300|NCT02546609|Drug|Sildenafil 1.0 mg|Sildenafil 1.0 mg
1557301|NCT02546609|Drug|Metformin|500 mg Metformin BID
1557302|NCT02546609|Drug|Leucine|1000 mg Leucine BID
1557303|NCT02546609|Drug|Placebo|Placebo
1557304|NCT02546609|Drug|Sildenafil Citrate 0.5 mg|Sildenafil 0.5 mg BID
1557305|NCT02546596|Device|Electro-hyperthermia|Addition of electro-hyperthermia to radiation
1557308|NCT02546570|Drug|Oxytocin|See arm/group descriptions for dosage amount and procedure.
1557309|NCT02546570|Drug|Placebo|See arm/group descriptions for dosage amount and procedure.
1557310|NCT02546557|Procedure|Coronary Artery Bypass Graft surgery|
1557312|NCT02546531|Biological|Defactinib|
1557313|NCT02546531|Biological|Pembrolizumab|
1557314|NCT02546531|Drug|Gemcitabine|
1557315|NCT02546518|Device|Moniri Otovent|Please see Arm Description.
1557316|NCT02546518|Device|Tympanostomy tube in the ear drum|Insertion of tympanostomy tube/Grommet in the ear drums.
1557317|NCT02546505|Other|Front-of-pack nutrition labeling|Introduction of a Front-of-pack nutrition label (5-CNL) on selected categories of foods.
1557318|NCT02546505|Other|Consumer information|Information specifically targeting nutritional information and explaining the 5-CNL is presented to the subject (this information will consist in a concept shown to respondents before the shopping session).
1557319|NCT02546492|Drug|Acthar gel|Administration of the study drug in addition to the current maintenance immunosuppressive agents
1557356|NCT02546180|Other|Standard preoperative education|Standard preoperative education will be provided by the surgeon, physician extender and paramedical staff in the clinic.
1557357|NCT02546167|Biological|CART-BCMA|
1557358|NCT02546154|Drug|10% Iron Isomaltoside 1000|Standard clinical practice and following the Monofer® label (SPC)
1557359|NCT02546141|Other|skimmed milk (UHT)|
1557360|NCT02546141|Other|skimmed milk (pasteurized)|
1557320|NCT02546466|Procedure|Functional Star-shape taping (SFT)|For the SFT procedure, four tapes will be applied in the form of an elastic ''I'' with the aim of facilitating muscle activation. The taping will be applied when the participant is in a seated position. The taping will be positioned covering the entire lumbar region and lower part of the thoracic region (T11, T12), and placed first at the center and then on the ends (Castro-Sanchez et al. 2012).The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
1557321|NCT02546466|Procedure|Sham Functional Taping (Sham-FT)|For the Sham-FT procedure, a single bandage 20 cm in length was positioned horizontally, passing through the spinous process of the second lumbar vertebra (Castro-Sanchez et al. 2012). The tension of the taping was 25%, this protocol being recommended by the Kinesio taping manual to facilitate muscle activation (Castro-Sanchez et al. 2012; Kase et al. 2003). The participant will remain for on week with FT.
1557322|NCT02546466|Behavioral|Minimal Intervention Strategy (MIS)|The MIS group will receive an educational and counseling booklet (The Back Book) as recommend by Dupeyron et al. (2011) containing information about the low back pain clinical features, risk factors and prognosis, fear avoidance beliefs, how to deal with an acute pain crisis, the early resumption of normal or vocational activities, even when still experiencing pain, and the importance of improvement in functional activity levels and posture, not just pain relief (Delitto et al. 2012). Participants from this group will not receive FT intervention and the investigator will encourage participants to not receive any kind of treatment during the one month epoch after the initial assessment. They will be followed by one of the investigators that will make phone calls to clarify doubts and reinforce the counseling.
1557323|NCT02546453|Biological|Tumoral specific genetic alterations|A buccal swab and a blood sample will be used at the diagnostic to identify the specific genetic alterations of tumoral cells.
1557324|NCT02546453|Biological|Tumoral specific genetic alterations|Collection of blood (maximum 9 samples of 3 to 5 ml), bone marrow (maximum 3 samples of 3 to 5 ml) and cerebral spinal fluid (maximum 3 samples 500µl to 1ml).
1557325|NCT02546440|Drug|dimethylfumarate|dose escalation from 30 mg/d to 720 mg/d over 9 weeks following a preset design in psoriasis treatment in Germany, oral medication in tablet form. Treatment will last 24 weeks or until unacceptable side effects occur
1557326|NCT02546427|Radiation|Helical TomoTherapy (HT)|
1557327|NCT02546427|Radiation|CyberKnife SBRT|
1557328|NCT02546427|Radiation|Permanent Prostate Implant (PPI)|
1557329|NCT02546427|Radiation|HDR brachytherapy|
1557330|NCT02546414|Other|Platelet count/spleen diameter ratio|Platelet count were evaluated by complete blood count, and ultrasound was used to measure the longest diameter of the spleen.The platelet count/spleen diameter ratio was calculated
1557331|NCT02546401|Drug|Insulin Aspart|Injection of Insulin Aspart before or after meals
1557332|NCT02546388|Drug|Indium-111 Pentreotide|
1557333|NCT02546375|Drug|Bosutinib|Bosutinib 100mg film-coated tablets; Bosutinib 500mg film-coated tablets Dosage as prescribed at treating institution; (observational study)
1557334|NCT02546362|Device|Cefaly|
1557335|NCT02546349|Drug|fluticasone/salmeterol, tiotropium|In group (either high or low eNO), patients will be randomized to receive either 2 puffs of fluticasone/salmeterol 250/25 mcg/puff twice daily or 2 inhalations of tiotropium respimat 2.5 mcg/inhalation once daily for 12 weeks.
1557336|NCT02546336|Device|Ultrasound-Guided Cooled Radiofrequency Hip Denervation|Light neuroleptic anesthesia and skin preparation will be performed. Under Ultrasound guidance, an active probe will be inserted. Sensory and motor stimulation will be administered. Anteroposterior fluoroscopy image will be recorded. Lesioning of articular branches of femoral and obturator nerves via radiofrequency will be performed after lidocaine injection. WOMAC, EQ-5D and SF-12 questionnaires will be used for measuring outcomes postoperatively.
1557337|NCT02546323|Drug|Rosuvastatin|20mg tablets, orally once daily for the duration of the 104-week treatment period
1557338|NCT02546323|Drug|Placebo|Matching placebo tablets, orally once daily for the duration of the 104-week treatment period.
1557339|NCT02546310|Drug|HTL0009936|
1557340|NCT02546310|Drug|HTL0009936 matching placebo|
1557341|NCT02546297|Drug|Symbicort|drug are used for six months，and then exchanged in the 7th month
1557342|NCT02546297|Drug|Tiotropium Bromide|drug are used for six months，and then exchanged in the 7th month
1557343|NCT02546284|Drug|lenzilumab|
1557344|NCT02546271|Behavioral|GPS|
1557345|NCT02546258|Device|A Fungal Nail Treatment|treats the signs of mild fungal nail infections
1557346|NCT02546245|Behavioral|Heroes of Knowledge|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
1557347|NCT02546245|Behavioral|Attention/Time Control Game|Participants will play their assigned game(s) on a tablet computer for 1-1.5 hours, 2-3 times per week for 2-4 weeks (to accumulate 6-8 hours of gameplay).
1557348|NCT02546232|Drug|Carboplatin|Chemotherapy
1557349|NCT02546232|Drug|Paclitaxel|Chemotherapy
1557350|NCT02546219|Other|Eosinophil isolation and characterization.|Peripheral blood and esophageal biopsies will be obtained from study subjects for further analysis of eosinophils integrin profiles.
1557351|NCT02546206|Dietary Supplement|Probiotic Yoghurt|Probiotic yoghurt consumption
1557352|NCT02546206|Dietary Supplement|Natural Yoghurt|Natural yoghurt consumption
1557353|NCT02546193|Device|Foley catheter|The Foley catheter is a device used to achieve cervical ripening at the start of labor induction. It is a single balloon catheter placed transcervically by a provider, either digitally or using a speculum for visualization. The balloon is placed above the internal os but below the fetal head, amniotic membranes, and placenta and is inflated. In this study, it will be inflated with 60 cc of normal saline and taped to the patient's thigh for traction. Over several hours, the balloon gradually dilates the cervix. The catheter is typically expulsed when the cervix is 3-4 centimeters.
1557354|NCT02546193|Drug|Misoprostol|Misoprostol is a prostaglandin E1 analogue that is used for cervical ripening during labor induction. A 25 microgram tablet is placed in the vagina by a provider. A new 25 mcg tablet can be used vaginally every 4 hours for up to 6 total doses.
1557355|NCT02546180|Other|Viewing YouTube videos|The on-line patient education program will highlight postoperative care.
1557361|NCT02546141|Other|skimmed yoghurt|
1557363|NCT02546141|Other|non-homogenized full-fat milk (pasteurized)|
1557364|NCT02546141|Other|full-fat cheese (semi-matured)|
1557365|NCT02546141|Other|whey protein|
1557366|NCT02546141|Other|micellar casein|
1557367|NCT02546128|Device|Extra-Corporeal Shockwave Therapy (ESWT)|The use of ESWT from a commercially available machine at approved settings already in routine clinical use
1557368|NCT02546128|Other|structured rehabilitation programme|a structured and standardised rehabilitation programme specific to the tendon in question - already in routine clinical use
1557369|NCT02546115|Device|tension night splint|this is the use of a commercially available tension night splint device, to be worn by the patient
1557370|NCT02546115|Other|standard practice - a structured rehabilitation programme|this is the standardised structured rehabilitation programme of home exercises given to patients, with supporting literature, and instructions on how to progress the regime themselves
1557371|NCT02546102|Biological|ICT-107|Autologous dendritic cells pulsed with peptides associated with tumor antigens
1557372|NCT02546102|Biological|Placebo|
1557373|NCT02546089|Other|Autologous Blood Injection|ultrasound-guided autologous blood injection procedure
1557374|NCT02546089|Other|Structured rehabilitation programme|(this intervention is given to patients in both arms of the study) - a standardised structured rehabilitation programme of home exercises that the patient is instructed on how to start, and how to progress during the study period
1557375|NCT02546089|Other|dry needling injection|(this intervention is given to patients in both arms of the study) - ultrasound-guided dry needling injection performed under ultrasound guidance
1557376|NCT02546076|Device|Laser coagulation|The treatment consists in performing Er:Yag laser with long-pulsed Erbium mode
1557377|NCT02546076|Device|Laser w/o coagulation|The treatment consists in performing Er:Yag laser with true pulsed Erbium mode
1557378|NCT02546063|Other|Smartphone App|The GoCARB system is a smartphone application designed to support type 1 diabetic patients with carbohydrate counting by providing automatic, accurate and near real-time CHO estimation for non-packed foods.
1557379|NCT02546050|Drug|Metformin|
1557380|NCT02546037|Device|FX100 dialyzer|comparison of dialyzers
1557381|NCT02546037|Device|SOLACEA 21H|comparison of dialyzers
1557382|NCT02546024|Drug|Standard care|Standard care according to Care Pathway for depression by Mental Health of Older Adults Services Clinical Academic Group of the South London and Maudsley NHS Foundation Mental Health Trust
1557383|NCT02546011|Other|Fetal Heart Rate Monitor|Standard of care, not part of research
1557384|NCT02545998|Other|Telehealthcare|Telephone consultation plus e-mail with attached PAAP and video link
1557385|NCT02545985|Device|Prolim stent deployment|Prolim stent was implanted in patients who signed the informed consent and met the exclusion and inclusion criteria.
1557386|NCT02545972|Drug|tacrolimus extended release|daily dosing of tacrolimus
1557387|NCT02545959|Drug|Rituximab IT|CSF injection of intrathecal rituximab (20mg)
1557388|NCT02545959|Drug|methylprednisolone IV|blood infusion of methylprednisolone IV (120mg)
1557389|NCT02545959|Drug|Rituximab IV|Blood infusion of rituximab (375mg/m2)
1557390|NCT02545946|Device|vessel loop|using the vessel loop to hold the place of the surgical wound that is made during I&D
1557391|NCT02545946|Other|traditional I&D with or without packing|abscess will be drained with a traditional I&D with or without packing (as deemed appropriate by ER doctor)
1557392|NCT02545933|Drug|Prasugrel|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
1557393|NCT02545933|Drug|Vorapaxar|Vorapaxar will be administered at the dose of 2.5mg once daily
1557394|NCT02545933|Drug|Aspirin|Aspirin will be administered at the dose of 81mg once daily
1557395|NCT02545933|Drug|Ticagrelor|Patients will continue treatment with either prasugrel (10mg once daily) or ticagrelor (90mg twice/daily)
1557396|NCT02545920|Other|no intervention|observational study
1557397|NCT02545907|Drug|Carfilzomib|Lyophilized carfilzomib for injection reconstituted with water to a final concentration of 2 mg/mL.
1557398|NCT02545907|Drug|Thalidomide|50mg capsule.
1557399|NCT02545907|Drug|Dexamethasone|2mg tablet.
1557400|NCT02545894|Behavioral|Cognitive therapy|"The tasks are:
visually tracking a picture as it moves across the computer screen
pressing a button every time a picture is seen on the screen
pressing a button every time a specific picture is seen on the screen
Pressing a button every time a specific sound is heard
Matching objects to a picture
Matching gestures to objects
Matching two connected objects
Sorting objects by categories
Matching sounds to objects
Complete the category and odd on out with objects
Choosing target objects by pointing
Choosing objects to complete the category by pointing"
1557401|NCT02545881|Other|Magnetic Resonance Imaging (MRI)|MRI of the prostate prior to prostatectomy
1557402|NCT02545868|Biological|23-PPV|The 23-PPV vaccine will be given as a 0.5-milliliter (mL) intramuscular (IM) injection in the deltoid muscle on Day 112 (Group A) or Day 28 (Group B).
1557403|NCT02545868|Biological|13-PCV Booster|The 13-PCV booster will be given as an IM injection in the deltoid muscle on Day 140 (select participants in Group A).
1557404|NCT02545868|Biological|Influenza Vaccine|The influenza vaccine will be given as an IM injection in the deltoid muscle at any time between Day 85 and Day 144 (select participants in Group A) or any time between Day 1 and Day 85 (Group B).
1557405|NCT02545868|Biological|KLH|KLH will be given as a 1-mg subcutaneous (SC) injection on Days 84, 112, and 140 (Group A) or Days 1, 28, and 56 (Group B).
1557406|NCT02545868|Drug|OCR|OCR will be given as an intravenous (IV) infusion at a dose of 300 or 600 mg according to the specifications described in the corresponding Group A and Group B arms.
1557407|NCT02545868|Biological|TT Vaccine|The TT-containing adsorbed vaccine will be given as a 0.5-mL IM injection in the deltoid muscle on Day 85 (Group A) or Day 1 (Group B).
1557408|NCT02545855|Device|High-flow nasal cannula therapy|All subjects will receive nocturnal high-flow nasal cannula therapy with the myAIRVO2®, in addition to their current HOT. The myAIRVO2® is used for at least 4 hours per day with flow rates in the range 30-40 L/min. The investigator can adjust the nocturnal oxygen flow rates to keep SpO2 88-92% stably. If the subjects report discomfort, the investigator can adjust the flow rates in the range at least 20 L/min.
1557409|NCT02545855|Device|Home oxygen therapy (HOT)|All subjects will continue their current HOT which kept original usage conditions at the time of enrollment throughout the entire duration of the study regardless of treatment arm assignment.
1557410|NCT02545842|Drug|INSULIN GLARGINE|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1557411|NCT02545829|Drug|HIP1302|Tenofovir 292mg
1557412|NCT02545829|Drug|HGP1406|Tenofovir 300mg
1557413|NCT02545816|Device|Bispectral index (BIS) EEG monitoring|The Bispectral Index (BIS) EEG monitor is a simplified EEG monitoring device which was originally designed to monitor the depth of hypnosis during general anesthesia. It does this by analyzing changes in the processed electroencephalogram (EEG) which occur with the hypnotic state and creating a measure (or index) indicative of these changes. A number between 0 and 100 is derived, with values above 70 associated with an awake state. The monitor also provides a single channel EEG, an electromyogram (EMG) and an index of signal quality (SQI), all in real time.
1557414|NCT02545803|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation
1557415|NCT02545790|Procedure|Echocardiogram|2 and 3-dimensional echocardiographic images will be obtained to estimate LV mass, ejection fraction (Simpson's biplane), fractional shortening (M mode Doppler), and pulse-wave estimated pressure gradient across the outflow obstruction.
1557416|NCT02545790|Biological|Serology|protein analysis targeting several potential protein biomarkers for cardiac remodeling and hypertrophy as well as targeting known miRNAs.
1557417|NCT02545777|Drug|diclofenac sodium enteric-coated|
1557418|NCT02545777|Drug|Oral medicine of tonifying spleen and descending turbid|Ingredient:cortex phellodendrine, rhizoma atractylodis, radix cyathula, coix seed, cotton Bi Xie,rhizoma smilacis glabrae
1557419|NCT02545777|Drug|Steeping and washing medicine of descending turbid and clearing heat|Ingredient: turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica,garden balsam stem, pseudobulbus cremastrae seu pleiones
1557420|NCT02545777|Drug|Wet wrapping medicine of descending turbid and clearing heat|Ingredient:turmeric, rhubarb, cortex phellodendrine, rhizoma atractylodis, rhizoma arisaema, angelica dahurica, pseudobulbus cremastrae seu pleiones.
1557421|NCT02545764|Other|Strength and neuromuscular exercise programme|12 weeks strength and neuromuscular exercise programme for the lower extremity
1557422|NCT02545751|Radiation|Stereotactic Body Radiation Therapy|SBRT is given during combined therapy to one of the metastatic lesions, 25Gy in 5 fractions (5Gy per fraction) over one week, conformally to maximally spare normal tissue or organ.
1557423|NCT02545751|Drug|Thymalfasin|Thymalfasin treatment is given twice a week with an interval of 3-4 days each week for a total of 8 weeks. Tumor response is evaluated by assessing clinical and CT/MRI response for all the measurable metastatic sites.
1557424|NCT02545738|Drug|Liraglutide|active treatment
1557425|NCT02545738|Drug|placebo|placebo
1557426|NCT02545725|Other|Questionnaire on Quality of Life|The patients were asked to complete a questionnaire on Quality of Life
1557427|NCT02545712|Other|Exposure to ethanol|The drug source(s) and amount administered daily are noted.
1557428|NCT02545712|Other|Exposure to propylene glycol|The drug source(s) and amount administered daily are noted.
1557429|NCT02545712|Other|Exposure to benzyl alcohol|The drug source(s) and amount administered daily are noted.
1557430|NCT02545712|Other|Exposure to acesulfam potassium|The drug source(s) and amount administered daily are noted.
1557431|NCT02545712|Other|Exposure to aspartame|The drug source(s) and amount administered daily are noted.
1557432|NCT02545712|Other|Exposure to glycerol|The drug source(s) and amount administered daily are noted.
1557433|NCT02545712|Other|Exposure to sorbitol|The drug source(s) and amount administered daily are noted.
1557434|NCT02545712|Other|Exposure to methyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
1557435|NCT02545712|Other|Exposure to propanyl-p-hydroxybenzoate|The drug source(s) and amount administered daily are noted.
1557436|NCT02545712|Other|Exposure to polysorbate-80|The drug source(s) and amount administered daily are noted.
1557437|NCT02545699|Device|G-EYE™ Colonoscopy|G-EYE™ Colonoscopy
1557438|NCT02545699|Device|Standard Colonoscopy|Standard Colonoscopy
1557443|NCT02545673|Behavioral|Enhanced linkage to care|
1557444|NCT02545673|Behavioral|Standard-of-care plus|
1557445|NCT02545660|Other|QLF Image|At each of the three visits tooth brushing advice will be given. The participants in the intervention group will be shown the QLFD images or white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
1557489|NCT02545270|Procedure|Level of pneumoperitoneum 11-8-5 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (11-8-5 mmHg) during desufflation.
1557446|NCT02545660|Other|White Light Image|At each of the three visits tooth brushing advice will be given. The participants in the white light image group will be shown white light images.Standardized oral hygiene reinforcement shall be given based on the images. The oral hygiene instruction will focus on the areas of the teeth which require greater emphasis, as shown by the images. Thus the patients should benefit from this detailed instruction.
1557447|NCT02545647|Device|BRYGB|65 patients undergo a banded RYGB
1557448|NCT02545634|Dietary Supplement|L. helveticus R0052 and B. longum R0175|See arm descriptions for intervention description.
1557449|NCT02545634|Other|Placebo|
1557450|NCT02545621|Other|RAGE TXNIP Inflammasome axis|
1557451|NCT02545608|Device|Restylane Vital|
1557452|NCT02545595|Drug|Sugammadex 1 mg/kg|
1557453|NCT02545595|Drug|Sugammadex 2 mg/kg|
1557454|NCT02545595|Drug|Sugammadex 4 mg/kg|
1557455|NCT02545582|Device|VITARIA System|Implantable vagus nerve stimulator
1557456|NCT02545569|Device|hearing aid (MD class IIa) - ITE, BTE, RIC|
1557457|NCT02545556|Procedure|HepaSphere combined with cryosurgery|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）combined with cryosurgery
1557458|NCT02545543|Biological|Seqirus QIV|"Seqirus QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
1557459|NCT02545543|Biological|Comparator QIV|"The US-licensed Comparator QIV, inactivated, split-virion, thimerosal-free, quadrivalent influenza vaccine, administered as a 0.5 mL intramuscular dose. The vaccine is presented in a prefilled needleless syringe.
The subject's age and influenza vaccination history determines the dosing regimen (a single vaccination or a 2-vaccination regimen administered 28 days apart) according to the most recent US ACIP guidelines for seasonal influenza vaccination."
1557460|NCT02545530|Drug|transdermal clonidine|2.5mg/patch per week
1557461|NCT02545517|Biological|Purified Chick-Embryo Cell Rabies Vaccine|1 booster dose of 1.0 mL of Purified Chick-Embryo Cell Rabies Vaccine intramuscular (IM)
1557462|NCT02545504|Drug|Andecaliximab|800 mg administered intravenously on Days 1 and 15 of each 28-day treatment cycle
1557463|NCT02545504|Drug|Placebo|Administered intravenously on Days 1 and 15 of each treatment cycle
1557464|NCT02545504|Drug|Leucovorin|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
1557465|NCT02545504|Drug|5-fluorouracil|Administered intravenously per standard of care on Days 1 and 15 of each treatment cycle
1557466|NCT02545504|Drug|Oxaliplatin|Administered intravenously per standard of care on Days 1 and 15 of Cycles 1 to 6
1557467|NCT02545491|Behavioral|Care for Child Development (CCD) program|The Care for Child Development (CCD) Program developed by World Health Organization (WHO) /UNICEF provides recommendations for stimulating child development through play and communication activities.
1557468|NCT02545491|Behavioral|Infant and Young Child feeding training by World Vision|Training on breastfeeding benefits, solid introduction and food safety
1557469|NCT02545465|Drug|Riociguat (Adempas, BAY63-2521)|As per the treating physicians discretion
1557470|NCT02545452|Drug|Anastrozole / Levonorgestrel (BAY98-7196)|Release rate of the IVR: 1050 μg/d ATZ + 40 μg/d LNG
1557471|NCT02545452|Drug|Gyno-Daktarin|400 mg miconazole nitrate per day for 3 consecutive days
1557472|NCT02545452|Drug|Sobelin vaginal creme|100 mg clindamycin 2-dihydrogen phosphat per day for 3 consecutive days
1557473|NCT02545452|Drug|Patentex oval|75 mg Nonoxynol-9 per day for 3 consecutive days
1557474|NCT02545452|Other|Tampon|
1557475|NCT02545439|Drug|ALKS 5461|Sublingual tablet given alone and in conjunction with Rifampin
1557476|NCT02545426|Other|Change the dialysate calcium concentration|The dialysate calcium concentration will be changed according to the prior concentration
1557477|NCT02545413|Drug|Probiotic VSL#3|
1557478|NCT02545413|Drug|Placebo|
1557479|NCT02545374|Other|Telemedicine|
1557480|NCT02545374|Other|Control|
1557481|NCT02545361|Drug|KAHR-102|"KAHR-102 is a dual signaling protein (DSP).KAHR-102 will be administrated subcutaneously. In Stage 1A, 3 KAHR-102 SC injections will continue to be given every 14 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.
In Stage 1B and Stage 2, subjects will be administered 3 KAHR-102 SC injections given every 7 days with an interval of 28 days after 1st cycle and 14 days after 2nd cycle and following cycles.
Planned doses for stage 1:
Cohort A: 2µg/kg Cohort B: 4 µg/kg Cohort C: 8 µg/kg Cohort D: 12 µg/kg Each cohort will only begin its first administration of KAHR-102 SC injection when the cohort preceding it will not meet criteria for a DLT (at least 7 days)."
1557482|NCT02545348|Procedure|Sentinel Lymph Node Biopsy|First, the detection of the sentinel node will be preformed at the beginning of the surgery. Differents detection methods are use and the efficacy of each will be recorded. Second, dissection and extraction of the sentinel node will be performed, to send it to the frozen section examination. Third, other lymph node could be removed if the surgeon evaluate that it is feasible and necessary. In this group, the false negative rate will be also evaluate.
1557483|NCT02545322|Radiation|Follow-up CT scans during week 3 and week 5 of treatment|Scheduled follow-up planning CT scan and re-optimisation of the intensity modulation radiation therapy (IMRT)-based radiotherapy Treatment plan. Dosimetric Evaluation and assessment of morphologic changes.
1557484|NCT02545296|Other|In-vitro Diagnostics|Ex-vivo performed diagnostic blood based test.
1996349|NCT02496689|Biological|asfotase alfa|Patients participating in this program will receive 6 mg/kg/week asfotase alfa (administered at a dosage regimen of 1 mg/kg 6 times per week or 2 mg/kg 3 times per week at the discretion of the Investigator) by SC injection. During follow-up visits, dose adjustments to account for changes in body weight will be made. Additional incremental dose adjustments for lack of efficacy or safety reasons may also be decided upon by the Investigator in consultation with the Alexion Medical Monitor.
1557488|NCT02545270|Procedure|Level of pneumoperitoneum 12-9-6 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (12-9-6 mmHg) during desufflation.
1557490|NCT02545270|Procedure|Level of pneumoperitoneum 10-7-4 mmHg|Elective laparoscopic inguinal hernia procedures will be used to make video-recordings under 3 different levels of pneumoperitoneum (10-7-4 mmHg) during desufflation.
1557491|NCT02545257|Other|Coordinated medication management model|Stage I: a prescription review conducted by community pharmacists Stage II: practical nurse-administered Drug-related Problem Risk Assessment Tool Stage III: Required health care action based on the result of the DRP -Risk Assessment Tool
1557492|NCT02545244|Dietary Supplement|Black Tea|0.5% Black Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
1557493|NCT02545244|Dietary Supplement|Green Tea|0.5% Green Tea 5mL used as Mouthwash twice daily for two weeks after scaling of teeth.
1557494|NCT02545244|Drug|0.12% Chlorhexidine Mouthwash.|5mL of 0.12% Chlorhexidine used as mouthwash twice daily for two weeks after scaling of teeth.
1557495|NCT02545231|Drug|Pitavastatin 1mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
1557496|NCT02545231|Drug|Pitavastatin 4mg|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
1557497|NCT02545231|Drug|Placebo|To compare different doses of statins on atherosclerosis progression and neointimal hyperplasia
1557498|NCT02545218|Procedure|Perineorraphy|Surgery for improperly healed perineal tear
1557499|NCT02545218|Other|Pelvic floor exercise|Pelvic floor exercise tutored by physio therapist.
1557500|NCT02545205|Device|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed, 1 session/day, 4 days/week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective walking time with HAL).
1557501|NCT02545205|Other|Conventional gait training|The conventional gait training is performed according to current best evidence based practice and may include over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support and training of gait function in activities of daily living.
1557502|NCT02545192|Device|Low Field Magnetic Stimulation|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1000Hz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. A fully detailed description of the electromagnetic field distribution and waveform has been presented in the IDE submission to the FDA (and determined to be a non-significant risk device).
1557503|NCT02545179|Other|web-based daily care training|12 week interactive web based caring training education
1557504|NCT02545153|Drug|Tisseel, Baxter (Aprotinin and Fibrinogen)|After introducton of t tube and closure of the incision with running sutures, fibrin sealant is applied on the incision.
1557505|NCT02545153|Drug|Control|No fibrin sealant applied
1557506|NCT02545140|Other|No intervention|
1557509|NCT02545114|Drug|Tolvaptan|Use of Tolvaptan to treat SIADH-induced hyponatremia in selected patients with acute neurological injuries.
1557510|NCT02545088|Device|Hybrid Assistive Limb (HAL)|Intensive gait training with Hybrid Assistive Limb (HAL) is performed 1 session/day, 3 days/week for 6 weeks and each session will not exceed 60 min of effective walking time with HAL. In addition, each session will include conventional gait training that will not exceed 30 min effective training time.
1557511|NCT02545088|Other|1st control group|Conventional gait training performed 1 session/day, 3 days/week for 6 weeks that will not exceed 1h 30 min effective training time.
1557512|NCT02545088|Other|2nd control group|The 2nd control group will not receive an intervention.
1557513|NCT02545075|Drug|Ipilimumab|
1557514|NCT02545075|Drug|Dacarbazine|
1557515|NCT02545062|Other|MoCa test|The MoCa test is actually used for the screening of Mild Cognitive Impairment . It is a one page 30 points test that can be done in 10 minutes in a routine annual visit to the Diabetes Clinic. The MoCa assesses several cognitive domains, and it is available in hebrew language.
1557518|NCT02545036|Other|Traditional Chinese Medicine (TCM) daycare model|Traditional Chinese Medical (TCM) daycare model provides multiple approaches of traditional Chinese medical treatment, including 5 tones of Chinese music, massage for meridians and collaterals, acupuncture, and patient education. The treatment course is one time a week, for 12 weeks (12 treatments in total).
1557519|NCT02545023|Other|Quality-of-Life Assessment|Complete an in-person one-on-one interview
1557520|NCT02545023|Other|Questionnaire Administration|Complete the demographics questionnaire, SCNS-34, SF-36, and Lifestyle Needs Survey
1557521|NCT02545010|Drug|Paclitaxel|"All patients will receive weekly paclitaxel at a pre specified dose of 80 mg/m2, 70 mg/m2, 60mg/m2 or 50 mg/m2 via intravenous infusion according to institution specific standard practices.
Cycles of chemotherapy will be administered weekly without interruption on Days 1,8,15,22,29,36 for a total of 6 weekly cycles in combination with LDWART. Post treatment assessments will be conducted starting Day 43.
Patients will then continue chemotherapy off trial protocol with weekly paclitaxel without concurrent LDWART starting Day 50 till disease progression, intolerable toxicity, patient refusal or deemed inappropriate to continue treatment by treating physician."
1557522|NCT02545010|Radiation|LDWART (Low Dose Whole Abdominal Radiation Therapy)|"LDWART will be given at 60 cGy fractions, twice daily for two days, with a minimum of 4 hours inter fraction interval, starting on day 1 of each cycle of weekly paclitaxel for 6 weeks.
LDWART will not be administered if doses of weekly paclitaxel are withheld for any reason since it functions as a chemosensitizer. LDWART will be administered together weekly paclitaxel immediately at point of recovery from toxicity and patient is deemed to be able to continue with treatment by investigator."
1557523|NCT02544997|Drug|Poziotinib|12mg P.O. for 2wks q21days
1557524|NCT02544984|Drug|Azithromycin|Patients will receive azithromycin at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
1557525|NCT02544984|Drug|placebo|Patients will receive placebo at a dose of 5 mg/kg to be given once a day on Monday, Wednesday, and Friday. The dosage will not be adjusted if a new weight is obtained during the trial period.
1557526|NCT02544971|Behavioral|Neurofeedback|Neurofeedback is based on the learned change in a particular neural signal or a combination of neural signals when feedback and reward of these signals are repeatedly presented to the organism. Thus, individuals learn to modulate their neural activity through a closed NF loop.
1557527|NCT02544971|Other|Control|Treatment as usual
1557528|NCT02544958|Device|Er:YAG laser|Er:YAG laser treats enlarged pores on both sides of the face for 4 treatments of 1 month interval.
1557529|NCT02544945|Other|3D printed bolus|Using the Cat Scan for treatment planning, a 3D plastic shell can be produced which is shaped exactly to the shape of the patient's chest wall. This shell will act as bolus - the substance that is placed on the skin during chest wall radiotherapy. The bolus allows the right dose of radiotherapy to get to the skin and the underlying chest wall.
1557530|NCT02544945|Other|Standard bolus|A standard 5mm-thick piece of rubber is placed on the patient's chest wall
1557531|NCT02544932|Drug|dabigatran|After randomization, patients of this group was will be treated to dabigatran 110mg or 150mg twice a day for 24months
1557532|NCT02544932|Drug|ribaroxaban|After randomization, patients of this group was will be treated to ribaroxaban 20mg once a day for 24months.
1557533|NCT02544932|Drug|Warfarin|After randomization, patients of this group was will be treated to warfarin and controlled by INR 2-3 for 24months.
1557534|NCT02544919|Drug|SMOF lipid (SMOFLIPID) pre treatment|Experimental Arm
1557535|NCT02544906|Drug|Propofol|Infusion of propofol to prevent emergence agitation in liver transplanta recipients
1557536|NCT02544906|Drug|dexmedetomedine|Infusion of dexmedetomedine to prevent emergence agitation in liver transplanta recipients
1557537|NCT02544893|Drug|bupivacaine|21 ml 0.5 %bupivacaine is applied paravertebral space
1557538|NCT02544893|Drug|dexmedetomidin|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied paravertebral space
1557539|NCT02544893|Drug|serum physiologic|21 ml serum physiologic is applied paravertebral space
1557540|NCT02544880|Drug|Tadalafil|"Tadalafil or placebo will be administered once daily orally (po) for 19 days in conjunction with the first vaccination course (pre-surgery). Thereafter, Tadalafil or placebo will be administered for 14 days in conjunction with each subsequent vaccination course (Courses 2, 3 and 4), except for the last vaccination at which no Tadalafil will be administered (Course 5).
The dose range of Tadalafil will be normalized to the patient's body weight, as follows:
Weight (lb) --> Daily oral dose of Tadalafil (mg)
≤ 140 lbs --> 10 mg
>140 lbs and ≤ 230 lbs --> 15 mg
>230 lbs --> 20 mg"
1557541|NCT02544880|Biological|Anti-MUC1 Vaccine|"The Anti-MUC1 vaccine or placebo will be administered on Day 7 of Course 1, Day 10 of Courses 2, 3 and 4, and on Day 1 (of 1) of Course 5 (5-7 months after Course 4, day 10 and 11-13 months after Surgery).
The anti-MUC1 vaccine will be administered intramuscularly (IM) in the right upper limb of each patient."
1557542|NCT02544880|Biological|Anti-Influenza Vaccine|"The Anti-Influenza vaccine (Flublok®) or placebo will be administered on Day 7 of Course 1, Day 10 of Courses 2, 3 and 4, and Day 1 (of 1) of Course 5 (5-7 months after Course 4, day 10 and 11-13 months after Surgery).
The anti-influenza vaccine will be administered intramuscularly (IM) in the left upper limb of each patient."
1557543|NCT02544880|Other|Tadalafil Placebo|Placebo for Tadalafil.
1557544|NCT02544880|Other|Vaccine Placebo|Placebo for Anti-MUC1 and Anti-Influenza vaccines.
1557545|NCT02544880|Procedure|Peripheral Blood Collection|Approximately 50 mL (PBMC and Sera) collected prior to planned (initial) Tadalafil/Placebo administration (or ≤ 21-days prior to intended surgery), on day of intended Surgery, On day 10 (day of the vaccination) of Course 2, 3, 4 and 5, two weeks after Course 4, two weeks after Course 5.
1557546|NCT02544880|Procedure|DTH Skin Test|Delayed-type hypersensitivity (DTH) skin testing for candida antigen and MUC1 will be performed prior to planned (initial) Tadalafil/Placebo administration (or ≤ 21-days prior to intended Surgery), on the day of surgery, and two weeks after Course 4 for patients receiving study therapy.
1557547|NCT02544880|Procedure|Tumor specimen collection|Tumor specimen collection from surgical resection of recurrent/second primary tumor, after Course 1 of Tadalafil/Placebo administration
1557548|NCT02544867|Behavioral|Sedentary behavior|Participants were randomized to either reduce their total sitting time or increase sit-to-stand transitions. Information was provided in person, through written materials and by emails and phone calls in both conditions. Both groups received written educational materials on the dangers of excessive sitting and reviewed a generic day to illustrate how many sitting opportunities individuals face each day. During each session, the health educator also discussed the benefits of sitting less or increasing sit-to-stand transitions (depending on study condition) and brainstormed potential barriers to implementing the new behavior as well as strategies to overcome these barriers.
1557549|NCT02544854|Drug|Propofol|"Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:
First 15 minutes: 15 mg/kg/min
16 to 30 minutes: 13 mg/kg/min
31 to 60 minutes: 11 mg/kg/min
61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.
Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:
5, 15 and 25 minutes of starting infusion,
1, 3, 5, 7, 9 and 12 minutes of bolus and,
5, 25, 60 and 120 minutes of infusion ended."
1557550|NCT02544841|Behavioral|Safer Sex Intervention (SSI)|Safer Sex Intervention (SSI) is an in-person, individual-level, clinic-based intervention implemented by a female health educator trained in the intervention. It is intended to be implemented in one initial session lasting 30-50 minutes and three booster sessions lasting 10-30 minutes at one, three, and six month intervals.
1557551|NCT02544841|Behavioral|Female Sexual Health|Female Sexual Health is a knowledge-based intervention that intends to provide information on how STIs are contracted, the consequences of contracting STIs, and how to prevent them. Female Sexual Health includes the information-only component of the first session of SSI and baseline exposure to a health educator but does not include booster sessions.
1557552|NCT02544828|Drug|Iron Sucrose 200mg|Iron Sucrose 200mg is administered after anesthesia induction.
1557553|NCT02544828|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
1557554|NCT02544815|Drug|Digoxin|Digoxin 0.25 mg pills
1557555|NCT02544815|Drug|Placebo|Placebo pills
1557556|NCT02544802|Drug|Adipose-Derived Mesenchymal Stem Cells|
1557684|NCT02543853|Other|veres needle entry|veres needle entry to provide pneumoperitoneum
1557712|NCT02543658|Drug|The traditional treatment|the traditional treatments according to associated guidelines
1557557|NCT02544789|Drug|Clofarabine|Clofarabine (Betta Pharmaceuticals Co., Ltd, Zhejiang, China) was administered intravenously at 52 mg/m2 over 2 hours daily for 5 consecutive days. During the first two induction cycles, patients who did not achieve an objective response were taken off the study, and responsive patients continued to receive consolidation for a maximum 11 cycles if non-hematological toxicity was grade 2 or less.
1557558|NCT02544776|Drug|Clomifene citrate ( clomid 50 mg )|
1557559|NCT02544776|Drug|Amlodipine|
1557563|NCT02544737|Drug|Apatinib|Patients with metastatic lesions of esophageal cancer after been treated with surgery or definitive chemoradiotherapy receiving Apatinib (850mg) daily over 4 weeks.
1557564|NCT02544724|Biological|NM-IL-12|Single SC administration of NM-IL-12 will be administered at least 48 hours after completion of the last chemotherapy dose of each cycle
1557565|NCT02544711|Device|Patient specific instrument|The proposed innovation consists in using patient specific instrument (PSI) for tumor resection. It is compounded of a preoperative assistance to plan the surgery and an intraoperative assistance to reproduce the preoperative planning.
1557566|NCT02544711|Procedure|Conventional surgical treatment|The conventional treatment is planned on two-dimensional images (CT and MRI).
1557567|NCT02544698|Biological|One dose of PCV13a vaccine|
1557568|NCT02544698|Biological|One dose of PCV13a vaccine|
1557569|NCT02544698|Biological|three doses of PCV13a vaccine|
1557570|NCT02544698|Biological|three doses of PCV13a vaccine|
1557571|NCT02544685|Dietary Supplement|Probio-Fix Inum|"Dose of Probio-Fix Inum: 1 capsule daily first 14 days + 1 capsule twice daily for the rest of prophylaxis duration
Probio-Fix Inum: each capsule contains 2.7 billion lyophilized probiotic bacteria Lactobacillus rhamnosus GG, LGG, American Type Culture Collection (ATCC) 53103 and Bifidobacterium animalis subspecies. lactis BB-12 Chr. Hansen Beneo Synergy 1: oligofructose-enriched inulin"
1557572|NCT02544685|Dietary Supplement|Beneo Synergy 1|Dose of Beneo Synergy 1: depends on the age of the patient (full dose variation: 0,2g/100ml milk formula - 12g/daily), gradually increased as tolerated by the patient every 2-3 days in first 8-12 days
1557573|NCT02544685|Other|Placebo|Same dosage regimen as active drugs
1557574|NCT02544672|Device|Myoelectric Elbow-Wrist-Hand orthosis|An arm orthosis that uses myoelectric signals to control the level of mechanical assistance provided to a user's elbow and hand in order to overcome upper limb weakness or paralysis and achieve functional tasks.
1557575|NCT02544659|Drug|pamidronate disodium|the patients will be administered pamidronate disodium 1 mg/kg, IV, QD, for 3 days, and every 3 month (up to month 6)
1557576|NCT02544646|Other|Changes in Ocular rigidity|measured before the operation and 28±7 days after the operation
1557577|NCT02544633|Drug|MGCD265|MGCD265 is a small molecule multi-targeted receptor tyrosine kinase inhibitor
1557578|NCT02544620|Other|Does fulfil of discharge criteria on the day of the surgery|
1557579|NCT02544620|Other|Does not fulfil of discharge criteria on the day of the surgery|
1557580|NCT02544607|Drug|Ketamine|Ketamine 0.5mg/kg over 40 minutes IV
1557581|NCT02544594|Device|Extra-Corporal Life Support (ECLS)|Extra-Corporal Life Support (ECLS) (from Sorin)
1557582|NCT02544581|Other|Soberlink combined with aftercare services|Soberlink Alcohol Breath Analyzer System combined with aftercare services
1557583|NCT02544568|Other|Meals|At 4 different occasions the participants will receive meals with the same amount of calories and different composition of fat, protein, carbohydrate and fiber.The composition of the meals is: Low-fat / high-carbohydrate meal (18 E% proteins, 28 E% fat and 54% carbohydrates), high-fat meal (18 E% protein, 50 E% fat and 31 E% carbohydrate), high-protein meal (40 E% protein, 30 E% fat and 30 E% carbohydrates) and low-fat / high-carbohydrate and high fiber (18 E% proteins, 28 E% fat and 54 E% carbohydrates and 15 gram of fibers).
1557584|NCT02544555|Procedure|Intentional intraluminal approach|Interventionist performs intentional intraluminal approach to angioplasty. Dedicated 018 and 014 guidewire for Chronic Total Occlusion (CTO) lesion and Chronic Total Occlusion (CTO) devices such as Truepath or Frontrunner can be chosen by interventionist. Methods to confirm successful intraluminal wiring will be selected, as follows; 1) examination for guidewire position in different two angles on fluoroscopy or 2) intravascular ultrasound (IVUS) exam after predilation is performed with an appropriately sized angioplasty balloon. After the guidewire is passed through the lumen of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed, if the case that optimal ballooning response is not obtained.
1557585|NCT02544555|Procedure|Intentional subintimal approach|Interventionist performs Intentional subintimal approach to angioplasty. 035 Terumo guidewires will be used. If 035 Terumo guidewire is not able to re-entry, Re-entry devices such as Offroad or OUTBACK catheter can be used. After the guidewire is passed through the subintimal layer of target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Provisional stenting should be performed; the case that optimal ballooning response is not obtained should be enrolled. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
1557586|NCT02544542|Device|Rectum cooling system|
1557587|NCT02544542|Device|Hyper-hypothermia blanket|
1557588|NCT02544529|Drug|Echothiophate Iodide 0.03% Ophthalmic Solution|one drop to each eye three times per week for 18 weeks
1557589|NCT02544529|Drug|Carboxymethylcellulose Sodium (0.5%)|one drop to each eye three times per week for 18 weeks
1557590|NCT02544516|Other|cognitive tasks + PANSS+ IQ|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971), IQ test (IQ: PM38, Raven, 1960), and the PANSS (Positive and Negative Syndrome Scale, Kay et al., 1987
1557591|NCT02544516|Other|cognitive tasks|Patients will have cognitive tasks: reaction time (Alert TEA, Zimmermann and Fimm, 2005), Edinburgh laterality questionnaire (Oldfield, 1971),
1557596|NCT02544477|Device|High-flow Nasal Cannula Oxygen (HFNCO)|
1557597|NCT02544477|Device|Conventional oxygen treatment|
1557598|NCT02544464|Drug|ferric carboxymaltose 1000 mg|Ferric carboxymaltose is administered after anesthesia induction
1557599|NCT02544464|Drug|placebo|placebo (normal saline) is administered after anesthesia induction
1557600|NCT02544451|Drug|Ivacaftor|
1557601|NCT02544451|Drug|Lumacaftor|
1557602|NCT02544438|Drug|Astarabine (BST-236)|"Cohort # Astarabine Dose Number of Patients
0.5 gr/m2 (0.3 age>50) 3
1.5 gr/m2(0.8age>50) 3
3.0 gr/m2(1.5 age>50) 3
4.5 gr/m2(2.3 age>50) 6
4.5 gr/m2 (no age limit) 3 up to 6
6 gr/m2 (no age limit) 3 up to 6
Total number of patients: up to 24"
1557603|NCT02544425|Drug|Etoposide|Subjects will receive Etoposide 100 mg/m2 + 5% dextrose in water 500 mL intravenous over 90 mins D1-3 of VIDL chemotherapy. After that, Etoposide will be administered 375mg/m2 D1-2 with G-colony stimulating factor (10 ug/kg) injection in step of Peripheral Blood Stem Cell Collection. Also It will be administered 400mg/m2 on conditioning regimen.
1557604|NCT02544425|Drug|Ifosfamide|It will be administered1.2g/m2 + 5% dextrose in water 100 mL intravenous over 1 hr D1-3
1557605|NCT02544425|Drug|Dexamethasone|It will be administered 40mg/day PO or IV D1-3
1557606|NCT02544425|Drug|L-asparaginase|It will be administered 4000 IU/m2 intramuscular D8, 10, 12, 14, 16, 18, 20
1557607|NCT02544425|Drug|Busulfan|"Conditioning regimen for autologous stem cell transplantation:
Busulfan 3.2 mg/kg D -8, -7, -6"
1557608|NCT02544425|Drug|Melphalan|"Conditioning regimen for autologous stem cell transplantation:
Melphalan 70 mg/m2 D -3, -2"
1557609|NCT02544412|Behavioral|novel mindfulness-based well-being training|
1557610|NCT02544399|Other|3D CT scan|Measure of bone micro-architecture by 3D micro-tomography
1557611|NCT02544386|Procedure|MRI and 3D CT scan|Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
1557612|NCT02544373|Other|PAP therapy|Positive airway pressure treatment for obstructive sleep apnea
1557613|NCT02544360|Behavioral|Photoaging mobile app promoting poster campaign.|"Schools in this arm receive a photoaging mobile app promoting poster campaign revealing the effects of smoking on the users face via a self portrait (i.e. a selfie)."
1557614|NCT02544347|Other|gingival crevicular fluid|gingival crevicular fluid was collected
1557615|NCT02544347|Other|non-surgical periodontal treatment|scaling and root planing were performed
1557619|NCT02544321|Drug|Bromocriptine|
1557620|NCT02544321|Other|Placebo|
1557621|NCT02544308|Drug|Lenalidomide|Experimental Arm
1557622|NCT02544308|Drug|Dexamethasone|Experimental Arm
1557623|NCT02544308|Other|No further treatment|Comparator Arm
1557624|NCT02544295|Behavioral|Clinical interview|
1557625|NCT02544295|Behavioral|Virtual reality task|
1557626|NCT02544282|Drug|Levobupivacaine|Pecs II Block
1557627|NCT02544282|Drug|NaCl 0.9%|Placebo Pecs II block
1557628|NCT02544282|Drug|Sevoflurane|General Anesthesia
1557629|NCT02544282|Drug|Propofol|General Anesthesia
1557630|NCT02544282|Drug|Sufentanil|General Anesthesia
1557631|NCT02544282|Drug|Atracurium|General Anesthesia
1557632|NCT02544282|Drug|Paracetamol|Pain Relief
1557633|NCT02544282|Drug|Tramadol|Pain Relief
1557634|NCT02544282|Drug|Piritramide|Pain Relief
1557635|NCT02544269|Procedure|Ropivacaine|Lumbosacral plexus blockade with ropivacaine.
1557636|NCT02544269|Procedure|Bupivacaine|Regional anesthesia with bupivacaine titrated to the lowest effective dose
1557637|NCT02544256|Procedure|Mild hypothermia|Mild hypothermia during surgical clipping of brain aneurysm will be reached by cooling to body temperature 33,8° C - 34,8° and this temperature maintained up to the end of microcirculation measurement after aneurysm clipping.
1557638|NCT02544243|Drug|Vinorelbine|
1557639|NCT02544243|Drug|Gemcitabine|
1557640|NCT02544243|Drug|Cisplatin|
1557641|NCT02544217|Drug|KH176|
1557642|NCT02544217|Drug|placebo|
1557643|NCT02544204|Biological|JVS-100|Biological/Vaccine: JVS-100 Intramuscular Injection
1557644|NCT02544204|Biological|Placebo|Biological/Vaccine: Placebo Intramuscular Injection
1557711|NCT02543658|Drug|Neostigmine|Intramuscular injection of neostigmine
1557645|NCT02544191|Drug|GnRHa/ hCG/ hMG|GnRHa was injected subcutaneously at a dose of 3.6mg every 28 days for 5 months. After 2 months from the first GnRHa injection, all subjects were treated with hCG at a dose of 2000 IU once a week for 3 months. After 3 months from the first Goserelin injection, all subjects were treated with hMG at a dose of 150 IU every 3 days for 2 months.
1557646|NCT02544178|Radiation|brain radiotherapy|effect of cerebral radiotherapy on neurocognitive state
1557647|NCT02544165|Dietary Supplement|caffeine intake|The subjects of this group should intake 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
1557648|NCT02544165|Other|cigarette smoking|The subjects of this group should smoke one cigarette after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
1557649|NCT02544165|Other|Caffeine intake and Cigarette smoking|The subjects of this group should smoke one cigarette and should consume 100 mg of caffeine after the first measurement of haemodynamic parameters with the Finometer device and after the first measurement of the advanced glycation end products accumulation with AgeReader device.
1557650|NCT02544152|Drug|Lubiprostone|8 mcg administered orally twice daily (BID)
1557651|NCT02544152|Drug|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
1557652|NCT02544139|Other|Chagas Detect Plus|
1557653|NCT02544126|Device|Electronic Self-Management Resource Training for Mental Health|eSMART-MH is a software, which is set in a 3-D virtual primary care office environment in which a subject interacts with avatar virtual healthcare staff (medical receptionist, medical assistant, providers, and a virtual healthcare coach). The avatars are programed to behave like humans. The subject moves through the 3-D virtual primary care office and encounters virtual healthcare staff and providers. The subject practices discussing depressive symptoms with avatar healthcare providers and practices self-management skills related to symptoms of depression.The subject also interacts with the health care coach. The health care coach provides the subject with real-time strategies to enhance communication with healthcare providers during their virtual office visit. Overtime, coaching is decreased to build the the subject's self-confidence. eSMART-MH will be used once a month, for three months.
1557654|NCT02544126|Behavioral|Screen-based health education|Screen-based health education will be used and cover topics like depression, nutrition, physical activity, and sleep hygiene at the same frequency as the eSMART-MH intervention, which is used once a month, for three months.
1557655|NCT02544113|Drug|Thymoglobulin|Treatment with thymoglobulin and delayed CNI post OLT
1557656|NCT02544113|Drug|Placebo|Normal transplant immunosupression
1557658|NCT02544087|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
1557659|NCT02544087|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
1557660|NCT02544087|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
1557662|NCT02544061|Biological|NM-IL-12|single 12 µg unit subcutaneous (SC) dose of NM-IL-12
1557666|NCT02543957|Procedure|Cholangioscopy|All patients will receive pre-procedural antibiotics per protocol. A blood culture will be drawn from patients prior to the procedure (before antibiotics administration), 5 minutes after the procedure and 30 minutes after the procedure. Patients will be followed up for 7 days after the procedure for fever and or sepsis.
1557673|NCT02543931|Drug|Meriva|Meriva is an enhanced-bioavailability, curcuminoid-enriched turmeric dietary supplement that is sold over the counter in the United States and other countries.
1557674|NCT02543931|Drug|placebo|Placebo capsules containing inert ingredients
1557675|NCT02543918|Drug|Ixekizumab|Administered by SQ injection
1557676|NCT02543918|Drug|Boostrix®|Administered by IM injection
1557677|NCT02543918|Drug|Pneumovax®23|Administered by IM injection
1557678|NCT02543905|Procedure|Prostate MRI and Biopsy|All men will undergo a MRI and prostate biopsy
1557681|NCT02543879|Drug|FT-1101|FT-1101 will be supplied as 5 mg, 20 mg or 100 mg capsules and will be administered per the protocol defined frequency and dose level
1557682|NCT02543866|Biological|Fecal Microbiota Transplantation|Fecal Microbiota Transplantation
1557683|NCT02543853|Other|direct trocar entry|direct trocar entry to provide pneumoperitoneum
1557685|NCT02543840|Other|Replicating Effective Programs plus External Facilitation|Packaging, training and technical assistance according to the Replicating Effective Programs model plus External Facilitation
1557686|NCT02543840|Other|Educational Materials|Dissemination of educational materials on the collaborative chronic care model for 4 or 8 months prior to cross-over to REP-F
1557687|NCT02543827|Biological|MV140|The subjects will receive daily dose of MV140 during 3 or 6 months
1557688|NCT02543827|Biological|Placebo|The subjects will receive daily dose of placebo during 3 or 6 months
1557689|NCT02543801|Drug|Liposomal Bupivacaine|Periarticular injection
1557690|NCT02543801|Drug|Ropivacaine|Periarticular injection
1557691|NCT02543801|Drug|Bupivacaine|Included as an element of the Liposomal bupivacaine intervention periarticular injection
1557692|NCT02543801|Drug|Clonidine|Included as an element of both interventions as a standard of care periarticular injection
1557693|NCT02543801|Drug|Ketorolac|Included as an element of both interventions as a standard of care periarticular injection
1557694|NCT02543801|Drug|Epinephrine|Included as an element of both interventions as a standard of care periarticular injection
1557695|NCT02543788|Procedure|• Neuro-Ophthalmological examination, Visual Acuity, Fundus, Visual Field, Color Vision, OCT, EDSS • NEI-VFQ 25 and the 10-item • VEPs, p-ERG and mf-ERG|
1557696|NCT02543775|Procedure|Preoperative and intraoperative SLN Mapping|"Patients will undergo preoperative SLN mapping, which includes an injection of a radiocolloid and lymphosinctogram and SPECT/CT. Patients will also receive an intraoperative injection of blue dye. A handheld probe will be utilized to detect radiolabelled or hot nodes and direct visualization will identify blue nodes which will be labelled Sentinel Nodes and sent to pathology for intraoperative frozen section."
1557697|NCT02543762|Procedure|Chromoendoscopy|Chromoendoscopy involves the topical application of stains to improve tissue localization and characterization of lessions during endoscopy . Chromoendoscopy has been used in patients undergoing colonoscopy, including those undergoing surveillance for chronic ulcerative colitis. Using pit pattern classifications, chromoendoscopy has a high sensitivity and specificity for differentiating neoplastic from non-neoplastic lesions
1557698|NCT02543749|Biological|DC vaccine|Autologous DC pulsed with leukemia-associated peptides+adjuvant
1557699|NCT02543736|Device|Instrumented Treadmill System|Patients will perform twice a gait and a balance analysis on an instrumented treadmill system combined to a photoelectric cell system while controls will only perform once.
1557700|NCT02543723|Behavioral|Nurse Coach Intervention|Participants randomized to the intervention 2 group will receive the MEMS, plus a tailored nurse coach component. Participants will receive a 60-minute session conducted by the nurse coach. Participants will receive weekly phone calls from the nurse coach during the first month of the intervention, and then bi-monthly follow-up calls for the remainder of treatment or 6-month follow-up period (whichever occurs first). MEMS feedback will be used to show Participants their own medication-taking behavior via the MEMS Report, to correct any misperceptions of actual adherence and to identify problem areas. The nurse coach will modify the intervention plan to address identified barriers to adherence at this time.
1557701|NCT02543723|Behavioral|MEMs Intervention|Participants will be advised to only open their pill bottles when they take their medications. Participants will also be given a MEMS diary to record unscheduled cap openings, such as those to refill the bottle, so that those unscheduled events unrelated to adherence can be removed from analysis. Participants will meet with the nurse coach during their regularly scheduled monthly oncology visits where the MEMS data will be collected. During this monthly meeting, participants in the intervention 1 group will receive feedback of their medication-taking behavior via a MEMS report.
1557702|NCT02543710|Procedure|Biomarker (ER/PR) guided lymphadenectomy|"Lymphadenectomy in the pelvis and para-aortic, will, for patients who are considered otherwise low risk (endometrioid tumours grade 1 or 2, or grade 3 with <50% myometrial infiltration (MI), with no sign of extrauterine disease), be dependent on the preoperative hormone receptor status (ER and PR).
Patients will be defined low risk when endometrioid, grade 1 or 2, or grade 3 with <50% MI, AND positive hormone receptor status for both ER AND PR. These patients will not undergo lymphadenectomy.
Patients with endometrioid tumours grade 1 or 2, or grade 3 <50% MI,, with either negative ER or PR status, are defined high risk and will undergo pelvic and para-aortic lymphadenectomy as part of their surgical procedure.
Patients will receive routine clinical follow-up for 5 years. Follow-up data will be collected for the study, focusing on survival and recurrence of disease. All patients will, as part of the study fill out validated quality of life questionnaires (QoL) at follow-up."
1557703|NCT02543710|Drug|Biomarker guided weekly taxane treatment in endometrial/ ovarian cancer|"A 5mm tissue biopsy will be analysed for stathmin level in the recurrence as well as urine and a second 5mm biopsy on termination of study participation. The second biopsy could help explain why patients have stopped responding to the treatment. Determination of stathmin level both from the tissue and the urine will take place at the pathology department. Stathmin serves as an integrated biomarker, which enables a central biomarker analysis at Haukeland university hospital. Stathmin level is defined as high with an immunohistochemical score 9 (max score). All other scores are considered low. Pre-treatment all patients undergo CT or MRI, maximum 1 month prior to treatment start.
During treatment, urine and bloods will be collected every treatment cycle (weekly basis). Imaging will take place every 8 treatment cycles. Treatment will continue until disease progression."
1557704|NCT02543697|Radiation|Adrenal venous sampling|We go trough the femoral vein with a catheter up to the adrenal vein first on the left side, then on the right side. We take blood samples and analyze cortisol, metanefrin/ normetanefrin, aldosterone both from the adrenal veins and from the peripher vein. Then we use criteria from the Majo clinic to identify if the overproduction of cortisol is uni- or bilateral.
1557705|NCT02543684|Other|ready to eat mixed meal 1|wild greens pie providing 50g of carbohydrates
1557706|NCT02543684|Other|ready to eat mixed meal 2|chicken burgers with boiled broccoli and cauliflower providing 50g of carbohydrates
1557707|NCT02543684|Other|ready to eat mixed meal 3|vegetable moussaka providing 50g of carbohydrates
1557708|NCT02543684|Other|oral glucose load|glucose load providing 50g of carbohydrates
1557709|NCT02543671|Other|vitamin D3 enriched, reduced-fat yellow cheese|60 grams of vitamin D3 enriched, reduced-fat yellow cheese provide 5.7 micrograms of vitamin D per day for 8 weeks
1557710|NCT02543671|Other|plain (non-fortified) reduced-fat yellow cheese|60 grams of plain (non-fortified), reduced-fat yellow cheese provide 0 micrograms of vitamin D per day for 8 weeks
1557713|NCT02543645|Drug|Combination of Varlilumab and Atezolizumab|"Treatment cycles are 12 weeks each with varlilumab and atezolizumab administered every 3 weeks. During the treatment phase of the study, eligible patients will receive varlilumab for up to 3 cycles (with a 4th cycle possible following discussion with the Medical Monitor). There is no limit on the number of cycles of atezolizumab. Patients may be discontinued from receiving study treatment (atezolizumab or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.
Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg, or 3 mg/kg. The dose of atezolizumab is 1200 mg.
Phase ll Dose: The planned varlilumab dose will be established from the outcome of the Phase l portion of the study. Patients will receive atezolizumab at a dose of 1200 mg."
1557714|NCT02543632|Device|Parachute Implant System|The CardioKinetix Parachute Implant partitions an enlarged ventricle into dynamic and static chambers. The static chamber is a portion of the left ventricular volume that is taken out of circulation. Stresses placed on the partitioned myocardium and the forces transmitted to the apical segment are decreased both in diastole and systole, eliminating the forces responsible for left ventricular dilation. In addition to this regional unloading, the reduction in size of the dynamic chamber results in a decrease of the myocardial stress in the normal myocardium via Laplace Law, providing a global unloading of the ventricle.
1557715|NCT02543619|Other|Injection technique|One group received Gow-Gates technique and the other group received Infra Alveolar Nerve Block technique for their failed first one anesthesia
1557716|NCT02543606|Drug|Esomelone|powder for injection/ infusion Esomeprazole 40mg
1557717|NCT02543606|Drug|Nexium|powder for injection/ infusion Esomeprazole 40mg
1557718|NCT02543593|Device|Active tDCS or Sham tDCS|tDCS is a painless technique which consists in applying low direct-current through electrodes (one electrode serving as an anode, the other as a cathode) placed on the scalp to target the cerebral cortex. In patients with chronic pain, the anode is commonly placed over the motor cortex (M1) (Valeriani et al., 1999).
1557719|NCT02543580|Other|electroacupuncture|comparison of effects of single acupoint or two combination of acupoints stimulated with electroacupuncture
1557720|NCT02543567|Biological|Ad26.ZEBOV 5*10^10 viral particles (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 5*10^10 viral particles on Day 1
1557721|NCT02543567|Biological|Ad26.ZEBOV 2*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 2*10^10 viral particles on Day 1
1557722|NCT02543567|Biological|Ad26.ZEBOV 0.8*10^10 (vp)|Ad26.ZEBOV, live, replication incompetent vaccine, sterile suspension for intramuscular (IM) injection of 0.8*10^10 viral particles on Day 1
1557723|NCT02543567|Biological|MVA‐BN‐Filo 1*10^8 Infectious Unit [Inf. U.]|MVA‐BN‐Filo‐ live replication incompetent vaccine, IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57
1557724|NCT02543567|Biological|MVA‐BN‐Filo 5*10^7 Inf. U.|MVA‐BN‐Filo‐ live replication incompetent vaccine, IM injection of 5*10^7 Inf. U. once on Day 57
1557725|NCT02543567|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline administered once on Day 1 and Day 57
1557726|NCT02543554|Procedure|lung protective ventilation|Lung protective ventilation strategy, which aims to deliver safe tidal volumes, appropriate PEEP, limit plateau pressure, and limit hyperoxia.
1557727|NCT02543541|Behavioral|Structured palliative care|Supportive care for the patient and caregiver will be provided by the outpatient palliative care team which includes clinicians with specialized palliative care training, social workers, spiritual care specialists and mental health clinical nurse specialist.
1557728|NCT02543541|Behavioral|Standard supportive care|Supportive care for the patient and caregiver will be provided by the treating oncologist.
1557729|NCT02543528|Device|EC.0.2 (investigational material)|One fresh pair of contact lenses worn continuously in 6 nights / 7 days wear cycles for 6 months of total wear.
1557730|NCT02543528|Device|EC.1.2 (investigational material)|One fresh pair of contact lenses worn continuously in 6 nights / 7 days wear cycles for 6 months of total wear.
1557731|NCT02543528|Device|EC.2.2 (investigational material)|One fresh pair of contact lenses worn continuously in 6 nights / 7 days wear cycles for 6 months of total wear.
1557732|NCT02543528|Device|Etafilcon A (approved contact lens material)|One fresh pair of contact lenses worn continuously in 6 nights / 7 days wear cycles for 6 months of total wear.
1557733|NCT02543515|Procedure|office hysteroscopy|diagnostic procedure
1557734|NCT02543502|Procedure|periodontal treatment|treatment of periodontal cleaning
1557735|NCT02543489|Device|Flex IM rod|
1557736|NCT02543463|Device|Trident X3 Insert with Navigation system|
1557737|NCT02543463|Device|Trident X3 Insert with conventional instrumentation|
1557738|NCT02543450|Other|Cardiovascular and task-oriented training|
1557739|NCT02543450|Other|Upper limb strength training program|
1557740|NCT02543437|Device|Trident Acetabular X3 Insert|
1557742|NCT02543411|Drug|Lidocaine 1%|"Intravenous administration as bolus of lidocaine 1.5 mg/kg before sedation and infusion of lidocaine 2 mg/kg/hr during sedation.
Sedation with fentanyl and propofol"
1557743|NCT02543411|Drug|Normal saline|"Intravenous administration as bolus of normal saline 0.15 mL/kg before sedation and infusion of normal saline 0.2 mL/kg/hr during sedation.
Sedation with fentanyl and propofol"
1557745|NCT02543385|Drug|S Ketamine|S+ketamine will be given in group I only in the doses of 0.25mg/kg (iv bolus) before induction along with midazolam and 0. 25 mg/kg (iv bolus) 20 minutes prior to extubation
1557746|NCT02543372|Behavioral|Behavioral Couples Therapy (BCT)|BCT integrates cognitive behavioral techniques targeting problem gambling with a large focus on interventions for relationship functioning. The BCT condition requires active participation from both the gambler and the CSO.
1557831|NCT02542839|Procedure|Botulinum toxin injections|All participants will receive Botulinum toxin(BoNT) injections as part of their standard of care
1557747|NCT02543372|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT integrates cognitive behavioral techniques targeting problem gambling with some interventions for relationship functioning.The CBT condition requires active participation from the gambler, but not for the CSO.
1557748|NCT02543359|Behavioral|Training Models of PCIT|Agency participants are trained in one of three training model strategies: Train the Trainer Model (TTT), Learning Collaborative (LC), or Web-Supported Self Study (SS).One third of participating agencies will be randomized to the Train the Trainer training model.One third of participating agencies will be randomized to the Learning Collaborative training model.One third of participating agencies will be randomized to the Web-Supported Self Study.
1557749|NCT02543359|Behavioral|Training Models of PCIT|One-third of administrators are trained in the Learning Collaborative training model. One-third of administrators will be trained to usual treatment (none). One-third of administrators will be trained to usual treatment (none).
1557750|NCT02543359|Behavioral|Parent-Child Interaction Therapy (PCIT) Treatment|Parent-Child Interaction Therapy (PCIT), a parent coaching evidence-based protocol is given to each family from clinicians and supervisors in each training model.
1557751|NCT02543346|Drug|Cetirizine|Participants will receive either cetirizine (10mg tablet, orally) or a placebo (sugar pill) at one of the two treatment visits.
1557752|NCT02543346|Other|Placebo|Participants will receive either a placebo or cetirizine (10mg tablet, orally) at one of the two treatment visits
1557753|NCT02543320|Device|Electroencephalography (EEG)|Participants undergo a baseline EEG prior to starting radiotherapy, and during each neurotherapy session.
1557754|NCT02543320|Behavioral|Questionnaires|Pain and symptom questionnaires completed at baseline, before each LORETA neurofeedback session, 1 week after completion of neurofeedback sessions, and at the end of radiotherapy.
1557755|NCT02543320|Procedure|Neurotherapy|Participants undergo neurotherapy once a day, three days a week, for a total of 6 treatments over a two week time period, and during weeks 4 and 5 or 5 and 6 of radiotherapy, depending on when they start to experience pain of at least a 4 on a pain scale of 0-10 for three consecutive days. Neurofeedback training given in a video-game format.
1557756|NCT02543307|Procedure|Nurse-led Patient Pathways|The NPP include a comprehensive needs and goal assessment. Patients appreciated written information provided at an early stage of their hospital stay that helped to prepare them for discharge. The NPP continue with pre- and post-operative patient care, and conclude with a newly implemented follow-up phone call after hospital discharge. Nursing interventions were presented in a checklist format, based on scientific and clinical evidence. The NPP were developed with regard to patient and family centered goals and objectives and were explicitly emphasized in the NPP. NPP guided the nursing care plan. Nurses act as advocates for patients' interests. Therefore NPPs represent a means to formalize these nursing activities and contribute to transparency in relation to other health professionals.
1557757|NCT02543294|Device|Echocardiograms|Participants undergo echocardiograms with contrast done at baseline and at months 2, 4, 6, 12, 18, and 30.
1557758|NCT02543294|Device|Electrocardiogram|Electrocardiogram performed at baseline.
1557759|NCT02543294|Behavioral|Symptom Questionnaire|Symptom questionnaire completed at baseline and at months 1, 2, 4, 6, 12, 18, and 30.
1557760|NCT02543294|Behavioral|Telephone Follow-Up|Telephone follow-up by study staff at months 3 and 5.
1557761|NCT02543281|Device|Adaptive cardiac resynchronization therapy|The adaptive cardiac resynchronization therapy (aCRT) algorithm works by sometimes giving stimulation to only the left side of the heart, rather than to both sides, depending on how it senses the heart is functioning.
1557762|NCT02543281|Device|Conventional Cardiac Resynchronization Therapy|CRT without the adaptive algorithm works by giving stimulation to both sides of the heart.
1557763|NCT02543268|Biological|Ad26.ZEBOV‐Batch #1|Ad26.ZEBOV ‐ Batch #1, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
1557764|NCT02543268|Biological|Ad26.ZEBOV‐Batch #2|Ad26.ZEBOV ‐ Batch #2, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
1557765|NCT02543268|Biological|Ad26.ZEBOV‐Batch #3|Ad26.ZEBOV ‐ Batch #3, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles on Day 1
1557766|NCT02543268|Biological|MVA‐BN‐Filo|MVA‐BN‐Filo‐ live replication incompetent vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit [Inf. U.] once on Day 57.
1557767|NCT02543268|Biological|Placebo|One 0.5 ml IM injection of 0.9% saline once on Day 1 and Day 57.
1557768|NCT02543255|Drug|Abiraterone acetate with prednisone|Abiraterone acetate will be administered orally as a tablet at 1000 mg/day with prednisone (5 mg oral tablet, twice daily) for 24 weeks.
1557769|NCT02543255|Drug|Leuprolide|Leuprolide will be administered by subcutaneous injection at 22.5 mg dose every 12 weeks for 24 weeks.
1557770|NCT02543255|Drug|Cabazitaxel with peg-filgrastim|Cabazitaxel will be administered in 6 cycles, with 6 mg per cycle and 3 weeks between cycles.
1557771|NCT02543242|Device|InToneTM (InControl Medical, LLC) - Medical Device|
1557772|NCT02543229|Drug|OPT-302|OPT-302 will be administered by intravitreal injection once every month for 3 months
1557773|NCT02543229|Drug|Lucentis™|Lucentis™ (0.5 mg) will be administered by intravitreal injection once every month for 3 months
1557774|NCT02543216|Dietary Supplement|Sunflower oil|Study diets were isocaloric following the habitual diet of the participants with a supplement of 30-50 ml (25-45 g) sunflower oil daily depending on body weight. Thus, approximately 16-28 g (6 E%) LA were provided daily on top of the average intake of approximately 10-12 g (4.5 E%).
1557775|NCT02543203|Biological|Essential Oil Mixture A|Topical Essential Oils mixture and aromatic method
1557776|NCT02543203|Biological|Essential Oils Mixture B|Topical Essential Oils mixture and aromatic method
1557777|NCT02543190|Behavioral|compliance surveillance and improvement strategy|External monitor to ensure compliance with an educational protocol.
1557778|NCT02543177|Procedure|coronary angiography|
1557779|NCT02543177|Procedure|ischemic precondition|four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
1557780|NCT02543177|Procedure|prior kidney irrigation|
1557990|NCT02541604|Drug|Atezolizumab|Atezolizumab will be administered as IV infusion (maximum 1200 mg) on Day 1 of each 21-day cycle.
1557781|NCT02543164|Other|REFERENCE: white bread|"Determination of glycemic response after consumption of white bread:
Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
1557782|NCT02543164|Other|TEST: b-glucan enriched bread|"Determination of glycemic response after consumption of bread enriched with barley beta-glucans (Test A) :
Capillary glucose will be taken at 0 min (baseline sample), followed by 15, 30, 45, 60, 90 and 120 min after starting to eat the meal to calculate the area under the curve (AUC)."
1557783|NCT02543151|Procedure|SpyGlass (direct visualization system) choledochoscopy|SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
1557784|NCT02543138|Device|Trocar|Closed thoracostomy using the new trocar
1557785|NCT02543125|Device|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
1557786|NCT02543125|Device|NHFOV|"For infants in the NHFOV-group who failNHFOV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
1557787|NCT02543099|Drug|policosanol|Patients will receive policosanol 20mg Qd
1557788|NCT02543099|Drug|placebo|Patients will receive placebo 20mg Qd;
1557789|NCT02543086|Drug|KAE609|Study drug
1557790|NCT02543086|Drug|Piperaquine Phosphate|Pre-administration of Piperaquine Phosphate will be done to eliminate the asexual form of the parasite and induce gametocytaemia before characterizing the activity of KAE609 in clearing sexual blood stage parasites from the blood of healthy subjects in the Induced Blood Stage Malaria Challenge model in Part B of study
1557791|NCT02543073|Biological|MSCs|MSCs will be given at a median dose of 1×10^6 cells/kg once weekly for 4 weeks as one cycle treatment.
1557792|NCT02543073|Drug|AZM|AZM will be given （0.25g qd）for 4 weeks as one cycle treatment.
1557793|NCT02543073|Drug|Glucocorticoid|Glucocorticoid (prednison) will be given at the starting dose of 1mg/kg for 4 weeks as one cycle treatment.
1557794|NCT02543060|Drug|stannous fluoride toothpaste|0.454% stannous fluoride toothpaste
1557795|NCT02543060|Drug|cavity protection toothpaste|0.243% sodium fluoride toothpaste
1557797|NCT02543034|Device|Betafoam Wound Dressing|Foam dressing including Betadine iodine
1557798|NCT02543034|Device|Petrolatum Gauze|Gauze dressing
1557799|NCT02543034|Device|Allevyn Wound Dressing|Foam dressing
1557800|NCT02543021|Device|Virtual chromoendoscopy|Digital / virtual chromoendoscopy with FICE
1557801|NCT02543021|Procedure|Conventional chromoendoscopy|Conventional chromoendoscopy with indigo carmine dye spray
1557802|NCT02543008|Procedure|Physical activity plus thoracic mobilization|Information already included in arm/group descriptions.
1557803|NCT02543008|Procedure|Physical activity|Information already included in arm/group descriptions.
1557804|NCT02543008|Procedure|Placebo|Information already included in arm/group descriptions.
1557805|NCT02542995|Other|QI interventions|Intervention categories: communication improvement, chronic disease QI projects (for patients), workflow redesign
1557806|NCT02542982|Device|tDCS (Endomed 482; Enraf-Nonius B.V.)|non-invasive brain stimulation with pair of electrodes with saline-soaked pads through which the direct current of intensity of 2 mA is delivered
1557807|NCT02542969|Drug|Simvastatin|
1557808|NCT02542969|Drug|Rosuvastatin|
1557809|NCT02542969|Drug|MGL-3196|
1557810|NCT02542956|Drug|Exparel|receive Exparel by injection
1557811|NCT02542956|Drug|Marcaine|receive Marcaine in a pain pump
1557812|NCT02542956|Drug|Marcaine|receive Marcaine by injection
1557813|NCT02542943|Device|Experimental Oral Rinse 1|(1.5% w/w KOX, pH 4.5)
1557814|NCT02542943|Device|Experimental Oral Rinse 2|(1.5% w/w KOX, pH 7)
1557815|NCT02542943|Other|Placebo Oral Rinse|(0% w/w KOX, pH 4.5)
1557816|NCT02542943|Drug|Standard fluoride toothpaste|1000ppm fluoride as sodium monofluorophosphate
1557817|NCT02542930|Radiation|Radiotherapy|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin.
1557818|NCT02542930|Drug|Thymalfasin|Metastatic lesions of Non-small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin; Thymalfasin treatment is given twice a week with an interval of 3-4 days each week.
1557819|NCT02542917|Device|IBDoc home test for faecal calprotectin|IBDoc home test for faecal calprotectin
1557820|NCT02542904|Procedure|mesenteric excision|
1557823|NCT02542878|Device|Foam roller|A bout of 60 seconds of myofascial release with foam roller
1557825|NCT02542852|Drug|atazanavir 300 mg + ritonavir 100 mg + dolutegravir 50 mg|Switch to single arm treatment atazanavir-ritonavir 300-100 mg + dolutegravir 50 mg therapy for 24 weeks
1557826|NCT02542839|Device|NeuroStar TMS therapy|Application of repetitious transcranial magnetic stimulation (TMS) pulses using NeuroStar device to a specific brain target at predefined stimulation parameters.
1557827|NCT02542839|Device|Sham NeuroStar TMS therapy|Same procedure as real rTMS without stimulating the cerebral cortex.
1557828|NCT02542839|Other|Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS)|All participants will receive a clinical assessment of dystonia severity by using the TWSTRS test.
1557829|NCT02542839|Other|Craniocervical Dystonia Questionnaire (CDQ-24)|All participants will fill out the Craniocervical Dystonia Questionnaire (CDQ-24) quality of life questionnaire.
1557830|NCT02542839|Other|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
1557832|NCT02542826|Other|Pulmonary Rehabilitation|Patients will participate in 3 exercise training sessions/wk for a period of 7-12 wks at one of 4 sites in Quebec. Each training session will include 30-45 min of aerobic training (cycling and/or treadmill walking) at a target intensity of 80% of the maximal heart rate achieved during a symptom-limited incremental cycle exercise test performed prior to the pulmonary rehabilitation program; and 20-30 min of strength training exercises.
1557839|NCT02542800|Behavioral|Episodic memory task|
1557840|NCT02542800|Device|fMRI|
1557841|NCT02542787|Drug|VSN16R|Small molecule
1557842|NCT02542787|Other|Placebo|dummy tablet
1557843|NCT02542774|Other|No intervention is given.|This study is based on the analysis of linked electronic health records (CALIBER dataset)
1557844|NCT02542761|Device|Fiberglass Composite foot|The Rush foot is a fiberglass composite energy storage and return prosthetic foot.
1557845|NCT02542761|Device|Carbon Fiber Composite Foot|All types of currently commercially available carbon fiber energy storage and return prosthetic feet will be considered appropriate.
1557846|NCT02542748|Drug|Norepinephrine|norepinephrine injection
1557847|NCT02542748|Drug|Ephedrine|Ephedrine injection
1557848|NCT02542722|Behavioral|Control|General recommendations about a healthy diet and physical activity and referral to their general physician with a report of the study results in the event of detecting any risk factor or pathological finding
1557849|NCT02542722|Behavioral|Intensive Intervention|Based on office visits each 3 months during the first year, as well as monthly telephone calls during the first year. Each subject will also attend a group educational meeting each 6 months. At each visit they will be given a series of recommendations and their degree of adherence evaluated and the evolution of their weight checked. The recommendations are designed to re-educate the subjects concerning their dietary and physical activity habits
1557850|NCT02542709|Device|Active repetitive Transcranial Magnetic Stimulation|Active transcranial magnetic stimulation will induce real pulses using the transcranial magnetic stimulation device.
1557851|NCT02542709|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham transcranial magnetic stimulation will not induce any pulses using the same transcranial magnetic stimulation device but by also adding a sham block device.
1557852|NCT02542696|Drug|APL-130277|"Used to treat up to 5 OFF episodes per day"
1557853|NCT02542683|Other|structured physical activity program|a structured modest physical activity program
1557854|NCT02542670|Genetic|Whole genome sequencing|At least 50 ng of tumor DNA will be extracted from FFPE samples and/or fresh tissue and used for hybridization capture and NGS using the IlluminaMiSeqDx platform.
1557855|NCT02542657|Drug|Clarithromycin|Given PO
1557856|NCT02542657|Drug|Dexamethasone|Given PO
1557857|NCT02542657|Drug|Ixazomib Citrate|Given PO
1557858|NCT02542657|Drug|Pomalidomide|Given PO
1557859|NCT02542644|Device|Ultrahigh resolution Spectral Domain OCT|"The area of graft detachment will be measured by a customized ultra high-resolution OCT for the cornea.
A spectrometer based ultrahigh resolution Spectral Domain OCT (SDOCT) system operating at 800 nm for the anterior chamber will be employed in the present study. The spectrum of the Ti:Sapphire laser light source is centered at 800 nm. With a full width at half maximum bandwidth of 170 nm, the axial resolution is 1.3 μm in the cornea. The transverse resolution of the employed OCT system is 21 μm at the front surface of the cornea. For measurement, patients will place their head in a modified slit lamp head rest. During the measurement period, patients will be asked to look straight forward onto an internal fixation target and to avoid blinking. Different scattering patterns, e.g. raster, circular and spiral scans will be employed."
1557860|NCT02542631|Device|Bolus Insulin Patch (Calibra Finesse)|
1557861|NCT02542631|Device|Insulin Pen (Novo-Nordisk FlexPen®)|
1557862|NCT02542618|Behavioral|Inquiry Based Stress Reduction (IBSR)|
1557863|NCT02542618|Behavioral|Cognitive Behavioral Therapy (CBT)|
1557867|NCT02542592|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
1557868|NCT02542592|Drug|Isotonic Sodium Chloride|Placebo
1557869|NCT02542579|Genetic|16S rRNA pyrosequencing analysis|For H. pylori identification and genotyping, VAI-F(5'-ATGGAAATACAACAAACACAC-3') and VAI-R(5'-CTGCTTGAATGCGCCAAAC-3') will be used. For vacuolating cytotoxin A (vacA) s1/s2, VAG-F (5'-CAATCTGTCCAATCAAGCGAG-3') and VAG-R(5'-GCGTCAAAATAATTCCAAGG-3') will be used, and for cytotoxin-associated gene A (cagA), cag5c-F(5'-GTTGATAACGCTGTCGCTTC-3') and cag3c-R(5'-GGGTTGTAT GATATTTTCCATAA-3') will be used.
1557870|NCT02542566|Procedure|Physiotherapy rehabilitation|Physiotherapy rehabilitation
1557871|NCT02542553|Procedure|Bilateral BAL|
1557872|NCT02542540|Other|Training with Nintendo Wii console|Children with OI and draining for 3 months using Nintendo Wii console
1557873|NCT02542527|Procedure|Fluid filled breast pump|breast milk pumping with a fluid filled breast pump
1557874|NCT02542514|Drug|Ibrutinib|p.o. 560 mg once a day (four 140 mg capsules) for one year (12 cycles of 28 days)
1557991|NCT02541591|Other|Neuroprotective goal directed hemodynamic optimization|
1557992|NCT02541591|Other|MAP > 65mmHg|MAP > 65mmHg
1557875|NCT02542488|Other|STOPBANG Questionnaire|"8 question screening tool comprised of the following questions:
S: Do you Snore loudly? T: Do you often feel tired during daytime? O: Has anyone observed you stop breathing during your sleep? P: Do you have high blood pressure? B: Is your BMI >35 kg/m2? A: Are you >50 years old? N: Is your neck circumference >40cm? G: Is your gender male?"
1557876|NCT02542488|Procedure|Overnight pulse oximetry|All participants will be given a pulse oximeter to take home and apply to their finger overnight to measure their heart rate and oxygen saturations while they sleep.
1557877|NCT02542475|Device|Low Field Magnetic Stimulation|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain. The field and timing parameters of the LFMS pulses, such as pulse timing, duration, frequency, and electric and magnetic field distribution and direction are different from other neurostimulation methods. LFMS electromagnetic fields are significantly weaker (< 100x) than those used in ECT and rTMS.
1557878|NCT02542462|Drug|Rotarix®,|Single oral dose of licensed rotavirus vaccine given alone
1557879|NCT02542462|Drug|Rotarix®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
1557880|NCT02542462|Drug|RotaTeq®,|Single oral dose of licensed rotavirus vaccine given alone
1557881|NCT02542462|Drug|RotaTeq®, with other routine vaccines|Single oral dose of licensed rotavirus vaccine given with other routine vaccines
1557882|NCT02542449|Dietary Supplement|Globes®|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months Globes® and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
1557883|NCT02542449|Dietary Supplement|Placebo|At the end of a 3-month lifestyle intervention, all participants received twice a day for 3 months placebo and attended a monthly clinical visit during the supplementation period and 3 months after the end of supplementation.
1557884|NCT02542436|Other|No intervention|No intervention administered in this study
1557885|NCT02542423|Other|Endocan blood test samples|
1557886|NCT02542410|Drug|Cabergoline|
1557887|NCT02542410|Drug|Norethindrone acetate|
1557888|NCT02542397|Genetic|Pharmacogenomic Testing|Pharmacogenomic test results to guide drug/dose modifications
1557889|NCT02542384|Drug|CR845 IV 1 mcg/kg|"CR845 IV 1 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.
Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed. Saline infusion (IV 0.45%) for fluid replenishment will be provided."
1557890|NCT02542384|Drug|CR845 IV 0.5 mcg/kg|"CR845 IV 0.5 mcg/kg will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.
Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.
Saline infusion (IV 0.45%) for fluid replenishment will be provided."
1557891|NCT02542384|Drug|Placebo IV|"Placebo IV will be administered as an IV bolus 2x loading dose one hour prior to anesthetic induction for surgery, then a dose within 30 minutes of the patient being considered stable in the post operative recovery room. Subsequent dosing will be administered at 6, 12 and 18 hours.
Antinausea rescue medication (ondansetron 4 mg IV) may be requested, as well as analgesic rescue medication (morphine 5mg IV), post surgery, as needed.
Saline infusion (IV 0.45%) for fluid replenishment will be provided."
1557892|NCT02542371|Other|Arterial Imaging|
1557893|NCT02542345|Procedure|magnetic resonance imaging|
1557894|NCT02542332|Other|With Data|The participants received statistical data about lung cancer screening in order to help them answer the questionaire
1557895|NCT02542319|Dietary Supplement|Mablet 360 mg|
1557896|NCT02542319|Dietary Supplement|Placebo|
1557897|NCT02542306|Drug|fibrinogen concentrate|Investigators administered fibrinogen concentrate when the plasma fibrinogen level was below 1.5 g/L at 5 minutes after protamine reversal and completion of surgical hemostasis in patients, who comprised the fibrinogen concentrate-treated group.
1557898|NCT02542293|Biological|Durvalumab +Tremelimumab|
1557899|NCT02542293|Drug|Paclitaxel + carboplatin|Chemotherapy Agents
1557900|NCT02542293|Drug|Gemcitabine + cisplatin|Chemotherapy Agents
1557901|NCT02542293|Drug|Gemcitabine + carboplatin|Chemotherapy Agents
1557902|NCT02542293|Drug|Pemetrexed + cisplatin|Chemotherapy Agent
1557903|NCT02542293|Drug|Pemetrexed + carboplatin|Chemotherapy Agent
1557904|NCT02542280|Procedure|endometrial injury.|Endometrial injury using a pipelle biopsy catheter on day (5, 6 or 7) of the stimulation cycle combined with the intrauterine insemination.
1557905|NCT02542280|Procedure|intrauterine insemination|Placement of washed sperm in the uterus using a catheter, around the time of ovulation.
1557906|NCT02542280|Drug|ovarian stimulation|Inducing ovulation by human menopausal gonadotrophin ampoules given intramuscular starting from cycle day two, till the leading follicle reaches 16 - 18 mm.
1557907|NCT02542267|Device|Gore VIABAHN Endoprosthesis|
1557908|NCT02542254|Drug|Salbutamol|200 micrograms salbutamol administered using a pressurised metered dose inhaler (pMDI)
1557909|NCT02542254|Drug|Ipratropium|40 micrograms ipratropium administered using a pMDI
1557910|NCT02542254|Drug|RPL554|6 mg RPL554 administered using a nebuliser
1557911|NCT02542254|Drug|Salbutamol matched placebo|Placebo pMDI
1557912|NCT02542254|Drug|Ipratropium matched placebo|Placebo pMDI
1557913|NCT02542254|Drug|RPL554 matched placebo|Nebulised placebo
1557914|NCT02542241|Drug|Sodium Chloride [3%]|Subjects in this arm will receive an intravenous infusion of 3% hypertonic saline at a 50 cc / hour rate, the medicine will be administered by a infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
1557915|NCT02542241|Drug|Sodium Chloride [0.9%]|Subjects in this arm will receive an intravenous infusion of 0.9% hypertonic saline at a 50 cc / hour rate, the medicine will be administered by a infusion pump during the first 72 hours after the damage control surgery. A total of 3600cc will be administered throughout 72 hours ( 1200cc every 24 hours).
1557916|NCT02542228|Other|questionnaire survey|The HR-QOL PIDD survey will be administered to the patient by the site PI or the study coordinator. A second survey will be handed to the patient to take home with them and completed at 48-120 hrs. after the clinic visit. The study coordinator will contact the patient during this period to ensure that the patient completes this second survey and returns it to the local study site. A case report form (CRF) of their clinical condition and demographics will be collected at the time of informed consent.
1557917|NCT02542215|Drug|Cobiprostone|
1557918|NCT02542215|Drug|Placebo|matching placebo
1557919|NCT02542202|Other|Laboratory Biomarker Analysis|Correlative studies
1557920|NCT02542202|Radiation|Stereotactic Body Radiation Therapy|Undergo stereotactic body radiation therapy
1557921|NCT02542176|Other|Freeze-dried Whole Grape Powder|60 g of whole grape powder for 4 weeks
1557922|NCT02542176|Other|Grape Powder Placebo|60 g of grape powder placebo for 4 weeks
1557923|NCT02542150|Drug|acetate|acetate infusion, saline infusion, functional magnetic resonance imaging (fMRI) scan
1557924|NCT02542150|Drug|alcohol|"a jello shot containing alcohol, a jello shot containing no alcohol, fMRI scan."
1557925|NCT02542137|Radiation|Radiotherapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of small cell lung cancer.
1557926|NCT02542137|Drug|Thymalfasin|Patients with metastatic lesions of small cell lung cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
1557927|NCT02542124|Biological|NM-IL-12|The TSEBT treatment will start on Day 1 of the study. NM-IL-12 will be administered subcutaneously.
1557928|NCT02542111|Drug|Bortezomib|Bortezomib IV
1557929|NCT02542111|Drug|Gemcitabine|Gemcitabine IV
1557930|NCT02542111|Drug|Dexamethasone|Dexamethasone IV
1557931|NCT02542111|Drug|Cisplatin|Cisplatin IV
1557932|NCT02542098|Drug|HYD tablets|Hydrocodone bitartrate 20 mg to 120 mg extended-release tablets.
1557933|NCT02542085|Procedure|Laparoscopic repair|operative method
1557934|NCT02542085|Procedure|Hybrid repair|operative method
1557937|NCT02542059|Radiation|68Ga-exendin PET/CT|68Ga-exendin PET/CT
1557938|NCT02542046|Drug|Barium|Administration of barium oral contrast agent prior to CT scan
1557939|NCT02542046|Drug|Diatrizoate|Administration of diatrizoate oral contrast agent prior to CT scan
1557940|NCT02542046|Drug|Iohexol|Administration of iohexol oral contrast agent prior to CT scan
1557941|NCT02542033|Other|treated apple juice with low sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
1557942|NCT02542033|Other|un-treated apple juice with normal sugar content|Each study participant consumed 500 mL test juice at the morning of the interventional day. The 500 mL bottle content had to be ingested within 5 minutes. an intravenous catheter was inserted into a forearm vein for blood withdrawal at baseline, directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after starting the ingestion of the test product. From all samples plasma insulin was measured. From the blood samples taken at baseline and 120 minutes after consumption of the test product safety parameters were determined. Capillary blood was taken from the finger pad using a HemoCue® Safety Lancet at baseline (twice) and once directly before (time point 0) and 15, 30, 45, 60, 90 and 120 minutes after ingestion of the test product.
1557943|NCT02542007|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
1557944|NCT02542007|Device|sirolimus-eluting stent system|
1557945|NCT02541994|Device|Pachette3|Central corneal thickness will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
1557946|NCT02541994|Device|Lenstar-Think|Axial length will be measured with an ultrasound probe. This test will be performed while the corneas are anesthetized. This test will be performed as part of a standard, comprehensive dilated eye examination with optical coherence tomography and visual field testing as the regular care for benign intracranial hypertension.
1557947|NCT02541968|Behavioral|Cognitive-behavioral therapy (face-to-face)|
1557948|NCT02541968|Behavioral|Internet-based Cognitive-behavioral therapy|With therapist support
1557949|NCT02541968|Behavioral|Internet-based Cognitive-behavioral therapy without therapist support|
1557952|NCT02541929|Dietary Supplement|Docosahexaenoic acid|
1557953|NCT02541916|Other|Controlled weaning of immunosuppression|At week 0 patients have liver biopsy and liver functional tests (LFTs). Week 1-4 medication reduction to 1.5mg Tacrolimus (Tac) daily or 150mg Cyclosporine A (CsA). At week 4 LFTs. Week 5-8 medication reduction to 1mg Tac / 100mg CsA. Week 8 LFTs. Week 9-12 reduction to 0.5mg Tac/ 50mg CsA. Week 12 LFTs. Week 13-16 reduction to 0mg. Week 16 liver biopsy & LFTs. Weekly LFTs performed Week 17-20. Monthly LFTs for the next 3 months. LFTs every 3 months for monitoring.
1557955|NCT02541890|Behavioral|Work place intervention|Meeting at the work place including the patient, the employer and the rehabilitation therapist. Aim of meeting is to discuss challenges and possibilities in the patient's return to work process and to make a plan for return to work.
1557956|NCT02541877|Device|Down sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Down sizing valve implantation will be used in type-0 BAS.
1557957|NCT02541877|Device|Standard sizing valve in type-0 BAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in type-0 BAS.
1557958|NCT02541877|Device|Standard sizing valve in TAS|Subjects will undergo percutaneous retrograde trans-peripheral arterial aortic valve implantation with the self-expandable bio-prosthesis. Before implantation a balloon dilatation of the aortic annulus and a simultaneous aortic root angiography will be performed. Standard sizing valve implantation will be used in TAS.
1557959|NCT02541864|Drug|pantoprazole+bismuth+tetra+metro|pantoprazole 40 mg bid , bismuth subcitrate 120 mg qid., tetracycline 500 mg qid, and metronidazole 250 mg qid for 14 days
1557960|NCT02541864|Drug|Hybrid therapy|a dual therapy with pantoprazole 40 mg bid, amoxicillin 1 g bid for 7 days, followed by a quadruple therapy with pantoprazole 40 mg bid, amoxicillin 1 g bid, clarithromycin 500 mg bid, and metronidazole 500 mg bid for a further 7 days
1557961|NCT02541838|Other|Muscle power|
1557962|NCT02541838|Other|balance perturbation|
1557963|NCT02541838|Other|aerobic exercise|
1557964|NCT02541825|Device|the stent of diameter of 7mm|108 patients use the stent of diameter of 7mm in TIPS
1557965|NCT02541825|Device|the stent of diameter of 8mm|108 patients use the stent of diameter of 8mm in TIPS
1557966|NCT02541812|Device|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
1557967|NCT02541799|Procedure|Audio-visual telemedicine|Participants in an emergency department will have their care delivered using telemedicine, then they will be approached for a study by a study investigator using the same telemedicine link
1557968|NCT02541799|Procedure|Standard care|Participants in an emergency department will have their care delivered in person, then they will be approached by a study investigator face-to-face.
1557969|NCT02541786|Drug|dexlansoprazole based triple therapy|dexlansoprazole MR 60 mg once daily+clarithromycin 500 mg twice daily+ amoxicillin 1 g twice daily for 7 days
1557970|NCT02541786|Drug|rabeprazole-based triple therapy|rabeprazole 20 mg twice daily + clarithromycin 500 mg twice daily + amoxicillin 1 g twice daily for 7 days
1557971|NCT02541773|Device|Cardiac Resynchronisation Therapy|Routine implantation of CRT - part of standard of care
1557972|NCT02541760|Drug|Monteleukast|4 ml monteleukast daily for one month
1557973|NCT02541760|Drug|Mometasone|Inhaled mometasone 1 puff in each side of nose for one month
1557974|NCT02541747|Behavioral|massage|massage
1557975|NCT02541734|Drug|Gelofusine|Infusion of gelofusine
1557976|NCT02541734|Radiation|111In-exendin 4 SPECT/CT|111In-exendin 4 SPECT/CT
1557977|NCT02541734|Drug|Placebo|
1557978|NCT02541721|Device|LabiaStick#01|"This medical device has emollient agents whose main function is to increase the skin hydration, provide physical protection and decrease the symptoms and possibility of recurrence of vulvar dermatoses.
The medical device should be applied once daily, in the evening, after a gentle washing (plain water with no cleansing products), on the affected non-hairy vulvar area."
1557979|NCT02541708|Drug|Ferric carboxymaltose|Intravenous Ferric carboxymaltose given at a calculated dose of 20mg/kg body weight in 1-3 infusions according to severity of anemia
1557980|NCT02541708|Drug|Ferrous sulfate + folic acid|Three dried ferrous sulfate and folic acid tablets every morning 30 mins before the meal. If side effects occur the drug may be taken with the meal or in 2 separate doses per day. The treatment will be pursued for 3 months after correction of anemia
1557981|NCT02541695|Biological|E. coli strain E1392-75-2A|"At study day 14, after a standardized evening meal and an overnight fast, subjects will receive a single oral dose of the attenuated diarrhoeagenic E. coli strain E1392-75-2A (dose will be either 1E10 CFU (n=22) or 5E10 CFU (n=22)). Oral challenge will occur at 10.00 AM. Under supervision of the project team, subjects will get a NaHCO3 solution (100 ml 2% NaHCO3) to neutralize the gastric acid. After 5 minutes, they get a fruit juice (100 ml) containing the attenuated diarrhoeagenic E. coli strain at the above-mentioned dose. Subjects go home, but are not allowed to drink or eat for 1 hour.
At study day 35, after a standardized evening meal and an overnight fast, all subjects will receive a second inoculation 1E10 CFU of the diarrhoeagenic E. coli."
1557982|NCT02541682|Other|TEMPS-A (Temperament Evaluation of Memphis, Pisa, Paris and San Diego Auto-questionnaire)|Participants filled out the TEMPS-A survey at their first visit.
1557983|NCT02541669|Drug|TAK-491|TAK-491 tablets
1557984|NCT02541669|Drug|TAK-491 placebo|TAK-491 placebo-matching tablets
1557985|NCT02541656|Procedure|Study of preload dependence indices after volume expansion in laparoscopy with Saldinger technique.|The measurements of pulse pressure variation, plethysmographic waveform of pulse oximetry variation and stroke volume variation will be performed before pneumoperitoneum at the beginning of the surgery, and will be repeated after pneumoperitoneum insufflation applying each time modification of preload conditions (applying reverse Trendelenburg position followed by Trendelenburg position). The responses will be appreciated by the measurements of the stroke volume.
1557986|NCT02541643|Drug|Elotuzumab|"Elotuzumab will be administered intravenously at a dose of 10mg/kg weekly (Days 1, 8, 15, and 22 of a 4-233k cycle) of the first 2 cycles and every 2 weeks (Day 1 and Day 15) thereafter.
A window of -1 to +3 days is permitted in Cycles 1 and 2. In Cycle 1 and 2, an elotuzumab dose that falls outside of the pre-specified window must be skipped. In Cycles 3 and beyond, elotuzumab dosing may be delayed for up to 1 week as clinically indicated. If unable to administer within 1 week, then the dose should be skipped and resumption of the elotuzumab continues per the guidance document defined schedule. In addition the following premedication must also be administered 30-90 minutes prior to any elotuzumab:
H1 blocker: diphenhydramine (25-50mg PO or IV) or equivalent
H2 blocker: ranitidine (50mg IV) or equivalent
acetaminophen (650-1000mg PO)"
1557987|NCT02541630|Behavioral|Big Mind|mindfulness based intervention
1557988|NCT02541617|Procedure|Programming by community Neurologist|Deep Brain stimulator with be programmed by a community Neurologist
1557989|NCT02541617|Procedure|Standard of care|Deep Brain Stimulator will be programmed with at the implanting movement disorders center
1558000|NCT02541552|Drug|Ropivacaine 0.5%|Varying volume according to motor response of previous subject
1558001|NCT02541539|Dietary Supplement|Lactobacillus casei Zhang|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
1558002|NCT02541539|Dietary Supplement|Placebo|This project aims to study the benefits of probiotics namely Lactobacillus casei Zhang in prevention of upper respiratory and gastrointestinal illnesses, among adults in Malaysia aged from 18-81 years.
1558003|NCT02541526|Drug|Mirtazapine|One capsule (15 mg) oral mirtazepine daily will be started on day six of treatment for a period of 3 days followed by two capsules (30 mg) daily for a period of four months
1558004|NCT02541526|Drug|Placebo|Similar capsule containing placebo will be started on day six of treatment for a period of 3 days followed by two capsules of placebo daily for a period of four months
1558005|NCT02541513|Drug|paliparidone|All patients will begin receiving oral paliperidone 3 mg daily for three days, beginning on Day 5 of the inpatient phase. All patients will receive an injection of Paliperidone 150 mg injection on Day 8 of the inpatient phase. Patients will receive monthly 150 mg injection for the next 3 months.
1558006|NCT02541500|Drug|Minocycline|Oral minocycline 200 mg daily will be started on day six of treatment for a period of four months
1558007|NCT02541487|Dietary Supplement|Alli-nutritional supplement|Obese participants in the FIT-PLESE clinical trial randomized to the nutritional restriction /AlliTM/physical activity arm that achieve pregnancy.
1558008|NCT02541474|Other|Integrated care|The PACT model facilitates better care by : 1) a structured person centered needs assessment , 2) individual care plans , and 3) and an inter- professional team that coordinates services across specialties and levels of care.
1558009|NCT02541461|Procedure|Laparoscopic gastrectomy|Patient enrolled will undergo either a laparoscopic gastrectomy with Billoth 1 anastomosis or Roux-en-Y anastomosis
1558010|NCT02541448|Device|SurgiQuest AIRSEAL® Insufflation System (AIS)|"The SurgiQuest AirSeal Optical Trocar & Cannula System with integrated Insufflator DPIS 2000 (the DPIS 2000 System) is intended for use in diagnostic and/or therapeutic endoscopic procedures to distend the peritoneal cavity by filling it with gas (establish and maintain pneumoperitoneum), to establish and maintain a path of entry for endoscopic instruments, and to evacuate surgical smoke. The trocar of the DPIS 2000 System is indicated for use with or without visualization."
1558013|NCT02541409|Drug|Sofosbuvir|Direct acting antiviral agent used for the treatment of hepatitis C
1558014|NCT02541409|Drug|Pegylated Interferon alfa-2a|Antiviral agent used for the treatment of hepatitis C
1558015|NCT02541409|Drug|Ribavirin|Antiviral agent (guanosine analogue) used for the treatment of hepatitis C
1558016|NCT02541396|Drug|Wafermine|35 or 70 mg ketamine in a sublingual wafer
1558017|NCT02541396|Drug|Oxycodone|5 mg oxycodone capsule
1558018|NCT02541396|Drug|Placebo|Placebo capsule or placebo wafer
1558019|NCT02541383|Drug|Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)|Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation
1558020|NCT02541383|Drug|Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumab|Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation
1558021|NCT02541383|Drug|Daratumumab|Daratumumab 16mg/kg every 8 weeks for 2 years
1558022|NCT02541370|Biological|anti-CD133-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
1558023|NCT02541357|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises
1 week program, one introductory session and daily home practice"
1558024|NCT02541357|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery
1 single unit in the week before the surgery"
1558025|NCT02541344|Device|Dose 1 of IQP-VV-102|Dose 1 (D1) group will take 2 tablets with active ingredients and 2 placebo tablets.
1558026|NCT02541344|Device|Dose 2 of IQP-VV-102|Dose 2 (D2) group will take 4 tablets with active ingredients.
1558027|NCT02541344|Device|Placebo|"Placebo group will take 4 placebo tablets.
The placebo is designed to be identical to IQP-VV-102."
1558028|NCT02541331|Biological|ISMIGEN|Tablets of 30 billion organisms/mg - Sublingual use 1 tablet per day over 10 days for 3 successive months.
1558029|NCT02541331|Biological|PLACEBO|Matched tablets without any active substance.
1558030|NCT02541318|Behavioral|Duo-in exercise|Duo-in exercise was originated from China and with a 5000-years history. Ancient people adopted Duo-in to treat and prevent diseases.
1558031|NCT02541305|Other|propioceptive program|The training program has 6 specific proprioceptive exercises, each five minutes long, which will conducted in static and dynamic positions for a period of 30 minutes. Each exercise session will include 55 minutes (15 minutes of warm-up with slow walk, mobility and stretching exercise, followed by 30 minutes of a propioceptive exercises program, and finishing with 10 minutes of cool down through stretching and relaxation exercises)
1558032|NCT02541305|Other|No propioceptive program|The control group continued to perform their daily activities without changing any habit. Geriatric revitalization program without proprioceptive exercises.
1558034|NCT02541279|Procedure|Physiotherapy exercises guideline|Exercises controlled by a physiotherapist.
1558035|NCT02541266|Other|Questionnaire|A short questionnaire (9 questions) will be given to the participants to complete.
1558036|NCT02541253|Biological|GC3110A|A single 0.5mL dose intramuscular injection
1558037|NCT02541253|Biological|GCFLU Pre-filled Syringe inj.|A single 0.5mL dose intramuscular injection
1558038|NCT02541240|Other|Resilience Curriculum|The Resilience Curriculum consists of 4 modules, with one 2-hour module presented each week.
1558039|NCT02541227|Drug|Cerebrolysin|Cerebrolysin dosage, frequency and duration follows local clinical practice in accordance with the terms of the local marketing authorization
1558040|NCT02541201|Dietary Supplement|Plant sterols-enriched low-fat milk|The study product is a dried partly skimmed milk powder with no more than 12% milk fat (11.4g total fat/100g product) containing unesterified, unhydrogenated plant sterols.
1558041|NCT02541201|Dietary Supplement|Low-fat milk|The placebo product is a dried partly skimmed milk powder.
1558042|NCT02541188|Genetic|Genetic analysis|
1558043|NCT02541162|Behavioral|Oral information and interviews|interviews about sexuality and self experience during the disease
1558044|NCT02541149|Procedure|blood sample|
1558045|NCT02541136|Behavioral|Aerobic Exercise|"Each exercise class consisted of a warm-up, an aerobic and a cool-down phase, supervised by a physiotherapist. The warm up and cool down phases consisted of 5-7 minutes of low intensity aerobic exercise, < 40% Heart Rate Reserve (HHR), to allow the cardiopulmonary and musculoskeletal systems to adapt and recover, respectively.
The aerobic component initially consisted of 21 minutes at an intensity of 40-59% HRR and was progressed to 42 minutes at 55-75% HRR by week 8 until programme completion. All participants worked at the same intensity and duration at the various time points throughout the study. Continuous, rhythmic exercise using large muscle groups was prescribed using treadmills, cycle ergometers and other aerobic exercise that increased heart rate to its prescribed level."
1558046|NCT02541123|Other|Blood draw|Initial draw followed by additional blood draws every 4 hours thereafter, up to 24 hours from the initial blood draw (not to exceed 7 blood draws). Follow up blood draw at Day 7. Control group only undergoes 2 blood draws 4 hours apart on Day 1.
1558047|NCT02541097|Behavioral|Language therapy|Participants will receive semantic and phonological therapy for words they cannot retrieve spontaneously. They will be given an opportunity to practice the words in a group setting.
1558048|NCT02541084|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF therapy following the Summary of Product Characteristics
1558049|NCT02541071|Behavioral|Stress Film|
1558050|NCT02541071|Drug|Yohimbine|
1558051|NCT02541071|Drug|Clonidine|
1558052|NCT02541071|Drug|placebo|
1558053|NCT02541045|Drug|metadoxine|metadoxine 500mg tablets: 1 Tablet by mouth twice in day during 6 months
1558054|NCT02541045|Other|placebo|placebo tablets: 1 Tablet by mouth twice in day during 6 months
1558055|NCT02541032|Procedure|Intensive dental treatment|Up to five sessions of full-mouth removal of subgingival dental plaque by the use of scaling and root planning under local anesthesia. Any hopeless teeth will be extracted during this treatment period, which will be as short as possible, but will extend to no more than 4 weeks. In addition to standard scaling and root planning, the investigators seek to better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
1558056|NCT02541032|Procedure|Standard dental treatment|Supragingival mechanical scaling and polishing.
1558057|NCT02541032|Drug|Arestin|To better suppress the oral biofilm by administering Arestin locally into the periodontal pockets ≥6 mm.
1558060|NCT02541006|Drug|Tiotropium 18 mcg|tiotropium 18 mcg once a day
1558065|NCT02540941|Other|non|
1558066|NCT02540928|Drug|AMG 319 hydrate|
1558067|NCT02540928|Drug|Placebo|
1558068|NCT02540915|Other|Standard of Care - Registry|Standard of Care - Registry
1558069|NCT02540902|Device|All-polyethylene tibia (Aesculap AG)|Implantation of an all polyethylene tibial component.
1558071|NCT02540876|Drug|Ilorasertib|Given PO
1558072|NCT02540876|Other|Laboratory Biomarker Analysis|Correlative studies
1558073|NCT02540863|Other|myofascial release protocol and Rocabado exercise therapy|
1558074|NCT02540863|Other|exercise therapy|
1558075|NCT02540837|Drug|Bupivacaine|Obturator nerve block
1558076|NCT02540837|Drug|Saline|Obturator nerve block with saline(placebo)
1558077|NCT02540824|Drug|Apatinib single agent arm|For RET-fusion positive advanced NSCLC patients who failed to previous treatment,treat with apatinib, single agent, 750mg once daily, p.o until disease progression
1558079|NCT02540785|Procedure|lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), and the corneal flap in the superior region. After the suction was released, the flap was opened using a thin, blunt spatula and the free refractive lenticule was subsequently grasped with a forceps and extracted, after which the flap was repositioned carefully
1558080|NCT02540785|Procedure|small-incision lenticule extraction|Four femtosecond incisions were created in succession: the posterior surface of the refractive lenticule (spiral in), the lenticule border, the anterior surface of the refractive lenticule (spiral out), make a small incision
1558081|NCT02540772|Behavioral|Neuropsychological treatment|Participants had to learn some brief material (words, faces, pictures, news), after which they were asked for an immediate and a delayed recall. After both recalls, participants were confronted with feedback about correct responses, non-responses and errors (i.e., confabulations and errors of attribution). This type of feedback worked on: 1) selective attention during the learning phase, training patients to focus on the relevant details of the stimuli; 2) monitoring processes during the retrieval phase, reinforcing the strategic search and training patients to inhibit traces that were irrelevant; and 3) memory control processes after the retrieval phase. The treatment consisted of 9 sessions and lasted for 3 weeks and the participants performed a baseline before and after treatment.
1558082|NCT02540759|Dietary Supplement|Buglossoides oil|
1558083|NCT02540759|Dietary Supplement|High Oleic Sunflower Oil|
1558084|NCT02540746|Behavioral|ERG Skills Training|Group-based Dialectical Behavior Therapy Skills Training for 12 weeks
1558085|NCT02540746|Behavioral|Motivational Enhancement|Three week Motivational Enhancement group
1558086|NCT02540746|Behavioral|Family Skills Training|12-week group-based family skills training using Family Connections model
1558087|NCT02540720|Drug|Dexamethasone|
1558088|NCT02540720|Drug|Gamma globulin|
1558089|NCT02540720|Procedure|Hemoperfusion|
1558090|NCT02540707|Drug|solifenacin|solifenacin 5 mg per day for 12 weeks
1558091|NCT02540707|Drug|mirabegron|mirabegron 25 mg per day for 12 weeks
1558092|NCT02540694|Device|Endosonography|
1558093|NCT02540668|Drug|Lanabecestat|Administered orally
1558094|NCT02540668|Drug|Warfarin|Administered orally
1558095|NCT02540655|Biological|Stemchymal®|Patients will receive Stemchymal® through intravenous infusion
1558096|NCT02540655|Procedure|Excipients|Patients will receive excipients through intravenous infusion
1558097|NCT02540642|Dietary Supplement|METHYLCOBALAMIN 500 micrograms|Tab Methycobalamin 500 ug will be given with other regular antidiabetic drugs
1558099|NCT02540616|Device|Transcranial Electrical Stimulation|A form of external neuromodulation using electrodes on the surface of the head. We will be using the TCT tDCS device (www.trans.cranial.com) or devices constructed by our research group or collaborators.
1558100|NCT02540603|Device|F&P Jupiter Full Face Mask|Investigative F&P Jupiter full face mask to be used for OSA therapy
1558101|NCT02540590|Device|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
1558102|NCT02540590|Device|wound fluid measurement|Wound fluid at the gingival sulcus was volumetrically measured by Periotron 8000 instrument using filter strip
1558103|NCT02540551|Procedure|Injection of radioactive tracer combined with Patent Blue|Blue dye and the radioactive isotope will be injected in the remains of the ligamentum ovarium proprium (median side) and the ligamentum infundibulo-pelvicum (lateral side), just below the peritoneum. Four syringes containing 0,2 ml patent blue and 0,15 ml (20-MBq) radioactive isotope (99mTc-nanocolloid or Nanocoll®, GE Healthcare, Eindhoven, The Netherlands) will be given. After a 15-minute interval the radioactivity the SN(s) will be identified either by the mobile gamma-camera and /or gamma-probe and / or visually (blue dye) after opening the retroperitoneal space.
1558104|NCT02540538|Biological|HBVaxPro|3 vaccinations with HBVaxPro-10ug at 0, 30, and 180 days.
1558105|NCT02540538|Biological|HBAI20|2 vaccinations with HBAI20 at 0 and 30 days and 1 vaccination with HBVaxPro-10ug at 180 days.
1558106|NCT02540525|Device|Ophira|The procedure will be perfomed with a single incision in anterior wall vagina
1558107|NCT02540525|Device|Transobturator sling|Safyre T Plus ® system uses two helical needles for securing an average urethral sling mesh polypropylene soft tissue below the pubic bone by means of spinal anesthesia. Short form of the sling implantation is carried out as follows: a small longitudinal incision in the anterior vaginal wall approximately 2 cm is performed at 1 cm from the urethral meatus. Takes place below minimum dissection toward the lower branch of the ischium, and with the aid of the needle obturator and perforated membrane (outside-in maneuver). After that, the sling is attached to the needle carrying the same path. Subsequently, the passage of the needle is held in contraleral side. The procedure finishes performing the adjustment of the track with the aid of Kelly forceps type.
1558108|NCT02540512|Procedure|Auricular Acupuncture|Aiguille Semi-Permanent (ASP) acupuncture needles will be used following the Battlefield Acupuncture Protocol
1558109|NCT02540512|Device|Acupuncture|ASP Needles: Small, semi-permanent acupuncture needles that will be used for acupuncture in the ear or taped over the ear for placebo.
1558110|NCT02540512|Procedure|Placebo Acupuncture|The ASP needles will be double taped onto the ear for this procedure.
1558111|NCT02540512|Drug|hydrocodone / acetaminophen 5mg/325mg|"Narcotic/NSAID medication used as the standard medical treatment"
1558112|NCT02540512|Drug|Placebo Pill|Pills will be filled with methylcellulose and administered as a placebo for this intervention.
1558113|NCT02540499|Radiation|DIBH VMAT|Radiotherapy delivered in deep inspiration breath-hold with volumetric modulated arc therapy technique.
1558116|NCT02540473|Behavioral|Manualized Therapy|Relational psychotherapy mothers
1558117|NCT02540473|Behavioral|Control Group|one hour of free time to do with as they wish
1558118|NCT02540460|Drug|LCB01-0371 800mg|LCB01-0371 800mg
1558119|NCT02540460|Drug|LCB01-0371 800mg BID|LCB01-0371 800mg BID
1558120|NCT02540460|Drug|LCB01-0371 1200mg BID|LCB01-0371 1200mg BID
1558121|NCT02540460|Drug|Placebo|Placebo
1558122|NCT02540447|Procedure|Purge|In the recipient before portal declamping, the graft preservative solution and the mesenteric blood is washed out of the circulation into the abdominal cavity and sucked by external sucker through the incompletely anastomosed hepatic vein prior to portal declamping
1558123|NCT02540434|Device|ROTEM|ROTEM delta will be used to identify intraoperative coagulation abnormalities. A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
1558124|NCT02540434|Other|Cryoprecipitate|Subjects with hypofibrinogenemia who are randomized to the Cryoprecipitate arm will be transfused with Cryoprecipitate
1558125|NCT02540434|Drug|RiaSTAP|Subjects with hypofibrinogenemia who are randomized to the RiaSTAP arm will be transfused with concentrated fibrinogen
1558126|NCT02540395|Drug|Tacrolimus (for Group B)|Tacrolimus (for Group B) will be administered orally twice a day (bid). Tacrolimus (for Group B) will be initially given at the 0,1mg/kg bid to achieve a stable 12-hour trough level of 8-10 ng/mL during the first month after transplantation to progressively tapper to 6-8ng/ml thereafter.
1558127|NCT02540395|Drug|MMF (mycophenolate mofetil) (for Group B)|"MMF (mycophenolate mofetil) will be administered orally to patients in group B at conventional doses (1gr/12h) before transplant procedure and during the first 7 days after transplant. For subjects who develop nausea, diarrhea, or other MMF(mycophenolate mofetil) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to MMF), the MMF(mycophenolate mofetil) dose may be decreased to the maximally tolerated dose.
Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™) or to Myfenax.
From day 8 on, patients will not receive MMF."
1558128|NCT02540395|Drug|6-methyl prednisolone (Steroids) (for Group B)|"At the time of surgery, all patients will receive 500mg of 6-methyl prednisolone (Steroids, Urbason, Methypred).
Patients in group B will receive 250mg of 6-methyl prednisolone (or equivalent) on day 2, 125 mg on day 3, 60 mg on day 4 and 30 mg on day 5. From day 6 on, patients will receive 0.25 mg/kg/d of 6-methyl-prednisolone (Steroids, Urbason, Methypred) until month 1, then tapering until discontinuation on month 2 will be performed."
1558129|NCT02540395|Drug|Tacrolimus (for Group A)|"The study group A will receive Tacrolimus (for Group A) (Prograf) to achieve 4-8 ng/ml trough levels during all the duration of the study.
Tacrolimus (for Group A) (Tacrolimus) capsules should generally be administered on an empty stomach or at least 1 hour before or 2 to 3 hours after a meal, to achieve maximal absorption."
1558130|NCT02540395|Drug|Mycofenolate mofetil (MMF) (for Group A)|"Mycophenolate mofetil (MMF) (Cellcept, Myfortic, Myfenax) (for Group A) will be administered orally to patients in group A at conventional doses (1gr/12h). For subjects who develop nausea, diarrhea, or other Mycophenolate mofetil (MMF) (for Group A) -related gastrointestinal adverse effects (eg, symptoms fully assessed and deemed not to have an etiology other than intolerability to Mycophenolate mofetil (MMF) (for Group A), the Mycophenolate mofetil (MMF) (for Group A) dose may be decreased to the maximally tolerated dose.
Subjects unable to tolerate the reduced dose may be converted to mycophenolate sodium (Myfortic™).
The first dose of Mycophenolate mofetil (MMF) (for Group A) should be administered before transplantation."
1558131|NCT02540395|Drug|6-methyl prednisolone (Steroids) (for Group A)|"At the time of surgery, all patients will receive 500 mg of 6-methyl prednisolone (steroids for Group A).
Patients in arm A will receive 20 mg/day of 6-methyl prednisolone (steroids for Group A) (or the equivalent) during the first 2 weeks after transplantation, then tapering to 15 mg from week 3 to week 4 to finally be maintained at 5mg/day."
1558132|NCT02540382|Device|covered stent|A broad range of implant diameters and lengths for the treatment of in-stent restenotic peripheral and central lesions* in patients with AV grafts and AV fistulae Small incremental stent graft lengths to help maintain venous real estate and cannulation area Minimal shortening and radiopaque markers aid in excellent placement accuracy
1558133|NCT02540382|Device|bare stent|"A one piece laser cut, self-expanding nitinol stent combining a micromesh design with a multi segmental construction.
The 36 strut, 6 bridge construction of the Stent provides an unmatched balance of radial force, scaffolding, and longitudinal stability.
The design offers crush recoverable flexibility in the most challenging vasculature, with optimal wall apposition, conformability and minimal foreshortening.
It offers a broad portfolio of sizes for the treatment of routine and challenging Iliofemoral lesions."
1558137|NCT02540343|Other|questionnaires|fill out all questionnaires twice
1558138|NCT02540330|Drug|Fulvestrant|
1558139|NCT02540317|Behavioral|Internet-based CBT|Internet-based treatment with therapist support using an asynchronous messaging system. The treatment is comprised of 12 modules (similar to chapters) and the treatment is 12 weeks long. The treatment is based on cognitive behavior therapy
1558140|NCT02540304|Behavioral|Reducing the Risk|Safer Sex is a clinic-based intervention intended to reduce the incidence of STIs and increase condom use among high-risk sexually active female adolescents and delivered in face-to-face individualized sessions by a female health educator. Reducing the Risk is a sexuality-education curriculum, most often delivered in a school setting that provides instruction and practice in the social skills needed to put into action what students learn about preventing pregnancy and reducing unsafe behavior in future high-risk situations. ¡Cuidate! is adapted from the Be Proud! Be Responsible! curriculum and culturally tailored for Latino youth. It aims to reduce HIV risk and unintended pregnancies by affecting sexual behaviors such as intercourse, number of partners, and condom use.
1558141|NCT02540291|Drug|E7046|E7046 will be administered as a single agent orally once daily (QD) continuously in 21-day cycles. In the dose escalation part, increasing doses of E7046 ranging from 125 mg to 750 mg will be administered to cohorts of 6 participants. In the cohort expansion part, participants will be treated at the RP2D.
1558142|NCT02540278|Behavioral|Positive Prevention PLUS|PP+ has elven 45 minute lessons: (1) Getting Started, (2) Life Planning, (3) Healthy Relationships, (4) Relationship Violence, (5) Family Planning and Contraceptives, (6) Myths and Stereotypes, (7) HIV Disease and AIDS, (8) Recognizing and Reducing Risk, (9) Peer and Media Pressures, (10) Human Immunodeficiency Virus (HIV)/Sexually Transmitted Disease (STD) Testing and Community Resources, and (11) Steps to Success.
1558143|NCT02540265|Drug|N1539|
1558144|NCT02540265|Drug|Intravenous Placebo|
1558145|NCT02540252|Other|Nutritional status among patients with lower limb amputation|Patients nutritional status, inflammatory and metabolic pathway are observed during their hospitalization.
1558146|NCT02540239|Drug|2L PEG|
1558147|NCT02540239|Drug|2L PEG+simethicone|
1558397|NCT02538627|Drug|trametinib|trametininb
1558152|NCT02540213|Device|MIRCERA|Methoxy polyethylene glycol epoetin beta (0.6 mcg/kg q2w) will be administered using MIRCERA ready-to-use-syringes up to 9 months.
1558153|NCT02540200|Device|BST-CarGel|BST-CarGel is a scaffolding material after microfracture treatment is performed in order to treat the chondral lesions. It assists in the repair process by stabilizing the clot in the cartilage lesion via adhesion and inhibition of clot retraction.
1558154|NCT02540200|Procedure|Microfracture|It is a bone marrow stimulation technique, and the standard treatment for chondral lesions of the hip joint.
1558155|NCT02540187|Other|blood specimen|
1558156|NCT02540174|Procedure|integrated addiction treatment program|"At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.
At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption.
The first addiction consultation will be carried out directly in the cancer treatment unit, and integrated to the overall cancer treatment program. This first addiction consultation will concern :
For patients with lung cancer: tobacco and addiction or harmful use of alcohol according to classical criteria
For patients with upper aerodigestive tract cancer: tobacco and any use of alcohol"
1558157|NCT02540174|Procedure|standard of care|"The following actions will be performed by a nurse or by the study coordinator on site who have been trained in tobaccology and addictology :
At the inclusion, a 45 minutes interview for : the completion of questionnaires (Fagerström, AUDIT, CAST, Socrates, M.I.N.I) , the collection of socio-professional information, obstacles and incentives to stop the consumption of alcohol and tobacco, the record of alcohol-tobacco consumptions, the measurement of exhaled carbone monoxide rate expressed in particles per million (ppm) using the CO tester.
At 3, 6, and 12 months: a 20 minutes interview to assess the alcohol-tobacco consumption and the obstacles and incentives to stop the consumption"
1558158|NCT02540161|Drug|Sym004|Sym004 was dosed at 18 mg/kg intravenously every two weeks. Beginning in August 2017, the dose was increased to 24 mg/kg intravenously every two weeks.
1558159|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation|Active treatment with transpalpebral micro-current electrical stimulation device for 3 consecutive days during week1 and 1 day during week 2.
1558160|NCT02540148|Device|Nova Oculus™ Micro-current electrical stimulation - Sham treatment|Non-active treatment with transpalpebral micro-current electrical stimulation device for 3 consecutive days during week1 and 1 day during week 2.
1558161|NCT02540135|Other|fluorescein|fluorescein and conventional neuro-navigation
1558162|NCT02540135|Other|intraoperative MRI|conventional neuro-navigation and iMRI
1558163|NCT02540122|Device|Marketed Contact Lens 1|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
1558164|NCT02540122|Device|Marketed Contact Lens 2|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
1558165|NCT02540122|Device|Marketed Contact Lens 3|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
1558166|NCT02540122|Device|Marketed Contact Lens 4|Marketed contact lens being worn by the subject in a bilateral fashion for approximately 6 hours (+/- 30 minutes).
1558167|NCT02540109|Device|HD-tDCS (Soterix Medical, Active)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
1558168|NCT02540109|Device|HD-tDCS (Soterix Medical, Sham)|Subject will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets.
1558169|NCT02540096|Other|Mental practice|"The sessions will be individualized and carried out in a peaceful setting.The aim of the mental practice protocol was to promote motor imagery of the following activities: get up from a chair and walk and sit, which enrolls the basic and instrumental activities of daily living. The sessions will consist of six steps: (1) Physical Practice (2) Familiarization (3) Memory (4) Relaxation (5) Repeat and (6) post-practice mental relaxation. After the mental practice session, participants will be submitted to individual and structured physiotherapy sessions (the same as the control groups)."
1558170|NCT02540096|Other|Cognitive training and Relaxation|Cognitive training and relaxation session (lasting 30 minutes, three times a week), totaling 12 sessions. The sessions will consist of calculations, memorization, imagination and body relaxation exercises. These sessions will not have any motor imagery. After the cognitive training and relaxation session, participants will be submitted to individual and structured physiotherapy sessions lasting 40 minutes with muscle strengthening and stretching exercises.
1558171|NCT02540083|Device|Digital Breast Tomosynthesis|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
1558172|NCT02540083|Device|Full-Field Digital Mammogram|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
1558173|NCT02540070|Procedure|Periarticular|
1558174|NCT02540070|Procedure|Motor free|
1558175|NCT02540070|Procedure|Motor free with dex|
1558176|NCT02540070|Drug|Ropivacaine|
1558177|NCT02540070|Drug|epinephrine|
1558178|NCT02540070|Drug|morphine|
1558179|NCT02540070|Drug|Ketorolac|
1558180|NCT02540070|Drug|Dexmedetomidine|
1558181|NCT02540070|Drug|saline|
1558182|NCT02540057|Procedure|Flexor carpi radialis|Ligament reconstruction with tendon interposition completed using the flexor carpi radialis tendon
1558183|NCT02540057|Procedure|Abductor pollicis longus|Ligament reconstruction with tendon interposition completed using the abductor pollicis longus tendon
1558184|NCT02540044|Behavioral|ANSWER-2 decision aid|ANSWER-2 will consist of: 1) an Information Module that presents effectiveness and side effects of each treatment option, and 2) an interactive Value Clarification Module that guides patients to consider what matter to them the most, and the pros and cons of each treatment option. Within the Information Module, the decision support information (i.e., the benefits and harms of treatment options) will be presented in narrated text, graphics, and a series of animated patient stories demonstrating attributes required for effective communication with doctors and significant others.
1558185|NCT02540044|Behavioral|Control Group (TAS Consumer Guide)|The Arthritis Society Consumer guide pdf.
1558186|NCT02540031|Drug|"Additional oral preparation (3L of PEG+Asc, Coolprep®)"|"The interventional or experimental arm will receive 1l of additional PEG+Asc, Coolprep® on the day of colonoscopy
* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
1558187|NCT02540031|Drug|"Standard oral preparation (2L of PEG+Asc, Coolprep®)"|"The control arm will receive currently used oral preparation (2l of PEG+Asc, Coolprep®) for colonoscopy
* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g"
1558188|NCT02540018|Device|Transluminal Angioplasty with Paclitaxel-coated Luminor® Balloon Catheter in the Superficial Femoral and Popliteal Arteries|"Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure (DEB) is assigned by randomization.
Luminor35®-DEB PTA catheter is applied."
1558189|NCT02540018|Device|Transluminal Angioplasty with and non-coated (CE-marked) plain old angioplasty balloon (POBA) catheter|Endoluminal guidewire passage of the stenotic and occlusive femoro-popliteal lesion must be performed. A pre-dilatation follows. Then the investigational procedure is assigned by randomization. POBA catheter is applied.
1558190|NCT02540005|Other|ROTEM analysis|
1558191|NCT02539992|Device|Triathlon® CR/Kinematic Alignment|Total knee replacement using patient-specific cutting guides
1558192|NCT02539992|Device|Triathlon® CR/Neutral Overall Limb Alignment|Total knee replacement using patient-specific cutting guides
1558193|NCT02539992|Device|Triathlon® CR/Conventional Limb Alignment|Total knee replacement using traditional instrumentation
1558194|NCT02539979|Drug|Paracetamol|
1558195|NCT02539979|Drug|Placebo - Normal Saline|Normal Saline 100cc
1558196|NCT02539966|Device|Fantom Sirolimus-Eluting Coronary Bioresorbable Scaffold|Bioresorbable Drug-Eluting Scaffold Implantation for the Treatment of Coronary Artery Disease
1558197|NCT02539953|Device|Ambulatory blood pressure monitoring|Patients with dizziness on taking rivaroxaban will have ambulatory blood pressure monitoring to assess haemodynamic effects indirectly
1558198|NCT02539940|Device|Angioplasty Paclitaxel-eluted balloon catheter ELUTAX SV|Angioplasty for revascularization in below-the-knee arteries
1558199|NCT02539914|Other|Virtual Reality|Virtual reality based upper-limb motor and cognitive task
1558200|NCT02539914|Other|Standard|Standard upper-limb motor and cognitive rehabilitation tasks
1558201|NCT02539901|Behavioral|Evaluation of the detection of non-linguistic sounds|Evaluation of the detection of non-linguistic sounds (sound room)
1558202|NCT02539901|Behavioral|Free hearing test categorization|Free hearing test categorization evaluation
1558203|NCT02539901|Behavioral|Early Social Communication Scale (ECSP)|Early Social Communication Scale (ECSP) evaluation
1558204|NCT02539901|Behavioral|psychomotor infancy development scale|
1558205|NCT02539901|Behavioral|"NEPSY (two domains: memory and learning and attention and executive functions)."|NEPSY evaluation
1558207|NCT02539862|Other|cognitive behavioral therapy online|The cognitive behavioral therapy online program is delivered through an accessible web application on a web browser with a personal password
1558208|NCT02539862|Other|psychoeducation|the psychoeducation is delivered by a doctor
1558209|NCT02539849|Dietary Supplement|FOS|
1558210|NCT02539849|Drug|Adalimumab|
1558211|NCT02539836|Dietary Supplement|Dietary nutrition based on plant fermentation extract|The main ingredient of dietary nutrition is plant fermentation extraction which is from many fruit and vegetable fermented by probiotics.
1558212|NCT02539823|Drug|CBD 400 mg|Subjects in Arm CBD 400 mg will receive 400mg of Cannabidiol in each of the three test sessions
1558213|NCT02539823|Drug|CBD 800 mg|Subjects in Arm CBD 800 mg will receive 800mg of Cannabidiol in each of the three test sessions
1558214|NCT02539823|Drug|Control (placebo)|Subjects will receive a harmless, inactive solution to compare and validate the results of the other arms of the study
1558215|NCT02539810|Device|Renal artery Angioplasty plus stenting.|renal artery stenting
1558216|NCT02539810|Drug|Anti hypertensive, statin and antiplatelet medication.|Slow release indapamide 1.5 mg/d (or furosemide 40 mg/d if eGFR is < 30 mL/min/1.73m²) + irbesartan 300 mg/d + amlodipine 10 mg/d + aspirin 75 mg/d (or clopidogrel 75 mg/d in case of allergy or gastrointestinal intolerance to aspirin) + atorvastatin 20 mg/d. After randomization, bisoprolol 10 mg/d, prazosin 5 mg/d, and rilmenidine 1 mg/d and spironolactone 12.5 to 25 mg/d, will be sequentially added from months two to five in both groups if home blood pressure remains more than or equal to 135/85 mm Hg.
1558217|NCT02539797|Device|tDCS|comparing anodal, cathodal, and sham tDCS
1558218|NCT02539784|Device|"Kit for Spinal Cord Stimulator System  SCS Systems  : PRECISION® System"|3 frequencies of SCS are tested for each patient : 50, 100 and 130 Hz
1558219|NCT02539771|Other|Polysomnography and blood sample|"Blood collection is a specific intervention of protocol for the 3 arms. Polysomnography is a specific intervention for the arms  Diurnal VOC  and  Slightly symptomatic "
1558220|NCT02539758|Other|ocular massage|ocular massage could be applied over the globe over the closed eyelids with moderate massage strength for 15 minutes. The compression of the globe was given with finger, and press for 2 seconds, then by a 2 seconds release, with a frequency of 15 presses/minute.
1558221|NCT02539758|Device|LenstarLS900|observed changes of anterior chamber depth before and after ocular massage by LenstarLS900
1558222|NCT02539758|Device|Goldmann tonometer|observed changes of intraocular pressure before and after ocular massage by Goldmann tonometer
1558223|NCT02539745|Other|Vitamin D receptor polymorphic analysis|Vitamin D receptor polymorphic analysis was studied by real-time polymerase-chain reaction high resolution melting analysis.
1558224|NCT02539745|Other|Serum levels of 1a, 25-Dihydroxyvitamin D3|Serum levels of 1a, 25-Dihydroxyvitamin D3 were measured by enzyme-linked immunoabsorbent assay.
1558225|NCT02539719|Drug|SC-003|
1558226|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 8 to 14 of the menstrual cycle were considered to be at the follicular phase and Rocuronium 0,6mg/kg intravenous was applied
1558729|NCT02536196|Device|Embolic Protection Device|Embolic protection
1558227|NCT02539706|Drug|Rocuronium 0,6mg/kg|patients at days 18 to 24 of the menstrual cycle were considered to be at the luteal phase and Rocuronium 0,6mg/kg intravenous rocuronium was applied
1558228|NCT02539693|Drug|Clonidine 75 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 75 µg/mL clonidine in the anesthetic mixture
1558229|NCT02539693|Drug|Clonidine 150 µg/mL in sacrococcygeal block|Sacrococcygeal block will be performed using 150 µg/mL clonidine in the anesthetic mixture
1558230|NCT02539693|Drug|Lidocaine|3 ml lidocaine 1% is injected at each block site
1558231|NCT02539693|Procedure|Pilonidal sinus|Removal of pilonidal sinus
1558232|NCT02539680|Procedure|endoscopy|duodenal biopsies
1558235|NCT02539641|Radiation|Gastric emptying scintigraphy|Scintigraphy is performed to evaluate gastric emptying after eating a pancake labeled by 20 megabecquerel (MBq) Technetium-99m-Albumin (TC-99m-LyoMAA)
1558236|NCT02539641|Other|Determination of gut hormones|Gut hormone levels will be determined after eating a standard meal in the RYGB and SG groups.
1558237|NCT02539628|Drug|ropivacaine 0.2%|Adductor canal block. Placed immediately postoperative. Intervention stops on POD2 12PM
1558238|NCT02539615|Device|ForeCYTE Breast Aspirator|
1558239|NCT02539602|Behavioral|The Need to Know students received the N2K curriculum as described previously|
1558240|NCT02539589|Behavioral|BART|BART is an out of school educational program that intends to provide cognitive behavioral training to reduce HIV risk. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
1558241|NCT02539589|Behavioral|Healthy Living|Healthy Living is a knowledge-based intervention that intends to provide one HIV information-only session and seven sessions on nutrition, healthy eating, body image, and exercise. It is intended to be implemented in 8 sessions lasting 1.5-2 hours. Sessions are to be implemented by a male and female health educator in small gender specific groups of 5-15 participants.
1558242|NCT02539576|Drug|ABC/DTG/3TC FDC tablet|"ABC/DTG/3TC FDC will be supplied as purple, biconvex, oval tablets debossed with 572 Trı on one side and plain on the other side. A single dose, with a unit dose strength of 600 mg/50 mg/300 mg will be administered orally."
1558243|NCT02539563|Device|peanut shaped birthing ball|peanut ball will be utilized
1558244|NCT02539550|Drug|Placebo|Placebo
1558245|NCT02539550|Drug|PF-06266047|PF-06266047
1558246|NCT02539537|Drug|Gemcitabine|
1558247|NCT02539537|Drug|Folinic Acid|
1558248|NCT02539537|Drug|5-Fluoro-uracil|
1558249|NCT02539537|Drug|Oxaliplatin|
1558250|NCT02539537|Drug|Irinotecan|
1558251|NCT02539537|Drug|L-folinic|
1558252|NCT02539524|Other|Yoga bhastrika pranayama breathing exercise|Bhastrika Pranayama is formed by a set of 20 nasal forced and rapid expirations, followed by passive nasal inspirations, followed by 1 alternate nasal breath which always begins through the right nostril, and has a retention between intake and outflow. The set of this breathing exercise is supposed to bring respiratory relief.
1558253|NCT02539524|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation Group Intervention consisted of 12-week pulmonary rehabilitation. Two 1 hour sessions a week, consisting of: 30 min of aerobic training followed by resistance exercises for upper and lower limbs.
1558254|NCT02539511|Drug|CI-581a|
1558255|NCT02539511|Drug|CI-581b|
1558256|NCT02539511|Behavioral|Motivational Enhancement Therapy (MET)|
1558257|NCT02539498|Device|HR-pQCT|HR-pQCT to evaluate cortical and trabecular bone
1558258|NCT02539485|Other|heating precondition|The streamlined liner of the pharynx airway (SLIPA) was heated 2 hours before use.
1558259|NCT02539472|Other|Blood sampling|Blood sampling for quantitative evaluation of nine candidate biomarkers (CD158k/KIR3DL2, KIR2DL4, KIR2DS1, KIR2DS3, KIR3DL1, NKp46, PLS3/T-Plastin, Twist and TOX) by quantitative RT-PCR.
1558260|NCT02539459|Drug|Everolimus|10 mg tablets
1558261|NCT02539446|Behavioral|stable condition|
1558262|NCT02539446|Behavioral|unstable condition|
1558263|NCT02539446|Behavioral|attentional focus|
1558264|NCT02539433|Procedure|F-18-F-DOPA|F-18-F-DOPA i.v. injection of a dose of up to 8.5 mCi. PET scanning started 60-90 minutes post injection
1558265|NCT02539420|Device|BiPAP treatment|Patients will receive BiPAP (via Respironics V60 or Vision BIPAP device) as part of their treatment for status asthmaticus
1558266|NCT02539407|Other|Pharmacokinetics|
1558269|NCT02539381|Procedure|Formal Perimetry (Goldman or Octopus visual Field)|
1558270|NCT02539381|Procedure|Albert's visual inattention test|
1558271|NCT02539381|Procedure|Star cancellation visual inattention test|
1558272|NCT02539381|Procedure|Visual field assessment to confrontation|
1558273|NCT02539381|Procedure|Visual inattention assessment to bilateral stimuli|
1558274|NCT02539381|Device|Digital tumbling E visual accuity assessment|
1558275|NCT02539381|Device|Digital visual field assessment|
1558276|NCT02539381|Device|Digital line crossing assessment|
1558277|NCT02539381|Device|Digital shape cancellation assessment|
1558279|NCT02539355|Other|Diet A|12-week diet
1558280|NCT02539355|Other|Diet B|12-week Diet
1558320|NCT02539095|Device|Normal saline|"Supplementation of fluid and electrolytes (sodium or chlorine deficiency)
Diluent for injection solution Place the needle on the tip of the syringe and inject the product into the articular cavity."
1558321|NCT02539082|Device|Regenseal|Regenseal, collagen, injection in the defect area
1558322|NCT02539082|Drug|normal saline|placebo, normal saline, injection in the defect area
1558392|NCT02538640|Other|High-SDS biscuit|Consumption of the high-SDS product (50g) alone with a glass of water
1558393|NCT02538640|Other|Low-SDS extruded cereals|Consumption of the low-SDS product (42g) alone with a glass of water
1558394|NCT02538627|Drug|MM-151|MM-151
1558281|NCT02539342|Drug|Caphosol|"Subjects randomized to the Caphosol Arm will use Caphosol 4 times per day as follows:
Each dose consists of two 15 mL syringes, to be mixed at time of administration. Caphosol must be used within 15 minutes of mixing.
o Participants may increase the use to 6 times per day if you have symptoms of mucositis.
Using one of the syringes, rinse and gargle (if patient is able) for one minute and then spit. Repeat using the remaining syringe.
For younger patients (less than or equal to 6 years of age), volume may be reduced to two syringes containing 5-10 mL each.
For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Repeat using the second syringe.
Patients are to avoid other oral medications, other mouth cares and food or drink for 15 minutes after using Caphosol.
Patients may use Biotene (5-10 mL) to swish and spit after the 15 minutes has passed"
1558282|NCT02539342|Drug|Biotene|"• Use 5 to 10 mL of Biotene to swish and spit
o For patients unable to successfully rinse and spit, caregivers may paint their mouth (using medical sponge swabs) with the solution two times. Prior to swabbing the patient's mouth, pour Biotene into a cup and using the medical sponge, soak up the solution and use the swab to coat the inside of the patient's mouth. Repeat with a second swab."
1558283|NCT02539329|Other|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS), Rankin score) and 2 blood collection tubes for antibody screening
1558284|NCT02539316|Drug|Smoflipid|
1558285|NCT02539316|Drug|Médialipides|
1558286|NCT02539303|Drug|Yamani-15/5 chemical solution|A 20 ml of Yamani-15/5 will be directly infused into the diseased (calcific) arterial distribution.
1558287|NCT02539290|Behavioral|Detection of ovulation|Detecting the luteinizing hormone surge using test sticks in a urine sample
1558288|NCT02539290|Procedure|Uterine flushing|Injection of 20 millilitres of physiological saline by an intra-uterine catheter the day of the luteinizing hormone surge
1558289|NCT02539290|Procedure|Vaginal flushing|Injection of 10 millilitres of physiological saline intravaginally the day of the luteinizing hormone surge
1558290|NCT02539290|Behavioral|Sexual intercourse|Sexual intercourse within 12 hours after intervention
1558291|NCT02539277|Drug|Jinyebaidu granule|It is a chinese patent medicine extracted from four herbs: honeysuckle, isatis leaf, dandelion, and houttuynia cordata thunb.
1558292|NCT02539277|Drug|Fufangshuanghua granule|It is a Chinese patent medicne extracted from four herbs: honeysuckle, forsythia, radix Isatidis, andrographis paniculata.
1558293|NCT02539277|Drug|Jinyebaidu granule placebo|It is Jinyebaidu granule placebo.
1558294|NCT02539277|Drug|Fufangshuanghua granule placebo|It is Fufangshuanghua granule placebo.
1558295|NCT02539264|Other|Smoking|Influence of smoking on parameters derived from overnight PSG
1558296|NCT02539264|Other|Obesity|Influence of obesity on parameters derived from overnight PSG
1558297|NCT02539264|Other|Benzodiazepine use|Influence of benzodiazepine use on parameters derived from overnight PSG
1558298|NCT02539251|Behavioral|Arabic ASQ -3|Administration of a developmental questionnaire in Arabic (A-ASQ-3) and validation using BSID-III as a gold standard
1558299|NCT02539238|Other|Longitudinal practice and real-time feedback|Brief CPR practice distributed during working hours with real-time feedback
1558300|NCT02539225|Drug|Ramucirumab|Administered IV
1558301|NCT02539225|Drug|Placebo|Administered IV
1558302|NCT02539225|Drug|S-1|Administered PO
1558303|NCT02539225|Drug|Oxaliplatin|Administered IV
1558304|NCT02539225|Drug|Paclitaxel|Administered IV
1558311|NCT02539173|Other|Ultrasound scan|"Non-invasive and non-irradiating. The diaphragmatic thickening in recovery is measured before and after the completion of the anesthetic block using the ultrasound system, the ultrasound probe and of an aqueous gel by trans-thoracic approach.
It measures the thickness on deep inspiration and expiration in supine position. Each measurement is repeated twice. This measurement series lasts 4 minutes, is repeated 15 minutes after completion of the engine block when a block is found and contralateral. The total measurement time is about 12 minutes."
1558312|NCT02539160|Drug|ticagrelor|Diabetic patients with or without chronic kidney disease will be randomized 1:1 to either (A) standard dose (90mg twice daily of ticagrelor) for 7-10 days and then cross-over to low dose (60mg twice daily of ticagrelor) for 7-10 days; (B) low dose (60mg twice daily of ticagrelor) for 7-10 days (phase 1) and then cross-over to standard dose (90mg twice daily of ticagrelor) for 7-10 days (phase 2).
1558313|NCT02539147|Biological|blood samples|Isolation and stimulation of monocytes, preparation of cell lysates, measurement of cytokine production, Western blot
1558314|NCT02539134|Drug|TAK-935|TAK-935 oral solution
1558315|NCT02539134|Drug|Placebo|TAK-935 placebo-matching oral solution
1558316|NCT02539121|Device|Acupuncture|Acupuncture needles
1558317|NCT02539108|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2015 2016 formulation)
1558318|NCT02539108|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2015 2016 formulation)
1558319|NCT02539095|Device|CartiZol|The product, CartiZol, which contains absorbable collagen, is applied on the cartilage defect to stimulate the neovasculization and cell penetration and to assist the natural wound healing process. It supplements the defective or damaged cartilage. Place the needle on the tip of the syringe and inject the product into the articular cavity.
1558395|NCT02538627|Drug|MM-121|MM-121
1558323|NCT02539069|Device|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
1558324|NCT02539056|Device|Chondron Implantation|In one vial (0.4 ml), Main ingredient: 1.2 million or more autologous chondrocytes Culture solution: Adequate amount of Dulbecco's modified Eagle medium (DMEM) The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue.
1558325|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 Megahertz (MHz), and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random.
1558326|NCT02539043|Device|LIPOFOCUS|In cavitation focused ultrasound procedure for reduction of localized abdominal fat, the parameters will be used: maximum power of 8 Watts at a frequency of 1 MHz, and the transducer is used in a timely manner by performing a sweep of the area by 03 times, at random . The procedure is followed by stereodynamic drainage, where it will be used a printhead comprising three ERAs (effective radiation area) of 15 Watt each time this procedure is calculated through the area (size of the area to be treated) divided by ERA (cm² head size).
1558327|NCT02539030|Procedure|Microfracture|simple microfracture
1558328|NCT02539030|Device|CartiFill|add collagen when doing microfracture
1558329|NCT02539017|Drug|Chemo|Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
1558330|NCT02539017|Biological|Immunotherapy|Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
1558331|NCT02539004|Other|Ultrasound study|Ultrasound study using real-time image fusion with a previous NCCT
1558332|NCT02538991|Device|Bulkamid|"Urethral injections will be performed policlinically under local anesthesia (10 ml lidocain, two injections on both sides of the urethra). The Bulkamid-injections will be transurethral four injections (0.2 - 1ml) in locations ten, two and five and seven o'clock within 0.5 to 1 cm from the bladder - urethra junction.
Additional injections will be avoided and can be injected only if the first injections fail. After the operation the patient urinates to empty the bladder. The PVR is checked after the treatment with ultrasound simultaneously with evaluation of stability of the Bulkamid-injections. The treatment will be photographed as before and after still pictures for later evaluation."
1558333|NCT02538991|Device|Tension-free Vaginal Tape|TVT will be performed under local anesthesia (70 - 100 ml 0.25% prilocain cum epinephrine) with i.v. pain medication phentanyl two doses and more on request. Operation will be performed with TVT-Exact® kit. Operation can be performed policlinically or in an operation theatre depending on the patient's medical condition. Cystoscopy will be performed after the set of tapes. A cough stress test with 250 to 300 ml bladder fulfillment will show the right tension of the tape. Before the operation a prophylactic antibiotic of Cefuroxime 1.5 g i.v will be given (Dalacin 900 mg i.v in cases of allergy to penicillin). The patient can go home after 2 to 4 hours follow-up, when PVR is under 150 ml. A sick leave of 5 days is recommended.
1558334|NCT02538978|Biological|Autologous Bone Marrow Concentrate (aBMC)|"Aspirated bone marrow will be processed by centrifugation, separating out a concentrate (aBMC) comprising primarily white blood cells and platelets. These cells will be injected i.m. to loci determined by the operating physician using imaging and vascular flow criteria.
Device: SurgWerks-CLI Kit
Device: VXP System"
1558335|NCT02538978|Biological|Placebo Control (diluted autologous peripheral blood)|Diluted peripheral blood prepared in a blinded fashion to resemble bone marrow will be injected intramuscularly per the same procedure used for the Experimental Device Arm.
1558336|NCT02538965|Drug|Lenalidomide|Lenalidomide will be administered orally once daily for the first 21 days of every 28-day cycle. The starting dose will be 2 mg/kg/day with a maximum dose of 70 mg/day. Number of cycles: 12, or until evidence of progressive disease. Subjects will also be discontinued if unresolved toxicities as described in the protocol occur, or if dose reductions are required and subject does not tolerate minimum dose level of 1mg/kg/day.
1558337|NCT02538952|Device|Xpert device|"Interventions in the Experimental phase of this stepped-wedge trial include: (a) ensuring WHO-recommended TB screening adopted, (b) situating trained TB case finding nurses in the clinics, (c) training clinic personnel in the TB diagnostic algorithms, and (d) activation of the Xpert diagnostic device."
1558338|NCT02538952|Other|Intensified TB Case Finding (ICF)|Interventions in the active comparator phase of this stepped wedge trial only include: (a) adoption of the WHO-recommended 4-symptom TB screen for adults; (b) situating trained TB case-finding nurses in the 22 facilities; and (c) training health facility personnel in TB diagnostic algorithms. There is no Xpert device activation in this phase. Only the standard of care microscopy algorithm (smear microscopy and chest x-ray) are available during this phase.
1558339|NCT02538939|Drug|Sodium thiosulfate|
1558340|NCT02538926|Drug|Asparaginase|Given IM or IV
1558341|NCT02538926|Drug|Cyclophosphamide|Given IV
1558342|NCT02538926|Drug|Doxorubicin Hydrochloride|Given IV
1558343|NCT02538926|Drug|Etoposide|Given IV
1558344|NCT02538926|Drug|Imatinib Mesylate|Given PO
1558345|NCT02538926|Other|Laboratory Biomarker Analysis|Correlative studies
1558346|NCT02538926|Drug|Prednisone|Given PO
1558347|NCT02538926|Biological|Rituximab|Given IV
1558348|NCT02538926|Drug|Vincristine Sulfate|Given IV
1558349|NCT02538913|Behavioral|Exercise training|Daily pelvic floor muscle training and individualized regular exercise training (aerobic and strength exercise) three days per week.
1558350|NCT02538913|Procedure|Usual care|Patients randomized to the control group will receive standard care which does not include any pelvic floor muscle training or individualized exercise training
1558351|NCT02538900|Behavioral|Exercise|Participants in one of the exercise intervention groups will attend once weekly sessions at the medical center for the first four weeks of the study (Weeks 1-4, Phase I). During weeks 5-52 (Phase II), they will receive weekly telephone calls from a study coach.
1558390|NCT02538653|Other|Sandwich biscuit high in SDS|Consumption of the high SDS product (50g) alone with a glass of water
1558391|NCT02538653|Other|Co-extruded cereal low in SDS|Consumption of the low SDS product (48.3 g) alone with a glass of water
1558396|NCT02538627|Drug|MM-141|MM-141
1558352|NCT02538900|Other|Attention control|Our attention control group controls for the possibility that regular contact with the study team may improve outcomes in participants randomized to the intervention. Participants randomized to the control group will attend weekly one-hour educational sessions at Northwestern University for the first four weeks of the intervention (Phase I). These sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, and cancer screening. During Phase II (weeks 5-52), the attention control group will receive weekly telephone calls, lasting 5-15 minutes, with information on a health-related topic.
1558353|NCT02538887|Device|Radio Frequency Surgical Detection|
1558354|NCT02538874|Drug|BMS-986171|
1558355|NCT02538874|Other|Placebo|
1558356|NCT02538861|Radiation|SPECT Imaging Test at Baptist hospital|Single Photon Emission Tomography (SPECT) testing at Baptist Hospital.
1558357|NCT02538861|Radiation|CT Angiography and CT myocardial perfusion at West Kendall Baptist Hospital|The combined approach of CT Angiography and CT myocardial perfusion with new Revolution CT scanner
1558358|NCT02538861|Radiation|SPECT Imaging Test at West Kendall Baptist Hospital|Single Photon Emission Tomography (SPECT) testing at West Kendall Baptist hospital.
1558359|NCT02538848|Drug|HTD4010|injectable solution
1558360|NCT02538835|Behavioral|Metacognitive therapy|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each.
1558361|NCT02538835|Behavioral|Mindfulness based cognitive therapy, group|Group format, 10-12 participants in each group. 8 weekly sessions of two hours each following the manual described by Williams, Zindel & Segal.
1558362|NCT02538835|Behavioral|Support groups|Group format, 10-12 participants in each group. The sessions will only be of supportive character and will not focus on changing or restructuring thoughts, scripts or thought patterns. The format will follow a manual but compared to the other intervention groups the format allow participants to suggests themes for discussions.
1558363|NCT02538822|Device|dynamic imaging|In vivo study of biomechanical behavior of ATA from preoperative dynamic imaging : dynamic CT-scan and 4D-magnetic resonance imaging (MRI)
1558364|NCT02538822|Device|mechanical testing|In vitro study of with mechanical inflation testing of ATA tissue harvested during surgery.
1558365|NCT02538809|Other|measurement of cytokeratin concentration in urine|
1558366|NCT02538796|Other|TEA + Grober Test + Task 1 + Grober Test|"The Test of Everyday Attention (TEA) measures the reaction time of the participant during the occurrence of an expected stimulus.
The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.
The Task 1 consists of a stimulus that moves on the screen. The response of the patient is done on the keyboard. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
1558367|NCT02538796|Other|TEA + Grober Test + Task 2 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.
The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.
The Task 2 consists of a stimulus that is fixed on the screen. The response of the patient is done by pushing or pulling a lever. It is composed on two conditions: one is fast (without conscious), the other consists in assessing words (conscious). It includes food and non-food words."
1558368|NCT02538796|Other|TEA + Grober Test + Implicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.
The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.
The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are implicit condition to detect an A in the word (yes-no answer)."
1558369|NCT02538796|Other|TEA + Grober Test + Explicit Task 3 + Grober Test|"The TEA measures the reaction time of the participant during the occurrence of an expected stimulus.
The Grober Test with 16 words to learn and to remember, measures the episodic verbal memory long term.
The Task 3 is a compilation of tasks 1 and 2 to investigate the bidirectional link. The instructions are explicit condition to judge the emotional value of words (positive-negative answer)."
1558370|NCT02538783|Behavioral|Financial Incentive|Participants in the lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
1558371|NCT02538770|Other|Rapid diagnostics using Anyplex TMII RV16 Detection|Rapid diagnostics using Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR as soon as they are available
1558372|NCT02538770|Other|Delayed diagnostics Anyplex TMII RV16 Detection|Delayed diagnostics Anyplex TMII RV16 Detection, i.e. physician receives results of respiratory virus PCR after one week delay unless specifically solicited
1558373|NCT02538744|Drug|Doxazosin|Participants will be randomized into two groups: placebo and doxazosin 8 mg/d. The doxazosin dose will be increased every 4 days over 11 days, starting with 1mg on the first study day and and ending with 8mg 11 days later. Participants will receive one capsule daily that will contain either placebo or doxazosin.
1558374|NCT02538744|Drug|Modafinil|After titrating doxazosin to the target dose, study procedures will be completed three times, once during treatment with each dose of modafinil (0 [placebo], 200, and 300 mg/d), in pseudo-random order such that 200 mg precedes 300 mg).
1558375|NCT02538744|Drug|cocaine|On the 5th day of study medication treatment participants will receive non-contingent doses of cocaine (placebo, 20, 40 mg, IV) and participate in cocaine self-administration sessions.
1558376|NCT02538744|Drug|Placebo|
1558377|NCT02538731|Procedure|dilation-assisted stone extraction|
1558378|NCT02538731|Device|Spyglass Guided Laser Lithotrips|
1558379|NCT02538718|Drug|MgSO4|
1558380|NCT02538718|Drug|YTP(Ritodrine)|
1558381|NCT02538705|Drug|Neovasculgen|
1558382|NCT02538692|Drug|Tong-Xie-Yao-Fang|Tong-Xie-Yao-Fang is a traditional Chinese formula. It is used for diarrhea management.
1558383|NCT02538692|Drug|Placebo|The placebo is the same as Tong-Xie-Yao-Fang in appearance.
1558384|NCT02538679|Other|Placebo|The usual intraoperative and postoperative pain control; NO TAP block performed
1558385|NCT02538679|Drug|US TAP Bupivacaine/Epinephrine|Ultrasound guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
1558386|NCT02538679|Drug|Lap TAP Bupivacaine/Epinephrine|Laparoscopic guided bupivacaine 0.25% with epinephrine 1:400k will be injected to the transversus abdominis plane.
1558398|NCT02538614|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
1558399|NCT02538614|Drug|BI 836826|BI 836826 will be administered intravenously from Week 2 through Week 46.
1558400|NCT02538601|Behavioral|CBT-A|"CBT-A was an 8-session (1.5 hours/session) group treatment for quitting smoking comprised of an optimized protocol that incorporated all elements of the CBT-S treatment plus skills for reducing PTSD/anxiety symptoms and improving tolerance to withdrawal. The CBT-A intervention included skills based on a transdiagnostic approach: (1) repeated interoceptive exposures to feared bodily sensations (e.g., dizziness, racing heart); (2) corrective information about anxiety and cognitive restructuring of catastrophic misinterpretations of somatic sensations (e.g., I will lose control.); and (3) use of graduated in-vivo exposure to feared and avoided situational experiences related to anxiety, WTC-related PTSD triggers, and smoking (e.g., going to lower Manhattan; driving without smoking)."
1558401|NCT02538601|Behavioral|CBT-S|CBT-S was an adapted group-based CBT smoking cessation treatment delivered in 8 sessions (1.5 hours/session) based on the most recent clinical practice guidelines from the United States Department of Health and Human Services (USDHHS), Treating Tobacco Use and Dependence. Standard cessation elements included psychoeducation on reasons for smoking and barriers to quitting, enlisting social support, monitoring and tapering cigarette use, and counseling regarding high-risk smoking situations and unhelpful ways of thinking about smoking and abstinence. The treatment was similar to protocols used in other smoking cessation research.
1558402|NCT02538588|Device|Nebulizer 1|
1558403|NCT02538588|Device|Nebulizer 2|
1558404|NCT02538575|Other|6-minute walk test|a walk of 6 minutes repeated twice in an interval of 30 minutes
1558405|NCT02538549|Behavioral|ACE4|Activity Challenge 4 is a single player card game that is based on principles of behavioral activation. The game was used with crisis and transitional case management clients, with positive feedback.
1558406|NCT02538536|Drug|PBI4050|
1558407|NCT02537600|Drug|Cobimetinib + Vemurafenib combination treatment|Patients will be treated from day 1 to day 28 with Vemurafenib and from day 1 to day 21 with Cobimetinib. Day 1 to Day 28 corresponds to one cycle of treatment.
1558408|NCT02537587|Other|Control 1|67g of control bar
1558409|NCT02537587|Other|Control 2|86g of control bar
1558410|NCT02537587|Other|15/0|66g of experimental bar 15/0
1558411|NCT02537587|Other|15/0LS|84g of experimental bar 15/0LS
1558412|NCT02537587|Other|15/5|75g of experimental bar 15/5
1558413|NCT02537587|Other|10/5|72g of experimental bar 10/5
1558414|NCT02537587|Other|10/10|80g of experimental bar 10/10
1558415|NCT02537574|Drug|NTX/BUP|Daily doses
1558416|NCT02537574|Drug|NTX/PBO-B|Daily doses
1558417|NCT02537574|Drug|PBO-N/PBO-B|Daily doses
1558418|NCT02537561|Drug|Cisplatin|
1558419|NCT02537561|Drug|Gemcitabine|
1558420|NCT02537561|Drug|Talazoparib|
1558423|NCT02537535|Other|survey|This is a cross-sectional study without specific intervention
1558424|NCT02537522|Device|Contact Lenses with 8.5 BC|Subjects will wear the marketed, daily disposable contact lenses in 8.5 BC.
1558425|NCT02537522|Device|Contact Lenses with 9.0 BC|Subjects will wear the marketed, daily disposable contact lenses in 9.0 BC.
1558428|NCT02537496|Procedure|Repetitive Transcranial Magnetic Stimulation|Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec. Treatment will be applied in sequential order bilaterally to the left and right DLPFC.
1558429|NCT02537496|Procedure|Repetitive Transcranial Magnetic Stimulation - Sham|Same stimulation parameters and site as active condition will be used, but with placebo coil which will have minimal direct brain effects
1558430|NCT02537483|Drug|IDP-120 Gel|Investigational Product: IDP-120 Gel
1558431|NCT02537483|Drug|IDP-120 Component A|Comparator Product: IDP-120 Component A
1558432|NCT02537483|Drug|IDP-120 Component B|Comparator Product: IDP-120 Component B
1558433|NCT02537483|Drug|IDP-120 Vehicle Gel|Comparator Product: IDP-120 Vehicle Lotion
1558434|NCT02537470|Drug|Biphasic Remogliflozin Etabonate|Experimental Drug
1558435|NCT02537470|Other|Placebo|Placebo Comparator
1558436|NCT02537457|Drug|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule15mg for one day
1558437|NCT02537457|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet15mg for one day
1558438|NCT02538510|Other|Laboratory Biomarker Analysis|Correlative studies
1558439|NCT02538510|Biological|Pembrolizumab|Given IV
1558440|NCT02538510|Drug|Vorinostat|Given PO or via PEG
1558445|NCT02538471|Radiation|Radiation therapy|Imaging by PET/CT will be performed at baseline, 5 weeks and 15 weeks. The chosen metastatic sites will receive conformal external beam radiation 7.5 Gy/fraction x 3, to a total of 22.5 Gy over the course of one week.
1558446|NCT02538471|Drug|Study Drug|Patients will receive 300 mg/day of study drug administered via oral drug tablet every day for 14 days on and 14 days off (=28 day cycle) .
1558854|NCT02535299|Drug|Metformin|Metformin(1500mg-2000mg/day) treatment for 6 months
1558447|NCT02538458|Drug|3 % hypertonic saline up to 72H|Treatment by inhalation of 3 % hypertonic saline, up to 72H. Test group.
1558448|NCT02538458|Drug|3 % hypertonic saline up to 24H|"Treatment by inhalation of 3 % hypertonic saline, up to 24H.
followed by 48h of placebo : isotonic saline inhalation. Placebo control group."
1558449|NCT02538445|Other|Memorization of the verbs by miming the action|The participant reads aloud the verbs that appear on the screen, by performing the corresponding action verb.
1558450|NCT02538445|Other|Memorization of the verbs by imagining the action|The participant reads aloud the verbs that appear on the screen, by imagining the corresponding action verb.
1558451|NCT02538445|Other|Memorization of the action verbs by means of another word|The participant reads aloud the verbs that appear on the screen. Then, he reads, without memorizing it, a word associated with the action verb to be learnt to favor the memorization of that one. The word is written near the action verb.
1558452|NCT02538445|Other|Simple memorization of the verbs|The participant reads aloud the verbs that appear on the screen, without additional instructions (control condition).
1558453|NCT02538432|Drug|RQ-00000007|RQ-07 250 mg will taken orally, with or without food, each morning and evening, approximately 12 hours apart. Drug administration will be continuous. Every 21 day period will be considered one cycle of treatment.
1558454|NCT02538432|Drug|Gemcitabine|For patients with breast or lung cancer who have not previously received gemcitabine as part of their therapy or who may benefit from re-challenge with gemcitabine, gemcitabine will be administered at 1000 mg/m2 IV over 30 minutes for 3 out of 4 weeks after appropriate pre-medications. Every 4 week period (28 days) will be considered one cycle.
1558457|NCT02538406|Other|Segmental withdrawal|Interventional group will have at least 3 minutes dedicated to the right side of the colon during segmental withdrawal.
1558458|NCT02538393|Drug|Sorafenib (BAY43-9006) Film-coated tablet|Subjects received a single oral dose of 400 mg sorafenib marketed tablets (2 * 200 mg) in fasting state in Treatment A
1558459|NCT02538393|Drug|Sorafenib (BAY43-9006) Oral suspension|Treatment C: Subjects received a single oral dose of 200 mg sorafenib tablets for oral suspension (2 * 100 mg) in fasting state in the second intervention period; Treatment B: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) in fasting state in the third intervention period; Treatment D: Subjects received a single oral dose of 400 mg sorafenib tablets for oral suspension (4 * 100 mg) after a high-fat, high-calorie breakfast (fed state) in the fourth intervention period.
1558460|NCT02538380|Procedure|EUS-B-FNA followed by EUS-FNA for LAG analysis|
1558461|NCT02538367|Drug|YH12852 IR 0.05mg|
1558462|NCT02538367|Drug|YH12852 IR 0.1mg|
1558463|NCT02538367|Drug|YH12852 IR 0.3mg|
1558464|NCT02538367|Drug|YH12852 IR 0.5mg|
1558465|NCT02538367|Drug|YH12852 IR 1mg|
1558466|NCT02538367|Drug|YH12852 IR 2mg|
1558467|NCT02538367|Drug|YH12852 IR 3mg|
1558468|NCT02538367|Drug|YH12852 DR1 0.5mg|
1558469|NCT02538367|Drug|YH12852 DR1 1mg|
1558470|NCT02538367|Drug|YH12852 DR1 2mg|
1558471|NCT02538367|Drug|YH12852 DR1 4mg|
1558472|NCT02538367|Drug|YH12852 DR2 8mg|
1558473|NCT02538367|Drug|Prucalopride 2mg|
1558474|NCT02538367|Drug|Placebo|
1558475|NCT02538354|Dietary Supplement|Riboflavin supplementation|Supplementation of the normal diet with 1 capsule of 100 mg riboflavin (vitamin B2) during three weeks
1558476|NCT02538341|Biological|Herpes Zoster Vaccine|
1558477|NCT02538341|Drug|Placebo|
1558478|NCT02538328|Device|Harmonic scapel|different surgical devices used in the obesity surgery
1558479|NCT02538328|Device|Ligasure|Bipolar vessel sealing system used in obesity surgery
1558480|NCT02538315|Drug|[18F]FDOPA PET/CT|Implantation of fetal dopaminergic stem cell transplantation by neuro-surgeon followed by [18F]FDOPA PET/CT imaging
1558481|NCT02538302|Drug|Minirin|Minirin 5 to 10 mg daily for 6 months
1558482|NCT02538302|Drug|Oxybutynin|Oxybutynin 5 to 10 mg daily for 6 months
1558483|NCT02538289|Behavioral|Teaching talks|Two teaching talks specifically addressed to medical staff which concerns the adequate treatment and needs of dyspneic patients, including pharmacological and non-pharmacological treatment.
1558484|NCT02538263|Device|Volume-targeted noninvasive ventilation|
1558485|NCT02538250|Dietary Supplement|Nutricomp Drink Plus|Oral nutritional supplementation
1558486|NCT02538237|Drug|placebo|the mouthwash(ibuprofen 2% or placebo) Subgingival Irrigation of mouthwash with an insulin syringe 0.5 ml were rinsed.
1558487|NCT02538237|Drug|Ibuprofen 2% mouthwash|
1558488|NCT02538224|Drug|2.5%ketoprofen gel + 3 % doxycycline|"GroupA:(0.05cc, mixed gel) be put into the periodontal pocket using an insulin syringe.
Intervention category Treatment: drugs"
1558489|NCT02538224|Drug|:2.5%ketoprofen gel|GroupB:2.5%ketoprofen gel which be inserted into the periodontal pocket using an insulin syringe .
1558490|NCT02538211|Biological|Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine|All subjects will be given an oral dose of the rotavirus vaccine, RotarixTM, and intramuscular injections of the Tetanus vaccine and Pneumococcal vaccine, Pneumo 23.
1558491|NCT02538198|Drug|Lenalidomide|
1558492|NCT02538185|Device|NanoJect device (DebioJect™)|The investigational device used in this study is the NanoJect™ device developed by Debiotech company.
1558493|NCT02538185|Device|Classical syringe (1mL Becton Dickinson (BD) Luer-Lock™) with a 25 Guage (G) needle (Terumo® Neolus)|The comparator device used for standard ID injections is a classical syringe (1mL BD Luer-Lock™) with a 25G needle (Terumo® Neolus)
1558494|NCT02538185|Device|Classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)|The comparator device used for standard IM injections is a classical syringe (1mL BD Luer-Lock™) with a 22G needle (Terumo® Neolus)
1558495|NCT02538185|Drug|Vaccin rabique Pasteur®|
1558496|NCT02538185|Drug|Placebo|Sodium Chloride (NaCl) 0,9%; B. Braun
1558497|NCT02538172|Other|T-Track® CMV assay|
1558532|NCT02537886|Device|Patient Centered Virtual Multimedia Interactive Informed Consent tool (VIC)|Six asthma patients will comprise this post-launch focus group, with the goal of gathering opinions, beliefs, and attitudes about VIC.
1558533|NCT02537873|Drug|Lorcaserin|Lorcaserin HCL 10mg tablets (Belviq, Arena Pharmaceuticals)
1558498|NCT02538159|Device|CVC|The inclusion of any CVC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. In the case of CVC, the subclavian vein of choice will be followed by the femoral and jugular. Seldinger technique with direct radiation control in the operating room is used.
1558499|NCT02538159|Device|PICC|The inclusion of any PICC is an aseptic technique, so hand washing, mask, cap is required, sterile gloves and scoping insertion using sterile drapes. The skin disinfection is carried out with 2% chlorhexidine alcohol 17, to be dried completely before insertion of the catheter (30 seconds). No prophylactic antibiotic was administered before insertion. PICC vein of choice is the basilica vein with help of Ecography in the interventional radiology room.
1558500|NCT02538146|Dietary Supplement|acetyl-L-carnitine 1000mg 2X per day for 3 months|non-essential dietary amino acid
1558501|NCT02538133|Biological|99mTc-Exametazime (HMPAO)-labeled leukocytes|Hybrid tomoscintigraphy with labeled leucocytes for patients with suspected vascular prosthesis infection
1558502|NCT02538120|Other|Microvascular assessment|Microvascular assessment
1558503|NCT02538107|Drug|Methoxy-polyethyleneglycol epoetin beta|
1558504|NCT02538094|Device|Transcranial direct current stimulation|Delivery of transcranial direct current stimulation for 30 minutes or sham stimulation using Neuro-Conn Direct Current (DC) Stimulator Plus
1558505|NCT02538081|Drug|Risperidone plus Placebo|Standard of care including Risperidone plus Placebo
1558506|NCT02538081|Drug|Risperidone plus DMXB-A|Standard of care including Risperidone plus DMXB-A
1558507|NCT02538068|Behavioral|Daily Surveys|Participants complete 28 daily surveys of daily meaning, mood, and physical activities.
1558508|NCT02538068|Behavioral|Random Surveys (8)|Participants complete 8 random surveys of activities over the past 24 hours during the first 4 weeks.
1558509|NCT02538055|Behavioral|Living Healthy|This intervention tested the effects of a community health worker delivered lifestyle modification program based on cognitive behavioral therapy on diabetes and pain outcomes in individuals with diabetes and chronic pain.
1558510|NCT02538055|Behavioral|General Health Program|Participants in this arm worked with a Community Health Worker (CHW) who provided a general health program that consisted of didactic information of unrelated general health information. Participants received the same number of contacts with their CHW as the intervention arm. Participants and CHW interacted by telephone 8 times over 3 months.
1558511|NCT02538042|Drug|Nicotine Patch|Both groups will receive nicotine patches (21 mg/d if smoking ≥10 cigs/d or 14 mg/d if smoking <10 cigs/d) to wear for 3 weeks prior to the quit date. After the quit date, both groups will wear the nicotine patch for 10 weeks. Participants that smoked ≥10 cigs/d will wear a 21 mg/d patch for 6 weeks, a 14 mg/d patch for 2 weeks, and a 7 mg/d patch for 2 weeks. Participants that smoked <10 cigs/d will wear a 14 mg/d patch for 6 weeks, then step down to a 7 mg/d patch for 4 weeks.
1558512|NCT02538042|Drug|SPECTRUM Nicotine Research Cigarettes (0.07 mg)|For 3 weeks prior to their quit day, participants will switch to smoking SPECTRUM Nicotine Research Cigarettes instead of their usual brand.
1558513|NCT02538042|Behavioral|MCE+|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view smoking-related environments and smoke their assigned cigarettes.
1558514|NCT02538042|Behavioral|MCE-|During the 3-week, pre-quit period, participants will undergo six, 60 minute sessions during which they will view nature environments and smoke their assigned cigarettes.
1558515|NCT02538029|Behavioral|Dual Task Group|Performing motor-motor or motor-cognitive tasks at the same time.
1558516|NCT02538029|Behavioral|Single Task Group|Performing motor or cognitive tasks alone.
1558517|NCT02538016|Drug|Tolvaptan|
1558518|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(R)|Reference: taken drug before meal
1558519|NCT02538003|Drug|LCB01-0371 Tablet 800 mg(T)|Test: taken drug after meal
1558520|NCT02537977|Biological|CD19-directed CAR-T cells|CD19-directed CAR-T cell infusion will be given by vein
1558521|NCT02537964|Other|washcloths impregnated with 2% chlorhexidine gluconate|All infants in the NICU eligible for the study will be assigned for bathing three times a week with washcloths impregnated with 2% chlorhexidine gluconate
1558522|NCT02537951|Device|AFI microscope|measurement of AFI intensities following increasing nociceptive stimulus intensities
1558523|NCT02537951|Device|negative control 1: lidocaine/prilocaine|measurement of AFI intensities following lidocaine/prilocaine cream
1558524|NCT02537951|Device|negative control 2: 8% capsaicin|measurement of AFI intensities following 8% capsaicin patch
1558525|NCT02537938|Drug|NGP 555|
1558526|NCT02537925|Drug|Celecoxib|Celecoxib 200mg bid po, to the end of concurrent radiotherapy
1558527|NCT02537925|Drug|Nedaplatin|40 mg/m2, IV (in the vein) on day 1 of each 7 day cycle. Number of Cycles: to the end of concurrent radiotherapy
1558528|NCT02537925|Radiation|Concurrent Radiotherapy|The standard radiotherapy schedules were available as conventional radiotherapy and Intensity Modulated Radiotherapy (IMRT). The cumulative radiation dose was 68~74 Gy for primary tumor (2.0~2.3 Gy/f/day, 5 day/ week, /6~7 weeks), and 50~54 Gy for lymphatic positive area (1.8 ~ 2 Gy/f/day, 5 day/week, /5.0~5.5 weeks).
1558529|NCT02537912|Dietary Supplement|Sugarlock®|Subjects ingested 2 capsules (Experimental group) in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
1558530|NCT02537912|Dietary Supplement|Placebo|Subjects ingested 2 capsules placebo in the morning and 2 capsules in the evening (4 capsules/d) for a total of 6 weeks. Anthropometric measurements such as body weight, body fat, waistline, hipline, blood pressure (systolic blood pressure [SBP] and diastolic blood pressure [DBP]) and blood biochemical parameters including FBG, albumin, TC, TG, HDL-C, LDL-C, Cr, BUN, AST and ALT were measured every three weeks. Five subjects were randomly selected to take MRI abdominal scans before and after the trial. After 6-week consumption, anthropometric measurements were examined on week 8 for a follow-up observation.
1558531|NCT02537899|Drug|NeuroAiD|
1558534|NCT02537873|Drug|Cocaine Intravenous (IV)|Cocaine IV administered at doses of 10, 20 and 40 mg during 4 dosing sessions
1558535|NCT02537873|Drug|Placebo comparator|Dextrose in gelatin capsule
1558536|NCT02537860|Other|Paravertebral block injections from T12 to L2|Three anesthetic injections are done
1558537|NCT02537860|Other|Placebo at T11 and L3|Two injections that contain saline are performed
1558538|NCT02537860|Other|Paravertebral block injections between T11 and L3|Five anesthetic injections are done
1558539|NCT02537860|Procedure|Herniorrhaphy|Unilateral inguinal hernia repair
1558540|NCT02537860|Drug|Intravenous (IV) fentanyl|Patients will be given 1 μg/kg intravenous (IV) fentanyl as premedication
1558541|NCT02537860|Drug|Bupivacaine|Each patient will receive 75 mg bupivacaine during PVB
1558542|NCT02537847|Drug|Sitafloxacin|The patients in intervention group will receive carbapenem for the first 3 days then sitafloxacin for 7 days. Total of treatment duration is 10 days.
1558543|NCT02537847|Drug|Ertapenem|Control group will be given ertapenem only for 10 days.
1558544|NCT02537834|Drug|Tofogliflozin|
1558545|NCT02537834|Drug|GLP-1 analogue|
1558546|NCT02537795|Device|deep brain stimulation|Electrical stimulation of the anterior limb of the internal capsule or bed nucleus of the stria terminalis
1558547|NCT02537795|Procedure|anterior capsulotomy|
1558548|NCT02537782|Device|Cardiac resynchronisation therapy|
1558549|NCT02537782|Other|Echocardiography|
1558550|NCT02537782|Other|Magnetic Resonance Imaging|
1558551|NCT02537782|Other|Positron Emission Tomography|
1558552|NCT02537769|Device|Left ventricular assist device (LVAD)|Left ventricular assist device placement (LVAD). All participants will receive an LVAD as a part of routine care for their advanced heart failure.
1558553|NCT02537769|Procedure|Tricuspid Valve Repair (TVR)|Participants will be randomly assigned to receive a tricuspid valve repair (TVR) to repair their tricuspid valve regurgitation in addition to an LVAD placement. Only half of enrolled participants will receive this procedure.
1558555|NCT02537730|Device|Bioclean MPS VII|PHMB (Polyhexamethylene biguanide) base Disinfecting and Cleaning system
1558556|NCT02537730|Device|Aosept Clearcare|Hydrogen Peroxide Disinfecting and Cleaning system
1558557|NCT02537730|Device|comfilcon A|contact lens
1558558|NCT02537704|Behavioral|Group Lifestyle Balance Program|
1558559|NCT02537691|Drug|FP|ICS consisting of FP will be administered by DPI (or equivalent) as per investigator discretion.
1558560|NCT02537691|Drug|LABA|LABA will be administered as per investigator discretion.
1558561|NCT02537691|Drug|LTRA|LTRA will be administered as per investigator discretion.
1558562|NCT02537691|Drug|LAMA|LAMA will be administered as per investigator discretion.
1558563|NCT02537691|Drug|Theophylline|Theophylline will be administered as per investigator discretion.
1558564|NCT02537691|Drug|Oral Corticosteroids|Oral corticosteroids will be administered as per investigator discretion.
1558567|NCT02537665|Other|heating precondition|
1558568|NCT02537652|Other|Blood pressure assessment|Participants will undertake an overnight fast prior to each assessment (only water is allowed to be consumed prior to the assessment). Participants will take their medication the morning of each assessment in accordance with the normal pharmacological management procedures which are used on the acute stroke ward at the Royal Hampshire County Hospital. Following this, participants will rest supine (on an electrically operated bed) for a minimum of 15 minutes. Oscillometric pressure waveforms (using the SphygmoCor XCEL), recorded on the left upper arm, will assess haemodynamic parameters including central and peripheral blood pressure, pulse pressure, and augmentation index (fasted, supine condition).
1558569|NCT02537639|Device|Transesophageal echocardiography simulator|
1558570|NCT02537626|Device|Erchonia ALS Laser|The Erchonia ALS Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. The total energy delivered to the subject per procedure administration is 22.5 joules.
1558571|NCT02537626|Device|Placebo Laser|The Placebo Laser is administered to the subject's frontal cortex, temporal regions and base of the skull 8 times across 4 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration. There is no energy delivered to the subject.
1558572|NCT02537613|Drug|Obinutuzumab|Obinutuzumab given weekly during cycle 1, then monthly during cycles 2-6
1558573|NCT02537613|Drug|Ibrutinib|Ibrutinib given once daily by mouth
1558574|NCT02537444|Drug|Acalabrutinib|
1558575|NCT02537444|Drug|acalabrutinib and pembrolizumab combination|
1558576|NCT02537431|Biological|KRN23|KRN23 is a recombinant human immunoglobulin G isotype 1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).
1558579|NCT02537405|Drug|Rivaroxaban (BAY 59-7939)|Rivaroxaban granule 10mg for one day
1558580|NCT02537405|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Rivaroxaban tablet 10mg for one day
1558581|NCT02537392|Dietary Supplement|Vitamin B Complex and Folic Acid|Daily oral dose containing 2 mg vitamin B1, 2 mg vitamin B2, 2 mg vitamin B6, 2 μg vitamin B12, 2 mg calcium pantothenate, 15 mg nicotinamide and 0.4 mg folic acid.
1558582|NCT02537392|Dietary Supplement|Iron and Folic Acid|Daily oral dose of 60 mg iron and 0.4 mg folic acid.
1558583|NCT02537392|Dietary Supplement|Folic Acid|Daily oral dose of 0.4 mg folic acid.
1558584|NCT02537379|Drug|SOF|SOF 400 mg tablets administered orally once daily
1558585|NCT02537379|Drug|COPE|COPE tablets administered orally in a divided daily weight-based dose according to the package insert for the approved Copegus® labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and > 80 kg = 1000 mg)
1558586|NCT02537366|Drug|Dexmedetomidine|
1558587|NCT02537366|Drug|Placebo|
1558588|NCT02537353|Device|Metal clips|The group will be shot of adrenaline 1: 10,000 in four quadrants, associated with application of metal clips.
1558589|NCT02537353|Drug|Hemospray|The group will be shot of adrenaline 1: 10,000 in the four quadrants associated with application adsorption powder, marketed under the name Hemospray.
1558590|NCT02537353|Procedure|Endoscopy Exam|All patients will be submitted to endoscopy exam in 12 to 24 hours after the therapeutic procedure to confirm the success of the therapy and measure if there the presence of rebleeding.
1558591|NCT02537353|Drug|Adrenaline|The injection of adrenaline solution with 50% glucose at a proportion of 1: 10000 in four quadrants.
1558592|NCT02537314|Drug|benzocaine|0.5% benzocaine solution in saline/HCl administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
1558593|NCT02537314|Other|placebo|Placebo (saline) solution administered by intraduodenal infusion one time (6 ml bolus followed by 75 ml/hour for 105 minutes)
1558594|NCT02537301|Other|joining in the platform|The activities (contents, chatting frequency etc.) of ERCP doctors on the chatting group were retrospectively extracted. The data related to the performance of ERCP (such as case volume, cannulation success rate and PEP etc.) by ERCP doctors were collected by a questionaire.
1558595|NCT02537288|Drug|Fedovapagon|
1558596|NCT02537288|Drug|Moxifloxacin|
1558597|NCT02537288|Drug|Placebo (for fedovapagon)|
1558598|NCT02537275|Device|EyeLIKe Callamatch II, Koryo Eyetech Co, Seoul, Korea|tinted contact lens, daily-wear tinted lens
1558599|NCT02537275|Device|EyeLIKe Shine, Koryo Eyetech Co|clear lens
1558600|NCT02537262|Dietary Supplement|carbohydrate beverage|Carbohydrate group drinks carbohydrate beverage 400ml(9PM~MN) the day before the surgery and 200ml three hours before the surgery.
1558601|NCT02537262|Dietary Supplement|NPO(None Per Oral)|NPO group does not drink any water from the MN before the surgery.
1558602|NCT02537249|Drug|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. After one-lung ventilation, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 20 minutes.
1558603|NCT02537249|Drug|Normal saline|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
1558604|NCT02537236|Dietary Supplement|Omega-3 fatty acids|Omega-3 fatty acid supplementation with fish oil.
1558605|NCT02537236|Behavioral|TLC nutritional intervention|nutritional orientation.
1558606|NCT02537236|Dietary Supplement|Omega-3 fatty acid supplementation with fish oil and TLC nutritional intervention.|Omega 3 fatty acid supplementation with fish oil and nutritional counseling of TLC diet.
1558607|NCT02537223|Drug|BYL719|
1558608|NCT02537223|Drug|Cisplatin|
1558609|NCT02537223|Radiation|Intensity modulated radiation therapy (IMRT)|
1558610|NCT02537210|Drug|Mesalazine|Patients will be prescribed Asacol 2g daily for 12 months
1558611|NCT02537210|Drug|Placebo|Patients will be prescribed placebo 5 capsules daily for 12 months
1558612|NCT02537197|Drug|Naltrexone|Regular opioid antagonist dosing of disordered gamblers
1558613|NCT02537184|Procedure|Oral Clinical conditions|caries incidence assessment dental anxiety assessment
1558614|NCT02537171|Drug|apatinib|Patients will be randomly assigned on a 1:1 basis to treatment with Apatinib 750mg group or Apatinib 500mg group.
1558615|NCT02537158|Drug|Sorafenib|sorafenib group patients will accept sorafenib therapy for one year（400 mg bid,orally).
1558616|NCT02537158|Procedure|TACE|TACE group patients will accept TACE therapy once at a month after resection.
1558617|NCT02537132|Other|Adaptation and training to Non Invasive Ventilation (NIV)|Each person recruited after a respiratory evaluation (baseline spirometry and supine, maximal inspiratory and expiratory pressures (MIP / MEP) or sniff nasal inspiratory pressure (SNIP), 6 Minute Walking Test (6MWT) -if still ambulatory, arterial blood gas, nocturnal polygraphy) will be adapted to Non Invasive Ventilation (NIV). Moreover, the subject will be brought to the management of bronchial secretions (under the terms set out herein) during not less than five outpatient or house accesses, depending on who is randomly assigned to the experimental group or the control group. These accesses will take place weekly, for a period of two months, considering both the needs and the patient's clinical condition.
1558618|NCT02537119|Procedure|Dynamic massage therapy|Dynamic massage therapy on hamstring combined with knee extension
1558619|NCT02537119|Procedure|Massage therapy|Rubbing on hamstrings
1558622|NCT02537093|Behavioral|Psychiatric Consultation|
1558623|NCT02537080|Drug|Nimodipine group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
1558624|NCT02537080|Drug|Control group|the stability of the blood pressure will be managed in interval plus minus 15% of patient's resting blood pressure
1558625|NCT02537067|Drug|CHONDRON|"Harvesting of ankle or knee cartilage
The cells that fill the vial are sufficiently suspended, and a sufficient amount of suspension is grafted in the defect with fibrin glue."
1558626|NCT02537054|Drug|Aflibercept|Intravitreal injection
1558627|NCT02537041|Procedure|elastography function ShearWave Imaging|non-invasive assessment of myocardial stiffness by elastography
1558628|NCT02537041|Procedure|MRI|
1558632|NCT02537015|Drug|Bimatoprost Ocular Insert|ForSight VISION5 product (Bimatoprost Ocular Insert) used continuously for 12 weeks, then replaced with a new ForSight VISION5 product and used continuously for another 24 weeks.
1558633|NCT02537002|Drug|PF-05230907|A single intravenous dose of 3 μg/kg
1558634|NCT02537002|Drug|PF-05230907|A single intravenous dose of 5 μg/kg
1558635|NCT02537002|Drug|Placebo|A single intravenous dose of matched placebo
1558636|NCT02536989|Drug|omeprazole|receive intravenous omeprazole 80 mg stat and then 8mg/hr infusion for 3 days
1558637|NCT02536989|Drug|omeprazole|receive intravenous omeprazole 40 mg stat and then 40 mg q12h for 3 days
1558638|NCT02536976|Drug|mirabegron|
1558639|NCT02536976|Drug|Placebo|
1558640|NCT02536963|Device|Pediatric Vision Scanning device|The Pediatric Vision Scanner (PVS) performs a 3-second, non-invasive scan of both eyes simultaneously while a child looks at a single target. The scan will measure the frequency of the light waves that reflect off of the participants' eyes to determine the fixation state of the eye.
1558641|NCT02536963|Other|Reference examination|Reference examination of the eyes will be performed by a fellowship-trained pediatric ophthalmologist.
1558642|NCT02536950|Device|Fixed set point|Fixed set point arm: A fixed setpoint will be used initially. Staff will observe glucose control over 2 days while subjects remain in a hotel environment, and then over 5 more days in the same subjects in an outpatient setting. The clinical staff will adjust this target up or down by 15 mg/dl based on their glycemic control in the hotel setting.
1558643|NCT02536950|Device|Variable set point|Variable set point arm: The setpoint will be variable over a 30 mg/dl range and glycemic control will be optimized based on the preceding 24-hour window.
1558644|NCT02536937|Drug|eliglustat|"Pharmaceutical form: capsule
Route of administration: oral"
1558645|NCT02536924|Behavioral|Waiting Room Intervention|The waiting room intervention is called RESOLVE (Relaxation SOLving problem and cognitive errors), which is a short film.
1558646|NCT02536924|Behavioral|Treatment as usual.|The patient will receive treatment as usual.
1558647|NCT02536911|Drug|eliglustat|"Pharmaceutical form: capsule
Route of administration: oral"
1558648|NCT02536898|Other|Fracture Liaison Service|
1558649|NCT02536898|Other|Current treatment|
1558650|NCT02536885|Procedure|Liberal group|If the pressure decreases below 75% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 125% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
1558651|NCT02536885|Procedure|Restrictive group|If the pressure decreases below 90% of patient's baseline mean arterial pressure for more than 1 min, continuous application of noradrenalin will be initiated. If the blood pressure increases above 110% of patient's baseline mean arterial pressure for more than 1 min, Ebrantil (urapidil hydrochlorid) will be applied in dose of 5 mg intravenously with the possibility of repeated doses in 2 minutes intervals.
1558652|NCT02536872|Other|None - this is a prospective observational study. Patients will be prescribed their usual treatment (antibiotics) and the effect on urine studied|
1558656|NCT02536833|Drug|SM04690|
1558657|NCT02536833|Drug|Placebo|
1558658|NCT02536820|Behavioral|psychoneuroimmune therapy|
1558659|NCT02536820|Drug|Conventional treatment|Actual diabetes treatment in each participant
1558660|NCT02536807|Drug|Hyaluronan|HA gel injection
1558661|NCT02536794|Biological|Anti-B7H1 Monoclonal Antibody MEDI4736|Given IV
1558662|NCT02536794|Other|Laboratory Biomarker Analysis|Correlative studies
1558663|NCT02536794|Other|Pharmacological Study|Correlative studies
1558664|NCT02536794|Biological|Tremelimumab|Given IV
1558665|NCT02536781|Drug|Anthocyanin|Anti-inflammation gel
1558666|NCT02536781|Drug|Placebo|Blank gel
1558667|NCT02536768|Behavioral|Minimum package of interventions to improve ART adherence|Package of 5 interventions to antiretroviral therapy adherence including fast track initiation counselling, decentralized drug delivery, adherence clubs, fast patient tracing and spaced visits
1558668|NCT02536755|Drug|eliglustat|"Pharmaceutical form:capsule
Route of administration: oral"
1558669|NCT02536742|Drug|Palbociclib|125 mg, orally, daily for 3 weeks followed by 1 week off; repeated at every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
1558670|NCT02536742|Drug|Fulvestrant|500mg, intramuscularly on days 1 and 15 of cycle 1, then on day 1 (+/- 3 days) of every 28 days cycle until progression, lack of tolerability, or patient declines further protocol treatment.
1558671|NCT02536729|Drug|Oral Sodium Phosphate - Normal preparation|
1558672|NCT02536729|Drug|Oral sodium phosphate - Modified Preparation|
1558673|NCT02536729|Drug|polyethylene glycol + Electrolytes|
1558674|NCT02536716|Procedure|Platform-matched dental implant|A platform-matched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
1558675|NCT02536716|Procedure|Platform-switched dental implant|A platform-switched dental implant will be placed surgically, restored with a crown and evaluated for up to 12 months.
1558676|NCT02536703|Device|Lotus Valve System|Lotus Valve System
1558677|NCT02536690|Drug|Propofol|Propofol bolus dose administration according to the predetermined dose by biased coined design up-and-down study.
1558678|NCT02536690|Drug|Remifentanil|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration.
1558679|NCT02536690|Drug|Midazolam|Remifentanil 0.25 mcg/kg/min infusion for 5 min before propofol administration followed by midazolam 0.03 mg/kg administration 1 min after remifentanil infusion start.
1558680|NCT02536664|Drug|Rituximab|
1558681|NCT02536651|Procedure|Ankle surgery|Plastic or orthopedic surgery of the ankle
1558682|NCT02536638|Other|Exposure to pyelonephritis|Pyelonephritis group are patients with exposure to pyelonephritis Without pyelonephritis group are patients without pyelonephritis
1558683|NCT02536625|Other|prospective study|
1558684|NCT02536612|Other|Lottery|Opportunity for entry in lottery (each time, at months 3 and 6).
1558685|NCT02536612|Other|No Lottery|Transport compensation for study visits at baseline and at months 3 and 6. No chance to win lottery ticket.
1558686|NCT02536586|Drug|LY3023414|LY3023414 administered orally.
1558688|NCT02536547|Device|VAP|all patients with suspected VAP : biochemestry microbiology lung ultrasound
1558689|NCT02536534|Other|Correlation assessment|
1558690|NCT02536508|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
1558691|NCT02536508|Drug|GFF MDI 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate
1558692|NCT02536508|Drug|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate
1558693|NCT02536495|Drug|Docetaxel|Given IV
1558694|NCT02536495|Other|Laboratory Biomarker Analysis|Correlative studies
1558695|NCT02536495|Other|Pharmacological Study|Correlative studies
1558696|NCT02536495|Drug|Selinexor|Given PO
1558697|NCT02536482|Dietary Supplement|Amix|Treat the children with cow`s milk allergy for 5 months.
1558698|NCT02536469|Drug|HuMax-IL8|HuMax-IL8 drug product intended for intravenous infusion. Subjects will be treated every 2 weeks. Every 2 doses (4 weeks) will be considered 1 cycle
1558699|NCT02536430|Drug|Ketorolac Tromethamine|One group received a buccal infiltration of Ketorolac Tromethamine
1558700|NCT02536430|Drug|Placebo|buccal infiltration of Normal Saline.
1558701|NCT02536417|Drug|Melatonin|To determine the effectiveness of melatonin in preventing the development of delirium compared with placebo
1558702|NCT02536417|Drug|Sugar pill|To determine if placebo effect plays a part in preventing the development of delirium
1558703|NCT02536404|Drug|Etrasimod|
1558704|NCT02536404|Drug|Placebo|
1558705|NCT02536391|Drug|Ipatasertib (capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
1558706|NCT02536391|Drug|Ipatasertib (tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
1558707|NCT02536365|Behavioral|Sensory Integration Therapy|Children in the SIT treatment group will receive a manualized SIT intervention that follows the principles of sensory integration.
1558708|NCT02536365|Behavioral|Applied Behavioral Analysis|Children in the ABA treatment group will receive intervention that follows the principles of Applied Behavioral Analysis.
1558709|NCT02536352|Drug|Prenatal vitamin-mineral containing 3 mg fluoride|Prenatal vitamin-mineral containing 3 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
1558710|NCT02536352|Dietary Supplement|Prenatal vitamin-mineral containing 0 mg fluoride|Prenatal vitamin-mineral containing 0 mg fluoride to be taken daily, starting at 10-20 weeks gestation until delivery.
1558713|NCT02536326|Device|LEPU Renal Denervation System|LEPU Renal denervation system was similar to Symplicity Catheter System (Medtronic Inc.)
1558714|NCT02536313|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
1558715|NCT02536313|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1558716|NCT02536300|Drug|Idelalisib|Idelalisib tablet administered orally
1558717|NCT02536287|Procedure|total PTX without autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,but without autotransplantation.
1558718|NCT02536287|Procedure|total PTX with autotransplantation|All parathyroid glands were found and removed and sent for histological confirmation,and then a portion of the smallest, preferably nonnodular parathyroid gland was chosen for autotransplantation,sliced into pieces measuring 1*1 *1 mm,and placed into the subcutaneous of the forearm.
1558719|NCT02536274|Device|Lumbo Sensa® bandage|Patients have to wear it over 21-28 days for at least 8 hours a day
1558720|NCT02536274|Device|Dynaflex® flexion orthosis|Patients have to wear it over 21-28 days for at least 8 hours a day
1558721|NCT02536248|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
1558722|NCT02536248|Drug|Placebo|Placebo for 6 weeks
1558723|NCT02536235|Other|heat|activated heating pad to lower abdomen
1558724|NCT02536222|Other|Case investigation of malaria passively detected cases with FT/FDA|Systematic reactive malaria case investigation will be performed in all villages of the six intervention health posts. All malaria cases passively detected in a health post or in the community and confirmed with a positive rapid diagnostic test (RDT) will be considered an index case and will be investigated. A team (field worker and community health worker) will visit the household of the index case and the five closest households (in a 100 meter radius) and will test by RDT all the consenting individuals living in the households. Any households with at least one positive RDT (including the index case) will receive a systematic focal drug administration (FDA) treatment with DHAP through which all members will be treated.
1558725|NCT02536209|Drug|MT-8554 low dose|
1558726|NCT02536209|Drug|MT-8554 high dose|
1558727|NCT02536209|Drug|Oxycodone hydrochloride|
1558728|NCT02536209|Drug|Placebo|
1558730|NCT02536196|Procedure|Transcatheter aortic valve implantation (TAVI)|Transcatheter aortic valve implantation (TAVI)
1558731|NCT02536183|Device|Magnetic resonance high intensity focused ultrasound|Magnetic resonance (MR)-high intensity focused ultrasound (HIFU) provides precise controlled delivery of heat by focusing ultrasound energy inside a lesion using an external applicator that is completely non-invasive and non-ionizing.
1558732|NCT02536183|Drug|Lyso-thermosensitive liposomal doxorubicin|A heat-activated formulation of liposomal doxorubicin with unique property of heat-activated release of doxorubicin, an active agent in most pediatric solid tumors.
1558736|NCT02536157|Device|Thermoplastic splinting|
1558737|NCT02536144|Procedure|magnetic-controlled capsule endoscopy system|"A magnetic-controlled capsule endoscopy(MCCE) included camera,magnet,batter and high polymer material shell.
The MCCE would be turned to sleeping mode capturing picture at a rate of 0.5 frame per second after being swallowed.
While reaching cecum, the MCCE would be turned to a working mode capturing picture at a rate of 2 frame per second.
The MCCE would be controlled by the Magnetic-manipulator out of body to finish the motion of e rotation, somersault, Bird's-eye view, worm's eye view from cecum to anus."
1558738|NCT02536144|Procedure|Colonoscopy|"Bowel preparation should be well done before the examination.
A tube with illumination and camera system would insert into colon from anus.
From the pictures captured by the camera ,the doctor would see the mucous of the colon."
1558739|NCT02536131|Other|Gut-directed hypnotherapy|relaxation technique with hypnotic induction and suggestions aimed at fostering sense of control, acceptance and calming of bowels.
1558741|NCT02536105|Drug|Methylphenidate HCl ER tablets 1|
1558742|NCT02536105|Drug|Placebo|
1558743|NCT02536105|Drug|Methylphenidate HCl ER tablets 2|
1558744|NCT02536105|Drug|Methylphenidate HCl ER for suspension|
1558745|NCT02536092|Device|755nm and 1064nm Nd:YAG laser|Dual wavelength 755nm and 1064nm Nd:YAG laser
1558746|NCT02536079|Drug|NeuroAiD|
1558747|NCT02536066|Behavioral|Postprandial physical activity|Adding a minimum of 30 minutes of physical activity starting maximum 30 minutes after the last meal daily
1558748|NCT02536053|Procedure|Limb salvage|
1558749|NCT02536040|Drug|38% diammine silver fluoride|treatment of cavity with study agent
1558750|NCT02536040|Other|Water|Fluoride free, distilled water
1558751|NCT02536027|Procedure|continuous venovenous hemofiltration|Continuous renal replacement therapy (CRRT) has become routine for patients with AKI, chronic renal failure, ﬂuid overload as well as oliguria in ICU. In clinical practice, continuous venovenous hemofiltration (CVVH) is actually the method of choice for CRRT in critically ill and hemodynamic instable patients. CVVH has significant beneficial effects on removing inflammatory cytokines, improving oxygen index, decreasing vasopressor requirements, increasing cardiac index, and regulating immune dysfunction, specifically in patients with septic shock.
1558752|NCT02536014|Drug|Dexmedetomidine|Dexmedetomidine infusion (0.3㎍/kg/hr) from anesthetic induction to the end of pneumoperitoneum
1558753|NCT02536014|Drug|Saline|Saline infusion during the same time period
1558754|NCT02536001|Device|One mesh Endofast reliant system|One mesh (anterior One mesh Endofast reliant system) will be used to correct both anterior and apical prolapse
1558755|NCT02536001|Device|two meshes Endofast reliant system|Two meshes (anterior and posterior Endofast reliant system) will be used to correct separately the anterior compartment and the apical compartment
1558756|NCT02535988|Radiation|Radiation therapy|3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin for metastatic lesions of colorectal cancer.
1558757|NCT02535988|Drug|Thymalfasin|Patients with metastatic lesions of colorectal cancer receiving 3.5Gy per fraction to a total dose of 35Gy/10 fractions over 2 weeks with concurrent thymalfasin ( given twice a week with an interval of 3-4 days each week).
1558758|NCT02535975|Drug|Metformin|Tablets metformin 500 mg PO three times a day for 24 weeks
1558759|NCT02535975|Drug|Placebo|Tablets placebo PO three times a day for 24 weeks
1558760|NCT02535962|Biological|Lactobacillus acidophilus and Bifidobacterium lactis|study product will be freeze dried and put into foil sachets
1558761|NCT02535962|Other|Placebo|Placebo will look and taste like the investigational product. This also will be provided in a foil sachets
1558762|NCT02535949|Drug|Tranexamic Acid|Tranexamic acid is a man-made form of an amino acid (protein) called lysine. Tranexamic acid prevents enzymes in the body from breaking down blood clots.
1558763|NCT02535949|Other|Placebo|Matching Volume Normal Saline Placebo given IV over 10 minutes within 2 hours of initial injury
1558765|NCT02535923|Behavioral|Cognitive Behavioral Therapy-Insomnia|CBT-I addresses cognitive, arousal and behavioral factors related to sleep difficulties. Sessions combine assessment, conceptualization, psychoeducation, behavioral strategies and cognitive therapy, using a consistent structure including review of participants' sleep log and adherence to behavioral guidelines, modification of time in bed, cognitive therapy, and relaxation techniques. CBT-I also incorporates psychoeducation about biological and psychological elements that regulate sleep. Other strategies include stimulus control (i.e., getting out of bed when not sleepy) to extinguish the conditioned arousal common in insomnia, and relaxation techniques to reduce arousal associated with the bed, bedroom, or bedtime.
1558855|NCT02535286|Drug|Pembrolizumab|IV immunotherapy for cancer
1558856|NCT02535286|Drug|TGR-1202|A once daily oral agent
1558857|NCT02535286|Biological|ublituximab|IV anti-CD20 monoclonal antibody
1558766|NCT02535923|Behavioral|Health and Wellness|Health and Wellness is a general self-management curriculum focused on providing education and support for managing physical and emotional well-being. Each session follows a basic structure including review of previous session material, new educational information and discussion on several topics over the course of single or multiple sessions. Each session will focus on the impact of the topic on overall health and wellness, identifying benefits and challenges to improving or maintaining health in that area, and strategies that clients may find helpful to address challenges in that area. Example topics include physical activity/exercise, nutrition/healthy eating, managing medications and side effects, and addictive behaviors (e.g., substance use, gambling, eating).
1558767|NCT02535910|Dietary Supplement|vitamin D3|Subjects are asked to consume a breakfast rich in 20 µg vitamin D3
1558768|NCT02535910|Dietary Supplement|25(OH) D3|Subjects are asked to consume a breakfast rich in 20 µg 25(OH)D3
1558769|NCT02535910|Dietary Supplement|Control|Subjects are asked to consume a breakfast without vitamin D
1558770|NCT02535897|Dietary Supplement|Flavoured water|
1558771|NCT02535897|Dietary Supplement|Flavoured water + carbohydrate|
1558772|NCT02535897|Dietary Supplement|Flavoured water + carbohydrate + protein|
1558773|NCT02535884|Device|ACTIVA® PC neurostimulator (Model 37601)|the stimulator in the stimulation group will be turned on after implantation of the device
1558774|NCT02535871|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
1558775|NCT02535871|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
1558776|NCT02535858|Device|Heart and respiratory rate and VE|To evaluate the effectiveness of the virtual environment (VE) as a biofeedback of chemically dependent's vulnerability front situations of risk, a total of 50 volunteers who were drug users, monitored by 10 therapists, were enrolled.
1558777|NCT02535858|Device|Heart and respiratory rate and video|Anxiety is characterized by the average variability from both heart and respiratory rate of 30 volunteers undergoing stress environment situations.
1558778|NCT02535845|Behavioral|Project Voice|Project Voice tablet-based intervention plus informational video
1558779|NCT02535845|Behavioral|HPV Informational Video|Informational video only
1558780|NCT02535832|Drug|Pioglitazone|Pioglitazone CT Scan DXA scan Needle muscle biopsy
1558781|NCT02535832|Drug|Placebo|Placebo CT Scan DXA scan Needle muscle biopsy
1558782|NCT02535819|Procedure|Subluxation|One pole of The nucleus is hydrodissected until it lilts above the capsular bag. The tilted nucleus is rotated to face the incision and remaining half nucleus is then tumbled and emulsification continues from the opposite equator outside in until complete
1558783|NCT02535819|Procedure|Divide and Conquer|Cataract nucleus is fragmented into 4 pieces then aspirated by ultrasonic vibration
1558784|NCT02535806|Drug|Velcade|4 doses of study drug will be given.
1558785|NCT02535806|Drug|Methotrexate|Intrathecal dose For CNS negative patients, Day 1 and Day 8
1558786|NCT02535806|Drug|Methotrexate / Hydrocortisone / Cytarabine|Intrathecal dose for CNS positive patients, Day 1, 8, 15, 22
1558787|NCT02535806|Drug|Dexamethasone|Days 1-5 and 15-19
1558788|NCT02535806|Drug|Mitoxantrone|Days 1 and 2
1558789|NCT02535806|Drug|Vincristine|Days 1, 8, 15, 22
1558790|NCT02535806|Drug|Pegaspargase|Days 3 and 17
1558791|NCT02535793|Other|blood test (four dry tubes 7ml) and prick tests|
1558792|NCT02535780|Procedure|Transcranial magnetic stimulation|TMS
1558793|NCT02535780|Procedure|Transcranial direct current stimulation|tDCS
1558794|NCT02535767|Drug|Primaquine|A single low dose of primaquine will be crushed and dissolved in water, and administered in weight-based doses.
1558795|NCT02535754|Behavioral|ALIVE|The company assigned to this condition offered employees participation in the ALIVE program. This program was validated in a previous worksite-based randomized controlled trial (RCT). A baseline assessment includes questions asking about: presence of children at home, habits related to cooking and eating out, physical activity preferences, stage of readiness of change, and perceived barriers to achieving heath behavior goals. This information provides the basis for immediate feedback and individually-tailored messages that include goal-setting and tips to achieve these goals, interactive features, and health information. Biweekly messages are sent for a total of 48 weeks. Outcome data were based on all individuals who completed the baseline assessment.
1558796|NCT02535754|Behavioral|CCS BCY|The company assigned to this condition participated in a comprehensive year-long workplace wellness program intervention focusing on nutrition, weight control, and physical activity, led by the CCS BCY. The program was modeled after a previous successful CCS BCY tobacco control worksite program. This program stresses the importance of developing social and environmental supports at the worksite to promote behavior change . Such supports could include food availability (e.g., cafeteria and vending machine selections), the built environment (e.g., availability of bike racks); social environment (e.g., group lunchtime walking clubs), and health communications (e.g., company newsletters). Outcome data were based on all individuals who completed the baseline assessment.
1558797|NCT02535754|Behavioral|ALIVE + CCS BCY|The company assigned to this condition received both the ALIVE and CCS BCY programs. Employees were encouraged to take part in both ALIVE and company initiatives, but participation in these activities was based on individual preference. Outcome data were based on all individuals who completed the baseline assessment.
1558798|NCT02535741|Device|Triathlon CR Total Knee System|Primary total knee replacement
1558799|NCT02535715|Drug|ORMD-0801 capsules|ORMD-0801 capsules are an oral insulin that has shown promise in preliminary studies. Investigators will evaluate this novel insulin preparation as a potential therapeutic option in diabetic patients.
1558802|NCT02535676|Device|Transcranial Direct Current Stimulation|The device will produce a direct current of 2 mA from one electrode to the other. In active stimulation, the device will be turned on for 20 min and in sham stimulation the device will be turned in 2 mA for one minute and will be automatically turned off the remaining 19 minutes. The sham or active mode is chosen by a numeric code.
1558803|NCT02535663|Dietary Supplement|RG|The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture
1558804|NCT02535663|Dietary Supplement|Placebo|Same product without RG
1558805|NCT02535650|Drug|tipifarnib|Tipifarnib will be administered at a starting dose of 900 mg, po, bid on days 1-7 and 15-21 of 28-day treatment cycles. In the absence of unmanageable toxicities, subjects may continue to receive tipifarnib treatment for up to 12 months as long as the Investigator considers that the treatment is providing clinical benefit.
1558806|NCT02535637|Other|Exclusively breastfeed|There is no intervention other than mothers must exclusively breastfeed.
1558809|NCT02535611|Drug|Placebo|Beside the usual treatment of ischemic stroke, this group will receive placebo for 4 weeks.
1558810|NCT02535611|Drug|Memantine|Beside the usual treatment for ischemic stroke this group will be treated by memantine.
1558811|NCT02535598|Behavioral|Normal presentation|All the material will be presented as plain text.
1558812|NCT02535598|Behavioral|Enhanced presentation|The material of the intervention is designed to be as appealing as possible with clear organization, animated presentations, ample illustrations, etc.
1558813|NCT02535598|Behavioral|Normal support|Participants receive semi-standardized support once a week and there will be no formal training or competence.
1558814|NCT02535598|Behavioral|Enhanced support|Participants are offered daily support through the internet from trained therapists.
1558817|NCT02535572|Device|FEAST|FEAST is a new form of ECT, with directional current, rather than traditional alternating current which goes in both directions between the electrodes.
1558818|NCT02535572|Device|RUL UB|This is right unilateral ultrabrief ECT, the standard of care.
1558819|NCT02535559|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
1558820|NCT02535533|Drug|Selenomethionine (SLM)|SLM administrated orally twice daily for 14 days followed by SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
1558821|NCT02535533|Drug|Axitinib|Following SLM administrated orally twice daily for 14 days, SLM once daily in combination with Axitinib 5 mg twice daily with titration according to package insert
1558822|NCT02535533|Drug|Selenomethionine (SLM)|Maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 given orally twice daily for 14 days, followed by SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
1558823|NCT02535533|Drug|Axitinib|Following maximum tolerated dose (MTD) of SLM determined in the Escalation Part 1 given orally twice daily for 14 days, SLM once daily in combination with axitinib 5 mg twice daily with titration according to package insert
1558824|NCT02535507|Drug|Pyrotinib|Drug: Pyrotinib pyrotinib, single agent, 400mg p.o once daily until disease progressed
1558826|NCT02535481|Device|Epidermal grafting|The Cellutome Epidermal Graft Harvesting System will be used to harvest epidermal grafts.
1558827|NCT02535481|Procedure|Split thickness skin grafting|Split thickness skin grafting will be performed as per normal clinical practice.
1558828|NCT02535455|Behavioral|ACES Pilot|This pilot will consist of 5 individual sessions and an innovative bi-directional text message component that uses participant-written positive self-statements informed by the intervention content (e.g., self-compassion, positive self-reappraisal and nonjudgmental acceptance).
1558829|NCT02535429|Other|massage|
1558831|NCT02535403|Behavioral|ICBT|
1558832|NCT02535390|Behavioral|Action based cognitive remediation|This is a novel form of cognitive remediation in which participants engage in simulated real world tasks in groups and receive therapist feedback in addition to receiving standard cognitive remediation.
1558833|NCT02535390|Behavioral|Cognitive remediation|Cognitive remediation engages participants in computerized exercises meant to improve cognitive functions and provides therapist feedback for how these improvements manifest in everyday life.
1558834|NCT02535377|Other|Sperm cryopreservation|Sperm from the different groups are cryopreserved to evaluate their resistance to preservation.
1558835|NCT02535364|Biological|JCAR015 (CD19-targeted CAR T cells)|"Part A: Following leukapheresis and concurrent with generation of JCAR015, participants will receive, at the Investigator's discretion, cytoreductive chemotherapy based on the Investigator's choice of regimens and/or supportive care.
Part B: Participants who are eligible for treatment in Part B will receive two IV doses of JCAR015 CAR T cells. JCAR015 infusion will be preceded by lymphodepleting chemotherapy."
1558836|NCT02535351|Drug|sunitinib or pazopanib|First-line treatment
1558837|NCT02535351|Procedure|Cytoreductive nephrectomy|Cytoreductive nephrectomy and first-line treatment
1558842|NCT02535325|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal RT
1558843|NCT02535325|Drug|Cisplatin|Given IV
1558844|NCT02535325|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1558845|NCT02535325|Other|Laboratory Biomarker Analysis|Correlative studies
1558846|NCT02535325|Drug|Methoxyamine|Given PO
1558847|NCT02535325|Drug|Pemetrexed Disodium|Given IV
1558853|NCT02535299|Drug|Liraglutide|GLP-1 analog (1.2mg-1.8mg/day) treatment for 6 months
1558858|NCT02535273|Drug|Dexmedetomidine|load dosage：Intravenous injection dexmedetomidine 1 µg/kg，completed within 10 minutes.
1558859|NCT02535273|Drug|Lidocaine|local anesthesia：0.67% lidocaine local anesthesia layer by layer to the periosteum at the puncture site，Establish puncture channel, injection 5ml 0.67% lidocaine into the vertebral body through the catheter, and observe 5-10min before operation
1558860|NCT02535273|Drug|Low-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.3 μg/kg/min until the end of surgery
1558861|NCT02535273|Drug|Moderate-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.5 μg/kg/min until the end of surgery
1558862|NCT02535273|Drug|High-dose Dexmedetomidine|maintenance dose：Intravenous infusion of dexmedetomidine 0.7 μg/kg/min until the end of surgery
1558863|NCT02535273|Drug|normal saline|Intravenous injection normal saline equal quantity，completed within 10 minutes. Intravenous infusion of normal saline 0.125 μg/kg/min until the end of surgery
1558864|NCT02535247|Drug|MK-3475|
1558865|NCT02535221|Drug|Goserelin+TAM+AI|Goserelin 3.6mg subcutaneous injection per 4 weeks, for 16-20weeks. TAM 10mg oral twice a day for the first four weeks(to wait the Goserelin start to work in body) than change to AI 1mg oral once a day with Goserelin for the next 12-16 weeks.
1558866|NCT02535221|Drug|Epirubicin+CTX+5-Fu|Epirubicin(80-100 mg/m2 Q21 days) + CTX(600 mg/m2 Q 21days) + 5-Fu (600 mg/m2 Q21 days or 200 mg/m2 •day from Day1 to day 21) for four to six cycles.
1558869|NCT02535195|Dietary Supplement|Ginger supplement|
1558870|NCT02535195|Dietary Supplement|Placebo (starch)|
1558871|NCT02535182|Other|Blood Draw|"Lab will draw one tube of blood to be stored in 8 mL BD Vacutainer CPT tubes at three study time points as described in Table 4.7b. These time points include baseline, Day -2 (immediately prior to transplant, central line placement, or administration of any conditioning regimen), and Day +28.
Peripheral blood mononuclear cells (PBMCs) will be isolated from the whole blood samples collected from patients at the three designated time points (Baseline, Day -2, and Day +28). The lab will conduct western blotting on the cytosolic and membrane fractions of isolated PBMCs to determine the distribution of Rap1 in the different fractions, and the status of Rap1 prenylation in the cells."
1558872|NCT02535169|Behavioral|Health Education and Coaching Strategy|Utilizing health education and health coaching to intervene with adolescents who are at high risk for type 2 diabetes or prediabetes regarding nutrition and physical activity. A 16-week curriculum will be utilized and phone-based coaching visits will be performed.
1558873|NCT02535169|Behavioral|Dietary consult|A routine clinic-based dietary consult will be performed (approximately 1-hour).
1558874|NCT02535156|Drug|Risperidone|1 mg Risperidone
1558875|NCT02535156|Drug|Placebo|Lactose Placebo
1558876|NCT02535143|Other|Test Cavity Preparation|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block using an airotor and a tungsten carbide bur prior to consuming the test drink
1558877|NCT02535143|Drug|Taurine|250 ml of commercially available taurine containing energy drink to be administered three hours after the last meal and half an hour prior to performing the second test cavity
1558878|NCT02535143|Other|Post intervention test cavity|Subjects will be asked to prepare a cavity 2mmx 2mmx 2mm in an acrylic block 30 minutes after consuming the intervention drink using an airotor and a tungsten carbide bur prior to consuming the test drink
1558879|NCT02535143|Dietary Supplement|Carbonated Apple Juice|250ml of commercially available carbonated apple juice to be administered three hours after the last meal and half an hour prior to performing the second test cavity
1558880|NCT02535130|Device|Positive expiratory pressure|
1558881|NCT02535130|Drug|amikacine nebulization|
1558882|NCT02535117|Procedure|Laparoscopic Surgery(LS)|For LS, the patient was usually placed in the lithotomy position. Pneumoperitoneum was maintained at a pressure between 12 and 14 mmHg. Three to 4 working ports sized between 5 mm and 12 mm were used . Intra-operative ultrasonography was performed routinely. Parenchymal transection was performed using a Cavitron ultrasonic surgical aspirator (CUSA, Valleylab, Boulder, CO, USA). Large bile duct branches or vessels were clipped before division and minor hemostasis was carried out using bipolar diathermy. Large hepatic vein branches were divided by endovascular staplers. A 1.0-cm safety margin was planed to get during the liver resection.
1558883|NCT02535117|Procedure|RFA|RFA was performed according to the Guidelines of Radiofrequency Ablation Therapy for Liver Cancer: Chinese Expert Consensus Statement issued by the Chinese Society of Liver Cancer and Chinese Society of Clinical Oncology RFA was performed under real-time ultrasound guidance. RFA was performed by using a commercially available Cool-tipTM RFA system (Valleylab, Boulder, CO, USA), or a RF 2000 system (Radio-Therapeutics Mountain View, CA). Grounding was achieved by attaching 2 pads to the patient's back or legs.
1558884|NCT02535104|Drug|Ranpirnase|Topical application by subject
1558885|NCT02535104|Drug|Vehicle|Vehicle control
1558886|NCT02535091|Drug|YKP3089|
1558887|NCT02535078|Drug|IMCgp100|soluble gp100-specific T cell receptor with anti-CD3 scFV
1558888|NCT02535078|Drug|durvalumab|anti-PD-L1 monoclonal antibody
1558889|NCT02535078|Drug|tremelimumab|anti-CTLA-4 monoclonal antibody
1558890|NCT02535065|Device|Zenith Low Profile AAA Endovascular Graft and ancillary components|Treatment of patients with abdominal aortic, aortoiliac, or iliac aneurysms having morphology suitable for endovascular repair
1558891|NCT02535052|Biological|Seasonal influenza and pneumococcal polysaccharide vaccines|Vaccination
1558892|NCT02535039|Drug|Methylprednisolone|Anaesthesia in giving 1 mg/kg intravenous methylprednisolone, methylprednisolone (1 mg/kg * d for application to the third day after surgery
1558893|NCT02535039|Other|Physiological saline|The same volume of physiological saline will be given in Placebo group
1558948|NCT02534597|Behavioral|Delayed technical assistance|
1558894|NCT02535013|Device|Lung ultrasound|Lung ultrasound with appropriate interventions depending on the ultrasound finding
1558895|NCT02535000|Drug|Duloxetine|duloxetine 60 mg
1558896|NCT02535000|Drug|Placebo|placebo
1558897|NCT02534987|Other|iCPR2|clinical decision support guiding clinician through clinical prediction rule and associated evidence based orders for strep and pneumonia
1558899|NCT02534961|Drug|Cefazolin|Patients in the prophylactic group will receive antibiotic treatment right after randomization with intravenous cefazolin 2 g (3 g for patients weighing ≥120 kg) within 60 minutes before ablation therapy. Patients in the on-demand group will receive antibiotic therapy only when infection will be suspected or established. Antibiotics will be changed according to the antibiotic sensitivity test of cultured microorganisms.
1558900|NCT02534948|Behavioral|Mindfulness and acceptance group therapy|The manual group intervention will be provided as per the second edition of Mindfulness and Acceptance-Based Group Therapy for Social Anxiety Disorder: A Treatment Manual developed by Fleming, and Kocovski (2014). The intervention will consist of 10 group therapy sessions. Each session will be conducted in 120 minutes. It includes therapist manual, client handouts, and is written to be used in conjunction with The Mindfulness and Acceptance Workbook for Social Anxiety and Shyness. The treatment manual can be easily adapted for individual therapy clients.
1558901|NCT02534935|Biological|rLP2086 vaccine|60 mcg or 120mcg at 0, 2 and 6 months
1558902|NCT02534935|Biological|Pediatric HAV vaccine|0.5-mL dose at months 0 and 6. Normal saline at month 2.
1558903|NCT02534922|Biological|Prolanta, a human prolactin receptor antagonist|Daily subcutaneous dosing
1558904|NCT02534909|Biological|LFG316|LFG316 will be administered to all patients enrolled in the study
1558905|NCT02534896|Drug|Sunpharma1505 1|Sunpharma1505 1+ Placebo
1558906|NCT02534896|Drug|Sunpharma1505 2|Sunpharma1505 2 +Placebo
1558907|NCT02534896|Drug|Reference1505|Reference1505 + Placebo
1558908|NCT02534883|Drug|Misoprostol|To be place vaginally
1558909|NCT02534883|Drug|Placebo|To be placed vaginally
1558910|NCT02534870|Drug|ABT-450/r/ABT-267|Tablet
1558911|NCT02534870|Drug|ABT-333|Tablet
1558912|NCT02534857|Procedure|a shorter exposure of oocyte to spermatozoa|Shorter exposure of oocyte to spermatozoa group: oocytes will be exposed to spermatozoa for 2 hours
1558913|NCT02534844|Drug|VTS-270|Lumber intrathecal infusion of VTS-270 (dose to be selected after Part A)
1558914|NCT02534844|Drug|Sham Procedure Control|No experimental drug administered to patients. All intrathecal administrations are simulated.
1558915|NCT02534831|Procedure|Soft tissue manual therapy protocol|The STMTP consisted of a pre-determined set of seven (7) soft tissue techniques delivered as part of a single treatment session lasting approximately 30 minutes. The techniques and their respective durations were: suboccipital release (5 minutes), anterior thoracic myofascial and sternum release (5 minutes), anterior cervical myofascial release (5 minutes), costal ligament balance (5 minutes) and muscular energy technique (MET) to the following muscles - scalenes (1 minute and 40 seconds), pectoralis minor (1 minute and 40 seconds) and latissimus dorsi and serratus anterior (1 minute and 40 seconds)
1558916|NCT02534818|Drug|lower fluorescein sodium dosage 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on gastric intestinal metapalsia
1558917|NCT02534818|Drug|conventional fluorescein sodium dosage 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on gastric intestinal metapalsia
1558918|NCT02534792|Other|Revalvulation|
1558919|NCT02534779|Other|Placebo Vaginal Insert|Placebo insert
1558920|NCT02534753|Drug|Ascor L 500® (Ascorbic Acid Injection, USP)|A sterile, solution containing 500 mg ascorbic acid per mL
1558921|NCT02534740|Drug|tafamidis|relative bioavailability
1558922|NCT02534740|Drug|tafamidis|fasted
1558923|NCT02534740|Drug|tafamidis|fed
1558925|NCT02534688|Drug|LNG-IUS|
1558926|NCT02534688|Drug|DMPA|
1558927|NCT02534662|Device|ENDOMINA|Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
1558928|NCT02534649|Procedure|Newly obtained biopsy and Blood samples collection|"For each patient:
Frozen and paraffin embedded tumor material (archival or new biopsy) will be obtained for genetic profiling
Four blood samples will be obtained for genetic profiling and assessment of markers The results of each tumor profile will be discussed within a multidisciplinary tumor board which aims at discussing the genomic profiles and at providing a therapeutic decision for each patient.
Patients for whom no molecular aberration has been identified will be treated at the discretion of the investigator and followed until death or study termination whichever occurs first.
All the patients carrying a molecular aberration will be proposed to enter in a clinical trial depending on the possibility of inclusion at the time of molecular report."
1558929|NCT02534636|Drug|BMS-986165|
1558930|NCT02534636|Drug|Interferon alpha-2a recombinant|
1558931|NCT02534636|Drug|Famotidine|
1558932|NCT02534636|Other|Placebo|
1558933|NCT02534623|Procedure|Spinal anesthesia|
1558934|NCT02534623|Procedure|General anesthesia|
1558935|NCT02534623|Drug|bupivacaine|
1558936|NCT02534623|Drug|fentanyl|
1558937|NCT02534623|Drug|propofol|
1558938|NCT02534623|Drug|sevoflurane|
1558939|NCT02534610|Drug|Etoricoxib|120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
1558940|NCT02534610|Drug|Placebo|Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
1558941|NCT02534597|Behavioral|Promotores Training|
1558942|NCT02534597|Behavioral|Delayed Promotores training|
1558943|NCT02534597|Behavioral|Caregiver training|
1558944|NCT02534597|Behavioral|Delayed caregiver training|
1558945|NCT02534597|Behavioral|Materials support|
1558946|NCT02534597|Behavioral|Delayed materials support|
1558947|NCT02534597|Behavioral|Technical assistance|
1558949|NCT02534571|Device|Endoscopic Application of a Hemostatic Powder TC-325|Endoscopic Application of a Hemostatic Powder TC-325 <=150g once
1558950|NCT02534571|Device|Hemo-clipping|Hemo-clipping <=20 clips
1558951|NCT02534571|Drug|Epinephrine|epinephrine injection endoscopically <20 mls
1558952|NCT02534571|Device|thermo-coagulation|contact thermo-coagulation < = 4 pulses
1558953|NCT02534558|Biological|miR 29a|Effects of IL-1β, miR-29a precursor or antisense oligonucleotide treatment on the expressions of miR-29a, miR-29b or miR-29c in cell cultures are quantified
1558954|NCT02534545|Device|Doctormate® (200mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 200mmHg.
1558955|NCT02534545|Device|Doctormate® (60mmHg)|Limb ischemia was induced by Renqiao Remote Ischemic Conditioning Device (Doctormate®) inflating tourniquets to 60mmHg.
1558956|NCT02534532|Other|AF screening|Screening of AF in an opportunistic screening program using a smartphone device/application confirmed by ECG
1558957|NCT02534519|Other|Whole Genome Sequencing (WGS)|There will be no interventions needed other than blood sampling (20 mL blood) in the course of routine blood donation (450 mL blood) for 8 out of 10 individuals planned to be included as specimen, or reference samples in the study.
1558962|NCT02534467|Drug|Montelukast|daily dose according to age for 8 weeks out of 16 weeks of assessment
1558963|NCT02534454|Behavioral|Active Retraining|
1558964|NCT02534454|Behavioral|Sham Retraining|
1558965|NCT02534454|Device|Active transcranial direct current stimulation (TDCS)|
1558966|NCT02534454|Device|Sham transcranial direct current stimulation (TDCS)|
1558967|NCT02534454|Drug|Nicotine Replacement Therapy (Habitrol)|Administration of Nicotine Replacement Therapy Patches
1558968|NCT02534441|Other|Skin patch test|
1558969|NCT02534428|Other|wool clothing|superfine merino wool ensembles for baby wear
1558970|NCT02534415|Drug|Periodontal dressing material|Procedure:Palatal wound area was covered with periodontal dressing material at baseline and 3rd day
1558971|NCT02534415|Drug|0.2% Hyaluronic acid gel|0.2% topical hyaluronic-acid gel was applied to palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
1558972|NCT02534415|Drug|0.8% Hyaluronic acid gel|0.8% topical hyaluronic-acid gel was applied palatal wound area and covered with periodontal dressing material (Peripac®) at baseline and 3rd day
1558973|NCT02534402|Drug|Prednisone|Administration of prednisone to determine the effect on whole blood gene expression.
1558974|NCT02534389|Dietary Supplement|omega-3 fish oil|2,4g of EPA + DHA
1558975|NCT02534376|Drug|ezetimibe 10mg-simvastatin 40mg|Vytorin (ezetimibe 10mg-simvastatin 40mg) will be given on an outpatient basis. The drug will be taken orally each day until the subject undergoes radical prostatectomy. The start of Vytorin is timed so that patients get the last dose the day before surgery. Subjects receive a two to four weeks of Vytorin.
1558976|NCT02534363|Drug|Aripiprazole|Oral, dose range 5-30 mg/day, once or twice a day, during study duration
1558977|NCT02534363|Drug|Quetiapine|Oral, dose range 100-600 mg/day, once or twice a day, during study duration
1558978|NCT02534363|Drug|Ziprasidone|Oral, dose range 40-160 mg/day, once or twice a day, during study duration
1558979|NCT02534363|Behavioral|Cognitive battery|Completed in the following standardized sequence: 1—the Rey Auditory Verbal Learning Test (RAVLT); 2—WAIS-III digit symbol subtest; 3—Grooved Pegboard Test; 4—The Zoo Map Test; 5—Tower of London Test (ToL); 6—Rey Complex Figure (RCF); 7—Trail Making Test (TMT); 8—WAIS-III digits forward and backward subtests; 9—WAIS-III letter-number sequencing subtest; 10—WAIS-III vocabulary subtest that was used as measure of premorbid intelligence quotient (IQ); 11—Stroop Test; 12—letter (FAS) and semantic (animal) fluency tests; 14—Eyes Task; 15—Continuous Performance Test (CPT).
1558980|NCT02534350|Drug|Presatovir|Presatovir tablets administered orally once daily
1558981|NCT02534350|Drug|Placebo|Presatovir placebo tablets administered orally once daily
1558982|NCT02534337|Drug|GEMOX|gemcitabine 1000mg/m2 on Day 1 and oxaliplatin 100 mg/m2 on Day 2. The treatment was repeated every 2 weeks until disease progression or limiting toxicity.
1558983|NCT02534337|Drug|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1;Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
1558984|NCT02534324|Drug|Antihypertensive meds|Antihypertensive medications will be given to newly-diagnosed or non-compliant cases. The additional oral antihypertensive drugs instruction to adjust their current regimens will be given to the patients with underlying hypertension for more BP control. The choices of drugs will be at discretion of treating physicians.
1558985|NCT02534311|Drug|Tocilizumab|Tocilizumab will be administered at 162 mg SC injection for 48 weeks.
1558986|NCT02534298|Other|functional magnetic resonance imaging|functional magnetic resonance imaging
1558987|NCT02534285|Device|hearing protection|Attenuation of hearing during surgery
1558988|NCT02534272|Other|Stool sampling and sequencing of gut microbiota.|
1558989|NCT02534259|Other|Force monitoring of external fixator struts|
1558990|NCT02534246|Device|Ultrasound biopsy needle Echo Tip ProCore|Two passes preformed with Echo Tip ProCore ultrasound biopsy needle (Cook Medical 25 gauge) and two passes will be performed using SharkCore ultrasound biopsy needle (Medtronic [Beacon] 25 gauge) from single lesion.
1558991|NCT02534246|Device|Ultrasound biopsy needle SharkCore|
1558992|NCT02534233|Device|CryoBalloon|Esophageal tissue ablation with focal freezing using nitrous oxide via a single use balloon catheter
1558993|NCT02534220|Device|Manual Toothbrush|Gum Delicate Post-Surgical Toothbrush, Oral-B, Procter & Gamble, Cincinnati, OH
1558994|NCT02534220|Device|Oscillating-rotating toothbrush|Triumph 5000, Oral-B, Procter & Gamble, Cincinnati, OH
1558995|NCT02534207|Drug|Basmisanil|Single oral dose: Basmisanil doses between 20 milligrams (mg) and 960 mg may be used in this study. The planned doses for the first two participants are 160 mg and 480 mg, respectively. Basmisanil dose for subsequent participants will be decided by the investigator and sponsor during the study, based on on-going review of emerging data.
1558996|NCT02534194|Other|Image acquisition|Images of baby's face (including ear) and feet
1558997|NCT02534181|Drug|Caloric Management Protocol|Strategy based on reduction of nutritional intake and electrolyte replacement.
1558998|NCT02534168|Device|Skin conductance monitor for measuring skin conductance|"The Skin conductance monitor for measuring skin conductance on the palm of the hand or sole of the foot in microSiemens (µS); it then calculates the number of skin conductance responses per second and the area under the registration curve.
The device records sympathetic autonomous nervous system through its effect on skin.
The device (Med-Storm Innovation AS, Gimle Terrasse 4, NO-0264 Oslo, Norway, support@med-storm.com) includes cables, skin electrodes, a measurement unit and a monitor."
1558999|NCT02534155|Device|MitraClip®|one or more (if needed) MitraClip® devices are placed on the leaflets of the mitral valve during catheterisation in a catheter laboratory
1559000|NCT02534155|Procedure|Mitral valve Surgery|Repair or replace mitral valve
1559001|NCT02534129|Drug|Difinsa53|Difinsa53 cream is applied to one half of radiation field
1559002|NCT02534129|Drug|Aquaphor|Aquaphor is applied to one half of radiation field
1559003|NCT02534116|Procedure|Vacuum-assisted closure (VAC) therapy|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
1559004|NCT02534116|Procedure|Gauze dressing|Following closure of the incision, patients will either have a gauze dressing placed over the incision (control group), or incisional vacuum-assisted closure (VAC) therapy. The dressing will be removed over a time period of 2 to 5 days after surgery. The gauze dressing will be removed at 2 days and the wound VAC will be removed at 5 days.
1559005|NCT02534077|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
1559006|NCT02534077|Drug|Omegaven|Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 2 years.
1559007|NCT02534077|Drug|Omegaven|If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
1559008|NCT02534064|Dietary Supplement|CALIN+|Consumption of 2 CALIN+ pots per day during 16 weeks and follow up without product intake during 8 weeks.
1559009|NCT02534064|Dietary Supplement|CALIN+|Consumption of 1 CALIN+ pot per day during 16 weeks and follow up without product intake during 8 weeks.
1559010|NCT02534051|Other|Clinical Care Pathway|The clinical care pathway guides aspects of care specific to obese pregnant women:1st trimester: offer of testing for pre-existing diabetes with either 75g OGTT or 50g GCT, nuchal translucency ultrasound (u/s), calculation of body mass index, counselling about weight gain, advising about medical complications, screening for obstructive sleep apnea, and referral to Maternal-Fetal Medicine if history of bariatric surgery, 2nd trimester: offer of maternal-serum alpha fetal protein (spina bifida), anatomy u/s, and 50g GCT and 75g OGTT, 3rd trimester: offer of consultation with anesthesiology, u/s for growth & well-being, counselling about birth risks, and discussion of breastfeeding.
1559011|NCT02534038|Drug|AVP-786|d6-DM/Q
1559012|NCT02534038|Drug|Placebo|matching placebo
1559013|NCT02534025|Procedure|Ischemia preconditioining|Elavate blood pressure cuff pressure to 200
1559014|NCT02534012|Drug|Paravertebral block|Bilateral nerve stimulator-guided PVB is performed while patients are in lateral decubitis position. An intervertebral line is drawn at the appropriate levels and the injection site is marked 2.5 cm lateral to the midline on both sides. After aseptic preparation of the skin, 0.3 mL 2% lidocaine is infiltrated at the injection sites. A 22-G nerve stimulation needle (Stimuplex, B.Braun, Melsungen, Germany) is advanced 1-2 cm perpendicularly to the skin using a nerve stimulating current of 2.5-5.0 mA, while closely watching for contractions of the abdominal muscles. The tip of the needle is adjusted to continue to produce muscle contractions while reducing the stimulating current to approximately 0.5-0.6 mA. Depending on patient weight, 3-5 mL of the local anaesthetic mixture is injected at each injection site.
1559015|NCT02534012|Drug|General anesthesia|Anesthesia is induced with 1 µg/kg fentanyl, 1.5-2 mg/kg propofol and 1-2 mg midazolam. Then, endotracheal intubation is facilitated by 0.15 mg nimbex (cisatracurium). Anesthesia is maintained by 1-1.5% sevoflurane, 0.5 µg/kg/h fentanyl, 0.05 mg/kg/h nimbex, 60% nitrous oxide and 40% oxygen.
1559016|NCT02534012|Procedure|Major abdominal surgery|
1559017|NCT02533999|Device|PEAK® Plasma System|Surgical method for tonsillectomy and adenoidectomy.
1559018|NCT02533999|Device|Electrosurgery|Surgical method for tonsillectomy and adenoidectomy.
1559019|NCT02533986|Dietary Supplement|Berry peel drink|
1559020|NCT02533986|Dietary Supplement|Control drink|
1559021|NCT02533973|Drug|Xamiol® gel|
1559022|NCT02533973|Drug|Daivonex® scalp solution|
1559023|NCT02533960|Other|not applicable (observational study)|Observational study without study related intervention.
1559024|NCT02533947|Behavioral|Exercise|The exercise program will be developed through a pilot phase with 10 patients prior to the start of the main study.
1559025|NCT02533934|Drug|Harvoni|Treatment of Hepatitis C with Harvoni
1559032|NCT02533882|Behavioral|Movement to Music|
1559033|NCT02533882|Behavioral|Adapted Yoga|
1559034|NCT02533869|Radiation|Low-dose CT|Low-dose computed tomography for suspected acute uncomplicated appendicitis
1559035|NCT02533869|Procedure|Laparoscopic appendectomy|All patients diagnosed with an uncomplicated acute appendicitis on low-dose CT-scan will undergo laparoscopic appendectomy to evaluate the sensitivity and specificity of the CT diagnosis
1559036|NCT02533856|Other|ETOC|Services provided to assist patients in accessing needed healthcare services after emergency department discharge such as scheduling appointments, finding new doctors, getting medications, or addressing problems with insurance coverage.
1559038|NCT02533830|Biological|sugarless gum|"One Stick of Sugarless Gum (Samara for food & Chocolates Product Company)S.A.E. , for 15 Minutes Every 2 hours After Surgery Tell Defecation"
1559039|NCT02533830|Other|traditional management|Traditional Management (Oral Intake of Clear Fluid Allowed After Passage of Flatus and Regular Diet With The Passage of Bowel Movement.
1559040|NCT02533817|Dietary Supplement|Dietary sugar|This study examined the effect of high intakes of fructose compared to high intakes of glucose in a randomized crossover design. The treatment was in replacement of 20% of the daily caloric requirements for either fructose or glucose for each individual.
1559041|NCT02533791|Biological|4×10^10vp/1ml Ebola Zaire vaccine (Ad5-EBOV)|one dose, 4×10^10vp/1ml per dose
1559042|NCT02533791|Biological|1.6×10^11vp/2ml Ebola Zaire vaccine (Ad5-EBOV)|two doses, 0.8×10^11vp/1ml per dose, with one dose to each arm at the same time
1559043|NCT02533791|Biological|placebo|
1559044|NCT02533778|Device|mechanical thrombectomy|Mechanical thrombectomy by either Penumbra system, TREVO, or Solitaire retrieval device
1559045|NCT02533765|Drug|Olaparib|Olaparib dispensed to patients at the dose of 300 mg twice daily (BID) continuously until the patient completes the study, withdraws from the study or closure of the study.
1559046|NCT02533739|Behavioral|Cognitive and neuropsychological assesment|
1559050|NCT02533713|Device|Exoskeleton assisted gait training|Gait training will be performed 3 times a week for about an hour for 26 weeks. Gait training will be performed by a trained clinical physical therapist. The goal is to achieve 1 hour of continuous walking on a flat surface per training session. Gait training will continue for 26 weeks (78 sessions).
1559051|NCT02533700|Drug|CEOP/IVE/GDP chemotherapy regimen|"CEOP:
Cyclophosphamide 750mg/m2, ivgtt D1 Pharmorubicin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2,PO,D1-D5
IVE:
Fosfamide 2000mg/m2,ivgtt D1-D3 Pharmorubicin 70mg/m2, ivgtt D1 Etoposide 100mg/m2, ivgtt D1-D3
GDP:
Gemcitabine 1g/m2,ivgtt D1,D8
Cis-platinum 25mg/m2, ivgtt D1-D3
Dexamethasone 40mg, ivgtt D1-D4"
1559052|NCT02533700|Drug|CEOP chemotherapy regimen for 6 cycles|"CEOP:
Cyclophosphamide 750mg/m2, ivgtt D1 Pharmorubicin 70mg/m2,ivgtt D1 Vincristine 1.4mg/m2（max 2mg）, ivgtt D1 Prednisone 60mg/m2,PO,D1-D5 every 21 days for total 6 courses"
1559053|NCT02533687|Procedure|Bipolar TURP-1|Bipolar transurethral resection of prostate (TURP)
1559054|NCT02533687|Procedure|Bipolar TURP-2|Bipolar TURP
1559055|NCT02533687|Procedure|Monopolar TURP|Monopolar TURP
1559056|NCT02533674|Drug|Gemcitabine plus PM060184|
1559057|NCT02533661|Other|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
1559058|NCT02533648|Drug|2 capsules of allopurinol 150 mg daily for 3 month|2 capsules of allopurinol 150 mg daily for 3 month
1559059|NCT02533648|Drug|2 capsules of lactose daily for 3 month|2 capsules of lactose daily for 3 month
1559060|NCT02533635|Dietary Supplement|A Master Ganoderma Detox Tea|A Master Ganoderma Detox Tea is consisted of GANODERMA, HERBA HOUTTUYNIAE, GLYCYRRHIZAE RADIX ET RHIZOMA and RUCTUS MOMORDICAE.
1559061|NCT02533583|Device|pulse oximetry (PHILIPS intelliven MP5)|all newborn monitor pulse oximetry in left hand
1559062|NCT02533570|Drug|Brentuximab vedotin|
1559063|NCT02533570|Drug|Placebo|
1559107|NCT02533245|Other|Home-based indiviualized exercise training program|Based on these results of the cardiopulmonary exercise test (CPET) on a cycle ergometer, an individualized training program (cycling/hiking) is prescribed by a physical therapist for 6 months (3x/week, ≥30min/session).
1559064|NCT02533557|Device|stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice with the up-down direction at the different puncture site and LA is injected 15 mL at a time.
1P2I group: nerve stimulating needle is advanced twice with the up-down direction at the same puncture site and LA is injected 15 mL at a time."
1559065|NCT02533557|Drug|lidocaine mixed with epinephrine|2P2I group and 1P2I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time) with the up-down direction at the different puncture site. 1P2I group is injected LA at equally divided doses with the up-down direction at the same puncture site.
1559066|NCT02533544|Drug|tenofovir disoproxil fumarate|
1559067|NCT02533531|Device|1-Lead Patch|The 1-Lead Patch will record and transmit ECG data to a gateway, which will then transmit the data to a central database.
1559068|NCT02533518|Procedure|Rigid bronchoscopy with ultraviolet transmission|
1559069|NCT02533518|Other|Biopsy|
1559072|NCT02533492|Device|vicryl|wound closure with vicryl suture
1559073|NCT02533492|Device|Vicryl plus|wound closure with vicryl plus suture
1559074|NCT02533479|Other|Caloric restriction|three alternate days weekly along 4 weeks.
1559075|NCT02533466|Other|Sodium fluoride + potassium nitrate|Marketed toothpaste containing 1450ppm fluoride as sodium fluoride and 5% potassium nitrate
1559076|NCT02533466|Other|Potassium nitrate|Experimental toothpaste containing 5% potassium nitrate
1559078|NCT02533440|Procedure|EXPAREL and Local Anesthetics|Patients will receive EXPAREL and local anesthetics, as well as opioid and non-opioid analgesics prescription, (only use if needed, for post surgical pain)
1559079|NCT02533440|Procedure|Oral Opioid and Local Anesthetics|Patients will receive local anesthetics, as well as oral opioid or non-opioid analgesics, (only use if needed, for post surgical pain)
1559080|NCT02533427|Drug|SOF/VEL/GS-9857|SOF/VEL/GS-9857 (400/100/100 mg) FDC tablet administered orally once daily
1559081|NCT02533427|Drug|GS-9857|GS-9857 100 mg tablet administered orally once daily
1559082|NCT02533427|Drug|Norgestimate/ethinyl estradiol|Norgestimate 0.180 mg/0.215 mg/0.25 mg/ethinyl estradiol 0.025 mg tablet administered orally once daily according to the package insert
1559083|NCT02533414|Device|RIRS with UAS|Ureteral access sheath (UAS) will be used during RIRS.
1559084|NCT02533414|Device|RIRS without UAS|Ureteral access sheath will not be used during RIRS.
1559085|NCT02533401|Drug|Cyclophosphamide|Cyclophosphamide will be administered IV at 250 mg/m^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
1559086|NCT02533401|Drug|Fludarabine|Fludarabine will be administered IV at 25 mg/m^2/day on Day 2-4 of Cycle 1 and then on Day 1-3 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
1559087|NCT02533401|Drug|Rituximab|Rituximab will be administered IV at 375 mg/m^2 on Day 1 of Cycle 1 and then at 500 mg/m^2 on Day 1 of Cycles 2 to 6. Each cycle will be 28 days or 4 weeks in length.
1559088|NCT02533388|Device|Hwato Electronic Acupuncture Treatment Instrument|Thirty minutes prior to the induction of anaesthesia, the patients in the TEAS group started to receive TEAS by a stimulator (Hwato Electronic Acupuncture Treatment Instrument, model No.: SDZ-II, Suzhou Medical Appliances Co., Ltd., Suzhou, China) to the right hand, forearm and neck by an experienced acupuncturist at the Hegu (LI4), Neiguan (PC6), Lieque (LU7), Chize (LU5), Futu (LI18) and Renying (ST9) acupoints. TEAS was peformed with an alternate dense-disperse frequency of 2 and10 Hz ( 2 Hz for 10 s and 10 Hz for 5 s). The optimal intensity ranged from 6-15 mA, The stimulus continued until 5 min before the end of surgery.
1559089|NCT02533388|Device|Placebo|The patients in the Sham group were also connected to the apparatus, but electronic stimulation was not applied.
1559090|NCT02533375|Drug|Adalimumab|Adalimumab
1559091|NCT02533362|Drug|ANF-Rho|Pegylated version of recombinant human granulocyte-colony stimulating factor (G-CSF)
1559092|NCT02533349|Drug|Motilitone|30mg, 1 tablet, 3 times a day
1559093|NCT02533349|Drug|Pantoprazole|40mg, 1 tablet, 1time a day
1559094|NCT02533349|Drug|Placebo|30mg, 1 tablet, 3 times a day
1559095|NCT02533336|Drug|abamectin and fenpyroximate|
1559099|NCT02533310|Other|OST treatment with in-vivo spiders|Subjects are exposed to phobic stimuli with the aid of a trained psychotherapist during a session of maximum 3 hrs duration. The intensity of exposure is increased in four sequential steps, 1. learning to catch a spider with a glass and paper, 2. touching a spider, 3. letting a spider walk on your hand, 4. letting a spider walk on your body. These stages repeat with increasingly larger spiders. The goal of therapy is not absolute symptom reduction but sufficient reduction to allow the individual to expose themselves in everyday situations.
1559100|NCT02533310|Other|VR-OST treatment with virtual spiders|The VR-OST treatment introduces a virtual gamified version of OST treatment using a modern virtual reality headset. Individuals advance themselves through increasing levels of exposure intensity with the assistance of an automated virtual therapist.
1559101|NCT02533297|Other|Providing clinical skills conditions|
1559105|NCT02533271|Radiation|Short-course radiotherapy with neoadjuvant chemotherapy|Short-course radiotherapy with 4 cycles of neoadjuvant chemotherapy
1559106|NCT02533271|Radiation|Long-term chemoradiotherapy|Standard chemoradiotherapy
1559108|NCT02533245|Other|Supervised group training sessions|7 supervised group training sessions (cycling/hiking) are organized by a physiotherapist
1559109|NCT02533245|Other|Climb of the Mont Ventoux|Cycle or hike up the Mont Ventoux (25.7 km, average slope 4.5%)
1559110|NCT02533232|Drug|Minocycline|Minocycline 200mg per day
1559111|NCT02533219|Drug|18 F-DOPA|Subjects will undergo PET imaging with [18F]-DOPA. All PET imaging will be performed after administration of a single dose (0.08 - 0.16 mCurie/kg) of [18F]-DOPA. PET imaging can be performed on either Philips Ingenuity TF PET/MRI or PET/CT.
1559112|NCT02533206|Procedure|Endoscopic Polypectomy Performed in Clinic|Endoscopic polypectomy performed in clinic under local and topical anesthesia
1559113|NCT02533206|Procedure|Functional Endoscopic Sinus Surgery (FESS)|Functional Endoscopic Sinus Surgery
1559114|NCT02533193|Procedure|ERAS perioperative cares|"Patient's preoperative counseling & education before surgery
No Bowel preparation
Drug: Oral Carbohydrate Solution (OCS). Take 250ml OCS orally 2 hours before surgery
Fluid restriction & Management by pulse contour analysis or transesophageal doppler
Early mobilization
Early oral feeding (postoperative 1 day - liquid diet, 2 days - semifluid diet (SFD), 3 days - normal diet)
Intravenous patient controlled analgesics (no opioids analgesics)
Postoperative Nausea Active Control
No nasogastric tube
No drain insertion
Patients will be discharged at POD#4 if there's no problem"
1559115|NCT02533193|Procedure|Conventional perioperative cares|"No Patient's preoperative counseling & education before surgery
Bowel preparation
No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery
Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)
Conventional Mobilization
Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)
IV PCA
Postoperative Nausea Control if needed
No Thromboembolism prophylaxis
No or Low Content Oxygen therapy
Drainage tube insertion if needed"
1559116|NCT02533180|Biological|Immunosuppression withdrawal|"Participants will initiate calcineurin inhibitor (CNI) withdrawal after at least 3 weeks of stable liver function, as documented by liver function tests (direct bilirubin, alanine aminotransferase and gamma-glutamyl transferase) separated by at least 1 week in the 3 week period prior to withdrawal.
CNI withdrawal will occur in eight 3 week intervals with each subsequent reduction based on liver function tests over the prior 3 week interval.
Participants on CNI and prednisone will undergo withdrawal from the two therapies concurrently.
If participants are weaned off the CNI successfully, they will initiate non-CNI withdrawal. The non-CNI withdrawal includes two dose reductions of approximately 50% over a 6 week period each, after which the drug will be discontinued."
1559118|NCT02533154|Drug|Prosicca|Prosicca eyedrops Dosage: on demand Route of administration: topical
1559119|NCT02533154|Drug|Prosicca sine|Prosicca sine eyedrops Dosage: on demand Route of administration: topical
1559120|NCT02533154|Other|Bacterial culture|bacterial cultures obtained with conjunctival swabs
1559121|NCT02533141|Device|Dynamic Vessel Analyzer (DVA)|Measurement of flicker induced vasodilatation, retinal vessel diameters and oxygen saturation
1559122|NCT02533141|Device|Laser Doppler Velocimetry (LDV)|Measurement of red blood cell velocity in retinal vessels
1559123|NCT02533141|Drug|Simvastatin|Simvastatin Ranbaxy (Basics GmbH, Leverkusen, Germany) Dosage: 40 mg per day for 4 weeks, ingested in the morning Route of administration: peroral
1559124|NCT02533141|Other|Placebo|Placebo, once daily for 4 weeks
1559125|NCT02533128|Drug|Liberal blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 60 mmHg
1559126|NCT02533128|Drug|Tight blood pressure management|Protocolized hemodynamic management to maintain mean arterial pressure (MAP) > 75 mmHg
1559127|NCT02533115|Drug|CPX-351|"CPX-351 (cytarabine:daunorubicin) Liposome for Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio shown to act synergistically in pre-clinical studies. The liposome membrane is composed of distearoylphosphatidylcholine, distearoylphosphatidylglycerol and cholesterol in a 7:2:1 molar ratio.
CPX-351 is provided as a sterile, pyrogen-free, purple, lyophilized product in 50 mL glass, single-use vials. Each 50 mL vial after reconstitution contains 20 mL of CPX-351 (5 units/mL). Each unit (u) contains 1 mg cytarabine and 0.44 mg daunorubicin base in liposomes suspended in sucrose. Product is stored at 5˚ ± 3PoPC."
1559129|NCT02533089|Other|KT intervention|Multifaceted KT intervention employing peer-trainer led educational outreach, a point of care reminder tool, and a peer mentoring network.
1559130|NCT02533076|Other|Challenge agent: capsaicin|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.
In ring number 1 and 2, subjects will receive a topical dose of 1000 µg/20 µL capsaicin (single-blind). Change in dermal blood flow induced by capsaicin will be measured with Laser Doppler Imaging."
1559131|NCT02533076|Other|Challenge agent: placebo|"During the study period (Day 1), in each subject 3 equally spaced (minimum distance of 4 cm) 10-mm rubber O-rings (8 mm inner diameter) will be placed on the volar surface of the forearm. The most proximal ring (i.e. at least 15 cm proximal of the wrist crease) is referred to as ring number 1; the most distal ring is referred to as ring number 3; in between is ring number 2.
In ring number 3, subjects will receive a topical dose of placebo (single-blind).Change in dermal blood flow induced by placebo will be measured with Laser Doppler Imaging."
1559132|NCT02533076|Device|Mechanical stimulation with Von Frey filaments|Von Frey filaments will be used to measured the mechanical detection and pain threshold of the volunteers. The Von Frey filaments will be applied on the upper capsaicin spot in sequential order. The subject will be asked to indicate when he feels the application of the Von Frey filaments and when it hurts.
1559173|NCT02532777|Drug|Angiotensin-converting enzyme inhibitor(ACEI)|
1559174|NCT02532777|Drug|Methylprednisolone|
1559175|NCT02532764|Drug|QR-010|Single-stranded RNA antisense oligonucleotide in aqueous solution for oral inhalaton
1559176|NCT02532764|Drug|Placebo|Normal Saline
1560462|NCT02523599|Other|Placebo|Plain collagen implant (vehicle)
1559133|NCT02533076|Device|Temperature sensitivity measurement with Advanced Thermal Stimulation|Temperature sensitivity (detection and pain threshold) will be determined using Advanced Thermal stimulation. A thermode will be attached to the hand of the volunteer with a baseline temperature of 32°C. The thermode will heat up and cool down with a rate of 1°C/second and the volunteer will be asked to click on a computer mouse when he feels the change in temperature and when it hurts.
1559134|NCT02533063|Device|VibeTech One|"Vibration Training The VibeTech One Rehab Chair allows vibration exercise while seated. A force is applied on a footplate that simulates the weight of standing or partial bodyweight. The participants will train for 10 minutes 3 days per week. In the loading + vibration group (intervention group) vibratory acceleration will be 30Hz and the applied load will be 50% of body weight up to a device maximum applied load of 100 lbs. Vibration intensity will initially be set to 0.2 g and will increase by 0.2 g every other week, as tolerated by the subject, and max out at 1.0 g."
1559135|NCT02533050|Device|CPAP treatment|Patients treated wear a face mask during sleep which is connected to a pump (CPAP machine) that forces air into the nasal passages at pressures high enough to overcome obstructions in the airway and stimulate normal breathing.
1559136|NCT02533037|Other|Traditional Instability Tools|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use traditional instability tools.
1559137|NCT02533037|Other|Ankle Destabilization Shoes|Participants will complete 12 sessions over 4-weeks of impairment-based rehabilitation that incorporates ankle range of motion, ankle strength, balance, and functional activity exercises. For the balance and functional activity exercises, participants will use ankle destabilization shoes.
1559138|NCT02533024|Other|Electromyography|All subjects will have an EMG before, during and immediately after surgery.
1559139|NCT02533011|Other|HBP lab test|Plasma level of Heparin Binding Protein will be evaluated on extra blood specimens already collected as part of standard of care.
1559140|NCT02532998|Drug|AZD9977 oral suspension|AZD9977 oral suspension, single dose
1559141|NCT02532998|Drug|AZD9977 placebo oral suspension|oral suspension, single dose
1559142|NCT02532998|Drug|Fludrocortisone, tablets|Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
1559143|NCT02532998|Drug|Eplerenone, tablets|100 mg (2 x 50 mg tablets) single dose, may be modified based on emerging data (will not exceed 500 mg per treatment period)
1559144|NCT02532985|Other|Negative Control|No added fiber beverage
1559145|NCT02532985|Other|Positive Fiber Control|positive control fiber supplemented beverage provided over 4 servings
1559146|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
1559147|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
1559148|NCT02532985|Other|Novel Fiber|novel fiber supplemented beverage provided over 4 servings
1559149|NCT02532972|Device|Med-el MAESTRO Cochlear Implant with Flex 28 electrode array|Cochlear Implant (CI) surgery followed by device activation, testing, and clinical assessment for 12 months following surgery.
1559151|NCT02532946|Behavioral|Bedsider.org counseling|Contraceptive counseling was done while women kept the computer/tablet throughout their visit to facilitate discussion of website information with their providers.
1559152|NCT02532933|Device|DePuy Synthes Attune PS RP|
1559153|NCT02532907|Procedure|Liver Biopsy|patients will get a research liver biopsy pre-DAA treatment and either 4 or the standard 12 week time point. The liver biopsy is performed using standard protocol with ultrasound guidance.
1559154|NCT02532894|Device|Electronic cigarette|Inhaling e-cigarette vapor
1559155|NCT02532881|Other|Videos|Various videos showing four characteristic patient stories and five expert statements on special topics concerning inpatient psychosomatic rehabilitation.
1559156|NCT02532881|Other|Treatment as usual|Treatment as usual
1559157|NCT02532868|Drug|MK-0457|
1559164|NCT02532829|Other|blood sample analysis|Measurement of GLP-1, Peptide YY, Glucose and Insulin before and 30-60-120 minutes after Oral Mixed Meal Tolerance Test.
1559165|NCT02532816|Dietary Supplement|Nutrient dense complementary foods|"Mothers/caregivers will receive optimized CFRs to improve children diets and fortified biscuits (3 types of biscuit) for 6 days per week (in 12 months).
Nutrition eduction for mothers/caregivers. Monthly body weight and length/height measurements"
1559166|NCT02532803|Other|Novel Pelvic MRI scan assessment|A novel MRI assessment of early rectal cancers will be provided for all patients in MINSTREL
1559167|NCT02532790|Drug|Prednisone|1.5mg/kg/d
1559168|NCT02532790|Drug|ACEI|0.2-0.3mg/kg/d
1559169|NCT02532777|Drug|Prednisone|
1559170|NCT02532777|Drug|Cyclophosphamide(CTX)|
1559171|NCT02532777|Drug|Mycophenolate mofetil(MMF)|
1559172|NCT02532777|Drug|Leflunomide(LEF)|
1559177|NCT02532738|Drug|Routine Treatment of CD|The Drug including 6MP, AZA, infliximab and thalidomide
1559178|NCT02532738|Biological|MSC treatment 01|Injection of 3×10E6/kg of MSC
1559179|NCT02532738|Biological|MSC treatment 02|Injection of 6×10E6/kg of MSC
1559180|NCT02532738|Other|NS|Injection of NS
1559181|NCT02532725|Procedure|Cardiopulmonary Exercise Stress Test|Test preceded by warm-up treadmill walking 5 min at 4.8 km/h, 5% grade with a 1 min sitting rest period. Test, then, begins at 4.8 km/h, 2.5% grade with incremental grade increases every 2 min until exhaustion. Ambient environment is maintained at neutral, with effective temperature of 19-21° C. Heart, lungs, temperature, and sweating is monitored during testing.
1559182|NCT02532725|Procedure|Climatic-Controlled Cardiopulmonary Exercise Stress Test|Test includes 30 min walking bouts on the treadmill, with two 5 min sitting rest periods between bouts (Rest I and Rest II) and 15 min sitting recovery period (Rest III), in effective temperatures of 21.1 (baseline), 26.7, 29.4, 32.2, and 35.0° C. Heart, lungs, temperature, and sweating is monitored during testing.
1559183|NCT02532725|Procedure|Body Composition Evaluation|Multiple methods are used to accurately estimate percentage of body mass (weight) composed of fat, muscle, bone, and other connective tissues. Four different methods, including caliper and hydrostatic (underwater weighing) are used in this study to ensure an accurate estimation.
1559184|NCT02532725|Procedure|Pre-Exercise Risk Assessment|Includes non-invasive measurements of body functioning, a physical examination by a physician, and blood and urine testing to select subjects who can exercise with relative safety.
1559187|NCT02532699|Dietary Supplement|AC mycelia|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing either 420 mg of AC mycelia of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
1559188|NCT02532699|Dietary Supplement|Placebo|An 8 week double-blinded randomized placebo-controlled parallel study with 2 week follow-up period was performed in mild hypertension subjects. Consenting eligible subjects were receive three capsules per day containing 420 mg starch placebo of similar appearance for 8 weeks. The subjects were required to visit at baseline, every two weeks during the intervention period (8 weeks), and at follow-up 2 weeks after treatment had ended. During each study visit, systolic and diastolic BPs were recorded, fasting blood samples were collected and anthropometric measurements were performed. Compliance was evaluated using a food diary and monitored with biweekly telephone calls.
1559189|NCT02532686|Drug|DAAOI-2|500-2000mg/d, oral, for 6 weeks
1559190|NCT02532686|Drug|placebo|oral, for 6 weeks
1559191|NCT02532660|Drug|Escitalopram 10mg|Escitalopram 10mg (1 pill once a day)
1559192|NCT02532660|Drug|LABCAT TCJUSS|LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)
1559193|NCT02532660|Drug|LABCAT TCJUSS Placebo|LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);
1559194|NCT02532660|Drug|Escitalopram Placebo|Escitalopram Placebo (1 pill once a day)
1559195|NCT02532647|Drug|Remimazolam|
1559196|NCT02532647|Drug|Midazolam|
1559197|NCT02532647|Drug|Placebo|
1559198|NCT02532634|Drug|ramosetron, aprepitant, dexamethasone|ramosetron 0.3 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
1559199|NCT02532634|Drug|palonosetron, aprepitant, dexamethasone|palonosetron 0.25 mg IV D1 aprepitant 125 mg PO D1, 80 mg PO D2, 80 mg PO D3 dexamethasone 12 mg PO D1, 8 mg PO D2-4
1559200|NCT02532621|Device|Arterial & Venous InterGraft Connectors|A primary cohort of patients will receive the Arterial & Venous InterGraft Connectors to anastomose a standard 6 mm graft to the target artery and vein, respectively, to establish the AV shunt.
1559201|NCT02532621|Device|Venous InterGraft Connector|A separate cohort of patients will receive the Venous InterGraft Connector only to anastomose a standard 6 mm graft to the target vein and the arterial anastomosis will be sutured.
1559202|NCT02532608|Other|Acute sleep deprivation|Participants will stay awake for 36 hours
1559203|NCT02532595|Procedure|manual therapy and exercise|soft tissue mobilization, stretches, concentric and eccentric strengthening
1559204|NCT02532595|Procedure|trigger point dry needling|trigger point dry needling to trigger points located in the gastrocnemius, soleus and tibialis posterior
1559205|NCT02532569|Biological|Japanese encephalitis vaccine|Dosage and administration: After reconstitution with 0.7 mL of the provided diluent, 0.5-mL dose is administered subcutaneously in the lateral aspect of the upper arm.
1559206|NCT02532556|Device|Electrical stimulation (Digitimer)|Stimulation with Digitimer (DS7A HV, Digitimer Ltd, UK) over motor point of muscle in protocol. 1Hz, pulse duration 1ms, maximum compliance voltage 200V. Current set to twice motor threshold
1559207|NCT02532543|Biological|Allograft, Membrane|Allograft, Membrane- Symbios mineralized cortical-cancellous granule mix, Symbios OsteoShield Collagen Resorbable Membrane
1559208|NCT02532543|Biological|Alloplast, Membrane|Alloplast, Membrane- Symbios OsteoGraf/LD-300, Symbios OsteoShield Collagen Resorbable Membrane
1559209|NCT02532543|Biological|Xenograft, Membrane|Xenograft, Membrane- OsteoGraf/N-300,Symbios OsteoShield Collagen Resorbable Membrane
1559210|NCT02532543|Biological|Membrane|Membrane - Symbios OsteoShield Collagen Resorbable Membrane
1559211|NCT02532530|Device|Near-Infrared Spectroscopy (NIRS)|Near infrared spectroscopy (NIRS) is a non-invasive technique that uses near infrared light between 700 and 1100nm which penetrates several centimeters through skin and bone structures. Light is absorbed by chromophores. There are multiple chromophores which can be detected in the NIR spectrum such as water, lipids, melanin, myoglobin, oxygenated hemoglobin and deoxygenated hemoglobin. Each chromophore has a specific absorption spectrum. By using different wavelengths, it is possible to differentiate chromophores. The difference between oxygenated hemoglobin and deoxygenated hemoglobin can be calculated using the modified Beer-Lambert law, resulting in a numeric value which is a representation of the regional cerebral oxygen saturation.
1559386|NCT02531347|Behavioral|Telemedical home blood pressure measurements|
1559212|NCT02532504|Other|CBT|"8 sessions of CBT based intervention called change your life with seven sheets of paper by Prof. Chris Williams. These sheets cover key skills of CBT that are;
Five Areas vicious circle
Bad thought spotter
Amazing Bad thought Busting Programme (ABTPB)
Easy 4 Step plan
Things you do that mess you up/Confidence sheet
Happy List/ Things you do that boost how you feel sheet
Planner and Review sheets"
1559213|NCT02532491|Drug|Aripiprazole|Initial dose: 10 mg.
1559214|NCT02532491|Drug|Risperidone|Initial dose: 2 mg.
1559215|NCT02532465|Device|Air-Q|
1559216|NCT02532465|Device|i-gel|
1559217|NCT02532452|Biological|Viral Specific CTL Infusion|"3rd party donor derived CTL's will be infused into immunocompromised patients who have evidence of viral infection or reactivation defined as any of the following:
Blood adenovirus PCR ≥ 1,000
Blood CMV PCR ≥ 500
Blood EBV PCR ≥ 18,000
Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity by PCR or culture in one or more sites.
Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis
Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as proven by biopsy or probable by an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation."
1559218|NCT02532439|Device|HR-pQCT|"Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.
For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal."
1559219|NCT02532439|Device|DEXA|The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
1559221|NCT02532413|Drug|Poly IC|Poly IC can induce innate immune responses.It may enhance the antiviral efficacy of Entecavir.
1559222|NCT02532413|Drug|Entecavir|Entecavir can inhibit the replication of HBV.
1559223|NCT02532400|Drug|Neoadjuvant endocrine therapy|Goserelin: 3.6mg, d1, hypodermic injection , q28d*7 plus exemestane: 25mg, po, qd*24w, or anastrozole: 1mg, po, qd*24w
1559224|NCT02532400|Drug|Neoadjuvant chemotherapy|Docetaxel: 75mg/m2, d1, q3w*6, Epirubicin 75mg/m2, d1, q3w*6 and Cyclophosphamide: 500mg/m2, d1, q3w*6
1559225|NCT02532387|Other|Telephone follow-up|Prospectively enrolled subjects will have a 7- and 30-day phone call.
1559226|NCT02532374|Other|Nicorette® inhalator|Subjects will inhale the Nicorette® inhalator (15 mg) at the rate of one deep inhalation every 15 seconds on average, over approximately 20 minutes (80 inhalations in total).
1559227|NCT02532374|Other|P3L|Subjects will inhale P3L (50 µg/puff, 80 µg/puff and 150 µg/puff) at the rate of one inhalation every 30 seconds on average, over approximately 6 minutes (i.e., 12 inhalations in total).
1559228|NCT02532361|Device|Hysteroscopic device placement including Essure (ESS305, BAY1454032)|Essure is a permanent, minimally invasive, non-hormonal implantable device used for contraception and Adiana sterilization method is a combination of controlled thermal damage to the lining of the fallopian tube followed by insertion of a non-absorbable biocompatible silicone elastomer matrix within the tubal lumen
1559229|NCT02532361|Procedure|Tubal ligation|Tubal ligation or tubectomy is a surgical procedure for sterilization in which a woman's fallopian tubes are clamped and blocked, or severed and sealed, either method of which prevents eggs from reaching the uterus for implantation
1559230|NCT02532348|Other|Blood samples|Blood samples
1559231|NCT02532335|Drug|Obeticholic acid|active drug
1559232|NCT02532335|Drug|Obeticholic acid placebo|matching placebo
1559233|NCT02532322|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (1.5 mL/kg) IV loading dose prior to incision, followed by a 15 mg/kg (1.5 mL/kg) dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
1559234|NCT02532322|Drug|normal saline|normal saline 1.5 mL/kg IV loading dose prior to incision, followed by a 1.5 mL/kg dose given every 6 hours for the first 24 hours after surgery (total of 4 doses postoperatively)
1559235|NCT02532309|Drug|Rosuvastatin (5mg，10mg，20mg)|Rosuvastatin dose adjusted by LDL-c level( If LDL-C>1.1mmol/L and <1.8mmol/L, administrated as 5mg/day.If LDL-C ≥1.8mmol/L, adjusted every 4 weeks as 5mg，10mg，20mg.
1559236|NCT02532309|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg/day
1559237|NCT02532296|Behavioral|Transition Coach (TC)|"TC reviews patient's medical record to understand current admission and the medical/psycho-social history. TC makes introductory hospital visit(s) with patient to establish rapport and to define post-discharge needs.
Starting in-house and continuing after discharge, TC helps patient set transition goals to maximize healthcare outcomes. Post-discharge, TC offers a voluntary face-to-face visit with patient along with weekly outreach calls, which are designed to assist patient with goal setting and attainment, medical system navigation; medication management; medical follow-up; transportation; use of community resources; and self-care.
Intervention lasts 30 days post-discharge; afterwards TC seeks to handoff to an outpatient care team member, to ensure continuity of care."
1559238|NCT02532296|Behavioral|Control|Receives usual hospital-based care, discharge preparation, transitional care and outpatient care.
1559239|NCT02532283|Drug|JNJ-63623872|Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.
1559240|NCT02532283|Drug|Placebo|Participants will be administered placebo tablets orally twice daily for 7 days.
1559241|NCT02532283|Drug|Oseltamivir|Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.
1559242|NCT02532270|Drug|phenylephrine|When systolic blood pressure decreased by over 20% of the basic value or systolic blood pressure lower than 100mmHg after spinal anaesthesia,phenylephrine was administered 50ug in Group C and Group N.If systolic blood pressure did not improve after 1 minute,phenylephrine was administered repeatedly until systolic blood pressure return to normal.
1559243|NCT02532257|Drug|Lenalidomide|15 mg by mouth on Days 1-21 of Cycle, and 20 mg on Days 1 - 21 of Cycles 2 - 12.
1559244|NCT02532257|Drug|Rituximab|375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1, and Day 1 of Cycles 2 through 12.
1559245|NCT02532257|Drug|Ibrutinib|560 mg by mouth daily, starting on Day 1 of Cycle 1 and continued through 12 cycles.
1559246|NCT02532244|Other|sample collection|collection of blood, saliva and buccal cells
1559247|NCT02532231|Drug|Nivolumab|3 mg/kg by vein on Days 1 and 15 of a 28 day treatment cycle.
1559248|NCT02532218|Drug|ARI-3037MO|Lipid lowering treatment Statins
1559249|NCT02532192|Drug|Belinostat|"Dose Escalation Phase Starting Dose: 200 mg/m2/d by vein on Days 1 and 2 of a 21 day cycle.
Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
1559250|NCT02532192|Drug|Rituximab|Dose Escalation and Dose Expansion Phases: 375 mg/m2 by vein on Day 2 of a 21 day cycle.
1559251|NCT02532192|Drug|Cisplatin|Dose Escalation and Dose Expansion Phases: 100 mg/m2 by vein on Day 2 of a 21 day cycle
1559252|NCT02532192|Drug|Cytarabine|"Dose Escalation Phase: 2 g/m2 by vein on Day 3 of a 21 day cycle. Two doses given every 12 hours.
Dose Expansion Phase: 2g/m2 by vein on Day 2 of a 21 day cycle. Two doses given every 12 hours."
1559253|NCT02532192|Drug|Dexamethasone|Dose Escalation and Dose Expansion Phases: 40 mg by mouth on Days 2 - 5 of a 21 day cycle.
1559254|NCT02532192|Drug|Ciprofloxacin|500 mg by mouth twice daily for 10 days.
1559255|NCT02532192|Drug|Fluconazole|100 mg by mouth daily for 10 days.
1559257|NCT02532166|Other|Esophageal lichen planus|White light endoscopy compared to narrow band imaging and Lugol for detection of esophageal lichen.
1559258|NCT02532153|Drug|Ketamine Hydrochloride|Single open-label infusions
1559259|NCT02532140|Drug|WCK 5107 250 mg to 2000 mg|
1559260|NCT02532140|Drug|Cefepime 2000 mg|
1559261|NCT02532140|Drug|WCK 5107 1000/2000 mg with Cefepime 2000 mg combination|
1559262|NCT02532140|Drug|Placebo|
1559263|NCT02532127|Other|Saliva sampling|Cells will be collected from consenting participants just before and after (30 min and 24 hr) exposure to CBCT, by brushing a swab against the inner cheek, which can be done by the patients themselves. Swab kits are provided together with an envelope for sending the swabs back.
1559264|NCT02532114|Drug|Enzalutamide|Given PO
1559265|NCT02532114|Other|Laboratory Biomarker Analysis|Correlative studies
1559266|NCT02532114|Drug|Niclosamide|Given PO
1559267|NCT02532114|Other|Pharmacological Study|Correlative studies
1559268|NCT02532101|Dietary Supplement|Oil Palm Phenolics|Palm fruit derived phenolics compound
1559269|NCT02532088|Dietary Supplement|Oil Palm Phenolics|Palm fruit derived phenolics compound
1559270|NCT02532088|Dietary Supplement|Placebo|Placebo
1559271|NCT02532075|Other|Inspiratory Warm Up|Inspiratory muscle warm up. Inhaling against a resistance for two sets of 15 breaths using a PowerLung.
1559272|NCT02532075|Other|Expiratory Warm Up|Expiratory muscle warm up. Exhaling against a resistance for two sets of 15 breaths using a PowerLung.
1559273|NCT02532075|Other|Combination Warm Up|Combination of inspiratory and expiratory muscle warm up. One set of 15 breaths inhaling followed by one set 15 breaths exhaling.
1559274|NCT02532075|Other|Control Trial|Control Trial. No respiratory muscle warm up to act as a comparison to the other three intervention trials.
1559275|NCT02532062|Dietary Supplement|Cholecalciferol|4,000 IU, oral, once a day for one year
1559276|NCT02532062|Dietary Supplement|multivitamin|oral, once a day for one year
1559277|NCT02532062|Dietary Supplement|Placebo|oral, once a day for one year
1559278|NCT02532049|Biological|ChAd63 Pfs25-IMX313|
1559279|NCT02532049|Biological|MVA Pfs25-IMX313|
1559280|NCT02532036|Biological|Aerosol inhaled MVA85A|
1559281|NCT02532036|Biological|Intramuscular MVA85A|
1559282|NCT02532036|Biological|Intramuscular Saline placebo|
1559283|NCT02532036|Biological|Aerosol inhaled Saline placebo|
1559284|NCT02532023|Dietary Supplement|omega 3 fatty acid|omega 3 fatty acid supplement, 2× 1000 mg softgel daily (1800 mg EPA+DHA per day), 2 times a day, for 2 months
1559285|NCT02532023|Dietary Supplement|curcumin|curcumin supplement, 2× 500 mg softgel daily (1000 mg curcumin per day), 2 times a day, for 2 months
1559286|NCT02532023|Dietary Supplement|omega 3 fatty acid placebo|omega 3 fatty acid placebo softgel (Containing 2 g edible paraffin oil), 2× 1000 mg softgel daily (2 g per day), 2 times a day, for 2 months
1559287|NCT02532023|Dietary Supplement|curcumin placebo|curcumin placebo softgel (Containing 1 g starch powder), 2× 500 mg softgel daily (1 g per day), 2 times a day, for 2 months
1559288|NCT02532010|Drug|Pacritinib|Pacritinib is a novel Janus kinase 2-fms-like receptor tyrosine kinase 3 (JAK2-FLT3) inhibitor that has shown promising antitumor activity. Pacritinib is a potent inhibitor of JAK2 and FLT3 kinase activities (50% inhibitory concentration (IC50) = 23 nM and 22 nM, respectively). The drug also inhibits cellular proliferation in human leukemia and lymphoma cell lines selected for their dependence on either of the target kinases. Consistent with these activities, exposure to pacritinib resulted in the reduction of phos-JAK2, phos-STAT3 or phos-STAT5 in the relevant cell lines. Unlike some JAK2 inhibitors, pacritinib does not inhibit JAK1.
1559289|NCT02532010|Drug|Decitabine|Commercial drug: For each cycle Decitabine 20mg/m2 intravenous daily for 10 days combined with ongoing pacritinib 200 mg twice daily.
1559290|NCT02532010|Drug|Cytarabine|Commercial drug: For each cycle Cytarabine 20mg subcutaneous twice daily for 10 days combined with ongoing pacritinib 200mg twice daily.
1559291|NCT02531997|Behavioral|Hypnotic Relaxation Therapy|There are 3 induction scripts that build upon each other, each about 20 minutes in length. The first focuses on relaxation, feelings of wellness, wholeness, strength, and confidence. The second focuses more on body image related to sexuality, sexual desire, passion, and romanticism. The third includes suggestions from the previous inductions, but adds a behavior that the woman chooses to incorporate for the last 2 weeks of the intervention. A digital recording will be provided of the intervention content for home practice.
1559292|NCT02531997|Behavioral|Progressive Muscle Relaxation|Women will be instructed how to do progressive relaxation and will be given the opportunity to ask questions and express concerns. The research therapist will utilize a script to focus the conversation on relaxation and planning the implementation of the behavior. Participants will be given a digital recording of 4 pleasant background sounds to facilitate their relaxation practice. Home practice will be encouraged.
1559293|NCT02531984|Drug|Azithromycin|
1559297|NCT02531958|Other|Eggs|Participants will complete a 2-week washout period followed by intake of 1, 2, and 3 eggs per day for 4 weeks each.
1559298|NCT02531945|Device|Use of Biomod device|
1559299|NCT02531932|Drug|Carboplatin|Carboplatin will be administered if ANC > 1.0 and platelets are >75k
1559300|NCT02531932|Drug|Everolimus|The study drug Everolimus will be self-administered (by the patients themselves).
1559301|NCT02531919|Drug|Sodium Bicarbonate|Given PO
1559302|NCT02531906|Drug|Gabapentin|Given PO
1559303|NCT02531906|Drug|Methadone Hydrochloride|Given PO
1559304|NCT02531906|Drug|Oxycodone Hydrochloride|Given PO
1559305|NCT02531906|Other|Quality-of-Life Assessment|Ancillary studies
1559306|NCT02531906|Other|Questionnaire Administration|Ancillary studies
1559308|NCT02531867|Biological|Asfotase Alfa|
1559309|NCT02531854|Drug|ADXS11-001|
1559310|NCT02531854|Drug|Pemetrexed|
1559311|NCT02531841|Drug|Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®)|"Arm A 4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
Rituximab 375 mg/m²/d i.v. (d0,5)
Methotrexate 3.5 g/m² i.v. (d1)
Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
Thiotepa 30 mg/m² i.v. (d4) Consolidation 2 cycles of R-DeVIC (every 3 weeks):
Rituximab 375 mg/m²/d i.v. (d0)
Dexamethasone 40 mg/d i.v. (d1-3)
Etoposide 100 mg/m²/d i.v. (d1-3)
Ifosfamide 1500 mg/m²/d i.v. (d1-3)
Carboplatin 300 mg/m² i.v. (d1)"
1559312|NCT02531841|Drug|Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)|"4 cycles MATRix (every 3 weeks), stem-cell harvest after 2nd cycle:
Rituximab 375 mg/m²/d i.v. (d0,5)
Methotrexate 3.5 g/m² i.v. (d1)
Cytarabine 2 x 2 g/m²/d i.v. (d2-3)
Thiotepa 30 mg/m² i.v. (d4) Consolidation
High-dose chemotherapy (HDT-ASCT):
Carmustine* 400 mg/m² i.v. (d-6)
Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
Autologous Stem Cell Transplantation (d0)
* if carmustine is not available at the investigation site, busulfan can be administered instead:
Busulfan 3,2 mg/kg/d (d-8-(-7))
Thiotepa 2 x 5 mg/kg/d i.v. (d-5-(-4))
Autologous Stem Cell Transplantation (d0)"
1559313|NCT02531828|Device|Application of dressings for surgical correction.|Dressing for surgical correction
1559314|NCT02531828|Device|POLYSHAFT®|
1559315|NCT02531815|Biological|PF-06741086|PF-06741086, single dose, beginning with Cohort 1 dose level at 30 mg. Subsequent dose levels will be determined after data review of prior cohort(s)
1559316|NCT02531815|Drug|Placebo|Placebo for PF-06741086, single dose
1559317|NCT02531802|Biological|ETVAX|Varying dosages of liquid ETVAX via the oral route administered on Day 0 and 14
1559318|NCT02531802|Biological|dmLT|Varying dosages of dmLT via the oral route administered on Day 0 and 14
1559319|NCT02531802|Other|Sodium Bicarbonate Buffer|bicarbonate buffer dissolved in 150 ml of potable water
1559320|NCT02531789|Other|Observation|C3, C4, CRP, and the dilution marker total IgG, together with C3dg, TCC and Bb will be measured over a high-sampling frequency time course t=-1 (admission), 0 (induction), 2,4,8,16, 24, 36 and 48 hours.
1559321|NCT02531776|Device|Subcutaneous insertions of needles|"Various types of needles with different designs and mechanical properties.
Five marketed needles are included: NovoFine 28G x 12 mm (Novo Nordisk A/S, Denmark), NovoFine 30G x 6 mm (Novo Nordisk A/S, Denmark), NovoFine 32G tip x 6 mm (Novo Nordisk A/S, Denmark), BD Ultra-Fine 32G x 4 mm Pentapoint (Beckton, Dickinson & Company, USA), and Terumo Nanopass 34G x 5 mm (Terumo, Japan).
Ten needles have been exclusively manufactured for this clinical trial by Hart Needles, USA. These needles vary in diameter, number of needle tip grinding, and angles of grindings.
Three needles have been modified from the original (NovoFine 32G x 6 mm) with lack of lubrication or damaged needle tip for simulations of repeated use.
No drugs are injected. Only the needle insertion is evaluated."
1559322|NCT02531763|Behavioral|Social incentive intervention|Participant sign a pre-commitment pledge to try to achieve their goal. They are entered into a game with their teammate in which they have the chance to earn points and advance through levels (bronze, silver, gold, platinum). At the end, those in gold or platinum will receive a coffee mug as a reward
1559323|NCT02531750|Other|Immobilization due to an Achilles tendon rupture|
1559324|NCT02531737|Drug|vargatef®|Patients will be treated to oral nintedanib (vargatef®) 400 mg/d on days 2 to 21 of a 3-week cycle
1559325|NCT02531737|Drug|Docetaxel|Patients will be treated to IV docetaxel 75 mg/m² on day 1 of evry 3-week cycle
1559326|NCT02531724|Drug|Levosimendan|
1559327|NCT02531724|Drug|Placebo|Sodium chloride
1559328|NCT02531711|Other|Diet A|Experimental analgesic dietary intervention
1559329|NCT02531711|Other|Diet B|Healthy comparator diet
1559330|NCT02531698|Biological|Bivalent rLP2086 Vaccine|1 dose of 120 μg of bivalent rLP2086 by intramuscular injection at Months 0, 2, and 6 into the upper deltoid muscle of the arm.
1559331|NCT02531698|Biological|Licensed pediatric hepatits A vaccine|1 0.5 mL dose by intramuscular injection at Months 0 and 6 into the upper deltoid muscle of the arm.
1559332|NCT02531698|Other|Normal Saline|Sterile saline solution for injection (0.85% sodium chloride) in a 0.5 mL dose at Month 2.
1559335|NCT02531672|Drug|11C-choline|
1559336|NCT02531672|Device|PET/CT Scan|
1559337|NCT02531646|Radiation|Radiation|Radiation - Each human subject will receive one standard of care x-ray and one Duel Energy exposure or one standard of care x-ray and one Digital Tomosynthesis exposure. Phantoms were imaged using linear tomography and digital tomography.
1559387|NCT02531347|Behavioral|Conventional blood pressure monitoring|
1559561|NCT02530138|Dietary Supplement|synbiotic|2 symbiotics capsules per day for 28 weeks
1559338|NCT02531633|Drug|Sirukumab|Sirukumab will be provided as 1 millilitre (mL) Pre-filled Syringe (PFS), containing 100 mg/mL or 50 mg/mL of sirukuma, fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
1559339|NCT02531633|Drug|Placebo to match sirukumab|Placebo to match sirukumab will be provided as 1.0 mL PFS fitted with a spring-powered, disposable autoinjector device for single use SC administration of liquid biologic drug.
1559340|NCT02531633|Drug|Prednisone|Prednisone will be provided as tablets with dosage level up to-60 mg/day. The prednisone dose for all subjects will be determined by the Investigator and starting doses will be within 20-60 mg prednisone at Baseline (Randomization).
1559341|NCT02531633|Drug|Placebo to match prednisone|Placebo to match prednisone will be provided as tablets.
1559342|NCT02531620|Other|Physiatry Assessment|Physiatrists are physicians who are medical experts in maximizing a patient's overall ability to function well and live independently. The Investigators are proposing your participation in an initial pilot study in order to test the question as to whether or not participation with a physiatrist and any interventions recommended by said physician would help improve a patient's postoperative recovery.
1559343|NCT02531620|Other|Routine Care|Usual care for your disease process
1559344|NCT02531607|Other|blood and bile|20ml of blood will be obtained from consented participants. 5ml of bile will be collected during the endoscopic procedure.
1559345|NCT02531594|Behavioral|SBIRT|"The Social Worker will provide caregivers with the brief (10-15 minute) Advise, Assess, Assist intervention based on the Clinical Practice Guidelines, and tailored on levels of motivation to quit and tobacco dependence. Patients in this group will receive Nicotine Replacement Therapy vouchers, immediate connection to cessation resources, and intervention materials."
1559346|NCT02531594|Behavioral|HHC|"The Social Worker will provide caregivers with the brief (10-15 minute) Lets Go! 5-2-1-0 intervention which is a child obesity prevention program. Patients in this group will receive motivational interviewing in regards to helping children and families eat healthy and be active. This group will receive water bottle vouchers, immediate connection to 5-2-1-0 resources, and intervention materials."
1559347|NCT02531581|Drug|Furosemide|furosemide 40 mg bolus with second bolus to 4 hours so inadequate diuretic response defined as urine output <500cc
1559348|NCT02531581|Drug|NaCl 9% isotonic|normal saline 500 cc / 4 hours and 1 L / 24 hours
1559349|NCT02531568|Drug|Warfarin|
1559350|NCT02531568|Drug|MT-3995|
1559351|NCT02531555|Device|810 Nanometer Wavelenght GaAlAs Diode Laser|FDA approved 810 nanometer GaAlAs Diode Laser
1559352|NCT02531555|Device|Gracey curettes|
1559353|NCT02531542|Device|Echocardiography according to the READ method.|"Echocardiography will be performed before any therapy is initiated by a fully trained operator, according to the READ method. The results of this ultrasound will not be communicated to the clinician managing the patient in the emergency room.
A blood sample will be taken during the routine work-up for centralized evaluation of NT-proBNP levels."
1559354|NCT02531529|Drug|dexmedetomedine|intraoperative infusion
1559355|NCT02531529|Drug|Fentanyl|
1559362|NCT02531503|Other|Clinical asthma remission|Clinical asthma remission was defined as having no asthma symptoms and no use of medication during the past 12 months.
1559363|NCT02531490|Drug|Labetalol|
1559364|NCT02531490|Drug|Nifedipine|
1559365|NCT02531490|Drug|Methyldopa|
1559366|NCT02531477|Drug|propofol|intracarotid propofol as an anesthetic agent
1559367|NCT02531464|Other|Supportive care|Systematic distress screening and needs assessment of family caregivers of patients with lung cancer
1559368|NCT02531451|Drug|Ibuprofen|
1559369|NCT02531451|Drug|Acetylsalicylic acid|
1559370|NCT02531438|Drug|Omadacycline|Injection for IV; Oral tablets
1559371|NCT02531438|Drug|Moxifloxacin|IV solution; Oral tablets
1559372|NCT02531425|Biological|IT-pIL12-EP|Intratumoral pIL-12 injections followed immediately by electroporation into accessible tumor lesions
1559373|NCT02531412|Drug|Spironolactone|After a major surgery event a time 0, 24h and 48h
1559374|NCT02531412|Drug|Placebo|After a major surgery event a time 0, 24h and 48h
1559375|NCT02531399|Device|FDOCT|Measurement of retinal blood velocities
1559376|NCT02531399|Device|LDV|Measurement of retinal blood velocities
1559377|NCT02531399|Device|DVA|Measurement of retinal vessel diameters
1559378|NCT02531399|Device|LSFG|Imaging of retinal blood flow
1559379|NCT02531386|Device|6 blood glucose monitoring systems for self-testing (blood glucose meters)|
1559380|NCT02531373|Biological|V114 Medium Dose|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg) and Merck Aluminum Phosphate Adjuvant (125 mcg) in each 0.5 mL dose
1559381|NCT02531373|Biological|V114 High Dose|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) in each 0.5 mL dose
1559382|NCT02531373|Biological|V114 Medium Dose with Alternative Carrier Protein|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), serotype 6B (4 mcg), and Merck Aluminum Phosphate Adjuvant (125 mcg) with alternative carrier protein in each 0.5 mL dose
1559383|NCT02531373|Biological|V114 High Dose with Alternative Carrier Protein|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (4 mcg each), serotype 6B (8 mcg), and Merck Aluminum Phosphate Adjuvant (250 mcg) with alternative carrier protein in each 0.5 mL dose
1559384|NCT02531373|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
1559385|NCT02531360|Drug|[18F]MNI-815 (MNI-815)|All enrolled subjects will undergo an [18F]MNI-815 PET imaging visit. As a part of the screening visit, subjects will undergo [18F]florbetaben (FBB) PET imaging to determine if they have significant amyloid deposition.
1559467|NCT02530710|Drug|Q203|
1559388|NCT02531334|Dietary Supplement|TA-65|2 pills of TA-65 or placebo daily for 12 weeks. Subjects will be monitored weekly for side effects and every 4 weeks for compliance and safety monitoring. The whole intervention is a randomized double blind study for a duration of 27 weeks; 12 weeks for TA-65 or placebo allocated randomly and after a 3 week washout period, allocation to the alternate supplement TA-65 or placebo.
1559389|NCT02531321|Drug|Levonorgestrel and Ethinyl Estradiol|All participants will take a combined oral contraceptive containing 150mcg levonorgestrel and 30mcg ethinyl estradiol for 21 days. Pharmacokinetics and pharmacodynamics will be compared between participants using antiretroviral regimens including ritonavir-boosted protease inhibitors and those using regimens that do not interact with oral contraceptives.
1559390|NCT02531308|Drug|Metformin|Metformin upregulates AMPK activity which has been shown to have an anti-proliferative effect on lymphoma cells.
1559391|NCT02531308|Drug|Rituximab|monoclonal antibody against protein CD20 primarily found on the surface of B-cells
1559392|NCT02531308|Drug|Cyclophosphamide|Interferes with DNA replication
1559393|NCT02531308|Drug|Doxorubicin|anthracycline antitumor antibiotic
1559394|NCT02531308|Drug|Vincristine|Inhibits cell mitosis causing cell death.
1559395|NCT02531308|Drug|Prednisone|a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug. It is used to treat certain inflammatory diseases
1559396|NCT02531308|Drug|pegfilgrastim|stimulates the level of white blood cells (neutrophils).
1559397|NCT02531295|Drug|Euphorbia kansui extract powder prepared as tea|1 g of Euphorbia kansui extract powder, measured and reconstituted in 4 fluid ounces of boiled water allowed to cool and administered as tea, taken by mouth daily
1559398|NCT02531282|Behavioral|Patient education|Self-management patient education in groups once a week for 6 weeks. Each session include pain-related theory, group discussions and physical exercises focusing on posture and relaxation. Instructors with education in health promotion and behavioural change in addition to psychomotor physiotherapy.
1559399|NCT02531282|Behavioral|Physical activity|Physical activity once a week for a period of 6 weeks in form of walking and simple strength exercises outdoor in groups led by an instructor. Each session has a duration of one hour. The instructor has education in physical activity.
1559400|NCT02531256|Device|LMA Protector|Insertion of airway device for airway management during gynaecological procedure
1559401|NCT02531243|Behavioral|CALMS|Family Therapy; Multi-user Biofeedback Videogames
1559402|NCT02531230|Device|VascuFlex Multi-LOC®|Multi-LOC® peripheral stent system for bailout stenting after Plain Old Balloon Angioplasty (POBA) or Drug Coated Balloon (DCB) Angioplasty
1559403|NCT02531217|Biological|ATYR1940|Biological: ATYR1940
1559404|NCT02531204|Drug|ASP1585|oral
1559405|NCT02531191|Drug|ASP015K|oral
1559406|NCT02531178|Biological|ABBV-257|subcutaneous injection
1559407|NCT02531178|Biological|Placebo|Placebo for ABBV-257
1559408|NCT02531165|Drug|Fentanyl|Analgesia protocol using Fentanyl (initial dose: 50-100 mcg, additional doses of 25 mcg every 2-5 minutes to achieve adequate sedation, if required).
1559409|NCT02531165|Drug|Morphine|Analgesia protocol using Morphine (initial dose: 4-8 mg, additional doses of 2 mg every 5-15 minutes to achieve adequate sedation, if required).
1559410|NCT02531165|Drug|Ticagrelor|Pre-hospital Ticagrelor loading dose of 180 mg administered orally, followed by 90 mg bid
1559411|NCT02531165|Drug|Aspirin|500 mg loading dose orally (or intravenously), followed by 100 mg od
1559412|NCT02531165|Drug|Unfractioned Heparin|5'000 IU loading dose intravenously, additional doses to achieve an ACT >250 sec during PCI are allowed.
1559413|NCT02531165|Procedure|Primary PCI|Primary PCI with stent implantation according to the guidelines of the European Society of Cardiology.
1559414|NCT02531152|Drug|Latanoprost|
1559415|NCT02531152|Drug|SAR366234|
1559416|NCT02531139|Other|MAP maintained at 80 mmHg|Intervention group, MAP is maintained at 80 - 90 mmHg during anesthesia using continuous infusion of phenylephrine.
1559417|NCT02531139|Other|MAP maintained at 60 mmHg|Control group, MAP is maintained at minimum of 60 mmHg during anesthesia using continuous infusion of phenylephrine.
1559418|NCT02531126|Drug|RPC1063|
1559419|NCT02531113|Drug|RPC1063|
1559420|NCT02531100|Device|BonyPid 500TM implantation concomitantly to SOC treatment|BonyPid 500TM implantation concomitantly to SOC treatment
1559421|NCT02531100|Procedure|SOC treatment only|Standard of care treatment (Manual and ultrasonic debridement, and surface decontamination)
1559422|NCT02531074|Behavioral|Mobile Application|
1559423|NCT02531074|Behavioral|Food Journal|
1559424|NCT02531074|Behavioral|Usual Care|
1559425|NCT02531061|Device|HR-pQCT|"The Xtrem CT scanco device is a HR-pQCT. It was initially used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.
For the study, the device will be used to measure changes in erosion at the 2nd or 3rd metacarpal head. Only the patient's hand will be in contact with the medical device, the acquisition time will be 3 minutes."
1559426|NCT02531048|Device|laser stimulations on lower limbs|20 laser stimulations for each site : back foot, outer face of the legs, and anterior thigh
1559427|NCT02531048|Device|laser stimulations cervical|15 laser stimulations cervical areas below the ears.
1559428|NCT02531048|Device|20 laser stimulations for each site on the upper limbs|20 laser stimulations for each site : back of the hands and arms front face
1559429|NCT02531048|Device|laser stimulations on face and neck|15 lasers stimulations for each site : mandibular areas and areas below the ears.
1559432|NCT02531022|Behavioral|Financial incentive|A daily financial incentive framed as a loss of $2 each day goal is not acheived
1559433|NCT02531022|Behavioral|Daily feedback|Daily feedback from an activity tracking device worn on the wrist to track step counts and sleep patterns
1559434|NCT02530996|Drug|BH4|BH4 is between 5-20 mg/kg/day given to a total of 32 SSc patients (16 complicated, 16 uncomplicated)
1559435|NCT02530996|Other|Vasculopathy assessment|Non-invasive technique, flow mediated dilatation (FMD) to define vasculopathy in SSc.
1559436|NCT02530996|Drug|Placebo|This will be given to a total of total of 32 SSc patients (16 complicated, 16 uncomplicated)
1559437|NCT02530983|Other|Mayo Clinic Conduit Report Card Questionnaires|Patients will be asked to complete the Mayo Clinic Conduit Report Card Questionnaires at their one month surgical follow up visit and then every three months for 1 year after surgery, then with each surveillance clinic visit or a minimum of once per year for their lifetime. The questionnaire can be completed at their clinic visit, over the telephone, or by mail. The patient's medical record will also be reviewed to gather any other contributing information.
1559438|NCT02530957|Device|Non invasive ventilation + High flow nasal cannula oxygen|In the interventional group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% and combined to HNFC (nasal cannula oxygen of Fisher and Paykel) with Flow of 60L/min, FiO2 = 100% is applied.
1559439|NCT02530957|Device|Non invasive ventilation|In the reference group, a preoxygenation by NIV (venturi mask of Intersurgical or Respironics mask) only, with PS of 10 cm H2O, PEEP of 5 cm H2O, FiO2 = 100% is applied.
1559440|NCT02530931|Drug|Gadolinium|diffusion of gadolinium for a population with Meniere's disease in order to develop an imaging disease screening test
1559441|NCT02530918|Drug|DS-7080a|1.0, 2.0, or 4.0 mg administered by a 50 μL intravitreal (IVT) injection of solution
1559442|NCT02530918|Drug|Ranibizumab|0.3 mg or 0.5 mg administered by a 50 μL IVT injection of solution
1559443|NCT02530905|Drug|SRP-4045|
1559444|NCT02530905|Drug|Placebo|
1559445|NCT02530892|Procedure|EmbryoHug|"An embryo will be gently held by a micropipette, and a small inward pressure will be applied to the edge of the embryo. The response of the embryo to this pulling force will allow the investigators to measure its stiffness and viscosity. The term micropipette aspiration refers to the pressure applied to the edge of the embryo -- this procedure is not invasive and does not involve any sort of puncture or removal of material from the embryo."
1559446|NCT02530879|Drug|Omeprazole, Lansoprazole, Esomeprazole, Rantidine|1.Omeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 2.Lansoprazole-Dose range 15mg per day- 30mg twice a day 3.Esomeprazole- Dose range oral, 20mg once a day, up to 40mg twice a day 4.Rantidine-Dose range: 150 mg twice a day or 300 mg
1559447|NCT02530879|Behavioral|Voice therapy|Evaluation is completed over two, one-hour sessions. Once the evaluation is complete, the subject will begin weekly, individual voice therapy for 55 minute sessions per week with a second year graduate student under the direct supervision of the clinical faculty member.Treatment sessions will include a counseling component and an active exercise program.
1559448|NCT02530879|Other|Combination of anti-reflux medication and voice therapy|Subjects will receive both anti-reflux medication as detailed above and voice therapy as detailed above.
1559449|NCT02530866|Other|Lower glycemic targets|Women will be randomized to either standard or lower glycemic targets.
1559450|NCT02530853|Other|Laser acupuncture|Laser acupuncture
1559451|NCT02530840|Behavioral|medical team|Lowering HbA1c by behavioral changes in meetings with the medical team.
1559452|NCT02530840|Behavioral|peers group|Lowering HbA1c by behavioral changes in meetings with the peers group.
1559453|NCT02530840|Behavioral|SMS notification|Lowering HbA1c by behavioral changes in meetings with the SMS notification
1559454|NCT02530827|Drug|use of lipid-lowering drugs.|The patients shoud be in use of a lipid-lowering drugs previouly, at least one month before of the begining of the study.
1559455|NCT02530814|Other|Blood Collection|Onetime blood collection.
1559456|NCT02530801|Drug|Bevacizumab|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
1559457|NCT02530801|Drug|5 fluorouracil|Subconjunctival injection of Bevacizumab combined with 5 fluorouracil in the recurrent pterygium
1559458|NCT02530788|Drug|Selenium Supplement (sodium selenite)|"On the evening before operation the patient receives the first dosage of Selenium (300µg orally) orally as a pill.
After induction of anaesthesia and before being put on the heart-lung-machine the patient receives 3000µg Selenium as sodium selenite (selenase® T) intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives 1000µg Selenium as sodium selenite (selenase® T) intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
1559459|NCT02530788|Drug|Placebo|"On the evening before operation the patient receives the first dosage of placebo orally as a pill.
After induction of anaesthesia and before being put on the heart-lung-machine the patient receives placebo intravenous (as bolus infusion in the space of 30 minutes). In addition the patient gets placebo intravenous as bolus infusion in the space of 30 minutes after admission to ICU. On every POD the patient receives placebo intravenous as bolus infusion in the space of 30 minutes (until transfer to standard care unit or maximum substitution until 13th POD)."
1559460|NCT02530775|Procedure|instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
1559461|NCT02530775|Procedure|non-instrumented spinal fusion with laminectomy|"Once determined that a patient has single level static degenerative spondylolisthesis and is planning to schedule surgery the patient will be approached by a research team member explaining the study and reviewing the informed consent document. If the patient chooses to participate, he or she will be randomized to be apart of the non-instrumented arthrodesis with laminectomy group or the instrumented arthrodesis with laminectomy group. Both are standard approved surgical approaches; however, using instrumentation is the more commonly used approach."
1559462|NCT02530762|Other|Novel Fiber|novel fiber supplemented beverage provided in one serving
1559463|NCT02530762|Other|Positive Fiber control|positive control fiber supplemented beverage provided in one serving
1559464|NCT02530762|Other|Negative Control|No added fiber beverage
1559465|NCT02530736|Other|4 metre gait speed|Measurement of usual walking speed over 4 metres. Change in walking speed is measured at baseline (pre-pulmonary rehabilitation assessment) and 8 weeks later (post-pulmonary rehabilitation assessment)
1559469|NCT02530697|Drug|Meglumine antimoniate|20mgSb+5/kg/day meglumine antimoniate intravenous for 28 days.
1559470|NCT02530697|Drug|Miltefosine|Miltefosine 2,5mg/kg/day up to 50mg 2x/daily.
1559471|NCT02530697|Drug|Pentoxifylline|Pentoxifylline 20mg/kg/day up to 400mg 3x/daily for 28 days.
1559472|NCT02530684|Other|insole|Insoles available on the market without prescription
1559473|NCT02530671|Device|Toothbrushing with manual toothbrush|
1559474|NCT02530671|Device|Toothbrushing with power toothbrush|
1559475|NCT02530658|Other|Study Introduction Visit|Within 5±3 weeks following arrival at SJCRH, or at the participant/family's convenience, study introduction materials will be provided. Participants will also complete assessment questionnaires.
1559476|NCT02530658|Other|Informed Consent Visit|Within 1±3 weeks following the Study Introduction Visit, or at the participant/family's convenience, the study team will collect demographic, medical, family and physical examination information. All interviews will be audio-taped for later analysis. Participants will complete assessment questionnaires.
1559477|NCT02530658|Other|Informed Consent Follow-Up Visit|Within 2-4 weeks following the Informed Consent Visit, or at the participant/family's convenience, participants will complete questionnaires. A subset of participants (30-40) will participate in semi-structured interviews.
1559478|NCT02530658|Other|Return of Results Conversation|Depending on the availability of genomic results and preference of the participant and parents, audio-taped interviews will be conducted. Participants will complete the assessment questionnaires.
1559479|NCT02530658|Other|Return of Results Follow-Up Visits|Return of Results Follow-Up Visits will be conducted twice: the first within 8±4 weeks of the Return of Results Conversation, or at the participant/family's convenience, and the second within 32±8 weeks of the Return of Results Conversation or at the participant/family's convenience. At each visit, participants will complete assessment questionnaires. Semi-structured interviews with parents and adolescents will be conducted.
1559480|NCT02530658|Procedure|Tissue Sample|For patients who do not have a tissue sample in the St. Jude Tissue Bank and who give consent, a tumor and/or normal tissue sample will be obtained by biopsy as part of routine diagnostic evaluation for use in WGS, WES and RNA sequence analysis.
1559481|NCT02530658|Procedure|Blood Sample|A sample of blood will be obtained as a source of germline DNA.
1559482|NCT02530658|Procedure|Skin Biopsy|After consent, for participants with a diagnosis where peripheral blood is likely to be contaminated by tumor cells, skin biopsies may be done as a source of germline DNA.
1559483|NCT02530645|Behavioral|OnTrack|
1559484|NCT02530645|Behavioral|Treatment as Usual|
1559485|NCT02530645|Behavioral|Brief Motivational Interviewing|
1559486|NCT02530632|Drug|Propofol|General anesthesia maintained with intravenous propofol infusion
1559487|NCT02530632|Drug|Sevoflurane|General anesthesia maintained with inhalational sevoflurane
1559488|NCT02530632|Procedure|General anesthesia induction|Induce routine of general anesthesia, including propofol 1-3mg/kg, fentanyl 1-3mcg/kg, cisatracurium 0.2-0.3mg/kg.
1559489|NCT02530619|Drug|Alisertib|Given PO
1559490|NCT02530619|Other|Laboratory Biomarker Analysis|Correlative studies
1559491|NCT02530619|Other|Pharmacological Study|Correlative studies
1559492|NCT02530606|Procedure|Photoacoustic Imaging|Undergo PAI
1559493|NCT02530593|Behavioral|There is no intervention, only observation|
1559494|NCT02530580|Drug|20 mg AZD7325|A single 20 mg oral dose of AZD7325
1559495|NCT02530580|Drug|Placebo|A single oral dose
1559496|NCT02530567|Procedure|Intervention|All patients performing the biopsy will have an MRI to carry out the necessary measures.
1559500|NCT02530515|Drug|Rituximab|375 mg/m2 by vein on Day -5.
1559501|NCT02530515|Drug|Cyclophosphamide|250 mg/m2 by vein on Days -5, -4, and -3 per treating physician decision.
1559502|NCT02530515|Drug|Fludarabine monophosphate|"Chemotherapy + Activated T-Cell Infusion Group: 25 mg/m2 by vein on Day -5, -4, and -3.
Chemotherapy + Activated T-Cell Infusion + Lenalidomide Group: 20 mg/m2 by vein on Day -5, -4, and -3."
1559503|NCT02530515|Drug|Bendamustine|30 mg/m2 by vein on Days -5, -4, and -3 per treating physician decision.
1559504|NCT02530515|Biological|Activated T-Cell Infusion|Activated T-cell infusion, approximately 1 x 10^10, by vein on Day 0.
1559505|NCT02530515|Drug|Lenalidomide|5 mg by mouth 1 time each day for about 6 months after blood counts are high enough after activated T-cell infusion.
1559506|NCT02530515|Behavioral|Phone Calls|Study staff calls participant starting about a year and a half after the activated T-cell infusion every 6 months for up to 5 years.
1559507|NCT02530502|Other|Laboratory Biomarker Analysis|Correlative studies
1559508|NCT02530502|Biological|Pembrolizumab|Given IV
1559509|NCT02530502|Radiation|Radiation Therapy|Undergo focal RT
1559510|NCT02530502|Drug|Temozolomide|Given PO
1559511|NCT02530489|Drug|MPDL3280A|"1200 mg by vein every 3 weeks for 12 weeks before surgery.
Within 4 weeks after surgery, participants start another 4 cycles of MPDL3280A."
1559512|NCT02530489|Drug|Nab-paclitaxel|100 mg/m2 by vein weekly for 12 weeks before surgery.
1559513|NCT02530476|Drug|Selinexor|"Phase I Starting Dose of Selinexor: 80 mg by mouth twice weekly for a 28 day cycle.
Phase II Starting Dose of Selinexor: Maximum tolerated dose from Phase I."
1559514|NCT02530476|Drug|Sorafenib|"Phase I Starting Dose of Sorafenib: 400 mg by mouth twice daily for a 28 day cycle.
Phase II Starting Dose of Sorafenib: Maximum tolerated dose combination from Phase I."
1559515|NCT02530463|Drug|Nivolumab|3 mg/kg by vein every 2 weeks.
1559516|NCT02530463|Drug|Ipilimumab|3 mg/kg by vein every 3 weeks.
1559517|NCT02530463|Drug|5-azacitidine|75 mg/m2 by vein for 5 days every 4 weeks.
1559518|NCT02530450|Device|continuous glucose monitoring (CGM)|All subjects in Groups 1 and 2 wore the CGM device at time points 0, 3 months, and 6 months. Group 1 did not review CGM data at time 0, but did review CGM data at time point 3 months and 6 months. Group 2 reviewed CGM data at all time points.
1559562|NCT02530138|Dietary Supplement|Placebo|2 placebo capsules per day for 28 weeks
1559563|NCT02530125|Other|Laboratory Biomarker Analysis|Correlative studies
1559564|NCT02530125|Biological|Pidilizumab|Given IV
1559519|NCT02530437|Drug|Taladegib|"Phase IB: 400 mg by mouth daily for 38 days, starting on first chemoradiation day.
Phase II: Step 1 - (First 27 participants): As determined in Phase Ib mg (fixed dose) by mouth daily for 7 days followed by Taladegib plus chemoradiation.
Phase II: Step 2 - (Second set of 27 participants): As determined in Phase Ib mg (fixed dose) by mouth daily for 38 days, starting on first chemoradiation day."
1559520|NCT02530437|Drug|Paclitaxel|50 mg/m2/week by vein on first radiation day of each week for 5 doses.
1559521|NCT02530437|Drug|Carboplatin|AUC 2mg/ml/min by vein on first radiation day of each week for 5 doses.
1559522|NCT02530437|Radiation|Radiation Therapy|1.8 Gy per weekday for 5 1/2 weeks.
1559523|NCT02530437|Procedure|Endoscopy|Upper endoscopy performed on day 8 to obtain pictures of the tumor for comparison with the baseline and to obtain tumor tissue for biomarker assessment.
1559524|NCT02530424|Drug|Trastuzumab|Trastuzumab (8 mg/kg loading dose IV, then 6 mg/kg IV) will be given on day 1 q. 3 weeks for a total of 6 administrations
1559525|NCT02530424|Drug|Pertuzumab|Pertuzumab (840 mg as an i.v. infusion) will be given on day 1 q. 3 weeks for a total of 6 administration
1559526|NCT02530424|Drug|Palbociclib|Palbociclib will be given at the dose of 125 mg po q.d. x 21 every 4 weeks (i.e. 1 week rest period for a total of 5 cycles
1559527|NCT02530424|Drug|Fulvestrant|Fulvestrant will be administered according to local prescription guidelines and will be given intra-muscle at the dose of 500 mg every 4 weeks (repeat for 5 times) with an additional 500 mg dose given two weeks after the initial dose
1559528|NCT02530411|Drug|Fulvestrant|The pharmacology and mode of action studies established that fulvestrant is the first agent in a new class of anti-estrogens that down-regulate the estrogen receptor (ER), and can therefore be described as an ER down-regulator.
1559529|NCT02530411|Drug|Vandetanib|Vandetanib is a potent inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptor (VEGFR; also known as kinase insert domain containing receptor)-2, an endothelial cell receptor for vascular endothelial growth factor (VEGF), and also possesses activity against epidermal growth factor receptor (EGFR) and Rearranged during Transfection (RET) tyrosine kinases.
1559530|NCT02530398|Drug|Cinobufacini Injection|Cinobufacini injection is extracted from a traditional Chinese medicine Bufo toad skins, it's something cold and poisonous with damp evil. On one hand it can kill the cancer cells direct; on the other hand it has the ability to contract blood vessels and inhibit the formation of tumor new vessels. It has been widely used in the treatment of various malignancies.
1559531|NCT02530385|Other|Placebo Capsules|Placebo capsules contain powdered cocoa and gelatin
1559532|NCT02530385|Biological|FMT Capsules|Capsules will be generated as per FDA-approved procedures
1559533|NCT02530372|Device|UriCap-F|non-invasive urine collection device for women
1559534|NCT02530359|Drug|Pirfenidone extended release|Pirfenidone extended release 600mg per mouth
1559535|NCT02530359|Drug|Placebo equivalent|Placebo equivalent per mouth
1559536|NCT02530346|Drug|No Mechanical Bowel Preparation|no enemas or oral laxatives will be given in this group
1559537|NCT02530346|Drug|Mechanical Bowel Preparation|oral laxatives (polyethylenglycol at 100 ml/kg/dose for up to 3 times) and stoma enemas (20mlkgdo of normal saline 3 times a day) will be prescribed
1559538|NCT02530333|Other|Neuromuscular Prevention Program|Participants in the intervention group will complete at 6 week ACL injury prevention program previously described in the literature as being effective at reducing ACL injury risk. The prevention program lasts 20-25 minutes in duration and will take place as a warm-up prior to any practice. The frequency will depend solely on the number of practices each team holds throughout the given 6-week time period.
1559539|NCT02530320|Drug|Palbociclib|Palbociclib will be administered orally at a dose of 125 mg/day, until disease progression, unacceptable adverse side effects or study end.
1559540|NCT02530307|Drug|HT-3951|
1559541|NCT02530307|Drug|Placebo|
1559542|NCT02530294|Drug|DRM04 Topical Wipes|Topical wipes containing DRM04
1559543|NCT02530294|Other|Placebo|Placebo (vehicle) wipes, do not contain DRM04
1559544|NCT02530281|Drug|DRM04 Topical Wipes|Topical wipes containing DRM04
1559545|NCT02530281|Other|Placebo|Placebo (vehicle) wipes, do not contain DRM04
1559546|NCT02530255|Dietary Supplement|cycloastragenol|Oral telomerase activator - cycloastragenol.
1559547|NCT02530255|Dietary Supplement|placebo (for cycloastragenol)|placebo comparator, placebo for cycloastragenol.
1559548|NCT02530242|Device|End-tidal Carbon Monoxide Subjects|ETCO monitor will be used to measure CO levels in subjects and controls.
1559549|NCT02530242|Device|End-tidal Carbon Monoxide Controls|ETCO monitor will be used to measure CO levels in subjects and controls.
1559550|NCT02530216|Other|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|"AEGIS (Automated Evaluation of Gastrointestinal Symptoms) guides patients through questionnaires to measure symptom attributes including the timing, severity, frequency, location, quality, and character of their gastrointestinal (GI) symptoms, along with relevant comorbidities, family history, and alarm features. This information is transformed into a history of present illness (HPI) written in language familiar to clinicians. AEGIS also supports both the clinician and patient with an individualized education prescription which guides the patient through a library of multi-media educational materials on GI symptoms, conditions, and treatments. The prescription is created by the portal based on each patient's unique AEGIS fingerprint."
1559551|NCT02530203|Device|Spinal Cord Stimulation System|High frequency stimulation using a catheter placed in the lumen of the spine to inhibit sympathetic outflow to the heart
1559552|NCT02530203|Device|Holter Recording_ NEMon DR220 Holter Recorders|To measure primary endpoint and most of the secondary endpoints in all the patients enrolled in the study. The recording will start to before CABG procedure and will be stop at day 5.
1559553|NCT02530190|Device|intermittent pneumatic compression|20 minutes of intermittent pneumatic compression to lower extremities
1559554|NCT02530190|Procedure|massage|20 minutes of massage to lower extremities
1559555|NCT02530177|Other|Clinical Assessments|
1559556|NCT02530177|Behavioral|Questionnaires|
1559557|NCT02530177|Other|Saliva sample|(only once, preferably at baseline)
1559558|NCT02530164|Device|Transcranial direct current stimulation (tDCS)|active/sham tDCS as adjunctive treatment with a SSRI
1559559|NCT02530151|Drug|Morphine with clonidine|see arm description
1559560|NCT02530151|Other|Normal saline|see arm description
1559566|NCT02530099|Procedure|CN-group|Time limited simulation based training on camera navigation tasks on a virtual reality-simulator.
1559567|NCT02530099|Procedure|Procedure-group|Time limited simulation based training on laparoscopic procedure on a virtual reality-simulator.
1559568|NCT02530086|Procedure|Nasogastric tube placement|Placement of a Nasogastric tube
1559569|NCT02530086|Procedure|No Nasogastric tube use|No placement of a Nasogastric tube
1559570|NCT02530073|Device|Fetoscopic Endoluminal Tracheal Occlusion (FETO)|This study will position and remove an endoluminal tracheal balloon in utero (FETO) to study the feasibility of implementing FETO therapy in the most severe group of fetuses with left CDH (O/E LHR < 25%).
1559571|NCT02530060|Drug|Rilpivirine/Tenofovir Disoproxil Fumarate/Emtricitabine FDC|Fixed dose combination tablet contains 25 milligram (mg) of Rilpivirine, 300 mg of Tenofovir Disoproxil Fumarate (TDF) and 200 mg of Emtricitabine (FTC).
1559572|NCT02530047|Genetic|MSC-INFβ|"MSC-INFβ administered on an outpatient basis via intraperitoneal (IP) infusion.
Starting dose: 10^5 MSC/kg once a week for 4 treatments."
1559573|NCT02530047|Behavioral|Questionnaires|Symptom questionnaire completed once a week for 4 weeks.
1559574|NCT02530034|Drug|Hu8F4|"Phase I Starting dose of Hu8F4: 1 mg by vein over about 30 minutes on Days 0, 7, 14, and 21 of each 28-day cycle.
Phase II Starting dose of Hu8F4 is the maximum tolerated dose (MTD) from Phase I."
1559575|NCT02530021|Other|Heart rate monitor|One hour non-invasive ECG heart rate variability monitoring. The results will be blinded and interpreted independantly. Study results will not effect patient management.
1559576|NCT02529995|Drug|AZD9291 40 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
1559577|NCT02529995|Drug|AZD9291 80 mg|This is a two parts (Part A and Part B) study to determine the pharmacokinetics of AZD9291 administered orally at two dose levels (40 mg Cohort 1 and 80 mg Cohort 2) in patients with locally advanced or metastatic NSCLC who have progressed following prior therapy with an EGFR TKI agent (+/- additional chemotherapy regimens).
1559578|NCT02529982|Dietary Supplement|Curcumin|
1559579|NCT02529982|Dietary Supplement|Placebo|
1559580|NCT02529969|Dietary Supplement|curcumin|
1559581|NCT02529969|Dietary Supplement|Placebo|
1559582|NCT02529956|Drug|UCB4940|"Active Substance: UCB4940
Pharmaceutical Form: Solution for infusion
Concentration: 80 mg/ml
Route of Administration: Intravenous use"
1559583|NCT02529956|Other|Placebo|"Active Substance: Placebo
Pharmaceutical Form: Solution for infusion
Concentration: 0.9 % sodium chloride aqueous solution
Route of Administration: Intravenous use"
1559584|NCT02529943|Procedure|Surgical Decompression|
1559586|NCT02529917|Dietary Supplement|Hemp powder|Hemp powder supplement
1559587|NCT02529917|Dietary Supplement|Soy Powder|Soy powder supplement
1559588|NCT02529904|Biological|MF59 - ATIV|"All child participants will receive 2 doses of the MF59-ATIV, with the doses separated by 28 days.
Adult participants will receive one dose of MF59-ATIV."
1559590|NCT02529878|Drug|S1/Paclitaxel chemotherapy plus Apatinib|S1:60mg twice daily(after the breakfast and supper) for two weeks, and then suspend for one week Paclitaxel:150mg/m2,iv, 3h, at day1 Apatinib:500mg once daily
1559591|NCT02529865|Biological|Periurethral injection of autologous ADRCs and adipose tissue|1 mL of the isolated ADRC is injected into the region of the external urethral sphincter, and another 4 mL of the ADRC and 16mL autologous adipose cells is injected under the urethral mucosa.
1559592|NCT02529852|Drug|Lenalidomide|"Phase I Starting Dose Level: 15 mg by mouth on Days 1 - 14 of each 21 day cycle.
Phase II Starting Dose Level: Maximum tolerated dose from Phase I."
1559593|NCT02529852|Drug|Obinutuzumab|Phase I and II: 1000 mg by vein on Days 1, 8, and 15 of Cycle 1 and Day 1 of Cycles 2 - 6.
1559594|NCT02529852|Drug|Cyclophosphamide|Phase I and II: 750 mg/m2 vein over about 1 hour on Day 1 of all cycles.
1559595|NCT02529852|Drug|Doxorubicin|Phase I and II: 50 mg/m2 by vein over about 15 minutes each on Day 1 of all cycles.
1559596|NCT02529852|Drug|Vincristine|Phase I and II: 1.4 mg/m2 by vein on Day 1 of all cycles.
1559597|NCT02529852|Drug|Prednisone|Phase I and II: 100 mg by mouth daily on Days 1 - 5 of each 21 day cycle.
1559598|NCT02529839|Procedure|Autologous bone marrow transplantation|IMMUNOABLATIVE NONMYELOABLATIVE AUTOLOGOUS BONE MARROW TRANSPLANTATION on Day 0
1559599|NCT02529839|Drug|Fludarabine|30mg/m2 on days -6 through -3
1559600|NCT02529839|Drug|Cyclophosphamide|50mg/kg on days -5 through -4
1559601|NCT02529839|Drug|Alemtuzumab|3mg on day -3, 9mg on day -2, 12 mg on day -1
1559602|NCT02529826|Procedure|Testicular Biopsy|An open testicular biopsy will be performed by an attending urologist under general anesthesia.
1559603|NCT02529813|Drug|Fludarabine monophosphate|25 mg/m2 or 30 mg/m2 by vein on Days -5 to -3 at discretion of treating physician..
1559604|NCT02529813|Drug|Cyclophosphamide|250 mg/m2, or 300 mg/m2, or 500 mg/m2 by vein on Days -5 to -3 at discretion of treating physician.
1559605|NCT02529813|Procedure|T Cell Infusion|"Patient (Autologous)-derived CAR T cells infused for active disease following lymphodepleting chemotherapy.
Donor (Allogeneic)-derived CAR T cells infused 6-12 weeks following allogeneic hematopoietic stem-cell transplant (HSCT)
Starting level dose: > 1 x 10^5/kg but ≤ 1 x 10^6/kg"
1559606|NCT02529800|Drug|HIP1402|Tamsulosin HCl 0.4mg
1559607|NCT02529800|Drug|HGP0412|Tamsulosin HCl 0.2mg
1559608|NCT02529787|Drug|Doxirazole|1 capsule contains 60 mg Dexlansoprazole
1559609|NCT02529787|Drug|Dexilant|1 capsule contains 60 mg Dexlansoprazole
1559696|NCT02529033|Device|LIDCO Rapid, Pulmonary artery catheter|Hemodynamic monitoring systems
1559697|NCT02529020|Device|Mouthguard|Condition of wearing mouthguard
1559698|NCT02529020|Device|No mouthguard|Condition without mouthguard
1560579|NCT02522715|Drug|Prednisone|Given PO
1559610|NCT02529774|Drug|Floxuridine (FUDR),Dexamethasone (DXM), Heparin in combination with Oxaliplatin and Capecitabine (CapeOX) or in combination with Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Hepatic Artery Infusion for four cycles:
Floxuridine (FUDR) 500mg/d, Day 1-2; DXM 1mg/day added to FUDR 2-day infusion; Heparin 1000U/day added to FUDR 2-day infusion
In combination with Systemic Chemotherapy CapeOX for 8 cycles:
Oxaliplatin 130 mg/m^2 iv over 2 hours, Day 1. Capecitabine 850mg/m^2/d PO Bid, given in the morning and evening, Day 1-14
Or in combination with Systemic Chemotherapy mFOLFOX6 for 12 cycles:
Oxaliplatin 85mg/m^2 IV over 2 hours, Day 1. Leucovorin 400mg/m^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m^2 IV and then 2400mg/m^2 over 48 hours IV continuous infusion. Day 1"
1559611|NCT02529774|Drug|Oxaliplatin and Capecitabine (CapeOX) or Oxaliplatin and Leucovorin and 5-FU (mFOLFOX6)|"Systemic Chemotherapy CapeOX alone for 8 cycles:
Oxaliplatin 130 mg/m^2 iv over 2 hours, Day 1. Capecitabine 850mg/m^2/d PO Bid, given in the morning and evening, Day 1-14
Or Systemic Chemotherapy mFOLFOX6 alone for 12 cycles:
Oxaliplatin 85mg/m^2 IV over 2 hours, Day 1. Leucovorin 400mg/m^2 IV over 2 hours, Day 1 5-fluorouracil (FU) 400mg/m^2 IV and then 2400mg/m^2 over 48 hours IV continuous infusion. Day 1"
1559612|NCT02529761|Drug|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
1559613|NCT02529761|Procedure|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) particles until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
1559614|NCT02529748|Other|Participants for Surface Skin Sampling|Skin wipe samples will be collected to quantify the amount of the test substances transferred to and from the surface of the participants' skin.
1559615|NCT02529748|Other|Elemental metallic lead|Consumer product fishing tackle made of elemental lead will be handled by the participants.
1559616|NCT02529748|Other|Tinopal|Tinopal, a fluorescent tracer, will be handled by the participants.
1559617|NCT02529735|Other|efficiency study|Blood pressure values measured for comparative lower limb and arm
1559618|NCT02529709|Other|High-Protein Condition|The participants will be fed a high-protein meal
1559619|NCT02529709|Other|High-Monounsaturated Fat Condition|The participants will be fed a high-monounsaturated fat meal
1559620|NCT02529696|Device|Accelerometer|Measures patient movement
1559621|NCT02529683|Drug|Nuvaring|contraceptive vaginal ring with ethinyl estradiol and etonogestrel
1559622|NCT02529670|Procedure|Laser|Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.
1559623|NCT02529670|Procedure|Drug: Lidocaine|1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.
1559624|NCT02529670|Procedure|Radiofrequency|Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
1559625|NCT02529657|Radiation|Low Level Laser Therapy|In 23 randomized patients, LLLT (B-Cure, Good Energies ®, Israel), with CW diode laser - semiconductor Gallium Arsenide and aluminum (GaAlAs) will be applied during surgery (λ = 804 nm ± 2 , total exposure time of 240 s, energy density of 2.48 J/cm2 , average power of 40 mW , spot area of 3,876 cm2), in contact mode, for 60 seconds on the laminectomy site, 60 seconds and 120 seconds in the subcutaneous tissue of the skin over the wound bed, respectively. In the first and second day post surgery, will be collected the drainage output for analysis of interleukin 1, 4, 6, 8 and 10 (IL- 1, IL-4, IL -6, IL-8 and IL -10 ) and tumor necrosis factor alpha ( TNF -alpha ).
1559626|NCT02529657|Procedure|Placebo|In the operating room, lumbar laminectomy will be performed in 46 patients. During the surgery, 24 hours and 48 hours after surgery, the patients received the regular treatment after laminectomy and were induced to thing that were receiving low level laser therapy in their wound.
1559627|NCT02529644|Behavioral|Taking It to the Pews (Comparison)|Pastors and Health Action Team members will be trained and receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events. Comparison churches will receive: a) non-tailored project materials (videos, brochures) collected from health organizations and b) standard, non-tailored activities (e.g., community-based HIV testing events) coordinated by their church liaisons. The comparison churches will offer 3 HIV screening events and deliver 1-2 standard materials per month for the 12 month study period. All comparison churches will receive all Taking It to the Pews HIV Tool Kit materials after the completion of 12-month assessments.
1559628|NCT02529644|Behavioral|Taking It to the Pews (Experimental)|Pastors and Health Action Team members will be trained in treatment implementation procedures using the scripted, study implementation manual. Intervention churches will receive the TIPS HIV Tool Kit, including a study manual. These churches will hold a Kick-off event, where tools will be distributed, and motivational strategies implemented. After the Kick-off, liaisons will deliver 1-2 Tool Kit materials/activities per month through targeted multilevel church activities minimum of 24 tools over the 12 month study period. Two additional HIV screening events will be planned (one for community members) and will be open to all persons seeking screening, including study nonparticipants. Both groups will receive manualized pastor/church liaison trainings on study procedures, HIV basics and local resources and coordination of HIV screening events.
1559629|NCT02529631|Drug|orlistat 60 mg|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.
Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three orlistat 60 g capsules plus six placebo tablets."
1559630|NCT02529631|Device|polyglucosamine|"In order to have comparable calorie intakes, all participants followed the recommendations of the German clinical practice guidelines on the management and prevention of obesity.
Due to the different appearance of tablets and capsules, a double dummy design was chosen, a blister strip for each day and each participant had to take the same amount of capsules and tablets per day. The content of the blister strips: three blue placebo capsules plus two placebo tablets (morning) and four polyglucosamine tablets (noon and evening)."
1559699|NCT02529007|Device|Endo-cuff|Colonoscopy performed with endo-cuff attached to the colonoscope
1559700|NCT02529007|Other|Standard colonoscopy|Standard colonoscopy without end-cuff
1559631|NCT02529618|Device|integrated Display Enhanced Testing for Cognitive Impairment and mild traumatic brain injury (iDETECT)|iDETECT offers an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury.
1559632|NCT02529618|Device|Riddell High Impact Technology (HIT) System|The Riddell HIT system incorporates six acceleration sensors into standard football helmets worn during practice and game play. A computerized sideline system captures information on linear and rotational acceleration, as well as magnitude, duration, and location of impact for each player
1559633|NCT02529618|Device|i1 Biometrics Vector Mouth Guard|The i1 Biometrics Vector Mouth Guard is an impact intelligence system that contains a collection of impact sensing mouth guards, housing accelerometer and gyroscope technology that allows real-time collection and storage of biomechanical impact data. Sensors in the mouth guard communicate directly with a sideline assessment base station and allows for immediate assessment and evaluation of hit exposure.
1559634|NCT02529605|Dietary Supplement|Product B® IsaGenesis®|This will be a crossover comparison of a one time dose of the liquid-gel formulation contained in 2 capsules; 1280 mg/capsule.
1559635|NCT02529605|Dietary Supplement|IsaGenesis®|This will be a crossover comparison of a one time dose of the dried powder extract contained in 2 capsules; 1070 mg /capsule.
1559638|NCT02529579|Other|iAPA-DC/CTL adoptive cellular immunotherapy|twice DC cell infusion and CTL cell infusion for 6 times
1559639|NCT02529579|Drug|Gemcitabine|standard Gemcitabine therapy
1559640|NCT02529553|Drug|LY3076226|Administered IV
1559641|NCT02529540|Other|Adjustable glasses|The glasses will be used for refraction and wearing within professional instructions.
1559642|NCT02529540|Other|Custom standard glasses|The custom standard glasses are made by the traditional standards after refraction.
1559643|NCT02529540|Other|Ready-made glasses|The glasses have been made already before the refraction in the hospital. And they will be chosen by prescription after refraction.
1559644|NCT02529527|Behavioral|MyFamilyPlan|Web-based preconception health education tool (interactive self-assessment) - to be completed by patient
1559645|NCT02529514|Drug|Baclofen|25 mg for 7 days at 10 pm every day
1559646|NCT02529514|Drug|Placebo|Placebo for 7 days at 10 pm every day
1559647|NCT02529488|Device|AcrySof® IQ PanOptix™ Presbyopia-Correcting IOL|Multifocal IOL(near, intermediate, distance) implanted for long-term use over the lifetime of the cataract patient
1559648|NCT02529475|Drug|Gadoteric acid|Comparison with patients with Meniere's disease
1559649|NCT02529462|Genetic|NEUROPHARMAGEN-Guided Treatment|NEUROPHARMAGEN is a pharmacogenetic test developed by AB-BIOTICS S.A. that enables the specific analysis of Single-Nucleotide Polymorphisms related to the pharmacokinetics and pharmacodynamics of multiple psychoactive drugs. In this arm, psychiatrists have access to the results of the NEUROPHARMAGEN test to support their medication choices
1559650|NCT02529462|Drug|Treatment As Usual|Clinicians treat psychiatric patients in a naturalistic way, following their routine procedures, without access to the pharmacogenetic information provided by the NEUROPHARMAGEN test
1559651|NCT02529449|Drug|Placebo|Oral
1559652|NCT02529449|Drug|ASP1941|Oral
1559653|NCT02529423|Dietary Supplement|Multi‐nutrient supplement|"Omega 3 fatty acids
Folic acid
Calcium
Selenium
Vitamin D3"
1559654|NCT02529423|Behavioral|Behavioral Activation|21 sessions (15 individual sessions and 6 group sessions) The intervention will include detailed analysis of each individual's behavior to determine idiosyncratic triggers and functions of unhelpful (e.g., mood‐related snacking) and helpful food‐related behavior, thereby, to reinforce helpful behaviors and to implement effective alternatives to unhelpful behaviors, building on behavioural approaches proven effective in depression.
1559655|NCT02529423|Other|Placebo|Placebo pills identical in look and taste but including no active ingredients
1559656|NCT02529410|Procedure|Cardiac Resynchronisation Therapy|
1559657|NCT02529397|Behavioral|Adaptive Working Memory Training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using an adaptive cognitive training program which becomes increasingly challenging as the participant masters each level. Behavioral classes will teach the principles of weight management and exercise.
1559658|NCT02529397|Behavioral|Non-adaptive cognitive training|Participants will train for 30-40 minutes per day, five days per week at home for 5 weeks using a non-adaptive cognitive training program. Behavioral classes will teach the principles of weight management and exercise.
1559659|NCT02529384|Other|Breast magnetic resonance scanning|Just a muti-b value series in breast MRI
1559660|NCT02529371|Device|UriCap-RM|UriCap-RM is comprised of a reusable part and a single use adhesive tape. The reusable part is applied over the urethral meatus and is held in position by a stabilizer and adhesive tape. It is connected to a standard urine collection bag. The UriCap-RM is used on male patients who would otherwise use diapers, a condom-type urine collection device or an indwelling catheter for urine collection.
1559661|NCT02529358|Behavioral|standardized text messages|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies
1559662|NCT02529358|Behavioral|Personalized text messages|Patients write their own messages
1559663|NCT02529358|Behavioral|Standardized text messages after 10 weeks|Messages consist of relaxation techniques and mindfulness exercises as well as emotion regulation strategies which are send to the patients 10 weeks after completing inpatient therapy
1559664|NCT02529345|Device|RoadSaver stent|lesion treated with RoadSaver stent of Terumo
1559665|NCT02529332|Dietary Supplement|Omega-3|Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
1559666|NCT02529319|Procedure|MRI-Guided Ablation|Catheter ablation of AF will be guided by a DE-MRI of the patient's heart prior to the procedure.
1559667|NCT02529319|Procedure|Conventional Ablation|Catheter ablation of AF using pulmonary vein isolation (PVI) will be performed using the HRS guidelines.
1559668|NCT02529293|Drug|BioChaperone Lispro U-100|Injection of BioChaperone Lispro U-100
1559669|NCT02529293|Drug|BioChaperone Lispro U-200|Injection of BioChaperone Lispro U-200
1559670|NCT02529280|Behavioral|Intervention|Intervention includes 1) a 30-minute computer-based video (in English/Spanish), featuring instructional screens, graphics and animation to help participants understand the concepts presented. It will feature breast cancer patients who have participated in CTs, patients talking to their doctor or nurse and a bilingual narrator to guide participants. Video content will address common barriers and concerns regarding clinical trials, as well as the informed consent process, and how clinical trials are monitored and reviewed; 2) a bilingual easy to understand booklet with tailored information on clinical trials. The booklet will include many of the elements and messages featured in the video program; and 3) assistance from a trained, bilingual, bicultural, nurse navigator.
1559671|NCT02529267|Other|Standard of care|
1559672|NCT02529254|Behavioral|Video coaching session|A 30 minute video coaching session with a surgeon in witch the residaent and coach visualise the filmed anastomosis and where the surgeon gives constructive feedback.
1559673|NCT02529241|Drug|Group 1:LCB01-0371|"Period:LCB01-0371 Tablet 400 mg
Period: LCB01-0371 Tablet 400 mg"
1559674|NCT02529241|Drug|Group 2:LCB01-0371|"Period:LCB01-0371 Tablet 800 mg
Period: LCB01-0371 Tablet 1200 mg"
1559675|NCT02529228|Other|Meal (Eating) Frequency|Dividing meal intake into 2 or 6 meals with equal energy content
1559676|NCT02529228|Other|Protein Composition|Consuming meals with higher or lower protein.
1559677|NCT02529215|Behavioral|Just-in-time training (JITT)|The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
1559678|NCT02529202|Drug|Dexmedetomidine|Dexmedetomidine infusion
1559679|NCT02529189|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice containing ~5 mmol of inorganic nitrate
1559680|NCT02529189|Dietary Supplement|Beetroot Juice|70 ml of beetroot juice which is nitrate-depleted
1559681|NCT02529176|Behavioral|Best-practice alert|The best-practice alert notifies physicians that their patient's telemetry monitoring duration has exceeded national guidelines and gives the physician the option to: discontinue monitoring if they feel it is clinically appropriate, dismiss the alert, or re-alert in four hours.
1559682|NCT02529163|Other|Late-life Schizophrenia ICP|"The ICP medication algorithms first trial begins with:
Risperidone titrated to a max dose
Failure to Risperidone will lead to a second trial with either:
Quetiapine OR Aripiprazole
If subject refuses or if this trial does not work, then offer:
Ziprasidone or Loxapine
Failure of 2 anti-psychotic trials results in:
Clozapine trial
If subject refuses a Clozapine trial then:
Olanzapine offered
titrations occur over 33-36 day period (inpatient) or 12 week period (out patient) with each 0.5 mg titration after the target dose requiring a CGI-E
If compliance is an issue then a depot preparation:
Paliperidone
Risperidone
Flupentixol
Aripiprazole
Physicians will be prompted for non-pharmacological interventions"
1559683|NCT02529163|Other|Treatment as Usual|"The TAU group will be offered non-pharmacological interventions such as (but not limited to):
metabolic monitoring
skin hygiene
pain management
nutritional counseling
family counselling
Financial/housing support
Group CBT (Cognitive Behavioral Therapy)
Physicians treating this group will use their own discretion as they will not be prompted like the ICP group.
Pharmacological interventions contain anti-psychotic medication selected at the discretion of the treating physician provided it fall under the current standard of care such as:
Risperidone
Aripiprazole
Quetiapine
Olanzapine
Paliperidone
Clozapine
Ziprasidone
Max dosing and the time to reach the target dose is done at the discretion of the treating physician."
1559684|NCT02529150|Behavioral|Exercise|This is an exercise intervention study. All 10 participants will complete 26 weeks high dose exercise (60% of peak aerobic capacity 45 min/session, 5 sessions per week).
1559685|NCT02529124|Dietary Supplement|CONTROL|Maltodextrin (generic) in powder form, flavoured and instantised to be dissolved in water.
1559686|NCT02529124|Dietary Supplement|PROTEIN|The milk protein matrix (PROTEIN) comprised a 9:2:1 ratio of milk protein concentrate (MPC, 80% (w/w protein) Glanbia Nutritionals, Kilkenny, Ireland), whey protein concentrate hydrolysate, degree of hydrolysis 32% (WPC DH 32, 78% (w/w protein) Carbery Ingredients, Ballineen, Ireland), whey protein isolate hydrolysate, degree of hydrolysis 45% (WPI DH 45, 75% (w/w protein) Glanbia Nutritionals). The total protein content was 72.7g/100g powder. The protein matrix was supplemented with 2187mg/100g powder of milk-based calcium (Trucal™, Glanbia) and 57.3mg/100g powder vitamin D3 (cholecalciferol), flavoured and instantised to be dissolved in water.
1559687|NCT02529124|Behavioral|PHYSICAL ACTIVITY|A structured, progressive programme of exercises using resistance exercise bands supervised by clinical therapists undertaken three times per week for 24 weeks of the intervention.
1559688|NCT02529111|Device|"Echonavigator software"|
1559689|NCT02529098|Other|fMRI|functional magnetic resonance imaging
1559690|NCT02529085|Other|blood samples|blood samples for the bank
1559691|NCT02529072|Drug|nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes. Binding of PD-1 to its ligands, programmed death-ligands 1 and 2, results in the down-regulation of lymphocyte activation. Inhibition of the interaction between PD-1 and its ligands promotes immune responses and antigen-specific T cell responses to both foreign antigens as well as self-antigens. Nivolumab is expressed in Chinese hamster ovary cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies. The clinical study product is a sterile solution for parenteral administration.
1559692|NCT02529072|Biological|DC|DCs are potent immunostimulatory cells that continuously sample the antigenic environment of the host and specifically activate cluster of differentiation 4 positive (CD4+) and cluster of differentiation 8 positive (CD8+) T-cells and B-cells. They are at the crossroads of many of the elegant networks of the immune system, and DCs represent the most promising contemporary biologic entity for realizing the promise of immunotherapy. Potent immune responses and encouraging clinical results have been seen in Phase I and II human clinical trials in systemic cancers. Numerous animal studies and the investigator's institution's humans studies have demonstrated potent antitumor responses using DC-based immunotherapy against MGs.
1559693|NCT02529059|Drug|Eviplera|A single-pill fixed dose combination of tenofovir 245mg, emtricitabine 200mg and rilpivirine 25mg once daily for 24 weeks.
1559694|NCT02529046|Dietary Supplement|CLA|CLA group received supplementation at a dose of 3.2 g/day (mixture of isomers of CLA isomers predominantly c9, t11 - 50% and c12, t10 - 80%). Aerobic exercise associated with CLA
1559695|NCT02529046|Behavioral|Placebo|Placebo group received 4 g/day of olive oil. Aerobic exercise
1559701|NCT02528994|Dietary Supplement|L-serine|Participants will take dietary serine supplementation daily
1559702|NCT02528981|Drug|Probiotic|Lactobacillus GR-1 and RC-14
1559703|NCT02528981|Drug|Placebo|
1559704|NCT02528968|Behavioral|Educational Package|Patients will be invited to attend a PK educational session as part of the study protocol. This will form a discussion regarding clinical history and activity in the 6 months prior to study start, viewing of a short animated film giving additional detail on pharmacokinetics and prophylaxis in haemophilia A, followed by modelling of the patient's own PK and dose guidance based on 2 study blood samples.
1559705|NCT02528955|Radiation|A: De-Intensification RT primary tumor region|"A:
Reduction of radiation dose in the primary tumor region to 56 Gy,
Elective Radiotherapy of both neck sides"
1559706|NCT02528955|Radiation|B: De-Intensification RT contralateral lymph nodes|"B:
No dose reduction in primary tumor region (prescribed dose in primary tumor region: 64 Gy)
Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
1559707|NCT02528955|Radiation|C. De-Intensification RT primary tumor region AND contralateral lymph nodes|"C:
Reduction of radiation dose in the primary tumor region to 56 Gy, AND
Reduction of target volume: only elective radiotherapy of the ipsilateral neck, no contralateral neck irradiation"
1559709|NCT02528929|Dietary Supplement|Gluten-free diet|Patients with IBS-D will commence a gluten-free diet for 6 weeks following dietetic input. They will be informed they do not have coeliac disease. They will however be blinded to whether or not they have any markers of at-risk serology. They will self-complete validated questionnaires over 6 weeks. Any subjects who opt to continue with a gluten-free diet thereafter of their own volition will be kept under observation as per routine clinical care.
1559710|NCT02528903|Drug|MHAB5553A|Single intravenous administration, at various doses, depending on the cohort
1559711|NCT02528903|Drug|Matching placebo|Single intravenous dose
1559712|NCT02528890|Other|vaginal/anal swab for GBS from all participants|All eligible pregnant women, who meet the inclusion criteria and gave their informed consent to participate in the study has to complete a questionnaire and have a vaginal / anal swab taken to identify positive GBS carriers by PCR (polymerase chain reaction) test.
1559713|NCT02528877|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
1559714|NCT02528877|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoeitic stem cell transplant
1559715|NCT02528877|Drug|Fludarabine Phosphate|Given IV
1559716|NCT02528877|Other|Laboratory Biomarker Analysis|Correlative studies
1559717|NCT02528877|Drug|Melphalan|Given IV
1559718|NCT02528877|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo hematopoietic stem cell transplant
1559719|NCT02528877|Other|Pharmacological Study|Correlative studies
1559720|NCT02528877|Drug|Ruxolitinib Phosphate|Given PO
1559721|NCT02528877|Drug|Sirolimus|Given PO
1559722|NCT02528877|Drug|Tacrolimus|Given IV or PO
1559723|NCT02528851|Procedure|Extubation from endotracheal mechanical ventilation to CPAP|"Following randomization, the infants will be extubated to the higher CPAP group (CPAP level 2cm H2O higher than extubation EAP) or equivalent CPAP group (CPAP level equal to the extubation EAP) based on their allocation."
1559724|NCT02528825|Drug|Remifentanil titration|Initial concentration being 1.5ng/ml for the first patient The smooth emergence was defined as extubation without cough-a strong and sudden contraction of the abdomen. The predetermined concentration was decreased by 0.5 ng/ml for the next patient if the patient did not cough during emergence and similarly, if the patient coughed anytime during emergence, it was considered failed smooth emergence and predetermined concentration was increased by 0.5 ng/ml.
1559725|NCT02528812|Device|TheraBand Roller Massager|The roller massager was moved proximal to distal at a slow pace (2 seconds up and 2 second downs) over the muscle belly. Participants in the Sham group received very light pain-free cutaneous strokes of rolling massage with the same pace of rolling as performed for the Ipsi-R and Contra-R groups. The Control group did not receive any treatment.
1559726|NCT02528812|Other|Manual Massage|A massage therapist massaged the participant
1559727|NCT02528799|Biological|Nexvax2|Nexvax2 intra-dermal injections twice weekly
1559728|NCT02528799|Biological|Nexvax2 placebo|Sodium chloride 0.9% intra-dermal injections twice weekly
1559730|NCT02528760|Drug|Metaclopramide|23. Metoclopromide to be given 10mg iv 8 hourly
1559731|NCT02528760|Drug|Erythromycin|Erythromycin to be given 70mg iv 12 hourly.
1559732|NCT02528760|Other|Placebo|
1559733|NCT02528721|Device|Dual Mode BreathID Hp System|The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device
1559734|NCT02528708|Drug|fibrinogen concentrate|The dose of fibrinogen concentrate needed to achieve this target will be calculated using a formula that accounts for the baseline FIBTEM® - A10 value and the patient's body weight assessed at hospital admission . In general, a 70-kg patient requires a fibrinogen dose of approximately 0.5 g to increase the MCF by approximately 1 mm.
1559735|NCT02528708|Drug|Placebo|0.9% saline solution
1559736|NCT02528695|Radiation|18F-FDG PET/CT|18F-FDG PET/CT
1559737|NCT02528695|Device|euglycemic clamp|euglycemic clamp
1559738|NCT02528695|Device|hypoglycemic clamp|hypoglycemic clamp
1559739|NCT02528682|Biological|MiHA-loaded PD-L-silenced DC Vaccination|Eligible patients will receive one cycle of donor DC vaccination consisting of maximal 3 immunizations, given at 2 week intervals. PD-L1/L2-silenced, MiHA mRNA-electroporated donor DC will be infused intravenously (2.5x105/kg body weight).
1559741|NCT02528656|Device|Vacuum Bell|Patients will be submitted to a negative pressure treatment with the Vacuum Bell device.
1559742|NCT02528656|Device|Dynamic Compression System|Patients will be submitted to a dynamic compression system.
1559743|NCT02528643|Drug|enzalutamide|oral
1559744|NCT02528643|Drug|placebo|oral
1560864|NCT02520778|Other|Pharmacological Study|Correlative studies
1559745|NCT02528630|Other|Progressive resistance strength training program|Patients undergo to strength training for intrinsic muscles of the hand twice a week, during 12 weeks.
1559746|NCT02528630|Other|Joint protection and energy conservation advice|A session regarding joint protection and energy conservation for hands was done before randomization.
1559747|NCT02528617|Drug|Velaglucerase alfa|Enzyme replacement therapy
1559748|NCT02528604|Procedure|Catheter ablation|Left atrial ablation of persistent atrial fibrillation and implantable loop recorder insertion.
1559749|NCT02528604|Procedure|Pacemaker and AV node ablation|Permanent pacemaker implant followed by AV node ablation
1559750|NCT02528604|Procedure|DC Cardioversion|Electrical cardioversion for Persistent Atrial Fibrillation and implantable loop recorder insertion.
1559751|NCT02528604|Device|Implantable loop recorder|
1559752|NCT02528591|Device|oscillometric device (Arteriograph®, Medexpert)|Central blood pressure recorded in the non-fistula arm using a validated oscillometric device (Arteriograph®, Medexpert).
1559753|NCT02528578|Device|thermal stimulation delivered by a thermode.|Empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
1559754|NCT02528578|Other|functional MRI|MRI realised with thermal stimulations and empathetic context (neutral, empathetic, non-empathetic) when thermal stimulation
1559755|NCT02528565|Device|Adhesix Bioring|
1559756|NCT02528552|Device|LH80 PRO|
1559757|NCT02528552|Device|Sham Device|
1559758|NCT02528539|Other|ITP|"The study participants will receive weekly acupuncture treatment plus education on self-management for 10 weeks after axillary node dissection, then a total of five follow up acupuncture treatments once every 3 months at 6, 9, 12, 15, and 18 months. The education and self management will be reinforced monthly by telephone visit.
Acupuncture points include: LI 4, LV3, HT3, SP9, GB 20, KD 3, Yintang, and Ashi points"
1559759|NCT02528526|Drug|OXY111A|OXY111A intravenous infusion
1559760|NCT02528513|Drug|midazolam|Midazolam is started with an infusion bolus of 0.03-0.30 mg/kg and continuous infusion of 0.03-0.20 mg/kg/h, with the dosage adjusted to RASS score (-3 to 0).
1559761|NCT02528513|Drug|Fentanyl|Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
1559762|NCT02528513|Drug|propofol|After the spontaneous breathing trial safety screen is passed, midazolam is switched to propofol, which is administered at the maintenance dosage of 0.50-3.00mg/kg/h, with the dosage adjusted to RASS score (-2 to 0).
1559763|NCT02528513|Drug|Dexmedetomidine|After the spontaneous breathing trial safety screen is passed, midazolam is switched to dexmedetomidine, which is administered at an infusion bolus of 0.5μg/kg over 10 min (given or not according to patients' condition) and the maintenance dosage of 0.2-0.7ug/kg/h, with the dosage adjusted to RASS score (-2 to 0).
1559764|NCT02528513|Procedure|Procedure:sedation assessment|The nursing staff continuously monitored the sedation depth and adjusted the dosages of sedative and analgesic drugs to maintain the sedation target level. The sedation depth were assessed and recorded every 4 h (or more frequently when indicated).
1559765|NCT02528513|Procedure|Procedure:Weaning|the respiratory therapists managed patients with a daily interruption of continuous sedation and the spontaneous breathing trial (SBT) protocols daily.
1559766|NCT02528513|Drug|midazolam(used for passing the SBT safety screen)|After the spontaneous breathing trial safety screen is passed,in the midazolam group, midazolam will continue to be used for sedation, with the dosage adjusted to RASS score (-2 to 0).
1559767|NCT02528500|Device|GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis|Non-randomized, multicenter study designed to assess the initial feasibility of the GORE® EXCLUDER® Thoracoabdominal Branch Endoprosthesis (TAMBE Device)
1559768|NCT02528474|Device|balloon angioplasty with Pantera Lux|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with Pantera Lux for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
1559769|NCT02528474|Device|balloon angioplasty with SeQuent Please|Patient will be considered to be enrolled if ISR in DES was found by angiography. After randomization, patients will be treated with SeQuent Please for treatment of ISR. OCT will be performed just after balloon angioplasty for ISR lesion. Information will be collected and recorded on the treated study vessel including angiographic and OCT parameters. Follow-up OCT at 9 month will be performed.
1559770|NCT02528461|Drug|Galactose|A test to investigate the liver's ability to metabolize galactose to glucose by injecting galactose followed by measurements of blood glucose and the quantification of galactose in the urine.
1559771|NCT02528461|Procedure|Gastroscopy|
1559772|NCT02528461|Procedure|Liver biopsy|
1559773|NCT02528461|Procedure|Fibroscan|
1559774|NCT02528461|Procedure|Liver vein catheterization|
1559775|NCT02528461|Drug|Sofosbuvir|
1559776|NCT02528448|Drug|Plasma-lyte|Continuous 1 hour infusion of plasma-lyte 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
1559777|NCT02528448|Drug|0,9% saline|Continuous 1 hour infusion of 0,9% saline 15 micrograms/kg/hour for the first hour then 5 micrograms/kg/hour + amount needet for blood replacement
1559778|NCT02528422|Drug|Acyl-Ghrelin|
1559779|NCT02528409|Drug|Vortioxetine|Medication currently approved for major depression.
1559780|NCT02528409|Drug|Placebo|
1559781|NCT02528396|Drug|BioChaperone insulin lispro|Injection at t0,or t+15 minutes or t-15minutes with test meal
1559782|NCT02528396|Drug|Humalog®|Injection at t0,or t+15 minutes or t-15minutes with test meal
1559783|NCT02528383|Behavioral|Vagifem|"Women participating in the study will undergo clinical assessments, blood work and complete the quality of life questionnaire at baseline, 6 weeks and 12 weeks study time points. The following will be assessed:
Effect of low dose Vagifem, 10ug tablet on vaginal atrophy.
Effect of low dose Vagifem, 10ug tablet on sex hormones and bone health biomarkers.
Impact of treatment on quality of life"
1559833|NCT02528123|Procedure|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
1559784|NCT02528370|Device|telEPOC|The program consisted of: 1) Educational program about COPD. This educational program was carried-out by a respiratory nurse in two 30-minute speeches to the patient and career, once at their inclusion in the program and again 1 year later. 2) Training in using the device (smart phone) that supported the telemonitoring. 3) Daily phone calls to make self-confident the patient during the first week. Afterwards the phone calls were established according to the capacity of the patient to manage on their own.
1559785|NCT02528357|Drug|GSK3174998|Lyophilized powder 40 mg reconstituted to get a dose range of 0.003 to <=10 mg/kg to be given as IV infusion for 30 minutes (min), Q3W
1559786|NCT02528357|Drug|Pembrolizumab|Pembrolizumab as 100 mg/4 mL solution (dose: 200 mg) to be given as IV infusion for 30 min, Q3W
1559787|NCT02528344|Behavioral|HIIT|All participants will undergo high intensity interval training 3x/week for 10-12 weeks. Intense exercise will be interspersed with appropriate rest periods of low intensity exercise
1559788|NCT02528331|Device|Transcranial magnetic stimulation|
1559789|NCT02528331|Behavioral|Cognitive behavioral therapy|
1559790|NCT02528318|Drug|Lucinactant for inhalation|Lucinactant for inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
1559791|NCT02528318|Device|nCPAP alone|nCPAP therapy
1559793|NCT02528292|Procedure|Synovial biopsy|Ultrasound guided synovial biopsy of inflamed joint
1559794|NCT02528292|Drug|Anti-TNF therapy|Therapy will include, but not limited to Etanercept, Certolizumab Pegol, Adalimumab and Infliximab
1559795|NCT02528279|Drug|Coartem|"Patients will receive the study drug combination artemether-lumefantrine (Coartem®) orally as a 6 dose regimen for three consecutive days. Tablets are available as a fixed dose combination of 20mg artemether plus 120mg lumefantrine. The dosing will be based on the body weight and follow the manufacturer's recommendations:
Body weight 5-14kg: 1 tablet; Body weight 15-24kg: 2 tablets; Body weight 25-34kg: 3 tablets; Body weight > 34kg: 4 tablets; The respective amount of tablets is to be taken at hours 0, 8, 24, 36, 48 and 60 with fatty food."
1559796|NCT02528266|Device|Nerve Capping Device|
1559802|NCT02528240|Procedure|EMS|
1559803|NCT02528240|Device|+ occlusive membrane|
1559804|NCT02528240|Device|conebeam CT|
1559805|NCT02528227|Other|Know Your Baby Language Curriculum|Early language activities that parents can do with their infants
1559806|NCT02528227|Other|Reading Aloud Language Curriculum|Early language activity that parents can do with their infants
1559807|NCT02528227|Other|Sing A Long Language Curriculum|Early language activity that parents can do with their infants
1559808|NCT02528227|Other|Mimicking First Sounds Language Curriculum|Early language activity that parents can do with their infants
1559809|NCT02528227|Other|Language Games and Narrating Your Day Language Curriculum|Early language activity that parents can do with their infants
1559810|NCT02528227|Other|Feeding Safety|Part of Health and Safety Curriculum
1559811|NCT02528227|Other|Car Seat Safety|Part of Health and Safety Curriculum
1559812|NCT02528227|Other|Bath Safety|Part of Health and Safety Curriculum
1559813|NCT02528227|Other|Back to Sleep/SIDS prevention|Part of Health and Safety Curriculum
1559814|NCT02528227|Other|Taking a Temperature and Signs of Infection|Part of Health and Safety Curriculum
1559815|NCT02528227|Other|Infection Control Measures and Vaccine Information|Part of Health and Safety Curriculum
1559819|NCT02528201|Drug|Celecoxib 200 milligrams|Celecoxib 200 milligrams once a day
1559820|NCT02528201|Drug|Celecoxib 400 milligrams|Celecoxib 400 milligrams once a day
1559821|NCT02528201|Drug|diclofenac 50 milligrams|diclofenac 50 milligrams three times a day
1559825|NCT02528175|Device|Magnetic resonance-guided focused ultrasound|Targeted warming of the tumor via 3 weekly MR-guided ultrasound procedures. Concurrent with radiation and chemotherapy.
1559826|NCT02528175|Radiation|Standard Radiation|30.6 Gray (Gy) over 17 fractions concurrent with chemotherapy (institutional standard).
1559827|NCT02528175|Drug|Chemotherapy|3.5 weeks concurrent with radiation therapy (institutional standard).
1559828|NCT02528162|Behavioral|education|Evaluation of education for GDM
1559829|NCT02528149|Procedure|tissue of adjacent part and aneurysm of renal aneurysm|the samples are collected during surgery of renal artery aneurysms. Th tissue is cryopreserved in liquid nitrogen before analysis
1559830|NCT02528149|Other|blood sample|
1559831|NCT02528136|Drug|Carbetocin|
1559832|NCT02528136|Drug|Oxytocin|
1559834|NCT02528123|Drug|Tobramycin and dexamethasone|Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure
1559835|NCT02528123|Drug|Ofloxacin|Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
1559836|NCT02528123|Drug|Proxymetacaine 0.5%|Proxymetacaine 0.5% eye drops will be used as an anaesthetic during the procedure
1559837|NCT02528123|Drug|Oxybuprocaine 0.4%|Oxybuprocaine 0.4% eye drops will be used as an anaesthetic during the procedure
1559838|NCT02528110|Procedure|Hyperthermic intraperitoneal chemotherapy (HIPEC)|Normal saline 3000ml-4000ml, Paclitaxel 75mg/m2, 5-Fu 15mg/m2, 43°C, 60min.
1559839|NCT02528110|Procedure|D2 radical gastrectomy|radical gastrectomy with D2 lymphadenectomy
1559840|NCT02528110|Other|SOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Tegafur,Gimeracil and Oteracil Porassium Capsules 60mg, d1-14.
1559841|NCT02528110|Other|XELOX postoperative chemotherapy|Oxaliplatin 130mg/m2 d1, Capecitabine 1000mg/m2 d1-14.
1559842|NCT02528097|Drug|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
1559843|NCT02528097|Drug|Experimental|25% salt poor albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 or later only to those individuals with renal insufficiency and risk for renal failure (Cr > 1.0 or BUN or Cr > baseline)
1559844|NCT02528084|Procedure|yoga|patients watch and follow an online yoga video.
1559845|NCT02528084|Procedure|standard exercises|patients watch and follow an online standard exercises video.
1559847|NCT02528058|Procedure|Vitrectomy with internal limiting membrane peeling|
1559848|NCT02528045|Procedure|Vitrectomy with scleral shortening|
1559849|NCT02528032|Other|Echographic evaluation of heart function|Echocardiographic data collection and analysis, not fully exploited at present
1559850|NCT02528019|Drug|DPP-4 inhibiotors|
1559851|NCT02528019|Drug|SGLT2 inhibitors|
1559852|NCT02528019|Drug|Glimepiride|
1559853|NCT02528006|Device|Type 2 Thyroplasty using Titanium Bridges|
1559854|NCT02527993|Drug|Glucobay (acarbose)|Se arm description
1559855|NCT02527993|Drug|Januvia (sitagliptin)|Se arm description
1559856|NCT02527993|Drug|Verapamil HEXAL (verapamil)|Se arm description
1559857|NCT02527993|Drug|Victoza (liraglutide)|Se arm description
1559858|NCT02527993|Drug|Signifor (pasireotide)|Se arm description
1559859|NCT02527993|Device|Continuous glucose monitoring (CGM)|Continuous glucose monitoring will be performed during 6 days of the treatment period.
1559860|NCT02527993|Dietary Supplement|Meal tolerance test (MTT)|A meal tolerance test will be performed at the end of the treatment period. The subjects will consume the liquid meal at baseline and blood will be drawn for continuous blood sampling.
1559861|NCT02527980|Other|No intervention: observation only|For all participants: We will conduct a 2-year longitudinal cohort study comprising participants who smoke exclusively CCs (n=175) and dual users of e-cigs and CCs (n=275). We will use state-of-the-art ecological momentary assessments to determine: 1) dynamic patterns of e-cig and CC use and related outcomes (e.g., dependence, withdrawal symptoms, CC quit attempts and quitting success); 2) episodic (affective, contextual, social) and stable person-factor (lifestyle factors, demographics) variables that covary meaningfully with e-cig and CC use and related outcomes; and 3) biomarkers of tobacco and carcinogen exposure as well as other health-related outcomes (e.g., reduced pulmonary function.
1559862|NCT02527941|Drug|Metronidazole|Participants will be provided with oral metronidazole 400mg po tid for one week, and followed up one month after treatment initiation.
1559863|NCT02527928|Other|None intervention|
1559864|NCT02527915|Other|Mental Health eConsults|Providers in primary care clinics who receive the intervention will be able to use electronic consultations (eConsults) with psychiatrists. If a primary care provider wishes to use eConsults, he/she will enter a specific question about a patient in the electronic medical record system and submit as an eConsult. A psychiatrist will review the question and the patient's record, and send a response back to the primary care provider within one business day.
1559865|NCT02527915|Other|Care as usual|Providers in primary care clinics will deliver care as usual to their patients.
1559866|NCT02527902|Device|Holter|measure of ANS in IgAN patients
1559867|NCT02527889|Other|Exercise training|8-week resistive exercise training
1559868|NCT02527876|Behavioral|High Intensity Interval Training|High Intensity Interval Training
1559869|NCT02527876|Behavioral|Moderate Intensity|Moderate Intensity Training
1559870|NCT02527876|Behavioral|Delayed Control|Delayed Control
1559871|NCT02527876|Device|FitBit Flex|Use to measure increase in Physical Activity
1559872|NCT02527863|Drug|Tolvaptan|60 mg Tolvaptan pr day for 1 day
1559873|NCT02527863|Drug|Placebo|1 tablet Unikalk pr day for 1 day
1559874|NCT02527850|Device|B-cure laser|
1559875|NCT02527837|Drug|Sodium nitrite|Sodium nitrite, 240 micrograms/kg/hour for 2 hours
1559876|NCT02527837|Drug|Sodium chloride|Sodium chloride, isotonic 0.9%, 25 ml/hour for 2 hours
1559877|NCT02527824|Drug|Oxaliplatin, Irinotecan, S-1|"Treatment will be delivered every 2 weeks
Oxaliplatin 65 mg/m2 iv on day 1
Irinotecan 135 mg/m2 iv on day 1
S-1 80 mg/m2/day on day1-7"
1559878|NCT02527811|Drug|Ulinastatin|Ulinastatin will be diluted into saline solution and administered intravenously in the intraoperative and postoperative
1559883|NCT02527785|Drug|Oxaliplatin, Irinotecan, S-1(OIS)|"Treatment will be delivered every 2 weeks
oxaliplatin 65 mg/m2 iv on day 1
irinotecan 135 mg/m2 iv on day 1
S-1 80 mg/m2/day po on day 1-7"
1559997|NCT02526953|Drug|Mitomycins|10 mg/m2, IV, on day 1. Number of infusions: 1.
1559884|NCT02527772|Drug|Liposomal Doxorubicin+Gemcitabine|Gemcitabine 1000mg/m2,d1,8,iv; Liposomal Doxorubicin 30mg/m2,d1,iv.q4w of each 28 day cycle. 6 of Cycles: until progression or unacceptable toxicity develops or Progressive Disease.
1559885|NCT02527772|Drug|FOLFOX4|Oxaliplatin 85 mg/m2 intravenously on day 1; Leucovorin 200 mg/m2 IV(in vein) from hour 0 to 2 on days 1 and 2; and Fluorouracil 400 mg/m2 IV bolus at hour 2, then 600mg/m2 over 22 hours on days 1 and 2, once every 2 weeks until progression or unacceptable toxicity develops or Progressive Disease.
1559887|NCT02527746|Biological|F-627|F-627 subcutaneous injection on Day 3 of each cycle for 4 cycles. Dose-escalation method was used.
1559888|NCT02527746|Drug|EC regimen|Epirubicin 100 mg/m2 (in vein) and Cyclophosphamide 600 mg/m2 (in vein) on Day 1 of each cycle for 4 cycles.
1559889|NCT02527733|Drug|Ranibizumab|
1559890|NCT02527733|Drug|Ranibizumab and laser|
1559891|NCT02527720|Behavioral|Mindfulness Therapy|BBMT is a simplified form of MM. Its core components are near resonance-frequency breathing (RFB), mindfulness training, positivity and inward attention. A key component in BBMT is to be mindful of breathing whenever possible, and breathe at near resonance frequency (RF), known as heart rate variability biofeedback. The human cardiovascular system is known to have resonance characteristics, with the first RF at ~0.1 Hz. RF varies between 4.5 and 7 cycles per minute. Breathing at RF stimulates the cardiovascular system to oscillate at that frequency at a very high amplitude and greatly stimulates the baroreflex system. RFB is known to reduce depression and stress symptoms as well as various diseases related to malfunction of the autonomic nervous system, such as asthma and hypertension.
1559892|NCT02527707|Drug|lonafarnib|antiviral farnesyltransferase inhibitor
1559893|NCT02527707|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
1559894|NCT02527694|Device|Flexible EMS stretcher cart|The flexible stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.
1559895|NCT02527694|Device|mechanical CPR|
1559896|NCT02527681|Drug|ceftobiprole|single dose of ceftobiprole at 7.5 mg/kg body weight, given as a 4-hour constant-rate infusion of ceftobiprole medocaril
1559897|NCT02527668|Dietary Supplement|Calcifediol|One capsule orally of Calcifediol (20 µg) per day with a meal for a duration of 6 months
1559898|NCT02527668|Dietary Supplement|Vitamin D3|One capsule orally of Cholecalciferol (3200 IU) per day with a meal for a duration of 6 months
1559899|NCT02527668|Other|Placebo|One capsule orally of a Placebo capsule per day with a meal for a duration of 6 months
1559900|NCT02527655|Behavioral|Choice-Based Physical Activity and Active Transportation|
1559901|NCT02527642|Other|embryo culture in buffered media|compare media that supports human embryo development in the laboratory (in vitro) using Time-Lapse system.
1559902|NCT02527629|Other|Decellularized human heart valves|Decellularized human aortic heart valves
1559903|NCT02527616|Device|FFR Infusion Microcatheter and standard intra-venous (IV) infusion|Cross-over design where FFR is measured twice in the same lesion using standard standard intra-venous (IV) infusion and new method
1559904|NCT02527603|Procedure|Boss-Holzach-Matter method|The patient holds both his hands around his knees in a supine position until the dislocated shoulder is reduced
1559905|NCT02527603|Procedure|Spaso method|The physician holds the dislocated arm of the patient in a supine position and proceeds with gentle, soft movements of adduction, flexion and external rotation of the limb in this order until reduction is accomplished.
1559906|NCT02527603|Drug|Anti-Inflammatory Agents, Non-Steroidal|"All patients will be administered a dose of NSAI intra-muscular or orally (Dexketoprofen, Enantyum®) it is part of the normal treatment of these patients to cope with pain."
1559907|NCT02527590|Other|pneumatic stimulations(allodynic area)|2 series of 20 pneumatic stimulations (air jet) on a allodynic area for recording evoked potentials
1559908|NCT02527590|Other|pneumatic stimulations (healthy area)|2 series of 20 pneumatic stimulation on a healthy area (either contralateral or above or below allodynic area) will no pain triggering for recording evoked potentials
1559909|NCT02527590|Other|pneumatic stimulations no auditory masking|2 series of pneumatic stimulations (air jet) on the hand (without feeling pain) for recording evoked potentials
1559910|NCT02527590|Other|no stimulation (control)|no stimulation (control condition): air jet directed beside the hand
1559911|NCT02527590|Other|pneumatic stimulations with audidory masking|2 series of 20 pneumatic stimulations (air jet) on the hand (without feeling pain) with auditory helmet that totally masked the air jet noise.
1559912|NCT02527577|Drug|RopivacaIne chlorhydrate|3mg/kg injection Hour (H) 0, H12 ; H24, H36 ; H48
1559913|NCT02527577|Drug|Placebo|injection Hour (H) 0, H12 ; H24, H36 ; H48
1559914|NCT02527564|Drug|Suvorexant|
1559915|NCT02527564|Drug|Placebo|
1559916|NCT02527551|Other|Massage|6 weeks of deep haptic massage at 2 sessions of 30 minutes per week.
1559917|NCT02527538|Device|Pleth|apply the masimo probe on index fingertip and record the pleth variability and blood pressure during beach chair position
1559918|NCT02527525|Behavioral|Stepped Care|
1559919|NCT02527512|Drug|Povidone-Iodine|Chemical complex of polyvinylpyrrolidone (povidone, PVP) and elemental iodine
1559920|NCT02527512|Other|Normal Saline|Solution of 0.90% w/v of NaCl, 308 mOsm/L or 9.0 g per liter
1559921|NCT02527499|Behavioral|Ride-On Cars with Bimanual Training Program (ROCBT)|The car driving training includes 2 phases: I-car exploration and II-prompted driving. Participants can learn how to move and stop the car in the car exploration phase. Through prompted driving in phase II, they can use the car as a mean to explore environments (e.g., to the elevator, to different stores) and contact with people (e.g., drive to the caregiver and get the toy). Bimanual training involves activities which include perceptual motor tasks (e.g., smear both hands with color), holding and manipulative tasks (e.g., cutting toy vegetables or fruits), posture and balance (e.g., pull a cart), and self-care and activities of daily living (e.g., drinking water from a cup with two handles).
1559922|NCT02527499|Behavioral|Early Mobility Training Program|Most of the guidelines are similar with ROCBT, except for the bimanual training. The therapist and family will merely focus on independent mobility training and improving socialization. The training time and period is the same as ROCBT.
1559923|NCT02527499|Behavioral|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 9-week intervention phase.
1559924|NCT02527473|Other|Dispatcher-Assisted Basic Life Support CPR Education|"The training program focuses on working in a team with a dispatcher, re-enacting all steps during an emergency call from recognition of cardiac arrest to performing CPR.
The one hour training session is split into four parts:
Video self-instruction manikin practice (30 min), including a brief introduction to AED.
Practice in pairs (15 min): Role-playing a simulated emergency scenario as the dispatcher and the rescuer
Debriefing (15 min): Questions, answers and reflection
Homework: Information leaflet handed out including at-home tasks such as operating the speakerphone function on the layperson's own phone"
1559929|NCT02527421|Drug|DFD01 Spray|
1559930|NCT02527421|Drug|Comp01 Lotion|
1559931|NCT02527395|Other|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
1559932|NCT02527395|Other|Pain during 1 min. thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
1559933|NCT02527395|Other|Heat pain detection threshold|The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered. 4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements.
1559934|NCT02527382|Procedure|Closed stump|Before cutting the bowel, a peritoneal sample for bacterial culture is taken from the peritoneal cavity (pelvic pouch). Anastomosis is performed while a bowel clamp is placed on the rectal stump. A second bacterial sample is obtained at the completion of the anastomosis from the same place (pelvic pouch) as the first one.
1559935|NCT02527369|Device|XP1100RF|Treatment of adipose tissue within the fat layer with XP1100RF device.
1559936|NCT02527356|Behavioral|Ride-On Cars with Standing Posture (ROC-Stand)|The 2-hour training session is composed of two 30-minute driving sessions and two 25-minute natural play sessions, with a 10-minute break. Every week's treatment program will be before planned and adjusted by the therapist and the caregivers through discussion and clinical observation of participant's performance in the previous session. Training will concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving in a hospital, and upper limb use in functional tasks with driving and hand use in functional tasks for exploration in natural play session.
1559937|NCT02527356|Behavioral|Ride-On Cars with Standing Postures (ROC-Sit)|Most of the guidelines are similar with ROC-Stand, except for the posture of driving. The training time and period is the same as ROC-Stand. The two 30-minute driving sessions can also be divided into 4 times of 15-minute sessions, depending on the child's standing ability with supported condition.
1559938|NCT02527356|Behavioral|Regular Therapy Program|The research team will ask caregivers to identify goals (before intervention), and measure progress using goal-attainment scaling (GAS). The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child's natural play and driving performance at the hospital for 1 hour/per session, 1 session/per week during the 12-week intervention phase.
1559939|NCT02527343|Drug|volanesorsen|
1559940|NCT02527343|Drug|Placebo|
1559941|NCT02527330|Other|MR T2* imaging|Cardiac magnetic resonance imaging with T2* imaging
1559942|NCT02527317|Drug|Lipegfilgrastim|Investigate the incidence of treatment-related neutropenia following four cycles of dose dense (every 2 week) doxorubicin cyclophosphamide (AC) with lipegfilgrastim support (8 weeks).
1559943|NCT02527304|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo adaptive staged SBRT
1559944|NCT02527304|Other|Quality-of-Life Assessment|Ancillary studies
1559945|NCT02527304|Other|Questionnaire Administration|Ancillary studies
1559946|NCT02527304|Radiation|Stereotactic Body Radiation Therapy|Undergo adaptive staged SBRT
1559947|NCT02527291|Other|Blood test|Blood test for CMV PCR and IL28
1559948|NCT02527278|Procedure|Laparoscopic tubal ligation|Female permanent birth control method performed via a surgical procedure
1559949|NCT02527278|Procedure|Hysteroscopic sterilization|Female permanent birth control method performed via placement of a device
1559951|NCT02527252|Other|Craniosacral therapy|
1559952|NCT02527252|Other|Classic Massage|
1559953|NCT02527239|Other|Prospective observational study|Prospective observational study collecting data during a clinic vist including measurement of respiratory muscle strength, respiratory failure, lung function, physical performance and blood testing for enzymes related to Pompe's disease and muscle function.
1559954|NCT02527226|Behavioral|Facial exercises|A series of self-administered facial movements and expressions.
1559955|NCT02527213|Drug|Sodium thiosulfate|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
1559956|NCT02527213|Drug|Placebo|Additional treatment(s) due to lesion progression When intervention occurs, the date of the intervening event should be recorded in the source documents and the (CRF). The subject should continue in the study as scheduled.
1559998|NCT02526953|Drug|Mitomycins|12 mg/m2, IV, on day 1. Number of infusions: 1.
1559957|NCT02527200|Drug|liraglutide|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
1559958|NCT02527200|Drug|placebo|Injected s.c./ subcutaneously (under the skin) This trial consists of a part A and a part B. Part A of the trial is conducted in obese adolescents with PWS. Part B of the trial is conducted in obese children with PWS. Entry into part A and part B of the trial will be sequential.
1559959|NCT02527187|Biological|T502|The subjects will receive 4 doses of T502 in different concentrations.
1559960|NCT02527187|Other|Histamine dihydrochloride|The subjects will receive 1 dose for positive control
1559961|NCT02527187|Other|Glycerinated phenol saline solution|The subjects will receive 1 dose for negative control
1559962|NCT02527174|Drug|Volasertib|Addition of single dose of volasertib intravenously (IV) on Day 4 of treatment protocol.
1559963|NCT02527174|Drug|Idarubicin|Given IV daily on Days 1-3 of treatment protocol.
1559964|NCT02527174|Drug|Cytarabine|Given IV daily as 24-hour continuous infusion on Day 1-7 of treatment protocol.
1559965|NCT02527161|Device|ShapeMatch Cutting Guides with Triathlon|All participants will undergo medical imaging assessment using Magnetic Resonance Imaging (MRI) of the affected lower limb.These images will be used to manufacture the patient-specific cutting guides for preparation of the bones prior to implantation of the total knee replacement (Pre-operatively). Patients will undergo primary total knee arthroplasty with the Triathlon® Total Knee System (Stryker Orthopaedics, Mahwah, NJ USA) using the Shapematch cutting guides to guide the bone resection. Patients will follow the standard postoperative rehabilitation program established by the investigator at each site.
1559966|NCT02527148|Device|OtisMed® ShapeMatch® Technology|The appropriate Stryker ShapeMatch® Cutting Guides will be used to guide the surgeons bone resections. The surgeon will implant the knee prostheses following the surgical protocol for Triathlon® Knee System with OtisMed® ShapeMatch® Technology
1559967|NCT02527148|Device|Stryker Precision Knee Navigation|Stryker PrecisioN Knee (4.0) Navigation System, comprising of computer hardware and software and associated instrumentation, will be used for intra-operative alignment and orientation of implant. Navigation trackers will be secured to the femur and tibia and registration of the limb will be undertaken according to the PrecisioN Knee System surgical technique.Femoral and tibial resections, followed by device implantation, will be performed according to the Triathlon Knee System Surgical Protocol.
1559968|NCT02527148|Procedure|Total Knee Replacement|
1559969|NCT02527148|Device|Stryker Triathlon® Total Knee System|"Prosthetic components to be implanted including
Triathlon® Cruciate Retaining (CR) Total Knee System (cemented), including Femoral Component and Primary Tibial Baseplate;
Triathlon® Cruciate Substituting (CS) X3® polyethylene insert;
Triathlon® X3 Patella (asymmetric) - treated selectively by surgeon."
1559970|NCT02527135|Behavioral|Weekly HIV sensitization text messages|"Weekly HIV sensitization text messages with option to text back up to 3 times per week for additional messages. Message topics included pregnancy, condoms, sexually transmitted infections, contraceptives, anal sex and personal risk of HIV. All messages ended with the phrase Get tested for HIV."
1559971|NCT02527122|Diagnostic Test|Allergen extracts|
1559972|NCT02527109|Drug|Nifedipine|
1559973|NCT02527096|Drug|dolutegravir (Tivicay®) - Phase 1|• Phase 1 (8 weeks) : switch of the third agent with dolutegravir(Tivicay®) 50 mg once a day.
1559974|NCT02527096|Drug|lamivudine (Epivir®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
1559975|NCT02527096|Drug|dolutegravir (Tivicay®) - Phase 2|• Phase 2 (48 weeks): combination with lamivudine (Epivir®) 300 mg once a day + dolutegravir (Tivicay®) 50 mg once a day. Only participants with plasma HIV RNA ≤ 50 cp/mL at Week 8 will continue on phase 2.
1559976|NCT02527083|Drug|Propofol|
1559977|NCT02527083|Drug|Sevoflurane|
1559978|NCT02527083|Drug|Remifentanil|
1559979|NCT02527083|Drug|Ketamine|
1559980|NCT02527070|Device|RESPeRATE (Paced Breathing)|The subjects will be guided by a digital metronome to breath at 15, 10, and 6 breaths/min for 2 minutes each using the metronome function of the device RESPeRATE (InterCure, Israel) that guides breathing using musical tones played at selectable rhythm.
1559981|NCT02527070|Device|Quantum Warp10 (Red LED)|
1559982|NCT02527070|Device|Omnilux new-U (Near Infrared LED)|
1559983|NCT02527070|Other|Heat/cold provocation|Immersion of one foot in a warm water bath ( 43-45 degrees C) for few seconds and then immersion of the same foot in cold water bath (5-7 degrees C) for 1 min.
1559984|NCT02527057|Device|DW-MRI|Participants will perform four DW-MRI scanning as follows,before chemoradiation , at 2 weeks , 4 weeks after the start of radiotherapy and before the surgery.If participants can not receive surgery,the last scanning time will replaced at the end of radiotherapy.
1559985|NCT02527044|Procedure|Fractional Flow Reserve (FFR)|An FFR will be performed pre-operative to the CABG procedure
1559986|NCT02527031|Other|ECMO Insertion on pre hospital setting|ECMO Insertion on pre hospital setting
1559987|NCT02527031|Other|In Hospital ECMO|ECMO Insertion on in hospital setting for a refractory cardiac arrest
1559988|NCT02527018|Device|Sphygmomanometer|Non-invasive reliable method of continuous measuring arterial blood pressure in pregnant women. Nextfin provides continuous blood pressure, heart rate, cardiac output, stroke volume, systemic vascular resistance and left ventricular contractility indices.
1559989|NCT02527005|Drug|Sulphadoxine-pyrimethamine|Sulphadoxine-Pyrimethamine 500mg of Sulphadoxine and 25mg of Pyrimethamine 3tablets monthly for 3 doses
1559990|NCT02527005|Drug|Azithromycin|Tabs Azithromycin 500mg daily for 3 days
1559991|NCT02526992|Device|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at radius levels in humans.
1559992|NCT02526979|Drug|mirabegron|oral
1559993|NCT02526966|Biological|blood sample|dosage of anti-hinge region antibodies
1559994|NCT02526953|Drug|Paclitaxel|45 mg/m2, IV, weekly during the radiation. Number of infusions: 5.
1559995|NCT02526953|Drug|Capecitabine|625 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
1559996|NCT02526953|Drug|Capecitabine|825 mg/m2, bid, per os, only on days of radiation (Monday through Friday)
1559999|NCT02526953|Radiation|Radiotherapy|Dose: 44 Gy on regional nodes, 52-58 Gy on primary tumor, based on T stage
1560000|NCT02526940|Procedure|rectal biopsies|6 rectal biopsies
1560001|NCT02526940|Other|Blood samples|Blood samples
1560002|NCT02526927|Device|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in human
1560003|NCT02526927|Device|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA device that allows short duration measurements (< 15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
1560004|NCT02526927|Other|Blood samples|
1560005|NCT02526914|Drug|Intranasal Oxytocin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU Oxytocin. 5 puffs per nostril (1 puff = 2.5 IU Oxytocin).
1560006|NCT02526914|Drug|Intranasal vasopressin|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin. 5 puffs per nostril (1 puff = 2 IU vasopressin).
1560007|NCT02526914|Drug|Intranasal placebo|Through the use of 2ml bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: di-sodium hydrogen phosphate, critic acid, sodium chloride, glycerin, benzalkonium chloride and aqua bidest.
1560008|NCT02526901|Other|No intervention|
1560009|NCT02526888|Drug|ACT-541468|Oral capsule (25 mg) as single dose
1560010|NCT02526888|Drug|Diltiazem|Two oral capsules (2 x 120 mg) once daily from Day 1 to Day 7
1560011|NCT02526875|Drug|Telminuvo®Tab. 40/2.5mg|per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
1560012|NCT02526862|Device|Allevyn Thin®|Protection of the dermis with autoadhesive polyurethane dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
1560013|NCT02526862|Device|Askina Transorbent Border®|Protection of the dermis with semi-permeable hydrogel-foams adhesive dressing. The dressing will be standardized cut to avoid bias. The edges shape will be circular. They will be set in nasal bridge and cheekbones, avoiding frontal level. It will be checked every six hours, and if not properly fixed it will be applied again in the same way.
1560014|NCT02526862|Device|Linovera®|Protection of the dermis with hyper hydrogenated fatty acids. It will be applied with its doser and gently massaged in chin, cheekbones, nasal and frontal bridge as indicated in the product. It will be checked every six hours for proper hydration and if needed it will be applied again in the same way.
1560015|NCT02526849|Drug|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
1560016|NCT02526849|Behavioral|Conventional treatment|Conventional treatment was taken by both of two groups. If patients did not have a bowel movement for 3 or more consecutive days, they were permitted to take up to 20 g of Macrogol 4000 powder (Forlax®, Ipsen, Paris, France). If ineffective, an enema could be used.
1560017|NCT02526836|Procedure|Conventional Surgery|removal of the tumor with no ligation of the vessel centrally or removal of the whole mesocolon
1560018|NCT02526836|Procedure|Complete mesocolic excision with central vascular ligation|excision of the whole mesocolon plus ligation of the supplying blood vessel centrally
1560019|NCT02526823|Drug|R-CHOP/CHOPE or ABVD chemotherapy regimen|"R-CHOP:
Rituximab：375mg/m2，ivgtt，D0； Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；
CHOPE:
Epirubicin：70 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;
ABVD:
Epirubicin：35 mg/m2，ivgtt，D1、15； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
1560020|NCT02526823|Drug|R-CDOP/CDOPE or DBVD chemotherapy regimen|"R-CDOP:
Rituximab：375mg/m2，ivgtt，D0； PLD 30-40 mg/m2，ivgtt，D1 ； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5；
CDOPE:
PLD 30-40 mg/m2，ivgtt，D1； Cyclophosphamide：750 mg/m2，ivgtt，D1； Vincristine: 1.4 mg/m2 ivgtt，D1 ； Prednison：100mg/d，po，D1-5； Etoposide: 100 mg/（m2•d），ivgtt，D1-3;
DBVD:
PLD 15-20 mg/m2，ivgtt，D1； Bleomycin：10 mg/m2，ivgtt，D1、15； Vincristine：1.4 mg/m2，ivgtt，D1、15； Dacarbazine：375mg/m2，ivgtt，D1、15；"
1560021|NCT02526810|Drug|insulin lispro|continuous subcutaneous insulin injection( insulin lispro, Humalog) to reduce blood glucose in a certain level
1560022|NCT02526810|Drug|Insulin Glargine|long-acting insulin injection with metformin hydrochloride, Glucophage and gliclazide modified release tablets, Diamicron MR to reduce blood glucose in a certain level
1560023|NCT02526784|Drug|degarelix|
1560024|NCT02526771|Procedure|conventional lymph node dissection|conventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
1560025|NCT02526771|Procedure|unconventional lymph node dissection|unconventional lymph node dissection during resection of intrahepatic cholangiocarcinoma
1560026|NCT02526758|Drug|beclomethasone|
1560027|NCT02526758|Drug|formoterol|
1560028|NCT02526758|Drug|budesonide|
1560029|NCT02526745|Biological|the vaccine with high doses of virus content between 4.7～5.0 lgPFU|
1560030|NCT02526745|Biological|the vaccine with low doses of virus content between 4.7～5.0 lgPFU|
1560031|NCT02526745|Biological|the vaccine with high doses of virus content between 4.3～5.0 lgPFU|
1560032|NCT02526745|Biological|the vaccine with middle doses of virus content between 4.3～5.0 lgPFU|
1560033|NCT02526745|Biological|the vaccine with low doses of virus content between 4.3～5.0 lgPFU|
1560034|NCT02526745|Biological|placebo|
1560035|NCT02526732|Other|individual training program|Training period of 8 weeks: Independently running exercises for 30-45 minutes two to three times a week. Every two weeks group training sessions are offered accompanied by a sports physician.
1560076|NCT02526407|Behavioral|Singing|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will learn songs with their babies and help to create new musical material together.
1560077|NCT02526407|Behavioral|Group play|Sessions will be led by a professional practitioner assisted by students from the Royal College of Music. Participants will take part in group play activities.
1560036|NCT02526719|Procedure|Nipple Delay surgery|The nipple delay surgery will be performed by the plastic surgeon as an outpatient procedure in the minor procedure room under local anaesthetic 7 - 21 days prior definitive NSM with IBR. The skin flap will be elevated in the plane of the prophylactic mastectomy beneath the NAC. A nipple core biopsy and a 1cm thick biopsy of immediately subareolar ductal tissue will be submitted for permanent section pathology. This approach is consistent with the previous case series of nipple delay for NSM and has been approved by the multi-disciplinary breast cancer team at our institutions. Patients that have a positive nipple core or sub-areolar biopsy will have the NAC removed at time of definitive mastectomy.
1560037|NCT02526706|Other|VisionBlue|VisionBlue is a staining solution designed to assist in making complete capsulorhexis during cataract surgery. The dye is injected into the anterior chamber via a paracentesis port and stains the anterior lens capsule, assisting in adequate visualization of the anterior lens capsule. This study proposes to explore the use of VisionBlue during cataract surgery as a means to assess functioning of an existing filtering bleb placed during prior trabeculectomy in patients with glaucoma.
1560038|NCT02526693|Device|RAPDx Pupillography|The Konan RAPDx (Konan Medical USA, Irvine, CA) utilizes digital, high-definition, infrared machine-vision with eye-tracking and automated blink detection technology to analyze and quantify the pupillary response to light
1560039|NCT02526680|Device|OrCam|All thirteen glaucoma subjects in study used the OrCam low vision aid
1560043|NCT02526654|Device|Heidelberg Edge Perimeter|All glaucoma subjects and controls are tested on HEP machine to see how well the machine can detect glaucoma
1560044|NCT02526654|Device|Octopus Visual Field|All glaucoma subjects and controls are tested on OVF machine to see how well the machine can detect glaucoma
1560045|NCT02526654|Device|Optical Coherence Tomography|Patients obtain imaging of the optic nerve head by OCT.
1560046|NCT02526641|Procedure|Functional Hepatic Nitrogen Clearance (FHNC)|
1560047|NCT02526641|Procedure|Galactose Elimination Capacity (GEC)|
1560048|NCT02526641|Procedure|Liver vein catheterization|
1560049|NCT02526615|Drug|Rosiglitazone|Patients received either placebo, metformin or rosiglitazone
1560050|NCT02526615|Drug|Metformin|Patients received either placebo, metformin or rosiglitazone
1560051|NCT02526615|Drug|Placebo|Patients received either placebo, metformin or rosiglitazone
1560052|NCT02526602|Procedure|Preservation (endopelvic fascia)|Robotic assisted radical prostatectomy with preserving of endopelvic fascia
1560053|NCT02526602|Procedure|Opening (endopelvic fascia)|Robotic assisted radical prostatectomy with opening of endopelvic fascia
1560054|NCT02526576|Biological|Stromal Vascular Fraction|The SVF obtained from adipose tissue will be added to the graft
1560055|NCT02526576|Biological|Biopsy|a subgroup of each arm (2 subjects from each arm) will undergo a fat transfer behind each ear to be removed via biopsy after 12 months
1560056|NCT02526563|Procedure|ropivicaine|Blood draws to measure serum ropivicaine
1560057|NCT02526550|Biological|Live attenuated chimeric Japanese Encephalitis vaccine|0.5 mL dose containing ≥ 4.0 log10 plaque forming units (PFU) administered via the subcutaneous route into the left thigh
1560058|NCT02526550|Biological|Inactivated Hepatitis A vaccine|0.5 mL liquid dose for intramuscular injection administered via the intramuscular route into the right thigh
1560059|NCT02526524|Drug|Met DR|metformin delayed-release tablets
1560060|NCT02526524|Drug|Met IR|metformin immediate-release tablets
1560061|NCT02526524|Drug|Placebo|
1560062|NCT02526511|Procedure|Arterial Spin Labeling Magnetic Resonance Imaging|Undergo arterial spin labeled perfusion magnetic resonance imaging
1560063|NCT02526511|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic contrast-enhanced perfusion magnetic resonance imaging
1560064|NCT02526511|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging
1560065|NCT02526511|Procedure|Perfusion Magnetic Resonance Imaging|Undergo perfusion magnetic resonance imaging
1560066|NCT02526498|Radiation|Accelerated Partial Breast Irradiation|Undergo accelerated partial breast irradiation (APBI) using high-dose rate (HDR) brachytherapy
1560067|NCT02526498|Radiation|High-Dose Rate Brachytherapy|Undergo APBI using HDR brachytherapy
1560068|NCT02526498|Other|Questionnaire Administration|Ancillary studies
1560069|NCT02526485|Procedure|Blood Draw|A one time blood draw of 150 milliliters will be performed using a vein in the participants arm. Existing venous access will be used for the blood draw in preference of new venipuncture.
1560070|NCT02526472|Procedure|ET under transabdominal US guidance (UGET)|When UGET was used, a second physician performed trans-abdominal US, and the embryos were discharged when the tip of the catheter was visualized approximately at 1,5 cm from the fundal endometrial surface
1560071|NCT02526472|Procedure|ET after transvaginal US uterine measurement (mTVET)|When mTVET was scheduled, the physician performed a transvaginal US scan just before ET, measured the length of the cervix and of the uterine cavity, and calculated the distance between the internal uterine os and the fundal endometrial surface. Then, ET was performed inserting the inner cannula in order to discharge embryos at a point obtained subtracting 1.5 cm from the total length of the cavity.
1560072|NCT02526459|Behavioral|Birth plan|Patient will receive a birth plan
1560073|NCT02526446|Behavioral|Self-administered acupressure|"The intervention consists of a total of 28 hours over a period of 8 weeks:
i) Individual learning and practice: The training session will be one-on-one provided twice a week for two consecutive weeks (5 hours) in the participant's home.
ii) Self-practice at home: From 3rd to 8th week, participant will engage in self-administered acupressure at home for 15 minutes twice a day for 6 weeks (21 hours).
iii) Home follow-up: During the 3rd and 4th week (i.e. after the 2-week training session), a 1-hour home visit will be conducted for reinforcement of learning and self-practice by the same team of trainers once a week for 2 weeks (2 hours)."
1560074|NCT02526446|Other|wait-list control|The control group will receive a wait-list control condition (the same self-administered acupressure intervention but after the intervention group has completed the treatment condition).
1560075|NCT02526420|Drug|somavaratan|Long-acting recombinant human growth hormone therapy administered subcutaneously once monthly
1560078|NCT02526394|Biological|Meningococcal vaccine|Meningococcal vaccination
1560079|NCT02526394|Drug|Pertussis containing vaccine|Pertussis containing vaccination
1560080|NCT02526381|Drug|Danlou Tablets|Five tablets of Danlou Tablets (1.5g) will be given three times a day in addition to regular western medications for the 8 weeks
1560081|NCT02526381|Drug|Tongmai Yangxin Pills|Forty pills of Tongmai Yangxin Pills (4g) will be given two times a day in addition to regular western medications for the 8 weeks
1560082|NCT02526368|Drug|Pyruvate (13C)|Pyruvate injection followed by an MRI scan.
1560083|NCT02526355|Behavioral|Mobile based intervention|Learning through Play Plus Intervention delivered through mobile phone
1560084|NCT02526342|Device|V.A.C. UltraTM (KCI®,San Antonio, Texas, USA)|Free muscle flaps are treated with Negative Pressure Wound Therapy (V.A.C. Ultra (KCI®,San Antonio, Texas, USA)) for five days following surgery with a continuous subatmospheric pressure of 125 mmHg.
1560085|NCT02526329|Biological|donor regulatory T lymphocytes|Given IV
1560086|NCT02526329|Other|laboratory biomarker analysis|Correlative studies
1560087|NCT02526316|Biological|P16_37-63 peptide combined with Montanide® ISA-51 VG|Patients will receive P16_37-63 peptide (100 µg) combined with Montanide® ISA-51 VG vaccination subcutaneously once a week for four weeks, followed by a 4 week rest period
1560088|NCT02526316|Biological|P16_37-63 peptide without Montanide® ISA-51 VG|Patients will receive 30 mcg P16_37-63 peptide injected intradermally for test on delayed-type hypersensitivity (DTH) reactions.
1560089|NCT02526303|Drug|Nadroparin Calcium and Warfarin|Warfarin (with nadroparin calcium at the first 5 days at least) until recanalization or 1 year
1560091|NCT02526277|Device|MMF07 Foot Massager|
1560092|NCT02526277|Device|Heat Therapy|
1560093|NCT02526264|Other|Education program|Verbal education prior tu surgery administered to all patients in order to inform about the surgery and outcomes
1560094|NCT02526251|Other|observational|No intervention
1560095|NCT02526238|Device|TMS and trunk rotation|TMS and trunk rotation
1560096|NCT02526238|Device|Sham TMS and trunk rotation|Sham TMS and trunk rotation
1560097|NCT02526225|Drug|Ginkgo diterpene lactone meglumine injection|5 ml,oral,5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
1560098|NCT02526225|Drug|Ginkgo diterpene lactone meglumine injection simulation|5 ml,oral,5 ml/times, 1 time/day.Before use, the drug slowly added to the 0.9% sodium chloride injection diluted in 250 ml, slow intravenous drip.
1560099|NCT02526212|Behavioral|G-BMT|The G-BMT intervention will include weekly group visits (for 8 weeks) where 5-10 patients simultaneously receive care from a multidisciplinary team of a generalist physician and a behavioral specialist. Group visits will last 90 minutes and include: BMT education, instruction on self-management skills, peer support, and individual medical management.
1560100|NCT02526212|Behavioral|Treatment as usual|Primary care physicians who prescribe buprenorphine will be trained to follow a protocol of BMT intensification, which includes increased visit frequency, referral for mental health counseling, and referral to addiction treatment specialist.
1560101|NCT02526212|Drug|Buprenorphine|All participants will continue to receive maintenance treatment with buprenorphine-naloxone
1560102|NCT02526199|Drug|Bupivacaine|Sciatic nerve block
1560103|NCT02526199|Drug|Epinephrine|Adjuvant to perinerual block
1560104|NCT02526199|Drug|Dexamethasone|Adjuvant to perinerual block
1560105|NCT02526186|Device|Battlefield Auricular Acupuncture|
1560108|NCT02526160|Biological|KRN23|KRN23 is a recombinant human immunoglobulin G isotype 1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).
1560109|NCT02526160|Other|Placebo|Subjects may be randomized 1:1 to receive placebo administered subcutaneously (SC) every 4 weeks (Q4W). The placebo group will cross over to receive KRN23 treatment at Week 24.
1560110|NCT02526147|Other|Cash|
1560111|NCT02526147|Other|Voucher|
1560112|NCT02526147|Other|Food|
1560113|NCT02526134|Device|radio opaque markers (Echo Tip Ultra Fiducial Needle - ETUF)|
1560114|NCT02526121|Procedure|Phlebotomy|Volume of 400 mL every 3 weeks, 3 times.
1560115|NCT02526121|Behavioral|Dietary and lifestyle counseling.|Dietary and lifestyle counseling.
1560116|NCT02526108|Other|HIFT|Workout alternates short periods of intense exercise using varied, multiple-joint movements, with less-intense active recovery periods. Workout sessions will be led by a trained instructor.
1560117|NCT02526082|Other|Intervention|Multifactorial intervention with lifestyle changes and drugs as needed
1560118|NCT02526069|Behavioral|Acceptance and Commitment Therapy|An application based on Acceptance and Commitment Therapy
1560119|NCT02526056|Other|Physiotherapists|This study is a usability design with qualitative and quantitative aspects. The therapeutic relevance and design features will be explored.
1560120|NCT02526056|Other|elderly people|In one part, with patients, physical strain and designs facets will be investigated. During their game playing process, different measurements will be done. They will be asked about their opinions about the game.
1560121|NCT02526043|Procedure|laparoscopic hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by laparoscopy
1560122|NCT02526043|Procedure|Open hepatectomy|The HCC patients who meet the Louisville consensus will underwent liver resection by open surgery
1560123|NCT02526030|Drug|Aripiprazole|
1560124|NCT02526030|Drug|Quetiapine|
1560125|NCT02526030|Drug|Ziprasidone|
1560126|NCT02526017|Biological|FPA008|
1560127|NCT02526017|Biological|BMS-936558|
1560128|NCT02526004|Drug|Ceftazidime|
1560129|NCT02526004|Drug|Tobramycin|
1560130|NCT02525991|Device|Staccato® Delivery System Loxapine (ADASUVE®)|one dose Loxapine Staccato 9.1 mg
1560178|NCT02525653|Drug|gemcitabine|
1560179|NCT02525640|Device|Hearing Aid|Hearing aid comparison
1560180|NCT02525627|Device|Trident cup, X3 inserts, 28 mm head|Orthopaedic implant
1560131|NCT02525978|Behavioral|Video Task|Subjects are asked to watch a series of six two-minute video clips. The video clips are designed to induce sad or happy emotions or no emotion (neutral) and are taken from movies, documentaries, or instructional videos. There are two videos for each emotion condition. Videos and fixation cross screens are viewed on a laptop computer. In between video clips, patients are asked to quietly look at a fixation cross for one minute, describe their emotional reaction to the video for up to one minute, then again attend to a fixation cross for one minute. A video recording of the frontal view of the participant's face will be made during task performance.
1560132|NCT02525978|Other|Imaginal Task|Subjects are asked to think about happy or sad memories for 2 minutes. Subjects are asked to imagine performing neutral tasks, such as buying groceries. Subjects are then asked to think about a memory that makes them feel angry. A video recording of the frontal view of the participant's face will be made during task performance.
1560133|NCT02525965|Procedure|Wide resection margin >1cm|Surgical removal of lesions choosing the method of wide resection margin >1cm
1560134|NCT02525965|Procedure|Narrow resection margin <1cm|Surgical removal of lesions choosing the method of wide resection margin <1cm
1560135|NCT02525952|Procedure|Hepatectomy|Surgical removal of all lesions
1560136|NCT02525952|Procedure|TACE|Transarterial chemoembolization with lipiodol and pirarubicin
1560137|NCT02525939|Drug|dalcetrapib|Cholesterol Ester Transfer Protein inhibitor
1560138|NCT02525939|Drug|Placebo|matching placebo tablets
1560139|NCT02525926|Procedure|denervation|The examination proceeds under rigorous aseptic technique. Femoral, jugular or brachial venous access will be performed. A flexible catheter is first introduced across a 7-Fr venous introducer, and passed through the right heart chambers toward the origin of the pulmonary arteries. The pressures in the right heart chambers and the pulmonary artery will be measured. At the end of the examination, the catheter is removed, a dressing is applied and the venous puncture is compressed by hand.
1560140|NCT02525926|Procedure|sham procedure|"Right heart catheterism is mandatory in PAH patients care (for diagnosis and during follow-up) and will serve as a  sham  procedure. A usually performed and after a venous punction, cardiac outpout and pulmonary artery pressures will be recorded.
Acoustically isolated headphones will be given to patients during the procedure in order to assure simple-blind during the study."
1560141|NCT02525913|Device|RFA Applicator|
1560142|NCT02525900|Procedure|Wound Infiltration with 0.25% Bupivacine|
1560143|NCT02525900|Procedure|bilateral TAP block with 0.25% Bupivacaine|
1560144|NCT02525900|Procedure|bilateral TAP Catheter with repeat bolus of 0.25% Bupivacaine|
1560145|NCT02525887|Other|Observation|Observation and evaluation of care provided to patients that received DNA tests to determine metabolic pathways.
1560146|NCT02525874|Drug|dimethyl fumarate|Initial oral dose for 7 days with maintenance dose thereafter
1560148|NCT02525848|Drug|dexamethasone|dexamethasone 8 mg iv 2 minutes before induction of anesthesia
1560149|NCT02525848|Drug|Gabapentin|oral gabapentin 600 mg 1 hour before induction of anesthesia
1560150|NCT02525848|Drug|Aprepitant|oral aprepitan 80mg 1 hour before induction of anesthesia.
1560151|NCT02525835|Dietary Supplement|Low Dietary Sodium|Participants will be randomized to a low sodium diet (50 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
1560152|NCT02525835|Dietary Supplement|High Dietary Sodium|Participants will be randomized to a high sodium diet (250 mmol/24 hours) for 28 days (range allowed 25-31 days) with a 4 week washout period between (range 2-3 weeks).
1560153|NCT02525822|Drug|IDP-123 Lotion|Investigational Product: IDP-123 Lotion
1560154|NCT02525822|Drug|Tazorac Cream, 0.1%,|Comparator Product: Tazorac Cream, 0.1%
1560155|NCT02525822|Drug|Vehicle Cream|Comparator Product: Vehicle Cream
1560156|NCT02525822|Drug|Vehicle Lotion|Comparator Product: Vehicle Lotion
1560157|NCT02525809|Device|Novae E®|
1560158|NCT02525809|Device|Sunfit®|
1560159|NCT02525809|Device|Quartz®|
1560160|NCT02525796|Drug|eplerenone|eplerenone, titrated up to a maximum of 50mg BID
1560161|NCT02525796|Drug|amiloride|amiloride, titrated up to a maximum of 10mg BID
1560162|NCT02525796|Drug|Placebo|
1560163|NCT02525796|Drug|Cinacalcet|Cinacalcet, as add-on therapy in addition to eplerenone/amiloride/placebo, titrated up to a maximum of 30mg BID
1560164|NCT02525770|Device|radiostereometric analysis (RSA)|
1560165|NCT02525757|Drug|MPDL3280A|"1200 mg by vein every 3 weeks up to 1 year after completing consolidation chemotherapy.
Group 1: MPDL3280A given after receiving standard chemotherapy and radiation for 6-7 weeks, followed by a 3-4 week rest period.
Group 2: MPDL3280A given with standard chemotherapy, and radiation therapy for 6-7 weeks followed by a rest period of 3-4 weeks, during which time participants receive 1 dose of MPDL3280A but no chemotherapy or radiation."
1560166|NCT02525757|Drug|Carboplatin|AUC 2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Carboplatin given at AUC 6 by vein on Days 1 and 22 for 2 cycles.
1560167|NCT02525757|Drug|Paclitaxel|50 mg/m2 by vein once a week on Day 1 during radiation therapy. During consolidation chemotherapy, Paclitaxel given at 200 mg/m2 on Days 1 and 22 for 2 cycles.
1560168|NCT02525757|Radiation|Radiation Therapy|60-66 Gy in 30-33 fractions administered once-daily on Day 1, 5 days a week, for 6 to 7 weeks.
1560169|NCT02525744|Biological|LY900014|Administered SC
1560170|NCT02525744|Biological|Insulin Lispro|Administered SC
1560171|NCT02525718|Drug|Saline|If randomized to this arm, subjects will receive an intraoperative injection of saline. (2.5 mg/ml)
1560172|NCT02525718|Drug|0.25 % bupivacaine (2.5 mg/ml) w/ 1:100,000 epinephrine & 4 mg dexamethasone|"If randomized to this arm, subjects will receive a selective block with a local anesthetic solution containing 0.25 % bupivacaine.
(2.5 mg/ml) with 1:100,000 epinephrine and 4 mg dexamethasone intraoperatively."
1560173|NCT02525705|Biological|Oral Glucose|1.75g/kg of glucose is orally taken by the patient. Capillary glycemia is systematically realised before ingestion (H0) and after 30, 60, 90, 120, 180 and 240 min and/or if clinical signs of hypoglycemia are presented by the patient.
1560174|NCT02525692|Drug|ONC201|
1560175|NCT02525679|Drug|BI 655130|
1560176|NCT02525679|Drug|Placebo|
1560177|NCT02525653|Drug|albumin-bound paclitaxel|
1560181|NCT02525627|Device|Trident cup, X3 inserts, 40 mm head|Orthopaedic implant
1560182|NCT02525627|Device|Symax stem|Orthopaedic implant
1560183|NCT02525627|Device|Accolade TMZF stem|Orthopaedic implant
1560184|NCT02525614|Device|Triathlon Standard Keel|Implantation of Knee Prosthesis
1560185|NCT02525614|Device|Triathlon Short Keel|Implantation of Knee Prosthesis
1560186|NCT02525601|Device|Triathlon CR cemented|Implantation of Knee Prosthesis
1560187|NCT02525601|Device|Triathlon CR uncemented|Implantation of Knee Prosthesis
1560188|NCT02525588|Device|Triathlon CS fixed bearing total knee prosthesis|The patient will receive either the N2Vac polyethylene inlay or the X3 polyethylene inlay for their CS total knee.
1560189|NCT02525575|Behavioral|Project Life Force Group Treatment|"PLF, a 12-session, group psychotherapy intervention, combines Dialectical Behavioral Therapy (DBT) skill based and psychoeducational approaches, to enhance suicide safety planning development and implementation. Veterans revise their plans over several weeks while learning distress tolerance, emotion regulation, and friendship building/interpersonal skills to incorporate into their safety plans and also receive lessons on gun safety and minimizing access to lethal means. Sessions are augmented with 1) training in the use of a suicide safety planning mobile App to promote accessibility and maximize implementation, and 2) didactic information to bolster recovery, including fostering improved connection with the treatment team, and Veteran's family. Importantly, the group format mitigates loneliness and fosters increased belongingness, both key risk factors for suicide."
1560190|NCT02525562|Device|Triathlon Total Knee System with X3 insert|Total knee replacement
1560191|NCT02525562|Device|Scorpio NRG Total Knee System with X3 insert|Total knee replacement
1560192|NCT02525562|Device|Triathlon PKR System with X3 insert|Partial Knee Resurfacing
1560193|NCT02525549|Drug|Adapalene and Benzoyl Peroxide Gel|
1560194|NCT02525549|Drug|Adapalene and Benzoyl Peroxide Gel (Reference)|
1560195|NCT02525549|Drug|Placebo gel|
1560196|NCT02525536|Drug|Trebananib 3 mg/kg|Trebananib (AMG 386) 3 mg/kg, intravenous infusion.
1560197|NCT02525536|Drug|Trebananib 10 mg/kg|Trebananib (AMG 386) 10 mg/kg, intravenous infusion.
1560198|NCT02525536|Drug|Trebananib 30 mg/kg|Trebananib (AMG 386) 30 mg/kg, intravenous infusion.
1560199|NCT02525523|Drug|Alicaforsen|
1560200|NCT02525523|Drug|Placebo|
1560201|NCT02525510|Other|Pump Eligible - Normothermia - Pump Both Kidneys|Normothermia and Machine Perfusion Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery. Recovered kidneys will receive machine perfusion prior to implantation.OPO's protocol
1560202|NCT02525510|Other|Pump Eligible - Hyporthermia and Pump Right Kidney|"Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Right Kidney will receive machine perfusion prior to implantation and the Left Kidney will receive cold storage.
Recovered kidneys will be placed in University of Wisconsin for cold storage until reimplantation."
1560203|NCT02525510|Other|Pump Eligible - Hyporthermia and Pump Left Kidney|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery. Left Kidney will receive machine perfusion prior to implantation and the Right Kidney will receive cold storage.
1560204|NCT02525510|Other|Not Pump Eligible - Normothermia|"Deceased Donors will be kept normothermic (36.5-37.5 C) prior to organ recovery.
Pulsatile Perfusion of kidney grafts based on the respective OPO's protocol"
1560205|NCT02525510|Other|Not Pump Eligible - Hypothermia|Deceased Donors will be kept mildly hypothermic (34-35 C) for at least 12 hours prior to organ recovery.
1560206|NCT02525497|Device|FM peritoneal dialysis machine|FM peritoneal dialysis machine APD 10L/10h
1560207|NCT02525497|Device|HOMECHOICE peritoneal dialysis machine|HOMECHOICE peritoneal dialysis machine APD 10L/10h
1560208|NCT02525484|Drug|Pirfenidone|Pirfenidone 801 mg single oral doses will be given either in the form of tablet or capsules under fed or fasted conditions on Days 1, 4, 7 and 10.
1560209|NCT02525471|Drug|RNS60|"RNS60 will be administered in two ways: by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) for 24 weeks.
In addition, subjects will be given the option to continue to receive drug for approximately an additional 24 weeks, for a total of approximately 48 weeks on study drug. Study drug will be given by intravenous (IV) infusion one day a week (infusion dose: 375ml, infused over a 40-min period) and by inhalation (the remaining 6 days a week, 4 ml/day) during the extension phase."
1560210|NCT02525458|Device|QAMS-containing PMMA|Wear retainer with QMAS-containing PMMA on one side of retainer
1560211|NCT02525458|Device|QAMS-free PMMA|Wear retainer with QMAS-free PMMA on other side of retainer
1560212|NCT02525445|Procedure|acupuncture|acupuncture was administered (sharp needles diameter 0.25 x length 40 mm) bilaterally to the acupuncture point pericardium six (PC6) between the tendons of palmaris longus and flexor carpii radialis at two body-inches (one body-inch approximately 1.5 cm) proximal to the wrist at 0.5 body-inch depth. The therapists manually manipulated the needles three times per treatment by rotating, thrusting or lifting the needles. When the participant reported a sense of numbness or soreness and the therapist noted a minimal muscular contraction around the needle.
1560213|NCT02525445|Procedure|sham acupuncture|"sham acupuncture was administrated (blunt needles diameter 0.25 x length 40 mm) bilaterally to a non-acupuncture point four body-inch proximal and one body-inch radial from the PC6 point, with the telescopic non-penetrating Park´s sham needle [20]. Park's credible needle looks identical to a real needle but glides upward into its handle, giving an illusion of penetration. A marking tube, identical for both acupuncture types, held the sham needle in place. The therapists manipulated the needles a few seconds three times per session until the needles touched the skin, but no needle sensation occurred, and then lifted the needles up from the skin."
1560214|NCT02525445|Procedure|positive communication|"During the acupuncture treatment the therapist conveyed, at least three out of several positive statements, such as: Many acupuncture studies have shown excellent results concerning relaxation effects, Brain imaging studies show that acupuncture treatments affect areas that affect pulse, blood-pressure and muscle tension."
1560215|NCT02525445|Procedure|neutral communication|"During the acupuncture treatment the therapists conveyed, at least three out of several neutral statements, such as: During treatment you will just lie down and rest and I will not talk so much to you, We don´t really know if acupuncture is a good method for relaxation effects; thus we need to perform this study,"
1560218|NCT02525419|Behavioral|Weight Loss Phase|High Protein, Intermittent Fast, Low Calorie Diet
1560219|NCT02525419|Behavioral|HP-IF|High Protein, Intermittent Fast
1560220|NCT02525419|Behavioral|HH|Heart Healthy
1560221|NCT02525406|Other|All surgeries performed from Jan 01, 2010 to Dec 31, 2014|
1560222|NCT02525393|Device|tDCS|Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.
1560223|NCT02525393|Device|rTMS|Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.
1560224|NCT02525393|Device|Sham|Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.
1560225|NCT02525380|Procedure|Device(DC Bead)|Doxorubicin-Eluting-Bead Embolization (DEBDOX), DC Bead are a novel drug delivery embolization system
1560226|NCT02525367|Behavioral|Online cognitive training|The intervention is a computerized, online training programme which aims to train several cognitive abilities; especially the executive functions, attention, working memory and processing speed. The mental processes that are appealed to by the intervention are similar to processes that are trained in classic face-to-face training methods. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
1560227|NCT02525367|Behavioral|Active control condition|The active control condition consists of cognitive activities that do not intend to train cognitive functions based on 'cristallized intelligence', such as trivia. Both the intervention protocol and the active control condition will contain several games that have the participant train cognitive functions/perform cognitive activities for 8 weeks, 3 times a week, 45-60 minutes each session.
1560231|NCT02525328|Other|blood or saliva specimen|blood or saliva specimen is sampled for DNA extraction in CT family's members
1560232|NCT02525315|Device|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
1560233|NCT02525302|Drug|HT-100|HT-100 is Akashi Therapeutics' proprietary delayed-release formulation of halofuginone hydrobromide, a small molecule therapeutic with anti-fibrotic properties. May be administered in either fed or fasted state. Not mutation specific.
1560234|NCT02525289|Other|Bed Rotation Group|Patients received continuous lateral rotation by a mechanical device (Hill Rom Bed Rotation), consecutive cycles of to left and right side, plus supine position during 30 seconds for pause, in the first postoperative day until 48 hours. Additional breathing exercises.
1560235|NCT02525289|Other|Orthostatic Group|Patients were seated on the bed 6 hours post extubation for two hours. After, sitting in the bed with their feet on the floor for two minutes; standing up and walking in the place for two minutes, in the first 24 hours and 48 hours postoperative. Additional breathing exercises.
1560236|NCT02525276|Behavioral|exercise|The exercise intervention will conduct the following training program 4 days/week for 6 months: endurance training consisting of supervised training on a bike ergometer for 20 min at 70% of maximal heart rate (HR) the first week, increased by 5 min each week until reaching 40 min. Then the intensity will be increased to 80% of max HR over the next month and recalculated every month.
1560237|NCT02525276|Drug|Hormone treatment|"Continually estradiol and gestagens - tablets and patches or cyclic estradiol and gestagens - tablets or patches.
Including:
Drospirenon, Norethisteronacetat, Medroxyprogesteronacetat"
1560238|NCT02525263|Biological|Neo-Kidney Augment|NKA is made from expanded autologous selected renal cells (SRC) obtained from the patient's kidney biopsy. To manufacture NKA, kidney biopsy tissue from each enrolled patient will be sent to RegenMedTX, LLC, where renal cells will be expanded and SRC selected. SRC will be formulated in a gelatin based hydrogel at a concentration of 100 x 106 cells/mL, packaged in a 10 mL syringe, and shipped to the clinical site for use.
1560239|NCT02525250|Procedure|Realization of 3 Blood samples during study during treatment with lenalidomide|
1560240|NCT02525237|Drug|Apatinib|Apatinib (500 mg qd p.o.) until disease progression or intolerable toxicity
1560241|NCT02525237|Drug|S-1|S-1 (40 mg/m2 qd days 1-14 q3w p.o.) until disease progression or intolerable toxicity
1560242|NCT02525224|Dietary Supplement|Nutritional Supplement|2 Hard-shell liquid capsules taken twice daily with breakfast and dinner.
1560243|NCT02525224|Radiation|Minimal Erythema Dose (MED)|1, 2, and 3 MED of solar simulated radiation on the right or left sun protected buttock conducted at baseline visit and week 8 visit
1560244|NCT02525211|Drug|Ropivacaine|a bolus of 10 ml of ropivacaine 7,5 mg / l then by a diffuser of local anesthesic (Ropivacaine 2mg / ml in continuous flow 10ml / hour) connected on the catheter the day after the intervention before returning at home
1560245|NCT02525211|Drug|physiological saline|a bolus of 10 ml of physiological saline in the catheter of multi- drilled cicatricial perfusion
1560246|NCT02525198|Dietary Supplement|fatty acid/flavonoid blend|see arm description
1560247|NCT02525198|Dietary Supplement|Placebo|see arm description
1560248|NCT02525185|Other|Diagnostic interventions; PET, MRI, cardiac ultrasound.|
1560249|NCT02525172|Drug|Rituximab|
1560250|NCT02525172|Drug|intravenous immune globulin|
1560251|NCT02525172|Drug|Bortezomib|
1560253|NCT02525159|Dietary Supplement|DIM pills|Two pills of BioResponse DIM® 150 are equal to 75 mg of DIM pure
1560254|NCT02525159|Other|Placebo Pill|Placebo pills, proportionate by the same provider, vials and pills were the same size, shape and material containing the DIM pills
1560255|NCT02525146|Other|Modified ARTAS (Antiretroviral Treatment and Access to Services) intervention|
1560256|NCT02525133|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
1560257|NCT02525133|Other|Placebo|Plain collagen implant (vehicle)
1560258|NCT02525120|Device|Triojection|Triojection is system intended to deliver a specific amount of ozone to a herniated disc.
1560259|NCT02525120|Procedure|Surgical discectomy|Patients will receive surgery to remove the herniated disc material.
1560260|NCT02525107|Dietary Supplement|Omega-3 capsules|SCD patients on Hydroxyurea
1560261|NCT02525107|Dietary Supplement|Placebo|SCD patients on Hydroxyurea
1560262|NCT02525107|Dietary Supplement|Omega-3 capsules|SCD patients not on Hydroxyurea
1560263|NCT02525107|Dietary Supplement|Placebo|SCD patients not on Hydroxyurea
1560266|NCT02525081|Drug|Ramipril (ACE-inhibitor)|up to 10 mg
1560267|NCT02525081|Drug|placebo|up to 10 mg
1560268|NCT02525068|Drug|AZD5363|Until confirmed disease progression.
1560269|NCT02525068|Drug|Enzalutamide|Until confirmed disease progression.
1560270|NCT02525055|Biological|Infectious titre 1 (H3N2)|Infectious titre 1
1560271|NCT02525055|Biological|Infectious titre 2 (H3N2)|Infectious titre 2
1560272|NCT02525055|Biological|Infectious titre 3 (H3N2)|Infectious titre 3
1560273|NCT02525055|Biological|Infectious titre 4 (H3N2)|Infectious titre 4
1560275|NCT02525016|Biological|Blood sampling|
1560276|NCT02525016|Drug|Lidocaine|
1560277|NCT02525003|Dietary Supplement|Vitamin D2|Experimental group 2: daily vitamin D2 supplement 25ug/d for 8 weeks
1560278|NCT02525003|Dietary Supplement|Vitamin D3|Experimental group 3: daily vitamin D3 supplement 25ug/d for 8 weeks
1560279|NCT02525003|Other|Vitamin D2 fortified bread|Experimental group 4: vitamin D2 fortified bread containing 25 µg of vitamin D2/d (bread dose 87g/d) and placebo pill for 8 weeks
1560280|NCT02524990|Behavioral|Home-based follow-up with SQPT|Participants will be followed-up at home. They will receive an SQPT to perform at home two weeks after enrollment, and a scheduled follow-up phone call by study providers to determine the outcome of the procedure.
1560283|NCT02524964|Drug|sodium tanshinone IIA sulfonate|eligible participants were randomized to receive sodium tanshinone IIA sulfonate injection (drip 80 mg/day for 7 days immediately after PCI)
1560284|NCT02524964|Other|control|equivalent volume of sodium chloride solution
1560285|NCT02524951|Drug|MSI-1436C|Dose escalation, single intravenous infusion twice a week for 3 weeks on a 4-week cycle.
1560286|NCT02524938|Dietary Supplement|Chlorogenic Acid (CGA) enriched coffee|"Chlorogenic Acid (CGA) enriched coffee Phase I: CGA-enriched coffee provided with a CGA content of 70-90 mg/100g. Daily CGA intake of 400mg.
Phase II: recommendation for achieving a CGA-rich diet of at least 400mg/day (total polyphenol intake of at least 1g/day)"
1560287|NCT02524938|Dietary Supplement|Conventional coffee|Phase I: conventional coffee provided (low in CGA) Phase II: standard dietary advice
1560288|NCT02524925|Procedure|fast track protocol|Evaluation of postoperative stress
1560289|NCT02524899|Behavioral|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) will consist of fifteen 45-minute, twice weekly sessions over 7.5 weeks. During each session, subjects, seated at a desk in a private interview room in our research office suite, will work through exercises that are part of the Psychological Software Services CogReHab program. The software to be used is a multimedia, Windows-based program that consists of exercises aimed at improving areas of deficit within the schizophrenia spectrum, such as executive function, working memory, and social cognition.
1560290|NCT02524899|Drug|Guanfacine|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in the active treatment arm will begin with a guanfacine dose of 0.5mg/day and be titrated up to a maximum of 2mg/day according to our well-tolerated protocol in schizophrenia subjects. The dosing schedule of active guanfacine will be as follows: 0.5mg/d for week 1, 1.0mg/d for week 2, 1.0 mg bid for weeks 3, 4, 5, 6, and 7 and 1.0mg/d for week 8.
1560291|NCT02524899|Drug|Placebo|After completing baseline cognitive testing, subjects will be randomized to guanfacine or placebo. Subjects in placebo arm will have matching schedule as active arm.
1560292|NCT02524886|Device|GPi DBS with Medtronic electorde and Activa PC pulsegenerator|The electric stimulation of 2 leads implanted in the Globus Pallidus internus
1560293|NCT02524873|Device|Geneticure Collection Kit for Pharmaocogenetics of Hypertension|Buccal (cheek) swab kit for DNA collection for analysis of genes for hypertension
1560294|NCT02524860|Device|Focal-Fusion Bx|The Focal-Fusion Bx device uses hardware and software to overlay targets onto the live ultrasound image in real-time. This allows the urologist to take biopsy samples from tissue that looked suspicious on the patient's MRI.
1560295|NCT02524847|Drug|UVADEX® (methoxsalen) Sterile Solution in Conjunction with the THERAKOS® CELLEX® Photopheresis System|
1560296|NCT02524834|Procedure|Exclusion of thoracoabdominal lesion|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
1560297|NCT02524834|Device|Endovascular Device Implant|Endovascular repair of thoracoabdominal lesion with a physician modified Medtronic Valiant stent graft
1560298|NCT02524821|Device|Gelesis100|3 capsules each containing 0.75 mg
1560299|NCT02524821|Drug|Metformin|1 tablet of 850 mg
1560300|NCT02524795|Dietary Supplement|Hiomega-3 supplement of Naturalis® company -|Patients (N=22) were seen at baseline (T0) and at week 12 (T1) for clinical, laboratory and nutritional assessment, and were contacted by telephone in week 6 to check on compliance and any adverse events. Patients received, throughout 12 weeks, two tablets per day of omega-3 fatty acids (540mg of EPA and DHA of 100mg; Hiomega-3 supplement of Naturalis® company - registered in the National Health Department number 4.1480.0006.001-4). All participants were instructed not to take omega-3 rich foods during the study period.
1560301|NCT02524782|Biological|MEDI-4166|MEDI-4166 administered subcutaneously
1560302|NCT02524782|Biological|Placebo|Placebo administered subcutaneously
1560303|NCT02524769|Drug|conjugated estrogen|0.625 mg conjugated estrogen/gram and instructions to use 0.5 grams twice weekly with the applicator.
1560304|NCT02524756|Procedure|laparoscopic nerve-sparing radical hysterectomy-type III/C1|
1560305|NCT02524756|Procedure|laparoscopic radical hysterectomy (type III/C2).|
1560306|NCT02524743|Drug|acetaminophen|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated acetaminophen (50mg and 25 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
1560307|NCT02524743|Drug|Lidocaine|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated lidocaine (20 mg and 40 mg IV) before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
1560308|NCT02524743|Other|Placebo|The venous drainage was occluded for 120 seconds by using a rubber tourniquet on the upper arm and the patients were pretreated 5 ml iv normal saline before the injection of rocuronium.Twenty seconds after the administration of rocuronium, 5 mg/kg of thiopental was administered IV. After orotracheal intubation, anesthesia was continued with sevofluorane during 40 % oxygen and 60 % air. Twenty-four hours after the operation, the injection site was checked for any complications, such as pain (absent/ present), swelling or allergic reaction by an anesthesiologist who did not know which drug was administered.
1560309|NCT02524730|Device|Primary total knee replacement (Scorpio NRG CR Total Knee System)|Scorpio NRG CR Total Knee System
1560310|NCT02524717|Drug|JNJ-56021927|Participants will receive JNJ-56021927 240 milligram (mg) orally once on Day 1.
1560311|NCT02524704|Device|CT scan|Applied only when part of the patient's standard care
1560313|NCT02524678|Drug|Placebo|
1560314|NCT02524678|Drug|URC102|
1560315|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
1560316|NCT02524665|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
1560317|NCT02524665|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
1560318|NCT02524665|Other|MURAD Clarifying Cleanser (1.5% SA)|Available over the counter.
1560319|NCT02524665|Other|Exfoliating Acne Treatment Gel (1% SA)|Available over the counter.
1560320|NCT02524665|Other|Skin Perfecting Lotion|Available over the counter.
1560321|NCT02524652|Drug|Ropivacaine 0.5% 20 mLs|Injection of the local anesthetic at the end of surgery, either in the surgical sites by the surgeon, or in the adductor canal block by the anesthesiologist under ultrasound guidance.
1560323|NCT02524626|Procedure|Sham stimulation|
1560324|NCT02524626|Procedure|Vagus stimulation|
1560325|NCT02524613|Other|Pelvis CT scan|
1560326|NCT02524600|Device|myocardial IQ-SPECT imaging applied to scintigraphic imaging|
1560327|NCT02524600|Device|scintigraphic imaging|
1560328|NCT02524587|Device|standard polyethylene acetabular irradiated at 3 Mrad|
1560329|NCT02524587|Other|radio stereometric analysis (RSA) of the acetabular|
1560330|NCT02524587|Device|acetabular polyethylene vitamys®|
1560331|NCT02524574|Procedure|cardiac Rehabilitation|
1560332|NCT02524574|Other|Tomography Positron Emission|
1560333|NCT02524561|Drug|CEE pill|Conjugated equine estrogens 0.45 mg/day
1560334|NCT02524561|Drug|Estradiol patch|Climara 50 mcg/day
1560335|NCT02524561|Drug|Active Progesterone|Prometrium (micronized progesterone USP encapsulated with peanut oil) 200 mg daily for the first 12 days of each month at bedtime
1560336|NCT02524561|Other|Placebo tablet|Placebo tablet
1560337|NCT02524561|Other|Placebo patch|placebo patch
1560338|NCT02524561|Other|Placebo progesterone|placebo progesterone
1560339|NCT02524548|Other|SMS reminder|Weekly SMS reminder to take aromatase inhibitors as prescribed by doctor for 1 year
1560340|NCT02524535|Other|Therapeutic alliance|
1560341|NCT02524522|Device|INTELLiVENT-ASV mode|Discontinuation with INTELLiVENT-ASV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided by quick-wean option of INTELLiVENT-ASV mode
1560342|NCT02524522|Device|SIMV mode|Discontinuation with SIMV mode: discontinuation with SIMV mode: discontinuation from mechanical ventilation in the early postoperative period will be provided in SIMV mode using physician driven algorithm
1560343|NCT02524483|Behavioral|Therapeutic Challenge Program|The Therapeutic Challenge Program will consist of a 5 minute warm-up, 20 minutes of challenging balance training, and 20 minutes of challenging treadmill and overground walking.
1560344|NCT02524483|Behavioral|Therapeutic Exercise Program|The Therapeutic Exercise Program will consist of 15 minutes of strength training and flexibility exercises, 15 minutes of balance exercises, and 15 minutes of treadmill walking.
1560345|NCT02524470|Device|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
1560346|NCT02524470|Device|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
1560347|NCT02524457|Other|This is an observational study. There are no interventions|
1560348|NCT02524444|Drug|Mefloquine|Tabs Mefloquine 250mg
1560349|NCT02524444|Drug|Sulphadoxine-Pyrimethamine|Sulphadoxine 500mg , Pyrimethamine 25mg
1560350|NCT02524431|Other|Collection of trabecular meshwork tissue during surgery|Tissue is collected during surgery at Wills Eye and then processed at thomas jefferson to identify the trabecular meshwork using light microscope. The ocular tissue will be fixed and the mitochondrial cross sections at the longest extent will be measured under electron microscopy (EM) in order to identify the mitochondrial dynamics. Quantitative Polymerase Chain Reaction (qPCR) will be done to identify proteins responsible for mitochondrial fusion.
1560351|NCT02524418|Procedure|Cholangiopancreatoscopy|An ERCP with cholangioscopy/pancreatoscopy will be performed using the Spyglass DS. Clinical outcomes will be collected and analyzed.
1560352|NCT02524405|Other|Flutemetamol PET scan|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Brain amyloid PET scans using the radioligand Flutemetamol, which is not yet approved for clinical use in Canada, will be performed in all subjects.
1560353|NCT02524405|Device|Fluroescent Ligand Eye Scanning (FLES)|This is a cross-sectional study of patients with various forms of cognitive impairment and a healthy control group for comparison. Fluorescent Ligand Eye Scanning will be performed in all subjects using the Sapphire II System (a combination device/ointment system) to assess the presence of amyloid in the ocular lens.
1560354|NCT02524392|Other|Independent medical evaluation|The independent medical evaluation (IME) will be performed by specialists in general medicine, temporarily hired by the county welfare service. The independent medical evaluation (IME) procedure is developed by the Research Unit for General Practice at Uni Research Health in Norway.
1560355|NCT02524379|Drug|Diabeta Oral Product|3 day drug regimen beginning 8 hours after acute traumatic spinal cord injury.
1560356|NCT02524366|Device|Artificial Urinary Sphincter|
1560357|NCT02524353|Other|cardiac surgery|Surgical cardiac procedures despite benefiting the clinical condition of the patient with potential increased survival and reduced risk of death can cause both immediate and long-term functional changes that may influence the appropriate re-inclusion of this individual the daily life practices as well as labor and social activities. Such changes resulting from surgical procedures in the short term are already well documented but the occurrence of these same changes in the late period and its influence on patient's daily lives are not well documented.
1560358|NCT02524327|Other|Toolbox: Automated group|A dedicated algorithm controls the infusion rate of drugs depending on the magnitude of variation of the bispectral index
1560359|NCT02524327|Other|Manual group|The anesthesiologist controls the infusion rate of drugs depending of the magnitude of variation of the bispectral index
1560360|NCT02524314|Device|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
1560361|NCT02524301|Drug|Positron Emission Tomography using [11C]diprenorphine|PET using [11C]diprenorphine
1560362|NCT02524288|Drug|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
1560363|NCT02524275|Drug|Capecitabine|Given PO
1560364|NCT02524275|Drug|Docetaxel|Given IV
1560365|NCT02524275|Other|Quality-of-Life Assessment|Ancillary studies
1560366|NCT02524262|Dietary Supplement|Slow-release L-cysteine|Bind and inactivate acetaldehyde formed from ethanol by covalent binding to L-cysteine
1560367|NCT02524249|Drug|Caffeine|
1560368|NCT02524249|Drug|Placebo (dextrose)|
1560369|NCT02524236|Drug|Botox injection in the prostate|transrectal access of prostatic injection
1560370|NCT02524223|Other|Systematic HPV DNA assay in semen and cervicovaginal scrape|Screening of HPV status at the genital level of males enrolled in MAP program.
1560371|NCT02524223|Other|Systematic HPV DNA cervicovaginal scrape|Screening of HPV status at the genital level of females enrolled in MAP program.
1560372|NCT02524223|Other|systematic HPV Status in newborns in case of pregnancy|
1560373|NCT02524210|Drug|Dabigatran|dabigatran etexilate 150 mg/day (1 day)
1560374|NCT02524210|Drug|Rabeprazole and Dabigatran|rabeprazole 20 mg / day for 5 days, then the 6th day concomitant rabeprazole 20 mg of dabigatran etexilate 150 mg;
1560375|NCT02524210|Drug|Omeprazole and Dabigatran|omeprazole 20 mg / day for 5 days, then the sixth day concomitant omeprazole 20 mg and 150 mg dabigatran etexilate
1560376|NCT02524197|Drug|CR845 0.25 mg|Subjects will dose orally twice a day with CR845 0.25 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
1560377|NCT02524197|Drug|CR845 0.50 mg|Subjects will dose orally twice a day with CR845 0.50 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
1560461|NCT02523599|Drug|XaraColl|Surgical implantation of 3 bupivacaine collagen implants
1560378|NCT02524197|Drug|CR845 1 mg|Subjects will dose orally twice a day with CR845 1 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
1560379|NCT02524197|Drug|CR845 5 mg|Subjects will dose orally twice a day with CR845 5 mg tablets for two weeks. A diary will be kept for recording the individual's pain scores and dosing accountability.
1560380|NCT02524184|Drug|sildenafil|sildenafil 100 mg per day for 7 days.
1560381|NCT02524184|Drug|placebo|an identical placebo per day for 7 days
1560382|NCT02524171|Behavioral|Moral Reconation Therapy (MRT)|MRT is a group-based cognitive-behavioral intervention to restructure antisocial thinking. Patients will receive two groups per week of this intervention for approximately 12 weeks, in addition to the usual care they receive in the mental health residential rehabilitation treatment program.
1993948|NCT03101059|Procedure|Non invasive ventilation - Continuous Positive Airway Pressure|To identify, through bronchoscopy, the prevalence of collapse and whether it is possible to counteract an optimum pressure generated by NIV with CPAP that reduces tracheal and bronchial collapse in patients with SMK; To study the frequency of OSAS in patients with MKS ; Record reversal of collapse with CPAP using chest tomography; To identify the impact of CPAP on the distribution of pulmonary ventilation through the analysis of electrical impedance tomography.
1560384|NCT02524145|Other|Static Handgrip|Subjects will perform static handgrip at 40% of maximum voluntary contraction until fatigue.
1560385|NCT02524145|Drug|Dexmedetomidine|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
1560386|NCT02524145|Drug|Glycopyrrolate|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
1560387|NCT02524145|Drug|Isoproterenol|Subjects will be given dexmedetomidine to suppress sympathetic outflow to minimize sympathetic control over resting heart rate. Subjects will then be given glycopyrrolate to suppress parasympathetic tone to minimize parasympathetic control over resting heart rate. After achievement of autonomic blockade, cardiac beta receptor sensitivity will be assessed by graded infusions of isoproterenol until heart rate increases 30 beats above baseline.
1560388|NCT02524132|Behavioral|Physical Activity|
1560389|NCT02524119|Drug|LEE011|600 mg PO once daily will be given orally on days 1-21 of a 28 day cycle (3 weeks on / 1 week off) :until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason
1560390|NCT02524119|Procedure|Chemoembolization|Patients will be treated with chemoembolization once every 4 weeks with up to 4 total chemoembolizations within the first 6 months from the initial chemoembolization.
1560391|NCT02524106|Drug|Bococizumab|PF-04950615 is a humanized monoclonal antibody against the proprotein convertase subtilisin kexin type 9 (PCSK9) enzyme responsible for the degradation of the low-density lipoprotein receptor (LDLR), being developed by Pfizer, Inc for the treatment of primary hyperlipidemia and mixed dyslipidemia.
1560392|NCT02524106|Drug|Placebo|
1560393|NCT02524093|Behavioral|Positive Mental Training|Positive Mental Training consists of twelve eighteen minute audio tracks. Each is listened to in turn every day, once a day for a week (or at least 5 days in a week). This means that to use the treatment properly you need to spend 18 minutes a day for 12 weeks listening to it. Each track guides the listener through different instructions which aim to build skills and bring about positive change. The programme begins with simple relaxation, going on to support the creation of pictures in your head of safe places and a more positive future.
1560394|NCT02524093|Other|treatment as usual|
1560395|NCT02524080|Procedure|Triage to optimal healthcare level|Triage to optimal healthcare level
1560396|NCT02524067|Behavioral|Multifactorial circadian concept|Circadian light, systematic information, music, individual foreclosure
1560399|NCT02524041|Device|HR-pQCT|The Xtrem CT scanco device is a HR-pQCT used for 3D bone measurements at the tibia and the radius levels in humans
1560400|NCT02524041|Other|blood specimen|blood specimen
1560401|NCT02524015|Other|Novel physical therapy|
1560402|NCT02524015|Other|Standard physical therapy|
1560403|NCT02524002|Dietary Supplement|Accel Gel|Accel Gel by PacificHealth Labs in Matawan, NJ.
1560404|NCT02524002|Dietary Supplement|Usual clear diet|Usual clear liquids
1560405|NCT02523989|Other|study group|Explore the relationship of heavy metals and health related quality of life, including the relationship between the developmental delays and polymorphism of arsenic methylation enzymes, arsenic methylation capability and blood metals. Identify the interaction of children function, health condition, and quality of life and arsenic methylation and blood metals in children with developmental delays.
1560406|NCT02523976|Drug|Dasatinib|Second-generation tyrosine kinase inhibitor
1560407|NCT02523976|Drug|prednisone|
1560408|NCT02523976|Drug|cyclophosphamide|
1560409|NCT02523976|Drug|daunorubicin|
1560410|NCT02523976|Drug|vincristine|
1560411|NCT02523976|Drug|cytarabine|
1560412|NCT02523976|Drug|mercaptopurine|
1560413|NCT02523976|Drug|methotrexate|
1560414|NCT02523976|Drug|dexamethasone|
1560415|NCT02523976|Drug|mitoxantrone|
1560416|NCT02523976|Drug|etoposide|
1560417|NCT02523976|Procedure|allogeneic hematopoietic stem cell transplantation|
1560418|NCT02523976|Procedure|autologous hematopoietic stem cell transplantation|
1560419|NCT02523963|Other|family work shop|"The family work shop has 5 courses, with 6 families in one course.
One course of intervention: 2-3 hours per session, one time per week, for a total of 6 sessions in 6 week periods"
1560458|NCT02523625|Device|Ultrasound of temporal and axillary arteries|Each patient will have a clinical assessment and ultrasound examination of both temporal and axillary arteries
1560420|NCT02523950|Procedure|Staged phacoemulsification and DMEK|"Stage 1. Phacoemulsification is performed individually. During phacoemulsification, viscoelastic materials and anterior lens capsule are used to protect corneal endothelial cells.
Stage 2. DMEK is performed secondarily according to the corneal status of patients."
1560421|NCT02523950|Procedure|Combined phacoemulsification and DMEK|Routine phacoemulsification and DMEK are performed simultaneously.
1560422|NCT02523950|Device|Intraocular lens (IOL) implantation|After phacoemulsification and removal of all the lens material, a one-piece IOL is implanted into the lens capsule.
1560423|NCT02523937|Other|Soluble Fibrin|Evaluating the diagnostic performances of the assay in terms of sensitivity, specificity, negative and positive predictive values; from calculation of the area under the curve in comparison with the D-dimers.
1560424|NCT02523924|Drug|18F-DCFPyL|18F-DCFPyL PET/CT
1560425|NCT02523911|Drug|Simethicone|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
1560426|NCT02523911|Drug|Placebo|Patients will be randomized to receive either simethicone or placebo in addition to oral sodium sulfate/potassium sulfate/magnesium sulfate solution (Suprep), and will be blinded to whether they are in the simethicone arm or the placebo arm of the trial. Simethicone and placebo will be prepared as identically-appearing liquid solution (2.4 mL) with the assistance of a pharmacist. The simethicone or placebo solution will then be assigned to patients according to the randomization scheme and samples will be labeled with patient information prior to distribution. Only the pharmacist will participate in the labeling process and know which patients receive simethicone or placebo; administering staff, nurses, physicians, and patients will be blinded to this.
1560427|NCT02523911|Drug|sodium sulfate/potassium sulfate/magnesium sulfate solution|Both arms will receive sodium sulfate/potassium sulfate/magnesium sulfate solution for bowel preparation
1560428|NCT02523898|Drug|metformine|1500 mg metformine 8week plus 100 mg clomiphene for 5 days
1560429|NCT02523898|Drug|placebo|placebo 8 weeks plus 100 mg clomiphene for 5 days
1560430|NCT02523898|Drug|clomiphene citrate|100 mg clomiphene for 5 days starting from day 3 of their spontaneous menses or withdrawal bleeding induced by progestin administration
1560431|NCT02523859|Drug|Propofol|Hypnotic drug used for anesthesia
1560432|NCT02523859|Drug|Remimazolam|Benzodiazepine being developed for sedation and anesthesia.
1560433|NCT02523846|Drug|morphine|"Investigators use the formula that was published by Pamela Macintyre in her paper entitled Age is the Best Predictor of Postoperative Morphine Requirements. The estimation for the first 24-hour morphine requirement after surgery is calculated as: 100 - age (year).
So, half of the total 24-hour morphine requirement will be infused over 24 hours.
e.g. background morphine infusion= (100-Age)/ 2/ 24 (mg/hour)"
1560434|NCT02523846|Behavioral|Patient re-education|A similar leaflet will be used to re-educate patient at 4 hour after surgery. The correct method to initiate IV-PCA dose, possible side effects and addiction issue will be explained again and re-emphasized
1560436|NCT02523820|Drug|fluticasone propionate|Flixotide 1 mg + NSS upto 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
1560437|NCT02523820|Drug|Placebo|NSS 4 ml nebulized after extubation. Record vital signs and modified Westley score at 0, 15, 30, 60 min and 2,4,6 hours
1560438|NCT02523794|Other|Electro-kinetically Modified Water|Subjects assigned to this arm will receive the EMW
1560439|NCT02523794|Other|Placebo|Purified Drinking Water
1560440|NCT02523781|Other|information pamphlet|The intervention group receives the information pamphlet
1560441|NCT02523768|Drug|ATG-F|
1560442|NCT02523768|Drug|Simulect|
1560443|NCT02523755|Drug|Epidural analgesia Ropivacaine|Measurement of regional distribution as assessed by EIT before and after injection of local anesthetics
1560444|NCT02523755|Drug|Absence of epidural analgesia|Measurement of regional distribution as assessed by EIT before and after delivery
1560445|NCT02523742|Device|IMRf|
1560446|NCT02523742|Other|language task and a reference task (rest and Tamil)|
1560447|NCT02523729|Dietary Supplement|Anke Malz|non-alcoholic malt drink
1560448|NCT02523716|Other|Hypoxia|Participants live within an altitude residence facility. Hypoxic acclimatisation will be achieved by venting the rooms with air containing a reduced oxygen content. The degree of hypoxia is ramped over a 2-day period as participants experience 14 hours of overnight hypoxic exposure (simulating altitude of : 1830m on Day 1; 2130m on Day 2). The final 5 days will be spent entirely in the altitude residence facility at a consistent hypoxia level (simulating approximately 2440m).
1560449|NCT02523716|Other|Normoxia|Participants will live in the altitude residence facility. As a sham-control, normal sea level air will be circulated throughout the house.
1560450|NCT02523703|Biological|glutamate and aspartate|
1560451|NCT02523690|Drug|Lorcaserin|10 mg, oral or enteral, single dose. 30 mg, oral or enteral, single dose two days later
1560452|NCT02523690|Drug|Placebo|Oral or enteral, single dose. Oral or enteral, single dose two days later
1560453|NCT02523664|Drug|Hydrocortisone|effects of hydrocortisone on memory while fMRI
1560454|NCT02523664|Drug|Placebo|
1560455|NCT02523651|Genetic|DPSC injection|A 0.5ml saline preparation containing 1000000 DPSCs were injected at the local periodontal defects immediately after periodontal scaling and root planing.
1560456|NCT02523651|Other|Placebo|A 0.5ml saline preparation were injected at the local periodontal defects immediately after periodontal scaling and root planing.
1560457|NCT02523638|Drug|Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
1560464|NCT02523573|Procedure|Adult ARF ICU patients needing BAL with HFNC|bronchoalveolar lavage is performed in spontaneously breathing patients under high flow nasal cannula oxygen
1560465|NCT02523560|Other|home-based telerehabilitation|Patients qualified to the study group will undergo, at five medical units a 9-week program of early hybrid, comprehensive cardiac telerehabilitation.
1560466|NCT02523547|Drug|Cavir|0.5mg/day
1560467|NCT02523547|Drug|Baraclude|0.5mg/day
1560468|NCT02523534|Procedure|MRI|MRI images will be taken in conjunction with the clinically indicated cardiac MRI.
1560469|NCT02523534|Procedure|ECG|ECG readings will be taken prior to the participants clinically indicated procedure.
1560470|NCT02523521|Behavioral|Physical activity program|physical activity program for a bronchopulmonary dysplasia children.
1560471|NCT02523508|Behavioral|Experimental group|Subject will be put into lying position, small amplitude of passive movement on the lumbar spine of the subject. The procedure will last for 1 minute.
1560472|NCT02523508|Other|Control group|Passive limb mobilization which did not involve the spine
1560473|NCT02523469|Biological|ALT-803|"ALT-803: The starting dose level for ALT-803 is 6 microgram (µg)/kilogram (kg); the second dose level is 10 µg/kg; the third dose level is 15 µg/kg; and the fourth dose level is 20 µg/kg. ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles.
During week 6, no treatment will be administered."
1560474|NCT02523469|Biological|Nivolumab|"Nivolumab: The dose level for Nivolumab is 3 mg/kg. Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).
After 4 cycles, patients will be treated with Nivolumab alone following the same schedule.
During week 6, no treatment will be administered."
1560475|NCT02523469|Biological|ALT-803|"ALT-803: The dose level for ALT-803 will be based on the recommended dose from the Phase Ib part of the study. ALT-803 will be administered on Day 1 of weeks 1-5 of each cycle for up to 4 cycles.
During week 6, no treatment will be administered."
1560476|NCT02523469|Biological|Nivolumab|"Nivolumab: The dose level for Nivolumab is 3 mg/kg. Nivolumab will be administered Day 1 of every other week of each cycle starting with week 1 (Week 1, Week 3, Week 5).
After 4 cycles, patients will be treated with Nivolumab alone following the same schedule.
During week 6, no treatment will be administered."
1560477|NCT02523456|Behavioral|Training|The staff will be trained on early detection and management of clinically deteriorating patients based on the EWS selected.
1560478|NCT02523456|Behavioral|Introduce EWS|An EWS that is appropriate for use in the study setting will be selected during the second components of the study. This EWS will then be adapted for this component.
1560479|NCT02523443|Other|IV PCA|Patients undergoing IV PCA for pain control will have intravenous (IV) analgesia provided through a demand pump started in the recovery room.
1560480|NCT02523443|Other|PCEA|Patients in this group will have the epidural catheter placed by the anesthesia pain service team in the pre-surgical center (PSC) as performed routinely at MSKCC. The epidural will be used intra-operatively at the end of liver resection phase of the surgical procedure, once the specimen has been extracted, and continued subsequently in the post-operative phase for pain management.
1560481|NCT02523430|Procedure|interventional therapy|nasopharyngeal carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
1560482|NCT02523417|Procedure|interventional therapy|breast cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
1560483|NCT02523404|Procedure|interventional therapy|lung cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
1560484|NCT02523391|Drug|TA-8995|Capsule
1560485|NCT02523391|Drug|TA-8995|Tablet
1560486|NCT02523378|Behavioral|Edmonton Symptom Assessment Scale|Participants complete the symptom survey alone, or with the help of a research nurse or assistant.
1560487|NCT02523378|Behavioral|Interview|After completion of the symptom questionnaire, participants asked if they preferred completing the questionnaire alone, or if they preferred to have a nurse help them answer the questions.
1560488|NCT02523365|Procedure|interventional therapy|cervical carcinoma patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
1560489|NCT02523352|Procedure|Non-Invasive Mechanical ventilation - Recruitment maneuver|Progressive increase in airway pressure to open lungs atelectatic regions.
1560490|NCT02523352|Procedure|Non-Invasive Mechanical Ventilation - Decremental PEEP trial|PEEP will be decreased at consecutive steps. Static compliance of the respiratory system will be measured at each step. The optimal PEEP value for the patient will be chosen as the lowest PEEP level at witch the compliance of the respiratory system will be the best.
1560491|NCT02523352|Procedure|Esophageal catheter positioning|The esophageal tube (8 French diameter catheter) will be positioned in the larger nostril previous topical anesthesia
1560492|NCT02523326|Device|saliva samples obtained with mouthwash|saliva samples obtained with mouthwash
1560493|NCT02523313|Drug|Nivolumab + Placebo|Nivolumab will be applied at a dose of 3 mg/kg given as IV infusion every 2 weeks for up to 1 year after initial dosing or until PD + Placebo instead of Ipilimumab on weeks 1, 4, 7 and 10 + Placebo instead of Nivolumab on weeks 4 and 10.
1560494|NCT02523313|Drug|Nivolumab + Ipilimumab|Nivolumab (1 mg/kg) and Ipilimumab (3 mg/kg) will be applied as IV infusion every 3 weeks for 4 doses. Both study drugs are to be administered on the same day over the first 12 weeks + Nivolumab-Placebo on weeks 3, 5, 9 and 11. After week 12 Nivolumab is given as maintenance and will be applied at a dose of 3 mg/kg IV every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
1560736|NCT02521623|Device|Strattice™ Acellular Dermal Matrix|See arm description.
1560981|NCT02519881|Procedure|Microfracture|simple microfracture of ankle
1560495|NCT02523313|Drug|Double Placebo Control|Placebo instead of Nivolumab and Placebo instead of Ipilimumab will be applied as IV infusion every 3 weeks for 4 doses. Both placebos are to be administered on the same day over the first 12 weeks + Placebo instead of Nivolumab on weeks 3, 5, 9 and 11. After week 12 Placebo instead of Nivolumab is given as maintenance and will be applied intravenously every 2 weeks for up to 1 year after initial dosing (of the combination) or until PD.
1560496|NCT02523300|Procedure|TEVAR|The patients will be undertaken TEVAR
1560497|NCT02523300|Drug|Glucocorticoids|About 120 patients will be given glucocorticoids within 2h after TEVAR as experimental group
1560498|NCT02523300|Drug|saline|The other 120 patients will be given saline as control group
1560499|NCT02523287|Biological|Fluad|Randomized assignment
1560500|NCT02523287|Biological|Saline|Randomized assignment
1560501|NCT02523274|Drug|Resveratrol|Dietary compound commonly found in grapes and red wine. Will be given in 250 mg/day and 1000 mg/day dosages
1560502|NCT02523274|Drug|Placebo|Vegetable-based cellulose
1560503|NCT02523274|Behavioral|Exercise|Multi-modal exercise regimen, 3 days/week
1560504|NCT02523261|Procedure|direct aspiration procedure|Revascularization by endovascular thrombectomy using the distal aspiration first pass technique
1560505|NCT02523261|Procedure|stent retriever procedure|Revascularization by endovascular thrombectomy using a mechanical thrombectomy device
1560506|NCT02523248|Procedure|tonsillectomy|Tonsillectomy with cold steel
1560507|NCT02523248|Procedure|Uvulopalatopharyngoplasty|Tonsillectomy and uvulopalatoplasty with cold steel and single sutures of the palate and tonsillar pillars including palatopharyngeal muscle
1560508|NCT02523235|Drug|ropivacaine 0.2%|Perineural ropivacaine 0.2% at 8 mL/h (adductor) or 6 mL/h (popliteal) basal rate infusion and a 4 mL patient-controlled bolus with a 30 minute lockout
1560509|NCT02523222|Dietary Supplement|40% Dextrose gel|40% dextrose gel will be rubbed into the hypoglycemic infant's buccal mucosa at a dose of 0.5ml/kg.
1560510|NCT02523209|Device|HR-pQCT|HR-pQCT (High Resolution peripheral micro Computerized Tomography) is a device used for 3D bone measurements at the tibia and the radius levels in humans.
1560511|NCT02523209|Device|DEXA|The Lunar DEXA (Dual Energy X-ray Absorptiometry) is a third generation multi-captor DEXA (Dual Energy X-ray Absorptiometry) device that allows short duration measurements ( <15 min). It measures Bone Mineral Density at the spine (L1-L4) and the femoral neck
1560512|NCT02523196|Device|HepQuant-SHUNT|The HQ-SHUNT test is being evaluated for safety and effectiveness as an alternative to Hepatic Venous Pressure Gradient (HVPG) testing in patients with liver disease
1560513|NCT02523196|Device|Hepatic Venous Pressure Gradient (HVPG)|Hepatic Venous Pressure Gradient (HVPG) is a test for patients with liver disease
1560514|NCT02523183|Drug|Medical Cannabis|Pediatric patients with medically refractory epilepsy and treated with medicinal cannabis.
1560515|NCT02523170|Device|AQ-Flex 19 probe (Mauna Kea Technologies, Paris)|Needle-based Confocal Laser Endomicroscopy (nCLE)
1560516|NCT02523157|Other|Wellbeing Plan|The Wellbeing Plan is a short self-help leaflet designed to improve emotional wellbeing of women during and after pregnancy by providing information, raising awareness, helping a woman identify her own symptoms, provide coping strategies, and identify key people who can support the woman during this time.
1560517|NCT02523157|Other|Control task|Information about physical health in pregnancy, matched for readability (Flesch score) and length/duration with the Wellbeing Plan
1560518|NCT02523144|Drug|Chloral Hydrate|70mg/kg chloral hydrate
1560519|NCT02523144|Drug|Dexmedetomidine|2mcg/kg
1560520|NCT02523144|Drug|Dexmedetomidine|3mcg/kg
1560521|NCT02523144|Drug|Placebo|Flavored placebo syrup
1560522|NCT02523131|Device|FlorenceM|"The automated closed loop system (FlorenceM) will consist of:
Next generation sensor augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM and glucose suspend feature.
An Android smartphone containing the Cambridge model predictive algorithm and communicating wirelessly with the insulin pump using a proprietary translator device."
1560523|NCT02523131|Device|Medtronic insulin pump 640G|Next generation sensor-augmented Medtronic insulin pump 640G (Medtronic Minimed, CA, USA) incorporating the Medtronic Enlite 3 family real time CGM. Glucose suspend features will be turned off.
1560524|NCT02523105|Device|EEG monitoring|"EEG evaluation will be done using two off the shelf EEG devices for research and consumer use. The first one is a device called MindWave by NeuroSky ltd (http://neurosky.com) the second called EPOC by Emotiv ltd (https://emotiv.com/epoc.php).
EEG evaluation will be conducted for a total duration of 20 minutes with and without auditory stimulation. The auditory stimulation will be performed using standard headphone or earphones to reduce external noises."
1560525|NCT02523092|Drug|Acthar gel|Acthar gel given IM or SQ as per package insert
1560526|NCT02523079|Behavioral|Cognitive Behavioral Group Therapy for Insomnia|
1560527|NCT02523079|Behavioral|Cognitive Behavioral Self-help Therapy for Insomnia|
1560528|NCT02523079|Behavioral|Sleep Hygiene Guidance|
1560529|NCT02523066|Device|Magna Ease|This study is non-intervention
1560530|NCT02523053|Procedure|Hepatectomy|Surgical removal of all lesions
1560531|NCT02523053|Drug|5-Fluorouracil|Surgical removal of all lesions and intraoperative controlled release 5-Fluorouracil therapy
1560532|NCT02523040|Drug|Lenalidomide|
1560533|NCT02523027|Dietary Supplement|Oral nutritional supplement (List No S691/Z0)|(List No S691/Z0)
1560534|NCT02523027|Dietary Supplement|Oral nutritional supplement|(List No- P968/Z0)
1560535|NCT02523027|Other|Dietary Counselling|Regular dietary counseling conducted by a trained hospital dietitian.
1560536|NCT02523014|Drug|vismodegib|Given PO
1560537|NCT02523014|Drug|GSK2256098|Given PO
1560538|NCT02522988|Behavioral|Open-label placebo intervention|An open-label placebo intervention is an administered placebo that is fully disclosed to participants. It is delivered with a script that tells participants they are receiving placebos; placebos have been found to have effects that are comparable to some clinical treatments; placebos work because of conditioning, expectancies, interactions with care team and biochemical factors (i.e., dopamine, endorphins). Participants are given placebos to take for a 3-week period and will not receive placebos for a 4-week period (including a one-week washout period).
1560982|NCT02519881|Device|CartiFill|add collagen when doing microfracture
1560539|NCT02522975|Drug|EPIAO®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic / anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.
Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
1560540|NCT02522975|Drug|EPREX®|"Recombinant human erythropoietin falls under the pharmacological class of haematopoietic /anti anaemic agents. It has been developed for the treatment of anaemia in subjects with chronic kidney disease.
Erythropoietin, also known as EPO, is a glycoprotein hormone that controls erythropoiesis, or RBC production. It is a cytokine (protein signalling molecule) for erythrocyte precursors in the bone marrow. Human EPO has a molecular weight of 34,000."
1560541|NCT02522962|Behavioral|GroupCoreSIT|"Each group session lasts for 60 minutes. The physiotherapist will chose from an exercises bank of 32 exercises, each having up 5 levels of difficulty that are described and illustrated by photos. All exercises demand core activation, emphasise normal movement and emphasise somatosensory integration, feed forward and feed back strategies essential for balance.10-12 repetitions for each exercise with good quality of movement will be performed. Every session will start with exploring standing balance and end with active stretching/active relaxation, re-exploring balance and instructions for home exercises. The participants will perform 30-minute of exercises, optional to divide into smaller intervals, at home two days per week when there are no organized group training."
1560542|NCT02522962|Behavioral|Standard care|The control group receive standard care, which means to follow their ordinary physiotherapy services and/or routines/activities. The content of standard care may vary, and will be recorded for all the participants.
1560543|NCT02522949|Device|ColdZyme® mouth spray|
1560544|NCT02522949|Device|Placebo|
1560545|NCT02522936|Drug|Biotene oral spray|Biotene oral spray will be provided to participants.
1993950|NCT03100942|Drug|Filgotinib|200 mg tablet administered orally once daily
1993951|NCT03100942|Drug|GS-9876|30 mg tablet administered orally once daily
1560548|NCT02522910|Drug|BAY 1000394 (Roniciclib) in combination with docetaxel|The study (Phase Ib part and Phase II part) will be conducted as a single center study. This study part will be conducted in an open-label, non-randomized, Phase I conventional 3+3 dose-escalating design to define the safety, tolerability, pharmacokinetics, and MTD of BAY 1000394 (Roniciclib) given in a 3 days on / 4 days off schedule in combination with docetaxel in subjects with second- or third-line NSCLC.
1560549|NCT02522897|Drug|Ranibizumab|
1560550|NCT02522897|Device|Laser|
1560551|NCT02522884|Device|Tack Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack Endovascular System.
1560552|NCT02522871|Device|OCS™ Liver System|
1560553|NCT02522871|Other|Control|
1560554|NCT02522858|Drug|Atropine|"To evaluate the effectiveness of atropine on prevention bradycardia,atropine 0.01~0.03mg/kg up to 0.5mg would be injected intravenously just before starting loading dose of dexmedetomidine in group A.
During operation, heart rate decreasing 30% from initial heart rate or under 40/min would be regarded as bradycardia needing treatment, and atropine 0.5mg will be injected intravenously. This intervention would be applied to both group."
1560555|NCT02522858|Drug|Dexmedetomidine|Dexmedetomidine is a highly selective a2 adrenergic receptor antagonist used as sedative agent. After confirming the fixation level of spinal anesthesia, the loading dose(0.6ug/kg) of dexmedetomidine which is diluted with normal saline as 4ug/mL would be started for 10 minutes.Maintenance dose(0.25ug/kg/hr) would be continued after loading dose.
1560556|NCT02522858|Drug|Ephedrine|Systolic blood pressure decreasing 30% from basal blood pressure or under 90 mm Hg would be regarded as hypotension needing treatment, and ephedrine 5mg will be injected intravenously.
1560557|NCT02522845|Device|Class II Compression Stockings (no specific device used)|This study will be looking at the effect of compression therapy in patients having endothermal treatment for truncal incompetence of their varicose veins
1560558|NCT02522832|Other|Titre 1|Virus infection
1560559|NCT02522832|Other|Titre 2|Virus infection
1560560|NCT02522832|Other|Titre 3|Virus infection
1560561|NCT02522819|Device|CPAP|Use of CPAP over 5 nights for the treatment of obstructive sleep apnea in the acute phase of stroke.
1560563|NCT02522793|Other|No intervention; this is an observational study|
1560568|NCT02522754|Biological|Placebo Protesomal Vaccine|Intranasal vaccine Protesomal Vaccine
1560569|NCT02522754|Biological|Experimental: Protesomal Vaccine 1 x 30 µg|Experimental: Protesomal Vaccine 1 x 30 µg
1560570|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 30 µg|Experimental: Protesomal Vaccine 2 x 30 µg
1560571|NCT02522754|Biological|Experimental: Protesomal Vaccine 2 x 15 µg|Experimental: Protesomal Vaccine 2 x 15 µg
1560572|NCT02522741|Behavioral|Parenting STAIR|Parenting-STAIR is an adaptation of a 16 session study therapy entitled Skills Training in Affective and Interpersonal Regulation/Modified Prolonged Exposure (STAIR/MPE). It generally is comprised of approximately 23 sessions and includes seven didactic interaction parenting sessions. There are threskill building in areas such as e modules within Parenting STAIR: 1) Module 1 focuses on skill building (awareness of emotional states, management of negative feelings, regulation of emotional intensity, etc.); 2) Module 2 involves the processing of memories of trauma and creating a coherent and meaningful life narrative; 3) Module 3 includes both the mother and child, and focuses on increasing maternal attunement and improving parenting skills.
1560573|NCT02522728|Device|Triathlon CR|Implantation of Knee Prosthesis
1560574|NCT02522728|Device|Triathlon PS|Implantation of Knee Prosthesis
1560575|NCT02522715|Drug|Cabazitaxel|Given IV
1560576|NCT02522715|Drug|Enzalutamide|Given PO
1560577|NCT02522715|Other|Laboratory Biomarker Analysis|Correlative studies
1560578|NCT02522715|Other|Pharmacological Study|Correlative studies
1993952|NCT03100942|Drug|Tirabrutinib|40 mg tablet administered orally once daily
1993953|NCT03100942|Drug|Filgotinib placebo|Tablet administered orally once daily
1993954|NCT03100942|Drug|GS-9876 placebo|Tablet administered orally once daily
1993955|NCT03100942|Drug|Tirabrutinib placebo|Tablet administered orally once daily
1560580|NCT02522702|Other|Photography of polyps, resection of polyps|Ther is no study specific intervention. Still images will be taken if polyps are found in the colon. Polyps will then be resected routinely.
1560581|NCT02522689|Procedure|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
1560582|NCT02522689|Procedure|Endoscopic kidney stone surgery|Micro PCNL will be performed.
1560583|NCT02522676|Procedure|Endoscopic kidney stone surgery|Conventional PCNL will be performed.
1560584|NCT02522676|Procedure|Endoscopic kidney stone surgery|Mini PCNL will be performed.
1560585|NCT02522676|Procedure|Endoscopic kidney stone surgery|Ultra-mini PCNL will be performed.
1560586|NCT02522676|Procedure|Endoscopic kidney stone surgery|Micro PCNL will be performed.
1560587|NCT02522676|Procedure|Endoscopic kidney stone surgery|Retrograde intrarenal surgery will be performed.
1560588|NCT02522676|Procedure|Non-invasive kidney stone treatment|Extracorporeal shock wave will be performed.
1560589|NCT02522663|Other|24/7-telephone support|ICU nurses answer the calls from treated AVR patients during the first month after discharge, and use an evidence-based information manual to answer questions from the patients.
1560592|NCT02522637|Other|Exercise training|"The workout will start with a workload of 50% of the theoretical maximum Watts indirectly assessed by the 6-Minutes Walking Test (6MWT) with equation of Luxton et al. Each training session will begin with three minutes of warm-up and cool-down with a low load.
At the end of each session, the physiotherapist will administer the Borg Scale (i.e. for dyspnea and muscle fatigue) and detect the oxygen saturation. The sessions will be conducted at constant load for 25 minutes and increase following the Maltais protocol (the workload increase in the next session will be 10 W, if dyspnea and muscle fatigue, evaluated at the Borg Scale, were each < 5 ).
The patients will perform a supervised 20-min light warm-up gym exercise before the endurance training session. The training will be carried out with the oxygen level necessary to maintain the saturation level ≥ 91%."
1560593|NCT02522624|Behavioral|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of health insurance plans in addition to usual care.
1560595|NCT02522598|Drug|VVZ-149 injections|Colorless, transparent liquid in water for injection
1560596|NCT02522598|Drug|Placebo|water for injection
1560597|NCT02522585|Other|Conservative management|Control of CIN-II with cytology and colposcopy to try to avoid unnecessary surgery
1560598|NCT02522572|Drug|plerixafor|Plerixafor will be dosed subcutaneously and administered based on group assignment.
1560599|NCT02522572|Drug|Bortezomib|Bortezomib will be given via IV push over 3-5 seconds and administered based on group assignment.
1560600|NCT02522572|Other|plasmapheresis|Plasmapheresis will be administered based on group assignment.
1560601|NCT02522559|Other|Spice Intervention|Spice Intervention:Novel herb and spice blends will be used in cafeteria recipes.
1560602|NCT02522546|Other|nasopharyngeal swab|nasopharyngeal swab
1560603|NCT02522533|Other|Physical Therapy|6 weeks of an exercise program.
1560604|NCT02522520|Behavioral|Pedometer intervention|12 weeks physical activity intervention (supervised/non-supervised)
1560605|NCT02522520|Behavioral|Pedometer + hospital based intervention|12 weeks physical activity intervention (supervised/non-supervised)
1560606|NCT02522520|Device|Omron Walking Style pro. 20|
1560607|NCT02522507|Behavioral|Empowering youth towards employment|Experimental: Empowering youth towards employment This is a behavioural e-mentor intervention. Trained mentors will facilitate employment readiness learning and engage youth in discussions over a 12-week period. Each week the mentors will introduce a new employment topic and will engage youth in a discussion and answer questions.
1560608|NCT02522494|Behavioral|Pamphlet|An educational intervention delivered prior to patients' visits with primary care physicians.
1560609|NCT02522494|Behavioral|Video|An educational intervention delivered prior to patients' visits with primary care providers.
1560610|NCT02522481|Drug|Lumason|Lumason (sulfur hexafluoride-type A microspheres) an ultrasound contrast agent will be administered as 2 single 2-mL IV injections during rest and stress echocardiography
1560611|NCT02522468|Procedure|Radioactive Seed Localization|
1560612|NCT02522468|Procedure|Wire Localization|
1560613|NCT02522455|Other|Flow-cycle ventilation|Pressure support level set as per previous pressure requirements to deliver a tidal volume of 5ml/kg (the same pressure amount used as the peak inspiratory pressure in the time-cycled mode)
1560614|NCT02522455|Other|Time-cycle ventilation mode|Peak inspiratory pressure set to deliver 5ml/kg tidal volume, Rate set as per previous requirements
1560615|NCT02522442|Device|CPAP|Continuous positive airway pressure
1560616|NCT02522442|Device|Auto BiLevel|AUto Bilevel positive airway pressure with Flex
1560617|NCT02522429|Device|Focused Ultrasound Device|Low Intensity Focused Ultrasound Pulsation (LIFUP) of thalamus (a key area for the consciousness network) will be performed during two sessions (one occurring after deep sedation is stopped and the second one occurring just before discharge). The proposed experiment will involve behavioral (i.e., CRS-R) and paramedical (i.e., MRI/fMRI and EEG) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session).
1560618|NCT02522416|Device|Central corneal thickness measurement|
1561029|NCT02519582|Drug|Niclosamide|2 g per day orally
1560621|NCT02522390|Other|Research activities|"Measurements are primarily based on do-it-yourself non-invasive or minimally invasive methods. Participants upload collected data to the Personal Health Portal.
The measurements are divided into required and optional measurements. The required measurements mainly include routine methodology (e.g. weight, blood pressure, blood glucose); the latter also include methods under development that will be fine-tuned along the project. Which additional measures will be offered to participants is dependent on if funding or in-kind sponsoring is available. Participants will receive measurement kits for these analyses at-home and will be responsible for collection, labeling and shipment of samples themselves. After analysis the resulting data are uploaded to the user accounts."
1560622|NCT02522377|Drug|Ketamine|inter venous injections
1560623|NCT02522377|Drug|Midazolam|inter venous injections
1560626|NCT02522351|Other|Cereal extract concentration 1|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
1560627|NCT02522351|Other|Cereal extract concentration 2|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
1560628|NCT02522351|Other|Cereal extract concentration 3|Cereal extract will be given to see the effect on penetration and aspiration in patients with dysphagia problem
1560629|NCT02522351|Other|Thicken up clear concentration 1|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
1560630|NCT02522351|Other|Thicken up clear concentration 2|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
1560631|NCT02522351|Other|Thicken up clear concentration 3|Thicken up clear will be given to see the effect on penetration and aspiration in patients with dysphagia problem
1560632|NCT02522338|Drug|iohexol|10 ml de l'iohexol (300 mgI/ml)
1560633|NCT02522325|Drug|Phendimetrazine|Phendimetrazine will be administered in divided doses twice daily.
1560634|NCT02522325|Drug|Cocaine|Intranasal cocaine will be administered during experimental sessions.
1560635|NCT02522325|Drug|Placebo|Placebo capsules will contain only cornstarch.
1560636|NCT02522312|Other|No Intervention|No drug is administered in this study
1560642|NCT02522273|Device|EKF Diagnostics 'SensPoint' Lactate Meter|
1560643|NCT02522260|Other|Resistance and aerobic training|Group 1) includes strength exercise of the large muscle groups (2-3 sets, 8-12 repetitions on an intensity of 80 % of 1-RM) and 3x3 min high intensity aerobic exercise (16-18 on Borg scale) on an exercise bike or treadmill twice a week for 16 weeks
1560644|NCT02522260|Other|Aerobic training|Group 2) includes aerobic exercise on an exercise bike or treadmill, 20 min moderate intensity (13-15 on Borg scale), and 3x3 min high intensity (16-18 on Borg scale) twice a week during 16 weeks
1560645|NCT02522260|Other|Standard supportive care|Standard supportive care
1560646|NCT02522247|Procedure|UPP|surgery with cold steel in general anesthesia
1560647|NCT02522234|Biological|F-627|F-627 administrated by s.c. injection on Day 2 of each cycle for up to 6 cycles.
1560648|NCT02522234|Drug|TAC regimen|Chemotherapy (docetaxol, doxorubicin and cyclophosphamide, 75 mg/m2, 50 mg/m2 and 500 mg/m2, respectively) administrated in vein on Day 1 of each cycle for up to 6 cycles.
1560649|NCT02522221|Drug|Warfarin|Warfarin is an oral vitamin K antagonist anticoagulant.
1560650|NCT02522221|Drug|tecarfarin|Tecarfarin is an oral vitamin K antagonist anticoagulant
1560651|NCT02522208|Drug|BiDil XR|fixed combination capsule
1560652|NCT02522208|Drug|BiDil Immediate Release (IR)|fixed combination tablet
1560653|NCT02522182|Behavioral|Nurse-led Intensive Secondary Prevention Programme|Information related to intervention description have been already included in arm/group description
1560654|NCT02522182|Behavioral|Usual Treatment|Information related to intervention description have been already included in arm/group description
1560655|NCT02522169|Drug|Infliximab|"This is a randomized, prospective, parallel -controlled study, simple blinded and multicenter designed. Study centers are the Department of Child and Adolescent Medicine of the Ernst von Bergmann Hospital, Potsdam, and the Department of Child and Adolescent Medicine of Charité, Berlin.
We estimate a sample size of 50 patients per center. Study inclusion begins with given consent of the patient and the legal guardian. Patients will be randomized in control- and intervention group separately for Cohn's disease. An equal age and gender distribution is targeted for both control and intervention group. Sub groups will be formed depending on the time span from completed Infliximab induction to study enrollment (group A< 6month, group B < 6 month). Observation period is one year."
1560656|NCT02522156|Behavioral|Looming Vulnerability Induction|guided imagery aimed at inducing smoking cessation attempts. See description of the looming vulnerability arm.
1560657|NCT02522156|Behavioral|Control|Neutral guided imagery scenarios making no reference to smoking.
1560658|NCT02522143|Behavioral|Informational sessions describing BPD characteristics|Control intervention consists of informational sessions describing BPD characteristics/ treatment and time- / stress-management skills
1560659|NCT02522143|Behavioral|Condensed-DBT treatment intervention|The Intervention consists of an 8-week manual based psychoeducational group utilizing modified condensed-DBT Treatment manual previously used in a treatment study (Moen et al, 2012).
1560660|NCT02522130|Drug|Lidocaine|intracervical injection
1560661|NCT02522130|Drug|oral misoprostol|oral treatment
1560662|NCT02522130|Drug|naproxen|oral treatment
1560663|NCT02522130|Other|placebo|oral treatment
1560664|NCT02522117|Drug|Atorvastatin|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
1560665|NCT02522117|Drug|Placebo|Patients were assigned to two groups; one of them received oral atorvastatin (study group), and the other homologated placebo (control group) for 4 weeks before transplant. Then IL2, IL6, TNFalpha and HLA levels were assessed in the recipient's kidney graft by visual analog scale at prior reperfusion, and after 3 and 12 months.
1560666|NCT02522104|Drug|Siklos|
1560667|NCT02522091|Device|functional brain MRI|
1560668|NCT02522091|Other|Neuropsychology tests|
1560669|NCT02522078|Drug|dry misoprostol|400 µg of dry misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
1560670|NCT02522078|Drug|wet misoprostol|400 µg of wet misoprostol will be introduced into the vaginal fornices 3 or more hours before uterine evacuation
1560671|NCT02522052|Other|Blue mussel diet|5 meals a week containing blue mussels
1560672|NCT02522052|Other|Meat/Control diet|5 meals a week containing meat
1560673|NCT02522039|Drug|Latanoprost|1 drop of latanoprost was given to study eye after washout period of 1 week between drugs
1560674|NCT02522039|Drug|Timolol|1 drop of timolol was given to study eye after washout period of 1 week between drugs
1560675|NCT02522039|Drug|Dorzolamide|1 drop of dorzolamide was given to study eye after washout period of 1 week between drugs
1560676|NCT02522013|Drug|Aminophylline|
1560677|NCT02522013|Drug|isotonic saline|
1560678|NCT02521987|Procedure|8mm port|Participate in this arm will have their procedure performed with an 8mm laparoscopic port.
1560679|NCT02521987|Procedure|12mm port|Participate in this arm will have their procedure performed with a 12mm laparoscopic port.
1560680|NCT02521974|Biological|SABIN monovalent OPV2|SABIN monovalent OPV2 is a licensed, monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells. Each two-drop dose (0.1 mL) contains not less than 105.0 CCID50 of Type 2
1560681|NCT02521961|Other|Informational Intervention|Watch a Chair-robics DVD
1560682|NCT02521961|Other|Informational Intervention|Receive community resource booklet
1560683|NCT02521961|Other|Quality-of-Life Assessment|Ancillary studies
1560684|NCT02521961|Other|Questionnaire Administration|Ancillary studies
1560685|NCT02521961|Procedure|Support Group Therapy|Attend support group sessions
1560687|NCT02521935|Device|Complete traditional dentures|"Arm 1-Standard Treatment Sequence for Traditional Removable Dentures in a Dental School Clinic (9 Appointments):
Appointment 1: Examination & diagnosis & initial impressions.
Appointment 2: Secondary impressions.
Appointment 3: Secondary or definitive impressions (Often 2 appointments are needed to border mold and impression)
Appointment 4: Maxillo-mandibular jaw relation records (both centric and vertical relation). Tooth selection.
Appointment 5: Wax-trial denture try-in.
Appointment 6: Insertion and instructions for care of definitive prostheses.
Appointments 7-9 Post adjustments"
1560688|NCT02521935|Device|Complete CADCAM dentures|"Arm 2-Standard Treatment Sequence for Digital Dentures in a Dental School Clinic (5 appointments):
Appointment 1: Exam, diagnosis, & tray selection (begin impressions)
Appointment 2: Definitive impressions and Maxillomandibula relations
Appointment 3: Wax-trial arrangement
Appointment 4: Insertion and instructions for care of definitive prosthesis
Appointment 5: Post adjustment/s (Less post insertion adjustments are anticipated due to CADCAM milling of the denture base and less polymerization shrinkage"
1560689|NCT02521922|Device|VSP System - NEHB Configuration|VSP System - NEHB Configuration will take and record participant vital signs. NEHB is the last name of the physician who developed the configuration. It is not an acronym.
1560690|NCT02521922|Device|VSP System - PAL Configuration|VSP System - PAL Configuration will take and record patient vital signs. PAL is the name created by the engineering team of this device. It is not an acronym.
1560691|NCT02521909|Device|ProMark (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
1560692|NCT02521909|Device|Root ZX II (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
1560737|NCT02521610|Drug|Placebo|Participants will receive the placebo equivalent to RG7625 once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
1560767|NCT02521441|Drug|Epirubicin and Cyclophosphamide|Epirubicin, 100 mg/me and Cyclophosphamide, 600 mg/m2 administrated in vein on Day 1 of each cycle for 4 cycles.
1560693|NCT02521909|Device|NRG Rider (Tooth Extraction for Assessment of Different Apex Locators)|The purpose of this study is to compare the accuracy of different apex locators on teeth that are scheduled for extractions. Before root canal therapy, dentists use a device called an electronic apex locator (EAL) to measure the root canal and to locate its opening at the tip of the tooth's root (called the apical foramen). A root canal is the space inside the root of a tooth. If the tissue within the root canal becomes infected, dentists may perform root canal therapy.
1560694|NCT02521896|Device|Steerable Sheath System|The Vado™ Steerable Sheath consists of a dilator and steerable sheath which are designed to provide intracardiac access and flexible catheter positioning in the cardiac anatomy.
1560695|NCT02521883|Device|Sooma tDCS|2mA current applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
1560696|NCT02521883|Device|Sham tDCS|sham stimulation (current phased off after 20 secs) applied for 30 minutes in electrode locations F3 (anode) and F4 (cathode).
1560697|NCT02521870|Drug|SD-101|SD-101 administered intratumorally at escalating doses (up to 11 doses)
1560698|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200 mg Q3W for two years (up to 35 doses)
1560699|NCT02521870|Drug|SD-101|SD-101 administered intratumorally (up to 14 doses)
1560700|NCT02521870|Biological|Pembrolizumab|Pembrolizumab administered intravenously, 200mg Q3W for two years (up to 35 doses)
1560701|NCT02521857|Drug|ALKS 5461|Sublingual tablet administered followed by consumption of 240 mL (8 ounces) of water at different timepoints
1560702|NCT02521844|Drug|ETC-1922159|
1560705|NCT02521818|Other|Modified Atkins Diet|
1560706|NCT02521818|Other|NIA Diet for Seniors|
1560707|NCT02521805|Other|Animal protein|
1560708|NCT02521805|Other|Vegetable protein|
1560709|NCT02521805|Other|Dietary fiber (cereal food matrice)|
1560710|NCT02521805|Other|Dietary fiber (meat food matrice)|
1560711|NCT02521805|Other|Dietary fiber (vegetable food matrice)|
1560712|NCT02521792|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules may be opened and the contents added onto specific food.
1560713|NCT02521779|Other|Low-fat Treatment Meal|Isocaloric test meal that provided 20% fat.
1560714|NCT02521779|Other|Saturated-fat Treatment Meal|Isocaloric test meal that provided 35% fat with saturated fat (16 g).
1560715|NCT02521779|Other|N-3 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-3 (DHA = 500mg)
1560716|NCT02521779|Other|N-6 fat Treatment Meal|Isocaloric test meal that provided 35% fat with n-6 (7.4 g).
1560717|NCT02521753|Drug|Metformin|Intervention also includes weight reduction diet and exercise therapy
1560718|NCT02521753|Dietary Supplement|Magnesium|Intervention also includes weight reduction diet and exercise therapy
1560719|NCT02521753|Dietary Supplement|PUFA|Intervention also includes weight reduction diet and exercise therapy
1560720|NCT02521740|Other|Research questionnaires, blood sample|assessment of health (frailty, nutrition, physical performance, depression, burden, sense of coherence, caregiver reaction)
1560721|NCT02521714|Drug|Lenalidomide|
1560722|NCT02521701|Drug|NFL101|"Level 1: 100 µg
50 µg per injection (in each arm), two injections at day 1 and two injections at day 29
The 140 µg must be diluted in 2.8 mL of dilution solution in order to obtain a 50 µg.mL-1 concentration.
Level 2: 200 µg
100 µg per injection (in each arm), two injections at day 1 and two injections at day 29
The 140 µg must be diluted in 1.4 mL of dilution solution in order to obtain a 100 µg.mL-1 concentration. Therefore, for this level only, two vials are needed to inject 2 x 1.0 mL."
1560723|NCT02521688|Procedure|incisional biopsy from placenta and GCF sample|A small piece of villous placental tissue (approximately 1 cm3) will be dissected free of maternal decidua from the placental bed after delivery of fetus processed to prepare tissue homogenate according to the standardized technique (Keelan JA, et al. 1999) GCF will be obtained from each patient by filter paper inserted in gingival crevice for few seconds after isolation by cotton.
1560724|NCT02521675|Behavioral|Usual algorithm|"The patient will be fitted with a CGMS (continuous glucose monitoring system) (data not shown) and it will be given the booklet to collect events + food survey
The patient goes home and he must perform 3 physical activities during the week (30-60 minutes) using its usual algorithms (glucose administration or adaptation of the BR), in the afternoon, and spacing them at least 24 hours :
Moderate activity 3 hours after lunch
Intense activity 3 hours after lunch
Moderate activity 90 min after lunch These activities should not exceed 1 hour in wherever possible"
1560725|NCT02521675|Behavioral|Diabrasport algorithm|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey
The patient goes home and he must perform 3 physical activities during the week (identical to those carried out during the week test algorithms usual and during comparable periods) using DIABRASPORT algorithms, the afternoon and in the spacing at least 24 hours:
Moderate activity 3 hours after lunch
Intense activity 3 hours after lunch
Moderate activity 90min after lunch These activities shall not exceed one hour"
1560726|NCT02521675|Behavioral|Rest|"The patient will be fitted with a CGMS (data not shown) and it will be given the booklet to collect events + food survey.
The patient goes home and he will not perform any physical activity during the week"
1560727|NCT02521675|Device|Holter Glycemic Ipro2, Medtronic|
1560728|NCT02521662|Drug|Nicotine patch|A transdermal patch that slowly releases nicotine into the body through the skin.
1560729|NCT02521662|Device|e-cigarette|A electronically powered device that delivers to the user an aerosol of propylene glycol and/or glycerine, with or without flavourings and nicotine.
1560730|NCT02521662|Drug|Nicotine|Nicotine contained in e-liquid (e-juice) used in e-cigarettes
1560731|NCT02521662|Behavioral|Behavioural support|Withdrawal-oriented behavioural support
1560732|NCT02521649|Drug|G17DT|
1560733|NCT02521636|Other|Antibiotic therapy randomization|
1560734|NCT02521636|Other|Serum PCT dosage|
1560735|NCT02521623|Device|SurgiMend® Acellular Dermal Matrix|See arm description.
1560738|NCT02521610|Drug|RG7625|Participants will receive RG7625 as oral capsules once or twice daily for 8 days. The first dose will be administered on Day 1 and the regimen will be continued during Days 3 to 9, with only a single dose given on Day 9.
1560739|NCT02521597|Device|Cellscope|The CellScope Oto, is a portable video-otoscope that allows residents and staff to share diagnostic-quality images
1560740|NCT02521597|Device|Traditional otoscope|Use of a regular otoscope
1560741|NCT02521571|Behavioral|Resiliance Alliance|"The intervention is 6 months long & is delivered through weekly sessions held in the participating child protective offices. The sessions follow a 4-week cycle with the participants changing each week of the cycle: (1) CPS alone, by units; (2) CPS/Supervisor units; (3) Child Protective Manager and CPS/Supervisor units; and (4) CPSs & Supervisors/Managers separately.
Participating staff are introduced to a resilience-related topic or skill, and receive a brief didactic training on that topic. Staff then engage in a group activity, which is designed to help them apply the new topic or skill to the workplace. Each module wraps up with a relaxation or exercise to help staff transition back into their work responsibilities; the facilitator can pick among the selection provided based on their sense of what would be helpful for the group. Staff are also given handouts and activities to do during the week."
1560742|NCT02521571|Behavioral|Secondary traumatic stress training|"These trainings will take place in two parts (for a total of 3 hours) and include an overview of secondary traumatic stress and its impact on child welfare staff, and some strategies staff can use to protect themselves from STS - essentially a summary version of what the intervention group will receive over the 24 weeks of the intervention. The investigators consider this training to represent treatment as usual, as from our experience it is often how child welfare agencies address the issue of secondary traumatic stress among their staff."
1560745|NCT02521545|Drug|BIIB061|Capsule
1560746|NCT02521532|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
1560747|NCT02521532|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
1560748|NCT02521519|Other|Medial branch block in one side|MBB: Using sterile conditions, 25G needles will be placed in the desired position. In its final position for the L3 and L4 vertebrae the needle tip should reside at the junction of the superior articular process and the transverse process. At the L5-S1 level the needle tip should reach the junction between the sacral ala and the superior articular process of S1. Following a negative aspiration 0.5ml of injectate will be injected into each site.
1560749|NCT02521519|Other|paravertebral deep intramuscular (PDI) injection|injections will target the deep para-spinal muscles between the spinous process and inter-pedicular line of the L3-5 vertebrae. Under fluoroscopic guidance, a 25-gauge needle will be advanced, directed towards the lamina at the mid-distance between inter-pedicular line and the spinous process of the L3, L4 and L5 vertebrae, until touching the bone. A straight forceps will be attached to the junction of the skin and the needle; the needle will then be withdrawn by 1.4cm, to reside inside the muscle bulk. A five ml syringe diameter will be used to point 1.4 cm withdrawal. Following a negative blood aspiration, each level will be injected with 0.5 ml of the injectate.
1560750|NCT02521506|Device|Verio Pattern Alert® activated|
1560751|NCT02521506|Device|Verio Pattern Alert® deactivated|
1560752|NCT02521493|Drug|Asparaginase|Given IM or IV
1560753|NCT02521493|Drug|Asparaginase Erwinia chrysanthemi|Given IM or IV
1560754|NCT02521493|Drug|Cytarabine|Given IT and IV
1560755|NCT02521493|Drug|Daunorubicin Hydrochloride|Given IV
1560756|NCT02521493|Drug|Etoposide|Given IV
1560757|NCT02521493|Other|Laboratory Biomarker Analysis|Correlative studies
1560758|NCT02521493|Drug|Mitoxantrone Hydrochloride|Given IV
1560759|NCT02521493|Drug|Thioguanine|Given PO
1560760|NCT02521480|Device|Active Transcranial Magnetic Stimulation|TMS is a non-invasive treatment. During TMS treatment, a coil, which creates a magnetic field, will be placed on the left prefrontal area of the head. Active TMS will stimulate for 4 seconds, pause for 26 seconds, and repeat this for approximately 40 minutes. There will be a total of 3000 pulses during treatment. We expect TMS to decrease pain and depression. In order to find out if this is true, we will compare real TMS with sham (inactive) TMS.This will allow us to decide if active TMS is successful because of electrical stimulation, or because of the support, concern, and understanding of the research team.
1560761|NCT02521480|Device|Sham Transcranial Magnetic Stimulation|Inactive treatment (simulation of active TMS)
1560762|NCT02521467|Biological|Platelets Rich Fibrin in healing of palatal donor tissue|Platelets Rich Fibrin (PRF) is a second generation of platelets concentrate full of growth factors as PDGF, IGF, TGF which had a role in hemostasis fasten the healing and decrease the pain.
1560763|NCT02521467|Other|Placebo|the other group is a control group, had no biologic in the palatal wound, only palatal stent
1560764|NCT02521454|Behavioral|MBRT|
1560765|NCT02521441|Biological|F-627|F-627 at doses of 10 mg/dose or 20 mg/dose, s.c. on Day 3 of each cycle for up to 4 cycles.
1560766|NCT02521441|Biological|Filgrastim|Filgrastim at dose of μg/kg/day for up to 2 weeks, s.c. start from Day 3 of each cycle for up to 4 cycles.
1560768|NCT02521428|Other|retrospective analysis|Approximately 200 patients will be enrolled in the study. They are followed up until their death on the ICU. In clinical routine end-of-life decisions are documented for decision-makers and procedures in the patients´ records. Patients´ characteristics and therapeutic approaches are documented in the electronic patient data management system.
1560769|NCT02521415|Drug|ketamine|intranasal (IN) sub-dissociative ketamine (1mg/kg)
1560770|NCT02521415|Drug|fentanyl|Intranasal (IN) fentanyl (1.5 micrograms/kg)
1560771|NCT02521415|Drug|ibuprofen or acetaminophen|10 mg/kg of ibuprofen or 15 mg/kg of acetaminophen will be given to participants prior to the randomized intervention
1560772|NCT02521402|Biological|Biovance|decellularized, dehydrated human amniotic membrane
1560773|NCT02521389|Drug|PWT-143|phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) delta inhibitor
1560775|NCT02521363|Device|KIBUR MICRODEVICE|This device contains 16 reservoirs, each with a unique single agent or drug combination in microdose amounts of less than one millionth of a systemic patient dose. The device is implanted directly into the tumor during a biopsy procedure, and remains in situ for ~24 hours.
1560776|NCT02521363|Drug|anthracycline and taxane based chemotherapy|Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
1560777|NCT02521337|Other|observation|observation
1560778|NCT02521324|Device|DGB2|DGB guides its user in reducing breathing rate gradually from normal values (12-20 breaths/min) to slow rates (4-6 breaths/min) while increasing the relative duration of the exhalation phase. This is done by composing in real time musical tones from monitored respiration data with which the user synchronizes breathing .
1560779|NCT02521311|Drug|Clemastine|12mg (4mg 3x/day) clemastine for 7 days followed by 8mg clemastine (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
1560780|NCT02521311|Drug|Placebo|Equivalent placebo. 12mg (4mg 3x/day) placebo for 7 days followed by 8mg placebo (4mg 2x/day) until 3 months. Patients will be off treatment from 3-9 months and will be reevaluated at 9 months.
1560781|NCT02521298|Other|Strength Training|
1560782|NCT02521298|Procedure|Placebo|
1560783|NCT02521298|Drug|Cortico-Steroid Injection. Depomedrol 40mg/1ml.|
1560784|NCT02521298|Procedure|Dry Needling|
1560785|NCT02521285|Drug|Aspirin|Given PO
1560786|NCT02521285|Other|Laboratory Biomarker Analysis|Correlative studies
1560787|NCT02521285|Other|Placebo|Given PO
1560788|NCT02521285|Other|Questionnaire Administration|Ancillary studies
1560789|NCT02521272|Other|Breathing in the simulated avalanche snow.|Breathing in the simulated avalanche snow with zero air pocket and one-liter air pocket.
1560790|NCT02521272|Device|air pocket|Zero air pocket or one-liter air pocket in the snow.
1560792|NCT02521246|Drug|Candesartan + Chlorthalidone|
1560793|NCT02521246|Drug|Candesartan + Chlorthalidone|
1560794|NCT02521246|Drug|Losartan+hydrochlorothiazide|
1560795|NCT02521233|Drug|Candesartan + Chlorthalidone (8mg+12,5mg)|
1560796|NCT02521233|Drug|Candesartan + Chlorthalidone (8 mg + 25 mg)|
1560797|NCT02521233|Drug|losartan+hydrochlorothiazide|
1560798|NCT02521220|Dietary Supplement|L-citrulline|L-citrulline 2 times daily 3 gram (6g/day)
1560799|NCT02521220|Dietary Supplement|Placebo|Maltodextrin 2 times daily 3 gram (6g/day)
1560800|NCT02521207|Drug|Ibuprofen|
1560801|NCT02521194|Behavioral|Questionnaire|Questionnaire completion regarding opinion of the inpatient occupational therapy session patient received.
1560802|NCT02521181|Drug|Lower Dose Sodium Bicarbonate|Lower dose oral Sodium Bicarbonate (0.5 milliequivalents (mEq)/kg-LBW/day)
1560803|NCT02521181|Drug|Higher Dose Sodium Bicarbonate|Higher dose oral Sodium Bicarbonate (0.8 mEq/kg-LBW/day)
1560804|NCT02521181|Drug|Placebo|Oral placebo equivalent to either 0.5 mEq/kg-LBW/day or 0.8 mEq/kg-LBW/day of Sodium Bicarbonate
1560805|NCT02521168|Drug|Oral triiodothyronine|Oral triiodothyronine is given peri-operatively through naso-gastric tube
1560806|NCT02521168|Drug|Placebo|Placebo consist of saccharin lactis that has the same appearance as Tetronine
1560807|NCT02521155|Behavioral|Safeguard Your Smile an oral health literacy intervention|"Safeguard Your Smile intervention will consist of following five components:
i) Reviewing photonovel (educational booklet) with participants to help them understand adequate oral hygiene self-care behavior. ii) Demonstrating adequate tooth brushing, flossing and tongue cleaning (frequency, duration and technique) on dentoform iii) Helping participants to make a concrete plan (specifying when where and how will they perform oral hygiene self-care behavior and a coping plan). Also, to identify a prompt/cue that would act as a reminder. iv) Assigning a task to participants to daily check-mark their behavioral progress on a calendar provided in the photonovel for the next three months. v) Follow up by making three phone calls to each participant of the intervention group once a month."
1560808|NCT02521142|Other|Non-invasive OCT based optical angiography|This measurement will be obtained after the dilation of the pupil. Optical coherence tomography (OCT) is a non-invasive optical imaging modality enabling cross-sectional tomographic in vivo visualization of internal microstructure in biological systems. In ophthalmology OCT has become a standard device in visualizing the retina and is also considered a standard tool in the diagnosis of retinal disease. In optical angiography blood vessels contrasting against static tissue are visualized in a full depth resolved and label-free manner.
1560809|NCT02521142|Other|Oxymap T1|The Oxymap system T1 is installed on a conventional fundus camera (Topcon TRC-50DX), which is operated as for color photography. The Oxymap T1 simultaneously acquires two images of the same area of the fundus at two different wavelengths of light. One of the two wavelengths is sensitive to oxygen saturation, i.e. the light absorbance changes with the oxygen saturation, while the other is insensitive to oxygen saturation and is used to calibrate the light intensity. The two spectral images are automatically processed by the Oxymap Analyzer software. Oxymap Analyzer detects blood vessels and estimates the light absorbance (optical density) at each point along the vessels at each wavelength. The ratio of the optical densities (optical density ratio or ODR) has been shown to be linearly related to hemoglobin oxygen saturation.
1560810|NCT02521142|Other|Spectralis OCT and Topcon DRI OCT|The Spectralis OCT (Heidelberg Engineering) and the high definition Topcon DRI OCT (Topcon), will be used. Both are standard OCT devices for non-invasive imaging of retinal and choroidal structures.
1560811|NCT02521142|Other|FLA/ICG angiography|Fluorescein Angiography and Indocianine Angiography
1560812|NCT02521129|Device|Biopsy Track Ablator (STARmed, Goyang, Korea)|After percutaneous ultrasound guided biopsy for hepatic masses is performed, biopsy track is ablated with a new track ablation device.
1560813|NCT02521116|Other|Dynamic Vessel Analyzer|
1560814|NCT02521116|Other|Oxymap T1|
1560815|NCT02521103|Device|Triathlon Tritanium Cone Augments|The Triathlon Tritanium Cone Augments are an extension of the Triathlon Total Stabilizer (TS) system, intended to be used as an optional accessory component in primary or revision TKA
1560816|NCT02521090|Biological|EGFRBi-Armed Autologous T Cells|Given IT and IV
1560817|NCT02521090|Other|Laboratory Biomarker Analysis|Correlative studies
1560818|NCT02521077|Drug|Ascorbic Acid|500 g ascorbic acid dissolved in 500 ml sterile water.
1560819|NCT02521077|Other|Normal Saline|Saline 0.9%
1560820|NCT02521064|Dietary Supplement|Exclusive Enteral Nutrition (EEN)|Patients will be treated with 8 weeks of Exclusive Enteral Nutrition (EEN). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
1560821|NCT02521064|Drug|Prednisone|Patients will be treated with 8 weeks of prednisone (corticosteroid). Patients will continue to receive usual medical care, and concurrent IBD treatments will be permitted.
1560822|NCT02521051|Drug|Alectinib|
1560823|NCT02521051|Drug|Bevacizumab|
1560825|NCT02521025|Other|Intermittent feeding pattern|Intermittent feeding
1560826|NCT02521025|Other|Continuous feeding pattern|Continuous feeding
1560827|NCT02521012|Dietary Supplement|Vitamin D 10 micrograms|Vitamin D supplementations of 10 micrograms/day will be given to depressed individuals for three months
1560828|NCT02521012|Dietary Supplement|Vitamin D 100 micrograms|Vitamin D supplementations of 100 micrograms/day will be given to depressed individuals for three months
1560829|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 0mmHg(control)|Blood pass through infusion set without external pressure.
1560830|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 150mmHg|Blood pass through infusion set under external pressure (150mmHg)
1560831|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 200mmHg|Blood pass through infusion set under external pressure (200mmHg)
1560832|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 250mmHg|Blood pass through infusion set under external pressure (250mmHg)
1560833|NCT02520999|Device|Auto PC(Acemedical, Goyang-si, Korea) - 300mmHg|Blood pass through infusion set under external pressure (300mmHg)
1560834|NCT02520986|Device|Carbon dioxide Laser ablation|surgical Instrument to achieve excision of genital warts by a pulsed laser of 15 Watt voltage
1560835|NCT02520986|Device|Electrocoagulation|surgical Instrument to achieve excision of genital warts by a deep tissue electrocoagulation of 80 Watt voltage
1560836|NCT02520973|Other|Sputum sample|
1560837|NCT02520947|Device|BIS|Bispectral index monitoring
1560838|NCT02520947|Drug|Desflurane|volatile agent for maintenance of anesthesia
1560839|NCT02520934|Drug|Miglustat|combine miglustat and ERT to see if neurologic manifestations can be improved
1560840|NCT02520934|Drug|ERT|enzyme replacement therapy
1560841|NCT02520921|Drug|Novel strategy Aspirin|Aspirin twice a day : enteric coated enteric coated aspirin given twice a day, 100 mg in the morning and 100 mg in the evening (i.e. 200mg/day)
1560842|NCT02520921|Drug|Conventional strategy Aspirin|Aspirin once day: enteric coated aspirin 100 mg in the morning (i.e. 100mg/day)
1560843|NCT02520908|Procedure|HSCT|Hematopoietic stem cell transplantation
1560844|NCT02520908|Other|Standard Care|
1560845|NCT02520895|Biological|blood samplings|patients will have blood samplings at different time : D0: day of inclusion = day of the first course of chemotherapy or the 1st day of the confirmation of the diagnosis (group 8) M3: 3 months (+/- 1 month) after the start of treatment (except for group 8) M6: 6 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) M12 : 12 months after the start of treatment (group 6 and 7) M18: 18 months (+/- 1 month) after the start of treatment or after the 1st day of the confirmation of the diagnosis (group 8) R: to relapse if it occurs before 18 months or at the time of first treatment if it occurs before 18 months (group 8)
1560846|NCT02520882|Drug|68Ga-NOTA-Aca-BBN|68Ga-NOTA-Aca-BBN(7-14) were injected into the patients before the PET/CT scans
1560847|NCT02520882|Device|PET/CT|
1560848|NCT02520869|Procedure|swim-up technique|swim-up technique used
1560849|NCT02520869|Procedure|zeta test technique|zeta test technique used
1560850|NCT02520856|Other|blood sample|
1560851|NCT02520843|Drug|stromal vascular fraction (SVF)|stromal vascular fraction (SVF) is administered to the patient suffering of Refractory Crohn's disease around of the fistula by local mico injection
1560852|NCT02520830|Dietary Supplement|Blueberry Group|22 grams freeze-dried blueberry powder per day. Sustained intake (2x 11 grams daily over 1 month) of a drink consisting on freeze-dried wild blueberry powder dissolved in water
1560853|NCT02520830|Dietary Supplement|Placebo Group|Sustained intake (2x 11 grams daily over 1 month) of a drink consisting in placebo powder dissolved in water
1560854|NCT02520817|Dietary Supplement|175 mg zinc gluconate, 50000 IU vitamin A, 500 mg vitamin C and 100 mg vitamin E once daily plus lactulose; dose 30-60 ml/day for 3 months|
1560855|NCT02520817|Dietary Supplement|Lactulose|
1560856|NCT02520804|Drug|sterofundin|sterofundin for shock patients in the first 72 hours
1560857|NCT02520804|Drug|normal saline|Normal saline for shock patients in the first 72 hours
1560861|NCT02520778|Other|Laboratory Biomarker Analysis|Correlative studies
1560862|NCT02520778|Drug|Navitoclax|Given PO
1560863|NCT02520778|Drug|Osimertinib|Given PO
1560868|NCT02520739|Dietary Supplement|Virgin Olive Oil (VOO)|VOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of VOO distributed over 3 meals. Daily doses of VOO were blindly prepared in special containers, with the corresponding 30 mL VOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed VOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
1560869|NCT02520739|Dietary Supplement|Optimized High Phenolic Content Oil (OHPCO)|OHPCO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of OHPCO distributed over 3 meals. Daily doses of OHPCO were blindly prepared in special containers, with the corresponding 30 mL OHPCO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed OHPCO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
1560870|NCT02520739|Dietary Supplement|Functional Olive Oil (FOO)|FOO was sequentially administered over 3 periods of 3 weeks preceded by 2-week washout periods in which participants were requested to avoid olives and olive oil consumption. During intervention periods, they were requested to ingest a raw daily dose of 30 mL of FOO distributed over 3 meals. Daily doses of FOO were blindly prepared in special containers, with the corresponding 30 mL FOO daily dose were delivered at the beginning of each intervention period to the participants. The participants were instructed to return the containers when collecting the next daily doses for the amount of unconsumed FOO to be registered. During washout periods participants were provided of sunflower oil for raw and cooking purposes.
1560871|NCT02520726|Drug|Sertraline|< 65years: sertraline 50mg PO qday increasing by 50mg per day per week until 200mg for one week, then stop.
1560872|NCT02520713|Genetic|Genetic testing and GAIN report|All patients enrolled will submit specimens for genetic analysis. If successful the report will be reviewed to look for possible recommendations and a GAIN report will be generated regardless of possible recommendations.
1560873|NCT02520700|Device|Daylight and Maquet Power 500 LED surgery light|Comparing the use of daylight and a surgical light (Maquet Power 500 LED surgery light) to activate ALA cream for treatment of actinic keratoses
1560874|NCT02520687|Dietary Supplement|Beetroot juice|200mls daily for seven days
1560875|NCT02520687|Dietary Supplement|Nitrate-depleted beetroot juice|200mls daily for seven days
1560876|NCT02520674|Other|optic nerve head ophthalmoscopy|Patients underwent undilated smartphone ophthalmoscopy followed by undilated slit-lamp biomicroscopy for the grading of the vertical cup-to-disc ratio of the optic nerve head.
1560877|NCT02520661|Behavioral|Care Transitions Intervention|The Care Transitions Intervention uses coaches, in this case paramedics, to support patients being discharged home by transferring skills to activate patients.
1560878|NCT02520648|Other|Neuro-lymphatic treatment|The physical therapist applied direct firm rotary pressure, via thumb or tip finger, for 1 minute, from the transverse processes of T1 to the transverse processes of T12. To finish the intervention, hands were placed on the skull and sacrum during 2 minutes without movement.
1560879|NCT02520648|Other|Articulatory spinal manual therapy|Then the therapist performs pressures in the transverse apophysis from D1 to D12 (level of the paravertebral muscles, at a distance of 2 fingers of the spinous apophysis), applying sustained pressure during expiratory time until the articulatory barrier is reached.
1560880|NCT02520648|Other|Articulatory costal Manual therapy|The therapist performs costal-vertebral articulatory movement, from 1st to 12th rib (level of the outside paravertebral muscles, at a distance of 4 fingers from the spinous apophysis on the back of the costal body) applying a sustained pressure during expiratory time and promoting its biomechanics, up to the articulatory barrier.
1560881|NCT02520635|Drug|supra-early TEMODAL® chemotherapy|
1560882|NCT02520635|Drug|standard TEMODAL® chemotherapy|
1560883|NCT02520635|Radiation|Radiotherapy 60Gy|
1560884|NCT02520622|Behavioral|Digital photographs loaded onto a mobile device|
1560885|NCT02520622|Behavioral|Skin exam reminders|
1560886|NCT02520622|Behavioral|Social support network|
1560887|NCT02520596|Other|Bioavailability of Raspberry polyphenols|
1560888|NCT02520583|Dietary Supplement|Lactic acid bacteria and bifidobacteria|
1560889|NCT02520583|Other|Placebo|
1560890|NCT02520570|Drug|ulinastatin|We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
1560891|NCT02520557|Other|Blood or Saliva|To screen for HLA genotypes that may place patients at high risk of SCAR when they use ESL.
1560892|NCT02520544|Device|Accolade stem|Total hip replacement
1560893|NCT02520544|Device|Accolade II stem|Total hip replacement
1560894|NCT02520544|Device|Trident/Tritanium cup|Total hip replacement
1560895|NCT02520531|Device|Scorpio PS (posterior stable)|Implantation of total knee prosthesis
1560896|NCT02520531|Device|Scorpio NRG PS|Implantation of total knee prosthesis
1560897|NCT02520518|Drug|Dapagliflozin|
1560898|NCT02520518|Drug|Placebo|
1560899|NCT02520518|Behavioral|Weight maintenance|
1560900|NCT02520518|Behavioral|Ad libitum dietary intake|
1560901|NCT02520518|Behavioral|Dietary restriction|
1560902|NCT02520505|Drug|Supraovulation clomiphene citrate|Treatment with clomiphene citrate during day 3 to 7 of the menstrual cycle.
1560903|NCT02520505|Behavioral|Timed intercourse|Timing intercourse during the fertile window in the menstrual cycle. Patients may also utilize an ovulation predictor kit to determine time of ovulation.
1560904|NCT02520505|Procedure|Intrauterine Insemination|Intrauterine insemination will be performed ~36 hours after the time the woman ovulates, as determined by an ovulation predictor kit.
1560905|NCT02520492|Device|noninvasive method of ICP measurements (Elios)|
1560910|NCT02520453|Drug|Durvalumab|
1560911|NCT02520453|Drug|Placebo|
1560912|NCT02520440|Biological|Monitoring of plasmatic levels of Citrulline|Measured plasma amino-acids levels
1560913|NCT02520440|Device|Intra-abdominal pressure monitoring|Intra-abdominal Hypertension is defined as an average pressure of the day ≥ 12 mmHg; abdominal compartment syndrome is defined as a sustained (minimally two standardized measurements, performed 1-6 h apart) increase in Intra-abdominal pressure above 20 mmHg with new onset organ failure.
1560914|NCT02520440|Biological|Monitoring of plasmatic levels of Arginine and Glutamine|Measured plasma amino-acids levels
1560915|NCT02520427|Drug|AMG 330|0.5-960 µg/day cIV infusion in cycles from 14 to 28 days
1560916|NCT02520414|Device|Symphion® Bipolar Hysteroscopic Tissue Resection System|
1560917|NCT02520401|Other|Probiotic - BioGaia|Use of a probiotic tablet
1560918|NCT02520401|Other|Placebo|Use of a placebo tablet
1560919|NCT02520388|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 Doses: 40, 60 or 80 mg
1560920|NCT02520388|Drug|Placebo|
1560921|NCT02520375|Other|Prebiotic|
1560922|NCT02520375|Other|Control|
1560923|NCT02520362|Drug|denosumab|subcutaneous injection
1560924|NCT02520362|Drug|bisphosphonate|The assessment of bisphosphonates includes branded oral bisphosphonates (eg, alendronate [Fosamax®], risedronate [Actonel®], ibandronate [Boniva®/Bonviva®] oral); generic bisphosphonates, including alendronate, neridodronate, and olpadronate; intravenous bisphosphonates including ibandronate IV, and zoledronate [Reclast®/Aclasta®].
1560925|NCT02520349|Device|MarkTen and e-Go e-cigarettes|
1560926|NCT02520336|Behavioral|Reminder|
1560927|NCT02520323|Other|Blood draw|
1560928|NCT02520323|Procedure|Bronchoscopy|
1560929|NCT02520323|Behavioral|Questionnaires|
1560930|NCT02520310|Device|AVJ-514|Patients receiving AVJ-514 device
1560931|NCT02520297|Drug|TRV130|Drug
1560932|NCT02520284|Biological|GS-5745|GS-5745 150 mg administered subcutaneously
1560933|NCT02520284|Biological|Placebo|GS-5745 placebo administered subcutaneously
1560934|NCT02520271|Behavioral|Behavioral Activation|BA consists of at least 4 intervention sessions with a focused, active working style by the therapist. The therapy initiation includes a focused interview targeting at determining 1-2 main problems, on which the therapy will be focused. Specific therapeutic methods for BA include the use ABC analysis, targeting at hitting the negative consequences of current problematic behavior and motivating for change. Further, recognizing the obstacles for change (TRAP) is the next method to be used. The therapist encourages the client for active behavioral monitoring through assigned homework during the therapy process. The final step and method used is strengthening the gained change (ACTION).
1560935|NCT02520271|Behavioral|Motivational Interview|"Motivational interview (MI) is a therapeutic intervention that focuses on resolving client ambivalence towards changing problematic behavior. MI involves a client-centered approach that encourages the client to develop his or her own motivation. The therapeutic alliance in MI is predominantly a partnership, rather than an expert/client dynamic.
MI has been studied primarily in addiction problems, but there are numerous reports of its efficacy in several chronic somatic conditions, and lifestyle problems."
1560936|NCT02520258|Other|Oral glucose tolerance test (OGTT)|OGTT will be conducted following a ten (10) hour fast on Screening Visit 2 (Screening Visit 2 may be conducted between Day -42 to Day 1).
1560937|NCT02520258|Other|Diet soda containing aspartame only|7 days of 36 oz diet soda po daily (Week 1), followed by 21 days washout (Weeks 2-4), and 7 days rechallenge (Week 5); Prudent metabolic diet; Oral glucose tolerance test (OGTT) on days (+/-2) 3, 7, 10, 14, 21, 28, 31, 35
1560938|NCT02520245|Drug|REGN2810|Patients will receive REGN2810 by intravenous (IV) infusion
1560939|NCT02520232|Behavioral|Combination of aerobic and strength exercises|Combination of aerobic and strength exercises
1560940|NCT02520232|Behavioral|Stretching and balance exercise program|Stretching and balance exercise program
1560941|NCT02520219|Drug|GDP|GDP is a a combination therapy,repeated every 21 days. GEM(gemcitabine)1000mg/m2,ivgtt,30,d1、8; DXM(dexamethasone),40mg/d,p.o,d1-4; DDP(cis-platinum),75mg/m2,ivgtt,>1h,d1; or DDP25 mg/m2,ivgtt,>1h,d1-3.
1560942|NCT02520219|Biological|Endostar|"Endostar is a continuous intravenous injection pump, continuous intravenous pumped by seven consecutive days,d1- d7, which is 168 hours .Endostar pumping well dose is 30 mg every 24 hours.
Repeated every 21 days."
1560943|NCT02520193|Procedure|Protocolized early mobilization in ICU|
1560944|NCT02520180|Device|Firehawk™ stent system|MicroPort Firehawk™ biodegradable polymer rapamycin target eluting stent
1560945|NCT02520180|Device|Abbott Xience family Everolimus-Eluting Stent|Abbott Xience family Everolimus-Eluting Stent
1560946|NCT02520167|Behavioral|Dietary and Lifestyle Counseling|Dietary and lifestyle education; Peer group support.
1560947|NCT02520154|Drug|Carboplatin|AUC 6 by vein on Day 1 every 21 days for a total of 3 cycles of therapy. After participants undergo interval cytoreductive surgery, they receive same dose and schedule of Carboplatin for three more cycles.
1560948|NCT02520154|Drug|Paclitaxel|80 mg/m2 by vein on Days 1,8,15 every 21 days for a total of 3 cycles of therapy. After participants undergo interval cytoreductive surgery, they receive same dose and schedule of Paclitaxel for three more cycles.
1560949|NCT02520154|Drug|Pembrolizumab|200 mg by vein on Day 1 every 21 days for a total of 3 cycles. After participants undergo interval cytoreductive surgery, Pembrolizumab maintenance therapy 200 mg by vein every 21 days for a total of 20 cycles or until progression.
1560950|NCT02520141|Drug|Ramucirumab|8 mg/kg by vein on Day 1 of each 14 day cycle.
1560983|NCT02519868|Device|Electrical block|Nerve stimulator switched on at an intensity of 5 mA for 15 minutes, with the needle tip positioned close to the carotid bifurcation with the aid of the echography
1561030|NCT02519569|Other|Internet-based cognitive-behavioral therapy|The intervention consists of ten writing assignments
1560952|NCT02520115|Drug|Dexamethasone|Given PO
1560953|NCT02520115|Other|Laboratory Biomarker Analysis|Analysis of serum and tissue samples
1560954|NCT02520115|Drug|Valproic Acid|Given PO
1560955|NCT02520102|Drug|sargramostim GZ402664|"Pharmaceutical form: lyophilized powder in vial
Route of administration: subcutaneous"
1560958|NCT02520076|Drug|Alpha-1 Antitrypsin|"Subjects will receive their islets treated with Aralast NP during islet isolation process.
Subjects will receive Aralast NP at a dose of 120 mg/kg (at an infusion rate of 0.2 mL/kg/min or less), dependent on patient tolerance, based on Day -1 admission weight and dose rounded to the nearest 20 mg) at the following time points:
Pre-transplant Day -1
Post-transplant Day 3
Post-transplant Day 7
Post-transplant Day 14"
1560959|NCT02520063|Drug|Letrozole|A dose of 2.5 mg of letrozole will be given orally once each day until one day before surgery. This drug is commercially available and is not provided by the study.
1560960|NCT02520063|Drug|Everolimus|The dose of everolimus will be escalated from 5 mg to 10 mg daily depending upon the cohort in Phase I. It is administered as an oral pill to be taken once daily up until four weeks prior to surgery.
1560961|NCT02520063|Drug|TRC105|The dose for TRC105 is either 15 or 10 mg/kg to be given intravenously every two weeks and continued until four weeks prior to surgery.
1560962|NCT02520050|Behavioral|Traditional MNT|Will follow the nutritional recommendations set by the American Diabetes Association in 2013.
1560963|NCT02520050|Behavioral|Structured MNT|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula.
1560964|NCT02520050|Behavioral|Structured MNT plus Weekly Support|Will follow a meal plan developed at Joslin plus use of use of diabetes-specific nutritional formula; in addition to receiving weekly coaching from a registered dietitian
1560965|NCT02520024|Behavioral|self-directed care|
1560969|NCT02519998|Other|Concussion|Study groups are differentiated based on presence of concussion. No intervention is being made in either population (observational study)
1560970|NCT02519985|Device|ArcScan Insight 100 very high-frequency digital ultrasound|"The ArcScan Insight 100 VHF digital ultrasound scanner that can measure individual layers within the cornea with very high precision, as well as being able to image the interior of the eye including the chamber between the iris and the cornea, the lens and other structures behind the iris.
The ArcScan Insight 100 device is a digital ultrasound scanner, meaning that it uses ultrasound waves to measure parameters of the eye. The Insight examination involves the patient sitting in front of the ultrasound unit and looking through a disposable goggle-like eyepiece at a light source. Warm sterile balanced saline solution (like natural tears) are used to fill the space between the light source and the eye, to allow ultrasound transmission. There is no contact between the instrument and the eye other than being immersed in this water bath."
1560971|NCT02519972|Device|low dose computed tomography|Participants will receive 3 round of low dose computed tomography screening every year
1560972|NCT02519946|Other|On-Line Diet and Exercise Intervention|Initial 16 weeks of on-line, live exercise instruction 3x/week and on-line, diet sessions followed by 16 weeks of weekly exercise and diet sessions.
1560973|NCT02519933|Procedure|mNT-BBAVF|mNT-BBAVF was performed under local anesthesia. A transverse incision of approximately 4 cm was made in the antecubital area. The basilic vein was isolated, and its side branches were ligated; followed by the isolation of brachial artery. A venotomy of 5 mm was performed, followed an arteriotomy of 5 mm. The two vessels then had a side-to-side anastomosis, followed by the ligation of the vein above anastomosis. All the perforating veins located in an area 2-4 cm down the antecubital fossa from anastomosis were separated and ligated carefully. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters (diameters, blood velocities and blood volume) detected by Ultrasound.
1560974|NCT02519933|Procedure|BCAVF|BCAVF was performed under local anesthesia. A transverse incision of approximately 4 cm in length was made in the medial antecubital area. The cephalic vein was isolated, followed by the isolation of brachial artery. The distal end of cephalic vein was ligated and dissected. Patency of the proximal vein was verified by the warmed saline injection. The artery was then incised after clamping, and an end-to-side anastomosis (4-0 silk suture) between the cephalic vein and the brachial artery was performed. At last the skin is sutured (1-0 silk suture). At last the skin is sutured. After surgeries, all patients will be followed up for 12 months. The outcomes are patency (primary unassisted patency and secondary), complications and hemodynamic parameters detected by Ultrasound.
1560975|NCT02519920|Drug|fluorescein sodium 0.01ml/kg|fluorescein Sodium Dose of 0.01ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
1560976|NCT02519920|Drug|fluorescein sodium 0.02ml/kg|fluorescein Sodium Dose of 0.02ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
1560977|NCT02519920|Drug|fluorescein sodium 0.05ml/kg|fluorescein Sodium Dose of 0.05ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
1560978|NCT02519920|Drug|fluorescein sodium 0.1ml/kg|fluorescein Sodium Dose of 0.1ml/kg on confocal laser endoscopy image quality and yellow discoloration of the skin
1560979|NCT02519907|Device|Surface Electrical Stimulation|Please see information under 'Detailed description'
1560980|NCT02519894|Behavioral|Dietary Scanning Calculator|
1560984|NCT02519868|Device|Chemical block|Injection of lidocaine 1%, 15 mLs, with the needle tip positioned close to the carotid bifurcation, with the aid of the echography
1560985|NCT02519855|Biological|ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (concomitant) or at Week 4 (nonconcomitant)
1560986|NCT02519855|Biological|Placebo to ZOSTAVAX™|A single blinded administration of 0.65 mL subcutaneous injection on Day 1 (nonconcomitant) or at Week 4 (concomitant)
1560987|NCT02519855|Biological|Influenza Vaccine|A single open-label administration of 0.5 mL intramuscular injection on Day 1
1560988|NCT02519842|Drug|Fosaprepitant|
1560989|NCT02519842|Drug|Placebo for fosaprepitant|
1560990|NCT02519842|Drug|Ondansetron|
1560991|NCT02519842|Drug|Dexamethasone|
1560992|NCT02519842|Drug|5-HT3 antagonist|
1560993|NCT02519829|Procedure|Monocryl closure|Total Hip Arthroplasty with monocryl closure of wound
1560994|NCT02519829|Procedure|Vicryl and Staple closure|Total Hip Arthroplasty with vicryl and staple closure of wound
1560995|NCT02519829|Procedure|Tegaderm dressing|Total Hip Arthroplasty with monocryl closure of wound and tegaderm dressing
1560996|NCT02519829|Procedure|Gauze dressing|Total Hip Arthroplasty with vicryl and staple closure of wound and gauze dressing
1560997|NCT02519816|Other|Autologous peripheral blood mononuclear cells ex vivo depleted for reactive T cells, using TH9402 based photodynamic therapy, in a final formulation of 10% DMSO, 30% autologous plasma in PlasmaLyte.|
1560998|NCT02519777|Drug|Placebo for maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
1560999|NCT02519777|Drug|Placebo for dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
1561000|NCT02519777|Drug|Dolutegravir (DTG)|Administered orally as one 50 mg tablet BID OR one 50 mg tablet QD depending upon background ARV regimen
1561001|NCT02519777|Drug|Maraviroc (MVC)|Administered orally as one 150 mg tablet BID OR two 300 mg tablet BID OR one 300 mg tablet BID depending upon background ARV regimen
1561002|NCT02519764|Other|Hydration when thirsty.|Volunteers in this arm habitually follow a hydration protocol that advises hydration when thirst is felt.
1561003|NCT02519764|Other|Not hydration when thirsty|"Volunteers in this arm habitually follow any other kind of hydration protocol, i.e. not a hydration when thirsty protocol."
1561004|NCT02519751|Dietary Supplement|D3 Creatine|One dose of D3 Creatine (60mg capsule) given orally on Day 1
1561005|NCT02519751|Dietary Supplement|Creatine|Participants will consume an individual dosed level of creatine, based on their estimated muscle mass in doses of 0.03, 0.035, 0.04, 0.045 g.kg.Lean mass/day, increasing on a weekly basis. Final dose of 0.05 g.kg.Lean mass/day is then maintained throughout the study.
1561009|NCT02519725|Other|ICU diary|The intervention is the elaboration of an ICU diary by caregivers and families The first pages of the diary is standardized to include an explanation of the purpose of the diary. The diary is maintained by the family and ICU staff. The only instruction given to the families and staff members about diary entries is to refrain from writing about confidential matters that could not be shared among the patients, the staff and the relatives. Staff members are free to express compassion and their hope, or absence thereof, that the patient would recover. Relatives can speak freely with the patients without receiving guidance from the ICU staff. At the minimum, the ICU staff write a brief entry at each weekly staff meeting. For patients discharged to wards and if he can receive the diary, the diary is given to the patient. If the patient died, the diary is given to the family.
1561010|NCT02519712|Drug|Induction Chemotherapy|Patients with newly diagnosed AML will receive standard induction chemotherapy with daunorubicin and cytarabine (7+3 scheme). Patients who achieve CR may undergo consolidation chemotherapy at the discretion of the treating leukemia physician.
1561011|NCT02519712|Procedure|G-PBSC Infusion|G-CSF-mobilized peripheral blood cells will be collected from the donors in the Donor Room according to standard MSKCC BMT guidelines. Patients will be infused by infusion of unmanipulated G-PBSC from a haploidentical related donor.
1561012|NCT02519699|Drug|norepinephrine|Increase in mean arterial pressure using norepinephrine
1561013|NCT02519673|Device|Measurement of stromal tissue ablation|Stromal tissue consumption will be estimated preoperatively by WaveLight Allegretto EX-500 laser and central corneal thickness will be measured by Pentacam. One month after refractive surgery, during follow-up,central corneal thickness will be again measured by Pentacam.
1561014|NCT02519660|Drug|Lidocaine/Tetracaine patch|
1561015|NCT02519660|Drug|Lidocaine/Prilocaine cream|
1561016|NCT02519647|Device|Tracheal intubation with Gliderite|Tracheal intubation with Gliderite
1561017|NCT02519647|Device|Tracheal intubation with S-guide|Tracheal intubation with S-guide
1561020|NCT02519621|Device|NPWT PRO|NPWT PRO without irrigation.
1561021|NCT02519621|Device|NPWT PRO|NPWT PRO with irrigation (saline)
1561022|NCT02519621|Device|KCI Ulta|KCI Ulta NPWT without irrigation
1561023|NCT02519608|Drug|Aspirin 100 mg|Patients with COPD and SCAD undergoing PCI and stent implantation will receive aspirin
1561024|NCT02519608|Drug|Ticagrelor|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + ticagrelor (loading dose 180 mg + maintenance 90 mg x2)
1561025|NCT02519608|Drug|Clopidogrel|Patients with COPD and SCAD undergoing PCI and stent implantation will receive according randomization aspirin + clopidogrel (loading dose 600 mg + maintenance 75 mg)
1561026|NCT02519595|Drug|Ketamine IV 1mg/kg|Intervention: Ketamine IV 1mg/kg
1561027|NCT02519595|Drug|Ketamine IV 1.5mg/kg|Intervention: Ketamine IV 1.5 mg/kg
1561028|NCT02519595|Drug|Ketamine IV 2mg/kg|Intervention: Ketamine IV 2 mg/kg
1561031|NCT02519556|Drug|Probiatop|Dilute one sachet in 100ml of water and take it in every morning, once a day for 6 months.
1561032|NCT02519556|Drug|Placebo|1 sachet, once a day for 6 months. Dilute one sachet in 100ml of water and take it in every morning.
1561033|NCT02519543|Drug|Placebo|placebo to be given twice daily, once with breakfast and once with supper
1561034|NCT02519543|Drug|Metformin|active experimental drug to be given twice a day, 500 mg with breakfast and 1,000 mg with supper.
1561035|NCT02519530|Behavioral|Teen Outreach Program|The Teen Outreach Program (TOP) is a positive youth development program that uses weekly educational peer group sessions, Community Service Learning (CSL), and positive adult guidance to help youth in grades 6-12 build healthy behaviors, life skills, and a sense of purpose. For this study, TOP was implemented in traditional public high schools in Florida and delivered by local health department staff, who were trained and certified as TOP facilitators. Youth enrolled in these classes received the TOP intervention in addition to, not as a replacement for, all business-as-usual curriculum content.
1561036|NCT02519517|Procedure|Permissive hypercapnia|During one lung ventilation, right ventricular function was assessed by transesophageal echocardiography (TEE) and the effect of increased carbon dioxide pressure was evaluated
1561037|NCT02519491|Other|Modified Allen Test|The Modified Allen's Test (MAT) will be performed in a well-lit room on both of the participant's hands. This technique will involve compression of both the radial and ulnar arteries by the investigator to assess patency of the contralateral artery. The participant will then be asked to clench and open their hand several times. The participant will then be asked to maintain their hand in an open position. The investigator will then release the compression over the ulnar artery and observe for palmar blush. The length of time to achieve maximal palmar blush will be recorded. This technique will then be repeated by maintaining compression over the ulnar artery and releasing of the compression over the radial artery.
1561038|NCT02519491|Other|Iphone artery assessment|The iRADIAL iPhone app (Heart Rate, Azumio software) will be used to assess radial and ulnar artery patency. Briefly, the iPhone camera will be placed over the participant's thumb and patency assessed before and immediately following isolated contralateral artery compression for a maximum of two minutes.
1561039|NCT02519478|Behavioral|Helmetless Tackling Training (HuTT)|see previous sections
1561040|NCT02519465|Other|10l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 10l/min
1561041|NCT02519465|Other|30l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 30l/min.
1561042|NCT02519465|Other|50l/min|For inhalation was used diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) and 0.9% saline solution with a total volume of 1 ml using vibrating mesh inhaler (Aerogen Ltd, Galway , Ireland) with the respiratory care system for the high flow ( Fisher & Paykel healthcare, New Zealand) and nasal cannula (Fisher & Paykel healthcare, New Zealand) with flow 50l/min.
1561046|NCT02519426|Procedure|Mandibular third molar surgery|Mandibular third molar surgery is a mandibular wisdom tooth removal procedure in which surgical access is required to completely remove a tooth. Even if the tooth is visible in the mouth without surgically exposing it, surgical techniques may be necessary to remove the tooth. This includes sectioning the tooth into two or more pieces, corticotomy, and removal with forceps and elevators, whether or not a soft tissue incision is made.
1561047|NCT02519413|Drug|dimethyl fumarate|delayed release capsules
1561048|NCT02519400|Drug|Amitriptyline|Single oral dosing
1561049|NCT02519387|Drug|Buprenorphine Transdermal Patch|
1561050|NCT02519374|Drug|Placebo (including Maltodextrin)|
1561051|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 1
1561052|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 2
1561053|NCT02519374|Drug|PROMITOR® (including Maltodextrin)|Investigational product dose 3
1561057|NCT02519335|Drug|Dexrazoxane|Dose escalation every 4 subjects from 200mg/m2/dose; 300mg/m2/dose to 400mg/m2/dose
1561058|NCT02519322|Drug|Nivolumab 1mg/kg|Group B Neoadjuvant Phase: Nivolumab 1 mg/kg by vein every 3 weeks on weeks 1, 4 and 7 prior to surgical excision.
1561059|NCT02519322|Drug|Ipilimumab|Group B Neoadjuvant Phase: Ipilimumab 3 mg/kg by vein every 3 weeks on weeks 1, 4 and 7 prior to surgical excision.
1561060|NCT02519322|Drug|Nivolumab 3 mg/kg|"Group A Neoadjuvant Phase: Nivolumab 3 mg/kg by vein every 2 weeks on weeks 1, 3, 5 and 7 prior to surgical excision.
Group A Adjuvant Phase: Nivolumab 3 mg/kg by vein every 2 weeks postoperatively for 6 months.
Group B Adjuvant Phase: Nivolumab 3 mg/kg by vein every 2 weeks postoperatively for 6 months."
1561061|NCT02519309|Other|Virta Program|In-person administration vs Virtual administration of dietary intervention
1561062|NCT02519296|Behavioral|Prolonged Exposure Therapy|8 sessions with prolonged exposure therapy and fMRI.
1561063|NCT02519296|Behavioral|Observation|fMRI.
1561064|NCT02519296|Device|fMRI|Functional Magnetic Resonance Imaging of the brain
1561065|NCT02519283|Behavioral|GUIDED-HF|"Participants in this arm will receive a tailored discharge plan via a transition nurse coordinator directed team (TNC Team).
Disease education: Health literacy screen will identify barriers to understanding discharge and medication instructions.
Lifestyle interventions: Includes receiving smoking cessation information and instructions to track daily weights.
Guideline recommendations for medications and device referral: Includes determining the need for prescriptions for ACEIs, ARBs, beta blockers, aldosterone antagonists, anticoagulants and referral for pacemaker/defibrillator consideration.
Outpatient follow-up appointment: TNC Team will provide a scheduled appointment within 7 days and will conduct a home visit within 48 hours of ED discharge."
1561066|NCT02519283|Behavioral|Standard of Care|"Those in the standard care arm will receive structured ED discharge assessment to include:
discharge instructions;
medication reconciliation
encourage follow-up."
1561068|NCT02519257|Procedure|CAD|Patients with CAD diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
1561069|NCT02519257|Procedure|VHD|Patients with valve diseases proposed to have cardiac operations will be enrolled in this study, but those with congestive heart failure are excluded. Besides, those patients with valve diseases should have patent coronary arteries on coronary angiography.
1561070|NCT02519244|Device|Ekso® (Wearable lower limb exoskeleton)|The wearable lower limb exoskeleton is a powered, robotic lower limb exoskeleton with actuated hips and knees. A control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
1561071|NCT02519231|Drug|Naproxen|Naproxen 440mg 1x pid
1561072|NCT02519231|Drug|Placebo|Placebo tablet 440mg 1x pid
1561073|NCT02519218|Device|Ellipse Technologies Intramedullary High Tibial Osteotomy Nail System|
1561074|NCT02519205|Other|Survey|
1561075|NCT02519192|Device|V.A.C.Ulta™ Negative Pressure Wound Therapy System|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
1561076|NCT02519192|Procedure|Vac sponge irrigations|VAC Arm will consist of a group of patients assigned to VAC negative pressure therapy with regular sponge irrigation with normal saline (the V.A.C.Ulta™ Negative Pressure Wound Therapy System) .
1561077|NCT02519192|Procedure|ostomy bag applications|Non Vac Arm will receive ostomy bag applications.
1561078|NCT02519192|Procedure|wet to dry dressing changes|Non Vac arm will receive wet to dry dressing changes.
1561079|NCT02519179|Behavioral|Opaque, weighted bottle|This is the experimental condition; mothers will be asked to feed their infants from an opaque, weighted bottle.
1561080|NCT02519179|Behavioral|Clear, conventional bottle|This is the control condition; mothers will be asked to feed their infants from a clear, conventional bottle.
1561081|NCT02519166|Biological|1 clinical examination of the wound, 1 sample taken with the curette, 1 sample by swabbing|
1561082|NCT02519153|Drug|Sildenafil|placebo will take nitrofuratoin once daily for 4 weeks . sildenafil arm will take sildenafil 50 mg once daily for 4 weeks
1561083|NCT02519140|Drug|Cook Medical EMR Gel|Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
1561084|NCT02519127|Other|Low glycaemic load diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a low glycemic load diet for 6 weeks.
1561085|NCT02519127|Other|Western diet|Subjects will first be subjected to a 2-week run-in diet consisting of products that fit into a typical 'Western' diet. Thereafter subjects will be allocated to a 'Western' diet for 6 weeks.
1561086|NCT02519114|Procedure|Donor Bone Marrow stem cell transplantation|KIR-mismatched haploidentical Bone Marrow stem cell transplantation
1561087|NCT02519101|Device|continuous noninvasive blood pressure monitoring ClearSight-Device|Noninvasive continuous blood pressure monitoring using the volume clamp method (ClearSight-Device)
1561088|NCT02519075|Other|No intervention|Observational study
1561089|NCT02519062|Other|No intervention|This is a retrospective study
1561090|NCT02519049|Other|No intervention|This is an observational study
1561091|NCT02519036|Drug|IONIS HTTRx|
1561092|NCT02519036|Drug|Placebo|
1561093|NCT02519023|Drug|Liposomal Bupivacaine|In one arm the TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine injected followed by 20 mL of a 50:50 mixture of liposomal bupivacaine and normal saline. This will then be repeated on the contralateral side.
1561094|NCT02519023|Drug|Bupivacaine|Surgical Infiltration of the study solution will be performed both prior to incision and at the end of surgery just prior to closure of incisions. At each time, the surgeon will inject 5 mL of 0.25% bupivacaine into each of the port site incisions.
1561095|NCT02519023|Device|Ultrasound|An ultrasound, which is a beam of high frequency sound that allows one to visualize images in the body, will be used to aid investigators to observe the local anesthetic being infiltrated into the plane
1561096|NCT02519023|Drug|Epinephrine|TAP infiltration will contain 10 mL of 0.25 % bupivacaine with epinephrine.
1561097|NCT02519023|Drug|acetaminophen|all individuals will receive scheduled acetaminophen (1 gram every 6 hours),
1561098|NCT02519023|Drug|ibuprofen|all individuals will receive scheduled ibuprofen (800 mg every 8 hours)
1561099|NCT02519023|Drug|Oxycodone|all individuals will receive PRN oxycodone 5-10mg q4h if pain is rated at more than 5 out of 10 on a numerical pain scale.
1561100|NCT02519010|Drug|Amlodipine/Valsartan|1 tablet contains Amlodipine 10 mg &valsartan 160 mg
1561101|NCT02519010|Drug|Exforge|1 tablet contains Amlodipine 10 mg &valsartan 160 mg
1561102|NCT02518997|Other|Parental Reading Aloud|Infants will be exposed to parental reading aloud or to a recording of the parent's voice reading during times of cardio-respiratory monitoring.
1561103|NCT02518971|Drug|Tamsulosin|0.4 mg daily
1561104|NCT02518971|Drug|Placebo|one capsule daily
1561105|NCT02518958|Drug|RRx-001|
1561106|NCT02518958|Drug|Nivolumab|
1561107|NCT02518945|Drug|Dapagliflozin|Dapagliflozin or Farxiga is a SGLT-2 inhibitor
1561109|NCT02518945|Drug|Liraglutide|Victoza(Liraglutide) is a GLP-1 agent.
1561110|NCT02518945|Drug|Dapagliflozin placebo|Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
1561111|NCT02518932|Drug|Last 5 amino acids of GLP-1|To examine insulinomimetic properties of LVKGR
1561112|NCT02518932|Drug|placebo saline|
1561115|NCT02518906|Behavioral|Adolescent Identity Treatment|"Integrative Approach for the treatment of adolescents with Personality Disorder.
Manual was published in 2013."
1561116|NCT02518906|Behavioral|DBT-A|Dialectic Behavioral Treatment for Adolescents is the most commonly used Approach for the Treatment of adolescents with Boderline Personality Disorder
1561117|NCT02518893|Other|Demographic Data|Demographic data will be collected from up to 50 service members who have participated in health research or who have previously declined research participation.
1561118|NCT02518893|Other|Interview|Up to 40 service members will participate in individual, in-depth, semi-structured interviews in person or via telephone.
1561119|NCT02518880|Other|Parabolic flight|
1561120|NCT02518880|Other|plasma volume measurements|
1561121|NCT02518867|Other|high intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (high intensity , 100% of active motor threshold) TBS for 3 days.
1561122|NCT02518867|Other|low intensity iTBS|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low intensity, 80% of active motor threshold) TBS for 3 days.
1561123|NCT02518867|Other|sham iTBS|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment.
1561124|NCT02518841|Device|ThermaWedge TM|ThermaWedge TM is a foam wedge device that is designed to be used in the treatment of plantar fasciopathy.
1561125|NCT02518841|Other|Achilles Tendon Stretching|Participants will be asked to perform achilles tendon stretching exercises which will be demonstrated at the initial orientation.
1561126|NCT02518828|Other|High SpO2|SpO2 range ≥96%
1561127|NCT02518828|Other|Low SpO2|SpO2 range 90-92%
1561128|NCT02518815|Device|3M Bair Paws Warming System|20 minutes of prewarming immediately pre-operatively using 3M Bair Paws warming system
1561129|NCT02518802|Drug|Gefitinib|Gefitinib 250mg per day for 2 years.
1561130|NCT02518802|Drug|Pemetrexed|Pemetrexed, 500mg/m2, day 1; Cisplatin 75mg/m2, day 1. Three weeks as a cycle. Four cycles in total.
1561131|NCT02518789|Drug|Low-dose Dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 0.5 µg/kg ，completed within 15 minutes.
1561132|NCT02518789|Drug|High-dose dexmedetomidine|Pretreatment：Intravenous injection dexmedetomidine 1 µg/kg ，completed within 15 minutes.
1561133|NCT02518789|Drug|normal saline|Pretreatment：Intravenous injection normal saline equal quantity，completed within 15 minutes.
1561134|NCT02518789|Drug|Etomidate|"After 90 seconds of Pretreatment，intravenous infusion of etomidate fat emulsion 0.3mg/kg.
-Does not offer any other drugs within 5 min after completion of etomidate."
1561135|NCT02518789|Drug|midazolam，fentanyl，rocuronium|Anesthesia induction：Intravenous injection midazolam 0.03 ~ 0.05 mg/kg, fentanyl 5 ~ 8 g/kg, rocuronium 0.6 mg/kg
1561136|NCT02518789|Drug|propofol，remifentanil，cis atracurium|Anesthesia maintenance：Intravenous infusion of propofol 4 ~ 6 mg/kg/h, remifentanil 0.1 ~ 0.3 μg/kg/min, intermittent intravenous injection of cis atracurium 0.05 ~ 0.1mg/kg
1561137|NCT02518776|Behavioral|Neuropsychological tests|Neuropsychological tests
1561138|NCT02518763|Drug|Vitamin D3, 100 000 IU weekly, 4 times|
1561139|NCT02518763|Biological|25 OH vitamin D serum concentration measurements|
1561140|NCT02518750|Drug|Dexamethasone|Given orally (PO).
1561141|NCT02518750|Drug|Panobinostat|Given PO.
1561142|NCT02518750|Drug|Liposomal vincristine|For intravenous (IV) use only.
1561143|NCT02518750|Drug|Mitoxantrone|Given IV.
1561144|NCT02518750|Drug|Peg-asparaginase|"Given IV or intramuscularly (IM).
In case of allergy or intolerance to Peg-asparaginase, Erwinia L-asparaginase (Erwinase®) will be used. Erwinia L-asparaginase is given by either IV or IM injection."
1561145|NCT02518750|Drug|Bortezomib|Given by IV push over 3 to 5 seconds. For IV use only.
1561146|NCT02518750|Drug|Intrathecal Triples|Given IT as ITMHA.
1561147|NCT02518750|Drug|High-dose methotrexate|Given intrathecally (IT) or IV.
1561148|NCT02518750|Drug|6-Mercaptopurine|Given PO at consistent time each day.
1561149|NCT02518750|Drug|High-dose cytarabine|Given IT or IV.
1561150|NCT02518750|Drug|Nelarabine|Given IV
1561151|NCT02518750|Drug|Cyclophosphamide|Given IV.
1561152|NCT02518750|Drug|Etoposide|"Given IV.
In case of etoposide reactions, IV etoposide phosphate (Etopophos®) will be used."
1561153|NCT02518750|Drug|Clofarabine|"Given IV.
Clofarabine will be given instead of nelarabine for patients with B-lymphoblastic leukemia and lymphoma in stratum II."
1561154|NCT02518737|Other|Meal Test|
1561155|NCT02518724|Procedure|RIPC intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 200 mmHg for 5 min followed by 5 min without pressure X 4 repeats
1561156|NCT02518724|Procedure|placebo intervention exposure|placing a sphygmomanometer on the non-dominant hand and applying pressure of 100 mmHg for 5 min followed by 5 min without pressure X 4 repeats.
1561157|NCT02518711|Behavioral|Behavioral Teacher Program|This program was based on the evidence-based Summer Treatment Program (MTA Cooperative Group, 1999), involving psycho-education for the teacher and universal and individual behavioral techniques that focused on classroom structure and contingency management
1561159|NCT02518685|Device|TransPyloric Shuttle|
1561160|NCT02518685|Behavioral|lifestyle counseling|
1561162|NCT02518672|Dietary Supplement|MAG-DHA|MAG-DHA 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
1561163|NCT02518672|Dietary Supplement|Placebo|Placebo (sunflower oil) 8 x 625 mg softgels by mouth, every day at bedtime for 90 days.
1561164|NCT02518659|Dietary Supplement|Inulin|This is the Intervention
1561165|NCT02518633|Device|Continuous positive airway pressure devices|overnight use of CPAP device
1561166|NCT02518620|Biological|ALX-0061|Multicenter open-label extension study
1561167|NCT02518607|Drug|MGB-BP-3|Treatment of CDI
1561168|NCT02518607|Other|Placebo|Placebo
1561169|NCT02518594|Drug|Vaginal progesterone|200mg micronized vaginal progesterone softgel capsule, daily from randomization to < 35 wks
1561170|NCT02518594|Drug|Placebo|placebo softgel capsule, daily from randomization to < 35 wks
1561171|NCT02518594|Device|Arabin Pessary|Placement management from randomization to < 35 wks
1561172|NCT02518581|Procedure|Doubly labelled water method|DLW (doubly labeled water) method measures isotope dilution spaces and elimination rates to assess total energy expenditure (TEE). After enriching the body water of a subject with DLW (2H and 18O), it is only necessary to collect urine samples at defined time points, usually over a period of 1-2 weeks, so that the measurement can be done in individuals able to engage in their typical habits without restrictions. The resulting TEE measurement represents an integral value over the measurement period.
1561173|NCT02518568|Drug|V0355|Oral administration (2 tablets)
1561174|NCT02518555|Biological|Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed|Given IM
1561175|NCT02518555|Drug|Ibrutinib|Given PO
1561176|NCT02518555|Other|Laboratory Biomarker Analysis|Correlative studies
1561177|NCT02518555|Other|Pharmacological Study|Correlative studies
1561178|NCT02518555|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
1561179|NCT02518555|Other|Quality-of-Life Assessment|Ancillary studies
1561180|NCT02518555|Biological|Trivalent Influenza Vaccine|Given IM
1561181|NCT02518542|Procedure|Endoscopic intervention A|POEM: Per oral endoscopic myotomy
1561182|NCT02518542|Procedure|Endoscopic intervention B|PRD: Prolonged dilatation by temporary implantation of large diameter stent . Stents are additionally attached to the esophageal wall by different technical options.
1561183|NCT02518542|Procedure|Endoscopic intervention C|Endoscopic balloon dilatation
1561184|NCT02518542|Procedure|Laparoscopic Surgery|Laparoscopic Heller myotomy
1561185|NCT02518529|Biological|G17DT|
1561186|NCT02518516|Drug|Rosuvastatin (≥10 mg)|"Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed >120 days of the index date (i.e. no exposure within 120 days of the index date)."
1561187|NCT02518516|Drug|Atorvastatin (≥20 mg)|"Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
1561188|NCT02518516|Drug|Simvastatin (≥40 mg)|"Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
1561189|NCT02518516|Drug|Fluvastatin|"Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
1561190|NCT02518516|Drug|Pravastatin|"Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to pravastatin will be defined as a prescription for any dose of pravastatin (ATC C10AA03) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
1561191|NCT02518516|Drug|Lovastatin|"Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to lovastatin will be defined as a prescription for any dose of lovastatin (ATC C10AA02) dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
1561192|NCT02518516|Drug|Atorvastatin (<20mg)|"Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
1561193|NCT02518516|Drug|Simvastatin (<40 mg)|"Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-365 days, or 366-730 days).
Past exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed >120 days prior to the index date (i.e. no exposure within 120 days of the index date)."
1561194|NCT02518503|Drug|Rosuvastatin (≥10 mg)|Current cumulative exposure to high dose rosuvastatin (ATC C10AA07) will be defined as a prescription for ≥10 mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
1561296|NCT02517775|Dietary Supplement|Cranberry deprived supplement|Cranberry deprived supplement Acute intake of 500 mL (1x daily)
1561297|NCT02517762|Behavioral|Physical activity|
1561195|NCT02518503|Drug|Atorvastatin (≥20 mg)|Current cumulative exposure to high dose atorvastatin (ATC C10AA05) will be defined as a prescription for ≥20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
1561196|NCT02518503|Drug|Simvastatin (≥40 mg)|Current cumulative exposure to high dose simvastatin (ATC C10AA01) will be defined as a prescription for ≥40 mg of simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
1561197|NCT02518503|Drug|Fluvastatin|Current cumulative exposure to fluvastatin (ATC C10AA04) will be defined as a prescription for any dose of fluvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
1561198|NCT02518503|Drug|Pravastatin|Current cumulative exposure to pravastatin (ATC C10AA03) will be defined as a prescription for any dose of pravastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
1561199|NCT02518503|Drug|Lovastatin|Current cumulative exposure to lovastatin (ATC C10AA02) will be defined as a prescription for any dose of lovastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
1561200|NCT02518503|Drug|Rosuvastatin (<10mg)|Current cumulative exposure to low dose rosuvastatin (ATC C10AA07) will be defined as a prescription for <10mg of rosuvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
1561201|NCT02518503|Drug|Atorvastatin (<20mg)|Current cumulative exposure to low dose atorvastatin (ATC C10AA05) will be defined as a prescription for <20 mg of atorvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
1561202|NCT02518503|Drug|Simvastatin (<40 mg)|Current cumulative exposure to low dose simvastatin (ATC C10AA01) will be defined as a prescription for <40 mg simvastatin dispensed prior to the index date in one of the following exposure duration categories (≤120 days, 121-<365 days, or 366-730 days).
1561203|NCT02518477|Other|exercise|progressive resistance training
1561204|NCT02518464|Drug|Ticagrelor 90 mg twice per day|Patients will be loaded with 180 mg of Ticagrelor during the enrollment office visit and provided with a 28 day supply of Ticagrelor, 90 mg twice per day. P2Y12 reactivity unit (PRU) testing will be conducted at 7-14 days. If the patient has a positive response, they will have the option of continued access of Ticagrelor 180 mg for another 2 months. Participants will be reminded via text message daily to complete a headache survey on line in order to track their headaches.
1561205|NCT02518451|Drug|Valsartan 160 mg film-coated caplets (test formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
1561206|NCT02518451|Drug|Valsartan 160 mg film-coated caplets (reference formulation)|In each of the two study periods (separated by a washout of one week) a single dose of test or reference formulation was administered.
1561207|NCT02518438|Drug|Tramadol|A preprepared 20 ml solution was subcutaneously infiltrated after closure of the uterine incision and the rectus fascia.
1561208|NCT02518412|Other|tDCS|Transcranial Direct Current Stimulation (tDCS) is a non-invasive treatment method, using a low Direct current stimulation to increase excitability and thus stimulate plasticity and cognitive functions.
1561209|NCT02518412|Other|Placebo tDCS|Half of the patients will receive Placebo tDCS. The procedure is the same as for active tDCS, but the in the Placebo tDCS the stimulation is non-active / sham.
1561212|NCT02518386|Other|No intervention|No intervention is planned
1561213|NCT02518373|Biological|G17DT|G17DT is a therapeutic immunogen, formulated as a white, sterile, semi-viscous, water-in-oil emulsion (30:70 weight for weight). It was manufactured and supplied by Nova Laboratories Ltd., in glass ampoules containing 0.5 mL at a concentration of 1.25 mg/mL, as a single dose to be administered by intramuscular injection.
1561214|NCT02518373|Drug|Omeprazole|Proton pump inhibitor used in the treatment of dyspepsia, peptic ulcer disease, gastroesophageal reflux disease, laryngopharyngeal reflux, and Zollinger-Ellison syndrome.
1561215|NCT02518360|Other|Osteopathic|Body adjustment in three sessions (20 minutes/session).
1561216|NCT02518360|Other|Auto Stretching|The patients realize auto stretching in three sessions (20 minutes/session).
1561217|NCT02518347|Dietary Supplement|FDS-Strawberry|Natural frozen and dried strawberries
1561218|NCT02518347|Dietary Supplement|Placebo|Placebo powder matched for carbohydrates and fiber in the strawberries
1561220|NCT02518321|Device|Technology-Assisted Toileting|
1561222|NCT02518295|Other|Positive control|200ml milk containing 18g lactose
1561223|NCT02518295|Other|Probiotic S. thermophilus|200ml milk containing 18g lactose + probiotic S. thermophilus
1561224|NCT02518295|Other|Probiotic B. longum|200ml milk containing 18g lactose + probiotic B. longum
1561225|NCT02518295|Other|Negative control|200 ml of UHT Lactose free milk
1561226|NCT02518282|Other|Serum levels of high-sensitivity troponin T|Serum levels of hs-cTn will be measured before surgery, upon arrival at the ICU, as well as every 6 hours for 24 hours, then every 8 hours the following 24 hours and a last blood sample will be taken 72 hours after surgery.
1561227|NCT02518282|Other|Twelve-lead ECGs|Twelve-lead ECGs obtained the day prior to heart valvular surgery, immediately upon arrival at the ICU, and then 24, 48 and 72 hours post-surgery will be reviewed by a cardiologist to evidence signs of MI.
1561298|NCT02517749|Device|Chest Drain Insertion and Talc Pleurodesis|
1561228|NCT02518282|Other|Transthoracic echocardiography (TTE)|A TTE will be also performed by a cardiologist after cardiac valvular surgery to determine the ejection fraction of left ventricle and the occurrence of a new regional wall motion abnormality. This TTE will be compared, by the same cardiologist, with a TTE performed before cardiac valvular surgery.
1561229|NCT02518269|Procedure|Hip Arthroplasty|Hip Arthroplasty comparing 3 different bearings.
1561230|NCT02518256|Procedure|Lavage of the Cavum uteri and proximal fallopian tubes|
1561231|NCT02518243|Other|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :
aromatherapy
music therapy
cognitive training in multimedia application offering cognitive games"
1561232|NCT02518230|Device|Neurally Adjusted Ventilatory Assist|The subject will be crossed over from the baseline ventilator mode to Neurally Adjusted Ventilatory Assist
1561233|NCT02518230|Device|Synchronized Interm. Mandatory Assist|The subject will be crossed over from the baseline ventilator mode to Synchronized Intermittent Mandatory Assist with Pressure Support
1561234|NCT02518217|Behavioral|Weight Loss Apps|Provision of commercially available smartphone applications for healthy eating, physical activity, and weight loss.
1561235|NCT02518217|Behavioral|ShapeUp Empower|Online intervention with training in behavioral strategies for healthy eating, physical activity, and weight loss. Includes periodic feedback on weight loss progress and engagement with the intervention platform.
1561236|NCT02518217|Behavioral|Financial Incentives for Engagement|Financial incentives for completing tasks such as viewing instructional information and reporting self-monitored body weights via the study website.
1561237|NCT02518204|Other|BPT|Brain Performance Test (BPT) computerized cognitive assessment battery developed by Lumos Labs, Inc.
1561238|NCT02518204|Other|NP|"Conventional in-person Neuropsychological Assessments (NP)
Subtests from:
HRB: Halstead-Reitan Battery
MATRICS: Measurement and Treatment Research to Improve Cognition in Schizophrenia
WAIS-IV: Weschler Adult Intelligence Scale - IV"
1561239|NCT02518191|Drug|GnRHa|3.6mg subcutaneous injection every 28 days.Initiated 1-2 weeks before chemotherapy and ended 4-8 weeks after chemotherapy.
1561240|NCT02518178|Device|NFC Necklace|
1561241|NCT02518178|Device|Voice Reminder|Dialect-specific reminders will be issued to the mother's cell phone, informing about the upcoming immunization camp and the importance of vaccination
1561242|NCT02518178|Device|NFC Sticker|NFC Sticker on existing immunization card (MAMTA card) serves as a comparator to the pendant and pendant+voice call arms.
1561243|NCT02518165|Dietary Supplement|Proprietary spearmint extract|Water extracted spearmint extract
1561244|NCT02518165|Other|Placebo|Microcrystalline Cellulose
1561245|NCT02518152|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
1561246|NCT02518152|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
1561247|NCT02518152|Procedure|OFD with Platelet rich fibrin (PRF)+1% Alendronate|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF)+1% Alendronate placement into the bone defect
1561248|NCT02518139|Drug|TD-4208|There is not a placebo, there is a comparator (Tiotropium) arm, and the subjects are blinded to one of two doses of 4208 or un-blinded to Tiotropium.
1561249|NCT02518126|Other|blood sample and tissue sample|After birth and fetal umbilical cord disconnection, a blood sample will be taken from the umbilical cord (cord blood) of IUGR and of AGA fetuses (5cc) for cytokine ELISA testing. Also a small sample of the placenta will be examined in order to assess the level of ACTH protein in IUGR and AGA embryos
1561253|NCT02518100|Device|Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 3-Lead (NEHB) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
1561254|NCT02518100|Device|Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration|Vital signs will be taken using the Vital Signs Patch (VSP) System 1-Lead (PAL) Configuration on each study participant in each Arm of this study for comparison against the same vital signs taken with traditional methods used by the facility.
1561255|NCT02518087|Device|OXIRIS®|"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication [OXIRIS® (Baxter Gambro)].
PrismafleX eXeed™ II (Hospal) with OXIRIS® set will be irrigated with saline during preparation and irrigation of CPB circuit. PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.
OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
1561256|NCT02518074|Other|Hearing and Vestibular Interactions|in two body positions (standing / supine) and three gravity conditions (weightlessness hyper gravity and normal gravity).
1561257|NCT02518061|Other|No intervention|This is a retrospective study
1561258|NCT02518048|Drug|LEO 90100 Aerosol foam|
1561259|NCT02518048|Drug|Betesil® 2.25 mg|
1561260|NCT02518035|Drug|Silicone Gel|Silicone gel will be applied twice per day in the experimental group
1561261|NCT02518022|Drug|Insulin|Insulin for beer
1561262|NCT02518009|Other|Genetic men treated with estrogen|Observational during estrogen treatment
1561263|NCT02518009|Other|Genetic women treated with androgen|Observational during androgen treatment
1561299|NCT02517749|Device|Indwelling Pleural Catheter Insertion and Talc Pleurodesis|
1561300|NCT02517736|Drug|Sorafenib at a dose of 800 mg / day|
1561340|NCT02517489|Drug|Hydrocortisone|Hydrocortisone will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
1561682|NCT02515305|Drug|Placebo gel (combination)|
1561264|NCT02517996|Drug|Lidocaine|Total 20cc (10cc bilateral) of 1% Lidocaine: Lidocaine is a commonly used anesthetic agent suitable for infiltration, block and surface anesthesia. It is characterized by a rapid onset of action, intermediate duration of efficacy, and its elimination half-life is 90-120 minutes. Lidocaine alters signal conduction in neurons by blocking the fast voltage gated sodium (Na) channels in the neuronal cell membrane that are responsible for signal propagation. With sufficient blockage the membrane of the postsynaptic neuron will not depolarize and will thus fail to transmit an action potential. This creates the anesthetic effect by not merely preventing pain signals from propagating to the brain but by stopping them before they begin. Adverse drug reactions are rare when lidocaine is used as a local anesthetic and when administered correctly.
1561265|NCT02517996|Drug|Placebo|Patients randomized in this arm will receive preemptive bilateral pudendal nerve block with 20 cubic centimeters normal saline after anesthesia induction.
1561266|NCT02517983|Other|epidemiology|Relative prevalence of different chronic respiratory disease phenotypes
1561267|NCT02517970|Behavioral|Technology distraction|Infants will be fed with classical music playing in the background for one feeding and with a television show playing for the mother to watch during the other.
1561268|NCT02517957|Drug|Furoic acid loperamide hydrochloride cream|Apply to lesion area without erosion, drainage, 1 times a day, continuous use 1 week after according to disease reduction or withdrawal, the longest do not exceed 4 weeks. Pure dry area or no skin itching area should not be applied.
1561269|NCT02517957|Drug|Mullite ointment|Applies to a blister, pustule, erosion, ulcer, leaking or comorbid folliculitis, in skin lesions of 2 times a day, 5 days for one period of treatment, but for two consecutive period of treatment
1561270|NCT02517957|Drug|3% boric acid solution|3% boric acid solution is suitable for the erosion seepage skin, can open intermittent shi fu, 5-10 min each time, 2 times daily or several times.
1561271|NCT02517957|Drug|Zine oxide|In wet apply the break to zinc oxide preparation for external use only, when erosion seepage control is disabled in skin lesions.
1561274|NCT02517918|Drug|Sirolimus combined with CP, MT and ZA|"Cyclophosphamide, Methotrexate and Sirolimus will be administrated orally. Zoledronic Acid will be administrated by infusion (IV).
Trial based on a dose escalating study design assessing two dose levels of sirolimus when prescribed in combination with metronomic cyclophosphamide (CP), methotrexate (MT) and zoledronic acid (ZA) followed by an expansion cohort once the MTD is established."
1561275|NCT02517905|Drug|Bupivacaine liposome|Local administration
1561276|NCT02517905|Drug|Placebo|Local administration
1561277|NCT02517892|Procedure|Biopsy|
1561278|NCT02517879|Other|Community point distribution|Households were invited to a central location in their community (i.e. school, church, etc) where they received their allotment of ITNs (one per sleeping space, as pre-registered ahead of study activities). Households were provided with malaria prevention messaging at the distribution. They were called up one-by-one in front of other members of the community to mitigate misrepresentation of households.
1561279|NCT02517879|Other|Community health worker hang-up visit|CHWs visited households to take stock of how many ITNs that were distributed during the distribution were hung and to hang any unhung ITNs.
1561281|NCT02517853|Device|Posterior tibial nerve stimulation|
1561282|NCT02517853|Device|Sham posterior tibial nerve stimulation|
1561283|NCT02517827|Device|Atherectomy and paclitaxel-coated balloon angioplasty|Directional atherectomy and paclitaxel-coated balloon angioplasty (optional with stentimplantation) of the common femoral artery
1561284|NCT02517827|Procedure|Open, surgical endarterectomy|open, surgical endarterectomy of the common femoral artery
1561285|NCT02517814|Dietary Supplement|Vitamin D|
1561286|NCT02517801|Dietary Supplement|Anthocyanin capsules|Chronic intake of 2 capsules for 30 days (2x daily). Capsules with 80 mg of anthocyanins.
1561287|NCT02517801|Dietary Supplement|placebo capsules|Chronic intake of 2 capsules for 30 days (2x daily). 2 capsules devoid of anthocyanins.
1561288|NCT02517788|Drug|Interferon beta-1a HSA-free biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution without albumin
1561289|NCT02517788|Drug|Interferon beta-1a HSA+ biosimilar|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution combined with albumin solution
1561290|NCT02517788|Drug|Interferon beta-1a original|6 MIU/0.50 mL in pre-filled glass syringe solubilized in HSA and mannitol solution (marketed formulation)
1561291|NCT02517775|Dietary Supplement|Cranberry 320|Dietary Supplement: Cranberry beverage with 320 mg of (poly)phenols Acute intake of 500 mL (1x daily)
1561292|NCT02517775|Dietary Supplement|Cranberry 640|Dietary Supplement: Cranberry beverage with 640 mg of (poly)phenols Acute intake of 500 mL (1x daily)
1561293|NCT02517775|Dietary Supplement|Cranberry 960|Dietary Supplement: Cranberry beverage with 960 mg of (poly)phenols Acute intake of 500 mL (1x daily)
1561294|NCT02517775|Dietary Supplement|Cranberry 1280|Dietary Supplement: Cranberry beverage with 1280 mg of (poly)phenols Acute intake of 500 mL (1x daily)
1561295|NCT02517775|Dietary Supplement|Cranberry 1600|Dietary Supplement: Cranberry beverage with 1600 mg of (poly)phenols Acute intake of 500 mL (1x daily)
1561301|NCT02517723|Behavioral|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. The clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.
NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
1561302|NCT02517723|Behavioral|Dialectical Behavior Therapy|"Dialectical behavior therapy is a cognitive behavioral treatment program developed by Marsha Linehan to treat suicidal clients meeting criteria for BPD. It directly targets suicidal behavior, behaviors that interfere with treatment delivery, and other dangerous, severe, or destabilizing behaviors.
Via standard DBT patients improve behavioral capabilities, motivation for skillful behavior, generalization of gains to the natural environment, structuring the treatment environment so that it reinforces functional rather than dysfunctional behaviors. It also targets the therapist capabilities and motivation to treat patients effectively. Patients get weekly individual psychotherapy (1 h/wk), group skills training (3.75 h/wk), a weekly therapist consultation team meetings."
1561303|NCT02517723|Behavioral|Standard Inpatient Care|Unspecific group therapy that is identical in both groups (music therapy etc.)
1561304|NCT02517723|Other|Waiting List|Treatment as usual in the community (no DBT, no exposure of trauma memories)
1561305|NCT02517710|Procedure|Stratafix synthetic barbed suture|hysterotomy closure in Cesarian section
1561306|NCT02517697|Drug|14 Nitrogen (N) Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 12 weeks
1561307|NCT02517697|Drug|Placebo|oral formulation of matching placebo three times daily for 12 weeks
1561308|NCT02517684|Drug|Infliximab|
1561309|NCT02517684|Drug|Prednisolone|
1561310|NCT02517684|Other|Exclusive enteral nutrition|
1561311|NCT02517684|Drug|Azathioprine|
1561312|NCT02517671|Device|Enhanced External Counterpulsation (EECP)|EECP is a non-invasive therapy that has been approved by the United States Food and Drug Administration (FDA) for the management of refractory angina and heart failure. This study is using the device to potentially improve 1.5 mile run times and VO2max in healthy volunteers.
1561315|NCT02517632|Behavioral|Exercise, nutritional and pharmaceutical counceling|The exercise group will be submitted to a physical exercise intervention protocol performed three times per week, 60 minutes per session, during 6-month period, and a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
1561316|NCT02517632|Behavioral|Nutritional and pharmaceutical counceling|The control group will be submitted to a monthly counseling from pharmaceutical and nutritional professionals provided during the follow-up and consisted on general guidance about healthy eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
1561317|NCT02517619|Drug|Dexamethasone Phosphate Ophthalmic Solution|40 mg/mL
1561318|NCT02517619|Drug|Prednisolone Acetate Ophthalmic (1%)|Prednisolone Acetate (1%)
1561319|NCT02517606|Other|Conventional physical therapy plus HPCS|Conventional physical therapy plus the addition of hip posterolateral complex strengthening
1561320|NCT02517606|Other|Conventional physical therapy|Conventional physical therapy (combination of manual therapy techniques and exercises for spinal segmental stabilization)
1561327|NCT02517554|Behavioral|Penn genetic counselors provides counseling and test results disclosure by videoconferene to patient at community site|Baseline and follow up survey
1561328|NCT02517554|Behavioral|Penn genetic counselor provides counseling and test results disclosure by telephone to patient at community site|Baseline and follow up surveys
1561329|NCT02517554|Behavioral|Patient receives written information on how to find genetic services in their area|Baseline and follow up surveys
1561330|NCT02517541|Device|SenSura Mio Convex Soft|SenSura Mio Convex Soft is a CE marked ostomy product manufactured by Coloplast
1561331|NCT02517528|Drug|ABT-450/r/ABT-267|Tablet
1561332|NCT02517528|Drug|ABT-333|Tablet
1561333|NCT02517528|Drug|Ribavirin|Tablet
1561338|NCT02517502|Drug|DHA|4 capsules of 400 mg DHA daily
1561339|NCT02517502|Drug|Placebo|Matched, blinded placebo
1561380|NCT02517229|Other|Parabolic flight|
1561381|NCT02517229|Other|balance control measurements|
1561382|NCT02517229|Device|electromagnetic maneuverable postural platform|
1561383|NCT02517216|Other|parabolic flight|
1561384|NCT02517216|Device|MRI|
1561385|NCT02517190|Other|Parabolic flight|
1561341|NCT02517489|Drug|Placebo|Placebo will be given in a double-blind fashion for 8 or 14 full days. The intravenous route will be used. The treatment course will include 4 or 7 days of full dose (200 mg/day by continuous infusion), 2 or 4 days of half dose (100 mg/day by continuous infusion), and 2 or 3 days of tapering dose (50 mg/day by continuous infusion). Duration of treatment is chosen upon patient initial improvement.
1561344|NCT02517450|Behavioral|an adventure-based training programme|The programme consisted of five education sessions (around 75 minutes each) and a day's adventure-based training camp at the end of the academic year
1561345|NCT02517450|Other|a placebo control programme|Subjects in the control group were invited to attend five 75-minute sessions of leisure activities, organised by a community centre, which included a cartoon film show, handicraft workshops, a health talk on the prevention of influenza and age-appropriate physical leisure activities, such as table tennis, badminton, chess and Chinese billiards. Additionally, they were invited to join a day visit to Hong Kong Ocean Park at the end of the academic year.
1561346|NCT02517437|Drug|Suprascapular & axillary blocks|After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots to achieve circumferential spread around the nerve.The axillary nerve block will be performed next in the posterior aspect of the operative arm. The neurovascular bundle encompassing the humeral artery, posterior circumflex artery, and axillary nerve is visualized in the lateral edge of the quadrangular space, deep to the deltoid muscle, inferior to the teres minor muscle, and superior to the triceps tendon. After infiltration with 1 mL of 1% lidocaine, local anesthetics (20 mL of 0.5% ropivacaine) will then be injected in 5 mL aliquots after negative aspiration to achieve circumferential spread around the bundle.
1561347|NCT02517437|Drug|Interscalene block|After sterile skin preparation with chlorhexidine and infiltration with 1 mL of 1% lidocaine, a 5 cm 22 G insulated needle is then inserted and local anesthetic solution (20 mL of 0.5% ropivacaine) will be injected in 5 mL aliquots after negative aspiration for blood to achieve spread posterior to or between the C5 and C6 nerve roots.
1561348|NCT02517424|Drug|High THC/Low CBD Cannabis|Dried cannabis
1561349|NCT02517424|Drug|High THC/High CBD Cannabis|Dried cannabis
1561350|NCT02517424|Drug|Low THC/Low CBD Cannabis|Dried cannabis
1561351|NCT02517411|Other|Standard care|The standard care of stable COPD is based on long-acting bronchodilators (LABD).
1561352|NCT02517411|Other|Physiotherapy added to standard care|The treatment will be based on domiciliary physiotherapy program during 8 weeks, twice a week added to standard care. The duration of the sessions will be 45-60 minutes. The physiotherapy treatment includes: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband. This will be a home-based program supervised by a physiotherapist.
1561353|NCT02517398|Drug|MSB0011359C|Subjects will receive intravenous infusion of MSB0011359C once every 2 weeks in a dose escalation fashion until confirmed progression, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product (IMP) occurs.
1561354|NCT02517385|Drug|Phosphatidylcholine|Pharmaceutical form:Paste Route of administration: Oral
1561355|NCT02517372|Drug|CRD007|
1561356|NCT02517359|Drug|RV6153 single dose|Safety and tolerability of single doses
1561357|NCT02517359|Drug|RV6153 matching placebo single dose|Safety and tolerability of single doses
1561358|NCT02517359|Drug|RV6153 14 day repeat dose|Safety and tolerability of repeat doses
1561359|NCT02517359|Drug|RV6153 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
1561360|NCT02517359|Drug|RV6153 28 day repeat dose|Safety and tolerability of repeat doses
1561361|NCT02517359|Drug|RV6153 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
1561362|NCT02517346|Other|Standard follow-up|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
1561363|NCT02517346|Other|Telemonitoring|Follow up by telemonitoring system during 3 months
1561364|NCT02517333|Other|EPIC Club|Weekly exercise gym sessions (1-2 times weekly) for 45-60 mins each session. Participants will start with a warm-up of 30 mins cardiovascular training either doing cycling, treadmill running or cross-training. The remainder of the session consists of strength/resistance and weight-training involving leg press, leg extensor, pull downs, kettle bells, dumbbells. Gym sessions aim to involve bursts of high-intensity and monitoring of heart rate (potentially with wrist activity monitors with heart rate monitoring and accelerometers) to identify level of physical activity intensity. Participants will also have the opportunity to engage in 'Have a go' sports days run by the Oxfordshire Sports Partnership.
1561365|NCT02517320|Drug|MT-3995 Low|
1561366|NCT02517320|Drug|MT-3995 Middle|
1561367|NCT02517320|Drug|MT-3995 High|
1561368|NCT02517320|Drug|Placebo|
1561369|NCT02517307|Drug|Intralipid/Heparin|Co-infusion of intralipid and heparin solutions during a hyperinsulinemic euglycemic clamp
1561370|NCT02517307|Drug|Glycerol/Saline|Co-infusion of a glycerol/saline solutions during a hyperinsulinemic euglycemic clamp
1561371|NCT02517307|Drug|Hyperinsulinemic euglycemic clamp|Infusion of insulin at at 40 mU/m2/min for 5 hours. Blood glucose will be monitored every 5 min during the insulin infusion and euglycemia will be maintained throughout the clamp by infusing 20% dextrose at a variable rate.
1561372|NCT02517294|Device|Parker flex-tip nasotracheal tube|specially designed nasotracheal tube used for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
1561373|NCT02517294|Device|Standard nasotracheal tube|standard nasotracheal tube for nasotracheal intubation assess nasopharynx for severity of bleeding grade adenoid size
1561374|NCT02517281|Procedure|Biopsy|
1561375|NCT02517268|Procedure|Pancreaticoduodenectomy|
1561376|NCT02517255|Device|Cardiac Magnetic Resonance Imaging|7 day-Cardiac MRI: T1 and T2 images; 3 and 6 month-Cardiac MRI: T1, T2 and stress perfusion images
1561377|NCT02517242|Device|Pens Device|
1561378|NCT02517242|Device|Syringe|
1561379|NCT02517242|Other|Monitoring capillary blood glucose with blood glucose monitor, lancet tapes and capillary blood glucose tests (3 tests/day)|
1561386|NCT02517190|Other|neuro-endocrine measurements|psychic stress tests, stress hormones: prolactin, cortisol, endo-cannabinoids
1561387|NCT02517190|Other|immunological measurements|blood cell counts, B2 integrins, cytokines, C-reactive protein
1561388|NCT02517190|Other|cellular energy metabolism measurements|purines, lactate
1561389|NCT02517177|Other|Parabolic flight|
1561390|NCT02517177|Other|Cardiovascular parameters measurements|
1561391|NCT02517164|Other|Measurement of serum 25-hydroxyvitamin D|
1561392|NCT02517164|Other|"Analysis of global cognitive efficiency score assessed by the Montreal Cognitive Assessment (MoCA)."|
1561393|NCT02517151|Drug|Ferric carboxymaltose|
1561394|NCT02517151|Drug|Placebo|
1561395|NCT02517138|Other|Parabolic flight|
1561396|NCT02517138|Other|Measurements of eye movements and perception|
1561397|NCT02517125|Device|Transoral robotic-assisted surgery with Da Vinci Xi|
1561398|NCT02517112|Other|Parabolic flight|
1561399|NCT02517112|Other|Cardiovascular parameters measurements|with Ballistocardiography (BCG), electric cardiography (ECG), impedance cardiography (ICG) and echocardiography
1561400|NCT02517112|Device|3D-BCG sensor|
1561401|NCT02517099|Drug|Beclometasone|Beclometasone dipropionate 200mcg bd for 4 months
1561402|NCT02517099|Drug|Co-amoxiclav|Co-amoxiclav 0.3ml/kg bd for 4 weeks
1561403|NCT02517099|Drug|Azithromycin|Azithromycin 10mg/kg od for 4 weeks
1561404|NCT02517086|Other|therapeutic exercises|The applied therapeutic exercises involve shoulder movements including flexion, extension, abduction, adduction, internal and external rotation in isolated or combined movements, with ten repetitions of each movement, associated with the music, and stretching movements finalizing the sequence of movements.
1561405|NCT02517086|Other|elastic compression|exercises for upper limb will be performed for an hour associated with the use of elastic compression. Elastic compression will be effected through a clamp brand compression of 30-40 mmHg according to the measures of voluntary member.
1561406|NCT02517086|Other|functional compressive bandaging|exercises for upper limb will be performed for an hour associated with the use of functional compressive bandaging. The functional compressive bandaging will be held with the volunteer sitting with ipsilateral upper limb resting on the support surgery. After hydration member a cotton mesh is used to prevent friction density 1cm strip of foam on the member to be wrapped. Elastic bandages of cotton will be involved 5 cm, 10 cm, 15 cm from the fingers to the axillary region multilayered
1561408|NCT02517034|Other|Comprehensive Geriatric Assessment|Follow geriatric assessment-driven treatment plan
1561409|NCT02517034|Other|Quality-of-Life Assessment|Ancillary studies
1561410|NCT02517034|Other|Questionnaire Administration|Ancillary studies
1561411|NCT02517034|Other|Survey Administration|Ancillary studies
1561412|NCT02517021|Drug|Pro-netupitant/Palonosetron|
1561413|NCT02517021|Drug|Netupitant/Palonosetron|
1561414|NCT02517021|Drug|Dexamethasone|
1561415|NCT02517008|Other|Mama kit|A low-cost non-monetary incentive (mama kit) was provided to all women who delivered at the facility between June 1, 2013 - Aug 31, 2013. Women were told about the intervention during ANC, and safe motherhood groups in the community promoted the intervention in the catchment areas of the treatment facilities.
1561416|NCT02516995|Device|Functional magnetic resonance imaging|
1561417|NCT02516995|Device|Ultrasound|
1561418|NCT02516982|Other|Whooley Questions|The Whooley questions are a case-finding instrument for depression in primary care. This 2-question instrument screens for depressed mood and anhedonia that have been present during the past month. Respondents are required to answer Yes or No to each of these questions. An affirmative answer to any of them should be followed by further assessment, including the use of a validated screening instrument or referral to a general practitioner or a mental health practitioner.
1561419|NCT02516982|Other|Edinburgh Postnatal Depression Scale|The Edinburgh Postnatal Depression Scale (EPDS) is a 10-item self-administered survey that screens for symptoms such as feelings of guilt, sleep disturbance, reduced energy levels, anhedonia and suicidal ideation that have been present during the 7 days preceding its administration. Each question is scored on a 4-point scale ranging from 0 to 3 points. Overall scores between 10 and 12 points suggest increased risk for depression; scores of 13 points or above indicate that the diagnostic criteria for major depression disorder have probably been met. In addition, item 10 deals with suicidal thoughts. The EPDS is a valid and reliable tool for identifying women at risk of depression, both during pregnancy and postpartum, and is sensitive to changes in the severity of depression over time.
1561420|NCT02516982|Other|Momentary questions|These will consist of 5 questions on a 5-point pictorial scales, assessing participants' mood, sleep, energy, enjoyment and worry.
1561421|NCT02516982|Other|Contextual questions|Two questions asking for participants' location and activity at the time they were asked to complete the momentary questions.
1561422|NCT02516969|Radiation|Stereotactic Body Radiotherapy|Radiation
1561423|NCT02516956|Other|Breakfast consumption|Participants will consume the assigned breakfast each morning for 7 days. Participants will express a hedonic rating of the breakfast through 7-point Likert Scales before (overview) and after breakfast consumption.
1561424|NCT02516956|Other|Blood tests|On the third day, participants will be involved in blood tests. Blood will be taken at baseline (fasting), and up to 4 hours after consuming the breakfast. Participants will complete serial visual analog rating scales of hunger and fullness before (fasting) and every 30 minutes up to 4 hours after breakfast consumption.
1561425|NCT02516956|Other|Food choices and energy intakes assessments|Following the last blood sample, participants will be given the opportunity to consume food ad libitum from a buffet lunch. Double weighing of food will be set up to evaluate food choices and energy intake of lunch. During the test week, participants will record all foods and beverage on a 7-day food dairy.
1561426|NCT02516956|Other|Attention tests|On the fourth day, 4 hours after the breakfast consumption and avoid other foods, participants will be involved in attentional test (Mackworth Clock Test for sustained attention and Stroop Test for selective attention).
1561427|NCT02516956|Other|fRMI tests|On the fifth day, 4 hours after the breakfast consumption and avoid other foods, participants will focus on a set of photographs (stimuli will be randomly choose from three categories of pictures including food, nonfood, and blurred baseline images) during an fMRI brain scan procedure to scan brain activation responses
1561428|NCT02516943|Other|Control|The patient's ABGs were test according to a 4 - hour routine
1561429|NCT02516943|Other|Guideline|The patient's ABGs were test according to the guideline for requests Arterial Blood Gas status post cardiac surgery
1561430|NCT02516930|Behavioral|crowdsourced video|video promoting condom use
1561431|NCT02516930|Behavioral|social marketing video|
1561432|NCT02516917|Behavioral|Attention Training Technique|
1561433|NCT02516904|Drug|CD101 IV|antifungal
1561434|NCT02516904|Drug|Placebo|normal saline
1561435|NCT02516891|Device|Drug-Eluting Stents implantation in bifurcation lesions|
1561436|NCT02516878|Procedure|Acupuncture|"Eight body acupuncture points will be chosen as Tianshu(ST-25), Daheng(SP-15), Daimai(GB-26), Qihai(CV-6), Zhongwan(CV-12), Zusanli(ST-36), Fenlong(ST-40), Sanyinjiao(SP-6). The needles will be retained for 30 minutes.
Participants of the treatment group will additionally receive unilateral auricular acupressure at four auricular points as Hunger, Shen men, Spleen and Stomach with Semen Vaccariae embedded within adhesive tape in each treatment session. Acupressure will be applied by the subjects with repeat pressing of the tape with fingertips for 3 minutes per point, 3 times per day. The embedded tape will be retained in-situ until the next visit and then the alternate side of ear will be treated."
1561437|NCT02516865|Device|Fitbit activity tracker|Tracks steps taken, floors climbed, and distance traveled. Sleep quality is an additional measurement.
1561438|NCT02516865|Device|Ankle weights|Worn during typical daily activities.
1561439|NCT02516852|Other|Egg production|Establishment and support of a community-owned and -operated egg production facility located at a central location in the community
1561440|NCT02516852|Behavioral|Community nutrition education|Establishment of a behavior change communication campaign (nutrition education) promoting healthy maternal, infant, and young child diets and eating behaviors
1561441|NCT02516839|Behavioral|Regulation of Cues (ROC)|Participants are provided information about basic learning theory and how physiological responses to food cues develop and can be managed. Lack of sensitivity to appetite and satiety cues and increased sensitivity to food cues will be discussed. Coping skills are presented to assist in mastery and toleration of food cue sensitivity. Participants will complete experiential learning exercises with food, and taught to monitor their hunger,satiety, and cravings. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs.
1561442|NCT02516839|Behavioral|Behavioral Weight Loss (BWL)|All participants will be instructed on how to consume a balanced deficit diet of conventional foods; individual goals for energy intake will be based on initial body weight. Participants will be instructed in measuring portion sizes, counting calories (with a calorie counter provided or on their phone), and self-monitoring food intake. The physical activity program will focus on increasing both lifestyle activity and structured exercise programs. Behavior change recommendations include stimulus control, self-monitoring, goal setting, managing high-risk situations, meal planning, slowing eating, problem solving, social support, cognitive restructuring, lapse and relapse prevention skills, and maintaining weight loss.
1561443|NCT02516839|Behavioral|BWL + ROC|BWL and ROC will be integrated for this arm, to capitalize on the strengths of both treatments. All participants will be taught to decrease caloric intake and increase physical activity, and to use all of the behavioral skills provided in BWL. However, they will also be taught models of hunger and satiety and about food cue reactivity, and will learn skills to manage these. This arm will include an experiential component, including hunger monitoring during dinner and participating in exposure sessions in the clinic.
1561444|NCT02516839|Behavioral|Nutrition Education, Stress Management and Social Support|Topics included will be stress management/relaxation, social support, and nutrition education. There will be a strong mindfulness component to this group.
1561445|NCT02516826|Drug|Rosuvastatin|
1561446|NCT02516826|Drug|Olmesartan|
1561447|NCT02516826|Drug|Combination|Rosuvastatin/Olmesartan(Combination)
1561448|NCT02516826|Drug|Placebo of Rosuvastatin|
1561449|NCT02516826|Drug|Placebo of Olmesartan|
1561450|NCT02516826|Drug|Placebo of Rosuvastatin/Olmesartan(Combination)|
1561458|NCT02516787|Other|Parabolic flight|
1561459|NCT02516787|Other|EEG measurement|Electro cortical power in alpha frequency ranges (EEG-LORETA)
1561460|NCT02516787|Other|NIRS measurements|Brain tissue oxygenation ( oxy- or deoxygenated hemoglobin values) - NIRS
1561461|NCT02516774|Drug|Adalimumab|
1561462|NCT02516761|Other|Low-impact aerobic exercise combined with music therapy|Intervention consists in working the muscles which are mostly affected by fibromyalgia through group exercises, which are dynamic, smooth and aim functionality. Each session consists of 60 minutes with 3 parts: initial warming up time, main part through games, group dynamics and pure aerobic workout, and final cool down with stretching. This exercise is done to the rhythm of melodic music, adapted to the tastes of the participants and also adapted on the way to perform the exercise. For this, they were shown a list of 100 music compositions from which participants choose a minimum of 20 preferences. All exercises are performed with proper postural control both dissociated and global and within a framework of therapeutic proprioceptive gymnastics.
1561463|NCT02516761|Other|Low-impact aerobic exercise|Low-impact aerobic exercise. Then intervention is like the previous group but with the difference that physical activity is not performed to the rhythm of chosen melodic music. Therefore, exercises are done with general chill-out music throughout the session, without adaptation of the exercise to the music.
1561464|NCT02516761|Other|Control group|With this group no intervention is done, but they are assessed like the other groups.
1561465|NCT02516748|Behavioral|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own accuracy of optical diagnosis
1561466|NCT02516735|Device|I-scan with magnification|
1561467|NCT02516735|Device|Standard endoscopy|
1561469|NCT02516709|Radiation|Linear LDR Source|The Linear LDR source is a permanent interstitial brachytherapy implant containing palladium-103 sources for the treatment of prostate cancer.
1561470|NCT02516696|Drug|Clarithromycin|500mg PO twice daily on days 1-28 for a 28-day cycle.
1561471|NCT02516696|Drug|Lenalidomide|25 mg PO days 1-21 followed by a 7 day rest period for each 28-day cycle
1561472|NCT02516696|Drug|Dexamethasone|20 mg PO on Days 1, 8, 15, and 22 for each cycle for subjects 75 years and younger.
1561473|NCT02516683|Other|Shigella sonnei infection|A Shigella-exposed cohort of 124 hospital employees who had been infected by Shigella sonnei due to contaminated food in the employee-cafeteria in Gangnam Severance Hospital, Seoul, Korea, at December 2001.
1561474|NCT02516670|Dietary Supplement|Ascorbic Acid|Given IV
1561475|NCT02516670|Drug|Docetaxel|Given IV
1561476|NCT02516670|Other|Laboratory Biomarker Analysis|Correlative studies
1561477|NCT02516670|Other|Pharmacological Study|Correlative studies
1561478|NCT02516670|Other|Placebo|Given IV
1561479|NCT02516670|Other|Quality-of-Life Assessment|Ancillary studies
1561480|NCT02516657|Drug|Liraglutide|Liraglutide 0.6 mg
1561481|NCT02516644|Behavioral|Virtual Reality|12 sessions of 1 hour (30 min of virtual reality and 30 min of aerobic exercise with treadmill training): three times a week over four weeks
1561482|NCT02516644|Behavioral|Conventional Therapy|12 sessions of 1 hour of conventional physiotherapy: three times a week over four weeks
1561483|NCT02516631|Drug|Angusta™|One tablet of Angusta™ (25 µg) given every 2 hours
1561484|NCT02516631|Drug|Cytotec®|1/8 of a tablet of Cytotec® (25 µg) given every 2 hours. Drug administration should be repeated every 2 hours until labour has commenced.
1561485|NCT02516631|Drug|Angusta™|Two tablets of Angusta™ 25 µg given every 4 hours
1561486|NCT02516631|Drug|Cytotec®|¼ of a tablet of Cytotec® given every 4 hours. Drug administration should be repeated every 4 hours until labour has commenced.
1561487|NCT02516631|Drug|Angusta™|Two tablets of Angusta™ (total dose of 50 µg), given every 4 hours
1561488|NCT02516631|Drug|Cytotec®|¼ of a tablet of Cytotec® (50 µg), given every 4 hours. Subjects should not swallow for a period of 5 minutes. Drug administration should be repeated every 4 hours until labour has commenced.
1561489|NCT02516618|Drug|Fasinumab|
1561490|NCT02516618|Drug|Placebo|
1561493|NCT02516592|Drug|QVA149 110/50 micrograms|QVA149 110/50 micrograms o.d. capsules for inhalation, supplied in blisters via a single dose dry powder inhalater (SDDPI)
1561494|NCT02516592|Drug|Salmeterol/fluticasone 50/500 microgrammes|Salmeterol/fluticasone 50/500 microgrammes b.i.d.dry inhalation powder delivered via Accuhaler / Diskus device
1561495|NCT02516579|Drug|Siklos|
1561496|NCT02516566|Other|PEEP|Mechanical ventilation with PEEP 8 cmH2O
1561499|NCT02516540|Behavioral|Structured exercise training plus mediterranean diet|Structured exercise training plus mediterranean diet
1561500|NCT02516527|Drug|Ipilimumab|
1561501|NCT02516514|Procedure|Single-sampling strategy vs multi-sampling strategy for the diagnosis of bacteremia|Comparison between two strategies of blood culture (single-sampling strategy and multi-sampling strategy) for the diagnosis of bacteremia
1561502|NCT02516501|Dietary Supplement|Ketogenic breakfast|The breakfast consisting of increasing doses up to 250 ml of betaquick plus MAP will be taken directly after each RT fraction.
1561503|NCT02516501|Dietary Supplement|Ketogenic diet|MAP will be used as a supplement for the ketogenic diet. MAP has a net nitrogen utilization of 99%, so that almost no glucose will be created out of the maino acids.
1561504|NCT02516501|Radiation|Radio(chemo)therapy|Radio(chemo)therapy as recommended by the institutional interdisciplinary tumor board.
1561505|NCT02516475|Dietary Supplement|zinc sulfate|1 zinc sulfate capsule for 15 weeks
1561506|NCT02516475|Other|corn starch|1 corn starch capsule for 15 weeks
1561507|NCT02516462|Device|IVM media|Media to support the nuclear maturation and cytoplasmic competence of human oocytes in culture.
1561508|NCT02516462|Drug|Follicle Stimulating Hormone (FSH)|Low dose FSH is administered to stimulate follicle growth.
1561509|NCT02516449|Other|Patient decision aid|"The patient decision aid is a 12-page A3 size color-printed booklet entitled Should I take asthma inhaled controller medication to optimize asthma control?"
1561510|NCT02516436|Drug|BEMA Buprenorphine NX|Buprenorphine with naloxone
1561511|NCT02516436|Drug|Buprenorphine|Buprenorphine
1561512|NCT02516423|Drug|ixazomib|oral
1561513|NCT02516423|Drug|lenalidomide|oral
1561514|NCT02516423|Drug|dexamethasone|oral
1561515|NCT02516423|Drug|zoledronic acid|IV
1561516|NCT02516410|Drug|VX-661|
1561517|NCT02516410|Drug|ivacaftor|
1561518|NCT02516410|Drug|placebo|
1561765|NCT02514681|Drug|Paclitaxel|
1561521|NCT02516384|Biological|Fecal Microbiota Transplantation|We will use fecal microbiota transplantation (FMT), with fecal material obtained from OpenBiome or donor directed, to assess safety (as primary outcome) and efficacy (as secondary outcome) in adult (>18 year old) patients with active ulcerative colitis (UC).
1561522|NCT02516371|Other|lymphocyte|To evaluate the subpopulation of lymphocytes in cancer patients
1561523|NCT02516345|Device|Fitbit|Fitbit devices are wireless pedometers that track the steps of participants, and will be offered in conjunction with a tailored website with customized information for participants.
1561524|NCT02516345|Behavioral|Incentives|Incentives will be awarded to participating children for meeting step targets as measured by the Fitbit pedometer.
1561525|NCT02516332|Drug|Lexapro|
1561526|NCT02516332|Drug|Placebo|
1561527|NCT02516332|Behavioral|Supervised Aerboic Exercise|
1561528|NCT02516319|Drug|ICG Dye|
1561529|NCT02516306|Drug|EV06 Ophthalmic Solution|
1561530|NCT02516306|Drug|Placebo Ophthalmic Solution|
1561531|NCT02516293|Behavioral|Exercise, nutritional and pharmaceutical counseling|Physical exercise intervention protocol was performed three times per week, 60 minutes per session, during 8 months. Exercise sessions consisted of 30 minutes of aerobic exercise on a treadmill or on a cycle ergometer, 20 minutes of strength exercises for the major muscle groups (sit-ups, push-ups, and pull-ups), and 10 minutes of stretching exercises. Nutritional and pharmaceutical consisted on general guidance about adequate eating habits for patients with heart failure, mainly sodium and water intake, and medication usage, particularly drug dosage and compliance.
1561532|NCT02516280|Device|Cryoton ™|In the intervention group, participants received hyperbaric gaseous cryotherapy delivered with a Cryoton ™ device (Cryonic Médical, Salins-les-Bains, France) within an hour after the surgery and two times per day the next postoperative days. The tip of the nozzle was kept 10-15 cm above the dry skin as the gaseous CO2 was sprayed on three zones of 5 cm by 10 cm (medial, lateral and posterior, respectively) using a slow and regular sweeping movement for approximately 30 seconds after a skin temperature of 2°C is reached.
1561533|NCT02516280|Device|Control ice bag|In the control group, participants received two 20-minute treatments of cryotherapy within an hour after the surgery and two times per day the next postoperative days. Cryotherapy was performed using an ice bag that was applied directly on the anterior aspect of the knee. The ice bag is a square latex bag of 30 cm by 30 cm filled with crushed ice and wrapped in a thin pillow case. The treatment assessor applied the intervention in a standardized manner by ensuring that the knee was fully extended while covering the surgical incision and both lateral and medial aspects of the knee with the iced bag.
1561534|NCT02516267|Device|Multiplate ADP®|Patients will be evaluated by platelet function testing (Multiplate ADP®) daily until the value obtained> 46 AU, when they will be immediately released to CABG
1561535|NCT02516254|Dietary Supplement|fortified bread|50 g of fortified bread + placebo daily
1561536|NCT02516254|Dietary Supplement|supplement|vitamin D supplement+ plain bread
1561537|NCT02516254|Dietary Supplement|placebo|plain bread+placebo
1561538|NCT02516241|Drug|MEDI4736|IV infusion
1561539|NCT02516241|Drug|Tremelimumab|IV infusion
1561540|NCT02516241|Drug|Cisplatin|IV infusion
1561541|NCT02516241|Drug|Carboplatin|IV infusion
1561542|NCT02516241|Drug|Gemcitabine|IV infusion
1561543|NCT02516228|Device|GeodesicTranscranial Electrical Neuromodulation (GTEN 100)|"In this feasibility study, patients will be randomly assigned to receive either continuous direct current stimulation or a slow-pulsed electrical current. Stimulation will be focused on the seizure generating cortex.
All patients enrolled in the study will have a one-month, pre-treatment baseline evaluation period. During this time, the patient (and/or family) will maintain the seizure diary that simply tracks the number of seizure the patient experiences each day.
During this baseline period, two three-hour EEG recordings (to be completed on 2 separate days) will be acquired. This baseline EEG data will be used to establish baseline inter-ictal spike rate as well as classification of the inter-ictal spikes used to localize seizure onset zone."
1561544|NCT02516215|Other|No intervention|
1561549|NCT02516189|Other|Strength training program|"Strength Training program applied twice a week for sixteen weeks. Each training exercises has a total time of 50 minutes. Warm-up: 5 minutes of stretching. Training: Leg press; Leg Curl; Vertical traction; Chest press; Abdominal crunch; Lower back. Gametherapy.
Relaxation: 5 minutes of stretching."
1561550|NCT02516176|Behavioral|treadmill training|Paretic leg step training while standing on a treadmill sideways and responding to treadmill being turned on suddenly.
1561551|NCT02516163|Device|Shapematch Cutting Guides|Participants will undergo pre-operative assessment using MRI of the affected limb. At the time of surgery, a repeated-measures methodology will be implemented in which the position of the femoral and tibial cutting guides will be measured using the Navigation system. The same surgeon will position each cutting guide a total of 3 times for each patient. Multiple participants will be assessed by each surgeon. No bone cuts will take place using the patient-specific cutting guides. After the study-specific measurements have been taken, the total knee procedure will resume using the Navigation system and associated instruments. No post-operative evaluations will be undertaken as part of this sub-study
1561552|NCT02516150|Drug|Ethanol|IV infusion of ethanol to stabilize BAC (blood alcohol content) at 0.1%
1561553|NCT02516150|Drug|Glucagon|injection of 50 micrograms of glucagon
1561554|NCT02516137|Procedure|Dry needling|Dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A Seirin L- type 50 mm needle will be inserted into each of the two points to a depth no greater than three-quarters length of the needle into the hamstring muscle for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes.
1561605|NCT02515838|Other|Placebo|Placebo for IV infusion
1561766|NCT02514681|Drug|Nab-paclitaxel|
1561555|NCT02516137|Procedure|Sham needling|Sham dry needling will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. The plastic tube of a Seirin L- type 50 mm needle will be placed against the skin and the needle will be tapped once so that it is inserted subcutaneously no deeper than 5 mm for 30 seconds using a vertical pistoning technique and then statically up to 10 minutes in each location.
1561556|NCT02516137|Procedure|Blunt needle placement|Blunt needle placement will be performed on two points over the hamstring muscles on the randomly determined side. Points 2 cm distal to the ischial tuberosity and halfway between the ischial tuberosity and popliteal crease within the medial and lateral muscle bellies will be identified and the skin cleansed with rubbing alcohol. A blunt needle handle is inserted into a plastic tube which will be placed over the identified points for 30 seconds and then for an additional 10 minutes each. The blunt needle handle only touches the skin without puncturing it.
1561557|NCT02516137|Other|Standard hamstring stretching exercise|Subjects will be instructed to stretch the back of their thighs, once a day for 3 repetitions, holding for 30 seconds each time performed bilaterally.
1561558|NCT02516124|Procedure|Autologous HSCT|1st AHSCT
1561559|NCT02516111|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
1561560|NCT02516111|Biological|OFD with PRF|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
1561561|NCT02516111|Drug|OFD with ALN|Oral prophylaxis followed by Open flap debridement (OFD) with 1% ALN gel placement into the bone defect
1561562|NCT02516111|Drug|OFD with ATV|Oral prophylaxis followed by Open flap debridement (OFD) with 1.2% ATV gel placement into the bone defect
1561563|NCT02516098|Drug|hyoscine butylbromide|
1561564|NCT02516085|Drug|Metformin|
1561565|NCT02516085|Drug|L-Arginine|
1561566|NCT02516072|Other|RIPC|IV hydration prior to procedure dependent on classification of risk as per eGFR + RIPC
1561567|NCT02516059|Drug|oxycodone/naloxone|Oxycodone and naloxone (Targin®; Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10mg/5mg on POD 3 and move to 20mg/10mg the other day.
1561568|NCT02516059|Drug|Oxycodone|Oxycodone (Oxycontin®, Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals, starting with 10 mg on POD 3 and move to 20 mg the other day.
1561569|NCT02516059|Drug|Placebo|Placebo (Mundipharma Medical Company and Mundipharma Research GmbH & Co Basel, Switzerland): Will be orally administered at 12 hours intervals starting on POD 3.
1561570|NCT02516059|Device|epidural catheter|
1561571|NCT02516046|Drug|18F-AV-1451|Subjects will receive a single IV bolus injection of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451. Some subjects may receive a second injection after 6 months have passed since the first injection.
1561572|NCT02516020|Drug|Global|Embryos are cultured in single step culture from day 1 to day 5
1561573|NCT02516020|Drug|Origio|Embryos are cultured in sequential medium from Day1 to Day 3 and from Day 3 to Day 5 (Sequential Blast)
1561574|NCT02515994|Device|senofilcon C|Investigational contact lens
1561575|NCT02515994|Device|comfilcon A|Marketed Monthly Replacement Lens (Control)
1561576|NCT02515981|Behavioral|NH Medicaid Incentives Program|
1561577|NCT02515968|Drug|Desflurane|Anesthesia is maintained with desflurane in Desflurane group according to the randomly allocated groups.
1561578|NCT02515968|Drug|Propofol|
1561579|NCT02515955|Drug|JNJ-54175446|Participants will receive JNJ-54175446, at increasing dose levels using 2 oral formulations i.e. 0.5 mg/ml and 20 mg/ml as suspension for oral dose once daily.
1561580|NCT02515955|Drug|Minocycline|Participants will receive minocycline 100 mg as capsule twice daily.
1561581|NCT02515955|Drug|JNJ 54175446 Matching Placebo|Participants will receive placebo matching with JNJ 54175446 once daily orally.
1561582|NCT02515955|Drug|D Amphetamine|Participants will receive 20 mg d-amphetamine (AMPH) 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
1561583|NCT02515955|Drug|D Amphetamine Matching Placebo|Participants will receive d-amphetamine (AMPH) matching placebo, 2 hours after administration of study drug (JNJ-54175446/placebo or minocycline/placebo) on Day 7 and Day 10.
1561584|NCT02515942|Drug|CLG561|
1561585|NCT02515942|Drug|LFG316|
1561586|NCT02515942|Drug|Sham injection|Empty syringe (without a needle) placed against the eye
1561587|NCT02515929|Dietary Supplement|Oligomeric Proanthocyanidins|
1561588|NCT02515929|Dietary Supplement|Placebo|
1561592|NCT02515890|Drug|Dexmedetomidine|Subjects will receive this drug during a portion of the study
1561593|NCT02515890|Drug|Midazolam|Subjects will receive this drug during a portion of the study
1561594|NCT02515890|Device|Peripheral nerve stimulation|Experimental acute pain stimulus will be delivered using a nerve stimulator. These painful shocks will be paired randomly with some of the auditory experimental cues.
1561595|NCT02515890|Drug|Ketamine|Subjects will receive this drug during a portion of the study
1561596|NCT02515877|Radiation|External radiotherapy + curietherapy|External radiotherapy: 45 Gy in 5 weeks Curietherapy: 15Gy
1561597|NCT02515877|Drug|Vistide|VISTIDE® (mg/kg) Level 1: 1mg/kg Level 2: 2,5 mg/kg Level 3: 5 mg/kg Level 4: 6,5 mg/kg
1561598|NCT02515877|Drug|Carboplatin|AUC= 2,5 (Calvert formula)
1561599|NCT02515864|Drug|FYU-981|
1561600|NCT02515864|Drug|Placebo|
1561601|NCT02515864|Drug|Moxifloxacin|
1561602|NCT02515864|Drug|Moxifloxacin Placebo|
1561604|NCT02515838|Drug|Sevuparin|The Drug Product sevuparin solution for IV infusion
1561606|NCT02515825|Device|CADence System|Obtain CADence data under normal conditions of use for comparison of results with those of coronary angiogram
1561607|NCT02515812|Drug|I-123-MIBG|
1561608|NCT02515812|Device|CZT Camera (D-SPECT)|
1561609|NCT02515812|Device|Anger Camera|
1561610|NCT02515799|Drug|Tacholiquine|Inhaled Tacholiquine ®1% - 5ml
1561611|NCT02515799|Other|Placebo|Inhaled Placebo
1561612|NCT02515786|Other|oxygen humidification|humidification for oxygen delivered by nasal catheter
1561613|NCT02515773|Drug|Metformin|Metformin - to achieves maximum insulin-sensitizing effects
1561614|NCT02515773|Behavioral|healthy lifestyle intervention (LIFE)|Healthy Life style intervention
1561617|NCT02515747|Procedure|percutaneous coronary intervention|elective percutaneous coronary balloon angioplasty and/or stenting
1561618|NCT02515747|Procedure|coronary artery bypass grafting|elective surgical myocardial revascularisation
1561619|NCT02515734|Drug|fluorouracil|
1561620|NCT02515734|Drug|Leucovorin|
1561621|NCT02515734|Drug|irinotecan|
1561622|NCT02515734|Drug|oxaliplatin|
1561623|NCT02515734|Biological|bevacizumab|
1561624|NCT02515734|Biological|cetuximab|
1561625|NCT02515721|Device|pCLE-TB|Patients will receive white-light endoscopic imaging, followed by probe-based Confocal Laser Endomicroscopy scanning on suspected lesions and 5 standardized locations. Then targeted Biopsies will be performed on locations with intestinal metaplasia, intraepithelial neoplasia, and carcinoma.
1561626|NCT02515721|Device|virtual chromoendoscopy-TB|Patients will receive virtual chromoendoscopy using iScan. Standard biopsies will be performed on all suspected lesions and standardized loctaions.
1561627|NCT02515708|Device|Normothermic Liver perfusion Device|The liver grafts will be preserved at physiological temperature and have continuous perfusion with oxygen and nutrient supply in the ex vivo organ preservation phase.
1561628|NCT02515695|Drug|Interferon beta-1a|6 MIU/0.53 mL in pre-filled glass syringe solubilized in aqueous isotonic buffered solution
1561629|NCT02515682|Dietary Supplement|High equol group|Participants will be give natural S-equol 20mg/d for 24 weeks.
1561630|NCT02515682|Dietary Supplement|Low equol group|Participants will be give natural S-equol 10mg/d for 24 weeks.
1561631|NCT02515682|Dietary Supplement|Placebo|Participants will be give placebo for 24 weeks.
1561632|NCT02515669|Biological|BMS-986089|
1561633|NCT02515669|Biological|Placebo|
1561637|NCT02515643|Other|Endothelial dysfunction|"One month before surgery and one year after, the following procedures will be performed in donors and recipients:
Blood samples will be obtained for the measurement of endothelial dysfunction and low grade inflammation markers.
Atherosclerotic burden: carotid ultrasound to determine the number of plaques and intima-media thickness, carotid-femoral pulse wave velocity (m/s) will be performed by pulse tonometry.
Ambulatory blood pressure monitoring with overnight-automated ABPM monitor
Estimation of glomerular filtration rate by Iohexol method"
1561638|NCT02515630|Drug|MMB|Momelotinib (MMB) tablet administered orally once daily
1561639|NCT02515617|Device|Endotracheal tubes not allowing SSD|In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure
1561640|NCT02515617|Device|Endotracheal tubes allowing SSD|"In each participating center, a bundle of VAP prevention will be applied: elevate the head of the bed to 30°-45°, regular oral care, manage patients with sedation algorithm, assess readiness to extubate daily, intermittent control of endotracheal tube cuff pressure.
In addition, SSD will be realized using a 10 ml syringe at in attending frequency of 2 hours."
1561641|NCT02515604|Drug|Misoprostol|
1561642|NCT02515591|Other|Bronchoalveolar Lavage validation study|Bronchoalveolar lavage involved the washing out of the right middle lobe of the lung of a healthy volunteer with 200mls of warmed normal saline with or without sedation.
1561643|NCT02515578|Other|Enhanced practice transformation support|
1561644|NCT02515578|Other|Standard practice transformation support|
1561645|NCT02515565|Drug|cephalosporin with or without erythromycin|Second- or third-generation cephalosporin (cefuroxime, cefotaxime, or ceftriaxone) with or without erythromycin, given parenterally; parenteral therapy should continue until the patient has been afebrile for more than 24 hours and oxygen saturation exceeds 95 percent.
1561646|NCT02515565|Other|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes added to the standard medical treatment. I will include breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
1561647|NCT02515552|Behavioral|The Fibromyalgia Wellness Project|Web-based symptom and behavior self-monitoring program with automated feedback derived from the user's personal data. A personal informatics approach is used involving proprietary within-subject statistical analysis procedures to determine user feedback that provides behavioral guidance based on statistically significant change in symptom levels associated with specific user behavior and self-management strategies.
1561648|NCT02515539|Device|CardiAQ TMVI System (Transapical & Transfemoral DS)|CardiAQ TMVI System using either the Transapical or Transfemoral Delivery System
1561649|NCT02515526|Drug|caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Reference period
1561650|NCT02515526|Drug|ethanol multiple doses plus caffeine, tolbutamide, omeprazole, dextromethorphan, digoxin, midazolam single doses|Test period
1561652|NCT02515500|Behavioral|Gradual Cessation|
1561653|NCT02515500|Behavioral|Gradual Cessation w/ Quitbit|
1561681|NCT02515305|Drug|Clindamycin and Benzoyl Peroxide Gel (Reference) (combination)|
1561767|NCT02514681|Drug|Vinorelbine|
1561654|NCT02515487|Other|Brain Fitness Program (BFP)|The program is designed to improve processing speed of auditory information and attention. The BFP is comprised of six computerized subtests that continuously adjust in the level of difficulty to maintain an 85% correct response rate. The subtest exercises include discrimination of confusable syllables, recognition of sequences of syllables, matching pairs of confusable syllables, reconstruction of sequences of verbal instructions and identification of details in a verbally presented story. Participants will participate in 40 one-hour training sessions over a 12 week period to complete all cognitive remediation training sessions. Since this intervention is presented both visually and verbally, noise cancelling headphones will be provided to the participants.
1561655|NCT02515474|Procedure|Laparoscopy|After removing the gallbladder, Laparoscopic common bile duct exploration (LCBDE) was performed by one fulltime attending in laparoscopy in a routine fashion. Access from the opening of the anterior wall of common bile duct or from the dilated cystic duct was acceptable, removed stone(s) and irrigated the duct followed by choledochoscope detection simultaneously. Cholangiograms were also can be a alternative method to obtain stone clearance. If needed, all fluoroscopy was performed by the principal author in the presence of and concurrence with the ERCP endoscopist. Once the LCBDE was completed, the incision of the bile duct was sewed intermittently by absorbed threads, or ligated cystic duct. T-tube was acceptable if needed.
1561656|NCT02515474|Procedure|Endoscopy|Initially endoscopic retrograde cholangiopancreatography (ERCP) was performed by a fulltime attending and concurrence of the principal author in endoscopy. Patients randomized to ERCP+ LC group were scheduled to undergo the endoscopic procedure using fluoroscopy in the endoscopy center under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Gastric intestinal atony during ERCP was routinely achieved using scopolamine butylbromide injection. Sphincterotomy (EST) and Endoscopic papillary balloon dilatation (EPBD) can be choose accordingly. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible following the ERCP in one month.
1561657|NCT02515461|Device|Low energy shockwave therapy|"Procedure: The patient lies on supine position during treatment. Kidney will be localised in line ultrasound. 3000 shockwaves at a frequency of 4 Hz are applied to each kidney per session. The kidney will be divided into three treatment areas including 1000 shockwaves applied to each treatment area.
Patients will receive 6 sessions over 3 weeks. Treatments are carried out on day 1, day 3, day 7, day 10, day 14, and day 17 after enrollment (average time points).
Treatment is performed using the MODULITH SLX-F2, manufactured by STORZ MEDICAL AG."
1561658|NCT02515448|Drug|gentamicin|
1561659|NCT02515435|Drug|apatinib single agent|For those heavily treated non-squamous non-small cell lung cancer, treat with apatinib single agent, 500mg or 750mg Qd, p.o based on the status of patient, continue until disease progression, dose reduction was admitted
1561660|NCT02515422|Drug|Ketamine|Subcutaneous infiltration of ketamine
1561661|NCT02515422|Drug|Bupivacaine|Subcutaneous infiltration of bupivacaine
1561662|NCT02515422|Drug|Placebo (0.9% saline solution)|
1561663|NCT02515409|Device|HHHFNC|After the treatment with CPAP fails, the participants will use HHHFNC as a treatment for OSAS.
1561664|NCT02515409|Device|CPAP|CPAP, as a first line treatment in OSAS.
1561665|NCT02515396|Drug|MMI-0100|
1561666|NCT02515396|Drug|Placebo|
1561667|NCT02515383|Behavioral|MD Anderson Symptom Inventory (Adolescent Version)|"Part 1: Adolescent participants complete the MDASI (adolescent version).
Part 2: MDASI (adolescent version) administered twice, one day apart, to assess test-retest reliability. MDASI (adolescent version) then administered at 5 additional time points, each a week apart."
1561668|NCT02515383|Behavioral|Interview|"Part 1: Participants are interviewed by study staff regarding the symptom questionnaire.
Part 2: First 20 participants are interviewed by study staff regarding the symptom questionnaire."
1561669|NCT02515383|Behavioral|Questionnaires|"Part 1: Participants complete the EQ-5D and a single-item quality of life (QOL) questionnaire.
Part 2: Participants complete the EQ-5D and a single item quality of life question only after first MDASI (adolescent version) completion."
1561670|NCT02515370|Other|Friends for Life Circles (FLCs).|"The intervention 'Friends for Life Circles (FLCs) will build dynamic peer group support in the community aimed at supporting maternal adherence to appointment keeping and taking lifetime antiretroviral drugs"
1561671|NCT02515357|Behavioral|Mediterranean lifestyle|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean lifestyle (food and food group consumption according to the Mediterranean diet, beneficial culinary practices, seasonality and locality of foods consumed, socialization during meals, adequate rest during the day through night sleep and siesta nap, sleep hygiene recommendations and adoption of a physically active lifestyle) and at achieving a 5-10% weight loss.
1561672|NCT02515357|Behavioral|Standard care|General written instructions regarding the adoption of a healthy lifestyle.
1561673|NCT02515357|Behavioral|Mediterranean diet|Comprehensive 6-month lifestyle intervention (7 60-min group counselling sessions) aiming at promoting adherence to the Mediterranean dietary pattern (food and food group consumption according to the Mediterranean diet, beneficial culinary practices and seasonality and locality of foods consumed) and at achieving a 5-10% weight loss.
1561674|NCT02515344|Other|Providing a list of patients not compliant with CRC sreening|GPs allocated to the intervention group (A) will receive a list of the patients who are not compliant to colorectal cancer screening, while GPs allocated to the others groups will not receive this information.
1561675|NCT02515344|Other|Providing general information about CRC sreening|
1561676|NCT02515331|Drug|LHW090|Capsule - oral dose
1561677|NCT02515331|Drug|Placebo|Capsule - oral dose
1561678|NCT02515318|Other|Physiotherapy program|The physiotherapy treatment will be performed during the hospitalization, every day during 45-60 minutes, and included: breathing exercises, electrostimulation in quadriceps with voluntary contraction and exercises with theraband.
1561679|NCT02515318|Drug|Medical standard treatment|"The standard medical treatment consists on:
Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).
Glucocorticoids:
Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.
- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β‐lactamase inhibitor and fluoroquinolones."
1561680|NCT02515305|Drug|Clindamycin and Benzoyl Peroxide Gel (combination)|
1561683|NCT02515279|Drug|Peginterferon alfa-2a|180 micrograms subcutaneous weekly for 48 weeks.
1561684|NCT02515279|Drug|Ribavirin|1000-1600 mg day orally for 48 weeks.
1561685|NCT02515266|Other|nutrition: protein intake|additional protein fortification of human milk
1561686|NCT02515253|Other|Bra prescription|
1561687|NCT02515253|Other|Standard Care|
1561688|NCT02515240|Biological|PPV23|23 valent pneumococcal polysaccharide vaccine in Healthy adults.
1561689|NCT02515227|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
1561690|NCT02515227|Drug|Pembrolizumab|Humanized monoclonal antibody (mAb) specific for PD-1.
1561691|NCT02515201|Drug|Taurolidine|taurolidine in central catheter lumen
1561692|NCT02515201|Drug|Heparin|heparin in central venous catheter lumen
1561693|NCT02515188|Drug|Propacetamol|Randomly selected patients of the propacetamol group are given intravenous propacetamol 2g for 15 minutes on the beginning of the procedure.
1561694|NCT02515188|Drug|Placebo|Placebo group are given intravenous Normal Saline 2g for 15 minutes on the beginning of the procedure.
1561698|NCT02515162|Procedure|Fischer Cone Biopsy Excisor|Electrosurgical excision method using a triangular electrode to remove the abnormal cervical Transformation zone
1561699|NCT02515162|Procedure|Loop Excision Procedure|Electrosurgical excision method using a circular electrode to remove the abnormal cervical Transformation zone
1561700|NCT02515149|Device|Point of care CD4 device (Alere PIMA)|for persons testing + with home-based HIV testing using Kenya's two rapid test algorithm, intervention arm participants received point of care CD4 testing followed by counseling on results which included their treatment eligibility
1561701|NCT02515136|Behavioral|Stimulus-response|See summary
1561702|NCT02515123|Device|E-Motion System|"E-Motion Tube: A disposable oro/nasogastric feeding tube fitted with stainless steel electrodes along its length that delivers the stimulation to the esophageal mucosa.
E-motion EPG 1000: a durable, touchscreen operated, bedside control unit that generates the electric stimulation pattern and sends it via the feeding tube to the esophagus.
By applying predetermined sequences of electrical stimulation to various locations along the esophagus asynchronous esophageal motion is induced, resulting is reduction of reflux and increased GI motility, enabling safer and better feeding."
1561703|NCT02515123|Device|Sham E-Motion System|The sham EPG will resemble the investigational EPG. The external shape, interface, lights, and switches will be exactly the same. The Sham device will emit a low intensity pulsation so that, it will not unblind the patient nor health care professional. In the event that unblinding does occur, we will take steps to mask the identity of the EPG by covering the number of the device with tape to prevent members of the clinical team becoming aware of which device is active or sham.
1561704|NCT02515110|Radiation|External Beam Radiation Therapy|Undergo hypofractionated RNI
1561705|NCT02515110|Other|Questionnaire Administration|Ancillary studies
1561706|NCT02515110|Other|Laboratory Biomarker Analysis|Correlative studies
1561707|NCT02515097|Drug|IDP-122 Lotion|Medicated lotion
1561708|NCT02515097|Drug|IDP-122 Vehicle Lotion|Vehicle lotion with no active ingredient
1561709|NCT02515084|Device|PET|A FDG PET scan and a diffusion-weighted Magnetic Resonance Imaging will be performed to compare the efficacy to diagnose relapse in thyroid carcinoma
1561710|NCT02515084|Device|MRI imaging|
1561711|NCT02515071|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
1561712|NCT02515071|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be consumed on a daily basis during the intervention by the study subjects.
1561715|NCT02515045|Drug|TriMoxiVanc|triamcinolone acetonide 15 mg / ml with moxifloxacin 1 mg/ml, vancomycin 10 mg/ml to be injected at time of cataract surgery.
1561716|NCT02515045|Drug|Moxifloxacin HCl 0.5%|Antibiotic to be used 1 drop, QID for 3 days prior to surgery and will continue for 2 weeks after surgery and then discontinue.
1561717|NCT02515045|Drug|Ilevro|NSAID to be used 1 drop QD starting 3 days before surgery and QD for 4 weeks after surgery.
1561718|NCT02515045|Drug|Prednisolone acetate 1%|Steroid to be started after surgery 1 drop QID for 2 weeks, tapered to BID for 2 weeks, and then discontinued.
1561719|NCT02515032|Dietary Supplement|Nutrifriend Cachexia|2 daily for 12 weeks
1561720|NCT02515032|Dietary Supplement|Isocaloric placebo|2 daily for 12 weeks
1561721|NCT02515019|Device|Bispectral index Monitoring|In group SevoBIS, the sevoflurane concentration was titrated to maintain a target BIS value between 40 and 60.
1561722|NCT02515006|Other|Homeopathy Medicine|Homeopathy, or homeopathic medicine, is a holistic system of treatment. Individualized homeopathy remedy was based on the most characteristic and clear mental symptoms. Secondly, general symptoms were taken into account.C-potencies were provided and manufactured according to the Homeopathic Pharmacopoeia and Hahnemann's methodology. Each individualized homeopathic remedy were be prescribed in C-potencies
1561723|NCT02514980|Drug|Bupivacaine|Infraorbital nerve block using bupivacaine 0.25% on each side.
1561724|NCT02514980|Drug|Ketamine|Infraorbital nerve block using 0.5mg/kg ketamine on each side.
1561725|NCT02514967|Drug|Blisibimod|Administered via subcutaneous injection once per week
1561726|NCT02514967|Drug|Placebo|Administered via subcutaneous injection once per week
1561727|NCT02514954|Drug|Biochaperone® Combo|Subcutaneous injection of an individualized dose
1561728|NCT02514954|Drug|Humalog® Mix25|Subcutaneous injection of an individualized dose
1561729|NCT02514941|Drug|paracetamol|Administration of 5 ml Paracetamol Saft Hexal (= 200 mg paracetamol)
1561730|NCT02514941|Drug|amoxicillin|Administration of 5 ml Amoxypen® 250 mg Saft (= 250 mg amoxicillin)
1561731|NCT02514941|Drug|talinolol|Administration of 1 tablet Cordanum® 50 (= 50 mg talinolol) dissolved with 40 ml tap water
1561732|NCT02514941|Procedure|gastroduodenoscopy with biopsy|Gastroduodenoscopy with biopsy of the lower duodenum before the first pharmacokinetic study period
1561733|NCT02514941|Procedure|gastrojejunoscopy with biopsy|Gastrojejunoscopy with biopsy of the jejunum about one year after proximal Roux-en-Y gastric bypass
1561734|NCT02514941|Procedure|proximal Roux-en-Y gastric bypass|sampling of a tissue specimen from the jejunum during the operation
1561735|NCT02514928|Procedure|resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy|Resection of the nerve plexus on the right half of celiac and SMA associated with extended pancreatoduodenectomy. Regional lymph nodes includes group 5,6,8a,8p,9,12a,12b,12c,12p,13,14a,14b,14c,16,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
1561736|NCT02514928|Procedure|standard pancreatoduodenectomy|Standard pancreatoduodenectomy with regional lymph nodes includes group 5,6,8a,12b,12c,13,14a,14b,17, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
1561737|NCT02514915|Radiation|Stereotactic Radiosurgery|Radiation therapy
1561738|NCT02514902|Device|Lateral Flow Device|A drop of whole blood from a finger stick is placed on the lateral flow device at two different time points to indicate the presence of a neuronal specific biomarker. The results will also be correlated to severity of clinical and radiographic injury. Separate drops are evaluated similarly for serum levels. The objective is to determine feasibility of a diagnostic tool for stroke (ischemic and hemorrhagic and traumatic brain injury (TBI). No diagnostic results or resulting treatments will be applied to any subject.
1561741|NCT02514876|Device|Foresight ICE System|The Foresight ICE System is composed of a sterile, single-use catheter intended to operate with a Foresight ICE PIM and Hummingbird Console.
1561742|NCT02514850|Drug|Biochaperone Combo|Injection of BioChaperone Combo
1561743|NCT02514850|Drug|Humalog Mix25|Injection of Humalog Mix25
1561744|NCT02514850|Drug|Humalog|Injection of Humalog
1561745|NCT02514850|Drug|Lantus|Injection of Lantus
1561746|NCT02514850|Drug|Placebo|Injection of saline 0.9% solution
1561747|NCT02514837|Device|RTM|Both the internal temperature and skin temperature will be measured non-invasively through the skin using the RTM device
1561748|NCT02514824|Drug|MLN0128|Investigational mTOR kinase inhibitor
1561749|NCT02514811|Behavioral|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
1561750|NCT02514798|Other|Esophageal and gastric balloons|Esophageal and gastric pressures will be measured with an esophageal ballon positioned at the lower third of the esophagus, filled with 0.5 mL of air and a gastric balloon filled with 1 mL of air. The proper position of balloons will be verified using the occlusion test as previously described. Transdiaphragmatic pressure (Pdi) is calculated as the difference between gastric (Pga) and esophageal (Pes) pressure. The pressure time integrals of the diaphragm and the other inspiratory muscles are calculated per breath (PTPdi/b and PTPes/b, respectively) and per minute (PTPdi/min and PTPes/min). Measurements will be collected at baseline, at each randomized HFNC and CPAP settings during the last 4 minutes of each 10 minutes session.
1561751|NCT02514798|Other|Respiratory Inductance Plethysmography (RIP) system|Inspiratory tidal volume (VTi), respiratory rate (RR), breath duration (Ttot), inspiratory time (Ti) and fractional inspiratory time (Ti/Ttot) will be determined using a Respiratory Inductive Plethysmography (RIP) system. This will measure the thoracic and abdominal excursion of the subjects via two inductive wires which are sewn into the elastic bands that encircle the thorax and abdomen. The acquired signals represent changes in cross-sectional area and, following calibration to determine the relative contribution of each signal, and volume calibration using spirometry, their weighted sum will reflect VTi. The RIP companion software will be used to derive RR, Ttot, Ti and Ti/Ttot on a breath by breath basis.
1561752|NCT02514798|Other|Sentec transcutaneous monitoring system|The oxygenation, the level of carbon dioxide, and the heart rate will be recorded using the Sentec transcutaneous monitoring system: a probe will be placed at the earlobe or on the forehead, and it will measure in a noninvasive way these parameters.
1561753|NCT02514798|Device|High-flow humidified nasal oxygen delivery system|
1561754|NCT02514798|Device|CPAP (Positive Control)|
1561757|NCT02514759|Behavioral|The Teen Outreach Program|Students received the Teen Outreach Program as described previously.
1561758|NCT02514746|Biological|SA-14-14-2 live, attenuated JE vaccine|0.5 ml (single dose), Subcutaneous
1561759|NCT02514720|Other|cigarette|Participants will be allowed to smoke a cigarette prior to a PET scan and be abstinent from smoking prior to the other PET scan
1561760|NCT02514694|Drug|LEO32731|
1561761|NCT02514694|Other|Placebo|
1561762|NCT02514681|Drug|Trastuzumab|
1561763|NCT02514681|Drug|Pertuzumab|
1561764|NCT02514681|Drug|Docetaxel|
1561772|NCT02514655|Device|Nosten® pressure control (it's not an antibiotic, but simple device)|One experimental group with the control of the cuff pressure by Nosten® device
1561773|NCT02514655|Other|Manual pressure control|One control group with the manual monitoring of the cuff pressure and inflation of the balloon
1561774|NCT02514642|Drug|low-dose ticagrelor|low-dose ticagrelor (22.5 mg twice daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of clopidogrel (75mg once daily)
1561775|NCT02514642|Drug|Clopidogrel|clopidogrel (75mg once daily) for 7 days,followed by a 2-week washout period then a 7days crossover phase of low-dose ticagrelor (22.5 mg twice daily)
1561776|NCT02514629|Drug|Placebo|
1561777|NCT02514629|Drug|Metformin|
1561778|NCT02514629|Drug|Testosterone Undecanoate|
1561779|NCT02514629|Drug|Metformin + Testosterone Undecanoate|
1561780|NCT02514616|Procedure|Laparoscopic IPG and lead implant procedure|EST placement
1561781|NCT02514616|Device|Active Electric Stimulation Therapy|Device programming by the technician to deliver the EST system active (Treatment group) or no stimulation (Control group) for the following 12 weeks, at the 2 weeks visit.
1561782|NCT02514616|Device|Delayed Electric Stimulation Therapy|Device programming by the technician to deliver the EST system no stimulation for the following 12 weeks at the 2 weeks visit. Active Electric Stimulation Therapy will be programmed at the 14 weeks visit.
1561783|NCT02514603|Drug|Prexasertib|Administered IV
1561784|NCT02514590|Device|Freedom SCS System - High Frequency|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 10kHz therapy.
1561785|NCT02514590|Device|Freedom SCS System - Low Frequency|This Freedom SCS System is based on wireless neuromodulation technology. This technology includes octapolar stimulators with embedded receivers. The energy source is a small, external, rechargeable transmitter, which is worn by the subject. The device is programmed to have a 5-1500 therapy.
1561786|NCT02514577|Drug|IDP-122 Lotion|lotion
1561787|NCT02514577|Drug|IDP-122 Vehicle Lotion|lotion
1561788|NCT02514564|Behavioral|Exercise|Patients included in the study will be enrolled in a cardiac rehabilitation program, in an independent manner of the study protocols.
1561791|NCT02514538|Drug|Non- effervescent Paracetamol kern|1g
1561792|NCT02514538|Drug|Effervescent paracetamol termalgin|1 g
1561794|NCT02514512|Device|MLC Tracking|Treat patient with Non FDA approved MLC Tracking
1561795|NCT02514499|Other|Questionnaires|
1561796|NCT02514486|Behavioral|Questionnaire|
1561800|NCT02514460|Device|plaque excision system|
1561801|NCT02514460|Device|Stent|
1561807|NCT02514421|Device|Electroporation|Irreversible electroporation (IRE) will be performed under computed tomography (CT) guidance, during which 2 to 6 needles are advanced into the pancreatic tumor where a specified field strength will be applied.
1561808|NCT02514421|Drug|gemcitabine|The chemotherapy schedule will include administration of gemcitabine 1000mg/m2 IV infusion over approximately 30 minutes on days 1, 8, and 15 of each 28 day cycle.
1561809|NCT02514421|Drug|nab-paclitaxel|The chemotherapy schedule will include administration of nab-paclitaxel 125mg/m2 intravenous (IV) over approximately 30 to 45 minutes on Days 1, 8, and 15.
1561810|NCT02514408|Procedure|Catheter Management|Insertion of venous catheter under ultrasound guidance
1561811|NCT02514408|Other|Cytology Specimen Collection Procedure|Collection of blood samples
1561812|NCT02514408|Other|Laboratory Biomarker Analysis|Correlative studies
1561813|NCT02514395|Other|disability index administration -self report form|Final T12 version of KOOS was given to the participants by an assistant who was not involved with any prior procedure. At the same time SF- 36 v2[32] generic health measure was also handed over. Filled forms were collected by the same assistant. Next day participants were given another blank copy of Marathi KOOS T12 versions. Hence each participant filled three forms.
1561814|NCT02514382|Drug|Bortezomib|Given SC or IV
1561815|NCT02514382|Drug|Dexamethasone|Given PO, IV, or IM
1561816|NCT02514382|Other|Laboratory Biomarker Analysis|Correlative studies
1561817|NCT02514382|Other|Pharmacological Study|Correlative studies
1561818|NCT02514382|Biological|Wild-type Reovirus|Given IV
1561819|NCT02514356|Behavioral|Own adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant.
1561820|NCT02514356|Behavioral|Own and group level adherence|In this intervention group, participants receive weekly SMS messages informing them of their adherence that week as measured by the wise pill device used by the participant. In addition, in the same message they are informed of the adherence demonstrated by the other participants
1561821|NCT02514343|Drug|Magnesium Sulfate|1ml of 10% magnesium sulfate with 1.5 ml of sterile water
1561822|NCT02514343|Drug|Bupivacaine|1.5 ml of Bupivacaine 5mg/ml plus 1 ml of 10% magnesium sulfate
1561893|NCT02513914|Device|Cerebrospinal Fluid Shunting|See Cerebrospinal Fluid Shunting arm.
1561823|NCT02514330|Other|Interval Training at 1% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect
1561824|NCT02514330|Other|Interval Training at 10% incline|Six stimuli were performed to exhaustion. The vertical drop jump strategy (height and kinematics) served to establish the magnitude of the concurrent effect.
1561825|NCT02514317|Procedure|percutaneous treatment|
1561826|NCT02514317|Device|Ultrasound|
1561827|NCT02514291|Behavioral|Sleep intervention|Standard pediatric neurology care plus education and augmented support around adequate sleep habits, appropriate daylight exposure, and beneficial and safe physical activity tailored to each epileptic child's capabilities.
1561828|NCT02514278|Drug|Neoadjuvant chemotherapy Folfirinox, 4 cycles|"oxaliplatin: 85 mg/m2
irinotecan: 180 mg/m²
folinic acid: 400 mg/m2
5FU: 2400 mg/m2"
1561829|NCT02514278|Radiation|50 Gy, 2 Gy/session; 25 fractions|Radiochemotherapy 5 weeks
1561830|NCT02514278|Procedure|Local excision in good responders|"If local excision:
Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)
Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1."
1561831|NCT02514278|Procedure|Rectal excision in bad responders|
1561832|NCT02514278|Drug|Capecitabine|1600 mg/m2 daily 5 days/7
1561833|NCT02514252|Drug|Fentanyl Sublingual Spray (FSS)|"Stage 1: First Pain Episode - Single dose of breakthrough opioid given from existing PCA pump equivalent to 10% of their MEDD.
Second Pain Episode - Single dose of FSS equivalent to 16-32% of MEDD. If not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum.
Third Pain Episode (at least 4 hours after second episode) - Participant required 2 breakthrough FSS doses for the last episode of breakthrough pain, or if the effective dose has not been identified, he/she will double the last administered dose. If breakthrough pain not effective at 30 minutes, participant repeats same dose one more time (with a cap of 1600 mcg total; i.e. dose given 30 minutes ago + dose now = 1600 mcg maximum).
Stage 2: If FSS successful in hospital, upon discharge, FSS used as first choice of pain medication instead of oral pain medication for pain for up to 4 weeks."
1561834|NCT02514252|Behavioral|Questionnaires|Symptom questionnaire completed at baseline and after last dose of FSS while hospitalized. After Day 28, questionnaire completed over the phone about participant's opinion of research study.
1561835|NCT02514252|Behavioral|Mental Ability Tests|Mental ability tests given while hospitalized 30 minutes after first dose of current pain medication, and 30 minutes after each FSS dose.
1561836|NCT02514252|Behavioral|Study Diary|Participants given study diary to document pain level, how many times FSS used, and any side effects experienced each day.
1561837|NCT02514239|Drug|BI 836909|
1561838|NCT02514226|Procedure|supragingival treatment|In G1, all participants will receive supragingival treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil). Supragingival treatment will be performed above the gingival margin.
1561839|NCT02514226|Procedure|periodontal treatment|All participants receive periodontal treatments by an experienced specialist with universal curettes (Hu-Friedy) and ultrasound (Ultra Sound Dabi Atlante - Profi Neo US, Ribeirao Preto, Brazil) in a full mouth manner.
1561840|NCT02514226|Procedure|periodontal treatment and photodynamic therapy|In G3, the periodontal treatment will be performed identical as G2. PDT will be administered in periodontal pockets > 4mm. Methylene blue will be applied in the deep of periodontal pockets. After 5 minutes of application the red laser diode (λ = 660 nm) will be applied with output power of 100 mW (Therapy XT, DMC, São Carlos, Brazil) with 90 seconds of exposure, i.e. 9J in each point. Applications will be held in six sites around the tooth in all teeth. To finalize, 1 minute of irradiation in scan around each tooth and rinsing with saline solution to remove the FS.
1561841|NCT02514226|Other|dental hygiene orientation|Plaque Control through the use of toothbrush and floss
1561842|NCT02514213|Biological|2mg INO-5150 and electroporation device CELLECTRA®-5P|2mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
1561843|NCT02514213|Biological|8.5mg INO-5150 and electroporation device CELLECTRA®-5P|8.5 mg INO-5150 delivered IM followed by electroporation using CELLECTRA®-5P
1561844|NCT02514213|Biological|2mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|2mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
1561845|NCT02514213|Biological|8.5mg INO-5150 plus 1mg INO-9012 and electroporation device CELLECTRA®-5P|8.5mg INO-5150 plus 1 mg INO9012 delivered IM followed by electroporation using CELLECTRA®-5P
1561846|NCT02514213|Device|Electroporation using CELLECTRA®-5P|Electroporation device CELLECTRA®-5P
1561847|NCT02514200|Procedure|Topography-based CXL (KXL2)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a topography-based arcuate shape with the Avedro KXL2® with an energy from 7.2-15.0 J/cm2 depending on the severity of the keratoconus.
1561848|NCT02514200|Procedure|Conventional pulsed CXL (pCXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, and then soaked in Riboflavin by repeated topical application every 3 minutes during 10 minutes. The cornea is then irradiated with pulsed ultraviolet light (1s on/1s off) in a central round 8mm zone with the Avedro KXL2® with an energy of 5.4 J/cm2.
1561849|NCT02514200|Drug|Riboflavin|Riboflavin is added topically immediately before the treatment every 3 minutes during 10 minutes in the eye to be treated
1561850|NCT02514200|Device|Avedro KXL II|The KXL II™ System crosslinking device from Avedro, Inc. is used for ultraviolet irradiation of the cornea after riboflavin application in both treatment arms.
1561851|NCT02514187|Drug|Cyclotron-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.
All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
1561891|NCT02513927|Drug|Nifedipine|Nifedipine was given orally in a dose of 30 mg/day to treat patients in the amlodipine group for 12 weeks.
1561892|NCT02513914|Device|Dural Venous Sinus Stenting|See Dural Venous Sinus Stenting arm.
1561930|NCT02513550|Drug|Placebo|Administered SQ
1561852|NCT02514187|Drug|Generator-produced 99mTc|"Each research subject will serve as his/her own control, and will undergo imaging using both generator- and cyclotron-produced 99mTc. The study will follow the usual clinical procedure for routine imaging in the nuclear medicine department.
All subjects will be contacted by phone or in person the day following the injection of both generator and cyclotron-produced 99mTc to monitor for potential adverse events."
1561853|NCT02514174|Drug|Afatinib|afatinib starting at 30 mg daily dose
1561854|NCT02514161|Other|Inspiratory Muscle training|This protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama)
1561855|NCT02514161|Other|IMT + Manual Therapy and Motor Control Exercise|The Inspiratory Muscle Training protocol will be performed using the Powerbreathe classic level 1 device and Yoga Respiratory Exercises (Pranayama). Manual Therapy and Motor Control Exercises will consist of joint mobilization/manipulation and exercises in the neck and thoracic regions
1561856|NCT02514148|Behavioral|Therapeutic patient education|Therapeutic patient education based on pain physiology from a biobehavioral perspective adding a training in coping strategies.
1561857|NCT02514148|Other|Therapeutic exercise|Therapeutic exercise consist on stretch of cervical-scapular muscles ( Trapezius and angular of the scapula), Cranium-cervical flexor stabilization exercise, auto cervical tractions, shoulders rotation, low intensity exercise ( walking), craniocervical extension, cervical flexion and extension.
1561858|NCT02514148|Other|No intervention|No intervention consist on measure the whole variables in chronic migraine patients to compare it with experimental interventions
1561859|NCT02514148|Other|Manual Therapy|Manual therapy consist on ; oscillatory traction , maintained craniocervical traction, upper cervical flexion mobilization, side glide roll, anterior-posterior upper cervical mobilization with wedge, lateral glide at the C1-C2 and C2-C3 levels, retraction technique, trigeminocervical neural mobilization , and upper cervical traction, followed by posterior-anterior glide at C4.
1561860|NCT02514135|Other|No intervention|
1561863|NCT02514109|Other|Neurological assessment and Blood sample|Neurological assessment (physical examination, electroneuromyography , International Prognostic Score (ISS), Overall Disability Scale (ODS)) and 2 blood collection tubes for antibody screening
1561868|NCT02514057|Other|Questionnaire|Form filling only
1561869|NCT02514044|Drug|Dexedrine|10 mg immediate release of Dexedrine
1561870|NCT02514044|Device|Active tDCS|1.5 mA tDCS anodal tDCS
1561871|NCT02514044|Behavioral|Speech Therapy|60 min of speech therapy
1561872|NCT02514044|Drug|Placebo|
1561873|NCT02514044|Device|Sham tDCS|
1561874|NCT02514031|Drug|ARQ-761|"Dose Level 1:
ARQ761 195 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1, 8, 15 Nab paclitaxel 125 mg/m2 D1, 8, 15
Dose Level 2:
ARQ761 290 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15
Dose Level 3:
ARQ761 390 mg IV D1, D15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-paclitaxel 125 mg/m2 D1,8,15
Expansion Dose Level:
ARQ761 390 IV mg or as tolerated D1, 15 Gemcitabine 1000 mg/m2 D1,8,15 Nab-Paclitaxel 125 mg/m2 D1,8,15"
1561875|NCT02514031|Drug|Gemcitabine|"Therapy after lead in Phase:
You will receive Gemcitabine (1000mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
1561876|NCT02514031|Drug|nab-paclitaxel|"Therapy after lead in phase:
You will receive nab-paclitaxel (125 mg/m2) administered intravenously on Days 1,8, 15-every 28 days. All cycles are 28 days in duration and there are no rest periods between cycles. You may continue treatment after cycle 6 until disease progression."
1561877|NCT02514018|Biological|Live-attenuated varicella-zoster virus vaccine|Commercial vaccine used to prevent shingles
1561878|NCT02514005|Other|Manual therapy|- Manual Therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
1561879|NCT02514005|Device|Dry needling|"Manual therapy. Study treatment consists of a comprehensive joint treatment of the lumbar region and the lower limbs that are related to the biomechanics of the knee. In this way, the aim is to globally balance the possible dysfunctions that may exist in the lower lumbar region and sacroiliac joint, hip, knee and ankle.
Dry needling (DN). Dry needling is performed in the MTrPs of the vastus lateralis and vastus medialis muscles of the quadriceps."
1561880|NCT02513992|Procedure|intra-arterial injection of tracer|intra-arterial ictal injection of perfusion tracer
1561881|NCT02513992|Drug|99m-Technetium Ethyl Cysteinate Dimer|administration of perfusion tracer 99m Tc-ECD during epileptic seizure
1561882|NCT02513992|Device|intra-arterial catheter|placement of intra-arterial catheter via femoral artery
1561883|NCT02513992|Device|pressure injector|the injection of the perfusion tracer will be delivered with a pressure injector
1561884|NCT02513979|Drug|Angiotensin type II receptor antagonists|Angiotensin type II receptor antagonists given to hypertensive patients treated with high blood pressure
1561885|NCT02513953|Procedure|Laparoscopic|Four Port Laparoscopic cystectomy
1561886|NCT02513940|Drug|Testosterone|Subjects will receive transdermal testosterone gel 1% 100 mg daily for 7 days
1561887|NCT02513940|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
1561888|NCT02513940|Drug|Placebo|
1561889|NCT02513940|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects in all phases to moderately lengthen the QT interval
1561890|NCT02513927|Drug|metoprolol|Metoprolol was given orally in a dose of 95 mg/day to treat patients in the metoprolol group for 12 weeks.
1561894|NCT02513901|Drug|Chidamide|Chidamide will be given by mouth on Day 0, 3, 7, 10, 14, 17, 21, 24.
1561895|NCT02513888|Dietary Supplement|vitamin D + diet and lifestyle|subjects will be given vitamin D along with diet and lifestyle modification counselling
1561896|NCT02513888|Dietary Supplement|Placebo + diet and lifestyle|placebo along with diet and lifestyle modification counselling
1561897|NCT02513875|Dietary Supplement|vitamin D|60,000 IU per week for 8 weeks
1561898|NCT02513875|Dietary Supplement|Placebo|placebo +diet and lifestyle
1561899|NCT02513862|Device|Autologous Platelet-Rich Plasma Harvest Technique|15 to 20 mL/kg of whole blood is collected before the administration of heparin from a large-bore central venous access,and is separated into red blood cells component and autologous platelet-rich plasma component by an autologous transfusion system(Sorin Group Electa Essential; Sorin Group Italia, Milan, Italy).
1561900|NCT02513849|Drug|Tamoxifen|Daily tamoxifen tablet for approximately 4 weeks
1561901|NCT02513836|Other|no intervention|
1561902|NCT02513823|Dietary Supplement|2,000 International Units (IU)of vitamin D3|2,000 IU vitamin D taken daily for 10 weeks
1561903|NCT02513810|Device|BioFreedom with 1 month DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
1561904|NCT02513810|Device|BioMatrix Flex with 6 to 12 months DAPT|The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
1561907|NCT02513784|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate is a germicidal mouthwash that reduces bacteria in the mouth.
1561908|NCT02513771|Drug|Sitagliptin|100 mg one tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up
1561909|NCT02513771|Drug|Placebo for sitagliptin|One tablet taken orally daily for 16 weeks, followed by a 4-week post-treatment follow-up.
1561910|NCT02513758|Other|sample|Men will have blood sampling tubes of 10 ml each, a saliva sample and a sample of sperm Women will have a two blood sampling tubes of 10 ml each, a saliva sample and a sampling cervicovaginal secretions
1561911|NCT02513745|Device|Conventional|Routine cataract surgery by phacoemulsification before laser-assisted cataract surgery.
1561912|NCT02513745|Device|Verion|Laser-assisted cataract surgery with the digital surgical planning and positioning tools, and intraoperative aberrometry.
1561913|NCT02513732|Device|XIENCE Xpedition 2.25 mm stent|Patients receiving XIENCE Xpedition 2.25 mm stent
1561915|NCT02513693|Drug|Standard neuromuscular blockade|Standard neuromuscular block provided by rocuronium to TOF-count 1-2. Reversal of the block with neostigmine.
1561916|NCT02513693|Drug|Deep neuromuscular blockade|Deep neuromuscular block provided by rocuronium to PTC 1-2. Reversal of the block with sugammadex.
1561917|NCT02513680|Device|Infrared Laser + Amber LED|This group will make the application on the machine program that uses laser and led together to photorejuvenation . Laser is applied for 30 seconds and soon after begins the LED by 2:30 minutes in each region to apply.
1561918|NCT02513680|Device|Amber LED|This group will make the application on the machine program that uses LED photorejuvenation only 3 minutes of time for each area to be applied.
1561919|NCT02513667|Drug|Ceritinib|Patients will receive ceritinib at a dose of 750 mg (150 mg capsules times 5 capsules once a day) for 10 weeks. Patient will stop taking Ceritinib 72 hours before SABR radiation. The patient may start taking Ceritinib again 72 hours after radiation is complete. Patient will continue to take certinib for up to 8 months.
1561920|NCT02513667|Radiation|Stereotactic ablative body radiation|Patients will receive study drug for 10 weeks. They could get 1, 3 ,or 5 treatments on consecutive days with 18 hours between each treatment or every other day (doctor's determination).
1561921|NCT02513654|Drug|Lamotrigine|Lamotrigine dispersible tablets supplied in 3 different strengths 25 mg, 50 mg and 100 mg. These dispersible tablets appear as white or off-white tablets.
1561922|NCT02513641|Device|Hypoxico Altitude Training Systems|Participants will sleep in a tent (which will fit his/her personal mattress) simulating an altitude of ~2,400 meters for 7-12 hours each night for a period of 14 days. Baseline testing measures will include a oral glucose tolerance test (OGTT) and body composition (iDXA). Post-treatment testing measures will include OGTT only.
1561923|NCT02513602|Procedure|Dental implant insertion|Dental implant insertion will be carry out in the mandible of the patients enrolled, through a surgical template in order to repeat the same position of the simulating implant insertion. After a trephine bur passage, the final two or three twist-drills will be used to realize the implant socket. After implant positioning, a cover screw will be tightened and the mucosa sutured above.
1561924|NCT02513589|Drug|18F-PBR06|Positron Emission Tomography / Computed Tomography (PET-CT) using 18F-PBR06
1561925|NCT02513576|Other|physiotherapy exercises|Consisted of trunk stabilization exercises.The exercises were undertaken for 15 minutes every day for tree weeks. Patients were the contract their abdominal muscles with an emphasis on the transverse abdominal. Patients were to contract their abdominal muscles in a supine,sitting and stand up position.
1561929|NCT02513550|Drug|Ixekizumab|Administered SQ
1561931|NCT02513524|Procedure|Direct Observed Therapy test|There is one group only, all of whom will undergo direct observed therapy testing
1561932|NCT02513511|Procedure|laryngoscopy under hypnosis|patient will be put in an hypnotic state before performing a laryngoscopy followed by oro-tracheal intubation
1561933|NCT02513498|Drug|Ixazomib Citrate|Given PO
1561934|NCT02513498|Other|Laboratory Biomarker Analysis|Correlative studies
1561935|NCT02513498|Other|Quality-of-Life Assessment|Ancillary studies
1561936|NCT02513498|Other|Questionnaire Administration|Ancillary studies
1561937|NCT02513485|Drug|Levodopa+carbidopa|Sinemet is a combination of 250 mg levodopa and 25 mg carbidopa. Sinemet will be administered orally at Visit 2 (within 1 week of Screening) or at Visit 3 (within 2-4 weeks of Screening).
1561938|NCT02513485|Drug|Placebo|A placebo is a sugar pill that has no therapeutic effect and will be administered orally at Visit 2 (within 1 week of Screening) or at Visit 3 (within 2-4 weeks of Screening).
1561939|NCT02513472|Drug|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 mg/m2 IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the subject withdraws consent.
1561940|NCT02513472|Drug|Pembrolizumab|Pembrolizumab will be administered as a 200 mg IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the subject withdraws consent.
1561943|NCT02513446|Drug|BI 1026706|Single dose of BI 1026706 on Day 1
1561944|NCT02513446|Drug|Itraconazole|7 days of itraconazole treatment combined with a single dose of BI 1026706 on the fourth day
1561945|NCT02513433|Drug|Bupivacaine|Local anesthetic
1561946|NCT02513433|Drug|Levobupivacaine|Local anesthetic
1561947|NCT02513433|Drug|Ropivacaine|Local anesthetic
1561948|NCT02513420|Behavioral|Perineal muscle training|It is a combination of perineal massage and Kegel exercises.
1561949|NCT02513407|Behavioral|Behavioral Dietary Intervention|Attend healthy nutritional education session
1561950|NCT02513407|Other|Educational Intervention|Attend EML educational session
1561951|NCT02513407|Behavioral|Exercise Intervention|Attend exercise educational session
1561952|NCT02513407|Behavioral|Exercise Intervention|Receive fitness tracker
1561953|NCT02513407|Other|Laboratory Biomarker Analysis|Correlative studies
1561954|NCT02513407|Other|Questionnaire Administration|Ancillary studies
1561955|NCT02513394|Drug|Palbociclib|
1561956|NCT02513394|Drug|Standard Adjuvant Endocrine Therapy|
1561957|NCT02513381|Other|Vitamin D3, 3200IU|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
1561958|NCT02513381|Other|Placebo|Each participant will receive either Vitamin D3, 3200IU or Placebo daily for three months.
1561959|NCT02513368|Device|augmentation procedure with Bio-Oss® and Bio-Gide®|soft tissue management using GBR procedure
1561960|NCT02513368|Procedure|augmentation procedure with connective tissue graft|soft tissue management using the bilaminar technique
1561961|NCT02513355|Biological|Endostar|Endostar 15mg/m2, 21 days per cycle, 4 to 6 cycles
1561962|NCT02513355|Drug|Changchun marina|25mg/m2,d1 and d8,q21d×4
1561963|NCT02513355|Drug|cisplatin|80mg/m2,d1, q21d×4
1561964|NCT02513355|Drug|Taxol|135-175mg/m2,d1,q21d×4
1561965|NCT02513355|Drug|parapl|AUC=5-6,d1,q21d×4
1561966|NCT02513342|Biological|Endostar|Endostar 30mg continuous intravenous injection pump,d1-d7；
1561967|NCT02513342|Drug|Docetaxel|d4 Docetaxel，75（mg/m2），iv；
1561968|NCT02513342|Drug|Cisplatin|d4，cisplatin，75（mg/m2），iv；
1561969|NCT02513329|Drug|Bupivicaine|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive bupivacaine. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
1561970|NCT02513329|Drug|Saline|A computer-generated 1:1 block randomization scheme will be used to assign participants to receive saline. Randomization will be performed by the injectionist immediately before the injection procedure by opening an opaque envelope to reveal the participant number and group assignment printed on an index card.
1561972|NCT02513290|Drug|Bilastine|
1561973|NCT02513290|Drug|Loratadine|
1561974|NCT02513251|Other|Chronic pain|Chronic pain patients would complete the Traditional Chinese-Cantonese version of Short Form McGill Pain Questionnaire
1561975|NCT02513238|Drug|Mesenchymal stem cell|Stemcells injected into submandibularis
1561976|NCT02513238|Drug|Isotonic NaCl|
1561977|NCT02513225|Behavioral|Project EMPWR|Participants will receive both Adapted Project EMPWR and Optimized Standard Care (OSC).
1561978|NCT02513225|Other|Optimized Standard Care (OSC)|Participants will receive Optimized Standard Care (OSC) alone.
1561979|NCT02513212|Device|Potassium Oxalate|Professionally applied liquid
1561980|NCT02513212|Drug|Stannous fluoride paste|SnF2 Paste
1561981|NCT02513212|Device|Manual toothbrush|Marketed manual toothbrush
1561982|NCT02513212|Device|Power toothbrush|Marketed power toothbrush
1561983|NCT02513199|Radiation|SBRT|Radiation is to be delivered to 30-45 Gy in 5 fractions. 40 Gy in 5 fractions will be utilized, unless dose constraints preclude it. Treatment will optimally be delivered every other day with no more than 3 fractions per week. The ideal treatment team will be less than 15 total days.
1561984|NCT02513199|Drug|TACE|two sessions of standard TACE with ethiodol separated by a 4-week interval.
1561995|NCT02513147|Drug|Dolutegravir|
1561996|NCT02513147|Drug|PI|(Fosamprenavir, atazanavir, lopinavir or darunavir) boosted with 100 mg of ritonavir, or atazanavir (400 mg / d) not boosted with ritonavir,if the 2 NRTIs are abacavir + Lamivudine
1561997|NCT02513147|Drug|2 NRTI|
1561998|NCT02513147|Drug|2 NRTI|
1561999|NCT02513121|Other|Dietary modification|The intervention is a modification of the family's habitual diet with a low sugar version of their diet.
1562000|NCT02513108|Procedure|same day discharge|same day discharge after PCI for stable CAD
1562001|NCT02513095|Drug|Dantrolene sodium for injectable suspension|Ryanodex will be administered as a rapid IV push as a single doses of 2 mg/kg or as 1 mg/kg.
1562002|NCT02513082|Procedure|Sono guided nerve block|Sono guided nerve block is effectively and safely performed for pain relief after total knee arthroplasty
1562003|NCT02513069|Drug|Nicotine gum|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine gum as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
1562004|NCT02513069|Behavioral|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided reinforcement for videos that suggest smoking abstinence.
1562005|NCT02513069|Behavioral|Telephone counseling|Participants receive five sessions of cognitive-behavioral telephone counseling, and a participant manual. The telephone counseling protocol included in this application is based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation and is informed by behavioral treatment principles .
1562006|NCT02513069|Drug|Nicotine patch|Participants will be prescribed nicotine patches to be used during the post-quit phase of the study.
1562007|NCT02513069|Drug|Nicotine lozenge|"Participants will be prescribed one form of nicotine replacement rescue treatment (i.e., gum, lozenge), and may choose nicotine lozenge as the preferred rescue treatment. Participants will be instructed to use the rescue method as needed during the post-quit phase of the study to reduce cigarette cravings."
1562008|NCT02513069|Device|Smart phone|Participants in the experimental condition will be loaned a smart phone to use during the mobile contingency management intervention period. The phone will be used to record videos of carbon monoxide readings to determine smoking abstinence.
1562009|NCT02513069|Device|Carbon monoxide monitor|Participants in the experimental condition will be loaned a CO monitor to use during the mobile contingency management intervention period. The monitor will be used to determine carbon monoxide content in the breath as a measurement of smoking.
1562010|NCT02513056|Other|MRI|MRI
1562013|NCT02513017|Behavioral|Stimulus Control Instructions and Sleep Restriction Therapy|Please refer to arm/group descriptions.
1562014|NCT02513004|Drug|Ticagrelor|Patients will receive first dose of 90mg ticagrelor tablets (powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure, followed by 90mg of ticagrelor 12 hours after the first dose. The third dose of ticagrelor will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 90mg of ticagrelor orally bid, at approximately 12-hourly intervals. The total study period is 3 months.
1562015|NCT02513004|Drug|Clopidogrel|Patients will receive a loading dose of 300mg clopidogrel tablets (four 75mg capsules powdered) taken via nasogastric tube after LIMA-LAD bypass establishing, the close of thorax and before PCI procedure. The second dose of clopidogrel will be given to patients after the 24 hour blood sample has been obtained and 24 hours after the first dose. Thereafter, the patients will take 75mg of clopidogrel capsules orally od. The total study period is 3 months.
1562016|NCT02512991|Other|Helicopter Emergency Medical Service|May 1st 2010, the first Danish Helicopter Emergency Medical System (HEMS) was implemented in Region Zealand and the Capital Region of Denmark.
1562017|NCT02512978|Drug|Levothyroxine|Levothyroxine is used to normalize the thyroid hormone level of patients allocated to levothyroxine.
1562018|NCT02512965|Radiation|20 Gy in 5 fractions|
1562019|NCT02512965|Radiation|Conventional SBRT: 24 Gy in 2 fractions|
1562020|NCT02512952|Procedure|Open flap debridement (OFD)|Oral prophylaxis followed by Open flap debridement (OFD)
1562021|NCT02512952|Procedure|OFD with Platelet rich fibrin (PRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Platelet rich fibrin (PRF) placement into the bone defect
1562022|NCT02512952|Procedure|OFD with Titanium Platelet rich fibrin (TPRF)|Oral prophylaxis followed by Open flap debridement (OFD) with Titanium Platelet rich fibrin (TPRF) placement into the bone defect
1562023|NCT02512939|Procedure|blood test, not yet marketed, no trade name|blood test using the new TB diagnostic test
1562024|NCT02512926|Drug|Carfilzomib|Carfilzomib in combination with cyclophosphamide and etoposide for children with relapsed and refractory solid tumors and leukemias
1562025|NCT02512926|Drug|Cyclophosphamide|
1562026|NCT02512926|Drug|Etoposide|
1562027|NCT02512913|Behavioral|Adapted/enhanced MAPS|The plan is for recruitment at the first prenatal care visit followed by a proposed eight-session phone counseling sequence for the women, consistent with the session frequency in the original MAPS intervention: 1st call at 14 weeks gestation (75% of Romanian women begin prenatal care in 1st trimester), three monthly calls through the 2nd trimester (18-22-26 weeks gestation), a 5th and 6th calls in the 3rd trimester (32 and 36 weeks), and two postnatal calls (2 and 6 weeks postpartum). Four calls are planned for the partners: at 14-, 22-, and 32-weeks, and at 2-weeks postpartum.
1562028|NCT02512900|Drug|MEDI9929, 140 mg|On Day 1, two MEDI9929 subcutaneous injection of 70 mg each were given into the anterior aspect of one thigh immediately followed by the second injection into the anterior aspect of the contralateral thigh to make the required dose of 140 mg in participants of 12 to 17 years of age.
1562029|NCT02512887|Drug|Caudal Block Anesthesia (bupivacaine without epinephrine)|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine 1mL/kg without epinephrine into the caudal canal, which is the sacral portion of the spinal canal.
1562030|NCT02512887|Drug|Dorsal Penile Block Anesthesia (bupivacaine without epinephrine)|Anesthesia will be delivered via inhalation induction with air/nitrous oxide and sevoflurane, and injection of 0.25% bupivacaine without epinephrine into the dorsal portion of the penis.
1562031|NCT02512874|Other|Pulmonary Rehabilitation|Measures of frailty taken before and after pulmonary rehabilitation.
1562032|NCT02512874|Device|Dynamometer|Grip Test
1562033|NCT02512874|Radiation|DEXA|Body Composition Testing
1562034|NCT02512874|Other|Gait Speed Test|15 foot walk test
1562035|NCT02512874|Device|Activity Monitor|Measures energy expenditure and activity
1562036|NCT02512874|Other|Questionnaires|Health-related questionnaires measuring self-reported exhaustion, emotions and disease symptoms.
1562037|NCT02512861|Drug|Bupivacaine|"Bupivacaine will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:
Under 20kgs weight: 0.25% Bupivacaine at 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5% Bupivacaine at 0.5 ml/kg up to a maximum of 25ml of 0.5% Bupivacaine for patients > 50 kgs"
1562038|NCT02512861|Drug|Placebo|"Saline will be administered bilaterally to the parasternal intercostal spaces during surgery according to these doses:
Under 20kgs weight: 1 milliliter/kilogram (1ml/kg); Above 20kgs weight: 0.5 ml/kg up to a maximum of 25ml for patients > 50 kgs"
1562039|NCT02512835|Other|Community vital signs|We will present clinicians with information about their patients' communities
1562041|NCT02512809|Drug|Isoflurane|
1562042|NCT02512809|Drug|Dexmedetomidine|
1562043|NCT02512796|Drug|Gadolinium contrast dye|Gadolinium contrast dye administered during MRI
1562044|NCT02512783|Drug|Lidocaine|Administration of 1ml of pre-treatment 1% lidocaine 1-minute prior to sedation
1562045|NCT02512783|Drug|Normal Saline|Administration of 1ml of pre-treatment normal saline 1-minute prior to sedation
1562046|NCT02512783|Drug|Propofol|Intravenous administration of propofol according to standard care to sedate patient.
1562047|NCT02512770|Procedure|endoscopic dilatation|
1562048|NCT02512744|Procedure|Decannulation protocol.|Comparison of two different decannulation protocols: one protocol based on capping trial tolerance to decide when to decannulate vs. protocol based on suctioning frequency of respiratory secretions to decide when to decannulate (criteria: ≤2 aspirations every 8 h along 24 consecutive hours).
1562049|NCT02512744|Device|High flow conditioned oxygen therapy|High flow conditioned oxygen therapy will be applied during all study period through tracheal cannula in the experimental arm (suctioning frequency based protocol) and during periods out of capping trials in the control arm (capping trials based protocol).
1562050|NCT02512731|Device|Esophageal Doppler Monitor|Esophageal doppler monitoring (EDM) is a minimally invasive means of continuously measuring the cardiac output from the pattern of blood flow in the descending thoracic aorta.
1562051|NCT02512718|Drug|Omegaven|Comparison of FOLE vs. SOLE
1562052|NCT02512718|Drug|Soybean oil lipid emulsion|Comparison of FOLE vs. SOLE
1562053|NCT02512705|Device|Pinel Restraints|
1562054|NCT02512705|Behavioral|Seclusion Room|
1562055|NCT02512692|Device|SIR-Spheres microspheres (Yttrium-90 Microspheres)|On Day 3 or 4 of cycle 1 90Y TARE will be administered
1562056|NCT02512692|Drug|Gemcitabine|On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
1562057|NCT02512692|Drug|Cisplatin|On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
1562058|NCT02512679|Drug|Cyclophosphamide Dose Level 1|given by IV at a total dose of 105 mg/kg, to be divided into three doses of one 35 mg/kg dose per day, for 3 days on the first level. After ten patients the de-escalation will begin if the stopping rule is not met.
1562059|NCT02512679|Drug|Cyclophosphamide Dose Level 2|Level 2 will be 70mg/kg in 2 divided given once a day for 2 days;
1562060|NCT02512679|Drug|Cyclophosphamide Dose Level 3|Level 3 will be 35mg/kg as a one-time dose.
1562061|NCT02512679|Drug|Cyclophosphamide Dose Level 4|Level 4 will be no cytoxan.
1562062|NCT02512666|Device|AM4113-N5UT Dino-Lite|
1562063|NCT02512653|Biological|Cupressus arizonica|Four different concentrations of Cupressus arizonica allergen extract, positive control and negative control
1562064|NCT02512640|Procedure|Volume-controlled ventilation|a tidal volume of 8 ml/kg
1562065|NCT02512640|Procedure|Pressure-controlled ventilation|a peak airway pressure to maintain a tidal volume of 8 ml/kg
1562066|NCT02512627|Behavioral|Cognitive training|
1562067|NCT02512627|Behavioral|Physical exercise|
1562068|NCT02512627|Behavioral|Sequential training|
1562069|NCT02512627|Behavioral|Dual-task training|
1562070|NCT02512614|Other|Antimicrobial Hand Towel|Novel antimicrobial hand towel.
1562071|NCT02512601|Drug|Sulodexide|Sulodexide (two capsules of Sulodexide 15 mg twice daily).
1562072|NCT02512601|Other|Compression therapy|"Compression:
With an orthosis: Compression 22-29 mmHg, length of 20 cm above the DVT area.
With a bandage: 7-10 m long and 10 cm wide.
Both strategies (orthosis vs bandage) are equally applicable."
1562073|NCT02512588|Drug|BTD-001|
1562074|NCT02512588|Drug|Placebo|
1993956|NCT03100149|Drug|RO7046015|RO7046015 will be administered at dose of 4500 milligrams (mg) for participants with body-weight greater than or equal to (>/=) 65 kilograms (kg) or 3500 mg for participants with body-weight less than (<) 65 kg.
1562081|NCT02512549|Other|Pulmonary Rehabilitation|
1562082|NCT02512536|Drug|Botulinum Toxin Type A|Ultrasound scan guided injection into supraspinatus muscle belly with Botulinum Toxin Type A
1562083|NCT02512523|Drug|Teneligliptin|
1562084|NCT02512523|Drug|Sitagliptin|
1562085|NCT02512510|Drug|TD-4208|
1562086|NCT02512497|Drug|Romidepsin|"Part 1: Romidepsin dosed per actual body weight/actual body surface area. Romidepsin administered on Day -6, -5, -4, and -3 at escalating doses of 1 mg/m2, 2 mg/m2, and 3 mg/m2 by vein to determine the maximal tolerated dose.
Romidepsin Maintenance Therapy - Part 2: Starting between Day +28 and Day +100, if participant is eligible based on disease status, they will continue to receive Romidepsin 8 mg/m2 by vein over 1 hour on Day 1 of each 2-week cycle."
1562087|NCT02512497|Drug|Busulfan|Part 1: The first two doses of Busulfan of 80 mg/m2 administered on day -13 and -12. Busulfan administered at the dose calculated to achieve a total (including first two doses delivered on Day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
1562088|NCT02512497|Drug|Fludarabine|Part 1: Fludarabine 40 mg/m2 by vein on Days -6 to -3.
1562089|NCT02512497|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
1562090|NCT02512497|Drug|Thymoglobulin|Participants receiving a graft from a matched unrelated donor receive rabbit Thymoglobulin; 0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1.
1562091|NCT02512484|Procedure|venepuncture, sputum collection, xray|venepuncture, sputum collection, xray
1562092|NCT02512471|Drug|Ropivacaine|brachial plexus block with ropivacaine 0.275%, MEV90 for USG-SCB (young group) brachial plexus block with ropivacaine 0.325%, MEV90 for USG-SCB (middle-aged group)
1562094|NCT02512445|Behavioral|Trauma Informed Guilt Reduction Therapy|Trauma focused therapy
1562095|NCT02512445|Behavioral|Supportive Care Therapy|Supportive therapy
1562096|NCT02512432|Device|INTACS|asymmetrical corneal inserts to reduce, or eliminate myopia and astigmatism in patients with keratoconus to decrease dependence on contact lenses and spectacle correction, while potentially deferring need for corneal transplantation.
1562097|NCT02512419|Behavioral|Text-Enhanced Physical Activity Intervention Arm|Participants in the Text-Enhanced Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, print-based + text-message physical activity intervention that specifically addresses the physical activity barriers and intervention needs/preferences of Mexican and Mexican American men.
1562098|NCT02512419|Behavioral|Health Education Control Arm|Participants will receive a Spanish language, print-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
1562099|NCT02512419|Device|Actigraph GT3X|
1562100|NCT02512406|Other|The Sensory Profile|60 item questionnaire administered to participants age 6-10 with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
1562101|NCT02512406|Other|The Adult/Adolescent Sensory Profile|60 item questionnaire administered to participants age 11 and older with questions pertaining to sensory processing categories of Taste/Smell, Movement, Visual, Touch, Activity Level, and Auditory. Scores are tallied for each category. Results are plotted along an x and y-axis with one axis being perception or stimulus (low registration to sensory sensitivity) and the other being response to stimulus (sensation seeking to sensation avoiding). Each category is plotted along this axis and compared to normative data which is included in this tool.
1562102|NCT02512406|Other|Children's Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 6-14. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
1562103|NCT02512406|Other|Yale-Brown Obsessive Compulsive Scale|10-item symptom checklist questionnaire administered by a physician to participants aged 15 and older. 1st part is a yes/no checklist of obsessions (1-42) and compulsions (43-67) experienced in the past or present. 2nd part is a scored severity scale with 10 questions in which they assign a 0-4 severity score which is summed for a total score.
1562104|NCT02512406|Other|Yale Global Tic Severity Scale|Clinician administered questionnaire given to all participants. Part 1 asks about 10 types of motor tics, 12 types of vocal tics (current, ever, age of onset, description). Part 2 is a severity rating that scores both motor and vocal tics on a 0-5 scale for each severity item: number of tics, intensity, frequency, complexity, interference, impairment. Totals are summed for all items.
1562105|NCT02512406|Other|Demographic Data|Data will be collected including: Age, duration of symptoms, presence or absence of autism spectrum disorder, presence or absence of OCD, presence or absence of ADHD.
1562106|NCT02512393|Device|Active tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 20 minutes once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
1562218|NCT02511522|Other|Best Supportive Care|Including analgesics, palliative care and/or pain specialist assessment as needed
1562262|NCT02511171|Other|Cranial osteopathic manipulative therapy|
1562107|NCT02512393|Device|Sham tDCS|This group will receive tDCS with a constant current of 2 mA intensity will be applied for 30 seconds once a day for five consecutive days using a pair of thick (0.3 cm) rectangular surface sponge electrodes (5 cm x 7 cm) saturated with 10 mL of saline solution. The anode electrode will be placed over M1 (C3 or C4 according to the 10-20 system for EEG electrode placement) of the hemisphere contralateral to the affected knee, and the cathode electrode will be placed over the supraorbital region (SO) ipsilateral to the affected knee (M1-SO montage).
1562108|NCT02512380|Drug|Docetaxel;oxaliplatin;s1|Docetaxel 60mg/m2 was administered on day 1 of every 14 days.oxaliplatin 85 mg/m2 was administered on day 2 every 14 days. 40-60 mg of oral S-1 according to body-surface area twice a day was given for 10 days every 14 days .
1562109|NCT02512380|Drug|oxaliplatin;s1|oxaliplatin 100 mg/m2 on day 1 every 21 days.40-60 mg of oral S-1 according to body-surface area twice a day was given for 2 weeks every 21 days .
1562110|NCT02512367|Other|Dental care education program|
1562111|NCT02512367|Other|Surveillance|
1562112|NCT02512354|Other|Sample of a fragment of fetal tissue|
1562113|NCT02512354|Other|Blood samples|
1562114|NCT02512341|Device|Computer Aided Auscultation (CAA)|
1562115|NCT02512328|Device|APP supported colonoscopy preparation|additional usage of an app for colonoscopy preparation
1562116|NCT02512315|Drug|Docetaxel (DOC)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Docetaxel is given at a dose of 75mg/m2 on the first day of every cycle.
1562117|NCT02512315|Drug|Cisplatin (DDP)|Neoadjuvant chemotherapy (NACT) is administrated every 3 weeks with the regimen comprised of docetaxel plus cisplatin. A total of 4 cycles of NACT is applied. Cisplatin is given at a dose of 75mg/m2 on the first day of every cycle.
1562118|NCT02512315|Radiation|Concurrent chemoradiation (CRT)|"The technology of radiotherapy is intensity-modulated radiation therapy (IMRT). A total dose of 66-72Gy is given to gross tumor of nasopharynx (GTVnx), 60-70Gy to positive neck lymph nodes (GTVnd), 60Gy to high-risk region (CTV1), and 50-54Gy to prophylactic irradiation region (CTV2).
The regimen of concurrent chemotherapy is single-agent cisplatin 40mg/m2 weekly."
1562119|NCT02512302|Drug|SUN-101 via eFlow nebulizer|50 mcg glycopyrrolate via Electronic Nebulizer
1562120|NCT02512302|Drug|SUN-101 via eFlow nebulizer with activated charcoal|50 mcg glycopyrrolate via Electronic Nebulizer with activated charcoal
1562121|NCT02512302|Drug|Seebri® Breezhaler®|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI
1562122|NCT02512302|Drug|Seebri® Breezhaler® with activated charcoal|63 mcg glycopyrronium bromide (50 mcg glycopyrronium) via DPI with activated charcoal
1562123|NCT02512302|Drug|Glycopyrrolate Injection|50 mcg glycopyrrolate via IV
1562124|NCT02512289|Device|tDCS (ELDITH) and RAT (REAplan)|Transcranial direct-current stimulation( ELDITH) and Robot-assisted therapy by using REAplan
1562125|NCT02512276|Behavioral|Telepharmacist intervention|The intervention consists of a brief telephonic consultation with a clinical pharmacist using behavioral interviewing techniques tailored to patient's level of health activation and progress reports of medication-taking and disease control. Based on the barriers identified during the initial telephone consultation, patients will be offered more intensive support including reminder and motivational text-messages, video visits and pillboxes.
1562126|NCT02512263|Procedure|Home-based training program|A home-based training program of 8 exercises to do 5 times a week during 9 weeks
1562127|NCT02512250|Other|Registry|
1562128|NCT02512237|Drug|ARX788|ARX788, an antibody drug conjugate
1562129|NCT02512224|Device|Parenteral nutrition|Participants are retrospectively selected with propensity score matching
1562130|NCT02512224|Device|Enteral nutrition|Participants are retrospectively selected with propensity score matching
1562131|NCT02512198|Behavioral|Prescription Data Feedback to GP Practices|GP practices will be randomly assigned to receive reports on one of the two topics. They will get these three times at six-monthly intervals. Within the feedback, alongside the patient-level analysis, there will be action-orientated messages to guide the GP practice.
1993957|NCT03100149|Drug|RO7046015|RO7046015 will be administered at dose of 1500 mg to all participants in the indicated arm.
1562135|NCT02512159|Procedure|drenovac handcrafted|under local anesthesia, sepsis and antisepsis, place sterile field, prepared area go out all devitalized or necrotic tissue using liquid soap surgical and irrigation back saline 0.9%. We introduce a device to distribute the negative pressure or vacuum on ulcer; conducted margins make recommendations 5-12 mm over the edge of the wound, applying negative pressure or vacuum retracted sponges, likewise for the spare fewer gauze was placed Sterile adhesive film covering the defect to seal the system cover adequately the probe output nelaton not to submit drain the system. Connect the probe to the sterile nelaton this hose and a suction system with pressure gauge, pressure -80-125 mmHg. Change it every 72 hours.
1562136|NCT02512159|Procedure|Healing|"Were handled as follows:
Under local anesthesia, prior asepsis and antisepsis of the skin ulcer with iodinepovidone sterile fields are placed, we proceeded to debridement of all necrotic tissue or devitalized then a cure with liquid soap surgery was performed and was irrigated with 1000 cc of solution physiological 0.9%, and finally the ulcer was covered with sterile gauze.
healing of skin ulcers were performed every 24 hours.
the evolution of skin ulcers was evaluated every 3 days, requesting a differential valuing of clinical and biochemical form the aforementioned variables."
1562137|NCT02512146|Procedure|colonoscopy|Patients will undergo colonoscopy and participants will get biopsies from the colon.
1562138|NCT02512133|Device|MIGS Hydrus Ivantis|implant of the micro stent in the nasal Schlemm's canal
1562139|NCT02512133|Procedure|360 degrees SLT|Laser Solutis SLT laser (Quantel Medical, Clermont-Ferrand, France): this frequency-doubled, Q-switched Nd:YAG laser emits light at a wavelength of 532 nm, with a pulse duration of 4 ns, a spot size of 400 µm and pulse energy ranging from 0.2 to 2 mJ
1562140|NCT02512120|Device|volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied VCV by Zeus®(Dräger, Germany).
- Tidal volume : 8ml/kg(ieal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
1562219|NCT02511522|Radiation|Palliative Radiation Therapy|8 Gy in 1 fraction in whole liver or near whole liver. Including anti-emetic pre-medications
1562141|NCT02512120|Device|autoflow-volume controlled ventilation|"After induction of anesthesia and intubation, patients will be applied autoflow- VCV by Zeus®(Dräger, Germany).
- Tidal volume : 8ml/kg(ideal body weight), inspiration:expiration ratio = 1:2, FiO2 = 0.5, fresh gas flow = 3L/min respiratory rate(RR) : 12/min. After position, RR can changed 2 times each per 5 minutes to maintain end tidal CO2 around 35. Positive end expiratory pressure will not used."
1562142|NCT02512107|Dietary Supplement|Juice Plus+|Dried fruit and vegetable juice capsule.
1562143|NCT02512107|Other|Placebo|Placebo capsule
1993958|NCT03100149|Drug|Placebo|RO7046015 placebo will be administered to all participants in the indicated arm.
1562148|NCT02512042|Drug|Test-Brinzolamide 1% Ophthalmic suspension|
1562149|NCT02512042|Drug|Reference-Brinzolamide 1% Ophthalmic suspension|
1562150|NCT02512029|Drug|18F-AV-1451|
1562151|NCT02512016|Other|Study Procedures|"Pelvic Organ Prolapse Quantification exam (3rd tri, 8 wks and 1 yr postpartum)
Intra-abdominal pressure measure. At 8 weeks: IAP during lifting 12.5 kg and abdominal muscle endurance testing. At 1 year: IAP during lifting 17.5 kg and abdominal muscle endurance testing.
Accelerometry: Wrist accelerometer (objective quantification of physical activity) x 1 wk 2-3 and 5-6 wks and 6 mo postpartum.
Measures of strength and body habitus:
8 weeks and 1 year postpartum: Abdominal muscle endurance Abdominal adiposity Body mass index
1 year postpartum: Pelvic floor muscle strength: tested using a Peritron manometer Body composition: using air displacement plethysmography using the BodPod
Qualitative interviews: A smaller number of participants will be purposefully selected for the qualitative interviews in order to understand examples of the postpartum sensations and experiences of women with a wide variety of characteristics and from various social and cultural settings."
1562152|NCT02512003|Device|Fantom Scaffold|
1562153|NCT02511990|Biological|3 mg/kg, single dose IV administration of 10-1074|3 mg/kg, single dose IV administration of 10-1074
1562154|NCT02511990|Biological|10 mg/kg, single dose IV administration of 10-1074|10 mg/kg, single dose IV administration of 10-1074
1562155|NCT02511990|Biological|30 mg/kg, single dose IV administration of 10-1074|30 mg/kg, single dose IV administration of 10-1074
1562156|NCT02511977|Other|peri-implant examination|The prostheses were removed and all implants were evaluated: probing depth, plaque index and bleeding index.
1562157|NCT02511964|Behavioral|Interval Training at 1% Incline|Six Sessions of Running at 1% incline
1562158|NCT02511964|Behavioral|Interval Training at 10% Incline|Six Sessions of Running at 10% incline
1562159|NCT02511951|Procedure|pancreaticojejunostomy|"To create the posterior suturing layers, the needle is inserted from the posterior interior side of the pancreatic duct, passing through the dorsal region of the parenchyma of the pancreatic stump to the posterior surface of the pancreas approximately 0.5 cm distal to the cut edge. The other side of the needle starts from the inside of the jejunum lumen to the subserosa and then passes through the seromuscular layer to the posterior surface of the bowel.The anterior suturing layer is performed in the same manner.
Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
1562160|NCT02511938|Other|Menu Only|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants.
1562161|NCT02511938|Other|Menu Plus intervention|Restaurants will collaborate with project to develop and introduce new healthy kid's menu items. Project will provide recipes, preparation support, nutritional information, and printed menus to restaurants. In addition, project will provide promotional materials and brief restaurant staff trainings to promote the new menu.
1562162|NCT02511925|Other|Weekly poster of unit performance|Weekly feedback is provided to the ICU about current levels of hand hygiene compliance amongst doctors, nurses, and allied healthcare professionals
1562163|NCT02511925|Other|Daily email of personal feedback|Healthcare workers receive private and personal feedback via email regarding their individual performance benchmarked against the average performance for their professional grouping.
1562164|NCT02511925|Other|Active reminder from badge|The badge the healthcare worker is wearing vibrates if opportunities to perform hand hygiene are missed
1562165|NCT02511912|Procedure|V-Wave|The V-Wave shunt implantation procedure is a standard femoral venous access and inter-atrial septal puncture intervention. The shunt is placed through the Fossa Ovalis.
1562166|NCT02511899|Dietary Supplement|Mango fruit powder|Dietary supplement; Mango fruit powder
1562167|NCT02511886|Drug|Arbaclofen Placarbil|Arbaclofen Placarbil
1562168|NCT02511886|Drug|Placebo|Placebo matched tablets
1562169|NCT02511873|Drug|Fycompa|Subjects will take Fycompa for 6 weeks with a dose range of 2mg to 8mg daily
1562170|NCT02511873|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) for 6 weeks with a dose range of 2mg to 8mg daily
1562171|NCT02511860|Dietary Supplement|Burdock|Subjects will consume burdock daily and will undergo laboratory tests to determine the effect of burdock, if any, on organ function.
1562172|NCT02511860|Dietary Supplement|Placebo|Methylcellulose (inert) tablet taken as placebo
1562173|NCT02511847|Drug|Afatinib|"Afatinib 40 mg per day for 14 days, then evaluation, every subject will go into the following phase no matter whether she had response or not
Afatinib 40 mg per day, day 1 to day 21, in combination with paclitaxel 80 mg/m² on days 1, 8, 15 in a 3-weekly course."
1562174|NCT02511834|Device|VEST External Support|
1562175|NCT02511834|Procedure|Coronary Artery Bypass Surgery|
1562176|NCT02511821|Other|Computer-Assisted Intervention|Complete online surveys
1562177|NCT02511821|Device|Vivofit watch|Wear Vivofit watch
1562178|NCT02511821|Other|Quality-of-Life Assessment|Ancillary studies
1562179|NCT02511821|Other|Questionnaire Administration|Ancillary studies
1562180|NCT02511808|Behavioral|Brief Advice|Brief Advice (BA) consists of a 20-minute session delivered by a study therapist, adhering to the NIAAA's Clinician Guide to Problem Drinkers. It includes personalized, normative feedback based on NIAAA drinking norms, goal selection, instructions on self-monitoring, discussion of drink reduction strategies, and distribution of the NIAAA bibliotherapy guide.
1562181|NCT02511808|Behavioral|Motivational Interviewing|Motivational Interviewing will consist of standard techniques, such as developing discrepancy, enhancing motivation, and developing a change plan, that have been adapted to treatment for problem drinkers.
1562182|NCT02511808|Behavioral|Behavioral Self-Control Training|Behavioral Self-Control Training will consist of Cognitive Behavioral Therapy adapted to problem drinkers, whose core components include a functional analysis, skills training, daily self-monitoring, homework, and graded exposures and mastery of high risk situations.
1562185|NCT02511782|Device|D-SQUAME Skin Sampling Discs|A D-SQUAME Skin Sampling Disc is a noninvasive patch that collects skin cell samples when affixed to the superficial stratum corneum (top layer of skin). The patch is applied with gentle pressure to the desired quadrant of the forearm and removed 2 minutes after application.
1562186|NCT02511769|Behavioral|WEB-MAP Educational Control Group|OPEC (Online Patient Education Control) Group: The purpose of the patient education control group is to control for time, attention, and computer usage. This group will serve as an attention control condition. Children will continue with the standard medical care that has been prescribed for their pain problem. Children and parents will be provided with access to a revised version of the Web-MAP study website, which will have two functional components: 1) information from publicly available educational websites about pediatric chronic pain management, 2) diary and assessments. This version of the website differs from the one accessed by the treatment condition in that it does not provide access to behavioral and cognitive skills training via treatment modules for children and parents.
1562187|NCT02511769|Behavioral|WEB-MAP CBT|Web-MAP Group: Participants will have access to the full version of the web program. They will be asked to log in to the website using their own personal computer at home, work, school, or a public library. Participants in the Web-MAP group will have access to treatment modules and daily diaries on the web site. The online treatment will take between 8 and 9 weeks for participants to complete. Children and parents will be asked to log onto the web site, read through the treatment modules, and complete practice assignments to learn new skills (e.g., relaxation). Adolescents and parents will be asked to complete a total of 8 modules each.
1562188|NCT02511756|Device|Computed tomography X-ray system|Contrast-enhanced computed tomography of liver metastases
1562189|NCT02511743|Other|physicians|physicians taking care of patients with chronic Hepatitis B Virus infection, without intervention
1562190|NCT02511730|Device|FFDM Plus DBT|FujiFilm Aspire Cristalle System
1562191|NCT02511730|Device|FFDM|FujiFilm Aspire Cristalle System
1562192|NCT02511717|Other|Transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the medial malleolus, and 5-10 cm above the medial malleolus of the same leg, just behind the medial tibial edge. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be titrated up to patient's maximum nonpainful tolerance (between 0.5-10mA). This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
1562193|NCT02511717|Other|Sham transcutaneous tibial nerve stimulation|Patch electrodes applied posterior to the lateral malleolus, and 5-10 cm above the lateral malleolus of the same leg. Bipolar stimulation setting will be used, with a frequency of 10 Hz, 200ms pulse, and the amplitude will be set a 1mA. This will be done by the patients at home 3x/week for 30 minutes, over 12 weeks.
1562194|NCT02511704|Drug|Nicotine|Multiple dose nicotine
1562195|NCT02511704|Drug|Nicotine|Multiple dose nicotine
1562196|NCT02511691|Drug|18F-PSS232|Diagnostic PET Tracer
1562198|NCT02511665|Drug|Metformin|Given metformin
1562199|NCT02511665|Radiation|PET-MRI Scan|Patients will under go 2 PET-MRI scans in the PET-MRI substudy arm one before treatment with metformin and one after
1562200|NCT02511665|Drug|Placebo|Given placebo
1562201|NCT02511652|Device|Ambu AuraGain evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
1562202|NCT02511652|Device|LMA Supreme evaluation|Evaluation of clinical performance in terms of Insertion, ventilation, position and complications
1562203|NCT02511652|Procedure|Laparoscopic surgery|Gynecologic laparoscopic surgery in the trendelemburg position
1562204|NCT02511639|Drug|Everolimus|Everolimus is formulated as tablets of 10 mg strength for oral administration.
1562205|NCT02511639|Drug|Aromatase Inhibitors|Anastrozole is formulated as tablets of 1 mg strength for oral administration. Letrozole is formulated as tablets of 2.5 mg strength for oral administration. Exemestane is formulated as tablets of 25 mg strength for oral administration.
1562206|NCT02511613|Drug|Squalamine Lactate Ophthalmic Solution, 0.2%|Squalamine Lactate Ophthalmic Solution, 0.2% administered BID
1562207|NCT02511613|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution, administered BID
1562208|NCT02511613|Drug|ranibizumab|ranibizumab intravitreal injection
1562209|NCT02511600|Other|Progel Sealant|After pleurectomy decortication, Progel® sealant added to the surface of the lung prior to closure of the chest.
1562210|NCT02511600|Other|Talcum Powder|After pleurectomy decortication, talcum powder added to the surface of the lung prior to closure of the chest.
1562211|NCT02511600|Behavioral|Pain Questionnaire|Participants complete pain scale 3 times each day while in the hospital. Pain is rated on a pain scale of 0 - 10.
1562212|NCT02511587|Biological|FSME-Immune vaccination|booster vaccination with FSME-Immune
1562213|NCT02511574|Drug|natural progesterone|
1562214|NCT02511574|Device|cervical pessary|
1562215|NCT02511561|Drug|OTO-201 (ciprofloxacin)|
1562216|NCT02511548|Other|Financial incentive|Financial incentive will be proposed to participant of the intervention arm
1562217|NCT02511535|Biological|TBE booster vaccination|
1562220|NCT02511509|Device|Bifrontal electroconvulsive therapy|The centre of each electrode will be placed 4-5 cm above the outer canthus of the eye along a vertical line perpendicular to a line connecting the pupils.
1562221|NCT02511509|Device|Bitemporal electroconvulsive therapy|The centre of the stimulus electrodes will be applied 2-3 cm above the midpoint of the line connecting the outer canthus of the eye and the external auditory meatus on each side of the individual's head.
1562222|NCT02511483|Drug|Propranolol PO|20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.
1562223|NCT02511483|Drug|IV-PCA morphine|Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.
1562224|NCT02511483|Drug|Placebo PO|Placebo tablets administered with the same schedule of Propranolol tablets
1562225|NCT02511483|Procedure|Quantitative Sensory Testing (QST)|Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.
1562226|NCT02511483|Other|Psychometric assessment|Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)
1562227|NCT02511483|Genetic|COMT-haplotypes|Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.
1562228|NCT02511470|Other|Metronome on|Metronome on during participants performance of CPR on a pediatric manikin
1562229|NCT02511470|Other|Metronome off|Metronome off during participants performance of CPR on a pediatric manikin
1562230|NCT02511444|Other|GBS culture and real time PCR|patients with signs and symptoms of threatened preterm labor, or indications for preterm delivery will have GBS colonization screened by culture and real time PCR.
1562234|NCT02511418|Drug|Simvastatin|
1562235|NCT02511405|Drug|VB-111 + bevacizumab|"VB-111 will be administered intravenously at a dose of 1x10e13 VPs every 2 months
Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks"
1562236|NCT02511405|Drug|Bevacizumab|Bevacizumab will be administered intravenously at a dose of 10mg/kg every 2 weeks
1562237|NCT02511392|Procedure|rTMS-1Hz|
1562238|NCT02511392|Procedure|rTMS-10 Hz|
1562239|NCT02511392|Procedure|Sham rTMS|
1562240|NCT02511379|Other|Propylene Glycol 0.6% eye drops|
1562241|NCT02511366|Other|Ileal infusion of casein|Intraileal infusion of casein
1562242|NCT02511366|Other|Ileal infusion of tap water|Intraileal infusion of tap water
1562243|NCT02511353|Drug|ivermectin|
1562244|NCT02511353|Drug|placebo|Placebo for ivermectin.
1562245|NCT02511353|Drug|dihydroartemisinin-piperaquine|
1562246|NCT02511340|Drug|Flumatinib mesylate tablet 600 mg qd|Flumatinib mesylate tablet 600 mg qd in CML-AP or CML-BP patients
1562247|NCT02511327|Drug|Infant pertussis vaccination|Infants receive pertussis vaccines according to the national recommended schedule
1562248|NCT02511314|Device|TENA Identifi|TENA Identifi
1562249|NCT02511301|Device|Cyrcadia CBR™ device placement for abnormality screening|Cyrcadia CBR™ device, including adhesive patches on both breasts connected to a small recorder, is placed on the study subject for 2 to 24 hours. After the test period, the CBR™ will be removed and the data will be downloaded to a central site for analysis.
1562250|NCT02511275|Procedure|Renal microdialysis|Renal microdialysis is an innovative and promising technique in the monitoring of renal ischemia. Its sterile nature enables intraoperative use to give us real-time reflection of the in situ metabolism. In Patients who participated in clinical research with this microinvasive technique, no complications including bleeding has been reported.
1562251|NCT02511262|Device|illumigene® Mycoplasma Direct, illumipro-10|DNA amplification assay
1562252|NCT02511236|Behavioral|Group Cognitive Behavioral Therapy|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include a functional analysis of smoking patterns, environmental cues, and motivation for change, and cover nicotine addiction and withdrawal, health consequences, benefits of cessation, stress management, negative affect, alcohol use, triggers, coping responses, cognitive restructuring, social support, decision making, weight control, and physical activity.
1562253|NCT02511236|Behavioral|General Health Education|The four-week CBT protocol includes 4 sessions during week 1, 2 sessions during week 2, 1 session during week 3, and 1 session during week 4. Sessions may include didactic information on tobacco-associated morbidities, such as heart disease, diabetes, and hypertension. Content may include Power Point-delivered lectures on the prevalence, etiology, basic pathology, symptom patterns, and treatment of the conditions, and discussion questions designed to facilitate learning and interest. Smoking cessation specific topics will not be addressed, and coping skills will not be provided. Participants will be allowed to share feelings regarding smoking (if they mention them) and general questions will be answered, although no specific behavioral quitting advice will be provided (i.e., they will be encouraged to adhere to the TNP protocol).
1562254|NCT02511236|Drug|Transdermal Nicotine Patch|Participants will be prescribed up to 8 weeks of transdermal nicotine patch therapy, including 21 mg for 4 weeks, 14 mg for 2 weeks, and 7 mg for 2 weeks. Dosages will be adjusted per manufacturer recommendations.
1562255|NCT02511223|Drug|OLAPARIB|Olaparib 300 MG twice a day per os given every day until disease progression or toxicity
1562256|NCT02511210|Behavioral|regional anesthesia|preoperative anxiety
1562257|NCT02511210|Behavioral|general anesthesia|preoperative anxiety
1562258|NCT02511197|Drug|68Ga-NOTA-PRGD2|68Ga-NOTA-PRGD2 were injected into the patients before the PET/CT scans
1562259|NCT02511197|Device|PET/CT|
1562263|NCT02511158|Procedure|Ligament of the knee reconstruction|Reconstruction of ligaments of the knee by autografts
1562264|NCT02511145|Other|occlusive bandage|
1562265|NCT02511145|Device|ablative fractional CO2 laser pretreatment|
1562266|NCT02511145|Device|Microneedles pretreatment|
1562267|NCT02511145|Drug|METVIXIA Cream|
1562268|NCT02511132|Biological|Vigil|Vigil 1.0 x 10e7 cells/injection, intradermally on Day 15 and every 43 weeks thereafter.
1562269|NCT02511132|Drug|Temozolomide|oral temozolimidetemozolomide 100 mg/m2 daily (Days 1 - 5, total dose 500 mg/m2/cycle)
1562270|NCT02511132|Drug|Irinotecan|irinotecan 50 mg/m2 daily (Days 1 - 5, total dose 250mg/m2/cycle), orally or irinotecan 20mg/m2 daily (Days 1 - 5, total dose 100mg/m2/cycle ), intravenously
1562273|NCT02511093|Behavioral|TBC intervention|"A structured collaborative intervention delivered by trained nurses of ambulatory clinics and by community pharmacists working in collaboration with physicians during 6-month of follow-up includes:
BP measurements;
an educational and counselling intervention on patient adherence;
an educational and counselling intervention on lifestyle (physical activity and diet) Physicians adjust antihypertensive medications based on nurse and pharmacist feedback."
1562274|NCT02511080|Device|Spot-On|use of active hot measures
1562275|NCT02511067|Drug|Tocilizumab|Intravenous Infusion of Tocilizumab ( 8.0 mg/kg)
1562276|NCT02511067|Drug|Ranibizumab|Intravitreal injection of Ranibizumab (0.3mg)
1562277|NCT02511054|Drug|Chloroquine (CQ)|Chloroquine Phosphate is a 4-aminoquinoline compound that is commercially available for oral administration. It is a white, odorless, bitter tasting, crystalline substance freely soluble in water; and widely used for the treatment andprophylaxis of malaria. It is supplied and manufactured in tablets of 500 mg (equivalent to 300 mg chloroquine phosphaste base)
1562278|NCT02511054|Drug|Pyrimethamine (PYR)|PYR is a folic acid antagonist that is commercially available; and has been commonly used as antimalarial drug for both treatment and prevention of malaria, usually in combination with sulfadoxine in adults, pregnant women, and children worldwide. It is manufactured in tablets of 25 mg.
1562279|NCT02511054|Biological|Sanaria PfSPZ Challenge (NF54)|Sanaria PfSPZ Challenge are aseptic, cryopreserved P.falciparum sporozoites used for CHMI trials, produced by the biotechnology company; Sanaria Inc. In brief, manufacture includes the production, under traditional environmental conditions, of eggs from a colony of A. stephensi mosquitoes housed in a controlled environmental chamber. The sporozoites are purified, counted, and, at a specified concentration, cryopreserved. Cryopreservation commences with the addition of cryoprotective additives to the purified sporozoites to produce the Sanaria PfSPZ Challenge product. Sanaria PfSPZ Challenge is dispensed into screw-cap vials containing 15,000, 50,000, or 100,000 PfSPZ in a 20 L aliquot. Sanaria PfSPZ Challenge is stored in liquid nitrogen vapour phase at 140 (Infinite)C to -196 (Infinite)C.
1562280|NCT02511041|Drug|N-Acetylglucosamine (GlcNAc)|N-acetylglucosamine (GlcNAc), 2-acetamino-2-deoxy- <=-Dglucose, or 2- acetylamino)-2- deoxy-D-glucose, is a monosaccharide derivative of glucose. It is classified as dietary supplement in the United States. In general, it is a white and slightly sweet powder that melts at 221 degrees C. The solubility of GlcNAc is 25% in water, and 1% aqueous solutions are colorless and clear. GlcNAc is contraindicated for patients receiving warfarin, chemotherapy or diabetes drugs. As GlcNAc may interfere with blood sugar control during and after surgery, it is contraindicated during the two weeks prior to major surgery.
1562281|NCT02511041|Drug|Uridine|Uridine 5 -monophosphate (UMP) disodium salt is a water soluble colorless crystalline powder which melts at 202oC.
1562283|NCT02510976|Drug|prucalopride|
1562284|NCT02510976|Drug|placebo|
1562285|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 24week of gestation
1562286|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 28week of gestation
1562287|NCT02510963|Drug|Tenofovir Disoproxil Fumarate|Use Tenofovir at 32week of gestation
1562288|NCT02510950|Biological|Personalized peptide vaccine|
1562289|NCT02510950|Drug|Poly-ICLC|
1562290|NCT02510950|Drug|Temozolomide|
1562291|NCT02510937|Drug|CC-90001|
1562292|NCT02510924|Device|Tracheal intubation|tracheal intubation with Airtraq sp vs Airtraq mobile
1562293|NCT02510911|Drug|Caffeine (100 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 100 mg caffeine together with the meals.
First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.
Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
1562294|NCT02510911|Drug|Caffeine (200 mg)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 200 mg caffeine together with the meals.
First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.
Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
1562295|NCT02510911|Drug|corn starch (250 mg approx.)|"Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.
First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.
Treatment consists of 10 capsules and will be stopped after the first solid bowel movement."
1562296|NCT02510911|Other|Radiopaque marker|"On the morning of the first, second and third day after surgery patients will take 1 capsule each day with radiopaque markers .
On day 4 after surgery an abdominal X-ray will be performed to localize the markers.
Each gelatin capsule contains 10 markers consisting of polyurethane encapsulated barium sulfate (40%)."
1562342|NCT02510521|Device|daily workout sequence with NMES in one week|
1562343|NCT02510521|Other|rest situation|
1562344|NCT02510508|Behavioral|Group CRAFT|CSOs will receive seven weekly 90 min sessions of CRAFT + Self-Directed CRAFT Delivery
1562345|NCT02510508|Behavioral|Self-Directed CRAFT Delivery|CRAFT self-help book (Self Directed CRAFT Delivery)
1562346|NCT02510508|Other|Non-intervention|Non-intervention
1562409|NCT02510040|Procedure|Botox Injection|Botulinum toxin injection
1562297|NCT02510898|Behavioral|6-week Writing to Heal course|"During this 6-week class, a writing-to-heal instructor will coach participants through a simple progression of writing exercises. Participation requires neither any prior writing experience nor any aspiration to become a writer. In fact, the practices cultivate participants' natural abilities to express the ideas that define who they are and how they experience their lives.
Weekly sessions build on previous sessions to provide a progression of experiences for participants to develop their natural styles of writing-to-heal. The instructor will guide participants through a variety of modes of writing that enhance health in different ways."
1562298|NCT02510885|Device|AngioVue SD-OCT|OCT-A allows noninvasive, high-resolution imaging of the microvasculature of the retina and choroid, without intravenous dye administration. SD-OCT units use the light source used in commercially available and FDA-cleared OCT units on a modified platform. Optovue, Inc. has developed a customized SD-OCT system that implements a novel algorithm, the amplitude-based method of split-spectrum amplitude-decorrelation angiography (SSADA) for OCT-A. This detects motion in the blood vessel lumen by measuring the variation in reflected OCT signal amplitude between consecutive cross-sectional scans. Optovue has integrated the novel SSADA algorithm into their commercially approved RTVue SD-OCT unit for their OCT-A unit, the AngioVue. This unit is being conducted under an abbreviated IDE.
1562299|NCT02510872|Other|18F-FDG PET combined with CT with iodinated contrast injection|
1562300|NCT02510872|Other|18F-FDG PET combined with CT without injection|
1562301|NCT02510859|Other|Systematic nutritional consultation at home|"Patients will be followed by a dietician at the patient's home at weeks 2 (S2) and 4 (S4) of radiotherapy, then at the end of radiotherapy at T0. Monitoring will be continued 15 days after the end of irradiation and then one month (T1 and 2 months (T2). A personalized follow will be performed and a document entitled Dietary own program will be given to the patient."
1562302|NCT02510846|Behavioral|Intensive educative management|5 hours a week
1562303|NCT02510833|Behavioral|Exercises oriented, manual and monitoring by phone|Individual meeting to guide therapeutic exercises (stretching, mobility, balance and strength), manual with these exercises for support in practice at home and weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
1562304|NCT02510833|Behavioral|Exercises oriented, manual and without monitoring by phone|Lectures (optatives) about therapeutic exercises (stretching, mobility, balance and strength) in days of medical consultation, manual with these exercises for support in practice at home, without weekly monitoring by phone. Patients will be oriented to do exercises three times per week for twelve weeks.
1562305|NCT02510820|Device|comfilcon A|soft contact lens
1562306|NCT02510820|Device|Synergi|Multipurpose solution
1562307|NCT02510820|Device|Biotrue|Multipurpose solution
1562308|NCT02510820|Other|stenfilcon A|daily disposable contact lenses for washout period
1562309|NCT02510807|Other|Pedometer|The use of a pedometer will demonstrate improvement in the following health outcomes in patients with PAD by acting as a method of surveillance to improve compliance with a walking regimen
1562311|NCT02510781|Drug|Epirubicin|75mg/m2 d1 evry 21days
1562312|NCT02510781|Drug|Docetaxel|75mg/m2 d1 evry 21days
1562313|NCT02510781|Drug|Trastuzumab|6mg/kg(loading dosage is 8mg/kg)
1562314|NCT02510781|Drug|Carboplatin|Area Under Curve(AUC)=6 d1 evry 21days
1562315|NCT02510768|Device|ELAPR002f|Intradermal implant
1562316|NCT02510768|Device|ELAPR002g|Intradermal implant
1562317|NCT02510768|Device|Saline|Intradermal implant
1562318|NCT02510755|Other|MRI|
1562319|NCT02510742|Device|Neurostimulation|Neurostimulation of sphenopalatine ganglion (SPG) of 20 Hz
1562320|NCT02510742|Device|Sham stimulation|Sham stimulation of sphenopalatine ganglion (SPG) with amplitude=0
1562321|NCT02510729|Device|Neurostimulation|
1562322|NCT02510729|Device|Sham stimulation|
1562323|NCT02510716|Behavioral|SGR|
1562324|NCT02510716|Behavioral|Support message only|
1562325|NCT02510703|Other|Coronary endothelial function measurements by quantitative method (TEP at 15O-H2O)|
1562326|NCT02510677|Other|myocardial perfusion scintigraphy|
1562327|NCT02510664|Behavioral|Diabetes Strengths Study|"The intervention consists of: (A) assessing youth and family diabetes strengths and adherence prior to each visit, and (B) training diabetes care providers to tailor their clinical encounters around reinforcing each patient and family's unique diabetes strengths profile generated from the strengths and adherence assessments."
1562328|NCT02510651|Procedure|Melanocyte-keratinocyte suspension|Treatment of non-segmental vitiligo by CO2 laser followed by melanocyte-keratinocyte suspension.
1562329|NCT02510625|Procedure|Anatomic Glenoid Reconstruction|Distal tibia bone graft
1562330|NCT02510625|Procedure|Arthroscopic bankart Repair|Arthroscopic bankart Repair
1562331|NCT02510612|Drug|Dexmedetomidine|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Dexmedetomidine(D) group, patient will be given dexmedetomidine 1μg/Kg for 10 minutes In anesthesia maintenance, D group will be given dexmedetomidine 0.4μg/Kg.h until 40 minutes before the end of surgery
1562332|NCT02510612|Drug|placebo|During anesthesia induction, all patients will be given propofol,fentanyl,vecuronium bromide.But before induction start in Placebo(P) group, patient will be given placebo for 10 minutes In anesthesia maintenance, D group will be given placebo until 40 minutes before the end of surgery
1562333|NCT02510599|Drug|solithromycin|
1562334|NCT02510586|Drug|Sevoflurane|administer 1.0 MAC (1.7~2.0 vol%) of sevoflurane for 30 minutes after vascular anastomosis completed
1562335|NCT02510560|Drug|NTRA-2112|
1562336|NCT02510560|Drug|Placebo|
1562339|NCT02510534|Drug|Menopur 150 international units|Menopur 150 international units given x 1 dose
1562340|NCT02510534|Drug|Endometrin 100 mg|Endometrin 100mg twice daily x 14 days
1562341|NCT02510521|Device|acute muscle exercise by NMES|
1562347|NCT02510495|Procedure|"30 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 30 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
1562348|NCT02510495|Procedure|"60 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 60 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
1562349|NCT02510495|Procedure|"180 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 180 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
1562350|NCT02510495|Procedure|"300 group"|A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
1562353|NCT02510456|Device|Diffuse Optical Spectroscopy Imaging (DOSI)|Subjects will have up to seven DOSI scans at 7 different time points during the course of their chemotherapy. The time course of chemotherapy may vary between 39 months depending on the type chemotherapy subjects receive. Depending on chemotherapy schedule, subjects may or may not be asked to participate in all the 7 measurement time points. The number of DOSI scans each subject requires will be decided during consent. Each DOSI scan will take about 30-45 minutes, although scans at infusion timepoint will take longer in total due to repeated or continuous measurements.
1562354|NCT02510443|Device|ESS305 (Essure, BAY1454032)|Bilateral insert placement
1562355|NCT02510430|Behavioral|Re-Patterning Sitting Time Group|This is a behavioral intervention to help women interrupt long bouts of sitting time by incorporating standing breaks into their lifestyle.
1562356|NCT02510430|Behavioral|Reducing Sitting Time Group|This is a behavioral intervention to help women reduce their overall accumulated sitting time by 2 hours per day.
1562357|NCT02510430|Behavioral|Usual Care|This intervention consists solely of follow-up contact to control for attention effects and reduce attrition.
1562358|NCT02510417|Biological|VSTs|most closely HLA-matched multivirus-specific T cell lines obtained from a bank of allogeneic virus-specific T cell lines (VSTs) have antiviral activity against three viruses: EBV, CMV and adenovirus
1562360|NCT02510391|Behavioral|PIPA|Parent-training Intervention for Preschoolers with Anxiety (PIPA) is a behaviorally based modular treatment program for emotional and behavioral problems in young children. 12 sixty minute sessions will be delivered weekly. This intervention employs a modular format following a treatment algorithm in which therapy modules are selected by the therapist and supervisor on a session-by-session basis to address the most pressing clinical needs. Minimum session requirements for parent training/education and fear hierarchy/exposure are set to insure adequate dose of core exposure and response prevention for anxiety across cases.
1562361|NCT02510378|Radiation|Short course radiotherapy|"Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.
After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy."
1562362|NCT02510365|Biological|Functional collagen scaffold|Patients will receive functional neural regeneration collagen scaffold and patients will undergo a comprehensive rehabilitation and psychological measures after surgery.
1562363|NCT02510339|Other|Observation|Administration of two questionnairs during post operative visits.
1562364|NCT02510313|Other|Sugira Muryango|"Strong Families, Thriving Children Sugira Muryango is a home-visiting intervention that empowers low-income families enrolled in Rwanda's social protection system to support early childhood development and healthy family functioning."
1562365|NCT02510313|Other|Vision 2020 Umurenge (VUP)|Eligible families, lowest poverty, receive a variation of cash transfer in exchange for labour.
1562368|NCT02510287|Drug|Bupivacaine and Fentanyl Initial Dose|10 ml of 0.1% bupivacaine (2 ml of 0.5% bupivacaine and 50 mcg / ml fentanyl in 7 ml of normal saline solution)
1562369|NCT02510287|Drug|Bupivacaine and Fentanyl: Continuous Epidural Infusion|0.1% bupivacaine and fentanyl 2 mcg / ml (8-12 ml / hour)
1562370|NCT02510287|Drug|Bupivacaine and Fentanyl: Programmed Intermittent Epidural Bolus|A 0.1% bupivacaine and fentanyl 2 mcg / ml (8-12ml) bolus will be administered each hour at a rate of 500ml/hour
1562371|NCT02510287|Drug|Rescue Bolus|Upon patient request, rescue bolus of 8-10 ml of 0.1% bupivacaine will be administered.
1562372|NCT02510287|Drug|Lidocaine|If needed, during the second phase (9-10 centimeters of cervical dilation) a 2% lidocaine without epinephrine (8-10 cc) bolus will be administered.
1562373|NCT02510274|Drug|ASP3325|oral
1562374|NCT02510261|Drug|Patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
1562375|NCT02510248|Drug|AL-704|JNJ-54257099 (also known as ALS-022704 or AL-704) is a hepatitis C virus (HCV) nonstructural (NS)5B inhibitor, belonging to the nucleoside / nucleotide inhibitor class, and is being developed as an orally administered anti-HCV therapeutic.
1562376|NCT02510248|Drug|Placebo|Placebo to match AL-704
1562377|NCT02510235|Device|Lubricin|Lubricin 150 µg/ml eye drops
1562378|NCT02510235|Device|Sodium Hyaluronate|Sodium hyaluronate 0.13% eye drops
1562379|NCT02510222|Dietary Supplement|Oral magnesium sulfate|Magnesium sulfate 4% concentration in a dose of 65 mg/day for infants and children aged 1-3 years , 110 mg/day for those 3-8 years and 350 mg/day for those above 9 years .Each 1 ml of the magnesium sulfate used contains 0.325 mEq (milliequivalent) of elemental magnesium which equals to 4 mg elemental magnesium .
1562380|NCT02510222|Other|Placebo|
1562381|NCT02510209|Behavioral|Teen Outreach Program|TOP® is a youth development and service learning program for youth ages 12 to 17 designed to reduce teenage pregnancy and increase school success by helping youth develop a positive self-image, life management skills, and realistic goals. The TOP® program model consists of three components implemented in school, after school, or in community settings over nine consecutive months: (1) weekly curriculum sessions, (2) community service learning (CSL), and (3) positive adult guidance and support. The TOP® Changing Scenes® curriculum is separated into four age- and stage-appropriate levels, which range from Level 1, typically for youth ages 12 or 13, to Level 4, typically for youth age 17.
1562383|NCT02510183|Device|Acupressure Wrist Band|Acupressure wrist band is a knitted elasticated wrist band, which operates by applying pressure on the P6 acupressure point on each wrist by means of a plastic stud.
1562384|NCT02510183|Device|Placebo Acupressure Wrist Band|Placebo Acupressure Wrist Band is a knitted elasticated wrist band without a plastic stud.
1562385|NCT02510170|Other|no intervention|
1562386|NCT02510157|Drug|Dexamethasone|active comparator
1562387|NCT02510157|Drug|Normal Saline|placebo controlled intervention
1562388|NCT02510157|Drug|sugammadex|sugammadex is administered in both groups to reverse deep neuromuscular blockade at the end of surgery
1562389|NCT02510144|Drug|Skin Prep Chlorhexidine|3 day preoperative skin prep prior to surgery
1562390|NCT02510144|Drug|Skin Prep Benzoyl Peroxide|
1562391|NCT02510131|Behavioral|Exercises|To compare Hyacinth exercise with Kegel's exercise in improving urinary incontinence
1562392|NCT02510118|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m^2) via ambulatory pump administered for a period of 46 to 48 hours.
1562393|NCT02510118|Drug|XELOX|XELOX is a combination therapy of Oxaliplatin 130mg/ m^2 d1 Intravenous infusion, every 3 weeks. and Capecitabine 1000mg/m^2 bid, days 1-14, every 3 weeks
1562394|NCT02510118|Drug|Placebo ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
1562395|NCT02510118|Drug|ChangTai Keli|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of dampness stasis type of spleen deficiency will be given placebo ChangTai Keli, twice daily for 26 weeks for lower dosage.
1562396|NCT02510105|Device|VDR4 ventilator (Intrapulmonary Percussive Ventilation)|
1562397|NCT02510105|Device|CT scan|
1562398|NCT02510105|Device|Servo-i|
1562399|NCT02510105|Device|- Intubation|
1562400|NCT02510105|Device|Ventilation ( with an ICU conventional ventilator)|
1562401|NCT02510092|Device|Percutaneous coronary intervention with new generation fully resorbable scaffold|
1562402|NCT02510079|Biological|Autologous human Schwann cells|Schwann cells harvested from the sural nerve will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
1562403|NCT02510066|Device|Acupuncture|Disposable stainless steel filiform needles (40mm in length and 0.30mm in diameter) are inserted perpendicularly into T8-T12 Jiaji (Ex-B2) points bilaterally to a depth of 25 mm. After De Qi sensation is achieved, the handles of needles on homolateral T8 and T12 Jiaji are respectively connected to the Han's acupoint nerve stimulator at a frequency of 2/100 Hz and a current of 1mA with a disperse-dense waveform for 30 minutes.
1562404|NCT02510066|Device|Placebo acupuncture|Placebo acupuncture needles (Dongbang AcuPrime Acupuncture Inc., South Korea) are used on the non-point points at the same level as T8 and T12 Jiaji, 4.5 cun lateral to the posterior median line. The needles with blunt tips are quickly put onto points without inserting into the skin. The needles on homolateral points at the same level as T8 and T12 Jiaji are then connected to the electric stimulator, but with zero frequency and electric current.
1562405|NCT02510053|Drug|Caspofungin|40 patients with suspected/preoperation/confirmed IFI in ICU received Caspofungin
1562406|NCT02510040|Device|Prism|Ground-in or Fresnel prism
1562407|NCT02510040|Other|Orthoptic Exercises|Orthoptic exercises- fusion, convergence, divergence, and others, including computer-based therapy
1562408|NCT02510040|Procedure|Eye Muscle Surgery|"Bilateral medial rectus muscle resection surgery
Single medial rectus muscle resection surgery
Recess lateral rectus muscle resection medial rectus muscle surgery
Bilateral lateral rectus muscle recession surgery
Single lateral rectus muscle recession surgery
Bilateral lateral rectus muscle resection surgery
Single lateral rectus muscle resection surgery
Recess medial rectus muscle resection lateral rectus muscle surgery
Bilateral medial rectus muscle recession surgery
Single medial rectus muscle recession surgery
Vertical rectus muscle recession surgery
Vertical rectus muscle mini-tenotomy (snip) surgery"
1562410|NCT02510027|Other|HPV screening and triage tests|All cervical and/or vaginal specimens are tested for hrHPV using the Cobas® 4800 HPV test. Triage testing will be performed on all participants with a positive HR-HPV test declared consent at recruitment visit: HPV16/18 genotyping, Cobas® 4800 HPV test, HPV16/18/45 genotyping, BD OnclarityTM HPV Assay, OncoE6 Cervical Test, Liquid based cytology with Papanicolaou stain and p16INK4a/ Ki-67 immunostain.
1562411|NCT02510014|Drug|SUBOXONE sublingual film|Suboxone sublingual film used for induction therapy. Participants to take sublingual film for 4-14 days at doses from 8mg-24mg
1562412|NCT02510014|Drug|high dose RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose can be adjusted to low dose based on the medical judgment of the Investigator
1562413|NCT02510014|Drug|low dose RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose can be adjusted to high dose based on the medical judgment of the Investigator
1562414|NCT02510001|Drug|PF-02341066|PF-02341066 (Crizotinib) 250mg OD or 200mg BD or 250mg BD Days 1-28 continuously
1562415|NCT02510001|Drug|PD-0325901|PD-0325901 2mg - 8mg BD with Run in Day -7 to Day-1 on Cycle 1 Day1, then Day 1-21 every 28 day cycle.
1562416|NCT02510001|Drug|Binimetinib|Binimetinib 30mg or 45 mg BD either continuously or Days 1-21 every 28 days
1562417|NCT02509988|Dietary Supplement|Study nutritional drink|Study nutritional drink containing a mix of micronutrients, probiotics and myo-inositol.
1562418|NCT02509988|Dietary Supplement|Standard nutritional drink|Standard nutritional drink containing a mix of micronutrients.
1562419|NCT02509975|Device|Prostate artery embolization.|Embolization of the prostatic vasculature with OCL 503 using a microcatheter.
1562420|NCT02509962|Dietary Supplement|Slow sodium tablets|6 g sodium chloride per day over 14 days
1562421|NCT02509949|Drug|Dexmedetomidine|
1562422|NCT02509949|Drug|Saline|
1562423|NCT02509936|Behavioral|Home-based nutrition education|Health promoters will use 24-hour dietary recall information to assess meal frequency and dietary diversity and then provide tailored nutrition coaching to parents.
1562424|NCT02509936|Dietary Supplement|Standard-of-care nutrition support|Subjects will be provided with a standard food ration and with a multiple micronutrient powder dietary supplement (Chispitas)
1562425|NCT02509923|Drug|Z-215 10mg|Z-215 10mg, capsules
1562426|NCT02509923|Drug|Z-215 20mg|Z-215 20mg, capsules
1562427|NCT02509923|Drug|Rabeprazole Sodium 10mg|Rabeprazole Sodium 10mg tablets
1562428|NCT02509923|Drug|Rabeprazole Sodium 20mg|Rabeprazole Sodium 20mg tablets
1562429|NCT02509897|Other|Hypoxic training|Hypoxic training 3 times per week four four weeks
1562430|NCT02509897|Other|Normoxic training|Normoxic training 3 times per week four four weeks
1562431|NCT02509871|Other|Body composition measurement|DXA, impedance
1562432|NCT02509858|Drug|thyroxine|treatment with 50μg of thyroxine once daily for two months.
1562433|NCT02509858|Drug|Placebo|treatment with 50μg of placebo, once daily, for two months.
1562434|NCT02509858|Other|A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein)|
1562435|NCT02509845|Drug|C16G2|Antimicrobial peptide
1562436|NCT02509845|Other|Placebo|Placebo
1562437|NCT02509832|Device|Cooling + PCI|Cooling with ZOLL Proteus IVTM System before and after Percutaneous Coronary Intervention (PCI)
1562438|NCT02509832|Device|PCI only|Standard of Care for PCI
1562439|NCT02509819|Device|Heel Cushion Material Bulk (foam)|The heel wedge is made of a rubber style urethane foam. Heel wedges of specified heights and durometers will be inserted into the standard shoes, one at a time, during the test session only. The heel wedges used during the test session are made of the same foam as the heel wedges that are used clinically.
1562441|NCT02509793|Drug|Tetrabenazine|Xenazine, pill, dose to effect, three times a day, for 12 weeks
1562442|NCT02509780|Other|Vichy|Volunteers will be asked during 3 days to take their usual intake of fluids. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 1 pm. For the following 7 days, they will take the usual intake of fluids plus 250 ml of Vichy water at 7 am and 7 pm. Ph and density measurement of urine will be made three times a day, at 7 am, 2 pm and 8 pm.
1562443|NCT02509767|Drug|Subcutaneous depot medroxyprogesterone acetate|Based on study arm, subjects will either be taught to self-inject or will be administered DMPA sc by qualified clinic personnel.
1562444|NCT02509754|Procedure|Atrial fibrillation catheter ablation|
1562445|NCT02509754|Procedure|Rate control|Composite of optimal medical therapy and device implantation
1562449|NCT02509728|Dietary Supplement|choline supplementation|in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days
1562450|NCT02509728|Dietary Supplement|DHA supplementation|in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days
1562451|NCT02509728|Dietary Supplement|standard nutrition|standard nutrition
1562452|NCT02509715|Procedure|Intraoperative nerve monitoring|Intraoperative nerve monitoring during thyroid surgery
1562453|NCT02509702|Behavioral|Connected to Care|mHealth messages sent on month -12, -10, -6, -5, -3. mHealth quizzes sent on month -9, -4, -2. Sms-reminders of check-up appointment sent on days -30, -7 days, -1, +1, +7.
1562454|NCT02509689|Behavioral|Global Z-Score Neurofeedback Training|"The experimental intervention in this study, Global Z-Score Neurofeedback Training, is a non-pharmacological EEG Biofeedback training process using a specific new technology that allows for the training to be semi-automated and to train based on referencing EEG activity in 19 sites on the scalp, whilst comparing in real time to a database of non-clinical normative EEG data. Subjects will be scheduled to receive 20 treatment sessions of GZNT over a six-week period, aiming for four treatment visits per week, but allowing for some missed appointments due to holidays and duty obligations.
Training will be conducted for a continuous time which will begin at 10 minutes in the first session, and progress to a maximum of 30 minutes by the sixth or seventh session, and then remain at 30 minutes of training per session for the remainder of the sessions."
1562455|NCT02509676|Other|stretching exercise|dynamic stretching exercises with 5 repetitions, each lasting 45 seconds, for 5 days a week and 3 times a day
1562456|NCT02509663|Procedure|Functional Endoscopic Sinus Surgery|Balloon Sinuplasty uses a small, flexible, balloon catheter to open up blocked sinus passageways and facilitate drainage of the mucus that builds up in patients suffering from frontal sinusitis symptoms. When the sinus balloon is inflated, it restructures and widens the walls of the sinus passageway while maintaining the integrity of the sinus lining.
1562457|NCT02509663|Procedure|Functional Endoscopic Sinus Surgery using rigide instrumentation|"FESS (Functional Endoscopic Sinus Surgery) using rigide instrumentation is conventional therapeutic strategy.
The procedure works by cutting to remove bone and tissue to enlarge the sinus opening."
1562458|NCT02509663|Device|Sinuplasty balloon|
1562459|NCT02509663|Device|Endoscope|
1562460|NCT02509637|Device|Flutter|Flutter is a small device, simple, like a plastic pipe with a mouthpiece at one end and a perforated cover on the other, containing a steel ball resting in a plastic cone inside. When the patient exhales through the flutter expiratory flow causes movement of the ball, creating an oscillatory positive pressure.
1562461|NCT02509637|Other|Chest Compression|Manual chest compression is based on the application of forces resulting from the action of respiratory muscles or physiotherapist manual action in order to increase the alveolar pressure creating a pressure gradient to promote change in pulmonary flow and volume.It consists of vigorous compression of the chest at the beginning of expiration or during expiration.
1562462|NCT02509637|Other|Control|
1562463|NCT02509637|Other|Impulse Oscillometric|"For this measure will be used IOS Jaeger (Jaeger, Wurzburg, Germany). to minimize the effect of the bad positioning of the tongue will use a mouth free-flow, which contains a depressant for keeping the tongue in the mouth soil, stabilizing it and reducing oral resistance. Volunteers will support hands firmly on the cheeks to reduce the effect of oscillation thereof. The measures will be carried out with the volunteer sitting, using nasal, relaxed and your head in neutral clip, breathing normally through the mouthpiece to his lips tightly sealed to prevent air leaks."
1562464|NCT02509637|Other|Dyspnea scale|Dyspnea will be evaluated across the range Medical Research Council (MRC) for use in patients with chronic obstructive pulmonary disease in Brazil.
1562465|NCT02509637|Other|Acceptability and tolerance|patients will complete scales 1-7, 1: extremely and 7: none) on usefulness, ease to understand the instructions, easy to perform the exercises, degree of fatigue and discomfort
1562466|NCT02509637|Device|Pulse oximetry|During therapy the patient will remain monitored with digital oximeter and the information will be recorded before and after the procedures
1562467|NCT02509637|Other|Difficulty sputum|Patients inform the ease or difficulty sputum according to a scale of 1 to 5, where 1 = no difficulty and 5 = extremely difficult.
1562468|NCT02509624|Drug|GS-4997|GS-4997 6 mg tablet administered orally in a fed state
1562469|NCT02509611|Other|Hatha yoga|Yoga programs that were used in previous PD studies will be incorporated into the design of the proposed intervention program. Two yoga experts who are specialized in musculoskeletal/neurological disorders will review the program. The yoga intervention classes will be taught by a Registered Yoga Teacher. The 60 minute long yoga session will be held twice a week for 12 weeks at a community center in St. Louis Park.
1562472|NCT02509585|Drug|Tc99m tilmanocept|A single dose of 2 mCi (74 MBq) and 50 ug of Tc99m tilmanocept administered peritumorally approximately 1-2 hours before surgery
1562473|NCT02509572|Behavioral|Sexual health screen (SHS)|Decision support for STI screening through a novel sexual health screen
1562474|NCT02509559|Drug|propranololhydrochloride|oral administration of one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose) together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3 with subsequent measuring of propranolol and its clinically relevant metabolites
1562475|NCT02509559|Drug|placebo|oral administration of one placebo capsule together with 240 ml tap water and blood sampling at time points blank, 15, 30, 45 min, 1, 2, 3, 4, 6, 8, 10, 12 h of study days 1 and 3 and urine sampling for 24 h at study days 1 and 3
1562476|NCT02509559|Device|Net Station® System and compatible Geodesic Sensor Nets®|Electrocortical activity will be assessed by continuous EEG recording using Net Station® System and compatible Geodesic Sensor Nets® (Electrical Geodesics Incorporated, Eugene, OR, USA), measured at days 1, 3 and 10 of the study. Event related potentials at encoding (late positive potential, LPP) and at retrieval (ERP memory old/new effect) will be computed off-line after acquisition of the data.
1562477|NCT02509559|Device|VITAPORT|Measurement of the skin conductance by VITAPORT (Vitaport EDV Systeme GmbH, Erftstadt, Germany) on study days 1 and 3 at the time points before administration of the study medication, during the psychophysiological measurement and at 4 h. Furthermore, the skin conductance responses will be measured on day 10 during the psychophysiological measurement.
1562478|NCT02509559|Device|ergoselect II 100/200|Performance of an ergometry by ergoselect II 100/200 (ergoline GmbH, Bitz, Germany) on study days 1 and 3 at 120 min. The burden will be the same wattage over 4 min, that corresponds to that of reaching 80% of the maximal heart frequency in the prestudy examination.
1562479|NCT02509559|Device|SpiroScout|Performance of a spirometry (SpiroScout, Ganshorn Medizin Electronic GmbH, Niederlauer, Germany) with measuring of the forced expiratory volume in 1 second (FEV1) on study days 1 and 3 before administration of the study medication and at 120 min.
1562480|NCT02509559|Device|Mobil-O-Graph® PWA|Measurement of pulse waves by Mobil-O-Graph® PWA (I.E.M., Stollberg, Germany) on study days 1 and 3 at the time points -10 min, 20, 40, 60, 80, 120 min, 3, 5, 7, 11 h.
1562481|NCT02509559|Procedure|Saliva collection|Saliva collection will be performed on study days 1 and 3 at time points -10 min, 80 min, 120 min with subsequent measuring of the concentration of α -amylase
1562482|NCT02509546|Other|Laboratory Biomarker Analysis|Correlative studies
1562483|NCT02509546|Other|Pharmacological Study|Correlative studies
1562484|NCT02509546|Drug|8-chloro-adenosine|Given IV
1562485|NCT02509533|Device|V.A.C.®|Patients received V.A.C.® Therapy (KCI medical) after a transplants of leg ulcers.
1562486|NCT02509533|Device|dressing|Patients received usual dressing method (compresses) after a transplants of leg ulcers
1562487|NCT02509520|Dietary Supplement|MPR and High Protein Supplement (HPRO)|The MPR provides functional strength and cardiopulmonary endurance training, which will consist of closed kinetic chain exercises to promote function movements. Intensity will be based on patient's hemodynamic responses and subjective reporting using Modified Borg Dyspnea Scale. Intensity, duration, or type of activity will be modified each session to achieve a physiologic response of moderate intensity. The HPRO intervention is based on caloric needs, calculated using validated equations to maintain positive nitrogen balance. Protein will be supplemented as isolated amino acids twice/day to deliver ~15g of essential amino acids (~5g Leucine) per serving, with a goal of 1.6 g/kg/day protein. This dose has been used in bed rest studies of adults to prevent muscle loss.
1562488|NCT02509520|Device|MPR and Neuromusc Electric Stimulation (NMES)|The MPR exercise intervention will be combined with the NMES intervention which includes daily treatment with NMES. The NMES protocol requires that large (7.6 x 12.7 cm) self-adhesive surface electrodes be placed on quadriceps muscles specifically on the vastus lateralis, vastus medialis and rectus femoris and the gastrocnemius of both legs. This protocol is developed based upon previous NMES protocols used to acutely stimulate muscle protein synthesis rates in older type 2 diabetic patients preserve and restore muscle mass in intensive care patients and increase strength in older adults recovering from total knee replacement. Treatments will be twice daily.
1562489|NCT02509520|Other|MPR and NMES and HPRO|This is a combination of three above MPR, NMES, and HPRO interventions.
1562490|NCT02509507|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection only into liver tumors, with ultrasound or computerised tomography guidance. The initial dose of talimogene laherparepvec is 10^6 PFU/mL up to 4 mL in cohorts 1 and 2 and up to 8 mL in cohort 3 of Group A and Group B of Part 1. Subsequent doses of talimogene laherparepvec are up to 4 mL of 10^7 PFU/mL in cohort 1, up to 4 mL of 10^8 PFU/mL in cohort 2, and up to 8 mL of the maximum tolerated concentration from cohorts 1 and 2 (either 10^7 or 10^8 PFU/mL) in cohort 3 of Group A and Group B of Part 1. Subsequent doses of talimogene laherparepvec to be administered for the expansion cohorts of Group A and B of Part 2 will be the maximum tolerated dose (ie, maximum tolerated concentration multiplied by maximum tolerated volume) of talimogene laherparepvec determined in Group A and Group B of Part 1, respectively.
1996464|NCT02473549|Device|Sham TDCS|Placebo stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
1996465|NCT02473549|Device|Anodal TDCS|Excitatory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
1996466|NCT02473549|Device|Cathodal TDCS|Inhibitory stimulation is applied to the unaffected motor cortex while participants perform rehabilitation exercises for the upper extremity
1562495|NCT02509481|Drug|Ivermectin|
1562496|NCT02509481|Drug|Albendazole|
1562497|NCT02509468|Drug|Sirolimus|"each patient will be followed during a 12-month-period
each patient will start by an observational period and end being treated by sirolimus
at a random date (between month 4 and month 8), each patient will switch from the observational period to the sirolimus period"
1562498|NCT02509442|Procedure|Diffusion of direct electric stimulation|During the neurosurgery awakened consisting in resecting a low-rank infiltrative glioma , the potential evoked further to the direct electric stimulation of the brain will be recorded by electroencephalography and electrocorticography.
1562499|NCT02509429|Device|Insulin therapy (aspart, lispro ou glulisine) with Control-to-Range algorithm|The insuline used is usual patient insuline. There is no specific insulin for this protocol
1562500|NCT02509429|Device|Insulin therapy ((aspart, lispro ou glulisine) withThreshold Low Glucose Suspend|The insuline used is usual patient insuline. There is no specific insulin for this protocol
1562501|NCT02509403|Drug|Essential oils infused Perineal Hygiene wipe|Each participant will be asked to complete a treatment period of one month's duration. At the start of the study, the participants will be asked to fill-out a baseline questionnaire and will be given a month's supply of the perineal hygiene towel with instructions about its use. At day 15, 30 and 45 follow-ups will be conducted.
1562502|NCT02509390|Procedure|Blood samples|Investigators analyze hematological parameters with blood sampled daily in severe trauma patients
1562503|NCT02509377|Procedure|Open Fetal Repair of Myelomeningocele|Open Fetal Repair of Myelomeningocele when mothers BMI is elevated
1562504|NCT02509364|Other|No intervention|
1562505|NCT02509351|Drug|misoprostol|400 microgram of misoprostol is given preoperatively in patients undergoing elective cesarean section
1562506|NCT02509351|Drug|placeboo|women will recive 2 identical tablets as placeboo
1562507|NCT02509338|Device|Electrode deep brain stimulation (Monopolar DBS Lead Model 09064-40cm)|Deep brain stimulation surgery with implantation of one contact-electrode deep brain stimulation electrodes bilaterally in the internal globus pallidum for treating dystonia
1562508|NCT02509325|Device|Parkinson's Kinetigraph|
1562509|NCT02509312|Drug|Ketorolac|Patients in experimental arm will receive ketorolac at time of cord clamp and then for 3 more doses every 6 hours
1562510|NCT02509312|Drug|Epidural Morphine|All patients, including those in both the experimental and control groups, in this study will receive epidural morphine prior to removal of epidural catheter as part of routine obstetric care for cesarean delivery.
1562511|NCT02509312|Drug|Hydromorphone|Post-operatively all patients patients will have intravenous hydromorphone on an as needed basis to control their pain, as part of routine obstetric care for cesarean delivery.
1562512|NCT02509299|Other|Physiotherapy program 1|the standard medical treatment and additionally they will receive physiotherapy. The program will be performed every day during the hospital stay and it will include daily resistance lower limbs exercises.
1562513|NCT02509299|Other|Physiotherapy program 2|COPD patients included in this group will receive the standard medical treatment and additionally they will receive a physiotherapy program. The program will be performed every day during the hospital stay and included daily controlled breathing exercises and active mobilization.
1562548|NCT02509078|Drug|cisastracurium besylate|Patients randomized to the early neuromuscular blockade arm will receive a cisastracurium besylate bolus of 15 mg, followed by a continuous infusion of 37.5 mg/hour for 48 hours. Patients randomized to the control arm will receive no protocol specified neuromuscular blockade.
1562599|NCT02508623|Drug|Rifaximin|Rifaximin 550 mg tablet BID for 60 days
1562600|NCT02508623|Drug|Placebo|Placebo 1 tablet BID for 60 days
1562514|NCT02509299|Drug|Standard medical treatment|"The standard medical treatment consists on:
Inhaled bronchodilators: Short acting inhaled β2 agonists ( salbutamol and terbutaline) and anticholinergic agents (ipratropium and oxitropium bromide).
Glucocorticoids:
Inhaled glucocorticoids including beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate and triamcinolone acetonide, depending on the expert criteria.
- Antibiotics: The antibiotics were administered according to the GOLD criteria including the β‐lactamase inhibitor and fluoroquinolones."
1562522|NCT02509273|Drug|Clonidine|
1562523|NCT02509273|Drug|Midazolam|
1562524|NCT02509260|Device|Prevena wound management system|Patients will have the Prevena wound management system applied post-operatively.
1562525|NCT02509260|Other|Standard wound dressings|Control patients with standard wound dressings will have gauze and tape dressings applied
1562526|NCT02509247|Device|Telemonitoring|Wireless telemonitoring
1562527|NCT02509234|Drug|Combined chemotherapy with trabectedin followed by irinotecan|"Day 1:
Trabectedin 1,1 - 1,5 mg/m²/day i.v.
Day 3-5 and 10-12:
Irinotecan 30- 90 mg/m²/day p.o. or i.v."
1562528|NCT02509208|Device|SurgiClot haemostatic dressing|haemostatic dressing
1562529|NCT02509195|Drug|Triumeq|Subjects will take the last dose of their current antiretroviral combination at its usual time on the day before the baseline visit (day 1) and will switch on day 1 to Abacavir/lamivudine/dolutegravir 600mg/300mg/50mg (Triumeq) fixed dose combination once daily between day 1 and day 180.
1562530|NCT02509182|Drug|60% oxygen|An inspired oxygen concentration of 60% will be administered during pulmonary lobectomy surgery.
1562531|NCT02509182|Drug|100% oxygen|An inspired oxygen concentration of 100% will be administered during pulmonary lobectomy surgery.
1562532|NCT02509169|Drug|TAE plus P53 gene|Trans-catheter embolization combined with recombinant adenoviral human p53 gene therapy
1562533|NCT02509169|Other|TAE|Trans-catheter embolization
1562534|NCT02509156|Biological|Allo-MSCs|20 transendocardial injections of 0.4ml allo-MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
1562535|NCT02509156|Biological|Placebo|20 transendocardial injections of 0.4ml Buminate solution administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
1562536|NCT02509143|Procedure|High-dose acupuncture with intravenous infusion of ramosetron|"Three sessions of acupuncture will be provided within 48 hours after surgery. Electrical stimulation with an alternating frequency of 2 to 100 Hz will be applied to selected points (PC6 to LI4, ST36 to ST37, and bilateral SP6).
An embedded acupuncture technique for preoperative anxiety will be applied to the bilateral acupuncture points of Liver (LI4), Heart 7 (HT7), Stomach (ST36), Yin-Tang, ear Shen-Men,and ear sympathetic and will be removed the next day. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience. The same stimulation of P6 points and antiemetics will be provided to the P6 acupuncture-point stimulation group."
1562537|NCT02509143|Device|P6 stimulation with intravenous infusion of ramosetron|Stimulation of P6 points will be maintained from one hour before and for 48 hours after surgery by wearing a wristband that produces pulse-type transcutaneous electrical stimulation. Antiemetics will be provided, the same as the standard antiemetic medication alone group.
1562538|NCT02509143|Drug|Intravenous infusion of ramosetron|"Intravenous infusion of (oxycodone 20mg, ketorolac 120mg, ramosetron 0.3mg) as standard antiemetic medication will be provided. A dose of continuous infusion will be reduced by 0.1 ml/hr when a patient complaints of nausea.
When vomiting occurs, a dose of continuous infusion will be reduced by 0.2 ml/hr and a bolus infusion of ramosetron 0.3 mg will be provided. A bolus infusion of ramosetron 0.3 mg will be also given if a patient feels greater than or equal to six points of nausea as measured on a 0 to 10 numeric rating scale (NRS) (nausea-severity scale) or by the patient's request, regardless of the severity of the nausea."
1996467|NCT02473549|Device|Magnetic Resonance Imaging (MRI)|Participants will receive a MRI of their brain to allow the research investigators to determine how the stroke has affected regions of the brain processing movements.
1996468|NCT02473003|Behavioral|high intensity exercise|high intensity exercise 80-90%
1562547|NCT02509091|Drug|Bronchoalveolar Lavage and Local Amikacin Injection|injecting 0.4g of AK in 100 ml to 250 ml, not exceeding 300 ml. And generally, repeat it for 3 to 5 times.
1562597|NCT02508636|Drug|Enzalutamide|
1562598|NCT02508636|Drug|Leuprolide|
1996469|NCT02473003|Behavioral|low/medium intensity exercise|low/medium intensity exercise 40-50%
1996470|NCT02473003|Behavioral|Behavioral medicine strategies|Motivational and self-regulatory behavioral medicine support strategies
1996471|NCT02471716|Drug|FPA008|FPA008 will be administered by IV infusion over approximately 30 minutes every 2 or 4 weeks
1996472|NCT02470156|Behavioral|High Intensity Arm (Intervention)|The high intensity intervention involves monthly wellness coaching, personalized goal setting, and progress tracking in addition to monthly group activities and social support.
1562549|NCT02509065|Device|Bionic Pancreas|Participant wears the bionic pancreas, including an insulin and/or glucagon pump depending on which arm they are in. The 100 mg/dl arm for type 1 diabetes patients will deliver insulin and glucagon. The 100 mg/dl arm for type 2 diabetes patients will deliver just insulin. The 115 mg/dl arm will deliver insulin and glucagon. The 120 mg/dl arm will deliver just insulin. The 145 mg/dl arm will deliver just insulin. The 130 mg/dl and 110 mg/dl arms will deliver insulin and placebo, or insulin and glucagon, and will be double blinded.
1562550|NCT02509065|Other|Usual Care|Participant cares for their diabetes according to their usual practice, with blinded CGM monitoring. No medication will be administered by the study in this intervention.
1562551|NCT02509052|Other|Laboratory Biomarker Analysis|Correlative studies
1562552|NCT02509052|Drug|Leflunomide|Given PO
1562553|NCT02509052|Other|Pharmacological Study|Correlative studies
1562554|NCT02509039|Drug|CC-122|5 continuous days out of 7 days per week intermittent dosing
1562556|NCT02509000|Other|air purifier|filtration units randomly allocated to active- and sham-mode in 20 recruited households for four weeks
1562557|NCT02508961|Behavioral|Exercise|web-based physio exercise programme
1562558|NCT02508935|Drug|XARTEMIS XR|XARTEMIS XR (oxycodone hydrochloride and acetaminophen) Extended-Release Tablets
1562559|NCT02508922|Dietary Supplement|Vitamin D3|2,000iu vitamin D drops will be taken daily for 20 weeks
1562560|NCT02508922|Dietary Supplement|Placebo|Matching placebo drops will be taken daily for 20 weeks
1562561|NCT02508909|Procedure|Videoscopic ilioinguinal dissection|Inguinal dissection is performed after subcutaneous inflation via three ports. Iliac dissection is obtained through a pro-peritoneal access.
1562567|NCT02508857|Drug|Ketorolac|Patients received intravenous injection of ketorolac (30 mg) in bolus; then, saline solution was continuously infused during the entire procedure (Group K),
1562568|NCT02508857|Drug|Magnesium|Patients received intravenous magnesium sulfate (20 mg/kg) in bolus, then magnesium sulfate (2 mg/kg/h) was continuously injected during the procedure (Group M)
1562569|NCT02508857|Drug|Saline solution|intravenous saline solution (20 ml) was injected in bolus, followed by continuous infusion of saline solution during the entire procedure (Group S).
1562570|NCT02508844|Dietary Supplement|Vivomixx®|probiotics intake (four capsules of Vivomixx®; total of 450 billion CFU/day) from gestational age 14-20 until delivery
1562571|NCT02508844|Dietary Supplement|Placebo|Four capsules/day from gestational age 14-20 until delivery. The placebo capsule contains microcrytalline cellulose, magnesium stearate and silicon dioxide.
1562572|NCT02508831|Procedure|Double upper limb allograft|Patients with bilateral amputation of upper limb will receive a double upper limb allograft
1562573|NCT02508818|Other|Parabolic flight|
1562574|NCT02508818|Other|Cardiovascular measurements|
1562575|NCT02508805|Drug|Neuromultivit|
1562576|NCT02508805|Drug|Voltaren|
1562577|NCT02508805|Drug|Sirdalud|
1562578|NCT02508792|Device|LASER|Low level LASER therapy will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
1562579|NCT02508792|Device|LASER PLACEBO|The low level LASER therapy turned off (placebo) will be applied in six different regions of the thight from the dominant limb, before a fatigue protocol using a isokinetic equipment.
1562580|NCT02508779|Behavioral|Bump2be|Bump2be is an internet intervention focusing on six topics (called cores) psycho-educational in nature with the goals of improving individuals' ability to: a) anticipate extreme BG levels, b) detect the presence of extreme BG levels, c) address current extreme BG levels, and d) prevent future extreme BG levels. The program includes didactic information, self-assessment tools, and active learning exercises.
1562581|NCT02508779|Other|Routine Care|Participants will continue to receive care from their clinician.
1562582|NCT02508766|Procedure|Plantar stimulation|The manipulation was performed with the subject in the supine position. The intervention lasted ten minutes and consisted of four stages: 5 glide pressures focused on each interdigital space, that lasted 10 seconds in duration, 5 compression-decompression of each metatarsophalangeal joint, 5 glide pressures applied for 5 seconds each, on the region of metatarsal heads, 5 static pressures applied for 10 seconds each, focused on four points of the sole.
1562583|NCT02508753|Drug|CXA-101/tazobactam|1000/500 mg single IV dose administered over 60 minutes
1562584|NCT02508753|Drug|CXA-101/tazobactam|3000/1500 mg single IV dose administered over 60 minutes
1562585|NCT02508753|Drug|Moxifloxacin|400 mg tablet
1562586|NCT02508753|Drug|placebo|single IV dose of a saline solution administered over 60 minutes plus oral over-encapsulated moxifloxacin placebo tablet administered at the start of infusion.
1562587|NCT02508740|Drug|bevenopran|Single oral dose
1562588|NCT02508727|Other|MRI|
1562589|NCT02508727|Other|3D cardiac ultrasound|
1562590|NCT02508714|Device|Orsiro|stents will be implanted in case of significant coronary artery disease
1562591|NCT02508714|Device|Resolute Onyx|stents will be implanted in case of significant coronary artery disease based on coronary angiography
1562593|NCT02508688|Procedure|thoracoscopic diaphragmatic repair|patients with refractory hepatic hydrothorax (> 3 times thoracentesis and failure to maximal doses of diuretics) who underwent thoracoscopic diaphragmatic repair
1562594|NCT02508662|Other|Review of Screening Tests and Molecular Test Results|Review of screening tests and molecular test results in participant's medical records. Study staff and study doctor work together to find an off-label use for an FDA approved therapy that is best for participant.
1562601|NCT02508597|Other|Physicians receiving smoking cessation training|On the training day, the investigators will explain at the beginning of the workshop the purpose of the training, and the details of the brief smoking cessation intervention to all physicians who attend the training workshop.
1562602|NCT02508584|Biological|anti-mycoplasma hominis antibodies|provision of customized anti-mycoplasma hominis antibodies in the context of a treatment IND.
1562606|NCT02508558|Other|motion perception and locomotor operation performance measurements|
1562607|NCT02508558|Other|parabolic flight|
1562608|NCT02508545|Other|perceived egocentric distance (PED) measurements|
1562609|NCT02508545|Other|Parabolic flight|
1562611|NCT02508519|Procedure|Acupuncture|An acupuncture needle insertion according to zonal or balance method.
1562612|NCT02508506|Drug|ALKS 5461|Single dose, given orally
1562613|NCT02508493|Other|THINC-it Tool|"Digitalized cognitive test application administering the following cognitive test components:
Digit Symbol Substitution Test (DSST)
Choice Reaction Time (CRT)
One-back working memory tool
Trail Making Test B (TMT-B)
Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)"
1562614|NCT02508493|Other|Pencil-and-paper Cognitive Tests|"Pencil-and-paper versions of the following cognitive tests:
Digit Symbol Substitution Test (DSST)
Trail Making Test B (TMT-B)
Perceived Deficits Questionnaire-5 Depression (PDQ-5-D)
Variant of Choice Reaction Time (CRT)
Variant of the One-back working memory tool"
1562615|NCT02508480|Behavioral|Photovoice|"The 10-session, peer-led Photovoice program, designed to empower individuals with SMI to confront public prejudice and discrimination and reduce personal stigma (self-stigma and perceived stigma), was developed and pilot tested at our Center, with primary contributions from staff with a lived experience of mental illness.
In the Photovoice sessions, participants will be given a workbook titled Combating Prejudice and Discrimination through Photovoice Empowerment. Peer leaders will facilitate discussions based on topics in the workbook. Participants will be given cameras and guidance on taking pictures and writing narratives descriptions about the pictures, specifically the ways in which the pictures relate to experiences of prejudice and discrimination."
1562616|NCT02508480|Behavioral|Enhanced Control|The control SAU condition will be enhanced with a 60-minute peer-led manualized educational group session (Leaders' Guidelines and Handout for Participants are attached). It will provide participants with information about the nature of stigma and the laws in the U.S. that protect people with disabilities from discrimination. Participants will be engaged in a discussion about their use of different strategies for proactive coping with psychiatric stigma. This session will be co-led by the same peers who will be delivering the Photovoice program to the experimental group at relevant wave and study sites. Participants randomized to the enhanced Services as Usual control condition will be invited to join a Photovoice group once they complete the final 6-month follow-up assessment.
1562617|NCT02508467|Drug|BLU-554|
1562618|NCT02508441|Drug|Andes-1537 for Injection|"Part 1: Andes-1537 subcutaneous injection, 100 to 1000 mg twice a week per 4-week cycle
Part 2: Andes-1537 subcutaneous injection, recommended phase 2 dose administered twice a week per 4-week cycle"
1996473|NCT02470156|Behavioral|Low Intensity Arm (Comparison)|The low intensity intervention involves wellness coaching, personalized goal setting, and progress tracking at baseline, 4 months, 8 months, and 12 months.
1562621|NCT02508415|Other|Non Surgical Periodontal Therapy|OHE, scaling root planing, mouth wash
1562622|NCT02508402|Drug|Dexamethasone|"The participant of Dexamethasone Group will receive a prefilled syringe with two milliliters (8 mg) of Dexamethasone intramuscular, and the participants of Group II will not receive Dexamethasone or any other cervical ripening agent.
All the participants in both groups will randomly be assigned by computer list.
II. After six hours of the initial dose, the labour induction will start via Oxytocin using"
1562623|NCT02508402|Drug|Placebo|two milliliters of normal saline given to placebo group .
1562624|NCT02508389|Drug|Low Dose GC4419: 30mg/day|Low Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
1562625|NCT02508389|Drug|High Dose GC4419: 90mg/day|High Dose GC4419 will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
1562626|NCT02508389|Drug|Placebo|Placebo will be administered by 60 minute IV infusion, within 1 hour prior to daily IMRT fractions, until IMRT is complete (generally M-F for approximately 7 weeks).
1562627|NCT02508376|Other|AP10-602|AP10-602 contains GLA formulated with liposomes and an additional immunological adjuvant. The ID93 (10 mcg) + AP10-602 (5 mcg) arm will receive intervention on days 1, 29 and 57. The ID93 (10 mcg) + AP10-602 (10 mcg) arm will receive intervention on days 1, 29 and 57.
1562628|NCT02508376|Biological|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE). The ID93 (10 mcg) + GLA-SE (5 mcg) arm will receive intervention on days 1, 29 and 57
1562629|NCT02508376|Biological|ID93|ID93 is a fusion polyprotein comprising four Mtb antigens (Rv2608, Rv3619, Rv3620, Rv1813). All arms will receive 10 mcg ID93 IM on days 1, 29 and 57
1562630|NCT02508363|Behavioral|questionnaires|
1562631|NCT02508350|Drug|Daptomycin|Drug: Daptomycin for Injection（Cubicin,AstraZeneca） dosage: 10-12mg/kg/day frequency: once a day duration: 14 days
1996476|NCT02469389|Behavioral|Engaging in Community Roles and Experiences (ENCoRE)|"Engaging in Community Roles and Experiences (ENCoRE)
includes evidence-based psychosocial treatment
strategies to target the affective-motivational deficits,
negative expectancies, and behavioral skills deficits
that are central to the maintenance of negative
symptoms. Behavioral strategies include motivational
enhancement, psychoeducation, cognitive therapy, and
social skills tr"
1562632|NCT02508350|Other|determination of plasma concentration|A maximum of 12 blood samples (1.5mL) were collected in Ethylenediaminetetraacetic acid disodium salt (EDTA-Na2) tubes over a 6-dose administration sequence.Sampling was done prior to the administration of the first dose, at 30 minutes (end of infusion),and at 4,12,and 24 hours after the initial dose.Additional blood samples were collected at the end of infusion (peak) and prior to the subsequent dose (trough) for doses 2-5.After the sixth dose the blood samples were collected prior to the administration and at 4,and 24 hours after the end of infusion.
1562633|NCT02508337|Drug|XG-102|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
1562634|NCT02508337|Drug|Placebo|Comparison of XG-102 versus placebo for the treatment of ocular inflammation and pain associated with cataract surgery
1562635|NCT02508324|Biological|haplo-identical cells (donor)|Treatment: Haplo-identical healthy related donor. i.e. Parent, child, sibling, possibly third degree or further removed relative (cousin, aunt, nephew etc). They will be collected using standard methods and approximately 3 x10^6 CD34 cells/kg will be infused within 72 hours after completion of the treatment.
1562636|NCT02508324|Biological|umbilical cord blood unit (CBU)|Treatment: The CBU unit must supply a minimum of 0.5 x107/kg and a maximum of 2.5x107/kg nucleated cell dose pre-cryopreservation. The unit must match at a minimum of 4 of 6 at HLA-A, -B antigens, -DRB1 alleles with the recipient. Mismatches (0-2) can be at any loci -. Although molecular level typing will be available for the patient and the CBU unit, a match is defined at intermediate resolution for HLA-A and -B and at high resolution for -DRB1. The CBU donor will also have undergone HLA typing of the mother, thus allowing determination of the CBU-IPA and NIMA. CBU grafts used in this study will be investigational units that meet all criteria for clinical use. Better matching units will be preferred over less matching units as long as the CBU dose exceeds 0.5 x107 NBC/kg
1562639|NCT02508298|Procedure|HVPG|HVPG will be performed by placing a placing a 7F venous catheter into a supra-hepatic vein and then advancing a 5F balloon-tipped catheter into the right hepatic vein. Wedged hepatic venous pressure (WHVP) and free hepatic venous pressure (FHVP) will be measured by connection to an external transducer and polygraph (PowerLab, ADInstruments Inc., Colorado Springs, CO). After inflating the balloon catheter, adequacy of the occlusion will be established by injection of a small amount of radiologic contrast medium. Hepatic Venous Pressure gradient (HVPG) will be calculated as the difference between WHVP and FHVP.
1562640|NCT02508298|Drug|Indocyanine Green Retention test|As decribed in arm descriptions
1562641|NCT02508298|Device|Liver stiffness measurement|As decribed in arm descriptions; perfromed by ARFI
1562642|NCT02508298|Device|Spleen stiffness measurement|As decribed in arm descriptions; performed by ARFI
1562651|NCT02508220|Drug|Syntocinon|Oxytocin nasal spray
1562652|NCT02508220|Drug|Placebo|distilled water in nasal spray
1562653|NCT02508207|Drug|VX-661/ivacaftor|
1562654|NCT02508207|Drug|ivacaftor|
1562655|NCT02508207|Drug|VX-661/ ivacaftor matching placebo|
1562656|NCT02508207|Drug|ivacaftor matching placebo|
1562662|NCT02508168|Drug|Alogliptin|Alogliptin 12.5 mg tablets
1562663|NCT02508168|Drug|Metformin Hydrochloride|Metformin hydrochloride 1000 mg tablets
1562664|NCT02508168|Drug|SYR-322MET|SYR-322MET (alogliptin 12.5 mg and metformin 1000 mg) fixed-dose combination (FDC) tablets
1562669|NCT02508142|Drug|Hyoscine-N-Butylbromide|"Study Drug: 20 mg/2 mL Hyoscine-N-Butylbromide in 98 mL normal saline (totally 100 mL) ıntravenous form of Hyoscine-N-Butylbromide in normal saline is in the same appearance with placebo Study drug: 100 mL normal saline (placebo) (totally 100 mL)
Drug: Fentanyl 1 mcg/kg as rescue analgesia at 30th minute"
1562708|NCT02507778|Device|CellCollectorTM (Gilupi, Germany) needle|needle will be inserted before and after biopsy and will measure circulating tumor cells.
1562673|NCT02508116|Genetic|CYP2C19 genotyping|The study utilizes a genotyping device, SpartanRx™ (Spartan Bioscience, Ottawa, Canada) that provides identification of a patient's CYP2C19 *2, *3, and *17 genotypes determined from genomic DNA from a buccal swab sample with 1 hour turnaround time
1562674|NCT02508103|Drug|Oxytocin|Intranasal Oxytocin spray (40 IU, 3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
1562675|NCT02508103|Drug|Placebo|Intranasal Placebo spray (3x/day) self-administered during laboratory testing session and then for 4-5 days until menses begins
1562676|NCT02508077|Drug|Fluorouracil|Given IV
1562677|NCT02508077|Drug|Irinotecan Hydrochloride|Given IV
1562678|NCT02508077|Other|Laboratory Biomarker Analysis|Correlative studies
1562679|NCT02508077|Drug|Leucovorin Calcium|Given PO
1562680|NCT02508077|Biological|Panitumumab|Given IV
1562681|NCT02508064|Drug|BMS-663068|BMS-663068
1562682|NCT02508051|Behavioral|Article email links|Email links to specific articles, published in 2 journals M-Fr with a reminder to take the same test every six month
1562683|NCT02508051|Behavioral|Blog email links|Emailed web links to blog posts M-Fr based on the same articles as in Email links group; each blog post will focus on a specific article with links to the corresponding article. Every six months group 3 will get a reminder to take the same test.
1562684|NCT02508038|Procedure|TCRαβ+/CD19+ depleted Haploidentical HSCT|Patients will undergo a reduced-intensity conditioning regimen prior to transplant with a haploidentical donor peripheral blood stem cell graft depleted of TCRαβ+ cells and CD19+ cells using the CliniMACS System.
1562685|NCT02508038|Drug|Zoledronate|Given IV. Patients (except those in Cohort A) will receive two doses of Zoledronate (at a 28 day interval) following transplant. Dose and post-transplant timing of Zoledronate administration is dependent upon patient Cohort.
1562686|NCT02508025|Other|Functional Capacity Evaluation|Assessment of work related physical capacity
1562687|NCT02508012|Other|Immuno monitoring|treatment optimization
1562688|NCT02507999|Device|Flotrac|Flotrac guided intervention
1562689|NCT02507986|Device|Single lead ECG device|The single lead ECG device is a smartphone compatible handheld device that produces a single lead ECG after 30 seconds of measurement. It is non-invasive, electrically safe and easy to use.
1562690|NCT02507986|Device|7-Day Holter monitor.|The Holter is a conventional 7-Day Holter monitor.
1562691|NCT02507973|Other|Airway Pressure Release Ventilation|Airway pressure release ventilation (APRV) is a mode of mechanical ventilation that switches between high (PHigh) and low (PLow) continuous positive airway pressure while allowing spontaneous breathing at both phases. Alveolar recruitment and oxygenation occur during PHigh whereas ventilation occurs during brief releases to PLow.
1562692|NCT02507973|Other|Low Tidal Volume Ventilation|After enrollment and collection of baseline Intracranial pressure and hemodynamic status for 30 minutes the participants will undergo low tidal volume mechanical ventilation (LOTV), serving as a control mode of ventilation. LOTV is most commonly used for trauma patients with lung injury. LOTV provides oxygen in smaller amounts, without overstretching the lungs
1562693|NCT02507960|Device|The Gamma Pod|Immobilization of breast during radiation.
1562694|NCT02507960|Device|CT simulation|See arm description
1562695|NCT02507934|Device|Lubricin|Lubricin 150 µg/ml eye drops
1562696|NCT02507934|Device|Sodium Hyaluronate|Sodium hyaluronate 0.18% eye drops
1562697|NCT02507895|Device|MI-BCI|Subjects will be seated comfortably in front of a computer screen. An EEG cap will be comfortably worn over the head of the subject to record EEG traces of any activated cortical areas. If subjects are able to activate the device and are agreeable to participate in the second phase of the study, they will be enrolled in a 4-week BCI-MI training program of 12 sessions. Subjects will be required to perform 160 trials of MI altogether with assigned rest periods (5 mins) every 40 trials. Each session will last approximate 45 minutes excluding set up time.
1562698|NCT02507882|Biological|IL28B Polymorphism|SNP rs12979860 and 4803217 will be determined in whole blood by allelic discrimination using specific probes by real time PCR.
1562699|NCT02507882|Biological|miRNA quantification|"RNAs will be extracted from serum using miRNeasy Mini Kit (Quiagen) according to the manufacturer's instruction.
The RNA purity will be assessed by the RNA concentration and quantified by NanoDrop ND-1000 (Nanodrop, United States).
cDNA will be obtained by miScript II Reverse Transcription Kits (Quiagen) A Preamplification will be performed using miScript PreAMP PCR Kits (Quiagen) Real Time PCRarray will be done using miScript miRNA PCR Arrays, with SYBR Green PCR Master Mix (Quiagen)."
1562700|NCT02507869|Behavioral|Positive affective response|Participants adjust the intensity of their exercise to maintain a pleasant affective response.
1562701|NCT02507869|Behavioral|Moderate-intensity heart rate|Participants adjust the intensity of the exercise to maintain a heart rate in the moderate range (64-76% of their HRmax).
1562702|NCT02507843|Drug|Cholecalciferol|Oral Cholecalciferol(100000 IU) will be administered in Vitamin D group monthly for 6 months.
1562703|NCT02507843|Drug|Placebo|Placebo will be administered in placebo group monthly for 6 months.
1562704|NCT02507817|Other|blood sample and tissue sample|"Maternal LIF levels prior and after delivery.After birth and disconnection of the cord, we also will take a blood sample from the umbilical cord (5cc) for cytokine ELISA testing.
A small sample of the placenta will be examined in order to assess the level of ACTH protein"
1562705|NCT02507804|Other|Patient diary PROMs|
1562706|NCT02507804|Other|Counselling|
1562707|NCT02507791|Other|Fitbit Charge HR plus weekly phone calls to review physical activity data|Patients during weekly Healthy Kids, Healthy Weight classes will also upload their Fitbit data, which will be remotely accessed by the study team and weekly phone calls will be implemented to discuss activity
1562712|NCT02507739|Other|no possibility to walk during labor|
1562713|NCT02507739|Other|possibility to walk during labor|
1562714|NCT02507726|Device|Flexima Active soft convexe|The Investigational Device will be used during 14 +- 3 days.
1562715|NCT02507700|Procedure|Popliteal block|In group P, popliteal block will be performed with ultrasound guidence.
1562716|NCT02507700|Drug|Sevoflurane|Sevoflurane will be used to all patient's for anesthesia induction and maintenance
1562717|NCT02507700|Device|Ultrasound|For recognize the nerve (sciatic nerve), ultrasound will be used in group P.
1562718|NCT02507700|Other|Plaster cover|Plaster cover will be used to control group for sham procedure
1562719|NCT02507700|Drug|bupivacaine|Bupivacaine 0.25% will be performed for popliteal block to group P.
1562720|NCT02507700|Other|Laryngeal mask airway|After anesthesia induction, laryngeal mask airway will be inserted to all patients
1562721|NCT02507687|Drug|Bimatoprost SR|Bimatoprost sustained-release (SR) Dose A administered on Day 4, Weeks 16 and 32.
1562722|NCT02507687|Other|Sham Bimatoprost SR|Sham Bimatoprost SR administered on Day 4, Weeks 16 and 32.
1562723|NCT02507687|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty administered on Day 1.
1562724|NCT02507687|Other|Sham Selective Laser Trabeculoplasty|Sham Selective Laser Trabeculoplasty administered on Day 1.
1562725|NCT02507674|Device|ultrasound|
1562726|NCT02507661|Procedure|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 2 months|
1562727|NCT02507661|Procedure|no-preservation of alveolar ridge - 2 months|
1562728|NCT02507661|Procedure|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 4 months|
1562729|NCT02507661|Procedure|no-preservation of alveolar ridge - 4 months|
1562730|NCT02507661|Procedure|preservation of alveolar ridge with beta tricalcium phosphate + collagen - 9 months|
1562731|NCT02507661|Procedure|no-preservation of alveolar ridge - 9 months|
1562732|NCT02507648|Drug|Oseltamivir|1 tablet contains 75 mg oseltamivir
1562733|NCT02507648|Drug|Tamiflu®|1 tablet contains 75 mg oseltamivir
1562734|NCT02507635|Drug|Levocetirizine|administration of Levocetirizine 5 mg/day for 4 weeks
1562735|NCT02507635|Drug|Desloratadine|administration of Desloratadine 5 mg/day for 4 weeks
1562736|NCT02507622|Other|measurement of the concentration of C02, CO and NH4, 3 exhaled gas with E-Nose system|
1562737|NCT02507622|Other|Parabolic flight|
1562738|NCT02507609|Other|Moderate neuromuscular blockade|TOF count is maintained to 1 to 2 by intermittent intravenous injection of rocuronium bromide 5 mg during operation
1562739|NCT02507609|Other|Deep neuromuscular blockade|PTC is maintained to 1 to 2 degree by continuous infusion of rocuronium bromide intravenous route
1562740|NCT02507596|Biological|Nano-crystalline hydroxyapatite silica gel|it is a type of synthetic bone graft.
1562741|NCT02507596|Procedure|open flap debridement|a periodontal surgical procedure for the purpose of debridement.
1562743|NCT02507570|Drug|Enzalutamide|used concomitantly
1562744|NCT02507570|Radiation|Radium ra 223 dichloride|
1562745|NCT02507544|Drug|TRX-818 capsules|
1562746|NCT02507518|Procedure|PET scan imaging|a PET scan will be done 2 weeks before the start of maintenance therapy and another 16 days after to predict the earlier response to treatment
1562747|NCT02507505|Procedure|Regional Anesthesia|Regional anesthesia involves temporarily numbing parts of the body with nerve blocks. Spinal anesthesia is a type of regional anesthesia that uses medications injected into the fluid surrounding the spinal cord to temporarily numb the legs and lower abdomen. Spinal anesthesia is the most widely used type of regional anesthesia for hip fracture surgery. While intravenous sedation is typically used for comfort with spinal anesthesia, invasive airway interventions are not typically required.
1562748|NCT02507505|Procedure|General Anesthesia|General anesthesia uses injected or inhaled medications to keep people unconscious during surgery. Since general anesthesia depresses breathing and impairs protective airway reflexes, invasive airway interventions such as breathing tube placement and mechanical ventilation are usually required.
1562749|NCT02507492|Drug|RM-493|
1562750|NCT02507479|Drug|Thiotepa|Chemotherapy given prior to allogeneic stem cell transplantation
1562751|NCT02507466|Behavioral|exercise|Variable conditions of stepping practice
1562752|NCT02507453|Other|parabolic flight|
1562753|NCT02507453|Other|mass/weight perception estimation|estimate the mass/weight perception, expressed by verbally report the absolute and relative mass of the object using a scale from 1 to 10 (1 being light and 10 being heavy)
1562754|NCT02507453|Device|ESA short-arm human centrifuge (SAHC)|
1562755|NCT02507440|Drug|Lidocaine|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
1562756|NCT02507440|Drug|Placebo|Prior to initiation of anesthesia viscous lidocaine or placebo will be administered.
1562757|NCT02507440|Drug|Propofol|All patients will receive intravenous propofol as anesthesia for EGD
1562758|NCT02507427|Device|NIM-Eclipse|Using NIM-Eclipse, nerve monitoring and mapping are performed
1562759|NCT02507414|Other|Blood samples|15 arterial blood samples (pre-, intra- and one day postoperatively); no more than 180ml in total over two days.
1562760|NCT02507414|Other|Measurement of microcirculation|Measurement of microcirculation with Laser Speckle Contrast Imaging (non-touch setup with no side effects); continuous measurement of the microvascular blood flow on the forehead up to 60 minutes starting one minute before the surgical procedure.
1562761|NCT02507414|Other|Head down tilt|"At three different time points the participants will be head down tilted in 20 degrees.
End of surgery (A) One hour postoperatively (B) 18 hours postoperatively (C)"
1562764|NCT02507375|Drug|Erlotinib|Erlotinib will be administered as oral tablets.
1562765|NCT02507375|Drug|Pertuzumab|Pertuzumab will be administered as intravenous (IV) infusion.
1562766|NCT02507362|Radiation|adjusted corneal collagen cross-linking|UV-A irradiation for 7 minutes
1562767|NCT02507362|Radiation|accelerated corneal collagen cross-linking|UV-A irradiation for 10 minutes
1562768|NCT02507362|Drug|riboflavin 0.1% combined with dextran 20 %|after mechanical epithelial removal riboflavin drop will be instilled every 5 minutes for 30 minutes and then instillation will be continued during irradiation
1562769|NCT02507362|Procedure|epithelial debridement|corneal epithelium will be removed by a cottons swab
1562772|NCT02507336|Drug|Thalidomide|
1562773|NCT02507336|Other|Clinical/Laboratory Evaluations|Annual Clinical/Laboratory evaluations will include Physical Exam, Complete Blood Count (CBC), Comprehensive Metabolic Panel (CMP), Lactate dehydrogenase (LDH)
1562774|NCT02507336|Other|Survival|Patient will be followed for survival by annual telephone contact or in-person visit.
1562775|NCT02507323|Drug|ticagrelor|A platelet aggregation inhibitor
1562776|NCT02507323|Drug|prasugrel|a thienopyridine class inhibitor of platelet activation and aggregation
1562777|NCT02507323|Drug|Placebo|placebo
1562778|NCT02507310|Other|thermostat|ambient temperature as modified by thermostat
1562779|NCT02507297|Device|Positive Airway Pressure (PAP)|Positive airway pressure therapy entails use of a machine that blows pressurized room air through the airway (via a mask or nasal pillows, worn on the face) at a sufficient pressure to keep the upper airway open. The pressurized air acts as a splint. Participants randomized to PAP treatment will be offered PAP therapy using an auto-titrating device.
1562780|NCT02507284|Drug|SRX246|
1562781|NCT02507284|Drug|Placebo|
1562782|NCT02507271|Other|Brain Fitness Program|This intervention involves work on a computer by responding to sounds for five hours a week, approximately one hour a day five days a week at the Rusk Institute for Rehabilitation.
1562783|NCT02507271|Other|Weekly Telephone Contact|This intervention involves weekly telephone calls over a period of approximately 8 weeks to inquire about the participant's involvement in cognitively stimulating activities (such as reading, working on the computer, puzzles, etc.)
1562784|NCT02507258|Device|PROFEMUR® Am Femoral Stem w/ PROCOTYL® O Shell|PROFEMUR® Am cementless stems with PROCOTYL® O HA Coated Acetabular Component
1562785|NCT02507245|Drug|Growth Hormone-Releasing Hormone|From Baseline Visit (T0) to 6th Month Visit 0,025 mg/kg Growth Hormone/die. From 6th Month Visit to 12th Month Visit 0,030 mg/Kg Growth Hormone/die.
1562786|NCT02507232|Device|NovoTTF-200A|12 cycles
1562787|NCT02507232|Drug|Temozolomide|50 mg/m2/day rounded to the nearest 5 mg. One cycle is 28 days and will be given for 12 cycles
1562789|NCT02507206|Drug|DAR 0-100A|15 mg DAR 0100A is dissolved in 150 cc NS administered over 30 minutes intravenously.
1562790|NCT02507206|Drug|Placebo|15 mg DAR placebo is dissolved in 150 cc NS administered over 30 minutes intravenously.
1562791|NCT02507193|Procedure|Open reduction internal fixation|An incision is made at the site of the break or injury, and the fracture is carefully re-aligned . The plate and screws are installed, and the incision is closed with staples or stitches. Synthes and Stryker plate and screws will be used.
1562792|NCT02507193|Procedure|Intermedullary Nail|An incision is made at the site of the break or injury, and the fracture is carefully reduced. The nail in inserted through the medullary canal after proper imaging for accurate placement. The incision is closed with staples or stitches. Acumed fibula nail will be used.
1562793|NCT02507180|Other|LEFt clinical decision rule|"The LEFt rule
Predictor Points Left leg symptoms +1 Extremity swelling (≥ 2 cm difference in calf circumference +1 First trimester symptom onset +1
Clinical probability Unlikely: 0 or 1 point Likely: > 1 point"
1562794|NCT02507167|Dietary Supplement|mixed meal|250 ml Fortimel compact (chocolate)
1562795|NCT02507167|Drug|Rifampin|oral rifampin administration (600 mg EREMFAT®)
1562796|NCT02507154|Drug|Cetuximab + NK cells|
1562797|NCT02507141|Device|Reflectance Confocal Microscopy|Reflectance Confocal Microscopy imaging will be performed during surgery. The imaging procedure is expected to last no more than 15-20 minutes. The approach will be essentially similar to the imaging of skin cancer on patients, which is routinely performed in our Dermatology Service.
1562798|NCT02507128|Drug|liraglutide|Liraglutide were taken 30 min before PCI.
1562799|NCT02507128|Drug|placebo|Placebo were taken 30 min before PCI.
1562800|NCT02507115|Behavioral|TMAP|Text messages for Alcohol Risk Reduction
1562801|NCT02507115|Behavioral|Mojo Texts|Motivational texts not alcohol related
1562802|NCT02507102|Device|Voyager|Non-invasive RFE therapy
1562803|NCT02507089|Behavioral|Tailored sleep health education materials.|Tailored sleep health materials.
1562804|NCT02507089|Behavioral|Generic sleep health education materials.|
1562805|NCT02507076|Drug|isolated limb perfusion|Undergo ILP with melphalan
1562806|NCT02507076|Drug|melphalan|Undergo ILP with melphalan
1562807|NCT02507076|Procedure|quality-of-life assessment|Ancillary studies
1562808|NCT02507063|Procedure|ultrasound|Ocular ultrasound to look at the optic nerve sheath diameter in patients with an intracranial monitoring device or with a ventriculoperitoneal shunt malfunction requiring revision
1562809|NCT02507050|Drug|Ivabradine|To start Ivabradine 6 weeks prior to PCI.
1562810|NCT02507037|Dietary Supplement|gum+PEG|chew sugarless gum
1562811|NCT02507037|Drug|polyethylene glycol|2L PEG
1562812|NCT02507024|Other|Online questionnaire|
1562813|NCT02507011|Drug|Carvedilol|Beta-adrenergic receptor blocker
1562814|NCT02507011|Drug|Placebo|Placebo
1562815|NCT02506998|Biological|DLE|Adjuvant treatment
1562816|NCT02506998|Other|Second generation anti histamines + Nasal corticosteroids|Standard treatment
1562817|NCT02506985|Drug|rivaroxaban|Immediately following completion of alteplase infusion, patients will receive rivaroxaban 15 mg oral bid for 21 days followed by 20 mg oral daily.
1562818|NCT02506985|Drug|warfarin|Immediately following completion of alteplase infusion, patients will continue on unfractionated heparin or low-molecular weight heparin with initiation of warfarin adjusted to INR of 2-3.
1562819|NCT02506972|Other|Classic Quaker Quick Oats|Various doses of oats without or with sugar
1562820|NCT02506972|Other|Cream of Rice Cereal|Various doses of cereal without sugar
1562821|NCT02506959|Drug|Busulfan|Busulfan 32 mg/m2 by vein Test Dose before admission if outpatient, and Day -10 if inpatient. Busulfan AUC 4,000 by vein on Days -8 to -5.
1562822|NCT02506959|Drug|Palifermin|60 microgram/kg by vein on Days -12, -11, -10, 0, +1 and +2, or -14, -13, -12, 0,+1 and +2.
1562823|NCT02506959|Drug|Panobinostat|Panobinostat 20 mg by mouth on Days -9 to -2.
1562824|NCT02506959|Drug|Gemcitabine|Gemcitabine 1,875 mg/m2 by vein on Days -8 and -3.
1562825|NCT02506959|Drug|Melphalan|Melphalan 60 mg/m2 by vein on Days -3 and -2.
1562826|NCT02506959|Drug|Dexamethasone acetate|Dexamethasone 8 mg by vein 2 times a day on Days -9 through Day -2.
1562827|NCT02506959|Drug|Caphosol|Caphosol oral rinses 30 mL four times a day from day -9 until discharge.
1562828|NCT02506959|Drug|Glutamine|Glutamine 15 g four times a day, swished, gargled and spit started on day -9 until discharge.
1562829|NCT02506959|Drug|Pyridoxine|Pyridoxine 100 mg by vein or mouth three times a day from Day -1.
1562830|NCT02506959|Procedure|Stem Cell Transplant|Stem cell transplant performed on Day 0.
1562831|NCT02506933|Other|Laboratory Biomarker Analysis|Correlative studies
1562832|NCT02506933|Biological|Multi-peptide CMV-Modified Vaccinia Ankara Vaccine|Given IM
1562833|NCT02506933|Other|Placebo|Given IM
1562835|NCT02506894|Drug|Magnesium Sulfate|magnesium sulfate will be given for 24 hours
1562836|NCT02506894|Other|0.9% sodium chloride solution|normal saline will be given as intravenous drip over 24 hours
1562837|NCT02506881|Drug|Darbepoetin alfa|
1562838|NCT02506868|Drug|Darbepoetin alfa|Weekly sc administration of darbepoetin alfa
1562839|NCT02506855|Drug|Ropivacaine|
1562840|NCT02506855|Other|Placebo|
1562841|NCT02506855|Procedure|Transversus Abdominis Plane Block|
1562842|NCT02506842|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
1562843|NCT02506842|Drug|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats until there is disease progression or recurrence.
1562844|NCT02506842|Drug|oxaliplatin|Patients receive oxaliplatin 85 mg/m^2 (iv, 2 hours) on days 8 and 22 with 42 days as a cycle. Treatment repeats until there is disease progression or recurrence. Oxaliplatin is given before folinic acid and fluorouracil when the three drugs are given on the same days.
1562845|NCT02506842|Drug|folinic acid|Patients receive folinic acid 200 mg/m^2 (iv) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
1562846|NCT02506842|Drug|fluorouracil|Patients receive fluorouracil 2000 mg/m^2 (iv, 24 hours) on days 1, 8, 15 and 22 for 4 weeks, followed by 2 weeks without treatment. Treatment repeats until there is disease progression or recurrence.
1562847|NCT02506829|Behavioral|Smoking cessation counseling (Quitline)|
1562848|NCT02506829|Behavioral|Smoking cessation pharmacotherapy (e.g, nicotine replacement therapy)|
1562849|NCT02506829|Behavioral|Financial incentives|
1562850|NCT02506816|Drug|Olaparib|Drug exposure has a limited duration 28 (+/- 5) days and at lower dose (600mg/day) than therapeutical accepted (800mg/day).
1562851|NCT02506803|Drug|NAC-GEMABR|NAC-GEMABR regimen includes gemcitabine 1000mg/m2 plus nab-paclitaxel 125mg/m2 3 times weekly 1week rest.
1562852|NCT02506790|Drug|metformin|
1562853|NCT02506790|Drug|Melatonin|
1562854|NCT02506790|Drug|Toremifene|
1562855|NCT02506777|Drug|metformin|
1562856|NCT02506777|Drug|Fluoruracil|
1562857|NCT02506777|Drug|Doxorubicin|
1562858|NCT02506777|Drug|Cyclophosphamide|
1562859|NCT02506777|Drug|melatonin|
1562860|NCT02506751|Drug|liothyronine|All eligible subjects will be treated with the study drug as per the standardized dose-escalation protocol. Subjects will be required to report to the study site every six weeks for the duration of the study in order to receive their study drug and to monitor drug safety and tolerability.
1562861|NCT02506738|Device|Intervention using mHealth|Patients in the intervention used at home a mobile system to monitor their clinical and health status.
1562862|NCT02506725|Other|prenatal care in groups|We will do prenatal care in groups using centering care pregnancy methodology
1562863|NCT02506712|Device|SmartDrive assisting device|oxygen consumption
1562864|NCT02506712|Device|Standard manuel wheelchair|oxygen consumption
1562865|NCT02506699|Other|analgesic effect of rTMS|
1562870|NCT02506660|Drug|Bupivacaine|
1562871|NCT02506660|Drug|Perineural dexamethasone|Dexamethasone in nerve block
1562872|NCT02506660|Drug|Intravenous dexamethasone|
1562873|NCT02506660|Drug|Intravenous saline|
1562874|NCT02506660|Drug|Perineural saline|Saline in nerve block
1562875|NCT02506647|Drug|Gan & Lee insulin glargine followed by Lantus|0.4 IU/kg Gan & Lee insulin glargine injection SC, Lantus 0.4 IU/kg injection SC
1562876|NCT02506647|Drug|Lantus followed by Gan & Lee insulin glargine|Lantus 0.4 IU/kg injection SC, 0.4 IU/kg Gan & Lee insulin glargine injection SC,
1562877|NCT02506634|Drug|Esomeprazole MUPS, 20 mg|The treatment period would be 4 to 8 weeks according to the findings under upper endoscopy. For patients with esophagitis, this period would be 8 weeks(Esomeprazole MUPS, 20 mg bid); for patients with normal findings, this period would be 4 weeks(Esomeprazole MUPS, 20 mg bid).
1562878|NCT02506621|Device|R test|
1562879|NCT02506621|Device|Nuubo|
1562880|NCT02506621|Device|TECHNOMED pocket ECG|
1562881|NCT02506621|Device|ZIO xt patch|
1562882|NCT02506621|Device|MoMe|
1562883|NCT02506608|Procedure|Operation of sensorized hand prosthesis|"Four TIME-4H electrodes will be implanted in the median and ulnar nerves of he amputees. The electrodes will be connected with the STIMEP electrical multichannel stimulator. The stimulator will be connected with one of the two sensorized hand prosthesis. Afferent and efferent signals will be elaborated and integrated by the ODROID software.
The amputees will be able to control the prosthetic hand movement and receive a sensory feedback from the prosthesis sensors.
The use of the prosthesis during different tasks will be considered the intervention."
1562884|NCT02506595|Behavioral|ERRT-M for Nightmares|Exposure, Relaxation, and Rescripting Therapy Military version (ERRT-M) - Five 60-90 minute sessions administered once weekly. ERRT-M includes psychoeducation, sleep habit modification, relaxation training, written exposure to and rescription of nightmare content and imagery rehearsal of rescripted dream content.
1562885|NCT02506582|Dietary Supplement|jerusalem artichoke and fermented soybeans powder mixture|40 g jerusalem artichoke and fermented soybean powder mixture
1562886|NCT02506582|Dietary Supplement|placebo|40 g powdered rice flour
1562887|NCT02506569|Device|Implantable Cardioverter Defibrillator therapy|Tachycardia Fast Heart Beat
1562888|NCT02506569|Other|Magnetic Resonance Imaging (MRI)|MRI scan of the head and lower body parts
1562889|NCT02506556|Drug|BYl719|"Treatment: BYL719 350mg orally daily Treatment will be given daily until progression, undue adverse events or withdrawal of consent.
Dose reductions (two levels) are allowed. Each cycle is 28 days"
1562890|NCT02506543|Behavioral|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 13-19 year old girls in three refugee camps in Ethiopia. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
1562891|NCT02506543|Behavioral|No intervention|Wait list control group will not receive an intervention. After the follow-up study, the wait-list control group will receive the regular COMPASS program
1562892|NCT02506530|Procedure|intensive decongestive treatment|intensive decongestive treatment
1562893|NCT02506530|Device|Cellu M6|Use of Cellu M6
1562894|NCT02506517|Drug|Afatinib|
1562895|NCT02506504|Device|Inspiratory help then sham ventilation|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
1562896|NCT02506504|Device|Sham ventilation then Inspiratory help|The Inspiratory Pressure Support is used to increase the intensity and the duration of training session. For the sham ventilation, the device deliver a non effective quantity of oxygen.
1562897|NCT02506491|Other|Pilates exercise|2 sessions/week, 1 hour/session during 22 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
1562898|NCT02506491|Other|Muscular exercise|2 sessions/week, 1 hour/session during 22 weeks. Intensity determined from 6 to 9 points, controlled by the Resistance exercise scale of perceived exertion (OMNI-RES).
1562899|NCT02506491|Other|Control Group|No exercise
1562900|NCT02506478|Other|Beverage procurement|All Emergency Department patients will be approached to ask their beverage preferences in a randomly permuted data collection form. If they would like juice, the flavor will be recorded and the juice (and/or water) will be procured by a research assistant if the patient would like that, though the actual procurement of the juice is not part of the study.
1562901|NCT02506465|Device|iTIND|Temporary Implantable Nitinol Device (iTIND)
1562902|NCT02506465|Procedure|Sham Arm|Foley catheter will be placed and immediately removed.
1562903|NCT02506452|Other|Biovance®|Application of Biovance® for up to 12 weeks or until wound closure, whichever is sooner. Non-active moist wound treatment, debridement as needed, off-loading
1562904|NCT02506452|Other|Standard of Care, Diabetic Foot Ulcers|Non-active moist wound treatment, debridement as needed, off-loading for up to 12 weeks or until wound closure, whichever is sooner
1562905|NCT02506439|Dietary Supplement|10 mcg Vitamin D3|Once daily, 10mcg (400IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
1562906|NCT02506439|Dietary Supplement|20 mcg Vitamin D3|Once daily, 20mcg (800IU) dose of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
1562907|NCT02506439|Dietary Supplement|Placebo|Once daily, placebo capsule containing 0mcg (0IU) of vitamin D3 taken from baseline visit (approx 15 weeks gestation) until endpoint (delivery)
1562908|NCT02506426|Procedure|Endoscopic sinus surgery + Septoplasty|Opening of the paranasal sinuses along with correcting the nasal septum
1562909|NCT02506426|Procedure|Septoplasty alone|Straightening of the nasal septum without opening the paranasal sinuses
1562910|NCT02506413|Other|MamaToto Package|The MamaToto Package is an MNCH intervention that builds upon a prior successes in Uganda and will be adapted to meet the needs in Misungwi District in Tanzania. The intervention includes low-cost programming that builds upon the existing district health system structure and resources in order to strengthen the MNH capacity and training of the district, health facilities, and community health workers.
1562911|NCT02506387|Device|mitraclip|The decision to implant mitraclip is not part of this observational study but is made by the heart-team.
1562912|NCT02506348|Drug|Diclofenac|
1562913|NCT02506348|Drug|Nepafenac|
1563090|NCT02504814|Device|Nasal Highflow (NHF)|changes in breathing physiology in NHF
1562914|NCT02506335|Drug|Cholate testing|The patient receives simultaneously an oral dose of d4-cholate and an IV dose of 13C-cholate, which are stable isotopes; there is no radioactivity or radiation exposure.
1562915|NCT02506322|Behavioral|SEKT - Cognitive-Behavioral-Emotional|"This Bipolar Disorder specific psychotherapy has 4 modules:
psychoeducation, life chart, relapse experiences, personalized explanation, early symptoms and recognition of a new episode, self observation
Stress regulation, sleep-wake cycle, social rhythm, daily and weekly structure of life, life balance
dysfunctional cognitions, cognitive techniques, meta-cognitive techniques, emotion regulation methods
behavior changes, (social, problem solving) skill training, communication skills, crisis management"
1562916|NCT02506322|Behavioral|FEST - Clinical Supportive Educational|This active control psychotherapy has 2 modules: (a) psychoeducation about Bipolar Disorder, the etiology and development of this disorder, drug options, effects and side effects of medication, compliance, how to handle unwanted side effects (b) group discussion and exchange about disorder relevant and personal relevant topics related to Bipolar Disorder, therapist is passive, encouraging, listening, verbalizing feelings and emotion, strengthening subjects resources
1562917|NCT02506309|Device|TOT - inside-out trans-obturator tape/sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
1562918|NCT02506309|Device|SIS - Innovative fixation single incision sling|Patients were randomized by envelope technique at the time of surgery indication to either TOT or SIS anti-incontinence surgical procedure with mid-urethral slings (MUS)
1562919|NCT02506296|Drug|DPPIV inhibitor -|Mixed Meal Tolerance Test with or without a DPPIV inhibitor
1562920|NCT02506296|Device|Continuous glucose monitoring system.|participant's will self-monitor blood glucose over a 4-6 day period via a CGM monitor inserted just under the skin.
1562921|NCT02506283|Device|Zamar Therapy CT clinic|Zamar Therapy is a certified medical product (directive 93/42/EEC and ISO 134 85:2012) (www.zamarmedical.com)
1562922|NCT02506270|Device|Airseal Trocar|28 patients are treated with the AirSeal insufflation and trocar system
1562923|NCT02506270|Device|conventional trocar|28 patients are treated with a conventional insufflation and trocar system
1562924|NCT02506257|Drug|0.04% PHMB|0.04% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
1562925|NCT02506257|Drug|0.06% PHMB|0.06% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
1562926|NCT02506257|Drug|0.08% PHMB|0.08% PHMB eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
1562927|NCT02506257|Drug|PHMB Vehicle|PHMB vehicle eye drops, 1 drop 12 times daily for 7 days, followed by 1 drop 6 times daily for additional 7 days
1562928|NCT02506244|Device|iRhythm ZIO XT Patch|Single-lead ECG monitoring via a wearable patch
1562929|NCT02506244|Device|Wristband by Amiigo|Determines pulse rate using photoplethysmography.
1562930|NCT02506231|Drug|Folinic acid|
1562931|NCT02506231|Drug|Placebo|
1562932|NCT02506218|Dietary Supplement|10 + 20 g protein consumption|whey isolate
1562933|NCT02506218|Other|30 g protein breakfast|30 g mixed meal breakfast
1562934|NCT02506218|Other|10 g protein breakfast|10 g mixed meal breakfast
1562935|NCT02506205|Behavioral|Lee Silverman Voice Treatment (SVLT) LOUD|
1562936|NCT02506192|Drug|Delayed-Release Prednisone|Delayed-Release Prednisone oral tablets (2x5mg) daily for 8 weeks
1562937|NCT02506192|Drug|Placebo|Placebo oral tablets (2x5mg) daily for 8 weeks
1562938|NCT02506166|Device|Positive Airway Pressure Therapy|Positive Airway Pressure Therapy will be used in Group 3 for treatment of predominant obstructive sleep apnea
1562945|NCT02506140|Drug|Ticagrelor and Acetylsalicylic acid|This group will receive a 180 mg loading dose of ticagrelor on the day of randomization, followed by 90 mg twice/day ticagrelor from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
1562946|NCT02506140|Drug|Clopidogrel and Acetylsalicylic acid|This group will receive a 300 mg loading dose of clopidogrel on the day of randomization, followed by 75 mg once/day clopidogrel from Day 2 to 3 months; combined with Aspirin given in a total dose of 100-300 mg on the first day, followed by 100 mg once/day from Day 2 to Day 21.
1562947|NCT02506127|Device|Neuronetics XPLOR system|
1562948|NCT02506114|Biological|PROSTVAC V/F|PROSTVAC-V/F is a PSA (prostate-specific antigen)-based immunization strategy. It is intended to generate immune responses to prostate specific antigens and prostate cancer cells. It uses poxviral vectors to introduce modified PSA to the patient in an immunogenic manner to break self-tolerance, and thereby induce immune responses directed against prostate cancer cells.
1562949|NCT02506114|Drug|Ipilimumab|
1562951|NCT02506088|Behavioral|Your Voice Your View|Session 1 of the intervention involves background information, an introduction to social norms, and bystander intervention skills training. Session 2 of the intervention establishes conditions for consent, types of abusive behavior and identifying abuse. Session 3 of the intervention addresses risk reduction strategies for girls. Session 3 of the intervention addresses false accusations, masculinity, and additional practice on identifying conditions for consent for boys. Session 4 of the intervention includes active practice of bystander intervention skills.
1562952|NCT02506075|Device|Transcranical direct current stimulator|approved by Conformity European as safe treatment device for stroke patients
1562953|NCT02506075|Behavioral|Visual inattention training|
1563085|NCT02504931|Drug|Sertraline|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Sertraline is the active medication treatment arm.
1562954|NCT02506062|Device|Manual blood pressure cuff inflation over brachial artery|A manual blood pressure cuff (sphygmomanometer) is used in the study as a tourniquet in order to perform a controlled, consistent level of ischemia (200mmHg/active arm or 60 mmHg/placebo arm).
1562956|NCT02506036|Other|Brain HQ|Brain HQ is a web application that will be used to provide patients with a training intervention that addresses deficits in social-emotional functions. These include areas such as identifying facial expression, understanding tone of voice, and predicting how people may react in certain situations. The training will take about 30 hours over the course of 4-6 weeks and is done at home.
1562957|NCT02506023|Drug|Desmopressin|Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.
1562958|NCT02505997|Drug|Midazolam|Single 5 mg oral dose of midazolam syrup given in the AM on Day 1 and Day 8.
1562959|NCT02505997|Drug|Delafloxacin|Oral 450 mg delafloxacin tablets given twice daily (Q12h) on Days 3 to 8
1562960|NCT02505984|Drug|Oxytocin|Study participants will be randomized to a placebo or drug group.
1562961|NCT02505984|Drug|Placebo|Study participants will be randomized to a placebo or drug group.
1562962|NCT02505971|Drug|Nadolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day. In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be escalated (by 0.5 mg/kg/day at any following study visit) up to 3 mg/kg/day based on the clinical response to maintain the dose that led to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.
S/he will be monitored until Week 52."
1562963|NCT02505971|Drug|Propranolol|"Patients will be administered twice-daily doses of medication as follows: since Day 0- 0.5 mg/kg/day ; since Day 7-1.0 mg/kg/day and since Day 14- 1.5 mg/kg/day.
In all subsequent visits the dosage will be adjusted based on the current weight rather than the baseline weight to maintain 1.5 mg/kg/day. Or the dose may be increased by investigator, based on clinical response by 0.5 mg/kg/day at any study visit (up to 3 mg/kg/day divided twice a day) to maintain the dose that lead to at least 75% reduction in the hemangioma size until Week 24, when unblinding happen. At Week 24 paticipants can start weaning by 10% per week or continue with the last dose, depending on the investigator's decision.
S/he will be monitored until Week 52."
1562964|NCT02505958|Other|high caloric intake|Volunteers will be started on a diet program for 4 ½ days, consisting of 3 meals and 3 snacks over a 24 hour period and containing ~ 6000 Kcal/24 h.
1562965|NCT02505958|Other|reduced caloric intake|On days 5 and 6, volunteers will received 3 meals (~333 calories each) totaling ~ 1,000 calories/24 hours.
1562968|NCT02505932|Procedure|Arthroscopic Latarjet procedure|arthroscopic approach (set Depuy-Mitek, Raynham, MA)
1562969|NCT02505932|Procedure|Mini-open Latarjet procedure|mini-open approach (set Arthrex, Naples, FL)
1562970|NCT02505919|Device|AQUABEAM System|To utilizes proprietary heat-free high-pressure waterjet technology to resect and remove prostate tissue using the AQUABEAM system, which is a personalized image-guided tissue removal system.
1562971|NCT02505919|Procedure|Transurethral Resection of the Prostate (TURP)|Transurethral resection of the prostate (TURP) is a type of prostate surgery done to relieve moderate to severe urinary symptoms caused by an enlarged prostate, a condition known as benign prostatic hyperplasia (BPH)
1562972|NCT02505906|Radiation|Simultaneous Integrated Boost Technique|
1562973|NCT02505893|Biological|Human pancreatic islet|One thousand and five hundred (1,500) equivalent islet for Kg of body weight, isolated from a single brain-dead donor, will be infused into the patient's liver.
1562974|NCT02505893|Drug|ATG|ATG will be administered IV (central vein) at a total dose of 6 mg/kg up to day 6 post-transplant
1562975|NCT02505893|Drug|Pegylated G-CSF|Pegylated G-CSF (6 mg/dose) will be administered SC every 2 weeks for 6 doses (12 weeks) beginning after the last ATG infusion
1562976|NCT02505893|Drug|Rapamycin|Rapamycin will be administered orally at a starting dose of 0.2 mg/kg once a day, then targeted to blood trough level of 8-10 ng/mL and suspended one month after transplant.
1562977|NCT02505880|Other|Local anesthetic + Hypnosis|Modified state of consciousness allowing to be at the same time here and somewhere else. The individual is going to dive into his imagination to extract of an uncomfortable situation. And local anesthetic (solution of Xylocaine with adrenaline 1 % dabbed in 20 % of bicarbonate of sodium 4,2 %, maximal dose of 0,5ml / kg)
1562978|NCT02505880|Drug|General anesthesia|Sufentanil intravenous (0.1 in 0.2 µg / kg) and propofol (5 in 10 mg / kg on 3 mn) administration
1562979|NCT02505867|Device|Adaptive Servo Ventilation|Participants are provided with an Adaptive Servo Ventilation (ASV) device for targeted treatment of SDB during inpatient hospitalization or shortly after discharge.
1562980|NCT02505854|Dietary Supplement|Probiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of maltodextrin
1562981|NCT02505854|Dietary Supplement|Symbiotic|Hypocaloric diet associated with capsule containing 1billion UFC Bifidobacterium lactis and sache of fructooligosaccharide
1562982|NCT02505854|Dietary Supplement|Placebo|Hypocaloric diet associated with capsule containing 50g of gelatin and sache of maltodextrin
1562983|NCT02505841|Other|TAP block with Ropivacaine|Ultrasound-guided transversus abdominis plane block wih Ropivacaine injection 0.2% at 0.3 ml/kg
1562984|NCT02505841|Drug|Curare|Atracurium injection at 0.5 mg/kg at least 3 minutes before the surgical incision
1562985|NCT02505828|Procedure|Articular punction, salivary samples, blood sample|
1562986|NCT02505815|Procedure|Surgery|
1562987|NCT02505815|Procedure|Cortisol Level Measurement|
1562988|NCT02505815|Procedure|Neurocognitive Testing|
1562989|NCT02505802|Drug|BoNT-A injection|In BoNT-A treatment group patients received 200 units BoNT-A injection in the triceps surae (150iu) and tibial muscle posterior (50iu).
1562990|NCT02505789|Other|Determining the source of EBV in severe EBV infections|Blood units administered to patients with severe EBV infection will be traced back to the donors who in turn (with consent) will be serologically assessed for EBV, and all seropositive donors will have their EBV strain genotyped for comparison to the patient's strain.
1562991|NCT02505776|Drug|Bimatoprost cutaneous solution 0.03%|Bimatoprost cutaneous solution 0.03% (GLASH VISTA™) prescribed as per standard of care in clinical practice.
1562992|NCT02505763|Procedure|Strategy with thoracic ultrasound|This strategy involves the systematic use of thoracic ultrasound for the treatment of pleural effusion, treatment and follow up care.
1562993|NCT02505750|Radiation|3D conformal EBRT|External Beam Radiation Therapy
1562994|NCT02505750|Device|Contact X-ray brachytherapy 50 kV|
1562995|NCT02505750|Drug|Capecitabine|
1562996|NCT02505737|Behavioral|TH-CBT|Telephone-Based Cognitive Behavioral Therapy (TH-CBT). A 10-session treatment protocol that incorporates behavioral activation, thought monitoring and restructuring, relaxation training, worry control, sleep hygiene, and caregiver psychoeducation and support
1562997|NCT02505737|Other|Enhanced Usual Care|Community-based treatment as usual and supplemental reading material
1562998|NCT02505724|Behavioral|conventional training|After completing the initial assessment, faculty randomized to the conventional training group received a link to a web-based instructional video. In addition, they were given a laparoscopic box trainer, laparoscopic instruments and sutures that they could use to practice with at their leisure.
1562999|NCT02505724|Behavioral|peer-coaching|Faculty randomized to the peer-coaching group received ½ hour of peer-coaching after completing the initial assessment on the simulator. Each faculty member sutured on the box trainer while being observed by his or her peer-coach. All study participants had the same peer-coach.After the coaching session, study participants received a link to the web-based video as well as the box trainer and supplies to independently practice laparoscopic suturing. Similar to individuals in the control group, no specific guidance regarding the amount of independent practice was given.
1563000|NCT02505711|Behavioral|Homestead Food Production program|Training and support for vegetable gardening and poultry rearing, and education on young child nutrition, hygiene and health topics, in women's groups, as designed by the international non-governmental organization (NGO) Helen Keller International (HKI).
1563001|NCT02505672|Radiation|Chemoradiotherapy for nasopharyngeal carcinoma|Note that this is standard care for NPC and patients are not assigned to different intervention groups. All patients in the study will receive the same treatment (chemoradiotherapy) and will be observed for changes in vestibular function.
1563002|NCT02505659|Behavioral|Preoperative re-education|Preoperative re-education (behavior): 8 re-education sessions of 30 to 40 minutes, 2 times a week, for 4 weeks
1563003|NCT02505646|Other|Observational study. No special intervention will be made|Data will be recorded in a context of fluid load in a context of circulatory failure. Stroke volume will be monitored, before, after an abdominal compression and after a fluid load.
1563004|NCT02505633|Device|Stimuplex insulated needle|"2P2I group: nerve stimulating needle is advanced twice and LA is injected 15 mL at a time.
1P1I group: nerve stimulating needle is advanced once and LA is injected 30 mL."
1563005|NCT02505633|Drug|lidocaine mixed with epinephrine|2P2I group and 1P1I group use the same LA (1.5% lidocaine mixed with 1:200,000 epinephrine). But 2P2I group is injected LA at equally divided doses (15 mL at a time). 1P1I group is injected LA 30 mL at once.
1563006|NCT02505620|Procedure|Treatment of OSAS with CPAP mask|Interventional treatment addresses the treatment with a CPAP (continuous positive airway pressure) mask in oder to open patients upper airway obstructive permanently while sleep.
1563007|NCT02505620|Procedure|Surgical Treatment with multilevel operation|Surgical treatment addresses a surgical multilevel anti-obstructive operation in order to eliminate upper airway obstruction permanently.
1563008|NCT02505607|Other|Overactive Bladder Care Plan counseling|"Use of a printed Overactive Bladder Plan of Care information sheet."
1563009|NCT02505581|Drug|Extra dosage - cefuroxime (750mg) I.V|In both groups a second intravenous dose of cefuroxime (750mg) will be administered if the intraoperative time elongates more than three hours or there is an intraoperative bleeding over 1000cc
1563010|NCT02505581|Procedure|Colorectal Surgery|Both groups undergo colorectal surgery. This section does not include rectal surgery ( see Inclusion/exclusion criteria)
1563011|NCT02505581|Drug|Cefuroxime 750mg oral|An oral antibiotic pattern of ciprofloxacin (750mg / 12h, 2 doses) the day before surgery.
1563012|NCT02505581|Drug|Metronidazole 250mg oral|An oral antibiotic pattern of metronidazole (250 / 8h, 3 doses) the day before surgery.
1563013|NCT02505581|Drug|Metronidazole 1,5gr Intravenous|An intravenous antibiotic pattern of cefuroxime 1g during anesthetic induction.
1563014|NCT02505581|Drug|Cefuroxime 1g Intravenous|An intravenous antibiotic pattern of metronidazole 1,5gr during anesthetic induction.
1563015|NCT02505568|Drug|Infliximab|Participants will receive infliximab 5 milligram per kilogram (mg/kg) infusion at Week 0, Week 2, and Week 6 for the induction phase. Participants who complete the induction phase will continuously receive 5 mg/kg infliximab infusion every 8 weeks up to week 32 in the maintenance phase.
1563016|NCT02505555|Device|four dimensional hysterosalpingo-contrast sonography|compare accuracy and tolerability of 4D-HyCoSy with that of laparoscopy and chromotubation
1563019|NCT02505529|Other|Resistance Exercise Training|Behavioral interventions of resistance exercise
1563020|NCT02505529|Other|Mental Imagery|Behavioral intervention of mental imagery
1563021|NCT02505516|Other|metformin|
1563022|NCT02505503|Device|Unloading shoes|The unloading shoe will be a trainer-type shoe with a rocker sole incorporated. The sole is designed to influence the line of action of the ground reaction force to pass close to the anatomical joint centres and so reduce the moments needed to be generated for ambulation by the muscles acting across those joints in the lower limb. Additionally it is designed to place the ankle into a relatively plantarflexed position where the ankle plantarflexors use less energy than for instance when placed in dorsiflexion.
1563124|NCT02504580|Drug|HTX-011A|
1563023|NCT02505503|Device|Unadapted control shoe|During the control condition assessments, participants wear a pair of appropriately-sized shoes, which are similar in appearance to the unloading shoes, but do not contain the altered sole.
1563024|NCT02505490|Other|Television|The purpose is to determine whether television impacts liking of food.
1563025|NCT02505490|Other|No Television|The purpose is to determine whether the lack of television impacts liking of food.
1563026|NCT02505477|Drug|N-acetylcysteine|N-acetylcysteine is a safe, widely available supplement currently FDA-approved for treatment of acetaminophen antidote and as a mucolytic. It has effects on glutamate in the brain via the NMDA receptor as well as the glutathione antioxidant system (it is a precursor to glutathione).
1563027|NCT02505477|Other|Treatment as Usual|Treatment for schizophrenia which may include medications, therapy, or other types of treatment as determined by the subject's VA or community psychiatrist or mental health treatment team
1563028|NCT02505451|Drug|dobutamine|In each participant, dobutamine will be administered via intravenous infusion in doses of 10, 20, 30 and 40 lg/kg/min during 3-min stages and 2D strain echocardiography will be performed at each stage.
1563029|NCT02505438|Behavioral|Exercise|
1563030|NCT02505425|Behavioral|Behavioral Support|"ENABLE CHF-PC includes:
In-person comprehensive Palliative Care Team (PCT) Consultation- as soon as feasible after enrollment.
Palliative Care Nurse Coach (PNC) embedded within HF teams, instituting a phone-based 6-session patient and a 4-session caregiver curriculum followed by monthly phone-based supportive care for 48 weeks or patient death.
The PNC uses the manualized curriculum: Charting Your Course (CYC): An Intervention for Patients with Heart Failure and their Families.
Usual Care: Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines."
1563031|NCT02505425|Behavioral|Usual HF Care|Usual heart failure care includes any available supportive care resources and heart failure patient medical management based on national HF guidelines.
1563032|NCT02505399|Drug|ticagrelor|"Ticagrelor will be administered orally, according to the following scheme:
180 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),
90 mg the following morning (D Day before rotational atherectomy and angioplasty),
90 mg the following evening (D Day after rotational atherectomy and angioplasty),
90 mg twice daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
1563033|NCT02505399|Drug|clopidogrel|"Clopidogrel will be administered orally, according to the following scheme:
300 mg the evening preceding (and at least 6 hours before) rotational atherectomy (Day -1),
75 mg the following morning (D Day before rotational atherectomy and angioplasty),
0 mg the following evening (D Day after rotational atherectomy and angioplasty),
75 mg once daily the day after the procedure of rotational atherectomy and angioplasty (Day +1)."
1563034|NCT02505386|Drug|Ertapenem|
1563035|NCT02505373|Behavioral|Attempted Suicide Short Intervention Program (ASSIP)|"The brief therapy ASSIP consists of three to four sessions, which are ideally administered within a period of 2 to 4 weeks. Therapy sessions are scheduled for 60 to 90 minutes.
Session 1: A narrative interview is conducted, in which the patient is asked to tell his or her personal story which led to the suicidal crisis. The narrative is video-recorded.
Session 2: Using video-playback of the recorded narrative, patient and therapist explore further details of the suicidal process.
Session 3: A case conceptualization focusing on the patient's vulnerability and the trigger of the suicidal crisis is formulated in writing. A list of safety strategies for the prevention of future suicidal behaviour is developed jointly with the patient.
Regular letters are sent to patients over a period of 2 years."
1563036|NCT02505373|Behavioral|Control Group (CG)|Participants assigned to the control group underwent a single clinical interview that included a structured assessment of suicide using the SSF (Jobes, 2006).
1563037|NCT02505360|Other|Measurements of concentration of hyaluronic acid as well as in type 1 collagen and 3|
1563038|NCT02505347|Other|No splint|Can move arm as tolerated with no restrictions on mobility
1563039|NCT02505347|Device|Splint|Wear splint for 6 weeks, only to remove for rehab and personal care
1563040|NCT02505334|Drug|liraglutide|Injected subcutaneously s.c. (under the skin) once daily.
1563041|NCT02505321|Other|Oral Triglyceride Tolerance Test (OTTT)|Participants consume a fatty drink. An intravenous catheter is inserted into the antecubital veins in one arm for intermittent sampling over the following 4 hours. The OTTT permits simple evaluation of postchallenge triglyceride levels and is acceptable to participants.
1563042|NCT02505321|Procedure|Abdominal fat biopsy (optional)|A sample of abdominal fat will be obtained by firstly injecting some local anaesthetic into an accessible area of the abdomen. Using a scalpel, a small incision (approx 2-3 cm) will be made to a depth of approx 15mm and two small pea-sized samples of fat will be removed. The wound will be closed with simple sutures or steristrips.
1563043|NCT02505308|Other|Glucose-Potentiated Arginine-Induced Insulin Secretion|Intravenous catheters are inserted into antecubital veins in both arms. One arm is used for infusion of glucose/amino acid (Arginine). The other arm is used for intermittent sampling.
1563044|NCT02505295|Drug|Selenium|4 vials selenase stat and 2 vials daily for 5 days
1563045|NCT02505295|Drug|normal saline|
1563046|NCT02505282|Other|Vitamin K status|Vitamin K status indicated by desphospho-uncarboxylated matrix Gla protein level
1563047|NCT02505269|Drug|Brentuximab Vedotin|
1563048|NCT02505269|Drug|Adriamycin|
1563049|NCT02505269|Drug|Dacarbazine|
1563050|NCT02505256|Other|No intervention|
1563051|NCT02505230|Behavioral|Eating|Participants will have 20 minutes to eat as much or as little of a meal (consisting of pasta alone or pasta with zucchini and squash presented in 3 different ways)
1563052|NCT02505204|Other|Clonidine|The anesthetic mixture will contain: lidocaine 2% 7 mL, lidocaine 2% 6 mL with epinephrine 5µg.mL-1, bupivacaine 0.5% 5 mL, and clonidine 2 mL.
1563053|NCT02505204|Other|Placebo|the same anesthetic mixture will be administrated however the clonidine will be substituted with 2 mL saline.
1563054|NCT02505191|Drug|St. John's wort prolonged-release tablet 500 mg|
1563055|NCT02505191|Drug|St. John's wort film coated tablets 250 mg|
1563086|NCT02504931|Drug|Placebo|A Randomized Controlled Trial Design will randomize subjects to one of two arms. Placebo is the control medication treatment arm.
1563056|NCT02505178|Other|Problem Solving Therapy|PST is a minimally invasive treatment. The five sessions of CM implemented PST will involve psychotherapy also known as talk therapy between the CM's and study participants in a group setting. Psychogeriatric interdisciplinary staff (CM's) i.e. psychiatric nurses, social workers who have been previously trained in PST will function in the roles of facilitator, cofacilitator and scribe. The roles can be shared amongst the professionals to build capacity in each role or maintained over time if so desired. Sessions will be approximately one-and-a-half to two hours in length and conducted at the Cherry Hill Mall library in London.
1563057|NCT02505165|Behavioral|IMPACT|• The intervention is 6 sessions lasting approximately 45 minutes reviewing ways to help prevent and respond to illness uncertainty. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
1563058|NCT02505165|Other|ESO|This control is 6 sessions lasting approximately 45 minutes providing education on cancer etiology, medical treatments, side effects, potential short- and long-term effects of treatment and resources that are often helpful to parents of children with cancer. Sessions occur weekly at already scheduled clinic appointments. Interventions will be delivered by a trained interventionist.
1563059|NCT02505152|Procedure|Percutaneous transhepatic intrahepatic portosystemic shunt|Under fluoroscopic guidance, portal vein(PV) was punctured with a 22-gauge Chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 7-French sheath inserted over the wire. Then retrohepatic inferior vena cava(RIVC) or hepatic vein(HV) was punctured with a 20-gauge, 30-cm Chiba needle through sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm stiff shaft wire was then introduced through the transjugular sheath and manipulated into main portal vein(MPV) and then into superior mesenteric vein(SMV). Afterward the PTIPS procedure was completed in the standard transjugular fashion.
1563060|NCT02505139|Other|the number of circulating tumor cells|
1563061|NCT02505126|Device|Active tDCS|One daily session (13:20:13) : active current flows continuously twice for 13 minutes with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
1563062|NCT02505126|Device|Placebo tDCS|One daily session (13:20:13) : inactive current flows continuously twice for 13 with a rest interval (no stimulation) of 20 min 5 sessions (once a week for 5 consecutive days)
1563063|NCT02505113|Drug|Montelukast|Montelukast (10mg, q.d., p.o.)
1563064|NCT02505100|Other|Touching relaxant|
1563065|NCT02505100|Other|Hypnoses|
1563066|NCT02505087|Drug|N-Acetylcysteine followed by Placebo|"Arm receiving N-Acetylcysteine (NAC) for 6 months and then placebo for 6 months.
Treatment periods are separated by a 2 month washout."
1563067|NCT02505087|Drug|Placebo followed by N-Acetylcysteine|Arm receiving placebo for 6 months then N-acetylcysteine (NAC) for 6 months. Treatment periods are separated by a 2 month washout.
1563068|NCT02505074|Procedure|Valve replacement with the Melody valve|This study will only review patients who have had the Melody valve surgically inserted into the Mitral and/or Tricuspid positions. We will not be reviewing any other intervention type.
1563069|NCT02505061|Behavioral|Hospital-based Program|The research team will discuss with the clinical therapists who will provide training program in a hospital for 120 minutes/per session, 2 sessions/per week for a total of 9-week intervention. In addition, the research team will videotape the child‟s natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase. The treatment program of the two sessions will be preplanned and adjusted by the occupational therapist through clinical observation of participant's performance in the previous session. Training will still concentrate on building the concept of casual-effect on the switch and car motion, goal-oriented driving (e.g., driving 200 meters and reach for a toy or contact with a person), and upper limb use in functional tasks with driving in a hospital,discussed by the family, the treating therapist and the research team.
1563070|NCT02505061|Behavioral|Regular Therapy Program|The regular therapy group will continue the regular therapy, including physical, occupational and speech therapy. The general propose of the training is to improve the developmental scales, mobility, socialization and upper limb use in functional tasks. The research team will videotape the child‟s natural play and driving performance at the hospital for 20 minutes/per session, 1 session/per week during the 9-week intervention phase
1563071|NCT02505048|Drug|rucaparib|600 mg bid per os , 28 day cycle, number of cycles: until progression or unacceptable toxicity develops.
1563072|NCT02505035|Behavioral|Default ordering of palliative consult|
1563073|NCT02505022|Drug|Pharmacotherapy|Participants may receive pharmacotherapy in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
1563074|NCT02505022|Behavioral|Behavioral treatment|Participants may receive behavioral treatment in the course of treatment-as-usual. This observational study does not influence the type of treatment administered.
1563075|NCT02505009|Drug|Engerix-B|The case group will receive 5 Engerix-B injections during the last 6 months of a 3-year NA therapy.
1563076|NCT02505009|Drug|Tenofovir|Both case and control will receive 300 mg Tenofovir for at least 3 years
1563077|NCT02505009|Drug|Entecavir|Both case and control will receive 0.5 mg entecavir therapy for at least 3 years
1563078|NCT02504996|Drug|Paracetamol|1 g paracetamol via intravenous route in 100 ml normal saline
1563079|NCT02504996|Drug|morphine|0.1 mg/kg morphine via intravenous route in 100 ml normal saline
1563080|NCT02504996|Drug|Placebo|Intravenous 100 ml normal saline
1563081|NCT02504983|Drug|sorafenib|sorafenib is an oral, multikinase inhibitor approved for the treatment of advanced hepatocellular carcinoma
1563082|NCT02504983|Procedure|TACE|Transcatheter arterial chemoembolization was performed by the injection of small embolic particles coated with chemotherapeutic agents selectively into an artery directly supplying a tumor.
1563083|NCT02504957|Procedure|Photodynamic therapy using polyhematoporphyrin|
1563084|NCT02504944|Drug|Propranolol 0.2% eye drops|Enrolled preterm newborns will receive propranolol as ophthalmic solution (0.2%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, four times daily (every 6 hours). Propranolol treatment will be always associated to the conventional approach adopted by the Early Treatment for Retinopathy of Prematurity Study (ETROP) Cooperative Group.
1563089|NCT02504827|Drug|Ceftazidime/avibactam|Ceftazidime/avibactam 2.5gm iv q8h for 3 doses
1563091|NCT02504801|Drug|Budesonide|To test the hypothesis that nebulizer Pulmicort Respules could reduce post operation pulmonary complication incidence in primary lung cancer patients with COPD. Compare post-operation pulmonary complication incidence in two arms among primary lung cancer patients with COPD required single lobectomy from 3 days before operation to 7 days after operation.
1563092|NCT02504788|Radiation|hippocampal-sparing WBRT|
1563093|NCT02504775|Drug|Mejoral® 500 Tablets|500 mg tablet of paracetamol
1563094|NCT02504775|Drug|Tylenol® Caplets|500 mg tablet of paracetamol
1563095|NCT02504762|Procedure|Treatment|Hybrid Coronary Intervention = MICS CABG + Percutaneous Coronary Intervention. This study is a surgical intervention, which does not involve a drug or device intervention.
1563096|NCT02504762|Procedure|Control|Conventional CABG. This study is a surgical intervention, which does not involve a drug or device intervention.
1563097|NCT02504749|Procedure|general anasthesia,spinal anasthesia|"Randomization done by computer generated random number in sealed opaque envolopes.Each patient was given a study information sheet and a consent was signed. Sample size was calculated to prevent type II error. Based on these data, we would need to study 225 cases in each arm to be able to reject the null hypothesis that the rates for the experimental and control groups are equal with a probability of 80%. The type I error probability associated with this test for the null hypothesis is 0.05. We used an uncorrected chi-squared statistic to evaluate this null hypothesis. Additionally, to compensate for discontinuations, we recruited 225 women in each arm.
450-pregnant women with an indication for caesarean section were randomly allocated ."
1563098|NCT02504723|Drug|carvedilol|Oral carvedilol is started after randomization at an initial dose of 6.25 mg daily. Doses are increased every 3 days during the admission or every 7 days in the out-patient clinics until the maximum tolerated dose was achieved or up to 25 mg daily, aiming at reducing resting pulse rate by 25 percent but not below 55 beats per minute with systolic blood pressure >90 mm Hg.
1563099|NCT02504723|Drug|cyanoacrylate|The patients undergo repeated endoscopic cyanoacrylate injection every 3-4 weeks until obturation of gastric varices.
1563100|NCT02504710|Device|Kinematic Real Time Feedback|
1563101|NCT02504710|Other|Traditional systems of manual therapy teaching|
1563102|NCT02504697|Other|Biosamples from airway and blood|Identify biomarkers in biosamples from airway and blood for the preclinical detection of lung cancer.
1563103|NCT02504684|Device|Endovenous 1920-nm diode laser|Patients with saphenous veins treated with a new 1920-nm diode endolaser.
1563104|NCT02504684|Device|Endovenous 1470-nm diode laser|Patients with saphenous veins treated with the standard 1470-nm diode endolaser.
1563109|NCT02504658|Behavioral|Lifestyle text messages|"Throughout the course of the four-week study, the experimental participants will receive one text message each morning related to general nutrition and exercise goals, and an additional goal status update message on Monday, Wednesday, and Friday evenings. The goal status update message will ask the participants about the status of attaining their nutrition or physical activity goals. Participants may log their progress toward attaining their goals by using the mobile health dashboard feature on BodiMojo.com from a computer or a web-enabled smartphone to indicate their goal status (still working on it or completed it). Participants will be encouraged, via the text messages, to look at information on the BodiMojo program found on the Bodimojo.com website."
1563110|NCT02504658|Behavioral|Attention Control Group|"Once participants randomized to the control group have completed the baseline assessment, they will be asked to write down two health goals with the RA. The same goals will be suggested for this group as for the Intervention group (see Appendix). They will take home a copy of the goals they have set. The participants will be also given a 16-page pamphlet from NIDDK A Guide for Teenagers: Take Charge of Your Health! to take home to read over."
1563111|NCT02504645|Drug|IPP-201101|
1563112|NCT02504645|Drug|Placebo|
1563113|NCT02504645|Other|Standard of Care|
1563114|NCT02504632|Other|test|"Peripheral venous citrated blood will be collected just before and 10-15 min after the implantation of the valve. Samples will be obtained after starting the infusion of contrast media. In peripheral venous blood before 24 h and after the procedure and at hospital discharge, 4-6 days when the usual transient thrombocytopenia after TAVI has recovered.
The results will be used to analyse the kinetics of haematological changes in peripheral blood following aortic valve replacement.
Platelet activation will be monitored by flow cytometry to assess the expression of specific membrane markers and the phosphorylation of signalling proteins, as well as the formation of platelet/monocyte aggregates."
1563115|NCT02504632|Other|control group|In this group, only one sample (2 tubes filled with 4.5 ml, i.e. 9ml) will be obtained in venous peripheral blood to establish reference values in age-matched, aspirin-treated, atherosclerotic population.
1563116|NCT02504619|Biological|CordIn|CordIn™ is a cryopreserved stem/progenitor cell-based product of purified CD133+ cells composed of ex vivo expanded allogeneic UCB cells.
1563117|NCT02504606|Drug|Besylsartan|Amlodipin besylate 6.944mg+Losartan K 100mg
1563118|NCT02504606|Drug|Amosartan|Amlodipin besylate 7.841mg+Losartan K 100mg
1563119|NCT02504593|Device|mHealth platform employing Fionet Deki Readers to ensure quality of community-based malaria diagnosis|The investigators propose to implement a new mobile interface that automatically reads and troubleshoots malaria rapid diagnostic test (RDT) cassettes. This device, called a Deki reader (DR), will allow the investigators to establish an extensive quality assurance program of malaria diagnosis performed by trained community health volunteers (CHVs). To ensure high-quality diagnosis by CHVs, the study team will deploy 10 Fionet DRs and rotate them amongst 200 CHVs who have been trained to do RDTs. In the first phase, each CHV will use the device for 10 successive clients presenting themselves for malaria diagnosis to the CHV, and then the device will be rotated to another CHV.
1563120|NCT02504580|Drug|HTX-011|
1563121|NCT02504580|Drug|Placebo|
1563122|NCT02504580|Drug|HTX-002|
1563123|NCT02504580|Drug|Bupivacaine Hydrochloride Injection|
1563128|NCT02504567|Device|Laser ablation|Pulmonary vein isolation using the laser ablation catheter
1563129|NCT02504567|Device|RF ablation|Pulmonary vein isolation using the RF ablation catheter
1563130|NCT02504554|Drug|oral Vancomycin|an antibiotic
1563131|NCT02504554|Drug|MoviPrep|a bowel cleanse
1563132|NCT02504554|Drug|Prilosec|a stomach acid suppressan
1563133|NCT02504554|Biological|human fecal material; processed, frozen administered orally|human fecal material; processed, frozen, administered orally
1563134|NCT02504554|Biological|human fecal material; processed, frozen; administered orally and rectally|human fecal material; processed, frozen; administered orally and rectally
1563135|NCT02504541|Drug|Testosterone enanthate auto-injector|Dose Adjustment 100 mg / 75 mg / 50 mg
1563136|NCT02504528|Other|house dust mites|house dust mites(two-fold increasing concentration of house dust mite (HDM) extract, dilutions prepared starting from 1:8, 1:16, 1:32, 1:64, 1:128, 1: 256, 1:512, 1:1024,……)
1563137|NCT02504515|Other|World Health Organization Quality of Life Bref Questionnaire|"The World Health Organization Bref (WHOQOL-BREF) questionnaire will be applied in three different moments: Baseline, after 6 months, and after 12 months.
The WHOQOL-BREF instrument comprises 26 items, which measure the following broad domains: physical health, psychological health, social relationships, and environment. The WHOQOL-BREF is a shorter version of the original instrument that may be more convenient for use in large research studies or clinical trials."
1563138|NCT02504502|Other|Routine Care Plus Enhanced Report|Routine clinical care vs. enhanced genomic report
1563139|NCT02504502|Other|Routine Care with Crossover|Participants will receive routine clinical care. After 3 month survey completion the participants will also receive the enhanced genomic report.
1563140|NCT02504489|Drug|Docetaxel + Plinabulin (DP)|Docetaxel 75 mg/m2 IV + Plinabulin 30 mg/m2
1563141|NCT02504489|Drug|Docetaxel (D)|Docetaxel 75 mg/m2 IV
1563142|NCT02504476|Drug|AMG 581|Active drug
1563143|NCT02504476|Drug|Placebo|Placebo
1563144|NCT02504476|Drug|Midazolam|Interaction
1563145|NCT02504463|Drug|Samidorphan IV|Single IV administration
1563146|NCT02504463|Drug|[14c]-Samidorphan sublingual|Single sublingual administration containing radiolabel
1563147|NCT02504463|Drug|[14c]-Samidorphan oral|Single oral administration containing radiolabel
1563148|NCT02504450|Drug|Adasuve|Inhaled medication to treat acute agitation in the emergency department
1563149|NCT02504450|Drug|Alternative medications|Medication given to treat acute agitation in the emergency department
1563150|NCT02504437|Biological|BMMSCs|
1563151|NCT02504424|Device|AeroForm Tissue Expander|The AeroForm Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
1563152|NCT02504411|Device|Device Assisted Colonoscopy|This will be similar to the standard colonoscopy except the endocuff device will be used.
1563153|NCT02504411|Device|Standard Colonoscopy|No endocuff device will be used on the study participants undergoing standard colonoscopy.
1563154|NCT02504398|Other|Fast injection speed by immunizer|
1563155|NCT02504398|Other|Slow injection speed by immunizer|
1563156|NCT02504385|Device|Virtual Reality Timocco|Timocco virtual reality system is a motion based comuter games that was designed for child development therpay. The children will play Timocco for 15 minutes every session.
1563157|NCT02504385|Other|Conventional OT intervention|Traditional Occupational Therapy intervention will be givven to the control group.
1563158|NCT02504372|Biological|pembrolizumab|
1563159|NCT02504372|Other|Placebo|
1563160|NCT02504359|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
1563161|NCT02504359|Drug|Carmustine|Given BEAM chemotherapy
1563162|NCT02504359|Drug|Cytarabine|Given BEAM chemotherapy
1563163|NCT02504359|Drug|Etoposide|Given BEAM chemotherapy
1563164|NCT02504359|Drug|Ixazomib Citrate|Given PO
1563165|NCT02504359|Other|Laboratory Biomarker Analysis|Correlative studies
1563166|NCT02504359|Drug|Melphalan|Given BEAM chemotherapy
1563167|NCT02504359|Drug|Methotrexate|Given IV
1563168|NCT02504359|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
1563169|NCT02504359|Other|Quality-of-Life Assessment|Ancillary studies
1563170|NCT02504359|Drug|Tacrolimus|Given IV or PO
1563171|NCT02504346|Drug|AZD9291|
1563172|NCT02504333|Drug|nab-paclitaxel|Day 1-8-15: Intravenous, 125 mg/m2 over 30 minutes
1563173|NCT02504333|Drug|gemcitabine|Day 1-8-15: Intravenous, 1.000 mg/m2 over 30 minutes
1563174|NCT02504333|Drug|m-FOLFOX|Day 28 according to the dose levels stablished in Phase I
1563175|NCT02504333|Drug|nab-paclitaxel|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
1563176|NCT02504333|Drug|gemcitabine|Day 1-8-15: Intravenous 30 minutes according to the dose levels stablished in Phase I
1563177|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F1|Febuxostat extended-release (XR) capsules formulation 1
1563178|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F2|Febuxostat XR capsules formulation 2
1563179|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F3|Febuxostat XR capsules formulation 3
1563180|NCT02504320|Drug|Febuxostat XR 80 mg Capsule F4|Febuxostat XR capsules formulation 4
1563181|NCT02504307|Device|Sirolimus Eluting Stent Inspiron|Angioplasty with Sirolimus Eluting Stent Inspiron implantation
1563182|NCT02504307|Device|Bare Metal Stent|Angioplasty with Bare Metal Stent Cronus implantation
1563183|NCT02504294|Biological|Epoetin Hospira Arm|Epoetin Hospira Arm: Epoetin Hospira will be administered intravenously (IV) per the analogous version of the Fresenius Medical Care North America (FMCNA) cMAB 1 (inclusive of version 1.0, 1.1,...)erythropoietin stimulating agents (ESA) dosing algorithm for Epoetin Hospira for 24 weeks. Subjects will have Epoetin Hospira initiated using the same ESA dose level and frequency of administration for Epogen prior to randomization into the trial. Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
1563535|NCT02501759|Procedure|Multiparametric Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
1563184|NCT02504294|Other|Standard of Care Arm|Standard of care arm: No interventions will be performed in this arm for the clinical study; and subjects will receive ongoing standard of care, which includes Epogen administered IV per the FMCNA cMAB 5 (inclusive of versions 5.0, 5.1,....) ESA dosing algorithm and IV iron per the FMCNA protocol that is standard of care, at FMCNA clinics during the contemporaneous 24 week period.
1563185|NCT02504294|Drug|IV Iron|Subjects will also receive IV iron per the FMCNA protocol that is standard of care at FMCNA clinics.
1563186|NCT02504268|Drug|Abatacept|
1563187|NCT02504268|Drug|Methotrexate|
1563188|NCT02504268|Other|Abatacept Placebo|
1563189|NCT02504268|Other|Methotrexate Placebo|
1563190|NCT02504255|Biological|Biological samplings|Blood, urine and faecal sampling every 3 months
1563191|NCT02504255|Other|Questionnaires|patients fill several questionnaires every month to assess stress and adaptation parameters
1563192|NCT02504242|Device|Inject BMP|
1563193|NCT02504242|Procedure|Locally Harvested Bone|
1563194|NCT02504229|Biological|autologous dendritic cells co-cultured with cytokine-induced killer cells|
1563195|NCT02504229|Drug|Gimeracil and Oteracil Porassium Capsules|
1563196|NCT02504229|Drug|Oxaliplatin|
1563199|NCT02504203|Biological|BCG-Denmark 1331 (Statens Serum Institute)|See above
1563200|NCT02504177|Drug|novel oral anticoagulant for 30 days|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
1563201|NCT02504177|Drug|novel oral anticoagulant for 24 hour|novel oral anticoagulant includes 'dabigatran,Pradaxa®', 'rivaroxaban,Xarelto®', and 'apixaban, Eliquis®'.
1563202|NCT02504164|Drug|midazolam 0.02mg/kg|
1563203|NCT02504164|Drug|No premedication|No premedication before sedation for endoscopic submucosal dissection
1563204|NCT02504151|Drug|Cannabidiol|
1563205|NCT02504151|Drug|Placebo|
1563206|NCT02504138|Drug|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
1563207|NCT02504138|Drug|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
1563208|NCT02504125|Drug|Tranexamic Acid|1 g of tranexamic acid in 100 mL of normal saline intravenously approximately 15 minutes before incision
1563209|NCT02504125|Drug|Normal saline|100 mL of normal saline intravenously approximately 15 minutes before incision
1563210|NCT02504112|Other|there is no intervention|
1563214|NCT02504086|Behavioral|Online Support|3 months online support, including access to online personal health record and 2.5 hours of online video teleconsultations with certified health professionals
1563215|NCT02504073|Other|No intervention|No intervention
1563216|NCT02504060|Drug|Starch Placebo|
1563217|NCT02504060|Drug|N-acetyl-D-glucosamine|
1563218|NCT02504047|Procedure|T-Cell replete haplo-transplant|Infusion of haploidentical related donor peripheral blood stem cells following myeloablative conditioning (fludarabine 200 mg/m2, busulfan 12.8 mg/kg and total body irradiation (TBI) 400 centigray -or- fludarabine 200 mg/m2, busulfan 9.6 mg/kg). GVHD prophylaxis will be with cyclophosphamide 50 mg/kg/day x 2 on days 3 & 4, mycophenolate mofetil 1 gm p.o. bid days 5 - 35 and tacrolimus (5-15 ug/ml) days 5 - 100.
1563219|NCT02504034|Procedure|Transhepatic portosystemic shunt|Portal vein (PV) was punctured with a 22-gauge chiba needle. A 0.018-inch guidewire was advanced through the needle into PV lumen. The needle was exchanged and a 6-French sheath inserted over the wire. Then middle hepatic vein (MHV) was punctured with a 20-gauge reformed needle through the transhepatic sheath. Another 0.018-inch guidewire was advanced through the needle into right internal jugular vein and then snared out of body. A 0.035-inch, 260-cm-long stiff shaft wire was introduced through the transjugular sheath and manipulated into main portal vein (MPV) and then into SMV. The parenchymal tract was dilated with balloon catheter, then one or more bare metal stents and one or more covered stents were inserted to line the parenchymal tract.
1563220|NCT02504034|Device|6-French sheath|
1563221|NCT02504034|Device|22-gauge chiba needle|
1563222|NCT02504034|Device|260-cm-long stiff shaft wire|
1563223|NCT02504034|Device|Balloon catheter|
1563224|NCT02504034|Device|Bare metal stent|
1563225|NCT02504034|Device|Covered stent|
1563226|NCT02504021|Behavioral|Family Consultation|This intervention is based on psychoeducation, social support mobilization, and motivational interviewing techniques.
1563229|NCT02503995|Behavioral|Physical Exercise Participation|
1563230|NCT02503982|Drug|prophylactic Valganciclovir|The common practice dose at Schneider Children's Medical Center dosing guidelines of valganciclovir is 17 mg/kg once daily for prophylaxis, with stratified dose reductions for impaired renal function. Max dose was 900 mg.
1563231|NCT02503969|Other|Exposure to having a long-term condition.|"Long-term conditions are self-reported: twelve named conditions are recorded, along with an other condition - these shall all be considered with the exception of the named condition cancer."
1563232|NCT02503956|Device|Perforated Punctal plugs|Perforated punctal plugs
1563233|NCT02503956|Procedure|Crawford tube insertion|
1563234|NCT02503956|Device|Crawford lacrimal tube|
1563235|NCT02503943|Drug|"Liraglutide and Mitiglinide"|"Liraglutide(1.2mg/d) and Mitiglinide (50mg, 3/d)"
1563236|NCT02503943|Drug|"Metformin and Mitiglinide"|"Metformin(500mg, 3/d) and Mitiglinide(50mg, 3/d)"
1563237|NCT02503943|Drug|"Mitiglinide"|"Mitiglinide (50mg, 3/d)"
1563238|NCT02503930|Device|Active tDCS|In this group subjects will receive 20 min of treatment.
1563239|NCT02503930|Device|Sham tDCS|In this group subjects will receive 20 min of sham stimulation.
1563240|NCT02503904|Procedure|Concomitant Tumescent Antibiotic Delivery & IV Delivery|Concomitant subcutaneous infiltration of a dilute antibiotics (cefazolin and metronidazole) in a dilute solution of tumescent lidocaine and epinephrine at the site of a proposed surgical incision.
1563241|NCT02503904|Device|Subcutaneous Tumescent Infiltration|Subcutaneous tumescent infiltration using HK tumescent infiltration cannulas and HK tumescent infiltration pump
1563242|NCT02503904|Drug|cecefazolin and metronidazole (in a dilute solution of tumescent lidocaine, epinephrin and sodium bicarbonate in 0.9% physiologic saline)|
1563243|NCT02503891|Device|MP-1 Polymer on Ceramic Articulation system|MP-1 Polymer liner on Ceramic head
1563244|NCT02503878|Device|Masimo Sedline brain function monitors|"Masimo Sedline brain function monitors are sensors (stickers) placed on a the forehead to monitor levels of sedation based on a bilateral 4-channel electroencephalogram (EEG). The purpose of this study is to observe the effectiveness of the Sedline monitor to detect the unilateral hemispheric EEG changes seen in Wada testing"
1563245|NCT02503865|Drug|Xenical, Pionorm, Diroton, Diltiazem, Atorvastatin|Xenical (Orlistat) - 120 mg/day in integration of Pionorm (Pioglitazone hydrochlorid) - 30 mg/day, Diroton (Lizinopril) - 20 mg/day, Diltiazem - 90 mg/day, Atorvastatin (Liprimar) - 40 mg/day
1563246|NCT02503865|Dietary Supplement|"Analimentary detoxication"|Vegetable and salt diet
1563247|NCT02503852|Device|Puregraft System|The Puregraft System prepares purified adipose tissue for subcutaneous scalp injection.
1563248|NCT02503852|Device|Celution System|The Celution System prepares adipose derived regenerative cells (ADRCs) for subcutaneous scalp injection.
1563249|NCT02503852|Procedure|Kerastem Therapy|The Kerastem Therapy is the subcutaneous scalp injection of purified adipose prepared with the Puregraft System enriched with ADRCs prepared from the Celution System.
1563250|NCT02503852|Procedure|Liposuction|Tissue collection involving the micro-harvest of subcutaneous adipose tissue.
1563259|NCT02503813|Procedure|venous blood gas|Venous blood gas will be measured at the time of arterial blood gas measurement.
1563260|NCT02503787|Device|Spinal Cord Stimulation (SCS)|SCS programming options
1563264|NCT02503748|Other|Online tutorial|website informing about treatment options in localized prostate cancer
1563265|NCT02503735|Drug|Sofosbuvir/Ledipasvir FDC|12 weeks treatment with Harvoni
1563266|NCT02503722|Other|Laboratory Biomarker Analysis|Correlative studies
1563267|NCT02503722|Drug|Osimertinib|Given PO
1563268|NCT02503722|Other|Pharmacological Study|Correlative studies
1563269|NCT02503722|Drug|Sapanisertib|Given PO
1563270|NCT02503709|Drug|CDKI AT7519|Given IV
1563271|NCT02503709|Other|Laboratory Biomarker Analysis|Correlative studies
1563272|NCT02503709|Drug|Onalespib|Given IV
1563273|NCT02503709|Other|Pharmacological Study|Correlative studies
1563274|NCT02503696|Device|Stool Collection Kit|Stool Collection Kit.
1563275|NCT02503683|Drug|ALN-AAT|Single or multiple doses of ALN-AAT by subcutaneous (sc) injection
1563276|NCT02503683|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
1563277|NCT02503670|Behavioral|Psychoeducational modules to prevent/reduce depression|Psychoeducational learning modules and tools. Men will choose modules based on interest and need.
1563278|NCT02503670|Other|Control Group|Continue with standard care.
1563279|NCT02503657|Drug|tipelukast|A novel, orally bioavailable small molecule compound that demonstrates anti-inflammatory and anti-fibrotic activity
1563280|NCT02503657|Drug|Placebo|Excipients of MN-001/tipelukast
1563281|NCT02503644|Drug|IVA337|Capsules of 200mg IVA337
1563282|NCT02503644|Drug|Placebo|Identical capsules without active substance
1563283|NCT02503631|Device|Stool Sample Collection Kit|Stool sample collection kit
1563284|NCT02503605|Drug|Biosimilar recombinant FSH|Controlled ovarian stimulation with 150 IU/day biosimilar recombinant FSH
1563285|NCT02503605|Drug|Urinary FSH|Controlled ovarian stimulation with 150 IU/day urinary FSH
1563287|NCT02503579|Behavioral|physical training|physical activity program, 30 minutes
1563288|NCT02503566|Device|Optical coherence tomography|Optical coherence tomography performed during regular coronary angiography
1563289|NCT02503553|Behavioral|Option grid for cerebral aneurysm treatment|Patients will receive an option grid during the preoperative visit. They will be given the chance to read it and ask questions. The option grid will include head to head comparative answers for the two interventions available for cerebral aneurysms (surgical clipping and endovascular coiling). The interaction with the aneurysm surgeon will be voice recorded.
1563290|NCT02503553|Behavioral|Control|Patients will receive the standard information booklet for cerebral aneurysms during the preoperative visit. They will be given the chance to ask questions. The interaction with the aneurysm surgeon will be voice recorded.
1563291|NCT02503540|Drug|Aflibercept|Intravitreal aflibercept will be given q4 wks for 6 treatments and then q 8 weeks through month 12.
1563447|NCT02502448|Procedure|Acute normovolemic hemodilution (ANH)|applying acute normovolemic hemodilution (ANH) by using HES 130/0.4 of 5 ml/kg before the initiation of cardiopulmonary bypass
1563292|NCT02503527|Other|Diben 1.5 kcal HP|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
1563293|NCT02503527|Other|Fresubin HP Energy Fibre (1.5 kcal)|Continuous (24h) application according to a standardized enteral feeding protocol via nasogastric tube or percutaneous endoscopic gastrostomy (PEG); pump-assisted application (Charriére (CH) > 8), duration according to patient's tolerance and requirements for a maximum of 5 days. Dosage: 21 - 24 kcal/kg body weight/day (corresponding to 14 to 16 ml/kg body weight/day).
1563294|NCT02503501|Drug|Insulin glulisine|
1563295|NCT02503501|Drug|Placebo|Bacteriostatic 0.9% Sodium Chloride
1563296|NCT02503488|Behavioral|Narrative Exposure Therapy for Forensic Offender Rehab|See arm description.
1563297|NCT02503488|Behavioral|Treatment as Usual|See arm description
1563298|NCT02503475|Other|Real-Time fMRI|"Real-Time fMRI: AR, CR, Sham, and Free Strategy groups will be compared to determine the following:
(1) whether a cognitive strategy improves rtfMRI neurofeedback to modulate brain activity and pain; (2) which strategy is most effective at individual and group levels at modulating brain activity and pain; and (3) whether the investigators can predict individual ability to modulate brain activity or pain using a particular strategy and applying mixed effects modeling of treatment efficacy using baseline measurements."
1563299|NCT02503475|Behavioral|CBT or MBSR|CBT/MBSR: The study will investigate whether CBT versus MBSR differentially enhance behavioral and neural indices of the ability to implement cognitive regulation (CR) and attention regulation (AR) during evoked pain in the lower back in participants with chronic low back pain. An additional wait list control (WL) group will be used to determine the effects of time on pain symptom severity and well-being.
1563300|NCT02503475|Device|Acupuncture|Acupuncture: The investigators will compare the efficacy and mechanisms of verum and sham electroacupuncture.
1563301|NCT02503462|Drug|Darunavir|darunavir 800 mg once daily will be first given together with ritonavir 100 mg once daily for one month (period 1) and then darunavir 800 mg once daily will be given together with cobicistat 150 mg once daily for one month (period 2). Afterwards, all patients will be switched back to darunavir/ritonavir (800/100 mg once daily).
1563302|NCT02503462|Drug|ritonavir|ritonavir 100 mg once daily will be used to boost darunavir 800 mg once daily (period 1).
1563303|NCT02503462|Drug|cobicistat|cobicistat 150 mg once daily will be used to boost darunavir 800 mg once daily (period 2).
1563304|NCT02503423|Drug|ASTX660|described above
1563308|NCT02503397|Device|Auditory brainstem evoked response (ABR)|Bilateral monaural auditory brainstem response (ABR) test would be recorded in each subject with a Bio-logic Navigator Evoked Response System (Bio-logic Systems, USA) between 24 and 48 hours after birth by an audiologist skilled in administering ABR to newborn infants. ABRs shall be performed using 80 dB nHL broadband click stimuli with insert earphones and with the subject lying supine in a quiet room and normal skin temperature. The clicks would be presented at a repetition rate of 29.9/second, and three runs of 2000 repetitions to be recorded for each ear. The 2 most replicable runs for each ear shall be averaged and used for analysis. Absolute latencies of waves I, III, V and IPL (I-III, III-V, and I-V) shall be measured and considered outcomes
1563309|NCT02503371|Other|Blood coagulation anyalsis by Thromboelastogram|Two blood tests will be taken during routine tests from all parturient s undergoing IVF treatment before starting gonadotropins treatment (the first few days of menstruation) and at the height of hormone therapy prior to egg retrieval Coagulation parameters will be measured by the use of Thromboelastogram
1563310|NCT02503358|Other|Laboratory Biomarker Analysis|Correlative studies
1563311|NCT02503358|Drug|Paclitaxel|Given IV
1563312|NCT02503358|Other|Pharmacological Study|Correlative studies
1563313|NCT02503358|Drug|Selumetinib|Given PO
1563314|NCT02503345|Drug|ALLN-177 low dose|ALLN-177 1,500 units (1 capsule)/meal PO 3 times per day
1563315|NCT02503345|Drug|ALLN-177 mid dose|ALLN-177 3,000 units (2 capsules)/meal PO 3 times per day
1563316|NCT02503345|Drug|ALLN-177 high dose|ALLN-177 7,500 units (5 capsules)/meal PO 3 times per day
1563317|NCT02503345|Drug|Placebo|Placebo: 1, 2 or 5 capsules with meals PO 3 times per day
1563318|NCT02503332|Drug|APL-2|
1563319|NCT02503332|Other|Sham Procedure|
1563320|NCT02503319|Drug|Tranexamic Acid|"2 vials ( =1 gram) of Tranexamic Acid oral administered within 5 minutes from the delivery (third stage after labor)
2 vials (=1 gram ) of Tranexamic Acid administered slow intravenous infusion within 5 minutes from the delivery (third stage after labor)"
1563321|NCT02503319|Drug|Tranexamic Acid|2 vials ( =1 gram) of Tranexamic Acid slow intravenous infusion administered within 5 minutes from the delivery (third stage after labor)
1563322|NCT02503319|Drug|Oxytocin|2 vials (=10 IU/International Unit) of oxytocin administered intramuscularly within 5 minutes from the delivery (third stage after labor)
1563323|NCT02503306|Drug|AVANAFIL|Pharmaceutical form:tablets Route of administration: oral
1563324|NCT02503306|Drug|placebo|Pharmaceutical form:tablets Route of administration: oral
1563353|NCT02503124|Other|Treatment as usual - inpatient care|All patients are admitted due to severe depression and are under observation and most receive antidepressive medication and if necessary anxiolytic/antipsychotic medication.
1563354|NCT02503124|Other|Informative meeting|A short sleep hygiene consultation.
1563448|NCT02502448|Drug|hydroxyethyl starch (HES 130/0.6)|
1563536|NCT02501759|Procedure|Transrectal Biopsy|Undergo transrectal MRI-guided biopsy
1563325|NCT02503293|Device|Chrono Super PID then Generic Syringe-Gammanorm|"Each patient will receive the study treatment of Gammanorm using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:
• pump and then syringe
The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).
Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
1563326|NCT02503293|Device|Generic Syringe then Chrono Super PID-Gammanorm|"Each patient will receive the study treatment using each of the two studied delivery devices according to the sequence randomly assigned based on a cross-over design:
• syringe and then pump.
The use of automatic, programmable, compact pumps (such as CRONO SUPER PID) allows patients to remain mobile without interrupting their activities. Patients can infuse several sites simultaneously with infusion rates of up to 40 mL/h at 2 to 4 sites (abdomen, thighs, upper arms, lower back).
Rapid and manual administration of SCIg using a syringe could therefore represent an alternative method by decreasing the duration of administration (around 10 minutes per injection at 1 or 2 sites simultaneously). The injection is self-administered by the patient. The infusion rate usually is 1 to 2 mL/min. The use of low viscosity products could facilitate injection"
1563327|NCT02503280|Drug|Autologous hMSCs|Autologous hMSCs: 40 million cells/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 2 x 10^8 (200 million) hMSCs.
1563328|NCT02503280|Drug|Autologous Human C-Kit CSCs II|Autologous hMSCs PLUS autologous C-Kit hCSCs: Mixture of 39.8 million hMSCs and 0.2 million C-Kit hCSCs/ml delivered in 0.5 ml injection volumes times 10 injections for a total of 1.99 x 10^8 (199 million) hMSCs and 1 million C-Kit hCSCs.
1563329|NCT02503280|Drug|Placebo|Placebo (ten 0.5 ml injections of phosphate-buffered saline [PBS] and 1% human serum albumin [HSA]).
1563330|NCT02503280|Device|Biosense Webster MyoStar NOGA Injection Catheter System|Biosense Webster MyoStar NOGA Injection Catheter System will be used to administer the study drug
1563331|NCT02503267|Other|none intervention|
1563332|NCT02503254|Other|CHTP 1.0|CHTP 1.0 ad libitum for 5 days in confinement
1563333|NCT02503254|Other|Conventional Cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
1563334|NCT02503241|Procedure|Recruitment maneuver|Progressive increase in airway pressure to open lungs atelectatic regions.
1563335|NCT02503241|Procedure|PEEP titration|PEEP will be decreased at consecutive steps. Static compliance of the respiratory system will be measured at each step. The optimal PEEP value for the patient will be chosen as the lowest PEEP level at witch the compliance of the respiratory system will be the best.
1563336|NCT02503228|Other|Receiving MOPS-Preserved Cartilage|The Missouri Osteochondral Allograft Preservation System (MOPS) preserves donated cartilage tissue that is meant to be transplanted from the time it is obtained from the donor to the time it is transplanted into the recipient. The MOPS is a different media formulation from the standard media that is usually used to preserve the cartilage tissue.
1563337|NCT02503215|Device|Compression Stockings|To evaluate the effects of compression stockings on fluid shift and sleep apnea in hemodialysis patients with obstructive sleep apnea
1563338|NCT02503202|Biological|V920 Consistency Lot A|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot A, live, attenuated, sterile solution for intramuscular injection
1563339|NCT02503202|Biological|V920 Consistency Lot B|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot B, live, attenuated, sterile solution for intramuscular injection
1563340|NCT02503202|Biological|V920 Consistency Lot C|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine consistency Lot C, live, attenuated, sterile solution for intramuscular injection
1563341|NCT02503202|Biological|V920 High-dose Lot|V920 (rVSV-ZEBOV-GP) Ebola Zaire vaccine high-dose lot, live, attenuated, sterile solution for intramuscular injection
1563342|NCT02503202|Biological|Placebo to V920|Sodium chloride 0.9%, sterile solution for intramuscular injection
1563343|NCT02503189|Drug|KCT-0809 ophthalmic solution|
1563344|NCT02503189|Drug|Placebo|
1563345|NCT02503176|Drug|KCT-0809 ophthalmic solution|
1563346|NCT02503163|Drug|KCT-0809 ophthalmic solution|
1563347|NCT02503150|Biological|APDC + Chemotherapy|Patients in Arm APDC+Chemotherapy receive maximum 12 cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1,and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours).On day 8 of cycle1-3 and 7-9, patients also receive APDC vaccine infusion in 100ml saline. After 12 cycles, patients in Arm APDC+chemotherapy will receive 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks) plus APDC therapy (once every 3 months). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
1563348|NCT02503150|Drug|Chemotherapy|Patients in Arm Chemotherapy receive maximum 12cycles (14days/cycle) mFOLFOX6 chemotherapy. Each cycle chemotherapy consist of Oxaliplatin at 85mg/ m2 infused for 2 hours only on day 1, and Leucovorin at 400 mg/m2 was administered intravenously for 2 hours, followed by continuous intravenous administration of 5-Fluorouracil at 400 mg/m2 (2.4g/m2 for 46 hours). After 12 cycles, patients in Arm chemotherapy will receive only 5-Fluorouracil /Leucovorin (Leucovorin at 400 mg/m2/day administered intravenously for 2 hours, intravenous bolus of 5-Fluorouracil at 400 mg/m2 , followed by continuous intravenous administration of 5-Fluorouracil at 1200 mg/m2/d for 2 days, repeated every 2 weeks). Treatments will continue unless disease progression, intolerable toxicity or patients withdrawal).
1563349|NCT02503137|Drug|Topical SM04554 solution|
1563350|NCT02503137|Drug|Topical Vehicle solution|
1563351|NCT02503124|Behavioral|Single night's wake therapy|Eligible patients are assisted in maintaining total sleep deprivation during one night
1563352|NCT02503124|Device|Bright light|Bright light according to patients´ own circadian rhythm each morning for a week.
1563490|NCT02502097|Drug|Gefapixant first, then Placebo|
1563491|NCT02502097|Other|Placebo first, then Gefapixant|
1563355|NCT02503124|Drug|Treatment as usual - medicine|Since all patients are admitted due to a severe mental illness, they will receive medication according to indication. Most patients have already tried more than one antidepressant at the time of admission. In cases of severe anxiety, anxiolytics are prescribed but this is kept to a minimum.
1563356|NCT02503111|Device|The Hyfrecator ® 2000 Electrosurgical System|Lesion is ablated by the The Hyfrecator ® 2000 Electrosurgical System. During electrocautery (EC) with The Hyfrecator, a gentle brushing technique occurs and the tissue is removed with forceps.
1563357|NCT02503111|Other|Observation Alone|No treatment to AIN-2 or AIN-3, only active surveillance.
1563358|NCT02503098|Behavioral|Recovery Record adaptive smartphone application|
1563359|NCT02503098|Behavioral|Recovery Record standard smartphone application|
1563361|NCT02503072|Behavioral|Small lottery prizes based on adherence|Clients coming for clinic visits have their MEMS data extracted, and if they show 95% adherence or higher are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
1563362|NCT02503072|Behavioral|Small lottery prizes based on timely clinic visits|Clients coming for clinic visits have their patient booklet checked to confirm that they came on their scheduled day; if so, they are eligible to draw a number (1-6) out of a closed bag without looking; if they draw a '6' they win a small prize.
1563363|NCT02503046|Other|Estimation of Pentraxin3|5ml of blood to be collected from each subject, centrifuged, to separate the plasma for estimation of Pentraxin3 (Quantikine ELISA)
1563364|NCT02503046|Genetic|Estimation of P.Gingivalis levels|Pooled plaque sample will be collected and sent for DNA Extraction by PCR for assessment of levels of PGingivalis
1563365|NCT02503033|Drug|HMPL-523|Oral administration, once daily
1563366|NCT02503020|Dietary Supplement|Preterm infants formula A|Group A will receive a preterm infants formula supplemented with AA (0.6%) and DHA (0.3%) until they have three months corrected age. At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (2/1) until one year corrected age.
1563367|NCT02503020|Dietary Supplement|Preterm infants formula B|"Group B will receive other Preterm infants formula very similar, but with AA (0.3%) and DHA (0.3%) also until they have three months corrected age.
At 3 and 6 months of corrected age, we changed the type of milk according to the nutritional requirements, but maintained the same ratio of AA and DHA (1/1) until one year corrected age."
1563368|NCT02503007|Dietary Supplement|Placebo|
1563369|NCT02503007|Dietary Supplement|HMB-FA|
1563370|NCT02502994|Drug|GEN0101|
1563371|NCT02502981|Drug|Spironolactone|25mg orally once a day for 40 weeks
1563372|NCT02502981|Drug|Chlortalidone|25mg orally once a day for 40 weeks
1563373|NCT02502968|Drug|Cytarabine|
1563374|NCT02502968|Drug|BL-8040|
1563375|NCT02502968|Drug|Placebo (for BL-8040)|Powder for solution for injection manufactured to mimic BL-8040
1563376|NCT02502955|Procedure|Comparison autopsy methods|Comparison of post-mortem angiography/virtual autopsy and medical autopsy
1563377|NCT02502942|Behavioral|Upper Airway Muscle Exercise|Patients will use an individualized oral retainer device for upper airway muscle training exercises daily for 20 minutes each day (10 minutes in the morning and 10 minutes in the afternoon/evening) for 6 weeks.
1563378|NCT02502942|Behavioral|Sham Exercise|Patients will be given an individualized oral retainer device and instructed to do deep breathing exercise twice daily for 6 weeks.
1563382|NCT02502903|Drug|TNT009|
1563383|NCT02502903|Other|Placebo|
1563384|NCT02502877|Drug|Midazolam|The investigators will administer 0,05mg/kg of midazolam, being 2/3 administered before the neuraxial block and 1/3 after.
1563385|NCT02502877|Drug|Propofol|The investigators will administer 0,033mg/kg of midazolam before the neuraxial block, and immediately after installation of the block the investigators will start a propofol TCI pump (Schnider model) with an effect concentration set at 1mcg/mL. This pump will be turned off at the end of the surgery.
1563386|NCT02502877|Drug|Standard|The investigators will administer to every patient: cefazolin 2g iv bolus, ketorolac 30 mg iv bolus, pantoprazole 40 mg iv bolus, paracetamol 1g iv perfusion (initiated 30 minutes before the end of surgery).
1563387|NCT02502877|Device|SpotOn|Central temperature will be monitored with the SpotOnTM3MTM device from entering till leaving the operating room, through a sensor placed in the patient's forehead
1563388|NCT02502864|Drug|Standard of Care: Docetaxel|Pharmacokinetic(PK)-guided docetaxel. Cycle 1: 75 mg/m^2, intravenously (IV) on Day 1 for 60 minutes. Beginning with cycle 2, the docetaxel dose will be individually adjusted before each cycle.
1563389|NCT02502864|Drug|Standard of Care: Cyclophosphamide|Cycle 1: 600 mg/m^2, via IV on Day 1 for 30 minutes. The cyclophosphamide dose will not be changed unless dictated by toxicity.
1563390|NCT02502864|Other|Function Assessment of Cancer Therapy (FACT) Surveys|Participants will complete the FACT-Taxane and FACT-Breast quality of life assessment written surveys at baseline, during each chemotherapy cycle, and 3-5 weeks following the last cycle in which PK monitoring was performed.
1563391|NCT02502851|Device|Rotational Atherectomy|Calcified lesion preparation using rotational atherectomy before implantation of the Orsiro drug eluting stent
1563392|NCT02502851|Device|Cutting/Scoring Balloon|Calcified lesion preparation using cutting/scoring balloons before implantation of the Orsiro drug eluting stent
1563393|NCT02502825|Other|methacholine|methacholine (0.03,0.06,0.125,0.5,1.0,2.0,4.0,8.0,16.0 mg/ml),Canada
1563394|NCT02502825|Device|Wright Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
1563395|NCT02502825|Device|Devilbiss646 Nebulizer|nebulized for 2 minutes with an output of 0.13ml/min
1563396|NCT02502812|Drug|Clop F1|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
1563397|NCT02502812|Drug|Clop F2|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
1563398|NCT02502812|Drug|Innovator|A single oral dose of clopidogrel (bisulfate) 75 mg tablet will be administered with approximately 240 mL water in fasted state.
1563399|NCT02502799|Behavioral|Brief Early Intervention|Adolescents receive 5 individual sessions designed to strengthen the following skills: problem-solving, resisting peer pressure, and coping with emotions. Parents join portions of 3 sessions.
1563400|NCT02502799|Behavioral|Parent Training with Adolescent Cognitive Behavioral Therapy|Participants receive 12 family sessions with individual adolescent, parent, and joint adolescent and parent time. Includes additional parent training in behavioral modification, adolescent and parent contracting, and adolescent decision-making skills.
1563401|NCT02502799|Drug|Methylphenidate|Adolescents will receive methylphenidate.
1563404|NCT02502773|Drug|Hydroxethyl starch|
1563405|NCT02502760|Behavioral|Physical Exercise Program|Physical exercises personalized by a kinesiologist consisting of walking or stationary bike and elastic band exercises.
1563406|NCT02502760|Dietary Supplement|Whey Protein Isolate Powder|"Nutritional counselling is given to patients to ensure their daily proteins and energy requirements are met. Whey Protein Isolate Powder (Immunocal) is provided.
Immunocal1.5g/kg PO (by mouth) per day separated in 2 daily doses"
1563407|NCT02502760|Behavioral|Relaxation Techniques|Relaxation techniques consisting of breathing exercises and using a relaxation CD.
1563408|NCT02502747|Drug|rhu G-CSF|rhu G-CSF will be administered 5 µg/kg twice daily for 5 days, subcutaneously
1563409|NCT02502747|Drug|optimal standard of care|Optimal standard of care
1563410|NCT02502747|Procedure|Myocardial Contrast Echocardiography|Myocardial Contrast Echocardiography with sulphur hexafluoride.
1563411|NCT02502734|Drug|Fluticasone furoate|FF will be provided as a dry powder inhaler containing 50 μg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
1563412|NCT02502734|Drug|Placebo|Placebo will be provided as dry powder inhaler containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
1563413|NCT02502734|Drug|Salbutamol|Salbutamol will be provided as a inhaler.
1563414|NCT02502721|Drug|DWC20151|
1563415|NCT02502721|Drug|DWC20152|
1563416|NCT02502708|Drug|Indoximod|
1563417|NCT02502708|Drug|Temozolomide|
1563418|NCT02502708|Radiation|Conformal Radiation|
1563419|NCT02502695|Other|VATS-associated best practices|
1563420|NCT02502682|Drug|Sage 2% Chlorhexidine Gluconate Cloth Patient Preoperative Skin Preparation|Daily bathing.
1563421|NCT02502669|Drug|Finasteride 23.5 mg tablets|
1563422|NCT02502669|Drug|Finasteride 33.5 mg tablets|
1563423|NCT02502669|Drug|Placebo tablets|
1563424|NCT02502643|Drug|OK-432 pleurodesis|1.Pain medications (if no contraindications) Before half hour; Bain (IM ,0.15mg / kg). 2. Make the patient supine position 3. Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.4. 20 cc of 2% lidocaine hydrochloride (400 mg) was instilled into the pleural cavity through the chest tube 5. A solution of 30 cc of normal saline containing 5 KE of OK-432 (KE Z Klinische Einbeit; 1 KE contains 0.1 mg of dried cocci).6. Inject air 20 cc 7. The injection site will cover with op site and the rubber tube that connecting the chest tube and chest bottle was raised 40-60 cm above the patient to trap the sclerosing agent but allow air to pass 8. Patients will reposition (left and right side)every 30 minutes in 2 hours
1563425|NCT02502643|Drug|normal saline pleurodesis|Make the patient supine position , Near the body of patient's chest tube is the injection site disinfection with the alcoholic Betadine and alcohol repeated three times.injected a solution of 30 cc of normal saline , and then injected into 20 cc air to the rubber chest tube , so that normal saline can completely into the chest, the injection site will cover with op site, use a rubber band to the rubber chest tube for hanging from the patient's body 40-60 cm high.Patients will reposition (left and right side)every 30 minutes in 2 hours
1563426|NCT02502630|Device|microwave ablation|pulmonary metastases from colorectal cancer are destructed/ablated using microwave ablation
1563427|NCT02502617|Dietary Supplement|medical nutrition|The participants are expected to improve their body weight with 10-30% during a closely monitored inpatient-treatment comprising nutritional rehabilitation.
1563428|NCT02502604|Behavioral|Goal Management Training|Goal management training sessions will be 2 hours in length and focus on learning skills that will assist in planning, carrying out, and monitoring goal-directed behaviours.
1563429|NCT02502591|Drug|Pudendal Nerve Block|An injection of local anaesthetic (3 ml of 0.25% bupivacaine) will be administered around the trunk of the pudendal nerve.
1563430|NCT02502578|Drug|CNT-01 500 mg capsule|After being informed about the study and potential risks, all patients giving written informed consent undergo screening tests to determine eligibility for study enrollment. On Day 1, patients who meet the eligibility criteria will start taking CNT-01 500mg orally three times daily for 14 days. On Day 15, patients will take CNT-01 500 mg only once after blood drawing.
1563431|NCT02502565|Other|Uric acid level|
1563432|NCT02502552|Other|blood specimen|blood specimen
1563433|NCT02502539|Procedure|Controlled physical activity|
1563434|NCT02502526|Device|Centurion® Vision System, 45° Balanced Tip|
1563435|NCT02502526|Device|Centurion® Vision System, 45° MFK Tip|
1563436|NCT02502526|Device|lnfiniti® Vision System, 45° MFK Tip|
1563437|NCT02502526|Device|INTREPID® Ultra infusion sleeve|
1563438|NCT02502526|Device|Ultra infusion sleeve|
1563439|NCT02502513|Behavioral|Brief computerized intervention|"Computer game Tetris"
1563440|NCT02502500|Drug|Celecoxib|
1563441|NCT02502500|Drug|AKB-6548|
1563442|NCT02502487|Procedure|Dorsal Penile Nerve Block|Dorsal penile nerve block with 0.33% ropivacaine using 22-G needle in the sub-pubic space at the base of the penis
1563443|NCT02502487|Drug|Ropivacaine|0.33% Ropivacaine administered around dorsal penile nerve using 22-G needle in the sub-pubic space at the base of the penis
1563444|NCT02502487|Drug|Tetracaine|1% Tetracaine gel instilled into urethra
1563445|NCT02502474|Other|Staphylococcus aureus carriage|nasal, throat, rectal and groin sampling with swabs. Colonic sampling by colonic biopsy
1563446|NCT02502461|Procedure|cuff palpation|Inflated endotracheal tube cuff palpated through anterior extra-thoracic trachea while tube is gently moved to place the cuff midway between cricoid and sternal notch.
1563534|NCT02501759|Radiation|Gadodiamide|Given IV
1563449|NCT02502422|Device|Classic laryngeal mask airway|"measurement of head and neck
Ht,Wt,BMI, neck circumference above a thyroid cartilage, mandible circumference( from the lower part of earlobe-mandible angle-mentum-mandible angle to the lower part of earlobe), neck length (mastoid tip~sternal notch), modified mallampati classification under sitting position, thyromental distance.
laryngeal mask airway insertion and measuring cuff pressure by pressure transducer
# 4.0 for female, #5.0 for male
initial cuff volume(air) : maximum volume recommended by the manufacturer
check pressure : if it exceed 60cmH20, we will remove air until 60cmH20
remove air until gas leak occured around the cuff under airway pressure 15cmH20, fresh gas flow 6liters/min. Check the volume and pressure just before leakage occured."
1563450|NCT02502409|Other|Standard care with blood and urine sample collection|
1563451|NCT02502396|Other|Retrospective Chart Review|Retrospective chart review study to evaluate Rivaroxaban's utilization in cancer patients for venous-thromboembolism (VTE) or non-valvular atrial fibrillation (NVAF). Study conducted from from January 1, 2012 to November 7, 2016 at MD Anderson Cancer Center in Houston, Texas.
1563454|NCT02502370|Drug|observation alone|
1563455|NCT02502370|Drug|LV5FU2|
1563456|NCT02502370|Drug|FOLFOX|
1563457|NCT02502357|Other|Healing Statements|"Before the patient in the experimental group is placed under general anesthesia, the study staff member will repeat 5 times:
Following this operation, [the participant] will feel very comfortable and [the participant] will heal very well.
Toward the end of the surgery, the study staff member will say 5 times:
The operation has gone very well. Following the operation, [the participant] will be hungry. [The participant] will be thirsty and urinate easily."
1563458|NCT02502344|Behavioral|healthy lifestyle|food control and intensive exercise to lose weight
1563459|NCT02502344|Drug|Metformin|use metformin to reduce insulin resistance
1563460|NCT02502331|Biological|Test Oral Cholera Vaccine|Thimerosal free, manufactured at 600 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
1563461|NCT02502331|Biological|Euvichol®|Licensed, manufactured at 100 L scale killed bivalent (O1 and O139) whole cell-oral cholera vaccine (WC-OCV) manufactured by Eubiologics Co., Ltd.
1563462|NCT02502318|Procedure|Video-thoracoscopy|
1563463|NCT02502318|Procedure|thoracotomy|
1563464|NCT02502305|Behavioral|liveonline course|physical activity and healthy diet are targeted and should be enhanced, health literacy (HL) in older people should be improved
1563465|NCT02502292|Behavioral|Fotonovela|"Comparing fotonovela brochure to traditional brochure, as a template communicative behaviors embedded in a picture story where the older people could use before and during primary care consultations with their GP. Relevant communicative behaviors will include 'asking questions', 'expressing lack of or misunderstanding', 'expressing uncertainty', 'expressing preferences and needs' and other relevant communicative behaviors which are based on communication theory / literature and on the output of the focus group discussions.
The researchers will randomly assigned the participants into four groups as described earlier. Mainly to identify the outcomes of the comparison between fotonovela and traditional brochure in both traditional hard-copy and in tablet."
1563466|NCT02502279|Device|Engström Datex-Ohmeda ICU Ventilator|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation.
1563467|NCT02502279|Device|Postoperative CPAP mask|patients will be mechanically ventilated and a vital capacity manoeuvre for lung inflation will be done by increasing the PIP to 35 cmH2o for 15 seconds followed by PEEP until extubation and a CPAP mask will be applied immediately postoperative.
1563476|NCT02502227|Behavioral|Mindfulness|Mindfulness training practices aim to foster attention and acceptance toward one's present moment experience. Mindfulness consists of two components-- (1) deploying attention to monitor one's moment-to-moment experience, and (2) fostering an attitude of acceptance toward one's moment-to-moment experience
1563477|NCT02502201|Other|six-minute walk study indoors|Performance of a six-minute walk test according to American Thoracic Society standard.
1563478|NCT02502201|Other|six-minute walk study outdoors|Performance of a six-minute walk test.
1563479|NCT02502188|Drug|CC-90005|
1563480|NCT02502188|Drug|Placebo|
1563481|NCT02502175|Drug|opium|
1563482|NCT02502175|Drug|methadone|
1563483|NCT02502162|Drug|LDN|
1563484|NCT02502162|Drug|Placebo|Sugar pill
1563485|NCT02502149|Biological|rFVIIIFc|As per arm description
1563486|NCT02502136|Procedure|carbon dioxide insufflation during endoscopy|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
1563487|NCT02502136|Procedure|Room air insufflation during endoscopy (Placebo)|Efficacy and safety study of carbon dioxide insufflation instead of air during sedated endoscopy
1563488|NCT02502123|Other|No Intervention|No intervention was administered in this study.
1563489|NCT02502110|Drug|rosuvastatin|All recruited patients with paroxysmal atrial fibrillation will be randomly allocated to receive oral rosuvastatin 20mg/day or blank control from 7 days before ablation and last for 3 months.
1563492|NCT02502084|Device|3NT flexible endoscope|The nasal anatomy will be accessed and viewed with the device during functional endoscopic sinus surgery (FESS) procedure.
1563493|NCT02502071|Drug|sodium bicarbonate|All participants will receive 2 doses of 1950mg sodium bicarbonate
1563494|NCT02502058|Device|Densah Bur™ , osseodensification|Densah™ bur (Versah Osseodensification Company™) is used to prepare dental implant sites, in human subjects, by compacting (osseodensification ) bone vs. removing bone to create the opening in the jaw bone into which the dental implant is then placed. This osseodensification process results in increased bone-ridge width, increased compact bone in the outer wall of the prepared sites, and; it is believed, increases implant stability.
1563495|NCT02502045|Device|Morning Simulated Sunlight|Timed morning simulated sunlight (Philips Wake Up Light, Model HF3520) peaking at 300 lux delivered over a 40 minute ramp between 5-9 a.m. for 14 consecutive days
1563496|NCT02502045|Device|Non-therapeutic Red Light|Non-therapeutic red light control at 5 lux will be used as the control condition
1563497|NCT02502032|Drug|Cisatracurium|Different groups received different pretreatments of cisatracurium.
1563499|NCT02502006|Drug|Celecoxib|
1563500|NCT02502006|Drug|Naproxen|
1563501|NCT02502006|Drug|Placebo|
1563502|NCT02501980|Biological|Biomarker testing and Ultrasonography|
1563503|NCT02501967|Other|COMET|The intervention consists of completion of the tool by means of a telephone interview prior to the primary care visit and provision of the tool's output to the patient and PCP.
1563513|NCT02501915|Device|Kinesio Taping|Group A received the application of KT from muscle Origin to Insertion and group B Insertion to Origin, with both groups taped the nondominant limb and the dominant limb was used as control group. Diferent tensions will be applied with the tape to see its possible different affect in the outcomes.
1563518|NCT02501876|Other|There is a retrospectiv observational study. No intervention|There is a retrospectiv observational study. No intervention will be performed
1563519|NCT02501863|Drug|Femoral nerve block with ropivacaine+fentanyl|Ropivacaine+fentanyl are used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
1563520|NCT02501863|Drug|Femoral nerve block with ropivacaine|Ropivacaine is used for continuous femoral nerve block, spinal anesthesia, IV-PCA with hydromorphone
1563521|NCT02501850|Drug|Liraglutide|Treatment with liraglutide, exenatide or lixisenatide
1563522|NCT02501850|Drug|metformin|Treatment with metformin and/or sulphonilurea
1563523|NCT02501837|Drug|Syntocinon-Spray|Intranasal administration of 24 IU Oxytocin
1563524|NCT02501824|Other|anthroposophic therapeutic speech|anthroposophic therapeutic speech
1563525|NCT02501811|Biological|Mesenchymal Stem Cells (MSC)|15 transendocardial injections of 0.4ml MSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
1563526|NCT02501811|Biological|Cardiac Stem Cells (CSC)|15 transendocardial injections of 0.4ml CSCs administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
1563527|NCT02501811|Biological|Placebo (Plasmalyte A)|15 transendocardial injections of 0.4ml placebo administered to the left ventricle via NOGA Myostar injection catheter (single procedure)
1563528|NCT02501798|Drug|Methylphenidate|Drug: Methylphenidate
1563529|NCT02501798|Drug|Placebo|Drug: Placebo
1563530|NCT02501785|Behavioral|Caregiver Reaction Assessment (CRA)|
1563531|NCT02501785|Behavioral|The Caregiver Quality of Life - Cancer (CQOLC)|
1563532|NCT02501772|Device|acupressure by ankle band|
1563533|NCT02501759|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo diagnostic multiparametric endorectal MRI with gadodiamide contrast
1990317|NCT02095132|Drug|Irinotecan Hydrochloride|Given PO
1990318|NCT02095132|Other|Laboratory Biomarker Analysis|Correlative studies
1990319|NCT02095132|Other|Pharmacological Study|Correlative studies
1990320|NCT02095132|Drug|WEE1 Inhibitor AZD1775|Given PO
1563537|NCT02501759|Procedure|Ultrasound-Guided Prostate Biopsy|Undergo TRUS-guided biopsy
1563538|NCT02501746|Other|Usual Clinical Care|Non-hypertensive diabetic individuals will not be pharmacologically treated for BP reduction; those with BP 120-139/80-89 will be advised on lifestyle changes to reduce BP as recommended by the 2013 Standards of Medical Care in Diabetes. Care will be provided to each individual at the rural health facility by a rural clinician mentored by the CDM Program, including regular monthly consultation, vital signs, physical examination, and prescriptions. CHWs will assist with linkage and retention of patients to the care program, and provide health education. The 12-month follow-up BP will be measured in the rural health facility, in order to mimic real-world practice. If the patient does not present to the rural health facility for the 12-month visit, the local CHW will trace the patient at home and will check the 12-month BP at that time, again consistent with real-world conditions.
1563539|NCT02501746|Other|Group Medical Visits|"The CHW will facilitate a group discussion about a self-care or health education topic chosen by the group while the rural clinician reviews the BP, sugar, and adherence data to determine a clinical recommendation as per the CDM clinical algorithm. which is communicated to each individual patient privately by the rural clinician in a five-minute breakout time. The rural clinician will not change the regimen for non adherence but instead will use the breakout time to assess barriers to adherence and try to help the patient identify solutions to those barriers.The breakout time can also be used to perform a physical examination or other assessments as clinically required. After all patients have had individual consultations with the rural clinician, the entire group re-convenes for a closing session, which consists of a question-and-answer period and determination of the next session's self-care or health education topic."
1563540|NCT02501746|Other|Microfinance Groups|The rural clinician and the CHW will organize a meeting with AMPATH's Safety Net Program representatives, who will introduce the concept of microfinance groups, the potential benefits, and encourage the formation of new groups to meet monthly. The microfinance groups need to incorporate an element of self-selection and self-formation, so that individuals have the freedom to choose with whom they will create a group. The groups are therefore formed voluntarily, and usually along geographical boundaries, which facilitates participation, retention, and meeting logistics.
1563542|NCT02501720|Procedure|post burn flexion contractures release under tourniquet control|post burn flexion contractures will be released under tourniquet control
1563543|NCT02501720|Procedure|post burn flexion contractures release using tumescent solution|post burn flexion contractures will be released using tumescent solution
1563544|NCT02501720|Procedure|Contracture release and application of FTSG|Post burn flexion contractures will be released and full thickness skin graft(FTSG) will be applied.
1563545|NCT02501694|Other|Auscultation|Electronic stethoscope
1563546|NCT02501681|Other|priming solution during cardiovascular surgery|
1563547|NCT02501655|Device|phase 1 - jet nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 4 ml using jet nebulizer (NS - mark) and 8l/min of the oxygen
1563548|NCT02501655|Device|Phase 2- mesh nebulizer|Aerosol generators diethilene penta-acetic triamine technetium (99mTc-DTPA) with radioactivity of 1 millicuries (Noble et al., 2007) mixed with 0.9% saline solution with a total volume of 2 ml using vibrating mesh inhaler with valved chamber adapter (Aerogen Solo with Ultra Adapter, Aerogen Ltd).
1563549|NCT02501642|Behavioral|Concussion Coach|smart phone app with educational material on postconcussion symptoms and behavioral self-monitoring/strategies
1563550|NCT02501642|Other|Treatment as usual|Treatment as usual
1563553|NCT02501616|Drug|Metformin|
1563554|NCT02501616|Drug|Dapagliflozin|
1563555|NCT02501603|Drug|afatinib|Afatinib 40mg daily oral administration
1563556|NCT02501603|Drug|paclitaxel|Paclitaxel 80mg/m2 IV weekly (day 1,8,15)
1563557|NCT02501577|Device|SAD 1|Placement and fiberoptic control
1563558|NCT02501577|Device|SAD 2|Placement and fiberoptic control
1563559|NCT02501564|Drug|Naproxen Sodium Codeine|One tablet twice a day
1563560|NCT02501564|Drug|Placebo|One tablet twice a day
1563561|NCT02501551|Drug|regorafenib|160mg regorafenib once daily with a low fat breakfast for the first 21 days of each 28-day cycle
1563562|NCT02501538|Device|TransCu O2 device|A portable device that delivers continuous diffusion of oxygen.
1563563|NCT02501525|Device|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
1563564|NCT02501525|Device|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
1563565|NCT02501499|Other|Breastfeeding Buddies|a 2 hour breastfeeding workshop and if mother chooses, she is matched with a buddy who will contact her and offer breastfeeding support
1563566|NCT02501486|Other|ACTH stimulation test|An ACTH stimulation test will be done
1563567|NCT02501473|Drug|G100|GLA is a fully synthetic toll-like receptor-4 (TLR4) agonist
1563568|NCT02501473|Drug|Pembrolizumab|PD-1 Inhibitor
1563569|NCT02501460|Other|Educational handouts|Both groups of participants will receive educational handouts that explain the Physical Activity Guidelines for Americans at enrollment.
1563600|NCT02501226|Other|Treatment as usual|Treatment as usual consisting of clinical management including assessment of the psychiatric symptoms and subsequent prescription of antidepressants.
1563648|NCT02500836|Drug|Cocaine HCl 10% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
1563649|NCT02500836|Drug|Placebo Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
1563570|NCT02501460|Other|Resistance training|"Individuals in both groups will participate in an individually tailored progressive resistance training program 3 times/week for 24 weeks. During weeks 1-4 participants will be supervised twice a week tapering to once a week in weeks 5-12, every other week in weeks 13-20 and then once a month in weeks 21-24 by an American College of Sports Medicine (ACSM) Certified Exercise Specialist (trainer).
Adherence: To assure fidelity and safety of the resistance training component of the intervention, participants will initially be supervised more frequently They will complete an exercise log for each of their sessions. As the supervision level for exercise is tapered, participants may receive reminders to exercise and take their supplement/placebo via text, phone, or e-mail as needed."
1563571|NCT02501460|Dietary Supplement|Supplementation|A medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
1563572|NCT02501460|Other|Placebo|A placebo that appears to be identical to the medical quality protein supplement powder will be mixed with water or a sugar free drink mix to be taken daily within 60 minutes of training on exercise days or mid-morning on non-exercise days.
1563575|NCT02501421|Biological|tuberculosis vaccine|Live recombinant influenza vectored tuberculosis vaccine
1563576|NCT02501421|Biological|Placebo|Buffer
1563579|NCT02501369|Behavioral|Self-directed Teen Triple P|Manualised parenting programme that parents will complete at home. This involves reading weekly modules of the manual and completing small exercises to practice the skills taught. These include strategies to help build positive relationships between parent and child, helping parents to effectively manage challenging childhood behaviours, and providing parents with the skills to support their child's independence and independent management of their cystic fibrosis.
1563580|NCT02501356|Dietary Supplement|ISOThrive Supplement|Consumption of ISOThrive supplements for 3 months
1563581|NCT02501356|Dietary Supplement|Placebo Supplement|Consumption of Placebo supplement (Magnesium stearate or methylcellulose) for 3 months
1563582|NCT02501343|Drug|Sodium Bicarbonate Oral Capsule|Sodium bicarbonate 1680 mg will be administered prior to the meal
1563583|NCT02501343|Drug|Placebo|Sodibic-matching placebo (Stenlake Compounding Chemist, NSW, Australia) will be administered prior to the meal on a different day 1 to 2 weeks apart
1563585|NCT02501317|Behavioral|Active Perineal Rehabilitation protocol|Active Perineal Rehabilitation Protocol available in http://www.perineo.info/wordpress/book-active-perineal-rehabilitation/
1563586|NCT02501317|Behavioral|Kari Bo protocol|Group exercises to pelvic floor rehabilitation
1563587|NCT02501304|Device|ReVENT Sleep Apnea System|The ReVENT Sleep Apnea System consists of minimally invasive biocompatible devices that are placed into the tongue base and palate of patients with obstructive sleep apnea
1563588|NCT02501291|Drug|Thalidomide|
1563589|NCT02501278|Biological|INO-3112 vaccine|"INO-3112 i.e. the combination of VGX-3100 and INO-9012, specifically:
VGX-3100 (HPV16 and HPV18 E6-E7 DNA vaccine) will be administered at 3 mg per plasmid (6 mg total DNA)
INO-9012 (IL-12 DNA plasmid) will be administered at 1 mg per dose will be administered using the CELLECTRA® electoporation device"
1563590|NCT02501278|Radiation|Radiotherapy (Extrernal beam radiotherapy + brachytherapy)|"The whole pelvis will be irradiated with 45 - 50.4 Gy in 25-28 fractions in fractions of 1.8 Gy over 5 weeks daily.
Those patients with pelvis positive and/or para-aortic positive lymph nodes should be treated with an elective dose to the para-aortic area of 45 Gy in fractions of 1.6-1.8 Gy in 25-28 fractions.
Pelvic and para-aortic nodes known to contain gross/macroscopically visible disease and heavily involved parametria or tumor areas that may lie beyond the high-dose range of brachytherapy should be treated with additional small volume boost of EBRT to a total dose of 60-65 Gy using a combination of either sequential and/or concomitant boost. Fractions of 1.8-2 Gy can be used in the sequential boost."
1563591|NCT02501278|Drug|Cisplatin chemotherapy|Cisplatin chemotherapy will be administered i.v. at a dose of 40 mg/m2 (total 5 cycles during week 1-5) weekly in concomitance with RT with the total dose not to exceed 70 mg per week.
1563592|NCT02501265|Behavioral|High-Intensity Behavioral Treatment|High-Intensity Behavioral Treatment (HIT) is a video-based intensive group-therapy intervention that integrates motivational interviewing, cognitive behavioral skills training, mindfulness training, and group therapy techniques. HIT is comprised of seven weekly meetings (2 ½ hours each) with a 6½-hour meeting on the quit day (24 total hours), and is taught by DSCP Instructors (typically therapists). Intervention participants are provided with web-based access to the Instructional Video, Course Manual and a Guided Audio Recording to practice relapse prevention skills.
1563593|NCT02501265|Behavioral|Low-Intensity Behavioral Treatment|Low-Intensity Behavioral Treatment (LIT) consists of a 20-minute video accessed via Internet plus written smoking cessation materials. The video and written materials include guided instruction in skills such as identifying motivations to quit, identifying and avoiding triggers, garnering social support, quit day planning, and development of urge management strategies.
1563594|NCT02501265|Drug|Varenicline|Day 1-3: 0.5 mg once per day (AM); Day 4-7: 0.5 mg twice per day; Day 8 to end of 14 weeks: 1 mg twice per day
1563595|NCT02501265|Drug|Bupropion|Day 1-3: 150 mg once per day (AM); Day 4 to end of 13 weeks: 150 mg twice per day
1563596|NCT02501265|Drug|Nicotine patches|21 mg per day for 12 weeks
1563597|NCT02501252|Procedure|trained midwives and nurses working in the community to provide skilled SBA services|After the completion of all the necessary preparations, trained CORNs will be deployed for ten months in their respective study sites (arms) to provide the required RH services at home, community and health posts.
1563598|NCT02501239|Behavioral|Accept Yourself!|
1563599|NCT02501239|Behavioral|Weight Watchers|
1563650|NCT02500810|Drug|monosialoganglioside|40mg in the vein on day 1 - day 8 of each 21 days cycle. Number of Cycles: 2 cycles.
1563601|NCT02501226|Behavioral|ENVIE psychoeducational program|The intervention will consist of 9 weekly, 90 min sessions led by two animators. The program ENVIE will provide:1.Presentation of the program 2.Education on depressive symptoms. 3.Information about the causes leading to depression. 4.The depression's consequences. 5.Teaching about the last neurobiological and neuroanatomical knowledges about depression, through didactic presentations. 6.How to recognize his own mood state, the prodromal symptoms of relapse. 7.Didactic explanation of the neurobiological action of antidepressant, and other evidence-based medical treatments. 8 and 9. Recommendations about lifestyle and skills of behavioral activation.To enhance the active role of the patient, each session will be accompanied with homework for the patient.
1563602|NCT02501213|Drug|Spironolactone (+/- Furosemide)|Administration of spironolactone alone 100 mg/day each morning, increased in increments of 100 mg / week to a maximum of 400 mg / day in the absence of efficiency. In case of ineffectiveness or hyperkalemia: addition of Furosemide 40 mg / day increased in increments of 40 mg / week to a maximum of 160 mg / day in the absence of efficiency.
1563603|NCT02501200|Drug|CKD-391|Investigational product is prescribed to all of randomized subjects for two times.
1563604|NCT02501200|Drug|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
1563605|NCT02501187|Procedure|Levator advancement|A transcutaneous procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
1563606|NCT02501187|Procedure|Müller's muscle-conjunctival resection procedure|A transconjunctival procedure in which part of the muller muscle and conjunctiva are resected.
1563607|NCT02501187|Procedure|White line advancement|A transconjunctival procedure in which the Levator palpebrae aponeurosis is advanced and attached to the tarsus.
1563610|NCT02501148|Device|carotid artery stenting|Post-dilation of deployed self-expanding carotid stent with the Paladin Post-Dilation Balloon System with Integrated Embolic Protection
1563611|NCT02501135|Procedure|Femoral nerve block with ropivacaine or bupivacaine|
1563612|NCT02501122|Other|Pediatric Health Information System (PHIS), Partners for Kids (PFK) and Nationwide Children's Hospital Perioperative Database|Utilizing these databases to assess standards for quality of care measures in adenotonsillectomy patients.
1563613|NCT02501109|Drug|Aripiprazole|Healthy volunteers will receive Aripiprazole Oral Soluble Fim(OSF) 10mg orally a single of dose within 28 days
1563614|NCT02501096|Drug|Lenvatinib|Lenvatinib will be administered with water orally once a day (with or without food) continuously in 21-day treatment cycle.
1563615|NCT02501096|Drug|Pembrolizumab|Pembrolizumab will be administered as a dose of 200 mg Q3W, IV in 21-day treatment cycle.
1563616|NCT02501083|Other|no intervention|The study will not include any intervention.
1563617|NCT02501057|Behavioral|Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings.
1563618|NCT02501057|Behavioral|Enhanced Motivational Interviewing|Brief motivational interview plus the use of a smart phone application to monitor alcohol use and health behaviors.
1563619|NCT02501057|Behavioral|Enhanced Clinician's Guide|An evidence-based, NIAAA-advocated approach to brief intervention for heavy drinking in primary care settings plus the use of a smart phone application to monitor alcohol use and health behaviors.
1563620|NCT02501031|Dietary Supplement|Ground flaxseed|2 tablespoons of ground flaxseed taken daily for approximately 50 days.
1563621|NCT02501018|Biological|CLBS12|Intramuscular transfusion of CLBS12.
1563622|NCT02501018|Drug|SOC|Standard of care (SOC) is defined as pharmacotherapy with approved drugs (e.g., antiplatelets, anticoagulants, and vasodilators including prostanoids).
1563623|NCT02501005|Procedure|VT ablation|Catheter ablation of ventricular tachycardia
1563624|NCT02500992|Procedure|Transrectal sigmoidectomy|
1990321|NCT02093325|Drug|Eltrombopag|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
1563629|NCT02500966|Device|DUDA device|Insertion DUDA device
1563630|NCT02500966|Procedure|LEEP|Loop Electrosurgical Excision Procedure
1563631|NCT02500953|Drug|ASP3325|
1563632|NCT02500953|Drug|Placebo|
1563633|NCT02500940|Drug|Cisplatin|Neoadjuvant chemotherapy regimen with cisplatin
1563634|NCT02500940|Drug|Fluorouracil|Neoadjuvant chemotherapy regimen with Fluorouracil
1563635|NCT02500940|Radiation|Radiation therapy|Intensity-Modulated Radiation Therapy
1563636|NCT02500940|Drug|Leucovorin|Neoadjuvant chemotherapy regimen with Leucovorin
1563637|NCT02500927|Drug|ASP8273 Capsules|oral
1563638|NCT02500927|Drug|ASP8273 Capsules A|oral
1563639|NCT02500914|Drug|SC-002|SC-002 will be administered by IV infusion over approximately 30 minutes every 3 weeks
1563640|NCT02500901|Drug|Enzalutamide|Following completion of 28-day lead-in cycle, enzalutamide 160 mg PO daily will continue to be administered in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
1563641|NCT02500901|Drug|Niraparib|Niraparib will be administered daily in three dose-escalation cohorts of 6 subjects per dose levels of 100mg PO, 200mg PO or 300mg PO in 28-day cycles until documented progression, unmanageable toxicity, or decision to discontinue for any reason.
1563642|NCT02500888|Radiation|Radiosurgery|Only one radiation session of about 180 Gy in bilateral internal capsule.
1563643|NCT02500875|Device|PTNiA|
1563644|NCT02500875|Device|PTNiB|
1563645|NCT02500875|Device|PTN|
1563646|NCT02500849|Genetic|SB-728mR-HSPC Infusion 3 days following busulfan conditioning|
1563647|NCT02500836|Drug|Cocaine HCl 4% Topical Solution|Topical solution, up to 4 mL, is applied for 20 minutes via cotton or rayon pledget(s) to the accessible mucous membranes of the nasal cavities.
1990322|NCT02093325|Drug|Placebo|This will be a Phase III, randomized, double-blind, placebo-controlled clinical trial. Qualified subjects will be randomly assigned to receive either the test treatment or the placebo at 2:1 ratio. Once subjects are randomized, they will be treated with Arm A: Eltrombopag 50 mg/day (n=55) or Arm B: placebo (n=28) once a day for 7 days.
1563655|NCT02500784|Drug|Formoterol A|20mg/2mL, BID inhaler for 12 months: until progression or unacceptable toxicity develops.
1563656|NCT02500784|Drug|Formoterol B|2mL, BID inhaler for 12 months
1563657|NCT02500771|Behavioral|ABA therapy enhanced with V-Motive software|Tutors will use the V-Motive software to enhance their delivery of Applied Behavioral Analysis therapy.
1563658|NCT02500758|Procedure|Preparatory handwash|Preparatory handwash follows the UNE-EN 12791 standard using a diluted soft soap, 200g/1000g, made in community pharmacy service and sterilize in autoclave. Washing hands were prepared without use of a brush for 1 minute with 10 ml of soft soap. After being rinsed with running tap water, they are thoroughly dried with paper towels.
1563659|NCT02500758|Procedure|Preoperative surgical scrubbing using 3% PCMX|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
1563660|NCT02500758|Procedure|Preoperative surgical scrubbing using 4% CHG|Both hands were scrubbed using a sterile disposable surgical scrub brush with plastic bristles on one side and a foam sponge on the other side. The bristled side was used to scrub the entire hands, including all nails, palm and back of the hand, and interdigital spaces, and the foam side was used to rub between the fingers. Each side of each finger, between fingers and back al palm of the hand were rubbed for two and a half minute. Then, the forearms were rubbed from the wrist to the elbow, maintaining the hand highest than the arm, using a minute to wash each side. Both hands were rinsed by current water in an one-way (from the fingertips to the elbow), and wiped with a sterile disposable towel, including nails and interdigital spaces.
1563663|NCT02500719|Other|Fitted Q Learning Algorithm|A reinforcement learning algorithm, fitted Q learning, will be applied to fMRI and skin conductance response (SCR) data to identify distributed patterns of co-activated brain regions that specifically encode high emotional arousal (i.e,. high SCR) to the stress/trauma memory. The resulting idiosyncratic brain map would inform the neurofeedback phase in the next stage of fMRI data collection. This approach will first be piloted in the healthy participant group, then implemented in the PTSD participant group.
1563664|NCT02500706|Drug|Faster-acting insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal. Postmeal dosing is defined as injecting 20 minutes after the start of the meal.
1563665|NCT02500706|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily for 26 weeks. Dose individually adjusted.
1563666|NCT02500706|Drug|insulin aspart|Injected subcutaneously (under the skin) three times daily for 26 weeks. Dose individually adjusted. Mealtime dosing is defined as injecting 0-2 minutes before the meal.
1563667|NCT02500693|Biological|Isolation of circulating tumor cells (CTC) from veinous blood|Thirty ml of peripheral blood will be collected in buffered EDTA, maintained at 4°C, and processed within 1 hour for filtration. After blood filtration, the membrane will be gently washed with PBS, disassembled from the filtration module, and allowed to air-dry. The determination of CTC number present on filters will be carried out by combining four color immunofluorescent (anti-pancytokeratins/anti-vimentin/DAPI/anti-CD45) staining and cytomorphological examination after Diff-quick and Mayer Hemalun staining in three spots per patient sample. Imaging of immunofluorescent and cytological staining will be performed at x20 magnification using the automated Ariol system. CTCs are identified by relocating images of immunofluorescent and cytological staining.
1563668|NCT02500680|Biological|MER4101|
1563669|NCT02500680|Biological|Inactivated Influenza Vaccine|Fluzone quadrivalent Influenza Vaccine
1563670|NCT02500667|Drug|N91115|200 mg BID
1563671|NCT02500667|Drug|Rifampin|600 mg QD
1563672|NCT02500654|Device|Emdogain®|Surgery and Emdogain®
1563673|NCT02500654|Device|Surgery alone|Surgery alone
1563674|NCT02500641|Drug|Febuxostat 80/120mg/day|Starting dose and dose regimen of Febuxostat : the initial daily dose is 80 mg. In case the patient has the serum urate concentration > 6 mg/dl after 2 weeks of treatment the dose will be escalated to 120 mg and if tolerated will be maintained for the duration of the study.
1563675|NCT02500641|Drug|Allopurinol 100 up to 600mg/day|Starting dose and dose regimen of allopurinol : the initial daily allopurinol dose is 100 mg, to be increased by 100 mg every 2 weeks in patients with serum urate concentration >6 mg/dl. The maximum daily dose of allopurinol achievable in the study will depend on kidney function and tolerability, but will not exceed 600 mg.
1563676|NCT02500641|Drug|Colchicine|Colchicine 0.5 mg tablets.To prevent flares in the initial stages of treatment, patients will be treated for at least 6 months with colchicine 0.5 - 1 mg QD
1563677|NCT02500641|Drug|Naproxen|Naproxen sodium 550 mg film coated tablets. In case of colchicine intolerance patients will be treated for at least 6 months with Naproxen 550 mg BID and Omeprazole (20-40 mg once daily), if indicated to be used.
1563678|NCT02500641|Drug|Omeprazole|Omeprazole 20 mg capsules, co-administered to patients for gastric protection.
1563680|NCT02500615|Other|ECIG liquid vehicles|The ratio of propylene glycol and vegetable glycerin will be changed while all other factors of the electronic cigarette provided to participants will be held constant.
1564229|NCT02496884|Drug|DS-5565|DS-5565 7.5 mg tablet
1563683|NCT02500589|Behavioral|Behavioral mood management|The mood-management sessions are informed by CBT and emphasize psycho-educational and skills-based approaches to CBT. CBT has been used extensively to address mood management. Specifically, SMK-MM enhancement includes behavioral activation, cognitive restructuring (working with automatic thoughts, problem solving, and behavioral skills (i.e., activity scheduling, relaxation training/controlled breathing). The SMK-MM-enhanced participant manual will also include additional worksheets developed for the investigator's pilot based on Lewinsohn's self-help guide to controlling depression. The main objective of the worksheets will be to provide Veterans with an opportunity to gain mastery over selected behavioral and cognitive skills thought to facilitate mood management. As is customary in CBT, homework based on the worksheets will be discussed during counseling calls.
1563684|NCT02500589|Other|Health education|"In the contact-equivalent health education condition, participants will receive parallel smoking cessation content on the same schedule as in the MM-enhanced arm; however, health education content will supplant the MM content. The educational content will be based on the VA National Center on Health Promotion and Disease Prevention's Health Living Messages on such topics as being safe, eating wisely, getting recommended immunization and screening tests, and being involved with the participant's health care. Participants also will receive chronic-disease-specific self-management information."
1563693|NCT02500563|Other|Amino acid based infant formula|
1563694|NCT02500563|Other|Extensively hydrolyzed casein infant formula|
1563695|NCT02500563|Other|Mother's own breast milk|
1563696|NCT02500550|Biological|ATIR101|T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).
1563697|NCT02500537|Device|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology|Endo GIA™ Reinforced Reload with Tri-Staple™ Technology (Universal Handle)
1563698|NCT02500524|Drug|Cocamide diethanolamine|Topical lotion
1563699|NCT02500524|Drug|Permethrin|Topical creme rinse
1563700|NCT02500511|Biological|NmVac4-A/C/Y/W-135-DT™|no intervention in this study, received test vaccine in trial JN-NM-002
1563701|NCT02500498|Drug|Nulojix|
1563702|NCT02500485|Drug|SHR3824, SP2086|One 100-mg tablet of SP2086 once daily on Day 1,2,3,4 followed by two 10-mg tablets of SHR3824 once daily on Day 11,12,13,14, followed by one 100-mg tablet of SP2086 and two 10-mg tablets of SHR3824 on Day 15,16,17,18.
1563703|NCT02500472|Dietary Supplement|Kava|3 doses equaling 250 mg kavalactones per day. Participants will take 1 capsule three times daily at 8:00 (± 2 hours), 14:00 (± 2 hours) and 20:00 (± 2 hours) for 7 consecutive days.
1563704|NCT02500459|Drug|topotecan|intraparenchymally-administered topotecan will use the Cleveland Multiport Catheter to directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). This drug is already FDA approved to be administered intravenously.
1563705|NCT02500459|Device|Cleveland Multiport Catheter|The Cleveland Multiport Catheter will directly infuse topotecan into the tumor site of patients with suspected recurrent/progressive high grade glioma (HGG). Standard treatment is to adminsiter the drug intravenously.
1563706|NCT02500446|Drug|dolutegravir|Each film-coated tablet contains dolutegravir sodium equivalent to 50 mg dolutegravir.
1563707|NCT02500446|Other|Placebo|A film-coated tablet identical in appearance to the active drug tablet but not containing any dolutegravir or any other active ingredient
1563708|NCT02500433|Other|Device: Kinect-Xbox 360TM|Based around a webcam-style add-on peripheral for the Xbox 360 console, it enables users to control and interact with the Xbox 360 without the need to touch a game controller, through a natural user interface using gestures and spoken commands. Participants were asked to practice 30 minutes per day, 2 days per week for 2 months, added to their conventional treatment. The games used were Kinect Sports ITM, Kinect Joy RideTM and Kinect Disneyland AdventuresTM and involved balance and trunk movements, general and visual-manual coordination and limb tasks. Each subject followed instructions on the screen with the help of his physiotherapist, with points awarded based on degree and speed of movement and level of difficulty.
1563709|NCT02500433|Other|Conventional therapy|
1563710|NCT02500420|Other|Diagnosis examens|"Cardiac MRI: is usually recommended in the diagnosis or in the follow-up of the disease. The MRI will respect the standard protocol: cineMRI sequences, perfusion sequences, LGE sequences at 10 minutes after gadolinium injection. The investigators will realize some additional sequences: T1 mapping before and after gadolinium injection to study the diffuse fibrosis and stress perfusion sequences after injection of a vasodilatator (Persantine°).
Exercice stress echocardiography: is realized almost systematically in all the diagnosis of HCM and it's very informative. The investigators will research left ventricular dysfunction: in particular segmentary hypokinesia and anomalies of deformation parameters (2D Strain) and the development of a dynamic left ventricular outflow obstruction or a mitral regurgitation at exercice."
1563713|NCT02500394|Procedure|Ionosteril|biomarker guided volume substitution with Ionosteril
1563717|NCT02500368|Device|silicone hydrogel lens (test)|contact lens
1563718|NCT02500368|Device|enfilcon A lens (control)|contact lens
1563719|NCT02500355|Procedure|Carpal Tunnel Release via limited approaches|Carpal tunnel release with partial excision of the flexor retinaculum via two small incisions.
1563720|NCT02500355|Procedure|Carpal Tunnel Release via standard approach|Carpal tunnel release with partial excision of the flexor retinaculum via the standard incision.
1563721|NCT02500355|Procedure|Endoscopic Carpal Tunnel Release|Carpal tunnel release under endoscope.
1563722|NCT02500355|Device|endoscope or an arthroscopic device|
1563723|NCT02500342|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
1563724|NCT02500342|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
1563725|NCT02500329|Drug|Gemigliptin|Gemigliptin for 4 weeks
1563726|NCT02500329|Drug|Acarbose|Acarbose for 4 weeks
1563727|NCT02500316|Drug|MOD-4023|Once weekly subcutaneous injection
1563728|NCT02500277|Device|Cryoprobe pleural biopsy first|Four pleural biopsy specimens will be obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm) followed by 6-10 pleural biopsy specimens obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter).
1563729|NCT02500277|Device|Flexible forceps biopsy first|Six to ten pleural biopsy specimens will be obtained using the flexible thoracoscopic forceps (FB-55CR, Olympus Medical Systems, 2 mm diameter) followed by four pleural biopsy specimens obtained using the flexible cryoprobe (ERBOCRYOCA, ERBE, Tubingen, Germany; outer diameter 1.9 mm, length 900 mm)
1563730|NCT02500264|Device|TENS|
1563731|NCT02500251|Drug|belimumab|Belimumab will be administered per study protocol.
1563732|NCT02500251|Drug|Bortezomib|Bortezomib will be administered per study protocol.
1563733|NCT02500251|Drug|Rituximab|Rituximab will be administered per study protocol.
1563734|NCT02500251|Drug|Plasmapheresis|Plasmapheresis will be administered per study protocol.
1563735|NCT02500238|Other|Saliva sample|All participants will provide a saliva sample.
1563736|NCT02500238|Other|Urine Sample|All participants will provide a urine sample.
1563737|NCT02500238|Other|Toe nail clippings|All participants will provide toe nail clippings.
1563738|NCT02500238|Other|Breath carbon monoxide test|All participants will provide breath carbon monoxide tests
1563739|NCT02500225|Drug|Etomidate|0.2 mg/kg etomidate
1563740|NCT02500225|Drug|Sevoflurane|8% Sevoflurane
1563741|NCT02500212|Drug|ENVARSUS®|
1563742|NCT02500212|Drug|ADVAGRAF®|
1563743|NCT02500199|Drug|Pyrotinib|Pyrotinib maleate, is provided as yellow, film-coated, immediate release tablets containing pyrotinib maleate at dosage strengths of 80 and 160 mg. Multiple tablets of pyrotinib will be administered daily to achieve targeted doses of pyrotinib: 320 mg, 400 mg, 480 mg, 560 mg and 640 mg. Tablets will be orally administered with water, once daily, 30 min after a meal.
1563744|NCT02500186|Drug|Luseogliflozin|Study patients orally receive luseogliflozin 2.5 mg s.i.d. before breakfast for 7 days from the 8th day of starting the study meal to the 14th day.
1563745|NCT02500186|Other|Meal containing different carbohydrate ratio and GI value|High GI meal containing 55% carbohydrate Low GI meal containing 55% carbohydrate High GI meal containing 40% carbohydrate
1563746|NCT02500173|Radiation|Radiation|Radiation therapy
1563749|NCT02500147|Drug|Metformin|Metformin ER 500 mg once a day for one week and 1000 mg once a day for the remainder of the six months
1563750|NCT02500147|Drug|Placebo|One placebo pill per day for one week and then two placebo pills per day for the remainder of the six months
1563751|NCT02500134|Other|Optical coherence tomography study on limbus|Optical coherence tomography study on limbus
1563752|NCT02500121|Other|Placebo|Normal saline
1563753|NCT02500121|Drug|Pembrolizumab|Pembrolizumab, 200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or for up to 24 months
1563754|NCT02500108|Drug|Domperidone|"Current exposure to domperidone will be defined as a prescription dispensed within 30 days before the index date.
Recent exposure to domperidone will be defined as a prescription dispensed between 31 and 90 days before the index date (without a dispensing during the 30 days period preceding index date).
Past exposure to domperidone will be defined as a prescription dispensed between 91 and 365 days before the index date (without prescription in the 90 days period prior index date)."
1563755|NCT02500095|Other|Fasting|72 hours of fasting
1563756|NCT02500095|Drug|Saline|Concomitant saline during fasting
1563757|NCT02500095|Drug|Pegvisomant|Concomitant Growth hormone receptor blockade with Pegvisomant during fasting
1563809|NCT02499770|Drug|Carboplatin|
1563810|NCT02499770|Drug|Placebo|
1563811|NCT02499770|Drug|Trilaciclib|
1563812|NCT02499770|Drug|Etoposide|
1564333|NCT02496078|Drug|Daclatasvir|Daclatasvir tablet 60mg
1563758|NCT02500082|Drug|triheptanoin|Triheptanoin (UX007) is a medium chain triglyceride of three seven-carbon fatty acids (C7), on a glycerol backbone, with a molecular formula of C24H44O6. It is being evaluated as a substrate replacement therapy for the treatment of long-chain fatty acid oxidation disorders (LC-FAOD) and for the treatment of seizures associated with Glut 1 DS. Triheptanoin is metabolized to provide substrate replacement for both fatty acid metabolism and anaplerosis (replacement of TCA cycle intermediates) required to restore the efficient generation of energy and the net production of glucose in patients. The mechanism of action of triheptanoin in restoring energy metabolism is dependent on its medium-chain length as well as its odd-carbon properties. Triheptanoin is a highly purified form intended for oral administration.
1563759|NCT02500069|Other|placebo|infusion of tap water in all regions (duodenum, jejunum and ileum)
1563760|NCT02500069|Other|Casein (in duodenum)|infusion of protein in duodenum
1563761|NCT02500069|Other|Casein (in jejunum)|infusion of protein in jejunum
1563762|NCT02500069|Other|Casein (in ileum)|infusion of protein in ileum
1563763|NCT02500056|Device|Optilene LP mesh|Lichtenstein hernioplasty
1563764|NCT02500056|Device|Ultrapro mesh|Lichtenstein hernioplasty
1563767|NCT02500030|Procedure|Glossopharyngeal Breathing|Glossopharyngeal Breathing is a type of lung recruitment technique where the patients take a multiple inssuflations with their glossopharyngeal muscle.
1563768|NCT02500030|Procedure|Air Stacking|Air Stacking is a type of lung volume recruitment technique where insufflations are stacked in the lungs to maximally expand them, here done with a manual resuscitator.
1563769|NCT02500017|Dietary Supplement|Melatonin|5mg rapid release melatonin capsule
1563770|NCT02500017|Other|Placebo|matching placebo capsule
1563771|NCT02500004|Radiation|18F-FDG PET-MRI-imaging|BAT activity: 18F-FDG PET-MRI-imaging.
1563772|NCT02500004|Radiation|DXA scanning|Body composition: DXA scanning, D2O and MRI.
1563773|NCT02500004|Procedure|Abdominal subcutaneous adipose tissue biopsy|Inflammatory and metabolic profile of adipose tissue: abdominal subcutaneous adipose tissue biopsy.
1563774|NCT02500004|Procedure|Blood sampling|Systemic inflammatory profile: blood sampling.
1563775|NCT02500004|Other|Indirect calorimetry|Resting metabolic rate: indirect calorimetry.
1563776|NCT02500004|Device|Accelerometry|Physical activity level: accelerometry.
1563777|NCT02500004|Other|Double-labeled water|Body composition: DXA scanning, D2O and MRI. Total daily energy expenditure: double-labeled water.
1563779|NCT02499978|Drug|Darunavir/Cobicistat|Fixed dose combination medication
1563780|NCT02499978|Drug|Dolutegravir|single tablet medication
1563781|NCT02499965|Drug|Ethyl Chloride Topical Aerosol Anesthetic|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
1563782|NCT02499965|Drug|Nature's Tears Sterile Water|Sprayed on the skin for 5-8 seconds immediately before IV cannulation
1563783|NCT02499952|Drug|Pembrolizumab|200mg IV every 3 weeks until progressive disease, unacceptable toxicity, or after 52 weeks of therapy.
1563784|NCT02499939|Behavioral|Standard Care|Education and home exercises
1563785|NCT02499939|Other|Ultrasound Therapy|"Ultrasound is a therapeutic modality that is used by physical therapists to help reduce local tissue pain and inflammation. Ultrasound is applied using a round-headed wand or probe that is placed in direct contact with the patient's skin. Ultrasound gel is used on all surfaces of the ultrasound head to reduce friction and assist in the transmission of the ultrasonic waves. For the purposes of treatment for CIPN, the ultrasound will be applied for 5 minutes to each limb (right toes, left toes, right fingers, left fingers) at frequency of 3.0 megahertz (MHz) and an intensity of 0.7-0.8 watts per cm2.
(For CIPN, the ultrasound will be administered at a lower intensity in order to avoid a heating effect on the tissues.)"
1563786|NCT02499926|Dietary Supplement|Arginine|"Graded arginine excess intake will start at 50mg/kg/d on study day 1 followed by 100 mg/kg/d on study day 2 till the level reaches 300mg/kg/d on study day 6.
Consisting of oral consumption of eight hourly experimental meals per study day - Includes 4 tracer free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals."
1563787|NCT02499913|Behavioral|breath alcohol monitoring|Daily breath alcohol monitoring
1563788|NCT02499913|Behavioral|contingency management|Participants can earn chance to win prizes for negative breath alcohol samples.
1563789|NCT02499900|Drug|Copaxone®|Subcutaneous Injections of 40 mg/mL Three Times a Week Compared to 20 mg/mL Daily
1563790|NCT02499887|Drug|beclamethasone dipropionate|Inhaler
1563791|NCT02499887|Drug|albuterol|Inhaler
1563792|NCT02499887|Drug|Prednisone|Oral corticosteroid
1563797|NCT02499861|Drug|Decitabine and Genistein|intravenous Decitabine with oral genistein
1563798|NCT02499848|Drug|PRX302|Single prostate cancer lesion injected with PRX302.
1563799|NCT02499835|Biological|Pembrolizumab|Given IV
1563800|NCT02499835|Biological|pTVG-HP Plasmid DNA Vaccine|Given ID
1563801|NCT02499822|Drug|Nifedipine GITS|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
1563802|NCT02499822|Drug|Ramipril|Commercially available drug formulations are used. Study medication will be assumed in a single morning (7-10 a.m.) administration per os.
1563803|NCT02499809|Other|Recovery mode|After the gradual maximal exercise the subjects will use different recovery modes (vibration therapy or passive and active recovery).
1563804|NCT02499796|Device|Hygrovent Gold|
1563805|NCT02499796|Device|Heated and moisture exchanger (HME)|
1563806|NCT02499796|Device|Heated humidifier (HH)|
1563813|NCT02499757|Device|flavor and sweetener|maltol added as sweetener to e-cigarette with flavor
1563814|NCT02499757|Device|flavor and nicotine|12 mg of nicotine added to e-cigarette with flavor
1563815|NCT02499757|Device|flavor, nicotine and sweetener|12 mg nicotine and maltol (sweetener) added to e-cigarette with flavor
1563816|NCT02499757|Device|flavor|flavored e-cigarette stand alone without added nicotine and maltol (sweetener)
1563817|NCT02499744|Device|NIPPV|"For infants in the NIPPV-group who failNIPPV (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
1563818|NCT02499744|Device|HHFNC|"For infants in the HHFNC-group who failHHFNC (see definition below), need immediate intubation, a invasive Rescue-Treatment may be provided. The decision to attempt Rescue-Treatment, the mode of respiratory support and the ventilator settings used are at the discretion of the attending clinician."
1563821|NCT02499718|Device|BiPAP mode|Noninvasive ventilator
1563822|NCT02499705|Dietary Supplement|Sucralose|2 packets
1563823|NCT02499705|Dietary Supplement|Sucrose|equisweet to sucralose
1563824|NCT02499705|Dietary Supplement|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
1563825|NCT02499692|Device|SYNERGYTM Coronary Stent System|SYNERGYTM MONORAILTM Everolimus-Eluting Platinum Chromium Coronary Stent System
1563826|NCT02499666|Procedure|Percutaneous Coronary Intervention|As clinically indicated, patients will have a percutaneous balloon angioplasty and stent deployment of a chronic total occlusion (i.e., an artery that has a 100% blockage for several months).
1563827|NCT02499666|Device|Coronary stent|As clinically indicated, patients will have a coronary stent placement into their occluded coronary artery after successful balloon angioplasty
1563828|NCT02499666|Drug|Clopidogrel|As clinically indicated, patients who are not already on dual antiplatelet therapy will be started on a second agent such as clopidogrel.
1563829|NCT02499653|Behavioral|Psychological Intervention|
1563830|NCT02499653|Behavioral|Videos|
1563831|NCT02499640|Other|immersion cold water|immersion cold water at different temperatures and exposure times
1563832|NCT02499627|Drug|Brentuximab Vedotin|Brentuximab will be given intravenously at a total dose of 1.8 mg/kg on day 1 of each 21 days-based cycle, for 6 cycles.
1563833|NCT02499627|Drug|Bendamustine|Bendamustine will be administered at a dose of 90 mg/m2 on day 1 and 2 of each 21 days-based cycle, for 6 cycles.
1563835|NCT02499601|Device|CORolla™ TAA device|
1563836|NCT02499588|Device|Esteem Plus with ConvaTec Moldable Technology|
1563837|NCT02499588|Device|Natura with ConvaTec Moldable Technology|
1563838|NCT02499588|Device|Natura Accordion with ConvaTec Moldable Technology|
1563839|NCT02499588|Device|Esteem synergy Plus with ConvaTec Moldable Technology|
1563840|NCT02499575|Drug|0.5% ropivacaine|Adductor block: 10 mL of 0.5% ropivacaine; popliteal block: 30 mL of 0.5% ropivacaine
1563841|NCT02499575|Drug|Exparel|106 mg (8 mL, equivalent to 120 mg bupivacaine HCl)
1563842|NCT02499562|Drug|Hydronidone|The investigational products in the test groups and control group shall be orally taken 30 minutes before meals for 52 continuous weeks. There are respectively 60 cases in the test group I, II, III and the control group, totally 240 cases.
1563843|NCT02499562|Drug|Placebo|
1563844|NCT02499562|Drug|Entecavir|
1563845|NCT02499549|Drug|cocamide diethanolamine|10% Cocamide DEA aqueous lotion is applied directly to dry hair and is washed off with water only
1563846|NCT02499536|Device|ultrasound|Juxtapleural consolidation, loss of A lines, presence of B lines, air bronchogram, loss of sliding sign and presence of pulse sign on lung ultrasound finding will be investigated and recorded.
1563847|NCT02499523|Procedure|THR with conventional technique|THR with conventional technique.
1563848|NCT02499523|Procedure|THR with Acetabular Cup Orientation Guides (ACOG)|THR with the ACOG System.
1563849|NCT02499510|Device|GoldenFlow Stent|The GoldenFlow stent (Lifetech Science, Shenzhen, China) is a TiN coated self-expanding stent consisting of interwoven nitinol wires braided in a closed cell design. Stents used in this study ranged from 4-12mm in diameter and 20-160mm in length.
1563850|NCT02499497|Drug|LY2452473|LY2452473 is a selective androgen receptor modulator which is agonist on the muscle but which spares the prostate.
1563851|NCT02499497|Drug|Placebo|The participants will receive pills containing no active drug.
1563852|NCT02499484|Drug|glyceryl trinitrate|Topical GTN will be used daily in combination with a eccentric home exercise program
1563853|NCT02499484|Other|Placebo ointment|Topical placebo ointment will be used in combination with a eccentric home exercise program
1563854|NCT02499484|Other|Eccentric exercise program|All participants will complete the eccentric exercise program as a home exercise program daily.
1563855|NCT02499471|Other|Levothyroxine therapy (137.75 ± 23.75 μg/day)|This study was a longitudinal study in an academic center, with a follow-up period of 6 months. Ten patients with well-differentiated thyroid carcinoma eligible for surgical treatment and subsequent radioactive iodine ablation therapy were studied in a hypothyroid state after thyroidectomy and in a subclinical hyperthyroid state (TSH-suppression according to standard treatment protocol).
1563856|NCT02499458|Other|None- observational study|
1563857|NCT02499445|Drug|Remifentanil|administering remifentanil for anesthesia maintenance
1563858|NCT02499445|Drug|sevoflurane 1|administering sevoflurane 1 for anesthesia maintenance
1563859|NCT02499445|Drug|sevoflurane 2|administering sevoflurane 2 for anesthesia maintenance
1563860|NCT02499445|Drug|propofol|administering propofol for anesthesia maintenance
1563861|NCT02499445|Drug|sufentanil|administering sufentanil for anesthesia maintenance
1563862|NCT02499432|Behavioral|Motivational Enhancement|Motivational Enhancement/Interviewing is a form of discussion that seeks to increase change behavior.
1563863|NCT02499406|Behavioral|Dialectical behavior therapy skills group|Skills training in emotion regulation, distress tolerance, interpersonal effectiveness, and mindfulness
1563864|NCT02499393|Drug|Magnesium Sulfate|intravenous infusion of magnesium sulphate
1563865|NCT02499380|Device|PneumRx Coil System|
1563866|NCT02499367|Drug|Nivolumab|nivolumab 3 mg/kg, every 2 weeks after induction treatment
1563867|NCT02499367|Radiation|Radiation therapy|20 Gy to metastatic lesion
1563868|NCT02499367|Drug|Low dose doxorubicin|15 mg flat dose, once weekly for 2 weeks
1563869|NCT02499367|Drug|Cyclophosphamide|metronomic schedule, 50 mg daily orally for 2 weeks
1563870|NCT02499367|Drug|Cisplatin|40 mg/m2, weekly for 2 weeks
1563871|NCT02499354|Drug|Ferumoxytol intravenous|IV iron, 2 vials of 510 mg given 2-7 days apart
1563872|NCT02499354|Drug|Ferrous sulfate|Oral iron, 325 mg tabs taken morning and evening
1563873|NCT02499341|Drug|Tramadol|Tramadol administered intravenously (1mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of tramadol (0.2mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
1563874|NCT02499341|Drug|Ketamine|Ketamine administered intravenously (0.5mg/kg) thirty minutes before the expected end of surgery, followed by a continuous infusion of ketamine (0.12mg•kg-¹•h-¹) for up to 48 h after major upper abdominal surgery, in patients receiving PCA morphine postoperatively at a bolus dose of 1 mg with a lockout period of 8 minutes.
1563879|NCT02499315|Drug|AMG 357|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
1563880|NCT02499315|Drug|Placebo|Oral tablets in 20 count bottles. Dose strengths include 5, 25, and 50 mg tablets.
1563881|NCT02499302|Behavioral|Mental training|
1563882|NCT02499276|Device|PSV, NAVA, PAV, Variable-PSV|Each patient enrolled in the study will be ventilated in all the following modes: PSV, NAVA, PAV and variable PSV
1563883|NCT02499250|Device|remote ischemic conditioning (TDFT-12-A2)|"The subjects will receive twice daily of 4×5min/5min ischemic/reperfusion of both arms (remote ischemic conditioning) over 30 days using the TDFT-12-A2 device produced by Shenzhen TDF Tai Smart technology Co., Ltd."
1563884|NCT02499250|Drug|Optimal medical treatment|The subjects will receive optimal medical treatment according up-to-date guidelines, including adequate antiplatelet therapy, statins, β-blocker and nitrates, plus angiotensin converting enzyme inhibitor(ACEI)/angiotensin receptor blocker(ARB),oral anticoagulants, if necessary.
1563885|NCT02499237|Drug|Denosumab|Treatment of low bone mass with subcutaneous injections of denosumab 60 mg every 6 months for one year
1563886|NCT02499237|Drug|Zoledronic acid|Treatment of low bone mass with a single infusion of zoledronic acid 5 mg for one year
1563887|NCT02499224|Drug|YYB101|"Dose-escalation cohort: YYB101 of each dose level (0.3mg/kg to 5mg/kg), IV infusion on Day 1, Day 29, and followed by every 2 weeks until disease progression or unacceptable toxicity development.
Dose-expansion cohort: YYB101 of MTD (or RP2D), IV infusion every 2 weeks until disease progression or unacceptable toxicity development"
1563888|NCT02499211|Other|Intervention stores|"In-store marketing strategies will focus on placement and promotion of healthier items (lower calorie options) in the milk, frozen food, beverage checkout cooler, bread, salty snacks, and cheese sections of the store.
Intervention efforts in the dairy section promote lower calorie milk (skim, 1%, and 2%), while diminishing the presence of whole milk. The visual order of the milk displays will be changed, and the number of facings, or the fronts of packages the consumer can see, of whole milk will be decreased by 30% while increasing the facings of the lower calorie milk. In the other product categories, target products will be moved to eye level and the number of facings will be increased.
Call-out signs will be placed by the target products that list the name and price of the product. No health information or claims will be included. Signage will be rotated monthly to increase the chances that customers will notice them."
1563889|NCT02499198|Drug|[D4]Nornicotine - Highest|Level equal to highest level of [D4]Nornicotine found in commercial tobacco based snuff
1563890|NCT02499198|Other|[D4]Nornicotine - Mean|Level equal to mean level of [D4]Nornicotine found in commercial tobacco based snuff
1563891|NCT02499198|Other|[D4]Nornicotine - Lowest|Level equal to lowest level of [D4]Nornicotine found in commercial tobacco based snuff
1563892|NCT02499198|Other|[D4]Nornicotine - 50% Lowest|Level equal to 50% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff
1563893|NCT02499198|Other|[D4]Nornicotine - 10% Lowest|Level equal to 10% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff
1563894|NCT02499198|Other|[D4]Nornicotine - 5% Lowest|Level equal to 5% of the lowest level of [D4]Nornicotine found in commercial tobacco based snuff
1563895|NCT02499198|Other|13C6-NNN|0.5µg/g - below traditional levels found in moist snuff
1563896|NCT02499198|Other|Herbal Snuff|A tobacco-free herbal snuff, such as Smokey Mountain or similar
1563897|NCT02499185|Device|Nephro Check Test|Urine sample
1563898|NCT02499185|Other|serum creatinine measurement|Blood sample
1563899|NCT02499172|Biological|Shanchol|Oral cholera vaccine
1563900|NCT02499172|Other|Non-intervention|Non recipients of the vaccine
1563901|NCT02499159|Drug|Liposomal Bupivicaine|266 mg, 20 mL total, diluted at surgeon's discretion, delivered by 22 gauge needle.
1563902|NCT02499159|Drug|0.25% standard bupivicaine|standard 0.25% bupivacaine, 20 mL total, delivered by 22 gauge needle.
1563903|NCT02499146|Drug|Palbociclib|125 mg orally once daily with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle
1563904|NCT02499146|Drug|Letrozole|2.5 mg , orally once daily (continuously)
1563905|NCT02499133|Other|language and cognitive tests|The participants will undergo seven different. The tests will include different cognitive and language examinations. The main test of the study will be The Hebrew Focused Stress Test (HFST). The HFST includes three subtests. The first subtest requires identification of the stressed word in a sentence based on psychoacoustic abilities alone. The second and the third subtests require understanding the meaning of focused stress in different contexts - lexical grammatical and pragmatic/social. The test includes forty eight recorded sentences. In each sentence one word is stressed. The participants will be asked to listen to the recordings and answer a closed question regarding the stressed word.
1563909|NCT02499107|Dietary Supplement|Rice treatment|All arms are given to all participants, in a randomized (cross over) order
1563910|NCT02499107|Dietary Supplement|Pasta treatment|
1563911|NCT02499107|Dietary Supplement|Boiled and mashed potato treatment|
1563912|NCT02499107|Dietary Supplement|Baked french fries treatment|
1563913|NCT02499107|Dietary Supplement|Fried french fries treatment|
1563914|NCT02499094|Other|Behavioral-data driven support|Phone-based support (e.g. triaging of the situation, emotional support, and guidance on next steps for the patient) and in-app support (health education content based on cognitive behavioral therapies, mindfulness, and behavioral activation)
1563915|NCT02499081|Drug|Ixazomib|
1563916|NCT02499068|Device|Telehealth|Monitoring devices installed at patients home and patients are monitored on a daily bases for early detection of exacerbations and prompt clinical intervention.and being follow-up on a daily bases for early detection and prompt intervention.
1563917|NCT02499055|Behavioral|FearFighter|FearFighter™ is a nine session cognitive behavioural self-help therapy program delivered over the internet during nine weeks. Each session on FearFighter excluding the homework takes about 30-40 minutes to finish. A support person will make a weekly contact of 10 minutes in average to secure understanding of the program and compliance.
1563918|NCT02499042|Drug|Oxygen|oxygen delivery by ETT/ SGA connected to bag/valve/oxygen reservoir
1563921|NCT02499016|Procedure|suprapubic single-incision laparoscopic appendectomy|the approach of appendectomy
1563922|NCT02499003|Drug|Obinutuzumab and Pixantrone|Obinutuzumab: 1000 mg flat dose on day 1, 8, 15 of cycle one and day 1 of subsequent cycles, Pixantrone: 50 mg/m² Pixantrone on day 1,8,15 of each 28 d cycle
1563923|NCT02498990|Behavioral|Low calorie diet followed by life style intervention|"Low calorie diet of 800 kcal/day for 7 weeks.
Life style intervention for the remaining study period"
1563924|NCT02498977|Genetic|Biomarker|Real time polymerase chain reaction (PCR) gene expression measurement
1563925|NCT02498977|Drug|Tacrolimus, cyclosporine and/or mycophenolic acid, mycophenolate mofetil or azathioprine|Immunosuppression drugs as per protocol
1563926|NCT02498964|Other|Teaching,education,feedback and practice sessions to help improve as needed|Group discussion,individual attention and teaching as needed,more teaching using different modalities like powerpoint and hands on experience
1563927|NCT02498951|Procedure|Cognitive Assessment|Ancillary studies
1563928|NCT02498951|Biological|Obinutuzumab|Given IV
1563929|NCT02498951|Other|Quality-of-Life Assessment|Ancillary studies
1563930|NCT02498938|Genetic|SERPINA1 gene|2ml blood sample collected from patients to extract DNA for assessment of SERPINA1 gene polymorphism
1563931|NCT02498925|Behavioral|Behavioral Activation|Behavioral Activation is a psychosocial treatment for depression focused on gradually re-engaging patients with sources of reinforcement and reward in their environment (e.g., increasing activites and interpersonal interactions). In contrast to Cognitive Behavioral Therapy, and as the name implies, Behavioral Activation focuses on behavioral change strategies to improve mood and places little emphasis on cognitive restructuring techniques.
1563932|NCT02498912|Procedure|Production of Genetically-modified T cells|
1563933|NCT02498912|Drug|Cyclophosphamide|
1563934|NCT02498912|Device|IP Catheter Insertion|
1563935|NCT02498912|Genetic|Infusion of 4H11-28z/fIL-12/EFGRt+ Genetically-modified T cells|
1563936|NCT02498899|Behavioral|Questionnaires|Participants complete questionnaires at baseline, after watching a video, and after reading a story about the patient in the video.
1563937|NCT02498899|Behavioral|Video|Participants watch a video lasting about 4 minutes.
1563938|NCT02498886|Dietary Supplement|IHAT|Iron hydroxide adipate tartrate (IHAT): Single dose capsule containing IHAT equivalent to 60mg iron with 2 mg isotopically enriched with 58Fe.
1563939|NCT02498886|Dietary Supplement|Ferrous sulphate|Ferrous sulphate: Single dose capsule containing ferrous sulphate heptahydrate equivalent to 60 mg iron with 10 mg isotopically enriched with 57Fe.
1563940|NCT02498873|Behavioral|Linear Periodization|Linear Intensity Periodization Running
1563941|NCT02498873|Behavioral|Non Linear Periodization|Non Linear Periodization Running
1563942|NCT02498860|Drug|Pemebit|500mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
1563943|NCT02498860|Drug|Cisplatin|75mg/m2 on day 1 of every 3-week cycle, for a maximum of 4 cycles
1563985|NCT02498561|Procedure|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
1564334|NCT02496078|Drug|Asunaprevir|Asunaprevir soft capsule 100 mg
1563944|NCT02498847|Behavioral|ENGAGE|"Participants are introduced to ENGAGE program by the study OT. The ENGAGE program is located on a website and has several modules. The modules include a video in which a health provider is featured. This health provider gives a short presentation on a topic related to OA, symptom management or lifestyle change. Within each module, there is downloadable homework and additional information which can be printed. The modules are:
What is Osteoarthritis?
Information about treatments
Exercise
Sleep hygiene
Relaxation
Pleasant Activity Scheduling
Goal setting
Problem Solving
Pacing
Communication"
1563945|NCT02498834|Behavioral|Educational Video and Question Prompt List|Educational Video and Question Prompt List
1563946|NCT02498821|Device|Chest X-ray|A Chest X-ray will be taken after healthcare providers have inserted the PICC to make sure it is in the correct location. The X-ray can tell your healthcare providers where the PICC is and whether is has been inserted correctly.
1563947|NCT02498821|Device|Sherlock 3CG® TCS|The Sherlock 3CG® TCS is a device that is placed on the subject during the PICC insertion procedure, which helps your healthcare providers know where the PICC is as the healthcare providers are inserting it. It uses magnets and measures electrical activity of the heart to determine the location of the catheter in your body.
1563948|NCT02498821|Procedure|Peripherally Inserted Central Catheter (PICC)|A peripherally inserted central catheter (PICC) is a form of intravenous access that can be used for a prolonged period of time (e.g., for chemotherapy, antibiotics, total parenteral nutrition)
1563949|NCT02498795|Other|Group of Dry Needling|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
1563950|NCT02498795|Other|Group of Electrolysis|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
1563951|NCT02498795|Other|Control Group|Every group will receive a total of 4 treatment distributed throughout 8 weeks of treatment. The program of eccentric exercises that will have to realize it in his domicile every day.
1563952|NCT02498782|Drug|Fexinidazole|
1563953|NCT02498782|Drug|Placebo|
1563954|NCT02498769|Drug|Botulinum Toxin Type A|The botulinum toxin will be injected into epicardial fat pads shortly after cardiopulmonary bypass is initiated.
1563955|NCT02498769|Drug|Placebo|
1563956|NCT02498756|Biological|Cytokine-induced killer cells|CIK cells are transferred every 3 months for 1 year.
1563957|NCT02498756|Drug|Ipilimumab|Ipilimumab are delivered every 3 weeks for one year
1563958|NCT02498743|Procedure|echocardiography|TV was connected to display the cartoon video during the echocardiography: the episode number 125 of 'Dora the Explorer': 'Baby Winky Goes Home!' was reproduced during the echocardiography.
1563959|NCT02498743|Behavioral|Watching Animated cartoons|
1563960|NCT02498730|Behavioral|Interval Training|High Intensity Interval Training at 100% VO2Max
1563961|NCT02498730|Behavioral|Continuous Training|Continuous Stimulous at 60% VO2Max
1563962|NCT02498730|Behavioral|Control|Only Dependent Variables Measures
1563963|NCT02498717|Device|GameReady|Cryotherapy and compression
1563964|NCT02498717|Other|RICE|SOC ice and elevation
1563965|NCT02498704|Procedure|Dry Needling|Trigger point dry needling to hamstring muscle group.
1563966|NCT02498704|Other|Sham Needling|Superficial palpation of trigger point, skin is not punctured.
1563967|NCT02498691|Biological|Biological collection|Blood and saliva samples, placenta and cord blood collection
1563968|NCT02498678|Procedure|Tetanus|tetanic electric stimulation
1563972|NCT02498639|Procedure|percutaneous balloon aortic valvuloplasty|"Percutaneous BAV is performed according to the standard retrograde technique. The measurement of the trans-aortic gradient is given by two catheters placed one in the left ventricle, the other in ascending aorta. An extra stiff wire is placed in the left ventricular cavity. A balloon (size fitting the valve annulus) is inserted over the wire and a series of three inflations is performed at nominal pressure.
The procedure terminates in case of:
Reduction of the mean aortic gradient ≥50%.
Aortic pressure drop during the inflations, indicative of valve orifice sealing.
Intraprocedural complication.
Poor compliance of the patient. If none is met, the balloon is changed with a bigger one and a new series of three inflations performed. Aortic gradient is finally recorded."
1563973|NCT02498626|Other|venous saturations|Samples of venous saturations from the central venous line (CVP), from venous side of the heart lung machine and from the pulmonary artery were taken at 10 min after being on CPB and after correction of the cardiac defects.
1563979|NCT02498600|Biological|Ipilimumab|Given IV
1563980|NCT02498600|Other|Laboratory Biomarker Analysis|Correlative studies
1563981|NCT02498600|Biological|Nivolumab|Given IV
1563982|NCT02498574|Device|Transcranial Direct Current Stimulation|Non-invasive brain stimulation applied to the surface of the scalp
1563983|NCT02498574|Behavioral|Working Memory Training|Cognitively challenging game played concurrently with transcranial direct-current stimulation
1563984|NCT02498561|Procedure|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
1564153|NCT02497313|Drug|Metformin placebo|
1564154|NCT02497313|Drug|Cholecystokinin|
1563986|NCT02498561|Procedure|nonsurgical periodontal therapy|Scaling and root planning under local anaesthesia, in a total of four clinical visits Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush.
1563987|NCT02498561|Procedure|oral hygiene instructions|Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush
1563988|NCT02498548|Behavioral|Trained SCI Knee|Individuals with SCI will perform downhill walking training 3 times a week for 12 wks with a 4 wk follow-up period. This intervention will be delivered by trained therapists. In order to focus on rehabilitation of knee control, members of this group will be trained at moderate gait speeds,
1563989|NCT02498535|Drug|Nitric Oxide 160 ppm|Nitric Oxide 160 ppm
1563990|NCT02498522|Drug|Metformin|83 patients will continue metformin until end of 1st trimester
1563991|NCT02498509|Drug|CKD-342|treatment for 4 weeks after randomization
1563992|NCT02498509|Drug|Mometasone furoate|treatment for 4 weeks after randomization
1563993|NCT02498509|Drug|Levocabastine HCL|treatment for 4 weeks after randomization
1563994|NCT02498496|Drug|Magnesium Sulfate|Administration of a bolus of 2 g of MgSO4 in 20 min, one dose.
1563995|NCT02498496|Drug|Placebo|Administration of 100 mL of Normal Saline
1563996|NCT02498483|Drug|Acetaminophen|
1563997|NCT02498470|Procedure|percutaneous coronary intervention|All the patients receiving coronal artery angiography or percutaneous coronary intervention therapy by standard protocol
1563999|NCT02498444|Drug|Treprostinil|Administration of drug (treprostinil) vs placebo (saline) in the post-operative period
1564000|NCT02498431|Procedure|percutaneous coronary intervention|a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease
1564001|NCT02498431|Procedure|coronary angiography|is a procedure performed along with cardiac catheterization that uses X-ray imaging to see your heart's blood vessels
1564002|NCT02498431|Device|Stent, Medronic Resolute Integrity|A stent is placed in an artery as part of a procedure called percutaneous coronary intervention (PCI) to restore blood flow through narrow or blocked arteries. A stent helps support the inner wall of the artery in the months or years after PCI.
1564003|NCT02498418|Drug|Rifaximin 200mg Tablet|Generic rifaximin tablets
1564004|NCT02498418|Drug|Xifaxan 200mg Tablet|Brand reference standard for comparison
1564005|NCT02498418|Drug|Placebo Tablet|Placebo tablets in the same image of the generic rifaximin
1564006|NCT02498392|Drug|JNJ-42165279|JNJ-42165279 will be administered orally at a dose of 25 milligrams (mg) tablet once daily for 6 weeks.
1564007|NCT02498392|Other|Placebo|Matching Placebo will be administered orally.
1564008|NCT02498379|Drug|Cu[64]-25%CANF-Comb|Intravenous injection of 4-8 mCi of Cu[64]-25%CANF-Comb with PET-CT scans performed 1-4 hours, 5-10 hours, and 22-26 hours or 46-50 hours after injection.
1564009|NCT02498366|Other|physical tests|"each subject will undergo the following physical tests: day 1 - anthropometric measurements, wingate test and after 1 hour rest VO2max test. lactic acid levels will be measured before and after both tests.
day 2 - step test day 3 - running on the anaerobic threshold. blood sample, lactic acid level (measured in blood drop - finger sting) and urine sample will be taken before and after every test in days 2 and 3."
1564010|NCT02498353|Radiation|preoperative short-course radiotherapy with local boost|Except the clinical target volume(CTV),a gross tumour volume（GTV）is delineated，and give a dose of PTV-GTV:30Gy/5F
1564011|NCT02498353|Radiation|preoperative short-course radiotherapy without local boost|Preoperative short-course radiotherapy without local boost,the dose of radiotherapy is PTV-CTV 25Gy/5F
1564012|NCT02498353|Procedure|TME surgery|both study group and control group received surgery under TME principle after radiotherapy
1564013|NCT02498340|Dietary Supplement|non- fava beans|Patients will be subjected to eat non- fava beans diet at doses of 10 -30 gm (small to moderate amount) of 3 different types of non- fava beans, each one will be given once daily for 3 days.
1564014|NCT02498327|Other|Gelatine Capsule|Gelatine capsules containing only the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
1564015|NCT02498327|Other|Venavine Intensive®|Gelatine capsules containing 360 mg Red Vine Leaf extract, 60 mg of Horse Chestnut extract, 35 mg of Butchers Broom extract and 3,2 mg of Vitamin B6 as well as the inactive ingredients of starch amyral white, di-calcium phosphate DC and magnesium stearate fine.
1564016|NCT02498314|Other|Grade I-II SZ mobilization|Hip grade I-IISZ traction in a resting position is applied using gentle repetitive traction movements during 10 minutes. The mean peak force applied is 2,71N (S.D= 0,94), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
1564017|NCT02498314|Other|Grade II TZ mobilization|Hip grade IITZ traction in a resting position is applied during 10 minutes. The traction force is applied during 45 seconds with 15 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 5.94 N (S.D= 1), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
1564018|NCT02498314|Other|Grade III mobilization|Hip grade III traction in a resting position is applied during 10 minutes. The traction force is applied during 30 seconds with 30 seconds rest, until complete the 10 minutes of treatment. The mean peak force applied is 7.04 N (S.D= 0.32), according to previous study. Peak forces were measured using dynamometer and the therapist used it as a feedback to ensure mean peak force levels remain consistent.
1564019|NCT02498301|Drug|Rifaximin|Rifaximin will be provided to subjects either daily with placebo, or twice daily depending on which of the two experimental arms they are randomized to
1564020|NCT02498301|Drug|Placebo|Placebo will be administered twice daily or once daily with rifaximin depending on which experimental arm they are randomized to
1564021|NCT02498288|Drug|Isotretinoin: Reference Medication 1|Isotretinoin reference medication 1 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
1564022|NCT02498288|Drug|Isotretinoin: Reference Medication 2|Isotretinoin reference medication 2 will be 40 mg in the pharmaceutical form of capsule (2 capsules of 20 mg each)
1564023|NCT02498288|Drug|Isotretinoin: Test Medication|Isotretinoin test medication will contain isotretinoin 40 mg (2 capsules of 20 mg each) in the same type of pharmaceutical presentation, containing the same drug but possible to have a different excipients.
1564024|NCT02498262|Other|Virtual Reality System|The participants will use a virtual reality system that is like a large video game and complete some job skill tasks in the virtual world video game.
1564025|NCT02498249|Device|low level laser therapy|Will be performed irradiation with low-intensity laser in upper trapezius muscle
1564026|NCT02498249|Device|Placebo low level laser therapy|Will be not performed irradiation with low-intensity laser in upper trapezius muscle
1564027|NCT02498236|Drug|Intranasal Oxytocin|
1564028|NCT02498223|Other|experiment protocol|"the subjects will undergo the following experiment protocol:
recruitment and medical examination day.
physiological evaluation day- the subjects will perform twice* a physiological stress protocol ; 3 min sitting followed by 20 min walking on treadmill (4 km/h, 4% slope), and then 3 min sitting for recovery examination. total 26 min.
biomechanical valuation day- the subjects will perform twice* a biomechanical protocol using the Zebris system; 2 min standing followed by 10 min walking on treadmill (4 km/h, 4% slope). total 12 min.
once carrying the weight calculated according to the army current instructions, and a second time carrying weight calculated according to the new LCI. 2 hours rest between the two performances."
1564029|NCT02498210|Other|In Vitro Maturation Procedure|POR patients will be treated in IVM cycle. After baseline evaluation on day 3, 150 IU/day recombinant FSH or HMG will be added for 3 days. A second evaluation will be performed on day 6 of the menstrual cycle. An injection of 10,000 IU hCG (Pregnyl; Organon, Oss, Holland) or Ovitrelle 250mcg (Merck Serono ) will be administered subcutaneously when the endometrial thickness will be ≥6 mm and the leading follicle will be at least 12 mm. Oocyte retrieval will be performed under ultrasound guidance with a 19G single-lumen aspiration needle (Cook; Queensland, Australia). The follicular fluid will be collected in culture tubes containing follicle flush buffer (Cook) with 2 IU/ml heparin. All aspirates were filtered to identify additional oocytes
1564030|NCT02498197|Behavioral|Participatory Intervention|
1564031|NCT02498197|Behavioral|Control|
1564032|NCT02498184|Other|acupuncture|
1564033|NCT02498171|Drug|Intrathecal morphine with fentanyl|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.
The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
1564034|NCT02498171|Drug|Intrathecal morphine with bupivacaine|"Parturients in this arm underwent a single shot spinal following standard procedure. the drug mixture was then introduced into the subarachnoid space following free flow of csf. the parturient was the monitored fo labour progression using the standard partogram, vital signs and the visual analogue scale score for pain recorded every 5 min.
The fetus was monitored with an ultrasonic aided fetal Doppler until delivery"
1564035|NCT02498158|Device|MRI scans|"20 subject (10 tolerant and 10 intolerant to heat) will undergo MRI scans (GE healthcare manufacturer) as follows:
anatomical scan according to standard protocol
functional scan according to the standard protocol of rest-state fMRI.
scans of 10 healthy subjects will be taken from existing scans at the imaging department."
1564036|NCT02498145|Other|Nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette with nicotine.
1564037|NCT02498145|Other|Non-nicotine e-cigarette|Patients will receive nicotine patch and intensive counseling plus e-cigarette without nicotine.
1564038|NCT02498132|Other|Behavioral Activation|BA is based in behavioral principles of depression that suggest that depression is caused by a lack of reinforcement in the environment for positive, non-depressed behaviors. As such, the goal of BA is to help the patient reengage in positive, non-depressed activities. In clinical trials, BA as a treatment component has been consistently superior to no treatment and treatment as usual control groups, and a large body of research has found that BA is either equally or more effective than CBT, CT, and antidepressant medications (Cuijpers, Van Straten, & Warmerdam, 2007; Dimidjian et al., 2006; Jacobson et al., 1996).
1564039|NCT02498132|Other|Cognitvie Based Therapy|CBT explores patterns of thinking that lead to self-destructive actions and the beliefs that direct these thoughts, people with mental illness can modify their patterns of thinking to improve coping
1564040|NCT02498132|Other|Treatment as Usual|Individuals will be provided with one on one therapy sessions
1564041|NCT02498106|Dietary Supplement|Orthica Soft Multi Mini and Orthica Fish EPA Mini|daily intake of 2 Orthica Soft Multi Mini capsules (containing vitamins [B1, B2, B3, B5, B6, B11, B12, C, D, E, Beta Carotene] and minerals [Iodine, Copper, Selenium, Iron, Zinc, Chrome, Manganese]) and 1 Orthica Fish EPA Mini capsule (containing n-3FA: eicosapentaenic acid [EPA] and docosahexaenic acid [DHA])
1564042|NCT02498093|Behavioral|Maximal strength training|
1564043|NCT02498093|Behavioral|conventional rehabilitation|
1564044|NCT02498080|Procedure|DEB PTA|paclitaxel drug eluting balloon PTA
1564045|NCT02498080|Procedure|Standard PTA|Standard PTA
1564046|NCT02498067|Behavioral|rPlan dual protection waiting room app intervention|
1564047|NCT02498054|Behavioral|Education with new meter feature.|The blood glucose meter has default settings for the colour range indicator which can be customized by the subjects and/or their healthcare professional. This colour range indicator will be presented to the subjects as a computer simulation to show subjects a range of typical blood glucose values and how this new feature would classify these results as being low (blue), in-range (green) or high (red).
1564048|NCT02498041|Procedure|Transnasal Endoscopy|Experimental procedure with transnasal endoscopy for the first 80% of the patients (n=90). The examination is limited to the esophagus and the proximal stomach.
1564049|NCT02498041|Device|Office-based disposable transnasal endoscopy Endosheath|Experimental procedure with portable, disposable transnasal endoscopy for the last 20% of patients only (n=25). The examination is limited to the esophagus and the proximal stomach.
1564050|NCT02498041|Device|Standard upper GI endoscopy|Upper GI endoscopy with standard gastroscope.
1564051|NCT02498041|Procedure|Esophageal biopsies|2 research biopsies taken if endoscopic evidence of columnar-lined esophagus
1564052|NCT02498028|Procedure|Cervical Fusion|Cervical Fusion is performed with a titanium cage (Company Peter Brehm, Weisendorf, Germany) and a plating system (Company Aesculap, ABC plating system, Tuttlingen, Germany)
1564053|NCT02498028|Procedure|Cervical disc Prostheses|The total disc replacement is performed with eiter a Freedom® Cervical Disc, AxioMed Spine Corporation, Garfield Heights, Ohio, USA or Active® C, Company, Aesculap, Tuttlingen, Germany
1564054|NCT02498015|Drug|"3D regimen"|"The 3D regimen contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily for genotype 1b without cirrhosis."
1564055|NCT02498015|Drug|"3D regimen with ribavirin"|"The 3D regimen with ribavirin contain paritaprevir/ritonavir/ombitasvir (75/50/12.5mg) once daily, dasabuvir 250mg twice daily, and ribavirin (1000 mg regardless of weight) daily in two divided doses for genotype 1a and genotype 1b with cirrhosis."
1564068|NCT02497989|Other|Inter-personal Communication (IPC)|RAs will meet older men in their households, and : i) approach the person(s), introduce self, develop rapport and request for time to discuss briefly about VMMC; ii) strike a conversation on reasons why they or their peers have not gone to be circumcised as well as reasons that would make them get circumcised, jotting down responses to guide the discussion; iii) using the 'VMMC Demand Creation Toolkit', discuss each reported barrier/facilitator carefully and completely, always ensuring the person(s) is/are engaged in the discussion (the goal is to pass correct and complete information in a relaxed and conversational manner); iv) revisiting each stated barrier/barrier and exploring what they now think about them after the discussion, and address any new or lingering concerns.
1564069|NCT02497989|Other|Dedicated Service Outlets (DSO)|RAs shall visit every household with eligible men to inform them about the availability of DSO sites in their neighborhoods. After describing the characteristics of DSO sites, the RA will share - both verbally and through a flyer, information on where to find DSO sites in the respective Location. RAs will respond to questions using 'All You Need to Know About VMMC' booklet, the same way current recruiters do. They will also inform potential participants that all other VMMC sites continue to serve all men regardless of age (i.e., including older men) while DSO sites will only serve men aged ≥25 years.
1564070|NCT02497976|Biological|Certolizumab pegol|400 mg
1564071|NCT02497976|Drug|Placebo|Normal saline
1564072|NCT02497963|Procedure|Foreskin Graft-Tubularized Incised Plate|TIP Urethroplasty with foreskin graft in primary hypospadias
1564073|NCT02497963|Procedure|Tubularized Incised Plate|TIP Urethroplasty without foreskin graft in primary hypospadias
1564074|NCT02497950|Device|HeartMate 3|Any patient that is determined to meet the HM3 commercially approved labelling indication and that is implanted with the HM3
1564075|NCT02497937|Drug|GSK2798745|GSK2798745 will be supplied as granule filled capsule with unit dose strength of 2.4 mg to be administered orally with 240 mL water.
1564076|NCT02497937|Drug|Placebo|Placebo will be supplied as blend filled capsule to be administered orally with 240 mL water.
1564077|NCT02497924|Drug|GBT440|GBT440 capsules followed by single dose of [C14] GBT440 oral suspension
1564078|NCT02497911|Procedure|Adductor Canal Catheter|0.5% Ropivicaine for primary block and 0.2% Ropivicaine infusion by OnQ Pump
1564079|NCT02497911|Procedure|Intraarticular Catheter|0.5% Bupivicaine for primary block and 0.125% Bupivicaine infusion by OnQ Pump
1564080|NCT02497911|Drug|Ropivicaine|
1564081|NCT02497911|Drug|Bupivicaine|
1564082|NCT02497898|Biological|Cytokine-induced killer cells (CIK)|Cytokine-induced killer (CIK) cells are able to eradicate lymphomas and other malignancies. CIK cells are generated by incubation of peripheral blood lymphocytes with an anti-cluster of differentiation 3 (anti-CD3) monoclonal antibody, interleukin-2 (IL-2), interleukin-1 (IL-1) and interferon-gamma.
1564083|NCT02497872|Procedure|Biliary stone removal|Biliary stones are removed from the common bile duct by means of a sphincterotomy performed by standardized endoscopic retrograde cholangiopancreatography
1564084|NCT02497859|Behavioral|Egg Breakfast (EB)|The EB will receive a breakfast of higher quality protein, but similar in macronutrient and energy density than the active comparator. The EB will have the following energy density, macronutrient composition, and protein score: weight 291 g,energy 400 kcal, energy density 1.37 kcal/g, carbohydrate 42.9%, fat 35.5%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 100, leucine 1.77 g, glycemic load 24, fiber 1.0 g.
1564085|NCT02497859|Behavioral|Cereal Breakfast (CB)|The CB will receive a breakfast of lower quality protein, but similar in macronutrient and energy density than the experimental treatment. The CB will have the following energy density, macronutrient composition, and protein score: weight 293 g, energy 398 kcal, energy density 1.3 kcal/g, carbohydrate 44.8%, fat 35.4%, protein 19.8%, protein digestibility corrected amino acid score (PDCAAS) 42, leucine 0.48 g, glycemic load 30.8, fiber 4.4 g.
1564155|NCT02497313|Drug|Metformin|
1564156|NCT02497300|Drug|Spironolactone|
1564157|NCT02497300|Drug|Amiloride|
1564230|NCT02496884|Drug|Placebo|Placebo tablet to match DS-5565 7.5 mg tablet
1564086|NCT02497859|Behavioral|Weight Loss Counseling|Weight loss counseling will be administered by a Registered Dietitian and will utilize information and materials derived from the Evidence Analysis Library (EAL) of the Academy of Nutrition and Dietetics (AND). Topics including portion control, macronutrient distribution, snacking, eating out, cooking and grocery shopping, will be discussed. Self-monitoring, motivational interviewing, goal setting, and problem solving will be the behavioral strategies used during counseling.
1564087|NCT02497859|Behavioral|Weight Loss Diet|Energy intake for study duration will be prescribed at 1,200-1,500 kcals adjusted for each individual's body weight.
1564089|NCT02497833|Dietary Supplement|retinoic acid|During the trial period, the participants are instructed to consume retinoic acid capsules twice daily (30 min after breakfast and supper).The retinoic acid capsules provided a total daily intake of 10 mg of retinoic acid.
1564090|NCT02497833|Other|placebo|During the trial period, the participants are instructed to consume placebo capsules twice daily (30 min after breakfast and supper).The placebo capsules are composed of starch and pigment.
1564091|NCT02497820|Drug|Aspirin|"Aspirin (acetylsalicylic acid) has a marketing approval for use in the EU and is widely available as an over the counter medicine. However it is not being used within its licensed indication and the aspirin (at any dose in this study) will be treated as an investigational medicinal product (IMP).
Tablets will be provided as enteric-coated 100mg or 300mg tablets for oral use. All patients will receive at least some dose of aspirin but blinding to the actual dose will be achieved by the use of 'dummy' tablets using the same excipients as in the active formulation of the aspirin minus the active ingredient.
The aspirin and dummy tablets should be stored at room temperature below 25⁰C in a dry place."
1564092|NCT02497794|Other|chew gum|The patients in the study group,will chew one sugarless gum for 30 minutes in postoperative 3., 5. and 7. hours. The control group will be followed without chew gum. Both patient groups will be mobilized in postoperative 6 hour and 8 hour after the operation, juicy food will be given. It will be introduced to solid foods after bowel movements and gas output occurs. All patients postoperatively 4, 6,8,10., 12., 24 and 48 hours will be examined and bowel sounds will be oscult. Gas evolution is still not, enema will be applied. All patients will note the time of first rumbling of the stomach, first feeling of hunger and the first gas outlet.
1564095|NCT02497768|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (pistachios or Brazils) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
1564098|NCT02497742|Other|Basic metabolic panel|Patients blood is collected in routine fashion for basic blood chemistries
1564099|NCT02497729|Procedure|Written Checklist|Use of a written checklist pre and peri-intubation
1564100|NCT02497729|Procedure|Head of Bed Up|Raising the patient's head of bed to 25 degrees
1564102|NCT02497703|Device|Knee robot|
1564103|NCT02497690|Behavioral|Telemedicine|Half of subjects will undergo six months of ART administered via telehealth. Therapy will be provided in the usual manner, except a computer will be used to facilitate the interaction.
1564104|NCT02497690|Behavioral|In-person ART|Half of subjects will undergo six months of ART administered in person. Therapy will be provided in the usual manner.
1564105|NCT02497677|Behavioral|Circle of Security -Parenting|The COS-P manual and video material has been translated to Danish (Tryghedscirklen - Forældreprogrammet, manual, Lier, 2013). Based on standard video material of parent-infant interactions, parents are trained to see and understand infant attachment behavior and especially to learn about infant miscuing attachment signals. In the current study parents will attend 10 sessions of 1.5 hour duration
1564106|NCT02497677|Behavioral|Care as Usual|CAU are different in the three participating districts and vary in content and duration. All three districts offer (a) group interventions for mothers who experience postnatal depressive symptoms and/or (b) extra counselling home-visits by a health nurse. Number and content of extra home-visits vary in accordance with the families' specific needs, and will rarely exceed 12 extra visits per year.
1564107|NCT02497664|Other|Active Breathing Control|
1564108|NCT02497651|Dietary Supplement|Liquid mixed meal|The subjects will ingest a 400 ml chocolate drink, rich on carbohydrates, fat and lipids. In the following 4 hours, blood samples will be drawn from a PVC for the measurement of plasma glucose, gut- and pancreatic hormones, acetaminophen etc. After the 4 hours, the subjects will be offered an ad libitum meal.
1564109|NCT02497651|Other|Skin Biopsy|All subjects will undergo a skin biopsy procedure. Two small (3 mm) biopsies will be taken from the hip area under local anaesthesia. Standard wound treatment will follow.
1564114|NCT02497625|Behavioral|Positive Therapeutic Alliance|Intervention involving reassurance and information related to the return to daily activities, advice on dealing with the pain and clear explanation of signs and symptoms. The session will take 60 minutes and will be structured to increase the therapeutic alliance and empathy. Patients will be instructed to return in a week for further consultation to clarify doubts.
1564115|NCT02497625|Behavioral|Usual care|Information about low back pain based on Back Book. The therapy will be performed with limited interaction between patient and therapist and the information will be transmitted in a clear and direct way. The limited interaction between patient and therapist in this group will be established at the first session lasting 45-60 minutes. Patients will be instructed to return for a visit after a week to clarify questions.
1564116|NCT02497625|Other|Control group|Patients will not receive intervention in the first month in which they are enrolled. After a year, the treatment offered to the Positive Therapeutic Alliance or Usual Care group will be available for patients who are interested.
1564120|NCT02497599|Drug|Indium-111-DOTA-Girentuximab-IRDye800CW|Indium-111-DOTA-Girentuximab-IRDye800CW tracer injection will be administered 7 days before (partial) nephrectomy
1564121|NCT02497599|Radiation|SPECT/CT|4 or 5 days after tracer injection a SPECT/CT of the abdomen will be acquired.
1564122|NCT02497599|Procedure|Intraoperative dual-modality imaging|7 days after dual-labeled girentuximab injection standard of care surgery will be performed extended with the use of dual-modality imaging.
1564123|NCT02497586|Radiation|Magnetic resonance spectroscopy|Magnetic resonance spectroscopy (MRS) is a type of scan which offers the possibility of assessing tumour function by measuring concentrations of chemicals (metabolites) within the abnormal tissue. It is a well-established technique in imaging brain cancers.
1564124|NCT02497573|Other|Diffuse Weighted MRI|The DW MRI scans will be used to measure ADC and to calculate change in ADC between the 2 scans. Each scan will take approximately 30 minutes. Images will be acquired and analysed as per the separate scanning protocol.
1564125|NCT02497560|Dietary Supplement|proprietary formula|
1564126|NCT02497547|Drug|Oxytocin|
1564127|NCT02497547|Drug|Placebo|
1564128|NCT02497508|Drug|nivolumab|
1564129|NCT02497495|Other|immersion cold water|immersion cold water at different temperatures and exposure times
1564134|NCT02497456|Behavioral|Follow-up counselling|
1564135|NCT02497443|Biological|Autologous mesenchymal stem cells|Autologous bone marrow-derived mesenchymal stem cells, expanded ex vivo and neuroinduced (a portion of the cells). The final autologous cultured MSCs (0.7 -1.4 x 106 cells/kg of weigh) and autologous neuroinduced MSCs (0.04 - 0.1 x 106 cells/kg of weigh) were used for intravenous administration (cultured MSCs) and a subsequent endolumbal injection (neuroinduced MSCs) one week later in the patients in an autologous manner.
1564136|NCT02497404|Drug|5-Azacytidine|"Patients will be given a five day course of subcutaneous 5-azacytidine followed by a reduced intensity conditioning regimen of fludarabine and melphalan with or without total body irriadiation prior to an allogeneic hematopoietic stem cell transplantation from a related or unrelated HLA matched donor. 5-Azacytidine 75 mg/m2 subcutaneously daily at the same time on days -11, -10, -9,
-8 and -7. This will be administered on an outpatient basis if possible."
1564137|NCT02497404|Drug|Fludarabine|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Fluddarabine will be given at 40 mg/m2 intravenously daily at the same time over 30 minutes on days -6,-5,-4,-3.
1564138|NCT02497404|Drug|Melphalan|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Melphalan will be given at 140 mg/m2 IV on day -3.
1564139|NCT02497404|Drug|Alemtuzumab|Conditioning regimen: Hospital admission will usually take place on the first day of the conditioning regimen. Alemtuzumab will be given at 20 mg subcutaneously on days -6, -5, -4, -3, -2 for unrelated donors, and on days -4, -3, -2 for related donors.
1564140|NCT02497391|Drug|Evacetrapib|administered orally
1564144|NCT02497365|Drug|Besifloxacin|
1564145|NCT02497365|Drug|Tobramycin and Cefazolin|Fortified Tobramycin and Cefazolin eye drops
1564146|NCT02497352|Dietary Supplement|flaxseed|
1564147|NCT02497352|Behavioral|lifestyle modification|
1564148|NCT02497339|Behavioral|Mindfulness training|Using mindfulness training (Thinking and Yoga class) to help women smokers in workplaces to quit smoking
1564149|NCT02497326|Drug|Polyfax & Lignocain gel or silvazine cream|olyfax skin ointment plus Lignocain gel will be applied on superficial PTB area and silver sulphadiazine cream on deep PTB in morning and evening after wound wash.
1564150|NCT02497326|Drug|Topical Heparin|"Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval"
1564151|NCT02497326|Drug|Tramadol|IV Analgesic ( Inj. Tramadol 10mg/dose) will only be given to the patients (in both groups) having pain score >4, assessed 3 times a day by Numeric Visual Analogue scale (NVAS).
1564152|NCT02497313|Drug|Isotonic saline|
1564163|NCT02497274|Other|taste assessment and epithelium gustatory smear and biopsy|assessment of taste perceptions and expression of taste receptors before and after bariatric surgery and epithelium gustatory smear and biopsy
1564164|NCT02497261|Procedure|Double-blind placebo-controlled peanut challenge|Children who are avoiding peanut will be gradually introduced to smoothies containing and not containing peanut, to see if they are able to tolerate eating peanut. This challenge does not change a child's ability to tolerate peanut, but will determine which children avoiding peanut are allergic to peanut and which children are not allergic and may begin eating peanut.
1564165|NCT02497248|Procedure|Pulmonary vein ablation|Simultaneous biatrial endocardial electroanatomical mapping by high-density basket catheter (64 pin) and customized body surface mapping (57 electrodes) followed by circumferential pulmonary vein ablation.
1564166|NCT02497235|Drug|TAK-935|TAK-935 oral solution.
1564167|NCT02497235|Drug|[18F]MNI-792 (tracer)|[18F]MNI-792 injection.
1564168|NCT02497222|Drug|RNS60|
1564169|NCT02497222|Drug|Normal Saline|
1564170|NCT02497196|Device|Active tPCS|A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will be used with a peri-aurical ear-clip electrode montage for 20 minutes.
1564171|NCT02497196|Device|Active tDCS|A current intensity of 2.0 mA will be used for 20 minutes. The electrodes that will be used will be standard sponge electrodes. The anode will be placed over left motor cortex. The cathode electrode will be placed over the contralateral supraorbitofrontal area.
1564172|NCT02497196|Device|Sham tPCS|Sham tPCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2mA and a stimulation frequency range of 6-10 Hz will still be used (only this will be turned off after 30 seconds using ramping) with a peri-aurical ear-clip electrode montage.
1564173|NCT02497196|Device|Sham tDCS|Sham tDCS stimulation will consist of applying the same parameters as for active, but the corresponding device will be turned off after 30 seconds, as to simulate the initial sensation of the active current. A current intensity of 2.0 mA will still be used (but turned off after 30 seconds using ramping). The electrodes that will be used will be same, standard sponge electrodes. The anode will be placed over the left motor cortex The cathode electrode will be placed over the contralateral supraorbitofrontal area.
1564174|NCT02497183|Device|ultrasound|A repeat ultrasound exam following oral contrast material consumption
1564175|NCT02497183|Other|iodine based solution of oral contrast material|A solution of oral contrast material that is routinely used in our institution prior to performing a computed tomographic (CT) examinations of the gastrointestinal tract will be given prior to performing the repeat ultrasound/
1564176|NCT02497170|Behavioral|Education of goal setting and achievement|Education of American Association of Diabetes Educations 7 behavioral goals and how to achieve them
1564177|NCT02497157|Drug|Oxaliplatin (L-OHP)|
1564178|NCT02497157|Drug|Irinotecan hydrochloride hydrate (CPT-11)|
1564179|NCT02497157|Drug|Continuous intravenous infusion of fluorouracil (CIV 5-FU)|
1564180|NCT02497157|Drug|Levofolinate calcium (l-LV)|
1564181|NCT02497157|Drug|Bevacizumab (Bmab)|
1564182|NCT02497144|Other|NMES Group|Neuromuscular electrical stimulation
1564183|NCT02497144|Other|Control Group|Breathing exercises
1564184|NCT02497131|Drug|Brentuximab Vedotin|Brentuximab vedotin will be administered on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg and is administered by outpatient IV infusion given over approximately 30 minutes
1564185|NCT02497118|Drug|Endostatin|Endostatin,7.5mg/m^2,intravenous, d1-14;
1564186|NCT02497118|Drug|Vinorelbine|vinorelbine,25mg/m^2,intravenous, d1, d8;
1564187|NCT02497118|Drug|Cisplatin|Cisplatin，75mg/m^2 intravenous,divide into d1-3
1564188|NCT02497105|Other|Ketogenic Diet|Dietary
1564189|NCT02497092|Other|Technique of injection|
1564224|NCT02496910|Drug|Telmisartan/Amlodipine 80/5 mg (FDC)|
1564225|NCT02496910|Drug|Chlorthalidone 25mg|
1564226|NCT02496897|Biological|FP-02.2 Vaccine|Synthetic Peptide Hepatitis B Vaccine
1564227|NCT02496897|Other|Placebo|Placebo
1564228|NCT02496897|Other|IC31® Adjuvant|IC31® Adjuvant
1564190|NCT02497079|Device|Nested PCR for formalin-fixed tissues|For nested PCR, formalin-fixed paraffin-embedded tissues were incubated in 1 mL of xylene at 60°C for 30 min and then centrifuged for 10 min. Paraffin and the supernatant were removed from the samples after centrifugation. The same procedures were repeated until deparaffinization was complete. After adding 1 mL of alcohol, the samples were centrifuged for 5 min, and the supernatant was removed. The sample was then air-dried as a pellet. DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
1564191|NCT02497079|Device|Nested PCR for fresh tissues|For nested PCR with specimens in sterile saline, DNA was extracted using QIAamp (Qiagen, Valencia, CA, USA). PCR amplifications were performed using Mycobacterium tuberculosis IS6110 primers. The first round using outer primers and the second round using inner primers amplified a 256- and 181-bp fragment, respectively. Finally, the PCR products were visualized in a 2% agarose gel.
1564192|NCT02497079|Device|Real-time PCR for fresh tissues|For real-time PCR, specimens in sterile saline were filtered and 1 mL of phosphate based saline was added. After centrifugation for 3 min, the supernatant was removed. Next, 50 μL of extraction buffer was added to the sample, and the sample was heated at 100°C for 20 min. After centrifugation for 3 min, the supernatant was used in PCR. Real-time PCR was performed using the AdvanSure TB/NTM real-time PCR kit. Three channels were used in the real-time PCR reaction (Mycobacterium tuberculosis complex, mycobacteria, and internal control). Signals for FAM, HEX, and Cy5 were measured in each channel. Mycobacterium tuberculosis was considered present if the cycle threshold of rpoB was less than 35 on each signal and greater than or equivalent to that of IS6110.
1564193|NCT02497066|Other|Neuropathic pain cream|Subjects will apply the cream to the painful area.
1564194|NCT02497066|Other|Nociceptive pain cream|Subjects will apply the cream to the painful area.
1564195|NCT02497066|Other|Mixed pain cream|Subjects will apply the cream to the painful area.
1564196|NCT02497053|Drug|pemetrexed/platinum chemotherapy|Four cycles of pemetrexed/platinum chemotherapy
1564197|NCT02497053|Drug|Pemetrexed/platinum chemotherapy|Six cycles of pemetrexed/platinum chemotherapy
1564201|NCT02497027|Other|pharmacogenetic testing|pharmacogenetic testing report released to physician at 4 weeks post enrollment
1564202|NCT02497027|Other|pharmacogenetic testing|pharmacogenetic testing report released to physician at 12 weeks post enrollment
1564203|NCT02497014|Device|1 Stent|Stenting of main vessel should be undertaken with a wire jailed in the side vessel to preserve side vessel flow and access. Stent diameter should be chosen according to diameter of the main vessel immediately distal to the bifurcation. Distal left main should be dilated with a short non-compliant balloon. Side vessel should be rewired and a kissing balloon inflation should be undertaken. Balloon sizes should be according to the diameter of the main and side vessel with individual high pressure inflation followed by a final lower pressure kiss dilatation. Proximal stented portion in the left main coronary artery should be dilated to full expansion using either low pressure dilatation of the kissing balloon pair or a separate individual balloon. It is preferred that non-compliant balloons should be used to limit overstretching of vessels. In case of specific situations described in the protocol the operator may choose to implant a side vessel stent, using same process as described above.
1564204|NCT02497014|Device|2 Stents|"Coronary guide wires should be passed to LAD and Cx/intermediate arteries respectively. One should be designated the main vessel and one should be designated the side vessel. The planned dual stent technique is at the discretion of the operator but should be one of culotte, minicrush, T or TAP. If a crush procedure is chosen, it should ideally be of the DK variety. Stent diameter should be chosen according to the diameter of the vessel immediately distal to the bifurcation. Wire jail, POT, non-compliant balloons, high pressure individual ostial dilatations and final dilatation of the stented proximal left main should be used in accordance with the advice of the EBC. Further treatment to proximal or distal aspects of the main vessel or side vessel can be continued at the discretion of the operator. At any stage, proximal or distal dissections may be treated as required with further stent implantations. At any stage, post-dilatations may be undertaken to optimise stent expansion."
1564205|NCT02497001|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol (PT010, BGF metered dose inhaler [MDI])
1564206|NCT02497001|Drug|GFF MDI (PT003) 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol (PT003, GFF MDI)
1564207|NCT02497001|Drug|BFF MDI (PT009) 320/9.6 μg|Budesonide and Formoterol Fumarate Inhalation Aerosol (PT009, BFF MDI)
1564208|NCT02497001|Drug|Symbicort® Turbuhaler® (TBH) Inhalation Powder|
1564209|NCT02496988|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
1564210|NCT02496988|Biological|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
1564213|NCT02496962|Drug|Atorvastatin|atorvastatin were taken daily for 5 days
1564214|NCT02496962|Drug|placebo|placebo were taken daily for 5 days
1564215|NCT02496949|Drug|Icaritin|600mg,800mg two doses, Bid, continuous dosing for 56 days, to assess the safety,tolerance,pharmacokinetics and efficacy of icaritin
1564216|NCT02496936|Other|SFA|High saturated fatty acid/SFA oil source
1564217|NCT02496936|Other|MUFA|High monounsaturated fatty acid/MUFA oil source
1564218|NCT02496936|Other|PUFA-LA|High polyunsaturated fatty acid (linoleic)/PUFA-LA oil source
1564219|NCT02496936|Other|ALA|High polyunsaturated fatty acid (alpha-linolenic)/ALA oil source
1564220|NCT02496936|Other|LCn3|High polyunsaturated fatty acid (omega-3)/LCn3 oil source
1564221|NCT02496923|Device|High flow nasal oxygen therapy (Optiflow™)|
1564222|NCT02496923|Device|Standard oxygen therapy (Hudson Type face mask or nasal prongs)|
1564223|NCT02496910|Drug|YH22162|
1564335|NCT02496065|Drug|BLZ-100|
1564231|NCT02496871|Behavioral|Group Phone Calls|University of Kansas Weight Management Program - Group Phone calls
1564232|NCT02496871|Behavioral|Social Media|University of Kansas Weight Management Program - Social Media (Facebook)
1564233|NCT02496845|Drug|VL#FIA3-30|Vasoactive dual treatment (MH30-01 & IS045-01)
1564234|NCT02496832|Drug|18F-Fluoroazomycin arabinoside|
1564235|NCT02496819|Other|Meta-cognitive self-regulated learning intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
1564236|NCT02496819|Other|Sensory integration intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
1564237|NCT02496819|Other|Activity-based intervention|It is a 12-week intervention programme with one 60 minutes sessions per week.
1564238|NCT02496806|Dietary Supplement|Seaweed extract|Treatment capsule containing seaweed extract (treatment)
1564239|NCT02496793|Behavioral|Peer-facilitated community support group|Support groups were composed of up to 20 women from community. Peer facilitator facilitated a total of 6 groups of a maximum of 20 women each. Women were exposed to 8 two hour sessions. Facilitators gave activities in support of MCH/PMTCT. Group met twice a month for four months. The support group meetings took place in the community at a convenient location for those attending (e.g. village meeting point, churches, schools or individual households). With local support through community leaders, the intervention involved trained peer facilitators working with pregnant and post-partum women to form ANC and PNC support groups through which they will present information on general maternal and child health and PMTCT specific topics using participatory learning and problem-solving approaches.
1564240|NCT02496780|Drug|novolog insulin|3x daily rapid-acting insulin
1564241|NCT02496780|Drug|levemir insulin|basal insulin once a day
1564242|NCT02496780|Drug|placebo|once or 3x daily
1564243|NCT02496767|Drug|tirasemtiv|
1564244|NCT02496767|Drug|Placebo tablets|
1564245|NCT02496754|Drug|GnRH-a|In experimental group, patients use long term GnRH-a;
1564246|NCT02496754|Drug|GnRH-a|In control group, patients use short term GnRH-a.
1564247|NCT02496741|Drug|Metformin and chloroquine combination|Metformin and chloroquine are two oral medications. Metformin is to be taken twice daily, chloroquine once daily.
1564248|NCT02496728|Behavioral|Mobile Health Application|An application on a smart phone that is designed to help individuals self-monitor health behaviors.
1564249|NCT02496728|Behavioral|Environmental Cues|Text messages, informational posts and reminders supporting healthy behaviors.
1564250|NCT02496728|Behavioral|Social Support|Participants may interact with each other through Facebook and Instagram.
1564251|NCT02496728|Behavioral|Educational Materials|Educational materials regarding healthy behaviors.
1564252|NCT02496715|Drug|Fluticasone propionate 100 mcg / salmeterol 50 mcg|Brand inhaler containing pMDI containing fluticasone and salmeterol
1564253|NCT02496715|Drug|Generic fluticasone propionate 100 mcg / salmeterol 50 mcg|Generic inhaler containing pMDI containing fluticasone and salmeterol
1564254|NCT02496715|Drug|Placebo|Placebo inhaler
1564260|NCT02496663|Other|Laboratory Biomarker Analysis|Correlative studies
1564261|NCT02496663|Biological|Necitumumab|Given IV
1564262|NCT02496663|Drug|Osimertinib|Given PO
1564263|NCT02496663|Other|Pharmacological Study|Correlative studies
1564265|NCT02496637|Behavioral|Appetite Awareness|Appetite Awareness Training (AAT) is an approach to increasing eating regulation through training individuals to eat in response to their appetite cues rather than external or emotional cues
1564266|NCT02496637|Behavioral|Nutrition Education|Nutrition education provides information about energy balance, dietary guidelines, portion and serving sizes, and other general dietary information.
1564267|NCT02496624|Other|Cone Beam CT localization and placement of microcoil|Cone Beam CT localization and placement of microcoil
1564268|NCT02496611|Drug|Exenatide extended-release for injectable suspension (BYDUREON™)|
1564269|NCT02496611|Dietary Supplement|Meal Replacement Therapy|A short-term meal replacement induction period designed to achieve >5% BMI reduction in 1, 2, or 3 months.
1564330|NCT02496117|Procedure|Electrial mapping, nerve stimulation guided renal denervation procedure|
1564270|NCT02496598|Procedure|In Vitro Follicle Activation (IVA)|Laparoscopic removal of ovarian tissue, followed by in vitro activation of dormant ovarian follicles and autografting back to the patient for follicle growth and egg retrieval.
1564271|NCT02496598|Drug|Follicle Activation|Ovarian cortical pieces will be treated in vitro with a PTEN activator (bpV(hopic)) and a PI3K inhibitor (740YP) in vitro to activate primordial ovarian follicles, prior to autografting.
1564272|NCT02496585|Drug|Nintedanib|
1564273|NCT02496585|Drug|Prednisone|
1564274|NCT02496585|Other|Placebo|
1564275|NCT02496572|Drug|Short course MDR-TB treatment regimen|"Intensive phase:
Pyrazinamide (Z) + Ethambutol (E) + Isoniazid (H) + Moxifloxacin (Mfx) + Capreomycin (Cm) + Prothionamide (Pto) + Clofazimine (Cfz) for at least 4 months and until one negative culture is documented with a maximum of 6 months duration.
Continuation phase:
Continuation phase of Pyrazinamide (Z) + Ethambutol (E) + Moxifloxacin (Mfx) + Prothionamide (Pto) + Clofazimine (Cfz) for fixed 5 months duration."
1564276|NCT02496559|Procedure|Pre-consultation CRP|Use of CRP test on all children with fever before the consultation (intervention) compared to where the doctor requests a CRP test (no intervention)
1564277|NCT02496546|Drug|LEO 32731 cream|Applied for 3 weeks
1564278|NCT02496546|Drug|LEO 32731 cream vehicle|Applied for 3 weeks
1564279|NCT02496533|Procedure|Hand Massage|The hand massage procedure comprises 4 minutes of manipulation of the subject's hands (2 minutes per hand) by a skilled massage therapist or appropriately trained staff.
1564284|NCT02496507|Other|Sit-stand workstation|After baseline, each participant had a sit-stand workstation installed on their existing workplace desk. A single or dual monitor WorkFit-A with Worksurface+ workstation was installed, dependent on the number of monitors. The monitor(s) and keyboard were housed on the workstation and the workstation could be quickly raised up and down by hand to enable seated or standing work. Participants were not prescribed an amount of time to use the station. Ergotron Ltd provided and installed the workstations and gave participants basic face-to-face training and ergonomic information on correct use. Participants received a web link to manufacturer ergonomic guidelines via an email from the research team. After end-intervention data collection, manufacturer staff uninstalled the workstations.
1564285|NCT02496494|Drug|Tacrolimus|Tacrolimus for maintenance immunosupression in kidney transplant recipients
1564286|NCT02496481|Behavioral|Motivational Interviewing|Motivational interviewing (MI) in the ED has been used to encourage a variety of health behaviors among at-risk patients. In this study, researchers will employ motivational interviewing with half of the study participants to investigate the effects of the technique on child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
1564287|NCT02496481|Behavioral|Tailored brochure|Tailored Print materials will be mailed to half of participants to investigate the effects of using patient-centered educational materials compared with generic educational materials to influence child passenger restraint behaviors in a population of parents of children birth to 10 years of age.
1564288|NCT02496455|Procedure|cesarean section|Women in 36 to 40 weeks of pregnancy undergoing cesarean section by Pfannenstiel technique
1564289|NCT02496455|Drug|Opioid Tramadol|Tramadol will be administered via patient controlled analgesia (PCA) pump in the postoperative period
1564290|NCT02496442|Device|Aqueduct|Using Aqueduct in procedures to continuously supply the irrigation solutions
1564291|NCT02496429|Device|BrownieForSymphony use|Professional will use the BrownieForSymphony Pumpset in their daily work. hospitalized lactating woman will pump with the BrownieForSymphony Pumpset
1564292|NCT02496416|Behavioral|Aquatic Exercise Program|The aquatic exercise program will consist of 45 minute classes held 3 days/week for 8 weeks (18 hours total). The program is based on guidelines provided by the National Multiple Sclerosis Society (NMSS) and will be led by an aquatic fitness instructor certified to teach individuals with MS at the YMCA in Scotch Plains-Fanwood. The exercises will focus on improving flexibility, balance and strength. Equipment such as water mitts, paddles, noodles and bands will be used to increase the level of difficulty as needed.
1564293|NCT02496403|Behavioral|Standard Medical Management (SMM)|SMM is designed to provide basic advice about opioid dependence and encouragement to adhere to treatment recommendations. Sessions provide support and monitoring of medication compliance, dose, withdrawal, adverse effects, and discussion of medical complications of opioid and other drug use. Early in treatment, the focus will be on helping patients adjust to the medications (e.g., monitoring withdrawal or other adverse symptoms, tolerating discomfort, curtailing illicit drug use, and referral to self-help). As treatment progresses, the practitioner may focus more on educating the patient about the social and behavioral factors perpetuating addiction and encourage behavioral and lifestyle change to support recovery.
1564294|NCT02496390|Biological|Autologous|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from the patient prior to colonic preparation.
1564295|NCT02496390|Biological|Allogeneic|Patients will have their normal microbiome reduced using an oral preparation (pico-salax) as used for routine colonic preparation for colonoscopy. • Administration of the FMT will be via a nasoduodenal tube inserted at the time of gastroscopy. Dosage - approx 100ml previously frozen fecal sample obtained from a lean donor prior to colonic preparation.
1564296|NCT02496377|Drug|ferrous glycine sulfate Tardyferon|
1564297|NCT02496377|Drug|Epoetin Alfa|
1564298|NCT02496377|Drug|ferric carboxymaltose Ferinject|
1564299|NCT02496364|Drug|Placebo (Topical)|Saline Solution 0,9% in situ, up to 100ml;
1564300|NCT02496364|Drug|Placebo (Intravenous)|Saline Solution 0,9% in the vein, up to 500ml: 200ml as loading dose over 15 minutes followed by 1ml/Kg/hr throughout the surgery, in a maximum volume of 300ml
1564301|NCT02496364|Drug|Tranexamic Acid (Topical)|30mg/ml of tranexamic acid in situ during surgery, up to 100ml
1564331|NCT02496104|Behavioral|Package n°1 of the APIB|
1564332|NCT02496091|Device|ATLANTIS Abutment|
1564302|NCT02496364|Drug|Tranexamic Acid (Intravenous)|5mg/ml of tranexamic acid in the vein, up to 500ml: 200ml (5mg/ml) as loading dose over 15 minutes followed by 1ml/Kg/hr (5mg/ml) throughout the surgery, in a maximum volume of 300ml.
1564303|NCT02496351|Device|TENS INTERVENTION|24 hours of TENS treatment in the immediately postoperative of limb amputation
1564304|NCT02496338|Other|Training program about menopausal health isues|A three sessions raining program about health issues during menopause for spouses of 45-60 years old
1564305|NCT02496325|Procedure|Ultrasound guided transperineal pudendal nerve block|Children under general anesthesia were positioned supine, flexed legs and balls of the feet joined. A 12 MegaHertz (MHz) (38 mm) ultrasound probe was positioned on a horizontal axis passing through the ischial tuberosity, previously palpated.The probe was then moved medially on the axis, until the rectum appeared. Pudendal artery was identified if possible, using colour Doppler. The needle (22 Ga, 50 mm) was then introduced at the middle of the superior edge of the probe, in an out-of-plane approach. Tip of the needle was identified by direct vision, through displacement of adjacent anatomical structures or with saline injection. Nerve stimulation was started after placement of the tip of needle in the ischiorectal fossa, before local anaesthetic injection. After a negative aspiration test, a mix of Ropivacaine 2 % and clonidine 0.2µg/kg was injected in the ischiorectal fossa under ultrasound guidance.
1564306|NCT02496312|Behavioral|Evaluation of Apathy Close to Real Life Situation|Quantitative Evaluation of Apathy Close to Real Life Situation by Means of a Multimodal Sensor System Integrated.
1564307|NCT02496299|Drug|Dexamethasone|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
1564308|NCT02496299|Drug|Bupivacaine|Comparison of analgesic effects of dexamethasone with plain bupivacaine during caudal blocks in children
1564309|NCT02496286|Drug|Intraperitoneal Bevacizumab|Bevacizumab 200mg diluted in 250 ml of normal saline
1564310|NCT02496273|Biological|CTL|Mononuclear cells (Dendritic Cell,DC precursor) were isolated from the peripheral blood of gasric cancer by density gradient centrifugation and infected with rAAV/CEA virus.Maturation of the DC was induced by granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-4 (IL-4) and tumor necrosis factor-alpha(TNF-alpha). On day 7, the DCs were collected and mixed with T cells at the ratio of 1 to 20 to induce cytotoxic T lymphocytes (CTL).The cells will be proliferated and infused by intravenous (IV) infusion into the patient.
1564311|NCT02496260|Procedure|Research Cardiac MRI|Cardiac MRI has increased use in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their physician. Treatment will not be altered based on MRI.
1564312|NCT02496260|Procedure|Biomarkers|"We have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.
All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their physician. Treatment will not be altered based upon the data collected from these samples."
1564313|NCT02496247|Other|Canned Herring|Families with children in this study arm will receive a weekly ration of herring throughout the 8-10 week study period (2 cans herring/day per study child).
1564314|NCT02496221|Drug|Albiglutide 50 mg|Albiglutide 50 mg pen is a single-use fixed dose, fully disposable pen injector system for SC delivery in the abdomen containing 67 mg lyophilized albiglutide and 0.65 mL diluents designed to deliver a dose of 50 mg in a volume of 0.5 mL after reconstitution
1564315|NCT02496221|Drug|Placebo|Placebo is a single-use fixed dose, fully disposable pen injector system for SC delivery of 0.5 mL injector volume in the abdomen
1564316|NCT02496221|Drug|CCK (Kinevac)|CCK (Kinevac) will be infused intravenously. Kinevac is supplied in vials containing 5 microgram (mcg)/vial. Infusion prepared aseptically by adding 5 mL of Sterile Water for Injection United States Pharmacopeia (USP) to the vial to create a solution of 1 mcg/mL. Infuse 0.003 mcg/kg dose in 100 mL of Sodium Chloride Injection USP, 0.9%
1564321|NCT02496182|Drug|Placebo|Placebo tablet only with the excipients of the Pirfenidone tablet
1564322|NCT02496182|Drug|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1800 mg
1564323|NCT02496182|Drug|Pirfenidone|Conventional Treatment (Prednisone+Azathioprine) plus Pirfenidone 1200 mg
1564324|NCT02496169|Device|eucaLimus|Percutaneous Coronary Intervention (PCI)
1564325|NCT02496156|Behavioral|Usual Clinical Practice|Diabetes management and education related to insulin pump or continuous glucose monitor as currently practiced at the enrolling site.
1564326|NCT02496156|Behavioral|Shared Medical Decision Making|Access to and use of multimedia decision aid websites to facilitate adolescent and parent decision making about incorporating these devices into the diabetes management regimen.
1564329|NCT02496117|Procedure|Electrical mapping, nerve stimulation checked renal denervation procedure|
1990716|NCT01858532|Drug|Atrasentan|Oral daily low dose for 48 months.
1990717|NCT01858532|Drug|Placebo|Oral daily dosing for 48 months.
1990718|NCT01857869|Biological|Malaria vaccine 257049_0,1,7M|RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
1564336|NCT02496052|Procedure|dried biological amnion graft|Uterine application of amnion membrane following hysteroscopic adhesiolysis. Other Name: Human amnion membrane
1564337|NCT02496052|Device|Foley balloon|Device: Foley balloon Uterine application of Foley balloon
1564338|NCT02496052|Drug|estradiol valerate tablets+dydrogesterone Tablets|oral estradiol valerate tablets+dydrogesterone Tablets
1564339|NCT02496039|Drug|NUEDEXTA®|NUEDEXTA® only
1564340|NCT02496026|Device|tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched on
1564341|NCT02496026|Device|Sham tDCS plus wrist robot therapy|Patients receive robotic rehabilitation session while tDCS stimulator is switched off.
1564342|NCT02496013|Drug|68Ga-NEB|68Ga-NEB were injected into the patients before the PET/CT scans
1564343|NCT02496000|Drug|ORMD-0801|Oral Insulin
1564344|NCT02496000|Drug|Placebo Comparator|Placebo
1564345|NCT02495974|Drug|enzalutamide|oral
1564346|NCT02495948|Device|Lotrafilcon B contact lenses|
1564347|NCT02495948|Device|Samfilcon A contact lenses|
1564348|NCT02495948|Device|Hydrogen peroxide solution|Used as a cleaning, disinfection, and storage solution for silicone hydrogel and soft contact lenses
1564349|NCT02495948|Device|Saline solution|Used for rinsing contact lenses, as needed
1564350|NCT02495012|Drug|placebo|Freeze-dried powder without snake venom will be dissovled in saline
1564351|NCT02495012|Drug|Anfibatide|Freeze-dried powder with snake venom will be dissovled in saline
1564354|NCT02494986|Drug|Rilpivirine|Participants will continue to receive oral tablets of rilpivirine (RPV) 25 milligram once daily (mg qd) or oral granules for weight adjusted RPV dose, as applicable, in combination with an investigator selected background regimen consisting of 2 nucleoside/nucleotide reverse transcriptase inhibitors (N[t]RTIs).
1564355|NCT02494973|Drug|Oxaliplatin HAI|Oxaliplatin 85 mg/m² in 2 hours HAI day (D)1,
1564356|NCT02494973|Drug|Oxaliplatin IV|Oxaliplatin 85 mg/m² in 2 hours IV day (D)1,
1564357|NCT02494973|Drug|mFOLFOX6|Acide folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg/m² IV in 46 hours.
1564358|NCT02494973|Drug|LV5FU2|Acide Folinique 400 mg/m² in 2 hours IV (concomitantly to oxaliplatin) D1, followed by 5FU bolus 400 mg/m² in 5-10 minutes IV D1 followed by 5FU 2400 mg / m² IV in 46 hours.
1564359|NCT02494960|Behavioral|The brief smoking cessation AWARD model|"Ask whether or not the patient currently smokes
Warn the patients that at least one out of two smokers will be killed by smoking. Recent research shows that two out of three smokers will be killed by smoking. The 10-20-second script could be like 'I warn you that smoking can kill you by many serious diseases and that your chance to be killed prematurely by smoking is about 50% to 67%.
Advice the patients to quit now or as soon as possible because quitting can reduce the excess risks substantially.
Refer the patients to a smoking cessation clinic or call telephone quitlines (if available) as soon as possible, emphasizing that smoking cessation counsellors are caring and helpful.
Do it again: Repeat the intervention among smokers who fail to quit or relapse, and encourage them to try to quit again."
1564360|NCT02494960|Behavioral|Placebo intervention|Advice the smokers to eat vegetables, and engage in regular physical activities, and offer the smokers a card which contains information about the benefits of eating vegetables and a pictorial information leaflet which shows the recommended amount of vegetables and fruits an adult should eat a day
1564361|NCT02494947|Behavioral|high intensity interval-based aerobic exercise|Interval exercises done 3 times weekly during 6 months according to standard procedures at the Department of Circulation and Medical Imaging.
1564362|NCT02494947|Other|Usual care|
1564363|NCT02494934|Behavioral|cognitive-behavioural therapy|The CBT program was adapted from a previously used group CBT program and included the following procedures: (1) education about PVD; (2) collaborative re-conceptualization of PVD as a multi-factorial pain condition; (3) desensitization exercises; (4) diaphragmatic breathing and other relaxation techniques; (5) discussion about and techniques for increasing sexual desire and arousal; (6) sexual communication skills training; (7) instructions on carrying out PFM exercises; (8) instructions on the use of silicone vaginal dilators to do progressive vaginal penetration activities at home; and (9) informal and formal cognitive restructuring techniques and the use of coping self-statements.
1564364|NCT02494934|Behavioral|physical therapy|The PT treatment protocol included the following procedures: (1) education about PVD; (2) targeted PFM exercises focused on contraction and relaxation including in-session practice and feedback; (3) manual techniques; (4) surface electromyographic biofeedback (sEMG); (5) progressive vaginal penetration activities through the use of four silicone vaginal dilators of varied diameter; (6) stretches of the hip muscles; (7) deep breathing and global body relaxation exercises; and (8) additional methods of managing pain and counseling about different sexual positions.
1564365|NCT02494921|Drug|Docetaxel|
1564366|NCT02494921|Drug|Ribociclib|
1564367|NCT02494921|Drug|Prednisone|
1564368|NCT02494921|Drug|Filgrastim|
1564369|NCT02494908|Behavioral|Playing a computer game simulating a car race|Playing a computer game simulating a car race
1564370|NCT02494895|Drug|Ticagrelor monotherapy|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to stop aspirin at 3 months after PCI.
1564371|NCT02494895|Drug|Ticagrelor with Aspirin DAPT(dual antiplatelet treatment)|Ticagrelor (Brilinta®) is indicated for the prevention of thrombotic events (for example stroke or heart attack) in people with acute coronary syndrome or myocardial infarction with ST elevation. Patients will be randomized to continue DAPT (aspirin+ticagrelor) up to 1 year.
1564372|NCT02494882|Drug|Ruxolitinib|
1564373|NCT02494882|Drug|Dasatinib|
1564374|NCT02494882|Drug|Dexamethasone|
1564379|NCT02494856|Drug|Surgery with Naproxen|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg was study.
1564380|NCT02494856|Drug|Surgery with Naproxen and Esomeprazole|After lower third molars surgeries, clinical efficacy of the Naproxen 500mg and Esomeprazole 20mg was study.
1564385|NCT02495896|Drug|Cisplatin|Given IV
1564386|NCT02495896|Drug|Docetaxel|Given IV
1564387|NCT02495896|Drug|Gemcitabine Hydrochloride|Given IV
1564388|NCT02495896|Other|Laboratory Biomarker Analysis|Correlative studies
1564389|NCT02495896|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1564390|NCT02495896|Other|Pharmacological Study|Correlative studies
1564391|NCT02495896|Biological|Recombinant EphB4-HSA Fusion Protein|Given IV
1564392|NCT02495883|Other|Ethanol|50ml of 40% Ethanol
1564393|NCT02495883|Drug|Propranolol|Beta blocker
1564394|NCT02495870|Other|Pork|
1564395|NCT02495857|Device|Hyaluronate Injectable Viscosupplement|Test product of a 1% sodium hyaluronate for injection
1564396|NCT02495857|Device|Euflexxa IA injection|Brand product of a 1% sodium hyaluronate for injection
1564397|NCT02495857|Device|Placebo|0.9% sodium chloride, sterile
1564398|NCT02495844|Drug|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 200 mg Route of Administration: Oral use
1564399|NCT02495844|Drug|UCB0942|Active substance: UCB0942 Pharmaceutical form: Film-coated tablet Concentration: 100 mg Route of Administration: Oral use
1564400|NCT02495844|Drug|Placebo|Pharmaceutical form: Film-coated tablet Route of administration: Oral use
1564401|NCT02495831|Drug|Diclofenac sodium|Diclofenac sodium 50 mg single dose
1564402|NCT02495831|Drug|Diclofenac sodium and safinamide|Diclofenac 50 mg single dose and safinamide 200 mg single dose
1564403|NCT02495818|Procedure|Lidocaine|Suprascapular Nerve Block Guided by Ultrasound with 5ml lidocaine at 2%.
1564404|NCT02495818|Procedure|Saline solution|Suprascapular Nerve Block Guided by Ultrasound with 5ml saline solution
1564405|NCT02495818|Other|Homemade exercises|Codman and Hughston exercises.
1564406|NCT02495805|Procedure|Continuous proximal adductor canal block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
1564407|NCT02495805|Procedure|Continuous femoral nerve block|Subjects will be randomized into 2 groups: those who will receive a continuous proximal adductor canal block (ACB) and those who will receive a continuous femoral nerve block (FNB).
1564409|NCT02495779|Drug|emtricitabine/tenofovir|Short-term episodic use for 2-3 weeks.
1564410|NCT02495779|Behavioral|CBT-based counseling|Brief CBT-based counseling to promote adherence
1564411|NCT02495766|Drug|XCEL-MC-ALPHA|Single infusion
1564412|NCT02495766|Drug|Placebo|Single infusion
1564413|NCT02495753|Procedure|Vaginal Cleansing|The vagina will be prepped in two passes with sponge sticks soaked in 1% povidone-iodine solution from a prepackaged sterile pouch.
1564414|NCT02495753|Procedure|Abdominal Cleansing|The abdomen will be cleansed using chlorhexidine or betadine according to surgeon's preference prior to cesarean.
1564415|NCT02495740|Behavioral|Commuting to work|Commuting by an electric assisted bike to work for a period of 4 weeks at least 3 times per week
1564416|NCT02495727|Behavioral|Step-reduction|Participants will reduce the number of steps they take each day to less than 1, 500 for two weeks, using a pedometer to monitor their daily step count.
1564417|NCT02495727|Behavioral|Pre-training|Participants will attend 10 strength training exercise sessions over a four week period prior to the step-reduction intervention. These exercise sessions will be focused on lower limb strength, fully supervised and will be progressive.
1564418|NCT02495727|Behavioral|Exercise snacking|Participants will perform three bouts of five minutes of exercise each day during the two week step-reduction intervention. These will consist of five discrete exercises, each performed continuously for one minute, with one minute of rest between each exercise. These exercises will be non-supervised, and require no specialist equipment.
1564419|NCT02495714|Behavioral|Active learning|Physical activity one hour a day as part of academic learning
1564420|NCT02495714|Behavioral|Dietary councelling|Teaching children and parents about a healthy diet
1564421|NCT02495701|Procedure|Hip arthroscopic surgery|Hip arthroscopic surgery
1564422|NCT02495688|Procedure|Regional anesthesia|Standard supraclavicular brachial plexus nerve block. Ultrasound-assisted. By an anesthesiologist. A mix of short- and medium lasting local anesthetics will be used.
1564423|NCT02495688|Procedure|General anesthesia|Standard procedure.
1564424|NCT02495675|Device|High flow nasal cannulas|Comparison of different flow levels
1564425|NCT02495675|Device|Conventional flow via nasal prongs|Low flow of air delivered through conventional nasal prongs
1564426|NCT02495662|Drug|PEG-liposomal prednisolone sodium phosphate|Liposomal prednisolone
1564427|NCT02495662|Drug|Placebo|0.9% normal saline
1564428|NCT02495649|Other|[18F]-DOPA|To evaluate the feasibility of PET-CT with [18F]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
1564429|NCT02495649|Device|PET-CT|To evaluate the feasibility of PET-CT with [18F]-DOPA to assess the myocardial sympathetic denervation in patients with or suspected with Parkinson's disease
1564430|NCT02495636|Drug|CDX-1401|CDX-1401 1mg will be administered intracutaneously every 2 weeks for 4 doses (priming), followed by every 12 week dosing (booster)
1564431|NCT02495636|Drug|MPDL3280A|MPDL3280A 1200 mg will be administered intravenously every 3 weeks.
1564432|NCT02495623|Drug|SYN-010 21 mg|
1564433|NCT02495623|Drug|SYN-010 42 mg|
1564434|NCT02495623|Drug|Placebo|
1564436|NCT02495597|Other|no intervention - just observational|
1564437|NCT02495584|Dietary Supplement|Fortified milk (10µg vitamin D3)|
1564438|NCT02495584|Dietary Supplement|Unfortified milk (placebo)|
1564439|NCT02495584|Dietary Supplement|10µg vitamin D3 supplement|
1564440|NCT02495584|Dietary Supplement|Placebo supplement|
1564441|NCT02495571|Other|Cough Assessment in ALS Patients|"Volitional Cough assessment by spirometer:
a) Peak Cough Espiratory Flow (PCEF)
Cough Reflex Test a) Peak Cough Espiratory Flow (PCEF)"
1564442|NCT02495558|Other|Reflex Cough Test|Peak of Cough Expiratory Flow of the reflex cough
1564443|NCT02495545|Procedure|CSFD and elevation of MAP|Lumbar drain placement with CSFD with elevation of MAP
1564444|NCT02495545|Procedure|Maintenance of MAP|Lumbar drain placement without CSFD and with maintenance of MAP
1564445|NCT02495532|Other|Lymph node clearing technique with Carnoy solution|"Procedure: lymph node clearing technique with Carnoy solution
(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with Carnoy solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
1564446|NCT02495532|Other|Lymph node clearing technique with GEWF solution|"Procedure: lymph node clearing technique with GEWF solution
(1) just after the surgical resection each specimen is fixed by formaldehyde; (2) lymph node harvesting is performed by a manual technique of vision and palpation; (3) lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy; (4) the surgical specimen is submitted to re-fixation with GEWF solution and another lymph node harvesting by manual technique of vision and palpation; (5) additional lymph nodes retrieved are counted, stained with hematoxylin and eosin and examined with light microscopy."
1564447|NCT02495519|Drug|Imatinib|Imatinib 400 mg/day until disease progression
1564448|NCT02495506|Other|Cold stored platelets|Intervention: Leukoreduced platelet concentrates stored at 4 degrees C for treatment of bleeding after Cardiac surgery
1564449|NCT02495506|Other|Room temperature platelets|Intervention: Leukoreduced platelet concentrates stored at 22 degrees C for treatment of bleeding after Cardiac surgery
1564450|NCT02495493|Drug|Induction DCS chemotherapy|docetaxel /cisplatin/S-1 followed by chemoradiotherapy (S-1/cisplatin)
1564451|NCT02495480|Device|A novel disposable sheath|a new sheath will be placed on the endoscope in sheathed group
1564452|NCT02495467|Drug|Glyceryl trinitrate|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
1564453|NCT02495467|Drug|MED Placebo|At least 4 applications of MED2005 prior to intercourse over a period of 4 weeks
1564454|NCT02495454|Drug|Ga101|
1564455|NCT02495441|Other|Use of Rapid Immunoassay Tests for the Detection of PROM|"After informed consent , both the ROM Plus®, ActimProm Amnioquick® Complete and AmniSure® bedside tests (without the use of a speculum) will be performed.
The patient will then undergo the standard clinical assessment, which includes a sterile speculum exam (SSE). If either 1) amniotic fluid is seen leaking from the cervical os, or 2) if at least two of the following three clinical signs are present: visual pooling of fluid in the posterior fornix, positive nitrazine test, and microscopic evidence of ferning, then the patient will be considered positive for ROM.
Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of IGFBP-1/AFP tests and Amnisure®."
1564456|NCT02495428|Procedure|Kinesio Tape Method|
1564457|NCT02495415|Drug|Fenretinide|Fenretinide intravenous emulsion administered as a continuous intravenous infusion for 5 days, once every 3 weeks in relapsed/refractory PTCL patients.
1564458|NCT02495402|Behavioral|Motivational Interviewing|Participants assigned to the experimental condition receive a single 20-30 minute motivational interviewing-based brief intervention for substance use.
1564459|NCT02495389|Drug|mirabegron|All study participants will be given mirabegron, 25 mg by mouth once a day for 12 weeks.
1564460|NCT02495376|Behavioral|MBSR|Based primarily on the instruction of mindfulness meditation and yoga, MBSR is a group-based, 8-week program that was developed at the University of Massachusetts Stress Reduction Clinic under the direction of Jon Kabat-Zinn. MBSR is comprised of a structured, developmentally sequenced curriculum that uses a group format to experientially instruct participants in the practice of mindfulness meditation and mindful Hatha yoga. Each session includes different forms of meditation practice, such as cultivating awareness of thoughts, feelings and bodily sensations, and learning to incorporate this awareness during stressful emotional and/or physical life situations.
1564495|NCT02495129|Drug|VAY736 higher dose|Patients will receive a total number of 3 monthly subcutaneous injections with the higher dose of VAY736
1564461|NCT02495363|Procedure|PECS Block|"As standard departmental protocol ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .
The concentration is determined by the upper dose limit to 2 mg / kg 11"
1564462|NCT02495363|Drug|Bupivacaine 0.25-0.5%|"Ultrasound guided PECS Block will be performed by identifying the thoracic muscles. Following the identification, the investigator will inject the anesthetic solution which will contain the conventional 25 cc of Bupivacaine 0.25-0.5% .
The concentration is determined by the upper dose limit to 2 mg / kg 11"
1564463|NCT02495350|Other|Questionarie|"Parturients will be asked to fill out a labor satisfaction questionnaire detailing initial desire for epidural analgesia, final desire for epidural analgesia, adequacy of pain relief during labor and satisfaction with laborOn the third day postoperatively the parturients will be called and assessed for mood and signs of postpartum depression using Edinborough Postnatal Depression scale validated into Hebrew (10) , and we will assess whether or not they are breastfeeding.
At 6 weeks we will follow-up to assess breastfeeding duration ,and postpartum depression using the Edinborough Postnatal Depression scale.
Our comparison will include average pain scores, breast feeding success, and postpartum depression assessment."
1564464|NCT02495337|Other|Tissue Collection|
1564465|NCT02495324|Drug|Placebo|2 weeks of placebo PO daily
1564466|NCT02495324|Drug|Fimasartan|60mg 1 tab PO daily for 2 weeks and 120mg 1 tab PO daily for 4 weeks
1564467|NCT02495324|Drug|Valsartan|80mg 1 tab PO daily for 2 weeks and 160mg 1 tab PO daily for 4 weeks
1564468|NCT02495324|Drug|Olmesartan medoxomil|10mg 1 tab PO daily for 2 weeks and 20mg 1 tab PO daily for 4 weeks
1564469|NCT02495311|Procedure|myomectomy or adenomyomectomy|
1564470|NCT02495298|Procedure|Fascial Manipulation|The Fascial Manipulation was performed by a physiotherapist on the spots indicated by clinician as the most painful ones due to CTS. The selected spots were informed to the physiotherapist after the clinical anamnesis.
1564471|NCT02495298|Procedure|Sham Fascial Manipulation|After the clinical anamnesis, a physiotherapist performed the Fascial Manipulation on different spots, rather than the spots the clinician considered the most painful ones due to CTS.
1564472|NCT02495285|Drug|Gelofusine 4%|
1564473|NCT02495285|Drug|Gelaspan 4%|
1564474|NCT02495272|Drug|Oxytocin|Oxytocin 10IU Administered intramuscularly.
1564475|NCT02495259|Device|ZU-bend stylet|Laryngoscopy and intubation after induction of anesthesia will be done using the GlideScope and the ZU-bend stylet. The ZU-bend is a specific shaping technique of the intubating stylet that is closely related to the GlideScope blade curvature. Zu-bend stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
1564476|NCT02495259|Device|GlideScope|Laryngoscopy and intubation after induction of anesthesia will be done using the the GlideScope technique. The GlideScope is a video laryngoscope that provides a real-time view of the airway and tube placement during intubation. GlideScope is removed after DLT is in the trachea, and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
1564477|NCT02495259|Device|GlideRite stylet|Laryngoscopy and intubation after induction of anesthesia will be done with the GlideScope using the GlideRite stylet. The GlideRite stylet is specifically designed to work with the GlideScope and provides the necessary rigidity and curvature to an otherwise flexible tube. GlideRite stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, GlideScope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
1564478|NCT02495259|Device|Macintosh blade|Direct laryngoscopy and intubation after induction of anesthesia will be done with the Macintosh blade and a regular double-lumen endobronchial tube (DLT) stylet. The Macintosh blade is used to facilitate visualization of the larynx during double or single lumen endobronchial tube placement. After intubation the Macintosh laryngoscope is removed and the confirmation of the successful placement of the double-lumen endobronchial tube in done in the standard fashion.
1564479|NCT02495259|Device|Regular Double-lumen endobronchial tube (DLT) Stylet|Direct laryngoscopy and intubation after induction of anesthesia will be done with a regular double-lumen endobronchial tube (DLT) stylet and the Macintosh blade. The DLT stylet is withdrawn as a part of placement procedure during the DLT advancement. Thereafter, Macintosh laryngoscope is removed and placement of the double-lumen endobronchial tube is verified with capnography and fiberoptic bronchoscopy in the usual manner.
1564480|NCT02495246|Biological|ChAd3-EBO-Z|
1564481|NCT02495246|Biological|Ad26.ZEBOV|
1564482|NCT02495233|Drug|ASP2215|oral
1564483|NCT02495233|Drug|Erlotinib|oral
1564484|NCT02495220|Drug|SB dexmedetomidine bupivacaine block|SB block with 0.05 mL/kg of 0.5%bupivacaine and 0.5µ/kg dexmedetomidine mixture
1564485|NCT02495220|Drug|intravenous dexmedetomidine|received 1µ/kg IV dexmedetomidine
1564486|NCT02495207|Device|Piezosurgery|This intervention is dependent on use of piezosurgery to conduct the required bone cuts to remove third molars.
1564487|NCT02495194|Behavioral|Horticultural Therapy|The Horticultural Therapy intervention consists of 1 hour sessions weekly for first 3 months, followed by monthly session for the next 3 months. They will be taught on the basic gardening techniques such as sowing, weeding and fertilization during the hands-on sessions. They will also be taken on walks to the various parks to enjoy the therapeutic effect of the park greenery
1564488|NCT02495181|Drug|IVT Aflibercept; Verteporfin PDT|
1564489|NCT02495181|Drug|IVT Aflibercept; Sham PDT|
1564490|NCT02495168|Drug|Symbicort|Reference Listed Drug Product
1564491|NCT02495168|Drug|Generic Budesonide/Formoterol fumarate dihydrate|Generic Test Formulation
1564492|NCT02495168|Drug|Placebo|Placebo
1564493|NCT02495155|Behavioral|PROSPECT|PROSPECT is an internet-based exercise and behavioral symptom management program developed for patients who experience long-term side effects from cancer treatment. The cancer-specific symptom management intervention is intended as a self-management adjunct to improve cancer- and treatment-related symptoms through non-pharmacologic approaches.
1564494|NCT02495129|Drug|VAY736 lower dose|Patients will receive a total number of 3 monthly subcutaneous injections with the lower dose of VAY736
1564598|NCT02494180|Drug|Midazolam|arm A receiving iv midazolam
1564498|NCT02495090|Genetic|Exome sequencing|Plain DNA sequencing
1564499|NCT02495077|Biological|Infliximab|A single dose, of 3mg/kg infusion
1564500|NCT02495077|Drug|Methylprednisolone|500mg will be Initiated just prior to or at the initiation of transplant surgery and prior to Infliximab and thymoglobulin infusion
1564501|NCT02495077|Drug|Mycophenolate Mofetil|Administered at a target dose of 2000mg daily, as tolerated, until study closure
1564502|NCT02495077|Drug|Tacrolimus|Administered at a target dose of 0.1mg/kg BID, post-op, then adjusted to target trough levels of 8-12ng/ml during 1st 3-months post-op and finally adjusted to target trough levels of 5-8ng/ml until study closure
1564503|NCT02495077|Biological|Thymoglobulin|Administered daily for 5 days with the intention of achieving a total dose of 4.5 to 6.0 mg/kg, as tolerated
1564504|NCT02495077|Drug|Acetaminophen|"30 to 60 minutes prior to the start of the infusion
Tylenol, 600 to 1000mg by mouth or
Suppository form"
1564505|NCT02495077|Drug|Loratadine|"30 to 60 minutes prior to the start of the infusion
Claritin (Loratadine) 10mg by mouth or
Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
1564506|NCT02495077|Biological|Placebo for Infliximab|A single dose is volume matched to Infliximab (250mL) infusion
1564507|NCT02495077|Drug|Prednisone|Prednisone will be administered peri-operatively according to center practice. Prednisone should be gradually tapered to no less than 5 mg/day or 10 mg every other day by 3 months post-transplant thereafter until study closure.
1564508|NCT02495077|Drug|Diphenhydramine|"30 to 60 minutes prior to the start of the infusion
Claritin (Loratadine) 10mg by mouth or
Benadryl (Diphenhydramine) 25 or 50 mg by mouth"
1564509|NCT02495064|Drug|Mometasone Furoate Cream|One side of patients' neck will begain to use MF cream from the first day of radiation therapy.
1564510|NCT02495051|Procedure|esophageal biopsies|
1564514|NCT02494843|Other|online Hemodiafiltration|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
1564515|NCT02494843|Other|Hemodialysis|Effects of high efficiency online hemodiafiltration on cardiac structure, function and myocardial perfusion were compared with standard haemodialysis.
1564516|NCT02494830|Drug|Ketamine|Intravenous infusion of 5 mg ketamine solution, diluted in 240 ml 0.9% saline within 30 min under fasting conditions on study day 1 and oral administration of one prolonged release tablet ketamine together with 240 ml table water under fasting conditions with increased dose (10, 20, 40 and 80 mg) and at least 7 days wash-out between the study days
1564517|NCT02494817|Behavioral|Male Couples Agreement Project|Couples assigned to the intervention group will first as individuals view general video about purpose of study and how to use website functions; timeline activity about their relationship; select top values about their relationship; learn about effective HIV prevention strategies; learn about sexual agreements; select what items they want to have in their agreement; explore a learning module about testing and view the sexual health resource center. As a couple, they will log back into the website to view and compare timelines and relationship values; watch a video about communicating more effectively; negotiate and decide together what items they want to include in their agreement; explore the sexual health resource center and/or any other modules from when they were logged into the website as individuals; download a corresponding smartphone app that will include a copy of their newly created agreement and sexual health resource center.
1564518|NCT02494804|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
1564519|NCT02494804|Biological|CIK|The patients received autologous cytokine-induced killer cells transfusion one week after Temozolomide treat
1564520|NCT02494791|Behavioral|Questionnaire, Educational Material|Participants in this study will be given educational material about Lynch Syndrome and genetic testing for this condition. They will be asked to complete questionnaires about their family cancer history, personal health history and attitudes toward genetic testing.
1564521|NCT02494778|Drug|Pridopidine|45 mg BID
1564522|NCT02494765|Device|I-gel TM|Airway management with I-gel
1564523|NCT02494765|Device|Ambu AuraOnce (AO)|Airway management with Ambu AuraOnce (AO)
1564524|NCT02494752|Procedure|Fat graft enriched with ex vivo expanded stem cells|Fat graft will be enriched with ex vivo expanded stem cells
1564525|NCT02494752|Procedure|Fat graft not enriched with ex vivo expanded stem cells|Fat graft will not be enriched with ex vivo expanded stem cells
1564526|NCT02494739|Other|Yogurt enriched with polyphenols|Yogurt enriched with polyphenols extracted from grape seeds
1564527|NCT02494739|Other|Yogurt not enriched with polyphenols|Yogurt not enriched with polyphenols
1564599|NCT02494167|Biological|MultiTAA-specific T cells|"The 3 dose levels are:
Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2
The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or central lie.
If patients with residual disease (Group B) have a partial response, complete response or stable disease, they will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions (or below the patient's original dose can be administered) at least 4 weeks apart."
1564528|NCT02494726|Other|Thromboelastography|TEG (Thrombelastography) measurements include: Split Point (SP) is the time elapsed for the clot to initially form fibrin when the blood is first placed in the TEG machine. Reaction Time (R) is the time elapsed from its initial fibrin formation until the clot reaches 2mm. K is the time measured from R until the level of clot firmness reaches 20mm, measuring the speed of clot strengthening. These are measured in minutes. Delta measures if the formation of the clot has been suppressed; measured as the difference between R and SP. Angle reflects the speed at which clots form by forming the slope of the TEG tracing at R from the horizontal line. Maximum Amplitude (MA) in mm is the measure of maximum strength of the clot, true platelet function. G is the measure of the clot firmness; measured by a formula (G=(5000*MA)/(100-MA) in dynes/cm2). LY30 is a measure of clot lysis at 30 minutes after MA is reached.
1564534|NCT02494700|Radiation|Radiation Therapy|Participants receive radiation to entire involved orbit for a total dose of 4 Gy in 2 fractions over two consecutive days with external beam radiotherapy.
1564535|NCT02494687|Drug|Oral Domperidone|10 mg of oral domperidone administered (four times a day) for two weeks
1564536|NCT02494687|Drug|Oral Domperidone|Increased to 20 mg four times a day for 2 weeks at the Investigator's discretion
1564537|NCT02494687|Drug|Oral Domperidone|Increased to 30 mg four times a day at the Investigator's discretion
1564538|NCT02494674|Behavioral|Bite Counter tracking|Participants will be asked to use the bite counter to track all meals and provide feedback on using the bite counter for dietary self-monitoring.
1564539|NCT02494661|Behavioral|Healthy Cart and Stress Management Videos|Healthy Cart and Stress Management Videos: educational videos on healthy food shopping and stress reduction.
1564540|NCT02494661|Behavioral|Healthy Cart Video|Healthy Cart Video: educational video on healthy food shopping
1564541|NCT02494648|Device|POWERbreathe Fitness Plus, (POWERbreathe International Ltd, UK) [Inspiratory muscles strengthening]|CAD patients participated in a 6-week (20 sessions of training) resistive inspiratory muscle training (RIMT) program for 10 minutes twice daily at a training intensity of 70% of maximum inspiratory pressure (MIP).
1564542|NCT02494648|Other|Control|
1564543|NCT02494635|Other|Laboratory Biomarker Analysis|Biomarker analysis
1564544|NCT02494609|Drug|sotagliflozin|400 mg sotagliflozin
1564545|NCT02494609|Drug|oral contraceptive|0.25 mg norgestimate/0.035 mg ethinyl estradiol
1564546|NCT02494609|Drug|oral contraceptive + sotagliflozin|0.25 mg norgestimate/0.035 mg ethinyl estradiol + 400 mg sotagliflozin
1564547|NCT02494596|Drug|Capecitabine|Participants will receive capecitabine on Days 1 to 14 of each 3-week cycle as 825, 1000, or 1250 mg/m^2 PO twice daily. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
1564548|NCT02494596|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 1050 mg via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
1564549|NCT02494583|Biological|pembrolizumab|IV infusion
1564550|NCT02494583|Drug|cisplatin|IV infusion
1564551|NCT02494583|Drug|5-FU|IV infusion
1564552|NCT02494583|Drug|capecitabine|oral tablet
1564554|NCT02494544|Device|Off the Shelf Total Knee Replacement|A knee replacement system by DePuy, Zimmer, Biomet, Smith & Nephew, or Stryker
1564555|NCT02494544|Device|ConforMIS iTotal Knee Replacement|A knee replacement performed with patient specific implant and surgical jigs.
1564556|NCT02494531|Radiation|Fluorodeoxyglucose-PET|Fluorodeoxyglucose-PET performed within 2 months
1564557|NCT02494531|Radiation|florbetapir F 18-PET|florbetapir F 18-PET performed within 2 months
1564558|NCT02494518|Behavioral|Forced Exercise & Upper Extremity Repetitive Task Practice|
1564559|NCT02494518|Behavioral|Voluntary Exercise & Upper Extremity Repetitive Task Practice|
1564560|NCT02494518|Behavioral|Stroke Education & Upper Extremity Repetitive Task Practice|
1564561|NCT02494505|Drug|Mycophenolate Mofetil|2g/day per os
1564562|NCT02494505|Drug|placebo|
1564563|NCT02494492|Other|intravitreous administration of regulator T-cells|The 3 levels of Tregs doses will be respectively 0.4, 1.2 and 3.6 million.
1564564|NCT02494479|Drug|Prurisol|50mg tablet
1564565|NCT02494479|Drug|Placebo|Sugar pill designed to match Purisol tablet
1564566|NCT02494466|Drug|montelukast sodium|4 mg peroral Montelukast Sodium, 10 days before surgery because of high IgE.
1564600|NCT02494154|Device|Airvo 2; Ficher and Paykel HealthCare|High flow nasal cannulas
1564601|NCT02494154|Device|Oxygen delivery via conventional nasal mask|Low flow of oxygen delivered through conventional nasal prongs
1564602|NCT02494141|Drug|Curcumin|Dietary Supplement
1564603|NCT02494141|Other|Placebo|
1564604|NCT02494128|Other|Education|Education in group leadership
1564605|NCT02494115|Procedure|subcutaneous drainage|
1564606|NCT02494102|Drug|Modafinil|Atypical Psychomotor stimulant
1564607|NCT02494102|Drug|Placebo|
1564608|NCT02494089|Other|distress analysis|
1564571|NCT02494414|Other|Long-term follow-up|Vital and neurological follow-up
1564572|NCT02494401|Other|Internet-based self-management program|
1564573|NCT02494401|Other|Scleroderma book|
1564574|NCT02494388|Procedure|Endoscopic ultrasound guided needle based confocal endomicroscopy|Needle based confocal laser endomicroscopy is a technique that enables in vivo microscopic analysis during ongoing endoscopy. It has good accuracy for predicting the final histopathological diagnosis based on immediate evaluation of tissue and vascular patterns. nCLE microprobe is a flexible probe thin enough that it can be passed through a 19-gauge needle. Thus under EUS guidance solid organs (i.e. the pancreas) can be accessed for real-time microscopic information.
1564575|NCT02494375|Other|Sleep and glucose assessments|Sleep characteristics, glycemic control, salivary amylase and body composition will be assessed 3 times, at 3-4 months intervals
1564576|NCT02494362|Other|Computer gaming hand exercise regimen.|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for 12 weeks.
1564577|NCT02494349|Drug|JLP-1207|The subjects will receive JLP-1207 under fed(high fat meal) condition. After washout period, the subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition.
1564578|NCT02494349|Drug|Solifenacin 5mg+Tamsulosin 0.2mg|The subjects will receive Solifenacin 5mg and Tamsulosin 0.2mg under fed(high fat meal) condition. After washout period, the subjects will receive JLP-1207 under fed(high fat meal) condition.
1564582|NCT02494323|Device|Functional Electrical Stimulation|Single channel and dual channel FES for balanced dorsiflexion for patients with dropfoot
1564583|NCT02494310|Device|High-Resolution Microendoscopy Imaging|Innovative technique to evaluate epithelial cell morphology in situ. The device is not invasive and does not exchange energy with human body.
1564584|NCT02494284|Drug|Clopidogrel|6-month DAPT followed by clopidogrel monotherapy
1564585|NCT02494284|Drug|Aspirin plus clopidogrel|standard long-term dual antiplatelet strategies (24-month DAPT followed by aspirin monotherapy)
1564587|NCT02494245|Other|STARFISH|The intervention group will take part in a four month physical activity intervention using the STARFISH app with the aim of increasing physical activity by 3000 steps per day. Participants will be provided with a smartphone for the intervention. Participants will work in groups of four but each participant will have their own individualised step count target, based on their baseline step count. If the participant reaches their step count target on at least five days of the week, then their target will be increased by 5% for the following week, up to a maximum increase of 3000 steps above baseline. Where a participant fails to reach their step count target, it remains unchanged for the following week.
1564588|NCT02494219|Procedure|Rapid Immunochromatographic streptococcal test|Throat swab obtained for rapid strep test in addition to throat culture,in order to check the accuracy of Rapid Immunochromatographic streptococcal test in detection of streptococcal pharyngitis
1564589|NCT02494206|Drug|QBX258|Once patients are registered for the trial, they will be treated with QBX258 (VAK694 3mg/kg and QAX576 6mg/kg) delivered via peripheral intravenous injection once every 4 weeks (+ 1 week) for 4 treatments.
1564590|NCT02494193|Other|Partial caries removal|The caries infected dentin will be removed mantaining the affected caries tissue.
1564591|NCT02494193|Other|Provisional restoration - control|After partial caries removal, a provisional restoration will be performed using a layer of calcium hydroxide paste covered by a layer of calcium hydroxide cement and resin-modified glass ionomer.
1564592|NCT02494193|Other|Provisional restoration - experimental|After partial caries removal, a provisional restoration will be performed using only resin-modified glass ionomer.
1564593|NCT02494193|Other|Total caries removal|After two months of their placement, the provisional restoration will removed followed by tota caries tissue removal.
1564594|NCT02494193|Other|Definitive restoration|Definite restoration will be performed using composite.
1564595|NCT02494180|Drug|fentanyl|arm A receiving iv fentanyl
1564596|NCT02494180|Drug|pethidine|arm B receiving iv pethidine
1564597|NCT02494180|Drug|Diazepam|arm B receiving iv diazepam
1564611|NCT02494063|Procedure|Sentinel lymph node biopsy|Bilateral sentinel lymph node biopsy, pathologic ultrastaging
1564612|NCT02494050|Behavioral|Behavioral Activation-Full|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
1564613|NCT02494050|Behavioral|Behavioral Activation-Short|Behavioral Activation proposes that symptom reduction occurs via monitoring daily activities to identify patterns of low reward and mood, assessing and assigning tasks that generate pleasure and competence, understanding and reducing unproductive avoidance, and improving skill deficits to promote action towards treatment goals.
1564614|NCT02494050|Behavioral|Bipolar Disorder Collaborative Care|This manualized treatment focuses on social support and educating patients about medication compliance. The primary focus is to strengthen the patients' self-management skills with education; supporting the clinician's decision making using practice guidelines; enhancing access to care, continuity of care, and information flow through the use of the clinician.
1564615|NCT02494024|Drug|Single dose C2N-8E12|C2N-8E12 is a humanized recombinant anti-human tau antibody.
1564616|NCT02494024|Drug|Single dose placebo|Subjects will be block randomized to receive a single dose of C2N-8E12 or placebo in two blocks of 4 subjects (3:1, C2N-8E12:placebo) per cohort.
1564617|NCT02494011|Other|traditional exercise|mobilization stretching exercise
1564618|NCT02494011|Other|Russian current stimulation|stimulation to wrist flexors for 15 minutes
1564619|NCT02494011|Other|closed kinetic chain exercise|wall press exercise plyometric exercise
1564620|NCT02493985|Other|0.5% CO2|The subjects will be randomized to breath 0.5% carbon dioxide during one of the -12 degree head down tilt body position periods in crossover design
1564621|NCT02493985|Other|ambient air|The subjects will be randomized to breath ambient air during one of the -12 degree head down tilt body position periods in crossover design
1564622|NCT02493972|Procedure|GelPort|Manual exploration of the peritoneal carcinosis by the system GelPort ® with calculation of peritoneal cancer index for evaluation of the resectability
1564623|NCT02493972|Procedure|laparotomy|laparotomy will be performed if indication confirmed by manual exploration
1564624|NCT02493959|Biological|PYY1-36 infusion|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs.
1564625|NCT02493959|Biological|PYY1-36 + sitagliptin|Infusion of 1.6 pmol/kg/min PYY1-36 for 2 hrs. Two doses of 100 mg sitagliptin are administered 10 and 1 hour before start of infusion, respectively.
1564626|NCT02493959|Biological|PYY3-36 infusion|0.8 pmol/kg/min infusion of PYY3-36.
1564627|NCT02493959|Biological|placebo|Infusion of saline for 2 hrs.
1564628|NCT02493946|Drug|Clostridium Botulinum Toxin Type A|
1564629|NCT02493946|Drug|Placebo|
1564630|NCT02493933|Drug|Phytoestrogens, Isosorbid mononitrate, N-acetyl cysteine|
1564631|NCT02493920|Other|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm).
1564632|NCT02493920|Device|mask using a T-piece system (Fabian,Acutronic Medical Systems AG, Switzerland).|
1564633|NCT02493894|Drug|PEG|PEG solution (80gr/1Litr) each 8 hours for 24 hours
1564634|NCT02493894|Drug|placebo|placebo each 8 hours for 24 hours
1564635|NCT02493894|Drug|Cefazolin|cefazolin 1gram, every 6hours for 2 days
1564646|NCT02493842|Device|Transverse Intrafasicular Multichannel electrode (TIME)|Peripheral nerve stimulation is conducted with Transverse Intrafasicular Multichannel electrode (TIME) version 4 electrodes to induce sensory sensations from the phantom hand, while subject is virtualizing a movement or event which may cause the specific sensation.
1564647|NCT02493829|Biological|AML Cell Vaccine|
1564648|NCT02493816|Drug|Gene-modified autologous fibroblasts|3 intradermal injections of COL7A1 gene-modified autologous fibroblasts will be administered on day 0 only.
1564649|NCT02493803|Behavioral|Dietary Advice|Detailed dietary advice and planning, complete with dietary information sheets which were developed with a dietitian and a dental psychologist
1564650|NCT02493790|Other|Cognitive and motor performances|
1564651|NCT02493777|Drug|HLD200 methylphenidate hydrochloride (MPH) Capsules|HLD200 doses: 20, 40, 60, 80 or 100 mg
1564652|NCT02493777|Drug|Placebo|
1564661|NCT02493738|Drug|Lozanoc 50mg|Lozanoc 50mg single dose under fed and fasted condition
1564662|NCT02493738|Drug|Sporanox 100mg|Sporanox 100mg single dose under fed condition
1564665|NCT02493712|Drug|High dose|6 capsules of IBD98-M, twice a day
1564666|NCT02493712|Drug|Low dose|4 capsules of IBD98-M
1564667|NCT02493712|Drug|Placebo|Placebo
1564668|NCT02493699|Other|physical exercise- based intervention (Karate techniques training)|
1564669|NCT02493686|Other|n.a.|
1564670|NCT02493673|Device|Continuous positive airway pressure device|(ResMed Spirit S8)
1564671|NCT02493660|Device|InSpace sub-acromial tissue spacer system|Arthroscopic implantation of InSpace sub-acromial tissue spacer system
1564672|NCT02493660|Procedure|Partial repair of rotator cuff|Arthroscopic partial repair of rotator cuff
1564673|NCT02493647|Behavioral|Love, Sex, & Choices|Investigators propose to conduct a two-arm clinical trial of guide enhanced LSC impact on reducing unprotected sex with high risk partners and increasing HIV testing in Black women in high HIV prevalence neighborhoods. Undiagnosed HIV is a significant factor fueling the epidemic. Recruitment into the study will be via Facebook or traditional on the ground.
1564674|NCT02493634|Procedure|pressure gradient measurement|A guidewire is used to introduce and position a pressure catheter under magnetic resonance guidance to conduct flow and pressure measurement in the aortic arch to evaluate vascular resistance.
1564675|NCT02493634|Device|MRWire|
1564676|NCT02493608|Device|scalpel|used to cut the abdominal wall.
1564677|NCT02493608|Device|Diathermy|Diathermy used to cut , coagulate the tissue
1564678|NCT02493582|Biological|Cytokine-Induced Killer Cells|CIKs are used with Apatinib to treat lung adenocarcinoma patients with wild-type EGFR
1564679|NCT02493582|Drug|Apatinib|Advanced lung adenocarcinoma patients with wild-type EGFR take Apatinib 850mg qd by mouth.
1564680|NCT02493569|Procedure|The radical mastectomy of breast cancer|The radical mastectomy of breast cancer could be used for the treatment of breast cancer during the observation.
1564681|NCT02493556|Device|LLLT before muscle damage|
1564682|NCT02493556|Device|Placebo LLLT before muscle damage|
1564683|NCT02493556|Device|LLLT after muscle damage|
1564684|NCT02493556|Device|Placebo LLLT after muscle damage|
1564685|NCT02493543|Other|Blood collection|Blood collection from the subject's arm
1564686|NCT02493530|Drug|TGR-1202|"Stage 1 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients already taking therapeutic levels of ruxolitinib, but who are not achieving maximal response at highest tolerated dose of ruxolitinib.
Stage 2 will include myelofibrosis or hydroxyurea-resistant/refractory PV patients who have never been on JAK-STAT inhibitory agents, and includes simultaneously initiation of both ruxolitinib and TGR-1202. TGR-1202 will be administered at or below the recommended dose established in Stage 1.
Expansion will commence after proper combination doses of both agents is established."
1564687|NCT02493530|Drug|ruxolitinib|
1564688|NCT02493517|Drug|Lanreotide Autogel®|Lanreotide Autogel 60mg, 90mg, and 120mg, pre-filled syringe, deep subcutaneous injection.
1564689|NCT02493517|Drug|Lanreotide Acetate|Lanreotide PR 40mg white freeze-drying cake, 40mg/vial, deep subcutaneous injection.
1564690|NCT02493504|Drug|Heparin|100units/kg of heparin were administered for the case group after dissection prior to anastomosis.
1564691|NCT02493465|Drug|Everolimus|Conversion from azathioprine to everolimus in kidneys transplant recipients with left ventricular hypertrophy.
1564692|NCT02493452|Drug|Plecanatide|
1564693|NCT02493452|Drug|Placebo|
1564694|NCT02493439|Behavioral|Best Possible Self|
1564695|NCT02493439|Behavioral|Daily Activities|
1564696|NCT02493426|Drug|Intranasal Oxytocin|
1564697|NCT02493426|Drug|Placebo|
1564733|NCT02493140|Dietary Supplement|Placebo|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner) during 12 weeks
1564698|NCT02493387|Other|Exercise|The group-based exercise program consists of 60-minute sessions twice a week for 3 months, including central circulatory exercise performed on an ergometer cycle and muscle training, and one or two occasions of home-based exercise. The exercise program are designed after the patients requirements and with the intensity 13-17 on the Borg RPE 6-20 scale
1564699|NCT02493387|Other|Physical activity|The patients randomized PAP will receive a PAP prescription and a physical activity diary. The PAP and physical activity diary will be followed up at 6 and 12 weeks after the inclusion.
1564700|NCT02493361|Drug|Pembrolizumab|
1564701|NCT02493361|Drug|pIL-12|
1564702|NCT02493348|Device|Rhythmic Sensory Stimulation|Rhythmic Sensory Stimulation (RSS) uses rhythmic sensory cues to induce brain entrainment based on the premise that the spontaneous electrical activity of the brain can synchronize to external periodic auditory, visual, or somatosensory stimuli. RSS can be delivered through sound devices. In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS) 1000 unit, which is a low-voltage consumer product device that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the sound (40 Hz RSS), the efficacy of the Sound Oasis VTS-1000 device to deliver this sound will also be observed.
1564703|NCT02493335|Drug|Budesonide 0.5mg orodispersible tablet twice daily|
1564704|NCT02493335|Drug|Budesonide 1mg orodispersible tablet twice daily|
1564705|NCT02493335|Drug|Placebo orodispersible tablet twice daily|
1564706|NCT02493322|Drug|Olmesartan Medoxomil 20mg + Chlorthalidone 12,5mg|1 tablet a day
1564707|NCT02493322|Drug|Olmesartan medoxomil 20mg + Chlortalidone 25mg|1 tablet a day
1564708|NCT02493322|Drug|Olmesartan 20mg + hydrochlorothiazide 12,5mg|1 tablet a day
1564709|NCT02493309|Other|Prolonged sitting|Condition A is referred to as the 'sitting' condition. Here participants will remain seated throughout the whole of the 7 ½ hour test period (8am - 3:30pm). On arrival, participants will have a cannula (a small tube that allows us to take blood) inserted into their arm; this will stay in the arm and allow us to take regular blood samples throughout the day. Blood samples and blood pressure will be taken at 30, 60, 120 and 180 minutes after breakfast. We will then provide a lunch meal and will continue taking blood samples and blood pressure at 30, 60, 120, 180 and 210 minutes after this lunch meal. In total, we will take 11 blood samples over the 7 ½ hour testing period.
1564710|NCT02493309|Other|Light activity breaks|Condition B is the 'light activity breaks' condition. Participants will go through exactly the same process as condition A but will also be asked to do 5 minute bouts of slow walking on a treadmill every 30 minutes following breakfast and lunch. In total they will do 12 five minute walks on the treadmill throughout the 7 ½ hour test period (60 minutes of walking in total). In total, we will take 11 blood samples on the day.
1564711|NCT02493296|Other|This observational study will not entail an intervention.|This study will entail measurement of central aortic haemodynamics before and after (clinically indicated) abdominal aortic aneurysm repair
1564712|NCT02493283|Drug|Dapsone single dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration), urine (0-24 h, 24-48 h, 48-72 h, 72-96 h, 96 -120 h) and feces (on treatment days 1-5)
1564713|NCT02493283|Drug|Dapsone multiple dose|Administration of two tablets Dapson-Fatol 50 mg Tabletten (= 100 mg dapsone) s.i.d. for 7 days and sampling of blood (before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration), urine (last treatment day 0-24 h) and feces (on treatment days 12-15)
1564714|NCT02493283|Biological|leucocytes|sampling for leucocytes collection: study days -1, 1, 14 and 15
1564715|NCT02493283|Biological|Met-Hb|sampling before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after single-dose administration, before and 0.5, 1, 1.5, 2, 2.5, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72 and 96 h after last repeated-dose administration and sampling for additional safety analyses (Met-Hb): study days 10, 12, 14 and hematology on study day 12
1564716|NCT02493270|Behavioral|Smoking cessation therapy|Multidisciplinary smoking cessation therapy, performed by a team comprising physicians, nurses, a psychologist and dentists. It consisted of four 1-h counselling lectures, psychologist-assisted cognitive behavioural therapy, nicotine replacement therapy and medication (bupropion or varenicline). Smoking cessation motivation was reinforced by dentists at the maintenance sessions, by means of motivational interviewing techniques
1564717|NCT02493270|Procedure|Non-surgical periodontal therapy|full-mouth supra and subgingival scaling and root planing (with curettes and ultrasonic scaler); oral hygiene instruction and motivation and removal of intra-oral plaque retentive factors
1564718|NCT02493257|Drug|Capsaicin|
1564719|NCT02493257|Drug|Placebo|
1564720|NCT02493244|Other|Cliradex|Cliradex is simply water and 4-Terpineol, a natural organic compound found Melaleuca alternifolia. The other ingredients in Cliradex are in less than 1% of the formulation and are Glycerin, Polysorbate 20, Polysorbate 80, Carbomer, Triethanolamine.
1564721|NCT02493231|Drug|Nefopam|
1564722|NCT02493231|Drug|Ketamine|
1564723|NCT02493231|Drug|Saline|
1564724|NCT02493218|Behavioral|Mindfulness Instruction|Age-appropriate instruction on mindfulness concepts and practices, adapted from the mindfulness-based stress reduction (MBSR) program. Classes are 45-90 minutes each and held weekly for 12 weeks.
1564725|NCT02493218|Behavioral|Health Education|Age-appropriate health education concepts and topics. Classes are 45-90 minutes each and held weekly for 12 weeks.
1564726|NCT02493192|Drug|pethidine and haloperidol injection|
1564727|NCT02493192|Other|birth ball|
1564728|NCT02493179|Drug|Serodase 5 mg|Serodase 5mg two tablets three times per day
1564729|NCT02493179|Drug|Placebo|Placebo two tablets three times per day
1564730|NCT02493166|Other|dual task cost (cognitive-motor interference)|comparing single versus dual task performance (on both motor and cognitive task)
1564731|NCT02493153|Procedure|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
1564732|NCT02493140|Dietary Supplement|Cashew apple extract (Cashewin)|6 capsules per day (2 capsules 3 times per day, to be taken before breakfast, lunch and diner, each capsule containing 200 mg of Cashewin) during 12 weeks
1564810|NCT02492529|Other|Experimental procedure|
1564734|NCT02493127|Other|Standard PCS|Subject completes the standard version of the PCS Questionnaire
1564735|NCT02493127|Other|Grip Strength|Research Assistant takes Grip Strength Measurements
1564736|NCT02493127|Other|Positively Adjusted PCS|Subject completes the positively-adjusted version of the PCS Questionnaire
1564737|NCT02493088|Other|Antisocial personality recording of behavior and contextual elements|aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
1564738|NCT02493075|Behavioral|The operator blinded to the contact force data or not.|"CF guided group: ablation will be performed with the guidance of real-time CF, ablation time, FTI, etc. CF will be controlled in the range of appropriate CF, which has been defined in phase I. Circumferential PV ablation will be performed orderly, isolated segment, acute reconnected segment , and unisolated segment will be also identified as described in phase I.
Usual ablation group:
Operator will be blinded to CF data, the procedure performance is the same as described in phase I."
1564739|NCT02493062|Device|Sonohysterogram|The sonohysterogram can measure the size and depth of the uterine scar allowing better predictive values for future pregnancies.
1564740|NCT02493049|Drug|Domperidone|Addition of Domperidone to current Disease Modifying Therapy.
1564741|NCT02493036|Drug|SYN-010|
1564742|NCT02493023|Device|navigated bronchoscopy|
1564743|NCT02493010|Device|Arousal-based biofeedback system|
1564744|NCT02492997|Device|Venus Versa|The Venus Versa system is a console that supports an applicators that simultaneously emits radio frequency (RF) and a Pulsed Magnetic Field (PEMF). This combination of energy can raise the temperature of treatment area quickly and homogeneously. The Pulsed Magnetic Field is induced by short pulses of electrical current through coil in the applicator. The magnetic field penetrates into the skin and results in Foucault (Eddy) electrical currents around the cell membranes of the treated tissues. Foucault currents change the electrical potential of charged receptors on the bi-lipid cell membrane layer of dermal cells, which results in the stimulation of molecular and cellular activities and reactions.
1564745|NCT02492997|Other|Glycerine gel|Gel used to protect the skin from the RF energy and to assist with energy distribution
1564746|NCT02492984|Drug|Intravenous infusions of Xyntha|Enrolled subjects will be treated with intravenous infusions of Xyntha for: • On-Demand treatment, • Surgical Prophylaxis at a dose and frequency prescribed by the subject's treating physician in accordance with the Xyntha label and will be adjusted solely according to medical and therapeutic necessity.
1564749|NCT02492945|Drug|3ml-Rejuvinex|They take the three times of the ultrasonography-guided 3ml-Rejuvinex as a PDRN group for four weeks(0,2,4 weeks) under double-blind.
1564750|NCT02492945|Drug|3ml-15%-dextrose solution|They take the three times of the ultrasonography-guided 3ml-15%-dextrose solution injections as a Dextrose group for four weeks(0,2,4 weeks) under double-blind.
1564751|NCT02492932|Device|Ultrasonography|Ultrasonography evaluation of the internal jugular vein.
1564752|NCT02492919|Device|Medixair®|Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
1564753|NCT02492906|Other|Osteoarthrosis|Primary severe knee osteoarthrosis and chronic knee pain.
1564754|NCT02492906|Other|Healthy|Healthy and non-symptomatic volunteers.
1564755|NCT02492893|Other|Hatha yoga|
1564756|NCT02492880|Device|Precision Spectra™ SCS system programming features|Precision Spectra™ SCS system programming features using the CoverEdge surgical lead.
1564762|NCT02492854|Device|PICO Single-Use Negative Pressure Dressings|Negative pressure wound therapy (NPWT), over the past several years, has provided a way to post-operatively manage complex wounds. This is a therapy with potential to decrease rates of SSIs post-LE bypass. Unlike standard gauze dressings, negative pressure wound therapy provides a sealed, moist environment and shuttles fluid away from the wound. A suctioning unit applies even, negative pressure (typically -80 to -120 mmHg) and exudate is suctioned and collected in a control unit. The investigators would like to investigate the efficacy of PICO (Smith&Nephew), a single-use one-step wound dressing which is effective for 7 days. It is lightweight and uses a small hand-held vacuum pump, both of which allow for ease of use. PICO has been FDA-approved.
1564763|NCT02492854|Other|Sterile Gauze Dressings|Current standard-of-care dressings used to cover surgical wounds post-operatively.
1564764|NCT02492841|Drug|Mineral trioxide aggregate|Mineral trioxide aggregate
1564765|NCT02492841|Drug|Calcium hydroxide|Classic calcium hydroxide root canal repair material. Inorganic compound (CA(OH)2. It is the gold standard direct pulp cupping material.
1564766|NCT02492841|Drug|Biodentine|Biodentine (trademark). Septodont. Biodentine root canal repair material. A predose capsule plus five drops of calcium chloride solution.
1564767|NCT02492802|Drug|posaconazole|collection plasma samples for measuring posaconazole drug concentration
1564768|NCT02492789|Biological|INCSHR01210 injection|"Part1: INCSHR01210 injection at a dose of 1, 3 or 10 mg/kg is administered every 2 weeks (3+3,q2w, except in the first cycle, in which subjects will be only dosed once on Day 1 for PK samplings and dose limiting toxicity observation). Response is assessed by every 2 cycles (4 weeks each cycle) by using irRECIST.
Part2: Additional patients (200mg dose cohorts will be enrolled in Part 2, depending on the data outcomes in Part 1, to further explore preliminarily clinical benefits of INCSHR01210 as well as the other objectives of the study."
1564769|NCT02492776|Drug|Omeprazole|20 mg oral capsules administered once daily for 8 days
1564770|NCT02492776|Drug|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 5 days
1564771|NCT02492776|Drug|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
1564772|NCT02492763|Drug|MK-8521|Dose strengths: 180 mcg QD administered subcutaneously; 300 mcg QD administered subcutaneously
1564773|NCT02492763|Drug|Placebo|Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 mcg QD administered subcutaneously; matching placebo for MK-8521 180 mcg QD administered subcutaneously
1564774|NCT02492763|Drug|Liraglutide|Dose strength: 1.8 mg QD administered subcutaneously
1564775|NCT02492763|Drug|Metformin|Metformin immediate release (IR) or metformin extended release (XR) administered ≥1000 mg QD as background therapy
1564776|NCT02492750|Biological|Anakinra|Given SC
1564777|NCT02492750|Drug|Dexamethasone|Given PO
1564778|NCT02492750|Other|Laboratory Biomarker Analysis|Correlative studies
1564779|NCT02492750|Drug|Lenalidomide|Given PO
1564780|NCT02492750|Other|Placebo|Given SC
1564781|NCT02492737|Drug|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
1564788|NCT02492698|Dietary Supplement|Probiotic group|The 2 g of probiotic powder contained 0.1 g of Lactobacillus curvatus HY7601, 0.1 g of Lactobacillus plantarum KY1032, 1.24 g of crystalline cellulose, 0.5 g of lactose, and 0.06 g of blueberry-flavoring agent.
1564789|NCT02492698|Dietary Supplement|Placebo group|The 2 g of placebo powder contained 1.34 g of crystalline cellulose, 0.6 g of lactose, and 0.06 g of blueberry-flavoring agent.
1564790|NCT02492685|Device|Quantitative analysis by using the new developed software program VueBox|After acquiring the EUS image by a regular procedure of EUS and contrast-enhanced with one of the fluoro-gas-containing contrast agents (SonoVue, Bracco, Germany), whole video is recorded on the embedded HDD (hard disk drive) of the US system for later analysis. The videos will be analyzed by using the VueBox software (Bracco Suisse SA, Geneva, Switzerland). After surgical treatment, we will compare the results of quantitative analysis with surgical pathology.
1564791|NCT02492659|Procedure|femtosecond laser-assisted cataract surgery|the femtosecond laser platform was used to generate capsulotomy with a diameter as described above in the control group, and lens fragmentation into 6 segments.
1564792|NCT02492659|Procedure|conventional phacoemulsification|continuous curvilinear capsulorhexis was performed with capsulorrhexis forceps. Following hydrodissection, phacoemulsification of the nucleus, aspiration of the residual cortex and capsular polishing were performed using a phacoemulsification machine
1564793|NCT02492646|Procedure|Saline group|After anesthetic induction, patients will be intubated with endotracheal tube which was immersed in normal saline before intubation.
1564794|NCT02492646|Procedure|Dry group|After anesthetic induction, patients will be intubated with endotracheal tube which was not immersed in normal saline.
1564795|NCT02492633|Behavioral|Control|The Standard Intervention will be offered to residents at all of Beacon Communities properties, regardless of the presence of this study. The standard intervention will be implemented as part of the smoke-free initiative roll out and will consist of: monthly articles in newsletters, re-usable shopping bag giveaways touting cessation messages, information provided via the property websites, and training of Residential Service Coordinators (RSCs) using the 8-session smoking cessation group training provided by the American Lung Association. The RSCs will offer group cessation counseling sessions for residents who would like support to quit smoking.
1564796|NCT02492633|Behavioral|Intervention|"At a subset of 6 Beacon Communities properties, residents will receive an 'enhanced intervention' in addition to the 'standard intervention' that Beacon Communities is already providing. The enhanced intervention will consist of the following:
A web-based smoking cessation intervention via Facebook
Enhanced gain-framed messaging communicated via several channels. Gain framed messages will incorporate themes of smoking cessation and policies which aim to distinguish from the vast 'library' of traditional messages which focus on loss-framing.
A behavioral nudge designed to enhance public support for the smoke free policy, through personal adoption and adherence to the policy. This will be done by promoting a publicly viewable pledge program."
1564797|NCT02492620|Drug|Ferric Citrate|Auryxia (ferric citrate) is a non calcium based phosphate binder indicated for the control of serum phosphorus levels in patients with chronic kidney disease on dialysis
1564798|NCT02492607|Other|Standard treatment|"wide local excision only or wide local excision and radiotherapy or mastectomy.
+/- hormonal therapy"
1564799|NCT02492607|Device|digital mammography|annual mammography
1564800|NCT02492607|Radiation|radiotherapy|according local policy
1564801|NCT02492594|Other|Peripheral blood sampling|Peripheral blood samples will be taken at 3-5 defined timepoints during febrile neutropenia, together with blood sampling for routine diagnostic purposes.
1564802|NCT02492581|Drug|Nalmefene|No intervention on the use of Selincro. The physician will prescribe Selincro following its usual practice.
1564803|NCT02492568|Drug|pembrolizumab|
1564804|NCT02492568|Radiation|Stereotactic Body Radiation Therapy|
1564805|NCT02492555|Other|SI|A routine scheduled (SI) screening of FC and DA every 3rd month
1564806|NCT02492555|Other|OD|A screening of FC and DA on demand (OD)
1564807|NCT02492542|Device|PHENIX USB 8.|Electrical stimulation program: frequency: 1/4/Hertz (HZ), pulse width: 270/230/270 μs, time: 30min. Electrode piece: 50*50mm sticky electrode plate. Position: an electrode piece is placed in the S3, and an electrode piece is placed in the bladder region.Current intensity adjusted according to the patient's tolerance, the maximum current intensity of the pain was not appropriate, generally not more than 100milliampere(mA).Devices PHENIX USB 8.
1564808|NCT02492529|Other|Neuropsychological tests|"Scales and tests to evaluate:
Global cognitive performance
Handedness
Memory functions performance
Gestural praxis functions performance
Lexical and semantic functions performance
Executive functions performance
Memory disorders
Way of life
Mood"
1564809|NCT02492529|Device|A cranial MRI|
1564811|NCT02492516|Biological|mesenchymal stem cells|mesenchymal stem cells injection via peripheral vein.
1564812|NCT02492503|Drug|Paclitaxel and carboplatin|Paclitaxel 60 mg/ m2 administered in 250 ml normal saline over 1 hour, and carboplatin AUC 2 administered in 250 ml 5%D over 1 hour. Therapy repeated every weekly
1564813|NCT02492503|Drug|Paclitaxel and carboplatin|Paclitaxel 175 mg/ m2 administered in 250 ml normal saline over 3 hours and carboplatin AUC 4-5 administered in 250 ml 5%D over 2 hours. Therapy repeated every three weekly
1564814|NCT02492490|Other|SVFderived MSC transplantations|"infusion of autologous SVF derived MSC to the recipients of DCD kidney transplant.
Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD. And the induction therapy of control group will be Basiliximab."
1564815|NCT02492490|Drug|Basiliximab|induction with Basiliximab before kidney transplantation and on POD 4
1564816|NCT02492477|Procedure|evaluation of PORT-A-CATH®|in patients in curative setting, clinical assessment, PORT-A-CATH® testing of possibility of saline-administration and blood withdrawal with vacutainer, laboratory assessment
1564817|NCT02492477|Drug|blocking with Medunasal®-Heparinblock|blocking of the functioning PORT-A-CATH® with heparinized 0,9% NaCl solution
1564818|NCT02492477|Drug|restoration of PORT-A-CATH® with Alteplase|by malfunction of the PORT-A-CATH® attempting of restoration with Actilyse® according to guidelines
1564819|NCT02492464|Dietary Supplement|Red yeast rice|1 capsule to be taken before to sleep, each day, for 6 months
1564820|NCT02492464|Dietary Supplement|Placebo|
1564821|NCT02492451|Other|Endometrial Injury|Endometrial injury in luteal phase of preceding cycle by pipelle canula
1564822|NCT02492451|Drug|progesterone (Crinone® %8 vaginal progesterone gel)|Luteal phase support with progesterone (Crinone® %8 vaginal progesterone gel) in IUI cycle Vaginal progesterone gel is administered from second day after insemination until pregnancy testing and is continued in the presence of pregnancy until the 12 weeks of pregnancy.
1564823|NCT02492438|Biological|PPV23 vaccination or PCV13 vaccination|
1564824|NCT02492412|Drug|HE 10|
1564825|NCT02492412|Drug|Restasis|
1564826|NCT02492399|Procedure|extended myectomy|The scheme of extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
1564827|NCT02492399|Procedure|myectomy by Morrow|A first myotomy is made into the septum just below the base of the right coronary leaflet at a point 2-3 mm to the right of the commissure between the left and right coronary leaflets. A second myotomy is made in the same manner, parallel to the first one and about 1 cm to the right of it. The two vertical myotomies are made and cornnected transversely in the interventricular septum. The muscle bar is then grasped with the angled rongeur and the instrument is pushed firmly toward the apex, peeling the mtusele from its anterior septal attachments. After completion of the resectioni, a rectangular channel about 1 X 1.5 cm is palpable from the valve ring toward the apex for a dis- tance of about 4 cm.
1564828|NCT02492386|Device|Bioabsorbable everolimus-eluting stent deployment|Bioabsorbable everolimus-eluting stent deployment
1564829|NCT02492373|Drug|topical 0.05% Clobetasol propionate ointment|Apply only on the treated area twice a day as mentions
1564830|NCT02492373|Device|Q switched Nd:YAG laser 532 nm|Treatment of facial lentigines. The energy using depends on the endpoint of immediate whitening of the lesions.
1564831|NCT02492360|Procedure|Blood sample collection|Six tubes of blood will be collected during one blood draw.
1564832|NCT02492360|Behavioral|Report of peripheral neuropathy after cisplatin therapy|Twenty questions about the peripheral neuropathy the patient is currently experiencing, and twenty questions about the worst peripheral neuropathy the patient ever experienced after cisplatin treatment.
1564833|NCT02492347|Procedure|Electrocardiogram|The ECG is a non-invasive screening tool. It will be performed when the neonate is settled and comfortable. The electrodes used are made with soft jelly adhesive which is stored at room temperature. The procedure will be conducted in a timely manner, taking no longer than 15 minutes. The electrodes are easily removed, and the neonate redressed.
1564834|NCT02492334|Drug|Doxazosin|Doxazosin is a quinazoline compound that is a selective inhibitor of the alpha-1 subtype of alpha-adrenergic receptors. The chemical name is 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl) piperazine methanesulfonate. The molecular formula for doxazosin is C23H25N5O5 • CH4O3S and the molecular weight is 547.6. Doxazosin is used clinically to treat hypertension and improve urination in men with benign prostatic hyperplasia.
1564835|NCT02492334|Drug|Placebo|Placebo, or inactive pill.
1564836|NCT02492321|Drug|EBI-005|
1564837|NCT02492321|Drug|Placebo Comparator|
1564838|NCT02492308|Procedure|SVF-MSC induction|"Procedure: infusion of autologous SVF derived MSC to the recipients of living-relative kidney transplant.
Subjects with uremia in the intervention group will undergo puncture to collect SVF, then SVF will be cultured to abstain MSC, and the abstained MSC will be infused to the recipients during kidney transplant operation and on 7, 14, and 21 POD"
1564839|NCT02492308|Drug|Basiliximab induction|The control group will be inducted with Basiliximab before living-relative kidney transplantation and on POD 4
1564840|NCT02492295|Drug|Propofol|"Propofol will be administered as a 0.5mg/kg (at a concentration of 10mg/mL, rounded to the nearest 0.5mL) initial bolus, followed by repeat 0.25mg/kg boluses (same rounding) every three to five minutes as needed to maintain RASS target -2 (light sedation - awakens to voice <10 seconds) to RASS target of -3 (moderate sedation - movement or eye opening without eye contact) for 15 minutes. No more than 1.5mg/kg of propofol will be administered over this time period. After the sedation session is complete, patients will be allowed to wake up and will be monitored in the ED for at least another hour prior to discharge."
1564841|NCT02492282|Device|Closed-Loop propofol and remifentanil system by Bispectral Index|
1565211|NCT02489422|Other|Daily Survey Administration|Ancillary studies
1564842|NCT02492282|Device|Open-Loop propofol and remifentanil by Target Controlled Infusion|
1564843|NCT02492282|Drug|propofol|
1564844|NCT02492269|Drug|Dexmedetomidine|
1564845|NCT02492269|Drug|Placebo|
1564846|NCT02492256|Device|Pulmonary vein isolation|CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. Conventional PVI by circumferential antral ablation according to standard procedures. Exit and Entrance block conformation. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia.
1564847|NCT02492256|Device|GP ablation guided by SUMO technology|"CARTO- reconstruction LA, preferably during same rhythm as SUMO map (generally sinus rhythm) for use during registration of SUMO map in CARTO. High frequency stimulation (HFS; 20-Hz frequency, 5-ms pulse duration, and 15-mA output) to access positive vagal response (the heart rate decreasing by 50% at baseline). RF Ablation of SUMO hotspots (in sinus rhythm if AF converts)
• Target a region of 1.0-1.5 cm diameter around the SUMO 'hotspot'. Control HFS. Attempt to induce sustained atrial tachycardia. Optional mapping and ablation of post-ablation atrial tachycardia."
1564848|NCT02492256|Device|ILR implantation|Implantation the ECG loop recorder according to standard procedure
1564849|NCT02492243|Device|PCI|
1564850|NCT02492243|Device|ILR implantation|
1564851|NCT02492230|Device|Left Atrial Appendage Closure Device (Watchman)|This device is a self-expanding nickel titanium (nitinol) frame structure with fixation barbs and a permeable polyester fabric cover. The device ranges in diameter from 21 mm to 33 mm to accommodate varying LAA anatomy and size. It will be implanted via a trans-septal approach by use of a catheter based delivery system to seal the ostium of the LAA. The implantation will be guided by fluoroscopy and TEE to verify proper positioning and stability. The dose of warfarin will be adjusted to maintain INR 2.0 - 3.0 for 45 days. If TEE data shows no additional flow in LAA, warfarin will be discontinued: Aspirin dose: 75 mg for all period of study; Clopidogrel dose: 75 mg for 6 months after procedure.
1564852|NCT02492230|Drug|Warfarin|"Warfarin dose adjusted to maintain INR 2.0-3.0 for all period of study; Aspirin dose-75mg for 45 days after randomization; Clopidogrel dose-75mg for 6 months after procedure.
All drugs will be started before PCI procedure. Low molecular weight heparins will be used before procedure and will be stopped when INR reach 1.8-2.0."
1564853|NCT02492217|Drug|Adalimumab|
1564854|NCT02492191|Device|Smartphone app Recovery Assessment by Phone Points (RAPP)|An e-assessed follow-up of day surgery patients postoperative recovery measured via smartphone app
1564855|NCT02492178|Drug|Intrarectal artesunate|
1564856|NCT02492178|Drug|Intravenous artesunate|
1564857|NCT02492178|Drug|Intravenous quinine|
1564858|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
1564859|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
1564860|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
1564861|NCT02492165|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine (IMOJEV®)|0.5 mL, Subcutaneous
1564862|NCT02492152|Device|Study group|Dianatal
1564863|NCT02492139|Device|Pumping CE-marked Symphony Pumpset|Pumping with the CE-marked Symphony Pumpset
1564864|NCT02492139|Device|Pumping BrownieForSymphony Pumpset|Pumping with the the BrownieForSymphony Pumpset
1564865|NCT02492126|Other|Citric Acid|Subjects will undergo cough reflex sensitivity testing to citric acid.
1564866|NCT02492113|Procedure|Positive end-expiratory pressure (PEEP)|"Titrated-PEEP. After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at Titrated-PEEP, with the PSV=0 and FiO2 unchanged."
1564867|NCT02492113|Procedure|ZEEP|"After recruitment maneuver and decremental PEEP trial, the Titrated-PEEP is identified. Patients will have two spontaneous breathing trials (SBTs). In this arm, patients will have SBT at PEEP = 0-5 cmH2O, with the PSV=0 and FiO2 unchanged."
1564868|NCT02492100|Behavioral|Multi-modality sexual dysfunction intervention|
1564869|NCT02492087|Drug|Topical tranexamic acid|Topical tranexamic acid 2g diluted with normal saline 0.9% to a volume of 120mls solution (Concentration 16.7mg/ml)
1564870|NCT02492087|Drug|Normal saline 0.9%|Sterile Normal saline 0.9% 120mls solution
1564871|NCT02492074|Drug|Delta-9-tetrahydrocannabinol|
1564872|NCT02492074|Drug|Cannabidiol|
1564873|NCT02492074|Drug|Placebo|
1564874|NCT02492061|Behavioral|Demand creation for couples' HCT|The demand creation for couples' HCT intervention aims at improving uptake of couples' HCT among married couples in Rakai, southwestern Uganda
1564875|NCT02492048|Device|Cellutome Epidermal Harvesting System|
1564876|NCT02492048|Procedure|Split Thickness Skin Graft|
1564877|NCT02492035|Behavioral|Lifestyle intervention|
1564878|NCT02492022|Dietary Supplement|Probiotic L008-1|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
1564879|NCT02492022|Dietary Supplement|Probiotic L008-2|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
1564880|NCT02492022|Other|Placebo|Dosing regimen of 2 capsules daily, once per day, for 14 weeks
1564881|NCT02492009|Behavioral|Standard Resource Sheet|Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
1564882|NCT02492009|Behavioral|Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:
Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;
(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and
A summary section that outlines the information reviewed and which benefits and risks they deemed most important.
At the end of the PDA, women allocated to this intervention will ALSO receive the standard resource sheet which is being used as the placebo comparator."
1565016|NCT02490943|Other|Cold Compress After Injection|Receive cold compress after injection for three treatments followed by warm compress before injection for three treatments.
1564883|NCT02491996|Behavioral|desire satisfaction-targeted intervention for disordered gamblers|This intervention consists of an initial psychiatric assessment, followed by psychoeducational approach based on desire satisfaction-targeted intervention by psychiatrists, and three group sessions based on CBT by psychologists. Patients with psychiatric comorbidities are treated with the appropriate pharmacological regimens.
1564884|NCT02491983|Drug|Palbociclib|
1564885|NCT02491983|Drug|Letrozole|
1564886|NCT02491983|Drug|Fulvestrant|
1564887|NCT02491970|Drug|Fluticasone/Formoterol|
1564888|NCT02491970|Drug|Fluticasone/Salmeterol|
1564889|NCT02491957|Other|LOFT Therapy|"LOFT Therapy™ will be performed 2 times a week for 4 weeks a total of 8 sessions. The patient will be wrapped with fabric cuffs, on up to four limbs. The cuffs are applied to the widest part of the biceps and upper thighs at pressures between 80-100 mmHg with minimal venous encroachment. The patients will ride a recumbent bike for 18 total minutes of sub-maximal exertion (up to 70% repetition maximum ), with the option of up to 2 periods of 15-second higher intensity exertions as tolerated, followed by individualized respiratory recovery periods determined by the relative decrease in breathing effort.
The 18-minute session will be preceded by a two-minute compression check, where the wraps will be adjusted based on any signs or symptoms of nerve or vessel impingement."
1564890|NCT02491944|Drug|AZD9291|Single oral dose of 80 mg AZD9291 tablet on Day 1 administered orally with 240 mL water following an overnight fast.
1564891|NCT02491944|Drug|[14C]AZD9291|Each healthy male subject will also receive a single, radiolabeled, 100 μg dose of [14C] AZD9291 administered as an IV microdose infusion starting at 5 hours and 45 minutes after receiving the oral dose.
1564892|NCT02491931|Dietary Supplement|Supplement/placebo intake|Patients will receive either GLN or placebo prior to cardiovascular surgery under extracorporeal circulation, during 3 days and one final dose 4 hours prior to anesthesia.
1564893|NCT02491918|Procedure|cataract surgery|cataract surgery in children
1564894|NCT02491918|Procedure|Intraocular lens implantation|intraocular lens implantation in the capsular bag or optic capture
1564895|NCT02491905|Drug|HL tablet|
1564896|NCT02491905|Drug|Placebo|
1564897|NCT02491892|Drug|Pertuzumab|Participants will receive one of two IV treatment regimens with pertuzumab: either 420 mg every 3 weeks, with an initial 840-mg loading dose, or 1050 mg every 3 weeks with no loading dose administered.
1564898|NCT02491879|Drug|Ketoprofen|2.5% Ketoprofen gel with a 2 g local use
1564899|NCT02491879|Other|Placebo|Placebo gel with a 2 g local use
1564900|NCT02491866|Other|to develop and validate a Computerized Adaptative Testing|"Elaboration of a pool of items, based on literature review and interview with patients.
Selection of the most relevant items based on a qualitative approach using cognitive interview with patients.
Calibration of the item bank : the psychometric properties of the item bank will be based on classical test and item response theories and approaches, including the evaluation of unidimensionality, item response theory model fitting, and analyses of differential item functioning.
Metrological validation of the CAT.
Analysis of the implementation of the CAT in clinical practice using interview with professionals and patients."
1564901|NCT02491853|Device|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator
1564902|NCT02491840|Procedure|Biopsy|Biopsy of Gastric and cardia adenocarcinomas
1564903|NCT02491827|Other|Cellvizio mini laser probe|Cellvizio mini laser probe is administered via the endoscopic device used during the neurosurgical procedures to provide the optical biopsy
1564904|NCT02491814|Other|1% M.F. Milk|
1564905|NCT02491814|Other|Yogurt Beverage|
1564906|NCT02491814|Other|Soy Beverage|
1564907|NCT02491814|Other|Almond Beverage|
1564908|NCT02491814|Other|Water|
1564909|NCT02491814|Other|Breakfast cereal|
1564910|NCT02491801|Other|Dietary intervention|All arms are given to all participants, in a randomized order
1564911|NCT02491788|Drug|Suvorexant|
1564912|NCT02491788|Drug|Placebo|
1564913|NCT02491762|Procedure|respiratory function tests|FVC, FEV1, MVV, FRC, RV, TLC, MIP, MEP
1564914|NCT02491749|Procedure|Ultra Fast-Track Anesthesia|early extubation at the end or within one hour post operatively
1564915|NCT02491736|Drug|Ketoprofen|2.5% ketoprofen gel
1564916|NCT02491736|Other|Placebo|Placebo gel
1564917|NCT02491723|Drug|Azithromycin|Patients with bronchiectasis treated with Azithromycin for three to five days.
1564918|NCT02491710|Device|Training on low-cost box trainer|
1564919|NCT02491710|Device|Training on standard box trainer|
1564920|NCT02491697|Biological|DC-CIK Immunotherapy|DC-CIK cells are used to treat advanced breast cancer with capecitabine.
1564921|NCT02491697|Drug|Capecitabine Monotherapy|All patients receive capecitabine monotherapy (2500 mg/m2 twice daily) for 2 weeks followed by a 1-week rest period.And the treatment is repeated every 3 weeks.
1564922|NCT02491684|Drug|Interferon beta-1a Nebuliser solution 48 μg/mL|Interferon beta-1a, 0,5 ml (24 μg, metered dose) once daily inhalation for 14 days
1564923|NCT02491684|Drug|Placebo|Placebo solution for once daily inhalation for 14 days
1564926|NCT02491658|Biological|UC-MSCs|Psoriasis Vulgaris patients will receive 6 times UC-MSCs infusions (each time 1×10^6/kg). The first time to fourth time will be given once a week for successive 4 weeks, then the last two times will be given once every two weeks.
1564927|NCT02491645|Other|Sensory interventions|"Tactile stimulation: Brushing technique , handling materials of various textures, bear hug and rug , play dough and find in rice techniques to be done.
Proprioception technique : Joint compression , popping bubbles, lifting weights of different measures and scooter board push activities to be done.
Movement/vestibular techniques :Bear hug and rug , swinging or rocking motion, jumping or spinning to be done.
Visual stimulation : picture recognition, dot colouring , lighting balls and toys , familiarisation of emotions to be done.
Auditory stimulation : Sound familiarisation and music time will be done."
1564928|NCT02491632|Drug|Dexamethasone|"High-Dose Group: 8 mg orally twice a day for 7 days.
Low-Dose Group: 4 mg orally twice a day for 7 days."
1564929|NCT02491632|Other|Physical Activity|Participants perform resistance exercises 3 days a week, and walk at least 5 day a week.
1565063|NCT02490592|Other|Fluoride gel|Fluoride gel - Flugel FFA (NaF 1.23%) (G2)
1564930|NCT02491632|Other|Physical Activity Tests|Participants perform physical activity tests at baseline, Days 8, 15, 29, and 57. Tests will include a 30-second chair-stand test and a 6-minute walk test.
1564931|NCT02491632|Behavioral|Questionnaires|Quality of life questionnaires completed at baseline, Days 8, 15, 29, and 57.
1564932|NCT02491632|Other|Phone Calls|Study staff calls participants 1 time each week while on study.
1564933|NCT02491619|Procedure|orthodontic decompensation|Evaluation of the correlation between bone thickness and tooth inclination previously and after orthodontic treatment of decompensation due to orthognathic surgery
1564934|NCT02491606|Drug|Tafenoquine|Tafenoquine 200mg and 400 mg
1564935|NCT02491606|Other|Placebo|Placebo
1564936|NCT02491593|Device|fecal occult blood test|
1564937|NCT02491554|Device|Conventional AC-PC based implantation of ACTIVA INS DBS system|Conventional AC-PC based implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the thalamic/subthalamic region (Vim-cZI).
1564938|NCT02491554|Device|MR-tractography guided implantation of ACTIVA INS DBS system|MR-tractography guided implantation of ACTIVA INS DBS system (manufactured by Medtronic) in the DRT.
1564939|NCT02491541|Biological|Changchun Werersai|"A rabies vaccine (Vero Cell) for human use produced by Changchun Werersai Biotech Pharmaceutical Co., Ltd.
1.0 ml experimental vaccine on day 0,3,7,14,28"
1564940|NCT02491541|Biological|Jilin Maifeng|"A rabies vaccine (Vero Cell) for human use produced by Jilin Maifeng Biotech Pharmaceutical Co., Ltd.
1.0 ml comparator vaccine on day 0,3,7,14,28"
1564941|NCT02491528|Biological|insulin Aspart injection|Subcutaneous injection of insulin Aspart prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
1564942|NCT02491528|Biological|insulin Aspart injection (NovoRapid)|Subcutaneous injection of insulin Aspart injection (NovoRapid) prior to three meals every day, while subcutaneous injection of Lantus at bedtime.
1564943|NCT02491515|Drug|Denosumab|every 6 month injection
1564944|NCT02491502|Device|Echopulse|HIFU Under ultrasound guidance
1564945|NCT02491489|Other|Glenohumeral mobilization|Participants will then be placed supine on a standard plinth. The investigators will then proceed to provide a mobilizing force to the participant's glenohumeral joints. Each of two investigators will, in sequence perform a 15 second longitudinal distraction, followed by a 15 second posteriorly directed glenohumeral glide with the shoulder placed in the open pack resting position (~50 degrees abduction, slight horizontal adduction, external rotation).
1564946|NCT02491476|Device|intracerebral micro-macroelectrodes|All patients will be implanted with usually 4 micro-macroelectrodes (replacing the regular clinical macroelectrodes). The primary and secondary outcomes will then be assessed.
1564951|NCT02491450|Drug|Heterosofir|1 tablet contains 400 mg sofosbuvir
1564952|NCT02491450|Drug|Sovaldi|1 tablet contains 400 mg sofosbuvir
1564953|NCT02491437|Drug|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
1564954|NCT02491437|Drug|intravaginal progesterone gel 90 mg|
1564955|NCT02491424|Device|Direct skeletal fixation of ITAP to lower limb amputees.|Intraosseous Transcutaneous Amputation Prosthesis (ITAPTM) fitting. The core ITAP™ design comprises of three discrete sections, the proximal section, which is the intramedullary stem secured into the medullary canal, the soft tissue integration flange and the transcutaneous component that passes through the skin.
1564956|NCT02491411|Drug|Dexamethasone|Given PO
1564957|NCT02491411|Drug|Enzalutamide|Given PO
1564958|NCT02491411|Other|Laboratory Biomarker Analysis|Correlative studies
1564959|NCT02491411|Other|Quality-of-Life Assessment|Ancillary studies
1564961|NCT02491385|Procedure|thoracic epidural analgesia|In a sitting position, an 18-gauge Tuohy needle is introduced at T6-7 or T7-8 intervertebral space using a paramedian approach. An epidural catheter is advanced 5 cm beyond the tip of the needle and secured with a sterile dressing. For TEA regimen, hydromorphone (8 mcg/ml) was added to 0.15% ropivacaine. TEA setting was bolus/lock out time/basal, 3 ml/15 min/5 ml.
1564962|NCT02491385|Drug|iv-PCA|iv-PCA setting was fentanyl 20 mcg/ml, bolus/lock out time/basal, 0.5 ml/15 min/0.5 ml.
1564963|NCT02491372|Behavioral|Acceptance and Commitment Therapy|ACT is a psychological intervention that aims to promote adaptive coping and encourages participants to move their focus away from trying to control emotions to accepting and adapting to them. It is relevant to all patients, not just those who are currently distressed.
1564964|NCT02491359|Drug|Carfilzomib|Given IV
1564965|NCT02491359|Other|Laboratory Biomarker Analysis|Correlative studies
1564966|NCT02491359|Other|Quality-of-Life Assessment|Ancillary studies
1564967|NCT02491359|Other|Questionnaire Administration|Ancillary studies
1564968|NCT02491346|Procedure|conventional empirical glycemic control|the patients' blood glucose is controlled by physician according to their experience through insulin subcutaneous injection or insulin continuous infusion whose dosage is determinated by the physician.
1564969|NCT02491346|Procedure|SGC directed glycemic control|the patients' blood glucose is controlled by SGC system through insulin continuous infusion whose dosage is determinated by SGC.
1564970|NCT02491333|Other|true acupuncture|True acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
1564971|NCT02491333|Other|sham acupuncture|Sham acupuncture treatment will be given three times per week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 4 month.
1564972|NCT02491333|Drug|metformin|Metformin will be given at 0.5g/times, 3 times one day and for 4 month.
1564973|NCT02491333|Drug|Placebo metformin|Placebo metformin will be given at 0.5g/times, 3 times one day and for 4 month.
1564974|NCT02491320|Other|Pre-treatment acupuncture|Acupuncture treatment will start on day 3-5 after a spontaneous period or after a withdrawal bleeding following progestin. They will receive acupuncture treatment three times a week. Each treatment session lasts for 30 minutes and can be separated by an interval of 1-3 days, with a maximum of 48 treatment sessions during 16 weeks.
1564975|NCT02491320|Drug|Letrozole|Starting from 2.5mg daily from day 3-5 for 5 days after a spontaneous period or after a withdrawal bleeding following progestin, one time per day.Participants are treated for up to 4 cycles.
1564976|NCT02491307|Other|Ginger.io Smartphone Application|Daily use of the Ginger.io smartphone application
1564977|NCT02491294|Behavioral|School|students receive Cooking With Kids (CWK) - Colorado cooking & tasting lessons, SPARK active recess, and Cafeteria Connections
1564978|NCT02491294|Behavioral|Family|students receive the FFF family component - family nights, parent blog, and action packs that go home after each CWK-Colorado lesson
1564979|NCT02491294|Behavioral|About Eating|parents who completed the parent survey are invited to access the 6 lesson online About Eating program
1564982|NCT02491268|Drug|Cilostazol|
1564983|NCT02491268|Drug|Placebo|
1564984|NCT02491255|Device|Lotus Valve System|Device: Lotus Valve System
1564985|NCT02491242|Other|Dolutegravir in a dual therapy regimen|None. Patients initiating Dolutegravir-based dual therapy because of nucleoside analogues toxicity or intolerance will be followed up during a year
1564986|NCT02491229|Other|Hepafast|Two weeks of Hepafast three times a day and additionally 200 kcal followed by 10 weeks of Hepafast two times a day and a meal according to LOGI diet
1564987|NCT02491229|Other|LOGI diet|For twelve weeks, this group eats meals according to the Low Glycemic and Insulinemic Diet (LOGI).
1564988|NCT02491216|Other|Acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS Homes. Designated para-medical staffs working in the elderly home or informal care giver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
1564989|NCT02491203|Other|Telerehabilitation system|Usual care plus home-based virtual reality telerehabilitation system.
1564990|NCT02491190|Behavioral|EMPOWER Educational Module|Evidence-based video module delivering content of the Right Question intervention from Deen et al. (2011)
1564991|NCT02491177|Behavioral|cMM|Home visits from community mentor mothers
1564992|NCT02491177|Behavioral|Text Messaging|Text messages received on mobile phone
1564995|NCT02491138|Behavioral|Appearance-based intervention|
1564996|NCT02491138|Other|Pamphlets|
1564997|NCT02491125|Dietary Supplement|soluble wheat bran fibre|12 weeks daily intake of 15g of soluble wheat bran fibre
1564998|NCT02491125|Dietary Supplement|Placebo|12 weeks daily intake of 15g of maltodextrin
1565000|NCT02491086|Drug|Nicotine replacement therapy (NRT) sampling|1-week free NRT
1565001|NCT02491086|Behavioral|Smoking cessation counseling|Smoking cessation counseling
1565003|NCT02491060|Drug|IDP-121 Lotion|Investigational Product: IDP-121 Lotion
1565004|NCT02491060|Drug|IDP-121 Vehicle Lotion|Comparator Product: IDP-121 Vehicle Lotion
1565005|NCT02491047|Device|BonyPid-1000TM|BonyPid-1000TM implantation concomitantly to standard of care (SOC) treatment
1565006|NCT02491047|Procedure|Standard of Care (SOC) treatment|Standard of Care (SOC) treatment only
1565007|NCT02491034|Behavioral|Depression Education Intervention|Depression Education Intervention (DEI) designed to increase disease literacy, and dispel myths about depression and its treatment among Hispanic patients thus reducing stigma and increasing treatment engagement.
1565008|NCT02491021|Other|Rehabilitation Class|A 6 week programme of exercise and education in an out patient setting
1565009|NCT02491008|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 mcg daily (reduced to 25 mcg in subjects <50 kg of body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) vs. matching placebo; at 3 months, if the serum TSH level is <0.4 mU/L, dose will be reduced by 25 mcg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6 mU/L, additional 25 mcg. The process will be repeated at 12 months, then annually; mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine which will be prescribed is 150 mcg (after 4 increments of 25 mcg at 3 months, 1, 2, 3 years; from the starting dose of 50 mcg).
1565010|NCT02491008|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
1565011|NCT02490995|Other|Movie|Besides the anesthesist explanations the children will have a movie explanation.
1565012|NCT02490982|Drug|Teriflunomide|The prescription of Teriflunomide administered orally as a 14mg daily compound to RRMS patients.
1565013|NCT02490969|Procedure|Routine management observation|Early rule out of myocardial infarction with combined copetine and troponin testing at admission
1565014|NCT02490956|Biological|Verorab® (PVRV; Purified Vero Cell Vaccine)|"Verorab® (PVRV; Purified Vero Cell Vaccine) 0.5 ml intramuscular
Standard intramuscular regimen: ESSEN on days 0, 3, 7, 14, 28 and booster at 1 year later on days 360 and 363"
1565015|NCT02490943|Other|Warm Compress Before Injection|Receive warm compress before injection for three treatments, followed by cold compress after injection for three treatments.
1565210|NCT02489422|Other|Questionnaire Administration|Ancillary studies
1565017|NCT02490930|Drug|Fingolimod|Oral fingolimod will be given 1 week prior to the initiation of concurrent radiation and temozolomide and will be discontinued immediately upon completion of the six weeks of therapy.
1565018|NCT02490917|Device|ACT™ device|Implantation of the Adjustable Continence Therapy device ACT®
1565019|NCT02490917|Device|AMS 800 ™ device|Implantation of the artificial urinary sphincter AMS 800 ™
1565020|NCT02490904|Drug|Eplerenon|Double blinded Eplerenon administrated for 4 days at 25mg each 12 hours
1565021|NCT02490904|Drug|Placebo|Double blinded Placebo administrated for 4 days at 25mg each 12 hours
1565022|NCT02490891|Device|RGD K5 PET scan|PET scan with a tracer specific for angiogenesis (RGD K5) will be performed before and after 2 cycles of chemotherapy
1565023|NCT02490878|Drug|bevacizumab|IV
1565024|NCT02490878|Drug|corticosteroids|IV
1565025|NCT02490878|Other|placebo|IV
1565026|NCT02490865|Drug|RNS60|RNS60, 4 ml dose nebulized twice daily
1565027|NCT02490865|Drug|Normal saline|Normal Saline, 4 ml dose nebulized twice daily
1565028|NCT02490852|Other|Investigational infant formula|fed ad libitum
1565029|NCT02490852|Other|Active Comparator: Commercially available Infant formula|fed ad libitum
1565030|NCT02490852|Other|Active Comparator: Human milk|fed ad libitum
1565031|NCT02490839|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
1565032|NCT02490839|Drug|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
1565033|NCT02490826|Other|Table-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on table top materials. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:
Auditory Bombardment;
Auditory and discrimination;
Letter-sound knowledge;
Phoneme identity and phoneme matching;
Blending;
Segmentation;
Rhyme;
Phoneme manipulation."
1565034|NCT02490826|Other|Tablet-based T2T intervention|"Phonological therapy consists of a combination of phonological awareness activities, auditory and discrimination and auditory bombardment activities. This activities will be based on digital materials presented on a tablet. The items used in the intervention will be based on the child's target speech production goals. This intervention will include the following areas:
Auditory Bombardment;
Auditory and discrimination;
Letter-sound knowledge;
Phoneme identity and phoneme matching;
Blending;
Segmentation;
Rhyme;
Phoneme manipulation."
1565035|NCT02490813|Dietary Supplement|Treatment - Chinese Herbal Formula - X|Wu Mei (Fructus Pruni Mume), Ling Zhi (Gonoderma), Huang Bai (Cortex Phellodendron), and Zhi Su (Perilla frutescens).
1565036|NCT02490813|Dietary Supplement|Placebo|Placebo will be starch with colorings
1565037|NCT02490800|Drug|Oral daily administration of BAL101553|oral administration
1565038|NCT02490787|Drug|Concizumab|Administered subcutaneously (s.c., under the skin) at five different dose levels (ranging from 0.25 to 1.5 mg/kg)
1565039|NCT02490787|Drug|placebo|Administered subcutaneously (s.c., under the skin)
1565040|NCT02490774|Drug|BAY1007626|Intrauterine device with 4 different in vitro release rates (low, low to medium, medium, high)
1565041|NCT02490774|Drug|Jaydess|Jaydess: Intrauterine device with a nominal in vitro release of 12 µg levonorgestrel/day
1565042|NCT02490774|Drug|Mirena|Mirena: Intrauterine device with a nominal in vitro release of 20 µg levonorgestrel/day
1565043|NCT02490748|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
1565044|NCT02490748|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
1565045|NCT02490735|Biological|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
1565046|NCT02490722|Other|Patient education|Four times two hours group based patient education
1565047|NCT02490709|Procedure|Local excision|Local excision for rectal cancer with good response
1565048|NCT02490696|Device|Miso PET scan|2 PET scans will be performed before surgery : the first one with F-Miso tracer and the second, 24 hours later, with FAZA tracer
1565049|NCT02490696|Device|FAZA PET scan|2 PET scans will be performed before surgery : the first one with FAZA tracer and the second, 24 hours later, with F-Miso tracer
1565050|NCT02490683|Dietary Supplement|Luna Rich X|
1565051|NCT02490683|Dietary Supplement|Placebo|Starch pill/or powder manufactured to mimic Luna Rich X and Reliv Now
1565052|NCT02490683|Dietary Supplement|Reliv Now|
1565053|NCT02490670|Drug|Cephalexin|Administered orally
1565054|NCT02490657|Drug|Inhaled iloprost|"Nebulized agents (Iloprost or normal saline) were randomized by computer-generated randomization. The patients and anesthesiologist, who administered inhalation and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication, was the only person recognizing of the randomization code during trial.
Enrolled patients were received 20 μg iloprost or placebo (norma saline). Iloprost was diluted in normal saline to obtain 2ml solution. Control group were inhaled comparable dose of normal saline. Iloprost or normal saline was inhaled through an ultrasonic nebulized system in inspiratory limb."
1565055|NCT02490657|Drug|normal saline (Saline 0.9%)|
1565056|NCT02490644|Procedure|Blood sampling|Blood sampling 5ml
1565057|NCT02490631|Drug|2% chlorhexidine gluconate cloths|Cleansing twice pre-operatively jawline to toes with 2% chlorhexidine gluconate cloths
1565058|NCT02490618|Other|Probiotic tablet- Biogaia|
1565059|NCT02490618|Other|Placebo tablet|
1565060|NCT02490605|Procedure|occlusal plate group|occlusal plate with criteria for occlusal stability (simultaneous, bilateral contacts with an absence of interference in the canine and anterior guides
1565061|NCT02490605|Procedure|therapeutic exercises|"The exercise will consist of the movement of repeatedly opening the mouth with the tongue cleaving to the roof of the mouth 3 times per day with each period consists of of 3 sets with 15 repetitions"
1565062|NCT02490592|Other|Fluoride Foam|Fluoride foam - Flúor Care (NaF 1.23%) (G1)
1565064|NCT02490579|Behavioral|Responses to Brief Video Messages (Facebook)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) self-efficacy about healthy eating, exercise and weight gain during pregnancy.
1565065|NCT02490579|Behavioral|Response to Brief Video Messages (Clinic)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) who in her social network she turns to for non-clinical health advice and what kinds of advice she gotten in the past.
1565066|NCT02490579|Behavioral|Response to Brief Video Messages (Social Network)|Participants view 1 of 6 brief video messages about health in pregnancy, then answer survey questions that will assess their a) acceptability, b) understanding of core messages, and c) how they advise their pregnant friend about different health topics.
1565067|NCT02490566|Other|Telehealth|Tablet with chronic disease apps will be given to this group, apps will be focused on patient's condition. Follow-up visits will be conducted through video-conferencing.
1565068|NCT02490553|Other|heteroevaluation scale by a nurse or doctor|
1565069|NCT02490540|Drug|Sufentanil SPI analgesia|Sufentanil is given based on SPI value in the SPI guided analgesia group. The targer SPI range is set indiviudally based on the initial value of SPI recorded 5 minutes after the induction of anesthesia plus 10 points. In the ANI group, Sufentanil is given based on the ANI value, the target ANI range is 50 - 70. Values lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially. In the anesthesiologist guided analgesia group, Sufentanil is administered in a standardized manner.
1565070|NCT02490540|Drug|Sufentanil ANI analgesia|Sufentanil is given based on ANI analgesia monitor figures in the sufentanil ANI analgesia group. Targeted ANI range is 50 - 70. Figures lower than 49 for 1 minute indicate the need of administering further dose of opioid, sufentanil is given in the same dose as initially and flushed with 20 ml of saline. The next dose of opioid can be given in the earliest after 3 minutes interval, if indicated according to ANI monitoring. The doses are repeated up to achievement of the targeted range of analgesia (ANI). The last dose of opioid can be given no later than 15 minutes before the end of surgery.
1565071|NCT02490540|Drug|Sufentanil anesthesiologist analgesia|Sufentanil is given based on the anesthesiologist decision in the sufentanil anesthesiologist analgesia group. Sufentanil is administered in 20 minute intervals in a standardized manner, the same dose as initially is given and flushed with 20 ml of saline. Indication for additional administration of opioid beyond this interval is 25 % increase of systemic arterial pressure over the baseline and/or 35% increase of heart rate over the baseline. The next dose of opioid can be given in the earliest after 3 minutes interval. The doses are repeated up to achievement of the haemodynamic stability. The last dose of opioid can be given no later than 15 minutes before the end of surgery.
1565072|NCT02490527|Dietary Supplement|Pure epicatechin capsules (100mg)|Epicatechin is a compound found naturally in dark chocolate.
1565073|NCT02490527|Drug|Simvastatin (40mg)|A cholesterol-lowering medication that blocks the production of cholesterol.
1565074|NCT02490527|Other|Placebo|A substance that has no therapeutic effect and will act as a control.
1565075|NCT02490514|Other|No intervention|No intervention was administered in this study.
1565076|NCT02490501|Procedure|SC0806 and rehabilitation|
1565077|NCT02490501|Other|Rehabilitation only|
1565078|NCT02490488|Drug|Masitinib (AB1010)|6 mg/kg/day
1565079|NCT02490488|Drug|Gemcitabine|1000 mg/m² administered by 30 minutes infusion once a week during 3 weeks followed by 1 week without infusion
1565080|NCT02490475|Drug|Docetaxel|Participants will receive docetaxel on Day 1 of each 3-week cycle as 60, 75, or 100 mg/m^2 via IV infusion. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
1565081|NCT02490475|Drug|RhuMab 2C4|Participants will receive rhuMab 2C4 on Day 1 of each 3-week cycle as 420 mg via IV infusion. For Cycle 1 ony, rhuMab will be administered on Day 2, at least 24 hours after docetaxel and following an initial 840-mg loading dose. Treatment may continue until disease progression, unacceptable toxicity, or consent withdrawal.
1565082|NCT02490462|Other|Education + Conventional PhysicalTherapy|The education program for parents will be held one day a week for 1 hour, with total duration of 12 weeks. During the parents or legal guardian meetings will be oriented to stimulate the drive to your child or ward during everyday activities such as bathing, dressing, eating, transferring, going to the bathroom. Parents will receive a diary to record the activities in the home environment. The orientation day for parents will take place in different days of the day the child will receive physical therapy, so that the physiotherapist responsible for the training of parents is shrouded in relation to the randomization of the subjects. This program will be associated with conventional physical therapy program that provides for movements based on neurodevelopmental concept.
1565083|NCT02490462|Other|Conventional Physical Therapy|The full program will be for 24 weeks, the first step will consist of 12 weeks of training with a frequency of twice a week should total at least 18 Conventional physical therapy interventions and 09 meetings of guidelines for parents. After this step be performed to start new reviews second step further 12 weeks with the same characteristics as the first 12 weeks. The conventional physiotherapy program will consist of functional muscle training focused on the task. Tasks will be individualized based on the results of the evaluations of Gross Motor Function and Inventory Pediatric Evaluation of Disability. The sessions will last 45 minutes carried out 2 times a week, training will have a total duration of 12 weeks.
1565084|NCT02490449|Drug|Dexlansoprazole MR|Administration of drug after or before diet
1565085|NCT02490436|Drug|Cetuximab|Randomized cross-over between cetuximab and placebo
1565086|NCT02490436|Drug|Placebo|Randomized cross-over between cetuximab and placebo
1565088|NCT02490410|Dietary Supplement|protein supplement|
1565089|NCT02490397|Other|Day Light|Patients are exposed to day light for 2 weeks after a heart attack. At the end of 2 weeks they will have blood drawn.
1565090|NCT02490397|Other|Room Light|Patients will be exposed to only room or natural light for 2 weeks after heart attack. At the end of 2 weeks they will have blood drawn.
1565091|NCT02490384|Procedure|Physical exam indicated cerclage|Cervical cerclage
1565092|NCT02490371|Device|Low frequency rTMS|1 Hz low frequency rTMS over contra-lesional M1 region for 1200 pulse at 90% resting motor threshold for 10 sessions.Patients in the rTMS-ex group will receive the experimental rTMS A Magstim Rapid Stimulator (Magstim Company, Whitland, UK) equipped with an air-cooled figure-of-eight coil (each loop 70 mm in diameter) and neuro-navigation system will be used to deliver the intervention.
1565093|NCT02490371|Behavioral|structured physiotherapy upper limb training|Structural Physiotherapy upper limb training for 30-minutes
1565094|NCT02490345|Drug|gabapentin|gabapentin usage as adjunctive treatment for pain control
1565095|NCT02490345|Drug|Placebo|Identical placebo
1565096|NCT02490332|Device|Ventilation tube treatment|Tympanostomy
1565097|NCT02490306|Device|Strokefinder MD100 measurement|A microwave measurement will be performed with the patient lying in the hospital bed or another suitable surface. Follow-up microwave measurements will be performed after the acute phase.
1565098|NCT02490293|Drug|Cephalosporin|"During the hospitalization, intake of pacetin, 2nd generation cephalosporin. 3 g per day divided into 3 times via intravenous route until the day of discharge.
After discharge, oral intakes of 500mg each (1 pill of cefaclor, the 2nd generation cephalosporin every 12 hrs) for three days."
1565099|NCT02490293|Drug|Placebo|"During the period of hospitalization, Intake of placebo (normal saline). 30cc per day divided into 3 times via intravenous route until the day of discharge.
After discharge, oral intakes of 1000mg each (2 pill of vitamin C every 12 hrs) for three days."
1565100|NCT02490280|Behavioral|Trier Social Stress Test|The TSST is the gold standard social stress test and involves speaking in front of confederate judges and completing arithmetic tasks. The task takes 10-15 minutes.
1565101|NCT02490267|Other|Quality of Life questionnaire|
1565102|NCT02490254|Other|Surveillance card|
1565103|NCT02490241|Drug|Lithium|Patients taking lithium as a mood stabilizer during pregnancy are eligible to participate in the study. Their dose and serum concentration levels of lithium will be monitored throughout pregnancy and up to three months postpartum.
1565104|NCT02490228|Procedure|TAURFUC|female patients with urethral caruncle will receive transurethral resection combine with extension tube.
1565105|NCT02490202|Drug|SANGUINATE|Two (2) infusions of 320 mg/kg of SANGUINATE at Baseline and Day 1
1565106|NCT02490202|Drug|Normal Saline|Two (2) infusions of Normal Saline at an equal volume to SANGUINATE at Baseline and Day 1.
1565107|NCT02490189|Behavioral|Mindfulness-based Intervention|Twelve week group intervention that includes training in mindfulness meditation, self-compassion and mindful exposure.
1565108|NCT02490189|Behavioral|Cognitive Behavior Group Therapy|Twelve week group intervention that focuses on the interaction between thoughts, feelings, and behaviors.
1565109|NCT02490176|Drug|liraglutide|Liraglutide were taken daily for 7 days
1565110|NCT02490176|Drug|placebo|Placebo were taken daily for 7 days
1565111|NCT02490163|Device|Spectra Optia|"The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself, 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software.
Terumo BCT developed a completely automated apheresis system: the Spectra Optia MNC and CMNC based on an automatic interface-controlled technology that allows MNCs collection without the intervention of an operator. The optical sensors continuously control and adjust the buffy coat layer by adjusting the plasma flow.
The Spectra Optia MNC collects MNCs by intermittent flow: MNCs accumulate and are flushed from a secondary chamber at intervals during the procedure. On the other hand, the very recently released Spectra Optia CMNC (developed especially to collect stem cells that reside in the MNCs layer) is able to collect MNCs by continuous flow."
1565112|NCT02490150|Drug|Corifollitropin alfa|
1565113|NCT02490137|Behavioral|Race Car Video Game|Repeatedly playing a race car video game
1565114|NCT02490111|Drug|DWJ1319|
1565115|NCT02490111|Drug|Placebo|
1565128|NCT02490072|Drug|Dexmedetomidine|Formula for administrated were randomized by computer-generated randomization. The patients and anesthesiologist, who administered and conducted all this trial, were blinded to the medication allocation. An anesthesiologist, who responsible for preparation of medication was the only person, recognized of the randomization code during trial. 10 minutes after anesthetic induction, dexmedetomidine group would start the loading of dexmedetomidine (1μg/kg) during 10 minutes followed infusion of dexmedetomidine(0.5 μg/kg/min). Bispectral index was monitored continuously targeting 40±5. Target concentration of remifentanil and fresofol were controlled stepwise in accordance with BIS. Using the transesophageal echocardiography, we will evaluate the changes of cardiac function including Tei index and cardiac output.
1565129|NCT02490072|Drug|normal saline(Saline 0.9%)|
1565130|NCT02490059|Other|bronchoscopy|Bronchoscopy for diagnosis of pulmonary nodules
1565131|NCT02490046|Dietary Supplement|D Mannose|Patients in both arms will receive D-mannose powder to be used 1.5 gm (one level-teaspoon) twice daily, to be added to any beverage, for 16 weeks.
1565132|NCT02490033|Device|Ablation Catheter|
1565133|NCT02490020|Biological|mesenchymal stem cell|
1565134|NCT02489994|Device|ePrime|The main intent of the ePrime for cellulite is to utilize a minimally-invasive approach to directly deliver RF energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.
1565135|NCT02489981|Drug|Spiriva|60 puffs
1565136|NCT02489968|Drug|empagliflozin 10 mg + linagliptin 5 mg|empagliflozin low dose + linagliptin once daily
1565137|NCT02489968|Drug|empagliflozin 10 mg|empagliflozin low dose once daily
1565138|NCT02489968|Drug|empagliflozin 25 mg + linagliptin 5 mg|empagliflozin high dose + linagliptin once daily
1565139|NCT02489968|Drug|empagliflozin 25 mg|empagliflozin high dose once daily
1565140|NCT02489968|Drug|Placebo|
1565141|NCT02489955|Drug|Amikacin|
1565142|NCT02489955|Drug|Tobramycin|
1565143|NCT02489955|Drug|Colomycin|
1565144|NCT02489942|Drug|Jardiance|Empagliflozin
1565145|NCT02489929|Other|blood samples|This clinical study aims at correlating the values in CDA levels with the risk of drug-related toxicities and to the clinical response to azacytidine treatment for patient suffering of MDS or Myeloid leukemia
1565146|NCT02489929|Drug|azacytidine|
1565147|NCT02489916|Drug|CM4307|CM4307 300mg bid, each 4 week cycle
1565148|NCT02489903|Drug|RRx-001|
1565149|NCT02489903|Drug|Cisplatin/carboplatin plus albumin (nab-paclitaxel or Abraxane)|To be dosed after RRx-001
1565150|NCT02489903|Drug|cisplatin/carboplatin plus etoposide|To be dosed after RRx-001
1565151|NCT02489903|Drug|carboplatin/paclitaxel.|To be dosed after RRx-001
1565152|NCT02489890|Biological|Cytokine-induced Killer Cells|chemotherapy plus 3 cycles of Cytokine-induced Killer Cells(CIK) treatment
1565153|NCT02489864|Drug|Terlipressin|
1565154|NCT02489851|Procedure|Quadratus Lumborum block|0.2 ml/kg bupivicaine 0.125% injected bilateraly at the posterior border of the quadratus Lumborum muscle
1565155|NCT02489851|Procedure|Tranversus Abdominis plane block|0.2 ml/kg bupivicaine 0.125% injected bilateraly between internal oblique and transversus abdominis muscles.
1565156|NCT02489825|Procedure|Augmentation vertebroplasty|Cement augmentation of fractured vertebral body
1565157|NCT02489825|Procedure|Augmentation and prophylactic vertebroplasty|Cement augmentation of fractured vertebral body and prophylactic augmentation of both adjacent vertebral bodies
1565158|NCT02489812|Behavioral|Music|This cross over trial aimed to analyze the use of music as a distraction resource during children dental treatment, evaluating their cardiac and respiratory frequency. Thirty-four children took part in this study, 16 boys and 18 girls, from 4 to 6 years old, with no previous dental experience, who had two carious lesions on occlusal surfaces of molars,
1565159|NCT02489799|Behavioral|Advance care planning video|This is a video involving interviews with patients, a family member, two surgeons, an anesthesiologist, and an ICU nurse; these interviewees describe the typical events during a hospitalization for a major surgery and encourage the viewer to do some planning before surgery - the planning includes: (i) naming a person to make decisions for the participant, (ii) having a conversation with that person about goals and values, and (iii) continuing that conversation with the participant's surgeon.
1565160|NCT02489799|Behavioral|Control video|This is a video showing the history of The Johns Hopkins Hospital and emphasizing that The Johns Hopkins Hospital is a great place to receive medical care.
1565161|NCT02489786|Drug|patients take 0.25 mg of digoxin daily except friday|
1565162|NCT02489786|Drug|patients take 0.25 mg of digoxin daily except thursday and friday|
1565163|NCT02489786|Drug|patients take 0.125 mg of digoxin daily|
1565164|NCT02489786|Drug|digoxin dose is calculated using Jusko-Koup method and given daily|
1565165|NCT02489760|Biological|Adalimumab|The treatment arm will receive adalimumab 40 mg subcutaneously biweekly
1565166|NCT02489760|Biological|Etanercept|The control arm will continue etanercept 25 mg subcutaneously twice a week
1565167|NCT02489747|Dietary Supplement|WBE|wheat bran extract (3 g/day)
1565168|NCT02489747|Dietary Supplement|Placebo|Placebo
1565169|NCT02489734|Drug|sevoflurane|extubation when end-tidal concentration of sevoflurane < 0.5%
1565170|NCT02489734|Drug|Sevoflurane|extubation when end-tidal concentration of sevoflurane >= 0.5%
1565173|NCT02489695|Drug|axitinib|
1565174|NCT02489682|Other|Long-form written Informed consent information|
1565175|NCT02489682|Other|Short-form written Informed consent information|
1565176|NCT02489682|Other|Video Informed consent information|
1565178|NCT02489656|Device|Double Loop Ureteral stent endoscopic placement.|A JJ stent placement may be indicated at the end of the endourological removal of kidney stones to ensure urine drainage and cicatrisation
1565179|NCT02489643|Procedure|Individualized practical training|
1565180|NCT02489630|Drug|Ketamine|0.1mg/kg ketamine IV
1565181|NCT02489630|Drug|Normal Saline|1ml/kg normal saline placebo
1565182|NCT02489630|Drug|opiate analgesic|0.1mg/kg dose of morphine (or morphine equivalent) at 30 min time intervals based on patient pain score or more frequently upon request
1565183|NCT02489617|Other|Pathologic evaluation of excised tissue|Up to 3 months after excisional biopsy
1565184|NCT02489604|Drug|177Lu-DOTATATE 25.9 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion. Total activity of 25.9 GBq 100 mCi for 7 cycles every 6 ± 2 weeks (700 mCi)
1565185|NCT02489604|Drug|177Lu-DOTATATE 18.5 GBq activity|177Lu-DOTATATE will be administered in a 30 minutes infusion Total activity of 18.5 GBq 100 mCi for 5 cycles , every 6 ± 2 weeks (500 mCi)
1565186|NCT02489591|Device|Oral appliance|Patients will bring their prescribed oral appliance.
1565187|NCT02489591|Device|BluePro oral appliance|Patients without a prescribed oral appliance will have a device provided for the duration of the study (BluePro, BlueSom; used for investigational purposes only). The device provided is a prefabricated thermoplastic customizable mandibular advancement splint.
1565189|NCT02489565|Other|Telemedicine|Outpatient discharge from tertiary care to primary care with a letter of referral explaining about the study containing phone number from telemedicine and a letter with the patient's history in the hospital. Two months after discharge, the telemedicine's cardiologist initiates contact with the primary care's physician about patient follow-up.
1565190|NCT02489539|Device|GORE® EXCLUDER® Conformable AAA Endoprosthesis|Endovascular Aneurysm repair (EVAR) is a minimally invasive procedure designed to exclude an aneurysmal segment of the aorta from blood circulation. The EVAR procedure involves delivery of a stent- graft compressed onto a catheter to an aneurysmal segment of the aorta from a remote access site, generally the femoral artery. Arterial access may be done by either percutaneous or cut-down technique.
1565191|NCT02489526|Drug|VVZ-149 Injections|A novel analgesic drug candidate, VVZ-149 Injections shows dual antagonistic activity with moderate potency on glycine transporter type 2 (GlyT2, IC50=0.86 μM) and serotonin receptor 2A (5HT2A, IC50=1.3 μM), which are therapeutic targets for pain. GlyT2 inhibitors have been studied by many pharmaceutical companies as a well-known and promising analgesic candidate because of their role in inhibitory (glycine) modulation and regional specificity.
1565192|NCT02489526|Drug|Placebo|Same formulation and appearance with VVZ-149 Injections
1565193|NCT02489513|Drug|[14C]-AG-120|Labeled investigational drug
1565194|NCT02489500|Drug|Bortezomib|"Conditioning Regimen:
Drug: Bortezomib: 1.0 mg/m2/dose D -6, D -3, D +1, D + 4 Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1"
1565195|NCT02489500|Drug|Melphalan|"Conditioning Regimen:
Drug: Melphalan: 70-100 mg/m2/dose D -2, D -1 Stem Cell Transplant: D 0"
1565196|NCT02489500|Drug|Neupogen|GCSF mobilization 16mcg/kg x 4 days
1565197|NCT02489500|Procedure|Stem Cell Collection|collect at least 2.5 million CD34+ stem cells
1565198|NCT02489500|Procedure|Stem cell infusion|infusion of previously collected autologous stem cells
1565199|NCT02489487|Drug|VM-1500|VM-1500 40 mg
1565200|NCT02489487|Drug|Darunavir|Darunavir 600 mg
1565201|NCT02489487|Drug|Ritonavir|Ritonavir 100 mg
1565202|NCT02489487|Drug|Raltegravir|400 mg Raltegravir
1565203|NCT02489461|Drug|VM-1500|VM-1500 up to 48 weeks
1565204|NCT02489461|Drug|Efavirenz|Efavirenz up to 48 weeks
1565205|NCT02489461|Drug|Antiretroviral therapy (ART)|ART up to 48 weeks
1565207|NCT02489435|Drug|VM-1500|VM-1500
1565208|NCT02489435|Drug|Placebo|Placebo
1565209|NCT02489422|Other|Laboratory Biomarker Analysis|Correlative studies
1565212|NCT02489422|Behavioral|Yoga Skills Training|The YST intervention consists of four 30 minute in-person sessions that instructs skills to enhance mindfulness and promote relaxation. Participants will also be encouraged to practice daily at home.
1565213|NCT02489422|Behavioral|Attention Control|The AC intervention consists of four 30 minute in-person sessions of supportive conversation. In addition, the interventionist will recommend that the patients write brief diary entries daily at home.
1565214|NCT02489422|Other|Actigraphy Assessment|Ancillary studies
1565215|NCT02489409|Drug|EndostarTM Injection|210 mg in 279 mL normal saline (NS), continuous pump, d1-d10 (2.5 mL/h)
1565216|NCT02489409|Drug|Gemcitabine|1.0 m/m2, iv 0.5h, d1, 8
1565217|NCT02489409|Drug|Navelbine|40 mg/d, iv, d1, 8
1565218|NCT02489409|Drug|Platinum|30 mg/m2, iv 3h, d1-3
1565219|NCT02489409|Drug|Xeloda Tablets:|2 000 mg/m2, po, d1-14
1565220|NCT02489396|Behavioral|Nutrition facts automatically or not automatically displayed|"For two months nutrition information on the Rosie site will be displayed in a tab that consumers can click on to display the nutrition facts panels of products. Investigators will use NuVal scores to determine the fifteen healthiest, and fifteen least healthy items in six grocery categories; chips, cookies, cereal & breakfast, yogurt, ice cream, and frozen pizza. We will then compare the number of clicks on nutrition information for healthier versus less healthy items to determine if there's a possibility of willful ignorance coming into play when choosing to purchase less healthy items."
1565221|NCT02489396|Behavioral|Nutrition facts in color|For two months the font on products' nutrition facts labels will be displayed in red or green. For this proof-of-concept intervention, the color of a label's display will be determined randomly, in order to gather a clearer picture of whether label color could be leveraged to influence product choice. Items in each grocery category will be randomly assigned to receive green or red labels during the intervention period, so 50% of products in each category have red nutrition facts labels, and 50% have green nutrition facts labels. We will then compare proportions of green to red items purchased during the intervention period with the proportion of those same items purchased during the baseline period, when all labels were in black font.
1565222|NCT02489396|Behavioral|Nutrition Facts Label in Larger Font|For two months the serving size and calorie lines on the nutrition facts labels will be displayed in a larger font for every item on the Rosie site. Average calories in customer purchases will be quantified using purchase data, and the average calories for online-grocery orders during baseline and intervention periods will be compared.
1565223|NCT02489396|Behavioral|Healthier Items First|For two months, instead of the product popularity default-display option in the online store, thirty healthier items will be displayed on the first page in each grocery category. All grocery categories where there is scoring variation between healthy and less-healthy options (i.e. cereal, chips, bakery, sauces, etc.) will be included in the intervention. The thirty-targeted healthy items will be identified using NuVal scores. NuVal scores will not actually be displayed as part of the shopping site, and will be used exclusively as a guide to systematically determine targeted items in each food category. The proportion of targeted healthy items purchased in each category versus non-targeted items purchased during the intervention will be compared to the proportion of targeted vs. non-targeted items purchased during the baseline period.
1565224|NCT02489383|Other|Continuous Exercise Training|The continuous training (CT) will be held in two weekly sessions lasting total of 40 minutes and 5 minutes for heating and 5 to slowdown, and the duration will be 24 sessions (3 months). The exercise sessions will be will be performed on a stationary bicycle, with the initial intensity of 70% of VO2max. If the subject sustain continuously training intensity for 2 consecutive sessions without symptoms breathing, exercise intensity will be increased by 5% of heart rate. The patient may stop the activity if he has any symptoms or respiratory distress, returning it as soon present improvement. Throughout the training, will be monitored heart rate and the level of perception subjective effort (modified Borg scale).
1565225|NCT02489383|Other|Interval Exercise Training|The interval training (IT) will be held in two weekly sessions. The IT is individualized and will be performed on a stationary bicycle. Training sessions will be performed with total duration of 40 minutes consisting of 5 minutes extender, 30 minutes from the main part (IT), finishing with five minutes back to calm. In the main part (of 5 to 30 minutes), the patient will perform the exercise with high intensity in the first two weeks, the exercise will be conducted with an intensity 80% of maximum capacity obtained in cycle ergometer test and will cycle for 30 seconds followed by a 30 second recovery period. In the 3rd and 4th weeks, the intensity will be increased to 100% of the maximum obtained. After this period, the intensity will be increased by 5% charge.
1565226|NCT02489383|Behavioral|Education Program|The education program will discuss issues related to asthma and physical activity. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peak flow meter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
1565227|NCT02489370|Device|Home telemonitoring|The intervention consists of daily monitoring the patients' weight and blood pressure directly from their home; automatically and securely transmit the values to a server at the hospital; and monitor the values by a trained nurse at the Heart polyclinic.
1565228|NCT02489357|Procedure|Cryosurgery|Undergo whole gland cryoablation
1565229|NCT02489357|Drug|Degarelix|Given SC
1565230|NCT02489357|Other|Laboratory Biomarker Analysis|Correlative studies
1565231|NCT02489357|Biological|Pembrolizumab|Given IV
1565232|NCT02489344|Drug|GZ/SAR402671|"Pharmaceutical form:capsule
Route of administration: oral"
1565236|NCT02489292|Biological|HepaStem|HepaStem will be administered in maximum 4 infusion days, spread over an 8-week period with an interval of 2 to 3 weeks between infusion days. The target total dose of cells will be 50x10E6 cells/kg body weight
1565284|NCT02488967|Other|Laboratory Biomarker Analysis|Correlative studies
1565237|NCT02489279|Behavioral|Attentional Intelligence Method|Participants use the mobile software, Attentional Intelligence Method, on their mobile device to develop sustained attention control and executive control skills that provides self-awareness of attention control. Participants use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
1565238|NCT02489279|Behavioral|Scrabble|Participants play Scrabble on their mobile device to develop concentration and executive control skills. They use the software for 5 minutes, 3 times per day, 5 days per week, for 10 weeks.
1565239|NCT02489266|Biological|AKTi-treated TIL|On day 0, cells will be infused intravenously (IV) over 20-30 minutes (between 1 and 4 days after the last dose of fludarabine).
1565240|NCT02489266|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days.
1565241|NCT02489266|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day for 5 days.
1565242|NCT02489266|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
1565243|NCT02489253|Other|CT coronary angiogram and carotid ultrasound|Scans in addition to routine clinical care
1565244|NCT02489240|Drug|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 days
1565245|NCT02489240|Drug|placebo|2000 IU placebo tablets were taken daily for 6 days
1565246|NCT02489227|Drug|CHS-1420|
1565247|NCT02489227|Drug|Adalimumab|
1565250|NCT02489188|Procedure|arthroplasty|patients, who are scheduled for arthroplasty, will be measured before and on average 6 months after surgery
1565251|NCT02489188|Other|manual therapy|patients, who are scheduled for manual therapy, will be measured before, immediately and on average 1 week after treatment
1565252|NCT02489188|Procedure|lumbar spinal stenosis decompression|patients, who are scheduled for lumbar spinal stenosis decompression, will be measured before and on average 6 months after surgery
1565253|NCT02489175|Device|Stomaplasty KoringTM|In these patients, the stomaplasty Koring will be implanted at the time of the primary definitive stoma creation. The implantation of the Koring will be performed by experienced surgeons (expertise based, best team approach) who have already implanted the Koring (e.g. participated in the observational study) and/or have reviewed the video documentation. To ensure standardization for all participating centres an operative manual with standardized video sequences is available.
1565254|NCT02489162|Device|MyotonPRO|MyotonPRO measurements of the biomechanical properties of facial mimic muscles
1565255|NCT02489162|Device|non-invasive electromyography (EMG)|Gold standard technique for measuring muscle
1565256|NCT02489149|Other|Multi-sector interventions|"Multi-sector interventions to enhance food security: Agricultural interventions are matched with field training for government sectors working with quilombolas communities on best agronomic practices to promote technical assistance for this communities. Stimulate the participation in the Program of Food Acquisition, supporting quilombolas agriculture.
For quilombolas participants: nutritional counseling based on traditional healthy cooking practices, using traditional recipes.
For health professionals: to strengthen food and nutrition actions at all levels of health care. Food and nutritional education training for primary care health professionals.
Helping families to have more knowledge about your citizen rights."
1565257|NCT02489149|Other|Control|Placebo Comparator: Conventional approach of current public food and nutrition policies.
1565258|NCT02489136|Other|"laying of hands (Spiritist passe)"|In a distance of 10 cm and to apply the spiritist passe for 10 minutes.
1565259|NCT02489123|Drug|Enzalutamide|Given PO
1565260|NCT02489123|Other|Laboratory Biomarker Analysis|Correlative studies
1565261|NCT02489110|Behavioral|Webnovela|
1565262|NCT02489110|Behavioral|Information|
1565263|NCT02489097|Drug|Nitrous Oxide|Administration of a concentration of 70% Nitrous Oxide with 30% Oxygen in the anaesthetic gas mixture
1565264|NCT02489097|Other|Placebo|Administration of a concentration of 70% Air with 30% Oxygen in the anaesthetic gas mixture
1565265|NCT02489084|Other|Blood sampling|
1565266|NCT02489071|Behavioral|Brain Training Program|
1565267|NCT02489071|Behavioral|Brain Health Program|
1565269|NCT02489032|Behavioral|SBIRT Training & Support Tool|Program to train EAP/behavioral health practitioners in conducting alcohol SBIRT
1565270|NCT02489032|Other|Waitlist Control|3-month wait-list and then provided access to the SBIRT training program
1565271|NCT02489019|Drug|Sodium chloride|Sodium chloride will be used as a placebo comparator in this trial
1565272|NCT02489019|Drug|Fentanyl|Fentanyl is a synthetic opioid analgesic that will be used as the experimental intervention in this trial
1565273|NCT02489006|Drug|Olaparib|
1565274|NCT02489006|Drug|Platinum-based Chemotherapy|Chosen by the study doctor, per standard of care.
1565275|NCT02488993|Other|Prospective Phase Rifaximin-α 550mg|Prospective data collection of all patients receiving rifaximin-α 550 mg from the point of study entry.
1565276|NCT02488993|Other|Prospective Phase No Rifaximin-α 550mg|Prospective data collection of all patients not receiving rifaximin-α 550 mg from the point of study entry.
1565277|NCT02488993|Other|Retrospective Phase|Review of medical records and electronic hospital admissions data for patients with HE who have not received rifaximin-α 550 mg during the previous 12 months.
1565278|NCT02488980|Drug|Tafenoquine|Tafenoquine 200 mg for three days followed by Tafenoquine 200 mg once a week for 24 weeks.
1565279|NCT02488980|Drug|Mefloquine|Mefloquine 250 mg for three days followed by Mefloquine 250 mg once a week for 24 weeks.
1565280|NCT02488980|Drug|Placebo|Placebo for three days followed by placebo once a week for 24 weeks
1565281|NCT02488967|Drug|Carboplatin|Given IV
1565282|NCT02488967|Drug|Cyclophosphamide|Given IV
1565283|NCT02488967|Drug|Doxorubicin Hydrochloride|Given IV
1565285|NCT02488967|Drug|Paclitaxel|Given IV
1565286|NCT02488954|Other|Probiotics in the form of cheese portion|
1565287|NCT02488915|Device|EmboTrap® Revascularization Device|
1565288|NCT02488902|Drug|Placebo|Placebo
1565289|NCT02488902|Drug|Tafenoquine 25mg|Tafenoquine 25mg
1565290|NCT02488902|Drug|Tafenoquine 50mg|Tafenoquine 50mg
1565291|NCT02488902|Drug|Tafenoquine 100 mg|Tafenoquine 100 mg
1565292|NCT02488902|Drug|Tafenoquine 200 mg|Tafenoquine 200 mg
1565293|NCT02488902|Drug|Mefloquine 250 mg|Mefloquine 250 mg
1565294|NCT02488889|Drug|Varenicline|
1565295|NCT02488889|Drug|Placebo pill (for varenicline)|
1565296|NCT02488889|Drug|Alcohol|
1565297|NCT02488889|Drug|placebo beverage (for alcohol)|
1565302|NCT02488850|Procedure|Surgery|
1565303|NCT02488850|Radiation|SABR|
1565304|NCT02488824|Procedure|Warm Temperature|Subjects will be exposed to a routinely encountered warm temperature (95 F) for up to to 2 hours, depending on their vital signs (BP, HR, Tcore) and tolerance (comfort).
1565305|NCT02488798|Procedure|2D grey scale vaginal ultrasound|To assess the endometrial thickness and echogenicity (whether the endometrium is uniform or non-uniform).
1565306|NCT02488798|Procedure|3D power Doppler vaginal ultrasound|To assess the endometrium using the IETA group criteria.
1565307|NCT02488798|Procedure|Office hysteroscopy|using the vaginoscopic approach to assess the uterine cavity and take sample.
1565308|NCT02488785|Behavioral|Virtual Diabetes Self-Care and Education Program|Participants will be able to share physical activity and glucose data with the diabetes educator using the smartphone they will receive. Participants will be given a Fitbit physical activity tracker which they can use to record their activity and share the information with the diabetes educator using the device's smartphone application. In addition, participants will receive a Glooko MeterSync Blue cable which is able to connect to most glucose meters in order to download glucose data to the Glooko Population Management tool on their smartphones. Information downloaded to the Glooko Population Management tool can be shared with the diabetes educator.
1565309|NCT02488785|Device|Fitbit|
1565310|NCT02488785|Device|Smartphone|
1565311|NCT02488772|Device|Sleep mask|
1565312|NCT02488772|Other|Standard of care|Standard of care as decided by treating emergency physician
1565313|NCT02488772|Device|Ear Plugs|
1565318|NCT02488746|Device|GERDX(TM)|Endoscopic full thickness resection of subepithelial gastric tumors using the GERDX suturing device.
1565319|NCT02488733|Procedure|LSG|In addition to all previously described aspects of conventional medical therapy, patients assigned to surgical treatment will undergo LSG, to be performed in accordance with current international guidelines
1565320|NCT02488733|Drug|CMT|CMT consists in the use of the best treatment strategies, involving pharmacological and dietary therapies, lifestyle and physical activity, with the aim of both glycemic control and weight loss, administered on the basis of the current guidelines of the American Diabetes Association (ADA)[50] and determined on an individual basis [52].The administration of such pharmacological and non-pharmacological therapies will be adjusted in accordance with the algorithms of the ADA .
1565321|NCT02488707|Procedure|laparoscopic intersphincteric resection (LISR group)|the patient undergo laparoscopic mesorectal excision with high inferior mesenteric vein ligation combined with transanal distal resection of the rectum
1565322|NCT02488707|Procedure|Transanal minimally invasive Total mesorectal excision (TAMIS group)|Transanal minimally invasive total mesorectal excision assisted with minilaparoscopy to ligate the inferior mesenteric vessels and splenic flexure mobilization.
1565323|NCT02488694|Drug|Afatinib|40 mg/d
1565324|NCT02488694|Drug|Pemetrexed|500 mg/m² i.v. on d1 of each 21-day cycle
1565325|NCT02488681|Device|Micra Pacemaker Implant|
1565326|NCT02488668|Device|Surface Electrical Stimulation|Surface electrical stimulation using the following devices; 1) INOMED surface stimulator, 2) The EPIONE Psychophysical Testing Platform software for stimulator control. Surface stimulation therapy is provided while providing visual guidance to the subject.
1565327|NCT02488655|Device|Echopulse|HIFU Under ultrasound guidance
1565328|NCT02488642|Drug|Isosorbide Dinitrate|
1565329|NCT02488642|Drug|Misoprostol|
1565330|NCT02488642|Drug|Oxytocin|Oxytocin was infused in a balanced electrolyte solution beginning with an infusion rate of 2 milli-International Units per minute (mIU/min) and doubling the dose every 15 minutes.
1565332|NCT02488616|Other|5-day intervention with single-hormone closed-loop strategy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. On the first day of the intervention, participants will be admitted to the clinical research facility anytime between 8:00 am and 11:30 am. Training on connection and disconnection of the system, meal boluses, etc. will be given.
Competency on the use of study devices will be assessed by a team member. Only participants demonstrating competency on use of study devices will be allowed to continue to the home study phase. Participants will be advised to continue with study intervention at home for the next 5 days."
1565333|NCT02488616|Other|5-day intervention with sensor-augmented pump therapy|"A sensor will be inserted on the day prior to the first day of the intervention by the participants. The participant will also have to install the study insulin pump. Participants will be advised to continue with study intervention at home for the next 5 days.
Participants will have been previously shown how to use the study insulin pump."
1565334|NCT02488616|Device|Insulin pump|MiniMed® Paradigm® Veo™, Medtronic
1565335|NCT02488616|Device|Continuous glucose monitoring system|Enlite sensor®, Medtronic
1565336|NCT02488616|Drug|Insulin|Participant's usual fast-acting insulin analog will be used: Lispro (Humalog), Aspart (NovoRapid) or Glulisine (Apidra)
1565337|NCT02488603|Behavioral|Decision aids (tamoxifen-related educational materials in brochure or mobile app)|Decision aids (tamoxifen-related educational materials in brochure or mobile app)
1565338|NCT02488603|Drug|tamoxifen|
1565339|NCT02488590|Drug|LABA + LAMA|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
1565340|NCT02488590|Drug|ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
1565341|NCT02488590|Drug|LABA + LAMA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
1565342|NCT02488590|Drug|LABA + ICS|An open label inhaled therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
1565343|NCT02488590|Drug|other|An open label therapy or no therapy is initiated once the diagnosis has been set based on clinical and testing criteria (algorithm). The treatment may be changed in function of the clinical evolution, which is left at the discretion of the general practitionar. Changes in treatment and treatment doses are registered during 1 year follow-up.
1565344|NCT02488577|Procedure|Transanal minimally invasive total mesorectal excision|
1565345|NCT02488577|Procedure|transanal minimally invasive locoregional resection|
1565346|NCT02488564|Drug|Liposomal doxorubicin|50 mg/m2 by intravenous infusion over a period of 1 hour on day 1 of each cycle repeated every 21 days. A final concentration of between 0.4 to 1.2 mg/ml doxorubicin hydrochloride, is required
1565347|NCT02488564|Drug|Docetaxel|30 mg/m2 by intravenous infusion over a period of 1 hour on day 2 and 9, every 3 week.They will be given for 6 cycles.
1565348|NCT02488564|Drug|Trastuzumab|4 mg/kg for the first administration (day 2 cycle 1) and 2 mg/kg for subsequent administrations. Trastuzumab will be given weekly for the duration of chemotherapy (day 2, 9, 16), then will be administered at the dose of 6 mg/Kg every 3 weeks until completion of 52 weeks of treatment.
1565349|NCT02488564|Drug|Metformin|It is administered as single agent from day -13 to 0. From day -13 to day -11, Metformin 1000 mg will be administered once a day; from day -10, Metformin 1000 mg will be administered twice a day continuously until end of the study treatment.
1565350|NCT02488551|Device|Computer-delivered CALM|This intervention includes the delivery of CALM via computer
1565351|NCT02488551|Other|Manual-delivered CALM|This active comparison condition includes the delivery of CALM via manual
1565352|NCT02488538|Drug|Combined oral contraceptives|Women will receive COC containing drospirenone daily for 21 days starting from the 3rd day of menstruation
1565353|NCT02488538|Drug|Fluoxetine|women will receive oral fluoxetine 20 mg daily
1565354|NCT02488538|Drug|Combined oral contraceptives placebo|women will receive oral placebo similar to COC daily for 21 days starting from the 3rd day of menstruation
1565355|NCT02488538|Drug|Fluoxetine placebo|women will receive a daily oral placebo similar in size, color and structure to fluoxetine.
1565356|NCT02488538|Procedure|Daily record of severity of problems|Women will record their symptoms daily using the daily record of severity of symptoms.
1565357|NCT02488525|Drug|Prophylactic treatment with Wilfactin|Prophylactic treatment with Wilfactin after implantation of continuous-flow left ventricular assist device reduces the frequency of bleeding in comparison to the usual care.
1565358|NCT02488512|Drug|90Y-DOTATOC|Each patient will receive a maximum cumulative 90Y-DOTATOC activity of 11.1 GBq (300 mCi) [45-46], divided into 4 cycles (1.8 - 2.8 GBq for each cycle) with an interval of 6 - 8 weeks between cycles. The activity to be administered will be measured in a dose calibrator, properly calibrated for the 90Y-radionuclide.
1565359|NCT02488499|Behavioral|Coping Power|15 sessions of concurrent parent and child group treatment
1565360|NCT02488499|Behavioral|Individualized Treatment|15 sessions of individualized child and parent treatment
1565361|NCT02488486|Device|Automated postoperative sedation|
1565362|NCT02488486|Drug|propofol|
1565363|NCT02488486|Drug|remifentanil|
1565364|NCT02488473|Drug|Dexmedetomidine|100 ug dexmedetomidine added to the ropivacaine nerveblock
1565365|NCT02488473|Drug|Ropivacaine|20 ml Ropivacaine 5mg/ml
1565366|NCT02488473|Drug|Isotonic Saline|Placebo
1565367|NCT02488460|Behavioral|Physically active math lessons|The intervention consists of a nine month period with physical activity as part of, and integrated, in math lessons
1565368|NCT02488434|Device|fertile chip|a new method for sperm selection on ivf cycles by using microchannel system.
1565369|NCT02488408|Drug|BGB324|
1565370|NCT02488408|Drug|Cytarabine|Low dose cytarabine will be administered with BGB324 at a dose selected dose from Part A of the study
1565371|NCT02488408|Drug|Decitabine|Decitabine will be administered with BGB324 at a dose selected dose from Part A of the study
1565372|NCT02488395|Other|fMRI|The investigators will use a non invasive fMRI technique centred on the superior colliculus during the presentation of flickered check-boards with varying contrast (1, 3, 5 and 9 %).
1565373|NCT02488395|Other|Ophthalmologic evaluation|The aim of this experiment is the evaluate the functional state of a visual structure. Therefore, with this ophthalmologic test, the investigators will control if the participant does not present major visual deficits. This examination will evaluate the visual acuity and the visual field. A funduscopic examination will also be performed to check the retina.
1565374|NCT02488395|Other|visual psychophysics test|This test will allow to control the sensitivity of the participant to our contrast. The participant will be asked to look at screen on which three static check-boards will be presented. The participant will have to choose the two check-boards with the closest contrast.
1565376|NCT02488369|Device|PET / CT|
1565377|NCT02488356|Dietary Supplement|Litramine|
1565379|NCT02488330|Drug|Onartuzumab|Onartuzumab 10 mg/kg or 15 mg/kg will be administered intravenously on Day 1 of each 14- or 21-day cycle as specified in the P-trial and as per clinical judgment and discretion of the investigator. The actual dose of onartuzumab will be determined on the bases of participants weight at the time of enrollment in extension trial (E-trial).
1565380|NCT02488330|Drug|Bevacizumab|All participants will continue on the same dose and schedule of control treatment (bevacizumab) as specified in their respective P-trial.
1565381|NCT02488330|Drug|Erlotinib|All participants will continue on the same dose and schedule of control treatment (erlotinib) as specified in their respective P-trial.
1565382|NCT02488317|Other|Decision Aid|Decision-making outcomes (e.g., self-efficacy) will be compared between patients who received and did not receive a decision aid. These arms were chosen because the current standard of care is for health care providers to discuss options with patients without using a decision aid.
1565383|NCT02488304|Radiation|HRCT scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 2, visit 3, visit 4, visit 5, visit 6, and visit 7.
An upper airway (UA) scan will be taken on visit 2."
1565384|NCT02488291|Drug|0.25 sufentanil|with different dosage
1565385|NCT02488291|Drug|0.5µg/ml sufentanil|0.5µg/ml sufentanil
1565386|NCT02488291|Drug|0.1% ropivacaine|0.1% ropivacaine
1565387|NCT02488278|Device|GlucoMe Glucose Monitoring Device|Perform a blood glucose test using the application and device
1565388|NCT02488265|Other|Balance Training|Balance training with rhythmical (BRT), is a motor program to improve balance associated with rhythmical auditory cues (RACs).
1565389|NCT02488265|Other|Screening to prevent falls|Questionary to Scheduled screening falls and progression in training will be used to indicate the capacity to continue to progress.
1565390|NCT02488252|Drug|Semi-individualised Chinese Medicine treatment|"A: Panax ginseng, Atractylodes macrocephala, Pinellia ternate, Pericarpium citri reticulatae, Herba Pogostemonis, Glycyrrhiza uralensis, Rehmannia-6 decoction
B: Cortex magnoliae officinalis, Atractylodes macrocephala, Common Floweringquince Fruit, Common Vladimiria Root, Tsaoko Amomum Fruit, Palmae Fruit, Radixaconiti laterlis perparata, Zingiber officinale Rosc., Glycyrrhiza uralensis, Rehmannia-8 decoction
C: Root of Pilose Asiabell, Astragalus membranaceus, Rehmannia glutinosa, Common Macrocarpium Fruit, Dioscorea opposita , Barbary Wolfberry Fruit, Cortex eucommiae, Chinese Angelica, Glycyrrhiza uralensis
D: Rehmannia-6 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb
E: Rehmannia-8 decoction, Fructus Ligustri Lucidi, Yerbadetajo Herb"
1565391|NCT02488252|Drug|Routine medical care (active comparator)|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker at stable dose
1565392|NCT02488239|Device|CRT-P indicated patients|Patients who are indicated for a CRT-P device are planned to be implanted with a CRT-P device
1565393|NCT02488226|Other|Gaze-contingent eye-tracking technology|When participants look away from a prototypical or expected norm, their gaze patterns are redirected to those prototypical locations.
1565394|NCT02488213|Other|Nutritional Counseling|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive nutritional counseling from the diet quality assessment with adopting some techniques of motivational interviewing, and delivery of educational support material. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
1565395|NCT02488213|Other|Usual Diet Guidance|The patients with type 2 diabetes mellitus treated in Endocrinology Division, Hospital de Clinicas de Porto Alegre will receive usual diet guidance from the current nutritional recommendations for diabetes, according to the routine performed. The patients will need to come to hospital for three more visits every two months throughout the study (2, 4, 6 months). They will also be contacted by telephone during the months when will not have query (1, 3 and 5 months). The study will total duration of six months.
1565396|NCT02488200|Other|No intervention|No intervention
1565397|NCT02488187|Device|ABUS|Automated breast ultrasound
1565398|NCT02488174|Other|PROOFcheck|
1565399|NCT02488161|Other|No intervention|
1565400|NCT02488148|Behavioral|Hot yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
1565434|NCT02487992|Biological|Cytokine-Induced Killer Cells|CIK cells transfected with cytokine genes possess an improved proliferation rate and a higher cytotoxic activity as compared to regular CIK cells.
1565401|NCT02488148|Behavioral|Non-heated yoga|Subjects in the two intervention groups will complete the standard 26-posture Bikram yoga series in a studio heated at 41ºC (traditional environment) or in a studio at a room temperature of 22ºC whereas control group subjects will be instructed to maintain physical activity patterns for the 12-week study duration. Yoga classes will be held at the Pure Bikram Yoga downtown Austin location. Classes will be completed 3 times weekly for 12 weeks and consist of 90 minutes of yoga postures and breathing exercises.
1565404|NCT02488122|Other|High Impact Exercise|In these workouts, both feet leave the ground at the same time.
1565405|NCT02488122|Other|Low Impact Exercise|A workout is low-impact if at least one of your feet remains in contact with the ground at all times.
1565406|NCT02488109|Other|Higher Calorie Refeeding|
1565407|NCT02488109|Other|Lower Calorie Refeeding|
1565408|NCT02488096|Device|TRUS-Guided Biopsy|The standard care TRUS-guided biopsy is a schematic 12 core biopsy scheme with 2 cores taken from each of standard 6 zones. In some cases, the radiologist may take additional cores beyond 12 if suspicious areas are suspected from clinical findings or TRUS. TRUS-guided biopsies will be performed by a designated group of radiologists. An overall score out of 5 of likelihood of clinically significant prostate cancer will be recorded for each individual patient. The biopsy will be scheduled within 1 week of referral.
1565409|NCT02488096|Device|MRI + TRUS-Guided Biopsy|"A designated radiologist will perform all MRI exams. The radiologist will identify locations of the prostate gland of the standard 12 cores to be taken and any additional lesions deemed to be suspicious for cancer.
The procedure for the MRI-targeted biopsy will be exactly the same as the TRUS-guided biopsy except that an additional 2 cores per area may be taken beyond the standard 12 cores in areas that were previously identified by MRI on the map. The systematic 12-core biopsy will always be performed first. The radiologist performing the MRI-targeted biopsy will review the MRI targets prior to the biopsy as per standard of care, and he/she will also perform the TRUS-guided biopsies for this group. Patients will be scheduled for their biopsy ~ 1 week after the MRI."
1565410|NCT02488083|Device|Ultrashape|circumference reduction
1565411|NCT02488070|Procedure|Computed Tomography|Part of PET/CT scan
1565412|NCT02488070|Drug|Gallium Ga 68-labeled PSMA Ligand Glu-urea-Lys(Ahx)|Intravenously-administered (IV) radioisotope
1565413|NCT02488070|Procedure|Magnetic Resonance Imaging|Part of PET/MRI scan
1565414|NCT02488070|Procedure|Positron Emission Tomography|Part of PET/CT and/or PET/MRI scans
1565415|NCT02488057|Drug|Liraglutide|Active comparator. See arm descriptions.
1565416|NCT02488057|Behavioral|Weight loss|Active comparator. See arm descriptions.
1565417|NCT02488044|Drug|AEB1102|modified human arginase I
1565418|NCT02488031|Behavioral|Error-reduction|"During this time participants will use a novel, custom designed computer interface to perform goal-directed movements with each leg in a 3D virtual environment designed to emphasize accurate movements. Leg movement will be detected using the LeapMotion sensor and we will quantify time endpoint errors by comparing the timing of the foot trajectory and the required time to target.
The error-reduction intervention will be a 4-week home-based program. Each participant will train 4 days a week for approximately 1 hours per day. Within a week, the task difficulty will increase by changing the presentation of the targets to be more unpredictable and by increasing movement speed."
1565419|NCT02488031|Behavioral|International Cooperative Ataxia Rating Scale|The ICARS is an assessment of the ataxia severity. The ICARS score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
1565420|NCT02488031|Behavioral|Scale for the Assessment and Rating of Ataxia|The SARA is an assessment of the ataxia severity. The SARA score is the total sum of the sub scores on specific movements and ranges from 0 to 100, with a score of 100 being indicative of the most severely affected outcome.
1565421|NCT02488031|Behavioral|Beck Depression Inventory, 2nd Ed|This is a 21 question self-report inventory for measuring severity of depression.
1565422|NCT02488031|Behavioral|Stroop|This test measures selective attention and cognitive flexibility through reading aloud of color names or color of the print.
1565423|NCT02488031|Behavioral|Purdue Pegboard|This test consists of a series of timed hand coordination and dexterity tasks.
1565424|NCT02488031|Behavioral|Brief Test of Attention|A cognitive test assessing focus and attention.
1565425|NCT02488031|Behavioral|6-minute Walk|This test consists on a timed 6-minute walk test to evaluate how much distance is covered.
1565426|NCT02488031|Behavioral|Hand Grip Dynamometer|This tests measures hand grip strength.
1565427|NCT02488031|Behavioral|Montreal Cognitive Assessment|This test is used to assess cognitive abilities.
1565428|NCT02488031|Behavioral|Physical Performance Function|This test consists of a series of physical activities used to evaluate speed, coordination, and ease of movement.
1565429|NCT02488031|Behavioral|Biomechanical Assessments of Dysmetria|Dysmetria will be assessed using a custom-made goal-directed movement protocol where participant perform unloaded limb movement tasks and attempt to reach a space-time target. During these task muscle activity is monitored using Electromyography (EMG) recording.
1565430|NCT02488031|Behavioral|Neurophysiological assessment of brain activity|Neurophysiology will be assessed by monitoring brain activity using Task-based fMRI and motor unit pool activity using a specialized EMG system.
1565431|NCT02488031|Behavioral|Biomechanical gait analysis|Participants will wear APDM's wireless sensors on the hands, legs, trunk and forehead and walk overground a distance of 7 m for 2 minutes. APDM quantifies 80 common biomechanical outcomes of gait (e.g. stride length variability).
1565432|NCT02488018|Biological|Provision of experimental honey|"Acacia, Becium grandiflorum, Croton macrostachys, Eucalyptus globules, Hypoestes, Leaucas abyssinica, Schefflera abyssinica, Syzygium guineense and reference glucose were used as test food.
25g available carbohydrate of the test food was provided to ten human subjects after fasted for 11 hours overnight."
1565433|NCT02488005|Device|Ultrasound|An ultrasound of the small bowel will be done by a radiologist or ultrasound technician. Subject should not eat or drink anything (i.e. no food and no water/beverages) for 8 hours prior to their ultrasound appointment
1565438|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): active (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. For active tDCS, the subject will undergo stimulation for 20 minutes.
1565439|NCT02487966|Behavioral|Mirror Therapy: active|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist.
1565440|NCT02487966|Device|transcranial Direct Current Stimulation (tDCS): sham (Soterix ©)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA on the primary motor cortex contralateral to the amputated leg. The subject will undergo stimulation for 20 minutes. This is the same parameters as the active one, except the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
1565441|NCT02487966|Behavioral|Mirror Therapy: Sham|Subjects will be asked to perform movements (15 minutes daily) using the unaffected limb while watching its mirrored reflection superimposed over the affected limb, only the mirror will be covered. During Mirror Therapy, subjects will be asked to consciously relate the movement observed in the mirror to their phantom limb and to keep their attention focused on the task. Instructions will be explained verbally, demonstrated by a therapist, and performed by the subject in front of the therapist. We will use the same all of these techniques as active Mirror Therapy only the mirror will be covered during all activities.
1565442|NCT02487953|Drug|Nicotine patch|21 mg/24 h for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
1565443|NCT02487953|Other|ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
1565444|NCT02487953|Other|Placebo patch|21 mg size for 2 weeks before the quit date and 12 weeks after the quit date, 14 mg size for 2 weeks, and 7 mg size for 2 weeks.
1565445|NCT02487953|Other|Placebo ENDS|As needed for 1 week before the quit date and 8 weeks after the quit date, then reduced use for 4 weeks.
1565446|NCT02487940|Drug|Intralipid 20%|Women with RIF received intralipid 20% (at a dose of 9mg/mL of the total blood volume, corresponding to 2 mL intralipid diluted at 20% in 250 mL normal saline) given over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
1565447|NCT02487940|Drug|Normal saline|Women with RIF received intravenous infusion of 250 mL physiological saline solution over 1-2 hours on the day of oocyte retrieval. Dose is repeated on/the following day of a positive pregnancy test, followed by a final dose 2-3 weeks later when attending for pregnancy scan.
1565448|NCT02487927|Behavioral|weaning|T piece
1565449|NCT02487914|Device|iontophoresis of Lidocaine 10% with interferential current (Dynatron 438)|drug delivery through interferential current.
1565450|NCT02487914|Drug|Lidocaine 10% was sprayed at the identified region|
1565451|NCT02487914|Device|interferential current|
1565452|NCT02487901|Device|ultrasonic osteotome|making gutter with ultrasonic osteotome
1565453|NCT02487901|Device|drill|making gutter with drill
1565454|NCT02487888|Other|Unblinded to Genetic Testing Results|The physicians of this group of patients will be unblinded to the results of the genetic testing.
1565455|NCT02487888|Other|Blinded to Genetic Testing Results|The physicians of this group of patients will be blinded to the results of the genetic testing. They will be un-blinded to the results of each patient once that patient has completed the study.
1565456|NCT02487875|Other|rehabilitation|
1990719|NCT01857869|Biological|Malaria vaccine 257049_0,1,2M|RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.
1565458|NCT02487849|Procedure|HIPEC|secondary cytoreductive operation
1565459|NCT02487849|Drug|Carboplatin|Hyperthermal Intraperitoneal Chemotherapy (HIPEC)
1565460|NCT02487836|Device|Type WallFlex or Evolution biliary, stent system|Laying of a stent biliary
1565464|NCT02487797|Drug|Oxytocin|
1565465|NCT02487797|Other|Sodium Chloride 0.9%|
1565466|NCT02487784|Procedure|Block allograft|A cancellous block allograft plus corticocancellous particulate allograft will be used as the positive control treatment.
1565467|NCT02487784|Procedure|Particulate allograft + autogenous bone chips|The test arm of this study will include a mix of particulate bone allograft and autogenous bone chips.
1565470|NCT02487758|Procedure|Ridge Preservation|Ridge Preservation Comparing the Clinical and Histologic Healing of Flap vs. Flapless Approach to Grafting
1565471|NCT02487745|Behavioral|Abstinence-contingent wage supplements|Before obtaining competitive employment, participants will be able to earn wage supplements for attending two individual placement and support (IPS) supported employment sessions per week, and for completing specific tasks prescribed by IPS including developing a worker profile, applying for appropriate jobs, and completing job interviews. Once a participant becomes employed, participants will be able to earn up to $5 per hour for every hour worked in a competitive job up to 40 hours per week verified by pay stubs. To maintain long-term drug abstinence, participants will be required to provide urine samples to earn the maximum in wage supplements.
1565472|NCT02487745|Behavioral|Individual Placement and Support (IPS) supported employment|Individual Placement and Support (IPS) supported employment involves rapid job search, promotes competitive employment, considers the participant's preferences, and provides job supports and benefits counseling. An employment specialist will establish relationships will potential employers and work with participants to identify potential jobs, prepare applications, and to apply for positions.
1565473|NCT02487732|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 5 weeks
1565474|NCT02487732|Drug|Prasugrel|Prasugrel 10mg once daily for 5 weeks
1565475|NCT02487719|Drug|Iron sulfate and Iron polymaltose for prevention of iron deficiency anemia|
1565476|NCT02487706|Drug|Dolutegravir|Dolutegravir 50mg/day per 5 days
1565477|NCT02487693|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
1565478|NCT02487693|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
1565479|NCT02487680|Dietary Supplement|Amino Acids and chromium-picolinate containing drink|Evaluation of the dietary supplement drink containing amino acids and chromium picolinate and aroma
1565480|NCT02487680|Dietary Supplement|Placebo drink|Evaluation of the placebo supplement drink containing only aroma
1565481|NCT02487667|Device|Therapeutic exercise by fitness machines|Therapeutic exercise program by using 8 exercise machine circuit
1565482|NCT02487654|Procedure|Pulmonary vein isolation|Catheter ablation within the left atrium that electrically disconnects these veins from the rest of the left atrium (pulmonary vein isolation)- Current standard of treatment.
1565483|NCT02487654|Procedure|Ganglionic plexi ablation|Catheter ablation around the nerve supplying the heart and destroying the collection of these nerve endings(ganglionic plexi ablation).
1565484|NCT02487628|Device|HQ® Matrix Soft Tissue Mesh|
1565485|NCT02487628|Device|ULTRAPRO® Partially Absorbable Lightweight Mesh|
1565486|NCT02487602|Device|Gelesis100|Gelesis100 capsules
1565487|NCT02487602|Other|Placebo|Sucrose (sugar) capsules
1565488|NCT02487589|Other|Telephone support, telemonitoring and tele-exercise|"The care model will provide 24/24 h assistance for six months and include:
Telephone Support: a nurse-tutor (NT) will follow-up the enrolled patients weekly mainly through scheduled appointments. NTs duties will be: 1 education (patients and family ' s health education on how to prevent falls, verification of the adherence to the pharmacological therapy, teaching on how to recognize problems that can conduct to falls) and 2. management. Occasional appointments will be required by patients on duty and managed by a nurse .
Telemonitoring: all patients will send proper biological traces and data will be registered on a personal health record.
Tele-exercise: Home exercises sessions will be provided by a DVD and monitored through a videoconference by a physiotherapist."
1565489|NCT02487576|Other|Carbohydrate-rich (HC)|65% Carbohydrate; 20% Fat; 15% Protein
1565490|NCT02487576|Other|Fat-rich (HF)|35% Carbohydrate; 50% Fat; 15% Protein
1565491|NCT02487563|Drug|decitabine|decitabine, 15mg/m2 daily intravenously for 3 consecutive days
1565492|NCT02487563|Drug|rhTPO|rhTPO, 300U/Kg, subcutaneous injection，qd x 18d
1565493|NCT02487550|Biological|DC-CIK|Patients with renal cell carcinoma will receive autologous dendritic cells loaded with autologous tumor lysate (dendritic cell vaccine) by venous infusion of CIK cells.
1565494|NCT02487550|Biological|IL-2/IFN-α|Patients with renal cell carcinoma will receive IL-2/IFN-α by venous infusion.
1565495|NCT02487537|Dietary Supplement|custom-made soft drink|
1565496|NCT02487524|Other|Cold water test|The patients immerse their hand into cold water for a maximum of 90 seconds and report their pain intensity every 15 seconds during the test.
1565497|NCT02487524|Other|Autonomic nervous system monitoring|The autonomic nervous system is monitored during the cold water test and 15 minutes thereafter.
1565498|NCT02487524|Other|QST|Quantitative sensory testing.
1565499|NCT02487511|Other|Duration of HP therapy|the comparison of HP eradication rate between 7 days and 14 days
1565504|NCT02487485|Drug|Ketamine|. Subjects will receive an infusion of ketamine (0.5 mg/kg infusion over approximately 40 minutes). All subjects will receive two ketamine infusions—once with a placebo and once with a single dose of sirolimus (6 mg, oral administration).
1565505|NCT02487485|Drug|sirolimus|Subjects will receive a single 6 mg oral dose via oral solution of sirolimus or a dose of placebo approximately two hours prior to the infusions. As above, the order of placebo and sirolimus is randomized. The sirolimus dose as well as the placebo solution will be given in 6 ounces of orange juice.
1565506|NCT02487485|Drug|Placebo|Placebo oral dose
1565514|NCT02487433|Drug|Tofacitinib MR 22 mg (Fed)|A single dose of tofacitinib modified release 22 mg tablet after receiving the standard FDA high-fat/high-calorie meal
1565515|NCT02487433|Drug|Tofacitinib MR 22 mg (Fasted)|A single dose of tofacitinib modified release 22 mg tablet after an overnight fast of 10 hours
1565516|NCT02487420|Behavioral|shorter or longer period of specific dietary restrictions|step by step gradual introduction of egg containing food products
1565517|NCT02487407|Drug|ODM-109|ODM-109 1 mg capsule for oral administration.
1565518|NCT02487407|Drug|Placebo for ODM-109|Placebo capsule for oral administration.
1565521|NCT02487381|Drug|delta-9-tetrahydrocannabinol|
1565522|NCT02487381|Drug|Cannabidiol|
1565524|NCT02487368|Device|Needle stimulation pad|
1565525|NCT02487355|Drug|Dexmedetomidine|Dexmedetomidine 1 μg/ kg
1565526|NCT02487355|Drug|Magnesium Sulphate|Magnesium Sulphate 50 mg
1565527|NCT02487355|Drug|Bupivacaine|1ml/kg of 0.25%of bupivacaine
1565528|NCT02487355|Drug|Dexmedetomidine + Magnesium Sulphate + Bupivacaine|Dexmedetomidine 1 μg/ kg + Magnesium Sulphate 50 mg + 1ml/kg of 0.25%of bupivacaine
1565529|NCT02487342|Other|milk|small serving (217 mL) of british semi-skimmed milk
1565530|NCT02487342|Other|orange fruit-juice|small serving (217 mL) of orange juice
1565531|NCT02487329|Other|Calcium Hydroxide|Exposed area was sealed with a self-hardening calcium hydroxide paste then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
1565532|NCT02487329|Other|Er,Cr:YSGG laser + calcium hydroxide|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, it was sealed with a self-hardening calcium hydroxide paste.Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
1565533|NCT02487329|Other|TheraCal LC|TheraCal LC was applied directly to the exposed pulp with a needle tip syringe in incremental layers that was not to exceed 1 mm in depth. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
1565534|NCT02487329|Other|Er,Cr:YSGG laser + TheraCal LC|After the exposed area was irradiated with Er,Cr:YSGG laser at an energy level of 0,5 W, a repetition rate of 20 Hz, 140 µs pulse duration with 0% water and 45% air for 10 s, TheraCal LC was used to seal the treated area. Then final restoration was completed using a resin-modified glass ionomer and a nanohybrid composite resin
1565535|NCT02487316|Drug|crizotinib|crizotinib 250mg, oral, bid from day 1 to 18 weeks. cyclophosphamide, 750mg/m2,d1, vincristine, 1.4mg/m2, maximal dose is 2mg d1, doxorubicin, 50mg/m2d1, prednison, 100 mg d1-5) every 3 weeks for up to six cycles.
1565536|NCT02487303|Drug|Acetaminophen Intravenous|IV 1 gram f3 doses over 24 hours
1565537|NCT02487303|Drug|Acetaminophen Oral|Oral 1 gram 3 doses over 24 hours
1565538|NCT02487290|Device|Aneufix ACP-T5|
1565539|NCT02487277|Drug|PEGPH20|
1565540|NCT02487277|Drug|Gemcitabine|
1565541|NCT02487277|Drug|Nab-paclitaxel|
1565542|NCT02487251|Behavioral|Meal Delivery|Participants receive a healthy, prepared family meal for consumption at home. Meals are received one per week for 8 weeks. Recipes for the meals are provided.
1565543|NCT02487251|Behavioral|Ingredient Delivery|Participants receive ingredients to prepare a healthy, family meal for consumption at home. Meal ingredients are received one per week for 8 weeks. Recipes for the meals are provided.
1565544|NCT02487251|Behavioral|Community Kitchen|Participants come to a Head Start site to prepare a family entree to take home, cook, and consume. Participants prepare their meals in small groups with an MSU Extension paraprofessional as a facilitator. The Community Kitchen is held once per week for 8 weeks.
1565545|NCT02487251|Behavioral|Healthy Eating Classes|Participants attend a small-group class on healthy eating, nutrition and meal planning ideas. Recipes are provided. Classes are held once per week for 8 weeks.
1565546|NCT02487251|Behavioral|Cooking Demonstrations|Participants meet in small groups and observe as an MSU paraprofessional demonstrates the preparation of a healthy family entree. Participants taste the recipe but do not take food home with them. Recipes are provided. Demonstrations are held once per week for 8 weeks.
1565547|NCT02487251|Behavioral|Provision of Cookware|Participants receive a set of basic cookware and dishes to use in preparing healthy family meals at home. Recipes are provided. The cookware set is provided at the beginning of the typical 8 week intervention cycle.
1565548|NCT02487251|Behavioral|Usual Head Start Exposure|Participants receive no supplemental information on family mealtimes beyond what is already addressed in Head Start programming.
1565549|NCT02487238|Biological|Fecal Microbial Enema|Active intervention.
1565550|NCT02487238|Biological|Normal Saline Enema|Placebo comparator.
1565551|NCT02487225|Drug|Pentoxifylline|Pentoxifylline is a competitive nonselective phosphodiesterase inhibitor which raises intracellular cAMP, activates PKA, inhibits TNF and leukotriene synthesis, and reduces inflammation and innate immunity. In addition, pentoxifylline improves red blood cell deformability (known as a haemorrheologic effect), reduces blood viscosity and decreases the potential for platelet aggregation and thrombus formation.Pentoxifylline is also an antagonist at adenosine 2 receptors
1565552|NCT02487225|Drug|Placebo|a harmless pill that has no therapeutic effect, used as a control in testing of investigational drug
1565553|NCT02487212|Drug|0.05% Clobetasol propionate|0.05% Clobetasol propionate was rubbed for 2 minutes on one side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser. The treatment was done in every 2 weeks for 4 sessions
1565554|NCT02487212|Drug|Petrolatum gel|Petrolatum gel was rubbed for 2 minutes on the other side of the scar immediately after treated with fractional Erbium: YAG (2,940-nm) laser.The treatment was done in every 2 weeks for 4 sessions
1565555|NCT02487212|Device|Fractional Erbium:Yag (2,940-nm) laser|The parameter of the laser was 28 J/cm2, 5% spot density, 1 pass for the whole scar. The treatment was done in every 2 weeks for 4 sessions
1565558|NCT02487186|Drug|Doxicicline|Association of doxycycline (DOX) encapsulated in PLGA microspheres to ultrasonic debridment for the treatment of patients with chronic generalized periodontitis.
1565559|NCT02487186|Procedure|Full-mouth debridment|"The patients will be treated by a single-session of periodontal debridement
during 45 minutes, using an ultrasonic instrument (Cavitron, Dentsply, Rio de
Janeiro, Brazil), under irrigation with sterile saline solution 20. After the debridement, local administration of microspheres loading doxycycline (DOX) (test) or empty microspheres (control) was performed."
1565560|NCT02487173|Device|Respirio Flu Test|The Respirio Flu Test is a rapid test for the detection of influenza A or influenza B in nasal secretions. The Respirio Flu Test is designed to be simple to use and generates a result within 20 minutes.
1565604|NCT02486939|Drug|CHS-0214|Open label
1565605|NCT02486926|Other|Sevoflurane|Anesthesia of patients was maintained only with sevoflurane.
1565606|NCT02486926|Drug|Remifentanil|Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
1565561|NCT02487173|Device|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)|Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) is a molecular diagnostic technique for the detection and identification of influenza viruses, both for clinical samples and isolates. The reverse-transcriptase polymerase chain reaction (RT-PCR) allows template viral RNA to be reverse transcribed producing complementary DNA (cDNA) which can then be amplified and detected.
1565562|NCT02487173|Device|Sofia® Influenza A+B Fluorescent Immunoassay (FIA)|Sofia® Influenza A+B Fluorescent Immunoassay (FIA) employs immunofluorescence to detect influenza A and influenza B viral nucleoprotein antigens in nasal swab, nasopharyngeal swab, and nasopharyngeal aspirate/wash samples taken directly from symptomatic patients.
1565563|NCT02487160|Device|SBL-3 multifocal intraocular lens|The SBL-3 intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
1565564|NCT02487160|Device|Control monofocal intraocular lens|The Control intraocular lens will be implanted after the cataractous natural lens has been removed, in those patients randomized into this group
1565565|NCT02487147|Device|Free Air Portable Air Powered Respirator|The Free Air PAPR is a portable air powered respirator that you will wear like a backpack with a mask and tubing attached.
1565566|NCT02487147|Device|N95 Respirator|The N95 respirator is a mask that is standardly used clinically at Wake Forest Baptist Health.
1565567|NCT02487134|Device|TIGR Matrix|Reinforcement of the suture line with resorbable mesh
1565568|NCT02487134|Device|Control|Closure of the abdomen with conventional technique
1565569|NCT02487121|Behavioral|variable interval schedule|12 group-based extended care treatment sessions scheduled in 3, 4-week periods over a 12-month period
1565570|NCT02487121|Behavioral|self-directed treatment|provision of treatment materials with instruction to work through materials at participant's own pace
1565571|NCT02487108|Drug|Hydrocodone bitartrate|5.0 mg, 7.5 mg, 10 mg
1565572|NCT02487108|Drug|Acetaminophen|325 mg
1565573|NCT02487108|Drug|Placebo|Matching Placebo
1565574|NCT02487095|Drug|Topotecan|Topotecan (in combination with VX-970) administered by IV Days 1-5 in a 21 day cycle, until disease progression or development of intolerable side effects.
1565575|NCT02487095|Drug|VX-970|VX-970 (in combination with Topotecan) administered by IV Day 5 or Days 2 and 5 in a 21 day cycle, until disease progression or development of intolerable side effects.
1565576|NCT02487082|Drug|Melatonin and Donepezil|The duration depends on group assignment.
1565577|NCT02487082|Other|Placebo|The duration depends on group assignment.
1565585|NCT02487043|Behavioral|A telephone-based case-management intervention|Regular Telephone support delivered by Health coaches
1565586|NCT02487030|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
1565587|NCT02487030|Drug|RBV|RBV tablets administered orally in a divided daily dose based on weight (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1565588|NCT02487017|Procedure|Transcatheter Arterial Chemoembolization (TACE)|"Transcatheter Arterial Chemoembolization (TACE):
5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml,the perfusion time should not be less than 20 min"
1565589|NCT02487017|Biological|DC-CIK|"Transcatheter Arterial Chemoembolization (TACE):
5-FU 400mg/m2 Hepatic arterial infusion ,lipiodol amount is usually 20 ml, the perfusion time should not be less than 20 min
DC-CIK:
8×10^9 DC-CIK cells for each infusion, IV (in the vein) for each infusion at least 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32"
1565590|NCT02487004|Device|hemodialysis|
1565591|NCT02486991|Procedure|Tunnel + AlloDerm®|A coronally positioned tunnel (CPT) technique for root coverage will be used alone with acellular dermal matrix (AlloDerm®).
1565592|NCT02486991|Procedure|Tunnel + AlloDerm® + Verticals|The use of intramucosal vertical incisions in addition to a coronally positioned tunnel (CPT) technique for root coverage will be used with acellular dermal matrix (AlloDerm®).
1565593|NCT02486978|Other|Control (109 g white bread)|Control meal of 109 g white bread to which the response of the test meals with dietary supplements will be compared to.
1565594|NCT02486978|Dietary Supplement|Dose 1|The test meal will contain a single dose of the supplements whose response will be compared to that of the control meal.
1565595|NCT02486978|Dietary Supplement|Dose 2|The test meal will contain a double dose of the supplements whose response will be compared to that of the control meal.
1565599|NCT02486952|Drug|Cyclophosphamide|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
1565600|NCT02486952|Drug|Hydroxydaunorubicin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
1565601|NCT02486952|Drug|Oncovin|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
1565602|NCT02486952|Drug|Prednisone|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
1565603|NCT02486952|Drug|Rituximab|Administered at the treating physician's discretion and according to package labeling, within approved indication and local approval status of the drug.
1565607|NCT02486926|Drug|Alfentanil|Anesthesia was maintained with both sevoflurane and continuous infusion of remifentanil. Alfentanil was administrated (5ug/kg) to patients 10 minutes before the end of surgery.
1565608|NCT02486926|Drug|Thiopental|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
1565609|NCT02486926|Drug|Rocuronium|General anesthesia was induced with thiopental 5 mg/kg, rocuronium 0.6 mg/kg and sevoflurane in all patients.
1565610|NCT02486913|Other|Enhanced Health Check|National Health Service Health Check enhanced by risk report
1565611|NCT02486900|Device|fMRI-based neurofeedback|During scanning patients will be exposed to picture stimuli (showing alcoholic drinks and life goals) projected on a screen behind the scanner and viewed through a mirror attached on the MRI head coil. In each session patients will be trained to down-regulate/up-regulate activation levels in brain areas that show reliable responses to the alcohol/life goals pictures in a 'localiser' scan. Self-regulation of these brain responses will then be guided by real-time feedback of alcohol/life goals-cue elicited activation, consisting of changes in the visible alcohol/life goals picture (decreasing size = successful down-regulation; increasing size = successful upregulation). Functional MRI data will be acquired in short blocks having a duration of 5-8 minutes.
1565612|NCT02486887|Device|telemonitoring of weight, pulse and blood pressure|
1565613|NCT02486874|Device|PoreSkin|a human acellular dermal matrix
1565615|NCT02486848|Drug|5% Topical Minoxidil Solution|5% Topical Minoxidil Solution
1565616|NCT02486848|Drug|15% Topical Minoxidil Solution|15% Topical Minoxidil Solution
1565617|NCT02486835|Device|Cough syrup for adults and children|Dosage is 5 ml three times a day for 4 nights, 3 days
1565618|NCT02486835|Device|Placebo|Dosage is 5 ml three times a day for 4 nights, 3 days
1565619|NCT02486822|Procedure|Amniotomy|Amniotomy, artificial rupture of membranes, is done with initial delay of labor (in partograph: extension beyond alert line, in labor scale: when progress reaches the membrane line)
1565620|NCT02486822|Drug|Oxytocin|Oxytocin augmentation: given with further delay of labour (according to the point of intervention of the partograph or the scale)
1565621|NCT02486822|Procedure|Cesarean Section|Cesarean section: done when progress is deemed arrested (according to the definition of the partograph or the scale)
1565622|NCT02486809|Drug|Lebrikizumab|Participants will receive a single SC dose of lebrikizumab, delivered via needle and syringe or PFS-NSD.
1565623|NCT02486796|Biological|Reishi mushroom extract|Reishi mushroom preparation produced water-ethanol extraction.
1565624|NCT02486796|Drug|Coenzyme Q10|Preparation of coenzyme Q10
1565625|NCT02486796|Drug|Melatonin|Preparation of melatonin
1565626|NCT02486770|Biological|Aerucin 2.0mg/kg|IV Aerucin 2.0 mg/kg over 1 hour
1565627|NCT02486770|Biological|Aerucin 8.0mg/kg|IV Aerucin 8.0 mg/kg over 1 hour
1565628|NCT02486770|Biological|Aerucin 20.0 mg/kg|IV Aerucin 20 mg/kg over 1 hour
1565629|NCT02486757|Drug|micronized progesterone|
1565630|NCT02486757|Drug|transdermal estradiol|
1565631|NCT02486744|Drug|Acthar Gel|Subjects will be given an injection subcutaneously 2x week for 6 months. Dosing will be randomly assigned as either 80 U or 40 U
1565632|NCT02486718|Drug|Atezolizumab|Participants will receive atezolizumab (1200 mg IV) Q3W for 16 cycles (cycle length=21 days).
1565633|NCT02486718|Drug|Cisplatin|Participants will receive cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of each of the four 21-day cycles.
1565634|NCT02486718|Drug|Vinorelbine|Participants will receive vinorelbine 30 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
1565635|NCT02486718|Drug|Docetaxel|Participants will receive docetaxel 75 mg/m^2 IV on Day 1 of each of the four 21-day cycles.
1565636|NCT02486718|Drug|Gemcitabine|Participants will receive gemcitabine 1250 mg/m^2 IV on Days 1 and 8 of each of the four 21-day cycles.
1565637|NCT02486718|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV on Day 1 of each of the four 21-day cycles. Pemetrexed will be administered only in participants with non-squamous cell NSCLC.
1565638|NCT02486705|Behavioral|PTSD Family Coach Full|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information, support resources, tools for coping with caregiver-related stress, and tools for self-monitoring stress symptoms.
1565639|NCT02486705|Behavioral|PTSD Family Coach Basic|PTSD Family Coach mobile app is an iOS mobile phone application designed to provide information and support resources,
1565641|NCT02486679|Drug|Prostin (PGE2) tablets|
1565642|NCT02486679|Device|Foley catheter|
1565643|NCT02486666|Drug|Enoxaparin|WEIGHT ADJUSTED FiXED DOSE OF LOW MOLECULAR WEIGHT HEPARIN (ENOXAPARIN) TO NEONATES WITH THROMBOSIS (FiXET)
1565648|NCT02486627|Drug|plazomicin|
1565649|NCT02486627|Drug|meropenem|
1565650|NCT02486627|Drug|levofloxacin (oral)|Oral switch after completion of study drug when clinically appropriate
1565651|NCT02486614|Procedure|CRRT|citrate based continuous renal replacement therapy
1565652|NCT02486601|Drug|nab-paclitaxel|nab-paclitaxel : 150 mg/m2 D1 every 2 weeks
1565653|NCT02486601|Drug|FOLFOX|Leucovorin: 400 mg/m2 D1 every 2 weeks Oxaliplatin: 85 mg/m2 D1 every 2 weeks Fluorouracil (5-FU) infusion: 2400mg/m2 48h infusion every 2 weeks
1565654|NCT02486588|Other|Messaging|See detailed study description for overview of the different messaging interventions in this study
1565655|NCT02486588|Other|Financial incentives|See detailed study description for overview of the different financial incentive-based interventions in this study
1565656|NCT02486575|Other|Self-learning|Every resident will train following the video instruction included in the FLS course material and related written instruction only
1565657|NCT02486575|Other|Mentoring|A tutor will follow each resident during learning, giving instruction, examples and any kind of suggestions.
1565658|NCT02486549|Procedure|Supraclavicular Block|Under ultrasound guidance an insulated needle is advanced with in- plane technique into the brachial plexus sheath and 20ml 0.25% bupivacaine will be administered
1565659|NCT02486549|Procedure|Interscalene Block|Under ultrasound guidance an insulated needle will be placed through the middle scalene muscle,into the interscalene groove with in-plane technique and 20ml 0.25%bupivacaine will be administered into the brachial plexus
1565660|NCT02486549|Drug|Bupivacaine|20ml 0.25% bupivacaine will be injected for brachial plexus block
1565661|NCT02486549|Device|Ultrasound|The Ultrasound will be used for brachial plexus visualization
1565662|NCT02486536|Drug|polyethylene glycol|
1565663|NCT02486536|Device|capsule endoscopy|
1565664|NCT02486523|Behavioral|Hygiene promotion sessions|Hygiene promotion sessions are provided weekly to the caretakers at the health center level. They contain 7 main messages this study is trying to get across: Allocate a protected space for children to play, limiting the likelihood of them ingesting soil or animal feces; Wash the child with soap (hand, face) when outside the protected area; Cleaning and rapid burial of children's stools; Key times for hand washing with soap for the child caretaker; Store drinking water in a closed container located in an elevated place out of reach of animals; Drinking water provided to the child should be treated with chlorine or boiled; Once weaned, avoid giving to the child leftover food, or only after warming it again.
1565665|NCT02486523|Device|Household WASH package|The content of the kit: 200 g soap, aquatab 67 g, 20 liters Jerry can, a cup, a plastic kettle for hand washing and the instructions leaflet.
1565666|NCT02486523|Behavioral|Household visit|A household visit conducted by village's community health volunteers and ACF intervention staff during and after the treatment, to provide refresh training on the messages and the use of the kit.
1565667|NCT02486523|Behavioral|Group discussions after successful discharge|Group discussions on hygiene and care practices with mothers at the community level after successful discharge.
1565668|NCT02486523|Procedure|Outpatient Therapeutic Programme|Home-based treatment and rehabilitation using Ready-to-use Therapeutic Food (RUTF) for children with severe acute malnutrition
1565670|NCT02486497|Biological|hENT1|hENT1 is a membrane transporter for gemcitabine. According to the hENT1 staining, patients will be treated with gemcitabine or 5-FU.
1565671|NCT02486484|Drug|ziv-aflibercept|zaltrap injection
1565672|NCT02486471|Procedure|Monsel´s Paste|surgical method to stop bleeding by using the hemostatic Agent monsel´s paste until no more bleeding is visible
1565673|NCT02486471|Other|Wait and see|finishing examination without hemostatic intervention, awaiting spontaneous coagulation
1565674|NCT02486458|Drug|5% sodium fluoride varnish|Fluoride varnish containing 22,600 ppm F, as NaF, in a neutral base
1565675|NCT02486458|Drug|1.23% sodium fluoride acidic gel|Fluoride gel containing 12,300 ppm F (as NaF) in an acidic pH (by addition of phosphoric acid)
1565676|NCT02486445|Drug|Rivaroxaban|Rivaroxaban 15 mg every 12 hours until the completion of the diagnostic work-up, which should not exceed 24 hours (maximum 2 tablets)
1565677|NCT02486432|Drug|Levodopa/Carbidopa (Sinemet)|Oral administration of 2 × 12.5 mg/50 mg Sinemet® tablet containing 13.5 mg carbidopa (equivalent to 12.5 mg anhydrous carbidopa) and 50 mg levodopa three times a day on Day -1 with 240 mL water Oral administration of 1 × 12.5 mg/50 mg Sinemet® tablets containing 13.5 mg carbidopa (equivalent to 12.5 mg of anhydrous carbidopa) and 50 mg levodopa administered with 100 mL water every hour for 16 hours on Day 1
1565678|NCT02486419|Other|Outdoor weather|Seasonal changes in temperature
1565684|NCT02486393|Procedure|Parotid surgery|Surgery of the parotid gland tumours
1565685|NCT02486380|Device|Simplus/Eson|Released product Simplus and Eson masks
1565686|NCT02486367|Drug|Clopidogrel|Standard ADP receptor blockade
1565687|NCT02486367|Drug|Ticagrelor|High potency ADP receptor blockade
1565688|NCT02486354|Drug|icotinib|Patients were administered with oral icotinib (tablet form, 125 mg) three times daily within two days after enrollment until disease progression or unacceptable toxicity.
1565689|NCT02486341|Drug|Insulin|Continuous glucose monitoring system over 120-hour period.
1565736|NCT02485938|Drug|Allogeneic Cardiosphere-Derived Cells (CAP-1002)|Intracoronary delivery of Allogeneic Cardiosphere-Derived Cells (CAP-1002)
1565694|NCT02486315|Device|AXXESS stent|Axxess stent is a conically-shaped, self-expanding nitinol stent, with a 0.006-inch strut thickness, specifically designed to preserve and to match the anatomy of the bifurcation at the carina level. The stent is coated with Biolimus A9™, a highly lipophilic, semi-synthetic sirolimus analogue, immersed in the biodegradable polylactic acid (PLA) applied primarily to the abluminal surface. PLA completely dissolves after 6 to 9 months.The stent has 3 radiopaque markers at the distal end and one at the proximal end to aid in the visibility and placement. The AxxessTM stent is 7 Fr guiding catheter or Sheathless Guiding Catheter compatible. During the study period, the AxxessTM stent was available in 3 different diameters (3.0, 3.5 and 4.0 mm) and lengths (9, 10 and 14 mm)
1565696|NCT02486289|Drug|Emeramide|Mercury chelator NBMI ((N1,N3-bis(2-mercaptoethyl) isophthalamide)
1565697|NCT02486289|Drug|Placebo|NBMI Placebo
1565698|NCT02486276|Drug|Cilostazol|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
1565699|NCT02486276|Drug|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
1565700|NCT02486276|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
1565701|NCT02486263|Other|Study|"Omeprazole 0.75-1.5 milligrams/kilogram/dose twice a day (BID)
Total fluid volume restriction (120-140 milliliters/kilogram/day)
Feeding duration over 30 minutes
Infant feeds with right side down
Infant is placed on back following feeds"
1565702|NCT02486250|Other|Validation Study|
1565703|NCT02486237|Other|None, observational study|None, it is an observational study
1565707|NCT02486211|Drug|Amantadine|100mg BID for 7 days at 0600 and 1200
1565708|NCT02486211|Drug|Placebo|Placebo comparator
1565709|NCT02486198|Drug|placebo|"For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), equal saline as placebo should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.
For patients who discontinue oxaliplatin-based chemotherapy, equal saline as placebo should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
1565710|NCT02486198|Drug|GM|"For patients with oxaliplatin-based chemotherapy(every 2 or 3 weeks), monosialotetrahexosylganglioside sodium injection(40mg for chemotherapy of every 2 weeks or 60mg for chemotherapy of every 3 weeks)should be used one hour before oxaliplatin for 1 week during every chemotherapy cycle, until neurotoxicity progressed.
For patients who discontinue oxaliplatin-based chemotherapy, equal monosialotetrahexosylganglioside sodium injection should be used daily until there is no neurotoxicity relief (neurotoxicity should be assessed at 2 and 4 weeks' treatment, up to 18 weeks)"
1565711|NCT02486198|Drug|oxaliplatin-based chemotherapy|chemotherapy contains oxaliplatin
1565712|NCT02486185|Other|SCREENING TEST|"Skeletal muscle mass, which will be estimated by calculating values for the mid-arm muscle circumference (MAMC) from brachial perimeter (BP) and triceps skinfold thickness (TSF).
Muscle force will be measured using a hydraulic dynamometer
Physical performance will be estimated from the subject's Gait speed using a 4 meter gait test (Gait speed 4-m)"
1565713|NCT02486172|Behavioral|Peer support program|Peer support program as an additional service to the routine clinical service
1565714|NCT02486159|Drug|Herbal plaster (Sanfujiu)|The Acupoint herbal plaster consisted of mustard seed, fumarate, asarum, angelica, cinnamon, and ginger at a ratio of 3:3:2:2:0.5:4, respectively. The treatment was prepared by dissolving the ginger in water and adding the powder to form a plaster. Mixtures were formed into cakes of approximately 1.5 × 1.5 × 0.5 cm3 and were held in position using plastic sheets.
1565715|NCT02486159|Procedure|Acupuncture|Eight (8) acupuncture treatment sessions over 4 weeks were performed for each volunteer. The standard protocol for acupuncture treatment covered the most commonly treated acupoints for allergic rhinitis: LI4, ST36, LI20 in both sides, and EX-HN3. After insertion of needles at each acupoint, manual stimulation of needles on LI20 and EX-HN3 was repeated 3 times at 5-minute intervals. Electrostimulation was applied to the needles inserted in ST36 and LI4 with a frequency of 3-5 Hz, and the intensity was adjusted according to each volunteer's tolerance. All needles were removed 20 minutes later in each treatment session.
1565716|NCT02486133|Drug|Prezista|once daily
1565717|NCT02486133|Drug|Norvir|once daily
1565718|NCT02486133|Drug|Tivicay|once daily
1565719|NCT02486133|Drug|Truvada|once daily
1565720|NCT02486133|Drug|Kivexa|once daily
1565721|NCT02486107|Procedure|surgical procedure|
1565722|NCT02486081|Device|smart soccer ball|smart soccer ball was used to measure participant's performance in total time and distance for completion, and acceleration
1565723|NCT02486068|Device|ABSORB scaffold|
1565724|NCT02486068|Device|Xience Prime|
1565725|NCT02486055|Drug|BPM31510 Oral Nanosuspension 4%|Oral nanosuspension formulation of BPM31510 (ubidecarenone, USP)
1565726|NCT02486042|Drug|Omegaven|
1565727|NCT02486016|Drug|Duragesic Reference Fentanyl Patch|25 µg/hour
1565728|NCT02486016|Drug|Apotex Generic Fentanyl Patch|25 µg/hour
1565729|NCT02486016|Drug|Mylan Generic Fentanyl Patch|25 µg/hour
1565730|NCT02485990|Drug|Tremelimumab|
1565731|NCT02485990|Drug|Olaparib|
1565732|NCT02485977|Device|Magnetic resonance Imaging|MRI study will be performed on 1.5 Tesla magnet, during the administration of Gadolinium
1565733|NCT02485964|Other|Blood draw|One time blood draw at time of consent. Blood will be stored until all subjects have been enrolled and then the enzyme-linked immunospot (ELISPOT) assay will be done to measure the antigen-specific interferon secretion.
1565734|NCT02485951|Procedure|Central air injection|Air was injected inside the trephination site in the central injection group.
1565735|NCT02485951|Procedure|Peripheral air injection|Air was injected at the corneal periphery outside the trephination site.
1565864|NCT02484963|Drug|placebo|
1565737|NCT02485925|Device|THERMOCOOL® SMARTTOUCH™|Pulmonary vein isolation by RF ablation treatment with the THERMOCOOL® SMARTTOUCH™ contact force sensing catheters (study device)
1565738|NCT02485912|Biological|ChAd3-EBO Z|This is a viral vectored vaccine using a chimpanzee adenovirus as a vector encoding a Zaire strain Ebola glycoprotein
1565739|NCT02485912|Biological|MVA-EBO Z|This is a viral vectored vaccine using a modified vaccinia Ankara virus as a vector encoding a Zaire strain Ebola virus glycoprotein
1565740|NCT02485899|Biological|BMN 190|300 mg ICV infusion administered every other week for up to 240 weeks
1565741|NCT02485886|Drug|68Ga-BMV101|68Ga-BMV101 were intravenously injected into the patients 1 h before the PET/CT scans.
1565742|NCT02485873|Drug|Rivaroxaban (Xarelto, BAY59-7939)|As prescribed by treating physicians
1565743|NCT02485873|Drug|Vitamin K antagonists|As prescribed by treating physicians
1565744|NCT02485860|Device|Melectis G|
1565745|NCT02485847|Procedure|Ophthalmology|A registry of ophthalmic ambulatory encounters which captures essential data elements for continuous quality improvement efforts, enhanced patient care outcomes, and pay for performance programs.
1565746|NCT02485834|Procedure|FDG-PET|
1565747|NCT02485834|Procedure|surgery|
1565748|NCT02485834|Drug|5-FU|200 mg/m^2/day IV
1565749|NCT02485834|Drug|capecitabine|oral 800 mg/m^2 BID
1565750|NCT02485834|Drug|docetaxel|30 mg/m^2 IV
1565751|NCT02485834|Drug|Irinotecan|50 mg/m^2 IV
1565752|NCT02485834|Radiation|3D-CRT|
1565753|NCT02485834|Radiation|IMRT|
1565754|NCT02485821|Drug|Estradiol|
1565755|NCT02485821|Drug|Placebo|
1565756|NCT02485821|Drug|Misoprostol|
1565757|NCT02485808|Other|None-observational|For surgical patients, follow-up assessments will occur 3 and 12 months after the surgery. For medical patients, follow-up assessments will occur 3 and 12 months after the baseline assessment.
1565758|NCT02485808|Procedure|Magnetic Resonance Imaging (MRI)|One time MRI scanning session examining brain structure and function in a resting state and after water consumption.
1565759|NCT02485808|Other|Multimodal Automated Sensory Testing System|Pressure pain thresholds will be assess using computer-controlled pressures delivered by a device called the Multimodal Automated Sensory Testing System (MAST) device on to the subjects thumbnail bed.
1565760|NCT02485808|Other|Auditory Sensitivity Test|Subjects' sensitivity to sound will be evaluated using a series of sounds delivered by a standard audiometer device.
1565761|NCT02485795|Other|Observational|This study will evaluate the impact of genetic testing information on medical regimen plans and whether this information results in benefits to patient care.
1565762|NCT02485782|Device|CardioScreen 1000 - Haemodynamic Measurement System, Medis|Impedance cardiography (ICG)
1565763|NCT02485782|Device|BCM- Body Composition Monitor, Fresenius Medical Care|Information about the individual fluid status and the nutritional status.
1565764|NCT02485782|Device|SCHILLER, BR-102 plus, Ambulatory Blood Pressure Monitoring System|Blood pressure monitoring every 15 min during hemodialysis
1565765|NCT02485769|Drug|PF-06650833|Suspension
1565766|NCT02485769|Drug|Placebo|Suspension
1565767|NCT02485769|Drug|PF-06650833|Tablet (Modified Release)
1565768|NCT02485769|Drug|Placebo|Tablet (Modified Release)
1565769|NCT02485756|Other|Educational handout|Topics include: interactions between AED and certain hormonal contraceptives, Center for Disease Control and Prevention (CDC) recommendations for alternative contraceptive methods that are not known to interact with AEDs, contraceptive failure rates
1565770|NCT02485743|Other|Active Diet Products|A range of Active Diet Products that will be provided as part of a weight maintenance diet which contain active ingredients aimed at increasing satiety (such as inulin, β-glucan, protein, and mycoprotein). All ingredients are accepted food ingredients approved for human consumption in Europe.
1565771|NCT02485743|Other|Placebo Diet Products|A range of Placebo Diet Products matching those provided in the Active Diet which will be provided as part of a weight maintenance diet but do not contain additional ingredients aimed at improving satiety (food matrices will be the same - e.g. shakes, cheeses etc but without active ingredients).
1565772|NCT02485717|Drug|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
1565773|NCT02485717|Other|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
1565776|NCT02485691|Drug|cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: intravenous
1565777|NCT02485691|Drug|enzalutamide|Pharmaceutical form:capsule Route of administration: oral
1565778|NCT02485691|Drug|abiraterone acetate|Pharmaceutical form:tablet Route of administration: oral
1565779|NCT02485691|Drug|prednisone|Pharmaceutical form:tablet Route of administration: oral
1565780|NCT02485678|Other|Proactive Telephone Toxicity Management|Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
1565781|NCT02485678|Other|Control Arm|Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
1565782|NCT02485678|Other|PRO Sub-Study|A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
1565783|NCT02485665|Device|Extracorporeal biofeedback device (Any Kegel)|Prostate cancer patients of intervention group will received extracorporeal biofeedback device (Any Kegel) for pelvic floor muscle exercise (PFME) to improve the post-prostatectomy incontinence after robot-assisted laparoscopic radical prostatectomy. Enrolled patients in intervention group should be performed PFME regularly, based on following protocols: total exercise time (10 minutes/day), intensity (1.2 kgf), tension duration (10 sec/ 1 contraction), total exercise number (4 times/day)
1565784|NCT02485652|Drug|HM61713|800 mg QD continuously in 21-day cycles until disease progression determined by investigator assessment per RECIST version 1.1, and as long as, in the investigator‟s opinion, they are benefiting from study treatment and they do not meet any of treatment discontinuation criteria.
1565785|NCT02485639|Biological|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season. All participants will receive vaccine IM on day 1.
1565786|NCT02485626|Procedure|2D tissue doppler echocardiography|
1565787|NCT02485613|Drug|bortezominb and dexamethasone|The initial BD regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). The dose of bortezomib and dexamethasone can be adjusted according to the patients' condition.
1565788|NCT02485587|Behavioral|Individualized Arousal-Biofeedback|biofeedback of biological measures of arousal (electrodermal activity)
1565789|NCT02485587|Behavioral|Treatment as usual|counseling, psychoeducation
1565790|NCT02485574|Procedure|transforaminal lumbar interbody arthrodesis|Anterior bridging cages augmented with auto bone plus β-calcium phosphate + hydroxyapatite in left side of disc space and anterior bridging cages augmented with auto bone in rt side of disc space in transforaminal lumbar interbody arthrodesis.
1565791|NCT02485561|Behavioral|Health communication intervention|This study will compare the effects of adding personal experiences with colon cancer screening to educational information to explore potential differences in reactions to different role models on individuals' screening intentions and behaviors.
1565792|NCT02485561|Behavioral|Education information|CDC Screen for Life campaign materials are used to present educational information to participants about colon cancer and screening tests.
1565793|NCT02485548|Drug|Raltitrexed|Patients will receive IMRT and concurrent raltitrexed and cisplatin
1565794|NCT02485548|Drug|5-fluorouracil|Patients will receive IMRT and concurrent 5-Fu and cisplatin
1565795|NCT02485548|Drug|Cisplatin|All patients will receive concurrent cisplatin.
1565796|NCT02485548|Radiation|IMRT|All patients will receive IMRT
1565797|NCT02485535|Other|Laboratory Biomarker Analysis|Correlative studies
1565798|NCT02485535|Drug|Selinexor|Given PO
1565799|NCT02485509|Drug|VM-1500/Placebo|VM-1500 or Placebo
1565800|NCT02485496|Device|Endovascular abdominal repair|
1565801|NCT02485470|Other|MPACT|Maintaining Physical Activity during Cancer Treatment
1565802|NCT02485457|Procedure|Volume loading|Volume loading with Ringer Lactate
1565803|NCT02485457|Drug|Ringer solution|
1565804|NCT02485444|Drug|Oxytocin|20 IU oxytocin in 500 ml normal saline will be infused 100 ml/h i.v. after fetus is delivered
1565805|NCT02485431|Drug|Deflazacort|
1565806|NCT02485418|Drug|Propofol|Intravenous propofol infusion at 20 mcg/kg/min for 20 minutes, followed by an increase to 30 mcg/kg/min for 20 minutes and then by an increase to 40 mcg/kg/min for 20 minutes.
1565807|NCT02485405|Other|Trier social stress test|Volunteers perform Trier social stress test
1565808|NCT02485392|Device|Da Vinci Single Site Robot-Assisted Cholecystectomy|
1565809|NCT02485392|Device|Single Incision Laparoscopic Cholecystectomy|
1565810|NCT02485379|Procedure|Prostate biopsy|"Systematic biopsies (SB) and targeted biopsies (TB) are performed in the same patients by two independent operators. In patients without abnormalities on mp-MRI, no targeted biopsies will be carried out and the detection of clinically significant cancer will be considered as negative for the TB strategy."
1565811|NCT02485366|Drug|Rejuvesol|Blood transfused during surgery will be treated with Rejuvesol.
1565812|NCT02485366|Procedure|Cardiac surgery|The study interventions will take place during a routine admission for pediatric open heart surgery. The anesthetic technique for subjects undergoing cardiac surgery is standard care and the research study interventions will not change these practices in any way.
1565813|NCT02485353|Drug|Vosaroxin and Cytarabine|
1565814|NCT02485340|Drug|5-ISMN (isosorbide-5-mononitrate)|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
1565815|NCT02485340|Drug|Sumatriptan|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
1565816|NCT02485340|Drug|Placebo|5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
1565817|NCT02485327|Drug|Technosphere Insulin SAR439065 Afrezza®|"Pharmaceutical form: dry powder
Route of administration: oral inhalation"
1565818|NCT02485314|Other|Participation|The PEM-CY will be field-tested with a sample of 650 caregivers of children with and without disabilities residing in the Turkey.
1565821|NCT02485262|Drug|Sofosbuvir and simeprevir|Hepatitis C treatment using Direct Acting Agents
1565822|NCT02485249|Drug|Dexamethasone Phosphate Ophthalmic|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
1565823|NCT02485236|Device|Low flow oxygen via nasal cannula|In the low flow oxygen group, patients will be supplemented with 1 liter per minute via nasal cannula. Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to an arterial saturation of oxygen of > 88%. Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
1565824|NCT02485236|Device|Humidified Nasal High Flow Therapy|Adjustment of initial setting upon floor arrival: To adjust oxygen 1-4 liters per minute to arterial saturation of oxygen > 88%. To adjust air flow to patient comfort (20-35 liters per minute). Continuous oximetry will be collected up to 48 hours. Standard postsurgical care.
1565825|NCT02485210|Procedure|Endodontic treatment|It will be done the endodontic treatment using the photosynamic therapy for decontamination of the root chanel.
1565826|NCT02485197|Other|7 continuous days of aerobic training|For 7 consecutive days, subjects will perform up to 45 minutes of exercise consisting of treadmill walking at a progressive intensity of about 60-65% of their maximum heart rate. This heart rate range is estimated to be below 60% VO2 max.
1565827|NCT02485184|Procedure|Transjugular intrahepatic portosystemic shunt|Transjugular intrahepatic portosystemic shunt refers to an interventional radiological procedure by placing a stent between portal vein and hepatic vein. No specific device was used in the Interventional field.
1565828|NCT02485184|Drug|Non-selective beta blockers|Non-selective beta blockers are the drugs for reducing the portal pressure.
1565829|NCT02485184|Procedure|Endoscopic therapy|Endoscopic therapy includes the endoscopic variceal band ligation
1565830|NCT02485184|Drug|Anticoagulation|Anticoagulation therapy includes heparin and warfarin.
1565831|NCT02485171|Device|SAFEWALKER|Medical device walking aids.
1565832|NCT02485158|Drug|THC|This is a within-subjects, double-blind, placebo controlled design. We administered oral THC to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
1565833|NCT02485158|Drug|AMP|This is a within-subjects, double-blind, placebo controlled design. We administered AMP to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
1565834|NCT02485158|Drug|ALC|This is a within-subjects, double-blind, placebo controlled design. We administered alcohol to healthy volunteers to measure their subjective response, which we later compared to their responses to two other drugs.
1565835|NCT02485158|Drug|Placebo capsules|This is a within-subjects, double-blind, placebo controlled design. We administered size 00 gelatin capsules containing dextrose to healthy volunteers as a control for when they received either amphetamine or THC.
1565836|NCT02485158|Drug|Placebo beverage|This is a within-subjects, double-blind, placebo controlled design. We administered a drink containing cranberry juice plus 1% alcohol added as a taste mask.
1565837|NCT02485145|Drug|A/B|This arm uses the test product first, which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm. The B arm is the second arm, and consists of the VersaPro cream alone.
1565838|NCT02485145|Drug|Placebo|The placebo, which consists of the VersaPro cream, will be utilized in the study.
1565839|NCT02485145|Drug|B/A|This arm uses the placebo product first, which consists of the VersaPro cream alone. This is the B arm. The A arm is the second arm, which consists of the test product which consists of Diclofenac 3%, Baclofen 2%, Orphenadrine 5%, and Bupivacaine 2% in a VersaPro cream. This is the A arm.
1565840|NCT02485132|Other|Observational|Investigators propose to perform a one-week baseline testing (pre-initiation of the SU), at initiation (first week after the first dose of the SU) and after a 3 months follow-up of treatment with a SU, including CGMS reading, medical history measures, quality of life and diabetes treatment satisfaction.
1565841|NCT02485119|Drug|BAY94-9343|Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
1565842|NCT02485106|Drug|Rifaximin|400mg three times per day for 28 days
1565843|NCT02485106|Drug|Corticosteroid or pentoxifylline|Corticosteroid 40mg/day or pentoxifylline 400mg three times per day for 28 days
1565844|NCT02485093|Device|Septal ventricular pacing|Ventricular pacing must be at least 90%, from the septum and with optimized AV delay
1565845|NCT02485093|Device|VIP|Ventricular pacing must be less than 10%.
1565846|NCT02485080|Drug|Simeprevir|
1565847|NCT02485080|Drug|Sofosbuvir|
1565848|NCT02485067|Drug|THVD-201|Combination of Tolterodine 2mg and Pilocarpine 9mg
1565849|NCT02485067|Drug|Placebo(For THVD-201)|
1565850|NCT02485067|Drug|Detrusitol 2mg tablet|Tolterodine 2mg
1565851|NCT02485067|Drug|Placebo(For Detrusitol 2mg tablet)|
1565852|NCT02485054|Other|Clinical, ophthalmological and neurological evaluation|Clinical : questionnaire about the symptoms and about the vascular risk factors Cerebral MRI, MRI angiography of the supra-aortic trunks, ECG, Holter, transthoracic echocardiography, blood count, erythrocytes sedimentation rate, C reactive protein, visual field, optical coherence tomography, retinography
1565853|NCT02485041|Drug|Dapoxetine 30mg|Tablet, Orally administered
1565854|NCT02485041|Drug|Mirodenafil 100mg|Table, Orally administered
1565855|NCT02485028|Drug|Dapoxetine 30mg tablet|
1565856|NCT02485028|Drug|Mirodenafil 50mg tablet|
1565857|NCT02485015|Biological|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells are used to treat advanced gastric cancer patients with Apatinib.
1565858|NCT02485015|Drug|Apatinib|Advanced gastric cancer patients take Apatinib 850mg qd by mouth.
1565859|NCT02485002|Device|RIRS with ureteral access sheath|Ureteral access sheath will be used during RIRS.
1565860|NCT02485002|Device|RIRS without ureteral access sheath|Ureteral access sheath will not be used during RIRS.
1565861|NCT02484989|Other|Surviellance card|
1565862|NCT02484976|Behavioral|Family Based Behavioral Treatment|Obese children accompanied by at least one parent or caregiver will attend 24 weekly in-person sessions. Sessions will include 25-30 min. meetings between an interventionist and each child/parent pair to individualize treatment, followed by separate child and parent group meetings lasting 40 - 45 min. Parents will serve as primary agents of change for their child and for themselves. Training will focus on food and physical activity education, parenting around food and physical activity, and use of behavioral skills (e.g., self-monitoring, environmental control, contingency management). Intervention groups of 9-11 children/families will be initiated every 3-6 mos. in study yrs. 1-3.
1565863|NCT02484963|Drug|Zolpidem|
1565867|NCT02484937|Other|Group 2 (PCP Treatment)|For the PCP group treatment will be performed (pain treatment/medications) by the Primary Care Physician in his/her office/clinic.
1565868|NCT02484937|Other|Group 1 (PMS Treatment)|For the PMS group treatment will be performed (pain treatment/medications) by the Pain Medicine Specialist in his/her office/clinic.
1565869|NCT02484924|Drug|Ticagrelor|No intervention- purely observational
1565870|NCT02484911|Drug|Olanzapine|5mg,twice a day orally on day 1 to day 4
1565871|NCT02484911|Drug|Aprepitant|125 mg capsule per oral, 1 hour before chemotherapy on day 1, 80 mg capsule daily in the morning during days 2 to 3.
1565872|NCT02484911|Drug|Palonosetron|0.25mg IV 30-60min before chemotherapy on day 1
1565873|NCT02484911|Drug|Dexamethasone|6mg IV on day 1 ，3.75mg IV on day 2 to 4
1565874|NCT02484885|Other|Hyperpolarized Xenon MRI|Hyperpolarized noble gas imaging using Xenon-129 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, 129Xe gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
1565878|NCT02484846|Behavioral|Time in bed|Habitual time spent in bed for the purpose of sleep was determined at baseline. This was used to calculated the experimental time in bed the subject was to spent on the one night prior to the second lab visit.
1565879|NCT02484833|Drug|Cetuximab|
1565880|NCT02484833|Drug|FOLFIRI|
1565881|NCT02484820|Device|Silicone pessary|Silicone pessary is used between 24 weeks of pregnancy and up to 6 weeks after the date of the term (maximum 6 months)
1565883|NCT02484794|Behavioral|Standard Outpatient Treatment|Standard treatment offered by the Nova Scotia Health Authority Eating Disorder Outpatient Program varies in intensity but involves therapy groups (e.g., goal setting and skill building groups), individual contact, and meal experiences. Minimal participation in the program consists of a weekly nutritional counselling group (Nutri-Logical) and one supervised meal a week. In the nutritional counselling group, patients keep a food journal (self-monitor), set eating goals, receive feedback from a psychologist and dietitian, and share experiences with the group.
1565884|NCT02484794|Behavioral|Smartphone App|The smartphone app is a mobile eating disorder self-monitoring tool that incorporates discrete reminders, positive feedback, social support, summative feedback, coping skill suggestions, and linking patients with their treating clinicians (psychologist and dietician). The app is CBT-based and was designed as an alternative to paper food records for use in clinical treatment.
1565885|NCT02484781|Other|Gait analysis on a trendmill|"Gait analysis on a trendmill GRAIL to analyse spatio-temporal kinetics and kinematics when flat walking and inclining"
1565886|NCT02484768|Drug|Iron isomaltoside 1000|Intravenous treatment
1565887|NCT02484768|Drug|Sodium Chloride 0.9%|Intravenous treatment
1565888|NCT02484755|Drug|Gefitinib|See Arm Description
1565889|NCT02484742|Behavioral|Insomnia symptom induction|Several nights during the 18-day stay will be disrupted, such that we delay sleep onset, advance sleep off set, and the sleep period will be disrupted by frequent nighttime awakenings.
1565890|NCT02484729|Drug|AZD9977, oral suspension|Single ascending doses of AZD9977 oral suspension (Part A) Single dose of AZD9977 oral suspension in IntelliCap® capsule in regional absorption part (Part B)
1565891|NCT02484729|Drug|Placebo, oral suspension|Matching placebo
1565892|NCT02484729|Drug|AZD9977, oral solution|AZD9977, single dose of oral solution in Part B as reference
1565893|NCT02484716|Drug|Timolol nasal spray|Timolol 0.5% is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
1565894|NCT02484716|Drug|Placebo nasal spray|Placebo (NaCl) is administered by the patient with a posology of one spray (50 µL) in each nostril twice a day for 4 weeks.
1565895|NCT02484703|Drug|Placebo|Participants will receive matching placebo PO BID. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
1565896|NCT02484703|Drug|RO5186582|Participants will receive 1 of 3 dosages of RO5186582 PO BID, including 40 mg, 60 mg, or 120 mg. Study medication will first be administered on Day 1, and only the morning dose will be given on the last day of treatment (Week 26).
1565897|NCT02484690|Drug|RO6867461|RO6867461 will be administered as per the regimen specified in individual arm.
1565898|NCT02484690|Drug|Ranibizumab|Ranibizumab will be administered as per the regimen specified in individual arm.
1565899|NCT02484677|Drug|Cisplatin|Antineoplastic cytostatic. Blood sampling for pharmacokinetic evaluation
1565900|NCT02484677|Drug|Docetaxel|Taxanes. Blood sampling for pharmacokinetic evaluation
1565901|NCT02484677|Drug|5-Fluorouracile|Antineoplastic and immunomodulating agents. Blood sampling for pharmacokinetic evaluation
1566105|NCT02483234|Drug|secukinumab|
1566443|NCT02480842|Other|Oncoplastic free ROM|
1565902|NCT02484664|Drug|Celecoxib|We will perform a pilot clinical trial to investigate the safety and tolerability of celecoxib therapy as a single agent for patients with LAM. LAM subjects who are not taking everolimus or rapamycin will be treated with celecoxib at 200mg PO QD for 6 months. They will be monitored for respiratory function and angiomyolipoma size. At the end of the 6 month period, celecoxib will be discontinued, and subjects will be monitored for another 6 months.
1565903|NCT02484651|Drug|Sugammadex|Reversal of deep neuromuscular block
1565904|NCT02484651|Drug|Rocuronium|Maintenance of deep neuromuscular block
1565907|NCT02484625|Other|Dietary treatment|Commercially available food products
1565908|NCT02484612|Behavioral|acute exercise|
1565909|NCT02484599|Behavioral|Computerized attention training (CAT)|Three sessions of active computerized attention training.
1565910|NCT02484599|Behavioral|Sham computerized attention training (control condition)|Three sessions of sham computerized attention training.
1565911|NCT02484586|Device|Etafilcon A|Prototype lens material
1565912|NCT02484586|Device|Etafilcon A|Control lens for presbyope group
1565913|NCT02484586|Device|Nelfilcon A|Control lens for presbyope group
1565914|NCT02484586|Device|Nesofilcon A|Control lens for presbyope group
1565915|NCT02484586|Device|Nelfilcon A|Control lens for non-presbyope group
1565916|NCT02484586|Device|Etafilcon A|Control lens for non-presbyope group
1565917|NCT02484586|Device|Somofilcon A|Control lens for presbyope group
1565918|NCT02484586|Device|58% Poly-HEMA|Control lens for presbyope group
1565919|NCT02484586|Device|Omafilcon A|Control lens for non-presbyope group
1565920|NCT02484573|Drug|Propanolol|
1565921|NCT02484560|Drug|Biological: Umbilical Cord Based Allogenic Mesenchymal Stem Cell|
1565922|NCT02484547|Drug|Aducanumab (BIIB037)|Low dose
1565923|NCT02484547|Drug|Aducanumab (BIIB037)|High dose
1565924|NCT02484547|Drug|Placebo|Placebo
1565925|NCT02484521|Device|PPI monitoring device protocol|The investigators would use a monitoring device that would assess startle reflex reaction measured by blinking or the eye. Monitoring would be done with electrodes of EMG device that would be located on orbicularis oculi muscle and will monitor response.
1565926|NCT02484521|Other|Questionnaires|"Group of patients diagnosed with schizophrenia would be interviewed using well validated questionnaires.
Questionnaires what would be used are:
GAF- Global assessment of functioning
PANSS- Positive and negative syndrome scale
SANS- Scale for the Assessment of Negative Symptoms
The Calgary Depression Scale for schizophrenia
Demographic Questionnaire
Hamilton Anxiety scale"
1565927|NCT02484508|Drug|Guli capsule|Guli capsule,as the experimental drug,is taken 3 grains each time, 3 time per day
1565928|NCT02484508|Drug|Kangguzengsheng capsule|Kangguzengsheng capsule, as the active comparator, is taken 3 grains each time, 3 time per day
1565929|NCT02484495|Other|Program evaluation (impact assessment)|"The program activities include: processed complementary food rations which will be distributed to all children 6-23 months of age, in a grain bank based on bartering of raw materials; enhanced Infant and Young Child Nutrition (IYCN) counselling will be given to the mothers of children 6-23 month of age, using improved Behavior messages based Change Intervention (BCI) on formative research.
Monthly 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day."
1565930|NCT02484482|Drug|CKD-519 200mg / Fasting, Standard Meal, High Fat Meal|
1565931|NCT02484469|Device|The Virtual Human Project|Virtual Human educational videos about leprosy
1565945|NCT02484391|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
1565946|NCT02484391|Drug|Cytarabine|Given IV
1565947|NCT02484391|Procedure|Hematopoietic Cell Transplantation|Undergo stem cell transplant
1565948|NCT02484391|Drug|Mitoxantrone Hydrochloride|Given IV
1565949|NCT02484378|Drug|CER-001|Engineered pre-beta HDL particle
1565950|NCT02484378|Drug|Placebo|Normal saline
1565951|NCT02484365|Other|No treatment|Attach adhesive probe on thumb or index finger
1565952|NCT02484352|Drug|saline|different dosage of IV oxycodone was given before intubation
1565953|NCT02484352|Drug|0.05 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
1565954|NCT02484352|Drug|0.1 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
1565955|NCT02484352|Drug|0.15 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
1565956|NCT02484352|Drug|0.2 mg/kg of oxycodone|different dosage of IV oxycodone was given before intubation
1566444|NCT02480842|Other|Oncoplastic limited ROM|
1565957|NCT02484339|Drug|Radium-223 dichloride|Arm A: EBRT and timely sequential start with Radium-223 dichloride 55 kBq/kgbw (6 i.v. injections every 4 weeks) and best supportive care until progression or intolerable toxicity.
1565958|NCT02484339|Other|Conventional or high dose radiotherapy|Arm B: External beam radiotherapy (EBRT)->->conventional or high dose radiotherapy
1565959|NCT02484326|Other|Grouping by different risk stratification|A simple risk score system based on 7 baseline clinical variables divided patients into four groups
1565960|NCT02484313|Other|dietary treatments|commercially available food products
1565961|NCT02484300|Dietary Supplement|Melatonin|
1565962|NCT02484300|Other|Placebo|
1565963|NCT02484287|Device|The Integra External Drainage Catheter.|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
1565964|NCT02484287|Device|The Ventriclear EVD Antibiotic Catheter|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
1565965|NCT02484287|Device|The Codman Bactiseal EVD Catheter Set|Participants will be randomly assigned to receive 1 of 3 drains, to determine the efficacy of antibiotic-impregnated vs non antibiotic-impregnated EVD catheters, in the reduction of infection rates associated with EVD use.
1565966|NCT02484274|Biological|Blood samples|1 blood sample of 9 ml. 3-day food diary , according to the European Food Safety Authority methodology
1565967|NCT02484261|Drug|Bortezomib|1.3 mg/m2/dose subcutaneously (SQ) daily (total 4 doses) on Days 1, 4, 8 and 11 (+/- 1 day with at least 72 hours between doses) q3 weeks. (For patients continuing to receive drug in cycles 6 or greater, at investigator discretion, the schedule may be changed to 1.3 mg/m2/dose SQ daily (total 3 doses) on Days 1, 8, and 15 (+/- 1 day with at least 72 hours between doses) every 4 weeks in an effort to decrease risk of peripheral neuropathy.)
1565968|NCT02484261|Drug|Pravastatin|10 mg for age < 8 years, 20 mg for age 8-<13 years, 40 mg for ages >14 years
1565969|NCT02484248|Drug|Ketotifen|Ketotifen is a anti-histamine approved by the U.S. FDA to prevent and treat itching of the eyes caused by allergies.
1565970|NCT02484248|Drug|Placebo|
1565971|NCT02484235|Other|HIIT|Group training with HIIT 3 times per week during 10 sessions
1565972|NCT02484235|Other|Strength|Group training with strength exercises 3 times per week during 10 sessions
1565973|NCT02484222|Drug|Fentanyl|Before the end of the procedure, spontaneous respiratory was recovered. All the patients were given 1 mcg/kg fentanyl i.v. after the end of the procedure.
1565974|NCT02484209|Drug|Metformin|Metformin 1500 mg daily for 16 weeks
1565975|NCT02484209|Drug|Glimepiride|glimepiride 2-4 mg twice daily for 16 weeks
1565976|NCT02484209|Drug|Metformin|metformin 1500 mg daily for 16 weeks
1565977|NCT02484196|Behavioral|Questionnaires|
1565978|NCT02484183|Device|bubble continuous positive airway pressure (CPAP)|This study will use an Airsep® oxygen concentrator and a Fisher & Paykel Bubble CPAP (bCPAP) system to deliver bCPAP. The Airsep® machine is connected to the Fischer & Paykel Bubble CPAP system and the CPAP delivers pressure and oxygen to the patient with appropriately sized masks and tubing. The Fischer & Paykel Bubble CPAP system can deliver up to 10 centimeters (cm) water (H20) pressure. Since an oxygen concentrator is being used as the flow driver of this bubble CPAP system patients receiving CPAP will therefore also be receiving 6-8 liters per minute (LPM) of concentrated oxygen flow. Per manufacturer specifications the Airsep oxygen concentrator delivers 90-97% fractional inspired oxygen concentration at the 6-8 LPM flows required to generate 4-10 cm H20 pressure.
1565979|NCT02484170|Drug|Mannitol cream|Apply to area of postherpetic neuralgia pain as needed for pain control. Usual frequency is 2 to 3 times per day.For crossover study, will be applied for 7 days. For observational study, will be applied up to 3 months
1565980|NCT02484170|Drug|Placebo|Apply to area of postherpetic neuralgia pain as needed for pain control.Usual frequency is unknown. For crossover study, will be applied for 7 days. Will not be used after crossover study
1565981|NCT02484157|Device|Hemochron|Activated coagulation time was checked serially by Hemochron Jr.
1565982|NCT02484157|Device|ACT Plus|Activated coagulation time was checked serially by ACT Plus.
1565983|NCT02484144|Other|modern information|information by video for coronarography
1565984|NCT02484144|Other|usual information|usual information for coronarography
1565985|NCT02484131|Behavioral|Educational materials/mail|Participants in this group will receive any educational materials by mail during hte follow-up period.
1565986|NCT02484131|Behavioral|Educational materials/participant choice|Participants in this group will not receive any educational materials by participant choice during hte follow-up period.
1565987|NCT02484118|Procedure|Hemodialysis blood flow|The impact of blood flow rates of 320 ml/m and 380 ml/m will be compared to determine any impact on hemodialysis urea clearance
1565988|NCT02484105|Behavioral|Comforting Conversation|Pain management, distraction, diversion, empathy. Dependent on qualitative study results.
1565989|NCT02484105|Behavioral|Standard Communication|Information on procedure type, duration, findings, key landmarks, possibility of analgesic treatment, pause in procedure.
1565990|NCT02484092|Genetic|SPK-9001|A novel, bioengineered adeno-associated viral vector carrying human factor IX variant
1565991|NCT02484079|Procedure|Polypectomy|
1565992|NCT02484066|Device|VBN (DirectPath; Olympus)|VBN is carried out by a VBN software（DirectPath; Olympus, Japan) which can automatically create virtual bronchoscopic images.
1565993|NCT02484066|Device|EBUS-GS (Olympus)|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
1565994|NCT02484066|Device|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
1565995|NCT02484053|Drug|Rituximab|Giving rituximab as a rapid infusion over a period of 90 or 120 minutes.
1565996|NCT02484040|Radiation|Two-week course of radiation|33 Gy in 10 fractions for 2 weeks
1565997|NCT02484040|Drug|Two-week course of radiation|oral capecitabine, 825mg/m2, bid
1566189|NCT02482714|Behavioral|Physical activity.|Have subject do moderate physical activity.
1565998|NCT02484027|Drug|Rosuvastatin|Patients will be randomly assigned to receive 2 different therapies for the first 3 days of hospitalization: no statins (non-statin-therapy group) or to immediately receive rosuvastatin orally at a dose of 20mg daily (statin-therapy group). From the fourth day onward, rosuvastatin 10 mg daily will be administered in all patients for 1 year
1565999|NCT02484014|Other|Tarang Adolescence Education programme|The comparison arm involves 'usual care' which in the study setting is the Tarang: Adolescence Education Programme comprising of 16 classroom sessions on process of growing-up, prevention of HIV/AIDS and other Sexually Transmitted Diseases (STDs), and prevention of substance and other drug abuse. This programme is delivered by a trained nodal teacher in the school over the academic year.
1566000|NCT02484014|Other|SEHER Intervention|"The SEHER intervention will be delivered by a trained teacher, called as Teacher-as-SEHER Mitra (Mitra meaning friend) or lay health worker called as SEHER Mitra being trained to facilitate following activities:
Awareness generation activities for all stakeholders in school
Wall-magazine
Speak-out box
Competitions
School Health Promotion Committee
School health policies
Peer groups of students of standard IX
Workshops and talks for all the students from standard IX, and for teachers
Counselling and referral services for all the students in the school This intervention will be delivered in each school over the academic year."
1566001|NCT02484001|Drug|ESL 800 mg|one (1) tablet of 800 mg (QD).
1566002|NCT02484001|Drug|ESL 1200 mg|one (1) and a half tablets of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
1566003|NCT02484001|Drug|ESL 1600 mg|two (2) tablets of 800 mg (QD).
1566004|NCT02484001|Drug|ESL 400 mg|half tablet of 800 mg (QD). ESL tablets are scored and can be divided in two equal halves (each one containing 400 mg ESL)
1566005|NCT02483975|Drug|FF|FF will be provided as a dry powder inhaler with 30 doses per device, each containing 50 mcg of FF as a dry white powder per blister, to be inhaled orally via ELLIPTA.
1566006|NCT02483975|Drug|Placebo|Placebo will be provided as dry powder inhaler with 30 doses per device, each containing placebo as a dry white powder per blister, to be inhaled orally via ELLIPTA.
1566007|NCT02483975|Drug|Montelukast|Montelukast will be provided as 4 mg and 5 mg chewable tablets.
1566008|NCT02483975|Drug|Albuterol/Salbutamol|Albuterol/Salbutamol will be provided as inhalation aerosol.
1566009|NCT02483962|Other|Gelatine capsule|Gelatine capsules containing no active ingredients.
1566010|NCT02483962|Other|Venavine Intensive®|Gelatine capsules containing 360 mg red vine leaf extract, 60 mg of horse chestnut extract, 35 mg of butchers broom extract and 3,2 mg of vitamin B6.
1566011|NCT02483949|Behavioral|Healthy Eating and Active Living for Diabetes - Gestational Diabetes Mellitus|
1566012|NCT02483936|Drug|Olmesartan medoxomil 40mg + chlorthalidone 12,5mg|1 tablet a day
1566013|NCT02483936|Drug|Olmesartan medoxomil 40mg + chlorthalidone 25mg|1 tablet a day
1566014|NCT02483936|Drug|Olmesartan 40mg + Hydrochlorothiazide 12,5mg|1 tablet a day
1566015|NCT02483936|Drug|Olmesartan 40mg + Hydrochlorothiazide 25mg|1 tablet a day
1566016|NCT02483923|Drug|Ultrasound guided serratus anterior block with ropivacaine|After induction of anesthesia, patients take ultrasound guided serratus anterior plane block with 0.5ml/kg of ropivacaine 0.375%. 30minutes before the end of operation, intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient.
1566017|NCT02483923|Drug|intravenous PCA only|same dose of intravenous patient controlled analgesia (Basal rate 0ml/hr, 0.5mcg/kg of fentanyl, lock-out time 10minutes) is connected to patient only.
1566018|NCT02483910|Behavioral|Direct Instruction-Language for Learning (DI-LL)|"DI-LL is composed of up to 150 lessons (15 sets of 10 lessons each - e.g., lessons 1-10, 11-20, 21-30, etc.) that build on one another. The program uses demonstrations and pictures to expand vocabulary and teach language skills to children in manageable steps. The curriculum focuses on teaching spoken language across six areas: actions, description of objects, general information, standardized prompts (show me or point to or say the whole thing), classification, and problem-solving strategies. For example, DI-LL moves from the identification of familiar objects to the description and classification of these objects. Children learn the precise meaning of both familiar and new concepts and use these concepts in statements and questions. The DI-LL also incorporates 15 assessment tests (one for each set of 10 lessons). These assessment tests are given after each set of 10 lessons to confirm mastery of the material and the child's readiness to move on to the next set of 10 lessons."
1566019|NCT02483910|Behavioral|Treatment as Usual|Usual care including speech therapy in school, community or both
1566020|NCT02483897|Drug|Tetracaine 0.5% ophthalmic drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
1566021|NCT02483897|Drug|Normal Saline placebo drops|0.8 mls. drops provided to be used hourly p.r.n. for pain control
1566022|NCT02483884|Drug|[68Ga]RM2|[68Ga]RM2 is a novel 68Ga labeled, radiopharmaceutical agent for PET imaging. It is administered intravenously as a single dose of 140 MBq (corresponding to ≤ 40 μg mass dose)
1566023|NCT02483884|Procedure|PET/CT|Patients received [68Ga]RM2 undergo PET/CT 60 min p.i. for at least 20 min
1566024|NCT02483871|Drug|Rosuvastatin|
1566025|NCT02483858|Drug|PQR 309|Intervention of this drug may include safety, tolerability, PK (pharmacokinetics) and efficacy
1566026|NCT02483845|Drug|Natalizumab|
1566027|NCT02483832|Behavioral|Educational materials|Educational materials about colorectal cancer and how to get screened will be presented to participants, with either gain- or loss-frame messages associated.
1566028|NCT02483806|Procedure|PEEP|After induction of anesthesia, including insertion of TEE probe, change position from supine to lateral position. Measure ABGA and cardiac indices for the baseline value. Apply each PEEP (0, 5, 10 cmH2O) serially at the random order. 6 sequences (0->5->10, 0->10->5, 5->10->0, 5->0->10, 10->5->0, 10->0->5) are equally applied to 6 patients (total 6x6=36 patients) who agreed to this study. Measure ABGA and cardiac indices after 20 min at each step of peep apply(3 times).
1566029|NCT02483793|Drug|Tamsulosin|
1566030|NCT02483793|Drug|Oxybutynin|
1566031|NCT02483780|Behavioral|Storytelling|The intervention will center on stories about living with hypertension, with patients speaking in their own words.
1566190|NCT02482701|Device|Captivator™ EMR|The Captivator ™ EMR Device is indicated for endoscopic mucosal resection (EMR) in the upper gastrointestinal (GI) tract.
1566034|NCT02483741|Biological|Manuka Honey|This material is going to be placed into the sockets of the extracted third molars in the experimental group
1566035|NCT02483728|Other|Patch Test|Patch testing is a technique used to diagnose an allergic skin disease called allergic contact dermatitis. It attempts to reproduce in small scale allergic reactions of the skin from things that come in contact with it.This is the standard of care to determine allergic contact dermatitis.
1566036|NCT02483715|Drug|High-dose dual therapy (rabeprazole, amoxicillin)|High-dose dual therapy ( rabeprazole 20 mg qid + amoxicillin 750 mg qid for 14 days)
1566037|NCT02483715|Drug|Bismuth-containing quadruple therapy (rabeprazole, tripotassium dicitrate bismuthate, metronidazole, tetracycline)|Bismuth-containing quadruple therapy (rabeprazole 20 mg bid + tripotassium dicitrate bismuthate 300 mg qid + metronidazole 250 mg qid + tetracycline 500 mg qid for 10 days)
1566038|NCT02483702|Other|Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
1566039|NCT02483702|Other|Non-Irradiated Blood Transfusions|Same as arm description - need to collect extracellular potassium values.
1566040|NCT02483689|Drug|Pre Incisional Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
1566041|NCT02483689|Other|Pre-Incisional Saline|Patient will be given a max of 30 cc injected through a 22g needle to area of incision.
1566042|NCT02483689|Drug|Post-Closure Local Anesthetic|Patient will be given a total of 0.5 mL/kg of 0.25% Bupivicaine either pre-incision: local will be to be given intradermally and onto the peritoneum under direct vision; or post-closure local will be injected intradermally after closure
1566043|NCT02483689|Other|Post-Closure Saline|Patient will be given a max of 30 cc injected through a 22g needle after closing sutures were made.
1566044|NCT02483676|Device|Treadmill plus anklebot|This intervention employs the use of the adaptive anklebot control system to complement treadmill exercise training over a 6-week intervention period.
1566045|NCT02483676|Behavioral|Treadmill only|This intervention employs the use of a treadmill for gait exercise training over a 6-week intervention period
1566054|NCT02483624|Drug|BR-DIM|DIM, a condensation product of indole-3-carbinol (IC3), is a phytochemical that has activity against certain tumor cells. Observations in lupus-prone mice treated with indole-3-carbinol suggest that DIM might have favorable biologic and clinical effects in human SLE.
1566055|NCT02483624|Drug|Placebo|Placebo
1566056|NCT02483611|Drug|Magnesium Sulfate|
1566057|NCT02483611|Drug|Lidocaine|
1566058|NCT02483611|Drug|Isotonic Solution|
1566059|NCT02483611|Drug|Cisatracurium|
1566060|NCT02483598|Drug|Buspirone|The primary aim of this study is to compare the relative difference between the area-under-the-curve (AUC) of buspirone alone (buspirone) with the AUC of buspirone in the presence of grapefruit juice (buspirone + GFJ) in patients who underwent RYGB 9-18 months prior versus a control group of participants who have not undergone bariatric surgery.
1566061|NCT02483598|Drug|Buspirone and Grapefruit Juice|Grapefruit juice will be given before and during buspirone administration to inhibit intestinal CYP3A4.
1566062|NCT02483585|Drug|AMG 334|AMG 334 Investigational Product
1566063|NCT02483585|Drug|Placebo|Placebo comparator
1566064|NCT02483572|Behavioral|Functional Communication Training|Functional communication training (FCT) is the most widely used treatment for severe destructive behavior that is maintained by social reinforcement, such as access to attention, tangible items, or escape from nonpreferred activities. Once clinicians determine the functional reinforcer for destructive behavior, the clinician can then teach the child an appropriate, functionally-equivalent response (e.g., exchanging a card to access parental attention) and the clinician would no longer provide the functional reinforcer for destructive behavior.
1566065|NCT02483559|Other|Amber Lenses|Glasses fitted with amber lenses that block the blue spectrum of light (~470 nm) to be worn prior to desired sleep onset time.
1566066|NCT02483559|Other|Placebo Lenses|Glasses fitted with placebo lenses that allow all visible spectrum of light to be worn prior to desired sleep onset time.
1566067|NCT02483546|Device|Laerdal®|simulation- based educational intervention
1566068|NCT02483546|Behavioral|huma patient based training|Students randomized to receive simulation training .The mannequin Siman 3G laerdal® displays multiple physiologic and pharmacologic responses. Three volunteers were involved in the scenario while the others were observers through an audiovisual projection. Students participating in the scenario were given 15 minutes to evaluate and manage a 60-year-old man with a known history of coronary artery disease and diabetes who presented to the emergency department with chest pain revealing an acute ST elevation myocardial infarction complicated by ventricular fibrillation. Students were required to recognize and manage ventricular fibrillation when the patient became pulseless and unresponsive. After performing the simulation, the entire group was convened for debriefing of the case.
1566445|NCT02480829|Device|Amphora OAB Device 3.0 mm|Treatment with the Amphora OAB Device
1566069|NCT02483546|Behavioral|traditionally teaching|Control group students received a traditional course using slides during 60 minutes about the management of cardio pulmonary resuscitation according to the latest recommendations of the AHA. This course is offered by the same trainer who participated in the simulation session. Students were free to ask questions as the progress of education. The same educational objectives were treated with the two groups.
1566070|NCT02483533|Drug|Salmeterol|
1566071|NCT02483520|Behavioral|FamTechCare|Caregiver submitted videos of challenging care situations are uploaded to a HIPAA secure site and reviewed by dementia care experts who provide feedback for improving care.
1566072|NCT02483507|Other|Ultrasound-guided approach to peripheral vascular access|the transversal approach is in short axis with an out of plane puncture, the longitudinal approach is in transversal axis with an in plane puncture, the oblique view approach is in obliques axis with an in plane puncture
1566073|NCT02483494|Other|APN-led Telemedicine|"Allocation to experimental or Usual care is 1:1.
The four study APNs will be delivering the care and have at least three years working experiences in coronary care settings. A telephonic script and study protocol is made available to ensure standardization of intervention."
1566074|NCT02483481|Procedure|shear wave ultrasound elastography|
1566075|NCT02483468|Behavioral|Cognitive Behavioral Therapy for Pain|Cognitive-behavioral therapy (CBT) for pain management takes an active problem-solving approach to tackling the many challenges associated with the experience of chronic pain. Rather than seeing ones self as helpless and disabled because of pain, CBT encourages individuals to take back control and re-engage in activities.
1566076|NCT02483468|Device|Transcranial Direct Current Stimulation|Electrical stimulation of the prefrontal cortex using 2mA of direct current
1566077|NCT02483468|Device|Sham Transcranial Direct Current Stimulation|Sham stimulation of the left dorsolateral prefrontal cortex
1566080|NCT02483429|Device|VRT Care|The VOG report includes direct device output (physiologic traces, quantitative measures) plus most likely diagnosis, category, and clinical trial care pathway (peripheral, equivocal, central) instructions. The VOG report becomes part of the patient's emergency department clinical record.
1566081|NCT02483403|Other|Hyperpolarized Helium-3|Hyperpolarized noble gas imaging using Helium-3 has been used to explore structural and functional relationships in the lung in patients with lung disease and healthy controls. In contrast to proton-based MRI imaging, Helium-3 gas is used as a contrast agent to directly visualize the airways, and thus ventilation. Whereas the normal density of gas is too low to produce an easily detectable signal, this is overcome by artificially increasing the amount of polarization per unit volume using optical pumping.
1566082|NCT02483403|Device|MRI|
1566083|NCT02483390|Other|psychosocial intervention|e-health services (e.g. by use of SKYPE) to the psychosocial needs of patients and their families who are getting services through home hospice care. In addition, the attitudes of the hospice staff will be investigated to the use of e-health methods.
1566084|NCT02483377|Other|Quality-of-Life Assessment|Ancillary studies
1566085|NCT02483377|Other|Questionnaire Administration|Complete questionnaires
1566086|NCT02483364|Other|HC-SVT-1001|A single application in the context of a single surgical intervention.
1566089|NCT02483338|Behavioral|Assessment of pain|Assessment of pain using FASS but without using this score to manage pain
1566091|NCT02483312|Biological|IL-12|
1566092|NCT02483299|Drug|Metformin|
1566093|NCT02483299|Drug|Glucophage tablets and Victoza|
1566094|NCT02483286|Behavioral|ICG|"Core 2-hour education course including practice of study home exercise program. Weekly professional led exercise program for 90 mins at NTUHBB site with reinforcement on osteoporosis related educations and care managements from study educational booklet and CD-rom for 3-month.
The exercise program included 15 minutes warm up with 10 minute brisk walks followed by gentle stretching. Resistance training (20-30 minutes) was provided with rubber band and bottled water (0.6-1L) as weight for major muscles of upper and lower limbs. Balance training were also provided for 10 minutes with tandem gaits and one leg standing, step up and down stairs, toe walking and heel walking.
Subjects are encouraged to practice study home exercise program at least twice weekly."
1566095|NCT02483286|Behavioral|MTG|MTG group subjects were invited to NTUHBB site to receive 2 sessions of 45-minute training using isotonic strength training machines on major muscle groups each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments by trained physical therapist
1566096|NCT02483286|Behavioral|XBG|XBG group subjects were invited to LCGMH site to receive 2 sessions of 45-minute training using x-box machine with combination programs selected from existing commercial programs with a exercise training specialist.
1566106|NCT02483221|Drug|Hydromorphone|Hydromorphone is given intravenously by TCI-PCA. The TCI-PCA system steer the hydromorphone infusion pump to achieve plasma and effect-site concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma and effect-site concentration range, lockout times and infusion speed.
1566107|NCT02483221|Drug|Morphine|Morphine is given intravenously by PCA. The PCA pump administers a predefined bolus dose on patient request considering the predefined lockout time and infusion speed.
1566108|NCT02483208|Drug|BAY81-8973|BAY81-8973 infusion to analyze pharmacokinetics
1566109|NCT02483208|Drug|Advate|Advate infusion to analyze pharmacokinetics.
1566110|NCT02483195|Drug|5% Minoxidil|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
1566111|NCT02483195|Drug|200mg Spironolactone|This will be a mixed combination of 5% Minoxidil and 200mg Spironolactone to be used once daily.
1566112|NCT02483195|Drug|5mg Finasteride|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
1566113|NCT02483195|Other|Placebo|This will be a mixed combination of 5mg Finasteride with placebo topical preparation to be used once daily.
1566114|NCT02483182|Drug|ZEP-3 ointment 1.0%|
1566115|NCT02483182|Drug|Acyclovir cream 5%|
1566116|NCT02483169|Drug|cilostazol|Cilostazol 100mg bid
1566117|NCT02483169|Drug|Probucol|Probucol 250mg bid
1566118|NCT02483169|Drug|Aspirin|Aspirin 100mg qd
1566119|NCT02483169|Drug|placebo of cilostazol|same shape and size of active cilostazol
1566120|NCT02483169|Drug|Placebo of aspirin|same size and shape of active aspirin 100mg
1566121|NCT02483169|Device|Intima-medial thickness|ultrasound measured IMT of both common carotid arteries
1566125|NCT02483143|Drug|NAC|3 gr NAC was made up to 1000 ml with NS; a 1 ml/3 mgr NAC solution was obtained and 3 ml/kg NAC+NS solution was administered for 1 h before CTPA and a 1 ml/kg per hour NAC+NS solution was administered for a minimum 6 h after CTPA.
1566126|NCT02483143|Drug|NaHCO3|132 mEq NaHCO3 was made up to 1000 ml with NS; and 3 ml/kg NaHCO3+NS solution was administered for 1 h before CTPA and 1 ml/kg per hour NaHCO3+NS solution was administered for a minimum of 6 h after CTPA.
1566127|NCT02483143|Drug|Normal Saline|3 ml/kg NS was administered for 1 h before CTPA and 1 ml/kg per hour was administered for a minimum of 6 h after CTPA.
1566128|NCT02483130|Dietary Supplement|N-Acetylcysteine|Participants will receive 2400mg of N-Acetylcysteine orally via 6 x 400mg capsules.
1566129|NCT02483130|Other|Placebo|Participants will receive 2400mg of placebo orally via 6 x 400mg capsules.
1566130|NCT02483117|Other|Adaptation of the CIA|Adaptation of the CIA into Spanish was performed using the backward-forward translation process, which ensures conceptual. Forward translation into Spanish was carried out by two independent native Spanish speaking translators who were fluent in English. Two other independent translators, totally blind to the original version, whose native language was English and who were fluent in Spanish, back-translated the consensus version into English. After reaching consensus on a final translated version, it was sent to the CIA's original author (Dr. Bohn) who gave her approval. We undertook a cognitive debriefing process with a group of 5 ED patients to identify any problems with language. The pre-final version was administered to two small groups, one made up of patients (a sample of 5 respondents) and the other of clinical experts (2 psychiatrists and 2 psychologists who were experts on ED).
1566131|NCT02483104|Drug|veliparib|Veliparib will be given orally, twice daily on Days 1-21, every 21 days.
1566132|NCT02483104|Drug|carboplatin|Carboplatin will be administered on Day 1 of each cycle, intravenously.
1566133|NCT02483104|Drug|paclitaxel|Paclitaxel will be administered on Days 1, 8, 15 of each cycle, intravenously.
1566134|NCT02483091|Behavioral|Multifaceted KT intervention|"The intervention consists of three webinars followed by the quiz, two online case scenario and a video on BAP model plus a printed copy of Clinical Practice Guideline (CPGs) on NSNP.
After completing these modules and learning the key strategies, each chiropractor will recruit five neck pain patients and implement the strategies on their patients to measure the clinical outcomes for a follow-up of three months.
The control group will receive only a printed copy of CPGs. A checklist of proxy measures embedded within patient encounter forms will be used to assess chiropractors' compliance with guideline recommendations at study onset and at three months."
1566135|NCT02483078|Drug|PRO 140|PRO 140 is a humanized IgG4,κ monoclonal antibody (mAb) to the chemokine receptor CCR5.
1566136|NCT02483078|Drug|Placebo|
1566137|NCT02483078|Drug|Optimized Background Regimen|Optimized background therapy (OBT) is chosen on the basis of a subject's resistance test results and treatment history.
1566138|NCT02483065|Other|mortality at discharge and 3-months after the admission in patients with and without dementia|Patients diagnosed of dementia who ingresed the hospital were informed of the goals of the study and invited to voluntarily participate. In order to take part in the study, patients were required to provide informed consent. All participants were first screened with the Alzheimer's Disease Test. A diagnosis of dementia was generated by an independent clinician experienced in old age psychiatry using a structured clinical assessment based on operationalized DSM-IV criteria. Clinical data were gathered from hospital notes. Information on sociodemographic data, premorbid basic and instrumental activities of daily living, quality of life and burden of the caregiver was gathered from carers and review of hospital notes. In both cohorts, participants were telephoned 3 months after hospital admission to respond the follow-up questionnaires. Patients who decided not to answer them were considered lost to follow-up. All information was kept confidential.
1566139|NCT02483052|Device|RejuvenAir|RejuvenAir
1566140|NCT02483039|Behavioral|AKI Follow-up Clinic|Participants randomized to this arm will be referred to the AKI Follow-up Clinic where they will see a nephrologist who will coordinate follow-up care. At the AKI Follow-up Clinic, assessment forms that were developed during the pilot study at St. Michael's Hospital may be used, but this decision will be left to individual sites. Routine laboratory investigations will be performed at minimum every three months.
1566141|NCT02483026|Dietary Supplement|Multi vitamin|Multi vitamin
1566142|NCT02483026|Dietary Supplement|vitamin D|Vitamin D
1566143|NCT02483013|Other|whitening dentifrices|Two groups: participants received the instructions to use only the blinded supplied whitening dentifrice (Colgate Luminous White® or Close up White Now®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
1566144|NCT02483013|Other|Placebo|One group: participants received the instructions to use only the blinded supplied non-whitening dentifrice (Sorriso®) and toothbrush to make the habitual oral hygiene, three times per day during four weeks
1566145|NCT02483000|Biological|Anti-CD20 B9E9 scFv-Streptavidin Fusion Protein|Given IV
1566146|NCT02483000|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
1566147|NCT02483000|Drug|Carmustine|Given IV
1566148|NCT02483000|Drug|Clearing Agent|Given IV
1566149|NCT02483000|Drug|Cytarabine|Given IV
1566150|NCT02483000|Drug|Etoposide|Given IV
1566151|NCT02483000|Radiation|Indium In 111-DOTA-Biotin|Given IV
1566152|NCT02483000|Other|Laboratory Biomarker Analysis|Correlative studies
1566153|NCT02483000|Drug|Melphalan|Given IV
1566154|NCT02483000|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
1566155|NCT02483000|Other|Pharmacological Study|Correlative studies
1566156|NCT02483000|Radiation|Yttrium Y 90-DOTA-Biotin|Given IV
1566157|NCT02482987|Device|dense polytetrafluoroethylene (dPTFE) membrane Cytoplast|ridge preservation intervention using the dPTFE membrane device
1566158|NCT02482987|Device|human amniotic-tissue derived membrane BioXclude|ridge preservation intervention using the dPTFE membrane device
1566159|NCT02482987|Procedure|Ridge Preservation with overlay graft|ridge preservation intervention with additional freeze dried bone allograft (FDBA) placed buccal to the socket
1566160|NCT02482987|Procedure|Ridge Preservation without overlay graft|ridge preservation without overlay graft / traditional FDBA placement into the socket only
1566161|NCT02482961|Drug|colistimethate sodium|At least once a week, all patients with carbapenem-resistant Acinetobacter baumannii infection were screened from the database at the clinical microbiology laboratory
1566162|NCT02482948|Device|Active Leptospermum Honey (Medihoney)|STudy agent to be applied to the wound daily.
1566163|NCT02482948|Drug|Collagenase|Study agent to be applied daily to the wound.
1566165|NCT02482922|Other|Exercise & Dietary Supplement|
1566166|NCT02482909|Procedure|Hepatic resection|Anatomical surgical resection of the liver including the tumor
1566167|NCT02482909|Procedure|Radiofrequency ablation|Percutaneous ablation using radiofrequency under the imaging guidance
1566168|NCT02482883|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|All patients will undergo placement of a facial transcutaneous electrical nervous stimulation (TENS) device, but device activation will be randomized [active stimulation vs non-active (placebo) stimulation], for an initial period of 10 days.
1566171|NCT02482857|Drug|Acetylsalicylic acid|To compare BID dosing with OD dosing with clinically used aspirin dosages.
1566172|NCT02482844|Other|pacemaker implantation|
1566173|NCT02482844|Other|holter implantation|
1566174|NCT02482831|Procedure|Subgluteal sciatic nerve block|All patients (either diabetic or non-diabetic patients) received an ultrasound-guided (nerve stimulator assisted) subgluteal sciatic nerve block with 0.75% ropivacaine 20ml.
1566175|NCT02482818|Drug|Pregabalin|Increasing dose regimen depending on tolerability followed by decreasing dose regimen.
1566176|NCT02482818|Drug|Control-Placebo|A control substance, Lactose is administered in place of Pregabalin.
1566180|NCT02482766|Drug|Poractant alfa, 200 mg/kg|Endotracheal Surfactant administration
1566181|NCT02482766|Device|Ventilator for High-frequency Oscillatory Ventilation (HFOV)|This device will be used to perform an HFOV recruitment maneuver before surfactant administration
1566182|NCT02482766|Device|Nasal Continuous Positive Airway Pressure (nCPAP)|After surfactant administration, the babies will be extubated within 30 minutes and will receive nCPAP (6-8 cm H2O)
1566183|NCT02482753|Drug|Chidamide|30 mg, administered orally twice per week (BIW)
1566184|NCT02482753|Drug|exemestane|25 mg, PO daily
1566185|NCT02482753|Drug|placebo|Administered orally twice per week (BIW)
1566186|NCT02482740|Drug|Letrozole|letrozole 2.5 mg qd was given for 12 months or till disease progress
1566187|NCT02482740|Drug|tamoxifen|tamoxifen was given 20 mg qd for 12 months or till disease progress
1566188|NCT02482727|Device|occlusion training with tourniquet (DELFI PTS ii portable tourniquet system)|A cuff will be wrapped around the most proximal portion of the arm of the involved extremity. In order to individualize the pressure for each subject, the limb occlusion pressure will be measured (with dopplar ultrasound over the radial artery at the wrist level) at the first scheduled therapy visit. The cuff pressure utilized during the post-operative exercises will be set at 50% of the limb occlusion pressure. The subjects' strength will be re-assessed approximately every 2-4 weeks and the load will be increased as tolerated.
1566191|NCT02482688|Behavioral|A New Rehabilitation Treatment following Stroke|A randomised control design, comparing individuals who will receive visual unisensory stimulation alone (i.e., the control rehabilitation) and those who receive multisensory stimulation (i.e., the experimental rehabilitation), will be used to assess the effects of multisensory rehabilitation on learning, performance accuracy and speed in participants with neglect/extinction.
1566192|NCT02482675|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
1566193|NCT02482675|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
1566194|NCT02482675|Other|Glucose with Whey Protein Isolate|Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.
1566195|NCT02482675|Other|Glucose with Sodium Caseinate|Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.
1566196|NCT02482662|Procedure|Diagnosis|Oral glucose tolerance test and self-monitoring blood glucose
1566197|NCT02482649|Behavioral|EAA/T|bi-weekly for 12weeks
1566198|NCT02482649|Drug|Methylphenidate|dosage adjustment according to clinical effectiveness, QD for 12weeks
1566199|NCT02482649|Drug|Atomoxetine|dosage adjustment according to clinical effectiveness, QD or BID, for 12weeks
1566200|NCT02482636|Biological|DTaP/IPV/Hib vaccine|Given at 2, 3 and 4 months to Group 1 and 2
1566201|NCT02482636|Biological|13 valent Pneumococcal Conjugate Vaccine|Given at 2,4 and 12 months in group 1, given at 3 and 12 months in group 2
1566202|NCT02482636|Biological|Rotavirus vaccine|Given at 2 and 3 months to Group 1 and 2
1566203|NCT02482636|Biological|4-component Meningococcal B vaccine|Given at 2, 4 and 12 months to Group 1 and 2
1566204|NCT02482636|Biological|Meningococcal C/Hib vaccine (MenC/Hib vaccine)|Given at 12 months to Group1 and 2
1566205|NCT02482636|Biological|Measles/Mumps/Rubella Vaccine (MMR vaccine)|Given at 13 months to Groups 1 and 2
1566206|NCT02482623|Behavioral|Dementia Symptom Management at Home Program|The DSM-H is a multi-modal interprofessional intervention that includes: 1. intensive training of clinician mentors; 2. disseminated online training for Registered Nurses, Physical Therapists, Occupational Therapists; 3. implementation of evidence-based care plans, assessment instruments, and teaching handouts.
1566207|NCT02482610|Other|Glucose|Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.
1566208|NCT02482610|Other|Glucose with Whole Fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of whole fat milk within five minutes.
1566209|NCT02482610|Other|Glucose with Non-fat Milk|Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.
1566210|NCT02482597|Device|Whole Body Periodic Acceleration|A bed that translates back and forth at different frequencies while the subject lies supine
1566211|NCT02482584|Device|CPAP|CPAP intervention
1566212|NCT02482584|Other|Control|Control
1566213|NCT02482571|Device|Mild Hypoxia|During normoxia, the computer-controlled gas blender provides a gas mixture that generates pressures of expired O2 and CO2 similar to the resting values measured for each subject (32-35mmHg and 100-110 mmHg, respectively). During mild hypoxia, we will target the same expired CO2 of normoxia and a 60 mmHg reduction of expired O2 from the resting value (to a minimum limit of 50 mmHg), which is expected to reduce arterial oxygen saturation to 82-85%. In mild hypoxia, the fraction of inspired oxygen is reduced from ~21% (room air) to ~12% (equivalent to an altitude of 4000 meters). During both conditions of normoxia and mild hypoxia, the brain activity of subjects is monitored with functional magnetic MRI (fMRI) and spectroscopy (fMRS) while they are presented with visual stimuli.
1566214|NCT02482558|Other|High/Low Glycaemic index test breakfast|High/Low Glycaemic index test breakfast on test days for a High/Low Glycaemic index 7-day diet
1566215|NCT02482545|Dietary Supplement|Meal replacement|
1566216|NCT02482532|Biological|tvs-CTL Vaccine|autologous, 14g2a.zeta chimeric receptor transduced, activated T-cells, enriched for vaccine specific cytotoxic T-lymphocytes (tvs-CTL)
1566217|NCT02482519|Other|High calorie diet|High calorie diet for 10 days
1566218|NCT02482519|Other|Fasting|10 day fast
1566219|NCT02482506|Behavioral|MF-WLP|The first meeting each week includes a 60-minute class that addresses health knowledge, attitudes, and self-monitoring of weight, food and physical activity; realistic goal setting; stimulus control; problem solving; cognitive restructuring and relapse prevention. Other class activities include weekly weigh-in; increasing awareness of portions by weighing and measuring foods; creating stimulus control plans for home, car and work; identifying barriers to healthy eating and/or exercise; going on a field trip to a local grocery store to practice reading food labels; creating an eating out management plan; and identifying high risk situations and brainstorming ways to manage them. This meeting also includes a 60-minute exercise class. The second meeting each week is a stand-alone 60-minute exercise class that will incorporate a variety of activities. A one-year CPD fitness club membership and home exercise DVDs will be provided.
1566220|NCT02482506|Behavioral|SG-WLP|Control participants will be provided with a 24-week weight loss curriculum; this includes a binder with their personal daily caloric recommendation, all intervention handouts, a copy caloric guidelines and useful weight loss tools. Upon randomization, each control participant will be introduced to the program materials and encouraged to tailor the weight loss program for themselves. The study team will call each control participant once a month during this 6-month program period to check in. In addition, after the follow-up data collection, control participants will receive a one-year membership to the CPD fitness center.
1566221|NCT02482493|Device|Sigma PFC|patients will receive either an all polyethylene tibial component or a metal- backed component
1566222|NCT02482480|Other|Exercise|Walking in community Oropharyngeal exercises Diet recommendations Dietary recommendations Education
1566223|NCT02482480|Other|Control|Dietary and general recommendations
1566224|NCT02482467|Other|Hormonal analysis, pelvic US|
1566225|NCT02482454|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance
1566226|NCT02482454|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
1566229|NCT02482428|Drug|Investigational Treatment|Applied twice daily for up to 12 weeks
1566230|NCT02482428|Drug|Aldara|Applied 3 times a week for 16 weeks
1566231|NCT02482415|Other|Psycho-educational|
1566232|NCT02482402|Drug|Inhaled Iloprost|Treatment effect will be controlled at each study visit and the dose and/or inhalation frequency will be adapted.
1566233|NCT02482402|Drug|Placebo|inhalation solution placebo
1566234|NCT02482389|Radiation|Single fraction of 7 Gy|All subjects will receive a single 7 Gy fraction of radiotherapy to the intact tumor prior to surgery.
1566235|NCT02482376|Radiation|Stereotactic body radiotherapy ( SBRT)|Single fraction of 21 Gy stereotactic radiotherapy (SBRT)delivered pre-operatively to subjects with early stage breast cancer
1566236|NCT02482363|Radiation|UVA radiation|20 minutes of low dose UVA from a phototherapy unit
1566237|NCT02482363|Radiation|Sham Control|20 minutes of sham control exposure
1566239|NCT02482337|Procedure|POEM|POEM procedure in the OR
1566240|NCT02482324|Drug|ALZT-OP1a|Mast cell stabilizer
1566241|NCT02482324|Drug|ALZT-OP1b|anti-inflammatory
1566242|NCT02482324|Device|Dry Powder Inhaler|The inhaler will be used to deliver ALZT-OP1a via oral inhalation for both days on study.
1566243|NCT02482311|Drug|AZD 1775|"AZD1775 will be taken orally approximately every 12 hours over 3 days at the start of week 1 and week 2 of each 21-day cycle (Days 1-3 and 8-10), for a total of 12 doses with each treatment cycle.
AZD1775 should be taken approximately 2 hours before or 2 hours after food."
1566246|NCT02482272|Drug|Lamivudine|Lamivudine 100mg/day orally
1566247|NCT02482272|Drug|Adefovir|Adefovir 10mg/day orally
1566248|NCT02482272|Drug|Entecavir|Entecavir 1mg/day orally
1566249|NCT02482233|Behavioral|ENDD (NJOY)|As described above.
1566250|NCT02482233|Drug|NRT (NicoDerm CQ)|As described above.
1566251|NCT02482233|Behavioral|telephone counseling|Referral to the California Smokers' Helpline. California Smokers' Helpline will call the patient 4 times, or as agreed upon by the patient.
1566252|NCT02482233|Behavioral|brief advice|"Brief advice lasting less than 2 minutes will be delivered by the research assistant, investigator, or healthcare provider. The advice will be similar to the following statement (customized as needed to the patient): The most important advice I can give you is that quitting smoking is the number one thing you can do for your health and to prepare yourself for surgery. Quitting smoking before surgery may improve your chances of healing quickly. There's evidence that the longer you quit before your surgery, the fewer complications you'll have. I encourage you to make use of the resources that have been provided to you to help you quit and set your quit date for as soon as possible."
1566253|NCT02482233|Behavioral|brochure|"A brochure from the ASA (American Society of Anesthesiologists) about quitting smoking before surgery.
Available free from the ASA: http://ecommerce.asahq.org/publicationsAndServices/PatientBrochure_%20For%20Posting.pdf"
1566254|NCT02482220|Behavioral|Physical activity intervention|
1566255|NCT02482207|Drug|Rosuvastatin|
1566256|NCT02482207|Behavioral|Life style modification|
1566257|NCT02482194|Biological|mesenchymal stem cells|autologous transplantation of mesenchymal stem cells in spinal cord injury patients
1566258|NCT02482168|Drug|APX005M|APX005M is a CD40 agonistic monoclonal antibody
1566259|NCT02482155|Drug|Ibuprofen|ibuprofen 400 mg single dose oral solution
1566260|NCT02482142|Dietary Supplement|Effect of phosphorus|Ingestion of 500mg of phosphorus ( 4 tablets, each of 125 mg of phosphorus)
1566261|NCT02482129|Drug|LME636 60 mg/mL ophthalmic solution|
1566262|NCT02482129|Drug|Dexamethasone 0.1% ophthalmic solution|
1566263|NCT02482129|Drug|LME636 Vehicle|Inactive ingredients used for masking purposes
1566264|NCT02482116|Other|malaria or pneumonia diagnosis|Diagnostic approaches for malaria (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, rapid diagnostic tests, Giemsa microscopy); Diagnostic approaches for pneumonia (lay diagnosis, as per IMCI guidelines by trained primary healthcare workers, clinical diagnosis by medically qualified doctor, chest x-ray)
1566265|NCT02482103|Procedure|Renal denervation|Catheter based renal nerve ablation
1566266|NCT02482090|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
1566267|NCT02482090|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
1566268|NCT02482090|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
1566269|NCT02482090|Drug|Interleukin-2|Interleukin-2 is administered as a continous i.v. infusion in a decrescendo regimen (18 MIU/m3 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU/m2 IL-2 over 24 hours followed by 4,5 MIU/m2 IL-2 over another 24 hours for three days).
1566270|NCT02482077|Drug|SOF+RBV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
1566271|NCT02482077|Drug|SOF+DCV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily. Daclatasvir (DCV) 60mg tablet administered once daily.
1566272|NCT02482077|Drug|LDV/SOF|Ledipasvir 90 mg /Sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
1567338|NCT02474472|Drug|bupivacaine liposomal injectable suspension|
1566273|NCT02482064|Other|Flexible resin|This material 'Flexible resin' is going to be used in the construction of the 'flexible obturators'.
1566274|NCT02482038|Device|geko|neuromuscular electrostimulator
1566275|NCT02482025|Other|MHV|My HealtheVet registration and enrollment
1566276|NCT02482025|Dietary Supplement|SMMRT|Secure Messaging for Medication Reconciliation Tool
1566277|NCT02482012|Other|Survey|This was a survey
1566278|NCT02481986|Behavioral|Community Health Worker|A community health worker is para-professional who performs education, case management, and social support.
1566279|NCT02481986|Behavioral|Certified asthma educator|A certified asthma educator has is certified and performs asthma education.
1566280|NCT02481973|Other|Individualised Homoeopathic Remedy|Each participant is to receive an individualised homoeopathic remedy prescribed according to their characteristic symptoms.
1566281|NCT02481960|Procedure|CM-BC2 Irinotecan drug-eluting bead|
1566282|NCT02481947|Drug|BLI400 Laxative|Oral laxative
1566283|NCT02481947|Drug|Lubiprostone|Oral laxative
1566284|NCT02481934|Procedure|NKAE cells infusion|Expanded and activated autologous NK cells infusion. Each patient will receive two infusions of 7.5 x 106 expanded and activated autologous NK cells/kg/cycle.
1566285|NCT02481934|Drug|Lenalidomide|Lenalidomide, 10 mg oral/day during 21 days (cycle). Patients will receive 4 cycles.
1566286|NCT02481934|Drug|Bortezomib|Bortezomib, 1.3 mg/m2, s.c., days 1, 4, 8 and 11/cycle. Patients will receive 4 cycles.
1566287|NCT02481921|Behavioral|Group medical visits|Or shared medical appointments where a multidisciplinary team of providers with expertise in nutrition, nursing, behavior and medication management join to manage heart failure in addition to and in support of, the patient's regular physician visits.
1566288|NCT02481908|Device|STI measurements at baseline and under Valsalva maneuver|STI measurements at baseline and under Valsalva maneuver
1566289|NCT02481895|Behavioral|E-neurocognitive module|The experimental group will take part of a 12-week extension with a total of 36 hours training with the e-neurocognitive module tailored for bipolar patients
1566290|NCT02481882|Device|Magnetic Resonance Imaging|All scanning will be performed using a 7 Tesla Philips Achieva scanner with multi-transit capability (Philips Medical Systems, Best, The Netherlands). The volunteers will be scanned with a 32-channel receive coil.
1566291|NCT02481882|Drug|Prohance (Gadoteridol)|A gadolinium based liquid administered intravenously in order to quantify blood flow in the brain using an MR scanner.
1566292|NCT02481869|Biological|Arthrocentesis/PRP|PRP (n=20): single intra-articular injection of 5 ml of a leukocyte-reduced platelet rich plasma (ACP, Arthrex, Naples, FL) at the time of closed reduction and initial stabilization using ankle-spanning external fixation
1566293|NCT02481869|Drug|Arthrocentesis/Saline|Control (n=20): single intra-articular injection of 5 ml of sterile 0.9% saline at the time of closed reduction and initial stabilization using ankle-spanning external fixation
1566294|NCT02481856|Drug|SQ tree SLIT-tablet|
1566295|NCT02481856|Drug|Placebo|
1566296|NCT02481843|Other|2 hours of hyperoxia (FiO2 = 1)|Patients received 2 hours of hyperoxia at FiO2 = 1
1566300|NCT02481817|Procedure|Endoscopic dilation of subglottic stenosis|This is accomplished with rigid instruments or inflatable balloons.
1566301|NCT02481817|Procedure|Endoscopic resection of the stenosis|This is accomplished with C02 lasers and paired with prolonged medical therapy after surgery.
1566302|NCT02481817|Procedure|Tracheal Resection|Resection of the affected tracheal segment with end-to-end anastomosis
1566303|NCT02481804|Other|Dietary intervention|"Patients will be counseled by a dietician for 14 weeks. A tailored diet advice for each NET patient will be based on the individual situation which includes gastrointestinal complaints, the location of the tumor, additional treatments like previous surgery and measured vitamine and tryptophan levels.
Dietician consults will be conducted by 1 out-patient visit and 3 follow up contacts."
1566304|NCT02481804|Other|Standard treatment|Standard treatment will be continued
1566305|NCT02481791|Drug|Remifentanil and/or propofol|Induction Phase: A dose of remifentanil 1mcg/kg by slow bolus, will be given to facilitate endotracheal intubation. Further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given to ensure an anaesthetised patient.
1566306|NCT02481791|Drug|Remifentanil and/or propofol|Settling Period: An infusion of the test dose of remifentanil will be commenced from an infusion prepared prior to the patient being anaesthetised. 1mg of Remifentanil (one vial) will be diluted to a volume of 50mls in normal saline 0.9% in a 50ml syringe. Maintenance dose of propofol 130 mcg/Kg/min for the first 5 minutes reduced to 100 mcg/kg/min thereafter. 40mls of propofol 1% (10mg/ml) will be drawn undiluted into a 50ml syringe. During the settling period further doses of either remifentanil (0.5 mcg/kg) or propofol (1-2mg/kg) may be given.
1566307|NCT02481791|Drug|propofol|Equilibrium Period: During this period propofol will be infused at a constant rate of 100mcg/kg/min
1566309|NCT02481765|Device|High definition transcranial direct current stimulation|
1566310|NCT02481752|Other|Approach Avoidance Training|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
1566311|NCT02481752|Other|SHAM Training|
1566312|NCT02481739|Other|retrospective study|
1566313|NCT02481726|Radiation|68Ga-labeled peptides of dimer RGD (Alfatide II) and 18F-FDG|
1566314|NCT02481713|Behavioral|motivational interviewing|motivational interviewing
1566315|NCT02481713|Behavioral|learning style interviews|interview and feedback about learning style
1566316|NCT02481700|Procedure|Third molar removal|The surgical removal of third molars by local or general anaesthesia
1566698|NCT02479035|Dietary Supplement|Red raspberry meal 1|~125 g fresh weight (1 cup equivalent)
1566317|NCT02481687|Other|Confocal laser endomicroscopy|Probe based confocal laser endomicroscopy is a contrast based technique, consisting of a flexible catheter probe representing a bundle of optical fibers linked to a micro-objective a laser scanning unit and the control and acquisition software. The flexible confocal miniprobes can be passed through the working channels of standard endoscopes. The principle of the technique is based on a laser beam of defined wavelength being focused towards the targeted tissue and the recaptured signal is displayed as 'optical biopsies' in a single horizontal plane. The device was intended to be used for faster diagnosis and evaluation of gut diseases, by allowin in vivo histology.
1566320|NCT02481661|Procedure|segmentectomy|segmentectomy in Arm I and lobectomy in Arm II
1566321|NCT02481648|Other|Exercise|
1566322|NCT02481635|Drug|Gemcitabine|
1566323|NCT02481635|Drug|Nab-paclitaxel|
1566324|NCT02481635|Radiation|Radiation Therapy|
1566325|NCT02481635|Procedure|Surgical Resection|
1566326|NCT02481609|Drug|N-acetyl cysteine (NAC)|
1566327|NCT02481596|Behavioral|REACH + FAMS|The intervention consists of REACH individual-focused text messaging, plus family-focused phone coaching sessions, goal-focused text messaging, and the option to invite a family member/support person to receive text messages.
1566328|NCT02481596|Behavioral|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, plus text messaging targeting other self-care behaviors (see NCT02409329).
1566329|NCT02481596|Behavioral|Helpline & A1c results|Participants have complete all study assessments, receive text messages advising how to access study A1c results, and have access to a helpline for study- or diabetes medication-related questions.
1566330|NCT02481583|Drug|Levosulpiride|different formulations of levosulpiride
1566331|NCT02481570|Other|pharmacokinetic simulation|The aim of the simulation is to recommend dosing adjustments to improve postoperative analgesia with a rapid emergence.
1566332|NCT02481557|Device|Oxalate Salt Solution|Applied by dentist
1566333|NCT02481544|Behavioral|Gratitude Journaling Plus SOC|
1566334|NCT02481544|Behavioral|Memorable Events Journaling Plus SOC|
1566335|NCT02481531|Other|Previously marketed infant formula|
1566336|NCT02481531|Other|Previously marketed formula using a similar protein|
1566337|NCT02481518|Drug|Magnesium|Pre loading fluid with Magnesium sulphate 16 milliequivalent plus potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
1566338|NCT02481518|Other|Control|Potassium chloride 20 milliequivalent in Normal saline 500 ml IV drip in 4 hours before Cisplatin administration
1566339|NCT02481505|Drug|Chloroprocaine HCl 1%|Intrathecal Route
1566340|NCT02481492|Device|No flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the glands, inner ring is placed into foreskin cavity, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Ring is detached spontaneously.
1566341|NCT02481492|Device|Flip technique of Shang Ring circumcision|Measure the diameter of the penis with a scale plate of holes, the diameter of the ring was accordance with the penis, inner ring is placed around the penis, flip foreskin over the inner ring, apply the outer ring on the skin covering inner ring, clamp the out ring and cut the redundant foreskin; Remove the ring 7days postoperatively.
1566342|NCT02481479|Drug|Saxagliptin|Eligible patients will undergo baseline CMR, commence treatment and then after 6 months undergo repeat CMR
1566343|NCT02481479|Drug|Saxagliptin|Eligible patients will undergo baseline echocardiogram, commence treatment and then after 6 months undergo repeat echocardiogram
1566344|NCT02481479|Drug|saxagliptin|Eligible patients will undergo baseline venipuncture, commence treatment and then after 6 months undergo repeat venipuncture
1566345|NCT02481466|Behavioral|Portfolio diet and structured exercise|"Diet: Foods will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).
Exercise: A program encouraging 150 minutes of exercise, based on the Quebec Heart and Lung Institute exercise program. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending on goals and tolerance). The target goal will be at least 10,000 steps daily."
1566346|NCT02481466|Behavioral|DASH-like diet and structured exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.
Exercise: A physical activity/exercise program encouraging 150 minutes of exercise, based on the exercise program developed at the Quebec Heart and Lung Institute. A short submaximal treadmill test will be used to assess cardiorespiratory fitness. A kinesiologist will work with participants using behavioral strategies to develop and support a plan that aims to achieve the target of 150 min/week of physical activity or exercise in 3 or 5 sessions weekly (vigorous, moderate or mild depending of goals and tolerance) in keeping with maximum achievable goals of participants. The target goal will be at least 10,000 steps daily recorded on their pedometers."
1566384|NCT02481297|Drug|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks on Days 1,8, 15, and 22 of Cycle 1. After Cycle 1, given on Day 1 of Cycles 2 - 12.
1566385|NCT02481284|Device|Laser Doppler perfusion imaging|LDPI is an extension of laser Doppler flowmetry (LDF) and was developed to generate a colour-coded perfusion image in a large area of skin.
1566386|NCT02481271|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises
1 week program, one introductory session and daily home practice"
1567457|NCT02473562|Drug|Varenicline|Tablet 1 mg BID
1566347|NCT02481466|Behavioral|Portfolio diet and routine exercise|"Diet: Foods on the dietary portfolio plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley and oat bran breads) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers and other soy meat analogues, soy milks, yogurts and cheese) and 22.5 g peanuts or equivalent of tree nuts/1000 kcal (Table 1A) and increased MUFA (as olive and canola oils, avocados, nuts etc.). The glycemic index will be reduced from 83 to 70 GI units (bread scale).
Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
1566348|NCT02481466|Behavioral|DASH-like diet and routine exercise|"Diet: Participants will be encouraged to follow a diet of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals), reduce meat consumption, choose low fat dairy foods and a control margarine.
Exercise: Participants in this group will receive standard of care for individuals being seen by a general practitioner. They will be advised to achieve the current recommended targets for daily physical activity and educational material published by Health Canada (Canada's Physical Activity Guide, Health Canada). They will undergo treadmill tests at the start and end of each 1 year period. They will not receive the more frequent, targeted visits with a kinesiologist."
1566349|NCT02481453|Drug|Rapamycin|Experimental: rapamycin oral solution, 2 mg/day during one year Comparator: placebo
1566350|NCT02481453|Drug|Placebo|Comparator: placebo
1566351|NCT02481440|Biological|Umbilical Cord Mesenchymal Stem Cells|Intrathecal administration of UC-MSCs
1566352|NCT02481427|Procedure|Unicondylar Knee Replacement|UKA involves only the replacement of affected medial compartment. In the study, the operation will be performed through standard medial parapatellar incision with midline skin incision, but the knee joint and fascia will be opened like in standard Oxford minimally invasive incision. The procedure will be performed by using Oxford Microplasty instrumentation and following Microplasty surgical technique (Biomet Orthopedics). Intraoperative local infiltration analgesia is used for postoperative pain management. Drain is not used.
1566353|NCT02481427|Procedure|Total Knee Replacement|TKA is performed through a standard medial parapatellar incision, which provides easy access to the knee joint. Skin incision is done to midline. Intramedullary guide is used for alignment of femoral and tibia saw cuts and component positions. Components will be cemented in position. The patella will not be resurfaced. Intraoperative local infiltration analgesia (LIA) is used for postoperative pain management. Drain is not used.
1566354|NCT02481414|Biological|Pepcan+Candin|
1566355|NCT02481414|Biological|Candin|
1566356|NCT02481401|Behavioral|Intensive Individual Intervention Program|
1566357|NCT02481401|Behavioral|Peer-To-Peer Program Intervention|
1566358|NCT02481388|Other|Maximal exercise ramp test|The maximal exercise ramp test, symptom-limited, performed by all patients in the study was performed based on treadmill ramp protocol through ErgoPC Elite® software associated with 12-channels electrocardiogram. Respiratory variables were obtained in standard conditions of temperature, pressure and humidity (StPD), breath-by-breath, with the patient breathing through a face mask without leaks coupled to gas analyzer (Cortex - Metamax 3B, Germany).To ensure that patients reached maximum effort during the examination, only the tests which patients obtain a respiratory exchange ratio (RR) ≥1.1 were accepted .
1566359|NCT02481375|Dietary Supplement|Multiple micronutrients|12-wk supplementation of vitamin A, B1, B2, B6 ,B12, D, E, niacin, folic acid, zinc, copper, selenium, iodine
1566360|NCT02481375|Dietary Supplement|Iron|12-wk supplementation of iron
1566361|NCT02481375|Dietary Supplement|Placebo|12-wk supplementation of placebo
1566362|NCT02481362|Other|CAKE|For the CAKE condition, participants will play a computer task to earn points for cake that they can consume.
1566363|NCT02481362|Other|APRICOTS|For the APRICOTS condition, participants will play a computer task to earn points for apricots that they can consume.
1566364|NCT02481349|Other|Hatha Yoga|Participants and their caregivers take part in up to 15 sessions of Hatha yoga over the course of radiation therapy (up to 5 weekly sessions based on participant's schedule for usually 5-6 weeks). Most of the yoga sessions may be videotaped.
1566365|NCT02481349|Behavioral|Hatha Yoga Questionnaires|During each week of radiation therapy, participant completes a questionnaire about the Hatha yoga sessions.
1566366|NCT02481349|Behavioral|Quality of Life Questionnaires|Participant completes about 9 questionnaires before first radiation treatment, and again after completion of radiation treatment schedule (usually 6 weeks later). The questionnaires ask about participant's health, symptoms, mood, level of fatigue, sleeping habits, relationship, and quality of life. It should take about 45 minutes to complete these questionnaires.
1566367|NCT02481336|Other|Questionnaires|EORTC CIPN20 and EQ-5D-3L
1566368|NCT02481336|Procedure|Peripheral nervous system examination|nerve conduction velocity (NCV), quantitative sensory test (QST), and nerve excitability test (NET)
1566369|NCT02481336|Genetic|Whole Genome Sequence|Genetic Test : 10 mL blood will be collected in Blood Sample Collection
1566370|NCT02481323|Drug|isosorbide mononitrate|slow release nitric oxide donor that enhances vasodilation and widely used in angina prophyaxis
1566371|NCT02481323|Drug|cilostazol|phosphodiesterase 3-inhibitor that enhances vessel wall function with weak antiplatelet effects
1566372|NCT02481310|Drug|Cyclophosphamide|Given IV
1566373|NCT02481310|Drug|Cytarabine|Given IT or intraventricularly
1566374|NCT02481310|Drug|Doxorubicin Hydrochloride|Given IV
1566375|NCT02481310|Drug|Etoposide|Given IV
1566376|NCT02481310|Drug|Ixazomib Citrate|Given PO
1566377|NCT02481310|Other|Laboratory Biomarker Analysis|Correlative studies
1566378|NCT02481310|Drug|Methotrexate|Given IT or intraventricularly
1566379|NCT02481310|Drug|Prednisone|Given PO
1566380|NCT02481310|Biological|Rituximab|Given IV
1566381|NCT02481310|Drug|Therapeutic Hydrocortisone|Given IT or intraventricularly
1566382|NCT02481310|Drug|Vincristine Sulfate|Given IV
1566383|NCT02481297|Drug|Lirilumab|3 mg/kg by vein given on Day 1 of each 28 day cycle.
1566441|NCT02480842|Other|Alloplastic free ROM|
1566442|NCT02480842|Other|Alloplastic limited ROM|
1566387|NCT02481271|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery
1 single unit in the week before the surgery"
1566388|NCT02481258|Drug|Ataciguat (HMR1766)|
1566389|NCT02481258|Other|Placebo Comparator: Matching Placebo|
1566390|NCT02481245|Drug|Bezafibrate|30 patients with Bipolar I disorder who are experiencing an acute bipolar depressive episode will be given bezafibrate XR 400 mg daily added on to adequate doses of an FDA-approved anti-manic medication.
1566391|NCT02481232|Biological|freeze-dried group ACYW135 MCV|Group A, C, Y and W135 Meningococcal conjugate vaccine is suitable for immune prevention of epidemic cerebrospinal meningitis more than 2 months of age population
1566392|NCT02481219|Device|PillCam® COLON 2 procedure-CONTROL|
1566393|NCT02481219|Drug|Senna tablets|
1566394|NCT02481219|Drug|PEG|
1566395|NCT02481219|Drug|Metoclopramide|
1566396|NCT02481219|Drug|Erythromycin|
1566397|NCT02481219|Drug|SUPREP oral sulfate solution|
1566398|NCT02481219|Drug|Bisacodyl|
1566399|NCT02481219|Drug|SUPREP oral sulfate solution with Gastrografin|
1566400|NCT02481206|Device|Wearable Cardioverter Defibrillator|Wearable Cardioverter Defibrillator
1566401|NCT02481193|Drug|Cisatracurium|Different doses of cisatracurium pretreatment
1566402|NCT02481180|Drug|T0001|injection (SC) T0001 15mg weekly for 12 weeks
1566403|NCT02481180|Drug|T0001|injection (SC) T0001 30mg weekly for 12 weeks
1566404|NCT02481180|Drug|T0001|injection (SC) T0001 30mg every two weeks for 12 weeks
1566405|NCT02481180|Drug|T0001|injection (SC) T0001 50mg every two weeks for 12 weeks
1566406|NCT02481180|Drug|Enbrel|injection (SC) enbrel 50mg twice a week for 12 weeks
1566410|NCT02481128|Procedure|without preoperative access to lymphoscintigraphy findings|axillary sentinel lymph node biopsy without access to lymphoscintigraphy findings
1566411|NCT02481089|Other|validation group|
1566412|NCT02481076|Device|Flowtron Hydroven and Coban2 Lite|The patient in the intervention group will use both compression boot and compression bandage, as described in intervention arm
1566413|NCT02481076|Other|Braun frame|The leg is elevated on a Braun frame
1566414|NCT02481076|Device|compression bandage|application of flowtron hydroven boot and compression bandage
1566415|NCT02481063|Other|Control|3 Consecutive Days Running at 80% Maximus Heart Rate
1566416|NCT02481063|Other|Eccentric Overload|Training with Eccentric Overload (Squat in Yoyo Technology) during 6 Weeks 3 Consecutive Days Running at 80% Maximus Heart Rate
1566417|NCT02481050|Drug|Eribulin Mesylate|Eribulin Mesylate will be administered as a 1.4 mg/m2 intravenous (IV) injection over 2 to 5 minutes biweekly on Day 1 and Day 15 of each 28-day cycle.
1566421|NCT02481011|Drug|antithrombotic drugs|
1566422|NCT02480998|Biological|IL-YANG Flu Vaccine QIV 0.5mL|
1566423|NCT02480998|Biological|IL-YANG Flu Vaccine TIV 0.5mL|
1566424|NCT02480985|Other|Pituitary function evaluation|"Pituitary function evaluation performed at hospital discharge, 6 and 12 months
Thyroid-stimulating hormone, free T4 and T3
Follicle stimulating hormone, luteinizing hormone, estradiol, bioavailable testosterone
Adrenocorticotropic hormone stimulation test
Glucagon test (growth hormone deficit)
Risk factors evaluation of pituitary dysfunction
Demographic data
Daily data (clinical exam, secondary brain injuries)
Hormone levels on day 1, 3 and 7
Biomarkers on day 1, 3 and 7
Brain CT-Scan on day 1
Pituitary MRI on day 7
Outcome measures at 6 and 12 months
Neurological recovery (GOSe)
Independent functioning (FIM)
Quality of life (EQ-5D-5L)
Life satisfaction (LISAT-11)
Depression (PHQ-9)"
1566425|NCT02480972|Procedure|magnetic resonance imaging|"multiparametric MRI as follows:
diffusion weighted imaging using multiple b-values
Fat quantification sequence
perfusion MRI using ECCM agent
MR elastography
routine MRI using hepatocyte specific agent (optional in patients with focal liver lesion)"
1566426|NCT02480959|Procedure|Surgical treatment for recurrent patellar instability|Either medial plication or MPFL reconstructuion surgery
1566427|NCT02480946|Drug|MBS2320|As described in the arm descriptions
1566428|NCT02480946|Drug|Placebo|As described in the arm descriptions
1566429|NCT02480946|Drug|Methotrexate|Background therapy as described in the arm descriptions
1566430|NCT02480933|Procedure|Bilateral mastectomy|Bilateral mastectomy and imaging study of cadaveric breasts
1566431|NCT02480933|Other|Biopsy|Biopsy of BI-RADS 3 and superior lesions
1566432|NCT02480907|Behavioral|Workshop Group|Workshop support group
1566433|NCT02480907|Behavioral|Internet-based support group|Internet based support group with E-mail coaching
1566434|NCT02480894|Drug|BMS-663068|BMS-663068
1566435|NCT02480894|Drug|Maraviroc|Maraviroc
1566436|NCT02480881|Drug|BMS-663068|Investigational product
1566437|NCT02480881|Drug|Oral Contraceptive|Subject's existing combination OC tablet containing EE and progestin
1566438|NCT02480881|Drug|Loestrin 1.5/30|OC containing EE and norethindrone acetate (NEA)
1566439|NCT02480868|Device|ARTEBONE|4,3 g Bone Void Filler
1566440|NCT02480855|Other|Questionnaire and feedback|
1566447|NCT02480803|Drug|Continuous intrajejunal infusion of levodopa-carbidopa|Continuous delivery of levodopa-carbidopa intestinal gel through an intrajejunal percutaneous tube (Duodopa, CLI, CILI)
1566448|NCT02480803|Device|deep brain stimulation|Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN)
1566449|NCT02480777|Biological|Autologous Human Schwann cells|Schwann cells harvested from the sural nerve and debrided, injured sciatic nerve of the participant will be autologously transplanted along sural nerve autografts wrapped in a collagen matrix (Duragen).
1566450|NCT02480764|Drug|Azilsartan medoxomil|azilsartan medoxomil tablets
1566451|NCT02480764|Drug|Valsartan|Valsartan 80 mg capsules
1566452|NCT02480764|Drug|Azilsartan medoxomil Placebo|Azilsartan medoxomil placebo-matching tablets
1566453|NCT02480764|Drug|Valsartan Placebo|Valsartan placebo-matching capsules
1566454|NCT02480751|Drug|Beraprost|
1566455|NCT02480751|Drug|Placebo|
1566456|NCT02480738|Behavioral|Computerized Cognitive Training Apparatus|"CoCoTA was developed through collaborative research with the Korean Institute of Science and Technology (KIST) and Primpo Co. Ltd. (www.primpo.com). It was designed to stimulate numerous cognitive domains simultaneously by using sounds and objects familiar to Korean elderly. Training themes and scenarios were developed and evaluated by six board-certified neurologists and three neuropsychologists who specialize in dementia.
Each subject participated in a total of 24 sessions of cognitive training, which consisted of 40 minutes of training, twice per week. To assure the consistency of cognitive training, trained personnel stayed nearby the subjects to help throughout the training process."
1566457|NCT02480725|Procedure|collect CSF (Cerebrospinal fluid) sample|collecting CSF samples for thrombin activity assay
1566458|NCT02480712|Drug|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet administered orally once daily
1566459|NCT02480699|Biological|Recurring blood sample|
1566460|NCT02480699|Other|dietary survey|A dietary survey will be performed in all patients and every 3 months (4 surveys about 1 year). This survey will be given to the patient filled for 7 consecutive days. He must record during these 7 days, all of his food intake in quality and quantity. During a dialysis session this questionnaire will be taken with the patient by a dietician to better define the food intake. This surveys requires good patient compliance as well as his involvement that his collection is well within its food intake.
1566461|NCT02480686|Drug|SOF+PEG+RBV|Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
1566462|NCT02480673|Dietary Supplement|Chia|The subject will eat 25 gr of chia in 2 oatmeal cookies at day
1566463|NCT02480673|Dietary Supplement|Oatmeal|The subject will eat 2 oatmeal cookies a day containing the exactly same quantity of oats in the oatmeal cookies with chia.
1566464|NCT02480673|Behavioral|Normocaloric diet|The healthy diet plan distribution will be 50% carbohydrate, 25 % protein, 35 % fat to less than 7 % saturated fat and less than 200 mg/d cholesterol and 20-30 g of fiber.
1566465|NCT02480660|Behavioral|Educational Video|The video highlights key elements found in the existing literature critical for transition including understanding and taking charge of their health, creating a medical summary, learning more about health insurance, introducing the idea of organizing a health care transition team and creating a plan. The video also educates patients on the opportunities to take a tour of an adult floor, talk with social workers and learn more about adult providers during their hospital stay.
1566466|NCT02480647|Drug|Levonorgestrel|20μg/day.
1566467|NCT02480647|Drug|Etonogestrel|20μg/day.
1566468|NCT02480634|Drug|Zoledronic acid|Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
1566469|NCT02480634|Radiation|Radiotherapy|High dose：30Gy/10f Low dose：15Gy/5f
1566471|NCT02480608|Drug|Imatinib|
1566472|NCT02480608|Drug|Hydroxyurea|
1566473|NCT02480595|Device|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
1566474|NCT02480582|Other|Almonds|Whole raw almonds provided as a mid-morning snack - 0.9g\kg
1566475|NCT02480582|Other|Cheese Savouries|Cheese savoury crackers provided as a mid-morning snack - 0.9g/kg
1566476|NCT02480569|Other|FFR Measurement|
1566477|NCT02480556|Procedure|manual seperation of the placenta|manual separation of the placenta will be done immediately after fetal extraction & cord clamping, where the fingers of the surgeon will be insinuated between the margin of the placenta and the uterine cavity, then by sawing movement and controlled traction by the other hand till placenta is separated from the uterine cavity
1566478|NCT02480556|Procedure|Conservative separation of placenta|"Conservative separation of placenta:
in group B but following fetal extraction and cord clamping, the placenta will be left insitu & uterus is massaged awaiting spontaneous placental separation"
1566480|NCT02480530|Behavioral|Individual Feedback|Patient gets feedback reports on adherence weekly.
1566481|NCT02480530|Behavioral|Feedback Friend|In addition to individual feedback reports this information will be sent to an assigned family/friend or reciprocal peer.
1566482|NCT02480517|Device|Ultrasound|
1566483|NCT02480517|Device|Sham Ultrasound|
1566484|NCT02480504|Other|dietary intervention intermittent energy restriction|Randomized clinical trial
1566485|NCT02480504|Other|continuous energy restriction|
1566486|NCT02480491|Other|measuring cell freeDNA|measuring cell free DNA using PCR
1566487|NCT02480465|Drug|Lobelitazone 0.5mg|Lobelitazone 0.5mg, placebo of Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
1566488|NCT02480465|Drug|Sitagliptin 100mg|placebo of Lobelitazone 0.5mg, Sitagliptin 100mg, orally, 2 tablet once a day for 24 weeks with metformin
1566489|NCT02480439|Drug|TAK-648 Tablet|Tak-648 tablet
1566490|NCT02480439|Drug|TAK-648 Oral Solution|TAK-648 oral solution
1566491|NCT02480426|Device|CT-image guidance|TIPS creation is performed under the guidance of 3D CT-image.
1566492|NCT02480426|Drug|CO2 portograms guidance|TIPS creation is performed under the guidance of two-dimensional (2D) CO2 portograms.
1566493|NCT02480413|Other|Accuracy of an algorithm and the pediatric emergency tape.|No intervention
1566494|NCT02480400|Drug|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
1566495|NCT02480400|Drug|Escitalopram|Patients diagnosed with MDD and will fulfill the inclusion and exclusion criteria will start with escitalopram 10mg, according to the Summary of Product Characteristics. At week 2, patients with a baseline MADRS between 22 and 29 continue on 10mg, and patients with a baseline MADRS > 30 receive a fixed dose 20mg until the end of treatment.
1566496|NCT02480387|Drug|Ledipasvir/Sofosbuvir FDC|
1566498|NCT02480361|Device|acupuncture|Acupuncture treatment after gastric cancer surgery during 5 postoperative days
1566500|NCT02480335|Drug|bosentan|62.5 mg oral twice daily for 4 weeks, then 125 mg oral twice daily.
1566501|NCT02480322|Procedure|bariatric surgery (sleeve resection, proximal RYGB, distal RYGB)|
1566502|NCT02480296|Drug|MYK-461|
1566503|NCT02480296|Drug|Placebo|Placebo comparator
1566504|NCT02480283|Procedure|Bronchoscopy|Passage of a thin flexible tube through the mouth, into the windpipe and then into the bronchial tubes so that the study doctor can look into the lungs to perform Bronchoalveolar lavage (BAL), cytologic brushing, and protected specimen brushing.
1566505|NCT02480283|Radiation|Chest X-ray|To identify any previously undiagnosed lung disease that will either increase the risk of bronchoscopy or confound results of the study.
1566506|NCT02480283|Procedure|Venipuncture|To collect blood cells and serum for analyses.
1566507|NCT02480283|Procedure|Intravenous Catheter|To administer the appropriate medications for the bronchoscopy procedure.
1566508|NCT02480257|Behavioral|TARA|The intervention consists of four 3-week modules: 1. Autonomic regulation: Learning and practicing the ability to create a calm and safe inner state through breathing exercises and movement/physical activity. 2. Interoceptive awareness: Attention training, targeting external stimuli then sensory stimuli using short body scan exercises and guided meditations. 3.Emotion regulation: Recognizing, labeling, externalizing, and befriending emotions. 4. Metacognition, core-values, and committed action: Understanding social triggers to negative emotions and experiential avoidance strategies and their impact on obtaining desired life-goals. Home practice of TARA skills is encouraged, with breathing instructions and short, guided meditations provided via audio tracks.
1566509|NCT02480244|Behavioral|Behavioral Intervention|Intervention participants attend up to 12 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions are conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support are also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
1566510|NCT02480244|Other|Control|Control arm receives no health-related behavioral intervention
1566511|NCT02480231|Device|Retropubic Midurethral Sling|
1566512|NCT02480218|Other|Neuropsychological test battery|Participants will have been prescribed their endocrine therapy for the treatment of breast cancer prior to enrollment. Neuropsychological test batteries will be administered at baseline and at one-year follow-up to assess changes in cognition.
1566513|NCT02480205|Device|NeuroBox to deliver the NeuroPAP|"The patients will be studied during the following conditions:
On conventional NIPPV device with the clinically prescribed settings (30 min)
With NeuroPAP and no change of Pmin (=peep) (60 min)
With NeuroPAP and adjusted Pmin (decreased by 2 cmH2O) (60 min)
During CPAP delivered with NeuroPAP device (15 min)
Again with original NIPPV device and settings for 30 minutes"
1566514|NCT02480192|Other|Cognitive Behavioural Therapy for Menopausal Symptoms|This 12-week CBT- based group treatment program consists of a combination of components including: a) psychoeducation about the nature of menopause including examination about thoughts and beliefs, b) cognitive and behavioural modification related to vasomotor symptoms, c) cognitive-behavioural strategies for depression, e) cognitive-behavioural strategies for anxiety and panic, d) sleep hygiene and cognitive-behavioural strategies for sleep difficulties, f) psychoeducation and lifestyle and behavioural modifications for urogenital complaints, and g) psychoeducation and cognitive-behavioural strategies for sexual concerns.
1566515|NCT02480179|Device|H.E.G. (hematoencephalography) based neurofeedback|H.E.G. is a relatively new neurofeedback technique which, similar to fMRI is based on differential oxygenated blood supply according to regional brain activity.
1566516|NCT02480166|Drug|8 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are treatment naïve and without cirrhosis will be assigned to 8 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
1566517|NCT02480166|Drug|12 weeks SOF/LED|Eligible and consenting patients will be treated with sofosbuvir 400 mg daily and ledipasvir 90 mg daily for 8 weeks. Patients that are not treatment naïve or have cirrhosis will be assigned to 12 weeks of treatment. The drug will be administered orally, per manufacturers' instructions, and can be taken with or without food.
1566556|NCT02479958|Procedure|Antimicrobial Photodynamic Therapy 1|Partial carious tissue was removed with conventional dentine curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with 200 µL of O-Toluidine blue dye (0.1 mg/mL) for 60 s. After this, a red LED light source with wavelength of 630 nm was used at 100 mW power, 9.0 J of energy, for 60 s with energy density of 30.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement Vitremer was placed.
1567458|NCT02473562|Drug|Placebo (for varenicline)|Tablet 1 mg BID
1566520|NCT02480140|Other|Self-regulated constraint-induced movement therapy|There were 10 tasks to practice in total, they included fold laundry, put clothes on hanger, brush teeth, dress upper garment, dress lower garment in week one; and use telephone, prepare a cup of tea, sweep floor, wash towel, wash dishes in week two. In the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using SR strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
1566521|NCT02480140|Other|Constraint-induced movement therapy|They practised the same 10 tasks as in the SR-CIMT and control groups. The same as the experimental intervention group (SR-CIMT), in the 4 hours when the participants had their non-hemiplegic arm in the restrain, they received one hour therapist-guided training using the strategy on task relearning as described above. Therefore, all participants received 10 one-hour therapist-guided training sessions (daily on weekdays, total two weeks). The intervention was delivered by occupational therapist. For the rest of the 3 hours in the restrain, the participants' wearing of the restrain was monitored by the nursing staff in the ward.
1566522|NCT02480140|Other|Conventional occupational therapy|They practised the same 10 tasks as in the SR-CIMT group described above. They received training for 2 weeks, 5 days a week (therapy days), the same as in the SR-CIMT and CIMT groups.
1566523|NCT02480127|Procedure|PIPELLE Endometrial injury|The endometrial injury which is induced with pipelle.
1566524|NCT02480114|Other|Educational Intervention|Undergo oral care and pain management education session
1566525|NCT02480114|Drug|Gabapentin|Given PO
1566526|NCT02480114|Other|Pain Therapy|Receive usual oral health care
1566527|NCT02480114|Other|Quality-of-Life Assessment|Ancillary studies
1566528|NCT02480114|Other|Questionnaire Administration|Ancillary studies
1566529|NCT02480114|Drug|Oxycodone/Acetaminophen|Analgesia
1566530|NCT02480114|Drug|Hydrocodone/Acetaminophen|Analgesia
1566531|NCT02480114|Drug|Fentanyl|Transdermal Analgesia
1566532|NCT02480114|Drug|Ibuprofen|NSAID Analgesia
1566533|NCT02480114|Drug|Magic Mouthwash|Oral Solution to treat mucositis
1566534|NCT02480101|Biological|H7N9 live influenza vaccine|H7N9 live influenza vaccine
1566535|NCT02480101|Biological|Placebo|Lyophilized purified allantoic fluid of chicken embryos with stabilizers
1566538|NCT02480075|Other|Observational|Observational Study only
1566539|NCT02480062|Other|mWELLCARE|mWELLCARE intervention arm will include a software application loaded on a tablet computer that will be used by Nurse Care Coordinators (posted in community health centers) in the course of their jobs to register patients with hypertension or diabetes, to generate clinical decision support recommendations, to track these patients over time and to improve follow-up care. Decision support recommendations will be printed and given to a doctor, who will make the final call on the management plan that will be used for the patient. Registered patients will also receive customized messages on their mobile phone. In addition, at sites where network connectivity permits, the doctor may also be equipped with a doctor's app on a tablet that will be largely the same as the NCC app.
1566540|NCT02480062|Other|Usual Care|Usual care at the community health centers
1566541|NCT02480049|Drug|Asmakast|1 tablet contains 10 mg of montelukast
1566542|NCT02480049|Drug|Singulair|1 tablet contains 10 mg of montelukast
1566543|NCT02480036|Radiation|IORT with Kyphoplasty|IORT with kyphoplasty is give concurrently for the treatment of spinal metastases
1566544|NCT02480036|Device|Intrabeam®|
1566545|NCT02480023|Radiation|calcaneal quantitative ultrasound assessment|QUS for calcaneus bone of right foot will be done for this group of Pregnant women at the third trimester
1566546|NCT02480010|Drug|Pertuzumab|Participants will receive pertuzumab on Day 1 of each 3-week cycle. In Cohort A, an 840-mg loading dose will be administered prior to the 420-mg IV infusion. In Cohort B, the 1050-mg IV infusion will be administered with no loading dose.
1566547|NCT02479997|Drug|Indocyanine green|"ICG is cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, and liver blood flow, and for ophthalmic angiography.
In this study, Investigator uses ICG as a fluorescent dye which is used in medicine as an indicator substance . And it will allow detection of SLN more convenientlty."
1566548|NCT02479997|Drug|Radioisotope|Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
1566549|NCT02479984|Procedure|Staging Laparoscopy|"Resectable pancreatobiliary cancer confirmed by radiologic studies (CT scan, MRI, PET-CT) and no evidence of distant metastasis.
Staging laparoscopy will perform through 2 ports and a 30˚ laparoscope is inserted into the peritoneal cavity. Examining the whole abdominal wall, including the parietal and visceral peritonea, we will observe the liver surface from the dome area to the inferior surface and hepatoduodenal ligament in order to find metastatic nodules. Laparoscopic ultrasound (US) will be used to overcome in inspecting the posterior part of the liver. After complete laparoscopic examination, peritoneal lavage will be performed through the laparoscopic port."
1566550|NCT02479984|Device|Laparoscopic ultrasound|
1566551|NCT02479971|Drug|Clindamycin-gentamicin irrigation|An irrigation of the entire abdominal cavity with 500 ml gentamicin-clindamycin solution will be performed.
1566552|NCT02479971|Drug|Normal saline irrigation|An irrigation of the entire abdominal cavity with 500 ml normal saline will be performed.
1566553|NCT02479958|Procedure|Rubber dam isolation|Tooth was isolated using a rubber dam isolation in order to collect the dentin samples
1566554|NCT02479958|Procedure|Tooth drying|The tooth was dried with air jet.
1566555|NCT02479958|Procedure|Dentin wash with chlorhexidine 2%|Partial carious tissue was removed with conventional dentinal curette and collection of dentin with a micropunch (Ø = 1mm) was performed. The remaining dentin was washed with chlorhexidine 2%. After that a a new dentin collection was performed at another site of the cavity, and restoration with resin-modified glass ionomer cement was placed.
1566557|NCT02479958|Procedure|Antimicrobial Photodynamic Therapy 2|Partial carious tissue was removed with conventional dentine curette and initial collection of dentin with a micropunch (Ø = 1mm) was performed. Treatment of the remaining dentin was performed with 200 µL of methylene blue dye 0.01% for 5 min and after this, a red low level LASER light source with wavelength of 660 nm was used at 100 mW power, 9.0 J of energy, for 90 s with energy density of 320.0 J/cm2 . A new dentin collection was performed after this treatment at another site of the cavity and restoration with resin-modified glass ionomer cement was placed.
1566558|NCT02479945|Other|Obtaining biospecimen|
1566559|NCT02479932|Other|Transperitoneal cesarean technique|Pfannenstiel-Kerr technique for laparatomy and uterine entry
1566560|NCT02479932|Other|Extraperitoneal cesarean technique|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
1566561|NCT02479919|Device|Magstim® Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
1566562|NCT02479919|Device|Magstim® Sham TBS|Sham stimulation
1566563|NCT02479906|Device|Deep TMS System|Deep TMS treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions.
1566564|NCT02479906|Device|Sham Treatment|Sham treatments will be administered 3 times a week for 4 weeks and additional 2 booster treatments at the 5 and 9 week follow-up visits, for a total of 14 treatment sessions
1566565|NCT02479893|Procedure|polypectomy|Polyps size up to 0.8 cm will removed from the left colon.Re examination in 6 months period with biopsy from the scar of polypectomy.
1566566|NCT02479880|Drug|Tenofovir DF|Tenofovir DF 300 mg tablet administered orally once daily for up to 96 weeks
1566567|NCT02479880|Radiation|DEXA Scan|Dual energy x-ray absorptiometry (DEXA) scans administered at protocol-specified time points
1566568|NCT02479867|Drug|Cefadroxil|1 tablet from test vs 1 tablet from reference
1566569|NCT02479854|Drug|Asmakast|1 chewable tablet contains 5 mg montelukast
1566570|NCT02479854|Drug|Singulair|1 chewable tablet contains 5 mg montelukast
1566571|NCT02479841|Other|Self management program|
1566572|NCT02479828|Drug|Fascia iliaca compartment block|40 ml ropivacaine 0,5% injected under fascia iliaca using ultrasound
1566573|NCT02479828|Drug|Ropivacaine|
1566574|NCT02479828|Device|ultrasound|
1566575|NCT02479828|Drug|Placebo|
1566576|NCT02479815|Dietary Supplement|Micronutrient Powder (MNP)|Every month, 15 MNPs sachets will be provided to all children 6-23 months of age with the instruction to add them to their complementary food, to enable point-of-use fortification on every alternate day. The MNPs sachets will contain 6 mg Fe together with 14 other vitamins and minerals.
1566577|NCT02479802|Biological|Albumin|"27 plasma exchange procedures using Albumin 5% (estimated 3000 mL per plasma exchange) as replacement solution:
three weeks of intensive treatment with two plasma exchanges per week
twenty-one weeks of maintenance treatment with one weekly plasma exchange"
1566578|NCT02479789|Drug|Lidocaine|
1566579|NCT02479789|Drug|Placebo|
1566580|NCT02479776|Biological|stem cell injection|Injection of autologous bone marrow derived stem cells
1566581|NCT02479763|Procedure|Waveform-confirmed loss-of-resistance|Using waveform analysis to confirm thoracic epidural space
1566582|NCT02479750|Device|ColdZyme® mouth spray|
1566583|NCT02479750|Device|Placebo|
1566584|NCT02479737|Device|Blood drainage post cardiac surgery using PleuraFlow System|
1566585|NCT02479724|Device|continuous non-invasive blood pressure monitor|continuous blood pressure monitoring using device in parallel with Gold Standard (A-line)
1566586|NCT02479711|Other|composite restoration|The tooth will be isolated with cotton rolls and the caries will be removed. Enamel and dentin conditionings were performed with a self-etching adhesive system (Adhese One F, Ivoclar Vivadent, Liechtenstein). Bulk fill composite (Tetric EvoCeram® , Ivoclar Vivadent, Liechtenstein) will be injected in a single bulk increment of less than 4 mm to fill the preparations. The material was condensed with a flat instrument. Once set, it will be polished with finishing cups (Enhance® , Dentsply , Milford, USA). An interproximal strip will be used to finish the final contour.
1566587|NCT02479711|Other|glass ionomer cement|The tooth will be isolated wit cotton rolls and the caries will be removed. The dentist will mix and handle the materials in accordance with the manufacturers' instructions. The material was condensed with a flat instrument. Once set, it will be polished. An interproximal strip will be used to finish the final contour. G-Coat Plus (GC, America) will be applied to the surface and margins of the restoration.
1566588|NCT02479698|Biological|Cytotoxic T lymphocytes (CTLs)|"CTL dose infused will not be greater than 2 x 10^5 cells/kg BKV-specific CD3+ T cell line as a single infusion.
If a participant has a partial response, stable disease or progressive disease they will be eligible to receive seven (7) additional doses of CTL at a minimum of 2 weeks interval from the previous CTL infusion If participant has a partial response, stable disease or progressive disease, they will be eligible to receive one additional dose of CTL at a minimum of 2 weeks interval from the first CTL infusion."
1566589|NCT02479685|Procedure|PKS BILL-PKS PlasmaSORD Versus Conventional surgical techniques|To verify if the operative time of a standard laparoscopic sacral colpopexy associated to subtotal hysterectomy for the treatment of POP could be further reduced using PKS BILL: bipolar laparoscopic loop (a laparoscopic loop using advanced bipolar energy) (Olympus Medical Systems Corp, Tokyo) and PKS PlasmaSORD (Solid Organ Removal Device) vs. conventional monopolar hook and conventional mechanic morcellator.
1566590|NCT02479672|Device|laryngoscopy|Placement of endotracheal tube. If successful intubation does not occur after the first attempt at laryngoscopy, airway equipment used in further attempts will be selected at the discretion of the attending anesthesiologist.
1566591|NCT02479672|Procedure|Manual Inline Stabilization|Manual immobilization of Patient's neck with intention to minimize movement from baseline position
1566592|NCT02479672|Device|VividTrac®|
1566593|NCT02479659|Other|HIV testing commodity reinforcement|HIV testing commodities were replenished directly (outside of the government supply) in the event of a stock-out by study staff. Treatment facilities were visited monthly to assess stock levels, and facility staff could contact study staff when stock levels were low.
1566699|NCT02479035|Dietary Supplement|Red raspberry meal 2|~250 g fresh weight (2 cup equivalent)
1566594|NCT02479659|Other|Policy reinforcement meeting|District health officials met with facility staff to remind them of the current HIV testing policies for mothers and newborns in Zambia. Current policy states mothers with unknown or previously negative status should be tested every 3 months until the infant is 18 months of age. HIV-exposed newborns should be tested at 6 weeks and 6 months.
1566595|NCT02479659|Other|Opt-out HIV testing for mothers and newborns|"Facility staff were instructed to examine the maternal HIV status on the under-five (U-5) or antenatal care (ANC) card for all infants attending their first U-5 visit and do the following:
If marked Confirmed Exposed (CE), the health care worker conducted the DBS test on the infant only.
If marked, Mother Status Unknown (MSU) or Confirmed Not Exposed (CNE) the mother or caregiver was asked if the mother had ever tested HIV-positive. If yes, a DBS was done on the infant only. If no, the mother was offered an HIV antibody test in an opt-out manner."
1566596|NCT02479659|Other|Operational support for service integration|The evaluation team worked with facility staff to identify efficient allocations of staff and tailor the order of services. A key component of the operational optimization was a new patient triaging approach that sorted patient U-5 cards into bins and used separate queues for three types of patients: 1) first visit infants (six weeks), 2) second visit or later infants who required immunizations and 3) infants who were scheduled to only receive growth monitoring.
1566597|NCT02479659|Other|Community sensitization|Health facility staff were instructed to communicate all aspects of the Comprehensive Intervention during ANC appointments, in-facility child birth deliveries, and postnatal care (PNC) visits. Additionally, at six week immunization visits, mothers and caregivers received group counseling on opt-out HIV screening service and the importance of regular HIV screening for mother and child health. Finally, the research team engaged Safe Motherhood Action Groups (SMAGs), community health workers (CHWs), and active neighborhood health committee members to further increase awareness in facility catchment areas. These community members completed low-touch community sensitization over changes that would be made to U-5 services.
1566598|NCT02479646|Biological|MYL-1401H|
1566599|NCT02479646|Biological|EU-Neulasta|
1566600|NCT02479646|Biological|US-Neulasta|
1566601|NCT02479633|Other|Coronally advanced flap with connective tissue graft|"Two oblique, divergent releasing incisions extending beyond the mucogingival junction were performed. An intra-sulcular incision was performed at the buccal aspect of the involved tooth. Subsequently, a partial-thickness flap was raised beyond the MGJ. The papilla adjacent to the involved tooth were then de-epithelialized.
The CTG was harvested using a single incision approach from the palate. The graft was positioned on the instrumented root surface immediately apical of the CEJ and then stabilized using a sling compressive crossing suture. The flap was coronally displaced 1-2 mm above the CEJ. A sling suture was placed to stabilize the flap in a coronal position, followed by interrupted sutures on the releasing incisions with an apico-coronal direction."
1566603|NCT02479607|Device|Smartphone or tablet|
1566604|NCT02479594|Behavioral|competence-feedback|competence-feedback
1566605|NCT02479594|Other|control|control group without competence-feedback
1566695|NCT02479048|Dietary Supplement|Test meal 1|High fat meal (HF) with ½ avocado (~68g), matched to CM for energy content; not matched for macronutrient content or type (e.g., fat type).
1566700|NCT02479035|Dietary Supplement|Control meal|0 g red raspberry
1566626|NCT02479568|Dietary Supplement|Control|500 mL (250 mL; 2 times/day) of placebo drink for 12 weeks
1566627|NCT02479568|Dietary Supplement|100% Florida OJ|500 mL (250 mL; 2 times/day) of 100% Florida OJ for 12 weeks
1566628|NCT02479568|Dietary Supplement|100% Florida OJ-enriched|500 mL (250 mL; 2 times/day) of 100% Florida OJ-enriched for 12 weeks
1566629|NCT02479555|Drug|Dexamethasone sodium phosphate injection, USP, 4 mg/mL|"Post-balloon angioplasty revascularization, the unblinded Pharmacist will prepare a sterile 20 mL syringe (Luer locking) with 16 mL of investigational drug or placebo per assignment. The unblinded Pharmacist provides syringe to investigator. Syringe shall only be labeled with the study number, patient number, randomization number and Investigational Drug.
Investigational Drug will be administered via Bullfrog Micro-Infusion Device."
1566630|NCT02479542|Other|Standard Gauze Dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the control arm, only standard gauze dressings will be applied and changed daily. Wounds with the standard gauze dressings will be photo-documented and measured with the same variables every 72 hours. Wounds and dressing will be evaluated daily for drainage, exudate, presence of infection, and gauze dressings will be changed daily.
1566631|NCT02479542|Device|WiCare NPWT dressing|Following consenting of participant, the wound will be photographed with the Wound Zoom imaging system and measured for greatest length, width, and depth. For patients randomized to the simplified NPWT arm, the standard gauze dressing will be placed then the the WiCare NPWT dressing will be applied. Wounds and WiCare NPWT device will be evaluated daily for drainage, exudate, presence of infection, drainage in pump, integrity of air tight seal. Wounds will be changed by protocol with photo documentation every 72 hours for a total of 18 days or achievement of primary endpoint.
1566632|NCT02479529|Drug|Norepinephrine|Administration and weaning of norepinephrine is based on dynamic arterial elastance
1566633|NCT02479529|Drug|Norepinephrine|The usual procedure of withdrawal norepinephrine is based on hemodynamic parameters (blood pressure, cardiac output), clinical (cutaneous perfusion, mottling, hourly diuresis) and biological (SVO2, arterial lactate).
1566634|NCT02479516|Behavioral|Community Health Assessment Program Philippines (CHAP-P)|
1566635|NCT02479503|Procedure|Antibiotic prophylaxis in adult heart transplantation|
1566636|NCT02479490|Drug|Prednisone + Everolimus|"Prednisone + Everolimus: Everolimus is formulated as tablets of 5-10 mg strength, blister-packed under aluminium foil in units of 10 tablets. Prednisone will be dispensed to patients at the dose of 5 mg twice daily (BID). Everolimus at dose of 10 mg (one 10 mg tablet or two 5 mg tablets). Both drugs will be self-administered orally, continuously from Day 1 (Visit 2) until progression of disease, unacceptable toxicity, death or discontinuation for any other reason.
A treatment cycle consists of 28 days."
1566637|NCT02479477|Other|kinesio therapy|during for fifteen minutes the nursing assistants will perform stretching exercises and muscle relaxation of large muscle groups the orthostatic position
1566638|NCT02479464|Genetic|Genotyping results|Genotyping results provided in Phase II
1566639|NCT02479451|Drug|Theophylline|The study medication will be provided by Foundation Care.
1566640|NCT02479438|Other|Diagnosed with GERD|Recording of patient outcomes
1566641|NCT02479425|Procedure|patient positioning|positioning patients, every 2 hours, either to standard (right, back, left sides) or only to right and left sides
1566642|NCT02479412|Drug|800 μg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
1566643|NCT02479412|Drug|250 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
1566644|NCT02479412|Drug|58 µg AZD7594 once daily|Once daily dosing of 800 µg AZD7594 for 14 days; each dose of AZD7594 inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
1566645|NCT02479412|Drug|Placebo once daily|Once daily dosing of Placebo to AZD7594 for 14 days; each dose of Placebo inhalation powder will be administered via a dry powder monodose inhaler as 2 hard capsules with 2 inhalations per capsule
1566646|NCT02479412|Drug|Salbutamol|Inhalation as needed
1566647|NCT02479399|Drug|ipragliflozin|Tablets
1566648|NCT02479386|Other|No intervention|No intervention was administered in this study.
1566649|NCT02479373|Other|Ren-Ex Machine|The exercise is performed once per week with individualized instruction using moderate resistance on Ren-Ex Machines, ultra-low-friction equipment to minimize force on joints.
1566650|NCT02479373|Other|Dual-Emission X-ray Absorptiometry (DEXA) scan|To study body composition
1566651|NCT02479373|Other|Biodex dynamometer|To study muscle strength
1566652|NCT02479373|Other|Sub-maximal test|To study lung capacity, a sub-maximal (limited exercise) test on a stationary bicycle is performed.
1566653|NCT02479373|Other|Quality of life questionnaires|
1566654|NCT02479347|Drug|Chlorhexidine|Preoperative skin preparation with tinted chlorhexidine gluconate 2% in 70% isopropyl alcohol administered with single-dose applicator
1566655|NCT02479347|Drug|Povidone-Iodine|Preoperative skin preparation with povidone-iodine 10% aqueous solution
1566656|NCT02479334|Other|Fat challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
1566696|NCT02479048|Dietary Supplement|Test meal 2|High fat meal (HF) with 1 avocado (~136g) matched for energy but not macronutrient content or type.
1566657|NCT02479334|Other|Fat challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high fat breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 20:60:20
1566658|NCT02479334|Other|Carbohydrate challenge breakfast|In this intervention, subjects are asked to consume 200 ml control drinks (non-energy flavored water). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
1566659|NCT02479334|Other|Carbohydrate challenge breakfast+spices|In this intervention, subjects are asked to consume 200 ml spices drinks (non-energy flavored water + spices extract). Following 10 min. beverage consumption, subjects will be given standardized high carbohydrate breakfast corresponding to % Energy of Carbohydrate:Fat:Prot / 60:20:20
1566660|NCT02479321|Other|PGDT based on noninvasive monitoring|"Before entering the operating room, hemodynamic optimization start by optimizing preload with Fluid Challenge according to evidence-based PGDT protocols. Once stabilized the cardiovascular system after induction of anesthesia, hemodynamic optimization continue with Mini Fluid Challenge.
In the intra and postoperative period (4 hours), hemodynamic optimization is based on maintaining systolic blood pressure and stroke volume. In case of instability a Mini Fluid Challenge is administered to patients who respond to volume or a vasoactive drug according cardiac index for non-responders."
1566661|NCT02479321|Device|System ClearSight® and Platform EV Clinic 1000®|Hemodynamic control is held by non-invasive continuous monitoring techniques (system ClearSight® and Platform EV Clinic 1000®). Monitored variables: blood pressure, heart rate, oxygen saturation, cardiac output, cardiac index, stroke volume and stroke volume index. We will also collect hourly diuresis and blood loss.
1566662|NCT02479308|Drug|Moxifloxacin|Single administration
1566663|NCT02479308|Drug|ALKS 5461|Daily administration for a total of 12 dosing days
1566664|NCT02479308|Drug|Placebo|Placebo will be matched to Moxifloxacin or ALKS 5461
1566665|NCT02479295|Device|Tenckhoff catheter|Peritoneal dialysis catheters for long term use
1566666|NCT02479282|Procedure|natural cesarean section|
1566667|NCT02479282|Procedure|traditional cesarean section|
1566668|NCT02479269|Other|Aerobic exercise|Aerobic exercise for 8 weeks
1566669|NCT02479256|Drug|Clomiphene citrate|Women will receive one tablet of clomiphene citrate oral tablets 50 mg (Clomid®, aventis/Egypt) twice daily 12 hours apart (total dose 100 mg daily) from the 3rd day of the menses for 5 days, for only one menstrual cycle.
1566670|NCT02479256|Drug|Tamoxifen Placebo|Women will receive one tablet of placebo of tamoxifen oral tablets twice daily 12 hours apart from the 3rd day of the menses for 5 days, for only one menstrual cycle.
1566671|NCT02479256|Drug|Tamoxifen|Women will receive one tablet of tamoxifen oral tablets 10 mg (Tamoxifen®, amriya/Egypt) twice daily 12 hours apart (total dose 20 mg daily) from 3rd day of the menses for 5 days, for only one menstrual cycle.
1566672|NCT02479256|Drug|Clomiphene citrate placebo|Women will receive one tablet of placebo of clomiphene citrate twice daily 12 hours apart from 3rd day of the menses for 5 days, for only one menstrual cycle.
1566673|NCT02479230|Biological|tumor blood vessel antigen peptide-pulsed alpha-type-1 polarized dendritic cell vaccine|Given ID
1566674|NCT02479230|Drug|gemcitabine hydrochloride|Given IV
1566675|NCT02479217|Drug|Docetaxel|
1566676|NCT02479217|Drug|Xeloda|
1566677|NCT02479204|Drug|ACT-334441 2 mg|capsule containing ACT-334441 at a strength of 2 mg
1566678|NCT02479204|Drug|ACT-334441 4 mg|capsule containing ACT-334441 at a strength of 4 mg
1566679|NCT02479204|Drug|Placebo|ACT-33441-matching placebo
1566680|NCT02479204|Drug|Atenolol|film-coated tablet containing atenolol at a strength of 50 mg
1566681|NCT02479204|Drug|Diltiazem ER|film-coated tablet containing diltiazem at a strength of of 120 mg
1566682|NCT02479191|Device|Ovation Abdominal Stent Graft Platform|
1566683|NCT02479178|Drug|BIND-014 (docetaxel nanoparticles for injectable suspension)|docetaxel nanoparticles for injectable suspension
1566684|NCT02479165|Drug|Ibuprofene|The Ibuprofene group is given an ibuprofen based analgesic regimen, to be compared with the standard opiod based regimen.
1566685|NCT02479165|Drug|Oxycodone|The opioid group is given an oxycodone based analgesic regimen.
1566686|NCT02479152|Device|LUCAS2 AD|LUCAS™ 2AD with compressions like the standard LUCAS™ 2 but added decompressions above the initial start position.
1566687|NCT02479139|Biological|Vehicle|Vehicle for ANT-1207 liniment formulation without active ingredient.
1566688|NCT02479139|Biological|ANT-1207|Botulinum toxin Type A topical liniment (ANT-1207).
1566689|NCT02479113|Procedure|Blood sampling|At 12 - 32 weeks: All patients need blood sampling for OGTT + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: All patients need blood sampling for fasting glucose + insulin + C-peptide + fasting triglyceride + NEFA At 36 weeks/ delivery: only GDM patients need blood sampling for HbA1c + fructosamine
1566690|NCT02479100|Procedure|Contrast Enhanced Spectral Mammography|
1566691|NCT02479087|Drug|Plasma-derived FVIII/VWF concentrate|"The investigational treatment is with lyophilized plasma-derived Factor VIII. The product belongs to the factor VIII concentrates class, containing also VW Factor in an average ratio VW/VIII of > 1: 4.5.
The product is as a powder and a solvent solution for continuous infusion of Factor VIII. The specific activity of Factor VIII is of approximately 80 IU/mg protein.
The number of units of FVIII administered is expressed in International Units (IU), which are consistent with current WHO standards for products containing Factor VIII. The activity of Factor VIII in plasma is expressed either as a percentage (compared to normal human plasma) or in International Units (compared to the international standard for FVIII in plasma)."
1566692|NCT02479074|Drug|Montelukast (High FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take (oral use) one tablet per day for 28 days
1566693|NCT02479074|Drug|Prednisolon, Montelukast (High FeNO)|Prednisolone 5 mg, patients to take 4 tablets per day for 14 days then take Montelukast 10 mg tablet per day for another 14 days.
1566694|NCT02479074|Drug|Montelukast (Low FeNO group)|Montelukast 10 mg film-coated tablet contains montelukast sodium equivalent to 10 mg montelukast patients to take one tablet per day for 28 days
1566697|NCT02479048|Dietary Supplement|Control Meal (CM)|High carbohydrate, high saturated fat control meal (CM) without avocado.
1566701|NCT02479022|Drug|Insulin 320|Subjects will be randomised to receive a single dose of Insulin 320 orally, at 7 escalating dose levels from 300 nmol to 21600 nmol. Progression to next dose level will be based on a safety evaluation.
1566702|NCT02479022|Drug|insulin glargine|As an open label active comparator, subjects will be randomised to receive a single dose of insulin glargine subcutaneously (s.c., under the skin), at all dose levels. The insulin glargine dose will be the same at all dose levels.
1566703|NCT02479022|Drug|placebo|Subjects will be randomised to receive a single dose of placebo orally as a comparator Insulin 320, at all dose levels.
1566704|NCT02479009|Device|Fluoroscopy|Each patient will undergo fluoroscopy-imaging evaluation in the office to determine whether the fracture moves (instability). The investigators will deviate the wrist from ulnar to radial and back in posteroanterior, oblique and lateral views with the wrist in neutral flexion. Any angulation or translation at the fracture site or more than one millimeter displacement or gap will be considered as a sign of instability. The fluoroscopy will be viewed and an image showing the largest gap will be saved. The diagnosis of instability (which is the same as displacement with this test) will be made by consensus of the research team.
1566706|NCT02478983|Device|LMA Supreme|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
1566707|NCT02478983|Device|LMA Proseal|The device will be inserted according to manufacturer's guideline. Time of insertion will be recorded. The oropharyngeal airway leak pressure will be measured when the device successfully inserted. The time taken to insert the LMA is recorded and the insertion success rate is documented. The larynx will be visualized with fibreoptic bronchoscope inserted through the LMA. Intraoperative complications will be recorded.
1566708|NCT02478970|Device|Konan SP4000|current standard of care at Kellogg Eye Center
1566709|NCT02478970|Device|NIDEK CEM-350|newly marketed device
1566710|NCT02478957|Drug|PA101|40 mg PA101 administered via inhalation three times daily for 6 weeks
1566711|NCT02478957|Drug|Placebo|matching placebo administered via inhalation three times daily for 6 weeks
1566712|NCT02478944|Device|Manometry|Flexible tube catheter pressure measurement of oesophageal contractions. Measurement without any sedation, transnasal
1566713|NCT02478918|Other|Phone call|Automated phone call reminder
1566715|NCT02478892|Device|prophylactic endoscopic ultrasound|The patients will be followed up clinically with routine, prophylactic endoscopic ultrasound surveillance every 12 months for a duration of 5 years.
1566716|NCT02478879|Drug|ZP-PTH|Patch applied daily for 30 minutes, 14 days
1566717|NCT02478879|Drug|FORTEO|Subcutaneous injection administration daily for 14 days
1566718|NCT02478866|Drug|BPI-9016M|Seven dose cohorts will be evaluated, including 100mg, 200mg, 300mg, 450mg，600mg, 800mg, 1000mg. BPI-9016M will be administered orally to patients once daily for each dose cohort.
1566719|NCT02478853|Other|Implementation of a new regional care framework|Integrated care framework for the prevention and management of cardio-metabolic chronic diseases in primary care
1566720|NCT02478840|Drug|Lamazym|recombinant human alpha-mannosidase
1566721|NCT02478827|Behavioral|Cognitive training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). Users will receive an account where they will only have access to the training games they have been assigned to and where their activity will be logged. Participants randomized one of the cognitive training arms will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
1566722|NCT02478814|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.6 g/kg/day
1566723|NCT02478801|Dietary Supplement|amino acids intake|amino acids intakes will be varied at 0.2-2.8 g/kg/day
1566724|NCT02478788|Drug|mixed amphetamine salts-extended release (MAS-XR)|MAS-XR is a psychostimulant medication composed of amphetamine and dextroamphetamine, has been systematically studied in adolescents with ADHD, and is FDA-approved for the treatment of ADHD in adolescents.
1566725|NCT02478788|Drug|Placebo|Pills with no medication in it
1566728|NCT02478762|Procedure|Normal glycemic control|Use diet, physical exercise of insulins to reach normal glycemic control.
1566729|NCT02478762|Procedure|Low glycemic control|Use diet, physical exercise of insulins to reach low glycemic control.
1566730|NCT02478749|Procedure|arm retraction|gently pulling through the ipsilateral arm to the knee
1566731|NCT02478736|Other|No actual intervention|Contact with enrolled subjects requires application of ceberal oximetry electrodes and the preoperative ultrasound (transcranial doppler) of the both MCA. No actual intervention done to subject.
1566733|NCT02478710|Drug|Aerosolized Tobramycin or Vancomycin|Tobramycin: 300 mg diluted in 5 mL of 0.9% normal saline q.12h. Vancomycin: 125 mg diluted in 5 mL 0.9% normal saline q.8h.
1566734|NCT02478710|Drug|Aerosolized Placebo|Placebo tobramycin: 5 ml 0.9% normal saline q. 12h. Placebo vancomycin: 5m 0.9% normal saline q. 8 hr.
1566735|NCT02478697|Behavioral|ProChange ExpertSystem|The computer program assesses stage of change and TTM constructs of temptations, decisional balance, and processes of change. Repeat intervention contacts occur at baseline, 3- and 6-months follow-up, providing iterative computerized feedback reflecting prior responses with encouragement for quitting smoking and relapse prevention.
1566979|NCT02476981|Drug|midazolam|All patients were premedicated with midazolam 0.02 mg/kg before induction.
1566736|NCT02478684|Other|30 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant
1566737|NCT02478684|Other|60 Seconds of placental blood transfusion|By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
1566738|NCT02478671|Device|TR Band|The radial artery will be compressed using a Terumo TR Band and artery diameter and perfusion will be measured
1566739|NCT02478658|Other|exercise training|high-intensity resistance training
1566740|NCT02478645|Drug|ramosetron 0.3|The ramosetron 0.3 group receives ramosetron 0.3 mg at the end of surgery.
1566741|NCT02478645|Drug|ramosetron 0.45|The ramosetron 0.45 group receives ramosetron 0.45 mg at the end of surgery.
1566742|NCT02478645|Drug|ramosetron 0.6|The ramosetron 0.6 group receives ramosetron 0.6 mg at the end of surgery.
1566744|NCT02478619|Other|IMT group|"Patients will be instructed to do a daily inspiratory muscle training at home with the preset load at 50% of the maximal inspiratory pressure, during 30 minutes for 4 weeks before bariatric surgery.
They will also receive the routine physical therapy in the post operative period."
1566745|NCT02478619|Other|Control group|Patients will be instructed to do a daily inspiratory muscle training at home with the minimal inspiratory load of the respiratory resistance device, during 30 minutes for 4 weeks before bariatric surgery. They will also receive the routine physical therapy in the post operative period.
1566746|NCT02478606|Other|Muscle Stretching Exercises|The training consists of a four-week program of passive stretching exercise with three times week/sessions with interval of 48 hours between them. Each session will consist of carrying out a single repetition of stretching exercise with 30s of duration, static or PNF, according to the group to which voluntary membership. The two lower members receive training but only the lower limb data drawn will be used for analysis.
1566747|NCT02478593|Behavioral|Educational booklet|Participants in the intervention group will receive an 8-page booklet that includes a list of generic and brand benzodiazepine names, benzodiazepine medication knowledge test, information about the associated risks of benzodiazepine use, and a list of safe alternative to their potentially inappropriate medication, as well as a stepwise tapering method. Recommendations to discuss decreasing use of benzodiazepines with physicians as well as to consult physicians before stopping any medication are also advised in the booklet. Participants in the control group will receive a booklet, produced by the Centers for Disease Control and Prevention, containing information regarding the important of exercise for seniors.
1566750|NCT02478567|Other|Rotator Cuff Training|four specific band-resisted strength training exercises for scapula
1566751|NCT02478567|Other|Scapular Training|four specific band-resisted strength training exercises for rotator cuff
1566752|NCT02478554|Other|Customized fetal growth curves|Fetal weight will be plotted against growth curves specific for height, weight, parity and ethnicity
1566753|NCT02478541|Other|Sugar study|Subjects are given a single test meal on two study days that has a sugary drink that varies in the amount of fructose and glucose it contains. They consume the same amount of fat on both study days.
1566754|NCT02478528|Device|Energy-Light lamp|Exposure of the subject, at 5am, to the light source of Energy-Light lamp (Philips)
1566755|NCT02478528|Device|Luminettes lamp|Exposure of the subject, at 5am, to the light source of Luminettes lamp (Lucimed)
1566756|NCT02478528|Other|control condition|No exposure of the subject to any light sources (control condition)
1566757|NCT02478515|Drug|Ranibizumab|Intraviteal injection of 0.5mg ranibizumab
1566758|NCT02478502|Drug|cabazitaxel|cabazitaxel is given to patients with progressive testicular cancer after cisplatin-based chemotherapy
1566759|NCT02478489|Drug|Oral naltrexone (PO-NTX)|oral naltrexone
1566760|NCT02478489|Drug|Extended-release injectable naltrexone (XR-NTX)|injectable naltrexone
1566763|NCT02478450|Biological|Q-Cells|cellular therapeutic comprised of human cells of the glial lineage
1566764|NCT02478437|Procedure|Conventional radiofrequency ablation (RFA)|A conventional RFA electrode with a 10mm active tip will be used. RFA lesions will be performed for 90 seconds with the maximum electrode temperature raised to 80°C.
1566765|NCT02478437|Procedure|Cooled Radiofrequency Ablation (CRFA)|Following 18G C-RFA electrode positioning, 1cc of 2% lidocaine will be injected through the introducer needle for anesthesia during the ablation. The maximum electrode temperature is 60°C.
1566766|NCT02478424|Drug|Cannabidiol|"Patients will receive standard GVHD prophylaxis consisting of cyclosporine A twice daily starting on day -1 with target trough levels of 200-400 ng/mL and a short course of methotrexate (15 mg/ m2 on day 1 and 10 mg/ m2 on days days 3 and 6). Patients transplanted from unrelated donors will receive ATG Fresenius at a low dose of 5 mg/kg on days -3 to -1.
Patients will be given oral CBD 150 mg BID starting 7 days before transplantation until day 100."
1566767|NCT02478424|Drug|cyclosporine|
1566768|NCT02478424|Drug|Methotrexate|
1566769|NCT02478411|Procedure|Cycle ergometer physiotherapy|15 minutes of cyclo ergometer physiotherapy with MOTOmed ® Letto 2 device with passive, motor-assisted and active-resisted exercise of the lower and upper extremity, and 15 minutes of conventional physiotherapy
1566770|NCT02478411|Procedure|Conventional physiotherapy|30 minutes of conventional physiotherapy
1566978|NCT02476981|Drug|Dexmedetomidine|Patients receiving dexmedetomidine were given that drug at 0.3-0.4 µg/kg over 10 min, followed by continuous infusion of 0.2 1 µg/kg/h
1566778|NCT02478385|Other|Supportive care in a specially designed labour room|Light and sound effects, homelike design in furniture and wall paper, sound insulation of walls, covering medical devices in walls, apparatus, and cupboards
1566779|NCT02478372|Drug|Patient Controlled Epidural (PCEA)|Following the operation, 4ml of 0.25% levobupivacaine was administered and the catheter was connected to a PCEA. Self-medication with a bolus 2ml of 0.125% bupivacaine via the PCEA system with a lockout time of 15 minutes until the following morning (post-operative day one) when it was stopped.
1566780|NCT02478372|Drug|Local Infiltration Analgesia (LIA)|Subcutaneous infiltration during surgery using 200ml of 0.2% plain ropivacaine.
1566781|NCT02478359|Behavioral|Physical Activity Coaching (Walk On!)|The 12-month Walk On! intervention includes a baseline in-person assessment, collaborative monitoring of steps using two types of activity sensors, semi-automated step goal recommendations using an interactive voice response system or web application, ongoing individualized reinforcement from a physical activity coach, and peer/family support.
1566782|NCT02478346|Drug|Fluorescein Sodium|Conventional microsurgical and biopsy procedures and techniques including histopathology and intraoperative imaging will be performed through the completion of the surgery. The surgeon will resect and remove what he believes is the tumor based on previously known criteria (standards of care) regardless of what the Fluorescein angiography demonstrates. For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
1566783|NCT02478333|Drug|ALS-008176 (250 mg)|Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions.
1566784|NCT02478333|Drug|ALS-008176 (500 mg)|Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions.
1566785|NCT02478333|Drug|ALS-008176 (750 mg)|Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
1566786|NCT02478333|Other|Placebo|Participants will receive placebo oral suspension once on Day 1 under fasted conditions.
1566787|NCT02478320|Drug|Ilorasertib|200 mg administered by mouth twice daily on Days 1, 8, and 15 of each 28-day cycle.
1566788|NCT02478307|Other|Cognitive Therapy|
1566789|NCT02478307|Other|Mindfulness Meditation|
1566790|NCT02478307|Other|Mindfulness-Based Cognitive Therapy|
1566791|NCT02478294|Procedure|Thoracoscopic LAA Excision plus AF Ablation|In this group, patients receive thoracoscopic LAA excision plus AF ablation, which means thoracoscopic left atrial appendage excision plus atrial fibrillation ablation.
1566792|NCT02478294|Drug|Warfarin or Novel Oral Anticoagulants|In this group, patients receive warfarin or novel oral anticoagulants
1566793|NCT02478281|Drug|Methylene Blue|
1566794|NCT02478268|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject TLC followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
1566795|NCT02478268|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
1566796|NCT02478255|Drug|Hyperpolarized 129-Xenon gas|Hyperpolarized xenon will be administered in multiple doses in volumes up to 25% of subject total lung capacity (TLC) followed by a breath hold of up to 15 seconds. Subsequent 129Xe doses will only be administered once the subject is ready to proceed.
1566797|NCT02478255|Device|MRI|Conventional 1H MRI will be used to provide anatomical reference scans, as well as pulmonary perfusion.
1566798|NCT02478242|Drug|Nafamostat mesilate|nafamostat mesilate use for anticoagulation
1566799|NCT02478242|Drug|Normal saline|
1566800|NCT02478229|Drug|Sofosbuvir (SOF) and Ledipasvir (LDV)|
1566801|NCT02478216|Procedure|Remote ischemic preconditioning|The tourniquet was applied at the opposite site from operation thigh in the both groups. The thigh was covered with blanket to conceal the tourniquet inflation and deflation. A total of 3 cycles of tourniquet inflation for 5 minutes with 2 × systemic systolic arterial blood pressure of arrival at operation room and deflation were performed.
1566802|NCT02478203|Device|Airtraq|videolaryngoscope for difficult airway
1566803|NCT02478203|Device|Glidescope|videolaryngoscope for difficult airway
1566804|NCT02478203|Device|direct laryngoscopy|gold standart for intubation
1566805|NCT02478190|Other|Tight control: goal glucose 350 mg/dL or lower|Goal glucose at discharge will be 350 mg/dL or less.
1566806|NCT02478190|Other|Loose control: goal glucose 600 mg/dL or lower|Goal glucose at discharge will be 600 mg/dL or less.
1566807|NCT02478164|Drug|Ponatinib|
1566809|NCT02478138|Procedure|Sentinel lymph node mapping|Thirty (30) patients will be enrolled under informed consent based upon their medical diagnosis, planned surgical procedures, and suitability for the procedure. During the study, patients will receive injections of ICG and will be imaged using a commercial NIR imaging system (Pinpoint, Novadaq, Waterloo ON). After the study, patients will continue with their planned management.
1566810|NCT02478138|Drug|Indocyanine Green (ICG)|
1566811|NCT02478138|Device|near-infrared fluorescence (NIR) imaging (Pinpoint, Novadaq, Waterloo)|
1566812|NCT02478125|Drug|Burixafor Hydrobromide|Investigators will determine the kinetics of PCa cell release into the blood with four daily dosages of Burixafor hydrobromide alone or in combination with G-CSF
1566813|NCT02478125|Drug|Docetaxel|Investigators will administer a single 75 mg/m2 IV dose of docetaxel. Twenty-one days later investigators will re-treat enrolled men with the optimal mobilization strategy + docetaxel IV. The second dose of docetaxel being given in combination with the optimal mobilization strategy will be chosen according to a standard 3+3 dose escalation schema, in which the dose of bruixafor +/- G-CSF will be held constant and the dose of docetaxel will escalate between three dose-levels: 1) docetaxel 30 mg/m2 IV, 2) docetaxel 60 mg/m2 IV, and 3) docetaxel 75 mg/m2
1566814|NCT02478125|Drug|G-CSF|G-CSF will be given as a daily subcutaneous (SC) injection beginning 4 days prior to Burixafor hydrobromide and continuing through the 4 days of Burixafor hydrobromide treatment
1566815|NCT02478112|Device|Biodegradable balloon implant|Implantation under general anaesthesia of a biodegradable balloon before radiation therapy for prostate cancer
1566816|NCT02478099|Drug|MPDL3280A|Anti-PD-L1 antibody
1566819|NCT02478060|Biological|Birch-SPIRE|
1566820|NCT02478060|Biological|Placebo|
1566821|NCT02478047|Drug|only antiemetic (Ramosetron, Tropisetron and dexamethasone)|The control group will receive standard antiemetic alone. Standard antiemetic for all groups is based on American Society of Clinical Oncology clinical practice guideline. 5-hydroxytryptamine-3 (5-HT3) antagonist (Ramosetron, Tropisetron) and dexamethasone are supplied from the first day of chemotherapy, and lasting for 3-5 days.And plus antiemetic drug as the comparator group.
1566822|NCT02478047|Other|Matching points ST36+CV12 plus antiemetic drug|"Choose both Zusanli(ST36) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
1566823|NCT02478047|Other|Matching points PC6+CV12 plus antiemetic drug|"Choose both Neiguan(PC6) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
1566824|NCT02478047|Other|Matching points CV13+CV12 plus antiemetic drug|"Choose both Shangwan(CV13) and Zhongwan point(CV12). Manipulating until achieving a de Qi sensation, then the needles are connected through a electro-acupuncture apparatus, the positive poles are linked to the needle, and the reference poles are located near the acupoint about 1cm with a paster. Frequency 10Hz,the intensity of stimulation is adjusted according to the patient's tolerance, and the electric current is less than 10mA. The operation lasts for 30 min. The treatment is scheduled to occur within 30min-60min before chemotherapy infusion for 4 days.And plus antiemetic drug as the comparator group."
1566825|NCT02478034|Other|Fludrocortisone|effects of fludrocortisone on cognition compared to placebo
1566826|NCT02478021|Other|Hydrocortisone|Effects of hydrocortisone compared to placebo on cognition
1566827|NCT02478008|Device|CardiAQ TMVI System (Transapical DS)|
1566828|NCT02477995|Biological|DTaP Vaccine A|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine A(Bejing minhai Biological Co., LTD) of 0.5ml, three doses, 28 days interval
1566829|NCT02477995|Biological|DTaP Vaccine B|Adsorption tetanus-diphtheria-acellular pertussis (DTaP) Vaccine B(Changchun changsheng Biological Co., LTD ) of 0.5ml in 600 infants aged 3-5months on day 0, 28, 56.
1566830|NCT02477969|Drug|PEX168(100µg)|PEX168,100µg,Subcutaneous injection,once a week. continued for 52 weeks
1566831|NCT02477969|Drug|PEX168(200µg)|PEX168,Subcutaneous injection,once a week. continued for 52 weeks
1566832|NCT02477969|Drug|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then followed by PEX168 100µg,qw sc. or 200µg qw sc.for 28 weeks.
1566833|NCT02477969|Drug|Metformin|0.5mg,oral,tid.
1566834|NCT02477956|Dietary Supplement|vitamin D3 (Replesta)|vitamin D group receive 2 replesta tablets (100,000 IU/month) of cholecalciferol.
1566835|NCT02477956|Dietary Supplement|vitamin D|
1566836|NCT02477943|Device|BrainScope Battery|The BrainScope Battery consists of 3 components to collect brain electrical activity, a cognitive assessment and a balance/sway measurement.
1566837|NCT02477943|Device|Advanced MRI Neuroimaging|Diffusion tensor imaging (DTI) is a magnetic resonance imaging technique that enables the measurement of the restricted diffusion of water in tissue in order to produce neural tract images instead of using this data solely for the purpose of assigning contrast or colors to pixels in a cross sectional image.
1566838|NCT02477930|Other|No interventions are done|No intervention is done. This is a registry study.
1566839|NCT02477917|Biological|Allergovac depot with Parietaria judaica pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
1566841|NCT02477891|Drug|Daratumumab|Participants will receive daratumumab (16 milligram per kilogram [mg/kg]) as intravenous infusion on Day 1, 8, 15, and 22 of Cycles 1 and 2 (weekly dosing), on Day 1 and 15 of Cycles 3 to 6 (every 2 weeks dosing), and on Day 1 of Cycle 7 and subsequent cycles (every 4 weeks dosing) until documented progression, unacceptable toxicity, or study end. Each cycle is of 28 days.
1566842|NCT02477878|Biological|BPX-501|Biological: T cells transduced with CaspaCIDe suicide gene
1566843|NCT02477878|Drug|AP1903|AP1903 administered to treat GVHD
1566844|NCT02477865|Drug|PEX168(100µg)|100µg,Subcutaneous injection,once a week. continued for 52 weeks
1566845|NCT02477865|Drug|PEX168(200µg)|200µg,Subcutaneous injection,once a week. continued for 52 weeks
1566846|NCT02477865|Drug|Placebo|0.5ml,Subcutaneous injection,once a week.continued for 24 weeks,then use PEX168 100µg or 200µg qw sc.for 28 weeks.
1566847|NCT02477852|Drug|Isoniazid|preoperative treatment of spinal tuberculosis with Isoniazid
1566848|NCT02477852|Drug|Rifampicin|preoperative treatment of spinal tuberculosis with Rifampicin
1566849|NCT02477852|Drug|Ethambutol|preoperative treatment of spinal tuberculosis with Ethambutol
1566850|NCT02477852|Drug|Pyrazinamide|preoperative treatment of spinal tuberculosis with Pyrazinamide
1566853|NCT02477826|Drug|Nivolumab|
1566854|NCT02477826|Drug|Ipilimumab|
1566855|NCT02477826|Drug|Carboplatin|
1566856|NCT02477826|Drug|Cisplatin|
1566857|NCT02477826|Drug|Gemcitabine|
1566858|NCT02477826|Drug|Pemetrexed|
1566859|NCT02477826|Drug|Paclitaxel|
1566860|NCT02477813|Drug|Temozolomide|200 mg/m2 die for 5 consecutive days every 28 days. Treatment will be continued until tumor progression, intolerable toxicity or patient refusal
1566861|NCT02477800|Drug|Aducanumab (BIIB037)|Low dose
1566862|NCT02477800|Drug|Aducanumab (BIIB037)|High dose
1566863|NCT02477800|Drug|Placebo|Placebo
1566864|NCT02477787|Biological|allogeneic, donor-derived NK cells|"Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.
For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.
Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions."
1566865|NCT02477774|Device|ARISTA|According to the manufacturer, Arista uses Microporous Polysaccharide Hemospheres (MPH) technology to catalyze the clotting cascade and effectively dehydrate tissue to initiate hemostasis in broad areas. Major advantages of Arista are that it has been shown to be safe and effective across multiple surgical disciplines, is completely absorbed in 24-48 hours, and contains no human or animal components
1566866|NCT02477761|Dietary Supplement|Nutrient preload|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
1566867|NCT02477748|Drug|MDX|Immediate-release/slow-release,bilayer tablet PO of 1400 mg, taken once daily for 10 weeks.
1566868|NCT02477748|Drug|Placebo|Tablet PO, taken once daily for 10 weeks.
1566869|NCT02477735|Device|Actigraphy|Actigraphy will be conducted for each participant for 7 consecutive nights prior to TTI and for 7 consecutive nights 4-6 weeks following TTI.
1566870|NCT02477722|Other|EFP-NF|
1566871|NCT02477722|Other|Sham|
1566872|NCT02477709|Drug|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) - single dose only
1566873|NCT02477696|Drug|ACP-196|
1566874|NCT02477696|Drug|ibrutinib|
1566875|NCT02477670|Drug|AVP-786|
1566876|NCT02477670|Drug|Placebo|
1566877|NCT02477657|Procedure|Paracentesis|
1566878|NCT02477657|Device|Tunneled Intraperitoneal Drain (IPD)|
1566879|NCT02477657|Device|Peritoneal-Venous shunts (PVS)|
1566880|NCT02477644|Drug|Olaparib|Tablets, per os, 300 mg twice daily;
1566881|NCT02477644|Drug|Placebo|Tablets, per os, 300 mg twice daily.
1566882|NCT02477631|Drug|Deferiprone|This is a single-arm, open-label, multi-center study in 20 patients with MDS. All participants will be treated with deferiprone for up to 4 months.
1566883|NCT02477618|Drug|SAGE-547|
1566884|NCT02477618|Drug|Placebo|Placebo
1566885|NCT02477605|Device|CONSTELLATION® 27-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 27-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 27-gauge EDGEPLUS® Valved Entry System comprised of 3 trocar/cannulas and related accessories.
1566886|NCT02477605|Device|CONSTELLATION® 23-gauge Combined Surgical Pak|Sterile single-use supplies necessary to perform 1 vitrectomy surgery: 1 ULTRAVIT® 23-gauge 7500 cuts per minute (cpm) vitrectomy probe and a 23-gauge EDGEPLUS® trocar/cannula set comprising of 3 trocars/cannulas and related accessories.
1566887|NCT02477605|Procedure|Vitrectomy surgery|Microincisional pars plana vitrectomy (PPV) surgery for the treatment of various vitreoretinal diseases ranging from simple to advanced cases
1566888|NCT02477592|Procedure|individualized substrate modification|CPVI ablation and left atrial roof linear ablation first,then substrate mapping in sinus rhythm followed by individualized substrate modification.
1566889|NCT02477592|Procedure|stepwise ablation|CPVI ablation,left atrial roof linear ablation,mitral isthmus linear ablation,complex fractionated atrial electrograms ablation step by step.
1566890|NCT02477579|Device|NovaCross|The NovaCross™ is a guidewire positioning and support microcatheter for improving chronic total occlusion (CTO) crossability. The NovaCross™ gains its supportive characteristics through the use of a unique operator-controlled Nitinol scaffold and an extendable segment, both at its distal tip.
1566891|NCT02477566|Drug|Long-acting Triptorelin|Pituitary down-regulation with Long-acting Triptorelin 1.875mg during the luteal phase
1566892|NCT02477566|Drug|Short-acting Triptorelin|Pituitary down-regulation with Short-acting Triptorelin 0.1mg/d,x10d, then 0.05mg/d until E2<40pg/ml in serum, was initiated during the luteal phase
1566893|NCT02477553|Behavioral|DA - Quantitative|
1566894|NCT02477553|Behavioral|DA - Verbal|
1567820|NCT02471092|Other|Skim milk products|Milk treatments will be served with 58g of breakfast cereal.
1566895|NCT02477540|Drug|Cellgram-CLI|"Appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip
Main ingredient: Autologous bone marrow-derived mesenchymal stem cells
Dosage: 50,000,000 cells/10ml, 2-time injection
Storage: An airtight container, 20~25℃
Injection Method: Intramuscular"
1566896|NCT02477527|Drug|Stribild|Change subjects from Atripla one tablet per day to elvitegravir/ cobicistat/ emtricitabine/ tenofovir disoproxil one tablet per day.
1566897|NCT02477514|Drug|midazolam|2 mg (1 mL of 2 mg/mL oral syrup) administered as a single dose on Days 1 and 14
1566898|NCT02477514|Drug|rosuvastatin|10 mg tablet administered as a single oral dose on Days 3 and 16
1566899|NCT02477514|Drug|tedizolid phosphate|200 mg oral tablet administered once daily on Days 5-17
1566902|NCT02477488|Drug|Allopurinol|Administration of allopurinol is changed to bedtime (hs) for each patient, at the same dosage as was previously prescribed.
1566903|NCT02477462|Other|Clinic visit|Blood draw every 3 months; quality of life surveys and imaging annually
1566904|NCT02477462|Other|Baseline visit|Blood draw and quality of life surveys
1566905|NCT02477449|Drug|istaroxime|8 subjects in 0.25ug/kg/min group were administrated Istaroxime + 0.9% NS fo12 subjects in 0.5ug/kg/min or 1.0 ug/kg/min group randomly received Istaroxime placebo + 0.9% NS (2 subjects), 0.9% NS alone (2 subjects) and Istaroxime + 0.9% NS (8 subjects).
1566906|NCT02477449|Drug|9% Saline (NS)|infusion for 24 hours
1566907|NCT02477436|Drug|Avanafil|"One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.
Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the investigational product.
Investigational products were administered prior to the sexual intercourse for total 8 weeks."
1566908|NCT02477436|Drug|Placebo|"One capsule should be taken with water, 30 minutes before sexual intercourse. It should be taken only once a day.
Intemperance in eating and drinking should not be done, 2 hours before and 2 hour after taking the placebo.
Placebos were administered prior to the sexual intercourse for total 8 weeks."
1566909|NCT02477423|Drug|Ampicillin|Ampicillin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
1566910|NCT02477423|Drug|Gentamicins|Gentamicin will be given as routine antibiotic coverage for those in the active arm, as the standard initial antibiotic used within the neonatal unit. It may also be used for patients who are not eligible for randomization.
1566911|NCT02477423|Drug|Placebo|Normal saline will be given as placebo for those in the placebo comparator group.
1566912|NCT02477410|Dietary Supplement|Hydrolysed porcine protein from blood|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
1566913|NCT02477410|Dietary Supplement|Hydrolysed porcine protein from muscle|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
1566914|NCT02477410|Dietary Supplement|Hydrolysed whey protein|Effects of hydrolysed porcine proteins on muscle protein synthesis and appetite
1566915|NCT02477397|Drug|Spiromax Budesonide/formoterol|1. In Group A, Patients will be treated with Spiromax® budesonide/formoterol 160/4.5 μg two inhalations twice daily + Spiromax® budesonide/formoterol 160/4.5 μg as needed with a maximum of 8 additional inhalations daily.
1566916|NCT02477397|Drug|Diskus Fluticasone/salmeterol|2. In group B, Patients will be treated with Diskus® fluticasone/salmeterol 500/50 μg one inhalation twice daily + salbutamol 100 μg as needed with a maximum of 8 inhalations daily.
1566917|NCT02477384|Procedure|8mm-TIPS|
1566918|NCT02477384|Procedure|Endoscopic variceal ligation|
1566919|NCT02477384|Drug|Propranolol|
1566920|NCT02477384|Device|8mm ePTFE-covered stent|
1566921|NCT02477371|Procedure|Fractional flow reserve-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting and where FFR-measurements are made, only receive grafting if FFR-value is ≤ 0,8. Arteries with FFR-values > 0,8 are deferred.
1566922|NCT02477371|Procedure|Angiography-guided CABG|Coronary arteries with angiographical significant stenoses, that are planned for grafting at the heart team meeting all receive grafting. FFR-measurements are still made, but not used for guidance of grafting.
1566925|NCT02477345|Drug|Omegaven IV|"Omegaven will be initiated at a dose of 0.5 gram/Kg/day and is infused over 24 hours for 1-2 days, and then advanced to
1 gram/Kg/day. Omegaven will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven will continue until weaned from PN. Monotherapy with Omegaven can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/Kg/day, advancing to 1 gm/kg/day."
1566926|NCT02477332|Biological|QGE031|
1566927|NCT02477332|Biological|Omalizumab|
1566928|NCT02477332|Other|Placebo|
1566929|NCT02477319|Other|Observational|
1566930|NCT02477306|Drug|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
1566931|NCT02477306|Drug|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
1566932|NCT02477293|Drug|Hyeonggaeyeongyo-tang|
1566933|NCT02477280|Drug|Methylphenidate|Cross-over
1566934|NCT02477280|Drug|Placebo|Medikinet
1566935|NCT02477267|Drug|SL spray|
1566936|NCT02477267|Drug|SL film|
1566937|NCT02477254|Biological|Vaccination|A quadrivalent HPV vaccine
1566938|NCT02477241|Procedure|Uroflowmetry|A cystometric test measures how much urine the bladder can hold, how much pressure builds up inside the bladder as it stores urine, and how full it is when the urge to urinate begins. Uroflowmetry is the measurement of urine speed and volume.
1566939|NCT02477241|Device|fMRI|Functional magnetic resonance imaging or functional MRI (fMRI) is a functional neuroimaging procedure using MRI technology that measures brain activity by detecting associated changes in blood flow. This technique relies on the fact that cerebral blood flow and neuronal activation are coupled. When an area of the brain is in use, blood flow to that region also increases.
1566940|NCT02477228|Procedure|conventional ERCP|ERCP was done through the papilla. duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
1566941|NCT02477228|Procedure|Precut ERCP|ERCP was done through precut from the start duration of cannulation, number of trials for cannulation, number of pancreatic cannulation, bleeding during cannulation and its management, need to convert to the other approach in cannulation.
1566942|NCT02477215|Drug|MLN9708|4 mg of MLN9708 delivered on days 1, 8 and 15 of a 28 day cycle.
1566943|NCT02477215|Drug|Dexamethasone|40 mg oral on Days 1, 8, 15 of each 28 day cycle.
1566944|NCT02477215|Drug|Bendamustine|80mg/m2 days 1,2
1566945|NCT02477202|Device|Mirena® intra-uterine device (IUD)|In this study, a Mirena® IUD will be inserted into volunteers scheduled for a risk-reducing salpingo-oophorectomy (RRSO) or risk-reducing salpingectomy (RRS) at Memorial Sloan Kettering Cancer Center (MSK). Alternatively, women with a Mirena® IUD already in place and who will be scheduled for an RRSO or RRS at MSK can also participate. We are seeking 14 evaluable participants. FTF tissue (and ovarian inclusion cyst tissue, when available) collected at the time of risk-reducing salpingectomy (RRS) will be tested by immunochemistry staining for Ki67 (a protein that is significantly increased when cells are preparing for division).
1566946|NCT02477189|Procedure|Silicone Block|
1566947|NCT02477176|Other|Discectomy|Lumbar discectomy
1566950|NCT02477137|Device|smartphone or tablet|Patients in the intervention group are given access to an application for a smartphone/tablet for daily reporting of symptoms, access to self-care advice and health-care professionals in real time.
1566951|NCT02477124|Device|transvaginal digital colposcope (TVDC)|TVDC is a miniature colposcope used to obtain images of cervical tissue.
1566952|NCT02477124|Other|Standard of care screening|Standard of care screening varies from institution to institution but is either visual inspection with the naked eye, colposcopy, or visual inspection with a camera or microscope
1566953|NCT02477111|Device|Endovascular abdominal aortic aneurysm repair|Subjects with infrarenal abdominal aortic aneurysms who meet all inclusion criteria and none of the exclusion criteria will be treated with the INCRAFT Stent Graft System.
1566954|NCT02477098|Drug|preoperative 0.5% ropivacaine hydrochloride preoperative|Before surgery (Pre RSB) , a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.
1566955|NCT02477098|Drug|postoperative 0.5% Ropivacaine hydrochloride|Before surgery, a bilateral RSB with saline will be performed under ultrasound guidance by one anaesthesiologist.At the end of surgery, a bilateral RSB with ropivacaine hydrochloride will be performed under ultrasound guidance by one anaesthesiologist.
1566956|NCT02477085|Other|all women with an induced labor|all women who have an induced labor
1566957|NCT02477072|Procedure|ACT|Blood samples for ACT will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
1566958|NCT02477072|Procedure|TEG|Blood samples for TEG will be collected following induction of anesthesia, 30 minutes after heparin administration, and on arrival in the recovery room.
1566959|NCT02477072|Procedure|Ankle-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
1566960|NCT02477072|Procedure|Toe-brachial index|Peripheral blood flow will be assessed prior and after surgery using the ankle-brachial and toe-brachial indexes.
1566961|NCT02477072|Drug|Heparin|Heparin doses will be administered according to the assigned group.
1566962|NCT02477059|Drug|tocilizumab|Le tocilizumab is administered by intravenous infusion at a dose of 8 mg / kg.
1566963|NCT02477059|Drug|saline solution|La saline solution is administered by intravenous infusion.
1566967|NCT02477033|Dietary Supplement|Butyricicoccus pullicaecorum 25-3T|
1566968|NCT02477033|Other|Maltodextrin|
1566969|NCT02477020|Drug|TAK-063 20 mg|TAK-063 tablet.
1566970|NCT02477020|Drug|Placebo|TAK-063 matching-placebo tablet.
1566971|NCT02477007|Drug|Paracetamol|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
1566972|NCT02477007|Drug|Ibuprofen|Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg). Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
1566973|NCT02477007|Drug|paracetamol + ibuprofen|Paracetamol will be an oral solution of 30 mg/ml. The doses of paracetamol will be 15 mg/kg (maximum dose: 1g) Ibuprofen will be an oral suspension of 20mg/ml. The doses of ibuprofen 10 mg/kg (maximum dose: 400 mg).
1566974|NCT02477007|Drug|Placebo|Placebo will have the closest flavour, smell and aspect to the active substances, respectively paracetamol and ibuprofen. Placebo will be prepared in bottles with a fake label of active substances for a better blinding both for the nurse and the patient. Labels will be hiding by a mask.
1566977|NCT02476981|Drug|Remifentanil|Patients given remifentanil received continuous infusion of the drug at 1-5 µg/kg/h
1567821|NCT02471079|Radiation|Radiotherapy|
1566980|NCT02476981|Drug|propofol|All patients in both groups received a bolus dose of propofol 0.3 mg/kg for sedative effect.
1566981|NCT02476981|Drug|ephedrine|Ephedrine 5 mg was injected when systolic blood pressure decreased below 90 mmHg
1566982|NCT02476968|Drug|Olaparib|"Olaparib Capsule - 50 mg. Olaparib capsules will be packed in high-density polyethylene (HDPE) bottles with child-resistant closures. Each bottle will contain 120 capsules and 4 bottles will be dispensed for a 4 weekly visit, with a 2 day overage.
Patients will be administered olaparib capsules orally at a dose of 400 mg twice daily.
Eight 50 mg olaparib capsules should be taken at the same time each day approximately 12 hours apart with approximately 240 mL of water."
1566986|NCT02476942|Drug|Bypassing Agents|Episodic or prophylactic treatment with the use of bypassing agents must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
1566987|NCT02476942|Drug|FVIII Replacement|Episodic or prophylactic treatment with the use of FVIII replacement must be documented for at least the last 6 months prior to the study. During the study, treatment for bleeds will be documented. The choice of coagulation product is at the discretion of the investigator according to local practice standards in this non-interventional study and there are no specific protocol-defined interventions.
1566988|NCT02476929|Device|Nasal nitrous oxide|Electrochemical device (NOVario Analizer FILT), to determine reference values of Nasal nitrous oxide.
1566989|NCT02476929|Device|Electronic nose|To determine reference values of different patterns of specific volatile organic compounds with the electronic nose (Cyranose 320®).
1566990|NCT02476916|Drug|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety, tolerability and clinical efficacy. AG-348 will be administered by mouth (orally) each day for a period of 24 weeks.
1566991|NCT02476903|Drug|Monovisc|
1566992|NCT02476890|Drug|Gefapixant|Gefapixant 50 mg tablets administered twice daily
1566993|NCT02476890|Drug|Matching placebo for gefapixant|Matching placebo tablets administered twice daily
1566994|NCT02476864|Drug|Treatment A (adult formulation)|Single oral administration of one film-coated tablet containing 10 mg of macitentan as active substance and lactose, magnesium stearate, microcrystalline cellulose, povidone, sodium starch glycolate type A, polysorbate as inactive ingredients.The film coat contains titanium dioxide, talc, xanthan gum, polyvinyl alcohol, and soy lecithin.
1566995|NCT02476864|Drug|Treatment B (pediatric formulation)|Single oral administration of two dispersible tablets, each containing 5 mg of macitentan as active ingredient and Mannitol delta polymorphic crystals, mannitol, isomalt, isomalt agglomerated, croscarmellose sodium, and magnesium stearate as inactive ingredients.
1566996|NCT02476851|Device|POLFA (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
1566997|NCT02476851|Device|Kawasumi (Needle Assembly)|Each subject receives the same intervention and blood is drawn into both the INA and CNA. The difference is the order in which the CNA or INA is applied.
1566999|NCT02476825|Drug|Fluticasone propionate|Flixotide Accuhaler 500 micrograms b.i.d.
1567000|NCT02476825|Device|Accuhaler|Flixotide Accuhaler 500 micrograms b.i.d.
1567001|NCT02476812|Behavioral|Positive Piggy Bank|Already noted.
1567002|NCT02476799|Procedure|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
1567003|NCT02476799|Drug|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
1567004|NCT02476799|Other|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
1567005|NCT02476799|Drug|IV-PCA containing Fentanyl and Ketorolac|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl and 150 mg of ketorolac for 48 hours postoperatively.
1567006|NCT02476786|Behavioral|FACT-B|The FACT-B (Version 4) is a 37-item measure that contains the four general subscales along with the Breast Cancer-Specific subscale that assesses symptoms/concerns of particular relevance to breast cancer (e.g., body image, arm swelling and tenderness).
1567007|NCT02476786|Drug|Goserelin|
1567008|NCT02476786|Drug|Anastrozole|
1567009|NCT02476786|Drug|Exemestane|
1567010|NCT02476786|Drug|Fulvestrant|
1567011|NCT02476786|Drug|Tamoxifen|
1567012|NCT02476786|Other|Archived tissue collection|
1567013|NCT02476773|Biological|Na-GST-1/Alhydrogel plus GLA-AF|
1567014|NCT02476773|Biological|Na-APR-1 (M74)/Alhydrogel|
1567015|NCT02476773|Biological|Na-APR-1 (M74)/Alhydrogel plus GLA-AF|
1567016|NCT02476773|Biological|Sterile Saline Placebo|
1567017|NCT02476760|Drug|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1567018|NCT02476760|Drug|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace
1567019|NCT02476760|Drug|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
1567227|NCT02475239|Behavioral|Normal daily activity|The patients did not follow any postural restrictions and were asked to live as normally as possible.
1567020|NCT02476760|Drug|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1567021|NCT02476760|Drug|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1567022|NCT02476760|Drug|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1567023|NCT02476760|Drug|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1567024|NCT02476760|Drug|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event) day.
1567025|NCT02476747|Other|EMR|performing EMR for patients with small polyp
1567026|NCT02476747|Other|CSP|performing CSP for patients with small polyp
1567027|NCT02476734|Biological|CART-19 autologous T-cells|
1567028|NCT02476734|Radiation|FDG-PET/CT|
1567029|NCT02476721|Other|detection of pulmonary embolism|
1567030|NCT02476708|Dietary Supplement|curcumin 1800mg|Curcumin, derived from turmeric root, is an over-the-counter supplement which is tolerated well.
1567031|NCT02476708|Dietary Supplement|Placebo|oral placebo capsule
1567032|NCT02476695|Device|FibroTouch Examination|Liver stiffness measurements are performed using FibroTouch and the procedure is non-invasive and painless.
1567033|NCT02476695|Device|FibroScan Examination|Liver stiffness measurements are performed using another transient elastography, FibroScan, and the procedure is non-invasive and painless.
1567034|NCT02476695|Device|Ultrasonic B Examination|The ultrasonic B examination is made at an empty stomach for ≥8h. The inner diameter of liver, spleen, gallbladder, portal vein and splenoportal vein is measured through the ordinary two-dimensional ultrasonic examination. The echo data of liver surface/edge/parenchyma and gallbladder wall is scored to evaluate the severity of fibrosis.
1567035|NCT02476682|Other|blood or stool samples will be collected|blood or stool samples will be collected
1567036|NCT02476643|Other|Integrative Therapy|This group receives an integrative therapy at the Department of Internal and Integrative Medicine, i.e. a combination of conventional diagnostic and therapeutic interventions with specific naturopathic, and complementary medicine approaches, and physical therapy.
1567037|NCT02476630|Device|StO2 measurement|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
1567038|NCT02476630|Other|Blood Gases|All participants will have a measurement of the tissue oxygen concentration (StO2) level after applying the noninvasive probe to the thenar eminence. This measurement is done at the same time as a blood gas from the central venous catheter is obtained. The StO2 measurement is documented once for the subject in the study.
1567039|NCT02476617|Drug|ombitasvir/paritaprevir/ritonavir|ombitasvir/ABT-450/ritonavir tablets
1567040|NCT02476617|Drug|dasabuvir|dasabuvir tablets
1567041|NCT02476617|Drug|ribavirin|ribavirin tablets
1567042|NCT02476604|Behavioral|health coaching and electronic messaging|Using using an iPAD or notebook PC, students will receive electronic messaging aimed at encouraging adherence to behavioral goals previously set via discussions with the health coaches. The messages will be received 3 to 6 times per week for the 8 week intervention period.
1567043|NCT02476591|Behavioral|Charge Transparency|"Providers caring for patients in the Charge Transparency cohort will be given access to patient specific charge data on a daily basis via an interactive dashboard which allows for full charge transparency to patients admitted to the Vanderbilt ICUs"
1567044|NCT02476578|Other|Email|Automated Email to the primary doctor and nurse, with the details of the patient, the condition found and the relevant measures to consider.
1567045|NCT02476565|Device|LMA-Supreme supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
1567046|NCT02476565|Device|I-gel supraglottic device|The fiberscope (with the Aintree loaded on top of it) will be advanced through the supraglottic device into the trachea. Next, the supraglottic device will be removed and the endotracheal tube will be advanced into the airway over the Aintree airway intubation catheter. Finally, the Aintree catheter is removed and the endotracheal tube will be left in the airway.
1567047|NCT02476552|Drug|Niraparib Oral Capsules (Labeled)|Single 300 mg dose of niraparib
1567048|NCT02476552|Drug|Niraparib IV (Labeled)|Intravenous (IV) infusion of 100 μg niraparib (containing approximately 1 μCi of [14C]-niraparib)
1567049|NCT02476552|Drug|Niraparib Oral Capsules (Unlabeled)|Single 300 mg dose of niraparib (unlabeled active pharmaceutical ingredient)
1567050|NCT02476539|Drug|Hemay022|
1567051|NCT02476526|Drug|Low Volume iso-osmolar non-ionic radio contrast medium|Intravenous injection of low volume (30 cc) iso-osmolar non-ionic radio contrast medium as part of the 64-MDCT Scanning procedure (intervention group only)
1567052|NCT02476526|Drug|Acetylcysteine Inhalation|Mucomyst 1200 mg po BID x 48 hours starting the day prior to the CT scan (both experimental and control groups)
1567053|NCT02476526|Drug|Sodium Bicarbonate Solution|Isotonic Sodium Bicarbonate 3 ml/kg/hr iv for 1 hour prior to the CT scan and for 6 hours after the CT scan (both experimental and control groups)
1567054|NCT02476526|Procedure|64-MDCT Scanning|Both experimental and control groups will undergo 64-MDCT scanning over the thoracic area
1567055|NCT02476500|Procedure|LLETZ on a training model|LLETZ is performed on a sausage-based training model using all surgical devices used in the original procedure
1567228|NCT02475226|Other|type of the brain injury|epidural hematoma
1567056|NCT02476487|Procedure|FDG PET CT|"FDG-PET CT will be performed on day 7-14 since the first positive blood culture. 1. Patients fulfilling current criteria for a short course (2 weeks) of antibiotic treatment: treatment will be prolonged if PET CT demonstrates a focus of residual infection.
2. Patients with risk factors mandating prolonged antibiotic treatment (4-6 weeks) according to current guidelines without IE: antibiotics will be stopped at 2 weeks if PET CT is normal."
1567057|NCT02476474|Procedure|3 cm start of resection|Investigators will start the resection of the LSG 3 centimeters from the antrum of the stomach.
1567058|NCT02476474|Procedure|6 cm start of resection|Investigators will start the resection of the LSG 6 centimeters from the antrum of the stomach.
1567059|NCT02476461|Drug|xiapex|
1567060|NCT02476461|Procedure|percutaneous needle fasciotomy|
1567061|NCT02476448|Drug|Normal saline|Used to distend the bladder for cystoscopic evaluation
1567062|NCT02476448|Drug|Phenazopyridine|Administered orally preoperatively and assessed during cystoscopy
1567063|NCT02476448|Drug|Dextrose 10%|Used to distend the bladder for cystoscopic evaluation
1567064|NCT02476448|Drug|Sodium Fluorescein|Administered intravenously and assessed during cystoscopy
1567067|NCT02476422|Drug|Diclofenac potassium|Single dose of diclofenac 50 mg soft gelatin capsule
1567068|NCT02476422|Drug|Ibuprofen|Single dose of ibuprofen 400 mg tablet
1567069|NCT02476422|Drug|Placebo to ibuprofen|Single dose of placebo to ibuprofen 400 mg tablet
1567070|NCT02476422|Drug|Placebo to diclofenac potassium|Single dose of placebo to diclofenac potassium 50 mg soft gelatin capsule
1567071|NCT02476409|Drug|tolvaptan|Study will test the addition of tolvaptan to augmentation of loop diuretic as standard of care for outpatients presenting with worsening heart failure.
1567072|NCT02476409|Other|Placebo|Placebo for tolvaptan
1567073|NCT02476396|Procedure|Carotid Endarterectomy|"Carotid endarterectomy is a procedure to treat carotid artery disease. This disease occurs when fatty, waxy deposits build up in one of the carotid arteries. The carotid arteries are blood vessels located on each side of your neck (carotid arteries).
This buildup of plaques (atherosclerosis) may restrict blood flow to your brain. Removing plaques causing the narrowing in the artery can improve blood flow in your carotid artery and reduce your risk of stroke.
In carotid endarterectomy, you an anesthetic. Your surgeon makes an incision along the front of your neck, opens your carotid artery and removes the plaques that are clogging your artery. Your surgeon then repairs the artery with stitches or a patch made with a vein or artificial material (patch graft).
Source: Mayo Clinic"
1567074|NCT02476383|Procedure|spinal manipulative therapy|refer to arm descriptions
1567075|NCT02476370|Behavioral|relaxation program|"relaxation and mindfulness techniques such as body scan, breathing meditation or imagination exercises
1 week programm, one introductory session and daily home practice"
1567076|NCT02476370|Behavioral|surgery education|"intensified education unit to reduce anxiety and stress, by using pictures and videos of rooms, and procedures of the planned surgery
1 single unit in the week before the surgery"
1567077|NCT02476357|Device|Harmonic scalpel|
1567078|NCT02476344|Other|experiment protocol|"each subject will perform the following 3 days experiment protocol, consisting of army training exercises:
sack carrying exercise.
crawling exercise.
combined exercise: sack carrying, crawling and sprints.
heart rate, core temperature, lactic acid and CPK levels will be monitored continuously."
1567079|NCT02476331|Behavioral|Working memory training|The neurocognitive training program will be provided by an online platform called BrainGymmer (https://www.braingymmer.com/en/brain-games/). The experimental group will complete the working memory training, which involves three games: N-back, Multi-Memory, and Moving Memory. These games are designed to engage processes involving updating and manipulation of information. All of the training games provided by BrainGymmer are adaptive, meaning that the level of difficulty increases as users develop expertise on a given task. Participants randomized to the cognitive training arm will complete the training games for 30 minutes per day, 5 days a week, for a total of 10 weeks.
1567080|NCT02476318|Device|ArterX Vascular Sealant|
1567081|NCT02476305|Device|"cryoprobes"|Patient undergo percutaneous cryoablation of desmoid tumor, with cryoprobes
1567082|NCT02476292|Other|online questionnaire|The online questionnaire includes questions about vasculitis, employment and work status before diagnosis and over the course of the disease, work capacity and the financial impact of vasculitis.
1567083|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP, NO prophylactic pancreatic stent placement|
1567084|NCT02476279|Other|Indomethacin 100 mg rectally immediately after ERCP AND prophylactic pancreatic stent placement|
1567085|NCT02476266|Other|Resistance Training|Resistance training has been shown to improve balance and muscle weakness in those with PD as well as reducing the number of falls experienced, albeit not significantly. However to date no study has investigated forms of resistance training in the same study. To disentangle which form of resistance training might be more effective at reducing the risk of falls, improving balance and muscle strength, the proposed study will compare power training and conventional strength training.
1567086|NCT02476253|Drug|Sodium Bicarbonate|Intravenous 4.2% Sodium Bicarbonate 125ml to 250ml / 30min up to 1000ml/24h to maintain plasma pH equal or greater than 7.30
1567087|NCT02476240|Behavioral|Parkinson's disease Sensory Attention Focused Exercise|The first half of the exercise class will include walking exercises that include large magnitude and coordinated movements. All walking will be performed slowly. Walking exercises will be followed by balance, stretching, and coordination exercises while sitting in, or standing near, standard office chairs, utilizing latex Thera-bands®. To ensure that balance and coordination are constantly challenged throughout the intervention, the exercise program progresses each week, increasing in difficulty. Depending on the task, the first set of each exercise will be performed with 'eyes-open' to familiarize participants with the task, and subsequent sets will be performed with 'eyes-closed'. If there is only one set for a specific exercise, the first half of the repetitions will be performed with 'eyes-open' and the second half with 'eyes-closed'.
1567088|NCT02476227|Procedure|Ablation using CARTO system|automated algorithm (Visitag)-based vs. manual collection of RF ablation points during AF ablation
1567089|NCT02476214|Behavioral|group prenatal care|"Intervention group Groups of 8-12 women who are in similar week of pregnancy / due date. The first group session will begin at 12-14 week (depends on gestational age at first OBGYN visit). The group meetings will be held once a month until 28 weeks of pregnancy. From 28 weeks and until the end of pregnancy or 40 weeks, it will be held once every two weeks (according to the Ministry of Health guidelines). The last session will be held approximately 6 weeks after birth.
There will be about 10 group sessions. Each session will be around 90 minutes. At the beginning of every group meeting, the nurse will preform a short anamnesis and measures in private, followed by discussion and guidance. At the end of the session, if needed, women can have private time with the nurse."
1567090|NCT02476201|Device|MPP ON|Patients implanted with a Cardiac Resynchronization Therapy CRT-D device and a Quartet Left Ventricular (LV) quadripolar lead and with the MultiPoint Pacing (MPP) feature activated
1567092|NCT02476175|Drug|Mirabegron|Patients will keep the antimuscarinic providing some efficacy and that is tolerated and Mirabegron will be added (dual therapy).
1567093|NCT02476162|Device|iHealth Wireless Blood Pressure Monitor|"Participants will be provided with an iHealth Wireless Blood Pressure (BP) Monitor and instructions for proper use (based on a standard protocol). The iHealth device pairs easily with a cell phone or other mobile device equipped with the iHealth app (freely available on app stores for both Apple and Android devices). Participants place the cuff on their arm and press start on their mobile device. The device measures BP using the oscillometric method and automatically downloads measurements and timing to a cloud-based server.
Participants will be educated that individual BP readings can be highly variable and that any one high or low reading has little or no significance. They will also be encouraged not to measure their blood pressure more than twice in the morning and twice in the evening."
1567094|NCT02476149|Procedure|Corneal Cross-linking|All participants recruited for the study will be scheduled for corneal crosslinking treatment
1567095|NCT02476136|Drug|paroxetine, duloxetine, fluoxetine or venlafaxine|
1567096|NCT02476123|Biological|Mogamulizumab: KW-0761, Nivolumab: (ONO-4538/BMS-936558)|i.v. administration
1567097|NCT02476110|Dietary Supplement|Oral nutritive supplements|
1567098|NCT02476097|Drug|Esomeprazole: Nexium® 20mg, Astra Zeneca|Comparison of the prevalence of clinical symptoms of acid rebound, between patients with progressive (esomeprazole ) or sudden (placebo) discontinuation of Proton pump inhibitors.
1567099|NCT02476097|Other|CYP2C19 phenotypical analysis|All patients included will undergo an assessment of the CYP2C19 activity by the administration of omeprazole 40mg and following measurement of omeprazole metabolic ratio respectively, once during the study.
1567100|NCT02476097|Drug|Placebo|
1567105|NCT02476071|Other|Mass media|Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
1567106|NCT02476071|Other|Stylish Man (SMEvent)|"Stylish Man Events: community mobilization via music, contests, testimonials from satisfied VMC adopters. Messages on how VMC, in conjunction with other HIV prevention, can make men feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.
The Stylish Man Van (SMV) accompanies the SMEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages."
1567107|NCT02476058|Drug|JNJ-42847922|JNJ-428479, 20 milligram (mg) capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
1567108|NCT02476058|Drug|Diphenhydramine|Diphenhydramine 25 mg capsule, orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
1567109|NCT02476058|Drug|Placebo|Matching placebo (capsules containing neutral pellets), orally, once daily, at bedtime for 10 days in women of childbearing potential (WOCBP) or for 4 weeks in all other participants.
1567110|NCT02476045|Drug|5-fluorouracil,leucovorin,panitumumab|Maintenance treatment (ARM A)
1567111|NCT02476045|Drug|panitumumab|Maintenance treatment (ARM B)
1567112|NCT02476045|Drug|Oxaliplatin, 5-fluorouracil,leucovorin,panitumumab|Induction treatment
1567115|NCT02476019|Drug|ISIS-FGFR4RX|ISIS-FGFR4RX administered subcutaneously
1567116|NCT02476019|Drug|Placebo|Placebo administered subcutaneously
1567117|NCT02476006|Drug|ALIROCUMAB SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
1567118|NCT02476006|Drug|placebo (for injection training only)|Pharmaceutical form:solution Route of administration: subcutaneous
1567119|NCT02475993|Device|SMART app|Subjects assigned to the intervention group will be given the pre-programmed SMART app on an iPad mini loaned to you for use during the study along with the medication plan as outlined in the discharge instructions and an appointment within 12 days. This will include SCD-related medications. Subjects will be asked to log entries each time they take their medications and will be reminded by SMART to take their medications based on their advised schedule. Follow up appointment time and date are also programmed into SMART, and reminders are given to the subject 3 days prior and on the day of appointment. Compliance will also be confirmed by pill count of all medications at the 30-day visit.
1567120|NCT02475980|Behavioral|Comprehensive contraception counseling|The study intervention will consist of comprehensive contraceptive counseling through a standardized bundle of services, including a 10-minute educational DVD, handouts on contraceptive methods, and one-on-one contraceptive counseling by the PED physician.
1567229|NCT02475226|Other|type of the brain injury|subdural hematoma
1567230|NCT02475226|Other|type of the brain injury|subarachnoid hematoma
1567121|NCT02475967|Other|Intervention group|The intervention group patients have access to the eLearning platform in addition to conventional cardiac care.The content of platform will be gathered from a multidisciplinary input of both medics (e.g. cardiologists) and paramedics (e.g. psychologists). Patients will also contribute to platform content.
1567122|NCT02475967|Other|Control group|The control group patients receive conventional cardiac care alone.
1567125|NCT02475941|Other|Non Weight bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).
The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
1567126|NCT02475941|Other|Early Weight Bearing|"The design will be a surgeon based prospective cohort supported in the literature to answer research questions in which surgeons may have a preferred treatment type. Each surgeon will treat study subjects by his or her single chosen method (weight bearing as tolerated post operatively versus non weight bearing).
The benefits of early weight bearing are accelerated functional recovery, increased independence, decreased impact on the family, increased psychological benefits, reduced use of healthcare resources, decreased need for family intervention, and family to take care of the patient."
1567127|NCT02475928|Dietary Supplement|zinc gluconate|Zinc supplementation plus nutritional education
1567128|NCT02475928|Dietary Supplement|Placebo|
1567129|NCT02475928|Behavioral|Nutritional education|
1567130|NCT02475915|Drug|Vorinostat|Vorinostat (suberoylanilide hydroxamic acid) inhibits histone deacetylases class I and II. Vorinostat is supplied as 100mg capsules and will be administered at 400mg/ day in 2 week cycles beginning at week 0 for 10 weeks - 42 doses.
1567131|NCT02475915|Drug|Hydroxychloroquine|Hydroxychloroquine is supplied as 200mg tablets and will be administered at week 0 for 10 weeks
1567132|NCT02475915|Drug|Maraviroc|Maraviroc will be administered at 150 to 600mg/ml twice daily depending on the subject's ART regimen at week 0 for 10 weeks
1567133|NCT02475915|Drug|Tenofovir|NRTI. Tenofovir will be administered at 300mg 1 X day at week 0 for 10 weeks
1567134|NCT02475915|Drug|Emtricitabine|NRTI. Emtricitabine will be administered at 200mg 1 X day at week 0 for 10 weeks
1567135|NCT02475915|Drug|Efavirenz|NNRTI. Efavirenz will be administered at 600 mg 1 X day at week 0 for 10 weeks
1567136|NCT02475915|Drug|Darunavir|Protease Inhibitor. Darunavir will be administered at a dose of 900mg 1 X day for subjects on NNRTI based ART beginning at week 8 until week 10
1567137|NCT02475902|Behavioral|Computer guided home exercise program|Participants will follow a computerized fall prevention home exercise program with MS Kinect camera tracking 3 times per week for one month.
1567138|NCT02475902|Behavioral|Paper guided home exercise program|Participants will follow a fall prevention home exercise program outlined in a paper booklet 3 times per week for one month.
1567139|NCT02475889|Procedure|Hepatic RFA|Hepatic RFA was performed under guidace of ultrasonography (US) or computed tomography (CT) before primary tumor resection.
1567140|NCT02475889|Procedure|Primary tumor resection|Primary tumor resection were performed pre- or post-RFA for liver metastases.
1567141|NCT02475876|Drug|Clindamycin|"Route of administration is IV for all Cohorts. Dosing interval is every 8 hrs. for all Cohorts:
Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 9 mg/kg;
Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose =12 mg/kg;
Cohort 3; No. Subjects = 5; Age >1-2 years; Dose =12 mg/kg.
Cohort 4; No. Subjects = 4; Age >2-6 years; Dose =12 mg/kg.
Cohort 5; No. Subjects = 4; Age >6-12 years; Dose =10 mg/kg.
Cohort 6; No. Subjects = 4; Age >12-16 years; Dose =10 mg/kg."
1567142|NCT02475876|Drug|trimethoprim-sulfamethoxazole|"Route of administration is PO for all Cohorts. Dosing interval is every 12 hrs. for all Cohorts:
Cohort 1; No. Subjects = 5; Age 1-5 months; Dose = 6 mg/kg.
Cohort 2; No. Subjects = 5; Age >5 months to 1 year; Dose = 6 mg/kg.
Cohort 3; No. Subjects = 5; Age >1-2 years; Dose = 6 mg/kg.
Cohort 4; No. Subjects = 4; Age >2-6 years; Dose = 6 mg/kg.
Cohort 5; No. Subjects = 4; Age >6-12 years; Dose = 6 mg/kg.
Cohort 6; No. Subjects = 4; Age >12-16 years; Dose = 4 mg/kg."
1567143|NCT02475863|Device|Warfarin Dosing Aid|A pharmacokinetic/pharmacodynamic model-based dosing algorithm for warfarin
1567144|NCT02475863|Other|Standard Practice|Warfarin dose adjustments according to standard unit protocol
1567145|NCT02475850|Other|Evidence-based tailored fall prevention|
1567146|NCT02475850|Other|Usual care|
1567147|NCT02475837|Drug|Vorapaxar sulfate|The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.
1567148|NCT02475837|Drug|Placebo|The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
1567149|NCT02475824|Drug|Midazolam®|midazolam (0.05 mg/kg, 30% reduction for patients if age ≥70 or ASA class III-IV; Bukwang Pharm Co., Seoul, Republic of Korea)
1567150|NCT02475824|Drug|"Meperidine (pethidine®)"|Meperidine (50mg. 25mg for patients aged ≥70 years; pethidine HCL, Hana Pharm Co., Seoul, Republic of Korea).
1567151|NCT02475824|Drug|Propofol®|Repeated doses of 10-20 mg propofol are titrated to achieve the target level of sedation.
1567152|NCT02475824|Drug|Dexmedetomidine (Precedex®)|Dexmedetomidine (1μg/kg/h, Precedex; Hospira, Seoul, Republic of Korea) or the same volume of normal saline were administered in the MMD and midazolam-meperidine group
1567231|NCT02475226|Other|type of the brain injury|intraparenchymal hematoma
1567232|NCT02475226|Other|type of the brain injury|scull fracture
1567233|NCT02475226|Other|type of the brain injury|brain contusion
1567153|NCT02475811|Radiation|3D ultrasonography|The angle of volume sampling varied throughout gestational age with a maximum limit of 75° in the third trimester. After scanning the volume, multiplanar imaging in the 3 orthogonal ultrasonographic sections was analyzed to reconstruct the 3D ultrasound image. Before its volume was analyzed, each lung was carefully identified on the 3 orthogonal multiplanar imaging sections. We used the rotational technique that entails the VOCAL imaging program to measure lung volume. A transverse section of the multiplanar imaging was chosen as the reference image for volume analyses
1567154|NCT02475798|Device|Zenith® Branch Endovascular Graft-Iliac Bifurcation,|Implantation of the following devices: Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Atrium iCAST™, and the Zenith® Flex AAA Endovascular Graft.
1567155|NCT02475785|Device|FFRD and mini plates group|FFRD direct loading over mini plates inserted in the mandibular symphysis
1567156|NCT02475785|Device|Conventional FFRD|FFRD inserted between maxillary and mandibular arches with the pushrods placed distal to mandibular canines
1567157|NCT02475772|Drug|Cisplatin and doxorubicin|The first 5 patients will receive doxorubicin 1.5 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 7.5 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 2.25 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 11.25 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. The next 5 patients will receive doxorubicin 3 mg/m2 body surface in 50 ml NaCl 0,9% and cisplatin 15 mg/m2 in 50 ml NaCl 0,9% q 4 weeks for three courses. This schedule represents a three-step, 50% dose-escalation. Dose density will not be changed.
1567158|NCT02475772|Procedure|Cisplatin and doxorubicin|intraperitoneal chemotherapy with cisplatin and doxorubicin in a dose-escalation scheme
1567159|NCT02475759|Dietary Supplement|optimal caloric formula|nutritional intervention received two weeks before surgical intervention
1567160|NCT02475759|Dietary Supplement|sub-optimal caloric formula|nutritional intervention received one weeks before surgical intervention
1567161|NCT02475746|Drug|PF-06372865|single dose of 7.5 mg PF-06372865 alone (period 1) or co-administered with itraconazole (period 2)
1567162|NCT02475746|Drug|itraconazole|Interacting drug which will be given 200 mg QD for 8 days in period 2
1567163|NCT02475733|Drug|Ceftazidime -avibactam|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
1567164|NCT02475733|Drug|Meropenem|Randomisation (3:1) to CAZ AVI plus metronidazole or meropenem treatment
1567165|NCT02475733|Drug|Metronidazole|Randomisation (3:1) to ceftazidime -avibactam plus metronidazole or meropenem treatment
1567166|NCT02475707|Biological|MultiTAA-specific T cells|"The 3 dose levels are:
Dose Level 1: 5 x 10e6 cells/m2; Dose Level 2: 1 x 10e7 cells/m2; Dose Level 3: 2 x 10e7 cells/m2
The T cells are given from 30 days post-HSCT. They are administered by intravenous injection over 1-10 minutes through either a peripheral or a central line.
Patients being treated on Arm A (adjuvant) or Arm B (active disease) who have a partial response, complete response or stable disease, will be eligible to receive up to 6 further doses of multiTAA-specific T cells at the same dose as the initial infusions at a minimum of 4 weeks apart."
1567167|NCT02475694|Other|No intervention|No treatment
1567168|NCT02475681|Drug|Acalabrutinib|
1567169|NCT02475681|Drug|Obinutuzumab|
1567170|NCT02475681|Drug|Chlorambucil|
1567171|NCT02475668|Device|Pulse oximeter|Hypoxia
1567172|NCT02475655|Drug|Ruxolitinib|10 mg orally twice daily for 5 weeks
1567173|NCT02475642|Other|PVI-ADT|Discontinue antiarrhythmic drugs at randomisation (3 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are discontinued at the moment of randomisation in this arm
1567174|NCT02475642|Other|PVI+ADT|Discontinue antiarrhythmic drugs 9 months after randomisation (12 months post ablation). As per the eligibility criteria, all patients randomised are taking either Flecainide, Cibenzoline, Propafenon, Sotalol or Amiodarone. These are continued in this arm until 9 months post randomisation at which point they are stopped
1567175|NCT02475629|Biological|ibalizumab|2000mg intravenous ibalizumab (loading dose), followed 14 days later by 800mg intravenous ibalizumab every 2 weeks
1567176|NCT02475629|Drug|Optimized Background Regimen (OBR)|All participants will be prescribed an Optimized Background Regimen of antiretroviral medications selected on the basis of treatment history and the results of Screening viral resistance and tropism testing. The prescribed regimen must contain at least one agent to which the participant's virus is known to be sensitive.
1567177|NCT02475616|Drug|PCO371|
1567178|NCT02475616|Drug|Placebo|
1567179|NCT02475603|Procedure|Total knee arthroplasty|Total knee arthroplasty
1567180|NCT02475590|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy
1567181|NCT02475590|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
1567182|NCT02475577|Device|Peripherals with HealthInterlink technology|home remote monitoring
1567183|NCT02475564|Drug|Placebo|40mg of starch
1567184|NCT02475564|Drug|Resveratrol|40mg of resveratrol (powder)
1567185|NCT02475551|Drug|IdeS|Intravenous infusion
1567186|NCT02475538|Device|Electroacupuncture|"Gradual Tapering Benzodiazepines will be tapered off over four weeks. The subjects will be told by a blinded researcher to reduce their daily dose by 25% in the 1st and 2nd week. For the remaining 50%, subjects will be asked to reduce the dose by 12.5% each time for 3-4 days in the 3rd and 4th week. Subjects who are unable to taper according to the suggested plan can reduce dose at a slower pace.
Electroacupuncture The subjects will be treated with electroacupuncture at bilateral Sishencong (EX-HN1), Anmian, Shuaigu (GB8), Touwei (ST8), Taiyang (EX-HN5), Toulinqi (GB15), Neiguan (PC6), Shenmen (HT7), Sanyinjiao (SP6), Taichong (LV3), and unilateral Yintang (EX-HN3), Shenting (GV24), and Baihui (GV20). De qi is achieved if possible. The intensity of electric-stimulation will be adjusted up to a level the subject can tolerate without undue discomfort. The needles will be left for 30 min."
1567234|NCT02475213|Biological|Enoblituzumab|enoblituzumab is administered by IV infusion once per week for up to 51 doses.
1567235|NCT02475213|Biological|Pembrolizumab|Pembrolizumab is administered by IV infusion every 3 weeks for up to 17 doses.
1567236|NCT02475200|Device|Atherectomy|Selectively cut and remove atheromatous plaque in the lower extremities. Debulking and removal of atherosclerotic burden plaque with Phoenix Atherectomy System.
1567237|NCT02475174|Other|Without upper limb elevation|Lymphatic drainage without elevation of the upper limb.
1567187|NCT02475538|Device|Placebo acupuncture|"Gradual Tapering The gradual tapering procedure will be the same as in the Electroacupuncture combined with gradual tapering group.
Placebo acupuncture Placebo needles designed by Streitberger will be used. The placebo needles are inserted to the site 1 inch beside the acupoints of the electroacupuncture group in order to avoid acupressure effect. The needles are held by surgical tape or hair pin to imitate the procedure of acupuncture. The needles are connected to an electric-stimulator with zero frequency and amplitude. The number, duration and frequency of treatment session will be the same as in the Electroacupuncture combined with gradual tapering group."
1567188|NCT02475525|Dietary Supplement|Arginine enriched oral nutritional supplement|oral nutritional supplement containing arginine
1567189|NCT02475512|Other|Wash wipes (3M)|
1567190|NCT02475512|Other|water and pH neutral soap|
1567191|NCT02475499|Drug|DPP-4 inhibitors|Ever-use of DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
1567192|NCT02475499|Drug|GLP-1 analogs|Ever-use of GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
1567193|NCT02475499|Drug|Sulfonylureas|Ever-use of sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
1567194|NCT02475499|Drug|Biguanides|Ever-use of biguanides (ATC A10BA) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
1567195|NCT02475499|Drug|Thiazolidinediones|Ever-use of thiazolidinediones (ATC A10BG) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
1567196|NCT02475499|Drug|Alpha-glucosidase inhibitors|Ever-use of alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
1567197|NCT02475499|Drug|Meglitinides|Ever-use of meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription occurring between (and including) base cohort entry and the index day - 365 days.
1567198|NCT02475486|Device|VistaO2|ANS (sympathetic nervous system) parameters are measured by VistaO2 device in RA patients
1567199|NCT02475473|Other|Exercise Training|Chronic High-Intensity Resistance Training
1567200|NCT02475460|Procedure|Less Invasive Surgery (LIS)|Less invasive HM 3 LVAD surgical implant procedure
1567201|NCT02475460|Device|HeartMate 3™|HM 3 LIS
1567202|NCT02475447|Drug|Asimadoline|kappa-opioid receptor agonist
1567203|NCT02475447|Drug|Placebo|placebo-matched control
1567204|NCT02475434|Dietary Supplement|Cream Supplement group|Infants in the intervention arm will receive the cream supplement in addition to the standard regimen.
1567205|NCT02475421|Biological|Glucagon|One hour glucagon-clamp followed by one hour of blood sampling
1567206|NCT02475408|Device|Amplatzer vascular plug|
1567208|NCT02475382|Drug|Nivolumab|Specified dose on specified days
1567209|NCT02475369|Drug|pancrelipase|
1567211|NCT02475343|Device|Schiotz tonometer|The corneal biomechanical properties will be measured using a Schiotz tonometer with routine manipulation protocol.This measurement will be used in normal people, keratoconic patients, patients received keratoplasty.
1567212|NCT02475343|Device|UVA/riboflavin|The UVA/riboflavin corneal crosslinking will be applied using a UV-X lamp (Peschke Meditrade GmbH, Switzerland) with routine manipulation protocol (3mW/cm2, 365nm, 30 minutes).This treatment will be used in keratoconic patients.
1567213|NCT02475343|Device|femto-LASIK|The keratoplasty mainly include femto-LASIK (Laser in situ keratomileusis), which will be applied using a Wavelight FS200 and Wavelight EX500 Excimer Laser (Alcon Inc. USA.).The keratoplasty will be applied in patients who would like to receive the surgery.
1567214|NCT02475343|Device|Tomey SP-100 Pchymeter , Topolyzer Vario|Cornea thickness will be measured with a pachymeter (Tomey SP-100 Pchymeter, Japan); cornea topography will be measured with Topolyzer Vario (Allegro, Wavelight GmBH, Germany); anterior chamber depth, white to white, and ocular axis length will be measured using a IOL master (Carl Zeiss Meditec, Germany). These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
1567215|NCT02475343|Device|Topcon CT-80, Topcon, Japan|Vision acuity will be measured with a decimal visual chart; IOP (Intra-ocular pressure) will be measured with a tonometer (Topcon CT-80, Topcon, Japan) , fundoscopy examination will be apllied with a direct ophthalmoscopy, slit lamp examination will be applied with a slit lamp. These examinations will be used in normal people, keratoconic patients, patients received keratoplasty.
1567216|NCT02475343|Device|Corvis-ST|Cornea biomechanical properties will be measured with a ocular response analyzer (Reichert, USA.) and/or a Corvis-ST (Oculus, Germany).These measurements will be used in normal people, keratoconic patients, patients received keratoplasty.
1567217|NCT02475330|Dietary Supplement|Flaxseed|Whole grain flaxseed diet consisting of 40g flaxseed ingested per day
1567221|NCT02475304|Drug|FP187|FP 187 is given as oral tablets twice daily, 500 mg daily
1567222|NCT02475304|Drug|Placebo|
1567223|NCT02475278|Biological|NoV GI.1/GII.4 Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with aluminum hydroxide for IM injection
1567224|NCT02475265|Drug|estradiol 0.045 mg/levonorgestrel 0.015mg|
1567225|NCT02475252|Procedure|hysteroscopy on a training model|Diagnostic hysteroscopy on a diagnostic hysteroscopy training model using a pelvic dummy and all surgical instruments also used in the original procedure. The performance of all participants will be scored using an OSATS scoring sheet developed for assessing surgical proficiency.
1567226|NCT02475239|Behavioral|Postural restriction|The patients were instructed to avoid head movements, wear a soft collar during the daytime, wear a supporting pillow and sleep in the semi-upright position at a 45 degree head elevation from the horizontal plane during the nighttime for 48 hours.
1568502|NCT02466308|Device|SAM Ultrasound Diathermy Device|
1567238|NCT02475174|Other|Upper limb elevation to 30º|Lymphatic drainage with elevation of the upper limb to 30º.
1567239|NCT02475161|Drug|JNJ-42847922|JNJ-42847922 will be administered as 20 mg tablet orally.
1567240|NCT02475161|Drug|Rabeprazole|Rabeprazole will be administered as 20 mg tablet orally.
1567241|NCT02475148|Drug|JNJ 54175446|
1567242|NCT02475148|Drug|Placebo|
1567243|NCT02475148|Other|High fat/high Calorie Breakfast|
1567251|NCT02475122|Other|azygos blood flow measurements by MRI|
1567252|NCT02475109|Drug|PAN-90806 Ophthalmic Solution|
1567253|NCT02475096|Behavioral|Internet-delivered CBT|"The treatment is based on an internet-delivered CBT-treatment for adults with IBS and on the adapted version for adolescents with functional gastrointestinal disorders. The protocol has been tested in an open face-to-face CBT study of children aged 8-12 years (n=20) with promising results.
Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the child, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire."
1567254|NCT02475083|Other|Virtual Reality|Rehabilitation with virtual reality, using Football games, Boxe, Bambolê and Tennis.
1567255|NCT02475083|Other|Conventional|Stretching exercises in limbs, trunk mobilization in the three planes, balance training in standing position, training of balance reactions and gait training.
1567256|NCT02475070|Drug|Vildagliptin|Vildagliptin added at 50 mg twice daily for two weeks followed by four weeks washout and then dapagliflozin 10mg once daily for two weeks
1567257|NCT02475070|Drug|Dapagliflozin|Dapagliflozin added at 10 mg once daily for two weeks followed by four weeks washout and then vildagliptin 50 mg twice daily for two weeks
1567258|NCT02475057|Drug|Degarelix (LHRH antagonist)|Two initial loading doses of 120mg Degarelix for 1 month followed by 80mg monthly for eleven additional months.
1567259|NCT02475057|Drug|LHRH agonist|LHRH agonist at the discretion of the treating Urologist/Oncologist for 1 year.
1567260|NCT02475057|Device|EndoPAT2000|Peripheral arterial plethysmography using an EndoPAT2000 device
1567261|NCT02475044|Behavioral|Cognitive-Behavioral Therapy|16 Sessions of CBT.
1567262|NCT02475031|Device|TAP-C|TAP catheters with ropivacaine infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
1567263|NCT02475031|Drug|TAP-S|Catheters with saline infusion are inserted into the TAP area after a single shot TAP block. Single shot TAP block is performed using 30ml 0.5% ropivacaine at the end of the case.
1567264|NCT02475018|Dietary Supplement|Milk fortified with plant sterol esters|250mL of Shuhua milk fortified with plant sterol esters(with plant sterol esters 262mg/100mL) has been taken twice per day. 500mL of Shuhua milk in total has been taken per day during the 60-days intervention.
1567265|NCT02475018|Dietary Supplement|Plain milk|250mL of placebo milk (plain milk) has been taken twice per day. 500mL of plain milk in total has been taken per day during the 60-days intervention.
1567266|NCT02475005|Behavioral|pain self management app on smartphone|
1567267|NCT02474992|Behavioral|Microclinic|Individuals randomized to this arm will be invited to recruit members of their social network to form a health team, or microclinic. These groups will proceed through a discussion-based health education curriculum led by local community health workers. Topics will include HIV biology, medications, the importance of social support, and community outreach for reducing HIV stigma. The curriculum will conclude with an opportunity for all group members to disclose their HIV status to one another.
1567268|NCT02474979|Device|CBPM-system|The bed is equipped with a pressure sensing mat including thousands of sensors. It is connected with a monitor that continuously registers the pressure between the body and the bed surface (interface pressure). The pressure is indicated by colors, where warmer colors indicate higher pressure.
1567269|NCT02474979|Other|Control|
1567270|NCT02474966|Device|Deep Transcranial Magnetic Stimulation (dTMS)|Patients will present on two consecutive days in order to receive dTMS followed by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI). Subjects will be randomized into two groups: the first group will be treated before with real-dTMS (the first day) and after with sham-dTMS (the second day); the second group will be treated before with sham-dTMS (the first day) and after with realTMS (the second day). At the end of each session of dTMS the patients will undergo by MRI exams.
1567271|NCT02474953|Dietary Supplement|Proprietary Curcumin Formulation|
1567272|NCT02474953|Dietary Supplement|Unformulated Comparator Curcumin Product|
1567273|NCT02474940|Behavioral|Intervention #1|Intervention #1 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve neurofeedback training. During neurofeedback training, sensors will be placed on a subject's head and ears, and s/he will be able to hear sounds on a computer that correspond to his/her brainwaves. The subject will learn how to change his/her brainwaves by changing the sounds heard. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one neurofeedback training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will also be done during two of the 11 sessions.
1567274|NCT02474940|Behavioral|Intervention #2|Intervention #2 consists of 11 treatment sessions over 6-12 weeks (1-2 sessions/week on average). Sessions 1-6 will involve mindfulness meditation training. During mindfulness training, subjects will be asked to focus their attention on an object of awareness, such as their breath. Subjects will then be asked to focus on their feelings/thoughts during the training. Session 7 will be a face-to-face self-hypnosis session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In sessions 8-11, subjects will listen to an audio recording of a self-hypnosis training session. Subjects will complete one mindfulness meditation training session immediately before each of these four hypnosis sessions. A relaxation and hypnotic exercise will be done during two of the 11 sessions. On three of the 11 sessions, research staff will also place sensors on a subject's head and ears to measure brainwaves.
1567275|NCT02474940|Behavioral|Intervention #3|Intervention #3 consists of five treatment sessions of self-hypnosis training during the treatment phase of the study (1-2 sessions/week on average). The treatment phase of the study will last about 6-12 weeks. During the first 4-5 weeks, subjects in Intervention #3 will not be asked by study researchers to do anything. At the end of this waiting period, subjects will complete a set of telephone interviews. Subjects will then attend one face-to-face self-hypnosis training session. During self-hypnosis training, subjects will learn to enter a state of focused attention, and then change how he/she experiences pain and/or fatigue. In the last four sessions, subjects will listen to an audio recording of a self-hypnosis training session. A relaxation and hypnotic exercise will also be done during two of the five sessions.
1567276|NCT02474927|Drug|Carfilzomib|Carfilzomib will be used in combination with the conventional therapy (plasma exchange and intravenous immunoglobulins)
1567277|NCT02474914|Drug|Octreotide|Octreotide will be given after PD
1567278|NCT02474914|Drug|Placebo|Octreotide will NOT be given after PD
1567281|NCT02474875|Other|Educational program|Patients in experimental groups will receive different educational sessions (contents and duration)
1567282|NCT02474862|Behavioral|Prenatal Walking Program|PWP is a gentle walking intervention tailored for pregnant women.
1567283|NCT02474862|Behavioral|Postpartum Prep Program|PPP participants will attend individually education sessions matched in number and duration to the sessions in PWP. PPP involves providing health information particularly relevant to expectant mothers, including both maternal and newborn well being.
1567284|NCT02474849|Other|Use electronic cigarette or smoke conventional cigarette|Use of electronic cigarette or smoking conventional cigarette ad libitum for 5 minute period
1567285|NCT02474836|Biological|Skin Prick Test - Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
1567286|NCT02474836|Biological|Skin Prick Test - Non Atopic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
1567287|NCT02474836|Biological|Skin Prick Test - Allergic subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
1567288|NCT02474823|Other|polysomnogram|all participants will undergo PSG for assessment of OSA
1567289|NCT02474823|Other|home sleep test|all participants will undergo HST for assessment of OSA
1567290|NCT02474823|Other|Easy Sleep Apnea Predictor|all participants will undergo ESAP for assessment of OSA
1567291|NCT02474810|Drug|Alteplase|Alteplase for CVC dysfunction.
1567292|NCT02474797|Device|Diaphragmatic ultrasonography|"Daily Measure of Diaphragmatic Thickening Fraction (DTF) will be performed by a trained physiotherapist. Physiotherapist (A. LE NEINDRE). The patient will be then instructed to perform breathing to total lung capacity and then to exhale to residual volume, when it is possible (awaken patient). Awakening status will be recorded. Mechanically ventilated patients will be evaluated in Pressure Support (PS) mode (during daily PS mode research for patients with Controlled Ventilation), with the lower PS level tolerated. PS level will be recorded.
Thickening fraction (TF) measure is performed in B-mode using the following formula: TF (%) = [(end-inspiration thickness - end-expiration thickness)/(end-expiration thickness) x 100]. Diaphragmatic dysfunction is defined like a DTF < 20% (7)."
1567293|NCT02474004|Procedure|medial meniscal surgery|one group/arm has meniscal repair as part of clinical routine one group/arm has meniscal partial resection as part of clinical routine both groups have gait analysis & knee scores 6 mo after the procedures
1567294|NCT02474745|Procedure|- Directed open-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:
After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible
Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:
After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
1567334|NCT02474485|Procedure|Control coronary angiography.|Control coronary angiography will be performed at 9 month follow-up.
1567335|NCT02474485|Procedure|OCT visualization.|OCT visualization will be performed during index procedure and at 9 month follow-up.
1567336|NCT02474485|Other|Clinical observation.|Patients will be informed that Investigator will contact them at 12, 24 and 60 months after the procedure. Investigator will collect information regarding clinical status of Patients, cardiac medications and any adverse events that occurred since the last follow-up.
1567337|NCT02474472|Drug|bupivacaine hydrochloride|
1567295|NCT02474745|Procedure|Directed closed-glottis pushing|"Description of the intervention in the intervention group: Directed open-glottis pushing (with prolonged exhalation) must be explained to the women and professionals as follows:
After inhaling deeply, the patient will exhale while pulling in her stomach in such a way they she can use the contraction of her abdominal muscles to help the fetus descend through the birth control. She should push as long as possible
Description of the intervention in the control group: Directed closed-glottis pushing (pushing while holding one's breath) should be explained to the women and professionals as follows:
After inhaling deeply, the patient should push very hard downwards to the perineum, while holding the inhaled breath in her lungs. She should push as hard and as long as possible."
1567296|NCT02474732|Device|Beactive(r) Brace|Determine if the subjects are able to understand and follow the directions to apply the Beactive Brace.
1567297|NCT02474719|Other|comparison of two regimens in peritoneal dialysis|Dialysate samples (8 by scheme, volume of 10 mL) are collected at each cycle (one at the beginning and one at the end of the cycle). A blood sample (5 mL) is collected at the beginning of the second scheme and a 24-hour urine sample at the end of the second scheme.
1567298|NCT02474706|Drug|Cefoxitin|
1567299|NCT02474706|Drug|imipenem|
1567300|NCT02474680|Genetic|Pharmacogenetic testing|Psychotropic genotyping panel
1567301|NCT02474667|Drug|BB3|
1567302|NCT02474667|Other|Placebo|
1567303|NCT02474654|Drug|Bupivicaine|15mg
1567304|NCT02474654|Drug|Fentanyl|15mcg
1567305|NCT02474654|Drug|Epimorphine|150mcg
1567306|NCT02474654|Drug|Normal Saline|0.3 ml
1567307|NCT02474654|Drug|Normal Saline|30ml
1567308|NCT02474654|Drug|Normal Saline|100 ml
1567309|NCT02474654|Drug|Ropivicaine|100 ml
1567310|NCT02474654|Drug|Epinephrine|600 mcg
1567311|NCT02474654|Drug|Ketorolac|30 mg
1567312|NCT02474654|Drug|Ropivicaine with Epinephrine|0.5% 1:400,000 30ml
1567313|NCT02474641|Radiation|Standard Radiation|"Conventionally fractionated radiotherapy of the breast followed by a tumor bed boost sequentially or
Conventionally fractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed or
Hypofractionated radiotherapy of the breast followed by a tumor bed boost sequentially"
1567314|NCT02474641|Radiation|Hypofractionation with SIB|Hypofractionated radiotherapy of the breast with simultaneous integrated boost to the tumor bed
1567315|NCT02474628|Dietary Supplement|sodium bicarbonate|
1567316|NCT02474628|Dietary Supplement|calcium carbonate|
1567317|NCT02474615|Procedure|ENDODONTIC SURGERY|ENDODONTIC SURGERY
1567318|NCT02474602|Device|Active or Placebo Phototherapy (MR4)|Participants performed a strength training. Forty-eight subjects practiced a training protocol with 80% of the load, measured through 1-repetition maximum test. The strength training lasted 12 weeks and the evaluations were done monthly. Phototherapy, active or placebo, were applied in 6 different points of quadriceps muscle depending the group randomized, before and after each training session.
1567322|NCT02474563|Drug|Bortezomib|Participants receiving Bortezomib 1.3 milligram per square meter (mg/m2) will be observed in this study.
1567323|NCT02474563|Drug|Melphalan|Participants receiving Melphalan 9 mg/m^2 will be observed in this study.
1567324|NCT02474563|Drug|Prednisone|Participants receiving Prednisone 60 mg/m^2 will be observed in this study.
1567325|NCT02474537|Drug|INC280|Single 200 mg dose INC280
1567326|NCT02474524|Behavioral|Health intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker, in addition to their routine care. Sessions will be structured by the worker and participant using a tablet computer to view materials on mental health self-management and personal recovery on a dedicated website for the trial. These will include information, videos, audio and exercises. Online materials make particular use of videos featuring people with lived experience of psychosis discussing how they have dealt with issues in their recovery, and will allow users to post comments on videos and in a forum. Participants may access online materials both during intervention sessions and outside sessions using any Internet-enabled device.
1567327|NCT02474524|Behavioral|Social intervention|Participants will receive 8 50-minute sessions during a 3 month window with a mental health worker in addition to routine care (treatment as usual). The social intervention will utilise a computer tablet (i.e., iPad) servicing online resources to extend a manualised befriending intervention, based upon social interaction, designed to control for therapist contact and computer use. Each session will involve interaction about non-health related topics of interest to the participants, which will be facilitated by use of viewing online material related to these interests on a tablet computer as a prompt to conversation.
1567328|NCT02474511|Other|general anesthesia and local anesthesia|the patient received generalanesthesia and local anesthesia randomly
1567329|NCT02474498|Drug|EMD|During flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments. The furcation defects in this group will receive the application of enamel matrix derivative (EMD - Emdogain® Straumann, Basel, Switzerland).
1567330|NCT02474498|Device|βTCP/HA|During flap access surgery, the granulation tissue will be removed and the root surfaces were carefully instrumented with ultrasonic and hand instruments. The furcation will be filled with a bone substitute consisting of beta tricalcium phosphate/hydroxyapatite (βTCP/HA- Bone Ceramic® Straumann, Basel, Switzerland)
1567331|NCT02474498|Procedure|Flap access surgery|In the furcation sites, during flap access surgery, the granulation tissue will be removed and the root surfaces will be carefully instrumented with ultrasonic and hand instruments.
1567332|NCT02474485|Device|BVS Absorb implantation.|Absorb bioresorbable vascular scaffold will be implanted to treat in stent restenosis in target vessel.
1567333|NCT02474485|Device|DEB Sequent Please inflation.|Inflation of drug eluting balloon Sequent Please will be performed to treat in stent restenosis in target vessel.
1567339|NCT02474459|Device|iPad-Based Clinical Support Care|Subjects in this treatment arm will receive deep brain stimulation (DBS) programming at regular intervals as part of routine clinical care. DBS stimulation programming will be done with the use of a iPad-based decision support system.
1567340|NCT02474459|Other|Standard Clinical Care|Subjects in this treatment arm will receive DBS programming at regular intervals as part of routine clinical care.
1567341|NCT02474446|Dietary Supplement|Vitamin D|150,000 IU of Vitamin D3 Oral solution
1567342|NCT02474433|Drug|Misoprostol (Cytotec)|
1567343|NCT02474420|Drug|Amlodipine|amlodipine titrated up to 10 mg daily or maximum tolerated dose, whichever comes first
1567344|NCT02474420|Drug|Deferasirox|Deferasirox administered per standard of care by the treating physician
1567345|NCT02474407|Drug|diazepam nasal spray|
1567346|NCT02474407|Drug|diazepam rectal gel|
1567347|NCT02474394|Device|Mcgrath|The patient will be intubated using McGrath series 5 video laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
1567348|NCT02474394|Device|Macintosh|The patient will be intubated using Macintosh laryngoscope and the intraocular pressure of the patient will be evaluated with Tonopen XL tonometer
1567349|NCT02474381|Biological|EPCs plus PTA|Intra-arterial infusion of autologous CD133+ cells on diabetic subjects with PAD,plus angioplasty
1567350|NCT02474381|Device|Single PTA|Angioplasty of arteries below tibial plateau level only
1567351|NCT02474368|Radiation|Intensity Modulated Radiation Therapy (IMRT)|
1567352|NCT02474368|Drug|Cisplatin|
1567353|NCT02474368|Radiation|Stereotactic Body Radiotherapy (SBRT)|
1567354|NCT02474355|Procedure|T790M+ Testing|If a previous lab report is unavailable, the patient will need to have T790M+ testing.
1567355|NCT02474355|Procedure|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
1567356|NCT02474355|Procedure|Baseline ECG|ECG to ensure absence of any cardiac abnormality
1567357|NCT02474355|Procedure|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
1567358|NCT02474355|Drug|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
1567359|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs
Injection dosage and volume of the study drugs:
Low dose: 1x10e7 cells/3mL
Number of injections : only once during the study period
Device: Ultrasound
Injection technique: Injection into the lesion by investigator"
1567360|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs
Injection dosage and volume of the study drugs:
Mid dose: 5x10e7 cells/3mL
Number of injections : only once during the study period
Device: Ultrasound
Injection technique: Injection into the lesion by investigator"
1567361|NCT02474342|Biological|Autologous Adipose Tissue Derived MSCs Transplantation|"Study drugs: Autologous adipose tissue derived MSCs
Injection dosage and volume of the study drugs:
High dose: 1x10e8 cells/3mL
Number of injections : only once during the study period
Device: Ultrasound
Injection technique: Injection into the lesion by investigator"
1567364|NCT02474316|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug/wk s.c for 48 weeks
1567365|NCT02474316|Drug|nucleos(t)ide analgoue|nucleos(t)ide analgoue (NA) 1 piece p.o for 48 weeks
1567366|NCT02474303|Drug|Truvada|Demonstration Study
1567368|NCT02474277|Other|30 sec chair stand test|diagnostic test for functional impairment
1567369|NCT02474264|Other|Endothelial function assessment|reactive hyperemia index
1567370|NCT02474264|Other|Cardiovascular biomarkers|Cardiovascular biomarkers will be measure to test other aspects of endothelial and cardiac function: high-sensitivity troponin (hsTn) , C-reactive protein , D-dimer, N-terminal pro-brain natriuretic peptide (NT-proBNP)
1567371|NCT02474264|Other|Endothelial cells|Endothelial Progenitor Cells and Circulating Endothelial Cells profiles- will be characterized to evaluate endothelial injury.
1567372|NCT02474251|Device|Continuous positive airway pressure device|GROUP B ONLY will be evaluated on two randomized counterbalanced nights, on one they will undergo a full night of therapeutic CPAP; on the other the investigators will withdraw CPAP during SWS only. A morning LP will be performed approximately 10 hours after sleep onset in both visits
1567373|NCT02474238|Device|The sequential technique|By using 'the double frequency YAG laser' to make the initial bore and 'the Nd:YAG laser' to complete the perforation on iris.
1567374|NCT02474238|Device|The pure Nd:YAG laser technique|By using 'the pure Nd:YAG laser' to make a complete perforation on iris.
1567375|NCT02474225|Drug|Intravitreal injection (bevacizumab or ranibizumab)|The intravitreal anti-vascular endothelial growth factor agent of 0.1 ml of bevacizumab (2.5 mg/0.1 ml) or ranibizumab (1 mg/0.1 ml)
1567376|NCT02474212|Drug|Enoxaparin|
1567377|NCT02474199|Biological|darTregs|A single intravenous infusion as described administered over a 20-30 minute interval with close monitoring prior to, during, and after the infusion.
1567378|NCT02474199|Drug|Acetaminophen|Pre-medication for darTregs infusion. A dose of 15 mg/kg will be administered 30 to 60 minutes prior to the darTregs infusion.
1567379|NCT02474199|Drug|Diphenhydramine|Pre-medication for darTregs infusion. A dose of 1-2 mg/kg diphenhydramine will be administered 30 to 60 minutes prior to the darTregs infusion.
1568665|NCT02465281|Other|Device: 3T scanner with MRI-compatible robot|
1567380|NCT02474199|Drug|Immunosuppression (IS) Withdrawal|"Subjects:1.) who fulfill study eligibility criteria will withdraw IS 2.) enter the study on calcineurin inhibitor (CNI) monotherapy or a CNI‐based regimen with either Prednisone or MMF as a second IS medication 3.) will proceed with changes in CNI dosing according to the protocol's CNI withdrawal algorithm.During the last 2 weeks of IS withdrawal (e.g., Step 2 in algorithm -CNI reduced 25%-pre darTregs), a single dose of darTregs will be infused IV. The subject will then, if eligible, proceed with IS withdrawal within 2 weeks after the infusion. Eligible subjects meeting the primary endpoint of 75% reduction in CNI from baseline after darTregs will be offered the opportunity to continue IS withdrawal until complete discontinuation of IS."
1567381|NCT02474199|Procedure|Study Mandated Procedures|Blood draws (venipuncture); collection of peripheral blood mononuclear cells (PBMCs) by a procedure known as leukapheresis or venipuncture; buccal (cheek) swab for HLA typing; liver biopsies (per protocol and for cause).
1567382|NCT02474186|Radiation|Radiation therapy|Patients with metastatic breast cancer and other metastatic solid tumors receiving single-agent chemotherapy will receive 3.5 Gy/fraction to a total dose of 35 Gy/10 fractions over 2 weeks with concurrent systemic therapy
1567383|NCT02474186|Drug|Xeloda|chemotherapy agent daily for two weeks
1567384|NCT02474186|Drug|paclitaxel|chemotherapy agent weekly for two weeks
1567390|NCT02474147|Other|Processed meat hamburger|MacMuffin Fresh 300 ml Cafe Latte + 21 g sugar Energy: 513.6 kcal Carbohydrates 55g (44.8%) Proteins 20.5g (16.7%) Lipids 22 g (38.6%)
1567391|NCT02474147|Other|Vegan sandwich|Burger with tofu + 300 ml green tea Energy 514.9 kcal Carbohydrates 54.2 g (44%) Proteins 19.9 g (16.2%) Lipids 22.8 g (39.8%)
1567392|NCT02474134|Drug|Interferon beta-1b (PF530, Betaferon)|Single subcutaneous administration
1567393|NCT02474121|Device|Bone marrow concentration device|Collection of autologous bone marrow aspirate and point-of-care concentration using the bone marrow concentration device, followed by intramuscular injection of concentrated bone marrow aspirate (cBMA) into the affected limb
1567394|NCT02474108|Procedure|surgical prevention of atrial fibrillation|Prophylactic surgical ablation is performed to prevent AF in patients during mitral valve surgery. Ablation is performed by radiofrequency electrode or cryoprobe. Pulmonary veins, posterior wall of the left atrium will be isolated by the scheme box-lesion with additional lines to the mitral valve and appendage of left atrium.
1567395|NCT02474108|Device|cardiomonitor|in both groups cardiac rhythm will be controlled by a cardiomonitor
1567396|NCT02474095|Other|Quality-of-Life Assessment|Ancillary studies
1567397|NCT02474095|Procedure|Transcutaneous Acupoint Electrical Stimulation|Undergo ALTENS
1567401|NCT02474043|Behavioral|Hep-Net Intervention|The Hep-Net Intervention is a web-based questionnaire and tailored feedback system designed to increase readiness to change with respect to several behaviors. The behaviors include (1) reducing or quitting drug use; (2) using sterile equipment every time one injects drugs; (3) undergoing screening for hepatitis C; (4) receiving training to use naloxone to prevent death due to opioid overdose.
1567402|NCT02474043|Behavioral|Usual Care|Clients receive health education and risk reduction counseling from a trained prevention specialist.
1567403|NCT02474017|Drug|MGR001|Fluticasone Propionate / Salmeterol administered using CRC749 inhaler
1567404|NCT02474017|Device|CRC749 inhaler|
1567405|NCT02473991|Radiation|ultrasound|The placental thickness was measured by placing the ultrasound transducer perpendicularly to the plane of the placenta, in the area of the cord insertion, near the mid-placental portion
1567406|NCT02473978|Device|INVOS Cerebral Oximetry|Participants will be connected to INVOS Cerebral Oximetry Cerebral Oximetry preoperativly and intraoperativly to ascess there cerebral perfusion throughout cesarean sections.
1567407|NCT02473965|Drug|IGIV-C|"Run-Phase: 1 loading dose of 2 g/kg IGIV-C and 2 maintenance doses of 1 g/kg IGIV-C
Corticosteroid Tapering/IGIV-C Maintenance Phase: 1 g/kg IGIV-C every 3 weeks for up to 36 weeks"
1567408|NCT02473965|Drug|Placebo|
1567409|NCT02473952|Drug|IGIV-C|IGIV-C: Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified
1567410|NCT02473952|Drug|Placebo|
1567411|NCT02473939|Drug|VR942 delivered via a Vectura Dry Powder Inhaler|
1567412|NCT02473939|Drug|Placebo delivered via a Vectura Dry Powder Inhaler|
1567413|NCT02473926|Behavioral|Physical Activity|Physical Activity Program Intervention
1567414|NCT02473926|Behavioral|Questionnaires|Participants in the usual care arm will receive three mailings during the intervention phase.
1567415|NCT02473913|Drug|Milk Thistle|
1567416|NCT02473913|Drug|Placebo|
1567417|NCT02473900|Drug|HIP1403|Oseltamivir 75mg
1567418|NCT02473900|Drug|HGP0919|Oseltamivir phosphate 75mg
1567419|NCT02473887|Drug|Ondansetron with1:1 ORA - sweet.|single dose of intravenous ondansetron form orally after being flavored with 1:1 ORA-sweet, the dose of ondansetron was determined based on the patient presenting weight.
1567420|NCT02473874|Device|Skin Spect dermoscope|Skin imaging
1567421|NCT02473874|Device|Spatially modulated quantitative|Skin imaging
1567422|NCT02473861|Other|Exercise|Moderate intensity aerobic and resistance training. Five minutes each of warm-up, cool-down, balance and flexibility will also be performed.
1567423|NCT02473848|Drug|ingenol mebutate 500 ucg|Ingenol mebutate gel, 0.05%, commercially supplied in a box of 2 single use, unit dose tubes for topical application for each 25cm2, four conjunctive 25cm2 areas (100cm2) will be treated. If the 100 cm2 area is not cleared at Day 57 (+/- 3 Days), a second treatment cycle will be initiated with commercially supplied drug in a box of 2 single use, unit dose tubes for topical application for each 25cm2 and four conjunctive 25cm2 areas (100cm2 ) will be treated. In total for the first cycle, 4 commercially supplied boxes (8 unit dose tubes) will be used, and for the second cycle an additional 4 commercially supplied boxes (8 unit dose tubes) will be used (in total 8 boxes, 16 unit dose tubes per patient).
1567424|NCT02473835|Other|Calorie restriction|Participants will reduce calorie intake by 50 % for a period of 3 consecutive days.
1567425|NCT02473835|Other|Activity monitoring|For 1 week, participants will be fitted with an activity monitor (Actiheart) to estimate energy expenditure (during the same week as the diet monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
1567426|NCT02473835|Other|Diet monitoring|For 1 week, participants will be asked to record all food and fluids consumed to estimate energy intake (during the same week as the activity monitoring). The activity and diet monitoring data will be used together to confirm that participants are in a state of energy balance and an average of these 2 values taken - 50 % of this average value will be the target calorie intake for the 3 day calorie restriction period.
1567427|NCT02473809|Drug|Liraglutide|Once daily
1567428|NCT02473809|Drug|Placebo|Once daily
1567429|NCT02473796|Other|Home based child care|HBNC included treatment of neonatal sepsis with Gentamicin once daily (5 mg for 10 days for preterm babies with birth weight <2000g; 7 mg for birth weight 2000-2500 gm or as per gentamicin chart for 7 days for normal term & weight ) by intramuscular injection. Acute respiratory infection was treated with co-trimoxazole syrup BID (2.5 ml for age 1-2 months, 5 ml for age 2 months - 1 year, 7.5 ml for age 1 - 5 years). Diarrheal illness was treated with ORS, furoxone (5 ml 8 hourly for 3 days) and metronidazole syrup (5 ml 8 hourly for 7 days). Malaria was treated with Syrup chloroquine (for 1 month to 1 year- 5 ml first dose , 2.5 ml after 6 hours, 2.5 ml after 12 hours , 2.5 ml after 12 hours). Syrup paracetamol was given 2.5 to 5 ml 8 hourly depending upon the body weight.
1567433|NCT02473731|Biological|KTN3379|
1567434|NCT02473718|Other|Fluid minimization protocol|Fluid nonresponsive patients will have continuous infusions concentrated, maintenance fluids discontinued, and carrier fluids minimized. Diuretics and/or ultrafiltration will be utilized to maintain an even to negative fluid balance in patients demonstrating fluid non-responsiveness.
1567435|NCT02473718|Device|Ultrasound|
1567436|NCT02473705|Dietary Supplement|Fish Oil and Bicarbonate|1280mg of fish oil per day and 1mg of bicarbonate per Kg of body weight per day
1567437|NCT02473705|Dietary Supplement|Fish Oil and Bicarbonate Placebo|1280mg of fish oil per day and bicarbonate placebo (Methylcellulose)
1567438|NCT02473705|Dietary Supplement|Fish Oil Placebo and Bicarbonate|Fish oil placebo (soybean oil) and 1mg of bicarbonate per Kg of body weight per day
1567439|NCT02473705|Dietary Supplement|Fish Oil Placebo and Bicarbonate Placebo|Fish oil placebo (soybean oil) and bicarbonate placebo (Methylcellulose)
1567440|NCT02473692|Other|Online Migraine Treatment Optimization|"The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:
Introduction to the series
Getting to know migraine
Making the most of your medical care
Partnering with your doctor
Best use of migraine medication
Keeping tabs on your migraine
Take home message (summary)"
1567441|NCT02473653|Biological|HER-2/neu Pulsed DC1 vaccine|There will be no exceptions to eligibility, contraindicated treatment/therapies/interventions or safety tests.
1567445|NCT02473627|Drug|DS-1971a|200mg tablet
1567446|NCT02473627|Drug|midazolam hydrochloride|2.5mg oromucosal liquid
1567447|NCT02473627|Drug|Omeprazole|20mg gastro-resistant capsule
1567448|NCT02473627|Drug|Pioglitazone hydrochloride|15mg tablet
1567449|NCT02473627|Drug|Buproprion|150mg Prolonged release tablet
1567450|NCT02473627|Drug|Tolbutamide|500mg tablet
1567453|NCT02473601|Drug|Mivacurium Chloride|"Anesthesia induction:
Intravenous injection of midazolam 0.05 mg/kg,Etomidate 0.3 mg/kg,Sufentanil 0.5 g/kg,TOF detection and adjustment of the first twitch height (T1)100%, Mivacurium Chloramine 0.07 mg/kg intraveous injecting in 5 minutes.
Anesthesia maintenance:
Two groups of sevoflurance 1%~8% inhalation anesthesia plus intravenous infusion of remifentanil 0.05～0.2 µg/kg/min,Mivacurium Chloramine 6mg/kg/h, Appropriate supplementary analgesia dose of sufentanil before skin incision and the abdomen was closed. The two groups were maintained until the Bis value was 40 ~ 60. PetCO2 was 30 ~ 35mmHg. Hemodynamic fluctuations did not exceed 20% of the baseline value.At least 20 minutes before the operation stopping Mivacurium infusion,Before the end of operation 5-10 minutes stopping infusion of remifentanil and sevoflurane."
1567454|NCT02473588|Device|Retia Medical Long Time Interval Analysis|"Retia Medical Long Time Interval Analysis will be used to analyze the blood pressure tracing of patients having surgery who have an arterial catheter"
1567455|NCT02473575|Dietary Supplement|caffeine gum|Gum is consumed 30 minutes before commencement of run
1567456|NCT02473575|Dietary Supplement|placebo gum|Gum is consumed 30 minutes before commencement of run
1567463|NCT02473536|Radiation|Stereotactic ablative radiation therapy|SABR
1567464|NCT02473523|Other|PedsQL Cancer Module|The PedsQL cancer module acute version is a 27 item assessment that includes eight scales including pain (2 items), nausea (5 items), anxiety related to procedures (3 items), anxiety related to treatment (3 items), worry (3items), cognitive problems (5 items), perceived physical appearance and communication (3 items). This assessment will take approximately 15-30 minutes to complete.
1567465|NCT02473523|Other|PedsQL Multidimensional Fatigue Scale|The Multidimensional Fatigue Scale is an 18 item questionnaire encompassing 3 subscales including general fatigue (6 items), sleep and rest fatigue (6 items) and cognitive fatigue (6 items). This assessment will take approximately 10-20 minutes to complete.
1567466|NCT02473523|Device|Biodex System 3 Dynamometer|"The Biodex System 3 Dynamometer will be used to measure isometric quadriceps muscle contractions. Participants will be stabilized in the chair with abdominal and shoulder straps. The isometric tests for knee extension will be done on both dominant and non-dominant leg. The tests consist of 3 maximal muscle contractions each lasting five seconds separated by 40 second rest intervals. This assessment will take approximately 10 minutes to complete."
1567467|NCT02473523|Device|Jamar Hydraulic Hand Dynamometer|"A calibrated Jamar hydraulic hand dynamometer will be used to measure grip strength. The participant will be seated in a chair with elbow flexion to 90 degrees against torso and the forearm in neutral. The participant will grasp the device and the handle will be adjusted so that digits are able to comfortably grasp the device. The maximum score after 2 trials will be recorded as grip strength for both right and left hand. This assessment will take no more than 5 minutes to complete."
1567468|NCT02473523|Other|Sit and Reach Test|Hamstring flexibility will be assessed by the Sit and Reach Test. The sit and reach is a test to measure hip, hamstring and lower back flexibility. To measure flexibility participants will perform the YMCA sit and reach test. Participants will sit down without shoes or socks with the soles of their feet against the vertical platform of the sit-and-reach box located at the 26 cm (a little over 10 inches) mark. Participants keep their legs straight and their hands overlapped, while reaching for a less than maximum distance twice as a warm-up. This test will take no more than 5 minutes to complete.
1567469|NCT02473523|Other|Test of Motor Proficiency|The Bruininks-Oseretsky Test of Motor Proficiency is a 9 item standardized assessment that includes standing with feet on a line with eyes open and closed, standing on a line with one foot with eyes open and closed, standing on a balance beam on one leg with eyes open and closed and standing heel to toe on a balance beam. These tests will be administered no more than two times with a maximum score of 10 seconds. Two additional subtests include walking forward on a line and walking heel to toe on a line for a maximum of 6 steps for both tasks. Total time to complete this test is approximately 10-20 minutes.
1567470|NCT02473523|Other|Verbal Numeric Pain Scale|The verbal numeric pain scale will be administered before and after each yoga session. The principal investigator (PI) will ask the participant about his/her pain on a scale of 0-10 and the PI will record the number. This will take less than 10 seconds.
1567471|NCT02473523|Other|:Yoga Therapy|Those who consent will participate in 60-minute yoga sessions 2-3 times per week for 4-6 weeks. Only specified yoga poses will be implemented during the classes. Additional detail is included in the Description sections of this registration. The principal investigator is a Certified Yoga Therapist (CYT) and is a registered yoga teacher with 500 hours of training (RYT 500).
1567472|NCT02473510|Biological|Trivalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU per strain of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
1567473|NCT02473510|Other|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
1567476|NCT02473458|Drug|Licorice whole extract|"Patients randomly received one of below capsules labeled with codes during the first 24 hours after stroke attack:
Starch-filled capsules (as placebo)
450 mg whole licorice extract capsules
900 mg whole licorice extract capsules"
1567477|NCT02473458|Drug|Placebo|
1567478|NCT02473445|Drug|Cysteamine Bitartrate Delayed-release Capsules|Treatment with experimental drug as detailed in arm/group descriptions
1567479|NCT02473432|Procedure|RMT + usual care|Respiratory muscle training is performed with the Orygen Dual valve (inspiratory and espiratory trainer)
1567480|NCT02473432|Procedure|NMES|Neuromuscular electrical stimulation is performed with the Vital Stim ® device (approved by the FDA for dysphagia treatment). It consists in the placement of two electrodes located in suprahyoid muscles as above described.
1567481|NCT02473432|Procedure|Usual care|Standard swallow therapy consists of physiotherapy, occupational therapy and speech therapy targeting specific swallow impairments. In the case of dysphagia, the standard pattern includes measures to protect the airway and compensatory techniques.
1567482|NCT02473419|Drug|Vayarin|
1567483|NCT02473419|Drug|Placebo|
1567484|NCT02473406|Drug|Thymosin Alpha 1|In addition to the standard treatment, thymosin therapy will be started after admission: 1.6mg I.H q12h for the first 7 days and 1.6mg I.H, qd for the following 7 days or until discharge.
1567485|NCT02473406|Drug|physiological saline|Placebo inject will be given at the same dose as Thymosin in addition to the standard treatment.
1567486|NCT02473393|Drug|OPS-2071 tablet|
1567522|NCT02473198|Drug|Toradol|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
1568666|NCT02465268|Biological|pp65-shLAMP DC with GM-CSF|
1567487|NCT02473380|Device|Fluorescence spectroscopy guided surgery|A prototype of intraoperative fluorescence spectroscope will be used for fluorescence spectroscopy during a surgical procedure (open surgical approach only). The experimental probe dedicated to the spectroscopic system will be positioned against the surface of the brain, emission spectrum will be acquired and measured, and finally compared with anatomopathology exams. One specific medication will be used as contrast agent in the study: 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
1567488|NCT02473367|Drug|Raltegravir 1200 mg|Two tablets of 600 mg raltegravir administered orally, once daily, over 5 days of Pre-treatment, and once at the start of Periods 1-4.
1567489|NCT02473367|Drug|TUMS|Three tablets of TUMS Ultra Strength (US) 1000, taken orally, concomitantly with raltegravir in Period 2, and 12 hours after raltegravir in Period 4
1567490|NCT02473367|Drug|Leader Antacid|20 mL Leader Antacid Maximum Strength (MS) taken orally 12 hours after raltegravir, in Period 3
1567491|NCT02473354|Drug|Remifentanil|The opioid used for this study is Remifentanil and is commonly used in the operating room. Remifentanil will be given under normoxic (breathing room air [21% Oxygen]) and hyperoxic (breathing 50% oxygen) conditions to determine if the measurement of the specific respiratory parameters will predict the OIRD response.
1567492|NCT02473354|Drug|Oxygen|Remifentanil will be administered under normal oxygen (normoxia) and increased oxygen (hyperemic) conditions.
1567493|NCT02473354|Drug|Carbon dioxide|Carbon dioxide is used as part of the hypercapnia ventilatory response measurement (HCVR)
1567494|NCT02473341|Drug|Bovine Colostrum|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Pasteurized Bovine colostrum as a freeze dried powder (20 gm thrice a day) for 4 weeks.
+ Antibiotics + Diuretics +Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed +drugs for HE if indicated"
1567495|NCT02473341|Drug|Placebo|"Protein 1.5 gm/kg/day, energy (kcal) 30-40/day, B complex vitamins daily. Placebo (Pasteurised Milk Powder) 20 gms thrice a day for 4 weeks
+ Antibiotics + Diuretics + drugs for HE + Terlipressin for HRS + acid suppression for prophylaxis against gastrointestinal hemorrhage + EVL for variceal bleed + if indicated."
1567496|NCT02473328|Drug|Atazanavir 200 mg/r|"In patients signed an informed consent and meeting all the eligibility criteria at the time of the run-in (S-4),
switch of antiretroviral therapy Atazanavir 300 mg/ritonavir 100 mg once a day to Atazanavir 200 mg/ritonavir 100 mg once a day without changing the combination of 2 NRTIs associated.
The administration will be done once a day orally for 48 weeks.
The usual recommended dose of atazanavir is 300 mg once daily with 100 mg of ritonavir once daily with food. Ritonavir acts by potentiating the pharmacokinetics of atazanavir."
1567497|NCT02473315|Other|cryotherapy|"The treatment arm :Whole body cryotherpy (WBC) (20 sessions of 3 minutes at a temperature of -110 degrees Celsius, on the basis of two sessions a day, spread over two weeks).
The control arm : Whole body cryotherpy (WBC) (20 sessions of 1 minute at a temperature of -60 degrees Celsius, on the basis of two sessions a day, spread over two weeks)."
1567498|NCT02473302|Other|ham|160g per day during 4 days
1567499|NCT02473302|Other|ham + pomegranate extract|160g per day during 4 days
1567500|NCT02473302|Other|ham + tocopherol|160g per day during 4 days
1567501|NCT02473302|Other|rare sirloin steak|110g per day during 4 days
1567502|NCT02473302|Other|marinated rare sirloin steak|110g per day during 4 days
1567503|NCT02473302|Other|marinated cooked sirloin steak|110g per day during 4 days
1567504|NCT02473289|Drug|Sirukumab 50 mg|Participants will receive sirukumab 50 mg as subcutaneous injection on Day 1, 28 and 56.
1567505|NCT02473289|Drug|Placebo|Participants will receive matching placebo on Day 1, 28 and 56.
1567506|NCT02473276|Drug|Morphine|preservative free morphine given either via an epidural or intrathecal catheter
1567507|NCT02473276|Drug|Sterile normal saline|sterile normal saline, given either via an epidural or intrathecal catheter
1567508|NCT02473263|Drug|Ceftriaxone|Ceftriaxone 2g IV will be infused in the first 60 minutes, for non nosocomial severe septic syndrome
1567509|NCT02473263|Drug|Piperacillin tazobactam|Piperacillin/tazobactam 4g IV will be infused in the first 60 minutes, for nosocomial severe septic syndrome
1567510|NCT02473263|Drug|Norepinephrine|Norepinephrine will be infused after failure of hemodynamic optimization using vascular fluid loading
1567511|NCT02473263|Drug|Hydrocortisone|Hydrocortisone 100mg IV will be infused after failure of hemodynamic optimization using norepinephrine with at least 1.5mg/h
1567512|NCT02473250|Drug|Fluoxetine|Bipolar depressed patients will be treated with fluoxetine in combination with a mood stabilizer (valproate).
1567513|NCT02473250|Drug|Citalopram|Bipolar depressed patients will be treated with citalopram in combination with a mood stabilizer (valproate) if fluoxetine is not clinically warranted.
1567514|NCT02473237|Drug|indacaterol|Indacaterol, one inhales capsule, 150 mcgr, by dry powder dispositive
1567515|NCT02473237|Drug|Tiotropium|Tiotropium 18 mcgr, one inhaled capsule, by dry powder inhaler handihaler
1567516|NCT02473224|Biological|Norovirus GII.2 Challenge|GII.2 Snow Mountain Norovirus Filtrate. Cohort 1: 1.2x10^4 Genome Equivalent Copies (GEC) oral dose on Day 1. Cohort 2: either 1.2 x 10^2 GEC or 1.2 x10^6 GEC oral dose on Day 1, depending on the results of prior Cohort 1. Cohort 3: either 1GEC, 1.2 x 10^1 GEC, 1.2 x 10^2 GEC, 1.2 x 10^3 GEC, 1.2 x 10^5 GEC, or 1.2 x 10^6 GEC, or 1.2 GEC x 10^7 oral dose on Day 1, depending on the percentage of subjects with illness from Cohorts 1 and 2. Cohort 4: optimal dose of GEC as determined by the results of cohorts 1-3
1567517|NCT02473224|Other|Placebo|Placebo: 80 ml of sterile water for oral administration
1567518|NCT02473211|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered once daily
1567519|NCT02473211|Drug|Daclatasvir|Daclatasvir 60mg tablet administered once daily
1567520|NCT02473198|Drug|Exparel|Prior to cementing of the prosthesis (minimum 20 minutes later), injection with mixture of 40 mL normal saline solution and 20mL 1.3% Exparel.
1567521|NCT02473198|Drug|Femoral Nerve Block Bupivacaine|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
1567613|NCT02472626|Drug|Daunorubicin Hydrochloride|Given IV
1567523|NCT02473198|Drug|Morphine Sulfate|The patient will then undergo an ultrasound guided femoral nerve block in the preoperative area with bupivacaine 0.25% 20 cc. All patients will undergo unilateral TKR using a medial parapatellar approach. Intraoperatively prior to cementing of the TKR, patients will also receive a local anesthetic injection of a mixture of 30cc 0.25% bupivicaine with epinephrine, 30mg of toradol and 10 mg of morphine sulfate into the posterior capsule of the knee joint.
1567524|NCT02473185|Drug|Methylphenidate|Cross-over
1567525|NCT02473172|Device|Pressure Support ventilation|Assisted mechanical ventilation
1567526|NCT02473172|Device|Neurally Adjusted Ventilatory Assist|Assisted mechanical ventilation
1567527|NCT02473159|Drug|indocyanine green|As inject only indocyanine green (ICG), it provide the surgeon visual guidance to ensure better outcome.
1567528|NCT02473146|Drug|Gemtuzumab ozogamicin (GO)|
1567529|NCT02473133|Radiation|Personalized dose redistribution|Patients will receive an individualized radiotherapy prescription up to a total dose of 74 Gy given in 6.6 weeks if they have a positive FDG-PET at 42Gy. An initial dose of 50 Gy will be delivered in 5 weeks (single daily fractions of 2 Gy), then an additional dose up to 24 Gy will be delivered over 1.6 week.
1567530|NCT02473133|Radiation|No personalized dose redistribution|Patients will receive a single prescription of 66 Gy in 33 fractions in 6.6 weeks, with 2 Gy fractions given once daily, 5 days a week, without target volume reduction or adaptation (whatever the FDG-PET2 result).
1567531|NCT02473120|Biological|Determination of ESR1 mutations|Blood sample prelevement. Plasma issued from patient with metastatic breast cancer will be analysed at progression by Digital PCR to detect ESR1 mutations
1567532|NCT02473107|Other|Advanced caries lesions detection (no activity assessment)|The diagnosis strategy will based on detection of only moderate and advanced caries lesions (ICDAS scores 3 to 6). Initial caries lesions will be considered as sound surfaces. Caries activity status will not be evaluated. Clinical decision-making will be proposed for all lesions detected, based on evidence-based protocols.
1567533|NCT02473107|Other|All caries lesions detection (+activity assessment)|The diagnosis strategy will based on detection of initial, moderate and advanced caries lesions (ICDAS scores 1 to 6). Caries activity status will be also evaluated. Clinical decision-making will be proposed for all active lesions detected, based on evidence-based protocols. inactive caries lesions will not be treated.
1567534|NCT02473094|Drug|Capecitabine|Capecitabine 825mg/m2 bid, D1-D5 q7d
1567535|NCT02473094|Drug|Metformin|Metformin up to 2500mg/d
1567536|NCT02473094|Radiation|Radiotherapy|3D radiotherapy 50,4Gy divided in 25 fractions
1567537|NCT02473094|Drug|Placebo|Placebo up to 2500mg/d
1567538|NCT02473081|Behavioral|Minimal psychological intervention|Minimal psychological intervention (MPI) was used to help adults with chronic illness to manage their psychological burden by breaking through a negative spiral between thoughts and behaviors.
1567539|NCT02473081|Other|Usual care|Usual care was given by their family physicians.
1567540|NCT02473068|Device|CPAP|
1567541|NCT02473055|Other|Kangaroo Care|skin-to-skin, chest-to-chest placement of diaper clad preterm infant up against his mother's chest and covered by a receiving blanket folded into fourths for 2-3 hours from one feeding to the next.
1567542|NCT02473042|Procedure|Electrical Stimulation|Electrical stimulation to the wrist initiated at 1mHz, 1 pulse/second using two leads on a nerve stimulator. Stimulation continued throughout the breast surgery.
1567543|NCT02473042|Drug|Zofran|4 mg by vein for 1 dose.
1567544|NCT02473042|Drug|Dexamethasone|10 mg by vein for 1 dose.
1567545|NCT02473042|Drug|Phenergan|6.25 mg by vein for 1 dose.
1567546|NCT02473042|Drug|Pepcid|10 mg by vein for 1 dose.
1567547|NCT02473042|Behavioral|Questionnaire|Questionnaire completed about 15 minutes after participant wakes up after surgery, then every 30 minutes until they leave the clinic. It should take about 2 - 3 minutes to complete the questionnaire.
1567548|NCT02473029|Radiation|Vascular tomodensitometry|
1567549|NCT02473029|Other|Magnetic resonance angiography|
1567550|NCT02473029|Other|Vascular ultrasonography|
1567551|NCT02473029|Other|Retinal angiography|
1567552|NCT02473029|Other|Retinal optical coherence tomography|
1567553|NCT02473016|Drug|Carbon Dioxide Drug Delivery System (CDDS)|Doses will be administered to the nostril on the side of the trigeminal episode [ipsilateral nostril].
1567557|NCT02472990|Other|No drug and no placebo were used in this study|measures of muscular strength of legs, motor function, walk testing and analysis (3D video recording), RMI
1567558|NCT02472977|Drug|Ulocuplumab|
1567559|NCT02472977|Drug|Nivolumab|
1567564|NCT02472951|Other|Low carbohydrate meals|"Meal macronutritional energy composition:
Carbohydrate 30% Protein 30% Fat 40%"
1567565|NCT02472951|Other|Standard carbohydrate meals|"Meal macronutritional energy composition:
Carbohydrate 55% Protein 15% Fat 30%"
1567566|NCT02472938|Drug|dimethyl fumarate|dimethyl fumarate 120 mg capsules
1567567|NCT02472938|Other|Placebo|Placebo for BG00012
1567568|NCT02472925|Behavioral|MedSignals Pill Box|Pill box will provide feedback to the study team regarding subjects' compliance and provide reminders depending on Arm.
1567569|NCT02472912|Biological|BMO-2|Volunteers randomized in Treatment A will receive a single subcutaneous injection of BMO-2 (40mg / 0.8mL).
1567570|NCT02472912|Biological|EU-Humira|Volunteers randomized in Treatment B will receive a single subcutaneous injection of EU-Sourced Humira (40 mg / 0/8 mL)
1567571|NCT02472912|Biological|US-Humira|Volunteers randomized in Treatment C, will receive a single subcutaneous injection of US-sourced Humira (40 mg / 0.8 mL).
1567572|NCT02472899|Other|Blood sample|Non-interventional study based on blood samples taken at a single study visit
1567573|NCT02472886|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
1567574|NCT02472886|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1567575|NCT02472873|Procedure|Aspiration and Sclerotherapy of endometriomas.|Aspiration and Sclerotherapy During Laparoscopy Using 95% Ethanol for the Treatment of Endometriomas
1567576|NCT02472873|Procedure|cystectomy of endometriomas.|cystectomy of endometriomas during laparoscopy
1567577|NCT02472873|Drug|Ethanol|
1567578|NCT02472860|Behavioral|Targeted Cognitive Training (TCT)|The investigators have selected a set of computer exercises designed to specifically target aspects of cognition relevant to autism spectrum disorder (including attention and executive functions). The tasks were designed to benefit subjects through principles of learning dependent plasticity.
1567579|NCT02472860|Other|Youth Appropriate Online Games|Engaging games not designed to improve cognition
1567580|NCT02472847|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants will receive dronabinol.
1567581|NCT02472847|Drug|Placebo|Placebo is administered only once by the oral route and contains only dextrose in opaque capsules. Half of the participants will receive placebo.
1567582|NCT02472834|Dietary Supplement|Amino acid supplementation NephrAmine®|Dialysis patients will be randomized to receive either 250 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing ~14 grams of essential amino acids during each dialysis session (3 times weekly for 8 weeks) or no treatment (standard-of-care)
1567583|NCT02472821|Behavioral|Interactive youth educational program|Participation in a community-based face-to-face interactive youth educational program focusing on hearing health (i.e., noise hazards, risk of noise-induced hearing loss, mechanism of injury to the internal ear, and preventive measures)
1567584|NCT02472821|Behavioral|Internet-based educational booster|Visit to an educational Web site focused on hearing health
1567585|NCT02472808|Other|cTBNA without ROSE|Patients will undergo conventional TBNA and endobronchial biopsy and transbronchial lung biopsy
1567586|NCT02472808|Other|cTBNA with ROSE|Patients will undergo conventional TBNA with rapid on site evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
1567587|NCT02472808|Other|EBUS-TBNA without ROSE|Patients will undergo EBUS-TBNA and endobronchial biopsy and transbronchial lung biopsy
1567588|NCT02472808|Other|EBUS-TBNA with ROSE|Patients will undergo EBUS-TBNA with rapid onsite evaluation of cytology smear and endobronchial biopsy and transbronchial lung biopsy
1567589|NCT02472795|Drug|ACT-334441|Selective Sphingosine 1-phosphate (S1P) modulator
1567590|NCT02472795|Drug|Placebo|Placebo matching ACT334441 capsules or Experimental doses
1567591|NCT02472782|Drug|Teriparatide|The study will include patients from pre‐defined groups of individuals (postmenopausal, male, and steroid-induced osteoporosis) who would any way receive teriparatide for their condition according to standard medical practice and Greek treatment guidelines
1567592|NCT02472769|Drug|IBP-9414|
1567593|NCT02472769|Drug|Placebo|Sterile water
1567594|NCT02472756|Drug|Chemotherapy|The choice of the chemotherapy regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
1567595|NCT02472756|Drug|Rituximab|The choice of the rituximab regimen will be established on a per center basis, according to the standard in use in the country and in the center. Protocol does not specify any particular chemotherapy regimen.
1567596|NCT02472743|Device|Custom-built phototherapy lamp|Described in the arm description
1567597|NCT02472730|Device|Distal Attachment Cap|Colonoscopies are performed under the supervision of board certified attending gastroenterologists experienced in colonoscopy. Attending physicians will provide assistance at their discretion or at the request of the trainee. All close examinations for polyps will be carried out on withdrawal of the colonoscope.
1567598|NCT02472717|Drug|liraglutide|Liraglutide 0.6mg sc daily for 1 week, 1.2mg sc daily for 11 weeks
1567599|NCT02472717|Other|Placebo|Placebo sc daily for 12 weeks, volume titration at week 2 to mirror liraglutide arm
1567600|NCT02472704|Dietary Supplement|Gluten challenge|gluten (20 g/day) (identical powder sachets than placebo, mixed with meals) rechallenge while on a gluten-free diet
1567601|NCT02472704|Dietary Supplement|Placebo challenge|placebo (maltrodextrin) (identical powder sachets than gluten, mixed with meals) rechallenge while on a gluten-free diet
1567605|NCT02472678|Other|Web-based tailored information and support system|Access to the web-based tailored information and support system (with a username/password)
1567606|NCT02472678|Other|Standard care|The control group will receive standard care.
1567607|NCT02472665|Drug|plasma-derived FVIII/VWF concentrate Fanhdi|1 single dose of 80 IU VWF:RCof/kg of Fanhdi will be administered
1567608|NCT02472652|Drug|Abilify Maintena|For subjects who meet inclusion/exclusion criteria for this study a switch from Palliperidone Palmitate or Risperidone injectable will be made to Abilify Maintena for a 3 month period to determine if there are changes in sexual dysfunction ratings over this time period
1567609|NCT02472639|Device|Ostom-i Alert Sensor|Wear the Ostom-i Alert Sensor
1567610|NCT02472639|Other|No Ostom-i Alert Sensor|Patient will not use device
1567611|NCT02472626|Drug|6,8-Bis(benzylthio)octanoic Acid|Given IV
1567612|NCT02472626|Drug|Cytarabine|Given IV
1567618|NCT02472600|Drug|Colistin|
1567619|NCT02472600|Drug|Neomycin|
1567620|NCT02472600|Drug|Fecal microbiota transplantation (FMT)|FMT consist in the administration of fecal material obtained from healthy donors that has been diluted, homogenized, filtered and reconcentrated. In this study the processed fecal material will be frozen at -80°C after processing and will be administered to patients for up to six months after freezing via a nasogastric tube or via capsules.
1567621|NCT02472600|Drug|Omeprazole|Administered to inhibit gastric acid secretion before FMT administration if FMT administered via nasogastric tube approach (not used for capsule approach).
1567622|NCT02472587|Other|Questionnaire|
1567623|NCT02472574|Device|YL-1 type of intracranial hematoma puncture needle|YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe. To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale hematoma, gives the filament resolver interrupted for liquefication drainage afterward.
1567624|NCT02472574|Drug|rt-PA|Up to 4 doses of 0.3~1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
1567625|NCT02472561|Other|Fitbit Physical Activity Monitor|Physical Activity: The study team will provide an individualized goal of total number of steps to attain daily and will be monitored using a Fitbit activity tracker. The total daily step goal will be reviewed by study staff and modified at weeks 4 and 8.
1567626|NCT02472561|Other|mHealth Glucometer|Blood Glucose: The participant will monitor their fasting blood glucose once per week by using an mHealth Glucometer and mobile app.
1567627|NCT02472561|Other|mHealth Blood Pressure|Blood Pressure: The participant will monitor their blood pressure once per week by using an mHealth Blood Pressure cuff and mobile app.
1567628|NCT02472548|Biological|DPX-RSV(A)|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
1567629|NCT02472548|Biological|RSV(A)-Alum|Prophylactic peptide vaccine targeting RSV will be administered intramuscularly.
1567630|NCT02472548|Other|Placebo|Normal saline (0.9 % sodium chloride) will be administered intramuscularly.
1567631|NCT02472535|Other|Run-In Period: Placebo|2 capsules, once a day for two weeks
1567632|NCT02472535|Drug|MBX-8025 50 mg (Dose Escalation Period 1)|"1 capsule once a day for 4 weeks
(MBX-8025 50 mg capsule)"
1567633|NCT02472535|Drug|MBX-8025 50 mg or 100 mg (Dose Escalation Period 2)|"1 capsule once a day for 4 weeks
(MBX-8025 50 mg or 100 mg capsule)"
1567634|NCT02472535|Drug|MBX-8025 50 mg, 100 mg or 200 mg (Dose Escalation Period 3)|"1 or 2 capsules once a day for 4 weeks
(MBX-8025 50 mg, 100 mg or two (2) 100 mg capsules)"
1567635|NCT02472522|Drug|Ropivacaine + Dexmedetomidine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine and 1 micrograms/kg dexmedetomidine (combination drug) diluted with 0.9% saline to a total volume of 40 ml (20 ml each side) for the TAP block
1567636|NCT02472522|Other|Ropivacaine|Patients satisfying inclusion criteria will receive Subarachnoid Block with Bupivacaine Heavy 0.5% (11 mg/2.2 ml) with 25 micrograms of fentanyl. At the end of the procedure, bilateral TAP block will be performed using Landmark Technique with 2.5 mg/kg of ropivacaine diluted with 0.9% saline to a total volume of 40 ml (20 ml each side)
1567641|NCT02472457|Other|Crohn Disease Exclusion Diet|The CDED is divided into 4 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase I, and weeks 25-52 maintenance phase II.
1567642|NCT02472457|Other|Free Diet|This diet contains no restrictions.
1567643|NCT02472431|Other|Intracavernosal administration of autologous ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate adipose-derived regenerative cells (ADRC). After isolation autologous ADRC suspension will be injected intracavernosally.
1567644|NCT02472431|Procedure|Liposuction|
1567645|NCT02472431|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
1567649|NCT02472405|Device|595/1064nm Multiplex Laser|The multiplex cynergy laser will be used for this study. A third of the scar will solely be treated with the 595nm PDL.
1567650|NCT02472405|Device|595nm PDL|One third of the scar will be treated with 595nm PDL solely for 3 weeks (1 treatment session per week).
1567651|NCT02472392|Drug|Rabbit anti-thymocyte globulin|Active treatment
1567652|NCT02472392|Drug|Busulfan|comparitor
1567653|NCT02472392|Drug|Melphalan|comparitor
1567654|NCT02472392|Drug|Fludarabine|comparitor
1567655|NCT02472392|Drug|Cyclophosphamide|comparitor
1567656|NCT02472379|Behavioral|Writing: Group 1|Writing about experiences with familiar individuals in their lives, once a week for 6 weeks.
1567657|NCT02472379|Other|Writing: Group 2|Writing about experiences with familiar places, once a week for 6 weeks.
1567658|NCT02472366|Drug|ILUVIEN|
1567659|NCT02472353|Drug|Metformin|Metformin will begin to be administered prior to treatment with doxorubicin. Metformin will continue to be given throughout doxorubicin cycles until the completion of doxorubicin therapy.
1567660|NCT02472353|Drug|Doxorubicin|Standard of care treatment with doxorubicin
1567661|NCT02472340|Procedure|Muscle Biopsy|Muscle Biopsy
1567662|NCT02472327|Behavioral|Pre-operative support|
1567663|NCT02472314|Drug|1.3% Liposomal Bupivacaine|local tissue infiltration of Liposomal Bupivacaine during surgery
1567664|NCT02472314|Drug|0.125% Bupivacaine|Continues nerve block with Bupivacaine during surgery and postoperatively
1567665|NCT02472301|Dietary Supplement|cowpeas complementary food|cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
1567666|NCT02472301|Dietary Supplement|corn-soy flour|Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
1567667|NCT02472301|Dietary Supplement|common bean complementary food|common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
1567668|NCT02472288|Device|Electroacupuncture (EA)|The EA group receives 10 sessions of EA therapy (5 per a week, 2 weeks). After inserting needles by 5-10 mm (stainless steel, 0.25 mm in diameter and 4.0 mm in length, Dong Bang Acupuncture Inc., Korea) using the Park sham guide tube on the 8 points (BL31, BL32, BL33, and BL34, bilateral sides), de qi response is elicited. The electrical stimulation is then presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea). Conventional treatments (western/traditional herbal medications, rehabilitation, or acupuncture without electro-stimulation for stroke, and western/traditional herbal medications or acupuncture without electro-stimulation for urinary retention) are allowed during the intervention period. The practitioner should have over 1-year clinical experiences.
1567669|NCT02472288|Device|Sham electroacupuncture|The patients in sham group receive totally 10 sessions of the sham EA (5 sessions per a week, for 2 weeks). Non-penetrating needles of Park sham device are implemented on the bilateral points of BL31, BL32, BL33, and BL34 (total 8 acupoints). Then, the electro-stimulation is presented for 20 minutes by middle frequency (30 Hz) (STN-111, Stratek, Korea), even though the electrical stimulation is not delivered through the skin. Conventional treatments for stroke and urinary retention along with EAT are not eliminated. It is also necessary for the practitioner with more than 1-year experiences on the clinical field.
1567670|NCT02472275|Drug|Antiandrogen Therapy|Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
1567671|NCT02472275|Other|Laboratory Biomarker Analysis|Correlative studies
1567672|NCT02472275|Drug|Multitargeted Tyrosine Kinase Inhibitor PLX3397|Given PO
1567673|NCT02472275|Radiation|Radiation Therapy|Undergo radiation therapy
1567674|NCT02472262|Dietary Supplement|Cow pea complementary food|A legume-based complementary food made from cowpeas will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
1567675|NCT02472262|Dietary Supplement|Corn soy flour|Corn flour with 10% soy will be given for 6 months, 200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
1567676|NCT02472262|Dietary Supplement|Common bean|A legume-based complementary food made from common beans will be given for 6 months,200 kcal/day for children 6-9 months old and 300 kcal/day for children 9-11 months old.
1567677|NCT02472249|Radiation|CT perfusion|Two dynamic CT perfusion acquisitions of the whole liver will be performed with a 320-detectors CT, prior and after to the norepinephrine injection.
1567678|NCT02472249|Drug|Norepinephrine intra-arteriel/hepatic|A small dose (24 ug) of norepinephrine will be injected in the hepatic artery over 10 seconds. The half-life of the drug is 90 seconds.
1567679|NCT02472236|Drug|PEX168|200µg,injected subcutaneously,once a week.
1567680|NCT02472236|Drug|Digoxin|0.5mg,oral,two times.
1567681|NCT02472223|Drug|Betadine 5%|"One-time, in-office administration of Betadine 5%.
Betadine 5% exposure to the ocular surface is limited to 2 minutes in-office administration, followed by saline lavage per labeling instructions."
1567682|NCT02472223|Drug|Artificial Tears|Standard of care
1567683|NCT02472210|Drug|Botulinum Toxin|An individualized dose will be injected in the painful limbs: up to 200 units in the upper limbs or up to 300 units in the lower limbs according to the average doses that subjects with PD pain in the limbs received in our clinic, as per our retrospective study. Each injection will contain 25 Units of Botulinum Toxin this way the number of injections will be from 1 to 8 for the upper limbs and from 1 to 12 in the lower limbs. The pattern of injections will be decided by the study investigator according to the localization. The involved muscles will be targeted using EMG guidance. of pain and will be the same at visit 2 and 3.
1567684|NCT02472197|Procedure|Hysteroscopic morcellation|The endometrial polyp is resected by a transcervical approach. During the procedure, the polyp is placed by suction against the window of the device, then cut by mechanical energy, in chips which are directly aspirated by the device.
1567685|NCT02472197|Procedure|Standard hysteroscopic resection|The endometrial polyp is resected by a transcervical approach in several chips using a mono or bipolar cove after distension of the uterine cavity under endoscopic control.
1567686|NCT02472184|Procedure|Office hysteroscopy|Office hysteroscopy is a procedure performed in the office in which a flexible hysteroscope is inserted into the uterine cavity. The patient is positioned in a dorsal lithotomy position and teh cervix is visualized with a speculum. Normal saline is used to distend the cavity, and the hysteroscope is used to visualize any abnormalities within the cavity.
1567687|NCT02472184|Procedure|Endometrial biopsy|An endometrial biopsy is a procedure in which a pipelle instrument is inserted into the uterine cavity and suction from the pipelle is used to obtain endometrial tissue. This is performed with the patient in the dorsal lithotomy position and a speculum is used to visualize the cervix.
1567688|NCT02472171|Dietary Supplement|High saturated fat meal, placebo powder and sunflower oil|High saturated fat meal with a blueberry flavored shake and sunflower oil
1567689|NCT02472171|Dietary Supplement|High saturated fat meal, blueberry powder and sunflower oil|High saturated fat meal with blueberry powder shake and sunflower oil
1567690|NCT02472171|Dietary Supplement|High saturated fat meal, placebo powder and DHA|High saturated fat meal with a blueberry flavored shake and DHA
1567691|NCT02472158|Device|chlorhexidine-gel-impregnated dressing|Chlorhexidine Patients receive a chlorhexidine-gel-impregnated dressing ( 3M Tegaderm CHG IV securement dressing™ ) after insertion of central venous catheter
1567692|NCT02472158|Device|Polyurethane film dressing|Polyurethane film dressing Patients receive a transparent polyurethane film dressing (3M Tegaderm IV dressing™) after insertion of central venous catheter.
1567693|NCT02472145|Drug|Decitabine 20 mg/m^2|Decitabine 20 milligram per square meter (mg/[m^2]) from Day 1, 2, 3, 4 and 5 of a 28-day cycle.
1567694|NCT02472145|Drug|Talacotuzumab 9 mg/kg|Talacotuzumab 9 milligram per kilogram mg/kg on Day 8 and 22 of a 28-day cycle.
1567695|NCT02472132|Device|POC US|Use of point of care ultrasound in insertion of CVC
1567696|NCT02472119|Dietary Supplement|rusks made of wheat flour enzymatically treated|100 g of rusks obtained from commercial wheat flour enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
1567697|NCT02472119|Dietary Supplement|rusks made of wheat flour not enzimatically modified|100 g of rusks obtained from commercial wheat flour NOT enzymatically treated with mTGasi and lysine ethyl ester, every day for 3 months
1567698|NCT02472119|Dietary Supplement|Gluten-free diet|gluten-free diet
1567699|NCT02472106|Device|Post-dilatation|Post-dilatation in self-expanding TAVI device procedures
1567700|NCT02472093|Other|Physical exercises treatment|Includes different types of exercises: low-impact to moderate aerobic training; walking fast in a circle, alternating with periods of going up and down the stairs (3 steps for 10 minutes) for a total of 20 consecutive minutes; posture exercises for the back and proprioceptive exercises for the trunk in the supine position to improve axial stability, including diaphragmatic breathing. The heart rate was monitored through the use of a heart rate monitor, which allowed not to exceed the threshold.
1567701|NCT02472093|Other|Perceptive Rehabilitation Treatment|therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips.
1567702|NCT02472093|Other|Control group|The control group did brief educational sessions.
1567703|NCT02472080|Drug|gemcitabine -oxaliplatine combination|gemcitabine (2g/50mL)-oxaliplatine (200mg /40mL) combination, IV,every 2 weeks for 8cycles
1567705|NCT02472054|Drug|Alemtuzumab|
1567706|NCT02472054|Drug|Methyl Prednisolone (MP)|
1567707|NCT02472054|Drug|Cyclosporin A (CSA)|
1567708|NCT02472041|Device|Reanimator group|Resuscitator of Muller Group (intermittent positive pressure): Patients allocated to this group received intermittent positive pressure breathing (resuscitator Muller, Engemed, Brazil), adjusting the positive pressure around 1.5 kgf / cm2, which corresponds to 15 20 cm / H2O, positive pressure was applied through a face mask (Respironics®).
1567709|NCT02472041|Device|Control|Control Group: In position Fowler 45, patients assigned to this group was administered as treatment lung expansion exercises using the incentive inspiratory flow (Respiron, NCS, Mexico) and concomitantly blocking contralateral to the drain maneuvers were performed, compression / decompression associated with the incentive spirometry (Respiron) consisting of 4 sets of 10 active patient breaths with an interval of two minutes between sets. Since the load of the respiratory stimulator will be zero throughout treatment. Guidelines to the active, progressive and early mobilization.
1567710|NCT02472028|Other|blood pressure lowering algorithm|"The treatments used in the enhanced strategy arm are those proposed by national (HAS2013, SFHTA2013) and international (ESH 2013) recommendations, according to their Marketing Authorization and Summary of Product Characteristics : Diuretics, beta-blockers, Angiotensin Converting Enzyme inhibitors, Angiotensin Receptor Blockers, Calcium Channel Blockers Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. All drugs of these classes may be used , no specific drug is tested in this study."
1567711|NCT02472028|Other|usual strategy|The implementation of antihypertensive therapy the current recommendations to reach the blood pressure target in usual care. Throughout the study, choice of drugs in each therapeutic class is left on the investigator's initiative. Combinations of different pharmacological classes can be tested in order to find the most effective and best tolerated combinations.
1567712|NCT02472015|Procedure|telemedicine|psycho-behavioural care by telemedicine
1567713|NCT02472002|Biological|Mesenchymal cell therapy|"Name of the experimental cell preparation: Concentrated mesenchymal stem cells (MSCs) derived from autologous bone marrow
Registry Type: autologous
Qualitative and quantitative composition of the finished product: The product is a cell suspension consisting of mesenchymal stem cells (MSC) 40 x 106 MSC / ml suspended in human albumin (ALBUNORM ® 5% OCTAPHARMA France).
Route of administration: endomyocardial injection
Dose administered: 120-140 x106 MSC (mesenchymal stem cells)"
1567714|NCT02471989|Dietary Supplement|Low-FODMAP diet|
1567715|NCT02471989|Dietary Supplement|GERD diet|
1567782|NCT02471456|Other|MACCE review|MACCE will be assessed by contacting the patient's GP and/or Cardiologist at least 1 year after their surgery.
1567783|NCT02471443|Procedure|Surgery for severe endometriosis|Consecutive patients undergoing excisional surgery for severe endometriosis with bowel involvement
1567716|NCT02471976|Other|strategy promoting early consideration and collegiate vulnerability of patients|One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti
1567717|NCT02471963|Drug|Empagliflozin|
1567718|NCT02471963|Drug|Placebo|
1567719|NCT02471950|Procedure|2.5 % Isoflurane administration|Anaesthesia maintained during cardiopulmonary bypass with 2.5% isoflurane administered via the oxygenator of the bypass circuit.
1567720|NCT02471937|Biological|Bacteriological analyses on clinical samples performed with Eswabs|"Clinical samples analysed :
mothervagina, breast milk, baby oral cavity, baby stool. Techniques: bacteriological cultures, Real time PCR"
1567721|NCT02471924|Other|Trans thoraciq cardiac ultrasonography|Establish a diagnosis power of the ΔITVAo ( aortic velocity peak )measured with cardiac Trans thoraciq ultrasonography after passiv leg rising to predict hypotension after spinal anesthesia for elective caesarean. Every patients participate for 30 minutes (time to perform the echography). Outside echographic evaluation, medical taking of participating patients will be exactly the same than what is done for all elective caesarean section.
1567722|NCT02471911|Drug|KPT-330|KPT-330 administered orally on days -5 and -3 prior to starting chemotherapy. Once chemotherapy starts, KPT-330 will be administered on days 1, 3, and 5 of each cycle. Dose levels will range from 20 mg to 100mg with a standard 3+3 escalation schema.
1567723|NCT02471911|Drug|Rituximab|IV Rituximab 375 mg/m2 on D1
1567724|NCT02471911|Drug|Etoposide|IV Etoposide 100 mg/m2 on D1-3
1567725|NCT02471911|Drug|Carboplatin|IV Carboplatin AUC 5 on D2
1567726|NCT02471911|Drug|Ifosfamide|IV Ifosfamide 5 g/m2 on D2
1567727|NCT02471911|Drug|Dexamethasone|20 mg qd on Days -5 and -3. 20 mg qd on Days 1-5
1567728|NCT02471898|Drug|HTX-011|
1567729|NCT02471898|Drug|Placebo|Saline
1567730|NCT02471885|Procedure|Remote Ischaemic Conditioning|each cycle of Remote Ischaemic Conditioning (RIC) consists of inflating a blood pressure cuff on the upper limb (arm) upto 200mm Hg (systolic BP + 20 mm Hg for low platelets, e.g. 50-150 x 10^9/L; skip RIC if platelets < 50 x 10^9/L) for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
1567731|NCT02471885|Other|Placebo|Sham control blood pressure cuff placement at 10 mm Hg for 5 minutes, then deflated to 0 mm Hg for 5 minutes.
1567732|NCT02471872|Behavioral|Air Pollution Education|Students are presented with a one-hour interactive session on air pollution.
1567733|NCT02471872|Other|Non-Air Pollution Education|Students are presented with a one-hour interactive session on vaccines.
1567734|NCT02471859|Drug|GDC-3280|GDC-3280 at various doses, depending on the cohort and treatment period
1567735|NCT02471859|Drug|Placebo|Placebo at various doses, depending on the cohort and treatment period
1567736|NCT02471846|Drug|Atezolizumab|Participants will receive atezolizumab at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle with the exception of biopsy cohort A, where atezolizumab administration will start on Cycle 2 Day 1.
1567737|NCT02471846|Drug|GDC-0919|Participants will receive GDC-0919 by mouth (PO) twice daily (BID), specifically every 12 hours. During the dose-escalation stage, the first cohort will receive GDC-0919 at a starting dose of 50 mg PO BID. Dosing will commence on Day -1 for Cycle 1 and follow subsequent 21-day (Days 1 to 21) dosing cycles. The dose will be modified based upon evaluation of DLTs, with single dose escalations not to exceed 2.5-fold of the previous dose. The proposed dosages for evaluation are 50, 100, 200, 400, 600, and 1000 mg PO BID. During the expansion stage, selected solid tumor types will be treated at the MTD or MAD as determined during the dose-escalation stage.
1567738|NCT02471833|Drug|Telmisartan 20mg|Subjects will be given 20 mg of Telmisartan to be taken orally once a day before bedtime. Subjects will be on Telmisartan 20mg for a duration of 8 months.
1567739|NCT02471833|Drug|Telmisartan 40mg|Subjects will be given 40 mg of Telmisartan to be taken orally once a day before bedtime. Subjects will be on Telmisartan 40mg for a duration of 8 months.
1567740|NCT02471833|Drug|Placebo|Subjects will be given placebo to be taken orally once a day before bedtime. Subjects will be on placebo for a duration of 8 months.
1567741|NCT02471820|Drug|Lenalidomide|Lenalidomide 25 mg by mouth for the first 21 days of a 28-day-cycle for 4 cycles
1567742|NCT02471820|Drug|Adriamycin|Adriamycin as intravenous bolus infusion at a dose of 9 mg/m2, on days 1-4 of a 28-day cycle for 4 cycles
1567743|NCT02471820|Drug|Dexamethasone|Dexamethasone by mouth at a dose of 40 mg, on days 1, 8, 15, and 22 of a 28-day cycle for 4 cycles
1567744|NCT02471807|Device|Edwards FORMA Tricuspid Transcatheter Repair System|
1567745|NCT02471794|Behavioral|Personalized Health Planning Shared Medical Appointment|The PHP SMA group will combine personalized health planning with a modified version of the standard shared diabetes medical appointment. Modifications include: a self-assessment of health status, greater emphasis on a collaborative patient-provider health goal-setting process, a plan to meet goals, a mindfulness practice included in each session, and the creation of a 'personalized health plan' participant notebook for each individual to document health goals and track progress to review at each session. The participant notebook also includes educational handouts and worksheets to complement the educational curriculum
1567746|NCT02471781|Device|Zenith TX2 Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms or ulcers of the descending thoracic aorta having morphology suitable for endovascular repair.
1567748|NCT02471755|Device|Eelectro-acupuncture|The bilateral acupoints of EX-CA1, ST25, SP6 and RN4 were selected for the treatment program.After regular disinfection,adhesive pads were placed on surface of all these acupoints. For RN4, EX-CA1, ST25, needles (0.30*75mm) were inserted into the points vertically throughout the pads, skin, fat tissue, and abdominal muscles until the participant had feeling of pricking. For SP6, needles were inserted into the acupoint to a depth of 1 cun,accompanied by manipulation of lifting, thrusting, and twisting 3 times. Electronic stimulator was connected to EX-CA1 and ST25 with dilatational wave, 10/50HZ, 0.1 to 1.0mA. The current intensity was adjusted to abdomen shivering without pain. Treatment lasted for 30 minutes and acupuncture manipulation for RN4 and SP6 were performed every 10 minutes.
1567784|NCT02471430|Drug|Panobinostat|Panobinostat will be administered orally.
1568667|NCT02465268|Biological|unpulsed PBMC and saline|
1567749|NCT02471755|Device|Sham Eelectro-acupuncture|Non-acupoints approximate to RN4, ST25, EX-CA1 and SP6 were selected bilaterally, and adhesive pads were placed on the surface of selected non-acupoints' location. Blunt needles were inserted into the pads and to touch, rather than penetrate the surface of skin. Meanwhile, like EA group, manipulations of lifting, thrusting and twisting on non-acupoint approximate to RN4 and SP6 were performed 3 times. Sham Electronic stimulator was applied to the non-acupoint approximate to EX-CA1 and ST25, providing the outward appearance of the procedure in EA group but with no current intensity actually applied. Any other interventions were rigorously maintained the same as in the EA group.
1567750|NCT02471742|Procedure|NAC-sparing mastectomy|patients treated with mastectomy with conservation of nipple-areola complex
1567751|NCT02471742|Procedure|conventional mastectomy|patients treated with mastectomy without conservation of nipple-areola complex
1567752|NCT02471729|Device|EnligHTN™ Renal Denervation System|The renal nerve ablation will be performed according to the EnligHTN™ Renal Denervation System Instructions for Use. This system has the CE mark and is marketed in Europe and manufactured in France. The ablation catheter is indicated for use in renal denervation procedures for the treatment of hypertension.
1567754|NCT02471703|Device|Total hip arthroplasty|Total hip arthroplasty
1567755|NCT02471690|Drug|Oritavancin|IV - Single dose 1200 mg Oritavancin
1567756|NCT02471690|Drug|Dextrose|D5W 5% in Water
1567757|NCT02471677|Drug|Elonva|corifollitropin alfa (Elonva): a single injection 100 or 150 ug (depending on patient body weight) on Day 2/3 of menstrual cycle
1567758|NCT02471677|Drug|Puregon|follitropin beta (Puregon): daily injections 150 IU from Day 2/3 of menstrual cycle until adequate follicle development is achieved
1567760|NCT02471651|Drug|Dexamethasone intravitreal implant (0.7 mg)|Subjects with persistent DME who are randomized to this arm may get up to 3 treatments with the implant (0.7 mg dexamethasone).
1567761|NCT02471651|Drug|Intravitreal anti-VEGF injection|This injection may be ranibizumab, bevacizumab, or aflibercept.
1567762|NCT02471638|Device|PQ Bypass System for Femoropopliteal Bypass|To access, deliver guidewires and implant stent grafts for a percutaneous fem-pop bypass.
1567763|NCT02471625|Device|ClearView Scanning|
1567764|NCT02471599|Procedure|tonsillectomy|The tonsillectomy will be performed by the otolaryngologist. In addition, all subjects will receive the conventional drug treatments, defined as treatment of participants using the angiotensin-converting enzyme inhibitor (ACEi)/angiotensin II receptor blocker (ARB), anticoagulants, antihypertensives, corticosteroids so on, according to individual status.
1567765|NCT02471599|Other|non-tonsillectomy|The non-tonsillectomy group received conventional drug treatments defined as treatment of participants using the ACEi/ARB,Anticoagulants, Antihypertensives, corticosteroids and so on, according to individual status.
1567766|NCT02471586|Procedure|Coronary PCI guided by IVUS|Imaging type
1567767|NCT02471586|Procedure|Coronary PCI guided by OCT|Imaging type
1567768|NCT02471586|Procedure|Coronary PCI guided by Angiography|Imaging type
1567769|NCT02471573|Procedure|Freeze-all protocol|Embryos are selected for cryopreservation using vitrification technique. Two vitrified embryos will be warmed and transferred in subsequent cycle.
1567770|NCT02471573|Procedure|Fresh transfer protocol|Two embryos are selected and transferred fresh in the same cycle.
1567771|NCT02471560|Drug|dimethyl fumarate|As per the prevailing local label.
1567772|NCT02471560|Drug|injectable MS DMT|As described above.
1567773|NCT02471547|Other|BWT with Mitomycin-C prior TURBT|"Participants will randomly assign, according to random computerized software, to those who receive the heated thermo-chemo therapy and those who will not. The intravesical instillation will take place up to 6 hours prior TURBT in the following matter: The Elmedical BWT system will introduce intravesically a 40mg of heated Mitomycin MMC, diluted in 50cc of saline at a uniform temperature (44-44.50C). The length of the procedure - 50 minutes"
1567774|NCT02471534|Procedure|abdominal compression|When there are clinical signs of hypovolemia, such as hypotension, decreased urine output and central venous pressure less than 5 mmHg, right upper abdomen is gently compressed for 10 seconds. Changes of blood pressure are continuously recorded during this period. About 3 min later, intravenous colloid fluid 10 mL/kg is infused for 20 min.
1567777|NCT02471508|Device|Body-mapping Tank-top Embedded with Biofeedback System|In this study, the eligible subjects will be given tailor-made tank-top embedded with biofeedback system to wear it 8 hours daily. Monitor, observation and additional posture training sessions will be provided during the 6 months wearing period. The effectiveness of the biofeedback tank-top will be evaluated by pre-and post- treatment ultrasonic imaging device (measuring the angle of the spine) and electromyography muscle signal
1567778|NCT02471495|Device|Synergo® RITE + MMC|"Synergo® system delivers homogenous microwave hyperthermia to the bladder wall in combination with bladder instillation of cold chemotherapeutic agent - Mitomycin C (MMC).The energy-delivering unit and the intravesical irrigation system are computer-controlled, The irrigation system consists of a disposable tubing line and catheter set. The catheter is a triple-lumen, silicone, transurethral Foley-type catheter.
MMC is constituted as a powder (40 mg) dissolved in 50 ml sterile water for injection."
1567779|NCT02471482|Other|Mozart music lullaby|Recorded Mozart Lullaby will be played. The noise level will be kept below 45db as recommended by American Academy of Pediatrics and will be monitored by sound monitor placed in incubator during the study period. Enrolled babies will have hearing screening performed prior to discharge from hospital.
1567780|NCT02471469|Drug|Enzalutamide, 160mg, 40 mg soft capsules, once daily|Exclusively determine pharmacokinetics and pharmacodynamics of enzalutamide for the indication according to the drug label
1567781|NCT02471456|Other|Quality of Life Questionnaire|Quality of Life Questionnaire will be completed at least 1 year after their surgery.
1569078|NCT02462317|Drug|Baclofen|baclofen oral tablet
1567785|NCT02471430|Drug|Pegylated Interferon-alpha2a|Pegylated Interferon-alpha2a will be administered subcutaneously in one shot.
1567786|NCT02471417|Dietary Supplement|Dietary nitrate|140ml of nitrate rich beetroot juice provides 12.9mmol nitrate and will be on a single occasion by the study subjects.
1567787|NCT02471417|Dietary Supplement|Placebo|140ml of nitrate depleted beetroot juice provides 0.5mmol nitrate and will be on a single occasion by the study subjects.
1567788|NCT02471404|Drug|Dapagliflozin|10 mg, orally Green, plain, diamond-shaped, film-coated tablet
1567789|NCT02471404|Drug|Saxagliptin|5 mg, orally Plain, yellow, biconvex, round, film-coated tablet
1567790|NCT02471404|Drug|Glimepiride|1, 2, or 4 mg, orally Opaque gray capsule
1567791|NCT02471404|Drug|Placebo for dapagliflozin|Does not contain active ingredient, orally Green, plain, diamond-shaped, film-coated tablet
1567792|NCT02471404|Drug|Placebo for saxagliptin|Does not contain active ingredient, orally Plain, yellow, biconvex, round, film-coated tablet
1567793|NCT02471404|Drug|Placebo for glimepiride|Does not contain active ingredient, orally. Opaque gray capsule
1567794|NCT02471391|Drug|ABT-199|
1567795|NCT02471391|Drug|Ibrutinib|
1567799|NCT02471274|Drug|sotagliflozin|single 400 mg dose
1567800|NCT02471248|Device|Ankle Robot with Power Assistance|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 * 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote gait recovery and physical fitness.
They will wear the Ankle Robot during the gait training. The motor will synchronise with the paretic-side gait pattern to provide dorsiflexion moment during swing phase, and free the ankle joint when the sole is loaded."
1567801|NCT02471248|Device|Sham|"Stroke patients will enrol in a 20-session gait training program for at least two sessions per week. In each session, the stroke patient will walk overground continuously for 2 * 10 minutes and walk up/down a staircase (about 10 steps per flight) for 10 minutes, rest will be provided in between each round of walking or stair climbing. This training can promote physical fitness.
They will wear the Ankle Robot during the gait training. The robot will synchronise with the paretic-side gait pattern to the Ankle Robot provides very low assistance which can be barely perceived by the stroke patient but does not suffice to support the ankle dorsiflexion."
1567802|NCT02471235|Behavioral|Physiotherapy|Pulmonary rehabilitation
1567803|NCT02471222|Drug|ADS-5102|Oral capsules to be administered once daily at bedtime for 4 weeks
1567804|NCT02471222|Other|Placebo|Oral capsules to be administered once daily at bedtime for 4 weeks
1567805|NCT02471209|Drug|Sevoflurane|general anesthesia with 2% followed by 3% sevoflurane
1567806|NCT02471196|Drug|ORM-12741|ORM-12741 low dose twice a day
1567807|NCT02471196|Drug|ORM-12741|ORM-12741 high dose twice a day
1567808|NCT02471196|Drug|Placebo|Placebo twice a day
1567809|NCT02471183|Drug|Selexipag|Tablet for oral administration twice a day. The individual dose will be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).
1567810|NCT02471157|Other|Observation|
1567811|NCT02471144|Biological|Experimental : Secukinumab low dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 50 kg b) 150 mg if weighing 50 kg or more. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
1567812|NCT02471144|Biological|Experimental: Secukinumab high dose|Depending on weight group subject will receive per dose a) 75 mg if weighing less than 25 kg b) 150 mg if weighing between 25 and less than 50 kg c) 300 mg if weighing more than 50 kg. Secukinumab injections (one or two per dose, depending on the weight group) will be administered subcutaneously at Randomization, Weeks 1, 2, 3, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, and 48, and Placebo secukinumab at Weeks 13, 14 and 15 during the blinded phase of the study; thereafter at Week 52 and every 4 weeks during the extension treatment period until Week 232.
1567813|NCT02471144|Biological|Placebo Comparator: Secukinumab Placebo|Placebo secukinumab (one or two subcutaneous injections per dose, depending on weight group) at Randomization and Weeks 1, 2, 3 4 and 8. At Week 12, subjects in the placebo group based on their PASI 75 response status at Week 12 will proceed as follows: • PASI 75 responders will discontinue study treatment at Week 12 and enter the treatment-free follow-up period • PASI 75 non-responders will receive high dose or low dose secukinumab, according to the pre-assignment at the Randomization visit. They will receive their treatment based on the weight category(<25 kg, 25- <50kg, ≥50 kg), on Weeks 12, 13, 14, 15, and then every four weeks starting at Week 16 until Week 48 during the maintenance period; thereafter at week 52 and every 4 weeks during the extension treatment period until Week 232.
1567814|NCT02471144|Biological|Active Comparator: Etanercept|Etanercept 0.8 mg/kg of subject weight and up to a maximum of 50 mg per dose. Subcutaneous etanercept 0.8 mg/kg (one or two injections per dose) once per week, for 51 weeks administered at home (self-injected or by caregiver) or at the study site. At Wk 52 subjects in the etanercept group will move into the treatment-free follow up period and terminate the study.
1567815|NCT02471131|Device|WATCHMAN Device implantation|The implantation of the device will be done into the left atrial appendage according to the guidelines.
1567816|NCT02471118|Drug|Adalimumab 40 mg|Adalimumab will be self-administered via subcutaneous (SC) injection
1567817|NCT02471118|Drug|Placebo|Placebo will be self-administered via subcutaneous (SC) injection
1567818|NCT02471105|Drug|Preserved Bimatoprost 0.01%|Eye drops solution Topical use Once in the evening 3 months
1567819|NCT02471105|Drug|Tafluprost Unit Dose Preservative Free 15microgram/ml|Eye drops solution Topical use Once in the evening 3 months
1569079|NCT02462317|Drug|Placebo toxin|placebo injection
1567822|NCT02471066|Device|rTMS|"Study 1 : 5 daily sessions of rTMS 1 Hz, 95% x resting motor threshold (RMT) applied on M1 / sham
Study 2 : 3 weekly sessions of rTMS 1 Hz, 95% x RMT on M1 combined with ericksonian hypnosis session"
1567823|NCT02471053|Other|Moderate Intensity Exercise|Exercise sessions will be held twice-weekly and will begin with a group warm-up activity, followed by 45 minutes of aerobic activity and ending with a cool down. All aerobic exercise will be performed at a moderate intensity, defined as exercise that elicits a heart rate (HR) between 40-60% of heart rate reserve (HRR). Prior to the initial exercise session target heart rates will be calculated for each subject based on the maximum HR achieved during their baseline stress test.
1567824|NCT02471040|Drug|Beta-hydroxybutyrate|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
1567825|NCT02471040|Other|Normal Saline|Both healthy subjects and type 1 diabetic subjects will receive a bolus-continuous infusion of 40umol/min/kg of BHB for 5 min, followed by a 12µmol/min/kg of BHB or infusion of a comparable volume of normal saline (placebo) to control for possible volume effects for the remainder of the study.
1567826|NCT02471027|Procedure|Neoadjuvant chemotherapy|There is no uniform schemer,commonly used drugs including carboplatin,cisplatin,paclitaxel,vincristine,bleomycin,fluorouracil,ifosfamide,mitomycin,gemcitabine,and so on.Methods including intravenous chemotherapy and artery intervention chemotherapy,also has not been unified.
1567827|NCT02471014|Drug|Pneumovax 23|All participants will receive a single 0.5 mL Pneumovax 23 intramuscular vaccine at baseline.
1567828|NCT02471014|Other|Blood tests|All participants will have two 50 milliliter blood draws: at baseline and up to 6 weeks later.
1567829|NCT02471014|Other|Questionnaires|"All participants will answer the following questionnaires:
UCLA Loneliness Scale Questionnaire will be used to measure a difference between the groups.
Perceived Stress Scale-10 Questionnaire will be used to measure a difference between the groups.
Interpersonal Support Evaluation List-12 will be used to measure a difference between the groups Life Orientation Test-Revised will be used to measure a difference between the groups."
1567830|NCT02471001|Biological|Blood samples|Two additional blood samples will be taken from in-situ catheters during heart surgery.
1567831|NCT02470988|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|
1567832|NCT02470988|Behavioral|CBASP Without DPI|
1567833|NCT02470962|Other|Observation|Observation by serial echocardiography with extended techniques and cardiac magnetic resonance imaging
1567834|NCT02470949|Behavioral|Low Social Status|The participants will be randomized to the Low Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
1567835|NCT02470949|Behavioral|High Social Status|The participants will be randomized to the High Social Status Condition. On their second visit, they will undergo the condition in which they were not randomized to on their first visit.
1567837|NCT02470923|Drug|Nicotine replacement therapy|
1567838|NCT02470923|Behavioral|Intensive counseling|
1567839|NCT02470923|Behavioral|Medical advice|
1567840|NCT02470910|Device|Magnetic Resonance Imaging|
1567841|NCT02470897|Radiation|Radiation Therapy Treatment Planning and Simulation|Undergo urethral-sparing IMRT planning
1567842|NCT02470897|Radiation|SBRT|Undergo moderate dose SBRT with SIB
1567843|NCT02470897|Radiation|SBRT|Undergo uniform dose SBRT
1567844|NCT02470884|Device|Boston Scientific Fully Absorbable Scaffold|Attempt to implant the Boston Scientific Fully Absorbable Scaffold.
1567845|NCT02470871|Biological|Eptacog alfa (activated) or pdFVII|"Comparator Drug 1: Recombinant activated FVII (rFVIIa). Subjects with eptacog alfa (activated) as their routine FVII replacement therapy will receive a single dose of eptacog alfa (activated) in the study.
Comparator Drug 2: Plasma-derived FVII (pdFVII). Subjects with pdFVII as their routine FVII replacement therapy will receive a single injection of pdFVII in the study."
1567846|NCT02470871|Biological|CSL689|Experimental Drug: Recombinant fusion protein, linking activated FVII with albumin (rVIIa-FP). Subjects will receive a single dose of CSL689 at either a low dose (Arm 1) or a high dose (Arm 2)
1567847|NCT02470858|Drug|LDV/SOF+ASV|Ledipasvir/sofosbuvir (LDV/SOF) 90 mg/400 mg fixed-dose combination (FDC) tablet; administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
1567848|NCT02470858|Drug|SOF+DCV+SMV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Simeprevir (SMV) 150 mg tablet orally once daily.
1567849|NCT02470858|Drug|SOF+DCV+ASV|Sofosbuvir (SOF) 400 mg tablet administered orally once daily; Daclatasvir (DCV) 60 mg tablet administered orally once daily; Asunaprevir (ASV) 200mg, administered orally twice daily.
1567850|NCT02470845|Drug|herbal patches of Tian Jiu group|The formula of herbal patch consists of BaiJieZi (Sinapis Semen), Yan Hu Suo（CorydulisRhizoma）、ZhiGan Sui (Kansui Radix)、Xi Xin (Asari Radix et rhizama) and Rengong She xiang(Moschus Artifactus) . The four herbs will be ground into powder, mixed thoroughlywith 20% BaiJieZi (Sinapis Semen), 25% Yan Hu Suo（CorydulisRhizoma), 15% ZhiGan Sui (Kansui Radix), and 40% Xi Xin (Asari Radix et rhizama), and the mixed powder will mix with fresh ginger juice in the ratio of 20g to 25 ml. The mixture will be made to a patch weighted as 2g and 1cm*1cm round size. 0.02g artificial She Xiang (Moschus Artifactus) will be added on top of each patch. Each patch will be applied on one acupoint.
1567851|NCT02470845|Drug|placebo patches of placebo-control group|The placebo patch consists of flour and edible pigments. These two ingredients will be mixed with water and made to patches weighted as 2g and 1cm*1cm round size.Each patch will be applied on one acupoint.
1567852|NCT02470832|Drug|RG1662|
1567853|NCT02470832|Drug|itraconazole|
1567854|NCT02470819|Genetic|Genetic profiling|genetic profiling
1567855|NCT02470806|Device|PICO|Negative Pressure Wound Therapy (NPWT) at 80mmHg (nominal) +/- 20 mmHg to the wound surface
1567856|NCT02470806|Device|tNPWT|NPWT from -25 mmHg and up to -200 mmHg; intensity settings of either low, medium and high; delivery modes of continuous or intermittent. The pressure, intensity and delivery settings will be left to the Investigator's discretion at each study treatment visit.
1567857|NCT02470793|Procedure|Descemet Stripping Automated Endothelial Keratoplasty|Descemet Stripping Automated Endothelial Keratoplasty
1567858|NCT02470793|Procedure|Descemet Membrane Endothelial Keratoplasty|Descemet Membrane Endothelial Keratoplasty
1567859|NCT02470780|Drug|Rifaximin|Rifaximin is an antibiotic used to treat SIBO. It is a 7-day course of treatment followed by three or six months of follow-up. This is a placebo-controlled study designed so that all participants will receive the active drug at least once during the study.
1567860|NCT02470780|Drug|Placebo|Placebo matching Rifaximin treatment.
1567861|NCT02470767|Drug|Direct Oral Anticoagulant (DOAC)|Treatment pattern following the summary of product characteristics
1567862|NCT02470754|Device|Tobacco Cigarette|Usual brand tobacco cigarette smoked by study participant.
1567863|NCT02470754|Device|Electronic Cigarette|Usual brand electronic cigarettes smoked by study participant.
1567864|NCT02470741|Drug|Letrozole|
1567865|NCT02470741|Other|Placebo|
1567866|NCT02470728|Other|New Clinical Pathway|
1567867|NCT02470715|Genetic|Molecular profile|Patients and their treating physician will obtain the patient's genetic risk assessment
1567868|NCT02470702|Drug|Oritavancin|
1567869|NCT02470702|Drug|Placebo (D5W)|
1567870|NCT02470689|Drug|Diacerin cream|Diacerin tablet solubule in ultraphil cream
1567871|NCT02470676|Device|Pessary|Two optional pessary sizes with the following dimensions: 65/17/35 or 70/17/35 and 200 mg daily progesterone vaginal suppositories (Utrogestan)
1567872|NCT02470676|Drug|Progesterone|200 mg daily of vaginal progesterone suppositories (Utrogestan)
1567873|NCT02470663|Dietary Supplement|DENSITYTM caplets (marketed as Amorphical)|supplementation
1567874|NCT02470663|Dietary Supplement|Calcium carbonate 600 mg once daily|supplementation
1567875|NCT02470650|Drug|elvitegravir/cobicistat/emtricitabine/tenofovir|1 recovered tablet once Per day ● Specify total dose (number and unit): 150 mg de elvitegravir, 150 mg cobicistat, 200 mg emtricitabine , 245 mg tenofovir disoprox milligram(s)
1567876|NCT02470650|Drug|Darunavir|Darunavir 800 mg (Prezista®) 1 recovered tablet 800 mg once a day
1567877|NCT02470650|Drug|abacavir/lamivudine|Abacavir 600 mg /lamivudine 300 mg recovered tablet once a day
1567878|NCT02470650|Drug|Ritonavir|Ritonavir 100 mg recovered tablet once a day
1567879|NCT02470650|Drug|Lamivudine|lamivudine 300mg (Epivir) 1 recovered tablet
1567880|NCT02470650|Drug|rilpivirine|rilpivirine (Edurant®) 1 recovered tablet 25 mg. once a day
1567881|NCT02470637|Drug|SAR439065|"Pharmaceutical form:dry powder insulin
Route of administration: inhalation"
1567882|NCT02470637|Drug|Insulin lispro|"Pharmaceutical form:solution for injection
Route of administration: subcutaneous"
1567883|NCT02470624|Other|treatment following current guideline|
1567884|NCT02470611|Drug|Sodium alendronate|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss > 3mm and proximal bone defects) received 1% sodium alendronate gel
1567885|NCT02470611|Other|Placebo|After manual quadrant-wise scaling and root planing, at the final treatment appointment the randomized selected periodontal site (showing pocket depth ≥ 5mm, clinical attachment loss > 3mm and proximal bone defects) received 1% placebo gel
1567886|NCT02470598|Other|Treatment with Adapted Automated Peritoneal Dialysis (aAPD)|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists
1567892|NCT02470572|Other|Omnyx™ IDP system|Omnyx™ IDP system for Whole Slide Images (WSI)
1567893|NCT02470572|Other|Conventional light microscope|Conventional light microscope
1567894|NCT02470559|Biological|Aldesleukin|Given SC
1567895|NCT02470559|Biological|HER2Bi-Armed Activated T Cells|Given IV and IP
1567896|NCT02470559|Other|Laboratory Biomarker Analysis|Correlative studies
1567897|NCT02470559|Biological|Sargramostim|Given SC
1567898|NCT02470546|Drug|Metformin|Metformin 1000mg twice a day
1567899|NCT02470546|Drug|Placebo|Placebo 1000mg twice a day
1567900|NCT02470533|Radiation|Radiation therapy|6 fractions of 8-9Gy
1567901|NCT02470533|Device|chemoembolization|Up to 4 sessions
1567902|NCT02470520|Procedure|CRRT|continuous renal replacement therapy
1567903|NCT02470507|Other|AKI|development of immune dysregulation and rise in inflammatory markers and activation of immune cells
1567904|NCT02470494|Device|Sound amplification provided via the EarLens CHD|Subjects with mild to severe hearing impairment receiving sound amplification treatment with EarLens CHD.
1567905|NCT02470481|Other|No Intervention|This is an obervational study
1567906|NCT02470468|Biological|DCVAC add on to SOC|DCVAC add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
1567907|NCT02470468|Biological|DCVAC and immune enhancers add on to SOC|DCVAC +/- immune enhancers (Interferon-α and Hydroxychloroquine) add on to SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
1567908|NCT02470468|Other|Standard of Care Chemotherapy|SOC (Carboplatin, Paclitaxel): until progression or intolerance or death
1567909|NCT02470455|Drug|Atorvastatin|Some patients were receiving 20 mg of Atorvastatin wheras others were on a higher dose of 40-80mg daily. Patients were taking statins for either dyslipidemia, or primary or secondary prevention of cardiovascular disease.
1567910|NCT02470442|Drug|Sevoflurane/Desflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with desflurane
1567911|NCT02470442|Drug|Sevoflurane|Anesthesia induced with sevoflurane and anesthetic maintenance with sevoflurane
1567912|NCT02470429|Device|SYSTANE HYDRATION lubricant eye drops|Preserved with POLYQUAD (polidronium chloride) 0.001%
1567913|NCT02470429|Device|Hyabak 0.15% eye drops|Preservative-free
1567914|NCT02470429|Drug|0.9% saline eye drops|Preservative-free, one drop 4 times a day in each eye (run-in period)
1568045|NCT02469480|Drug|Ferro sanol|200 mg ferro sanol per day over 12 weeks
1567915|NCT02470416|Device|Small bowel video capsule endoscopy (VCE) GIVEN/COVIDIEN LTD|Cases and controls will have a standard VCE procedure at our institution.
1567916|NCT02470403|Drug|LIK066|LIK066 25 mg tablets
1567917|NCT02470403|Drug|Placebo|Matching placebo tablets
1567919|NCT02470377|Device|Transcranial Magnetic Stimulation|A form of external neuromodulation using pulsatile magnetic fields on the surface of the head.
1567920|NCT02470338|Procedure|MBP plus arthroscopy (Group A)|
1567921|NCT02470338|Procedure|MBP alone (Group B)|
1567922|NCT02470325|Drug|Avidekel oil|Avidekel cannabis oil 6:1 CBD:THC
1567923|NCT02470325|Drug|Enriched Avidekel oil|Enriched Avidekel cannabis oil 20:1 CBD:THC
1567924|NCT02470312|Procedure|CRT implantation|It is a novel 3D electromagnetic navigation system (MediGuide™) that is capable of non-fluoroscopic navigation of sensor-enabled tools in the x-ray environment
1567925|NCT02470312|Device|MediGuide|
1567926|NCT02470312|Procedure|EP|
1567927|NCT02470299|Drug|Ketorolac|"Ketorolac tromethine 15 mg or 30 mg doses will be administered via intravenous (IV) push undiluted over 15 - 30 seconds
Ketorolac will be dosed according to FDA approved recommendations. For planned three daily dose (IV) based on clinical scenario:
Patients < 65 years of age: Daily dose of 30 mg for three doses.
Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses
Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
1567928|NCT02470299|Other|Placebo|"Equivalent volume of normal saline will be set in the syringe for each daily dose registered for the patient in a blinded fashion. The volume will be determined by the dose calculation as follows: For planned three daily dose (IV) based on clinical scenario:
Patients < 65 years of age: Daily dose of 30 mg for three doses.
Patients ≥ 65 years of age, renally impaired and/or less than 50 kg (110 lbs) of body weight: Daily dose of 15 mg for three doses.
Blood and peritoneal fluid will be drawn prior to each dose (time 0, 24, 48, 72 hr) as well as at 6 hr after the first dose"
1567929|NCT02470286|Drug|SA001|
1567930|NCT02470286|Drug|Placebo|
1567931|NCT02470247|Other|Remote Ischemic Preconditioning (RIPC)|"RIPC is accomplished by performing 4 cycles of alternating 5-minute inflation and 5-minute deflation of a standard upper-arm blood pressure cuff, to induce transient and repetitive arm ischemia and reperfusion.
RIPC will be started just before the CTA, and the time between the last inflation cycle and the beginning of the CTA will be less than 45 minutes."
1567932|NCT02470247|Other|SHAM Remote Ischemic Preconditioning (SHAM RIPC)|"The SHAM Remote Ischemic Preconditioning (SHAM RIPC) will be carried out with the same number of cycles that the RIPC but cuff will be inflated to the diastolic pressure of the subject and the cuff will be deflated to10 mmHg in order to maintain a non- ischemic compression (blind patient protocol)."
1567933|NCT02470234|Drug|Methylphenidate HCl ER Capsules|Methylphenidate Hydrochloride Extended-Release Capsules administered once daily in the morning
1567934|NCT02470221|Device|Flo-Trac monitoring system|Applying Flo-Trac monitoring system to monitor Stroke Volume Variation and Cardiac Output and further manage intra-operative fluid therapy.
1567935|NCT02470221|Device|Conventional fluid therapy|Applying conventional fluid therapy according to Peking Union Medical College Hospital standard.
1567936|NCT02470195|Behavioral|workshop|workshop for procedural simulation for education in difficult airway situation
1567937|NCT02470169|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
1567938|NCT02470169|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
1567939|NCT02470169|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
1567940|NCT02470169|Device|shepherd catheter|
1567941|NCT02470169|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
1567944|NCT02470143|Behavioral|Bike application arm|The intervention patients will use the cycling application on a smartphone, in combination with a wrist-worn heart rate monitor. During the study, the patients will use the cycling application for one month, in which they can make use of the cycling application each time they are cycling outdoor in their home environment.
1567945|NCT02470130|Behavioral|relaxation|5 min of conversational relaxation red by one of the instructor between simulation and debriefing
1567946|NCT02470117|Drug|Alginate-based reflux suppressant|
1567947|NCT02470117|Drug|magnesium-aluminium antacid gel|
1567948|NCT02470104|Biological|Breastmilk|"A registered dietician will supervise milk provision.
If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
1567949|NCT02470091|Biological|Denosumab|Given SC
1567950|NCT02470091|Other|Laboratory Biomarker Analysis|Correlative studies
1567951|NCT02470091|Other|Pharmacological Study|Correlative studies
1567998|NCT02469792|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
1567999|NCT02469792|Procedure|Arthroscopic surgery|
1567954|NCT02470065|Drug|Afatinib|once daily afatinib at a dose of 40 mg for 8 weeks
1567955|NCT02470065|Procedure|Immediate surgery|anatomical resection and systematic lymph node dissection
1567956|NCT02470052|Device|OL-BF-001|Subjects assigned to this study will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe. The subjects will also receive medical management.
1567957|NCT02470039|Drug|insulin 338 (GIPET I)|Oral administered once daily in combination with metformin with or without DPP-4 inhibitor
1567958|NCT02470039|Drug|insulin glargine|Injected s.c./subcutaneously (under the skin) once daily in combination with metformin with or without DPP-4 inhibitor
1567959|NCT02470039|Drug|placebo|Administered once daily
1567960|NCT02470026|Drug|yohimbine|single low dose treatment
1567961|NCT02470026|Drug|placebo|single control treatment
1567962|NCT02470013|Dietary Supplement|Balanced, energy dense, moderate protein sip feed|2x 125 ml bottles (equiv. 600 kcal) of Fortimel Compact daily for 3 months in addition to normal eating habits
1567963|NCT02470000|Device|Intravascular laser irradiation of blood (ILIB)|continuous-wave ILIB is performed using a 632.8nm (red light) laser beam from a He-Ne laser machine (Y-J ILIB-5, Bio Human Energy Cooperation, New Taipei City, Taiwan, R.O.C.).The participants sit on a sofa with their arms relax and supported on the table. A 24-gauge catheter is inserted to a superficial vein in upper extremity under sterile preparation, and an optic fiber channel is connected to the catheter for blood irradiation.
1567964|NCT02470000|Device|Transcutaneous electrical nerve stimulation|TENS over neck for 15 minutes.
1567965|NCT02470000|Other|Stretching exercise|stretching exercise to the involved muscle for 15 minutes.
1567966|NCT02469987|Drug|MYL-1402O|Treatment A - single 1mg/kg dose of MYL-14020 IV infusion over 90 mins.
1567967|NCT02469987|Drug|US marketed Avastin(R)|Treatment B - single 1mg/kg dose of US marketed Avastin® IV infusion over 90mins
1567968|NCT02469987|Drug|EU marketed Avastin(R)|Treatment C - single 1mg/kg dose of EU marketed Avastin® IV infusion over 90mins.
1567969|NCT02469974|Drug|RUXOLITINIB / INC 424|Administered orally 5-20 mg twice daily x 16 weeks of therapy prior to attempted peripheral blood stem cells (PBSC) collection, during the collection and rest period and 3 months of therapy after high dose chemotherapy (HDC).
1567970|NCT02469974|Drug|Filgrastim|Peripheral blood stem cells (PBSC) will be mobilized with filgrastim 10 mcg/kg/day IV
1567971|NCT02469974|Drug|Busulfan|Conditioning for autologous Hematopoeitic Stem Cell Transplantation (HSCT) will consist of IV busulfan 2.0 mg/KBW once daily x 4 for days -5 to -2
1567972|NCT02469961|Drug|Dexmedetomidine|Participants will receive an interscalene block and will be sedated with Dexmedetomidine and compared to sedation with propofol
1567973|NCT02469961|Drug|Propofol|Participants will receive an interscalene block and be sedated with Propofol and compared to sedation with Dexmedetomidine
1567974|NCT02469961|Other|Interscalene block|Interscalene block is used for the main anesthetic for the case
1567975|NCT02469948|Drug|Botulinum toxin type A|To inject Botulinum toxin type A on the spasticity lower extremity for stroke patients by Ultrasonography direct-guidance, Electric stimulation and Surface anatomy landmark.
1567976|NCT02469935|Procedure|ultrasound|surgeon-performed ultrasound
1567977|NCT02469922|Device|Positron emission tomography|
1567978|NCT02469922|Radiation|radiochemotherapy|Every patients will be treated with radiochemotherapy as a standard of care
1567979|NCT02469909|Other|Overnight observation|patients in the immediate decannulation group would be admitted for an overnight in intensive care unit or the otolaryngology department. they would be monitored for any respiratory or airway complications.
1567980|NCT02469909|Other|Pre-discharge evaluation|After an overnight observation, patients in the immediate decannulation group would would undergo clinical and laboratory evaluation including vital signs and blood gases.
1567981|NCT02469909|Other|outpatient clinic follow ups|all patients would visit the otolaryngology outpatient clinic in 7, 30 and 90 days following decannulation for an evaluation of any respiratory complications following decannulation
1567982|NCT02469909|Procedure|immediate decannulation|the tracheostomy tube is removed at once
1567983|NCT02469909|Procedure|Gradual tracheostomy tube decrease|The tracheostomy tube will be reduced in 2 sizes compared with the initial inner diameter of the tube. The patients will remain with the reduced tube for 48 hours, and the tube will be removed if the patients would meet pre-decannulation evaluation
1567984|NCT02469896|Drug|Tocilizumab|IV Infusion
1567985|NCT02469896|Other|Placebo|IV Infusion
1567986|NCT02469883|Drug|Sinotecean|
1567987|NCT02469870|Behavioral|Autism Parent Trainer (APT)|Experimental condition
1567988|NCT02469870|Behavioral|self-paced ABC training online|Content comparison group.
1567991|NCT02469831|Drug|Rocuronium|
1567992|NCT02469805|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
1567993|NCT02469805|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL.
1567994|NCT02469805|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
1567995|NCT02469805|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
1567996|NCT02469805|Device|Shepherd catheter|Processes semen will be drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
1567997|NCT02469792|Procedure|Liposuction|
1568000|NCT02469792|Other|Intraarticular administration of autologous ADRC|
1568001|NCT02469779|Behavioral|Surveys|At baseline participants complete survey about their mental and physical health and their opinions concerning health information and the internet. The survey will take about 15-20 minutes to complete.
1568002|NCT02469779|Behavioral|ASPIRE Website|Participants view the ASPIRE website containing videos, activities, and health information facts about the effects of smoking, the benefits of meditation, and healthy living. This viewing will be videotaped
1568003|NCT02469779|Behavioral|ASPIRE Text-Based Website|Participants view the ASPIRE text-based website containing health information facts about smoking, the benefits of meditation, and healthy living.
1568004|NCT02469779|Behavioral|Follow Up Survey|Participants complete a follow-up survey about their opinions concerning health information and the internet immediately after they have completed their last session on the website.
1568005|NCT02469766|Procedure|SWL|Patients in this arm will undergo SWL
1568006|NCT02469766|Procedure|Semirigid URS|Patients in this arm will undergo semirigid URS
1568007|NCT02469766|Procedure|Flexible URS|Patients in this arm will undergo Flexible URS
1568008|NCT02469753|Drug|NSAIDs|continuous daily
1568009|NCT02469753|Drug|NSAIDs|on demand
1568010|NCT02469753|Drug|anti-TNF|
1568011|NCT02469740|Drug|Ticagrelor|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 90 mg BD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 90 mg BD orally for 5 weeks (4 weeks plus a 1 week washout period).
1568012|NCT02469740|Drug|Clopidogrel|Patients that are randomly selected to receive ticagrelor during the first phase of the study will receive the dose of 75 mg OD orally. This will be continued for 4 weeks before the endothelial function test will be performed. If the patients are assigned in the 2nd phase of the study, they will receive 75 mg OD orally for 5 weeks (4 weeks plus a 1 week washout period).
1568013|NCT02469727|Behavioral|Fitbit|Participants will use the FitBit device to track their physical activity
1568014|NCT02469727|Behavioral|Facebook group|Participants will receive and post messages and receive badges on the Facebook group
1568016|NCT02469701|Drug|nivolumab and ablation|
1568017|NCT02469688|Drug|ASP4070|intramuscular or intradermal
1568018|NCT02469688|Drug|Placebo|intramuscular or intradermal
1568019|NCT02469675|Device|Transcranial magnetic stimulation|One TMS pulse every 10 seconds for 20 minutes
1568020|NCT02469675|Device|Median nerve stimulation|One median nerve pulse every 10 seconds for 20 minutes
1568021|NCT02469675|Device|Cervical transcutaneous stimulation|One cervical pulse every 10 seconds for 20 minutes
1568022|NCT02469662|Device|Nexel Total Elbow|Nexel Total Elbow used in primary or revision total elbow arthroplasty
1568023|NCT02469649|Device|Dipole Density Mapping with AcQMap followed by ablation|
1568024|NCT02469636|Device|Dipole Density Mapping with AcQMap followed by ablation|
1568025|NCT02469623|Device|Dipole Density Mapping with AcQMap followed by ablation|
1568026|NCT02469610|Other|Intercostal block Bupivacaine based|Intercostal Bupivacaine block of 100ml over five intercostal spaces.
1568027|NCT02469597|Drug|Furosemide|1 mg/kg intravenous or oral (will give oral unless patient has peripheral IV access in place), maximum dose 10mg (1ml), x 1 dose
1568028|NCT02469597|Drug|Placebo|0.1ml/kg intravenous or oral (Normal Saline) (will give oral unless patient has peripheral IV access in place), maximum dose 1ml, x 1 dose
1568029|NCT02469584|Procedure|small stitch anterior colporrhaphy|A midline plication will be performed with continuous delayed absorbable sutures (3-0 polydioxanone) and the distance between the sutures will be 0.5 cm.
1568034|NCT02469545|Drug|Lactobacillus Plantarum 299v|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and probiotic - 2x1 caps. per day of Lactobacillus Plantarum 299V (10mld colony forming units in 1 caps.) for 8 weeks.
1568035|NCT02469545|Drug|Crystalline cellulose powder|Administering antidepressant drug (SSRI - selective serotonin reuptake inhibitor) and placebo of probiotic - 2x1 placebo caps. filled with micro-crystalline cellulose powder for 8 weeks.
1568036|NCT02469545|Drug|Escitalopram|5-20mg daily
1568037|NCT02469545|Drug|Sertraline|50-100mg daily
1568040|NCT02469519|Drug|Betamethasone - ACTIVE|antenatal corticosteroid (ACS) is to be given by injection 24 hours apart for two doses.
1568041|NCT02469519|Other|Normal Saline - PLACEBO|normal saline of the same quantity as with the experimental drug is to be given by injection 24 hours apart for two doses
1568042|NCT02469506|Device|Neuromuscular Electrical Stimulation (NMES)|The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
1568043|NCT02469493|Device|acupuncture (Huatuo)|The needles used were Huatuo brand (Suzhou, China) sterile disposable stainless steel filiform; needles sized 0.25*25 mm. After disinfection, needles were inserted 0.5 to 0.8 inches into the skin and were manipulated manually to obtain Deqi. An electric stimulator (Huatuo SDZ-V, Suzhou, China) was connected to the needles and delivered a constant-current, 0.2-ms, density-wave, stimulus of 2 to 10-Hz frequency, level of intensity was as much as tolerable, but not painful to the subjects. The needles were left for 30 minutes and then removed.
1568044|NCT02469480|Drug|FerInject|FerInject: max. 2.000 mg of ferric carboxymaltose over max. 2 weeks (max. 1.000 mg per week).
1568046|NCT02469467|Dietary Supplement|VS-505|VS-505 is orally administered with meal for 8 weeks
1568047|NCT02469454|Drug|early insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 48 h postpartum.
1568048|NCT02469454|Drug|conventional insertion|Postpartum women into whom the etonogestrel-releasing contraceptive implant (Implanon®, N.V. Organon, Oss, Netherlands) will be inserted in the first 6 week of delivery.
1568049|NCT02469428|Other|Clean air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
1568050|NCT02469428|Other|Ozone|Each subject will be exposed to 0.3 ppb ozone for 2 hours. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 20 L/min/m2 BSA followed by a 15 minute rest period, repeated 4 times.
1568051|NCT02469415|Drug|Pacritinib|"Part 1: Pacritinib 200 mg taken by mouth twice daily.
Part 2: Pacritinib dose decreased to 200 mg in the morning and 100 mg in the evening for the first cycle of combined therapy. If no toxicity is observed in first cycle of combined therapy, Pacritinib dose may be increased to 200 mg twice a day on subsequent cycles of combined therapy."
1568052|NCT02469415|Drug|5-azacitidine|Part 2 Starting Dose of 5-azacitidine: 75 mg/m2 by vein on Days 1 - 5 of Cycles 5 and beyond.
1568053|NCT02469415|Drug|Decitabine|Part 2 Starting Dose of Decitabine: 20 mg/m2 by vein on on Days 1 - 7 of Cycles 5 and beyond.
1568054|NCT02469402|Dietary Supplement|Standard infant formula|
1568055|NCT02469402|Dietary Supplement|Protein reduced alpha-lactalbumin formula, with higher levels of alpha-lactalbumin|
1568058|NCT02469376|Drug|[18F]-GP1|Radiopharmaceutical Product (Tracer) to visualize with Positron Emission Tomography a thrombus in humans.
1568059|NCT02469363|Device|Macintosh laryngoscope|Hemodynamic parameters after endotracheal intubation with Classic laryngoscope (Macintosh)
1568060|NCT02469363|Device|Mc-Coy laryngoscope|Hemodynamic parameters after endotracheal intubation with Mc-Coy laryngoscope
1568061|NCT02469363|Device|C-Mac videolaryngoscope|Hemodynamic parameters after endotracheal intubation with C-Mac videolaryngoscope
1568062|NCT02469363|Device|McGrath videolaryngoscope|Hemodynamic parameters after endotracheal intubation with McGrath videolaryngoscope
1568063|NCT02469350|Other|Serious game|Rehabilitation with serious game
1568064|NCT02469337|Drug|Dichloroacetate|Dichloroacetate, an analog of acetic acid has been shown to increase the activation of PDC by inhibiting PDK4 in humans. This drug is expected to shift the metabolism of pyruvate from glycolysis and towards oxidative pathway in the mitochondria
1568065|NCT02469337|Dietary Supplement|Carbohydrate drinks|preoperative carbohydrate drinks
1568066|NCT02469337|Behavioral|Moderate intensity exercise|30 min exercise using a semi-recumbent exercise bike, at about 70% of their age estimated heart rate
1568067|NCT02469324|Behavioral|Cognitive Behavioral Therapy|The course will be two weeks long, including the didactic portion of each course and the follow-up exercises (meditations for the CMT condition and exercises for the CBT condition) practiced daily for a total of two weeks. The course will contain two distinct parts. Part (a) will consist of a 45-minute didactic lesson that covers the basics of each approach. The course will provide a narrative rationale and the motivation for participants to complete the exercise portion of the course. Part (b) will be presented following completion of the didactic portion of the course. Participants will receive an automatically generated email following completion of the didactic that will include information on the follow-up exercises, suggestions for how to continue practicing, and a link to the the didactic portion of the course in case they want to review it again. Two weeks after enrollment and the completion of Part (b), participants will be invited to complete the post baseline measures.
1568068|NCT02469324|Behavioral|Compassionate Mind Training|see above
1568069|NCT02469311|Other|chlorhexidine impregnated cloths|Pre-operative use of Chlorhexidine cloths night before and morning of surgery
1568070|NCT02469311|Other|Standard of care bathing with antibacterial soap and water|Patients had standard pre-operative bathing with antibacterial soap and water the night before surgery.
1568071|NCT02469298|Drug|GSK1325756 (Danirixin)|It will be supplied as capsule shaped white film coated tablet containing 75 mg GSK1325756 for oral use
1568072|NCT02469298|Drug|Placebo To Match GSK1325756|It will be supplied as capsule shaped white film coated placebo tablet for oral use
1568073|NCT02469298|Drug|Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing 75 mg Oseltamivir phosphate and overfill of pre-gelatinized starch for oral use
1568074|NCT02469298|Drug|Placebo To Match Oseltamivir Phosphate|It will be supplied as size 0 Swedish Orange capsule containing pre-gelatinized starch and magnesium stearate for oral use
1568075|NCT02469285|Dietary Supplement|Modified pork|Pork with modified fatty acid composition
1568076|NCT02469285|Dietary Supplement|Pork|Pork with normal fat composition
1568077|NCT02469285|Dietary Supplement|Pork and berries|Pork with normal fat composition and Finnish berries
1568079|NCT02469259|Drug|Oxytocin|
1568080|NCT02469259|Other|Placebo|
1568088|NCT02469207|Other|Removal of tissue post-mortem|
1568089|NCT02469194|Other|Blood Draw|5-10 cc of whole blood will be obtained using standard, sterile venipuncture techniques
1568090|NCT02469168|Device|Recell|ReCell Treatment over wound pretreated with INTEGRA™ MBWM Wound Matrix
1568091|NCT02469168|Procedure|Control|Standard meshed split thickness skin graft over wound pretreated with INTEGRA™ MBWM Wound Matrix
1568092|NCT02469155|Drug|ITI-007|
1568093|NCT02469155|Drug|Risperidone|
1568094|NCT02469155|Drug|Placebo|
1568095|NCT02469142|Procedure|ADM tension-free hernia reparation|Use ADM as opposed to nothing to repair incarcerated inguinal hernia
1568096|NCT02469129|Drug|[18F]FluorThanatrace|"For the Dosimetry Studies, 10 mCi of [18F]FTT will be injected intravenously, and participants will be placed in the following groups to be imaged with PET at the specified time points: 0 minute group--image at 0 and 120 min. after tracer injection; 30 minute group--image at 30 and 150 min. after tracer injection; 60 minute group--image at 60 and 180 min. after tracer injection; and 90 minute group--image at 90 and 210 min. after tracer injection.
For the Kinetic Studies, 10 mCi of [18F]FTT will be injected intravenously, and a 60-minute dynamic PET scan will be obtained starting at the time of injection."
1568097|NCT02469116|Drug|Docetaxel|
1568098|NCT02469116|Drug|Carboplatin|
1568099|NCT02469116|Drug|Pegylated G-CSF|
1568100|NCT02469103|Device|C2|C2 and colonoscopy will be performed one after another on the same day
1568101|NCT02469103|Procedure|colonoscopy|
1568102|NCT02469090|Drug|APL-130277|"Use to treat up to 5 OFF episodes per day"
1568103|NCT02469090|Drug|Placebo|placebo
1568104|NCT02469077|Behavioral|exercise|Each exercise session will consist of a 5 minute warm-up, 30 minutes of aerobic exercise, followed by a 5 minute cool-down period. Aerobic exercise will consist of treadmill walking/running, stepping, elliptical, or cycling exercise as preferred by the participant. Duration of exercise will be standardized at 30 minutes with a target exercise intensity between 70-85% Heart Rate Reserve (RPE = 15, hard). Because of the focus on de-conditioned individuals with Chronic Low Back Pain, the duration and intensity of exercise will be progressively increased up to target during the first two weeks to avoid symptom exacerbation and minimize study drop-out.
1568105|NCT02469077|Drug|Placebo|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will receive: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each)
1568106|NCT02469077|Drug|Morphine|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will receive: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each)
1568107|NCT02469077|Drug|naloxone|In randomized order (crossover) across 3 laboratory sessions each approximately 5 days apart, participants will receive: 1) 4 doses of saline placebo (20ml each), 2) an 8mg dose of naloxone (in 20ml saline vehicle), followed by saline, 4mg naloxone, and saline, or 3) morphine sulfate (0.03 mg/kg in 20ml saline vehicle initially, followed by 3 incremental doses of 0.02mg/kg each)
1568110|NCT02469051|Device|Breathhold SPECT-MPI|Respiratory triggered SPECT myocardial perfusion imaging
1568111|NCT02469051|Device|Standard freebreathing SPECT-MPI|Clinically indicated, standard non-respiratory triggered SPECT myocardial perfusion imaging
1568112|NCT02469051|Device|Coronary CT angiography|Clinically indicated coronary CT angiography serving as standard of reference
1568113|NCT02469038|Device|AccuCath catheter|Ultrasound-guided insertion of an AccuCath catheter during a standard of care procedure.
1568114|NCT02469038|Device|Control|Ultrasound-guided insertion of a conventional IV catheter during a standard of care procedure.
1568115|NCT02469025|Other|Manual caudal traction mobilization in resting position|
1568116|NCT02469025|Other|Manual caudal traction mobilization in end range position|
1568117|NCT02469025|Other|Selftreatment|Each subject is advice to do some exercises at home
1568118|NCT02469012|Drug|Combination #1|Sofosbuvir + Ribavirin
1568119|NCT02469012|Drug|Combination #2|Sofosbuvir + Daclatasvir
1568120|NCT02469012|Drug|Combination #3|Sofosbuvir + Daclatasvir + Ribavirin
1568121|NCT02469012|Drug|Combination #4|Sofosbuvir + Ledipasvir
1568122|NCT02469012|Drug|Combination #5|Sofosbuvir + Ledipasvir + Ribavirin
1568123|NCT02468999|Drug|human insulin|
1569080|NCT02462317|Drug|placebo baclofen|placebo oral tablet
1568124|NCT02468973|Behavioral|Life style counseling|Life style counseling for chronic patients by medical students
1568130|NCT02468934|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the leg that underwent lead placement. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
1568131|NCT02468921|Procedure|Thyroidectomy|Regular thyroidectomy or hemithyroidectomy through Kocher's skin incision
1568132|NCT02468908|Drug|Molgramostim|
1568133|NCT02468908|Drug|Placebo|
1568134|NCT02468882|Dietary Supplement|Watercress|100g of watercress daily during radiation therapy
1568135|NCT02468869|Other|"Communication skills training emotional skills"|
1568136|NCT02468869|Other|"Communication skills training information structuring"|
1568137|NCT02468856|Drug|armodafinil|Armodafinil 250 mg tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Area under the plasma concentration versus time curve (AUC), Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
1568138|NCT02468856|Drug|Placebo (for armodafinil)|Placebo tablet single dose administration. Outcome measures: Driving simulator performance, Electroencephalogram activity, Motor Praxis Task, the Visual Object Learning Test, the Fractal-2-Back, the Abstract Matching, the Line Orientation Test, the Digit-Symbol Substitution Task, the Balloon Analog Risk Test, and the Psychomotor Vigilance Test
1568139|NCT02468843|Device|Biphasic DBS stimulation|"The following protocol will be followed for each subject. In between, baseline and novel stimulation settings there will be a 30-minute washout period with DBS in the off state.
Current best/optimized DBS setting (considered baseline)
DBS off for 30 minutes
Biphasic pulse stimulation mode (immediate assessment)
Biphasic pulse stimulation mode (assessment at 1h)
Biphasic pulse stimulation mode (assessment at 2h)"
1568140|NCT02468843|Other|Unified Dystonia Rating Scale|Neurologist use the UDRS to determine the severity and duration of dystonia on 14 body areas.
1568141|NCT02468843|Other|Burke-Fahn- Marsden scale|Neurologist use the BFMDRS to rate the severity of dystonia in 9 regions of the body.
1568142|NCT02468830|Drug|mirabegron|Switch treatment from antimuscarinic to study medication. A dose up-titration will be possible if well tolerated and sub-optimal efficacy.
1568143|NCT02468817|Procedure|Treadmill Exercise|2 (two) 1-hour of vigorous exercise bouts under different thermal conditions
1568144|NCT02468817|Procedure|Magnitude of Ca loss during Exercise at 26 degrees Celcius|Blood samples at 15-min intervals starting 15 min before exercise and ending 60 min after exercise
1568145|NCT02468804|Device|rTMS|TMS: Repetitive TMS will be administered using a 70-mm diameter air-cooled figure-of-8 coil and SuperRapid2 Stimulator (Magstim, Jali Medical US distributors, Woburn, MA). Repetitive pulses will be delivered to the right and left pre-frontal cortex (Brodman area 46) using a frameless stereotactic navigation system and the subject's MRI in Brainsight software. Stimuli will be delivered at 20 Hz at 90% of the subjects resting motor threshold (rMT) for 25 trains of 30 pulses per train, inter-train interval of 30 seconds for a total of 750 pulses per hemisphere. The same TMS parameters as active stimulation but with the coil held at 90° to the scalp to induce similar somatic sensations and noise as in the active group with minimal direct brain effects.
1568146|NCT02468804|Device|Sham TMS|Sham TMS will be administered with a Magstim sham coil with electrodes attached to mimic the sounds and sensation of real TMS. The site and frequency of stimulation will be identical to the real TMS described above.
1568147|NCT02468791|Drug|Rituximab|
1568148|NCT02468778|Device|HeartMate PHP|The HeartMate PHP System is a temporary (<6 hours) ventricular assist device indicated for use during high risk percutaneous coronary interventions (PCI) performed in elective or urgent, hemodynamically stable patients with severe coronary artery disease and depressed left ventricular ejection fraction.
1568149|NCT02468778|Device|Any Abiomed Impella® device approved for use in high-risk PCI|Any Abiomed Impella® device approved for use in high-risk PCI
1568150|NCT02468765|Other|Neuropsychological and emotional evaluation with monitoring|Recognition tasks of emotional facial expressions with electroencephalogram, electrodermal activity measure and heart rate measure, questionnaires and neuropsychological tests
1568151|NCT02468752|Drug|Oxygen|
1568152|NCT02468752|Other|Air|
1568153|NCT02468739|Drug|EC-T or TC plus GM1|"EC-T: Patients will receive dose-dense EC (epirubicin and cyclophosphamide) every 2 weeks followed by taxotere (every 3 weeks) or paclitaxel (every 2 weeks or weekly).
TC: Patients will receive taxotere and cyclophosphamide every 3 weeks.
GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day 0) to the completion of chemotherapy (Day 2), and the dosages of GM1 are 80mg per day."
1568154|NCT02468739|Drug|EC-T or TC plus placebo|"EC-T: Patients will receive dose-dense EC (epirubicin and cyclophosphamide) every 2 weeks followed by taxotere (every 3 weeks) or paclitaxel (every 2 weeks or weekly).
TC: Patients will receive taxotere and cyclophosphamide every 3 weeks.
Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day 0) to the completion of chemotherapy (Day 2), and the dosages of placebo are 80mg per day."
1568155|NCT02468726|Device|NER1008 enema|NER1008 enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
1568156|NCT02468726|Drug|Fleet|Fleet enema administered to cleanse the bowel bewteen 1 and 3 hours prior to flexible sigmoidoscopy
1568157|NCT02468713|Drug|Combiflex® lipid peri|total parenteral nutrition solutions containing glucose, amino acids, electrolyte, soybean oil
1569081|NCT02462304|Procedure|End-Point-Management grid laser|
1568158|NCT02468713|Drug|Winuf® peri|total parenteral nutrition solution containing glucose, amino acids, electrolyte, soybean oil, medium chain triglyceride, olive oil and fish oil
1568161|NCT02468687|Drug|N-methyl-pyrrolidone|NMP will be taken each morning as a single daily dose of oral suspension at a concentration of 50mg/ml on an empty stomach at least 30 minutes prior to food.
1568162|NCT02468674|Drug|bimagrumab|"bimagrumab low dose bimagrumab moderate dose bimagrumab high dose
Bimagrumab was administered as an intravenous infusion starting on Day 1 until week 25 in the core study. No intervention in the extension study."
1568163|NCT02468674|Drug|Placebo|"Placebo
Placebo was administered as intravenous infusion from Day 1 to Week 25 in the core study. No intervention in the extension study."
1568169|NCT02468635|Other|upper limb exercises|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESISTANCE STAGE: upper limb exercises with weight training equipment or dumbbells (the patient's adaptation) with 50% of maximum load reached the maximum repetition test. Series 2 minutes and rest interval between sets 1-2 minutes. RESPIRATORY TRAINING : Strengthening of the respiratory muscles 5-15 minutes with Threshold with load of 50% of the affected MIP (measure maximal inspiratory pressure) evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
1568170|NCT02468635|Other|without training for upper limb|HEATING PHASE: diagonals for upper and lower limbs (5-10 minutes). AEROBIC PHASE: aerobic exercise on a treadmill or bicycle between 5 - 30 minutes and rest 1-2 minutes according to the Borg scale and patient tolerance (Borg scores for dyspnea 4-5); RESPIRATORY TRAINING: Strengthening respiratory muscles 5-15 minutes with Threshold with load of 50% of MIP hit in the evaluation. RELAXATION: Stretching and muscle massage therapy group involved in the 5-10 minute workout.
1568171|NCT02468622|Other|Blood samples|There is no intervention, but we will take blood samples during a spontaneous migraine attack
1568172|NCT02468609|Radiation|Ultralow-Dose-CT|Patients undergoing thoracic normal dose-CT with undergo an additional Ultralow-Dose-CT
1568173|NCT02468596|Other|QTRAC assessment|Computerized analysis of the muscular response of musculus abductor pollicis brevis, to series of electrical stimulations of the median nerve
1568174|NCT02468596|Other|Clinical assessment of peripheral nerve function|Clinometric assessment using RT-MRC, Martin vigirometer, RT-mISS, T25W, 9 hole peg test, and ataxia scale
1568175|NCT02468583|Drug|FX006|Experimental
1568176|NCT02468583|Drug|Kenalog®-40|Comparator
1568177|NCT02468570|Other|Administration of CANTAB and Subject Global Assessment|At designated visits, subject will perform the CANTAB tasks and complete the Subject Global Assessment Questionnaire
1568178|NCT02468557|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
1568179|NCT02468557|Drug|Nab-paclitaxel|Nab-paclitaxel administered intravenously on Days 1, 8 and 15 of each 28 day cycle
1568180|NCT02468557|Drug|mFOLFOX6|mFOLFOX6 will be administered intravenously on Days 1 and 15 of each 28 day cycle. This regimen consists of levoleucovorin 200 mg/m^2 or racemic leucovorin 400 mg/m^2, oxaliplatin 85 mg/m^2, bolus 5-fluorouracil 400 mg/m^2, and a 46 hour infusion of 5-fluorouracil 2, 400 mg/m^2.
1568181|NCT02468544|Other|Text messaging|Text messaging mHealth intervention to improve HIV Primary Care Engagement among clients of methadone maintenance treatment programs who are living with HIV.
1568182|NCT02468531|Other|oxygen|50% oxygen inhalation
1568183|NCT02468531|Drug|Xenon|50% Xenon inhalation
1568184|NCT02468518|Drug|Vitamin E capsule|Capsules will be distributed to each participant free of cost
1568185|NCT02468505|Behavioral|STEPS|time-limited behavioral counseling, online materials, training
1568186|NCT02468492|Biological|Platelet Rich Plasma|Platelet rich plasma injection into knee versus placebo (saline) injection.
1568187|NCT02468492|Other|Normal Saline|Platelet rich plasma injection into knee versus placebo (saline) injection.
1568188|NCT02468479|Other|No relevant intervention.|No relevant intervention.
1568189|NCT02468466|Behavioral|Multi-level suicide prevention programs|The intervention included both screening and educational components. The screening component invited residents aged 36-64 years to participate in a two-step screening program. In the initial screening, a self-report questionnaire were mailed to all of those residents in the priority districts with a past high suicide rate. The second stage was conducted for the participants who screened positive though a semi-structural interview. Based on the results, participants who were diagnosed with a major depressive episode were provided with a referral to a psychiatry and support for treatment adherence. Written feedback on the screening results was mailed to all respondents. The educational component was implemented through workshops open to the general public (3 times every year) and local public newsletters (twice every year) designed to improve access and adherence to treatment and to reduce stigma associated with suicide and depression.
1568190|NCT02468466|Behavioral|Suicide prevention program as usual|Usual mental health program (not including depression screening among middle-aged)
1568191|NCT02468453|Device|velos|VELOS combines 595nm pulsed dye laser energy with bipolar RF energy. The study device can deliver 0.45 to 40 ms laser pulses at a maximum of 25 J/cm2
1568192|NCT02468440|Other|ESPAIR|ESPAIR is an educational therapy's program with 6 group session,and if patients ask for it, individual session are possible
1568193|NCT02468427|Other|hands-on teaching|Training session of 30 minutes duration with every proband performing a vacuum extraction on a pelvic training model.
1568194|NCT02468427|Other|Frontal teaching|Training session of 30 minutes duration consisting of a video which demonstrates how to perform a vacuum extraction on a pelvic training model.
1568195|NCT02468414|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (18-25 IU/Kg/day)
1568196|NCT02468414|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO (35-45 IU/Kg/day)
1568197|NCT02468401|Procedure|Percutaneous coronary intervention|Patients planned for coronary angiography or percutaneous coronary intervention will be managed using a protocol that allows us to use minimal volumes of contrast dye
1568198|NCT02468388|Other|maltitol|maltitol chewing gum: 66% SweetPearlTM Maltitol +30.91% gum base+1.93% Lycasin R 85/55+0.39% glycerin; two pellets for 10 min five times each day
1568199|NCT02468388|Other|xylitol|xylitol chewing gum: 67.73% xylitol +30.02% gum base+1.13% Lycasin R 85/55+0.38% glycerin; two pellets for 10 min five times each day
1568200|NCT02468388|Other|gum base|gum base: 99% gum base; two pellets for 10 min five times each day
1568201|NCT02468375|Drug|mirabegron 50mg|434 OAB patient intake mirabegron 50mg/day for 12 weeks.
1568202|NCT02468362|Procedure|laparoscopic intersphincteric resection|laparoscopic intersphincteric resection for low rectal cancer
1568203|NCT02468362|Procedure|open intersphincteric resection|
1568204|NCT02468349|Other|Telemedicine|Participants enrolled will be randomised 1:1 to either telemedicine arm or standard care arm.
1568205|NCT02468336|Device|AngioDefender|
1568206|NCT02468336|Device|Ultrasound|
1568207|NCT02468323|Drug|Placebo|Patients will receive regular spinal anesthesia
1568208|NCT02468323|Drug|Ondansetron|Patients will receive slow intravenous injection of ondansetron 4 mg after cord clamping
1568209|NCT02468323|Drug|Palonosetron|Patients will receive slow intravenous infection of palonosetron 75 mcg after cord clamping
1568210|NCT02468310|Other|Maternal and neonatal emergency protocols|Protocols for management of Maternal and Neonatal emergencies based on the Safe Motherhood protocol adopted by the Ghana Health Service to improve maternal and neonatal health
1568211|NCT02468297|Device|Electronic Acupunture Shoes|"Experiment group receives a one-hour treatment given by Electronic Acupuncture Shoes three times a week. 6 weeks of treatment was given.
Control group received the six-week treatment as well, yet the subjects received pseudo electrotherapy."
1568212|NCT02468297|Drug|Ibuprofen|Experiment group took placebo only in the first week. Control group took ibuprofen(400mg, TID) only in the first week. No more placebo or medicine was prescribed to either two groups since the second week.
1568214|NCT02468258|Procedure|endometrial flushing|Oocytes were retrieved 34-36 h after hCG administration and aspirated FF was collected and centrifuged at 600 rpm for 10 min and 5-ml sample of supernatant was obtained for ELISA estimation of tumor necrosis factor-α (TNF-α), granulocyte colony-stimulating factor (G-CSF), leptin and anti-Mullerian Hormone (AMH) levels in both groups. The remaining amount was used for endometrial flushing
1568215|NCT02468245|Behavioral|weekly telephone follow up|For the study group, at the initial education visit, a time for each phone call that is convenient for the patient will be scheduled. At each phone call, the OCN will get a pill count and discuss reasons for missed doses if applicable; grade any AE's experienced and interventions for those side effects; and answer any questions or concerns that they patient may be having. Patients will then return for the standard 4 week clinic visit.
1568216|NCT02468245|Behavioral|usual care|The control group will receive the standard chemotherapy education and will return for the standard 4 week follow up clinic visit.
1568221|NCT02468219|Behavioral|cardiovascular rehabilitation program|"Phase I - respiratory muscle training and neuromuscular electrical stimulation 7x/week for 6 weeks.
Phase II - 8 weeks of supervised, structured, combined endurance and resistance training."
1568222|NCT02468206|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
1568223|NCT02468206|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
1568224|NCT02468206|Drug|N-butyl-2-cyanoacrylate|
1568225|NCT02468206|Drug|Lauromacrogol|
1568227|NCT02468180|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
1568228|NCT02468180|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
1568229|NCT02468180|Drug|N-butyl-2-cyanoacrylate|
1568230|NCT02468180|Drug|Lauromacrogol|
1568231|NCT02468167|Procedure|Balloon-occluded retrograde transvenous obliteration|Balloon-occluded retrograde transvenous obliteration
1568232|NCT02468167|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection
1568233|NCT02468167|Drug|N-butyl-2-cyanoacrylate|
1568234|NCT02468167|Drug|Lauromacrogol|
1568235|NCT02468154|Device|custom made splint|Splints have been made by wrapping synthetic bandages around a leg-foot manufactured splint padded at the heel to off-load the heel. When the desired shape has been obtained, the splint is opened and the manufactured device is removed, thus obtaining a device that is used under the casts of lower limbs.
1568236|NCT02468154|Other|standard off-load plaster cast|To avoid pressure at the heel placing and maintaining the limb with the cast on cushions or folded sheets so that the heel is not resting on the bed plane
1568237|NCT02468141|Drug|SJDBT|Sipjeondaebo-tang
1568238|NCT02468141|Drug|Placebo|Placebo
1568239|NCT02468128|Drug|Sebacoyl Dinalbuphine Ester|Intramuscular injection 2mL/vial (75mg/mL)
1568240|NCT02468128|Drug|Placebo|Sebacoyl Dinalbuphine Ester injection placebo, 2mL/vial
1568241|NCT02468115|Drug|VIS410|Single fixed IV dose of VIS410
1568242|NCT02468115|Drug|Placebo|Single IV dose of placebo
1568314|NCT02467595|Drug|Rocuronium bromide 0.15 mg kg-1|Rocuronium bromide 0.15 mg kg-1 was injected at I.V. line to patients (R 0.15 group), as muscle relaxants during anesthesia for adenotonsillectomy.
1568315|NCT02467595|Drug|Rocuronium bromide 0.3 mg kg-1|Rocuronium 0.3 mg kg-1 was injected at I.V. line to patients (R 0.3 group), as muscle relaxants during anesthesia for adenotonsillectomy.
1568245|NCT02468089|Drug|Carbepenem|
1568246|NCT02468089|Drug|Albumin|
1568247|NCT02468089|Drug|GMCSF (of Granulocyte-Monocyte Colony-Stimulating Factor) .|
1568248|NCT02468076|Device|Radiofrequency ablation (StarMed)|Radiofrequency ablation into bile duct
1568249|NCT02468063|Drug|Low dose terlipressin|Terlipressin-2mg (low dose )
1568250|NCT02468063|Drug|Noradrenaline|Noradrenaline at 7.5 mcg/min, maximum of 60mcg/min. stepped up every 15 min
1568251|NCT02468063|Drug|Noradrenaline|Noradrenaline- 3.75 mcg/min to 30 mcg/min. stepped up every 15 min
1568252|NCT02468050|Behavioral|Moderate intensity exercise training|6 weeks of moderate intensity exercise training (50 - 75% of heart rate reserve). Sessions are facility and home based and include cardiovascular warm-up, cardiovascular training, muscular conditioning, and flexibility exercises.
1568253|NCT02468050|Behavioral|Self Management of exercise|In addition to the 6 week exercise program (refer to Exercise Treatment Group), participants randomly assigned to the Self Management Group will learn strategies for the self management of exercise.
1568254|NCT02468037|Procedure|Phlebotomy|Patients donate blood until tissue iron levels are in the lowest quartile of normal.
1568257|NCT02468011|Other|vibration|vibration will be applied at 35 Hz
1568258|NCT02467998|Device|NPWT|SVAP polyurethane foam, RENASYS foam, RENASYS gauze, AMD gauze, VAC white sponge, VAC black sponge, applied with various NPWT devices, in addition to various dressings to protect wound edges
1568259|NCT02467985|Procedure|FIGARO|flow of insufflation set to 2-3L / min. Once the intervention is complete, the CO2 insufflation is discontinued, accessories trocars are removed under direct vision and the incisions the sites of these trocars will be closed with or without fascial closure according to the standard display. Patients will be placed in the Trendelenburg position 30 degrees, head tilted down. The umbilical trocar is opened. A suction is inserted into the trocar, taking care to stay inside the jacket of the trocar. Active suction gas will during lung recruitment. This maneuver will be performed by the anesthesiologist who apply 5 subsequent forced breaths, up to 40 cm H2O pressure, taking care to maintain the insufflation last 5 seconds. Once completed, the suction will be removed, the laparoscope is inserted into the trocar to verify the absence of trauma to underlying structures. The patient will be given to neutral at the end of the procedure.
1568260|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added unripe banana flour|Ready-to-eat frozen soups added unripe banana flour (18 portions; 3 times/week)
1568261|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added maltodextrin|Ready-to-eat frozen soups added maltodextrin (18 portions; 3 times/week)
1568262|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added inulin|Ready-to-eat frozen soups added inulin (18 portions; 3 times/week)
1568263|NCT02467972|Dietary Supplement|Ready-to-eat frozen soups added nisin|Ready-to-eat frozen soups added nisin (18 portions; 3 times/week)
1568264|NCT02467946|Drug|Adcetris-Levact|Association of Adcetris (1.2 mg/kg intravenously every 3 weeks) with Levact (90 mg/m2/day intravenously for 2 days every 3 weeks) during at least 6 cycles.
1568265|NCT02467933|Other|Placebo letter|The placebo letter describes a new rule in Medicare that requires prescribers to enroll in Medicare
1568266|NCT02467933|Other|Initial Informative letter|The intervention is a letter that describes the Seroquel prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
1568267|NCT02467933|Other|Followup Informative Letter|The followup informative letter is identical to the initial informative letter except it provides an update on more recent prescribing rather than a description of earlier prescribing.
1568268|NCT02467920|Drug|glargine + exenatide|glargine ( once-daily subcutaneous injection at bedtime) combination with exenatide (subcutaneous injection, twice-daily)
1568269|NCT02467920|Drug|aspart 30|aspart 30 ( subcutaneous injection, twice daily)
1568270|NCT02467907|Drug|Bevacizumab|Intravenous (i.v.) administration of 15 mg/kg bevacizumab once every 3 weeks
1568271|NCT02467907|Drug|Carboplatin|Administration of carboplatin at 5 milligrams per milliliter*minute (mg/mL*min) on Day 1 every 3 weeks for at least 6 cycles
1568272|NCT02467907|Drug|Paclitaxel|Administration of paclitaxel at a dose of 175 milligrams per square meter (mg/m^2) on Day 1 every 3 weeks for at least 6 cycles
1568273|NCT02467894|Other|Group-based Care|There will be self-care activities, blood pressure measurements and other vitals, including discussion of specific topics initiated by the participants.
1568316|NCT02467595|Drug|Fentanyl|Fentanyl 2 mcg kg-1 was injected at I.V. line to patients
1568317|NCT02467595|Drug|Propofol|Propofol 2.5 mg kg-1 was injected at I.V. line to patients
1568318|NCT02467595|Drug|Sevoflurane|After mask ventilation with 5 vol% sevoflurane in 100% oxygen for 2 minutes, tracheal intubation was done.
1568319|NCT02467582|Drug|Aspirin|Aspirin 100 mg daily
1568320|NCT02467582|Drug|Placebo|Placebo
1568321|NCT02467569|Drug|Hemay020|
1568322|NCT02467556|Drug|Morphine, memantine|Morphine up to 30 mg per day orally and memantine up to 40 mg per day orally if tolerated for 10 weeks.
1568274|NCT02467881|Behavioral|Physical Activity Increase (GLB-MOD)|"The Group Lifestyle Balance (GLB) program was adapted from the original DPP lifestyle intervention. As in the original DPP lifestyle program, the GLB goals are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes/week of moderately intense physical activity similar to a brisk walk.
The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.
The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
1568275|NCT02467881|Behavioral|Sedentary Time Decrease (GLB-SED)|"As in the original DPP, the GLB goal for weight is to achieve and maintain a 7% weight loss. For this intervention arm, instead of focusing on increasing moderate physical activity, the GLB curriculum will be adapted to address decreasing sitting time. Participants will have a goal of decreasing sitting time by 45 minutes/day. The curriculum will be administered in intervention groups with an average of 10-15 individuals per group; sessions will be conducted by trained coaches, with participants attending 22 sessions over one year.
The two intervention arms will only differ in the aerobic activity portion of the intervention, which is covered in sessions #4, #10 and 19 as well as participant record keeping and goal setting in regards to activity/inactivity progression."
1568276|NCT02467881|Other|6-month delayed (DELAYED)|Individuals assigned to 6 month delay will wait for 6 months from baseline to be randomly assigned to one of the two interventions and will begin intervention at that time. During the waiting period they will receive health information newsletters.
1568277|NCT02467868|Biological|MYL-1401H|During each chemotherapy cycle MYL-1401H (6 mg) is administered s.c. 24 hours after chemotherapy.
1568278|NCT02467868|Biological|Neulasta|During each chemotherapy cycle Neulasta (6 mg) is administered s.c. 24 hours after chemotherapy.
1568279|NCT02467855|Other|No Intervention|No intervention was administered in this study.
1568280|NCT02467842|Biological|NBP607-QIV(Quadrivalent)|0.5ml, intramuscular, a single dosing at Day 0
1568281|NCT02467842|Biological|NBP607-Y(Trivalent)|0.5ml, intramuscular, a single dosing at Day 0
1568282|NCT02467842|Biological|NBP607-V(Trivalent)|0.5ml, intramuscular, a single dosing at Day 0
1568283|NCT02467829|Device|Increase in handle height|Elbow flexion is measured with the child standing in their walker using an electronic goniometer. Approximately 10° of elbow flexion is current recommended practice. 30° and 50° are increased handle heights.
1568284|NCT02467816|Behavioral|SmartMeal application|The SmartMeal application is a smartphone application that will allow students to pre-order school meals, receive nutrition information about school meals, and provide feedback about school meals to Student Nutrition Services.
1568285|NCT02467816|Behavioral|Distributed points of sale|To increase points of sale for school meals (outside the cafeteria), school meals will be sold at hot and cold mobile food carts and vending machines throughout the school.
1568286|NCT02467816|Behavioral|Staff wellness curriculum|A wellness curriculum will be implemented that encourages teachers and staff members to eat school meals and promote them to students.
1568287|NCT02467803|Other|Scapula mobilization|
1568288|NCT02467803|Other|Shoulder ROM exercises|
1568289|NCT02467790|Drug|PEX168|PEX 168: 200µg,Subcutaneous,one time.
1568290|NCT02467777|Device|Bair Hugger|
1568291|NCT02467777|Device|VitaHeat|
1568292|NCT02467764|Other|Retrospective study|
1568296|NCT02467725|Other|Dynamic culture platform|Patients will have their cohort of embryos split in half. Half will be cultured in the dynamic platform and the other half cultured in static.
1568297|NCT02467686|Behavioral|WHOQOL questionnaire|WHO defines Quality of Life as individuals perception of their position in life in the context of the culture and value systems in which they live and in relation to their goals, expectations, standards and concerns.
1568298|NCT02467686|Behavioral|FSFI questionnaire|FSFI questionnaire application for evaluation of sexual function at the first visit, 3-month and 6-month follow-up.
1568299|NCT02467686|Behavioral|kupperman scale|Kupperman scale is a tool to help evaluate the severity of menopausal symptoms
1568300|NCT02467686|Drug|Cimicifuga racemosa|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer
1568301|NCT02467686|Drug|tamoxifen|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using tamoxifen
1568302|NCT02467686|Drug|exemestane|The Cimicifuga racemosa effects on the sexuality of women with Breast cancer using aromatase inhibitor.
1568303|NCT02467673|Drug|Micronized estradiol + progesterone|Administration of micronized estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
1568304|NCT02467673|Drug|Nanoparticulate estradiol + progesterone|Administration of nanoparticulate estradiol + progesterone daily by a metered-dose pump during 12 weeks in postmenopausal women with no clinical evidence of cardiovascular disease.
1568305|NCT02467660|Behavioral|Mindfulness Meditation|Using study-provided iPod device to listen to guided meditations daily
1568306|NCT02467660|Behavioral|Health & Wellness Education|Using study-provided iPod device to listen to educational podcasts daily
1568307|NCT02467647|Drug|Thalidomide|
1568308|NCT02467647|Drug|HLJDT|
1568309|NCT02467634|Biological|HuCNS-SC sub-retinal transplantation|HuCNS-SC sub-retinal transplantation in subjects with bilateral GA AMD
1568312|NCT02467608|Drug|Isoniazid with HUEXC030 and RZE|Subjects will receive oral study drug daily in accordance with the following regimen, that is, INH, RMP, PZA, and EMB for the first 2 months followed by INH, RMP and EMB (if medically indicated) daily for 4 additional months
1568313|NCT02467608|Drug|HRZE|the same as experimental group,without the excipient of HUEXC030 only
1568762|NCT02464722|Drug|Rocuronium|Anesthesia was induced with rocuronium 0.6 mg kg-1
1568323|NCT02467556|Behavioral|Psychological intervention|To help patients shift perspective from pain and CRPS-symptoms, to increase body awareness, to create vivid imagenary, to increase the use of a CRPS hand with mindfulness exposure exercises, to increase flexibility in behavioral repertoire, to explore the fusion of emotions, automatic cognitions and learned responses and to help patients to integrate new skills in their lives.
1568324|NCT02467556|Other|Physiotherapy intervention|Graded motor imagenary with group and individual weekly sessions with daily practices at home.
1568325|NCT02467543|Other|20% Ethanol|Unmedicated 20% Ethanol
1568326|NCT02467543|Other|Viburnum opulus 3X|Viburnum opulus 3X in a vehicle of 20% ethanol.
1568327|NCT02467530|Other|AGE|
1568328|NCT02467517|Drug|Ketamine|
1568329|NCT02467517|Drug|Magnesium Sulfate|
1568330|NCT02467517|Drug|placebo : sodium chloride|
1568331|NCT02467504|Drug|hrIL-2 active|hrIL-2 active (1 million U doses of hrIL-2s.c.injection)
1568332|NCT02467504|Drug|hrIL-2 placebo|hrIL-2 placebo (1 million U doses of hrIL-2 placebo s.c.injection)
1568333|NCT02467504|Drug|MTX|Methotrexate (oral administration)
1568334|NCT02467504|Drug|Folic Acid|Folic Acid (oral administration)
1568335|NCT02467504|Drug|Loxoprofen|Loxoprofen (oral administration)
1568336|NCT02467491|Device|Jintronix|The participants will perform light exercises using the Jintronix software. Jintronix is an easy-to-use virtual physical activity platform designed for physical and occupational therapy. It combines common exercise movements, virtual games and motion sensing cameras to offer a fun and effective tool for physical activity.
1568337|NCT02467478|Drug|Linagliptin|5 mg tablet once daily for 12 weeks
1568338|NCT02467478|Drug|Placebo|1 tablet daily for 12 weeks
1568339|NCT02467465|Other|Physical therapy|Massage, movilization of ankle dorsiflexion and improve flexibility with stretching of calf muscles.
1568340|NCT02467465|Device|Dry needling|
1568341|NCT02467452|Drug|BDP/FF/GB|
1568342|NCT02467452|Drug|FlF/VI + Tiotropium|
1568343|NCT02467439|Other|Notification cards|detection of AHI, contract partner notification, and social contact referral to find persons unaware of their HIV infection.
1568344|NCT02467426|Drug|Chemotherapy|intraarterial infusion of cisplatin and mithoxantrone
1568345|NCT02467413|Drug|BAC|(vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof)
1568346|NCT02467413|Other|BAC Matched Vehicle|BAC Matched Vehicle
1568347|NCT02467400|Drug|Atenolol|beta blocker
1568348|NCT02467400|Drug|Nebivolol|beta blocker
1568349|NCT02467400|Drug|Propranolol|beta blocker
1568350|NCT02467400|Drug|placebo|placebo
1568351|NCT02467387|Drug|Allogeneic Mesenchymal Bone Marrow Cells (aMBMC)|One time infusion Allogeneic Mesenchymal Bone Marrow Cells (aMBMC) 1.5 million cells/kg.
1568352|NCT02467387|Drug|Lactated Ringer's Solution|One time infusion 1.5mL/kg
1568353|NCT02467374|Behavioral|Behavior Therapy|"BT for OCD focuses primarily on exposure with response prevention (ERP). ERP involves gradual exposure to anxiety-provoking situations (things or situations that frighten or disturb some people), and will help to prevent compulsions (repetitive behaviors)."
1568354|NCT02467361|Drug|BBI608|Patients in this trial will receive BBI608 at assigned dose-levels according to the study arm the patient is enrolled into. BBI608 Dose Level 1: 240 mg twice daily, Dose Level 2: 480 mg twice daily. The assigned dose of BBI608 will be administered twice daily with approximately 12 hours between doses.
1568355|NCT02467361|Drug|Ipilimumab|Ipilimumab 3 mg/kg is administered intravenously over 90 minutes every 21 days for a total of 4 doses.
1568356|NCT02467361|Drug|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes every 14 days.
1568357|NCT02467361|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every 21 days.
1568358|NCT02467348|Drug|Albumin|Intravenous albumin 8 gms/L of ascitic fluid
1568359|NCT02467348|Drug|Ascitic fluid|
1568360|NCT02467335|Drug|BMS-663068|BMS-663068
1568361|NCT02467322|Drug|Albumin|MVP of less than 5 liters with iv albumin at a dose 8 gms/L of ascitic fluid.
1568362|NCT02467322|Drug|ascitic fluid|
1568363|NCT02467296|Other|Dietary plan with controlled amount of Sodium|Dietary plan with 1.5 gr vs 3 gr of Sodium
1568364|NCT02467283|Genetic|Genom-based whole-genome transcriptomic|Gene expression profiling is a powerful means of generating comprehensive genome-level data sets.
1568365|NCT02467270|Drug|ponatinib 45 mg|45 mg tablet, taken orally once daily
1568366|NCT02467270|Drug|ponatinib 30 mg|30 mg tablet, taken orally once daily
1568367|NCT02467270|Drug|ponatinib 15 mg|15 mg tablet, taken orally once daily
1568369|NCT02467244|Drug|Levothyroxine|At first visit, after taking detailed history including baseline symptomatology, clinical evaluation, and laboratory investigation, treatment will be started with levothyroxine (50 microgram/day). The dosage of levothyroxine (LT4) will be adjusted (at 4th and 8th week) in an attempt to keep the serum FT4 and TSH concentrations within the normal range. After 12 weeks, all the patients will be followed up, clinical and laboratory tests will be repeated.
1568370|NCT02467218|Other|Hyperbaric Oxygen Treatment|Baseline and follow up fMRI and Oxygen treatment, 90 minutes, once daily, five times a week for 8 consecutive weeks in the hyperbaric chamber (40 treatments with 100% oxygen at 2.0 ATA)
1568371|NCT02467205|Other|pedometer supported walking and education|"A Physical activity; pedometer will be given to each person in the intervention group at the first education session. Participants will be encouraged to use the pedometer for a 6 month period.
The strength exercises will be performed at home. Education will incorporate the behavioural change techniques (BCTs) known to be effective in increasing physical activity (Goal setting,Self-monitoring of behaviour,Feedback on outcomes of behaviour,Problem solving,Relapse Prevention (RP) and social support)."
1568372|NCT02467192|Device|Low dose CT|Thoracic CT scan will be performed within the first 48-72 hours of admission, with an analysis and conclusion by a radiologist
1568373|NCT02467179|Device|Amigo™ Robotic Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.
In this study, this group will be assigned to robotic catheter manipulation."
1569082|NCT02462304|Drug|ranibizumab|
1568374|NCT02467179|Device|Manual Catheter Manipulation|"Ablation is a standard procedure that patients may undergo for the atrial flutter.
In this study, this group will be assigned to manual catheter manipulation."
1568375|NCT02467166|Device|Circa™ Probe|The Circa™ probe will be used to monitor esophageal temperature and guide ablation power and duration during the RFCA procedure. Following ablation esophagoscopy will be performed to assess for esophageal lesions.
1568376|NCT02467153|Other|RET|"RET: A supervised group exercise programme with a maximum of n=10-12 participants per group to be attended 3 times per week for 6 months.
The RET programme includes elements of current established programmes for falls prevention/ core stability (i.e., OTAGO, PEPPI) and will tailored to a range of abilities within the target group.
Vitamin D3 supplementation: vitamin D3 given orally as tablets at a dosage of 800 IU/day for 6 months."
1568377|NCT02467153|Dietary Supplement|Placebo|Placebo given orally as tablets; 1 tablet per day for 6 months.
1568378|NCT02467153|Dietary Supplement|Vitamin D3|Placebo given orally as tablets; 800 IU as 1 tablet per day for 6 months.
1568379|NCT02467140|Device|Parietex ProGrib self-fixating mesh|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh.
1568380|NCT02467140|Device|Tack fixation|Laparoscopic transabdominal preperitoneal inguinal hernioplasty using the Parietex ProGrib self-fixating mesh using tack fixation.
1568381|NCT02467127|Dietary Supplement|vitamin D supplementation|In patients with headache and with low vitamin D plasma levels, will be administered a vitamin D supplementation.
1568382|NCT02467114|Device|Transcranial magnetic stimulation (TMS)|This method will be applied to measure cortical excitability and as an interference approach; real TMS stimulation will be compared with sham stimulation and no stimulation
1568383|NCT02467114|Device|Sham coil stimulation|Stimulation with a sham coil as a comparison
1568384|NCT02467114|Other|Control without stimulation|
1568385|NCT02467101|Other|Corticosteroid/Saline|"Corticosteroid/Saline
Two groups were defined: group A and group B.
Group A receives treatment with intralesional triamcinolone acetonide on the right half-head and placebo on the left half-head
Group B receives administration of intralesional triamcinolone acetonide on left half-head and placebo on the right half-head.
Same patient will be injected with intralesional triamcinolone acetonide and a saline solution.
Each patient will be injected on half-head."
1568386|NCT02467088|Other|Individualised Homeopathic Remedy|Each participant will receive an individualised homoeopathic remedy prescribed according to the individualised symptoms of their PMS.
1568387|NCT02467075|Drug|Iopamidol 300 (Contrast)|Patients will be randomized to receive IV iopamidol 300 (1.25 mL/kg, max 125 mL) with their CT scan
1568388|NCT02467075|Drug|Placebo (Normal Saline)|Patients will be randomized to receive IV normal saline (1.25 mL/kg, max 125 mL) with their CT scan
1568389|NCT02467062|Device|MRI|MRI measurement to evualuate for 4D blood flow pattern
1568390|NCT02467049|Device|ECG-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
1568391|NCT02467049|Device|ULTRASOUND-guided insertion of PICC|Comparison of placement of a PICC (Peripherally Inserted Central Catheter) by ECG-guidance vs. ULTRASOUND-guidance
1568393|NCT02467023|Device|Muscle stimulation with Niveus medical stimulator|Subjects will be treated five days per week, for 30 minutes each session. Muscle stimulation will be conducted for four seconds every 15 seconds, thus the subjects will undergo four stimulations per minute. Muscle stimulation will be adjusted until there is a visible or palpable bilateral quadriceps contraction.
1568394|NCT02467023|Device|measurement of maximal isometric twitch strength|Quadriceps strength will be measured on the initial day of study approximately every seven days thereafter and on the final day of study participation. For this measurement, patients will remain supine in their bed and the dominant leg will be placed on a frame that will hold the knee at a 60° angle. A cuff will be placed around the ankle and connected to an electronic dynamometer that will record the force generated during the stimulation. The muscle will be stimulated to contract with magnetic stimulators placed over the body of the quadriceps muscle and stimulated at 100% of power output.
1568395|NCT02467023|Procedure|Muscle Biopsy|"This procedure will be done at the end of participation in the study.The biopsy will be performed with a sterile needle, which will be inserted through the skin. A skin incision (approximately 1/4 long) will be made in order to insert the needle. The biopsy procedure yields two small pieces of muscle tissue (200 mg total), each about half the size of the eraser on a pencil. After the biopsy is taken, the incision will be closed using a steri-strip bandage (no stitches are required), and a sterile dressing will be placed over the site to reduce the risk of bleeding."
1568396|NCT02467023|Drug|Muscle Biopsy Medication: Lidocaine|Biopsy samples will be obtained under local anesthesia (up to 20 milliliters of 1% Lidocaine administered subcutaneously). Lidocaine, a drug to numb your pain will be injected into the skin and muscle tissue. The injection of the numbing medication will be slightly painful and is similar to receiving a shot into your arm for a vaccination. This medication numbs the skin and muscle so that you do not feel pain when the biopsy is obtained.
1568397|NCT02467023|Drug|Muscle Biopsy Medication: Versed|Prior to starting the muscle biopsy, you can receive a drug, Versed, to help you relax during the procedure. 1-2 milligrams of Versed will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
1568398|NCT02467023|Drug|Muscle Biopsy Medication: Fentanyl|Prior to starting the muscle biopsy, you can receive a drug, Fentanyl, to make you more comfortable during the procedure. 50-100 micrograms of Fentanyl will be administered intravenously (in the vein) through an existing peripheral or central intravenous catheter. This procedure drug is given as needed and can be repeated one time as needed.
1568501|NCT02466321|Procedure|Inverse/Reverse Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Inverse/Reverse System
1568399|NCT02467023|Other|Blood and Urine Sampling|Blood and urine samples will be obtained and examined for markers inflammation and muscle catabolism. Sampling will occur at time of entry into study, and then once every 2-4 days and on the final day of participation or the last day of study (day 28). Peripheral blood will be collected from an existing venous line, or by venipuncture, if required. Urine will be collected from an existing catheter or if the patient is able to void on their own then we will provide a specimen cup. There will be no more than 14 ml of blood drawn at any given time point and a collection of 15 ml of urine at each time point.
1568400|NCT02467023|Device|ineffective muscle stimulation|An investigator will perform range of motion on both legs, five days per week. The range of motion activity will include the investigator helping you bend and straighten each knee approximately 12 times. Rotation of the leg at the hip will also be performed by bending your knee and gently rotating your upper leg in a clockwise and counterclockwise motion. The range of motion will be performed on each leg and repeated five days per week.
1568401|NCT02467010|Drug|Bortezomib|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.
Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
1568402|NCT02467010|Drug|Cyclophosphamide|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.
Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
1568403|NCT02467010|Drug|Dexamethasone|"Re-induction chemotherapy with bortezomib, cyclophosphamide and dexamethasone. All patients with first relapse or primary refractory multiple myeloma and bortezomib naive will be given 6 cycles of re-induction therapy. Patients will be evaluated for response after cycle 3 and 6.
Maintenance therapy with bortezomib and cyclophosphamide Maintenance therapy with bortezomib and cyclophosphamide will start at 4 weeks after the last cycle of re-induction chemotherapy if ANC ≥ 2.0 x 109/l and platelets > 75 x 109/l. Bortezomib is administered once every other week and cyclophosphamide (50 mg) every day for 1 year or until progression or death of any cause."
1568404|NCT02466997|Drug|tacrolimus|tacrolimus 0.1% ointment applied twice a day for the experimental group during 24 weeks placebo ointment applied twice a day for the control group during 24 weeks
1568405|NCT02466997|Drug|Placebo|
1568406|NCT02466984|Drug|metoclopramide intravenous|Administration route
1568414|NCT02466958|Drug|levomilnacipran|antidepressant
1568415|NCT02466958|Drug|Placebo|an inactive drug
1568416|NCT02466945|Device|V063B-DP3003|The medical device V063B-DP3003 has been developed to relieve and decrease dentinal hypersensitivity in patients by creating a film around the sensitive tooth in order to prevent pain. Application modalities: apply a pea size amount of product (around 0.5g) onto each of the sensitive teeth, 3 times a day, by gentle massage with clean finger after each brushing of teeth. Do not rinse
1568417|NCT02466932|Device|Galilei Dual-Scheimpflug Analyzer|Measuring of Anterior Segment by Galilei Dual-Scheimpflug Analyzer
1568418|NCT02466919|Drug|Pantoprazole|H. pylori eradication therapy
1568419|NCT02466919|Drug|Amoxicillin|H. pylori eradication therapy
1568420|NCT02466919|Drug|Metronidazole|H. pylori eradication therapy
1568421|NCT02466919|Drug|Levofloxacin|H. pylori eradication therapy
1568422|NCT02466919|Drug|Clarithromycin|H. pylori eradication therapy
1568423|NCT02466906|Drug|rhGM-CSF|rhGM-CSF was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. During adjuvant therapy of XELOX, rhGM-CSF was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15) or stopped when ANC>20.0X109/L.
1568424|NCT02466906|Drug|placebo|Placebo was injected subcutaneously of 3± 0.3ug/kg/d per day for 5 days before and 2 days after surgery. . During adjuvant therapy of XELOX, placebo was continuous injected for 6 days when finishing each cycle of chemotherapy (from d15).
1568425|NCT02466893|Other|Adapt/Standard Stent Retriever (SR) Group|If the patient is randomized to mechanical thrombectomy, the groin puncture to initiate the procedure should occur within 1 hour of the clinical imaging used to determine trial candidacy. An introducer sheath will be placed in the femoral artery. Diagnostic angiography is initially performed via the transfemoral approach with catheterization of the carotid artery appropriate to the patient's presenting symptoms. Once thrombus in the appropriate vessel is identified, the thrombectomy procedure will be initiated.
1568426|NCT02466880|Device|Telemedicine|A diabetes self-management and education program delivered via telemedicine
1568427|NCT02466880|Other|Usual care|A 15-30 minute diabetes self-management session. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
1568428|NCT02466867|Drug|Naftin® Cream, 2% (younger pediatric cohort)|Approximately 3 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 2 to 5 years, 11 months.
1568429|NCT02466867|Drug|Naftin® Cream, 2% (older pediatric cohort)|Approximately 4 grams of Naftin® Cream, 2% ist to be applied once per day for subjects aged 6 to 11 years, 11 months.
1568431|NCT02466828|Drug|Feraheme®|Drug will be diluted in 50 cc normal saline and infused over 15-60 minutes depending on patient condition.
1568432|NCT02466815|Drug|JNJ-42756493 Current Clinical Formulation (G-018)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as current clinical formulation (G-018) in treatment A in either period 1, 2 or 3 as per treatment sequence.
1568433|NCT02466815|Drug|JNJ-42756493 Prototype Formulation I (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation I (G-025) in treatment B in either period 1, 2 or 3 as per treatment sequence.
1568434|NCT02466815|Drug|JNJ-42756493 Prototype Formulation II (G-025)|JNJ-42756493 10 milligrams (2 tablets of 5 mg each) will be administered as Prototype Formulation II (G-025) in treatment C in either period 1, 2 or 3 as per treatment sequence.
1568435|NCT02466802|Drug|Regorafenib|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors. Regorafenib Administration and Treatment Schedule. Regorafenib will be taken orally once daily for the first 21 days of each 28-day cycle. Regorafenib will not be taken on the last 7 days of each cycle. Patients will be instructed as follows: Take regorafenib once daily with a low fat meal that contains less than 30% fat. Take the regorafenib tablets at about the same time each day. Swallow the tablets whole.
1568436|NCT02466802|Drug|Sildenafil Citrate|Combination of regorafenib and of sildenafil when given to patients with advanced solid tumors.Sildenafil Administration and Treatment Schedule. Sildenafil will be taken orally once daily at the same time the regorafenib dose is taken for the first 21 days of each 28-day cycle. Sildenafil will not be taken on the last 7 days of each cycle.
1568437|NCT02466776|Device|Absorbable subcuticular suture|Patients will receive absorbable subcuticular suture for skin closure at time of cesarean section.
1568438|NCT02466776|Device|Stainless steel staples|Patients will receive stainless steel staples for skin closure at time of cesarean section.
1568439|NCT02466763|Procedure|Cochlear implant surgery|Surgical placement of a cochlear implant device.
1568444|NCT02466711|Drug|Relamorelin|Double blind RM-131 will be delivered three times by injection during the course of the study
1568445|NCT02466711|Drug|Placebo|Double blind Placebo will be delivered three times by injection during the course of the study
1568446|NCT02466698|Procedure|Intestinal Lavage|A nasojejunal tube and fecal management system will be inserted. Intestinal lavage with PEG is initiated and increased to a goal rate of 400cc/hour to a total of 8L of PEG. In the absence of an ileus, lavage should be initiated at 200cc/hr. Tolerance is confirmed if the rectal effluent volume is ≥50% of the lavage volume over the first 6 hours and no emesis has developed. If the consulting surgical service suspects a significant ileus, the lavage is initiated at 100cc/hr. If tolerance is confirmed the lavage rate is increased in a stepwise fashion. Antibiotic regimen will consist of Vancomycin 500mg via nasojejunal every 6 hours and Metronidazole 500 mg IV three times daily for 14 days. PEG will be held for 2 hours after administration of Vancomycin.
1568447|NCT02466698|Drug|Vancomycin|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
1568448|NCT02466698|Drug|PEG|Polyethylene glycol 3350, 8L in 48 hours, via a nasojejunal tube will be used to facilitate intestinal lavage.
1568449|NCT02466698|Drug|Metronidazole|Patients will receive standard antibiotic treatment for severe CDI. This includes an antibiotic regimen of Vancomycin 500mg orally every 6 hours and Metronidazole 500mg IV three times daily for 14 days. The standard medical care group (active comparator group) will receive the same antibiotic doses as the experimental arm of the study For both arms, indications to escalate treatment to surgical intervention will ultimately be based on the clinical assessment by the surgical service. An absolute indication for surgery is perforation. Other indications such as toxic megacolon, worsening peritonitis or biochemical profile lavage are relative indications that vary according to clinician and individual patient characteristics.
1568450|NCT02466685|Drug|JNJ-18038683|JNJ-18038683 10-20 mg/day for 8 weeks
1568451|NCT02466672|Other|none - observational only|
1568453|NCT02466646|Drug|Klorhex® Gel, rinse and sprey|nitial periodontal treatment was performed in 2 sessions with application of chlorhexidine to the intra-oral niches within 24 hours (Klorhex® Gel 1% for 10 minutes, Klorhex® Sprey 0,2% and Klorhex® rinse 0,2% for 3 weeks).
1568454|NCT02466646|Procedure|Conventional IPT|Initial periodontal treatment was performed in a quadrant-wise manner at 1-week intervals.
1568455|NCT02466646|Procedure|Full-mouth IPT|Initial periodontal treatment was performed in 2 sessions within 24 hours.
1568456|NCT02466633|Other|In-hospital cardiac monitoring method|Method for monitoring hospitalized patients at risk for cardiac arrhythmias (non-ICU)
1568457|NCT02466607|Device|RETeval color flicker ERG|Flicker ERGs obtained to 56 CIE 1931 (created by the International Commission on Illumination (CIE) in 1931) colors series. White flash of 0,33, 0,33 was used for comparison.
1568458|NCT02466607|Device|RETeval dilated versus un-dilated flicker ERG|Two series of white flashes: 3,0 cd/m2/sec and Trolands equivalent assuming 3,7 mm pupil size, delivered at 3 min interval over 30 min.
1568459|NCT02466607|Other|pupil dilation|Pupil will be dilated using Proparacaine 0.5% and Tropicamide 0.5%
1568460|NCT02466594|Device|Hilotherm Clinic®|Controlled Thermoregulation using a water circulation based system (Hilotherm Clinic®). Controlled Thermoregulation with Hilotherm Clinic® - Flap Temperature is altered by passive warming (dressing), active warming (38 C) and active cooling (10 C) each for 60 minutes following free flap transfer in every subject at the day of surgery and the following three days
1568461|NCT02466581|Drug|Sulphasalazine + Hydroxychloroquine OR Prednisolone|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
1568462|NCT02466581|Biological|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
1568463|NCT02466581|Biological|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
1568464|NCT02466581|Biological|RoActemra|Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week. Methotrexate: 25mg/week
1568467|NCT02466555|Behavioral|Music Therapy|During the educational music therapy intervention, member(s) of the Adult Sickle Cell Disease team will share with the patients the medical information pertinent to the appointment, ask health related questions of the patients and respond to any pertinent inquiries. The Music Therapist will then engage the patients and member(s) of the Adult Sickle Cell Disease team in a music therapy intervention designed to teach and reinforce the skills and knowledge presented. These music therapy interventions may include but are not limited to original songs/rap/instrumental playing, vocal and/or instrumental improvisation, patient-contributed lyrics, mnemonics, and stress and pain reducing strategies. The music therapy interventions will be tailored to best convey the educational message.
1568468|NCT02466542|Drug|Placebo group|Patients will receive regular general anesthesia
1568469|NCT02466542|Drug|Esmolol group|Patients will receive regular general anesthesia plus esmolol infusion
1568470|NCT02466516|Drug|GS-4997|GS-4997 tablets administered orally once daily
1568471|NCT02466516|Biological|SIM|Simtuzumab (SIM) 125 mg/mL single-dose vials administered subcutaneously once weekly
1568472|NCT02466503|Drug|Fluticasone propionate|Inhaled corticosteroid, pMDI
1568473|NCT02466503|Drug|Salmeterol (as xinafoate)|Beta-agonist, LABA, pMDI
1568474|NCT02466490|Drug|Fimasartan|Fimasartan tablets
1568475|NCT02466490|Drug|Fimasartan; Hydrochlorothiazide|Fimasartan plus hydrochlorothiazide fixed dose combination tablets
1568479|NCT02466464|Device|Microporous Polysaccharide Hemospheres|Two grams of Arista powder will be placed into the nose followed by four minutes of pressure and a moustache dressing.
1568480|NCT02466464|Device|Nasal Tampon|8 cm of Merocel dressing will be placed into one or both sides of your nose for the next three to five days and will then be removed by the physician.
1568481|NCT02466451|Other|Questionnaires|"For not collaborative patients, under the age of 4 years:
Standardized questionnaire collecting anamnestic-clinical data
Stress Parenting Index questionnaire and COPE brief questionnaire(Questionnaire assessing adaptation strategies of parents).
For collaborative patients, over the age of 4 years:
Standardized questionnaire collecting anamnestic-clinical data
Fractional exhaled nitric oxide (FeNO) assessment (oral and alveolar )
Spirometry
6-minutes walk test (WT 6')
Prick tests
Children Quality of life questionnaire (KINDL questionnaire)
Psychological test (Raven Matrices)
Stress Parenting Index questionnaire and COPE brief questionnaire (Questionnaire assessing adaptation strategies of parents)"
1568482|NCT02466438|Drug|Piperacillin-tazobactam|"Normal renal function receiving new optimized piperacillin-tazobactam dosing regimen per age, dosing (mg/kg), duration of infusion
Age (2-5 months): 80 mg/kg/dose of medication every 8 hours for 4 hours
Age (≥6 months-6y): 130 mg/kg/dose of medication every 8 hours for 4 hours
Acute Kidney injury : Dosing as prescribed by treating physician"
1568483|NCT02466425|Drug|SHP465|12.5mg and 25mg capsules (one capsule daily)
1568484|NCT02466425|Drug|Placebo|Matching placebo capsule that appear identical in size, weight, shape, color
1568485|NCT02466412|Other|CHTP 1.1 M|Single use of the Carbon Heated Tobacco Product 1.1 Menthol (CHTP 1.1 M)
1568486|NCT02466412|Other|mCC|Single use of subject's own menthol conventional cigarette (mCC)
1568487|NCT02466399|Drug|POLAT-001|Subconjunctival injection
1568488|NCT02466399|Drug|Latanoprost ophthalmic solution|Latanoprost ophthalmic solution q.d., evening
1568489|NCT02466386|Drug|SPD489|SPD489 will be provided in 5, 10, 15, 20, and 30mg strength capsules. Subjects will be instructed to take 1 capsule daily throughout the study.
1568490|NCT02466373|Drug|Clonidine (Catapresan®) 0,150 mg/ml, ampoule 1 ml|clonidine intravenous
1568491|NCT02466360|Behavioral|Back Belief questionnaire|
1568492|NCT02466360|Behavioral|QUEBEC scale|
1568493|NCT02466360|Behavioral|Fear Avoidance beliefs questionnaire|
1568494|NCT02466360|Behavioral|Visual analog scale|
1568495|NCT02466360|Behavioral|individual interviews|
1568496|NCT02466360|Behavioral|Focus groups|
1568497|NCT02466347|Drug|Fluticasone propionate|Inhaled corticosteroid, pMDI
1568498|NCT02466347|Drug|Salmeterol (as xinafoate)|Long Acting Beta-agonist (LABA), pMDI
1568499|NCT02466334|Drug|Calcitonin-Gene Related Peptide|1,5 µg/min of IV CGRP over 20 mins
1568500|NCT02466334|Drug|Placebo|40 ml of normal saline over 20 mins
1568503|NCT02466295|Other|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
1568504|NCT02466295|Other|Pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
1568505|NCT02466282|Device|Angiography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. PCI will be performed with BVS under conventional coronary angiography without any other intravascular imaging modality.
1568506|NCT02466282|Device|optical coherence tomography-guided PCI with bioresorbable vascular scaffold|Everolimus-eluting bioresorbable vascular scaffold (Absorb, Abbott Vascular, Santa Clara, CA, USA) was made from a bioabsorbable polylactic acid backbone which is coated with a more rapidly absorbed polylactic acid layer that contains and controls the release of the antiproliferative drug, everolimus. For optimized PCI, both conventional coronary angiography and optical coherence tomography can be used before and after stent implantation. OCT study should be checked at the final post-procedure and stent implantation is optimized.
1568508|NCT02466256|Procedure|Intraocular lens implantation|Intraocular lens implantation
1568509|NCT02466256|Device|Autosert Injector|Motorised injection device for intraocular lens implantation
1568510|NCT02466256|Device|Royale Injector|Manual, plunger type injection device for intraocular lens implantation
1568511|NCT02466256|Device|Monarch III Injector|Manual, screw type injection device for intraocular lens implantation
1568512|NCT02466243|Drug|JBT-101|Part A: 20 mg once daily on Days 1-28, then 20 mg twice daily on Days 29-84;
1568513|NCT02466243|Drug|Placebo|Part A: Once daily on Days 1-28, then twice daily on Days 29-84;
1568514|NCT02466243|Drug|JBT-101 Open-label|Part B: JBT-101 20 mg q.a.m and 20 mg q. p.m on days 1-365.
1568515|NCT02466230|Device|Repetitive transcranial magnetic stimulation|Active repetitive transcranial magnetic stimulation for 25 days (Monday through Friday for 5 consecutive weeks). Active rTMS with the FDA approved Neuronetics TMS system. Each treatment will target the left dorsolateral prefrontal cortex. rTMS will be administered at 10Hz with a duty cycle of 4 seconds on and 26 seconds off for 37.5 min.
1568516|NCT02466217|Other|1: AID groups|Clinical and Biological investigations
1568517|NCT02466217|Other|2: Control groups|Clinical and Biological investigations
1568518|NCT02466204|Drug|corifollitropin alfa|Drug is injected subcutaneously. Seven days after, 300 IU FSH daily injected subcutaneously, until at least two leading ovarian follicles reach 17mm in diameter.
1568519|NCT02466204|Drug|Follitropin Beta|Drug is injected subcutaneously, daily, until at least two leading ovarian follicles reach 17mm in diameter.
1568520|NCT02466191|Drug|Memantine|
1568521|NCT02466191|Drug|Gabapentin|
1568522|NCT02466178|Device|Serene RF System|The Serene RF System provides percutaneous delivery of radiofrequency (RF) energy to a targeted nerve.
1568523|NCT02466165|Behavioral|Physical exercise|
1568524|NCT02466152|Drug|GSK2894512 Topical Cream|GSK2894512 will be supplied as white to off-white topical cream in doses of 2.0% (20 milligrams/gram [mg/g]) and 1.0% (10 mg/g)
1568525|NCT02466126|Behavioral|bCBT|"The bCBT intervention uses 6 active-treatment sessions, each lasting 30 to 40 minutes, and telephone booster sessions to solidify changes. All participants receive an initial (core) session. In this session, participants work with their study clinician to set goals that are not restricted to emotional health (e.g., depression) but may also address physical health concerns (e.g., diet, exercise, managing a chronic condition). Following the core session, clinicians provide participants with a series of module choices, from which they select skills that match their most pressing needs. Each module focuses on a CBT technique (e.g., behavioral activation, changing thoughts), introduced and customized to the patient's immediate goals, regardless of the focus (physical or mental health)."
1568526|NCT02466113|Other|A 6 microRNA stratified tool|Investigators randomly assign patients to be assessed by a 6 microRNA stratified tool. MicroRNA(miRNA) tool contains miRNA of miR-21、miR-20a-5p、miR-103a-3p、miR-106b-5p、miR-143-5p and miR-215. Investigators evaluate these miRNA status of surgical specimens using qRT-PCR and calculate their risk score(risk score =(0.108×status of miRNA-21-5p)+(0.086×status of miRNA-20a-5p)+(0.240×status of miRNA-103a-3p)+(0.095×status of miRNA-106b-5p)-(0.238×status of miRNA-143-5p)-(0.237×status of miRNA-215),low expression status equals 0 and high expression status equals 1). Investigators defined high risk patient if their score larger than 1, the others as low risk patient.The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
1568527|NCT02466113|Other|A classic stratified tool|Investigators randomly assign patients to be assessed by by classical pathological features. Pathological features include poorly differentiated histology(exclusive of those cancers that are MSI-H),lymphatic/vascular invasion,bowel obstruction and <12 lymph nodes examined. Investigators defined high risk patient if they had any pathological features, the others as low risk patient. The high risk group should receive adjuvant chemotherapy while the low risk group deserve observation.
1568528|NCT02466100|Behavioral|goals of care|. Patients in the GoC intervention group, telephone coaching by a research nurse to help patients role-play talking with their HF providers. Both patients and their providers, will be provided with summaries of individualized, patient-centered information about patient preferences for communicating about end-of-life care and patient self-identified barriers to and facilitators of communication about end-of-life care with tips on how to initiate goals of care discussions. Providers of patients in the intervention group will also be provided with patient-specific prognostic information based on the Seattle Heart Failure Model.
1568530|NCT02466074|Drug|Acetazolamide|see arm description
1568531|NCT02466074|Drug|Placebo|Placebo arm
1568567|NCT02465840|Procedure|custom-made dynamic hand splint|custom-made dynamic splinting with more early active exercises intervention.
1569083|NCT02462304|Drug|Bevacizumab|
1568532|NCT02466061|Behavioral|Telemedicine Weight Management plus Wi-Fi Scale (Arm A)|Telephonic weight loss counseling by trained interventionists, with guided digital scale measurements of weight, lean mass, and fat mass. Counseling sessions and digital weight recording occur at regularly scheduled intervals over a six-month intervention period.
1568533|NCT02466061|Behavioral|Text for Diet (Text4Diet) Group (Arm B)|Short Message Service (SMS) text messaging in which participants receive 3-5 text messages each day during a six-month intervention period. The text messages provide tips and reminders to encourage healthy eating and weight loss. Participants on this arm also receive a digital scale to track and report weight as prompted once per week through the text program.
1568534|NCT02466061|Behavioral|Enhanced Usual Care Group (Arm C)|Participants are provided with handouts based on American Cancer Society guidelines for healthy eating and exercise.
1568535|NCT02466048|Procedure|Spinal Fusion|Spinal fusion, also known as spondylodesis or spondylosyndesis, is a surgical technique used to join two or more vertebrae. Supplementary bone tissue, from the patient (autograft), is used in conjunction with the body's natural bone growth (osteoblastic) processes to fuse the vertebrae. Either the right or left side of one patient will be selected for the study group, and the other, for the control group, through randomization. In the study group site, SurgiFill™ and the autogenous bone mixture shall be transplanted, whereas in the control group site, only the autogenous bone shall be transplanted. The autogenous bones are from iliac part.
1568536|NCT02466048|Device|SurgiFill™|SurgiFill™ is a gel-type high-purity ateolcollagen for bone grafting. SurgiFill™ is used with autogenous iliac graft for dorsolateral spinal fusion.
1568538|NCT02466022|Drug|Dexmedetomidine|Bolus dose prior to spinal anesthetic
1568539|NCT02466022|Drug|Bupivicaine|Intrathecal hyperbaric bupivicaine 12.75mg
1568540|NCT02466022|Drug|Normal Saline|Bolus 0.1cc/kg Normal Saline over 10 min
1568541|NCT02466022|Drug|Fentanyl|Intrathecal Fentanyl 10ug
1568542|NCT02466022|Drug|Midazolam|0-4mg of IV Midazolam prn for rescue sedation
1568543|NCT02466009|Drug|Regorafenib|Regorafenib 120 mg (3 tablets) each day for 21 days of a 28 day cycle with the possibility of an increase in the dose to 160 mg (4 tablets).
1568544|NCT02465996|Device|pCLE examination|All FD patients received pCLE examination.
1568545|NCT02465996|Drug|Puyuanhewei|FD patients willing to receive Puyuanhewei were given 4 pills three times a day regardless of PDS or EPS for 4 weeks after pCLE examination.
1568546|NCT02465983|Biological|CART-meso-19 T cells|A single dose of CART-meso-19 cells (combination therapy with CART-meso and CART19 cells) will be administered intravenously as two separate infusions. The dose is 1-3x107/m2 (Cohort 1) or 1-3x108/m2 (Cohort 2) CART positive cells. The infusion will be scheduled to occur 3 (±1) days after a single dose of 1.5 grams/m2 of cyclophosphamide, which will be administered according to standard procedures in the outpatient setting. Patients will receive CART cell treatment on an outpatient basis.
1568547|NCT02465983|Drug|Cyclophosphamide|A single dose of chemotherapy to be administered prior to dosing of the CART-meso-19 cells
1568548|NCT02465970|Device|STARSTIM|"Multifocal transcranial direct current stimulation.
CE-marked device, comprising a cap with 2 to 8 electrodes, connected with a programmable mobile stimulator.
The stimulation is applied during a 60 min session"
1568549|NCT02465970|Device|sham TDCS|
1568551|NCT02465944|Drug|FFP104|Three intravenous infusions of FFP104 over 15 days (d0, d7 and d14)
1568552|NCT02465944|Drug|Placebo|Three intravenous infusions of 0.9% Saline over 15 days (d0, d7 and d14)
1568553|NCT02465931|Other|Paper-Based Informed Consent|Paper-based informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, simplified overview of informed consent form will be provided in person just once. For MacCAT Questions, All questions will be asked after the disclosure information has been presented. Questions will have the same wording as experimental condition. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). There will be multiple choice options rather than open-ended. Finally, data collection will be done through paper and pencil.
1568554|NCT02465931|Device|Tablet-Based Consent|Paper informed consent form will be sent to participant and family before data collection visit. They will be able to review as many times as they wish before visit. During visits, the participant can go through the tablet-based tool up to 3 times. All questions will be embedded within the vignettes/presentation of disclosure information. Question will use simplified wording, similar to flipchart. Procedures will mimic MacCAT/flipchart (incorrect or partial credit will be given opportunity to answer question again after disclosure information is repeated). Multiple choice options will be utilized rather than open-ended. Finally, response data stored within tool and exported to dataset for analysis.
1568555|NCT02465918|Device|motor cortex stimulation (Change of Stimulation Timing)|
1568556|NCT02465905|Other|raw milk|
1568557|NCT02465905|Other|Heated milk|
1568558|NCT02465892|Behavioral|Pillars4Life|The Pillars4Life program will guide participants through activities that will help to identify stress and anxiety triggers, plan ways to cope with the stress of life and cancer, manage anxiety, deal with chronic pain, and balance competing priorities in life.
1568559|NCT02465879|Other|Therapist Triage|An extended role occupational or physical therapist will triage each subject in the study to determine the urgency of their case and how soon they need to see the rheumatologist.
1568560|NCT02465866|Drug|CL-108|Hydrocodone bitartrate/acetaminophen/promethazine 7.5 mg/325 mg/12.5 mg single dose by mouth
1568561|NCT02465866|Drug|Vicoprofen|Hydrocodone Bitartrate and Ibuprofen 7.5 mg/200 mg single dose tablet by mouth
1568562|NCT02465866|Drug|Ultracet|Tramadol HCl/acetaminophen 37.5 mg/325 mg single dose tablet by mouth
1568563|NCT02465866|Drug|Phenergan|Phenergan (Promethazine HCl, USP) 12.5 mg single dose tablet by mouth
1568564|NCT02465853|Drug|Hyaluronic Acid|Injection Hyaluronic Acid in the experimental group
1568565|NCT02465853|Drug|Physiological saline solution|Injection 0.9% Physiological saline solution<1.0 ml
1568566|NCT02465853|Other|physical therapy and occupational therapy|rehabilitation
1568568|NCT02465840|Procedure|custom-made protective hand splint|Immobilization splint with gentle ROM exercises
1568569|NCT02465840|Other|physical therapy and occupational therapy|both the immobilization and Kleinert programs including physical therapy and occupational therapy for 2-3 times per week.
1568570|NCT02465827|Drug|nerve block with ropivacaine|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with ropivacaine 0.75% for both nerve branches
1568571|NCT02465827|Drug|nerve block with ropivacaine and with saline|nerve blocks of the saphenous nerve with ropivacaine 0.75% and obturator nerve, posterior branch with saline
1568572|NCT02465827|Drug|nerve block with saline|Ultrasound guided nerve blocks of the saphenous and obturator nerve, posterior branch with saline for both nerve branches
1568573|NCT02465814|Drug|Vilaprisan (BAY1002670)|Vilaprisan 2 mg (12 weeks), Vilaprisan 2 mg (12 weeks)
1568574|NCT02465814|Drug|Vilaprisan (BAY1002670|Placebo (12 weeks),Vilaprisan (12 weeks)
1568575|NCT02465814|Drug|Vilaprisan (BAY1002670|Vilaprisan 2 mg (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
1568576|NCT02465814|Drug|Vilaprisan (BAY1002670)|Placebo (12 weeks), treatment break, Vilaprisan 2 mg (12 weeks)
1568577|NCT02465814|Drug|Ulipristal|Ulipristal 5 mg (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
1568578|NCT02465814|Drug|Ulipristal|Placebo (12 weeks), treatment break, Ulipristal 5 mg (12 weeks)
1568579|NCT02465814|Drug|Ulipristal|Ulipristal (12 weeks), treatment break, Placebo (12 weeks)
1568580|NCT02465801|Drug|HSA-GCSF 1.2 mg|Human Serum Albumin GCSF 1.2mg at day 3 and Day 7
1568581|NCT02465801|Drug|HSA-GCSF 1.5 mg|Human Serum Albumin GCSF 1.5 mg at day 3 and Day 7
1568582|NCT02465801|Drug|GCSF|GCSF 5 mcg/kg/day
1568583|NCT02465788|Device|GentleTouch|Four distinct areas on each selected anatomical area will be treated with different treatment parameters.
1568584|NCT02465775|Device|UltraShape treatment|Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
1568585|NCT02465762|Device|ultrashape Fat reduction|Ultrashape Device focused ultrasound to produce localized mechanical motion within fat tissues and cells for the purpose of producing mechanical cellular membrane disruption. It is intended for reduction in abdominal circumference.
1568586|NCT02465749|Drug|Continuous oxygen|Continuous oxygen intake at a concentration of 93±3%, 3L/min flow-rate, 2h/bid, five days a week;
1568587|NCT02465749|Device|blue light-absorbing sunglasses|Wearing blue light-absorbing sunglasses at daily time;
1568588|NCT02465749|Drug|Compound thrombosis capsule sig: 1.5g/tid|Compound thrombosis capsule sig: 1.5g/tid
1568589|NCT02465749|Drug|Ginkgo biloba pills sig: 300mg/tid;|Ginkgo biloba pills sig: 300mg/tid;
1568590|NCT02465749|Drug|Vitamin B sig: 10mg/tid|Vitamin B sig: 10mg/tid
1568591|NCT02465749|Drug|Vitamin AD sig: 1 tablet/tid|Vitamin AD sig: 1 tablet/tid
1568592|NCT02465736|Drug|Docetaxel|25mg/ m2 Docetaxel dose administered on days 1, 8, 15, and 22.
1568593|NCT02465736|Drug|Cisplatin|25mg/ m2 on days 1, 8, 15 and 22.
1568594|NCT02465736|Radiation|Radiation|Patient will receive 4 weeks of radiation therapy (44 Gy/20 fractions).
1568595|NCT02465736|Procedure|Surgery|McKeown esophagectomy, Ivor Lewis esophagectomy or minimally invasive esophagectomy will be performed 4-8 weeks after chemoradiotherapy. Two-field lymphadenectomy with total mediastinal lymph node dissection is performed during surgery.
1568596|NCT02465736|Drug|Vinorelbine|25mg/ m2 on days 1, 8 of each cycle (i.e. every 21 days).
1568597|NCT02465736|Drug|Cisplatin|75mg/ m2 on day 1 of each cycle only (i.e. every 21 days).
1568598|NCT02465723|Device|MRI with IVIM DW-MRI|
1568599|NCT02465723|Other|Blood draw|For each patient enrolled, 8-10 mL of whole blood will be collected into glass, anti-coagulant-free tubes and allowed to clot 20-30 minutes.
1568600|NCT02465710|Procedure|Pelvic organ prolapse surgery without mesh|retrospective study
1568601|NCT02465710|Procedure|Pelvic organ prolapse surgery with mesh|
1568603|NCT02465684|Procedure|unicondylar knee arthroplasty|
1568604|NCT02465658|Other|Medical records were reviewed.|retrospective study
1568605|NCT02465645|Drug|Carvedilol|
1568606|NCT02465645|Drug|Carvedilol + Simvastatin|
1568607|NCT02465632|Drug|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|
1568608|NCT02465632|Drug|BenzaClin® Topical Gel, Clindamycin 1%/Benzoyl Peroxide 5%|
1568609|NCT02465632|Drug|Placebo|
1568610|NCT02465606|Drug|Lebrikizumab|
1568611|NCT02465606|Drug|Topical corticosteroid (TCS) cream|
1568612|NCT02465593|Drug|PEP503|The volume of PEP503 to be administered is based on the baseline tumor volume of each patient. There will be 4 dose levels in Phase Ib.
1568613|NCT02465593|Drug|5-fluorouracil|225 mg/m2 a day, 5 days/week for 5 weeks during radiotherapy period
1568614|NCT02465593|Drug|capecitabine|825 mg/m2 BID 5 days/week for 5 weeks during the radiotherapy period
1568615|NCT02465593|Procedure|surgical resection|Approximately 8 weeks after the completion of chemoradiotherapy, surgical resection of the tumor (total mesorectal excision, TME) will be performed once the tumor become resectable.
1568616|NCT02465593|Radiation|Radiotherapy|Intensity-modulated radiation therapy (IMRT) or intensity modulated arc therapy (IMAT) of 5,000 cGy in 25 fractions (200 cGy/fraction, 5 times/week) to gross tumor and involved nodes and 4,500 cGy in 25 fractions (180 cGy/fraction, 5 times/week) to pelvis, starting at 24 hours after PEP503 injection.
1568617|NCT02465580|Drug|hrIL-2 active|active group: placebo group =1:1
1568618|NCT02465580|Drug|hrIL-2 placebo|active group: placebo group =1:1
1568623|NCT02465554|Procedure|Myocardial contrast echocardiography|Myocardial contrast echocardiography will be performed to further stratify risk as described in the cohort section.
1568664|NCT02465294|Dietary Supplement|Probiotic|This group will receive the blend of Bifidobacterium and Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
1568624|NCT02465541|Procedure|Gentle yoga therapy|Mindfulness in Motion is a mindfulness based intervention that is an 8-10 week program for adults interested in learning a practical strategy for stress reduction, intended to be delivered on the worksite or home.
1568625|NCT02465541|Other|counseling intervention|Undergo dietary counseling that will include 10 (20-min) nutritional counseling sessions with a registered dietitian.
1568626|NCT02465541|Other|educational intervention|Undergo enhanced usual care
1568627|NCT02465541|Other|quality-of-life assessment|Ancillary studies
1568628|NCT02465541|Other|questionnaire administration|Ancillary studies
1568629|NCT02465528|Drug|Ceritinib (LDK378)|Ceritinib will be dosed on a flat scale of 750 mg (e.g. 5 x 150 mg capsules) once daily for continous dosing cycle. Complete dosing cycle is 28 days.
1568633|NCT02465502|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg orally once a day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off).
1568634|NCT02465489|Drug|Deferiprone extended release|Deferiprone 1000 mg extended release tablet formulation
1568635|NCT02465489|Drug|Deferiprone immediate release|Ferriprox (deferiprone) 500 mg immediate release tablet formulation
1568636|NCT02465476|Procedure|telemedicine|treatment pathway organized by telemedicine
1568637|NCT02465463|Procedure|Fecal microbiota transplant (FMT)|250 mL of donor stool will be infused into the colon by flexible sigmoidoscopy
1568638|NCT02465463|Device|flexible sigmoidoscopy|
1568639|NCT02465450|Drug|JBT-101|Subjects will receive JBT-101 1 mg qd or JBT-101 5 mg qd on Days 1-28. Subjects will receive either JBT-101 20 mg q am (with placebo q pm) or JBT-101 20 mg twice a day on Days 29-84.
1568640|NCT02465450|Other|Placebo|Subjects will receive placebo once a day on Days 1-28, placebo q pm on Days 29-84 (with JBT-101 20 mg q am), or placebo bid on Days 29-84.
1568644|NCT02465424|Other|quality of life questionnaires|Randomised allocation of 4 validated quality of life questionnaires followed by study specific overview questionnaire
1568645|NCT02465411|Device|Dexcom G4 or later generation|Continuous glucose monitoring with DexCom G4 platina or later generations
1568646|NCT02465398|Procedure|Fracture Shoulder Arthroplasty|Implantation of the Anatomical Shoulder Fracture System
1568647|NCT02465385|Drug|Linaclotide|Every participant with be given 290 mcg of linaclotide 1 hour prior to receiving their capsule, in place of the standard (golytely) preparation
1568648|NCT02465372|Behavioral|CSPAP|Comprehensive School Physical Activity Program.
1568649|NCT02465359|Drug|Immune Globulin Subcutaneous (Human)|Patients who have CIDP and are on IVIG will be allowed in the study to try subcutaneous immune Globulin (SCIG) as part of an open label study.
1568650|NCT02465346|Device|MSU-based stroke management|Prehospital stroke treatment with a mobile stroke unit
1568651|NCT02465346|Device|Control stroke management|Conventional stroke management
1568652|NCT02465333|Procedure|Heel Fat Grafting|"Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the heel fat pad using specialized injection cannulas.
Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
1568653|NCT02465333|Drug|Local anesthetic|"To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.
Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. <200ml). Only a few cc's of fat are needed for injection into the foot."
1568654|NCT02465320|Drug|COL-1077|single dose of 150mg lidocaine (10%w/w) administered by intravaginal insertion
1568655|NCT02465320|Drug|Placebo|single dose of bioadhesive gel administered by intravaginal insertion
1568656|NCT02465307|Behavioral|Confusion Assessment Method|Confusion Assessment Method (CAM) score
1568657|NCT02465307|Device|Accelerometer|3 accelerometers (placed on upper arm, wrist and ankle) and 1 placed on wall as ambient light sensor
1568658|NCT02465307|Device|Commercially available camera|As part of facial recognition video system
1568659|NCT02465307|Device|Internet Pod (iPod)|Monitors noise levels in the room
1568660|NCT02465294|Dietary Supplement|Probiotic|This group will receive the Lactobacillus probiotic, which will be taken as a capsule once daily for 12 weeks.
1568661|NCT02465294|Behavioral|Behavioral lifestyle intervention|All participants will participate in weekly group meetings of 15 to 20 participants for a facilitated discussion of specific nutritional, behavioral, and physical activity topics chosen to promote weight loss.
1568662|NCT02465294|Other|Placebo|This group will receive the placebo and will be taken as a capsule once daily for 12 weeks. The placebo will contain encapsulated potato starch which is used the matrix in the probiotic supplements.
1568663|NCT02465294|Other|Blood Test|All subjects will have blood tests performed.
1569323|NCT02460640|Drug|Morphine|
1568668|NCT02465268|Drug|Td|All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.
1568669|NCT02465268|Drug|Saline|
1568670|NCT02465268|Drug|pp65-flLAMP DC with GM-CSF|
1568671|NCT02465255|Drug|Ketorolac|
1568672|NCT02465255|Drug|Tramadol|
1568673|NCT02465255|Drug|Acetaminophen|
1568674|NCT02465229|Procedure|Multimodal tissue-sampling methods before and after stricture dilation|Each participant will receive the following tissue-sampling methods in order : 1)intraductal suction, 2)intraductal forceps biopsy, 3)brushing cytology, 4)stricture dilation, 5)intraductal suction, 6)intraductal forceps biopsy and 7)brushing cytology during endoscopic retrograde cholangiopancreatography.
1568675|NCT02465216|Other|Placebo|Placebo
1568676|NCT02465216|Biological|ID93 + GLA-SE|ID93 + GLA-SE
1568678|NCT02465164|Device|Cook catheter|
1568679|NCT02465164|Drug|Oxytocin|
1568680|NCT02465151|Other|Protein-based beverage|protein-based beverage
1568681|NCT02465138|Drug|Ketorolac|Intravenous ketorolac
1568682|NCT02465138|Drug|Placebo|Intravenous saline
1568683|NCT02465125|Biological|red blood cell transfusion|
1568684|NCT02465112|Drug|In111-Pentetréotide|
1568685|NCT02465112|Other|simple monitoring without active therapy|
1568688|NCT02465086|Other|Training of linguistic recursion|Training of recursion comprehension will include cooperative dialogue and feedback on the sentences and small dialogues. The training conditions will be further divided into marking the change of the truth-value.
1568689|NCT02465073|Device|NXTSC wound gel|Subjects will receive NXTSC wound gel only.
1568690|NCT02465073|Device|NXTSC wound gel plus Standard of Care|Subjects will be randomized to the NXTSC wound gel plus Standard of Care of only.
1568691|NCT02465073|Device|Standard of Care Group|Subjects will receive Standard of Care only.
1568715|NCT02465047|Other|Self-help booklet|See Arm/Group Description
1568716|NCT02465034|Device|Transcranial Magnetic Stimulation (Magstim)|Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator to measure transient cortical excitability. Single pulse transcranial magnetic stimulation applied at low frequencies (not greater than 0.25 Hz) will be used. The may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
1568717|NCT02465034|Device|Traditional Paired Associative Stimulation|Paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25Hz for 12 minutes. Median nerve stimuli at 300% of the perceptual threshold will be applied 25ms prior to transcranial magnetic stimulation delivery over the ipsilesional (stroke) or non-dominant (control) cortex. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This traditional paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
1568718|NCT02465034|Device|Median Nerve Stimulation|Stimulation of the median nerve will be performed using a bipolar bar electrode affixed to palmar aspect of the forearm proximal to the crease of the wrist bilaterally. Stimuli will be delivered 23ms prior to the transcranial magnetic stimulation (TMS) pulse with 0.1ms rectangular pulses at an intensity to evoke a 1mV response in the abductor pollicis brevis (APB) muscle. This may may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
1568719|NCT02465034|Device|Corticocortical Paired Associative Stimulation|Corticocortical Paired associative stimulation (ccPAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. 180 paired stimuli are delivered at 0.25Hz for 12 minutes. The interstimulus interval will range from 5-15ms depending on site of stimulation.Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This corticocortical paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
1568763|NCT02464709|Drug|Aminolevulinic Acid|A 0,25mm-thick layer of BF-200 ALA (aminolevulinic acid, Ameluz®) light sensitizer gel is applied on one randomized treatment side of face.
1569324|NCT02460640|Drug|Ropivacaine|
1568720|NCT02465034|Device|Sham Paired Associative Stimulation|The sham paired associative stimulation (PAS) is a combination of transcranial magnetic stimulation (TMS) and electrical stimulation of the median nerve. The coil is rotated and separated from the head with a plastic spacer to ensure indirect contact with the head.180 paired stimuli are delivered at 0.25Hz for 12 minutes. Transcranial Magnetic Stimulation (TMS) will be performed using the Magstim BiStim^2 paired pulse stimulator unit and a bipolar bar electrode will be used for median nerve stimulation. This sham paired associative stimulation may be repeated at multiple study visits. All five study visits will be completed within four weeks of the initial visit.
1568721|NCT02465021|Other|Dietary intervention|All arms are given to all participants, in a randomized order
1568722|NCT02465008|Drug|Levobupivacaine|
1568723|NCT02465008|Drug|Placebo|
1568724|NCT02464995|Device|Bronchial thermoplasty with the Alair System|
1568725|NCT02464982|Procedure|Tattoo|tattoo device with EC standards, and sterile single-use only needle
1568726|NCT02464969|Drug|Apixaban|Tablet or Solution
1568727|NCT02464969|Drug|Standard of Care|Unfractionated heparin, low molecular weight heparin, and/or a vitamin K antagonist.
1568728|NCT02464943|Device|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
1568729|NCT02464917|Device|Device: simple facemask to administer supplemental oxygen|
1568730|NCT02464904|Device|Cryotherapy|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). The procedure will involve 2 to 3 applications of cryospray on the location of the disease. After establishing cryofrost over a minimum of a 2 x 2 cm area, cryospray will continue for 15 to 20 seconds, allow a thaw period of 60 seconds followed by one to two repeats in the same location before proceeding onto the next location. We will treat a minimum of 6 x 6 cm area in aggregate. The freezing procedure will be video-recorded and freezing locations and time will be recorded. Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection.
1568731|NCT02464904|Other|Control|Subjects will have their blood drawn prior to undergoing a staging pleuroscopy. During the pleuroscopy pleural fluid will be collected as well as pleural biopsies (4 to 8 research biopsies). Approximately, 14 days following the staging pleuroscopy patients will undergo surgical treatment as per standard of care, with repeat blood, pleural fluid and tissue collection
1568732|NCT02464891|Drug|CCX168|
1568733|NCT02464878|Drug|Alpha 1-Antitrypsin|Patients will receive three times a week AAT infusions in the peri-transplant period for three weeks.
1568734|NCT02464878|Procedure|Islet Transplantation|
1568735|NCT02464878|Drug|Thymoglobulin|Patients will receive a total of 5 doses between Day -2 and Day +2
1568736|NCT02464878|Drug|Basiliximab|Basiliximab will be used for subsequent transplants.
1568737|NCT02464878|Drug|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
1568738|NCT02464865|Drug|Thiamine 1|"If severe symptoms and signs of thiamine deficiency are present, thiamine is prescribed.
Intervention 1 : severe symptom (heart failure, convulsion, or coma) : 50 mg thiamin administered very slowly intravenously, followed by a daily intramuscular dose of 10 mg for a week, and finally followed by 3-5 mg of thiamine per day orally for at least 6 weeks"
1568739|NCT02464865|Other|Non-thiamine|no symptoms and signs of thiamine deficiency
1568740|NCT02464865|Drug|Thiamine 2|"If symptoms and signs of thiamine deficiency are present, thiamine is prescribed.
If mild symptom : a daily oral dose of 10 mg thiamin during the first week, followed by 3-5 mg of thiamin per day orally for at least 6 weeks"
1568741|NCT02464852|Behavioral|Head movements|Participants will be asked to perform a series of movements of exploration of their maximum neck range of motion, including: flexion, extension, right and left lateral flexion, right and left axial rotation.
1568742|NCT02464852|Behavioral|Activities of daily living (drinking, washing hand and eating)|Patients will be asked to perform a series of activities of daily living (drinking, eating and washing hands).
1568743|NCT02464852|Device|Sheffield Support Snood|
1568744|NCT02464852|Device|sEMG|
1568745|NCT02464826|Drug|Nailprotex|Nailprotex apply to the abnormal nail twice daily
1568746|NCT02464813|Drug|Pregabalin|Patients will receive pregabalin twice preoperatively and twice daily for 5 days after surgery.
1568747|NCT02464813|Drug|Sugar pill|Patients will receive placebo twice preoperatively and twice daily for 5 days after surgery.
1568748|NCT02464813|Drug|Oxycodone|All patients will receive oxycodone as analgetic treatment administered by PCA. Oxycodone consumption will be measured.
1568749|NCT02464800|Procedure|Vitrectomy for proliferative diabetic retinopathy|25-gauge vitrectomy
1568751|NCT02464774|Procedure|Breast-Conserving Therapy|Patients undergo lumpectomy with surgical axillary staging with all lesions resected to negative margins.
1568752|NCT02464774|Procedure|Mastectomy|Patients undergo mastectomy with surgical axillary staging with all lesions resected to negative margins.
1568753|NCT02464774|Drug|Adjuvant Chemotherapy|Patients with stage I and II receive adjuvant chemotherapy using TC and TAC regimen respectively.
1568754|NCT02464774|Radiation|Radiation Therapy|N0: Radiation therapy to whole breast (+boost to tumor bed) or consideration of partial breast irradiation in selected patients; (2) N1: Radiation therapy to whole breast (+boost to tumor bed), infraclavicular region, and supraclavicular area with or without radiation therapy to internal mammary nodes.
1568755|NCT02464761|Drug|Visudyne|
1568756|NCT02464748|Other|TiM telehealth arm|
1568757|NCT02464735|Device|Polysomnography|
1568758|NCT02464722|Drug|Dexmedetomidine|1 mcg/kg iv loading dose of remifentanil over a period of 60 seconds. Later, an infusion was started at the rate of 0.2-0.4mcg/kg/min.
1568759|NCT02464722|Drug|Remifentanil|1 mcg/kg iv loading dose of remifentanil over a period of 10 minutes. Later, an infusion was started at the rate of 0.4-0.8mcg/kg/min.
1568760|NCT02464722|Drug|Epinephrine|Before the start of surgery, 1/100000 epinephrine infiltration was administered to the nasal passages by the surgeon.
1568761|NCT02464722|Drug|Propofol|Anesthesia was induced with propofol 2 mg kg-1
1568764|NCT02464709|Drug|Methyl 5-aminolevulinate|A 0,25mm-thick layer of MAL (methyl 5-aminolevulinate, Metvix®) light sensitizer cream is applied on one randomized treatment side of face.
1568765|NCT02464696|Other|Non-Invasive Positive Pressure Ventilation (NIPPV)|2 hours on NIPPV, alternating with < 2 hours off NIPPV, with continuous NIPPV at night or while sleeping with a minimum recommended time of 8 total hours of NIPPV/day.
1568766|NCT02464696|Other|High Flow Nasal Cannula Oxygen Therapy|Participants maintained on high flow nasal cannula oxygen therapy.
1568767|NCT02464683|Dietary Supplement|VitaminD|200 International Units (oral dose) daily of 60 days
1568768|NCT02464670|Biological|INO-4201|INO-4201 delivered IM followed by Electroporation
1568769|NCT02464670|Biological|INO-4202|INO-4202 delivered IM followed by Electroporation
1568770|NCT02464670|Biological|INO-4201|INO-4201 delivered ID followed by Electroporation
1568771|NCT02464670|Biological|INO-4212|INO-4212 delivered IM followed by Electroporation
1568772|NCT02464670|Biological|INO-4212 + INO-9012|INO-4212 + INO-9012 delivered IM followed by Electroporation
1568773|NCT02464670|Biological|INO-4201 + INO-9012|INO-4201 + INO-9012 delivered ID followed by Electroporation
1568779|NCT02464644|Other|Questionnaire|To capture large sufficiently large numbers of individuals for appropriate statistical power (see below), a web based questionnaire design was considered the most appropriate tool. SurveyMonkey was identified as the most suitable means to generate the questionnaire, facilitate confidential answers by the target populations, and for analysis of questionnaire data. The designed survey can also be presented in paper format, and used in our clinical service.
1568780|NCT02464631|Drug|Sofosbuvir + Ribavirin 1|
1568781|NCT02464631|Drug|Sofosbuvir + Ribavirin 2|
1568782|NCT02464631|Drug|Sofosbuvir + Ribavirin 3|
1568783|NCT02464618|Behavioral|Social contact intervention|The social contact of the patients in this arm will be engaged to improve adherence to out-patient endoscopy
1568784|NCT02464605|Biological|SEL-037 (pegsiticase)|Intravenous infusion of SEL-037
1568785|NCT02464592|Procedure|Transbronchial lung biopsy.|Transbronchial lung biopsy with cryoprobe and with conventional forceps.
1568786|NCT02464566|Behavioral|Intensive lifestyle intervention|
1568787|NCT02464566|Other|Health Education|
1568788|NCT02464553|Other|periradicular therapy (PRT)|RTG controlled periradicular therapy (PRT) is a microinvasive interventional pain release procedure. Advantage of targeted pain therapy is exact administration of effective drugs to the nerve root in the area of the thoracic, lumbar or sacral spines.
1568789|NCT02464540|Procedure|Laminate veneers luted with light-cured resin cement|After the use of light-cured luting agent the color of laminate venners will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL*a* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
1568790|NCT02464540|Procedure|Laminate veneers luted with light-cured flowable composite|After the use of light-cured luting agent the color of laminate veneers will be performed with visual evaluation based on Vita and 3D Master scales and with a spectrophotometer Vita Easyshade (Vita Zahnfabrik / Bad Saeckingen, Germany) based on CIEL*a* b system. Data collected will be evaluated for translucency parameter (TP) and color variation (ΔE) according to luting agent, thickness and color of the LVs as well as color of dental substrate. Additionally, the color obtained with visual evaluation and with spectrophotometer will be compared to evaluate the level of agreement between the color observed by the operator and the color named by the spectrophotometer.
1568791|NCT02464527|Behavioral|Stimulus-stimulus pairing|The participants will attend clinic-based treatment sessions for one hour per day, five days per week, for 6-weeks.The stimulus-stimulus pairing procedure will consist of sounds and words being systematically paired with delivery of a preferred item.
1568792|NCT02464527|Other|Vocal recorder|The vocal recorder is a voice recording device that enhances vocalization data. The parent/ guardian will be instructed on how to use the vocal recorder. The vocal recorder will then be deployed at the participant's homes via parent/guardian. The parent/guardian will record vocalizations for approximately 1 hour while in the home or community setting pre, mid, and post treatment. The parent/guardian will return the vocal recorder to the study team for analysis of the recordings.
1568793|NCT02464514|Other|High carbohydrate meal|65% carbohydrate, 17% protein, and 18% fat
1568794|NCT02464514|Other|High fat meal|58% fat, 17% protein, and 25% carbohydrate
1568795|NCT02464501|Other|Paclitaxel administration using the OPC|
1568796|NCT02464488|Other|Plasma drug concentrations|Measure of plasma concentrations of the anticoagulant drug taken by the patient
1568797|NCT02464475|Other|osteopathic manipulative treatment|
1568798|NCT02464475|Other|sham osteopathic treatment|
1568799|NCT02464462|Dietary Supplement|vitamin D3 and calcium|1800 IU vitamin D3 plus 720 mg Calcium
1568800|NCT02464462|Other|Placebo|Rice powder pills
1568801|NCT02464449|Behavioral|Behavioral: AI-CBT|AI CBT engine will make recommendations to step-down or step-up intensity of CBT follow-up based on what patient reports and what other similar patients report. Stepped care model.
1568802|NCT02464449|Behavioral|Behavioral: Standard Telephone CBT|Controls receive 10 hour-long standard telephone CBT sessions, a pedometer/log after baseline, and a Patient Handbook.
1568803|NCT02464436|Drug|hRPC|Participants will undergo vitrectomy surgery and subretinal implantation of hRPC in the study eye.
1568804|NCT02464423|Behavioral|Trauma-Informed Cognitive Behavioral Therapy enhanced (TI-CBTe)|
1568805|NCT02464410|Behavioral|Motivational intervention|The intervention session combines elements of motivational enhancement (ME) and cognitive behavioral therapy (CBT). Similar to other ME brief interventions, the intervention content will be covered in a single session. Participants are presented with a variety of risk reduction strategies and strategies for coping with pain that may reduce reliance on opioids for managing pain.
1568806|NCT02464410|Behavioral|Psycho-educational control|The educational control condition provides educational content related to the biology of pain response and an overview of pain conditions. The overall style is didactic.
1568807|NCT02464410|Other|Long-term opioid therapy informed consent|The Veterans Health Administration instituted a requirement that all patients receiving long-term opioid therapy receive an informed consent process that reviews the risks of opioid therapy. All individuals eligible for this study will meet this definition of long-term opioid therapy. The study therapists for both study arms will deliver the informed consent process during the sessions as part of treatment as usual.
1568808|NCT02464397|Device|Stent|In the study, either OPTIMAX or SYNERGY stent will be implanted in coronary artery lesion
1568809|NCT02464384|Procedure|Venipuncture, ultrasound, MRI, x-ray|Collection of blood samples and ultrasound / MRI and x-ray examination
1568810|NCT02464371|Other|kinetic of microRNAs|blood samples will be drawn to measure microRNAs
1568811|NCT02464358|Behavioral|IMB Intervention Group|Participants in the IMB group received information specific to HPV, cervical cancer, and the HPV vaccine. This information was delivered in a group setting, and it was delivered via a PowerPoint presentation that included short video clips.
1568812|NCT02464358|Behavioral|Attention Control|Participants in the attention control arm watched a PowerPoint that contained a series of short video clips encompassing aspects of women's general and sexual health. This was also conducted in a group setting.
1568813|NCT02464345|Behavioral|HAPIFED|HAPIFED is adapted from CBT to promote a positive relationship with food, eating and activity, appetite awareness, and weight loss to be achieved over a longer and more intensive period of therapy, thus recognizing the importance of longer-term therapy in weight loss (Casazza et al., 2013). Notably, HAPIFED is also multidisciplinary. Clinical practice and consensus views are to utilize the special expertise of dietitians and other allied health professionals (Robinson, 2009).
1568814|NCT02464345|Behavioral|CBT-E|CBT-E therapy
1568815|NCT02464332|Drug|BLZ-100|"All subjects enrolled in the study will receive doses of BLZ-100, an investigational drug for imaging tumors.
Three different imaging windows will be investigated during the study:
Early Imaging (imaging occurs within 1 day post-BLZ-100 dose); Intermediate Imaging (imaging occurs within 2-3 days post-BLZ-100 dose); Late Imaging (imaging occurs 4-7 post-BLZ-100 dose)
All subjects in Part 1 of the study will be imaged in the Intermediate Imaging group. Subjects in Part 2 of the study will be randomized into one of the three imaging groups."
1568816|NCT02464319|Drug|hrIL-2 active|1 million U doses of human recombinant interleukin-2 s.c. injection active group: placebo group =1:1
1568817|NCT02464319|Drug|hrIL-2 placebo|1 million U doses of placebo s.c. injection active group: placebo group =1:1
1568818|NCT02464306|Drug|fidaxomicin|Patients will be treated with fidaxomicin 200 mg PO twice daily for 10 days.
1568819|NCT02464293|Other|Mindfulness-based cognitive therapy|An 8 week course of mindfulness-based cognitive therapy
1568820|NCT02464280|Other|Tomosythesis scan of the lung or the wrist|All study participants will undergo Tomosynthesis imaging of the lung or the wrist. The radiation dose of each method will be recorded.
1568821|NCT02464280|Other|CT scan of the lung or the wrist|All study participants will undergo CT imaging of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
1568822|NCT02464280|Other|conventional X-ray of the lung or the wrist|All study participants will undergo conventional X-ray of the lung or the wrist, for which they where originally scheduled. The radiation dose of each method will be recorded.
1568823|NCT02464254|Behavioral|Physical activity plus positive affect|Subjects will be randomized to a physical activity goal and will receive the positive affect component.
1568824|NCT02464254|Behavioral|Physical activity plus education|Subjects will be randomized to a physical activity goal and will receive the educational component.
1568825|NCT02464241|Other|only examination|
1568829|NCT02464202|Other|stereolithography tooth replica|Tooth replica will be made and used for preparing the receiving tooth socket during autotransplantation
1568830|NCT02464189|Other|Q-Kap|
1568831|NCT02464176|Drug|Dexamethasone|A lumbar plexus nerve block will be performed for patients undergoing hip arthroplasty. A total of 25cc's of 0.25% bupivacaine with 1:400,000 epinephrine will be administered for postoperative analgesia. Surgical anesthesia will be provided either by an intrathecal spinal block or general anesthesia. Successful blockade will be assumed if the patient has a decrease or loss of pinprick sensation in the femoral nerve distribution, which innervates the anterior thigh. If no evidence of blockade is present, testing will occur again at 30 minutes post block. Testing will be performed with a 25 gauge Whitacre needle and once present the area of testing will be marked with a surgical marking pen so that repeat sensory testing can be undertaken at that same site over the course of the study. The subjects will then receive dexamethasone (4 or 8 mg) or placebo (saline) based on arm placement.
1568832|NCT02464176|Drug|Bupivacaine|Bupivacaine will be used in lumbar plexus nerve block mixture.
1568833|NCT02464176|Drug|Epinephrine|Epinephrine will be used in lumbar plexus nerve block mixture.
1568834|NCT02464176|Procedure|Lumbar Plexus Nerve Block|This is the procedure that will be performed.
1568835|NCT02464176|Drug|Saline|Patients randomized to the placebo group will receive normal saline intravenously.
1568838|NCT02464150|Dietary Supplement|Gluten challenge|Challenge done in the form of a gluten containing cookie once daily.
1568839|NCT02464137|Radiation|radiation|Patients in each dose cohort will all be treated as a single group. The starting dose will be 8.5 Gy per fraction for 5 fractions (total dose = 42.5 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per fraction.
1568840|NCT02464124|Drug|Nitazoxanide|• Nitazoxanide dosing: 500 mg tablets twice daily
1568841|NCT02464124|Drug|Lactulose|• Lactulose dosing: 30-60 mL PO TID with goal 2-3 semisoft stools per day
1568842|NCT02464111|Other|Treatment 1: Control|No supplement provided.
1568843|NCT02464111|Dietary Supplement|Treatment 2: Bolus (LNS)|One LNS supplement provided in a single bolus dose in the morning
1568844|NCT02464111|Dietary Supplement|Treatment 3: Divided Dose (LNS)|One LNS supplement provided in 3 separate portions throughout the study visit
1568845|NCT02464085|Other|Longitudinal evaluation of recovery|Stroke survivors will be assessed at four time frames post stroke to evaluate neuroplastic and clinical changes in arm recovery over the first 12-months post stroke.
1568846|NCT02464072|Procedure|Subtotal Parathyroidectomy|Subtotal parathyroid resection leaving the estimated mass of two normal parathyroid glands in situ. The type of operation is the intervention. No new device or drug is involved.
1568847|NCT02464072|Procedure|Total Parathyroidectomy + 45 autografts|Immediate autograft of 45 fragments of parathyroid tissue, after a total parathyroidectomy.This type of operation is the standard intervention at the institution at the moment. No new device or drug is involved.
1568848|NCT02464072|Procedure|Total Parathyroidectomy + 90 autografts|Immediate autograft of 90 fragments of parathyroid tissue, after a total parathyroidectomy.The type of operation is the intervention. No new device or drug is involved.
1568850|NCT02464046|Drug|JNJ-42847922|Participants in arm JNJ-42847922 then Placebo will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 1 and participants in arm Placebo then JNJ-42847922 will receive 2*20 mg tablet of JNJ-42847922 orally once daily from Day 1 to Day 5 in Period 2.
1568851|NCT02464046|Drug|Placebo|Participants in arm JNJ-42847922 then Placebo will receive matching Placebo orally once daily from Day 1 to Day 5 in Period 2 and participants in arm Placebo then JNJ-42847922 will receive matching placebo orally once daily from Day 1 to Day 5 in Period 1.
1568852|NCT02464033|Drug|GAD-Alum|
1568853|NCT02464033|Drug|Vitamin D|
1568854|NCT02464033|Drug|Etanercept|
1568855|NCT02464020|Drug|Vancomycin|Oral vancomycin: 500mg suspended in prefilled syringes for oral use
1568856|NCT02464007|Biological|rSIFN-co|Artificial recombinant super-compound interferon (rSIFN-co) is a product of patented technological research made possible through protein modulation by spatial conformation control technology, and was developed by Sichuan Huiyang Life Science and Technology Corporation.
1568857|NCT02463994|Drug|MPDL3280A|Patients will receive 1,200 mg I.V. Q 3 weeks of MPDL3280A until progression.
1568858|NCT02463994|Radiation|Hypofractionated Radiotherapy|Hypofractionated Image-Guided Radiotherapy (HIGRT)
1568860|NCT02463968|Procedure|Venipuncture for blood draw|Samples will include blood. Blood samples will be collected via venipuncture.This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
1568861|NCT02463968|Procedure|Arthrocentesis for synovial fluid draw|Samples will include joint fluid analysis in participants with a knee effusion. Synovial fluid will be drawn via arthrocentesis under sterile conditions. This is a part of standard of care of new new onset joint effusion and is not a novel intervention.
1568862|NCT02463955|Device|flexible video endoscope|Thoracoscopy is done using flexible video endoscope
1568863|NCT02463955|Device|video-rigid thoracoscope|Thoracoscopy is done using video-rigid thoracoscope
1568864|NCT02463942|Drug|Doxycycline|Beside symptomatic therapy, patients will receive oral Doxycycline 100 mg, Doxy® twice daily.
1568865|NCT02463942|Drug|Symptomatic therapy|Patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics, and parenteral hydration: metamizole, Analgin®, paracetamol, Lekadol®, thiethylperazine, Kytril®, saline.
1568866|NCT02463942|Other|Questionnaire|Subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms such as headache, fatigue, arthralgia, myalgia.
1568867|NCT02463929|Drug|Diphenhydramine|Intravenous Injection
1568868|NCT02463929|Drug|normal saline|Intravenous Injection
1568869|NCT02463929|Drug|Ketamine|Ketamine 0,1 mg/kg intravenously used as rescue tranquilizer if the subject becomes agitated, repeated dose of 0,05 mg/kg every minute can be given if the agitation does not resolve, maximum ketamine dose for tranquilizer 0,25 mg/kg to prevent deep sedation
1568870|NCT02463929|Drug|Sevoflurane|Sevoflurane as single sedation agent for general anesthesia in both arm. 8% Sevoflurane in 100% oxygen used as induction agent, and 2% sevoflurane in 50% oxygen used as maintenance agent
1568871|NCT02463929|Drug|Bupivacaine|Bilateral extraoral infraorbital nerve block with 0,125% Bupivacaine as analgetic for operation and post operation.
1568872|NCT02463916|Other|Exercise|8 week structured exercise programme
1568873|NCT02463903|Behavioral|Coping Effectiveness Training (CET)|The participants in the intervention group will receive a work book explaining the theme and home assignment as well as providing a brief summary of every group session. The group leader has a manual. Both work book and manual have been translated to Swedish and adjusted to patients with chronic heart failure.
1568874|NCT02463890|Other|Training|
1568875|NCT02463890|Other|Control|
1568876|NCT02463877|Procedure|Minimally-Invasive Procedure|Laparoscopy
1569000|NCT02462889|Drug|Intravitreal aflibercept injection|Intravitreal aflibercept injection
1568877|NCT02463864|Other|Intervention exercise|Twice daily, individual, targeted, strengthening, balance and endurance exercises for the duration of the hospital stay, prescribed and delivered by a senior physiotherapist.
1568878|NCT02463864|Other|Sham Exercise|Twice daily stretching and relaxation exercises for the duration of the hospital stay, by a senior physiotherapist.
1568879|NCT02463851|Device|PVAC GOLD multielectrode catheter|Cardiac ablation for Atrial Fibrillation
1568880|NCT02463851|Device|Contact Force single-tip ablation catheter|
1568881|NCT02463838|Other|Care Support Intervention|Case management and care coordination intervention delivered in person to SFHP members who are frequent users of emergency department and inpatient hospital services.
1568882|NCT02463825|Drug|Pimozide 2 mg per day|
1568883|NCT02463825|Drug|Pimozide 4 mg per day|
1568884|NCT02463825|Drug|Placebo (Lactose tablet)|
1568885|NCT02463812|Drug|Intralipid|
1568886|NCT02463812|Drug|Saline|
1568887|NCT02463799|Drug|Radium-223|6 infusions of radium-223 with 3 infusions of sipuleucel-T starting after second dose of radium-223
1568888|NCT02463799|Biological|Sipuleucel-T|3 infusions of sipuleucel-T alone
1568889|NCT02463786|Other|No intervention|No intervention
1568890|NCT02463773|Device|Ultrasound|Diaphragmatic excursion ultrasound assessment
1568891|NCT02463760|Other|Medical imaging|
1568892|NCT02463747|Drug|Piperacillin/tazobactam|Initial treatment will be with Piperacillin + Tazobactam
1568893|NCT02463747|Drug|Ceftazidim|Patient with sensitivity to penicillin will receive Ceftazidim
1568894|NCT02463747|Drug|Meropenem|In cases of hypotension that do not respond to fluids resuscitation , and in consultation with the infectious diseases unit - we will start empirical treatment with Meropenem
1568895|NCT02463747|Drug|Vancomycin|Supplementation of Vancomycin will be at the discretion of the treating physician
1568896|NCT02463721|Other|ascitic fluid culture and microbiological testing|ascitic fluid culture and microbiological testing for 100 patients with liver cirrhosis and ascites with suspicion of SBP
1568897|NCT02463708|Behavioral|BHL COTP|The BHL COTP starts with an initial baseline assessment; following the baseline assessment, it is then divided into several core services. CG receive care management services, which includes contact, support, and active listening, as well as written material regarding caregiving and dementia and referral to appropriate community services. CGs also are offered the Telehealth Education Program (TEP) a manualized program developed to provide both education and psychosocial support for individuals caring for older adults with clinically significant cognitive impairment/dementia.
1568898|NCT02463695|Procedure|cortical vestibular evoked potentials (CVEPs)|CVEPs utilise an existing method used to interrogate cortical projections from the auditory system in which sound waves stimulate the inner ear and the resulting electrical responses from the brain are recorded (known as Cortical Auditory Evoked Potentials CAEPs)
1568899|NCT02463682|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump
1568900|NCT02463682|Device|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:
DiAs - a smart-phone medical platform; Dexcom Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
1568901|NCT02463669|Device|Point-of-care ultrasound|Enrolled patients will undergo POCUS of the spleen by the treating emergency physician (resident, fellow or attending). Canadian Emergency Ultrasound Society (CEUS) certified residents, fellows and attending physicians will conduct the bedside ultrasonography after receiving specific training for the purposes of this study. The spleen will be assessed using a curved 2-6 Megahertz (MHz) transducer with the participant in the supine position. The cranio-caudal splenic length will be measured and its maximum dimension will be recorded on the standardized study data sheet.
1568902|NCT02463643|Drug|Z-215 10mg|Z-215 10mg, capsules
1568903|NCT02463643|Drug|Z-215 20mg|Z-215 20mg, capsules
1568904|NCT02463643|Drug|Z-215 Placebo|Z-215 placebo-matching capsules
1568905|NCT02463643|Drug|Rabeprazole Sodium|Rabeprazole Sodium 10mg tablets
1568906|NCT02463643|Drug|Rabeprazole Sodium Placebo|Rabeprazole Sodium Placebo placebo-matching tablets
1568907|NCT02463630|Procedure|Posterior Approach Compression Distraction Reduction|Patients was placed in prone position. Via midline skin incision, expose the occipital squama and spinal process, vertebral plate and facet joints of C2. 2 multi-axial screws were inserted into the bilateral C2 or C3 pedicles. The posterior edge of the FM up to the lower boundary of cerebellar tonsil (width, 3mm) was removed. A compression occipital plate (COP) was fixed to the occipital bone. 2 titanium rods connect C2/C3 screws and plate heads bilaterally. The COP screw cap was screwed in, compress the beginning of the pre-bending formed titanium rod downward, driving the odontoid process forward to restore the horizontal dislocation. After restoration of horizontal dislocation is confirmed, applying distraction force between the occipital screw and the C2 pedicle screws, restore the vertical dislocation. tight up the screw cap. Graft bone was harvested from the posterior inferior iliac crest bone and implanted into posterior end of the foramen magnum and posterior lamina of axis.
1568908|NCT02463617|Other|magnetic resonance imaging|
1568909|NCT02463604|Procedure|Coronary Angiography|Coronary angiography is performed following usual site standards
1568910|NCT02463591|Drug|Beriplex|Beriplex 50 IU/Kg i.v. , single dose.
1568911|NCT02463565|Other|no intervention|
1568912|NCT02463552|Drug|Naproxen|The patient will receive a single-dose of Naproxen (500 mg) one hour before the bleaching procedure.
1568913|NCT02463526|Other|Mobilization with Movement (MWM) condition/ Sham condition|The treatment condition consists in the application of a posterolateral glide (MWM) in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. One hand will be placed over the scapula posteriorly while the thenar eminence of the other hand will be placed over the humerus head anterior aspect. A posterior glide will be applied to the humeral head. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. Sham condition will replicate treatment condition except for the hand positioning. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed.
1568914|NCT02463526|Other|Sham condition/ Mobilization with Movement (MWM) condition|The Sham condition consists in the application of a simulated anterior glide in the affected shoulder. Subjects will be seated and the therapist will stay beside the participants on the opposite side to the affected shoulder. The therapist will place one hand along the clavicle and the other on the humeral head posterior aspect of the affected shoulder. A simulated anterior glide will be performed. Three sets of 10 repetitions will be applied with a 30 seconds rest interval between each set. The treatment condition will replicate treatment condition except for the hand positioning. The therapist will place one hand over the scapula posteriorly while the thenar eminence of the other hand will be placed over the anterior humerus head. A posterior glide will be applied to the humeral head.
1568915|NCT02463513|Dietary Supplement|Placebo comparator|2 week placebo washout + 16 weeks intervention (placebo)
1568916|NCT02463513|Dietary Supplement|1.6mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (1.6mg riboflavin per day)
1568917|NCT02463513|Dietary Supplement|10mg riboflavin (Vitamin B2)|2 week placebo washout + 16 weeks intervention (10mg riboflavin per day)
1568918|NCT02463500|Other|DFU|Standard care.
1568919|NCT02463487|Device|Cardinal Pro +Simultaneous Irrigation (NPWTi)|NPWT with low volume irrigation (15 cc/hr) with 1% polyhexanide biguanide (PHMB), Prontosan®
1568920|NCT02463487|Device|Cardinal Pro (NPWT) Therapy|NPWT 125 mm Hg continuous pressure with foam interface
1568921|NCT02463474|Behavioral|mHealth Intervention|Ten, short, engaging, entertaining and culturally relevant videos delivered to participants' cell phones provide breast cancer health information.
1568922|NCT02463461|Device|ActiSleep Activity Monitor|Subjects in this group will wear a ActiSleep Activity Monitor.
1568923|NCT02463461|Device|Jawbone Activity Monitor|Subjects in this group will wear a Jawbone Activity Monitor.
1568924|NCT02463461|Device|Actiwatch 2 Activity Monitor|Subjects in this group will wear a Actiwatch 2 Activity Monitor.
1568925|NCT02463461|Device|FitBit Activity Monitor|Subjects in this group will wear a FitBit Activity Monitor.
1568926|NCT02463461|Device|Actigraph by Ambulatory Monitoring Activity Monitor|Subjects in this group will wear a Actigraph by Ambulatory Monitoring Activity Monitor.
1568927|NCT02463448|Biological|Autologous Muscle Derived Cells|A small sample of the subject's own thigh muscle is obtained by needle biopsy. The biopsy sample is sent to Cook Myosite, Inc. for growth and processing. When the ample cell dosage is achieved the cells are frozen and sent back to the treatment site. The cells are thawed, diluted and injected under lighted instrumentation and visualization into about 30 sites in the bladder wall.
1568928|NCT02463435|Behavioral|Nutritional intervention|Conventional treatment (Nutritional intervention) consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity.
1568929|NCT02463435|Other|Nutritional intervention plus olive oil|Nutritional intervention consists of prescription of individualized food plan to reduce 5 to 10% of initial body weight, nutritional counseling for comorbidities and promoting healthy eating habits and physical activity. Additionally, dietary supplementation with extra virgin olive oil (52 mL daily) will be held, divided in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
1568930|NCT02463435|Dietary Supplement|Olive oil|Patients will be instructed to maintain habitual food consumption and consume 52 mL of extra virgin olive oil daily in four (4) sachets per day, two (2) at lunch and two (2) at dinner.
1568931|NCT02463409|Drug|Theophylline|24 hour infusion of IV theophylline
1568933|NCT02463383|Drug|Alcohol + ibuprofen|2.3 g alcohol + 400mg ibuprofen
1568934|NCT02463383|Drug|Alcohol + placebo|2.3 g alcohol + a placebo tablet
1568935|NCT02463370|Other|suprazygomatic maxillary area infiltration|Local anesthetic infiltration in two injections on each side of the face at the maxillary and infra-orbital areas.
1568936|NCT02463370|Other|non-suprazygomatic maxillary area placebo|The remaining injections at supratrochlear area, medial to the medial canthus, nasal still and anterior septum are placebo (saline)
1568937|NCT02463370|Other|non-suprazygomatic maxillary area infiltration|Local anesthetic infiltration in five injections on each side of the face at the infra-orbital area, supratrochlear area, medial to the medial canthus, nasal still and anterior septum.
1568938|NCT02463370|Other|suprazygomatic maxillary area placebo|The remaining maxillary injection is placebo.
1568939|NCT02463357|Dietary Supplement|Quercetin|
1568940|NCT02463357|Drug|Nifedipine extended release|
1568941|NCT02463357|Drug|Methazolamide|
1568942|NCT02463357|Drug|Metformin|
1568943|NCT02463357|Drug|Placebo|
1568944|NCT02463357|Drug|Nitrite|
1568945|NCT02463344|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
1568946|NCT02463331|Drug|Chloroquine diphosphate|One pill of chloroquine diphosphate per day until the end of the study
1568947|NCT02463331|Drug|prednisone|Prednisone 5-15 mg/day until the end of the study
1568948|NCT02463331|Drug|azathioprine|azathioprine 1-2mg/Kg/day until the end of the study
1568949|NCT02463318|Drug|Melatonin|Melatonin is used for healthy subjects and multiple sclerosis patients
1568950|NCT02463318|Other|Hydrogen peroxide|Hydrogen peroxide is only used for healthy subjects
1568953|NCT02463292|Other|no intervention|no intervention
1568954|NCT02463279|Device|Sinusys Dilation System|Dilation of frontal recess and/or sphenoid sinus ostia
1568955|NCT02463266|Behavioral|SUSTAIN Clinical Monitoring|SUSTAIN Clinical Program participants who agree to follow-up Monitoring which consists of up to 4 brief (5-10 minutes), structured assessments following the baseline assessment. These follow-up contacts are conducted over the telephone by the HT/BHP and take place during the initial 12 weeks of pharmaceutical treatment. These brief interviews monitor adherence, side effects, and response to treatment.
1569001|NCT02462889|Drug|Placebo|Sham injection
1569002|NCT02462876|Device|GORE® VIABAHN® Endoprosthesis|Treatment of Popliteal Artery Aneurysm with the GORE® VIABAHN® Endoprosthesis.
1569003|NCT02462863|Dietary Supplement|Arginine and fish oil|Dietary supplements
1569004|NCT02462850|Drug|CL-108|
1568956|NCT02463266|Behavioral|SUSTAIN Clinical Care Management|SUSTAIN Clinical Program participants who agree to Care Management which incorporates the use of a BHP who has expertise in mental health assessment and is well versed in the delivery of algorithm-based management strategies for disorders such as depression and anxiety. The BHP monitors and encourages patient acceptance and adherence to treatment recommendations through support, education, and motivational engagement.
1568957|NCT02463227|Biological|VRC01|"40 mg/kg of VRC01 administered IV in 100 mL of 0.9% sodium chloride for injection, USP.
Administered over about 30 to 60 minutes using a volumetric pump."
1568959|NCT02463201|Behavioral|Weight loss|
1568960|NCT02463188|Behavioral|Sleep Fitness Intervention|The intervention consists of 5-7 sessions. Each session includes interactive and small group discussions. The intervention also includes lessons on sleep science, behavior change strategies, and one-on-one motivational interviews on behavior change motivation.
1568963|NCT02463162|Other|Conversations Matter videos|2 videos about Advance Care Planning and Goals of Care Designations respectively. These 2 videos were developed by Alberta Health Services and are each 8 minutes long.
1568964|NCT02463149|Behavioral|Youth Chef Academy|Nutrition and culinary curriculum delivered in the classroom
1568965|NCT02463136|Behavioral|questionnaires|Clinical questionnaires and behavioural computer-based paradigms, such as the Overlap task (Cohen Kadosh et al., 2014)
1568966|NCT02463136|Device|Functional magnetic resonance imaging w neurofeedback|"The general framework of the scanning part of this experiment consists of a localiser task (lasting approximately 8 minutes), 4 neurofeedback runs (each lasting approximately 5 minutes) and an anatomical scan (approximately 10 minutes).
Immediately prior and following the scanning session, participants will also be asked to completed several), as well as an attentional control task with emotional stimuli, such as a behavioural version of the Overlap task (Cohen Kadosh et al., 2014)."
1568967|NCT02463123|Device|Indirect calorimetry|Resting energy expenditure will be studied using indirect calorimeter CCM Express (Medgraphics Inc, USA).
1568968|NCT02463110|Drug|Sertraline|Sertraline one capsule (50mg per day), which can be increased up to 200mg per day (maximum dose) for 6 months.
1568969|NCT02463110|Drug|No treatment|
1568970|NCT02463110|Drug|Placebo|
1568971|NCT02463097|Device|Insulin Pump|Closed Loop Algorithm
1568972|NCT02463097|Other|i-STAT blood testing|Intravenous i-STAT blood testing is used for reference validation
1568973|NCT02463097|Other|Blood Glucose Meter testing|Frequent finger stick blood glucose testing using a Blood Glucose meter is required
1568974|NCT02463084|Other|Low Diet|a 28-day course of 3 meals per day plus 2 snack that are either low in saturated fats, glycemic index and salt.
1568975|NCT02463084|Other|High Diet|a 28-day course of 3 meals per day plus 2 snack that are either high in saturated fats, glycemic index and salt.
1568976|NCT02463071|Drug|AZD0585|1g soft capsule
1568977|NCT02463071|Drug|AZD0585 placebo|1g soft capsule
1568978|NCT02463058|Other|exercise under hot and humid conditions protocol|"acclimatization day protocol: 2 hour effort performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (40 deg. centigrade & 40% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously
experiment days (3 days): 2 hour effort (2 cycles of: 50 min walk and 10 min rest-sitting) performed in a climatic chamber, which include walk on a treadmill at 5 Km/h on a 2% incline under heat conditions (30 deg. centigrade & 60% RH) Core (rectal) and skin temperature and heart rate will be monitored continuously."
1568979|NCT02463045|Drug|TOP1288|
1568980|NCT02463032|Drug|GTx-024|To determine whether either or both doses result in an acceptable clinical benefit rate.
1568981|NCT02463019|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate
1568982|NCT02463006|Drug|Porous variant of Bioactive Glass.|Flap surgery with Porous variant of Bioactive Glass.
1568983|NCT02463006|Drug|Non porous variant of Bioactive Glass.|Flap surgery with non-Porous variant of Bioactive Glass.
1568984|NCT02462993|Drug|Aloe Vera|Local drug delivery of aloe vera gel
1568985|NCT02462980|Device|Mapping and Ablation|ablation of atrial fibrillation
1568986|NCT02462967|Drug|GR-MD-02|GR MD 02 (galactoarabino rhamnogalacturonate), a complex carbohydrate drug that binds to galectin 3
1568987|NCT02462967|Drug|Placebo|Placebo for GR-MD-02
1568988|NCT02462954|Device|ContraGel|
1568989|NCT02462954|Device|HEC Universal Placebo gel|
1568990|NCT02462941|Drug|Adenosine|Testing escalating doses of adenosine in pediatric heart transplant patients
1568991|NCT02462941|Procedure|Cardiac catheterization|(non-experimental) standard procedure
1568995|NCT02462915|Device|i-gel|"a supraglottic airway devices without cuff and the material was Styrene Ethylene Butadiene Styrene.
gastric channel to the The gastric suction channel can facilitate venting and reduce the aspiration."
1568996|NCT02462915|Device|endotracheal tube|traditional and regularly use in many surgeries for maintaining the airway.
1568997|NCT02462915|Drug|lidocaine, propofol, fentanyl and cisatracurium|
1568998|NCT02462902|Drug|5% albumin Infusion|colloid, 5% albumin (250 ml over 15 to 30 minutes).
1568999|NCT02462902|Drug|0.9% sodium chloride solution|0.9% sodium chloride solution (total of 30ml/kg over 15 to 30 minutes)
1569005|NCT02462837|Drug|Mirabegron|
1569007|NCT02462824|Behavioral|Home-based exercise intervention|The home-based exercise intervention focuses on walking exercise and consists of two phases. Phase I (weeks 1-4) consists of four on-site visits to an exercise facility, where participants will meet the telephone coach, learn to use the Fitbit activity monitor, become familiar with the study website, learn behavioral skills necessary for long-term adherence to home-based exercise, and get started on their exercise program. Phase II (weeks 5-36) is entirely home-based and includes a) use of the Fitbit for self-monitoring; and b) regularly scheduled telephone calls from the study telephone coach to monitor and support participants' home exercise activity' c) use of the study website; d) optional group telephone calls.
1569008|NCT02462811|Drug|CL-108 (hydrocodone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
1569009|NCT02462811|Drug|Placebo|
1569010|NCT02462811|Drug|Norco (hyrdocodone 7,5 mg, acetaminophen 325 mg)|
1569011|NCT02462798|Other|Whole grain rye bread|Whole grain rye bread baked without sourdough fermentation (normal yeast-based fermentation)
1569012|NCT02462798|Other|Whole grain sourdough rye bread|Whole grain rye bread fermented with sourdough culture before baking
1569013|NCT02462785|Behavioral|In-person Carbohydrate Counting Class|An in-person carbohydrate counting class led by a registered dietician. The in class session covers topics including the role of CHO in nutrition and diabetes, sources of CHO, different CHO and non-CHO foods, resources for CHO counting, label reading, and meal planning. This is the standard procedure for CHO counting education at SickKids.
1569014|NCT02462785|Behavioral|Online Carbohydrate Counting Tutorial|A web-based CHO counting tutorial that covers the same concepts reviewed during the standard in-person instructional session held at SickKids. A teen delivers the educational messages in short segments using techniques designed to maintain the viewer's attention (e.g., visuals of food portions and short segment highlights to emphasize important points). The online module includes brief interactive question/answer components for reinforcement. The secure online tutorial will be accessible for one week through a link provided by REDCap. Users will be able to repeat sessions, log on and off during sessions, and choose specific modules for repetition/review. The investigators will be able to capture the number of times patients log on and detail frequency and specifics of usage.
1569015|NCT02462772|Drug|cabotegravir|Cabotegravir 30 mg tablets are formulated as white to almost white oval-shaped coated tablets for oral administration. The cabotegravir LA is formulated as a sterile white to slightly coloured suspension containing 400mg/2mL of cabotegravir LA for administration by IM injection.
1569016|NCT02462772|Drug|Placebo|Placebo tablets for cabotegravir are formulated as white to almost white oval-shaped coated tablets to visually match the active cabotegravir tablets. Placebo for cabotegravir injectable suspension is Intralipid® 20%. Intralipid® is a fat emulsion with no pharmacological action. It is a white, milky emulsion, consisting of purified soyabean oil, purified egg phospholipids and anhydrous glycerol. Intralipid® 20% is supplied in infusion bags.
1569017|NCT02462759|Drug|Nusinersen|Administered by intrathecal injection.
1569018|NCT02462759|Procedure|Sham Procedure|Small needle prick on the lower back at the location where the IT injection is normally made.
1569019|NCT02462746|Dietary Supplement|L-Cysteine|The trade name is New Root Herbal Inc.
1569020|NCT02462733|Behavioral|Tools of the Mind (TOM)|TOM is play-based but features explicit, scripted, teacher-directed activities aimed specifically at helping to improve children's self-control skills. Early evidence supports the program efficacy and suggests benefits for children's development more generally (including language, reading and mathematics).
1569021|NCT02462733|Behavioral|Playing to Learn (PTL)|PTl is a play based preschool program now in wide use in YMCA childcare settings across Canada (and some in the United States). The activities in PTL are child initiated and are not prescribed. Teachers are trained to observe children at play and to capitalize on learning opportunities as they arise.
1569024|NCT02462707|Drug|PF-03084014|gamma-secretase inhibitor, formulated in tablets for oral administration containing 10 mg, 50 mg and 100 mg. Patient will receive 80 mg, 100 mg or 150 mg twice daily of PF-03084014 with continuous dosing schedule
1569025|NCT02462694|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
1569026|NCT02462694|Behavioral|Treatment As Usual|TAU for these subjects involves close tracking by the Suicide Prevention Coordinator and treatment by their individual team of clinicians. Additionally, a support group with psychoeducation about suicide prevention will be offered as part of TAU
1569027|NCT02462681|Drug|paravertebral block|Thoracic paravertebral blocks will be performed as described by Moore and Katz. Intradermal lidocaine will be used at the site of the needle insertion. The superior aspect of the spinous processes of T1- T6 will be marked. The skin entry points will 3 cm laterals to the marks. A 22- gauge quincke spinal needle attach to extension tubing to a syringe containing study drugs will be used. The needle will be inserted perpendicular to the skin for a distance of 2 to 4 cm until the transverse process will contact. The needle will be withdrawn and walk cephalad off the transverse process and advance for a further 1.5 to 2 cm.
1569028|NCT02462668|Procedure|Bag-mask ventilation|The control group receives preoxygenation with bag-mask ventilation
1569029|NCT02462668|Procedure|Noninvasive positive pressure ventilation(NIPPV)|The NIPPV group receives noninvasive positive pressure ventilation during fibreoptic bronchoscopy assisted intubation
1569030|NCT02462668|Procedure|fibreoptic bronchoscopy assisted intubation|All patients will receive fibreoptic bronchoscopy assisted intubation.
1569031|NCT02462655|Other|Pre-lipid apheresis|Blood samples will be taken just before the start of the lipid apheresis treatment.
1569032|NCT02462655|Other|Post-lipid apheresis|Blood samples will be taken following the lipid apheresis treatment.
1569033|NCT02462642|Dietary Supplement|Brahmi|Brahmi extract - 225 mg filled in each hard gelatin capsule. Two such capsules per day, to be taken by the subjects for 12 weeks.
1569034|NCT02462642|Other|Placebo|Dry maize starch filled in identical hear gelatin capsule. Two such capsules will be taken by each subject per day for 12 weeks.
1569035|NCT02462642|Dietary Supplement|Brahmi|Brahmi Extract 225 mg filled in hard gelatin capsule. Two such capsules will be consumed by the subjects each day for 84 days.
1569036|NCT02462642|Other|Placebo|Placebo capsules - Dry starch filled in identical hard gelatin capsules
1569037|NCT02462629|Drug|BLZ-100|
1569038|NCT02462616|Other|not intervention|This is a cross-sectional study, no intervention was performed.
1569039|NCT02462603|Drug|EPI-589|EPI-589 is a redox active molecule and will be provided in a 250 mg tablet formulation.
1569040|NCT02462590|Drug|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
1569041|NCT02462590|Drug|Placebo - Microcrystalline Cellulose|Microcrystalline Cellulose
1569042|NCT02462577|Drug|local instillation of morphine to surgical wound|comparison between different drug doses effects on pain
1569043|NCT02462551|Device|Focal Electrically Administered Seizure Therapy|A focal administration of the right unilateral configuration of electro-convulsive therapy for the treatment of recurrent and treatment-resistant depression.
1569044|NCT02462538|Drug|Brentuximab vedotin|Brentuximab vedotin is given in a 21 day cycle intravenously starting at 1.8 mg/kg on day 1 of the first cycle and will be administered by IV infusion given over approximately 30 minutes on day 1 of each 21-day cycle.
1569045|NCT02462538|Drug|Imatinib|Imatinib will be given orally at a dose of 100mg daily starting from day 1 of the first cycle. The dose will be increased to 200mg daily starting from day 1 of the second cycle if no DLT occurs during the first cycle and will be continued at 200mg for 48 weeks.
1569046|NCT02462525|Drug|ABBV-838|Varying doses of ABBV-838
1569047|NCT02462525|Drug|Pomalidomide|Administered orally per the label.
1569048|NCT02462525|Drug|Dexamethasone|Administered orally per the label.
1569049|NCT02462499|Drug|Inspra (eplerenone)|
1569053|NCT02462473|Drug|Aripiprazole|Participants will receive aripiprazole at a dose of 5 milligram (mg) or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
1569054|NCT02462473|Drug|Olanzapine|Participants will receive olanzapine at a dose of 5 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
1569055|NCT02462473|Drug|Paliperidone|Participants will receive paliperidone 3 mg or higher dose as oral formulation once daily or 39 mg or higher dose once every 4 weeks for 12 weeks as part of participant treatment.
1569056|NCT02462473|Drug|Quetiapine|Participants will receive quetiapine at a dose of 150 mg or higher, as oral formulation once daily for 12 weeks as part of participant treatment.
1569057|NCT02462473|Drug|Risperidone|Participants will receive risperidone 1 mg or higher dose, as oral formulation once daily or as injection of 12.5 mg or higher dose once every 2 weeks for 12 weeks as part of participant treatment.
1569058|NCT02462460|Device|MRI|
1569059|NCT02462460|Behavioral|Optional Screening Questionnaire|
1569060|NCT02462447|Drug|11C-sarcosine|Radiotracer injection for PET/CT scan
1569061|NCT02462447|Drug|11C-choline|Radiotracer injection for PET/CT scan
1569062|NCT02462434|Behavioral|Early palliative care team consultation|The palliative care team will evaluate the patient and family with the following core palliative care goals in mind: evaluating maternal understanding of their child's diagnosis and eliciting maternal concerns regarding their child's physical symptoms, identifying maternal social support systems and additional life stressors, identifying maternal expectations and hopes for their child's medical care, and assessing maternal fears surrounding their child's diagnosis and medical treatments. Palliative care team support and resources will then be provided in areas of necessity identified for the family. Palliative care team follow up will then be determined based on the level of need identified for each individual study participant.
1569063|NCT02462421|Drug|Canagliflozin|A single dose of canagliflozin (300 mg, p.o.) will be administered prior to assessing pharmacodynamic response.
1569064|NCT02462408|Procedure|Posterior approach|The needle insertion point was over the trapezius muscle sufficiently posterior to allow the needle to pass between the clavicle and the scapula in the direction of the axillary artery. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
1569065|NCT02462408|Procedure|Conventional approach|The needle insertion point would be at the cephalad (lateral) aspect of the ultrasound probe, beneath the clavicle and medial to the coracoid process. The insertion point was strictly aligned with the long axis of the ultrasound beam i.e. in-plane technique.
1569066|NCT02462395|Device|tDCS|"Sponge-electrodes (5 x 7 cm) will be postioned at Fz (anode) and over the spinous process of C7 (cathode). Stimulation intensity will be set to 2 mA.
A first group of CCH patients will have to apply the neurostimulation outside of an attack every day for 20 minutes during 4 weeks. A second group will use the tDCS device everyday for 8 weeks.
Adherence to the treatment will be evaluated by monitoring the time during which the device is switched on via an in-built software."
1569067|NCT02462382|Procedure|Arthroscopic Rotator Cuff Repair|During arthroscopic rotator cuff surgery, the surgeon inserts a small camera, called an arthroscope, into your shoulder joint. The camera displays pictures on a television screen, and your surgeon uses these images to guide miniature surgical instruments to repair the torn ligament.
1569068|NCT02462382|Drug|Ropivacaine|
1569069|NCT02462382|Drug|Saline|
1569070|NCT02462369|Drug|Saxagliptin|
1569071|NCT02462369|Drug|glimepiride|
1569074|NCT02462343|Other|walk tests|
1569075|NCT02462330|Drug|Autologous MSC from bone marrow|After bone-marrow aspiration by an authorized person, MSCs were isolated and cultured during 17±2 days by the French Blood Establishment. Then, patients receive intramyocardial injections of MSCs using the electromechanical NOGA-XP system.
1569076|NCT02462330|Drug|Placebo comparator|injections of human albumin
1569077|NCT02462317|Drug|botulinum A toxin|botulinum toxin injection
1569084|NCT02462291|Other|Ecological Environmental therapy|The program of EET consist of the physical interaction (visual, tactile, olfactory) between natural ecological elements such as flowers, trees, grass, and the patients with AD.
1569085|NCT02462278|Device|TempuRing|
1569086|NCT02462265|Drug|Oshadi D & Oshadi R;|Oshadi D (180mg/TID) & Oshadi R (180mg TID) will be administrated;
1569087|NCT02462265|Drug|salvage therapy cytosar and mitoxantrone|Salvage therapy - HAM: Hi dose cytosar (5 or 6 days) and mitoxantrone (2 or 3 days)
1569088|NCT02462252|Drug|BL-8040|Subjects will receive subcutaneous (SC) injections of BL-8040 monotherapy on days 1-10 of the study. Beginning on Month 2 day 1, (M2/D1), and continuing monthly through Month 6, BL-8040 will be administered daily as part of the maintenance period for the first 5 days of each month.
1569089|NCT02462252|Drug|horse anti-thymocyte globulin (hATG)|From Day 11 through Day 14 of first month, subjects will receive hATG infusion over 6-8 hours each day.
1569090|NCT02462252|Drug|Methylprednisolone|From Day 11-14 of first month, subjects receive infusion of methylprednisolone 30 minutes prior to hATG infusion. Treatment with methylprednisolone will continue for 30 days. (After day 14, subjects may receive oral prednisone dose equivalent to IV methylprednisolone dose. The oral dose will be tapered off over 30 days.
1569091|NCT02462252|Drug|Cyclosporine|From Day 11 through end of treatment (Month 6 Day 30), subjects will receive oral dose of cyclosporine.
1569092|NCT02462239|Other|Whole-body FDG PET-CT|
1569093|NCT02462226|Behavioral|The-Optimal-Lymph-Flow|"The-Optimal-Lymph-Flow ™ is a web-based educational and behavioral program focusing on self-care strategies to manage pain and symptoms related to lymphedema. The Optimal Lymph-Flow™ is the only evidence-based self-care program designed to effectively help women treated for breast cancer manage daily pain and symptoms related to lymphedema. Grounded in research-driven behavioral strategies, the program is premised on empowering, rather than inhibiting, how breast cancer survivors live their lives. It emphasizes what to do, rather than what to avoid. It features a safe, feasible and easily-integrated-into-daily-routine of exercises to promote lymph flow and drainage, as well as guidance to maintain an optimal BMI."
1569094|NCT02462226|Behavioral|Arm Precaution|"The webpage also has a section entitled Arm Precautions, representing current patient education that emphasizes precautionary lifestyle behaviors, such as avoidance of repetitive limb movement, lifting weighted objects, needle punctures, blood draw, and the use of compression garments for air travel in the affected limb."
1569097|NCT02462200|Procedure|Breast-conserving surgery (BCS)|
1569098|NCT02462200|Procedure|Cavity shave margins (CSM)|
1569099|NCT02462200|Behavioral|BREAST-Q Questionnaire|
1569100|NCT02462200|Device|3-D breast imaging|Using a 3-D breast imaging camera Vectra 3-D XT
1569101|NCT02462200|Other|Indocyanine green|
1569102|NCT02462200|Device|Intraoperative imaging device|The goggle device is wearable, compact, and battery-operated, and it allows for hands-free operation by the wearer. The goggles provide functional information via a NIR light-emitting diode (LED) integrated within one of the eyepieces, which causes NIR fluorescence excitation of the molecular probes within the surgical field
1569103|NCT02462200|Procedure|Peripheral blood draw|-Time of surgery if coordinator is available
1569104|NCT02462187|Drug|NVN1000|Applied topically, co-administered with hydrogel
1569105|NCT02462187|Other|Vehicle Gel|Applied topically, co-administered with hydrogel
1569106|NCT02462174|Drug|Ketamine|0.5 mg/ kg ketamine with bupivacaine by caudal route after anesthesia and before start of surgery.
1569107|NCT02462174|Drug|Ketamine|0.5 mg/ kg ketamine with bupivacaine will be sprayed around the spermatic cord before wound closure.
1569108|NCT02462174|Drug|Bupivacaine|1 ml/kg bupivacaine 0.25% (maximum volume = 20 ml) by caudal route
1569109|NCT02462174|Drug|Bupivacaine|0.3 ml/kg bupivacaine 0.25% will be sprayed around the spermatic cord before wound closure
1569110|NCT02462161|Drug|Insulin aspart|Participants will administer 20 IU insulin aspart two times per day with an intranasal delivery device.
1569111|NCT02462161|Drug|Placebo|Participants will administer placebo two times per day with an intranasal delivery device.
1569112|NCT02462148|Drug|Dexamethasone|Used in nerve block mixture
1569113|NCT02462148|Drug|Bupivacaine|Used in nerve block mixture
1569114|NCT02462148|Drug|Epinephrine|Used in nerve block mixture
1569115|NCT02462148|Procedure|Saphenous Peripheral Nerve Block|Peripheral nerve block.
1569116|NCT02462135|Behavioral|Virtual interactive memory training|Training sessions of the VIMT group are divided into initial training and booster training. Each training session is 45 minutes/day, 3 sessions/week, for 12 weeks for both initial training and booster training (36 sessions each). The training content of the four memory training include: (1) spatial encoding memory training task, (2) updating-spatial memory training task, (3) updating-visual memory training task, and (4) rehearsal-visuospatial memory training task.
1569117|NCT02462135|Behavioral|Passive information activities|The active control group (Passive information activities) only accepts the initial training phase, which training content of the two types to include: (1) listening to audio books, and (2) reading online newspaper.
1569120|NCT02462109|Drug|Lorazepam|Lorazepam was given based on the weight of the child with Catatonia. The lower dose (0.5 mg) was used as starting dose for patients with <30 kg body weight, while the higher dose (1 mg) as the starting dose for patients with >30 kg body weight.
1569121|NCT02462096|Device|ReLeaf|The ReLeaf catheter is expected to enable a physician to create tissue leaflets that, in turn, generate a valve effect in the deep veins of the legs.
1569122|NCT02462083|Drug|IDP-118 Lotion|Applied topically once daily
1569123|NCT02462070|Drug|IDP-118 Lotion|Lotion
1569124|NCT02462070|Drug|IDP-118 Vehicle Lotion|Lotion
1569126|NCT02462044|Drug|240 mg Iodine|
1569127|NCT02462044|Drug|300 mg Iodine|
1569128|NCT02462044|Drug|370 mg Iodine|
1569129|NCT02462031|Drug|KD101|200mg, 400mg, 800mg, 1400mg
1569130|NCT02462031|Drug|placebo|200mg, 400mg, 800mg
1569131|NCT02462018|Device|WalkAide|"Patiants with hemiplegic or asymmetric diplegic CP will use WalkAide device for 4 months .First month for adjustment and three months of daily using of the device.
For each patient two assessments will be conducted: at baseline and at post-intervention follow-up.
During the assessments each child will go through:
A. Medical interview and neurological and physical therapist examination. B. Motor function tests: 6 min walk test, Gross motor function measure (GMFM) ,Timed up and down stairs test (TUDS), walking on a ramp ,with and without the FES device.
C. Gait analysis test with and without FES device. D. Parents will be requested to complete questionnaires on the frequency of falling.
E. On the second assessment parents wiil be requested to complete a questionnaire about the compliance to the FES."
1569132|NCT02461992|Drug|Intravenous infusions of Xyntha|A single dose 50IU/kg dose of Xyntha administered by intravenous infusion within 10 minutes on Day 1
1569133|NCT02461979|Other|The VDR genotype|The VDR genotype will determined by polymerase chain reaction (PCR) amplication and restriction length fragment polymorphisms.
1569135|NCT02461953|Device|hemoperfusion apparatus|
1569136|NCT02461953|Device|low flux dialyzer|
1569137|NCT02461953|Device|high flux dialyzer|
1569138|NCT02461940|Behavioral|Adolescent Behavioral Intervention|Session 1 focuses on STI/HIV education and self-reflection. Session 2 aims to increase the awareness of STI/HIV preventive strategies by instilling condom use and negotiation skills. Motivational Interviewing is used during the behavioural counselling. Session 3 reviews the goal on safer sex set by the participant and examines the successful strategies on safer sex and identifies triggers for relapse. Success stories are shared to renew their motivation. Session 4 reinforces the progress of the participant by recapitulating the knowledge and motivation explored in previous sessions. The online sessions, by phone/SMS/Whatsapp are conducted 2 months after the second and third sessions to find out if they face any difficulties and to reinforce prevention information covered previously.
1569139|NCT02461927|Drug|Ketamine + Naltrexone|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular naltrexone (380 mg) once a month (a total of 2 injections).
1569140|NCT02461927|Drug|Ketamine + Placebo|Subjects in this arm will receive (1) intravenous ketamine (0.5 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
1569141|NCT02461927|Drug|Placebo (psychoactive placebo midazolam) + Placebo|Subjects in this arm will receive (1) intravenous psychoactive placebo midazolam (0.045 mg/kg) once a week for 4 weeks (a total of 4 infusions) and (2) intramuscular placebo once a month (a total of 2 injections).
1569142|NCT02461914|Drug|PEX168|200µg,injected subcutaneously,once a week.
1569143|NCT02461914|Drug|Warfarin|5mg,oral,two times.
1569144|NCT02461901|Other|Environmental sampling|Sampling of five sites in the patient's immediate environment for C. difficile spores
1569145|NCT02461901|Other|Skin swab sampling|Collection of swabs from three sites on the skin for C. difficile spores
1569146|NCT02461901|Other|Fecal sampling|Collection of fecal samples for C. difficile spores
1569147|NCT02461888|Drug|Ixazomib|Chemotherapy
1569148|NCT02461888|Drug|Cyclophosphamide|Chemotherapy
1569149|NCT02461888|Drug|Dexamethasone|Chemotherapy
1569150|NCT02461875|Drug|Cabergoline|Patients receive cabergoline 0.5 mg p.o at bed time for 8 days starting on the day of HCG administration.
1569151|NCT02461875|Drug|GnRH antagonist rescue & cabergoline|when the leading follicle reaches 16 mm, HP-uFSH is continued at daily dose of 75 IU/day till the day of HCG administration. Moreover, Gn RH agonist (triptorelin) is discontinued and GnRH antagonist (Cetrorelix acetate)0.25 mg S.C is administered daily till the day of HCG administration. Serum estradiol is measured daily and HCG (5,000 IU/I.M) is administered when serum estradiol level drops below 3500 pg/ml . Moreover, cabergoline 0.5 mg p.o is administered at bed time for 8 days starting on the day of HCG administration.
1569152|NCT02461862|Behavioral|Application of the Visual Analog Scale of pain|Evaluation of pain previous and 5 minutes after outpatient insertion of IUD / IUS using the Visual Analog Scale of Pain
1569153|NCT02461862|Procedure|Evaluation of blood pressure|Evaluation of Blood pressure ( mmHg), previous and 5 minutes after outpatient insertion of IUD / IUS by sphygmomanometer.
1569154|NCT02461862|Procedure|Evaluation of radial pulse|Evaluation of radial pulse (beats per minute) previous and 5 minutes after outpatient insertion of IUD / IUS by pulse oximetry
1569155|NCT02461849|Drug|Imatinib|Imatinib 400mg qd daily
1569156|NCT02461836|Drug|Gemcitabine|Protocol: Gemcitabine 1000mg/m2.body surface area (BSA), IV infusion for at least 30 mins, administered at Day1, Day8, Day15)
1569157|NCT02461836|Radiation|SBRT|Protocol: 5 Gy/d, for 5 consecutive days
1569158|NCT02461823|Device|Zirconia crown|patients will receive a Zirconia crown, the Zirconia crown will cover the natural crown.
1569159|NCT02461823|Device|Porcelain metal crown|patients will receive a porcelain fused to metal crown, the Porcelain metal crown will cover the natural crown.
1569160|NCT02461810|Device|Vertebral fracture surgery SpineJack®|Vertebral augmentation for one osteoporotic vertebral compression fracture
1569161|NCT02461810|Procedure|Balloon Kyphoplasty|
1569162|NCT02461797|Other|healthy controls|biopsy of nasal mucosa for healthy controls
1569163|NCT02461797|Other|AR patients without medication|biopsy of nasal mucosa for allergic rhinitis patients without allergy medication
1569164|NCT02461797|Other|AR patients with use of nasal corticoid spray|biopsy of nasal mucosa for allergic rhinitis patients with use of nasal corticoid spray
1569165|NCT02461784|Procedure|Semen & Data Collection|"If participants decide to participate in this research they will be asked to complete the informed consent process as well as asked a few questions such as age and race/ethnicity. If participants volunteered for this study because tehy have IBD, investigators will also collect some information from the participants medical record. Completing this portion of participation will take less than 1 hour.
Participants will then be scheduled to complete the semen collection at the UW Health Generations Fertility Clinic located at 2365 Deming Way in Middleton, WI. This collection visit will take less than 1 hour to complete. Once participants have finished the collection visit they will have completed their participation in this research project."
1569166|NCT02461771|Drug|APL-2|On treatment day, subjects will be administered a single 100 μL IVT injection of APL-2 at the dose corresponding to their treatment assignment.
1569167|NCT02461758|Biological|Influenza vaccine|40 patients will be enrolled in the TNF Monotherapy Group and randomized in a 1:1 fashion to HDIV or SDIV. Randomization will generated by a random number generator and investigator will be blinded to randomization scheme.
1569168|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir + ribavirin|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets) + RBV (ribavirin tablets) for 12 weeks
1569169|NCT02461745|Drug|ombitasvir, paritaprevir/r, dasabuvir|VIEKIRA PAK (two 12.5/75/50 mg ombitasvir, paritaprevir, ritonavir tablets, and two 250 mg dasabuvir tablets)
1569170|NCT02461732|Behavioral|Treatment for Integrated Posttraumatic Stress and Substance Use (TIPSS)|"Topics covered include:
drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities; education on PTSD and trauma/PTSD/substance use associations; discussion and written statement of impact of trauma on beliefs about self, others, world; written account of trauma memory and in-session review and discussion; cognitive exercises and cognitive restructuring regarding trauma-related thoughts; review of any between-session trauma-relevant substance use and cravings"
1569171|NCT02461732|Behavioral|Cognitive-Behavioral Therapy for Substance Dependence|"Topics covered include:
drug triggers; antecedents/consequences of drug use; relapse prevention; coping skills; problem thinking; changing problem thinking; lifestyle balance; values; increasing non-drug activities"
1569174|NCT02461706|Drug|cannabidiol|All subjects will have a dosing titration starting with 25 mg/kg/day and will be titrated weekly as tolerated based on clinical response. All subjects will be clinically evaluated at baseline, once a month for three months and every three months thereafter. In order to ensure safe use at higher doses, patients receiving more than 600 mg of daily CBD will be evaluated at least monthly until they achieve steady state at the final fixed maintenance dose.
1569175|NCT02461706|Other|Blood Test|All subjects will have the following clinical laboratory tests including changes in bone marrow (CBC), liver (AST, ALT), and kidney function (creatinine, electrolytes, BUN) will be assessed at baseline, each month during months 1 to 3, and every 3 months thereafter.
1569176|NCT02461693|Drug|Caffeine|200mg delivered as pill; one-time dose
1569177|NCT02461693|Drug|Placebo|Lactose-based pill; one-time dose
1569178|NCT02461680|Procedure|tangential resection|the tendon's injury is treated with a tangential resection performed with a surgical blade N°11 The shape of the tangential resection was adapted such that the cross-section disappered
1569179|NCT02461680|Procedure|suture|
1569180|NCT02461667|Drug|SRP plus Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
1569181|NCT02461667|Drug|SRP plus Alendronate gel|Alendronate (ALN) After SRP, ALN gel was delivered subgingivally into the pocket
1569182|NCT02461667|Drug|SRP plus Metformin gel|Metformin (MF) After SRP, MF gel was delivered subgingivally into the pocket
1569183|NCT02461654|Other|Disc FX|Disc FX is an innovative system allowing for a safe and effective approach to a damaged disc without injury to the surrounding structures. The procedure consists of three phases: during the first phase, the disc is punctured with a special needle that functions as a working channel. This needle is used to remove part of the degenerate inner tissue. Then, using a radio-frequency probe, the disc is sealed to minimize the risk of repeated herniation. In the final step, the pathological nerves in the back part of the disc are destroyed with the use of radio-frequency.
1569184|NCT02461641|Other|NuShield|NuShield is a sterilized dehydrated amnion chorion membrane patch.
1569185|NCT02461641|Other|Affinity|Affinity is a aseptically produced hypothermically stored amniotic membrane patch.
1569186|NCT02461641|Other|Standard of Care|Standard of Care for this study is defined as sharp debridement, moist wound dressing and offloading of the area using a DARCO shoe.
1569187|NCT02461628|Behavioral|Malaria RDT & conditional voucher for ACT from retail sector|Trained community health volunteers will offer eligible household members free malaria rapid diagnostic tests and a voucher allowing the purchase of a qualified ACT at a reduced fixed price in the retail sector conditional on a positive test
1569191|NCT02461576|Device|Xpert HIV-1 VL Assay|in vitro diagnostic test to quantify HIV-1 RNA
1569192|NCT02461563|Drug|200 mg MK-1075|Two 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
1569193|NCT02461563|Drug|400 mg MK-1075|Four 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
1569194|NCT02461563|Drug|800 mg MK-1075|Eight 100 mg tablets of MK-1075 administered orally, once daily for 7 consecutive days
1569196|NCT02461537|Drug|HAM|High-dose cytarabine 1 - 3 g/m2 (days 1-3)/Mitoxantrone 20 mg/m2 (days3-5)
1569197|NCT02461537|Drug|LDAC and/or Mitoxantrone|Low-dose cytarabine 20 mg/m2 (days 1-10) and/ or mitoxantrone 10mg/m2 (max 3 doses)
1569198|NCT02461524|Device|Endurant Evo AAA Stent Graft System|
1569199|NCT02461524|Procedure|Endovascular aneurysm repair (EVAR)|
1569200|NCT02461511|Other|Therapeutic Education|participation in a therapeutic education program on diabetes
1569201|NCT02461485|Other|Fermented milk product containing Probiotics|2 pots/day during 28 days
1569202|NCT02461485|Other|Fermented Milk Product containing Probiotics + Fibers C|2 pots/day during 28 days
1569203|NCT02461485|Other|Fermented Milk Product containing Probiotics + Fibers W|2 pots/day during 28 days
1569204|NCT02461485|Other|Non fermented Milk Product|2 pots/day during 28 days
1569205|NCT02461472|Other|not intervention|This is a cross-sectional study, no intervention was performed.
1569208|NCT02461407|Drug|Anlotinib|Anlotinib p.o. qd
1569209|NCT02461407|Drug|Placebo|Placebo p.o. qd
1569210|NCT02461394|Device|Blood glucose monitoring systems for self-testing|
1569211|NCT02461381|Other|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
1569212|NCT02461368|Drug|Glenohumeral triamcinolone injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
1569213|NCT02461368|Drug|Glenohumeral triamcinolone injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
1569214|NCT02461368|Drug|Glenohumeral lidocaine injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
1569215|NCT02461368|Drug|Glenohumeral lidocaine injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
1569216|NCT02461368|Drug|Glenohumeral normal saline injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
1569217|NCT02461368|Drug|Glenohumeral normal saline injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
1569218|NCT02461368|Drug|Glenohumeral Omnipaque injection by anterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by anterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
1569219|NCT02461368|Drug|Glenohumeral Omnipaque injection by posterior approach|Glenohumeral steroid injection is performed under ultrasound-guidance by posterior approach. The injection mixture was: 1 mL triamcinolone, 4 mL lidocaine, 4 mL normal saline, and 3 mL Omnipaque (Iohexol, General Electronics Healthcare).
1569220|NCT02461355|Behavioral|Aphasia therapy|Aphasia therapy using a computerized scripting program
1569221|NCT02461355|Device|Anodal tDCS|Anodal transcranial direct current stimulation using the Chattanooga Ionto device
1569222|NCT02461355|Device|Sham tDCS|Sham transcranial direct current stimulation using the Chattanooga Ionto device
1569223|NCT02461342|Other|not intervention|This is a cross-sectional study, no intervention was performed.
1569224|NCT02461329|Drug|Gelofusine® B. Braun|Volume therapy by Gelatine solution infusion via intravenous boluses to achieve hemodynamic targets
1569225|NCT02461329|Drug|Ringerfundin ® B. Braun|Volume therapy by Balanced Crystaloid solution solution infusion via intravenous boluses to achieve hemodynamic targets
1569226|NCT02461316|Other|No intervention|No intervention administered in this study: Rituximab in combination with fludarabine and cyclophosphamide for 6 months according to registered indication.
1569228|NCT02461290|Radiation|Chemotherapy|
1569229|NCT02461290|Drug|Rituximab|
1569230|NCT02461277|Other|Fast-track protocol|Preoperatory management, epidural anesthetic management, avoiding the need opioid in postoperatory analgesia and use of an standardized postoperatory management protocol to an early oral intake and early mobilization. At the postoperative recovery room, after extubation and fully awake, patients started physiotherapy exercises, as physical exercises of moving up upper and lower extremities accompanied by deep breathing exercises. After than, the patients standed up beside the bed and if there was no complications, patients performed ambulation. The physiotherapist aided the patients during all period.
1569231|NCT02461264|Drug|Single red blood packed cells Transfusion|
1569232|NCT02461264|Drug|Two packed red blood cells Transfusion|
1569234|NCT02461238|Other|Vouchers|The vouchers sent to families can be used in supermarkets for fresh, frozen or canned fruits and vegetables, excluding potatoes. The amount of the vouchers takes into account family composition, calculated to correspond to a serving per day per person.
1569235|NCT02461238|Other|Nutrition education|Nutrition education workshops taught by a dietician
1569236|NCT02461212|Procedure|Magnetic Resonance Imaging (MRI)|A MRI scan which will include magnetic resonance spectroscopy (MRS) of the liver to determine hepatic triglyceride content, a hepafat scan to measure volume fraction of fat in liver tissue, and a MRI for detection of liver fibrosis. The scan will last approximately 15 minutes.
1569237|NCT02461199|Biological|Fecal microbiota transplantation|Transplantation of 100 ml of fecal microbiota suspension obtained from healthy unrelated donor in two consecutive days via the nasoduodenal tube
1569238|NCT02461186|Drug|Arterolane maleate-piperaquine phosphate (Synriam)|
1569239|NCT02461186|Drug|Dihydroartemisinin-piperaquine phosphate (Duocotexin)|
1569240|NCT02461173|Drug|Merional|On the 3rd day of menstruation women will have a vaginal ultrasound and will receive daily intramuscular 150 IU of human menopausal gonadotropins (hMG, Merional ®, IBSA, Lugano, Switzerland) starting from the 3nd day of menstruation.
1569241|NCT02461173|Procedure|IUI|Semen will be processed and drawn into a shepherd catheter attached to a 1 mL syringe and injected into the uterus
1569242|NCT02461173|Procedure|Ovulation detection|Women will be asked to test their morning urine specimen for luteinizing hormone daily starting 4 days before the expected day of ovulation. This will be done using a qualitative kit
1569243|NCT02461173|Drug|Choriomon|Administration of 10000 IU of human chorionic gonadotropin (hCG; Choriomon®, IBSA) when at least 2 follicles measuring 18 mm are observed during vaginal ultrasound and is associated with serum E2 of 500-3000 Pg/mL
1569244|NCT02461173|Device|shepherd catheter|
1569245|NCT02461160|Drug|TAK-915 suspension|TAK-915 oral suspension
1569246|NCT02461160|Drug|Midazolam|Midazolam oral solution
1569247|NCT02461160|Drug|Placebo|Placebo-matching TAK-915 suspension
1569248|NCT02461160|Drug|TAK-915 tablet|TAK-915 tablet
1569249|NCT02461147|Procedure|Cholecystectomy with intraoperative cholangiogram|cf. arm/group description. This intervention is not assigned by the investigators: it is the standard treatment at the investigators institution.
1569250|NCT02461134|Drug|Ponesimod|Oral film-coated tablets at the doses of 2, 3, 4, 5, 6, 7, 8, 9, 10, and 20 mg. One tablet of ponesimod at any dose will be taken orally once daily.
1569251|NCT02461121|Genetic|HLA mismatched stem cell|HLA mismatched donor G-CSF mobilized peripheral stem cell infused 24 hours (day 0) after the completion of chemotherapy
1569252|NCT02461121|Genetic|HLA matched stem cell|HLA matched donor G-CSF mobilized peripheral stem cell infused after the conditioning reginmen
1569253|NCT02461121|Drug|cyclosporine A|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
1569254|NCT02461121|Drug|Mycophenolate mofetil|The GVHD prophylaxis included cyclosporine A and mycophenolate mofetil
1569255|NCT02461121|Drug|Ara-C|2.0 to 3.0g/m2 per 12 hours intravenously for 6 dose
1569256|NCT02461121|Drug|fludarabine|30 mg/m2/d for 5days
1569257|NCT02461121|Drug|anti-lymphocyte globulin|1.5-2 mg/kg/d for 4 days
1569258|NCT02461121|Drug|cyclophosphamide|40 mg/kg/d for 2 days
1569259|NCT02461108|Behavioral|Subsidy|Frame the price difference as a 10% subsidy on nutritious food items.
1569260|NCT02461108|Behavioral|Tax|Frame the price difference as a 10% tax on less nutritious food items.
1569261|NCT02461108|Behavioral|Tax and subsidy|Frame the price difference as a 5% tax on less nutritious food items and a 5% subsidy on nutritious food items, creating a 10% relative price difference between the types of foods.
1569262|NCT02461095|Other|Impairment based approach|This intervention will consist of exercise, mechanics training, education, manual therapy and modalities. The treatment will address the impairments found during the evaluation. This approach is a typical individualized physical therapy treatment approach.
1569263|NCT02461095|Other|PFPS Algorithm approach|Physical Therapy treatment for Patellofemoral Pain Syndrome based upon a treatment algorithm that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patient with the goals of low fear avoidance beliefs, flexibility, body mechanics, and strength and are performed in a sequential manner
1569266|NCT02461069|Drug|Dimethyl fumarate|Dimethyl fumarate (Tecfidera®) treatment is initiated by daily administration of 120 mg Tecfidera® p.o. in the morning in week 0. At week 1, the dose is increased to 120 mg Tecfidera® p.o. twice daily, split into a morning and an evening dose. At week 2, the daily dose is further increased to 240 mg Tecfidera® p.o. in the morning and 120 mg Tecfidera® p.o. in the evening. Finally at week 3, the dose will be increased to the final daily dose of 240 mg Tecfidera® p.o. in the morning and 240 mg Tecfidera® p.o. in the evening and maintained throughout the study.
1569267|NCT02461056|Drug|Ibuprofen|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was ibuprofen 50 mg. The maximum doses was ibuprofen 800 mg. Combination index (CI) (additive: 0.9-1.1, synergism: <0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
1569268|NCT02461056|Drug|Hydromorphone|Drug was administered by the Dixon and Mood up-and-down method. Starting doses was hydromorphone 0.25 mg. The maximum doses was hydromorphone 2 mg. Combination index (CI) (additive: 0.9-1.1, synergism: <0.9, antagonism: >1.1), dose reduction index (DRI, a measure of how much the dose of each drug in a combination can be reduced), and isobologram were used to define the nature of their interaction.
1569269|NCT02461043|Drug|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
1569270|NCT02461043|Radiation|radiation|radiation
1569271|NCT02461030|Drug|In-office and at home Colgate sensitive pro-relief - CSPR|Prophylaxis with rubber cup using In-office Colgate sensitive pro-relief (CSPR), after non-surgical periodontal therapy, and tooth brushing with at home CSPR toothpaste.
1569272|NCT02461030|Drug|In-office Villevie® prophy paste + Colgate Toothpaste|Prophylaxis with rubber cup using In-office Villevie® (fluoride-free) prophy paste + Colgate Toothpaste, after non-surgical periodontal therapy.
1569273|NCT02461030|Procedure|Non-surgical periodontal treatment|Full-mouth debridment, scaling and root planing with ultrasonic/hand instruments
1569274|NCT02461017|Other|Assess for Audible Endotracheal Leak|In supine position, the head will be positioned in neutral position. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed and pressure in the inspiratory circuit is slowly increased until an audible leak is heard at the mouth. That pressure will be recorded.
1569275|NCT02461017|Other|Assess for Endotracheal Leak with direct visualization under rigid bronchoscope|In the same patient position, a flexible nasal laryngoscope will be inserted and positioned superior to the laryngeal inlet by the surgeon. With fresh gas flow at 2-5L/min, and pop off valve in the anesthesia machine closed, the pressure in the inspiratory circuit will be increased slowly until a leak around the TT will be visualized by inspecting the supraglottic area for bubbles or air movement around the TT. The peak pressure at which leak is observed physically will be recorded. This is the end of the study.
1569276|NCT02461004|Drug|CKD-391|Investigational product is prescribed to all of radomized subjects for two times.
1569277|NCT02461004|Drug|Atrovastatin and Ezetimibe combination therapy|Investigational products are prescribed to all of radomized subjects for two times.
1569282|NCT02460926|Procedure|Scaling & Root Planing|It consists in the non-surgical debridement of the sub gingival area affected by periodontal disease
1569283|NCT02460913|Procedure|Acupuncture|Acupuncture session of 20 to 30 minutes. Treatment protocols were determined through review of major clinical manuals and textbooks, literature review, and a panel of specialist acupuncturists from Chinese medicine backgrounds.
1569284|NCT02460913|Drug|Morphine titration|Patients in this group received IV titrated morphine. Morphine was prepared onsite and diluted in a manner to obtain a dose of 1mg in each ml of normal saline. The initial dose was 0.1 mg per kg and a titration dose of 0.05 mg per Kg was repeated every 5 minutes until reaching objective. The maximum allowed dose was 1.5 mg/kg.
1569285|NCT02460900|Drug|Varenicline|
1569286|NCT02460900|Behavioral|Positively Smoke Free|
1569287|NCT02460900|Drug|Placebo|
1569288|NCT02460900|Behavioral|Standard of Care|
1569289|NCT02460887|Drug|Gemcitabine|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
1569290|NCT02460887|Drug|cisplatin|Experimental arm: Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 2 cycles before IMRT.
1569291|NCT02460887|Drug|cisplatin|Active Comparator arm: Patients receive weekly cisplatin 40 mg/m² up to 7cycles during IMRT.
1569292|NCT02460887|Radiation|Intensity-modulated Radiotherapy|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.33 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor.
1569293|NCT02460874|Drug|Glyburide|1.25mg, twice a day
1569294|NCT02460874|Other|Placebo|1.25mg, twice a day
1569295|NCT02460861|Procedure|biopsies of the prostatic fossa in Magdeburg|intraoperative Open surgical biopsies of the prostatic fossa after prostatevesiculectomy in Magdeburg
1569296|NCT02460861|Procedure|RPVE|Open Radical prostatovesiculectomy in Magdeburg
1569297|NCT02460861|Procedure|ETRARP|Robotassisted Radical prostatovesiculectomy in Gronau
1569298|NCT02460861|Procedure|CE|Open cystectomy in Magdeburg/Gronau
1569299|NCT02460861|Procedure|biopsies of the prostatic fossa in gronau|intraoperative endoscopic robotassisted biopsies of the prostatic fossa after prostatevesiculectomy in Gronau
1569300|NCT02460848|Other|Outpatient therapeutic program, counseling and cash transfer|"Each household will receive an unconditional cash transfer of $40 value every month during a 6 months' period.
The amount of cash per household per month was defined according to the results of the Household Economy Approach survey. This amount represents 70% of supplement to the monthly average household income characterized as very poor to meet their basic needs. This threshold corresponds to the total of food and income necessary to cover 100% of energy needs food (2100 kcal per day per person), the costs associated with the preparation and consumption of food (e.g. salt, soap, kerosene and / or firewood for cooking and basic lighting) and finally all expenses for access to water for human consumption."
1569301|NCT02460848|Other|Outpatient therapeutic program and counseling|
1569302|NCT02460835|Radiation|Adaptive Radiation Therapy|
1569303|NCT02460822|Device|MyChemoCare iPad application|
1569305|NCT02460796|Other|Hippotherapy|The sessions began with a 5 minutes warm up that involved stretching and body awareness exercises. Then, the training was conducted for 20 minutes with arms and torso exercises, changes of direction called serpentine movements; up and down hip movements with feet on stirrups, and forced expiration. In the final 5 minutes, exercises for relaxation were conducted with the horse which involved moving the hand on the horse's neck, laying forward on the head and stroking the horse. The horses walking speed was between 5.8 and 6.4 Km/h.
1569308|NCT02460770|Drug|Autologous mesenchymal stem cells|After bone-marrow aspiration by an authorized person, mesenchymal stem cells were isolated and cultured during 17 days by the French Blood Establishment. Then, patients receive intramyocardial injections of mesenchymal stem cells during device surgery.
1569309|NCT02460757|Other|Laryngoscopy|Observation of glottic width in different arms
1569310|NCT02460744|Radiation|Hypofractionation|Radiation dose of 34Gy in 10 fractions over 2 weeks.
1569312|NCT02460718|Behavioral|ENCOURAGE Study|This intervention tested the effects of a peer coaching program plus brief diabetes education versus brief diabetes education alone on diabetes outcomes.
1569313|NCT02460705|Drug|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
1569314|NCT02460692|Drug|Placebos|Administration of vaporized cannabis plus either dronabinol or placebo pill
1569315|NCT02460692|Drug|dronabinol|Administration of vaporized cannabis plus either dronabinol or placebo pill
1569316|NCT02460692|Drug|Vaporized Cannabis 3.7% THC/5.6% CBD|Administration of vaporized cannabis plus either dronabinol or placebo pill
1569317|NCT02460679|Drug|EPI-589|An immediate release film-coated table at a 250 mg dosage strength.
1569318|NCT02460666|Behavioral|Tai-Chi-Chih (TCC)|
1569319|NCT02460666|Behavioral|Health Education and Wellness Classes (HEW)|
1569321|NCT02460640|Procedure|Tap block|intravenous patient-controlled analgesia with morphine and tap block with subcostal and posterior approach with ropivacaine 0,5% 15ml+15ml
1569322|NCT02460640|Procedure|intravenous Patient controlled analgesia|intravenous patient-controlled analgesia with morphine
1569325|NCT02460627|Drug|Lidocaine adhesive tape|700 mg for 12 hours
1569326|NCT02460627|Other|Adhesive tape|For 12 hours
1569327|NCT02460614|Procedure|Rhinopharyngeal clearance|At the end of the expiratory time, the child's mouth was closed by the hand of the researcher (raising the lower jaw), leading the child to perform a nasal aspiration maneuver.
1569328|NCT02460614|Procedure|Aspiration|A sterile aspiration catheter was connected to an extension and carefully introduced into the nasal cavity of the patient.
1569329|NCT02460614|Other|0.9% saline|0.9% saline consists of physiological solution and was instilled in both experimental groups.
1569330|NCT02460601|Drug|Qizhiweitong granule|
1569331|NCT02460588|Drug|Cyclophosphamide|"Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
Intravenous Cyclophosphamide (CYC), 600 mg/m² (adapted to age and renal function, maximal dose of 1.2 g) at Day 0, Day 15, M1, M2"
1569332|NCT02460588|Drug|Placebo|Population is IPF patients with an AE who meet the inclusion and exclusion criteria defined below.
1569333|NCT02460588|Drug|Corticosteroid (prednisolone)|All patients will receive non experimental medication with high dose of corticosteroid.
1569334|NCT02460575|Biological|Lactobacillus reuteri 17938|probiotic
1569335|NCT02460575|Biological|Placebo|Composition Sunflower oil, medium chain triglyceride oil and silicon dioxide. Total viable count of L. reuteri is zero CFU/ 5 drops.
1569338|NCT02460549|Behavioral|therapeutic education program|
1569339|NCT02460536|Behavioral|Attention Bias Modification treatment (ABMT)|Attention training via repeated trials of a dot-probe task intended to direct attention away from threat stimuli using threat and neutral face stimuli.
1569340|NCT02460536|Behavioral|Exposure only +ABMT|Identical discrimination task including exposure to a single threat or neutral face stimulus in each trial.
1569341|NCT02460536|Behavioral|Attention training only +ABMT|Attention training via repeated trials of a dot-probe task using non-emotional stimuli.
1569342|NCT02460536|Behavioral|Placebo group|Identical discrimination task including a single non-emotional stimulus in each trial.
1569343|NCT02460523|Procedure|conservative|1- Patients in conservative treatment group will receive medical treatment in the form of antibiotics (3rd generation cephalosporine), analgesics (NSAID eg Ibuprofen) and antispasmodics for 3 days. These patients will be followed up for improvement on the ground of clinical symptoms and serum bilirubin level and abdominal US for CBD stones.
1569344|NCT02460523|Procedure|ERCP|2- Patients in ERCP group will undergo ERCP and wide papillotomy and stone extraction directly then laparoscopic cholecystectomy (LC) within 3 days.
1569345|NCT02460510|Drug|Mannitol|
1569346|NCT02460510|Drug|3% hypertonic saline|
1569347|NCT02460497|Drug|Treatment: Minoxidil 2% / Botanical Hair Solution for Women|
1569348|NCT02460484|Biological|Autologous Cord Blood Infusion|Intravenous infusion
1569349|NCT02460471|Radiation|palliative radiation therapy|thermoplastic mask immobilization. CT in treatment position. radiation dose of 25 Gy in 5 daily fractions over one week 6 MV photons by intensity modulation. Target volume is the symptomatic tumour volume with a 5 mm margin
1569350|NCT02460445|Procedure|Phlebotomy|Scheduled standard phlebotomy every three months from month 3 to 12 of follow-up.
1569351|NCT02460445|Drug|ethinylestradiol|35 mcg ethinylestradiol qd for 21 days per month as usual clinical practice.
1569352|NCT02460445|Drug|Cyproterone Acetate|2 mg cyproterone acetate qd for 21 days per month as usual clinical practice.
1998709|NCT01070017|Other|DOT-HAART|For 8 months, DOT-HAART of all doses in the participant's home or alternate location. DOT worker ensures that HIV medications are taken as indicated and witnesses ingestion of all medications including other medications prescribed by physician. The worker will be trained to identify, triage and notify providers of any psychosocial and medical problems/complications. Transition to self-administration begins in months 9-12 when DOT will be tapered and greater participation of treatment supporter to prepare patients for self-administration.
1569355|NCT02460419|Drug|capecitabine|capecitabine 1250mg/m2 bid, oral, for 14 days, every 3 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
1569356|NCT02460419|Other|Best supportive care (BSC)|Best supportive care and following-up every 6-8 weeks
1569357|NCT02460406|Other|traditional physiotherapy|We are applying routine traditional physiotherapy consisted of neurodevelopmental treatment (stretching, weight bearing, functional reaching & walking so on).
1569358|NCT02460406|Other|progressive functional strength training|"Participants allocated to the experimental group completed three times a week, 12-week progressive resistance training protocol. This protocol consisted of functional squat system with virtual reality in leg press, plyometric exercises, exercises with Bosu ball & heel-rise exercises. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
1569359|NCT02460393|Drug|Humanized TNFα monoclonal antibody|"Subcutaneous injection of different doses for healthy people
Subcutaneous injection of different doses in healthy people"
1569360|NCT02460393|Other|placebo|Subcutaneous injection of different doses for healthy people
1998710|NCT01065701|Drug|Dexmedetomidine|Intranasal dexmedetomidine is given as premedication prior to induction of anesthesia
1569363|NCT02460367|Drug|Docetaxel|Docetaxel given as an IV infusion over one hour at a dose of 75mg/m2 given every three weeks (on Day 1 of each cycle ) until disease progression or significant toxicity.
1569364|NCT02460367|Biological|Tergenpumatucel-L|HAL-1, HAL-2 and HAL-3 immunotherapy components. 300M cells administered as an intradermal injection given every 3 weeks for up to a total of 18 doses.
1569365|NCT02460367|Drug|Indoximod 600mg|600mg by mouth three times a day everyday until disease progression or significant toxicity.
1569366|NCT02460367|Drug|Indoximod 1200mg|1200mg by mouth three times a day everyday until disease progression or significant toxicity.
1569367|NCT02460354|Drug|Metformin|Metformin 500 mg pill dispensed once orally
1569368|NCT02460341|Drug|ondansetron|Ondansetron 8mg, 16mg, 24mg
1569369|NCT02460341|Drug|placebo|placebo pill
1569370|NCT02460315|Procedure|early cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 1 will be managed by early laparoscopic cholecystectomy (LC) within 3 days after ERCP
1569371|NCT02460315|Procedure|late cholecystectomy|Those patients are primarily managed by endoscopic sphincterotomy and stone extraction for management of CBD stones. Then, the study population will be divided into 2 groups; group 2 will be managed by late LC one month after ERCP.
1569372|NCT02460302|Drug|Vaginal progesterone|Micronized vaginal progesterone 100mg inserted vaginally
1569373|NCT02460302|Drug|Placebo|Placebo suppository inserted vaginally
1569374|NCT02460289|Drug|Treatment: Minoxidil 5% / Botanical Hair Solution for Men|
1569375|NCT02460276|Drug|Lenalidomide|
1569376|NCT02460276|Drug|Ibrutinib|
1569377|NCT02460276|Drug|Rituximab|
1569378|NCT02460263|Device|Tablo Hemodialysis System|
1569379|NCT02460250|Procedure|Fibroscan|All included patients will undergo a Fibroscan (either Fibroscan Touch model or 402 model which enable CAPTM data extraction) once all eligibility criteria have been checked.
1569380|NCT02460237|Procedure|Disease Screening|Complete HPV self-test
1569381|NCT02460237|Other|Educational Intervention|Receive culturally appropriate instructions for using and returning the HPV self-test device and a photo story information sheet about HPV and HPV self-testing
1569382|NCT02460237|Other|Informational Intervention|Receive standard instructions and information sheet
1569383|NCT02460237|Other|Laboratory Biomarker Analysis|Correlative studies
1569384|NCT02460237|Other|Survey Administration|Ancillary studies
1569385|NCT02460224|Drug|LAG525|study drug 1
1569386|NCT02460224|Drug|PDR001|study drug 2
1569387|NCT02460211|Dietary Supplement|Vitamin D3|Those randomized to the treatment arm will receive three 50,000 unit oral doses of vitamin D3 supplementation. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
1569388|NCT02460211|Dietary Supplement|Placebo|Those randomized to the control arm will receive three placebo doses. The first dose will be given the evening before surgery. The second and third doses will be given either orally or per NG tube on days 1 and 2 after surgery.
1569389|NCT02460198|Biological|Pembrolizumab|IV infusion
1569390|NCT02460185|Behavioral|Study group: Maternal Physical Exercise|Exercise: 30 minutes of walking, 3 times a week at 4 Km/h.
1569391|NCT02460172|Device|Zip Surgical Skin Closure|Non invasive, reversible, skin closure device for closure of the skin layer following surgical incisions or laceration repair.
1569392|NCT02460172|Device|Steel Staples|Skin closure device for the closure of the skin layer following surgical incision.
1569393|NCT02460159|Drug|EZ 10 mg/Atorva 20 mg FDC|
1569394|NCT02460159|Drug|EZ 10 mg/Atorva 10 mg FDC|
1569395|NCT02460146|Drug|CXA-10|CXA-10 (10-nitro-9(E)-octadec-9-enoic acid) is a specific isomer of nitrated oleic acid
1569396|NCT02460146|Other|CXA-10 placebo|The placebo contains olive oil with BHT (0.08% to 0.10%).
1569397|NCT02460133|Drug|Paritaprevir|
1569398|NCT02460133|Drug|Ritonavir|
1569399|NCT02460133|Drug|Dasabuvir|
1569400|NCT02460133|Drug|Ombitasvir|
1569401|NCT02460133|Drug|Ribavirin|In genotype 1b individuals without cirrhosis, treatment will NOT include ribavirin.
1569402|NCT02460120|Device|Archimedes System|The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
1569403|NCT02460107|Biological|Botulinum toxin type A|
1569404|NCT02460107|Other|Normal saline|Placebo
1569405|NCT02460094|Drug|BMS-986168|
1569406|NCT02460094|Drug|Placebo|(0.9% Sodium Chloride for Injection or 5% Dextrose Injection if Sodium Chloride is not available)
1569407|NCT02460081|Drug|PDA-002|
1569408|NCT02460081|Drug|Placebo|
1569409|NCT02460068|Drug|Fotemustine|Fotemustine: fotemustine at 100 mg/mq intravenously (i.v.) over 60 minutes once every week for 3 doses, and once every 3 weeks from week 9 for 6 doses.
1569410|NCT02460068|Drug|Fotemustine and Ipilimumab|Fotemustine and ipilimumab:fotemustine 100 mg/m2 i.v. over 60 minutes once every week for 3 weeks (Weeks 1, 2, 3) plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 3 weeks for 4 cycles (Weeks 1, 4, 7, 10); fotemustine 100 mg/m2 i.v. over 60 minutes once every 3 weeks from week 9 for 6 doses plus ipilimumab at 10 mg/kg i.v. over 90 minutes every 12 weeks from week 24.
1569411|NCT02460068|Drug|Ipilimumab and nivolumab|ipilimumab and nivolumab: ipilimumab 3 mg/kg i.v over 90 minutes combined with nivolumab 1 mg/kg i.v over 60 minutes every three weeks for 4 doses, then nivolumab 3 mg/kg IV over 60 minutes every two weeks.
1569412|NCT02460055|Device|endotracheal tube|This study will determine if the placement of an ETT will lead to dysphagia.
1569413|NCT02460055|Drug|propofol|propofol 3mg/kg will be administered to facilitate endotracheal intubation
1569414|NCT02460055|Drug|Fentanyl|Fentanyl 1mcg/kg will be administered to facilitate endotracheal intubation
1569415|NCT02460055|Drug|Dexamethasone|Dexamethasone 0.15mg/kg up to 20 mg will be used for anti-emesis prophylaxis
1569416|NCT02460055|Drug|Ondansetron|Ondansetron 0.15mg/kg up to 4mg will be used for anti-emesis prophylaxis
1569417|NCT02460055|Drug|sevoflurane, nitrous oxide and oxygen|Inhalational agents will be used to induce general anesthesia
1569418|NCT02460042|Procedure|drug coated balloon angioplasty|percutaneous transluminal angioplasty with peripheral balloon catheters
1569419|NCT02460042|Device|SeQuent® Please OTW Paclitaxel Coated Balloon Catheter|
1569420|NCT02460029|Other|Ventral hernia|Visualization of the mesh surface and the confirmation with MRI scan at 1 month and 13 months after standardized retromusculare incisional hernia repair with the visible CICAT mesh (Dynamesh®).
1569421|NCT02460016|Drug|AK0529|AK0529 pellets for oral administration
1569422|NCT02460003|Behavioral|Physiotherapy|A program of physiotherapy including manual therapy, exercise, pain education.
1569423|NCT02460003|Other|Home exercise program|Home exercise program
1569424|NCT02459977|Drug|Basiliximab|Basiliximab induction therapy
1569425|NCT02459977|Drug|No basiliximab|No basiliximab induction therapy
1569426|NCT02459977|Procedure|Kidney transplantation|kidney transplantation
1569427|NCT02459964|Drug|Fentanyl Nasal Spray|Fentanyl nasal spray 100 mcg delivered at time 0 (defined as the time when intranasal Fentanyl spray is administered) with a rescue dose allowed at time 0.5 hour (h)
1569428|NCT02459964|Drug|Hydromorphone Hydrochloride|Hydromorphone hydrochloride 1.5 mg pushed intravenously (IV) at time 0 (defined as the time of completion of opioid IV push) with a rescue dose allowed at time 0.5 hour (h).
1569429|NCT02459964|Behavioral|Phone Call|Study nurse to call patient 24 hours after participation to ask about side effects since taking part in the study. The phone call should last about 5 minutes.
1998714|NCT01046305|Behavioral|Interview & Questionnaires|30 Minute Interview about what it is like to have CML, followed by symptom questionnaire, quality-of-life questionnaire, and demographic questions taking another 10 minutes for all 3 questionnaires.
1569431|NCT02459938|Drug|Glucagon (ZP-Glucagon)|chemically synthesized glucagon as delivered via transdermal microneedle patch system for 30 minutes
1569432|NCT02459938|Drug|Glucagon (GlucaGen)|recombinant glucagon administered via subcutaneous injection
1569433|NCT02459925|Behavioral|CBT- Mental Health Program|Manualized Stress Management class; brief individual behavioral counseling.
1569434|NCT02459925|Behavioral|MOMS GROW|MOMS GROW (Generating Real Opportunities for Work) Teaching, coaching, and supportive services for participants as they navigate their journeys to sustainable employment that pays a family-supporting wage.
1569435|NCT02459912|Procedure|Unilateral Nerve-Sparing Cryoablation of the Prostate|The side of the prostate affected by cancer will be treated with nerve-sparing cryoablation in two freeze-thaw cycles under transrectal ultrasound guidance. The unaffected side of the prostate will not be treated.
1569436|NCT02459912|Device|Precise Cryoablation System with IceRod Needles|Galil Medical Precise Cryoablation System with IceRod Needles will be used for performing Unilateral Nerve-Sparing Cryoablation
1569437|NCT02459899|Drug|Placebo|Placebo, once daily, before the first meal of the day
1569438|NCT02459899|Drug|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
1569439|NCT02459899|Drug|Sotagliflozin|Middle dose Sotagliflozin,once daily, before the first meal of the day
1569440|NCT02459899|Drug|Sotagliflozin|High dose Sotagliflozin,once daily, before the first meal of the day
1569441|NCT02459886|Drug|BIIB054|IV infusion
1569442|NCT02459886|Drug|Placebo|IV infusion
1569443|NCT02459873|Behavioral|Computer games to assess change in executive function skills|Children get access to computer games for 10 weeks for an hour each week.
1569444|NCT02459860|Behavioral|Problem Solving Treatment|Individual, face-to-face PST sessions over a span of 8 weeks will be held at PACE sites. The first session will last one hour while subsequent sessions will last 45 minutes. After the last PST session, each subject will have 3 monthly booster sessions (about 15 minutes). The PST protocol is intended to be highly structured, time-limited, and manual-driven; sessions include PST hand outs and homework as well as social and behavioral activation strategies, i.e., pleasant activities scheduling. All interventionists will document attendance and provide a post-session fidelity summary. 10% of the individual sessions will be videotaped with patient consent to assess fidelity and training needs.
1569445|NCT02459860|Behavioral|Enhanced Usual Care|EUC patients will receive psychoeducational materials on depression and depression treatment of older persons. EUC patients will continue to receive the full complement of PACE services (medical, rehabilitation, social) including referrals to specialty mental health services, if indicated.
1569446|NCT02459847|Behavioral|Mindfulness Training|
1569447|NCT02459847|Behavioral|Sonographic Biofeedback|
1569448|NCT02459847|Other|Standard Care|
1569449|NCT02459834|Other|Allulose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
1569450|NCT02459834|Other|Fructose|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
1569451|NCT02459834|Other|Control|"A double-blind, randomized, multiple-crossover equivalence design. Each participant will act as their own control receiving the treatments in random order, each separated by a 1 week washout period. The treatment will be developed by Tate & Lyle."
1569452|NCT02459821|Other|GE-O SYSTEM|The first group will be subjected to RAGT for 9 weeks (2 sessions/ week) with a total of 18 sessions by mean of GE-O System (9). During each session, the patients will practice 15 to 20 min of simulated floor walking followed by 5 to 10 min of repetitive simulated stair climbing up and down. Breaks will be optional, but uninterrupted training intervals of at least 5 min for simulated floor walking and 3 min of simulated stair climbing will be required. When the patient reaches the maximum amount of time, speed of gait will then be progressively increased. Each session will last up to 50 minutes, the first 30 minutes will be dedicated to gait training and the last 20 minutes to stretch the lower limb's muscles.
1569453|NCT02459821|Other|Conventional training|The conventional walking group will be subjected to a conventional gait training for 9 weeks (2 sessions/week) with a total of 18 sessions. Each session will last altogether 50 minutes, the first 30 minutes will be dedicated to gait and stair climbing up and down training while the last 20 minutes to stretch the lower limb's muscles.
1569454|NCT02459795|Drug|Ingenol Mebutate (Perrigo)|
1569455|NCT02459795|Drug|Ingenol Mebutate (Reference)|
1569456|NCT02459795|Drug|Placebo gel|
1569457|NCT02459782|Procedure|Ultrasound guided Dual Quadrant Peribulbar Anaesthesia|Landmark Guided single injection vs Ultrasound guided dual quadrant injection
1569458|NCT02459769|Behavioral|Exercise for Cancer Patients|a standardized, daily, 6 week, home-based, progressive exercise program
1569459|NCT02459756|Other|Beverage: Spray dried blackcurrant powder dissolved in water|
1569553|NCT02459067|Biological|ImmuniCell®|Autologous γδ T Lymphocytes
1569460|NCT02459756|Other|Beverage: Placebo (sucrose, glucose, fructose, maltodextrin, malic acid, citric acid, vitamin C, artificial blackcurrant flavouring and low-nitrate water)|
1569461|NCT02459730|Procedure|ART with GIC containing 1.25% CHX.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using GIC KetacMolar Easymix® containing 1.25% chlorhexidine digluconate (n= 41 tooth surfaces).
1569462|NCT02459730|Procedure|ART with GIC.|Carious lesions were prepared by removing infected dentin with hand instruments. No local anesthesia was administered. Then, the cavities were filled with the press finger technique using KetacMolar Easymix® (n = 66 tooth surfaces).
1569463|NCT02459717|Other|Probiotics and prebiotic|Patients will receive daily (at breakfast) a fermented milk (125 grams), containing multiple probiotics strains and prebiotic fiber
1569464|NCT02459717|Other|Placebo|Patients will receive daily (at breakfast) a placebo (pasteurized fermented milk without prebiotics)
1569465|NCT02459704|Procedure|Semilunar coronally positioned flap|Semilunar coronally positioned flap with enamel matrix derivative (Emdogain) or alone.
1569466|NCT02459704|Device|Enamel matrix derivative (Emdogain)|Enamel matrix derivative associated to semilunar coronally positioned flap (SCPF + EMD - test group)
1569467|NCT02459691|Behavioral|Vida Sana|Vida Sana is a Diabetes Prevention Program-based, culturally-adapted intervention that will have 2 distinct stages: The intensive treatment stage will implement a culturally adapted year-long Group Lifestyle Balance curriculum. The curriculum uses a goal-based approach to promote positive outcome expectancies and foster self-efficacy. The maintenance stage will be focused on (1) facilitating continued behavior change; (2) fostering participants' self-efficacy and independence; and (3) reinforcing problem-solving and behavior maintenance skills. These will be done via secure e-messaging.
1569468|NCT02459691|Other|Usual Care Only|Patients assigned to this group will continue medical care as usual. That is, they will continue to see their primary care provider and any specialist he/she may recommend. They may also access additional health education resources available at the Palo Alto Medical Foundation. They will continue to receive general age and gender-appropriate reminders of health maintenance tests/exams and immunizations, per Palo Alto Medical Foundation standard practice.
1569469|NCT02459678|Behavioral|Enhanced Adherence Package|The enhanced adherence package is yet to be designed, but may target all HIV-infected women with methods that are currently reserved only for late clients or clients of unknown status.
1569470|NCT02459678|Other|Standard of Care|Currently, the standard of care is based on the 2010 national HIV care and treatment guidelines, health care providers are encouraged to use a number of different means to improve ART adherence.
1569471|NCT02459665|Biological|Vaginal probiotics for prevention of BV recurrence (Ecologic Femi vaginal capsule)|Vaginal probiotics to restore the vaginal microbiome and prevent BV recurrence after metronidazole treatment for BV or TV
1569472|NCT02459665|Drug|Prophylactic use of metronidazole pills (500 mg)|Prophylactic use of metronidazole pills to prevent BV recurrence after metronidazole treatment for BV or TV
1569473|NCT02459665|Biological|Vaginal probiotics for prevention of BV recurrence (Gynophilus vaginal tablet)|
1569474|NCT02459652|Drug|S-1|S-1 is administered orally at a dose of 40 mg/m2 twice daily on the day of irradiation (Monday through Friday) during radiation therapy.
1569475|NCT02459652|Radiation|Radiation Therapy|Radiation therapy is delivered with >6-megavolts (MV) photons, using a multiple field technique. A total dose of 50.4 Gy is delivered in 28 fractions over 5.5 weeks.
1569476|NCT02459639|Other|Anthroposophic integrative care rehabilitation program|"The programme for chronic pain at AIC consists of two phases:
A three-week in-patient period. During the first three-week in-patient stay, patients meet regularly with a multi-professional team. Usually, each patient receives two of the following therapies 2-4 times per week: art therapy, massage, physiotherapy, eurhythmy and baths. Nursing care is provided twice daily. Moreover, patients are offered to participate in group activities.
Two-three day inpatient follow-up and treatment period closure. The second phase of the treatment programme consists of a 2-3 day inpatient stay, 6 months after closure. During this time, physician, nurse and therapist appointments are made according to individual needs. The patients who have been engaged in group activities are gathered in groups."
1569477|NCT02459639|Other|Conventional multi-modal care rehabilitation|The standard approach at Linköping University Hospital admits patients for bio-psycho-social assessment, pharmacological treatment and multimodal rehabilitation (main components: education, intense physical exercise, cognitive behavioural therapy and workplace interventions) for a 6 week intensive phase period (75%) followed by 4 weeks (25%). Here a number of professional disciplines collaborate and form a team of professionals focused on individual patient needs The multimodal rehabilitation outpatient program delivered by this team has the following aims: 1) reduce pain and psychological burden, 2) improve work capacity and decrease sick-leave and 3) increase perceived health and quality of life. These general aims are combined with the aims of the patient in a plan of rehabilitation.
1569479|NCT02459613|Other|99mTc-Annexin V-128 SPECT|
1569480|NCT02459600|Other|instulling cyclopentolate drops in the eye|measuring refraction with and wirthout cyclopentolate drops under general anesthesia
1569481|NCT02459587|Behavioral|Crisis Line Facilitation (CLF)|This single session therapist-delivered intervention addresses Veterans' perceived barriers and facilitators of crisis line use during periods of suicidal crisis. The CLF session culminates with the Veteran calling the Crisis Line with the therapist in the room as a way for the Veteran to practice the logistics of making the call and to have direct experiences that may counter any negative beliefs about Crisis Line use.
1569482|NCT02459574|Procedure|AVATAR-AF ablation|Experimental ablation protocol
1569483|NCT02459574|Drug|Anti-Arrhythmic therapy|"Group 2 will be prescribed medication listed below:
Amiodarone; Dronaderone; Sotalol Beta blockers; Calcium channel blockers; Flecainide; or Propafenone.
You will then be discharged from clinic. A research nurse will contact you by phone to make sure there are no problems and can make hospital appointments if needed."
1569484|NCT02459574|Procedure|Conventional AF ablation|Conventional ablation procedure
1569485|NCT02459561|Device|EndoBarrier TM Gastrointestinal Liner|If subjects are randomised into the EndoBarrier Group of the trial they will receive the device for 12 months followed a 12 months follow-up period.
1569486|NCT02459561|Other|Best Medical Care|If subjects are randomised into the Control Group of the trial they will receive best medical care and dietitian advice for 12 months followed a 12 months follow-up period.
1569487|NCT02459548|Other|Follow up in Sleep Unit Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
1569488|NCT02459548|Other|Follow up in Primary Care Group|Compare the results of a program of treatment and follow-up by Primary Care in patients with obstructive sleep apnea on CPAP treatment, versus the usual practice of control by the Sleep Unit.
1569489|NCT02459535|Other|oral stimulation glucose|oral stimulation with glucose, AS or glucose+AS in fasted state, blood samples from fasted state up to 120 min post-ingestion
1569490|NCT02459535|Other|oral stimulation saccharin|
1569491|NCT02459535|Other|oral stimulation aspartame|
1569492|NCT02459535|Other|oral stimulation sucralose|
1569493|NCT02459522|Other|not intervention|This is a cross-sectional study for estimation of diagnostic performance.
1569494|NCT02459509|Drug|Dexmedetomidine|Either 2mcg/kg or 4mcg/kg of intranasal dexmedetomidine will be given to assess efficacy of preoperative sedation
1569495|NCT02459496|Behavioral|dietary consulting and advise|first phase: 3 weeks of very-low calory diet (low-carb or normo-carb) second phase: 49 weeks of eucaloric diet under DGE guidelines
1569496|NCT02459483|Behavioral|Nurse phone call|
1569497|NCT02459470|Procedure|Fluid loading|fluid loading was performed by using 7ml/kg of 6% hydroxyethyl starch within 10 min to all patients
1569498|NCT02459457|Drug|Paclitaxel and Cisplatin|patients get Paclitaxel and Cisplatin according to protocol
1569499|NCT02459457|Drug|Paclitaxel and Fluorouracil|patients get Paclitaxel and Fluorouracil according to protocol
1569500|NCT02459457|Drug|Paclitaxel and Carboplatin|patients get Paclitaxel and Carboplatin according to protocol
1569501|NCT02459457|Radiation|Radiotherapy|1.8Gy/d, d1-5/week, 34Fx
1569502|NCT02459444|Device|Powerbreathe|Respiratory equipment for physiotherapy, offering to load muscles inspiratory
1569503|NCT02459444|Other|Physiotherapy|This was contemplated cinesioterapia unloaded, muscle stretching, coughing technique, sedestração and ambulation if the participant was fit.
1569504|NCT02459431|Other|21 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 21 G needle, by random assignment
1569505|NCT02459431|Other|22 G needle group|Patients with a clinico radiologic suspicion of sarcoidosis will undergo endobronchial ultrasound guided transbronchial needle aspiration with 22 G needle, by random assignment
1569508|NCT02459405|Procedure|NIR anastomotic perfusion assessment|Patient will have their anastomosis assessed by near infrared technology after indocyanine green has been injected i.v. The procedure will be repeated twice, once before the anastomosis and the second time after the anastomosis has been performed.
1569509|NCT02459405|Device|Near infrared camera|Use of the Pinpoint laparoscopic scope (Novadaq, Vancouver, Canada) after injection of indocyanine green
1569510|NCT02459392|Other|Epiduroscopy|"Epiduroscopy has two main uses in the pain clinic:
Releasing epidural adhesions for the relief of chronic sciatica. Adhesions can form around the lower lumbar nerve roots after decompressive surgery for disc disease or after a bad bout of inflammatory sciatica in the absence of surgery. Epidural adhesions can usually be identified on an enhanced magnetic resonance scan using intravenous gadolinium. They also cause uneven spread of X-ray contrast when performing an epidurogram.
Injecting mixtures of local anesthetic and depot steroid around inflamed nerve roots when epidural injections / nerve root blocks have been unsuccessful. The presence of adhesions can prevent epidurally injected drugs from reaching the inflamed nerve roots."
1569511|NCT02459392|Drug|Hyaluronic Acid|
1569512|NCT02459392|Drug|DepoMedrol|
1569513|NCT02459379|Radiation|MRI Scan|MRI will be performed for clinical reason for which no other imaging study will provide the data required on patients with pacemaker or implantable defibrillator
1569514|NCT02459353|Drug|Dapagliflozin|
1569515|NCT02459353|Drug|Placebo|
1569516|NCT02459340|Other|therapeutic treatment (inpatient and outpatient setting)|
1569517|NCT02459327|Behavioral|Video Interaction Project|VIP utilizes pediatric well-child visits to build a relationship with an interventionist who facilitates self-reflection regarding interactions with the child through review of videotapes of the parent and child made that day and further facilitates interactions through provision of learning materials (toys and books).
1569518|NCT02459327|Behavioral|Family Check Up|FCU utilizes home visitation to build a relationship with an interventionist who assesses family strengths and challenges and uses motivational interviewing and evidence-based family management strategies to support parent and child behavioral change.
1569519|NCT02459314|Dietary Supplement|plant sterol and soluble fiber-enriched soymilk|Sterols compete with LDL-C for absorption in GI tract. A meta-analysis of 41 trials indicated that an intake of 2 g sterols/stanols reduces the LDL-C level by 10%. Additive effects occur when sterols are combined with statins; the combination being more efficacious than a 2 times up-dosing of statins alone. Soluble dietary fibers also have significant cholesterol lowering effects. In a meta-analysis, Brown et al estimate that a daily soluble fiber intake ranging from 9-30 g/d, were associated with 10.6% reduction in LDL-C levels.
1569550|NCT02459093|Device|poliglecaprone 25 suture|cesarean delivery incision closure with poliglecaprone 25 suture
1569551|NCT02459093|Device|polyglactin 910 suture|cesarean delivery incision closure with polyglactin 910 suture
1569552|NCT02459080|Drug|TD-4208|
1569520|NCT02459314|Dietary Supplement|soymilk|Soy protein is another LDL-C and total cholesterol lowering food. A meta-analysis by Reynolds K et al. discovered that volunteers receiving 20 to more than 61 g of soy protein had reductions in total cholesterol by 5.26 mg/dL (95% CI -7.14 to -3.38), and LDL-C by 4.25 mg/dL (95% CI -6.00 to -2.50), with an increase of HDL-C by 0.77 mg/dL (95% CI 0.20 to 1.34). Reductions in LDL cholesterol were larger in hypercholesterolemic than in normocholesterolemic subjects.
1569522|NCT02459288|Drug|Clopidogrel first|After randomization, 2 weeks Clopidogrel (Plavix) 75 mg QD will be given and then crossover with following 2 weeks Ticagrelor (Brilinta) 90 mg bd
1569523|NCT02459288|Drug|Ticagrelor first|After randomization, 2 weeks Ticagrelor (Brilinta) 90 mg bd will be given then crossover with following 2 weeks Clopidogrel (Plavix) 75 mg QD
1569524|NCT02459275|Other|PEP uP Protocol|Semi-elemental tube feeds are started at the hourly goal rate as determined by the 24 hour volume goal. Protein supplements will be started at the initiation of tube feeds to target a daily delivery of 2 g/kg/day. A promotility agent will be started empirically concomitant with EN initiation. GRV will be checked every 4 hours and will be reinfused to the patient each time it is checked. GRV threshold is 500 ml. Once the patient shows tolerance of semi-elemental formula, the tube feeds will then be converted to standard polymeric formula. Daily, the patient will be reassessed for the need to continue promotility agents.
1569525|NCT02459262|Biological|GBS-NN vaccine|Three dose levels will be administered, with and without Alhydrogel®
1569526|NCT02459249|Other|Healthy Lifestyle|A physician and a nutritionist will be give recommendations for diet and exercise emphasizing the importance of a healthy lifestyle (suggesting moderate-intensity activity at least 150 minutes/week and to eat less sodium, fat, sugar, portions and calories). Verbal and written individualized recommendations from trained professionals (nutritionists, and physician) will be provided. Monthly sessions of at least 30 minutes covering diet, exercise, and behavior modifications were held. The first was a one-to-one meeting and was followed by group sessions based on behavioral counseling
1569527|NCT02459249|Other|Placebo Comparator (Treatment of Mexican Health Minister)|General and unspecific recommendations of diet and physical activity for the metabolic syndrome treatment, given for a physician
1569528|NCT02459236|Drug|CERC-301|CERC-301, a highly selective, orally bioavailable, NMDA receptor subunit 2B (NR2B), also referred to as Glutamate NMDA receptor subunit epsilon-2 (GluN2B) antagonist
1569529|NCT02459236|Drug|Placebo|
1569532|NCT02459210|Behavioral|CLUES|Cognition for learning and for understanding everyday social situations intervention described above
1569533|NCT02459210|Behavioral|therapy and computer games|Weekly psychotherapy+ computer games such as sporcle
1569534|NCT02459197|Behavioral|Heat Pain Stimuli A|
1569535|NCT02459197|Behavioral|Heat Pain Stimuli B|
1569536|NCT02459197|Behavioral|Positive Video|
1569537|NCT02459197|Behavioral|Neutral Video|
1569538|NCT02459197|Drug|Administration of T4P1001 capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
1569539|NCT02459197|Drug|Administration of Placebo capsules|This treatment is given as add-on therapy to patient's regular analgesic treatment
1569540|NCT02459184|Other|Income Security Health Promotion|"The ISHP will work to improve the income security of participants within this study. To that end, her activities include:
Providing one-to-one case management support and ongoing follow-up to diverse low-income patients and families regarding their income security.
Developing and implementing targeted information self-help sessions, such as; banking basics, income tax submissions, and social service forms, for the target population
Developing and maintaining up-to-date detailed knowledge of financial issues and financial services affecting low-income people, and applying this knowledge in his/her work.
Assisting individual low-income patients with income security-focused interventions, including access to tax benefits, applications for income security programs such as social assistance and seniors and child benefits, and navigation of disability support programs."
1569545|NCT02459158|Drug|ME1100 inhalation solution|Low dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
1569546|NCT02459158|Drug|ME1100 inhalation solution|High dose of ME1100 inhalation solution twice daily for up to 14 days to be administered via eFlow nebulizer system
1569547|NCT02459145|Behavioral|Graduated exercise protocol|Intervention involves exercise protocols starting at 50% of maximum age-adjusted heart rate (MHR) for 10 minutes (warm-up and Recovery)_ plus 5 minutes of target heart rate per day 5 days a week for 2 weeks, supervised by the athletic trainer or parent. The protocol increases the intensity of target heart rate by 10% MHR and duration of 50% MHR by 2 minutes every 2 weeks if there is no symptom exacerbation.
1569548|NCT02459132|Behavioral|High-intensity aerobic interval exercise|See arm/group description
1569554|NCT02459054|Device|SynCardia 50cc temporary Total Artificial Heart (TAH-t)|Replacement of both ventricles and all four valves with the investigational device as a bridge to transplantation.
1569555|NCT02459041|Other|Elastography, contrast enhancement|"Elastography is an ultrasound method used for the reconstruction of tissue elasticity distribution in real-time. The main intended use is to differentiate between benign and malignant focal lesions based on the significantly smaller strain of the latter real time. Tissue elastography can be easily performed with conventional probes, including the linear EUS probes used for the examination of the pancreas and/or lymph nodes.
Contrast-enhancement Ultrasound contrast agents in conjunction with contrast specific imaging techniques are increasingly accepted in clinical use for diagnostic imaging. Pancreatic adenocarcinomas are usually hypovascular tumors."
1569556|NCT02459028|Behavioral|Positive Psychology intervention|"Intervention group: Participants are instructed to practice 4 out of 10 differentPositive Psychology Exercises (Gratitude, Optimism, Act of Kindness, Social Relations, Forgiveness, Flow, Savoring, Goals, Spirituality, Taking Care of the Body) for at least 15 minutes, at least one day every week including on bad days (defined as days with higher than average levels of pain intensity or feeling down in the dumps) for 8 weeks."
1569557|NCT02459028|Behavioral|Positive Psychology intervention (Control exercise)|Control group: Control Exercise (Attention Training): Participants assigned to the control group are instructed to be more attentive to their surroundings and write about three specific events or activities from the past 7 days for at least 15 minutes once a week for 8 weeks. This condition is designed to control for the effects of time and participation in an intervention activity.
1569558|NCT02459015|Device|Implantation|A peripheral nerve defect up to 26 mm in the finger will be repaired by implantation of either a Reaxon® Nerve Guide or an autologous nerve graft (depending on the randomization group) on day 0.
1569559|NCT02459002|Behavioral|QOL Questionnaire|Participant outcomes assessed with survey
1569560|NCT02459002|Behavioral|Caregiver Satisfaction Questionnaire|Caregiver satisfaction with quality of care assessed with surveys
1569561|NCT02458989|Procedure|Scalpel|Use of a scalpel as a first incision during thyroid operation
1569562|NCT02458989|Procedure|Electrocautery|Use of an electrocautery as a first incision during thyroid operation
1569563|NCT02458976|Device|PDL|
1569564|NCT02458963|Procedure|IVF|Women will undergo one IVF cycle
1569565|NCT02458963|Drug|Gonadotropin|Women will be subjected to ovarian stimulation for 6 months with the gonadotropin low-dose step-down protocol
1569566|NCT02458937|Other|Functional Mobility Assessment|Functional Mobility Assessment (FMA) is a tool that was developed to measure functional mobility in children and adolescents with lower-extremity sarcoma. It is comprised of well-established outcome measures that examine various domains of function. The six categories tested by the FMA include pain, functional mobility, use of assistive devices, satisfaction with quality of gait, participation in the community, and endurance.
1569567|NCT02458937|Other|GAITRite® System|Subjects will be required to walk at a self-selected comfortable pace and again at fast speed. Software will then calculate and report the temporo-spatial gait parameters for collection and evaluation by the primary investigator.
1569568|NCT02458937|Other|Range of Motion|Measurements will include hip flexion, hip abduction and adduction, and hip internal and external rotation. Range of motion (ROM) will be attempted on bilateral lower extremities, however if post-operative ROM precautions are implemented, the involved extremity will not be measured. Goniometry is a reliable and valid measure for active and passive ROM when following standardized procedures.
1569569|NCT02458924|Biological|Niacin skin test|Two concentrations including 0.5 ml solutions of 0.01 M and 0.1 M diluted methyl nicotinate were applied for one minute to the inside of the different forearms of each individual.
1569570|NCT02458911|Device|Paclitaxel-eluting balloon|
1569571|NCT02458898|Behavioral|Educational Text Message Reminders|45 unique text messages designed by the Stanford Pediatric Gastroenterology physicians and nutritionists
1569572|NCT02458872|Behavioral|safety huddle alarm intervention|The intervention consists of a monitor alarm dashboard that displays the numbers and types of alarms for each patient, and an accompanying checklist to guide data-driven discussion of 2-4 patients with high alarm rates.
1569573|NCT02458859|Device|PICO (single use portable negative pressure wound therapy)|Single use portable negative pressure wound therapy
1569574|NCT02458846|Device|Pediatric Vision Scanner|
1569575|NCT02458846|Device|Preschool Randot Stereo test|
1569576|NCT02458846|Other|Gold Standard Eye Exam|
1569577|NCT02458846|Device|Spot photorefractor|
1569578|NCT02458846|Device|PlusoptiXphotorefractor|
1569579|NCT02458833|Behavioral|Home Plate|Home Plate is a community-based, peer mentored intervention aimed at improving home food preparation practices in families with young children. Through 6 classes, this intervention explores topics related to regularly preparing healthy foods at home.
1569580|NCT02458820|Procedure|DSA EEG|Color density spectral array (DSA) is a quantitative electroencephalogram (EEG) technique that uses Fourier transformation to present EEG power (amplitude2/Hz, by color) and frequency (y-axis) over time (x-axis). It is commercially available and used routinely by neurophysiologists for EEG interpretation. Up to several hours of EEG can be displayed as a single image.
1569581|NCT02458794|Procedure|function tests|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric tube insertion
1569582|NCT02458794|Device|LMA SupremeTM|
1569583|NCT02458794|Device|Ambu-Aura GainTM|
1569584|NCT02458781|Drug|Metronidazole|Metronidazole 500mg given twice daily for 14 days
1569585|NCT02458781|Drug|Ciprofloxacin|Ciprofloxacin 500mg given twice daily for 14 days
1569586|NCT02458781|Drug|Placebo|Placebo given twice daily for 14 days
1569587|NCT02458768|Drug|IVF-M HP Inj.|
1569588|NCT02458768|Drug|Menopur® Inj.|
1569589|NCT02458755|Drug|High-dose statin: Atorvastatin 40mg or Rosuvastatin 20mg|Atorvastatin 40mg or Rosuvastatin 20mg
1569590|NCT02458742|Drug|Morphine|0.5%Hyperbaric bupivacaine 2 ml add morphine 50 mcg for spinal anesthesia
1569591|NCT02458742|Drug|Placebo|0.5%Hyperbaric bupivacaine 2 ml for spinal anesthesia
1569592|NCT02458729|Drug|Tranexamic Acid 5%,5ml/amp (intraoperative)|tranexamic acid 1g administered intravenously five minutes before deflation of the tourniquet
1569654|NCT02458326|Other|Control Training|10 minutes of heating on the treadmill with a low speed that does not cause patient effort
1569593|NCT02458729|Drug|Tranexamic Acid 5%,5ml/amp (3 hours after operation)|tranexamic acid 1g administered intravenously 3 hours after operation
1569594|NCT02458729|Drug|0.9% Normal Saline (intraoperative)|0.9% Normal Saline 20ml administered intravenously five minutes before deflation of the tourniquet
1569595|NCT02458729|Drug|0.9% Normal Saline (3 hours after operation)|0.9% Normal Saline 20ml administered intravenously 3 hours after operation
1569596|NCT02458729|Drug|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14
1569597|NCT02458716|Procedure|Robotic Assisted Radical Prostatectomy|Undergo RARP
1569598|NCT02458716|Procedure|Conventional open retropubic radical prostectomy|Undergo conventional open RRP
1569599|NCT02458716|Other|Laboratory Biomarker Analysis|Correlative studies
1569600|NCT02458716|Other|Quality-of-Life Assessment|Ancillary studies
1569601|NCT02458716|Drug|ADT (androgen deprivation therapy) (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)|LHRH agonist or antagonist (i.e. leuprolide) plus an androgen receptor inhibitor (i.e. bicalutamide)
1569602|NCT02458703|Other|Cardiopulmonary exercise test|"Subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down, they will fill in a short questionnaire describing how they feel. 20-30mls of blood will be taken for analysis."
1569607|NCT02458677|Drug|PRX003|
1569608|NCT02458677|Other|Placebo|
1569609|NCT02458664|Genetic|Genetic analysis on tumor kept in tumor bank|
1569610|NCT02458651|Other|No intervention|No intervention administered in this study
1569611|NCT02458638|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.
1569612|NCT02458625|Dietary Supplement|Iron sucrose 500 mg|
1569613|NCT02458625|Dietary Supplement|Iron bisglycinate 60 mg|
1569614|NCT02458612|Other|control group|We will apply traditional physiotherapy including upper limb exercises in three times a week for 12 week.
1569615|NCT02458612|Other|intervention group|"Participants allocated to the experimental group completed three times a week, 12-week mirror therapy combined with progressive strength training. This protocol consisted of mirror therapy with a mirror box, strength training with Thera-band and exercises for scapular dyskinesis. This intensity of training is approximately equal to training at an intensity of 60% to 80% of one-repetition maximum according to National Strength and Conditioning Association (NSCA) protocols. Intensity of exercise is gradually increased 10% bi-weekly."
1569616|NCT02458599|Dietary Supplement|Test product|Whey protein hydrolysate (20 g)
1569617|NCT02458599|Dietary Supplement|Reference product 1|Iso-energetic carbohydrate (20 g)
1569618|NCT02458599|Dietary Supplement|Reference product 2|Negligible energy placebo (20 g)
1569619|NCT02458586|Dietary Supplement|Dietary intervention / counseling|dietary counseling and daily intake of 50 g of dietary oil over a period of 8 weeks
1569620|NCT02458573|Other|continuous epidural analgesia|the continuous epidural analgesia group: epidural analgesia started from induction of anesthesia and continued for 48 h.
1569621|NCT02458573|Other|continuous intravenous analgesia|the continuous intravenous analgesia group: intravenous analgesia started from induction of anesthesia and continued for 48 h.
1569622|NCT02458560|Device|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
1569623|NCT02458547|Procedure|Desflurane|Inhalation anesthesia with desflurane at age-adjusted MAC of 0.8~1.0
1569624|NCT02458547|Procedure|Propofol|Total intravenous anesthesia with propofol target controlled infusion
1569625|NCT02458547|Procedure|Bupivacaine|Spinal anesthesia with 0.5% bupivacaine
1569655|NCT02458313|Drug|DMXB-A|150 mg DMXB-A (3-(2,4-dimethoxybenzylidene anabaseine) b.i.d. for 12 weeks.
1569626|NCT02458534|Other|Mcgrath Mac videolaryngoscope|Participants perform three intubation attempts using Mcgrath Mac videolaryngoscope in the manikin with the normal airway and difficult airway settings.
1569627|NCT02458534|Other|C-MAC videolaryngoscope|Participants perform three intubation attempts using C-MAC videolaryngoscope in the manikin with the normal airway and difficult airway settings.
1569628|NCT02458534|Other|macintosh laryngoscope|Participants perform three intubation attempts using macintosh laryngoscope in the manikin with the normal airway and difficult airway settings.
1569629|NCT02458521|Device|Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. TMS sessions will consist of both 10 Hz left pre-frontal stimulation for 3,500 pulses followed by 1 Hz right pre-frontal stimulation for 1,500 pulses per session, for a total stimulation time of approximately one hour per session. These pulse sequences have theoretical targets that may be implicated in conditions of poor resiliency, apathy, depression and anxiety.
1569630|NCT02458521|Device|Sham Transcranial Magnetic Stimulation|Treatment will consist of 30 sessions of TMS over approximately 7 weeks. More specifically, the active or sham TMS treatments will be conducted five times a week for 5 consecutive weeks, followed by a tapering of three sessions during week 6 and two sessions during week 7. The TMS system will have three coils, one designated active and the other two unlabeled and identical in appearance, weight, and noises emitted, one of which will be active and one of which will be sham.
1569631|NCT02458495|Behavioral|Diabetes MAP Intervention|
1569632|NCT02458482|Device|AccuPAP|The AccuPAP device used by participants will give 2.5mg and 0.5mg nebulized Albuterol and Ipratropium over 5 minutes. Inspiratory and expiratory pressures to be set at 6 and 12 cm H20 respectively. This therapy is repeated at 20 and 40 minutes for a total of three AccuPAP treatments.
1569633|NCT02458482|Drug|Albuterol and Ipratropium Continuous Nebulizer|10mg Albuterol and 1.5mg Ipratropium continuous nebulizer treatment will be administered to a Control group over a one hour period.
1569634|NCT02458469|Drug|Buspirone|The initial dose of Buspirone is 15 mg daily (7.5 mg bid.). To achieve an optimal therapeutic response, at intervals of 2 to 3 days the dosage may be increased 5 mg per day until a maximum dose 30mg/day is reached.
1569635|NCT02458469|Drug|Trazodone|100 mg dose before bed-time
1569636|NCT02458469|Drug|Placebo|One placebo pill before bed-time
1569637|NCT02458456|Other|Isometric resistance training|Isometric exercise using a hand dynamometer.
1569638|NCT02458443|Other|Isometric resistance training|Isometric handgrip exercise using a hand dynamometer
1569639|NCT02458417|Device|ReCell|A split-thickness skin biopsy will be taken from the hip region of the patient. The skin biopsy that is obtained will be treated in the ReCell kit (Avita Medical Europe Ltd, Cambridge, UK): it will be placed in the heated enzyme solution, containing trypsin, in the device for 15-20 minutes to allow cell disaggregation. After that period, the biopsy will be taken from the enzyme solution and will be dipped in sodium lactate buffer solution. The biopsy will then be scraped to disaggregate the cells from the dermal epidermal junction. The epidermal cells are drawn up in a syringe. The prepared suspension will be dripped on both donor and acceptor site.
1569640|NCT02458417|Device|Full surface CO2 laser 200 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 200 mJ (depth 144 µm) and density 3
1569641|NCT02458417|Device|Full surface CO2 laser 150 mJ|Full surface pretreatment with the CO2 laser (Ultrapulse, ActiveFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 150 mJ (depth 144 µm) and density 3
1569642|NCT02458417|Device|Fractional CO2 laser 7.5 mJ, 20%|Pretreatment with the fractional CO2 laser (Ultrapulse, DeepFX handpiece, Lumenis Inc., Santa Clara, CA, USA) at 7.5 mJ/microbeam (depth 225 µm) and 20% density.
1569643|NCT02458404|Drug|Estradiol Valerate|"Participants will undergo three, separate endometrial preparatory cycles. These cycles will consist of estrogen supplementation to mimic normal, above normal, and highly elevated estradiol levels."
1569644|NCT02458404|Drug|Progesterone|Patients will receive 2 doses of 10mg of intramuscular progesterone on consecutive days
1569645|NCT02458404|Drug|Leuprolide acetate|Patients will begin leuprolide acetate in the luteal phase of the cycle immediately preceding the study cycle in order to down regulate the pituitary during the treatment cycle.
1569646|NCT02458391|Other|Standard of care complete decongestive therapy|Participants will receive standard of care complete decongestive therapy consisting of meticulous skin and nail care, manual lymphatic drainage, compression bandaging, remedial exercises and self-care training.
1569647|NCT02458365|Behavioral|Teen Choices: A Program for Healthy Nonviolent Relationships|A 3-session online, multimedia TTM-based intervention for teen dating violence prevention. For most students, the intervention seeks to reduce risk for dating violence by facilitating progress through the stages of change for using healthy relationship skills; daters are encouraged to use those skills in their dating relationships, and non-daters in their peer relationships, as relationships with peers serve as the foundation for experiences in romantic relationships. For victims of dating violence experiencing fear, the intervention does not focus on healthy relationship skills; instead, it seeks to facilitate progress through the stages of change for keeping oneself safe in relationships.
1569648|NCT02458365|Behavioral|Health In Motion|A 3-session online, multimedia, TTM-based intervention which targets physical activity, screen time, and healthy eating for obesity prevention. Health In Motion sessions were administered following the baseline, 6-month, and 12-month assessments to increase the benefits of study participation for Comparison schools and students.
1569649|NCT02458352|Device|Ultra low dose non-contrast enhanced CT|Non-contrast enhanced CT for CACS and AC using a novel protocol for ultra low dose radiation dose exposure
1569650|NCT02458352|Device|Standard dose non-contrast enhanced CT|Clinically indicated non-contrast enhanced CT for CACS and AC according to routine protocol
1569651|NCT02458339|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain
1569652|NCT02458339|Drug|Methotrexate|4, 6, or 8 mg into fourth ventricle of the brain via the Ommaya Reservoir for 2 days a week for 3 weeks with week 4 is a rest week. Each patient will undergo three cycles.
1569653|NCT02458326|Other|Aerobic training|Treadmill training with proper heart rate for aerobic workout to 20 minutes duration and frequency of three times a week for three months.
1569656|NCT02458313|Other|Placebo|Placebo capsules b.i.d. for 12 weeks
1569657|NCT02458300|Other|Nebulization of hypertonic saline|application of hypertonic saline serum through a mask fogging or a box fogging
1569658|NCT02458300|Other|Prolonged slow expiration technique (PSE)|Passive expiratory aid implemented baby. the child is placed supine on a hard surface. Thoracoabdominal slow manual pressure that begins at the end of a spontaneous and continuous exhalation to residual volume is exercised. Oppose reaches 2 or 3 breaths. Vibrations can accompany the art. The goal is to achieve a greater expiratory volume.
1569659|NCT02458300|Other|Patient coughing Provocation (TP)|Tp is based on the mechanism reflects cough induced by stimulation of the buttons on the wall of the trachea extrathoracic mechanoreceptors. The child is placed supine. A short pressure is done with the thumb on the tracheal conduit (in the sternal notch) at the end of inspiration, or at the beginning of expiration. With the other hand holding the abdominal region we prevent the dissipation of energy and make the explosion tussive more effective. It is done after the PSE.
1569660|NCT02458300|Other|inspiratory maneuver to rhinopharyngeal cleaning DRR|After the inspiratory reflection following the PSE, the TP or crying. At the end of expiratory time the child's mouth is closed with the back of his hand just finished his chest support, raising the jaw and forcing the child to an inspiration with the nose
1569661|NCT02458300|Other|Aspiration of secretions|Suctioning with a probe by a vacuum system installed on the wall.
1569666|NCT02458274|Other|Dosage of Microparticles (MPs) in broncho-alveolar lavage fluid (BALF)|
1569667|NCT02458248|Behavioral|Sodium Reduction|In addition to usual care, those randomised to the intervention arm will receive specific counseling on behavioural and environmental factors that promote sodium reduction after randomization and at all specified post-randomisation visits, targeting sodium intake of <100mmol/day (<2.3g/day). A research dietitian will develop the specific components of the intervention, based on standardised approaches to education interventions.
1569668|NCT02458235|Drug|azacitidine|40mg/m2 IV/SC daily x 4 days, maximum of 7 cycles at 6 weekly intervals
1569669|NCT02458235|Biological|donor lymphocyte infusion|For patients with cells available for DLI who are in the high risk group and do not have graft-versus-host disease (GVHD), DLI will be adminstered on day 5 of each cycle.
1569670|NCT02458222|Other|language game therapy|participants will take part in 3 different types of game therapy, differentiated by type of language facilitation offered, or no facilitation
1569671|NCT02458222|Other|standard therapy|usual clinical care
1569672|NCT02458209|Biological|bococizumab PFS:Pfizer|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Pfizer Andover
1569673|NCT02458209|Biological|bococizumab PFS: BIP|150 mg bococizumab administered SC in a prefilled syringe using drug substance manufactured at Boehringer Ingelheim Pharma.
1569674|NCT02458209|Biological|bococizumab PFP|150 mg bococizumab administered SC in a prefilled pen using drug substance manufactured at Pfizer Andover
1569675|NCT02458196|Drug|Prednisone|Prednisone: started with prednisone alone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, and maintained at 10mg/d to 12 months.
1569676|NCT02458196|Drug|Prednisone and Mycophenolate mofetil|"Prednisone: started with prednisone 0. 6-0. 8mg/kg.d for 1 month, decreased 5mg per 2 weeks, maintained at 7.5mg to 10mg/d to 12 months.
Immunosuppressive drugs: Mycophenolate mofetil 1g/d-1.5g/d for 6 months and 0.5/d-1.0g/d for 6 months."
1569677|NCT02458183|Biological|DTaP-IPV combination vaccine|0.5-mL IM
1569678|NCT02458183|Biological|DTaP vaccine and IPV vaccine|0.5-mL IM
1569679|NCT02458157|Drug|Furosemide (Furix)|"Loading dose: 40 mg I.V.
Infusion rate 40 mg/h
Continued until neutral cumulative fluid balance is achieved (the overall treatment goal) or average negative fluid balance is below 1 ml/kg/h for 8 hours."
1569680|NCT02458157|Other|Continuous renal replacement therapy (CRRT)|"Initiated in case of contraindications or inadequate effect of furosemide.
Fluid removal is started at 2 ml/kg/h
The efficacy is evaluated 3 times daily and removal rate increased by 0.5 ml/kg/h if the therapeutic goal is not achieved"
1569681|NCT02458157|Other|Resuscitation|"The physiologic response to fluid removal is monitored with three variables indicating inadequate circulation. These are:
Mottling beyond the edge of kneecaps
Hypotension (MAP < 50) resistant to inotropes and vasopressors
Plasma lactate ≥ 4 mmol/l
Mottling and MAP are monitored continuously and lactate is measured routinely 4-6 times each day and on clinical indication. If one or more variable is present:
Fluid removal is paused
A crystalloid fluid bolus of 250-500 ml is given
Circulatory status is reevaluated within 30 minutes
Step 1-3 is repeated until signs of inadequate circulation have been resolved for minimum 1 hour
Fluid removal is restarted in 25% reduced dose for minimum 4 hours before evaluation of effect."
1569682|NCT02458157|Other|Usual Care|"All interventions are performed at the discretion of the treating physician apart from initiation of renal replacement therapy which is discouraged unless one or more of the following criteria are met:
Hyperkalaemia (p-K+ > 6 mmol/l)
Severe metabolic acidosis attributable to AKI (pH < 7.25 and standard base excess < -10 mmol/l) resistant to IV bicarbonate infusion
Severe respiratory failure with PaO2/FiO2 < 13 kPa and bilateral infiltrates/oedema on the chest x-ray.
Progressive azotaemia and a blood urea nitrogen (BUN) > 25 mmol/l."
1569683|NCT02458144|Procedure|Total hip arthroplasty|"The minimally invasive anterior approach The patient is in supine position. The femoral neck is exposed in the interval between tensor fasciae latae, glutei medius and minimus muscles laterally, and sartorius and rectus femoris muscles medially. After osteotomy of the neck and extraction of the head the acetabulum is reamed to prepare for cup prosthesis. Following peritrochanteric capsulotomy the externally rotated, adducted and elevated femur is broached.
The MIS anterolateral approach The MIS anterolateral technique is a modified Watson-Jones Approach. The patient is in supine position. This approach uses the intermuscular plane between the gluteus medius and the tensor fascia latae. After the anterior capsule is excised, a disc of the femoral neck is removed."
1569684|NCT02458131|Behavioral|TEEN HEED|Peer-led workshops will cover behavioral skills including goal setting, self-monitoring, problem solving, contingency management, coping skills, and social support.
1569685|NCT02458118|Drug|Secretin|Secretin 1 IU/kg over 3 min
1569686|NCT02458105|Behavioral|Acceptance & Commitment Therapy|A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
1569687|NCT02458105|Behavioral|Attention|Supportive conversation at a frequency and length corresponding to the experimental condition.
1569688|NCT02458092|Biological|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
1569689|NCT02458092|Biological|Rabipur|Rabipur is a licensed rabies vaccine.
1569690|NCT02458079|Drug|Pentoxiphylline|
1569691|NCT02458079|Drug|Stool microbiota transplantation|
1569692|NCT02458066|Other|IRS: bendiocarb|carbamate insecticide
1569693|NCT02458066|Other|IRS: deltamethrin|Pyrethroid insecticide
1569694|NCT02458053|Behavioral|Attends with partner|The index partner will participate in intervention as a couple with their female counterpart.
1569695|NCT02458053|Behavioral|Couples Skill Training|Participants and their partners will attend a pre session covering topics to assist them in working together to facilitate lifestyle changes.
1569696|NCT02458053|Behavioral|Face to face group sessions|Group sessions will consists of components in traditional weight management programs.
1569697|NCT02458053|Behavioral|Self Monitor|Participants will be instructed to monitor their eating and physical activity behaviors online/mobile application.
1569698|NCT02458053|Other|Notebook|The notebook will consist of behavioral lessons, diet and physical activity plans, and additional resources to assist participants in achieving their behavioral goals.
1569699|NCT02458053|Behavioral|Feedback|Each participant will receive a tailored email providing feedback on their weekly progress.
1569700|NCT02458040|Drug|Drug selected in the study|
1569701|NCT02458027|Dietary Supplement|Hemp Shake|Hemp Protein Shake
1569702|NCT02458027|Dietary Supplement|Hemp Shake|Hemp Protein Shake
1569703|NCT02458027|Dietary Supplement|Soybean Shake|Soybean Protein Shake
1569704|NCT02458027|Dietary Supplement|Soybean Shake|Soybean Protein Shake
1569705|NCT02458027|Dietary Supplement|Control|Non-Protein Shake
1569706|NCT02458014|Drug|Blinatumomab|In first induction cycle, initial dose of Blinatumomab is 9 μg/day for the first 7 days of treatment by a central venous catheter, which then will be escalated (dose step) to 28 μg/day starting on day 8 (week 2) through day 29 (week 4). For all subsequent cycles, 28 μg/day is the dose for all 4 weeks of continuous treatment.
1569707|NCT02458014|Behavioral|Phone Calls|Participants called by study staff 1 time each month for up to 18 months after all participants have been enrolled in the study.
1569708|NCT02458001|Behavioral|SAFFRON stepped care|"Behavioral: SAFFRON stepped care Stepped care (Improving Access to Psychological Therapies, 2012; Richards et al., 2012) adapted for the gynaecological cancer setting to produce a 3-step model including a clinical assessment and treatment algorithm.
Assessment Algorithm FSFI Interventions
Level 1:
Best available self-help literature on psychosexual difficulties after cancer as judged by the project team and two patient advocates.
Level 2:
A 3-5 session manualised psycho-educational intervention delivered fortnightly by study trained CNSs with taping and supervision for adherence to protocol and manual.
Level 3:
16 weekly session manualised brief psychotherapy adaptation of InterPersonal Therapy, IPT (Interpersonal Psychotherapy for Sexual Adjustment post Gynaecological Cancer, IPT-APGyC)"
1569710|NCT02456883|Drug|gilteritinib|oral
1569711|NCT02456883|Drug|14C-labeled gilteritinib|oral
1569712|NCT02456870|Other|Overfeeding|Consumption of 40% excess calories for 7 consecutive days
1569713|NCT02456857|Drug|Everolimus|7.5 mg by mouth on Days 1 - 21 of each 21 day cycle.
1569714|NCT02456857|Drug|Liposomal Doxorubicin|30 mg/m2 by vein on Day 1 of each 21 day cycle.
1569715|NCT02456857|Drug|Bevacizumab|15 mg/kg by vein on Day 1 of each 21 day cycle.
1569716|NCT02456844|Drug|Montelukast, Flurbiprofen, Midazolam, Digoxin, Pravastatin and BMS-986142|"Montelukast 10-mg tablet: On Days 1 and 8,Single oral dose
Flurbiprofen 50-mg tablet: On Days 1 and 8,Single oral dose
Midazolam syrup 2.5 mL × 2 mg/mL (5 mg): On Days 1 and 8,Single oral dose
Digoxin (Lanoxin®) 0.25 mg tablet: On Days 1 and 8,Single oral dose
Pravastatin 40-mg tablet: On Days 1 and 8,Single oral dose
BMS-986142: On Days 6 through 12."
1569717|NCT02456844|Drug|Methotrexate, Leucovorin and BMS-986142|"Methotrexate (MTX) single oral dose of 3 × 2.5-mg tablet (Days 1 and 8)
Leucovorin single oral dose of 15-mg tablet (Days 2 and 9; 24 hours after MTX administration)
BMS-986142 on Days 6 through 10."
1569718|NCT02457949|Other|Non-synchronized social assistance receipt|Social assistance disbursement outside government cheque issue week
1569719|NCT02457949|Other|cheque divided into two equal disbursements|Social assistance disbursement divided into two equal payments
1569720|NCT02457936|Behavioral|Mindfulness Based Cognitive Therapy|8 weekly meetings in which basic mindfulness and meditation skills are taught, such as breathing meditation, body scan meditation, open awareness meditation, movement meditation, and targeting depression related cognitions and emotions in a mindful manner, as well as awareness exercises, group discussions, and daily home meditation practice routines
1569721|NCT02457923|Other|Mobile phone counselling|i) Data collection and counselling by ASHA using the cell application (App) developed by CommCare Dimagi ii) Mobile phone counselling iii) Routine counselling schedules
1569722|NCT02457910|Other|Biomarker Analysis|Correlative studies
1569723|NCT02457910|Drug|Enzalutamide|Given PO
1569724|NCT02457910|Other|Pharmacological Study|Correlative studies
1569725|NCT02457910|Drug|Taselisib|Given PO
1569727|NCT02457884|Other|Temporal Group|Visual Processing Training
1569728|NCT02457884|Other|Spatial Group|Spatial visual span training
1569729|NCT02457884|Other|Combined Group|Visual processing speed and spatial visual span training
1569730|NCT02457884|Other|Control Group|Leisure reading activities
1569731|NCT02457871|Behavioral|Ecological Nurse Case Management|The Ecological Nurse Case Management (ENCM) intervention allows for individualized case management based on client preferences through mutual goal setting and client choice points, nursing assessments, the nurse's analytic decision-making process and critical thinking, and nursing actions.
1569732|NCT02457858|Drug|Islet isolation using BMX-010|BMX-010 will be used as a supplement in islet isolation process.
1569733|NCT02457845|Biological|G207|Single dose of HSV-1 (G207) infused through catheters into region(s) of tumor defined by MRI
1569734|NCT02457832|Behavioral|Adapted Tango Dancing|Composed of simple steps, tango involves frequent movement initiation and cessation, multi-directional perturbations and varied rhythms. Participants focus on trunk control and stepping strategies, coordination, somatosensory awareness, attention to partner, path of movement, and aesthetics. Sessions will begin with a typical dance class warm-up consisting of breathing, limbering and postural alignment to upbeat music. Novel step elements will be introduced every class period. Those with PD will partner with an individual without PD. After novel step introduction, the instructor will present rhythmic training, which is indispensable to partnered dancing. Participants will learn 'typical' rhythms from tango and Latin dances, based upon the system of quicks (Q) and slows (S), ubiquitously used in ballroom dance training to understand the temporal relationship of movement to music.
1569735|NCT02457832|Behavioral|Behavioral Control (BC) Condition|Group health education sessions adapted to the needs of individuals with PD, about pharmacological management, nutrition, sleep disorders, cognitive deficits, bereavement coping, mobility, balance and home safety.
1569736|NCT02457819|Drug|Dasotraline|Dasotraline 2 mg, 4 mg, 6 mg, once daily, flexibly dosed
1569737|NCT02457806|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Active Spray with deliverable volume of 0.1 mL
1569738|NCT02457806|Drug|Placebo spray|Aqueous solution to deliver 0.1 mL per unit
1569739|NCT02457793|Drug|Cobimetinib|
1569740|NCT02457793|Drug|GD0-994|
1569741|NCT02457780|Behavioral|Relaxation Response Resiliency Program (3RP)|The 3RP is designed to decrease psychiatric and physical health symptoms and build resiliency by teaching skills to (1) elicit the relaxation response, (2) decrease stress reactivity and (3) increase social connectedness. Eliciting the relaxation response involves sustained mental focus with an attitude of receptive awareness with strategies aimed at reducing muscle tension, breathing rate, heart rate, and blood pressure. Decreasing stress reactivity involves increasing awareness of the stress response and learning skills to proactively address stress. Increasing connectedness involves skills to promote positive growth, self-efficacy and social support. Other skills and experiential exercises focus on increasing acceptance, optimism, empathy, and appreciation to promote resiliency.
1569742|NCT02457780|Behavioral|Health Enhancement Program (HEP)|The HEP is designed to address comorbid physical and mental health symptoms via psychoeducation, self-monitoring and goal setting techniques. It is an 8 session manualized group intervention which addresses topics including sleep hygiene, nutrition, exercise, working with a healthcare team, and substance use. The program uses a variety of in-session activities to engage participants in discussion related to self-care and wellness principles. Relapse prevention and long-term goal setting are addressed. The program is designed to be implemented by professionals with a background in mental health.
1569743|NCT02457728|Device|LiquiBandFix8|Using LiquiBandFix8 for mesh fixation and peritoneal closure following TAPP repair.
1569744|NCT02457702|Other|Orally administered labeled glycerol|Oral administration of labeled glycerol
1569745|NCT02457689|Biological|GTU®-MultiHIV B Clade Vaccine|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein) built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of an HAN2 HIV-1 B clade isolate.
1569746|NCT02457689|Other|Sodium chloride BP|For use in prophylactic and replacement therapy, requiring the use of isotonic saline solution.
1569747|NCT02457676|Behavioral|Alert Program for Self-Regulation|"Children attend 12 1.5 hour weekly sessions. Alert uses the analogy of a car engine to help children identify their own self-regulatory behavior. Children learn strategies to regulate their own engine speed in different situations."
1569748|NCT02457663|Procedure|Blood Draw|Blood is to be collected at admission, prior to the 1st operating procedure, once daily for the following 7 consecutive days, at day 15, and at discharge (11 blood draws total). Blood will be taken from IV catheter or routine venipuncture if the catheter is not in place. The blood draw will occur prior to the induction of anesthesia or operating surgical procedure.
1569749|NCT02457650|Drug|Cyclophosphamide|On days -7 through -6, Cyclophosphamide 60mg/kg/day IV will be infused over 60 minutes.
1569750|NCT02457650|Drug|Fludarabine|On days -5 through -1, Fludarabine 25mg/m2/day IV will be infused over 30 minutes.
1569751|NCT02457650|Biological|Anti-NY ESO-1 TCR-transduced T cells|Modified cells will be infused IV over 30 minutes.
1569752|NCT02457637|Other|standard treatment|
1569753|NCT02457624|Behavioral|Education and feedback|Experienced endoscopists will receive education on Kimura-Takemoto classification and feedback for their answers for classification tests.
1569754|NCT02457611|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
1569759|NCT02457585|Drug|remicade (anti tumor necrosis factor inhibitor)|single arm:remicade treatment group
1569760|NCT02457572|Procedure|Valsalva maneuver|Valsalva maneuver was performed after sternotomy with the constant airway pressure of 30cmH2O for 2 breaths duration.
1569761|NCT02457572|Other|Fluid loading|We record the cardiac index values before and after volume expansion with 6ml/kg of balanced crystalloid
1569762|NCT02457559|Drug|Tirabrutinib|Tablets or capsules administered orally
1569763|NCT02457546|Biological|EVICEL Fibrin Sealant|
1569764|NCT02457546|Device|Hydrogel sealant|
1569765|NCT02457533|Behavioral|Lifestyle behavioral. Health plan, telephone support|'Lifestyle behavioral. Health plan, telephone support'
1569800|NCT02457247|Drug|Adcal-D3|Adcal-D3 (Calcium 600mg/400 IU Vitamin D3)
1569766|NCT02457520|Drug|Isotretinoin|ABSORICA® (isotretinoin) capsules 0.5 mg/kg/day for 4 weeks followed by 1.0 mg/kg/day for 16 weeks
1569767|NCT02457507|Dietary Supplement|Vitamin B12|2 tablets
1569768|NCT02457507|Dietary Supplement|Placebo|2 tablets
1569769|NCT02457481|Device|Embryo Culture medium|Two step sequential embryo culture medium system
1569770|NCT02457468|Device|coflex|
1569771|NCT02457442|Drug|Propofol and Remifentanil|High propofol and low remifentanil, changing remifentanil (up-and-down method)
1569772|NCT02457442|Drug|Propofol and Remifentanil|Low propofol and high remifentanil, changing propofol (up-and-down method)
1569773|NCT02457442|Drug|Sevoflurane and Remifentanil|High sevoflurane and low remifentanil, changing remifentanil (up-and-down method)
1569774|NCT02457442|Drug|Sevoflurane and Remifentanil|Low sevoflurane and high remifentanil, changing sevoflurane up-and-down method)
1569775|NCT02457442|Drug|SPR 1|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.
SPR 1: Changing Propofol for skin incision."
1569776|NCT02457442|Drug|SPR2|"Triple combination with intermediate propofol and sevoflurane and intermediate remifentanil.
Changing Sevoflurane for skin incision."
1569777|NCT02457429|Device|Experiemental diagnostic procedure: Dx-pH measurement system|"The Dx-pH Measurement system (Dx-pH; Respiratory Technology Corp., San Diego, CA) is a sensitive and minimally invasive transnasal device for detection of aerosolized extra-oesophageal acid reflux in the posterior oropharynx.
The sterile single use Dx-pH catheter will be passed trans-nasally into the same nostril as the same nostril as the other catheter. The internal pH value of the oesophagus is then continuously measured and recorded onto a small ambulatory device. The 2 catheters are connected to the ambulatory recording devices and recording commences. The duration of the investigation is 24 hours."
1569778|NCT02457429|Other|Peptest assay|A saliva sample of 0.5-1 ml will then be taken for pepsin assay (Peptest). The saliva sample will be drawn into a micro-centrifuge tube (0.5ml) and centrifuged. 80 microlitres is taken from the supernatant layer, vortex mixed, then applied to the assay test strip. The result is obtained after 15 minutes. The saliva sample will then be securely disposed.
1569779|NCT02457429|Other|GORD symptom questionnaire|A validated 7 domain GORD symptom questionnaire (GSQ-YC) to quantify the GORD related symptoms their child suffers with is to be completed prior to any intervention.
1569780|NCT02457416|Other|Peanut|Treatment with peanut in increasing doses until a maintenance dose
1569781|NCT02457403|Device|ROTEM|Assess coagulopathy with ROTEM device compared to conventional laboratory tests. ROTEM will be used on all patients, however, determination of blood products used will be based on patient's randomization group.
1569782|NCT02457403|Other|Conventional Therapy|Assess coagulopathy with conventional laboratory tests (PT/INR, Hemoglobin, Platelet count). Conventional laboratory tests will be obtained on all subjects, however, determination of blood products used will be based on patient's randomization group.
1569783|NCT02457390|Procedure|CE-LUS|"To assess the use of contrast enhanced LUS during robot assisted primary CRC surgery. Does CE-LUS detect any unrecognized liver metastases.
The patient will get a contrast-enhanced CT scan 3 month after surgery as a control to the CE-LUS procedure."
1569784|NCT02457377|Procedure|laparoscopic cerclage|The vesico-uterine peritoneum is opened & the urinary bladder is dissected downwards . Both needles are passed through the lower uterine tissue medial to uterine vessels on the right & left sides . Then, both needles are passed through the remaining cervical tissue medial to uterosacral ligaments towards the posterior vaginal fornix (on the right & left sides) guided by laparoscopic illumination . When the needles' blunt ends pierce the vaginal vault, the assistant pull them through the posterior vaginal fornix . After trimming of both needles, the Mersilene tape is tied tightly behind the intravaginal segment of the cervix with five knots &
1569785|NCT02457351|Drug|Roniciclib (BAY 1000394)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 mg Cycle 1 Day 6: Single dose 2.5 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single dose 2.5 or 5 mg (based on Part 1 data) Cycle 1 Day 6: Single dose 2.5 or 5 mg (based on part 1 data)
Part 1 & Part 2
Cycle 2 and subsequent 21-day cycles:
Day 1-3 of each cycle: 5 mg bid Day 4-7 of each cycle: no dose"
1569786|NCT02457351|Drug|Itraconazole (Sporanox)|Part 1 & Part 2 of Cycle 1 Cycle 1 Day 4: 200 mg bid Cycle 1 Day 5-11: 200 mg qd
1569787|NCT02457338|Dietary Supplement|Bifidobacterium|
1569790|NCT02457312|Drug|Letrozole|letrozole 10 mg daily for 7 days before suction evacuation
1569791|NCT02457312|Drug|Placebo|placebo tablets which look identical to the letrozole tablets for 7 days before suction evacuation
1569792|NCT02457299|Procedure|Two Stage Esophagectomy|Patients will undergo laparoscopic staging and ischemic gastric conditioning and pyloric Botox injection 7-10 days prior to an esophagectomy with gastric pull-up reconstruction
1569793|NCT02457299|Procedure|One Stage Esophagectomy|Patients will undergo an esophagectomy with gastric pull-up reconstruction without any preconditioning.
1569794|NCT02457286|Drug|Metformin|Although metformin is FDA approved to treat type 2 diabetes, it is not FDA approved for the treatment of NAFLD and is considered investigational for the purpose of this study.
1569795|NCT02457286|Behavioral|Lifestyle modifications|Recommendations for lifestyle modification will be based on the Diabetes Prevention Program 2002 (26) and will include recommendations for greater than 150 minutes of physical activity weekly, referrals to group and/or individualized sessions with nutritionists and/or lifestyle coaches as well as educational materials
1569796|NCT02457286|Device|Fibroscan device (Echosens)|This study will be incorporating the use of a Fibroscan device (Echosens) at the initial visit and upon completion of the study, which works by measuring shear wave velocity.
1569797|NCT02457273|Drug|TLC 388|40 mg/m2 of TLC 388, given as a 30 (+3) minute intravenous infusion, on Days 1, 8 and 15 of a 28-day cycle until PD, unacceptable toxicity or consent withdrawal occurs.
1569798|NCT02457260|Drug|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg three times daily for 4 weeks
1569799|NCT02457247|Drug|Calcichew D3|Calcichew D3 500/400 (Calcium 500 mg/400 IU Vitamin D3) Calcichew D3 500/800 (Calcium 500 mg/800 IU Vitamin D3)
1569801|NCT02457247|Drug|Kalcipos-D|Kalcipos-D (Calcium 500mg/800 IU Vitamin D3)
1569802|NCT02457234|Behavioral|Cultural immersion|The primary intervention was the cultural immersion within CIC. Unique to the Traditions study were culturally-adapted nutrition lessons incorporated into CIC and UDC. CIC had a high cultural dose as the Traditions lessons were implemented within the cultural immersion context of the camp. The UDC had moderate cultural dose from the Traditions lessons only. RSC was without cultural immersion and Traditions lessons or had zero cultural dose.
1569810|NCT02457195|Drug|granisetron|Application granisetron transdermal patch preoperatively
1569813|NCT02457169|Behavioral|Parent Preschool Engagement intervention|This 1-2 session intervention (2-4 hours total) will involve one-on-one session(s) for parents whose children (all of whom have received a diagnosis of ASD through our study) are turning 3 and therefore transitioning from the Early Intervention system to the public school special education system. The intervention will utilize motivational interviewing (MI) principles to equip parents with the skills, knowledge, and clarity of goals necessary to collaborate effectively with school special education staff and teachers, to advocate for their children's needs, and to be empowered to navigate the special education system.
1569814|NCT02457169|Behavioral|Attention Control|The attention control condition is parallel in format (one-on-one between parent with interventionist) and intensity (1-2 sessions, or 2-4 hours total). It involves open-ended interviews with parents about their child's development and plans for school.
1569818|NCT02457143|Behavioral|Letter|
1569819|NCT02457143|Behavioral|Phone call|
1569820|NCT02457130|Drug|Ticagrelor|
1569821|NCT02457130|Drug|Clopidogrel|
1569822|NCT02457117|Radiation|CyberKnife Stereotactic Accelerated Partial Breast Irradiation (CK-SAPBI)|Five fraction radiation therapy to the lumpectomy cavity
1569823|NCT02457104|Procedure|Colonoscopy|Patients selected from those undergoing screening colonoscopy. During colonoscopy, stool aspirates and biopsies will be taken from the terminal ileum, cecum, and sigmoid colon.
1569824|NCT02457104|Behavioral|Weight and diet questionnaire|Brief questionnaire outlining weight history, type and dose of PPI, and diet.
1569825|NCT02457091|Behavioral|Resistance exercise|strength training consists of 1-3 sets , 10-15 repetitions of 10 exercises targeting lower body, upper body and core muscle groups
1569826|NCT02457091|Behavioral|Stretching exercise|The stretching condition will consist of 1-3 sets, 30-40 seconds of 12 stretching movements targeting lower body, upper body, and core areas performed 2 days per week.
1569827|NCT02457078|Dietary Supplement|Postnatal Dietary Supplement|Dietary Supplement: docosahexaenoic acid, lutein, and α-tocopherol (vitamin E). 1 capsule per day will be consumed beginning immediately after birth and continuing for 9 months.
1569828|NCT02457078|Dietary Supplement|Control Supplement|Placebo Supplement:soybean oil and α-tocopherol (vitamin E)
1569829|NCT02457065|Behavioral|Sun protection behaviors|We give the patients a small 3.5 by 2 inch wooden plaque that celebrates their survival of melanoma and reminds them to engage in skin-protective behaviors
1569830|NCT02457052|Device|DATP|Medical device allowing a custom sitting to help patients with swallowing disorders
1569831|NCT02457039|Procedure|Dense cranial electroacupuncture stimulation|"DCEAS is a is a novel stimulation mode in which electrical stimulation is delivered on acupoints located on the forehead.
Six pairs of acupoints are used: Baihui (GV20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8).
Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation, followed by electrical stimulation (ITO ES-160, continuous waves at 2 Hz)."
1569832|NCT02457039|Procedure|Body acupuncture|"Following acupoints are used: Shui-Gou (GV26), Shen-Men (HT7). He-Gu (LI4), Wai-Guan (TE5), Zhong-Wan (CV12), Guan-Yuan (CV4), Zu-San-Li (ST36), Feng-Long (ST40) and San-Yin-Jiao (SP6).
Disposable acupuncture needles (Hwato®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm perpendicularly or obliquely into acupoints. Manual manipulation is then conducted to evoke needling sensation. No electrical stimulation is delivered."
1569833|NCT02457039|Procedure|Least acupuncture stimulation|The acupoints chosen are less related to the treated syndromes based on Traditional Chinese Medicine (TCM) theory; the number of acupoints used and the intensity of electrical stimulation are also lower than the comprehensive acupuncture regimen. The following 6 acupoints will be used in LAS control: bilateral Tong-Tian (GB17), bilateral Shou San-Li (LI10) and bilateral Fu-Yang (BL59). Electrical stimulation will be only performed on bilateral Tong-Tian (GB17) and the intensities are adjusted to a level at which patients just start feeling the stimulation.
1569834|NCT02457039|Drug|Cytoxan-containing chemotherapy regimens|"Each subject shall receive oral administration or venous injection or both with adjuvant or neoadujuvant chemotherapy regimens, as decided by clinical oncologist.
In clinical practice, the most commonly used Cytoxan-containing regimens include but are not limit to:
AC (x4) [Adriamycin + Cytoxan], TC (x4) [Taxotere + Cytoxan], AC-P (4+4) [Adriamycin + Cytoxan + Paclitaxel], TAC (x6) [Taxotere + Adriamycin + Cytoxan], or AC-PH (4+4) [Adriamycin + Cytoxan + Paclitaxel + Herceptin]."
1569835|NCT02457026|Drug|Aflibercept|Aflibercept is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1.
1569836|NCT02457026|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic corticosteroid indicated for treatment of ocular inflammatory conditions, uveitis, sympathetic ophthalmia, and temporal arteritis.
1569837|NCT02457026|Drug|Verteporfin|Verteporfin is a benzoporphyrin derivative, and is a medication used as a photosensitizer for photodynamic therapy.
1569838|NCT02457013|Device|HFNC|Hygh flow nasal canula HFNC
1569839|NCT02457013|Device|nCPAP|nasal nCPAP
1569840|NCT02456987|Device|Samsung Gear|Intervention arm will be exposed to a series of virtual reality experiences using the Samsung Gear hardware one time during their inpatient stay at Cedars-Sinai.
1569841|NCT02456974|Procedure|blood sampling in patients receiving amoxicillin-clavulanate as part of routine clinical care|
1569842|NCT02456974|Procedure|blood sampling in patients receiving piperacilline-tazobactam as part of routine clinical care.|
1569843|NCT02456974|Procedure|blood sampling in patients receiving vancomycin as part of routine clinical care.|
1569844|NCT02456974|Procedure|blood sampling in patients receiving teicoplanin as part of routine clinical care.|
1569845|NCT02456974|Procedure|blood sampling in patients receiving meropenem as part of routine clinical care.|
1569846|NCT02456974|Procedure|blood sampling and urine smapling in patients receiving ciprofloxacin as part of routine clinical care.|
1569847|NCT02456974|Procedure|blood sampling in patients receiving amikacin as part of routine clinical care.|
1998715|NCT01046305|Behavioral|Rating Questionnaire|Questionnaire developed in Part 1 to rate the relevance of symptom items, given to 3-5 physicians, 3-5 nurses, 2-4 patients and their family caregivers, taking about 10 minutes.
1998716|NCT01046305|Behavioral|MDASI-CML Questionnaire|Patient questionnaires about CML symptoms over 1 year, completed in person or using Interactive Voice Response (IVR) system every 2 weeks.
1569855|NCT02456948|Drug|Minocycline|6 weeks 200mg/day Minocycline add-on
1569856|NCT02456948|Drug|Placebo|6 weeks Placebo add-on
1569857|NCT02456935|Drug|CJ-12420 100 mg QD|CJ-12420 100 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of CJ-12420 100 mg.
1569858|NCT02456935|Drug|Esomeprazole 40 mg QD|Esomeprazole 40 mg tablets will be orally administered, once daily, for up to 8 weeks. For subjects whose erosive esophagitis is not endoscopically healed at Week 4, subjects will receive additional 4 week treatment of Esomeprazole 40 mg.
1569859|NCT02456922|Device|Harmony 1 Sensor|Use of Harmony 1 Sensor over 10 days in arm and abdomen and used with the Guardian Mobile App in subjects aged 2-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
1569860|NCT02456909|Device|Patient-Controlled Analgesia pump with Cues|The end of the lockout period will be cued via the PCA pump
1569861|NCT02456909|Device|Patient-Controlled Analgesia pump without Cues|The PCA pump will be programmed such that no cues will be provided to the end of the lockout period.
1569862|NCT02456909|Drug|Morphine|Morphine will be administered for post-operative pain in both the Cues and Non-Cues groups
1569864|NCT02456831|Other|Experimental Infant Formula 1|method A phytate reduction and 5% protein hydrolysis
1569865|NCT02456831|Other|Experimental Infant Formula 2|method A phytate reduction and 10% protein hydrolysis
1569866|NCT02456831|Other|Experimental Infant Formula 3|method B phytate reduction and 5% protein hydrolysis
1569867|NCT02456831|Other|Active Comparator: Control Infant Formula|Ready-to-Feed (RTF) Soy Infant Formula
1569868|NCT02456805|Other|Infant Formula 1|Feed ab libitum
1569869|NCT02456805|Other|Infant Formula 2|Feed ab libitum
1569870|NCT02456792|Procedure|IVF|Women will undergo one IVF cycle
1569871|NCT02456792|Procedure|LOD|Women will be subjected to LOD followed by ovarian stimulation if spontaneous ovulation does not occur within 2 months
1569872|NCT02456779|Other|in vitro diagnostic test (Peptest)|saliva samples obtained and tested in laboratory conditions for the presence of pepsin using Peptest
1569873|NCT02456779|Other|Questionnaire|all recruited subjects to complete the RDQ as a determinant of inclusion criteria
1569874|NCT02456779|Other|Questionnaire|control subjects to complete RSI as a determinant of inclusion criteria
1569875|NCT02456766|Device|FibroTouch|
1569876|NCT02456766|Procedure|Liver Biopsy|
1569877|NCT02456753|Device|trans-perineal ultrasonography|Assesment of the fetal head-perineum distance via a trans-perineal ultrasonography
1569878|NCT02456740|Drug|AMG 334|Investigational Product
1569879|NCT02456740|Drug|AMG 334|Investigational Product
1569880|NCT02456740|Drug|Placebo|Placebo Comparator
1569881|NCT02456727|Procedure|Group/Community Acupuncture|Acupuncture treatment in a group setting.
1569882|NCT02456727|Procedure|Individual Acupuncture|Acupuncture treatment in an individual setting.
1569883|NCT02456714|Drug|FOLFIRINOX|
1569884|NCT02456701|Biological|KTN3379|IV every 2 weeks
1569885|NCT02456701|Drug|vemurafenib|960 mg po bid
1569886|NCT02456688|Drug|Imrecoxib|
1569887|NCT02456675|Drug|INCB040093 Monotherapy|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
1569888|NCT02456675|Drug|INCB040093|INCB040093 sustained release (SR) tablets will be administered orally twice daily (BID) without regard to food.
1569889|NCT02456675|Drug|itacitinib|The dose of itacitinib will be given orally once daily (QD).
1569890|NCT02456662|Drug|Ondansetron|8mg PO ondansetron 30 minutes prior to 200mg PO doxycycline
1569891|NCT02456662|Drug|Placebo|placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
1569892|NCT02456649|Device|MarginProbe|Intraoperative MarginProbe use as adjunct to standard practice MarginProbe will be used on the lumpectomy specimen within 20 minutes of excision, prior to specimen Xray or gross pathology evaluation. This may take up to 5 minutes. MarginProbe will indicate a positive or negative reading for each of the 6 circumferential margins, and the results will be recorded. Any margins determined by to < 5-10 mm by specimen Xray or gross pathology examination will be re-excised. In addition, any additional margins not already identified as < 5-10 mm, but identified as positive by MarginProbe will be re-excised where feasible.
1569896|NCT02456623|Behavioral|Intervention|Home-based session targeting the parent
1569897|NCT02456623|Behavioral|Attention Control|Attention condition with newsletters and support phone calls
1569898|NCT02456610|Biological|CMV/EBV specific CTLs|Patients will receive approximately 1x10e6 CTLs/kg as a single infusion via IV injection and may receive 1 to 8 additional infusions at intervals of one week.
1569899|NCT02456597|Drug|lidocainhydrochlorid|Lidocaine injected through the novel Catheter
1569900|NCT02456597|Drug|Isotonic Saline|Isotonic saline injected through the novel Catheter
1569901|NCT02456584|Drug|DMPA 150|injectable contraceptive
1569902|NCT02456584|Drug|DMPA 300|injectable contraceptive
1569903|NCT02456584|Drug|DMPA 104|injectable contraceptive
1569904|NCT02456571|Device|CTC biomarker expression prevalence|
1569905|NCT02456558|Drug|Intravenous deferiprone|In Cohort 1, the subjects who were randomized to get active product will receive deferiprone at a dose of 1.5 g per infusion, and if there are no significant safety concerns, the subjects in Cohort 2 who were randomized to get active product will receive it a a dose of 2 g per infusion.
1569906|NCT02456558|Drug|Placebo|In both cohorts, the subjects who were randomized to get placebo will receive an infusion of placebo solution that is equal in volume to that of the active product.
1569907|NCT02456545|Other|≥ 1 potential risk factor for BD|exposure to ≥ 1 potential risk factors for BD (e.g. (sub)threshold affective symptomatology, anxiety, sleep disturbances, family history, episodic substance misuse)
1569908|NCT02456545|Other|depressive syndrome|in- and outpatients with depressive syndrome
1569909|NCT02456545|Other|ADHD|in- and outpatients with ADHD
1569910|NCT02456532|Drug|placebo|
1569911|NCT02456532|Drug|Zolpidem CR|
1569912|NCT02456532|Drug|Eszopiclone|
1569913|NCT02456519|Other|PaedQoR-15 questionnaire|Children/ young people and one parent/ guardian will complete the questionnaire before and after general anaesthesia for surgery or diagnostic imaging.
1569914|NCT02456506|Radiation|Hyperfractionated IMRT|
1569915|NCT02456506|Radiation|Conventional Fraction IMRT|
1569916|NCT02456480|Drug|CLS001|topical gel
1569917|NCT02456480|Drug|Vehicle|topical gel
1569918|NCT02456454|Drug|Risperidone|Liquid risperidone
1569919|NCT02456454|Drug|Valproic Acid|Liquid valproic acid
1569920|NCT02456454|Drug|Placebo Valproic Acid|PCB
1569921|NCT02456441|Other|Intervention group|"The device current generator TENS used was  Neurodyn Portable Tens / Fes  of IBRAMED brand. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used. Through a chain of 1Hz, the aim is to correctly identify the tibial nerve. This position is confirmed with the rhythmic movement of the finger flexion. The frequency is then changed to 10Hz, the pulse width set at 200 microseconds and adjusted according to the intensity threshold for each patient, below motor threshold. This current generator also has a device, the VIF (variation in intensity and frequency) that aims to ease the accommodation of sensory receptors and enhance its effects. The application time is 30 minutes"
1569922|NCT02456441|Other|Placebo group|The placebo group received an active current for 15 seconds by means of an apparatus also IBRAMED brand externally similar to that used in GI. Two self-adhesive electrodes, one immediately behind the medial malleolus and the other 10 cm above will be used.The application time for GP also was 30 minutes .
1569923|NCT02456428|Drug|DPP-4 inhibitors|Current exposure to DPP-4 inhibitors (ATC A10BH, A10BD07-A10BD13) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1569924|NCT02456428|Drug|GLP-1 analogs|Current exposure to GLP-1 analogs (ATC A10BX04, A10BX07) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1569925|NCT02456428|Drug|Insulins|Current exposure to insulin (ATC A10A) will be defined as any use of insulin between base cohort entry and the index day.
1569926|NCT02456428|Drug|Biguanides|Current exposure to biguanides (ATC A10BA) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1569927|NCT02456428|Drug|Sulfonylureas|Current exposure to sulfonylureas (ATC A10BB or A10BC) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1569928|NCT02456428|Drug|Thiazolidinediones|Current exposure to thiazolidinediones (ATC A10BG) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1569929|NCT02456428|Drug|Alpha-glucosidase inhibitors|Current exposure to alpha-glucosidase inhibitors (ATC A10BF) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index day.
1569930|NCT02456428|Drug|Meglitinides|Current exposure to meglitinides (ATC A10BX02, A10BX03) will be defined as a prescription duration plus a 30-day grace period (to account for non-adherence and the biological half-lives of these drugs) that overlaps with the index (event)day.
1570014|NCT02455739|Other|chewing gum|postoperative gum chewing to improve gastrointestinal function
1569931|NCT02456415|Device|K-MET™ Bioresorbable Bone screw|The biodegradable screw inserted into bone with an appropriate driver is slowly degraded and is completely degraded after completion of bone union and absorbed into the body. The screw is indicated for fixing damaged bone.
1569932|NCT02456402|Device|Drug Coated Balloon|If post balloon angioplasty FFR is more than 0.80, either DCB treatment or BMS implantation will be carried out based on randomization of 1:1. DCB (SeQuent Please paclitaxel-coated balloon catheter, B. Braun, Melsungen, Germany) will be applied at the predilated lesions. PCB will be delivered rapidly and inflated for 60 seconds with nominal pressure.
1569933|NCT02456402|Device|Bare Metal Stent|BMS (Vision®) will be applied at the predilated lesions after angiographic confirmation of the target lesion.
1569934|NCT02456389|Other|Preoperative risk stratification|Preoperative risk-prediction tool based on patient demographics/co-morbidity and planned procedure
1569935|NCT02456389|Other|Postoperative risk stratification|Postoperative risk-prediction tool based on intraoperative variables
1569936|NCT02456389|Other|Risk-based, escalating levels of care|Postoperative observation in regular unit vs. telemetry unit vs. stepdown unit vs. ICU
1569937|NCT02456389|Other|Risk-based, escalating levels of monitoring|Varying frequencies of vital signs monitoring Varying use of telemetry, pulse oximetry, and early warning system
1569938|NCT02456389|Other|Risk-based, escalating levels of co-management|Varying use of Hospitalist co-management
1569939|NCT02456389|Other|Standard postoperative care|Routine postoperative care, as medically indicated
1569940|NCT02456376|Procedure|Sensory Integration Testing|Investigate how sensory information are integrated during upright stance when visual and body senses are challenged in a virtual reality environment
1569941|NCT02456376|Procedure|SR stimulation & Sensory integration testing|Use SR stimulation to improve sensory integration when visual and body senses are challenged in a virtual reality environment
1569942|NCT02456363|Biological|TNF alpha|Depending on patient need to use different TNF alpha
1569943|NCT02456363|Drug|NSAIDs and sulfasalazine|randomized case, combine with use of NSAIDs(-/+) and sulfasalazine(-/+)
1569944|NCT02456350|Drug|Fludarabine|On days -5 through -3, Fludarabine 30mg/m2 IV will be infused over 30 minutes.
1569945|NCT02456350|Drug|Cyclophosphamide|On days -5 through -3, Cyclophosphamide 300mg/m2 IV will be infused over 60 minutes followed by fludarabine.
1569946|NCT02456350|Biological|Anti-CD19-CAR transduced T cells|Modified cells will be infused IV over 30 minutes (2-4 days after the last dose of fludarabine).
1569947|NCT02456337|Device|Mucograft|Coronally advanced flap associated to Xenogenous collagen matrix graft (mucograft) for the treatment of gingival recessions Miller Class I or II.
1569948|NCT02456337|Device|Emdogain|Coronally advanced flap associated to Enamel Matrix Derivative (Emdogain) for the treatment of gingival recessions Miller Class I or II.
1569949|NCT02456337|Procedure|Coronally Advanced flap|Coronally advanced flap for the treatment of gingival recessions Miller Class I or II.
1569950|NCT02456324|Device|PICS-AF Device|This is a specialized closure system for anorectal fistulas that is sphincter sparing
1569951|NCT02456324|Device|Historical Controls Treated with Commercially Available Fistula Plugs|These are patients previously treated with commercially available fistula plugs.
1569952|NCT02456311|Device|HARMONIC ACE+7|Pulmonary artery sealing with Harmonic Ace+7 in open lobectomy in humans
1569953|NCT02456298|Behavioral|Standard FA+FCT|Standard Functional Analysis and Functional Communication Training
1569954|NCT02456298|Behavioral|Pragmatic FA+FCT|Pragmatic Functional Analysis and Functional Communication Training
1569955|NCT02456285|Procedure|Primary/Bowel-first Surgery|Patients undergoing primary/bowel-first surgery as part of a staged curative procedure. The liver metastases will be resected in a second planned operation.
1569956|NCT02456285|Procedure|Liver-first surgery|Patients undergoing liver-first surgery as part of a staged curative procedure. The colorectal primary will be resected in a second planned operation.
1569957|NCT02456285|Procedure|Synchronous resection surgery|Patients undergoing a synchronous colorectal primary resection and liver resection in a single operation.
1569958|NCT02456285|Procedure|No surgery|Patients who have no surgery.
1569959|NCT02456272|Device|External hearing aid|The external hearing aid (monaural) with an auditory prosthesis contour type, brand PHONAK type Bolero Q70 will be provided to the patients during a minimum of 2 months.For reasons of standardization and comparability of results, only one type of prosthesis (medium-high range) will be provided. The settings will be performed by audiologists of ENT service during the inclusion visit.
1569960|NCT02456272|Procedure|Otosclerosis surgery|Surgical restoration of the columellar effect consists of the intraoperative verification of the stapedo-vestibular ankylosis which provides diagnostic. Then a stapedotomy (laser or Ototool°) is performed and partial ossicular prosthesis s inserted between stapedotomy and the long process of the incus.
1569961|NCT02456259|Procedure|Neck cannula insertion|Neck cannula insertion is necessary for establishing of cardiopulmonary bypass for Minimally Invasive Cardiac Surgery. It is routine procedure for this type of cardiac surgery.
1569962|NCT02456246|Procedure|FLT-PET|Positron emission tomography scan using the 18f-FLT (3'deoxy-3'-fluorothymidine) tracer
1569963|NCT02456233|Procedure|Conventional AF Ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation (PVI) alone
1569964|NCT02456233|Procedure|FIRM-guided ablation plus PVI|Substrate ablation for AF, via ablation of rotors and focal sources. Conventional (PVI) ablation will also be performed.
1569965|NCT02456220|Device|Herbst appliance|Group treated with conventional Herbst appliance for mandibular advancement during orthopedic treatment.
1569966|NCT02456207|Drug|SCT400|
1569967|NCT02456207|Drug|Rituximab|
1569968|NCT02456194|Device|Calcium Sulfate + Antibiotics + Internal Fixation|STIMULAN Rapid Cure, mixed with antibiotic, and prepared in bead form. Must be used in conjunction with internal fixation. Choice of antibiotic is left to the surgeon's discretion.
1569969|NCT02456181|Behavioral|JumpMath|
1569970|NCT02456155|Procedure|placing nasal jejunal tube with ultrasound|bedside placing nasal jejunal tube with ultrasound confirmation versus placing endoscopically
1569971|NCT02456155|Procedure|placing nasal jejunal tube endoscopically|
1569972|NCT02456142|Drug|caudal bupivacaine|
1569973|NCT02456142|Drug|intravenous morphine|
1569974|NCT02456129|Drug|Vilaprisan (BAY1002670)|single oral doses of 4 mg tablet Vilaprisan, administered once without the comedication of ITZ (period 1) and once with the comedication of ITZ (period 2)
1569975|NCT02456129|Drug|[14C] Vilaprisan|an intravenous microtracer dose of [14C]Vilaprisan administered together with the 1st single oral dose of Vilaprisan
1569976|NCT02456129|Other|Itraconazole(ITZ)|Itraconazole(ITZ) 200 mg as solution, once daily for 14 days
1569977|NCT02456116|Device|acupuncture/PCA/NSAID|"standard program with defined points:
Ear acupuncture needles bitten once (day 0-5)
Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5 - 1 cm, with DeQI feeling/sensation is released"
1569978|NCT02456116|Device|sham acupuncture/PCA/NSAID|"standard program with defined points:
Ear acupuncture needles bitten once (day 0-5)
Body acupuncture, once a day 20 minutes (day -1/ 0/ 2/ 4), depth of the prick 0.5"
1569979|NCT02456116|Other|PCA/NSAID|standard boli of morphine by pressing a button of PCA
1569980|NCT02456103|Drug|Ataluren|
1569981|NCT02456077|Behavioral|Multimodal Vaccine Program|Efforts will be made to collaborate with pediatric and family medicine offices to utilize a multimodal intervention to improve adolescents' HPV immunization rates. As part of the overall intervention, four intervention strategies will be used: 1) a tailored website, iVac -HPV , 2) Motivational Interview Training for providers, 3) HPV Fact Sheets and 4) The Decision Aid for HPV Vaccines
1569982|NCT02456064|Behavioral|Lifestyle counseling|"Group medical visits
Telephone medical consultations
Expert patient
Training workshops"
1569983|NCT02456038|Drug|Asfotase Alfa (ALXN1215)|
1569984|NCT02456025|Drug|Topical tacrolimus|Topical tacrolimus 0.01% twice daily for one month
1569985|NCT02456012|Drug|oral esomeprazole 20 mg twice daily|for 36 weeks
1569986|NCT02456012|Drug|oral esomeprazole 20 mg once daily|for 36 weeks
1569987|NCT02455999|Drug|SYL1001|SYL1001 eye drops dose C administration for 10 consecutive days
1569988|NCT02455999|Drug|SYL1001|SYL1001 eye drops dose D administration for 10 consecutive days
1569989|NCT02455999|Drug|Placebo|Placebo eye drops administration for 10 consecutive days
1569990|NCT02455986|Behavioral|The StepSmart Challenge|A six month pedometer based intervention designed to increase Physical Activity in school children
1569991|NCT02455973|Behavioral|Lifestyle modification and cardiovascular risk|Group meetings will be performed in the presence of a member of the nursing staff, physiotherapy, nutrition and psychology. The meetings are weekly, lasting 1 hour and 45 minutes. In the first 1 hour and 15 minutes will be addressed health issues related to lifestyle modification (self-care, healthy eating and physical activity) using the fundamentals of motivational interviewing technique. All topics will be focused on the major cardiovascular risk factors considered modifiable.Likewise, it is envisaged to include a time of physical activity (30 minutes) oriented in conjunction with the research team. Run in: There will be a meeting with the parents in order to inform them about the participation of children in the program and guide them about the procedures of the research protocol.
1569992|NCT02455973|Behavioral|Health Education|The meetings will be weekly with 45 minutes duration on a schedule of lectures about cardiovascular risk
1569993|NCT02455960|Dietary Supplement|L-arginine|Comparison of the efficacy of L-arginine 3 grams for days versus placebo in contrast induced AKI prevention
1569994|NCT02455960|Dietary Supplement|Placebo|
1569995|NCT02455947|Other|Inquiry Based Stress Reduction (IBSR)|During a 12-week intervention program, participants will be encouraged to identify and inquire their stressful thoughts.All the sessions were standardized according to a training manual, and were assessed after each session for maintaining consistency in the program.
1569996|NCT02455934|Dietary Supplement|D-allulose|Eligible subjects will come for visit 1 to consume varying dose of D-allulose with sucrose beverage with 1 of 5 beverages in a random order which will be blinded for both subjects and investigators. They will have to do 24-hour dietary record a day prior to each visit. Subjects have to be abstained from energy diet within 8 hours prior to each visit. Venous blood samples will be collected 6 mL for measurement of FPG and insulin before taking any study product. Subjects have to drink all within 1 minute. Blood samples will be drawn again 6 mL at 30, 60, 90 and 120 min after consumption for measurement of PG and insulin. Every subject will be asked to come back to finish OSTT with 5 study products in a random order, each at 7 days or >5 days and <12 days apart.
1569997|NCT02455921|Drug|neostigmine - atropine|Efficacy, safety and effect on cognitive and behavioural function
1569998|NCT02455921|Drug|Sugammadex|Efficacy, safety and effect on cognitive and behavioural function
1569999|NCT02455908|Drug|Proleukin®|
1570000|NCT02455895|Device|iLid Cleanser|Application of iLid Cleanser to reduce bacterial load on the lid and lash margins
1570001|NCT02455869|Drug|SRP and Placebo gel|After SRP, placebo gel was delivered subgingivally into the pocket
1570002|NCT02455869|Drug|SRP and Atorvastatin|After SRP, Atorvastatin gel was delivered subgingivally into the pocket
1570003|NCT02455869|Drug|SRP and Alendronate|After SRP, Alendronate gel was delivered subgingivally into the pocket
1570004|NCT02455856|Drug|JNJ-42847922|Participants will receive single dose of 5 milligram (mg) JNJ-42847922 as 5 mg/milliliter [mL] oral solution on Day 1 and Day 6.
1570005|NCT02455856|Drug|Itraconazole|Participants will receive single dose of itraconazole as 200 mg (2*100 mg capsule) from Day 2 to Day 6.
1570006|NCT02455843|Other|Microwave ablation|Patients assigned to the combination group will be treated with microwave in the primary tumor site
1570007|NCT02455830|Biological|Autologous cord blood cell therapy|The neonates receive their own non-cryopreserved volume- and red blood cell-reduced cord blood cells. The cord blood cells are divided into 3 doses and intravenously infused at 12-24, 36-48, and 60-72 hours after the birth.
1570008|NCT02455804|Device|Stenting procedure|All subjects will be treated with the NIRxcell Stent System and followed at 30 days, 9 months and 1, 2 and 3 years post-index stenting procedure. An unscheduled follow up may be conducted as clinically warranted.
1570009|NCT02455791|Procedure|Ultrasound-Guided Biopsy|Ultrasound-guided biopsy of tumor site. A needle is inserted into the affected area using an ultrasound to collect cells or tissue from a tumor mass. Two (2) types of samples collected.
1570010|NCT02455778|Dietary Supplement|Cinnamon|
1570011|NCT02455778|Dietary Supplement|Placebo|
1570012|NCT02455765|Other|Rice and Amino Acid mixtures|Rice and amino acid mixture
1570013|NCT02455752|Procedure|LE-TME|Retroperitoneal approach for total mesorectal excision
1570015|NCT02455726|Dietary Supplement|Magnesium oxide|Oral magnesium oxide 300 mg twice a day
1570016|NCT02455726|Dietary Supplement|Fructose|Oral fructose 10 g twice a day
1570017|NCT02455726|Drug|Oxycodone|Oxycodone hydrochloride 5 mg at 8 am
1570018|NCT02455726|Drug|Pregabalin|Pregabalin 25 mg at 8 pm
1570019|NCT02455713|Device|PEEP and PIP|Changing ventilator settings and measuring oxygen delivery and cardiac output
1570020|NCT02455700|Device|Interproximal Enamel Reduction|removal of enamel between lower incisor teeth as part of orthodontic treatment plan to achieve the aims of treatment
1570021|NCT02455687|Drug|Intravenous magnesium sulfate|
1570022|NCT02455687|Drug|Inhaled budesonide|
1570023|NCT02455687|Drug|normal saline|
1570024|NCT02455661|Device|TR Band (TM)|
1570025|NCT02455661|Device|AngioSeal(R)|
1570026|NCT02455648|Procedure|ESD/EMR plus Cell Sheet|"Patients receive ESD/EMR plus CellSheet:
Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) that are inserted 2 weeks later on the occasion of the ESD or EMR"
1570027|NCT02455648|Procedure|ESD/EMR|"only ESD/EMR: Autologous oral mucosa/buccal-derived epithelial cells, cultured on temperature-sensitive membrane (Cell Sheet) but NOT used for insertion in the patient during/after ESD/EMR two weeks later"
1570028|NCT02455635|Procedure|office hystroscopy|Office hysteroscopythrough vaginoscopic approach was done in gynecology out-patient clinic using a 4 mm endoscopic sheath & 30 ᵒ endoscopic camera with saline distension medium using 90-100 mmHg pressure
1570029|NCT02455622|Drug|Elaprase for intravenous (IV) infusion|Patients enrolled in this study will receive once-weekly IV infusions of Elaprase at a dose of 0.5 mg/kg and will be followed for a minimum of 5 years after initiation of Elaprase treatment, or until they reach their 10th birthday, whichever is longer.Height and weight data from HOS will be utilized in the Primary Growth Analysis for this study.
1570030|NCT02455609|Procedure|intrathecal drug administration|pre-emptive intrathecal administration of analgesic medications for control of postoperative pain.
1570031|NCT02455609|Drug|Dexmedetomidine|
1570032|NCT02455609|Drug|ketamine|
1570033|NCT02455609|Drug|Bupivacaine|
1570034|NCT02455596|Drug|Recombinant anti-tumor and anti-virus protein for injection (Novaferon)|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times for first week,followed by 20μg for two weeks, and followed a maintenance dose of 30μg, the frequency of administration is three times per week.
1570035|NCT02455583|Behavioral|Project AIM (Adult Identity Mentoring)|Project AIM consists of 14 sessions that are delivered twice a week. Each session is 40 minutes long.
1570036|NCT02455570|Other|No intervention|No intervention
1570037|NCT02455557|Other|Laboratory Biomarker Analysis|Correlative studies
1570038|NCT02455557|Drug|Montanide ISA 51 VG|Given SC
1570039|NCT02455557|Biological|Sargramostim|Given SC
1570040|NCT02455557|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
1570041|NCT02455557|Drug|Temozolomide|Given PO or IV
1570042|NCT02455518|Drug|Oxycodone/acetaminophen|
1570043|NCT02455518|Drug|Hydrocodone/acetaminophen|
1570044|NCT02455518|Drug|Codeine/acetaminophen|
1570045|NCT02455518|Drug|Ibuprofen/acetaminophen|
1570046|NCT02455505|Behavioral|background questionnaire|
1570047|NCT02455505|Behavioral|bereavement risk screening tool|
1570048|NCT02455492|Other|stroke or myocardial infarction or pneumonia|There are three main exposure groups with exposure defined as a binary variable (yes/no): Stroke in the six months prior to surgery; Myocardial infarction in the six months prior to surgery; Pneumonia in the six months prior to surgery
1570049|NCT02455479|Biological|dAd5GNE Vaccine|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
1570050|NCT02455479|Biological|Placebo|dAd5GNE Vaccine or Placebo dAd5GNE Vaccine
1570051|NCT02455453|Drug|18F-FFNP|
1570052|NCT02455453|Device|CTI/Siemens Biograph 40 PET/CT Scanner|"Will include (1) 18-FDG-PET/CT scan
Will include (2) 18F-FFNP-PET/CT scans"
1570053|NCT02455453|Drug|Estradiol|
1570054|NCT02455453|Drug|18F-FDG|
1570055|NCT02455440|Drug|Esmolol|effect of esmolol on intraoperative fluctuations of propofol and sevoflurane. Propofol and sevoflurane intraoperative concentration will be expressed as mean ± SD. Differences in categorical data will be evaluated using the student t test.
1570056|NCT02455440|Drug|Placebo|
1570057|NCT02455440|Drug|Propofol and sevoflurane|
1570058|NCT02455427|Device|Active tDCS|Active tDCS will be applied with the anode positioned over the ipsilesional primary motor cortex and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
1570059|NCT02455427|Other|Physical Therapy|Physical therapy will be administered for 60 minutes
1570060|NCT02455427|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
1570061|NCT02455401|Drug|High dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 1.0 mcg/kg for 2 minutes
1570062|NCT02455401|Drug|Low dose remifentanil|Intervention: continuously intravenous infusion of remifentanil 0.1 mcg/kg/min after bolus injection of remifentanil 0.5 mcg/kg for 2 minutes
1570063|NCT02455401|Drug|No remifentanil|Intervention: no remifentanil will be administrated
1570064|NCT02455388|Dietary Supplement|High added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with high (25%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
1570065|NCT02455388|Dietary Supplement|Low added sugar diet|Controlled feeding study. Participants will be provided with daily coolers containing foods with low (5%) added sugar to consume for 7 consecutive days. Fasting fingerstick blood samples and weight checks will be performed each morning.
1570066|NCT02455362|Drug|Morphine sulfate|Treatment with sustained-release morphine sulfate is given as one double-blind capsule in the morning.
1570067|NCT02455362|Drug|Placebo|
1570068|NCT02455336|Drug|Fenofibrate|Fenofibrate is a peroxisome proliferator-activated receptor alpha agonist that is demonstrated to reduce triglyceride concentrations in the blood.
1570069|NCT02455336|Other|No intervention|A cohort of participants will be randomized to receive no study drug, but will engage in study encounters.
1570070|NCT02455323|Other|Suboccipital inhibitory|According to this technique, the suboccipital musculature is palpated until contact is made with the posterior arch of the atlas, and progressive and deep gliding pressure is applied, pushing the atlas anteriorly. The occiput rests on the hands while the atlas is supported by the fingertips. Finger pressure must be maintained for 10 minutes to produce the therapeutic effect of inhibiting the suboccipital soft tissues. The aim is to suppress spasm of the muscles and in general of the suboccipital soft tissues which are responsible for any dysfunctional mobility of the occiput, atlas, or even the axis.
1570071|NCT02455323|Other|Spinal manipulative|This technique is performed along an imaginary vertical line passing through the odontoid process of the axis. No flexion or extension and very little lateroflexion are used. Application is bilateral. First, cephalic decompression is performed lightly, followed by small circumductions. Selective tension is applied to take up tissue slack and create a firm joint barrier. Manipulation is then performed with rotation towards the manipulated side in a helicoidal cranial movement. This technique is designed to correct a generalized dysfunction with the aim of restoring occiput, atlas, and axis joint mobility
1570072|NCT02455323|Other|Combined treatment|Consisted in applying the above two techniques using exactly the same sequence: first the SI technique, and then the SM technique.
1570073|NCT02455323|Other|Control group.|The subjects received no treatment, but attended the same number of sessions, maintaining the resting position for longer than the experimental groups, and underwent the same evaluations (test for arterial compromise, and the three assessments).
1570075|NCT02455297|Drug|Copanlisib (BAY80-6946)|Starting dose 60 mg (dose reduction due to toxicities to 45 mg allowed). Administered in slow IV bolus on days 1, 8 and 15 of each 28 day cycle until disease progression or until another criterion is met for withdrawal from study treatment.
1570076|NCT02455284|Device|MRI|In vivo MRI with B0 cartography, FLAIR, 3D T1 anatomic images, DWI, and Tractography from DWI images
1570077|NCT02455271|Drug|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
1570078|NCT02455258|Other|Dance/Movement Therapy (DMT)|Each DMT session follows a similar structure of Opening, Warm up, Development, Cool Down and Closure. Various themes dedicated to an aging population are addressed by the supervising dance/movement therapist through movement activities and using support material (i.e., props, music). This group is provided in a group setting of maximum 10 participants at a time and occurs 3 times per week for 1 hour each session over the course of 12 weeks.
1570079|NCT02455258|Other|Aerobics Exercise (AE)|The aerobics exercise program is composed of warm up exercises followed by cardiovascular training on a recumbent bicycle. The intensity is set and progressively increased using each participants' individualized maximal aerobic power obtained in the baseline VO2 evaluation. This program respects the recommendations made by the American College of Sports Medicine and their adaptations for aging populations. Each session is supervised by a kinesiologist with 2 participants at a time. The training occurs 3 times per week for 1 hour each session over the course of 12 weeks.
1570080|NCT02455245|Drug|Carboplatin|
1570081|NCT02455245|Drug|Vincristine|
1570082|NCT02455232|Procedure|upper limb muscle block|
1570083|NCT02455232|Drug|4cc of lidocaïne®|
1570084|NCT02455219|Device|Prototype UHRSZ (UltraHigh Resolution Smart Zoom) Collimator|In DATScan SPECT scans, the UHRSZ collimator will be exchanged for the standard collimator following completion of the clinically ordered scan. A scanning sequence will be repeated with the prototype collimator in place. Images from the two scanning sequences will be compared.
1570085|NCT02455206|Behavioral|physical activity counseling|5 face-to-face sessions a 30 minutes during 12 weeks pulmonary rehabilitation program.
1570086|NCT02455206|Behavioral|Usual care|
1570087|NCT02455193|Behavioral|Exercise|
1570088|NCT02455193|Behavioral|Diet|
1570089|NCT02455180|Drug|Ascorbic Acid|Patients receive vitamin C 4 times in either high (5g) or moderate (1g) dose. Vitamin C will be administered intravenously (ascorbinezuur CF 100 mg/ml, Centrafarm BV, Etten Leur, Netherlands) in 50ml of NaCl 0.9%, infused over 30 minutes.
1570090|NCT02455167|Drug|Simeprivir (SMV)|Experimental Single arm study. All participants will get the same treatment.
1570091|NCT02455167|Drug|Sofosbuvir (SOF)|Experimental Single arm study. All participants will get the same treatment.
1570092|NCT02455167|Drug|Ribavirin (RBV)|Experimental Single arm study. All participants will get the same treatment.
1570093|NCT02455154|Drug|Letrozole|Letrozole endocrine therapy for 2.5mg qd po.
1570094|NCT02455154|Drug|Zhongyaofufang|Traditional Chinese Medicine for patients with Osteoporosis
1570095|NCT02455154|Drug|Xianlinggubao|Traditional Chinese Medicine for patients with Osteoporosis
1570096|NCT02455141|Drug|Epirubicin plus Cyclophosphamide|Epirubicin 90mg/m2, d1, q3w*4 Cyclophosphamide: 600mg/m2, d1, q3w*4
1570097|NCT02455141|Drug|Taxanes|Paclitaxel: 80mg/m2, d1, qw*12 or Docetaxel: 80-100mg/m2,d1,q3w*4
1570098|NCT02455141|Drug|Taxanes plus Carboplatin|Paclitaxel: 80mg/m2, d1,d8,d15, q4w*4 Carboplatin AUC=2, d1,d8,d15, q4w*4 or Docetaxel: 75mg/m2,d1,q3w*4 plus Carboplatin AUC=5-6, d1, q3w*4
1570099|NCT02455128|Other|Therapeutic listening|Method of responding to others in order to encourage better communication and clearer understanding of personal concerns.
1570100|NCT02455115|Other|Alternating mean arterial pressure|In normovolemic patients directly after liver transplantation, target mean arterial pressure is altered using norepinephrine according to study protocol.
1570101|NCT02455115|Drug|Norepinephrine|Infusion rate of norepinephrine is raised and lowered, respectively, in order to reach MAP 60, 75 and 90 mmHg in patients already requiring vasopressor for adequate blood pressure control.
1570102|NCT02455115|Drug|Chromium ethylenediaminetetraacetic acid|Extraction of 51Cr-EDTA measured for FF and GFR
1570103|NCT02455102|Other|Electronic warning alert|A newly-installed warning system for stroke prevention in atrial fibrillation.
1570137|NCT02454764|Drug|Tenofovir + Interferon alpha 2b|
1570104|NCT02455089|Other|GADD34 RNA level measurement.|"Blood analysis including GADD34 RNA level measurement is performed every 3 months up to 1 year for SLE patients.
A modal including physical exam, standard biological results and GADD34 RNA level is correlated to a SLE flare occurence in the next 3 months."
1570109|NCT02455050|Drug|Carboxymethylcellulose Sodium Based Eye Drops|1 to 2 drops of Carboxymethylcellulose Sodium Based Eye Drops [New Eye Drop Formula] in each eye.
1570110|NCT02455050|Drug|Systane® Gel Drops|1 to 2 drops of Systane® Gel Drops in each eye.
1570111|NCT02455050|Drug|Genteal® Lubricant Gel Drops|1 to 2 drops of Genteal® Lubricant Gel Drops in each eye.
1570112|NCT02455037|Other|Neck Strengthening|Targeted neck strengthening exercises
1570113|NCT02455011|Biological|REMD-477|
1570114|NCT02454998|Other|orthodontic treatment|Braces on the upper dental arch previous to surgical alveolar bone grafting. the goal is optimizing the structure of dental-alveolar structure.
1570115|NCT02454972|Drug|lurbinectedin (PM01183)|
1570116|NCT02454959|Device|GFF MDI (PT003) with Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) with Aerochamber Plus Valved Holding Chamber
1570117|NCT02454959|Device|GFF MDI (PT003) without Aerochamber|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI) without Aerochamber Plus Valved Holding Chamber
1570118|NCT02454933|Drug|AZD9291|Once daily tablet 80 mg
1570119|NCT02454933|Drug|MEDI4736|10mg/kg q2w (IV) infusion
1570120|NCT02454907|Other|Communication with the clinic|Over the course of the study, subjects will receive brief periodic communications on their cellular phone from the doctor's office.
1570121|NCT02454894|Drug|lidocaine|surface anesthesia with lidocaine
1570122|NCT02454894|Procedure|postoperative management|lying without the pillow for half an hour after lumbar puncture
1570123|NCT02454881|Drug|Dexmedetomidine|
1570124|NCT02454881|Drug|Oxycodone|
1570125|NCT02454868|Drug|Remifentanil|Remifentanil for intubation without neuromuscular blockade
1570126|NCT02454855|Drug|melatonin|"Oral supplementation with melatonin (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line chemotherapy.
Melatonin supplementation is achieved by the administration of (Circadin) at a dose of 2 mg / day according to its MA form of prolonged-release tablet of 2 mg."
1570127|NCT02454855|Drug|placebo|Oral supplementation with placebo (tablets) will be administered for 3 months once daily , 1-2 hours before bedtime. It will start on the day of the first administration of the new line chemotherapy.
1570128|NCT02454842|Drug|TH-4000 (Tarloxotinib)|TH-4000 (Tarloxotinib) is a hypoxia-activated prodrug
1570129|NCT02454829|Other|questionnaire|A questionnaire will be send concerning the patient's ovarian function since the cryopreservation procedure i.e: progression of puberty, menstrual cycle, hormonal treatment, desire for pregnancy, occurence of pregnancy, details of pregnancy, need for ART (Artificial Reproductive Techniques), and about the patient's satisfaction concerning the cryopreservation procedure. Data collected will be correlated with treatments received.
1570130|NCT02454816|Device|Single HIV RDT and single syphilis RDT|It is a diagnostic intervention, at the cluster level This arm includes a single (separate) rapid test for HIV and Syphilis. In this case pregnant women enrolled are sampled with two drops of blood (one for each cassette). Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
1570131|NCT02454816|Device|Dual HIV/syphilis RDT|It is a diagnostic intervention, at the cluster level. This arm includes a dual rapid test for HIV and syphilis, which means that in the same cassette will be available the information about the results for both conditions. In this case pregnant women enrolled are sampled with one drop for the cassette, which is enough to get both of the results. Positive patients for syphilis are treated immediately and reactive patients for HIV continue with their diagnostic algorithm, in any case patients receive appropriate counseling
1570132|NCT02454790|Radiation|Radiotherapy|
1570133|NCT02454777|Behavioral|Exercise Intervention|Undergo HIT
1570134|NCT02454777|Other|Laboratory Biomarker Analysis|Correlative studies
1570135|NCT02454777|Other|Quality-of-Life Assessment|Ancillary studies
1570136|NCT02454777|Other|Questionnaire Administration|Ancillary studies
1998721|NCT01035372|Dietary Supplement|dried plum powder|subjects will have 25% of their diet substituted by dried plum powder
1998733|NCT01012817|Other|Laboratory Biomarker Analysis|Correlative studies
1998734|NCT01012817|Other|Pharmacogenomic Study|Correlative studies
1998735|NCT01012817|Other|Pharmacological Study|Correlative studies
1998736|NCT01012817|Drug|Topotecan Hydrochloride|Given IV
1998737|NCT01012817|Drug|Veliparib|Given PO
1998738|NCT01009437|Drug|ritonavir|"Phase I: Dose escalation will be used with 3 levels of ritonavir given - 200 mg twice a day (bid), 400 mg bid, and 600 mg bid.
Phase II: Dose will be maximum tolerated dose from Phase I."
1998739|NCT01009437|Procedure|therapeutic conventional surgery|Tissue collection is from all patients, including the control, phase I and phase II patients.
1570138|NCT02454764|Drug|Tenofovir disoproxil Fumarate|
1570139|NCT02454751|Drug|fentanyl|One time dose of 50mcg of fentanyl administered intranasally
1570140|NCT02454738|Radiation|Ultralow dose chest CT scan|Ultralow-dose chest CT scan is performed using a 64-row multidetector CT system (Discovery CT750HD; GE Healthcare, Waukesha, WI) with 1.25-mm-thick axial slices at less than 1 mSv (volume computed tomography dose index: 0.39 milligray).
1570141|NCT02454725|Behavioral|Social Network|Leaders of social networks will undergo small group training to develop skills to convey information effectively and deliver messages endorsing regular HIV testing to members of their social networks.
1570142|NCT02454725|Behavioral|Comparison|All participants will receive HIV counseling and rapid testing following the Wisconsin Department of Health guidelines. Sexually active men who receive a negative test result will be told that they should be HIV-tested every three to six months, unless they have a monogamous HIV negative partner
1570143|NCT02454712|Drug|PF614|PF614 is an oxycodone prodrug
1570144|NCT02454712|Drug|Oxycodone extended-release|Oxycodone extended-release is the comparator drug
1570145|NCT02454699|Drug|MBX400|MBX-400, a white to off-white crystalline powder, will be given orally x 7 days to 4 cohorts. Cohort 1 receives 100 mg/day, Cohort 2 receives 350 mg, Cohort 3 receives 750 mg, Cohort 4 receives 1000 mg.
1570146|NCT02454699|Other|Placebo|Placebo capsules are supplied as white opaque, hard gelatin capsules filled with microcrystalline cellulose. 2 subjects from each cohort receive Placebo orally once per day x 7 days.
1570147|NCT02454660|Behavioral|SMS (Text messages)|Up to 1 text message a day. The artificial agent will determine whether to send a message each day. If it sends a message, it will also determine which of five message types to send.
1570148|NCT02454647|Drug|Induction chemotherapy|
1570149|NCT02454647|Radiation|Radiotherapy with concurrent chemotherapy|
1570150|NCT02454647|Procedure|Salvage surgery|
1570151|NCT02454634|Drug|IDH1 peptide vaccine|
1570152|NCT02454621|Behavioral|Volitional help sheet|Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
1570155|NCT02454595|Behavioral|Registry|Physician will complete a series of four questionnaires to capture the treatment decisions based upon standard clinical-pathological information and with the addition of the result of genomic testing (Prolaris test).
1570156|NCT02454582|Device|Somanetics INVOS Cerebral Oxymeter 5100C|Non- invasive transcranial near infrared cerebral oxygenation with or without CPAP
1570157|NCT02454556|Drug|FOLITIME®|
1570158|NCT02454556|Drug|Gonal-F®|
1570159|NCT02454543|Procedure|Radical prostatectomy|Study participants randomized in the intervention arm receive best systemic therapy in addition to radical prostatectomy with extended lymphadenectomy. It is not crucial whether the radical prostatectomy is performed open or robot-assisted.
1570160|NCT02454543|Drug|Best systemic therapy|"For the antiandrogenic therapy a non-steroidal antiandrogen (e.g. flutamide, bicalutamide) or a gonadotropin-releasing hormone (GnRH) analogues (e.g. goserelin, leuprolide) are available.
The selection of best systemic therapy is up to the judgment of the treating urologist."
1570161|NCT02454530|Biological|Nivestim®|
1570168|NCT02454504|Drug|sugammadex|
1570169|NCT02454504|Drug|Neostigmine|
1570170|NCT02454491|Drug|Heparin|intraradial administration of heparin 5000 ui
1570171|NCT02454491|Drug|Verapamil|intraradial administration of verapamil 5 mg
1570172|NCT02454478|Drug|Lenvatinib|
1570173|NCT02454478|Drug|Everolimus|
1570174|NCT02454465|Other|Acceptance and Commitment Therapy group|Six week, Acceptance and Commitment Therapy group for those with adjustment difficulties following an acquired/traumatic brain injury or other neurological condition.
1570175|NCT02454452|Procedure|Radiofrequency|Radiofrequency treatment applied to the vein with VNUS Closure Fast catheter
1570176|NCT02454452|Procedure|Saphenous vein stripping|Saphenous vein stripping
1570177|NCT02454452|Procedure|CHIVA|conservative hemodynamic treatment venous insufficiency
1570178|NCT02454439|Other|CRT implantation|
1570179|NCT02454426|Drug|Vortioxetine|open label treatment
1570180|NCT02454413|Other|denture brushing with water and soap|denture brushing with water and soap
1570181|NCT02454413|Other|ultrasonic denture cleaning|ultrasonic denture cleaning
1570182|NCT02454413|Other|cleansing tablet|addition of a cleansing tablet to the water in which the dentures are stored overnight
1570183|NCT02454400|Other|Pre-surgery physiotherapy|"Physiotherapy guided intervention twice a week for nine weeks. The program includes:
Active physiotherapy according to a treatment based classification:
Specific exercises and mobilization
Motor control exercises
Traction
Tailor-made general supervised exercise program
Behavioral approach to reduce fear avoidance and increase activity level.
Standardized information about:
the surgery
post-surgery rehabilitation
to stay active"
1570184|NCT02454400|Other|Waiting-list|"Standardized information about:
the surgery
post-surgery rehabilitation
to stay active"
1570185|NCT02454387|Drug|ONO-4474 Part A1|Healthy volunteers
1570186|NCT02454387|Drug|Placebo Part A1|Healthy volunteers
1570187|NCT02454387|Drug|ONO-4474 Part A2|Healthy volunteers
1570188|NCT02454387|Drug|Placebo Part A2|Healthy volunteers
1570189|NCT02454387|Drug|ONO-4474 Part B|Healthy volunteers
1570190|NCT02454387|Drug|Placebo Part B|Healthy volunteers
1570191|NCT02454387|Drug|ONO-4474 Part C|Healthy volunteers
1570192|NCT02454387|Drug|Placebo Part C|Healthy volunteers
1570193|NCT02454387|Drug|ONO-4474 Part D|Healthy volunteers
1570194|NCT02454387|Drug|Placebo Part D|Healthy volunteers
1570195|NCT02454374|Procedure|Knee Loading protocol|The clinician will review the patient at follow up appointments a further two to four times during the treatment period (dependent on symptom resolution/response), progressing to the next level of exercises or by increasing intensity, duration or repetitions as appropriate (each participant will be asked to maintain a home treatment diary sheet). The physiotherapist will encourage compliance during the treatment period and beyond.
1570196|NCT02454374|Procedure|Routine Physiotherapy Care|Routine Physiotherapy Care
1570197|NCT02454361|Drug|KBP-7072|KBP-7072
1570198|NCT02454361|Drug|Placebo|Placebo
1570199|NCT02454348|Drug|Vasopressin|Subjects will receive vasopressin (0.04 units/min) by continuous infusion to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
1570200|NCT02454348|Drug|Norepinephrine|Subjects will receive norepinephrine (0.05 to 0.5 mcg/kg/min) by continuous infusion with titration by bedside nurse to achieve and maintain a target mean arterial pressure (65-75 mm Hg). The treating physician may choose the initial dosage of norepinephrine within the initial range of 0.05-0.5 mcg/kg/min. The treating physician may alter the target mean arterial pressure if clinically indicated.
1570202|NCT02454322|Drug|Magnesium Sulfate|Standard of care Magnesium Sulfate given to women with a diagnosis of a hypertensive disorder of pregnancy.
1570203|NCT02454309|Dietary Supplement|Cranberry concentrate|
1570204|NCT02454309|Dietary Supplement|Placebo|
1570205|NCT02454296|Drug|Paracervical Block with lidocaine|Performance of paracervical block, using 18 mL of 1% lidocaine buffered with 2 mL 8.4% sodium bicarbonate, prior to laminaria insertion
1570206|NCT02454296|Drug|Sham paracervical block|A capped needle will be placed on the cervix prior to laminaria insertion for purposes of blinding both the participant and research staff assessing outcomes
1570207|NCT02454283|Drug|Vanoxerine HCl|
1570208|NCT02454283|Drug|Placebo|
1570209|NCT02454270|Drug|Part 1 (Dose Escalation): Duvortuxizumab|Participants currently enrolled in the study will continue to receive duvortuxizumab every 14 days (biweekly dosing) in each 28 ‑day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8 and Day 22, of a 35-day Cycle 1, and then every 14 days in each subsequent 28-day cycle. The cohorts will be opened where participants will receive duvortuxizumab every 7 days (for investigating weekly dosing schedule) in each 28‑day cycle as an intravenous infusion. In the priming dose regimen, a priming dose will be administered on Day 1 followed by full doses on Day 8, Day 15, Day 22, and Day 28 of a 35-day Cycle 1, and then every 7 days in each subsequent 28-day cycle.
1570210|NCT02454270|Drug|Part 2 (Dose Expansion): Duvortuxizumab|Participants will receive intravenous infusion of duvortuxizumab at the recommended Phase 2 dose (RP2D) defined in Part 1 for their disease type either with or without a priming dose.
1570211|NCT02454244|Behavioral|ART with Mindfulness|"Introduction of ART with Mindfulness. Visualization of 100% recovery
Developing Fibromyalgia and CFS. How stress triggers the central nervous system. The benefits of Mindfulness in chronic stress. Mindfulness Practice. Breathing meditation
The ART. Breaking the negative thoughts related to the illness. Walking meditation
Mindfulness and the Body Scan. Breaking the cycle of stress. Body-scan meditation
Mindfulness and self-compassion. Kindly awareness meditation
The accelerator of ART. Behaviors related to CFS and Fibromyalgia. Metta meditation
Aware of negative thoughts related to stress stimulus. Mindfulness in daily activities
Limiting beliefs, identity patterns. Motivation and sense of life. Meditation on values
The recovery, cycles and stages. Fear of fail about recovery. Positive Visualization of future self
Return to regular life. Mindfulness practice"
1570212|NCT02454244|Behavioral|Mindfulness Compassion|"Introduction.Definition of Compassion
Self-Esteemed and Compassion
Cultivate the understanding of the nature of inner experience. Working positive and negative thoughts.Connecting with difficult emotions
Identifying the causes of suffering.How participants contribute to their own suffering. Attachments.Practice of Vulnerability
Love,affection and self-compassion.How participants connect with the suffering of others
Equanimity
Forgiveness
Interdependence. Gratitude.Affection to unknown people
Developing affection and empathy.Empathy and burn out
Review of the practices and meditations"
1570213|NCT02454244|Behavioral|Relaxation|10 sessions based on relaxation techniques as active comparator intervention
1570214|NCT02454231|Biological|Transplantation of circulating CD14+CD34+cells|intramuscular injection of circulating EPC at leg level
1570215|NCT02454231|Biological|Transplantation of BM MNC|intramuscular injection of BM MNC at leg level
1570216|NCT02454218|Device|Transcranial Direct Current Stimulation|"The intervention session with tDCS lasts for 20 minutes. tDCS uses rubber electrodes that are within sponges that are moistened with saline. These electrodes are placed on the participant's head. Through these electrodes will pass a weak electrical current that can at most cause mild itching at the site where the electrode is positioned. The generated electric current is equivalent to a small common battery that we use to run toys or radios. The procedure does not require that the patient be subjected to shocks, cuts or surgery.
The participant will receive active tDCS or placebo, but receive both types of intervention during the performance of the two sessions."
1570217|NCT02454205|Drug|Linezolid|600mg Linezolid po daily, reduced to 300mg po daily if toxicity occurs.
1570218|NCT02454205|Drug|Bedaquiline|400mg po daily for 2 weeks, followed by 200mg three times per week .
1570219|NCT02454205|Drug|Levofloxacin|750mg (<50kg) 1000mg (>50kg)
1570220|NCT02454205|Drug|Pyrazinamide|1000-1750mg (40-50kg) 1750-2000mg (51-70kg) 2000-2500mg (71-90kg)
1570221|NCT02454205|Drug|Isoniazid|high dose Isoniazid 500mg (40-50kg) 750mg (51-70kg) 750-1000mg (71-90kg)
1570222|NCT02454205|Drug|Ethionamide|15mg/kg (max 900mg)
1570223|NCT02454205|Drug|Terizidone|750mg (40-70kg) 750-1000mg (71-90kg)
1570224|NCT02454205|Drug|Moxifloxacin|400mg po daily.
1570225|NCT02454205|Drug|Kanamycin|500-750mg (40-50kg) 1000mg (51-90kg) intramuscular daily during 6-8 month intensive phase.
1570226|NCT02454192|Behavioral|CHAMPS|
1570227|NCT02454179|Drug|pembrolizumab|
1570228|NCT02454179|Drug|Acalabrutinib|
1570229|NCT02454166|Other|Ischemic stroke TCM syndromes Diagnostic Scale|A scale for Chinese medical differentiation
1570230|NCT02454166|Other|Meridian Energy Analysis Device|A Device to assess involving meridian in certain diseases
1570231|NCT02454153|Device|REMStar Postive Airway Pressure|Positive airway pressure therapy is the standard of care for managing obstructive sleep apnea
1570232|NCT02454153|Behavioral|LifeStyle Counseling|Lifestyle guidelines developed by the American Diabetes Association for weight loss will be provided to all subjects.
1570233|NCT02454140|Radiation|SBRT|Fixed five-fraction stereotactic radiotherapy
1570234|NCT02454127|Behavioral|Atkins Diet|Dietary counseling for 1 year
1570235|NCT02454127|Behavioral|Zone Diet|Dietary counseling for 1 year
1570236|NCT02454127|Behavioral|Weight Watchers Diet|Dietary counseling for 1 year
1570237|NCT02454127|Behavioral|Ornish Diet|Dietary counseling for 1 year
1570238|NCT02454114|Other|HOMEFIRST|HOMEFIRST patients receive monitoring and review of; vital signs, symptoms, mental state, nutrition and hydration, urine output, skin turgor and integrity, mobility, coping ability, medication concordance, smoking and nutrition and hydration. Individualised verbal and written self-management plans, a list of symptoms (including red flag symptoms) to prompt contact with the study team and a 24hr emergency contact number are provided. Clinical bloods and other investigations will be taken/requested as necessary. Questionnaires will be completed as follows; SF-12 - at recruitment and 6 weeks, CAP-SYM - at recruitment and 6 weeks. Satisfaction questionnaires are conducted over the telephone at 2 wks by an independent assessor. As part of usual clinical practice patients will have bloods and radiology requested as required.
1570239|NCT02454114|Other|Standard Hospital Care|"No research investigations will occur except for questionnaires; as part of usual clinical practice patients will have bloods and radiology requested as desired by their usual clinical team.
SF-12 (physical and mental function) [performed twice in total] - at recruitment (day 0) and 6 weeks
CAP-SYM [performed 3 times in total] - at recruitment day 0 (twice including day minus 30) and 6 weeks
Patient (and carer/consultee) satisfaction - conducted over the telephone at 2 wks by an independent assessor."
1570240|NCT02454101|Procedure|cord milking|milking of the cord 5 times toward the neonate
1570241|NCT02454101|Procedure|delayed cord clamping|delay clamping of the cord for 120 seconds
1570242|NCT02454088|Other|Calcium Hydroxylapatite and Triamcinolone acetate|Combination Therapy Triamcinolone acetate and Calcium Hydroxylapatite
1570243|NCT02454088|Device|Calcium Hydroxylapatite and Placebo|Calcium Hydroxylapatite and Placebo
1570245|NCT02454062|Drug|TAS-114|TAS-114 is an inhibitor of dUTPase, a gatekeeper protein in pyrimidine-metabolism.
1570246|NCT02454062|Drug|S-1|S-1 is an oral antimetabolite; a combination of three pharmacological compounds: tegafur (FT), gimeracil (CDHP), and oteracil (Oxo)
1570247|NCT02454049|Dietary Supplement|beetroot juice|6mmol nitrate
1570248|NCT02454049|Dietary Supplement|sodium nitrate|6mmol sodium nitrate
1570249|NCT02454049|Dietary Supplement|water|plain water
1570250|NCT02454036|Behavioral|BBI intervention|Psychological intervention designed to reduce stress and enhance quality of life
1570251|NCT02454023|Device|Portable sleep monitor (ApneaLink Air)|Use of a portable sleep monitor that records respiratory effort, pulse, oxygen saturation and nasal flow, and reports apneas, hypopneas, flow limitation, snoring and blood oxygen saturation in order to detect obstructive sleep apnea.
1570252|NCT02454023|Device|In-laboratory polysomnography|Level 1 in-laboratory polysomnography for the detection of obstructive sleep apnea.
1570253|NCT02454010|Biological|FF21101|(90Y) radio-labeled FF21101 (therapeutic monoclonal antibody to P-cadherin expressed by the CDH3 gene)
1570254|NCT02453984|Other|89Zr-MPDL-3280A-PET scans|89Zr-MPDL3280A tracer injection and 89Zr-MPDL-3280A-PET scans
1570255|NCT02453971|Other|German Version of eCHECKUP TO GO|It is an online prevention program targeting alcohol consumption.
1570256|NCT02453958|Device|Multi-modal assessment system|Subjects were assessed using a multi-modal concussion assessment battery incorporating eye-tracking, balance, and neurocognitive tests
1570257|NCT02453945|Device|Adjustable Support Bra|A ClearPoint Medical support bra
1570258|NCT02453932|Drug|Tianzhi granule and placebo identified to donepezil|1 pack Tianzhi granule (5g), 3 times per day and placebo identified to donepezil, 1 pill per day for 24 weeks
1570259|NCT02453932|Drug|Donepezil and placebo identified to Tianzhi granule|donepezil 5mg per day and placebo identified to Tianzhi granule (5g, 3 times per day) for 24 weeks
1570260|NCT02453932|Drug|Placebo|placebo identified to Tianzhi granule (5g, 3 times per day) and placebo identified to donepezil ,1 pills per day for 24 weeks
1570261|NCT02453906|Other|XNKQ|stimulation at 5 acupuncture points according to XNKQ acupuncture
1570262|NCT02453906|Other|Control 1|no stimulation at 5 acupuncture points according to XNKQ acupuncture
1570263|NCT02453906|Other|Control 2|stimulation at 5 control points
1570264|NCT02453906|Other|Control 3|no stimulation at 5 control points
1570265|NCT02453893|Drug|Iloperidone|
1570266|NCT02453893|Drug|Risperidone|
1570267|NCT02453880|Behavioral|Web-based Cognitive Behavioral Therapy|"Participants will be asked to complete a web-based cognitive behavioral therapy self-help program. The program consists of six weekly modules, in which participants practice new ways of thinking (e.g. how to recognize and change distorted thinking, utilizing a thought change record, identifying cognitive errors, and modifying automatic thoughts) to reduce symptoms of anxiety and depression. Participants receive text message reminders to complete the weekly session."
1570268|NCT02453867|Other|Reduced immunosuppression|Stop steroids at month 3 Stop mycophenolate at month 6 continue tacrolimus once daily (Advagraf, trough levels > 5ng/ml) Stop mycophenolate at month 6
1570269|NCT02453867|Drug|Tacrolimus|Tacrolimus is used in both the acitve comparator arm and the interventional arm
1570270|NCT02453867|Drug|mycophenolate|Mycophenolate is used in the acitve comparator arm for the whole study period; Mycophenolate is stopped at month 6 after Transplantation (month 3 of the study) in the experimental arm
1570271|NCT02453867|Drug|Steroids|Steroids are used continually in the active comparator arm and are stopped at the beginning of the study (month 3 after Transplantation) as an Intervention in the experimental arm
1570272|NCT02453854|Behavioral|Group motivational interviewing|Monthly group meetings were held for two hour sessions each month and verifiable (treatment fidelity checked) motivational interviewing employed in helping clients make health behaviour changes.
1570273|NCT02453841|Drug|Oxymetazoline|
1570274|NCT02453828|Procedure|Non-cardiac surgery|patients having non-cardiac surgery
1570275|NCT02453815|Procedure|non-cardiac surgery|all surgical procedures except cardiac
1570276|NCT02453815|Other|arterial catheter|arterial catheter
1570277|NCT02453802|Drug|Tranexamic Acid 5%,5ml/amp|Intraarticular application of tranexamic acid 3g (60ml) in 100 ml normal saline into knee joint after closure of the joint capsule
1570278|NCT02453802|Drug|Tranexamic Acid 5%,5ml/amp|IV TXA group: Primary total knee replacement with 1 g tranexamic acid administrated intravenously before deflection of the tourniquet
1570279|NCT02453802|Drug|rivaroxaban (10mg)|Oral rivaroxabam (10mg) QD on PostOp Day 1 to 14.
1570280|NCT02453802|Drug|0.9% Normal Saline|Primary total knee replacement with intravenous normal saline (20 ml) administration before deflation of the tourniquet
1570281|NCT02453802|Drug|0.9% Normal Saline|Topical 160 ml normal saline application after closure of joint capsule.
1570282|NCT02453789|Drug|Alginate oligosaccharide|Inhalation of dry powder for inhalation (DPI)
1570283|NCT02453789|Drug|Placebo|
1570284|NCT02453776|Drug|PRECISION dosing Infliximab|Patients in the PRECISION dosing arm will recieve model based dosing, whereas proactive adjustments in treatment can be made by measuring the Infliximab concentration.
1570285|NCT02453763|Device|Transcranial direct current stimulation|All participants will receive transcranial direct current stimulation. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
1570286|NCT02453763|Procedure|MRI|All participants will receive an MRI. During the MRI images of the head a battery-powered device pulses a small current between a pair of the electrodes which will be immediately followed by more MRI images. The current pulses will be very short and there should be no feeling from the pulses. The entire imaging period will be at most 90 minutes.
1570289|NCT02453737|Radiation|Brachytherapy APBI|
1570290|NCT02453737|Radiation|3D-CRT (photon) APBI|
1570291|NCT02453737|Radiation|Proton APBI|
1570292|NCT02453724|Device|Observation for safety|The investigators will perform the routine lung exam used in emergency department evaluations for shortness of breath in patients scheduled for computed tomography. The investigators will observe if there are any parenchymal changes noted on the chest tomography scan.
1570293|NCT02453711|Drug|semaglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
1570294|NCT02453711|Drug|liraglutide|Once-daily subcutaneous (s.c., under the skin) administration with dose escalation.
1570295|NCT02453711|Drug|placebo|Once-daily subcutaneous (s.c., under the skin) administration.
1570296|NCT02453698|Drug|Methylphenidate|oral dose of methylphenidate. The MPH dose was selected based on previous studies in healthy adults (Mehta et al., 2000; Volkow, Fowler, Wang, Ding, & Gatley, 2002) and adults with ADHD (Aron et al., 2003). MPH reaches its peak plasma concentration 1-3 hours after an oral dose, and has a plasma half-life of 1.5-2.5 hours.
1570297|NCT02453698|Other|Placebo|Lactose Placebo
1570301|NCT02453672|Biological|SB8|SB8, proposed bevacizumab biosimilar
1570302|NCT02453672|Biological|EU sourced Avastin®|EU sourced Avastin® (bevacizumab, Roche Registration Ltd.)
1570303|NCT02453672|Biological|US Sourced Avastin®|US Sourced Avastin® (bevacizumab, Roche Registration Ltd.)
1570304|NCT02453659|Behavioral|Distress Tolerance Treatment for Weight Concern (DT-W)|
1570305|NCT02453659|Behavioral|Health Education (HE)|
1570306|NCT02453659|Behavioral|Smoking Cessation counseling|
1570307|NCT02453659|Drug|Transdermal Nicotine Patch|
1570359|NCT02453373|Drug|Etomidate|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
1570360|NCT02453373|Procedure|Neurothrombectomy|If indicated, neurothrombectomy will be performed using an FDA-cleared device within the FDA-cleared treatment window.
1570309|NCT02453633|Other|Emotional SMS text|"SMS appointment reminder with the following text (translated from Norwegian):
Reminder about your appointment. There are many who are waiting for treatment. Please notify us if you can not make your appointment on: Tuesday 31 March at 10:00.
tel. 23225501 or send email to kirpolonh@lds.no later than one weekday prior to your appointment.
No-show fee: Kr. 640.
Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat. Do not reply to this message per SMS."
1570310|NCT02453633|Other|Standard SMS text|"SMS appointment reminder with the following text (translated from Norwegian):
Reminder of appointment at Lovisenberg Diakonale Hospital, Department of Surgery, Ear, Nose and Throat: Wednesday 11.feb 2015 at 10:00. For a change, call tel. 23225501 or send email to kirpolonh@lds.no. Do not reply to this message per SMS."
1570317|NCT02453607|Drug|Infliximab|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
1570318|NCT02453607|Drug|thiopurine|Drug is prescribed by treating physician and is not a part of the study. This study is non-interventional. Patients, to be elgibile, are being prescribed either monotherapy inlfiximab or combo therapy infliximab with azathiopurine.
1570320|NCT02453581|Drug|OZ439|OZ439 Powder for Oral Suspension
1570326|NCT02453529|Drug|WCK 4873|Oral tablets
1570327|NCT02453516|Procedure|Serratus Block|Ultrasound-guided nerve block using ropivacaine 0.5% (0.4ml/kg) injected between the serratus anterior and external intercostal muscles
1570328|NCT02453516|Procedure|Placebo Block|Subcutaneous injection of 1ml sterile normal saline solution in the midaxillary line
1570329|NCT02453516|Drug|ropivacaine|Drug indicated for regional anesthesia
1570330|NCT02453516|Drug|epinephrine|Drug indicated to prolong the action of regional anesthesia
1570331|NCT02453516|Other|sterile saline|Neutral injection (no drug involved)
1570332|NCT02453503|Drug|Licorice|licorice mucoadhesive films evey 6 hours for two weeks
1570333|NCT02453503|Drug|Triamcinolone Acetonide|Triamcinolone acetonide mucoadhesive films 1 mg every 6 hours for two weeks.
1570334|NCT02453490|Drug|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Oxaliplatin:85mg/m2 iv,d1, q2w
1570335|NCT02453490|Drug|Raltitrexed-based chemotherapy|Raltitrexed: 2.0mg,iv,15min,d1,Irinotecan:180mg/m2 iv,d1, q2w
1570336|NCT02453490|Drug|5-fluorouracil-based chemotherapy|5-fluorouracil:400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Oxaliplatin:85mg/m2 iv,d1,q2w
1570337|NCT02453490|Drug|5-fluorouracil-based chemotherapy|5-fluorouracil: 400mg/m2,ivp,2h,d1,1200mg/m2/d*2d(2400mg/m2,iv46-48h); Irinotecan:180mg/m2 d1, iv,q2w
1570338|NCT02453477|Genetic|Autologous hematopoietic stem cells genetically modified with GLOBE lentiviral vector encoding for the human beta-globin gene|Autologous CD34+ cell enriched fraction containing hematopoietic stem cells (HSC) transduced with the GLOBE lentiviral vector encoding for the human beta-globin gene resuspended in their final formulation medium. The target dose in the transduced product is 5x10^6 cells/Kg CD34+ cells, with a minimum dose of 2 x 10^6/Kg and a maximum dose of 20 x 10^6/Kg, depending on the yield of cells. The product will be injected intraosseously.
1570339|NCT02453464|Drug|Sevacizumab|escalating doses of Sevacizumab : 3mg/kg，4mg/kg，5mg/kg
1570340|NCT02453464|Drug|Irinotecan|Irinotecan: IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
1570341|NCT02453464|Drug|5-FU|5-FU: IV solution, IV bolus over 2-4 minutes, 400 mg/m²; IV infusion over 46 hours, 2400 mg/m²; Every 14 days, Until disease progression/toxicity
1570342|NCT02453464|Drug|Leucovorin|Leucovorin: IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
1570343|NCT02453451|Other|2D-/3D-TTE|recording of 3 cardiac cycles
1570344|NCT02453451|Other|3D-TEE|with colour-Doppler techniques for recording the ASD and the mitral valve
1570345|NCT02453451|Other|Walking Test|for 6 minutes
1570346|NCT02453451|Procedure|MitraClip procedure|catheter-based non-surgical procedure in which the atrioventricular valves were stuck together permanently via a clip (during the regular patient care)
1570347|NCT02453438|Other|Patient Reported Outcomes|Patient reported outcomes will be collected using a variety of questionnaires that assess mood symptoms.
1570348|NCT02453425|Other|MAP 60 mmHg|Norepinephrine adjusted to reach MAP 60 mmHg
1570349|NCT02453425|Other|MAP 75 mmHg|Norepinephrine adjusted to reach MAP 75 mmHg
1570350|NCT02453425|Other|MAP 90 mmHg|Norepinephrine adjusted to reach MAP 90 mmHg
1570351|NCT02453412|Device|AVF-simulation|A mathematical computational tool, which is developed to calculate estimates for postoperative AVF hemodynamical changes in the upper extremity. The model is based on physical laws and calculations are carried out on patient-specific duplex measurements.
1570352|NCT02453399|Device|Randomized treatment/placebo delivery of transcutaneous electro stimulation via a dedicated device Avital.|Transcutaneous electro stimulation
1570355|NCT02453373|Device|ThermoSuit Cooling Induction|Rapid induction of therapeutic hypothermia (32-34 degrees C) using the Life Recovery Systems ThermoSuit System
1570356|NCT02453373|Drug|Magnesium Sulfate|Magnesium sulfate will be administered intravenously as needed to control shivering
1570357|NCT02453373|Drug|tPA|tPA will be administered intravenously if indicated
1570358|NCT02453373|Drug|Propofol|Induction doses of propofol or etomidate will be used to aid in the suppression of patient discomfort
1570361|NCT02453360|Procedure|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
1570362|NCT02453360|Drug|Adductor Canal Block|Following negative aspiration, SSACNB volume will be randomized and subjects will receive 5, 10 or 20 ml of 0.5% bupivacaine will be incrementally injected. Randomization of the volume of bupivacaine will be determined by opening a sequential, pre-sealed envelope with the group assignment designated within. All studied volumes are well within the acceptable range for SSACNB.
1570370|NCT02453308|Drug|ACT|"Artemether-lumefantrine for 3 days
Dihydroartemisinin-piperaquine for 3 days.
Artesunate-mefloquine for 3 days"
1570371|NCT02453308|Drug|TACT|"Artemether-lumefantrine for 3 days plus Amodiaquine for 3 days.
Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days.
Dihydroartemisinin-piperaquine for 3 days plus Mefloquine hydrochloride for 3 days."
1570372|NCT02453295|Behavioral|Intervention Group|The IG will meet weekly for 2 hours for 8 weeks. Administration of questionnaires (Meaning of Illness, MIQ; Herth Hope Index, HHI; Short Form 12, SF-12; Lymphedema Quality of Life, LYMQOL) will be completed by phone at all timepoints. The questionnaires will also be administered at 4 weeks post-intervention (T3) and 8 weeks (T4) post-intervention. All participants will also complete a demographic questionnaire at T0, developed in S2 as well as a Workshop Evaluation 2 days following the final workshop (T2).
1570381|NCT02453269|Behavioral|Transdisciplinary program|
1570382|NCT02453256|Drug|Placebo|Participants will receive matching placebo subcutaneous (SC) injections once weekly for 48 weeks of double-blind treatment.
1570383|NCT02453256|Drug|Tocilizumab|Participants will receive 162 mg SC tocilizumab once weekly for 48 weeks of double-blind treatment. The same regimen will be given to all eligible participants for 48 weeks of open-label treatment.
1570384|NCT02453243|Behavioral|Safety Planning|Suicide screen-positive patients who are to be discharged from the ED will receive personalized safety planning by a mental health clinician or nurse
1570385|NCT02453243|Behavioral|A Lean Implementation Strategy|"The Safety Planning Intervention will be implemented using Lean performance improvement strategies.
Sites will be trained on the Safety Planning Intervention and Lean."
1570386|NCT02453230|Behavioral|Lights on|Determine if ambient room light stimulation changes the amount of time required to perform the fetal biophysical profile.
1570387|NCT02453217|Behavioral|Chinese CHIP|The CHIP physical health screening tool will be used by community psychiatric nurses in the treatment group to assess patients' physical health risk and identify problematic lifestyle behaviours. The findings from the assessment will be used to devise an individualized care plan with patients. This treatment plan may involve community psychiatric nurses collaborated with psychiatrists, drawing patients attention to indicators of physical health risk by using a traffic light system The community nurses will use motivational interviewing approaches to make patients be aware of their physical health risks and enhance their motivation to adopt healthier behaviours.
1570388|NCT02453217|Other|Treatment as usual|The routine community mental health care provided by the community psychiatric nursing service and outpatient clinic.
1570389|NCT02453204|Behavioral|Sitting|
1570390|NCT02453204|Behavioral|Standing|
1570391|NCT02453204|Behavioral|Walking|
1570392|NCT02453191|Drug|talimogene laherparepvec|talimogene laherparepvec
1570393|NCT02453191|Radiation|Radiotherapy|Concurrent Preoperative Radiation. External Beam Radiation Therapy (EBRT) will be given at the standard dose for resectable soft tissue sarcomas. according to the NCCN sarcoma guidelines.
1570394|NCT02453178|Behavioral|Cycling|The experimental group will complete a 3 month exercise program that includes working up to cycling at a moderate intensity for 50 minutes/session 3 times a week. The comparison group will complete a 3-month exercise program that includes intermittent cycling (alternating between passive and moderate intensity) for 50 minutes/session 3 times a week. Both groups will exercise in our laboratory at Spence Labs, and will be supervised by an exercise trainer that is trained in working with elderly and special populations.
1570526|NCT02452255|Drug|Fenofibrate|Fenofibrate by mouth given daily throughout hospitalization for up to 12 months
1570395|NCT02453165|Procedure|TRANSVAGINAL SUTURE|The closure of the vaginal cuff will be performed transvaginally using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with vaginal valves and needleholders
1570396|NCT02453165|Procedure|LAPAROSCOPIC SUTURE|The closure of the vaginal cuff will be performed laparoscopically using a 0-poly-g-lactin braided and coated medium-term reabsorbable suture with laparoscopic needleholders
1570397|NCT02453152|Other|History and physical|Subjects will undergo a physical exam and medical history review, including review of genetic test results.
1570398|NCT02453152|Other|Tidal breathing|Subjects' breathing patterns will be evaluated at rest and at reduced/eliminated ventilator support.
1570399|NCT02453152|Other|Maximal respiratory pressures|Subjects' strongest inspiratory and expiratory pressures will be measured.
1570400|NCT02453152|Other|Peak cough flow|Subjects' strongest coughs will be measured.
1570401|NCT02453152|Other|Pediatric Evaluation of Disability Inventory|Assesses the functional capabilities of children with disabilities.
1570402|NCT02453152|Other|PedsQL Multidimensional Fatigue Scale|Assesses general fatigue, sleep/rest fatigue, and cognitive fatigue.
1570403|NCT02453152|Other|Review of ventilation requirements|Subjects's use of mechanical ventilation reviewed by the study team.
1570404|NCT02453139|Behavioral|Exercise|6 month supervised and home based aerobic exercise intervention
1570405|NCT02453113|Other|low power laser|Signaling in Human Skin Associated with Low-Power, Infrared Laser Treatment
1570411|NCT02453074|Other|Online survey - Follow up for Better Care|
1570412|NCT02453061|Drug|Triheptanoin oil|Triheptanoin oil orally administered at 1g/kg/day
1570413|NCT02453061|Drug|Placebo|Safflower oil orally administered at 1g/kg/day
1570414|NCT02453048|Biological|BPZE1|Intranasal live, attenuated vaccine
1570415|NCT02453048|Other|Placebo|Diluent
1570416|NCT02453035|Device|PTCA - Desolve Scaffold|Percutaneous Coronary Artery Intervention with a DESolve bioresorbable coronary scaffold
1570417|NCT02453022|Drug|Danirixin HBr 50 mg IR Tablet|Danirixin HBr 50 mg IR Tablet is white, film-coated, oval-shaped tablet for oral administration.
1570418|NCT02453022|Drug|Danirixin FB 50 mg IR Tablet|Danirixin FB 50 mg IR Tablet is white, film-coated, capsule-shaped tablet for oral administration.
1570419|NCT02453022|Drug|Prilosec (omeprazole) 40mg Delayed-Release capsule|Prilosec (omeprazole) 40 mg delayed-release capsule is opaque, hard gelatin, apricot, and amethyst colored capsules, coded 743 on cap and PRILOSEC 40 on the body for oral administration.
1570420|NCT02453009|Drug|Docetaxel|Pharmaceutical form:solution Route of administration: intravenous
1570421|NCT02453009|Drug|Prednisone|Pharmaceutical form:tablet Route of administration: oral
1570422|NCT02453009|Drug|Enzalutamide|Pharmaceutical form : soft gelatin capsules Route of administration: oral
1570423|NCT02452996|Drug|GNbAC1|Single dose of IMP, IV infusion
1570424|NCT02452983|Drug|Sertraline|
1570425|NCT02452983|Procedure|Bone Marrow Aspirate/Biopsy|
1570426|NCT02452970|Drug|RRx-001|RRx-001 (10 mg/m2) intravenously twice weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 30 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
1570427|NCT02452970|Drug|Gemcitabine and cisplatin|RRx-001 (20 mg) intravenously weekly for up to six weeks followed by retreatment with Gemcitabine 1000 mg/m2 and Cisplatin 25 mg/m2 on Days 1 and 8 of a 21 Day Cycle until tumor progression
1570428|NCT02452944|Device|nerve stimulator (stimuplex HNS12)|whether using the nerve stimulator or not when the investigators do the ultrasound-guided obturator nerve block
1570429|NCT02452944|Device|ultrasound|we did obturator nerve block with ultrasound guided method for searching the fascias where the anterior and posterior branches of obturator nerve run.
1570430|NCT02452931|Drug|Leuprolide Acetate 45 mg|Subcutaneous injection
1570431|NCT02452918|Drug|Oritavancin|a single 1200 mg IV dose of Orbactiv (oritavancin)
1570435|NCT02452879|Device|Electroacupuncture|For the deep needling acupoint group, needle on bilateral BL33 50-60mm with a 60°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3). Needle with 75mm long needle. An electric stimulator is put on. SDZ-V Hua Tuo Brand electric stimulator (produced by Suzhou Medical Instrument Co.Ltd). continuous wave(CW), 10Hz. Stop turning up the current intensity when patients could not stand. 3 times a week. Once every other day The treatment period lasts eight weeks. totally 24 times.30min/time.
1570436|NCT02452879|Device|Sham Electroacupuncture|with the patient in the prone position. The acupoint routine disinfection of skin, and then the fixed pad is adhered on the acupoint. The 1.5 inches blunt tip needle pierce through the fixed pad, then it reaches the surface of the skin, uniform lifting thrusting and twirling all 3 times but do not pierce the skin. Then connect the electric acupuncture apparatus with special power supply wire electrode (special power line as the middle wire cut, looks as normal; that electroacupuncture instrument display connected to the state, but the actual without electricity), in the bilateral Zhongliao points, Hui Yang points on the needle handle; the period of treatment and the other manipulation of the placebo group are same as the deep needling acupoint group.
1570437|NCT02452879|Drug|Solifenacin Succinate|made by the Anse Tailai Pharmaceutical (China) R & D limited company) 5mg / tablet
1570438|NCT02452866|Drug|SYM-1219|Administered with 4 ounces of unsweetened applesauce, and 8 ounces of water
1570795|NCT02450279|Other|Preoperative spirometry|
1570439|NCT02452853|Procedure|HR|"HR:
HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus"
1570440|NCT02452853|Drug|FOLFOX4|"FOLFOX4(Oxaliplatin + 5-Fluorouracil/Leucovorin):
4 weeks after HR; Drug: Oxaliplatin + 5- Fluorouracil/Leucovorin Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.
Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion. Repeated every 2 weeks"
1570441|NCT02452840|Other|No Intervention|No Intervention
1570442|NCT02452827|Other|Biomechanical parameters|
1570443|NCT02452827|Other|MRI|MRI of cervical spine
1570444|NCT02452801|Drug|ALKS 5461|Single dose, given orally
1570445|NCT02452788|Other|Pharmaceutical care|Pharmacist-provided education on medication adherence in hemodialysis patients.
1570446|NCT02452775|Biological|OC-L|
1570447|NCT02452775|Other|Montanide|
1570448|NCT02452775|Other|poly-ICLC (Hiltonol),|
1570449|NCT02452762|Drug|Vitamin D3|
1570450|NCT02452762|Drug|Placebo|
1570451|NCT02452749|Dietary Supplement|Cardiovascular health dietary supplement|Herbal/mineral dietary supplement
1570452|NCT02452736|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System|
1570453|NCT02452723|Biological|ISC-hpNSC|
1570454|NCT02452710|Other|Placebo|Open-label placebo
1570455|NCT02452697|Biological|NK Cell enriched-DLI only|"The first NK cell-enriched DLI will be administered one to six months post transplant. The second NK cell-enriched DLI will be administered one to three months post the first infusion, in patients who have ≤ grade II aGVHD at the time of infusion and have not had unacceptable toxicities from the first infusion. Patients will continue on their stable dose of immunosuppressive agents started for therapy of acute GVHD before the NK cell-enriched DLI, and will not taper until at least 6 weeks following the each NK cell-enriched DLI (unless disease progression or patient toxicity from the agents requires earlier taper). The donor NK cells will be infused over 30 minutes intravenously.
If signs of GVHD occur after NK cell-enriched DLI, immunosuppressive agents may be started."
1570456|NCT02452697|Biological|NK-DLI + DUK-CPG-001|"DUK-CPG-001 was synthesized by Agilent Technologies (Boulder, CO) in 2013. Bulk DUK-CPG-001 has been resuspended in normal saline with a final concentration of 10 mg/mL, aliquoted into 0.75 mL (7.5 mg) per tube and stored at -20oC in the Investigational Chemotherapy Service pharmacy at Duke. DUK-CPG-001 will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI. The drug will be used within 4 hours of thawing.
On the day of NK cell-enriched DLI, for those patients who are randomized to receive DUK-CPG-001, 0.5 mL (5 mg) aliquots of DUK-CPG-001 will be dispensed to nurse. It will be thawed at room temperature right before use and injected intravenously right after NK cell-enriched DLI."
1570457|NCT02452684|Drug|Eszopiclone|The usual dosage of eszopiclone is 2 mg per dose for adults and 1 mg per dose for elderly participants, taken orally before bedtime. The dosage may be adjusted according to the participant's symptoms, but a single dose should not exceed 3 mg in adults and 2 mg in elderly participants.
1570458|NCT02452658|Other|Changed menu|After making the hypothetical choice, participants will be exposed to a menu with changed calorie and price labels, as well as several other changes.
1570459|NCT02452645|Behavioral|Healthy Food and Physical Activity Environments|Tailored written materials, videos, telephone counseling, active toys
1570460|NCT02452645|Behavioral|Comparison Group|Written materials, videos, books, and telephone counseling.
1570461|NCT02452632|Drug|ASP1941|oral
1570462|NCT02452632|Drug|Placebo|oral
1570463|NCT02452619|Other|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy
1570464|NCT02452606|Drug|Stalevo®|"Sleep disorders in Parkinson's disease
Analysis by Parkinson's Disease Sleep Scale(PDSS) scores.
If the PDSS score is improving at least 15 percent than the baseline score, It can be determined to be effective."
1570466|NCT02452580|Other|Family Centered Care|Neonatal intensive care toward premature infants and their parents in a unit physically and culturally optimized for parent-infant interaction 24 hours a day 7 days a week from birth to discharge.
1570467|NCT02452567|Other|Moderate (8-10%) diet-induced weight loss|MAL participants will meet with the study dietitian to lose ~8-10% of their body weight through diet-intervention.
1570468|NCT02452554|Other|Laboratory Biomarker Analysis|Correlative studies
1570469|NCT02452554|Biological|Lorvotuzumab Mertansine|Given IV
1570470|NCT02452554|Other|Pharmacological Study|Correlative studies
1570471|NCT02452541|Other|Prognostic tests|"Brain CT-Scan on day 1, 3 and 7
Brain MRI on day 7
SomatoSensory Evoked Potentials on day 7
Electroencephalogram on day 7
Serum biomarkers on day 1, 3 and 7
Daily clinical exams"
1570476|NCT02452515|Drug|BAY1142524|5 mg BAY1142524 or placebo given as 5 mg IR tablet twice daily for 2 weeks
1570477|NCT02452515|Drug|BAY1142524|10 mg BAY1142524 or placebo given as 2 x 5 mg IR tablets twice daily as for 2 weeks
1570478|NCT02452515|Drug|BAY1142524|25 mg BAY1142524 or placebo given as 5 x 5 mg IR tablets twice daily for 2 weeks
1570479|NCT02452515|Drug|BAY1142524|50 mg BAY1142524 or placebo given 1 x 50 mg IR tablet once daily for 2 weeks
1570480|NCT02452515|Drug|Placebo|The patients will be treated orally with combinations of IR tablets containing placebo to achieve the indicated dosages.
1570481|NCT02452502|Device|atorvastatin|Atorvastatin high or moderate dose daily for 2 weeks administrated within 24 hours after receiving rt-PA thrombolysis, continued statin use for at least 12 months
1570527|NCT02452255|Drug|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months
1570482|NCT02452489|Device|acupuncture|Patients will be acupuncture with Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
1570483|NCT02452489|Device|acupuncture|Patients in Combination of He-Mu points group,will be acupuncture with Zusanli(ST36) and Zhongwan(RN12),needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment, follow-up after 4 weeks.
1570484|NCT02452489|Device|acupuncture|Patients in Control group,will be acupuncture with at the junction of deltoid and biceps,needle 1 times a day,30 min/time,5 days for a period of treatment,the treatment interval for two days,three intervention treatment,follow-up after 4 weeks.
1570485|NCT02452476|Drug|CHF5633|Rescue treatment (if needed)
1570486|NCT02452476|Drug|Poractant alfa|Rescue treatment (if needed)
1570487|NCT02452463|Other|Laboratory Biomarker Analysis|Correlative studies
1570488|NCT02452463|Drug|Nintedanib|Given PO
1570489|NCT02452463|Other|Placebo|Given PO
1570490|NCT02452463|Procedure|Quality-of-Life Assessment|Ancillary studies
1570491|NCT02452450|Drug|Ibuprofen Acid|
1570492|NCT02452450|Drug|Ibuprofen Lysine|
1570493|NCT02452450|Drug|Ibuprofen Sodium|
1570494|NCT02452450|Drug|Ibuprofen Liquid Capsules|
1570495|NCT02452450|Drug|Paracetamol|
1570496|NCT02452437|Drug|Oxycodone|Controlled release oxycodone 40 mg twice daily
1570499|NCT02452411|Behavioral|Cognitive Behavioral Treatment approach supported by virtual reality and positive psychology strategies.|The CBT program consists of 6 weekly sessions (and 2 additional ones depending on the patient's needs) with the following main therapeutic components: educational component, exposure/processing of the stressful event with VR (EMMA's World) and relapse prevention. EMMA's World is an open and flexible VR system that uses symbols (e.g., 3D-objects, pictures, sounds) to reflect and evoke the negative emotions associated to the stressful event. Also, several strategies from Positive Psychology (e.g., My best virtues or strengths exercise) and others based on Neimeyer's (2000) suggestions for pathological grief (e.g., projection letter to the future) are also included in the protocol.
1570500|NCT02452398|Device|Venus Versa|"The Venus Versa system is a multi-application device intended to be used in aesthetic and cosmetic procedures.
The device consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated. The applicator that will be used for this study (HR 690) has a wavelength of 690 nm and has a spot size (treatment area) of 30 mm by 10 mm."
1570501|NCT02452398|Other|IPL gel|water based gel used to protect the skin during light based treatments. Also used during ultrasound treatments.
1570502|NCT02452385|Drug|CM082 tablet|CM082 tablets taken orally
1570503|NCT02452372|Drug|ALN-AS1|Single or multiple doses of ALN-AS1 by subcutaneous (sc) injection
1570504|NCT02452372|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
1570505|NCT02452359|Device|Venus Versa|The Venus Versa system consists of a console and 4 detachable applicators that deliver optical energy in the form of Intense Pulsed Light to the patient skin. The intense pulsed light lamp delivers non-coherent light distributed over a range of wavelengths from 500 nm to 1200 nm. Different filters are embedded in the different applicators so that each applicator can deliver the desired spectrum according to the indications to be treated.In this study, the IPL applicator SR580 will be evaluated for the treatment of Striae Distensae, depending on the patient's skin type.
1570506|NCT02452359|Other|IPL gel|water based gel used to protect the skin during light based treatments. Is also commonly used during ultrasound treatments.
1570507|NCT02452346|Drug|Tosedostat|120 mg PO once daily continuously for each 28 day treatment cycle
1570508|NCT02452333|Procedure|Oncoplastic Approach Excisional Breast Biopsy|Evidence based quadrant by quadrant oncoplastic algorithm reinforced with videoscopic applications for peripheral lesions.
1570509|NCT02452333|Procedure|Conventional Excisional Breast Biopsy|Conventional Excisional Breast Biopsy
1570510|NCT02452333|Other|Tezel Method of Breast Volume Measurement|Tezel Method is a simple, accurate and non-invasive method of measuring differences in breast volume based on Archimedes' principle
1570511|NCT02452333|Other|Cosmetic Assessment|Cosmetic Assessment with Harris scale graded by patient, surgeon and professional third party. A standardised photograph of front, side and mediolateral oblique views will be taken using a digital camera for professional third party observers.
1570512|NCT02452320|Drug|intravenous acetaminophen|administration of 1000mg of intravenous acetaminophen or placebo every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
1570513|NCT02452320|Drug|Placebo|Subjects randomized to placebo will receive every 6 hours for a total of 4 doses; first dose to be administered after induction of general anesthesia
1570514|NCT02452307|Biological|Peptide vaccine|subcutaneous
1570515|NCT02452307|Drug|Montanide ISA-51|subcutaneous
1570516|NCT02452307|Drug|Granulocyte macrophage colony stimulating factor (GM-CSF)|intradermal
1570517|NCT02452307|Drug|Imiquimod|epicutaneous
1570518|NCT02452307|Drug|mRNA|subcutaneous
1570519|NCT02452307|Drug|Protamin|subcutaneous
1570520|NCT02452307|Procedure|local hyperthermia|
1570521|NCT02452294|Drug|Buparlisib|Patients will receive oral buparlisib 100 mg once daily and continue on study treatment until evidence of disease progression, death, or unacceptable adverse events
1570522|NCT02452281|Drug|ipilimumab|3 mg/kg, IV one day (a minimum of 12 hours and not more than 48 hours) before HSPPC-96 every 21-25 days for a total of 4 cycles.
1570523|NCT02452281|Drug|HSPPC-96|25 μg by intradermal injection always 12 - 48 hours following ipilimumab on a weekly basis for the first 4 weeks and then every 3 weeks always 12 - 48 hours after ipilimumab; for at least 6 cycles of HSPPC-96 up to 12 doses.
1570524|NCT02452268|Drug|NIZ985|Subcutaneous administration of hetIL-15 three times a week for two consecutive weeks
1570525|NCT02452268|Drug|PDR001|• PDR001 is a human monoclonal antibody (MAb) administered day 1 of each cycle
1570528|NCT02452255|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
1570529|NCT02452242|Drug|ABX464|25, 50, 75, 100, 150 mg, i.e. 1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
1570530|NCT02452242|Other|Placebo|1, 2, 3, 4 or 6 capsules respectively, every 3 days or every day for 2 weeks
1570531|NCT02452229|Other|Review of the Literature for Human Herpes Virus infections|"Review of the Medline database (PubMed and Ovid interface) for human herpes virus infections in burns as well as Web of Science interface.
PRIMSA (preferred reporting items for systematic reviews and meta-analyses) guidelines and checklist were used."
1570532|NCT02452216|Drug|Ferumoxytol|Undergo ferumoxytol-enhanced MRI
1570533|NCT02452216|Other|Tissue Analysis|Correlative analysis for macrophage detection and quantification. This applies for all patients in the experimental arm who undergo ferumoxytol infusion.
1570534|NCT02452216|Procedure|Magnetic Resonance Imaging|All subjects in the experimental arm who undergo ferumoxytol infusion will subsequently have MRI.
1570535|NCT02452203|Behavioral|Floating|Floating in either a pool saturated with Epsom salt or in a zero-gravity chair
1570536|NCT02452190|Drug|Reslizumab|Reslizumab will be administered subcutaneously in a dose of 110 mg every 4 weeks.
1570537|NCT02452190|Drug|Placebo|Matching Placebo
1570538|NCT02452177|Drug|Vitamin D|
1570539|NCT02452164|Other|Teaching|
1570540|NCT02452164|Device|(CellScopeOTO)|
1570541|NCT02452151|Drug|Infliximab-Biosimilar|
1570542|NCT02452151|Drug|Infliximab-Innovator|
1570543|NCT02452138|Other|Severe sepsis management|
1570544|NCT02452125|Dietary Supplement|Nicotine gum|Nicotine chewing gum
1570545|NCT02452112|Drug|5% Lidocaine patch|5% Lidocaine patch to be placed on the site of pain
1570546|NCT02452112|Drug|Placebo|Placebo patch to be placed on the site of pain
1570547|NCT02452099|Procedure|Cryopreservation of HSCs using 5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 5% DMSO concentration.
1570548|NCT02452099|Procedure|Cryopreservation of HSCs using 7,5% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 7,5% DMSO concentration.
1570549|NCT02452099|Procedure|Cryopreservation of HSCs using 10% DMSO concentration|Cryopreservation of HSCs obtained by leukapheresis will be performed using 10% DMSO concentration.
1570550|NCT02452086|Device|Low Level Laser(Ga-As)|Low level laser therapy(904 nm Wavelength), 90 milliwatt, 2 Joule/centimeter2
1570551|NCT02452086|Procedure|Placebo|LLLT with zero intensity
1570552|NCT02452073|Other|Thyroid function tests|
1570553|NCT02452060|Drug|Ketamine|0.4mg/kg infusion
1570554|NCT02452060|Other|Placebo Comparator|0.4mg/kg infusion
1570555|NCT02452047|Drug|Imipenem+Cilastatin/Relebactam|Imipenem+Cilastatin/Relebactam 200/100 mg to 500/250 mg, depending on renal function, IV infusion once every 6 hours
1570556|NCT02452047|Drug|Colistimethate sodium (CMS)|Colistimethate base activity 300 mg (~720 mg CMS) IV infusion loading dose, followed by colistimethate base activity 75 mg to 150 mg (~180 to 360 mg CMS), depending on renal function, once every 12 hours
1570557|NCT02452047|Drug|Imipenem+Cilastatin|Imipenem+cilastatin 200 mg to 500 mg, depending on renal function, IV infusion once every 6 hours
1570558|NCT02452047|Drug|Placebo to CMS|Placebo to CMS IV infusion once every 12 hours
1570561|NCT02452008|Drug|Enzalutamide|160mg of enzalutamide is administered orally once a day on days 1-28 of each cycle.
1570562|NCT02452008|Drug|LY2157299|150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
1570563|NCT02451995|Device|Ripple Mapping guided AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of Ripple Mapping
1570564|NCT02451995|Device|Conventional AT ablation|Diagnosing the mechanism and delivering ablation within the atria in patients with atrial tachycardia on the basis of activation mapping and entrainment
1570565|NCT02451982|Drug|Cyclophosphamide|200 mg/m2
1570566|NCT02451982|Biological|GVAX pancreatic cancer|5x10^8 cells
1570567|NCT02451982|Drug|Nivolumab|3 mg/kg
1570568|NCT02451969|Biological|investigational 23-valent PPV|The investigational vaccine was manufactured by Sinovac Biotech Co., Ltd.
1570569|NCT02451969|Biological|control 23-valent PPV|The control vaccine was manufactured by Chengdu Institute of Biological products Co., Ltd.
1570570|NCT02451956|Drug|AZD5363|Dosage and Schedule : AZD5363 400mg bid 4 days on/ 3 days off of a 7 day cycle for each week
1570571|NCT02451956|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle.
1570572|NCT02451943|Drug|Olaratumab|Administered IV
1570573|NCT02451943|Drug|Doxorubicin|Administered IV
1570574|NCT02451943|Drug|Placebo|Administered IV
1570575|NCT02451930|Drug|Necitumumab|Administered IV
1570576|NCT02451930|Drug|Pembrolizumab|Administered IV
1570579|NCT02451904|Other|Observation|
1570580|NCT02451891|Biological|MVA-EBO Z|
1570581|NCT02451891|Biological|ChAd3-EBO Z|
1570582|NCT02451878|Behavioral|E-Couch|e-couch is an online CBT based intervention
1570583|NCT02451865|Drug|Binimetinib|Given PO
1570584|NCT02451865|Drug|Docetaxel|Given IV
1570585|NCT02451865|Other|Laboratory Biomarker Analysis|Correlative studies
1570586|NCT02451852|Drug|AZD9291|AZD9291 80mg tablet once daily, open label
1570587|NCT02451826|Drug|Ulipristal acetate|CVR delivering Ulipristal acetate and one tablet levonorgestrel.
1570588|NCT02451813|Procedure|Apposition of needle bevel against femoral nerve|Indentation of femoral nerve and fascia iliaca by block needle and measurement of opening injection pressure during the controlled injection of 1 ml of dextrose (D5W) solution
1570589|NCT02451800|Other|in-class yoga|In-person yoga classes that meet for 3x/week for 3 months. Each class is 1 hour.
1570590|NCT02451800|Other|yoga by DVD|Individuals are asked to follow a 1-hour DVD on yoga 3x/week for 3 months.
1570591|NCT02451800|Other|stretching by DVD|Individuals are asked to follow a 1-hour DVD on stretching exercises 3x/week for 3 months.
1570592|NCT02451787|Dietary Supplement|Vitamin D|2400 units per day for 3 months
1570595|NCT02451761|Biological|Blood sampling|
1570596|NCT02451748|Other|Lab Work|Lab work to measure IL-7 and IL-7R
1570599|NCT02451722|Device|Kyboot shoes|The Kyboot shoe - construction is based on a soft, supple air cushioned sole. The honeycomb air structure of the kyBoot sole creates an air cushion between your foot and the ground, with one fifth of the volume of air being pumped into the foot area at every step. This design could offer a better distribution of pressure
1570600|NCT02451709|Device|Activated Smartinhaler or Smartturbo|Medication reminder alarms
1570601|NCT02451709|Other|Feedback of adherence data|Review of adherence data with action planning
1570602|NCT02451709|Device|Deactivated Smartinhaler or Smartturbo|Alarms deactivated and no feedback
1570603|NCT02451696|Drug|Everolimus|This study will measure if the drug called Everolimus effects mTOR signaling (an electrical activity signal in the brain) in patients with Tuberous Sclerosis Complex (TSC) and Focal Cortical Dysplasia (FCD) with treatment resistant epilepsy (TRE) who will be undergoing brain surgery. One group of patients will be treated with Everolimus, for 7-28 days prior to epilepsy surgery and another will not. We will determine if there is a difference in mTOR signaling between the patients who were treated with Everolimus and those who were not
1570604|NCT02451683|Other|Electrophysiology Assessment of Time Domain|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability.
1570605|NCT02451683|Other|Electrophysiology Assessment of Location|Kinematics, Spinal Cord Excitability and Cortical Spinal Motor Excitability
1570606|NCT02451683|Other|Training with some stimulation|motor task combined with real or sham stimulation
1570607|NCT02451670|Behavioral|Wizard algorithm risk reduction advice|Wizard algorithm risk reduction advice is made available by web-based Clinical Decision Support algorithms estimate the patient's cardiovascular risk and quantify decreases in cardiovascular risk with appropriate management of out-of-control cardiovascular risk factors. The algorithms identify evidence-based treatment options to address each uncontrolled cardiovascular risk factor. Lifestyle treatment recommendations are also provided, when appropriate.
1570609|NCT02451644|Device|pedometer|patient will cary pedometer
1570610|NCT02451631|Other|Traditional care with paper|Healthcare staff-driven care, Diabetes mgmt. guide-book provided. Patient self-monitoring of blood glucose(SMBG) with paper.
1570611|NCT02451631|Device|Health-on G App. + Physician Web|Patients use their smart-phone or receive rental phone, and download Health-On G application. Algorithm-based personalized feedback are provided when patients' data are linked to Health-On G Application. Patient self-monitoring blood glucose data from glucometer are transferred to App. automatically by bluetooth, or input manually, check medication regimen, input food intake and exercise, and step counts are linked by Activity tracker. Personalized feedback are instantly provided based on data. Entered data are also connected to web-based physician portal. Physician web portal is provided, where they're able to review their patient's all data. Health-On G is defined as a U-Healthcare medical device consisting of gateway and decision support system.
1570612|NCT02451605|Drug|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade (Ropivacaine) for total knee replacement surgery.
1570613|NCT02451605|Procedure|Total knee replacement surgery.|Total knee replacement surgery.
1570614|NCT02451579|Drug|Antihistamine Cetirizine Hydrochloride|Prophylactic use of antihistamine prior to and following topical 5-aminolevulonic acid photodynamic therapy
1570615|NCT02451579|Other|Placebo|Use of placebo prior to and following topical 5-aminolevulonic acid photodynamic therapy
1570616|NCT02451566|Device|Ovation Prime Abdominal Stent Graft System|
1570620|NCT02451540|Radiation|HRCT scan|HRCT scan of thorax, at baseline and after 3 months
1570621|NCT02451540|Drug|Placebo of Roflumilast|Placebo, once a day in the morning during 3 months
1570622|NCT02451540|Drug|Roflumilast|Roflumilast, once a day in the morning during 3 months
1570623|NCT02451527|Drug|Digoxin|Digoxin 0.5mg tablet by mouth on Day 1 and Day 38
1570624|NCT02451527|Drug|PEX168|PEX168 in subcutaneous injection on Day8，15，22，29 and Day 36
1570785|NCT02450357|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
1570626|NCT02451501|Device|AKITA|
1570627|NCT02451488|Drug|GM-CSF|14 days in a dose of 125 µg/m^2
1570628|NCT02451488|Other|Standard of Care|No neo-adjuvant therapy prior to surgical intervention
1570629|NCT02451475|Drug|Amitriptyline|Amitriptyline 25 mg/day
1570630|NCT02451475|Drug|Venlafaxine|Venlafaxine 75 mg/day
1570631|NCT02451475|Drug|Paroxetine|Paroxetine 25 mg/day
1570632|NCT02451462|Drug|Zoledronic acid|
1570633|NCT02451436|Behavioral|Sleep and Media Use Intervention|
1570634|NCT02451436|Behavioral|Study Skills Control Group|
1570635|NCT02451423|Drug|MPDL3280A Dose Level 1|1200 mg x 1 dose
1570636|NCT02451423|Drug|MPDL3280A Dose Level 2|1200 mg every 3 weeks x 2 doses
1570637|NCT02451423|Drug|MPDL3280A Dose Level 3|1200 mg evert 3 weeks x 3 doses
1570639|NCT02451384|Procedure|routine surgery|To observe if the surgeries can influence the countings of circulating tumor cells of the patients.
1570640|NCT02451384|Procedure|no-touch surgery|
1570641|NCT02451384|Procedure|laparoscopic surgery|
1570642|NCT02451371|Device|tDCS|2mA direct current, 20 minutes per session, 2 sessions per day with at least 3hours interval between sessions, a total of 10 tDCS sessions
1570643|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (2 injections 28 days apart for participants aged 6 to 35 months )
1570644|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
1570645|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2 injections 28 days apart for participants aged 3 to 8 years)
1570646|NCT02451358|Biological|Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
1570647|NCT02451345|Behavioral|Personalized coaching intervention|"A health coach (members of the Patient Support Corps at the University of California San Francisco) will contact each subject individually to discuss his tailored/personalized web-portal report on his risk of aggressive disease and the pro/cons of treatment versus active surveillance.
The contact between subject and the health coaches will be done before subject's visit with his primary urologist. Subjects will be asked to complete different questionnaires on four different occasions: one at first visit to the interactive secure web portal; one before coach's call; one after the coaching (after the urologist visit), and one at 6 months. The questionnaire after subject's visit with the urologist includes discussion about their management choice, decision quality, anxiety and satisfaction with care."
1570648|NCT02451332|Biological|inactivated seasonal flu vaccine|Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
1570649|NCT02451319|Procedure|Retrograde Intrarenal Surgery|Endoscopic treatment of Kidney Stones
1570650|NCT02451306|Drug|Quetiapine|See information in arm description.
1570651|NCT02451306|Drug|Placebo|See information in arm description.
1570652|NCT02451293|Drug|Melatonin (N-acetyl-5-methoxytryptamine)|
1570653|NCT02451293|Drug|Placebo|
1570654|NCT02451280|Procedure|Unilateral Hybrid Intervention|For the unilateral RT training, participants will practice with their affected arms following a unilateral training protocol of BMT for 45 minutes (Yang, et al., 2012). For the UAT training, participants will receive training of the affected UL in functional tasks with behavioral shaping for 45 minutes (Lin, Wu, et al., 2009).
1570655|NCT02451280|Procedure|Bilateral Hybrid Intervention|For the bilateral RT training, patients will focus on training involving both arms using the BMT robot for 45 minutes. During the 45 minutes BAT training, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs.
1570656|NCT02451280|Procedure|Robot-Assisted Training|The RT intervention will be matched in duration and intensity with the hybrid interventions. Participants in the RT group will practice on the BMT with bilateral protocols for 90 minutes. The tasks will be tailored according to the level
1570657|NCT02451267|Other|physical therapy treatment with aerobic exercise|neck exercise strengthening program with neck massage and aerobic exercise (leg bicycling with relaxed shoulders)
1570658|NCT02451267|Other|physical therapy treatment|neck exercise strengthening program with neck massage
1570659|NCT02451254|Procedure|circumferential ablation|circumferential ablation of the pulmonary veins
1570660|NCT02451254|Device|SVT ablation|SVT ablation
1570661|NCT02451241|Other|acupuncture|electroacupuncture
1570662|NCT02451215|Device|Laser Interstitial Thermotherapy (LITT)|Magnetic resonance imaging (MRI)-guided laser interstitial thermal therapy (LITT) is a minimally invasive surgical option to treat CNS tumors. LITT uses laser energy delivered to a target (i.e. CNS tumor) through a fiberoptic catheter, which results in damage to intracellular proteins and DNA, and subsequent cell death. LITT provides a sharp demarcation between ablated and unharmed tissue, which, when combined with the ability to monitor and control the ablation via MR thermal imaging, results in a high level of precision and control.
1570663|NCT02451202|Procedure|Deep Neuromuscular Blockade|"During maintenance phase, if recovery after 1 Post-Tetanic-count (PTC) responses, a continuous infusion can be initiated to maintain deep NMB (TOF =0, PTC 1-2).
At the end of surgery, continuous infusion Rocuronium and Propofol are discontinued and paralysis will be simultaneously reversed by Sugammadex 4mg/kg from PTC 1-2."
1570664|NCT02451202|Procedure|Moderate Neuromuscular Blockade|- During maintenance phase, if recovery at the presence of <10% of control T1 of TOF from initial doses of 0.6 mg rocuronium, a continuous infusion can be initiated to maintain TOF = 1 - 2. The initial pump rate will be set at 0.5 mg/kg per hour.
1570665|NCT02451202|Drug|Sugammadex|
1570666|NCT02451202|Drug|Rocuronium|
1570667|NCT02451189|Dietary Supplement|Inulin acetate ester|Inulin acetate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and oral glucose tolerance test (OGTT) on day 30.
1571054|NCT02448628|Drug|CS-3150|
1570668|NCT02451189|Dietary Supplement|Inulin propionate ester|Inulin propionate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
1570669|NCT02451189|Dietary Supplement|Inulin butyrate ester|Inulin butyrate ester supplementation (10g/d) for 30 days. Appetite measurements on day 15 and OGTT on day 30.
1570670|NCT02451176|Device|Davol Bard Soft Mesh synthetic|soft mesh synthetic
1570671|NCT02451176|Device|LifeCell Strattice Reconstructive Tissue Biologic|biologic mesh
1570672|NCT02451163|Dietary Supplement|wheat polysaccharides|Consumed once daily for 12 weeks.
1570673|NCT02451163|Dietary Supplement|maltodextrin|Consumed once daily for 12 weeks.
1570674|NCT02451150|Drug|Azilsartan|Azilsartan tablets
1570678|NCT02451124|Device|non-endoscopic inflatable balloon for the esophagus|Undergo non-endoscopic brushing of the esophagus using a non-endoscopic inflatable balloon for the esophagus
1570679|NCT02451124|Other|Questionnaire Administration|Ancillary studies
1570680|NCT02451124|Other|Laboratory Biomarker Analysis|Correlative studies
1570681|NCT02451124|Procedure|esophagogastroduodenoscopy|Standard of care, patients digestive tract scoped post balloon brushing
1570682|NCT02451111|Drug|Ibrutinib|Patients will be instructed by the Investigator to take the amount of 560 mg Ibrutinib/Placebo (4 x 140 mg capsules) orally once daily with a glass of water at approximately the same time every day.
1570683|NCT02451111|Drug|Rituximab|Rituximab 375 mg/m2 has to be administered i.v. for the first four (4) infusions in all patients. After i.v. administration of Rituximab for the induction therapy, the administration mode can be changed to s.c. (1400 mg) in the maintenance phase dependent on the local standard of care.
1570684|NCT02451098|Drug|Atorvastatin10mg, Ezetimibe10mg|Atorvastatin10mg, Ezetimibe 10mg (Duration: 8weeks)
1570685|NCT02451098|Drug|Atorvastatin10mg, Ezetimibe placebo|Atorvastatin10mg, Ezetimibe placebo(Duration: 8 weeks)
1570686|NCT02451098|Drug|Atorvastatin20mg, Ezetimibe10mg|Atorvastatin20mg, Ezetimibe 10mg (Duration: 8weeks)
1570687|NCT02451098|Drug|Atorvastatin20mg, Ezetimibe placebo|Atorvastatin20mg, Ezetimibe placebo(Duration: 8weeks)
1570688|NCT02451098|Drug|Atorvastatin40mg, Ezetimibe10mg|Atorvastatin40mg, Ezetimibe 10mg (Duration: 8weeks)
1570689|NCT02451098|Drug|Atorvastatin40mg, Ezetimibe placebo|Atorvastatin40mg, Ezetimibe placebo(Duration: 8weeks)
1570690|NCT02451085|Behavioral|training with video therapy|training with video therapy
1570691|NCT02451085|Behavioral|conventional exercise|training in conventional way
1570692|NCT02451072|Drug|Placebo|Capsules containing mannitol looking identical to LSD per os
1570693|NCT02451072|Drug|LSD|100µg per os, single dose
1570694|NCT02451072|Drug|Ketanserin|40mg per os, single dose looking identical to LSD per os
1570695|NCT02451059|Behavioral|WE CARE survey|The WE CARE survey, consists of 14 questions used to identify seven unmet material needs (education, employment, food security, housing, childcare, household heat, language). The survey will be administered with patient's developmental screening forms at all health supervision visits from birth to two years of age. The office staff will instruct parents to give the WE CARE survey, along with the developmental screening tool, to their child's provider at the visit.
1570696|NCT02451059|Behavioral|WE CARE Community Resource Handout|Providers will be trained to review the WE CARE survey at health supervision visits and generate referrals thru the EMR. Specifically, they will receive a one-hour teaching session one week prior to the study implementation. The goals for the session will include providing an overview of pediatric practice guidelines, introducing the WE CARE survey, reviewing the referral process, and discussing the role of peer patient navigators. Investigators will conduct regular booster sessions every 4 months; investigators will also train new providers should there be staff turnover
1570697|NCT02451059|Behavioral|Patient Navigator|Peer patient navigators will offer guidance to families with accessing community resources. They will be available at least 1.5 days per week at intervention health centers to meet with families and offer guidance as well as be available via a hotline number. The navigator will speak with families and offer guidance on community resources and offer assistance with completing applications. In addition, they will offer to schedule and, if desired, accompany parents to the agencies. Interpreter services will be utilized at the health centers in case the navigator does not speak the parent's language. Navigators will also place an update note in the EMR within 1-month post-visit and one week after any contact with families.
1570698|NCT02451033|Drug|standard medical therapy|diuretics, albumin infusion, antibiotics, nutrition, and variceal banding wherever needed
1570699|NCT02451033|Drug|G-CSF|G-CSF at the dosage of 5 µg/Kg subcutaneously every 12 hr for five consecutive days then every 3 monthly for 3 days till 1 year
1570700|NCT02451033|Drug|Growth Hormone|Growth Hormone in low dose of 1unit sc daily for 1 year
1570701|NCT02451020|Other|Altitude exposure|Participants will stay for 3 weeks at an altitude of 3200 m
1570702|NCT02451007|Drug|lurbinectedin (PM01183)|
1570703|NCT02450994|Drug|Dexamethasone|
1570704|NCT02450994|Drug|Placebo|
1570705|NCT02450981|Drug|Bevacizumab (BCD-021)|Bevacizumab is a monoclonal antibody against vascular endothelial growth factor A (VEGF-A)
1570706|NCT02450968|Drug|Dexamethasone|
1570707|NCT02450968|Drug|Placebo|
1570708|NCT02450955|Other|Massage|A superficial massage was performed for 10 minutes in the cervical region consisting of gentle rubbing and kneading, five minutes prone and five minutes supine with a focus on cervical and suboccipital muscles in order to induce a global relaxation of the cervical and suboccipital region. Resting position. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
1570786|NCT02450344|Behavioral|Interactive health promotion|An Internet quiz game competition utilising quiz questions related to alcohol
1570787|NCT02450344|Behavioral|Passive health promotion|An electronic package of information related to alcohol
1570788|NCT02450331|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg).
1570709|NCT02450955|Other|Occiput-Atlas-Axis Technique|This technique was applied as described previously and is used with the aim of restoring joint mobility between the occiput, atlas and axis. It is a structural technique applied bilaterally, performed on a vertical axis passing through the dens process of the axis without extension or flexion and very little side-bending. After the treatment, both groups rested for 10 minutes in a supine position with neutral ranges of neck flexion, extension, lateral flexion, and rotation.
1570710|NCT02450942|Drug|18F-FDS|18F-FDS were intravenously injected into the patients 1 h before the PET/CT scans
1570712|NCT02450890|Drug|Placebo First, then ORADUR®|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
1570713|NCT02450890|Drug|ORADUR® First, then Placebo|ORADUR®-Methylphenidate is available in three dosage forms (22mg, 33mg or 44mg). The optimal dose for each subject will be determined in the open-label titration period. After randomization, subjects will be subjected to the 4-week double-blind two-way cross-over treatment phase with 2 study periods (2 weeks of placebo and 2 weeks of ORADUR®-Methylphenidate oral capsule at the optimal dose, according to a pre-determined randomization schedule).
1570714|NCT02450877|Drug|Azacitidine|
1570715|NCT02450877|Other|Control Arm|
1570716|NCT02450864|Other|ESWT|Preoperatively, the ROM of the shoulder is measure with the patient in a sitting position. A goniometer is used to measure the angle to which the patient could maximally passively forward flex or abduct the shoulder. External rotation and internal rotation of the shoulders are determined with the patient's arm in a resting position. The investigators assessed shoulder ROM using the SROMD. Normal shoulder ROM without scapular stabilization is considered to be 180° of forward flexion, 180° of abduction, 90° of external rotation, and 90° of internal rotation with the arm at the side. By summation of the measured deficit of ROM, the SROMD is obtained. Patients are defined as having shoulder stiffness if SROMD >270degrees.
1570717|NCT02450838|Biological|V180|Tetravalent recombinant subunit dengue vaccine; V180 will contain 10 µg, 10 µg, 10 µg, and 20 µg of the DENV1, DENV2, DENV3, and DENV4 antigens, respectively.
1570718|NCT02450838|Biological|Alhydrogel™|Aluminum hydroxide gel adjuvant
1570719|NCT02450838|Biological|Placebo|
1570720|NCT02450825|Procedure|Lung ultrasound examination on Day 1 and Day 2 to 4|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 and repeated on Day 2 to 4. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
1570721|NCT02450825|Procedure|Lung ultrasound examination on Day 1|A standardized lung ultrasound examination using the GE Vivid ultrasound system will be performed following the tomographic scan on Day 1 only. Correlation of ultrasound-based aeration scores will be done with lung aeration measured by computed tomographic images.
1570722|NCT02450825|Device|GE Vivid Ultrasound system|The GE Vivid ultrasound system will be used for all lung ultrasound examinations performed in this study.
1998749|NCT01004861|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
1570724|NCT02450799|Device|Acrylic IOL|Acrylic IOL for long-term implantation in the cataract patient
1570725|NCT02450799|Device|Silicone IOL|Silicone IOL for long-term implantation in the cataract patient
1570726|NCT02450799|Device|PMMA IOL|Polymethylmethacrylate IOL for long-term implantation in the cataract patient
1570727|NCT02450786|Drug|Donepezil|Donepezil is started in patients with Parkinson's disease mild cognitive impairment with 5mg for 8 weeks followed by dose up to 10mg and then maintained for 40 weeks. Participants who are not tolerable to dose of 10mg due to any issues of adverse effects would be maintained with donepezil 5mg exclusively in remained period.
1570728|NCT02450773|Drug|Furosemide|40 mg furosemide on postpartum day 1-6
1570729|NCT02450773|Drug|Potassium chloride|20 meq potassium chloride on postpartum day 1-6
1570730|NCT02450773|Drug|Placebo #1|Placebo (for furosemide)
1570731|NCT02450773|Drug|Placebo #2|Placebo (for KCl)
1570732|NCT02450760|Other|Social incentive|Quantify adherence to 90 days of home blood pressure monitoring and to determine if a social incentive improves adherence
1570733|NCT02450747|Device|etafilcon A MULTIFOCAL|Subjects will wear the test lens for four weeks.
1570734|NCT02450734|Procedure|Ultrasound-guided intermediate cervical plexus block|
1570735|NCT02450721|Other|Biomarkers serum level measurement|"Biomarker serum level measurement was performed with ELISA using following kits: Lp-PL-A2 ELISA- Cloud-CloneCorp. (USA); PAPP-A ELISA- IBL (Germany); Lp (a) ELISA Kit-AssayPro (USA ), ADMA ELISA Kit- ImmunDiagnostik ( Germany); hsCRP ELISA- Biomerica (Germany); according to the manufacturer's instructions . Absorbance of standards and samples was measured with a microplate reader Bio-Tek (USA) at a wavelength specified by the kit manufacturer . The calculation of the determined biomarkers concentration was performed using the software SOFTmaxPRO."
1570736|NCT02450708|Genetic|KIR genotyping|
1570737|NCT02450708|Genetic|HLA genotyping|
1570738|NCT02450695|Device|rTMS|
1570739|NCT02450682|Drug|Apixaban|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
1570740|NCT02450682|Drug|Warfarin|Anticoagulant agent for Atrial Fibrillation and undergo CIED generator change
1570741|NCT02450656|Drug|Afatinib|Tablet
1570742|NCT02450656|Drug|Selumetinib|Capsule
1570743|NCT02450656|Drug|Docetaxel|
1570744|NCT02450643|Other|Test extensively hydrolyzed formula|extensively hydrolyzed formula made with a new enzyme
1570745|NCT02450643|Other|Control extensively hydrolyzed formula|commercially available extensively hydrolyzed formula
1570789|NCT02450318|Other|Slow-paced walking|Subjects will walk on a treadmill at a slow pace for 47 minutes
1570790|NCT02450292|Procedure|Bioabsorbable screw fixation|
1570791|NCT02450279|Drug|technetium-99m - Diethylenetriaminepentaacetic acid|
1570792|NCT02450279|Device|Vibrating-mesh nebulizer|
1570793|NCT02450279|Device|Jet Nebulizer|
1570794|NCT02450279|Other|Planar scintigraphy|
1998750|NCT01004003|Drug|Sorafenib|
1570746|NCT02450630|Behavioral|Strenghtened referral of children|Community awareness on referral+ trained private providers in using RDTs/ICCM to treat and refer sick children + supervision and regular meetings between the private and public sector.All health workers in the intervention arm will be trained on how to recognize and distinguish uncomplicated & severe malaria, supplying unit-dose packaged Coartem® to customers with uncomplicated malaria, and administration of rectal artesunate pre-referral treatment and referral for sick children with severe and complicated malaria, diarrhoea and pneumonia.Private outlets in intervention arm will be trained to improve diagnosis, treatment and referral of children. The intervention will thus contribute to better health seeking practices at a community level and improved quality of care in the private sector
1570747|NCT02450617|Behavioral|Conventional individual treatment|Individual psychotherapeutic treatment and case-management delivered by public outpatient clinics or private practicing psychologist/psychiatrist
1570748|NCT02450617|Behavioral|Stabilizing group treatment for PTSD|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training.
1570749|NCT02450617|Behavioral|Stabilizing group treatment for Dissociative disorders|20 sessions group psychotherapy for patients with PTSD, focused on psychoeducation and skills-training
1570750|NCT02450604|Genetic|Diagnosis of Fabry disease|The diagnosis of Fabry disease necessitates biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females.
1570751|NCT02450591|Drug|Erlotinib|
1570752|NCT02450591|Other|Local Therapies|Definitive local therapies include surgical resection, stereotactic radiosurgery, ablation and conventional radiation therapy
1570753|NCT02450578|Drug|DSM265 400mg|DSM265 400mg, single oral administration in a fed state
1570754|NCT02450578|Drug|Placebo to DSM265 400 mg|Placebo to DSM265 400mg, single oral administration in a fed state
1570755|NCT02450578|Biological|Plasmodium falciparum sporozoite challenge|IV Plasmodium falciparum sporozoites (3200) by direct venous inoculation
1570756|NCT02450578|Drug|Malarone|250 mg atovaquone, 100 mg proguanil hydrochloride
1570757|NCT02450565|Other|Questionnaire|
1570758|NCT02450552|Drug|Ezogabine|Potiga is FDA-approved for adjunctive treatment of partial-onset seizures in patients aged 18 years and older who have responded inadequately to several alternative treatments.
1570759|NCT02450552|Drug|Placebo|Matched placebo
1570760|NCT02450539|Drug|Abemaciclib|Administered orally
1570761|NCT02450539|Drug|Docetaxel|Administered IV
1570762|NCT02450526|Drug|Dysport|
1570763|NCT02450526|Drug|Botox|
1570764|NCT02450526|Other|AbobotulinumtoxinA Placebo|50 Units
1570765|NCT02450526|Other|OnabotulinumtoxinA Placebo|20 Units
1570766|NCT02450513|Drug|Adalimumab|160 mg at week 0, 80 mg at week 2 and 40 mg every two weeks onwards
1570767|NCT02450500|Behavioral|Lifestyle counselling|This will consist of a web-based lifestyle app and personalised behaviour modification advice by a registered dietitian delivered via messaging. Participants will be issued with a pedometer and instructed to wear this daily. Participants will access web-based material on prediabetes through the lifestyle app. Contact between the dietitian and participants will consist of weekly messaging to facilitate changes in diet and activity behaviour through motivational and cognitive behavioural strategies. Changes in diet and activity levels will be recorded as personalised goals which will be monitored and reviewed by both the participants and dietitian. In addition participants will be encouraged to complete a food diary to self-monitor their progress against dietary recommendations.
1570768|NCT02450487|Drug|Piroxicam|After extraction of at least one third molar, 100 patients will be treated with Piroxicam (20 mg once daily for 4 days) for pain control, collect the saliva to be genotyped and phenotyped for CYP2C9 (by PCR) and their post-operative notes (pain, swelling, trismus, temperature) will be analyzed. For the pharmacokinetics of piroxicam saliva samples will be collected from 10 of these patients at different times after ingestion of a capsule of 20 mg Piroxicam (before, 1, 2, 3, 4, 5, 6, 8, 11, 24, 48 and 72 hours after ingestion).
1570769|NCT02450474|Device|Intermittent pneumatic compression device|Flowtron, Circulation Booster and Sports XL devices will be used.
1570770|NCT02450474|Device|Neuromuscular electrical stimulation|Flowtron, Circulation Booster and Sports XL devices will be used.
1570771|NCT02450461|Other|no intervention|
1570772|NCT02450448|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
1570773|NCT02450448|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
1570774|NCT02450435|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
1570775|NCT02450435|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
1570776|NCT02450422|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
1570777|NCT02450422|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
1570778|NCT02450409|Procedure|Implantation of TKA using the gap technique|Implantation of total knee arthroplasty using a specific operative technique (GT) serving as control.
1570779|NCT02450409|Procedure|Implantation of TKA using anatomical alignment|Implantation of total knee arthroplasty using a specific operative technique (AA) being experimental.
1570782|NCT02450370|Behavioral|Low FODMAP diet|Subjects in this group will follow a low FODMAP diet for up to 10 weeks. Foods that are high in oligosaccharides, disaccharides, monosaccharides and polyols will be avoided. They will receive 3 dietetic consultations at week 0,6 and 10. Dietary leaflets, including meal samples and Yes/No food lists will be provided.
1570783|NCT02450370|Behavioral|Conventional IBS diet group|Subjects in this group will follow a conventional diet for up to 10 weeks. They will receive 3 dietetic consultations at week 0,6 and 10. This diet will focus on small frequent meals, no skipping meals and dietary adjustments for bloatedness, diarrhea and constipation. Advice on intake of caffeine and alcohol will also be given. Dietary leaflets will be provided.
1570784|NCT02450357|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
1570796|NCT02450266|Device|Systematic transrectal ultrasound-guided prostate biopsy|12-18 systematic biopsy cores
1570797|NCT02450266|Device|MRI/ultrasound fusion-guided prostate biopsy|2 targeted biopsy cores from each prostate lesion
1570798|NCT02450253|Drug|Tadalafil|single dose, 20 mg capsule p.o.
1570799|NCT02450253|Drug|Placebo|single dose, matching capsule p.o.
1570800|NCT02450253|Behavioral|Cognitive functioning tests|Cognitive function tests will be performed prior to MRI scan 1 performed prior to IMP dosing on 2 occasions as patient will act as their own control
1570801|NCT02450253|Behavioral|Neuropsychological tests|"Neuropsychological tests will be performed prior to pre IMP dose MRI scan & then parallel V2 of the tests repeated 3-5 post IMP dose and before 2nd MRI scan.
Participants act as own controls as 1 IMP occasion will be placebo- 2nd IMP occasion will be active. 7-30 days apart"
1570802|NCT02450253|Other|MRI Scan - Arterial Spin Labelling|Pre and post IMP dose on 2 occasions to detect difference in blood flow in deep brain 4 MRI scans in total
1570803|NCT02450240|Behavioral|standardized diagnostic assessment|
1570804|NCT02450240|Behavioral|self-report questionnaires|
1570805|NCT02450240|Behavioral|behavioral tasks|
1570806|NCT02450240|Other|physiological measurements|
1570807|NCT02450240|Other|structural and functional magnetic resonance imaging and EEG|
1570808|NCT02450240|Other|biomarker and microbiome assessments|
1570809|NCT02450240|Other|blood to derive induced pluripotent stem cells|
1570810|NCT02450240|Other|genetic and epigenetic assessments|
1570811|NCT02450227|Dietary Supplement|Spinach - Whole leaf (10 mg lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
1570812|NCT02450227|Dietary Supplement|Spinach - Minced (10 mg/lutein)|Identical spinach meals processed in two different ways by Frigodan, served alone or together with habitual diet
1570813|NCT02450214|Drug|Saline|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
1570814|NCT02450214|Drug|Ketamine|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
1570815|NCT02450214|Drug|Ketamine + magnesium|50 mL syringe will be infused at 0.3 mL/Kg in bolus and then 0.15 mL/Kg/h 100 mL flask will be infused at 1mL/Kg in bolus for 30 min and then 0.25mL/Kg/h
1570816|NCT02450201|Drug|Pyruvate|
1570817|NCT02450188|Drug|Vardenafil|"In this study we used Vardenafil 10 mg orodispersible tablets. These are the only orodispersible tablets on commerce indicated for the treatment of ED. We choose this kind of tablets because of their easy way of assumption that can also have a minor psychological impact on patients.
Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
1570818|NCT02450188|Behavioral|CBST|"The CBST cognitive intervention, in according with Beck (1976), includes to help patients and their partners to gain a commonsense understanding and reframe their problems.
On the other side, the CBST behaviour intervention, how described by Meichenbaum (1993), is a method to teach patients to practice different behaviours that allows the replacement of the compromised behaviour with a functional one.
CBST interventions used in this study includes: psycho-educational interventions on ED maintaining, on anxiety's role and sexual homework. This course is structured in 10 weekly meetings. Male patients will begin taking Vardenafil 10 mg orodispersible tablets 2 times a week for 10 weeks."
1570819|NCT02450175|Drug|Everolimus|10 mg of Everolimus daily (by mouth)
1570820|NCT02450175|Drug|Letrozole|2.5mg taken daily (by mouth)
1570821|NCT02450162|Procedure|lateral rectus recession (bilateral)|Two types of recession (conventional or hang-back method) are typical surgeries for correcting intermittent exotropia. It depends on surgeon's decision at the time of surgery.
1570822|NCT02450149|Drug|sorafenib|
1570823|NCT02450136|Drug|pazopanib|
1570824|NCT02450123|Drug|sunitinib|
1570825|NCT02450110|Device|Spinal cord stimulation|
1570826|NCT02450097|Other|Caloric restriction|
1570827|NCT02450084|Procedure|Rectus sheath block|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
1570828|NCT02450084|Drug|Ropivacaine|Ultrasound-guided bilateral rectus sheath block of RSB group using 0.25% Ropivacaine
1570829|NCT02450084|Other|Bandage|After the surgery, a bandage will be attached on injection site where is same as the incision site of surgery.
1570830|NCT02450084|Drug|IV-PCA containing Fentanyl|All patients will use total 100 ml of IV-PCA containing 800 µg of fentanyl for 48 hours postoperatively.
1570831|NCT02450058|Drug|5-fluorouracil|600 mg/m2 intravenously on day 1, every 21 days for six cycles
1570832|NCT02450058|Drug|epirubicin|60 mg/m2 intravenously on day 1, every 21 days for six cyles
1570833|NCT02450058|Drug|cyclophosphamide|600 mg/m2, intravenously on day 1, every 21 days for six cycles
1570834|NCT02450058|Drug|epirubicin|90 mg/m2 on day 1, every 21 days for four cycles
1570835|NCT02450058|Drug|paclitaxel|175 mg/m2, 3-hour infusion on day 1, every 21 days for four cycles
1570836|NCT02450045|Procedure|Continuous femoral nerve block|
1570837|NCT02450045|Drug|0.5% Ropivacaine/0.125% Bupivacaine local anesthetic mixture|
1570838|NCT02450032|Biological|G17DT|
1570839|NCT02450019|Procedure|Traditional to protective ventilation|Traditional ventilation will be set with 9 ml/kg with predicted body weight of tidal volumes and no PEEP and switched to protective ventilation after intracranial pressure measurement.
1570840|NCT02450019|Procedure|Protective to traditional ventilation|Protective ventilation will be set with 7 ml/kg tidal volume, 5 cm H2O PEEP, and 0.4 inspired O2 fraction (FiO2), and switched to traditional ventilation after intracranial pressure measurement.
1570841|NCT02449993|Device|MammaTyper™|MammaTyper™ is an in vitro molecular diagnostic test for the quantitative detection of the biomarkers estrogen receptor (ESR1), progesterone receptor ( PgR), Human epidermal growth factor receptor 2 (HER2) and proliferation antigen Ki-67 on the basis of the values of the messenger ribonucleic acid (mRNA).
1570842|NCT02449980|Procedure|Primary Surgery Group|Patients will received immediate surgical intervention, as previously described, for the spontaneous pneumothorax. Patients will then be admitted postoperatively and monitored until discharge criteria are met
1571466|NCT02445807|Drug|Vehicle Cream|Twice daily topical application for 14 days.
1570843|NCT02449980|Procedure|Initial Non-operative management|Patients will receive percutaneous drainage or chest tube placement as initial management for spontaneous pneumothorax. This will be followed by an observation period until discharge criteria are met.
1570844|NCT02449967|Procedure|interventional therapy|pancreatic cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
1570845|NCT02449954|Drug|Intravenous morphine sulphate|Group I:received IV 0.1mg/kg morphine sulphate.
1570846|NCT02449954|Drug|Intravenous tramadol HCL|Group II:received IV 2 mg/kg tramadol HCL.
1570847|NCT02449954|Drug|Intravenous ketorolac tromethamine|Group III: received IV 30 mg ketorolac tromethamine
1570848|NCT02449941|Drug|PPI (proton pump inhibitor)|"Pre ESD (endoscopic submucosal dissection)
Assessment atrophy and metaplasia in stomach, Check Helicobacter pylori
Use of PPI for 2 months
Post ESD 1 (After 2 months)
Assess the distribution of helicobacter pylori after using PPI.
Stop of PPI
Post ESD 2 (After 4 months)
Assess the distribution of helicobacter pylori after stop of PPI."
1570849|NCT02449928|Drug|sodium lactate Ringer's injection(Baxter, ShangHai, China)|use sodium lactate Ringer's injection to resuscitate the septic shock patients(lactate group)
1570850|NCT02449928|Drug|Compound Sodium Chloride Injection (CR Double-Crane, Beijing, China)|use Compound Sodium Chloride injection to resuscitate the septic shock patients(control group)
1570853|NCT02449902|Drug|Estradiol|1 10 µg capsule inserted vaginally for 14 days.
1570854|NCT02449902|Drug|placebo|1 placebo capsule inserted vaginally for 14 days.
1570857|NCT02449876|Other|Neuroscience Education|"The following topics will be discussed in the education
Basic structure of the nervous system
Basic physiology of the nervous system
The function and importance of pain
Strategies to lessen the impact of pain
The instruction will be delivered in an interactive manner so that questions are addressed immediately. At the conclusion of the session each subject will receive the book: Why Do I Hurt by Adriaan Louw to reinforce the information discussed in the session. Subjects will be asked to read the 50 page book prior to the second session.
Session 2:
The session will begin with a review of the topics discussed in Session 1 and contained in the book. Subject will be encouraged to ask questions and get clarification on any of the topics that are unclear."
1570858|NCT02449863|Other|Lung ultrasound|Lung ultrasound performed to newborns with respiratory distress
1570859|NCT02449850|Other|Food intervention|Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age
1570860|NCT02449850|Other|Skin care|Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.
1570861|NCT02449837|Other|Blood draw|Blood samples will be collected at up to 4 time points before and during radiation. Blood will be collected at least 4 to 12 weeks post-treatment. Additional post-treatment blood draws will be performed at each subsequent follow-up clinic visit, but no more than every 3 months, up until 24 months after completion of radiation.
1570863|NCT02449811|Drug|Perindopril|
1570864|NCT02449811|Drug|Olmesartan|
1570865|NCT02449811|Drug|Amlodipine|
1570866|NCT02449811|Drug|Hydrochlorothiazide|
1570867|NCT02449798|Device|"AccuCath 2.25 BC Intravascular Catheter"|Long peripheral IV catheter designed for difficult IV access patients requiring deeper vessel access, often used with ultrasound guidance.
1570868|NCT02449785|Device|MR measurements of lung morphological changes in cystic fibrosis (Avanto dot, Siemens)|
1570869|NCT02449785|Device|CT measurements of lung morphological changes in cystic fibrosis|
1570870|NCT02449772|Other|No intervention|No intervention
1570871|NCT02449759|Behavioral|ACT Intervention Group|A six chapter, 58 page self-help manual based on the principles of Acceptance and Commitment Therapy
1570872|NCT02449746|Biological|Plasma Exchange|PLEX is a procedure in which the subject's blood is passed through a medical device which separates out plasma from the other blood components, and replaces the plasma with albumin or plasma or other colloid. PLEX therefore removes circulating pathogenic antibodies, and furthermore therapeutic benefit after PLEX supports an antibody mediated pathogenesis of disease. In PLEX, 200-250 mL plasma per kg body weight is exchanged typically over 7-14 days using 5% albumin as replacement, often at alternate days which increases the amount of immunoglobulin removed due to equilibrium effects. PLEX modality (centrifugation or filtration), type of anticoagulation, and dose scheduling will be determined by local centre practice.
1570873|NCT02449746|Biological|Intravenous immunoglobulin|"Active Comparator: Intravenous Immunoglobulin (IVIG) IVIG is a pooled blood product from 3000-100,000 human blood donors with direct immunomodulatory effects.
IVIG will be given at a dose of 2g/kg over 4 days. Dosing at 2g/kg is established in neurological disorders, with limited evidence that lower doses are less effective although adequate dosing studies have not been performed."
1570874|NCT02449733|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
1570875|NCT02449733|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
1570876|NCT02449733|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
1570877|NCT02449733|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|"FTC/TDF is a once daily oral tablet taken with or without food. The tablet includes 200 mg of emtricitabine (FTC) and 300 mg of tenofovir disoproxil fumarate (TDF).
For men who meet eligibility criteria, Pre-exposure prophylaxis (PrEP) with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit."
1570878|NCT02449733|Other|HIV Testing|Rapid HIV testing at multiple time points
1570879|NCT02449733|Other|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for sexually transmitted infections (STIs )will be treated at the clinic site.
1570880|NCT02449733|Procedure|Post-exposure prophylaxis (PEP)|Two to three antiretroviral medicines as soon as possible (recommended is emtricitabine/tenofovir disoproxil fumarate plus either raltegravir or dolutegravir), but no more than 72 hours (3 days) after one may have been exposed to HIV, to try to reduce the chance of becoming HIV-positive. They must be taken for 28 days.
1570881|NCT02449733|Behavioral|Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
1570882|NCT02449720|Drug|Ropivacaine|Intraperitoneal instillation and infusion
1570883|NCT02449720|Drug|0.9% Saline|Intraperitoneal instillation and infusion
1570884|NCT02449707|Procedure|Lateral Window Technique Augmentation for Maxillary Sinus|Maxillary sinus augmentation will be performed using the lateral window technique
1570885|NCT02449707|Device|Ultrasound activated resorbable poly-D-L-lactide pins|The titanium membrane placed during the maxillary sinus augmentation procedure will be stabilized using ultrasound activated resorbable poly-D-L-lactide pins
1570886|NCT02449707|Device|Purus® Cancellous Allograft|Allograft material placed in the sinus to acheive sinus augmentation
1570887|NCT02449707|Device|Resorb X Membrane|The membrane placed over the graft material before placement of the ultrasound activated pins
1570888|NCT02449707|Device|Biomend|Collagen healing membrane placed over the graft material on the side where no ultrasound activated pins are being used
1570889|NCT02449707|Procedure|Cone Beam CT image of the Sinus|Cone beam CT will used to assess the thickness of bone formation after the placement of the graft
1570890|NCT02449707|Procedure|Trephine Biopsy|Trephine Biopsy will be performed at the time of the placement of implant to study the quality of bone formed
1570891|NCT02449694|Device|OCS Liver|OCS Liver will be used to preserve the donor liver
1570892|NCT02449681|Drug|TH-4000|
1570893|NCT02449668|Device|Acupuncture|Acupuncture techniques with a plastic insertion tube was used to introduce every needle. The needles were perpendicularly inserted to a depth of 2-3 cm. The needles were applied to the area of the injured shoulder while the patient was lying in a lateral decubitus position on the stretcher. The skin was prepared with clorhexidine and the needles were sterile. They measured 40 mm long and 0.25 mm in diameter. The sessions lasted 20 minutes and the Qi sensation was sought by consistent manipulations, with rotation of the needles in both senses and scratching of the handle.
1570894|NCT02449668|Device|Sham Acupuncture|
1570895|NCT02449655|Drug|AZD5363|AZD5363 4800mg bid 4 days on/ 3 days off of a 7 day cycle for each week
1570896|NCT02449655|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
1570897|NCT02449655|Drug|AZD2014|AZD2014 50mg BD 3 days on 4 days off of a 7 day cycle
1570898|NCT02449655|Drug|paclitaxel|paclitaxel 80mg/m2 given days 1, 8 and 15 of a 28 day cycle
1570899|NCT02449616|Drug|MST-188|Intravenous administration as 100 mg/kg for 1 hour followed by 30 mg/kg/hour for up to 48 hours.
1570900|NCT02449603|Drug|Exenatide|
1570901|NCT02449603|Drug|Biphasic insulin Aspart 30|
1570902|NCT02449590|Dietary Supplement|Onion powder|Hot meals with onion powder; 10 g/day onion powder corresponding to 100 g/day fresh onion in meals with potato and beef Intervention period 14 days.
1570903|NCT02449590|Dietary Supplement|Placebo|Hot meals without onion powder; Control meal with potato, beef, soy protein, and sucrose to match macronutrient composition of active treatment
1570904|NCT02449577|Other|Beverage sequence ABCD|Participants receive test beverages in the randomised order ABCD
1570905|NCT02449577|Other|Beverage sequence CADB|Participants receive test beverages in the randomised order CADB
1570906|NCT02449577|Other|Beverage sequence DACB|Participants receive test beverages in the randomised order DACB
1570907|NCT02449577|Other|Beverage sequence CBAD|Participants receive test beverages in the randomised order CBAD
1570908|NCT02449577|Other|Beverage sequence ABDC|Participants receive test beverages in the randomised order ABDC
1570909|NCT02449577|Other|Beverage sequence DABC|Participants receive test beverages in the randomised order DABC
1570910|NCT02449577|Other|Beverage sequence DCAB|Participants receive test beverages in the randomised order DCAB
1570911|NCT02449577|Other|Beverage sequence DBCA|Participants receive test beverages in the randomised order BDCA
1570912|NCT02449577|Other|Beverage sequence ADCB|Participants receive test beverages in the randomised order ADCB
1570913|NCT02449577|Other|Beverage sequence BADC|Participants receive test beverages in the randomised order BADC
1570914|NCT02449577|Other|Beverage sequence ACDB|Participants receive test beverages in the randomised order ACDB
1570915|NCT02449564|Drug|sirolimus|sirolimus 1mg daily
1572375|NCT02438722|Drug|Afatinib Dimaleate|Given PO
1570916|NCT02449551|Drug|Volitinib|Volitinib is an orally available, potent, selective, small molecule c-MET inhibitor. Volitinib 800 mg will be administered orally once a day for 21 days as one cycle.
1570917|NCT02449538|Drug|everolimus|everolimus 10 mg qd daily one cycle is 28days.
1570918|NCT02449525|Procedure|Perfusion of flaps by a special bypass system|Free flaps are perfused via a special bypass perfused by a new technique supported by a intermittent perfusion support system.
1570919|NCT02449486|Drug|Ropivacaine|
1570920|NCT02449473|Biological|Tralokinumab|Subcutaneous Injection
1570921|NCT02449473|Other|Placebo|Subcutaneous Injection
1570922|NCT02449447|Behavioral|Cognitive behavioral therapy|CBT based on behavioral activation and cognitive therapy techniques including homework
1570923|NCT02449447|Other|Treatment as usual|Treatment as usual in primary care including antidepressants and counselling
1570924|NCT02449421|Behavioral|Quality Improvement Learning Community|Consultation with CPT experts to effectively use evidence-based psychotherapy.
1570925|NCT02449421|Behavioral|Fidelity-oriented Learning Community|The Fidelity-oriented Learning Community arm will receive fidelity consultation (adherence and competence) feedback by a CPT expert via online meetings.
1570926|NCT02449408|Other|Measurement of leptin and adiponectin obtained through blood sampling via venipuncture or finger/heelstick using novel screening tool|
1570927|NCT02449382|Procedure|continuous venovenous hemofiltration|If the serum sodium concentration >150mmol/L, When filter occurred clotting, replace the filter to CVVH treatment
1570928|NCT02449382|Drug|Control group|If the serum sodium concentration ≤150mmol/L, When filter occurred clotting, as the end of treatment.
1570929|NCT02449369|Drug|Preop acetaminophen IV|
1570930|NCT02449369|Drug|Preop orphenadrine IV|
1570931|NCT02449369|Drug|Postop oral oxycodone & acetaminophen|
1570932|NCT02449369|Drug|Postop hydromorphone IV|
1570933|NCT02449369|Drug|Postop oral orphenadrine|
1570934|NCT02449369|Drug|Postop oral oxycodone|
1570935|NCT02449369|Drug|Postop acetaminophen IV|
1570936|NCT02449369|Drug|Postop orphenadrine IV|
1570937|NCT02449356|Device|prone position endotracheal tube(PPT)|some special kind of endotracheal tube,including traditional air tube ,fixed device, fixed rope, and two through holes
1570938|NCT02449343|Drug|Anlotinib|Anlotinib p.o. qd
1570939|NCT02449343|Drug|Placebo|Placebo p.o. qd
1570940|NCT02449330|Drug|Teneligliptin|
1570941|NCT02449317|Other|Bioimpedance guided|"bioelectrical impedance analysis guided hydration therapy : 7.5% Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV in 6 hours rate was adjusted regarding to extracellular water/total body water
extracellular water/total body water < 0.36 : 4 ml/kg/hr
extracellular water/total body water 0.36-0.4 : 2 ml/kg/hr
extracellular water/total body water > 0.4 : 1 ml/kg/hr"
1570942|NCT02449317|Other|standard hydration|standard hydration : 7.5%Sodium bicarbonate 150 ml + 5% dextrose in water 850 ml IV 1 ml/kg/hr in 6 hours
1570943|NCT02449304|Device|Endometrial ablation (4th gen)|Radiofrequency Bipolar endometrial ablation device that is inserted into the uterine cavity to destroy the endometrial lining
1570944|NCT02449291|Drug|APD421|
1570945|NCT02449291|Drug|Placebo|
1570946|NCT02449278|Radiation|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-site radiotherapy (ISRT).
Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.
The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR)."
1570947|NCT02449278|Radiation|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy followed consolidation involved-field radiotherapy (IFRT).
Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.
The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR)."
1570948|NCT02449278|Drug|cyclophosphamide|Patients in both arms will be given cyclophosphamide chemotherapy
1570949|NCT02449278|Drug|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy
1570950|NCT02449278|Drug|vincristine|Patients in both arms will be given vincristine chemotherapy
1570951|NCT02449278|Drug|prednisone|Patients in both arms will be given prednisone chemotherapy
1570952|NCT02449265|Radiation|Consolidation involved-site radiotherapy (ISRT)|"6 cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.
The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 20~25 fractions of 2 Gy 5 days per week for partial response (PR)."
1570953|NCT02449265|Radiation|Consolidation involved-field radiotherapy (IFRT)|"6 cycles modern CHOP chemotherapy. Radiotherapy field of IFRT defined by CALGB is encompassed the prechemotherapy gross tumor.
The general dose had been guided that 30-36Gy in 15~18 fractions of 2 Gy 5 days per week was managed for patients with complete response (CR) after chemotherapy and 40-50Gy in 15~18 fractions of 2 Gy 5 days per week for partial response (PR)."
1570954|NCT02449265|Drug|cyclophosphamide|Patients in both arms will be given cyclophpsphamide chemotherapy.
1570955|NCT02449265|Drug|doxorubicin|Patients in both arms will be given doxorubicin chemotherapy.
1570956|NCT02449265|Drug|vincristine|Patients in both arms will be given vincristine chemotherapy.
1570957|NCT02449265|Drug|prednisone|Patients in both arms will be given prednisone chemotherapy.
1570958|NCT02449252|Radiation|Consolidation involved-site radiotherapy (ISRT)|"six cycles modern CHOP chemotherapy. Involved-site radiotherapy (ISRT) is based on defining the site of gross disease before chemotherapy, the GTV and using a CT-based volume with an expansion to form a CTV in the cranio-caudal direction.
Involved-site radiotherapy (ISRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week."
1571135|NCT02448043|Drug|Bimatoprost 0.01%|Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
1570959|NCT02449252|Radiation|Consolidation involved-field radiotherapy (IFRT)|"six cycles modern CHOP chemotherapy. Radiotherapy field of involved-field radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
Involved-field RT (IFRT) is given in 24Gy~30Gy in 12~15 fractions of 2 Gy 5 days per week."
1570960|NCT02449252|Drug|cyclophosphamide|patients in both arms will be given cyclophosphamide chemotherapy.
1570961|NCT02449252|Drug|doxorubicin|patients in both arms will be given cyclophosphamide chemotherapy.
1570962|NCT02449252|Drug|vincristine|patients in both arms will be given cyclophosphamide chemotherapy.
1570963|NCT02449252|Drug|prednisone|patients in both arms will be given cyclophosphamide chemotherapy.
1570965|NCT02449200|Other|Multimodal physiotherapy|Manual therapy, exercise and neural unloading tape provided twice weekly over 4 weeks by an experienced musculoskeletal physiotherapist
1570966|NCT02449187|Drug|JLP-1310, Fasted followed by fed|"In period 1, the subjects will receive an oral pill of JLP-1310 under fasted condition.
In period 2, the subjects will receive an oral pill of JLP-1310 under fed condition."
1570967|NCT02449187|Drug|JLP-1310, Fed followed by fasted|"In period 1, the subjects will receive an oral pill of JLP-1310 under fed condition.
In period 2, the subjects will receive an oral pill of JLP-1310 under fasted condition."
1570968|NCT02449174|Biological|Frozen Microbiota|Frozen Mcirobiota will be delivered via enema route.
1570969|NCT02449174|Biological|Lyophilized Microbiota|Lyophilized Microbiota will be delivered orally.
1570972|NCT02449148|Other|Calorie Restriction|diet intervention to reduce the risk for obesity associated diseases
1570973|NCT02449135|Procedure|interventional therapy|Pancreatic cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）.
1570974|NCT02449122|Procedure|interventional therapy|Lung cancer patients received drug interventional therapy using the digital subtraction angiography（DSA.）
1570975|NCT02449109|Procedure|interventional therapy|Liver cancer patients received drug interventional therapy using the digital subtraction angiography（DSA）
1570976|NCT02449096|Device|Arthroscope|AORIF - arthroscopically assisted open reduction and internal fixation of acute ankle fractures
1570977|NCT02449096|Other|No arthroscope|ORIF - open reduction and internal fixation of acute ankle fractures
1570978|NCT02449083|Procedure|MRI|MRI
1570979|NCT02449083|Procedure|coronary angiography|coronary angiography
1570980|NCT02449070|Drug|Nicorandil|4 mg iv after randomization, 2 mg ic just before ballooning, 2 mg ic just before stenting
1570981|NCT02449057|Other|JUST|Swift, certain, and proportionate sanctions for violations of terms of community supervision.
1570982|NCT02449044|Drug|Tolvaptan|Once Daily
1570983|NCT02449031|Drug|TOBI Podhaler|
1570984|NCT02449031|Drug|TOBI|tobramycin inhalation solution, USP
1570985|NCT02449031|Drug|Bethkis|tobramycin inhalation solution
1570986|NCT02449031|Drug|Cayston|aztreonam for inhalation solution
1570989|NCT02449005|Biological|BM-MSCs/fibrin glue/collagen fleece|Xeno-free, clinical-grade, autologous alveolar bone marrow mesenchymal stem cells enriched with autologous fibrin glue and loaded into a commercially available collagen fleece.
1570990|NCT02449005|Other|Fibrin glue/collagen fleece|The biocomplex of autologous fibrin glue and collagen fleece devoid of stem cells will fill the osseous defect
1570991|NCT02449005|Procedure|Open flap debridement|Group C will receive minimally invasive surgery employing papilla preservation techniques in addition to retaining the soft tissue wall of the pocket. There will be no use of grafting materials
1570992|NCT02448992|Radiation|hippocampal-sparing WBRT|
1570993|NCT02448979|Procedure|Left thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
1570994|NCT02448979|Procedure|Right thoracotomy|Transthoracic approach is the surgical procedure including the open and minimally invasive thoracotomy.
1570995|NCT02448966|Procedure|open esophagectomy|
1570996|NCT02448966|Procedure|Minimally invasive esophagectomy|
1570997|NCT02448953|Procedure|Two-field lymphadenectomy|Thoracic-upper abdominal two-field lymphadenectomy
1570998|NCT02448953|Procedure|Three-field lymphadenectomy|Cervical-thoracic-upper abdominal three-field completely lymphadenectomy
1570999|NCT02448940|Dietary Supplement|Species of Lactobacillus|2 capsule a day Lactofem probiotics containing Species of Lactobacillus
1571000|NCT02448940|Dietary Supplement|lactose|2 capsule a day containing lactose
1571001|NCT02448927|Device|balloon aortic valvuloplasty|
1571002|NCT02448927|Device|Transcatheter Aortic Valve Implantation|
1571003|NCT02448914|Drug|TRIGEL|All patients will receive TRIGEL. Treatment order is determined by randomization.
1571004|NCT02448914|Drug|Duodopa|All patients will receive Duodopa. Treatment order is determined by randomization.
1571005|NCT02448901|Drug|Edoxaban|In vitro study. Various concentrations of Edoxoban added to blood sample and tested
1571006|NCT02448888|Other|Adapted exercise|2 months, 3 times/week
1571007|NCT02448888|Other|General exercise recommendations|2 months, 3 times/week
1571008|NCT02448875|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. The CyPass Micro-Stent is designed to be permanently implanted in the eye.
1571009|NCT02448875|Device|CyPass Micro-Stent + 60 ul viscoelastic|In addition to CyPass Micro-Stent implantation, 60 ul of ophthalmic viscoelastic will be used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
1571055|NCT02448602|Other|acupuncture|Patients will be treated with Shenmen(HT7), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
1571136|NCT02448043|Other|placebo: saline|Placebo drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days
1572376|NCT02438722|Biological|Cetuximab|Given IV
1571010|NCT02448862|Device|Fentanyl based IV-PCA|We have used a disposable PCA pump (Ambix Anaplus®; E-Wha Fresenius Kabi, Korea or accufuser plus®; Woo Young Medical, Korea) and fentanyl was diluted in 100 mL with saline for 48 hrs PCA infusion. The pump was set as follows: infusion rate as 2 ml/hr, bolus dose as 0.5 ml or 1 ml, lockout time as 15 min. It was decided at the anesthesiologist's option whether the additional analgesic drug (ketorolac or nefopam) and the antiemetic drug (ondansetron, ramosetron or palonosetron) would be added in PCA or not. The anesthesiologist who performed the anesthesia decided the amount of chosen drugs.
1571011|NCT02448849|Biological|Percutaneous injection|percutanous implantation of bone marrow derived mesenchymal stromal cells in patients with nonunion fracture.
1571012|NCT02448849|Other|Percutaneous injection|Percutaneous implantation of placebo in patients with nonunion fracture.
1571013|NCT02448836|Device|dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of dTMS treatment for two weeks (4 sessions every week).
1571014|NCT02448836|Device|Sham: dTMS H-coil system:magstim stimulator rapid2,BrainswayH1coil|Patients will undergo 8 sessions of Sham dTMS treatment for two weeks (4 sessions every week).
1571015|NCT02448823|Other|Mass media and Stylish Events|"Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
Stylish Man/Living Event (SMLEvent) community mobilization/service provision. SMLEvent activities. Messages on how CHP (including behaviors such as sexual risk reduction) can make men and women feel more in control of their lives, less stressed, and more Stylish are interwoven through the mobilization.
The Stylish Man Van (SMV) accompanies the SMEvent. The Van includes multimedia and health mobilizers who insert HIV prevention messages, testimonials by satisfied CHP customers and where appropriate their spouses."
1571016|NCT02448823|Other|Mass Media|1. Mass media (MM): Radio broadcasts, dramatized dialogues, interviews with opinion leaders and satisfied clients . Posters.
1571023|NCT02448797|Drug|Icotinib|125 mg three times daily (375 mg per day) orally, until disease progression or untolerable toxicity.
1571024|NCT02448797|Drug|Chemotherapy|"vinorelbine 25 mg/m^2, intravenously guttae, day 1 and day 8, 21 days/cycle, 4 cycles.
cisplatin 75 mg/m^2, intravenously guttae, day 1, 21 days/cycle, 4 cycles."
1571025|NCT02448784|Drug|Donepezil Hydrochloride|Initial dose for oral use is 3 mg once daily. The dose is increased to 5 mg after 1-2 weeks. Following at least 4 weeks of dosing at 5 mg, the dose is increased to 10 mg. The dose may be decreased to 5 mg depending on the symptoms of the participant.
1571026|NCT02448771|Drug|Palbociclib|
1571027|NCT02448771|Drug|Bazedoxifene|
1571028|NCT02448745|Device|Insecticide treated wall lining|Polypropylene non-woven fabric.
1571029|NCT02448732|Drug|ACM-1|intravitreal injection with 50ul ACM-1 at a concentration of 1600ug/ml
1571030|NCT02448719|Drug|TAK-792 30 mg|TAK-792 30 mg will be administered in the morning after a fast.
1571031|NCT02448719|Drug|TAK-792 30 mg placebo|TAK-792 30 mg placebo will be administered in the morning after a fast.
1571032|NCT02448719|Drug|TAK-792 100 mg|TAK-792 100 mg will be administered in the morning after a fast.
1571033|NCT02448719|Drug|TAK-792 100 mg placebo|TAK-792 100 mg placebo will be administered in the morning after a fast.
1571034|NCT02448719|Drug|TAK-792 250 mg|TAK-792 250 mg will be administered in the morning after a fast.
1571035|NCT02448719|Drug|TAK-792 250 mg placebo|TAK-792 250 mg placebo will be administered in the morning after a fast.
1571036|NCT02448719|Drug|TAK-792 500 mg|TAK-792 500 mg will be administered in the morning after a fast or after breakfast.
1571037|NCT02448719|Drug|TAK-792 500 mg placebo|TAK-792 500 mg placebo will be administered in the morning after a fast or after breakfast.
1571038|NCT02448719|Drug|TAK-792 750 mg|TAK-792 750 mg will be administered in the morning after a fast or after breakfast.
1571039|NCT02448719|Drug|TAK-792 750 mg placebo|TAK-792 750 mg placebo will be administered in the morning after a fast or after breakfast.
1571040|NCT02448719|Drug|TAK-792 1250 mg|TAK-792 1250 mg will be administered in the morning after a fast.
1571041|NCT02448719|Drug|TAK-792 1250 mg placebo|TAK-792 1250 mg placebo will be administered in the morning after a fast.
1571042|NCT02448706|Device|Hearing Aid Fitting A|
1571043|NCT02448706|Device|Hearing Aid Fitting B|
1571044|NCT02448693|Device|WLE|Evaluation of the polypectomy scar with High Definition White Light Endoscopy (WLE)
1571045|NCT02448693|Device|NBI|Evaluation of the polypectomy scar with Narrow Band Imaging (NBI, Evis Exera III, Olympus).
1571046|NCT02448680|Biological|Coagulation FVIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
1571047|NCT02448667|Dietary Supplement|FAXE Kondi|Sucrose and glucose containing softdrink
1571048|NCT02448667|Dietary Supplement|Faxe Kondi Free|Diet softdrink with artificial sweeteners aspartame and acesulfame potassium. Both sweeteners are approved for use as food additives in the European Union and by the FDA. Aspartame metabolism is well understood and normal doses does not affect plasma concentrations of lipids, amino acids, glucose levels, key regulatory hormones or skeletal muscle metabolism. Acesulfame Potassium is not metabolized in humans and is excreted as the parent compound in urine. Since the two artificial sweeteners does not affect skeletal muscle metabolism or blood glucose levels, and both compounds have a well documented safety profiles, FAXE Kondi Free is considered to be an ideal placebo soft drink in this study.
1571056|NCT02448602|Other|acupuncture|Patients in Sancai coordinated points group, will be treated with Baihui(DU20), Shenmen(HT7), Sanyinjiao(SP6), needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
1571057|NCT02448602|Other|acupuncture|Patients in Control group, will be treated with at the junction of deltoid and biceps, needle 1 times a day, 30 min/time, 5 days for a period of treatment, the treatment interval for two days, five intervention treatment, follow-up after 4 weeks.
1571058|NCT02448589|Drug|TAS-119|
1571059|NCT02448576|Radiation|prophylactic cranial irradiation|Prophylactic cranial irradiation in patients with advanced triple negative breast cancer who had a response to first line chemotherapy
1571060|NCT02448563|Behavioral|Nutrition and physical activity education|Eight weekly in-person groups
1571061|NCT02448550|Drug|Bivalirudin|
1571062|NCT02448550|Drug|Unfractionated heparin|
1571063|NCT02448537|Drug|PM01183|
1571064|NCT02448537|Drug|Doxorubicin|
1571065|NCT02448537|Drug|Gemcitabine|
1571066|NCT02448524|Device|MiStent|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
1571067|NCT02448524|Device|TIVOLI|Primary in situ coronary artery disease patients (all patients enrolled with a maximum of two target lesions in different blood vessels and maximum of 2 stents per lesion. Lesions with reference diameter of 2.5mm-3.5mm (by visual measurement) and with length ≤40mm (by visual measurement).
1571068|NCT02448511|Other|Ozone|ozone gas generated by a generator applied to the affected part for a period of one hour each day under sub atmospheric pressure condition.
1571069|NCT02448511|Device|Placebo|a similar looking device was applied to the affected part for a period of one hour each day under sub atmospheric condition. the device did not produce any gas.
1571070|NCT02448511|Other|Conventional treatment|Conventional treatment for ulcers in the form of daily dressings, debridement and antibiotics was administered to both groups
1571071|NCT02448498|Behavioral|Exercise Intervention|
1571072|NCT02448485|Procedure|Aortic Valve Intervention (surgical or transcatheter)|Surgical or interventional aortic valve implantation
1571073|NCT02448472|Other|Observational study, none intervention|
1571074|NCT02448459|Drug|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.
Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.
The triggering will be performed using leuprorelin 1 mg (subcutaneous)."
1571075|NCT02448446|Drug|ranibizumab 0.3mg|intravitreally administered
1571076|NCT02448433|Device|Phototherapy light-emitting glasses|"The intervention consists of four weeks of bright light exposure with light-emitting glasses (blue-green 500 nm dominant wavelength; 506 Lux lm/m^2) upon awakening and progressive shift to earlier wake-up times.
Participants are encouraged to complete the light exposure sessions for 60 min each day. Participants are also instructed to progressively shift their schedule 15 min earlier every day. This shift continues until the end of the four weeks of the intervention, or stops if the target wake-up time of 7:30am is reached (in which case, participants keep a stable wake-up and light session schedule at 7.30am for the remainder of the intervention). If participants already wake-up before 7.30am at study entry, they do the light exposure sessions upon awakening across the four weeks of the intervention.
During the intervention, participants are asked to note down the time of each light exposure session in a diary. Adherence is also monitored and promoted through weekly phone calls."
1571077|NCT02448420|Drug|Palbociclib|oral dose of 200 mg/day for 2 weeks, followed by 1 week off.Number of Cycles: until progression or unacceptable toxicity develops.
1571078|NCT02448420|Drug|Trastuzumab|8 mg/kg in the first dose, followed by 6 mg/kg every 3 weeks.Number of Cycles: until progression or unacceptable toxicity develops.
1571079|NCT02448420|Drug|Letrozole|daily oral dose of 2.5 mg. Number of Cycles: until progression or unacceptable toxicity develops.
1571080|NCT02448407|Biological|Platelet rich plasma|Three intraarticular injections of platelet-rich plasma, one each fifteen days
1571081|NCT02448407|Drug|Hyaluronic acid|Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
1571082|NCT02448394|Other|Community Support Worker|At each of the intervention sites, all newly enrolled participants will have an HIV community support worker (CSW) assigned them. CSW responsibilities include: education on HIV treatment and health promoting behaviors, social support/counseling, facilitated communication with the HIV clinic, referrals as needed for other support needs.
1571088|NCT02448355|Device|OCT swept source DRI-Atlantis, Topcon|3-dimensional scanning protocol with 3 μm axial resolution and a speed of 100,000 A-scans per second. 256 B-scans to be taken on an area of 12 × 9 μm.
1571089|NCT02448342|Device|Remote Dielectric Sensing (ReDS) Wearable System|The ReDS device provides noninvasive measurement of lung fluid content. It comprises a wearable vest with embedded sensors and a bedside console, with touch-screen display. A measurement reading is provided within 90sec. Results are shared with the treating physician via a secured web portal.
1571090|NCT02448329|Drug|AZD1775|AZD1775 225 mg BID q 12 hours (x5 doses, 2.5 days) administered days 1~3
1571091|NCT02448329|Drug|paclitaxel|paclitaxel 80 mg/m2 given days 1, 8 and 15 of a 28 day cycle
1571092|NCT02448316|Procedure|endoscopic surgery|"Through 2 portals profound for the fascia plantaris (deep-fascial) lateral and medial a heel-spur will be resected and the medial half of the fascia is released from its attachment to the calcaneus.
A mikroskopic X-ray sensitive pearle (Tantalum-pearle) will be inserted in the fascia in the proximal end of the distal part of the remaining fascia for measuring distance (resorbtion).
Three weeks after operation, the patients are instructed to start a specific training program. Training is supervised every third week by a physiotherapist (week 3,6,9,12 after operation), and daily training is carried out at home. Sutures are removed after 10 days,"
1571093|NCT02448316|Drug|methylprednisolon|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
1571094|NCT02448316|Drug|lidokaine|1ml methylprednisolon is mixed with 1ml of Lidocain and injected underneath the plantar fascia as close to the medial attachment on calcaneus as possible
1571095|NCT02448316|Behavioral|Training|the patient is instructed in reduction in impact. strength training 3 times weekly and stretching exercises daily are recommended.
1571096|NCT02448303|Drug|Pembrolizumab|
1571097|NCT02448303|Drug|Acalabrutinib|
1571098|NCT02448290|Drug|docetaxel plus selumetinib|Selumetinib will be administered orally 75mg twice a day continuously. Docetaxel will be administered as an IV infusion over 1 hour at 60 mg/m2 every 3 week of a 21 days schedule.
1571099|NCT02448277|Device|Macintosh Laryngoscope|the device is to assist nasotracheal intubation
1571100|NCT02448277|Device|Pentax Airway scope|the device is to assist the nasotracheal tube into trachea
1571101|NCT02448277|Device|Glidescope|the device is to assist the nasotracheal tube into trachea
1571102|NCT02448264|Drug|BCX7353|
1571103|NCT02448264|Drug|Placebo to match BCX7353|
1571104|NCT02448251|Drug|AC0010MA|Following Phase I, a protocol amendment will be submitted to the IND to specify the selected dose and dose justification to be used in Phase II.
1571105|NCT02448238|Other|VSL#3® probiotic|"Other: VSL#3® probiotic VSL#3® DS (Sigma-Tau Pharmaceuticals) is a well characterized water soluble, live (9 × 1011 bacteria/sachet), lyophilized preparation of 8 probiotic bacterium that have been detailed previously. Subjects will take 1 sachet of powder orally daily for 12 weeks. As many Malian homes lack refrigeration, subjects will be issued a special canari, a commonly used earthenware water container also containing sand that works on the principal of trans-evaporation to keep contents at room temperature (~24°C) even in warmer climates. We have verified this in country. Probiotics will be placed in a sealed plastic bag within a sealed jar in the sand of the canari. At the research site, probiotics will be kept refrigerated (4-8°C) in a study provided refrigerator"
1571106|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT - standard of care
1571107|NCT02448225|Procedure|Computed Tomography|Undergo 18F-FSPG PET/CT
1571108|NCT02448225|Radiation|fluorodeoxyglucose F-18|Undergo 18F-FDG PET/CT - standard of care
1571109|NCT02448225|Drug|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET/CT
1571110|NCT02448225|Other|Laboratory Biomarker Analysis|Correlative studies
1571111|NCT02448225|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT - standard of care
1571112|NCT02448225|Procedure|Positron Emission Tomography (PET)|Undergo 18F-FSPG PET/CT
1571113|NCT02448212|Drug|TS-121|Oral
1571114|NCT02448212|Drug|[11C]TASP0410699|Intravenous radiotracer
1571115|NCT02448212|Radiation|Positron Emission Tomography (PET)|Imaging scanning procedure
1571116|NCT02448199|Drug|Meloxicam and Glucosamine|Experimental
1571117|NCT02448199|Drug|Meloxicam|Active Comparator
1571118|NCT02448199|Drug|Glucosamine|Active Comparator
1571119|NCT02448186|Behavioral|ESTEEM|10-session cognitive behavioral treatment
1571120|NCT02448173|Biological|OncoVAX and Surgery|OncoVAX is comprised of sterile, live but non-dividing tumor cells obtained following standard-of-care surgical tumor resection for Stage II colon cancer
1571121|NCT02448173|Procedure|Surgery|Surgical resection of Stage II colon cancer
1571122|NCT02448160|Device|alfapump|Implantation of alfapump
1571123|NCT02448160|Drug|salt-poor Human Albumin solution|Patients implanted with an alfapump will receive intermittent salt-poor human albumin solution
1571124|NCT02448147|Behavioral|Interval training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have two levels of intensity: one minute at respiratory compensation point heart rate intercalating with two minutes at anaerobic threshold heart rate during thirty minutes.
1571125|NCT02448147|Behavioral|Continuous training|Patients will be submitted to three months aerobic exercise training, three times per week. Each session will have only one level of intensity during stimulus phase of exercise, lasting thirty minutes: heart rate (HR) target is defined as 1/3x(HR at respiratory compensation point) + 2/3x(HR anaerobic threshold)
1571127|NCT02448121|Procedure|Stem Cell Graft Group|All patients will undergo autologous bone marrow stem cell implantation into the necrotic lesion area using a minimally invasive technique.
1571128|NCT02448121|Biological|Autologous bone marrow stem cell|Bone marrow ficoll separated mononuclear autologous cells. Autologous bone marrow cells collection under sedation, then processed through a ficoll gradient.
1571129|NCT02448108|Behavioral|i-IPSRT|"internet IPSRT (a form of psychotherapy for individuals with bipolar disorder) will be offered via 12 specially-designed modules.
CH will have participated in a two day training about Bipolar Disorder and IPSRT."
1571130|NCT02448108|Other|Written Psychoeducation|Written material about the importance of social rhythm regularity to mood stability in bipolar disorder
1571131|NCT02448095|Drug|Ponatinib|Observation of tolerability and safety profiles
1571132|NCT02448082|Other|Shampoo (inactive)|Shampoo which is made to look and feel the same as the experimental shampoo but does not contain the active ingredient of sodium shale oil sulponate 1%.
1571133|NCT02448082|Other|Sodium shale oil sulponate 1% shampoo|Shampoo containing the active ingredient of sodium shale oil sulponate 1%.
1571134|NCT02448069|Drug|Argatroban|All patients will receive a 3.0 mcg/kg/min continuous infusion of Argatroban, preceded by a 100 mcg/kg bolus. Infusion will be titrated to achieve an aPTT of 2.25 times baseline (not to exceed 10 mcg/kg/min) for a maximum of 12 hours.
1571137|NCT02448030|Other|Functional electric stimulation|The FES will be placed at the flexor muscles of the forearm and knee extensors, for evaluation of upper and lower limbs, respectively. The stimulation frequency will be 20 Hz. The pulse width used will be 0.5 milliseconds and the contraction time will be 60 seconds (TON: 60s) with a 1-second rest interval (TOFF: 1s). The total time of application will be determined for the muscle fatigue that will be evaluated by 10-point Borg scale and by the measurement of lactate accumulation that must not exceed 30 minutes. The intensity will be adjusted individually, taking into account the patient's ability to promote the full flexion of the wrist / knee extension and comfort during contractions. Along with the application of FES a 1 Kg overload will be applied to intensify the fatigue time.
1571138|NCT02448030|Other|Isometric exercise|For the upper limbs the isometric contraction exercise with handgrip will be performed for 5 minutes with 30% of loading, previously measured by maximum voluntary contraction test. For the lower limbs the knee extension exercise will be conducted in a training station. The SBP, DBP, MBP and HR will be recorded through the protocols. Fatigue will be determined every minute by the 10-point Borg scale and by measurement of lactate accumulation before, immediately after the protocol, and 5 minutes during the recovery period.
1571139|NCT02448017|Device|The Herbst appliance|Orthodontic functional appliance
1571140|NCT02448017|Device|Twin block appliance|Orthodontic functional appliance
1571141|NCT02448004|Drug|JNJ-63623872|Participants will receive a single 600-mg dose of JNJ-63623872 administered as three capsules containing 14C-labeled and unlabeled JNJ-63623872.
1571142|NCT02447991|Drug|Rizatriptan|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of this study.
1571143|NCT02447991|Drug|Placebo|During the study either placebo or Rizatriptan will be given to subjects to take during the treatment phase of the study.
1571144|NCT02447978|Biological|Infanrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed Indicated as a 5-dose series in infants and children 6 weeks to 7 years of age.
1571145|NCT02447978|Biological|Pediarix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed, Hepatitis B (Recombinant) and Inactivated Poliovirus Vaccine Indicated as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers. PEDIARIX may be given as early as 6 weeks of age through 6 years of age (prior to the 7th birthday).
1571146|NCT02447978|Biological|Kinrix|Diphtheria and Tetanus Toxoids and Acellular Pertussis Ad-sorbed and Inactivated Poliovirus Vaccine
1571147|NCT02447965|Drug|Bupivacaine|Using ultrasound guidance bupivacaine will be injected into the active group's rectus abdominis sheath.
1571148|NCT02447965|Drug|Normal Saline|Using ultrasound guidance normal saline will be injected into the placebo group's rectus abdominis sheath.
1571149|NCT02447952|Device|Faros Sensor (FS) and LifeInsight Hub|Each subject will be issued one FS and a MAT LifeInsight Hub for use during the study. At each clinic visit in the Pilot and Core Study Phases, the Faros sensor will be placed on the subject just prior to the defined reference tasks and will be worn on the subject's sternum during completion of the tasks. The morning after the clinic visit, the subject will re-attach the sensor and wear it for approximately 3 days. In between visits during the Core Study Phase the subject will wear the FS every month for approximately 3 days to enable data collection on a monthly basis over the 48 week study period. Movement/physical activity data will be collected by the FS throughout the study.
1571150|NCT02447952|Device|Fast Fix electrode patch|The Fast Fix electrode patch will be worn with the FS on the subject's sternum according to the same schedule as the FS. The Fast Fix electrode patch will be replaced by the subject on a daily basis during the 3 day monitoring period. Subjects will be provided instructions on how to operate and wear the Fast Fix electrode patch.
1571151|NCT02447952|Procedure|Quantitative Measure of Speech (Core Phase Only)|Subjects will follow simple prompts on a computer screen instructing them to say a series of vowels, words, and paragraphs which will be recorded using a high definition digital microphone and stored securely on a laptop. The speech waveform data will be sent via secure method to GSK/MAT for processing.
1571152|NCT02447939|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt).
1571153|NCT02447939|Drug|Trametinib|Trametinib study will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
1571154|NCT02447926|Procedure|Leukapheresis|"Catheter placement will occur for about 1 hour. The research nurse will schedule leukapheresis on the next day following catheter placement.
On the day of leukapheresis, a blood draw will monitor blood counts, kidney function, liver function, and blood clotting ability. Vital signs will be checked three times over the course of intervention.
During the procedure, blood is mixed with anticoagulant and separated (i.e. red blood cells, white blood cells, platelets, and plasma). 1-1.5 cups of white blood cells will be collected. Leukapheresis will last 3-6 hours.
Remaining components, except for 100-200 ml of plasma, are returned through the catheter. Two teaspoons of blood will be drawn to determine when catheter removal can occur. This part of intervention lasts about 2.5-4 hours."
1571155|NCT02447913|Behavioral|Voucher|"Introduction of vouchers will improve uptake of family method as well as child immunization.
Incentivizing the providers to improve their counseling skills will improve the provider client relationship and better compliance of Family planning method"
1571156|NCT02447900|Device|BioXmark|
1571157|NCT02447887|Drug|Ixazomib|The prescribed administration of ixazomib doses in this study is 1.5-4.0 mg ixazomib weekly for 3 out of 4 weeks in each cycle (1 cycle=28 days).
1571158|NCT02447887|Drug|Pegylated IFN-alpha 2b|Weekly injection
1571205|NCT02447510|Procedure|group 1 bio-oss bone xenograft|bone substitute (bio-oss)
1571206|NCT02447510|Procedure|group 2 platelet rich in growth factor (autogenous platelet rich in growth factor)|platelet rich in growth factor (autogenous platelet rich in growth factor)
1571163|NCT02447835|Drug|Olanzapine|Olanzapine is approved for the treatment of schizophrenia and mania associated with bipolar disorder. Olanzapine is a psychotropic agent that belongs to the thienobenzodiazepine class. The chemical designation is 2-methyl-4-4methyl-1 piperazinyl-10H-thienol (2,3-b)[1,5]benzodiazepine. The molecular formula is C17H20N4S which corresponds to a molecular weight of 312.44.Olanzpine is a yellow crystalline solid which is practically insoluble in water. Olanzapine is a selective monoaminergic antagonist with high affinity binding to the following receptors:5HT2A2C, 5HT6, dopamine 2-4, histamine H1, and adrenergic α-1. In addition olanzapine is an antagonist with moderate affinity for muscarinic M1-5 and 5HT3. The mechanism of action of olanzapine is unknown although it may be mediated through a combination of dopamine and serotonergic type 2 receptors.
1571164|NCT02447822|Drug|Thymoglobulin|6.0 mg/kg vs 4.5 mg/kg Thymoglobulin
1571165|NCT02447809|Drug|Clopidogrel|(ASA 100mg daily and Clopidogre 75mg daily)* 12 month.
1571166|NCT02447809|Drug|acetylsalicylic acid (ASA)|
1571167|NCT02447796|Drug|Propofol|Propofol was administered at 1 mg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 mg/kg/h until the the begining of skin suture (n=24).
1571168|NCT02447796|Drug|Dexmedetomidine|DEX was administered at 1 μg/kg over a 10-min period followed by a continuous infusion at a rate of 1-1.5 μg/kg/h until the begining of skin suture (n=24).
1571169|NCT02447783|Dietary Supplement|Control Capsules|Cocoa-based, flavanol-free, control-matched capsules consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
1571170|NCT02447783|Dietary Supplement|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process and containing 500 mg of cocoa flavanols per capsule consumed for 12 weeks (Week 1: 2 capsules/day; Week 2: 3 capsules/day; Week 3-12: 4 capsules/day; Week 12-14: no capsule intake).
1571171|NCT02447770|Dietary Supplement|Mars Cocoa Extract Capsules|Capsules containing Mars Cocoa Extract manufactured by the Cocoapro® process, providing 500 mg of cocoa flavanols per capsule: 1000 mg of cocoa flavanols consumed daily during week 1 and 2, 1500 mg of cocoa flavanols consumed daily during week 3 and 4, and 2000 mg of cocoa flavanols consumed daily during week 5 and 6, and no capsule consumed (washout) during week 7 and 8.
1571172|NCT02447757|Drug|remifentanil|Remifentanil analgesia during delivery
1571173|NCT02447744|Behavioral|Mindfulness based stress reduction|The intervention will be an 8-week structured program about mindfulness based stress reduction that teaches skills of mindfulness meditation and mindful yoga.
1571174|NCT02447731|Device|"Induction of sound waves in lungs by sonic oscillator"|A device called sonic oscillator will add sonic waves to the inhaled gases while the subjects are going through 3 tests measuring the variations made in pulmonary functions induced by sound waves.
1571175|NCT02447718|Biological|Prevnar®13|A single dose of Prevnar®13 will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
1571176|NCT02447718|Biological|Pneumovax® 23|A single dose of Pneumovax® 23 will be administered to subjects approximately 2 months after Prevnar®13
1571177|NCT02447718|Biological|Pediacel®|A single dose of Pediacel® will be administered to subjects with ALL who are 6-12 months post-completion of chemotherapy.
1571178|NCT02447705|Drug|telbivudine|telbivudine replace Lamivudine
1571179|NCT02447692|Other|PSV ventilation strategy|An algorithm for adjusting the level of pressure support according to usual clinical parameters; patients not tolerating PSV will be switched to Assist/Control mode according to predefined criteria
1571180|NCT02447692|Other|PAV+ ventilation strategy|An algorithm for adjusting the level of support (gain) to maintain a predefined range of respiratory muscle pressure; patients not tolerating PAV+ (Puritan Bennett™ 840 or 980 ventilator) will be switched to Assist/Control mode according to predefined criteria
1571181|NCT02447679|Drug|thalidomine|thalidomine (400mg/day) for 1 year to prevent HCC recurrence
1571182|NCT02447679|Drug|tegafur-uracil|tegafur-uracil (2 tablelet twice a day) for 1 year to prevent HCC recurrence
1571183|NCT02447666|Drug|Azacitidine|
1571184|NCT02447653|Device|G7 HA Acetabular Component|G7 HA Acetabular Component
1571185|NCT02447653|Device|G7 PPS Acetabular Component|G7 PPS Acetabular Component
1571186|NCT02447640|Drug|ADX48621|ADX4862, an investigational compound, is a potent, selective, negative allosteric modulator of the metabotropic glutamate receptor 5 (mGlu5 NAM).
1571187|NCT02447640|Radiation|[18F]FPEB|radiotracer used for PET scanning
1571188|NCT02447614|Procedure|Adenotonsillectomy|Adenotonsillectomy
1571189|NCT02447614|Other|Conservative treatment|Mometasone Furoate Aqueous Nasal Spray or uticasone propionate (1/once qd) and（or）Leukotriene antagonists(4 or 5mg/once qn) or H1 receptor antagonists
1571190|NCT02447614|Other|no treatment|just regular follow-up
1571191|NCT02447601|Drug|PEX168|200µg,injected subcutaneously,once a week.
1571192|NCT02447601|Drug|Simvastatin|40mg,oral,two times
1571193|NCT02447588|Other|IAD at 36 hours|Intrauterine insemination with sperm donor at 36 hours post-hCG
1571194|NCT02447588|Other|IAD at 24 hours|Intrauterine insemination with sperm donor at 24 hours post-hCG
1571195|NCT02447575|Device|Pre-Education Use of MDI|Subject will demonstrate use of MDI) with electronic flowmeter in place before short education process to demonstrate current use of MDI
1571196|NCT02447562|Device|Platform NOMHADchronic|Intervention group with a health Platform NOMHADchronic
1571197|NCT02447562|Other|Phone-based care group|
1571198|NCT02447562|Other|Usual care group|
1571199|NCT02447549|Radiation|WBRT|One RT plan with whole bladder treated to standard dose.
1571200|NCT02447549|Radiation|SART|Three plans (small, medium & large) generated with the standard dose of RT focused on the tumour, sparing the normal bladder from full dose radiation. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
1571201|NCT02447549|Radiation|DART|Three plans (small, medium & large) generated with a higher dose than standard focused on the tumour and the remainder of the bladder treated to the same dose as in the SART group. Pretreatment cone beam CTs will be used to select the best fitting of the three plans prior to treatment.
1571202|NCT02447536|Biological|BCG-Denmark 1331 (Statens Serum Institute)|See above
1571203|NCT02447536|Biological|BCG-Russia-I (Serum Institute of India)|See above
1571204|NCT02447523|Procedure|Elective abdominal surgery|
1571207|NCT02447510|Procedure|group 3 platelet rich fibrin (autogenous platelet rich fibrin)|platelet rich fibrin (autogenous platelet rich fibrin)
1571208|NCT02447497|Drug|3M CHG/IPA|Chlorhexidine gluconate 2% / Isopropyl alcohol 70%
1571209|NCT02447497|Other|Normal Saline|0.9% sodium chloride applied with foam applicator
1571210|NCT02447484|Behavioral|Mujer Segura Siempre|Participants receive personalized text messages twice a day, five days per week. Messages are designed to encourage women to maintain positive behavioral changes they have made in response to the baseline safer-sex training that is delivered to all participants regardless of intervention assignment. Message content is based upon theoretical constructs of behavior-change maintenance as articulated by Voils et al. (Health Education & Behavior, 2013). Personalization elements include participant's name, times of day when she prefers to receive messages, and specific motivators of behavior change she expressed in the baseline interview.
1571211|NCT02447484|Behavioral|General Health Message Texts|Participants receive generic health-promotion text messages twice a day, five days per week.
1998751|NCT01004003|Drug|BIBF 1120|Dose escalated in phase I until MTD or adjusted by investigator, dose in phase II part based on phase I data
1571213|NCT02447458|Drug|MLN3126|MLN3126 tablets
1571214|NCT02447458|Drug|MLN3126 Placebo|MLN3126 placebo-matching tablets
1571215|NCT02447445|Procedure|Grip strength assessment|Grip strength will be measured by the ward nurse using a Jamar dynamometer by asking the patient to squeeze with each hand twice, starting with the right hand using the standardised protocol The maximum GS measurement will be recorded. Patients who have low maximum GS values (men < 27 kg and women <16 kg) or those who are unable to perform the test will receive a care plan. The care plan will focus on review of dietary energy and protein intake and any need for oral nutritional supplements or dietetic review, and review of mobility with any need for physiotherapy review with regard to progressive resistance exercises to increase muscle strength.
1571216|NCT02447432|Biological|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (4-dose presentation)|4 doses by intramuscular injection in the right left anterolateral thigh
1571217|NCT02447432|Biological|Pneumococcal vaccine GSK1024850A (10Pn-PD-DiT) vaccine (1-dose presentation)|4 doses by intramuscular injection in the right anterolateral thigh
1571218|NCT02447432|Biological|DTPw-HBV/Hib|3 doses by intramuscular injection in the left anterolateral thigh
1571219|NCT02447419|Drug|Gefitinib|Gefitinib 250mg will be administered orally daily
1571220|NCT02447406|Drug|AZD6094|
1571221|NCT02447406|Drug|docetaxel|
1571222|NCT02447393|Drug|levocetirizine|levocetirizine
1571223|NCT02447393|Drug|cetirizine|cetiridine
1571224|NCT02447393|Drug|placebo|placebo
1571225|NCT02447380|Drug|AZD6094|AZD6094 600MG qd
1571226|NCT02447380|Drug|Docetaxel|Docetaxel 60 mg/m2
1571227|NCT02447367|Drug|JLP-1207(Fasted)|Fasted followed by fed in period 1, the subjects will receive an oral pill of JLP-1207 under fasted condition.
1571228|NCT02447367|Drug|JLP-1207(Fed)|Fed followed by fasted in period 1, the subjects will receive an oral pill of JLP-1207 under fed condition
1571230|NCT02447315|Drug|Pilocarpine|oral
1571231|NCT02447315|Drug|Placebo|oral
1571232|NCT02447302|Drug|Etrasimod|
1571233|NCT02447302|Drug|Placebo|
1571234|NCT02447289|Drug|Intranasal ketamine|
1571235|NCT02447289|Drug|Oral ketamine|
1571236|NCT02447289|Drug|Intranasal midazolam|
1571237|NCT02447289|Drug|Oral midazolam|
1571238|NCT02447276|Drug|REGN475|
1571239|NCT02447276|Drug|Placebo|
1571240|NCT02447263|Procedure|interventional therapy|liver cancer patients received HepaSphere interventional therapy using the digital subtraction angiography（DSA）
1571241|NCT02447250|Drug|Varied albuterol dose response|Subjects will be evaluated in three sessions. The sessions will occur within a 7 day time span, beginning between 14-28 days of life. In each session, pulmonary function tests (PFTs) will be performed prior to and 15 minutes after a dose of albuterol. The dose will be different in each session. In the first session, a sinlge dose of 180 micrograms (2 puffs) of albuterol sulfate via metered dose inhaler. The dose will be 270 micrograms in the second session and 360 micrograms in the third session. PFTs will be performed during quiet sleep while the baby is spontaneously breathing or while the baby is intubated and receiving mechanical ventilation. Resistance and compliance will be measured using the single breath occlusion technique.
1571242|NCT02447237|Other|dietary counselling|the participants will receive dietary counselling in fulfilling their need of energy and protein according to the group they are randomized to (either solid or liquid food).
1571243|NCT02447224|Drug|1 gm IV ertapenem at enrollment|
1571244|NCT02447224|Drug|1 gm IV ertapenem at Day 2 and oral metronidazole and cefdinir to complete 10 days|
1571245|NCT02447224|Procedure|Appendectomy|
1571246|NCT02447211|Drug|Doxepin cream 5%|Patients use doxepin creamtwice daily for one weeks
1571247|NCT02447211|Other|Placebo|Patients use cream without doxepin ingredient twice daily for one weeks
1571248|NCT02447185|Drug|Ranibizumab|"A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection.
All subjects in Ranibizumab group will get Ranibizumab 0.2 mg/0.02 ml intravitreal injection just after the operation."
1571249|NCT02447185|Drug|Triamcinolone Acetonide|"A week before 25-gauge vitrectomy, all subjects in TA group will receive Triamcinolone Acetonide 4mg/0.1ml intravitreal injection.
During operation all subjects in Ranibizumab group and in TA group will be injected Triamcinolone Acetonide 4 mg/0.1ml.
All subjects in TA group will get Triamcinolone Acetonide 1mg/0.025 ml intravitreal injection just after the operation."
1571250|NCT02447172|Drug|Gentamicin Collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
1571251|NCT02447172|Other|Placebo|Matching placebo sponge
1571252|NCT02447159|Behavioral|Conditional Cash Transfers|Each participant in the intervention arm will receive conditional cash transfers when she: (1) registers pregnancy, (2)picks up her medication in the first two months after her first visit, (3) delivers at the health clinic, and (4) receives early infant diagnosis test for newborn. Eight to ten weeks after delivery, the participant will also be asked to participate in an endline survey and will be compensated for her time.
1571253|NCT02447146|Other|Resistance Training|The TG performed the RT program using weight machines. Before the training period, participants underwent three weeks with eight familiarization sessions to ensure proper technique execution. The protocol aimed to workout major muscle groups and involved the following exercises: chest press, knee extension, hamstrings curl, leg press, and seated row. Training sessions lasted approximately 50-60 minutes with 2 sets of 10-12 repetitions until fatigue.
1571254|NCT02447146|Other|Lectures on the disease|The control group attended an orientation program with lectures on health, quality of life and scientific update on disease.
1571255|NCT02447133|Device|3D OCT-1 Maestro|OCT Machine used for diagnostic purposes
1571256|NCT02447120|Device|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
1571257|NCT02447107|Other|Electronic Diary|The electronic diary asks subjects questions about their compliance with mobile application usage. The questions contained in this diary ask patients how often their personal mobile device has been on their person, if and how long the applications relevant to the study were turned off, and why patients failed to comply with study requirements.
1571258|NCT02447107|Other|Questionnaire|Study patients will be asked to complete a questionnaire at the 1 and 2-week endpoints. This questionnaire is administered in order to measure patient satisfaction with the mobile applications.
1571259|NCT02447094|Drug|Alteplase|Intravenous (i.v.) tPA per the standard of care
1571260|NCT02447081|Device|Subjects implanted with Amulet Device|Percutaneous Left Atrial Appendage occlusion with successful implant of occlusion device.
1571261|NCT02447068|Device|Luma Light System|The Luma Light System combines a NBUVB light with an occlusive dressing.
1571262|NCT02447068|Device|Luma Light|NBUVB light
1571263|NCT02447068|Device|Occlusive Dressing|Off-the-shelf occlusive dressing
1571264|NCT02447055|Biological|Tocilizumab|
1571265|NCT02447055|Drug|Melphalan|
1571266|NCT02447055|Drug|Fludarabine|
1571267|NCT02447055|Drug|Cyclophosphamide|
1571268|NCT02447055|Drug|Tacrolimus|
1571269|NCT02447055|Drug|Mycophenolate mofetil|
1571270|NCT02447055|Drug|Filgrastim|
1571271|NCT02447042|Procedure|Fluid challenge with crystalloids|Intravenous infusion of 2, 3, 4 or 5 ml/Kg of crystalloids over 5 minutes.
1571272|NCT02447042|Device|Measurement of Pmsf-arm|Measurement of stop-flow arterial-venous equilibrium pressure in the arm where the radial arterial pressure is measured by inflating a pneumatic cuff with an automatic pneumatic tourniquet during 60 seconds before and after the fluid challenge in patients receiving 2 ml/Kg, 3 ml/kg, 4 ml/kg and 5 ml/kg of crystalloids in 5 minutes
1571273|NCT02447029|Drug|vaginal 2% Xylocaine|patient-administered vaginal lidocaine jelly versus provider-administered standard lidocaine paracervical block
1571274|NCT02447029|Drug|standard lidocaine paracervical block|1% lidocaine paracervical injection
1571275|NCT02447016|Drug|Tenofovir disoproxil/emtricitabine/rilpivirine|
1571276|NCT02447016|Drug|Tenofovir disoproxil/emtricitabine/efavirenz|
1571277|NCT02447003|Biological|Pembrolizumab|IV infusion
1571278|NCT02446990|Drug|Ivabradine|5 mg, 7.5 mg or 10 mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
1571279|NCT02446990|Drug|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 48 months.
1571280|NCT02446977|Drug|Vitamin B2 Streuli®|4ml IV
1571281|NCT02446977|Other|Solution for injection|4ml IV
1571282|NCT02446964|Procedure|Bone Marrow Transplantation|Undergo bone marrow transplant
1571283|NCT02446964|Drug|Cyclophosphamide|Given IV
1571284|NCT02446964|Drug|Fludarabine Phosphate|Given IV
1571285|NCT02446964|Other|Laboratory Biomarker Analysis|Correlative studies
1571286|NCT02446964|Drug|Mycophenolate Mofetil|Given PO or IV
1571287|NCT02446964|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
1571288|NCT02446964|Drug|Tacrolimus|Given IV and PO
1571289|NCT02446964|Radiation|Total Marrow Irradiation|Undergo TMLI
1571290|NCT02446938|Procedure|Esophagus balloon catheter insertion.|Esophagus balloon catheter will be inserted and the position of the balloon will be confirmed by a air injection test.A bolus of 30 ml of air was injected to the gastric lumen of the catheter just next to the distal edge of the balloon, during the onset of end-expiratory phase. The presence of a positive disturbing wave (PDW) in esophageal pressure waveform to this air injection will be the indicator of the right balloon position.
1571291|NCT02446925|Device|Surefire® Infusion System|Utilization of Surefire® Infusion System for Y-90 glass microsphere embolization
1571292|NCT02446925|Device|Standard End-hole catheter|Utilization of Standard End-hole catheter for Y-90 glass microsphere embolization
1571293|NCT02446912|Biological|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
1571294|NCT02446912|Drug|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48
1571295|NCT02446899|Biological|Anifrolumab|Anifrolumab IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
1571296|NCT02446899|Drug|Placebo|Placebo IV administration every 4 weeks from Week 0 to Week 48 for a total of 13 doses
1571297|NCT02446886|Drug|Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar®)|"Adrenocorticotropic hormone (ACTH) gel, a long-acting formulation of the full sequence ACTH that includes other pro-opiomelanocortin (POMC) peptides, is considered an alternative to corticosteroids in the treatment of relapses (currently FDA approved for this indication).
ACTH (H.P. Acthar®) gel exerts direct anti-inflammatory and immune-modulating effects within the CNS, specifically on infiltrating macrophages and resident microglia as well as protecting mature oligodendrocytes from inflammation-related damage and excitotoxicity. These effects are mediated not only via induction of endogenous corticosteroid production but also via effects on melanocortin receptors."
1571298|NCT02446873|Other|Egg supplementation|A weekly supply of eggs will be given to the mother in the egg supplementation group with instructions to give the child one egg per day.
1571299|NCT02446860|Drug|nivolumab|Nivolumab 3 mg/kg by intravenous infusion, given every two weeks for eight weeks prior to nephrectomy, then post-operatively until patient is no longer deriving clinical benefit.
1571300|NCT02446847|Drug|3BNC117|3BNC117 infusions
1571301|NCT02446847|Other|ART Interruption|Antiretroviral therapy will be discontinued 2 days after the first 3BNC117 infusion (day 2) and resumed at week 12.
1571302|NCT02446834|Behavioral|intensive lifestyle intervention|3 months low GI diet and exercise
1571303|NCT02446834|Drug|GLP-1 Receptor Agonists|Use GLP-1 Receptor Agonists 3 months to treat PCOS
1571304|NCT02446834|Drug|Metformin|Use metformin 3 months to treat PCOS
1571305|NCT02446834|Drug|Acarbose|Use acarbose 3 months to treat PCOS
1571306|NCT02446821|Device|VeraCept|IUD placement of VeraCept
1571307|NCT02446808|Device|Intraoperative nerve monitoring|Intraoperative nerve monitoring (electromyography) is used to identify the location of somatic pelvic nerves critical to urinary continence control and erectile function in real time during robotic-assisted laparoscopic prostatectomy surgery
1571308|NCT02446795|Drug|Sunitinib|Sunitinib: 50mg once daily orally for 4 weeks followed by 2 weeks off treatment (either at 8 a.m. or at 8 p.m.)
1571309|NCT02446795|Drug|Isoquercetin|Isoquercetin: 225mg twice a day(at 08 a.m. and at 4 p.m)/Isoquercetin: 450 mg twice a day(at 08 a.m. and at 4 p.m).
1571310|NCT02446795|Drug|Placebo|Placebo: 225mg twice a day(at 08 a.m. and at 4 p.m)/Placebo: 450 mg twice a day(at 08 a.m. and at 4 p.m).
1571311|NCT02446782|Drug|Cefazolin|Cefazolin 2 gm administered in 100 mL normal saline (after skin sensitivity testing) 15-30 minutes before the start of the procedure. Clindamycin 900 mg to be administered if sensitivity detected to cefazolin.
1571312|NCT02446782|Other|saline|100 mL normal saline 15-30 minutes before the start of the procedure
1571313|NCT02446769|Device|AVAPS-AE Non-invasive ventilation therapy|Participants will use the device greater than or equal to 4hrs per night for the 60 days after discharge.
1571314|NCT02446756|Other|acupuncture|
1571315|NCT02446756|Other|physiotherapy|
1571317|NCT02446730|Device|BES (biodegradable polymer biolimus-eluting stent)|BES implantation
1571318|NCT02446730|Drug|Prasugel|
1571319|NCT02446730|Drug|Clopidogrel|
1571320|NCT02446717|Drug|ABT-493, ABT-530|ABT-493 (tablet) dosed with ABT-530 (tablet)
1571321|NCT02446717|Drug|ribavirin (RBV)|Tablet
1571322|NCT02446717|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
1571325|NCT02446691|Biological|Menveo®|Four Intramuscular doses of MenACWY vaccine at 2, 4, 6 and 12 months of age followed by two blood samples at 13 and 24 months of age.
1571326|NCT02446678|Device|PillCam ESO2|Capsule endoscopy
1571328|NCT02446652|Drug|Hydralazine/Magnesium|(Hydralazine: 1 oral tablet every 24 hours, 182 mg for rapid acetylators, and 83 mg for low acetylators and Magnesium valproate: orally 30 mg/K weight every 8 hours) starting 1 week prior the first day of the QT
1571329|NCT02446652|Drug|Placebo|Placebo (orally) starting 1 week before the first day of the QT
1571330|NCT02446652|Drug|Carboplatin|5 AUC 1 hour/day 1 for every 21 days for 6 cycles
1571331|NCT02446652|Drug|Paclitaxel|175mg/m2/SC 3hour/day 1 for every 21 days for 6 cycles.
1571332|NCT02446639|Other|Blood collection|
1571336|NCT02446613|Other|Pollen allergen extract|Pollen (tree, grass or ragweed) allergen extracts will be provided by the research unit and diluted as required in normal saline. The specific pollen allergen extract that will be used for the nasal allergen challenge will be selected according to each subject's individual allergic sensitivity demonstrated in the previous study, TL7116958. If possible, extracts remaining from this study in 2014 will be used, provided they have not reached their expiry date.
1571346|NCT02446587|Device|Mechanical Thrombectomy|Mechanical thrombectomy includes the use of stent retrievers (i.e. Trevo®, Solitaire®, or other stent retriever devices) as recommended by AHA guidelines (July 2015). A stent retriever is delivered directly to a thromboembolus that is occluding a cerebral artery to restore blood flow.
1571350|NCT02446561|Drug|MRXXX|
1571351|NCT02446561|Drug|MR1XXX|
1571352|NCT02446561|Drug|MR2XXX|
1571353|NCT02446561|Drug|MR3XXX|
1571354|NCT02446548|Drug|aliskiren|aliskiren will be administered at a dose of 150 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M., except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
1571427|NCT02446119|Device|EndoFLIP|Measurement of pyloric resistance and compliance
1571355|NCT02446548|Drug|losartan|losartan will be administered at a dose of 50 mg, each dose was to be taken orally with water once daily at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Drug compliance will be assessed by tablet counts.
1571356|NCT02446548|Other|Placebo|placebo will be administered once daily orally (1 tablet) in the morning with water at approximately 8:00 A.M. except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed. Compliance will be assessed by tablet counts. Placebo was prapared in Department of Pharmaceutical Technology MU Gdańsk
1571357|NCT02446535|Other|achievement of the DW by means of the BIA DW (RE.S.T.)|
1571358|NCT02446522|Procedure|Open vein harvesting|Open vein harvesting was performed as a continuous incision under vision control. The GSV was identified two fingers proximal to the medial malleolus according to the standard practice. The vein was harvested using Metzenbaum scissors, and a continuous incision was made along the route of the vein. Care was taken not to traumatize the nerve, vein or its branches. Vein branches were ligated with titanium clips. The wound was closed in layers with continuous 2-0 Polysorb sutures and 3-0 skin sutures.
1571359|NCT02446522|Procedure|Endoscopic vein harvesting|Endoscopic vein harvesting was performed through minimal incisions with use of Vasoview 6 system (Maquet Medical Systems, Wayne, NJ, USA.) The vein was identified through a 3 cm incision below the knee. The incision site was sealed using a balloon port to create a tunnel inside the leg. A second unit with cautery was inserted via the port to cut and seal the tributary branches. A 1 cm skin incision was made near the groin to ligate the distal end of the GSV and remove the vein, which was checked for leakage. The wound was closed with 3-0 skin sutures
1571360|NCT02446509|Behavioral|Psychoeducation|Caregivers will meet once a week for 90-minute sessions in a group setting. Dates and times of the group sessions will be arranged according to the convenience of the subjects. The major content will include the causes of bipolar disorder, signs and symptoms of bipolar disorder, the role of stress and life events, types of medications and what they do, self-management of the disorder, understanding the course of the disorder, genetic and biological predispositions, how the family can help, management of relapse.
1571361|NCT02446509|Behavioral|Psychoeducation - Delayed|The wait list control group will receive the same intervention as the experimental group, but 7 weeks later.
1571362|NCT02446496|Drug|Cefadroxil tablets manufactured by GSK|Cefadroxil tablets manufactured by GSK contains 1 mg of Cefadroxil
1571363|NCT02446496|Drug|Cefadroxil tablets manufactured by NP|Cefadroxil tablets manufactured by NP contains 1 mg of Cefadroxil
1571364|NCT02446483|Drug|Idiazole 20mg DR tabs|Delayed release tablets containing 20 mg of rabeprazole
1571365|NCT02446483|Drug|PARIET 20 mg DR tabs|Orally administered, delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
1571366|NCT02446470|Procedure|Sinus Tarsi approach|
1571367|NCT02446470|Procedure|Extensile Lateral approach|
1571371|NCT02446444|Drug|Enzalutamide|
1571372|NCT02446444|Drug|Conventional NSAA|
1571373|NCT02446444|Drug|LHRHA|
1571374|NCT02446444|Radiation|External Beam Radiotherapy (78 Gy in 39 fractions or 46 Gy in 23 fractions plus brachytherapy boost)|
1571375|NCT02446431|Drug|Bevacizumab|Avastin is an anti-angiogenic therapy that disrupts a tumor's ability to grow by blocking the vascular endothelial growth factor protein, or VEGF. In tumors, cells produce excess VEGF therefore avastin's ability to block VEGF may prevent the growth of new blood vessels, including normal blood vessels and blood vessels that feed tumors. Avastin is not a chemotherapy; the purpose of Avastin is to block the blood supply that feeds the tumor. In this study Avastin is given IV at 10 mg/kg twice monthly for 10 cycles. This totals 20 administrations over a 1.12 year period.
1571376|NCT02446431|Drug|Cyclophosphamide|Cyclophosphamide is an alkylating agent related to nitrogen mustard and is inactive until it is metabolized by P450 isoenzymes (CYP2B6, CYP2C9, and CYP3A4) in the liver to active compounds. The initial product is 4-hydroxycyclophosphamide (4-HC) which is in equilibrium with aldophosphamide which spontaneously releases acrolein to produce phosphoramide mustard. Phosphoramide mustard has been shown to produce interstrand DNA cross-link analogous to those produced by mechlorethamine. The plasma half-life ranges from 4.1 to 16 hours after IV administration. Cytoxan is taken orally as a 25 mg/m2 tablet daily for 14 days for 10 cycles (max dose =50mg). This totals 140 days over a 1.12 year period.
1571377|NCT02446431|Drug|Valproic Acid|Valproic acid is a short chain fatty acid (VPA, 2-propylpetanoic acid) and approved for the treatment of epilepsy, bipolar disorders, migraines, and clinically used for schizophrenia. Currently, VPA is examined in numerous clinical trials for different leukemias and solid tumor entities. In addition to clinical assessment, the experimental examination of VPA as anti-cancer drug is ongoing. Although other mechanisms may also contribute to VPA-induced anti-cancer effects, inhibition of histone deacetylases appears to play a central role. Valproic acid is either given in suspension or tablet form 5 mg/kg, TID for 13 days for 10 cycles. This totals 130 days in a 1.12 year period.
1571378|NCT02446431|Drug|Temsirolimus|Temsirolimus [an ester of the immunosuppressive compound sirolimus, (rapamycin, Rapamune®)] blocks cell cycle progression from the G1 to the S phase by binding to the intracellular cytoplasmic protein, FK506 binding protein (FKBP)12. This complex inhibits activity of the enzyme mTOR (mammalian target of rapamycin), inhibiting translation of several key proteins that regulate progression through the G1 phase in response to growth factors. Sirolimus, the major metabolite of temsirolimus, also binds to FKBP12. Given twice monthly at 25 mg/m2 via IV administration for 10 cycles totalling 20 administrations for 1.12 years.
1571379|NCT02446418|Drug|Fluticasone Furoate|FF 92 mcg or 184 mcg blended with lactose administered once daily via ELLIPTA DPI
1571380|NCT02446418|Drug|Vilanterol|Vilanterol 22 mcg blended with lactose and magnesium stearate administered once daily via ELLIPTA DPI
1571381|NCT02446418|Drug|Fluticasone propionate|FP 250 mcg or 500 mcg blended with lactose administered twice daily via DISKUS DPI
1571428|NCT02446106|Dietary Supplement|Soup with MSG|0.5% MSG + 0.48% salt
1571382|NCT02446418|Drug|Salmeterol|Salmeterol 50 mcg blended with lactose administered twice daily via DISKUS DPI
1571383|NCT02446418|Drug|Budesonide|Budesonide 200 mcg or 400 mcg blended with lactose administered twice daily via TURBUHALER DPI
1571384|NCT02446418|Drug|Formoterol Fumarate|Formoterol Furoate 6 mcg or 12 mcg blended with lactose administered twice daily via TURBUHALER DPI
1571385|NCT02446405|Drug|Enzalutamide|
1571386|NCT02446405|Drug|NSAA|
1571387|NCT02446405|Drug|LHRHA or Surgical Castration|
1571388|NCT02446392|Other|No intervention.|
1571389|NCT02446379|Drug|The marketed product 2-5 MBq/kg 18F-fluorodeoxyglucose|The FDG is injected at least 120 minutes prior to the imaging by the EnLightTM and LightPathTM Imaging Systems
1571390|NCT02446379|Device|EnLightTM|The surgical cavity and the resected lymph nodes (if any) will be imaged by the EnLightTM system to establish whether radioactive tissue remains after surgery.
1571391|NCT02446379|Device|LightPathTM Imaging System|The resected tumour excision specimens and the resected lymph nodes (if any)will be imaged by CLI and by WLI to establish whether they contain radioactive tissue.
1571392|NCT02446366|Other|Laboratory Biomarker Analysis|Correlative studies
1571393|NCT02446366|Other|Quality-of-Life Assessment|Ancillary studies
1571394|NCT02446366|Radiation|Stereotactic Body Radiation Therapy|Undergo hypofractionated SBRT
1571395|NCT02446353|Drug|Apetrol ES / Megace|Sequences of administered drugs
1571398|NCT02446327|Other|Blood sampling for biomarker assessment|
1571399|NCT02446314|Dietary Supplement|Placebo|Formulation containing inert artificially colored maltodextrin, once daily, in a 2-hard capsule regimen
1571400|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 450mg|Formulation containing 225 mg wild blueberry powder + 22.5 mg L-Cysteine @ 2.5 mg L-Glutathione 250 mg placebo powder, once daily, in a 2-hard capsule regimen
1571401|NCT02446314|Dietary Supplement|Wild Blueberry Powder - 900 mg|Formulation containing 450 mg wild blueberry powder = 45 mg L-Cysteine + 5 mg L-Glutathione once daily, in a 2-hard capsule regimen
1571402|NCT02446314|Dietary Supplement|Wild Blueberry extract 100mg|Formulation containing 100 mg wild blueberry powder + 10 mg L-Cysteine + 1 mg L-Glutathione + 389 mg of placebo, once daily, in a 2-hard capsule regimen
1571403|NCT02446301|Drug|Bain®|Nalbuphine HCl 20mg, IM injection
1571404|NCT02446301|Drug|SDE|Sebacoyl Dinalbuphine Ester 150mg/2ml, IM injection
1571405|NCT02446288|Device|TMJ Next Generation|
1571406|NCT02446288|Device|DSG Relaxer|
1571407|NCT02446275|Other|Sternocleidomastoid MTRP and stretching|The sternocleidomastoid was treated with ischemic compression. The patient's head was passively moved into contralateral rotation and the patient was asked to relax completely. Sustained pressure was then applied to the sternocleidomastoid muscle until the pain threshold was reached. During the application of pressure, pain decreases so the pressure was gradually increased over a duration of 1 minute. The pressure was then reduced progressively.
1571408|NCT02446275|Other|Trapezius MTRP and stretching|The central MTRP of the trapezius was treated as described above for the sternocleidomastoid. Subsequently stretching was performed, whereby the therapist supported the patient's head and performed passive contralateral inclination and ipsilateral rotation of the head. The therapist placed one hand over the patients shoulder while the other hand performed the stretching and simultaneously controlled the position of the head to achieve suitable stretching
1571410|NCT02446236|Drug|Lenalidomide|Dose escalation of lenalidomide. Patients will receive 10, 15, 20, or 25 mg PO days 1-21
1571411|NCT02446236|Drug|Ibrutinib|560 mg PO daily
1571412|NCT02446236|Drug|Rituximab|375 mg/m2 IV Day 1
1571413|NCT02446223|Drug|Inggenol Mebutate 0.015%|
1571414|NCT02446210|Device|Magstim 200|Transcranial Magnetic Stimulation
1571415|NCT02446210|Device|Digitimer electrical stimulator|Transcranial Magnetic Stimulation paired with Electrical Peripheral Nerve Stimulation
1571416|NCT02446197|Other|Patient Directed Exercise Group|Combination of PT and OT activities that will be individually prescribed based on an evaluation by the therapy team completed pre-intervention. The activities will be added to the comprehensive inpatient rehabilitation program.
1571417|NCT02446184|Procedure|Fetal Cystoscopy|Fetal cystoscopy will be performed under maternal local anesthesia and fetal anesthesia. The dilated posterior urethra will be directly evaluated. Laser fulguration will be performed in case of posterior urethral valves. However, if a non membrane-like structure is found, even with the fluid injection or the guide-wire, urethral atresia (UA, US or Prune Belly syndrome) will be diagnosed and we will not attempt to perforate this structure. A vesicoamniotic shunting placement will be performed in this situation depending on the patient's consent prior to the surgery.
1571418|NCT02446184|Procedure|Fetal vesicoamniotic shunt|Fetal vesicoamniotic shunt will be performed under ultrasound guidance
1571419|NCT02446171|Drug|Naloxegol 25 mg tablet, crushed, suspended in water, given orally|naloxegol 25 mg (1 tablet) crushed, suspended in water, given orally
1571420|NCT02446171|Drug|Naloxegol 25mg tablet crushed, suspended in water, given via nasogastric tube|naloxegol 25 mg (1 tablet) crushed, suspended in water, given via nasogastric tube
1571421|NCT02446171|Drug|Naloxegol 25 mg (10 mL oral solution)|naloxegol 25 mg (10 mL oral solution)
1571422|NCT02446171|Drug|Naloxegol 25 mg tablet, given orally|naloxegol 25 mg (1 tablet) whole tablet, given orally
1571423|NCT02446158|Drug|Chlorhexidine gluconate|The intervention group received daily cleaning of the exit site and application of 4% chlorhexidine (Antigerm Solution, Shining BioMedical Com. Ltd) with a swab. The chlorhexidine was rinsed off after 3 min of air drying and then gauze was applied.
1571424|NCT02446145|Drug|Eltrombopag|"Patients will receive EPAG in addition to their background standard treatment with Decitabine
- concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes"
1571425|NCT02446145|Drug|Placebo|"Patients will receive Placebo in addition to their background standard treatment with Decitabine
- concomitant medication: Decitabine days 1-5 of each cycle: 20 mg/qm i.v. over 30 minutes"
1571426|NCT02446132|Drug|AVP-786|
1571429|NCT02446106|Dietary Supplement|Control soup no MSG|Negative control match for sodium (no MSG + 0.635% salt)
1571430|NCT02446093|Biological|GMCI|Intratumoral cytotoxic immunotherapy using an adenoviral vector expressing HSV-tk followed by anti-herpetic prodrug valacyclovir
1571431|NCT02446093|Drug|mFOLFIRINOX|fluorouracil, irinotecan and oxaliplatin
1571432|NCT02446093|Drug|Gemcitabine|Gemcitabine chemotherapy given with radiation
1571433|NCT02446093|Radiation|Radiation|
1571434|NCT02446093|Procedure|Surgery|Pancreaticoduodenectomy (Whipple)
1571435|NCT02446080|Dietary Supplement|Milk drink with probiotic culture|The Probiotc group was asked to drink 150 ml per day of dairy drinks with probiotic culture
1571436|NCT02446080|Dietary Supplement|Milk drink|The control group was asked to drink 150 ml per day of dairy drinks.
1571437|NCT02446067|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|The motor threshold for the left abductor pollicis brevis was determined using a figure-of-eight-shaped coil at 1 Hz frequency. Ten (over 2 weeks) rTMS sessions were administered over the right dorsolateral prefrontal cortex with an air-cooled figure-of-eight coil, angled tangentially to the head. At right DLPFC, active high-frequency (10 Hz) stimulation was administered for 4.9 seconds per train, with inter-train interval of 30 seconds, and a total of 20 trains per session. Each patient received 1000 pulses per day. The sham group was administered rTMS with the same parameters, but using a figure-of-eight sham coil.
1571438|NCT02446054|Dietary Supplement|Musashino T2DM diet|provide Musashino T2DM diet for 12 weeks to T2DM patients, to evaluate the effect on glycosylated hemoglobin (HbA1c), progression and compliance during study period.
1571439|NCT02446041|Other|Non-Interventional Study|Non-Interventional Study
1571440|NCT02446028|Drug|BIOD-531|
1571441|NCT02446028|Drug|Humalog® Mix 75/25|
1571442|NCT02446015|Drug|SYSTANE® ULTRA Lubricant Eye Drops|
1571444|NCT02445989|Drug|NuvaRing|Provide NuvaRing to women seeking contraception
1571445|NCT02445976|Drug|Seviteronel: given orally once daily in 28-day cycles|Oral Seviteronel given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
1571447|NCT02445950|Behavioral|Technology-aided phone wellness counselling|The intervention provides phone wellness counselling with the help of web-based interventions, digital profiling and suggestion tool in occupational health.
1571448|NCT02445950|Behavioral|Phone wellness counselling|The intervention provides phone wellness counseling in occupational health.
1571449|NCT02445937|Other|ICU Family Communication|The Comparator group for this Comparison Effectiveness Trial will receive an ICU Family Communication intervention delivered by key nurse/social workers within the ICU. The nurse/social worker interventionist will have received 4hours of training designed to aid in clinician-family communication. The nurse/social worker will touch base with families daily, attend to emotion, and facilitate a clinician-family meeting on or before day 4 of the ICU admission with at least the MD and family and nurse/social worker who acts as their advocate.
1571450|NCT02445937|Behavioral|PARTNER II|"The PARTNER intervention is a multifaceted intervention delivered by a trained PARTNER Champion who has undergone 16 hours of intense communication training, with audit and feedback, quarterly booster training, and expert implementation support. Additionally, there is academic detailing of ICU physicians and ICU bedside nurses to augment the intervention. The PARTNER Intervention deploys three strategies to improve: 1) the timeliness and frequency of clinician-family communication, 2) the emotional and decision support provided to families and 3) the appropriate involvement of palliative care specialists."
1571453|NCT02445898|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
1571454|NCT02445898|Drug|Isotonic Sodium Chloride|Placebo
1571455|NCT02445885|Procedure|PCI|Guideline directed Percutaneous Coronary Intervention
1571456|NCT02445872|Drug|Aprepitant|Aprepitant:The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3
1571457|NCT02445872|Drug|Palonosetron|
1571458|NCT02445872|Drug|Dexamethasone|
1571461|NCT02445846|Device|dual HIV/syphilis rapid diagnostics tests|
1571462|NCT02445833|Behavioral|Lifestyle on-line intervention|The self-applied on-line intervention will comprise a behavioural intervention composed by 9 modules seeking to develop gradually achieving the goals of changing eating habits and physical activity in participants (Themes: 1.motivation for change; 2. nutrition and physical activity education; 3. barriers to change, healthy eating principles and how to be active; 4. Influence of thoughts; 5. Emotional eating and self-control; 6. Problem solving; 7. Body image and assertiveness; 8. Relapse prevention)..The program will be established as follows: The first day the participant log in the website where can access the processing modules. A web page was developed specially for this study.
1571463|NCT02445820|Drug|HES|2500 mL of balanced HES 130/0.4
1571464|NCT02445820|Drug|Crystalloid|2500 mL of balanced crystalloid.
1571465|NCT02445807|Drug|DFD06-Cream|Twice daily topical application for 14 days.
1571467|NCT02445794|Drug|RT001|RT001 is encapsulated di-deutero synthetic homologue of linoleic acid ethyl ester. Each capsule contains 900 mg of RT001.
1571468|NCT02445794|Drug|RT001 comparator|RT001 comparator is encapsulated non-deuterated linoleic acid ethyl ester.
1571469|NCT02445781|Device|Glucose clamp|Different levels of hypoglycemia
1571470|NCT02445768|Other|Neurocognitive therapeutic|Neurocognitive therapeutic
1571471|NCT02445768|Device|3T scanner with MRI-compatible robot|
1571472|NCT02445742|Drug|Bosutinib|500 mg/day of Bosutinib during the study until disease progression, unacceptable toxicity, or withdrawal of consent occurs
1571473|NCT02445729|Other|Dressing removal at 24 hours|Dressing will be removed 24 hours after cesarean section and wounds will be assessed for healing and presence of infection.
1571474|NCT02445729|Other|Dressing removal at 48 hours|Dressing will be removed 48 hours after cesarean section and wounds will be assessed for healing and presence of infection.
1571477|NCT02445703|Biological|Inactivated Hepatitis A vaccine (HAV)|Dosage of HAV is 250u hepatitis A antigen/0.5ml/dose.
1571478|NCT02445703|Biological|Combined hepatitis A and hepatitis B vaccine (HABV)|Dosage of HABV is 250u hepatitis A antigen and 5µg hepatitis B antigen/0.5ml/dose
1571479|NCT02445677|Device|Active transcutaneous electrical nerve stimulation (TENS)|TENS is a technique use to relieve pain in an injured or diseased part of the body in which electrodes applied to the skin deliver intermittent stimulation to surface nerves and block the transmission of pain signals. In this research, the frequency will be set at 100 Hz, implusion duration at 60 μsec and intensity will be increase until having strong but confortable stimulations.
1571480|NCT02445677|Device|Simulated transcutaneous electrical nerve stimulation (TENS)|A modification of the TENS connexion parameters will prevent the current from reaching the electrods (once a first sensation will be perceived).
1571481|NCT02445664|Behavioral|Educational video|Video: Information on osteoporosis and alendronate treatment.
1571482|NCT02445651|Dietary Supplement|Intravenous and Oral n—acetyl cysteine|
1571483|NCT02445638|Other|Whole egg|Subjects will be provided with the equivalent of 2 whole eggs daily.
1571484|NCT02445638|Other|Yolk-free egg|Subjects will be provided with the equivalent of 2 yolk-free eggs daily.
1571485|NCT02445625|Device|BCI to train joint attention in ASD|The intervention comprehends seven BCI sessions spread over four months. The first four sessions are planned to occur weekly, and the rest monthly. In each session, the subject is asked to identify objects of interest based on the gaze direction of an avatar. The subject response is interpreted from the EEG signal (using the P300 component, as established in our previous work).
1571486|NCT02445612|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
1571487|NCT02445599|Drug|Diclofenac|Orally 100 mg Diclofenac, administered 1 hour before surgery
1571488|NCT02445599|Drug|Midazolam|5 mg Dormicum intramuscularly, administered 1 hour before surgery
1571489|NCT02445599|Drug|Atropine|0.5 mg Atropine intramuscularly, administered 1 hour before surgery
1571490|NCT02445599|Drug|bucain + fentanyl|Via the thocacic epidural cannula 1mg/ml bucain + 5microgr/ml fentanyl solution, with 0.1ml/kg body mass/hour speed is administered.
1571491|NCT02445599|Drug|Nalbuphine|1st choice for rescue analgetic 10-20 mg intravenously
1571492|NCT02445599|Drug|Diclofenac|2nd choice for rescue analgetic 250ml intravenously
1571493|NCT02445599|Drug|Metamizole-sodium|Additional rescue analgetic 2g intravenously
1571494|NCT02445599|Drug|Tramadol|Additional rescue analgetic 100mg intravenously
1571498|NCT02445573|Other|EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In EA group, participants were needled at bilateral BL33 at an angle of 30 to 45 degree inward and downward, and at bilateral BL35 slightly toward upside and outside, to a depth of 50 to 60 mm using acupuncture needles of size 0.30×75 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral BL33 and BL35 (using real electrodes) respectively, with a continuous wave of 50 Hz and a current intensity of 1-5 milliampere (mA) for 30 min. Participants were treated with EA 3 sessions a week on alternate days for 6 successive weeks.
1571575|NCT02444975|Dietary Supplement|Mineral water|1.5L/day of water on top of the normal fluid intake for 1 year
1571576|NCT02444975|Other|Coaching program|Coaching program to support increased water intake
1571577|NCT02444975|Other|No intervention|No intervention
1571578|NCT02444962|Device|HAVD-implant|
1571579|NCT02444949|Drug|endostar|
1571499|NCT02445573|Other|sham EA|When acupuncturing, adhesive pads were first pasted on acupoints after sterilization in either group. In sham EA group, participants were needled at sham BL33 and sham BL35, which were about 20 mm lateral to BL33 and BL35, respectively, with blunt needle tips piercing adhesive pads and not piercing the surface of the skin, using placebo needles of size 0.30×25 mm. Needles were then lifted, thrusted and twirled evenly for 3 times. Paired electrodes of EA apparatus were attached transversely to bilateral sham BL33 and sham BL35 (using sham electrodes) respectively. The parameters of sham EA apparatus and the treatment course were the same as in the EA group.
1571500|NCT02445560|Dietary Supplement|Probiotic capsule and Fiber Sachet|"A probiotic capsule and fiber sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The fiber sachet consists of 5 g of chicory root fiber.
During the treatment period, in addition to consuming the probiotic capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
1571501|NCT02445560|Dietary Supplement|Probiotic capsule and Placebo sachet|"A probiotic capsule and placebo sachet will be consumed daily for 2-weeks. The probiotic capsule contains a mixture of Bifidobacterium bifidum, Bifidobacterium breve, Bifidobacterium longum, Lactobacillus acidophilus and Lactobacillus plantarum. The placebo sachet consists of 5 g of maltodextrin.
During the treatment period, in addition to consuming the probiotic capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
1571502|NCT02445560|Dietary Supplement|Placebo capsule and Fiber Sachet|"A placebo capsule and fiber sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of chicory root fiber.
During the treatment period, in addition to consuming the placebo capsule and fiber sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
1571503|NCT02445560|Dietary Supplement|Placebo capsule and Placebo sachet|"A placebo capsule and placebo sachet will be consumed daily for 2-weeks. The placebo capsule will contain potato starch, magnesium stearate and ascorbic acid. The fiber sachet consists of 5 g of maltodextrin.
During the treatment period, in addition to consuming the placebo capsule and placebo sachet participants will consume a controlled diet consisting of foods that provide an average of approximately 2 g/kg/day of protein."
1571504|NCT02445547|Other|UC-MSCs by peripheral intravenous infusion|
1571505|NCT02445547|Drug|received hormone maintenance therapy|
1571506|NCT02445534|Biological|Autologous stem cell therapy|All patients received granulocyte-colony stimulating factor (G-CSF; 5 mg/kg, 5 days). CD34+ cell were then collected by apheresis and injected transendocardially or intracororonary.
1571507|NCT02445508|Drug|Sevelamer|
1571508|NCT02445508|Drug|Cholecystokinin|
1571509|NCT02445508|Drug|Sevelamer placebo|
1571510|NCT02445508|Drug|Isotonic saline|
1571511|NCT02445495|Device|GenesisPlus 1064 nm Nd:YAG laser|Genesis Plus 1064 nm Nd: YAG laser to treat onychomycosis
1571512|NCT02445482|Procedure|Biopsy|archival tissue or fresh biospsy
1571513|NCT02445469|Other|MRI exam of the brain|MRI exam of the brain
1571514|NCT02445456|Drug|Sienna+ injection|Endoscopic injection of magnetic tracer
1571515|NCT02445456|Other|MRI scan|MRI scan of pelvis to detect spread of magnetic tracer
1571516|NCT02445456|Procedure|Surgery to excise rectal cancer|Surgery as scheduled according to size and stage of rectal cancer. This will be either radical surgery or transanal endoscopic microsurgery (TEM)
1571517|NCT02445456|Device|Sentimag probe|Probe to detect the previously injected magnetic tracer (Sienna+)
1571518|NCT02445443|Device|LEGION Hinge Knee System|All enrolled/treated subjects will receive the LEGION Hinge Knee System.
1571519|NCT02445404|Drug|CHOP|cyclophosphamide, 750mg/m² IV day1 doxorubicin, 50 mg/m² IV day1 vincristine, 1.4 mg/m² (max 2 mg) IV day1 prednisone ,40 mg/m² PO day1~5 every 3 weeks
1571520|NCT02445404|Drug|fractionated ICED|ifosfamide, 1.67 g/m² IV day1~3 carboplatin, AUC =5 IV day1 etoposide, 100mg/m² IV day1~3 dexamethasone 40 mg PO or IV day1~4 every 3 weeks
1571521|NCT02445391|Drug|Capecitabine|Given PO
1571522|NCT02445391|Drug|Carboplatin|Given IV
1571523|NCT02445391|Drug|Cisplatin|Given IV
1571524|NCT02445391|Other|Laboratory Biomarker Analysis|Correlative studies
1571525|NCT02445391|Procedure|Quality-of-Life Assessment|Ancillary studies
1571526|NCT02445391|Other|Questionnaire Administration|Ancillary studies
1571527|NCT02445378|Procedure|Aromatherapy and Essential Oils|Undergo aromatherapy and essential oils
1571528|NCT02445378|Other|Placebo|Undergo placebo intervention using rose water
1571529|NCT02445378|Other|Questionnaire Administration|Ancillary studies
1571530|NCT02445365|Device|AutoRIC device|
1571531|NCT02445352|Drug|Rosuvastatin 5mg|
1571532|NCT02445352|Drug|DP-R207 5/10mg|
1571533|NCT02445352|Drug|Rosuvastatin 10mg|
1571534|NCT02445352|Drug|DP-R207 10/10mg|
1571535|NCT02445352|Drug|Rosuvastatin 20mg|
1571536|NCT02445352|Drug|DP-R207 20/10mg|
1571537|NCT02445352|Drug|Placebo (for Rosuvastatin 5mg and DP-R207 5/10mg)|
1571538|NCT02445352|Drug|Placebo (for Rosuvastatin 10mg and DP-R207 10/10mg)|
1571539|NCT02445352|Drug|Placebo (for Rosuvastatin 20mg and DP-R207 20/10mg)|
1571540|NCT02445339|Drug|XR-NTX+CM (Extended-Release Naltrexone plus Care Management)|The intervention arm will receive extended-release naltrexone (XR-NTX) 380mg (4 mL) to be administered as an intramuscular gluteal injection every 28 days up to 12 doses total. Expedited referral to alcohol-medical management. Care Management will include coordination of health care and social services for at least 12 months. Harm-reduction counseling and motivational interviewing to identify and work towards goals. The Standard care arm will receive an expedited alcohol-medical management referral.
1571580|NCT02444949|Radiation|intensity modulated radiation|
1571581|NCT02444949|Drug|cisplatin|
1571544|NCT02445300|Other|AQUACEL® Ag Surgical dressing (study group)|The AQUACEL® Ag Surgical dressing was applied to the wound in the operating theater by the surgeon. Clinical indications for removal of the AQUACEL® Ag Surgical dressing were leakage from the dressing beyond the hydrocolloid exterior layer and more than a 50% saturation of the Hydrofiber® inner layer10. If there were no indications to change the dressing, it was changed at the day of discharge usually the 4th or 5th postoperative day (POD) and remained cover of the wound for 7 days except for exudate across the dressing.
1571545|NCT02445300|Other|Sofra-Tulle® dressing (control group)|The Sofra-Tulle® dressing was applied to the wound in the operating theater by the surgeon. The Sofra-Tulle® dressing was routinely changed at a daily basis. If there were strikethrough on the gauze, the nursing staff would proceed the dressing change automatically between the daily routine. After discharge from the hospital, the family who had been taught well to do this job during the patient's stay in the hospital conducted the daily dressing change.
1571546|NCT02445287|Radiation|Radiation|Cadaveric specimens will be imaged with 2D devices: CARESTREAM DRX-Evolution general radiograph and CARESTREAM Cone Beam Computed Tomography (CBCT) general radiograph, and 3D devices PHILLIPS Multi Detector Computed Tomography (MDCT) and CARESTREAM Cone Beam Computed Tomography (CBCT). Human subjects will be imaged with CARESTREAM Cone Beam Computed Tomography (CBCT) 3D only.
1571547|NCT02445274|Procedure|Anterior lens capsule was reserved|The anterior lens capsule was reserved after continuous curvilinear capsulorhexis. The reserved anterior capsule was pressed flattened by the optical surface of the IOL and attached onto the posterior lens capsule.
1571548|NCT02445261|Radiation|mobile phone|Each woman was subjected to 15 minutes CTG trace recording before using mobile phone and repeated while the phone is in the dialing mode for 10 minutes. Umbilical artery (UA) Doppler ultrasound was done after the initial CTG trace and was repeated 5 minutes after hanging up the mobile phone.
1571550|NCT02445235|Other|Patient Reported Outcome Survey Tool|Patient Reported Outcome Survey Tool
1571551|NCT02445222|Genetic|Previously treated CART CD 19 patients|Lentiviral-based CD19 directed CART cell therapy
1571552|NCT02445209|Other|EOX|combined chemotherapy regimen: epirubicin + oxaliplatin + capecitabine
1571553|NCT02445209|Other|mDCF|combined chemotherapy regimen: docetaxel + leucovorin + 5fluorouracil + cisplatin
1571554|NCT02445196|Behavioral|PTSD Coach|PTSD Coach is a mobile app that aims to teach individuals self-management strategies for symptoms of PTSD.
1571555|NCT02445196|Device|Smartphone|All participants must have a smartphone, either apple or android.
1571556|NCT02445183|Other|None, N/A|
1571557|NCT02445170|Procedure|Amputation|Transmetatarsal or below-knee amputation
1571558|NCT02445157|Other|4MGS|Measurement of usual gait speed over 4 metres (metres/second)
1571559|NCT02445131|Drug|Bendamustine|Debulking: Cycles 1 - 2, d1 & 2: 70 mg/m2 i.v.
1571560|NCT02445131|Drug|GA101|"Induction: Cycle 1: d1: 100mg, d1(or2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg
Maintenance: Cycle 1-8 (Duration 12 weeks): d1 1000 mg."
1571561|NCT02445131|Drug|CAL-101|"Induction: Cycle 2-6: d1-28: 150 mg p.o.
Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84 150 mg p.o."
1571562|NCT02445118|Other|Adipose Allograft Matrix (AAM) injection|Adipose Allograft Matrix (AAM) injection, Non-dominant wrist
1571563|NCT02445105|Behavioral|Autism Navigator Enhanced Practice|Community service providers will receive training in Autism Navigator for Primary Care, a 6-hour online professional development course with extensive video illustration of the early signs of autism in toddlers, collaborating with families, developmental milestones, screening and referral practices, and early intervention basics. This web-based platform includes an automated screening for communication delay and autism, an automated monthly electronic monitoring, and digital tools for families to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
1571564|NCT02445105|Behavioral|Family Engagement plus Autism Navigator|Community service providers will receive a 6-hour training on the use of Motivational Interviewing, an evidence-based counseling method to improve engagement of families who are ambivalent about screening or intervention for their toddler. Community service providers will also receive a 6-hour training with the Autism Navigator for Primary Care professional development course and use of the web-based platform that includes an automated communication and autism screening and monthly electronic monitoring to address practical obstacles to screening toddlers 9-18 months of age and referral to early intervention.
1571565|NCT02445092|Other|washing the insemination catheter with sperm washing media|"Intervention: pre-washing of the IUI catheter
Throughout the research period all of the insemination catheters used for patients recruited in our study, will be prepared as follows:
Connection: The catheter used for insemination, will be connected to the sperm filled syringe as per our standard procedure.
Catheter washing: The sperm washing media will be aspirated and then flushed through the insemination catheter..
Sperm loading: catheters washed or not connected to the syringe will be loaded with the washed sperm sample as our standard procedure.
Labeling:
Patient identification data will be labeled on the syringe and place back in the original package cover to ensure proper blinding and sterility of the catheter."
1571566|NCT02445079|Other|This is an observational study only|Observational study only
1571567|NCT02445066|Dietary Supplement|Vitamin D3|
1571568|NCT02445053|Drug|ivacaftor|
1571569|NCT02445040|Device|Babylog VN500 in HFOV Mode|Treatment with high frequency oscillatory ventilation with investigational device for up to 14 days
1571570|NCT02445027|Device|MGH OCT Imaging Capsule|Imaging of the esophagus using the OCT Capsule and system.
1571571|NCT02445014|Device|MGH SECM Imaging Capsule|Imaging of the Esophagus using the SECM capsule and SECM Imaging system
1571572|NCT02445001|Procedure|ICG loaded erythrocytes|For each subject, on the morning of the day angiography was scheduled, or no longer than 4 days prior to angiography, 9 ml of blood will be withdrawn from an antecubital vein. Using sterile procedures, erythrocyte ghosts produced from the blood will be loaded with ICG dye (for the diagnostic part of the study) or with ICG and one of several drugs (for the therapeutic part of the study) by the following procedure, which requires about 2 hours and yields approximately 1 ml of packed cells (80% Ht) that, after microscopic examination, are ready for autologous re-injection
1571573|NCT02444988|Other|0.9% Saline|0.9% Saline will be used whenever an isotonic crystalloid is ordered
1571574|NCT02444988|Other|Physiologically-balanced isotonic crystalloid|Lactated Ringers or Plasma-Lyte© A will be used whenever an isotonic crystalloid is ordered
1571583|NCT02444923|Device|Scleral rigid gas permeable contact lenses (Zenlens™)|Custom manufactured scleral rigid gas permeable contact lenses. These lenses are designed to fit the eye with high level of precision. The aim is to bridge the cornea and fit in alignment with the sclera, thus avoiding any detrimental effects associated with the corneal rigid gas permeable lenses.
1571584|NCT02444923|Device|Corneal lenses (Rose K2)|The Rose K2 lens is a widely used corneal gas permeable lens designed for keratoconus and other irregular cornea disorders
1571586|NCT02444897|Drug|Epidural PCA Ropivacaine|"Epidural catheter insertion at T10 level before surgery, the tip of catheter location at T8-9 level.
Total volume: 500ml, 16.7mcg/kg+0.75% Ropivacaine 80ml+N/S"
1571587|NCT02444897|Drug|IV PCA Fentanyl+nefopam+Ramosetron|Total volume: 84ml, Fentanyl 1000mcg+nefopam 120mg+Ramosetron 0.3mg Basal infusion: 1ml/hr, Bolus: 0.5ml with a lockout time 15min.
1571588|NCT02444884|Drug|MLN8237|
1571589|NCT02444858|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous injection(5×10^5/kg) ，once a day,a total of three times.
1571590|NCT02444858|Other|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
1571591|NCT02444819|Drug|HM61713|HM61713 will be administered to evaluate efficacy and safety of subjects.
1571592|NCT02444806|Other|Full polysomnography|Full sleep and respiratory monitoring with EEG
1571593|NCT02444806|Other|Oximetry-capnography|Limited monitoring with nurse observation and continuous oximetry-capnography overnight for NIV titration.
1571596|NCT02444780|Procedure|no intervention, blood is sampled for routine|no intervention, blood sampled for standard evaluation will be used for determination of plasma glutamin
1571597|NCT02444767|Drug|13mg Bimatoprost Ocular Insert|13mg Bimatoprost Ocular Insert in each eye.
1571598|NCT02444754|Other|Medical Chart Review|Obtain medical data
1571599|NCT02444754|Other|Questionnaire Administration|Complete demographics questionnaires
1571600|NCT02444754|Other|Survey Administration|Complete surveys
1571601|NCT02444741|Drug|Pembrolizumab|"Phase I: Starting dose of Pembrolizumab (MK-3475) 100 mg by vein on Day 1 of each 3-week cycle.
Phase II: Starting dose of Pembrolizumab at the maximum tolerated dose from Phase I."
1571602|NCT02444741|Radiation|Stereotactic Body Radiation Therapy|Stereotactic body radiation therapy (SBRT) delivered at 50 Gy in 4 daily fractions.
1571603|NCT02444741|Radiation|Wide-Field Radiation Therapy|Wide-field radiation therapy (WFRT) delivered at 45 Gy in 15 daily fractions.
1571604|NCT02444728|Drug|Hydroxychloroquine|Hydroxychloroquine 200 mg BID for 12 months
1571605|NCT02444728|Drug|Cyclophosphamide|Cyclophosphamide 1000mg intravenous infusion every month for 6 months
1571606|NCT02444728|Drug|Azathioprine|After Cyclophosphamide treatment, Azathioprine 100mg once daily for 6 months
1571607|NCT02444728|Drug|Methylprednisolone|Methylprednisolone 40-50 mg once daily for 1 months and then taped for 12 months
1571608|NCT02444715|Behavioral|Standard care|Participants receive only the usual care including blood analyses, blood pressure controls and individual advice on healthy lifestyle during the outpatient treatment given by the neurologist, by the general practitioner and by other physicians.
1571609|NCT02444715|Behavioral|CAPSYS|In addition to the usual care, patients are asked to call the CAPSYS system twice a week.
1571610|NCT02444689|Behavioral|Electronic Media Application|Children in the intervention group will receive motivation, education and coaching regarding therapeutic lifestyle changes via a smart phone electronic media application.
1571611|NCT02444689|Behavioral|Standard of care education|
1571612|NCT02444676|Other|Stratification and outcomes|No necessary
1571613|NCT02444663|Radiation|Clinician Valgus|Clinician performed valgus stress X-ray under fluoroscopy
1571614|NCT02444663|Radiation|Clinician Varus|Clinician performed varus stress X-ray under fluoroscopy
1571615|NCT02444663|Radiation|Device Valgus|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed valgus stress X-ray under fluoroscopy.
1571616|NCT02444663|Radiation|Device Varus|Device (Oxford Stress System for Knee Arthroplasty Radiographs (OSSKAR)) performed varus stress X-ray under fluoroscopy.
1571617|NCT02444650|Device|Pulse wave velocity measurement Photoplethysmogram|Correlation of pulse wave velocity measurement.
1571618|NCT02444650|Device|tonometer|
1571619|NCT02444637|Drug|Rivastigmine|
1571620|NCT02444611|Drug|BCG Vaccine|intradermal vaccination
1571621|NCT02444611|Drug|Hepatitis B Vaccine|intramuscular vaccination
1571624|NCT02444585|Drug|Denosumab|Intended to prevent periprosthetic loss of bone mineral density
1571625|NCT02444572|Drug|Enoxaparin 4000 UI|
1571626|NCT02444559|Drug|Ropivacaine 20ml 5mg/ml+ Clonidine 150ug|
1571627|NCT02444559|Drug|Ropivacaine 20ml 5mg/ml+ Placebo|
1571631|NCT02444533|Drug|Liposomal Bupivacaine|Injection of 8 ml of liposomal bupivacaine total in the tonsillar fossae after tonsillectomy.
1571666|NCT02444234|Drug|Tedizolid PO/IV|Participants will be randomized to receive tedizolid oral 200mg once daily for 3 days and crossed over to IV after a 1 week washout.
1571667|NCT02444234|Drug|Tedizolid IV/PO|Participants will be randomized to receive tedizolid IV 200mg once daily for 3 days and crossed over to PO after a 1 week washout.
1571668|NCT02444208|Behavioral|Active Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of cocaine cues.
1572377|NCT02438722|Other|Laboratory Biomarker Analysis|Correlative studies
1571632|NCT02444520|Behavioral|Integrated GP Care|"The overall aims of the intervention are to help the patient:
develop an understanding of the relationship between cognitive, emotional, physiological and behavioral aspects of their problem;
understand factors that may be maintaining the problem;
learn how to modify the behavioral and cognitive responses which may be maintaining the problem;
adopt a healthy sleep routine which can promote healthy living.
The approach will be manual based, which is important for subsequent roll-out. Hand-outs will be available for GPs to give to patients, but the structure of the intervention allows for treatment to be formulation-based so that particular issues raised in the consultation that might be maintaining symptom severity (e.g. avoidance) can be addressed."
1571633|NCT02444507|Drug|Nexium powder for injection and infusion 40 mg|Reference Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
1571634|NCT02444507|Drug|Esomelone Powder for Solution for Injection / Infusion 40 mg|Test Drug, Active substance: Esomeprazole 40 mg, Each single dose of esomeprazole 40 mg will be administrated as intravenous infusion over 30 minutes.
1571635|NCT02444481|Drug|Polygynax combinaison of polymyxin, Neomycin and Nystatin|
1571636|NCT02444468|Device|Flowtron ACS800|Flowtron ACS800 and bandage
1571637|NCT02444468|Other|Bandage|Bandage only
1571638|NCT02444455|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intravenous infusion(5×10^5/kg) once a day,a total of three times.
1571639|NCT02444442|Device|Renal Denervation|Deliberate disruption of the renal nerves via radio frequency energy delivery to renal arteries.
1571640|NCT02444442|Other|Sham control|Arterial access only. No delivery of radio frequency energy to renal arteries.
1571641|NCT02444429|Drug|Corticosteroid boluses Methylprednisolone|"Intensification of the corticotherapy in accordance with the validated protocol for the treatment of classic and subclinical acute rejections: 3 bolus Methylprednisolone 500 mg IV at D1, D2 and D3 then decreasing during 10-15 days at 1mg/kg/d and down to the maintenance dose.
An anti-pneumocystis and anti-CMV prophylaxis will be systemically introduced for 3 months.
The rest of maintenance immunosuppressive regimen (mycophenolate mofetil and anti-calcineurin) will remain unaltered"
1571642|NCT02444429|Other|No therapeutic modification|No therapeutic modification: continuation of the corticotherapy at the maintenance dose and maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
1571643|NCT02444429|Other|Stop maintenance corticotherapy|Immediate withdrawal of maintenance corticotherapy. Maintaining unaltered the rest of immunosuppressive treatment (mycophenolate mofetil and anti-calcineurin).
1571644|NCT02444416|Procedure|blood sample|
1571646|NCT02444390|Procedure|Biopsy|biopsy of a metastasis
1571647|NCT02444377|Behavioral|Interval training|
1571648|NCT02444364|Drug|Sitagliptin|Subjects will receive 90 tablets of 100mg sitagliptin
1571649|NCT02444351|Drug|botulinum toxin type A (Nabota®) injection into the gastrocnemius muscle|ultrasound-guided botulinum toxin type A (Nabota®, Daewoong co. Seoul, Korea) injection into the gastrocnemius muscle (maximum 200unit per each calf).
1571650|NCT02444351|Other|no intervention|Patients in the control group will not receive any injection on the gastrocnemius muscle.
1571651|NCT02444338|Device|MitraClip|Implantation of the MitraClip System for patients with chronic heart failure.
1571652|NCT02444338|Other|standard of care|
1571653|NCT02444325|Behavioral|Group prenatal care|Women will receive their prenatal care in a group rather than in the 1:1 traditional manner.
1571654|NCT02444312|Behavioral|Benefit-finding Writing Activity|Caregivers will be instructed to write about the benefits of caring, considering things such as improved social relationship, appreciation of life and loved ones, and the positive consequences with respect to these.
1571655|NCT02444312|Behavioral|Neutral Writing Activity|The control group will be instructed to write number of things about the weather that day. Although the sentences can be as long or as short as they like, they will be encouraged to try and aim for about 3 or 4 sentences at least.
1571656|NCT02444299|Device|Shoulder hemi-arthroplasty|
1571657|NCT02444273|Procedure|Exercise|Subjects will be given and individualized exercise program.
1571658|NCT02444260|Drug|Midazolam|Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.
1571659|NCT02444260|Drug|Intravenous Normal Saline|Intravenous normal saline will be infused by non-blinded anaesthetist
1571660|NCT02444260|Drug|Bupivocaine|Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg
1571661|NCT02444260|Drug|Lignocaine HCl|Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
1571662|NCT02444247|Other|High Dose Exercise (300 kcal)|Subjects will participate in 3 physical activity sessions per week expending 300 kcal per session and rate their liking of exercise.
1571663|NCT02444247|Other|Low Dose Exercise (150 kcal)|Subjects will participate in 3 physical activity sessions per week expending 150 kcal per session and rate their liking of exercise.
1571664|NCT02444247|Other|No Exercise (0 kcal)|Subjects will participate in 3 sessions per week expending 0 kcal per session and rate their liking of exercise.
1571665|NCT02444247|Other|Sedentary Option|Subjects will rate their liking of sedentary activities (reading magazines, playing word games, puzzles) as an alternative to exercise.
1571711|NCT02443896|Procedure|No sealant of permanent molars|No sealant applied to permanent molars.
1571669|NCT02444208|Behavioral|Neutral Inhibitory Control Training|Subjects will learn to inhibit responding in the presence of neutral cues.
1571670|NCT02444195|Behavioral|Guided Imagery With Audio Media|Subjects assigned to the experimental arm will be asked to participate in meditation daily using the audio media provided for the 7 days prior to surgery, in the preoperative holding area, for the 7 days following surgery, and are encouraged to engage in affirmations module use at least weekly in the 6-8 week postoperative period.
1571671|NCT02444182|Dietary Supplement|Probiotics|A half of the participants will be randomly allocated to the probiotics group. They will receive a probiotics lozenge twice a day for 4 weeks. Pre and Post intervention clinical exam will be conducted
1571672|NCT02444182|Dietary Supplement|Placebo|A half of the participants will be randomly allocated to the placebo group. Lozenges with no probiotics will be given twice daily for 4 weeks. Pre and Post intervention clinical exam will be conducted
1571673|NCT02444169|Device|Ultherapy|Focused ultrasound energy delivered below the surface of the skin.
1571674|NCT02444169|Drug|Incobotulinumtoxin A|An injectable medicine used to temporarily improve the look of moderate to severe frown lines between the eyebrows (glabellar lines) in adults.
1571675|NCT02444169|Device|Radiesse|An injectable dermal filler that temporarily adds volume to help smooth moderate to severe facial wrinkles and folds, such as nasolabial folds (the creases that extend from the corner of the nose to the corner of the mouth).
1571676|NCT02444169|Device|Belotero Balance|An injectable dermal filler to temporarily smooth out and fill in moderate-to-severe nasolabial folds (the folds or wrinkles that go from the side of the nose to the corner of the mouth).
1571677|NCT02444156|Other|Indoor rowing|
1571678|NCT02444143|Drug|tacrolimus extended release|
1571679|NCT02444130|Device|contact lenses|Presbyopia was compensated with contact lenses by monovision and multifocality.
1571680|NCT02444117|Other|functional rehabilitation of social communication|
1571681|NCT02444091|Drug|Cyclophosphamide|Cyclophosphamide intravenous infusions four weeks apart, in total six infusions. First infusion: cyclophosphamide 600mg/m2. Infusions 2 to 6: cyclophosphamide 700 mg/m2 . Follow-up for 12 months.
1571682|NCT02444078|Other|Exercise|Exercise training will take place in the NH, twice weekly, around 60 minutes per session (session duration can be shorter during the first weeks of intervention according with participants' physical capacity), during 6 months; interval between two exercise sessions will be of at least 48 hours. The exercise program will be a multicomponent training, with exercises specifically developed to improve participants' flexibility (10 minutes), coordination and balance (10 minutes), muscle toning (10 minutes), and cardiorespiratory capacity (25 minutes). The exercise intensity targeted will be moderate. All exercise sessions will be accompanied by music.
1571683|NCT02444078|Other|Social Activity|Interventionists will be health professionals external to the NH, preferentially psychologists. Interventions will take place in the NHs, at the same frequency and duration than the exercise intervention (twice weekly, 60 minutes per session, during 6 months).
1571684|NCT02444065|Behavioral|Cognitive Behavior Therapy (CBT)|The CBT intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol developed by the investigators. It uses standard CBT for eating disorders interventions, including orientation to the CBT model, psychoeducation, commitment and goal setting, behavioral strategies for normalizing eating and reducing bulimic symptoms, planning, and homework. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
1571685|NCT02444065|Behavioral|Motivational Interviewing (MI)|The MI intervention is a 4 session (1 hour each) individual psychotherapy intervention that uses a manualized treatment protocol (Carter & Bewell-Weiss, 2012). It uses standard MI for eating disorders interventions, including decisional balance, exploring values, readiness and confidence rules, and MI communication strategies. 1-2 sessions are delivered before starting day hospital treatment, and the remaining sessions are delivered in the first weeks of day hospital.
1571686|NCT02444052|Device|Zimmer Puros Cancellous Allograft|Right side will have an extraction followed by an allogenic bone graft zimmer puros followed by implant placement.
1571687|NCT02444052|Device|Nobel Biocare Creos Cancellous Allograft|Left side will have an extraction followed by an allogenic bone nobel biocare creos graft followed by implant placement.
1571688|NCT02444039|Device|SL-D301|Slit Lamp
1571689|NCT02444039|Device|DC-4|Digital Camera Attachment
1571690|NCT02444039|Device|SL-3G|Slit Lamp
1571691|NCT02444026|Behavioral|iCBT for Insomnia|Internet-delivered Cognitive Behavioural Therapy for Insomnia
1571692|NCT02444013|Drug|Folic acid|
1571693|NCT02444013|Drug|Placebo|
1571694|NCT02444000|Drug|PCV chemotherapy alone|"PCV cycles are 6 weeks long
PCV chemotherapy is given as:
Day 1: CCNU 110 mg/m2 orally; Days 8 and 29: vincristine 1.4 mg/m2 IV; Days 8 to 21: procarbazine 60 mg/m2 orally"
1571695|NCT02444000|Drug|Radiotherapy+PCV chemotherapy|Radiotherapy followed by 6 cycles of PCV
1571697|NCT02443974|Device|Brace (Fisiotensor®)|
1571698|NCT02443974|Device|Sleeve (Fisiotensor®)|
1571699|NCT02443961|Biological|Mesenchymal Stem Cell (MSC) therapy|3 doses of 5 million MSC will be administered
1571700|NCT02443948|Other|Vena puncture for blood collection|Cf-DNA blood samples will be collected in EDTA tubes (20 ml) during the routine blood test
1571701|NCT02443935|Drug|MGN1703|60 mg s.c. twice weekly for 4 weeks
1571702|NCT02443935|Drug|MGN1703|60 mg s.c. twice weekly for 24 weeks
1571703|NCT02443922|Drug|Glimepiride|Glimepiride 2mg qam
1571704|NCT02443922|Drug|Sitagliptin|Sitagliptin 100mg qam
1571705|NCT02443922|Drug|Metformin|Metformin as prescribed
1571706|NCT02443909|Procedure|Retrograde Intrarenal Surgery|endoscopic stone treatment with flexible ureteroscopy and 20w holmium laser device
1571707|NCT02443909|Procedure|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working over 20w power)
1571708|NCT02443909|Procedure|Retrograde Intrarenal Surgery|Retrograde Intrarenal Surgery with 30w Holmium laser device(working under 20w power)
1571709|NCT02443909|Device|Holmium laser device|
1571710|NCT02443896|Procedure|Pit and Fissure Sealant of permanent molars|The tooth is thoroughly cleaned, prepared with a special solution, and dried. The liquid sealant is then applied and allowed to set hard
1571713|NCT02443857|Device|ChARMin|The aim is to investigate the applicability (technical aspects, patient-related aspects, operability/handling of the robot, the different control modes of the device, safety and the software interface) of ChARMin.
1571714|NCT02443857|Device|ChARMin|The aim is to determine whether differences between game scores, kinematic and kinetic metrics provided by ChARMin, additionally applied physiological measures and adverse events differ when participants train with the free non-supported mode, the assist-as-needed mode and the fully guided mode.
1571715|NCT02443857|Device|ChARMin|The aim is to determine the psychometric properties (validity, reliability and responsiveness) of the assessments integrated in ChARMin.
1571716|NCT02443857|Device|ChARMin|The aim is to describe the application of the system in 30 participants and evaluate the concomitant changes in upper extremity motor function (open labelled interventional study without control group).
1571717|NCT02443857|Device|ChARMin|The aim is to perform specific motor learning studies in 120 patients investigating whether children with neurological diagnoses can improve arm and hand task performance during repetitive training with ChARMin, are able to retain improved levels of task performance and how task performance is influenced by other interventions.
1571718|NCT02443857|Device|ChARMin|The aim is to perform an ecological study monitoring safety, functional progress and (changes in) the application of ChARMin in 120 participants following an in- or out-patient program (comparable to subproject ChARMin-4).
1571719|NCT02443844|Procedure|Transurethral Resection|Endoscopic treatment of bladder cancer
1571720|NCT02443844|Drug|Tamsulosin|Medical treatment for benign prostate hyperplasia
1571721|NCT02443831|Procedure|Leukapheresis|Patients will undergo an unstimulated leukapheresis to isolate the required immune cells to produce the CD19 CAR T-cells
1571722|NCT02443831|Drug|Lymphodepletion with fludarabine|Patients will receive lymphodepleting chemotherapy with iv fludarabine 30 mg/m2 on days -7 to -3 prior to CD19CAR T-cell infusion.
1571723|NCT02443831|Drug|Lymphodepletion with cyclophosphamide|Patients will receive lymphodepleting chemotherapy with iv cyclophosphamide 0.5 g/m2 on days -4 to -2 prior to CD19CAR T-cell infusion.
1571724|NCT02443831|Biological|CD19 CAR T-cells|A single dose of 1 x 10^6/kg CD19CAR transduced T-cells will be given as an intravenous injection through a Hickman line or PICC line(peripherally inserted central catheter) on day 0.
1571725|NCT02443818|Drug|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
1571726|NCT02443805|Biological|300 IR|300 IR tablet of HDM Allergen Extracts
1571727|NCT02443805|Biological|Placebo|Placebo tablet
1571728|NCT02443792|Procedure|Unicirc with tissue adhesive|As above
1571729|NCT02443792|Procedure|Open Surgical|As above
1571730|NCT02443766|Other|Meditation Retreat|Weeklong retreat which includes meditation and prayer.
1571731|NCT02443753|Device|EndoBarrier SANS|Eligible subjects will be implanted with the EndoBarrier® SANS™ Device for a period of 3 months. The GI Dynamics' EndoBarrier® SANS™ is an endoscopically positioned device that represents an alternative to the use of gastric bypass operative techniques as a means of re-routing food and altering the gut-hormone axis. The EndoBarrier® SANS™ provides an alternate passage of chime through the duodenum and proximal sixty centimeters of jejunum replicating in part the bypass of bariatric surgery.
1571735|NCT02443727|Drug|Syntocinon (synthetic oxytocin)|Dosage and details described in arm.
1571736|NCT02443727|Other|Placebo|Dosage and details described in arm.
1571737|NCT02443714|Device|Needle-free jet injection with insulin lispro|Subjects injected by jet injectors which deliver insulin lispro
1571738|NCT02443714|Device|Conventional pen injection with insulin lispro|Subjects injected by conventional insulin pens which deliver insulin lispro
1571739|NCT02443701|Other|Exercise|Warmup program, maximum isometric strengthening, and jump training
1571740|NCT02443701|Other|LASER|a cluster with 03 diodes with 850nm wavelength and the following parameters: Power 50mW diode, diode energy by 2J, power per point of 6J, totaling 36J per member
1571741|NCT02443701|Other|NMES|electrical stimulation, medium frequency current (1kHz), Burst duration equal to 2ms with, modulated at 70Hz, cycle Work 10% T-on and T-10 seconds off and 30 seconds intensity used will vary according to the capacity and tolerable for each individual
1571742|NCT02443688|Drug|CTX-4430|
1571743|NCT02443688|Drug|Placebo|
1571745|NCT02443649|Behavioral|Sleep hygiene program|Sleep hygiene program
1571746|NCT02443649|Behavioral|Sleep hypnosis|Hypnosis recording with personalized goals and imagery for sleep improvement
1571747|NCT02443623|Biological|Vaccination with ACAM2000|In this study (VA-008), healthy adult male and female volunteers who meet the requirements for source plasma donors and study entry criteria will be vaccinated with the ACAM2000 smallpox vaccine for collection of plasma to be used in the manufacture of VIGIV. There are possible risks associated with ACAM2000 vaccination. To ensure the safety of plasma donors, risk factor screening procedures and the collection of post-vaccination safety data will be assessed throughout the study.
1571748|NCT02443597|Other|ultrasound|trans abdominal or trans vaginal ultrasound to detect some of the soft markers of trisomy screening
1571749|NCT02443584|Other|pharmacogenetic testing|pharmacogenetic testing for anti-depressant/anti-psychotic medications
1571751|NCT02443558|Other|Brain-Computer Interface control of robotic arms.|The patients will be trained to modulate self-paced Visual Motor Imagery (VMI) and Kinesthetic Motor Imagery (KMI) under EEG recording in order to achieve BCI-control of a custom-built bimanual arms robot (MERCURY v2.0). In KMI they will be asked to modulate brain waves in order to learn to control the BCI and in VMI they will additionally be projected a visual cue (representation of the intended movement).
1572379|NCT02438696|Drug|BI 1060469, iFF, Test|
1571752|NCT02443558|Device|MERCURY v2.0 robotic arms|MERCURY v2.0 robotic arms is a non-commercial 6-degree-of-freedom anthropomorphic bimanual robotic arms device that was built and developed by the research team of the Medical Physics Lab.
1571753|NCT02443545|Drug|Deferiprone|
1571754|NCT02443532|Behavioral|Structured group education|The group intervention consists of interactive sessions for groups of 5-7 patients, dealing with different aspects of management of type 1 diabetes: insulin therapy and hypoglycemia, management of insulin doses, diet, physical exercise, sick days, etc. The intervention is designed for the acquisition of specific skills of self-management. This intervention is provided by a team including physicians, dietitians, and nurses.
1571755|NCT02443532|Behavioral|Individual education|Usual care (individual consultations as routinely performed)
1571756|NCT02443519|Behavioral|MBCT for Migraine|8 75-90 minute individual sessions of the manualized Mindfulness-based Cognitive Therapy plus a manual and homework
1571757|NCT02443506|Drug|AMG 623|Single dose of AMG 623 administered as subcutaneous and intravenous doses
1571758|NCT02443506|Drug|Placebo|Single dose of matching AMG 623 placebo administered as subcutaneous and intravenous doses
1571759|NCT02443493|Device|Low-level laser|Low-Level Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
1571760|NCT02443493|Device|sham laser|Sham Laser Therapy will be applied, twice a week, from the start of radiotherapy treatment (14 sessions in total) in combination with the standard skin care.
1571761|NCT02443493|Radiation|radiotherapy|
1571762|NCT02443467|Other|No intervention|
1571763|NCT02443454|Device|Device: Complior Analyse System|Monitoring of Arterial Stiffness and Central Aortic Pressure
1571764|NCT02443454|Device|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
1571765|NCT02443402|Drug|Sitagliptin|Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) < 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
1571766|NCT02443402|Drug|Placebo|One pill daily until discharge
1571767|NCT02443402|Drug|Regular Human Insulin|Continuous intravenous insulin given to ICU patients with a BG > 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
1571768|NCT02443402|Drug|Insulin glargine|"When regular insulin is discontinued, if needed, insulin glargine will be given once daily. Patients who required continuous insulin infusion at an average rate >2U/h will be transitioned to basal (to be given approx. 4 hours prior to discontinuing the insulin drip) starting at a dose 0.2 U/Kg/d.
Subjects with a BG at 140-200 mg/dL will start glargine at 0.2 U/kg weight per day. And subjects with BG between 201-400 mg/dL will start glargine at 0.2 U/Kg/day
The basal insulin dose will be adjusted as follow:
If fasting and pre-dinner BG is between 100 - 180 mg/dL in the absence of hypoglycemia the previous day: no change
If fasting and pre-dinner BG is between 180 - 240 mg/dL in the absence of hypoglycemia: increase glargine by 10% every day
If fasting and pre-dinner BG is > 241 mg/dL in the absence of hypoglycemia the previous day: increase glargine dose by 20% every day
If fasting and pre-dinner BG is < 100 mg/dL in the absence of hypoglycemia: stop glargine"
1571769|NCT02443402|Drug|Supplemental insulin (Insulin lispro)|"Insulin lispro will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.
For the subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin lispro
BG between 221-260 mg/dL; 3-5 units of insulin lispro
BG between 261-300 mg/dL; 4-6 units of insulin lispro
BG between 301-350 mg/dL; 5-7 units of insulin lispro
BG between 351-400 mg/dL; 6-8 units of insulin lispro
BG > 400 mg/dL; 7-9 units of insulin lispro"
1571770|NCT02443402|Drug|Supplemental insulin (Insulin aspart)|"Insulin aspart will be administered before meals in addition to scheduled insulin dose following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at BG >240 mg/dL will be given.
For the subjects receiving supplemental insulin aspart with BG levels greater than 180 mg/dL, then supplemental insulin scale is as follows:
BG between 181-220 mg/dL; 2-4 units of insulin aspart
BG between 221-260 mg/dL; 3-5 units of insulin aspart
BG between 261-300 mg/dL; 4-6 units of insulin aspart
BG between 301-350 mg/dL; 5-7 units of insulin aspart
BG between 351-400 mg/dL; 6-8 units of insulin aspart
BG > 400 mg/dL; 7-9 units of insulin aspart"
1571771|NCT02443376|Device|Complior Analyse System|Pulse Wave Velocity PWV and central Pressure analysis
1571772|NCT02443376|Device|BCM- Body Composition Monitor|"BCM - Body Composition Monitor gives information about:
Overhydration Urea distribution volume (V) Total body water, extracellular and intracellular water Lean Tissue Index (LTI) Fat Tissue Index (FTI) Body Cell Mass (BCM)"
1571773|NCT02443363|Other|Estimating of formula MDRD, CKD-EPI, Cockroft-Gault,|
1571774|NCT02443363|Device|Tanita BC 418- Bioelectrical impedance analysis|The device measured the size of total body water (TBW), fat mass (FM%), visceral fat%, fat free mass (FFM), and basal metabolic rate (BMR) (kcal).
1571775|NCT02443337|Drug|LY3023414|Administered orally
1571776|NCT02443337|Drug|Necitumumab|Administered IV
1571777|NCT02443324|Drug|Ramucirumab|Administered IV
1571778|NCT02443324|Drug|Pembrolizumab|Administered IV
1571914|NCT02442245|Dietary Supplement|XSurge|During part one of the study, 28 days of supplementation with XSurge will be provided. During the second part of the study 6 weeks of supplementation with XSurge will accompany a training program.
1571915|NCT02442245|Other|Placebo: Microcrystalline Cellulose|
1571783|NCT02443285|Drug|Cefotaxime|Cefotaxime 2 gram every12 hours for 5 days
1571784|NCT02443285|Drug|ceftriaxone|Ceftriaxone 2 gm every 24 hours for 5 days
1571785|NCT02443272|Procedure|Vessel Loop Drainage|Minimally invasive approach will utilize a vesi-loop device for the vessel loop drainage technique by placing 2 peripheral stab incisions into the abscess with a tunnel through the abscess cavity, and loop passed through the tunnel and tied atop the skin.
1571786|NCT02443272|Procedure|Incision and Drainage|Standard of care treatment will utilize incision and drainage over the center of the abscess cavity with or without packing at physicians discretion.
1571787|NCT02443246|Drug|Vitamin D3 B.O.N. Injection (cholecalciferol 200,000IU)|
1571788|NCT02443246|Drug|Placebo|
1571789|NCT02443220|Device|TEAS(transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Hegu before anesthesia"
1571790|NCT02443220|Device|TEAS (transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on Danzhong and Juque before anesthesia"
1571791|NCT02443220|Device|TEAS (transcutaneous electric acupoint stimulation)|"transcutaneous electric acupoint will commence at 30 min on 2 cm parallel to the right of Danzhong and Juque before anesthesia"
1571792|NCT02443194|Drug|duloxetine|after randomization the patient will receive cymbalta/ placebo for 3 months
1571793|NCT02443194|Drug|PLACEBO|after randomization the patient will receive cymbalta/ placebo for 3 months
1571794|NCT02443181|Device|Activa PC+S|Implementation of closed loop DBS for essential tremor
1571795|NCT02443168|Drug|AG-221|Part 1: oral solution containing 100 mg [14C]-AG-221
1571796|NCT02443168|Radiation|14C AG-221|5 mL of 100 micrograms [14C] AG-221 given intravenously 4 hours after swallowing the formulated tablet.
1571797|NCT02443155|Drug|NNC0114-0006|NNC0114-0006 12 mg/kg administered i.v (intravenously) every 6 weeks. Subjects will continue their pre-trial insulin treatment
1571798|NCT02443155|Drug|liraglutide|Liraglutide 1.8 mg administered s.c. (subcutaneously) daily. Subjects will continue their pre-trial insulin treatment
1571799|NCT02443155|Drug|placebo|Placebo administered s.c (subcutaneously) or i.v ( intravenously). Subjects will continue their pre-trial insulin treatment
1571800|NCT02443142|Drug|Ibuprofen|Ibuprofen 800 mg orally three times per day for two days for study subjects who are randomized to the ibuprofen arm.
1571801|NCT02443142|Drug|Acetaminophen|Acetaminophen 1000 mg orrally three times per day for two days for subjects who are randomized to the acetaminophen arm.
1571802|NCT02443129|Device|DRI-1 Swept source OCT, Atlantis, Topcon|Fundus imaging
1571803|NCT02443116|Biological|NGM282|
1571804|NCT02443116|Other|Placebo|
1571806|NCT02443090|Drug|fispemifene|
1571807|NCT02443090|Other|Placebo|
1571818|NCT02443064|Drug|Vancomycin|"Vancomycin was administered for Chinese patients with MRSA blood stream infection and endocarditis Pharmacokinetics: 5 blood samples collected at steady state for the determination of plasma concentrations for population pharmacokinetics (PPK) analysis.
Microbiology: blood cultures for MRSA isolation, MIC of vancomycin against MRSA; molecular typing will be analyzed on bacterial strains including heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and vancomycin-intermediate Staphylococcus aureus （VISA); Safety evaluation: hepatic and renal function, blood routine test, and so on."
1571819|NCT02443051|Behavioral|Attention Bias Modification|Computer delivered modification in 80% of trials
1571820|NCT02443038|Other|Yoga|"16 bi-weekly 50-60 minute yoga classes, followed by daily, 10 minute home exercise poses and 5 minute relaxation, the control group will practice 5 minutes relaxation, each day between classes.
The first of 3 classes is the 8-10 member advisory board, the second and third classes with 10-15 participants in each workshop will be held in other counties. There will be 2-3 months between the first set of classes and second and third set of classes to refine methods and conduct enrollment and testing for the subsequent groups."
1571821|NCT02443025|Behavioral|Teens Against Tobacco Use|Teens Against Tobacco Use teen teachers develop and then deliver anti-tobacco presentations to the target population of younger students.
1571822|NCT02443012|Drug|Topical Gutt Nepafenac 0.1%|Topical Nepafenac as an adjunct to focal/grid laser
1571823|NCT02443012|Procedure|Laser|Grid/Focal Laser Photocoagulation
1571824|NCT02442999|Other|Screening for obstructive sleep apnea|
1571825|NCT02442999|Device|CPAP - continuous positive airway pressure|
1571826|NCT02442973|Procedure|Control group (CG): standard practice|Standard practice group
1571827|NCT02442973|Procedure|Ultrasound group (UG):|"SpineView3D™ anatomical scouting approach"
1571828|NCT02442973|Device|Accuro SpineView3D™|subject will be scanned with 'Accuro SpineView3D
1571829|NCT02442960|Drug|Herbal treatment (SA100)|This treatment has been used extensively in traditional medicine practices for hundreds of years.
1571916|NCT02442245|Other|Control: No supplementation|
1571830|NCT02442947|Other|clothing type, protective garments of Paul Boye Technologies|The experiment aimed at evaluating the physiological stress obtained when dressed in different clothing (NBC protective garment [charcoal base], combat garment and 2 different types of work uniforms- (1)50% cotton and 50% polyester (2)80% cotton and 20% polyester) and during exertion under heat conditions.
1571831|NCT02442934|Other|Administration of the IPREA3 questionnaire|On the day of the ICU discharge, the bedside nurse administers to the patient the 18-item IPREA questionnaire i.e the nurse asks the patient to rate the severity of each discomfort source contained in the IPREA3 questionnaire experienced during the entire stay in the ICU
1571832|NCT02442934|Other|Immediate feedback through electronic reminder messages|After the nurse had administered the questionnaire, warning messages are displayed on the screen corresponding to the key points to prevent the three discomforts reported with the highest scores
1571833|NCT02442934|Other|Targeted interventions in each ICU to reduce discomforts|"These targeted interventions are implemented through the coordination of two local champions.
The central coordination IPREA3 team sends each month to the local champions monthly and cumulative discomfort scores of their unit (overall score of discomfort and scores for each item) and their ranking relative to other units assigned to the interventional arm i.e applying the IPREA3 program.
The local champions organize monthly meetings with the unit staff to present the results in terms of perceived discomforts measured by the IPREA questionnaire, identify main discomfort sources and actions to be conducted to reduce the discomforts reported with the highest scores in the unit and those that are most easily preventable, and assess the efficacy of already applied measures."
1571834|NCT02442921|Drug|Colchicine|up to 2mg of Colchicine daily
1571835|NCT02442921|Drug|Placebo|Daily placebo
1571836|NCT02442908|Dietary Supplement|Nutrifriend Cachexia|2 daily for 12 weeks
1571837|NCT02442908|Dietary Supplement|Isocaloric placebo|2 daily for 12 weeks
1571838|NCT02442869|Behavioral|Treatment as usual (TAU)|4-8 weeks of treatment typically provided by that counselor with the caveat that neither DBT nor CAMS can be provided.
1571839|NCT02442869|Behavioral|CAMS short|4-8 weeks Collaborative Assessment and Management of Suicidality (CAMS) short course
1571840|NCT02442869|Behavioral|CAMS long|4-16 weeks Collaborative Assessment and Management of Suicidality (CAMS) long course
1571841|NCT02442869|Behavioral|Dialectical Behavioral Therapy (DBT) long|4-16 weeks of Dialectical Behavioral Therapy (DBT) long course
1571842|NCT02442856|Device|Thigh Cuff|
1571843|NCT02442843|Device|Active tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
1571844|NCT02442843|Device|Sham tDCS|Participants will be randomized into active or sham stimulation in the first tDCS session. Participants will then have the option to complete 9 additional session of tDCS which will be active tDCS or a combination of active and sham tDCS in a non-randomized manner over two consecutive weeks. Each session will last 1 - 2 hours.
1571845|NCT02442830|Device|Early Video Capsule Endoscopy|"The intervention is the use of video capsule endoscopy as the first test in a patient presenting to the ED with active bleeding. The capsule allows for visualization of the entire GI tract.
Once a capsule has been given to a study patient, a staff member will use the capsule's real-time viewer to see if there is any active bleeding in the stomach. If bleeding is seen the investigators will pursue an upper endoscopy. If no bleeding is seen a staff member will review the entire findings of the capsule and make a decision regarding which therapeutic measure to pursue."
1571846|NCT02442817|Drug|Linagliptin|12 weeks of treatment and week for assessment. Linagliptin, 5 mg by mouth once per day for 12 weeks, in combination with continued antipsychotic treatment.
1571847|NCT02442804|Dietary Supplement|POMx|Pomegranate supplement (1g) by mouth twice per day for 7 days
1571848|NCT02442804|Other|Placebo|Placebo (for POMx, containing no antioxidant contents; 1g) capsule by mouth twice per day for 7 days
1571849|NCT02442791|Drug|Byetta (Lilly, Exenatide)|See description of Arms
1571850|NCT02442791|Other|20% Human Albumin|See description of Arms
1571855|NCT02442752|Drug|Dexlansoprazole|Dexlansoprazole capsules
1571856|NCT02442739|Drug|Ketamine|Ketamine 0.5 mg/kg mixed with syrup will be given by mouth once a week for 12 weeks.
1571857|NCT02442739|Other|Placebo|Placebo syrup will be given by mouth once a week for 12 weeks.
1571858|NCT02442726|Device|CO2-Laser stimulation (Laser Stimulation Device, SIFEC)|Laser stimuli are evenly applied in 15 spots (each 6 mm in diameter) in the primary hyperalgesic zone (application zone of the contact thermode) and in the secondary hyperalgesic zone (1 cm outside the application zone of the contact thermode).
1571860|NCT02442700|Drug|pitavastatin|Treatment A = administration pitavastatin for 12 weeks
1571861|NCT02442700|Drug|placebo|Treatment B = administration placebo for 12 weeks
1571862|NCT02442687|Drug|JKB-121: 5 mg twice daily|
1571863|NCT02442687|Drug|JKB-121: 10 mg twice daily|
1571864|NCT02442687|Drug|Placebo|
1571865|NCT02442674|Drug|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg Tablets.
Dosage: Depending on age, weight and serum sodium response:
Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: 30 (+2) days"
1571866|NCT02442674|Other|Placebo|Placebo tablet matching active drug
1571867|NCT02442648|Drug|Carfilzomib|Carfilzomib will be administered for desensitization per study protocol.
1571868|NCT02442648|Drug|Rituximab|Rituximab will be administered for desensitization per study protocol.
1571869|NCT02442635|Behavioral|Yoga|Yoga breathing and postures; After this initial 3 arm experiment, yoga breathing and postures will be studied in combination.
1571870|NCT02442622|Other|Occupational therapy|Occupational therapy for de Quervain's Tenosynovitis
1571871|NCT02442622|Other|Occupational therapy with ASTYM|Occupational therapy for de Quervain's Tenosynovitis plus ASTYM
1571872|NCT02442609|Other|questionaire|questionaire before surgery
1571917|NCT02442206|Drug|QVA149|QVA149 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
1571873|NCT02442583|Other|Brochure regarding sedentary behavior|This pilot will occur in two phases. Phase 1 will occur in two steps. In Step 1, we will conduct one-on-one telephone interviews with 15 early stage CRC (colorectal cancer) survivors to obtain their knowledge and insights about sedentary behaviors and ways to reduce them. Their input will be used to help create a brochure on sedentary behaviors. In Step 2, we will conduct one-on-one telephone interviews with 5 early stage CRC survivors to provide feedback about the brochure. In Phase 2, we will recruit 15 CRC survivors. After completing a baseline survey, they will be asked to both wear an ActiGraph and self-report their daily sedentary behaviors for one week. They will receive tailored feedback as to their average weakly levels of sedentary behaviors and receive the brochure. One month post-intervention, they will be asked to take part in telephone survey assessing sedentary behaviors, PA (physical activity), and use of brochure.
1571874|NCT02442570|Biological|recombinant human alpha B-crystallin|intravenous injections
1571875|NCT02442570|Other|Placebo comparator|intravenous injection
1571876|NCT02442557|Biological|recombinant human alpha B-crystallin|intravenous injection
1571877|NCT02442557|Other|placebo comparator|intravenous injection
1571878|NCT02442544|Dietary Supplement|Prebiotic|1:1 oligofructose: inulin 8 g orally /day
1571879|NCT02442544|Dietary Supplement|Placebo|maltodextrin 3.3g orally/day
1571880|NCT02442531|Drug|CriPec® docetaxel|-3 weekly IV dose. Dose escalation; start dose 15 mg/m2. Number of cycles: 6 or until progression or unacceptable toxicity develops
1571881|NCT02442518|Procedure|antenatal ultrasound|Transabdominal and Transvaginal ultrasound examinations were performed in the third trimester (with some fluid in the bladder so that the uterine bladder interface could be evaluated well).
1571882|NCT02442505|Device|Microlife WatchBP03 device|Microlife WatchBP03 device which is an automated oscillometric device using a new algorithm to detect atrial fibrillation
1571883|NCT02442492|Drug|Sildenafil|Sildenafil 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
1571884|NCT02442492|Drug|Placebo|Placebo 25 mg tablets three times daily orally from randomization until delivery or 31+6 weeks of gestational age, whichever is sooner.
1571885|NCT02442479|Behavioral|resistance training|
1571886|NCT02442466|Drug|Endothelin Receptor B inhibitor BQ788|
1571887|NCT02442466|Drug|PBS|
1571888|NCT02442453|Drug|Topical application of curenext gel|Topical application of curcuma longa gel along with scaling and root planing in chronic periodontitis subjects
1571889|NCT02442453|Drug|Placebo|Topical application of placebo gel along with scaling and root planing in chronic periodontitis subjects
1571890|NCT02442440|Drug|anisodamine|Anisodamine will be given first as bolus of 10 mg, followed by 0.1-0.5mg/kg/hr. The adjustment of pump infusion rate is largely at the discretion of treating physician, with the aim of improving microcirculation and limit the side effect to a minimum. For example, if serum lactate continues to elevate, the infusion rate can be increased. Discontinuation on severe side effect or recovery of shock (normalized lactate, weaned from vasopressor) or death.
1571891|NCT02442427|Drug|Palivizumab|A single dose of IV palivizumab 15 mg per kilogram body weight (maximum dose =100 mg). The study medication will be given by IV infusion over 30 minutes using a syringe infusion pump.
1571892|NCT02442427|Other|Placebo|An equal volume of 0.9% normal saline
1571893|NCT02442414|Drug|KBP-5209|Single oral dose beginning at 20 mg with daily dosing for 28 day cycles.
1571894|NCT02442401|Device|The negative pressure wound therapy|
1571895|NCT02442388|Procedure|Instrumentation technique with hand file|type of instrumentation technique for root canal treatment
1571896|NCT02442388|Procedure|Instrumentation technique with ProTaper|type of instrumentation technique for root canal treatment
1571897|NCT02442388|Procedure|Instrumentation technique with WaveOne|type of instrumentation technique for root canal treatment
1571898|NCT02442375|Radiation|standard dose prescription|"standard elective dose
no intermediate dose-level
visual interpretation of FDG-PET-scan"
1571899|NCT02442375|Radiation|FDG‐PET guided gradient dose prescription|"de-escalation of elective dose
intermediate dose-level
standardized methods to evaluate FDG-PET-scan"
1571900|NCT02442362|Drug|paclitaxel+oxaliplatin+fluorouracil|"Patients treated with paclitaxel+oxaliplatin+fluorouracil: paclitaxel (135 mg/m2 iv) on day 1, oxaliplatin (100 mg/m2 iv) on day 1, fluorouracil (500 mg/m2 continuous iv) on day 1-5twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14."
1571901|NCT02442362|Drug|oxaliplatin+S1|"Patients treated with oxaliplatin+S1: oxaliplatin (130 mg/m2 iv) on day 1 and S-1 (40 mg twice/day for body surface area < 1.25 m2 and 60 mg twice/day for body surface area between 1.25 and 1.50 m2 orally) on days 1-14"
1571902|NCT02442349|Drug|AZD9291|Once daily tablet 80 mg
1571903|NCT02442336|Behavioral|My Journey AHead|The intervention program will contain information and interactive activities around swallowing concerns, proper oral care, healthy eating and nutrition, speech issues, stress and coping with cancer, and pain management.
1571904|NCT02442323|Behavioral|Walking Intervention|12-week walking program
1571905|NCT02442310|Drug|Deferiprone delayed release tablet formulation|Deferiprone 600 mg delayed release tablet formulation
1571906|NCT02442310|Drug|Deferiprone oral solution|Deferiprone 100 mg/mL oral solution
1571907|NCT02442297|Biological|HER2-specific T cells|"Dose Level 1: 1x10^7 cells
Dose Level 2: 3x10^7 cells
Dose Level 3: 1x10^8 cells*
* due to volume restriction, this dose will be given in two 5x10^7 cells aliquots on two successive days
The initial safety profile will be done at 6 weeks following the HER2-specific T-cell infusion. If the patient has documented stable disease or a response by the RECIST criteria evaluations they are eligible to receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the cell number at the highest safety established dose level."
1571910|NCT02442271|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
1571911|NCT02442271|Drug|ribavirin|Tablet
1571912|NCT02442258|Drug|ABT-493|A single dose of ABT-493 will be given orally in combination with ABT-530.
1571913|NCT02442258|Drug|ABT-530|A single dose of ABT-530 will be given orally in combination with ABT-493.
1571918|NCT02442206|Drug|Placebo|Placebo to QVA140 capsules 100/50 µg for inhalation via Concept-1-inhaler, taken once daily
1571919|NCT02442193|Other|Individual Placement and Support|Individual Placement and Support is a form of supported employment.
1571920|NCT02442180|Drug|G-CSF (Filgrastim injection)|G-CSF (Filgrastim injection) 5ug/kg subcutaneous injection daily for 5 days and every 3 days (total 12 doses)
1571921|NCT02442180|Drug|steroid|oral prednisolone 40mg qd or iv methylprednisolone 32 mg if oral medication is not tolerable
1571922|NCT02442180|Drug|placebo|equivalent to G-CSF doses
1571923|NCT02442154|Procedure|Tracheostomy|It is a surgical procedure which involves making an incision on the anterior aspect of the neck and opening a direct airway through an incision in the trachea with stitching the trachea to the skin and placement of a tube
1571924|NCT02442128|Drug|propofol /Fentanyl|fentanyl 2 μg/kg and propofol 2 mg/kg Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
1571925|NCT02442128|Drug|Fentanyl / propofol|fentanyl 2 μg/kg and propofol 3 mg/kg. Both test drugs will be made up to 10 ml with saline. fentanyl will be first administered intravenously over 30 s followed by propofol over 20 s.
1571926|NCT02442115|Other|Treatment of Functional Constipation by|The NASPGHAN protocol is used by pediatric gastroenterologist to treat functional constipation. Status is monitored at 4 visits and adjustments to treatment are made based on clinical standards and judgment.
1571927|NCT02442102|Behavioral|Exercise and sensory stimulation|60-minute sessions with sensory electrical stimulation (SES) applied 5 days per week with oromotor exercises completed when patient is able to participate
1571928|NCT02442089|Behavioral|Health Call|Health Call is an automated interactive voice reminder system that can contact guardians of patients ahead of their child's appointment, asks then confirms a security question about the patient, then, if the call recipient passes the security screen, provides a reminder about upcoming appointment.
1571929|NCT02442063|Drug|Radium Ra 223 dichloride (Xofigo, BAY88-8223)|50 kBq/kg intravenous injection once every 4 weeks, will be administrated from cycle 2 up to 6 cycles
1571930|NCT02442063|Drug|paclitaxel|90 mg/m2 intravenous injection per week in a 3-week-on / 1-week-off regimen, will be administered as per local standard of care, starting in cycle 1
1571931|NCT02442050|Other|del Nido solution|1.0-liter of del Nido Cardioplegia after the aortic cross-clamp is applied to the ascending aorta. Delivery of del Nido solution will be administered in a 1:4 ratio of blood:crystalloid at a temperature of 6-10 degrees centigrade.
1571932|NCT02442050|Other|Blood-based cardioplegia|An induction dose of whole blood cardioplegia ranging from 1.0-2.0 liters of solution will be given, with subsequent doses of cardioplegia every 20 minutes.
1571933|NCT02442037|Biological|UCMSC group|Human umbilical cord MSCs are transplanted three times by intravenous infusion(1×10^6/kg) ,once every week，a total of three times.
1571934|NCT02442037|Other|Control group(Normal saline)|Normal saline in same volume as MSCs are transplanted to patients.
1571935|NCT02442024|Behavioral|Modified Diet|Two months of a diet in which the ingestion of protein and lipid precedes that of carbohydrates.
1571936|NCT02442024|Behavioral|Standard Diet|Two months of a diet in which the ingestion of protein and lipid follows that of carbohydrates.
1571937|NCT02441998|Other|Education intervention: Training in Narrow Band Imaging|Two hour training session in interpretation and application of narrow band imaging technology
1571938|NCT02441985|Device|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
1571939|NCT02441985|Device|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
1571940|NCT02441985|Other|Fahn-Tolosa-Marin Tremor Rating Scale (TRS)|All participants will receive a clinical assessment of tremor severity by using the TRS test.
1571941|NCT02441985|Other|"Timed Up & Go Test (TUG) test"|All participants will receive a clinical assessment of basic mobility skills by using the TUG test.
1571942|NCT02441985|Other|10m walk test|All participants will receive a clinical assessment of walking speed by using the walk test.
1571943|NCT02441985|Other|Tremor electrophysiology|All participant tremors will by analyzed using an EMG system
1571944|NCT02441985|Other|Cerebellar-brain Inhibition (CBI)|All participants will have a measure of the cerebellar-brain inhibition(CBI) which will be conducted by using a TMS device determining the ability of the coil to activate the cerebellum.
1571945|NCT02441972|Drug|18F-Al-NOTA-PRGD2 PET/CT|18F-Al-NOTA-PRGD2(PET imaging agent) given by vein before PET scans.Perform PET/CT for each enrolled volunteer or patient at 60-90min.
1571946|NCT02441959|Procedure|Lumbar discectomy Open|Open Discectomy
1571947|NCT02441959|Procedure|Lumbar discectomy Endoscopic|Endoscopic Discectomy
1571951|NCT02441933|Drug|taxane plus carboplatin|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane plus carboplatin for 4 cycles The taxane plus carboplatin regimen can be selected based on the investigator's discretion from among the following two regimens.
Docetaxel (75 mg/m2) IV plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles
Paclitaxel (80 mg/m2) IV weekly for 12 doses plus carboplatin (AUC 5) IV every 3 weeks for 4 cycles"
1571952|NCT02441933|Drug|Taxane|"Doxorubicin (60 mg/m2) IV + cyclophosphamide (600 mg/m2) IV every 3 weeks for 4 cycles followed by taxane for 4 cycles The taxane regimen can be selected at the investigator's discretion from among the following two regimens.
Docetaxel (75 mg/m2) IV every 3 weeks for 4 cycles
Paclitaxel (80 mg/m2) IV weekly for 12 doses"
1571954|NCT02441894|Drug|CABAZITAXEL XRP6258|Pharmaceutical form:solution Route of administration: intravenous
1571955|NCT02441894|Drug|PEG-G-CSF|Pharmaceutical form:solution Route of administration: subcutaneous
1571956|NCT02441894|Drug|Prednisolone|Pharmaceutical form:tablet Route of administration: oral
1571957|NCT02441894|Drug|Dexchlorpheniramine or Diphenhydramine|Pharmaceutical form:tablet, powder, or solution Route of administration: oral, intravenous or intramuscular
1571958|NCT02441894|Drug|Ranitidine|Pharmaceutical form:tablet or solution Route of administration: oral, intravenous or intramuscular
1571959|NCT02441894|Drug|Metoclopramide, Granisetron, or Ondansetron|Pharmaceutical form:tablet, powder, jelly, or solution Route of administration: oral, intravenous or intramuscular
1571960|NCT02441894|Drug|Dexamethasone|Pharmaceutical form:tablet, capsule, or solution Route of administration: oral or intravenous
1571964|NCT02441868|Behavioral|Shortness of breath recognition and treatment|Hospice registered nurses will train family caregivers about how to recognize patient shortness of breath. This training will employ a guided learning tool the Respiratory Distress Observation Scale-Family. Training will be done with a DVD and return demonstration of the skills using the patient. In addition, the family will be taught the bundle of evidence-based interventions to treat shortness of breath.
1571965|NCT02441855|Device|echocardiography|echocardiography: Left and right ventricular functions and aortic elastic properties.
1571966|NCT02441842|Drug|atenolol|administered 60 minutes pre procedure
1571967|NCT02441842|Drug|lisinopril|administered 60 minutes pre procedure
1571968|NCT02441842|Other|glucose|administered 60 minutes pre procedure
1571969|NCT02441829|Drug|Eleclazine|Eleclazine tablets administered orally in morning with food
1571970|NCT02441816|Drug|Aflibercept|
1571971|NCT02441816|Other|Extend Treatment|In year 2 of the study a treat and extend protocol will be applied, if a patient has signs of disease activity (eg macular fluid on SDOCT) they will be brought back at 8 weeks after the visit and given an intravitreous injection. They will then be reviewed 8 weeks post treatment for a further treatment with follow-up and treatment interval extended to 10 weeks if the disease is quiescent (if no macular fluid at the subsequent visit the patient could be extended to 12 weeks interval with treatment).
1571972|NCT02441803|Drug|Busulfan|Test dose Busulfan 32 mg/m2 given by vein on Day -8. Busulfan AUC 5,000 by vein on Days -6 to -3.
1571973|NCT02441803|Drug|Fludarabine|Fludarabine 10 mg/m2 by vein on Days -6 to -3.
1571974|NCT02441803|Drug|Clofarabine|"Salvage Chemotherapy Before Transplant: Clofarabine 15 mg/m2 by vein on Days 6 - 9.
Stem Cell Transplant: Clofarabine 40 mg/m2 by vein on Days -6 to -3."
1571975|NCT02441803|Radiation|Total Body Irradiation (TBI)|Total body irradiation (TBI) delivered at 2Gy on Day -2.
1571976|NCT02441803|Drug|Thymoglobulin|Thymoglobulin 2.0 mg/Kg by vein on Days -3 and -2.
1571977|NCT02441803|Biological|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood (PB) progenitor cells infused on Day 0. Goal is to infuse 4 X 106 CD34+ cells/kg if PB or >3.0 X 108 marrow mononuclear cells/kg if bone marrow.
1571978|NCT02441803|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg by vein on Days +3 and +4.
1571979|NCT02441803|Drug|Tacrolimus|Tacrolimus 0.015 mg/kg/day by vein or mouth on Day +5.
1571980|NCT02441803|Drug|Mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg/dose by vein or by mouth three times a day from Day +5 to Day+100.
1571981|NCT02441803|Drug|Decitabine|20 mg/m2 by vein on Days 1 - 5.
1571982|NCT02441803|Drug|Cytarabine|1 g/m2 by vein on Days 6 - 10.
1571983|NCT02441803|Drug|Idarubicin|10 mg/m2 by vein on Days 6 - 8.
1571984|NCT02441790|Behavioral|Early Active Range of Motion|3-9 days
1571985|NCT02441790|Behavioral|Standard Immobilization|21-27 days
1571986|NCT02441777|Device|Polarization-Sensitive OFDI|OCT Imaging of the eye
1571987|NCT02441751|Procedure|intra-operative blood loss|surgery in the urology and orthopedics
1571988|NCT02441738|Procedure|Hybrid Ablation|The procedure will be performed following standard of care guidelines.
1571989|NCT02441738|Procedure|Catheter Ablation|The procedure will be performed following standard of care guidelines.
1571990|NCT02441725|Other|1-minute sit-to-stand test|Validation of the 1-minute sit-to-stand test in a COPD patient population
1571991|NCT02441712|Device|Patterned Electrical Neuromuscular Stimulation administered by the Omnistim® FX² Pro Stimulation device|
1571992|NCT02441699|Behavioral|Improved water supply and sanitation|Village-level reticulated water supply with distribution to household taps; pour-flush pit latrines.
1571993|NCT02441686|Drug|Bortezomib|
1571994|NCT02441686|Drug|Lenalidomide|
1571995|NCT02441686|Drug|Dexamethasone|
1571996|NCT02441673|Drug|Nefopam|Nefopam 0.15mg/kg would be made up to 10mls using sterile water for injection
1571997|NCT02441673|Drug|Tramadol|Tramadol 1mg/kg would be made up to 10mls using sterile water for injection
1571998|NCT02441673|Drug|Metoclopramide|10mg would be given morning of surgery as a prokinetic premedication for all patients.
1571999|NCT02441673|Drug|Ranitidine|50mg would be given to each patient morning of surgery as a premedicant to reduce the acidity of the gastric contents. It is routine for CS.
1572000|NCT02441673|Drug|Pethidine|25mg would be used to stop shivering where a repeat dose of the primary intervention drugs have not been effective.
1572001|NCT02441673|Drug|Ephedrine|A vasopressor. Would be used to combat any hypotension that occurs due to the neuroaxial block. Would be used in aliquots of 3mg.
1572002|NCT02441673|Drug|oxytocin|Would be used for all patients following delivery of the baby to aid contraction of the uterus.
1572003|NCT02441660|Drug|Capsaicin 8% Patch|Applied topically for 1 hour
1572004|NCT02441660|Drug|Low Dose Capsaicin 0.04% gel|
1572006|NCT02441621|Other|passive leg raising|The passive leg raising maneuver (PLR) involves a leg elevation up to 45° with the trunk in a horizontal position and is performed to induce hemodynamic effects by a volume challenge, turning unstressed blood volume to stressed volume proportional to body size.
1572007|NCT02441621|Other|premedication|patients receive premedication with midazolam 7.5 mg p.o.
1572008|NCT02441621|Other|intubation and mechanical ventilation|After induction of anesthesia with sufentanil (0.5 µg/kg) and propofol (1.5 mg/kg), orotracheal intubation is facilitated with rocuronium (0.6 mg/kg). Anesthesia is maintained with sufentanil (1 µg/kg/h) and propofol (3 mg/kg/h) and patients are ventilated with an oxygen/air mixture in volume-controlled mode, using a tidal volume of 8 ml/kg related to the ideal body weight. Positive end-expiratory pressure is set at 5 cmH2O.
1572378|NCT02438709|Drug|COX-2 inhibitor|oral COX-2 inhibitor intake 60mg qd
1572009|NCT02441621|Other|central venous catheter|a central venous catheter in the right or left internal jugular vein.
1572010|NCT02441621|Other|arterial catheter|Continuous monitoring is performed including electrocardiogram, radial arterial pressure catheter
1572011|NCT02441621|Other|transesophageal echocardiography|Before placement of a transpulmonary thermodilution catheter a transesophageal echocardiography (TOE) is performed. TOE is used to detect diastolic dysfunction of the left ventricle and to exclude right ventricular dysfunction.
1572012|NCT02441621|Other|transpulmonary thermodilution catheter|In presence of left ventricular dysfunction a transpulmonary thermodilution catheter is placed in the femoral artery and connected to a PiCCO2 monitor (PiCCO2, Pulsion Medical Systems, Munich, Germany).
1572014|NCT02441595|Behavioral|MBCP|Eight weekly sessions 2,5 h and homework 30 min/day. Practicing various mindfulness meditations coupled with practical skills and theory of birthing and parenting.
1572015|NCT02441595|Behavioral|Psychoprophylaxis|Three sessions 3h each, and practices to do at home. Practical skills of relaxation and breathing techniques for labor as well as knowledge of birthing and parenting.
1572016|NCT02441582|Other|Telemetry|
1572017|NCT02441582|Other|Non-telemetry|
1572018|NCT02441569|Behavioral|Common factors engagement training for provider|Primary care providers have received brief training in communication skills designed to promote family engagement in care including understanding of treatment and empowerment.
1572019|NCT02441569|Behavioral|Standard pediatric advice for childhood anxiety|Providers will be free to use their existing knowledge of anxiety problems to offer routine counseling.
1572020|NCT02441556|Device|endovascular treatment|The endovascular treatment is comprised of thrombolysis, mechanical thrombectomy, stenting, or a combination of all these approaches. Generally, Solitaire FR is preferred, other devices such as Trevo or future advanced devices can also be considered which will be decided by the executive committee.
1572021|NCT02441556|Other|standard medical therapy|If the patient meets the criteria for IV rt-PA within 4.5 h of stroke onset, he/she will receive a single alteplase dose of 0.9 mg/kg IV(maximum dose: 90mg), with 10% given as a bolus, followed by continuous IV infusion of the other dose within 1h. All patients will receive standard medical therapy. The standard medical therapy conforms with the current American Heart Association/American Stroke Association guidelines.
1572022|NCT02441530|Dietary Supplement|Vitamin D|
1572023|NCT02441530|Dietary Supplement|Vitamin E|
1572024|NCT02441530|Drug|Ibuprofen|
1572025|NCT02441517|Drug|Enzalutamide|oral
1572026|NCT02441504|Other|Low intensity Exercise|aerobic exercise training using walking and running
1572027|NCT02441491|Drug|Cyclophosphamide|"Cyclophosphamide will be given by vein once a day for four straight days.
Ten days after starting cyclophosphamide, filgrastim, a drug that helps normal blood cells to grow, by vein once every day to try to help your blood cells grow faster."
1572028|NCT02441478|Radiation|functional magnetic resonance imaging exam|
1572029|NCT02441465|Drug|Vemurafenib|Oral vemurafenib will be administered at a dose of 960 milligrams BID from Day 1 to Day 28.
1572030|NCT02441465|Drug|^14 C-Labeled Vemurafenib|Intravenous (IV) infusion of ^14 C-labeled vemurafenib will be administered at a dose of 20 micrograms (mcg) on Day 21.
1572031|NCT02441452|Other|Early rehabilitation|The physical exercises and breathing exercises are started as soon as after the Nuss procedure
1572032|NCT02441439|Dietary Supplement|Iron sucrose 200 mg|I.V Iron sucrose 200 mg 2-3 times per week. Each time for 20-30 minutes
1572033|NCT02441439|Dietary Supplement|Iron sucrose 500 mg|I.V Iron sucrose 500 mg once per week. Each time for 3.5 hours
1572034|NCT02441413|Radiation|High Resolution Computed Tomography scans|"A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.
An Upper Airway (UA) scan will be taken on visit 1."
1572035|NCT02441400|Device|EndoStim LES Stimulation System|
1572036|NCT02441387|Drug|Antidepressant|Sertraline 50-250mg/day for 1 year or Escitalopram 10-20mg/day for 1 year or Mirtazapine 15-45mg/day for 1 year or Venlafaxine 37,5-300mg/day for 1 year or Lithium 300-900mg/day for 1 year.
1572037|NCT02441387|Other|Psychoeducation|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score <or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment). The psychoeducation program consists of 10 individual sessions, conducted by a trained psychologist who will explain the main concepts of depression and its symptoms, the importance of adhering to treatment, the main side effects of pharmacological treatment, and how to cope with daily difficulties.
1572038|NCT02441387|Other|Treatment as usual (only pharmacological treatment).|Patients who are in the antidepressant treatment group and does not reach remission (MADRS score <or =8) until visit 4 will be invited to be part of a psychoeducation program. If the patient accepts the psychoeducation intervention, he will be randomized to psychoeducation (pharmacological treatment plus psychoeducation) or treatment as usual (only pharmacological treatment).
1572039|NCT02441374|Device|Tubular mesh.|Rehabilitation in upper limb during and after applying of FUT (through the tubular mesh) post stroke.
1572040|NCT02441374|Other|Classical kinesiotherapy.|Applying classical kinesiotherapy in upper limb post stroke.
1572041|NCT02441361|Other|Exercise training|Exercise training will comprise aerobic and strength exercises
1572042|NCT02441348|Behavioral|Conversation Training Therapy|Conversational speech as the primary focus of voice therapy in individuals with muscle tension dysphonia or vocal fold lesions.
1572043|NCT02441322|Device|Novo-TTF|Procedures: MRI and advanced MRI sequence Advanced brain MRI's with special sequences will be obtained. First MRI prior to starting Novo-TTF therapy, second MRI up to 2-3 weeks after beginning therapy, third MRI up to 2 months from starting treatment and the last MRI up to 4 months after starting treatment.
1572046|NCT02441296|Other|Formula with lactose|
1572047|NCT02441296|Other|Formula with maltodextrins|
1572048|NCT02441283|Drug|ABT-493|Drug is not administered in this study. This study is a follow up for subjects previously receiving the drug.
1572049|NCT02441283|Drug|ABT-530|Drug is not administered in this study. This study is a follow up for subjects previously receiving the drug.
1572050|NCT02441270|Drug|Cyclophosphamide|
1572051|NCT02441270|Radiation|Stereotactic body radiotherapy|
1572052|NCT02441257|Procedure|control ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
1572053|NCT02441257|Procedure|spontaneous ventilation|patients are randomly divided to receive control or spontaneous ventilation randomly.
1572054|NCT02441244|Drug|Visbiome|Visbiome probiotic
1572055|NCT02441244|Other|Placebo|Placebo
1572056|NCT02441231|Drug|Visbiome|Visbiome probiotic
1572057|NCT02441231|Other|Placebo|Placebo
1572058|NCT02441218|Drug|Ivabradine|2.5mg, 5mg or 7.5mg tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
1572059|NCT02441218|Drug|Placebo|Matching placebo tablets to be taken orally twice daily, at 12-hours intervals, in the morning and in the evening during meals up to 42 months.
1572060|NCT02441205|Behavioral|High Intensity Interval training|all subjects will undergo high intensity interval training 3 x per week for 10-12 weeks. the intervals of high-intensity (~85% of maximal capacity) will be 5 to 10 bouts of 30 seconds at this intensity with rest periods in between intervals that range from 30 seconds to 2 minutes
1572061|NCT02441192|Other|Training resistance|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
1572062|NCT02441192|Other|Training aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
1572063|NCT02441192|Other|Training resistance+aerobic|After the baseline tests they were distributed in four randomized groups for the 6 weeks of training: aerobic (AT), resistance (RT), aerobic+resistance (AT+RT) and control (C).
1572064|NCT02441179|Other|Acute Intermittent Hypoxia|Patients will breath 9% oxigen for 1.5 minutes interspersed with 1.5 minutes of 21% oxigen (normoxia), 15 times for a total of 45 minutes.
1572065|NCT02441179|Other|Body weight-assisted treadmill training|Patient´s gait will be trained through a weight-assisted treadmill (BWSTT). All recruited patients will start BWSTT at a speed of 0.6 km/hr. The physical therapist will manually correct posture to assure an adequate gait, increasing the speed of treadmill progressively depending upon the patient progress and tolerance. This training will be done immediately after the protocol of AIH or Sham and it will last 45 minutes.
1572066|NCT02441179|Other|Sham Protocol|It consists of continuous normoxia (FiO2=0.21) for 45 minutes for 5 consecutive days and then 3 times per week for 3 weeks. Total time: 4 weeks.
1572068|NCT02441153|Other|Extended Timing|Surgery will be performed at 10-11 weeks after completion of chemoradiotherapy.
1572069|NCT02441140|Procedure|Culdocentesis|A sterile speculum will be placed in the vagina and the cervix identified. The cervix will be elevated using a tenaculum and a spinal needle inserted through the posterior vaginal fornix. Fluid from the posterior cul de sac will be collected
1572070|NCT02441140|Procedure|Vaginal Swab|. A sterile speculum will be placed in the vagina and a Pap smear spatula will be used to swab the posterior fornix of the vagina. This swab will then be rinsed in a tube of saline.
1572071|NCT02441140|Procedure|Chromopertubation|Chromopertubation is a common gynecologic technique used to test the patency of fallopian tubes during infertility evaluations. Fluid is flushed through the cervix and uterus and out the fallopian tubes.
1572072|NCT02441140|Procedure|Blood collection|Intravenous blood collection will be drawn from an IV
1572073|NCT02441140|Procedure|Tissue collection|As part of the standard surgical procedure for presumed ovarian cancer, the primary tumor will be resected and a sample obtained for evaluation
1572074|NCT02441127|Device|diode laser group|the laser tip was used to remove all visible epithelium in the outer side of the defined graft area. The treatment was performed from the coronal to the apical aspect in parallel paths, and care was taken to avoid any laser contact to the palatal bone and periosteum by aiming the laser beam at a 450 angle to the palatal soft-tissue. The resultant layer on the surface was totally removed with knife and moist gauze. Then, the graft was harvested from the de-epithelized area with a 15c blade.
1572075|NCT02441127|Procedure|scalpel control group|In the control group tissue was obtained by two horizontal and two vertical incisions defining the area to be harvested. The blade was oriented perpendicular to the bone along the coronal horizontal incision and once an adequate soft tissue thickness was obtained; it was rotated in order to be parallel to the superficial surface. The thickness of the graft was maintained uniform while proceeding apically with the blade until the FGG was harvested. The palatal wound was protected with equine-derived collagen maintained by compressive sling 5-0 sutures
1572076|NCT02441114|Drug|HCP0910 and HGP1011|Inhalation of HCP0910 (Seretide 250 diskus (Fluticasone Propionate 250 mcg/Salmeterol Xinafoate 72.5 mcg)) and HGP1011 (Spiriva capsule for inhalation (Micronized Tiotropium Bromide Monohydrate 22.5 mcg))
1572077|NCT02441101|Device|RV DDD(R)-60 with AV optimization|Device to be programmed for RV pacing with AV interval optimization at the bedside to produce QRS fusion with the native conduction down the native left bundle on surface EKG
1572078|NCT02441101|Device|RV DDD(R)-60|AV settings programmed to minimize RV pacing - standard demand pacing programming.
1572079|NCT02441088|Drug|90Y-DOTA-tyr3-Octreotide|90Y-DOTATOC is a radiopharmaceutical that will be used in this a dosimetry-guided theranostics trial for both children and adults with neuroendocrine and other somatostatin receptor positive tumors. Each subject will receive three doses of 90Y-DOTATOC.
1572080|NCT02441088|Radiation|Dosimetry-Guided Peptide Receptor Radiotherapy|90Y-DOTATOC delivers radiation to rumor cells that express somatostatin receptors.The dose of 90Y-DOTATOC administered in this dosimetry-guided theranostics trial will be determined by dosimetry that estimates the amount of radiation delivered to the kidneys during treatments one and two.
1572334|NCT02439086|Device|PET-CT Scan|patients will have 2 PET CT scans: one before radiotherapy, and one 9 weeks after.
1572081|NCT02441088|Drug|Aminosyn II|Aminosyn II is a solution of amino acids that will decrease the amount of 90Y-DOTATOC that recirculates through the body after injection, therefore decreasing radiation dose to the kidneys.
1572082|NCT02441075|Other|70% Ethanol|the study will use 70% ethanol lock in the CVLs. A 2ml 70% ethanol lock will be instilled into the white lumen of the CVL for 2 hours. At the end of 2 hours, the ethanol will be withdrawn; the CVL lumen flushed with normal saline, and the CVL would be available for normal use for that day.
1572083|NCT02441062|Drug|68Ga-DOTATOC PET/CT|Ga-68 DOTATOC PET-CT on management of patients with somatostatin receptor positive tumors
1572084|NCT02441049|Behavioral|Home-based promotora family intervention|A promotora-delivered family intervention in the participant's home. Promotoras used a telenovela-style DVD and accompanying manual to deliver 11 home sessions to the family, and 4 support telephone calls, over a 4 month period.
1572085|NCT02441036|Device|Ultherapy Treatment|Focused ultrasound energy delivered below the surface of the skin.
1572086|NCT02441023|Behavioral|Nutritional therapy and education|"Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association standards for medical care in diabetes.
Education with multimedia application: Patients were exposed to the multimedia application previous to the nutritional counseling. Multimedia application comprises the following modules: 1) Introduction, 2) Nutrition, 3) Physical Exercise, 4) Diabetes myths 5) Metabolic control indicators 6) Knowing diabetes, 7) Diabetes complications including testimonials."
1572087|NCT02441023|Behavioral|Nutritional therapy|Nutritional therapy guidance according to sex, age, weight and comorbidity present. The recommendations of calories and macronutrients intake were indicated according to the Official Mexican Standards for Diabetes treatment and the American Diabetes Association Standards for medical care in diabetes.
1572088|NCT02441010|Device|meridian therapy instrument|The meridian therapy instrument are widely used to improve the physical and relieve fatigue and pain in many hospitals by the field-effect.
1572089|NCT02441010|Other|health information push technology|The health information push technology regularly send health information on the measurements of body weight control and the improvement of a healthy lifestyle.
1572090|NCT02441010|Device|monitoring device|The monitoring device is used to monitor a person's blood pressure, blood glucose, oxygen saturation, body weight, and energy consumption by Bluetooth Wireless technology.
1572091|NCT02440997|Other|aromatherapy|
1572092|NCT02440997|Other|foot bath|
1572093|NCT02440984|Procedure|Colonic biopsies during endoscopy|eligible patients will have physical examination, colonic biopsies during endoscopy and anal manometry with barostat. these investigations are part of the usual healthcare. Colonic biopsies will be used to study intestinal permeability, colonic inflammation and enteric nervous system.
1572094|NCT02440971|Device|S9-Autoset CS-A|The S9-Autoset CS-A is an adaptive servo-ventilation (ASV) machine. It adjusts the level of inspiratory support automatically in response to the patient's respiratory effort. Inspiratory support is increased in the presence of hypoventilation and decreased in the presence of hyperventilation.
1572095|NCT02440958|Drug|modified FOLFIRINOX regimen|Modified FOLFIRINOX regimen consisted of oxaliplatin at a dose of 60 mg per square meter, given as a 2-hour intravenous infusion, after 60 minutes, of irinotecan at a dose of 120 mg per square meter, given as a 90-minute intravenous infusion, immediately followed by leucovorin at a dose of 400 mg per square meter, given as a 2-hour intravenous infusion through a Y-connector. This treatment was immediately followed by fluorouracil at a dose of 400 mg per square meter, administered by intravenous bolus, followed by a continuous intravenous infusion of 2400 mg per square meter over a 46-hour period every 2 weeks
1572096|NCT02440945|Device|Collection of blood|Blood test on blotting paper DBS (for the patients recruting)
1572097|NCT02440932|Dietary Supplement|Phenylketonuria-type diet|Breakfast, lunch and open buffet dinner
1572098|NCT02440932|Other|Normal (control) diet|Breakfast, lunch and open buffet dinner
1572099|NCT02440919|Other|Hyperoxygenation 100% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 100% oxygen.
1572100|NCT02440919|Other|Hyperoxygenation 20% FiO2|Endotracheal suction associated with Hyperoxygenation involved supplying 20% oxygen above FiO2 basal.
1572101|NCT02440919|Other|Hyperinflation (PEEP- ZEEP) Basal FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and involved no hyperoxygenation, keeping the oxygen already offered to the patient.
1572102|NCT02440919|Other|Hyperinflation (PEEP- ZEEP) 20% FiO2|Endotracheal suction associated ventilator hyperinflation (PEEP-ZEEP maneuver) and hyperoxygenation involved supplying 20% oxygen.
1572103|NCT02440906|Behavioral|Patient-Directed Wellness Account|The intervention group (n=629) continue to receive usual care and receive a financial incentive to use in meeting their health goals.
1572104|NCT02440906|Behavioral|Health Navigator|The intervention group (n=629) will work with a health navigator on a monthly basis to develop and refine patient-centered health goals. Motivational interviewing techniques are used to establish the wellness goals.
1572106|NCT02440880|Drug|Dexamethasone in addition to TAP block in dose of 4 mg|Dexamethasone in addition to TAP block in dose of 4 mg
1572107|NCT02440880|Drug|Dexamethasone in combination with TAP block in dose of 8 mg|Dexamethasone in combination with TAP block in dose of 8 mg
1572108|NCT02440880|Drug|Dexamethasone intravenous 4mg+ TAP block|Dexamethasone intravenous in addition to TAP block in dose of 4 mg
1572109|NCT02440880|Drug|Dexamethasone intravenous in addition to TAP block in dose of 8 mg|Dexamethasone intravenous + TAP block in dose of 8 mg
1572110|NCT02440880|Other|control|TAP block without Dexamethasone neither intravenous nor in combination with the block
1572111|NCT02440867|Device|Active TBS|Non-invasive transcranial magnetic stimulation inducing changes in cortical excitability depending on the cortical target (except for sham stimulation)
1572112|NCT02440867|Device|Sham TBS|Sham stimulation
1572113|NCT02440841|Drug|fedovapagon|
1572114|NCT02440841|Drug|Itraconazole|
1572115|NCT02440841|Drug|rifampicin|
1572116|NCT02440828|Drug|tobramycin inhalation|tobramycin inhalation 300 mg twice daily
1572117|NCT02440828|Drug|placebo|NaCl 0.9% inhalation 4 ml twice daily
1572118|NCT02440815|Behavioral|Problem Solving Therapy|Problem Solving Therapy (PST) is a brief evidence based psychotherapy that is commonly utilized for treatment of LLD. The problem solving therapy includes 12 weekly in person 50 minute sessions.
1572119|NCT02440802|Genetic|Saliva sample collection for genetic analyses|Patients with Prostate cancer receiving androgen deprivation treatment with a GnRH antagonist will be followed-up for 6 months for quality of life. At Baseline, 3 months and 6 months of treatment QoL data will be collected, as well as body parameters. At Baseline, once, a saliva sample will be collected for genetic analyses.
1572120|NCT02440789|Drug|Sirolimus|
1572121|NCT02440750|Procedure|operative hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
1572122|NCT02440750|Drug|Dienogest|21 days administration of dienogest 2 mg/die
1572123|NCT02440750|Drug|Ulipristal acetate|21 days administration of ulipristal acetate 5 mg/die
1572124|NCT02440737|Other|Educational Intervention|"Receive publication, When Someone You Love is Being Treated for Cancer, a preliminary individualized Survivorship Care Plan (SCP), a final individualized SCP, and the REACH for Survivorship handbook."
1572125|NCT02440737|Other|Follow-Up Care|Complete Survivorship Care Planning session at end of treatment
1572126|NCT02440737|Procedure|Psychosocial Assessment and Care|Undergo the NEST intervention
1572127|NCT02440737|Other|Questionnaire Administration|Ancillary studies
1572128|NCT02440724|Device|Winged stent (partially covered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
1572129|NCT02440724|Device|Winged stent (uncovered)|A winged stent is a newly designed self-expandable metal stents(SEMS). Partially covered, or uncovered winged stent will be placed via the endoscopic intervention for malignant gastric outlet obstruction.
1572130|NCT02440711|Device|Energy storing foot (ESF)|A commercially-available energy storing prosthetic foot
1572131|NCT02440711|Device|Modified running specific foot (mRSF)|A running specific prosthetic foot customized for both running and walking activities
1572132|NCT02440698|Behavioral|Genetic test for personalized nutrition|
1572135|NCT02440672|Device|JOURNEY™ II CR Total Knee System (J II CR TKS)|TKA with Journey II CR Total Knee System
1572136|NCT02440646|Radiation|Coronary computed tomography angiography|The coronary arteries will be visualized with the 128-slice CT scan Aquilion CX (Toshiba, Tokyo, Japan).
1572137|NCT02440646|Radiation|Quantitative coronary angiography|Coronaries will be shot with AXIOM Artis dFC (Siemens, Munich, Germany).
1572138|NCT02440633|Drug|14C-OPS-2071|Subjects will swallow Single 25 mL of suspension containing 50 mg of 14C-OPS-2071 directly.
1572139|NCT02440607|Other|Electronic Cognitive Aid|
1572140|NCT02440607|Other|Static Cognitive Aid|
1572142|NCT02440581|Drug|Alendronate|
1572143|NCT02440581|Drug|Teriparatide|
1572144|NCT02440581|Drug|Cinacalcet|
1572145|NCT02440568|Drug|Omacetaxine|Omacetaxine (at assigned dose level) administered subcutaneously Q12 hours Days 1 to 7. Dose levels include: 0.625, 1.25, 2.0, 3.0, and 4.2 mg/m^2
1572146|NCT02440568|Drug|Cytarabine|Cytarabine (100mg/m2/day) in 1000ml NS as a continuous IV infusion over 24 hours x 7 days.
1572147|NCT02440568|Drug|Idarubicin|Idarubicin (12 mg/m2/day) IVPB in 100 mL NS over 15 minutes daily from Days 1 to 3.
1572148|NCT02440555|Other|fulfill the self-administered questionnaire|Patients viewed in a pharmacy or a hospital fulfill the self-administered questionnaire before having a capillary blood glucose measurement.
1572149|NCT02440542|Other|Survey of outcomes following popliteal nerve block|Patients will be instructed to complete journals of pain and narcotic use until postoperative day 10. On first follow-up visit, patients will complete a patient satisfaction survey. VAS Pain scores and pain medication use will be collected up to 12 weeks postoperatively.
1572150|NCT02440529|Behavioral|Verbal+Visual Aid|Detailed Discussion of how cigarette smoke impacts Orthopaedic Management plus Powerpoint Presentation.
1572151|NCT02440529|Behavioral|Verbal Group|Detailed Discussion of how cigarette smoke impacts Orthopaedic Management
1572152|NCT02440516|Other|Early treatment group|Physical- and occupational Therapy
1572153|NCT02440516|Other|Late treatment group|Waiting list - then Physical- and occupational Therapy
1572154|NCT02440490|Behavioral|Computerised cognitive training|
1572155|NCT02440490|Behavioral|Video watching|
1572156|NCT02440477|Other|clinical shoulder tests|Three clinical shoulder tests (Neer impingement sign,Hawkins-kennedy, empty can) performed in three different sitting positions: normal resting posture, slouched posture, and upright posture with scapular retraction and shoulder. and in addition shoulder muscle strength test with handheld dynamometer
1572157|NCT02440464|Procedure|Allogeneic HSCT|Eligible patients with a Human Leukocyte Antigen (HLA)-matched related or unrelated donor will undergo allogeneic hematopoietic stem cell transplant at Day 0. For GVHD prophylaxis, patients will be given Tacrolimus from Day -3 until at least 6 months following initiation, at an intravenous daily dose of 0.015 mg/kg. This will be combined with an intravenous administration of Methotrexate at 5 mg/m2 on Days +1, +3, +6, and +11.
1572158|NCT02440464|Drug|Fludarabine|Patients will receive conditioning treatment before and after HSCT. Fludarabine will be given at 30 mg/m2 intravenously on Day -6 through Day -3.
1572159|NCT02440464|Drug|Melphalan|Melphalan will be given at 70 mg/m2 intravenously on Days -4 and -3.
1572160|NCT02440464|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2 intravenously on Day -3.
1572374|NCT02438748|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
1572161|NCT02440464|Drug|Ixazomib|Between 60 and 120 days following HSCT, patients randomized to the experimental arm will receive Ixazomib maintenance. Maintenance will begin at 3-mg oral doses on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule, following successful completion of 3 cycles at the previous dosage, for a total of 12 cycles.
1572162|NCT02440464|Drug|Placebo|Between 60 and 120 days following HSCT, patients randomized to the control group will be given 3 mg of placebo orally on Days 1, 8, and 15 of a 28-day cycle. This will increase to 4-mg doses on the same cycle schedule following successful completion of 3 cycles of placebo maintenance at the 3-mg dose. This will continue for a total of 12 cycles.
1572163|NCT02440451|Device|Neurofeedback (BCI using neuroimaging)|This group will undergo five sessions of neurofeedback intervention in the fMRI scanner. Each subject will also undergo neuropsychological evaluations before the first neurofeedback session (week 0) and after the last neurofeedback session (week 7). The first four sessions are weekly while the last one is one month later. The intervention will take a total of four months. Follow up will be performed in the the first week and 6 months after the last intervention session.
1572164|NCT02440438|Biological|Blood sampling|Blood samples of 10 mL will be performed every 2 days from the first symptoms of CDI and until clinical recovery and/or hospital discharge
1572167|NCT02440412|Other|Massage Therapy|It's a Physical Therapy manual procedure, based in Swedish technique, and applied in a standirzed way for all participants (stroke, kneading, pressure).
1572168|NCT02440412|Other|Rest in supine|It's only rest, in a clinic stretcher, with warm ambient temperature, and listening relaxing music with headphones.
1572169|NCT02440399|Drug|Tramadol hydrochloride|Please see arm description
1572170|NCT02440399|Drug|Morphine|Please see arm description
1572171|NCT02440399|Drug|Paracetamol|
1572172|NCT02440399|Drug|Diclofenac|
1572173|NCT02440399|Drug|TAB. Percocet (Oxycodone 5MG/Paracetamol 325 MG)|
1572174|NCT02440386|Behavioral|Conditional economic incentive|"Individuals in the intervention arm will receive the standard of care. In addition, individuals in the intervention arm receive a voucher worth R300. They are told that they will get this money if they:
Initiate ART at any clinic within 3 months from the time of their CD4 count test at the Tutu Tester; and
send a text message to the study team to let us know they have started ART;
Schedule a meeting with a member of the study team to show their clinic card and ARVs to confirm ART initiation."
1572175|NCT02440360|Behavioral|PSH|Please see arm description.
1572176|NCT02440360|Behavioral|Usual Care|Please see arm description.
1572177|NCT02440347|Device|Computer controlled anesthetic delivery by Anaeject|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by computer controlled local anesthetic delivery system (Anaeject).
1572178|NCT02440347|Device|Conventional anesthetic delivery by carpule syringe|Single dose of 0.6ml 4% articaine with epinephrine (1:100.000) delivered by conventional syringe (carpule syringe).
1572179|NCT02440334|Drug|Optison|Optison is an ultrasound contrast agent. The agent is a blood pooling agent administered via catheter and provides improved ultrasound visualization of the vasculature.
1572180|NCT02440321|Behavioral|Parent-child interactive program|
1572181|NCT02440321|Other|written materials|
1572182|NCT02440308|Drug|68Ga-DOTA-Bombesin|"68Ga-DOTA-Bombesin is a gallium-68-labeled gastrin-releasing peptide receptor (GRPr) antagonist. DOTA is [4,7,10-Tris-(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]-acetyl.
68Ga-DOTA-Bombesin is administered intravenously (IV)"
1572183|NCT02440308|Procedure|Magnetic Resonance Imaging (MRI) scan|
1572184|NCT02440308|Procedure|Positron Emission Tomography (PET) scan|
1572185|NCT02440295|Procedure|Lower Extremity Amputation|
1572186|NCT02440295|Device|SPY Elite Imaging System|The SPY Elite Imaging System is an adjunctive tool that can be used to assess tissue perfusion in real-time and provides surgeons with information that may change their operative plan before leaving the operating room. (http://novadaq.com/products/spy-elite) The system is comprised of two components, the first is the Spy Elite Kit, which is a single-use package containing one 25 mg vial of indocyanine green, one 10 ml vial of sterile Water for injection, and one SPY Elite sterile drape. The second component to the system is the SPY Elite Device which contains a near-infrared light source that illuminates the fluorescent agent within the tissues, an HD video camera captures the intensity of fluorescent marker in real-time, and software that allows the user to capture relative and absolute perfusion values within the surgical field.
1572187|NCT02440295|Drug|Indocyaine Green|Indocyaine Green (ICG) is a non-nephrotoxic fluorescent imaging agent with a half-life of 2.5-3 minutes that is administered intravenously.
1572188|NCT02440256|Other|Expanded HIV care in Opioid Substitution Treatment|The EHOST intervention entails in-person presentations and consultation sessions with individual OST sites that will: (i) provide rationale for the study (ii) outline action items of the intervention; and (iii) describe guidelines around HIV testing and care. The EHOST intervention will be delivered at three distinct times: (i) at point of OST entry; (ii) following 7 days non-adherence; and (iii) at bi-annual intervals. The interventions are comprised of HIV test offers for individuals of unknown HIV status; offers of HIV-related care, including cluster of differentiation 4 (CD4), plasma viral load (pVL) and resistance tests, along with HAART initiation for those known to be HIV-positive, not on HAART; and regular monitoring for those known to be HIV positive, on HAART.
1572191|NCT02440230|Drug|OFS + Anastrozole|"Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
Patients will take anastrozole 1mg qd."
1572192|NCT02440230|Drug|OFS + Exemestane|Patients will take exemestane 25mg qd. Ovarian function suppression can be achieved by choice of goserelin at a dose of 3.6 mg administered by means of subcutaneous injection every 28 days,bilateral oophorectomy,or bilateral ovarian irradiation.
1572196|NCT02440191|Radiation|3DCRT|conventional radiotherapy
1572197|NCT02440178|Drug|Micafungin|
1572198|NCT02440165|Behavioral|Nursing nutrition intervention|"The early nursing nutrition intervention will include malnutrition screening (during outpatient clinic visit) with the MUST. If patients are ´at risk for malnutrition´ or ´malnourished´, a standardized nutrition care plan will be discussed with the patient by the nurse. This nutrition care plan will include:
Information and advice;
Examples of energy and protein rich meals;
patients will be asked to register their nutritional intake for two days at home;
after a week, the nurse will call the patients to answer questions and to give advice.
This nutrition care plan will be tailored to the individual patient requirements.
Furthermore, if patients are 'malnourished', a visit to the dietician is always suggested, because this is usual care."
1572199|NCT02440152|Device|Suzhou Sceneray® DBS System|We plan to use the SceneRay 1242 (SceneRay, SuZhou, China) electrode with a diameter of 1.27 mm and 4 contacts. The SceneRay 1242 electrode combined with the SceneRay 1181 implantable pulse generator has the advantage of adaptive coverage area for the Ventral Capsule/Ventral Striatum, enabling simultaneous implantation in the nucleus accumbens (NAc; 2 ventral contacts) and the anterior limb of the internal capsule (ALIC; 2 dorsal contacts) with independently programmed parameters such as frequency, amplitude, and voltage; and remote and wireless programing, which allows for convenient and prompt adjustments in emergency situations. The contact length is 3.0 mm and the spacings between the ventral and dorsal contacts are 2 mm, 4 mm, and 4 mm, respectively, spanning a total length of 22.5 mm (3 + 2 + 3 + 4 + 3 + 4 + 3 mm, with 0.5 mm projecting from the electrode tip).
1572200|NCT02440139|Device|ClearRead CT Insight|During the second reading session (concurrent read), the radiologist will be presented with a standard appearing CT with CADe marks placed and the vessel suppressed same slice with the vessel suppressed view as the intervention. The second image, vessel suppressed, will be grayed out until the radiologist move the mouse to the second panel. The radiologist will mark locations. These may or may not correspond to the locations of the CAD markers. As before, the radiologist will assign a level of suspicious to each mark and indicate the need, if any, of an additional diagnostic action (CT Follow-up, Contrast CT, PET-CT, or Biopsy).
1572201|NCT02440113|Device|Nellix|Nellix Implantation
1572202|NCT02440100|Drug|PF-06648671|experimental Pfizer compound which will be dosed as oral suspension, once a day for 14 days
1572203|NCT02440100|Drug|Midazolam|commercial available oral solution of 2 mg midazolam as CYP3A probe substrate for drug interaction evaluation. Midazolam will be given as single dose with and without co-administration of PF-06648671
1572204|NCT02440100|Drug|Placebo|Matching placebo which will be given as oral suspension, once a day for 14 days
1572205|NCT02440087|Dietary Supplement|Refill Bypass|Dietary supplement
1572206|NCT02440074|Other|Autologous bone marrow mesenchymal stem cells|Bone marrow collection from patient, mesenchymal cells isolation and expansion under Good Manufacturing Practice (GMP) conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by intradiscal injection.
1572207|NCT02440061|Drug|Synthetic human AG|Synthetic human AG (0.28 μg/kg) bolus over 1 minute followed by 2 μg/kg/hr continuous infusion for 4.5 hours.
1572208|NCT02440061|Drug|Arginine|Arginine hydrochloride (5 g) intravenously over 45 seconds.
1572209|NCT02440061|Drug|0.9% saline solution|A continuous infusion of 0.9% saline solution (control) for 4.5 hours.
1572210|NCT02440048|Device|Bond Apatite synthetic bone substitute|Synthetic bone grafts had been successful for ridge preservation. Calcium sulfate is the oldest material, being in use in dentistry for more than 30 years ago, and in orthopedics for more than 100 years ago. Calcium sulfate is completely absorbed and constitutes a matrix on wich bone is able to grow (osteoconductive). It does not induce inflammation and does not alter calcium levels in the blood flow.Previous studies has shown that calcium sulfate is completely replaced by bone. On the other hand, fast absorption of calcium sulfates can alter the dimensional stability of the graft. Adding Hydroxy Apatite may improve stability during bone remodeling.
1572211|NCT02440048|Device|BioOss bovine bone substitute|To assess efficiency of ridge preservation (in vertical and horizontal dimensions) after tooth extraction using Calcium Sulfate with HA (®Bond-apatite) compared to the use of bovine bone substitute (BioOss®) and to extraction only as negative control.
1572212|NCT02440035|Biological|Ad35.RSV.FA2|Participants will receive Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 and 85 in Group 1. Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 and 169 in Group 2. Intramuscular injection of Ad35.RSV.FA2 (1x10^11) virus particles on Day 1 in Group 3.
1572213|NCT02440035|Biological|Ad26.RSV.FA2|Participants will receive Intramuscular injection of Ad26.RSV.FA2 (5x10^10 virus particles [vp]) on Day 169 in Group 1. Intramuscular injection of Ad26.RSV.FA2 (5x10^10) virus particles on Day 169 in Group 3. Intramuscular injection of Ad26.RSV.FA2 (5x10^10) virus particles on Day 169 in Group 4.
1572214|NCT02440035|Drug|Placebo|Participants will receive intramuscular injection of placebo (sterile formulation buffer) on Day 85 in Group 2. One intramuscular injections of placebo on Day 85 in Group 3. Two intramuscular injections of placebo on Day 1, and Day 85 in Group 4.
1572215|NCT02440022|Combination Product|Lutonix DCB|
1572216|NCT02440022|Device|Standard Balloon Angioplasty Catheter|
1572217|NCT02440022|Procedure|Percutaneous Transluminal Angiography|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
1572218|NCT02440009|Drug|Itraconazole|Oral itraconazole 200 mg BD for 6 months
1572219|NCT02440009|Drug|Glucocorticoids|Oral prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue by the end of 4 months.
1572220|NCT02439996|Drug|IVIG (1g/kg,once)|The KD children will be randomly assigned to three groups and receive three doses of IVIG (1g/kg once, 1g/kg twice, 2g/kg once). Patient age, gender, white blood cell count, hemoglobin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), red blood cell specific volume (HCT) , serum albumin, the fever days,and the cost of hospital stay will be analyzed among the three groups. All the patients will be detected the 6 genes polymorphisms including ITPKC、CASP3、HLA、BLK、FCGR2A and CD40. The final outcome is the rates of IVIG unresponsiveness and the incidence of coronary artery lesions .
1572221|NCT02439996|Drug|IVIG (1g/kg,twice)|The KD children will be randomly assigned to three groups and receive three doses of IVIG (1g/kg once, 1g/kg twice, 2g/kg once). Patient age, gender, white blood cell count, hemoglobin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), red blood cell specific volume (HCT) , serum albumin, the fever days,and the cost of hospital stay will be analyzed among the three groups. All the patients will be detected the 6 genes polymorphisms including ITPKC、CASP3、HLA、BLK、FCGR2A and CD40. The final outcome is the rates of IVIG unresponsiveness and the incidence of coronary artery lesions .
1572222|NCT02439996|Drug|IVIG (2g/kg.once)|The KD children will be randomly assigned to three groups and receive three doses of IVIG (1g/kg once, 1g/kg twice, 2g/kg once). Patient age, gender, white blood cell count, hemoglobin, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), red blood cell specific volume (HCT) , serum albumin, the fever days,and the cost of hospital stay will be analyzed among the three groups. All the patients will be detected the 6 genes polymorphisms including ITPKC、CASP3、HLA、BLK、FCGR2A and CD40. The final outcome is the rates of IVIG unresponsiveness and the incidence of coronary artery lesions .
1572223|NCT02439983|Dietary Supplement|Proprietary Nutritional Supplement|2 capsules taken by mouth with morning and evening meals.
1572224|NCT02439983|Dietary Supplement|Placebo|2 capsules taken by mouth with morning and evening meals.
1572225|NCT02439970|Drug|Brincidofovir|
1572226|NCT02439970|Drug|Valganciclovir|
1572227|NCT02439957|Drug|Brincidofovir|
1572228|NCT02439957|Drug|Valganciclovir|
1572229|NCT02439944|Drug|Nicotine patch|
1572230|NCT02439944|Drug|Nicotine mouthspray|
1572231|NCT02439931|Behavioral|Remote psychosocial intervention|
1572232|NCT02439905|Drug|Dexmedetomidine|In dexmedetomidine group, dexmedetomidine infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
1572233|NCT02439905|Drug|Placebo control|In normal saline group, normal saline infusion starts at the time after induction of general anesthesia and before one lung ventilation. The infusion has continued until end of the operation.
1572234|NCT02439892|Behavioral|Exercise and nutrition during radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements. The exercise sessions will be conducted twice a week for 30 minutes each time during the RT treatment period, and include a main part of progressive resistance training (PRT). The PRT will be conducted by conventional upper and lower body exercises at a load of 60 - 80 % of 1 repetition maximum (RM) in 3-4 sets of 6-12 repetitions. The patients will receive nutritional information and dietary advice, and up to 2 energy dense oral nutritional supplements (ONS) daily. A nutrition interview will be conducted at study baseline and individual goals and targets will be set during the first counselling and monitored during the intervention period.
1572235|NCT02439892|Behavioral|Multidimensional rehabilitation after radiotherapy|The intervention consists of physical exercise, nutritional counselling and supplements and patient education. The exercise sessions will be conducted 3 times a week for 45 minutes each time during the 3 week rehabilitation programme, and include a main part of progressive resistance training (PRT). PRT will be conducted as described in the intervention during treatment. The nutritional intervention will be carried out as described in the intervention during treatment. Patient education will be run as 45-60 minutes lecture/group discussion on relevant topics, lead by health professionals.
1572236|NCT02439879|Drug|Alpha lipoic acid|Alpha lipoic acid 1800 mg PO divided in 3 doses for 4 weeks . If total symptoms score decreased >3 points patients received alpha lipoic acid 600 mg PO each day or no treatment for 16 weeks.
1572237|NCT02439866|Drug|placebo|gelatinous capsules filled with sugar as placebo
1572238|NCT02439866|Drug|Intravenous methylprednisolone|Intravenous methylprednisolone (Solu-Medrol, Pharmacia Pharmaceutical Company, Belgium) 500 mg twice a day for 3 days followed by 2 weeks of oral prednisolone 1mg/kg/day (Prednisolone Fort; Sina Daroo, Iran
1572239|NCT02439866|Drug|normobaric oxygen with face mask|normobaric oxygen100% with face mask in sitting position, at a flow rate of 5 liters per minute for 1 hour twice a day for two weeks
1572240|NCT02439853|Behavioral|Monthly Check-in Session|Subjects in the Check-In group will have an online session with a speech-language pathologist 3-, 4-, and 5-months from the subject's enrollment date.
1572241|NCT02439827|Behavioral|"Fortaleça sua Saúde program"|The program duration was of one academic semester (approximately four months) in 2014. The intervention strategies focus on teachers' training and activities on health in curriculum (including a specific training to Physical Education teachers), active opportunities in the school environment (availability of spaces and materials for PA) and health education (production and exhibition of health material at school, and distributing pamphlets to students and parents).
1572242|NCT02439814|Drug|Pregnenolone|Pregnenolone is a steroid that occurs naturally in the body, and early studies have shown that pregnenolone may block the effects of marijuana intoxication
1572243|NCT02439814|Other|Placebo|Inactive comparator
1572244|NCT02439801|Procedure|PEEP 0|0 cmH2O positive end expiratory pressure
1572245|NCT02439801|Procedure|PEEP 5|5 cmH2O positive end expiratory pressure
1572246|NCT02439801|Procedure|PEEP 8|8 cmH2O positive end expiratory pressure
1572247|NCT02439788|Drug|cyclophosphamide|500 mg/m2/day x 2 days; for patients <12 kg the dose is 16.7 mg/kg/day x 2 days; Cyclophospamide will be given daily starting Day -4 prior to administration of GINAKIT cells.
1572248|NCT02439788|Drug|Fludarabine|30 mg/m2/day x 3 days; for patients <12 kg the dose is 1 mg/kg/day x 3 days; Fludarabine will be given daily starting Day -4 prior to administration of GINAKIT cells
1572249|NCT02439788|Genetic|GINAKIT Cells|"Dose Level 1 = 3 x 10^6
Dose Level 2 = 1 x 10^7
Dose Level 3 = 3 x 10^7
Dose Level 4 = 1 x 10^8
After the end of the 4 week evaluation period, if subjects have not had a severe side effects and if disease has not gotten worse, the subjects may be offered additional doses of the same cell dose in the future."
1572252|NCT02439762|Behavioral|Cognitive Behavioral Therapy (CBT)|The therapeutic intervention group consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained CBT therapist. These sessions are designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
1572253|NCT02439762|Behavioral|Supportive Psycho-education (SPC)|This active control condition consists of 8, one-hour individual therapy sessions delivered over the course of 3-4 weeks with a trained therapist. The sessions will provide detailed information about substance use, suicide risk, and depression to those enrolled.
1572256|NCT02439736|Other|Blood draw within 12 hours of head injury|
1572257|NCT02439723|Drug|Regorafenib|
1572258|NCT02439710|Other|Quality of life measure (survey)|The QoL tool is a questionnaire
1572259|NCT02439697|Other|Darbepoetin alfa|Conversion from Aranesp® to NESP®
1572260|NCT02439671|Behavioral|McGill Transition Support Program|"The McGill Transition Support Program is manual-based, including 15 modules of curriculum, five in each of the following domains of skills:
Social communication (e.g. listening, perspective taking)
Self-determination (e.g. problem-solving, self-advocacy)
Working with others (e.g. knowing your context, teamwork)
Nine out of the 15 modules are selected for each group according to the common needs endorsed by participants on a needs assessment questionnaire. Each group consists of 4 adults and two facilitators who were graduate students in Speech Language Pathology or Educational Psychology.
The intervention follows a Self-Determination Learning Model of Instruction (SDLMI) that considers the individual's strengths and needs in the development of personal goals and plans for one's future. A workbook is used to accompany each module with the aim of having the participants practice and generalize the main content messages."
1572261|NCT02439658|Drug|Dofetilide and/or sotalol|This is an observational study of patients receiving Dofetilide and/or sotalol as part of their routine clinical care. Patients receiving either of these medications will be compared with population controls for genetic analysis.
1572262|NCT02439632|Drug|prulifloxacin|
1572263|NCT02439632|Drug|Levofloxacin|Levofloxacin hydrochloride tablet 250 mg/tablet, oral administration of a tablet daily for a total of 3 days.
1572264|NCT02439632|Drug|Prulifloxacin Placebo|Placebo of prulifloxacin film-coated tablet without active components.
1572265|NCT02439632|Drug|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet without active components.
1572266|NCT02439619|Other|TechCare|The TechCare software is being developed specifically for use on a touch screen mobile phone. The mobile application will alert participants through notifications and ask a number of questions. Based on participant responses the app will provide a CBT based response to individuals or the service users preferred multimedia such as music, images and videos.
1572267|NCT02439606|Device|Glide Rite Rigid Stylet group|Intubation with the GlideScope® video-laryngoscope and styletted the tracheal tube using manufacturer's GlideRite Rigid Stylet (GRS) (GVL - ST1; Verathon Medical Inc., Bothell, WA, USA). Time till successful intubation of the patient is calculated.
1572268|NCT02439606|Device|Parker Flex-It directional stylet group|Intubated with the GlideScope® video-laryngoscope and styletted the tracheal tube using Parker-Flex-It directional Stylet (Parker Medical, Colorado, USA) (Flexi-Stylet). Time till successful intubation of the patient is calculated.
1572269|NCT02439593|Other|Chemoradiotherapy (CTRT)|CTRT arm: Locoregional radiotherapy along with concurrent weekly gemcitabine
1572270|NCT02439593|Other|Thermochemoradiotherapy (CTRTHT)|Locoregional hyperthermia with concurrent chemoradiotherapy with weekly gemcitabine
1572271|NCT02439580|Dietary Supplement|Annona muricata extract|ethanol-soluble fraction of water extract
1572272|NCT02439580|Dietary Supplement|Placebo|maltose
1572273|NCT02439567|Device|Fibroscan: Liver and Spleen elastography|In cirrhotic patients treated with antivirals for HCV infection, repeated liver and spleen stiffness measures with Fibroscan will be performed to predict the presence of clinically significant and severe portal hypertension.
1572274|NCT02439541|Biological|UCMSC group|Human umbilical cord MSCs are transplanted by intracoronary infusion(1×10^7)
1572275|NCT02439528|Genetic|Genetic analysis|"One part of these patients is already included in a cohort: for them the blood sample will be centralized and then analyzed.
The other part of these patients will be recruited during the study: for them intervention will be blood samples for further genetic analysis."
1572276|NCT02439515|Device|Cycling|Voluntary cycling augmented by electrical stimulation and biofeedback
1572277|NCT02439515|Device|Balance|Balance control exercises with visual biofeedback
1572278|NCT02439515|Other|Standard physical therapy|It consists of stretching, muscular conditioning, exercises for trunk control, standing, and walking training, and upper limb rehabilitation.
1572279|NCT02439502|Device|Fuse® system|Fuse® system will be used to perform gastro and endoscopic diagnostic procedures for upper and lower GI tract.
1572280|NCT02439489|Drug|BKM120-CIS|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Cisplatin will be delivered intravenously at the dose of 75 mg/m2 on day 1 every 3 weeks at each dose level of BKM120.
In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
1572373|NCT02438761|Drug|PF-05212384|"PF-05212384 will be delivered by intra-venous route at a fixed dose of 150 mg per week. Each treatment cycle includes four weekly injections
The treatment is administered in cycles of 28 days for a period of 4 cycles. Patients will be treated on a weekly basis continuously during 112 days or until progression."
1572281|NCT02439489|Drug|BKM120-CARBO|"BKM120 will be delivered orally once daily on continuous at the dose of 60 mg (dose level 1), 80 mg (dose level 2) and 100 (dose level 3). Carboplatin will be delivered intravenously at AUC 5 on day 1 every 3 weeks at each dose level of BKM120. Should dose level 3 be completed, carboplatin will be given at AUC 6 and BKM120 at 100 mg.
In the absence of BKM120 DLT, each level will be administered to 3 patients A minimum of 2 cycles per each dose level will be administered in the absence of disease progression or toxicity"
1572282|NCT02439463|Procedure|Below-knee amputation|Patients with traumatic below-knee amputation.
1572283|NCT02439450|Biological|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
1572284|NCT02439450|Drug|Nivolumab|Patients will receive nivolumab per the package insert for the treatment of NSCLC (3 mg/kg as an i.v. infusion over 60 minutes every two weeks) until disease progression or unacceptable toxicity
1572286|NCT02439424|Device|Reactive ATP|"Reactive ATP turned to on"
1572287|NCT02439411|Drug|Trametinib|
1572288|NCT02439398|Other|Allogeneic human cardiac stem cells (CSCs)|Allogeneic human CSCs is a new cell medicine based on cells isolated from human heart biological samples (right atrium appendage of donors) and expanded in vitro.
1572289|NCT02439398|Other|Human Serum Albumin-HSA 5%|Human Serum Albumin (HSA) is a well-known physiologic protein widely used in clinical practice and without known toxicity after parenteral administration.
1572290|NCT02439385|Drug|Avastin/FOLFIRI|Avastin: 5mg/kg iv on day1, every 14 days. Irinotecan: 180 mg /m2 iv on day1, every 14 days. Leucovorin: 200 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil bolus: 400 mg/m2 iv on day1,2 every 14 days. 5-fluorouracil infusion: 1200 mg/m2 iv on day1,2 every 14 days.
1572291|NCT02439385|Dietary Supplement|Curcumin|Dietary supplement of nanostructured lipid curcumin particle 100mg po bid daily
1572292|NCT02439359|Drug|CF-301|Dose escalation
1572293|NCT02439359|Drug|Placebo|
1572294|NCT02439346|Drug|BAY1143269|BAY1143269 will be given orally at a starting dose of 5 mg once daily. Each treatment cycle will last 21 days.
1572295|NCT02439346|Drug|BAY1143269|BAY1143269 will be given orally at the MTD (to be determined from Arm 1) once daily. Each treatment cycle will last 21 days.
1572296|NCT02439346|Drug|BAY1143269 + Docetaxel|BAY1143269 will be given orally at the MTD (to be determined from Arm 1) once daily in combination with IV docetaxel at 75 mg/m2 every 3 weeks. Each treatment cycle will last 21 days.
1572297|NCT02439333|Device|Nasal high flow cannula (Fisher & Paykel Healthcare, Auckland, New Zealand)|Nasal high flow therapy
1572298|NCT02439333|Device|nasal catheter or Venturi mask|Conventional oxygen therapy
1572299|NCT02439320|Drug|Lasmiditan 100 mg|
1572300|NCT02439320|Drug|Lasmiditan 200 mg|
1572301|NCT02439320|Drug|Placebo (matches lasmiditan doses)|
1572302|NCT02439307|Drug|Rifaximin|1200 mg of rifaximin for 2 weeks.
1572303|NCT02439307|Drug|Placebo|Placebo for 2 weeks
1572304|NCT02439294|Other|Without Obstructive Sleep Apnea (syndrome)|
1572305|NCT02439294|Other|Mild or moderate Obstructive Sleep Apnea (syndrome)|
1572306|NCT02439294|Other|Severe Obstructive Sleep Apnea (syndrome)|
1572307|NCT02439294|Device|CPAP|
1572310|NCT02439255|Other|Laboratory Biomarker Analysis|Correlative studies
1572311|NCT02439255|Dietary Supplement|Phytochemical|Given BRB nectar PO
1572312|NCT02439255|Other|Placebo|Given PO
1572313|NCT02439255|Other|Screening Questionnaire Administration|Ancillary studies
1572314|NCT02439242|Drug|fluid challenge of saline|250 ml of saline
1572315|NCT02439216|Drug|Edasalonexent|67 mg/kg/day
1572316|NCT02439216|Drug|Edasalonexent|100 mg/kg/day
1572317|NCT02439216|Drug|Placebo|
1572318|NCT02439203|Drug|JM-010|
1572319|NCT02439203|Drug|Placebo|
1572320|NCT02439190|Drug|BMS-986120|
1572321|NCT02439190|Drug|Aspirin|
1572322|NCT02439190|Drug|Clopidogrel|
1572323|NCT02439177|Device|Blood glucose monitoring system (Omnitest 3)|
1572324|NCT02439177|Device|Blood glucose monitoring system (Omnitest 5)|
1572325|NCT02439164|Drug|Midazolam|specific benzodiazepine agonist midazolam will be used titrate to desired sedation level, its specific antagonist flumazenil will also be used
1572326|NCT02439151|Device|New lung ventilation strategy|New ventilation strateg: PCV molel; FiO2 0.3; regulate the PC allows transpulmonary pressure at the end of inspiration less than 20cmH2O; Ti 1s; frequency 10bpm; regulate the PEEP allows transpulmonary pressure at the end of expiration greater than 0cmH2O and less than 5cmH2O.
1572327|NCT02439151|Device|Conventional ventilation strategy|Conventional ventilation strategy: PCV molel; FiO2 0.3; PC 10cmH2O; Ti 1s; frequency 10bpm; PEEP 10cmH2O.
1572328|NCT02439138|Drug|GS-1101|Oral twice daily for 6 months followed by once daily until disease progression or unacceptable toxicity.
1572329|NCT02439125|Drug|Eltoprazine HCl|2.5 mg b.i.d. orally for 3 weeks
1572330|NCT02439125|Drug|Eltoprazine HCl|5.0 mg b.i.d. orally for 3 weeks
1572331|NCT02439125|Drug|Eltoprazine HCl|7.5 mg b.i.d. orally for 3 weeks
1572332|NCT02439125|Drug|Placebo|b.i.d. orally for 3 weeks
1572333|NCT02439112|Other|Exercise|"8 supervised in-hospital training sessions in a period of 10 weeks. On a general level, the intervention will follow the Danish physical activity guidelines for elderly >65 years (Sundhedsstyrelsen 2011, see link) and consist of strength exercise, aerobic exercise and physical activity.
Bone involvement will taken into consideration in all parts of the exercise program by excluding and including specific exercises and mode of exercise according to location and extent of bone involvement (Galvão 2011; Cormie 2013)"
1572335|NCT02439073|Behavioral|Rehabilitation|The postoperative intervention are the same in both intervention groups and consists of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.The postoperative physical exercise consists of an individually prepared supervised strength exercise - and a group-based cardiovascular exercise twice a week (60 minutes/session) on non-consecutive days for 12 weeks, a total of 24 sessions.
1572336|NCT02439060|Other|Acellular Cadaveric Dermal Matrix|Undergo intraperitoneal prophylactic mesh placement
1572337|NCT02439047|Procedure|Biological samples collection|"-Peritoneal samples : will be collected during abdominal surgery
A biopsy from 1 to 2 cm2 will be performed in healthy peritoneum
- Adipose tissue samples : will be collected during surgery for breast reconstruction"
1572338|NCT02439034|Drug|Paracetamol|Paracetamol 1 g IV then 1 g 3 times a day IV or oral (PO)
1572339|NCT02439034|Drug|Ketoprofen|Ketoprofen* 100 mg (IV then PO) : Ketoprofen 100 mg IV 2 times a day or Ketoprofen LP 100 mg PO 2 times a day.
1572340|NCT02439021|Device|COBRA|
1572341|NCT02439021|Device|LMA|
1572342|NCT02439008|Procedure|Blood samples collection before radiotherapy|"Nine blood samples (35 mL each) will be collected in each patient before, during and after radiotherapy treatment.
Before radiotherapy:
Sample T0: after registration, in the days running up to the administration of the first fraction of radiotherapy"
1572343|NCT02439008|Procedure|Blood samples collection during radiotherapy|"Sample T1: within 15 minutes after the administration of the first fraction,
Sample T2: within 15 minutes after the administration of the second fraction,
Sample T3: within 15 minutes after the administration of the third fraction"
1572344|NCT02439008|Procedure|Blood samples collection after radiotherapy|"Sample T4: one week after the end of the radiotherapy,
Samples T5 to T8: respectively 3 months, six months, 9 months and 12 months after the end of the radiotherapy."
1572345|NCT02439008|Radiation|Radiotherapy|
1572346|NCT02438995|Drug|Intraarterial Cetxuimab (Erbitux)|Super-Selective Intraarterial Infusion of Cetuximab (Erbitux)
1572347|NCT02438982|Drug|Tacrolimus|Oral Tacrolimus (Tablet form) 0.2mg/kg/day starting dose. Targeting trough level of Tacrolimus (T0) 5-7 ng/ml.
1572348|NCT02438982|Drug|Rituximab|Two rituximab infusions will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2). Circulating B cells will be measured 24 hours after rituximab administration. If >5 B cells per mm3, it will be measured again after 1 week. If count is still >5 B cells per mm3, third & fourth doses of rituximab will be given.
1572351|NCT02438943|Other|Audit|An assessment of medical records using a pre-specified audit instrument to assess the level of care given for clinic attendees with cardiovascular disease including dyslipidemia
1572352|NCT02438943|Other|Physician Intervention|Feedback Training sessions for physicians inclusive Motivational Interviewing training and the use of physician reminders on medical records before each clinic session
1572353|NCT02438930|Behavioral|Motivational interviewing intervention during HIV testing|
1572354|NCT02438930|Behavioral|Standard-of-care counseling during HIV testing|
1572355|NCT02438904|Biological|CD34 Positive Stem Cell Infusion|Participants infused by vein with around 1 - 4 million/kg CD34+ selected cells.
1572356|NCT02438891|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is a form of tinnitus psychotherapy which aims to help patients control negative thoughts or emotions associated with tinnitus.
1572358|NCT02438865|Drug|Immediate instillation of intravesical chemotherapy-Epirubicin-|
1572359|NCT02438865|Drug|Maintainance therapy of intravesical chemotherapy-Epirubicin-|
1572360|NCT02438852|Other|Placebo|Given IV
1572361|NCT02438852|Other|Questionnaire Administration|Ancillary studies
1572362|NCT02438852|Drug|Ropivacaine Hydrochloride|Given IV
1572365|NCT02438813|Other|No Intervention|
1572366|NCT02438800|Behavioral|LARC First Video|LARC First is an evidence-based, 12-minute video developed by the CHOICE project that features women of all racial and ethnic backgrounds describing LARC methods of contraception in simple, understandable language with summary text when appropriate.
1572367|NCT02438787|Drug|Placebo|Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1.
1572368|NCT02438787|Drug|Ustekinumab 45 mg|Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 2.
1572369|NCT02438787|Drug|Ustekinumab 90 mg|Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 52 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 52 in Group 3.
1572370|NCT02438787|Drug|Golimumab 50 mg|Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 52 in Group 1, 2 and 3.
1572371|NCT02438774|Behavioral|post-harvest intervention package|The intervention group received post-harvest intervention package. The package is composed of 5 components, namely 1) hand sorting, 2) drying surface, 3) proper drying, 4) application of insecticide, 5) dehulling . The intervention will last for 7 months.
1572372|NCT02438774|Behavioral|Routine agriculture extension services|This group continued to receive routine agriculture education on good practices for handling crops; an agricultural extension service offered to farmers regularly by village agriculture extension officer at village level. The extension services provided includes the provision of farmers with knowledge, information, experiences and technologies needed to increase and sustain productivity and avoiding crop spoilage during storage for improved wellbeing and livelihoods
1572380|NCT02438696|Drug|BI 1060469, iFF, Test|
1572381|NCT02438696|Drug|BI 1060469, TF1, Reference|
1572382|NCT02438696|Drug|BI 1060469, TF2, Test|
1572383|NCT02438696|Drug|BI 1060469, TF2, Test|
1572384|NCT02438696|Drug|BI 1060469, iFF, Test|
1572385|NCT02438696|Drug|BI 1060469, TF1, Reference|
1572386|NCT02438696|Drug|BI 1060469, iFF, Test|
1572387|NCT02438696|Drug|BI 1060469, iFF, Test|
1572388|NCT02438696|Drug|BI 1060469, TF1, Reference|
1572389|NCT02438696|Drug|BI 1060469, TF2, Test|
1572390|NCT02438696|Drug|BI 1060469, TF1, Reference|
1572391|NCT02438696|Drug|BI 1060469, TF1, Reference|
1572392|NCT02438696|Drug|BI 1060469, TF2, Test|
1572393|NCT02438696|Drug|BI 1060469, TF2, Test|
1572394|NCT02438696|Drug|BI 1060469, iFF, Test|
1572395|NCT02438696|Drug|BI 1060469, TF2, Test|
1572396|NCT02438696|Drug|BI 1060469, TF1, Reference|
1572397|NCT02438683|Drug|BI 409306|medium dose, single dose, oral administration
1572398|NCT02438683|Drug|BI 409306|low dose, single dose, oral administration
1572399|NCT02438683|Drug|Placebo|single dose, oral administration
1572402|NCT02438657|Procedure|median nerve block|
1572403|NCT02438618|Procedure|Surgery for Ponto bone anchored hearing aids|
1572404|NCT02438605|Device|Nellix|
1572405|NCT02438579|Other|Nasal Irrigation & Gargling|Participants are advised to perform the intervention as frequently as required (expected frequency around 6 times a day for the first two days, reducing in frequency from day 3 as symptoms improve).
1572406|NCT02438566|Drug|Tranexamic Acid (Oral)|OTA will be given as 1950 mg 1-2 hours prior to OR and 1950 mg 2 hours after surgical close, before discharge from PACU.
1572407|NCT02438566|Drug|Tranexamic Acid (Intravenous)|IVTA will be given as 1 g intravenously at time of first incision (THA or bTKA without tourniquet) or just before 1st tourniquet application (bTKA), and then again, 1 g after final surgery closure.
1572408|NCT02438553|Device|OSTNS Neurostimulator|Non-invasive transcutaneous neurostimulation.
1572409|NCT02438553|Device|Placebo OSTNS Neurostimulator|Placebo non-invasive transcutaneous neurostimulation
1572410|NCT02438540|Drug|metformin|metformin tablet 500 mg
1572411|NCT02438540|Other|acupuncture|Electro body acupuncture and auricular acupuncture
1572412|NCT02438527|Behavioral|Chart for CPR guidance|
1572413|NCT02438514|Other|Biological Sample Collection|"Anthropomorphic biomarkers including height, weight, heart rate, and blood pressure will be taken for each participating mother and child by a research assistant trained to accurately perform these procedures.
Blood spots will be collected in finger stick proficiency, using trigger activated lancets to administer finger sticks.
Each participating mothers and child will provide a saliva sample using Oragene DNA saliva collection kits"
1572414|NCT02438501|Radiation|Low-dose involved-field radiotherapy|Low-dose involved-field RT (LD-IFRT) is given in 2 daily fractions (2×2 Gy). Involved-field of radiotherapy defined by CALGB is encompassed the prechemotherapy gross tumor.
1572415|NCT02438501|Radiation|Involved-field radiotherapy|Involved-field RT (IFRT) is given in 24 Gy in 12 fractions. Radiotherapy field defined by CALGB is encompassed the prechemotherapy gross tumor.
1572416|NCT02438475|Device|Mynx Vascular Closure System|MynxGrip is being used to seal femoral vein access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing a 5F, 6F or 7F procedural sheath.
1572417|NCT02438475|Other|Manual Compression|manual pressure applied to your groin for approximately 5-10 minutes
1572418|NCT02438462|Other|Soluble Fibrin|Calculating the area under the ROC curve of the Soluble Fibrin assay for the diagnosis of PE before evaluating the diagnostic performance of the assay.
1572419|NCT02438449|Procedure|Breast Reconstruction Surgery|AAT-based orTE/I reconstruction in all patients undergoing breast reconstruction following mastectomy
1572420|NCT02438436|Dietary Supplement|simo decoction|
1572421|NCT02438436|Other|gum chewing|
1572422|NCT02438423|Biological|Inactivated influenza vaccine|Seasonal trivalent inactivated influenza vaccine FDA-approved for 2014-2015 influenza season
1572423|NCT02438423|Other|Placebo|
1572424|NCT02438397|Drug|premix insulin|Premix-insulin(human insulin or analog) treatment will continue
1572425|NCT02438397|Drug|metformin|500 mg tid by Merck
1572426|NCT02438397|Drug|Acarbose|100mg tid by Bayer
1572429|NCT02438371|Drug|Nifedipine|Nifedipine will be given for the treatment of preterm labor
1572430|NCT02438371|Drug|Indomethacin|Nifedipine and indomethacin will be give for the treatment of pretermlabor
1572433|NCT02438345|Biological|PRO 140|Humanized monoclonal antibody to CCr5
1572434|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 1 Breast Implants|Surgical implant
1572435|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
1572436|NCT02438332|Device|Smooth NATRELLE® INSPIRA® TruForrm® 2 Breast Implants|surgical implant
1572437|NCT02438332|Device|Textured NATRELLE® INSPIRA® TruForm® 1 Breast Implants|surgical implant
1572438|NCT02438319|Other|manual planimetry|Manually marking of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
1572439|NCT02438319|Other|automated planimetry|Automatic detection of the boundaries of the optic disc and it's excavation on color photographs of the optic disc.
1572440|NCT02438306|Biological|Autologous cell therapy|
1572441|NCT02438306|Device|CardiAMP cell therapy|
1572442|NCT02438306|Other|Sham|Optimal medical/device therapy
1572445|NCT02438241|Procedure|Conventional physiotherapy Group|Patients randomized to this group will receive only conventional physiotherapy. The treatment protocol Control Group, will consist of weathered active exercises to manually lower limbs in bed (triple flexion, abduction and adduction, plantar / dorsiflexion), free active exercises of the upper limbs in the bed (shoulder flexion, shoulder flexion and horizontal functional diagonal shoulder), bronchial hygiene techniques, flow redirection, positive expiratory pressure and ventilatory blowing patterns.
1572446|NCT02438241|Procedure|TENS Group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), and the end of that service, will be applied TENS. TENS is accomplished through the use of an electrical stimulation device with symmetrical biphasic current pulse. The following parameters are used: frequency: 100 Hz, pulse width: 100 µs, intensity to the greatest sensory threshold of the patient and total session time: 30 minutes. Self-adhesive electrodes will be used (Valutrode, size 5x9 cm) to be positioned in the posterolateral portion of the chest to 2 cm skin incision both upper and lower.
1572447|NCT02438241|Procedure|Placebo TENS group|Patients randomized to this group will receive conventional physical therapy (the treatment protocol Control Group), will be held the same procedure as TENS group, except that TENS will be offered to the patient only for 45 seconds, and in the first 30 seconds is reached the sensory threshold of the patient and in the last 15 seconds will turn off the electrical current by 29 remaining period minutes and 15 seconds off.
1572448|NCT02438228|Other|Cardiac output measurement|Measurement of cardiac output by transpulmonary thermodilution, nine different pulse contour algorithms and esophageal doppler before, during and after a PLR-maneouvre and every 10 minutes before and after cardiopulmonary Bypass.
1572449|NCT02438215|Drug|IRX4204|IRX4204 is a potent and highly selective orally available and brain penetrant RXR nuclear receptor agonist small compound administered as gel capsules.
1572450|NCT02438202|Device|Thymatron IV device (Somatics)|Patients will be treated with a modified routine ECT/maintenance ECT series.
1572451|NCT02438189|Device|Hyperglycemia Minimization Algorithm|The hyperglycemia minimization algorithm will be running actively on the study laptop during the night and dose insulin if the algorithm predicts hyperglycemia. If hypoglycemia is predicted, the system will suspend the pump.
1572452|NCT02438176|Procedure|single trans-septal puncture|The investigators will compare bilateral groin puncture AF ablation and single groin puncture AF ablation with 1:2 randomization.
1572453|NCT02438176|Procedure|conventional bilateral groin puncture|Bilateral groin puncture AF ablation is control procedure exactly same to routine AF ablation with double trans-septal puncture.
1572454|NCT02438163|Device|Theta Burst Stimulation|"During the first session, After determining the parameters of stimulation (stimulated target : part of the left motor cortex responsible for the contraction of the right first dorsal interosseous muscle ; Activity Motor Threshold (AMT) ; Intensity of Stimulation providing a Motor Evoked Potential (MEP) with an Amplitude of 1mV (MEP 1mV)), a Baseline consisting of 15 MEP (intensity MEP 1mV) is measured. Then each subjet receive a TBS protocol (cTBS or iTBS) (intensity of stimulation 80% of AMT). After receiving the stimulation, sets containing 10 MEP are regularly measured by each subject.
During a second session, the same protocol is done again with the other TBS stimulation (cTBS or iTBS) the subject didn't get during the first session."
1572455|NCT02438150|Behavioral|Hospital fire video training|Participants will watch a video about hospital fire training which last for 30 minutes
1572456|NCT02438150|Behavioral|Non hospital fire video training|Participants will watch a video about volcanic eruption which last for 30 minutes
1572457|NCT02438137|Drug|Dimethyl fumarate|Dimethyl fumarate capsules will be dispensed during routine study appointments. 120 mg tablets will be dispensed to facilitate dose titrations. Drug will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the medication with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
1572458|NCT02438137|Drug|Placebo|Placebo capsules will be dispensed during routine study appointments. Placebo will be dispensed in 1 month supply, so that compliance can be reconciled at monthly follow-up visits, and recorded in accountability logs. Participants will be instructed to take the placebo with food, in the morning and at dinnertime. If participants miss a dose, they will be instructed to resume their normal dose at the next scheduled time, and be instructed not to take an extra dose at their next dosing interval if they previously miss a dose.
1572459|NCT02438124|Behavioral|Neuropsychological evaluation|The subjects are submitted in one hearing stimulus while they realize a walking test
1572460|NCT02438111|Genetic|metagenome|metagenome
1572461|NCT02438098|Drug|Rivaroxaban 10 mg|Patients receive the day before the surgical intervention the first dose of Rivaroxaban (10 mg) p.o. The second tablet Rivaroxaban is administered on the third postoperative day.
1572462|NCT02438085|Other|prospective collection of data and follow-up|prospective collection of data and follow-up of all patients admitted to hospital for ACS
1572463|NCT02438072|Drug|Omeprazole (10 mg, A02BC01)|The cocktail of drug substrates will be given one time, one day during the study, to explore the activity of CYP 1A2, 2B6, 2C9, 2C19, 3A4, 2D6, and the P-gp
1572464|NCT02438059|Behavioral|SoSu-liv website and app|A 38 weeks web- and app-based tool for lifestyle changes intervention.
1572465|NCT02438046|Procedure|Palatal wound bandage|Treatment of Palatal wounds by Platelet Rich Fibrin or absorbable gelatin sponge.
1572466|NCT02438033|Device|Medtronic Activa PC+S Sensing Deep Brain Stimulator Generator|Patients undergoing deep brain stimulation for Parkinson's disease based on clinically indicated criteria will have the option to enroll in this study, in which the Activa PC+S generator and corresponding extension leads will be implanted rather than the standard Activa PC system. Patients will be assessed every month for 3 months and then every 3 months after, including off and on medication assessments.
1572467|NCT02438020|Drug|Metformin|One tablet of 500 mg will be ingested before the main meal
1572468|NCT02438020|Other|Placebo|A placebo tablet will be ingested daily before main meal.
1572469|NCT02438007|Drug|Galeterone|2550 mg galeterone tablets once daily PO
1572470|NCT02438007|Drug|Enzalutamide|160 mg enzalutamide capsules once daily PO
1572471|NCT02437994|Behavioral|Pulmonary Rehabilitation|The rehabilitation program will be multidisciplinary and will include mandatory supervised exercise training at appropriate training intensity, other components of the program can be breathing control and relaxation techniques, methods of clearance of pulmonary secretions, disease education, dietary advice, and psychological support on issues relating to chronic disability. Six minute walking tests, and improvements in dyspnea sensation (CRDQ) will be used to benchmark the effect of a program provided by a given team.
1572472|NCT02437981|Drug|PrEP|Oral pre-exposure prophylaxis (PrEP) for HIV infection using a daily combination tablet of tenofovir disoproxil fumarate and emtricitabine
1572473|NCT02437968|Behavioral|Camp Cope-A-Lot (Computer-assisted CBT program)|Camp Cope-A-Lot is a computer-assisted program that includes psychoeducation and clinician guided exposure tasks for anxious children.
1572474|NCT02437955|Other|Ferrous sulfate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
1572475|NCT02437955|Other|ferrous sulfate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled ferrous sulfate and stable isotopes
1572476|NCT02437955|Other|Ferrous fumarate fortified bread with tea|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
1572477|NCT02437955|Other|Ferrous fumarate fortified bread with water|Fasting subjects will be served a wheat roll fortified with labelled Fe Fumarate and stable isotopes
1572479|NCT02437929|Procedure|Mobilization|
1572480|NCT02437929|Procedure|Positioning|
1572481|NCT02437929|Procedure|Personal Hygiene Care|
1572482|NCT02437929|Procedure|Bladder catheterization|
1572483|NCT02437929|Procedure|Wound care|
1572484|NCT02437929|Procedure|Subcutaneous drugs administration|
1572485|NCT02437916|Drug|AMG 228|AMG 228 will be administered intravenously
1572486|NCT02437903|Device|JUVÉDERM VOLUMA™ XC|Subjects will receive up to 4, 1mL syringes of JUVÉDERM VOLUMA™ XC for their initial injection and a maximum of 6, 1mL syringes of JUVÉDERM VOLUMA™ XC for the study. Subjects will undergo one touch-up injection approximately 2 weeks post initial treatment, and will continue to be evaluated at month 1, month 3, month 6, month 9, and month 12.
1572487|NCT02437890|Biological|ALX-0061|
1572488|NCT02437890|Biological|Placebo|
1572490|NCT02437851|Procedure|Therapeutic Conventional Surgery|Undergo surgery to remove anal or perianal cancer (SISCCA)
1572491|NCT02437838|Other|No Intervention|No Intervention
1572492|NCT02437825|Drug|octreotide|Octreotide has been in clinical use for thirty years and approved for use in Israel in acromegaly and functional gastroenteropancreatic tumours. It is currently being used extensively in surgical patients to prevent pancreatic fistulae1, and in lymphorrhea (both lymphatic malformations and leaks from the thoracic duct)
1572493|NCT02437825|Other|placebo|placebo ( saline) act as comperator in this study.
1572494|NCT02437812|Drug|Metformin|Metformin with standard chemotherapy
1572495|NCT02437812|Drug|Paclitaxel|Standard chemotherapy
1572496|NCT02437812|Drug|Carboplatin|Standard chemotherapy
1572497|NCT02437799|Other|Dicrotic wave analysis|We will download data from the pulse oximeter that is being used to monitor the patient during their surgery.
1572498|NCT02437786|Drug|GRAZAX|GRAZAX
1572499|NCT02437773|Behavioral|Cognitive Behavioral Therapy - Adolescents|"A therapy which gradually yet repeatedly exposes adolescent patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
1572500|NCT02437773|Behavioral|Stress Management Therapy - Adolescents|An active control therapy with minimal effects on OCD symptoms.
1572501|NCT02437773|Behavioral|Optional CBT - Adolescents|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
1572502|NCT02437773|Behavioral|Cognitive Behavioral Therapy - Adults|"A therapy which gradually yet repeatedly exposes adult patients to their obsessive compulsive-relevant error cues during a task performance until their anxiety habituates."
1572503|NCT02437773|Behavioral|Stress Management Therapy - Adults|An active control therapy with minimal effects on OCD symptoms.
1572504|NCT02437773|Behavioral|Optional CBT - Adults|This is the cross-over element for those that completed the SMT treatment group and opt to have the OCD treatment.
1572505|NCT02437773|Other|fMRI only - Healthy Control Adults|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adults and is used only as a means for observation, NOT as an intervention to be studied.
1572506|NCT02437773|Other|fMRI only - Healthy Control Adolescents|Two fMRI's only, scheduled at 12-weeks apart. This is for Healthy Control Adolescents and is used only as a means for observation, NOT as an intervention to be studied.
1572507|NCT02437760|Other|serum and pleural effusion CA-125 level|"serum and pleural effusion(if exist) CA-125 are collected:
at time of diagnosis
every 3 month during treatment
stop at the progression or after 12 months"
1572508|NCT02437747|Drug|SRP + Aloe|Scaling and root planing along with aloe vera application was done
1572509|NCT02437747|Procedure|SRP|Scaling and root planing was done
1572510|NCT02437734|Procedure|Percutaneous Coronary Intervention|A phase II, observational, analytical study of coronary angiography and computational fluid dynamics in 100 adults with coronary artery disease undergoing coronary angiography.
1572511|NCT02437721|Other|infant formula containing folic acid|
1572512|NCT02437721|Other|infant formula containing MTHF|
1572513|NCT02437708|Procedure|REP with L-PRF|
1572514|NCT02437708|Procedure|REP|
1572515|NCT02437708|Biological|stem and progenitor cells|
1572516|NCT02437669|Drug|Hydromorphone|To be administered by intranasal route using mucosal atomization device.
1572518|NCT02437643|Behavioral|Weight Loss|Participants will be prescribed hypo-caloric diet prescription.
1572519|NCT02437643|Dietary Supplement|Dairy Protein|Participants will be provided dairy products: WL-LoEx will be provided 1 dairy serving per day and Pro-WL-LoEx will be provided 8 dairy servings per day.
1572520|NCT02437643|Behavioral|Low intensity exercise|Participants in both groups will participate in chair exercises 3 times a week.
1572521|NCT02437630|Procedure|Oesophageal balloon to measure intra-thoracic pressure|An oesophageal balloon will be inserted via a nostril after instillation of local anaesthetic and swallowed until the tip is in the lower third of the oesophagus. This will allow the intrathoracic pressure to be monitored via a pressure sensor attached to the oesophageal balloon catheter and placed next to the subject. This will allow us to observe the changes in oesophageal pressure during quiet breathing under a variety of applied positive pressure conditions.
1572522|NCT02437630|Procedure|Fibre-optic laryngoscopy|A fibre-optic laryngoscope will be inserted through the opposite nostril to that used for the oesophageal balloon and placed with its tip abve the larynx where the laryngeal movement can be observed This will allow us to observe the changes in laryngeal aperture under a variety of applied positive pressure conditions.
1572523|NCT02437630|Other|standard lung function tests|These will be carried out in any subject who has not had lung function testing in the previous 6 weeks and will be carried out by a lung function physiologist from the institution in accordance with standard procedures for lung function testing
1572524|NCT02437630|Procedure|face mask CPAP|The subjects will wear a facemask with apertures for the oesophageal balloon and fibre-optic devices to cover the mouth and nose. airflow and volume will be recorded with a pneumotachograph and there will be tubing to connect to a positive pressure source (CPAP) to allow mouth pressures to be altered between 0-15cm H20.( 1cm H20 is the pressure produced by a column of water of 1centimetre in depth)
1572525|NCT02437630|Procedure|variation of mouth pressure with CPAP|Once the other procedures are completed the subject will have his mouth pressure varied via application of positive pressure via a commercial CPAP device as used for treatment of obstructive sleep apnoea. The pressure will be varied randomly between 0-15cm H2O (water)for periods of 5 minutes both sitting and lying. Oesophageal balloon recording of intra-thoracic pressure and laryngeal movement and mouth airflow and volume will be recorded simultaneously and at the end of each 5 minute period the subject will be requested to take as big a breath in as possible to allow measurement of functional residual capacity and inspiratory capacity. This will allow us to observe the effect of changing mouth pressure with CPAP on laryngeal aperture and oesophageal pressures and airflow.
1572526|NCT02437630|Other|facemask pneumotachograph|The facemask will incorporate a pneumotachograph to allow measurement of airflow and volumes throughout the respiratory cycle. This will allow us to observe the pattern of airflow with varying applied CPAP
1572527|NCT02437617|Procedure|Tumor Tissue|Tumor tissue collected previously from surgery or a prior biopsy (archived tissue) used for genetic testing.
1572528|NCT02437604|Drug|Treatment A: Fp MDPI|Fp MDPI 200 mcg, 1 inhalation
1572529|NCT02437604|Drug|Treatment B: FS MDPI|FS MDPI 200/12.5 mcg, 1 inhalation
1572530|NCT02437604|Drug|Treatment C Flovent|FLOVENT DISKUS 250 mcg, 2 inhalations
1572531|NCT02437604|Drug|Treatment D: Advair|ADVAIR DISKUS 500/50 mcg, 1 inhalation
1572532|NCT02437591|Drug|fidaxomicin|oral
1572533|NCT02437565|Other|Stainless steel crown|Placement of stainless steel crowns for teeth that have undergone pulpotomy for the treatment of pulpitis induced by severe early childhood caries under general anesthesia
1572534|NCT02437565|Other|Occlusal Template|Use of an occlusal template for the placement of stainless steel crowns under general anesthesia
1572535|NCT02437552|Device|ergometer cycle exercise|
1572536|NCT02437552|Other|routine physiotherapy|routine physiotherapy
1572537|NCT02437539|Drug|Injection of 68Ga-NOTA-AE105|One injection of 68Ga-NOTA-AE 105
1572538|NCT02437539|Device|Positron Emission Tomography scans|Following injection of 68Ga-NOTA-AE105 the patients will be PET scanned at 10 minutes, 1 hour and 2 hours post injection
1572539|NCT02437526|Other|Analytic treatment interruption|
1572540|NCT02437513|Device|NewBreez|Intralaryngeal prosthesis to protect the airways
1572541|NCT02437500|Drug|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
1572542|NCT02437487|Drug|SER-109|SER 109 is a rationally designed ecology of bacterial spores enriched from stool donations obtained from healthy, screened donors.
1572543|NCT02437487|Drug|Placebo|Placebo will be identical to the investigator product but will not contain product spores or non-spore solids. Placebo will consist of 92% glycerol and 8% normal saline.
1572544|NCT02437474|Behavioral|Omnivorous diet|Adopting or continuing the selected diet for 6 months (omnivorous)
1572545|NCT02437474|Behavioral|Lacto-ovo-vegetarian diet|Adopting or continuing the selected diet for 6 months (lacto-ovo-vegetarian)
1572546|NCT02437474|Behavioral|Vegan diet|Adopting or continuing the selected diet for 6 months (vegan)
1572548|NCT02437448|Other|No intervention|
1572549|NCT02437435|Other|Reproductive Technique Gimilio|"Patient supine, legs in triple flexion, feet on table, controlling legs left hand and right hand bent on uterine body contact.
Both hands catch utero withdrawal into one on another with arms outstretched. Fixed uterus right hand, left hand, with levers legs combines lateroflexion-rotation parameters of lumbar spine to improve uterine ligaments stretch, repeat technique to tissue relaxation. Then perform massage-cranial caudo zigzag with anteroposterior thrust. (overall hemodynamic maneuver). Finally do anteroposterior pumping about uterine body generating positive and negative pressures.
Hand therapist will keep in touch at all times on the suprapubic region of the patient."
1572550|NCT02437422|Biological|SANGUINATE|Single two-hour infusion of SANGUINATE
1572551|NCT02437409|Device|pREset thrombectomy retriever|Interventional recanalization of acute cerebral vessel occlusions with the pREset thrombectomy system alone or in combination with intravenous or intraarterial thrombolytics (rt-PA).
1572552|NCT02437383|Drug|Propranolol ER|Capsules given orally according to schedule at Visit 1, Visit 2, Visit 3, and Visit 4.
1572553|NCT02437383|Drug|Placebo|Gelatin capsules with a microcrystalline cellulose filler manufactured to mimic propranolol ER 60 mg capsules
1572554|NCT02437370|Drug|Pembrolizumab|Given IV
1572555|NCT02437370|Drug|Docetaxel|Given IV
1572556|NCT02437370|Drug|Gemcitabine Hydrochloride|Given IV
1572557|NCT02437357|Other|Metacognitive Training|8 group sessions á 60 min
1572558|NCT02437357|Other|Positivity Training|8 group sessions á 60 min
1572559|NCT02437344|Drug|CI-581aa|92 minute infusion of CI-581aa
1572560|NCT02437344|Drug|Naltrexone titration and XR-NTX initiation|participants will be provided a titration of naltrexone that culminates in the injection of XR-NTX
1572564|NCT02437305|Behavioral|ABCDEs of Melanoma Skin Cancer|Modified melanoma educational intervention that is targeted towards people of color.
1572565|NCT02437305|Behavioral|ABCDEs of Melanoma|Conventional melanoma educational intervention.
1572566|NCT02437292|Other|Ischemic compression with stretching|
1572567|NCT02437279|Procedure|Surgery of the tumor|
1572568|NCT02437279|Drug|Infusion with ipilimumab 3 mg/kg q3wks|
1572569|NCT02437279|Drug|Infusion with nivolumab 1 mg/kg q3wks|
1572570|NCT02437266|Other|Scapular mobilization|
1572571|NCT02437253|Drug|Adalimumab|Subjects will be treated with adalimumab (20 mg [weight 15-<30 kg] or 40 mg [weight ≥30 kg] administered subcutaneously [subQ] every other week) or placebo for 16 weeks, then cross-over to the other group for 16 weeks.
1572572|NCT02437253|Other|Placebo|Saline placebo
1572573|NCT02437240|Behavioral|Pilates-based CPT|To emphasize the self-perception of breathing and body core control during in-patient cardiopulmonary physical therapy following cardiac surgery
1572574|NCT02437240|Behavioral|Traditional CPT|A traditional in-patient cardiopulmonary physical therapy following cardiac surgery including airway clearance, breathing exercises, chest mobility and reconditioning exercises and so on
1572575|NCT02437227|Drug|CCT3833|CCT3833 is a poorly soluble crystalline compound. It is multi-polymorphic and one form, designated Form D, has been purified and typically has a particle size of about 15-20 μm. Form D readily absorbs and desorbs water, but is not a hydrate and has been selected as the form to take forward into clinical development.
1572576|NCT02437214|Other|Use of music for anxiety in children|"The Baby Go to Sleep CD played a combination of the sound of an actual human heartbeat and children's songs. The concept behind the Baby Go to Sleep CD is to blend heart beat sounds, which are known to be calming to infants and children, with children's music. The basic principles of relaxation were incorporated in the arrangements of heartbeat and children's songs, ie: simplicity, repetition, predictability, and simple symmetry (short repeated patterns). The adult human heart in the Baby Go to Sleep CD was recorded from the chest and set in consistent tempos for each song ranging from 62 to 78 beats per minute(BPM). The sound of the heartbeat continued between and during songs. Tempo changes occurred between each song."
1572577|NCT02437201|Behavioral|Liberty Program|
1572578|NCT02437188|Behavioral|ACT (Acceptance and Commitment Therapy)|The 1-day training session with ACT proposed for this study is designed to reduce behavioral avoidance and to enhance acceptance-based coping. The intervention includes: 1) Behavioral Change Training (2.5 hours) involving a) teaching patients how to recognize ineffective patterns of behavior and habits, b) exploring and setting life goals and goals related to mental and physical health, and c) promoting effective and committed actions to achieve these goals despite the urge to do otherwise; 2) Acceptance and Mindfulness Training (2.5 hours) emphasizing new ways of managing troubling thoughts, feelings, and physical sensations (e.g., learning how to recognize, and develop cognitive distance from, unhelpful thoughts and learning how to willingly face experiences that cannot be changed.
1572579|NCT02437175|Dietary Supplement|ENDO 1/ENDO 2|NUTRI ENDO 1 (1 sequence of 10 tablets on the morning) and NUTRI ENDO 2 ( sequence of 10 tablets at the evening), daily, during 120 days.
1572580|NCT02437175|Dietary Supplement|Placebo|Placebo: 1 sequence of 10 tablets on the morning and 1 sequence of 10 tablets at the evening, daily, during 120 days.
1572581|NCT02437162|Drug|Placebo|Participants will receive Placebo subcutaneous (SC) injection at Weeks 0, 4, and 16 in Group 1 and at Week 24 in Group 2 and Group 3.
1572582|NCT02437162|Drug|Ustekinumab 45 mg|Participants will receive Ustekinumab 45 mg SC injection at Weeks 24 and 28 followed by every 12 weeks (q12w) dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 45 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 2.
1572583|NCT02437162|Drug|Ustekinumab 90 mg|Participants will receive Ustekinumab 90 mg SC injection at Weeks 24 and 28 followed by q12w dosing, with the last administration of study agent at Week 100 in Group 1. Participants will start with ustekinumab 90 mg SC injection at Weeks 0 and 4, followed by q12w dosing, with the last administration of study agent at Week 100 in Group 3.
1572584|NCT02437162|Drug|Golimumab 50 mg|Participants who meet EE criteria (less than [<] 10 percent [%] improvement from baseline in both total back pain and morning stiffness measures at both Week 12 and Week 16) will be administered open-label golimumab 50 mg SC administrations at Week 16 and every 4 weeks (q4w) thereafter through Week 100 in Groups 1, 2 and 3.
1572588|NCT02437136|Drug|entinostat|An orally available histone deacetylases inhibitor (HDACs)
1572589|NCT02437136|Drug|pembrolizumab|A selective humanized monoclonal antibody (mAb)
1572590|NCT02437123|Behavioral|The Cedar Project mHealth intervention|
1572591|NCT02437110|Drug|Darunavir|Orally-administered medication approved for HIV treatment. MOA is as a protease inhibitor. Dose is 600mg twice daily.
1572592|NCT02437110|Drug|Ritonavir|Orally-administered, FDA-approved medication for HIV treatment. Used in combination with darunavir. Dose is 100 mg twice daily.
1572593|NCT02437110|Drug|Raltegravir|Orally-administered, FDA-approved medication to treat HIV. It acts as an integrase inhibitor. Dose is 400mg twice daily.
1572594|NCT02437110|Drug|Zidovudine|Orally-administered, FDA-approved medication used to treat HIV. It acts as a nucleoside reverse transcriptase inhibitor. Dose is 300mg twice daily.
1572595|NCT02437097|Other|Aerobic exercise|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
1572596|NCT02437097|Other|Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
1572597|NCT02437097|Other|Aerobic exercise and Video Gaming|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
1572598|NCT02437097|Other|Control|The research design used will be a randomized control trial using a Latin square in order to randomize the treatment conditions. Subjects will take one of four conditions: 1) Aerobic exercise only 2) Aerobic exercise and Gaming simultaneously 3) Gaming only 4) Sitting quietly. All the conditions will take 30 minutes. The independent variables are the four conditions and the dependent variables are the Stroop test and modified Trails B which measure executive function.
1572599|NCT02437084|Drug|Atorvastatin|study subjects divided into 2 groups as described earlier and both receiving atorvastatin 40 mg for 8 weeks.
1572600|NCT02437071|Drug|Pembrolizumab|Pembrolizumab will be administered as a 30 minute IV infusion (every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps from site to site, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
1572601|NCT02437071|Radiation|Radiotherapy|
1572602|NCT02437071|Procedure|Radiofrequency ablation|
1572603|NCT02437058|Other|preidictive model|
1572604|NCT02437045|Drug|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
1572605|NCT02437045|Drug|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
1572606|NCT02437032|Drug|recombinant FSH|Controlled ovarian stimulation with 150-300 UI recombinant FSH
1572607|NCT02437032|Drug|Urinary FSH|Controlled ovarian stimulation with 150-300 UI urinary FSH
1572608|NCT02437032|Drug|hMG|Controlled ovarian stimulation with 150-300 UI hMG
1572609|NCT02437019|Drug|PCI-32765 (Ibrutinib)|Participants will receive PCI-32765 (ibrutinib) 420 mg (three 140-mg capsules) oral once daily continuously on a 28-day cycle.
1572610|NCT02437006|Other|exercise|cycle ergometry
1572611|NCT02436993|Drug|Carboplatin|Area Under the Curve (AUC) 2 IV over 60 minutes weekly for 12 doses
1572612|NCT02436993|Drug|Paclitaxel|80 mg/m^2 IV over 1-3 hours weekly for 12 doses
1572613|NCT02436993|Drug|Bevacizumab|10mg/kg IV over 90 or 60 or 30 minutes every other week for 5 doses
1572614|NCT02436993|Drug|Trastuzumab|4mg/kg induction, followed by weekly 2mg/kg IV-induction over 90 minutes, then weekly over 30-60 minutes for 12 doses
1572615|NCT02436993|Drug|Pertuzumab|840mg induction, followed by 420mg every 3 weeks IV-induction over 60 minutes, then every 3 weeks over 30-60 minutes for 4 doses
1572616|NCT02436980|Drug|Tramadol|GROUP T
1572617|NCT02436980|Drug|Midazolam|GROUP M
1572618|NCT02436967|Other|Carotid endarterectomy in clinical healthcare.|For the this study itself there is no intervention caused by the extra CT or MRI. The patients are scheduled for surgery as the routine intervention to reduce the risk of a new stroke in clinical practice. The performed extra diagnostic CT and MRI in this study before surgery will compare the vessel wall images with histology regardless of the patients status or medication.
1572619|NCT02436954|Procedure|CO2 insufflation at intra-abdominal pressure 8 mmHg|
1572620|NCT02436954|Procedure|CO2 insufflation at intra-abdominal pressure 12 mmHg|
1572621|NCT02436941|Radiation|Proton or Photon|
1572622|NCT02436928|Biological|AT-501 High Dose vaccine|Comparison of each dose of vaccine
1572623|NCT02436928|Biological|AT-501 High Dose vaccine with Adjuvant|Comparison of each dose of vaccine
1572624|NCT02436928|Biological|AT-501 Low Dose vaccine|Comparison of each dose of vaccine
1572625|NCT02436928|Biological|AT-501 Low Dose vaccine with Adjuvant|Comparison of each dose of vaccine
1572628|NCT02436902|Procedure|TACE|
1572629|NCT02436902|Drug|Sorafenib|
1572630|NCT02436902|Drug|TACE plus sorafenib|
1572631|NCT02436902|Procedure|transarterial chemotherapy plus embolization|
1572632|NCT02436889|Drug|Mirabegron|
1572633|NCT02436889|Drug|Tolterodine Tartrate|
1572634|NCT02436876|Drug|MBN-101|MBN-101 is a locally administered, anti-infective drug product
1572635|NCT02436876|Other|Placebo|The placebo is comprised of the vehicle/excipients used to formulate MBN-101, but does not contain the active pharmaceutical ingredient
1572636|NCT02436863|Procedure|Surgical performance|Two different surgical performances
1572809|NCT02435563|Drug|ticagrelor 180 mg administrated alone|
1572637|NCT02436850|Procedure|Thoracentesis|An invasive procedure to remove fluid or air from the pleural space for diagnostic or therapeutic purposes.
1572638|NCT02436837|Other|sessions with virtual reality|sessions with virtual reality to improve the balance
1572639|NCT02436824|Drug|AB001 patch|Two AB001 patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
1572640|NCT02436824|Other|Placebo patch|Two placebo patches will be applied to the low back once daily for 14 days, the patches shall be removed after approximately 12 hours after daily application.
1572641|NCT02436811|Behavioral|Written form instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. Participants in writing intervention will receive a brochure containing information on diet and oral health. This leaflet was produced in accordance with the recommendations of the Ministry of Health regarding eating habits for children under two years (BRAZIL, 2002) and according to the Health Book of the Child: Growth and Development (BRAZIL, 2012).
1572642|NCT02436811|Behavioral|Standardized oral instruction|60 women aged between 12 and 50 and gestational period of up to 32nd weeks. A trained individual will present the same information arranged in the educational brochure in the intervention group on standardized oral form. This examiner will be trained in a unified way in relation to the instructions available in the form of written guidance. Thus, the only difference between the two measures is the interaction between the participant and researcher orally.
1572643|NCT02436811|Behavioral|Control|60 women aged between 12 and 50 and gestational period until 32nd weeks.The control group will receive a leaflet on oral cancer.
1572644|NCT02436798|Drug|Ondansetron|All patients will be receiving treatment with ondansetron as part of standard care.
1572645|NCT02436785|Other|Music Therapy|In-vivo relaxation where the live music is manipulated in terms of speed and intensity to bring on a state of relaxation for approximately an hour. There will be a brief therapist-led discussion before and after the relaxation portion to increase a sense of group cohesion. Procedures that will be used are based on evidence-based practice for trained Music Therapists.
1572646|NCT02436785|Other|Music Listening|Listening to relaxing music on a CD player for approximately an hour.
1572647|NCT02436759|Drug|RVL-1201|RVL-1201 Ophthalmic Solution 0.1%
1572648|NCT02436759|Drug|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
1572649|NCT02436733|Procedure|pleurectomy/decortication|Lung sparing procedures consist of the resection of the pleura without removing the lung
1572650|NCT02436733|Drug|Pemetrexed/Cisplatin|On day 1 of each cycle, pemetrexed 500 mg/m2 should be administered as IV infusion followed by cisplatin 75 mg/m2 as IV.
1572651|NCT02436707|Drug|Ibrutinib|
1572652|NCT02436707|Drug|Rituximab|
1572653|NCT02436707|Drug|Gemcitabine|
1572654|NCT02436707|Drug|Dexamethasone|
1572655|NCT02436707|Drug|Cisplatin|
1572656|NCT02436707|Drug|Mesna|
1572657|NCT02436707|Drug|Cyclophosphamide|
1572658|NCT02436707|Drug|Etoposide|
1572659|NCT02436707|Drug|G-CSF|
1572660|NCT02436694|Drug|Local Anesthetic ropivacaíne|Femoral and sciatic nerve block with ropivacaíne
1572661|NCT02436694|Drug|Perineural Dexamethasone|Addition of perineural dexamethasone to local anesthetic for femoral and sciatic nerve block
1572662|NCT02436681|Device|MIROMESH|
1572663|NCT02436668|Drug|Ibrutinib|
1572664|NCT02436668|Drug|Gemcitabine|
1572665|NCT02436668|Drug|Nab-paclitaxel|
1572667|NCT02436642|Device|AVERT Plus System|
1572668|NCT02436629|Dietary Supplement|Nitrate-rich concentrated beetroot juice|James White, Beet It Sport Shot, 70ml (Standard)
1572669|NCT02436629|Dietary Supplement|Nitrate-depleted concentrated red beetroot juice|Beet It Sport Shot, 70ml (Placebo)
1572670|NCT02436616|Device|microEEG|"microEEG is a miniature, wireless, and battery-powered EEG device used to obtain EEG recording in challenging environment. All infants have an initial EEG at study enrollment. Follow up microEEGs will be performed at approximately 2-4 week intervals, depending on the Corrected Gestational Age (CGA).
If ABD events have not resolved at 34 weeks, an 8 hour recording will be performed prior to discharge or at 42 weeks CGA, whichever comes first. EEG will be assessed in 3 hour epochs. The EEG will be reviewed off line by two blinded neurologists and classified as normal or abnormal based on CGA and other findings. Follow up EEGs will be scored similarly, with emphasis on maturation."
1572671|NCT02436603|Behavioral|Nutrition/Mind-Body Coaching|Following the four-week treatment intervention, participants will then be enrolled in an 8-week health coaching follow-up period. During this time participants will have a 45-60 minute telephone session with a health coach weekly for two weeks, then biweekly for four weeks.
1572673|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 150 mL of water|Ticagrelor 90 mg OD tablet, single dose
1572674|NCT02436577|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|Ticagrelor 90 mg OD tablet, single dose
1572675|NCT02436577|Drug|Ticagrelor IR tablet (90 mg) administered with 150 mL of water|Ticagrelor 90 mg IR tablet, single dose
1572676|NCT02436564|Genetic|Organoid in vitro culture|Generation of 'organoids' using in vitro culture techniques, genomic DNA and RNA sequencing, application of genome editing technology, investigation of anti-tumour drugs, investigation of biological and functional properties of tumour cells, transplantation of organoid lines into animal models.
1572677|NCT02436551|Other|Observation|
1572678|NCT02436538|Other|Anti Mullerian hormone level; Mullerian duct anomaly type|Diagnosis of Mullerian duct anomaly type Clinically or by Imaging Anti-Müllerian Hormone levels
1572679|NCT02436525|Device|conventional stainless steel orthodontic brackets ligated with stainless steel ligature (Oromco - USA)|
1572680|NCT02436525|Device|passive self-ligating stainless steel orthodontic brackets (Oromco - USA)|
1572681|NCT02436525|Device|active self-ligating stainless steel orthodontic brackets (Oromco - USA)|
1572726|NCT02436161|Behavioral|"Care management program PROMIC"|intensive coaching intervention to optimize care and prevent readmissions, using educational selfcare and worsening symptoms recognition by patients and carers
1572810|NCT02435563|Drug|Ticagrelor adjusted dose + ritonavir 100mg|
1572682|NCT02436512|Drug|Inhaled Nitric Oxide|"The investigational product is inhaled nitric oxide delivered via nasal cannula or venturi mask with the GeNOsylTM Delivery System or GeNOsylTM Acute DS, during RHC as follows:
(Dose 1): 5 ppm inhaled nitric oxide for 15 minutes
(Dose 2): 40 ppm inhaled nitric oxide for 15 minutes"
1572683|NCT02436499|Drug|Botulinum Toxin-A|
1572684|NCT02436486|Drug|Placebo|Capsules, orally, single dose
1572685|NCT02436486|Drug|ldalopirdine 120 mg|Two 60 mg encapsulated film-coated tablets, orally, single dose
1572686|NCT02436486|Drug|Idalopirdine 360 mg|Four 90 mg encapsulated film-coated tablets, orally, single dose
1572687|NCT02436486|Drug|Moxifloxacin 400 mg|Encapsulated tablets, orally, single dose
1572688|NCT02436473|Drug|Toothpaste containing 1150ppm F|US marketed toothpaste containing 1150ppm of F
1572689|NCT02436473|Other|Toothpaste containing 0ppm F|Experimental toothpaste containing 0ppm F
1572690|NCT02436473|Drug|Toothpaste containing 250ppm F|Experimental toothpaste containing 250ppm F
1572691|NCT02436473|Drug|Toothpaste containing 1150ppm F|Experimental toothpaste containing 1150ppm F
1572692|NCT02436460|Biological|AbGn-168H|Humanized monoclonal antibody
1572693|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with normal renal function.
1572694|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with mild renal impairment.
1572695|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with moderate renal impairment
1572696|NCT02436447|Drug|MTP-131|MTP-131 administered as once-daily 1- hour intravenous infusion for 7 consecutive days in subjects with severe renal impairment
1572697|NCT02436434|Device|pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA)|Intra-articular pulsed radiofrequency (Neurotherm NT1000, Neurotherm Inc., USA) in treated joint
1572698|NCT02436421|Other|Best Practice Alert based in the Electronic Medical Record|
1572699|NCT02436408|Drug|Vismodegib|
1572700|NCT02436395|Procedure|Group A (povidone-iodine wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with povidone-iodine wash the surgical incision
1572701|NCT02436395|Procedure|Group B (normal saline wash the surgical incision)|Gastric cancer patients underwent conventional open D2 total or subtotal gastrectomy and with normal saline wash the surgical incision
1572702|NCT02436382|Other|change in temperature|increase in ambient room temperature
1572703|NCT02436369|Dietary Supplement|low fat yogurt enriched with flaxseed|daily intake of low fat yogurt enriched with flaxseed for 8 weeks
1572704|NCT02436369|Dietary Supplement|low fat yogurt|daily intake of low fat yogurt for 8 weeks
1572705|NCT02436356|Device|Osteoprobe-RPI|Diagnostic tool used for bone indentation to measure the ability of the tissue to resist microindentation (bone mineral strength).
1572706|NCT02436356|Radiation|Dual-energy X-ray absorptiometry (DXA) Scans|Assessment of Fracture Risk
1572707|NCT02436356|Radiation|MRI|Determines bound water and pore water of bone.
1572708|NCT02436343|Other|echocardiogram|"At each echocardiographic evaluation, the investigator will obtain the following parameters:
Left ventricular internal dimensions at end diastole Left ventricular posterior wall thickness Left ventricular end systolic stress Left ventricular fractional shortening Velocity of circumferential shortening Left ventricular mass Contractility and indices of preload Stroke volume"
1572709|NCT02436330|Behavioral|Exergaming|"6 months of weight management programming consisting of 10 weekly sessions:1 hour of session was spent exergaming, which included active video game play and traditional group exercises. Some examples include: Dance, Dance, Revolution, Exerbike, Treadwall, Yoga, Spin class, etc."
1572710|NCT02436330|Behavioral|Didactic health teaching|6 months of weight management programming consisting of 10 weekly 1-hour sessions of didactic classes teaching behavioral and dietary curricula. Followed by monthly 1 hour didactic health teaching sessions for the remainder of the 6 month period.
1572711|NCT02436317|Device|Point Of Care Ultrasound|Examination with an ultrasound machine
1572712|NCT02436304|Drug|EXE844 Sterile Otic Suspension, 0.3%|
1572713|NCT02436304|Procedure|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
1572714|NCT02436291|Device|CURE-EX device|Treatment with CURE-EX device twice daily for 24-30 weeks.
1572715|NCT02436278|Other|4MGS|Usual walking speed measured over 4 metres
1572716|NCT02436265|Drug|Dexamethasone|IV dexamethasone
1572717|NCT02436265|Drug|Ropivacaine|Ropivacaine only
1572718|NCT02436252|Drug|DSP-7888|3.5-10.5 mg/body,Id every 2-4 weeks
1572719|NCT02436239|Drug|Vilazodone|Vilazodone tablets, once daily, oral administration
1572720|NCT02436226|Drug|Clomiphene citrate and Human chorionic gonadotropin (HCG)|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and HCG (200 IU/day SC from day 7 of cycle)
1572721|NCT02436226|Drug|Clomiphene citrate|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle)
1572722|NCT02436213|Other|Cardiopulmonary exercise test|"On Day 1, subjects will have the test in the Exercise Suite of Hammersmith Hospital, London, UK. They will have painless skin probes placed on their fingers, chest, and legs to monitor heart rate, ECG, blood oxygen levels, and oxygen delivery during the test. Subjects will also be shown how to breathe through a mouthpiece with a nose clip on, and how to indicate on a sliding device whether they feel breathless. They will then start cycling against a very low resistance at a steady speed. As long as they feel comfortable, there will be a gradual increase in work load until they feel they cannot keep going at the same speed. They can also stop sooner for any reason. Afterwards, while they are cooling down (within the hour on Day 1), they will fill in a short questionnaire describing how they feel."
1572723|NCT02436213|Procedure|Blood test|On same day (Day 1), the subject will have 20-30mls of blood (that is, 4-6 teaspoonful) taken for analysis.
1572724|NCT02436200|Device|Neuromuscular Electrical Stimulation|Revitive IX neuromuscular electrical stimulation device will be given to all participants as per protocol.
1572725|NCT02436174|Device|novel device|novel device being used to measure shivering
1572727|NCT02436148|Other|Prosthetic for major lower limb amputation|Prosthetic for major lower limb amputee
1998754|NCT01000883|Other|biologic sample preservation procedure|approximately 16-20 milligrams of tumor tissue per core will be obtained for research purposes.
1572730|NCT02436109|Device|Ultrasound|Parturients backs will be scanned using 3D ultrasound to measure the depth to the epidural space
1572731|NCT02436096|Drug|TNX-102 SL Tablet, 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
1572732|NCT02436096|Drug|Placebo SL Tablet|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
1572733|NCT02436083|Drug|antibiotic (use of penicilline, unacid, cefuroxime)|prophylactic antibiotics
1572734|NCT02436070|Behavioral|Targeted text messages|Subjects received text messages specific to post ED asthma follow-up
1572735|NCT02436070|Behavioral|General text messages|Subjects received text messages generalized to children with asthma
1572736|NCT02436057|Other|AEGIS (Automated Evaluation of Gastrointestinal Symptoms)|
1572737|NCT02436044|Procedure|HAIC using oxaliplatin plus fluorouracil/leucovorin|Hepatic arterial infusion chemotherapy using oxaliplatin plus fluorouracil/leucovorin
1572738|NCT02436044|Drug|Oxaliplatin|Oxaliplatin, 130mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
1572739|NCT02436044|Drug|Fluorouracil|Fluorouracil, 1-st.400mg/m2, bolus injection, on day 1,every 3 weeks 2-nd.2400mg/m2, intraarterial infusion for 46 hours, on day 1-2,every 3 weeks
1572740|NCT02436044|Drug|Leucovorin|Leucovorin, 200mg/m2, intraarterial infusion for 2 hours, on day 1,every 3 weeks
1572741|NCT02436031|Drug|Desipramine|200 mg administered 2 hours before normal sleep time
1572742|NCT02436031|Drug|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
1572743|NCT02436018|Device|WEI NASAL JET|Oxygen is supplied through WEI NASAL JET by a manual jet ventilator
1572744|NCT02436018|Device|Nasopharyngeal airway without jet ventilator|Oxygen is supplied directly through WEI NASAL JET without jet ventilator
1572745|NCT02434913|Device|SR PIP Implant System|HUD for use in arthroplasty of the PIP joint
1998755|NCT01000883|Other|laboratory biomarker analysis|Evaluation of biomarkers will occur as questions are asked in subsequent correlative studies.
1572747|NCT02434874|Device|StimGuard Sacral Nerve Stimulator System|The StimGuard Sacral Nerve Stimulator System is a wirelessly powered neurostimulator for urge urinary incontinence. This technology includes a quadripolar stimulator with an embedded receiver. The energy source is a small, external, rechargeable transmitter, which is worn by the patient. The transmitter sends the therapy program and power through the skin and to the receiver.
1572748|NCT02435992|Drug|RPC1063|
1572749|NCT02435992|Drug|Placebo|
1572750|NCT02435979|Other|hand therapy|Treatment can include stretching, motion, and strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase. Modalities for pain control and tissue mobility, and bracing or splinting if necessary. All treatments for the traditional hand therapy treatment group will occur seated at the hand therapy treatment table.
1572751|NCT02435979|Other|Proximal Strengthening|Patients will perform a standardized proximal strengthening protocol consisting of cervical, periscapular, and shoulder strengthening exercises. Depending on the pace and guidance needed for these exercises 25-30 minutes will be spent on proximal strengthening exercises. As the patients endurance and strength increased the repetitions and/or resistance of these exercises will increase.
1572752|NCT02435966|Device|Dry needling|Dry needling of the most active trigger point either in the upper trapezius or the levator scapulae with 40mm x 0,32mm ener-qi guided needles (EQ1132)
1572753|NCT02435966|Device|Sham Dry needling|Sham Dry needling with a retractile needle (Park Sham Placebo Acupuncture Device) of the most active trigger point either in the upper trapezius or the levator scapulae
1572754|NCT02435966|Other|Manual therapy|Standard manual therapy in the upper trapezius or the levator scapulae
1572755|NCT02435953|Procedure|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
1572756|NCT02435953|Procedure|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
1572757|NCT02435927|Drug|ASLAN001+ CAPOX (Oxaliplatin, capecitabine)|ASLAN001 in combination with oxaliplatin and capecitabine
1572758|NCT02435927|Drug|ASLAN001 + mFolfox6 (5-FU, leucovorin)|ASLAN001 in combination with 5-FU and leucovorin
1572759|NCT02435914|Drug|AGN-223575 ophthalmic solution|AGN-223575 ophthalmic solution once or twice daily
1572760|NCT02435914|Drug|AGN-223575 vehicle ophthalmic solution|Vehicle to AGN22375 ophthalmic solution once or twice daily.
1572761|NCT02435901|Drug|alemtuzumab (Campath IH)|Alemtuzumab (Campath IH) is given daily over first 4 days, Day -20 to Day -17
1572762|NCT02435901|Drug|Fludarabine|Fludarabine 35/m2 is given daily over 4 days on Day -7 to Day -4.
1572763|NCT02435901|Drug|Melphalan|Melphalan 70mg/m2 is given daily over 2 days on Day -3 to Day -2.
1572764|NCT02435901|Drug|Cyclosporine|Immunosuppressant to prevent graft vs host disease is given on Day -1 prior to stem cell infusion
1572765|NCT02435901|Drug|Mycophenolate mofetil|Immunosuppresant to prevent graft vs host disease is given on Day -1.
1572766|NCT02435901|Drug|Tacrolimus|Immunosuppresant to prevent graft vs host disease is given Day -1 prior to stem cell infusion
1572767|NCT02435901|Biological|Hematopoietic Stem Cell Transplantation|Human Leukocyte Antigen (HLA) matched or mismatched; related or unrelated hematopoietic stem cells to be transplanted on Day 0.
1572769|NCT02435862|Drug|1.0mg Luminate®|
1572770|NCT02435862|Drug|2.0mg Luminate®|
1572771|NCT02435862|Drug|3.0mg Luminate®|
1572772|NCT02435862|Other|Balanced Salt Solution for intravitreal injection in 0.10cc|
1572773|NCT02435849|Biological|Single dose of CTL019|2 to 5 x 10(6) autologous CTL019 transduced cells per kg body weight, with a maximum dose of 2.5 x 10(8) autologous CTL019 transduced cells via intravenous infusion.
1572774|NCT02435836|Drug|Aripiprazole|
1573085|NCT02433106|Other|Control|Usual training
1572775|NCT02435823|Device|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
1572776|NCT02435797|Drug|Nicorandil|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Subjects in the NicorandilGroup were then given 2 mg intracoronary nicorandil through the lesions via thrombus aspiration catheter, and an additional intracoronary dose of 2 mg nicorandil before stent implantation. A minimum 5-min interval occurred between the first and second doses of nicorandil to reduce adverse effects.
1572777|NCT02435797|Drug|normal saline|All patients received antiplatelet agents (aspirin, ticagrelor) and heparin.Diagnostic coronary angiography (CAG) was performed via the right (or left) femoral artery or radial artery using the Seldinger method.The guidewire was passed into the culprit lesion. Normal saline in the Placebo Group were then given 2 ml through the lesions via thrombus aspiration catheter,and an additional intracoronary dose of 2 ml before stent implantation. A minimum 5-min interval occurred between the first and second injection.
1572778|NCT02435784|Other|The Two-Way Communication Checklist|The Two-Way Communication Checklist (2-COM) is a communication tool developed by Van Os et al. (2002). It aims to provide an opportunity for patients to voice their needs and problem to minimize the discrepancy and miscommunication between patient and professional carer. 2-COM questionnaire was designed to give patients while they are waiting for consultation. Patients can either tick yes or no in the questionnaire to decide which the perceived problems are and which needs they want to discuss with the clinician. During the consultation, the ticked items would be discussed.
1572779|NCT02435784|Other|Treatment as usual|Patients will attend a psychiatric consultation as usual.
1572780|NCT02435771|Drug|Ergocalciferols|Treatment 1- 400,000 IU
1572781|NCT02435771|Drug|Ergocalciferols|Treatment 2- 800,000 IU
1572782|NCT02435758|Procedure|Preservation of Denonvilliers Fascia during L-PANP surgery|In this group, the patients accept L-PANP surgery, as well as preservation of Denonvilliers Fascia
1572783|NCT02435732|Drug|Placebo saline solution|saline solution
1572784|NCT02435732|Drug|Heparin|Added to the one of the arms receiving 200U/kg dose of CINRYZE
1572785|NCT02435732|Drug|CINRYZE|200U/kg IV dose with or without heparin, or 500U/kg IV dose
1572786|NCT02435706|Procedure|Flapless immediate implant placement|No elevation of flap prior to immediate implant placement
1572787|NCT02435706|Procedure|Flap assisted immediate implant placement|Flap will be elevated prior to immediate implant placement
1572788|NCT02435706|Device|Implant and temporary crown|Standard intervention/procedure (non-experimental)
1572789|NCT02435693|Other|PHARMACEUTICAL CARE programe|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
1572790|NCT02435693|Other|Without PHARMACEUTICAL CARE programe|
1572791|NCT02435680|Drug|MCS110|taken by I.V
1572792|NCT02435680|Drug|carboplatin|taken by I.V
1572793|NCT02435680|Drug|gemcitabine|taken by I.V
1572794|NCT02435667|Other|Resistance Exercise Training|"Aerobic Exercise
a. Each participant will engage in 5 minutes of aerobic based exercise on an arm/leg ergometer (NuStep Cross Trainer) at an intensity of 12-14 on the Borg Rating of Perceived Exertion Scale as a warm-up prior to the exercise session and again as a cool-down at the end of the exercise session.
Resistance Exercise - 2 sets of 8-12 repetitions - beginning at 60% of the initial 1 RM.
a) Leg Extension, b) Bicep Curl, c) Leg Press, d) Chest Press, e) Leg Curl, f)Seated Row (horizontal or pulldown), g) Calf Raises
Core Strengthening Exercises a. 5-10 minutes of stability ball and balance exercises"
1572795|NCT02435667|Radiation|DEXA bone scan|A DEXA scan that provides bone density measures.
1572796|NCT02435667|Other|Cardiopulmonary Max Exercise Test|Pedaling on a cycle ergometer to volitional fatigue.
1572797|NCT02435667|Other|Quality of Life Questionnaire|A 10 minute questionnaire that measures quality of life.
1572798|NCT02435667|Other|Submaximal Exercise Test|Two short submaximal constant-load exercise sessions at 20 Watts. Each session will include 6 minutes of cycling (baseline). Following baseline, the sessions will be randomized to continued constant-load cycling for an additional 9 minutes (for echocardiographic measures) or randomized sub-systolic inflation of bilateral thigh pressure tourniquets to 40 and 80 mmHg for 3 minutes with 3 minutes of deflation between inflations to stimulate locomotor muscle neural feedback.
1572799|NCT02435667|Other|Blood Draw|A blood draw amounting to 1 teaspoon of blood drawn.
1572800|NCT02435654|Drug|olanzapine|olanzapine will be initiated at 2.5 or 5 mg/day according to patient's weight, and the dose could be increased by 2.5 or 5 mg every 4-7days at the investigator's discretion.A effective dose would be titrated in two weeks with no tolerability or safety issues are apparent,
1572801|NCT02435641|Other|Questionnaires|All subjects (patients and caregivers) will complete a battery of psychological questionnaires at baseline (ICU admission), 3 months post-baseline, and 6 months post-baseline.
1572802|NCT02435628|Other|Questionnaires|All subjects will complete baseline psychological assessments prior to their medical visit. Upon completion of their routine medical visit, subjects will complete a post-test assessment measuring their satisfaction with the visit.
1572804|NCT02435602|Procedure|NBI endoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with NBI endoscopy Biopsy at the visually abnormal lesions
1572805|NCT02435602|Procedure|Lugol chromoendoscopy|GI endoscopy examination and additional the entire length of esophagus is evaluate with Lugol chromoendoscopy Biopsy at the unstained lesions >= 5 mm diameter Pathologic examination of all biopsy tissue specimens
1572806|NCT02435589|Other|Systematic pain assessment|Systematic assessment of pain twice daily with the use of 2 different behavioral pain tools (Behavioral Pain Scale - BPS, and Critical Care Pain Observation Tool - C-POT) for non-communicative patients and Numerical Rating Scale (NRS) 1-10 for communicative patients.
1572807|NCT02435589|Other|Notification of results of assessments|Pain assessments will be carried out by independent investigators who will notify the results to ICU nurses and physicians and observe and document their reaction
1572811|NCT02435550|Genetic|Molecular diagnostic testing|Molecular diagnostic testing will be performed on peripheral blood, bone marrow aspirate and saliva samples that will be collected from each patient as part of routine care. Tests performed may include: cytogenetics, FISH, chromosome copy number variation, next generation DNA sequencing, methylation, and metabolomics.
1572812|NCT02435537|Drug|Dexmedetomidine (Precedex)|intrathecal administration
1572813|NCT02435537|Drug|Bupivacaine|intrathecal 10 mg bupivacaine
1572814|NCT02435537|Drug|Morphine|intrathecal 0.5mg morphine
1572815|NCT02435524|Behavioral|A&T infant and young child feeding intervention|"Interpersonal communication delivered by community workers and volunteers during home visits and at monthly mother's group meetings to:
Increase mother's knowledge about optimal breastfeeding and its benefits
Increase mother's self-efficacy related to breastfeeding
Improve mother's perceptions about social norms relating to breastfeeding
Community mobilisation activities to:
- Raise awareness of the benefits of optimal breastfeeding among opinion leaders, and family members, and increase the support they provide to breastfeeding mothers
Enhanced training of government health workers in infant and young child feeding to:
Improve their ability to support mothers and provide timely information about infant feeding"
1572816|NCT02435511|Other|HealtheRx|The HealtheRx is an informational intervention. The HealtheRx is generated and administered at the point of care. It includes a list of community resources, tailored to a patient's needs based on diagnoses, that are located near the patient's home. A health care provider and/or administrative staff administers and reviews the HealtheRx with the patient.
1572817|NCT02435498|Other|Interactive website|The interactive website called Online User Centered Home Pain Management for Fractures (OUCH PMF) will cover 4 domains of knowledge: 1. Fracture-related pain 2. Analgesic dosing regimens 3. Indications, risks and safety of analgesia in children 4. Signs and symptoms of pain in children
1572818|NCT02435498|Other|Video|The online video will contain the same information within the website.
1572819|NCT02435498|Other|Standard of care|Standard of care includes a pamphlet with cast care instructions and verbal instructions on caring for the child at home.
1572820|NCT02435485|Device|Biodex balance training|1.weight shift training, 2. random control training with Biodex balance system.
1572821|NCT02435485|Other|Rehabilitation including core spinal stabilization exercise|Rehabilitation: 2-3 times a week, up to 8 weeks, 15 sessions in total. Each session will include hot packing, interferential therapy, core spine stablilzation exercise and low extremity strengthening exercise.
1572822|NCT02435472|Behavioral|Exercise|This Phase 2, open-label, dual-center, two-arm randomized controlled trial (RCT) will investigate the effects of 16 weeks of structured aerobic training, relative to usual care (print material with physical activity guidance) in 76 men with histologically confirmed low-risk prostate adenocarcinoma on active surveillance. The only investigational therapeutic agent being tested in this trial is a behavioral intervention in the form of aerobic training.
1572823|NCT02435459|Procedure|No lining|No lining material placed under amalgam dental restorations
1572824|NCT02435459|Procedure|Calcium Hydroxide cement|placement of lining material under amalgam dental restorations
1572825|NCT02435459|Procedure|RMGI cement|placement of lining material under amalgam dental restorations
1572826|NCT02435459|Procedure|Resin Bonding Agent|placement of lining material under amalgam dental restorations
1572827|NCT02435446|Device|Cone-beam computed tomography|Cone-beam computed tomography
1572830|NCT02435420|Device|EMPERION Modular Primary Stem|Primary total hip arthroplasty using the EMPERION Modular Primary Stem
1572831|NCT02435407|Behavioral|SOS|Ten (10) children will be randomized to participate in the SOS intervention arm. The intervention will be divided into two groups of 5 children with 2 therapists assigned. The children will attend 1 hour intervention sessions once a week for 12 weeks. Here they will be introduced to different types of foods that they would not have typically eaten in a play based group session. The SOS intervention utilizes the principle of hierarchal desensitization.
1572832|NCT02435407|Other|Education|Parents will be given three 1 hour educational talks around the aetiology and management of feeding difficulties in children with autism spectrum disorder. This will be administered at 3 distinct time points; baseline, week 6 and week 12 of the study.
1572833|NCT02435394|Behavioral|Remote Coach plus Asthma Module|The intervention is for a remote coach to assist patients with asthma for practices which will use Asthma module for guidance for asthma care.
1572834|NCT02435394|Behavioral|Asthma Module- No Coach|The intervention is for practices to use the Asthma module for guidance for asthma care without assistance by a remote coach.
1572835|NCT02435394|Behavioral|CHADIS- no Asthma Module|The practices will use the general CHADIS tool without access to the Asthma Module add-on to assist in asthma care.
1572836|NCT02435381|Drug|Carisbamate|600mg Orally on days 2-4
1572837|NCT02435381|Drug|Placebo|Placebo treatment only
1572838|NCT02435368|Drug|mycophenolic acid|Monocytes were co-cultured with LPS and/or MPA.After 12 hours, the supernatants were harvested and stored at -80°C for ELISA.
1572839|NCT02435355|Behavioral|telephone-based counselling|The objective of the first session was to assess the patient's knowledge about the disease, device and health consequences. The importance of good adherence was emphasized, encouraging the patients to use the CPAP device throughout sleep every day. Objectives of the other educational sessions were first to identify disadvantages or obstacles to follow CPAP treatment and then focus on the benefits linked to use of CPAP. A particular effort was made to discuss misconceptions about sleep apnea and barriers to use, concerns fears and beliefs, as well as the perceptions of their partners and family, in order to increase patients' positive expectations regarding CPAP benefits.
1572840|NCT02435342|Drug|dalazatide|Subcutaneous injection twice per week for a total of 9 doses, followed by four weeks of follow-up.
1572841|NCT02435342|Drug|placebo|placebo, Subcutaneous injection twice per week for a total of 9 doses
1572842|NCT02435329|Other|Baseline comparison of microcirculation and bone metabolism|Baseline comparison of microcirculation and bone metabolism among the 5 different groups
1572978|NCT02433925|Dietary Supplement|Resveratrol|
1572979|NCT02433925|Dietary Supplement|Placebo|
1572843|NCT02435316|Other|Case vignette-based teaching of cell recognition|Intervention group members will be taught peripheral blood smears by using power point slides and utilizing additive microskills using the compare/ contrast technique to recognize various cell types. Memory will be reinforced by using cases to help recognize the clinical importance of learning about individual cell types.
1572844|NCT02435316|Other|Compare-contrast basic science teaching of cell recognition|The control group will be given a traditional 60-minute lecture using board review questions with accompanying pictures of peripheral blood smears, without explaining individual cell type.
1572845|NCT02435303|Drug|Sildenafil|
1572846|NCT02435303|Drug|Placebo|
1572847|NCT02435290|Behavioral|determine the incidence , type , and severity of prescribing errors in the oncology department|"patients' files are revised according to BCCA reference protocols to report errors which are categorized according to type,and severity including: BSA calculation, the eligibility of the chemotherapy protocol , the dosage form ,dosage , the modification of doses according to toxicity and laboratory data results ,frequency ,duration of treatment , intention of treatment , the omitted or duplicated medications ,and the drug interactions.
the impact of the risk factors on the incidence , and type of prescribing errors are studied including :The tumor type, Cancer stage , co morbid illness,The number of drugs in the treatment regimen ,The route of administration of chemotherapy ,Dosing Frequency of treatment, The toxicity of chemotherapy experienced by the patient, The number of abnormal lab data,The type of abnormal lab data ,the age of patient."
1572852|NCT02435264|Other|Healthier Dining Program Intervention|The food environment at the intervention centers will be modified to increase the availability of healthier foods and low calorie meals.
1572853|NCT02435251|Device|dual energy X-ray absorptiometry|
1572854|NCT02435225|Behavioral|Mindfulness Based Stress Reduction for Teens Group|A 12-Week weekly group intervention to train adolescents in mindfulness practice
1572855|NCT02435212|Drug|Deferasirox granule formulation|Deferasirox granules will be provided as stick packs containing 90 mg, 180 mg and 360 mg granules for oral use.
1572856|NCT02435212|Drug|Deferasirox DT formulation|Deferasirox DT will be provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use
1572857|NCT02435199|Drug|EMA401 600mg|
1572858|NCT02435199|Drug|Placebo|
1572859|NCT02435186|Drug|p53 gene|p53 gene will be given intraperitoneally.
1572860|NCT02435186|Drug|Cisplatin|150 mg/m^2 cisplatin will be given intraperitoneally.
1572861|NCT02435186|Drug|Paclitaxel|Paclitaxel (175 mg/m2, 3 h) will be given by iv
1572862|NCT02435173|Drug|CDZ173|up to 140 mg per day
1572863|NCT02435160|Biological|Fecal Microbiota Transplantation|
1572865|NCT02435134|Other|no intervention|
1572866|NCT02435121|Drug|SAR125844|Pharmaceutical form:Concentrate for solution Route of administration: intravenous
1572867|NCT02435108|Drug|crizotinib|crizotinib 250mg bid daily
1572868|NCT02435095|Drug|Maintenance treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) for at least 12 months.
All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
1572869|NCT02435095|Drug|Intermittent treatment|"Treatment with antipsychotic drug (either second-generation antipsychotics or low-dose first generation antipsychotics) only for first episode of schizophrenia, tapering-off medication after remission of positive symptoms, reinstatement of treatment only in case of recurrence of positive symptoms.
All antipsychotics approved in Germany are permitted (amisulpride, aripiprazole, benperidol, bromperidol, chlorprothixene, clozapine, flupentixole, fluphenazine, fluspirilene, haloperidol, levomepromazine, loxapine, lurasidone, melperone, olanzapine, paliperidone, perazine, perphenazine, pimozide, pipamperone, prothipendyl, quetiapine, risperidone, sertindole, sulpiride, thioridazine, ziprasidone, zuclopenthixole)."
1572870|NCT02435069|Drug|NS and USP Glycerin - Dose Response|This trial uses a repeated measures, single subjects alternating treatments A-B-C-Bʹ-Cʹ-B1ʹ withdrawal design in which all subjects are tested under all conditions and each subject acts as his or her own control. The subjects will be randomly assigned to either normal saline or USP glycerin to control for order effects. Baseline data A will serve as the control and will be obtained pre-operatively. This arm will evaluate dose-response relationship and will be used to identify the minimum dosing volume and frequency while promoting fecal continence of ACE administration for NS and USP glycerin. When the optimal dose has been identified, the child will continue on that dose for 2 weeks to insure treatment stability and effectiveness.
1572871|NCT02435069|Drug|NS and USP Glycerin - Effectiveness|To prevent statistical bias from subject loss due to treatment failure, each child will be randomized to a second treatment sequence once they have achieved continence on optimal dosing with minimal side effects. The second phase Bʹ-Cʹ-B1ʹ of the study will compare the two regimens at optimal dose and administration frequency. This phase will establish the effectiveness of NS and USP Glycerin on degree of continence, procedural time, side effects, parent/patient satisfaction, colonic microbiota, and gut mucosal health
1572872|NCT02435056|Other|IEPR Approach|"Adoption of Interactive Electronic Patient Record (IEPR) that consists of the following clinically-relevant main components:
Minimum Data Set for supporting the diagnosis
Electronic Diary with associated alerting system for monitoring the patient during the follow-up period
Second opinion system for improving the management"
1572933|NCT02434471|Device|Respiratory-triggered T1w DISCO LAVA|"The study will acquire extra image sets using DISCO LAVA with one breath hold during the arterial imaging phase. No additional breath holds will be required.
Respiratory-triggered T1w DISCO LAVA precontrast
Respiratory-triggered T1w DISCO LAVA in the portal venous phase
Respiratory-triggered T1w DISCO LAVA in the equilibrium phase"
1572873|NCT02435043|Other|Nature based rehabilitation|ten weeks of nature-based rehabilitation, as add-on to standard management. A rehabilitation program in groups up to 8 patients in an especially designed garden at the Swedish University of Agricultural Sciences, Alnarp. The intervention was grounded in environmental psychology and occupational therapy, supported by a multimodal rehabilitation team that utilized the garden/nature for sensory stimulation, body awareness, meaningful occupations and nature experiences.
1572874|NCT02435043|Other|standard management after stroke|standard management after stroke is individualised.
1572875|NCT02435004|Device|Spinal Modulation Axium™|"The participants will undergo implantation of electrodes for stimulation of fuor dorsal ganglia (Spinal Modulation, Inc., Menlo Park, CA, USA). Each participant will have one to four electrodes positioned according to the individual distribution of pain in the extremities. After implantation the electrode will be connected to an external neurostimulator: Spinal Modulation Axium™ for 3-30 days to evaluate their effectiveness (test stimulation).
If during the trial treatment the pain will decrease significantly (> 50%) a neurostimulator will be 'implanted for the continuation of the permanent neurostimulation. The neurostimulator is implanted in the abdomen in a subcutaneous pocket."
1572876|NCT02434991|Device|Barostat|"During this study, the investigators will ask you to fill out questionnaires about your swallowing, chest pain, and heartburn. The investigators hope the patient will answer all of the questions, but patients can skip any questions they do not want to answer. The questionnaires will take about 15 minutes to complete.
A urine pregnancy test for females of childbearing years.
Patients will be asked to fast overnight (nothing to eat or drink for 8 hours) prior to the barostat test.
At this point healthy controls have completed the study.
Patients with achalasia will then undergo treatment for achalasia at the discretion of the primary clinician managing their case.
Patients will be contacted to complete a phone survey 3 & 6 months and 2 & 4 years after treatment."
1572877|NCT02434978|Device|Supplementary endoscopy with doppler-guided therapy|Patients randomized to supplementary doppler-guided therapy undergo repeat endoscopy with doppler evaluation within 24 hours from the primary endoscopy. At the control endoscopy the ulcer base is examined using a doppler device. If active doppler flow is demonstrated the ulcer is treated with a thermal probe until a control doppler-scan is negative. All patients are observed for rebleeding at a specialized GI-bleeding unit.
1572878|NCT02434978|Drug|IV. PPI|All patients receive 80mg of Esomeprazole iv as a bolus followed by 8mg Esomeprazole per hour for 72 hours.
1572879|NCT02434978|Other|Endoscopic treatment at primary endoscopy|All patients are initially treated with endoscopic therapy using a minimum of two different treatment modalities. The primary endoscopy is performed wihtin 24 hours from time of admission to hospital
1572880|NCT02434965|Drug|HPDSC|Autologous HPDSC collected after birth will be infused in aliquots. one-half of the HPDSC infused on Day 2; one-half of the collected HPDSC will be infused on Day 8.
1572881|NCT02434965|Drug|Cord blood|Autologous Cord Blood collected after birth will be infused in aliquots. One-third of the collected cord blood will be infused within the first 24 hours after birth (Day 0); one-third of the collected cord blood will be infused on day 3; and one-third of the collected cord blood unit will be infused on Day 7.
1572882|NCT02434952|Drug|Dihydroartemisinin piperaquine (DHA PP)|
1572883|NCT02434952|Drug|Primaquine|
1572884|NCT02434939|Drug|Low dose ketamine|Children in this arm shall receive a slow infusion of ketamine at a sub-anesthetic dose and monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
1572885|NCT02434939|Drug|Morphine|Children in this arm shall receive intravenous infusion of morphine at analgesic dose and then monitored for pain, vital signs and side effects for 2 hours. Records will be taken at 5, 10, 20, 40, 60, 80, 100 and 120min.
1572886|NCT02434861|Drug|Rolapitant|
1572887|NCT02434861|Drug|Digoxin|P-gp substrate
1572888|NCT02434861|Drug|Sulfasalazine|BCRP substrate
1572889|NCT02434861|Drug|Cooperstown Cocktail|Midazolam, omeprazole, warfarin, caffeine, and dextromethorphan
1572890|NCT02434848|Drug|Engerix B|"Engerix B 20 micrograms/1ml Licensee: GlaxoSmithKline UK Intra-muscular
Prescription and administration:
The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.
Shelf life and storage The product must be kept refrigerated (2°C - 8°C). Prescriptions will be written and dispensed from pharmacy on the day of consent, screening and vaccination. The shelf life is 3 years."
1572891|NCT02434848|Drug|Fendrix|"Fendrix suspension for injection GlaxoSmithKline UK
Route of Administration, dose regimen:
Intra-muscular Dose: 0.5ml (20mcg of Hepatitis B Surface Antigen) per vaccination at baseline and weeks 4, 8 and 24.
Prescription and administration:
The vaccine will be stored in the Investigators pharmacy as clinical trial stock and dispensed on a subject by subject basis.
Packaging and labeling The vaccine will have clinical trial labeling. Shelf-life and storage The product must be kept refrigerated (2°C - 8°C).
The shelf life is 3 years."
1572892|NCT02434835|Drug|[14C]KWA-0711|
1572893|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
1572894|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
1572895|NCT02434822|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
1572896|NCT02434809|Procedure|Bronchoscopic Implantation|Calypso transponders
1572897|NCT02434809|Device|Cone-Beam CT-Guided|
1572898|NCT02434809|Radiation|stereotactic body radiation treatments|
1572899|NCT02434796|Behavioral|Male Peer Groups|In Intervention Arm 1, male partners participate in male peer group workshops on gender norms, IPV and HIV prevention. Men's peer groups address gender inequality and transformation of gender power relations, positive masculinities and accountability of men in the perpetration of violence against women. This intervention aims to improve knowledge and attitudes among men about the harms of IPV on women, men and children; the confidence to internalize positive masculine ideals and to challenge gender stereotypes; and the ability to formulate positive outcome expectations regarding IPV and healthy relationships with their spouses and communities. Male peer group workshops will be conducted as a series of four workshops for a total of 24 hours spread out over a 5-month period.
1572934|NCT02434432|Behavioral|music therapy selected by mothers|mothers' choice of music
1572935|NCT02434432|Behavioral|Music therapy recorded lullaby|recorded lullaby
1574062|NCT02426190|Device|Anti-gravity treadmill|
1572900|NCT02434796|Behavioral|Male Peer Groups and Community Dialogues|Men participate in male peer group workshops as in Intervention Arm 1. In addition, village level community leaders engage in community mobilization/sensitization activities that include women members of savings groups and their male partners who participate male peer groups. Community dialogues focus on gender norms, IPV and HIV prevention. First, a one-day workshop for community leaders on topics similar to those raised in male peer group sessions. Second, trained community leaders facilitate community dialogues on IPV, HIV prevention, and gender norms with savings groups members and their male partners who participate in male peer groups. Each workshop will be a day-long event.
1572901|NCT02434770|Biological|TiantanBio bOPV lot 1|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 CCID50/dose and 105.8 CCID50/dose, respectively
1572902|NCT02434770|Biological|TiantanBio bOPV lot 2|Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 CCID50/dose and 105.8 CCID50/dose, respectively
1572903|NCT02434770|Biological|Bivalent Type 1 & 3 Oral Poliomyelitis Vaccine (BioFarma)|Each dose of tOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 106 and 105.8 infective units per dose, respectively
1572904|NCT02434757|Drug|H.P. Acthar Gel|Acthar 40 U given SC daily for 7 days. Depending on the response and the Investigator,Acthar 40 U will continue Acthar 40 U 2x per week or increase to Acthar 80 U daily for 7 days followed by 2x per week
1572905|NCT02434744|Drug|KD026|Dosed in combination
1572906|NCT02434744|Drug|Placebo|Dosed in combination
1572907|NCT02434744|Drug|Metformin|Drug prescribed by each subject's prescribing physician
1572908|NCT02434731|Device|Buzzy® device|Buzzy® is a battery-powered device for venipuncture pain relief combining cold, vibration, and distraction.
1572909|NCT02434718|Drug|Aducanumab|As described in the treatment arm
1572910|NCT02434718|Drug|Placebo|IV administration of 0.9% sodium chloride
1572912|NCT02434692|Device|ARGOS-IO system|Implantation of ARGOS-IO pressure sensor after cataract surgery on day 0 (V01)
1572913|NCT02434666|Drug|CPC-201|
1572914|NCT02434653|Other|Monitoring hemoglobin levels following anemia associated symptoms|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to patients with symptoms consistent with anemia, severe postpartum hemorrhage or hemoglobin level below 8 g/dL.
1572915|NCT02434653|Other|Monitoring hemoglobin levels to detect anemia by screening of women at increased risk for post partum anemia|Post-partum anemia will be diagnosed after vaginal delivery by taking hemoglobin levels to high risk women for post-partum anemia, defined as hemoglobin levels of 10.5 g/dl or below around delivery, or severe postpartum hemorrhage with or without symptoms associated with anemia
1572916|NCT02434640|Drug|BAY1128688|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
1572917|NCT02434640|Drug|Placebo|Part A: Single dose and multiple dose for 14 days (postmenopausal women)
1572918|NCT02434640|Drug|BAY1128688|Part B: Multiple dose for 28 days (premenopausal women)
1572919|NCT02434627|Drug|Sodium Nitrate|Patients will be given sodium nitrate daily in the form of beetroot juice.
1572920|NCT02434614|Drug|Docetaxel,Cisplatin,Fluorouracil|Induction chemotherapy: patients receive 60 mg/m2 docetaxel intravenously on day 1, 60 mg/m2 cisplatin intravenously on day 1, and 600 mg/m2/d fluorouracil as a continuous infusion on days 1-5; three cycles were administered at intervals of 3 weeks.
1572921|NCT02434614|Radiation|Intensity-modulated radiation therapy (IMRT)|IMRT is given as 2.0-2.3 Gy per fraction with five daily fractions per week for 6-7 weeks, Cumulative doses were > 66 Gy to the primary tumor and > 50 Gy to the bilateral cervical lymph nodes and potential sites of local infiltration.
1572922|NCT02434614|Drug|Cisplatin|Concurrent chemotherapy: patients received weekly intravenous cisplatin at 30 mg/m2 for 6-7 weeks.
1572923|NCT02434601|Procedure|Treatment of Dentin Surface|"Experimental Group 1: Increase the etching time to 30 seconds, performed with phosphoric acid gel at 37%, prior to application of the resin adhesive.
Experimental Group 2: Prophylaxis cavity probe / blunt tip of ultrasound, applied for 30 seconds on the dentin surface hypermineralized of cervical lesions non-carious.
Both restorative procedures were performed using a conventional adhesive system and composite restorative nanoparticulate."
1572924|NCT02434601|Procedure|Dentin Surface|Treatment of Dentin Surface: Increased etching dentin for 15 seconds to 30 seconds
1572925|NCT02434601|Procedure|Treatment|Treatment of Dentin Surface: Intervention with the cavity prophylaxis probe ultrasound blunt applied for 30 seconds in Surface hypermineralized non-carious dentin cervical lesions. Therefore, the restoration was done following the protocol recommended by the manufacturer of the material.
1572926|NCT02434588|Device|Bhattacharjee ring|Insertion of a Bhattacharjee ring to stabilise the pupil during cataract surgery
1572927|NCT02434562|Other|Serum (with or without urine) samples|
1572928|NCT02434549|Drug|Dysport®|Intramuscular injections in spastic muscle with regional muscle-related pain
1572929|NCT02434549|Drug|Normal saline|Intramuscular injections in spastic muscle with regional muscle-related pain
1572930|NCT02434523|Drug|Amitriptyline|Subjects in this arm will receive pills composed of amitryptline and Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
1572931|NCT02434523|Other|Placebo|Subjects in this arm will receive pills composed of only Avicel (cellulose filler), starting at 12.5mg nightly, and allowed to increase daily dose by 12.5mg with each subsequent week after enrollment if symptoms not resolved and no adverse effect noted at prior dose, up to maximum dose of 50mg nightly. Treatment duration is 8 weeks
1998756|NCT01000883|Procedure|biopsy|cancer tissue will be taken from the primary breast cancer site as well as the metastatic tumor sites. Two tubes of whole blood will also be collected.
1572936|NCT02434419|Device|PENS|The participants underwent one 30-min session every week for 12 consecutive weeks. PENS was delivered by a needle electrode inserted in the medioclavicular line, 2 cm below the clavicle at a 90° angle towards the skin at a depth of approximately 1 cm. PENS was undertaken at frequency of 20 Hz at the highest amplify (0-20 mA) without causing pain. PENS was delivered simultaneously in both pectoral muscles.
1572937|NCT02434419|Other|Specific training|Patients underwent specific training exercises to improve pectoral fitness.
1572938|NCT02434406|Behavioral|internet-What Am I Worried About|This web-based intervention consists of three sections: 1) Is this for me? 2) Practice 3) Understanding. The three main sections are divided up into nine sessions. Participants will get access to the program for eight weeks and can access the sessions more than once. Sessions are made up of multimedia presentations and worksheets that are completed online.
1572939|NCT02434380|Dietary Supplement|Euro D|Vitamin D3 Euro D 10,000 IU (1 tablet) plus Euro D Placebo (1 tablet) weekly, alternating with Euro D Placebo (2 tablets) weekly, starting at the second trimester and continued until delivery.
1572940|NCT02434380|Dietary Supplement|Euro D|Vitamin D3 Euro D 10,000 IU (2 tablets, equivalent to 20,000 IU) weekly, starting at the second trimester and continued until delivery.
1572941|NCT02434367|Behavioral|Walk With Ease Arm A|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The interention is a self directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes per day, five days per week.
1572942|NCT02434354|Drug|pembrolizumab|200 mg Subjects will receive 1 dose of neoadjuvant pembrolizumab, followed by complete resection and then a year of adjuvant pembrolizumab
1572943|NCT02434328|Drug|RTH258 solution for IVT injection|Administered as a 6 mg/50 µL dose
1572944|NCT02434328|Drug|Aflibercept solution for IVT injection|Administered as a 2 mg/50 µL dose
1572945|NCT02434315|Device|FreeStyle Libre Pro 4 sensor wears, 2 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 2 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
1572946|NCT02434315|Device|FreeStyle Libre Pro 6 sensor wears, 4 with reviews|Subjects will wear the FreeStyle Libre Pro System for 14 days. 4 period of FreeStyle Libre Pro Sensor wear for data review followed by 2 further periods of Sensor wear for time in range measurement with 28 day interval between wears.
1572947|NCT02434315|Device|FreeStyle Libre Pro 3 sensor wears|Subjects will wear the FreeStyle Libre Pro System for 14 days. 3 periods of Sensor wear for time in range measurement over a period of approximately 8 months.
1572948|NCT02434289|Dietary Supplement|Dietary protein products|Increased protein intake via dairy products, guided by a dietician.
1572949|NCT02434289|Other|Resistance exercise training|Resistance exercise training in small groups for twelve weeks, two times a week, guided by physiotherapists.
1572950|NCT02434276|Biological|VAX2012Q|Recombinant influenza hemagglutinin (HA) vaccine consisting of two influenza A subtypes and two influenza B lineages
1572951|NCT02434276|Biological|Fluzone Quadrivalent|Fluzone Quadrivalent (Influenza Vaccine)
1572952|NCT02434263|Device|Hydra TAVI|Percutaneous Replacement of the Diseased Aortic Valve
1572953|NCT02434250|Procedure|Selective Laser Trabeculoplasty|Selective Laser Trabeculoplasty is a laser treatment procedure to enhance trabecular aequous humor outflow and thus decrease intraocular pressure.
1572954|NCT02434224|Procedure|Music Therapy|2 to 3 sessions per week of individualized creative music therapy
1572955|NCT02434211|Other|Questionnaire and focus group|
1572956|NCT02434172|Other|Pre-emptive screening and treatment for cryptococcal disease|Preemptive screening for cryptococcal disease among individuals with CD4 counts below 100 cells/mm3 with anti fungal therapy for those what are Cryptococcus antigen positive. These participants will be followed longitudinally for 12 months to determine clinical outcome, with their outcome compared with similar patients who are cryptococcal antigen negative, who will also be followed longitudinally for 12 months.
1572957|NCT02434159|Other|Heart scan|
1572959|NCT02434133|Procedure|Blood Draw/Data Collection|Participation will involve an extra 8ml tube of blood and a review of their medical records for medications and immunization history.
1572960|NCT02434107|Procedure|Completion Lymphadenectomy|
1572961|NCT02434107|Procedure|Clinical Monitoring (Palpation and node ultrasound)|
1572962|NCT02434094|Behavioral|eDAPT on-line training program|A series of modules used to train on the web based training system for the artificial pancreas (AP) prototype, DiAs.
1572963|NCT02434081|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody that targets the programmed death-1 (PD-1) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.Binding of PD-1 to its ligands, 1 (PD-L1) and 2 (PD-L2), results in the down-regulation of lymphocyte activation. Nivolumab inhibits the interaction of programmed cell death Protein 1 (PD-1)with its ligands, PD-L1 and PD-L2, resulting in enhanced T-cell proliferation.
1572964|NCT02434068|Other|CT|followup
1572965|NCT02434055|Device|AVERT PLUS|
1572966|NCT02434042|Dietary Supplement|BB536|Intervention consists of daily administration of 1g probiotic Bifidobacterium longum BB536, administer daily for five days a week at a fixed dosage of 9 log CFU/day for BB536 and continue for 10 months.
1572967|NCT02434042|Other|Placebo|Intervention consists of daily administration of 1g of 100% dextrin, administer daily for five days a week and continue for 10 months.
1572968|NCT02434029|Drug|Budesonide 1mg orodispersible tablet twice daily|
1572969|NCT02434029|Drug|Placebo orodispersible tablet twice daily|
1572970|NCT02433977|Dietary Supplement|Conjugated Linolenic Acid|CLA is a polyunsaturated fatty acid Subjects will receive capsules for daily oral administration at the dose of 4.56 g/day
1572971|NCT02433977|Drug|Sodium Nitrite|Subjects will receive capsules for daily oral administration at the dose of 20 mg (2 x 10 mg)
1572972|NCT02433977|Drug|Sodium Nitrate|Subjects will receive capsules for daily oral administration at the dose of 1g (2 x 500 mg)
1572973|NCT02433964|Other|Grupo LED|
1572974|NCT02433964|Other|Placebo|ledterapia off + price
1572975|NCT02433951|Other|Cardiopulmonary exercise test|Maximal exercise test with ergospirometry.
1572980|NCT02433912|Procedure|Test - Laterally positioned flap|Laterally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
1572981|NCT02433912|Procedure|Control-Coronally positioned flap|Coronally positioned flap. Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days. chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days.
1572982|NCT02433912|Drug|750 mg paracetamol|Systemic analgesics consisting of 750 mg of paracetamol was taken every six hours for four days
1572983|NCT02433912|Drug|chlorhexidine gluconate|chlorhexidine gluconate (2.0%) gel applied in saturated cotton swabs twice a day for 14 days
1572984|NCT02433899|Procedure|MICROSURGERY|Semilunar coronally repositioned flap performed under magnification with a surgical microscope
1572985|NCT02433899|Procedure|MACROSURGERY|Semilunar coronally repositioned flap performed without magnification
1572986|NCT02433899|Drug|Dexamethasone|8mg Dexamethasone, single dose, 1 hour before surgery
1572987|NCT02433899|Drug|Chlorhexidine gluconate|Oral rinses with chlorhexidine gluconate, BID, for 14 days
1572988|NCT02433899|Drug|2.0% Mepivacaine + 1:100.000 epinephrine|Regional block
1572989|NCT02433886|Procedure|Gamma Ventral Capsulotomy|
1572990|NCT02433873|Dietary Supplement|Isomalto-oligosaccharide|Isomalto-oligosaccharide (IMO) is a non-digestible type of oligosaccharide commonly used as a low-calorie sweetener mixed with a variety of other food and beverage products for the purpose of sweetening.
1572991|NCT02433860|Behavioral|pharmacist nicotine cessation counseling using SCRIPT protocol|"Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.
Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.
Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.
At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately > 36 weeks gestation or at delivery."
1572992|NCT02433847|Drug|Mosapride|
1572993|NCT02433834|Drug|Glycopyrronium MDI|GP MDI
1572994|NCT02433834|Drug|Serevent Diskus 50 μg|
1572995|NCT02433834|Drug|Placebo|
1572996|NCT02433821|Other|Pilates|
1572999|NCT02433795|Drug|bendamustine plus rituximab|Bendamustine 90mg/m2 IV on days 1-2 up to 6th cycle Rituximab 375mg/m2 IV on day 1 at 1st cycle Rituximab 1400mg SC on day 1 from 2nd cycle every 4 weeks up to 8th cycle
1573001|NCT02433769|Device|TOFscan|"Data from the TOFscan will be compared to simultaneously measured data from the TOF-Watch-SX (gold standard)"
1573002|NCT02433769|Device|TOF-Watch-SX|Data from the TOF-Watch-SX will be compared to simultaneously measured data from the TOFscan
1573003|NCT02433756|Device|CRTD|
1573004|NCT02433743|Dietary Supplement|Ready-to-use therapeutic food (RUTF)|HIV-infected patients were randomly allocated to receive standard hospital diet (Control: n=33), or this diet combined with 100 g/day of RUTF (RUTF: n=32). All patients was follow-up during hospitalisation and 9 week after discharge at home
1573005|NCT02433730|Drug|Testosterone|intramuscular injection
1573006|NCT02433730|Drug|placebo|intramuscular injection
1573007|NCT02433717|Drug|Paliperidone ER|Fixed dose (9 mg/day) of paliperidone ER will be given in the first two weeks of trial (from day 1 to day 14). Since the third week (day 15), the dosage can be adjusted in the range of 6 to 12 mg per day.
1573008|NCT02433704|Device|New Intraosseous|Intraosseous administration of prophylactic antibiotics
1573009|NCT02433704|Drug|Cefazolin|Cefazolin 1 gram will be given through an intraosseous cannula, placed into the medial aspect of the proximal tibia, after draping and before skin incision. The cefazolin will be administered as a bolus in 200 mL of normal saline.
1573010|NCT02433691|Other|simultaneous aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes while receiving memory training.
1573011|NCT02433691|Other|sequential aerobic exercise|stationary bicycling at 65% of heart rate reserve for 30 minutes followed by memory training.
1573012|NCT02433691|Other|stretching and toning|anaerobic stretching and toning followed by memory training.
1573013|NCT02433678|Drug|dapagliflozin|SGLT-2 inhibitor for the treatment of type 2 diabetes
1573014|NCT02433678|Drug|Placebo|
1573015|NCT02433665|Drug|Iopamidol|Iopamidol is the contrast material being used for this study. 100 subjects will receive a fixed dose and rate (150 mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of 3 mL/sec for a total dose of 45 grams of iodine) and 400 subjects will be administered a customized dose and rate (X mL of iopamidol with a concentration of 300 mg of iodine/mL at an injection rate of X mL/sec for a total dose of X grams of iodine).
1573016|NCT02433665|Device|Mydose|400 subjects will receive a customized dose of contrast material (iopamidol) based on the experimental algorithm Mydose using a combination of subject parameters.
1573017|NCT02433652|Biological|Recombinant live attenuated trivalent dengue vaccine|Contains 10^3.3 plaque forming units (PFU)/mL of rDEN1Δ30, 10^3.3 PFU/mL of rDEN3Δ30/31-7164 and 10^3.3 PFU/mL of rDEN4Δ30. It is administered in 0.5 mL containing 10^3.0 PFU of each component.
1573018|NCT02433652|Biological|Placebo|
1574063|NCT02426190|Device|PENS - neuro-muscular stimulation|
1573019|NCT02433652|Biological|rDEN2Δ30-7169 vaccine|Live recombinant attenuated DENV-2 candidate vaccine virus; will be administered at a dose of 10^3 PFU
1573020|NCT02433639|Drug|TH-302 monotherapy|TH-302 (480 ) mg/m2 D1, D8, D15 Q 4 weeks
1573021|NCT02433626|Drug|COTI2|COTI-2 is a third generation thiosemicarbazone.
1573022|NCT02433600|Other|Cow's milk-based infant formula|
1573023|NCT02433600|Other|Cow milk-based infant formula with enriched protein fractions|
1573024|NCT02433587|Drug|Aspirin|
1573025|NCT02433587|Drug|Clopidogrel|
1573026|NCT02433574|Radiation|Neoadjuvant Stereotactic body radiation (SBRT)|"Dose escalation of neo-adjuvant SBRT in operable patients with locally advanced non-small cell lung cancer.
The first cohort will be treated with a dose of 35 Gy in 10 fractions, the second cohort will be treated with a dose of 40 Gy in 10 fractions, the third cohort will be treated with a dose of 45 Gy in 10 fractions, the fourth cohort will be treated with a dose of 50 Gy in 10 fractions. The SBRT doses will be escalated only once all patients in the previous cohort will have completed safely their treatments."
1573027|NCT02433561|Procedure|Intraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound within the brachial plexus between C5 and C6
1573028|NCT02433561|Procedure|Extraplexic catheter location (Contiplex® C, B. Braun Melsungen, AG)|The catheter tip will be placed with the aid of the ultrasound 2 mm away from the lateral part of the brachial plexus
1573029|NCT02433548|Procedure|Fascia iliaca block|injection of 30 mLs below the fascia iliaca
1573030|NCT02433548|Procedure|Sham injection|subcutaneous of 5 cc of normal saline
1573031|NCT02433535|Drug|Simvastatin|Simvastatin is used to lower cholesterol, however, it also possess anti-inflammatory and immunomodulatory properties that may also alleviate allergic airway inflammation in asthma.
1573032|NCT02433535|Other|Placebo|A placebo pill will be given to the placebo group. There will be no detectible differences between study drug pill and placebo pill.
1573033|NCT02433522|Drug|rituximab|500 mg rituximab infusion at the randomization visit and every 6 months for 18 months. Each infusion will be preceded by an infusion of 1000 mg paracetamol, 100 mg methylprednisolone and 5 mg dexchlorpheniramine.
1573034|NCT02433522|Drug|Placebo|
1573035|NCT02433509|Other|Human Umbilical Cord Blood mononuclear cells and 20% mannitol|"The cord blood need to be infusion within 72 hours after the onset of stroke, and the cord blood mononuclear cells 200 million ~ 500 million will used.
20% mannitol 200 ml iv for 30±10 min/q8h±2h will be administered twice after cord blood infusion ."
1573036|NCT02433496|Other|Physician coaching|"The coach will present the latest research on the benefits and risks of long-term opioid use. The presentation will be followed by a brainstorming exercise where the coach joins the clinic team in experiencing clinical practices from the perspective of a patient with chronic pain. The coach will help the clinic team flowchart clinical workflows and determine the best course for implementing aspects of a checklist-based implementation guide developed to support adoption of the guidelines for opioid prescribing.
The coach will help the team implement ideas using Plan-Do-Study-Act change cycles. The coach will maintain monthly email and phone contact with the clinic lead and clinic team after the initial site visit to monitor implementation progress and offer advice."
1573040|NCT02433470|Device|Transcranial direct current stimulation|Transcranial direct current stimulation over the motor cortex
1573041|NCT02433457|Drug|CC-292|
1573042|NCT02433457|Drug|Oral Omeprazole (OMP)|
1573043|NCT02433444|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP's performed at Cedars-Sinai Medical Center.
1573044|NCT02433431|Behavioral|Mindfulness Training|Mindfulness training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
1573045|NCT02433431|Behavioral|Mindful Attention Only Training|Mindful attention training intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
1573046|NCT02433431|Behavioral|Analytic Thinking Training|Comparison analytic thinking intervention consisting of 14 x 20-minute audio-guided lessons that participants access on their smartphones during the 14-day intervention period.
1573047|NCT02433418|Procedure|Tubal flushing by Urografin®|Women will have tubal flushing through HSG using water soluble media (Urographin ®)
1573048|NCT02433418|Drug|Diclofenac|Women will receive oral diclofenac 50 mg (voltaren ®) 1 hour before hysterosalpingography
1573049|NCT02433405|Biological|Fetuin-A|Acute phase protein
1573050|NCT02433405|Biological|Serum Amyloid A|Acute phase protein
1573051|NCT02433392|Procedure|CM-BC2|CM-BC2 is a drug-eluting bead, a drug-device combination
1573053|NCT02433353|Drug|Venlafaxine XR|Serotonin norepinephrine reuptake inhibitor
1573054|NCT02433353|Behavioral|EMDR|psychotherapy
1573055|NCT02433353|Drug|Placebo|Look-alike venlafaxine XR tablets containing no active drug
1573056|NCT02433340|Drug|ABT-122|
1573057|NCT02433327|Other|PEWS - trigger tool|PEWS - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
1573081|NCT02433132|Other|Nasal brushing|The CCBN test is to evaluate the ion transport in the nasal epithelial cells taken from a subject by brushing the inferior turbinate with a mini-brush after local anesthesia. Analysis of ion transport is carried out ex vivo on the primary culture of nasal epithelial cells after brushing
1573082|NCT02433119|Drug|OROSARTAN® 5/160mg|
1573058|NCT02433327|Other|RM - trigger tool|RM - trigger tool A PEWS tool is a simple physiological scoring system that can be calculated at the patient's bedside, using parameters, which can easily be measured. Both PEWS tool consist of 7 parameters to be measured, and each individual measuring result would provide the patient with a score from 0-4. The 7 scores should then be added together giving the total PEWS. The children included into the study will be monitored using one of the two different PEWS models. Both model includes measuring vital signs with different intervals according to the child's conditions. Underlying both PEWS tool are algorithms of action for intervention in the critically ill child, interprofessional guidelines and guidance for standardised monitoring.
1573059|NCT02433314|Drug|SAGE-547|
1999066|NCT00499083|Genetic|reverse transcriptase-polymerase chain reaction|delta Ct (quantitative real time- reverse transcription-polymerase chain reaction (qRT-PCR)) of COX-2 and VEGF will be divided into the upper or lower median and Fisher Exact test used to assess the difference in response.
1573062|NCT02433262|Other|WHO (World Health Organisation)|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using WHO criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
1573063|NCT02433262|Other|IADPSG|Participants will need to undergo oral glucose tolerance test which involve drinking a 75g oral glucose. Venous blood for fasting and 2 hours post glucose intake will be taken. Diagnosis of gestational diabetes mellitus (GDM) will be made using IADPSG criteria. Once GDM is diagnosed, they will undergo blood sugar profile monitoring and treatment which includes diet control and/or insulin treatment if required
1573064|NCT02433249|Behavioral|1 Physical Activity|Fall reducing strength (5), balance (12) and flexibility (4) exercises as well as walking. Participants were also given a Fitbit One with instructions on how to use
1573065|NCT02433249|Behavioral|Interpersonal Motivation|Strategies used to support Interpersonal motivational targets include: a) discuss and model ways to provide and receive more support for physical activity, b) identify environmental barriers to being physically active, c) problem-solve environmental and social barriers to being physically active, d) use and create new resources that support physical activity behavior
1573066|NCT02433249|Behavioral|Intrapersonal Motivation|Strategies used to support intrapersonal motivation included a) use of the goal attainment scale, b) facilitating the formation of action plans, c) identify and problem solve personal barriers to being active, d) identify satisfying aspects of being active, e) self-evaluate physical activity patterns and progress.
1573067|NCT02433236|Drug|Fostamatinib Disodium tablet 100 mg|
1573068|NCT02433236|Drug|Fostamatinib Disodium tablet 150 mg|
1573069|NCT02433210|Device|ELISIO-15H|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
1573070|NCT02433210|Device|Revaclear|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
1573071|NCT02433210|Device|Optiflux|Each patient to undergo 3 successive hemodialysis/week with this dialyzer.
1573072|NCT02433197|Device|Aerobic program|"The intervention will be an 8-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and enduranceas well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.
In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
1573073|NCT02433184|Drug|Etanercept|Etanercept will be administered subcutaneously at a dose of 50 mg weekly and will be discontinued at the primary endpoint (48 weeks).
1573074|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg and will be increased to 25mg weekly at 2 weeks.
1573075|NCT02433184|Drug|Sulfasalazine|Sulfasalazine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered orally at a dose of 1g twice daily. Will be discontinued if starting etanercept at 24 weeks.
1573076|NCT02433184|Drug|Hydroxychloroquine|Hydroxychloroquine will be added at weeks 8,12,16 or 20 if the subject fails to achieve low disease activity, administered at a dose of 200mg daily. Will be discontinued if starting etanercept at 24 weeks.
1573077|NCT02433184|Drug|Etanercept|Etanercept will be added at 24 weeks, if a subject fails to achieve clinical remission,at a dose of 50 mg weekly and will be discontinued at 48 weeks with the exception of those patients who are eligible to continue according to local prescribing guidelines (NICE guidelines)
1573078|NCT02433184|Drug|Methotrexate|Methotrexate will be administered orally at a starting dose of 15 mg weekly, increasing to 20mg and 25mg weekly at weeks 4 and 8 respectively.
1573079|NCT02433171|Procedure|Standard of Care FDG-PET Imaging|[11C]Methionine [11]. This natural amino acid, and its various fluorinated derivatives, has been widely used in brain tumor studies due to a) high tumor-to-normal brain contrast, and b) its sensitivity to biological functions including amino acid transport and utilization. [11C]PBR28 [12]. This ligand is one of a series of second-generation tracers that bind to TSPO (translocator protein), a protein that is upregulated in activated microglia.
1573080|NCT02433158|Drug|Rivipansel|Rivipansel will be infused intravenously every 12 hours up to a maximum of 15 doses. Subjects aged 12 and over who weigh >40 kg, will receive a loading dose of 1680 mg followed by a maintenance dose of 840 mg. Subjects 6 to 11 years of age or subject who weighs 40 kg, will receive a loading dose of 40 mg/kg (maximum of 1680 mg) followed by a maintenance dose of 20 mg/kg (maximum of 840 mg).
1573083|NCT02433119|Drug|CODIOVAN® 160/12.5mg|
1573084|NCT02433106|Other|GAA 15|Neuromuscular injury prevention training
1573086|NCT02433093|Drug|Basimglurant|Participants will receive once-daily oral basimglurant capsules in a multiple ascending dose regimen. Basimglurant dose will be titrated over 22 days; dose escalations will be separated by at least 4 days, with the final dose administered for a minimum of 14 days. The minimum starting dose will be 1.5 mg, which can be titrated up to a maximum dose of 4.0 mg. Intrapatient dose increments will not exceed 1.0 mg every 4 days.
1573087|NCT02433093|Drug|Placebo|Participants will receive 22 days of once-daily oral matching placebo capsules.
1573088|NCT02433080|Behavioral|Shape-Up following cancer treatment|"The programme is based on Social Cognitive Theory and Control Theory. The focus of the programme lies on self-control, self-efficacy, and relapse prevention."
1573089|NCT02433067|Other|Physical activity intervention|Patients in arm A (interventional) will carry out a physical activity intervention during 3 months. Patients should perform an interval training program on cycle-ergometer during 3 sessions per week.
1573090|NCT02433067|Other|Control Group|standard oncologic care
1573091|NCT02433054|Device|CE-certified dedicated venous stents|Implantation of self-expanding nitinol venous stents in the iliofemoral veins and/or inferior vena cava.
1573092|NCT02433041|Drug|Haloperidol|Haloperidol 0.005mg/kg at induction of anesthesia
1573093|NCT02433041|Drug|Ketamine|Ketamine 1mg/kg at induction of anesthesia to test its power to prevent postoperative delirium
1573094|NCT02433041|Drug|Haloperidol + Ketamine|Haloperidol 0.005mg/kg + Ketamine 1mg/kg at induction of anesthesia to test their power to prevent postoperative delirium if given together
1573095|NCT02433041|Drug|Saline solution (NaCl 0.9%)|Placebo being used in one of the four groups
1573096|NCT02433015|Other|Electronic Cigarette|eGo-type electronic cigarette with a supply of 18mg/ml nicotine solution
1573097|NCT02433015|Other|Tobacco Cigarette|Smoke own brand of cigarette as previously
1573098|NCT02432989|Behavioral|Exercise|Light-moderate exercise on a stationary bike and leisurely walks.
1573099|NCT02432976|Drug|Exenatide|"Exenatide. Exenatide: bolus of 0.05 µg/min infused during the 1st hour of treatment, followed by a continuous infusion of 0.025 µg/min until the end of treatment.
The exenatide therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured. A of exenatide will be intravenously .
The treatment will be administrated during the first postoperative 48 hours in the intensive care unit or until intensive care unit discharge if this event occurs earlier."
1573100|NCT02432976|Drug|Insulin|"Insulin: Humalog (insulin lispro human analog). The insulin therapy will begin as soon as a blood glucose level is above 140 mg/dl will be measured.
The dose of insulin intravenously infused will be adapted to blood glucose measurements, following the insulin therapy protocol used in our department.
The insulin therapy protocol used in our department and prescribed as the benchmark treatment in the present study has been validated in a previous study. It has been derived from the protocol validated by Goldberg et al."
1573101|NCT02432963|Other|Laboratory Biomarker Analysis|Correlative studies
1573102|NCT02432963|Biological|Modified Vaccinia Virus Ankara Vaccine Expressing p53|Given SC
1573103|NCT02432963|Biological|Pembrolizumab|Given IV
1573104|NCT02432950|Dietary Supplement|Dietary Intervention|Participate in the PNP
1573105|NCT02432950|Other|Educational Intervention|Participate in the PNP
1573106|NCT02432950|Other|Laboratory Biomarker Analysis|Correlative studies
1573107|NCT02432950|Other|Quality-of-Life Assessment|Ancillary studies
1573108|NCT02432937|Drug|Corever|Corever
1573109|NCT02432924|Behavioral|Instant + Multidimensional Physical Activity Feedback|
1573110|NCT02432911|Drug|CAG regimen (Aclacinomycin, cytarabine, with/w/o G-CSF)|Aclacinomycin 20mg/d for 4 days combined with cytarabine 20mg bid for 10 days with/without G-CSF 6ug/m2 from 1 day before therapy to day 10 of therapy.
1573111|NCT02432911|Drug|low dose cytarabine|cytarabine 20mg bid for 10 days.
1573112|NCT02432898|Device|3D OCT-1|Spectral Domain OCT Device
1573113|NCT02432898|Device|3D OCT-2000|Spectral Domain OCT Device
1573114|NCT02432898|Device|DRI OCT-1|Swept Source OCT Device
1573115|NCT02432898|Device|NW-300|Fundus Camera
1573116|NCT02432898|Device|CT-1P|Tonometry
1573117|NCT02432898|Device|TRK-2P|Tonometry, Corneal Topography
1573118|NCT02432898|Device|SP-1P|Specular Microscopy
1573119|NCT02432898|Device|SL-D701|Slit Lamp Imaging
1573120|NCT02432898|Device|MC-4S|Visual Acuity Testing
1573121|NCT02432885|Drug|Enalapril|up to 20mg bid
1573122|NCT02432872|Drug|Daunorubicin|defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses
1573123|NCT02432872|Drug|Cytarabine|medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
1573124|NCT02432859|Procedure|Electrical Stimulation|Direct current with sensory intensity for one hour
1573125|NCT02432859|Procedure|Placebo|Direct current with zero intensity for one hour
1573126|NCT02432846|Biological|Intuvax (ilixadencel)|Therapeutic vaccine: allogeneic, pro-inflammatory dendritic cells.
1573127|NCT02432846|Drug|Sunitinib|Cytostatic/cytotoxic drug: protein kinase inhibitor .
1573128|NCT02432833|Drug|ENVARSUS®|Envarsus® tablets, once daily, oral formulation. Prolonged -release formulation of tacrolimus
1573129|NCT02432833|Drug|PROGRAF®|Prograf® hard capsules, twice daily, oral formulation
1573130|NCT02432833|Drug|ADVAGRAF®|Advagraf® prolonged-release hard capsules, once daily, oral formulation
1573131|NCT02432807|Drug|Vancomycin 1.1%|Vancomycin hydrochloride ophthalmic ointment 1.1%
1573132|NCT02432807|Drug|Placebo|Placebo
1573133|NCT02432794|Procedure|delay phenomenon by arteriographic approach|we improve the microvascularization of the gastric fundus occluding the right and left gastric artery, and splenic artery two weeks before surgery by arteriography
1573134|NCT02432781|Dietary Supplement|Carbohydrate-rich drink|
1573135|NCT02432781|Dietary Supplement|10% dextrose solution mixed with insulin 16 unit 100 mL/h|
1573136|NCT02432768|Drug|Triheptanoin|Anaplerotic dietary oil
1573137|NCT02432768|Other|Placebo oil|Safflower oil
1573226|NCT02432209|Drug|Orlistat|Subjects on Active comparator will use an over-the-counter weight loss medication, Orlistat, a gastric lipase inhibitor that limits gut fat absorption.
1573138|NCT02432755|Behavioral|home-based MTOT|The home-based MTOT group will receive 30 minutes of MT followed by 30 minutes of TOT per session. The intervention will take place in the participant's home environment. During the mirror practices, the patient will seat close to a table which the mirror box will be placed at the mid-sagittal plane. During MT, the participant will be encouraged to actively move their paretic arm and hand concurrently with the mirror reflection of the movement of the nonparetic arm and hand as possible as they can. If necessary, the therapist will assist the participant in moving the paretic hand to synchronize the movement with the nonparetic hand.
1573139|NCT02432755|Behavioral|hospital-based therapy|The control group will receive a dose-matched, individualized occupational therapy at a hospital. The participants will receive customary rehabilitation programs as usual performed at hospitals for 1 hour per session. The treatment protocol will include: (a) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques, (b) fine motor or dexterity training, (c) arm exercises or gross motor training, (d) muscle strengthening of the affected upper limb, and (e) activities of daily living training or functional task practice.
1573140|NCT02432755|Behavioral|hospital-based MTOT|The hospital-based MTOT group will also receive 30 minutes of MT followed by 30 minutes of TOT per session at a hospital. The intervention will take place in the occupational therapy clinic. The treatment modalities in the hospital will be selected and provided for this group. Most of the treatment principles and components are the same as aforementioned in the home-based MTOT. However, the major differences between home-based and hospital-based MTOT are the treatment contexts, environments and functional modalities used.
1573141|NCT02432742|Device|Restylane Perlane|Intradermal injection
1573142|NCT02432742|Device|Restylane|Intradermal injection
1573143|NCT02432716|Drug|Insulin glulisine|Insulin (glulisine) Glulisine 20 IU/IN (.1ml/10 units intranasal in each nostril), once per study
1573144|NCT02432716|Drug|Saline|Placebo Comparator: Placebo Sterile Normal Saline 20 IU/IN (.1ml intransal in each nostril), once per study
1573147|NCT02432690|Drug|BBI503|BBI503 will be administered orally, once daily. Dosing will begin at 200 mg once daily, preferably at bedtime and 2 hours after a meal. Dose modification in case of adverse events is allowed according to the schedule below; Full dose: 200 mg daily, Modification Level-1: 100 mg daily, Modification Level-2: 50 mg daily.
1573148|NCT02432677|Drug|Remifentanil|Remifentanil (IV infusion): 0,06mcg.kg.min. The infusion starts 10min before tDCSThe infusion will be stopped in the event of: a decrease in respiratory rate below 7 breaths / min, a peripheral oxygen saturation below 85%, a lower heart rate of 40 beats per minute, a lower mean arterial pressure of 60 mmHg, sedation causing inadequate management switch stimuli tests and occurrence of vomiting.
1573149|NCT02432677|Device|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
1573150|NCT02432677|Device|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after starting stimulation (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session.
1573151|NCT02432677|Drug|Placebo|Saline infusion - Infusion 10min before the tDCS session, during the tDCS session and after the tDCS session, until the end of pain tests.
1573152|NCT02432664|Drug|ODM-108 Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
1573153|NCT02432664|Drug|Placebo Part I|Single oral escalating dose of ODM-108. Each volunteer will receive either one dose of ODM-108 or placebo
1573154|NCT02432664|Drug|ODM-108-Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
1573155|NCT02432664|Drug|Placebo Part II|Multiple escalating doses based on the results of Part 1. Either ODM-108 or placebo 1 - 4 times a day for 7 days
1573156|NCT02432664|Drug|ODM-108 Part III|Oral capsules 1 - 4 times daily for 7 to 10 days
1573157|NCT02432664|Drug|Midazolam|Single dose as a solution 3 days prior to the first dose of ODM-108 and on the last day of dosing with ODM-108
1573158|NCT02432651|Drug|6 mg xanthohumol per day|Participants will consume non-alcoholic beverage with 2 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
1573159|NCT02432651|Drug|12 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 2 mg xanthohumol at breakfast and lunch and 8 mg at dinner for 3 weeks.
1573160|NCT02432651|Drug|24 mg xanthohumol per day|Participants will consume a non-alcoholic beverage with 8 mg xanthohumol at breakfast, lunch and dinner for 3 weeks.
1573161|NCT02432651|Drug|Placebo|Participants will consume a placebo non-alcoholic beverage (0 mg xanthohumol) at breakfast, lunch and dinner for 3 weeks.
1573162|NCT02432612|Drug|Sativex|Sativex is supplied as a liquid containing 27 mg/mL Δ9-tetrahydrocannabinol (THC) and 25 mg/mL Cannabidiol (CBD) plus peppermint flavoring. Each 100 µL actuation of the pump-action spray delivers 100 µL 27 mg THC and 25 mg CBD.
1573163|NCT02432599|Radiation|F18-choline PET examination|F18-choline PET examination will be performed before surgery
1573164|NCT02432586|Behavioral|Intensive Education|Participants will attend a 3 day family-centered, multidisciplinary, intensive education session at our regional diabetes camp, Camp Sweeney. A second 'booster' session will be conducted 6 months later.
1573165|NCT02432573|Behavioral|Delayed rounds|
1573166|NCT02432560|Drug|Sirolimus|Sirolimus treatment will be part of a participant's clinical care and will be managed by their physician.
1573167|NCT02432560|Drug|Everolimus|Everolimus treatment will be part of a participant's clinical care and will be managed by their physician.
1573227|NCT02432209|Other|Moderate physical activity|All subjects in both arms will be encouraged to engage in moderate physical activity with target of 10,000 steps a day.
1573228|NCT02432196|Device|Mitral Valve Repair|Harpoon Medical TSD-5
1573230|NCT02432157|Drug|HTS 3%|3% HTS at a dose of 250 ml every 6 hours for 7 days
1573168|NCT02432547|Drug|Aflibercept|Aflibercept is a soluble decoy receptor and is produced by fusing all-human DNA sequences of the second immunoglobulin (Ig) domain of human VEGF receptor (VEGFR) 1 to the third Ig domain of human VEGFR-2, which are then fused to the Fc region of human IgG-1. By binding to VEGF-A, aflibercept prevents activation of the native VEGF receptors, VEGFR-1 and VEGFR-2. The study sites will be supplied by Bayer with aflibercept. Intravitreal injection of 2mg in 0.05 ml aflibercept will be administered to the study eye, according to a pre-defined treat and extend regimen.
1573169|NCT02432547|Procedure|Targeted laser therapy|In the experimental group, targeted laser photocoagulation will be applied to areas of peripheral retinal ischaemia 1 month after the initial intravitreal aflibercept. The trial design allows another session of targeted laser photocoagulation 1 month later to complete the treatment if required. Wide-field photography is planned at 3 months to determine if further targeted laser photocoagulation is required, and if so a third session can be applied. The laser settings are based on those used in current clinical practice and have been prospectively defined in the protocol.
1573170|NCT02432534|Drug|Atorvastatin|The patients will be treated with the combination of oral atorvastatin and NBUVB phototherapy twice a week for 6 months. The initial starting dose of the oral atorvastatin will be 40mg daily and after 1 month, if tolerated clinically and biologically following blood tests, the dose will be increased to 80mg daily.
1573171|NCT02432534|Other|UVB|The patients will be receiving only NB-UVB phototherapy twice a week for 6 months.
1573172|NCT02432521|Other|Conventional rehabilitation program from IMREA|The IMREA rehabilitation program lasts about 18 weeks and consists of two weekly sessions of 60 minutes of physical therapy, occupational therapy, as well as weekly sessions of speech therapy, nursing, nutrition, psychology and social work. Conventional therapies are typically composed of stretching and strengthening exercises both upper and lower limbs, mobilizations, functional training. The only fact that differ the subjects from the protocol from the patients from the IMREA Institute are the clinical and neurophysiological evaluations that will be performed before and after the end of the conventional rehabilitation program previously described.
1573173|NCT02432508|Device|Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (50mW, 655nm)
1573174|NCT02432508|Device|Sham Laser acupuncture (Olympic)|Physiolaser Olympic laser acupuncture device (Low dose of laser energy: 5mW, 655nm)
1573175|NCT02432495|Other|ANTERIOR SCREW FIXATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone anterior screw fixation of type II odontoid fractures
1573176|NCT02432495|Other|HALOV VEST IMMOBILIZATION|Patients aged 65 years or older with an ASA score of 2 or higher who had undergone halo immobilization of type II odontoid fractures
1573177|NCT02432482|Behavioral|mobile Positively Smoke Free (mPSF)|mPSF is a targeted, intensive behavioral cessation intervention designed for HIV-infected smokers. It is guided by the Social Cognitive Theory model. It includes 8 weekly sessions of audio/video messages to users, daily text messages, and a variety of other smartphone capabilities, e.g. play-a-tune, play-a-game, phone-a-friend, call the quitline.
1573178|NCT02432482|Behavioral|Standard care|Brief advice to quit (<5 minutes) Self-help brochure Offer of nicotine patches
1573179|NCT02432469|Behavioral|APP intervention|The APP contains education materials about secondary intervention of coronary artery disease, patients can surf and read them very easily. The APP also collects information on medication prescription by doctors, reminds patients at every time of taking medications, and asks for feedback from patients at 8 pm every day. The APP also pushes a patient-specific questionnaire with 10-15 questions weekly, to collect information about patients' medication adherence and self-management on blood pressure, blood lipid, blood glucose, physical activity, diet and body weight. APP pushes series of recommendations right after patients' finishing the questionnaire to help them improve their secondary prevention.
1573231|NCT02432157|Drug|Standard fluid management|Routine fluid management strategy as pre-specified by our SAH management protocol.
1573281|NCT02431780|Device|ANSeR Software System|ANSeR Software System a stand alone, software medical device for Neonatal seizure decision support tool
1573188|NCT02432443|Behavioral|Motor and pre-literacy program|The program will run for 60 minutes once per week for 10 consecutive weeks and will consist of three components: direct FMS instruction, unstructured exploratory free-play, and an interactive storybook reading activity. The curriculum and teaching strategies to be used for the first two segments of our intervention have been successfully implemented in previous research to improve the motor skills of 4 year old children with autism (Bremer, Balogh, & Lloyd, 2014). Specific strategies and books were selected from an existing evidence-based curriculum (Justice & McGuinty, 2009). There will be active involvement of at least one parent in the direct instruction and reading components.
1573189|NCT02432443|Other|Wait-list Comparison|The participants will not participate in the motor and pre-literacy program for 10 weeks after enrollment and will continue with their normal daily life without any intervention. After the experimental arm completes the motor and pre-literacy program, the wait-list group will receive the exact same motor and pre-literacy intervention.
1573190|NCT02432430|Behavioral|QI support to improve DTP/Hep B/MMR/Var/PCV/Hib/IPV coverage|Quality improvement technical support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
1573191|NCT02432430|Behavioral|Incentives to improve DTP/HepB/MMR/Var/PCV/Hib/IPV coverage|Financial incentives to support to help providers' ability to institute best practices to improve delivery of the following vaccines: DTP, HepB, MMR, Var, PCV, Hib, IPV
1573192|NCT02432417|Drug|Chloroquine|CQ will start with one week before the start of radiotherapy and end on the last day of radiotherapy.
1573193|NCT02432404|Drug|NuvaRing|
1573194|NCT02432391|Behavioral|GEM|GEM is an integrated lifestyle modification program that focuses on reducing postprandial blood glucose through replacing high with low glycemic load foods and increasing routine physical activity guided by systematic blood glucose monitoring.
1573195|NCT02432378|Biological|Cisplatin + celecoxib + DC vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + intranodal vaccine injections once per cycle
1573196|NCT02432378|Biological|Cisplatin + CKM + Celecoxib + DC Vaccine|Cisplatin 50 mg/m2 by IP once per cycle (21 days) + celecoxib daily 200 mg by mouth daily + IFN by IP once per cycle + rintatolimod 200 mg by IP once per cycle + intranodal vaccine injections once per cycle
1573200|NCT02432352|Behavioral|Our Family Our Future|The Our Family Our Future Program is a family preventive intervention that uses resilience and prevention focused strategies to reduce sexual risk behaviors and build mental wellbeing among adolescents.
1573201|NCT02432339|Drug|mycophenolate mofetil (MMF)|an immunosuppressant - 500 mgs twice a day for 7 1/2 days - in capsule form
1573202|NCT02432339|Drug|Placebo|a sugar pill - 500 mgs twice a day for 7 1/2 days - in the same capsule form as the MMF
1573205|NCT02432313|Drug|Modified Release Formulation x (MRx)|Subject receives 1 dose of a MRx and is followed. 7-day washout before dosing with another formulation
1573207|NCT02432287|Drug|Metformin|To determine if treatment with metformin (1700 mg/day) will restore the gene expression profile of older, glucose intolerant adults to that of young healthy subjects.
1573208|NCT02432287|Drug|Placebo|
1573209|NCT02432274|Drug|Lenvatinib|Cohort 1: Lenvatinib will be administered orally, once daily on Days 1 to 28 of each 28-day cycle at a starting dose of 11 mg/m2. Dose can be de-escalated to 9 mg/m2 or escalated to 14 and 17 mg/m2.
1573210|NCT02432274|Drug|Lenvatinib|Cohort 2A: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
1573211|NCT02432274|Drug|Lenvatinib|Cohort 2B: Lenvatinib (RD determined in Cohort 1) will be administered orally, once daily on Days 1 to 28 of each 28-day cycle.
1573212|NCT02432274|Drug|Lenvatinib|Cohort 3A: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at 20% lower than RD determined in Cohort 1 (starting dose).
1573213|NCT02432274|Drug|Lenvatinib|Cohort 3B: Lenvatinib will be administered orally, once daily on Days 1 to 21 of each 21-day cycle at the RD as determined in Cohort 3A.
1573214|NCT02432274|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
1573215|NCT02432274|Drug|Etoposide|Etoposide 100 mg/m2/day (starting dose) will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
1573216|NCT02432274|Drug|Ifosfamide|Ifosfamide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
1573217|NCT02432274|Drug|Etoposide|Etoposide dose identified in Cohort 3A will be administered on Days 1 to 3 of each 21-day cycle for a total of 5 cycles.
1573218|NCT02432261|Drug|Nestorone® /testosterone gel|Nestorone® /testosterone combined gel
1573219|NCT02432261|Drug|Testosterone only gel|Testosterone only gel
1573220|NCT02432248|Drug|Dehydroepiandrosterone|75mg/day, PO for 90 days
1573221|NCT02432248|Other|placebo(medical starch)|75mg/day, PO for 90 days
1573223|NCT02432222|Behavioral|Visual Arts Training|Visual arts training
1573224|NCT02432222|Behavioral|Music Training|Music training
1573225|NCT02432209|Other|Caloric Restriction|Subjects on Active comparator will have Caloric Restriction to a 1200-1500 kcal/day diet through use of Nutrisystem Meal Plan.
1573324|NCT02431533|Dietary Supplement|PX0612|PX0612 is a probiotic contained in a veggie capsule.
1573368|NCT02431234|Other|serum RANKL|
1573232|NCT02432144|Drug|UX003|UX003 is a sterile liquid buffered saline formulation of rhGUS that contains enzyme at a concentration of 2 mg/mL filled to allow the withdrawal of a 5.0 mL deliverable volume and supplied in a 10 mL glass vial. UX003 will be administered QOW by slow IV infusion over approximately 4 hours. Infusions will be administered on a rate schedule involving a slower infusion rate initially followed by an increase in rate to minimize the potential for IARs; the infusion rate may be slowed to manage or reduce IARs.
1573233|NCT02432118|Procedure|Lumpectomy|Undergo lumpectomy
1573234|NCT02432118|Other|Questionnaire Administration|Ancillary studies
1573235|NCT02432118|Procedure|Radiofrequency-Guided Localization|Undergo radiofrequency-guided localization
1573236|NCT02432105|Drug|EXE844 Sterile Otic Suspension, 0.3%|
1573237|NCT02432105|Procedure|Tympanostomy Tube Insertion|Surgical procedure for treating pediatric cases of recurrent or chronic otitis media
1573240|NCT02432053|Drug|Advagraf|
1573241|NCT02432040|Drug|Atorvastatin|Atorvastatin is a hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor used to treat dyslipidemia
1573242|NCT02432040|Drug|Placebo|Placebo tablets, made to look like the interventional drug
1573243|NCT02432027|Drug|C-82 Topical Gel, Placebo|placebo
1573244|NCT02432027|Drug|C-82 Topical Gel, 1%|active
1573245|NCT02432027|Drug|Daivonex cream|comparator
1573246|NCT02432027|Drug|Diprosis gel|comparator
1573247|NCT02432014|Behavioral|PMTO-PTC Group clinic-based|
1573248|NCT02432014|Behavioral|PMTO Individual home-based|
1573249|NCT02432014|Behavioral|PMTO Individual clinic-based|
1573250|NCT02432014|Behavioral|Services as Usual|
1573251|NCT02432001|Procedure|Image-Guided Biopsies|
1573252|NCT02431988|Procedure|Leukapheresis|Patients will undergo leukapheresis prior to pre-conditioning chemotherapy to provide the immune cells required to produce the therapeutic product.
1573253|NCT02431988|Drug|Cyclophosphamide|Patients will receive a standard pre-conditioning regime with cyclophosphamide 60mg/kg/day IV over 1 hour for 2 days (day-7 and day-6).
1573254|NCT02431988|Drug|Fludarabine|Fludarabine 25mg/m2/day IV over 15/30 minutes for 5 days (Day-5 to day-1).
1573255|NCT02431988|Biological|CAR19 T-Cells|"The CAR19 T-cells are to be administered on day 0 at the dose specified by the Cancer Trials Centre (CTC) at the time of registration.
Three dose cohorts are planned:
Dose Level 1: 2x105 CAR19 T-cells/kg
Dose Level 2: 1x106 CAR19 T-cells/kg
Dose Level 3: 5x106 CAR19 T-cells/kg"
1573256|NCT02431975|Drug|Nevirapine|"Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.
The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network."
1573257|NCT02431975|Drug|Zidovudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.
ZDV will be dosed as per standard guideline and routine practices."
1573258|NCT02431975|Drug|Lamivudine|"An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.
3TC will be dosed as per standard guideline and routine practices."
1573259|NCT02431975|Drug|LPV/r|"Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.
LPV/r will be dosed as per standard guideline and routine practices."
1573260|NCT02431962|Procedure|Computed Tomography|Low dose chest CT screening annually x 3
1573261|NCT02431962|Behavioral|Active smokers - Smoking cessation arm|Phone based smoking cessation counseling
1573262|NCT02431962|Behavioral|Active smokers - Control arm|Subjects will be provided with general information on available smoking cessation resources
1573263|NCT02431949|Other|Admission to BCPP|There is no intervention associated with this study.
1573264|NCT02431936|Drug|Prazosin|Double blind placebo controlled cross over trial to determine effectiveness of alpha adrenergic blocker in reducing sodium retention during stress.
1573265|NCT02431936|Drug|Placebo|Sugar pill made to look identical to Prazosin intervention.
1573266|NCT02431910|Other|Functional elastic tape|application of KT with tension in the vastos medialis, rectus femoris and vastus lateralis muscles
1573267|NCT02431910|Other|placebo Functional elastic tape|application of KT without tension in the vastos medialis, rectus femoris and vastus lateralis muscles
1573268|NCT02431897|Drug|Conjugated Estrogens Cream|0.625mg/1g cream, 1g applied vaginally nightly for 2 weeks then 2x/week for 6-8 weeks before surgery, then 2x/week for 1 year after surgery.
1573269|NCT02431897|Drug|Placebo Cream|1g applied vaginally nightly for 2 weeks then 2x/week for 6-8 weeks before surgery, then 2x/week for 1 year after surgery.
1573271|NCT02431858|Device|E-Catheter (Pajunk)|
1573272|NCT02431858|Device|Sonolong Catheter (Pajunk)|
1573273|NCT02431845|Drug|SSRIs|usual dose SSRI for obsessive-compulsive disorder, i.e. fluoxetine 40~80 mg dose equivalents
1573274|NCT02431832|Drug|Augmentin tab|
1573275|NCT02431819|Device|contention socks|Patients wear contention socks during 15 days.
1573279|NCT02431793|Behavioral|EMC2 Strategy|Patients of providers randomized to the EMC2 arm will received study related educational tools at the time of their discharge including: (a) health-literacy appropriate MedSheet for hydrocodone-acetaminophen and (b) prescription written with Universal Medication Schedule Take-Wait-Stop language. Additionally, providers related to the patient will be prompted to counseling the patient including: (c) (c-1) ED providers prompted via EHR, (c-2) PCP prompted to counsel on follow-up visit via automated inbox message and (c-3) pharmacists prompted to counsel via request printed on prescription.
1573280|NCT02431793|Behavioral|SMS Texting Reminders|In addition to the components of the EMC2 strategy arm, patients will received daily text message reminders about the safe use of opioids for 7 days.
1573285|NCT02431754|Drug|Tadalafil|Administered orally
1573286|NCT02431754|Drug|Placebo|Administered orally
1573287|NCT02431754|Drug|Alpha1 Blocker|Administered orally
1573288|NCT02431741|Device|Mepilex Transfer Ag|
1573289|NCT02431728|Dietary Supplement|Melatonin|5 mg capsule p.o. at bedtime daily
1573290|NCT02431728|Dietary Supplement|Matched Placebo|5 mg capsule p.o. at bedtime daily
1573291|NCT02431715|Drug|[18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)|"All patients will have their weight and baseline vital signs recorded.
The study subject will have an intravenous catheter inserted and receive a slow bolus intravenous dose of 185 - 370 MBq (5 -10mCi) 18F-FDOPA.
The patient will rest in a comfortable reclining chair in a warm, private shielded room for 45 to 60 minutes.
Patients are positioned supine and centered on the scanner bed for an average total scan time (CT and PET) of approximately 30 minutes.
Images will be interpreted by qualified and experienced physicians. Findings of significance from the PET/CT scan, and any incidental findings of significance from the CT scan, will be included in the single final report that will be issued to referring physicians."
1573292|NCT02431702|Drug|Aripiprazole|Aripiprazole will be administered in accordance with the label or Investigator's discretion
1573293|NCT02431702|Drug|Haloperidol|Haloperidol will be administered in accordance with the label or Investigator's discretion
1573294|NCT02431702|Drug|Olanzapine|Olanzapine will be administered in accordance with the label or Investigator's discretion
1573295|NCT02431702|Drug|Oral Paliperidone ER|Paliperidone Extended Release (ER) tablets 1.5 to 12 milligram (mg) per day will be administered orally.
1573296|NCT02431702|Drug|Perphenazine|Perphenazine will be administered in accordance with the label or Investigator's discretion
1573297|NCT02431702|Drug|Quetiapine|Quetiapine will be administered in accordance with the label or Investigator's discretion
1573298|NCT02431702|Drug|Oral Risperidone|Risperidone tablets 1-6 mg per day will be administered orally.
1573299|NCT02431702|Drug|Paliperidone Palmitate Injection (PP1M)|Participants will receive 5 doses of PP1M. First dose at a starting dose of 234 mg on Day 1 and a second dose of 156 mg on Day 8 and then 78 to 234 mg (in 3 flexible doses), every month up to Day 92.
1573300|NCT02431702|Drug|Paliperidone Palmitate Injection (PP3M)|Paliperidone Palmitate injection (PP3M) will be administered once every 12 weeks intramuscularly. The initial dose will be calculated as 3.5 fold multiple of the final PP1M dose administered on Day 92 (or Day 176). Dose will be increased based on Investigator's discretion.
1573301|NCT02431689|Procedure|IVF/ICSI|controlled ovarian hyperstimulation with various protocols, follow up till stimulated follicles measure from 18-20 mm, then ovum pickup followed by embryo transfer is done.
1573302|NCT02431676|Drug|Metformin|Participants will receive metformin, an oral medication for type 2 diabetes.Participants randomized to the metformin intervention will receive metformin up to 2,000 mg per day.Dosing can be flexible, two or three times per day with meals as tolerated for 12 months.
1573303|NCT02431676|Behavioral|Coach Directed Behavioral Weight Loss|Behavioral-based telephonic coaching with web-based support to promote healthy lifestyle and weight loss in overweight and obese adults.The goal of this intervention is to achieve at least 5% weight loss in the first six months of the intervention and maintain these improvements through month twelve by meeting dietary and exercise goals
1573304|NCT02431676|Behavioral|Self-control weight loss|
1573305|NCT02431663|Drug|Ketamine|Intravenous administration in continuous
1573306|NCT02431650|Drug|OZ439|
1573307|NCT02431650|Drug|Primaquine|
1573308|NCT02431637|Biological|Administration of the malaria inoculum|Each participant in the cohort will be inoculated on Day 0 with ~2,800 viable parasites of Plasmodium falciparum-infected human erythrocytes (BSPC) administered intravenously. The threshold for commencement of treatment will be when PCR quantification of all participants is ≥ 5,000 parasites/mL.
1573309|NCT02431637|Drug|Piperaquine Phosphate 480 mg|When PCR quantification of all participants is ≥ 5,000 parasites/mL, participants will receive a single dose of 480 mg Piperaquine Phosphate
1573310|NCT02431624|Drug|BTDS|
1573311|NCT02431611|Behavioral|Biomarker feedback (phone based smoking cessation counseling)|Feedback on maternal cotinine and likely infant NNAL Phone based behavioral smoking cessation counseling
1573312|NCT02431611|Behavioral|Control condition (phone based smoking cessation counseling)|phone-based behavioral smoking cessation counseling
1573313|NCT02431598|Drug|gadoxetate disodium|
1573314|NCT02431598|Drug|gadoterate dimeglumine|
1573315|NCT02431598|Drug|Saline|
1573316|NCT02431585|Dietary Supplement|gluten|
1573317|NCT02431585|Dietary Supplement|placebo|
1573318|NCT02431572|Other|PBR PET|
1573319|NCT02431572|Biological|Cancer Immunotherapy|Subjects who are to be treated with immunotherapy for glioblastoma or melanoma brain metastases will be eligible for 2 of the 3 arms.
1573320|NCT02431572|Radiation|Radiation and chemotherapy|Subjects with glioblastoma will receive or will have received treatment with chemotherapy and radiation per the standard of care.
1573321|NCT02431559|Drug|Durvalumab|
1573322|NCT02431559|Drug|Pegylated Liposomal Doxorubicin|
1573323|NCT02431546|Behavioral|Mobile Health Application|"Health coaching is an innovative, holistic approach oriented towards one's full health and wellbeing. Coaches provide mentoring and support regarding many areas of life that impact one's health with a focus on skill-building. Health coaches do not provide medical advice, treat any medical conditions, provide mental health therapy, or provide individualized assessments of nutrient needs. Health coaches will not conduct medication counseling activities that would alter the prescribed regimen nor provide medication information/advice that would be considered the practice of medicine or pharmacy.
A Fitbit activity monitor will be used to track daily physical activity and provide real-time feedback to the participant."
1574064|NCT02426190|Device|Recumbent bike or Nu-step|
1573325|NCT02431533|Dietary Supplement|Di-Calcium Phosphate|Patients in the 'placebo' group will receive the placebo capsules. The main ingredient in the placebo capsule is Di-Calcium Phosphate
1573326|NCT02431520|Procedure|Self-collection|Women allocated to this arm will be asked to obtain a specimen of vaginal/cervical by self-collection for HCII.
1573327|NCT02431520|Procedure|Gynecologist collection|Women allocated to this arm will be asked to attend to medical office to have their Pap smear obtained by a gynecologist
1573328|NCT02431507|Device|Magnap|This is a non-randomized clinical trial.Patients 21-70 years diagnosed with moderate to severe obstructive sleep apnea will have the Magnap Magnetic Apnea Device surgically implanted on the subject's hyoid bone and used in conjunction with an external neck brace and magnet to open airway during sleep in treatment of Obstructive Sleep Apnea. We will monitor for safety, brace compliance and improvement of symptoms of sleep apnea for a total of 13 months.
1573329|NCT02431494|Device|Blue light phototherapy|Blue light phototherapy (BLU-U Blue Light Photodynamic Therapy Illuminator manufactured by DUSA Pharmaceutical Inc. Wilmington, MA) At each session, the affected areas of the participant's face will be exposed to a light source using blue light phototherapy machine between 15 to 20 minutes. The duration of each session will be approximately 20 minutes.
1573330|NCT02431494|Device|Microcurrent therapy|Microcurrent therapy (Micro Current Electro-Device w/gloves and carrying case, SKU:DSE-X1008 Classic Spa Collection) The investigators will place one electrode in one of the regional areas of the lymph nodes or affected area (i.e. the forehead) and move the second electrode systematically from the affected area towards the stationary electrode. Once the entire affected area has been covered, the investigators will move the first electrode to another regional area of the lymph nodes or affected area and the process will be repeated. This will continue until all of the affected areas have been treated. The duration of each session will be approximately 45 minutes.
1573331|NCT02431494|Device|Combination of BLP and Microcurrent|Same devices as described above. At each session, participants will receive MCT portion as described in above followed by BLP portion as described above. These visits will last approximately 65 minutes.
1573333|NCT02431468|Drug|Bryostatin 1|The investigational drug product, bryostatin, is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution. Placebo is a sterile, pyrogen-free, lyophilized powder intended for IV infusion upon reconstitution and dilution.
1573334|NCT02431468|Other|Placebo|The placebo is a sterile, pyrogen-free, lyophilized powder identical in appearance to the active drug, intended for IV infusion upon reconstitution and dilution.
1573335|NCT02431455|Device|Incentive spirometer|Incentive spirometer is provided to the patient, this is the current standard of care, and is the control arm.
1573336|NCT02431455|Device|No incentive spirometer|No incentive spirometer is provided to the patient, this is the study arm.
1573337|NCT02431442|Drug|RM-493|
1573338|NCT02431442|Drug|Placebo|
1573339|NCT02431429|Drug|Miltefosine|
1573340|NCT02431416|Drug|Gonadotropin releasing hormone (GnRH)|Gonadotropin releasing hormone GnRH (Relefact LHRH) iv injection, single dose, 100 micrograms/square meter body surface, maximum dose: 100 microgram.
1573341|NCT02431416|Drug|Sodium Chloride|Sodium chlorid 9 mg/mL will be given as a single iv injection with the same volume as the volume used for the active substance injection.
1573342|NCT02431403|Drug|ESHAP-Imatinib|After selection of the maximum-tolerated dose of the combination ESHAP with imatinib a phase 2 of the study will be performed in order to evaluate the ORR of ESHAP-imatinib.
1573343|NCT02431390|Device|RAPAELⓇ Smart Glove digital treatment system|The RAPAELⓇ Smart Glove digital treatment system is constituted for stroke rehabilitation. For use, stroke patients wear the gloves and play the games or puzzle for rehabilitation of upper limbs. The system provides biofeedback to user.
1573344|NCT02431390|Behavioral|Additional occupational therapy|30 minutes of additional conventional occupational therapy session composed of hand dexteriy training
1573345|NCT02431377|Other|S-26 Gold|A commercial whey protein dominant, first age formula, containing whey protein concentrate with alpha-lactalbumin
1573346|NCT02431364|Drug|Verdinexor|
1573347|NCT02431364|Other|Placebo|
1573348|NCT02431351|Drug|Selinexor|60 mg on Day 1 of each week for a 4 week cycle, given for ≥6 cycles.
1573349|NCT02431338|Procedure|Remote ischemic conditioning|Intermittent arm ischemia through four cycles of alternating 5-minute inflation followed by 5-minute deflation of a blood pressure cuff placed around the upper arm.
1573350|NCT02431325|Drug|Teduglutide|
1573351|NCT02431325|Drug|Placebo|
1573352|NCT02431312|Biological|Group A: INO-1800 alone delivered by EP|
1573353|NCT02431312|Biological|Group B: INO-1800 + INO-9112 delivered by EP|
1573354|NCT02431312|Drug|Nucleos(t)ide Analogue Treatment|Continue treatment with Nucleos(t)ide Analogue Treatment
1573355|NCT02431286|Drug|Aprepitant|aprepitant will be administered in preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
1573356|NCT02431286|Drug|Placebo|Placebo will be administered in the preoperative period; intravenous palonosetron and dexamethasone will be administered intraoperatively
1573357|NCT02431286|Drug|Dexamethasone|Dexamethasone and plonosetron will be administered intraoperatively in both groups, durong surgery
1573358|NCT02431273|Drug|TDF IVR|
1573359|NCT02431273|Drug|TDF-FTC IVR|
1573360|NCT02431273|Drug|TDF-FTC-MVC IVR|
1573361|NCT02431260|Drug|INCB054329 Monotherapy|Initial cohort dose of INCB054329 monotherapy at the protocol-specified starting dose in the treatment group A (TGA), with subsequent cohort escalations in the three treatment groups (TGA, TGB, and TGC) based on protocol-specific criteria
1996528|NCT02463214|Other|Engineered Room|"Touchless devices:
Hand sanitizers, faucets, paper towel dispensers, call devices, Ultraviolet C Aseptix™ Disinfection devices above bathroom doors
Copper products:
Room and bathroom entrance door hardware, over bed table and bed side table surfaces, chair metal arms, wardrobe handles and knobs, weigh scale, sinks, grab bars, light switch panels, toilet flush handles, faucets and handles, patient bed rails.
Titanium dioxide paint:
Room walls, head walls, light switches, bathroom wall shelves, toilet tank and bowl, head wall unit fixed equipment, television remote and Bed Control remote"
1996529|NCT02463175|Drug|Plasmalyte|Boluses of 5ml/kg of plasmalyte
1996530|NCT02463175|Procedure|Goal-directed fluid therapy (GDT)|Intraoperative goal-directed fluid therapy (GDT)
1573369|NCT02431221|Drug|Perhexiline|perhexiline maleate, oral, 25mg or 100mg tablets Whenever initiating PHM therapy, subjects will receive a loading regimen of PHM as indicated in in the Heart Metabolics Dose Justification document. Drug levels will be measured first on Day 4 +/- 1 day, with an initial dose adjustment performed on Day 7 +/- 1 day, as needed. The next sampling will occur on Day 21 +/- 1 day for potential dose adjustment, as advised by the DCC, on or about Day 24. Subsequent dosing will be monitored and advised by a Dose Control Center
1573370|NCT02431221|Drug|Placebo|
1573371|NCT02431208|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Participants will receive intravenous (IV) atezolizumab until loss of clinical benefit, withdrawal, or study end. Cohorts A to C will receive 1200 milligrams (mg) on Day 1 of each 21-day cycle. Cohorts D to F (combination with daratumumab) will receive 840 mg on Days 2 and 16 of Cycle 1 and on Days 1 and 15 of each 28-day cycle thereafter.
1573372|NCT02431208|Drug|Daratumumab|Participants will receive 16 milligrams per kilogram (mg/kg) IV daratumumab until loss of clinical benefit, withdrawal, or study end. Treatment will be per the U.S. Package Insert and given on Days 1, 8, 15, 22 of Cycles 1 and 2; on Days 1 and 15 of Cycles 3 to 6; and on Day 1 of each 28-day cycle thereafter.
1573373|NCT02431208|Drug|Lenalidomide|Lenalidomide will be administered orally (PO) until loss of clinical benefit, withdrawal, or study end. Cohort B1 will receive 10, 15, or 25 mg, ascending-dose lenalidomide, on Days 1-14 of each 21-day cycle. Cohort C will receive 10 mg on Days 1-14 of each 21-day cycle, beginning in Cycle 4. Cohort E (combination with daratumumab) will receive 10, 15, or 25 mg on Days 1-21 of each 28-day cycle. Participants in Cohort E1 will receive ascending-dose lenalidomide, and those in Cohort E2 will receive lenalidomide at the MTD as determined in Cohort E1.
1573374|NCT02431208|Drug|Pomalidomide|Pomalidomide will be administered PO until loss of clinical benefit, withdrawal, or study end. Cohort F (combination with daratumumab) will receive 2 or 4 mg on Days 1-21 of each 28-day cycle. Participants in Cohort F1 will receive ascending-dose pomalidomide, and those in Cohort F2 will receive pomalidomide at the MTD as determined in Cohort F1.
1573375|NCT02431182|Behavioral|Memory Training Workshop|"Presentation of the workshop: Objectives and Methodology
Explanation of the different types of memory and its implication in normal life
Strategies for gathering and codification of the information
Strategies for selection and storage the information
Strategies for gathering, codification, selection, storage and recuperation of the information. Importance of the context and the meaning of things. Semantic and episodic memory
Strategies for gathering, codification, selection, storage and recuperation of the information. Individual differences
Strategies for recuperation according to the individual profile. Improving self-esteem
Strategies for recuperation Social skills.
Personal and social skills
New contexts and opportunities
Evaluation of the workshop"
1573376|NCT02431156|Other|Assessment of visual capacity|"Visual capacity (VC) is variable comprised by three sub-variables: a) (DVC) Visual capacity for activities requiring distant vision, b) (IVC) Visual capacity for activities requiring intermediate vision, and c) (NVC) Visual capacity for activities requiring near vision.
VC will be measured in a scale from 1 to 100 as the sum of the DVC, IVC and NVC"
1573377|NCT02431143|Drug|Miltefosine|
1573378|NCT02431130|Other|low-fidelity instructor driven simulation training|
1573379|NCT02431104|Device|532-nm KTP/1064-nm Nd:YAG Dual-Pulse Duration Laser|Cutera enlighten dual wavelength 532nm KTP/1064nm Nd:YAG laser
1573380|NCT02431091|Other|Optical Coherence Tomography|Optical Coherence Tomography provides a non invasive evaluation of the thickness of different layers of the retina
1573381|NCT02431078|Procedure|Routine comprehensive treatment|Radical gastrectomy for gastric cancer and postoperative adjuvant chemotherapy
1573382|NCT02431065|Procedure|Rectus sheath block|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:
Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.
Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
1573383|NCT02431065|Drug|Ropivacaine|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:
Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.
Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
1573384|NCT02431065|Other|Normal saline|"Local anesthetics (Ropivacaine 0.75% 10ml) or normal saline (10ml) will be injected in the rectus sheath via different methods:
Control group Normal saline 10mL will be injected under ultrasonography guidance into the right, left rectus sheath at the end of the operation before emergence from general anesthesia.
Ultrasonography group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under ultrasonography guidance into the right left rectus sheath at the end of the operation before emergence from general anesthesia.
Direct injection group Local anesthetic (Ropivacaine 0.75% 10 mL) will be injected under direct visualization into the right, left rectus sheath at the end of the operation before emergence from general anesthesia."
1573385|NCT02431052|Drug|DRM01|
1573386|NCT02431052|Other|Vehicle|
1573387|NCT02431039|Device|NEOSORB PLUS|Fascia and subcutaneous tissue repaired by antibacterial suture materials (Chlorhexidine diacetate coated PGLA910)
1573388|NCT02431039|Device|NEOSORB|Fascia and subcutaneous tissue repaired by non-antibacterial suture materials (PGLA910)
1573389|NCT02431026|Device|Cooling pack activated Excel Cryo Cooling Collar|Cooling pack will be activated before insertion into collar. The first cooling pack will be replaced 20 minutes later with a new, activated cooling pack.
1573390|NCT02431013|Drug|Simvastatin|Simvastatin 40 mg on Day 1 & Day 8.
1573391|NCT02431013|Drug|Pravastatin|Pravastatin 20 mg on Day 1 & Day 8.
1573392|NCT02431013|Drug|Cilostazol|Cilostazol 100 mg twice a day for 6 days & on Day 8 with statin.
1574065|NCT02426177|Drug|Labetalol|anti-hypertensive agents
1573394|NCT02430987|Other|questionnaire|will be applied questionnaire about sexuality
1573395|NCT02430974|Drug|Icotinib|Patients in experimental group will receive oral Icotinib for 4-8months.
1573396|NCT02430948|Other|Color-coded materials|A summary of treatment recommendations for each cancer screening is color-coded to indicate the strength and direction of the recommendation
1573397|NCT02430948|Other|Academic detailing|Educational outreach to address the rationale and data supporting recommendations for and against screening
1573398|NCT02430948|Other|Standard support|Screening recommendations presented in standard format
1573399|NCT02430948|Other|No academic detailing|Physician receives study orientation for not the academic detailing curriculum
1573400|NCT02430935|Behavioral|Cognitive Adaptation Training|Cognitive Adaptation Training (CAT) is a manual-driven standardized approach that uses environmental supports to improve multiple domains of adaptive functioning including adherence to medication, grooming, and activities of daily living in patients with schizophrenia. Interventions for each functional deficit are based on two dimensions 1) level of impairment in executive functions (determined by neurocognitive tests) and 2) whether the overt behavior of the individual is characterized more by apathy (poverty of speech/movement/inability to initiate and follow through on behavioral sequences), disinhibition (distractibility/behavior which is highly cue-driven) or a combination of these styles (based on the Frontal Lobe Personality Scale (FLOPS).
1573401|NCT02430935|Behavioral|Action Based Cognitive Remediation|ABCR is applied in once weekly 2 hour sessions in small groups (6-8 per group). In these group sessions, simulated bridging activities are done immediately following computerized cognitive activation to increase the chance that participants retain the strategies just developed in a real life environment.
1573402|NCT02430922|Device|iVolution nitinol stent|
1573403|NCT02430909|Biological|Bimekizumab|"Pharmaceutical form: Solution for infusion
Concentration: Vials at 80 mg/ml will be diluted with 0.9% sodium chloride to a final concentration to achieve the correct dose
Route of administration: iv infustion"
1573404|NCT02430909|Biological|Certolizumab Pegol|"Pharmaceutical form: Prefilled syringes
Concentration: 200 mg/ml
Route of administration: Subcutaneous injection"
1573405|NCT02430909|Other|Placebo|"Pharmaceutical form: Solution for infusion
Concentration: 0.9% saline
Route of administration: Intravenous infusion"
1573408|NCT02430883|Procedure|Retrograde Intrarenal Surgery|endoscopic treatment of kidney stones with flexible renoscopy
1573409|NCT02430870|Drug|TAK-648|TAK-648 solution
1573410|NCT02430870|Drug|Placebo|TAK-648 placebo-matching solution
1573411|NCT02430857|Other|OMT|Manuel osteopathic treatment of the spine
1573412|NCT02430831|Dietary Supplement|Nidina|
1573413|NCT02430831|Dietary Supplement|Placebo|
1573414|NCT02430818|Drug|ketamine|
1573415|NCT02430818|Drug|morphine|
1573416|NCT02430805|Other|dna extraction and genotyping|blood and urine sample
1573417|NCT02430792|Behavioral|Football|The football training will consist of sessions of 20 minutes of warm-up exercises. Followed by 20 minutes dribbling, passing, shooting exercises. Ends with 20 minutes of 5-7 a-side games.
1573418|NCT02430779|Procedure|rreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Renal Pelvic and Ureteral Neoplasms guide with ultrasound or/and CT.
1573419|NCT02430779|Device|NanoKnife|
1573420|NCT02430766|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Lymph Node Metastases guide with ultrasound or/and CT.
1573421|NCT02430766|Device|NanoKnife|
1573422|NCT02430753|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Lung Neoplasms accompanied by Respiratory Function Insufficiency guide with ultrasound or/and CT.
1573423|NCT02430753|Device|NanoKnife|
1573424|NCT02430740|Drug|recFSH|
1573425|NCT02430714|Drug|Lenvatinib|24mg once daily oral dosing to Unresectable thyroid cancer patients
1573426|NCT02430701|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Esophageal Neoplasms guide with ultrasound or/and CT.
1573427|NCT02430701|Device|NanoKnife|
1573428|NCT02430688|Procedure|Irreversible electroporation (IRE)|
1573429|NCT02430688|Device|NanoKnife|
1573430|NCT02430675|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
1573431|NCT02430675|Device|NanoKnife|
1573432|NCT02430662|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
1573433|NCT02430662|Device|NanoKnife|
1573434|NCT02430649|Procedure|Irreversible electroporation (IRE)|
1573435|NCT02430649|Device|NanoKnife|
1573436|NCT02430636|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Stomach Neoplasms guide with ultrasound or/and CT.
1573437|NCT02430636|Device|NanoKnife|
1573438|NCT02430623|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Urinary Bladder Neoplasms guide with ultrasound or/and CT.
1573439|NCT02430623|Device|NanoKnife|
1573440|NCT02430610|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Uterine Cervical Neoplasms guide with ultrasound or/and CT.
1573441|NCT02430610|Device|NanoKnife|
1573442|NCT02430597|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Hilus Pulmonis Neoplasms guide with ultrasound or/and CT.
1573443|NCT02430597|Device|NanoKnife|
1573444|NCT02430584|Other|Observational - no intervention|
1573445|NCT02430558|Biological|OD-PHOENIX|dellelularized, freeze-dried, irradiated osteochondral allograft
1573446|NCT02430545|Drug|Glasdegib|Subjects receive a 100mg oral dose of glasdegib under fasted conditions with washout, then single 100mg oral dose of glasdegib under fasted following dosing to steady state with rifampin
1573447|NCT02430545|Drug|Rifampin|Subjects receive rifampin 600 mg oral dose daily [Day -6 to day 4]
1573448|NCT02430532|Drug|dimethyl fumarate|capsule
1573449|NCT02430532|Other|Placebo|matched placebo capsule
1573450|NCT02430519|Procedure|Furcation treatment with PRF|PRF Placed into the furcation after flap elevation and debridement
1573451|NCT02430519|Procedure|Furcation Treatment with Allograft and GTR|Allograft and GTR placed into furcation after flap elevation and debridement
1573452|NCT02430519|Device|allograft and guided tissue regeneration (GTR) membrane (DFDBM and Healiguide)|
1573453|NCT02430519|Device|autologous platelet-rich fibrin|
1573454|NCT02430506|Biological|Placebo|This is the identical buffer solution in which AERAS-402 is formulated.
1573455|NCT02430506|Biological|AERAS-402|Given to 8 participants that were QFT-G(-) at screening and 8 participants that were GFT-G(+) at screening.
1573458|NCT02430467|Behavioral|Caregiver-guided pain management training (CG-PMT)|Patient-caregiver dyads in the CG-PM arm of the study will receive 3 50-minute sessions via Skype with a masters-level therapist over a 3-week period. The intervention integrates educational information about cancer pain and its management with a behavioral training program to teach patients and caregivers pain coping skills including relaxation, imagery, and activity pacing, and to teach caregivers how to guide and coach the patient in the practice and application of these pain control techniques.
1573459|NCT02430467|Behavioral|Enhanced treatment-as-usual (TAU)|Patient-caregiver dyads in the Enhanced TAU condition will receive the same educational video and booklet on cancer pain and its management that is used as part of the CG-PMT intervention. They will also receive iPads with icons linked to reputable websites that provide educational information on cancer including cancer pain (e.g., ACS, NCI) and will be encouraged to utilize them for information and support. However, they will not meet with a study interventionist nor receive any training in behavioral pain coping skills.
1573460|NCT02430454|Behavioral|Increased cognitive load|simulated conditions to increase cognitive load: encourage first impression, time-limit, distractions
1573462|NCT02430415|Device|laryngoscope-assisted lightwand intubation|laryngoscope-assisted lightwand intubation
1573463|NCT02430415|Device|traditional lightwand intubation|traditional lightwand intubation
1573464|NCT02430402|Other|Rehabilitation in warm climate|
1573465|NCT02430389|Drug|Remifentanil|Ninety seconds before pinning, an IV bolus of 10 mL of remifentanil (0.7 µg•kg-1 based on ideal body weight) will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
1573466|NCT02430389|Drug|Normal Saline|Ninety seconds before pinning, an IV bolus of 10 mL of normal saline will be administered from the study syringe and an IV bolus of propofol (0.7 mg•kg-1) will be administered
1573467|NCT02430363|Drug|MK - 3475|Administered Intravenously
1573468|NCT02430363|Biological|Suppressor of the PI3K/Akt pathways|Capsules orally with food
1573469|NCT02430350|Drug|Compound Edaravone Injection|
1573470|NCT02430350|Drug|Edaravone Injection|
1573471|NCT02430337|Behavioral|Technology-Assisted SafeCare|A technology-enhanced version of SafeCare
1573472|NCT02430337|Behavioral|SafeCare|SafeCare, an evidence-based home visiting program
1573473|NCT02430324|Other|posttraumatic cerebral infarction|the difference between groups refers to the developing of cerebral infarction after traumatic brain injury
1996533|NCT02463305|Drug|Creatine monohydrate|
1573477|NCT02430298|Drug|Melatonin|Drug: Melatonin 20 mg/ 10 ml melatonin suspension gargle for 2 minutes before radiation 15 minutes and 20 mg melatonin gelatin capsule taken orally after 21:00 hours each night throughout the study
1573478|NCT02430298|Drug|Matched Placebo|Drug: Melatonin 20 mg/ 10 ml placebo suspension gargle for 2 minutes before radiation 15 minutes and 20 mg placebo gelatin capsule taken orally after 21:00 hours each night throughout the study
1573479|NCT02430285|Procedure|Endoscopic Ultrasound|Endoscopic Ultrasound
1573480|NCT02430285|Device|Olympus 180 series echoendoscope|
1573481|NCT02430272|Drug|Glycopyrrolate|Intravenously administered 0.005mg/Kg of glycopyrrolate in intervention group
1573482|NCT02430259|Drug|Weekly INH / RRT given by DOT|weekly oral Rifapentine 15 mg/kg (up to 900mg) plus Isoniazid 15 mg/kg (up to 900mg) for 12 doses
1573483|NCT02430246|Dietary Supplement|Urex Plus|Probiotic
1573484|NCT02430246|Other|Placebo|capsule without active ingredient
1573485|NCT02430246|Dietary Supplement|Probotic capsule containing L. rhamnosus GR-1and L. reuteri RC-14|
1573486|NCT02430233|Drug|micronized progesterone 400 mg (Utrogestan)|participants receive vaginal micronized progesterone (Utrogestan- 200mg×2 PV(per vagina) per day)
1573487|NCT02430233|Other|Placebo|The control group will receive the inert solvent material as a placebo
1573488|NCT02430207|Procedure|temporary pacing femoral vein|Temporary pacing via femoral or subclavian vein
1573489|NCT02430207|Procedure|temporary pacing subclavian vein|
1573490|NCT02430194|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
1573491|NCT02430194|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
1573492|NCT02430194|Drug|PEG IFN-a|immunomodulator
1573493|NCT02430181|Drug|lonafarnib|antiviral farnesyl transferase inhibitor
1573494|NCT02430181|Drug|PEG IFN-a|immunomodulator
1573495|NCT02430181|Drug|Ritonavir|CYP 3A4 inhibitor, lonafarnib booster
1573496|NCT02430168|Procedure|Percutaneous nephrolithotomy|
1573497|NCT02430168|Procedure|Retrograde intrarenal surgery|
1573498|NCT02430155|Device|Bakri balloon|is a 100% silicone construction, dual channel balloon catheter specifically designed and approved by FDA for intrauterine placement in cases of PPH. The Bakri balloon contains no latex, and therefore can be safely used in patients with latex allergies
1573630|NCT02429219|Drug|Saline Irrigation with Ethanol|Saline Irrigation with Ethanol (alcohol)
1996534|NCT02463305|Other|Placebo|
1996535|NCT02462213|Other|Amyloidosis|Patients with amyloidosis without cardiac involvement will undergo cardiac MRI and possible biochemical analysis during the course of the study.
1573499|NCT02430155|Device|Condom loaded foley's catheter|Under aseptic precautions a sterile rubber catheter was inserted within the condom and tied near the mouth of the condom by a silk thread.
1573500|NCT02430142|Other|Vasoocclusive testing|Forearm vasoocclusive testing with a laser-doppler spectrophotometry system, transpulmonary thermodilution and blood sampling;
1573501|NCT02430129|Procedure|Total knee arthroplasty|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
1573502|NCT02430129|Procedure|Unicompartment knee arthroplasty|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
1573503|NCT02430129|Device|Persona|Zimmer Persona posterior cruciate retaining total knee arthroplasty (ZImmer, Warsaw, IN)
1573504|NCT02430129|Device|Oxford|Biomet Oxford mobile-bearing unicompartmental knee arthroplasty (Biomet, Warsaw, IN)
1573505|NCT02430116|Procedure|Ischemic postconditioning|In the Treat group, the procedure involved 5 min before opening the ascending aorta, aortic unclamping for 30 s, and cross-clamping for 30 s for three cycles, after which the ascending aorta was completely opened.
1573506|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
1573507|NCT02430090|Drug|Fentanyl|this used in intratechal area and for spinal anesthesia in ceserean section
1573508|NCT02430090|Drug|Sufentanil|this used in intratechal area and for spinal anesthesia in ceserean section
1573509|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
1573510|NCT02430090|Drug|Levobupivacaine|this used in intratechal area and for spinal anesthesia in ceserean section
1573511|NCT02430077|Drug|Obeticholic Acid|Capsules of obeticholic acid (OCA) or an identical placebo in the dose of 25 mg/day for a period of 4 months .
1573512|NCT02430077|Drug|Placebo|Identical to Obeticholic Acid - placebo drug
1573513|NCT02430064|Other|Low PAMP diet|
1573514|NCT02430051|Behavioral|Sensory Adapted Dental Environment|The SADE intervention includes adaptations such as dimmed lighting, moving projections on the ceiling (fish, bubbles), exposure to soothing music, and application of a butterfly vest with wings that wrap around the child to provide calming sensations.
1573515|NCT02430012|Behavioral|Quality improvement strategies|Training with guidelines of secondary preventions; determining improvement goals; tools (workflow posters and cards, checklists to inform the use of secondary prevention medications); periodical quality feedback report.
1573516|NCT02429999|Drug|Letrezole plus FSH|letrozole, 10 mg daily from day 3-7 and FSH 75IU/day from day 5 continuously and GnRH antagonist (orgalutran 0.25) is given when the follicle size equal to 14 mm till hCG injection.
1573517|NCT02429999|Drug|Standard protocol for induction of ovulation|0.1 decapeptyl from day 21 in the previous cycle and continuously stimulated by FSH (150-225IU/day) from day 2.
1573518|NCT02429986|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation proceeds by continually measuring either minute ventilation or airflow and calculates a target ventilation to be applied as needed.
1573519|NCT02429973|Drug|Gemcitabine plus rapamycin|Gemcitabine and rapamycin given in combination
1573520|NCT02429960|Device|Analgesia monitor (PhysioDoloris®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
1573521|NCT02429960|Device|Analgesia monitor (SPI®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
1573522|NCT02429960|Device|Analgesia monitor (AlgiScan®)|Comparison of three different analgesia monitoring systems (PhysioDoloris®, SPI® and AlgiScan®).
1573523|NCT02429960|Drug|Remifentanil|Remifentanil will be increased step-by-step from 0.05 mcg/kg/min to 0.2 mcg/kg/min. After ensuring a steady-state period of remifentanil infusion of at least 5 minutes, the standardized painful stimuli will be applied.
1573524|NCT02429934|Drug|abatacept|125mg injected subcutaneously weekly for 16 weeks
1573525|NCT02429934|Drug|Placebo|
1573526|NCT02429921|Dietary Supplement|high-selenium lentils|lentils grown on naturally selenium-rich soils in the Canadian Prairies
1573527|NCT02429921|Dietary Supplement|Low-Se lentils|lentils grown on selenium-deficient soils in Idaho, USA.
1573528|NCT02429908|Device|TM-Ardis Interbody|The TM Ardis implant is a single device manufactured wholly from Trabecular Metal™ (porous tantalum) material, a highly porous, three-dimensional biomaterial designed for biologic fixation. is indicated for use with autogenous bone graft as an intervertebral body fusion device at one or two contiguous levels in the lumbosacral region (L2- S1) in the treatment of degenerative disc disease (DDD) with up to Grade 1 spondylolisthesis or retrolisthesis at the involved level(s).
1573529|NCT02429895|Drug|ABT-122|Injection
1573530|NCT02429882|Drug|Brodalumab 210 mg|210 mg brodalumab will be administered subcutaneously
1573531|NCT02429882|Drug|Placebo|Placebo will be administered subcutaneously
1573532|NCT02429869|Drug|everolimus|
1996536|NCT02462213|Other|Cardiac Amyloidosis|Patients with confirmed cardiac amyloidosis will undergo cardiac MRI and possible biochemical analysis during the course of the study.
1573534|NCT02429843|Drug|TRC105|Each patient will be dosed with 6, 8, or 10 mg/kg of TRC105 up to a maximum dose of 850 mg for women and 1,000 mg for men based upon overall body weight.
1573536|NCT02429817|Drug|Technetium-99m - Diethylenetriaminepentaacetic acid|99mTc-DTPA solution placed on the nebulizer reservoir
1573537|NCT02429817|Device|Aeroneb Solo|
1573538|NCT02429817|Device|Jet Nebulizer|
1573539|NCT02429817|Other|Single photon emission computed tomography|Imaging technique to investigate lung aerosol distribution
1573540|NCT02429817|Other|Spirometry|FEV1, FVC assessment
1573541|NCT02429804|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo contrast-enhanced MRI
1573542|NCT02429804|Drug|Fludeoxyglucose F-18|Given IV
1573543|NCT02429804|Drug|Fluorine F 18 Sodium Fluoride|Given IV
1573544|NCT02429804|Procedure|Magnetic Resonance Imaging|Undergo PET/MRI
1573545|NCT02429804|Procedure|Positron Emission Tomography|Undergo PET/MRI
1996538|NCT02461082|Device|Expiratory muscle strength training (EMST)|The EMST is performed 4 weeks, 5 days per week, for 20 minutes per day, using a calibrated or sham, handheld device (EMST 150, Aspire Products, Gainesville, FL).
1996539|NCT02461082|Other|Transcranial magnetic stimulation (TMS)|A sham or active transcranial magnetic stimulation is performed at the last 5 days of EMST training.
1996540|NCT02459301|Drug|IPH2201|
1573549|NCT02429778|Behavioral|Diaphragmatic Breathing|Deep or diaphragmatic breathing is taught prior to relaxation.
1573550|NCT02429778|Behavioral|Progressive Muscle Relaxation|Tensing and releasing muscle groups in a specified order to help reduce tension and anxiety.
1573551|NCT02429765|Drug|ACL/FOR|
1573552|NCT02429765|Drug|Placebo|
1573553|NCT02429752|Other|Inspiratory muscle training|Subjects that demonstrate unresolved BPD's upon reassessment after PT treatment, will have the option to participate in the second phase of the study. These subjects will be scheduled twice a week to receive IMT using the RT2 device and software program. The IMT protocol uses biofeedback to train at a specific percentage of MIP and SMIP for each inspiratory effort.
1573554|NCT02429739|Behavioral|Working memory Training|"The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30 - 45 minutes and the family has 6 weeks to complete the training. Each session consist 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
Other name: Cogmed RoboMemo"
1573555|NCT02429726|Drug|rAdp53|Recombinant adenoviral p53 human gene will be administered by intra chest cavity infusion
1573556|NCT02429726|Drug|Cisplatin|Cisplatin will be administered by intra chest cavity infusion
1573557|NCT02429726|Drug|rAdp53 plus cisplatin|Recombinant adenoviral p53 human gene combined with cisplatin will be administered by intra chest cavity infusion
1573558|NCT02429713|Procedure|Short-duration tourniquet|Short-duration tourniquet group:inflate the tourniquet immediately before cement application and deflated after its hardening
1573559|NCT02429713|Procedure|Long-duration tourniquet|Long-duration tourniquet group: inflate the tourniquet immediately before incision and deflated after the hardening of the cement
1573560|NCT02429700|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours
1573561|NCT02429700|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
1573562|NCT02429700|Drug|Bleomycin|Bleomycin 30000IU IV/IM on day 1/8/15 for 12 weeks.
1573563|NCT02429700|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3 cycles.
1573564|NCT02429700|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity.
1573565|NCT02429687|Drug|Paclitaxel|Patients receive paclitaxel 175mg/㎡ IV over 3 hours
1573566|NCT02429687|Drug|Carboplatin|and carboplatin AUC 5-6 IV over 1 hour on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
1573567|NCT02429687|Drug|Bleomycin|Bleomycin 30000IU IV/IM on day 1/8/15 for 12 weeks.
1573568|NCT02429687|Drug|Etoposide|Etoposide 100mg/㎡ IV per day for 5 days every 3 weeks for 3 cycles.
1573569|NCT02429687|Drug|Cisplatin|Cisplatin 20mg/㎡ IV per day for 5 days every 3 weeks for 3 cycles in the absence of disease progression or unacceptable toxicity.
1573570|NCT02429674|Behavioral|TranS-C and IPT-A|The goal of IPT-A is to decrease depressive symptoms by focusing on current interpersonal difficulties and helping the adolescent improve his or her relationships and interpersonal interactions. This is accomplished through psychoeducation about the adolescent's depression and its link to interpersonal relationships, review of the adolescent's significant relationships, identification of interpersonal problem areas on which to focus the treatment, development of interpersonal problem solving and communication skills, and role-playing. The sleep disturbances intervention will include several modules selected because they are successful treatments for insomnia, and/or may help promote adherence to some of the recommendations related to sleep.
1573571|NCT02429661|Behavioral|Peer support groups|
1573572|NCT02429648|Procedure|DCC first then PVI|DCC performed prior to PVI
1573573|NCT02429648|Procedure|PVI then DCC after|DCC performed after PVI, if patient remains in Atrial Fibrillation
1573574|NCT02429635|Behavioral|My exercise|"Health Screening I and II Questionnaires on health and lifestyle, physiological test of fitness, physiological health tests and blood profile - compiled in a health profile report. Individual guidance and advice from professional health advisor.
Team-workshop I and II A 2 hours' workshop lead and facilitated by a trained and professional health advisor. It consists of short talks on exercise and health, and on health behavior change and motivation in addition to work with self-reflection and discussion tasks. Competence, support and advice during 2. workshop.
Exercise groups Small groups with similar exercise level and ambitions who support each other in their efforts to establish new exercise habits according to their individual exercise plan"
1573575|NCT02429622|Radiation|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage once respectively
1573576|NCT02429622|Drug|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week concurrent with radiotherapy for 5weeks
1573577|NCT02429622|Drug|Nedaplatin|Nedaplatin 25mg/m2 per week concurrent with radiotherapy for 5weeks
1573578|NCT02429622|Procedure|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
1573579|NCT02429609|Device|Moorfields Acuity Chart|
1573580|NCT02429596|Drug|Experimental|Switch from brand to generic
1573581|NCT02429583|Drug|Recombivax|Injection of Recombivax HBV vaccine administered IM, at 0, 1, and 6 months after enrollment
1573583|NCT02429557|Other|Abdominal compression|Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
1573584|NCT02429557|Other|Sham abdominal compression|Sham abdominal compression of 5 mmHg with a commercial inflatable cuff applied during head up tilt
1573585|NCT02429557|Drug|Placebo pill|Placebo pill given 1 hour before the second heat up tilt
1573586|NCT02429557|Drug|midodrine|Midodrine single dose 2.5-10mg PO given 1 hour before the second head up tilt
1573587|NCT02429544|Behavioral|Residential Program|Participants attend a 7-day offsite, residential support program. On Day 5 of the program, participant joined by spouse or caregiver.
1573740|NCT02428413|Device|Standard oxygen mask|Provide supplemental oxygen
1573588|NCT02429544|Behavioral|Questionnaires|Questionnaires completed about mood, sleep, fatigue, how participant has been feeling, and their general quality of life at baseline visit, 1 month after baseline, 7 days after residential program ends, and again about 3 months later.
1573589|NCT02429544|Device|Electroencephalogram (EEG)|EEG performed at baseline with simultaneous computer testing consisting of 3 tests to check attention, short-term memory, and levels of emotions. EEG repeated 7 days after the residential program ends, and then again about 3 months later.
1573590|NCT02429544|Other|Saliva Testing|Day after baseline visit, saliva collected for 3 days at different times to measure cortisol levels. Saliva testing repeated 7 days after the residential program ends, and then again about 3 months later.
1573591|NCT02429544|Behavioral|Study Diary plus Actigraph|For seven days after baseline visit, participants complete study diary describing sleeping habits. An actigraph also worn during this time to record physical activity and sleeping habits.
1573592|NCT02429531|Biological|Pneumovax 23 (Sanofi Pasteur MSD)|Intramuscular injection of Pneumovax 23 vaccine (0.5 ml).
1573593|NCT02429531|Biological|Typhim Vi (Sanofi Pasteur MSD)|Intramuscular injection of Typhim Vi vaccine (0.5 ml).
1573594|NCT02429518|Drug|Miltefosine|
1573595|NCT02429505|Drug|Miltefosine|miltefosine: target 2.5 mg/kg/day for 28 days
1573596|NCT02429492|Device|Electrophysiology|EMG recordings conditioned by electrical peripheral nerve stimulation and/or transcranial magnetic stimulation
1573597|NCT02429479|Behavioral|Making Your Wishes Known|Making Your Wishes Known provides tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a healthcare team.
1573598|NCT02429479|Behavioral|Standard advance care planning|This is a online simple living will form.
1573599|NCT02429466|Drug|SGI-110|SGI-110 will be given subcutaneously, daily, 30 mg/m2 on days (1-5) followed by cisplatin 100mg/m2 on day 8 every 4 weeks.
1573600|NCT02429453|Drug|Four Factor Prothrombin Complex Concentrate|A purified, non-activated prothrombin complex concentrate containing factors II, VII, IX and X and proteins C & S
1573601|NCT02429453|Biological|Fresh Frozen Plasma|A pooled collection of plasma from donors
1573602|NCT02429440|Biological|peptide vaccine|subcutaneous
1573603|NCT02429440|Drug|Granulocyte Macrophage Colony Stimulating Factor|intradermal
1573604|NCT02429440|Drug|Montanide ISA-51|subcutaneous
1573605|NCT02429427|Drug|Celecoxib|Patients will receive 400mg of Celecoxib once daily for two years or until disease progression (if before the two years limit) or until development of unacceptable toxicities. In addition ER(+) patients will receive endocrine treatment according to local practice.
1573606|NCT02429427|Other|Placebo|Two capsules once daily with food
1573607|NCT02429414|Device|Non-Video Double Lumen Tube (DLT)|Participant receives non-video double lumen tube (DLT) placement before surgery.
1573608|NCT02429414|Procedure|Fiberoptic Bronchoscopy (FOB)|Fiberoptic bronchoscopy (FOB) performed to check placement of non-video DLT.
1573609|NCT02429414|Device|Video Double Lumen Tube (VDLT)|Participant receives video double lumen tube (VDLT) placement before surgery.
1573610|NCT02429401|Behavioral|Non-adapted brief motivational interview|1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
1573611|NCT02429401|Behavioral|Culturally adapted brief motivational interview|Addresses impact of acculturative stress and drinking norms based on screening results and 1) provide personalized feedback based on screening and baseline assessment, 2) explore decisional balance (pros and cons) of alcohol use from the patient's perspective, 3) build motivation for change through the assessment and discuss the patient's self-report of lf levels of importance, confidence, and readiness to change drinking, 4) enhance commitment to change by exploring the patient's options for change, and developing a change plan if indicated, 5) provide formal alcohol treatment referrals and community resources.
1573612|NCT02429388|Drug|Spironolactone|Administration of spironolactone 25-50mg orally twice daily for two days and subsequently titrated upto 100mg twice daily with daily serum potassium monitoring. Spironolactone will continue until patient is euvolemic and appropriate for discharge. Titration of loop diuretics in this arm will not be escalated.
1573613|NCT02429375|Drug|Mocetinostat Plus Brentuximab Vedotin|All patients will receive a 1-week lead-in with mocetinostat alone (administered days 1, 3, and 5). Patients with palpable peripheral lymph nodes will undergo FNA before and after this 1 week treatment. Cycle 1 will then begin 15 days (+/-3 days) following initiation of the lead-in.
1573615|NCT02429323|Drug|Sevoflurane|use of 8% sevoflurane in compared to incremental dose increased each few breaths from 1% to 8%
1573616|NCT02429310|Device|Revitive IX|This is a neuromuscular electrical stimulation device
1573617|NCT02429297|Other|HITCM-only|HITCM-only group: patients receive weekly automated calls with feedback to the clinical team.
1573618|NCT02429297|Other|HITCM+CP|HITCM + CP group: patients receive weekly automated calls with feedback to the clinical team and their CarePartner receives updates via phone or email.
1573619|NCT02429271|Drug|Ticagrelor|
1573620|NCT02429271|Drug|Clopidogrel|
1573621|NCT02429271|Procedure|Percutaneous Coronary Intervention (PCI)|
1573622|NCT02429271|Procedure|Coronary Angiography|
1573623|NCT02429258|Drug|Farxiga|Farxiga 10mg/day
1573624|NCT02429258|Drug|Placebo|Placebo
1573625|NCT02429258|Drug|Metformin|Metformin background therapy >/= 1500mg/day
1573626|NCT02429258|Drug|Insulin|Insulin >/= 30 units
1573627|NCT02429245|Other|Retrospective study|
1573628|NCT02429232|Drug|Pioglitazone|Pioglitazone 30mg/tablet once daily
1573629|NCT02429232|Drug|Linagliptin|Linagliptin 5mg/tablet once daily
1573631|NCT02429219|Procedure|transurethral resection of the prostate|transurethral electro-resection of the prostate (TURP)
1573632|NCT02429219|Procedure|photoselective vaporisation of the prostate|photoselective laser-vaporisation of the prostate (PVP)
1573633|NCT02429206|Other|SQIN|Each patient will be asked to self-apply both creams (experimental vs positive control) on the right and left sides of their body (sides will be randomly assigned).
1573634|NCT02429206|Other|standard moisturizing cream (Glaxal Base)|
1573637|NCT02429180|Other|Rehabilitation|"ReTrain: an exercise-based functional training programme comprising two phases: (1) weekly supervised sessions; (2) monthly drop-in sessions, plus home-based exercise in each phase.
Week 1: one-to-one consultations with trainer to introduce programme, assess individual's concerns and capabilities, introduce and negotiate initial goals
Weeks 2-11: bi-weekly 90 minute group class with group-based activities and one-to-one coaching, based on ongoing goal negotiation review and progression.
Week 12: one-to-one consultations with trainer to review goals and plan ongoing unsupervised exercise programme
Weeks 13-24: monthly drop-in sessions for one-to-one consultation, support and progression."
1573638|NCT02429154|Other|Normocapnia|Normoventilation in order to have an end-tidal carbon dioxide (ETCO2) of 5.5 kiloPascal (kPa)
1573639|NCT02429154|Other|Mild Hypercapnia|Decrease in minute ventilation in order to increase ETCO2 to 6.5 kPa
1573640|NCT02429141|Procedure|US-guided periarterial techique|The needle will be inserted in the axillary fossa in-plane (cranial to caudal) close to the intersection of the pectoralis and biceps muscles. Two separate injections of local anesthetic will be made deep and superficial to the axillary artery
1573641|NCT02429141|Procedure|US-guided multi-injection technique|The median, ulnar and radial nerves will be identified by ultrasound. Local anesthetic will be injected adjacent to each nerve
1573642|NCT02429128|Other|14 weeks exercise training|
1573643|NCT02429115|Other|Mentoring|Six months of peer-mentoring.
1573644|NCT02429102|Drug|MT-8554|
1573645|NCT02429102|Drug|Placebo|
1573646|NCT02429089|Drug|LEE011|"The first 12 patients will receive cetuximab associated with LEE011 at doses of 400 mg and 600 mg daily to determine the DLTs and safety.
In the expansion part, besides safety, objective response rate, progression-free survival and overall survival will be calculated with the inclusion of 14 patients."
1573647|NCT02429076|Drug|IV methylphenidate|IV methylphenidate will be administered to induce emergence from general anesthesia.
1573648|NCT02429076|Drug|Placebo|normal saline
1573649|NCT02429076|Drug|Sevoflurane|Inhaled anesthetic
1573650|NCT02429076|Drug|Propofol|IV anesthetic
1573651|NCT02429063|Device|Bright White Light|The light will be administered via a Litebook Elite (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
1573652|NCT02429063|Device|Dim Red Light|The light will be administered via a Litebook Elite (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
1573653|NCT02429050|Drug|sustained release morphine|Patients will receive morphine SR 10mg two to three times daily or placebo. Hard gelatin capsules of size AA in Swedish orange containing one morphine SR tablet 10 mg per capsule will be produced. Morphine SR has a marketing authorisation for pain and will be used according to current Dutch and international guidelines for treatment of dyspnea.
1573654|NCT02429050|Drug|placebo|Patients in the control group will receive placebo, consisting of microcrystalline cellulose (FMC BioPolymer). Hard gelatin capsules of size AA in Swedish orange containing microcrystalline cellulose will be produced.
1573655|NCT02429037|Drug|rAd-p53|multi-point injections of rAd-p53 into tumor on day 1, 8 and 15 at a dose of 2 × 10^12 viral particles (VP) in a 21-days cycle.
1573656|NCT02429037|Radiation|radiation|radiation therapy will be given at a total dose of 60 Gy by 2.0 Gy/fraction, daily Monday-Friday for 6 weeks.
1573657|NCT02429037|Drug|Cisplatin|Cisplatin 100 mg/m2 IV on days 1 plus paclitaxel 30 mg/m2 IV on day 1, 8 and 15
1573658|NCT02429024|Device|OneTouch Reveal® Mobile APP|Diabetes management application for use on a mobile phone.
1573659|NCT02429024|Device|OneTouch Verio® Flex BGMS|Blood Glucose Monitoring System (BGMS)
1573660|NCT02428998|Dietary Supplement|Korean Red Ginseng|
1573661|NCT02428998|Dietary Supplement|Placebo|
1573663|NCT02428972|Drug|Propofol|Propofol infusion @100-200 mcg/kg/min Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
1573664|NCT02428972|Drug|Sevoflurane|MAC of Sevoflurane will be maintained between 0.8-1.2 Fentanyl 1mcg/kg Vecuronium 0.1mg/kg Mannitol 1 gm/kg
1573665|NCT02428959|Drug|Amyl Nitrite|Amyl nitrite is the chemical compound with the formula C5H11ONO. It relaxes vascular smooth muscle; decreases venous ratios and arterial blood pressure; reduces left ventricular work; decreases myocardial oxygen consumption. The method of administration is via inhalation with onset of action within of 30 seconds and ends 2-3mins. In a study by Dodds et al., amyl nitrite is used as part of radiologic esophagram test in order to distinguish patients with pseudoachalasia from those with idiopathic achalasia since amyl nitrite has transient effect on the lower esophageal sphincter (LES). The study revealed that the LES pressure in achalasia patient decreases substantially in response to amyl nitrite with the measurable increase in LES diameter of 3 mm to an average of 4.6m. In contrast, amyl nitrite does not relax the LES segment in pseudoachalasia and has no change in LES diameter. Thus, the investigators anticipate amyl nitrite inhalation will be beneficial at the LES during HREM.
1574066|NCT02426177|Drug|Nifedipine|calcium channel blocker ,for lowering blood pressure
1573666|NCT02428946|Drug|Bromocriptine|Investigating the randomized order for timing of bromocriptine administration
1573667|NCT02428933|Drug|Bromocriptine|The investigators will look at the physiological effect of dopamine on BAT activity rather than on the effect of the drug itself
1573668|NCT02428920|Behavioral|Peer Groups|The intervention group arm will attend biweekly or monthly peer group meetings to discuss health successes and challenges.
1573669|NCT02428907|Behavioral|simulation training|teamtraining of endoscopy staff
1573670|NCT02428894|Device|LVAD|
1573671|NCT02428881|Drug|onabotulinumtoxinA|Patients received 100U onabotulinumtoxinA injection into the external urethral sphincter
1573672|NCT02428868|Drug|tranexamic acid (Exacyl®)|1 gram diluted in 20 mL saline solution, in 30 minutes, five minutes before skin incision and a second 1 gram, 3 hours later
1573673|NCT02428868|Drug|intravenous iron (Ferroven®)|2 vials of 10 mL containing each one 100 mg iron, diluted in 100 mL normal saline over 30 minutes before induction of anesthesia and repeated on day two and three.
1573674|NCT02428868|Other|Saline|20 mL saline in 30 minutes, five minutes before skin incision and 20 ml 3 hours later.
1573675|NCT02428855|Drug|Dasatinib|
1573676|NCT02428842|Procedure|Tumor biopsies|Tumor biopsies will be performed before and after treatment.
1573677|NCT02428842|Procedure|Blood sampling|Blood sampling will be performed before and after treatment.
1573678|NCT02428829|Procedure|Attempt walking from 4 hours post operatively, on the day of their surgery.|Intervention group will be seen by a physiotherapist to attempt walking from 4 hours post operatively, on the day of their surgery.
1573679|NCT02428829|Procedure|Control - standard treatment|standard physiotherapy in line with current hospital protocol including first walking approximately 24 hours post operatively.
1573680|NCT02428816|Other|MRI acquisition|MRI acquisitions
1573681|NCT02428816|Behavioral|behavioral evaluations|Evaluations about motor abilities, sleep, cognition and lifestyle
1573682|NCT02428803|Other|Telemedicine|Patients will be administered the KDQOL-SF and the IIRS and will all start in the standard of care arm. During this time period the patients will receive 6 months of visits as per the usual standard of care. At the end of 6 months the KDQOL-SF and IIRS will again be administered. The patient will then transition to the telemedicine arm of the study for the duration of 6 months. During this time, the patient will come to the dialysis unit on a quarterly basis for a standard visit with labs being drawn in-center and for an in-center Kt/V. For the 2 months following the visit ,however, the patient will not be required to come to the dialysis unit. The monthly face to face and labs will be achieved remotely
1573683|NCT02428777|Drug|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure.
1573684|NCT02428777|Drug|Diclofenac|Women will receive oral diclofenac 100 mg 1 hour before the procedure
1573685|NCT02428777|Drug|Placebo|Women will receive an oral placebo 1 hour before the procedure
1996541|NCT02460809|Device|Transcranial direct current stimulation (tDCS)|Transcranial direct current stimulation (tDCS) uses two surface electrodes placed on the scalp. These electrodes pass a low voltage current and modulate membrane potentials of underlying neurons.
1996542|NCT02460731|Other|Fresh Frozen Plasma|Fresh Frozen Plasma [young (<30 years of age) healthy male donors] Solution for intravenous infusion
1996543|NCT02460653|Device|HFNC Flow Rate|We only change the flow rates between low, medium and high settings.
1573690|NCT02428751|Drug|Pegylated liposomal doxorubicin|30 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
1573691|NCT02428751|Drug|Doxorubicin|50 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
1573692|NCT02428751|Drug|Rituximab|375 mg/m2, IV (in the vein) on day 0 of each 21 day cycle
1573693|NCT02428751|Drug|Cyclophophamide|750 mg/m2, IV (in the vein) on day 1 of each 21 day cycle
1573694|NCT02428751|Drug|Vincristine|1.4 mg/m2 (2mg in maxium), IV (in the vein) on day 1 of each 21 day cycle
1573695|NCT02428751|Drug|Prednisone|100mg/d, PO on day 1-5 of each 21 day cycle
1573696|NCT02428725|Other|blood sample|Biological samples will be done to determine platelet reactivity testing by VASP-index, will be obtained between 6 and 12 hours after receiving ticagrelor
1996544|NCT02459119|Drug|Regorafenib|Regorafenib will be packaged as 40 mg tablets in a bottle. Patients will be instructed to maintain a daily medication calendar.
1996545|NCT02457988|Device|Vivify Kit|home telemonitoring devices with vital sign capturing capabilities, i.e. blood pressure, weight, pulse, and specific questionnaires targeted to the cirrhosis diagnosis.
1573700|NCT02428686|Drug|Epoetin beta (NeoRecormon)|Epoetin beta 60 000 IU/week
1573701|NCT02428673|Other|Assisted Standing Treatment Program|
1573702|NCT02428660|Genetic|Pharmacogenetic testing|Genetic testing for 2D6, 2C9, 2C19, 3A4, 3A5 polymorphisms
1573703|NCT02428660|Other|Software-based drug & gene interaction risk analysis|By assessing a patient's medication list along with the frequencies of variant phenotypes in the population, YouScript is able to identify whether a patient might be at risk for an adverse drug event and suggest when testing might be appropriate.
1573704|NCT02428660|Other|MTM|Medication Therapy Management
1573705|NCT02428647|Dietary Supplement|MNP|MNP containing containing 10 mg zinc and 14 other nutrients, including 6 mg iron, 0.56 mg copper, 17 μg selenium, 90 μg iodine, 400 μg RE vitamin A, 5 μg vitamin D, 5 mg vitamin E, 30 mg ascorbic acid, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 0.5 mg vitamin B6, 0.9 μg vitamin B12, and 150 μg folate
1573706|NCT02428647|Dietary Supplement|preventive zinc supplement|7 mg zinc daily as dispersible tablet
1573707|NCT02428647|Dietary Supplement|therapeutic zinc supplement|20 mg zinc per day for 10 days during diarrhea episodes, as dispersible tablet
1573708|NCT02428647|Dietary Supplement|preventive placebo supplement|dispersible daily placebo tablet
1573709|NCT02428647|Dietary Supplement|therapeutic placebo supplement|dispersible placebo tablet for 10 days during diarrhea episodes
1573710|NCT02428647|Dietary Supplement|placebo powder|placebo powder
1573711|NCT02428634|Behavioral|PSIE13|The Program SI! is implemented from 1st to 3rd grade of Elementary. A total of 40 hours of intervention on 1st and 2nd grade and 30 hours on 3rd grade has been established as the minimum intervention per year.
1574493|NCT02423122|Drug|VX-745|Orally-Active Selective P45 MAP Kinase inhibitor
1573712|NCT02428634|Behavioral|PSIE46|The Program SI! is implemented from 4th to 6th grade of Elementary. A total of 30 hours of intervention has been established as the minimum intervention per year.
1573713|NCT02428621|Device|Twicare® appliance|"Early orthodontic treatment with the Twicare®. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.
The Twicare® is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
1573714|NCT02428621|Device|Removable Herbst appliance|"Early orthodontic treatment with the removable Herbst appliance. The Class II treatment is initiated at the age of 7-12 years and continued as long as the Class I is achieved.
The Herbst appliance is adjusted in mandibular protraction based on the 2/3 of the condylar test and was were worn during 12 to 14 hours a day (at least 4 hours during the day and all night)."
1573715|NCT02428608|Biological|DWP-450 (Botulinum purified neurotoxin, Type A)|Botulinum toxin, Type A
1573716|NCT02428595|Device|Eclipse™ System|"The Eclipse System is a vaginal bowel control (VBC) therapy intended to provide bowel control for women with fecal incontinence. It is comprised of a non-surgical device placed in the vagina (referred to as the Eclipse Insert) and a pressure-regulated pump which is used to inflate and deflate the Insert. A Sizing Kit, for use during the fitting process, and an evaluation Insert (referred to as the Trial Insert) are also part of the Eclipse System."
1573717|NCT02428582|Device|Covered stent (Atrium Type V12)|An endovascular treatment that consists of inserting a covered stent into the stenosed vessels.
1573718|NCT02428582|Device|Bare stent (Brand Cordis Type Palmaz Blue)|An endovascular treatment that consists of inserting a stent into the stenosed vessels.
1573719|NCT02428569|Behavioral|PREPARED Decision Support|The PREPARED DVD presents patient and health care provider testimonials that characterize the pros and cons of different kidney replacement treatment options, including in-center hemodialysis, home hemodialysis, peritoneal dialysis, kidney transplant, and conservative management (i.e., no dialysis or transplant). The PREPARED book reinforces differences between the treatments by showing (in lay language) summaries of scientific evidence on treatment outcomes associated with each kidney replacement option.
1573720|NCT02428556|Other|Facts only|Communicate basic information about breakthrough drugs provided in FDA press release without using Breakthrough label
1573721|NCT02428556|Other|promising language|"Communicate basic information about breakthrough drugs provided in FDA press release, using language commonly used by FDA in describing breakthrough drugs (promising drug)"
1573722|NCT02428556|Other|breakthrough only|Communicate basic information about breakthrough drugs provided in FDA press release using Breakthrough label (similar to information found in FDA press releases)
1573723|NCT02428556|Other|"breakthrough with may warning"|"Adding a tentative disclaimer (similar to that found on the FDA labels of some breakthrough designation drugs): Continued approval for this indication may be contingent upon verification and description of clinical trial benefit in confirmatory trials"
1573724|NCT02428556|Other|"breakthrough with is warning"|"Adding a more definitive disclaimer to minimize inaccurate inference from Breakthrough terminology: Continued approval for this indication is contingent upon verification and description of clinical trial benefit in confirmatory trials."
1573725|NCT02428543|Drug|Ponatinib and Cytarabine|Prospective, non-randomized, open-label, multicenter, dose-escalation phase I-II trial; an adaptive Bayesian logistic regression dose-escalation model incorporating escalation with overdose control will be used (Babb 1998, Tighiouart 2005). Each cohort will consist of 3 evaluable patients
1573726|NCT02428530|Other|Questionnaires|Norbeck Social Support Questionnaire (NSSQ)
1573727|NCT02428517|Procedure|AlloHCT for Young/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Cyclophosphamide 60 mg/kg (D-3 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
1573728|NCT02428517|Procedure|AlloHCT for Young/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-4) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
1573729|NCT02428517|Procedure|AlloHCT for Old/MSD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 1.5 mg/kg (D-3 to D-1)
1573730|NCT02428517|Procedure|AlloHCT for Old/MUD&FMD|Allogeneic hematopoietic cell transplantation with conditioning as follows; Busulfan 3.2 mg/kg (D-7 to D-6) Fludarabine 30 mg/m2 (D-7 to D-2) Thymoglobulin 3.0 mg/kg (D-3 to D-1)
1573731|NCT02428491|Biological|DTaP-IPV-Hep B-PRP-T combined vaccine (Hexaxim™)|0.5 mL, Intramuscular
1573732|NCT02428491|Biological|DTaP-IPV-Hep B-PRP-T combined vaccine (Hexaxim™)|0.5 mL, Intramuscular
1573733|NCT02428478|Drug|Desipramine|200 mg administered 2 hours before normal sleep time
1573734|NCT02428478|Drug|Placebo|Placebo-matching desipramine administered 2 hours before normal sleep time
1573735|NCT02428465|Behavioral|Purposeful Parenting|Purposeful Parenting reinforces responsive interactions that help promote emerging developmental skills. This information is presented over the course of a child's first 12 months, such that core lessons are the same but specific skills are designed to be developmentally appropriate. This repetitiveness, along with the provision of age-appropriate behavioral guidance, will allow parents to successfully engage in responsive interactions with their children.
1573736|NCT02428452|Behavioral|Social ABCs parent-mediated intervention program|The 6-month Social ABCs parent-mediated intervention consists of 12 weeks of parent training and a 12 week implementation phase. 15 training (parent coaching) sessions are provided by a Research Trainer. Each session with the trainer includes a review of the program manual, practice of the techniques in the child's home, and a 15 min video of the parent-child dyad practicing the intervention. Week 9 and 11 are phone consultations. After the active training is complete, the parent enters the 12-week implementation phase, which includes practicing the techniques on their own, with no trainer instruction or contact. The trainer re-visits the parent and child at Week 24 to collect three 15 min videos; 2 generalization videos are also taken with an untrained examiner.
1573738|NCT02428426|Other|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
1573739|NCT02428413|Device|ISO-Gard Mask|to scavenge waste anesthetic gases from patients and provide supplemental oxygen
1573741|NCT02428400|Biological|TG1050|TG1050: adenovirus serotype 5 vector based immunotherapeutic product in adenovirus reference material (ARM) buffer
1573742|NCT02428400|Biological|Placebo|Placebo: adenovirus reference material (ARM) buffer
1573743|NCT02428387|Behavioral|My Tools 4 Care|On-line self-administered (My Tools 4 Care) transition toolkit includes interactive activities and resources to help caregivers deal with their transitions
1573744|NCT02428374|Drug|Rosuvastatin plus clopidogrel|Crestor 40 mg daily plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
1573745|NCT02428374|Drug|Rosuvastatin plus ticagrelor|Crestor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
1573746|NCT02428374|Drug|Simvastatin plus clopidogrel|Zocor 40 mg plus Plavix 600 mg (initial dosis) and 75 mg daily up to 6-mo
1573747|NCT02428374|Drug|Simvastatin plus ticagrelor|Zocor 40 mg plus Brilinta 180 mg (initial dosis) and 90 mg bid up to 6-mo
1573749|NCT02428348|Other|Interview about prototype EEG-cap|
1573750|NCT02428322|Dietary Supplement|Placebo|Soft gel capsules will be identical to the vitamin D intervention but contain no vitamin D.
1573751|NCT02428322|Dietary Supplement|VItamin D3|Soft gel capsules will contain 2,000IU vitamin D.
1573752|NCT02428309|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|
1573754|NCT02428283|Drug|Ropivacaine|0.25% ropivacaine 2-3 ml was injected around the scalp nerves that are located on the head.
1573755|NCT02428283|Drug|Remifentanil|Remifentanil 1 μg/kg was injected before skin incision.
1573756|NCT02428283|Drug|Sevoflurane|Anesthesia was titrated with sevoflurane, maintaining mean arterial pressure and heart rate within 20% baseline value.
1573757|NCT02428270|Drug|GSK2256098|Small molecule inhibitor of focal adhesion kinase (FAK)
1573758|NCT02428270|Drug|Trametinib|Allosteric inhibitor of mitogen-activated extracellular signal-regulated kinase (MEK)1 and MEK2 activation and kinase activity.
1573759|NCT02428257|Procedure|continuous spinal anesthesia|Spinal puncture performed with a 19-gauge Tuohy needle at the L4-L5 or L3-L4 interspace using a midline approach. 3 cm of a 22-gauge catheter introduced through the needle, directed to the fractured side.
1573760|NCT02428257|Drug|hypobaric bupivacaine|hypobaric bupivacaine was prepared diluting each 1 ml of 0.5% isobaric bupivacaine with 1 ml of sterile water.
1573761|NCT02428257|Drug|isobaric bupivacaine|0.5% isobaric bupivacaine
1573762|NCT02428257|Drug|ephedrine|
1573763|NCT02428244|Behavioral|Motivational Interviewing|Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
1573764|NCT02428244|Behavioral|Motivational Interviewing + Follow-up|"Motivational Interviewing coupled with education will be provided to help participants understand the risks associated with smoking and their fracture care. They will be referred to the quitline.
In this intervention, the participants will receive additional motivational interviewing sessions at 2 weeks, 6 weeks, 3 months and 6 months."
1573765|NCT02428231|Drug|dimethyl fumarate|Participants will be dosed twice daily for 12 weeks.
1573766|NCT02428218|Drug|dimethyl fumarate|enteric-coated microtablets
1573767|NCT02428218|Drug|Placebo|enteric-coated microtablets
1573768|NCT02428205|Drug|Propranolol|Participant will receive Propranolol prior to each EIBI session
1573769|NCT02428205|Drug|Placebo|Participant will receive placebo prior to each EIBI session
1573773|NCT02428179|Procedure|StOP? - Control group|Control group - Surgical procedure without Study Intervention
1573774|NCT02428179|Procedure|StOP? - Intervention group|Intervention group - Surgical procedure with intraoperative briefings, optional interventions: Transparent drape between anesthesia and sterile team, Controlling noise and potential distractors during wound closure, Nutritional support during the operation
1573775|NCT02428153|Other|stretching exercises|static stretching exercise of 5 repetitions, with a duration of 45 seconds to the right gastrocnemius muscle and dynamic stretching exercise of 5 repetitions, with a duration of 45 seconds to the cases' left gastrocnemius muscles
1573778|NCT02428127|Dietary Supplement|Carbohydrate beverage powder|Carbohydrate beverage powder fortified with multiple micronutrients. 20g of study product will be administered orally twice a day
1573779|NCT02428127|Dietary Supplement|Calorie matched beverage powder|Calorie matched beverage powder with 80% protein.20g of study product will be administered orally twice a day
1573780|NCT02428127|Other|Water|lukewarm water
1573782|NCT02428088|Drug|Dasotraline|Dasotraline 2 mg once daily
1573783|NCT02428088|Drug|Dasotraline|Dasotraline 4 mg once daily
1573784|NCT02428088|Drug|Placebo Comparator|Placebo once daily
1573785|NCT02428075|Behavioral|FCHV visit|Female Community Health Volunteer will visit selected households 3 times a year for providing health promotion messages and measure the blood pressure
1573786|NCT02428062|Procedure|Hemodynamic target|"The anaesthesiologist is requested to maintain intraoperative mean arterial blood pressure of the patient within 10% of the baseline mean arterial blood pressure (recorded during the preoperative evaluation) of that patient. In order to reach this hemodynamic target the anesthesiologist can choose between one or more of the following four sub-interventions:
vasoconstrictor agents (either phenylephrine, ephedrine, epinephrine, norepinephrine or dopamine)
intravenous fluids
patient's positioning
reduction of depth of anesthesia"
1573787|NCT02428062|Drug|Phenylephrine|Phenylephrine 0.1-0.2 mg intravenous bolus
1573788|NCT02428062|Drug|Intravenous fluids|A crystalloid fluid bolus is given intravenously (5-10 ml/kg)
1573789|NCT02428062|Procedure|Patient's positioning|The operating table is positioned so that the patient's head lies below the level of the patient's feet (Trendelenburg position) in order to increase venous return
1574762|NCT02421107|Other|iStat intermittent testing|
1573790|NCT02428062|Procedure|Reduction of depth of anesthesia|The halogenated anesthetic vapor's inspiratory fraction is decreased in order to reduce the associated peripheral vasodilation
1573791|NCT02428062|Drug|Ephedrine|Ephedrine 5-25 mg intravenous bolus
1573792|NCT02428062|Drug|Epinephrine|Epinephrine 5-10 mcg intravenous bolus
1573793|NCT02428062|Drug|Norepinephrine|Norepinephrine 0.01 - 0.1 mcg/kg/min intravenous continuous infusion
1573794|NCT02428062|Drug|Dopamine|Dopamine 5 - 10 mcg/kg/min intravenous continuous infusion
1573795|NCT02428049|Radiation|Stereotactic or conventional radiotherapy and chemotherapy in curative intent|
1573796|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^6 TCID50/mL.
1573797|NCT02428036|Biological|TBI-1401(HF10)|Patients will receive intratumoral administrations of TBI-1401(HF10). The dose is 1 mL of 1x10^7 TCID50/mL.
1573799|NCT02427997|Behavioral|Treadmill training with Virtual Reality|"VR is defined in general as a high-end-computer interface that involves real time simulation and interactions through multiple sensorial channels. The VR system to be used requires subjects to negotiate virtual obstacles while walking on a treadmill, in a safe environment. This dual task activity has large cognitive components such as information processing, planning, and attention while allowing for training in a more stimulating and enriching environment that includes both cognitive and motor components."
1573800|NCT02427997|Behavioral|Treadmill training|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
1573801|NCT02427984|Other|Metal ions dosage and evaluation of local/systemic reaction|"Dosage of Chromium and Cobalt on several biological matrices deriving from each patients.
Determination of local/systemic reaction"
1573802|NCT02427984|Other|Noise registration and metal ions determination|"Dosage of Vanadium and Titanium on several biological matrices deriving from each patients.
Determination of range of noise"
1573803|NCT02427984|Other|Metal ions dosage, evaluation of local/systemic reaction, noise registration|"Dosage of Chromium, Cobalt, Vanadium and Titanium on several biological matrices deriving from each patients.
Determination of local/systemic reaction"
1573804|NCT02427958|Drug|Leuprorelin|Suspension for injection
1573805|NCT02427945|Behavioral|Provision of information on safe water|A promoter from Evidence Action will visit the household and provide information on safe water.
1573806|NCT02427945|Behavioral|Provision of information on safe water and child nutrition|A promoter from Evidence Action will visit the household and provide information on safe water, as well as child nutrition (including hygiene on food preparation and storage). Households will be given a poster to hang in their dwellings with basic nutrition information. The poster might be smaller and in black and white, or larger and in color.
1573807|NCT02427932|Drug|Ampicillin|Pregnant participants will receive Ampicillin 2g IV loading dose followed by 1g IV every 4 hrs until delivery for Group B Strep prophylaxis; non-pregnant participants will receive Ampicillin for qualifying diagnosis
1573808|NCT02427932|Drug|Ampicillin and Gentamicin|Pregnant participants will receive Ampicillin 2g IV every 6hrs along with Gentamicin 5mg/kg IV every 24 hrs for chorioamnionitis; non-pregnant participants will receive for qualifying diagnosis
1573809|NCT02427932|Drug|Gentamicin|Prescribed to non-pregnant participants
1573810|NCT02427919|Drug|G-CSF|Comparison of the effect of G-CSF use
1573811|NCT02427893|Drug|Cobimetinib|A potent and highly selective inhibitor of MEK1 and MEK2, central components of the RAS/RAF pathway.
1573812|NCT02427893|Drug|Vemurafenib|A low molecular weight, orally available inhibitor of the activated form of the BRAF serine-threonine kinase enzyme, which is commonly found in melanoma
1573813|NCT02427880|Drug|Acetazolamide and Hydrochlorothiazide Followed by Furosemide|
1573814|NCT02427880|Drug|Furosemide and Hydrochlorothiazide Followed by Furosemide|
1573815|NCT02427867|Other|Remote ischemic preconditioning|
1573816|NCT02427867|Other|no ischemic preconditioning|
1573817|NCT02427854|Behavioral|Education by animated training video|Training performed by watching an animated educational video.
1573818|NCT02427854|Procedure|Interactive hands-on bedside training|Training performed as a traditional bedside training supported by a trainer in person.
1573819|NCT02427841|Drug|Fluorouracil|Given IV
1573820|NCT02427841|Drug|Gemcitabine Hydrochloride|Given IV
1573821|NCT02427841|Radiation|Image Guided Radiation Therapy|Undergo IG-IMRT
1573822|NCT02427841|Radiation|Intensity-Modulated Radiation Therapy|Undergo IG-IMRT
1573823|NCT02427841|Other|Laboratory Biomarker Analysis|Correlative studies
1573824|NCT02427841|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1573825|NCT02427841|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1573826|NCT02427828|Device|Visensia Respiration Rate Estimation Service (VRES)|Medical device product to provide respiration rate from PPG signal
1573827|NCT02427815|Behavioral|Intervention Group|Participants randomly assigned to the intervention arm will receive OSA health education and social support from a trained Peer Educator.
1573828|NCT02427802|Drug|Gentamicin collagen sponge|Up to 4 topical Gentamicin Collagen Sponges each containing 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
1573829|NCT02427802|Other|Placebo|Matching collagen sponge
1573830|NCT02427789|Other|Physical Exercise|physical exercise
1573831|NCT02427776|Biological|Autologous CD4+T cells stimulated and expanded ex vivo by a MOG peptide modified by the introduction of a thioreductase motif into the flanking residues of the T cell epitope|1 administration comprising 5 - 50 millions of cells
1573832|NCT02427763|Device|hours of use (Essix)|the patient will use de thermoplastic device during the night or during all day
1573833|NCT02427763|Other|collect saliva|the patient spit during 30 seconds in a small bottle
1573834|NCT02427763|Other|collect biofilm|a sterile swab is rubbed at the buccal surface of the upper teeth
1573835|NCT02427763|Other|collect epithelium|a sterile cytobrush is rubbed at the buccal surface of gingiva at the upper arch
1573836|NCT02427750|Biological|Aggripal®|TIV
1574763|NCT02421094|Drug|GR-MD-02|GM-MD-02 active
1573842|NCT02427711|Device|Bipolar sealer|Prospective trial with Aquamantys for surgical skin and capsula incision w a retrospective control group using a conventional scalpel skin and capsula incision.
1573843|NCT02427698|Procedure|cyrolipolysis (CoolSculpting device)|Treatment will be a cold exposure for up to 120 minutes using the CoolSculpting device with a commercially available treatment setting.
1573844|NCT02427698|Procedure|subcision|The skin will be punctured using a subcision needle to cut the septa responsible for the skin depression after cryolipolysis.
1573845|NCT02427685|Device|Pulse Co-Ox|Comparison of pulse co-oximeter to blood gas analyzer.
1573846|NCT02427672|Device|Transcranial direct current stimulation|
1573847|NCT02427672|Device|Sham transcranial direct current stimulation|
1573848|NCT02427659|Behavioral|Virtual Reality Distraction|The subjects will receive a 20-minute Virtual Reality Distraction (VRD) during their wound care procedure. The nurse will be doing their wound care.
1573849|NCT02427659|Behavioral|Audio (sound of nature)|"The subjects will listen to an audio recording called Sounds of Nature during their wound care."
1573850|NCT02427659|Behavioral|Control standard nurse wound care|The subjects will receive their standard care during wound care. The nurse will be doing the wound care.
1573851|NCT02427646|Drug|IncobotulinumtoxinA|A serotype of botulinum toxins that has specificity for cleavage of SYNAPTOSOMAL-ASSOCIATED PROTEIN 25 (SNAP-25). BoNT-A's pharmacological action is to inhibit the release of acetylcholine from the neuromuscular junction. BoNT-A peripherally applied using optimal parameters by intramuscular injections to treat tremor in the most bothersome upper extremity every 16 weeks over 96 weeks. The study will be extended for those participants who benefited and will receive treatment every 12 weeks over 96 weeks. BoNT-A dose will range from 50-300 U per arm.
1573852|NCT02427633|Other|Educational Intervention UKRC 1997|Educational poster intervention indicating the modified UKRC 1997 recovery position
1573853|NCT02427633|Other|Educational Intervention UKRC 2010|Educational poster intervention indicating the modified UKRC 2010 recovery position
1573854|NCT02427620|Drug|Ibrutinib|Part 1: 560 mg by mouth on Days 1 - 28 of a 28-day cycle.
1573855|NCT02427620|Drug|Rituximab|"Part 1: 375 mg/m2 by vein every week during the first cycle, then Day 1 of Cycles 3 - 12 of a 28 day cycle.
Part 2 First Combination: 375 mg/m2 by vein on Day 1 of a 28 day cycle.
Part 2 Second Combination: 375 mg/m2 by vein on Day 1 of a 21 day cycle."
1573856|NCT02427620|Drug|Cyclophosphamide|Part 2 First Combination: 300 mg/m2/per dose by vein every 12 hours for 6 doses starting at any time after Rituximab infusion ends on Days 2 - 4 of a 28 day cycle.
1573857|NCT02427620|Drug|Dexamethasone|Part 2 First Combination: 40 mg by mouth or vein on Days 1 - 4 of a 28 day cycle.
1573858|NCT02427620|Drug|Mesna|Part 2 First Combination: 600 mg/m/dose by vein daily on Days 2, 3, and 4 of a 28 day cycle.
1573859|NCT02427620|Drug|Vincristine|Part 2 First Combination: 1.4 mg/m2 (maximum 2 mg) by vein on after last dose of Cyclophosphamide on Day 5 of a 28 day cycle.
1573860|NCT02427620|Drug|Doxorubicin|Part 2 First Combination: 50 mg/ m2/day by vein after last dose of Cyclophosphamide and before or after Vincristine on Day 5 of a 28 day cycle.
1573861|NCT02427620|Drug|G-CSF|"Part 2 First Combination: 480 mcg subcutaneously daily starting 24 - 36 hours after last dose of Cyclophosphamide until granulocytes more than 4 x 10 3/dl.
Part 2 Second Combination: 480 mcg daily starting 24 - 36 hours after last dose of Cytarabine until granulocytes more than 4 x 10 3/dl."
1573862|NCT02427620|Drug|Methotrexate|Part 2 Second Combination: 200 mg/m2 by vein, then 800 mg/m2 by vein on Day 2 of a 21 day cycle.
1573863|NCT02427620|Drug|Cytarabine|Part 2 Second Combination: 3 g/m2 by vein every 12 hours for 4 doses on Day 3 and Day 4 of a 21 day cycle.
1573864|NCT02427620|Drug|Citrovorum|Part 2 Second Combination: 50 mg by mouth 2 hours after Methotrexate infusion is completed followed by 15 mg by mouth every 6 hours for 8 doses in a 21 day cycle.
1573866|NCT02427594|Drug|Sodium bicarbonate|Drug/dietary supplement is used in a crossover design to lower the nonvolatile acid load of the diet compared to the control period.
1573867|NCT02427594|Other|Controlled diet|Diet without sodium bicarbonate supplementation
1573868|NCT02427581|Biological|Personalized synthetic long peptide vaccine (Poly ICLC)|
1573869|NCT02427581|Drug|Poly ICLC|
1573870|NCT02427568|Drug|MDMA|Subjects undergo two day-long experimental sessions of psychotherapy
1573871|NCT02427568|Drug|Placebo|Subjects undergo two day-long experimental sessions of psychotherapy
1573872|NCT02427555|Other|Barley kernel bread|3 days intervention with barley kernel bread
1573873|NCT02427555|Other|white wheat bread|3 days intervention with white wheat bread
1573874|NCT02427542|Other|CBT for Depersonalization/Derealization|In addition to treatment as usual, six sessions of Cognitive Behavioural Therapy for Depersonalization/Derealisation covering psychoeducation, formulation, coping strategies.
1573875|NCT02427542|Other|Treatment as usual|Treatment as usual - in most cases case management/care coordination and may include medication
1573876|NCT02427529|Drug|Human Chorionic Gonadotropin|The addition of hormone to a daily low calorie diet to potentially aid in selective fat loss, or muscle-sparing.
1573877|NCT02427529|Drug|Placebo|
1573878|NCT02427529|Other|Low calorie diet|
1573879|NCT02427503|Procedure|Asthma with NP and require surgery|To evaluate the effect on asthma of functional endoscopic sinus surgery of bilateral sinonasal polyposis in patients diagnosed with persistent asthma and grade II or III sinonasal polyposis.
1573919|NCT02427256|Device|Device: Topcon Specular Microscope SP-1P|Device: Topcon Specular Microscope SP-1P
1996556|NCT02453386|Drug|tozadenant|
1996557|NCT02453386|Drug|placebo|
1996558|NCT02453282|Biological|MEDI4736 (Durvalumab)|
1573880|NCT02427490|Behavioral|Problem-Solving Intervention|The problem-solving approach that will be taught in the problem-solving intervention is based on the ADAPT model, which encourages participants to follow five steps when solving problems: focus on adopting a positive attitude to problem-solving, define the problem and set goals, generate a list of alternative solutions to the problem, predict consequences of the alternative solutions, and try implementing the most promising solution from among the list of alternatives. The problem-solving intervention will be delivered by a trained interventionist in three structured sessions using videoconferencing tools.
1573881|NCT02427490|Other|Unenhanced Monitoring|Study participant completes standardized questionnaires upon study enrollment and at two, four, and eight weeks after study enrollment.
1573882|NCT02427477|Device|senofilcon A|Subjects will wear the contact lenses in both eyes for seven days
1573883|NCT02427477|Device|delefilcon A|Subjects will wear the contact lenses in both eyes for seven days
1573886|NCT02427451|Drug|Bcl-2 Inhibitor GDC-0199|Given PO
1573887|NCT02427451|Biological|Obinutuzumab|Given IV
1573888|NCT02427451|Drug|Ibrutinib|Given PO
1573889|NCT02427451|Other|Pharmacological Study|Correlative studies
1573890|NCT02427451|Other|Laboratory Biomarker Analysis|Correlative studies
1573891|NCT02427451|Other|Quality-of-Life Assessment|Ancillary studies
1573894|NCT02427425|Device|TENS|
1573895|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected into the knee joint at the end of surgery, 3 g diluted in 30 ml saline water.
1573896|NCT02427412|Drug|Saline water|30 ml of Saline water injected into the knee capsula at the end of surgery.
1573897|NCT02427412|Drug|Tranexamic Acid|An anti-fibrinolytic drug injected intravenous at the beginning of surgery for BOTH groups.
1573898|NCT02427399|Other|Letter and informational sheet|The patients in this group will be mailed a letter at time 0. The letter will inform the patient that she is overdue for a Pap and will also contain an informational sheet about cervical cancer and Pap tests.
1573899|NCT02427399|Other|Email|The same text shared in the letter will be sent as an email to the patients in this intervention group, again at time 0, 1, and 2 months, as necessary for nonresponders.
1573900|NCT02427399|Other|Phone|The patient will be telephoned and informed that they are due for a Pap, and given the opportunity to schedule an appointment over the phone immediately. Patients will be contacted at time 0, 1, and 2 months as necessary for nonresponders.
1573901|NCT02427399|Other|Multimodal|The patient will be sent a letter/informational sheet at time 0. If she does not respond within one month, she will be sent an email. If she does not respond by 2 months after the start of the intervention period, she will be called.
1573902|NCT02427386|Drug|dynamized estrogen|The dosage of the homeopathic medicine or placebo will be of 3 drops, 2 times a day throughout the period of study, and can be reduced in case of finding of homeopathic aggravation of symptoms. 30 ml bottles will be sufficient for the proposed dosage every 8 weeks of treatment (bimensal period).
1573903|NCT02427386|Drug|placebo|The dosage of the placebo (alcohol solution) will be of 3 drops, 2 times a day throughout the period of study.
1573904|NCT02427373|Dietary Supplement|fish oil ethyl ester|
1573905|NCT02427373|Dietary Supplement|fish oil triglyceride|
1573906|NCT02427373|Dietary Supplement|krill oil|
1573907|NCT02427347|Other|Acupuncture|Acupuncture needles of 0.3mm in diameter and 100mm in length are inserted into gallbladder-meridian(GB)26 about 25-65mm deep by an angle of 15°, following the path of Dai Meridian (towards medial and downside) . The other acupoints are inserted with needles of 0.25-0.3mm in diameter and 25-40mm in length approximately 10-30mm deep, with an angle of 90°. Electro-acupuncture is applied to both sides of GB26 and stomach-meridian(ST)25: cathode is connected to GB26; anode to ST25. Dense-disperse wave pattern and a wave frequency of 2/100 Hertz is chosen. The intensity of the electro-acupuncture is adjusted on average 4-8 milliampere. The needles are subsequently retained for 20min. The results of the study are based on 8 weeks, each week consisting of 3 sessions.
1573908|NCT02427347|Other|Healthy education|Healthy knowledge lectures and issuing brochures are given. Education of patients for conditioning and changing bad habits, diet, quit smoking, limit alcohol consumption, salt restriction, appropriate increase in physical activity.
1573909|NCT02427334|Drug|Dienogest|women will receive oral dienogest 2mg for 14 days starting from the 15th day of menstruation
1573910|NCT02427334|Drug|Fluoxetine|women will receive oral fluoxetine 20mg for 14 days starting from the 15th day of menstruation
1573911|NCT02427334|Drug|Placebo|women will receive oral placebo for 14 days starting from the 15th day of menstruation
1573912|NCT02427321|Device|Video recording of flexible cystoscopic examination|The video feed from the flexible cystoscopic examination will be recorded for all participants in the study. Proof-of-concept device will record high-definition video in a lossless format to a computer hard-drive from any existing cystoscopy equipment
1573913|NCT02427308|Drug|Miltefosine|target dose = 2.5 mg/kg/day for 28 days
1573914|NCT02427295|Drug|Sandostatin (Octreotide Acetate)|"For the patients outlined above (refer to 2), subjects who are not able to be treated by surgery alone:
Dose: Sandostatin LAR® 20mg per 4 weeks for 3 months -> If serum IFG-1 levels fails to normalize, the dose of LAR will be increased to 30 mg.
Frequency: every 4 weeks.
Route of administration: IM injection."
1573915|NCT02427282|Device|miniscrew-supported Frog molar distalizing appliance|miniscrew 10mm length and 1.7mm diameter FORESTADENT company
1573916|NCT02427282|Device|Standard Frog molar distalizing appliance|Nance buttons attached to first premolars band
1573922|NCT02427230|Behavioral|Pelvic floor muscle training|"The intervention in group 1 consists of three private lessons in PFMT conducted by a physiotherapist every 4th week.
At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks."
1573923|NCT02427230|Behavioral|Pelvic floor muscle training|"The intervention in group 2 consist of three private lessons in PFMT and intravaginal NMES conducted by a physiotherapist every 4th week.
At each consultation the physiotherapist will use manual palpation of the pelvic floor muscles and Electromyography Biofeedback (EMG). Patients will be instructed to carry out three series of approximately 10 near-maximal pelvic floor muscle contractions held for approximately 6-8 seconds daily during 12 weeks.
Additionally, patients will be instructed on how to use intravaginal NMES and each patient receives a vaginal electrical stimulator (CefarPeristim Pro). The NMES settings consist of two different frequencies, 40 Hz and 10 Hz, and patients are instructed to use both settings daily for maximum 30 minutes during 12 weeks."
1573924|NCT02427230|Drug|vaginal electrical stimulator (CefarPeristim Pro)|electrical stimulation
1573925|NCT02427217|Biological|FCH|FCH is a heat-treated, lyophilized fibrinogen (coagulation factor I) powder made from pooled human plasma. FCH is administered as an IV infusion.
1573928|NCT02427178|Biological|Hematopoietic Allogeneic Stem Cells|HLA 10/10 matched allogeneic bone marrow cells will be infused into recipient (patient).
1573929|NCT02427165|Drug|RPL554|A dual PDE3 and PDE4 inhibitor
1573930|NCT02427165|Drug|Salbutamol|a beta-2 receptor agonist
1573931|NCT02427165|Drug|Placebo|RPL554 placebo containing no active ingredients
1573932|NCT02427139|Device|ANSiStim|ANSiStim allows continuous point stimulation over a period of several days while offering the patient a high degree of comfort and mobility at the same time. Use of the ANSiSTIM therapy provides overwhelming advantage over drug therapy minimizing possible side-effects caused by pain medications (i.e. opioid) such as, for example, impaired reactions. In most cases, the patient continues to lead its life as normal, without side effects or any loss of quality of life.
1573933|NCT02427126|Drug|Apixaban|Apixaban is an oral anticoagulant currently approved for prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation, for the treatment of deep vein thrombosis and pulmonary embolism, and for the prophylaxis of systemic embolism after orthopedic surgery
1573934|NCT02427126|Drug|Aspirin|Acetylic Salicylic Acid 100mg o.d.; 12 Months
1573935|NCT02427113|Other|Sound Oasis Vibrating Chair|Sound oasis vibroacoustic chair will be used as treatment for managing TMD related pain
1573936|NCT02427113|Other|Self-Select Music|The self-select music of the participants will be applied for managing the painful symptoms of TMD
1996559|NCT02453282|Biological|MEDI4736 (Durvalumab)+Tremelimumab|
1573938|NCT02427087|Behavioral|Continuous Aerobic Training twice|Supervised aerobic exercise program of 60 min/2 days/week at 60-85% of heart rate reserve for 24 weeks and healthy diet
1573939|NCT02427087|Behavioral|Healthy Diet|Diet group (21) Recommendation for healthy diet.
1573940|NCT02427074|Procedure|Balloon Compression Rhizotomy|The balloon compression rhizotomy is performed in a percutaneous fashion where a Fogarty catheter is positioned in the gasserian ganglion and inflated with 0,7 milliliters of radiopaque dye during 120 seconds.
1573941|NCT02427074|Procedure|Radiofrequency Thermal Coagulation Rhizotomy|The gasserian ganglion is submitted to a controlled thermal coagulation with a electrode with 80 Celsius degrees of temperature during 60 seconds on the specific division.
1573942|NCT02427061|Behavioral|Intervention Program (Manhood 2.0)|
1573943|NCT02427061|Behavioral|Control Program (Job Skills Training)|
1573944|NCT02427048|Behavioral|Feedback with Peer Comparison|Email detailing adherence to CAP and SS CPG for every month since start of study. Physicians will be provided individualized feedback and given patient identifiers for each patient that received non-adherent care.
1573945|NCT02427035|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
1573946|NCT02427035|Other|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
1573947|NCT02427022|Other|CTI|CTI is an empirically supported, time-limited case management model designed to prevent homelessness and other adverse outcomes in people with mental illness following discharge from hospitals, shelters, prisons and other institutions. CTI was originally developed and tested by researchers and clinicians at Columbia University and New York State Psychiatric Institute with significant support from the National Institute of Mental Health and the New York State Office of Mental Health.
1573948|NCT02427009|Other|Prone position for 1 hour after blood patch|After performing a blood patch, the patient will be placed in a prone position for 1 hour. This applies to all blood patches required during her hospitalization.
1573949|NCT02427009|Procedure|Blood patch|And indicated in inclusion criteria, patients in this protocol will have at least 1 blood patch. The amount of blood to be injected into the peridural space is fixed at 20 ml, but can be less in case of pain.
1573950|NCT02426996|Procedure|Scan of shoulder|A scan (no injection) of the concerned shoulder will be performed at 3 months post-surgery. Cuts in three planes of space, including all of the glenoid. 3D reconstructions.
1573951|NCT02426983|Device|Direct Current Stimulation|"Comparison between active Direct Current Stimulation (2 mA, 20 minutes) and Sham stimulation (the device is set up, but only turned on for 30 seconds).
Conductive saline-soaked rubber electrodes super-imposed on sponge plates will be placed on the scalp overlying the left auditory cortex (anodal electrode) and on the contralateral forehead above the orbit (reference/cathode). Stimulation will be applied using a battery-driven constant-current regulator (Oasis Pro, Edmonton). In active tDCS sessions, the DC current will be initially increased in a ramp-like fashion over 10 s until reaching 2 mA and will be similarly decreased at the end of stimulation. In active tDCS, stimulation will be maintained for a total of 20 minutes. This will occur in two separate sessions, occurring within weeks. For 'sham' stimulation, the device will only be turned on for 30 seconds. This will occur in two separate sessions, occurring within weeks."
1574764|NCT02421094|Drug|Placebo|Placebo
1996560|NCT02453282|Drug|Paclitaxel + Carboplatin|Chemotherapy Agents
1996561|NCT02453282|Drug|Gemcitabine + Cisplatin|Chemotherapy Agents
1996562|NCT02453282|Drug|Gemcitabine + Carboplatin|Chemotherapy Agents
1573952|NCT02426983|Drug|Dextromethorphan|Comparison between Dextromethorphan and a no-sugar placebo. Dextromethorphan (DMO), a non-competitive NMDA antagonist, will be delivered in the form of generic Life Brand Clear Cough Syrup DM (Trillium Healthcare Products Inc, Brockville, ON), which has high dose of DMO (15 mg/5 ml) with no other major additives. Each subject will receive a dose of 50 ml DM with no-sugar cranberry juice (100 ml) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks. Each subject will receive a dose of a placebo (150 ml of no-sugar cranberry juice) to drink from a mug, while wearing a nose plug. This same dose will be delivered in two separate sessions, occurring within weeks.
1573954|NCT02426944|Drug|NOAC|Medical arm, patients will be treated by NOAC.
1573955|NCT02426944|Device|Left atrial appendage closure|The patients will be treated by interventional closure of the left atrial appendage.
1573956|NCT02426931|Device|the tip-flexible ureterorenoscope|Ureteroscopy will be conducted using the tip-flexible semi-rigid ureterorenoscope to treat renal calculi. Holmium laser and basket can be used to perform the technique.
1573957|NCT02426931|Device|the classic flexible ureteroscope|Ureteroscopy will be conducted using the classic flexible ureteroscope (Flex x2 STORZ, Germany) to treat renal calculi. Holmium laser and basket can be used to perform the technique.
1573964|NCT02426905|Drug|trientine dihydrochloride|A retrospective review of patients' medical records
1573965|NCT02426892|Biological|ISA 101|100 mcg administered subcutaneously for a total of 3 doses at 3 to 4 weeks intervals starting on Day 1.
1573966|NCT02426892|Drug|Nivolumab|3 mg/kg administered by vein every 2 weeks beginning on Day 8 after the first vaccine dose.
1573967|NCT02426879|Procedure|esophagectomy with three-field lymphnode dissection|robot assisted thoraco-laparoscopic esophagectomy with three-field lymphnode dissection
1573968|NCT02426866|Drug|Efavirenz|
1573969|NCT02426853|Behavioral|Questionnaires|Participants complete 1 questionnaire at beginning of study, 1 after receiving education about how to protect skin from sun and how to avoid tanning beds, and 1 at about 3 months after receiving skin protection education.
1573970|NCT02426853|Other|Photos|At beginning of study, 2 photos taken of the face. One photo is a standard photo, the other photo is taken with an ultraviolet (UV) filter.
1573971|NCT02426853|Behavioral|Pamphlets|At beginning of study, handouts given that discusses skin cancer prevention, sun protection, and how to avoid tanning beds.
1573972|NCT02426840|Dietary Supplement|High dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food. In addition, participants will receive vitamin D2 capsule containing 20,000 IU of ergocalciferol, which will be administered as 1 capsule orally once weekly at any time (not related with meal).
1573973|NCT02426840|Dietary Supplement|Normal dose vitamin D and calcium|participants will receive a FDC tablet containing 1500 mg of calcium carbonate (equivalent to 600 mg of elemental calcium) and 200 IU of vitamin D3. This drug will be administered as 1 tablet orally twice daily and is to be taken with food
1573974|NCT02426827|Device|Spinal Cord Stimulation|
1573975|NCT02426814|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use.
1573976|NCT02426814|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders and allows patients to self-manage their medication adherence.
1996563|NCT02453282|Drug|Pemetrexed + Cisplatin|Chemotherapy Agents
1996564|NCT02453282|Drug|Pemetrexed + Carboplatin|Chemotherapy Agents
1573979|NCT02426788|Behavioral|Cognitive behavioural therapy (CBT)|Behavioral: Cognitive behavioural therapy (CBT) The CBT intervention used in the trial has been adapted for people with PPS, and it is based on a model of understanding PPS (Deary et al 2007). The therapy aims to help the patient develop an understanding of the relationship between cognitive, physiological and behavioural aspects of their problem; to understand factors that may be maintaining the problem and to learn how to modify their behavioural and cognitive responses in order to prevent ongoing symptoms and disruption to healthy living. The approach is de factor transdiagnostic in that it targets processes and underlying mechanisms that affect disorders similarly, rather than focusing on how they are diagnostically different. The approach is personalised during therapy following a detailed assessment.
1573980|NCT02426775|Drug|Carglumic Acid|Carglumic Acid 50 mg/kg/day (twice daily)
1573981|NCT02426762|Procedure|Laparoscopic surgery|"Various laparoscopic operations are performed for participants. Once all surgical procedures are successfully applied, surgical wounds which are associated with laparoscopic surgery would be sealed by a quick sealant. In all, the following surgical wounds would be left:
4-5 trocar-produced incisions (5/10mm, minor incision)
1 sample-retrieval incision (4-5cm, small incision)"
1573982|NCT02426762|Device|Skin sealant|After surgery, a quick skin sealant is applied in two layers of each wound to achieve skin closure. The sealant would be smeared twice on the wound area with 30 seconds of dry time required to form a firm seal.
1996565|NCT02453282|Biological|Tremelimumab|
1996566|NCT02453100|Behavioral|Mobility and pelvic floor exercise|Mobility and pelvic floor exercises
1996567|NCT02453100|Behavioral|Education|Education on simple ways to manage incontinence
1996568|NCT02453087|Drug|DCDS0780A|Participants will receive escalating doses of DCDS0780A as intravenous infusion.
1996569|NCT02453087|Drug|Rituximab|Participants will receive rituximab at a dose of 375 mg/m^2 of body surface area as intravenous infusion.
1996570|NCT02453087|Drug|Obinutuzumab|Participants will receive obinutuzumab at a dose of 1000 milligrams (mg) as intravenous infusion.
1996571|NCT02451657|Other|No Intervention|No intervention was administered in this study
1996572|NCT02452424|Drug|PLX3397|PLX3397 capsules, 200 mg
1996573|NCT02452424|Biological|Pembrolizumab|Pembrolizumab, 200 mg, IV
1996575|NCT02449161|Drug|MPA|
1996576|NCT02449161|Drug|placebo|
1573983|NCT02426749|Device|Active repetitive Transcranial Magnetic Stimulation (rTMS)|The treatments will be administered daily (five days/week) for two weeks, followed by three days on the third week (total of 13 treatments). Patients of both real and sham treatment groups will undergo rTMS treatment of 1.5-second duration trains of pulses at 20 Hz for a total of 25 trains with intertrain interval of 10 seconds applied to DLPFC bilaterally at 100% of the resting motor threshold. Thus, there will be a total of 1500 pulses per two sides of the brain per day, which is well within the safety limit of the rTMS application. During the intertrain intervals, the patients will be presented a series of objects and actions and asking to name them. The images will be projected on the wall in front of patient with duration of three seconds for each image. The aim is to keep the brain active while we stimulate it with rTMS.
1573984|NCT02426749|Device|Sham repetitive Transcranial Magnetic Stimulation (rTMS)|Sham rTMS is similar to Active rTMS but instead of a real coil, it uses a coil that attenuates the pulses such that no current will be induced in the brain.
1573988|NCT02426723|Drug|Phase 1a: CWP232291|CWP232291 administered alone twice weekly every 4 weeks.
1573989|NCT02426723|Drug|Phase 1b: CWP232291, Lenalidomide, Dexamethasone|CWP232291 administered twice weekly every 4 weeks. Lenalidomide and Dexamethasone administered per standard therapy.
1573990|NCT02426710|Device|Intracardiac echocardiography|Flutter ablation will be done using intracardiac echocardiography.
1573991|NCT02426697|Drug|fentanyl transmucosal|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
1573992|NCT02426697|Drug|Placebo|Participation to the trial will be proposed to the patient by the investigator in charge of the analgesic irradiation during preliminary scanner session. When starting the radiotherapy session, investigator will collect the signed inform consent form, deliver the treatment, will collect pain intensity value using VAS (before and after the radiotherapy session).
1573993|NCT02426684|Drug|IdeS®|First ten patients will receive 0.24mg/kg, if no PK/PD/safety/tolerability issues are observed, dose will increased to 0.5mg/kg IdeS on day 0 for final 10 patients. (n=20)
1573994|NCT02426671|Device|MuteButton sensory stimulation device|Participants are asked to use the MuteButton daily for 30-40 minutes. They receive 'pink noise' through headphones and transcutaneous stimulation on the tongue using a 'lollipop' sensor that sits on the anterior section (tip) of the tongue.
1573995|NCT02426658|Other|Laboratory Biomarker Analysis|Correlative studies
1573996|NCT02426658|Drug|Pemetrexed Disodium|Given IV
1573997|NCT02426658|Other|Quality-of-Life Assessment|QOL studies
1573998|NCT02426632|Drug|Formulation A|Reference formulation, 10 milligram/milliliter (mg/mL)oral solution without sweetener/flavor.
1573999|NCT02426632|Drug|Formulation B|10 mg/mL oral solution containing 2 mg/mL sucralose, masking flavor and orange flavor.
1574000|NCT02426632|Drug|Formulation C|10 mg/mL oral solution containing 10 mg/mL sucralose.
1574001|NCT02426632|Drug|Formulation D|10 mg/mL oral solution containing 2 mg/mL sucralose and raspberry flavor.
1574002|NCT02426632|Drug|Formulation E|10 mg/mL oral solution containing 2 mg/mL sucralose and strawberry flavor.
1574003|NCT02426632|Drug|Formulation F|10 mg/mL oral solution containing 2 mg/mL sucralose and orange flavor.
1574004|NCT02426632|Drug|Formulation M1|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
1574005|NCT02426632|Drug|Formulation M2|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
1574006|NCT02426632|Drug|Formulation M3|Best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
1574007|NCT02426632|Drug|Formulation N1|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
1574008|NCT02426632|Drug|Formulation N2|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
1574009|NCT02426632|Drug|Formulation N3|Second best scoring formulation from Session 1 with a varying concentration of sucralose (maximum 10 mg/mL).
1574010|NCT02426619|Device|SDF solution|around 1 mL of 30% silver diammine fluoride (SDF) solution is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
1574011|NCT02426619|Device|NaF varnish|around 1 mL of 5% NaF (sodium fluoride) varnish is placed in a small disposable container and a small brush will be used to apply a very small quantity of the solution onto the surface of the dental caries lesion in the tooth
1574012|NCT02426606|Other|Various lentil varieties (varying in slow digested starch content)|"Randomized, cross-over block design.
Comparison of glycemic and insulinemic responses following meals composed of:
white rice or white rice combined with 1 of 3 different lentil varieties or
white potato or white potato combined with 1 of 3 different lentil varieties
Participants with be assigned to either the white rice or white potato group. Meals will provide 50g available carbohydrate (AC). In meals containing lentils, whole cooked lentils will provide 25g AC either white rice or white potato will provide 25g AC.
Meals will be randomly consumed across 6 study visits, with 2 white bread control meals (one of which will take place on the first visit)."
1574013|NCT02426593|Device|IMED-4|Non-invasive novel lung hydration status sensor.
1574014|NCT02426580|Behavioral|wechat|The wechat model of dietary education every 1 month by cellphone
1574015|NCT02426567|Other|Exclusive Enteral Nutrition (EEN)|One week course of an isocaloric exclusive milk-based diet
1574016|NCT02426567|Other|Crohn's Disease TReatment-with-EATing diet (CD-TREAT diet)|One week course of an isocaloric, exclusion food-based diet
1574017|NCT02426554|Dietary Supplement|DDU-supplement|DDU: Vitamin D, DHA, Uridine
1574018|NCT02426554|Dietary Supplement|Placebo supplement|
1575381|NCT02416986|Behavioral|6 hour smoking abstinence|
1574021|NCT02426528|Other|Cultural and Social exposure|"The intervention protocol will consist of 24 months of guided exposure and participation in social and cultural activities undertaken in the Casa del Popolo. The participant will be asked to register for a specific type of event (fine arts, performing arts, and social and volunteering activities), duration and date in order that this information can be supplied for further evaluation. Control group participants will be asked to carry on their lives normally and maintain regular cultural and social activity throughout the duration of the study. At twelve months from the beginning of the observation participants of both groups will be checked (intermediate phase)."
1574022|NCT02426515|Device|Hilotherm® cooling device and face mask|Hilotherm® is an external cooling device and facial mask through which water circulates at a controlled temperature This allows continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
1574023|NCT02426502|Drug|Conversion to Advagraf|Prograf treated patients will convert to Advagraf using a 1: 1 conversion for a period of one week. The dose will then be titrated based on tacrolimus trough levels obtained 7 days after conversion. Cyclosporine (Neoral) treated patients will initiate Advagraf 0.075 mg/kg/day, 24 hours after their last cyclosporine dose. Participants will be provided with Advagraf and instructed how to start this new medication
1574024|NCT02426502|Drug|conversion of non-immunosuppressant drugs to once daily|"Conversion of anti-hypertensive medications: converted to once daily alternatives with the goal of maintaining blood pressure at the same or lower level prior to conversion.
Conversion of all other medications: changed to once daily formulations of the same medication or a once daily alternative."
1574025|NCT02426502|Drug|Conversion to once daily MPA|"Conversion to once daily MPA: Patients taking mycophenolate mofetil (MMF) will receive 1.0 gram once daily, while patients receiving Myfortic will receive 720 mg once daily.
Conversion to once daily Myfortic: Patients prescribed proton pump inhibitors (PPIs) and MMF will be switched to equivalent dose Myfortic for a period of one month prior to conversion to once daily MPA.
Patients taking azathioprine will be maintained on the same dose.
Patients will be maintained on the same prednisone dose."
1574026|NCT02426489|Device|MRI + PEM image|Effect of positron emission mammography on diagnostic accuracy
1574027|NCT02426476|Behavioral|active heart rate variability biofeedback training|resonant frequency breathing, attention focusing, positive emotional state
1574028|NCT02426476|Behavioral|sham HRVB training|passive relaxation
1574029|NCT02426463|Drug|propofol|
1574030|NCT02426463|Drug|oxycodone|
1574031|NCT02426450|Procedure|RFA|"RFA:
RFA was performed by using a commercially available system (RF 2000; Radio-Therapeutics Mountain View, CA), and a needle electrode with a 15 Ga insulated cannula with 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; RadioTherapeutics)."
1574032|NCT02426450|Drug|Oxaliplatin|4 weeks after RFA; Drug: Oxaliplatin Day 1: Oxaliplatin 85mg/m² 2h IV infusion. Repeated every 2 weeks
1574033|NCT02426450|Drug|5-Fluorouracil/Leucovorin|"4 weeks after RFA; Drug: 5-Fluorouracil/Leucovorin Day 1, after Oxaliplatin 85mg/m² 2h IV infusion: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.
Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.
Repeated every 2 weeks"
1574034|NCT02426437|Other|Pulmonary Rehabilitation (PR)|Patients enrolled in PR will undergo a 6-8 week rehabilitation program.
1574035|NCT02426437|Other|Usual Care|Patients enrolled in usual care will be followed-up by their most responsible physician as determined by the admitting team.
1574036|NCT02426424|Device|Watchpat|WatchPAT ™ is an FDA-approved portable diagnostic device that uses the most innovative technology to ensure the accurate screening, detection, and the follow-up treatment of sleep apnea.
1574037|NCT02426424|Device|CPAP|Continuous positive airway pressure (CPAP) is a form of positive airway pressure ventilator, which applies mild air pressure on a continuous basis to keep the airways continuously open in a patient who is able to breathe spontaneously on his or her own.
1574038|NCT02426411|Drug|EMA401 200 mg|
1574039|NCT02426411|Drug|EMA401 600 mg|
1574040|NCT02426411|Drug|Placebo|
1574041|NCT02426385|Device|FineVision Toric|Posterior chamber IOL which consists in a small plastic lens with plastic side struts, called haptics, to hold the lens in place within the capsular bag inside the eye
1574042|NCT02426372|Biological|QBECO SSI|QBECO Site Specific Immunomodulators
1574043|NCT02426359|Drug|Q301 Cream|
1574044|NCT02426359|Drug|Placebo|
1574045|NCT02426346|Behavioral|Behavioral weight control|Prescription of diet & physical activity and behavioral strategies for weight control
1574046|NCT02426346|Behavioral|Group-based physical activity|Teens exercise for 60 minutes with their group
1574047|NCT02426346|Behavioral|Group-based incentives|Adolescents earn reinforcements within group
1574048|NCT02426346|Behavioral|Parent-based incentives|Adolescents earn reinforcements from their parents (outside of group)
1574049|NCT02426333|Other|Abiraterone Acetate|Exclusively determine pharmacokinetics and pharmacodynamics of abiraterone for the indication according to the drug label (CRPC)
1574050|NCT02426320|Other|Sedation Interruption Protocol|
1574051|NCT02426320|Other|Standard Sedation Protocol|
1574052|NCT02426307|Procedure|TAVR|TAVR: Transcatheter Aortic Valve Replacement
1574053|NCT02426307|Procedure|SAVR|SAVR: surgical Aortic Valve Replacement
1574054|NCT02426294|Drug|Pioglitazone|
1574055|NCT02426294|Drug|Glimepiride|
1574056|NCT02426281|Drug|nab-paclitaxel|nab- paclitaxel 125mg/m2 D1, 8 15 every 4 weeks.
1574057|NCT02426281|Drug|gemcitabine|gemcitabine 1000mg/m2 D1, 8 15 every 4 weeks.
1574058|NCT02426255|Other|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, Simplified Acute Physiological Score II (SAPS II), Sequential Organ Failure Assessment (SOFA), procedures and complications during ICU stay will be collected.
1574059|NCT02426242|Other|Collection of medical data from ICU patients|A code will be applied to each patient included. Medical data such as demography, ISS, clinical exam at time of extubation, extubation failure, tracheotomy, will be collected during ICU stay.
1574060|NCT02426229|Drug|dabigatran etexilate|dabigatran etexilate 75mg orally twice a day for 6 months
1574061|NCT02426203|Procedure|Pulmonary endarterectomy|Echocardiographic assessment right ventricular function prior to, during, and following Pulmonary Endarterectomy surgery.
1574067|NCT02426164|Drug|Liposomal bupivacaine|Periarticular infiltration of the liposomal bupivacaine with 20cc of normal saline
1574068|NCT02426164|Drug|bupivacaine HCl, morphine, epinephrine, methylprednisolone|Periarticular infiltration of 24c of bupivacaine HCl, 0.8cc morphine, 0.3cc epinephrine, and 1cc of methylprednisolone
1574069|NCT02426151|Drug|BEPO-A|BEPO-A (Bioreactor manufacturing process)
1574070|NCT02426151|Drug|REPO-A|REPO-A (Roller bottle manufacturing process)
1574071|NCT02426138|Other|Medically Tailored Meal Delivery (MTM)|Patients will receive delivery of medically tailored meals for 12 weeks
1574072|NCT02426138|Other|Usual Care + Choose MyPlate|Patients will receive usual diabetes care + a Choose MyPlate healthy eating brochure
1996577|NCT02447874|Drug|Arginine|"Arginine will be dispensed intravenously (in the vein) in the standard dose of arginine as 100 mg/kg three times a day for seven days or until discharge.
Loading dose: 200 mg/kg once
Continuous IV: 300 mg/kg/24 hours"
1574076|NCT02426112|Drug|Azithromycin|
1574077|NCT02426112|Drug|Placebo|
1574078|NCT02426099|Drug|Low dose spironolactone|4-week add-on low dose spironolactone in resistant hypertension
1574079|NCT02426099|Other|Routine intensification of antihypertensive treatment|4-week guidelines oriented intensification of antihypertensive treatment
1574082|NCT02426060|Drug|Imrecoxib|
1574083|NCT02426060|Drug|Warfarin|
1574084|NCT02426047|Dietary Supplement|betaquik®|Participants will add betaquik® (a liquid emulsion of medium chain triglycerides) for a 10 day time interval starting 2 days prior to and encompassing the primary catamenial pattern.
1574085|NCT02426034|Drug|Apatinib|Apatinib Mesylate Tablets 850 mg qd p.o. The observation period is 28 days
1574086|NCT02426021|Drug|MLN1202|Subcutaneous administration of MLN1202
1574087|NCT02426021|Drug|MLN1202 Placebo|Subcutaneous administration of MLN1202 placebo
1574088|NCT02426008|Other|Growth Factors and Cytokine adding to embryo culture media|
1574089|NCT02426008|Other|No Intervention|Nothing to Add
1574090|NCT02425995|Procedure|Arthroscopic intercondylar and posteromedial portal|Diagnosis of lesions of the Posterior Horn of the Medial Meniscus in Arthroscopic intercondylar and posteromedial portal in addition with standard ACL reconstruction, during the same surgery.
1574091|NCT02425982|Procedure|Operative treatment|The exact treatment depends on the surgeon, but the majority are anticipated to be elbow arthroscopy followed by either arthroscopic or open extensor carpi radialis brevis release.
1574092|NCT02425982|Procedure|Conservative treatment|The treatment consists of physiotherapy, activity modification, pain medication and watchful waiting. Injection therapies will be avoided.
1574093|NCT02425969|Procedure|PCI|Patients will have balloon angioplasty and coronary stent insertion for their grey-zone FFR lesion.
1574094|NCT02425969|Drug|Optimal Medical Therapy|Optimal Medical therapy consists of secondary prevention which will include high dose statin and aspirin as well as anti-anginal therapy according to ESC 2013 international treatment guidelines for stable angina as follows; B-Blocker or Calcium channel blocker as first line agents and Nicorandil or Nitrates or Ranolazine as second line treatment titrated against symptoms to maximum tolerated dose. ACE inhibitors or Angiotensin Receptor Blockers will be prescribed if patients also have a diagnosis of hypertension, LVEF ≤40%, diabetes or CKD where appropriate.
1574095|NCT02425956|Device|GE Optima/Discovery® MRI data of the liver|GE Optima 1.5T®/Discovery 3.0T® MRI data scanning data of the liver and surrounding tissues will be acquired using both field strengths for GE IDEAL IQ® and single field strength with FerriScan® (Resondence Health) Specialized Reconstruction Service, according instructions provided by manufacturer
1574096|NCT02425943|Device|injectable poly-L-lactic acid Sculptra Aesthetic|
1574097|NCT02425930|Procedure|gastrectomy plus D2 lymphadenectomy|A classic total or subtotal gastrectomy plus D2 lymph nodes dissection would be performed for all enrolled patients. Patients in both groups would undergo the identical therapeutic approach for gastric cancer, mainly decided by a multidisciplinary treatment group in our center.
1574098|NCT02425930|Drug|S-1+Oxaliplatin|"A postoperative systemic chemotherapy would be performed for some subjects who have advanced gastric cancer. The concrete chemo regimen for adjuvant chemotherapy is also determined by a MDT group. Generally, SOX chemo regimen is the first-line treatment in our center, as following described:
S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）
Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
1574099|NCT02425917|Device|geko|neuromuscular electrostimulator
1574100|NCT02425917|Device|IPC-Calf|IPC used on calf with or without geko
1574101|NCT02425904|Drug|Clofarabine|Evaluation of response to clofarabine
1574102|NCT02425891|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab at a fixed dose of 840 milligrams via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
1574103|NCT02425891|Drug|Nab-Paclitaxel|Nab-Paclitaxel at a starting dose of 100 milligrams per square meter via IV infusion on Days 1, 8, and 15 of each 28-day cycle. Nab-Paclitaxel will be administered for a target of at least 6 cycles, with no maximum in the absence of disease progression or unacceptable toxicity.
1574104|NCT02425891|Drug|Placebo|Placebo administered via IV infusion on Days 1 and 15 of each 28-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
1574105|NCT02425878|Drug|Ulipristal Acetate|
1574106|NCT02425878|Drug|Placebo|
1574107|NCT02425865|Drug|GOLIMUMAB|Increase/ or Decrease/ Interruption Dose of Golimumab depending on Continuous Clinical Response or Relapse
1574108|NCT02425852|Drug|Azathioprine|Azathioprine alone versus Azathioprine and IFX
1574109|NCT02425852|Drug|Infliximab|
1574110|NCT02425852|Drug|Prednisolone|
1574111|NCT02425852|Drug|Hydrocortisone|
1574112|NCT02425839|Device|Ultrasound exam by Supersonic Shear Imaging® technique|Each of the two observers performs twice ultrasound examination and measures of the masseter thickness and its elastic modulus, at rest and maximal voluntary contraction.
1574113|NCT02425839|Device|EMG examination by electromyograph Keypoint system|Experimented neurologist performs EMG examination.
1574114|NCT02425826|Drug|Apremilast|Apremilast 30 mg tablets orally twice daily (BID) weeks 0 to 52.
1574115|NCT02425826|Drug|Placebo|Participants randomized to the placebo treatment group received placebo tablets (identical in appearance to the apremilast 30 mg tablets) orally BID for from weeks 0-16.
1574116|NCT02425826|Drug|Placebo-Apremilast|At Week 16, those randomized to placebo were switched to apremilast 30mg BID for an additional 36 weeks (52 weeks total)
1574117|NCT02425813|Drug|Budesonide|Given PO
1574118|NCT02425813|Drug|Methylprednisolone Sodium Succinate|Given IA and IV
1574119|NCT02425800|Other|Cytology Specimen Collection Procedure|Undergo collection of tissue samples
1574120|NCT02425800|Other|Laboratory Biomarker Analysis|Correlative studies
1574121|NCT02425787|Behavioral|Interview|"This is a prospective study with a semi-structured in-depth qualitative interview. Interviews will be solely conducted by the study PI. However, in order to ensure that the interviews are conducted sensitively, the first 10 interviews will be observed and supervised by a clinically credentialed St. Jude faculty member, and an additional 10% of the interviews will be observed after that.
In order to ensure that the PI does not lead the participant, or in turn, that the participant does not feel limited in regards to what they believe is an appropriate or desired response, the semi-structured interview questions are general and intended to produce broad responses in regards to participant experiences."
1574122|NCT02425787|Behavioral|Focus Group|"Focus groups will be conducted with a two-fold purpose in mind:
With bereaved parents: to validate the findings of the preliminary analyses of the initial interviews &/or to suggest avenues of further inquiry to expand and more deeply define the grief journey of bereaved parents.
With Hematology/oncology Fellows: to receive input regarding the applicability and use of the findings during the training and future careers of these medical providers."
1574123|NCT02425774|Procedure|Vagus stimulation|
1574124|NCT02425774|Procedure|Sham stimulation|
1574125|NCT02425774|Drug|Prucalopride|
1574126|NCT02425774|Drug|Placebo|
1574127|NCT02425761|Procedure|Ventriculoperitoneal shunt insertion surgery|The most common treatment for hydrocephalus is the placement of a ventriculoperitoneal shunt in the operating room. A shunt is a flexible tube placed into the ventricular system, fluid filled chambers, of the brain that diverts the flow of CSF into another region of the body, usually the abdomen, also known as the peritoneal cavity, where it can be absorbed.
1574128|NCT02425748|Biological|DC-CIK|DC-CIK cells will be used against tumor cells.
1574129|NCT02425748|Biological|γδ T Cell|γδ T cells will be used against non small lung tumor.
1574130|NCT02425748|Biological|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against lung tumor.
1574131|NCT02425735|Biological|DC-CIK cells|DC-CIK cells will be used against tumor cells.
1574132|NCT02425735|Biological|γδ T cells|γδ T cells will be used against breast tumor.
1574133|NCT02425735|Biological|γδ T/DC-CIK cells|γδ T/DC-CIK cells will be used against breast tumor.
1574134|NCT02425722|Drug|ASP0456|oral
1574135|NCT02425722|Drug|Placebo|oral
1574136|NCT02425709|Drug|Diclofenac|Women will receive oral diclofenac 50 mg 1 hour before the procedure
1574137|NCT02425709|Drug|Tramadol|Women will receive oral tramadol 50 mg 1 hour before the procedure
1574138|NCT02425709|Drug|Placebo|Women will receive an oral placebo 1 hour before the procedure
1574139|NCT02425683|Drug|Regorafenib|120 mg or 160 mg by mouth each day for first 21 days of each 28-day cycle, for maximum of 6 cycles
1574140|NCT02425670|Other|BMSCs|30-500 million Autologous BMSCs will be given intravenously to patients with acute ischemic stroke (onset from 7 to less than 30 days).
1574141|NCT02425657|Behavioral|Training of junior doctors|Training program
1574142|NCT02425644|Drug|ponesimod|20 mg
1574143|NCT02425644|Drug|teriflunomide|14 mg
1574144|NCT02425631|Device|SImmetry Sacroiliac Joint Fusion System|Minimally invasive surgery for implantation of the SImmetry System
1574145|NCT02425618|Procedure|Volume-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the volume-controlled mode with tidal volume 8 ml/kg during surgery.
1574146|NCT02425618|Procedure|pressure-controlled ventilation|I-gel will be inserted into the patient's mouth. After confirmation of adequate ventilation with the i-gel, the patient's lungs will be mechanically ventilated using the pressure-controlled mode with tidal volume 8 ml/kg during surgery.
1574147|NCT02425618|Device|I-gel|
1574148|NCT02425605|Radiation|CCRT|The subject is treated with a total of 45 Gy of external beam radiotherapy (1.8 Gy per session, 5 sessions a week, for 5 weeks), with hepatic arterial infusion of 5-flourouracil (5-FU) during the first and last 5 days of radiation therapy (5-FU 500 mg infusion for 5 hours) for radiosensitization through the pre-inserted chemoport.
1574149|NCT02425605|Drug|sorafenib|Four weeks after completion of CCRT, the subject is given daily sorafenib treatment and will be followed for survival.
1574150|NCT02425579|Drug|Inhaled Carbon Monoxide at 100ppm|Inhaled Carbon Monoxide at 100ppm for up to 90 minutes daily for 5 days
1574151|NCT02425579|Drug|Placebo for Inhaled Carbon Monoxide at 100ppm|Inhaled Medical Air for up to 90 minutes daily for 5 days
1574152|NCT02425579|Drug|Inhaled Carbon Monoxide at 200ppm|Inhaled Carbon Monoxide at 200ppm for 90 minutes daily for 5 days
1574153|NCT02425579|Drug|Algorthim Specified dose of iCO to achieve COHb of 6-8%|iCO not to exceed 500 ppm to achieve a COHb of 6-8% for up to 90 min for 5 days
1574154|NCT02425579|Drug|Placebo for Inhaled Carbon Monoxide at 200ppm|Inhaled Medical Air for up to 90 minutes daily for 5 days
1574155|NCT02425579|Drug|Placebo for Cohort 3|Inhaled Medical Air for up to 90 minutes daily for 5 days
1574156|NCT02425566|Drug|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
1574157|NCT02425566|Drug|Nitroglycerin|Sublingual nitroglycerin (0.3-0.6 mg) will be given after baseline measurements.
1574158|NCT02425553|Other|Diet|High calorie (1200 kcal), high fat (50% energy), 400 ml juice (230 kcal)
1574159|NCT02425553|Other|Diet|High calorie (1200 kcal), low fat (20% energy), 400 ml juice (230 kcal)
1574160|NCT02425553|Other|Diet|Low calorie (600 kcal), low fat (20% energy), 400 ml juice (230 kcal)
1574161|NCT02425553|Other|Diet|High calorie (1200 kcal), high fat (50% energy), 300 ml wine (40 g alcohol, 230 kcal), 100 ml water
1574162|NCT02425540|Device|Pelvic MRI|
1574163|NCT02425527|Behavioral|The rehabilitation gaming|The web-based cognitive training platform CogniFit includes about 33 mini games designed with the purpose of improving the user's cognitive abilities as brain exercises. For the purpose of the research, a selection of CogniFit mini games will be included in the intervention. The mini game tasks will be adapted to players' skills getting more difficult as the players progress. The game tasks are targeting different cognitive abilities such as memory, visual-spatial ability, attention, tracking and fast decision making.
1574164|NCT02425527|Behavioral|The entertaining gaming|The gameplay will consist of these main elements: 1) the player will be playing the main character of the game, 2) the character will be presented for the player from an isometric perspective, 3) the player will control the character by navigating in partly open-ended 3D environments in which the player must decide a direction and move towards it by avoiding obstacles; 4) the player will engage with real-time action events and act quickly by making strategic and tactical decisions; 5) the player must memorize locations, characters, dialogue and tasks; as well as 6) track, follow or aim at several objects simultaneously. Gaming requires also patience as participants can only make progress in games by trial and error.
1574165|NCT02425514|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
1574166|NCT02425514|Device|NovoMax™|The ACDF surgery will be carried out with NovoMax™ after randomization procedure.
1574169|NCT02425475|Device|LIMES|All patients will undergo dermoscopic diagnosis and be documented with a video image storing. The diagnosis based on dermoscopy will be immediately documented. Then, as a second diagnostic procedure, fluorescence diagnostics based on the two photon excitation from a dye-laser will be performed. The classification as non-melanoma or malignant melanoma by the medical device LIMES will also be documented immediately. Afterwards, the lesion will be excised and undergo histo-pathologic examination by the respective histopathologist of the participating centers. The histopathologic diagnosis will serve as gold standard for subsequent evaluations of the diagnostic accuracy.
1574171|NCT02425449|Drug|Succinylcholine|will be administered succinylcholine in a dose of 0.1 mg/kg in Arm 1, 0.15 mg/kg in Arm 2, 0.2 mg/kg in Arm 3, 0.25 mg/kgin Arm 4, 0.3 mg/kg in Arm 5.
1574172|NCT02425436|Drug|Ginkgo Biloba Extract|
1574173|NCT02425436|Other|Placebo|
1574174|NCT02425423|Dietary Supplement|New thickened formula|
1574175|NCT02425410|Other|Collect of data on viral environment of T1D patients|Questionnaires on viral events during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
1574176|NCT02425410|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotypage)
1574177|NCT02425397|Genetic|Genetic study|study of mutations of metabolic enzymes and membrane transport genes, which will be performed by sequencing.
1574178|NCT02425397|Genetic|Genetic study MT-RN1|study of mutations of the mitochondrial gene MT-RN1, which will be performed by sequencing.
1574179|NCT02425384|Behavioral|Intervention Group (motivational website, activity meter)|The activity meter linked to a motivational website is designed to motivate middle school-aged children to increase their rates of physical activity by providing feedback on the amount of activity, and rewards based on the amount and duration of activity.
1574180|NCT02425384|Behavioral|Active Control (active video game, activity meter)|The active video game, Dance Dance Revolution, requires physical movement as part of game play and may motivate users to engage in more activity. The same activity meter used in the Intervention Group is provided to this group to track physical activity but does not link to the motivational website nor does it provide any feedback on levels or duration of activity.
1574181|NCT02425384|Other|Passive Control (activity meter)|Participants are provided the same activity meter used in the other study groups to track physical activity but it does not link to the motivational website nor does it provide any feedback on levels or duration of activity. Participants are asked to go about their normal activities.
1574182|NCT02425371|Other|Screening and treatment of comorbidities|Screening and treatment of comorbidities
1574183|NCT02425371|Other|Placebo Comparator|No screening of comorbidities
1574184|NCT02425358|Other|BMC therapy within 24 hours|The BMCs were isolated by Ficoll density gradient centrifugation on Lymphocyte Separation Medium. BMCs were infused into IRA at the site of the previous occlusion. This was accomplished with the use of a microtubular. After positioning of the microtubular into the distal segment vessel of the stent position in the infarct-related artery, 15 milliliter of the whole cell suspension was slowly administered via microtubular. The usual time should be over 10min to prevent back-flow and to prolong cellular contact time for cellular migration into the tissue. Patients in BMC therapy group within 24 hours remained in the cath-lab until the entire procedure, including primary PCI and intracoronary BMC infusion, was completed.
1574185|NCT02425358|Other|BMC therapy within 3-7 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
1574186|NCT02425358|Other|BMC therapy within 7-30 days|Patients in this group, who underwent a second procedure, to receive BMC transplantation in the cath-lab during the same hospitalization or returned for a second hospitalization.
1574187|NCT02425358|Other|PCI only|The saline was intracoronary infusion with the use of microtubular.
1574188|NCT02425345|Behavioral|Physical Activity|The PA intervention will consist of a multimodal activity program of aerobics, balance, strength, flexibility. The intervention will involve encouraging participants to increase all forms of PA throughout the day and to decrease sedentary time, such as sitting. This may include activities such as leisure sports, gardening, use of stairs instead of escalators, leisurely walks with friends, and less use of remote control devices.An interactive voice response (IVR) coach will be available. The intervention is conducted primarily by mail and optionally by phone and the IVR.
1574189|NCT02425332|Device|Lokomat gait trainer|
1574190|NCT02425306|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
1574191|NCT02425306|Drug|Montanide ISA-51|Montanide ISA-51 (Incomplete Freund's Adjuvant), local adjuvant
1574192|NCT02425306|Drug|polyICLC|polyICLC, local adjuvant
1574193|NCT02425306|Drug|Cyclophosphamide|Cyclophosphamide, systemic adjuvant
1574194|NCT02425293|Behavioral|asthma patient education|
1574195|NCT02425280|Behavioral|Narrative Exposure Therapy|
1574196|NCT02425280|Behavioral|Treatment as Usual|
1574197|NCT02425267|Other|Rehabilitation (Physiotherapy)|The training program will be carried out twice a day, and at every day during the eight-week program, either by telerehabilitation or in the clinic or by autonomous unsupervised way. During weeks 1, 3 and 5, the patient will perform his/her exercises twice a week by telerehabilitation/clinic and the other without supervision. During the other weeks (2, 4, 6, 7, 8), the patient will benefit from one exercise session by telerehabilitation/clinic per week and will perform all other without supervision. Supervised sessions allow the therapist and the patient to adjust the program in case of problems and to ensure a smooth implementation of the program.
1574198|NCT02425254|Drug|Intravenous paracetamol|1000mg intravenous solution for infusion
1574199|NCT02425254|Drug|Intravenous saline 0.9%|0.9% sodium chloride in order to ensure double-blinding
1574200|NCT02425241|Biological|pSG2.HIVconsv DNA vaccine|pSG2.HIVconsv DNA 4 mg at weeks 0, 4 and 8.
1574201|NCT02425241|Biological|ChAdV63.HIVconsv booster vaccine|ChAdV63.HIVconsv 5 x 10^10 vp at week 12.
1574202|NCT02425241|Biological|MVA.HIVconsv booster vaccine|MVA.HIVconsv 2 x 10^8 pfu at week 20
1574203|NCT02425241|Drug|CPHPC|40 mg CPHPC IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
1574204|NCT02425241|Other|Placebo|Placebo IV infusion for 26 hours at weeks 0, 4 and 8 during which pSG2.HIVconsv is administered after 24 hours.
1574205|NCT02425228|Device|Targeted biopsy|conventional/systematic biopsy, targeted fusion biopsy and cognitive biopsy
1574206|NCT02425202|Drug|Ketamine|Post-operative continuous infusion until 0600 the next day
1574207|NCT02425202|Other|Saline infusion|Post-operative continuous infusion until 0600 the next day
1574208|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 50U|"Drug intervention:
The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
Drug is only injected once at baseline"
1574209|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 100U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
1574210|NCT02425176|Drug|Botulinum toxin A (BoNT-A) 200U|The total dose is divided equally and injected into 4 salivary glands (submandibular and parotid gland bilaterally) via a 25G or 23G needle with ultrasound guidance. One site is injected per gland.
1574211|NCT02425163|Device|Transrectal shear wave elastography of the prostate|Transrectal shear wave elastography of the prostate with SuperSonic Imagine Ultrasound System AIXPLORER and an endocavity sonic head SE12-3 (SuperSonic Imagine, Aix-en-Provence, France)
1574212|NCT02425163|Procedure|Transrectal random biopsy of the prostate|TRUS-SWE-guided random biopsies of the Prostata with 18G-gun
1574213|NCT02425150|Procedure|Corneal reshaping/crosslinking (CRXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. A flat, rigid contact lens is sutured to the cornea and the cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
1574214|NCT02425150|Procedure|Corneal Crosslinking (CXL)|The keratoconus cornea is treated with epithelial debridement in local anesthesia, is soaked in Riboflavin by repeated topical application during 30 minutes. The cornea and is then irradiated with ultraviolet light 5.4 J/cm2 during 30 minutes.
1574215|NCT02425137|Drug|S-1/Gemcitabine|Eligible patients will receive gemcitabine 800 mg/m2/day on day 1 and S-1 orally 80-120 mg/day (depending on patient's body surface area (BSA)) on day 1 to 10 in a 2-week cycle.
1574216|NCT02425124|Behavioral|PC101+Mental Health|Facility-based stepped care intervention combining stress and depression case detection and management by non-physician clinicians and referral pathways for anti-depressant medication and/or group/individual counselling delivered by lay-health workers for patients with depression.
1574217|NCT02425111|Drug|Vedolizumab|Vedolizumab intravenous injection
1996578|NCT02447874|Drug|Arginine (Loading)|Arginine will be dispensed intravenously (in the vein) as an initial bolus (loading) arginine dose at 200 mg/kg once
1574220|NCT02425085|Procedure|multi-endodiathermy retinectomy|patients will receive multi-endodiathermy retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
1574221|NCT02425085|Procedure|relaxing retinectomy|patients will receive relaxing retinectomy; 6 months later, patients will receive the removal of intraocular silicone oil.
1574222|NCT02425072|Device|NovoTTF-100A plus chemotherapy|NovoTTF-100A System with Physician's Choice Chemotherapy
1574223|NCT02425059|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Rectal Neoplasms guide with ultrasound or/and CT.
1574224|NCT02425059|Device|NanoKnife|
1574355|NCT02424110|Device|bipolar radiofrequency (AtricuteTM)|The investigators plan to use bipolar radiofrequency(AtricuteTM) in the bipolar radiofrequency group
1574225|NCT02425046|Behavioral|health coaching|Health coaching using motivational interviewing focus on family diet and exercise change and connection with community resources specific to goals set.
1574226|NCT02425046|Behavioral|community screening|Screening for community resources that families may be eligible for to receive help with basic needs including shelter, food, health insurance etc.
1574227|NCT02425033|Procedure|POEM|Under general anesthesia, patient undergoes upper endoscopy and a small longitudinal submucosal incision is created and a dilating balloon is inserted submucosally via the created incision. The balloon is slightly inflated to allow entrance of the endoscope. The gastroscope is advanced into the submucosal space and the tunnel is created via endoscopic or blunt dissection as appropriate. The tunnel is created distally and is stopped several centimeters beyond the lower esophageal sphincter (LES), which can easily be identified using endoscopic landmarks. Using a dissection knife, the clearly visible circular muscles are divided. The longitudinal layer is left intact and the mucosal entry is closed.
1574228|NCT02425020|Dietary Supplement|Meat Protein|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of meat protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
1574229|NCT02425020|Dietary Supplement|Whey protein|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing 20g of whey protein mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
1574230|NCT02425020|Dietary Supplement|Carbohydrate|Immediately (<10 min) after completing each training session (resistance training or sport specific workout), participants will consume a beverage containing about 20g of maltodextrin mixed with 250 ml of orange juice and water. On non-training days supplement will be ingested before breakfast.
1574231|NCT02425007|Device|Incentive spirometry|
1574232|NCT02424994|Other|No intervention|
1574233|NCT02424981|Device|Threshold inspiratory muscle training|Inspiratory muscle training
1574242|NCT02424942|Drug|placebo|"Pharmaceutical form:solvent for parenteral use
Route of administration: intraarticular"
1574243|NCT02424942|Drug|GZ389988|"Pharmaceutical form:suspension for injection
Route of administration: intraarticular"
1574244|NCT02424929|Procedure|Sedation|Propofol anesthesia administered during entire surgery.
1574245|NCT02424929|Procedure|Original Surgery|No intervention, surgery will be conducted as usual. With sedation only during the drilling of the burr holes.
1574246|NCT02424916|Biological|Melanoma antigens-specific CD8+ T lymphocytes|The intervention uses an autologous somatic cell therapy medicinal product. It consists in the intravenous injection of melanoma antigens (Melan-A and MELOE-1) - specific CD8+ T lymphocytes followed by subcutaneous injections of Proleukin.
1574247|NCT02424890|Other|MDT simulation sessions of management of life-threatening events over 1 year|9 simulation sessions over 1 year for Repetitive Sim Group and 3 simulation sessions over 1 year for Control Group
1574248|NCT02424877|Procedure|SandRA|SandRA software sends SMS messages to a patient asking questions about the usage and adverse effects of prescribed drugs and about the severity of rheumatoid arthritis. The answer messages are interpreted automatically.
1574249|NCT02424864|Other|4d PET-CT|Patients will be imaged with 4D-CT images in addition to the normal protocol of FDG-CT image acquisition
1574250|NCT02424851|Drug|Bortezomib|"1.3 mg/m2 subcutaneously* days 1, 4, 8 and 11 of each cycle. Number of cycles: Four 21 day cycles (participants not suitable for ASCT (autologous stem cell transplant) will continue up to 6 cycles on the treatment regimen to which they were randomised).
*intravenous infusion available in case of patient intolerance to subcutaneous bortezomib"
1574251|NCT02424851|Drug|Thalidomide|100 mg daily orally, preferably at night, days 1-21 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
1574252|NCT02424851|Drug|Bendamustine|60 mg/m2 i.v. days 1 and 8 of each cycle. Four 21 day cycles (participants not suitable for ASCT will continue up to 6 cycles on the treatment regimen to which they were randomised)
1574253|NCT02424851|Drug|Dexamethasone|40mg orally days 1-2, 4-5, 8-9 and 11-12 of each cycle
1574257|NCT02424825|Behavioral|Cooking Course|This is a month-long online cooking course, aimed at promoting a low-fat, plant-based diet.
1574258|NCT02424812|Behavioral|Lifebuoy School of Five Handwashing Intervention|
1574262|NCT02424786|Other|STOPP/START criteria|Evaluation of medication lists
1574263|NCT02424773|Device|High Flow Nasal Canula (HFNC)|
1574264|NCT02424773|Device|Venturi mask|
1574265|NCT02424773|Drug|Oxygen|
1574266|NCT02424760|Device|Shoulder hemi-arthroplasty|
1574267|NCT02424747|Other|Acute Kidney Injury|"We will identify and observe exposure to Acute Kidney Injury during Intensive Care admission."
1576109|NCT02412059|Drug|Prednisolone acetate|
1574272|NCT02424695|Drug|Gabapentin Enacarbil (GEn)|"HORIZANT Extended-Release Tablets containing 600 mg of gabapentin enacarbil are white to off-white, with occasional black/grey spots, oval-shaped tablets debossed with GS LFG, supplied as:
600 mg: NDC 53451-0101-1.The drug will be stored at 25°C (77°F) (excursions permitted 15° to 30°C (59° to 86°F)) Matching placebo will be provided by Xenoport Inc."
1574273|NCT02424695|Drug|Placebo|
1574274|NCT02424682|Other|No intervention|No intervention administered in this study
1574275|NCT02424669|Other|ALS Functional rating Scale-revised (ALS FRS-R)|
1574276|NCT02424669|Other|slow vital capacity|
1574277|NCT02424669|Other|Blood sample|
1574278|NCT02424669|Other|Cerebrospinal Fluid (CSF) sample|
1574279|NCT02424656|Procedure|MRI|EEG-functional MRI, structural MRI, diffusion MRI
1574280|NCT02424656|Procedure|TMS-EEG|Single pulse TMS combined with EEG, resting-state EEG, noise masking (auditory stimulation), electrical stimulation
1574281|NCT02424656|Procedure|FDG-PET|
1574282|NCT02424656|Other|Clinical scales|Evaluation of DOC: Coma recovery scale-Revised (CRS-R) and Rancho Los Amigos Scale (RLAS). Evaluation of function: Functional Independent Measure (FIMTM), and Early Functional Assessment (EFA).
1574283|NCT02424643|Behavioral|Monetary Incentive|$20 Amazon.com gift card
1574284|NCT02424643|Behavioral|Altruistic Incentive|"A preliminary statement of the importance of participation, and periodic inspirational messages throughout the length of the survey emphasizing the value to men's health by completing the survey"
1574285|NCT02424643|Behavioral|Dashboard Incentive|"A sample dashboard will compare data subjects enter in their survey to the data already collected from other men who have taken the survey. For the dashboard, men who complete the survey will be shown how their own reported data about certain topics compared to other men's data."
1574290|NCT02424617|Drug|erlotinib|erlotinib is used to treat non-small cell lung cancer (NSCLC), pancreatic cancer and several other types of cancer. It is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
1574291|NCT02424617|Drug|BGB324|Study investigational product.
1574292|NCT02424591|Drug|Ketamine|Infusion at a rate of 10 mcg/kg/min
1574293|NCT02424591|Other|Placebo|Placebo IV
1574294|NCT02424578|Drug|Diclofenac Capsules low dose|
1574295|NCT02424578|Drug|Diclofenac Capsules high dose|
1574296|NCT02424565|Drug|IODEX® balm|2 ± 0.2 g of test balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
1574297|NCT02424565|Other|Placebo balm|2 ± 0.2 g of placebo balm will be applied topically in a crossover fashion at a gap of 3 days between the two product applications.
1574298|NCT02424552|Drug|Vitamin D3|Initial single dose 100000 IU, beginning from the second day 4000 IU/day for 24 weeks.
1574299|NCT02424552|Drug|Placebo|Filling material: lactose monohydrate, cellulose, magnesium stearate
1574300|NCT02424539|Drug|FFNS|FF as a aqueous suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose administered via a metered side-actuated nasal spray device.
1574301|NCT02424539|Other|Placebo|Placebo as a aqueous suspension to match the other study treatments minus the active component(s) for intranasal inhalation administered via a metered side-actuated nasal spray device.
1574302|NCT02424526|Other|home-based treadmill training|the child will walk on a pediatric treadmill with the help of the parent/caregiver and with weekly supervision of a physical therapist
1574303|NCT02424526|Device|Treadmill|
1574304|NCT02424513|Radiation|[89Zr]Df-IAB2M|A single intravenous infusion of 2.5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg.
1574305|NCT02424487|Procedure|Intracuff pressure measurement in one-lung ventilation during thoracic surgery|
1574306|NCT02424474|Device|Genetic NIPT|Both tests are realized in a population of pregnant women (with and without in vitro fertilisation (IVF)) concomitantly at the same time.
1574307|NCT02424474|Biological|Regular serum screening|
1574308|NCT02424461|Drug|Ceftriaxone|1 injection 1 g per day for 2 days
1574309|NCT02424461|Drug|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for seven days
1574310|NCT02424461|Drug|Ofloxacine|400 mg/jour (200 mg/ jour in case of renal failure) for 14 days
1574311|NCT02424461|Drug|Placebo of ofloxacine|Placebo of ofloxacine for 7 days
1574354|NCT02424110|Device|argon beam coagulator （American，Valleylab）|Argon beam coagulator（American，Valleylab）will be used in the argon beam coagulator ablation group
1576110|NCT02412046|Procedure|Muscle biopsy|
1574312|NCT02424448|Procedure|Biopsies, blood and urine samples|"Session 1: Biopsies will be taken from the main study lesion and up to 2 metastatic sites at 1 visit or over 3 visits. Both formalin fixed and snap frozen material will be collected. At the session (i.e. once over the potential maximum of 3 visits in a session) a urine sample, blood samples for circulating tumour cells (CTC) and an exploratory blood sample (processed to plasma) will be taken.
Session 2: 7 days +/-3 following the last biopsy taken from Session 1, repeat biopsies from the same tumour sites will be obtained. In cases where this is not possible, it is acceptable to biopsy alternative lesions. As in Session 1 biopsies may be taken at 1 visit or over 3 visits and urine, CTC blood samples and an exploratory blood sample (processed to plasma) will be taken."
1574313|NCT02424435|Drug|Methylprednisolone|Oral tablets of methylprednisolone 8 mg. Subjects will receive a monthly prescription bottle of 25 tablets (standard quantity) and will self-administer 21 tablets over a 28-day dosing cycle.
1574314|NCT02424409|Behavioral|2: Intervention|"The corticoid treatment (Prednisolone or Prednisone) given from the ED for the first day if the patient is discharged at nighttime or during the weekend.
A detailed prescription including 1) A written prescription of the corticosteroid treatment given orally for a total treatment length of 7 days 2) A written prescription describing the adaptation of the inhaled treatment 3) Peak expiratory flowmeter
A written action plan with formalized recommendations for the patient
A formal letter and recommendations to the general practitioner including information about the ED visit, and the necessity to program a follow up with regular consultations as well as to program spirometry evaluation for his patient.
The ED doctor at discharge will explain all these documents orally
Recommendations for an early contact with the general practitioner;
Telephone call of the emergency department to the patient at day 7 +/-1 in order to ensure the link with the general practitioner."
1574315|NCT02424409|Behavioral|1: Control|patients without discharge protocol
1574316|NCT02424396|Drug|IL2|Induction period: repeated administration of low-dose IL-2 Maintenance period: treatment with IL-2
1574317|NCT02424396|Drug|Placebo|
1574318|NCT02424383|Device|PTA (Lutonix® 035 DCB Catheter)|"Percutaneous Transluminal Angioplasty (PTA) will involve the insertion of a catheter into one of the femoral arteries. Once the catheter is in place, a tiny balloon on the end of the catheter will be inflated to press against the narrowing (or blockage) in the artery to try to open the blockage, and allow more blood to flow through the artery. The balloon may need to be inflated several times in order for the narrowed area to open up sufficiently to improve the blood flow. The area will be viewed with specialized x-ray or other imaging devices to see if the artery has opened enough.
The Lutonix® DCB through the blood vessel to the narrowed area to be treated."
1574319|NCT02424370|Procedure|TAVR|Percutaneous aortic valve replacement
1574323|NCT02424331|Other|Pursed Lips Breathing|Pursed Lips Breathing for six minutes.
1574324|NCT02424331|Other|Quiet Breathing|
1574326|NCT02424305|Drug|LEO 43204 gel 0.018%|
1574327|NCT02424305|Drug|LEO 43204 gel 0.1%|
1574328|NCT02424305|Drug|LEO 43204 gel 0.037%|
1574329|NCT02424292|Other|Physical activity|Physical activity in a personalised program.
1574330|NCT02424279|Procedure|Splanchnicectomy|
1574331|NCT02424266|Device|None invasive imaging of the tear film (AdOM)|White light tomography imaging
1574332|NCT02424253|Drug|ZPL-3893787|ZPL-3893787
1574333|NCT02424253|Drug|Placebo|Matched Placebo
1574334|NCT02424240|Other|IGF-1/IGFBP-3 ratio|IGF-1/IGFBP-3 ratio for the diagnosis of GHD Vs. IGF-1, IGFBP-3 and IGF-1 & IGFBP-3 combination
1574335|NCT02424214|Other|Artificial Oocyte activation|
1574336|NCT02424214|Drug|Ca Ionophore|
1574337|NCT02424214|Drug|Strontium Chloride|
1574338|NCT02424201|Drug|Misoprostol|experimental
1574339|NCT02424201|Drug|vitamin c|control
1574340|NCT02424188|Other|TRIIUMPH Intervention|Group and individual smoking cessation and weight management counseling, pharmacotherapy with varenicline or bupropion and nicotine replacement therapy, group exercise, and text messaging support
1574342|NCT02424162|Device|+2.75 diopters multifocal intraocular lens|
1574343|NCT02424162|Device|+3.25 diopters multifocal intraocular lens|
1574344|NCT02424149|Drug|Phenazopyridine|
1574345|NCT02424136|Other|Questionnaire|5 minute questionnaire focused on symptoms of allergic disease
1574346|NCT02424136|Other|Peanut Skin prick test|Skin prick testing with peanut antigen, according to ASCIA Skin Prick testing manual
1574347|NCT02424136|Other|Fraction of exhaled nitric oxide|Measurement of exhaled nitric oxide, according to American Thoracic Society/ European Thoracic Society (ATS/ERS) standardised procedures
1574348|NCT02424136|Other|Spirometry|Measurement of lung flows/volumes, according to ATS/ERS standardised procedures
1574349|NCT02424136|Other|Serum Peanut and Ara h2 specific immunoglobulin E|Peanut and Ara h2 specific IgE antibodies
1574350|NCT02424136|Other|Collection of blood biomarker|Correlation of blood biomarker levels in patients with successful or unsuccessful peanut food challenge
1574351|NCT02424136|Other|Peanut food challenge|Open label peanut challenge conducted according to ASCIA's peanut challenge protocol and PRACTALL consensus report
1574352|NCT02424110|Procedure|argon beam coagulator ablation|The investigators plan to use argon beam coagulator ablation plus bipolar radiofrequency ablation in the argon beam coagulator ablation group.
1574353|NCT02424110|Procedure|bipolar radiofrequency ablation|The investigators only use bipolar radiofrequency ablation in the left and right atrial radiofrequency ablation.
1576296|NCT02410668|Dietary Supplement|Placebo|
1996579|NCT02447874|Drug|Arginine (Continuous)|Arginine will be dispensed intravenously (in the vein) as a continuous IV infusion of 300 mg/kg/24hr
1996580|NCT02446665|Device|MR Elastography (MRE) and FibroScan|
1996581|NCT02446002|Drug|Lofexidine + Naltrexone|Lofexidine HCl (two 0.2 mg tablets) will be administered as a single oral dose (0.4 mg) on Day 1 and on Day 11.Commercially available naltrexone HCL tablets will be administered as a single oral 25 mg dose on Day 4 and as a single oral 50 mg dose on Days 5 through 13. On Day 11 administration of both naltrexone and lofexidine will occur. Dose administration times for each drug are to be standardized for all treatment days. The scheduling of the naltrexone dose is to be standardized so that the naltrexone dose is administered 2 hours after the lofexidine dose on Day 11 when both drugs are administered.
1574356|NCT02424097|Drug|CPP-ACP 5% sodium fluoride varnish & 900ppm fluoride paste|"MI Paste & MI Varnish- in-office:
varnish application once every 3 months; at baseline, at the end of month 3, 6, and 9 (4 applications)
- at-home: brushing with regular 1,100ppm F-toothpaste, 2x per day and MI Paste Plus, home application after brushing in the evening; 3-5 minutes with in-home application tray"
1574357|NCT02424097|Drug|1,100pm F-toothpaste and 0.5%NaF rinse|"Standard of care at-home:
Crest tooth brushing 2x per day - (recommendation OTC Fluoride-rinse in the evening at home 1x per day)"
1574358|NCT02424084|Device|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy
1574359|NCT02424071|Drug|Melatonin|
1574360|NCT02424071|Drug|placebo|
1574361|NCT02424058|Device|Spinal Mouse® measurement|The sagittal thoracic spinal curvature and mobility of all participants were assessed with Spinal Mouse® (Idiag, Fehraltorf, Switzerland) in standing position.
1574362|NCT02424058|Behavioral|Neck pain intensity measurement|The neck pain intensity of the patients was questioned by Visual Analogue Scale
1574363|NCT02424045|Drug|BCD chemotherapy (Bendamustine, Carboplatin, Dexamethasone)|All patients are scheduled to receive 2 cycles of three-weekly BCD. After 2 cycles of BCD, if the patients with complete remission (CR) or partial remission (PR) would be eligible for autologous stem cell transplantation (ASCT), stem cell collection after 3rd cycle of BCD and high dose chemotherapy and ASCT will be conducted. While ineligible patients to ASCT with non-progressive disease after 2 cycles of BCD, will be given 4 additional courses of the BCD regimen.
1574364|NCT02424032|Behavioral|"Exercise and connective tissue massage"|Cervical and scapulothoracic stabilization exercises with connective tissue massage were performed.The program was carried out for 12 sessions, 3 days/week in 4 weeks.
1574365|NCT02424032|Behavioral|"Exercise"|Cervical and scapulothoracic stabilization exercises were performed. The program was carried out for 12 sessions, 3 days/week in 4 weeks.
1574366|NCT02424019|Drug|ILUVIEN®|
1574367|NCT02424006|Device|RHCIII-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A RHCIII-MPC cornea 350 um thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
1574368|NCT02424006|Device|Donor cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to 350 um of corneal thickness and then a lamellar dissection will be created. Trephine diameter will be 7.5 mm. Alternatively a femtosecond laser may be used to create the dissection. A human donor cornea graft 350 um thick and 0.25 mm larger diameter is placed and sutured. The sutures will be removed in 3-6 months or as determined by physician.
1574369|NCT02423993|Behavioral|Education by structured programme|"Thе structured programme was developed in Endocrinology Research Centre. It is based on the following principles: education in group setting, using structured program; intensive insulin treatment using insulin pumps; self-adjustment of insulin dose and pump settings; intensive self-monitoring of blood glucose, including continuous glucose monitoring in real-time (CGM-RT); flexible physical activities and meals regimen (liberal diet, based on carbohydrates account using bread units; possible shifts of meals schedule and volume supported by appropriate treatment adjustment). Duration of education course - 8 days (35-37 hours); planned group volume is 7-10 patients."
1574370|NCT02423993|Device|CSII|The intensified insulin therapy by means of continuous subcutaneous insulin infusion will be provide by Medtronic insulin pumps: Paradigm MMT-712/715, Paradigm Real-Time MMT-722, Paradigm VEO MMT-754.
1574371|NCT02423993|Device|CGM-RT|"Continuous glucose monitoring (CGM) will be provide by means of Paradigm Real-Time MMT-722 and Paradigm VEO MMT-754 Medtronic sensor-augmented insulin pumps. For monitoring the Sof-Sensor and MiniLink transmitter (Medtronic) will be use. Each sensor will be use for 6 days. CGM will be use for self-monitoring of blood glucose on permanent basis (more than 6 days per week) within 4 month."
1574372|NCT02423993|Procedure|Screening for Complications|To assess diabetic retinopathy a fundoscopy will be held. Diabetic nephropathy will be assessed by microalbuminuria screening, serum creatinine evaluation and calculation of CKD-EPI glomerular filtration rate. Diabetic neuropathy will be assessed by all kinds of sensitivity evaluation (vibrating, tactile, temperature).
1574373|NCT02423993|Procedure|Glycaemic control assessment|Glycemic control effectiveness changes will be assessed by measure of glycated hemoglobin (HbA1c). The frequency of blood glucose self-monitoring will be estimated by patient's diaries evaluation, individual glucometer data evaluation and insulin pump reports. Bolus calculator use and hypoglycemia nonsevere frequency will be assessed by reports received from insulin pumps.
1574374|NCT02423993|Procedure|QoL assessment|"For Quality of Life (QoL) assessment will be used the following validated questionnaires (in Russian):
The Medical Outcomes Study 36-Item Short Form Health Survey - SF-36.
The Audit of the Diabetes-Dependent Quality of Life - ADDQoL (С. Bradley et al, 1999, adjusted by Starostina E.G., 2003)."
1574375|NCT02423993|Procedure|Knowledge assessment|For the knowledge assessment of disease management the standard Questionnaire for patients with type 1 diabetes will be used. Maximum score equals 37 grades; the satisfactory level of knowledge is scored 27.
1574376|NCT02423980|Drug|Glucagon|
1574377|NCT02423967|Biological|Transplant uses frozen anonymous stool|The intervention is using frozen anonymous donor stool instead of fresh stool from family members for the fecal microbial transplant to treat recurrent CDI.
1574378|NCT02423967|Biological|Transplant uses fresh familial stool|The intervention is using fresh familial donor stool for the fecal microbial transplant to treat recurrent CDI
1574379|NCT02423954|Drug|Temsirolimus|
1574380|NCT02423954|Drug|Irinotecan|
1574381|NCT02423954|Drug|Irinotecan + capecitabine|
1574382|NCT02423954|Drug|nivolumab|
1574383|NCT02423941|Procedure|Retrogade reperfusion|Retrogade caval reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
1574384|NCT02423941|Procedure|Antegrade reperfusion|Antegrade conventional portal reperfusion of the donor liver during the transplant procedure with consequent arterial reperfusion.
1574494|NCT02423096|Drug|Risperidone|Patients with schizophrenia will be treated with antipsychotic drugs as routine care.
1574385|NCT02423928|Biological|Dendritic cell based cryoimmunotherapy|Autologous dendritic cells will be obtained following leukapheresis and cytokine induction and will be injected into cryoablated prostate cancer tissue under ultrasound guidance.
1574386|NCT02423928|Drug|Cyclophosphamide|Low-dose cyclophosphamide will be given metronomically for the purpose of selective inhibition of T regulatory cells for 6 months following start of treatment.
1574387|NCT02423928|Drug|ipilimumab|The antibody and immune checkpoint inhibitor ipilimumab (Yervoy) will be given for the last 10 patients enrolled into the study in addition to cryoimmunotherapy and low-dose cyclophosphamide.
1574388|NCT02423915|Drug|Rituximab|375 mg/m2 by vein on Day -12 for for participants with CD20+ malignancies.
1574389|NCT02423915|Drug|Fludarabine|40 mg/m2 by vein on Days -8 to -5.
1574390|NCT02423915|Drug|Cyclophosphamide|50 mg/kg by vein on Day -8.
1574391|NCT02423915|Radiation|Total Body Radiation|2 Gy delivered on Day -4.
1574392|NCT02423915|Procedure|Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10^6/kg Fucosylated T-reg cells on Day -1.
Phase II: Participants treated at cell dose level 2: 1 x 10^7/kg Fucosylated T-reg cells on Day -1."
1574393|NCT02423915|Procedure|Cord Blood Infusions|Cord blood transplant, MRD, or MUD infused on Day 0.
1574394|NCT02423915|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Day -3 to Day +100 in the absence of GVHD.
1574395|NCT02423915|Drug|Sirolimus|12 mg by mouth load followed by 4 mg by mouth daily from Day -3 to Day +180 in the absence of GVHD.
1574396|NCT02423915|Procedure|Bone Marrow Aspiration|Bone marrow aspiration performed at 1, 3, 6, and 12 months after transplant to check status of disease.
1574397|NCT02423915|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on D+0, and continuing until absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
1574398|NCT02423915|Procedure|Non-Fucosylated Regulatory T Cells|"Phase I: Participants treated at cell dose level 1: 1 x 10^7/kg Non-Fucosylated T-reg cells on Day -1.
Phase II: Participants treated at cell dose level 2: 1 x 10^7/kg Non-Fucosylated T-reg cells on Day -1."
1574399|NCT02423902|Biological|Ad-RTS-hIL-12|Approximately 1.0x10^12 viral particles (vp) per injection
1574400|NCT02423902|Drug|Veledimex|7 oral doses of veledimex
1574401|NCT02423889|Radiation|Radiotherapy|
1574402|NCT02423876|Drug|Epidural analgesia|"Receive epidural placement. Standard epidural medications and dosage are as follows:
0.1% ropivicaine + 10 mcg/mL hydromorphone at 6 mL/hr continuous rate
3 mL/hr RN bolus, to be used as needed based on pain ratings
3 mL/30 minutes patient bolus, which is available on patient demand."
1574403|NCT02423876|Other|Intraoperative Complication Management and Prevention|Undergo ERP
1574404|NCT02423876|Procedure|Pain Therapy|Undergo ERP
1574405|NCT02423863|Biological|Hiltonol|Priming treatment course, which consists of a total of 6 IT injections of 0.5 mg poly-ICLC followed by boosting treatment course, consisting of IM injections of Poly-ICLC twice weekly for 3 treatment cycles and a 6 week maintenance cycle with administration of 1 mg IM Poly-ICLC twice weekly. Study subject's response will be defined as Disease Control (CR, PR, SD) or PD
1574406|NCT02423850|Device|3D photooptical camera|
1574407|NCT02423837|Drug|Rituximab, bendamustine|
1574409|NCT02423811|Dietary Supplement|Fursultiamine|Use of Fursultiamine in addition to CCRT
1574410|NCT02423798|Device|Glucose sensor (Enlite)|This is a postmarket, interventional, open-label, non-randomized, single center clinical research trial. The trial will adopt a prospective single-sample design using the Yellow Spring Instruments (YSI) plasma glucose reference sampling procedure in the clinic and selfmonitoring of blood glucose (SMBG) plasma glucose reference sampling procedure at home. The trial will consist of 6 visits to the investigational site: a visit for informed consent procedures (Visit 0), a screening visit (Visit 1), 3 study visits (Visit 2-4) and a final examination (Visit 5).
1574411|NCT02423772|Behavioral|Acceptance and Commitment Therapy + Mindfulness-Based Relapse Prevention + Treatment as Usual (TAU)|
1574412|NCT02423759|Drug|ciprofloxacin|500mg ciprofloxacin twice daily starting the day before biopsy and continued for 3 days after
1574413|NCT02423759|Drug|ciprofloxacin and gentamycine|standard chemoprophylaxis plus gentamicin 160mg intramuscular once just before the biopsy
1574414|NCT02423759|Drug|culture based chemoprophylaxis|Patients will receive antibiotic according to rectal swab culture at time of biopsy and then after for 3 days.
1574415|NCT02423746|Behavioral|Family Check Up Behavioral Parenting Training Program (BPT)|"The Family Check Up is an evidence-based Behavioral Parenting Training (BPT) program focused on harnessing parents' motivation to change and skills training.
Intervention parents receive the initial assessment session followed by 3 Family Check-up Sessions within one month of baseline assessment followed by a post-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
1574416|NCT02423746|Behavioral|Behavioral Placebo|"The Behavioral Placebo sessions will consist of presentations of information about healthy lifestyles.
Parents in the control group will receive an initial assessment session followed by three behavioral placebo sessions followed by a post-placebo-intervention assessment. All sessions will be delivered in the patients' usual hearing clinics and will last between 60 and 90 minutes. One month post-intervention, participants will complete post-test measures repeating baseline measures, plus acceptability ratings of intervention."
1574454|NCT02423447|Device|G5 Intervention|An assigned respiratory therapist performed airway clearance on each participant with the G5 device following the 2012 CFF therapy guidelines
1574635|NCT02422082|Dietary Supplement|L. reuteri|Dietary supplementation with L. reuteri twice daily for 12 months
1574417|NCT02423733|Other|The Journal|"The Journal is a free internet based program for the self-management of depression (www.depression.org.nz) that was developed in New Zealand and capitalizes on the social marketing appeal of Sir John Kirwan, an ex All Black who has described his experiences of depression to help destigmatize mental illness. . The self-help program is based on the cognitive behavioral techniques of behavioral activation and problem solving which teaches patients the skills of problem solving and delivers an evidence based intervention which is personalized for their individual care."
1990720|NCT01857869|Procedure|Sporozoite-infected mosquitoes challenge|"Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.
The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21)."
1574419|NCT02423707|Drug|ALK Alutard Birch and/or 5-grasses|"3 intralymphatic injections of 1000 SQ-U birch and/or grass allergen with 4 weeks interval.
The substance used for the three intralymphatic injections is ALK-alutard SQ Betula verrucosa® and ALK-alutard SQ 5-grasses ® under ATC-code V01AA, V04CL and V07AB which is a depot formulation for subcutaneous use."
1574420|NCT02423707|Drug|ALK Diluent|This placebo group will receive 3 injections of 0.3% human albumin instead of active substance
1574423|NCT02423681|Device|ThermoSmart|Heated humidification as first intention (HH1st) with ThermoSmart
1574424|NCT02423681|Device|Without ThermoSmart|ThermoSmart is switched off
1574425|NCT02423668|Procedure|50% Partial adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 50% partial adjustment of the PE1.
1574426|NCT02423668|Procedure|No adjustment|IOL power selection for the second eye irrespective of first eye prediction error
1574427|NCT02423668|Procedure|Full adjustment|Second eye refinement in the IOL power selection for the second eye using a theoretical 100% partial adjustment of the PE1.
1574428|NCT02423655|Other|Algorithm for deferred dialysis intervention|Use combined indications to guide researchers to defer dialyzing progressive CKD patients. Asymptomatic patient will not start dialysis treatment until his eGFR becomes less than 5 ml/min/1.73m2. Or until 1. Patient's Kraemer index is >6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's Subjective Global Assessment method (SGA) assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment
1574429|NCT02423655|Other|Algorithm for routine dialysis intervention|"Use combined indications to guide researchers to initiate dialysis in progressive CKD patients routinely. Researchers will start dialysis treatment for a patient when his eGFR reaches 7 ml/min/1.73m2 in asymptomatic patients.
Or patients have indications below: 1. Patient's Kraemer index is >6 or with overt fluid overload after trying all conservative means（including appropriate medicines） 2. Patient's SGA assessment is grade C 3. Patients have indications for emergency dialysis 4. Sever symptoms which cannot be relieved by conservative treatment"
1574430|NCT02423642|Procedure|Continuous renal replacement therapy with regional citrate anticoagulation|"CRRT with anticoagulant : regional citrate anticoagulation
Filter : AQUAMAX™ (Edwards Lifesciences)"
1574431|NCT02423642|Procedure|Continuous renal replacement therapy with no anticoagulation or heparin|CRRT with any anticoagulant : no anticoagulation or heparin Filter : AQUAMAX™ (Edwards Lifesciences)
1574432|NCT02423629|Device|Agili-C™ implantation procedure|Candidates for Agili-C™ implantation will be screened for possible inclusion in the trial. Candidates that are approved by the adjudication committee will be considered for study enrollment and then operated. Note: in case intra-operatively a medical condition is observed which is not aligned with the inclusion/exclusion criteria, the Subject will not be implanted with the Agili-C™ device and will not be considered enrolled in the study.
1574433|NCT02423616|Other|Healthy individuals|INSPIRATORY PRESSURE AND HAND GRIP FORCE CORRELATION
1574434|NCT02423603|Drug|Paclitaxel|Patient receive Once a week for three weeks - with one week off treatment
1574435|NCT02423603|Drug|AZD5363|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
1574436|NCT02423603|Drug|Placebo|Patients receive AZD5363/Placebo in an intermittent treatment schedule. Please see study arms for full information.
1574437|NCT02423590|Drug|Apatorsen (OGX-427)|Apatorsen (OGX-427) is a second generation antisense oligonucleotide designed to bind to Hsp27 mRNA
1574438|NCT02423590|Drug|Gemcitabine|"Gemcitabine is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Gemcitabine is classified as an antimetabolite"
1574439|NCT02423590|Drug|Carboplatin|"Carboplatin is an anticancer drug (antineoplastic or cytotoxic) chemotherapy drug. Carboplatin is classified as an alkylating agent."
1574440|NCT02423577|Drug|FF-3 dry powder|FF-3 dry powder administered by nasal inhalation
1574441|NCT02423577|Drug|Placebo|Placebo dry powder administered by nasal inhalation
1574442|NCT02423564|Dietary Supplement|Digesta Lac|
1574443|NCT02423564|Other|Placebo|
1574445|NCT02423538|Drug|SHR0302|Oral tablets (1 mg, 5 mg, 10 mg)
1574446|NCT02423538|Drug|SHR0302 placebo comparator|Oral tablets (1 mg, 5 mg, 10 mg) (matching corresponding study medication)
1574448|NCT02423486|Device|Electromagnetic stimulation therapy (BIOCON-2000)|
1574449|NCT02423486|Device|Electromagnetic stimulation therapy with biofeedback|
1574450|NCT02423473|Procedure|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
1574451|NCT02423473|Procedure|Composite resin restoration (Filtek Supreme - 3M)|Restorative procedure do treat tooth structure loss
1574452|NCT02423460|Other|Threonine|Threonine will be fed at various intake levels ranging from high to low in order to determine its requirement in healthy males and in patients with Crohn's disease and Ulcerative colitis.
1574453|NCT02423447|Device|Electro-Flo Intervention|An assigned respiratory therapist performed airway clearance on each participant with the Electro-Flo device following the 2012 CFF therapy guidelines
1576297|NCT02410668|Behavioral|Exercise recommendation|
1574455|NCT02423434|Other|Exposure: Corneal nerve fibre morphology by the CCM Procedure|"CCM is a non-invasive method for direct visualization of corneal nerve fibers. Previous research work has confirmed that corneal nerves status correlates with both small and large fibre damage as assessed by quantitative sensory testing and nerve conduction.
In the current trial subjects will undergo a bilateral examination of the Bowman's layer of the cornea using the Rostock Cornea Module of the Heidelberg Tomograph III (Heidelberg Engineering, Smithfield RI, USA) to determine their corneal nerve fiber length, corneal nerve fiber density, corneal nerve branch density, and the tortuosity coefficient. Topical anaesthetic and a viscous gel medium will be applied to the eye, which will create a visual gel bridge between the cornea and the sterile single-use cap on the microscope objective lens. After the interface between the corneal epithelium and Bowman's layer is identified, batches of images will be taken and the most technically sound images will be identified and analyzed."
1574456|NCT02423421|Other|Faecal microbiota transplantation|Human Stool.
1574457|NCT02423408|Drug|TNX-201|TNX-201 capsule
1574458|NCT02423408|Drug|Placebo|Placebo capsule
1574459|NCT02423395|Drug|orphenadrine|Orphenadrine in muscle cramps in cirrhotic patients
1574460|NCT02423395|Drug|Placebo|calcium in muscle cramps in cirrhotic patients
1574461|NCT02423382|Procedure|Silicone oil removal|The patients in each group will receive the same procedure of silicone oil removal.
1574462|NCT02423369|Procedure|Cerebral near infrared spectroscopy|At the start of anesthesia on the patient's forehead two electrodes are attached the for continuous measurement of cerebral near infrared spectroscopy during surgery.
1574463|NCT02423369|Other|S-100B protein in serum|0,5-1 ml of blood from periferal site for determination of serum S-100B concentration.
1574464|NCT02423369|Other|NSE protein in serum|0,5-1 ml of blood from periferal site for determination of serum NSE concentration.
1574465|NCT02423356|Procedure|Echocardiogram|An echocardiogram uses sound waves to produce images of the heart. This commonly used test allows doctors to see how your the heart is beating and pumping blood. Doctors can use the images from an echocardiogram to identify various abnormalities in the heart muscle and valves.
1574466|NCT02423343|Drug|Galunisertib|Administered orally
1574467|NCT02423343|Drug|Nivolumab|Administered IV
1574468|NCT02423330|Device|Strattice-LIFT|Patients undergoing surgery for transsphincteric anal fistulas will undergo the Strattice-LIFT procedure. A standard LIFT procedure will be performed with the addition of Strattice placed into the intersphincteric space.
1574469|NCT02423317|Device|Intubation with Miller's blade|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Miller's blade.
1574470|NCT02423317|Device|Intubation with Airtraq|Intubation is insertion of a hollow tube inside the trachea. It is done after laryngoscopy with Airtraq.
1574471|NCT02423304|Genetic|blood samples collected from all patients|blood samples collected from brachial pluxes
1574472|NCT02423291|Drug|Brentuximab Vedotin|Brentuximab vedotin, 1.8 mg/kg, administered via outpatient IV infusion on Day 1 of each 21-day cycle.
1574473|NCT02423278|Procedure|Radical Gastrectomy Plus D2 Lymphadenectomy|"This surgical procedure is performed by the same high-experienced surgical team as the control arm.
All lymph nodes around stomach (station 1&2 LNs) must be removed to achieve a radical lymphadenectomy. Para-aortic lymph nodes should not be dissected even if a suspected lymph node metastasis is diagnosed from radiographic exams."
1574474|NCT02423278|Procedure|Radical Gastrectomy Plus D4 Lymphadenectomy|"This surgical procedure is also performed by the same high-experienced surgical team as the control arm.
Lymph nodes around stomach (station 1&2 LNs) and para-aortic lymph nodes must be removed during the operation."
1574475|NCT02423278|Drug|S-1+Oxaliplatin|"A perioperative chemotherapy, known as SOX regimen, should be performed in each enrolled patient with three-cycle treatments followed after a pathological carcinoma diagnosis. After a radical operation (arm groups), additional five-cycle treatments of adjuvant chemotherapy (SOX regimen) would be performed, followed by follow-up program. The treatment bundles are listed as follows:
S-1: 40~60mg bid，po, Day1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid）
Oxaliplatin: 130mg/m2，iv drip for 2h，Day1"
1574476|NCT02423265|Drug|Ranolazine|Ranolazine: 500 mg twice day, up-titrated after 1 week to 1000 mg twice a day
1574477|NCT02423265|Drug|Placebo|Matching placebo: up-titration after 1 week
1574478|NCT02423252|Behavioral|Massage, Relaxation, Guided imagery and music listening.|In addition to standard care, patients in the intervention group will receive a 60 minutes individually delivered programme, administered once per day by a nurse (the researcher) for up to 5 days during staying in ICU. This session aims to induce relaxation and involves interpersonal support, touch/massage and through a headphone system relaxation and guided imagery exercises and music listening. Patients are provided a CD of the relaxation instructions, after their discharge, for own use
1574479|NCT02423252|Other|No Intervention|The control group will receive the standard care which includes the routine standard care provided by nurses, physiotherapists and intensivists or specialists (e.g. surgeons)
1574480|NCT02423239|Drug|Dexanabinol|Patients will receive dexanabinol given once a week, as a slow intravenous infusion (i.v.) over a 3 hour period
1574481|NCT02423239|Drug|Sorafenib|Patients will receive Sorafenib at a dose of 400 mg bid (oral administration)
1574482|NCT02423239|Drug|Nab-paclitaxel|Patients will receive Nab-paclitaxel at a dose of 125mg/m2 intravenous infusion
1574483|NCT02423239|Drug|Gemcitabine|Patients will receive Gemcitabine at a dose of 1000mg/m2 intravenous infusion
1574484|NCT02423226|Procedure|Computed tomography guided radioactive seeds implant|Computed tomography guided radioactive seeds implant were performed one week before chemotherapy.
1574485|NCT02423226|Drug|Systemic chemotherapy (FOLFIRI)|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
1574486|NCT02423200|Drug|VX-745|Orally-active P38 MAP kinase alpha-selective inhibitor
1574487|NCT02423187|Other|No Intervention|
1574488|NCT02423174|Procedure|Total Mesorectal Excision|Surgical intervention with the FMwand Surgical System
1574489|NCT02423174|Device|FMwand Surgical System|
1574490|NCT02423148|Drug|Indocyanine green (ICG)|
1574491|NCT02423148|Device|FluoSCOPE|
1996582|NCT02445859|Drug|Cefuroxime 4 hourly bolus|Cefuroxime loading dose followed by a continuous infusion dosed according to renal function. Dosed to target a serum concentration of 64mg/L.
1574497|NCT02423018|Drug|Pregabalin|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
1574498|NCT02423018|Drug|Placebo|In replacement of their morning 75mg pregabalin or placebo dose on Days 6 and 8, all participants will receive either a single dose of 300mg of pregabalin or placebo, in a randomized, double-blind, crossover manner. This is when steady state concentrations of pregabalin occur.
1574499|NCT02423005|Device|Neurotech Vital Compact|Neuromuscular electrical stimulation of the pelvic floor via an arrangement of external electrodes held in place by a garment.
1574500|NCT02423005|Device|itouch Sure Pelvic Floor Exerciser|Vaginal probe with electrodes designed to deliver electrical stimulation to the pelvic floor muscles.
1574501|NCT02422979|Drug|RM-1929|Dose-escalation, fixed low fluency light application study to determine the drug dose that can be safely given to saturate the epidermal growth factor receptor (EGFR) at the tumor
1574502|NCT02422979|Device|Photoimmunotherapy|Light dose-escalation, fixed drug dosing infusion study to determine the optimal light application, in combination with the Part I drug dose, needed to achieve clinical response with an acceptable safety profile.
1574503|NCT02422966|Drug|Paracetamol|
1574504|NCT02422966|Drug|Ibuprofen|
1574505|NCT02422953|Dietary Supplement|Wheat Soya Blend (WSB)|A monthly ration of 5 Kg of WSB will be given to pregnant women every month during pregnancy and lactating mothers for six months after giving birth
1574506|NCT02422953|Dietary Supplement|Wawa Mum|Children 6-23 months of age will receive a daily ration of 50 gram of Wawa Mum during study period
1574507|NCT02422953|Dietary Supplement|Micronutrient Powders (MNP)|Children 24-59 months of age will receive a sachet of MNP in alternate days
1574508|NCT02422953|Behavioral|Behavior change and preventive health massages|Behavior change and preventive health massages will be delivered by lady health workers (LHWs) during monthly visits and in group meetings
1574509|NCT02422940|Drug|dalfampridine-ER 7.5 mg|
1574510|NCT02422940|Drug|dalfampridine-ER 10 mg|
1574511|NCT02422927|Dietary Supplement|Nutraceutical Combination|red yeast rice extract 200 mg (equivalent to 3 mg monacolins), policosanol 10 mg, berberine 500 mg, 0.2 mg folic acid, coenzyme Q10 2 mg, and astaxanthin 0.5 mg once daily
1574512|NCT02422927|Other|Standard of Care|low-cholesterol/low-saturated fat diet and regular aerobic physical activity schedule
1574513|NCT02422927|Other|Placebo|placebo
1574514|NCT02422914|Behavioral|Smoking cessation program TFC and activity tracker|Participants will receive a free TFC device and sufficient nicotine cartridges (8 mg/ml) to last the last of the procedure. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks. The nicotine cartridges use will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)
1574515|NCT02422914|Behavioral|Smoking cessation program TFC-free and activity tracker|"Participants will receive a free TFC device and a set of 10 ml flacons enough to complete the trial. Participants will be instructed to use the device ad libitum one week before their quit day (to be decided at the first contact) to familiarise themselves with its operation and on their designated quit day will stop smoking tobacco cigarettes and instead use the TFC exclusively for the next 11 weeks.
The actual use of the device and smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit)."
1574516|NCT02422914|Behavioral|Smoking cessation program and activity tracker|Participants undergo a motivational interview and low-intensity at distance counseling (the same counseling program of other groups) without any device.The actual smoking habits will be monitored through the weekly diary and the monthly telephone. Lifestyle change will be monitored by the use of an activity tracker device (FitBit).
1574517|NCT02422901|Drug|vitamin C|According to the character of an observational study no intervention other than the administration of Pascorbin® 7.5g (which is administered routinely in these cases) is provided.
1574518|NCT02422888|Drug|Ticagrelor|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a maintenance dose of ticagrelor 90 mg twice a day for 1 year.
1574519|NCT02422888|Drug|Prasugrel|After a standard loading dose of 180 mg ticagrelor in the ambulance (before primary PCI), patients will receive a single loading dose of prasugrel 60 mg (1 day after standard loading dose ticagrelor),followed by a maintenance dose of prasugrel 10 mg once a day for 1 year.
1574520|NCT02422862|Other|UC-TSM|"Upper cervical translatoric spinal mobilization: a 30 minutes treatment consisting of 30 series of translatoric mobilizations of the upper cervical spine with 10 rest between sets. For that purpose, the patient is positioned in supine, with the cervical spine in neutral position. The therapist place a hand dorsally at the level of the vertebral arch of C1 with the metacarpophalangeal and radial border of the index finger. The other hand is placed posteriorly under the occiput, with the shoulder positioned anteriorly on the patient's forehead. The mobilization force is directed dorsally from the shoulder until the therapist feel a marked resistance and then apply slightly more pressure in order to perform a stretching mobilization."
1574521|NCT02422849|Other|hospital specialist|
1574522|NCT02422849|Other|General Practitioner|
1574523|NCT02422836|Other|Three Product Anti-Aging Treatment Regimen|Cream Skin Cleanser RD04033B, twice daily, 8 weeks; Anti-aging Cream RD04034B, twice daily, 8 weeks; and Sunscreen SPF 50 RD04036, once daily, reapply as needed, 8 weeks
1996583|NCT02445859|Drug|Cefuroxime bolus-continuous infusion|Cefuroxime 1.5 grams pre-operatively, repeated 4 hourly during surgery.
1996584|NCT02445716|Drug|Testosterone|"It consists of a 12-week treatment with 300mcg of transdermal testosterone phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
Participants will be submitted to a physical examination including vital signs and breast and pelvic examination. Women who met the eligibility criteria is invited to attend a baseline randomization visit. They will be randomly assigned in a 1:1 ratio to receive a transdermal testosterone nanoemulsion (0.8g per dose) delivering 300 mcg/day testosterone or an identical placebo provided by Evidence Pharmaceuticals LTDA, SP, BRAZIL.
Women are asked to return all unused pumps, and treatment compliance was checked by counting weighting returned packs at their final visit."
1996585|NCT02445716|Drug|Placebo|It consists of a 12-week treatment with placebo phase involving three study visits. Participants will attend at the Federal University of Sao Paulo in Brazil for their study visits.
1574530|NCT02422784|Dietary Supplement|Rooibos Iced-Tea (Control)|Participants will consume 240 mL of Rooibos iced-tea daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
1574531|NCT02422784|Dietary Supplement|Rooibos Tea - Vitamin D3|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
1574532|NCT02422784|Dietary Supplement|Rooibos Tea- Vitamin D3 & Calcium|Participants will consume 240 mL of Rooibos iced-tea fortified with 1000 IU of water soluable Vitamin D3 and 360 mg of Calicum daily for 6 weeks. The iced-tea beverage will not contain any added sugar or artificial sweeteners. Beverages will be prepared fresh weekly and picked up by participants during their weekly study visits.
1574533|NCT02422771|Other|FIFA 11+ warm-up|A sequence of 15 exercises performed before soccer practices and games. The exercises include strength, agility, balance and motor control components and take about 15-20 minutes to perform. The intervention replaces any previous warm-up the athletes may have done.
1574534|NCT02422758|Device|3M™ Bair Hugger™ Preoperative & Outpatient Care Blanket|3M™ Bair Hugger™Preoperative & Outpatient Care Blanket will cover the whole body. Patients will be prewarmed for 20 minutes with forced air warming system. Unit will be at average power.
1574535|NCT02422758|Other|Passive Prewarming|
1574536|NCT02422745|Dietary Supplement|Cocoa extract|2 capsules each day containing a total of 600 mg cocoa flavanols, including 80 mg (-)-epicatechin, and 50 mg theobromine
1574537|NCT02422745|Dietary Supplement|Multivitamin|Multivitamin
1574538|NCT02422745|Dietary Supplement|Cocoa extract placebo|Cocoa extract placebo
1574539|NCT02422745|Dietary Supplement|Multivitamin placebo|Multivitamin placebo
1574540|NCT02422732|Other|Neuropsychological assessments|"IQ (WISC-IV)
Reading tests (reading accuracy, reading speed, reading comprehension and strategy):
Alouette, Lobrot, Odedys tests. Visuo-spatial skill (JLO, Thurston, CORSI tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
1574541|NCT02422732|Radiation|morphological and functional MRI (fMRI)|"The fMRI will consider on the acquisition of a 3D anatomical sequence in T1 high resolution in axial slices of 1mm with an acquisition time of 10 min and a T2 sequence and a Flair to allow UBO location."
1574542|NCT02422732|Genetic|genetic analysis|Blood collection in 3 tubes (2 PAXgen® and 1 EDTA) and analysis to study the NF1 gene deletion.
1574543|NCT02422719|Drug|Radotinib|Radotinib 400mg bid
1574544|NCT02422706|Drug|Nitazoxanide|Nitazoxanide based treatment regimens as a new treatment regimens for helicobacter pylori infection
1574545|NCT02422706|Drug|Metronidazole(MTZ)|Metronidazole 500 mg twice daily
1574546|NCT02422706|Drug|Omeprazole|Omeprazole 20 twice daily
1574547|NCT02422706|Drug|Clarithromycin|KLacid twice daily
1574548|NCT02422706|Drug|Levofloxacin|Tavanic. Tavacin
1574549|NCT02422706|Drug|Doxicycline|Vibramycin 100 mg twice daily
1574550|NCT02422693|Other|Aquatic Exercises|Exercises performed in the water.
1574551|NCT02422693|Other|Deep-water running|It is a non-impact form of running executed in place in (higher than 2 meters) the water wearing a flotation belt. Heart rate is controlled by heart rate watch
1574552|NCT02422680|Procedure|No intervention, purely observational.|No intervention is made other than following existing guidelines for colonoscopy. Further treatment and/or renewed colonoscopy in case of positive findings follows existing guidelines. The group is used only used to collect quality assurance data.
1574553|NCT02422667|Other|Patient Registry|Orthopedic Data Registry
1574554|NCT02422654|Drug|eliglustat|"Pharmaceutical form:liquid formulation
Route of administration: oral without ingestion"
1574555|NCT02422641|Drug|High-dose Methotrexate (8 gm/m2; HD-MTX)|Enrolled patients will undergo treatment with HD-MTX (8 g/m2) as per current standard practice on an every 2 week schedule until disease progression or death from any cause. Treatment will be performed according to standard clinical practice. Surveillance imaging with or without cytologic evaluation will be performed as per standard clinical practice after every 2 cycles (~28 days). Treatment will continue until there is unequivocal evidence of clinical or radiographic CNS or systemic disease progression, death from any cause, or intolerance.
1574559|NCT02422602|Drug|Xarelto|Taking conventional charge
1574560|NCT02422602|Other|Experimental: Personalized information intervention|
1574561|NCT02422589|Drug|ceritinib|
1574562|NCT02422589|Drug|warfarin|
1574563|NCT02422589|Drug|midazolam|
1574636|NCT02422082|Dietary Supplement|Placebo|Dietary supplementation with placebo twice daily for 12 months
1574568|NCT02422563|Procedure|hysterectomy|radical hysterectomy
1574569|NCT02422563|Radiation|Radiation|
1574570|NCT02422563|Drug|Cisplatin|
1574571|NCT02422563|Drug|Paclitaxel|
1574572|NCT02422563|Drug|Carboplatin|
1574573|NCT02422563|Drug|Ifosfamide|
1574575|NCT02422537|Dietary Supplement|Unmodified wheat bran|
1574576|NCT02422537|Dietary Supplement|Wheat bran with reduced particle size|
1574577|NCT02422537|Dietary Supplement|Destarched pericarp-enriched wheat bran|
1574578|NCT02422537|Dietary Supplement|No wheat bran fraction|
1574579|NCT02422524|Drug|PA-824|PA-824 is a nitroimidazooxazine. All subjects will receive a single oral dose of 200 mg PA-824 on day 1.
1574580|NCT02422511|Genetic|Genomic sequencing|Both sick and healthy infants randomized to receive genomic sequencing will receive a 'Genomic Newborn Sequencing Report' (GNSR) which will include pathogenic or likely pathogenic variants identified in genes associated with childhood-onset disease.
1574581|NCT02422511|Other|Family history report|Participants from all arms of the study will have a family history taken by a study genetic counselor. Information collected through the family history will be summarized in a family history report that will be reviewed with all participants.
1574585|NCT02422485|Drug|Salsalate|Salsalate is a non-acetylated dimer of salicylic acid, and is classified as a NSAID. The chemical name of salsalate is 2-hydroxy-benzoic acid, 2-carboxyphenyl ester. Salsalate has a molecular weight (MW) of 258.226 Da and a molecular formula of C14H10O5.
1574586|NCT02422472|Device|Ultrasound guided peripheral IV placement|Accucath™ 20 Gax 5.7cm catheter
1574587|NCT02422459|Behavioral|COMMENCE|ChrOnic pain self-ManageMent support with pain science Education and exerCisE (COMMENCE) consists of two visits with a physiotherapist per week over six weeks. One of the two visits is in a group setting, where the emphasis is on pain neurophysiology education and provision of self-management strategies. The second visit each week is an individualized, one-to-one session in which the focus is on providing support for implementing self-management strategies and developing of an individualized, goal-oriented exercise program.
1574588|NCT02422446|Drug|Icosapent ethyl|icosapent ethyl is eicosapentaenoic acid, an omega-3 fatty acid that naturally occurs in fish
1574589|NCT02422433|Device|OFDI Capsule Marking|Marking and imaging of the esophagus using the OFDI Capsule and system.
1574590|NCT02422420|Behavioral|Financial Incentives|Use of financial incentives to promote health behaviors.
1574591|NCT02422407|Procedure|Biopsy|Salivary Gland
1574592|NCT02422394|Drug|Eltrombopag|
1574593|NCT02422381|Drug|MK-3475|Investigational drug.
1574594|NCT02422381|Drug|Gemcitabine|Standard care drug.
1574595|NCT02422368|Drug|Methylprednisolone + ASTED|"ASTED tablet: Twice daily for 6 months
Methylprednisolone:
Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
1574596|NCT02422368|Drug|Methylprednisolone +Placebo|"Placebo: twice daily
Methylprednisolone:
Methylprednisolone tablet of 50 and 5 mg, company….) 1mg/kg for the first 2 weeks, 0.8mg/kg for 2 weeks, 0.7 mg/kg for 2 weeks, and then tapering off the methylprednisolone in 6 weeks (total duration of 12 weeks) by 8-10 mg per week. For example, a patient with 75 kg weight will receive 75 mg for 2 weeks, 60 mg for 2 weeks, 52.5 mg for 2 weeks, and then decreasing by 8-10 mg per week for 6 weeks. The dose regiment will be written and handed to the patient on the first visit and will be monitored during the follow ups."
1574597|NCT02422355|Device|FNS|Surgical intervention using the FNS
1574598|NCT02422342|Device|Pulse Oximeter CMS50FW (Contec Medical)|"The patients will be wearing the pulse oximeter during the test period (20-30 minutes).
The data from the oximeter will be sent by Bluetooth to the mobile application"
1574599|NCT02422329|Behavioral|Questionnaires|Participants complete questionnaires at baseline and after intervention.
1574600|NCT02422329|Behavioral|Video|Participants watch a 3-minute educational video describing symptoms of constipation and importance of regular bowel movements.
1574601|NCT02422329|Behavioral|Fact Sheet|Participants read educational material describing symptoms of constipation and importance of regular bowel movements.
1574602|NCT02422316|Other|Non-contrast Cardiac CT scan|
1574603|NCT02422303|Drug|ketamine|Ketamine 0.5mg/kg will be given intravenously to group A at induction of general anesthesia.
1574604|NCT02422290|Drug|Ketamine|Single infusion of IV Ketamine, 0.5mg/kg
1574634|NCT02422095|Procedure|EUS of pancreatic cyst lesion|All pancreatic cyst lesions evaluated by EUS will be documented in this registry. Information collected will include patient demographics, pancreatic cyst characteristics, tests undertaken on cyst contents and follow-up data.
1574605|NCT02422277|Device|LI-ESWT group|"The patients in this arm will be subjected to Penile LI-SWT in the following parameters: 6 to 12 sessions with 1500 shocks per session. Each session will comprise the application of 300 shock waves (energy intensity of 0.09 mJ/mm2) to each of five different sites on the penis: three along the penile shaft and two at the crura with Frequency: 4 HZ. Energy level: 8 mJ/mm2. Rate: 120 shocks per minute.
-Intervals: 2 treatment sessions per week for 3 weeks, then 3-weeks no-treatment interval, then 3-weeks treatment period of 2 treatment sessions per week."
1574606|NCT02422277|Drug|PDE-5 inhibitors group|The patient in this arm will receive 50 mg of phosphodiesterase-5 inhibitors, oral intake once daily for 6 monthes.
1574609|NCT02422251|Device|Mobile high congruency bearing (Columbus)|Columbus high congruency bearing on a rotating platform tibia.
1574610|NCT02422251|Device|Fixed high congruency bearing (Columbus)|Columbus high congruency bearing on a fixed platform tibia.
1574611|NCT02422251|Device|Fixed high congruency bearing (Columbus)|Columbus deep dish bearing on a fixed platform tibia.
1574612|NCT02422225|Device|Eldith DC-STIMULATOR|"Transcranical direct current stimulator (Neuroconn GmbH, Ilmenau, Germany) approved by Conformity European as safe treatment device for stroke patients
tDCS intervention]
Intensity: 1.5mA for 20min Device: Neuroconn GmbH, Ilmenau, Germany
Stimulation site <Experimental group>
Anode-Anode dual stimulation group Anode: affected pharyngeal motor cortex / Cathode: affected supraorbit Anode: non-affected pharyngeal motor cortex / Cathode: non-affected supraorbit
Anode-Cathode dual stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected pharyngeal motor cortex
Single stimulation group Anode: affected pharyngeal motor cortex Cathode: non-affected supraorbit <Control group> Sham stimulation"
1574613|NCT02422225|Device|Sham Eldith DC-STIMULATOR|
1574614|NCT02422212|Other|patients eat a mixed solid meal|The three groups were given an indirect calorimetry examination to measure their resting metabolic rate (RMR), respiratory exchange rate (RER) and DIT. The patients collected urine during 24 hours for urinary nitrogen analysis. Immediately after the RMR measurement, patients received a solid mixed meal (270 kcal, with 62% carbohydrate, 12% protein and 26% lipid). Ten minutes after beginning this food intake, postprandial (PP) energy expenditure measurements were taken in the following sequences (in minutes): 10-20, 20-30, 30-40, 60-70, 70-80, 80-90, 110-120, 120- 130, 130-140, 160-170 and 170-180.The DIT was calculated for each time interval.
1574615|NCT02422199|Drug|pyrotinib|
1574616|NCT02422199|Drug|Lapatinib|
1574617|NCT02422199|Drug|capecitabine|
1574618|NCT02422186|Drug|Esketamine|All participants will start with first dose (Day 1 as 28 milligram [mg]); second dose (Day 4) is either 28 or 56 mg. All subsequent doses may be 28, 56 or 84 mg. After the first dose, all dosing decisions are determined by the investigator based on efficacy and tolerability.
1574619|NCT02422186|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4-weeks as a flexible dose regimen in the Double-Blind Induction Phase.
1574620|NCT02422186|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital -Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
1574621|NCT02422186|Drug|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be given at a dose of 10 mg/day throughout the Double-Blind Induction Phase. This dose (10 mg/day) is the also the minimum therapeutic dose.
1574622|NCT02422186|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
1574623|NCT02422186|Drug|Venlafaxine Extended Release (XR) (New Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release may be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
1574624|NCT02422173|Device|Anodal transcranial direct current stimulation|The active electrode is placed on the affected hemisphere
1574625|NCT02422173|Device|Cathodal transcranial direct current stimulation|The active electrode is placed on the unaffected hemisphere
1574626|NCT02422173|Device|Bilateral transcranial direct current stimulation|The cathode and anode is positioned as active electrodes on the unaffected and affected hemisphere,respectively.
1574627|NCT02422173|Device|Sham transcranial direct current stimulation|Placebo stimulation, with emission current by only 30 seconds
1574628|NCT02422160|Other|No interventions are planned|No interventions are planned
1574629|NCT02422147|Procedure|Ablation of PCL|All procedures are standard of care and will be undertaken using a curvilinear echoendoscope. The cyst will be punctured using a 22G needle and after subtotal evacuation of the cyst, injection is performed with a volume of alcohol that is equal to the quantity aspirated, and the cyst will be lavaged for 3 to 5 minutes. The injected ethanol will then be evacuated at the end of lavage, leaving just enough fluid to outline the cavity. A second ablative agent such as paclitaxel is then injected and left in the cyst cavity. At the completion of the procedure, the needle will be removed from the cyst cavity.
1574630|NCT02422134|Other|Cytokine group|Testing the efficacy of adding Cytokine to embryo transfer medium
1574631|NCT02422121|Drug|RNS60|
1574632|NCT02422121|Drug|Placebo|
1574633|NCT02422108|Drug|Denosumab|
1576346|NCT02410447|Device|Defocused shock wave therapy (DUOLITH® SD1)|
1574637|NCT02422056|Drug|Tranexamic Acid|Tranexamic acid bolus of 10 mg / kg at the beginning of palatoplasty, followed by infusion of 1 mg / kg / h until the end of the procedure
1574638|NCT02422056|Drug|Saline|Infusion of saline in the same rate used for the intervention group
1574639|NCT02422043|Other|Questionnaires and audio-tape interviews|therapeutic patient education programs (TPE) to type 1 diabetic adolescents are designed to make the teenager to self manage their disease and their treatment. Based on Bandura's social cognitive theory, effects of educational activities for TPE should lead to the strengthening of self-efficacy
1574640|NCT02422030|Drug|Lipitor Tab. 40mg|
1574641|NCT02422030|Drug|Trilipix 135mg|
1574642|NCT02422017|Drug|Timolol|Patients will receive one drop of timolol every 6cm ² every other day for twelve weeks applied on the ulcer of interest
1574643|NCT02422017|Other|Local care treatment|Local care treatment with dressing compression in accordance with standards applied every other day
1574644|NCT02422004|Other|Range of motion|25 range of motion exercises of the ankle, 5 times per day.
1574645|NCT02422004|Other|Delayed weight-bearing|No weight-bearing during the first six weeks, and partial weight-bearing during the two following weeks
1574646|NCT02421991|Behavioral|Telephone Delivered Intervention|
1574647|NCT02421965|Behavioral|FOCUS (Smartphone Application)|Participants in the FOCUS group will be given a study smartphone device with FOCUS application and trained by the mHealth support specialist on how to use the functions of the smartphone (i.e. using a touchscreen, call, text) and different features of the FOCUS intervention.
1574648|NCT02421965|Behavioral|WRAP (Wellness Recovery Action Planning)|Participants allocated to the WRAP group will be provided all other materials (i.e. WRAP binder, handouts) in their first session and will meet weekly in groups with trained facilitators.
1574649|NCT02421939|Drug|ASP2215|tablet, oral
1574650|NCT02421939|Drug|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
1574651|NCT02421939|Drug|Azacitidine|SC or IV injection
1574652|NCT02421939|Drug|MEC (Mitoxantrone, Etoposide, Cytarabine)|IV injection
1574653|NCT02421939|Drug|FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)|SC (G-CSF) and IV (Fludarabine, Cytarabine, Idarubicin) injection
1574654|NCT02421926|Drug|IDEAL-E observation (investigators choice of imatinib, nilotinib, dasatinib, radotinib)|After the end of follow-up period of IDEAL study, subjects who agree with this extension study (IDEAL-E) will be enrolled and be followed up for additional 4 years to evaluate the duration of treatment response, disease progression, and survival status. Subjects who will be enrolled in this prospective observational study will be treated with drugs - imatinib 300-600mg / nilotinib 600mg / dasatinib 100mg / radotinib 800mg - which has been chosen by the each investigator according to the drug compliance and overall response. The drug choice will be at the discretion of each investigator, and the overall adverse event / molecular response will be monitored every 6 months in this prospective observational study.
1574655|NCT02421913|Drug|S(+)-Ketamine|S(+)-Ketamine 0,3mg/kg/hr intraoperative
1574656|NCT02421900|Other|radio-frequency catheter ablation of atrial fibrillation|radio-frequency catheter ablation of atrial fibrillation
1574657|NCT02421887|Drug|Antioxidant Supplement|An antioxidant combination including Vitamin C, Vitamin E, folic acid, selenium, zinc, and L-carnitine
1574658|NCT02421887|Other|Placebo|Placebo
1574659|NCT02421874|Behavioral|Wraparound Team Monitoring System electronic health record|Wraparound Team Monitoring System (Wrap-TMS) is a web-based, electronic behavioral health information system (EBHIS) for the most widely implemented care coordination model in children's behavioral health, the wraparound process
1574660|NCT02421874|Behavioral|Education about fidelity maintenance and monitoring|As an active comparator, we will educate practitioners randomized to the control condition about the importance of maintaining fidelity and monitoring fidelity and progress via a 3 hour training.
1574661|NCT02421861|Behavioral|Anxiety Management in the ICU|"The AM intervention is based on a Cognitive-Behavioral Therapy (CBT) approach, empirically supported in other settings, though we do not know whether this approach will be effective for ICU patients. It will offer all participants core aspects of CBT including: (1) establish rapport/therapeutic alliance; (2) anxiety psychoeducation; (3) normalization of difficulties; (4) establishment of a sense of hope; (5) reflective listening; (6) supportive statements; (7) exposure to anxious thoughts/feelings; (8) directive statements; and (9) provision of coping strategies. It will consist of modules that include the aforementioned core aspects and optional modules based on each participant's anxiety experience and preference."
1574662|NCT02421861|Other|Usual Care (UC)|The UC group will receive usual care as per the Harborview Medical Center usual care standard. Because this is an effectiveness trial, treatment decisions for UC participants will be left to the discretion of the primary provider and/or primary medical team and may or may not include: (1) referral to rehab psychology C&L service; (2) referral to psychiatry C&L service; or (3) pharmacologic management.
1574663|NCT02421835|Dietary Supplement|Olive leaf extract|132 mg of oleuropein per day suspended in olive leaf extract 700 mg
1574664|NCT02421835|Dietary Supplement|Placebo|700 mg Maltodextrin per day
1574666|NCT02421770|Other|Chamaemelum nobile 2%|"Experimental Chamaemelum Nobile 2% gel Active During the 6-week double-blind phase, all patients will be randomly assigned to receive Chamaemelum Nobile 2% gel Active or its vehicle twice daily with occlusion on the affected are"
1574667|NCT02421770|Other|placebo|
1574668|NCT02421757|Device|Transcutaneous Magnetic Stimulation|Transcutaneous Magnetic Stimulation
1574669|NCT02421757|Device|Placebo|The placebo TCMS device
1574731|NCT02421328|Device|HHHFNC first (Fisher & Paykel Healthcare)|Infants will start on HHHFNC for 60 minutes and then switched to nasal CPAP for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
1574759|NCT02421133|Other|standard care program|The patients will be discharged according to the usual care plan of each participating hospital. The medical team does a medical and geriatric assessment of the patients according to the recommendations. The communication of information to the primary care providers (nurse, primary care physician…) is left to the discretion of the medical teams of the discharging hospitals, according to their habits of work.
1574670|NCT02421744|Behavioral|Task Oriented Circuit Training|TOCT includes six different workstations in which subjects exercise for 5 minutes in each one (3 minutes of exercise and 2 minutes of rest). During each session, subjects undergo 2 laps that take about 60 minutes (6 workstation × 5 minutes × 2 laps), with 10 minutes of rest after each lap. In addition, walking endurance is trained by 30 minutes walking on the treadmill including rests if necessary. This is a progressive circuit and subjects while exercising receive feedbacks (visual and auditory) by the physiotherapist. Rests are used to discuss about difficulties and to provide further feedbacks. One session includes up to 3 patients and lasts 120 minutes, 5 days/week for 2 weeks. After this period they will receive a home-exercise maintenance program for 3 months.
1574671|NCT02421744|Behavioral|Delayed Onset TOCT|The control group will not receive any specific rehabilitation treatment for gait performance and mobility improvement. At any case, the control group will be authorized, at will, to exercise in non-rehabilitative contexts (i.e. swimming, walking, yoga) for 14 weeks. After this period they will receive TOCT as treatment plus a home-exercise maintenance program for 3 months.
1574672|NCT02421731|Device|Robot-assisted gait training|Patients will receive 12 training sessions, lasting for an hour with 30 minutes of real walking time, over 4 weeks (3 sessions/week) of RAGT. Subjects will wear a harness attached to a system to provide body weight support and they will walk on a treadmill with the help of a robotic-driven gait orthosis. The legs are guided according to a physiological gait pattern. The torque of the knee and hip drives can be adjusted from 100% to 0% for one or both legs. The speed of the treadmill can be adjusted from 0 km/h to approximately 3 km/h and body weight support from 0% to 100%. During the first session we will set these parameters according to subject characteristics and demand level. As training will progress, adjustments in the three parameters previously described will be performed.
1574673|NCT02421731|Other|Conventional therapy|The control group will receive 12 conventional therapy sessions over 4 weeks (3 sessions/week), that will focus on gait training. Subjects will receive 1 hour of individual conventional physiotherapy for session. During the first 5-10 minutes the subjects will perform lower-limb and core stretching exercises to increase muscles flexibility; then they'll deal with lower-limb muscles strengthening exercises tailored on their baseline characteristics (10 minutes). After that, assisted over-ground walking training will be performed.
1574674|NCT02421718|Radiation|Radiotherapy|
1574675|NCT02421705|Other|Sample collection|Collection of blood, feces samples, sample of nasal mucosa and biopsies (rectum and colon descendens), questionnaires and performance of rectal sensitivity measurement (barostat), MR scan of brain and transit measurement of colon
1574676|NCT02421692|Other|Progressive Rehabilitation|Progressive, high-intensity strengthening and functional interventions to facilitate independence with functional activities.
1574678|NCT02421666|Behavioral|PNMI|eligible patients will receive patient navigator led plus mobile phone text messaging intervention(PNMI) or standard care. Bilingually trained patient navigators will be recruited from our existing patient navigator training network and receive intensive training on HBV prevention, diagnosis and treatment management. The PN-led plus mobile phone text messaging intervention will offer three education sessions and serve as a liaison with respective clinics. The phone-based, text messaging will be designed by and for HBV patients who will craft appropriate reminders for follow up appointments or treatment, educational and motivational messages
1574679|NCT02421653|Dietary Supplement|MNP90|90 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
1574680|NCT02421653|Dietary Supplement|MNP45|45 µg iodine-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
1574681|NCT02421653|Dietary Supplement|IODISED OIL|200 mg iodine oil capsule; oral route; once at study start
1574682|NCT02421653|Dietary Supplement|INERT OIL|Non-iodised evening primrose oil capsule; oral route; once at study start
1574683|NCT02421653|Dietary Supplement|INERT MNP|Un-fortified powder sachet (maltodextrin, no micronutrients); oral route; 1 daily
1574684|NCT02421653|Dietary Supplement|NON-IODISED MNP|Un-fortified micronutrient powder sachet (14 micronutrients); oral route; 1 daily
1574685|NCT02421640|Drug|Cisplatin+TIL|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy,then TIL infusing following concurrent chemoradiotherapy
1574686|NCT02421640|Drug|Cisplatin|cisplatin 100mg/m2(every three weeks),D1,D22,D43 of radiotherapy only
1574687|NCT02421627|Device|moxibustion|Mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin, keeping the spot warm and making it reddened, but not burnt.The temperature maintained at 43 ± 1℃。
1574688|NCT02421627|Device|Placebo moxibustion|Placebo mild-warm moxibustion is a type of moxa stick moxibustion that is performed by holding an ignited moxa stick a certain distance above the patient's skin (farther than the real moxibustion), keeping the temperature maintained at 37 ± 1℃。
1574689|NCT02421614|Other|high-protein low-carbohydrate diet with high olive oil|
1574690|NCT02421614|Other|high-protein low-carbohydrate diet with high sunflower oil|
1574691|NCT02421601|Drug|Condoliase|1.25 U, intradiscal injection, one time
1574692|NCT02421588|Drug|Lurbinectedin (PM01183)|
1574693|NCT02421588|Drug|Pegylated liposomal doxorubicin (PLD)|
1574694|NCT02421588|Drug|Topotecan|
1574695|NCT02421575|Drug|Hydroxychloroquine|Given PO
1574696|NCT02421575|Other|Laboratory Biomarker Analysis|Correlative studies
1574697|NCT02421562|Procedure|training in hypnoanalgesia|training nurses in hypnoanalgesia techniques to perform painful procedures in children followed in the outpatient hematology oncology clinic
1574698|NCT02421549|Device|Unpaired remote monitoring transmitter|
1574699|NCT02421536|Other|Vibrogent Smartphone Application|
1574700|NCT02421523|Procedure|Aim 2 Exercise group|The experimental group will participate in an isometric exercise strengthening intervention with a frequency of ~three times/week for 12 weeks. Training will include using a custom-built exercise set-up and a live monitoring system for all of the subjects who participate in the experimental group. Progression of the exercise program will only occur after safety assessments at weeks 3, 6, and 9. The safety assessments to occur at baseline, 1 week, 6 weeks, and 12 weeks include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. The safety assessments to occur at 3 weeks and 9 weeks include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
1574701|NCT02421523|Procedure|Aim 1 Exercise Dosing|The maximal voluntary contraction (MVC) will be determined for each subject. The first four subjects will exercise at an intensity of ~30% of the subject's MVC. Subjects will be asked to perform ~4 sets of 6 reps of knee extension and knee flexion contractions. 48hs after the exercise is completed a safety assessment will be performed for muscle damage. If none has occurred, four additional subjects will perform the exercise at the next level of intensity (~50% MVC). Similarly, if no damage has occurred at ~50% MVC, four more subjects exercise at ~70% MVC. All safety measures will be performed 48hrs after the exercise has been completed at each of the levels. These safety assessments include T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels.
1574702|NCT02421523|Procedure|Aim 2 Control group|This group will receive safety assessments at baseline, 1 week, 6 weeks, and 12 weeks including T2 MRI, Spectroscopic relaxometry, pain rating scale, and CK levels. They will also receive safety assessments at 3 weeks and 9 weeks that will include the pain rating scale and CK levels. Participants in this group may also be tested for strength assessments (of the knee flexors and extensors) and time to climb 4 stairs.
1574706|NCT02421484|Biological|Allogeneic mesenchymal stromal cells|The allogeneic mesenchymal stromal cells will be administered intravenously.
1574707|NCT02421471|Drug|Ingenol mebutate 0.015 percent or 0.05 percent gel|Topical treatment with ingenol mebutate gel 0.015 percent or 0.05 percent gel of skin areas affected by AK
1574708|NCT02421458|Radiation|6 x 6 Gy|radiation in 6 fraction of 6 Gy, twice a week during 3 weeks
1574709|NCT02421458|Radiation|16 x 3.125 Gy|radiation in 16 fraction of 3.125 Gy, 4 times a week during 4 weeks
1574710|NCT02421432|Procedure|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
1574714|NCT02421406|Behavioral|Internet Behavioral Intervention|A series of 12 multi-media lessons will be accessible to participants on their own computers. The lessons (each of which takes about 15 minutes to complete) are based on the Diabetes Prevention Program (DPP) and Look AHEAD. Participants will be taught to record their weight, the calories and the fat grams in each food item, and their physical activity (in minutes) on a daily basis. At the end of the week, they will submit their self-monitored information to the study website and receive an automated feedback message about their progress to date. The lessons will also present key behavior change strategies such as cognitive restructuring, problem solving and relapse prevention.
1574715|NCT02421406|Behavioral|Internet Education Intervention|A series of 12 lessons will be accessible to participants on their own computers. Participants will be given information about normal, overweight and obese categories of body mass index, and provided information on the health problems that are associated with being overweight and the benefits of weight loss for treating and preventing such problems. General information about healthy eating will be provided. Participants will be educated about the benefits of increasing their physical activity, and strategies for increasing activity safely.
1574716|NCT02421393|Other|supervised exercise training|"Two weekly sessions of 75 min each, supervised by an exercise specialist in a dedicated gym facility. Each session will include: 5 min of warm up; 20 min of aerobic training using treadmill; 15 min of resistance training of muscle groups of skeletal sites of fragility fractures; 15 min of weight bearing exercises using weighted vests; 8 min of core stability training; 8 min of balance training; and 4 min of flexibility training. Weighted vest worn also during aerobic training and any occupational, home and leisure-time physical activity."
1574719|NCT02421354|Drug|Nivolumab|3 mg/kg given by vein approximately every 2 weeks for 8 doses followed by a maintenance regimen of one dose every 12 weeks.
1574720|NCT02421354|Behavioral|Questionnaire|Questionnaire completed about participant's quality of life completed at baseline, Day 1, 7, 14 of Cycle 1, Days 1 and 14 of Cycles 2 - 5, and Day 1 of every third cycle after that. It should take about 10 minutes to complete each time.
1574721|NCT02421354|Behavioral|Phone Call|Study staff to call participant to ask about side effects about 30, 60, and 100 days after last dose of the study drug. This call should last about 10 minutes.
1574722|NCT02421341|Drug|Fentanyl|During study visits 2 and 3 you will receive an intrathecal (fluid filled space surrounding the spinal cord) injection of either fentanyl or placebo (saline). Fentanyl is an opiate (narcotic) drug and a common medication, however the way fentanyl is being used in this study is considered investigational.
1574723|NCT02421341|Procedure|Catheters|A catheter (small plastic tube placed in a blood vessel) will be placed in an artery in your arm and a second catheter will be placed in a vein in your leg. Local anesthetic will be used to minimize discomfort. These catheters will allow us to measure blood pressure, leg blood flow and draw blood.
1574724|NCT02421341|Other|Exercise|You will be asked to exercise, ride a stationary bike, at maximal exertion.
1574725|NCT02421341|Radiation|DEXA|During study visit one you will have a DEXA scan. This procedure requires you to lie on a table while a small x-ray tube passes under your body.
1574726|NCT02421341|Other|Pulmonary Function Tests|During study visit one you will be asked to perform 5 different breathing tests to help us better understand your lung function.
1574727|NCT02421341|Other|Blood Draw|You will have approximately 350 mls (1.25 cups) of blood drawn during the duration of this study.
1574728|NCT02421341|Other|Chemosensitivity Test|Using a bag you breath in and out your own air.
1574729|NCT02421341|Drug|Placebo|
1574730|NCT02421328|Device|CPAP first (Fisher & Paykel Healthcare)|Infants will start on nasal CPAP for 60 minutes and then switched to HHHFNC for anther 60 minutes. Ultrasonographic assessment of diaphragmatic dimensions and excursion will be done at the end of each 60 minute epochs.
1574760|NCT02421120|Drug|Ceftolozane/Tazobactam|1 hour intravenous infusion
1574761|NCT02421107|Other|Glysure CGM|
1574732|NCT02421315|Behavioral|Exposure & Response Prevention (EX/RP) and when indicated medication treatment|Cognitive Behavioral Therapy (CBT) for OCD involves gradually exposing patients to anxiety provoking stimuli while having patients refrain from engaging in compulsive rituals and/or avoidance behaviors. There are three major components of CBT treatment for OCD, specifically: (1) exposure to anxiety provoking stimuli, (2) response prevention, and (3) cognitive techniques intended to decrease anxiety during the exposure and response prevention processes.
1574733|NCT02421302|Dietary Supplement|RUTF|This is ready-to-use-therapeutic-food
1574737|NCT02421276|Other|Phlebotomy|White blood cell analysis: Subtypes of white blood cells will be counted by flow cytometry
1574738|NCT02421263|Drug|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
1574739|NCT02421250|Device|Radical-7 Noninvasive Hgb Monitor|
1574740|NCT02421237|Behavioral|Narrative Enhancement and Cognitive Therapy|
1574741|NCT02421237|Behavioral|Supportive Group Therapy|
1574742|NCT02421224|Behavioral|Usual Care|Participants will receive in-person group counseling from a trained smoking cessation counselor. Participants will learn about reasons to quit smoking, strategies for quitting smoking, and additional resources available to support the quit attempt. Participants will also complete a quit plan.
1574743|NCT02421224|Behavioral|Deposits|Participants will have to deposit a certain amount of their own money at enrollment. Participants will be able to make additional voluntary deposits above the minimum amount during the intervention period. The participant will be refunded all deposits if he quits smoking at 3 months, as verified by a urine cotinine test. The participant will forfeit all deposits if he continues to smoke at 3 months, as verified by a urine cotinine test.
1574744|NCT02421224|Behavioral|Small Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test.
1574745|NCT02421224|Behavioral|Large Individual Bonus|Each participant will receive a monetary bonus from the study investigators if he or she quit smoking, as verified by a urine cotinine test. The bonus is twice the value of that in the Small Individual Bonus group.
1574746|NCT02421224|Behavioral|Teammate|Each participant will be randomly assigned one teammate to provide social support during the quit attempt. Each participant will be assigned to a participating coworker who speaks the same primary language and works the same work shift as the participant.
1574747|NCT02421224|Behavioral|Team Bonus|If the participant and assigned teammate both quit smoking at 3 months, as verified by a urine cotinine test, then each will receive a monetary bonus. The team bonus is equal in value to that in the Large Individual Bonus group.
1574748|NCT02421211|Drug|Simeprevir (SMV)|Participants will receive 150 milligram (mg) of SMV (Treatment A) once daily in Panel 1 and Panel 2.
1574749|NCT02421211|Drug|Ledipasvir (LDV)|Participants will receive 90 mg of LDV once daily as FDC tablet with SOF (Treatment B) in Panel 1 and Panel 2.
1574750|NCT02421211|Drug|Sofosbuvir (SOF)|Participants will receive 400 mg of SOF alone (Treatment C) in Panel 1 and as FDC tablet with LDV (Treatment B) once daily in Panel 2.
1574753|NCT02421172|Biological|CJM112|Fully human IgG1 monoclonal antibody
1574754|NCT02421159|Behavioral|Seek and Test Phase|The primary endpoint for this phase is the proportion of newly identified HIV infections of the RDS-ASTN intervention. Components for eligible and willing participants are a computerized baseline interview, counseling session, blood draw for HIV testing, HIV pre-test counseling, use of blood samples for clinical lab tests if found to be HIV infected, semi-structured interviews (if selected), the opportunity to recruit peers for the study, and the post-test counseling session.
1574755|NCT02421159|Behavioral|Treat and Retain Phase|The primary endpoints for this phase are: proportion linked to care within three months and time to the HIV care appointment. Participants with HIV infection who are interested in participating will be enrolled in this phase and navigated to HIV primary care over three months. Components are the locator form, patient navigation and support contacts, medical report form, follow-up contacts to update locator information, semi-structured interviews, follow-up interview, and blood draw for clinical lab testing.
1574756|NCT02421146|Device|Transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
1574757|NCT02421146|Device|Transcranial direct current stimulation - Sham|Transcranial direct current stimulation (tDCS) is a form of neurostimulation which uses constant, low current (at 2 mA) delivered to the brain area of interest(anode over the left DLPFC while cathode over the right suborbital region) via electrodes on the scalp.
1574758|NCT02421133|Other|Transitional care program.|"During the patient's stay in hospital, the transition nurse creates a transitional care file including information about the patient (inpatient medical and nurse care plan, medications), the discharge plan, and the contact information of the relevant primary care providers. She notifies the patient's primary care physician of the date of the discharge to home, of the potential medical problems and of the discharge care plan; a primary care physician visit is planned the month following the discharge.
The day of the hospital discharge: meeting with the patient to review the follow-up recommendations. The transition nurse verifies that the medications are prescribed accordingly with the discharge plan, that the patient and his caregiver understand the prescription and are informed with the planned appointments and the biological monitoring.
During 4 weeks after the hospital discharge: follow-up by the transition nurse once a week, alternately by telephone and home visit."
1574765|NCT02421081|Procedure|vessel microsurgery|That is a surgery ro repair artery laceration.
1574766|NCT02421081|Procedure|tendon repair|That is a surgery ro repair tendon cut.
1574767|NCT02421081|Procedure|nerve microsurgery|That is a surgery ro repair median/ ulnar/ radial nerve cut.
1574768|NCT02421055|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
1574769|NCT02421055|Procedure|Laparoscopic Sleeve Gastrectomy|
1574770|NCT02421042|Drug|Lenvatinib|5- or 10-mg single oral dose of E7080, depending on their hepatic status [Mild (10 mg), Moderate (10 mg), and Severe Hepatic Impairment (5 mg) and Normal Hepatic Function (10 mg)].
1574771|NCT02421029|Drug|edetate calcium disodium|All subjects will receive a 250 mL 5% dextrose intravenous infusion over 1 hour that contains 1 gr of edetate calcium disodium
1574772|NCT02421016|Device|SYNERGY EES|Bioresorbable polymer everolimus-eluting stent
1574773|NCT02421016|Device|ABSORB [BVS]|Everolimus-eluting bioresorbable backbone stent
1574774|NCT02421003|Procedure|heart surgery|
1574775|NCT02420990|Behavioral|Medication Integration Protocol (MIP)|
1574776|NCT02420990|Behavioral|Changing Academic Support in the Home for Adolescents with ADHD (CASH-AA)|
1574777|NCT02420977|Drug|Pelvic DCFPyL PET-MRI fusion or PET/MRI|"Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months of ADT
Pelvic DCFPyL PET-MRI fusion or PET/MRI compared before and after 2-3 months"
1574778|NCT02420964|Other|video instruction|Patient Directed Video Instruction
1574779|NCT02420964|Other|Nurse instruction|Nurse directed instruction
1574780|NCT02420951|Drug|Bupivacaine|Injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
1574781|NCT02420951|Other|No Intervention|No injection of local anesthetic immediately prior to catheter removal, 24 hours postop.
1574782|NCT02420938|Drug|Rituximab|375 mg/m2 by vein weekly for the first 4 weeks (Days 1, 8, 15, 22) then the day prior to each subsequent dose of Urelumab for the 12-week course.
1574783|NCT02420938|Drug|Urelumab|8 mg by vein given every 3 weeks for 4 doses, starting Day 2 of the 12-week course.
1574784|NCT02420925|Procedure|Celiac Plexus Block|Patients will undergo celiac plexus block via upper endoscopy with endoscopic ultrasound guidance. Injections will be performed using 0.75% bupivicaine and 40mg/ml of triamcinolone, ideally 1ml each directly into the celiac ganglia. If no ganglia is identifiable, then the injection will be performed into the celiac space, located at the take off of the celiac artery from the aorta.
1574785|NCT02420912|Drug|Nivolumab|3 mg/kg by vein on Days 1 and 15 of Cycles 1-24 for the first cycle to assess for monotherapy toxicities of Nivolumab.
1574786|NCT02420912|Drug|Ibrutinib|"Group 1: Ibrutinib 420 mg given by mouth daily at the start of Course 2 on Days 1 and 15 of Cycles 1-24. Cycle of therapy is 28 days.
Group 2: Ibrutinib given by mouth daily, at same dose currently receiving, on Days 1 and 15 of Cycles 1-24. Cycle of therapy is 28 days."
1574787|NCT02420899|Drug|rosuvastatin|10mg/d or 20mg/d,po
1574788|NCT02420886|Other|Adding LIF, HB-EGF and GM-CSF to Lifeglobal human IVF culture media|
1574789|NCT02420873|Drug|Lorvotuzumab Mertansine (IMGN901)|100 mg/m2 by vein on Day 1 and 8 of a 21-day cycle.
1574799|NCT02420834|Other|Hypromellose 0.15%|Tear supplement to be taken as required to relieve symptoms
1574800|NCT02420834|Other|Hypromellose 0.4%|Tear supplement to be taken as required to relieve symptoms
1574801|NCT02420834|Other|Carboxymethylcellulose|Tear supplement to be taken as required to relieve symptoms
1574802|NCT02420834|Other|Liposomal Spray|Tear supplement o be taken as required to relieve symptoms
1574803|NCT02420821|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab at a fixed dose of 1200 milligrams (mg) via intravenous (IV) infusion on Days 1 and 22 of each 42-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
1574804|NCT02420821|Drug|Bevacizumab|Bevacizumab as 15 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 22 of each 42-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
1574805|NCT02420821|Drug|Sunitinib|Sunitinib as 50 mg orally, once daily on Days 1 through 28 of each 42-day cycle until loss of clinical benefit, unacceptable toxicity, symptomatic deterioration attributed to disease progression, or death.
1574806|NCT02420795|Drug|ONC201|"Phase I starting dose of ONC201: 125 mg taken by mouth taken Day 1 of every 21-day cycle (Arm A, closed to new enrollment February 2016) or once weekly (Arm B).
Phase II starting dose: Maximum tolerated (MTD) dose from Phase I."
1574807|NCT02420795|Behavioral|Phone Call|After end-of-dosing visit, study staff will call participant every 3 months for 1 year.
1574808|NCT02420782|Drug|ASP6282|oral
1574809|NCT02420782|Drug|Itraconazole|oral
1574810|NCT02420782|Drug|Pilocarpine|oral
1574811|NCT02420782|Drug|Placebo|oral
1574812|NCT02420782|Drug|Midazolam|oral
1574814|NCT02420743|Procedure|serum ferritin|serum ferritin will be measured serially at 26, 30 and 34 weeks gestation.
1574815|NCT02420743|Procedure|MCA Doppler|MCA peak systolic value will be assessed at 26, 30 and 34 weeks gestation.
1574816|NCT02420730|Drug|AGN-232411|AGN-232411 topical ophthalmic solution
1574817|NCT02420730|Drug|AGN-232411 Vehicle|Vehicle for AGN-232411 topical ophthalmic solution.
1574818|NCT02420717|Drug|Ruxolitinib|Starting dose of Ruxolitinib: 15 mg by mouth twice daily.
1574819|NCT02420717|Drug|Dasatinib|Starting dose of Dasatinib: 100 mg by mouth once daily.
1574820|NCT02420717|Drug|Rituximab|375 mg/m2 days 1 and 11 for cycles 1 and 3, and days 1 and 8 for cycles 2 and 4.
1574821|NCT02420717|Drug|G-CSF|5 mcg/kg/day within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher for Hyper-CVAD chemotherapy all courses.
1574822|NCT02420717|Drug|Pegfilgrastim|6 mg subcutaneously for one dose approximately 24 hours after completion of the chemotherapy may be substituted for G-CSF at the discretion of the treating physician for Hyper-CVAD chemotherapy all courses.
1574823|NCT02420717|Drug|Methotrexate|"12 mg (6 mg via Ommaya reservoir) day 2 of each of the first 4 cycles of Hyper-CVAD chemotherapy.
200 mg/m2 by vein over 2 hours followed by 800 mg/m2 by vein over 22 hours day 1 of Hyper-CVAD chemotherapy Courses 2, 4, 6, 8.
20 mg/m2 by mouth weekly for maintenance phase chemotherapy (POMP maintenance). Treatment cycle is 28 days."
1574824|NCT02420717|Drug|Cytarabine|"100 mg day 7 of each of the first 4 cycles of Hyper-CVAD chemotherapy during cycles 1 and 3 of Hyper-CVAD Courses 1, 3, 5, 7.
3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Hyper-CVAD Courses 2, 4, 6, 8."
1574825|NCT02420717|Drug|Cyclophosphamide|300 mg/m2 by vein over 3 hours every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for Hyper-CVAD (Courses 1, 3, 5, 7).
1574826|NCT02420717|Drug|Mesna|600 mg/m2/d by vein continuous infusion daily for 24 hours days 1 - 3 for Hyper-CVAD (Courses 1, 3, 5, 7).
1574827|NCT02420717|Drug|Doxorubicin|50 mg/m2 by vein over 24 hours on day 4, after last dose of Cyclophosphamide given for Hyper-CVAD (Courses 1, 3, 5, 7).
1574828|NCT02420717|Drug|Vincristine|"2 mg by vein on day 4 and day 11 for Hyper-CVAD (Courses 1, 3, 5, 7).
2 mg by vein approximately every 28 days for maintenance phase chemotherapy (POMP maintenance)."
1574829|NCT02420717|Drug|Dexamethasone|40 mg by vein or mouth daily days 1 - 4 and days 11 - 14 for Hyper-CVAD (Courses 1, 3, 5, 7).
1574830|NCT02420717|Drug|Solumedrol|50 mg by vein over 2 hours approximately every 12 hours for 6 doses days 1 - 3 for Hyper-CVAD chemotherapy Courses 2, 4, 6, 8.
1574831|NCT02420717|Drug|6-mercaptopurine|50 mg tablets by mouth 3 times daily for maintenance phase chemotherapy (POMP maintenance). Treatment cycle is 28 days.
1574832|NCT02420717|Drug|Prednisone|200 mg by mouth daily days 1 to 5 approximately every 28 days, starting with vincristine (if given) for maintenance phase chemotherapy (POMP maintenance).
1574833|NCT02420717|Drug|Leucovorin|50 mg by vein followed by 15 mg by vein every 6 hours for 8 doses (or until MTX cleared) beginning 12 hours post MTX completion for courses 2, 4, 6, 8.
1574834|NCT02420704|Procedure|Embryo transfer|For fresh cycles, embryos were transferred 3-5 days after oocyte retrieval; For frozen thawed cycles, embryos were transferred 3-5 days after starting to use progesterone based on the stage of cryopreservation.
1574835|NCT02420691|Drug|LEE011|600 mg by mouth daily on Days 1 - 21 of a 28 day cycle.
1574836|NCT02420665|Drug|Proflavine|0.01% Proflavine applied topically to the cervix after colposcopy and HRME cervical images obtained.
1574837|NCT02420665|Device|HRME Imaging|HRME images obtained from one visually normal cervical site, and from up to 3 visually abnormal lesions based on exam and/or colposcopic findings.
1574838|NCT02420665|Behavioral|Phone Call|Study staff follow up with participant by phone one month after procedure.
1574839|NCT02420665|Procedure|Colposcopy|Colposcopy performed after visual inspection of cervix.
1574840|NCT02420665|Drug|Acetic Acid|3 - 5% added to cervix before visual inspection.
1574841|NCT02420652|Drug|Aspirin|Given PO
1574842|NCT02420652|Other|Laboratory Biomarker Analysis|Correlative studies
1574843|NCT02420652|Drug|Metformin Hydrochloride|Given PO
1574844|NCT02420652|Other|Placebo|Given metformin hydrochloride placebo PO
1574845|NCT02420652|Other|Placebo|Given aspirin placebo PO
1574846|NCT02420639|Device|Esophageal Cooling Device (ECD), manufactured by Advanced Cooling Therapy, Inc.|Use of the Esophageal Cooling Device for control of patient temperature.
1574847|NCT02420613|Drug|Vorinostat|"Newly Diagnosed DIPG Group:
Dose Escalation Phase Starting Dose of Vorinostat: 230 mg /m2 by mouth daily. During radiation, participants receive Vorinostat daily from Mon-Friday along with radiation. After radiation therapy, participant rests for 4 weeks in which no radiation therapy or study drug received .
Maintenance Phase Starting Dose for Vorinostat: 230 mg/m2/dose by mouth once daily in a 28 day cycle.
Progressive DIPG Group:
Dose Escalation Phase Starting Dose of Vorinostat: at 230 mg/m2 by mouth from Day 1 to Day 8.
Maintenance Phase Starting Dose for Vorinostat: 230 mg/m2/dose by mouth once daily of a 28 day cycle."
1574848|NCT02420613|Radiation|Radiation Therapy|Radiation therapy (RT) administered in single daily fractions of 1.8 Gy for 30 treatments over 6-7 weeks. Total dose of radiation 54 Gy.
1574849|NCT02420613|Drug|Temsirolimus|"Newly Diagnosed DIPG Group:
Maintenance Phase Starting Dose for Temsirolimus: 25 mg/m2 by vein on Day 1 and Day 8 of a 28 day cycle.
Progressive DIPG Group:
Dose Escalation Phase Starting Dose of Temsirolimus: 25mg/m2 by vein on Day 1 and Day 8.
Maintenance Phase Starting Dose for Temsirolimus: 25 mg/m2 by vein on Day 1 and Day 8 of a 28 day cycle."
1574850|NCT02420587|Drug|AMG 208|Dose of AMG 208 is 400 mg by mouth daily given in 6 weeks cycles.
1574851|NCT02420587|Behavioral|Questionnaire|Questionnaire completion about pain at baseline, Day 22 of Cycle 1, Day 1 of Cycle 2, Day 22 of Cycle 2, every 6 weeks, and at end of study visit.
1574852|NCT02420574|Drug|albendazole BENDEX|randomized clinical trial with 2 parallel arms
1574853|NCT02420574|Drug|albendazole OVIS|
1574854|NCT02420561|Behavioral|Motivational Interviewing|"One in-person motivational interviewing session intervention that lasts for 45-minutes
Additional two 15-minute telephone booster sessions post in-person 45 minute sessions"
1574855|NCT02420561|Behavioral|Control (brochure)|Participants received a brochure on alcohol and drug use risks.
1574856|NCT02420548|Behavioral|Parent Ed. and Youth Skills Coaching|The experimental intervention will have two components: (1) a caregiver parenting group, including all caregiver types (biological, foster, kinship), that meets weekly for 90-minutes for four months, focused on increasing parenting skills, and (2) a Life Coach component where trained and supported skills coaches meet individually with youth weekly for 60 minutes over the same four-month period to build the girls' social skills and peer/partner relationships skills.
1574857|NCT02420548|Behavioral|Services as Usual|Services as usual as provided by community service organizations from which the sample was drawn.
1574858|NCT02420535|Behavioral|Immediately Receive Tool|
1574859|NCT02420535|Behavioral|One Month Delay|
1574860|NCT02420522|Device|Repetitive Transcranial Magnetic Stimulation|A non-invasive method of brain stimulation.
1574861|NCT02420522|Device|Sham Transcranial Magnetic Stimulation|A device designed to look, sound, and feel like a real magnetic stimulation coil without actually stimulating the brain.
1574862|NCT02420509|Drug|systemic chemotherapy|twelve months of 5-FU or capecitabine with bevacizumab starting 4-8 weeks after surgery
1574863|NCT02420496|Drug|Enteral fish oil|
1574864|NCT02420496|Drug|Ursodeoxycholic Acid|
1574865|NCT02420496|Drug|Placebo|
1574866|NCT02420483|Other|Cardiopulmonary resuscitation chest compressions|
1574867|NCT02420457|Procedure|Epidural injection|After evaluation by their pain physician, if the clinician offers an epidural injection for their back pain, they will be followed for this study before and after the injection.
1574868|NCT02420457|Drug|transforaminal epidural steroid injection as determined by routine care provider|Betamethasone Triamcinolone Dexamethasone Methylprednisolone Lidocaine Bupivacaine Ropivacaine Normal saline
1574869|NCT02420444|Biological|BCG SSI|The dose volume administered for BCG was 0.1 mL, and the mode of administration was ID injection to the deltoid area.
1574870|NCT02420444|Biological|Placebo|This is the identical buffer solution in which H4:IC31 was formulated. The dose volume administered for Placebo was 0.5mL, and the mode of administration was an IM injection.
1574871|NCT02420444|Biological|AERAS-404|AERAS-404 vaccine was reconstituted on site by adding 0.2 mL H4 antigen solution to 0.8 mL IC31 adjuvant solution. The dose volume administered for AERAS-404 was 0.5mL, and the mode of administration was an IM injection.
1574872|NCT02420431|Behavioral|Metacognitive Therapy|Metacognitive therapy (MCT) helps clients to identify episodes of worry and rumination in response to negative thoughts and bring these responses under control. This process is facilitated by exercises that enhance the flexibility of attention control, challenge unhelpful beliefs about thinking and enable new relationships with thoughts
1574873|NCT02420431|Behavioral|Cardiac Rehabilitation (treatment as usual)|Stress management, relaxation training, exercise and dietary advice.
1574874|NCT02420418|Dietary Supplement|N-acetyl-cysteine (NAC)|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in outpatient smokiing cessation. The dosage will be fixed 1800 mg/day of NAC administered in capsules taken 2 before breakfast and 2 before dinner is equal doses.
1574875|NCT02420418|Other|Placebo|Patients will be randomly allocated into two groups, double-blind, to receive NAC or placebo for a period of 12 weeks. All groups remain receiving maintenance treatment in smoking cessation service
1574876|NCT02420405|Procedure|Routine gene testing|For those diagnosed with nonsquamous NSCLC, routine gene testing including EGFR, ROS1 and ALK will be performed.
1574877|NCT02420405|Procedure|Next-generation sequencing|For those diagnosed with nonsquamous NSCLC and have done routine gene testing, NGS will be perform on those that have adequate rest tissues.
1574878|NCT02420392|Drug|Dapagliflozin|8 weeks treatment of dapagliflozin added to the type 2 diabetes patients with unsufficiently controlled with metformin or sulfonylurea
1574879|NCT02420379|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks.
1574880|NCT02420353|Drug|Somatropin|GH dose will be calculated by nomogram estimation of body surface area, and will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin GH treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take GH, but otherwise patients will take GH every day over this 6 week period.
1574881|NCT02420353|Drug|Placebo|A placebo diluent that will be administered via subcutaneous injection in the abdominal area twice per day (BID) at a dose of the equivalent concentration of 0.5mg GH per body surface area (BSA) in m2 (0.5mg/m2). Patients will begin treatment one week prior to surgery and will continue through 5 weeks after surgery. On the day of surgery, patients will not take medication, but otherwise patients will take medication every day over this 6 week period.
1574882|NCT02420340|Behavioral|"HOPES Program (Helping Older People Experience Success)"|Weekly group skills training classes aimed at improving skills and knowledge in areas related to successful living in the community including: independent living, healthy living, social skills, leisure skills, and management of health care.
1574883|NCT02420327|Drug|Nicotine|nicotine patch (7 mg/24 hrs)
1574884|NCT02420327|Drug|Galantamine|galantamine capsule (4 mg)
1574885|NCT02420327|Drug|Placebo|Placebo Patch
1574886|NCT02420327|Drug|Placebo|Placebo capsule
1574887|NCT02420314|Drug|Paclitaxel|"Administered intravenously (IV)
Prescribed at 200 mg/m2 (standard dose)
Given once every 21 days (i.e., one cycle)
Up to 4 cycles are administered depending on disease response"
1574888|NCT02420314|Drug|Carboplatin|"Administered intravenously (IV)
Prescribed at AUC = 6 using the Cockcroft-Gault formula (standard dose)
Given once every 21 days (i.e., one cycle)
Up to 4 cycles are administered depending on disease response"
1574889|NCT02420314|Drug|Ascorbic Acid|"Administered intravenously (IV)
75g per infusion
Two infusions per week
1 cycle is 3 weeks
given up to 4 cycles
may be given while chemotherapy if delayed due to low counts"
1574890|NCT02420301|Other|Tuina exercises|
1574891|NCT02420301|Other|Placebo Tuina exercises|
1574932|NCT02420015|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up
1575080|NCT02419235|Other|20% ethanol|Unmedicated 20% ethanol.
1574892|NCT02420288|Behavioral|Exercise Group|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (before week 16 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
1574893|NCT02420275|Other|placebo|THIS GROUP WILL RECEIVE NO BRIGHT LIGHT
1574894|NCT02420275|Device|"Luminette,Lucimed Belgium"|THIS GROUP WILL RECEIVE BLEU LIGHT ENRICHIDED IN WITHE BRIGHT LIGHT
1574898|NCT02420249|Behavioral|Qigong training|Participants will learn the 18 Forms of Tai Chi Internal Qigong. Detailed movement and breathing descriptions of the Qigong training protocol can been found in Mak YK. 18 Forms Tai Chi Qigong [in Chinese]. 7th ed. Hong Kong: Wan Li Book Co.; 2012.
1574899|NCT02420236|Behavioral|High-intensity resistance training|
1574900|NCT02420236|Behavioral|General physical activity|
1574901|NCT02420236|Behavioral|Multidisciplinary rehabilitation program|
1574902|NCT02420223|Drug|Propranolol|
1574903|NCT02420210|Drug|Bendamustine Hydrochloride|Given IV
1574904|NCT02420210|Biological|Obinutuzumab|Given IV
1574905|NCT02420210|Drug|Dexamethasone|Given PO
1574906|NCT02420210|Other|Quality-of-Life Assessment|Ancillary studies
1574907|NCT02420210|Other|Laboratory Biomarker Analysis|Correlative studies
1574908|NCT02420197|Behavioral|High-intensity resistance training|
1574909|NCT02420197|Behavioral|General physical activity|
1574910|NCT02420197|Behavioral|Multidisciplinary rehabilitation program|
1574911|NCT02420184|Device|CPAP|Participants randomized into the experimental CPAP therapy arm will receive CPAP in addition to their standard medical therapy for CKD. CPAP will be worn whenever the participant sleeps for the duration of the study.
1574912|NCT02420184|Other|No CPAP|Participants randomized into the placebo comparator no CPAP arm will receive standard medical therapy for CKD.
1574913|NCT02420171|Other|Adding insulin to In Vitro culture media|We will add insulin for in vitro culture of human embryos
1574914|NCT02420158|Device|Trans-cutaneous vagal nerve electrical stimulation|
1574915|NCT02420145|Behavioral|Yoga|12 weeks of yoga, twice weekly for 90 minutes plus a whole-day workshop
1574916|NCT02420132|Other|Ranibizumab|Ranibizumab administered as part of standard-of-care
1574917|NCT02420119|Other|non interventional|
1574919|NCT02420093|Device|"Pelvis Support Assembly"|"Use of a portable and adjustable Pelvis Support Assembly in the seat of the subject's work or home desk chairs as tolerated during the 3 weeks intervention interval. This pelvic support device supports the user from the pelvis and aids in maintaining a more anatomically neutral lumbar and pelvic position in sitting. This device is not officially named at this time but is as represented in US Patent number is US 8,857,906 B2."
1574920|NCT02420080|Drug|Brincidofovir|Rates of adenovirus progression and mortality in subjects with adenovirus infection and/or disease. Sites participating in the CMX001-304 study will be asked to participate in the CMX001-305 study retrospective data collection study.
1574921|NCT02420054|Behavioral|Intermittent fasting|Eating every other day for at total of 20 days.
1574922|NCT02420054|Other|Time control|Time control period with no change in eating habits.
1574923|NCT02420041|Procedure|Active comparator: Fluoroscopic Guided SIJ injection|"Needle entry point is in the lower one-third of the SIJ
Sterile preparation (with chlorhexidine) and draping and 3 mL of 1% lidocaine injected subcutaneously at site of needle entry
Under fluoroscopy guidance, Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a coaxial fashion into the SIJ
1 mL of contrast (iohexol 300 mg/mL) is injected to outline the SIJ and to ensure no vascular uptake
Injection of 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine
Patient observed in recovery bay for 20 minutes and then discharged home"
1574924|NCT02420041|Procedure|Ultrasound Guided Sacroiliac Joint Injection|"Sterile preparation (with chlorhexidine) and drape
Using ultrasound guidance (SonoSite S-nerve) with a low frequency (2-5 Hz) curvilinear transducer in a sterile cover, the transducer is placed in a transverse plane over the SIJ and needle entry point is chosen at the medial end of the ultrasound transducer
3 mL of 1% lidocaine is injected subcutaneously at site of needle entry
Under ultrasound guidance, a Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle is inserted in a medial to lateral direction and guided into the SIJ. (0.5-2 mL of normal saline may be injected during needle insertion to locate tip of needle and to ensure solution does not spill out onto sacrum).
After using the Doppler function to identify any surrounding vessels (to avoid intravascular injection), 20 mg of triamcinolone diluted in 4 mL of 1% lidocaine is injected.
Patient observed in recovery bay for 20 minutes and then discharged home"
1574925|NCT02420041|Device|"Havel's Inc. EchoStim (facet tip) 21 Gauge 4 needle"|
1574926|NCT02420041|Device|SonoSite S-nerve|
1574927|NCT02420041|Device|iohexol|
1574928|NCT02420041|Drug|triamcinolone/lidocaine|
1574929|NCT02420028|Device|Insertion of OptiVein IV catheter|Placement of OptiVein IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
1574930|NCT02420028|Device|Insertion of Vasofix Certo IV catheter|Placement of Vasofix Certo IV catheter inside the vein allowing for fluid or drug delivery or blood withdrawal.
1574931|NCT02420015|Drug|Nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
1574969|NCT02419807|Radiation|Technetium Tc-99m Sulfur Colloid|Given via injection
1575117|NCT02419001|Drug|Period 2 - Treatment Sequence AC|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 150 mg
1574933|NCT02420015|Behavioral|cognitive-behavioral smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
1574934|NCT02420015|Behavioral|Mobile Contingency Management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
1574935|NCT02420015|Behavioral|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
1574936|NCT02420015|Behavioral|SMS text messaging|Patients assigned to this condition will receive text messages relevant to their current status in their smoking quit attempt, including messages reminding participants to take their smoking cessation medication.
1574937|NCT02420002|Drug|Use of MEOPA during suturing|Patients randomized to this arm will receive usual care, including MEOPA inhalation during local anesthetic injection and suturing of a wound.
1574938|NCT02420002|Other|Use of Hypnosis during suturing|Patients randomized to this arm will receive usual care as in the other arm, but before MEOPA inhalation is started, hypnosis will be tried. The local anesthetic injection and suturing of the wound will therefore take place under hypnosis (and MEOPA if necessary).
1574939|NCT02420002|Procedure|Stitch removal|6 to 15 days after the initial suturing, stitches will be removed according to usual procedures.
1574940|NCT02419976|Other|a breath analysis using the Aeonose|"using the Aeonose per standard acquisition protocol which spans 15 minutes of which the individuals breaths normally through a sterile disposable mouthpiece with sterile disposable air filters for 10 minutes during signal acquisition while wearing a nose plug. This will be completed in the office setting prior to their endoscopic procedure.
Following their scheduled standard of care endoscopic procedure the patient will be allowed to consume a standardized refreshment (such as juice or soda) prior to discharge from the post procedure area. These refreshments are already provided as standard care. The participant will return to the office setting and repeat the same breath analysis acquisition process that was done prior to the procedure."
1574941|NCT02419976|Device|Aeonose|
1574942|NCT02419963|Procedure|endoscopy for tissue biopsy|endoscopy to obtain tissue biopsy for analysis of biomarker status
1574943|NCT02419963|Other|Blood Sample|Blood draw to evaluate serotonin and Vit D level.
1574944|NCT02419963|Other|Stool Sample|Stool sample to evaluate microbiome fingerprint.
1574945|NCT02419950|Device|Fixation of mesh in TEP|An endoscopic operative technique were mesh for preperitonelal placement in patients with inguinal hernias can be fixated in Place or left without fixation
1574949|NCT02419911|Procedure|Laparoscopic surgery|gastrointestinal, gynecologic, urologic or bariatric laparoscopic surgery;
1574950|NCT02419911|Device|FloShield Defogging and Cleaning System|Sterile, single-use in vivo device to clean and defog the laparoscope camera lens
1574951|NCT02419911|Device|Clearify Defogging and Cleaning System|Single-use, ex vivo device to clean and defog the laparoscope camera lens
1574952|NCT02419872|Drug|Marketed antagonists|Medication for each patient is determined by the physician based on the patient's individual clinical profile and in accordance with the approved indication and label of the prescribed drug
1574953|NCT02419859|Device|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device which delivers U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
1574954|NCT02419859|Drug|Insulin, Asp(B28)-|a fast-acting analog of human insulin
1574955|NCT02419846|Other|Educational Intervention|Attend 10-20 minute PowerPoint presentation that will discuss prostate cancer facts, screening guidelines, risks, benefits, and consequences
1574956|NCT02419846|Procedure|digital rectal examination|Undergo digital rectal exam by a licensed healthcare professional. The results of this exam will be subjective as per clinician; however, will be coded as normal or abnormal. This is considered standard of care for prostate cancer screening
1574957|NCT02419846|Other|Pre-test administration|15 questions which test participants' knowledge of prostate cancer according to ACS guidelines. Questions will be multiple choices and true/false/unsure answers
1574958|NCT02419846|Other|Survey Administration|Survey will be administered at the end of the program for participants to assess their experience
1574959|NCT02419846|Other|Prostate-specific antigen measurement|PSA levels will be drawn and run as per institutional Laboratory standards. Criteria for referral and follow up will be assessed as per National Comprehensive Cancer Network (NCCN) guidelines
1574960|NCT02419846|Other|Post test administration|Post test will include the same 15 questions as on the pretest to assess for improvement in knowledge and understanding
1574961|NCT02419833|Procedure|Immediate invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery as soon as possible and/or within 2 hours of admission
1574962|NCT02419833|Procedure|Delayed invasive intervention|Invasive coronary angiography followed by either percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG) surgery during the hospitalization and/or within 2-72 hours of admission
1574963|NCT02419833|Device|Coronary artery stenting|Implantation of coronary stents
1574964|NCT02419820|Drug|APD791|Temanogrel
1574965|NCT02419820|Drug|Clopidogrel|Clopidogrel
1574966|NCT02419820|Drug|Aspirin|Aspirin
1574967|NCT02419820|Drug|Placebo for APD791|Placebo for APD791
1574968|NCT02419807|Drug|Indocyanine Green Solution|Given subdermally
1574970|NCT02419807|Procedure|Lymphoscintigraphy|This is a method used to check the lymph system for disease. A radioactive substance that flows through the lymph ducts and can be taken up by lymph nodes is injected into the body. A scanner or probe is used to follow the movement of this substance on a computer screen. Lymphoscintigraphy is used to find the sentinel lymph node (the first node to receive lymph from a tumor), which may be removed and checked for tumor cells. Lymphoscintigraphy is also used to diagnose certain diseases or conditions, such as lymphoma or lymphedema.
1574971|NCT02419807|Procedure|Axillary Lymph Node Biopsy|Undergo biopsy
1574972|NCT02419794|Procedure|endovascular treatment|endovascular treatment for acute ischemic stroke patients with large vessel occlusion
1574973|NCT02419781|Procedure|Rescue endovascular therapy|endovascular treatment using any devises for acute ischemic stroke patients with large vessel occlusion and not respond to intravenous recombinant tissue plasminogen activator (rt-PA) therapy
1574974|NCT02419781|Procedure|No endovascular therapy|
1574975|NCT02419768|Other|Physical Exercise|The physical exercise program will include 30 sessions of 60 minutes (twice a week). According to the recent guidelines, the program will include a specific work on balance, posture, gait, fitness, dual tasks and stretching.
1574976|NCT02419755|Drug|Bortezomib|Bortezomib will be given as a 1 mg/mL solution intravenous (IV) push over 3 to 5 seconds. For subcutaneous (SQ) administration, bortezomib will be mixed at 2.5 mg/ml.
1574977|NCT02419755|Drug|Vorinostat|Vorinostat should be taken orally (PO) with food.
1574978|NCT02419755|Drug|Mitoxantrone|Given by intravenous (IV) injection.
1574979|NCT02419755|Drug|Cytarabine|Given by intravenous (IV) injection.
1574980|NCT02419755|Drug|Methotrexate|Methotrexate will be given intrathecally (IT) along with hydrocortisone and cytarabine.
1574981|NCT02419755|Drug|Hydrocortisone|Hydrocortisone will be given intrathecally (IT) along with methotrexate and cytarabine.
1574982|NCT02419755|Drug|Peg-L-Asparaginase|Given by intravenous (IV) or intramuscular (IM) injection.
1574983|NCT02419755|Drug|Erwinia L-Asparaginase|To be used in case of allergy or intolerance to PEG-Asparaginase. Given by intravenous (IV) or intramuscular (IM) injection.
1574984|NCT02419755|Drug|Dexamethasone|Given orally (PO) or intravenously (IV).
1574985|NCT02419755|Drug|Mercaptopurine|Given orally (PO).
1574986|NCT02419755|Drug|Doxorubicin|Given intravenously (IV).
1574993|NCT02419729|Device|CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each application using minimal parameters suggested by the laser's software ( Power of 30 W, 1000us emission time, 1000um spacing and a level of SmartStack 2)
1574994|NCT02419729|Drug|Estrogen|Topical estrogen cream treatment: Estriol 1mg daily.
1574995|NCT02419729|Drug|Placebo of Estrogen|Placebo of topical estrogen cream.
1574996|NCT02419729|Device|Placebo of CO2 laser|SMARTXIDE2 V2LR (DEKA-Pulse) was used in each applications using minimal parameters suggested by the laser's software but power of 0.5 W was stipulated for the placebo intervention and other parameters remained unchanged.
1574997|NCT02419716|Device|Cologuard|Prescription of Cologuard for at-home stool collection
1574998|NCT02419703|Device|STAR™ Tumor Ablation System|Targeted Radiofrequency ablation of painful metastatic tumor in the vertebral body.
1574999|NCT02419690|Behavioral|text message intervention|Subjects will be sent 58 messages (3-5 per week) over 12 weeks, plus reminder messages for follow up interviews. The content of these messages will focus on contraception methods and effectiveness, sexually transmitted infection (STI) transmission, condom use, partner and parental communication, and healthy relationships. There will also be several text messages asking the participant if they would like to have a health educator contact them. The format will include facts, quizzes, true/false and some will have links to videos/pictures and websites, and some will request a response.
1575000|NCT02419677|Procedure|Radiofrequency ablation|Radiofrequency ablation is performed percutaneously under CT/US guidance.
1575001|NCT02419677|Biological|Cytokine-induced killer cells|The patients received autologous cytokine-induced killer cells transfusion one week after RFA treatment.
1575002|NCT02419664|Procedure|Gallium-68 DOTATOC PET|The intervention is to administer Ga-68 DOTATOC in pituitary patients doing PET/CT
1575003|NCT02419651|Drug|Tramadol|Women will receive oral tramadol 100 mg 1 hour before the procedure
1575004|NCT02419651|Drug|Diclofenac|Women will receive 100 mg diclofenac 1 hour before the procedure
1575005|NCT02419651|Drug|Placebo|Women will receive a placebo 1 hour before the procedure
1575006|NCT02419638|Drug|Rebif (IFN β-1a subcutaneous three times per week)|
1575007|NCT02419638|Drug|Tecifdera (dimethyl fumarate)|
1575008|NCT02419625|Behavioral|questionnaires|questionnaires , serum samples will be used
1575015|NCT02419586|Other|bubble gum|Chewing gum group patients performing gum chewing on postoperative day 1 at three times daily for 30 minutes after operation and until discharged.
1575019|NCT02419547|Drug|Versed|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
1575020|NCT02419547|Drug|Fentanyl|Phase 1: Standard induction of controled sedation with intravenous agent then programed stimulation to induce ventricular tachycardia
1575021|NCT02419547|Drug|Propofol|Phase 2: Standard induction of GETA with intravenous agent then programed stimulation to induce ventricular tachycardia
1575022|NCT02419547|Drug|Sevoflurane|Phase 3: Standard induction of GETA with inhalent agent then programed stimulation to induce ventricular tachycardia
1575023|NCT02419534|Drug|Polyethylene glycol|Laxative to treat constipation
1575024|NCT02419534|Drug|Polyethylene glycol with Diltiazem|Laxative and topical calcium channel blocker
1575026|NCT02419508|Drug|Brinzolamide 1%/brimonidine 0.2% tartrate ophthalmic suspension|
1575027|NCT02419508|Drug|Brinz/brim vehicle|Inactive ingredients used as a placebo for masking purposes
1575028|NCT02419508|Drug|Prostaglandin analogue|
1575029|NCT02419495|Drug|Selinexor|"Arm A, C, D, E, F, G, I Dose Escalation Phase Starting Dose: 60 mg given orally once a week for 3 weeks.
Arm B Dose Escalation Phase Starting Dose: 60 mg given orally twice a week for the first two weeks of each 3 week cycle.
Arm H Dose Escalation Phase Starting Dose: 40 mg given orally once a week for 4 weeks.
Arm J Dose Escalation Phase Starting Dose: 40 mg given orally once a week for 3 weeks.
Arm K Dose Escalation Phase Starting Dose: 40 mg given orally twice weekly for 4 weeks.
Arm L Dose Escalation Phase Starting Dose: 40 mg given orally twice weekly for 4 weeks.
All Arms Dose Expansion Phase Starting Dose: MTD from dose escalation phase."
1575030|NCT02419495|Drug|Carboplatin|"Arm A: Carboplatin given by vein at fixed dose of 6 AUC on day 1 of each 21 day cycle for up to 6 cycles.
Arm E and Arm F: Carboplatin given intravenously at fixed dose of 4 AUC on day 1 of each 21 day cycle for 6 or up to 8 cycles dependent on cancer type."
1575031|NCT02419495|Drug|Paclitaxel|"Arm B: Paclitaxel given intravenously at a fixed dose of 80 mg/m2 on Day 1 and Day 8 of every 21-day cycle (weekly for 2 weeks on and 1 week off) for up to 8 cycles.
Arm E: Paclitaxel given at doses of 175 or 200 mg/m2 by vein every 3 weeks for up to 8 cycles dependent on cancer type."
1575032|NCT02419495|Drug|Eribulin|Arm C: Eribulin given intravenously at fixed dose of 1.0 mg/m2 on Days 1 and 8 of every 21-day cycle for 6 cycles.
1575033|NCT02419495|Drug|Doxorubicin|Arm D: Doxorubicin given intravenously at fixed dose of 60 mg/m2 on Day 1 of each 21 day cycle for 6 cycles.
1575034|NCT02419495|Drug|Cyclophosphamide|Arm D: Cyclophosphamide given intravenously at fixed dose of 600 mg/m2 on Day 1 of each 21 day cycle for 6 cycles.
1575035|NCT02419495|Drug|Pemetrexed|Arm F: Pemetrexed given at fixed dose of 500 mg/m2 by vein every 3 weeks for up to 6 cycles. After completion of carboplatin and pemetrexed treatment, pemetrexed can be given as a combination maintenance therapy until disease progression. Participants with mesothelioma continue with pemetrexed treatment.
1575036|NCT02419495|Drug|Topotecan|Arm G starting dose of Topotecan 0.5 mg/m2 given intravenously on days 1 - 5 of each 21 day cycle for 8 cycles.
1575037|NCT02419495|Drug|Irinotecan|"Arm H: Irinotecan 180 mg/m2 by vein every 2 weeks or Days 1 and 15 of each 28-day cycle for 6 cycles.
Arm I: Irinotecan 125 mg/m2 by vein on Days 1 and 8 of each 21-day cycle (2 weeks on and 1 week off) for 8 cycles."
1575038|NCT02419495|Drug|5-FU|Arm H: 5-FU 2400 mg/m2 (continuous by vein over 48 hours) and 5-FU 400 mg/m2 bolus every 2 weeks or Days 1 and 15 of each 28-day cycle for 6 cycles.
1575039|NCT02419495|Drug|Capecitabine|Arm J: Capecitabine 900 mg/m2 taken orally twice daily for Days 1-14 of each cycle for 8 cycles.
1575040|NCT02419495|Drug|Oxaliplatin|Arm J: Oxaliplatin 130 mg/m2 by vein every 3 weeks for 8 cycles.
1575041|NCT02419495|Drug|Olaparib|Arm K: Olaparib 400 mg/m2 taken orally twice daily continuously for as many cycles at the discretion of the attending physician.
1575042|NCT02419495|Drug|Pembrolizumab|Arm L: Pembrolizumab given at the fixed dose of 2 mg/kg by vein every 3 weeks for as many cycles at the discretion of the attending physician.
1575043|NCT02419495|Drug|Nivolumab|Arm M: Nivolumab 240 mg by vein every 2 weeks or Days 1 and 15 of each 28-day cycle.
1575044|NCT02419482|Behavioral|4x4 minutes high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, 4x4 minute intervals at 90-95% of maximum heart rate separated by 3-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
1575045|NCT02419482|Behavioral|10x1 minute high intensity interval training|Treadmill running/walking with 10 minutes varm-up at 60-70% of maximum heart rate, ten 1-minute intervals at maximal intensity (that can be performed for one minute), separated by 1-minutes active pauses at 60-70% of maximum heart rate, and 3 minutes cool-down.
1575046|NCT02419469|Drug|Cytarabine|"Participants initially receive intrathecal treatment using Cytarabine 100 mg on Day 1. Induction chemotherapy must begin within 3 days of the intrathecal Cytarabine dose.
Consolidation Therapy 1: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and 8 - 11.
Consolidation Therapy 3B: Cytarabine 75 mg/m2 subcutaneously Days 1 - 4 and Days 8 - 11."
1575047|NCT02419469|Drug|Daunorubicin|Induction Therapy: Daunorubicin 25 mg/m2 by vein weekly for 4 doses.
1575081|NCT02419235|Other|Homoeopathic complex|20% ethanol medicated with Amylenum nitrosum 6cH, Crataegus oxyacantha 6cH, Natrium muriaticum 6cH and Scutellaria lateriflora 6cH.
1575189|NCT02418468|Drug|Indacaterol|Indacaterol 150µg capsules for inhalation daily
1575048|NCT02419469|Drug|Vincristine|"Induction Therapy: Vincristine 1.5 mg/m2 by vein weekly for 4 doses.
Consolidation Therapy 1: Vincristine 1.5 mg/m2 by vein Week 3 and Week 4.
Consolidation Therapy 2: Vincristine 1.5 mg/m2 by vein every 10 days for 5 doses.
Consolidation Therapy 3A: Vincristine 1.5 mg/m2 by vein weekly for 3 doses.
Consolidation Therapy 3B: Vincristine 1.5 mg/m2 by vein Weeks 3 and 4.
Maintenance Therapy (24 months): Vincristine 1.5 mg/m2 by vein every 28 days."
1575049|NCT02419469|Drug|Prednisone|Induction Therapy: Prednisone 60 mg/m2/day by mouth for 28 days.
1575050|NCT02419469|Drug|PEG asparaginase|"Induction Therapy: PEG asparaginase 2000 IU/m2 by vein on Day 4 of induction.
Consolidation Therapy 1: PEG-asparaginase 2000 IU/m2 by vein Week 3 and Week 7.
Consolidation Therapy 2: PEG-asparaginase 2000 IU/m2 by vein Weeks 1 and 4.
Consolidation Therapy 3A: PEG-asparaginase 2000 IU/m2 by vein in Week 1.
Consolidation Therapy 3B: PEG-asparaginase 2000 IU/m2 by vein Week 3."
1575051|NCT02419469|Drug|Ofatumumab|"Induction Therapy: Ofatumumab 300 mg by injection or vein on Day 2 and Ofatumumab 2000 mg by injection or vein on Day 15.
Consolidation Therapy 1: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.
Consolidation Therapy 2: Ofatumumab 2000 mg by injection or vein Week 1 and Week 5.
Consolidation Therapy 3A: Ofatumumab 2000 mg by injection or vein Week 1 and Week 3."
1575052|NCT02419469|Drug|Rituximab|"Induction Therapy: If Ofatumumab not available, Rituximab 375 mg/m2 by vein on Day 1 and on Day 15.
Consolidation Therapy 1: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.
Consolidation Therapy 2: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 5.
Consolidation Therapy 3A: If Ofatumumab not available, Rituximab 375 mg/m2 by vein Week 1 and Week 3."
1575053|NCT02419469|Drug|Methotrexate|"Induction Therapy: Intrathecal methotrexate 12 mg on Day 8 and Day 29.
Consolidation Therapy 1: Intrathecal methotrexate 12 mg Weekly, Weeks 1 - 4.
Consolidation Therapy 2: Methotrexate by vein every 10 days starting at 100 mg/m2 and increasing by 50 mg/m2 as tolerated. and Intrathecal methotrexate 12 mg Week 1.
Consolidation Therapy 3A: Intrathecal methotrexate 12 mg in Week 1.
Consolidation Therapy 3B: Intrathecal methotrexate 12 mg Week 1 and 2.
Maintenance Therapy (24 months): Methotrexate 20 mg/m2 by mouth weekly, hold on days of intrathecal methotrexate.
Maintenance Therapy (24 months): Intrathecal methotrexate 12 mg every 3 months for 4 doses."
1575054|NCT02419469|Drug|Cyclophosphamide|"Consolidation Therapy 1: Cyclophosphamide 1 gram/m2 by vein Week 1 and Week 5.
Consolidation Therapy 3B: Cyclophosphamide 1 gram/m2 by vein Week 1."
1575055|NCT02419469|Drug|Mercaptopurine|"Consolidation Therapy 1: Mercaptopurine 60 mg/m2/day by mouth Days 1 - 14.
Maintenance Therapy (24 months): Mercaptopurine 75 mg/m2 by mouth nightly."
1575056|NCT02419469|Drug|Doxorubicin|Consolidation Therapy 3A: Doxorubicin 25 mg/m2 by vein weekly for 3 doses.
1575057|NCT02419469|Drug|Dexamethasone acetate|"Consolidation Therapy 3A: Dexamethasone 10 mg/m2 by mouth on Days 1 - 7 and Days 15 - 21.
Maintenance Therapy (24 months): Dexamethasone 6 mg/m2/day by mouth Days 1 - 5 every 28 days."
1575058|NCT02419469|Drug|Thioguanine|Consolidation Therapy 3B: Thioguanine 60 mg/m2/day by mouth for 14 days.
1575059|NCT02419456|Drug|MK-2048A IVR (Low Dose)|Contains 91 mg of vicriviroc (MK-4176) and 10 mg of MK-2048.
1575060|NCT02419456|Drug|MK-2048A IVR (Original Dose)|Contains 182 mg of vicriviroc (MK-4176) and 30 mg of MK-2048.
1575061|NCT02419443|Drug|Gabapentin|Gabapentin is a structural analogue of GABA that decreases activation of voltage-activated calcium channels which may decrease release of excitatory neurotransmitters such as glutamate. Its analgesic mechanisms have been utilized effectively for the treatment of chronic pain in several disorders such as cancer, fibromyalgia and diabetic peripheral neuropathy.
1575062|NCT02419443|Drug|Placebo|Control group
1575063|NCT02419430|Behavioral|MBRT ClassRoom and Phone Application|2 hours/week for 6 week, in classroom intervention involving mindfulness based resilience training.focused on mindfulness and self-compassion training, including body awareness, breath awareness, mindful movement, awareness of thoughts, and awareness of emotion. Core concepts included: normalizing experience of stress and changing one's relationship with an experience; learning to be a compassionate observer of self in order to appreciate the moment; recognizing undue efforts to control something that has already happened; shifting attention to felt body sense and away from the narrative; and redirecting attention to a value as a way of evoking positive states that enhance the present moment experience. Participants also use the smartphone to track their sleep and subjective well-being.
1575064|NCT02419430|Behavioral|Phone application only|"Participants will track their sleep and subjective well-being and also choose one of the following weekly challenges, which is completed via smartphone interactions:
Joys of Life
Count your blessings
Think differenc, feel better
Exercising --> Happier
+ Exercising --> Sleep
Pre-Sleep routine
Eat that frog
Mindful Meditation"
1575065|NCT02419430|Behavioral|Questionnaires|At baseline, immediately after the last MBRT session (6 weeks) and again at 3 and 6 months, all participants will complete questionnaires, including: 1) WHO-5 Well-Being Index; 2) DASS-21; 3) VAS-Fatigue; 4) MBI-Human Services version; 5) Self-Compassion Scale; 6) Connor-Davidson 2-item resilience scale; 7) Compassion to others scale.
1575066|NCT02419417|Drug|BMS-986158|
1575067|NCT02419391|Biological|MVA BN RSV|Liquid frozen suspension of MVA-mBN294B
1575068|NCT02419391|Other|Placebo|Tris Buffered Saline, sterile
1575069|NCT02419378|Drug|Alemtuzumab|
1575070|NCT02419352|Drug|Sugammadex|
1575071|NCT02419352|Drug|Neostigmine/atropine|
1575072|NCT02419339|Procedure|Extravesical ureteral reimplantation|Extravesical ureteral reimplantation with or without tapering
1575073|NCT02419326|Behavioral|Psychotherapy treatment|UNITE is a manualized, 22-session CBCT (cognitive behavioral couples therapy) intervention that engages the couple to target the core psychopathology of BED and address the uniquely challenging stress that BED places on intimate relationships.
1575074|NCT02419313|Drug|incobotulinumtoxinA|Subjects randomized to the active drug intervention arm will receive incobotulinumtoxinA (Xeomin). A series of rating scales and examinations will take place prior to treatment and for 24 weeks after treatment. At 12 weeks the subjects will cross over to the placebo (saline) arm.
1575075|NCT02419313|Drug|Saline|same volume as injected for incobotulinum toxin A into forearm muscles under EMG guidance.
1575077|NCT02419287|Drug|crizotinib|
1575078|NCT02419261|Drug|Analgesic nerve blockade (Ropivacaine)|Analgesic nerve blockade for Arthroscopic surgical repair of the anterior cruciate ligament
1575079|NCT02419261|Procedure|Arthroscopic surgical repair of the anterior cruciate ligament|
1575082|NCT02419222|Behavioral|Prism Adaptation|PAT uses wedged prism lenses to displace the entire visual field horizontally to the left or right (depending on the orientation of the base of the prism). The left-base prism lenses (thicker on the left) shift the entire visual field to the right. The result is a curving reaching trajectory, aiming toward the image location (right to the actual location) and then corrected toward the actual location. After several reaching movement, the coordinates of motor and visual systems are aligned, which in other words, is that the motor output adapts to the visual input, and thus the reaching trajectory is straight ahead to the object. This visually-guided goal-oriented movement is essential in PAT.
1575083|NCT02419209|Other|Sucrose pillules medicated with the Individualised Homeopathic Remedy|Sucrose pillules medicated with the Individualised Homeopathic Remedy and potency as selected by the researcher in accordance with the laws that govern individualised homeopathic prescribing.
1575084|NCT02419196|Other|Perioperative pulmonary function tests|Pulmonary electrical impedance tomography, spirometry, pulse oximetry and query performed preoperatively, at the first and the third postoperative day
1575085|NCT02419183|Other|SAMSTAR|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
1575086|NCT02419183|Other|RAVLT|This is a non-interventional study based on computer-administered WLR (SAMSTAR) test and examiner-administered WLR (RAVLT) test to investigate whether the performance of participants is equivalent.
1575087|NCT02419170|Procedure|Standard of care surgery|
1575088|NCT02419170|Procedure|Apheresis|
1575089|NCT02419170|Drug|Cyclophosphamide|
1575090|NCT02419170|Biological|Personalized mature dendritic cell vaccine|
1575091|NCT02419157|Drug|Selective enamel etching with 36% phosphoric acid|Etch: selective 36% phosphoric acid enamel etching
1575092|NCT02419157|Drug|No selective enamel etching with 36% phosphoric acid|Non-etch: without phosphoric acid selective enamel etching
1575093|NCT02419157|Device|Clearfil SE Bond|
1575094|NCT02419157|Device|Xeno V|
1575095|NCT02419144|Behavioral|AMI and campaigns|The intervention we are proposing is a tailored bi-level intervention with two components, an individual level component (component A) with tailored messages based on performance on clinical assessment results, ADLs and cognitive domains in the survey delivered through adapted motivational interviewing with practice to mastery (AMI-PM); , and a building level campaign (component B) for those enrolled in the study (but open to all building residents that includes building tailored messages based on cognitive domains and skills reinforcement through Practice to Mastery.
1575096|NCT02419131|Behavioral|Behavioral Headache Therapy|A standard, manualized behavioral intervention for primary headache disorders
1575097|NCT02419131|Behavioral|Cognitive Processing Therapy|A gold-standard treatment for PTSD, called Cognitive Processing Therapy
1575098|NCT02419131|Behavioral|Treatment as Usual|Treatment as usual, receiving standard care for PTHA
1575099|NCT02419118|Drug|Daratumumab|Treatment of myeloma patients with Daratumumab
1575100|NCT02419118|Drug|Lenalidomide|Treatment of myeloma patients
1575101|NCT02419118|Drug|Dexamethasone|Treatment of myeloma patients
1575102|NCT02419105|Drug|Testosterone|transdermal gel, 75 mg daily
1575103|NCT02419105|Drug|Colecalciferol|drink solution, 24000 IU once per month
1575104|NCT02419105|Drug|Placebo drink solution|drink solution, 0 IU Colecalciferol once per month
1575105|NCT02419105|Drug|Placebo transdermal gel|transdermal gel, 0 mg testosterone daily
1575106|NCT02419053|Other|Surgical Safety Checklist|An Ontario hospital-wide introduction of a surgical safety checklist based on the WHO guidelines, as mandated by the Ontario Ministry of Health
1575107|NCT02419040|Procedure|Barbotage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
1575108|NCT02419040|Procedure|Corticosteroid injection|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 9 ml of 1% Lidocain hydrochlorid and 1 ml (20 mg) of Triamcinolon will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
1575109|NCT02419040|Procedure|Lidocain injection (sham)|The tip of the 18-gauge needle will be placed in the soft parts outside of the rotator cuff and movements mimicking the lavage procedure will be performed. A lavage procedure usually takes 5 minutes and the same period of time will have to be used for the mimicking maneuver. Finally, a new 21-gauge needle will be introduced into the subacromial-subdeltoid bursa and 10 ml of 1% Lidocain hydrochlorid will be injected into the subacromial-subdeltoid bursa. All patients will be instructed by a physioteherapist in home exercises.
1575110|NCT02419027|Dietary Supplement|GI Flora|
1575111|NCT02419027|Dietary Supplement|Placebo|
1575112|NCT02419014|Device|Active CES Device Alpha-Stim®|The Alpha-Stim® device is a Class II FDA-approved device for the delivery of cranial electrotherapy using microcurrents that are delivered via two electrodes worn on the earlobes. Active CES devices will be pre-programmed by the manufacturer to deliver a bipolar, asymmetric rectangular waveform at a current of 100 µa, a level that is generally undetectable by the wearer of the device. At these settings, the manufacturer recommends a treatment duration of 60 minutes. Participants will not be able to alter the settings in any way.
1575113|NCT02419014|Device|Sham Device|The inactive (sham) devices look identical to the active device but are inactivated by the manufacturer so as not to deliver any electrical current.
1575114|NCT02419001|Drug|Period 1 - Treatment Sequence AB|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
1575115|NCT02419001|Drug|Period 1 - Treatment Sequence AC|Period 1: Ceftriaxone 1 g infused IV over 30 minutes only, no SYN-004
1575116|NCT02419001|Drug|Period 2 - Treatment Sequence AB|Period 2: Ceftriaxone 1 g infused IV over 30 minutes and SYN-004 75 mg
1575118|NCT02418988|Drug|TACE plus rAd-p53 artery injection|Trans-catheter chemo-embolization (TACE) with rAd-p53 injection will be given every 21 days
1575119|NCT02418988|Drug|TACE|Trans-catheter chemo-embolization (TACE) without rAd-p53 injection will be given every 21 days
1575120|NCT02418975|Other|Very low-calorie protein-based diet|Patients will receive a homemade very low-calorie (~5 kcal/kg of ideal body weight /day) protein-based formula (milk proteins; 1.2 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
1575121|NCT02418975|Other|Hypocaloric diet|Patients will receive a commercial balanced enteral formula (~20 kcal/kg of ideal body weight /day; protein content, 1.0 g per kilogram of ideal body weight) for 4 weeks by a polyurethane nasogastric feeding tube.
1575122|NCT02418962|Biological|PfSPZ Vaccine|Aseptic, purified, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites vaccine
1575123|NCT02418962|Other|Normal Saline|0.9% Sodium chloride solution for injection
1575124|NCT02418949|Drug|Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.
Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
1575125|NCT02418949|Drug|Placebo for Cyproheptadine|"Cyproheptadine will be titrated up to the chronic dose prior to involvement in hand therapy as well as gradually down to zero in the two weeks following treatment.
Week 1 dose: 4mg taken twice daily (orally) Week 2 dose: 8mg taken twice daily (orally) Week 3 dose: (chronic dose): 8 mg taken three times daily (orally). Week 4-9: (chronic dose): 8 mg taken three times daily (orally). Week 10: 8 mg taken twice daily (orally). Week 11: 4 mg taken twice daily (orally). Week 12: no drug"
1575126|NCT02418949|Other|Active Movement Practice (AMP)|Participants will alternate between active training with a custom video game and a robot active-assistive Voice and EMG-Driven Actuated (VAEDA) glove during active training occupational therapy.
1575127|NCT02418949|Other|Passive Cyclical Stretching|Participants will wear the actuated device/glove for the duration of the training sessions (2 20-min stints followed by 10 min of rest) during which time the actuated glove will cyclically stretch the joints of the digits in the hand between flexion and extension while remaining passive/relaxed.
1575128|NCT02418936|Device|gene diagnostic kit|
1575129|NCT02418923|Other|Procedure: Blood specimen collection|Blood specimen collection
1575130|NCT02418884|Drug|rosuvastatin|CAD patients with diabetes who confirmed CAC will receive rosuvastatin (20mg/d) therapy for 24 months.
1575131|NCT02418871|Device|FluidVisionTM accommodating intraocular lens|
1575132|NCT02418858|Procedure|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery awake vs. asleep
1575133|NCT02418845|Drug|SYM-1219|
1575134|NCT02418845|Drug|Placebo|
1575135|NCT02418832|Procedure|Sperm cell aspiration and TEFNA|Testicular Fine Needle Aspiration (TEFNA)
1575140|NCT02418806|Behavioral|Psychotherapy groups|
1575141|NCT02418806|Behavioral|Self-help groups|
1575142|NCT02418793|Drug|MOD-5014|Long Acting Factor VIIa
1575143|NCT02418780|Other|Tai Chi|6-month Tai Chi exercise program meeting 2 times per week plus DVD for home practice
1575144|NCT02418767|Drug|MOD-4023|
1575145|NCT02418767|Drug|Placebo|
1575146|NCT02418754|Drug|REGN2176-3|
1575147|NCT02418754|Drug|Intravitreal Aflibercept Injection (IAI)|
1575148|NCT02418741|Other|Neck flexion|Patient's neck was flexed using a 4 cm or 8 cm height of pillow
1575149|NCT02418728|Other|subcutaneous adipose tissue microdialysis under local beta/alpha blockade|adipose tissue lipolysis under local beta/alpha blockade in abdominal subcutaneous adipose tissue, using microdialysis
1575150|NCT02418715|Other|Water Aerobics Training|
1575151|NCT02418702|Drug|0.2 mg/kg ketamine|20 patients will randomly be assigned 0.2 mg/kg of Ketamine
1575152|NCT02418702|Other|placebo|20 patients will randomly be assigned a placebo
1575153|NCT02418689|Drug|NOV120101 (Poziotinib)|NOV120101 (Poziotinib) 12 mg PO once daily for 2 weeks followed by a 1-week drug-free interval between cycles until disease progression or unacceptable toxicity development
1575154|NCT02418676|Drug|Gel with HPβCD-I complex|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with hydroxypropyl-beta-cyclodextrin complexed with insulin (HPβCD-I) was placed on the pressure ulcer and covered with sterile gauze and a transparent film.
The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
1575155|NCT02418676|Drug|Gel with insulin|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of gel with insulin was placed on the pressure ulcer and covered with sterile gauze and a transparent film.
The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
1575184|NCT02418494|Other|Concept Elicitation|Complete cognitive interview to elicit relevant HSIL symptoms, compare to study index of symptoms, and rank symptoms in relation to effect on health-related quality of life
1575185|NCT02418494|Other|Comprehension Assessment|Comprehension assessment of draft quality of life assessment
1575186|NCT02418481|Biological|DC-CIK|DC-CIK cells will be used against tumor cells.
1575187|NCT02418481|Biological|γδ T Cell|γδ T cells will be used against breast tumor.
1575156|NCT02418676|Drug|Control gel|"Initially, the pressure ulcer was cleaned with saline. With the aid of a paper ruler, the ulcer was measured and photographed, as the ruler included the date and the initials of the patient. After measuring, a quantity of 5 grams of control gel was placed on the pressure ulcer and covered with sterile gauze and a transparent film.
The curative was changed once a day during the treatment period, unless there was leakage of fluid, contamination, or signs of infection. Every three days the pressure ulcers of all patients were measured and photographed again, resulting in a total of six measurements per patient. The photos of pressure ulcers were evaluated for measurement of pressure ulcers and any kind of irritation."
1575157|NCT02418663|Drug|Fluid challenge (250 ml Lactated Ringer's solution)|"When VE is prescribed to a patient, a fluid challenge of 250mL Lactated Ringer's solution will first be administered. The ccNexfin system will be used to predict FR (SV increases by at least 15% in response to a fluid challenge). The remaining amount of fluid ordered by the treating team will then be administered, and SV will again be measured.
Additionally, a daily fluid challenge with 250mL of Lactated Ringer's will also be administered, with FR recorded as above"
1575158|NCT02418650|Drug|ODM-201 300 mg tablet|
1575159|NCT02418650|Drug|intravenous14C-ODM-201|
1575160|NCT02418650|Drug|300 mg 14C-ODM-201 oral solution|
1575161|NCT02418637|Other|Worksite screening for DM, HTN and hyperlipidemia|Six monthly visits to worksite to perform screenings
1575162|NCT02418624|Drug|carboplatin, olaparib|2 cycles of carboplatin and olaparib combination therapy followed by olaparib monotherapy.
1575163|NCT02418598|Genetic|Cohort1|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 3x10^11 vg/subject.
1575164|NCT02418598|Genetic|Cohort2|AAV-hAADC-2 is administered via bilateral intra-putaminal infusion. The number of vector genomes (vg) administered in this cohort is 9x10^11 vg/subject.
1575165|NCT02418585|Drug|Esketamine|Participants will self-administer either 56 mg or 84 mg of esketamine, intranasally, twice per week as a flexible dose regimen in the Double-Blind Induction Phase.
1575166|NCT02418585|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a flexible dose regimen in the Double-Blind Induction Phase.
1575167|NCT02418585|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
1575168|NCT02418585|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
1575169|NCT02418585|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
1575170|NCT02418585|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
1575171|NCT02418572|Drug|Testosterone gel|"Patients will receive once daily application of 0.55 gr testosterone gel-TTG (GROUP A) (Testosterone gel 1%; Laboratories Besins International, Paris, France) with a 5.5 mg/d nominal delivery rate of testosterone starting from day 1 or 2 of the following menstrual cycle, for approximately 65 days.
The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.
TTG will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of TTG or placebo will continue for 35 days (21days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG). Ovarian stimulation will commence the day after last testosterone gel application. (GROUP A)"
1575172|NCT02418572|Drug|Placebo gel|"Patients will receive once daily application of 0.55 gr of placebo gel from day 1 or 2 of the following menstrual cycle, for approximately 65 days.
The application will be administered in the morning by the patient onto clean dry healthy skin over external surface of the thighs. The gel will be simply spread on the skin gently as a thin layer.
Placebo gel will start on the day of enrollment and will continue until patients' menstruation (28-30 days). Daily administration of placebo gel will continue for 35 days (21 days until the initial of downregulation with triptorelin and for 14 more days until the initiation of ovarian stimulation with HP-hMG"
1575173|NCT02418559|Drug|JNJ-63623872 (300 mg)|Participants will receive JNJ-63623872 300 mg tablet orally once on Day 1 under fasted conditions.
1575174|NCT02418559|Drug|JNJ-63623872 (600 mg)|Participants will receive JNJ-63623872 600 mg (2*300 mg) tablet orally once on Day 1 under fasted conditions.
1575175|NCT02418559|Drug|JNJ-63623872 (1200 mg)|Participants will receive JNJ-63623872 1200 mg (4*300 mg) tablet orally once on Day 1 under fasted conditions.
1575176|NCT02418559|Drug|Placebo|Participants will receive placebo tablet orally once on Day 1 under fasted conditions.
1575177|NCT02418546|Behavioral|In-Person Nutritional Counseling by a Registered Dietitian|
1575178|NCT02418546|Behavioral|Nutritional counseling using an e-Health Application|
1575179|NCT02418533|Drug|menotropin|Menopur is used for controlled ovarian stimulation (COH)
1575180|NCT02418533|Drug|Recominant Follicle Stimulating Hormone (rFSH)|Gonal-f is used for controlled ovarian stimulation (COH)
1575181|NCT02418520|Biological|Oral hygiene with Miswak|Oral hygiene with Miswak chewing sticks and normal tooth brush
1575182|NCT02418507|Dietary Supplement|Proprietary Probiotic Blend|A proprietary probiotic blend: Lactobacillus acidophilus, Bifidobacterium lactis, Bifidobacterium longum, and Bifidobacterium bifidum at 56.75 mg
1575183|NCT02418507|Other|Placebo|The placebo is administered to randomized healthy participants
1575188|NCT02418481|Biological|Combination|γδ T/DC-CIK cells will be used against breast tumor.
1575303|NCT02417493|Behavioral|Simulation of epinephrine self-injection|
1575190|NCT02418468|Drug|Placebo|Matching placebo indacaterol capsules for inhalation daily
1575191|NCT02418455|Drug|UX003|
1575192|NCT02418429|Other|waxy maize starch|pancake test meal with waxy maize starch only
1575193|NCT02418429|Other|waxy maize starch and Whey Protein|pancake test meal with waxy maize starch and whey protein
1575194|NCT02418429|Other|Resistant Starch|pancake test meal with resistant starch only
1575195|NCT02418429|Other|resistant starch and whey protein|pancake test meal with resistant starch and whey protein
1575196|NCT02418416|Other|Oocyte double chemical activation|Oocyte double chemical activation
1575197|NCT02418403|Behavioral|Financial incentive|Offer of money designed to overcome barriers to advance care planning.
1575198|NCT02418403|Behavioral|Educational website|"Research-verson of the Prepare for your care website (www.prepareforyourcare.org)"
1575199|NCT02418390|Procedure|prophylactic central lymph node dissection|dissection of level VI compartment by AAHNS (American association of head and neck surgeons) classification
1575200|NCT02418364|Other|Placebo reflexology treatment|Placebo reflexology treatment will be done in the same rate as the reflexology treatment itself, but will be superficial in particular,and will be directed to organs and organ systems which are not relevant to the research topic.
1575201|NCT02418364|Other|Reflexology treatment|Reflexology treatment will be done until the eggs implant. If the patient is not pregnant, she will start another reflexology treatment cycle. There will be minimum 4 and up to 6 reflexology treatments in every IVF cycle (maximum three IVF cycles) . Rate treatment will be two or three times a week.
1575202|NCT02418351|Biological|Autologous Bone Marrow-Derived Mononuclear Stem Cells|Super selective intravenous administration of 50 million Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and intrathecal administration of BM-MNCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
1575203|NCT02418351|Other|Liberation therapy|
1575204|NCT02418338|Other|speckle tracking (2D strain) echocardiography|2D echocardiography videos of both ventricles to perform 2D strain post-examination evaluation
1575205|NCT02418325|Biological|Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells|Super selective intravenous administration of 50 million Allogeneic Human Umbilical Cord Tissue-Derived Mesenchymal Stem Cells (UC-MSC) and intrathecal administration of UC-MSCs in dose of 100 million along with liberation therapy (when associated with CCSVI)
1575206|NCT02418325|Other|Liberation therapy|
1575209|NCT02418299|Device|IncontiLase Er:YAG laser treatment|Each patient will receive 2-3 sessions of Er:YAG laser treatment for stress and mixed urinary incontinence (IncontiLase)
1575210|NCT02418286|Other|Observation|There are no interventions associated with this registry as it is purely observational.
1575211|NCT02418273|Drug|denosumab|These subjects will receive two doses of denosumab.
1575212|NCT02418260|Procedure|Bridge Plate osteosynthesis|Trough two anterior skin incisions, the 4.5mm narrow DCP plate will be placed on the anterior surface of the humerus and, after indirect reduction, it will be fixed to the bone with 2 proximal and 2 distal screws.
1575213|NCT02418260|Procedure|Locked intramedullary nail osteosynthesis|Trough an anterolateral approach to the shoulder, the supraspinatus tendon will be longitudinally splited allowing the insertion of the intramedullary nail.
1575214|NCT02418260|Procedure|Open reduction and plate osteosynthesis|Trough an posterior or anterolateral approach, the fracture will be directly reduced and fixed with a broad DCP 4.5mm plate.
1575215|NCT02418247|Drug|I131|
1575216|NCT02418247|Drug|I123|
1575217|NCT02418234|Other|mutation detection|
1575218|NCT02418234|Other|ARMS and ddPCR|
1575219|NCT02418234|Genetic|ctDNA analysis|
1575220|NCT02418221|Dietary Supplement|DAOSiN®/ Placebo & ProvokAmin® Ingestion|Proband is randomly assigned Daosin® or the Placebo before provocation with ProvokAmin®
1575221|NCT02418221|Procedure|Drawing blood, measuring BP & pulse|Taking of a blood sample and recording of blood pressure & pulse
1575222|NCT02418195|Drug|ketamine|IV infusion of ketamine 0.5mg/kg at a rate of 40mL over 40 minutes
1575225|NCT02418156|Device|CorMatrix ECM for Vascular Repair|Standard femoral arterial interventional procedure using CorMatrix ECM for arterial repair.
1575226|NCT02418143|Device|CorMatrix CanGaroo ECM Envelope|Subjects who have received CorMatrix CanGaroo ECM Envelope for an implantable electronic device placement following a battery change or upgrade.
1575227|NCT02418130|Drug|Ursodeoxycholic acid, taurine, ginsenoside, thiamine, inositol|
1575228|NCT02418130|Drug|Placebo|
1575229|NCT02418117|Other|Stereolitographic template|Flapless (atraumatic) dental implants insertion with the aid of a stereolitographic template.
1575230|NCT02418104|Drug|CHS-1701|
1575231|NCT02418104|Drug|Pegfilgrastim (Neulasta)|
1575232|NCT02418091|Behavioral|Telehealth|Using Telehealth to slow progression of diabetic kidney disease automated population program identifies patients and engages them to optimize DKD medication adherence and health behaviors using 2-way communication via patient-selected technology (mobile/web-based applications, text messaging, interactive voice response, or e-mail) backed by case management via the phone for suboptimal control or health status. The STOP-DKDAutomated Population Program will deliver a tailored, multi-factorial intervention to address medication self-management and modify multiple risk factors simultaneously through a combination of patient self-monitoring, behavioral therapies and education that optimize adherence and self-efficacy.
1575233|NCT02418078|Procedure|local infiltration anesthesia and sedation|the surgical site is infiltrated with local anesthetic agents and the patients are sedated with intravenous agents
1575234|NCT02418065|Other|training on ergonomic bicycle|
1575235|NCT02418065|Drug|Testosterone|
1575236|NCT02418065|Drug|Oral nutritional supplementation|
1575237|NCT02418065|Drug|n3 polyunsaturated fatty acid|
1575304|NCT02417480|Behavioral|Vegan diet|Participants in the omnivorous arm will be asked to follow their normal diet for one week and then follow a vegan diet for one week.
1575238|NCT02418052|Procedure|neck flexion|After the cervical esophagogastric anastomoses is completed and the skin incision is closed, the patient's occiput will be lifted, and then the neck will be maintained in flexing position by an assistant. The underside of the chin will be fixed to the anterior chest wall with two stout nylon sutures by the surgeon. The neck will be fixed in the neutral flexing position for 7 to 10 days after surgery.
1575239|NCT02418039|Dietary Supplement|High protein diet|It has been suggested that administrating a high protein diet in patients with liver cirrhosis and with minimal hepatic encephalopathy could prevent the development of malnutrition, increase the detoxification of ammonia by the muscle to consequently delay the onset overt hepatic encephalopathy and prolong patient survival. However, information is scarce and inconclusive regarding the potential role of dietary protein in the prevention and treatment of minimal hepatic encephalopathy.
1575240|NCT02418039|Dietary Supplement|Normal protein|A normal protein diet will be administrated in patients with MHE.
1575241|NCT02418026|Other|hypnosis|Conversational hypnotic induction and therapeutic suggestions
1575242|NCT02418013|Other|Fresh cord blood(experimental group A)|"Cord blood is administered through intravenous at CHA clinical trail institute.
Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered prior to the treatment."
1575243|NCT02418013|Other|Frozen cord blood(experimental group B)|"Cord blood is administered through intravenous at CHA clinical trail institute.
Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
1575244|NCT02418013|Other|Frozen plasma(experimental group C)|"Cord blood is administered through intravenous at CHA clinical trail institute.
Chlorpheniramine maleate at the concentration of 0.6ml/10kg is administered"
1575245|NCT02418013|Other|Placebo group|"A placebo agent is administered through intravenous at CHA clinical trail institute.
It should be certain that when administered, participants are not aware of which treatments are preformed."
1575247|NCT02417987|Other|Placebo|The skin was penetrated with a needle and few drops of saline injected in the soft tissue away from the tendon
1575248|NCT02417987|Drug|High Volume injection|Injection with10 mls 0.5% bupivacaine hydrochloride and 20 mg of Depomedrol 40 mls saline (NaCl) around the tendon
1575249|NCT02417987|Biological|Autologous conditioned plasma (ACP)|Injection with 4 mls of ACP around the tendon
1575250|NCT02417974|Biological|Fecal Microbiota Transplant (FMT)|Fecal Microbiota Transplant (FMT)
1575251|NCT02417961|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
1575252|NCT02417948|Other|Written Educational Brochure|Receive brochure with skin cancer education and preventative information
1575253|NCT02417948|Other|Online educational video|Watch 30-minute online tutorial video about skin cancer, preventive behaviors, and skin self-examinations
1575254|NCT02417935|Drug|Duloxetine|Administered orally
1575255|NCT02417935|Drug|Pregabalin|Administered orally
1575256|NCT02417935|Drug|Placebo|Administered orally
1575257|NCT02417922|Other|Saline|4 mls of saline is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
1575258|NCT02417922|Other|ACP|4 mls of ACP is injected 4 times around the injured tendon area every 2nd week during the 8 weeks of conservative treatment.
1575259|NCT02417909|Other|questionnaires about quality of life|all teenagers included in the trial and their parents must complete the questionnaires given of them the day of enrollment.
1575260|NCT02417896|Drug|Spironolactone|Spironolactone is administered orally to cardiac surgical patients by a study investigator (100 mg 12-24 hrs before surgery); subsequently three further doses of 25 mg are administered orally in the morning of postoperative days 1, 2 and 3. A total 1 x 100 mg and 3 x 25 mg doses of spironolactone in the intervention group will be given. If the patient has not been extubated, spironolactone is administered nasogastrically. Oral drugs will be delayed by up to 4 hours if extubation has just occurred.
1575261|NCT02417883|Drug|Furosemide|Evaluate urinary excretion rate fo furosemide
1575262|NCT02417870|Biological|aldesleukin|
1575263|NCT02417857|Procedure|Laparoscopic Cholecystectomy (Single Incision)|We performed Single Incision Laparoscopic Cholecystectomy (SILC) operation to the group-1
1575264|NCT02417857|Procedure|Laparoscopic Cholecystectomy (Conventional)|We performed Conventional Laparoscopic Cholecystectomy (CLC) to group-2
1575265|NCT02417844|Drug|tamsulosin (Astellas)|
1575266|NCT02417844|Drug|Tamsulosin HCL|
1575267|NCT02417831|Drug|tamsulosin capsules|
1575268|NCT02417831|Drug|tamsulosin HCl|
1575269|NCT02417818|Device|Plasma Therapy (PlasmaDerm)|Plasma Therapy (PlasmaDerm)
1575270|NCT02417818|Device|Repetitive Plasma Therapy (repetitive PlasmaDerm)|Repetitive Plasma Therapy (Repetitive PlasmaDerm)
1575271|NCT02417805|Procedure|Intervention: Remote Ischemic Preconditioning|Remote Ischemik Preconditioning is performed using a Blood Pressure Cuff with a pressure slightly above patients' blood pressure on the upper arm.
1575272|NCT02417779|Device|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
1575273|NCT02417779|Device|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)|Repetitive Extracorporeal Shock Wave Therapy (Device Name: PiezoWave)
1575274|NCT02417753|Drug|AZD9150|AZD9150 IV infusion over 3 hours Cycle 1: days 1, 3, 5, 8, 15 and 22 of a 28 day cycle. Cycle 2 and beyond Days 1, 8, 15 and 22 of a 28 day cycle
1575278|NCT02417688|Device|Cu[64]-25%-CANF-Comb PET-MR|Single IV injection of a novel radiopharmaceutical for diagnostic imaging of atherosclerosis by PET-MR
1575305|NCT02417480|Behavioral|Follow habitual, usual diet|Participants will be asked to consume their habitual, usual diet.
1575306|NCT02417467|Other|Nicotine E-Cigarette|
1575307|NCT02417467|Other|Non-Nicotine E-Cigarette|
1575308|NCT02417467|Behavioral|Counseling|
1576429|NCT02409836|Drug|Marketed Flavored Dentifrice|Bubble Gum Flavored
1575279|NCT02417675|Other|Community-based Adherence Clubs|"Women in the AC arm are prescribed 2 months of their current ART medication (compared to 1 month in the SOC) and will be advised to go to the AC office immediately, where they will be scheduled for their first session. Women will attend AC meetings every two months. At these meetings, women will receive a 2 month supply of medication, health education and peer-support. A trained Community Health Worker (CHW) will also collect blood samples, weight, and current signs/symptoms from women.
Each participant has 5 working days after their AC session to come and collect her medication. Those who have defaulted will be followed up by the CHW via phone calls and, possibly, home visits. If reached, women will be told to return immediately to the main ART facility for receipt of ART care."
1575280|NCT02417675|Other|Standard of Care for Mothers|Women will be referred immediately from the maternity ART clinic to their nearest adult ART clinic at their first postpartum clinic visit. At referral, they receive an initial 1-month supply of their current ART medication. At the first appointment after transfer into the general ART service, patients undergo clinical history and examination by a doctor or clinical nurse practitioner. Laboratory investigations are ordered according to standard protocols or based on clinician discretion. For the 1st 4 months in the new service, stable patients are dispensed 1 month of ART; subsequent visits are 2-monthly for medication refill, with clinician review 6-monthly; patients with particular clinical or psychosocial concerns may be reviewed more regularly, or referred to higher levels of care.
1575281|NCT02417675|Other|Standard of Care for Infants|All infants will receive care at their nearest primary care clinic. Following national protocols, all HIV-infected mothers are issued a 6-week supply of nevirapine syrup after delivery and counselled on daily nevirapine prophylaxis. Infant follow-up takes place within 1 week postpartum with the mother (at the MOU) and then at 6 weeks postpartum (at the nearest primary care clinic) when HIV PCR testing of the infant is carried out. Following national protocols, infants who are breastfed beyond 6 weeks receive HIV PCR testing 2-4 weeks after the cessation of breastfeeding, again conducted at the nearest City of Cape Town primary care clinic.
1575282|NCT02417662|Radiation|Radical Radiotherapy (Conventional RT and SABR)|Radical radiotherapy (conventional or SABR) to primary and SABR to the metastases
1575283|NCT02417662|Other|Non-investigational platinum-based doublet chemotherapy|There is no intervention in the control group, patients will receive standard chemotherapy alone.
1575284|NCT02417649|Biological|Placebo|"The placebo will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.
Three months of rest, according to the indications, will be allowed.
A second cycle (the same as point 1.) will be performed
A second three month rest (according to point 2.) will be provided."
1575285|NCT02417649|Biological|Ismigen|"The tablet will be administered for a period of three months. The first ten days of each month, one tablet per day will be given. The tablet will be melted under the tongue. After the ten day therapy, a twenty day of rest will be provided. Then the second and the third month the administration schedule will be identical.
Three months of rest, according to the indications, will be allowed.
A second cycle (the same as point 1.) will be performed
A second three month rest (according to point 2.) will be provided."
1575286|NCT02417636|Other|Task Shifting|Participants will be screened for eligibility for ART and the study and then enrolled initiated on ART by a Nursing Officers and then followed and monitored for ART adherence on a monthly basis for 24months. Quarterly, sexual behavior and quality of life questionnaires will be administered. CBC, CD4, HIV-1 Viral load, renal and liver function test will be done biannually. Nursing Officers will be free to consult with clinicians on the management of patients.
1575287|NCT02417623|Behavioral|Smartphone Application group|Intervention group will receive a 12-month weight loss programmed that implements recommendations of a Clinical Practice Guideline, complemented with a smartphone app
1575288|NCT02417610|Device|Polynucleotide - PNHA - Newart|gel polynucleotides and hyaluronic acid
1575289|NCT02417610|Device|Hyaluronic acid - HA - Ialart|Hyaluronic acid
1575290|NCT02417597|Biological|Recombinant Hepatitis E Vaccine (Escherichia Coli)|Participants would intramuscularly receive 3 doses of Recombinant Hepatitis E Vaccine (Escherichia Coli) at 0, 1, 6 month.
1575291|NCT02417584|Device|positive airway pressure (PAP)|Positive Airway Pressure (PAP) is a non-invasive machine providing air pressure f to prevent the collapse of the oropharyngeal walls and the obstruction of airflow during sleep, which occurs in obstructive sleep apnea hypopnea syndrome.
1575292|NCT02417571|Device|Ambulatory blood pressure monitoring (ABPM)|24-hour ambulatory BP monitoring using TM-2430 device (A&D Company, Tokyo, Japan)
1575293|NCT02417558|Behavioral|Alterniity Augmented Reality (AAR)|AAR is a patent pending exercise and gaming (exergaming) computer platform with a physical training component (PTC) and a cognitive training component (CTC). It fully immerses a user inside a virtual environment where he is practising complex everyday activities, such as going shopping, using the transportation, visiting a foreign city, eating at a restaurant, cooking dinner etc. His motor behaviour is monitored by means of motion capture, while immersed at this full-body immersion. In addition his cognition is monitored in real-time with Personalized Brain Network Activity (PBNA) screening. Both the motor and brain analyses are then used to update the configuration, type and difficulty of the AAR scenarios.
1575294|NCT02417558|Behavioral|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
1575295|NCT02417558|Behavioral|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
1575296|NCT02417558|Behavioral|VideoGrade|Active cognitive training by use of the VideoGrade software by Aristotle University of Thessaloniki.
1575297|NCT02417532|Device|Rehabilitation using REX|Exercises of wheelchair dependent subjects using REX
1575298|NCT02417519|Other|DAR|Volunteers ingested 300 mL of coffee with a dark roast containing low levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
1575299|NCT02417519|Other|LIR|Volunteers ingested 300 mL of coffee with a light roast containing high levels of chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
1575300|NCT02417519|Other|CTR|Volunteers ingested 300 mL of water containing no chlorogenic acids followed 30 min later by by 75g glucose and 300 mL water
1575301|NCT02417506|Other|E-OA-07 (Lanconone)|
1575302|NCT02417506|Drug|Ibuprofen|
1575380|NCT02416999|Drug|Temozolomide|
1575312|NCT02417428|Dietary Supplement|Citrulline|Twelve weeks of citrulline oral supplementation will be taken by half of the participants (other are taken a placebo). Citrulline supplementation will be taken orally. Ten grams of citrulline (white powder) will be mixed with a liquid daily. Supplementation will be consumed once at lunch time.
1575313|NCT02417428|Other|Placebo|Twelve weeks of oral placebo will be taken by half of the participants. Ten grams of placebo (maltodextrin white powder) will be mixed with a liquid and will be consumed once daily at lunch time.
1575314|NCT02417428|Behavioral|Exercise|Participants will also take part in twelve weeks of HIIT (30s at 85% and up of maximal heart rate + 1m30sec at 60-75% of maximal heart rate (HR max). 3 times/ week during 30 continuous minutes. Each period are supervised and monitored using borg scale and polar system.
1575315|NCT02417428|Other|without exercise|No exercise program will be assigned to participants.
1575316|NCT02417415|Other|Passive heat stress|Passive heat stress will be applied with a commercial heating pad that covers all the abdomen and part of the torso to provide local heating at ~44ºC continuously for 2 hr.
1575317|NCT02417415|Other|Control (non-heating)|Heating pad will be applied over the abdomen and part of the torso but it will be turned off.
1575320|NCT02417389|Drug|cinacalcet|During Phase 1 (months 1-12): oral administration; 30 mg twice/day (dose to be increased if needed).
1575321|NCT02417389|Drug|Alendronate|During Phase 2 (months 13-24): oral administration; 70 mg once/week (in addition to cinacalcet 30 mg twice/day as during Phase 1).
1575322|NCT02417376|Device|piezoelectric ultrasonic scaler (frequency of 28-36 KHz)|Periodontal treatment in the form of scaling and root planing (SRP) is provided to the patients assigned to the experimental group, after baseline examination. Scaling is performed using piezoelectric ultrasonic scaler (frequency of 28-36 KHz) and root planing is performed using area specific Gracey curettes (set of 7 instruments number #1-14). SRP is completed in two appointments of 45 min to 1 hour, within 24 hours period.
1575323|NCT02417376|Device|Gracey curettes|set of 7 instruments number #1-14
1575324|NCT02417350|Other|Ketogenic diet for four weeks, then a 15 week washout, and finally a NFA recommended diet for four weeks|
1575325|NCT02417350|Other|NFA recommended diet for four weeks, then a 15 week washout, and finally a ketogenic diet for four weeks.|
1575332|NCT02417298|Drug|Normal saline|Normal saline intravenous push (with volume to be administered equivalent to that of ketamine 0.3mg/kg, if the patient was to receive ketamine) followed by a normal saline infusion at the same rate as ketamine arm
1575333|NCT02417298|Drug|Ketamine|0.3mg/kg IVP ketamine followed by 0.1mg/kg/hr of ketamine infusion for 3 hours
1575334|NCT02417285|Drug|Obinutuzumab|1000 mg administered IV on Days 2, 8, and 15 of Cycle 1 and on Day 1 of Cycles 2 though 8.
1575335|NCT02417285|Drug|CC-122|CC-122 1mg, 2mg, 3mg, 4mg or 5mg administered orally once daily on a 5/7-day schedule in each 28-day cycle. In addition, subjects will be enrolled on the CC-122 formulated capsule (F6) and evaluated for safety and tolerability in combination with GA101 (Obinituzumab) in a separate cohort. The CC-122 dose will be escalated until the MTD is established on the CC-122 formulated capsule (F6) in combination with GA101 (Obinituzumab).
1575336|NCT02417272|Device|Surgical treatment of cervical degenerative disc disease (CP ESP®)|
1575337|NCT02417272|Device|Surgical treatment of cervical degenerative disc disease (Axelle®)|Axelle®
1575338|NCT02417246|Drug|Toprol XL|Both groups will receive this to compare if there is a difference in the clinical response.
1575339|NCT02417246|Device|SmartPill Capsule|Both groups will have a continuous measure of pH by a SmartPill Capsule as it moves through the gastrointestinal tract.
1575340|NCT02417246|Procedure|Exercise Treadmill|Both groups will have a treadmill exercise test performed.
1575341|NCT02417246|Procedure|24 hour holter monitor|Both groups will have a 24 hour holter monitor performed.
1575342|NCT02417246|Other|24-hour pharmacokinetic parameters|Both groups will have this test performed.
1575343|NCT02417246|Drug|Wockhardt metoprolol|Both groups will receive this to compare if there is a difference in the clinical response.
1575344|NCT02417246|Drug|Activas metoprolol|Both groups will receive this to compare if there is a difference in the clinical response.
1575347|NCT02417220|Behavioral|Weight Watchers Online 2015 Program|Access to the Weight Watchers Online 2015 program available via the Internet on personal computers, tablet computers, and/or smartphones already owned by participants.
1575348|NCT02417220|Other|Electronic Scale with Feedback|Provision of an electronic scale that automatically transmits body weights to the Weight Watchers Online 2015 program, which generates a weekly feedback message on weight loss progress.
1575349|NCT02417207|Drug|Entecavir combined long-term low-dose HBIG group intramuscular|HBIG scheme is: the use of intraoperative muscle injection of 800 IU HBIG, postoperative week 1 intramuscular injection HBIG 400 IU 1 times a day, 1 week after intramuscular injection HBIG 400 IU 2 times per week, dosage and time interval according to the HBsAb drops in patients with degree of level adjustment, target drops for 3 months or more after 500 IU/mL, 3 ~ 6 months or 300 IU/mL, after six months of 100 IU/mL or more.
1575350|NCT02417207|Drug|Entecavir combined HBIG group short-term high-dose intravenous|Preoperative HBV DNA level is less than 1000 IU/ml, intraoperative intravenous drip of 2500 IU HBIG static note type, postoperative 1 and 15 days respectively to give 2500 IU HBIG static note type, a total of three times, then no longer apply. Preoperative HBV DNA level greater than 1000 IU/ml, the use of HBIG solution for: intraoperative intravenous drip of 5000 IU HBIG static note type, postoperative day 1, 15 days and 30 days respectively to give 2000-2500 IU HBIG static note type, a total of four times, since then no longer apply. Preoperative HBV DNA level of the unknown, preoperative immediate detection of DNA, intraoperative intravenous drip of 5000 iu HBIG static note type, choose according to test results after dosing frequency.
1575351|NCT02417181|Other|Care provided by Physician Assistants|Patients will receive care at the out-of-hours primary care service by a Physician Assistant instead of a General Practitioner (substitution of care from physicians to nurses).
1575352|NCT02417155|Behavioral|Hyper/hypoventilation|"Subjects are asked to hyperventilate for an average of 30 breaths. Subsequently, the subjects exhaled and hold their breath for approximately 2 minutes (retention phase). The duration of breath retention will be entirely at the discretion of the subject himself. Breath retention is followed by a deep inhalation breath, that will be held for 10 s. Subsequently a new cycle of hyper/hypoventilation begins."
1575353|NCT02417155|Behavioral|Strength ventilation|This exercise consists of deep inhalations and exhalations in which every inhalation and exhalation is followed by breath holding for 10 s, during which the subject tightens all his body muscles.
1575354|NCT02417142|Drug|Exenatide|Exenatide (plus existing treatment) 2mg/week for 24 weeks.
1575355|NCT02417142|Drug|Placebo|Placebo (plus existing treatment) for 24 weeks.
1575356|NCT02417129|Drug|Rituximab|BI 695500 375 mg/M2
1575357|NCT02417129|Drug|BI 695500|BI 695500 375 mg/M2
1575358|NCT02417116|Other|Tear supplement|Application as required to improve comfort
1575359|NCT02417116|Other|Tear supplement 2|Application as required to improve comfort
1575360|NCT02417116|Dietary Supplement|Omega 3 nutrition supplement|Taken each day
1575361|NCT02417116|Device|Eye bag|Applied following microwave heating to closed eyelids for 5 minutes each day
1575362|NCT02417116|Other|Saline|Application as required to improve comfort
1575363|NCT02417103|Drug|GLP-1 (Liraglutide)|GLP-1 Analogon
1575364|NCT02417103|Drug|Placebo|Placebo
1575365|NCT02417090|Drug|Insulin|Pregnant women who used insulin to treat gestational diabetes
1575366|NCT02417090|Drug|Metformin|Pregnant women who used metformin to treat gestational diabetes
1575367|NCT02417077|Other|Photographic Review|Photographic review of subjects who received treatment with onabotulinumtoxinA for crow's feet lines.
1575374|NCT02417051|Behavioral|Disaster Worker Resiliency Training|The Disaster Worker Resilience Training (DWRT) Program is a 4 hour program which consists of a participant training manual, an instructor-training manual, and a digital presentation. It uses adult training techniques that emphasize active participation in individual and group experiential learning activities. The curriculum is organized into a preface and four chapters, each with action oriented learning objectives. Overall program objectives include a demonstrate an ability to: 1) Recognize signs and symptoms of disaster work-related stress, 2) Obtain support through employer and community resources, and 3) Build resilience by using stress reduction and coping strategies.
1575375|NCT02417038|Device|Capnostream|The Capnostream capnograph (is registered with the FDA) is supplied by Covidien. The Capnostream is a portable CO2 monitor with a pulse oximetry module to measure and record SpO2 (oxygen saturation) and heart rate continuously. The Capnostream provides waveform patterns for respiratory rate and EtCO2 measurement.
1575376|NCT02417025|Behavioral|PE|Prolonged Exposure
1575377|NCT02417012|Behavioral|U-TURN|Participants in this group will receive individual and group based interventions on obtaining and maintaining a healthy lifestyle, while having the pharmacological treatment regulated
1575378|NCT02417012|Behavioral|Standard care|Standard individual diabetes support
1575379|NCT02416999|Drug|Ultra-low dose Bevacizumab|
1575382|NCT02416986|Behavioral|Delay to Smoking Task (smoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard smoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
1575383|NCT02416986|Behavioral|Delay to Smoking Task (nonsmoking cues)|Participants will be presented with an unlit cigarette of their brand and an opportunity to initiate ad lib smoking at any time during the 60-minute task. During this period, participants will be allowed to read books or magazines, but will hear a tone alerting them to view cues (standard nonsmoking environments) for the final minute of each 6-minute period. A monetary reinforcer will be provided for each 6-minute period that a participant resists smoking. Once participants stop the task they can choose to smoke as much or a little as they want for the next 30 minutes. Participants will be provided with a smoking tab. Each cigarette they light will cost them from their tab.
1575384|NCT02416973|Device|Provant|
1575385|NCT02416960|Other|Low Glycemic Index Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, low glycemic index/load diet.
1575386|NCT02416960|Other|Conventional Diet Group|This diet will be designed as a moderate reduced-energy, moderate-to-high ﬁber, high glycemic index/load diet.
1575387|NCT02416947|Dietary Supplement|0 g SCF|0 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
1575388|NCT02416947|Dietary Supplement|10g SCF|10 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
1575389|NCT02416947|Dietary Supplement|20g SCF|20 grams of SCF will be administered daily in two equal doses in the form of a muffin and a drink.
1575390|NCT02416934|Drug|Treatment 1; Dexamethasone|Dexamethasone IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
1575391|NCT02416934|Drug|Treatment 0; Saline placebo|Saline (placebo) IV given within the first hour of surgery; second dose given 8 hours after first dose; third dose given 8 hours after second dose.
1575392|NCT02416921|Behavioral|Weight-gain Prevention|A 4-week weight-gain prevention curriculum will be delivered via Facebook. Participants will be provided tips to prevent weight-gain and will be given the opportunity to engage with the peer coaches and other participants in the group.
1575393|NCT02416921|Behavioral|Women's Health|A 4-week women's health curriculum will be delivered via Facebook. Participants will be provided tips for staying healthy and will be given the opportunity to engage with the peer coaches and other participants in the group.
1575394|NCT02416908|Drug|Selinexor|
1575395|NCT02416908|Drug|Cladribine|
1575396|NCT02416908|Drug|G-CSF|
1575397|NCT02416908|Drug|Cytarabine|
1575398|NCT02416908|Procedure|Bone marrow biopsy|
1575399|NCT02416895|Other|In vivo immunity model|A measure of in vivo immune function.
1575400|NCT02416882|Other|Aerobic Exercise|Subjects will sample and rate their liking of three cardiovascular machines (treadmill, cycle ergometer, elliptical step ergometer) to determine which one will be used during the test.
1575401|NCT02416882|Other|Resistance Exercise|Subjects will sample and rate their liking of three different resistance training circuits (upper body, lower body, core) to determine which one will be used during the test.
1575402|NCT02416882|Other|Sedentary Option|Subjects will rate their liking of three sedentary activities (reading magazines, playing puzzles, completing word games) as an alternative to exercise.
1575403|NCT02416869|Procedure|Intramuscular application|Patient receive 4mg of Dexamethasone by intramuscular application
1575404|NCT02416869|Procedure|Submucosal application|Patients receive 4mg of Dexamethasone by submucosal application
1575405|NCT02416869|Drug|4mg Dexamethasone submucosal|Patients receive 4mg of submucosal Dexamethasone
1575406|NCT02416869|Drug|8mg Dexamethasone submucosal|Patients receive 8mg of submucosal Dexamethasone
1575407|NCT02416869|Procedure|4mg Dexamethasone preoperative|Patients receive 4mg of Dexamethasone preoperatively
1575408|NCT02416869|Procedure|4mg Dexamethasone postoperative|Patients receive 4mg of Dexamethasone postoperatively
1575409|NCT02416843|Other|Consumption of a mixed meal|Participants will consume a mixed meal and postprandial responses in blood and adipose tissue will be investigated over 6 hours and compared to baseline.
1575410|NCT02416817|Other|Blood Products only|Based solely on massive transfusion triggers Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive blood products by prescription of the patient's anesthesiologist. The patient will be constantly observed and bleeding triggers will be reassessed hourly.
1575411|NCT02416817|Other|Point of Care guided|Based on massive transfusion triggers and thromboelastometry Patients with traumatic hemorrhage that fulfil the inclusion criteria will receive the drugs guided by the results of the thromboelastometry. The dosis of each drug will be based on the analysis of the thromboelastometry curves (established algorithm).
1575412|NCT02416804|Drug|Buprenorphine|Buprenorphine transdermal patch Initial : 5 μg/hr Sequential increasing of dose : 5 μg/hr -> 10 μg/hr -> 15 (5+10) μg/hr -> 20 μg/hr
1575413|NCT02416804|Drug|Tramadol|Tramadol Initial : 150 mg/d Sequential increasing of dose : 150 mg/d -> 200 mg/d -> 250 mg/d -> 300 mg/d
1575414|NCT02416791|Device|Robotic Therapy|Robotic therapy (MIT - Manus, Interactive Motion Technologies) will be administered for 40 minutes to the paretic upper limb.
1575415|NCT02416791|Device|Active tDCS|Active tDCS will be applied with the cathode positioned over the ipsilesional primary motor cortex and the anode over the contralateral supraorbital region for 20 minutes (1mA).
1575416|NCT02416791|Device|Sham tDCS|In sham tDCS, no current will be delivered through the tDCS device.
1575417|NCT02416791|Other|Physical Therapy|Physical therapy will be administered for 40 minutes.
1575418|NCT02416791|Other|Occupational Therapy|Occupational therapy will be administered for 40 minutes.
1575419|NCT02416778|Drug|Ferric carboxymaltose, Ferinject® 50mg Iron/ml Solution for Injection / Infusion|
1575731|NCT02414594|Drug|IONIS-APO(a)-LRx|Ascending single and multiple doses of IONIS-APO(a)-LRx by subcutaneous (SC) injection
1575420|NCT02416765|Other|15-hour intervention|Interventions will be conducted in outpatient settings. Subject's usual insulin will be used. Meals will not be standardized. Subjects will be allowed to eat whatever and when they want and will be allowed to drink alcohol. Subjects will be allowed to exercise, but they will be asked to do the same amount and intensity of exercise on all intervention visits. Subjects will be accompanied all the time by a member from the research team during closed-loop visits to implement hormonal infusions.
1575421|NCT02416765|Drug|Insulin (Lispro, Aspart or guilisine)|Patient's usual insulin (Lispro, Aspart or guilisine) will be used in all interventions.
1575422|NCT02416765|Drug|Glucagon (Eli Lilly)|In the dual-hormone CLS interventions, glucagon (Eli Lilly) will be used.
1575423|NCT02416765|Other|Closed-loop strategy|Every 10 minutes, the glucose level as measured by the real time sensor (Dexcom G4 Platinum, Dexcom) will be entered manually into the computer. The pumps' infusion rate will then be changed manually based on the computer generated recommendation infusion rates. The computer generated recommendations are based on a predictive algorithm.
1575424|NCT02416752|Drug|Remifentanil|The remifentanil infusion was used intra operatively in remifentanil group and intermittent boluses of morphine or fentanyl administered for conventional opioid group
1575425|NCT02416752|Drug|choice of intra-operative opioids were left to the discretion of anesthesiologist|
1575426|NCT02416739|Drug|Nicotinamide|Nicotinamide (1g/day) or placebo treatment is added to the standard drug treatment (gefitinib or erlotinib) to EGFR mutated NSCLC patients
1575428|NCT02416713|Device|Cellcontrol DriveID|Technology that blocks incoming and outgoing calls and texts.
1575429|NCT02416713|Other|Education Only|No active intervention, educational materials will be provided
1575430|NCT02416700|Procedure|immediate implant surgery|Surgery of dental implants in one side of the mouth.
1575431|NCT02416700|Device|implant surgery (Straumann®)|Dental implant surgery in one of the sides of the mouth
1575432|NCT02416687|Device|Implanon®|Postpartum women into whom the etonogestrel-releasing contraceptive implant was inserted in the first 48 h postpartum
1575435|NCT02416648|Behavioral|Clinician Client Centered (CCC) Counseling|"Counseling sessions were interactive allowing for listening, questions and answers. They were cultural sensitive and also consider issues related to gender and age. Areas covered during the brief counseling included; HIV transmission and prevention, healthy sexual practices, condom use, reduction in multiple sexual partners, beneficial disclosure, and individual risk assessment and reduction strategies.
Clinicians evaluated patients' readiness to change risky or maintain safer behaviors. They also assisted the patient to negotiate an individually tailored behavior change or maintenance plan of action."
1575436|NCT02416635|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
1575437|NCT02416635|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
1575443|NCT02416596|Procedure|Hysteroscopy|"Office hysteroscopy will be performed during the Luteal phase of the proceeding menstrual cycle.
All OH (office hysteroscopy) procedures will be performed with a vaginoscopic approach without utilizing a speculum and applying traction to the cervix with a tenaculum.
Antibiotic prophylaxis: None OH will be cancelled until after treatment of vaginal infection."
1575444|NCT02416596|Device|Hysteroscope|"The device used is a rigid hysteroscope (continuous flow, 30 degree forward oblique view) assembled in a 4-mm diameter diagnostic sheath with an atraumatic tip (Karl Storz Endoscopy).
Illumination: High intensity cold light source and fiberoptic cable Distention medium: solution of 0.9% normal saline with pressure at 100-120 mmHg"
1575445|NCT02416583|Drug|Oxytocin|
1575446|NCT02416583|Drug|Dinoprostone|
1575447|NCT02416583|Procedure|Membrane sweeping|
1575448|NCT02416570|Drug|Clarithromycin|
1575449|NCT02416570|Drug|Placebo|
1575450|NCT02416557|Procedure|PEEP|application of 10 cmH2O (centimeter of water) positive end expiratory pressure during mechanical ventilation
1575451|NCT02416544|Other|Lunch which is calorie-restricted and low-salt|Comparison of different duration of feeding lunch which is calorie-restricted and low-salt
1575455|NCT02416505|Behavioral|Verbal+Anatomic Model|
1575456|NCT02416505|Behavioral|Verbal+Video|
1575536|NCT02416011|Behavioral|GENERIC|The initial Stop Smoking for Good brochure, 10 Stop Smoking for Good booklets and 9 supportive My Story pamphlets delivered over 18 months, as used in our previous cessation study.
1576430|NCT02409823|Drug|Atypical Antipsychotics|any atypical antipsychotic
1575459|NCT02416479|Behavioral|SystemCHANGE|SystemCHANGE self-management supports patient-designed, interventionist-guided, small experiments using Deming's Plan-Do-Check-Act cycle26 to: (1) assess individual systems (including important others who shape medication taking), how they influence medication taking and their proposals for improving medication adherence, (2) implement the proposed individual systems' solutions to improve adherence, (3) track adherence data, and (4) evaluate adherence data.
1575460|NCT02416479|Behavioral|Patient-education attention control|The 6-month Patient education attention-control (AC) intervention includes 6 transplant educational materials, covering healthy post-transplant behavior, developed by the International Transplant Nurses Society. The RA calls Pps at 1, 2, 3, 4, 5 and 6 months to review the brochure information and answer any questions about it.
1575461|NCT02416466|Biological|anti-CEA CAR-T cells|Gene modified patient T cells.
1575462|NCT02416466|Device|Sir-Spheres|SIR-Spheres microspheres are a medical device used in Selective Internal Radiation Therapy (SIRT) for liver tumors. SIR-Spheres microspheres are a permanent implant and for single use only. The biocompatible resin microspheres containing yttrium-90 have a median diameter of 32.5 microns (range between 20 and 60 microns).
1575463|NCT02416453|Biological|MVA-BN-Filo|One 0.5 mL intramuscular (IM) injection of 1E8 Infectious Unit [Inf. U.] on Day 29, 57, or 85.
1575464|NCT02416453|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1.
1575465|NCT02416453|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and Day 29, 57, or 85.
1575466|NCT02416440|Other|blood sample|blood sample
1575467|NCT02416427|Drug|Atorvastatin|Atorvastatin will be administered at 80 mg/day for 3 weeks in the time window between diagnostic biopsy and curative surgery
1575468|NCT02416414|Device|QuantiFERON Monitor Assay|Assay to measure cell-mediated immune function using QuantiFERON Monitor assay.
1575469|NCT02416414|Device|Existing methodology|Assay to measure cell-mediated immune function using existing methodology.
1575472|NCT02416388|Drug|Idarubicin|"Induction chemotherapy :
Idarubicin 9mg/m² /day, from D1 to D5 (IV, 30min)
+ cytarabine 200mg/m²/day from D1 to D7 (IV 24 h)
Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
1575473|NCT02416388|Drug|Daunorubicin|"Induction chemotherapy :
Daunorubicin 90mg/m²/day, from D1 to D3 (IV, 30min)
+ cytarabine 200mg/m² /day from D1 to D7 (IV 24 h)
Bone marrow aspirate on D15 : if medullary blasts rate < 5% → G-CSF (5 μg/kg/day) until hematopoietic recovery (PNN ≥ 1 G/L)."
1575474|NCT02416388|Drug|HD Cytarabine|"Consolidation chemotherapy course (s) :
-High dose cytarabine: 3g/m² /12h on D1, D3 and D5
For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)
Up to 3 consolidation courses, depending on the patient AML risk group"
1575475|NCT02416388|Drug|Cyclosporine|"GvHD prophylaxis post allogeneic SCT :
-Cyclosporine : 3 mg/kg /day from D-1 (IV) or 6 mg/kg/day from D-3 (PO). Not to be stopped before D100"
1575476|NCT02416388|Drug|Methotrexate|"GvHD prophylaxis post allogeneic SCT :
-15 mg/m² on D+1 then 10 mg/m² on D+3, D+6 and D+11"
1575477|NCT02416388|Drug|Mycophenolic acid (MPA)|"GvHD prophylaxis post allogeneic SCT :
720 mg BID from D0 to D+28 for HLA-identical siblings
720 mg BID from D0 to D+45 for 10/10 HLA allele-matched unrelated donors"
1575478|NCT02416388|Drug|vosaroxin|"Consolidation chemotherapy course (s) :
-70 mg/m² on D1 and D4"
1575479|NCT02416388|Drug|ID cytarabine|"Consolidation chemotherapy course (s) :
-Intermediate dose cytarabine: 1.5g/m² /12h on D1, D3 and D5
For all patients, G-CSF (5 μg/kg/day) : SC or IV (30 min) from D8 until hematopoietic recovery (PNN ≥ 1 G/L)
Up to 3 consolidation courses, depending on the patient AML risk group"
1575480|NCT02416362|Other|Vibration at 30 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 30 Hz.
1575481|NCT02416362|Other|Vibration at 50 Hz|During the exercise protocol, the vibration platform will be turned on at a vibration frequency of 50 Hz.
1575482|NCT02416349|Other|Respiratory Muscles Stretching|"Respiratory Muscles Stretching The stretching will occur throughout the expiratory phase to allow respiratory muscles to reach their maximal length, and two sets with 10 consecutive incursions will be use for each stretching pattern with an interval of 30 seconds between series.
Pattern 1: Neck stretching Pattern 2: Upper chest stretching Pattern 3:Pectoralis major stretching Pattern 4:Lateral chest stretching"
1575483|NCT02416349|Other|Control Group|Control Group - all volunteers will be positioned at rest in a comfortable in a chair during 20 minutes.
1575484|NCT02416336|Device|Sentinella Intraoperative imaging protocol|"There is a holding time of 15-20 minutes after the lymph node is removed during which the node is further dissected, examined and prepared for pathological analysis. This occurs before the procedure is completed in case the surgeon determines that further surgical exploration or tissue removal is required.
In this study, the investigators will use this holding time to collect images of the sentinel lymph node area using the Sentinella camera for this study. Therefore, participation in this study will not increase the subject's overall procedure time. However, if the Sentinella camera detects something that the standard imaging techniques have missed, such as an additional sentinel node, the surgeon will do further exploration and tissue removal as needed."
1575485|NCT02416323|Other|AIM HI Training|
1575487|NCT02416297|Procedure|Micro-osteoperforation|Flapless cortical perforations will be made 8 months minimum after dental extraction. Surgical protocol will be flapless to preserve periodontal health. After local anesthesia, 3 micro osteoperforations will be done with manual instrument, between apex to the contour of free gum between the canine and second pre-molar. Perforations near each tooth will have 6-8 mm depth
1575537|NCT02416011|Behavioral|eTARGET|The product of Study I is expected to include the initial If You Vape brochure, a series of 10 If You Vape: Guide to Quitting Smoking booklets, distributed over 18 months, and 9 supportive My Story pamphlets, delivered in the months between booklets.
1576878|NCT02406495|Device|filcon IV 1|contact lens
1575488|NCT02416284|Other|NFBDG|"Intervention consists of:
Lecture presenting the NFBDG, Printed booklet containing the NFBDG, Suggested meal plan for a week, Recipes, Access to a restricted website with further information on the NFBDG, A Facebook-group where Vegetable of the day was presented with a suggested recipe, text-messages with encouragement to follow the guidelines, follow-up phone-calls, common exercise sessions, Free common meals (1 breakfast, 2 lunches, 1 dinner), Free foods (low-fat dairy products, a juice containing grapes, blueberries, chokeberries, and cherries and fruits)"
1575489|NCT02416271|Drug|Teriparatide|Administered SC
1575490|NCT02416271|Drug|Alendronate|Administered orally
1575491|NCT02416271|Dietary Supplement|Calcium|Administered orally
1575492|NCT02416271|Dietary Supplement|Vitamin D|Administered orally
1575493|NCT02416271|Drug|Placebo-Oral|Administered orally
1575494|NCT02416271|Drug|Placebo-SC|Administered SC
1575495|NCT02416258|Drug|LP0113 aerosol spray|
1575496|NCT02416258|Drug|Aerosol spray vehicle|
1575497|NCT02416258|Drug|LEO 90100 aerosol foam|
1575498|NCT02416258|Drug|Betamethasone dipropionate aerosol spray|
1575499|NCT02416258|Drug|Calcipotriol aerosol spray|
1575500|NCT02416258|Drug|Daivobet® gel|
1575501|NCT02416245|Dietary Supplement|Beverage powder fortified with micronutrients and Bacopa monnieri extract|Test beverage powder is fortified with micronutrients and Bacopa monnieri extract. Each sachet contains 32g of treatmemt product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
1575502|NCT02416245|Other|Non fortified isocaloric control (without added micronutrients and Bacopa monnieri extract)|Control beverage powder is the non-fortified isocaloric powder i.e. without micronutrients and Bacopa Monnieri extract. Each sachet contains 32g of placebo product and 6g dairy whitener. Entire content of the sachet will be stirred with 180mL of potable lukewarm water, and given orally twice daily
1575503|NCT02416232|Drug|Trametinib|Trametinib will be provided as tablets containing 0.5 milligram (mg) or 2.0 mg of trametinib parent (present as the DMSO solvate). The starting dose of trametinib will be administered orally 2.0 mg, once daily (QD)
1575504|NCT02416232|Drug|Dabrafenib|Dabrafenib is commercially available as capsules containing 50 mg or 75 mg as free base (present as the mesylate salt). Dabrafenib will be administered orally 150 mg, twice daily (BID).
1575505|NCT02416219|Procedure|Cricoid pressure|participants will ask to mark the place where they will apply cricoid pressure if the patients was undergoing rapid sequence induction. US will be used to confirm how accurate they are in their estimation.
1575506|NCT02416219|Device|Ultrasound|
1575507|NCT02416206|Drug|BeEAM|BeEAM
1575508|NCT02416193|Drug|Cholecalciferol|Participants will take randomly assigned high dose cholecalciferol once weekly for three months
1575509|NCT02416193|Drug|Cholecalciferol|Participants will take randomly assigned active comparator cholecalciferol once weekly for three months
1575510|NCT02416180|Device|SERETIDE MDI|Commercially available SERETIDE MDI (EVOHALER) containing fluticasone propionate/salmeterol. Subjects will use MDI as 2 inhalations twice daily at the dose equivalent to their usual maintenance treatment of SERETIDE via DISKUS Inhaler.
1575511|NCT02416180|Device|Placebo DISKUS Inhaler|Placebo dry powder inhaler to be used to demonstrate the use of DISKUS inhaler at Visit 1
1575512|NCT02416180|Device|Placebo MDI|Clear liquid propellant inhaler to be used to demonstrate the use of MDI at Visit 2
1575513|NCT02416167|Drug|FYU-981|
1575514|NCT02416167|Drug|Placebo|
1575515|NCT02416154|Procedure|Reproductive tract and blood sampling|Reproductive tract and blood sampling will be performed at enrollment only in this cross-sectional parallel cohort study.
1575516|NCT02416141|Drug|fast release oro dispersible tramadol 50 mg|idem arm 1
1575517|NCT02416128|Drug|Euphrasia|1 drop in the treated eye QID X 10 days
1575518|NCT02416128|Drug|Prednisolone acetate|1 drop in the treated eye QID X 10 days
1575519|NCT02416115|Drug|Ramosetron|Ramosetron was given iv.
1575520|NCT02416115|Drug|Naloxone|Naloxone added to PCA was given iv.
1575521|NCT02416115|Drug|saline|Saline was given iv.
1575522|NCT02416115|Drug|Morphine|Morphine in the PCA was given iv.
1575523|NCT02416102|Drug|Losartan 50 mg|COPD and subjects with chronic bronchitis not on ARB treatment will receive 50 mg for 4 weeks
1575524|NCT02416102|Drug|losartan 100 mg|COPD and subjects with chronic bronchitis not on ARB treatment will receive 100 mg for 4 weeks
1575525|NCT02416089|Device|Tampostat|
1575526|NCT02416089|Device|Condom catheter tamponade|
1575527|NCT02416076|Device|Ulthera Treatment at EL2|Focused ultrasound energy delivered below the surface of the skin.
1575528|NCT02416076|Device|Ulthera Treatment at EL4|Focused ultrasound energy delivered below the surface of the skin.
1575529|NCT02416063|Drug|Caudal Dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg
Drug: Caudal dexmedetomidine 1µg/kg
Intravenous: 10 ml normal saline
sevoflurane Induction and maintenance of anesthesia"
1575530|NCT02416063|Drug|Intravenous dexmedetomidine|"Drug:Caudal bupivacaine 0.25% 1ml/kg.
Drug:Intravenous dexmedetomidine1 μg /kg in a total volume of 10 ml
sevoflurane Induction and maintenance of anesthesia"
1575531|NCT02416063|Drug|Placebo|"Drug:Caudal bupivacaine 0.25% 1ml/kg
Intravenous: Normal saline 10 ml
sevoflurane Induction and maintenance of anesthesia"
1575532|NCT02416050|Procedure|Brain MRI imagery|Brain MRI performed during the first week of inpatient cocaine cessation
1575533|NCT02416037|Device|level of positive end expiratory pressure (Prone Proseva)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
1575534|NCT02416037|Device|level of positive end expiratory pressure (Prone Talmor)|PEEP based on PEEP/FIO2 table vs PEEP based on the value of oesophageal pressure
1575535|NCT02416024|Device|SphygmoCor system|Carotid-femoral pulse wave velocity (cfPWV) will be determined by applanation tonometry using the Sphygmocor system by sequentially recording ECG-gated carotid and femoral artery waveforms. Pulse wave signals will be recorded by tonometers positioned at the base of the right common carotid artery and over the right femoral artery. The time (t) between the feet of simultaneously recorded waves will be determined as the mean of 10 consecutive cardiac cycles. PWV is calculated by the system software from the distance between measurement points (D) and the measured time delay (t) as follows: cfPWV = D/Δt (m/s) where D is distance in meters and t is the time interval in seconds.
1575538|NCT02415998|Procedure|TEE|Epidural catheter will be placed under guidance of transesophageal echography in specific thoracic spinal segment.
1575539|NCT02415985|Drug|Lopinavir/r will be supplied by NHSO/GPO|200/50 mg tablet LPV/rtv
1575540|NCT02415985|Drug|Rifabutin|
1575541|NCT02415972|Other|Ultrasound perfusion imaging|Dynamic perfusion imaging of brain parenchyma with modern ultrasound is possible with the use of ultrasound contrast media that serve as echo signal amplifier.
1575542|NCT02415959|Drug|Creon IR|
1575543|NCT02415959|Drug|Creon® (DR/GR)|
1575546|NCT02415933|Behavioral|Trickle Up|"Female caregivers (mothers) receive a package of interventions on economic empowerment and livelihood strengthening:
Savings group formation and training for a group of 15-25 women which provides a place to save, take out emergency loans and builds community networks and social capital;
Provision of seed grants to assist in business start-ups through microfinance loans;
One-on-one mentoring and coaching on livelihood development, which is held on a bi-weekly or monthly basis;
Trainings on financial planning and household livelihoods."
1575547|NCT02415933|Behavioral|Trickle Up Plus|"In addition to the economic empowerment program for women (Trickle Up), all members of the household assigned to Trickle Up+ arm receive sensitization component on beliefs and knowledge related to protection of children from violence and exploitation. Training sessions are developed and delivered by a local organization, Aide aux Enfants et aux Familles Démunies (ADEFAD).
Sessions involve all members of the household and focus on knowledge and cultural norms associated with child protective outcomes (e.g. the dangers of child separation such as sending children away for work, the importance of education for girls, risks of child and forced marriage)."
1575548|NCT02415920|Drug|Oxytocin|Participants will be randomly assigned to intranasally administer either oxytocin or a placebo.
1575549|NCT02415920|Drug|Placebo|
1575550|NCT02415907|Drug|[ethyl-1-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67708 ([ethyl-1-14C]-idalopirdine) in one capsule for oral administration, single dose
1575551|NCT02415907|Drug|[benzyl-7-14C]-idalopirdine|120 mg/2.40 MBq Lu AF67709 ([benzyl-7-14C]-idalopirdine) in one capsule for oral administration, single dose
1575552|NCT02415881|Drug|Panitumumab IRDye 800|Patients will receive Panitumumab IRDye 800 prior to their scheduled surgery
1575554|NCT02415842|Other|Serum samples|The archived sera samples collected in previously completed pandemic influenza vaccine clinical trials (H1N1, H5N1, and H9N2 pandemic vaccines in 3 adult trials and H5N1 pandemic vaccine in a pediatric trial) will be tested in this study.
1575555|NCT02415829|Drug|capecitabine plus oxaliplatin|The neoadjuvant chemotherapy consisted of oxaliplatin, 130 mg/m² on day 1, with capecitabine, 1000 mg/m² twice daily for 14 days every 3 weeks (the XELOX regimen)
1575556|NCT02415816|Device|Diffusion Weighted Magnetic Resonance Imaging|Diffusion weighted magnetic resonance imaging (DWI MRI) is a method that does not involve radiation and can be used to assess the primary tumor as well as to image the entire patient, from head to toe. Diffusion weighted MRI uses a strong motion probing gradient to detect the movement of water in tissue. Tissues that are composed of tightly packed cells, such as tumors, allow less water movement than tissues with loosely packed cells. As tumors respond to therapy they become necrotic and cells are less tightly packed. This change in water diffusivity can be quantitated using DWI. Therefore, DWI provides a non-invasive, non-ionizing, and quantitative method of assessing tumor response at a cellular level and does not depend on a change in tumor size
1575557|NCT02415803|Drug|low-dose ticagrelor|90 mg loading dose, then 45 mg twice daily for 5 days
1575558|NCT02415803|Drug|conventional-dose ticagrelor|180 mg loading dose, then 90 mg twice daily for 5 days
1575559|NCT02415803|Drug|Clopidogrel|300 mg loading dose, then 75 mg once daily for 5 days
1575560|NCT02415790|Drug|E2027|Part A: E2027 capsules will be administered orally in doses of 10 mg to 1200 mg in Part A and in Part B, C, and D at doses not exceeding the highest dose achieved in Part A.
1575561|NCT02415790|Drug|E2027 matching placebo|E2027 matching placebo capsule will be administered.
1575562|NCT02415777|Drug|Ursodeoxycholic acid, thiamine, riboflavin|
1575563|NCT02415764|Behavioral|Behavioral/Attitudinal OnTrack Role-Playing Game|"The intervention will involve each participant sitting down at a computer for approximately one hour (over the course of one week) to complete the prototype game. Users will take on the role of a person who has experienced first-episode psychosis and moves through animated role-playing scenarios, learn practical tips for engaging in care, play mini-games to develop self-advocacy skills, and view stories of hope and recovery (brief video vignettes).
While the intervention does not require direct supervision by the research team, technical support will be available for the duration of the study via telephone, instant messaging and email. All participants receive identical baseline surveys and 2-week follow up surveys."
1575564|NCT02415751|Behavioral|heart failure self-care education|It is defined as a naturalistic decision-making process that patients use in the choice of behaviors that maintain physiological stability (symptom monitoring and treatment adherence) and the response to symptoms when they occur (Riegel 2004). This includes following advice regarding medications, sodium and water consumption, alcohol restriction, exercise, preventive behaviors, and monitoring of signs and symptoms.
1575565|NCT02415738|Procedure|Prone positioning|
1575566|NCT02415725|Drug|Indocyanine Green|visualization of the architecture of superficial lymphatic network after Indocyanine Green injection
1575567|NCT02415712|Drug|Fomepizole|The first dose of fomepizole is administered at a dose of 15 mg/kg, followed by the second to fifth doses administered at a dose of 10 mg/kg. The sixth and subsequent doses are administered at a dose of 15 mg/kg. The interval of the intravenous doses is 12 hours with one administration lasting more than 30 minutes.
1575568|NCT02415699|Drug|Fluorouracil|
1575569|NCT02415699|Drug|Oxaliplatin|
1575570|NCT02415699|Drug|Leucovorin|
1575571|NCT02415699|Biological|DC-CIK|
1575573|NCT02415660|Procedure|Thoracic spinal manipulation|All patients will receive 3 different thrust joint manipulations to the middle and upper thoracic spine region. Each technique will be applied up to 2 times, per the discretion of the treating therapist discretion
1576879|NCT02406495|Device|ocufilcon D|contact lens
1575574|NCT02415660|Procedure|Trigger point dry needling|The TDN treatment will consist of a trained investigator inserting a needle through the participant's skin, into the deep cervical extensor muscles and/or the upper trapezius muscles using FDA approved (FDA regulation # 880.5580) disposable 0.2-0.3 x 40-50 mm stainless steel Seirin J-type needles (Seirin, Japan). Those subjects randomized to TDN will undergo this treatment.
1575575|NCT02415660|Behavioral|Cervical range of motion exercises|The patient will be instructed to place 5 fingers along the manubrium, and to flex the neck down until the chin touches the fingers. The patient will then be instructed to rotate the head as far as comfortably possible to one side, and then to the other side for 10 repetitions to each side, 3-4 times per day. The patient will progress from 5 fingers, to 4, 3, 2 and eventually 1 finger as neck mobility improves.
1575576|NCT02415660|Behavioral|Posterior neck muscle activation exercise|The patient will be instructed to sit upright in a chair, and place 1-2 fingers over the C2 spinous process. Education to localize this landmark will be provided. The patient will then perform an isometric chin tuck exercise against the resistance they will apply at C2. This position will be held x 5 seconds and repeated 10 times, 3-4 times per day.
1575577|NCT02415660|Procedure|Trigger point dry needling sham|The sham group will receive a simulated TDN. Using a toothpick in a needle guide-tube, the investigator will tap, rest, and twist the toothpick for approximately 30 seconds in the same 2 muscles, 2 sites in each muscle. The sham treatment will not penetrate the skin.
1575578|NCT02415660|Device|Seirin J-type stainless steel needles, 0-2-0.3 x 40-50 mm|A trained investigator will insert the needle through the participants skin into the deep cervical extensors and/or the upper trapezius muscles. Needles are FDA approved (#880.5580)
1575579|NCT02415634|Other|RECAP|"Patients will receive an information pack at ICU discharge called the RECAP. This pack will include
Part 1: A critical care discharge summary (UCCDIP) (Bench and Day, 2012)
Part 2: A rehabilitation goal setting care plan
Part 3: A patient communication forum
Part 4: Useful supports and contact information
Part 5: Tailored exercise programme
The patient will have a consultation with the ICU physiotherapist before ICU discharge once weekly thereafter for 3 weeks . The focus of the session will be to discuss goal attainment and associated challenges.
The ICU therapist will meet once weekly with the patient's primary physiotherapist to provide clinical support if necessary, in determining the patient's needs post critical care."
1575580|NCT02415634|Other|Control|Participants allocated to the control group will receive standard physiotherapy intervention post ICU discharge
1575581|NCT02415621|Drug|Abiraterone Acetate|1000 mg by mouth (PO) every day (QD)
1575582|NCT02415608|Drug|Ibrutinib|Given PO
1575583|NCT02415608|Other|Quality-of-Life Assessment|All subjects will complete a Quality-of-Life Assessment (QOL) questionnaire to assess changes in mastocytosis related symptoms scores at screening, on day 1 of each study cycle, at EOT, and 30 days post EOT.
1575584|NCT02415608|Other|Laboratory Biomarker Analysis|Laboratory Biomarker Analysis will be performed using bone marrow biopsies (including aspiration, cytogenetics, flow, and core biopsy). Bone marrow biopsies will be performed at screening, at the end of cycle 3, and at the end of cycle 6 or End of Treatment (EOT) whichever comes first, and at the time of progression or loss of response.
1575585|NCT02415608|Other|Pharmacological Studies|Pharmacological Study samples for PK analysis will be collected on cycle 1 day 1, Cycle Day 15, and Cycle 2 Day 1. Samples will be drawn pre-dose, and at 1,2,4, and 6 hours post dose.
1575589|NCT02415582|Other|Aerobic exercise|Aerobic exercise on treadmill
1575590|NCT02415582|Other|Combined exercises|Combined resistance and aerobic exercise
1575591|NCT02415582|Other|Control|45 minutes resting sitting
1575592|NCT02415569|Drug|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
1575593|NCT02415569|Drug|2L PEG-ELP and 10mg bisacodyl|Subjects whose bristol stool forms are type 1 or 2, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure and 10mg bisacodyl the day before procedure.
1575594|NCT02415569|Drug|Standard Bowel Prep (2L PEG-ELP)|Subjects whose bristol stool forms are type 3 to 7, will be asked to take standard bowel prep (2L PEG-ELP) the same-day of procedure.
1575597|NCT02415543|Procedure|SIL-TEP Inguinal Hernia Repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single incision
1575598|NCT02415543|Procedure|TEP Inguinal Hernia Repair|perform the multiport laparoscopic total extraperitoneal inguinal hernia repair
1575603|NCT02415504|Behavioral|Enhanced care transition|Enhanced care transition discharge package: (1) an integrated behavioural care plan, (2) an in-person discharge meeting including family, post-care transition staff (LTC or another hospital unit) and unit staff, (3) videos of responsive behaviours and non-pharmacological interventions, (4) a briefcase of favoured activities, (5) an in-person care demonstration, and (6) involvement of a transitional care team.
1575732|NCT02414594|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
1575604|NCT02415504|Behavioral|Standard care transition|Standard care transition discharge package: The standard care transition varies by unit, and either consists of: (1) a discipline specific care plan, (2) a phone discharge meeting between unit staff and post-care transition staff (LTC or another hospital unit) and (3) a follow-up phone call with social work OR (1) a discipline specific care plan, (2) an in-person meeting between unit staff and (family) caregivers, (3) involvement of a transitional care team, and (4) a follow-up phone call with social work.
1575605|NCT02415491|Other|Correlation Heart Magnetic Resonance Imaging at rest and stress with Cardiopulmonary stress test|"MRI of the heart, coronary arteries and pulmonary artery at rest and stress induced will be performed. Cine pictures are taken for evaluation of pulmonary perfusion.
Afterwards induced stress MRI will be performed according to standard protocol with elevation of dobutamine levels until the reach of peak HR. If applicable the procedure will be stopped) in case of e.g. arrhythmia.
Cardiopulmonary exercise stress test will be performed; patient will sit at rest on the ergometer, the subject's gas exchange will be recorded; with the pedal speed constant, the resistance will be increased from 0.5 watt/kg to 3 watt/kg over 10 minutes. Electrocardiography and heart rate will be taken continuously during and until 10 minutes afterwards. Blood pressure will be taken before, during and after the stress test. Respiratory gas exchange parameters will be taken continuously, peak oxygen uptake (VO2) determined as well as Ventilatory Efficiency."
1575606|NCT02415478|Other|endoscopic lung volume reduction by valves|"Independent of the study, subject will get a bronchoscopy with chartis measurement in general anaesthesia. chartis measurement is a Balloon angioplasty. Balloon will be well-positioned in lung and filled by air for occlusion of lobe of the lung. System recognizes collateral ventilation of lobe of the lung via calculation of airflow resistance.
Negative result allows the endoscopic placement of selfexpandig endobronchial valves in the subject lung. Inhale airflow will be inhibit an enclosed air and liquids can exhaust."
1575607|NCT02415465|Procedure|Continuous Adductor Canal Block|Continuous Adductor Canal Block (0.2% ropivacaine running at 6-8mL/hr)
1575608|NCT02415465|Procedure|General|General Intraoperative Anesthesia
1575609|NCT02415465|Procedure|Epidural|Epidural (0.1% bupivacaine with fentanyl 5 mcg/mL running at 6mL/hr with 1mL q15 bolus)
1575610|NCT02415465|Procedure|Spinal|Spinal Intraoperative Anesthesia
1575611|NCT02415452|Procedure|drug-eluting stent implantation|The DES contains Firebird , sirolimus-eluting stents, paclitaxel-eluting stents , or zotarolimus-eluting stents . Unfractionated heparin was used during percutaneous coronary intervention .A loading dose of 300 mg clopidogrel was given to all patients prior to PCI, followed by a maintenance dose of 75 mg daily for 12 months before it was stopped.
1575612|NCT02415439|Drug|VBP15|
1575613|NCT02415439|Drug|Placebo|
1575614|NCT02415426|Behavioral|Metacognitive Training Program during mild to moderate depression|Diagnostic and therapeutical interventions are not part of this study. As part of this study, the change of cognitive and psychosocial achievement/behavior in patients with mild to moderate depression after taking part in the training program is being investigated. The training program seeks to enable group members to recognize and correct the often automatic and unconscious thought patterns that accompany depression, in part by viewing this depressive thought process at a distance (i.e., depersonalizing). In addition, dysfunctional assumptions about one's thought processes, as well as dysfunctional coping-strategies (i.e., thought suppression, rumination as problem-solving) are targeted (Lena Jelinek & Steffen Moritz, http://clinical-neuropsychology.de/metacognitive_training_for_depression.html).
1575623|NCT02415387|Biological|typhoid vaccine|Given IM
1575624|NCT02415387|Other|Placebo|Given IM
1575625|NCT02415374|Other|Avenanthramides|AVAs are a group of diphenolic acids that are found only in oats (Avena sativa). In this study, each dietary group of subjects will receive three cookies made with oat flour containing high-AVA (H-AVA, 229.56 mg/kg) and low-AVA (L-AVA, 32.69 mg/kg).
1575627|NCT02415348|Device|Fibroscan|
1575628|NCT02415335|Drug|dexamethasone phosphate|Intravenously administration minimum of 30 minutes preoperatively.
1575629|NCT02415335|Drug|Isotonic NaCl|Intravenously administration minimum of 30 minutes preoperatively
1575630|NCT02415322|Other|refer to mental health specialists|children who have diagnosed internet and/or smartphone disorder by psychiatrists referred to mental health specialists
1575631|NCT02415309|Dietary Supplement|2 mg Melatonin|40 patients will randomly receive 2 mg melatonin
1575632|NCT02415309|Dietary Supplement|10mg Melatonin|40 patients will randomly receive 10 mg melatonin
1575633|NCT02415309|Other|Placebo|40 patients will randomly receive a placebo/sugar pill
1575634|NCT02415296|Other|stage 1|The first stage of the project aims at providing a general description of the behaviour of French online gamblers, especially defining a typology of online gamblers.
1575635|NCT02415296|Other|stage 2|The second stage of the project aims at checking that the criteria selected in the first stage lead to a correct prediction whether the gambler is problematic or not. Particularly, this stage aims at determining the best possible score (calculated from gambling data) for defining the gambler's status.
1575636|NCT02415296|Other|stage 3|The third stage of the project aims at clinically validating the screening model. Result from the screening model will be compared to the diagnostic obtained with a clinical interview.
1575637|NCT02415283|Device|¹³C-Octanoate Breath Test|Breath testing utilizing 13C is a safe, non-invasive means for measuring a certain pathway's metabolic rate. 13C is a stable, non-radioactive isotope which can be incorporated into a specific location within a test substrate so it would be released when the compound is metabolized by the liver. Hepatic metabolism of the compound is assessed by measuring the ratio of 13CO2/12CO2 in exhaled breath.
1575728|NCT02414620|Device|Generation II Dental Vibe Unit|. The Dental Vibe emits strong pulsed vibration which is transmitted via a silicone mouth piece to mucosal tissue.
1575729|NCT02414607|Biological|Elderberry Juice|
1575641|NCT02415257|Drug|Gentamicin|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
1575642|NCT02415244|Procedure|TEE|Spinal cord segments will be imaged using the TEE
1575643|NCT02415231|Behavioral|humor|
1575644|NCT02415218|Biological|Mucosal cell sheet transplantation|The subjects will have their oral mucosal tissues retrieved for cell sheet preparation. The mucosal cell sheet will be transplanted over the affected cornea.
1575645|NCT02415192|Drug|Levacalm|
1575646|NCT02415192|Drug|Valsartan/amlodipine|
1575651|NCT02415153|Other|Laboratory Biomarker Analysis|Optional correlative studies
1575652|NCT02415153|Other|Pharmacological Study|Correlative studies
1575653|NCT02415153|Drug|Pomalidomide|Given PO
1575654|NCT02415140|Other|Rate of depression|
1575655|NCT02415127|Drug|Interferon γ-1b|Approximately 45 subjects will receive subcutaneous (SC) doses of ACTIMMUNE® three times a week (TIW) for a total of 26 weeks. The study drug dose is planned to be escalated on a weekly basis over the first 4 weeks of treatment (from 10 µg/m² to 25, 50, and 100 µg/m²). The dose may be reduced, interrupted, or held based on tolerability. By week 13, all subjects are to be on a stable tolerated dose of study drug in order to continue study participation; the dose may not be further increased after week 13, however, it may be reduced on a case-by-case basis to manage drug-related AEs.
1575656|NCT02415127|Drug|Placebo|Approximately 45 subjects will receive subcutaneous (SC) doses of placebo three times a week (TIW) for a total of 26 weeks. The volume of placebo is planned to correspond with volume of study drug that would be given to the patient if the patient was randomized to the study drug arm.
1575657|NCT02415114|Dietary Supplement|Omega Q Plus Resveratrol (with 50mg CoQ10)|Omega Q Plus Resveratrol (with 50mg CoQ10)
1575658|NCT02415101|Procedure|Resective surgery|
1575659|NCT02415088|Procedure|Interscalene block|block of the plexus brachialis in the interscalene region with local anaesthetics
1575660|NCT02415088|Procedure|Selective shoulder block|selective block of the suprascapular nerve and the axillary nerve with local anaesthetics
1575661|NCT02415075|Behavioral|medical rehabilitation|Participants who will take part in the study are asked to fill out a questionnaire when arriving at the rehabilitation clinic and will be invited to participate in two motivational telephone interviews after six and 12 months.
1575662|NCT02415062|Drug|Donepezil|23mg/day for 24 weeks versus 10mg/day for 24 weeks
1575663|NCT02415049|Other|Incremental Feeds|This arm of patients will be fed in the traditional standard of care manner following pyloromyotomy. They start with 15ml of pedialyte and advance by 15ml increments of formula or breastmilk to a goal of 100ml/kg/day
1575664|NCT02415049|Other|Ad lib feeds|This arm of patients will be fed ad lib following pyloromyotomy. They will be allowed to eat as frequently as they desire based on infant cues to a goal of 12.5ml/kg/feed
1575665|NCT02415036|Device|Delcath Hepatic Delivery System|
1575666|NCT02415036|Drug|Melphalan|
1575667|NCT02415023|Drug|fruquintinib+paclitaxel|28-day cycle of fruquintinib qd for 3 weeks followed by 1-week break combined with paclitaxel 80 mg/m2
1575668|NCT02415010|Device|Enterprise 2 Vascular Reconstruction Device|
1575669|NCT02414997|Procedure|RIPC|Surround left upper limb with cuff, inflate cuff to 200mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
1575670|NCT02414997|Procedure|Sham RIPC|Surround left upper limb with cuff, inflate cuff to 20mmHg and maintain 5 minutes, than deflate to 0mmHg. Change to right upper limb and repeat the procedure described above. Change back to left upper limb and repeat the same procedure. Perform once a day ( Thus 15 minutes a day).
1575671|NCT02414984|Biological|Golimumab|This is an observational study. Participants with rheumatoid arthritis in Colombia will be observed for 24 months.
1575672|NCT02414971|Other|There is no intervention|There is no intervention
1575673|NCT02414958|Drug|Empagliflozin|
1575674|NCT02414958|Drug|Empagliflozin|
1575675|NCT02414958|Drug|Placebo|
1575676|NCT02414945|Drug|Cyclophosphamide|
1575677|NCT02414945|Drug|Fludarabine|
1575678|NCT02414945|Biological|Autologous tumor infiltrating lymphocytes (TILs)|
1575679|NCT02414945|Biological|Interleukin-2|
1575680|NCT02414932|Drug|Ketamine|Ketamine hydrochloride 0.5 mg/kg; Pfizer Healthcare Ireland
1575681|NCT02414932|Drug|Midazolam|Midazolam 0.045 mg/kg; Roche Products Ireland Ltd
1575682|NCT02414919|Drug|Mirena (Levonorgestrel IUS, BAY86-5028)|Levonorgestrel-releasing intrauterine device 20 mcg/day
1575683|NCT02414919|Drug|ParaGard|Copper T380A
1575684|NCT02414919|Drug|Implanon/Nexplanon|Etonorgestrel contraceptive implant
1575685|NCT02414906|Other|Goal-directed therapy|Goal-directed therapy with fluids and dobutamine
1575686|NCT02414893|Procedure|Sleeve gastrectomy|Laparoscopic vertical gastrectomy as a bariatric procedure.
1575687|NCT02414880|Drug|Sugammadex|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of sugammadex 2mg/kg.
1575730|NCT02414607|Other|Placebo|
1575688|NCT02414880|Drug|Neostigmine|Rocuronium-induced neuromuscular blockade will be reversed at the end of the operation when two responses to train-of-four ulnar nerve stimulation are detected (T2) by injection of neostigmine 50 micro-gram/kg combined with atropine 20 micro-gram/kg.
1575689|NCT02414880|Drug|Rocuronium|An intubating dose of Rocuronium (0.6 mg/kg) will be given with induction of anesthesia and the degree of muscle relaxation will be evaluated through out the operation by recording the response of the hand muscles to train-of-four ulnar nerve stimulator (Mechanosensor Neuromuscular Transmission Module of General Electric AISYS Anaesthesia machine USA) according to the Good Clinical Research Practice (GCRP) guidelines for pharmacodynamic neuromuscular studies. Muscle relaxation will be maintained by additional top-up doses of Rocuronium (0.15mg/kg) which will be administered after detection of the first response to TOF stimulation (T1).
1575690|NCT02414854|Drug|Dupilumab|"Pharmaceutical form:solution
Route of administration: subcutaneous"
1575691|NCT02414854|Drug|placebo|"Pharmaceutical form:solution
Route of administration: subcutaneous"
1575694|NCT02414828|Biological|Placebo|This is the identical buffer solution in which AERAS-402 is formulated. The placebo (1.0 mL volume) was administered by intramuscular (IM) injection to the deltoid area on Study Day 0 for groups 1 and 2 and Study Day 0 and 42 for group 3.
1575695|NCT02414828|Biological|AERAS-402 3 x 10^8 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
1575696|NCT02414828|Biological|AERAS-402 3 x 10^9 vp|AERAS-402 was administered by single intramuscular (IM) injection to the deltoid area on Study Day 0
1575697|NCT02414828|Biological|AERAS-402 3 x 10^10 vp|AERAS-402 was administered by intramuscular (IM) injection to the deltoid area on Study Days 0 and 42.
1575698|NCT02414815|Device|Monophasic action potential(MAP) catheter|After ordinary procedure for electrophysiologic study or catheter ablation, the investigators will replace conventional catheter to monophasic action potential (MAP) recording catheter through right femoral sheath. MAP recording catheter is introduced to endocardial surface of atrium, and we record atrial MAP at variable pacing cycle lengths: steady state cycle lengths of 600, 400, 300, 240, 220, 240, 260, 300, 400 and 600 ms. At each cycle length, pacing was applied for 20 sec. It takes less than 5 min to acquire MAP recordings.
1575699|NCT02414802|Device|a manual spiral thrombus broken suction device|A manual spiral thrombus broken suction device will be used for thrombectomy before catheter-directed thrombolysis
1575700|NCT02414802|Procedure|catheter-directed thrombolysis|catheter-directed thrombolysis will be used in both arms
1575701|NCT02414802|Drug|low-molecular-weight heparin calcium|anticoagulation therapy will be administered via subcutaneous injection of low-molecular-weight heparin calcium (LMWH-Ca 5,000 U/12 h) in both arms at discharge
1575702|NCT02414802|Drug|urokinase|A total of 100,000 units urokinase once every 4-6 hours will be used during catheter-directed thrombolysis therapy
1575703|NCT02414789|Procedure|Skin biopsies|Skin biopsies of patients with Lyme disease (erythema migrans) infected with Borrelia burgdorferi sensu lato will be analyzed by three diagnostic techniques : molecular technique (PCR), biological technique (culture of the bacteria) and proteomics technique (SRM/ MS-MS)
1575704|NCT02414776|Drug|hydroxychloroquine|administration of hydroxychloroquine in combination with the current hormonal therapy
1575705|NCT02414763|Behavioral|Teachable Moment Brief Intervention|functional analysis, collaborative interpersonal style
1575706|NCT02414750|Drug|Vemurafenib plus cobimetinib|Molecular targeted therapy for BRAF mutated advanced melanoma patients
1575707|NCT02414750|Device|Positron Emission Tomography|Patient will need to undergo FDG and FLT PET scanning before and during treatment, and at time of progression
1575708|NCT02414750|Procedure|Tissue sampling|Before and during treatment and at time of progression patients will undergo tissue sampling of a melanoma lesion
1575709|NCT02414750|Procedure|Blood sampling|Before and during treatment and at time of progression patients will undergo blood sampling
1575710|NCT02414737|Drug|corifollitrophin alfa|use of a single dose of corifollitrophin alfa to provide adequate controlled ovarian hyperstimulation during IVF treatment
1575711|NCT02414724|Drug|Gemcitabine Hydrochloride|Given IV
1575712|NCT02414724|Other|Laboratory Biomarker Analysis|Correlative studies
1575713|NCT02414724|Other|Pharmacological Study|Correlative studies
1575714|NCT02414724|Drug|Ribociclib|Given PO
1575715|NCT02414711|Other|HSCL25 scale|The patient must answer to 25 questions of the HSCL25 scale. In function of the results, the patients was diagnosed depressed (≥1.75) or not depressed (<1.75)
1575716|NCT02414711|Other|PSE9 questionary|On the 900 patients recruited, 50 patients who was diagnosed depressed or no depressed have to have a psychological interview with the PSE9 questionary to validate the first diagnosis done by the HSCL25 scale
1575717|NCT02414698|Procedure|Percutaneous Hydrodiscectomy|The HydroD uses a thin supersonic stream of water to cut, ablation, remove disc material percutaneously via a skin puncture.
1575718|NCT02414698|Drug|TESI|Transforaminal epidural steroid injections given in the lumbar spine.
1575719|NCT02414685|Drug|Paclitaxel|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
1575720|NCT02414685|Drug|Ifosfamide|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
1575721|NCT02414685|Drug|Cisplatin|paclitaxel, ifosfamide, cisplatin until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements
1575722|NCT02414672|Behavioral|CareSTEPS|Caregivers receive a workbook and 6 one-hour telephone sessions with a trained interventionist.
1575723|NCT02414659|Procedure|Umbilical cord blood collection, in-utero|Umbilical cord blood was collected during cesarean, after delivery of the baby and after clamping of the cord. Blood was collected into a standard blood donation bag with (Capacity: 450 mL) a 16 G venipuncture needle. Needle was left in place after umbilical vein is collapsed and no more blood flow happens spontaneously.
1575724|NCT02414646|Other|Laboratory Biomarker Analysis|Correlative studies
1575725|NCT02414646|Other|Quality-of-Life Assessment|Ancillary studies
1575726|NCT02414646|Other|Questionnaire Administration|Ancillary studies
1575727|NCT02414646|Biological|Trastuzumab Emtansine|Given IV
1575733|NCT02414581|Drug|chlorhexidine 0.12%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 0.12%-based solution
1575734|NCT02414581|Drug|Ethyl Alcohol 7%|Mouth rinses with Ethyl Alcohol 7%-based solution
1575735|NCT02414581|Drug|Chlorhexidine 2%/Ethyl alcohol 7%|Mouth rinses with chlorhexidine 2%-based solution
1575736|NCT02414568|Drug|Bendamustine|Bendamustine 120 mg/m2 (IV) Day 1
1575737|NCT02414568|Drug|Prednisone|Prednisone 40 mg/m² PO
1575738|NCT02414568|Drug|Vinblastine|Vinblastine 6 mg/m² IV
1575739|NCT02414568|Drug|Doxorubicin|Doxorubicin 40 mg/m² IV
1575740|NCT02414555|Drug|vasopressor|Patients receive oesophageal doppler-based hemodynamic support either with fluid or with vasopressor
1575741|NCT02414555|Drug|fluid bolus|
1575742|NCT02414555|Device|oesophagus doppler (CardioQ)|
1575743|NCT02414555|Drug|Normal Saline|
1575744|NCT02414555|Device|arterial cannulation|
1575745|NCT02414555|Device|intravenous peripheral line insertion (17 gauge)|for fluid bolus administration
1575746|NCT02414555|Drug|Elo-Mel Isoton (balanced acetat-based infusate)|
1575747|NCT02414542|Device|MINIMA stem|
1575748|NCT02414529|Drug|Vitamin D2|Ergocalciferol 5000 units capsules given. 300,000 units PO once.
1575749|NCT02414529|Drug|Placebo|
1575750|NCT02414516|Drug|OBP-801|OBP-801 will be administered IV
1575751|NCT02414503|Drug|8IU intranasal oxytocin|
1575752|NCT02414503|Drug|24IU intranasal oxytocin|
1575753|NCT02414503|Drug|Placebo|
1575754|NCT02414503|Device|OptiNose Breath Powered Bi|
1575755|NCT02414490|Drug|Intravenous Immunoglobulin|The decision to treat with IVIg will be entirely at the discretion of the patient's treating physician.
1575756|NCT02414477|Drug|Deuterated NNN|Smokeless tobacco study product
1575757|NCT02414464|Other|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.
Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP 35% gel was applied to the vestibular faces of these teeth.
In the present study, the Whiteness HP 35% gel was applied without an external auxiliary source. As this is not a self-catalyzed system, the gel was removed after each 15-minute application and reapplied two more times, totaling 45 minutes of contact with the teeth."
1575758|NCT02414464|Other|35% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.
Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 35% gel was applied to the vestibular faces of these teeth for 40 minutes in each session."
1575759|NCT02414464|Other|20% hydrogen peroxide|"Prophylaxis was performed with a jet of sodium bicarbonate to remove extrinsic pigments and plaque.
Each patient underwent two bleaching sessions. A lip retractor (Arc Flex, FGM®) was placed. Cotton roles or gauze compresses were used to achieve relative isolation. A dental dam (Top Dam, FGM®) was placed over the free marginal gingival tissue and the inter-tooth papillae of teeth 14 to 24 in each session. The Whiteness HP Blue Calcium 20% gel was applied to the vestibular faces of these teeth 50 minutes in each session."
1575760|NCT02414451|Drug|Propranolol|Week 1: 40 mg propranolol (1 capsule, nightly) Week 2: 80 mg propranolol (2 40mg capsules, morning & night) Weeks 3 - 8: 100 mg propranolol (3 capsules, 40 mg/morning, 20mg/afternoon, & 40mg/night) Week 9: 60 mg propranolol (2 capsules, 40 mg/morning & 20mg/night) Week 10: 20 mg propranolol (1 capsule, nightly) Week 11: no capsules
1575761|NCT02414451|Drug|Placebo|"Placebo will be administered via lactose-filled oral capsule(s) daily for a period of 10 weeks. The schedule of placebo administration will be as follows:
Week 1: 1 capsule, nightly Week 2: 2 capsules, morning & night Weeks 3 - 8: 3 capsules, morning, afternoon, & night Week 9: 2 capsules, morning & night Week 10: 1 capsule, nightly Week 11: no capsules"
1575762|NCT02414438|Other|FirstStepDX PLUS and NextStepDX PLUS Webinar|A pre-recorded 20-minute webinar on FirstStepDX PLUS and NextStepDX PLUS
1575763|NCT02414438|Other|FirstStepDX PLUS and NextStepDX PLUS Test Results|Physicians receive a prompt to order and download FirstStepDX PLUS and NextStepDX PLUS Test Results
1575764|NCT02414425|Procedure|Rectoscopy|A rectoscopy will be performed for Botulinum toxin A or physiologic serum injection
1575765|NCT02414425|Procedure|Anorectal manometry|Anorectal manometry will be performed to evaluate efficacy of Botulinum toxin A or physiologic serum rectal injection
1575766|NCT02414425|Drug|Botulinum toxin A or physiologic serum injection|Botulinum toxin A or physiologic serum injection is performed during rectoscopy
1575767|NCT02414412|Dietary Supplement|Ulmus macrocarpa water extract|
1575768|NCT02414399|Drug|Azithromycin|oral administration of Azithromycin
1575769|NCT02414399|Drug|Placebo|5 days of taste/appearance/bottle-matched inactive substance
1575770|NCT02414386|Other|biospecimen retention|biospecimen retention to measure vitamin D, parathormone, calcium, magnesium, phosphate, globulin, albumin plasma levels
1575771|NCT02414373|Drug|Ropivacaine 2mg/ml|local anesthetics, which will epidurally administered
1575772|NCT02414373|Drug|Bupivacaine|local anesthetics, which will epidurally administered
1575773|NCT02414373|Device|6 French transurethral dual channel catheter (Gaeltec, Dunvegan, Scotland)|
1575774|NCT02414373|Device|14 French rectal balloon catheter (Gaeltec, Dunvegan, Scotland)|
1575775|NCT02414360|Other|Shortened Format|Shortened format of a systematic review
1575776|NCT02414360|Other|Full Length|Full length systematic review
1575777|NCT02414347|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
1575778|NCT02414334|Radiation|Stereotactic Ablative Radiotherapy (SABR)|
1575779|NCT02414308|Drug|Adipose tissue stem cell injection|Stem cell will be harvested through adipose tissue by liposuction and isolation occurred Injection will distribute through corpora cavernosa and dorsal penile artery
1575780|NCT02414295|Drug|Mesenchymal stem cell injection|Aspirated bone marrow then separation for Mesenchymal stem cell
1575781|NCT02414282|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
1575784|NCT02414256|Other|regional anesthesia in breast surgery|In the Hospitals involved in this study are performed routinely wall blocks (PECS I-II blocks and serratus block) during breast surgery
1575785|NCT02414243|Other|New Amino Acid formula|Ordesa's Amino-Acid based Infant Formula
1575786|NCT02414243|Other|Commercially available Amino Acid Formula|Commercially available Amino Acid Formula
1575787|NCT02414230|Drug|Drug: F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
1575788|NCT02414217|Behavioral|In-Person Diabetes Numeracy Education|"Participants randomized to the in-person education group attended four group classes, each addressing a specific set of diabetes self-care skills (i.e., understanding and using blood glucose numbers, counting carbohydrates, taking medications at the right dose and time). So that each class included a stable group of 8 and 16 participants, we ran classes in cohorts of 8-16 people. A participant always attended classes with his/her cohort."
1575789|NCT02414217|Behavioral|Online Diabetes Numeracy Education|Participants randomized to the online education group attended a single session, at which he/she completed a computerized education module that addressed understanding blood sugar values and using them to examine the impact of food, exercise, and medicines on blood sugar.
1575790|NCT02414204|Drug|Sildenafil|Sildenafil, a phosphodiesterase 5 inhibitor that enhances the effects of nitric oxide (NO), has been shown in experimental and clinical studies in cardiovascular disease to improve endothelial function and decrease vascular stenosis.
1575791|NCT02414204|Other|Placebo|Placebo will be over encapsulated to identical to drug comparison
1575792|NCT02414191|Behavioral|Benchmarked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of benchmarked feedback, which is the measure of their performance in comparison the standard set by the hospital.
1575793|NCT02414191|Behavioral|Ranked Feedback|Participants receive data, during the 6 month intervention phase, regarding their monthly temperature management performance in the form of ranked feedback, which is the measure of their performance in comparison to their peers.
1575794|NCT02414178|Drug|F 18 T807|Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
1575800|NCT02414152|Drug|anakinra|100mg of anakinra adminstered by a subcutaneous injection for a minimum of 28 days, retreatment with additional 28 day cycle based on clinical response
1575801|NCT02414139|Drug|INC280 (capmatinib)|
1575802|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours
st period: Spontaneous breathing for 10 minutes
nd period: CPAP for 10 minutes
rd period: Spontaneous breathing for 10 minutes to check the return to baseline.
After each period, the following parameters will be recorded during 5 minutes:
oesogastric pressures
air flow
gas exchange
right and left cardiac function
Patients > 6 years old will assess their dyspnea on a visual analogue scale"
1575803|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours
st period: Spontaneous breathing for 10 minutes
nd period: CPAP for 10 minutes
rd period: Spontaneous breathing for 10 minutes to check the return to baseline.
After each period, the following parameters will be recorded during 5 minutes:
oesogastric pressures
air flow
gas exchange
right and left cardiac function
Patients > 6 years old will assess their dyspnea on a visual analogue scale"
1575804|NCT02414126|Other|Effect of CPAP on respiratory work and cardiac function indices during wakefulness|"Comparison of three periods of 3 hours
st period: Spontaneous breathing for 10 minutes
nd period: CPAP for 10 minutes
rd period: Spontaneous breathing for 10 minutes to check the return to baseline.
After each period, the following parameters will be recorded during 5 minutes:
oesogastric pressures
air flow
gas exchange
right and left cardiac function
Patients > 6 years old will assess their dyspnea on a visual analogue scale"
1575805|NCT02414126|Device|CPAP|
1575806|NCT02414100|Other|Laboratory Biomarker Analysis|Correlative studies
1575807|NCT02414100|Other|Cytology Specimen Collection Procedure|Correlative studies
1575855|NCT02413710|Behavioral|Dietary Guidance|Subjects will be instructed on the 2010 Dietary Guidelines for Americans including publically available information from the United States Department of Agricultural (USDA) MyPlate program (www.choosemyplate.gov). Subjects in this intervention group will not receive study provided foods.
1575808|NCT02414087|Device|ICB Medical insoles|"Study group:
Participants in the study group will be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months.
Control group:
Participants in the control group will not be prescribed with customized full-length insoles (ICB Medical) to keep the subtalar joint in neutral position, using self chosen comfortable shoes, for 3 months"
1575809|NCT02414074|Behavioral|Youth Behavioral Intervention|Teen Intervene is an early intervention program for 12-19 year olds.
1575810|NCT02414074|Behavioral|Parent Education|Everyday Parenting is a parent training curriculum.
1575811|NCT02414061|Dietary Supplement|Whey Protein (Arla Foods Ingredients Group)|20 g whey protein isolate added to breakfast meal
1575812|NCT02414061|Other|Breakfast meal|Carbohydrate breakfast served as a standard portion (1799 kJ, 93/2/9% energy from carbohydrate/fat/protein)
1575813|NCT02414048|Drug|Pimonidazole|Pimonidazole will be administered orally and will serve to demarcate the hypoxic areas in the tumour
1575814|NCT02414009|Drug|Capecitabine|
1575815|NCT02414009|Drug|Temozolomide|
1575816|NCT02414009|Drug|Irinotecan|
1575817|NCT02414009|Drug|Fluorouracil|
1575818|NCT02414009|Drug|Leucovorin|
1575819|NCT02413996|Device|Kinetec® knee continuous passive motion (CPM )|CPM of the knee
1575820|NCT02413996|Behavioral|Functional activities|Stairs, walking
1575821|NCT02413996|Other|VRRS rehabilitation|exercise therapy through a virtual reality rehabilitation system (VRRS)
1575822|NCT02413996|Other|traditional rehabilitation|exercise therapy through a traditional rehabilitation training made by physiotherapists
1575823|NCT02413983|Procedure|hepatectomy conventional incision|This study was a single center, nonrandomized, observational comparative analysis of 3 different surgical technique. Three surgical teams operated alternately at our center, and donors undergoing hepatectomy via three different incision
1575824|NCT02413983|Procedure|hepatectomy midline incision|
1575825|NCT02413983|Procedure|hepatectomy transverse incision|
1575826|NCT02413970|Device|Inspire® UAS System|This is a single-arm study; all participants will be implanted with the Inspire® UAS System, which is a permanent, implantable therapy that consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the study subject receives a remote control to activate the therapy.
1575827|NCT02413957|Other|Medication Reconciliation|Pharmacist take the best possible medication history (BPMH), comparison of the BPMH with the admission order (AMO), clarify and solve al discrepancies between the BPMH and the AMO.
1575828|NCT02413957|Other|Pharmaceutical Care|Checking medication under safety considerations (medication at admission, during hospital stay, at discharge); recommendations for inappropriate medication (e.g. contraindications or interactions) or medication related problems. Pharmaceutical care includes Medication Reconciliation.
1575829|NCT02413944|Procedure|ACTH stimulation test|ACTH stimulation test
1575830|NCT02413931|Other|Routine management practices applied|all patients will be treated according to routine procedures, no intervention
1575832|NCT02413905|Biological|Stool samples|Stool samples
1575833|NCT02413879|Device|CleanCision|Wound protection during colorectal surgery.
1575834|NCT02413866|Behavioral|Calorie restriction only|Participants randomly assigned to this group will be instructed to reduce their daily energy intake to 95% of their resting metabolic rate.
1575835|NCT02413866|Behavioral|Sleep & calorie restriction|Participants randomly assigned to this group will be instructed to reduce their total time in bed by 90 minutes 5 days a week, in addition to restricting their dietary intake to approximately 95% of their resting metabolic rate.
1575836|NCT02413853|Drug|CBP/beta-catenin Antagonist PRI-724|Given IV
1575837|NCT02413853|Biological|Bevacizumab|Given IV
1575838|NCT02413853|Drug|Leucovorin Calcium|Given IV
1575839|NCT02413853|Drug|Oxaliplatin|Given IV
1575840|NCT02413853|Drug|Fluorouracil|Given IV
1575841|NCT02413853|Other|Laboratory Biomarker Analysis|Correlative studies
1575842|NCT02413840|Behavioral|Baduanjin qigong|
1575843|NCT02413827|Drug|Combination of varlilumab and ipilimumab|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.
Phase l dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg or 3 mg/kg. Ipilimumab dose is 3 mg/kg."
1575844|NCT02413827|Drug|Cohort A: varlilumab & ipilimumab; Cohort B: varlilumab, ipilimumab, CDX-1401 & poly-ICLC|"Eligible patients will receive assigned treatments once every 3 weeks for a total of 4 treatments.
Phase ll dose: The planned dose of varlilumab will be established from Phase I. Ipilimumab dose is 3 mg/kg. Patients assigned to receive CDX-1401 will receive a dose of 1 mg along with 2 mg poly-ICLC."
1575845|NCT02413814|Behavioral|Anger Reduction Treatment|Eight 30-minute sessions of interpretation modification to reduce angry interpretation biases.
1575846|NCT02413814|Behavioral|Control Condition|Eight 30-minute sessions of informative videos on healthy living and relaxation videos.
1575847|NCT02413788|Other|aerobic exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate)
1575848|NCT02413788|Other|combined exercise|aerobic training 40 minutes on a treadmill (60-80% of maximum heart rate); resisted training in equipment and free weights for 10 minutes with a set of 10 repetitions in quadriceps, triceps and biceps of the arms and legs
1575849|NCT02413788|Device|treadmill|
1575850|NCT02413762|Other|No intervention|No intervention
1575851|NCT02413736|Drug|Imatinib|Imatinib 400 mg/day
1575852|NCT02413723|Device|Videolaryngoscope|McGrath Mac videolaryngoscope will be use for first attempt of intratracheal intubation.
1575853|NCT02413723|Device|Standard laryngoscope|Macintosh laryngoscope will be use for first attempt of intratracheal intubation.
1575854|NCT02413710|Other|Soy protein containing foods|Daily consumption of 2 food products, each providing 15g of soy protein per day.
1575856|NCT02413697|Device|Two-dimensional ultrasound|Two-dimensional ultrasound guided embryo transfer
1575857|NCT02413697|Device|Three-dimensional ultrasound|Three-dimensional ultrasound guided embryo transfer
1575859|NCT02413671|Dietary Supplement|Lupin Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with lupin protein.
1575860|NCT02413671|Dietary Supplement|Whey Protein|Subjects received a standardized test meal rich in carbohydrates and supplemented with whey protein.
1575861|NCT02413671|Other|Reference|Subjects received a standardized test meal rich in carbohydrates and not supplemented with any protein.
1575862|NCT02413658|Drug|Phenytoin|Topical use of phenytoin solution on dressings of split thickness skin graft sites.
1575863|NCT02413658|Drug|Sugar solution|
1575869|NCT02413632|Other|creation of a STIs score risk|4 questionnaires 3 screening test ( syphilis, chlamydia, gonorrhea)
1575870|NCT02413632|Other|validation of a STIs score risk|DRIVER questionnaire (DRIVER STI score risk) 3 screening test ( syphilis, chlamydia, gonorrhea)
1575871|NCT02413619|Procedure|Vitrectomy|Vitrectomy
1575872|NCT02413619|Procedure|Cataract surgery|Cataract surgery
1575873|NCT02413619|Procedure|Combined surgery|Combined vitrectomy and cataract surgery at the same time
1575874|NCT02413606|Other|Reduced follow-up schedule|In the intervention group, the follow-up schedule will be limited to four follow-up visits at 3, 12, 24 and 36 months, under the specific condition that patients have easy and prompt access to care (specialised nurse of gynaecologist) if symptoms or questions occur. The content of the follow-up visits will be similar for both groups.
1575875|NCT02413593|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
1575876|NCT02413593|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1575877|NCT02413580|Biological|IGIV-C|an IV dose of 2 g/kg of IGIV-C will be administered as 2 doses of 1 g/kg on two consecutive days
1575878|NCT02413567|Device|DMR Procedure (Fractyl)|Endoscopic procedure
1575882|NCT02413528|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
1575883|NCT02413528|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
1575884|NCT02413515|Drug|Nifedipine (Adalat GITS, BAY1040)|Nifedipine GITS 60 mg tablet, once daily, oral intake, for 8 weeks treatment
1575885|NCT02413502|Biological|BCG|BCG Vaccine USP attenuated live culture for percutaneous use (Merck) at 1-8 x 10^8 CFUs.
1575886|NCT02413489|Drug|Daratumumab|Daratumumab 16 mg/kg will be administered as intravenous infusion to participants once every week for 8 weeks; then once every other week for 16 weeks; thereafter once every 4 weeks until documented progression, unacceptable toxicity, or study end.
1575887|NCT02413476|Procedure|Robotic-assisted Gastrectomy(RAG)|Surgical procedure will be performed with da vinci Surgical System.The type of reconstruction will be selected according to the surgeon's experience.
1575888|NCT02413476|Procedure|Laparoscopic-assisted Gastrectomy(LAG)|Surgical procedure will be performed with laparoscopic techniques.The type of reconstruction will be selected according to the surgeon's experience.
1575889|NCT02413463|Procedure|augmented recession|medial rectus muscle recession using augmented formula ( average of the distance angle with correction and the near angle without correction)
1575890|NCT02413463|Procedure|Faden|medial rectus muscle recession (using the distance angle with correction) with posterior scleral fixation( Faden)
1575891|NCT02413437|Other|CEUS guided biopsy|Biopsy was operated under contrast-enhanced ultrasound-guided.
1575892|NCT02413437|Other|US guided biopsy|Biopsy was operated under conventional ultrasound-guided.
1575893|NCT02413437|Device|Ultrasound|
1575894|NCT02413424|Dietary Supplement|Sucralose|60 ml of 2mM sucralose
1575895|NCT02413424|Other|Water|60 ml of water
1575896|NCT02413424|Dietary Supplement|glucose load|
1575897|NCT02413411|Behavioral|DA/MI Intervention|Patients randomized to the DA/MI intervention arm will be shown a decision aid video entitled, Treatment Choices for Knee Osteoarthritis. Following the viewing of the decision aid video, the participant will be engaged in a motivational interview by the research study interventionist.
1575898|NCT02413411|Behavioral|an educational program (an NIH-developed booklet)|
1575901|NCT02413385|Behavioral|HealtheSteps Program|6-month evidence-based lifestyle Rx program: At set time points over the 6-month period, participants have in-person visits with a HeS coach at the clinic setting. At each in-person session, the participant receives an individualized Rx for exercise, physical activity (step count) and healthy eating. The HeS Coach and participant then engage in a coaching/goal setting conversation to set detailed plans and goals to achieve their prescriptions. Participants independently choose which activities they will take part in to achieve their lifestyle Rx's and goals. In between in-person sessions, the participants have access to a suite of free-of-charge health technology support tools to: a) track their exercise, physical activity, and healthy eating; and b) receive virtual coaching and support.
1575907|NCT02413346|Drug|Sarecycline|Administered based on patient body weight.
1575908|NCT02413333|Device|Clear Care Plus contact lens solution|3% hydrogen peroxide solution with Hydraglyde Moisture Matrix for cleaning, disinfection and overnight storage of contact lenses
1575909|NCT02413333|Device|PeroxiClear contact lens solution|3% hydrogen peroxide solution for cleaning, disinfection and overnight storage of contact lenses
1575910|NCT02413333|Device|Silicone hydrogel contact lenses|2-week/monthly replacement contact lenses per participant's habitual brand
1575917|NCT02413294|Device|Re-Timer glasses|Participants will wear the Re-timer glasses for 30 minutes a day according to their sleep chronotype in weeks 3 and 4 of the study.
1575918|NCT02413281|Drug|ALKS 5461|Sublingual tablets, single administration
1575919|NCT02413281|Drug|Buprenorphine|Sublingual tablets, single administration
1575920|NCT02413281|Drug|Placebo|Sublingual tablets, single administration
1575921|NCT02413268|Drug|Nitroglycerin|
1575922|NCT02413255|Drug|TAK-020|TAK-020 oral solution
1575923|NCT02413255|Drug|TAK-020 Placebo|TAK-020 placebo-matching oral solution
1575925|NCT02413229|Drug|DSXS1411|DSXS (Taro Pharmaceuticals Inc.)
1575926|NCT02413229|Drug|Placebo|Placebo (vehicle) (Taro Pharmaceuticals Inc.)
1575927|NCT02413216|Behavioral|TicHelper|TicHelper.com is an 8-week online program designed to teach tic management skills. Content and activities included in TicHelper.com are based on existing empirically-supported treatments including Habit Reversal Training (HRT) and Comprehensive Behavioral Intervention for Tics (CBIT). TicHelper.com is designed to teach tic management skills including psychoeducation, relaxation training, awareness training, competing response training, and social support. It is also designed to teach patients/parents to recognize and reduce tic-exacerbating reactions and activities.
1575928|NCT02413216|Other|Internet Based Resources|The Internet-Based Resources (IBR) condition is designed to provide patients/parents with access to a wide range of educational materials. These materials contain up-to-date information regarding what is known about tic disorders and their management. Materials covering medical, educational, and behavioral/psychological topics are provided.
1575929|NCT02413203|Drug|Celecoxib|Blood and urine collections before and 3 hours after celecoxib administration.
1575930|NCT02413203|Drug|Placebo|Blood and urine collections before and 3 hours after placebo administration.
1575931|NCT02413177|Behavioral|EEG-no RTNF|All EEG sessions are done on an individual basis. Group 2 will receive EEG (no RTNF) at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
1575932|NCT02413177|Behavioral|EEG-RTNF|All EEG sessions are done on an individual basis. Group 1 will receive EEG-RTNF training from the PCC at weeks 3, 4, 6, and 7 of MBSR. At these time points, subjects will take part in a 1-hour EEG-RTNF session., comprised of six 3.5-minute runs. Each run will begin with a 30-second active baseline task in which subjects view adjectives and think about and decide if the word describes them. Following baseline, subjects will meditate for 3 to 7 minutes with EEG-RTNF. All subjects will be instructed to practice meditation during EEG-RTNF training, and to keep their eyes closed.
1575933|NCT02413164|Other|A multimodal physiotherapy programme|"Intervention group: One-hour sessions will be conducted two times per week during 12 weeks, consisting of An individualised Multimodal Physiotherapy Programme (MMPP) of therapeutic exercises combined with education healthy-style-of-life based.
Each session will be comprised of 60 min of land-based exercise. Land-based exercise included 10 minute of warm up, 25 minutes of a individual aerobic circuit-training, 15 min of full-body mobility and strecthing exercises and 10 minutes of warm-down.
Control group: care as usual"
1575936|NCT02413138|Drug|Somavaratan (VRS-317)|Long acting recombinant human growth hormone
1575937|NCT02413125|Device|ChitoRhino irrigation solution|ChitoRhino irrigation solution has been developed with chitosan, a natural polysaccharide demonstrated to have antibacterial and antifungal properties. This polysaccharide has beneficial properties in multiple clinic applications including wound healing and post-operative sinus surgery. Chitosan's antimicrobial function develops from its polycationic structure. Chitosan interacts with the negatively charge bacterial wall, leading to disruption and cell lysis.
1575938|NCT02413125|Drug|Normal saline|Most nasal irrigations use normal saline (0.9% sodium chloride), which approximates the physiological concentration of plasma in the blood. The saline solution is used to flush the nose of mucous and allergens.
1575939|NCT02413112|Behavioral|Resistance training|"Whole-body resistance training in the University gym that is supervised by researchers.
Training once per week, Training twice per week, Training thrice per week."
1577783|NCT02400099|Dietary Supplement|Control low calorie diet|
1990734|NCT01851642|Procedure|History and physical exam.|At every study visit, participant's will be asked about their medical history and will have a physical exam.
1990735|NCT01851642|Procedure|Blood draw.|At each study visit, participants will have an intravenous catheter (IV) placed in one of their veins and blood will be drawn from the IV for study testing.
1990736|NCT01851642|Procedure|Pulmonary function testing.|At every study visit, participants will have their lung function assessed. This is done by blowing forcefully at least 3 times into a tube. Testing will be done two times; before and after the use of an Albuterol inhaler.
1575940|NCT02413099|Drug|KBMSI-2|The KBMSI-2 capsules (6gm/capsule) and placebo were provided by Korean Bio Medical Science Institute (Seoul, Korea). KBMSI-2 was analyzed by high-performance liquid chromatography. KBMSI-2 contained major ginsenoside-Rb1: 260.53ug/g, -Rb2: 543.91ug/g, -Rc: 424.92ug/g, -Re: 377.32ug/g, -Rf: 1160.55ug/g, -Rg1: 703.97ug/g, Curcumin 60.73ug/g, Allantoin 98.66ug.g, and Loganin 744.13ug/g. During the study period, two capsules were taken daily for 8 weeks. The placebo capsules were identical in shape, color, and taste.
1575941|NCT02413086|Procedure|Early-stage amputation|Individuals with DFU were given early-stage amputation.
1575942|NCT02413086|Procedure|Amputation|Individuals with DFU were given amputation.
1575943|NCT02413086|Other|External herbs chitosan|Wound was given external herbs chitosan after amputation.
1575944|NCT02413086|Other|Traditional gauze|Wound was given traditional gauze after amputation.
1575945|NCT02413073|Procedure|Whole Body Vibration|We wil use vibration in patients with kidney disease
1575946|NCT02413060|Other|Resistance training|This training consists 4 exercises and every exercises lasts 5 seconds.
1575947|NCT02413060|Behavioral|Lifestyle counselling|Lifestyle counselling mainly indicates dietary instruction.
1575948|NCT02413047|Drug|Azathioprine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past.
1575949|NCT02413047|Drug|6 mercaptopurine|Medication will be given in pill form to patients to take daily as long as the patient has not been intolerant to it in the past as an alternative to imuran
1575950|NCT02413047|Drug|Methotrexate|Medication will be given in subcutaneous injection form once a week if the patient cannot take imuran or 6 mercaptopurine.
1575951|NCT02413034|Drug|Cefazolin|Cefazolin (vancomycin in the case of allergy to cefazolin)
1575952|NCT02413034|Other|Control group|no antibiotic prophylaxis
1575953|NCT02413021|Drug|Cytarabine|20 mg/m^2 , SC, two times a day for 10 days every 30 days for 1 cycle
1575954|NCT02413021|Drug|Deferasirox|20 mg/kg ,oral, per day
1575955|NCT02413008|Drug|estriol|
1575956|NCT02413008|Drug|Placebo|
1575957|NCT02412995|Other|Meal sequence 1-2-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
1575958|NCT02412995|Other|Meal sequence 1-3-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
1575959|NCT02412995|Other|Meal sequence 2-3-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
1575960|NCT02412995|Other|Meal sequence 2-1-3|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
1575961|NCT02412995|Other|Meal sequence 3-1-2|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
1575962|NCT02412995|Other|Meal sequence 3-2-1|The subjects were studied in three 2 h meal tests with a subsequent ad libitum meal on separate days, at least two days apart. The subjects were individually randomised to the sequence of the test meals using random permutation. The study included two berry meals based on 150 g of frozen berries; sea buckthorn (Hippophaë rhamnoides) and strawberry (Fragaria x ananassa), respectively, and one control meal which did not contain berries. Each meal contained 35 g of sucrose and was adjusted for protein and fat with whey protein and canola oil, respectively. The meals were served with 120 mL of water.
1575965|NCT02412969|Procedure|Lumbar Epidural|control group will receive lumbar puncture epidural
1575966|NCT02412969|Procedure|Dural Puncture Epidural|intervention group will receive a dural puncture epidural
1575967|NCT02412956|Behavioral|SmokefreeMOM Text|
1575968|NCT02412943|Other|Fresh Frozen Plasma|Liquid portion of human blood that was centrifuged, separated, and frozen solid within 6 hours of collection
1576017|NCT02412631|Drug|lorcaserin|lorcaserin is an FDA-approved weight loss medication for overweight and obese patients
1576018|NCT02412631|Drug|Varenicline|Chantix is an FDA approved medication for smoking cessation
1576019|NCT02412631|Drug|Placebo|Placebo for lorcaserin
1575969|NCT02412930|Procedure|Ultrasound-guided Paravertebral Block|"paravertebral block was performed by ultrasound guidance at T11, T12 and L1 levels, using 0.5% bupivacaine total dose of 15 mL in group P. The injection site was covered with sterile drapes, after cleaning with 10% povidone-iodine solution.
After, patients in both groups were performed patient controlled analgesia (PCA). The PCA was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion."
1575970|NCT02412930|Drug|Group Tramadol|Patients in group T were given intravenously a loading dose of tramadol of 1 mgkg-1, 45 minutes before the end of surgery. After,patients in both groups were performed patient controlled analgesia (PCA). The PCA (CADD Legacy PCA pump, Smiths Medical MD, Inc., St. Paul, MN) was prepared with 400 mg tramadol into 100 mL of saline. The doses of tramadol in the PCA were bolus dose 0.1 mgkg-1 every 20 minutes without a background infusion.
1575971|NCT02412930|Drug|Bupivacaine|
1575972|NCT02412930|Device|Ultrasound|
1575973|NCT02412917|Drug|FV-100|antiviral nucleoside analog
1575974|NCT02412917|Drug|valacyclovir|antiviral nucleoside analog
1575975|NCT02412904|Drug|rFSH|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and antral follicle count (AFC). This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
1575976|NCT02412904|Drug|HMG|the patients will be asked to schedule an ultrasound in the first three days of the menstrual cycle and starts the ovarian stimulation with the previous randomized selected gonadotropin (rFSH or hMG) using a dose between 150 - 300 IU according with their AMH and AFC. This dose will be maintained until day 6 of stimulation, when a second ultrasound will be performed and the GnRH antagonist will be initiated and continued until the end of the cycle. Seriated ultrasounds will be performed each two days
1575977|NCT02412891|Device|UroShield device|The UroShield device is Consists of two units:Actuator and Driver.
1575978|NCT02412891|Device|Sham UroShield device|
1575979|NCT02412878|Drug|Carfilzomib|
1575980|NCT02412878|Drug|Dexamethasone|
1575981|NCT02412865|Behavioral|Quit4Baby|
1575982|NCT02412865|Behavioral|Text4Baby|
1575985|NCT02412826|Device|Abstats sensor|The AbStats abdominal biosensor will be applied to the abdomen of patients who are admitted with acute pancreatitis.
1575986|NCT02412813|Device|LEGION OXINIUM|Investigational Group
1575987|NCT02412813|Device|LEGION Cobalt Chrome|Control Group
1575988|NCT02412787|Drug|Idursulfase-IT|Patients will receive idursulfase-IT treatment once every 28 days at a dose of 10 mg. Idursulfase will be administered intrathecally (IT) by an indwelling intrathecal drug delivery device (IDDD).
1575989|NCT02412774|Behavioral|DBs at the end of the main meal + Diet|Subjects are asked to have 250 ml DBs at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
1575990|NCT02412774|Behavioral|Water at the end of the main meal+ Diet|Subjects are asked to have 250 ml water at the end of their lunch as the main meal, while they are on a multidisciplinary diet plan for 24 weeks.
1575991|NCT02412761|Drug|Lisinopril|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 10 mg/dose). Maximum final dose: 40 mg/dose or 0.6 mg/kg/dose.
1575992|NCT02412761|Drug|Amlodipine|Initial dose: 0.1 mg/kg/dose orally, once daily (maximum initial dose 5 mg/dose). Maximum final dose: 10 mg/dose
1575993|NCT02412761|Drug|Hydrochlorothiazide|Initial dose: 1 mg/kg/dose orally, once daily (maximum initial dose 25 mg/dose). Maximum final dose: 50 mg/dose or 3 mg/kg/dose
1575994|NCT02412748|Behavioral|BBTF Intervention|The Building Bridges to Fatherhood (BBTF) intervention consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
1575995|NCT02412748|Behavioral|Financial Literacy Program|The Financial Literacy Program (FLP) attention control condition consists of 9 group sessions and 1 booster session as described in the arm/group descriptions.
1575996|NCT02412735|Drug|rexlemestrocel-L|"rexlemestrocel-L alone: 2.0 mL formulation of approximately 6 million rexlemestrocel-L cells - Intervention will be injected into the painful intervertebral disc"
1575997|NCT02412735|Drug|rexlemestrocel-L + HA|"rexlemestrocel-L + HA: 2.0mL 6 million rexlemestrocel-L cells with 1% HA - Intervention will be injected into the painful intervertebral disc"
1575998|NCT02412735|Drug|Placebo|saline control: 2.0 mL saline solution
1575999|NCT02412722|Drug|Milled MLN0128 API|Capsules containing milled MLN0128 active pharmaceutical ingredient (API)
1576000|NCT02412722|Drug|Unmilled MLN0128 API|Capsules containing unmilled MLN0128 active pharmaceutical ingredient (API)
1576001|NCT02412722|Drug|Paclitaxel|Paclitaxel
1576002|NCT02412709|Device|QTScreen ECG Recorder|Subjects will be randomly assigned to the: Parents Performing ECG (PPE) group or Staff Performing ECG (SPE) group. This will assess whether parents are able to use QTScreen on babies at home.
1576003|NCT02412696|Device|Positive Airway Pressure|Auto-titrating PAP + nasal dilator strips during sleep
1576004|NCT02412696|Other|Nasal Dilator Strips|Nasal dilator strips
1576005|NCT02412683|Other|oxaliplatin|
1576006|NCT02412670|Drug|Methotrexate|Given IV
1576007|NCT02412670|Drug|Vinblastine|Given IV
1576008|NCT02412670|Drug|Doxorubicin Hydrochloride|Given IV
1576009|NCT02412670|Drug|Cisplatin|Given IV
1576010|NCT02412670|Drug|Gemcitabine Hydrochloride|Given IV
1576011|NCT02412670|Drug|Carboplatin|Given IV
1576012|NCT02412670|Procedure|Therapeutic Conventional Surgery|Undergo nephroureterectomy and lymph node dissection
1576013|NCT02412670|Other|Laboratory Biomarker Analysis|Correlative studies
1576014|NCT02412657|Drug|Dexamethasone|After the performance of inter scalene plexus blockade, patients will either receive dexamethasone 10 mg i.v. (diluted with 17.5 mL normal saline), dexamethasone 4 mg i.v. (diluted with 19 mL normal saline), or normal saline 20 ml i.v.
1576015|NCT02412657|Drug|Normal Saline|
1990737|NCT01851642|Drug|Albuterol inhaler.|At every study visit, participating subjects will take 2 puffs of an Albuterol inhaler after the first set of PFTs, but before the second set of PFTs. There will be at least a 30 minute period after the use of the Albuterol inhaler and the second set of PFTs.
1576023|NCT02412605|Procedure|Trophectoderm embryo biopsy|"Day 5 embryos were incubated in calcium/Magnesium free culture. A laser beam was used to produce a hole in the zona pellucida. Trophectoderm cells were collected by gentle suction using the biopsy pipette.
Florescent in situ hybridization of the trophectoderm nuclei with probes specific to the X- and Y-chromosomes was performed. the embryos were frozen and the cycles deferred.The embryos were thawed in the following cycle and if possible 2 embryos of the desired sex were transferred."
1576024|NCT02412579|Other|None - Standard of Care|
1576025|NCT02412566|Drug|SMOFlipid|Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
1576026|NCT02412553|Other|Specific carbohydrate diet|
1576027|NCT02412553|Other|Elemental diet|
1576028|NCT02412540|Behavioral|Comprehensive Lifestyle Intervention|Dietary, behavioral and activity interventions designed to reduce weight.
1576029|NCT02412527|Other|Patch III heart rate sensor|
1576030|NCT02412514|Biological|bOPV (three dose)|bOPV administered at 6, 10, and 14 weeks of age.
1576031|NCT02412514|Biological|bOPV (two dose)|bOPV administered at 10 and 14 weeks of age.
1576032|NCT02412514|Biological|IPV|IPV administered at 6 weeks of age
1576035|NCT02412475|Drug|Decitabine|Dosing per protocol starting at hour 0 IV infusion over 1 hour on Days 1-5
1576036|NCT02412475|Drug|Vorinostat|180 mg per meter squared per day for those under age 18, 300mg BID for those age 18 and older. Given after the decitabine infusion by mouth on Days 1-5
1576037|NCT02412475|Drug|Fludarabine|30 mg per meter squared per day starting at hour 0 given immediately after G-CSF by IV infusion over 30 minutes on days 6-10
1576038|NCT02412475|Drug|Cytarabine|2000 mg per meter squared per day starting at hour 4 by IV over 3 hours on days 6-10
1576039|NCT02412475|Drug|Filgrastim|5 μ/kg/dose starting at hour 0 immediately before fludarabine by IV or SQ on days 5-12
1576040|NCT02412475|Drug|Cytarabine|"Patient Age (years) IT Cytarabine Dose > 1 30 mg
2 and < 3 50 mg
3 and ≤ 18 70 mg > 18 100 mg
given IT on day 0 or -1"
1576041|NCT02412475|Drug|Sorafenib|150 mg/m2/dose twice daily by mouth on days 11-28
1576042|NCT02412462|Drug|AB-16B5|
1576043|NCT02412449|Drug|AKB-6548 tablet, reference formulation given in the fasted state|
1576044|NCT02412449|Drug|AKB-6548 tablet, test formulation given in the fasted state.|
1576045|NCT02412449|Drug|AKB-6548 tablet, test formulation given in the fed state|
1576046|NCT02412436|Drug|depot medroxyprogesterone acetate|At study entry/week 0, participants will receive DMPA 150 mg administered intramuscularly (IM) as a single-dose.
1576047|NCT02412423|Drug|post-transplantation cyclophosphamide|
1576049|NCT02412397|Procedure|Total Shoulder Arthroplasty|
1576050|NCT02412384|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
1576051|NCT02412384|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
1576052|NCT02412371|Drug|Veliparib|Oral capsule of varying doses
1576053|NCT02412371|Drug|Paclitaxel|Administered via intravenous infusion on Day 1 of each treatment week/cycle.
1576054|NCT02412371|Drug|Carboplatin|Administered via intravenous infusion on Day 1 of each treatment week/cycle.
1576055|NCT02412371|Radiation|Radiotherapy|Radiation treatment administered on Day 1 through Day 5 of each week for approximately 30-34 visits.
1576056|NCT02412371|Other|Placebo for Veliparib|Oral capsule of varying doses
1576057|NCT02412358|Device|toothbrush|
1576058|NCT02412345|Procedure|Extracorporeal shockwave therapy|
1576059|NCT02412345|Procedure|Extracorporeal shockwave therapy - sham treatment|A probe similar to the treatment group will be used. The noise and appearance is similar. The probe emits zero energy during each treatment. Local application generates noise and a feeling of popping at the application site which will also be experienced by patients in the placebo group being impossible for the patient to discern which treatment group belongs.
1576060|NCT02412345|Other|Penile ultrasound Doppler with intracavernosal injection application 20 mcg alprostadil|Diagnostic test will be performed before treatment and after 3 to 4 months after therapy.
1576061|NCT02412332|Procedure|Bone marrow harvesting|Approximately 200 mL of bone marrow will be surgically collect from the iliac crest (pelvis) of the patient under spinal anesthesia.
1576062|NCT02412332|Procedure|Liposuction|Approximately 50 mL of adipose tissue (fat) will be surgically collected from the abdominal region of the patient under spinal anesthesia.
1576063|NCT02412319|Drug|Anti-HBV placenta transfer factor injection|Anti-HBV Placenta Transfer Factor Injection: 2mg/4ml, intramuscular injection, the 0-24 week, once every other day; week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
1576064|NCT02412319|Other|Placebo|Physiological saline injection: 2mg/4ml, intramuscular injection,the 0-24 week, once every other day, week 24-48, 2 times / week; entecavir tablets: 0.5mg/ tablet / time, daily bedtime fasting oral once, treatment course 96 weeks
1576065|NCT02412306|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIVI). A cycle = 6 weeks (4 weeks of blinatumomab treatment, 2-week treatment-free) . Each cohort in the study will receive a combination of 2 dose levels. In the first induction cycle, the initial dose of blinatumomab will be the lower assigned dose level (Days 1-7), then escalated (dose step) to the higher assigned dose (Days 8-29). For all subsequent cycles (beginning with the second induction cycle and continuing through consolidation and maintenance, for applicable subjects) the higher assigned dose level will be the dose for all 4 weeks of continuous treatment.
1577784|NCT02400099|Other|Anthropometrical measurements|
1576066|NCT02412293|Behavioral|Health Education & Promotion|Promotion of antenatal care, adequate nutrition, skilled delivery and healthy newborn care practices at household level.
1576067|NCT02412293|Other|Training of Health Workers|Training of health workers on recognition of danger sign that warrant referral to health care service.
1576068|NCT02412293|Behavioral|Community Mobilization|Community mobilization activities included formation of community health committees and creation of support for the uptake of the interventions.
1576069|NCT02412280|Other|retrospecive observational|
1576070|NCT02412267|Drug|O-ICE (ofatumumab, Ifosfamide, Carboplatin, Etoposide)|Ofatumab in combination with ICE (Ifosfamide, Carboplatin, Etoposide) are given to subjects according to protocol schedule
1576071|NCT02412254|Other|Best practices hearing rehabilitative treatment|Intervention comprises hearing needs assessment, counselling, sensory management with amplification devices, and rehabilitative training.
1576072|NCT02412254|Other|Successful aging intervention|One-on-one education sessions on healthy aging topics (cancer screening, smoking cessation, etc.) between a trainer and participant
1576073|NCT02412241|Other|LEF measures|Patient-reported outcome measure; clinician-reported outcome measures
1576074|NCT02412241|Procedure|Technical measure|Undergo standard CT scan
1576075|NCT02412241|Procedure|Technical measure|Undergo standard ultrasound
1576076|NCT02412228|Drug|Ixazomib|"Cycle 1:
Ixazomib: 4mg/day 1, 8, 15
Cycles 2-6:
Ixazomib: 4mg/day 1, 4, 8, 11, 15, 18,
Maintenance:
Ixazomib at 4 mg days 1, 8 and 15 of a 28 day cycle for 1 ½ years"
1576077|NCT02412228|Drug|Cyclophosphamide|"Cycle 1:
Cyclophosphamide: 50 mg/day continuous daily
Cycles 2-6:
Cyclophosphamide: 50 mg/day continuous daily"
1576078|NCT02412228|Drug|Dexamethasone|"Cycle 1:
Dexamethasone: 20 mg/day 1, 8, 15
Cycles 2-6:
Dexamethasone: 20 mg/day 1, 4, 8, 11, 15, 18"
1576079|NCT02412215|Procedure|Phacoemulsification with toric Nanoflex IOL implantation|A self-sealing incision is made with a 2.2mm knife at 110°. Phacoemulsification is performed. The foldable nanoFlex toric IOL is injected in the capsular bag using the nanoPoint single-use injector system (STAAR) or 1620 sofTip Injector (ASICO). The IOL is rotated to align the cylinder axis with the steep corneal meridian using Z align function by Callisto Eye. Every movement of the IOL axis marks are noted.
1576080|NCT02412215|Device|NanoFlex toric Intraocular Lens|
1576081|NCT02412202|Other|Monitoring of pulmonary oedema induced by weaning from mechanical ventilation|
1576084|NCT02412176|Procedure|Pacing site - the implantation in the right ventricular (RV) apex|Pacing site - RV apex. The lead will be implanted in the RV apex.
1576085|NCT02412176|Procedure|Pacing site - the implantation in the septum|Pacing site - septum. The lead will be implanted in the septum.
1576086|NCT02412163|Device|Ellipse IM HTO Nail|
1576087|NCT02412150|Drug|Desflurane|Anesthesia is maintained with desflurane
1576088|NCT02412150|Drug|Remifentanil|Remifentanil is infused for the maintenance of anesthesia during surgery and discontinued 15 min before end of surgery
1576089|NCT02412150|Procedure|Thyroidectomy|The aim of this study is evaluation of effect of dexmedetomidine on emergence response and postoperative outcome after thyroidectomy
1576090|NCT02412150|Other|Vital signs|"Systolic blood pressure, diastolic blood pressure, mean arterial pressure, and heart rate are measured before infusion of testing drugs, after infusion of them (5 min, 10 min, and 15 min), during extubation (0 min and 5 min after extubation), and at recovery room.
And the complications such as hypotension, hypertension, bradycardia, tachycardia, and desaturation after infusion of testing drugs are observed."
1576091|NCT02412150|Behavioral|Cough reflex|During recovery from anesthesia at operation room, cough reflex is measured and rated. [Grade 0, no cough; Grade 1, single cough with mild severity; Grade 2, cough persistence less than 5 s with moderate severity; Grade 3, severe, persistent cough for more than 5 s (bucking)]
1576092|NCT02412150|Behavioral|Ramsay Sedation Scale|"When the patient has fully awaken and transferred to the recovery room, Ramsay Sedation Scale is measured.
Awake Patient anxious and agitated or restless or both!
Patient cooperative, oriented and tranquil!
Patient responds to commands only!
Asleep A brisk response to a light glabellar tap or loud auditory stimulus!
A sluggish response to a light glabellar tap or loud auditory stimulus!
No response to a light glabellar tap or loud auditory stimulus"
1576093|NCT02412150|Other|Extubation time and Recovery time|"The time from discontinuing anesthetic gas to endotracheal extubation is measured.
And the time from the discontinuing of anesthetic gas to transferring to the recovery room is also measured."
1576094|NCT02412150|Behavioral|Visual analogue scale|The severity of pain after surgery is measured by VAS (at recovery room, POD 1, POD 2, and POD 3)
1576095|NCT02412150|Other|Postoperative bleeding|The amount of postoperative bleeding which is collected in the barovac is measured.
1576096|NCT02412150|Other|Postoperative complications|Postoperative complications after thyroidectomy such as hoarseness and hematoma, and reoperation due to such complication is observed.
1576097|NCT02412150|Other|Time to remove drainage and duration of hospital staying|The time from the end of surgery to remove drainage is measured. And the duration of hospital staying is measured.
1576098|NCT02412150|Drug|Dexmedetomidine|Dexmedetomidine has started infusion for 15 min (rate of 0.6 ug/kg/hr) before end of surgery as experimental intervention
1576099|NCT02412150|Drug|Normal saline|Normal saline has started infusion for 15 min (as same rate of dexmedetomidine) before end of surgery as control intervention
1576100|NCT02412137|Other|Counseled cohort|This group will be counseled after brace temperature/date/time data is logged at each visit.
1576101|NCT02412124|Procedure|Supportive Care|Complete W2W mentoring program
1576102|NCT02412124|Other|Quality-of-Life Assessment|Complete the FACT-G
1576103|NCT02412124|Other|Questionnaire Administration|Complete the W2W Patient Survey
1576107|NCT02412098|Drug|Eleclazine|Eleclazine tablets administered orally
1576108|NCT02412085|Drug|Golimumab|"Subcutaneous golimumab. Induction regimen: 200 mg (week 0), 100 mg (week 2)
Maintenance regimen:
body weight < 80kg: 50 mg every 4 weeks
body weight ≥ 80 kg: 100 mg every 4 weeks"
1576111|NCT02412033|Drug|Misoprostol|400 µg misoprostol vaginally 3 hours before IUD insertion.
1576112|NCT02412033|Drug|Placebo|This group will receive placebo
1576113|NCT02412020|Drug|PA101|
1576114|NCT02412020|Drug|Placebo|
1576115|NCT02412007|Other|Individualized comprehensive home centred activity based programme|"Simple activities would be advised on the basis of child's individual characteristics and parental expectations. These would include but would not be limited to
Standing up from squatting position to catch an object of interest.
Squatting from standing position to pick an object of interest.
Walking to reach an object of interest.
Climbing up steps to get an object of interest.
Climbing down steps to keep the above object of interest.
Cycling
Kicking a football
Dancing"
1576116|NCT02411994|Drug|Pyronaridine-artesunate|
1576117|NCT02411994|Drug|Artemether-lumefantrine combination|
1576118|NCT02411981|Other|Autogenic drainage|
1576119|NCT02411968|Other|111In-Girentuximab DOTA SPECT|
1576120|NCT02411955|Drug|Tazarotene Cream 0.1%|Tazarotene Cream 0.1% applied to lightly cover the entire face once daily for 84 consecutive days.
1576121|NCT02411955|Drug|Tazorac®|Tazorac® applied to lightly cover the entire face once daily for 84 consecutive days.
1576122|NCT02411955|Drug|Placebo|Placebo (vehicle of the test product) applied to lightly cover the entire face once daily for 84 consecutive days.
1576123|NCT02411942|Drug|Adapalene Gel 0.3%|Adapalene Gel 0.3% applied to the entire face once daily for 84 consecutive days
1576124|NCT02411942|Drug|Differin®|Differin® applied to the entire face once daily for 84 consecutive days
1576125|NCT02411942|Drug|Placebo|Placebo (vehicle of the test product) applied to the entire face once daily for 84 consecutive days
1576126|NCT02411929|Drug|Unlabeled ertugliflozin for oral use|15 mg oral (3 x 5 mg tablets)
1576127|NCT02411929|Drug|14^C-labeled ertugliflozin for IV use|100 µg (10 µg/mL solution IV) containing approximately 400 nCi 14^C (ie, radiolabeled ertugliflozin)
1576128|NCT02411929|Drug|14^C-labeled ertugliflozin for oral use|100 µg (10 µg/mL solution oral) containing approximately 400 nCi 14^C (ie, radiolabeled ertugliflozin)
1576129|NCT02411916|Biological|misoprostol|rectal insertion
1576130|NCT02411903|Drug|atorvastatin and clopidogrel|Dose: atorvastatin 40mg/d plus clopidogrel 75mg/d for 9 months.
1576131|NCT02411903|Drug|rosuvastatin and clopidogrel|Dose: rosuvastatin 20mg/d plus clopidogrel 75mg/d for 9 months.
1576132|NCT02411890|Procedure|Adductor canal block (active)|adductor canal block: single injection, 0.5% levobupivacaine 15 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
1576133|NCT02411890|Procedure|Femoral nerve block (active)|femoral nerve block: single injection, 0.25% levobupivacaine 30 ml with adrenaline 5 µg/ml, ultrasound guidance with nerve stimulator
1576134|NCT02411890|Procedure|Femoral nerve block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the inguinal area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance to create quadriceps contraction before injection
1576135|NCT02411890|Procedure|Adductor canal block (sham block)|30 mL of normal saline injected into absorbing cloth through stump needle at the midfemoral area but not penetrating skin, ultrasound guidance and nerve stimulator with percutaneous electronic guidance without muscle contraction
1576136|NCT02411877|Procedure|Normothermia|Device: Trevo Pro Retriever (Stryker Corp.)
1576137|NCT02411877|Procedure|Mild hypothermia|Device: Zoll Thermogard XP technology with the Quattro catheter Device: Trevo Pro Retriever (Stryker Corp.)
1576138|NCT02411877|Device|Trevo Pro Retriever (Stryker Corp.)|Device: Trevo Pro Retriever (Stryker Corp.)
1576139|NCT02411877|Device|Zoll Thermogard XP technology with the Quattro catheter|Device: Zoll Thermogard XP technology with the Quattro catheter
1576140|NCT02411864|Other|different low b-values distribution|
1576141|NCT02411851|Drug|ingenol mebutate 0.015%|one cycle of ingenol mebutate 0.015% on two 25 cm2 treatment areas
1576142|NCT02411851|Other|dermasil lotion|Dermasil lotion has 1% dimethicone as its active ingredient - part of the family of silicone oils, is a hypoallergenic, noncomedogenic, and nonacnegenic agent
1576143|NCT02411838|Other|Calorie restriction|"Calorie restriction will be achieved by alternate day fasting. During the day of fasting the subject will be allowed to eat two salads with light dressing, not to go over approximately 500 calories. The CR group subjects will fast on day 2 (second day of steroids) and then continue to fast on alternate days until day 15. This is the end of the Acute CR phase of the Study, and patients may discontinue the study at this point.
Chronic CR phase At the end of the Acute CR phase, both groups will be offered to enroll in the alternate day fasting regimen for 6 months (Chronic CR phase). During this phase, patients with a BMI <28 will follow a regimen of fasting for two days per week while patients with BMI>28 will follow a regimen of fasting for three days per week."
1576144|NCT02411825|Drug|SAR425899|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1576145|NCT02411825|Drug|placebo|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1576146|NCT02411825|Drug|metformin|"Pharmaceutical form: tablet
Route of administration: oral"
1576147|NCT02411812|Device|Herbst appliance with skeletal anchorage|Group treated with the Herbst appliance with indirect skeletal anchorage in mini-implants.
1576148|NCT02411812|Device|Herbst appliance with dental anchorage|Group treated with the conventional Herbst appliance with dental anchorage.
1576149|NCT02411786|Biological|pTVG-AR|Given ID
1576150|NCT02411786|Biological|gm-csf|Given ID
1576151|NCT02411773|Drug|Sodium Bicarbonate|Sodium bicarbonate tablet is 650 mg for one tablet. Oral sodium bicarbonate will be given out as 1300mg-2600mg (2-4 pills) prior to each exercise or stretching session. Serum bicarbonate measurements will be monitored throughout the study (at 2 weeks, then every 2-4 weeks thereafter), and bicarbonate dosages will be adjusted to avoid metabolic alkalosis (serum HCO3 > 30).
1576152|NCT02411773|Drug|Placebo|2-4 placebo pills will be given out prior to each exercise or stretching session
1576177|NCT02411565|Drug|Placebo|Dried and pulverized, white and black rice, 5.53 grams, combined with natural orange flavor and stevia Reb-A sweetener, to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
1576465|NCT02409498|Drug|no pudendal block|preemptive pudendal nerve blockade with 10 ml of normal saline to each side
1576153|NCT02411773|Other|Exercise Training|Exercise training consists of riding a stationary bicycle for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. The exercise program will follow the guidelines provided by the American College of Sports Medicine (ACSM) for optimizing cardiovascular fitness. Exercise intensity will begin at low levels (50 percent of resting heart rate) and increase to no greater than 80 percent of resting heart rate. Exercise time will progress, depending on subject's progress, from 20 minutes per session at first, to a maximum of 45 minutes. Trained staff members will give instructions throughout each exercise session. Before beginning each exercise session, subjects will be instructed on a warm-up focusing on preparing the legs for activity.
1576154|NCT02411773|Other|Stretching|Stretching exercise will consist of muscle stretching and toning for 20-45 minutes, 3 times per week, supervised by trained exercise specialists, for 6-12 weeks. Trained staff members will guide subjects with the stretching exercises, and activities are designed to increase flexibility and range of motion. Before beginning each stretching exercise session, subjects will be instructed to warm-up.
1576156|NCT02411747|Behavioral|Testing|
1576157|NCT02411747|Behavioral|Directed self-regulated simulation training|
1576158|NCT02411734|Behavioral|Rehabilitation|Rehabilitation after hospitalization
1576159|NCT02411721|Behavioral|Animal Assisted Intervention|"Initial conversation between dog handler and child. The purpose hereof is to let the child express any fear he experiences towards the examination. The presence of the dog allows the child to project his emotions on the dog and to speak more freely about his anxiety.
The dog handler informs the child on the various stages of the procedure. For this a booklet has been prepared in which a dog is the patient undergoing an MRI-scan. The child can identify with the dog in the story, and at the same time feel comforted by the dog present.
Procession of emotions. The child will play freely with the dog. The purpose hereof is to create a soothing atmosphere. In stroking the soft, friendly animal the child may feel more relaxed and therefore less anxious towards the examination."
1576162|NCT02411695|Drug|Brexpiprazole (OPC-34712)|Subjects who are deemed eligible for the trial will be assigned to a dosing cohort and will enter a Dose Titration Phase during which they will receive a starting dose of brexpiprazole for 2 to 10 days based on their assigned titration schedule. The Dose Titration Phase may be extended up to a maximum of 14 days, based on the observed safety and tolerability profile of the previous cohort's Dose Titration Phase. Following the Dose Titration Phase, subjects will enter the Fixed Dose Phase and will be administered the assigned dose for that cohort for 14 days.
1576163|NCT02411682|Other|Breakfast eating (YesB)|On YesB day the patients will eat Breakfast at 8:00, Lunch at 13:30 and Dinner at 19:00
1576164|NCT02411682|Other|Breakfast skipping (NoB)|On NoB day the patients will fast until lunch, then will eat Lunch at 13:30 and Dinner at 19:00
1576165|NCT02411669|Other|Operational patient centered care tools|"The FORAP (Fédération des Organismes Régionaux et territoriaux pour l'Amélioration des Pratiques et des organisations) and the la HAS (High Authority of Health) have developed and validated five tools promoting patient centered care at hospital.
They can be implemented one by one or in association according to hospital situation. Hospitals should identify the association of tools fitting the most to their objectives and the actions already done."
1576166|NCT02411656|Drug|MK-3475|200 mg administered on Day 1 of each 21 day cycle as a 30 minute infusion by vein.
1576167|NCT02411656|Behavioral|Follow Up/Phone Call|About 1 and 3 months after last dose of study drug, participant to have follow up or phone call. If participant is called, each call should last about 2 minutes.
1576169|NCT02411630|Drug|Emtricitabine/tenofovir disoproxil|"ATN 123 participants will not be administered Emtricitabine /Tenofovir disoproxil fumarate (Truvada®) as part of the ATN 123 study, but as part of the parent studies, ATN 110 or ATN 113. In order to be eligible for ATN 123, all participants must be co-enrolled in ATN 110 or ATN 113.
The only intervention for ATN 123 is the administration of the Interactive Questionnaire System (iQS), which is a new method to collect data on adherence. It will be utilized to collect adherence data across a variety of devices (i.e., computer/laptop, smartphone, tablet, etc.). Accuracy of this method will be determined; preference for this mode of data collection compared to other methods for adherence reporting used in the parent studies will be assessed."
1576170|NCT02411617|Device|Drain|Post modified radical mastectomy with either one or two drains Intervention is use of single or double drain
1576171|NCT02411604|Drug|Tacrolimus|Open label, multi-center, expanded access study for renal transplant patients with once daily Envarsus XR.
1576172|NCT02411591|Drug|Necitumumab|Administered IV.
1576173|NCT02411591|Drug|Abemaciclib|Administered orally.
1576176|NCT02411565|Drug|Fermented Wheat Germ Extract (FWGE)|5.53 grams of FWGE combined with natural orange flavor and stevia Reb-A sweetener to create an instant drink mix, dissolved in 150 mL of water, orally once-daily, for 2 to 4 weeks.
1576542|NCT02408965|Drug|Methergine|
1576543|NCT02408965|Drug|Placebo|
1577567|NCT02401633|Procedure|CO-CPR|CPR provided by bystander with chest-compressions only
1576178|NCT02411565|Other|Standard of Care: Planned Surgery|Participants will undergo their planned surgery during the 2nd to 4th week after entry into the study. However, if there are delays, patients can continue to take drug/placebo for a time period no greater than 2 months. If surgery has not occurred after this 2-month period, the patient will be removed from the study. Participants will take the study drug up until the day prior to surgery. The minimum amount of time on study drug is 2 weeks. A separate consent form will be obtained for the surgical procedure.
1576179|NCT02411565|Other|Quality of Life (QoL) Surveys: FACT-O|Quality of life questionnaire (FACT-O) at the time of enrollment, then weekly and the day of surgery.
1576180|NCT02411552|Behavioral|physical activity|4 strategies are: (1) increased activity time during physical education class, (2) active recess, (3) opportunities for activity before and after school, and (4) active classroom breaks
1576181|NCT02411539|Biological|VRC01|40 mg/kg of VRC01 administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
1576182|NCT02411539|Biological|Placebo|Normal saline administered as an intravenous infusion over about 30 to 60 minutes using a volumetric pump
1576183|NCT02411526|Drug|ZX003 (Risperidone-SABER®)|ZX003 administered as a SC injection
1576184|NCT02411526|Drug|Risperdal Consta|Risperdal Consta administered as a IM injection
1576185|NCT02411526|Drug|Oral Risperidone|Oral Risperidone given to ensure adequate therapeutic plasma concentrations from Risperdal Consta
1576186|NCT02411513|Device|CEFALY|
1576187|NCT02411500|Drug|TRV734|Subjects will be randomized to receive the oral TRV734 treatments on Days 1, 3, 5 and 7 in an open-label, 4-period, cross-over fashion. Days 2, 4, 6 and 8 are designated as washout days.
1576188|NCT02411448|Drug|Ramucirumab|Administered IV
1576189|NCT02411448|Drug|Placebo|Administered IV
1576190|NCT02411448|Drug|Erlotinib|Administered orally
1576191|NCT02411435|Drug|CAB|CAB 30 mg as 1 tablet will be administered orally with 240 mL of water in the fasted state.
1576192|NCT02411435|Drug|RIF|RIF 600 mg as 2 capsules of 300 mg will be administered orally with 240 mL of water in the fasted state.
1576193|NCT02411422|Device|Conventional endotracheal tube|Conventional endotracheal tube
1576194|NCT02411422|Device|Reinforced endotracheal tube|Reinforced endotracheal tube
1576195|NCT02411409|Behavioral|HealtheRx|The HealtheRx is a prescription for community self-care resources. It includes a printed list of self-care resources provided to the patient at an ambulatory visit and tailored based on data from the electronic medical record.
1576196|NCT02411396|Other|Patient Centered Outcomes|Comparison of treatment in patients with SCD in VOC in acute care settings
1576197|NCT02411383|Device|NeuRx Diaphragm Pacing System|NeuRx Diaphragm Pacing System electrodes are placed in the diaphragm during lung transplant surgery. The diaphragm will be continually paced until the patient is free from the ventilator or the patient is discharged from the ICU whichever. Diaphragm measurements are taken daily to assess tolerability and pacing success.
1576198|NCT02411370|Behavioral|phonetic tests|
1576199|NCT02411357|Behavioral|Treatment as usual|General information about contraceptive options and referral to contraceptive service providers
1576200|NCT02411357|Behavioral|WHO contraception protocol|World Health Organization's contraception protocol
1576201|NCT02411357|Behavioral|Incentives|Financial incentives contingent on follow-up visit attendance
1576202|NCT02411344|Drug|Pertuzumab|"Pertuzumab 840 mg loading dose iv on day one, followed by 420 mg iv every 3 weeks for 5 cycles
Trastuzumab 8 mg/kg loading dose iv on day 2, followed by 6 mg/kg iv on day 2 of each subsequent 3 weekly cycle
Letrozole 2.5 mg daily p.o. for five 21-day cycles (to be continued until surgery)."
1576203|NCT02411331|Drug|Ethanol 40% + Enoxaparine 400UI/ml|
1576204|NCT02411331|Drug|Vancomycine 5 mg/ml + Héparine 2500UI/ml|
1576205|NCT02411318|Other|Exercise|Subjects will ride a stationary bike and maintain their target heart rate (according to the American Heart Association guidelines) for 30 minutes.
1576206|NCT02411318|Drug|ProLab 200mg caffeine capsule|Subjects will swallow one ProLab caffeine 200mg tablet.
1576207|NCT02411318|Other|Ethanol ingestion|Subjects will consume a dose of 80 proof alcohol according to their body weight to reach a breath alcohol concentration of 0.05.
1576208|NCT02411292|Drug|Enoxaparin|Enrolled patients will receive real-time monitoring of peak and trough steady state anti-Xa levels. Out-of-range patients will receive real time dose adjustment of Enoxaparin using a clinical protocol developed with our inpatient pharmacists.
1576209|NCT02411279|Other|Equiped group with telemedicine systems|
1576210|NCT02411266|Other|ischemic conditioning group|application of a blood pressure cuff around a leg and inflating the cuff to 200mmHg to induce limb ischemia for 10min followed by 5min reperfusion. this will be done for 3 cycles every 24-48hours during the first 14 days after subarachnoid hemorrhage
1576211|NCT02411253|Drug|rhIL-2|Subcutaneous injections of IL2 according to regimen A Subcutaneous injections of IL2 according to regimen B
1576212|NCT02411253|Drug|Placebo|Subcutaneous injections of Placebo according to regimen A Subcutaneous injections of Placebo according to regimen B
1576213|NCT02411240|Device|Air filtering|The air filter will be placed in the living room of the elderly people. The efficiency of this device has been tested and a drop of ultrafine particles of more then 70 % is achieved.
1576215|NCT02411214|Other|survey|questionnaire survey sent by regular mail for 3 groups
1576216|NCT02411201|Drug|DOTAREM|Single intravenous injection of 0.1 mmol/kg body weight
1576217|NCT02411188|Behavioral|The STEP Program|Intervention: The 12-week STEP Program will include: initial individual consult/goal setting; weekly 90 minute information/interactive sessions; individualized patient centred care; journaling
1576218|NCT02411175|Other|Individualised Homeopathic Remedy|20% ethanol will be medicated with the Individualised Homeopathic Remedy in the potency determined by the researcher in accordance with the laws that govern individualised homeopathic prescribing. The medicated 20% ethanol will be administered as drops.
1576219|NCT02411175|Drug|20% ethanol|
1576293|NCT02410681|Radiation|Vertical bitewing radiograph|An intraoral vertical bitewing radiograph will be performed with the assistance of individually modified plate positioning devices at each visit (in total 8 visits during the 2-year follow-up period).
1577785|NCT02400099|Other|Body composition|
1576220|NCT02411162|Drug|Combination therapy GSK2894512 Cream A + GSK2894512 Cream B|GSK2894512 Cream A, 1% (10mg/g) will be topically applied daily for 7 days as a thin layer onto an area of the volar region of one forearm (up to 1.5% body surface area) and GSK2894512 Cream B, 1% (10mg/g), will be topically applied daily for 7 days to the opposite forearm from Cream A, onto an area of the volar region of one forearm (up to 1.5% body surface area). Both the creams will be weighed to deliver approximately 3mg drug per 1cm^2 of skin.
1576221|NCT02411162|Drug|Combination therapy Vehicle Cream A + Vehicle Cream B|Vehicle creams A and B will be supplied in individual tubes. Both the creams will be topically applied on Day 1 only to a separate area (at least 1.3 cm from study drug) of the forearm from where drug is applied.
1576222|NCT02411149|Drug|Adductor Canal Block|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine.
1576223|NCT02411149|Drug|Adductor Canal Block with Morphine|Use of ropivacaine 0.5% with 1:400,000 epinephrine in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine and 100mcg of intrathecal morphine (0.1ml of intrathecal morphine 1mg/ml)
1576224|NCT02411149|Drug|Local Infiltration|30 ml normal saline in the adductor canal along with a spinal anesthesia of 3ml 0.5% preservative-free bupivacaine, in addition to the local infiltration.
1576225|NCT02411136|Drug|AMG 623|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
1576226|NCT02411136|Drug|Placebo|Multiple doses of AMG 623 administered as subcutaneous and intravenous doses
1576227|NCT02411123|Genetic|IDgenetix Neuropsychiatric Test Panel|The IDgenetix Neuropsychiatric Test Panel is used to make recommendations on the medication therapy that might be impacted by the genetic background of the patient.
1576228|NCT02411110|Device|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
1576229|NCT02411110|Device|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy.
1576230|NCT02411097|Procedure|femoral nerve block|use the nerve stimulator,the femoral nerve block will be administered before or after the surgery
1576231|NCT02411084|Biological|Begelomab|BEGEDINA® (Begelomab) is a murine immunoglobulin G (IgG) 2b monoclonal antibody against CD26 (dipeptidyl peptidase-4; DPP4) and is produced by biotechnological means.
1576232|NCT02411084|Biological|Conventional Second-line Treatment|"There are no approved second-line treatments for aGvHD and due to the life-threatening nature of the disease it was agreed with the FDA and EMA that BEGEDINA® would be compared with best conventional second-line treatments which will be chosen by each center, based on the clinical conditions of the individual subject and according to the standard practice at the study center and which may vary between centers. Treatments are generally biological products and could include anti-thymocyte globulin, monoclonal antibodies, such as anti-CD147, basiliximab, daclizumab and alemtuzumab; mycophenolate mofetil; anti-TNF-alpha; pentostatin; dinileukin diftitox; N-acetyl-cysteine; sirolimus; and visulizumab."
1576233|NCT02411058|Behavioral|Uninformed|Users will receive 20x their usual incentives for two weeks, but will either receive no emails informing them about the incentive program.
1576234|NCT02411058|Behavioral|Informed|Users will receive 20x their usual incentives for two weeks, and they will receive emails informing them about the incentives (one announcement before the incentives begin, and one email every two days reminding them about the overall incentive program). These emails will contain information about the incentives and the purpose of the incentives. The reminder emails sent every two days, however, will include more information about the overall program incentives to maximize the number of participants who learn about the incentive program at some point.
1576235|NCT02411045|Behavioral|Take and send a selfie|Direction to take and send a selfie.
1576236|NCT02411045|Behavioral|Workout gears|Direction to wear workout gears.
1576237|NCT02411045|Behavioral|Exercise|Direction to complete a 30 minute workout.
1576238|NCT02411032|Behavioral|Reminder|Customer gets mailing that reminds them to take their medication.
1576239|NCT02411032|Behavioral|Fresh start|Customers receive a mailing around a fresh start event: New Year's or birthday
1576240|NCT02411032|Behavioral|Fresh start framing|The fresh start event will be highlighted in the mailings.
1576241|NCT02411019|Biological|GX-188E|In phase II study, 72 patients were assigned to two dose groups (1mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
1576242|NCT02411006|Behavioral|Prediction mailing|Ask people to predict their upcoming medication adherence
1576243|NCT02411006|Behavioral|Commitment mailing|Ask people to commit to their upcoming medication adherence
1576244|NCT02411006|Behavioral|Reminder|Remind people to take their medicine
1576245|NCT02411006|Behavioral|Anonymity|Keep patient predictions and commitment anonymous
1576246|NCT02411006|Behavioral|Identification|Ask patients to report their predictions and commitments
1576247|NCT02410993|Procedure|CABG surgery|
1576248|NCT02410980|Drug|Tretinoin cream 0.1%|Assessment of the skin change
1576249|NCT02410967|Behavioral|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
1576250|NCT02410967|Behavioral|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
1576294|NCT02410681|Other|Collection of biofilm sample|"Collection of peri-implant intrasulcular biofilm sample for DNA analysis of the biofilm composition. In total, samples will be collected three times:
At the baseline visit
Three months after the baseline visit
One year after the baseline visit"
1576295|NCT02410668|Dietary Supplement|flaxseed|
1576251|NCT02410954|Device|NeuroConn Direct Current stimulator Multiple Channel -4|(tDCS) will be administered with a multichannel tDCS device that can be programmed so that the operator doesn't know the combination of electrodes being used for stimulation, and, thereby allow double-blinding. The active tDCS electrode configuration to be used will be determined with the 3 round iterative procedure described above; based on electric field modeling and personalized electrical dose titration to find the lowest dose that is well-tolerated and engages the target in terms of inhibiting the AOT pupillary response.
1576252|NCT02410941|Behavioral|Clinical decision support|Establish evidence-based standardized clinical pathways implemented by local communities of practice focused on imaging utilization in ED settings as models of participatory research and integrated knowledge translation.
1576253|NCT02410928|Device|direct laringoscopy|the vocal cords will be visualized after extubation with direct laringoscopy
1576254|NCT02410928|Device|fiberoptic nasal laringoscopy|the vocal cords will be visualized after extubation with fiberoptic nasal laringoscopy
1576255|NCT02410928|Device|ultrasonograph|the vocal cords will be visualized after extubation with fiberoptic ultrasonography
1576256|NCT02410915|Device|Hybrid Assistive Limb (HAL); gait training|Training with HAL is performed in 1 session per day, 4 days per week during 4 weeks. Time for each session is individualised but does not exceed 60 minutes/session (effective time). Training with HAL is performed in combination with body-weight support system and on a treadmill. The training program is performed by 2 physiotherapists, who have been trained in the HAL method.
1576257|NCT02410915|Other|Control Group; Conventional gait training|Conventional gait training is individualized and performed according to current practice (approximately 30-60 minutes/session, 5 days a week) and may include standing, weight shifting, stepping, over ground walking with assistance and/or assistant devices as well as the use of a treadmill and body weight support. Conventional gait training is offered to both study groups.
1576258|NCT02410902|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
1576259|NCT02410902|Drug|PLACEBO|Single unit dose powder of non-active substance administered 3 times per day for 90 days
1576260|NCT02410889|Other|EEG-fMRI scanning|Patients undergo EEG-fMRI scanning
1576263|NCT02410863|Drug|Dabrafenib|150 mg twice daily
1576264|NCT02410863|Drug|Trametinib|2 mg daily
1576265|NCT02410850|Device|Oral Appliance|Mandibular Advancement Splints
1576266|NCT02410837|Procedure|Electromagnetic Navigation Bronchoscopy|
1576267|NCT02410824|Device|stenfilcon A toric lens|toric contact lens
1576268|NCT02410824|Device|etafilcon A toric lens|toric contact lens
1576269|NCT02410811|Other|Cardiac magnetic resonance imaging (CMR)|CMR is obtained on all participants in all arms/groups
1576270|NCT02410798|Device|TransLoc electrode|Patients will have 2 electrodes placed in either side of the diaphragm (total 4 electrodes) during their primary surgery.
1576271|NCT02410785|Device|Polyglucosamine|ß-1,4 polymer of D-glucosamine and N-acetyl-D-glucosamine from the shells of crustaceans
1576272|NCT02410785|Other|Placebo|Placebo tablet
1576273|NCT02410772|Drug|rifapentine|Regimen 2: Rifapentine is substituted for rifampin as the basis of 4-month treatment
1576274|NCT02410772|Drug|rifapentine and moxifloxacin|Regimen 3: In addition to the single substitution described for regimen 2, a second substitution is added, of moxifloxacin for ethambutol.
1576275|NCT02410772|Drug|control|standard six-month treatment
1576276|NCT02410759|Drug|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm IM
1576277|NCT02410759|Drug|Ergometrine|100 women with atonic PPH will receive Ergometrine 0.5 µgm IM
1576278|NCT02410746|Other|targeted chirocaine pec block|10ml 0.25% chirocaine in a specifically targeted in a nerve block
1576279|NCT02410746|Other|standard chirocaine infiltration|10ml 0.25% chirocaine is infiltrated into breast pocket in a non targeted fashion
1576280|NCT02410746|Other|standard post-operative analgesia|A dose of morphine 0.1mg/kg will be given intra-operatively. Thereafter morphine 0.1mg/kg will be given for breakthrough pain. Patients will be prescribed regular paracetamol and ibuprofen.
1576281|NCT02410733|Biological|Lipo-MERIT|vaccination
1576282|NCT02410720|Other|Instruction leaflet|Patients will receive the Picoprep solution with an instruction leaflet of how to use it and the dietary modifications needed
1576283|NCT02410720|Other|Mobile App|Patients will receive Picoprep solution with an instruction leaflet + Picoprep Mobile App which will be downloaded to their smartphones that has the same information plus a reminder utility
1576284|NCT02410720|Other|Explanation of paper and application instructions|The research fellow will explain instructions to patients
1576285|NCT02410720|Other|Picoprep solution|
1576286|NCT02410707|Drug|Nitrous Oxide arm|Patients undergoing procedural sedation with propofol will undergo an initial medical assessment including the history, physical examination, and vital signs. The patients will then receive Nitrous Oxide gas via a gas mixer device before receiving propofol. The device will mix and deliver nitrous oxide and oxygen in a 1:1 ratio, at a fixed concentration of 50%/50%. The on demand valve requires patient inspiration to trigger dosing.
1576287|NCT02410707|Drug|Propofol|The loading dose of propofol will be administered immediately after nitrous oxide discontinuation. All sedations in this trial will use propofol 1.0 mg/Kg initial dose, with 0.5 mg/Kg doses titrated to deep sedation. Once the patient is deeply sedated, the procedure will begin.
1576288|NCT02410707|Drug|Oxygen|If pulse oximetry declines to less than 92%, subject will be placed on nasal cannula with administration of 2 liter flow of oxygen and titrated in increments of 1 L flow to maintain pulse oximetry greater than 92%
1576289|NCT02410694|Drug|Ixazomib|
1576290|NCT02410694|Drug|Thalidomide|
1576291|NCT02410694|Drug|Dexamethasone|
1576292|NCT02410681|Device|Electromyographic recording of temporalis muscle activity during sleep|"Electromyographic recording of temporalis muscle activity during sleep. In total, 9 sleep recordings will be done at the home setting of each participant.
3 recordings after the baseline visit
3 recordings 6 weeks after the baseline visit
3 recordings one year after the baseline visit"
1576298|NCT02410655|Drug|Oxytocin|500 mL bag of oxytocin (30 IU / 500 mL) to be connected to the IV, and controlled at the obstetricians request. Up to two, 50 mL rapid infusion boluses to be given after delivery of anterior shoulder. Upon completing the bolus(es) flow rate should be continued at 100 mL / hour. This should total no more than 4.5 hours.
1576299|NCT02410655|Drug|Oxytocin|A total of two 1000 mL bags of oxytocin (20 IU/ 1000 mL) are to be connected to the IV sequentially, and controlled at the obstetricians request, are each to be administered over 8 hours after delivery of anterior shoulder in vaginal delivery. This will total 16 hours of oxytocin infusion.
1576300|NCT02410642|Procedure|cardiopulmonary bypass|Routine use of cardiopulmonary bypass as needed during cardiac surgery
1576301|NCT02410629|Device|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
1576302|NCT02410629|Other|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
1576303|NCT02410616|Behavioral|Blended CBT|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components. The core components of the CBT treatment are: (1) psychoeducation, (2) behavioural activation, (3) cognitive restructuring, and (4) relapse prevention.
1576304|NCT02410616|Behavioral|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the secondary care system. The investigators will not interfere with treatment as usual but they will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report.
1576305|NCT02410590|Drug|Rocuronium|
1576306|NCT02410590|Drug|Sugammadex|
1576307|NCT02410590|Drug|Cisatracurium|
1576308|NCT02410590|Drug|Neostigmine/Atropine|
1576309|NCT02410590|Drug|Succinylcholine|
1576310|NCT02410577|Drug|89Zr-J591|The intervention is the administration of an injection of 18-19mg of unchelated J591 to reach the total administered dose of antibody followed by 5 mCi (+/- 10%) of 89Zr-J591 (1 to 2 mg) . After administration of the experimental tracer, the patient will undergo a Brain PET/CT scan 24 hours, 48 hours post injection and 3-8 days. The 48 hour scan is strongly suggested, but optional.
1576311|NCT02410577|Device|PET/CT Scan|
1576312|NCT02410577|Device|MRI|
1576313|NCT02410577|Other|Blood draw|Bloods samples will be drawn immediately before and approximately 30 minutes after 89Zr-J591 injection.
1576314|NCT02410564|Behavioral|cognitive behavioral therapy for insomnia (CBTI)|SHUTi program is made up of six, weekly treatment Cores modeled after weekly facetoface(CBTI). Each Core begins by providing a rationale for learning the material, explains main content, homework page with suggestions for improving sleep, and a summarized review of main points. The main content each Core addresses myths about sleep, indepth information about topics, vignettes, and quizzes to evaluate users learning in an interactive. As well as being interactive, SHUTi allows for personalization.Modifications are made to sleep recommendations based in sleep diary data and individually set treatment goals. The cores include Overview, Sleep Behavior Core, Sleep Behavior Core 2, Sleep Education Core, Sleep Thoughts Core, and Problem Prevention Core. Each Core takes approximately 45 to 60 minutes to complete. Cores are presented one at a time; next Core becomes available to users a week after they complete one Core.
1576315|NCT02410564|Behavioral|Waitlist control condition|Phone calls with control participants, no advice regarding sleep will be given and if participants ask, they will be informed that such advice can be provided in a few weeks if they choose to crossover to the treatment condition at the end of the study.
1576316|NCT02410551|Drug|Pacritinib|200 mg by mouth twice a day for 60 days.
1576317|NCT02410551|Drug|Busulfan|Busulfan AUC of 4000 microMol-min per day providing that pharmacokinetic can be done, otherwise Busulfan dose given as a fixed dose of 100 mg/m2 daily for four days.
1576318|NCT02410551|Behavioral|Questionnaires|Questionnaires completed at baseline, 1, 3, 6, and 12 months after transplant.
1576319|NCT02410551|Behavioral|Phone Calls|Phone calls made by study staff to participant on second and third week of each month.
1576320|NCT02410551|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation (Allo TP) 60 days after starting Pacritinib but not more than 180 days.
1576321|NCT02410551|Drug|Fludarabine|Fludarabine taken along with Busulfan as per standard of care as preparative regimen for allogeneic stem cell transplantation (Allo TP).
1576322|NCT02410538|Other|"list of FAQ"|
1576323|NCT02410525|Drug|[11C]PF-06427878|Single administration via intravenous infusion of 20 ug [11C]PF-06427878 on Day 1 of all 3 Periods
1576324|NCT02410525|Drug|PF-06427878 10 mg|Single oral administration of 10 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration
1576325|NCT02410525|Drug|PF-06427878 600 mg|Single oral administration of 600 mg PF-06427878 on Day 1 of Period 2 or 3, at approximately 2.5 hours prior to [11C]PF-06427878 administration
1576328|NCT02410499|Drug|MLN1202 Placebo|MLN1202 placebo-matching solution for SC injection
1576329|NCT02410499|Drug|MLN1202|MLN1202 solution for SC injection
1576347|NCT02410434|Other|LGBT Stigma Reduction Intervention|Participants will complete a pre-test, followed by a performance ethnography where they will watch theatre performances that illustrate stigma experienced by LGBT persons in Swaziland and Lesotho. They will have the opportunity to participate in these theatre performances to demonstrate reduced stigma and increased acceptance of LGBT persons. They will then complete a post-test, followed by a 6 week follow up survey.
1576348|NCT02410421|Procedure|Functional magnetic resonance imaging used to individualize rTMS protocol using robotic coil positioning|
1576349|NCT02410408|Device|Apps Root Cause Analysis or patient safety ISO certification|Apps for conducting RCA or PSC
1576350|NCT02410408|Other|information package|Information on PSC and RCA
1576351|NCT02410395|Procedure|Conventional|Two-layer technique with the first layer performed as an un-locked, continuous suture without inclusion of the endometrium and the second layer performed as an un-locked, continuous suture with the stitches placed superficially, horizontally along the first layer.
1576352|NCT02410395|Procedure|Modified|The modified mattress suture is performed as a single-suture, double-layer technique with limited inclusion of the myometrium and broad inclusion of the serosal surface and myometrium, interchangeably
1576353|NCT02410382|Drug|Dexamethasone|oral dexamethasone 4 mg bid for 14 days
1576354|NCT02410382|Drug|Placebo|oral placebo
1576355|NCT02410369|Drug|S-588410|Following randomization, subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of S-588410.
1576356|NCT02410369|Drug|Placebo|Following randomization, subjects with HLA-A*2402 in the investigational arm will receive the subcutaneous administration of Placebo.
1576357|NCT02410356|Drug|TV-1106|The volume necessary to provide the required weekly dose will be calculated by the investigator; dose will be adjusted for IGF-I in the normal range.
1576358|NCT02410356|Drug|dGH|The dose levels of dGH will be the same as the stable rhGH dose taken prior to the study.
1576359|NCT02410343|Drug|TV-1106|Starting dose titrated to normal range for insulin-like growth factor 1 (IGF-I)
1576360|NCT02410343|Drug|Placebo|Placebo treatment will be administered in a blinded fashion
1576361|NCT02410330|Procedure|Therapeutic ultrasound with 20 usec|A custom designed high mechanical index (MI) impulses at 4-20 usec and >1.0 mechanical index designed for the 1.7 MHz S5-1 transducer
1576362|NCT02410330|Procedure|Repeated diagnostic high mechanical index|Repeated diagnostic high mechanical index impulses (all <2 usec pulse duration; MI=1.0) whenever very low mechanical index perfusion imaging detected microbubbles within the microvasculature
1576363|NCT02410317|Drug|Ropivacaine|
1576364|NCT02410317|Drug|Morphine|
1576368|NCT02410291|Other|Educational video|Patients in the control group will receive standard patient education Patients in the experimental group will receive standard education and an educational video
1576369|NCT02410278|Drug|dimethyl fumarate|Starting dose of 120 mg twice daily orally After 7 days, maintenance dose of 240 mg twice daily orally
1576370|NCT02410278|Drug|montelukast|As described in the treatment arm
1576371|NCT02410278|Drug|Placebo|Matched placebo
1576372|NCT02410265|Behavioral|Lantern: Guided self-help program|"Subject assigned to the Lantern intervention will receive 3-month access to a web-based, CBT-based guided self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD along with access to an e-coach who can monitor their progress in the program and provide feedback and encouragement via messaging and one voice call."
1576373|NCT02410265|Behavioral|Mental Health Online: Self-help program|Subject assigned to the Mental Health Online (MHO) intervention will receive 3-month access to a web-based, CBT-based self-help intervention for GAD. In the program, they receive psycho-education about GAD and the management of symptoms of GAD.
1576374|NCT02410252|Device|iThermonitor|The device is a continuous temperature monitoring tool for home monitoring of temperature
1576375|NCT02410239|Biological|Mesenchymal Stem Cells|
1576376|NCT02410226|Procedure|Double-space combined spinal-epidural anesthesia|Epidural space identification in Lumbar 2-3 or 3-4 space using loss of resistance to air technique with 18-gauge Tuohy needle, then threading a 20-gauge multi-orifice epidural catheter 4-5 cm into the epidural space. Spinal anesthesia administration in an appropriate lower intervertebral space with intrathecal bupivacaine 12.5 mg and fentanyl 10 mcg through a 27-gauge spinal needle.
1576377|NCT02410226|Radiation|Preprocedure spinal ultrasound|Lumbar spinal ultrasound using the 2-5 MHz curved probe, performed in both the longitudinal and transverse planes for identification of the appropriate intervertebral spce, estimation of the depth to the epidural space, and noting the proper angle for subsequent needle insertion. Then skin markings relying on the ultrasound procedure are made identifying 2 intervertebral spaces.
1576378|NCT02410226|Radiation|Sham ultrasound procedure|Applying the ultrasound probe on the patient`s back while the ultrasound machine is on the freeze position.Then skin markings relying on landmark palpation are made identifying 2 intervertebral spaces.
1576381|NCT02410187|Radiation|SBRT|10 Gy x 3 - 20 Gy x 3 (BED 60Gy-180 Gy) or 8 Gy x 4 - 17 Gy x 4 (BED 58-184 Gy)
1576382|NCT02410187|Drug|systemic therapy (chemotherapy, hormon therapy, target therapy etc)|"Physicians can choose all the options available chemotherapy, hormon therapy, target therapy etc.
Use of chemotherapy schemes containing potent enhancers of radiation damage (e.g. gemcitabine,adriamycin) are discouraged within the first month after SBRT."
1576383|NCT02410187|Radiation|palliative RT|fraction size of RT = < 3 Gy
1576384|NCT02410174|Radiation|Stereotactic Body Radiotherapy (SBRT)|
1576544|NCT02408952|Behavioral|Primary Care Physician|The screening, brief intervention and referral to treatment is delivered by the Primary Care Physician
1576386|NCT02410148|Device|Non-invasive ICP measurement (Vittamed 305)|The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA).
1576387|NCT02410135|Drug|Mirabegron|25 mg PO per day for four weeks. if tolerated then uptitrated to 50 mg PO per day for the remaining 8 weeks
1576388|NCT02410109|Behavioral|SCRIPT integrated model|Perinatal women will be screened for psychosocial risks at time of home visiting enrollment. Women exhibiting elevated depressive symptoms and/or have a history of clinical depression who are not currently clinically depressed will be referred for depression prevention services. Women experiencing a depressive episode will be referred for group CBT. Women who screen positive for elevated anxiety symptoms, PTSD symptoms, intimate partner violence, or substance abuse will be referred to a mental health or social service agencies. If a client is referred for services, the assessment worker will provide written educational materials about the risk factor that is being addressed through the referral. At the first home visit, the home visitor will discuss these educational materials.
1576389|NCT02410096|Other|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
1576390|NCT02410096|Other|Methacholine challenge|Nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
1576391|NCT02410096|Dietary Supplement|Oil supplementation verum|Patients and subjects will take double blind an oil supplementation with middle-chain and polyunsaturated fatty acids for four weeks
1576392|NCT02410096|Dietary Supplement|Oil supplementation placebo|Patients and subjects will take double blind sunflower oil for four weeks
1576393|NCT02410083|Drug|Clopirin 1|
1576394|NCT02410083|Drug|Clopidogrel-Aspirin(co-administration) 1|
1576395|NCT02410083|Drug|Clopirin 2|
1576396|NCT02410083|Drug|Clopidogrel-Aspirin(co-administration) 2|
1576397|NCT02410070|Procedure|Incision|The objective of this report is to compare a minimal invasive approach with the conventional flexor carpi radialis approach for volar plating of distal radial fractures.
1576398|NCT02410057|Dietary Supplement|Protein-reduced α-lactalbumin formula|Protein-reduced formula with levels of α-lactalbumin more similar to breast milk and higher than in whey formula
1576399|NCT02410057|Dietary Supplement|Protein-reduced whey formula|Protein-reduced whey formula with higher levels of α-lactalbumin than in standard infant formula
1576400|NCT02410057|Dietary Supplement|Standard infant formula|Standard infant formula
1576401|NCT02410031|Drug|Cyproterone acetate 2mg/ethinylestradiol 35 μg (Diane-35)|Cyproterone acetate 2mg/ethinylestradiol 35 μg
1576403|NCT02410005|Dietary Supplement|Calcitriol|
1576404|NCT02410005|Drug|Losartan|
1576405|NCT02409992|Behavioral|Parent Training plus Emotion Coaching|This intervention will combine a parent management training program called Helping the Noncompliant Child with elements of an Emotion Coaching parenting program.
1576406|NCT02409992|Behavioral|Parent Training only|This intervention will consist of a parent management training program called Helping the Noncompliant Child.
1576407|NCT02409979|Other|Carbon dioxide method|Insufflation with CO2 during insertion and withdrawal phases of colonoscopy.
1576408|NCT02409979|Other|Water Exchange-CO2|Insertion using water exchange, withdrawal using CO2 insufflation.
1576409|NCT02409979|Other|Water Exchange-AI|Insertion using water exchange, withdrawal using air insufflation.
1576410|NCT02409966|Procedure|Quadrant-wise scaling|"Patients underwent quadrant scaling under local anesthesia in four weekly sections. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.
Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
1576411|NCT02409966|Procedure|Full-mouth 24-hour scaling|"Patients underwent full-mouth scaling under local anesthesia in two sections within 24 hours. Three experienced trained periodontists carried out debridement procedures of both protocols with manual Gracey and McCall curettes and Hirschfield files.
Oral hygiene instructions were given for all participants and oral supplies were provided for the duration of the study."
1576414|NCT02409940|Biological|Mesenchymal Stem Cells|These Mesenchymal stem cells are derived from bone marrow of either renal transplant patients or their donors depending upon the group of study.
1576419|NCT02409901|Behavioral|Exercise Rehabilitation|12 month personalized exercise rehabilitation in addition to standard clinical care
1576420|NCT02409888|Behavioral|Motivational Enhancement Therapy|The motivational enhancement therapy will be delivered according to the Project MATCH manual.
1576421|NCT02409888|Behavioral|Cognitive Behavioral Therapy|The cognitive behavioral therapy will be delivered according to the Project MATCH manual.
1576422|NCT02409888|Other|FC Assessment|FC Assessment study participants are exposed to quarterly assessments across broad domains of functioning.
1576423|NCT02409888|Other|IB Assessment|IB Assessment study participants are exposed to semi-annual alcohol specific assessments
1576424|NCT02409862|Drug|Oxytocin Spray|This group will receive the single dose of 24 IU oxytocin, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
1576425|NCT02409862|Drug|Placebo Spray|This group will receive the single dose of 24 IU placebo, self-administered intranasally (IN). Prior to administration a saliva sampling will be done. Afterwards, they will participate in the Choices Study during EEG and eye tracking recording.
1576426|NCT02409849|Drug|Octreotide lar|
1576427|NCT02409836|Drug|Marketed Dentifrice|Marketed Dentifrice
1576428|NCT02409836|Drug|Marketed Flavored Dentifrice|Hawaiian Punch Flavored
1576431|NCT02409810|Drug|Dexmedetomidine|Prior to the burn dressing changes PCA-DEX patients will receive a bolus of dexmedetomidine (Precedex®) 0.25 mcg/kg administered over 10 minutes by nursing staff, followed by a continuous infusion of Precedex® at 0.4 mcg/kg/hr via a standard infusion pump (LifeCare PCA). Patients will self-medicate as needed for anxiety self-management by self-administering a bolus of Precedex® 0.1 mcg/kg. This dosage is within the FDA-approved package insert parameters. Heart rate, blood pressure and oxygen saturation will be closely monitored by a staff RN already trained to provide care in the procedure room. 1 hour prior to- and after completion of the burn dressing change each day using a 100-mm visual analog scale. Patients will both rate their satisfaction with PCA-DEX for anxiety management after each completion of the burn dressing change.
1576432|NCT02409797|Other|Flexion-Distraction (non-thrust) spinal manipulation|Enrolled participants will receive chiropractic care over a 2‐week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach and treatment frequency based upon a participant's clinical presentation. If provided, treatments will include low-velocity (non-thrust) spinal manipulation using the Flexion-Distraction procedure. Recommendations for exercise, lifestyle modifications, or other therapies may also be provided.
1576434|NCT02409771|Device|PRECIZON Presbyopic|Optical correction of aphakia in adults in whom the crystalline lens has been removed and who desire presbyopia correction.
1576435|NCT02409758|Behavioral|Voice therapy|Voice therapy applied during 6 weeks.
1576436|NCT02409745|Procedure|endometrial scratch|local injury to the endometrium by Pipelle
1576437|NCT02409732|Drug|aminolevulinic acid hydrochloride|
1576438|NCT02409732|Procedure|Photodynamic therapy with blue light|
1576439|NCT02409719|Other|Schedule|Illustrative daily planner to point the day that the exercise was performed
1576440|NCT02409693|Procedure|Myringotomy with tube insertion|
1576441|NCT02409680|Drug|Low dose aspirin|Daily administration of low dose (81 mg) aspirin [also known as acetylsalicylic acid (ASA], initiated between 6 0/7 weeks and 13 6/7 weeks GA and continued to 36 0/7 weeks GA compared to an identical appearing placebo. Compliance and outcomes will be assessed biweekly.
1576442|NCT02409680|Drug|Placebo|Placebo
1576443|NCT02409667|Biological|Secukinumab|Secukinumab 300 mg
1576444|NCT02409654|Other|Patient education|(i) Patient education (ii) Assess individual risk of stroke using the CHADS2 and CHA2DS2VASc score and risk of major bleeding using the HAS-BLED score (iii) Recommendation of evidence-based stroke prevention therapy based on international guidelines (iv) Patient audit and follow-up (v) Patients not on appropriate OAC without adequate explanation will be referred to Cardiology Outpatient Clinic for second opinion
1576445|NCT02409654|Other|Routine care|The iECG tracing and report is provided to the attending doctor. Prescription of OAC is left to the discretion of the attending doctor.
1576446|NCT02409641|Drug|Cyclopentolatehydrochloride 0,5% eye drops|1 drop in study eye
1576447|NCT02409628|Device|EktoTherix|The EktoTherix scaffold is applied to the fresh wound resulting from a full thickness excision of non-melanoma skin cancer and then bolstered by the application of a non-adhesive foam dressing (discontinued at the first visit); both scaffold and foam dressing are secured in place using a semi-occlusive film dressing. The EktoTherix-treated wound is assessed weekly as per standard of care.
1576448|NCT02409615|Other|Hypnosis Therapy|A technique called Wakeful Hypnosis that involves suggestions for healing given to a person while in a normal state of consciousness
1576449|NCT02409615|Other|Healing Touch Therapy|Healing Touch An energery based therapy that uses light body or above body touch to help balance the energy field and energy centers of the body to restore harmony within the body for greater healing.
1576450|NCT02409602|Other|Doppler ultrasonographic examination|Dorsal clitoral artery Doppler ultrasonographic examinations will be performed regularly in 3rd and 6th months after delivery, in order to evaluate the possible effects of BIIAL on clitoral blood flow.
1576451|NCT02409589|Device|ECG|The ECG-guided PICC tip detection method will be used to identify catheter tip location during the procedural placement of the catheter. This method involves an ECG monitor which will be connected to the guidewire used for catheter placement. The changes in the ECG p-wave will guide correct PICC placement. An X-ray radiograph will be conducted to confirm the tip location after PICC placement.
1576452|NCT02409589|Procedure|Surface prediction length method|The method will estimate the length of the catheter from puncture site to the junction of superior vena cava / right atrium (SVC-RA) . Tip location is placed according to the estimated length but later on will be determinated by chest X-ray performed after the placement procedure. If the tip location is not at an ideal place, additional procedures and X-ray radiograph would be required in order to ensure proper tip location.
1576453|NCT02409576|Biological|Expanded , Activated NK cells|"Chemotherapy - Each patient will receive immunosuppressive chemotherapy before infusion of NK cells.
Day -7 Cyclophosphamide at 60mg/kg Day -6 Fludarabine at 25mg/m2 daily for 5 days
Radiation - Each patient will receive radiation within 48 hr of NK cell infusion to make the tumor cells more sensitive to NK cell killing Radiation 2Gy
Cytokine support - Each pateint will receive IL-2 to support NK cell activation and expansion in vivo Day -1 alternate day for a total of 6 doses
NK cells - Expanded activated haploidentical NK cells will be infused on day 0."
1576454|NCT02409563|Drug|Budesonide nasal spray (100 mcg bid)|
1576455|NCT02409563|Drug|Budesonide nasal spray (50 mcg bid|
1576456|NCT02409550|Other|CARATKids Questionnaire|
1576457|NCT02409537|Dietary Supplement|red wine|the individuals were given red wine to consume for 1 month then a wash out period of 1 month
1576458|NCT02409537|Dietary Supplement|resveratrol|the individuals were given resveratrol for 1 month and then 1 month wash out period
1576459|NCT02409537|Other|placebo|the individuals were given placebo for 1 month
1576460|NCT02409524|Biological|AlloVax|Personalized anti-cancer vaccine (injection of AlloStim followed immediately by the injection of CRCL)
1576461|NCT02409524|Biological|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
1576462|NCT02409524|Biological|CRCL|Autologous tumor-derived chaperone protein mixture
1576463|NCT02409511|Other|non intervention|
1576464|NCT02409498|Drug|pudendal block|preemptive pudendal nerve blockade with 10 ml of 0 .5 % Bupivacaine with epinephrine.
1577568|NCT02401633|Procedure|S-CPR|CPR with Chest Compressions and Rescue Breaths in a ratio of 30:2
1576466|NCT02409485|Behavioral|Couples Skill-Training (CST)|Patients and partners each receive a workbook and 6 one-hour telephone sessions with a Masters level trained interventionist. Manual content is tailored based on role (patient or partner). Couples participate together via speaker phone for half the sessions and patients and partners receive separate (individual) intervention calls for the other half of the sessions.
1576467|NCT02409472|Other|surveillance program after completion of primary treatment|These are two different surveillance programs for Dukes B2-C colorectal cancer patients who have no evidence of disease at the end of their front line treatment (surgery and adjuvant radio-chemotherapy, if indicated). These programs differ greatly in the frequency of diagnostic imaging. They had similar schedules of physical examinations and carcinoembryonic antigen (CEA) assessments.
1576470|NCT02409446|Dietary Supplement|Anthocyanin|Open pilot study. 35 patients will receive anthocyanin 160 mg x 2 p.o for 16 weeks
1576471|NCT02409433|Drug|lacosamide|"Comparison of patients treated with IV lacosamide to those treated with phenytoin in the intensive care unit setting.
The lacosamide group will receive a loading dose of 400 mg IV, and on maintenance dose of up to 400 mg every 12 hours."
1576472|NCT02409433|Drug|Phenytoin|the phenytoin group will receive a loading dose of 20 mg/K IV, maximum of 2000 mg, given over 60 min. and will be started on a maintenance dose of 5 mg/K/day.
1576473|NCT02409420|Behavioral|Physiotherapy informed by Acceptance and Commitment Therapy|PACT Treatment consists of two 60 minute face-to-face sessions one week apart, of assessment, individualised treatment and exercise prescription, plus one follow-up phone call (lasting 20 minutes), one month after the last treatment session.
1576474|NCT02409407|Drug|Misoprostol , Prostaglandins E1 analogue|
1576475|NCT02409394|Drug|Hetrombopag Olamine|
1576476|NCT02409381|Drug|Motore|250 mg
1576477|NCT02409381|Drug|Alivium|600 mg
1576479|NCT02409355|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 milligrams (mg) by IV infusion on Day 1 of each 21-day cycle until loss of clinical benefit.
1576480|NCT02409355|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 5 IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
1576481|NCT02409355|Drug|Cisplatin|Cisplatin will be administered at 75 milligrams per square meter (mg/m^2) IV infusion once on Day 1 of each 21-day cycle for 4 or 6 cycles.
1576482|NCT02409355|Drug|Gemcitabine|Gemcitabine will be administered at 1000 mg/m^2 (when coadministered with carboplatin) or 1250 mg/m^2 (when coadministered with cisplatin) IV infusion on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles.
1576483|NCT02409342|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 milligram (mg) will be administered as intravenous infusion every 21 days until loss of clinical benefit (as assessed by the investigator), unacceptable toxicity, or death (maximum up to approximately 58 months).
1576484|NCT02409342|Drug|Carboplatin|Carboplatin will be administered as intravenous infusion at a dose of area under the concentration-time curve (AUC) 6 when given in combination with pemetrexed or at a dose of AUC 5 when given in combination with gemcitabine, every 21 days for 4 or 6 cycles as per local standard of care.
1576485|NCT02409342|Drug|Cisplatin|Cisplatin will be administered as intravenous infusion at a dose of 75 mg per meter squared (mg/m^2) every 21 days for 4 or 6 cycles as per local standard of care.
1576486|NCT02409342|Drug|Gemcitabine|Gemcitabine will be administered as intravenous infusion at a dose of 1250 mg/m^2 (in combination with cisplatin) or 1000 mg/m^2 (in combination with carboplatin), on Days 1 and 8 of each 21-day cycle for 4 or 6 cycles as per local standard of care.
1576487|NCT02409342|Drug|Pemetrexed|Pemetrexed will be administered as intravenous infusion at a dose of 500 mg/m^2 on Day 1 of each 21-day cycle as per local standard of care until disease progression (per RECIST v1.1), unacceptable toxicity, or death (maximum up to approximately 58 months).
1576488|NCT02409329|Behavioral|REACH|The intervention consists of daily text messaging tailored to user's individual barriers to medication adherence, text messages assessing user's adherence with feedback on progress, plus text messaging targeting other self-care behaviors.
1576489|NCT02409329|Behavioral|Helpline and A1c results|Participants complete study assessments, receive text messages advising how to access study A1c results, receive quarterly newsletters on healthy living with diabetes, and have access to a helpline for study- or diabetes medication-related questions.
1576490|NCT02409329|Behavioral|REACH + FAMS|The intervention consists of REACH individually-focused text messaging, plus family-focused phone coaching session, goal-focused text messaging, and the option to invite a family member/support person to receive text messaging.
1576491|NCT02409316|Drug|[18F]FES|[18F]FES PET/CT scan
1576493|NCT02409290|Drug|Regimen A locally-used WHO-approved MDR-TB regimen|Drug: Locally-used WHO-approved MDR-TB regimen
1576494|NCT02409290|Drug|Moxifloxacin|Moxifloxacin is an 8-methoxy quinolone, and an anti-bacterial fluoroquinolone
1576495|NCT02409290|Drug|Clofazimine|Clofazimine, is an antileprosy and anti-bacterial agent. Its chemical name is 3-(p-chloroanilino)-10-(p-chlorophenyl)-2, 10-dihydro-2-sopropyliminophenazine.
1576496|NCT02409290|Drug|Ethambutol|Ethambutol is a bacteriostatic that acts against virtually all strains of Mycobacterium tuberculosis and M. bovis and is also active against other mycobacteria such as M. Kansasii.
1576497|NCT02409290|Drug|Pyrazinamide|Pyrazinamide is bactericidal against intracellular mycobacterium tuberculosis. It is a prodrug that is converted into its active form, pyrazinoic acid, by a mycobacterial enzyme, pyrazinamidase, as well as through hepatic metabolism.
1576498|NCT02409290|Drug|Isoniazid|Isoniazid is a bactericidal in vitro and in vivo against actively dividing tubercle bacilli. Its primary action is to inhibit the synthesis of long-chain mycolic acids, which are unique constituents of mycobacterial cell wall.
1576499|NCT02409290|Drug|Prothionamide|Prothionamide has a bacteriostatic action.
1576500|NCT02409290|Drug|Kanamycin|Kanamycin is a bactericidal antibiotic from the group of aminoglycosides.
1576501|NCT02409290|Drug|Levofloxacin|Levofloxacin is a synthetic antibacterial agent of the fluoroquinolone class that acts on the DNA-DNA-gyrase complex and topoisomerase IV. It is the S (-) enantiomer of the racemic active substance ofloxacin.
1576502|NCT02409290|Drug|Bedaquiline|Bedaquiline is a novel diarylquinoline antibiotic with bactericidal activity
1576504|NCT02409264|Other|Individualised Homeopathic Remedy|Sucrose pillules will be medicated with the individualised homeopathic remedy as determined by the researcher, in the potency, dosage and repetition determined by the researcher in accordance with the laws governing homeopathic prescribing.
1576505|NCT02409251|Behavioral|Education and feedback|
1576506|NCT02409238|Drug|Metformin|Metformin dosage schedule: 250 mg thrice a day titrated from 250 mg once a day. Patients will first be started on Metformin 250 mg once a day with meals, and the dose increased to 250 mg twice a day at Day 8, to 250 mg three times a day at Day 15, subject to reports of poor tolerance of gastrointestinal symptoms or other side effects.
1576507|NCT02409238|Behavioral|Intensive Lifestyle Intervention|"The intensive lifestyle interventions for the Active Intervention groups will be done at the Lifestyle Intervention Centres. The aim would to achieve and maintain a weight reduction of at least 7 percent of initial body weight through a healthy reduced-calorie, low-fat diet and engagement in physical activity of moderate intensity for at least 150 minutes per week.
This will be accomplished through a programme of individualized fitness assessment and exercise prescription for cardiovascular, strength and functional training that is standardized across study sites and facilities. The programme comprises an initial 32 sessions (2 times weekly) for supervised gym workout over 16 weeks, followed by maintenance programme of regular unsupervised exercises."
1576508|NCT02409238|Behavioral|Standard LIfestyle Recommendation|The standard lifestyle recommendations for the Control groups are in the form of standard diabetic education pamphlets and a 20-to-30-minute individual session that emphasizes the importance of a healthy lifestyle to reduce their weight and to increase their physical activity. Activity will be monitored using a pedometer.
1576509|NCT02409225|Device|Home Monitoring|Remote monitoring of ICD/CRT-D function and patient condition allow decreasing costs of treatment of patients with ICD/CRT-D (hospitalization, visits in outpatient clinic) and reducing waiting time for medical intervention (remote or in outpatient clinic).
1576510|NCT02409225|Device|no Home Monitoring|Patients with ICD/CRT-D devices provided by St Jude Medical, Biotronik or Medtronic with HM option switched off.
1576511|NCT02409212|Behavioral|Aerobic exercise training|Aerobic exercise training will be undertaken for 12 months, combining supervised and independent exercise sessions. Behaviour change counselling will take place bi-monthly, either via face to face sessions during exercise or via telephone by study clinical exercise specialist according to participant preference.
1576512|NCT02409212|Behavioral|Placebo surveillance and written exercise guidelines|Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
1576513|NCT02409199|Drug|Docetaxel|
1576514|NCT02409199|Drug|apatinib|
1576515|NCT02409186|Drug|Nimotuzumab|400mg/w，d1, week 1-7
1576516|NCT02409186|Radiation|radiotherapy|Three dimensional conformal RT（3DCRT）/IntensityModulatedRadiationTherapy（IMRT）：1.8 Gy/f/day, T59.4 Gy/33f,week 1-7
1576517|NCT02409186|Drug|chemoradiotherapy Paclitaxel|45 mg/m2, d1, week 1-7
1576518|NCT02409186|Drug|chemoradiotherapy Cisplatin|20 mg/m2, d1, week 1-7
1576519|NCT02409186|Other|placebo|400mg/w，d1, week 1-7
1576520|NCT02409173|Device|Noninvasive positive airway pressure flow generator device|Noninvasive positive airway pressure flow generator device.
1576521|NCT02409173|Procedure|Bariatric Surgery|Standard Roux-en-Y gastric bypass
1576522|NCT02409160|Procedure|Standard Roux-en-Y gastric bypass|
1576523|NCT02409147|Procedure|Uterine Transplant|Surgical implantation of a deceased donor uterus, induction therapy with thymoglobulin or basiliximab, maintenance immunosuppression with Prograf, Cellcept, and Prednisone. Anti-infective treatment with Bactrim and Valcyte and Nystatin. Anti-platelet therapy with aspirin. IVF per standard protocol. At time of birth: ceasarean section. Ultimately, transplant hysterectomy.
1576524|NCT02409121|Behavioral|Education information system|Participants will receive a mobile tablet as an educational intervention during the patient's inpatient hospitalization
1576525|NCT02409108|Device|Exatherm-TBH system|One treatment of Total Body Hyperthermia
1576526|NCT02409095|Biological|DTP-HB-Hib vaccine|Diphtheria, Tetanus, Pertussis, Hepatitis-B and Haemophilus influenzae type-B conjugate vaccine (DTP-HB-Hib) has been developed and manufactured by SIIL. The vaccine is pre-qualified by WHO and licensed by the Indian regulatory authority for immunization in children to protect them against above five diseases.
1576527|NCT02409095|Device|Disposable Syringe Jet Injector (DSJI)|Stratis is a needle free injection device manufactured by Pharamjet Inc. and licensed in USA.
1576528|NCT02409095|Other|Needle & Syringe|The conventional needle syringe that is routinely used for vaccination.
1576529|NCT02409069|Device|Transcutaneous vagus nerve stimulation (Nemos®, Cerbomed GmbH)|
1576530|NCT02409069|Device|Sham stimulation (Nemos®, Cerbomed GmbH)|
1576531|NCT02409056|Behavioral|Workplace-tailored CDSMP|This is the CDSMP program which has been modified to fit the unique characteristics of the workplace and will be offered in worksites.
1576532|NCT02409056|Behavioral|Chronic Disease Self-Management Program|This is the standard CDSMP which has been implemented in community settings.
1576533|NCT02409043|Other|Blood draw|Blood drawn for comparison with other groups
1576534|NCT02409043|Other|Stroke blood draw|Participants presenting at the University of Florida Shands Emergency Department with an ischemic stroke. Blood drawn at day 1, day 3, and at 2-8 weeks after stroke, NIH stroke scale scores, modified Rankin scale scores, blood pressure, MRI infarct volumes, and hospital length of stay taken from the medical records. 3 month modified Rankin scale score collected by phone interview.
1576535|NCT02409017|Procedure|Insulin drip|
1576536|NCT02409004|Drug|Ataluren|
1576537|NCT02409004|Drug|Rifampin|
1576538|NCT02408991|Drug|Neupogen|Neupogen is given as an injection in your skin every three days for a total of 5 doses.
1576539|NCT02408991|Device|Art-Assist Device|The programmed pneumatic compression device (PPCD) is to be worn for a minimum of three hours daily while patient is sitting down
1576540|NCT02408978|Drug|OXP005|
1576541|NCT02408978|Drug|Naproxen|
1576545|NCT02408952|Behavioral|Behavioral Medicine Specialist|The screening, brief intervention and referral to treatment is delivered by the Behavioral Medicine Specialist.
1576546|NCT02408939|Drug|Stress-dose hydrocortisone|Patients with postresuscitation shock received stress-dose (300 mg) of hydrocortisone for 7 days maximum followed by gradual taper and discontinuation over 48 hours after either the resolution of their hemodynamic instability or day 7 of treatment.
1576547|NCT02408926|Biological|Boostrix|Pregnant women will be vaccinated with an acellular pertussis containing vaccine between 27 and 36 weeks of gestation.
1576548|NCT02408926|Biological|Infanrix hexa|Children from group A will be vaccinated with an acellular pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
1576549|NCT02408926|Biological|Quinvaxem|Children from group B will be vaccinated with a whole cell pertussis containing vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
1576550|NCT02408926|Biological|OPV|Children from group B will be vaccinated with OPV vaccine according to the official recommendations in Thailand at 2, 4, 6 and 18 months.
1576551|NCT02408913|Biological|VRC-EBOMVA079-00-VP (MVA-EbolaZ)|Ebola Modified Vaccinia Virus Ankara Vaccine
1576552|NCT02408913|Biological|VRC-EBOADC069-00-VP (cAd3-EBO)|Ebola Chimpanzee Adenovirus Vector Vaccine
1576555|NCT02408861|Biological|Ipilimumab|Given IV
1576556|NCT02408861|Other|Laboratory Biomarker Analysis|Correlative studies
1576557|NCT02408861|Biological|Nivolumab|Given IV
1576558|NCT02408848|Other|Observational|This is an observational study. There is no intervention.
1576559|NCT02408835|Device|PICO™|Negative pressure wound therapy device for closed surgical wounds.
1576560|NCT02408822|Device|PTA Balloon dilatation catheter Advance® (Cook® Medical)|2-minutes inflation of the plain balloon on pre-dilated stenosis segment, at nominal pressure
1576561|NCT02408822|Device|Drug-eluting PTA Balloon dilatation catheter Advance® 18 PTX®|2-minutes inflation of the drug-eluting balloon on pre-dilated stenosis segment, at nominal pressure
1576562|NCT02408809|Behavioral|General Smoking Cessation Discussion|This group receives the 5 A's of smoking cessation counseling incorporating how cigarette smoking negatively impacts general health (cancer, MI). 10 minutes in length.
1576563|NCT02408809|Behavioral|Orthopaedic Related Smoking Cessation Discussion|The participants in this group receive a discussion including the 5 A's of smoking cessation counseling incorporating an orthopaedic related smoking cessation discussion about the effects of smoking cigarettes on the musculoskeletal system. 10 minutes in length.
1576564|NCT02408796|Drug|OTO-201|
1576565|NCT02408770|Drug|ulipristal acetate|selective progesterone receptor modulator
1576566|NCT02408757|Procedure|Sonographic monitoring|Sonographic monitoring during weaning of cerebrospinal fluid drainage catheters
1576567|NCT02408744|Drug|Pirfenidone|Pirfenidone was supplied orally in the form of prolonged-released tablets according with body surface area (m2 BS) of each patient. The target dosage of PFD was 1200 mg two times a day (b.i.d.) for a full dosage of 2400 mg daily during three years. Therapy was initiated at 600 mg b.i.d. and escalated to full dosage after 3 weeks when symptoms were controlled.
1576568|NCT02408731|Drug|PMZ-2010 (Centhaquin)|As per the randomization schedule, injection of PMZ-2010 or placebo (100 ml normal saline) will be administered to each subject under supervision of investigator as an intravenous infusion over one hour. PMZ-2010 will be dissolved in normal saline (100 ml) before administration.
1576569|NCT02408718|Behavioral|Assistive Device Training|Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
1576570|NCT02408705|Drug|Liraglutide|They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
1576571|NCT02408705|Drug|Placebo|They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)
1576572|NCT02408705|Drug|Mixed Meal Tolerance Test with paracetamol|At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.
1576575|NCT02408679|Procedure|Blood sampling|One blood sampling will be performed for a serum vitamin D dosage. The volume of blood collected will not exceed 4 ml.
1576576|NCT02408679|Other|Predictive questionnaire for vitamin D insufficiency|The questionnaire includes 19 questions concerning the following topics : a) sun exposure, b) living situation, c) eating habits and Vitamin D dietary intakes. In addition, two questions will capture demographic data.
1576577|NCT02408666|Other|Interview|
1576578|NCT02408653|Device|EEG|
1576579|NCT02408640|Behavioral|Cannabishjalpen.se|
1576580|NCT02408627|Device|EEG|
1576581|NCT02408614|Other|Slow-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a slow-pace.
1576582|NCT02408614|Other|Moderate-paced walking|Subjects will complete 47 minutes of walking on a treadmill at a moderate pace.
1576583|NCT02408614|Other|Interval Training|Subjects will complete 40 minutes of walking on the treadmill alternating between a moderate and a fast pace.
1576584|NCT02408614|Device|Treadmill|
1576585|NCT02408601|Other|Helioseal - F|"Helioseal -F ( Resin based sealant)
isolate the tooth surface
etch the fissure anatomy with 37% phosphoric acid for 20 seconds
wash the tooth surface and dry it. No salivary contamination is accepeted
using a syringe based system, apply the sealant onto the fissures, do not overfill the fissures, run an explorer along the fissures to avoid any air entrapment.
light cure the sealant
check for high points and the occlusion"
1576721|NCT02407548|Dietary Supplement|coenzyme Q10 softgel|4 coenzyme Q10 softgels per day for 24 weeks. Keep normal lift style unchanged.
1577814|NCT02399852|Drug|Lomitapide|
1576586|NCT02408601|Other|ART sealant|"Fuji IX extra strength
isolate the tooth surface
condition the fissure anatomy using a GC conditioner for 10 seconds
wash the conditioner by using a cotton pellet for a couple of times, do not use a three way syringe.
dry the tooth surface
mix the GIC according to the standard powder: liquid ratio
place the mix onto the fissures using a plastic spatula
apply pressure on the occlusal surface with a gloved index finger( the gloved index finger must be coated with petroleum jelly)
apply pressure for 10-15 sec and withdraw the finger in a sideways motion
scrap out the excess material
check for the high points and the occlusion
apply petroleum jelly onto the GIC mix
advice patient not to eat or drink for 30 minutes."
1576587|NCT02408588|Other|Pulse oximeter|Place a pulse oximeter on the subject which will record the pulse oximeter waveform.
1576588|NCT02408575|Device|Notched filtering (verum)|Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3 The Hearing aid with notched amplification filters frequences in a specific manner, depending on the individual tinnitus frequency. Through this special filtering the neuronal functional changes of the auditory cortex are supposed to be affected therapeutically.
1576589|NCT02408575|Device|No filtering (placebo)|"Conventional hearing aid type Carat 7bx with M-Receiver Adjustment by Connexx 7.3
No notched filtering"
1576590|NCT02408562|Other|i.c.v. infusion of sNN0031 by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
1576591|NCT02408562|Other|i.c.v. infusion of aCSF by an Implanted infusion system|I.c.v. infusion during 2 12d cycles separated by 3 mo. 6 mo follow-up after 2nd cycle.
1576598|NCT02408484|Biological|Octafibrin|Plasma-derived Fibrinogen concentrate
1576599|NCT02408471|Device|Ascension® MCP Finger Implant|Patients who meet inclusion/ exclusion criteria are treated with the Ascension® MCP.
1576600|NCT02408458|Device|MIROMESH®|
1576602|NCT02408432|Biological|Human Mesenchymal Stem Cells (hMSCs)|hMSCs by vein delivered as 2 x 10^6 cells/Kg per week (one cycle) over 4 weeks.
1576603|NCT02408432|Other|Standard of Care|Participants receive standard of care drugs for heart failure.
1576604|NCT02408419|Drug|Bupivacaine|Bupivacaine is injected proximally to anesthetize the obturator nerve
1576605|NCT02408419|Drug|Saline|Saline is injected as a placebo
1576606|NCT02408406|Other|Internet-Based Intervention|Use PatientCareAnywhere system
1576607|NCT02408406|Other|Educational Intervention|Use PatientCareAnywhere system
1576608|NCT02408406|Other|Communication Intervention|Use PatientCareAnywhere system
1576609|NCT02408406|Other|Questionnaire Administration|Answer questionnaires
1576610|NCT02408406|Other|Quality-of-Life Assessment|Ancillary studies
1576611|NCT02408393|Drug|Saline|
1576612|NCT02408393|Drug|Ropivacaine|
1576615|NCT02408354|Drug|Triheptanoin|"Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. Triheptanoin is manufactured by chemical synthesis from glycerol and heptanoic acid. Triheptanoin is a liquid, intended for oral (PO) administration.
Participants will be given approximately 1g/kg of Triheptanoin divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose."
1576616|NCT02408354|Drug|Placebo|Placebo is a oily liquid, intended for oral (PO) administration. Participants will be given approximately 1g/kg of Placebo divided at least in three doses (at 8 am, 12 noon, and 8 pm). A one-day titration period will be used, using 0.5 g/kg increments before arriving at the full dose.
1576617|NCT02408328|Drug|Caffeine citrate|Loading dose and continues use of caffeine until 44 weeks postmenstrual age
1576618|NCT02408328|Device|Home monitor|Use of home monitor until 44 weeks postmenstrual age
1576619|NCT02408328|Other|Continued inpatient monitoring until apnea resolution|Continued inpatient monitoring until apnea resolution
1576620|NCT02408315|Drug|misoprostol/placebo|buccal or vaginal routes of administration/ placebo to compare methods for efficacy and safety during induction.
1576621|NCT02408302|Drug|Midazolam|comparison between 3 routes of administration of the drug Midazolam used for sedation for minor procedures in pediatric population. the routes are oral intranasal and buccal.
1576622|NCT02408289|Dietary Supplement|Lo-Flav|low-flavonoid cocoa powder with 0 mg of procyanidins and 0 mg epicatechin per kg of body weight will be consumed as a beverage.
1576623|NCT02408289|Dietary Supplement|Hi-Flav|High-flavonoid cocoa powder with 3.8 mg procyanidins per kg of body weight and 0.6 mg Epicatechin per kg of body weight will be consumed as a beverage.
1576624|NCT02408289|Dietary Supplement|Epicatechin|Low-flavonoid cocoa powder plus 1 mg epicatechin per kg of body weight will be consumed as a beverage
1576625|NCT02408289|Dietary Supplement|Procyanidins|Low-flavonoid cocoa powder plus 3.7 mg procyanidins per kg of body weight will be consumed as a beverage.
1576715|NCT02407613|Device|Philips Sonalleve MR-HIFU Breast Tumor Therapy System|Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) is a completely non-invasive treatment technique. HIFU uses focused ultrasound to achieve temperature rise in the targeted tissue. Real time monitoring of the treatment with MR-thermometry is used to ensure optimal safety.
1577935|NCT02398877|Other|stress|
1576626|NCT02408276|Other|dGEMERIC MRI technique|"Patients will be treated surgically (hip arthroscopy) or nonoperatively (physical therapy) and pain medications as needed. For surgical patients, cartilage samples and surgeon operative reports will be a source of research. For both cohorts, MRIs, radiographs and patient reported outcome surveys will be additional research sources.
All tests and imaging are part of standard of care except follow up MRI, which will be performed in a random group from within the cohort and paid for through this grant."
1576629|NCT02408250|Procedure|Exercise program|Exercise program in intensive care unit established from a decisional algorithm and applied to the critical care unit patients
1576630|NCT02408237|Device|Active tDCS Ambulatory|Procedure begins with the placement of an anode electrode placed on the primary motor cortex (cortex contralateral to the dominant) and the cathode is placed on the contralateral supraorbital region. It is used 1mA direct current transcranial stimulation applied for 20 minutes. Will be held a single session of stimulation. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
1576631|NCT02408237|Device|Sham tDCS Ambulatory|In sham group, we follow the same procedure and time as the active tDCS ambulatory protocol, but the device will be in the mode sham (inactive). The current is only applied for 30 seconds, so subjects feel a sense of the initial stimulation, but not the remainder receive current. In this group one session will also be held. The total time, with initial assessment, tDCS session and final evaluation will be approximately 4 hours.
1576632|NCT02408237|Device|Active tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. Will be explained to the participant as placement of the cap and the device management. This group will be made 11 sessions of tDCS, the first held in the Hospital, with supervision of the researcher. The remaining 10 will be held in the participant's home. The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
1576633|NCT02408237|Device|Sham tDCS Home use|The procedure and stimulation time is exactly the same that Active tDCS - ambulatory use, but will use the apparatus for domestic use. In sham group, we follow the same procedure and time as the active tDCS protocol, but the device will be in the sham mode (inactive). The total time of the first meeting, with initial assessment, tDCS session and final evaluation will be around 4 hours. The time of last evaluation is approximately 1 hour.
1576634|NCT02408198|Behavioral|Anxiety intervention|The intervention is based on a brief CBT for psychosis (CBTp) programme, focusing on understanding and managing anxiety processes that contribute to persecutory threat beliefs when in busy urban environments. The novel aspect of this intervention is that it is delivered in a group format. The intervention consists of six sessions which will be delivered on a weekly basis. Throughout the intervention there is an emphasis on setting tasks to practice applying the new skills outside of sessions, to help the person build confidence in being able to manage paranoia and feel less distressed in their daily life.
1576635|NCT02408185|Drug|Colistin 6 million units + 240mg/8h|240 mg of colistin methanesulfonate (CMS) every 8 hours, 3 million units (MU); 90 mg colistin base activity, (CBA)
1576636|NCT02408185|Drug|Colistin 6 million units + 360mg/12h|360 mg CMS every 12 hours (4.5 MU; 135 mg CBA)
1576637|NCT02408172|Drug|Amlodipine|Amlodipine was given orally in a dose of 5mg/day to treat patients in the OSA-amlodipine group for 12 weeks.
1576638|NCT02408172|Drug|metoprolol|Metoprolol was given orally in a dose of 47.5mg/day to treat patients in the OSA-metoprolol group for 12 weeks.
1576639|NCT02408159|Drug|Varicella Zoster Vaccine|
1576640|NCT02408159|Drug|Placebo|
1576641|NCT02408146|Procedure|conventional intravenous infusion pump|The first group receives conventional intravenous infusion pump of patient-controlled analgesia (fentanyl citrate 20 mg/mL/kg + ondansetron hydrochloride 16 mg/8 mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
1576642|NCT02408146|Drug|parecoxib|The second group has oral celecoxib before surgery, then receives 40 mg parecoxib sodium intravenously guttae twice a day for three days after surgery.
1576643|NCT02408146|Procedure|intravenous infusion pump of patient-controlled analgesia|The third group has oral celecoxib before surgery, and receives 40 mg parecoxib sodium intravenously guttae immediately after surgery, then uses new intravenous infusion pump of patient-controlled analgesia (parecoxib sodium 1 mg/mL + normal saline) for three days after surgery. The pump is infused continuously at the basic flow rate of 2 mL/h, 0.5 mL of bolus can be injected if the patients press the button once upon experiencing pain. The lock-out time for each bolus injection is 15 minutes.
1576644|NCT02408146|Drug|fentanyl citrate+ ondansetron hydrochloride + normal saline|
1576645|NCT02408146|Drug|celecoxib|
1576646|NCT02408133|Other|Home exercise|Will be offered to the group, instructional material (manual exercises) and point you to an exercise routine to be performed independently for range of motion and muscular fitness, using the environmental resources of the same household. A daily frequency in performing this exercise routine is suggested. Also, be given incentives and guidelines for the practice of active commuting (walking) to be accumulated at least 10 to 20 minutes of this activity daily. All control guidelines and training for the use of the exercise manual will be offered through an introductory lecture and subsequent weekly telephone contacts (2 times a week). The participants in this group should fulfill their respective program for a total period of 12 weeks.
1576716|NCT02407600|Drug|FOSAPREPITANT (Emend)|Uee of fosprepitant in EITHER first OR 2nd cycle of carboplatin containing combination chemotherapy in patients with advanced NSCLC
1576717|NCT02407600|Drug|Placebo|
1576718|NCT02407587|Device|cochlear implants|"PET scans for the mature patients with unilateral cochlear implants and preserved hearing
4 states and each state will be repeated 3 times Cochlear implant only Residual hearing only Combination of implant and residual hearing No auditory stimulation"
1576719|NCT02407574|Device|External Pacing Box|Atrial pacing using an external pacing box
1576650|NCT02408107|Behavioral|Physical activity|Physical activity (PA) intervention participants received a 30-45 min face-to-face consultation (1st visit), followed by 15-20 min support telephone calls (end of months 1, 2 and 3). During months 4 and 5 patients received reminder leaflets. Consultations were conducted by the primary researcher after baseline measurements and were based on the four core motivational interviewing principles. The topics covered in the consultation (e.g. goal setting, overcoming barriers, health and safety advice) were similar to other trials that incorporated a PA counselling component. The focus of the follow-up phone calls (end of months 1-3) was to prevent relapse and/or improve maintenance of PA. The intervention participants were encouraged to work towards accumulating at least 30min of moderate-intensity PA on 5-7 days/week.
1576656|NCT02408055|Drug|TA-8995|
1576657|NCT02408042|Drug|Pembrolizumab|
1576658|NCT02408042|Drug|Etoposide|
1576659|NCT02408042|Drug|Ifosfamide|
1576660|NCT02408042|Drug|Mesna|
1576661|NCT02408042|Drug|Carboplatin|
1576662|NCT02408042|Drug|Brentuximab vedotin|
1576663|NCT02408042|Drug|Rituximab|
1576664|NCT02408029|Other|Observational study - no intervention|
1576665|NCT02408016|Biological|Aldesleukin|Given SC
1576666|NCT02408016|Biological|Autologous WT1-TCRc4 Gene-transduced CD8-positive Tcm/Tn Lymphocytes|Given IV
1576667|NCT02408016|Drug|Cyclophosphamide|Given IV
1576668|NCT02408016|Other|Laboratory Biomarker Analysis|Correlative studies
1576669|NCT02408016|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
1576670|NCT02408003|Drug|Levosimendan|"Data is collected at baseline as two controls.
Three physiological interventions follows, and data is collected after each:
Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.
Raising cardiac preload by increasing central venous pressure through leg elevation.
Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.
Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
1576671|NCT02408003|Drug|Milrinone|"Data is collected at baseline as two controls.
Three physiological interventions follows, and data is collected after each:
Increasing heart rate in two steps by atrial pacing through a temporary pacemaker.
Raising cardiac preload by increasing central venous pressure through leg elevation.
Raising cardiac afterload by increasing systemic vascular resistance through administering of phenylephrine.
Baseline is restored, and data is collected before drug adminstration as two controls, then after a first (half) dose, and finally after a second (full) dose."
1576672|NCT02407990|Biological|BGB-A317|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
In the dose expansion part, patients will be assigned to different groups based on their tumor type."
1576673|NCT02407977|Other|Novel nano-scintillatorfiber-optic dosimeter ( nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter ( nanoFOD) for real time dosimetric monitoring of external beam radiotherapy.
1576720|NCT02407548|Dietary Supplement|coenzyme Q10 vitamin E softgel|4 coenzyme Q10 and vitamin E softgels per day for 24 weeks. Keep normal lift style unchanged.
1576674|NCT02407951|Behavioral|CBIT group|"Child group: 8 weekly group sessions lasting 90 mins, additional three monthly booster sessions.
During sessions, children create a tic hierarchy from most to least distressing, with more distressing tics addressed earlier in the treatment. Awareness training and competing response training is implemented and practiced. Competing response training is added, involving engagement in a voluntary behavior physically incompatible with the tic, contingent on the premonitory urge or other signs of impeding tic occurrence. Relaxation training addresses situations that sustained or worsened tics, training focuses on developing individual behavioral strategies to reduce the influence of these factor.
Parallel parent-group sessions simultaneously run during first 4 sessions of child-group. parents-group includes psycho-education and use of reward strategies.
Meetings executed by two trained clinicians."
1576675|NCT02407951|Behavioral|Psycho-Educational group|"Child group: 8 weekly group sessions lasting 90 mins each, as well as additional three monthly booster sessions afterwards.
During the educational group sessions, each session will focus on educating the participants in regard to a specific subject: Tourette syndrome, Self-esteem, Anger, OCD (obssesive compulsive disorder), School and bullying, Anxiety, Attention, and a final session Quiz.
Parent group: Parent-group sessions will simultaneously run during the first 4 sessions of the child-group. The parents-group will include psycho-education and the use of reward strategies.
All group meetings will be executed and managed by two trained clinicians."
1576676|NCT02407938|Other|Rice meal|
1576677|NCT02407925|Behavioral|Feedback|3-monthly or no 3-monthly feedback on results of optical diagnosis
1576678|NCT02407912|Drug|cisplatin|ciplatin in distilled water is injected into the chest for 48 h.
1576679|NCT02407899|Drug|Saxagliptin|saxagliptin tablet 5 mg p.o. qd, 104 week
1576680|NCT02407899|Drug|Vitamin D3|vitamin D drops 2000 IU, qd, 104 week
1576681|NCT02407899|Drug|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
1576683|NCT02407860|Other|osteopathic treatment|Treatment duration range between 30 to 40 minutes. The infant entire body is evaluated and then manipulative procedures are provided following palpatory results.
1576684|NCT02407860|Other|usual breastfeeding counselling|breastfeeding counselling and support by lactation consultant
1576685|NCT02407847|Other|care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
1576686|NCT02407834|Other|S1|Immersion in 0.25% sodium hypochlorite for 20 minutes, during 7 days.
1576687|NCT02407834|Other|S2|Immersion in 0.5% sodium hypochlorite for 20 minutes, during 7 days.
1576688|NCT02407834|Other|S3|Immersion in 10% Ricinus communis for 20 minutes, during 7 days.
1576689|NCT02407834|Other|S4|Immersion in Saline solution for 20 minutes, during 7 days.
1576690|NCT02407821|Drug|Escitalopram|Dose will be initiated at 5 mg daily. At two weeks, a safety and tolerability assessment will be performed, and if tolerated, the dose will be increased to 10 mg daily. At 24 weeks, the medication will be titrated downwards to 5 mg daily for a further two weeks before discontinuation.
1576691|NCT02407821|Drug|Placebo|The matching placebo will be up-titrated and down-titrated at the same time intervals as the active medication.
1576692|NCT02407808|Drug|THC|Active THC (0.0015-0.03 mg/kg) administered over 20 minutes.
1576693|NCT02407808|Drug|Placebo|Control: small amount of alcohol intravenously (quarter teaspoon), with no THC over 20 minutes.
1576694|NCT02407795|Radiation|conventional radiotherapy|1x8Gy
1576695|NCT02407795|Radiation|stereotactic radiotherapy|1x20Gy or equivalent dose fractionation schedule
1576696|NCT02407782|Drug|Ivermectin|oral ivermectin, 200μg/kg given at baseline and at day 10.
1576697|NCT02407782|Drug|Permethrin|topical permethrin 5% cream applied at baseline and at day 10.
1576698|NCT02407769|Dietary Supplement|Late evening supplementation with branched chain amino acids|The patients will drink a Enterex Hepatic bag (500 Kcal, 18.6g of proteins of which 8.63g are branched chain amino acids, 71.7g of carbohydrates and 15.4g of lipids) during late evening (after 19:00 hours) in comparison with the late evening snack group which will eat a snack based in food with the next nutrimental facts (480 Kcal, 19g of proteins based in casein and vegetables sources, 17g of lipids and 63g of carbohydrates) during the same schedule that intervention group.
1576699|NCT02407756|Drug|Dupilumab|
1576700|NCT02407743|Behavioral|Surgical patients' clinical progression|Study the dynamic nature of pain
1576701|NCT02407743|Genetic|Genetic markers|Research variants in genes related to pain sensitivity, analgesic sensitivity and opioid response
1576705|NCT02407691|Other|Primary care 101 plus mental health|A facility-based stepped care intervention combining depression case detection by non-physician clinicians with group counselling intervention delivered by lay-health workers.
1576706|NCT02407691|Other|Standard Primary Care 101|Standard Primary Care 101 guideline with standard training
1576707|NCT02407678|Genetic|AAV-mediated REP1 gene replacement|AAV vector carrying human REP1 gene is delivered into the treated eye by subretinal injection
1576708|NCT02407665|Behavioral|Tai Chi|Each Tai Chi session will last 60 minutes and will continue twice a week for 12 weeks. Our instructors, who have extensive experience conducting Tai Chi training programs, will follow the standardized Tai Chi protocol. We will also provide the participants with printed materials on FM and the Tai Chi Mind-Body program, including Tai Chi principles, practicing techniques, and safety precautions for participants with FM
1576709|NCT02407652|Behavioral|Cognitive Control Training|10 adaptive Paced Auditory Serial Addition Task (PASAT) sessions, 400 trials each
1576710|NCT02407652|Behavioral|Low Cognitive Load Training|10 low cognitive load sessions, 400 trials each
1576711|NCT02407639|Other|CO2|gas
1576712|NCT02407639|Other|air|air
1576713|NCT02407626|Drug|Propofol|Total intravenous anesthesia is a clinical standard procedure
1576714|NCT02407626|Drug|Sevoflurane|Volatile anesthesia is a clinical standard procedure
1576722|NCT02407548|Dietary Supplement|placebo softgel|4 placebo softgels per day. Keep normal lift style unchanged.
1576723|NCT02407535|Device|Intraoperative ultrasound|Diagnostic intraoperative ultrasound in the uterus after hysterectomy for assessing depth of tumor invasion
1576724|NCT02407522|Dietary Supplement|Black rice|They asked to keep their normal life style during intervention
1576725|NCT02407522|Other|follow-up|They asked not to consume any black rice or excess amount of food rich in anthocyanin compared to their normal life style, such as grapes, blueberry, red wine, black bean during intervention.
1576726|NCT02407509|Drug|RO5126766|
1576727|NCT02407496|Other|Behavioral assessment and NAT EEG tests|Individuals in both groups are asked to perform standard behavioral tests and an electroencephalography (EEG) test.
1576728|NCT02407483|Device|Laser Visual Guidance|Laparoscopic simulator training, tested with laser visual guidance
1576729|NCT02407483|Device|2 D vision|Laparoscopic simulator training, tested without laser visual guidance
1576730|NCT02407470|Drug|Rabbit antithymoglobulin (ATG)|Rabbit ATG at 3.5 mg/kg/dose IV is given from day -6 to -2.
1576731|NCT02407470|Procedure|Adipose derived mesenchymal stem cells ( AD-MSCs)|Participants will receive rabbit ATG at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-MSCs at a dose of 3000000 cells/kg/d on day 1-3.
1576732|NCT02407470|Procedure|AD-MSC transdifferentiated HSCs (AD-HSCs)|Participants will receive rabbit anti-thymocyte globulin at 3.5 mg/kg/dose IV from day -6 to -2, and then patient's own AD-HSCs at a dose of 3000000 cells/kg/d from day 1 to 4.
1576733|NCT02407457|Device|AFX EVAR AAA Graft System|Endvovascular Abdominal Aneurysm Repair (EVAR) using commerically available, FDA approved endovascular graft systems implanted via femoral access.
1576734|NCT02407457|Device|FDA Approved EVAR AAA Graft Systems|
1576735|NCT02407444|Other|Physiotherapy treatment & leg cycling|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.
In addition each patient in this group will train with stationary leg cycle ergometer for 20 minutes under physical therapist's supervision . Cycling exercise intensity subjectively determined by the patient using RPE Borg scale . Maximal intensity level determined as 14 in Borg scale."
1576736|NCT02407444|Other|Physiotherapy treatment & music listening|"All patients receive comprehensive care as part of routine rehabilitation program : individual physical therapy treatment, gym's training and balance training in virtual reality, occupational therapy treatment, strengthening and range of motion exercises as a group.
In addition each patient in this group will listen to music with earphone for 20 minutes while sitting under physical therapist supervision.
Overall treatment session will last 50 minutes."
1576737|NCT02407418|Other|Spinal Manipulation|Side-posture, high-velocity low-amplitude spinal manipulation targeting the lumbar spine and sacroiliac joints
1576738|NCT02407418|Other|Sham Manipulation|A simulated lumbar spine manipulation in which no vertebral contact was made
1576739|NCT02407405|Other|Laboratory Biomarker Analysis|Correlative studies
1576740|NCT02407405|Other|Pharmacological Study|Correlative studies
1576741|NCT02407405|Other|Quality-of-Life Assessment|Ancillary studies
1576742|NCT02407405|Drug|Selumetinib|Given PO
1576743|NCT02407392|Drug|Acetic Acid|During endoscopy Acetic acid will be sprayed onto Barrett's oesophagus and targeted biopsies of taken.
1576744|NCT02407392|Procedure|Non targeted quadrantic biopsies|During endoscopy patients will undergo current standard quadrantic Seattle protocol biopsies of Barrett's oesophagus
1576745|NCT02407379|Procedure|PAPD+SRP|Photoablation of the gingival epithelium was performed with at 810 nm diode laser (1 W output power, continuous wave mode, 66.7 J/cm2, a 0.6 mm optical fiber). SRP was performed using curettes. The periodontal tissues and the dental root were rinsed with the photosensitizer agent methylene blue (0.3% w/v in water). After 5 min., the treated areas were irradiated with at 635 nm diode laser (100 mW output power, continuous wave mode, 0.6 mm optic fiber). The photodynamic treatment was repeated once weekly until normalization of the cytodiagnostic parameters (range: 4-10 applications).
1576746|NCT02407379|Procedure|Sham-laser +SRP|Sham-treatment was similar to the previously described treatment but with switched off laser, followed by scaling and root planing
1576747|NCT02407366|Drug|Icotinib|Icotinib (125 mg ,Three times daily)
1576748|NCT02407366|Drug|Pemetrexed|Pemetrexed(500mg/m2)every 21 days
1576749|NCT02407366|Drug|Carboplatin|Carboplatin (AUC，5) every 21 days
1576750|NCT02407366|Radiation|Thoracic radiotherapy(TRT)|TRT (total dose 66Gy, 2Gy per time, once a day, five times a week, a total of 33 times)
1576751|NCT02407353|Drug|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension, single dose at 300 mg and/or 1-2 lower doses
1576752|NCT02407353|Drug|Placebo|Placebo which will be dosed as oral suspension, single doses to match PF-06648671
1576753|NCT02407340|Drug|oxytocin|40 international Units (IU) 3xday delivered as 5 sprays (0.1 mL) per nostril
1576754|NCT02407340|Drug|placebo|5 sprays (0.1 mL) per nostril 3xday; bottles are identical to those of active drug
1576755|NCT02407314|Procedure|Percutaneous Peripheral Intervention|Percutaneous peripheral intervention is a common procedure performed by cardiologists to revascularize peripheral arterial lesions in patients (stent placement). This procedure is considered standard of care and is not experimental.
1576756|NCT02407314|Device|Optical Coherence Tomography|This is an established medical imaging technique that uses light to capture micrometer-resolution, three-dimensional images from within optical scattering media. The device used is a cardiac catheter with OCT sensors on the tip of it. It will be used to assess the artery vessels after Percutaneous Peripheral Intervention.
1576757|NCT02407314|Other|Ankle Brachial Index|This a clinical assessment and consists of the calculation of the ratio of the blood pressure in the lower legs to the blood pressure in the arms. The ABI is calculated by dividing the systolic blood pressure at the ankle by the systolic blood pressures in the arm.
1576758|NCT02407314|Other|Six minute walk distance assessment|Assessment of the walking distance in 6 minutes.
1576826|NCT02406872|Drug|Remimazolam Tosilate|IV pumping for anesthesia
1576827|NCT02406872|Drug|Propofol|IV bolus for anesthesia
1576871|NCT02406547|Device|WLE|Withdrawal from cecum to sigmoid colon with High Definition White Light Endoscopy (WLE)
1576872|NCT02406534|Behavioral|HRQoL surveys|
1576759|NCT02407314|Drug|Aspirin|Aspirin, also known as acetylsalicylic acid [ASA], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels.
1576760|NCT02407314|Drug|Aspirin + Ticagrelor|This is a combination of drugs (Aspirin + Ticagrelor). Aspirin, also known as acetylsalicylic acid [ASA], is a salicylate drug, often used as an analgesic to relieve minor aches and pains, as an antipyretic to reduce fever, and as an anti-inflammatory medication. Aspirin also has an antiplatelet effect by inhibiting the production of thromboxane, which under normal circumstances binds platelet molecules together to create a patch over damaged walls of blood vessels. Ticagrelor is a platelet aggregation inhibitor due to its properties as an antagonist of the P2Y12 receptor. Ticagrelor is a nucleoside analogue: the cyclopentane ring is similar to the sugar ribose, and the nitrogen rich aromatic ring system resembles the nucleobase purine, giving the molecule an overall similarity to adenosine.
1576761|NCT02407301|Other|cough airflow measure|Participants will produce multiple voluntary coughs for cough airflow assessment.
1576762|NCT02407301|Other|vocal tasks|The assessment of glottal closure will be performed during phonation tasks.
1576763|NCT02407301|Other|true vocal fold movement|The true vocal fold (TVF) movement in cough will be observed and recorded during cough production.
1576764|NCT02407301|Other|spirometry test|The lung function test will require the participant to perform deep inhalations and forceful exhalations into the flow head of the spirometer during spirometry test.
1576765|NCT02407301|Other|maximum expiratory pressure (MEP)|The assessment of maximum expiratory pressure will require forceful exhalations into a mouthpiece of a manometer during maximum expiratory pressure (MEP) assessment.
1576766|NCT02407288|Device|transcranial dirrect current stimulation|The tDCS device will deliver a direct current of 2mA during 20 minutes. Cathode will be localized in front of the left orbito-frontal on the FP3 point according to the EEG international reference. Anode will be localized in front of the right cerebellum 3 cm below the inion and 1 cm right from the midline
1576767|NCT02407288|Device|Sham tDCS|
1576768|NCT02407275|Other|Biological sample|
1576769|NCT02407262|Dietary Supplement|Black seed oil|
1576770|NCT02407262|Other|Placebo|vegetable oil
1576771|NCT02407236|Drug|Placebo IV|Placebo will be administered as intravenous infusion.
1576772|NCT02407236|Drug|Placebo SC|Placebo will be administered Subcutaneously.
1576773|NCT02407236|Drug|Ustekinumab IV|Ustekinumab will be administered as intravenous infusion at Week 0 or Week 8 in Induction Study.
1576774|NCT02407236|Drug|Ustekinumab SC|Ustekinumab will be administered as subcutaneously.
1576778|NCT02407210|Drug|azilsartan|
1576779|NCT02407210|Drug|Olmesartan medoxomil|
1576780|NCT02407184|Other|Newborn exposure to mother vaginal microbiota|Babies are swabbed just after delivery with gauze containing their mother's vaginal microbiota.
1576781|NCT02407171|Drug|MK-3475|200 mg every 2 weeks by IV infusion
1576782|NCT02407171|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The starting dose will be 3000 cGy in 5 fractions; there will be one dose escalation cohort (3000 cGy in 3 fractions), and if necessary one dose de-escalation cohort (1000 cGy in a single fraction).
1576783|NCT02407158|Device|SonarMed Airwave Device|Measure the concordance of chest x-ray and the Airwave device for measuring the change of position of an endotracheal tube.
1576784|NCT02407145|Other|24 month follow up of women with validated questionnaire|24 month follow up (clinical and questionnaire based) of women who are already assigned to have a PVDF retropubic midurethral sling (DynaMesh®-SIS soft) as a part of their planned treatment of urodynamic stress incontinence.
1576785|NCT02407132|Behavioral|Family Model DSME|Participants assigned to this arm will received an intervention that includes culturally-adapted DSME with their participating family members in a family/home setting.
1576786|NCT02407119|Drug|7 day H.pylori eradication Omeprazole or Rabeprazole, Clarithromycin, Amoxicillin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Clarithromycin 500 mg bid for 7 days, Amoxicillin 1,000 mg bid for 7 days.
1576787|NCT02407119|Drug|Placebo, Omeprazole or Rabeprazole, Clarithromycin|Omeprazole 20 mg or Rabeprazole 10 mg bid for 7 days, Placebo for clarithromycin 500 mg bid for 7 days, Placebo for amoxicillin 1,000 mg bid for 7 days.
1576788|NCT02407106|Dietary Supplement|Streptococcus Salivarius BLIS K12|Once daily tablet of BLIS K 12 to be slowly dissolved orally every evening.
1576873|NCT02406521|Drug|Pazopanib|
1576791|NCT02407080|Drug|RG7388|RG7388 is supplied as film-coated tablets at dosage strengths of 50 mg, 200 mg, 300mg and 400 mg.
1576792|NCT02407080|Drug|Pegasys|PEGASYS is supplied as a clear, sterile solution for subcutaneous (SQ) injection available in prefilled syringes. weekly doses at 45ug subcutaneously
1576793|NCT02407067|Device|ChatterVox|A voice amplifier will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
1576794|NCT02407067|Device|Easy Listener FM system (Phonic Ear Corp.)|"A personal communication (FM) system will be attached to the participant and used for the treatment of low speech intensity (hypophonia) and reduced speech intelligibility in Parkinson's disease.
Personal Communication System"
1576798|NCT02407041|Drug|GR-MD-02|IV infusion
1576799|NCT02407028|Drug|Hyperbaric oxygen (1.5 ATA, no NBH)|HBO at 1.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
1576800|NCT02407028|Drug|Hyperbaric oxygen (2.0 ATA, no NBH)|HBO at 2.0 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
1576801|NCT02407028|Drug|Hyperbaric oxygen (2.5 ATA, no NBH)|HBO at 2.5 ATA for 60 minutes without NBH. Treatment will be twice a day for five days or until patient is following commands or brain dead
1576802|NCT02407028|Drug|Hyperbaric oxygen (1.5 ATA + NBH)|HBO at 1.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
1576803|NCT02407028|Drug|Hyperbaric oxygen (2.0 ATA + NBH)|HBO at 2.0 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
1576804|NCT02407028|Drug|Hyperbaric oxygen (2.5 ATA + NBH)|HBO at 2.5 ATA for 60 minutes followed by NBH for 3 hours. Treatment will be twice a day for five days or until patient is following commands or brain dead
1576805|NCT02407028|Drug|Normobaric Hyperoxia (NBH)|100% FiO2 for 4.5 hours twice a day for five days or until patient following commands or brain dead
1576806|NCT02407028|Other|Usual Care|Will be treated with usual and customary care for severe traumatic brain injury
1576807|NCT02407015|Other|Nintendo 3DS gameplay|
1576808|NCT02406989|Drug|MS-553|Study Drug
1576809|NCT02406989|Drug|Placebo|Matching placebo to MS-553
1576810|NCT02406976|Other|G1 -Exercise|"20 minutes of aerobic exercises of low intensity (2-4 on the Borg scale) in the rhythm of different songs that encourage their implementation. After these exercises will be performed five minutes of stretching exercises.
Furthermore the similar treatment to G3."
1576811|NCT02406976|Behavioral|G2- Exercise and Lifestyle|"Exercise more techniques of cognitive behavioral therapy based on principles of learning, in order to promote and maintain new healthy behaviors and the reduction or elimination of undesirable conduct.
Furthermore the similar treatment to G3."
1576812|NCT02406976|Other|G3- Control|Routine treatment in outpatient of bariatric surgery. Consists of individual consultations and 05 (five) information meetings organized by the multidisciplinary team composed by the surgeon, endocrinologist, psychologist, psychiatrist, nutritionist, physical education teacher, pulmonologist, cardiologist and nurse. The G1 and G2 will also receive this intervention.
1576813|NCT02406963|Other|Digital Photograph|A digital photograph sent by the family of the surgical site
1576814|NCT02406963|Other|Telephone Call|Standard telephone call with the nurse practitioner
1576815|NCT02406950|Drug|Sitagliptin|The brachial FMD before and after IR injury will be assessed. After randomization, study medication will be treated. In 2 hours later, the brachial FMD before and after IR injury will be assessed again. All volunteers had a wash-out period of 7 days. Seven days later, the subjects returned to crossover study medication (ie, sitagliptin or placebo), and the protocol described above was repeated.
1576816|NCT02406937|Dietary Supplement|Oral intake of Feihe New Formula|Oral intake of Feihe New Formula
1576817|NCT02406937|Dietary Supplement|Oral intake of Feihe Stage 1 Formula|Oral intake of Feihe Stage 1 Formula
1576818|NCT02406937|Dietary Supplement|Breast Feeding|Oral intake of breast milk
1576819|NCT02406924|Procedure|Biopsy|A cylinder of grafted bone will be removed from the location elected for the implant installation with an appropriate trephine
1576820|NCT02406924|Radiation|Computerized Tomography|An initial computerized tomography will be made before the first surgery, and a final computerized tomography will be made after 9 months, previously to the second surgery
1576821|NCT02406924|Other|Standardized periapical radiographs|A device will be adopted for the standardization, and radiographs will be taken at day 0, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
1576822|NCT02406924|Other|Intraoral scanning|Intraoral scanning will be made before the graft, at implant installation, 3 months, 6 months, 12 months, 18 months, 24 months after implant installation
1576823|NCT02406911|Drug|Ticagrelor|After randomization, each group will be treated as assigned dose of ticagrelor (ticagrelor 90mg once a day or 90mg twice a day) for 14 days. After 1 week wash-out period, cross-over study will be performed
1576824|NCT02406898|Device|morcellator uterine system (MH)Karl Storz, Tuttligen- Germany|
1576825|NCT02406885|Drug|Apixaban|New Oral Anticoagulants (NOACs) are currently available for prophylaxis against venous thromboembolism in patients undergoing total hip or knee replacement surgery.
1576874|NCT02406521|Drug|Sorafenib|
1576830|NCT02406846|Other|Flow cytometry (FCM)|Use FCM to test PBMCs/CTCs from volunteers/patients.
1576831|NCT02406846|Other|RT-PCR|Use RT-PCR to test PBMCs/CTCs from volunteers/patients.
1576832|NCT02406833|Drug|TGF-β2 antisense oligonucleotide|intravitreal injection
1576833|NCT02406833|Procedure|Trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control
1576834|NCT02406820|Device|Non-invasive hemodynamic monitoring (CVInsight™ [CVI])|
1576835|NCT02406807|Other|HVLA manipulation|participant is laying on the left side, the practitioner stands in front of the participant's abdomen. The practitioner contacts the interspinous space of the L5-S1 level with the caudal; with the cephalic hand, the practitioner rotates the participant's upper body until a sense of tension is palpated at the L5-S1 segment. The practitioner places his cephalic hand at interspinous, brings participant's leg to a flexion and places the foot at the popliteal fossa, places the forearm at the participant's deltopectoral groove and the caudal forearm at the gluteal region. Following the participant's expiration, the practitioner brings the L5-S1 level to the restrictive barrier by rotating the trunk and hips to opposite directions.
1576836|NCT02406807|Other|Sham Spinal lumbar manipulation|Sham manipulation
1576837|NCT02406794|Drug|Neuromuscular taping|The first group will receive a decalogue of healthy tips (general, to lead an active life) based on the best available evidence, and several strips of neuromuscular bandage will be applied on areas that refer pain (cervical, lumbosacral, both or wrist-forearm).
1576838|NCT02406781|Drug|Combination of MK3475 with Metronomic CP|"Combination of MK3475 with Metronomic CP CP (cyclophosphamide) will be administered per os bi-daily (50 mg x 2), and given on a week on/ week off schedule.
MK3475 will be administered intraveinously, and given every 3 weeks on day 8. A treatment cycle consists of 3 weeks. Treatment may continue until disease progression or study discontinuation."
1576839|NCT02406755|Other|one-sensory self care (Todo Dia®)|daily use of odorless body moisturizer (Todo Dia® - Natura)
1576840|NCT02406755|Other|multisensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura) + audiovisual stimulus
1576841|NCT02406755|Other|bi-sensory self care (Todo Dia®)|daily use of moisturizing body with cotton fragrance (Todo Dia® - Natura)
1576842|NCT02406742|Drug|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
1576843|NCT02406742|Drug|CC-122|CC-122 will be administered daily starting at Cycle 2 Day 1 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
1576844|NCT02406742|Drug|Ibrutinib|
1576845|NCT02406742|Drug|CC-122|CC-122 will be administered daily starting at Cycle 1 Day 9 in 28-day cycles until disease progression, unacceptable toxicity, or discontinuation for any other reason.
1576846|NCT02406742|Drug|Obinutuzumab|Obinutuzumab will be administered as an intravenous (IV) infusion at a dose of 100 mg on Cycle 1 Day 1 and 900 mg on Cycle 1 Day 2 and 1000 mg on Cycle 1 Days 8 and 15. The dose of obinutuzumab on Days 1 and 2 of Cycle 1 may be adjusted per institutional practice as long as the combined dose equals 1000 mg. Obinutuzumab will be administered at a dose of 1000 mg on Day 1 of Cycles 2 through 6.
1576847|NCT02406729|Biological|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
1576848|NCT02406729|Other|Placebo|Route:subcutaneous
1576849|NCT02406716|Other|Biospecimen retention|
1576850|NCT02406703|Drug|Chloroprocaine|
1576851|NCT02406703|Drug|Mepivacaine|
1576852|NCT02406690|Other|Estradiol Valerate, Progesterone in Oil, Leuprolide|Patients will undergo a Leuprolide endometrial preparatory cycle using estradiol valerate, progesterone in oil and once completed will have a uterine aspiration and biopsy performed.
1576854|NCT02406664|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
1576855|NCT02406651|Drug|Recombinant Human Interleukin-22 IgG2-Fc (F-652)|IV infusion of reconstitution lyophilized F-652.
1576856|NCT02406651|Drug|Systemic Corticosteroids|Prednisone (or equivalent) at the time of the onset of clinical symptoms consistent with GI and/or liver aGVHD, as per the standard of care. Prednisone (or equivalent) will be given at a dose of 2 mg/kg/day and tapered as needed.
1576857|NCT02406638|Other|3D pelvic floor ultrasound|Pelvic Floor 3D Ultrasound Clinical evaluation with pad-test, stress test and questionnaires of symptoms and quality of life
1576858|NCT02406625|Behavioral|Behavioral Therapy|16 therapeutic group sessions are delivered to both parents and adolescents; according to the assigned group for each family.
1576860|NCT02406599|Device|Margin Probe|The surgeon will use the MarginProbe System to identify cancerous tissue at the margins (≤ 1mm) of the main ex-vivo lumpectomy specimen following primary excision
1576861|NCT02406599|Other|Control: Additional inspection|The surgeon will perform additional inspection and assessment of the margins of the main ex-vivo lumpectomy specimen following primary excision
1576862|NCT02406586|Drug|Salsalate|Salsalate 750 mg
1576863|NCT02406586|Drug|Carvedilol|Carvedilol 3.125 mg
1576864|NCT02406586|Drug|Placebo|One tablet
1576865|NCT02406586|Drug|Intralipid 20%|24-hour infusion of Intralipid 20% solution at 20 mL/h (96 g/24 h)
1576866|NCT02406573|Device|Crest® Sensi-Stop™ Strips|
1576867|NCT02406560|Drug|tafamidis|fasted
1576868|NCT02406560|Drug|tafamidis|high fat meal
1576869|NCT02406560|Drug|tafamidis|
1576870|NCT02406547|Device|NBI|Withdrawal from cecum to sigmoid colon with Narrow Band Imaging (NBI, Evis Exera III, Olympus)
1576875|NCT02406521|Drug|Radium-223|
1576880|NCT02406482|Behavioral|Microfinance intervention (MF)|Six sessions provided three times per week over two weeks by a study team facilitator. The sessions focus on banking services, savings (including how to open an account), budgeting (including development of a household budget), debt management, and financial negotiations, 1:1 matched savings account for women, followed by vocational training: Women assigned to the HIVRR+MF arm decide during their financial literacy sessions which vocational training program in which they would like to be enrolled (24 sessions).
1576881|NCT02406482|Behavioral|HIV risk reduction (HIVRR)|Four sessions delivered twice a week for the first two weeks. Sessions derive from three evidence-based interventions with demonstrated efficacy to reduce drug and sexual HIV-risk behaviors in vulnerable women. Content focuses on basic transmission risk; educating about the risks of alcohol and drug use and how sexual behavior increases HIV risk; male and female condom use; examining the context for sexual risk including male partner sexual risk behavior (e.g. multiple partners) and violence against women; reducing other sexual risks (e.g., mutual masturbation, correct use of lubricants).
1576882|NCT02406469|Dietary Supplement|Oral consumption milk Tetra Pak|Oral consumption of assigned products in the form of Tetra Pak (A1 or A2 milk according to randomization), 250 ml/time, 2 times daily after meal, for a total of 28 days (14 days in each intervention phase).
1576883|NCT02406456|Other|Neurofeedback|
1576886|NCT02406430|Procedure|a combined cataract and ERM surgery|All patients underwent a combined cataract and ERM surgery owing to visual impairment or disabling metamorphopsia. A complete ophthalmological examination was performed before and at 1,6, and 12 months after the surgery, including best corrected visual acuity with Snellen charts converted into the logarithm of the minimum angle of resolution, slit-lamp biomicroscopy, indirect fundus, and macular optical coherence tomography
1576887|NCT02406417|Device|Investigation for pituitary dysfunction by blood tests.|Blood tests for pituitary function (one or more of the following tests: cortisol, LH, FSH, TSH, FT4, testosterone, prolactin) will be added to samples from patients identified as being at high risk from their initial blood results.
1576888|NCT02406417|Device|Dynamic function tests and pituitary imaging|Patients identified as being highly likely to have a pituitary dysfunction from the results of the blood tests for pituitary function added, will be referred to the Endocrine team for further tests in the form of dynamic function tests and pituitary imaging.
1576889|NCT02406404|Behavioral|Incentive spirometer training|The incentive spirometer, a device that can help improve breathing and strengthen inspiratory muscles. First, the subjects exhaled normally, then placed the mouthpiece in their mouth and sealed their lips around the mouthpiece. Then they inhaled slowly and deeply with their lips sealed tightly on the mouthpiece. After they inhaled as deeply as possible, held their breath for at least 3 seconds, and then removed the mouthpiece from their mouth and breathed out normally. Subjects repeated this technique 10-15 times. When they finished 10-15 exercises, they took a deep breath and coughed. The training was performed ten sessions daily, for 4 weeks.
1576890|NCT02406365|Device|Diagnostic imaging aid for one-visit management of cervical lesions|
1576891|NCT02406352|Device|Multispectral Digital Colposcope with probe|"Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study.
The standard of care for research participants will not change."
1576892|NCT02406339|Device|NMES|Neuromuscular Electrical Stimulation
1576893|NCT02406339|Device|Vascular Occlusion|Restriction of sanguine flow to the lower limbs
1576894|NCT02406313|Other|CTS|Standardized Thermal Cure
1576895|NCT02406313|Other|ETP|Patient Therapeutic Education
1576896|NCT02406300|Procedure|Subarachnoid Anesthesia|
1576897|NCT02406300|Procedure|PNB/GA|
1576898|NCT02406300|Drug|ropivacaine|
1576899|NCT02406300|Drug|sevoflurane or desflurane|
1576900|NCT02406300|Drug|bupivacaine or levobupivacaine|
1576901|NCT02406287|Drug|Netarsudil (AR-13324) Ophthalmic Solution|Topical ophthalmic solution
1576902|NCT02406287|Drug|Netarsudil (AR-13324) Ophthalmic Solution Placebo|Ophthalmic solution once a day
1576903|NCT02406274|Other|Contrast Enhanced Spectral Mammography (CESM)|Women presenting to MSKCC with a palpable abnormality within the breast either self palpated & or palpated by their physician will be offered CESM instead of FFDM alone. The breast imager assigned to care for the patient will interpret the low energy images (including any additional views they routinely obtain) & record their findings. They will then interpret the CESM & record those results. As per standard of care, the patient will have a targeted ultrasound as well. Appropriate clinical recommendations will be made. In patients with no specific imaging findings, follow-up will be determined by the degree of suspicion of the palpable finding & will either be called negative & followed clinically if not suspicious, or will go on to MRI , percutaneous biopsy by a surgeon or surgical biopsy if suspicious.
1576904|NCT02406261|Drug|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
1576905|NCT02406261|Drug|Simvastatin|20 mg simvastatin will be administered orally as 1 × 20-mg tablet
1576906|NCT02406261|Drug|Midazolam|500 mcg midazolam will be administered orally as 0.25 mL of 2-mg/mL syrup
1576907|NCT02406261|Drug|Midazolam|250 mcg midazolam will be administered intravenous (IV) as 0.25 mL of 1-mg/mL injection solution
1576908|NCT02406261|Drug|Donepezil|5 mg donepezil will be administered orally as 1 × 5-mg tablet
1576909|NCT02406261|Drug|Lanabecestat|50 mg lanabecestat will be administered orally as 1 × 50-mg tablet
1576910|NCT02406248|Drug|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)|Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)
1576911|NCT02406222|Drug|Pomalidomide|Chemotherapy
1576912|NCT02406222|Drug|Dexamethasone|Chemotherapy
1576913|NCT02406222|Drug|Cyclophosphamide|Chemotherapy
1576914|NCT02406209|Drug|NS2|NS2 ophthalmic drops (0.5%)
1576915|NCT02406209|Drug|Prednisolone acetate ophthalmic suspension (1%)|
1576916|NCT02406183|Radiation|Stereotactic body radiotherapy (SBRT)|The SBRT dose will be escalated in 3 steps as described above and will be given on d39, d41 and d43
1576917|NCT02406183|Drug|Ipilimumab|Ipilimumab 3mg/kg will be given IV on d1, d22, d43 and d64
1576918|NCT02406170|Drug|Regorafenib|The dose of regorafenib will be escalated in fixed increments to establish the maximum tolerated dose (MTD) from day 1-21 against a cytotoxic backbone of paclitaxel 80mg/m2 on days 1, 8 and 15 of a 28 day cycle
1576919|NCT02406170|Drug|Paclitaxel|Paclitaxel will be administered in combination with regorafenib to serve as a cytotoxic backbone, it will be given in a dose of 80mg/m2 on days 1,8 and 15 of a 28 day cycle.
1576922|NCT02406144|Drug|MLN9708|
1576923|NCT02406144|Drug|Lenalidomide|
1576924|NCT02406144|Drug|Dexamethasone|
1576925|NCT02406131|Other|Remote Ischemic Preconditioning|standard blood pressure cuffs applied to upper limb . The cuff will be inflated to 200 mmHg applied for 5 minutes alternating with 5 minutes rest to the total of 4 cycles
1576926|NCT02406118|Procedure|Transanal total mesorectal excision|Subjects will have their rectal cancer removed using a technique combining surgery through the anus and standard laparoscopy. Transanal visualization will be using endoscopy. At the end of the procedure, the rectum will be removed though the anus or ileostomy formation site, the bowel will be re-connected to the anus, and a temporary diverting stoma will be created, which is standard of care following surgery for this type of cancer.
1576927|NCT02406105|Radiation|Radiosurgical thalamotomy|Cybernetic microradiosurgery based thalamotomy
1576928|NCT02406105|Drug|CyberKnife|
1576929|NCT02406092|Drug|Rituximab|Rituximab SC 1400 mg
1576930|NCT02406092|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice.
1576931|NCT02406092|Drug|Doxorubicin|Doxorubicin will be administered as per standard local practice.
1576932|NCT02406092|Drug|Vincristine|Vincristine will be administered as per standard local practice.
1576933|NCT02406092|Drug|Prednisone|Prednisone will be administered as per standard local practice.
1576934|NCT02406092|Drug|Fludarabine|Fludarabine will be administered as per standard local practice.
1576935|NCT02406079|Procedure|tracheotomy|Tracheotomy is one of most performed surgical procedures to assure airway by making a hole in front of the trachea in ICU.
1576936|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a low dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
1576937|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a medium dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
1576938|NCT02406066|Drug|metyrapone & oxazepam|6 subjects will receive active study drug (a high dose combination of metyrapone & oxazepam) and 2 subjects will receive placebo.
1576939|NCT02406066|Drug|Placebo|Each cohort will have 2 subjects receiving placebo
1576940|NCT02406053|Genetic|oxidative and antioxidant biomarkers|the oxidative damage in these diseases by evaluating the oxidative and antioxidant biomarkers.
1576941|NCT02406040|Other|Energy Restriction|All meals will be provided for the duration of the energy restriction intervention and the energy deficit will be calculated based on estimated energy requirements by indirect calorimetry to provide 60% of energy requirements. In addition, one leg will be assigned to perform resistance exercise for 5 days during the 10 day energy deficit.
1576942|NCT02406027|Drug|JNJ-54861911, 10 mg|Participants will self-administer JNJ-54861911 tablet, 10 mg (2*5 mg), orally, once daily.
1576943|NCT02406027|Drug|JNJ-54861911, 25 mg|Participants will self-administer 1 tablet of JNJ-54861911, containing 25 mg orally, once daily.
1576944|NCT02406027|Drug|Placebo|Participants will self administer placebo matching to JNJ-54861911 orally once daily.
1576945|NCT02406027|Drug|JNJ-54861911, 5 mg|Participants will self-administer JNJ-54861911 tablet, 5 mg, orally, once daily.
1576946|NCT02406014|Drug|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
1576947|NCT02406014|Drug|Diclofenac sodium gel 3%|Diclofenac sodium gel 3% Solaraze® applied on the selected treatment area, twice daily for 90 days.
1576948|NCT02406001|Device|Tigran PTG|Open Flap Debridement
1576949|NCT02406001|Procedure|Surgical intervention|Open Flap Debridement
1576950|NCT02405988|Drug|Intravenous naloxone|Administer 2,5 mL, dose intravenous naloxone 1,0 mg
1576951|NCT02405988|Drug|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto's model at a target of 1,3 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone.
1576952|NCT02405975|Other|SCRIPT|An online tool designed to train doctors in all areas of prescribing
1576955|NCT02405949|Genetic|Genetic test|Analysis of the main genetic variants associated with obesity are evaluated, mainly those related to the regulation of appetite, energy expenditure, adipogenesis, diabetes, inflammation of adipose tissue and others .
1576956|NCT02405936|Procedure|Gynecologic surgery|The researchers prospectively will collect data on all patients undergoing gynecologic surgery at Kangbuk Samsung Hospital since March, 2015.
1576957|NCT02405923|Other|HRF|The subject will take the formula for a period of 12 months.
1576958|NCT02405923|Other|eHF|The subject will take the formula for a period of 12 months.
1576959|NCT02405910|Drug|Nab-paclitaxel|
1576960|NCT02405910|Drug|Gemcitabine|
1577569|NCT02401607|Other|Karasek questionnaire|
1576961|NCT02405897|Device|Cup forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using cup forceps
1576962|NCT02405897|Device|Alligator forceps|In patients with sarcoidosis, flexible bronchoscopy and transbronchial lung biopsy using alligator forceps
1576963|NCT02405884|Other|Kowa HA-2 Perkins applanation tonometer.|Patients were divided into groups according to the days on which they underwent hemodialysis. Intraocular pressure was measured with a Kowa HA-2 Perkins applanation tonometer. The tonometry included three measurements in the central region of the cornea before and after hemodialysis. In all patients, the measurements were performed three times on the days when hemodialysis sessions were performed, with 24 hours between each session, and the means of the measurements were obtained. All parameters were measured under prior corneal anesthesia with 0.1% proparacaine and 0.25% fluorescein eye drops.
1576964|NCT02405858|Drug|Abiraterone Acetate|Abiraterone acetate 1000 milligram (mg) (four 250 mg tablets) orally once daily up to Cycle 26.
1576965|NCT02405858|Drug|Prednisolone|Oral prednisolone 5 mg will be concomitantly administered twice a day (10 mg/day) up to Cycle 26.
1576966|NCT02405845|Radiation|Computed Tomographic Angiogram|1 additional non-clinical CTA per patient enrolled in the study. The estimated radiation risk from a single CTA of the neck and brain is approximately 3.6 millisieverts (mSv), an exposure similar to a single airplane flight across Canada.
1576967|NCT02405832|Dietary Supplement|Zinc|Oral administration of a 40 mg elemental zinc (in the form of zinc sulfate) lozenge, with sweetener and citrus flavor
1576968|NCT02405832|Dietary Supplement|Placebo|Placebo lozenge, with sweetener and citrus flavor, administered orally
1576969|NCT02405819|Other|'My Care Plan'|'My Care Plan' is a patient-initiated survivorship care planning tool.
1576970|NCT02405819|Other|'Survivorship Care Plan Builder'|'Survivorship Care Plan Builder' is a provider-initiated survivorship care planning tool.
1576971|NCT02405806|Dietary Supplement|low carbohydrate food|low carbohydrate food
1576972|NCT02405806|Dietary Supplement|standard food|standard food
1576973|NCT02405793|Drug|Meloxicam Test Capsules|
1576974|NCT02405793|Drug|Meloxicam Test Capsules|
1576975|NCT02405793|Drug|Meloxicam Tablets|
1576976|NCT02405780|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may continue to receive FKB327 40 mg every other week by subcutaneous injection for up to 76 weeks.
1576977|NCT02405780|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 28 weeks. Patients may then receive FKB327 40 mg every other week by subcutaneous injection from week 30 to week 76.
1576978|NCT02405767|Other|Foot ulcer impedance|lmpedence measured using ECG electrodes placed at the periphery of the wound (when the wound dressing is changed as part of standard care).
1576979|NCT02405741|Device|Hyperbaric chamber treatment|
1576980|NCT02405728|Device|Central Venous Catheters|Randomization between two well established clinical routine vascular access devices
1576981|NCT02405728|Device|PICCs|Randomization between two well established clinical routine vascular access devices
1576982|NCT02405715|Drug|Oxytocin|
1576983|NCT02405702|Other|restrospective study|
1576984|NCT02405689|Drug|Remifentanil|
1576985|NCT02405689|Drug|Dexmedetomidine|
1576986|NCT02405689|Drug|Sevoflurane|
1576987|NCT02405676|Drug|Prednisone,Vincristine, Cyclophosphamide|Prednisone 45mg/m2, D1~7; Vincristine 1.5mg/m2(MAX 2mg), D1; Cyclophosphamide 300mg/m2, D1; Intrathecal injection, D1;
1576988|NCT02405676|Drug|Cyclophosphamide, Vincristine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vincristine 1.5mg/m2 (MAX 2mg), D1; Cytarabine 1g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
1576989|NCT02405676|Drug|Ifosphamide, Etoposide, Methotrexate, Vincristine, Prednisone|Ifosphamide 1.2g/m2, D1~5; Etoposide, 60mg/m2, D3~5; Methotrexate, 0.5g/m2, D1;Vincristine 1.5mg/m2 (MAX 2mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1;
1576990|NCT02405676|Drug|Cyclophosphamide, Vindelsine, Cytarabine, Doxorubincin, Prednisone|Cyclophosphamide 800mg/m2, D1, then 200mg/m2, D2~4;Vindelsine 3mg/m2 (MAX 5mg), D1; Cytarabine 2g/m2/dose, (2 doses, 12-hour interval), D4;Doxorubincin 20mg/m2, D2,3; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
1576991|NCT02405676|Drug|Ifosphamide, Etoposide, Methotrexate, Vindelsine, Prednisone|Ifosphamide 1.2g/m2, D1~5; Etoposide, 100mg/m2, D3~5; Methotrexate, 5g/m2, D1;Vindelsine 3mg/m2 (MAX 5mg), D1; Prednisone 60mg/m2, D1~7;Intrathecal injection, D1,8;
1576992|NCT02405676|Drug|Rituximab|375mg/m2, 4 injections for patients in Risk group4; D0 of Protocol AA or BB;
1576993|NCT02405663|Procedure|manual removal|one of the standard procedures for placental delivery during caesarean section the surgeon will introduce his hand into the uterine cavity to cleave the placenta from the decidua basalis as soon as possible after the delivery of the baby
1576994|NCT02405663|Procedure|cord traction|one of the standard procedures for placental delivery during caesarean section the surgeon do external uterine massage and gentle traction on the exposed umbilical cord to facilitate placental delivery
1576995|NCT02405637|Drug|simulated amniotic fluid 20cc/kg/day enterally|simulated amniotic fluid 20cc/kg/day enterally for a maximum of 7 days.
1576996|NCT02405637|Drug|distilled water|distilled water 20 ml/kg/day for maximum of 7 days.
1576997|NCT02405624|Procedure|continuous positive airway pressure|CPAP training for muscle strength
1576998|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
1576999|NCT02405611|Behavioral|behavioral|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
1577000|NCT02405611|Behavioral|primary eduction|The intervention package contains behavior change techniques targeting outcome expectancy, self-efficacy, action planning, coping planning, and self-monitoring. The active control group receives an information sheet regarding recommendations on fruit and vegetable intake. There will be 3 assessment points in time, with 1 1 month and six months in between. All the intervention materials and information sheets will be handed to participants after the baseline assessment. The self-monitoring calendar will be collected at time 2 assessment.
1577001|NCT02405598|Drug|Salbutamol|"Albuterol Syrup (1mL= Salbutamol 0.4mg, 60ml/bot)
VENTOLIN TABLETS 2MG (SALBUTAMOL SULPHATE)"
1577002|NCT02405585|Drug|mFOLFIRINOX|mFOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours - given on days 15, 29, 43, 57, 71 and 85
1577003|NCT02405585|Biological|Algenpantucel-L Immunotherapy|HAPa1 and HAPa2 immunotherapy components Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection for up to 28 doses total.
1577004|NCT02405585|Radiation|SBRT|Subjects that have at least stable disease at evaluation (day 93-100) are eligible to receive SBRT radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
1577005|NCT02405585|Drug|Gemcitabine|"Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles after surgical resection."
1577006|NCT02405572|Other|infant formula|infant formulas
1577007|NCT02405559|Drug|Indocyanine Green|Intradermal injection of Indocyanine Green in the first interdigital space of the studied leg
1577008|NCT02405546|Other|Pre-Rotated (Group R)|In group R, placement of ETT over the FOS was done with 90° CCR from the beginning so that the bevel of the ETT faced posteriorly before it was advanced through the larynx.
1577009|NCT02405546|Other|No pre-rotation|ETT was not pre-rotated but rotated only if necessary
1577010|NCT02405533|Dietary Supplement|AHCC 3 grams once a day|AHCC supplementation x 6 months with Placebo x 6 months
1577011|NCT02405533|Other|Placebo|Placebo supplementation x 12 months
1577012|NCT02405520|Biological|low dosage HPV Vaccine|Participants would intramuscularly receive low dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
1577013|NCT02405520|Biological|medium dosage HPV Vaccine|Participants would intramuscularly receive medium dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
1577014|NCT02405520|Biological|high dosage HPV Vaccine|Participants would intramuscularly receive high dosage of HPV 6/11 bivalent vaccine at 0, 1, 6 month for 3 doses.
1577015|NCT02405520|Biological|Aluminium Adjuvant|Participants would intramuscularly receive aluminium adjuvant at 0, 1, 6 month for 3 doses.
1577016|NCT02405507|Dietary Supplement|wheat bread with wheat germ|
1577017|NCT02405507|Dietary Supplement|wheat bread without wheat germ|
1577018|NCT02405494|Dietary Supplement|Beverage 1|
1577019|NCT02405494|Dietary Supplement|Beverage 2|
1577020|NCT02405494|Dietary Supplement|Beverage 3|
1577021|NCT02405494|Dietary Supplement|Beverage 4|
1577022|NCT02405494|Dietary Supplement|Beverage 5|
1577023|NCT02405494|Dietary Supplement|Beverage 6|
1577024|NCT02405494|Dietary Supplement|Beverage 7|
1577025|NCT02405494|Dietary Supplement|Beverage 8|
1577026|NCT02405494|Dietary Supplement|Beverage 9|
1577027|NCT02405481|Behavioral|SEPA III|
1577032|NCT02405416|Procedure|Infrahepatic inferior vena cava clamping|Infrahepatic inferior vena cava is clamped in hepatectomy.
1577033|NCT02405416|Procedure|Selective hepatic vascular exclusion|Selected major hepatic vein is clamped in hepatectomy.
1577034|NCT02405416|Procedure|Portal triad clamping|Portal triad are clamped in hepatectomy.
1577035|NCT02405403|Drug|[18F]DPA-714 PET|[18F]DPA-714 Positron Emission Tomography
1577036|NCT02405390|Procedure|Video Laryngoscopy|Head motion will be measured by using Polhemus Patriot™ electromagnetic tracking system
1577037|NCT02405390|Procedure|Direct Laryngoscopy|Time for intubation will be measured from the laryngoscope entering the mouth to the endotracheal tube passing through the vocal cords
1577038|NCT02405390|Device|Storz C-Mac® laryngoscope|
1577039|NCT02405377|Procedure|hydration|Before the coronary procedures, investigators used the same 0.9% sodium chloride for hydration in all patients. Investigator monitored the central venous pressure (CVP) by placing an 5-French catheter in the jugular vein in the intervention group, and administration fluid rate was adjusted according to the CVP as follows: 3 ml/kg/h for CVP lower than 6 mmHg, 1.5 ml/kg/h for pressure of 6-12 mmHg, and 1ml/kg/h for pressure higher than 12 mmHg. The control group was hydrated with 0.9% sodium chloride at 1 ml/kg/h, continued for the duration of 12 h post-procedure in both groups. Thus, both study groups received intravenous fluids for the same duration but at different rates. All study participants received intra-arterial Visipaque(320 mg I/ml; GE Healthcare) iso-osmolar contrast medium.
1577040|NCT02405377|Drug|Visipaque|All study participants received intra-arterial (320 mg I/ml; GE Healthcare)
1577041|NCT02405377|Drug|0.9% sodium chloride ﬂuid administration|
1577042|NCT02405377|Device|5-French catheter|
1577043|NCT02405364|Drug|Carfilzomib/Lenalidomide/Dexamethasone|Induction:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Stem Cell harvest: HD Cyclophosphamide Intensification: HD Melphalan Consolidation:Carfilzomib/Lenalidomide/Dexamethasone (4 cycles every 28 days) Maintenance: Lenalidomide (13 cycles)
1577080|NCT02405065|Drug|HM95573|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
1577081|NCT02405052|Other|No intervention|Validation of the Panic Screening Score
1577044|NCT02405351|Behavioral|Adaptive Working Memory Training|"The working memory training task will consist of an online adaptive working memory program that will test and extend patients' working memory capacity.
Adaptive refers to the increase in the number of items that the patient is required to remember."
1577045|NCT02405338|Biological|WT1/PRAME vaccination|
1577047|NCT02405312|Behavioral|advance care planning|patient and family meeting with dialysis social worker and nephrologist with discussion of advance care planning and hospice resources
1577048|NCT02405299|Other|experimental groupe|exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
1577049|NCT02405286|Other|Upper gastrointestinal endoscopy|Upper gastrointestinal endoscopy, if stigmata of recent hemorrhage are seen, varices are either injected with ethanolamine or banded, depending on the clinical setting and availability .
1577050|NCT02405273|Procedure|Pulmonary Rehabilitation|The Intervention Group (IG) will receive an overall rehabilitation treatment based on 10 sessions of pre-operative outpatient PR, early inpatient post-operative PR, and long-term exercise beginning 1 month after surgery and lasting for 15 sessions
1577051|NCT02405273|Procedure|Standard care|Control Group (CG) will receive Standard Care (SC) based upon physiatrist counselling the day before surgery and early inpatient post-operative PR.
1577052|NCT02405260|Drug|TTP399 400 mg|once daily
1577053|NCT02405260|Drug|TTP399 800 mg|once daily
1577054|NCT02405260|Drug|Sitagliptin 100 mg|once daily
1577055|NCT02405260|Drug|Placebo|once daily
1577056|NCT02405247|Other|Patient Reported Outcome (PRO)|Exposure to Quality of Life Questionnaires (EORTC QLQ-LC13, EORTC QLQ-C30 and EQ-5D-5L) every 3 months during standard of care visits.
1577057|NCT02405234|Device|Carbon Modular Radial Head replacement|'Carbon Modular Radial Head replacement: The Ascension Radial Head is made of pyrocarbon, a material that testing has shown to be both wear resistant and biocompatible and has been used in surgical implants for years. The introduction of the pyrocarbon head should alleviate the problems associated with wear debris and fragmentation experienced with the silicone radial spacer.
1577058|NCT02405234|Device|Metal Radial Head replacement|Metal Radial Head replacement:The Ascension® Modular Radial Head (MRH) is an anatomically designed, single-use, modular prosthesis designed for replacement of the proximal end of the radius. FDA cleared this device for commercial distribution under 510(k) K032686. It is made from medical grade cobalt chromium alloy meeting ASTM F1537. Head components are available in six sizes and stem components are available in four sizes are interchangeable and assembled with a taper connection.
1577059|NCT02405221|Biological|TA-CIN|This pilot study is a single dose level assessment of the immunologic response as well as the safety and tolerability of administering TA-CIN vaccine via different sites in patients who have a history of HPV16-related cervical cancer.The dose of TA-CIN is fixed (180µg). The site of administration is assigned by randomization. Patients will receive 3 doses of the TA-CIN 4 weeks apart (Weeks 1, 5, and 9). Patients will be followed for 2 years after the 1st dose is given.
1577060|NCT02405208|Device|PyroTITAN HRA|Humeral resurfacing using the PyroTITAN HRA device
1577061|NCT02405195|Procedure|cardiopulmonary bypass|During cardiac surgery, the subjects are routinely undergoing cardiopulmonary bypass
1577062|NCT02405182|Other|Magnetic Resonance Imaging|
1577063|NCT02405169|Device|4 vs 6 implant treatment in the maxilla|
1577064|NCT02405156|Drug|Letrozole|
1577065|NCT02405156|Drug|Placebo|
1577066|NCT02405156|Drug|Misoprostol|
1577067|NCT02405143|Device|Active tACS using DC-Stimulator MC|Transcranial alternating current stimulation (tACS) is administered using DC-Stimulator MC (NeuroConn GmbH, Ilmenau Germany). Stimulation is administered through two 5 cm2 saline-soaked electrodes placed in the Fpz position and on the right arm. Stimulation will consist of short blocks, during which stimulation frequency will be ramped up to 30Hz with maximum current of 1.5mA. Stimulation will be administered for 20 minutes on 10 consecutive weekdays.
1577068|NCT02405143|Device|Sham stimulation using DC-Stimulator MC|Patients in the sham group will undergo the same preparations as the treatment group. This includes using an identical electrode placement and session duration as for the experimental arm. In order to create the effect of phosphenes, one 5Hz current burst per minute will be administered using the individual phosphene threshold of the patient. This is not expected to have therapeutic effects.
1577069|NCT02405130|Other|intracoronary epinephrine|after failure of standard therapy patients will treated with epinephrine
1577070|NCT02405130|Other|no intracoronary epinephrine|patients will receive standard therapy only
1577071|NCT02405117|Behavioral|LiveWell System|For 16 weeks, participants will be asked to carry a mobile phone and wear a wrist-worn device for measuring activity. Participants in this arm will receive the psychosocial intervention via a smartphone and context-dependent feedback based on self-report and behavioral data. Providers whose patients are randomized to this arm will also be asked to enroll in order to receive information and notifications about patient status for the duration of the study
1577072|NCT02405104|Drug|chlorzoxazone|ATC-code: M03BB03
1577073|NCT02405104|Drug|Placebo|Placebo
1577074|NCT02405104|Procedure|THA|Surgical treatment of osteoarthrosis in the hip, by replacement.
1577075|NCT02405104|Procedure|TKA|Surgical treatment of osteoarthrosis in the knee, by replacement.
1577076|NCT02405091|Drug|NBI-98854|
1577077|NCT02405078|Drug|18F-fluorodeoxyglucose|Participants injected with 18F-fluorodeoxyglucose intravenously with a typical dose range of 7-12 mCi (259 - 444 MBq) before each FDG-PET scan.
1577078|NCT02405078|Procedure|FDG PET/CT Imaging|With day 1 designated as start of chemotherapy, FDG PET/CT scans performed sequentially between day -21 - day 0 (baseline PET), day 4 (interim PET1, after completion of 1st high dose chemotherapy), day 21 (interim PET2, after completing 1st cycle of chemotherapy), and day 42 (end of therapy PET).
1577079|NCT02405078|Procedure|Blood Draws|Blood draws on day -5 - 0, day 4, day 8, day 21 and day 42.
1577082|NCT02405039|Drug|EBI-005|EBI-005 is an intervention into one of two (2) study arms; 5 mg/mL topical administered 3 times per day
1577083|NCT02405039|Drug|Placebo|Placebo or Vehicle control comparator is an intervention into one of two (2) study arms; vehicle topical administered 3 times per day
1577084|NCT02405013|Drug|Sofosbuvir|Sofosbuvir 400mg QD (Sovaldi®) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
1577085|NCT02405013|Drug|Ribavirin|Ribavirin weight-adjusted dosing (1000mg BID in patients < 75kg and 1200mg BID in patients ≥ 75kg) in treatment-naïve patients infected with HCV genotype 2 (12-week course)
1577086|NCT02405013|Drug|Sofosbuvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
1577087|NCT02405013|Drug|Ledipasvir|Sofosbuvir/Ledipasvir 400mg/90mg (Harvoni®) in treatment-naïve patients infected with HCV genotype 1 or genotype 4 (12-week course)
1577088|NCT02405000|Other|Intraoperative CT imaging|Intraoperative CT scan of the upper aerodigestive tract during laryngoscopy procedure
1577089|NCT02404987|Other|Nutritional Supplement|
1577090|NCT02404974|Behavioral|exercise|Participants will meet with a Certified Fitness Trainer and engage in shared goal setting and selection of a CDC-recommended exercise program for OA that best fits their needs and preferences, specifically addressing any identified barriers. The Trainer will use programs from a vetted list of programs that are appropriate for older adults with knee OA, and modify as needed. This list will be developed with the Certified Fitness Trainer and the PI. The Trainer will be available to answer questions and will contact each participant by phone every two weeks to find out how participants are doing; make adjustments to the program, if needed; and provide motivation and encouragement.
1577091|NCT02404961|Other|Vulvodynia|Comparison of reproductive, gynecological and environmental exposures, psychological trauma and psychiatric morbidity, and biological markers of immuno-inflammation and nerve fiber proliferation between cases and controls to determine potential etiology of vulvodynia.
1577092|NCT02404948|Other|Diagnostic algorithm|Validation of a diagnostic algorithm used to detect coronary artery disease and/or myocardial ischemia based on pulse wave analyses.
1577093|NCT02404935|Drug|Cetuximab|
1577094|NCT02404935|Drug|FOLFIRI and cetuximab|
1577095|NCT02404922|Drug|CTP-730|
1577096|NCT02404922|Drug|Placebo for CTP-730|
1577097|NCT02404909|Other|IVC diameters evaluation by intraoperative ultrasound|Out of consecutive patients who underwent hepatectomy for primary and secondary liver tumors, patients in whom IVC diameters were intraoperatively measured for clinical reasons were retrospectively selected and analyzed
1577098|NCT02404896|Drug|Metreleptin|Metreleptin open-label treatment
1577099|NCT02404883|Other|Online Decision-Aid Tool|
1577100|NCT02404870|Drug|Placebo|
1577101|NCT02404870|Drug|Canagliflozin|Canagliflozin is a new oral drug for the treatment of type 2 diabetes mellitus (T2DM), and is one of two recently FDA approved sodium glucose co-transporter 2 (SGLT2) inhibitors, which target renal glucose reabsorption and offer promising improvement in HbA1C.
1577102|NCT02404857|Device|EEG based Brain Computer Interface|Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
1577103|NCT02404844|Drug|BKM120|daily oral
1577104|NCT02404844|Drug|Tamoxifen|daily oral
1577105|NCT02404831|Other|Web-based PR|Participants will undertake web-based PR twice/week for 6 weeks in their own home. They will be given individual log-in details to access the website with access to exercises and education pages. Participants will be provided with a standardised exercise programme at the start of the study. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Participant log-ins and diaries will be monitored remotely and participants will be telephone at weeks 2 and 4 by their physiotherapist to discuss their progress and, at this time, exercises may be progressed by changing the level of difficulty/intensity. This is done remotely by physiotherapy staff.
1577106|NCT02404831|Other|Hospital-based PR|Participants allocated to this group will undertake hospital-based PR twice per week for 6 weeks in. Participants attend PR classes and complete a circuit based exercise class. The level of intensity of exercises will be progressed as appropriate on an individual basis for all participants in the group. Following each class they will receive educational information about their condition.
1577107|NCT02404818|Procedure|Cardiac Magnetic Resonance Imaging|A cardiac MRI will be performed.
1577108|NCT02404818|Procedure|Echocardiogram|An echocardiogram will be performed for the following information: M-mode, two-dimensional, Doppler blood flow measurements, and longitudinal strain and strain rate imaging
1577109|NCT02404805|Drug|dolutegravir|dolutegravir tablets 50mg, once daily x 7 days.
1577110|NCT02404805|Drug|simeprevir|simeprevir tablets 150mg, once daily x 7 days.
1577111|NCT02404792|Other|High-intensity cardiovascular and resistance exercise|
1577112|NCT02404792|Other|Moderate-intensity cardiovascular and resistance exercise|
1577113|NCT02404779|Drug|cisatracurium besilate|
1577114|NCT02404766|Other|C0-C1 dorsal glide manual mobilization|
1577115|NCT02404766|Other|C7-T1 ventral cranial glide manual mobilization|
1577116|NCT02404753|Drug|Neoadjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 3 courses.
1577117|NCT02404753|Procedure|Laparoscopic gastrectomy|Laparoscopic distal gastrectomy with D2 lymph node dissection
1577118|NCT02404753|Procedure|Open gastrectomy|Open distal gastrectomy with D2 lymph node dissection
1577119|NCT02404753|Drug|Adjuvant Chemotherapy|XELOX: Oxaliplatin 130mg/m2,iv.,d1;Capecitabine 1000mg/m2,po.,Bid,d1-14; Repeat every 21 days for 5 courses.
1577120|NCT02404740|Device|Pulse oximetry|Pulse oximetry
1577121|NCT02404727|Procedure|cup fixation|All patients will preoperatively, 3 months, 1 year, 2 year and 5 year have the hip DXA scanned, answer PROM, X-ray for RSA analysis and wear measurements, and wear accelerometry chip 14 days prior each outward clinic visit for movement analysis.
1577122|NCT02404727|Device|Avantage® Cup|
1577136|NCT02404675|Drug|icotinib|
1577123|NCT02404714|Device|Iontophoresis sweat test|The intervention is iontophoretic sweat testing which includes the stimulation, collection and analysis of sweat. The standard of care sweat testing used at each institution will be compared to a new iontophoresis sweat test called the CF Quantum.
1577124|NCT02404701|Dietary Supplement|Aloe vera with cactus|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
1577125|NCT02404701|Dietary Supplement|Cranberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
1577126|NCT02404701|Dietary Supplement|Green tea extract|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
1577127|NCT02404701|Dietary Supplement|Bilberry|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
1577128|NCT02404701|Dietary Supplement|Cinnamon|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
1577129|NCT02404701|Dietary Supplement|Milk thistle|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
1577130|NCT02404701|Dietary Supplement|Turmeric|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
1577131|NCT02404701|Dietary Supplement|Aloe vera|Eligible participants who provide consent/authorization will report for an orientation visit (1 of 3 visits), during which participants will: provide a medical history and a 24-hour diet recall, have height and weight measured, learn how to collect 24-hour urine, receive instructions on following a standardized diet for 7 days, learn to use a food scale and provide diet records, and receive a 4-day supply of the supplement they were allocated to take along with instructions. After 3 days on the diet (no supplement), participants will return their first (of 2) diet record and 24-hour urine collection. After 4 days on the diet while taking the supplement, participants will return their second (and final) completed diet record and their second (and final) 24-hour urine collection.
1577132|NCT02404688|Drug|Active delta-9-THC|"Low dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4 of a marijuana cigarette, or joint. Administered over 20 minutes."
1577133|NCT02404688|Drug|Placebo|Control: small amount of alcohol (quarter teaspoon), with no THC. Administered over 20 minutes.
1577134|NCT02404688|Drug|Active Ethanol|Target BrAC of 0.04% reached over 20 minutes and then clamped to maintain this dose for an additional 60 minutes. This dose is equivalent to consuming approximately 2 drinks over 1 hour. Administered over a total of 80 minutes.
1577135|NCT02404688|Drug|Placebo|Control: no alcohol, administered for a total of 80 minutes.
1577137|NCT02404662|Other|Supportive text messages intervention|"The supportive text messages are based on existing aphorisms in the recovery literature. Each day patients will receive one message targeting mood and another message targeting abstinence from alcohol in accordance with the primary aims of our study. An example text message aimed at improving mood is: Monitor changes in your mood; develop a list of personal warning signs. An example message targeting abstinence is: Keep Sobriety as a number one priority and you will reach your goals. None of the messages will be repeated. The messages will be sent in the morning and evening, with the theme (mood/alcohol) of the messages pseudo-randomised according to delivery time, so that no more than three successive days will have the same theme sent at the same time slot."
1577138|NCT02404662|Other|Control group|The control group will receive treatment as usual, as well as fortnightly thank you text messages and calls to ensure that they are still using their phone.
1577139|NCT02404649|Device|Two implant designs in a Sinus Bone Augmentation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus bone augmentation procedure.
1577140|NCT02404649|Device|Two implant designs in a Sinus Floor Elevation Procedure|Comparing TMDI (Zimmer Dental- Carlsbad, CA, USA) and Tapered Screw-Vent TSV-MTX (Zimmer Dental- Carlsbad, CA,USA) biological behavior after a sinus elevation only procedure.
1577141|NCT02404636|Other|Interview|Brief structured interview
1577142|NCT02404623|Dietary Supplement|Vitamin D|also known as Cholecalciferol, is one of the two most important compounds within the group of Vitamin D. It can be ingested from the diet and from supplements. In this study it is pharmacologically acquired and referred to as Vitamin D
1577143|NCT02404610|Procedure|Moderate Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of moderate. Moderate sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
1577144|NCT02404610|Procedure|Deep Procedural Sedation with a sedative medication.|procedural sedation with a target sedation depth of deep. Deep sedation is not a drug specific intervention, it is achieved with the use of a sedative or a combination of sedations and opioids.
1577145|NCT02404610|Drug|propofol|
1577146|NCT02404597|Device|NICOM (non-invasive cardiac output monitor)|"The non-invasive cardiac output monitor (NICOM) will be used to tailor fluid management to optimize resuscitation if the patient has an episode of hypotension (defined as systolic blood pressure <100 or mean arterial pressure <65). NICOM consists of two electrodes placed on the patient's chest and back and uses bioreactance technology to transduce signals to compute hemodynamic parameters on an associated monitor.
The electrodes will remain on the patient for twenty minutes. Once the electrodes are in place the patient's leg will be raised to 45 degrees and the monitor to which the electrodes are attached will generate a number that reflects stroke volume of the heart. The electrodes will be removed once this number is determined."
1577149|NCT02404571|Drug|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
1577150|NCT02404558|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: Subcutaneous injection
1577151|NCT02404558|Drug|tocilizumab|Pharmaceutical form:solution Route of administration: Subcutaneous injection
1577152|NCT02404545|Device|Ethicon Physiomesh|Ethicon Physiomesh will be paced at the time of radical cystectomy and ileal conduit.
1577153|NCT02404532|Device|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one placebo-embedded IEM tablet approximately every other hour, for a total of 4 ingestions. Subjects may eat as they wish over the course of the day. Placebo-embedded IEM tablets are being tested to measure the accuracy of IEM detection by the MIND1 system. Clinic staff will record the time of each ingestion of an IEM. Clinic staff will check the compatible computing device (eg, smartphone) at 30-minute intervals for the presence of a timeline ingestion tile and will record the time it is detected by the MIND1 System compatible computing device (eg, smartphone).
1577154|NCT02404519|Dietary Supplement|Menaquinone-7|1 tablet containing 180 micrograms MK-7 taken orally every day during 1 year
1577155|NCT02404519|Dietary Supplement|Placebo|1 tablet without MK-7 taken orally every day during 1 year
1577156|NCT02404506|Drug|Eribulin mesilate|Eribulin mesiylate 1.1mg/m2 d1, 8 every 3 weeks until Progressive disease PD
1577157|NCT02404493|Device|EpiCeram Skin Barrier Emulsion|EpiCeram Skin Barrier Emulsion
1577158|NCT02404493|Drug|1% Colloidal Oatmeal Balm|Experimental Product 1% Colloidal Oatmeal Balm
1577159|NCT02404480|Drug|PTC596|
1577161|NCT02404454|Procedure|Hysteroscopic metroplasty|
1577162|NCT02404454|Device|Autocross-linked acid hyaluronic gel|Patients received adhesion barrier with 5 ml of autocross-linked acid hyaluronic gel
1577163|NCT02404454|Procedure|Office second look hysteroscopy|Second-look hysteroscopy after three months
1577164|NCT02404441|Biological|PDR001|anti-PD1 antibody
1577165|NCT02404428|Dietary Supplement|Standard broccoli soup|300g/week of standard broccoli soup consumed for a period of six months delivering standard level of glucoraphanin (sulforaphane precursor)
1577166|NCT02404428|Dietary Supplement|Beneforte extra broccoli soup|300g/week of beneforte extra broccoli soup consumed for a period of six months delivering enriched levels of glucoraphanin (sulforaphane precursor)
1577167|NCT02404402|Other|LED|Low Level Light Therapy
1577168|NCT02404402|Other|sham LED|Inactive (sham) LED treatment
1577301|NCT02403570|Other|Brain MRI|
1577302|NCT02403557|Behavioral|Waitlist|Weekly check up.
1577656|NCT02400983|Device|Pacemaker, ICD|
1577174|NCT02404363|Drug|Clopidogrel|"Clopidogrel tablets 75 mg for six months:
In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> clopidogrel 75 mg/d If aspirin = 0 + LMWH = 0 --> clopidogrel 150 mg/d x 7days then 75mg/d"
1577175|NCT02404363|Drug|Placebo|"Placebo tablets 75 mg for six months:
In case of treatment with aspirin < or = 75 mg/d or prophylactic LMWH --> placebo 75 mg/d If aspirin = 0 + LMWH = 0 --> placebo 150 mg/d x 7days then 75mg/d"
1577176|NCT02404350|Biological|Secukinumab|Anti IL-17a monoclonal antibody
1577177|NCT02404337|Drug|Betaine|
1577178|NCT02404324|Other|Prescription of spectacles|All children are prescribed full optical correction of refractive errors with special attention to astigmatism up to 0.5 Dptr to achieve maximal clear image on the retina of both eyes.If necessary, direct occlusion or penalization are administered to the children.
1577179|NCT02404311|Biological|ALVAC-HIV|a lyophilized vaccine for injection at a viral titer ≥ 1 × 10E6 cell culture infectious dose (CCID)50 and < 1 × 10E8 CCID50 (nominal dose of 10E7 CCID50) and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for intramuscular (IM) injection as a single dose.
1577180|NCT02404311|Biological|Bivalent Subtype C gp120/MF59®|2 recombinant monomeric proteins, each at a dose of 100 mcg, mixed with MF59® adjuvant (an oil-in-water emulsion) delivered as a 0.5 mL IM injection
1577181|NCT02404311|Biological|ALVAC-HIV (vCP2438) Placebo|a sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1mL of sterile sodium chloride solution (NaCl 0.4%) for injection as a single dose IM
1577182|NCT02404311|Biological|Bivalent gp120/MF59® Placebo|Sodium chloride for injection, 0,9% delivered as a 0.5 mL IM injection
1577183|NCT02404298|Drug|IVIg|
1577186|NCT02404272|Other|Educational oral feeding nurse program|"A multidisciplinary group composed of childcare assistants, nurse guardians, speech therapist, physiotherapist, psychologist, and pediatricians will develop and implement the educational oral feeding program. They will provide the 2-day theoretical session as well as the three 2-hour practical sessions including reviews of video recording preterm neonates during bottle or breast feedings.
The program will focus on non-nutritive sucking for all neonates from 24 up to 34 weeks' of gestation, early oral feeding from 29 weeks' of gestation and oral stimulation for all preterm neonates admitted to the unit. Additionally, all preterm neonates presenting feeding difficulties symptoms will be evaluated weekly by a physiotherapist or speech therapist.
Each program session is composed of 20 nurses or childcare assistants. Six sessions will be organized in total and all nurses and childcare assistants will be trained"
1577187|NCT02404259|Drug|TDF (Tenofovir)|
1577188|NCT02404259|Drug|Efavirenz|
1577189|NCT02404259|Drug|lopinavir/ritonavir, atazanavir/ritonavir|
1577191|NCT02404233|Drug|darunavir/cobicistat|Darunavir/ cobicistat 800/ 150 mg tablet once daily taken with food
1577192|NCT02404233|Drug|rilpivirine|Rilpivirine tablet 25 mg once daily taken with food
1577197|NCT02404207|Other|Soybean oil|Participants will be fed soybean oil as part of a controlled (typical American) diet.
1577198|NCT02404207|Other|High-oleic soybean oil|Participants will be fed high-oleic soybean oil as part of a controlled (typical American) diet.
1577199|NCT02404207|Other|High-oleic soybean oil + fully hydrogenated soybean oil|Participants will be fed a blend of high-oleic soybean oil and fully hydrogenated soybean oil as part of a controlled (typical American) diet.
1577200|NCT02404207|Other|Palm olein + palm stearin|Participants will be fed a blend of palm olein + palm stearin as part of a controlled (typical American) diet.
1577201|NCT02404194|Behavioral|Targeted Cognitive Training|Targeted Cognitive Training is performed on the computer through Posit Science. Games are modern and engaging modifications of classic neuropsychological tests, such as set-shifting games modeled on the Wisconsin Card Sort Test, and cognitive control games modeled on Stroop-like interference tasks. Games will target two sets of skills: Targeted cognitive skills include: processing speed, memory, attention, flexibility/cognitive-control, and problem-solving. After 20 hours of training on these skills, participants will complete 20 hours of training on core social cognitive skills, including facial affect recognition, gaze direction perception, and face identity recognition, and theory of mind.
1577202|NCT02404194|Behavioral|Computer Games|The comparison intervention consists of 40 hours of commercially available and cognitively non-specific computer games. These computer games - such as checkers, solitaire, crossword puzzles - are entertaining and engaging but do not target specific neurocognitive skills.
1577203|NCT02404168|Drug|lamotrigine (brand Lamictal)|an anti-epileptic drug (brand)
1577204|NCT02404168|Drug|lamotrigine (generic Teva)|an anti-epileptic drug (brand)
1577205|NCT02404155|Drug|Clozapine|
1577206|NCT02404142|Drug|Curare (Atracurium)|Curare (Atracurium) versus saline isotonic solution for tracheal intubation
1577207|NCT02404142|Drug|saline isotonic solution|
1577657|NCT02400970|Other|malignant cells|
1577208|NCT02404129|Other|Turn 180 test|"The purpose of this study is to explore the TURN180 test ability to evaluate the risk of falling in the elderly population and compare it to the known gold standard clinical tests. The independent elderly subjects will be divided into three groups according to their falls history and undergo four balance tests: Timed Up and Go test (TUG), Tinetti Balance Test (Tinetti), Berg Balance Scale (BBS). The participants will be videotaped while performing the TUG test. Basic temporospatial aspects of turning during walking such as the number of steps taken during the turn and the time taken to accomplish the turn will be measured using both the slow-motion and stop-action capabilities of the VCR system and a time-code processor."
1577209|NCT02404116|Other|Metacognitive Therapy|Participants will receive treatment which focus's on helping reduce excessive thinking about health,
1577210|NCT02404116|Other|Wait List|Individuals are on a waiting list
1577212|NCT02404090|Radiation|CT-osteoarbsorptiometry|Conventional CT-scan analyzed by means of a specific tool (Analyze, Mayo Clinic).
1577213|NCT02404077|Drug|Clonidine|
1577214|NCT02404064|Drug|cefamezin 1g IV|perioperative antibiotics (Cefamizin 1g IV; )
1577215|NCT02404064|Drug|metronidazole 500 mg IV|perioperative antibiotics (metronidazole 500 mg IV )
1577216|NCT02404064|Drug|Placebo|No perioperative antibiotics
1577217|NCT02404051|Drug|Everolimus|10 mg daily tablets
1577218|NCT02404051|Drug|Exemestane|25 mg daily tablets
1577219|NCT02404051|Drug|Fulvestrant|500 mg i.m. on Days 1, 15 and 29 and every 28 days thereafter
1577220|NCT02404038|Drug|Nur-Isterate|Nur-Isterate is a progestogen-only injectable contraceptive (POIC) is a long-acting, reversible contraceptive. Nur-Isterate is administered as an intramuscular injection administered bi-monthly (every 8 weeks). Each ampoule of Nur-Isterate contains 1ml/200mg of norethisterone enantate (17alpha-ethinyl-17beta-heptanoyloxy-4-estrene-3-one).
1577221|NCT02404038|Device|Nuvaring|Nuvaring is the trade name for a combined hormonal contraceptive intravaginal ring, inserted once every 28 days, and removed after 21 days. The flexible plastic ring works in a similar way to the oral contraceptive pill to prevent pregnancy. It contains etonogestrel/ethinyl estradion and delivers 0.120mg/0.015mg per day.
1577222|NCT02404038|Drug|Triphasil|"Triphasil is a daily oral contraceptive: 21 active tablets followed by 7 inert tablets, starting initially on first day of menstrual cycle
Composition:
The six brown tablets of TRIPHASIL contain 30 µg ethinyl oestradiol and 50 µg levonorgestrel.
The five white tablets contain 40 µg ethinyl oestradiol and 75 µg levonorgestrel.
The ten yellow tablets contain 30 µg ethinyl oestradiol and 125 µg levonorgestrel.
The seven red tablets are inert"
1577223|NCT02404025|Biological|Eltrombopag|Eltrombopag is provided as white round film-coated tablets containing 12.5 mg or 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag).
1577224|NCT02404025|Biological|Rabbit ATG|Rabbit ATG, as an intravenous drip infusion, diluted by 500 mL of saline or 5% glucose injection will be administered at a dose of 2.5 to 3.75 mg per kg per day as a slow intravenous infusion over 6 hours.
1577225|NCT02404025|Biological|CsA|CsA as capsules, oral solution, or fine granule, will be administered at a dose of 3 mg per kg twice a day.
1577226|NCT02404012|Dietary Supplement|Oral iron supplementation|Participants will be provided supplementation for 8 weeks
1577230|NCT02403986|Device|Restylane Vital Skinboosters Lidocaine|
1577231|NCT02403973|Other|IN2005E|IN2005E is a validated questionnaire that measures patient satisfaction
1577232|NCT02403960|Dietary Supplement|probiotic|the patients used probiotic tablets in addition to scaling and root planning
1577233|NCT02403960|Dietary Supplement|placebo|the patients used placebo tablets in addition to scaling and root planning
1577234|NCT02403947|Drug|Mesenchymal stem cells|After the sampling of bone-marrow and culture of MSCs by the French Blood Establishment (Midi-Pyrénées), patients will receive an IV injection of MSCs.
1577235|NCT02403947|Drug|Suspension media|injection suspension media
1577236|NCT02403934|Device|Jaw Elevation Device (JED)|apply JED when End tidal O2 low
1577237|NCT02403908|Device|nMARQ Circular and Crescent catheters|Radiofrequency denervation of right and left pulmonary arteries ostia and of main pulmonary artery <2 mm proximal from both ostia of right and left pulmonary arteries.
1577238|NCT02403895|Drug|Open-label AZD2014|Dual TORC1/TORC2 inhibitor
1577239|NCT02403895|Drug|paclitaxel|Taxane
1577240|NCT02403882|Behavioral|Order|In the order intervention, the investigators place the targeted product at the front of the line for the treatment. For the control, the investigators place the targeted product at the end of the line.
1577241|NCT02403882|Behavioral|Packaging|In the packaging intervention, the investigator present the targeted product in the original package. In the control, the investigator repackage the targeted product in clear, plastic bags.
1577242|NCT02403882|Behavioral|Pricing|In the pricing intervention, the investigators price all or targeted products in the treatment. In the control, the investigators do not price the products.
1577243|NCT02403882|Behavioral|Relative Proportions|The investigators adjust the amount of the targeted good available relative to the other products. In the treatment, the targeted good is a larger proportion of the total goods offered in the section, while in the control the shares of the targeted and other goods are equal.
1577244|NCT02403882|Behavioral|Default Option|In an early site, the investigators offer a targeted product without an alternative. The subjects can accept or reject the offer. The subjects are told that an alternative product is available later. At the site where the alternative product is available, investigators offer subjects the opportunity to exchanged the targeted product for the alternative product.
1577245|NCT02403856|Drug|Sodium Chloride 0.9%|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of sterile physiological Saline (Sodium Chloride 0.9%) in the subacromial bursae.
1577246|NCT02403856|Drug|Methylprednisolone acetate|Needling and lavage of calcific tendinitis of the rotator cuff followed by the injection of methylprednisolone acetate in the subacromial bursae
1577247|NCT02403856|Procedure|Ultrasound-guided Needling and Lavage|
1577390|NCT02403050|Device|Fiducial markers|2 fiducial markers (Visicoils) to be placed in the tumor area
1577249|NCT02403830|Drug|Methylnaltrexone|Methylnaltrexone will be administered diluted with 5 ml of normal saline as a single iv bolus
1577250|NCT02403830|Other|Placebo|Placebo will be administered as a 0.9% sodium chloride iv injection
1577251|NCT02403830|Drug|Morphine|After methylnaltrexone, patients will receive 5-mg intravenous morphine
1577252|NCT02403830|Drug|Ticagrelor|After morphine administration, patients will receive a 180-mg ticagrelor loading dose
1577253|NCT02403817|Behavioral|Cognitive Training|A collection of video games that rely on various aspects of visual behavior (i.e. sustained attention, vigilance, rapid discrimination, etc) for successful play.
1577254|NCT02403817|Behavioral|Eye Motor Training|Gameplay will be controlled by the player's eye movements (via an eye tracking device)
1577255|NCT02403817|Behavioral|Hand Motor Training|Gameplay will be controlled by the player's hand movements (via a joystick).
1577256|NCT02403804|Dietary Supplement|phosphatidylcholine|phosphatidylcholine 3600 mg qam and 2700 mg qpm
1577257|NCT02403804|Dietary Supplement|betaine|Betaine anhydrous 588 mg qam and 412 mg qpm
1577258|NCT02403804|Dietary Supplement|betaine|Betaine anhydrous 1000 mg BID
1577259|NCT02403791|Device|Linear Ultrasonic Sounder|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
1577260|NCT02403791|Device|Bedside X-ray Machine|Chest Radiography is performed after clinical evaluation without using ultrasound assessment.
1577261|NCT02403778|Drug|All-Trans Retinoic Acid|All-trans retinoic acid (ATRA) is a vitamin A derivative that binds the retinoic acid receptor on MDSCs and differentiates immature monocytes into more mature dendritic cells (12). ATRA is a standard treatment for patients with acute promyelocytic leukemia (APL).
1577262|NCT02403778|Drug|Ipilimumab|Ipilimumab is current standard of care treatment for melanoma.
1577263|NCT02403752|Behavioral|Paired PLIE Program|Integrative exercise as described above
1577264|NCT02403739|Other|No Intervention|No Intervention
1577265|NCT02403726|Procedure|Operation|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with operation.
1577266|NCT02403726|Procedure|Non-operative treatment|Analyzation of demographic, medical, gender and socio-economic aspects of osteoporosis associated vertebral fractures treated with non-operative treatment.
1577267|NCT02403713|Drug|Fluticasone/formoterol BAI|Fluticasone/formoterol 125/5 µg breath actuated inhaler (BAI) (250/10 µg total dose)
1577268|NCT02403713|Drug|Formoterol|Formoterol
1577269|NCT02403713|Drug|Fluticasone/formoterol PMDI without spacer|Fluticasone/Formoteral 125/5µg pMDI without spacer
1577270|NCT02403713|Drug|Fluticasone/formoterol PMDI with spacer|Fluticasone/Formoteral 125/5µg pMDI with spacer
1577271|NCT02403713|Drug|Fluticasone/formoterol PMDI without spacer low dose|Fluticasone/Formoteral 125/5µg pMDI without spacer, low dose
1577272|NCT02403700|Device|Cone beam computed tomography (CBCT)|Dimensional changes are documented over a healing period of 8-weeks following single tooth extraction. To document these changes over time, two methods will be applied. Firstly, two cone beam computed tomographies (CBCT) will be obtained, one directly after tooth extraction, the other one at 8 weeks of socket healing prior to implant placement. The two CBCT's will be analyzed with a novel software program (InVivo Dental). Secondly, consecutive impressions will be made at day 0 (day of extraction), day 14, 28, 42, and 56 to digitally produce virtual 3D study models. These models can be analyzed with another software program (Geomagic Studi 10) to document the variations of the soft tissue in the extraction site.
1577273|NCT02403687|Drug|baclofen 2%|compound topical cream
1577274|NCT02403687|Drug|Bupivacaine hydrochloride 1%|compound topical cream
1577275|NCT02403687|Drug|Cyclobenzaprine hydrochloride 2%|compound topical cream
1577276|NCT02403687|Drug|Diclofenac Sodium 3%|compound topical cream
1577277|NCT02403687|Drug|Flurbiprofen 10%|compound topical cream
1577278|NCT02403687|Drug|Gabapentin 6%|compound topical cream
1577279|NCT02403687|Drug|Ketamine 10%|compound topical cream
1577280|NCT02403687|Drug|Lidocaine 2%|compound topical cream
1577281|NCT02403687|Drug|Prilocaine 2.5%|compound topical cream
1577282|NCT02403687|Drug|Meloxicam 0.09%|compound topical cream
1577283|NCT02403687|Drug|Sumatriptan 5%|compound topical cream
1577284|NCT02403687|Drug|Tizanidine 0.1%|compound topical cream
1577285|NCT02403687|Drug|Topiramate 2.5%|compound topical cream
1577286|NCT02403687|Drug|Capsaicin, USP 0.0375%|compound topical cream
1577287|NCT02403687|Drug|Menthol, NF 5.00 %|compound topical cream
1577291|NCT02403648|Drug|BIOD-961|BIOD-961 is a lyophilized glucagon formulation.
1577292|NCT02403648|Drug|Lilly Glucagon|
1577293|NCT02403648|Drug|Novo Glucagon|
1577294|NCT02403635|Drug|Midazolam|
1577295|NCT02403635|Drug|ASP2151|
1577296|NCT02403622|Drug|Fecal Microbiota Preparations|Frozen processed human fecal material for treating recurrent clostridium difficile infections.
1577297|NCT02403609|Other|BPT, Computerized Assessment|
1577298|NCT02403596|Drug|Exacyl®|
1577299|NCT02403596|Other|Placebo of Exacyl®|
1577300|NCT02403583|Behavioral|Intervention- Home Visits|If a woman has been randomized to the intervention arm, a lay health worker will obtain detailed locator information (including cell phone contacts) and consult with the woman about optimal times for a home visit. The woman will be given a letter for her male partner to inform him about the study and potential upcoming visits, given that our preliminary research revealed that notifying the male partner beforehand is important. As described above, the intervention arm will consist of three home visits conducted by one female and one male lay health worker.
1577303|NCT02403557|Behavioral|Tailored Internet-delivered CBT|Tailored Internet-delivered CBT during 8 weeks.
1577304|NCT02403544|Radiation|IGRT|IGRT: 45 to 54Gy, 1.8-3Gy per fraction.
1577305|NCT02403544|Drug|Capecitabine|Capecitabine: by oral, D1-14, every 21 days, 600mg/m2 bid per day in level 1, and then escalated every another dose level.
1577306|NCT02403544|Drug|Oxaliplatin|Oxaliplatin: intravenously, D1 and D8, every 21 days, 30mg/m2 per day in level 1, and then escalated every another dose level.
1577307|NCT02403531|Drug|Docetaxel|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
1577308|NCT02403531|Drug|Cisplatin|Include brand names, serial numbers and code names to improve search results on the ClinicalTrials.gov web site.
1577309|NCT02403531|Radiation|Radiotherapy|definitive radiotherapy
1577310|NCT02403518|Device|Freedom Spinal Cord Stimulator System|
1577311|NCT02403505|Drug|ABIRATERONE - Group 1|ZYTIGA - ABIRATERONE ACETATE TABLET plus DELTASONE - PREDNISONE TABLET plus XTANDI - ENZALUTAMIDE CAPSULE
1577312|NCT02403505|Drug|ABIRATERONE - Group 2|ZYTIGA - ABIRATERONE ACETATE TABLET plus DELTASONE - PREDNISONE TABLET plus XTANDI - NILANDRON - NILUTAMIDE TABLET
1577313|NCT02403492|Device|cPAP|All participants diagnosed with obstructive sleep apnea will be required to use cPAP for 6 months prior to the RCT component of this trial
1577314|NCT02403492|Device|cPAP, Continuation|Participants will be randomized to continue cPAP for a 2 week period
1577315|NCT02403492|Device|cPAP, Discontinuation|Participants will be randomized to discontinue cPAP for a 2 week period
1577318|NCT02403466|Behavioral|Resident Handoff Bundle|1) team training, 2) verbal mnemonics, and 3) standardization of written/computerized handoff tools
1577319|NCT02403440|Drug|Hetrombopag Olamine|Hetrombopag Olamine 2.5mg, 5mg and 7.5mg
1577320|NCT02403427|Device|VoiceDiab expert system|"Decision support system VoiceDiab this is computer-based system constructed for mobile phone devices working on the server.
Patients in experimental arm get the mobile phone application for 4 days. Glucose control will be done by two methods SMPG and CGM. Before every study's meal insulin dose with type of bolus will be indicate by VoiceDiab."
1577321|NCT02403414|Device|Fiberoptic|In the event of failed intubation under direct laryngoscopy, fiberoptic intubation will be performed.
1577322|NCT02403401|Drug|Levonorgestrel (BAY98-7196)|Levonorgestrel 40 µg/d intravaginal ring (treatment for 365 days, 28 days wearing period for each ring)
1577323|NCT02403388|Other|PRisM|A risk management program for each professional of care in multiprofessional primary care offices in France.
1577324|NCT02403375|Device|Accu-Chek Insight Pump System|Continuous subcutaneous insulin infusion pump
1577325|NCT02403362|Drug|EPO-018B|
1577326|NCT02403349|Drug|Fimasartan|
1577327|NCT02403349|Drug|Valsartan|
1577328|NCT02403349|Drug|Atenolol|
1577329|NCT02403336|Other|Training health professionals|Intervention on the professionals (3 training sessions for updating the knowledge and learning skills) and
1577330|NCT02403336|Behavioral|Behavioral group intervention|Intervention on patients (educational workshop).
1577331|NCT02403336|Other|Usual clinical practice|Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
1577332|NCT02403323|Drug|etrolizumab|105 mg etrolizumab subcutaneous administration every 4 weeks
1577336|NCT02403297|Device|Quik Check PD|The device is not an intervention. It is a device to determine if MMP-8 is present in a subjects saliva.
1577337|NCT02403284|Drug|Liraglutide|Subcutaneous injection by patient
1577338|NCT02403284|Drug|Sugar Pill|Subcutaneous injection daily
1577339|NCT02403271|Drug|Ibrutinib|BTK Inhibitor
1577340|NCT02403271|Drug|Durvalumab (MEDI4736)|Anti PDL-1
1577341|NCT02403258|Other|Plum-blossom needle group|Plum-blossom needle is a method of shallow insertion with multiple needles. It is made of five or seven stainless steel needles arranged in a pattern like the shape of plum blossom, thus named as 'plum-blossom needle'. Plum-blossom needle treat diseases by tapping specific skin areas or acupoints according to different illness based on the theory of meridian.
1577342|NCT02403258|Behavioral|HRT group|HRT consisted of (1) self-monitoring, (2) competing responses, (3) relaxation training, (4) contingency management.
1577343|NCT02403245|Other|Psychosocial stimulation|"Intervention consists in a session of social stimulation during about 40 minutes through where the speaker introduced himself to the residents and introduces the residents to each others. The date of the day was done to residents. Social stimulation consists here to an exercise about the four seasons. Residents are asked to mention the 4 seasons and to give all the characteristics they can about each season. Two exercises were proposed: 4 pictures of landscapes and residents were asked to tell which season is represent on the pictures and pictures of some fruits and residents tried to tell in which season we find the fruits. Finally, the psychologist speaks about the four season of the compositor Vivaldi and propose to the residents to listen some extracts of each pieces of music."
1577391|NCT02403037|Device|True auricular acupressure|A 5-day auricular acupressure at the specific ear acupoints using vaccaria seeds.
1577392|NCT02403037|Device|Sham auricular acupressure|A 5-day sham auricular acupressure at the same acupoints as in the true auricular acupressure arm using Junci Medulla but no pressure will be applied.
1577730|NCT02400437|Drug|Rituximab|Doses given on Day 1 of induction and maintenance cycles.
1577344|NCT02403232|Procedure|ASCs injection|"In the infiltration step, adrenalin in a saline solution is infiltrated using a 19-cm specially designed disposable blunt cannula.
The aspiration step is performed by a luer-lock syringe connected to a disposable 19-cm blunt cannula.
The harvested lipoaspirate can be progressively put into the device using multiple 10-cc syringes.
Subsequently, in lithotomy position, a seton will be removed and a fistula tract will be thoroughly curetted and irrigated. After a mucosal flap preparing round the internal opening, cells will be injected in the perianal adipose tissue."
1577345|NCT02403232|Device|ASCs injection|In general anesthesia subcutaneous abdominal adipose tissue will be collected by LIPOGEMS system to prepare ASCS.
1577346|NCT02403232|Device|Closure of fistula tract.|A SALVECOLL-E paste will be injected into the fistula tract.
1577347|NCT02403219|Drug|Botulinum toxin type A injection|Injection of botulinum toxin type A
1577348|NCT02403219|Other|Saline solution injection|Injection of saline solution
1577349|NCT02403206|Device|Femtosecond laser|Laser console and a patient interface used to cut tissue during cataract removal of the crystalline lens
1577350|NCT02403206|Procedure|Continuous Curvilinear Capsulorhexis (CCC)|Standard-of care manual procedure (using either needles or forceps) for creating capsulorhexis, ie., opening in capsular bag during anterior segment ophthalmic surgery
1577351|NCT02403193|Drug|PBF-509_80 mg|PBF-509: 80 mg, PO, twice daily (BID)
1577352|NCT02403193|Drug|PBF-509_160 mg|PBF-509: 160 mg, PO, twice daily (BID)
1577353|NCT02403193|Drug|PBF-509_320 mg|PBF-509: 320 mg, PO, twice daily (BID)
1577354|NCT02403193|Drug|PBF-509_640 mg|PBF-509: 640 mg, PO, twice daily (BID)
1577355|NCT02403193|Drug|Combo PBF-509 (160 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
1577356|NCT02403193|Drug|Combo PBF-509 (320 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
1577357|NCT02403193|Drug|Combo PBF-509 (640 mg) + PDR001|Drug 1: PDR001 administered intravenously. Drug 2: PBF-509 administered orally
1577358|NCT02403193|Drug|RP2D (PBF-509+PDR001)_immuno naïve|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
1577359|NCT02403193|Drug|Experimental: RP2D (PBF-509+PDR001)_immuno treated|Drug 1: PDR001 administered intravenously. Drug 2: PBF509 administered orally
1577360|NCT02403180|Device|DACP MF|Nelfilcon A multifocal contact lenses
1577361|NCT02403180|Device|PROCLEAR 1D MF|Omafilcon A multifocal contact lenses
1577362|NCT02402049|Drug|Natrum muriaticum 30C|3 globules of Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
1577363|NCT02402049|Drug|Lachesis 30C|3 globules of Lachesis applied once daily at days 7,8, and 9 after the start of the period.
1577364|NCT02402049|Drug|Sepia 30C|3 globules of Sepia applied once daily at days 7,8, and 9 after the start of the period.
1577365|NCT02402049|Drug|Nux vomica 30C|3 globules of Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
1577366|NCT02402049|Drug|Pulsatilla 30C|3 globules of Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
1577367|NCT02402049|Drug|Folliculinum 30C|3 globules of Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
1577368|NCT02402049|Drug|Placebo Natrum muriaticum|3 globules of placebo Natrum muriaticum applied once daily at days 7,8, and 9 after the start of the period.
1577369|NCT02402049|Drug|Placebo Lachesis|3 globules of placebo Lachesis applied once daily at days 7,8, and 9 after the start of the period.
1577370|NCT02402049|Drug|Placebo Sepia|3 globules of placebo Sepia applied once daily at days 7,8, and 9 after the start of the period.
1577371|NCT02402049|Drug|Placebo Nux vomica|3 globules of placebo Nux vomica applied once daily at days 7,8, and 9 after the start of the period.
1577372|NCT02402049|Drug|Placebo pulsatilla|3 globules of placebo Pulsatilla applied once daily at days 7,8, and 9 after the start of the period.
1577373|NCT02402049|Drug|Placebo Folliculinum|3 globules of placebo Folliculinum applied once daily at days 7,8, and 9 after the start of the period.
1577374|NCT02402036|Drug|Regorafenib|Regorafenib orally for 21 days every 28 day cycle
1577375|NCT02402023|Behavioral|Contingency Management (CM)|CM is standard care plus monetary payment delivered contingent on abstinence.
1577376|NCT02402023|Behavioral|Standard of Care (SC)|Standard of care consists of smoking cessation counseling sessions and nicotine patches.
1577377|NCT02402010|Behavioral|Adjunctive Yoga|
1577378|NCT02402010|Behavioral|Enhanced Treatment as Usual|
1577379|NCT02401997|Behavioral|sexual abstinence|The subjects participated in the study are divided into three groups according to the male partners sexual abstinence period during the day of sperm preparation for intrauterine insemination.
1577382|NCT02403141|Other|Questionnaire|
1577383|NCT02403128|Drug|aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline, and repeated no sooner than two months from the previous injection for persistent macular edema as defined in the protocol.
1577384|NCT02403115|Other|Serum collection|Clinical tests (renal function, complete blood count, CRP, ANA, dsDNA, urinalysis) will be performed at fixed time intervals (6, 12, 24 and 36 months) and the surplus of blood sample will form the serum bank used for the study
1577385|NCT02403089|Other|Tubes fund recovery blood count|Tubes fund recovery of blood counts among newborns
1577386|NCT02403089|Other|the rest of the blood test and stool sample|blood samples on the recovery kinetics after transplant. The rest of the blood test and stool sample done as part of a routine examination.
1577387|NCT02403063|Drug|Sugammadex|Administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
1577388|NCT02403063|Drug|Neostigmine|Administration of neostigmine 50µg/kg for enhanced recovery after neuromuscular blockade with rocuronium
1577389|NCT02403063|Drug|Neostigmine-sugammadex|Administration of neostigmine 50µg/kg followed 3 minutes later by administration of sugammadex 2mg/kg for enhanced recovery after neuromuscular blockade with rocuronium
1577393|NCT02403037|Drug|Standard anti-emetic treatment (5-HT3 receptor antagonists and/or Dexamethasone)|5-HT3 receptor antagonists and/or Dexamethasone will be administered to manage chemotherapy-induced nausea and vomiting.
1577394|NCT02403024|Behavioral|InterWalk|Patient allocated to the InterWalk-group will be introduced to the InterWalk app, including instructions on how to down load and use the application. and prescribed to perform Interval Walking for 150 min per week
1577395|NCT02403024|Behavioral|Waiting list control|Patients allocated to the waiting-list control group will be prescribed standard guidelines for the patient group, but will be asked not to download and use the InterWalk app (which is freely available) for the first 12 weeks of the study period. After the first 12 weeks (the control period), patients in this group will receive the same instructions for download and use of the InterWalk app in the following 12 weeks
1577396|NCT02403011|Other|soft tissue mobilization|soft tissue mobilization technique has three phases. First phase 'the passive mobilization phase' is applied by gentle but tight gripping of the SKM muscle two or three fingers below the muscle origo and the muscle is mobilized rhythmically in the antero-posterior direction. Secondly, after gently continue to hold the muscle the baby was encouraged to do active repetitive cervical rotation to the affected side by means of catching the babies attention with colored and sonorous toys. Third phase was mobilization with stretching. Caregiver holds the baby on his/ her affected side while the therapist gently grips and withholds the muscle. Therapist mobilizes the muscle in the antero-posterior direction and stretch the muscle
1577397|NCT02403011|Other|home program controlled once six weeks|Home program which consisted of positioning the neck and head, handling strategies, stretching exercises, strengthening exercises according to babies neurodevelopmental level and environmental adaptations
1577398|NCT02402998|Drug|Eltrombopag|Eltrombopag 50 mg/daily.
1577399|NCT02402985|Other|High animal protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
1577400|NCT02402985|Other|High plant protein diet group|25-30% protein, 40 % carbohydrates, 30-35 % fat over 6 weeks
1577401|NCT02402972|Drug|FUDR +oxaliplatin|IPC: one dose of fluorodeoxyuridine (FUDR) 1000 mg and oxaliplatin 100 mg were administered as a bolus into the regional vein
1577402|NCT02402972|Drug|oxaliplatin+Leucovorin+5-FU|Adjuvant chemotherapy (AC): All patients received mFOLFOX6 adjuvant chemotherapy: oxaliplatin+Leucovorin+5-FU
1577403|NCT02402959|Other|individualized treatment|Individualized treatment includes anything no matter what kind of interventions, like medicine, herbs, acupuncture, massage, behaviour therapy, diet and exercise therapy. The TCM experts should choose the intervention in accordance to the patients' preference, best existed evidence and their empirical knowledge.
1577404|NCT02402946|Behavioral|Biofeedback|
1577405|NCT02402946|Drug|Placebo|
1577406|NCT02402933|Drug|Glucagon|3 mg glucagon powder
1577407|NCT02402920|Drug|Etoposide|100 mg/m^2 given by vein on Days 1, 2, and 3 of each 3 week cycle.
1577408|NCT02402920|Drug|Cisplatin|80 mg/m^2 by vein on Day 1 of each 3 week cycle.
1577409|NCT02402920|Drug|Carboplatin|AUC 5 by vein on Day 1 of each 3 week cycle.
1577410|NCT02402920|Drug|MK-3475|"Limited Stage SCLC MK-3475 + Radiation Group - Part A: MK-3475 given by vein on Day 1 of every 3 week cycle. The first group of participants will receive the lowest dose level of MK-3475. Each new group will receive a higher dose of MK-3475 than the group before it until maximum tolerated dose achieved.
Extensive Stage SCLS MK-3475 + Radiation Group Part B: MK-3475 given by vein Day 1 of every 3 week cycle. The first group of participants will receive the lowest dose level of MK-3475. Each new group will receive a higher dose of MK-3475 than the group before it until maximum tolerated dose achieved."
1577411|NCT02402920|Radiation|Radiation Therapy|"Limited Stage SCLC MK-3475 + Radiation Group: Radiation therapy delivered to chest at 45 Gy twice a day for 15 days.
Extensive Stage SCLS MK-3475 + Radiation Group: Radiation therapy delivered to chest at 45 Gy once a day for 15 days."
1577412|NCT02402907|Device|2% chlorhexidine gluconate (CHG) cloth|administration of a 2% CHG cloth at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
1577413|NCT02402907|Device|Placebo cloth|administration of a cloth with the placebo (commercial cleansing cloth) at home on the night before and approximately 3 hours prior to cesarean delivery on the morning of the surgery.
1577414|NCT02402894|Other|no intervention|
1577415|NCT02402881|Behavioral|Patient-centered education bundle|A patient-centered education bundle that will be delivered as an in-person, 1-on-1 discussion session with a nurse educator. Supporting education materials include a 2-page patient education sheet and a patient education video.
1577416|NCT02402868|Drug|Ketamine and saline|Ketamine intravenous and intranasal
1577417|NCT02402855|Other|Delivery of a prepaid payment card|Delivery of a prepaid payment card credited according to consultations attended
1577418|NCT02402855|Other|Interview with a sociologist|For a sub-group of 40 womens
1577419|NCT02402855|Other|No intervention|
1577420|NCT02402842|Drug|Docetaxel, Cisplatin and 5-Fluorouracil|Patients will receive 6 cycles of DCF regimen (docetaxel 75 mg/m2 day, cisplatin 75 mg/m2 and 5 Fluorouracil at 750 mg/m2/day for 5 days) every 3 weeks or 8 cycles of modified-DCF regimen (docetaxel 40 mg/m2 day, cisplatin 40 mg/m2 day and 5-Fluorouracil at 1200 mg/m2/day for 2 days) every 2 weeks, according to their clinical status.
1577421|NCT02402829|Procedure|Peripheral Vein Blood draw|Drawing blood through a peripheral vein in the arm.
1577422|NCT02402816|Device|MultiPoint Pacing ON|MultiPoint Pacing ON
1577423|NCT02402816|Device|Implantable cardioverter-defibrillator (ICD)|Implantable cardioverter-defibrillator (ICD)
1577424|NCT02402803|Other|Dried blood spot testing and phlebotomy|At baseline and 4-6 week follow-up, a phlebotomy serum sample (5 ml) will be collected in one golden-top tube for clinical laboratory measurement of cholesterol (total cholesterol, LDL-C, triglycerides, HDL-C) . During the same phlebotomy, a fingerprick dried blood spot (DBS) sample and two lavender EDTA plasma tubes (5 ml each) will be collected for analysis of CVD protein markers
1577425|NCT02402764|Drug|Selinexor|Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m^2).
1577474|NCT02402465|Drug|Fluticasone/Azelastine nasal spray|Patients will receive Dymista nasal spray
1577426|NCT02402751|Procedure|acquisition of normative database with ultra high field MRI|characterize non-invasively with an unprecedented resolution and sensitivity (high field MRI), anatomy as well as certain physiological, hemodynamic and metabolic function of brain, spinal cord, musculoskeletal system, and heart
1577427|NCT02402751|Device|MRI|
1577428|NCT02402738|Behavioral|Interpersonal and Social Rhythm Therapy|
1577429|NCT02402738|Behavioral|Enhanced Treatment as Usual|
1577430|NCT02402725|Drug|Dexamethasone|(1 cycle = 28 days) D1: Dexamethasone 100mg IV; Dex 24mg PO every 6 hrs (begin immediately after IV dex) D2: Dex 24mg PO every 6 hrs D3: Dex 24mg PO every 6 hrs
1577431|NCT02402712|Drug|Docetaxel|Intravenous administration according to local label/clinical practice, after Herceptin and Perjeta.
1577432|NCT02402712|Drug|pertuzumab [Perjeta]|Intravenous infusion every 3 weeks. First dose: 840 mg. Subsequent doses: 420 mg
1577433|NCT02402712|Drug|trastuzumab [Herceptin]|Subcutaneous administration of 600 mg/5 mL every 3 weeks
1577434|NCT02402686|Drug|Tocilizumab|Dosing and treatment duration of tocilizumab collected as part of this non-interventional study are at the discretion of the physician in accordance with local clinical practice and local labeling. Observation period is 24 weeks from first SC tocilizumab administration.
1577435|NCT02402673|Other|Temporary activity modification and graded exercises|
1577436|NCT02402660|Drug|ALK-001|Daily, oral administration for 24 months
1577437|NCT02402660|Drug|Placebo|Daily, oral administration for 24 months
1577438|NCT02402647|Behavioral|CREST|"Compensatory Cognitive Training is a manualized, low-tech, cognitive training intervention designed to target cognitive impairments common in people with psychiatric illness. The CCT modules specifically selected for CREST map onto known areas of HD neurocognitive deficits or weakness and include training in prospective memory, prioritizing, problem solving, planning, and cognitive flexibility.
Symptoms of acquiring and saving are themselves avoidance behaviors that are performed to avoid internal distress related to negative thoughts and emotions. Avoidance serves to reduce distress related to the beliefs regarding the necessity and utility of possessions. In the CREST condition, the second part and the majority of treatment is dedicated to exposure therapy (ET) for discarding and not acquiring while in the control condition, the entire treatment will consist of ET."
1577439|NCT02402647|Behavioral|ET|The investigators propose to use a robust control condition, ET, with the same frequency and amount of therapist contact as CREST. Twenty-six weekly, individual ET sessions (6 months) will be delivered. The control group will receive ET for all 26 sessions and no cognitive training. As in CREST, the ET sessions will be manualized and copies utilized during session by both the patient and therapist.
1577440|NCT02402634|Other|Mechanical ventilatory lung care|
1577441|NCT02402621|Drug|fentanyl|fentanyl with antiemetic drug
1577442|NCT02402608|Dietary Supplement|dietary supplement|oral essential amino acid (EAA), whey protein and vitamin D mixture
1577443|NCT02402608|Dietary Supplement|placebo|placebo consisting of an equicaloric amount of maltodextrin with the same flavour and appearance as for the intervention product
1577444|NCT02402595|Drug|AVP-923|
1577445|NCT02402595|Drug|AVP-786|
1577446|NCT02402595|Drug|Itraconazole|
1577447|NCT02402582|Other|Family-centered empowerment model|First stage was including the perceived intensity and the perceived sensitivity. Self-efficacy in stage two was that the individual gets belief in that they can do a special task. Self- efficacy alludes to the individual's expectation of themselves and the ability to do action. Self-esteem in third stage was to clarify and identify the level of approval, acceptance and merit that the individual feels they have. Formative assessment was to encourage the patients more toward internalizing their locus of control and summative evaluation was to evaluate the effectiveness of this model on modifying, balancing and improving the health related quality of life (HRQOL) dimensions of MI patients after 3 months for eight points in the stage four.
1577448|NCT02402569|Device|32 channels Deep Brain Stimulator|
1577449|NCT02402556|Behavioral|MOCEP|Through parent support and an evidence-based curriculum, MOCEP uses education to reduce risk factors that hinder children's health and wellbeing.
1577450|NCT02402543|Drug|Gabapentin|
1577451|NCT02402543|Drug|Ketamine|Prior to the incision in the operating room, the anesthesiologist administers 0.15 mg/kg of ketamine IV push in patients randomized to the experimental arm, only.
1577452|NCT02402543|Drug|Acetaminophen|
1577453|NCT02402543|Drug|Dexamethasone|Prior to the incision in the operating room, the anesthesiologist administers 8 mg of dexamethasone IV push in patients randomized to the experimental arm, only.
1577454|NCT02402543|Drug|Placebo|
1577455|NCT02402530|Drug|Placebo|Matching placebo administered as intravenous infusion.
1577456|NCT02402530|Drug|Neridronic acid 62.5 mg|Neridronic acid administered as intravenous infusion.
1577457|NCT02402517|Other|Control|Non pulse extruded snack
1577458|NCT02402517|Other|Small particle size pea flour|Pulse extruded snack
1577459|NCT02402517|Other|Large particle size pea flour|Pulse extruded snack
1577460|NCT02402517|Other|Lentil flour|Pulse extruded snack
1577461|NCT02402517|Other|Navy bean flour|Pulse extruded snack
1577462|NCT02402517|Other|Pinto bean flour|Pulse extruded snack
1577463|NCT02402504|Other|Control|Non pulse extruded snack
1577464|NCT02402504|Other|Small particle size pea flour|Pulse extruded snack
1577465|NCT02402504|Other|Large particle size pea flour|Pulse extruded snack
1577466|NCT02402504|Other|Lentil flour|Pulse extruded snack
1577467|NCT02402504|Other|Navy bean flour|Pulse extruded snack
1577468|NCT02402504|Other|Pinto bean flour|Pulse extruded snack
1577469|NCT02402491|Drug|12 months of P2Y12 receptor antagonist|All subjects will be received 12 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
1577470|NCT02402491|Drug|24 months of P2Y12 receptor antagonist|All subjects will be received 24 months of dual antiplatelet therapy with a P2Y12 receptor antagonist (clopidogrel/prasugrel/ticagrelor) in addition to aspirin.
1577471|NCT02402491|Drug|Aspirin|The maintenance dose of aspirin is 100 mg daily, to be taken indefinitely.
1577472|NCT02402465|Drug|Placebo|Patients will be treated by placebo
1577473|NCT02402465|Drug|Fluticasone propionate|Patients will receive fluticasone nasal spray
1577475|NCT02402465|Procedure|Nasal Allergen Challenge|All subjects will receive a nasal challenge with allergen to mimick an allergic response and allow the investigation of the different drug effects on that response. Allergen extracts will be used as sprays into the nasal cavity. The extracts are approved by FDA for skin testing or desensitization therapy and an IND was obtained to allow intranasal administration
1577476|NCT02402452|Drug|GS-9857|GS-9857 100 mg tablet administered orally
1577477|NCT02402439|Drug|Islet cells|Transplantation of islets into the gastrointestinal submucosa
1577478|NCT02402439|Procedure|Islet transplantation into the gastrointestinal submucosa|Transplantation of islets into the gastrointestinal submucosa
1577479|NCT02402413|Procedure|Ultrasound|The patients will be subjected to ultrasound bi-dimensional or three-dimensional. Will Be calculated the ratio stroma/volume with both methods
1577480|NCT02402413|Procedure|Determination of concentrations of androgens|Determination of concentrations of serum levels of circulating androgens
1577481|NCT02402413|Device|Three dimensional ultrasound probe|Capture of ovarian three dimensional volumes
1577482|NCT02402400|Drug|Sub Lingual Ticagrelor|180mg sub-lingual ticagrelor
1577483|NCT02402387|Procedure|Neutral head position|
1577484|NCT02402387|Procedure|Flexed head position|
1577485|NCT02402387|Procedure|Extended head position|
1577486|NCT02402387|Procedure|Rotated head position|
1577487|NCT02402387|Device|Air-Q SP Airway|
1577488|NCT02402374|Device|Autologous platelet rich plasma gel|PRP gel application to exuding wounds, such as leg ulcers, pressure ulcers, and diabetic foot ulcers and for the management of mechanically- or surgically-debrided wounds
1577489|NCT02402374|Device|Placebo|Placebo control arm will be receiving commercial formulations of pre-prepared saline gel.
1577490|NCT02402348|Drug|Metformin|
1577491|NCT02402322|Behavioral|Scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone weekly.
1577492|NCT02402322|Behavioral|Non-scheduled support|Participants followed the online self-help program based on cognitive behavioral therapy for 8 weeks. They had the support of a therapist via phone when they required it.
1577493|NCT02402309|Drug|Active topical NS2 1% dermatologic cream|
1577494|NCT02402309|Drug|Vehicle placebo 0.0% NS2 dermatologic cream|
1577495|NCT02402296|Drug|β-1,3/1,6-D-glucan|15 patients (in group II) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of β-1,3/1,6-D-glucan oral supplementation for 40 days.
1577496|NCT02402296|Other|Placebo|15 patients (in group I) suffering from localized aggressive periodontitis followed a strict plaque control program (within two weeks); followed by a systemic course of placebo capsules oral supplementation for 40 days.
1577497|NCT02402283|Drug|Metronidazole benzoate oral granules|Single oral dose of 400 mg
1577498|NCT02402283|Drug|Flagyl 400 mg Tablets|Single oral dose of 400 mg
1577502|NCT02402257|Behavioral|CVC Train the Trainer|Trainees receive a simulation-based mastery learning intervention and train-the-trainer program on central venous catheter insertion
1577503|NCT02402244|Other|cytology specimen collection procedure|Undergo cytology specimen collection
1577504|NCT02402231|Drug|Omalizumab|Omalizumab is the treatment during oral immunotherapy with peanuts as protection
1577505|NCT02402218|Other|Usual care plus peer-mentors|Participants are assigned a peer mentor for support before and after treatment for HCV with Harvoni.
1577506|NCT02402218|Other|Usual care plus incentives|Participants are given incentives after completing treatment goals.
1577507|NCT02402218|Other|Usual Care|Participants receive standard of care in the clinic from their health care team.
1577508|NCT02402205|Behavioral|TF-CBT|Web TF-CBT implementation or Web + Live TF-CBT implementation
1577509|NCT02402192|Drug|Corifollitropin alfa|
1577510|NCT02402179|Other|Tryptophan|Tryptophan will be supplied at 13.2, 26.4, 39.7, or 52.9% of requirement; sourced from crystalline amino acid and white cornmeal maize.
1577512|NCT02402153|Device|Hyposafe device|Subcutanous EEG recorder for EEG measurements
1577513|NCT02402140|Other|Pharmaceutical Intervention|Patients allocated to group 1, with pharmaceutical intervention, received instructions on the proper use of immunosuppressants as doses, frequency, importance, schedules on the following days 3, 5, 7, 10, 14, 21, 28, 60 and 90 after kidney transplant. Teaching materials were designed to assist in the pharmaceutical guidelines that understood the importance of immunosuppressive drugs, the risk of rejection, the schedules and the most appropriate way for the administration. In addition to these guidelines, pharmacists helped patients in filling out the patient diary. This diary contains all the medications that the patient administers and encourages them to write down daily doses in order to remind them. This was a standardized pharmacist intervention.
1577514|NCT02402127|Device|Narafilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
1577515|NCT02402127|Device|Stenfilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
1577516|NCT02402127|Device|Somofilcon A contact lenses|Silicone hydrogel contact lenses for daily disposable wear
1577517|NCT02402114|Drug|Hydrocortisone|120 mg Hydrocortisone given orally one time.
1577518|NCT02402101|Device|Procedure: active tDCS|Intensity 2 mA during 20 minutes
1577519|NCT02402101|Device|Procedure: sham tDCS|sham condition as delivered by the stimulator
1577520|NCT02402088|Behavioral|Stress Imagery|"The stress imagery script will be based on subjects' description of a recent personal stressful event that they had experienced as most stressful. Most stressful is determined by having the subjects rate the perceived stress experienced by them on a 10-point Likert scale where 1=not at all stressful and 10=the most stress they felt recently in their life. Only situations rated as 8 or above on this scale are accepted as appropriate for script development. Examples of acceptable stressful situations include breakup with significant other, a verbal argument with a significant other or family member or unemployment-related stress, such as being fired or laid off from work."
1577521|NCT02402088|Behavioral|Food Cue Imagery|A food cue script will be developed from the subjects' experience of eating their most favorite foods. Examples include ordering pizza, cooking a favorite meal, or going out to a restaurant.
1577522|NCT02402088|Behavioral|Neutral-Relaxing|A neutral-relaxing script will be developed from the subjects' commonly experienced neutral-relaxing situations, such as a trip to the beach or park.
1577523|NCT02402062|Drug|TH-302 + Sunitinib|"Combination of the two drugs in cycles of 28 days, described as follows:
Sunitinib: 37,5 mg/day Oral everyday of each 28 day cycle.
TH-302: 340 mg/m2 IV on days 8, 15 and 22 of each cycle."
1577524|NCT02401984|Other|Screening|Participants will fill out a short screening questionnaire where different aspects of mental health and behavioral problems will be assessed.
1577525|NCT02401971|Drug|Thalidomide|Given orally
1577526|NCT02401971|Drug|CPT-11|Given Ivgtt
1577527|NCT02401958|Other|Resistance training|17 volunteers with RA and 17 without the disease, with a mean age of 54.7 + 6.63 underwent a resistance exercise session with a set of 12 repetitions at 50% of one repetition maximum (1RM ) and a set of 8 repetitions at 75% of 1RM. The exercises performed were: knee extension, knee flexion, hip abduction and hip adduction. Blood samples were obtained 30 minutes before, 5 minutes before, immediately after, 1 hour, 2 hours and 24 hours after the exercise session.
1577528|NCT02401945|Drug|DE-120|
1577529|NCT02401945|Drug|Aflibercept|
1577530|NCT02401932|Other|Hemophagocytosis|Best supportive care and immunosuppressive treatments
1577531|NCT02401919|Behavioral|Tell-us Card|Patients will be invited on a daily basis, during their stay in the hospital, to state what is important for them at that moment or before discharge
1577532|NCT02401906|Other|MRI|
1577533|NCT02401893|Biological|Influenza Vaccine|Everyone immunized as recommended by current guidelines
1577534|NCT02401880|Drug|Linagliptin|22 subjects will receive Linagliptin for 30 days
1577535|NCT02401880|Other|Placebo|22 subjects will receive Placebo for 30 days
1577536|NCT02401880|Drug|Empagliflozin|44 subjects will receive Empagliflozin for 60 days
1577537|NCT02401841|Drug|Two different types of drug for resolution of neuro-muscular blockade|
1577538|NCT02401828|Drug|Dolutegravir|Switch from combination antiretroviral therapy to dolutegravir monotherapy
1577542|NCT02401802|Dietary Supplement|Low-residue diet|Subjects will be instructed by members of the research team to follow a standardized low residue diet for 4 days
1577543|NCT02401802|Dietary Supplement|Usual care|Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by 24 hours of liquid diet
1577544|NCT02401789|Device|Implants (OsseospeedTM,EV Astra Tech System, DentsplyTM, Mölndal)|
1577545|NCT02401776|Dietary Supplement|Monster Energy Drink|Small Dose of Monster energy drink. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 16 ounce can of monster energy drink for a person weighing 75 kg).
1577546|NCT02401776|Dietary Supplement|Monster energy drink|Medium Dose of Monster Energy Drink. This will be given at a dose of 3 mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
1577547|NCT02401776|Dietary Supplement|Monster Energy Drink|Monster energy drink. This will be given at a dose of 3mg caffeine/kg body weight (equivalent to approximately one 24 ounce can of monster energy drink for a person weighing 75 kg).
1577548|NCT02401776|Dietary Supplement|Coffee|Coffee. This will be given at a dose of 2mg caffeine/kg body weight (equivalent to approximately one 8 ounce cup of coffee drink for a person weighing 75 kg).
1577549|NCT02401750|Drug|Oxycodone Naltrexone (a)|
1577550|NCT02401750|Drug|Oxycodone Naltrexone (b)|
1577551|NCT02401750|Drug|Placebo|Matches both experimental drugs
1577555|NCT02401724|Other|Transcranial direct current stimulation|
1577556|NCT02401724|Other|Action Training|
1577560|NCT02401698|Other|Functional clinical and TMS diagnostic|Functional clinical and TMS diagnostic examination to evaluate corticospinal motor tract activity and corticocerebellar tract activity and its relation with stroke recovery
1577561|NCT02401685|Other|Adjuvant therapy|Adjuvant therapy will include chemotherapy and/or endocrine therapy for all women, and radiotherapy to breast or chest wall if indicated. Human epidermal growth factor receptor 2 (HER2) targeted treatment may also be administered when indicated.
1577562|NCT02401685|Procedure|Axillary treatment|Axillary treatment can be axillary node clearance or axillary radiotherapy as per local guidelines.
1577563|NCT02401672|Device|Transcranial magnetic stimulation|Transcranial magnetic stimulation (TMS) is a noninvasive (and relatively painless) brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a TMS coil is able to focally stimulate the cortex by depolarizing superficial neurons inducing electrical currents in the brain. If TMS pulses are delivered repetitively and rhythmically, the process is called repetitive TMS (rTMS).
1577564|NCT02401659|Device|CareLinK|
1577565|NCT02401646|Dietary Supplement|Polygoni Multiflori Radix complex extract|Intervention is manufactured by Chun-Ho food
1577566|NCT02401646|Dietary Supplement|Placebo|The placebo is filled with starch, so does not contain the active ingredient.
1577570|NCT02401594|Drug|Rivaroxaban|10 mg once daily of Rivaroxaban active substance (10 mg tablet) plus a placebo syringe of enoxaparin 4000 UI once daily
1577571|NCT02401594|Drug|Enoxaparin|A syringe of enoxaparin active substance 4000 UI once daily plus a placebo tablet of Rivaroxaban 10 mg.
1577572|NCT02401581|Other|Catheter|The effectiveness of this model of management is defined by absence of a need for re-catheterization in the post -operative period of 24 hours, indications for resondage being cases of acute urinary retention (AUR ) or macroscopic hematuria necessitating a washes with drainage . Patients are followed for a period of 3 months with a post-operative visit at 30 days and a last follow-up visit at 90 days during which the effectiveness is evaluated by conventional means of clinical indicators ( flowmetry , postvoid residue, volumetry of the prostate , IPSS scores , QoL , EVA, IIEF ... ).
1577573|NCT02401568|Device|Dynamic CT|Various low dose CT acquisitions will be successively performed on the wrist to allow a four dimensional evaluation. The same type of acquisition will be performed during various manoeuvers (radio-ulnar deviation, clenching fist, and dart-throwing motion).
1577574|NCT02401568|Procedure|Arthrography|percutaneous intra-articular injection of contrast media in the medio-carpal and radio-carpal joints
1577575|NCT02401555|Device|Geenius HIV1/2 Supplemental Assay|The purpose of this study is to evaluate the performance of the Bio-Rad Geenius HIV1/2 Supplemental Assay test in finger stick whole blood, venous whole blood, serum or plasma (EDTA, heparin, sodium citrate).
1577576|NCT02401542|Drug|B-701|
1577577|NCT02401542|Drug|Docetaxel|
1577578|NCT02401542|Drug|placebo|
1577579|NCT02401529|Drug|IV dexamethasone|0.15 mg/kg
1577580|NCT02401529|Drug|Oral prednisolone|0.25mg/kg/day for 7 days then tapering for next 7 days
1577581|NCT02401529|Drug|Paracetamol|acetaminophen 15 mg/kg/dose every 6 hours
1577582|NCT02401529|Drug|IV saline|IV saline
1577583|NCT02401516|Device|Reprogramming insoles|1)Answer demographic, lifestyle and health questionnaire; 2)Weight and height evaluation; 3)ABPM (Ambulatory Blood Pressure Monitoring) and diary of activities assessment; 4)Postural Assessment software (SAPO), created by São Paulo's University (USP), which assesses posture through full body images of people with marked bone prominences on the body in all planes of motion. Images are captured by a Sony Cybershot 14 Megapixel camera, supported on a tripod, placed three meters away from the subject and at half its height. 5)Six-Minutes Walk Test in accordance with Britto and Souza25 and American Thoracic Society guidelines43; 6)analog manometer Globalmed® brand to assess respiratory muscle strength; 7)Dynamometer Jamar® brand to measure grip strength; 8)Wells bank to evaluate Flexibility.
1577584|NCT02401503|Drug|Bendamustine|Debulking: Cycles 1-2, d1 & 2: 70mg/m² i.v.
1577585|NCT02401503|Drug|GA101|Induction: Cycle 1: d1: 100mg, d1(or 2): 900mg, d8 & 15: 1000mg; Cycle 2-6: d1: 1000mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1: 1000mg
1577586|NCT02401503|Drug|ABT-199|Induction: Cycle 2: d1-7: 20mg, d8-14: 50mg, d15-21: 100mg, d22-28: 200mg; Cycle 3-6: d1-28: 400mg Maintenance: Cycles 1-8 (Duration 12 weeks): d1-84: 400mg
1577587|NCT02401490|Drug|Human albumin|1.5gr/Kg/day at least in the 24-48 hours after the hospitalization and 1.0 gr/Kg/day at 72 hours after the first dose.
1577588|NCT02401490|Drug|Placebo|
1577589|NCT02401477|Drug|Ilaprazole + Amoxicillin|Ilaprazole 40mg BID, dosage form : delayed release tablet Amoxicillin 750mg QID, dosage form : capsule
1577590|NCT02401464|Drug|TAK-536 Tablet|TAK-536 10 mg tablet
1577591|NCT02401464|Drug|TAK-536 Dry Syrup Formulation|TAK-536 dry syrup formulation
1577592|NCT02401464|Drug|TAK-536 Ganule Formulation|TAK-536 granule formulation
1577593|NCT02401451|Device|RhythmPadGP|ECG acquisition using a novel device RhythmPadGP
1577594|NCT02401438|Other|5D ultrasound|
1577595|NCT02401438|Other|2D ultrasound|
1577596|NCT02401425|Drug|Letrozole|
1577597|NCT02401425|Drug|Misoprostol|
1577598|NCT02401425|Other|Placebo|
1577599|NCT02401412|Device|Test Ostomy Barrier|
1577600|NCT02401412|Device|Control Ostomy Barrier|
1577601|NCT02401399|Dietary Supplement|Regular diet|The patients receive regular diet 900 Kcal/day during 15 days before surgery
1577602|NCT02401399|Dietary Supplement|High protein formula|The patients receive high protein formula during 15 days before surgery
1577603|NCT02401399|Dietary Supplement|Immunonutrition|The patients receive Immunonutrition formula during 15 days before surgery
1577604|NCT02401386|Behavioral|The Lu Eight Brocades|LEB Intervention:The 12-week LEB program will meet in groups of 31 subjects. Each 1-hour session twice a week will include each of 8 forms of LEB movements, a review of principles, and breathing techniques in LEB. Participants will be asked to practice LEB at home for 30 minutes each day, using an instructional Digital Video Disc. The program will be taught by experienced LEB masters.
1577605|NCT02401373|Biological|Ad5-EBOV|intramuscular injection
1577606|NCT02401360|Drug|China Crest® Pro-health 7 Complete Toothpaste|Crest® pro-health manual toothbrush Crest® pro-health gum protection rinse
1577607|NCT02401360|Drug|China Crest® Cavity Protection Toothpaste|Crest® meliliangje manual toothbrush
1577608|NCT02401347|Drug|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
1577609|NCT02401334|Device|Cook® Antimicrobial Hernia Repair Device|Device containing an antimicrobial to reinforce soft tissue during ventral or incisional hernia repair in clean-contaminated, contaminated, and dirty-infected
1577610|NCT02401321|Behavioral|Telephone-Based Intervention|Complete Taking Care of Her program
1577611|NCT02401321|Other|Caregiver-Assisted Training|Complete Taking Care of Her program
1577612|NCT02401321|Other|Questionnaire Administration|Ancillary studies
1577613|NCT02401321|Other|Quality-of-Life Assessment|Ancillary studies
1577614|NCT02401308|Procedure|Deep Brain Stimulation surgery|Deep Brain Stimulation surgery: awake vs. asleep
1577615|NCT02401295|Drug|ATRA|
1577616|NCT02401295|Drug|Celecoxib|
1577617|NCT02401295|Drug|Itraconazole|
1577618|NCT02401282|Behavioral|Attention Bias Modification|This is a modification of the dot-probe task (placebo task) designed to train attention away from threat
1577619|NCT02401282|Behavioral|Dot-probe task|This is the active control placebo condition that simply measures levels of attention to threat
1577620|NCT02401269|Drug|Aspirin|
1577621|NCT02401269|Drug|Placebo|
1577626|NCT02401243|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: pre-filled disposable pen
Route of administration: subcutaneous"
1577627|NCT02401230|Drug|Truvada|Truvada is a combination of 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate taken orally.
1577628|NCT02401230|Device|Gel lubricant|Five ml of an over the counter sexual lubricant will be dispensed using an applicator.
1577629|NCT02401217|Other|Phase 1- Arm 1 Infant Formula|Powder infant formula
1577630|NCT02401217|Other|Phase 2- Arm 2 Infant Formula|Powder infant formula
1577631|NCT02401217|Other|Phase 2- Arm 3 Infant Formula|Powder infant formula
1577632|NCT02401204|Other|Longitudinal surveillance study|"Regular specimens will be routinely collected as standard of practice.
A rectal swab and stool specimen will be collected twice a week since first admission on NICU until discharge from NICU.
If participant is intubated/ventilated, a throat swab will be collected."
1577633|NCT02401191|Drug|FEX60/PE10|Pharmaceutical form:tablet Route of administration: oral
1577634|NCT02401165|Other|Blood test|blood test
1577635|NCT02401152|Other|Sports drink 1|Sports drink with a specific source of CHO.
1577636|NCT02401152|Other|Sports drink 2|Sports drink with a specific source of CHO
1577637|NCT02401152|Other|Placebo|iso-caloric sports drink with maltodextrin as CHO source
1577638|NCT02401139|Drug|Ketamine|
1577639|NCT02401139|Drug|Placebo|
1577640|NCT02401126|Dietary Supplement|Nitrate supplementation|Nitrate supplementation: concentrated nitrate-rich beetroot juice (2 x 70 ml/day; approximately 10 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days.
1577641|NCT02401126|Dietary Supplement|Placebo|Placebo: nitrate-depleted beetroot juice (2 x 70 ml/day; approximately 0.01 mmol nitrate/day; Beet It, James White Drinks, Ipswich, UK) for 8 consecutive days. The placebo juice is similar to the concentrated beetroot juice in appearance, texture, smell and taste and is obtained by removing nitrate ions from the latter.
1577642|NCT02401113|Dietary Supplement|UA group|Ursolic Acid of Loquat Extract, 500mg/ day during 12 weeks
1577643|NCT02401087|Procedure|Anaesthesiological procedure|
1577644|NCT02401074|Biological|Segmental Bronchoprovocation with Allergen (SBP-Ag)|Premedication will consist of intramuscular glycopyrolate (0.2 mg), and midazolam (0.5-2.0 mg). Subjects will also be given a short-acting beta agonist, albuterol (2 puffs, 180 mcg) prior to bronchoscopy. Following nasopharyngeal anesthesia (topical lidocaine), the fiberoptic bronchoscope will then be passed into a pulmonary segment or subsegment. During the SBP-Ag challenge, approximately 15% of the Ag-PD20 allergenic extract will be instilled into the segment (5)
1577645|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 1 microgram of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
1577646|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 3 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 minutes, followed by four hours of observation.
1577647|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 6 micrograms of PRTX-100 per kilogram of patient weight, infused over 30 to 60 minutes, followed by four hours of observation.
1577648|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 12 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation.
1577649|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 18 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation.
1577650|NCT02401061|Drug|PRTX-100|Four weekly infusions of PRTX-100 at a level of 24 micrograms of PRTX-100 per kilogram of patient weight, infused over 60 minutes, followed by four hours of observation.
1577651|NCT02401048|Drug|Ibrutinib|
1577652|NCT02401048|Drug|MEDI4736|
1577654|NCT02401022|Drug|AZD8529|comparison of different dosages of drug
1994134|NCT03062111|Procedure|ProTouch Laser Enucleation of Prostate (LEP)|Laser enucleation of the prostate is a standard form of treatment for BPH used widely. The ProTouch laser is established to be safe and is newer than the holmium laser.
1994135|NCT03062111|Procedure|Transurethral Resection of Prostate (TURP)|TURP has been considered a gold standard for treatment of BPH in which rigid resectoscopes with bipolar cautery are used to endoscopically resect prostatic tissue.
1994136|NCT03061474|Drug|Nicotinamide|Niacinamide (nicotinamide; 99%) is produced in a 750 mg sustained release tablet.
1994137|NCT03061474|Drug|Placebo Comparator|Oral Tablet
1994138|NCT03060902|Behavioral|Dialectical Behavior Therapy Skills|DBT Skills Training will follow the DBT Skills Training Manual Second Edition and the DBT Skills Training Handouts and Worksheets Second Edition.
1994140|NCT03060135|Behavioral|Check Your Drinking|A anonymous brief survey designed to provide normative feedback of individual's drinking with the intent of motivating reductions in drinking
1994141|NCT03060135|Behavioral|Hello Sunday Morning|Brief online intervention that allows Individual's reflect on their drinking reductions progress and goals.
1577658|NCT02400957|Other|Silver nanoparticles|Half of the mouth was applied silver nanoparticles. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
1577659|NCT02400957|Other|Placebo|Half of the mouth was applied placebo. Allocation was randomized. Evaluate the effectiveness of silver nanoparticles incorporated into the primer orthodontic Transbond XT in preventing enamel demineralization adjacent to brackets.
1577660|NCT02400944|Behavioral|questionnaires|The study questionnaires (baseline and 2 follow-ups) will capture information on how modifiable factors, including the patients' smoking habits and body weight, have changed since last contact. RSA will conduct this interview at a time convenient to the patient either during a scheduled clinic visit or by telephone.
1577661|NCT02400944|Other|Saliva and/or urine sample|Patients will contribute approximately 5 mL of saliva at baseline, and at the time of their follow-up questionnaires. If the patient declines to contribute a saliva specimen, they can contribute approximately 10mL of urine. Urine is routinely collected from bladder cancer patients for clinically-related tests. We will also collect urine from every participant for whom the sample is not depleted by clinical tests at the end of the day. Saliva/urine specimens will be tested for cotinine which is regarded as the gold standard to detect recent smoking exposure and is widely used to identify active smokers in epidemiologic studies.
1577662|NCT02400931|Procedure|mask ventilation|In mask ventilation group, rocuronium of 0.6 mg/kg will be administered after the loss of consciousness. Mask ventilation wil be performed until there is no response on the train-of-four stimulus. No mask ventilation - In no mask ventilation group, rocuronium of 1.2 mg/kg will be administered after the loss of consciousness. Tracheal intubation will be performed after confirmation of no response on the train-of-four stimulus. The mask ventilation will not be performed before the tracheal intubation.
1577663|NCT02400931|Procedure|no mask ventilation|
1577664|NCT02400931|Drug|Rocuronium|
1577665|NCT02400918|Other|The Mindfulness and Acceptance-based Workbook for Social Anxiety and Shyness (Fleming & Kocovski, 2013)|An acceptance and commitment therapy-based self-help workbook for social anxiety and shyness. It includes an 8-week program.
1577666|NCT02400905|Device|BioMimics 3D Stent System|Femoropopliteal stenting
1577667|NCT02400892|Other|TTE Bubble Study|Bedside transthoracic echocardiogram bubble study to assess for the presence or absence of a PFO
1577668|NCT02400879|Drug|Remifentanil|administering remifentanil infusion 0.7-0.8 mcg/kg/min for anesthesia maintenance
1577669|NCT02400879|Drug|sevoflurane and sufentanil|administering sevoflurane and sufentanil for anesthesia maintenance
1577670|NCT02400866|Drug|Olanzapine|
1577671|NCT02400853|Device|Standard cranial echography|Standard cranial echography will be done at day 5 day 7 post-birth looking for radiological finding of intraventricular hemorrhage
1577672|NCT02400853|Procedure|Cord blood analysis|Cord blood will be collected during deliverance and analysed
1577673|NCT02400840|Procedure|cardiac MRI|Cardiac MRI is done using gadobenic acid intravenous injection 0.2 ml/kg one time
1577674|NCT02400840|Drug|gadobenic acid intravenous injection 0.2 ml/kg|gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
1577675|NCT02400827|Other|malignant cells|
1577676|NCT02400814|Drug|Anti-PD-L1 Monoclonal Antibody MPDL3280A|Given IV
1577677|NCT02400814|Radiation|Stereotactic Body Radiation Therapy|Undergo SAR
1577678|NCT02400801|Drug|triptorelin|gonadotropin-releasing hormone (GnRH) agonist
1577679|NCT02400801|Drug|ethinylestradiol + dienogest|oral oestroprogestogen
1577680|NCT02400788|Drug|Resminostat|
1577681|NCT02400788|Drug|Sorafenib|
1577682|NCT02400775|Drug|Azilsartan|Azilsartan tablets
1577683|NCT02400749|Drug|Apremilast|"Apremilast tablets will be provided to sites in blister cards.
Patients will be provided a titration blister pack containing apremilast 10 mg, 20 mg and 30 mg at the Day 0 and week 16 visits (refer to section 6.1). Following the 6 day titration period (for Day 0 and week 16) blister packs will contain apremilast 30 mg bid or placebo bid."
1577684|NCT02400749|Drug|Placebo|Placebo tablets will be provided to sites in blister cards.
1577685|NCT02400736|Behavioral|Individual Placement and Support (IPS)|"Individual Placement and Support (IPS) is supported employment and involves the following domains: 1) Competitive Employment: The IPS intervention assists participants to enter into competitive jobs; 2) Eligibility Based on Client Choice, i.e. zero exclusion; 3) Integration of IPS and Treatment Team, i.e. the PACT; 5) Personalized Benefits Counseling: IPS specialists help Veterans obtain information about their VA, Social Security, Medicaid, and other government entitlements; 6) Rapid Job Search: IPS specialists use a rapid job search, rather than providing lengthy pre-employment assessment, training, counseling; 7) Systematic Job Development: IPS specialists build an employer network based on Veterans' interests; 8) Time-Unlimited and Individualized Support: follow-along IPS supports are individualized and continue for as long as needed during the 12-month study."
1577686|NCT02400736|Other|Usual Care/Transitional Work Program (TWP)|Transitional Work Program (TWP) involves 1) Time-limited Set-Aside Employment: short-term transitional work experiences in a brokered or set-aside work setting; 2) Eligibility Criteria: no strict entrance criteria other than general medical clearance; 3) Limited Integration of TWP and Clinical Services: not integrated within PACT; 4) Less Patient-Centered: TWP jobs are pre-arranged, set-aside jobs are less likely to have a meaningful relationship to the Veterans' preferences; 5) Personalized Benefits Counseling: TWP specialists help Veterans obtain information about their VA, Social Security, Medicaid, and government entitlements; 6) Job Search: The TWP specialists provide variable and limited guidance for competitive job search; 7) Limited Job Development: TWP specialists do not engage in community based job development for a specific Veteran; 8) Time Limited Support: The TWP specialist does not provide long-term follow-up after the first job is obtained.
1577729|NCT02400437|Drug|Dexamethasone|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
1577690|NCT02400710|Behavioral|Clinician-Supported PTSD Coach|Brief primary care-based intervention provided by a mental health clinician who is located in primary care.
1577691|NCT02400710|Behavioral|Self-Managed PTSD Coach|One 10 minute session explaining how to use the PTSD Coach mobile app.
1577692|NCT02400697|Other|<30 wks gestation or 1500 grams|Outcomes of preterm infants recorded
1577693|NCT02400684|Biological|blood samples|Evolution of AMH before and after deep endometriosis surgery
1577694|NCT02400671|Behavioral|SMS messaging|
1577695|NCT02400658|Device|IORT with CT-Guided HDR Brachytherapy|This therapy targets the cancer cells directly, reducing the volume of breast tissue exposed to the radiation and the risks involved with the radiation. CT imaging will be used via a multichannel/multi-dwell balloon catheter to better sculpt the cancer away from the heart, skin, and ribs.
1577696|NCT02400645|Procedure|Pre-incisional wound infiltration|Intraoperative: Pre-incisional bupivacaine 0.25% up to 20 cc divided dose for trocar incisions
1577697|NCT02400645|Procedure|Laparoscope to place TAP block with liposomal bupivacaine|Intraoperative: Laparoscopic TAP block with Liposomal bupivacaine and bupivacaine 0.25%
1577698|NCT02400645|Drug|Liposomal bupivacaine|Use of Liposomal bupivacaine in laparoscopic TAP block
1577699|NCT02400645|Drug|Bupivacaine|20 cc Bupivacaine 0.25% plain will be used for either pre-incisional injection or added to laparoscopic TAP block solution.
1577700|NCT02400645|Drug|Ketorolac|Ketorolac 30mg to be given IV at end of surgical procedure unless contraindicated.
1577701|NCT02400632|Device|MAGIC-TOUCH Drug-eluting Balloon|in-stent restenosis treated with drug eluting balloon
1577702|NCT02400619|Device|shock waves|Swiss dolorclast smart EMS Registration: EN-60601-1 Type BF IP40. 93/42 CEE
1577703|NCT02400619|Drug|Botulinum Toxin Type A|Botulinum toxin type A Botox
1577704|NCT02400606|Other|Constructing VP cases|The participants were presented with a short case overview. The control group solved the cases, whereas the intervention group also received the final diagnosis and had to complete the history, physical findings, and lab results. After a week, participants completed a transfer test involving two standardized patients presenting a respiratory case and a cardiology case, respectively. Performances were video-recorded and subsequently assessed by two blinded raters using the Reporter-Interpreter- Manager-Educator (RIME) framework. Knowledge gains were assessed using a pre- and post-test of a 95-item Multiple-Response-Questionnaire (MRQ).
1577705|NCT02400606|Other|Solving VP cases|See above
1577706|NCT02400593|Behavioral|Meditation Workshop|Six weeks of formal instruction in Lovingkindness or Mindfulness meditation.
1994146|NCT03058731|Device|Matristem|Paraesophageal hernia repair with MatriStem Surgical Matrix
1994147|NCT03058731|Device|Control|Paraesophageal hernia repair with other biologic mesh
1577709|NCT02400567|Drug|Fluorouracile|
1577710|NCT02400567|Drug|Epirubicin|
1577711|NCT02400567|Drug|Cyclophosphamide|
1577712|NCT02400567|Drug|Letrozole|
1577713|NCT02400567|Drug|Palbociclib|
1577714|NCT02400554|Behavioral|Yappalli|"Month 1-3: Up to 8 group sessions on Choctaw history, traditions, cultural systems, & women's roles. Up to 3 individual Motivational Interviewing (MI) sessions to identify community leadership & personal change goals on the main outcome.
Month 2: Overnight Culture Camp to strengthen group cohesion & synthesize goals.
Month 3: Walk for a week on the Choctaw Trail of Tears, upon completion make a commitment to conduct a community-wide event based on personal & leadership goals & experience on the Trail.
Months 3-12: Up to 6 group meetings to plan community leadership events related to ATOD & obesity prevention. Includes: digital storytelling training to create a story related to ATOD & obesity prevention & an individual MI booster session to revise their personal & community leadership goals.
Month 12: Share digital stories & community event experiences & undergo a ceremony to transition to health leaders within their communities."
1577715|NCT02400541|Behavioral|Cognitive remediation therapy|"Our scheme comprises 10 biweekly sessions ( 5 in group and 5 single) . Each session last about 45 minutes.
Individual sessions will be held with the patient and a therapist trained in the CRT; group sessions will be led by two therapists trained in CRT and regroup the maximum 5 patients."
1577716|NCT02400541|Other|relaxation therapy|Our scheme comprises 10 biweekly sessions. Each session last about 45 minutes.
1577717|NCT02400528|Behavioral|quality of life questionnaires|
1577718|NCT02400515|Other|Exercise|This is a quasi-experimental study and the same group was evaluated before and after the exercise.
1577719|NCT02400502|Behavioral|I-CAT Therapy|I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life). Participants meet weekly with a master's level clinician over the course of 20 weeks.
1577720|NCT02400476|Drug|Neratinib|neratinib 240 mg (full treatment as extended adjuvant treatment for 13 cycles)
1577721|NCT02400476|Drug|Loperamide|intensive loperamide prophylaxis for two 28 day cycles (total 56 days) for neratinib and loperamide arm and budesonide arm, or 28 days for colestipol and bismuth subsalicylate or mesalamine arms
1577722|NCT02400476|Drug|Budesonide|budesonide extended release tablets 9 mg once daily with or without food for 28 days
1577723|NCT02400476|Drug|Colestipol|colestipol 2 g twice daily with or without food for 28 days
1577724|NCT02400476|Drug|Bismuth Subsalicylate or Mesalamine|bismuth subsalicylate 262 mg 3 times per day or mesalamine 2.4 g/day with food, for 28 days
1577725|NCT02400463|Drug|Ruxolitinib|
1577726|NCT02400450|Dietary Supplement|Functional Ingredient Group|Participants will be provided with a mix of 6 study products to use over the 12 week trial (2 per day). These will be a) oatmeal, b) pancake mix, c) chocolate crunch bar, d) cranberry nut bar, e) anytime sprinkle, and f) smoothie mix, standardized for the content of functional ingredients.
1577727|NCT02400450|Dietary Supplement|Control Ingredient Group|The control group will receive a comparable set of food items to use over the 12 week trial (2 per day). These food items will contain an equivalent amount of calories per portion but without the additional functional ingredients.
1577728|NCT02400437|Drug|Ixazomib|Doses given on Days 1, 8, and 15 in induction and maintenance cycles.
1577731|NCT02400424|Radiation|SBRT|54 Gy in 3 fractions D1-D3-D5. SBRT should be started within 3 to 4 weeks after the end of radiochemotheray (RT-CT).
1577732|NCT02400411|Other|Wheat bread|
1577733|NCT02400411|Other|margarine|
1577734|NCT02400411|Other|ham|
1577735|NCT02400411|Other|soup|
1577736|NCT02400411|Other|rye bread|
1577737|NCT02400398|Other|Tube feeding|Jejunal or gastrojejunal tube feeds will be given as continuous feeds via pump with Pepatmen(medical food), at the patient's home, for the duration of the protocol and as directed by the nutritionist.
1577738|NCT02400385|Drug|sunitinib|sunitinib 50mg/day po, 4 weeks on 2 weeks off
1577739|NCT02400385|Drug|nivolumab|nivolumab 3mg/kg IV ever 2 weeks
1577740|NCT02400372|Device|medihoney dressing|to evaluate the effect of medihoney dressing on the healing of split thickness skin graft donor site
1577741|NCT02400359|Drug|Lorcaserin HCl|Lorcaserin is a weight-loss drug developed by Arena Pharmaceuticals. It has serotonergic properties and acts as an anorectic.
1577742|NCT02400359|Drug|Placebo|This is a placebo oral pill that is a visual replica of the Lorcaserin medication but with no active ingredients.
1577743|NCT02400346|Drug|Adjunct brexpiprazole|"Weeks 1-4 titration from 0.5 up to 2 mg once daily, in weekly steps. For the rest of the 26 treatment weeks, maintenance with 1-3 mg once daily.
Tablets for oral use once daily during 26 weeks. Tablet strengths: 0.5 mg, 1 mg, 2 mg and 3 mg."
1577744|NCT02400346|Drug|ADT|Citalopram, ecitalopram, fluoxetine, sertraline, paroxetine IR, paroxetine CR, venlafaxine IR, venlafaxine XR (extended release), desvenlafaxine, duloxetine, mirtazapine, agomelatine, bupropion; dosing according to label
1577745|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered with 200 ml of water|90 mg single dose
1577746|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) administered without water|90 mg single dose
1577747|NCT02400333|Drug|Ticagrelor OD tablet (90 mg single dose) suspended in water administered via nasogastric tube|90 mg single dose
1577748|NCT02400333|Drug|Brilique®, Ticagrelor IR tablet (90 mg) administered with 200mL of water|90 mg single dose
1577749|NCT02400320|Drug|Topical Spray|Topical spray containing Diclofenac 1.16%, Linseed Oil 3%, Menthol 5%, Methyl salicylate 10%.
1577750|NCT02400320|Drug|Topical Gel|Topical gel containing Diclofenac 1.16%, Menthol 5%, Methyl salicylate 10%
1577751|NCT02400320|Other|Saline|Saline
1577752|NCT02400307|Drug|GS-9883|GS-9883 75 mg tablet administered orally
1577753|NCT02400294|Other|Toothbrushing|Toothbrushing associated with standard oral care in mechanically ventilated patients
1577754|NCT02400281|Drug|Crenolanib besylate|
1577755|NCT02400281|Drug|Idarubicin|
1577756|NCT02400281|Drug|Cytarabine|
1577757|NCT02400281|Drug|Azacytidine|
1577758|NCT02400281|Drug|Mitoxantrone|
1577759|NCT02400281|Drug|Etoposide|
1577760|NCT02400281|Drug|Fludarabine|
1577761|NCT02400281|Drug|G-CSF|
1577762|NCT02400268|Other|7 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
1577763|NCT02400268|Other|14 days course of antibiotic treatment|Standard antibiotic treatment approved for enterobacteraciae infections
1577764|NCT02400255|Drug|Crenolanib besylate|
1577765|NCT02400242|Drug|ACY-241|Dose escalation up to 480 mg administered orally on Days 1-21 of a 28 day cycle.
1577766|NCT02400242|Drug|Pomalidomide|4 mg qd dosed on days 1-21 of a 28 day cycle
1577767|NCT02400242|Drug|Dexamethasone|40 mg qd on days 1, 8, 15, 22
1577768|NCT02400229|Procedure|Computed tomography angiography (cardiac CT)|Clinical management/treatment decisions based on cardiac computed tomography including coronary calcium scoring and coronary computed tomography angiography
1577769|NCT02400229|Procedure|Invasive coronary angiography (ICA)|Clinical management/treatment decisions based on invasive coronary angiography
1577770|NCT02400203|Other|Control|
1577771|NCT02400203|Other|Hemp foods|
1577773|NCT02400177|Behavioral|emotion regulation training|This is a workshop for parents that help them to understand how to deal with emotions generally and specifically with their ASD children's emotion
1577774|NCT02400164|Device|alfapump system|The Sequana Medical alfapump system is an implanted subcutaneous device with a rechargeable battery that moves ascitic fluid from the peritoneal cavity to the urinary bladder where it is eliminated by spontaneous diuresis.
1577775|NCT02400151|Drug|Vitamin D supplementation|Patients randomized to this group will receive 4000 UI of Vitamin D3 per day for 90 days.
1577776|NCT02400151|Drug|Placebo|Patients randomized to this group will receive placebo for 90 days.
1577777|NCT02400151|Other|3 months lifestyle and dietary management|Lifestyle and dietary management at the Saint Pierre Institute (Palavas-les-Flots, France) occurs for three months. Nutritionally speaking, each child or adolescent receives a controlled and balanced diet, consistent with the recommendations appropriate for his/her age, slightly hypocaloric or normocaloric. This dietary approach is complemented by a nutrition education program and supervision by a doctor and a dietician. Three hours of exercise training per week are scheduled; these sessions include adapted aerobic activities supervised by instructors and educators at the center.
1577778|NCT02400151|Other|Normal control|Patients in this group do not have experimental intervention in order to provide measures of a real-life control group.
1577781|NCT02400112|Drug|Vancomycin|Vancomycin powder administered locally, intraoperatively at site of open fracture
1577782|NCT02400099|Dietary Supplement|High-protein low calorie diet|
1577786|NCT02400099|Other|8-h metabolic profile|
1577787|NCT02400099|Other|Liver biopsy|
1577788|NCT02400073|Device|AutoSet for Her|3 months nightly usage of the AutoSet for Her device
1577789|NCT02400060|Behavioral|Telephone-Based Intervention|Receive text messaging
1577790|NCT02400060|Other|Survey Administration|Ancillary studies
1577791|NCT02400060|Other|Laboratory Biomarker Analysis|Correlative studies
1577792|NCT02400047|Drug|Dexamethasone 0.2 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.2 mg / kg after general anesthesia induction and before surgery incision.
1577793|NCT02400047|Drug|Dexamethasone 0.4 mg/kg|Single injection of DXM (Mylan Dexamethasone® 20 mg/5 ml or 4 mg/1 ml injection ampoule solution) at 0.4 mg / kg after general anesthesia induction and before surgery incision.
1577794|NCT02400047|Drug|Ketoprofen 1 mg/kg|Single injection of ketoprofen (Medac ketoprofen ® 100 mg/4 ml injection ampoule solution) at 1 mg /kg after general anesthesia induction and before surgery incision.
1577795|NCT02400034|Other|Voiding trial|1 of 2 tests to assess bladder function after midurethral sling surgery with and without anterior or posterior colporrhaphy
1577796|NCT02400021|Drug|Prometrium|
1577797|NCT02400008|Procedure|Surgery for bilateral laryngeal reinnervation|Surgery for bilateral laryngeal reinnervation assessed for patient with bilateral vocal fold paralysis
1577798|NCT02399995|Behavioral|HRQoL questionnaires.|"Questionnaires/Forms to be completed preoperatively in clinic with assistance from research study administrator:
Baseline sociodemographic and clinical variable data sheet (RSA)
EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS
Baseline disease status and treatment assessment questionnaire Questionnaires/Forms to be completed at first postoperative clinic visit:
EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS
Questionnaires/Forms to be mailed to patients at ± 2 month window at the following time points 6,12,18,24, and 36 months following hepatectomy:
EORTC QLQ-C30, QLQ-LMC21, EuroQoL EQ-5D-5L/VAS
Post surgical follow up disease status and treatment assessment questionnaire
At 8 weeks following the mailing of the initial questionnaire package if no response has been received, research personnel will attempt to contact participants by phone."
1577799|NCT02399982|Other|CBT-GSH|The treatment will be based on Overcoming Binge Eating. The treatment is divided into a user-friendly section on binge eating and a six-step self-help program. The first session will last 60 min, with each subsequent section lasting 20-25 minutes in length. Sessions are weekly over 3 months. Working with the therapist, participants will use the self-help guide to develop regular and moderate eating using selfmonitoring, problem solving, and other CBT techniques.
1577800|NCT02399982|Other|Noom Monitor|This treatment will be exactly the same as CBT-GSH with the exception that all self-monitoring will be conducted through Noom Monitor and individuals will receive a specialized set of instructions on how to use the monitor. Therapists will also be asked to check feedback report on clients before each session. Therapists will receive weekly letter grades regarding each patient based on weekly level of OBEs/Purging, treatment adherence, and weekly weighing.
1577801|NCT02399969|Other|Battlefield Acupuncture|Patients with low back pain will be randomized to receive Battlefield Acupuncture, ASP indwelling needles in 5 auricular (ear) points plus standard of care, or patients will be randomized to receive standard of care alone.
1577802|NCT02399956|Other|Survey|Those who agree to participate will complete a cross-sectional survey on lactation outcomes (LACOUT). Eligible participants who consent to our study will complete the LACOUT questionnaire. The questionnaire uses the same breastfeeding measures as the CDC's Project First surveys and adds 21 items that are specific to the participant's cancer treatment and current health status.
1577803|NCT02399943|Drug|Trametinib|
1577804|NCT02399943|Drug|Panitumumab|
1577805|NCT02399930|Other|Respiratory & Heart Rate Data Collection|"This is a purely observational study - no intervention is being administered. Data is being collected from the medical record and patient monitoring devices.
Participants will wear the cableless device on their chest. This is a lightweight, small device that sticks onto the skin. We will record breathing rate and respiratory rate from this device. We will also collect this information from the medical record.
If a participant is placed on telemetry monitoring during the study period, we will collect information about alarm alerting patterns."
1577806|NCT02399917|Drug|5-azacytidine|"Phase I Starting Dose: 75 mg/m2 a day by vein or subcutaneously on Days 1 - 7 of a 28 day cycle.
Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
1577807|NCT02399917|Drug|Lirilumab|"Phase I Starting Dose: 1.0 mg/kg by vein on Day 8 of a 28 day cycle.
Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
1577808|NCT02399917|Behavioral|Phone Call|"If participant cannot come to the clinic, they will be called about 30 days after they go off study. This call will last about 5 minutes.
If participant goes off study for reasons other than the disease getting worse, they will be called every 3-6 months for up to 5 years. Each call should last about 5 minutes."
1577809|NCT02399904|Other|california tri-pull taping|To approximate the humeral head into the glenoid cavity participants were instructed to place their affected arm on a wooden table. Three piece of tape was used, firstly we applied cotton undercover pre tape and then we applied the rigid post tape on it. First piece (middle) of tape was applied from 1.5 inches below the deltoid tuberosity up to 2 inches above the glenoid cavity. Second piece (posterior) was applied from 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the mid spine of scapula. Third piece (anterior) was applied from the 1.5 inches below the deltoid tuberosity upto the 1.5 inches above the clavicle.
1577810|NCT02399891|Other|Quality Assurance Implementation|
1577811|NCT02399891|Other|Standard of Care|
1577812|NCT02399878|Drug|Inspiratory oxygen|
1577813|NCT02399865|Other|Youth Social Behaviour and Network Therapy|"The Y-SBNT will be delivered according to the developed purpose-designed therapy manual. Participants randomised to Y-SBNT will be offered six, 50 minute SBNT sessions for over a maximum period of 12 weeks. Where consent is obtained, sessions will audio-recorded and reviewed by the research team to ensure fidelity with the YSBNT manual and principles of practice.
Using the identification of the social network of the young person conducted in the first session as a platform, subsequent core strategies of the adapted YSBNT approach include motivational techniques, improving communication and coping mechanisms, and crucially given the nature of substance misuse, developing a network-based relapse management plan. Participants will be given the opportunity to invite members of their network to the treatment sessions. The therapeutic approach also has scope to address client-focussed elective areas, for example, educational requirements."
1577815|NCT02399839|Drug|lomitapide|As prescribed by Physician.
1577816|NCT02399826|Device|Offloading|"Provision of an offloading cam walker or cast boot, may also convert to total contact cast and add felt or foam to supplement"
1577817|NCT02399826|Procedure|Dressing Application|Application of a non adherent dressing, and a multi-layer compression dressing
1577818|NCT02399813|Drug|ADXS11-001|
1577819|NCT02399800|Procedure|Celiac Block with triamcinolone and bupivicaine|Endosonography of the pancreas performed following by analgesic injection
1577820|NCT02399800|Procedure|No Celiac Block|EUS but no celiac block performed
1577821|NCT02399800|Drug|Intra Plexus Triamcinolone and Bupivicaine Injection|Injection of Triamcinolone and Bupivicaine into celiac plexus for pain relief
1577822|NCT02399787|Other|blastocyst biopsy|Performed on day 5
1577823|NCT02399774|Device|Leboride|"Post-partum primi and multiparous women whom are interested in breastfeeding and have not begun yet. This arm will be randomized into 2 groups
Intervention group: participants will receive the dental device and be instructed to use it during breastfeeding.
Control group: participants will not receive any device for breastfeeding pain control
Post-partum women that have already begun breast feeding, will receive the dental device and each woman will be serve as her own control (breastfeeding before and after the use of the dental device."
1577824|NCT02399735|Biological|Low Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 5×10E9 NK cells.
1577825|NCT02399735|Biological|Normal Dose NK cells ×4 times|Received conventional treatment and NK cells once per two-week for the first two-month, at a dose of 1×10E10 NK cells.
1577826|NCT02399735|Biological|Normal Dose NK cells ×8 times|Received conventional treatment and NK cells once per two-week for the first four-month, at a dose of 1×10E10 NK cells.
1577827|NCT02399722|Device|WICVAC|combined wound therapy
1577828|NCT02399722|Device|VAC mono therapy|mono therapy
1577829|NCT02399709|Drug|simvastatin|
1577830|NCT02399709|Drug|Placebo|
1577831|NCT02399696|Behavioral|Primary Care-Brief Mindfulness Program|A 4-week group program adapted from the 8-week Mindfulness Based Stress Reduction (MBSR) curriculum
1577832|NCT02399696|Behavioral|Primary Care-Treatment as Usual|Typical VA primary care treatment, including mental health services delivered by primary care staff.
1577833|NCT02399683|Biological|Trichuris trichiura eggs|Live eggs from human whipworm, Trichuris trichiura
1577834|NCT02399657|Drug|Intravitreal dexamethasone 0.7mg implant|Ozurdex at day 0 (fixed), 5 months (fixed), 10 months pro re nata or 11 months pro re nata
1577837|NCT02399631|Other|Enhanced recovery program|Enhanced recovery program day-1: no mechanical bowel preparation, intake permit until 6 hrs before operation day0: operation, postoperative fluid therapy, antibiotics day1: liquid diet, early ambulation, removal of foley catheterization day2-3: soft diet day 4-5: discharge
1577838|NCT02399618|Drug|Fecal Microbiota Transplantation|Fecal microbiota transplant from healthy, unrelated donor via freeze-dried capsule
1577839|NCT02399605|Other|Stimulation|Subcutaneous abdominal electrical stimulation
1577840|NCT02399592|Drug|Bevacizumab|10 mg/kg q3w
1577841|NCT02399592|Drug|Tocotrinol|300 mg tid
1577842|NCT02399579|Other|Provocation test|The participants will perform 8 provocation tests. Every provocation test consists of petting the cat until the participants become symptomatic. The symptoms of cat allergic participants with the cat owner's cat will be recorded before and after petting the cat.
1577843|NCT02399566|Drug|Erlotinib, Pemetrexed|followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.
1577844|NCT02399553|Other|Soccer boot intervention|
1577845|NCT02399540|Device|Sham|Bihemispheric 1mA Sham protocol: sham - pause - sham
1577846|NCT02399540|Device|Conventional Paired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Paired tDCS protocol: 20 minutes tDCS - pause - sham
1577847|NCT02399540|Device|Conventional Unpaired tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Conventional Unpaired tDCS protocol: 20 minutes tDCS - pause - sham
1577848|NCT02399540|Device|Late LTP-like Plasticity tDCS|Bihemispheric 1mA Sham protocol: sham - pause - sham Late LTP-like Plasticity tDCS protocol: 10 minutes tDCS - 25 minutes pause - 10 minutes tDCS
1577849|NCT02399514|Other|Polysomnographic diagnostic|Polysomnographic diagnostic performed one prior to Coil Treatment, one six months after and one twelve month after Coil Treatment
1577850|NCT02399501|Procedure|hysteroscopy|Hysteroscopy is done under general anesthesia. The hysteroscopy used is rigid continuous flow diagnostic hysteroscopy (Tuttligen, Karl Storz, Germany). It has a 30º panoramic optic which is 4 mm in diameter and the diagnostic continuous flow outer sheath is 6.5 mm in diameter.
1577851|NCT02399501|Device|two dimensional ultrasound|Examination is performed after emptying of the bladder in dorsal lithotomy position .The probe is introduced into the posterior fornix of the vagina, then the following structures are examined, the uterus for site, size and mobility, the myometrium for fibroids and adenomyosis, the endometrium for uniformity, polyps, submucous fibroids and intrauterine adhesions, the cervix for nabothian follicles and polyps, the adenexa and ovaries for site, size, mobility, follicles, cysts and corpus luteum
1577852|NCT02399501|Device|saline sonohysterography|sterile speculum is introduced and the vagina and cervix is cleaned with povidone iodine 10%. Cook ET (embryo transfer) catheter is used. . After introduction of the catheter into the cervix, a twenty milliliter syringe which will be prefilled with the distending media (saline) then fitted to the catheter. The speculum is removed and endovaginal probe is introduced in the posterior vaginal fornix
1577936|NCT02398864|Procedure|EBUS with TBNA|endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
1577853|NCT02399501|Device|three dimensional ultrasound|The uterus is visualized in the longitudinal plane, the ultrasound probe is kept steady and the patient is asked to lie still on the examination bed. The volume mode is switched on. Three D volume is generated by the automatic rotation of the mechanical transducer through 360º. The acquired volume is in the shape of a transacted cone with a depth of 4.3 - 8.6 cm and a vertical angle α = 90º. Using the medium line density, the typical acquisition time is a round 10 seconds
1577854|NCT02399488|Device|Masimo Radical 7|Simultaneous determination of haemoglobin with the continuous haemoglobin monitor, the central lanboratory coulter and a POC:
1577855|NCT02399475|Drug|Levothyroxine|Oral levothyroxine with a total starting dose of 0.7mcg/kg/day split into three daily doses will be titrated to a target TSH level of 0.5 -1.5mU/L
1577856|NCT02399475|Drug|Liothyronine|Oral liothyronine with a starting dose of 1/3 of the weight-based LT4 dose divided into three daily doses titrated to a target TSH level of 0.5 -1.5mU/L
1577857|NCT02399475|Drug|Thyrotropin-Releasing Hormone|200 µg intravenous TRH will be given at study visit 1 (baseline), study visit 2 (on first thyroid treatment), and study visit 3 (on second thyroid treatment).
1577858|NCT02399462|Drug|Acthar|"Agent Dose Route Schedule H.P. Acthar Gel 40 units SC Twice weekly* Weeks 1 and 2 H.P. Acthar Gel 80 units SC Twice weekly* Weeks 3 through 24 H.P. Acthar Gel 80 units SC ONCE weekly* Weeks 25 through 26 H.P. Acthar Gel 40 units SC ONCE weekly* Weeks 27 through 28
*Injections are to be spaced 72-96 hours apart (+/-6 hours)."
1577859|NCT02399449|Drug|sodium ferric gluconate (brand)|brand product
1577860|NCT02399449|Drug|sodium ferric gluconate (generic)|generic product
1577861|NCT02399436|Behavioral|School-Based Healthy Snacking Campaign|"The school-based healthy snacking campaign includes the following activities:
Sales promotion of snack choices that meet federal Smart Snack guidelines during the school day and at school events, such as snack bars and after-school events;
The installation of new filtered water fountains outfitted with water-filling stations;
The distribution of re-usable water bottles to students at participating schools; and
A social marketing campaign to support adoption of the healthy snacks and water consumption by students."
1577862|NCT02399436|Behavioral|Community Cooking Classes|Cooking classes will be delivered to groups of 8-12 adult participants as a series of 8 weekly classes in community venues. The content of each class is driven by topics and themes identified and prioritized by community members, namely cooking healthy on tight budget.
1577863|NCT02399423|Behavioral|Weight gain|Weight gain of 7% body weight over 4-6 weeks by ingesting an extra 1500-2000 kcal/day
1577864|NCT02399423|Behavioral|Weight loss|Weight loss of 7-15% body weight over 12 weeks by increased exercise and either an alternate day fasting dietary regime or a weight watchers dietary regime
1577865|NCT02399410|Drug|perioperative chemotherapy plus bevacizumab|preoperative and postoperative combination chemotherapy with bevacizumab
1577866|NCT02399410|Procedure|cytoreductive surgery|complete or nearly complete removal of synchronous or metachronous peritoneal carcinomatosis from CRC.
1577867|NCT02399410|Drug|Intraperitoneal Oxaliplatin|Pump-driven intraperitoneal administration of oxaliplatin
1577868|NCT02399397|Procedure|Serial blood sampling|Serial blood samples are being collected at times 0, 2, 5, 10, 15, 20, 30, 60, 120, 180, 240 and 360 minutes after rocuronium administration.
1577869|NCT02399397|Procedure|Train of four monitoring|Neuromuscular blockade is being evaluated at the same time of blood sampling by stimulation of the adductor muscle of the thumb on the ulnar nerve through the train of four monitoring (TOF).
1577870|NCT02399397|Procedure|Blood testing for liver and renal function|Blood testing: urea, creatinine, aspartate aminotransferase, alanine aminotransferase, albumin, glycemia
1577871|NCT02399397|Drug|General anesthesia|All patients were induced with individual intravenous doses of midazolam, rocuronium, fentanyl and propofol.
1577872|NCT02399397|Procedure|Small to medium sized surgery under general anesthesia|Patients classified according American Society of Anesthesiologists (ASA) as ASA I-III and submitted to small-medium sized surgery under general anesthesia were recruited for the present investigation.
1577873|NCT02399371|Biological|Pembrolizumab|Given IV
1577874|NCT02399371|Other|Laboratory Biomarker Analysis|Correlative studies
1577875|NCT02399371|Other|Pharmacogenomic Study|Correlative studies
1577876|NCT02399345|Drug|ombitasvir/paritaprevir/ritonavir, dasabuvir|tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
1577877|NCT02399345|Drug|sofosbuvir (SOF)|tablet
1577878|NCT02399345|Drug|ribavirin (RBV)|tablet
1577879|NCT02399332|Other|Community pharmacist involvement|Collaborative involvement of the community pharmacists in formulating and following complex care plans
1577880|NCT02399319|Device|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
1577881|NCT02399319|Device|Symphyseal Plate|A plate that spans across the symphysis to maintain reduction and stability.
1577882|NCT02399306|Drug|nutrison|Enteral nutrition intervention：nutrison，15-25kcal/kg/d，according to the eating situation of patients，tube feeding or oral
1577883|NCT02399306|Radiation|radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) from week 1 to week 7,once a day, 5 times per week.
Radiotherapy dose：95% gross tumor volume（GTV-T） 60-66 Gy /30-33f，GTV-N 60-66 Gy /30-33f，CTV-T 50-54 Gy /25-27f，CTV-N 50-54 Gy /25-27f."
1577884|NCT02399306|Drug|Docetaxel, cisplatin|Concurrent chemotherapy：docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
1577885|NCT02399293|Behavioral|N-back|"The N-back task required patients to monitor a continuous sequence of stimuli (in this experiment audio and visual stimuli). Press a button if the current stimulus is the same as that shown N back in the sequence. N increases if performance is good and decreases if performance is poor.
Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
1577886|NCT02399293|Behavioral|Visual Search|"The Visual Search task consists of a NxN array of shapes. Press the button if a certain target stimulus is present in this array. N increases if performance is good and decreases if performance is poor.
Subjects train for 20 days, 12 blocks a day, 20+N trials per block. That is 240 blocks in total. A minimum of 10 blocks per day counts as a successfully trained day."
1577972|NCT02398630|Other|Transvaginal Echography|Transvaginal Echography for evaluating the female reproductive system
1577887|NCT02399280|Behavioral|Lunch as main meal(LM)+ Diet|Subjects are asked to have high caloric intake at lunch and low caloric intake at dinner, while they are on a multidisciplinary weight loss plan for 12 weeks.
1577888|NCT02399280|Behavioral|Dinner as main meal(DM)+ Diet|Subjects are asked to have high caloric intake at dinner and low caloric intake at lunch, while they are on a multidisciplinary weight loss plan for 12 weeks.
1577889|NCT02399267|Procedure|Once daily screening|RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
1577890|NCT02399267|Procedure|Twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met.
1577891|NCT02399267|Procedure|PS SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted on PS =< 8 cm H2O with PEEP =< 5 cm H2O.
1577892|NCT02399267|Procedure|T-piece SBTs|Patients are assigned a SBT technique. All SBTs for these patients must be conducted with T-piece.
1577893|NCT02399241|Device|Bluetooth enabled nebuliser device (I-neb)|
1577894|NCT02399228|Drug|0.25% EISO mouth rinse|A mouth rinse to be used three times a day during the course of radiation and/or chemotherapy to prevent or minimize oral mucositis
1577895|NCT02399215|Other|Laboratory Biomarker Analysis|Correlative studies
1577896|NCT02399215|Drug|Nintedanib|Given PO
1577897|NCT02399215|Other|Pharmacological Study|Correlative studies
1577898|NCT02399215|Other|Quality-of-Life Assessment|Ancillary studies
1577899|NCT02399202|Drug|osilodrostat|
1577900|NCT02399189|Drug|R-MT followed by auto-HSCT|Four cycles of Induction therapy: Rituximab 375mg/m2 d1; Methotrexate 3.5g/m2 d2;Temozolomide 100mg/m2 d2-6; for patients who reach a CR, PR, or SD, will proceed to autologous stem cell transplantation: Carmustine 400mg/m2 d1; Thiotepa 5mg/kg q12h, d2-3.
1577901|NCT02399176|Behavioral|Yoga|Subjects assume 10 physical postures for 30 seconds each
1577902|NCT02399163|Drug|Fluoride free toothpaste|Brushing with fluoride free toothpaste
1577903|NCT02399163|Drug|Fluoride toothpaste|Brushing with fluoride containing toothpaste
1577904|NCT02399163|Drug|Fluoride mouthwash|"Fluoride mouth wash to be followed after brushing with fluoride free toothpaste in Placebo dentifrice/Fluoride rinse arm and in Fluoride dentifrice/Fluoride rinse arm"
1577905|NCT02399150|Other|No intervention as observational study|
1577906|NCT02399137|Drug|MM-141|
1577907|NCT02399137|Drug|Placebo|
1577908|NCT02399137|Drug|Gemcitabine|
1577909|NCT02399137|Drug|Nab-Paclitaxel|
1577910|NCT02399124|Device|PROSENSE™|single arm, open label, PROSENSE™ treatment
1577911|NCT02399111|Device|Prevena Incision Management System|The PIMS unit is a single patient use, battery-powered, disposable unit that delivers continuous negative 125 mmHg pressure to the closed surgical incision for a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister. For the purposes of this clinical investigation, canisters can be replaced as often as is needed. A carrying case is also provided with the therapy unit, to allow for patient mobility during the therapy period.
1577912|NCT02399098|Behavioral|Attentional focus|The participants will learn the dart throwing task according to specific instructions. Participants in all groups will be given the same technical instructions on how to throw the dart. The technical instructions will be followed by attentional focus instructions that will differ between the groups.
1577913|NCT02399085|Drug|MOR00208|12 mg/kg
1577914|NCT02399085|Drug|Lenalidomide|25 mg
1577915|NCT02399072|Other|No intervention|No intervention administered in this study
1577916|NCT02399059|Procedure|Antibiotic lavage|Peritoneal irrigation with gentamycin-clindamycin solution
1577917|NCT02399059|Procedure|Normal saline lavage|Peritoneal irrigation with normal saline
1577918|NCT02399046|Device|Total Knee System made in China (Sigama, CoCr, PFC)|SIGAMA PS FEMUR; TIB tray Cem Cocr; SIGAMA STAB XLK INS; PFC SIG ROUND DOME PAT 3PEG
1577919|NCT02399046|Device|Total Knee System made outside of China (Sigama, NP, PFC)|SIGAMA PS CEM FEM; PFC MOD TIB TRAY NP; SIGAMA STAB XLK INS; PFC SIGAMA/RD/DOME PAT
1577920|NCT02399033|Drug|Xihuang Capsules|In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.
1577921|NCT02399020|Behavioral|Social Cognition and Interaction Training|manualized group treatment providing training in facial emotion recognition, understanding the role of emotion in social situations, training with videoed vignettes to avoid jumping to conclusions in order to avoid attributional biases, tolerating ambiguity and distinguishing facts from guesses, skill consolidation and generalization to everyday life situations.
1577922|NCT02399007|Device|Total Hip System made in China (SUN, CoCr, Duraloc, Marathon)|SUN Hip stem,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
1577923|NCT02399007|Device|Total Hip System made outside of China (Summit, CoCr, Duraloc, Marathon)|Summit Porocoat STD,CoCr Femoral Head,Duraloc Porocoat Sector acetabular shell,Marathon 10D polyethylene liner (ETO)
1577924|NCT02398994|Drug|Intravenous Methylprednisolone|
1577925|NCT02398994|Drug|Intravenous Immunoglobulin|
1577926|NCT02398981|Other|Clinical decision support tool|
1577927|NCT02398968|Dietary Supplement|iron fumerate|iron fumerate supplementation (6mg/kg/d) for arm 1 iron fumerate supplementation (1mg/kg/d) for arm 2
1577928|NCT02398955|Device|percutaneous coronary intervention|percutaneous coronary angioplasty with implantation of at least one Biomime stent
1577929|NCT02398929|Drug|Bisoprolol 2.5 mg|Bisoprolol 2.5 mg will be given once daily
1577930|NCT02398929|Drug|Placebo|Placebo tablets will be given once daily for 2 weeks during the run-in period.
1577931|NCT02398916|Behavioral|Music listening|
1577932|NCT02398903|Other|Blood samples for measurement of drug Css|Blood samples for measurement of drug Css
1577933|NCT02398903|Other|DXA and impedancemetry|Body composition by DXA and impedancemetry
1577934|NCT02398890|Other|routine care|routine care
1577937|NCT02398851|Behavioral|TacTic care model|Patients receive care in a trans-disciplinary chronic disease continuity of care model integrated with technology (mobile devices such as tablets, iPads and smartphones
1577938|NCT02398851|Behavioral|Standard of care|Patients receive care in a patient-centered, coordinated care model without the integration of technology
1577939|NCT02398838|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone.
1577940|NCT02398838|Drug|Home or clinic administration of 400 mcg buccal misoprostol|Home or clinic administration of 400 mcg buccal misoprostol
1577942|NCT02398812|Other|Medication assessment and treatment plan based on it|"Intervention
Phase I: A medication assessment conducted by an interprofessional team including nurse, pharmacist and physician. The assessment is based on current medication list and basic information cathered by nurse.
Phase II: This phase is needed if the assessment cannot be conducted safely without physical examination conducted by physician. The comprehensive interprofessional assessment takes place after the clinical examination conducted by home care physician."
1577943|NCT02398799|Behavioral|Psychoeducational support|"The intervention was based on a conceptual model from Stuifbergen. The model has sprung from Pender's model of health promotion and Bandura's self-efficacy theory. Cognitive-behavioral strategies were chosen to assist dyads in recognizing and modifying factors that contribute to physical and emotional distress by changing thoughts and behaviors and assisting dyads in solving problems related to implementing strategies for self-care.
Shared care is a dyadic process based on the assumption that each participant affects and is affected by the other. Shared goals and a shared commitment provide the essential building blocks of the dyad relationship. The dyad structure presents an opportunity for healthcare professionals to integrate a collaborative patient-partner centered effort."
1577944|NCT02398786|Other|Patient-entered data|This registry provides patient-entered data for future clinical trial and study use.
1577949|NCT02398760|Other|Motor Control Exercises|Subjects performed 8 weeks of motor control exercises intervention, 2 weekly 1 hour per session, instructed by trained physiotherapists to apply this program following a protocol developed in programs previously reported (Costa et al. 2009; Hodges et al. 2009). The first stage aims to improve the activity of muscles that have poor control and reduce overactivity of superficial muscles, previously assessed, through drawing in maneuver with feedback real-time ultrasound and via palpation. The second stage of the treatment involved more functional exercises, first using static and then dynamic tasks.
1577950|NCT02398747|Drug|AZD2014|50mg continuous dosing, 125mg intermittent dosing, 25 mg and 50mg intermittent dosing with weekly Paclitaxel
1577951|NCT02398734|Device|sonolysis|Continual transcranial Doppler monitoring of ipsilateral middle cerebral artery using a transcranial Doppler systems (e.g. DWL Multi-Dop T1, DWL, Sipplingen, Germany) with a diagnostic 2-MHz probe.
1577953|NCT02398708|Other|Questionnaires|Both groups will have questionnaires collected and compared.
1577954|NCT02398708|Other|Blood Sample|Both groups will have a blood sample collected and compared.
1577955|NCT02398708|Other|Stool Sample|Both groups will have a stool sample collected and compared.
1577956|NCT02398708|Other|Clinical data|Both groups will have clinical data collected and compared.
1577957|NCT02398695|Other|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
1577958|NCT02398682|Other|Rapid diagnosis of AKI cause|"The Outreach team will advise on an evidence-based package of care:
1) Rapidly establish a credible diagnosis of the cause of AKI including:
Improved assessment of volume status
Standardised use of urine dipstick .
Appropriate sepsis investigations.
Urgent ultrasound with suspected obstruction."
1577959|NCT02398682|Other|Rapid treatment of AKI cause|Rapid, limited treatment of hypovolaemia, with avoidance of iatrogenic fluid overload, recently recognised as a significant cause of mortality in AKI. Rapid sepsis therapy. Urgent relief of urinary tract obstruction.
1577960|NCT02398682|Other|Stopping 'nephrotoxic' drugs|Cessation of all potentially nephrotoxic drugs.
1577961|NCT02398682|Other|Early nephrology followup for stage 3 AKI|A rapid followup at discharge in an AKI clinic for survivors of stage 3 AKI, within 7 days of discharge for those in hospital, or within 7 days of the Alert for those not admitted to hospital.
1577962|NCT02398682|Other|Preventing recurrent AKI|Patients with AKI in the Intervention arm will receive information on preventing AKI during the study.
1577963|NCT02398682|Other|Good standard care|Good standard care will be provided for all patients in non Experimental arms; clinicians will continue to be able to rapidly refer patients for Nephrology advice or review; online guidance will be available for all clinicians and noted in the alerts for all cases of AKI.
1577964|NCT02398669|Drug|Lorcaserin hydrochloride|A single 10 mg dose of oral tablet formulation of lorcaserin hydrochloride will be administered with 240 mL of water.
1577967|NCT02398643|Other|Pulmonary Education (PE)|Patients enrolled in PE will undergo focused education sessions following discharge from hospital.
1577968|NCT02398643|Other|Usual Care|Patients enrolled in usual care will receive general education sessions following discharge from hospital.
1577969|NCT02398630|Radiation|TC Virtual Hysterosalpingography|Virtual hysterosalpingography: a new multidetector CT technique for evaluating the female reproductive system
1577970|NCT02398630|Other|MRI Virtual Hysterosalpingography|Magnetic Resonance Imaging Virtual hysterosalpingography
1577971|NCT02398630|Other|Antimullerian Hormone dosing|Blood Draw for Antimullerian Hormone dosing
1994151|NCT03056755|Drug|alpelisib|300 mg; oral; once daily
1577973|NCT02398617|Other|Decision Making Intervention|At their regularly scheduled admission follow-up visit with seven days of discharge, participants will be asked to bring their medical decision maker and participate in a semi-structured supplemental palliative care/education session facilitated by a heart failure nurse practitioner trained in palliative care discussions. Domains included in the intervention will include disease literacy and understanding, goals of care, legal issues for patients with terminal illness, symptom management, health-related quality of life, caregiver burden, patient autonomy, healthcare utilization, and establishment of end-of-life plans.
1577974|NCT02398604|Drug|Allo-hMSCs|Allogeneic Human Mesenchymal Stem Cells
1577975|NCT02398604|Drug|Placebo|Placebo
1577976|NCT02398591|Drug|JNJ 53718678|JNJ 53718678 will be orally administered once in a dose of 250, 500 or 1000 mg on Day 1.
1577977|NCT02398591|Drug|Placebo|Placebo matching to JNJ 53718678 will be orally administered once on Day 1.
1577978|NCT02398578|Device|Amphora OAB Device|Cystoscopic procedure to treat OAB
1577979|NCT02398565|Other|No intervention|
1577980|NCT02398552|Drug|Sunitinib|altenative schedules of sunitinib as first line therapy in metastatic renal cell carcinoma patients.
1577981|NCT02398539|Drug|Silver Nitrate|Silver Nitrate Sticks
1577982|NCT02398539|Drug|Triamcinolone|0.5% cream
1577983|NCT02398526|Drug|Radium-223 dichloride, (Xofigo, BAY88-8223)|Dosage and treatment duration according to the decision of the treating physician
1577984|NCT02398513|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg per oral
1577988|NCT02398487|Device|cigalike with nicotine|cigalike 24 mg nicotine or 16 mg nicotine
1577989|NCT02398487|Device|Personal Vaporizer with nicotine|Personal Vaporizer 16 mg nicotine or 9 mg nicotine
1577990|NCT02398474|Drug|TFP block ropivacaine|
1577991|NCT02398474|Drug|ropivacaine infiltration of the iliac crest bone|
1577998|NCT02398435|Biological|Tadekinig alfa (recombinant human IL-18 binding protein)|Patients received the study treatment three times a week subcutaneously.
1577999|NCT02398422|Behavioral|Listening Project Protocol|"The filtered-music intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
The non-filtered music intervention will consist of the same music as the filtered-music intervention."
1578000|NCT02398409|Behavioral|ANSWERS - Acquiring New Skills While Enhancing Remaining Strengths|"Randomized trial to evaluate the efficacy of the telephone intervention Acquiring New Skills While Enhancing Remaining Strengthsin informal caregivers of Veterans with stroke and TBI."
1578001|NCT02398409|Other|Control|8 week telephone usual care with education with nurse case manager
1578002|NCT02398396|Biological|4CMenB (Bexsero®) - Novartis Vaccines and Diagnostics|4CMenB vaccine (Bexsero - Novartis Vaccines and Diagnostics) 0.5ml intra-muscularly; two doses, administered 2 months apart. Each dose of vaccine contains recombinant Neisseria meningitidis group B NHBA fusion protein (50 micrograms); recombinant Neisseria meningitidis group B NadA protein (50 micrograms); recombinant Neisseria meningitidis group B FHbp fusion protein (50 micrograms) and Outer membrane vesicles (OMV) from Neisseria meningitidis group B strain NZ98/254 (25 micrograms measured as amount of total protein containing the PorA P1.4)
1578003|NCT02398383|Other|Oral Glucose Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Patients will drink 1.75 gm/kg glucose (Glucola) to a maximum of 75 gm. Venous samples for glucose and c-peptide will be drawn from the IV at 0, 30, 60, 90 and 120 minutes. Subjects will be instructed to eat at least 75 gm carbohydrates daily in the week prior to this test.
1578004|NCT02398383|Other|Mixed Meal Tolerance Test|Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling. Subjects will consume 6 kcal/kg (6 ml/kg) Boost High Protein Nutritional Energy Drink (Mead-Johnson) over five minutes to a maximum of 360 ml. Venous samples for glucose, glucagon, GLP-1, GIP, and c-peptide will be drawn at -10, 0, 15, 30, 60, 90, 120, 150, 180, 210, and 240 minutes.
1578005|NCT02398383|Other|Hypoglycemic Clamp|All subjects with CF and adult (but not pediatric) controls will undergo one-step hypoglycemic clamp. Subjects will be instructed to fast after midnight the night prior to the study. Subjects will be admitted to the research unit on the morning of the test for placement of blood-drawing IV for frequent sampling and a second IV for infusion of insulin and dextrose.
1578006|NCT02398370|Biological|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
1578007|NCT02398357|Drug|Nadroparin Calcium and Warfarin|Patients will take warfarin started at a dose of 2.5mg/d and with titration of dose to maintain a target INR of 2-3,alone with Nadroparin Calcium 4100IU／d，subcutaneous, when taking endoscopy therapy .
1578008|NCT02398344|Device|tDCS active|Transcranial direct current stimulation (tDCS) the active tDCS and placebo will be applied to the temporal cortex (T3) associated Cardiac Frequency Variability (HRV).
1578009|NCT02398344|Device|tDCS Sham|Active stimulation application time or placebo 20 minutes. In all sham stimulation, electrode placement procedures will also be performed like the procedures with anodic tDCS, the left and right temporal cortex, however, the stimulator is turned on for 30 seconds only, and the patient will be told that he will feel a slight initial tingling, but it will reduce, disappear or remain during the 20 minutes of application. Thus, individuals will feel it initially, but receive no stimulation in the remaining time. This procedure is a valid form of control in challenge studies transcranial direct current ³³. The equipment itself has a sham configuration.
1578010|NCT02398331|Other|Standardised information and education on sexuality in women with spinal cord injury|"Program of information and education on the physiology of sexual response in women with spinal cord injury 6 months after their first return to home:
Educational footage
Clinical neurological examination with educational aim
Structured consultation providing information on the physiology of sexual response in women with spinal cord injury"
1578011|NCT02398318|Device|Bilateral Nucleus Accumbens DBS (Suzhou Sceneray)|High frequency stimulation applied using Suzhou Sceneray® DBS hardware (1120 electrode, 1180 (S) battery).
1578012|NCT02398318|Device|Sham Bilateral Nucleus Accumbens DBS|DBS system switched off.
1578013|NCT02398305|Device|TR Band standard|Diminishing the air pressure in the TR Band following standard protocol
1578014|NCT02398305|Device|TR Band Quick|Diminishing the air pressure in the TR Band following a faster protocol
1578015|NCT02398292|Other|M3 Program|Participants and their study partners will learn about food, movement, and mindfulness through hands-on curriculum.
1578016|NCT02398292|Other|Control|Participants will not participate in M3 program but will have same outcomes measured at same time points (baseline, 6 weeks, 12 weeks).
1578017|NCT02398279|Dietary Supplement|L-Arginine|Experimental supplement
1578018|NCT02398279|Other|Placebo|Placebo capsules in the same color and shape with the experimental supplement
1578019|NCT02398266|Drug|Contrast ultrasound of leg muscle with Sonazoid (Contrast ultrasound microvascular perfusion imaging)|Skeletal muscle perfusion assessment of the thigh and calf skeletal muscle will be performed with contrast ultrasound of leg muscle with Sonazoid while at rest and during exercise stress
1578020|NCT02398253|Behavioral|CBT + Hypo-energetic Diet|This group will have cognitive behavioral therapy classes + follow the hypo-energetic diet after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
1578021|NCT02398253|Behavioral|Hypo-energetic Diet only|This group will receive the hypo-energetic diet only after losing at least 10% of their body weight by using a weight loss program. They will also have monthly follow-up to 6 months by fortnightly dietician visit.
1578022|NCT02398240|Drug|Brentuximab Vedotin|Day 1 and 15 Dose: 1.2 mg/kg/dose. (Maximum dose is 120 mg)
1578023|NCT02398240|Drug|Doxorubicin|Days: 1 and 15 Dose: 25 mg/m2/dose.
1578024|NCT02398240|Drug|Vincristine|Days: 1 and 15 Dose: 1.5 mg/m2/dose (max: 2 mg/dose).
1578025|NCT02398240|Drug|Rituximab|Days: 2 and 16 Dose: 375 mg/m2/dose.
1578026|NCT02398227|Behavioral|HOPE|Cognitive Behavioral Treatment for PTSD in Battered Women
1578027|NCT02398227|Behavioral|PCT|Present Centered Therapy for PTSD
1578028|NCT02398214|Behavioral|Sleep hygiene|LAST intervention (light, activity, and sleep training) consists of behavioral and educational strategies for increasing light exposure and physical activity, minimizing television viewing and reducing television viewing time to < 2 hours per day, and engaging activities suitable to the child's motor development to minimize sleep disturbance.
1578029|NCT02398201|Drug|Bezafibrate|Bezafibrate 200mg-600mg three times daily for 12 weeks.
1578030|NCT02398188|Drug|LIPO-202|
1578031|NCT02398188|Drug|Placebo|
1578032|NCT02398175|Other|reanimation/intubation|
1578033|NCT02398162|Procedure|Multi Blood Collections|At baseline (the day of presentation to hospital), 2 weeks, 12 weeks and 1 year later.
1578034|NCT02398162|Procedure|Single Blood Collection|On the enrollment day
1578035|NCT02398136|Drug|Ketamine|
1578036|NCT02398136|Drug|Midazolam|
1578037|NCT02398123|Other|Transversus abdominis plane block|Children who received transversus aAbdominis plane block with 0.25% bupivacaine with epinephrine 1 mL/kg guided by ultrasound
1578038|NCT02398123|Other|Caudal block|Children who received caudal 0.25% bupivacaine 1 mL/kg
1578039|NCT02398123|Drug|Bupivacaine|
1578040|NCT02398110|Procedure|transvaginal NOTES nephrectomy|A 5- and 10-mm trocar were placed at the right and left medial margin of umbilicus. A lengthened 10-mm trocar was placed through the vagina into the abdominal cavity
1578041|NCT02398110|Procedure|conventional laparoscopic nephrectomy|One 10-mm trocar was inserted at the midclavicular line 2 cm below the umbilicus, another 10-mm periumbilical trocar was placed for the camera, and a 5- or 10-mm trocar was placed 3 cm below the costal margin
1578042|NCT02398097|Biological|Agripal|2011/2012 influenza season standard dose trivalent subunit inactivated intramuscular vaccine, single dose
1578043|NCT02398097|Biological|IDflu9μg|2011/2012 influenza season reduced-content intradermal split vaccine, single dose
1578044|NCT02398097|Biological|IDflu15μg|2011/2012 influenza season standard-content intradermal split vaccine, single dose
1578045|NCT02398084|Other|Chewing of nuts|The volunteers will be asked to chew and spit 8 portions (4-5 g) of nuts (cashews or walnuts) on two separate visits. They will provide samples for particle sizing. Two portions will be used as practice samples in order to measure the number of chews. Two portions will be sieved. Two portions will be measured by laser diffraction. Two portions will be frozen for later lipid analysis.
1578046|NCT02398071|Device|A water pressure threshold device (BreatheMAX)|BreatheMAX®, the water pressure threshold breathing device contributed in our laboratory will be used. This device is small, simple, easy to use and also inexpensive since the device is developed and manufactured in Thailand. The depth of water in the body of the device provides the flow resistance during exhalation through the inlet tube in a water cylinder.
1578047|NCT02398058|Drug|trabectedin|trabectedin will be administered in a 24-h continuous i.v. infusion every 3 weeks
1578048|NCT02398058|Drug|olaparib|olaparib will be administered in a continuous daily dose every 12 hours
1578049|NCT02398045|Other|Computerised CBT for OCD|Computerised CBT for OCD
1578050|NCT02398032|Device|CPAP nasal|During the night
1578051|NCT02398032|Device|sham CPAP nasal|During the night
1578052|NCT02398019|Device|OXIRIS®|"OXIRIS® membrane set is composed of a 1.5 m2 copolymer of acrylonitrile and sodium methylsulfonate (AN 69) with polyethylenimine treated surface and adhered heparin during set´s fabrication [OXIRIS® (Baxter Gambro)].
PrismafleX eXeed™ II (Hospal) with OXIRIS® set will then be connected to CPB circuit. Blood flow between 150-200 ml/min will be derivatised from the CPB circuit into the PrismafleX eXeed™ so that it all flows through OXIRIS® membrane. Flow, pressure and alarms will be controlled by PrismafleX eXeed™ independently from CPB circuit.
OXIRIS® membrane will be only employed for adsorption (neither convection nor diffusion will be performed) during all CPB time."
1578053|NCT02398006|Other|a standard arm sling|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
1578054|NCT02398006|Other|a figure-of-eight bandage|Closed reduction (re-aligning the fragments of the fracture) will be not performed because the reduced position is practically impossible to maintain.
1578055|NCT02397993|Procedure|blood collection|blood will be taken for assessment of serum lipase, serum amylase and CA 19-9 prior to EUS-FNA
1578056|NCT02397993|Procedure|fine needle aspiration|During endoscopic ultrasonography, fine needle aspiration will be performed for cytological analysis of the pancreas
1578057|NCT02397993|Procedure|blood collection|blood will be taken 4h after EUS-FNA for assessment of serum lipase, serum amylase and CA 19-9
1578058|NCT02397980|Behavioral|Behavioral intervention|"What the dementia is
How to deal with behavioral problems in patients with dementia
How to manage caregiver's stress
How to care dementic patients as well as caregivers themselves"
1578059|NCT02397967|Other|Neuropsychological assessments|"Neuropsychological assessments:
Intelligence Quotient (WISC-IV)
Reading tests (reading accuracy, reading speed, reading comprehension and strategy):
Alouette test, Lobrot test, Odedys test. Visio-spatial skill (JLO, Thurston, Corsi tests) Attention (CPT 2, CBCL) Receptive oral language (EVIP)"
1578060|NCT02397954|Drug|Zimura|Subjects will receive monthly intravitreous injections of Zimura in combination with Lucentis, Avastin or Eylea.
1578061|NCT02397941|Other|Ultrasound|ultrasound measures
1578062|NCT02397928|Device|NovoTTF-100L device|Patients will be treated continuously with the NovoTTF-100L device. NovoTTF-100L treatment will consist of wearing four electrically insulated electrode arrays on the thorax. The treatment enables the patient to maintain regular daily routine.
1578063|NCT02397928|Drug|Pemetrexed|Pemetrexed 500 mg/m2 will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on day 1 of a 21-day cycle.
1578064|NCT02397928|Drug|Cisplatin or Carboplatin|Cisplatin 75 mg/m2 or carboplatin AUC 5 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end on the pemetrexed infusion on day 1 of a 21-day cycle.
1578065|NCT02397915|Drug|FF nasal spray|FF as a suspension for intranasal inhalation with unit dose strength of 27.5 mcg per dose x 4 doses (total dose 110 mcg) administered via a metered side-actuated nasal spray device.
1578066|NCT02397915|Drug|MF nasal spray|MF as a suspension for intranasal inhalation with unit dose strength of 50 mcg per dose x 4 doses (total dose 200 mcg) administered via a metered top-actuated nasal spray device.
1578067|NCT02397902|Dietary Supplement|High fat dairy|Add 4 daily servings per day of high fat dairy (yogurt, milk, cheese) for a period of 4 weeks
1578068|NCT02397902|Dietary Supplement|Plant-based|Add 4 daily servings of fruit (fruit cup, apple sauce) and/or plant-based milk, remove all dairy for a period for 4 weeks
1578069|NCT02397889|Drug|Ketamine|This arm will receive 0.5mg/kg repeated dose ketamine (6 intravenous infusions, 3 per week for 2 weeks).
1578070|NCT02397889|Drug|Midazolam|This arm will receive 0.045mg/kg repeated dose intravenous midazolam (6 intravenous infusions, 3 per week for 2 weeks).
1578071|NCT02397876|Other|Partially Hydrolyzed Whey formula|Patients who tolerate partially hydrolyzed whey formula will be continued on this formula for two years. Patients who do not tolerate the formula will be continued on their prior diet of cows milk avoidance.
1578072|NCT02397863|Drug|Cannabidiol (Epidiolex)|Daily dosage up to 25 mg/kg/day with an optional up titration to a maximal daily dosage up to 50 m/kg/day until End of Treatment.
1578073|NCT02397850|Behavioral|phone calls 30 min|Patients receive either seven 30 minutes phone calls over 6 months (psychotherapy/continuation treatment)
1578074|NCT02397850|Behavioral|phone calls 50 min|Patients receive either seven 50 minutes phone calls over 6 months (psychotherapy/continuation treatment)
1578075|NCT02397837|Drug|Pramipexole|Up to 4.5mg, PO, (by mouth) per day of the 12-week study.
1578076|NCT02397837|Drug|Placebo|placebo match study drug
1578077|NCT02397824|Other|Salivary and blood samples|
1578078|NCT02397811|Dietary Supplement|Enteric Coated Softgels|Enteric coated softgel capsule containing 4 mg astaxanthin, 3 softgels per dose
1578079|NCT02397811|Dietary Supplement|Liposomal astaxanthin|Liposomal astaxanthin containing 4.5 mg astaxanthin per gram. 3.66 grams per dose
1578080|NCT02397811|Dietary Supplement|Standard Softgel|Standard softgel containing 4 mg astaxanthin per softgel. 3 softgels per dose
1578081|NCT02397811|Dietary Supplement|Astaxanthin Water Soluble Emulsion|Astaxanthin water soluble emulsion containing 1% astaxanthin. 1.2 grams per dose
1578082|NCT02397811|Dietary Supplement|Astaxanthin Water Dispersible Powder|Astaxanthin water dispersible powder containing 3% astaxanthin. 0.4 grams per dose
1578083|NCT02397811|Dietary Supplement|Standard Softgel with Astaxanthin Gel|Standard softgel with astaxanthin gel containing 4 mg astaxanthin. 3 soft gels per dose
1578084|NCT02397798|Behavioral|Person-centered high-intense training under supervision|A person-centered training program including a person-centered high-intense aerobic / strength training
1578085|NCT02397798|Behavioral|Personalized exercise program to perform at home|Introduction to health-enhancing physical activity, personalized exercise program to perform at home three times a week
1578086|NCT02397785|Device|ApexM|Subjects will apply conductive gel, insert the device to a minimum depth of 4 inches, and inflate until comfortably snug. The intensity is set exclusively by the physician to a tolerated sensory level, avoiding muscle contraction. At the target amplitude, patients will feel a non-painful fluttering or tapping sensation, Subjects will perform this for 6 sessions per week at 12 minutes per session for an additional 12 weeks. At each follow-up visit, investigators will re-evaluate the stimulation level and adjust to avoid muscle contraction.
1578612|NCT02393833|Procedure|Adjuvant therapy|
1578087|NCT02397785|Device|Sham Device|Identical to ApexM but will not deliver any electrical stimulation
1578088|NCT02397772|Drug|albendazole|Single dose of albendazole (400 mg)
1578089|NCT02397759|Other|Blood draw and cerebrospinal fluid draw|
1578090|NCT02397746|Device|total hip arthroplasty implant|
1578091|NCT02397733|Radiation|Prophylactic cranial irradiation (PCI)|Prophylactic cranial irradiation (PCI): 25 Gy in 10 daily fractions, five times a week
1578092|NCT02397733|Radiation|Hippocampal avoidance PCI|Hippocampal avoidance prophylactic cranial irradiation 25 Gy in 10 daily fractions, five times a week
1578097|NCT02397707|Drug|GS-9857|GS-9857 100 mg tablet administered orally
1578098|NCT02397694|Drug|BIC|75 mg tablet administered orally once daily
1578099|NCT02397694|Drug|FTC/TAF|200/25 mg FDC tablet administered orally once daily
1578100|NCT02397694|Drug|DTG|50 mg tablet administered orally once daily
1578101|NCT02397694|Drug|BIC Placebo|Tablet administered orally once daily
1578102|NCT02397694|Drug|DTG Placebo|Tablet administered orally once daily
1578103|NCT02397694|Drug|BIC/F/TAF|50/200/25 mg FDC tablet administered orally once daily
1578104|NCT02397681|Other|Autonomic Function Testing|Autonomic nervous system index assessed with Task Force Monitor (CNSystems Medizintechnik AG, Graz, Austria)
1578105|NCT02397668|Device|CorMatrix ECM Tricuspid valve|CorMatrix ECM tricuspid valve to replace a diseased tricuspid valve, including tricuspid valve disease secondary to congenital heart disease.
1578106|NCT02397642|Procedure|IVF/ICSI|
1578107|NCT02397642|Drug|Human Chorionic Gonadotropin|given in different doses and timing to support the luteal phase
1578108|NCT02397629|Other|This study has no intervention|
1578110|NCT02397603|Drug|dexmedetomidine bupivacaine|perineural dexmedetomidine as an adjuvant to bupivacaine induced thoracic paravertebral block
1578111|NCT02397603|Drug|Bupivacaine saline|perineural bupivacaine saline mixture in the thoracic paravertebral catheter
1578112|NCT02397590|Drug|Fimasartan|
1578113|NCT02397590|Drug|Atorvastatin|
1578114|NCT02397577|Other|Solid test meal, liquid test meal on two separate occations|13C labeld solid test meal, 13C labeld liquid test meal on two separate occations
1578115|NCT02397564|Device|Er:YAG laser, traditional and fractional settings|Half the scar will be treated with traditional ablative setting and the other half will be treated with the fractional ablative setting
1578116|NCT02397551|Procedure|IVF/ICSI|
1578117|NCT02397551|Drug|Human Chorionic Gonadotropin|Given in different doses and timing to support the luteal phase
1578118|NCT02397538|Drug|Fimasartan|
1578119|NCT02397538|Drug|Amlodipine|
1578120|NCT02397538|Drug|Rosuvastatin|
1578121|NCT02397525|Drug|LIPO-202|
1578122|NCT02397512|Drug|application of lactulose|Subjects will ingest 50g of lactulose once
1578123|NCT02397512|Other|application of sucrose|Subjects will ingest 50g of sucrose once
1578124|NCT02397499|Drug|LIPO-202|
1578125|NCT02397499|Drug|Placebo|
1578126|NCT02397486|Drug|Pentoxifylline|
1578127|NCT02397486|Drug|Vitamin E|
1578128|NCT02397486|Drug|Cisplatin|
1578129|NCT02397486|Radiation|Radiation therapy|
1578132|NCT02397460|Drug|Gefapixant|
1578133|NCT02397460|Drug|Placebo (for gefapixant)|
1578134|NCT02397447|Drug|Momordica charantia|Momordica Charantia: 2000 mg per day for three months
1578135|NCT02397447|Drug|Placebo|Placebo: 2000 mg per day for three months
1578136|NCT02397434|Radiation|Adjuvant EBRT|Radiation up to a median dose of 50 Gy in 25 fractions will be delivered with IMAT to the pelvic lymph node regions. If there is a positive surgical margin, the operative bladder bed will be included in the radiation field. A simultaneous integrated boost to positive lymph nodes will be delivered.
1578137|NCT02397421|Drug|Dapagliflozin|Sodium Glucose Linked Transporter Type 2 (SGLT-2) Inhibitor
1578138|NCT02397421|Drug|Placebo|Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
1578139|NCT02397408|Drug|Choline PET/MR|
1578140|NCT02397395|Drug|Simeprevir (SMV) 150 mg|Simeprevir (SMV) 150 milligram (mg) capsule orally, once daily for a duration of 12 weeks.
1578141|NCT02397395|Drug|Daclatasvir (DCV) 60 mg|Daclatasvir (DCV) 60 mg tablet, orally, once daily for a duration of 12 weeks.
1578142|NCT02397382|Drug|Guselkumab|Guselkumab will be administered as a single dose of 200 milligram (mg) by subcutaneous injection (2*100 mg) on Day 8.
1578143|NCT02397382|Drug|Midazolam|Midazolam will be administered orally as probe cocktail containing 0.03 mg per kilogram (kg) once on Day 1, 15 and 36.
1578144|NCT02397382|Drug|Warfarin|Warfarin will be administered orally as probe cocktail containing 10 mg once on Day 1, 15 and 36.
1578145|NCT02397382|Drug|Omeprazole|Omeprazole will be administered orally as probe cocktail containing 20 mg once on Day 1, 15 and 36.
1578146|NCT02397382|Drug|Dextromethorphan|Dextromethorphan will be administered orally as probe cocktail containing 30 mg once on Day 1, 15 and 36.
1578613|NCT02393833|Drug|Docetaxel|
1578614|NCT02393833|Drug|Paclitaxel|
1578147|NCT02397382|Drug|Caffeine|Caffeine will be administered orally as probe cocktail containing 100 mg once on Day 1, 15 and 36.
1578148|NCT02397369|Other|Tobacco users: Self Help|This group will be given pictorial material and minimal written materials/ pamphlets describing health hazards of smokeless forms of tobacco and tips on tobacco cessation in general. The material will be interactively tailored to individual tobacco consumption characteristics and they will be followed up after 12 months.
1578149|NCT02397369|Behavioral|Tobacco users:Telephonic counseling|This group will be given proactive as well as reactive counseling. Medical social workers will proactively call all participants regularly and offer tobacco cessation counseling. In addition, they will call those participants who have planned their quit dates. Dedicated independent mobile numbers with 12 hours help lines will be made available to the participants to maximise the level of support. It will be scheduled in response to the needs to answer any type of help pertaining to quitting tobacco.
1578150|NCT02397369|Behavioral|Tobacco users:Behavioural therapy Only|"Focus Group discussion:
This tobacco cessation intervention session will involve thirty minutes of focus group discussion with group behavioral therapy in groups of 5-10 individuals for reinforcement of tobacco use prevention and cessation advice. Group discussion is intended to improve understanding by exploring, sharing and reflecting psychosocial, familial, environmental issues which attribute to the problem.
Individual tobacco cessation counseling sessions:
Individual counseling is commonly used to help people who are trying to quit tobacco. The counseling adopting an interactive problem-solving approach will be done by trained Medical Social Workers providing face-to-face sessions for 10-15 minutes per participant."
1578151|NCT02397369|Other|Tobacco users:Pharmacologic|"Pharmaco Therapy will consist of:
Nicotine Chewing Gums:
Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months Side effects: Bad taste, Throat irritation, burning in mouth, nausea, vomiting, hiccups, increased heart beat etc
Nicotine Transdermal patches:
Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks Side effects: Skin irritation, dizziness, sleep problems, increased heart beat etc"
1578152|NCT02397356|Drug|Ketamine first AB|Nebulised ketamine 1mg/kg
1578153|NCT02397356|Drug|Placebo first BA|Nebulised saline 1-2ml
1578154|NCT02397343|Drug|Hyperbaric oxygen|
1578155|NCT02397330|Drug|bupivacaine|
1578156|NCT02397330|Device|ultrasound|ultrasound guided nerve blocks
1578157|NCT02397330|Drug|morphine|
1578158|NCT02397317|Radiation|Multi-fraction SABR|All participants will receive Multi-Fraction SABR; 36.25 Gy (PTV D95) in 5 Fractions within 2-5 weeks
1578159|NCT02397304|Other|Exercise|Participants will complete two morning exercise sessions. One will be performed in the overnight fasted-state (i.e. no food or drink, except water, from 10pm the evening before) and the other will be performed in the fed-state having received a breakfast by the research team before exercise.
1578160|NCT02397291|Drug|Mannose|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
1578161|NCT02397291|Drug|Myoinositol|A primed constant infusion containing the stable isotopes of mannose and myoinositol is administered through a peripheral IV.
1578162|NCT02397291|Drug|Placebo|placebo
1578163|NCT02397278|Drug|Platelet rich plasma (PRP)|Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
1578164|NCT02397265|Device|Bi-hormonal closed loop pump|Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump
1578165|NCT02397265|Device|Standard opened loop pump|Using a standard opened loop pump
1578166|NCT02397252|Device|Eve Medical self-collection system©|The Eve collection system is a plastic device not much bigger than a tampon that is inserted in the vaginal cavity. A silicone brush is then swiped around the vagina to scrape a few vaginal cells for cervical cancer screening.
1578167|NCT02397252|Device|cobas® PCR Female swab self-sampling|Regular polyester swab for collection of vaginal cells.
1578168|NCT02397252|Procedure|Physician-collected sampling|Routine colposcopy sample collected by a physician.
1578169|NCT02397226|Procedure|Radiofrequency ablation|
1578170|NCT02397226|Procedure|High ligation/stripping|
1578171|NCT02397226|Device|Radiofrequency ablation catheter|
1578172|NCT02397226|Procedure|Tumescent anesthesia|
1578173|NCT02397226|Procedure|General anesthesia|
1578174|NCT02397226|Device|Vein stripping catheter|
1578175|NCT02397213|Drug|Ciclosporin|Single dose of CicloMulsion® 5 mg/ml, 2.5 mg/kg (=0.5 ml/kg) as intravenous injection preoperatively after anesthesia induction.
1578176|NCT02397213|Drug|Placebo|All components of the CicloMulsion® emulsion except ciclosporin: soybean oil (refined), triglycerides (medium-chain), egg lecithin, glycerol, oleic acid, sodium hydroxide and water for injection (=0.5 ml/kg).
1578177|NCT02397200|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
1578178|NCT02397200|Dietary Supplement|Placebo|Low caloric formula (Powder added to water), without added vitamins and minerals
1578179|NCT02397187|Behavioral|LOOP|"The LOOP conceptualizes the psyche by a three-dimension structure: the space (the potential of experiencing, the place where our experiences occur), the content (the experiences themselves; action, thoughts, feelings, experiences and being) and the order (the relationship between the various contents). The LOOP intervene with these three dimensions by a structures scheme, aimed at allowing the patient to quickly reclaim the responsibility on his psyche, stabilize and initiate long-term rehabilitation processes."
1578180|NCT02397174|Other|mediterranean diet, restricted calorie|50 pcos women will be assigned to hypocaloric mediterranean diet for 6 months
1578181|NCT02397174|Other|hypocaloric diet, restricted calorie|50 pcos women will be assigned to standardized hypocaloric diet for 6 months
1578182|NCT02397161|Other|EEG biofeedback mental attention-neuromuscular training|Mental attention training using EEG biofeedback and neuromuscular training using physio-therapeutic exercises
1578183|NCT02397161|Other|Neuromuscular training|Neuromuscular training using physio-therapeutic exercises
1578184|NCT02397161|Other|EEG biofeedback mental attention training|Mental attention training using EEG biofeedback
1578185|NCT02397148|Radiation|Computed Tomography|imagery with ionizing radiation
1578186|NCT02397148|Radiation|Cone Beam Computed Tomography|imagery with ionizing radiation
1578190|NCT02397096|Drug|MK-1439A|Single tablet containing MK-1439 (doravirine) 100 mg, lamivudine 300 mg, and tenofovir disoproxil fumarate 300 mg
1578191|NCT02397096|Drug|Baseline regimen of ritonavir- or cobicistat-boosted protease inhibitor|Baseline regimen of antiretroviral therapy with a ritonavir- or cobicistat-boosted protease inhibitor (atazanavir, darunavir, or lopinavir) administered according to the product circular
1578192|NCT02397096|Drug|Baseline regimen of cobicistat-boosted elvitegravir|Baseline regimen of antiretroviral therapy with cobicistat-boosted elvitegravir administered according to the product circular
1578193|NCT02397096|Drug|Baseline regimen of a non-nucleoside reverse transcriptase inhibitor|Baseline regimen of antiretroviral therapy with a NNRTI (efavirenz, nevirapine, or rilpivirine) administered according to the product circular
1578194|NCT02397096|Drug|Baseline regimen of two nucleoside reverse transcriptase inhibitors|Baseline regimen of antiretroviral therapy with two NRTIs administered according to the product circular
1578195|NCT02397083|Device|Levonorgestrel Intrauterine Device (LIUD)|Participants undergo treatment with the LIUD. Placement of LIUD done at the time of the dilation and curettage (D&C) or during a routine clinic visit.
1578196|NCT02397083|Drug|Everolimus|At 3 months after LIUD procedure, participants receive Everolimus administered at 10 mg taken by mouth daily for three months.
1578197|NCT02397083|Behavioral|Questionnaire|Quality of life (QOL) questionnaire completed at baseline visit.
1578198|NCT02397070|Procedure|Jaw exercise program|The jaw exercise program will consist of three cycles: 1st CYCLE - simple opening and closing mouth, right and left lateral excursions with mechanisms of proprioceptive neuromuscular facilitation and muscle coordination; 2 ° CYCLE - opening and closing exercises, right and left lateral excursions with a counter-resistance force imposed by the participant, with reciprocal inhibition, stretching, and muscular endurance mechanisms; 3rd CYCLE - specific exercises to disk capture attempt in cases of disk displacement with reduction and acute disk displacement without reduction (mouth opening and closing in protrusion) or chronic disk displacement without reduction (forced mouth opening in order to push the disc), with remodeling articulate mechanisms. The conduct will be individualized according to the need and symptoms of patients, which will be monitored fortnightly. It will be proposed 3 times a day, lasting a minute and a half per turn, in front of the mirror, during three months.
1578199|NCT02397070|Device|Occlusal Splint and counseling|The occlusal splints will be made from obtaining a plaster type IV model of upper arch using alginate and metal stock tray. A 2mm thick polyacetate blade will be adapted to the vacuum device plasticizer, heated and pressed over the previously cut U-shaped plaster model. After cooling, it will be added the self-curing acrylic resin on occlusal surface in order to increase the vertical dimension of occlusion in 2mm (anterior region). After polishing, the splints will be intraorally adjusted using carbon paper and clamp Muller, and installed obtaining maximum tooth contacts in centric relation. The splints will be flat and of full coverage for night use. Patients will be monitored every two weeks for the occlusal adjustment for three months. It will also be done counseling measures through a printed guide in relation to the daily care and the various contributing factors of TMD (diet, stress reduction, elimination of parafunctions and posture correction).
1578200|NCT02397057|Drug|Injectafer|
1578201|NCT02397057|Other|Placebo|
1578202|NCT02397044|Procedure|Implant surgery|Compare surgical protocols
1578203|NCT02397031|Behavioral|Mindfulness|weekly psychotherapy sessions for 10 weeks (120 min each)
1578204|NCT02397031|Behavioral|interpersonal effectiveness|weekly psychotherapy sessions for 10 weeks (120 min each)
1578205|NCT02397018|Biological|allogeneic umbilical cord blood|Umbilical cord blood units will be selected from a public cord blood bank based on ABO/Rh blood type and cell dose, targeting a range of 0.5 to 5 x 10^7 total nucleated cells per kilogram. The cord blood unit will be intravenously infused into the subject over 5-30 minutes at a rate not exceeding 5 mL/kg/hr. Subjects will not receive immunosuppressive medications or any other cytoreduction prior to infusion.
1578206|NCT02397005|Drug|ZL-2102|A selective and reversible inhibitor of Hematopoietic Prostaglandin D Synthase (HPGDS).
1578207|NCT02397005|Drug|Placebo matching ZL-2102|
1578208|NCT02396992|Other|Minimal-Massive Intervention|The intervention will consist in basic recommendations based on the evaluations done at admission and discharge: a) diet adaptation (solids and fluids) based on dysphagia clinical evaluation (V-VST) to avoid efficacy or safety alterations; b) nutritional supplements in case of malnutrition (MNA-sf; bioimpedance and blood analysis) to improve nutritional status;and c) oral health and hygiene recommendations (toothbrushing and antiseptic mouthwashes to decline bacterial colonization).
1578209|NCT02396979|Drug|Methadone|
1578210|NCT02396979|Behavioral|Holistic Health Recovery Program|
1578211|NCT02396953|Drug|Lanreotide PRF|
1578212|NCT02396940|Device|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
1578213|NCT02396940|Device|2D HD laparoscopy|Placebo
1578214|NCT02396927|Device|3D HD laparoscopy|Olympus 3D laparoscopy ENDOEYE FLEX in high definition with the use of passive, polarizing glasses.
1578215|NCT02396927|Device|2D HD laparoscopy|Placebo
1578216|NCT02396901|Other|Goal Direct Therapy|Goal Direct Therapy - in this group patients will receive the standard treatment according with institutional protocol.
1578217|NCT02396888|Drug|Insulin|Half of the wound surface was treated daily with 10 units of intermediate insulin.
1578218|NCT02396888|Drug|Placebo|Half of the wound surface was treated daily with 0.1 cc of normal saline.
1578219|NCT02396875|Procedure|Blood sampling and exercise protocol pre and post CRT implant|
1578220|NCT02396875|Procedure|Peripheral blood sampling|
1994152|NCT03056755|Drug|fulvestrant|500 mg; intramuscular injection on Days 1, 15 on Cycle 1 and Day 1 at each cycle thereafter
1994153|NCT03056755|Drug|letrozole|2.5 mg; oral; once daily
1994154|NCT03057119|Behavioral|Psycho-educational content (5 Minutes)|The interventionist will discuss substance use and misuse and the influence of substance use on self care.
1578221|NCT02396875|Procedure|Central blood sampling pre and post CRT implant|
1578222|NCT02396875|Procedure|Central blood sampling on one occasion and exercise protocol and 6 month peripheral sampling|
1578224|NCT02396849|Device|CPAP|Subjects assigned to this group will be asked to use the CPAP machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
1578225|NCT02396849|Device|CPAP Sham|Subjects assigned to this group will be asked to use the CPAP SHAM machine for a minimum of 4 hours/night at least 5 days/week for a total of 4 weeks.
1578226|NCT02396836|Other|6 step technique|Hand decontamination with alcohol hand rub using the World Health Organizations 6 step technique
1578227|NCT02396836|Other|3 step technique|Hand decontamination with alcohol hand rub using the 3 step technique
1578228|NCT02396823|Behavioral|Respiratory Muscle Training|Standard threshold Positive Expiratory Pressure Device and threshold Inspiratory Muscle Trainer assembled together using a T-shaped connector with flanged mouthpiece will be used. The participants will be instructed to perform inspiratory and expiratory efforts against a resistive load. Training session lasts 45 minutes per day, 5 days per week, for 4 weeks.
1578229|NCT02396810|Other|intra-operative MRI|Intra-operative magnetic resonance imaging under general anesthesia
1578230|NCT02396810|Procedure|Transsphenoidal resection of pituitary macroadenoma|Routine transsphenoidal resection of pituitary macro adenomas
1578231|NCT02396797|Behavioral|The new atWork intervention|"atWork is a cognitive intervention, and uses a nondirective delivery approach. It does not prescribe any change in lifestyle, but aims at establishing an understanding of common complaints and what to do when pain and health complaints occur. All information is based on the non-injury model, where pain and complaints are not signs of injury caused by wrongdoing or inappropriate behavior. The consistent take home message from all parts of the intervention is that keeping up usual activities, including going to work, is beneficial for health and recovery. This group will receive one management course, two workplace courses for all employees targeting mild mental disorders and nonspecific musculoskeletal complaints, and one reflection and review meeting."
1578232|NCT02396797|Behavioral|The original atWork intervention|This group will receive three workplace courses for all employees targeting nonspecific musculoskeletal complaints, and peer support. Peer support involves selecting a peer advisor at the workplace. A peer advisor is a fellow worker without former medical training who as part of the atWork intervention receive more in-depth medical knowledge and training about nonspecific musculoskeletal complaints. The peer advisors role is to give social support and to use their local knowledge of the work place to facilitate staying at work for colleagues with health complaints.
1578233|NCT02396771|Procedure|Uterine Massage|The massage will be performed as follows: palpating the uterine fundus, manually stimulating the fundus and the whole body of the uterus using fingers and palms steadily and repetitively.
1578234|NCT02396771|Procedure|Uterine Compression|The sustained uterine compression will be performed as follows: placing one hand in the vagina and pushing against the body of the uterus while the other hand compresses the fundus from above through the abdominal wall.
1578235|NCT02396758|Device|EkosSonic Endovascular System plus thrombolytic|
1578236|NCT02396745|Device|Subjects undergoing TECR with ECM placement (ACell MatriStem, Boston Scientific WallFlex))|"TECR will be performed to resect the entire length and area of the BE lesion in the in-patient setting.
ECM PLACEMENT:
Following resection, the exposed area will be covered with a 6 ply sheet of ACell MatriStem® Surgical Matrix PSMX ECM (ACell Inc., Columbia, MA). The ECM will be placed and held in position for 14 days (±4 days) using a Boston Scientific WallFlex™ Fully Covered Esophageal Stent (Boston Scientific, Boston, MA)."
1578237|NCT02396732|Drug|Aspirin|
1578238|NCT02396732|Drug|Enoxaparin|
1578239|NCT02396719|Device|LenSx® Laser|Used for cornea incision, capsulotomy and lens fragmentation during cataract surgery
1578240|NCT02396706|Drug|Ivy Leaves Cough Liquid|
1578241|NCT02396706|Drug|Placebo|
1578242|NCT02396693|Device|NIPPV|Ventilation with nasal intermittent positive pressure - Newborns randomized to this group underwent NIPPV, the respirators in TIME mode, set with the following settings : 5-6 centimeters of water (cmH2O) pressure positive end expiratory (PEEP); Flow rate of 6-8 liters per minute (L / min); PIP(positive inspiratory pressure) < 15 centimeters of water (cm H2O) ; respiratory frequency backup (FR) < 16 bpm; inspiratory time (IT) - 0.30 to 0.33 seconds (adjustable time constant according to the weight and baseline disease)
1578243|NCT02396693|Device|Bubble NCPAP|Bubble NCPAP - Newborns randomized to this group bubble NCPAP, adjusted with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min), provided through oxygen sources and compressed air (15 liters per minute - L / min), which passes through a heated humidifier through a breathing circuit that goes to the newborn, and from him, for a plastic container (250 milliliters (ml) capacity and 14 centimeters) containing sterile distilled water, which is the bubble.
1578244|NCT02396693|Device|Ventilator NCPAP|Ventilator NCPAP - Newborns randomized to this group ventilator NCPAP, of respirators in TIME mode set with the following settings: pressure positive end expiratory (PEEP) 5-6 centimeters of water (cm H2O) and Flow 6-8 liters per minute (L / min).
1578245|NCT02396667|Other|5D ultrasound|
1578246|NCT02396654|Other|2D and 5D LB ultrasound comparison for fetal weight estimation|2D and 5DUS LB will be done for term pregnant women and fetal weight will be estimated by the hadlock formula. Accuracy of estimated fetal weight by both techniques will be compared to actual birth weight.
1578247|NCT02396641|Other|Best Supportive Care Checklist|
1578248|NCT02396628|Drug|Experimental intervention|Treatment with Ruxolitinib at a dose of 10 mg BID orally addition to BAT according DGHO-Onkopedia guidelines
1578249|NCT02396628|Drug|Standard treatment|Treatment according to DGHO-Onkopedia guidelines for treatment of acute GvHD (as of August 2015). Optional cross over from BAT to Ruxolitinib and BAT in case of lack of response from day 28.
1578250|NCT02396615|Dietary Supplement|SATIN pineapple|Active juice with added fibre and ginseng
1578251|NCT02396615|Dietary Supplement|SATIN pineapple control|Control products without active ingredients
1578252|NCT02396602|Behavioral|miPlan intervention|miPlan mobile contraceptive counseling waiting room app intervention
1578750|NCT02392988|Other|Placebo Comparator|Placebo Comparator
1578253|NCT02396589|Behavioral|Education Group|Attention will be provided to the control group to ensure they experience the same effects of time and attention but no effect on the outcome of interest.
1578254|NCT02396589|Behavioral|Home Modifications Group|The standardized components include assessment, identification of five problematic activities (and environmental barriers), identification of three solutions (for each problem), implementation of a solution set selected by the participant, training, and active practice of daily activities in one's own home and community.
1578256|NCT02396563|Procedure|epidural analgesia|
1578257|NCT02396563|Drug|Ropivacaine|
1578258|NCT02396550|Behavioral|Positive Expectations|Give positive expectation of the treatment efficacy to patients
1578259|NCT02396550|Procedure|Mobilization with movement|Give neutral expectation of the treatment efficacy to patients
1578260|NCT02396537|Drug|Lidocaine|Administered intranasally prior to Midazolam administration.
1578261|NCT02396537|Drug|Midazolam|Administered to all patients immediately after study drug (Lidocaine or Placebo) administered.
1578262|NCT02396537|Drug|0.9% Saline|Administered intranasally prior to Midazolam administration.
1578263|NCT02396524|Behavioral|Hockey FIT Program|Active phase: a) Classroom-based education on successful weight management strategies and instruction on behaviour change techniques/dietary interventions; promote peer and other forms of social support; and b) Physical activity sessions in aerobic/strength/flexibility exercises. Maintenance phase: Participants independently set new lifestyle prescriptions and goals and track their exercise, physical activity, and healthy eating with the support of a suite of free-of-charge health technology support tools
1578264|NCT02396511|Biological|TRC105|weekly i.v. TRC105 in combination with every 2 weeks i.v.bevacizumab, until progression or unacceptable toxicity develops
1578265|NCT02396511|Biological|Bevacizumab|Every 2 weeks i.v.bevacizumab in combination with weekly i.v. TRC105, until progression or unacceptable toxicity develops
1578266|NCT02396498|Drug|HIPEC|Using cisplatin in HIPEC plus oral S-1
1578267|NCT02396485|Other|Regular diet within 6hrs postoperative|Patients will be randomized to regular diet within 6 hrs postoperative (Early group) versus remaining nothing per os (NPO, i.e nothing per mouth) for 12hrs, and the diet then advanced as tolerated after 12hrs (Routine Group) as standard postoperative protocol in the investigators' institution.
1578268|NCT02396472|Behavioral|Order by time and topic|
1578269|NCT02396472|Behavioral|Order by information relevance|
1578270|NCT02396472|Behavioral|Order by social relationship|
1578271|NCT02396472|Behavioral|Order by help giving|
1578272|NCT02396472|Behavioral|Order by self-disclosure|
1578273|NCT02396459|Drug|Triac|Triac, following a dose-escalation scheme
1578274|NCT02396446|Other|Abdominal acoustic measurement|
1578275|NCT02396433|Drug|Carboplatin|Carboplatin will be given on day 1 of each cycle.
1578276|NCT02396433|Drug|Eribulin|Eribulin will be given on days 1 and 8 of each cycle.
1578277|NCT02396433|Drug|E7449|E7449 will be given daily (days 1-21) during each cycle. Patients will continue to receive treatment until progression of disease or discontinuation due to unacceptable side effects.
1578278|NCT02396420|Device|Embosphere Microspheres|
1578279|NCT02396407|Behavioral|Combined water, sanitation, and hygiene|"Water: Free chlorine tablets (Aquatabs; NaDCC) and safe storage vessel to treat and store drinking water.
Sanitation: Free child potties, sani-scoop hoes to remove feces from household, and latrine upgrades to a dual pit latrine for all households in study compounds.
Handwashing: Handwashing stations including soapy water bottles and detergent soap.
Local promoters visit study compounds at least monthly to deliver behavior change messages that focus on (1) treating drinking water for children < 36 months of age, (2) use of latrines for defecation and the removal of human and animal feces from the compound, and (3) handwashing with soap at critical times around food preparation, defecation, and contact with feces."
1578280|NCT02396394|Behavioral|Two-Step Adherence Feedback|Intervention subjects will use an electronic pill container to hold their antiretroviral medications. Throughout the 6-month intervention (until subjects are 3 months post-partum), whenever an intervention subject fails to open her electronic pill container within 60 minutes of dose time (as indicated by lack of a pill container opening), she will be sent a text message reminder. Each intervention subject will also participate in monthly counseling sessions informed by the subject's most recent adherence data generated by the electronic pill container. The counselor will review the adherence report with the patient and 1) provide positive feedback when adherence is ≥95% in the previous month, or 2) discuss reasons for lapses and strategies for improving adherence when adherence is <95%.
1578281|NCT02396381|Other|THS 2.2|Ad libitum use of THS 2.2 in an ambulatory setting for 26 weeks
1578282|NCT02396381|Other|CC|Ad libitum use of CC in an ambulatory setting for 26 weeks
1578283|NCT02396368|Drug|Tasquinimod|Tasquinimod is a quinoline-3-carboxamide analog that has demonstrated significant improvements in progression-free survival and overall survival in men with CRPC in a phase II trial.Tasquinimod will be administered at three dose levels (dose levels 1, 2, and -1). During dose level 1, tasquinimod will start at 0.25mg/day orally with a goal of 0.5mg/day. Dose level 2 will start at 0.25mg/day with a goal of 1mg/day. Dose level -1 will be 0.25mg/day without dose titration.
1578284|NCT02396368|Radiation|Radium 223|Radium Ra 223 dichloride, an alpha particle-emitting pharmaceutical, is a radiotherapeutic drug. Radium 223 is supplied as a clear, colorless, isotonic, and sterile solution to be administered intravenously with pH between 6 and 8. Each milliliter of solution contains 1,000 kBq radium-223 dichloride (27 microcurie), corresponding to 0.53 ng radium-223, at the reference date. Radium is present in the solution as a free divalent cation.Radium-223 will be administered per FDA-approved dosing (six IV injections at a dose of 50kBq/kg of body weight, administered every 4 weeks).
1578285|NCT02396355|Device|Investigational BD FACSPresto System|Blood samples will be tested on the BD FACSPresto system for CD4 absolute count (CD4Abs), %CD4, and Hb concentration.
1578286|NCT02396355|Device|BD FACSCalibur flow cytometer|Blood samples will be tested on the predicate, currently marketed device. For CD4Abs and %CD4 measurement, the BD FACSCalibur flow cytometer will be used with BD Multiset software version 1.1 or later and BD Tritest CD3/CD4/CD45 reagent with Trucount tubes.
1578287|NCT02396355|Device|Sysmex hematology analyzer KX-21|Blood samples will be tested for hemoglobic concentration on the predicate, currently marketed Sysmex hematology analyzer KX-21
1578288|NCT02396342|Genetic|AAV5-hFIX|AAV5hFIX gene therapy
1578289|NCT02396329|Drug|Chlorhexidine|
1578290|NCT02396329|Drug|Povidone-Iodine|
1578291|NCT02396316|Drug|Aflibercept (Eylea, BAY 86-5321)|After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
1578292|NCT02396316|Drug|Sham Injection|After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
1578293|NCT02396303|Drug|Carbetocin|
1578294|NCT02396290|Procedure|fractional carbon dioxide laser with platelet rich plasma|fractional carbon dioxide laser followed by platelet rich plasma injection
1578295|NCT02396290|Procedure|fractional carbon dioxide laser with NS|fractional carbon dioxide laser followed by normal saline injection
1578296|NCT02396277|Procedure|Immobilization|This is not an intervention study; but the patients are subjected to immobilization with a cast as part of a regular clinical treatment for distal radius fracture.
1578297|NCT02396264|Other|mediterranean diet|50 pcos women will be assigned to normocaloric mediterranean diet for 6 months
1578298|NCT02396264|Other|normocaloric diet|50 pcos women will be assigned to standardized normocaloric diet for 6 months
1578299|NCT02396251|Device|HA experimental|
1578300|NCT02396251|Device|HA comparator|
1578301|NCT02396238|Device|Celution Device|ADRCs prepared using the investigational Celution Device
1578302|NCT02396238|Other|Placebo|Placebo
1578303|NCT02396225|Drug|Voriconazole|
1578304|NCT02396212|Biological|Canakinumab|Canakinumab 4mg/kg every 4 weeks
1578305|NCT02396199|Device|Zenith® p-Branch® in combination with the Atrium iCAST™ covered stents|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
1578306|NCT02396186|Device|PTCA Balloon Angioplasty|
1578307|NCT02396173|Other|Risk Score for non-return to work|"The WORRK tool will be filled in for all patients, even the patients in the control group. However, the probability score will only be accessible for the medical doctors in the intervention group, along with guidelines for interpretation (1. With a probability score over 50% (not to return to work), patient's allocation to the Evaluation Pathway should be considered 2. With a probability score over 70% (not to return to work), the Evaluation Pathway is probably the most suitable choice)."
1578308|NCT02396160|Dietary Supplement|Urox|Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs
1578309|NCT02396160|Other|Placebo|Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment
1578310|NCT02396147|Drug|TAK-385 T2 Formulation|TAK-385 T2 Formulation tablets
1578311|NCT02396147|Drug|TAK-385 T4 Formulation B|TAK-385 T4 Formulation B tablets
1578312|NCT02396147|Drug|TAK-385 T4 Formulation C|TAK-385 T4 Formulation C tablets
1578313|NCT02396134|Biological|CMVpp65-A*0201 peptide vaccine|Given SC
1578314|NCT02396134|Other|Placebo|Given SC
1578315|NCT02396134|Other|Laboratory Biomarker Analysis|Correlative studies
1578316|NCT02396121|Dietary Supplement|Oral nutritional supplement : Renutryl® Booster|
1578317|NCT02396108|Drug|Paclitaxel + Carboplatin + ASLAN001|"Phase I
IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle
IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle
PO ASLAN001 daily continuously (starting dose 500mg BID)
Phase II
•PO ASLAN 001 daily continuously at the recommended phase II dose x 2 weeks
Followed by:
IV Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle x 4 cycles
IV Carboplatin AUC of 1.5, day 1, 8, 15 of a 21-day cycle x 4 cycles
PO ASLAN001 daily continuously at the recommended phase II dose x 12 weeks"
1578318|NCT02396082|Behavioral|MIND-S Intervention|MIND at Home is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, and physician. Patients and families receive care coordination assistance, resource referrals, dementia care education and behavior management skills training, emotional support and problem-solving, and home safety education
1578319|NCT02396082|Other|Augmented Usual Care|Augmented usual care consists of an initial full in-home needs assessment for dementia-related needs and a written report that identifies unmet needs and provides recommendations for care sent to the participant and the primary care physician. Augmented usual care participants also receive an Aging and Caregiver Resource Guide that includes program and contact information for several local and national aging service organizations (e.g., Alzheimer's Association, Administration on Aging, Centers for Medicare and Medicaid). This condition likely exceeds the usual level of intervention in primary care settings
1578320|NCT02396069|Drug|JPI-289|PARP-1 inhibitor
1578321|NCT02396069|Drug|Placebo|Placebo
1578322|NCT02396056|Other|BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration.
1578323|NCT02396056|Other|Modified BioMend Extend|Biomend Extend is a resorbable collagen membrane used for guided tissue and bone regeneration. This membrane will be perforated to allow the passage of cells and growth factors that can potentially enhanced bone augmentation.
1578409|NCT02395367|Procedure|resection|This is an observational study. And we are interested in observing the outcome of different treatment methods.
1578331|NCT02396030|Drug|Magnesium sulfate 50% - 1g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
1578332|NCT02396030|Drug|Magnesium sulfate 50% - 2g/h|Patients will receive after the loading dose os magnesium sulfate, the maintenance dose of 1g/hour of intravenous of magnesium sulfate for 24 hours after loading dose
1578333|NCT02396017|Device|Capsule endoscopy|Endoscopic device
1578334|NCT02396017|Drug|Polyethylene Glycol|Bowel purgative
1578335|NCT02396004|Device|Near Infrared Red Spectroscopy (NIRS)|NIRS using INVOS cerebral/somatic oximeter
1578336|NCT02395991|Drug|gadoxetic acid|standard dose of gadoxetic acid (0.025mmol/kg) intravenous administration
1578337|NCT02395991|Other|Magnetic resonance imaging (MRI)|"Dynamic T1 weighted sequence consist of precontrast, arterial, portal, transitional and hepatobiliary phases.
precontrast, arterial and portal phases (prior to contrast media injection to 60 seconds after contrast media injection) are obtained continuously in free-breathing state. Transitional and hepatobiliary phases are obtained in breath-hold state."
1578338|NCT02395978|Drug|PDC-1421 Capsule|
1578339|NCT02395978|Drug|placebo|
1578340|NCT02395952|Drug|carboxymethylcellulose sodium|frequent topical lubrication with artificial tears
1578341|NCT02395952|Device|Acuvue Oasys Bandage Contact Lens|
1578342|NCT02395952|Device|Ambiodisk|
1578343|NCT02395952|Device|Prokera|
1578344|NCT02395939|Procedure|CT guided core biopsy|CT guided biopsy will be performed by a trained interventional radiologist using core biopsy.
1578345|NCT02395939|Procedure|Cryo-biopsy via Radial EBUS navigation|Cryo-biopsy will be performed via R-EBUS guidance. Cryo biopsy probe will be applied for 4 seconds for each biopsy and a minimum of 3 biopsies will be performed . Each patient will also have 3 forceps biopsies. The order of forceps biopsy or cryo biopsy will be randomly allocated.
1578346|NCT02395926|Drug|Choline CR 600mg|HT-003 600mg, administration 2 times per 1 day 8:00 a.m., 20:00
1578347|NCT02395926|Drug|Gliatilin 400mg|Gliatilin soft capsule 400mg, administration 3 times per 1day 8:00 a.m., 14:00, 20:00
1578348|NCT02395926|Drug|Choline CR 600mg|HT-003 600mg*2tab, administration 1 times per 1 day 8:00 a.m.
1578349|NCT02395913|Drug|Surfolase capsule (100mg)|Surfolase capsule one capsule twice one days fasting administration
1578350|NCT02395913|Drug|Surfolase CR (200mg, T1)|one tablet once one days fasting administration.
1578351|NCT02395913|Drug|Surfolase CR (200mg, T3)|one tablet once one days fasting administration.
1578352|NCT02395913|Drug|Surfolase CR (200mg, T4)|one tablet once one days fasting administration.
1578353|NCT02395900|Dietary Supplement|Flaxseed|
1578354|NCT02395900|Other|control|
1578355|NCT02395874|Procedure|tDCS + speech therapy|Patients either receive 20min of tDCS with 2mA + speech therapy every work for 6 weeks. The anodal electrode will be placed either on the homologous speech area (TACS) in the right hemisphere or on the speech area perilesional in the left hemisphere (PACS). The cathodal electrode will be placed contralateral. Patients in group B will follow the same protocol, except for the stimulation intensity (2 mA versus 0 mA) the speech therapist will apply the tdcs according to the protocol. The tdcs machine is out of sight of the patient, so that she/he does not see, whether the machine is switched on or not. In case of sham stimulation the device will be switched on very slowly for the first 20 s and will than be set back to 0mA within the following 10 s. So that the patient will feel also the characteristic tingling under the electrodes.
1578356|NCT02395861|Other|neuro-electrophysiologic analyses|mismatch negativity (MMN) cognitive evoked potentials (CEP) auditory evoked potentials (AEP)
1578357|NCT02395848|Drug|Fidaxomicin|200mg twice daily for 10 days followed by 200mg once daily for 20 days to prevent future recurrence of CDI
1578358|NCT02395822|Biological|IL-15|"Preparative Regimen:
Fludarabine 25 mg/m2 x 5 days start day -6 Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (if < 4 months from prior transplant, omit day -4 dose)
IL-15 Activated Donor NK Cells:
The apheresis product (collected day -1) will be enriched for NK cells with the large-scale CliniMacs® device (Miltenyi) by depletion of CD3+ cells to remove T-lymphocytes and depletion of CD19+ cells to remove B-lymphocytes. The NK cell enriched product will be activated by overnight incubation with10 ng/ml IL-15 under GMP conditions and infused on day 0.
IL-15 to Facilitate NK Cell Survival and Expansion:
IL-15 at 2 mcg/kg subcutaneously (SC) beginning day +1, once a day for 5 days followed by a 2 day rest, and then once a day for 5 days for 10 doses total"
1578359|NCT02395809|Procedure|lateral internal sphincterotomy|
1578360|NCT02395809|Procedure|TENS|
1578361|NCT02395796|Procedure|Epidural Pressure Waveform|When loss of resistance occurs, a high-pressure tubing extension will be connected to the needle and the pressure will be transduced and the waveform, recorded. An epidural catheter will then be passed through the needle and connected to a high-pressure tubing extension and the pressure will be transduced and recorded. A test dose of 3 mL of 2% lidocaine with epinephrine 1:200.000 will then be given to exclude potential spinal or intravascular injection. After 3 minutes, a loading dose of 10 mL of 0,125% bupivacaine will be given for labor analgesia and the presence or absence of a bilateral sensorial block at T10 or higher at 30 min will be assessed.
1578362|NCT02395783|Drug|Melatonin 10 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
1578363|NCT02395783|Drug|Melatonin 20 µg|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
1578364|NCT02395783|Other|Placebo|Determine the dose of prenatal administration of melatonin in preterm labor to reduce brain damage in the white matter detected by diffusion tensor imaging (DTI) analysis with spatial statistics (TBSS) to the theoretical term 40 weeks
1578365|NCT02395770|Other|Rehabilitation program|"Movement training: To re-educate control of movement, exercises of increasing difficulty in terms of movement plane, range of motion, speed and resistance were performed.
Strengthening: Using extremities weight, free weights or elastic bands, scapulothoracic and scapulohumeral strengthening was performed to increase strength and control of shoulder muscles.
Stretching & Manual Therapy: These modalities, performed only if needed, were aimed at addressing stiffness of posterior and inferior glenohumeral capsule and pectoralis minor.
Patient education: Participants received education regarding posture and body mechanics. They were instructed on preferred shoulder positioning during sleep, activities, work and sports"
1578366|NCT02395757|Device|MAIA™ (Centrevue, Padova, Italy; distributed in France by EDC Lamy, Carvin, France)|
1578367|NCT02395744|Other|Paclitaxel administration using the OPC|
1578368|NCT02395731|Behavioral|MIND at Home-Plus Intervention|MIND at Home-Plus is a home-based, care coordination that focuses on persons with dementia living at home and their family caregivers. Its goal is to help persons age in place safely while increasing quality of life. Delivered over 18 months, MIND-Plus systematically assesses and addresses unmet care needs of persons with dementia and their caregivers which are known to be linked to poor health and quality of life outcomes, and that put people at risk for long term care placement. The needs addressed in the MIND program cover a wide range of care domains, ranging from home and medication safety, to cognitive and behavior symptoms management, meaningful activities and legal considerations. The care team made up of a memory care coordinator, nurse, occupational therapist, and physician.
1578369|NCT02395718|Other|QDU|Treatment in a QDU. Intervention being fast track model for diagnostics and treatment with a goal of accomplishing a short-term hospitalisation (see description QDU arm)
1578370|NCT02395718|Other|DIM|Treatment at a ward at the DIM. Traditional inward hospitalisation
1578371|NCT02395705|Drug|cisplatin and paclitaxel|"Paclitaxel, 175mg/m2, d1, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
Paclitaxel, 87.5mg/m2, d1,d8, Cisplatin, 25mg/m2, d2-d4, 3 week, 2 cycles.
Paclitaxel, 175mg/m2, d1, Cisplatin, 75mg/m2, d1, 3 week, 2 cycles."
1578372|NCT02395692|Other|Laboratory Biomarker Analysis|Correlative studies
1578373|NCT02395692|Drug|Methoxyamine|Given PO
1578374|NCT02395692|Drug|Temozolomide|Given PO
1578375|NCT02395679|Biological|MesoCancerVac|A leukapheresis is performed of which the monocytes are used for differentiation to DCs using specific cytokines. Pulsed autologous DCs (MesoCancerVac) are re-injected 3 times every two weeks. After the third injection with MesoCancerVac, revaccinations to boost the immune system are given after 3 and 6 months.
1578376|NCT02395666|Drug|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
1578378|NCT02395640|Drug|Epirubicin|50mg/m2 ivgtt d1
1578379|NCT02395640|Drug|Oxaliplatin|
1578380|NCT02395640|Drug|Capecitabine|1000mg/m2 po d1-14
1578381|NCT02395627|Drug|Tamoxifen|
1578382|NCT02395627|Drug|Vorinostat|
1578383|NCT02395627|Drug|pembrolizumab|
1578384|NCT02395614|Drug|Chlorhexidine irrigation|- 0.05% chlorhexidine solution (IrriSept®) commercially prepared in 450 ml bottles will be used to irrigate one breast pocket. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
1578385|NCT02395614|Drug|triple antibiotic irrigation|"-triple antibiotic solution will contain 1 g of cefazolin, 50,000 U of bacitracin, and. Each patient will receive triple antibiotic solution on one breast and the CHG on the other breast.
80 mg of gentamicin in 500 mL of NS. If the patient is allergic to either component - the allergen will not be used in the solution - to irrigate one breast pocket"
1578386|NCT02395601|Drug|CPI-1205|Small molecule inhibitor of the enzyme EZH2
1578387|NCT02395588|Other|Guideline based care|Patient education using guideline based teaching guides
1578388|NCT02395549|Drug|0.375% (w/w) MTC896 Gel|0.375% (w/w) MTC896 Gel
1578389|NCT02395549|Drug|0.75% (w/w) MTC896 Gel|0.75% (w/w) MTC896 Gel
1578390|NCT02395549|Drug|1.5% (w/w) MTC896 Gel|1.5% (w/w) MTC896 Gel
1578391|NCT02395549|Drug|Vehicle Control Gel|
1578392|NCT02395536|Other|office setting|An office setting was defined as a procedure or office room with controlled entry and hard floors outside the walls of the hospital and not including ambulatory surgical centers
1578393|NCT02395536|Other|hosptial setting|A hospital setting was defined as an operating room or electrophysiology lab inside the walls of a hospital.
1578394|NCT02395523|Radiation|Proton Beam Therapy|"Definition of target volume:
Gross tumor volume (GTV) = gross tumor defined using a treatment planning CT scan
Clinical target volume (CTV) = GTV + internal target volume
Planning target volume (PTV) = CTV + 5 - 7 mm of lateral, craniocaudal, and anteroposterior margins.
Radiation dose and planning
Prescription dose to PTV: 70 GyE /10 fx, 7GyE fraction dose, 5 days/week
Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
1578395|NCT02395510|Drug|Vortioxetine|Vortioxetine 5-20mg
1578399|NCT02395458|Drug|Sequential therapy|Patient receive Omeprazole plus amoxicillin during 5 days and then omeprazole plus clarithromycin and metronidazole during another 5 days
1578400|NCT02395458|Drug|Triple therapy|Patient receive Omeprazole plus amoxicillin and Clarithromycin during 14 days
1578401|NCT02395445|Device|orotracheal intubation|
1578402|NCT02395432|Device|orotracheal intubation|
1578403|NCT02395419|Device|Orotracheal intubation with Totaltrack|
1578404|NCT02395419|Device|Orotracheal intubation with Airtraq|
1578405|NCT02395406|Device|Orotracheal intubation with Totaltrack|
1578406|NCT02395406|Device|Orotracheal intubation with Airtraq|
1578407|NCT02395393|Device|Alveoflex Confocal MiniprobeTM|-Alveolar imaging
1578408|NCT02395380|Other|C-reactive protein dosage|
1578615|NCT02393820|Drug|pazopanib|treatment will be given until progression or unacceptable toxicity .
1578410|NCT02395367|Radiation|adjuvant radiotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
1578411|NCT02395367|Drug|neoadjuvant chemotherapy or adjuvant chemotherapy|This is an observational study. And we are interested in observing the outcome of different treatment methods.
1578412|NCT02395354|Device|Placing a self-expanding metallic stent|"Income on short stay unit (SSU) post-procedure
Light sedation by the endoscopist vs anesthetist by center
Fully covered self-expanding metal stents Tae Woong Medical® type; prosthesis size at the endoscopist discretion
Clips can be placed at the distal end of the prosthesis according to the endoscopist.
Prosthesis removal time in 4 weeks."
1578413|NCT02395354|Device|A balloon dilatation|"Income on short stay unit (SSU) post-procedure
Light sedation by the endoscopist vs anesthetist by center.
Pneumatic ball type CRE Boston cientific®; balloon diameter at the endoscopist discretion
Up to 2 expansion will be made with a minimum interval between 15-30 days between each expansion
It shall be deemed failure to expansion if required> 2 expansions."
1578414|NCT02395328|Behavioral|Care Worker Home Visitation|Primary services include biweekly home visits from Care Workers trained, mobilized and supported by Futures Families, a South African non-government organization working to support OVC in six townships within the greater Tshwane area (also known as Pretoria) of South Africa.
1578415|NCT02395315|Device|Well-controlled diabetic (WC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
1578416|NCT02395315|Device|Poorly controlled diabetics (PC)|Each individual will receive one implant (4.1 Titanium-Zirconia, hydrophilic-Roxolid), that will be placed in the posterior mandible.
1578417|NCT02395302|Device|Dual Action Pneumatic Compression|Wear in sustained mode for 14 hours and pneumatic compression mode for 3 hours during the 4 week treatment period.
1578418|NCT02395289|Behavioral|Cognitive-Based Compassion Training (CBCT)|"Cognitive-Based Compassion Training (CBCT) is composed of secular, didactic instruction and meditation practices. CBCT includes the meditative practices of developing one-pointed concentration and mindfulness. CBCT will be one class per week, 2 hours each, for 8 weeks, for a total of 16 hours during the study. Each meditation class will include a didactic and discussion session that will describe the meditative technique introduced during the week and a practice meditation session. The training protocol is highly iterative and techniques introduced early in training are practiced daily. All participants will be asked to meditate approximately 30 minutes a day at home and will be given a meditation diary to record amount of time spent meditating per week."
1578419|NCT02395289|Behavioral|Health discussion|Health discussion therapy is one class per week, 2 hours each, for 8 weeks. Each class will use interactive teaching methods to present the health material in an engaging and relevant manner. Representative weekly topics that will be covered include healthy diet, the role of exercise in emotional health, and the importance of sleep and relaxation. It is important to note that the material presented in the health discussion group, although intended to be beneficial to participants, does not include a contemplative component and is not iterative in nature.
1578420|NCT02395276|Device|Whole body hypothermia|Treatment will be initiated within 6 hours of the event, the child will be dressed with a cooling suit and their temperature will be monitored. Cooling will be to 33 +/- 1 °C . Treatment period will be 48 hours with 24 hours warming up period.
1578421|NCT02395263|Drug|Yuxintine|
1578422|NCT02395250|Biological|anti-GPC3 CAR T|
1578423|NCT02395237|Drug|: Amaryl® M IR 2/1000|
1578425|NCT02395211|Behavioral|Usual Physiotherapy|"Usual physiotherapy consist of active or passive mobilization, extensor digiti and carpi functional electric stimulation, occupational therapy and taping.
The intervention will last 30 minute a day x 4 weeks"
1578426|NCT02395211|Device|Gloreha device|Proprioceptive stimulation under visual feedback are provided by the Gloreha device. The intervention will last 30 minute a day x 4 weeks
1578428|NCT02395172|Drug|Avelumab|Subjects will receive 10 milligram per kilogram (mg/kg) of avelumab as a 1-hour intravenous (IV) infusion once every 2 weeks.
1578429|NCT02395172|Drug|Docetaxel|Subjects will receive 75 mg per square meter (m^2) (per label) of docetaxel by IV infusion once every 3 weeks.
1578432|NCT02395146|Procedure|Monitoring|intraoperative EBSLN monitoring
1578433|NCT02395133|Drug|Dupilumab|
1578434|NCT02395133|Drug|Placebo|
1578435|NCT02395120|Behavioral|Standard letter|Standard referral letter according to Ohio Department of Health Bureau guidelines. This letter is consistent with others used across the country.
1578436|NCT02395120|Behavioral|Intervention letter|Referral letter based on the Common Sense Model of Self-Regulation (CSM). The letter includes the cognitive dimensions of the CSM (identity, cause, timeline, consequences and control).
1578437|NCT02395120|Behavioral|Reduced intervention letter|"Reduced (removing text corresponding to timeline) CSM theory-based referral letter. The letter includes the remaining cognitive dimensions of the CSM (identity, cause, consequences and control)."
1578438|NCT02395120|Behavioral|DIG|Dental information guide (DIG) to reinforce/change illness perception, knowledge about dental caries, and resources to seek care. DIG is a brochure with illustrations which provides myths and facts about dental caries, hints for getting dental care, making appointments and Medicaid access, transportation and dentist availability resources.
1578439|NCT02395120|Behavioral|Reduced DIG|"Text and illustrations related to the timeline construct of the CSM have been removed in the reduced dental information guide."
1578470|NCT02394834|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
1578441|NCT02395081|Dietary Supplement|600 IU Vitamin D3 in prenatal vitamin|Women will receive 600 IU 25(OH)D in prenatal vitamin.
1578442|NCT02395081|Dietary Supplement|2000 IU Vitamin D3 in prenatal vitamin|Women will receive 2000 IU 25(OH)D in prenatal vitamin.
1578443|NCT02395081|Dietary Supplement|4000 IU Vitamin D3 in prenatal vitamin|Women will receive 4000 IU 25(OH)D in prenatal vitamin.
1578444|NCT02395068|Drug|Nimotuzumab|single dose of nimotuzumab (100、200、400、600mg), with 3 weeks observation；Set 4 dose groups for Nimotuzumab, namely 100,200,400,600mg. Each group administered once a week for 6 weeks；600mg, administered once every 2 weeks for 8 weeks.
1578445|NCT02395068|Drug|irinotecan|"Single-dose PK：1 week after nimotuzumb administration, irinotecan (CPT-11) will be given at a dose of 180 mg/m2 once every 2 weeks, 2 weeks a cycle.
Bioweekly fixed dose PK：Nimotuzumab combined with irinotecan (180mg/m2), administering once every 2 weeks and considering 2 weeks as a period. If chemotherapy and Nimotuzumab are administered in the same day, chemotherapy should be infused after Nimotuzumab for at least 1h"
1578446|NCT02395055|Drug|Adalimumab (BCD-057)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
1578447|NCT02395055|Drug|Adalimumab (Humira)|Adalimumab is a monoclonal antibody against tumor necrosis factor alpha
1578448|NCT02395042|Drug|LiRIS®|LiRIS® is a drug-device combination product which is placed in the bladder during cystoscopy and remains in the bladder, gradually releasing lidocaine until removed from the bladder via cystoscopy.
1578449|NCT02395042|Drug|LiRIS Placebo|LiRIS placebo is a drug-device combination product, matching the LiRIS® which is placed in the bladder during cystoscopy, remains in the bladder until removed from the bladder via cystoscopy
1578450|NCT02395029|Biological|Placental Matrix-Derived Mesenchymal Stem Cells (PMD-MSCs)|
1578451|NCT02395016|Drug|nimotuzumab|nimotuzumab,400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
1578452|NCT02395016|Drug|Gemcitabine|Gemcitabine，1000mg/m2，Intravenous infusion over 30 minutes,Once every three weeks, rest one week (d1,8,15; q28d), Every 4 weeks for a period,Until disease progression or intolerable toxicity or subjects ask to leave the test.
1578453|NCT02395016|Other|Placebo|Placebo，400mg/w，Intravenous infusion over 60 minutes,Until disease progression or intolerable toxicity or subjects ask to leave the test.
1578454|NCT02395003|Other|Palmitate Diet|Subject with high VAT/SAT ratio will be randomized to a high or low palmitate oil diet.
1578455|NCT02394990|Behavioral|Violence Brief Intervention|Strategies for self assessment of consequences of violent behavior and strategies for avoidance of violence
1578456|NCT02394990|Behavioral|ABI|
1578457|NCT02394977|Device|Cardio First Angle|"Patients in the intervention group received CPR in accordance to published guidelines using the CFA device per manufacturer instructions. The Cardio First Angel TM (InotechGruppe, Nubberg, Germany) is a lightweight device that consists of three components . Application of400 ± 30 Newtons of force (41 kg or 90 lb of pressure), which correlates toa sternum compression depth of 50-60 mm, is followed by an audible click sound to alert the rescuer to cease compression. The click sound is also audible upon spring decompression alerting the rescuer to resume compression. When used properly rescuers may deliver approximately 100-120 compressions per minute. The device functions purely mechanically and does not require electrical power supply."
1578458|NCT02394964|Other|Sample Collection|Sample collection of blood, stool, and buccal and skin swab samples will be collected at baseline, week 4, and week 8
1578461|NCT02394938|Other|MUSIC|In addition to the standard care,patients assigned to the music group will listen recorded classical music. Music will be delivered with a mp3 Player and headphones Music will be listened by the patient in his home.The music play list will be formed by a classical repertoire.During the intervention patients will be recommended to listen to the music for 3 months. Also patients will be asked to listen to the music once or more than once per day, at any time, for a total of 30 minutes per day.Music will be listen at 50-60 decibels below the threshold of 85 db established for listening to portable media devices such as compact disc and MP3 players.Music in this protocol will have a tempo/rhythm in a range of 60-80 beats per minute (bpm).
1578462|NCT02394925|Device|Multifocal Test Contact lens|Used in a daily wear modality
1578463|NCT02394912|Device|vena cava filter implantation (LUMIFI with Crux VCF System)|
1578464|NCT02394899|Behavioral|Play therapy|Short films that have been developed to deliver a series of child development messages will be shown at the monthly visits. Nine modules of approximate length 3 minutes each have been developed and cover the topics: Love, Comforting baby, Talking to babies and children, Praise, Using bath time to play and learn, Looking at books, Simple toys mothers can make, Drawing and games, and Puzzles. Nurses at the Sickle cell Unit (SCU) will be trained to discuss the video messages with the mothers/caregivers, demonstrate activities they can do with their children and how to make simple toys from household materials. Mothers/caregivers will practice some of the activities and they will be encouraged to make them part of their daily routine.
1578465|NCT02394899|Other|Problem solving skills|Problem solving therapy (PST) aims to empower patients or caregivers in attending to daily challenges. It is based on cognitive behavioural therapy and can be used in primary care settings. It encourages persons to use existing resources and skills to function better and find solutions to problems. It will be delivered in 6 sessions over the 6-week period and will last for about 30 minutes per session. The stages of PST are: identification of the problems; generating possible solutions; evaluating and implementing preferred solution; and evaluating to see if the solutions were successful. The parent/caregiver will be taught a process of problem solving with reference to general everyday problems as well as specific problems which may arise while parenting a child with SCD.
1578466|NCT02394886|Biological|ALLO-ASC-DFU|
1578467|NCT02394873|Biological|ALLO-ASC-DFU|Dressing for second-degree burn wound.
1578468|NCT02394860|Other|echo Doppler lower limbs|
1578469|NCT02394847|Drug|propofol|
1578607|NCT02393833|Drug|Cyclophosphamide|
1578471|NCT02394834|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|oxaliplatin (OXA), levofolinate calcium (l-LV), bevacizumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
1994155|NCT03057119|Behavioral|Readiness Assessment (10 minutes)|The interventionist will give the patient feedback on their ASSIST score and assess the patient's readiness to change based on Prochaska's stages of change.
2008515|NCT03328455|Behavioral|Active training|Perceptual training is task-related.
1578474|NCT02394808|Device|senofilcon A|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
1578475|NCT02394808|Device|lotrafilcon B|One fresh pair of contact lenses worn for 11 (+/-2) days, for a minimum of 6 hours per day
1578476|NCT02394795|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
1578477|NCT02394795|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, bevacizumab|
1578478|NCT02394782|Device|RebiSmart®2.0|Rebif (interferon beta-1a) will be administered by RebiSmart®2.0 as specified in Summary of Product Characteristics.
1578479|NCT02394782|Device|MSdialog™|Rebif (interferon beta-1a) will be administered by MSdialog™ as specified in Summary of Product Characteristics.
1578480|NCT02394769|Drug|Aspirin|
1578481|NCT02394769|Drug|Placebo for Aspirin|
1578482|NCT02394756|Device|Marketed Soft Contact lens|Replacement schedule every 2 weeks
1578483|NCT02394756|Device|AIR OPTIX® AQUA|Replacement schedule every 4 weeks
1578484|NCT02394756|Device|Biofinity®|Replacement schedule every 4 weeks
1578485|NCT02394743|Radiation|18FDG-PET|
1578486|NCT02394730|Drug|vorapaxar|2.5mg of vorapaxar taken orally once daily for 12 weeks
1578487|NCT02394730|Drug|Placebo|Sugar pill taken orally once daily for 12 weeks
1578488|NCT02394717|Behavioral|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
1578489|NCT02394704|Other|Sensory attention training|"Participants will be instructed to attend to sensory stimuli and to press a button as quickly and accurately as possible while doing mental arithmetic. Speed and intensity of the task will change depending on participant progress. At high speeds, attention will need to be voluntarily recruited. At slow initial speeds, attention is expected to be automatically captured by each stimulus (not effortful). Stimuli will consist of non-painful electrical muscle stimulation (10Hz biphasic current with a pulse width of 200us with rectangular 2 electrodes placed on the back near the shoulders. Sessions will be approximately 45 minutes 3 session over the course of two weeks."
1578490|NCT02394691|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
1578491|NCT02394678|Device|AngioJet Thrombectomy System|Mechanical removal of blood, using a pressurised jet of water, from ventricles of patients suffering from intraventricular haemorrhage
1578492|NCT02394665|Radiation|Intensity Modulated Radiation Therapy|IMRT treatment will consist of 60 Gy in 30 fractions to PTV 60
1578493|NCT02394665|Drug|Temozolomide|"Concurrently during radiation therapy. Adjuvant therapy administered daily on days 1 - 5 for 12 cycles. One cycle = 28 days:
Concurrent during Radiation Therapy: 75 mg/m^2 orally for 6 weeks;
Post-radiation, adjuvant therapy: 150 mg/m^2 - 200 mg/m^2 orally daily on days 1 - 5 of each cycle."
1578494|NCT02394665|Behavioral|Functional Assessment of Cancer Therapy-Brain (FACT-Br)|FACT-Br Quality of Life (QOL) questionnaire to be completed by study patients as protocol specific timepoints
1578495|NCT02394665|Radiation|Stereotactic Radiosurgery Boost|"Patients will undergo SRS boost in a single fraction dose prior to IMRT treatment:
HTV Maximum dimension vs. Prescribed Dose to HTV: ≤ 20 mm = 21 Gy; 21 mm - 30 mm = 18 Gy; 31 mm - 40 mm = 15 Gy."
1578496|NCT02394665|Radiation|Simultaneous Integrated Boost|Treatment shall consist of 60 Gy in 30 fractions to planning target volume (PTV) 60 and 75 Gy in 30 fractions to PTV 75.
1578497|NCT02394665|Device|3D MRSI|Three Dimensional Magnetic Resonance Spectroscopy Imaging (MRSI) during pre-treatment, week 3 during radiation therapy, end of radiation therapy; will include standard gadolinium enhanced MRI prior to cycle 1, 5, 9, and post cycle 12 of adjuvant temozolomide therapy, per protocol.
1578498|NCT02394652|Drug|Metformin|
1578499|NCT02394652|Drug|Cisplatin|
1578500|NCT02394652|Drug|FAZA|
1578501|NCT02394639|Other|video-EEG monitoring|
1578502|NCT02394626|Procedure|Surgery followed by adjuvant second-line therapy|"Surgery:
Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. Surgery must take place between day 1 and 14 after study inclusion and within 21 days from the MRI on which recurrence was diagnosed. The modalities of surgery and the choice of pre- and intra-operative technical adjuncts is at the treating neurosurgery discretion. However, some form of intra-operative resection control (iMRI or intra-operative fluorescence) and function control (electrophysiology) should be available to the surgeon and used when warranted.
Adjuvant second-line therapy:
Patients will be seen after surgery by the treating neurooncologist. Modalities of adjuvant second-line therapy are individually defined according to local guidelines and are not stipulated by study protocol."
1578503|NCT02394626|Procedure|Second-line therapy alone|Patients randomized to the non-surgical cohort receive second-line therapy according to local guidelines. Modalities thereof are not stipulated by study protocol.
1578504|NCT02394613|Drug|ANX776|Single intravenous injection
1578507|NCT02394587|Behavioral|Mindfulness-based Stress Reduction|A non-pharmacological approach to pain management.
1578508|NCT02394574|Other|Clean Cookstove|Ethanol
1578509|NCT02394574|Other|Traditional Cookstove|Firewood / Kerosene
1578510|NCT02394561|Biological|Secukinumab|Secukinumab 300 mg will be administered to Cw6 positive and negative patients with plaque type psoriasis
1578511|NCT02394548|Radiation|Contralateral Esophageal Sparing Technique (CEST)|Determine whether CEST decreases rate of severe acute esophagitis
1578512|NCT02394535|Drug|Abraxane|"Dose Escalation Starting dose of Abraxane: 50 mg/m2 by vein weekly Day 1, 8, 15, 22 and 29.
Dose Expansion Starting Dose of Abraxane: MTD dose from Dose Escalation."
1578513|NCT02394535|Drug|Capecitabine|Dose Escalation and Dose Expansion Dose of Capecitabine: 825 mg/m2 by mouth twice a day only on days of radiation.
1578514|NCT02394535|Radiation|Radiation Therapy|Radiation Therapy delivered at a dose of 50.4 Gy in 1.8 Gy fractions, 1 time each day on Monday through Friday for 5½ weeks.
1578515|NCT02394535|Behavioral|Questionnaires|Symptom and Quality of Life (QOL) Questionnaire completed at baseline, and 4 - 6 weeks after radiation therapy.
1578516|NCT02394522|Device|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator
1578517|NCT02394522|Device|Active Ingredient|Transfluthrin (Active ingredient)
1578518|NCT02394522|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
1578519|NCT02394509|Behavioral|Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)|HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
1578520|NCT02394496|Drug|Fulvestrant|Fulvestrant 500mg (2 x 5ml) im injections as a loading dose on Day 0, followed by 500mg (2x5ml) on Day 14 (+/- 3 days) , Day 28 (+/- 3 days) and every 28 Days (+/- 3 days) thereafter.
1578521|NCT02394496|Drug|Lapatinib|1500mg (TBD) O.S. qd
1578522|NCT02394496|Drug|Aromatase Inhibitors|as indicated in the Summary Product Characteristic
1578523|NCT02394496|Drug|Placebo Lapatinib|1500mg (TBD) O.S. qd
1578524|NCT02394483|Drug|F901318 safety|Safety assessments
1578525|NCT02394483|Drug|F901318 tolerability|Tolerability assessments
1578526|NCT02394483|Drug|F901318 pharmacokinetics|Pharmacokinetic assessments
1578527|NCT02394483|Other|Placebo safety|Safety assessments
1578528|NCT02394483|Other|Placebo tolerability|Placebo tolerability
1578529|NCT02394483|Other|Placebo pharmacokinetics|Plaacebo pharmacokinetics
1578530|NCT02394470|Other|Deuterium oxide dilution|Reference standard for total body water: deuterium oxide dilution by mass spectrometry
1578531|NCT02394470|Other|Bioimpedentiometry|Bioimpedentiometry: measurement of whole body and thoracic resistance and reactance
1578532|NCT02394470|Other|Lung and subcutaneous ultrasound|Ultrasound: semiquantitative scoring of lung congestion (B lines) and peripheral edema (subcutaneous echography of the ankle)
1578533|NCT02394457|Drug|Cosyntropin|Intravenous Drug Infusion over 1 hour and a half
1578534|NCT02394457|Procedure|Epidural Blood Patch|Blood drawn from subject and then same Blood placed into Epidural space by anesthesia personnel.
1578535|NCT02394444|Other|Triadic parent-infant Relationship Therapy (TRT)|22 sessions, including home visits twice per month during the first four months, followed by monthly consultations in the neonatology ward, up to corrected age of 18 months.
1578536|NCT02394431|Other|Cardiac echography|Ejection fraction measured by Teicholz and planimetry, diastolic function, tissular doppler, myocardiac performance index, global longitudinal strain measured by speckle tracking, arterial pulmonary hypertension, left ventricular hypertrophy.
1578537|NCT02394431|Other|Biological parameters|Hemoglobin levels, red cells, hematocrit, iron, ferritin
1578538|NCT02394431|Other|Clinical parameters|Blood transfusion number, severity of the sickle cell disease damage, evolution duration of the sickness
1578539|NCT02394418|Drug|Sevoflurane|Treatment of delirium by inhaled sevoflurane
1578540|NCT02394418|Drug|Propofol|Treatment of delirium by propofol i.v. infusion
1578541|NCT02394418|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
1578542|NCT02394379|Device|Trulign™ Toric IOL|Trulign™ Toric Posterior Chamber IOL is a modified plate haptic lens
1578543|NCT02394366|Other|Original Healing Salve (OHS)|Topical salve (Puremedy, Inc.)
1578544|NCT02394366|Other|OHS base only|Olive and beeswax salve base
1578545|NCT02394353|Device|Transient hepatic elastography|
1578546|NCT02394340|Drug|Omeprazole 40mg|Each subject will receive a single dose of omeprazole 40mg on Day 1, 24 hours prior to starting treatment with Luliconazole Cream 1%, and on Day 8 after treatment
1578547|NCT02394327|Device|7-Fr Pigtail type naso-cholecystic drainage tube (Liguory nasal biliary drainage set; Wilson-Cook Medical, Salem, NC, USA)|Endoscopic
1578548|NCT02394327|Device|7-Fr double pigtail plastic stent (Zimmon; Wilson-Cook Medical, Salem, NC, USA)|
1578549|NCT02394314|Drug|MEDI0382|MEDI0382 administered subcutaneously
1578550|NCT02394314|Drug|Placebo|Placebo administered subcutaneously
1578551|NCT02394288|Procedure|Extremity orthopedic or trauma surgery|hip, leg, shoulder, arm
1578552|NCT02394275|Biological|Fecal Microbiota Transplant|All eligible patients will receive fecal microbiota transplant
1578553|NCT02394262|Radiation|Coronary CT-angiography|Sequential CCTA after one year follow-up. The first CCTA will be performed in terms of diagnostic work-up (referral outpatient Cardiology department).
1578554|NCT02394262|Other|Assesment of biomarkers involved in atherothrombosis|Sequential assesment of atherothrombis biomarkers: baseline and at 1 year follow-up.
1578555|NCT02394249|Behavioral|Physical activity regime|Information already included in arm descriptions
1578556|NCT02394236|Other|Aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
1578557|NCT02394223|Procedure|Full Field Optical Coherence Tomography (FFOCT) procedure|TRUS Prostate biopsy are performed under the care procedure Pathological examination of these prostate biopsy with FFOCT procedure, as compared to standard pathological evaluation
1578558|NCT02394197|Drug|Chloroquine phosphate|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
1578559|NCT02394197|Drug|primaquine|use at operational doses by age group according to the Mexican guidelines for vector borne diseases
1578560|NCT02394184|Procedure|transcatheter aortic valve replacement|
1578561|NCT02394171|Behavioral|Group Cohesion|See description in arm/group above
1578562|NCT02394158|Drug|Metformin|
1578563|NCT02394158|Drug|placebo|
1578608|NCT02393833|Drug|Doxorubicin hydrochloride|
1578609|NCT02393833|Drug|Epirubicin hydrochloride|
1578564|NCT02394145|Drug|Ticagrelor|Patients with normal kidney function and ESRD on hemodialysis will be treated by ticagrelor 90mg twice a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
1578565|NCT02394145|Drug|Clopidogrel|Patients with normal kidney function and ESRD on hemodialysis will be treated by clopidogrel 75mg or 150mg once a day for 14 days. After then, platelet reactivity will be assessed by light aggregometry and VerifyNow assay.
1578566|NCT02394132|Drug|Imiquimod|
1578567|NCT02394132|Radiation|Radiotherapy|
1578568|NCT02394119|Drug|Ofatumumab|1500 mg/1.73m2, administered once diluted in 1000 ml of normal saline
1578569|NCT02394119|Drug|Rituximab|375 mg/m2, administered once diluted in 100/250/500 ml of normal saline for dosage respectively between 100-250 mg, 260-500 mg, 510-1000 mg.
1578570|NCT02394106|Drug|Ofatumumab|Ofatumumab 1500 mg/1.73m2 administered once, diluted in 1000 ml of normal saline
1578571|NCT02394106|Other|Placebo|Normal saline, 1000 ml, administered once
1578572|NCT02394093|Drug|Aspirin (Acetylsalicylic acid, BAYe4465)|One stick pack containing 500 mg acetylsalicylic acid dry powder
1578573|NCT02394093|Drug|Aspirin (Acetylsalicylic acid, BAYe4465)|One tablet containing 500 mg acetylsalicylic acid
1578574|NCT02394093|Drug|Aspirin (Acetylsalicylic acid, BAYe4465)|One effervescent tablet containing 500 mg acetylsalicylic acid
1578575|NCT02394080|Device|Photodynamic Bone Stabilization System|Treatment of acute humerus fractures
1578576|NCT02394067|Other|Radiological Imaging|magnetic resonance imaging and magnetic resonance venography scans
1578577|NCT02394054|Drug|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
1578578|NCT02394054|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
1578579|NCT02394041|Device|Acupuncture|Method of acupuncture: check the condition of skin, disinfect if needed, insert sterile needles with special handling for each point, remove the needles after 15 minutes.
1578580|NCT02394041|Device|Sham acupuncture|Sham acupuncture with sham needles
1578581|NCT02394028|Drug|Etrolizumab 210 mg|Induction phase only: 210 mg dose subcutaneous injection administration at Weeks 0,2,4,8 and 12
1578582|NCT02394028|Drug|Etrolizumab 105 mg|Induction Phase : 105 mg dose subcutaneous administration at Weeks 0,4,8 and 12; Maintenance Phase : Single 105 mg dose subcutaneous administration Q4W
1578583|NCT02394028|Drug|Placebo|Matching placebo to either etrolizumab 105 mg or etrolizumab 210 mg according to the treatment schedule
1578584|NCT02394015|Drug|Trabectedin and Pegylated Liposomal Doxorubicin|Trabectedin and Pegylated Liposomal Doxorubicin (PLD ) in the Treatment of Patients With Platinum-sensitive Recurrent Ovarian Cancer (ROC), according to SmPC from October 28, 2009 to October 31, 2014
1578585|NCT02394002|Drug|Propofol|
1578586|NCT02393989|Procedure|posterior restoration|restorations for caries effected teeth
1578587|NCT02393976|Dietary Supplement|IMMUNONUTRITION|IMMUNONUTRITION SUPLEMENTS PERIOPERATIVE
1578588|NCT02393976|Dietary Supplement|STANDART NUTRITION|STANDART NUTRITION PERIOPERATIVE
1578589|NCT02393963|Drug|Tranexamic Acid|0.5g Tranexamic Acid in 0.9% Sodium Chloride (study group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
1578590|NCT02393963|Other|Placebo|0.9% Sodium Chloride (placebo group) will be injected into the joint after final closure through a temporary catheter that is brought out through the incision.
1578591|NCT02393950|Drug|ODM-106|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
1578592|NCT02393950|Drug|Placebo|Single oral escalating doses of ODM-106 will be administered. Each subject will participate in 4 study periods and will therefore receive 3 single doses of ODM-106 and one single dose of placebo.
1578593|NCT02393937|Drug|Reference: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
1578594|NCT02393937|Drug|Test: Metronidazole Gel 1%|Participants are assigned to one of three groups in parallel for the duration of the study
1578595|NCT02393937|Drug|Placebo Gel|Participants are assigned to one of three groups in parallel for the duration of the study
2008516|NCT03328455|Behavioral|Passive training|Training is not task-related.
1578597|NCT02393911|Dietary Supplement|Low Oxalate Diet|Low oxalate diet is a diet where products with oxalate will be eliminated, such as: tomatoes, berries, coffee, nuts
1578598|NCT02393898|Drug|Bevacizumab|Bevacizumab will be prescribed by the local clinician according to the SmPC and standard of care for up to 15 months. No treatment will be provided by the Sponsor in this non-interventional study.
1578599|NCT02393898|Drug|Carboplatin|Carboplatin will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
1578600|NCT02393898|Drug|Paclitaxel|Paclitaxel will be prescribed by the local clinician according to local labeling and standard of care for up to 18 weeks. No treatment will be provided by the Sponsor in this non-interventional study.
1578601|NCT02393885|Device|AtriCure Bipolar System and AtriClip® PRO LAA Exclusion System, Endocardial Ablation|
1578602|NCT02393872|Behavioral|Feel4Diabetes-intervention|Community-based intervention.
2008517|NCT03329326|Other|Functional tests and self-reported questionnaires|In this observational study no intervention is initiated. Patients included are only assessed with the non-invasive tests described earlier.
2008518|NCT03329313|Drug|Lowering sodium concentration dialysate|Concentration of sodium in dialysate at 140 mmol/l
1578605|NCT02393846|Drug|Ketoprofen gel|Topical ketoprofen as used in gel form.
1578606|NCT02393846|Drug|Placebo|Placebo gel which is identical in colour, form and smell compared to ketoprofen gel.
2008519|NCT03329313|Drug|Highing sodium concentration dialysate|Concentration of sodium in dialysate at 145 mmol/l
1578616|NCT02393807|Drug|PF 06260414 solid dose formulation|Single dose of 30 mg PF-06260414 given under fed/fasted conditions
1578617|NCT02393807|Drug|PF-06260414 nanosuspension|Single dose of 30 mg PF-06260414 given under fasted conditions
1578618|NCT02393794|Drug|Romidepsin|Histone deacetylase inhibitor
1578619|NCT02393794|Drug|Cisplatin|Platinum compound
1578620|NCT02393794|Drug|Nivolumab|Monoclonal antibody, checkpoint inhibitor
2008520|NCT03329300|Behavioral|Family-based Behavioral Treatment (FBT)|Family-based behavioral treatment (FBT) involves working with children and caregivers to modify diet and physical activity using behavioral strategies such as problem solving, goal setting, and self-monitoring. Children and caregivers will meet in group format on a weekly basis for 6 months. There will be 24 group session total, covering a variety of topics including nutrition, physical activity, and other aspects of health and wellness.
2008521|NCT03329287|Behavioral|SCBT|SCBT, one hour per session.
2008522|NCT03329287|Drug|SSRIs and/or SNRIs|SSRIs and/or SNRIs at a recommended dosage.
1578625|NCT02393742|Drug|Sodium nitrite|
1578626|NCT02393742|Drug|Placebo|
1578627|NCT02393729|Behavioral|Neuropsychological assessment|"The neuropsychological assessment will include an assessment of:
Intellectual ability
Laterality
Reading Skills
Motor skills
Oral Language
Attention
Child's behaviour"
1578628|NCT02393729|Other|MRI Study|"It will include a first session of about an hour outside MRI for familiarization with the environment of the MRI. The MRI will then be made after a break of 15 minutes
Morphological time: this time include the initial acquisition of a sequence of anatomical 3D T1-weighted high-resolution contiguous axial slices and the imaging of diffusion tensor.
Functional time: The experimental paradigm is a paradigm as a block with alternating phase of motor and rest conditions. The two motor tasks are: a Learning motor sequence or motor sequence task and Automated motor sequence or AT (automated task)."
1578629|NCT02393716|Device|Endurant Evo AAA Stent Graft System|
1578630|NCT02393716|Procedure|Endovascular aneurysm repair (EVAR)|
1578635|NCT02393677|Drug|Ropivacaine|Ropivacaine 0.5% 30 ml was used to block brachial plexus
1578636|NCT02393677|Drug|Ropivacaine with Dexmedetomidine|Dexmedetomidine 1 microgram per kilogram bodyweight was added with 30 ml 0.5% Ropivacaine to block brachial plexus
1578637|NCT02393664|Drug|propofol, bupivacaine|Nonintubated technique for thoracoscopic surgery using propofol infusion, intercostal and vagal blocks with bupivacaine infiltrations.
1578638|NCT02393664|Drug|sevoflurane, rocuronium|Conventional intubated general anesthesia for thoracoscopic surgery using sevoflurane and rocuronium, and tracheal intubation with a double-lumen tube or a endobronchial blocker.
1578639|NCT02393651|Device|tDCS|Late LTP-like plasticity tDCS (2 times per week) for 4 weeks.
1578640|NCT02393638|Other|Simulation and lecture|Endoscopic sphincterotomy on simulator and lecture
1578641|NCT02393638|Other|Lecture|Lecture
1578644|NCT02393612|Drug|DP-R202|Sarpogrelate HCl SR 300mg is administrated to patients with PAD for 12 weeks
1578645|NCT02393612|Drug|Anplag tab|Anplag tab 100mg is administrated to patients with PAD for 12 weeks
1578646|NCT02393599|Drug|Lorcaserin|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
1578647|NCT02393599|Drug|Placebo|10 mg 2 times per day from Day 3 to 9 and one time on Day 10
1578648|NCT02393599|Drug|Cocaine Infusion|Screening / Session 1, Study Day -2: 20 mg cocaine, followed by a saline infusion, followed by 40 mg cocaine Baseline/ Session 2, Study Day 1: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Baseline / Session 3, Study Day 2: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline Treatment / Session 4, Study Day 9: Saline or 20 mg cocaine followed by either 20 mg cocaine or saline Treatment / Session 5, Study Day10: Saline or 40 mg cocaine followed by either 40 mg cocaine or saline
1578649|NCT02393586|Drug|Faropenem|Single oral dose
1578650|NCT02393586|Drug|Amoxicillin/clavulanic acid 500mg/125mg|Single oral dose
1578651|NCT02393586|Drug|Rifampicin|Single oral dose
1578652|NCT02393573|Drug|Metformin|Patients will take metformin for two weeks before Surgery and 2 days after the surgery
1578653|NCT02393573|Drug|Placebo|Patients will take Placebo pills for two weeks before Surgery and 2 days after the surgery
1578654|NCT02393560|Procedure|DECT scan|
1578655|NCT02393547|Drug|Varenicline|All subjects receive Varenicline
1578656|NCT02393547|Drug|Lorcaserin|All subjects receive Lorcaserin
1578657|NCT02393534|Other|Telephone Visit|Eligible patients that are randomized to the telephone follow-up arm will have their next medical visit with their primary care provider via a telephone call.
1578658|NCT02393521|Device|Shindo® vibration mattress|vibration therapy was self-administered while the subject was laying in supine in a polyurethane mattress
1578659|NCT02393508|Other|Fresh Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
1578660|NCT02393508|Other|Aged Human Red Blood Cells|Red cell units for transfusion will be acquired from Canadian Blood Services (CBS), as a part of their usual stock to the Calgary Zone. Blood will be processed and prepared by CBS according to their standard protocol. The red cell units assigned to patients as a part of this trial will not be manipulated in any way prior to participant transfusion.
1578661|NCT02393495|Device|intrauterine device TCu 380A|
1578662|NCT02393482|Drug|Estroprogestinic therapy (Etinil-estradiol/levonorgestre)|Etinil-estradiol/levonorgestrel (100 mcg/20 mcg)/die
1578663|NCT02393482|Drug|Gonadotropin-releasing hormone agonist (Leuprorelin acetate)|Leuprorelin acetate (3,75 mg/2 ml)/month
1578664|NCT02393482|Drug|Add back therapy 1 (tibolone)|tibolone 5 mg/die
1578665|NCT02393482|Drug|Add back therapy 2 (calcium carbonate/colecalciferol)|calcium carbonate/colecalciferol (500mg/400UI)/die
1578666|NCT02393469|Other|pulmonary rehabilitation|Exercises breathing exercises are performed on a cycle ergometer for 30 minutes, monitored by 50% of your maximum heart frequency, strengthening exercises for major muscle groups of the upper and lower limbs with charges based on 70% of one repetition maximum, muscle stretching test, and in expiratory pattern
1578961|NCT02391415|Biological|VPM1002|Tuberculosis vaccine
1578667|NCT02393469|Other|Education and self-management for COPD|Two months of continuous and self management for COPD where patients know their disease, pathophysiology, treatment, exacerbation of symptoms, and better ways pharmacological treatment education will be conducted through a system of multidisciplinary lessons with professional Physiotherapists, Psychologists, Dieticians, Pharmacists , Physical Education Professionals and Doctors
1578668|NCT02393456|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
1578669|NCT02393456|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
1578670|NCT02393443|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
1578671|NCT02393443|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter.
1578672|NCT02393430|Drug|Rebamipide|Rebamipide is a
1578673|NCT02393430|Behavioral|optimization of life style|
1578674|NCT02393417|Biological|CANDIN|Candida albicans Skin Test Antigen for Cellular Hypersensitivity
1578675|NCT02393417|Other|Placebo|0.9% Sodium Chloride Injection USP (non-preserved)
1578676|NCT02393404|Other|PT-FMT|Physiotherapeutic functional movement-power training
1578677|NCT02393404|Other|FMT alone|Physiotherapeutic power training
1578678|NCT02393391|Device|Neuroelectrics STARSTIM|
1578679|NCT02393378|Drug|Namilumab 150 mg|Namilumab 150 mg/mL solution for injection.
1578680|NCT02393378|Drug|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously
1578681|NCT02393378|Drug|Methotrexate|methotrexate at existing stable dose
1578682|NCT02393378|Drug|Folic Acid|
1578683|NCT02393365|Other|Questionnaire|All patients admitted to the one day clinic for surgery and gastroenterology will be asked, after signing an informed consent, to fill in a questionnaire about HCV risk factors.
1578684|NCT02393365|Procedure|HCV serology|"In case of a pre-operative blood sample an HCV serology will also be done as part of a routine pre-operative screening.
In patients where no pre-operative blood sample is done an additional consent will be asked to perform a blood sample for HCV serology. This qualifies the study as 'interventional' according to the Belgian legislation."
1578687|NCT02393339|Drug|paracetamol|Pre-operative administration of Paracetamol syrup
1578688|NCT02393339|Drug|placebo|Pre-operative administration of placebo syrup
1578689|NCT02393326|Procedure|partial pulpotomy with biodentine|After caries removal resulted in a pulp exposure, the pulp at the exposed area is amputated to a depth of 2 mm. The wound surface is irrigated and dried. After homeostasis is obtained, biodentine is gently applied to the wound surface, and then covered with reinforced zinc oxide-eugenol
1578690|NCT02393326|Procedure|Formocresol pulpotomy|Following removal of the coronal pulp and achievement of homeostasis, a cotton pellet moistened with formocresol (1: 5 Buckley's solution) is placed on the amputated pulp for 5 min. The pulp stumps is then covered by IRM.
1578691|NCT02393326|Drug|biodentine|
1578692|NCT02393326|Drug|formocresol|1: 5 Buckley's solution
1578693|NCT02393313|Procedure|Cataract surgery|Rayner T-flex Toric IOLs (573T / 623T; Rayner Intraocular Lenses Ltd,East Sussex, United Kingdom) will be implanted in the lens capsule
1578694|NCT02393313|Device|Rayner T-flex Toric IOLs|
1578695|NCT02393300|Drug|normal saline|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
1578696|NCT02393300|Drug|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
1578697|NCT02393300|Drug|Tranexamic Acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
1578698|NCT02393287|Other|Eribulin (ReProLine)|this is an observational trial ; there is no intervention
1578699|NCT02393274|Device|Extra-corporeal membrane oxygenation life support|venoarterial extra-corporeal membrane oxygenation life support
1578700|NCT02393261|Other|2500ml Huaren peritoneal dialysate|use 2-3 bags of 2500ml Huaren dialysate in the daytime and keep 1 bag of 2500ml Huaren dialysate in the night
1578701|NCT02393261|Other|2000ml peritoneal dialysate|use 3-4 bags of normal 2000ml dialysate in the daytime and keep 1 bag of 2000ml dialysate in the night
1578702|NCT02393248|Drug|INCB054828|
1578703|NCT02393248|Drug|Gemcitabine+Cisplatin|
1578704|NCT02393248|Drug|Pembrolizumab|
1578705|NCT02393248|Drug|Docetaxel|
1578706|NCT02393248|Drug|Trastuzumab|
1578707|NCT02393235|Other|doppler ultrasonography|Ovarian, uterine and spiral artery pulsatility index and resistance index will measure
2008523|NCT03329287|Behavioral|Psychological Placebo|Supportive and relaxation therapy, one our per session.
1578708|NCT02393222|Other|Observing effect of routine HD|Observing effect of routine HD via transcranial doppler, neurocognitive questionnaires and (in some) brain MRI
1578709|NCT02393209|Drug|Docetaxel|Docetaxel IV.
1578710|NCT02393209|Drug|MLN1117|MLN1117 orally.
1578711|NCT02393196|Drug|hydroxyethyl starch (% 6 HES 130/0.4) (Voluven®)|Before spinal anesthesia
1578712|NCT02393196|Drug|hydroxyethyl starch (%6 HES 130/0.4) (Voluven®)|Just after spinal anesthesia
1578713|NCT02393183|Drug|ASTED|A tablet of ASTED will be taken twice a day
1578714|NCT02393183|Dietary Supplement|Selenium|A tablet of 100 microgram of Selenium (same shape and color) will be taken twice a day
1578715|NCT02393183|Other|Placebo|A tablet of Placebo (same shape and color) will be taken twice a day
1578716|NCT02393170|Other|self-training using video-games|"Individuals will receive a video-game console and will be taught how to play the games.
They will be requested to play 60 minutes a day for 5 weeks."
1578717|NCT02393170|Other|traditional self-training|Individuals will receive a manual and equipment and will be taught how to perform the exercises. They will be requested to perform the exercises 60 minutes a day for 5 weeks.
1578718|NCT02393157|Drug|Obinutuzumab|Drug will be given alone in a pre-phase and in combination with ICE chemotherapy.
1578719|NCT02393157|Drug|Liposomal ARA-C|Will be given intrathecally for both prophylaxis and treatment of CNS disease.
1578720|NCT02393157|Drug|Ifosfamide|Ifosfamide 3000 mg/m2/day as a 2 hour IV infusion daily x 3 days (Days 0,1,2) of Cycle 1 and 2.
1578721|NCT02393157|Drug|Carboplatin|Carboplatin: 635 mg/m2 as 1 hour IV infusion on Day 0 only of Cycle 1 and 2.
1578722|NCT02393157|Drug|Etoposide|Etoposide: 100 mg/m2/day as 1 hour IV infusion daily x 3 days (Days 0,1,2).
1578723|NCT02393144|Device|Transperineal ultrasonography, General Electric Healthcare Voluson Ultrasound System|Assessment of cervical dilatation, angle of progression and head position via transperineal ultrasonography
1578724|NCT02393144|Device|Cardiotocography, Bionet FC1400 Fetal Monitor|Assessment of strength of uterine contractions (Montevideo units) and fetal heart rate (beat per minute) with electronic monitors.
1578725|NCT02393144|Other|Amniotomy|Artificial rupture of membranes to assess meconium staining and induce labor speed.
1578726|NCT02393144|Drug|Analgesics, Opioid, Meperidine|Administration of meperidine for labor analgesia.
1578727|NCT02393144|Drug|Labor augmentation, Oxytocin|Oxytocin infusion for augmentation of labor.
1578728|NCT02393144|Drug|Labor induction, Oxytocin|Oxytocin infusion for induction of labor.
1578729|NCT02393144|Drug|Cervical ripening, labor induction, Dinoprostone|Administration of dinoprostone pessary for cervical ripening and labor induction.
1578730|NCT02393131|Radiation|Hippocampal avoidance WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
1578731|NCT02393131|Radiation|Conformal WBRT|Conformal Whole Brain Radiotherapy 30 Gy in 10 fractions with Hippocampal Avoidance using Intensity modulated radiotherapy, Volumetric arc therapy, or Tomotherapy
1578732|NCT02393118|Device|BrainPort V200 Device|Training in clinic on use of the device for 2-3 days (10 hours) followed by in-home use for a minimum of 300 minutes per month over 12 months.
1578733|NCT02393092|Behavioral|Brief Violence Awareness|The Brief Violence Awareness (BVA) will consist of a packet of information about violence prevention and local community resources.
1578734|NCT02393092|Behavioral|Brief Violence Prevention|The Brief Violence Prevention (BVP) will be a psycho-educational intervention administered by a case manager that will include an interactive discussion with youth regarding resources for remaining safe and preventing violence. The intervention will address the concerns and questions of youth and youth will be given information on how to access community based resources if needed.
1578735|NCT02393092|Behavioral|Emerging Leaders: East End curriculum|The Emerging Leaders: East End curriculum focuses on positive youth development and education, which includes an emphasis on health careers. The curriculum will be administered at the Boys and Girls Club of Metro Richmond, Martin Luther King Middle School site.
1578736|NCT02393079|Device|Transcranial LED Therapy (TCLT)|Whereas the geometry of the skull and to uniformly distribute the light radiation, the TLTC is applied using as light source a set of LEDs installed in a helmet, emitting radiation in the range between 600nm and 650nm with a peak at 630nm, so in the red region.
1578737|NCT02393079|Device|Sham|A SHAM identical helmet will be used in the control group.
1578738|NCT02393066|Drug|Propofol|Sedation
1578739|NCT02393066|Drug|Dexmedetomidine|Sedation
1578740|NCT02393053|Procedure|Treatment with subepithelial connective tissue graft (SCTG)|Miller Class I or II gingival recessions were treated with subepithelial connective tissue graft (SCTG)
1578741|NCT02393053|Procedure|Treatment with non-pedicled buccal fat pad graft (BFPG)|Miller Class I or II gingival recessions were treated with non-pedicled buccal fat pad graft (BFPG)
1994156|NCT03057119|Behavioral|Goal-Setting (5 minutes)|The interventionist will use motivational interviewing techniques to identify the patients' most salient reasons for addressing substance use issues.
1578743|NCT02393027|Drug|[18F] LBT-999 PET|
1578744|NCT02393014|Procedure|Simple physical exercises|"The participant must stay out of the bed 3 hours. This pre-required level prevents the occurrence of acute postural mismatch which can occur when elderly patients are bedridden and too long increases the risk of falling.
The participant stands standing in static equilibrium to a chair holding the back of it for 2 minutes. Depending on the patient's abilities, the exercise will be done on both feet or one foot.
The participant performs a transfer activity of sitting to standing repeated 5 times (FTSS test). According to the patient's abilities, the exercise will be done with physical assistance or not."
2008524|NCT03329261|Drug|Clopidogrel|COPIGREL® - clopidogrel dosed at 75 mg per tablet
2008525|NCT03329248|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
2008526|NCT03329248|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
1578749|NCT02392988|Other|acupuncture treatment|acupuncture treatment
2008527|NCT03329248|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
2008528|NCT03329248|Biological|haNK for infusion|NK-92 [CD16.158V, ER IL-2]
2008529|NCT03329248|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
1578751|NCT02392975|Procedure|Fast MR|Enrolled subjects will undergo fast MR within 24 hours of CT completion. Subjects will be scanned using one of 2 Philips Ingenia MR 3T scanners. The estimated duration of the fast MR is less than 5 minutes, even if up to 2 sequences are repeated for motion.
1578752|NCT02392975|Procedure|Computed Tomography|The Investigator will recruit children in whom a head CT is ordered as standard of care for TBI. Consenting subjects will undergo fast MR shortly after CT and results will be compared.
1578753|NCT02392962|Procedure|Static Stretching|To analyze the immediate effects of static stretching on performance of sprinters
1578754|NCT02392962|Procedure|Dynamic Stretching|To analyze the immediate effects of dynamic stretching on performance of sprinters
1578755|NCT02392949|Behavioral|Passive mobilization|An anterior-posterior manual pressure act on the cervical spine of the subject
1578756|NCT02392949|Other|Placebo|The elbows will be put into a 90 deg elevated position and held for 5 secs, then back to resting position
1578757|NCT02392936|Procedure|Sternotomy for coronary artery bypass graft, valvuloplasty, aortic surgery or combined procedures, under extracorporeal circulation or not, in emergency or scheduled.|
1578758|NCT02392910|Drug|Iron Sucrose|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag contained 200 ml isotonic saline solution 0.9% plus 200 mg of Iron Sucrose. Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
1578759|NCT02392910|Drug|Placebo|At each visit, the patient lay on a stretcher and underwent a vein cannulation in the forearm with a commercial canula no. 16, which was connected to IV tubing that was connected to a bag of isotonic saline solution 0.9% (200 ml). Each infusion was administered throughout 60 min. This scheme was followed for 5 consecutive weeks.
1578760|NCT02392897|Behavioral|High Eating Frequency|Free-living participants will complete a 21-day high eating frequency (high EF) Phase in which consume all daily energy at 6 eating occasions.
1578761|NCT02392897|Behavioral|Low Eating Frequency|Free-living participants will complete a 21-day low eating frequency (low EF) Phase
1578762|NCT02392884|Behavioral|Cognitive Rehabilitation|Provide cognitive techniques and teach compensatory strategies that subjects can use to help them remember to attend appointments, take their medications regularly, increase attention (conversational and task) and concentration, increase cognitive flexibility, develop better problem-solving skills.
1578763|NCT02392871|Radiation|Palliative radiotherapy|
1578764|NCT02392871|Drug|Dabrafenib and trametinib (combination)|Patients should be taking dabrafenib and trametinib for at least 2 weeks prior to enrolment into the study.
1578765|NCT02392858|Other|Control group|Influenza is a major cause of morbidity and mortality. The investigators' first goal is to evaluate soluble HLA-G5 isoform serum level as a potential marker of greater risk of death from Influenza respiratory illness in adult and pediatric patients hospitalized in reanimation. Secondly, the investigators collected respiratory samples in order to study the transcriptomic profiles of influenza-infected patients with severe symptoms.
1578766|NCT02392845|Drug|Combination of Docetaxel (DTX) and Epirubicin (EPI)|Six cycles of densified DTX+EPI chemotherapy (2 weeks per cycle) for each patient
1578767|NCT02392832|Biological|Fourstar® granule, 90 day and 180 day briquettes Bti/Bs|"In 2015: Two sites each in Kakamega and Vihiga counties in western Kenya will be randomly selected and treated with larvicides (intervention) and the other two sites will serve as control (no-intervention). Temporary habitats will be treated with FourStar® controlled release granule formulation, semi-permanent habitats will be treated with 90 day briquettes, and permanent habitats with 180 day briquettes. No retreatment.
Starts from 2016, fourteen sites in each of the two study sites will be assigned to treatment or control by a block randomization method. The Bti treatment will be the same as in 2015. The retreatment interval will be 4-5 months. After the third treatment, no treatment will be performed for the next 8 months. After this, a cross over will be performed. Previous control sites will receive 3 rounds of the same LLML treatment at appropriate time intervals and previous treatment sites will not receive any LLMLs."
1578768|NCT02392819|Dietary Supplement|Panax ginseng|Pananx ginseng is provided prior to a standardised breakfast, effects on test variables are determined at fasting and repeatedly postprandially the breakfast
1578769|NCT02392819|Dietary Supplement|Placebo|
2008530|NCT03329248|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
2008531|NCT03329248|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
1578772|NCT02392793|Drug|Talazoparib|Given orally once or twice on day 1 (depending on the dose level), then daily on days 2-6.
1578773|NCT02392793|Drug|Irinotecan|Given intravenously daily, days 2-6 immediately following the talazoparib dose.
1578774|NCT02392793|Drug|Temozolomide|Given orally daily. Dose to be determined after MTD established with talazoparib plus irinotecan.
1578775|NCT02392793|Drug|Filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless peg-filgrastim is given.
1578776|NCT02392793|Drug|Peg-filgrastim|Given subcutaneously (SubQ) once per day starting 24-36 hours after last dose of chemotherapy and continuing until post-nadir ANC is >2,000/μL, unless filgrastim is given.
1578777|NCT02392780|Drug|Cannabidiol|Oral cannabidiol at a dose of 150 mg BID up to 90 days.
1578778|NCT02392780|Drug|Methylprednisolone|IV methylprednisolone 2 mg/kg/day
1578779|NCT02392780|Drug|Calcineurin inhibitor|cyclosporine with dose adjusted based on drug trough levels (200-400 ng/ml) or tacrolimus with dose adjusted on drug trough levels (5-15 ng/ml)
1578780|NCT02392767|Dietary Supplement|Verum|2400 mg L-arginine, 80 mg Pycnogenol, 45µg vitamine K2, 10 mg R (+) alpha lipoic acid, 8 mg vitamine B6, 500 µg vitamine B12, and 600 mg folic acid.
1578781|NCT02392767|Dietary Supplement|Placebo|corn starch
1578782|NCT02392754|Device|Screening: Intervention - Atrial fibrillation screening (ZIO XT ECG monitor, Watch-BP)|The intervention group receives AF screening with a 2-week ambulatory ECG patch monitor (ZIO XT Patch) worn at baseline and again at 3 months, in addition to standard care for 6 months. The intervention group also receives a home BP monitor with automatic AF detection capability to be used twice daily for 2 weeks during the ECG monitoring periods.
1578962|NCT02391415|Biological|BCG|commercially available live vaccine BCG
2008532|NCT03329248|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
1578783|NCT02392741|Other|Physical exercise program|The intervention consists to an exercise program composed by a daily post prandial, 10' after breakfast, lunch and dinner, totaling 150' weekly, for eight weeks.
1578784|NCT02392728|Behavioral|Immersive Virtual Reality (VR)|Patients in this group will experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller. Following a resting period the patients will then experience the guided imagery session (e.g. visual images of pleasant scenery)
1578785|NCT02392728|Behavioral|Guided Imagery|Patients in this group will experience the guided imagery (e.g. visual images of pleasant scenery). Following a resting period the patients will then experience the virtual content (e.g., natural scenes) through a Head-Mounted-Display, simulating movement by manipulating a gesture controller
1578786|NCT02392715|Device|Inspiratory muscle training with Threshold by respironics|"Inspiratory muscle training
15 minutes, 3x/weeks, 36 sessions
Intensity: 15% of PiMax during the first week. Then increment of 5% each session until 60% of PiMax after the first month. The PiMax will be reassessed after 12 and 24 sessions in order to readjust the 60% of PiMax."
1578787|NCT02392715|Device|Sham Inspiratory muscle training|"with Threshold by respironics
15 minutes, 3x/weeks, 36 sessions
Intensity: 5 centimeters of water (cmH20)"
1578788|NCT02392702|Drug|C-10355|
1578789|NCT02392702|Drug|C-10358|
1578790|NCT02392702|Drug|Kalydeco|
1578791|NCT02392689|Other|Procalcitonin|Procalcitonin guided antibiotic therapy
1578792|NCT02392676|Drug|OLAPARIB|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
1578793|NCT02392676|Drug|PLACEBO|Patients should continue with therapy until objective radiological disease progression as per RECIST 1.1 despite rises in CA-125. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
1578794|NCT02392663|Other|Hypertonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
1578795|NCT02392663|Other|Hyaneb solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
1578796|NCT02392663|Other|Isotonic saline solution|All patients will perform 4 sessions during the same week. Each session will be include: inhalation period + bronchial drainage period. 20 minutes will be spent to perform the inhalation period. Moreover, 30 minutes will be spent to complete the bronchial drainage session post-inhalation.
1578797|NCT02392637|Drug|Abraxane (Nab-Paclitaxel)|100 mg/m2 by vein on Day 1 and Day 8 of a 21 day cycle.
1578798|NCT02392637|Drug|Cisplatin|25 mg/m2 by vein on Day 1 and Day 8 of a 21 day cycle.
1578799|NCT02392637|Drug|Gemcitabine|800 mg/m2 by vein on Day 1 and Day 8 of a 21 day cycle.
1578800|NCT02392637|Behavioral|Phone Calls|Participant receives phone call from study staff 30 days after last dose of study drugs, and every 12 weeks thereafter.
1578801|NCT02392624|Drug|Omalizumab|Omalizumab 300 mg administered SC Q4W.
1578802|NCT02392624|Drug|Placebo|Placebo matched to omalizumab administered SC Q4W.
2008533|NCT03329248|Drug|Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
2008534|NCT03329248|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
1578806|NCT02392585|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
1578807|NCT02392585|Procedure|Triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
1578808|NCT02392572|Drug|ONC201|"Phase I Starting dose of ONC201: 125 mg by mouth once every 3 weeks.
Phase II Starting dose of ONC201: MTD from Phase I."
1578809|NCT02392559|Drug|Evolocumab|Dose of subcutaneous Evolocumab every 4 weeks
1578810|NCT02392559|Drug|Placebo|Dose of subcutaneous placebo treatment every 4 weeks
1578811|NCT02392546|Drug|elobixibat|
1578812|NCT02392546|Drug|placebo|
1578813|NCT02392533|Other|Education|Education
1578814|NCT02392520|Drug|cetrorelix (cetrotide)|0.25 mg GnRH antagonist cetrorelix will be administered once daily for 4 days, starting on the day of severe early OHSS diagnosis
1578815|NCT02392520|Drug|Placebo|intravenous albumin administration, paracentesis of ascitic fluid, correction of electrolyte imbalance and intravascular volume
1578816|NCT02392507|Drug|Necitumumab|Administered IV
1578817|NCT02392507|Drug|Nab-Paclitaxel|Administered IV
1578818|NCT02392507|Drug|Carboplatin|Administered IV
1578819|NCT02392494|Drug|MK-1075|MK-1075 will be supplied as 10 mg or 100 mg tablets for oral administration.
1578820|NCT02392481|Procedure|Biofluid sampling|
1578821|NCT02392468|Drug|BI 409306 matching placebo|placebo
1578822|NCT02392468|Drug|BI 409306 matching placebo|placebo
1578823|NCT02392468|Drug|BI 409306|low dose
1578824|NCT02392468|Drug|BI 409306|high dose
2008535|NCT03329248|Drug|nab-Paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
2008536|NCT03329248|Drug|lovaza|Omega-3-acid ethyl esters
2008537|NCT03329248|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
2008538|NCT03329248|Procedure|SBRT|Stereotactic Body Radiation Therapy
2008539|NCT03329235|Drug|PRP|platelet rich plasma
2008540|NCT03329235|Drug|HA|hyaluronic acid
2008541|NCT03329222|Other|Specific hydrolysed proteins|An infant formula which contains specific hydrolysed proteins with a fat blend, prebiotics mixture, starch and reduced lactose
1578835|NCT02392390|Procedure|Topical Dynamic Phototherapy (TDP)|Metvixia cream is applied to the lesion (about 1mm thickness) and the treated zone is covered with an opaque dression for 3 hours. Any residual cream is removed an and the lesion immediately rinsed with saline solution when uncovering. One session (8 minutes) of phototherapy is then performed using an Altilite lamp in accordance with HAS (haute authorité de santé) recommendations.
1578836|NCT02392390|Drug|Metvixia cream|
1578837|NCT02392377|Drug|Paclitaxel|Given IV or IVPB
1578838|NCT02392377|Drug|Carboplatin|Given IV or IVPB
1578839|NCT02392377|Drug|Oxaliplatin|Given IV
1578840|NCT02392377|Drug|Leucovorin Calcium|Given IV
1578841|NCT02392377|Drug|Fluorouracil|Given IV
1578842|NCT02392377|Radiation|Radiation Therapy|Undergo radiation therapy
1578843|NCT02392377|Procedure|Therapeutic Conventional Surgery|Undergo esophagectomy
1578844|NCT02392377|Other|Laboratory Biomarker Analysis|Correlative studies
1578845|NCT02392364|Drug|Intravitreal Aflibercept Injection|
1578848|NCT02392338|Procedure|Hybrid procedure|Eletrophysiologic study via femoral vein approach to confirm pulmonary vein isolation lesion and box lesions in left atrium
1578849|NCT02392325|Biological|rDEN1Δ30|Administered subcutaneously in 0.5 mL containing 10^3.0 plaque-forming units (PFU)
1578850|NCT02392325|Biological|Placebo|Administered subcutaneously in 0.5 mL
1578851|NCT02392325|Biological|rDEN2Δ30-7169|Administered subcutaneously in 0.5 mL containing 10^3.0 PFU
1578852|NCT02392312|Drug|ATF-Fresenius S|intravenous
1578853|NCT02392286|Drug|Corticosteroid|Subjects will receive prednisone orally; if intravenous corticosteroid required initially they will receive methylprednisolone for the first 3-4 days of therapy.
1578854|NCT02392273|Drug|Ausanil|Patients with Primary Headache disorders will receive Ausanil in the context of usual and routine clinical care.
1578855|NCT02392260|Device|Vasculight|Comparative measre of Pulse Wave velocity with both Vasculight prototype and Echocardiographic machine.
1578856|NCT02392247|Device|Coagulation function|Coagulation function assessment tools TEG (standard of practice) vs SEER Quantra (novel coagulation function device)
1578857|NCT02392234|Drug|VX-661/ivacaftor|
1578858|NCT02392234|Drug|ivacaftor|
1578859|NCT02392234|Drug|VX-661/ ivacaftor placebo|
1578860|NCT02392234|Drug|ivacaftor placebo|
1578861|NCT02392208|Drug|Telavancin|A single 5 mg/kg dose of telavancin is administered intravenously (IV).
1578862|NCT02392208|Procedure|Pharmacokinetic Blood Sampling|Blood samples are collected to assess telavancin plasma concentrations.
1578863|NCT02392195|Other|Non-interventional|Observational
1578864|NCT02392182|Other|Fiberoptic bronchoscopy|All subjects will undergo a research fiberoptic bronchoscopy under moderate conscious sedation. There is no randomization
1578865|NCT02392169|Drug|Methylphenidate|Patients used Retina or Concerta twice a day lasting for one year.
1578866|NCT02392156|Biological|rFVIIIFc|As described in the treatment arm
1578867|NCT02392156|Biological|rFIXFc|As described in the treatment arm
1578868|NCT02392156|Drug|non-Fc FVIII replacement products|Standard plasma-derived (pd) or recombinant (r) FVIII concentrate and other traditional treatment options
1578869|NCT02392156|Drug|non-Fc FIX replacement products|Standard plasma-derived (pd) or recombinant (r) FIX concentrate and other traditional treatment options
1578870|NCT02392143|Other|Printed Education Material|The printed education material described the importance of early detection and prevention, risk factors, and the importance of talking to your doctor about CRC screening. The PEM highlighted colonoscopy as being the only test that can identify and prevent CRC and described how to prepare for a colonoscopy beginning seven days prior to the test [18]. The PEM also described other CRC screening tests, including the FOBT, FIT, sigmoidoscopy, barium enema and virtual colonoscopy.
1578871|NCT02392143|Other|Academic Detailing|Academic detailing (AD) involved an in-person visit from a member of the research team who attempted to communicate strategies for improving CRC screening uptake in the practice's patient panel. A brief description of the RCT was followed by a semi-structured interview assessing usual practice regarding CRC screening referral and follow up. The direction of the discussion was guided by PCP responses. A variety of resources were provided. Specific directives were following up to make sure patients had made appointments with a gastroenterologist and offering home stool tests. The detailer attempted to elicit a verbal commitment to do at least one new thing to strengthen the probability that patients would be screened.
1578872|NCT02392143|Other|Academic Detailing+Telephone Education|PCPs received AD as described in the Academic Detailing arm. In addition, participants received tailored telephone education (TTE) which focused on identifying and addressing barriers that might impede screening. Verbal commitments were elicited to speak with their PCP and make an appointment for a colonoscopy, or request a home stool test, as appropriate. Follow-up calls assessed progress towards achieving goals.
1578873|NCT02392130|Drug|Clobetasol propionate 0.05% ointment|
1578874|NCT02392130|Drug|LEO 130852A gel 1%|
1578875|NCT02392130|Drug|LEO 130852A placebo gel|
1578876|NCT02392117|Drug|insulin degludec|Tresiba® will be prescribed by the physician under normal clinical practice conditions and will be obtained/ purchased from the chemist based on physician prescription. No treatment given.
1578963|NCT02391415|Biological|VPM1002(Hyg+)|Tuberculosis vaccine
1579933|NCT02384421|Device|Continuous DBS (Activa PC+S Neurostimulator)|
1578877|NCT02392104|Drug|Warfarin|If the patient's INRs stay within goal range, their interval of INR follow-up will be extended based on a protocol to a maximum of 12 weeks.
1578878|NCT02392078|Device|NeuroBlate System|
1578879|NCT02392052|Behavioral|Reinvention Protocol Participants|A cognitive behavioral therapy (CBT), to enhance self-efficacy skills for caregivers of family members with SCI, with a focus on changing thinking styles to help people make emotional and behavioral changes.
1578880|NCT02392052|Behavioral|Wait List|This group will include individuals randomized to receive no treatment for the 18 weeks during which the interventional group will receive the active treatment and have their progress tracked.
1578881|NCT02392039|Drug|Pegfilgrastim|6 mg subcutaneously between 24 and 72 hours after completion of chemotherapy once per 21 day cycle.
1578882|NCT02392039|Drug|Loratadine|"Group 1 - Cycles 1 and 3: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
Group 2 - Cycle 2 and 4: Loratadine 10 mg by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
1578883|NCT02392039|Other|Placebo|"Group 1 - Cycle 2 and 4: Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days.
Group 2 - Cycle 1 and 3 : Placebo by mouth daily, starting on the day of Pegfilgrastim administration and continuing for a total of 7 days."
1578884|NCT02392039|Behavioral|Questionnaires|Three questionnaires completed about bone pain and quality of life. These are completed before Pegfilgrastim received during Cycles 1 - 4 (and if participant has pain, during Cycles 6 - 7), on Day 7, and 8 weeks after last dose of study drugs.
2008542|NCT03329222|Other|Standard cow's milk with prebiotics mixture|Standard cow's milk with prebiotics mixture
1578886|NCT02392013|Other|Home Modification|Removal of home barriers or hazards.
1578887|NCT02392000|Device|WatchPAT sleep monitor|Self-management of insomnia using a mobile sleep device
1578888|NCT02392000|Behavioral|CBT-i Coach mobile app|Self-management of insomnia using a mobile app based on Cognitive Behavioral Therapy for Insomnia
1578889|NCT02391987|Device|Tele-monitoring and health coaching|"Tele-monitoring involves a personal monitoring system used to analyze data to provide relevant health information back to the treating clinician and the user. The monitoring system remotely monitors electrocardiographic (ECG) signals, heart rate, breathing rate, and activity levels. Additional devices will be integrated with the monitoring device to assess blood pressure and weight.
Health Coaching involves a team of health care professionals including a registered nurse (RN) . The health care team creates a plan specific to the patient and provides guidance on nutrition' medications, and exercise. The data collected by the remote monitoring device will assist the care team in patient management."
1578890|NCT02391974|Device|PERIOSYAL FILL|"Injection 2 weeks after standard periodontal treatment procedure on all teeth that need to be treated.
Touch-up treatment provided at 3 and 6 weeks."
2008543|NCT03329209|Drug|Vedolizumab|Vedolizumab IV infusion
2008544|NCT03329196|Drug|MT-6548|Oral tablet
1994157|NCT03057119|Behavioral|Identifying and prioritizing needs (5 minutes)|The interventionist will use problem-solving techniques to help patients identify which services may best help them work towards their goals. Services will include (but are not limited to) emergency crisis services, counseling to deal with substance use, referral to local self-help groups (Alcoholics Anonymous, Narcotics Anonymous, etc.), legal assistance, faith-based counseling, mental health counseling or inpatient substance use treatment.
1994158|NCT03057119|Behavioral|Explanation of Peer Navigator and Session wrap (5 minutes)|The interventionist will use a referral resource guide to provide the contact information of agency representatives and help the patient formulate a plan for follow-up.
2008545|NCT03329196|Drug|Darbepoetin alfa|Subcutaneous
1578896|NCT02391922|Behavioral|First aid course|
1578897|NCT02391922|Behavioral|First aid instructions by mobile phone|
1578898|NCT02391909|Biological|Vivotif|
1578899|NCT02391896|Device|Dual energy and tomosynthesis xray|
1578900|NCT02391883|Drug|Clopidogrel|
1578901|NCT02391870|Behavioral|MBCT-PD|Using an iterative process, the investigators modified MBCT to include a focus on perinatal depression (MBCT-PD). The modifications took into account developmental processes associated with the perinatal period, characteristics and correlates of perinatal depression, and the physical aspects of pregnancy.
1578902|NCT02391857|Procedure|Gastric decompression|Insertion the Naso(Oro)-gastric tube for early gastric decompression during CPR
1578903|NCT02391844|Drug|Oxycodone|Oxycodone with Acetaminophen Extended Release
1578908|NCT02391805|Drug|Entecavir|Entecavir will be administered as per local labeling.
1578909|NCT02391805|Drug|Placebo|Participants will be administered PO placebo capsules matched to RO6864018, either QOD or QWk for 12 weeks of treatment.
1578910|NCT02391805|Drug|RO6864018|Participants will be administered RO6864018 as 200-mg PO capsules at a dose of 800 mg or 1200 mg, either QOD or QWk for 12 weeks of treatment.
1578911|NCT02391805|Drug|Tenofovir|Tenofovir will be administered as per local labeling.
1578912|NCT02391779|Dietary Supplement|BeneFlax®|Daily ingestion of 600 mg SDG/day in 1.6 g SDG-enhanced flax lignan (BeneFlax®) with walking training or flexibility training
1578913|NCT02391779|Behavioral|Walking training|30-60 minutes walking training, 5 days/week.
1578914|NCT02391779|Behavioral|Flexibility training|5 days/week; e.g. stretching training at home
1578915|NCT02391779|Dietary Supplement|Placebo (Whey Protein)|0.6 g/day (an amount equal in volume to BeneFlax®) with walking training or flexibility training
1578916|NCT02391779|Behavioral|Dash Eating Plan|Dietary Approaches to Stop Hypertension (DASH), a balanced eating plan - all participants in all treatment arms will be encouraged to adopt a DASH eating plan.
1578917|NCT02391766|Behavioral|empowerment|"The groups of 10 participants meet once a week for eight weeks. last for four hours
topics on dementia and prevention of further cognitive decline, active lifestyle and emotional well-being, spousal relationship, future planning kinds of active learning used are working in pairs and brainstorming sessions."
1578918|NCT02391766|Behavioral|usual care|
1579037|NCT02390869|Drug|R2-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles B) Lenalidomide (10 mg daily on days 1-21 every 28 days) for 24 cycles
1579038|NCT02390869|Drug|R-MANT|A) Rituximab 375 mg/sqm on day 1 every 90 days for 8 cycles
1578919|NCT02391753|Device|Transperineal 3D Ultrasound|Imaging was performed with women in lithotomy position with empty bladder. The probe was covered with a sterile film and placed on the perineum in the sagittal plane. The field of view angle was set to a maximum of 70° in the sagittal plane and the volume acquisition angle to 85° in the axial plane. Analysis of stored volumes was conducted offline by another experienced investigator blinded to clinical and delivery data.
1578920|NCT02391740|Other|Questionnaire|
1578921|NCT02391727|Biological|SYN004|subjects who have received effective treatment for their cancers are eligible
1578922|NCT02391714|Procedure|IUD insertion|The IUD (Mirena® or ParaGard®) insertion procedure will occur in the usual manner for both arms. A bimanual exam will be performed, the speculum placed and the cervix visualized. The cervix will then by cleaned with iodine solution. If you are allergic to iodine, we will use chlorhexidine instead. A tenaculum will be placed on the cervix and a uterine sound will be used to measure cavity length. The Mirena® or ParaGard® IUD will be inserted with the specific introducer.
1578923|NCT02391714|Drug|Povidone-Iodine|Povidone-Iodine 10% w/w antiseptic swab for the cervix prior to IUD insertion.
1578924|NCT02391714|Drug|Chlorhexidine|For patients with allergy to iodine - 2% w/v chlorhexidine gluconate and 70% v/v isopropyl alcohol antiseptic swab for the cervix prior to IUD insertion.
1578925|NCT02391714|Other|Oxygen|100% oxygen via nasal mask.
1578926|NCT02391714|Other|Nitrous oxide|Given in a fixed dose ratio of 50% nitrous oxide/50% oxygen via nasal mask.
1578927|NCT02391701|Behavioral|Diet|diet program 1 day a month for 3 months in 120-minute diet sessions + freely receive Atlantic Diet food (vegetables, cheese, olive oil, mussels and wine)
1578928|NCT02391688|Drug|Caffeine, omeprazole, flurbiprofen, dextromethorphan, midazolam|
1578929|NCT02391688|Drug|Bupropion|
1578930|NCT02391688|Drug|Fexofenadine|
2008546|NCT03329183|Drug|Irinotecan|High-dose FOLFIRI regimen (Irinotecan 260mg/m2 2h, leucovorin 400mg/m2, 5- fluorouracil 400mg/m2 , 5- fluorouracil 2400 mg/m2 46h, 14 days per course)
1578933|NCT02391649|Behavioral|bibliotherapy program|The PSBBP in this study consists of 5 modules (Module 1: Caregiver's well-being; Module 2:Getting the best out of support services; Module 3:Well-being of the person with schizophrenia; Module 4:Dealing with the [psychosocial] effects of the illness; and Module 5:Dealing with [physical and mental health] effects of the illness), helping each caregiver from developing a positive attitude to caregiving, identifying caring related problems and obstacles, predicting positive and negative implications of each alternative, to trying out the solution and monitor if it worked.
1578934|NCT02391649|Behavioral|Psycho-education program|The program consists of 12 two-hour sessions held weekly/biweekly completed in 5 months, with 4 main components, including 'introduction and goal setting'; 'an education workshop on mental illness, treatment and community services'; 'group exercises/rehearsals and discussion on symptom management, coping and self-care'; and 'review and future plan'.
1578935|NCT02391636|Drug|Carbetocin|at delivery of anterior shoulder
1578936|NCT02391636|Drug|Oxytocin|at delivery of anterior shoulder
1578937|NCT02391623|Drug|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=8).
1578938|NCT02391623|Drug|Placebo|Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
1578939|NCT02391623|Drug|PF-06427878|PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
1578940|NCT02391623|Drug|Placebo|Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
1578941|NCT02391610|Other|No intervention|
1578942|NCT02391584|Device|XprESS|Balloon dilation of the Eustachian tube
1578943|NCT02391584|Other|Control|Continued current medical management
1578944|NCT02391571|Drug|Oxycodone/Naltrexone Capsules|Oxycodone/Naltrexone to be taken with stable dose of Methadone
1578945|NCT02391571|Drug|Oxycodone|Oxycodone to be taken with stable dose of Methadone
1578946|NCT02391571|Drug|Placebo|2 day placebo run in prior to test and active drug phase of study
1578947|NCT02391545|Drug|IPI-145 (duvelisib)|PI3K Inhibitor
1578948|NCT02391545|Drug|Rituximab|
1578949|NCT02391545|Drug|Obinutuzumab|
1578950|NCT02391532|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|Ingestion of active lozenge twice daily for 12 weeks
1578951|NCT02391532|Dietary Supplement|Placebo|Ingestion of placebo lozenge twice daily for 12 weeks
1578952|NCT02391519|Procedure|Collection of myometrial, cord blood, and placental tissue samples|We propose to collect myometrial, cord blood, and placental tissue samples from women at high altitude (Summit County) and low altitude (Denver) in Colorado in order to determine if residence at altitude during pregnancy changes the vasoreactivity of myometrial arteries (MA).
1578953|NCT02391506|Device|Cartiva|Cartiva Synthetic Cartilage Implant
1578954|NCT02391493|Device|functional magnetic resonance imaging|"Stimuli will be presented in 3 language conditions, French, English and switch in which the participant alternates between English and French every trial. A block design will be used, with 7 line drawings per language condition. Four 9-minute runs will be performed, there being 2 action runs and 2 object runs. In each run, there are 6 blocks of each language condition, presented in a fixed random order. No drawings are repeated. Each stimulus is preceded either by an English or a French prompt word (to or faire for actions and, say or dire for objects) for 450 msec; stimuli are presented for 1.5 seconds and followed by a blank screen for 1 second. Language blocks are separated by a variable duration (from 8 to 10 seconds)."
1578955|NCT02391480|Drug|ABBV-075|ABBV-075 Oral tablets
1578956|NCT02391480|Drug|Venetoclax|Venetoclax tablets, film-coated
1578957|NCT02391454|Device|RunKeeper App|Group B will use the RunKeeper app for 12 weeks to self-monitor PA. In the scope of this study, patients merely have to self-monitor PA (e.g. swimming, biking, hiking, running) by GPS or stopwatch function with RunKeeper. Furthermore, patients are requested to activate the 'training reminder' option in the RunKeeper app, which is explained in the user's manual.
1578958|NCT02391454|Other|Usual care|
1578959|NCT02391428|Procedure|blood test|Blood test: Small volume (3 ml) of blood will be taken by venipuncture into ethylenediaminetetraacetic acid (EDTA) tube.
1578960|NCT02391428|Dietary Supplement|omega3 capsules|Only ADHD children will be given a supply of omega3 capsules (containing 400 mg EPA and 200 mg DHA)
1578964|NCT02391402|Behavioral|Cognitively Augmented Behavioral Activation|CABA uses Behavioral Activation (BA) to identify meaningful goals and activities while learning cognitive skills to aid in working toward those goals. Early sessions of CABA focus on learning about mTBI, PTSD, and lifestyle skills that can improve thinking abilities and mood. Cognitive skills taught each week include internal and external skills to help manage problems with memory, attention, and regulation of thinking processes. Investigators and patients will spend a part of each session applying the cognitive skills to managing real life situations and getting patients active in the service of personal goals.
1578965|NCT02391402|Behavioral|Treatment as Usual|"TAU care involves psychotherapy (counseling) provided by a specialist in the treatment of PTSD. Patients will be offered individual appointments with an experienced provider on the PTSD Clinical Team (PCT). Beyond this, the specific approach will be determined by the patient and his/her provider and may include skills for managing PTSD and/or a chance for the patient to process his/her traumatic experiences. Additional treatments may be offered to patients, such as group classes and medications. TAU care may also include additional evaluation and/or treatment of mTBI, provided by the usual care offered in Portland or Seattle's respective neuropsychology clinics. Treatment for mTBI includes individual or group sessions, and is based on clinical need."
1578966|NCT02391389|Procedure|CPAP or PPV during DCC|CPAP or PPV is provided during delayed cord clamping
1578967|NCT02391376|Other|moist heat pack; ;|Three sessions of 15 minutes of superficial heat through a moist heat pack-MHP applied on the lower back.
1578968|NCT02391376|Other|seed pack|Three sessions of 15 minutes of superficial heat through a seed pack-SP applied on the lower back.
1578969|NCT02391376|Other|gel pack|Three sessions of 15 minutes of superficial heat through a gel pack-GP applied on the lower back.
1578970|NCT02391363|Behavioral|Cognitive behavior treatment|Anxiety management skills with the option to included religious/spiritual beliefs and practices
1578971|NCT02391363|Behavioral|Information and referral|Resource counseling and follow-up for mental health and basic needs
1578972|NCT02391350|Behavioral|Education and re-assurance|Patients are provided the Back Book and the contents are reviewed emphasizing the favorable natural history of back pain and sciatica and the importance of remaining active.
1578973|NCT02391350|Procedure|Physical Therapy|Physical therapy will consist of repeated exercises, spinal mobilization and mechanical traction in an effort to maximize centralization of symptoms.
1578974|NCT02391337|Drug|Bisoprolol|Drug intervention
1578975|NCT02391337|Drug|Digoxin|Drug intervention
1578976|NCT02391324|Procedure|Lokomat (LOK)|Physical therapy provided using a robotic gait training system (Lokomat).
1578977|NCT02391324|Procedure|Gait focused physical therapy (fPT)|Overground physical therapy focussed on enhancing gait related motor skills
1578978|NCT02391324|Procedure|LOK + fPT|A combination of robotic gait training and gait focussed functional physical therapy.
1578979|NCT02391311|Device|transcranial direct current stimulation (tDCS)|tDCS is a low level electrical stimulation that will be applied to F10. The sham group will receive 2 mA (milliamps) for 30 seconds, while the experimental group will receive 2 mA for 20 minutes. Both groups will have 10, 1 hour sessions of playing cognitive remediation games, while receiving the respective level of tDCS for sham vs experimental conditions.
1578980|NCT02391298|Behavioral|Mindfulness Meditation|
1578981|NCT02391285|Device|dynamometer (Auckland vaginal elastometer)|"The elastometer is a modified vaginal speculum which captures pelvic muscle tone over 3 minutes and records this on an attached computer. In addition to the elastometer test, there are three further related tests, which patients would be suitable to participate in.
I. a questionnaire to fill in so as to obtain some feedback from patients regarding what they thought of the test and the device.
II. The investigators would like to repeat the elastometer measurement within a week of the first test to determine the reliability and accuracy of repeating the measurement after a few days.
III. The investigator would like to request that the patient have an MRI scan of the pelvic muscles to check whether the elastometer can pick up functional muscle weakness that would not otherwise be recognised except by performing an MRI scan. The investigators will therefore compare elastometer readings to the MRI scan findings."
1578982|NCT02391272|Drug|rhTPO|
1578983|NCT02391259|Drug|AMG 557|AMG 557 is for the treatment of sybjects with systemic lupus erythematosus
1578984|NCT02391259|Drug|Placebo|contains no active drug
1578985|NCT02391246|Other|Positron Emission Tomography Imaging|Participants will receive an intravenous injection of 250 MBq (megabecquerels) of 18F-Fluorodeoxyglucose (18F-FDG). The first Positron Emission Tomography (PET) acquisition of the head will occur one hour post-injection. The second acquisition will take place 3 hours post-injection. Both early and late PET images will be manually co-registered with the participant's most recent magnetic resonance images.
1578986|NCT02391233|Behavioral|E-WORTH|E-WORTH (Empowering African-American Women on the Road to Health) consists of 1 Streamlined HIV Testing session followed by 5 one-and-a-half hour group sessions that will be delivered by a probation provider at the probation site. The main multimedia components used in the E-WORTH: (1) Narrativity; (2) Skill acquisition using simulated video vignettes that provides instruction and demonstration of core skills (e.g., safer sex negotiation and problem-solving skills, technical condom use skills) using culturally congruent role models; (3) Individual interactive exercises and logs that are designed to enhance participant's recall of core knowledge and tracking of their individual progress in reducing risky behaviors and achieving risk reduction goals; and a (4) Facilitator interactive guide.
1578987|NCT02391233|Behavioral|Streamlined HIV Testing|In this intervention Black Women on Probation receive streamlined HIV Testing alone to test primary outcomes of decreasing biologically confirmed STIs and the number and proportion of unprotected sexual acts among Black Drug-involved women on probation.
1578988|NCT02391220|Other|LCA symbiotic fermented milk|LCA symbiotic fermented milk with the probiotic cultures Lactobacillus acidophilus La-5® and Bifidobacterium animalis ssp. lactis BB-12® and the Beneo dietary fibers.
1578989|NCT02391220|Other|heat-treated fermented milk|heat-treated fermented milk without probiotic cultures and dietary fibres
1578990|NCT02391207|Procedure|Hepatic vein-sparing hepatectomy|HV detachment, partial resection and section on the basis of HV-CLM relationship
1578991|NCT02391194|Drug|AVB-620|
1579079|NCT02390609|Drug|Ibrutinib (Treatment D)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment D under fasted conditions in one of the treatment periods.
1578992|NCT02391181|Drug|Iron Sucrose Azad|Test product Iron Sucrose Azad will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of test product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
1578993|NCT02391181|Drug|Venofer®|Reference product Venofer® will be administered intravenously via a 18 gauge (18G) needle. For intravenous injection, a 5 mL single dose of reference product (each mL containing 20 mg/mL elemental iron as iron sucrose in water for injection) will be diluted in 0.9% isotonic sterile sodium chloride (NaCl) up to 15 mL. The injection solution will be intravenously administered to the forearm vein, resulting in a total injection volume of 15 mL administered over a period of 5 minutes.
1578994|NCT02391155|Procedure|single lumen needle in oocyte retrieval|single lumen needle use during oocyte retrieval
1578995|NCT02391155|Procedure|double lumen needle in oocyte retrieval|after aspiration of follicles, 3 times flushing will be performed in double lumen needle.
1578996|NCT02391142|Drug|Lidocaine|0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
1578997|NCT02391129|Procedure|Operation for Periprosthetic fractures of the hip with stem loosening|
1578999|NCT02391103|Device|Compex 3 Professional (CefarCompex Medical AB) stimulator|NMES
1579000|NCT02391103|Device|sham-stimulation|no electricity applied
1579001|NCT02391090|Device|hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
1579002|NCT02391090|Device|sham hypoxia in hypoxic chamber|Intervention lasts 4 hours per day for 6 days in a row.
1579003|NCT02391090|Procedure|Pulse oximetry|Pulse oximetry will be performed hourly during sessions in the hypoxic chamber for safety reasons.
1579004|NCT02391090|Other|Asthma and Quality of Life Questionnaires|Before every session in the hypoxic chamber as well as on the day after the last session will be completed.
1579005|NCT02391090|Procedure|Lung function testing|On the day of the first session in the hypoxic chamber as well as on the day after the last session lung function testing will be performed.
1579006|NCT02391090|Procedure|Blood taking|On the day of the first session in the hypoxic chamber as well as on the day after the last session blood samples will be taken.
1579007|NCT02391090|Procedure|FeNO measurement|Before every session in the hypoxic chamber as well as on the day after the last session FeNO (forced exhaled nitric oxide) measurement will be performed.
1579008|NCT02391077|Other|Povidone-Iodine|Foreskin disinfection with Povidone-Iodine
1579009|NCT02391077|Other|Antibiotic topical cream|Application of 1gr of Antibiotic topical cream / ointment onto the exposed inner foreskin up to the coronal sulcus
1579010|NCT02391077|Other|Chlorhexidine 1%|Daily washes with Chlorhexidine 1% (2-3 times a day), for 6 days
1579011|NCT02391064|Behavioral|Cognitive evaluation|"Questionnaires for assessment of confounding factors
Cognitive evaluation
Walking tests and 9 Hole Peg Test"
1579012|NCT02391064|Behavioral|Expanded Disability Status Scale (EDSS) score|- EDSS score
1579013|NCT02391051|Radiation|HDR-Brachytherapy|HDR-Brachytherapy 2x 13,5 Gy
1579014|NCT02391038|Drug|MLN0264|MLN0264 IV.
1579015|NCT02391025|Procedure|Gallium-68 citrate PET|
1579016|NCT02391012|Biological|Fecal microbial l transplantation|infusion of preparation of fecal preparation from a healthy donor to a colitis patient
1579017|NCT02390999|Procedure|48 hours of therapeutic hypothermia|
1579018|NCT02390986|Drug|LON002|Extension study to provide continuing access to LON002 medication.
1579019|NCT02390973|Procedure|Sleeve Gastrectomy|
1579020|NCT02390973|Procedure|Roux-en-Y Gastric Bypass|
1579021|NCT02390973|Procedure|Biliopancreatic Diversion with Duodenal Switch|
1579022|NCT02390973|Other|Medical management|
1579025|NCT02390947|Drug|Famitinib|25 mg p.o. qd
1579026|NCT02390947|Drug|Placebo|25 mg p.o. qd
1579027|NCT02390934|Radiation|Radium 223|
1579028|NCT02390921|Drug|Fisiogen Ferro Forte|The patients will interrupt the endovenous treatment with iron and will receive liposomated iron 28mg/daily during 3 months.
1579029|NCT02390921|Drug|Venofer|The patients will continue their usual endovenous administration of Venofer 300mg every 3 month
1579030|NCT02390908|Behavioral|PLUS intervention|The Positive Living through Understanding and Support (PLUS) intervention consists of six sessions that utilizes motivational interviewing and cognitive behavioral skills training to reduce alcohol use and improve medication adherence.
1579031|NCT02390908|Behavioral|Enhanced treatment as usual (eTAU) wait-list condition|In addition to treatment as usual, participants will receive handouts with printed information about HIV, the importance of ART adherence, and problematic alcohol use and HIV disease progression. Following their assessment 12 months after their baseline visit, participants will receive the PLUS intervention.
1579032|NCT02390895|Procedure|endoscopic repair of myelomeningocele before 26 SA|prenatal minimally-invasive fetoscopic closure with iii) uterine exteriorization for a minimally-invasive repair under amniotic carbon dioxide insufflation iv) two trocars for the dissection and the cover with one patch or the suture of the skin edges by stitch
1579033|NCT02390895|Procedure|Postnatal Myelomeningocele Repair Surgery|repair of myleomeningocele after birth
1579034|NCT02390882|Drug|Placebo|Placebo
1579035|NCT02390882|Drug|HGP0412 capsule|Tamsulon high dose
1579036|NCT02390882|Drug|HIP1402 capsule|Tamsulon high dose
1579684|NCT02386280|Behavioral|Motivational Interviewing for Change of Parenting Styles|
1579039|NCT02390856|Device|Conventus DRS|The Conventus DRS (TM) is an intramedullary device intended to treat distal radius fractures. The device remains flexible during placement, but is made rigid at the completion of the surgical implant procedure. The implant is made from titanium alloy (Ti-6A1-4V) and Nitinol.
1579040|NCT02390856|Device|Volar Plate|A volar plate is a metallic plate fastened directly to the fractured bone with screws, to hold the fracture fragments in proper position. Volar plate fixation is the traditional surgical method for distal radius fractures.
1579041|NCT02390843|Drug|Simvastatin|The starting dose of simvastatin will be 140 mg/m^2/dose BID for 21 days for the first group. Dose escalation for subsequent groups will be 180 mg/m^2/dose BID, 225 mg/m^2/dose BID, and 290 mg/m^2/dose BID. If the maximum tolerated dose (MTD) has been exceeded at the first dose level, then the subsequent cohort of subjects will be treated at a dose of 100 mg/m2/dose BID (dose level 0). Simvastatin will be administered orally twice daily, approximately 12 hours apart. Feeding tube (nasogastric tube or gastrostomy tube, NOT a jejunum localized tube) administration is allowed. If a subject vomits a dose of simvastatin, it will not be repeated.
1579042|NCT02390843|Drug|Cyclophosphamide|The dose of cyclophosphamide will be fixed at 250 mg/m^2/dose. Cyclophosphamide will be administered intravenously over 30 minutes once daily for 5 days every 21 days.
1579043|NCT02390843|Drug|Topotecan|The dose of topotecan will be fixed at 0.75 mg/m^2/dose. Topotecan will be administered, after cyclophosphamide, intravenously over 30 minutes once daily for 5 days every 21 days.
1579044|NCT02390843|Drug|Myeloid growth factor|Myeloid growth factor (G-CSF or pegylated G-CSF) will be initiated 24-48 hours after the completion of topotecan and cyclophosphamide for all subjects, which would be day 6 or 7. Myeloid growth factor should continue until the absolute neutrophil count is greater than 2,000/mm^3
1579045|NCT02390830|Other|Falls Prevention|
1579046|NCT02390830|Other|Reduction of limitations at body function and activity levels|
1579047|NCT02390817|Drug|Sugammadex|Administration of Sugammadex
1579048|NCT02390817|Drug|Neostigmine|Administration of Neostigmine
1579049|NCT02390804|Device|single-port laparoscopic hysterectomy(single port trochar)|perform laparoscopic hysterectomy via single-port access
1579050|NCT02390804|Device|multi-port laparoscopic hysterectomy(multi port trochar)|perform laparoscopic hysterectomy via multi-port access
1579051|NCT02390791|Other|enhanced myADHDportal.com|Version of the myADHDportal.com web software enhanced with family-management support to enable parents to be active partners in optimizing and maintaining medication continuity for their child
1579052|NCT02390791|Other|treatment as usual standard portal|Standard version of myADHDportal.com web software
1579053|NCT02390778|Behavioral|Group Debriefing|Group Debriefing involves story-telling, identifying emotional responses to these stories, psycho-education and practical information to normalize group member reactions to a distressing event.
1579054|NCT02390778|Behavioral|leisure activity (film showing)|
1579056|NCT02390739|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 3 days (maximum of 9 doses).
1579057|NCT02390739|Drug|Fludarabine|Day -7 to -3:Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1579058|NCT02390739|Drug|Cyclophosphamide|Days -7 and -6:Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hour.
1579059|NCT02390739|Biological|Anti-Thyroglobulin mTCR PBL|On day 0, one to four days after last dose of fludarabine, cells will be infused intravenously (IV) over 20 to 30 minutes.
1579060|NCT02390726|Biological|Fecal Microbiota Transplant|
1579061|NCT02390726|Biological|Placebo|
1579062|NCT02390713|Device|MID-AVR|"Phase A (4 patients): After laparotomy and dissection of hepatic pedicle, feasibility of MID-AVR positioning around the portal vein by hepato-biliary surgeon and visual evaluation of potential spatial conflict with hepatic artery and choledochal. Mid-AVR is removed at the end of surgery. Each procedure will be filmed.
Phase B (12 patients): Mid-AVR is maintained at the end of surgery, and during 48 hours to evaluate the persistence of an hepatopetal portal flow without portal vein thrombosis upstream MID-AVR during the 48 hours after the liver surgery at bi-daily ultrasonography."
1579063|NCT02390700|Biological|Golimumab Intravenous|This is a non-interventional study. Participants with rheumatoid arthritis in Canada will be observed for 24 months.
1579064|NCT02390687|Drug|Probiotic|Each probiotic lozenge contains not less than 1 billion colony forming unit of Lactobacillus brevis CD2
1579065|NCT02390687|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
1579066|NCT02390674|Drug|Ciclosporin|Comparison between ciclosporin and placebo
1579067|NCT02390674|Drug|Saline|
1579068|NCT02390661|Device|Penrose drain placement|A penrose drain will be placed in the lumpectomy cavity after removal of the irradiation catheter
1579069|NCT02390648|Drug|Ginger|Ginger capsule (500 mg) taking twice a day by mouth during the first 5 days of chemotherapy cycle
1579070|NCT02390648|Drug|Placebo|Placebo capsule taking twice a day by mouth during the first 5 days of chemotherapy cycle
1579075|NCT02390622|Other|Fecal microbiota transplantation|bacteria liquid from 60g fecal was infusion via nasointestinal tube for three days
1579076|NCT02390609|Drug|Ibrutinib (Treatment A) [Reference]|Participants will receive Ibrutinib 560 milligram (mg) (4*140 mg) capsule as Treatment A under fasted conditions in one of the treatment periods.
1579077|NCT02390609|Drug|Ibrutinib (Treatment B)|Participants will receive Ibrutinib 560 mg suspension as Treatment B under fasted conditions in one of the treatment periods.
1579078|NCT02390609|Drug|Ibrutinib (Treatment C)|Participants will receive Ibrutinib 560 mg suspension as Treatment C under fed (high-fat) conditions in one of the treatment periods.
1579685|NCT02386280|Behavioral|Psicoeducation|
1579080|NCT02390609|Drug|Ibrutinib (Treatment E)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules as Treatment E under fed (high-fat) conditions in one of the treatment periods.
1579081|NCT02390609|Drug|Ibrutinib (Treatment F)|Participants will receive Ibrutinib 560 mg sprinkle capsule granules suspended in water as Treatment F under fasted conditions in one of the treatment periods.
1579082|NCT02390596|Drug|Anakinra|The dose of Anakinra will be 2mg/kg. If the patient remains febrile (fever >38°C), he will receive a double dose of anakinra (4mg/kg) at day 3 instead of 2mg/kg. Treatment will be continued until they have achieved complete response as defined in the outcome measurement section, and during a maximum of 15 days.
1579083|NCT02390583|Behavioral|CBT treatment of internet dependence|CBT treatment of internet dependence
1579084|NCT02390583|Behavioral|CBT treatment of sleep disorders|CBT treatment of sleep disorders
1579085|NCT02390570|Other|Patient Capacity Assessment Instrument|The Patient Capacity Assessment instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinicial conversations of primary care.
1579087|NCT02390544|Drug|Melphalan|Melphalan is a bifunctional alkylating agent that inhibits DNA and RNA synthesis, cross-links strands of DNA and acts on both resting and rapidly dividing cells including tumor cells. It is administered intravenously.
1579088|NCT02390531|Drug|Bevacizumab|Varying dosages in 10µl
1579089|NCT02390518|Radiation|Stereotactic Radiosurgery|"Patients with 1 to 5 brain metastases will be treated. Patients will be assigned to one of four cohorts based on the size of their brain lesions. For each patient, a single lesion will be treated at experimental dose level, other metastases (if present) will receive standard SRS doses.
Dose Level 1 Dose Level 2 Dose Level 3 Dose Level 4 Cohort 1a Diameter: ≤ 10 mm Volume: ≤ 0.5236 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 1b Diameter: 11-20 mm Volume: 0.5237-4.1888 cm3 26 Gy 28 Gy 30 Gy n/a Cohort 2 Diameter: 21-30 mm Volume: 4.1889-14.1372 cm3 20 Gy 22 Gy 24 Gy n/a Cohort 3 Diameter: 31-40 mm Volume: 14.1373-33.5103 cm3 17 Gy 19 Gy 21 Gy 23 Gy
Dose Escalation A non-standard 5+4 design will be used for the dose escalation. For each cohort, an initial group of 5 patients will be accrued at dose level 1 and receive experimental treatment to one of their lesions."
1579090|NCT02390505|Drug|Vitamin C|
1579091|NCT02390505|Drug|Placebo|
1579092|NCT02390492|Drug|Period 1 treatment|200 mg oral ipatasertib followed 1 hour later by 80-mcg/800-nCi intravenous [14C]-ipatasertib on Day 1 of study
1579093|NCT02390492|Drug|Period 2 treatment|200-mg/100-mcCi oral [14C]-ipatasertib on Day 15 of study
1579094|NCT02390479|Other|non surgical periodontal treatment|"SRP under local anaesthesia, in a total of four clinical visits
Oral hygiene instructions including the modified Bass technique, regular toothpaste, and an appropriate interdental cleaning device with dental floss and interdental brush."
1579095|NCT02390466|Biological|VAC-3S|Administered via intra-muscular injection in the arm
1579096|NCT02390453|Behavioral|Combined Cognitive and Physical|Combined modules provide Cognitive training from Posit Science designed to improve information processing speed, learning, memory, and attention, and Physical training focused on seated aerobic and progressive resistance exercises designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
1579097|NCT02390453|Behavioral|Cognitive|Cognitive modules from Posit Science are designed to improve information processing speed, learning, memory, and attention.
1579098|NCT02390453|Behavioral|Physical|Physical modules are focused on seated aerobic and progressive resistance training designed to improve aerobic capacity, muscular strength, and endurance consistent with current exercise recommendations for older adults.
1579099|NCT02390453|Behavioral|Control|Control modules provide social contact for group discussion and instruction in health self-management and successful aging.
1579100|NCT02390440|Drug|EXPAREL|
1579106|NCT02390401|Device|Vacuum-assisted closure|Prevena (VAC) device at the time of primary closure for a cesarean section, left in place for 5-7 days postoperatively.
1579107|NCT02390401|Device|Standard sterile dressing|Standard sterile dressing at the time of primary closure for a cesarean section, left in place for 1-2 days postoperatively.
1579108|NCT02390388|Procedure|pudendal nerve block|nerve stimulator-guided Pudendal block
1579109|NCT02390388|Procedure|caudal block|caudal block
1579110|NCT02390375|Drug|DW-0929|5/10mg
1579111|NCT02390375|Drug|DW-0929|10/10mg
1579112|NCT02390375|Drug|DW-0929|20/10mg
1579113|NCT02390375|Drug|Rosuvastatin|5mg F/U study: DW-0929 5/10mg
1579114|NCT02390375|Drug|Rosuvastatin|10mg F/U study: DW-0929 10/10mg
1579115|NCT02390375|Drug|Rosuvastatin|20mg F/U study: DW-0929 20/10mg
1579116|NCT02390362|Drug|Rituximab|We hypothesize that the anti-CD20 monoclonal antibody Rituximab will be more effective in maintaining remission in children who have already had one relapse while receiving MMF
1579117|NCT02390362|Drug|MMF|Subjects randomized to MMF, will continue MMF as scheduled by the investigator
1579118|NCT02390349|Other|Placebo|
1579119|NCT02390349|Dietary Supplement|Curamin|
1579120|NCT02390349|Dietary Supplement|CuraMed|
1579121|NCT02390336|Other|Real mobilization-with-movement (MWM)|For the MWM group, the investigator applied two techniques of mobilization with movement: one for flexion and one for medial rotation of the hip. With the hip in flexion, a stabilizing belt was placed on the medial side of the participant's thigh closest to the joint interline. The belt was placed around the pelvic region of the physical therapist, keeping a perpendicular direction to the participant's thigh. Maintaining a side slip, it was carried out a passive movement of 1) hip flexion (3x10) and 2) medial hip rotation (3x10) by the physiotherapist throughout painless amplitude.
1579122|NCT02390336|Other|Sham mobilization-with-movement (MWM)|In the sham group, the investigators conducted a technical simulation. The positioning of the patient and the physical therapist was the same, however, no accessory mobilization was performed with the help of the belt and did not performed repeated movements of passive flexion or medial rotation.
1579409|NCT02388399|Procedure|Device|Resting and hyperemic pressure pullback tracing will be done with motorized pullback system.
1579123|NCT02390323|Procedure|Lumbar Sympathetic Block|"A lumbar sympathetic block is an injection in the middle of the lower back, toward the left or right side. The lumbar sympathetic nerves are a small bundle of nerves that carries sympathetic nerve signals from the lower extremities. In some instances, certain injuries to the lower extremities can cause a burning, unusual pain called complex regional pain syndrome or reflex sympathetic dystrophy. Injecting a small amount of local anesthetic on the lumbar sympathetic nerves can identify whether or not this pain is carried by the sympathetic nervous system."
1579124|NCT02390323|Device|Skin conductance algesimeter|The real-time changes in skin conductance indices can be monitored at the skin level, by use of non-invasive electrodes attached to the skin (similar to EKG electrodes) connected to the skin conductance algesimeter. A computer program analyzes the data and produces a real-time graphic and numeric data demonstrating the skin conductance response. The initiation of successful sympathetic blockade can cause rapid cessation of the skin sympathetic activity that leads to a decrease in skin conductance within seconds.
1579125|NCT02390310|Device|Shang Ring|Comparison of healing times at 7 day and more than 7 days after circumcision.
1579126|NCT02390310|Drug|injectable anesthesia (lidocaine 1%)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
1579127|NCT02390310|Drug|topical anesthesia (lidocaine 2.5%, prilocaine 2.5% cream)|Comparison of Anesthesia methods for Shang Ring circumcision. Comparison of pain during Shang Ring circumcision when using injectable vs. topical anesthesia.
1579128|NCT02390297|Genetic|Blood tests|Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses
1579129|NCT02390284|Drug|Latanoprost|Lower intraocular pressure (IOP) by increasing outflow of fluid from the eye.
1579130|NCT02390284|Drug|Bimatoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
1579131|NCT02390284|Drug|Travoprost|Lower intraocular pressure by increasing outflow of fluid from the eye.
1579132|NCT02390284|Drug|Timolol|Lower intraocular pressure by decreasing production of fluid
1579133|NCT02390284|Drug|Dorzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
1579134|NCT02390284|Drug|Brinzolamide|Lowers intraocular pressure by decreasing intraocular fluid production
1579135|NCT02390284|Drug|Acetazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
1579136|NCT02390284|Drug|Methazolamide|Lowers intraocular pressure by decreasing intraocular fluid production
1579137|NCT02390271|Other|emotion focused therapy training|The Cardiac Coherence Training (CCT) incorporates a series of emotion-refocusing and restructuring techniques involving the use of biofeedback to control heart rate variability
1579138|NCT02390258|Drug|10mg XEN-D0103|
1579139|NCT02390258|Drug|Placebo|
1579140|NCT02390258|Drug|30mg XEN-D0103|
1579141|NCT02390258|Drug|60mg XEN-D0103|
1579142|NCT02390258|Drug|120mg XEN-D0103|
1579143|NCT02390258|Drug|200mg XEN-D0103|
1579144|NCT02390258|Drug|150mg XEN-D0103|
1579145|NCT02390245|Other|Use of patient navigation and social worker|This arm will include phoning patients to schedule appointments; confirming appointments by mailings, emails and/or text messaging; arranging transportation through Customized Community Transportation (CCT) and Philadelphia Paratransit Service; and scheduling trained medical interpreters.
1579151|NCT02390193|Procedure|Hemodialysis|"Daytime haemodialysis was standardised. It was performed 3 times per week, with a 4-h session duration, 250-mL/min blood flow, and 500-mL/min dialysate flow, using bicarbonate buffered dialysate with 1.25 mmol/L ionised calcium concentration, dialysate temperature of 36.5°C.
The ultrafiltration amount for each haemodialysis session was decided by individual dry weight, which was fixed during the trial. In addition, the patients were not permitted to change their medication or start new drugs, especially antiplatelet agents, angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, calcium-channel blockers, and β-blockers.
The patients who required a change in medication for medical reasons were subsequently excluded from the study."
1579152|NCT02390180|Other|Tasting solutions|Participants will taste a variety of food grade compounds including: hexenoic acid, decenoic acid, oleic acid, linoleic acid, glucose, fructose, salt, citric acid, acetic acid, quinine, urea, caffeine, sucrose octaacetate, propylthiouracil, phenylthiocarbamide, monosodium glutamate, and inosine monophosphate.
1579153|NCT02390167|Device|ONYX NEXT BGMS|Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
1579154|NCT02390154|Drug|roniciclib (BAY 1000394)|Single dose , 2.5 mg roniciclib spiked with 5.0 MBq of [14C] roniciclib solution
1579155|NCT02390154|Drug|roniciclib (BAY 1000394)|5 mg roniciclib tablet , Multiple dose, twice a day (bid), on a 3-days on/4-days off regimen in cycles of 21 days
1579156|NCT02390141|Drug|ZP4207|
1579157|NCT02390141|Drug|Placebo|
1579158|NCT02390128|Other|observational only|
1579159|NCT02390115|Other|Elastic tape application in shoulder|
1579160|NCT02390102|Drug|Erythropoietin|Combinaison drug of darboepoetin 0.75µg/Kg + 200mg intravenous iron sucrose
1579161|NCT02390102|Drug|Placebo|Saline solution 0.9%
1579162|NCT02390089|Drug|Capsaicin vapor|Single-breath and continuous inhalation paradigm to induce cough.
1579163|NCT02390089|Other|fog|Continuous inhalation of fog until a cough is produced, or up to 60 seconds (whichever is shortest)
1579164|NCT02390089|Radiation|Videofluoroscopic swallow evaluation|Fluoroscopic evaluation of oropharyngeal swallowing function.
1579165|NCT02390089|Device|Nebulizer|A hand-held nebulizer will be used to aerosolize the capsaicin and water solutions. Participants will inhale through the device's mouthpiece, and cough if they need to.
1579166|NCT02390076|Device|Left Low Level Light Therapy|Administration of left LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Left LLLT will target the left forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
1579167|NCT02390076|Other|Attention bias modification|The task will consist of a modified dot-probe paradigm. A pair of stimuli depicting a negative word and a neutral word will be presented, randomly located to the right and left side of the computer screen. The words will be presented for 1000 ms. The words will then disappear and a dot-probe will appear in the center of the screen location of one of the words (i.e., O or Q). This probe will appear on the screen until the participant presses one of two response buttons to indicate the identity of the probe. The presentation of the probe will be staggered to maximize attention for the neutral stimulus. Latency and accuracy of the button press responses are recorded by the computer.
1579168|NCT02390076|Device|Right Low Level Light Therapy|Administration of right LLLT consists of applying light of a specific wavelength (1064 nanometers) using a laser diode, the CG-5000 high density laser (Cell Gen Therapeutics, LLC). Right LLLT will target the right forehead. The diameter parameters of stimulation are the same that showed psychologically beneficial effects in Schiffer et al. (2009). At the power level described, the energy emitted by the CG-5000 at this setting is one quarter of the skin MPE (0.250 W/cm2), exposure to it is not deemed harmful to tissue, and it causes no detectable physical damage and negligible heat.
1579169|NCT02390076|Device|Sham Low Level Light Therapy|Administration of sham LLLT is designed to resemble active LLLT from the participant's perspective, but uses a dosage markedly below the minimal necessary threshold to elicit a response.
1579170|NCT02390063|Biological|ChAdOx1.5T4|A recombinant simian adenovirus encoding human tumour-associated antigen 5T4
1579171|NCT02390063|Biological|MVA.5T4|A recombinant replication deficient Modified Vaccinia Ankara virus encoding human tumour-associated antigen 5T4
1579172|NCT02390063|Drug|Cyclophosphamide|Metronomic cyclophosphamide (50mg bd)
1579173|NCT02390050|Drug|Bexagliflozin tablets|Bexagliflozin tablets are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
1579174|NCT02390050|Drug|Bexagliflozin tablets, placebo|Bexagliflozin tablets, placebo, are blue caplet-shaped, film-coated tablets that are intended for use in investigational studies in humans.
1579175|NCT02390024|Device|Invasive Mechanical Ventilation|"Mechanical ventilation parameters will be monitorized during the ICU stay in all patients Four types of ventilators will be used:
Servo Dräger Evita XL Dräger Evita 4 Puritan Bennet 840"
1579176|NCT02390011|Procedure|MRI|
1579177|NCT02389998|Other|Placebo Suspension|The study is divided into three phases: 1 one-week baseline assessment followed by 2 three-week study phases (phase A and phase B). Phase A will require subjects to take 1/4 teaspoon placebo suspension 2 times a day (morning and night), and a third dose if necessary. In phase B subjects will not take the placebo. After 3 weeks in initial phase (either Phase A or B), subjects will switch to the alternate phase and continue the study for another 3 weeks. Hyoscyamine is available as a rescue medication during Phase A and Phase B. Half of the subjects will be randomized to begin with Phase A and half will be randomized to begin with Phase B.
1579178|NCT02389998|Drug|Hyoscyamine|While not an intervention of interest to our study, patients will have hyoscyamine available as a rescue medication throughout the study. This can be taken on a PRN basis for breakthrough pain a maximum of 4x daily.
1579179|NCT02389985|Drug|CRLX101 and weekly paclitaxel|
1579180|NCT02389972|Drug|Dasatinib|
1579181|NCT02389959|Drug|Bevacizumab|Bevacizumab will be mixed by the Stanford Hospital Pharmacy to a total dose of 100mg in 4mL, and 50mg (2mL) will be injected into each side of the nose
1579182|NCT02389959|Drug|Placebo (Saline)|4mL of saline will be mixed by the Stanford Hospital Pharmacy as a control
1579183|NCT02389946|Device|Orsiro DES|Orsiro is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform), and a drug product (a formulation of sirolimus) contained in a bioabsorbable polymer coating.
1579184|NCT02389946|Device|Xience DES|
1579186|NCT02389920|Drug|Nilotinib|
1579187|NCT02389894|Device|Embol-X Embolic Protection Device|per the manufacturer's instructions for use (IFU).
1579188|NCT02389894|Device|CardioGard Cannula|CardioGard Cannula, per the manufacturer's instructions for use (IFU).
1579189|NCT02389881|Drug|TAK-058|TAK-058 Solution
1579190|NCT02389881|Drug|TAK-058 Placebo|TAK-058 placebo-matching solution
1579191|NCT02389868|Drug|Lovastatin|
1579192|NCT02389855|Procedure|NeuroBlate® System Therapy|
1579193|NCT02389842|Drug|Palbociclib + Taselisib / Pictilisib|
1579194|NCT02389829|Drug|Hydromorphone|
1579195|NCT02389829|Drug|Prochlorperazine|
1579196|NCT02389829|Drug|Diphenhydramine|
1579199|NCT02389803|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended DRI for Calories, high protein (25% of calories) and multi vitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake )
1579200|NCT02389803|Dietary Supplement|Placebo comparator|Low caloric formula (Powder added to water), without added vitamins and minerals
1579201|NCT02389790|Drug|MT-1303|
1579202|NCT02389777|Biological|Amnion-derived Cellular Cytokine Solution immediate|Amnion-derived Cellular Cytokine Solution will be applied immediately to the UV light burn wound topically by spray twice per day
1579203|NCT02389777|Biological|Amnion-derived Cellular Cytokine Solution delayed|Amnion-derived Cellular Cytokine Solution will be applied to the UV light burn topically by spray twice per day beginning 6-12 hours after the burn
1579204|NCT02389764|Drug|BIBF 1120|Initial dose is 200 mg twice daily orally for a 28 day cycle.
1579686|NCT02386267|Drug|L-leucine|L-leucine pills per os for 6 months
1579205|NCT02389764|Behavioral|Phone Call|Participant called by a member of the study staff every 3 months for up to 1 year after end-of-treatment visit. These calls should last about 2 minutes.
1579206|NCT02389751|Drug|Ganetespib|Starting dose of Ganetespib 80 mg/m2 by vein once a week during radiotherapy.
1579207|NCT02389751|Drug|Carboplatin|AUC=2 weekly by vein during radiation therapy.
1579208|NCT02389751|Drug|Paclitaxel|50 mg/m2 weekly by vein during radiation therapy.
1579209|NCT02389751|Radiation|Radiotherapy|Radiotherapy administered once-daily, 5 days a week, for 5.5 weeks, or a total of 28 treatments. Total dose 50.4 Gy (@ 1.8 Gy/fx/day) prescribed to the periphery of the planning target volume (PTV).
1579210|NCT02389738|Drug|Regadenoson|Regadenoson administration on post-op day 2 after temozolomide administration. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
1579211|NCT02389738|Drug|Temozolomide|Temozolomide administration on post-op day 1 and 2. Temozolomide plasma and dialysate concentrations will be obtained over 18 hours post temozolomde administration.
1579212|NCT02389738|Device|Microdialysis catheter|Microdialysis catheter placement post surgical resection and removed at the bedside after completion of obtaining all dialysate collections.
1579213|NCT02389725|Device|disposable elastic tourniquet|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
1579214|NCT02389725|Device|blood pressure cuff|Comparison of first time peripheral IV access success rate between the standard elastic tourniquet and a blood pressure cuff.
1579215|NCT02389712|Drug|Lamotrigine|Lamotrigine dosing: 25 mg daily x 2 weeks, 50 mg daily x 2 weeks, 100 mg daily x 2 weeks, 200 mg (100 mg bid)) x 4 weeks. If patient still has at least mild depressive symptoms, the dose can be increased to 300 mg daily for 2 weeks and 400 mg for 4 weeks. Dose will be held for treatment response and can be reduced for side effects.
1579216|NCT02389712|Drug|Fluoxetine|Fluoxetine dosing: 20mg for month 1, 40mg for month 2, and if still depressed (CGI ≥ 3) 60mg for month 3 and 4. Lower doses of fluoxetine will be prescribed for those with side effects. For known Cytochrome P450 2D6 poor metabolizers, fluoxetine will not be dosed > 40mg.
1579217|NCT02389699|Radiation|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
1579218|NCT02389699|Radiation|Whole breast radiation|whole breast radiation after BCS with 46-50 Gy
1579219|NCT02389686|Device|INTRABEAM (Carl Zeiss, Oberkochen, Germany)|Boost with 16 Gy during NSM for nipple-areola complex (NAC)
1579220|NCT02389673|Device|Intraoperative Radiotherapy|Boost with 20 Gy during BCS, EBRT with 46-50 Gy
1579221|NCT02389660|Behavioral|Blended Cognitive Behavioural Therapy (CBT)|
1579222|NCT02389660|Behavioral|Treatment as usual|
1579223|NCT02389621|Drug|Lusutrombopag|Tablets for oral administration
1579224|NCT02389621|Drug|Placebo|Tablets for oral administration
1579225|NCT02389608|Device|Transcranial direct current stimulation (tDCS)|The active tDCS and placebo will be applied to the primary motor cortex (M1) and FES active and placebo will be applied to the anterior tibial muscle (TA).
1579226|NCT02389608|Device|Functional electrical stimulation (FES)|
1579227|NCT02389608|Device|Sham stimulation|
1579228|NCT02389595|Other|HIV positive subjects|This group will provide a blood sample.
1579229|NCT02389595|Other|Non-infected control subjects|This group will be de-identified blood samples from a commercial source.
1579230|NCT02389582|Drug|Dabigatran|Use for 5 days
1579231|NCT02389582|Drug|Enoxaparin|Use for 5 days
1579232|NCT02389569|Procedure|Adhesive system|Etch-and-rinse and Self-etch adhesive system will be applied in volunteers that received different types of restoration protocol.
1579233|NCT02389569|Procedure|Restoration protocol|Volunteers will be treated by two types of protocol restoration : 1) Biosilicate (powder) or 2) Control (without Biosilicate). In sequence, adhesive (self-etch or etch and rinse) and composite resin will be used for restoration.
1579234|NCT02389543|Drug|Selinexor|Two different dosing schedules will be tested, once weekly and twice weekly. If the selinexor 80 mg dose is tolerated, the dose will be increased to 100 mg.
1579235|NCT02389543|Drug|Lenalidomide|In both arms, lenalidomide will be started at 15 mg/day (Dose Level 1) and, if tolerated per DLT criteria, will be escalated to 25 mg/day (Dose Level 2).
1579236|NCT02389543|Drug|Dexamethasone|"Dexamethasone will be given in combination with each dose of selinexor on the once weekly treatment arm.
For the twice weekly arm dexamethasone will be given in combination with each dose of selinexor and will also be given without selinexor on Days 22 and 24."
1579237|NCT02389530|Drug|Fluorescein|Fluorescein will be administered intravenously at a dose between 250 mg and 400 mg in the experimental arm.
1579238|NCT02389517|Drug|Ixazomib Citrate|Given PO
1579239|NCT02389517|Drug|Lenalidomide|Given PO
1579240|NCT02389517|Drug|Dexamethasone|Given PO
1579241|NCT02389504|Other|Dynamic Exertional Physical Therapy|By contrast, the dynamic exertion protocol includes the treadmill running aspect, but also incorporates other exercises that involve lateral movement (e.g., side lunges, lateral speed training exercises) as well as planar changes (e.g., burpees, squat thrusts) . Recovery on these exercises is measured based on time subjects are able to tolerate the exertion without symptom increase. Across all exertion protocols additional measures of subjective physical effort and objective measurement of heart rate are taken.
1579242|NCT02389504|Other|Standard Exertional Physical Therapy|Standard treadmill running, monitoring heart rate
1579243|NCT02389491|Dietary Supplement|normal density formula (Necocate)|In control group,there are 32 infants
1579244|NCT02389491|Dietary Supplement|high density formula(Infatrini)|In intervention group,there are 32 infants
1579245|NCT02389478|Procedure|Oropharyngeal administration of colostrums|rubbing drops of colostrum inside a baby's cheeks using a sterile syringe
1579246|NCT02389478|Procedure|Oropharyngeal administration of Normal saline|rubbing drops of Normal saline inside a baby's cheeks using a sterile syringe
1579249|NCT02389452|Drug|Synvisc-One|intraarticular injection
1579250|NCT02389439|Drug|Pyronaridine-artesunate|
1579251|NCT02389426|Device|TCD baseline|"Measurement of cerebral circulation parameters with transcranial doppler baseline.
This examination will be performed in patients with multiple sclerosis and in healthy controls."
1579252|NCT02389426|Device|TCD after bosentan administration|"Measurement of cerebral circulation parameters with transcranial doppler after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.
This examination will only be performed in patients with multiple sclerosis."
1579253|NCT02389426|Device|NIRS baseline|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy baseline.
This examination will be performed in patients with multiple sclerosis and in healthy controls."
1579254|NCT02389426|Device|NIRS after bosentan administration|"Measurement of frontal lobe oxygen saturation with near-infrared spectroscopy after administration of one tablet tracleer (Bosentan) 62,5 mg per oral.
This examination will only be performed in patients with multiple sclerosis."
1579255|NCT02389413|Drug|PQ912 oral|
1579256|NCT02389413|Other|Placebo|
1579257|NCT02389400|Drug|methotrexate|Single Group Assignment
1579258|NCT02389387|Other|Behavioral Interventions for Dialysis Facilities|"Educational seminars and monthly educational webinars
Peer-to-peer mentoring program
Bulletin boards about transplantation
Facility-specific feedback reports detailing transplant referral data for their center compared to state average
Formulate a facility-specific improvement plan to increase transplant referrals.
Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.
Monthly monitoring and reporting of patient referrals to ESRD Network
Conduct a patient and family education session about transplantation
Host a movie day to show Living ACTS (About Choices in Transplantation & Sharing) video"
1579259|NCT02389374|Drug|chloroquine|standard dose
1579260|NCT02389374|Drug|Artemether-lumefantrine combination|standard dose
1579261|NCT02389374|Drug|Primaquine|single dose
1579262|NCT02389374|Drug|Primaquine|14 days
1579263|NCT02389361|Drug|Zaldiar|Postoperative analgesia with oral Zaldiar (combination of tramadol and paracetamol)
1579264|NCT02389361|Drug|Paracetamol-Tramadol|Postoperative analgesia with intravenous Paracetamol and Tramadol
1579265|NCT02389348|Drug|DSM265|Single oral doses of DSM265
1579266|NCT02389348|Drug|OZ439|Single oral doses of OZ439
1579267|NCT02389322|Biological|5μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 5μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 5μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
1579268|NCT02389322|Biological|10μg/ml ESAT6-CFP10|The participants are injection intradermally with 0.1 ml 10μg/ml ESAT6-CFP10 12 weeks after BCG immunization or placebo immunization.This biological diagnostic reagents is injection agent .Every subject apply for the 10μg/mlRecombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 only one time after choosing into study population II .
1579269|NCT02389322|Biological|BCG|The participants are injected intradermally with 0.1 ml BCG.This BCG is Freeze-dried agent and with five people dose of each bottle,so each bottle of BCG must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
1579270|NCT02389322|Biological|placebo|The participants are injected intradermally with 0.1 ml placebo of Bacillus Calmette-Guerin.This placebo is Freeze-dried agent and with five people dose of each bottle ,so each bottle must dissolve by 0.5ml special diluent before administration.Every subject apply for the BCG vaccine only one time after choosing into study population II .
1579274|NCT02389296|Other|Questionnaire|Questionnaires will be distributed to nursing staff
1579275|NCT02389257|Device|MINIMAG / MEG|
1579276|NCT02389257|Device|MINIMAG / ECG|
1579277|NCT02389244|Drug|Regorafenib|4 tablets once daily until progression or unacceptable toxicity
1579278|NCT02389244|Drug|Placebo|4 tablets once daily and switch to regorafenib after confirmed progression
1579279|NCT02389231|Drug|Interleukine-2|"Four courses of IL2 ( [Proleukin, Novartis]) will be administered subcutaneously for 5 days.
The first course will be limited to a dose of 1.5 million IU per day and followed by a 9 day wash-out.
The other courses of 3 million IU per day will be initiated after a 16 day wash-out."
1579280|NCT02389218|Device|single ablation (CryoBalloonAblation (CBA)|Cryoablation at entry, after randomization to this group
1579281|NCT02389218|Drug|sequential drug adjustment (propafenone, sotalol or flecainide)|Correct drug dosage at entry, sequential adjustment / titration, in stage 2 amiodarone
1579282|NCT02389205|Other|kinesio group|"kinesio group, The kinesio Taping® Method is a definitive rehabilitative taping technique that is designed to facilitate the body's natural healing process while providing support and stability to muscles and joints without restricting the body's range of motion as well as providing extended soft tissue manipulation to prolong the benefits of manual therapy administered within the clinical setting.
The effect of intervention may affected by the varying durations and frequencies of exercise, different state of arthropathy and joint range of motion limitations of ankle , etc."
1579284|NCT02389179|Drug|Vitamin D3|The drug/dosage of Vitamin D3 will be given monthly or bi-weekly depending on the type of arm that the subjects are randomised into under direct supervision.
1579285|NCT02389166|Device|Optiflow|"Patients receive high flow oxygen delivery system, Optiflow, conventional clinical management and sequential used of NIV for a period of 36 hours at least.
High flow oxygen nasal therapy (Optiflow) : The flow will be set at 40l/min to 60l/min The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a SaO2 between 94% and 98%."
1579286|NCT02389166|Device|Conventional oxygen therapy|Patients receive conventional oxygen therapy with high concentration mask, conventional clinical management, and sequential use of NIV Conventional oxygen therapy: The inspired fraction of oxygen (FiO2) is the same as that defined at the end of VNI session and may be adjusted in order to obtain a Arterial Oxygen Saturation (SaO2) between 94% and 98%.
1579486|NCT02387905|Behavioral|MD Anderson Symptom Inventory - Spine Tumor (MDASI-SP)|Assessment form completed at months 3, 6, 9, 12, 18, and 24.
1579288|NCT02389140|Other|Trigger point release|Trigger point therapy
1579289|NCT02389140|Other|Ultrasound|sham ultrasound
1579290|NCT02389127|Device|Continuous glucose monitor (Dexcom, San Diego, CA)|(Group B) patients with known diabetes and cirrhosis with varying degrees of liver dysfunction will wear a continuous glucose monitor (Dexcom, San Diego, CA) for 2 continuous days during week days and week ends, every 4 weeks for 12 consecutive weeks.
1579291|NCT02389114|Other|Soy Protein|Soy protein is commonly consumed in Asian diet.
1579292|NCT02389114|Other|Polydextrose|Polydextrose is a randomly bonded polymer of glucose developed in the 1960s. It is widely recognized as a soluble fiber that is not digested in the upper gastrointestinal tract due to the complex structure and nature of the glycosidic bonds, but is partially fermented by the microbiota in large intestine generating short chain fatty acids.
1579293|NCT02389101|Other|68Ga-DOTANOC PET/CT; Diffusion weighted MRI|PET/CT: Radionuclide imaging using short-lived isotope Ga-68; MRI imaging w/o gadolinium contrast
1579294|NCT02389088|Drug|Letrozole|In Phase II, letrozole, 5 mg/day, will be given for 14 days
1579295|NCT02389075|Procedure|Pinch biopsies|Biopsies obtained during colonoscopy or flexible sigmoidoscopy.
1579296|NCT02389075|Procedure|Flexible sigmoidoscopy|Offered to subjects with ankylosing spondylitis who do not meet criteria for colonoscopy
1579297|NCT02389062|Other|Administration of gluten( food /wheat protein) capsules or placebo(cornstarch) capsules and tests for novel markers will be done at intervals.|After administering the capsules for 16 weeks during study periods, patients's blood will be tested for novel markers- Intestinal fatty acid binding protein(I-FABP), stool for gluten intestinal peptide (GIP), urine for gluten intestinal peptide(GIP), patient estimated gluten intake(PEGI), celiac severity index(CSI), Celiac dietary adherence test(CDAT) by standard questionnaire provided during the visits. These tests will be done over a period of 16 weeks and at a follow up 3 months later.
1579298|NCT02389036|Drug|SDD Paste|A six-hourly topical application of 0.5g paste, containing colistin 2%, tobramycin 2% and nystatin 2%,
1579299|NCT02389036|Drug|SDD Suspension|A six-hourly administration of 10 ml of a suspension containing 100 mg colistin, 80 mg tobramycin and 2 x 106 IU nystatin, to the gastrointestinal tract via a gastric/post-pyloric tube
1579300|NCT02389036|Drug|Intravenous Antibiotic|A four-day course of an intravenous antibiotic in patients not already receiving a therapeutic antibiotic
2008547|NCT03329170|Behavioral|educational intervention using motivational interviewing|A dental hygienist will offer the families verbal and written information regarding oral health and its importance in children with CHD at the cardiac ward, when child is <7 months. At 6, 12 and 18 months of age, oral health behaviour is assessed via internet, the parents of the child will be sent written information regarding oral health, a tooth brush and a 1000ppm Fluoride tooth paste, after which the dental hygienist will call the parents of the child, to provide additional counselling regarding oral health and its importance in children with CHD. The counselling will be done by motivational interviewing. The themes discussed will be the parents' concerns regarding main points in the written information from the cardiac ward: oral home care, eating habits and dental contact.
1579303|NCT02389010|Biological|Allogeneic cord blood platelet gel-CBPG|For the medication of patients, one CBPG unit (mean volume 10 mL, range 5-15; mean platelet concentration 1 x 109/L, range 0.8 - 1.2 x 109/L. 10 mL in plasma) will be administered every 3-4 days. CBPG units, cryopreserved and stored in a plastic bag in a -80°C freezer, will be thawed at 37°C in a waterbath and activated with Calcium gluconate and immediately transported to sites of clinical use and applied to the skin ulcer without breaking the sterility chain.
1579304|NCT02389010|Other|Standard Local Medications-SLM|Each clinical center will use their validated standard local medications. Details and specifications of the local standard medication procedures will be collected from each participating centre.
1579305|NCT02388997|Drug|omalizumab|This medication has been approved for clinical use to treat patients with moderate to severe asthma by the FDA in 2003 and for use in this study (BB-IND# 10510)
1579306|NCT02388997|Biological|Rhinovirus (strain 16)|This strain of pooled rhinovirus has been approved for use in experimental challenges (BB-IND# 15162) and for use in this study (BB-IND# 10510) by the FDA.
1579307|NCT02388984|Drug|Compound danshen dripping pills|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
1579308|NCT02388984|Drug|Placebo|Dosage form:pill. Dosage:20pills. Frequency:three times per day. Duration:24 weeks.
1579309|NCT02388971|Drug|MLN1202|MLN1202 solution
1579310|NCT02388971|Drug|Placebo|MLN1202 placebo-matching solution
1579311|NCT02388945|Other|APD|PDGO APD machines used in the PD patients for 8 weeks
1579312|NCT02388945|Other|CAPD|CAPD used in the PD Patients for 8 weeks
1579313|NCT02388932|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1579314|NCT02388932|Device|Positron Emission Tomography|Undergo PET/CT
1579315|NCT02388932|Device|Computed Tomography|Undergo PET/CT
1579316|NCT02388932|Other|Quality-of-Life Assessment|Ancillary studies
1579317|NCT02388919|Drug|Anlotinib|Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
1579318|NCT02388919|Drug|Placebo|Basic dosage, take once when limosis in the morning.
1579323|NCT02388880|Device|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
1579324|NCT02388867|Procedure|Polytetrafluoroethylene (PTFE) bypass grafting.|Polytetrafluoroethylene (PTFE) bypass grafting. Patients will undergo bypass procedure using PTFE graft : the inflow vessel may be the femoral artery or the iliac artery; the outflow vessel may be the popliteal artery or the anterior tibial artery.
1579489|NCT02387866|Drug|AG-221|
1579325|NCT02388867|Procedure|Autogenous vein bypass grafting|Autogenous vein bypass grafting. Patients will undergo Bypass procedure using autogenous veins (the great saphenous vein or the small saphenous vein or a composite bypass using great and small saphenous vein ). The inflow vessel may be represented by the femoral artery or the popliteal artery; the outflow vessel may be the anterior tibial artery or the posterior tibial artery or the peroneal artery.
1579326|NCT02388854|Genetic|Real Time- Polymerase Chain Reaction|Research of frequency of SNPs in women affected by endometriosis
1579327|NCT02388841|Radiation|Pulmonary embolism|the thrombus were assessed with Computed tomographic pulmonary angiography
1579328|NCT02388828|Biological|lentiviral-based CART meso therapy|
1579329|NCT02388815|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System masked for 14 days.
During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
1579330|NCT02388802|Procedure|Oocyte retrieval and freezing|10 Patients will undergo oocyte retrieval and freezing
1579331|NCT02388802|Procedure|Deceased Donor Allograft Excision|Appropriately matched uterine transplant allografts will be excised from deceased donors
1579332|NCT02388802|Procedure|Uterine Transplantation|Following egg freezing the patients will undergo uterine transplant from deceased donors
1579333|NCT02388802|Drug|Immunosuppressive Agents|Patients will be appropriately immunosuppressed, whilst being closely monitored clinically, radiologically and immunologically.
1579334|NCT02388802|Procedure|In-vitro fertilisation|12 months after successful transplantation,the patients will undergo IVF
1579335|NCT02388802|Procedure|Caesarean Section|Following successful conception and antenatal period, the babies will be born by Caesarean Section
1579336|NCT02388789|Other|active movement|same as arm description
2008548|NCT03329157|Other|Rebuilding Bridges|Psychosocial intervention to help veterans re-engage with family members called Rebuilding Bridges, developed for this project.
1579338|NCT02388763|Device|Stenfilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
1579339|NCT02388763|Device|Narafilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
1579340|NCT02388750|Drug|Palonosetron|Palonosetron 0.5 mg every other day until completion of radiation and at least one hour prior on days of RT
1579341|NCT02388750|Radiation|Low or moderate risk radiotherapy|Low or moderately emetogenic radiotherapy will be given to all patients on study.
1579342|NCT02388737|Drug|Vonoprazan|Vonoprazan tablets
1579343|NCT02388737|Drug|Lansoprazole|Lansoprazole capsules or tablets
1579344|NCT02388737|Drug|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
1579345|NCT02388737|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
1579346|NCT02388724|Drug|Vonoprazan|Vonoprazan tablets
1579347|NCT02388724|Drug|Lansoprazole|Lansoprazole capsules
1579348|NCT02388724|Drug|Vonoprazan Placebo|Vonoprazan placebo-matching tablets
1579349|NCT02388724|Drug|Lansoprazole Placebo|Lansoprazole placebo-matching capsules
1579350|NCT02388711|Other|C-TraC Intervention|C-TraC utilizes a nurse case manager to coordinate the patient's transitional care through active participation in inpatient multidisciplinary discharge rounds, a single brief protocol-driven inpatient encounter, and 1-4 protocol-driven post-hospital telephone calls with the patient/caregiver using spaced retrieval techniques.
1579351|NCT02388698|Procedure|Cervical swab|"Cervical Swab at baseline.
HPV testing at recurrence, if applicable."
1579352|NCT02388698|Radiation|PET-CT|PET-CT will be completed 3 month post chemoradiation.
1579353|NCT02388698|Biological|Plasma HPV|Plasma HPV will be drawn at baseline, post radiation, 3 month post chemoradiation and at progression (if necessary).
1579354|NCT02388685|Other|Exercise|Home exercise therapy
1579355|NCT02388672|Dietary Supplement|decaffeinated coffee|Decaffeinated coffee with low chlorogenic acid (224mg; low-CGA)
1579356|NCT02388672|Dietary Supplement|chlorogenic acid|Decaffeinated coffee with high chlorogenic acid (560mg; high-CGA)
1579357|NCT02388672|Dietary Supplement|green coffee bean extract supplement|Decaffeinated coffee together with green coffee bean extract supplement (560mg; high-CGA)
1579358|NCT02388672|Dietary Supplement|placebo|Decaffeinated coffee with placebo capsules as control group for green coffee bean extract supplement (224mg; low-CGA)
1579360|NCT02388646|Other|Exercise Only|This group will be given a set of 2 exercises to complete at home. The exercises are designed to strengthen the quadriceps muscle group.
1579361|NCT02388646|Device|Brace Only|This group will be fitted with a Reaction Web brace and asked to wear it when going about activities of daily living.
1579362|NCT02388646|Other|Bracing + Exercises|This group will be asked to both wear the Reaction Web brace during activities of daily living and complete a set of 2 exercises designed to strengthen the quadriceps muscle group.
1579363|NCT02388633|Procedure|Plasmapharesis|Clinically-indicated LDL apheresis
1579364|NCT02388620|Drug|LEE011|400 mg
1579365|NCT02388607|Other|measurements|performance measurements
1579366|NCT02388594|Drug|ZFN Modified CD4+ T Cells|
1579367|NCT02388594|Drug|Cyclophosphamide|
1579368|NCT02388581|Drug|Lansoprazole, Amoxicillin, Clarithromycin, Metronidazole|Anti-H. pylori Therapy
1579369|NCT02388568|Drug|Lorcaserin|Lorcaserin plus Lifestyle Modification
1579370|NCT02388568|Drug|Placebo|Placebo plus Lifestyle Modification
1579371|NCT02388555|Procedure|Posterior osteotomy correction|The DLS patients underwent osteotomy including pedicle subtraction osteotomy (PSO) or Smith-Petersen osteotomy (SPO)
1579490|NCT02387853|Drug|LEO 90100|
1579687|NCT02386241|Other|saliva or blood sample collection|Single saliva or blood sample measuring 10mL for genomic analysis.
1579372|NCT02388542|Behavioral|Educational Intervention|Employees above the age of 35 years will be risk stratified into moderate or high risk of developing cardiovascular disease using a simple non-lab based risk scoring system, they will be invited to participate in the pilot intervention study. This is a single arm before-after study.subject education will focus on life style medication and adherence to medication (if applicable).importantly the peer mentor will try to identify barriers to adopting a healthy lifestyle(tobacco, physical acitivity, diet, alcohol and strees) and adherence to cardiovascular disease prevention medication. peer mentors will be trained to interpret blood glucose and lipids, recognize abnormal valves, provide lifestyle counseling and refer to treating physician when appropriate.
1579373|NCT02388529|Drug|MTP-131|MTP-131 (low dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
1579374|NCT02388529|Drug|MTP-131|MTP-131 (intermediate dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
1579375|NCT02388529|Drug|MTP-131|MTP-131 (high dose) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
1579376|NCT02388529|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as once-daily 1- hour intravenous infusion for 5 consecutive days
1579377|NCT02388516|Dietary Supplement|Vitamin D3|
1579378|NCT02388516|Dietary Supplement|Placebo|
1579379|NCT02388503|Dietary Supplement|no added fruit extract|
1579380|NCT02388503|Dietary Supplement|fruit extract|
1579381|NCT02388503|Dietary Supplement|fruit extract|
1579382|NCT02388503|Dietary Supplement|fruit extract|
1579383|NCT02388503|Dietary Supplement|fruit extract|
1579384|NCT02388490|Drug|brentuximab vedotin|Brentuximab vedotin administered by IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle. The dose of brentuximab vedotin is 1.8 mg/kg q 3 weeks.
1579385|NCT02388477|Drug|Doxycycline|antibiotic used to treat infection
1579386|NCT02388477|Drug|sugar pill|placebo with no pharmacologic effect
1579387|NCT02388464|Drug|MTP-131|MTP-131 (low dose) administered as single intravenous infusion over 4 hours
1579388|NCT02388464|Drug|MTP-131|MTP-131 (intermediate dose) administered as single intravenous infusion over 4 hours
1579389|NCT02388464|Drug|MTP-131|MTP-131 (high dose) administered as single intravenous infusion over 4 hours
1579390|NCT02388464|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as single intravenous infusion over 4 hours
1579391|NCT02388451|Device|Feuerstein Program|The IE activity is administered by instructors in groups of 10 to 15 participants. The intervention comprises 30 twice weekly meetings of 90 minutes duration per group.
1579392|NCT02388438|Device|Bongener|
1579393|NCT02387333|Procedure|Polypropylene Mesh Stoma reinforcement technique with ileal conduit urinary diversion|"After standard steps of radical cystectomy and sparing of distal 15 cm of ileum as a conduit for diversion.
A preferred rectal muscle splitting approach is preferred for IC exteriorization.
Dissection of subcutaneous fat off the rectus sheath will be accomplished to create a potential space for mesh placement.
Then, 5 x 5 cm polypropylene mesh will be placed and incised at the center to create an orifice to allow IC exteriorization.
The mesh is then fixed to underlying rectus sheath with 1-0 non-absorbable proline sutures.
The IC is exteriorized through the central orifice and then fixed to the peritoneum and to the cut-edges of the rectus muscle using 3-0 polyglactin sutures.
A 12 CH subcutaneous tube drain will be left and the subcutaneous tissue is closed to collapse the dissected space around the mesh.
The stoma is then everted and fixed to the skin."
1579394|NCT02387333|Procedure|Ileal conduit urinary diversion|In this group, no mesh will be applied with ileal conduit urinary diversion
1579395|NCT02387320|Other|Self-Care Toolkit|The self-care toolkit was designed and created for individuals undergoing surgery and/or invasive medical procedures. It provides individuals with guided instruction to learn several evidence-informed mind-body skills (e.g., breathing, relaxation, meditation, guided imagery) and tools (e.g., acupressure wristbands, journal) in order to regulate their own physiologic and emotional reactions to stressful situations and to lessen symptoms associated with surgery (principally pain, anxiety, nausea, fatigue, sleep disturbance).
1579396|NCT02387307|Drug|rSIFN-co|rSIFN-co is a drug developed by Sichuan Huiyang Life Science and Technology Corporation for the treatment of solid tumors especially in non-small cell lung cancer and other tumor types. The study comprises of 2 stages: the dose-escalation stage and dose expansion stage.
1579397|NCT02387294|Biological|ntervention: Vaccination with Fluval AB Novo.|vaccination
1579398|NCT02387268|Device|CleanC system|Cleansing liquid and fecal matter during a standard colonoscopy procedure
1579399|NCT02387255|Device|Resoundant Driver System|This device is used to generate vibrations at the area of interest. The device has an active driver, a loud speaker sitting outside the scanner area, and a passive driver, which is shaped like a silicone paddle, which is secured with velcro straps to the area being imaged. Sound waves from the active driver travel through a tube attached to the passive driver and generate vibrations, images of which are captured by the MR scanner.
1579400|NCT02387242|Drug|Rifampicin|Single oral dose of rifampicin
1579401|NCT02387229|Drug|Rivaroxaban|15 mg
1579402|NCT02387229|Drug|Acetylsalicylic acid|100 mg
1579403|NCT02387216|Drug|MM-121|Investigational, fully human antibody targeting and inhibiting ErbB3
1579404|NCT02387216|Drug|Docetaxel|approved chemotherapy treatment for NSCLC
1579405|NCT02387216|Drug|Pemetrexed|approved chemotherapy treatment for NSCLC
1579406|NCT02387203|Drug|PrevPac (Prevacid, Amoxicillin, Clarithromycin)|30mg Prevacid, 1g amoxicillin, 500mg clarithromycin administered together for oral use, twice daily for 14 days preoperatively and twice daily for 14 days at least 4 weeks postoperatively
1579408|NCT02388399|Procedure|Device|Optical coherence tomography to evaluate plaque morphology and vulnerable features (ex> cap thickness, spotty calcification)
1579569|NCT02387112|Device|Early VAD implantation|Implantation of a left ventricular assist device
1579410|NCT02388386|Device|PROTEUS-SENSOR|An edible sensor system, Proteus Digital™ has been developed for electronically confirming medication adherence, gathering physiologic metrics and communicating these data to patients. The system consists of two major components: an edible sensor and a wearable receiver health monitor. An electrical signal is activated upon ingestion of the Proteus Digital micro-sensor with transmission of this signal to a receiving abdominal patch to quantify medication compliance.
1579411|NCT02388373|Drug|Fluticasone 250/formoterol 10|
1579412|NCT02388373|Drug|Fluticasone 250/salmeterol 25|
1579413|NCT02388373|Drug|Fluticasone 125/formoterol 5|
1579414|NCT02388360|Drug|topical prostaglandin analogs|
1579415|NCT02388347|Drug|Placebo SC|Participants will receive a single-dose of Placebo subcutaneous (SC) injection on Day 1.
1579416|NCT02388347|Biological|MEDI7836 Dose 1|Participants will receive a single-dose of MEDI7836 Dose 1 SC injection on Day 1.
1579417|NCT02388347|Biological|MEDI7836 Dose 2|Participants will receive a single-dose of MEDI7836 Dose 2 SC injection on Day 1.
1579418|NCT02388347|Biological|MEDI7836 Dose 3|Participants will receive a single-dose of MEDI7836 Dose 3 SC injection on Day 1.
1579419|NCT02388347|Biological|MEDI7836 Dose 4|Participants will receive a single-dose of MEDI7836 Dose 4 SC injection on Day 1.
1579420|NCT02388334|Other|to develop a standardized questionnaire|"to develop, from the caregivers' point of view, a standardized questionnaire evaluating 1) their quality of life (QOL) as related to the disease of the assisted and 2) their expectations concerning the global quality of professional management (care, coordination, information...).
The development of this standardized tool will also :
identify the specific support needs of the caregivers
study the links between the quality of care as perceived by the professionals, patients and caregivers
identify the characteristics of the caregivers (status) and patients (disease type, disease-modifying drug (DMD) initiation, disease duration) associated with questionnaire results."
1579423|NCT02388308|Device|Clarity ultrasound|Ultrasound imaging data will be recorded only. Treatment will not be altered as a result of this study.
1579424|NCT02388295|Drug|AZD3241|Drug: AZD3241 administered for 12 weeks orally as a tablet.
1579425|NCT02388295|Drug|Placebo|Placebo to match AZD3241 administered for 12 weeks orally as a tablet.
1579426|NCT02388282|Device|diaphragm ecography|recording of diaphragm ecography
1579428|NCT02388256|Device|acupuncture|"Points of Stomach 36 (ST36), Stomach 37 (ST37), Liver 3 (LR3), Large Intestine 11 (LI11), Large Intestine 4 (LI4), Spleen 6 (SP6), Spleen 4 (SP4) and Pericardium 6 (PC6) will be used. Electrical stimulation with alternating frequency of 2 to 100 Hz will be applied to the selected points (LI4 to LI11, ST36 to ST37, and bilateral SP6).
Rationale of acupuncture treatments will include both traditional theory of harmonizing gastrointestinal function and strengthening vital energy as well as modern experimental and clinical evidence of regulating gastrointestinal motility and other symptom managements. Treatments will be provided by qualified hospital staff (Korean medical doctors) with more than 10 years of clinical experience."
1579429|NCT02388256|Other|early recovery program after surgery|An enhanced recovery program after surgery that was designed and is currently implemented by surgeons, anesthetists, dietitians, and nurses will be provided. The program includes preoperative education, early water/food intake, early mobilization, early removal of Foley catheter and drains, structured nursing care, and nutritional support.
1579430|NCT02388243|Behavioral|Brief Intervention in Public Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing techniques, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a public clinic.
1579431|NCT02388243|Behavioral|Screening Results in Public Clinic|At each public clinic, a community health worker will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The community health worker will provide the results of the BMI, physical activity and the ASSIST and will offer a leaflet with further explanation about how to address problems with those lifestyles
1579432|NCT02388243|Behavioral|Brief Intervention in Private Clinic|The ASSIST-linked brief intervention includes a discussion, between the clinician and patient, of problem drinking and its associated adverse effects and how to address risky level of alcohol use, using motivational interviewing technics, assess and manage any complication or co-morbidity uncovered, and request to the patient to follow-up in one month. Clinicians will also be asked to record their baseline and follow-up clinical assessment and management through clinical follow-up forms. The total brief intervention should be around 15 minutes, with a follow-up visit of about the same length a month later. This intervention in happening in a private clinic.
1579483|NCT02387905|Radiation|Stereotactic Spinal Radiosurgery (SSRS)|Participants receive CT-guided spinal stereotactic radiosurgery using intensity modulated radiation therapy. Treatment planning based on group's current standards for organ-at-risk dose constraints; however, final target volume and treatment plan at discretion of attending physician.
1579484|NCT02387905|Procedure|Prophylactic Cement Augmentation|Participants receive prophylactic cement augmentation to spine within 4 weeks (before or after) radiosurgery treatment.
1579485|NCT02387905|Behavioral|Brief Pain Inventory Assessment Form|Assessment form completed at months 3, 6, 9, 12, 18, and 24.
1994169|NCT03056677|Dietary Supplement|Control|200mls water will be given prior to a mixed carbohydrate meal
1579433|NCT02388243|Behavioral|Screening Results in Private Clinic|At each private clinic, a support staff will ask patients presenting for consultation who are aged 18 years or older to be screened for healthy lifestyle and to receive feedback on their results. The screening will include self-reported weight and height, (for BMI calculation), level of physical activity, and the Alcohol, Smoking and Substance Involvement Screening Test (ASSIST). The inclusion of the BMI and level of physical activity is to mask the purpose of the intervention, by decreasing the focus on substance use. The support staff will provide the results of the BMI, physical activity and the ASSIST, and will offer a leaflet with further explanation about how to address problems with those lifestyles.
1579434|NCT02388230|Device|Ultrasound imaging|
1579435|NCT02388204|Procedure|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
1579436|NCT02388204|Procedure|Implantable spinal cord stimulation|Implantation of SCS electrode and pulse generator
1579437|NCT02388191|Drug|Naproxen sodium|550 mg, oral, on day 1. Number of Cycles: 1
1579438|NCT02388191|Other|Placebo tablet|
1579439|NCT02388178|Drug|Control toothpaste containing no anti-cavity ingredients|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
1579440|NCT02388178|Drug|Experimental toothpaste containing fluoride and amino acid (arginine)|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
1579441|NCT02388178|Drug|Fluoride toothpaste containing fluoride as the anti-cavity ingredient|Brush whole mouth with study toothpaste 2x/day for the 2 week test period. Each brushing routine is 1 minute whole mouth brushing with oral retainer in mouth, spit out toothpaste residue and wait for 1 minute before rinsing with water.
1994170|NCT03056677|Dietary Supplement|Normal Whey protein|Whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
1994171|NCT03056677|Dietary Supplement|Modified whey protein|Modified whey protein (50grams) drink will be given prior to a mixed carbohydrate meal
1579444|NCT02388152|Biological|Lu AF20513, low dose|
1579445|NCT02388152|Biological|Lu AF20513, medium dose|
1579446|NCT02388152|Biological|Lu AF20513, high dose|
1579447|NCT02388139|Procedure|renal artery angiography|preprocedural renal arteriogram is obtained after sterile preparation and draping of the patient, conscious sedation, infiltration of local anesthetic (lidocaine solution) at the femoral access site, placement of an arterial sheath in the femoral artery, and advancement of the renal guide catheter over a 0.035-in guidewire under fluoroscopic guidance. After the tip of the guide catheter is positioned at the ostium of the renal artery, an angiogram is obtained. After the guidewire is removed, the proximal end of the catheter is connected to a manifold, and 4-8 mL of contrast is manually injected during cineangiographic recording. An intravenous antithrombotic agent, usually heparin, is administered before the clinician proceeds with angioplasty.
1579448|NCT02388139|Procedure|coronarography|
1579449|NCT02388139|Procedure|coronary angioplasty|
1579450|NCT02388139|Procedure|pulse wave velocity measurement|is a measure of arterial stiffness with Sphigmocore device.
1579451|NCT02388139|Procedure|body composition monitoring|using Fresenius device
1579452|NCT02388126|Device|3T multiparametric MRI|Magnetom Verio 3T, Erlangen, Germany
1579453|NCT02388126|Device|Transrectal ultrasound|Bk Medical Pro Focus Ultraview 2202 system
1579454|NCT02388113|Behavioral|accumulated exercise|
1579455|NCT02388113|Behavioral|traditional exercise|
1579456|NCT02388100|Procedure|Capillary HbA1c collection|
1579457|NCT02388087|Device|ROX COUPLER|ROX coupler device is inserted to create an Iliacartero-venous anastamosis following right heart catheterisation.
1579458|NCT02388087|Procedure|Right heart catheterisation and routine care|Participants will have right heart catheterisation followed by routine care. Participants will be blinded to ROX coupler insertion.
1579459|NCT02388074|Device|CyPath®|CyPath® diagnostic assay for the early detection of lung cancer using sputum
1579460|NCT02388061|Drug|Tenecteplase|
1579461|NCT02388061|Drug|Tissue Plasminogen Activator|
1579462|NCT02388048|Drug|Ibrutinib + ofatumumab|
1579463|NCT02388035|Drug|Cefotaxime|
1579464|NCT02388022|Device|Degenerative Disc Disease|lumbar interbody with posterior screw and rod instrumentation
1579465|NCT02388009|Biological|Flexyn2a|Intramuscular doses of 0.5 mL
1579466|NCT02388009|Biological|Placebo|Intramuscular doses of 0.5 mL
1579467|NCT02388009|Biological|Flexyn2a plus adjuvant|Intramuscular doses of 0.5 mL
1994172|NCT03056638|Drug|Degarelix|Degarelix monthly for 6 months
1579469|NCT02387983|Drug|Posaconazole|Posaconazole 300 mg solid oral tablet
1579470|NCT02387970|Procedure|Immediate provisionalization|Stage one protocol: Individuals will receive temporary crowns at the same day as implant surgery, and a final restoration at four months after surgery.
1579471|NCT02387970|Procedure|Delayed provisionalization|Stage two protocol: Individuals will receive temporary crowns 3 months after implant surgery, and a final restoration at four months after surgery.
1579472|NCT02387970|Device|NobelParallel CC implant|Supports the comprehensive range of dental prosthetics as well as full range of prefabricated abutments.
1579473|NCT02387970|Device|Dental crown|"A tooth-shaped cap that is placed over a tooth or implant for teeth restoration and improvement in appearance."
1579474|NCT02387957|Drug|Fovista®|
1579475|NCT02387957|Drug|bevacizumab|
1579476|NCT02387957|Drug|ranibizumab|
1579477|NCT02387957|Drug|aflibercept|
1579478|NCT02387931|Dietary Supplement|Vitamin D3|Nature Made Vitamin D 2000IU, 1 softgel taken daily
1579479|NCT02387931|Dietary Supplement|Fish Oil|Nature Made ultra omega-3 mini fish oil 500mg, 2 soft gels taken daily
1579480|NCT02387931|Other|Placebo|Placebo capsule, 2 taken daily
1579481|NCT02387918|Drug|Dexamethasone|Patients will receive Intravenous dexamethasone 0.15 mg/kg immediately after induction of anesthesia.
1579482|NCT02387918|Device|Acupuncture|Acupuncture treatment (just after induction of anaesthesia and for approximately 20 minutes)
1994173|NCT03056638|Radiation|stereotactic body radiosurgery (SBRT)|SBRT 8 Gy x 5
1579491|NCT02387840|Device|Magnetic Resonance Imaging|Patients will have a scan of soft tissue using magnetic field and radio frequency pulses.
1579492|NCT02387840|Device|Magnetic Resonance Fingerprinting|Magnetic resonance fingerprinting (MRF) uses pseudo-randomized variation in acquisition parameters to generate a multi-parametric data signal that can be compared to signal patterns calculated from all possible combinations of parameters of interest. The closest match in signal patterns yields the parameters used to calculate the theoretical signal, in each voxel, and thus a map of all parameters of interest for that tissue. This process allows for rapid quantitation of MR relaxometry values (T1 and T2).
1579493|NCT02387827|Behavioral|Diet+ short term versus long -term physical activity|
1579495|NCT02387801|Drug|Ixekizumab|Administered SC
1579496|NCT02387788|Drug|AKB-9778|Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
1579497|NCT02387775|Device|Esophageal temperature control|"Insertion of the Esophageal Cooling Device (ECD) will take place as described in the product monograph. The ECD will be connected to the heat exchange unit Blanketrol Hyper-Hypothermia System® (Cincinnati Sub-Zero, Cincinnati, OH) and will be used for temperature control for a total of 36 hours. A patient target of 35°C will be set on the heat exchange unit. Once target is attained, it will be maintained for 24 hours. Slow rewarming will then be achieved by increasing the input target by 0.2°C per hour, until a target of 36.6°C is reached.
All temperature data (device, input target, and patient bladder temperature) will be captured automatically using Data Export Software® (Cincinnati Sub-Zero, Cincinnati, OH) on an external laptop connected to the external heat exchange unit."
1579498|NCT02387762|Drug|ACP-196|
1579499|NCT02387762|Drug|Placebo|
1579500|NCT02387762|Drug|Methotrexate|
1579502|NCT02387736|Behavioral|Dialectical Behaviour Therapy (6 months)|Modification of behaviours achieved with reframing thoughts and impulses
1579503|NCT02387736|Behavioral|Dialectical Behaviour Therapy (12 months)|Modification of behaviours achieved with reframing thoughts and impulses
1579504|NCT02387723|Biological|Allogeneic adipose derived stem cells (CSCC_ASC)|Culture expanded allogeneic adipose derive stem cells (CSCC_ASC)
1579505|NCT02387710|Drug|Tiagabine|GABA reuptake inhibitor
1579506|NCT02387710|Drug|Placebo|Placebo comparator
1579507|NCT02387697|Device|Edwards Sapien XT Valve|The device will be implanted in the present study to prevent abdominal venous congestion and to improve the function of the tricuspid valve which is located in the low pressure system in the right heart.
1579508|NCT02387671|Behavioral|Device: FitBit Flex wrist band|Participants will track their daily steps walked and hours of sleep by wearing the FitBit Flex wrist band during the 8 week study period. The data collected from the wrist band will be synced to participants' FitBit smart phone application and monitored by the study team.
1579509|NCT02387671|Behavioral|Device: FitBit Aria weight scale|Participants will record their daily body weight during the 8 week study period by stepping on the FitBit Aria weight scale. The data collected from the scale will be synced to participants' FitBit smart phone application accounts and monitored by the study team.
1579510|NCT02387671|Behavioral|Diet Intake Messages|The study team will send participants daily text messages regarding their dietary intake. Each message will contain five questions that yield a yes, or no response. Messages will be sent daily during the 8 week study period. Responses from the messages will be recorded and monitored by the study team to enhance the behavioral counseling intervention.
1579511|NCT02387671|Behavioral|Behavioral Counseling|Participants will engage in four phone calls with the study counselor to discuss behavioral several topics (physical activity, sleep, fatigue & dietary patterns) and to reflect on their data recorded by the FitBit devices. The calls will take place on a bi-weekly basis. During the weeks between calls, the counselor will maintain contact with the participants through asynchronous text messages to monitor their progress in the study.
1579512|NCT02387658|Procedure|translesional gradient measurement|Patients will be stratified into two groups based on the final mean translesional pressure gradient obtained in the femoropopliteal arterial bed after revascularization or just after angiography if no revascularization is done.
1579513|NCT02387645|Procedure|Lavage of the Uterus|The lavage will be performed in the operating theatre under general anesthesia. The ALPINE technique includes the following steps. A three way catheter (catheter for uterine and tubal lavage) is inserted into the cervical canal and a balloon is inflated to seal the cervical canal. The patient is put into anti-Trendellenburg positioning. Normal saline is slowly flushed into the uterine cavity and proximal tubes. After the lavage is finished, the balloon is deflated and the catheter is removed. A cap is put on the collection syringe and the syringe is sent to the laboratory.
1579514|NCT02387619|Drug|Rosuvastatin|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin once daily for 9 days
1579515|NCT02387619|Drug|Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Telmisartan/Amlodipine once daily for 9 days
1579516|NCT02387619|Drug|Rosuvastatin and Telmisartan/Amlodipine|Rosuvastatin and Telmisartan/Amlodipine: Rosuvastatin and Telmisartan/Amlodipine once daily for 9days
1579517|NCT02387606|Drug|Placebo|Participants will receive placebo once daily.
1579518|NCT02387606|Drug|JNJ-53718678|Participants will receive JNJ-53718678 as 20 milliliter (mL) (200 mg) or 50 mL (500 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 1. JNJ-53718678 dose in Cohort 2 will be decided based on Cohort 1 results. JNJ-53718678 as 7.5 mL (75 mg) oral solution (containing 10 mg JNJ-53718678 per mL) in Cohort 3.
1579520|NCT02387580|Drug|OZ439 + TPGS|
1579521|NCT02387580|Drug|OZ439 Prototype 1|
1579522|NCT02387580|Drug|OZ439 Prototype 3|
1579523|NCT02387580|Drug|PQP|
1579524|NCT02387567|Drug|Lidocaine|Paraspinal block with 3ml lidocaine injection at 1%.
1579525|NCT02387567|Drug|Sham Lidocaine|Sham injection, without lidocaine.
1579526|NCT02387567|Other|Standard treatment|Standard treatment only, without lidocaine or sham injection.
1579527|NCT02387554|Drug|HGP0904|
1579528|NCT02387554|Drug|HGP0608|
1579529|NCT02387554|Drug|HGP1405|
1579530|NCT02387528|Behavioral|MIndfulness Intervention|An intervention program integrating elements of Mindfulness Breathworks Institute Mindfulness based approaches for Pain and ilness (MBPI), (Burch , 2009) and Mindfulness Based Stress Reduction (MBSR), (Kabat Zinn, 2003), and Mindfulness based Cognitive Therapy (MBCT) shall be used. All programs are highly structured, lasting eight weeks, with a weekly meeting about two hours , and working with four main techniques during these meetings : mindfulness in breathing, body scan, walking meditation and mindfulness yoga. In order to facilitate the home practice of meditation by participants during and after the intervention protocol, all will receive a CD containing guided meditation sessions, covering the above techniques.
1579531|NCT02387528|Behavioral|Control Group meetings|Eight meetings where the participants will practice relaxation techniques.
1579532|NCT02387515|Other|intensive rehabilitation program|Patients will follow an intensive rehabilitation program (2x/week for 18 weeks), with emphasis on motor control training that is supported by technology. The technological system consists out of motion tracking sensors that register the movements and position of the lumbar spine.
1579533|NCT02387502|Device|Intubation- Macintosh laryngoscope|Difficult intubation was simulated by using rigid neck collar. Then patients were intubated according to the assigned laryngoscopes. In Macintosh group, tip of the laryngoscope blade was placed in the vallecula and epiglottis was lifted. After visualization of the vocal cord, patients were intubated.
1579534|NCT02387502|Device|Intubation- MacCoy laryngoscope|In MacCoy group, tip of the laryngoscope blade was placed in the vallecula and lever was pressed to flex the tip. After visualization of the vocal cord, patients were intubated.
1579535|NCT02387502|Device|Intubation- Airtraq laryngoscope|In Airtraq group, the laryngoscope was loaded with endotracheal tube. Airtraq laryngoscope was inserted through midline and after visualization of image of vocal cord through its eyepiece, endotracheal tube was passed.
1579536|NCT02387489|Behavioral|Brief in-person motivational intervention|Brief in-person motivational intervention tailored to participants' risk behaviors, delivered by a nurse.
1579537|NCT02387489|Behavioral|Computerized Brief Intervention|Computer-delivered motivational intervention tailored to participants' risk behaviors.
1579540|NCT02387450|Drug|Sildenafil|100 mg per day
1579541|NCT02387450|Drug|Placebo|Placebo with same presentation as the active drug
1579542|NCT02387437|Behavioral|SI recruitment|SI continuous positive airway pressure (CPAP) held at 40 cm H2O for 40 secs.
1579543|NCT02387437|Behavioral|IP recruitment|Incremental positive end-expiratory pressure (PEEP) with a fixed peak pressure (IP), PEEP increased in 5 cm H2O increments (allowing 30 secs/step) from a baseline PEEP of post-trial to 40 cm H2O while decreasing tidal volume to limit peak inspiratory pressure to 40 cm H2O. After CPAP of 40 cm H2O was held for 30 secs, PEEP was decremented in 5-cm H2O steps to the post-RM PEEP setting, while increasing tidal volume toward the baseline value of 10 mL/kg (as the 40 cm H2O peak pressure limit allowed).
1579544|NCT02387437|Behavioral|PCV recruitment|PCV peak pressure = 40 cm H2O, inspiratory to expiratory ratio = 1:2, and PEEP level = 15cm H2O for 2 min
1579545|NCT02387424|Behavioral|MBCT-PD|The 8-session MBCT protocol, with modifications for use in the context of pregnancy and in anticipation of the postpartum.
1579546|NCT02387424|Behavioral|OAR|Ongoing Assessment and Referral (OAR) consists of routine screening and referral to behavioral health services within obstetric clinical settings within Kaiser Permanente (KP) in Colorado and Georgia.
1579547|NCT02387411|Other|High-intensity interval exercise training|High-intensity interval exercise training [4 reps * (4 min at 80% VO2peak + 3 min at 50% VO2peak)]
1579548|NCT02387411|Other|Combined exercise training|High intensity [2 reps * (4 min at 80% VO2peak + 3 min at 50% VO2peak)] and strength exercise training (2-4 sets, 10-12 reps, 60-65% 1RM, for quadriceps and hamstrings, 14 min in total)
1579549|NCT02387398|Procedure|Early Angiography|Coronary Angiography within 120 minutes of admission for out-of-hospital cardiac arrest with ROSC
1579550|NCT02387385|Device|Whole body cooling (Tecotherm)|Whole body cooling to 33 to 34 C using Tecotherm
1579551|NCT02387372|Drug|Ceftolozane/Tazobactam - Multiple Doses|"4-6 doses of ceftolozane/tazobactam every 8 hours as a 60-minute intravenous infusion as follows:
Participants with CLCR > 50 mL/min will receive 4-6 doses of 3 g ceftolozane/tazobactam every 8 hours
Participants with CLCR 30 - 50 mL/min will receive 4-6 doses of 1.5 g ceftolozane/tazobactam every 8 hours
Participants with CLCR 15 - 29 mL/min will receive 6 doses of 750 mg ceftolozane/tazobactam every 8 hours"
1579552|NCT02387372|Drug|Ceftolozane/Tazobactam - Single Dose|Single dose of ceftolozane/tazobactam, 3 g, as a 60-minute intravenous infusion
1579553|NCT02387359|Drug|Plecanatide|
1579554|NCT02387359|Drug|Placebo|
1579555|NCT02387346|Device|Magstim Rapid 2 Repetitive Transcranial Magnetic Stimulation|
1579556|NCT02387346|Device|Magstim Rapid 2 Sham Stimulation|
1579557|NCT02387177|Behavioral|Stress Management Group 1|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
1579558|NCT02387177|Behavioral|Stress Management Group 2|Subjects will attend group stress management sessions via Skype once weekly for 8 weeks and learn stress/NF symptoms managements techniques.
1579559|NCT02387164|Drug|Alum-GAD|Two doses à 20 microgram 30 days apart subcutaneously administrated
1579560|NCT02387164|Drug|Vitamin D3|2000 Units (IE) (50 microgram) vitamin D3 daily
1579561|NCT02387151|Drug|mesenchymal stromal cells|2 doses of 1-2x10^6 allogeneic bone marrow derives MSCs IV per/kg body weight at weeks 25 and 26 after transplantation
1579562|NCT02387138|Drug|S-1|"S-1: Administered orally twice daily from day 1 for 7 consecutive days followed by a 7-day recovery period in a 14-day cycle.
The starting dose of S-1 will be two levels below the recommended dose defined in SIRI (20 mg/m² BID minimum) with a cohort dose escalation by 5 mg/m² increments (5 dose levels)."
1579563|NCT02387138|Drug|Irinotecan|Irinotecan : fixed dose of 180 mg/m² IV over 90 minutes on d1 of every cycle
1579564|NCT02387138|Drug|Oxaliplatin|Oxaliplatin : fixed dose of 85 mg/m² over 120 minutes on d1 of every cycle
1579565|NCT02387138|Other|G-csf|G-csf : d8 to d13 systematically
1579566|NCT02387125|Biological|CMB305|
1579567|NCT02387125|Biological|G100|
1579568|NCT02387125|Drug|Metronomic CPA|
1579926|NCT02384473|Procedure|SWE|Undergo SWE
1579570|NCT02387099|Drug|3 weeks Dose Induction of Everolimus|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.
All patients will be treated within the approved indication of everolimus in combination with exemestane.
Patients will be randomized in a 1:1 ratio"
1579571|NCT02387099|Drug|3 weeks Conventional Everolimus Dosing|"Comparing a conventional dosing approach starting with 10 mg at first dose versus a dose-escalating schema over 21 days in patients receiving everolimus in combination with exemestane for treatment of metastatic breast cancer.
All patients will be treated within the approved indication of everolimus in combination with exemestane.
Patients will be randomized in a 1:1 ratio"
1579572|NCT02387099|Drug|Open Label Phase with conventional 10mg Everolimus Dosing week 4-24|All patients will receive open label Everolimus with Exemestane for 21 weeks according to label
1579573|NCT02387099|Drug|Standard Care after 24 weeks|It is up to the discretion of the investigator to continue with Everolimus+Exemestane beyond 24 weeks
1579574|NCT02387086|Drug|Thalidomide|
1579575|NCT02387086|Drug|placebo|
1579576|NCT02387086|Drug|Gefitinib|
1579577|NCT02387086|Drug|Aspirin|
1579578|NCT02387073|Other|Electrical version patient reported outcome questionnaire|"Assess satisfaction of patients with electrical version patient reported outcome questionnaire."
1579579|NCT02387060|Drug|H-Bupivacaine|Intrathecal administration of hyperbaric bupivacaine 1.5 ml 0.75%
1579580|NCT02387060|Drug|Fentanyl|Intrathecal administration of fentanyl 25 mcg
1579581|NCT02387034|Behavioral|Physical activity on prescription|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and a patient-centered counselling about physical activity related to the disease. It leads to a Swedish Physical activity on prescription (PAP). It is an individualized written prescription on physical activity and includes specific mode of physical activity. The patient is contacted by telephone or visit the physiotherapist after three weeks, three months and six months.
1579582|NCT02387034|Other|General advice|Participants meet a physiotherapist for 60 minutes, get information about osteoarthritis, physical activity and weight control and receive an intervention with general advice about physical activity
1579583|NCT02387021|Procedure|Continuous femoral nerve block|
1579584|NCT02387021|Procedure|Continuous adductor canal block|
1579585|NCT02387021|Procedure|infragluteal Sciatic nerve block|
1579586|NCT02387021|Drug|Ropivacaine 0.2%|
1579587|NCT02387021|Drug|Saline|
1579588|NCT02387008|Device|GUIDOR® membrane with FDBA|horizontal bone augmentation with synthetic GUIDOR® membrane + FDBA
1579589|NCT02387008|Device|GUIDOR® membrane|horizontal bone augmentation with synthetic GUIDOR® membrane
1579590|NCT02387008|Device|Bio-Gide® membrane with FDBA|xenograft BioGide® membrane + FDBA
1579591|NCT02386995|Device|BIS monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia monitoring are then compared.
1579592|NCT02386995|Device|Entropy monitor|Both types of depth of anesthesia monitoring (BIS and entropy- electrodes) are applied on patients together with standard monitoring (heart rate, blood pressure, respiratory rate). The two different types of depth of anesthesia
1579593|NCT02386982|Drug|HMS5552|
1579594|NCT02386969|Device|active rTMS then sham rTMS|A first period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months
1579595|NCT02386969|Device|sham rTMS then active rTMS|A first period during which the patient will have 1 session of sham rTMS every 3 weeks for 3 months A 2nd period during which the patient will have 1 session of active rTMS every 3 weeks for 3 months
1579596|NCT02386956|Other|Active stretching|10 minutes of active stretching of the posterior muscle chain with RPG techniques
1579597|NCT02386956|Other|Dynamic Stretching|10 minutes of dynamic stretching of the sciatic nerve and the posterior muscle chain with manual techniques of mobilization the nerves
1579598|NCT02386956|Other|Control|10 minutes with the patient lying on a machine off of magnetotherapy
1579599|NCT02386943|Drug|Sitagliptin|100mg po once.
1579600|NCT02386943|Drug|Saxagliptin|5mg po once.
1579601|NCT02386943|Drug|Blank control|No medication is taken.
1579602|NCT02386930|Behavioral|Behvarioal lifestyle modification|A six months behavioral lifestyle program composed of 8 sessions; 4 individual consultations and 4 telephonic calls. The cognitive behavior theory (CBT) is the underpinning theory for the lifestyle intervention; hence CBT behavioral strategies like self monitoring and goal setting are used to improve compliance to healthy lifestyle practices
1579603|NCT02386917|Procedure|Gastric bypass|Weight loss surgery
1579604|NCT02386917|Behavioral|Very low calorie diet|Non-surgical weight loss procedure
1579605|NCT02386904|Drug|Phosphate Enema (Kleen® Enema)|120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
1579606|NCT02386891|Other|Thermal Environment|
1579607|NCT02386878|Behavioral|Interpersonal Psychotherapy for Groups (IPTG)|Interpersonal psychotherapy is a theory- and evidence-based treatment approach for depression developed by clinicians. World Vision has helped to pioneer the use of this model in sub-Saharan Africa including adapting the model for use with OVC within South Africa. Sessions are designed to provide participants with opportunities to learn and practice interpersonal skills for solving problems that bring about depression, and to facilitate the provision of emotional support between members of the group. Groups are implemented by a trained adult facilitator from the community who helps participants to identify people who are important in their lives, understand links between their psychological state and current problems, and practice new ways of problem-solving.
1579640|NCT02386644|Other|Nitrazine test|To assess acid , alkaline status of pooled fluid in vagina.
1579641|NCT02386631|Device|Custom Made Orthotic|Provides longitudinal arch support
1579682|NCT02386293|Drug|Irbesartan|Double blind placebo controlled cross over trial to determine effectiveness of an angiotensin receptor blocker in obese hypertensive African American patients.
1579683|NCT02386293|Drug|Placebo|Sugar pill made to look identical to irbesartan intervention.
1579608|NCT02386878|Behavioral|Vhutshilo 2|The Vhutshilo 2 model was developed in 2008 by the Centre for the Support of Peer Education (CSPE), a branch of the South African non-profit organization Health and Education Training and Technical Assistance Services. The Vhutshilo program was designed specifically for adolescent OVC in South Africa, and attends to risk factors and pathways considered particularly relevant for this population. Topics include finding and giving emotional support; dealing with grief and loss; alcohol and substance abuse; crime and sexual violence; HIV/AIDS; healthy and safe sexual relationships; and transactional sex. In addition to its knowledge component, the program places heavy emphasis on building relevant skills and efficacy.
1579609|NCT02386852|Drug|Placebo|Study subjects received, in a double blind fashion, placebo pills identical to the drug (drug 1-ginseng, group 1; drug 2-ginkgo biloba-group 2)
1579610|NCT02386852|Drug|Ginseng|The ginseng group received two capsules containing either 1000 mg or 500 mg of Panax Ginseng extract standardized to 3% of ginsenosides (GNC, USA) or similarly looking placebo capsules over a period of three days of testing.
1579611|NCT02386852|Drug|Ginkgo Biloba|The ginkgo group received two capsules containing either 240 mg or 120 mg of ginkgo biloba extract standardized to 24% ginkgo flavone glycosides and 6% terpene lactones (GBE24/6) or similarly looking placebo capsules over a period of three testing days.
1579612|NCT02386839|Drug|Mecasermin rinfabate|
1579613|NCT02386826|Drug|INC280|"Dose Escalation: INC280 by mouth (PO) twice daily for 28 days according to the following schedule until the maximum tolerated dose (MTD) is determined:
Dose Level 1 (starting dose): 200 mg (divided dose of 100 mg twice per day) Dose Level 2: 400 mg (divided dose of 200 mg twice per day) Dose Level 3: 800 mg (divided dose of 400 mg twice per day)
Dose Expansion: INC280 PO twice daily at the MTD determined in the dose escalation phase"
1579614|NCT02386826|Biological|bevacizumab|bevacizumab: 10 mg/kg IV every 2 weeks. Patients with unresectable GBM will be given 15 mg/kg IV every 4 weeks.
2008549|NCT03329144|Behavioral|Cognitive Behavioural Therapy|The transdiagnostic CBT-based curriculum is based on the extensive clinical experience of the research team with young women and those struggling with perinatal mental disorders. The team also has significant expertise delivering CBT for depression and anxiety (including perinatal variants) in groups. The manual was developed by the research team and is based on the state-of-the-art in resilience and CBT interventions in adolescents and young adults (e.g., the Penn Resiliency Program (60), Treatment for Adolescent Depression Study (61)). After it was developed, it was subjected to further scrutiny by public health nurses and STRIVE staff, who have extensive experience working with young mothers.
1579616|NCT02386787|Device|Ultrasonography|an ultrasonography will be conducted before the anesthesic procedure to provide reliable quantitative information about the volume of gastric content.
1579617|NCT02386774|Device|Handheld IVCM Vivascope 3000 (Caliber/Mavig) anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml|used anesthesic eyedrop : oxybuprocaïne Thea 1,6 mg/0,4 ml
1579618|NCT02386774|Device|Multifluorescence IVCM vivascope 1500 ML (Caliber/Mavig)|"used for Multifluorescence IVCM
anesthesic eyedrop : oxybuprocaïne (1,6 mg/0,4 ml)
Fluorescein 0,5%, Rose Bengal , Infracyanine"
1579619|NCT02386774|Procedure|microangiography|realization of the microangiography with intravenous injection of fluoresceine and indocyanine green.
1579620|NCT02386761|Drug|Single Ascending Dose (SAD)|
1579621|NCT02386761|Drug|Multiple Ascending Dose (MAD)|
1579622|NCT02386748|Dietary Supplement|Chewing gum|Chewing sugarless gum after the discharge from the operating room by two hours for at least half an hour at two hours intervals.
1579623|NCT02386748|Dietary Supplement|Oral fluids|Starting clear oral fluids after operating room discharge by six hours, then hearing intestinal sounds on second day before initiating full regular diet.
1579624|NCT02386748|Other|Intravenous fluids|Women in this group will not receive neither gum nor oral fluids, they will be on intravenous fluids (lactated ringer solution).
1579625|NCT02386735|Drug|Placebo|Three days prednisone 40mg, two days placebo
1579626|NCT02386735|Drug|Prednisone|Five days prednisone 40mg.
1579627|NCT02386722|Device|Smartinhaler/POEMS with audio reminders and additional support calls|Patients assigned to the intervention group will receive a Smartinhaler/POEMS, which will contain an audio reminder function. If the alarm function is on, a ring tone will be generated, after the time predesigned for inhalation. If the use of rescue medication doubles or if the inhaled medication is not inhaled as prescribed for more than two consecutive days, the investigator will call them to see if they need help and to find out the reason for non-adherence.
1579628|NCT02386709|Device|FDG PET|FDG PET1 before neoadjuvant chemotherapy FDG PET2 after one cycle of neoadjuvant chemotherapy
1579629|NCT02386696|Other|Ultrasound|Lung ultrasound examination on healthy volunteers
1579630|NCT02386683|Other|lung-protective ventilation|mechanical ventilated with a tidal volume of 6-8ml/kg ideal body weight (IBW) and 6-8 cm H2O PEEP in anesthesia
2008550|NCT03329131|Device|Cryotherapy|An Elasto gel™ frozen (4°C) glove and sock
2008551|NCT03329118|Drug|SHR3824, Simvastatin|two 20mg tablets of simvastatin once daily on Day 1 followed by one 10mg tablet of SHR3824 once daily on Day 4,5,6,7,followed by two 20mg tablets of simvastatin and one 10mg tablet of SHR3824 on Day 8.
1579633|NCT02386657|Other|Satisfaction|Satisfaction questionnaire to be filled in
1579634|NCT02386657|Other|Biological parameters|Measure of standard routine biological parameters (Hb, GB, Plaq, LDH, CRP, TCA, INR, D Dimers) and dosage of nitrous albumin (PNA).
1579635|NCT02386657|Other|Pain management|Validated pain scale questionnaire to be filled in
1579636|NCT02386644|Other|PAMG-1 Immunoassay|Immunoassay for presence of placental alfa microglobulin-1(PAMG) in vaginal fluids.
1579637|NCT02386644|Device|Ultrasound transperineal assessment|Transperineal ultrasound assessment of vaginal canal for pooling of amniotic fluid.
1579638|NCT02386644|Device|Ultrasound amniotic fluid index measurement|Calculation of amniotic fluid index in millimetres via ultrasonography by measuring four deepest pockets in four quadrants.
1579639|NCT02386644|Other|Speculum examination|Sterile speculum examination to evaluate vaginal pooling of amniotic fluid pooling.
2008552|NCT03329105|Other|Sea Salt Mouth Rinse|Rinsing mouth with a tablespoon of sea salt mouth rinse without any dilution, for 30 seconds, once in the morning and once before bed, in addition to Standardized Oral Health Practices.
1579642|NCT02386618|Procedure|Standardized endoscopic treatment of local residual neoplasia|Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN < 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN > 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN > 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
1579643|NCT02386605|Behavioral|Motivational Interviewing|group-based recovery-oriented Motivational Interviewing combined with cognitive-behavioral therapy to target the negative symptoms of schizophrenia
1579644|NCT02386605|Behavioral|Relaxation Skills|Relaxation skills training group for comparison condition for negative symptoms of schizophrenia
1579645|NCT02386592|Drug|Chlorhexidine gluconate (CHG)|All enrolled neonates admitted to the NICU during the implementation and intervention periods will undergo CHG bathing (sparing head and face) at the time of admission at and thereafter once weekly.
1579646|NCT02386592|Behavioral|Hand hygiene (HH)|Alcohol hand rub will be produced in the hospital pharmacy and will be readily available in the NICU (via wall-mounted dispensers) throughout the intervention period. Hand hygiene among NICU physicians and nurses will actively be promoted through the intervention period.
1579647|NCT02386592|Behavioral|Infection control training|All NICU healthcare workers will receive infection prevention training which will involve structure training on HH, universal precautions, neonatal skin antisepsis and peripheral IV placement and line care.
1579648|NCT02386592|Other|Infection control reminders via SMS text|Infection control practice reminders will be sent to NICU healthcare workers on a daily basis via SMS messages.
1579649|NCT02386579|Procedure|Blood sample measurements|Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
1579650|NCT02386566|Drug|natalizumab|As described in the treatment arm
1579651|NCT02386553|Drug|Nusinersen|Solution for intrathecal injection
1579652|NCT02386540|Behavioral|Health Coaching|The Alameda County Health Coach program pairs patients with a language-concordant health coach for six months following an ED visit. Health coaches are young adults from the local community employed through Alameda County and trained for three months in topics such as self-management support and motivational interviewing. Health coaches work one-on-one with participants in order to develop an action plan in order to achieve patient-identified health goals. Communication between the health coach and participant includes text messages (weekly), phone calls (twice a month), face-to-face visits (at least once), and accompaniment to a primary care visit (at least once). Health coaches may also assist participants in accessing community resources as related to the individualized action plan.
1579653|NCT02386501|Drug|ADXS31-164|
1579654|NCT02386488|Drug|Vortioxetine 10 mg single dose|10 mg tablet for oral use, single dose
1579655|NCT02386488|Drug|Vortioxetine 20 mg single dose|Two 10 mg tablets for oral use, single dose,
1579656|NCT02386488|Drug|Vortioxetine 10 mg multiple dose|10 mg tablet for oral use once, daily for 14 days.
1579657|NCT02386488|Drug|Vortioxetine 20 mg multiple dose|Two 10 mg tablets for oral use, once daily for 14 days.
1579658|NCT02386475|Other|placebo|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
1579659|NCT02386475|Drug|citalopram|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
1579660|NCT02386475|Drug|sinemet plus|In all cases, regardless of the assigned treatment group, will follow usual physiotherapy program and vascular risk factors, and treatment of stroke will be controlled according to current recommendations of the American Heart Association / American Stroke Association.
1579661|NCT02386462|Drug|Dexmedetomidine|The modified Dixon's up-and-down method was used to determine the bolus dose of dexmedetomidine, starting from 1.0μg/kg (step size; 0.1μg/kg)
1579662|NCT02386462|Drug|Propofol|
1579663|NCT02386449|Drug|sodium picosulfate, magnesium oxide and citric acid (Picoprep®)|
1579664|NCT02386449|Drug|mannitol|
1579665|NCT02386449|Drug|Bisacodyl|
1579666|NCT02386436|Drug|GSK2330811|GSK2330811 will be supplied as clear or opalescent, colourless, yellow to brown liquid administered as single dose s.c.
1579667|NCT02386436|Drug|Placebo|Placebo will be supplied as Normal Saline (0.9% weight by volume [w/v] Sodium Chloride) administered as single dose s.c.
1579668|NCT02386423|Device|RESTIFFIC™ Brand Pressure Application System|The device, RESTIFFIC™, was administered intermittently through the course of the study: one-week baseline period without the device (days 1-7), three weeks of initial testing with the device (days 8-28), a subsequent one-week period without the device (days 29-35), and three weeks of subsequent testing with the device (days 36-56).
1579669|NCT02386410|Behavioral|Group parent training for anxious parents|
1579670|NCT02386410|Behavioral|Internet delivered parent training for anxious parents|
1579671|NCT02386397|Drug|Regorafenib|Regorafenib: X mg/d, PO, from day 1 to day 14; day 15 to day 20: off-treatment
1579672|NCT02386397|Drug|GEMOX|mGEMOX: infusion on days 1 and 8: Gemcitabine 900 mg/m² IV in 30 minutes Oxaliplatin 80 mg/m² IV in 120 minutes immediately after Gemcitabine
1579673|NCT02386371|Procedure|tumorectomy|"Tumorectomy will be performed according to the current standards, obtaining clear margins. The axillary lymph node control will depend on the initial management (clinical and ultrasound) of these N0 patients, chosen by the teams."
1579674|NCT02386371|Radiation|Intra Operative Radiotherapy|After the excision of the tumor, IORT will be delivered. A single dose of 20 Gy by 50 kV photons (Intrabeam™) will be administered in tumor bed. The addition of IORT does not modify the surgical procedure
1579675|NCT02386358|Drug|Benznidazole|Benznidazole at a dose 5 mg/Kg/day until 60 days have been completed or development of non-acceptable toxicity-
1579676|NCT02386358|Drug|Placebo|Placebo at a dose 5 m/Kg/day until 60 days
1579677|NCT02386332|Procedure|transplantation|
1579678|NCT02386319|Drug|Melatonin|Gelatin capsules
1579679|NCT02386319|Drug|Placebo|Placebo capsules
1579688|NCT02386228|Genetic|collection of CSF and blood|collection of CSF and blood
1579689|NCT02386215|Behavioral|HIV self-test|"Two self-test kits will be distributed to women, each containing the following:
One standard OraQuick ADVANCE I/II test kit
Written pre-test information including test instructions in written and pictorial form
A phone number that participants can call to obtain additional information
Two vouchers with unique identifying numbers which can be redeemed at confirmatory testing"
1579690|NCT02386202|Other|No intervention|No interventions
1579691|NCT02386189|Behavioral|Care Coordination|Veterans in this group will share a comprehensive list of all of their providers (VA and non-VA) at future appointments. He/she will also be trained on how to create a VA Health Summary in My HealtheVet to share with their non-VA providers and how to use their community portals (if available) to share information back to VA providers. A VA and non-VA provider visit will be evaluated.
1579692|NCT02386163|Biological|MSC from synovial membrane and infrapatellar Fat Pad|
1579693|NCT02386150|Biological|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial
2008553|NCT03329105|Other|Standardized Oral Health Practices|Brushing teeth for two minutes using the modified Bass technique, twice per day with the provided dentifrice, and flossing once daily using the spool method
1579695|NCT02386124|Other|frailty evaluation|assessment of mental and physical frailty before discharge from cardiac departement
1579696|NCT02386111|Drug|Combination of varlilumab and sunitinib|"During the treatment phase of the study, eligible patients will receive varlilumab for up to 8 cycles. Treatment cycles are 6 weeks each with varlilumab administered once every 3 weeks and sunitinib administered daily for 4 weeks followed by a 2 week rest. There is no limit on the number of cycles of sunitinib. Patients may be discontinued from receiving study treatment (sunitinib or varlilumab) based on the results of disease assessments or if experiencing side effects that make study therapy intolerable.
Phase l Dose: The planned dose of varlilumab will be dependent on the cohort assigned at enrollment. Varlilumab doses are 0.3 mg/kg, 1 mg/kg or 3 mg/kg.
Phase ll Dose: The planned varlilumab dose will be established from the outcome of the Phase 1 portion of the study.
All patients will receive sunitinib at a dose of 50 mg."
1579697|NCT02386098|Drug|BMS-955176|HIV Maturation Inhibitor
1579698|NCT02386098|Drug|Atazanavir (ATV)|Atazanavir
1579699|NCT02386098|Drug|Ritonavir (RTV)|Ritonavir
1579700|NCT02386098|Drug|Dolutegravir (DTG)|Dolutegravir
1579701|NCT02386098|Drug|Tenofovir (TDF)|Tenofovir
1579702|NCT02386085|Procedure|Osteopathic manipulative treatment (OMT)|OMT will be provided as part of the patient's health care, prior to enrollment in the study.
1579705|NCT02386059|Drug|PLACEBO|received normal saline, intravenously
1579706|NCT02386059|Drug|Dexamethasone|4 mg, intravenously, at the start of surgery
1579707|NCT02386059|Drug|Ondansetron|4 mg, intravenously, 15 minutes before the end of surgery.
1579708|NCT02386059|Drug|Dexamethasone + Ondansetron|4 mg dexamethasone, intravenously at the start of surgery and 4 mg ondansetron intravenously 15 minutes before the end of surgery.
1579709|NCT02386046|Other|Pulse oxymeter measurements|Pulse oxymeter measurements done at the hospital and upon discharge, weekly until 46 weeks postconceptional age
1579710|NCT02386033|Drug|Atorvastatin (ATV)|After SRP, ATV gel was delivered subgingivally into the pocket
1579711|NCT02386033|Drug|Placebo Gel|After SRP, placebo gel was delivered subgingivally into the pocket
1579712|NCT02386020|Drug|aloe vera|After SRP, aloe vera gel was delivered subgingivally into periodontal pockets.
1579713|NCT02386020|Drug|placebo gel|After SRP, placebo gel was delivered subgingivally into periodontal pockets.
1579714|NCT02386007|Drug|DW-3101_150mg|
1579715|NCT02386007|Drug|DW-3101_300mg|
1579716|NCT02386007|Drug|DW-3101_600mg|
1579717|NCT02386007|Drug|Placebo|
1579718|NCT02385994|Device|enLighten Laser|enLighten Laser treatment with dual-pulse width and dual-wavelength
1579719|NCT02385981|Device|Stivax|
1579720|NCT02385955|Procedure|Myeloablative double unit cord blood transplantation|Two myeloablative conditioning regimens will be used in this study: (1) total body irradation (TBI, 12Gy), followed by cyclophosphamide (60 mg/kg/day on day -3 and -2) and cytarabine (3 g/m2 every 12 hours on day -5 and -4), or (2) thiotepa (5 mg/kg/day on day -7 and -6), busulfan (3.2 mg/kg/day on day -5, -4, and -3), and fludarabine (50 mg/m2/day on day -5, -4, and -3).
1579721|NCT02385942|Device|Smart phone|"measure the Live assessed wound size and the transmitted Smart phone-based wound size
determine dressing materials using Smart phone-based tele-consultation"
1579722|NCT02385929|Behavioral|Swallowing therapy & resistance training|"i) Individual instructions in swallowing and mouth opening exercises 3 days per week by occupational therapist throughout radiotherapy, ii) Progressive resistance training twice weekly by physiotherapist, either individually or group based, throughout radiotherapy, iii) Daily home-based swallowing and mouth opening exercises from beginning of treatment until 2 months after end-of-treatment.
iv) Weekly follow-up phone contacts with occupational therapists from end-of-treatment and 2 months onwards."
1579723|NCT02385916|Other|EstroSense®/MD|A natural product already approved by Health Canada
1579724|NCT02385916|Other|Placebo|Placebo
1579725|NCT02385903|Other|Flammacerium|
1579726|NCT02385903|Other|Standard dressing procedure|
1579727|NCT02385890|Other|Control|Non pulse ingredient bagel
1579728|NCT02385890|Other|Pea flour|Pulse ingredient bagel
1579729|NCT02385890|Other|Pea fibre|Pulse ingredient bagel
1579730|NCT02385890|Other|Pea protein|Pulse ingredient bagel
1579731|NCT02385890|Other|Pea flour + pea protein|Pulse ingredient bagel
1579732|NCT02385890|Other|Pea fibre + pea protein|Pulse ingredient bagel
1579733|NCT02385877|Drug|[18F]4F-MHPG|IV injection of [18F]4F-MHPG
1579734|NCT02385877|Drug|[18F]3F-PHPG|IV injection of [18F]3F-PHPG
1579735|NCT02385851|Drug|CHS-1701|
1579736|NCT02385851|Drug|Pegfilgrastim|
1579737|NCT02385838|Behavioral|5-CNL|The 5-CNL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
1579738|NCT02385838|Behavioral|MTL|The MTL front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
1579934|NCT02384408|Procedure|Endometrial Biopsy|Histological assessment
1579739|NCT02385838|Behavioral|GDA|The GDA front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
1579740|NCT02385838|Behavioral|Tick|The Tick front-of-pack nutrition label is introduced on foodstuffs in a controlled shopping environment
1579741|NCT02385825|Biological|RVEc|The composition of the final drug product, prior to any dilution, is 0.2 mg recombinant ricin toxin A-chain 1-33/44-198 (RVEc) in buffer and 0.2% Alhydrogel® at a final volume of 1 mL per vial.
1579742|NCT02385812|Procedure|Low-dose computed tomography Annual scan x3|Annual scan x3
1579743|NCT02385812|Procedure|Low-dose computed tomography Baseline scan only|Baseline scan only
1579744|NCT02385799|Drug|Sertraline Liquid Placebo|Liquid placebo given in parallel to active medication
1579745|NCT02385799|Drug|Sertraline|Active medication
1579746|NCT02385786|Behavioral|Mindfulness-Based Cognitive Therapy|Eight week course in mindfulness meditation training with elements of cognitive behavioral therapy
1579747|NCT02385773|Dietary Supplement|PTM202|Administration of study nutritional product once per day for 3 days starting immediately after enrollment
1579748|NCT02385773|Dietary Supplement|Enfamil Puramino|Administration of 30 ml of Enfamil Puramino as placebo once per day for 3 days starting immediately after enrollment
1579749|NCT02385760|Drug|CTX-4430|
1579750|NCT02385760|Drug|Placebo|
1579751|NCT02385747|Procedure|hystroscopy|Detailed hysteroscopic examination under general anesthesia Once the cavity entered, a panoramic view of the uterine cavity then systematic; first the fundus, then anterior, posterior and lateral walls of the uterus consecutively, ending by visualization of the uterine -tubal junctions, The thickness, colour, aspect and vasculature of the mucous membrane lining the uterine cavity was observed and recorded. If there is any intrauterine pathology detected; the shape, size and site were estimated.
1579752|NCT02385734|Other|Concentrated Growth Factor Membrane|Concentrated growth factor membrane is produced by the centrifugation of venous blood and platelets are concentrated in a gel layer containing fibrin matrix
1579753|NCT02385734|Procedure|Coronally Advanced Flap|Periodontal plastic surgery technique
1579754|NCT02385708|Drug|2% Chlorohexidine Gluconate|Use of 2% Chlorhexidine cloths chin to toes daily
1579755|NCT02385695|Procedure|Posterior Dynamic Stabilization|
1579756|NCT02385695|Procedure|Internal Fixation and Fusion|
1579757|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
1579758|NCT02385682|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
1579759|NCT02385669|Drug|Ipilimumab|Checkpoint blockade inhibitor
1579760|NCT02385669|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
1579761|NCT02385656|Drug|Modafinil|200mg of modafinil daily for 4 weeks
1579762|NCT02385643|Behavioral|SmartPhone Support System|
1579763|NCT02385630|Other|Standardized 400kcal semi-liquid meal|Used to assess post-prandial gut hormone response pre-operatively and at 10 days, 4 weeks, 6 months and 12 months post-operatively.
1579764|NCT02385617|Drug|Octreotide|Octreotide 100mcg (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
1579765|NCT02385617|Drug|Placebo|0.9% saline (1mL) single dose, subcutaneously, into the lower abdomen, 50 minutes prior to eating
1579766|NCT02385591|Behavioral|Telephone Support|telephone-based physical activity advice and support delivered by a trained professional facilitator.
1579767|NCT02385591|Behavioral|SMS Support|Telephone-based physical activity advice and support delivered by SMS.
1579768|NCT02385578|Other|an educational intervention|"the first step of the train the trainer plan(TTT) ,which including the diagnosis and operation hand in hand teach by Professor Yano Takeshiin,and the case discussion,and so on"
1579769|NCT02385565|Other|high fat diet|high fat diet as 10 % proteins, 30 % lipids, 60 % carbohydrates
1579770|NCT02385565|Other|normal fat diet|high fat diet as 10 % proteins, 45 % lipids,45 % carbohydrates
1579771|NCT02385552|Behavioral|Feedback|Experienced endoscopists will receive feedbacks from investigators about their own adenoma detection rates.
1579772|NCT02385539|Drug|The impact of 10 independent variables on the likelihood of not developing hypotension after intrathecal injection.|The study will be conducted to assess the impact of a 10 independent variables (dose and combination of Levobupivacaine with Fentanyl or Sufentanil, age, basal systolic blood pressure (SBP), basal mean arterial pressure (MAP), time to lowest spinal SBP, upper limit of sensory block (dermatoma level), time intervals of sensory recovery for two consecutive dermatoma level (two-segment regression), time intervals of sensory recovery to the twelfth thoracic dermatoma (T12 regression), time intervals of sensory recovery to the first sacral dermatoma (S1 regression) and Body Mass Index) on the likelihood of not developing hypotension after intrathecal injection.
1579774|NCT02385513|Biological|10-valent pneumococcal conjugate vaccine|
1579775|NCT02385500|Drug|Fesoterodine|"For each phase of the study, the participants will receive a total of 84 pills of fesoterodine 4 mg. The study medication will be provided by Pfizer.
For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.
The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
1579776|NCT02385500|Drug|Placebo|"For each phase of the study, the participants will receive a total of 84 placebo pills. The study medication will be provided by Pfizer.
For blinded distribution, each bottle of medications will be labeled with a random number for identification. The participant will indicate in a journal the dose taken each day.
The study participants will be monitored every 2 weeks with phone calls to assess tolerance or side-effects to the medication."
1579777|NCT02385474|Drug|12% SDF|12% silver diamine fluoride solution, of which the capability of arresting dental caries is not sure
1579778|NCT02385474|Drug|38% SDF|38% silver diamine fluoride solution, of which the capability of arresting dental caries is known
1579779|NCT02385461|Drug|Low Molecular Weight Heparins (LMWHs)|
1579780|NCT02385448|Drug|Dienogest|The dienogest group will receive dienogest 2mg daily for 24 months postoperatively
1579781|NCT02385448|Drug|Microgynon|The combined oral contraceptive pills group will be given cyclical Microgynon for 24 months.
1579782|NCT02385435|Drug|Bupivacaine|Caudal Bupivacaine 2 mg/kg single shot
1579783|NCT02385435|Drug|dexmedetomidine 1μg.kg-1|Caudal dexmedetomidine 1μg.kg-1, single shot
1579784|NCT02385435|Drug|dexmedetomidine 2μg.kg-1|Caudal dexmedetomidine 2μg.kg-1, single shot
1579785|NCT02385422|Drug|Carvedilol|Carvedilol is started at a dose of 6.25mg/d, and titrated to a maximum dose of 25mg/d. Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
1579786|NCT02385422|Drug|Propranolol|Patients receiving propranolol start at a dose of 30 mg/d and the dose will be increased to a maximum dose of 160 mg/d.Doses are increased every 2-3 days until ABPsys is not less than 90 mm Hg and HR is not less than 55 bpm.
1579787|NCT02385396|Dietary Supplement|Inofolic: myo-inositol and folic acid|4000 mg of myo-inositol and 0,4 mg of folic acid for 3 months preceding the ICSI procedure
1579788|NCT02385383|Drug|Iron-III Isomaltoside 1000|Protocol for optimizing preoperative Hb using IV Iron-III Isomaltoside 1000
1579789|NCT02385383|Other|Standard Care|Standard Care in a historical control cohort
1579790|NCT02385370|Drug|MMC|using 0.02 MMC soaked sponged under the conjunctiva for 1 to 3 minutes
1579791|NCT02385370|Drug|MMC|0.1 cc of 0.01% MMC is injected into the tenon.
1579792|NCT02385357|Dietary Supplement|Protein-enriched drink|Participants will drink 330 ml of a protein-enriched drink (6 g/ml of protein) after a high intensity exercise that induce muscle damage (30 min running downhill with a slope of -10º)
2008554|NCT03329092|Drug|ATM-AVI|"(Creatinine clearance > 50 mL/min) 6500 mg ATM/2167 mg (loading dose, extended loading dose and maintenance dose) by iv infusion on Day 1 followed by a total daily dose of 6000 mg ATM/2000 mg AVI
(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1417 mg AVI on Day 1 (loading dose, extended loading dose, maintenance dose) followed by total daily dose 3000 mg ATM/1000 mg AVI
(Creatinine clearance 16 - 30 mL/min) 2700 mg ATM/900 mg AVI on Day 1 (loading dose, extended loading dose maintenance dose), followed by total daily dose 2025 mg ATM/675 mg AVI"
1579794|NCT02385318|Drug|Ingenol Mebutate (Perrigo)|
1579795|NCT02385318|Drug|Ingenol Mebutate (Reference)|
1579796|NCT02385318|Drug|Placebo gel|
1579797|NCT02385305|Device|Pressure support ventilation by anesthesia machine (Apollo, Dräger)|Pressure support ventilation will be applied by anesthesia machine (Apollo, Dräger) with pressure support (PS) of 3, 8, 13 and 18 cmH2O in this order, with slope of 1.0 second and no PEEP. The fraction of inspired oxygen will be titrated to achieve SpO2 over 98%. Five minutes will be allowed to achieve equilibrium at each PS level after which an additional recording of one minute of data will be obtained. Once the Pressure support ventilation is completed at 18 cmH2O, ventilation will be carried out in reverse order of PS; 13, 8 and 3 cmH2O of PS.
1579798|NCT02385292|Device|Oculeve Intranasal Lacrimal Neurostimulator|The Oculeve Intranasal Lacrimal Neurostimulator applies a small electrical current to gently activate the body's natural tear production system.
1579799|NCT02385279|Device|MiStent|Percutaneous Coronary Intervention
1579800|NCT02385279|Device|XIENCE EES|Percutaneous Coronary Intervention
1579801|NCT02385266|Drug|D-Cycloserine|Pharmaceutical intervention aimed at altering central nervous system function takes place over 4.5 months with daily use of d-Cycloserine.
1579802|NCT02385266|Drug|Placebo (for D-cycloserine)|Lactose filled capsules to mimic DCS 200mg capsules
1579803|NCT02385253|Behavioral|Educational training program|"The educational training program (intervention) consists of four sequential phases:
Knowledge Acquisition
Skills Assessment
Deliberate Practice
Clinical Proficiency"
1579804|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Perrigo)|
1579805|NCT02385240|Drug|Brimonidine Topical Gel, 0.33 percent (Reference)|
1579806|NCT02385240|Drug|Placebo gel|
2008555|NCT03329092|Drug|MTZ|For cIAI only; 500 mg/100 mL metronidazole iv infusion over 1hr q8h
1579814|NCT02385214|Procedure|Wide Local Excision = 1cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
1579815|NCT02385214|Procedure|Wide Local Excision = 2cm Margin|"A wide local excision involves removing an extra safety margin of healthy skin surrounding the original melanoma site to ensure that any remaining scattered melanoma tumour cells are removed that may have been left behind after the first initial biopsy/surgery."
1579816|NCT02385201|Device|Senza|Spinal Cord Stimulation
1579817|NCT02385188|Drug|Imiquimod|topical 5% imiquimod cream 3 times a week for 16 weeks.
1579818|NCT02385188|Drug|paracetamol|
1579819|NCT02385188|Drug|lidocaine in Vaseline ointment|
1579820|NCT02385175|Other|Different objective clinical tests of Eustachian tube function|
1579821|NCT02385175|Other|Different patient-completed questionnaires relating to Eustachian tube dysfunction|
1579822|NCT02385149|Other|whole grain wheat|A twelve week intervention of 98g whole grain wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
1579823|NCT02385149|Other|refined wheat|A twelve week control intervention of refined wheat in the form of 4 slices of bread (is in total 100g bread) and 2 servings of ready to eat cereals (RTEC, is in total 33.4g RTEC).
1579824|NCT02385136|Drug|Temozolomide|
1579825|NCT02385123|Biological|Influenza Virus Vaccine Inactivated|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Trivalent influenza vaccine is formulated annually, based on influenza strains projected to be prevalent in the upcoming flu season.
1579826|NCT02385110|Drug|Alemtuzumab|"Induction Phase: Alemtuzumab total dose of 1.0 mg/kg subcutaneously or by vein over 4 days (days 1-4) during the 8 week induction phase. Day 1 0.1 mg/kg, Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
Maintenance Phase: 0.2 mg/kg once every 4 weeks for 6 weeks."
1579827|NCT02385110|Drug|Etoposide|"Induction Phase: 150 mg/m2 given by vein once a week for 8 weeks.
Maintenance Phase: Participants who have evidence of refractory disease or budding relapse during the maintenance phase may revert back to receiving Etoposide."
1579828|NCT02385110|Drug|Dexamethasone|"Induction Phase: 20 mg/m2 by vein daily for 1 week followed by 10 mg/m2 by mouth for 1 week followed by 5 mg/m2 by mouth for 2 weeks followed by 2.5 mg/m2 by mouth for 2 weeks followed by 1.25 mg/m2 by mouth for 2 weeks.
Maintenance Phase: 1.25 mg/m2 by mouth three times for 16 weeks."
1579829|NCT02385110|Drug|Methotrexate|Participants with central nervous system involvement receive intrathecal methotrexate 12 mg once a week for 5 weeks during the Induction Phase.
1579830|NCT02385110|Behavioral|Phone Call|If participant responds to study drugs, they will receive a phone call by study staff every 3 - 6 months for up to 5 years after completion of treatment. Each call will last about 5-10 minutes.
1579831|NCT02385110|Drug|Tocilizumab|Induction Phase: Tocilizumab at 4 to 8 mg/kg by vein. Day 1 0.1 mg/kg,Day 2 0.3 mg/kg, Day 3 0.3 mg/kg, Day 4 0.3 mg/kg.
1579832|NCT02385097|Drug|Chloroprocaine HCl 2%|Single Administration (20mL) by Axillary Nerve Route
1579833|NCT02385097|Drug|Ropivacaine 0.75%|Single Administration (20mL) by Axillary Nerve Route
1579834|NCT02385084|Drug|LY2409021|Administered orally
1579835|NCT02385071|Drug|Treatment A|150 milligram (mg) SMV capsule with water under fed conditions.
1579836|NCT02385071|Drug|Treatment B|Treatment B (3*50 mg capsules of SMV (including 50 mini-tablets of 1 mg each) with water under fed conditions.
1579837|NCT02385071|Drug|Treatment C|Treatment C (3*50 mg dispersible SMV tablets dispersed in water under fed conditions).
1579838|NCT02385071|Drug|Treatment D|*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3*50 mg dispersible SMV tablets dispersed in water under fed conditions.
1579839|NCT02385071|Drug|Treatment E|3*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with water or 3*50 mg dispersible SMV tablets dispersed in water under fasted conditions.
1579840|NCT02385071|Drug|Treatment F|3*50 mg SMV capsules (including 50 mini-tablets of 1 mg each) with yoghurt or 3*50 mg dispersible SMV tablets dispersed in apple juice under fed conditions.
1579841|NCT02385058|Drug|Mebendazole|Mebendazole 600 milligram (mg) tablet orally once starting on Day 1 and 21.
1579842|NCT02385058|Drug|Quinfamide|Quinfamide 200 mg tablet orally once starting on Day 1 and 21.
1579843|NCT02385058|Drug|Placebo|Placebo tablet orally once starting on Day 21.
1579844|NCT02385045|Device|i-scan|i-scan function is located on the head of the Pentax endoscopes
1579845|NCT02385045|Device|narrow band imaging|narrow band imaging function is located on the head of Olympus endoscopes
1579846|NCT02385032|Drug|Ursodiol|
1579847|NCT02385032|Drug|URSO Forte|
1579848|NCT02385019|Biological|Donor regulatory T cell adoptive immunotherapy in chronic graft versus host disease|"Regulatory T cells selected by a sequential 2 step procedure:
- Negative selection of CD8 and CD19 cells
- Positive selection of CD25 cells"
1579849|NCT02385006|Biological|Blood sample|
1579850|NCT02384993|Behavioral|Enhanced Physical Activity|This is a 26-week aerobic exercise intervention. The primary mode of training is treadmill walking, with the initial speed and duration calibrated to each participant's baseline aerobic capacity. Participants will train 3-4 days per week with the goal of attaining 150+ minutes of exercise per week by the seventh week. Exercise will be set between 50-60% of maximum heart rate reserve for weeks 1-4, 60-70% for weeks 5-8, and 70-80% for weeks 9-26. Exercise duration will be approximately 15-20 minutes per session during the first week and then increase by 5 minutes each week until a duration of approximately 38-50 minutes per session is reached. Each training session will begin with a 5-minute warm-up and end with a 5-minute recovery period.
1579851|NCT02384980|Device|FES (Gait MyoElectric Stimulator)|Functional Electrical Stimulation (FES) will be tested in a group of peripheral arterial disease patients using the Gait MyoElectric Stimulator. The FES device will be applied to the calf and shin muscles on both of the patients legs.
1579852|NCT02384967|Drug|Darunavir|to assess efficacy of a reduced dose strategy of darunavir to 400 mg/d in HIV-1 infected patients virologically suppressed under a once daily regimen including darunavir 800 mg/d and two nucleoside reverse transcriptase inhibitors (NRTI), to maintain the viral load lower than 50 copies / mL at 48 weeks of treatment.
1579853|NCT02384954|Biological|Rituximab|Intravenous infusion; Patients will receive a 4-week induction cycle consisting of Rituximab given on Day 1, 8, 15, 22. Eligible patients will receive a consolidation treatment consisting of Rituximab given on Day 78, 134, 190, 246.
1579854|NCT02384954|Biological|ALT-803|Intravenous infusion for cohort 1, 2 and 3; subcutaneous injection for cohort 4, 5, 6 and 7; Patients will receive a 4-week induction cycle consisting of ALT-803 given on Day 2, 8, 15, 22 for patients in cohort 1, 2, 3, 4 and Day 1, 8, 15 and 22 for patients in cohort 5, 6, 7. Eligible patients will receive a consolidation treatment consisting of ALT-803 given on Day 78, 134, 190, 246.
1579858|NCT02384928|Procedure|Shinbaro pharmacopuncture|Pharmacopuncture is a treatment that combines 2 of the most frequented Korean medicine treatment methods - traditional acupuncture and herbal medicine - by injecting herbal medicine extract at acupoints. One Hyeopcheok (Huatuo Jiaji, EX B2) acupoint most relevant to patient symptoms with reference to MRI will be administered Shinbaro pharmacopuncture.
1579859|NCT02384928|Device|Acupuncture|Five acupoints will be needled to about 1cm depth assisted by an acupuncture guide tube with no manual stimulation such as twirling or lifting and thrusting.
1579860|NCT02384928|Drug|Conventional medicine|Conventional drugs will be prescribed in an individually-tailored, pragmatic method with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics. The most frequently prescribed conventional drugs for LDH include aceclofenac (Drug class: nonsteroidal antiinflammatoy drugs (NSAIDs)), tramadol hydrochloride (Drug class: Opioids), talniflumate (Drug class: NSAIDs), diclofenac sodium (Drug class: NSAIDs), and loxoprofen sodium (Drug class: NSAIDs).
1579861|NCT02384928|Procedure|Physical therapy|Physical therapy will be prescribed with reference to most frequently used treatments in patients with a primary diagnosis of LDH (KCD disease classification: M51, M541) according to Korean Health Insurance Review and Assessment (HIRA) 2011 statistics.
1579927|NCT02384473|Drug|Definity Suspension for Injection|Participant will receive contrast agent by intravenous administration
1579862|NCT02384928|Behavioral|Educational program|Educational program sessions supervised by physicians will be provided once a week for 4 weeks.The education program will inform the patient of the favorable prognosis of LDH, and instructions for everyday activities and self-management. The education program will consist of handbooks handed out to each participant, and weekly reminders and encouragement from the physician.
1579863|NCT02384915|Drug|prilocaine|
1579864|NCT02384915|Drug|mepivacaine|
1579865|NCT02384915|Procedure|Sciatic-femoral Nerve Block|ultrasound-guided 25 ml 2% mepivacaine injection on both femoral and sciatic nerve
1579866|NCT02384915|Procedure|Spinal anesthesia|intrathecal injection of 40 mg hyperbaric prilocaine
1579867|NCT02384915|Device|Sonoplex, Pajunk|
1579868|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
1579869|NCT02384902|Other|low GI|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
1579870|NCT02384902|Other|conventional diet|All diets were designed with similar macronutrients content (30% fat, 0.8 g/kg/d protein and remained calorie requirement by carbohydrate). Additionally, we controlled phosphorus, sodium and potassium content of diets for three intervention groups. All dietary menus had less than 1500 mg phosphor and less than 2400 mg sodium and 2000 mg potassium.
1579871|NCT02384889|Drug|Difluoromethylornithine|Active Therapy with DFMO
1579872|NCT02384889|Drug|Placebo|Placebo Comparitor
1579873|NCT02384876|Drug|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.6, 0.8, 1.0, 1.2 and 1.4 mg/kG|
1579874|NCT02384876|Drug|Ephedrine 30mg/10mL injectable solution, single administration, dose : 0.1 mg/kG.|
1579875|NCT02384850|Drug|Selinexor|Dose Level 1: 40 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 2: 60 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level 3: 80 mg on day 1, 3 and 8 in a two-weeks cycle. Dose Level -1: 20 mg on day 1, 3 and 8 in a two-weeks cycle.
1579876|NCT02384850|Drug|Oxaliplatin|85 mg/m² IV over 2 hours, Day 1 of a two-weeks cycle
1579877|NCT02384850|Drug|5-FU|400 mg/m² IV bolus, Day 1 of a two-weeks cycle 2,400 mg/m² continuous infusion IV, Days 1-3
1579878|NCT02384850|Drug|Folinic Acid|400 mg/m2 IV over 2 hours, Day 1 of a two-weeks cycle
1579879|NCT02384837|Device|EXCEL biodegradable polymer-coated sirolimus-eluting stent|
1579880|NCT02384824|Procedure|Primary Percutaneous Intervention|angiography, manual aspiration thrombectomy and antiplatelet therapy
1579881|NCT02384811|Radiation|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.
The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
1579882|NCT02384798|Other|noninvasive ventilatory support|noninvasive ventilatory support with 5-minute ramp and positive end expiratory pressure (PEEP) of 5 cm H2O for 30 minutes, then there will be the interval aerobic training on a treadmill added to resistance exercises
1579883|NCT02384798|Other|interval training|interval training
1579884|NCT02384785|Device|Transcutaneous Electric Nerve Stimulation|Electric currents: 'Transcutaneous Electric Nerve Stimulation' and Transcranial Direct Current Stimulation will be applied on the back of the patients in parallel to the implanted electrodes. Implanted electrode will measure voltages that generated near the spinal cord tissue.
1579885|NCT02384772|Other|Survey|
1579886|NCT02384759|Drug|aflibercept|
1579887|NCT02384759|Drug|LV5FU2|
1579888|NCT02384746|Drug|Fulvestrant|500 mg intramuscular every 28 days
1579889|NCT02384746|Drug|MLN9708|Subjects will be treated in 3 dose cohorts of MLN9708, at 2.3, 3, and 4 mg orally on days 1, 4, 8, and 11 every 21 days.
1579890|NCT02384733|Radiation|Loco-regional RT|
1579891|NCT02384720|Other|Age: 20-40years|
1579892|NCT02384720|Other|Age: 41-64years|
1579893|NCT02384720|Other|Age: ≥65years|
1579894|NCT02384707|Other|allegic food|"Reintroduction procedure for small doses :
Administration of the first dose
Clinical monitoring for 45 minutes
Administration of the second dose"
1579895|NCT02384707|Other|Placebo|
1579896|NCT02384694|Other|Zumba dance|Twelve weeks, 3 times weekly 1 hour training
1579897|NCT02384681|Other|Exposure to auditory fatigue|12-hour auditory exposure
1579898|NCT02384668|Dietary Supplement|Cholecalciferol|One tablet per day. The duration of the intervention period is between 24-36 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18(-24) months after randomisation. Vitamin D supplementation will continue 12 months after withdrawal of ATD treatment or until relapse of Graves' Disease if this occurs prior.
1579899|NCT02384668|Dietary Supplement|Placebo|One tablet per day. Placebo tablet identical in appearance to cholecalciferol tablet. Duration and cessation of treatment identical to intervention with cholecalciferol.
1579900|NCT02384655|Drug|Fenugreek seed meal|3x3 capsules of fenugreek seeds per day for 14 days
1579901|NCT02384642|Behavioral|COMPASS|COMPASS (Creating Opportunities through Mentoring, Parental involvement and Safe Spaces) is a program for 10-14 year old girls in Eastern DRC. The program is a structured intervention that is intended to engage adolescent girls, through life skills training and establishing or supporting community-supported safe spaces for girls where they can come and gather among themselves and participate in a structured life-skills curriculum.
1579902|NCT02384642|Behavioral|COMPASS plus parenting|The COMPASS plus parenting intervention is the core COMPASS intervention, plus activities for the parents and caregivers of participants.
1579928|NCT02384473|Device|Philips Shear Wave Elastography|Type of equipment used for SWE
1579929|NCT02384460|Drug|SD-101-6.0 cream|applied topically once a day for 90 days
1579930|NCT02384460|Drug|SD-101-0.0 cream|applied topically once a day for 90 days
1579931|NCT02384434|Device|Low Level Laser Therapy|Red Light Therapy
1579932|NCT02384421|Device|Adaptive DBS (Activa PC+S Neurostimulator)|
1579903|NCT02384629|Device|OCT-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
1579904|NCT02384629|Device|OCT-guided PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. Optical coherence tomography (OCT), has enabled the evaluation of strut coverage and arterial healing after DES implantation with a superior resolution and delineation over other imaging modalities. With using these superiorities of OCT, there have been many studies assessing the neointimal coverage following various types of DES implantation in various periods.
1579905|NCT02384629|Device|Angio-guided PCI with AXXESS stent|The AXXESS stent (Biosensors Europe SA, Morges, Switzerland) is a dedicated self-expanding bifurcation stent eluting the sirolimus analog Biolimus A9 emulsed in a biodegradable polymer. It has the advantage to preserve the ostium of both distal branches and allows additional stent implantation in the distal branches for complete lesion coverage, while reducing large stent overlap and eliminating deformation. We use the conventional coronary angiography.
1579906|NCT02384629|Device|Angio-guided PCI with PCI with conventional DES (Biomatrix flex stent)|BioMatrix Flex is abluminal biodegradable polymer DES. Its abluminal coating is absorbed after 6 to 9months and turns the DES into a BMS. It combines the proven safety of a DES with an abluminal biodegradable polymer, the prove efficacy of BA9 and an advanced stent design. We use the conventional coronary angiography.
1579907|NCT02384616|Other|Oxygen|Delivery of high concentration of oxygen at induction, maintenance and extubation of children under general anesthesia.
1579908|NCT02384603|Other|Global postural reeducation|
1579909|NCT02384603|Other|Segmental muscle stretching exercises|
1579910|NCT02384603|Other|Cognitive behavioral therapy|
1579911|NCT02384590|Behavioral|Computerized cognitive behavioral therapy|"The Beating the Blues computerized cognitive behavioral therapy (CCBT) program is eight 50-minute online sessions that teach the participant how to better manage stress using cognitive behavioral therapy techniques. Cognitive behavioral therapy involves helping people change their thoughts and behaviors so they can limit the negative impact stress will have on their mood and pain experience."
1579912|NCT02384577|Drug|Budesonide, Formoterol Fumarate Dihydrate|
1579913|NCT02384564|Device|Ambu King Vision Video Laryngoscope aBlade|At time of tracheal intubation, the subject will be intubated using the Ambu King Vision Video Laryngoscope with the appropriately sized Ambu aBlade System based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
1579914|NCT02384564|Device|Direct Laryngoscopy via Miller Straight Blade|At time of tracheal intubation, the subject will be intubated via direct laryngoscopy using a straight laryngoscope blade, based on manufacturer guidelines and clinical judgement. The first attempt to successful intubation will be assessed. The Cormack Lehane and Percentage of Glottic Opening scores will be recorded via direct vision. Information on subsequent attempts, time to successful intubation, and ease of tracheal tube insertion will be assessed.
1579915|NCT02384551|Other|Dietary Carbohydrate|9 week menu of dietary carbohydrate modification
1579916|NCT02384538|Biological|ABT-981|ABT-981 administered by subcutaneous injection
1579917|NCT02384538|Biological|Placebo for ABT-981|Placebo for ABT-981 administered by subcutaneous injection
1579918|NCT02384525|Procedure|Fluid management by the value of over hydration in Bioelectrical impedance|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
1579919|NCT02384525|Procedure|Fluid management by clinical-based ultrafiltration|In this study, investigator measure the fluid status of the patients by bioelectrical impedance analysis and lung ultrasound. The patients are assigned into two groups, BIA and Lung Ultrasound based versus clinical-based assessment group. Ultrafiltration of BIA and Lung Ultrasound based group is adjusted to be equal to the value of over hydration measured only by BIA, not by Lung Ultrasound, because Lung Ultrasound cannot determine exact amount of the patient's fluid excess. Total amount of ultrafiltration will be removed from the patient for three days evenly. On the other hand, Ultrafiltration amount will be decided by the physician in the clinical based group. Amount of fluid removal for a day will be adjusted not to exceed 2000ml, so that total fluid removed from the patient will not exceed 6000ml for three days.
1579920|NCT02384512|Drug|Azilect®|AZILECT® 1mg Tablets
1579921|NCT02384499|Biological|ALLO-ASC injection|Allogenic-adipose-derived mesenchymal stem cells (ALLO-ASC) injection to the anal sphincter of patients with fecal incontinence
1579922|NCT02384499|Drug|Placebo|0.9% normal saline with fibrin glue injection to the anal sphincter of patients with fecal incontinence
1579923|NCT02384486|Behavioral|Training to Reduce Stress in Mothers of Children with (ASD)|The main objective of the proposed study is to examine the effect of implementing the proposed intervention on stress in mothers of children with ASD in SA
1579924|NCT02384486|Other|Nothing (treatment as usual)|Mothers in the control group will continue to receive treatment as usual during the trial
1579925|NCT02384473|Procedure|Real-Time CEUS|Undergo real-time CEUS
1579935|NCT02384408|Device|Transvaginal Ultrasound|Endometrial Thickness made by ultrasound
1579936|NCT02384408|Procedure|Endometrial Immunohistochemical|Immunoexpression of estrogen (ER) and progesterone receptors (PR) and Bcl-2 protein
1579937|NCT02384395|Drug|DTG/3TC/ABC FDC|DTG/3TC/ABC FDC as initial therapy for AHI
2008556|NCT03329092|Drug|MER|"Where pathogen initially not suspected of being MER-resistant:
(Creatinine clearance > 50 mL/min) 1000 mg meropenem by 30 min iv infusion q8h
(Creatinine clearance 26 - 50 mL/min) 1000mg meropenem by 30 min iv infusion q12h
(Creatinine clearance 16 - 25 mL/min) 500 mg meropenem by 30 min iv infusion q12h
Where pathogen initially suspected of being MER-resistant (Creatinine clearance > 50 mL/min) 2000 mg meropenem by 180 min iv infusion q8h
(Creatinine clearance 26 - 50 mL/min) 2000 mg meropenem by 180 min iv infusion q12h
(Creatinine clearance 16 - 25 mL/min) 1000 mg meropenem by 180 min iv infusion q12h"
1579939|NCT02384369|Drug|SNC-102 sustained release tablet|Sustained release oral tablet of SNC-102
1579940|NCT02384343|Drug|Dexmedetomidine|An intravenous bolus of dexmedetomidine 30 mcg (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
1579941|NCT02384343|Drug|Normal saline|An intravenous bolus of normal saline (7,5 mL) administered at least five minutes after birth, in participants with shivering grade 3 or 4 on a scale described by Crossley and Mahajan.
1579942|NCT02384317|Drug|CCX168|BID for 84 days
1579943|NCT02384304|Behavioral|Choice|A self help program consisting of 8 modules and access to therapist guidance either through messages or through chat sessions
1579944|NCT02384304|Behavioral|Messages|A self help program consisting of 8 modules and access to therapist guidance through messages
1579945|NCT02384304|Behavioral|Self help|A self help program consisting of 8 modules
1579946|NCT02384291|Device|Alpha-Bio GRAFT Natural Bovine Bone|Pure Hydroxyapatite ceramic mineral with high similarity to the human bone
1579947|NCT02384291|Device|natural bone substitute|natural bone substitute material derived from the mineral portion of bovine bone
1579948|NCT02384278|Behavioral|Internet-based CBT for alcohol problems|A 12-week internet-based program based on cognitive behavior treatment (CBT) and relapse prevention
1579949|NCT02384265|Behavioral|IM/SMS + Incentive Condition|See description of Intervention arm protocols above.
1579950|NCT02384252|Other|functional tissu atrial analysis|
1579951|NCT02384239|Drug|Palbociclib|
2008557|NCT03329092|Drug|COL|"Loading dose 9 million IU by 30 -60 min iv infusion (6 million IU where weight < 60 kg) followed by one of the following maintenance doses:
(Creatinine clearance > 50 mL/min) after a 12h interval, commence maintenance dosing 9 million IU daily in 2 or 3 divided doses by 30 -60 min iv infusions.
(Creatinine clearance 31 - 50 mL/min) After a 24 hr interval, commence maintenance dosing of 6 million IU daily in 2 divided doses by 30 -60 min iv infusion
(Creatinine clearance 21 - 30 mL/min) After a 24 hr interval, commence maintenance dosing 5 million IU daily in 2 divided doses by 30 -60 min iv infusion
(Creatinine clearance 16 - 20 mL/min) after a 24 hr interval, commence maintenance dosing 4 million IU daily in 2 divided doses by 30 -60 min iv infusion"
2008558|NCT03329079|Behavioral|Mobile Technology Plus|The intervention group MT+ will receive the Lose-It Premium mobile phone app with social comparison group, behavior change text messaging, and daily self-weighing via Wi-Fi scale.
1579957|NCT02384187|Drug|Gabapentin as premedication|Patients will receive 0.3 ml/kg (16 mg/kg) oral gabapentin solution (Neurontin 50 mg/ml, Pfizer Pharmaceutical) as premedication two hours before the induction of anesthesia
1579958|NCT02384187|Drug|placebo|Patients will receive 0.3 ml/kg of a placebo solution identical in taste, shape and color to the study medication two hours before the induction of anesthesia.
1579959|NCT02384174|Dietary Supplement|Resistant starch|
1579960|NCT02384174|Dietary Supplement|Dietary fibre (arabinogalactan, gum guar, pectin)|
1579961|NCT02384161|Other|Isometric exercise Intermittent|Intermittent isometric exercise is characterized by an interval muscle contraction (one period and another relaxed contracted period) in which there is no generation of voltage change in the length of the muscle fiber.
1579962|NCT02384148|Other|Circadian rhythm measurement|
1579963|NCT02384148|Procedure|Skin biopsy|A 2mm diameter skin biopsy is performed by a physician using standard procedure.
1579964|NCT02384135|Other|Three-month thromboembolic risk in patient with D-dimer levels between the usual cut-off and the age-adjusted cut-off|
1579965|NCT02384122|Drug|Octreotide|Two injections of 20 mg will be given monthly.
1579970|NCT02384083|Drug|Filanesib, pomalidomide and dexamethasone|Patients will be treated with 28-day cycles of Filanesib administered iv as a 1-hour (± 10-minute) infusion at escalating doses on days 1, 2, 15 & 16, + pomalidomide administered p.o. at escalating doses during 21 days with 7 days rest period + dexamethasone at a fixed dose of 40 mg po days 1, 8, 15 & 22. G-CSF prophylaxis is mandatory in all patients after Filanesib, starting from Day 3 and Day 17 (for a total of 7 days each). Treatment will be continued until progression or unacceptable toxicity.
1579971|NCT02384070|Procedure|FFR|Fractional flow reserve tracings were calculated using a Volcano pressure wire intra-coronary system after ensuring proper calibration of the aortic pressure transducer and the guidewire, using 6 Fr-guide catheters. Before crossing the stenosis, baseline pressure was measured by the guide catheter and the pressure guidewire were equalized according to the manufacturer's specifications. After advancing the pressure sensor across the stenosis, coronary hyperemia was induced using intravenous adenosine (140μg/kg/min until a steady state was reached for at least 3 minutes). Fractional flow reserve was considered positive if it was less than 0.80.
1579972|NCT02384070|Drug|Aspirin|All patients received a chewable aspirin of 325 mg at least 6 hours before the procedure
1579973|NCT02384070|Drug|Clopidogrel|All patient receiving clopidogrel, were loaded with 600 mg at least 6 hours before the procedure
1579974|NCT02384070|Drug|Bivalirudin|Dosed based on the weight at 0.75 mg/kg I.V. bolus dose followed by a 1.75 mg/kg/hr I.V. infusion for the duration of the procedure
1579975|NCT02384057|Other|Computerized cognitive training program|1000 minutes of computerized cognitive rehabilitation with C8 sciences program
1579976|NCT02384057|Other|Conventional cognitive rehabilitation|Same amount of conventional cognitive rehabilitation
1579977|NCT02384044|Device|Crest® Sensi-Stop™ Strips|
1579978|NCT02384044|Device|Colgate® Sensitivity Relief Pen|
1579979|NCT02384031|Device|Traumatic needle|Lumbar puncture is performed with a traumatic needle
1579980|NCT02384031|Device|Atraumatic needle|Lumbar puncture is performed with an atraumatic needle
1579981|NCT02384018|Biological|autologous mesenchymal stromal cell|Islet transplantation patients will receive autologous MSCs following islets infusion
1579982|NCT02384005|Other|Self-anal exam arm|After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
1579983|NCT02383992|Drug|3% H2O2 solution|
1579984|NCT02383992|Drug|0.9% normal saline|
1579985|NCT02383979|Device|Sham (Comparator) Plasma Ball|"will consist of undergoing a sham therapy with a 22 plasma globe involving contralateral limb interaction with the sphere."
1579986|NCT02383979|Device|Mirror|will undergo 14 days of daily mirror therapy sessions preoperatively which will consist of observing the unaffected limb reflected for 30 minutes in a mirror positioned in the midline to block the view of the affected limb
1579987|NCT02383966|Drug|Cetuximab|Cetuximab will be administered on a weekly basis until disease progression. The initial dose will be 400 milligrams per square meter (mg/m^2) as an intravenous infusion. The subsequent doses will be 250 mg/m^2.
1579988|NCT02383966|Drug|Cisplatin/Carboplatin|Cisplatin (or carboplatin at an equivalent dose in case of intolerability of cisplatin) will be administered at a dose of 75 mg/m^2 as a 60-minute intravenous infusion on Day 1 of each 21-day treatment cycle, to a maximum of 6 chemotherapy cycles.
1579989|NCT02383966|Drug|5-fluorouracil|5-fluorouracil (5-FU) will be administered after cisplatin or carboplatin, at a dose of 750 mg/m^2/day as a continuous intravenous infusion over 24 hours a day from Day 1 to Day 5 of each 21-day treatment cycle, to a maximum of 6 chemotherapy cycles.
1579990|NCT02383940|Drug|Sotagliflozin|Sotagliflozin high dose, once daily before the first meal of the day
1579991|NCT02383940|Drug|Placebo|Placebo, once daily before the first meal of the day
1579993|NCT02383901|Drug|Methotrexate|The study includes osteosarcoma patients who have received MAP treatment, MAP treatment contains 12 courses of Methotrexate
1579994|NCT02383888|Drug|BI 425809|
1579995|NCT02383888|Drug|BI 425809|
1579996|NCT02383888|Drug|Placebo|
1579997|NCT02383888|Drug|BI 425809|
1579998|NCT02383875|Behavioral|Opticourses|An intervention session consisted of five two-hour educative workshops which aimed to help people to improve the nutritional quality of food purchases under budgetary constraints.
1579999|NCT02383862|Other|Feedback Group|The intervention will consist of feedback provided to clinicians in the form of patients' baseline PROMIS scores
1580000|NCT02383823|Drug|Estrogens|Crossover study of estrogen or placebo in random order in menopausal women
1580001|NCT02383823|Other|Placebo|Crossover study of placebo or estrogen in random order in menopausal women
1580002|NCT02383810|Drug|Elsiglutide|
1580003|NCT02383810|Drug|Placebo|
1580004|NCT02383797|Biological|Varilrix|Vaccination against varicella in selected cartilage-hair hypoplasia patients
1580005|NCT02383784|Dietary Supplement|Low GI index diet|Low glycemic index diet
1580006|NCT02383784|Dietary Supplement|High GI diet|High glycemic index diet
1580007|NCT02383771|Drug|Ticagrelor|(Ticagrelor 90mg Bid) x 7days
1580008|NCT02383771|Drug|Aspirin + Ticagrelor|(Aspirin 100mg daily + Ticagrelor 90mg Bid) x 7days
1580009|NCT02383771|Drug|Control|No Anti-platelet Therapy
1580010|NCT02383771|Drug|Aspirin + Ticagrelor|Dual anti-platelet therapy (Aspirin 100mg daily + Ticagrelor 90mg Bid) after percutaneous coronary intervention (PCI)
1580011|NCT02383758|Drug|Glycerin Suppository|Nursing staff will administer one glycerin suppository in the bathroom if there is no continent bowl movement in the first 30 minutes. Subjects will be taken to the bathroom 5 minutes after the suppository is administered for a 30 minute sit or until a continent void occurs. If continent bowel movements maintain on two subsequent days (after bisacodyl suppositories are discontinued) the glycerin suppository will be discontinued. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
1580012|NCT02383758|Drug|Bisacodyl suppository|If a subject does not have a bowel movement during the 30 minute sit following administration of the glycerin suppository, they will be given a 1 hour break, after which a bisacodyl suppository will be administered. The participant will then sit for an additional 30 minutes.If continent bowel movements maintain for two subsequent days (after senna is discontinued) bisacodyl suppositories will be discontinued if it was required. At least one primary caregiver will be trained on all components of intervention still in use on the last day their child's admission. Four weekly follow-up appointments will be used to support them as they continue to implement the protocol at home, including continuing to fade out the use of medications for participants who are at least partially continent but not fully independent at the time of discharge.
1580013|NCT02383758|Drug|Senna|If no continent bowel movements occur for two consecutive treatment days, caregivers will be asked to administer senna each evening thereafter until medication tapering begins. Once there have been two successive days with continent bowel movements, senna will be removed from the intervention if it was required.
1580014|NCT02383745|Other|Acute EEG with fast EEG electrode|
1580083|NCT02383173|Other|Enhanced Implementation Approach|"Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using an Enhanced Implementation Approach with in-person, train-the-champion workshops to prepare PCCT members to be leaders and trainers at their home sites"
1580084|NCT02383160|Device|Bioventus Exogen 4000: Low-intensity pulsed ultrasound|Active low-intensity pulsed ultrasound
1580015|NCT02383732|Behavioral|Universal Safety Measures Module (All participants)|During the first session, the therapist conducts a home safety evaluation. During the second visit the therapist provides the caregiver with an individualized Elopement Prevention & Safety Plan (EPSP) based upon the results of the evaluation. The remainder of the session is spent helping caregivers make plans to implement the EPSP to reduce the risk of elopement or lessen the risk of harm to the child if they do successfully elope.
1580016|NCT02383732|Behavioral|Proximity Training Module (Bolting Prevention Participants)|During the first session a functional behavioral assessment (FBA) of bolting is conducted to identify the motivator(s) that evoke bolting. Caregivers identify a setting that is most problematic because it contains the item/activity that most frequently serves as a motivator for elopement. In the next session, caregivers are taught to identify effective alternative reinforcers. In subsequent sessions, antecedent and consequence based strategies are employed to reduce motivation for elopement and reinforce remaining within the designated proximity of a caregiver for increasing durations.
1580017|NCT02383732|Behavioral|Check-In Training Module (Wandering Prevention Participants)|This module employs behavioral strategies to teach a child to check in with a caregiver at frequent fixed intervals during periods of low supervision. Delivering potent reinforcement for checking in counteracts any motivation to wander. Furthermore, if the child does wander caregivers become aware of it immediately because they failed to check in. During the first session caregivers are taught to identify effective reinforcers. A vibrating alarm that can be carried in a participating child's pocket serves as a prompt to seek out a caregiver and check-in. Participants receive access to a previously identified and individualized reinforcer for checking-in with the caregiver.
1580018|NCT02383719|Device|Oro-nasal Mask|
2008559|NCT03329079|Behavioral|Mobile Technology|The comparison group MT will receive the Lose-It Basic mobile phone app only to self monitor eating, activity, and weight.
2008560|NCT03329066|Behavioral|MAST - Managing Asthma & Sleep in Teens|This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.
2008561|NCT03329066|Behavioral|ASMA - Asthma Self-Management for Adol|This behavioral intervention focuses only on asthma care.
2008562|NCT03329066|Behavioral|Information & Referral Control Group|Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
2008563|NCT03329053|Behavioral|The EAPC Exercise Prescription (EXPERT) Tool|"During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions, except recommendations for physical activities. This domain will be consulted exclusively through the digital training and decision support tool.
The EXPERT tool is an interactive digital training and decision support system for optimized exercise prescription in cardiovascular disease patients. The EXPERT tool was designed to provide optimized exercise prescription based on detailed overview of patient´s diagnosis, prognostics, complications and medication."
1580024|NCT02383693|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation
1580025|NCT02383680|Biological|Yellow Fever Vaccination|The Yellow Fever vaccination is actually not part of the study. Only individuals who have an indication for yellow fever vaccination according to Swiss vaccination recommendations will be enrolled. Study procedures will include blood collection to measure antibody development and viremia as well as data collection on possible side effects.
1580026|NCT02383667|Device|Electrocardiogram holter|
1580027|NCT02383654|Procedure|Autologous Adipose-Tissue Derived Stem Cells|"Intravenous and Intracerebral implantation of Autologous Adipose-Tissue Derived Stem Cells
Patient will receive brain implantation of approximately 100 -400million Autologous Adipose-Tissue Derived Stem Cells.
Patient will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice , before brain implantation, and will receive Intravenous of approximately 100-400 million Autologous Adipose-Tissue Derived Stem Cells twice, after brain implantation ."
1580028|NCT02383615|Procedure|Saphenous nerve block|Ultrasound guided saphenous nerve blocks with 0.5% Ropivacaine for patients undergoing elective foot and ankle surgery for post-operative pain relief.
1580029|NCT02383589|Drug|Mycophenolate Mofetil Placebo|MMF matching placebo will be administered orally Q12H.
1580030|NCT02383589|Drug|Mycophenolate Mofetil|MMF will be administered at a starting dose of 500 milligrams (mg) Q12H and the dose will be titrated to achieve a goal of 1 gram (gm) Q12H.
1580031|NCT02383589|Drug|Rituximab|Rituximab will be administered at a dose of 1000 mg via IV infusion.
1580032|NCT02383589|Drug|Rituximab Placebo|Rituximab matching placebo will be administered via IV infusion.
1580033|NCT02383563|Drug|metformin extended release|
1580034|NCT02383550|Other|Observational Cognitive assessments|Observational
1580035|NCT02383537|Other|Diabetes|the trial is observational with no intervention
1580036|NCT02383524|Procedure|Lumbar Radiofrequency Medial Branch Neurolysis|Numerous studies have concluded that facet joint pain can be accurately diagnosed if a significant (but temporary) reduction in pain is achieved with a procedure called a Medial Branch Block (MBB). The clinician delivers a targeted injection of local anesthetic to the joint itself, or in close proximity to the medial branch of the posterior rami of the dorsal root. A significant decrease in pain confirms that the pain originates from the facet joint. If or when the pain returns after successful MBB treatment the patient may be considered for radiofrequency denervation (neurotomy) which selectively disrupts the joint's nerve supply and provides longer-term sustained relief
1580037|NCT02383511|Drug|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, Placebo BID; Period 3, SMT C1100 2500 mg BID
1580038|NCT02383511|Drug|SMT C1100|Period 1, SMT C1100 1250 mg BID; Period 2, SMT C1100 2500 mg BID; Period 3, Placebo BID
1580039|NCT02383511|Drug|SMT C1100|Period 1, Placebo BID; Period 2, SMT C1100 1250 mg BID; Period 3, SMT C1100 2500 mg BID
1580044|NCT02383485|Behavioral|Exercise|Heart rate monitors worn by each child at each session
1580045|NCT02383485|Behavioral|After-school program|Supervised recreational program with token economy
1580085|NCT02383160|Device|Sham device|Placebo device with no active therapy
1580088|NCT02383121|Drug|Midodrine|Not appliciable
1580046|NCT02383472|Device|MedX Health Console model 1100|"All treatments will be administered using the MedX Health Console model 1100. These units were cleared by the FDA as non-significant risk in 2003 and approved for home treatment use in 2005 for temporary increase in local blood flow circulation . . . for temporary relief of minor muscle and joint aches. Cluster heads are 2 inches in diameter. Each contains 9 red (633nm wavelength) diodes and 52 near infrared (870 nm wavelength) diodes. LED cluster heads would be applied to the frontal, parietal and temporal areas, as well as the mid sagittal suture line"
1580047|NCT02383472|Device|MedX Health Console model 1100-placebo|The placebo machine is identical in appearance as the treatment machine; It vibrates, warms, and does everything the treatment machine does except it does not have LED lights on the marker, therefore it cannot emit light. Subjects enrolled in the placebo group will be on the same schedule as the treatment group. They will have two, 10 minute treatments, three times a week totaling 18 visits. The placebo allows the researchers to isolate the effect of the study treatment. If patient's in the LED treatment group fare significantly better than those in the placebo treatment group, the study helps support the conclusion that the LED therapy is effective.
1580048|NCT02383446|Device|Elan foot prosthesis|The research group will perform a gait analysis test (on a computerized treadmill) using their own non-computerized hydraulic foot, while in-socket pressures are measured. The prosthetic foot will then be replaced by a computerized prosthetic foot for one month, following which, the measurements will be repeated. Gait factors will be examined (spatio-temporal data, center of pressure movement) and internal loads inside the residuum will be evaluated. Comparison will also include patient's satisfaction and his ability to move around, evaluated by dedicated questionnaire.
1580049|NCT02383433|Drug|Regorafenib|Given PO
1580050|NCT02383433|Drug|Gemcitabine Hydrochloride|Given IV
1580051|NCT02383420|Radiation|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detector.
1580052|NCT02383407|Device|Medtronic Deep Brain Stimulation|
1580053|NCT02383394|Other|follow up antenatal care|ultrasound follow up of pregnancy
1580054|NCT02383381|Procedure|lateral rectus recession|typical surgery for correcting intermittent exotropia
2008564|NCT03329053|Behavioral|Standard Cardio-Care Lifestyle Counselling|During the 30-minute long consultation subjects will receive standard, usual-cardio-care lifestyle, hypertension and cardiovascular instructions also in the domain of recommendations for physical activities. The exercise prescription process during consultation will be constructed in accordance with published guidelines and recommendations for secondary prevention of cardiovascular diseases.
1580056|NCT02383355|Drug|Raltegravir|Raltegravir 400mg tablets administered twice daily together with continuation of their own backbone therapy
1580057|NCT02383355|Drug|Continuation of own regimen|Continuation of own antiretroviral medication during the 10 weeks follow-up
1580058|NCT02383329|Dietary Supplement|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml|The ONS provided to the children intervention group will be a ready to drink age adapted oral nutrition supplement providing 1,5 kcal/ml
2008565|NCT03329040|Other|No Intervention.|No intervention.
1580060|NCT02383303|Behavioral|Individual Development Account and financial education|The Program intervention includes a matched savings account (Individual Development Account) and financial education.
1580061|NCT02383290|Other|Decision support|Saliva samples will be collected from each participant for genetic testing. A genetic report will be fed back to the research server, and into the Family Physicians/pharmacist's electronic record. The electronic record is linked to the UBC TreatGx computer; the next time the participant is seen by the Family Physician / Pharmacist personalized prescribing recommendations will be available for use.
1580062|NCT02383277|Other|Stretching|Stretching of the rib cage muscles
1580063|NCT02383277|Other|Control|Rest without stretching (sham)
1580064|NCT02383277|Other|Exercise|Constant load exercise on a bike
1580065|NCT02383251|Drug|Pazopanib|Pazopanib 600mg during the fist cycle. Then, if there is not heptic triuyble, the dose could be increased to 800mg
1580066|NCT02383251|Drug|Paclitaxel|Arm 1 : Paclitaxel 65mg/m² Arm 2: Paclitaxel 80mg/m²
1580067|NCT02383238|Drug|Dapagliflozin|10 mg, oral for 6 weeks
1580068|NCT02383238|Drug|Placebo|oral for 6 weeks
2008566|NCT03329027|Device|Vibrating Capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
2008567|NCT03329027|Device|Sham capsule|Patients will receive vibrating capsule for 8 weeks of treatment (5 capsules/week)
2008568|NCT03329014|Drug|Remimazolam|For induction and maintenance of sedation
1580072|NCT02383212|Drug|REGN2810|
1580073|NCT02383212|Radiation|Hypofractionated radiotherapy|
1580074|NCT02383212|Drug|Cyclophosphamide|
1580075|NCT02383212|Drug|Docetaxel|
1580076|NCT02383212|Drug|Carboplatin|
1580077|NCT02383212|Drug|GM-CSF|
1580078|NCT02383212|Drug|Paclitaxel|
1580079|NCT02383212|Drug|Pemetrexed|
1580080|NCT02383186|Procedure|Dermal Suturing Only Wound Closure|The side assigned to dermal suturing only will be closed with a single layer of deep absorbable sutures. The method will be buried vertical mattress or set-back suturing at the surgeons discretion.
1580081|NCT02383186|Procedure|Layered Cutaneous Wound Closure|The side assigned to layered closure is closed with 5-0 fast acting gut.
1580082|NCT02383173|Other|Basic Implementation Approach|Comfort Care Education Intervention utilizing the established infrastructure of Palliative Care Consult Teams, using a Basic Implementation Approach with a teleconference to review educational materials and activate PCCTs to educate other providers.
2008569|NCT03329014|Drug|Placebo|Control arm
2008570|NCT03329001|Drug|Niraparib|Niraparib tablet formulation
2008571|NCT03329001|Other|Niraparib|Niraparib capsule formulation
2008572|NCT03328988|Procedure|QLB|bilateral single shot block, placed under ultrasound control between the thoracolumbar fascial structures close to the quadratus lumborum muscle
1580092|NCT02383095|Behavioral|metacognitive therapy|
1580093|NCT02383069|Other|Intervention Group|Aerobic training
1580094|NCT02383069|Other|Control Group|Chest physiotherapy: Flutter and muscle stretching
1580095|NCT02383056|Device|Omnilux|633nm
1580096|NCT02383043|Drug|Cocaine|
1580097|NCT02383043|Drug|Sustained Release d-Amphetamine|
1580098|NCT02383030|Drug|Fulvestrant|After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemotherapy
2008573|NCT03328975|Drug|Dexamethasone|The overall purpose of this study is to evaluate the effect of a corticosteroid shoulder injection on glucose levels in insulin-dependent diabetic men and women.
2008574|NCT03328975|Other|Placebo|the placebo group will not receive the corticosteroid medication in their injection to treat the inflammation and pain in their shoulder. Instead, they will receive an injection of 5 mL lidocaine only.
1580101|NCT02383004|Other|Acupuncture|If the child is to receive acupuncture, the sites will be cleaned with an alcohol wipe and acupuncture will be performed using a Seirin pionex press needles. A needle will be placed in the Shen Men points of each ear. Needles will also be placed at the left and right Heart 7 (HT-7) point. This acupuncture point is located on the ulnar side of the anterior carpal region, on the palmer crease of the wrist and radial to pisiform bone. The needles will be inserted bilaterally to a depth of 1.8 mm. Needles will not be inserted at a site of active infection or skin breakdown. Needles will remain for the duration of the operation. The needles will be removed before leaving the operating room.
1580102|NCT02382991|Device|3C60-NMPK|3 months with 3C60 - 10 days wash out - 1 month with NMPK
1580103|NCT02382991|Device|NMPK-3C60|1 month with NMPK - 3 months with 3C60
1580104|NCT02382978|Other|nurse-provided well child visit|
1580105|NCT02382965|Device|transcranial focused ultrasound|
1580106|NCT02382952|Device|Differential Dissector|
1580107|NCT02382952|Other|Standard Dissection Method|
1580108|NCT02382939|Drug|somapacitan|Administered subcutaneously (s.c., under the skin) with an investigational pen once weekly for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
1580109|NCT02382939|Drug|somatropin|Administered subcutaneously (s.c., under the skin) with a prefilled pen (Norditropin® FlexPro®) daily for a 26 week period (8 weeks' dose titration, 18 weeks' fixed dose treatment) followed by 1 week washout.
1580110|NCT02382926|Other|Capacitive ECG and contactless heart and breathing rate measurements via camera|During a 30 minute driving simulation cardiologic patients in rehabilitation undergo capacitive ECG measurements via sensors in the car seat as well as heart and breathing rate measurements via camera according to the Eulerian Magnification Method.
1580111|NCT02382913|Biological|aP booster|"Acellular pertussis vaccine:
Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
Biological: Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany) To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine."
1580112|NCT02382913|Biological|TdaP booster|"Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed) Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
1580113|NCT02382913|Biological|Licensed TdaP booster (Boostrix®)|"Licensed TdaP booster vaccine Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
Other: Saline solution Subjects received one injection of saline solution at one month after vaccination."
1580114|NCT02382900|Biological|quadrivalent human papillomavirus (types 6, 11, 16,18) recombinant vaccine|dose scheme (0 and 6 month)
1580115|NCT02382887|Procedure|tracheal intubation|tracheal intubation with the Airtraq
1580116|NCT02382887|Device|Airtraq|
1580117|NCT02382887|Device|fiberscope|
1580118|NCT02382874|Biological|Intravenous injection|Intravenous injection of AD-MSC to the patients with FSGS
1580119|NCT02382861|Device|Neurally adjusted ventilatory assist|In the NAVA group, the level of NAVA is daily adjusted to obtain Eadimax corresponding to 60 % of Eadimax of the patient during the SBT to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
1580120|NCT02382861|Device|Noninvasive pressure support ventilation|In the control group, the PSV is decreased of 2cmH2O daily or several times a day to obtain a good clinical and biologic tolerance, with a respiratory frequency between 15 and 30/min and a tidal volume at 6ml/kg.
1580121|NCT02382848|Drug|Prazosin|A starting dose of Prazosin (1mg capsule) will be given at Week # 1 of this arm. Symptoms will be reassessed and medication will be adjusted by 1-2 mg increments every 7 days for 3 weeks based on clinical response and severity of night mares, to achieve maximum therapeutic benefit while monitoring adverse effects using side effects scale on weekly basis (psychiatrist will be using the scale at every visit). The end point for capping the Prazosin dose will be 6 mg daily.
1580122|NCT02382848|Drug|Placebo|Placebo (sugar pill) is used for 3 weeks.
1580123|NCT02382822|Other|No intervention.|
1580124|NCT02382809|Drug|DC071|Mouthwash, twice daily
1580125|NCT02382809|Drug|Placebo|Mouthwash, twice daily
1580127|NCT02382783|Other|FLARE Intervention Group|"Everything being completed in this group is also being completed in the Standard of Care (SOC) Group except for the following...
The participants randomized to this group will be asked to complete FLARE Questionnaires on a monthly basis and will call us each month with their results. The last question on the questionnaire asks if the patient feels he/she is having a flare. If the patient says yes to this question, then the study coordinator will arrange for an appointment to be scheduled with a rheumatology health care provider at Mayo Clinic Rochester. The goal will be to have this appointment take place within seven days of the FLARE Questionnaire results being reported."
1580128|NCT02382770|Procedure|Open abdomen procedure|Patients who may need at the end of surgical procedure will be left with open abdomen dressed with different devices or dressing according to the institutional indications.
1580129|NCT02382757|Drug|insulin human|Children will receive conventional treatment with human insulin according to standard medical practice.
1580132|NCT02382731|Behavioral|Usual care + letters|A series of five postal educational reminders sent on behalf of each hospital's interventional cardiology team to the patient approximately 4, 8, 20, 32, and 44 weeks post-MI procedure, with an insert for the family physician and pharmacist at approximately 4 and 8 weeks post-MI procedure.
1580133|NCT02382731|Behavioral|Usual care + letters + automated calls|A series of five postal educational reminders as per the usual care + letters arm plus interactive voice response phone calls to the patient delivered approximately 2 weeks after the letters, as well as personalized telephone follow up by trained lay health workers for patients identified by the interactive voice response system as non-adherent. The automated algorithm is designed to identify patients who are non-adherent and who may benefit from personalized educational phone call and/or system navigation support by the lay health worker. Lay health workers will not provide clinical advice.
1580134|NCT02382718|Biological|FAST fish mCyp c 1|Subcutaneous immunotherapy
1580135|NCT02382718|Biological|Placebo|Subcutaneous immunotherapy
1580136|NCT02382679|Dietary Supplement|Experimental: Vitamin Mixture|Vitamins: B2 (riboflavin), magnesium, co-enzyme Q10, Omega 3 fatty acids
1580137|NCT02382679|Dietary Supplement|Placebo|Non-nutritional non-immunogenic non-allergic oil-based capsule with same appearance, weight and density of active experimental vitamin.
1580138|NCT02382666|Drug|Rolapitant|
1580139|NCT02382653|Drug|oral perixicam|Oral adminstration of buccal perixicam
1580140|NCT02382640|Drug|Febuxostat XR|Febuxostat extended-release (XR) capsules
1580141|NCT02382640|Drug|Maalox Advance Regular Strength liquid|Maalox Advance Regular Strength liquid containing Aluminum Hydroxide 200 mg, Magnesium Hydroxide 200 mg, and Simethicone 20 mg/5 mL or equivalent
1580142|NCT02382614|Device|Spiration Valve System|
1580143|NCT02382601|Radiation|Ultrasound|With 3-D and 4-D high-resolution color Doppler methods it is possible to map out the placental circulation, fetal circulation, fetal brain, and fetal cardiac function. Investigators will collect these data points prenatally.
1580144|NCT02382601|Radiation|MRI|Similar to the Ultrasound data, investigators will collect MRI images of the fetal brain and the placenta. MRI will allow investigators to collect more detailed images of both the fetal brain and placenta, and investigators will be utilizing this technique both prenatally and postnatally.
1580145|NCT02382601|Procedure|Blood collection|The maternal and cord blood will be collected for the processing of plasma and serum. There may be early biomarkers of IUGR in the maternal circulation that investigators can use to better determine the appropriate strategy for clinical management of care. Collection and subsequent analysis of molecular markers in the umbilical cord blood will be used to further confirm physiological dysfunction as detected by ultrasound and MRI techniques.
1580146|NCT02382601|Behavioral|Neurological Function Assessment|Neurological development tests called a Bayley exam and Pediatric Stroke Outcome Measure (PSOM) will be performed.
1580147|NCT02382601|Procedure|Placental Analysis|Placentas will undergo pathological evaluation for placental function.
1580148|NCT02382601|Procedure|Measurement of body fat|The baby's body fat will be measured in a special incubator called a PEAPOD or BODPOD when an infant.
1580149|NCT02382588|Drug|gancyclovir gel|0.15% gancyclovir gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days or until the healing of the dendrite, whichever is earlier.
1580150|NCT02382588|Drug|Hypromellose gel|0.3% hypromellose gel to be applied in the affected eye 5 times per day for a week, followed by 3 times per day for an additional 7 days.
1580151|NCT02382575|Drug|Rituximab|Two to four rituximab infusions (over 2-4 weeks) will be administered once every week at standard dose (Intravenous infusion of rituximab 375mg/mt2)depending on circulating B cells level.
1580152|NCT02382575|Drug|Tacrolimus|Standard dose with oral Tacrolimus 0.2 mg/kg/day in two divided doses till 6 month of relapse free survival.
1580153|NCT02382562|Behavioral|Brief Behavioral Activation Intervention|Clinical psychologists (investigators) will instruct the participant in ways to become more active in life, particularly with regards to activities that the participant finds pleasurable and meaningful. The intervention will take one hour to complete. Following the intervention, the participant will receive brief, weekly text or email reminders for the next 4 weeks (total of 4) to engage in pleasurable and meaningful activities during the week.
1580154|NCT02382549|Drug|dabrafenib|Braf inhibitor
1580155|NCT02382549|Biological|6MHP|6 melanoma helper vaccine comprised of 6 class II MHC-restricted helper peptides
1580156|NCT02382549|Drug|Trametinib|MEK1 AND MEK2 inhibitor
1580157|NCT02382536|Device|BD Scarlett Infusion set|Each subject will receive subcutaneous infusion from two investigational BD Scarlet infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
1580158|NCT02382536|Device|Medtronic QuickSet Infusion Set|Each subject will receive subcutaneous infusion from two Medtronic infusion sets simultaneously, using a commercially available insulin pump to deliver insulin diluent (placebo) into the abdomen. Each infusion will run for approximately 4 1/2 hours.
1580159|NCT02382523|Drug|Acthar 80 unit injection|"Subjects not responding after 3 months of therapy (increasing creatinine; proteinuria not lower by 30%), will continue therapy at a dose 120 U SC x2/wk. Treatment will be discontinued if improvement is not observed 6 months after initiation of therapy.
If partial remission is achieved with Acthar 80 U SC x2/wk or x3/wk then Acthar will be increased to 120 U SCx2/wk; if remission is achieved, treatment will be continued at this dose for a total of 12 months; otherwise, if response is not observed after 3 months of treatment with the higher dose, we will resume therapy with the original dose/schedule. We will check anti-ACTH antibodies in non-responders.
If relapse occurs during the follow-up period, a 6 month treatment with Acthar at 120 U SC x2/wk will be started (not for partial responders), and the response will be assessed."
1580160|NCT02382510|Drug|TRN-157|
1580163|NCT02382497|Device|AN Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.
tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.
The anode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement.
Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
1580164|NCT02382497|Device|AN Sham tDCS|The same electrode placement will be used as in the stimulation conditions (left anodal/right cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
1580165|NCT02382497|Device|BED Active tDCS|"The tDCS active stimulations will be directed to PFC regions for six weeks delivered for three times a week.
tDCS will be delivered by a battery driven, constant current stimulator through a pair of saline-soaked sponge electrodes kept firm by elastic bands.
For the OW/OB with diagnosis of BE, or food craving, the anode will be placed on the right PFC, F4 position according to the 10-20 international EEG system for electrode placement, while the cathode will be placed on the left PFC, F3 position according to the 10-20 international EEG system for electrode placement.
Stimulation intensity will be set at 1 milliampere (mA), the duration of stimulation will be 20 min."
1580166|NCT02382497|Device|BED Sham tDCS|The same electrode placement will be used as in the stimulation conditions (right anodal/left cathodal), but the current will be applied for 30 s and will be ramped down without the participants awareness, and will be held three times a week for six weeks.
1580167|NCT02382484|Device|A dual chamber pacing system (BackBeat Medical)|For each patient, one pacing electrode was placed in the right atrium and the second electrode was placed in the right ventricle. With a dual chamber pacing system (BackBeat Medical) it was possible to pace the heart with a wide variety of pacing settings.
1580168|NCT02382471|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
1580169|NCT02382471|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
1580170|NCT02382458|Behavioral|Newsletters on cancer prevention and control|E-mailed or mailed newsletters that provide information on how to prevent cancer
1580171|NCT02382458|Behavioral|Behavioral program to reduce inflammation|Group classes which will provide participants with information on achieving a healthy diet, increase physical activity, and manage stress
1580172|NCT02382445|Device|Anesthesia depth monitor|
1580173|NCT02382445|Device|Sham control|Standard care as usual. Bis m Standard care as usual. Bispectral index monitor is not visible for anesthesia provider.
1580174|NCT02382445|Drug|propofol and sevoflurane|
1580175|NCT02382432|Drug|Pethidine 0.4mg/kg|2ml intravenous bolus slowly injected in 2minutes.
1580176|NCT02382432|Drug|Dexmedetomidine|2ml intravenous bolus slowly injected in 2minutes
1580177|NCT02382419|Drug|carrageenan-containing gel|Applied vaginally
1580178|NCT02382419|Other|Placebo|Applied vaginally
1580179|NCT02382419|Other|Laboratory Biomarker Analysis|Correlative studies
1580180|NCT02382419|Other|Questionnaire Administration|Ancillary studies
1580181|NCT02382406|Drug|Carboplatin|Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
1580182|NCT02382406|Drug|Nab-paclitaxel|Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
1580183|NCT02382406|Drug|MK-3475 (Phase I)|"MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)
Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
1580184|NCT02382406|Drug|MK-3475 (Phase II)|"MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)
Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
1580185|NCT02382393|Other|Brain Performance Test (BPT, Lumos Labs, Inc)|A brief, repeatable, online battery of cognitive assessments used to measure functioning in five cognitive domains across time.
1580186|NCT02382393|Other|Computerized Assessment|a validated, computerized cognitive assessment tool
1580187|NCT02382380|Drug|Gadoterate|Patients who choose to receive Gadoterate will receive an MRI exam with standard pre-contrast and Gadoterate-enhanced acquisitions (0.2 mL/kg). The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
1580188|NCT02382380|Other|No Gadoterate|Patients who choose not to receive Gadoterate will receive an MRI exam with no Gadolinium contrast. The MRI protocol utilized in the study will be comprised of the standard Body protocols (routine abdomen, liver-pancreas, renal, prostate, angiography) as well as the standard Neurologic exam protocols (routine brain, orbital, brainstem, neck, angiography).
1580189|NCT02382367|Other|Blood sampling|Blood tests (Alpha-1 antitrypsin protein measurement, elastase-inhibitory capacity of plasma measurement, phenotypic and genotypic studies)
1580190|NCT02382354|Drug|remifentanil|The predetermined effect-site concentration of remifentanil was started using modified Dixon's up-and-down method
1580191|NCT02382354|Device|i-gel|I-gel insertion was inserted 5 min after anesthesia induction
1580192|NCT02382354|Device|laryngeal mask airway|laryngeal mask airway insertion was inserted 5 min after anesthesia induction
1580193|NCT02382354|Drug|propofol|Anesthesia was induced with propofol target-controlled infusion at the effect-site concentration of 5 μg/ml
1580194|NCT02382341|Device|BIOSURE™ HEALICOIL™ PK Interference Screw|Subjects will receive the appropriate sized BIOSURE™ HEALICOIL™ PK Interference Screw
1580195|NCT02382328|Drug|alpha lipoic acid|comparison of 600mg/24h oral, alpha lipoid acid, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
1580196|NCT02382328|Drug|Placebo|Placebo oral pills, 28 days before and 120 days after surgery (carpal tunnel release) versus placebo in carpal tunnel syndrome patients.
1580197|NCT02382315|Behavioral|Fear of Cancer Recurrence Intervention|A 6-week individual therapy intervention to address fear of cancer recurrence in male and female cancer survivors. Patients will learn tools and techniques to help manage their fears, and learn to tolerate the uncertainty associated with the possibility of their cancer recurring.
1580198|NCT02382302|Device|Telemedicine system|The data such as photographs can be collected simply using built-in cameras installed in smart-phones that used the standard touch-screen user interface (UI) and camera installed in the iPhone3GS and iPhone4 using iOS 3.0 and iOS 5.0, respectively. Subjects were instructed to transmit the photographs of the wounds then investigator performed the photography in such a manner that the size of pressure ulcer should be automatically measured based on a 1 cm x 1 cm-sized indicator on the screen.
1580199|NCT02382289|Procedure|radiofrequency ablation for sacroiliac joint arthropathy|comparing bipolar RF at 6 points with monopolar RF at 3 and 6 points for the treatment of SI arthropathy
1580200|NCT02382276|Drug|Nalmefene hydrochloride|
1580201|NCT02382263|Drug|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 150 mg/m2 + Gemcitabine 1000 days 1 & 15 in a 28 days cycle
1580202|NCT02382263|Drug|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 100 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
1580203|NCT02382263|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1 & 15 in a 28 days cycle
1580204|NCT02382263|Drug|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 + Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
1580205|NCT02382250|Behavioral|Survey|Survey will be given to all participants
1580206|NCT02382237|Device|PET/TDM|Evaluation of nutrition absorption by TEP/TDM
2008575|NCT03328962|Behavioral|Structured smoking cessation counselling based on motivational interviewing (MI) and adapted for the cancer setting eventually combined with provision of smoking cessation medication|structured smoking cessation counselling based on MI and adapted for the cancer setting eventually combined with provision of smoking cessation medication
2008576|NCT03328949|Device|Coronary Lithoplasty® System by Shockwave Medical, Inc|Shockwave Coronary Lithoplasty System is a lithotripsy enhanced, low pressure balloon dilation of calcified, stenotic de novo coronary arteries prior to stent placement.
1580209|NCT02382198|Drug|Glycopyrrolate|Drug to reduce drooling in patients with Parkinson's Decease.
1580210|NCT02382198|Drug|Placebo|
1580211|NCT02382185|Other|Fluid optimisation|The intervention will consist of optimising stroke volume with 250ml of Hartmanns solution
1580212|NCT02382185|Drug|Optimisation of blood pressure|Phenylephrine infusion will be used to target a mean arterial blood pressure to within 30% of baseline (preoperative) value
1580213|NCT02382185|Device|Application of clearsight monitor|The clear sight monitor will be applied to measure stroke volume.
1580214|NCT02382172|Behavioral|Social Cognition and Interaction Training for Autism (SCIT-A)|The group therapy program is aimed at improving social cognitions and skills of individuals who find social situations difficult, stressful and/or uncomfortable and with a desire to enhance skills required for social interactions.
1580215|NCT02382172|Other|Treatment as Usual (TAU)|Participants in the treatment as usual (TAU) group will continue to receive other interventions (e.g., individual therapy, job skills coaching) during the Social Skills Clinic. No participants in either group will participate in other group-based interventions concurrently with their participation in this study.
1580216|NCT02382146|Drug|dexamethasone ondansetron|dexamethasone 8 mg intravenous ondansetron 4 mg intravenous dimenhydrinate 1mg/kg intravenous
1580217|NCT02382146|Drug|Dexamethasone dimenhidrinate|dexamethasone 8 mg intravenous dimenhydrinate 1mg/kg intravenous
1580218|NCT02382133|Device|Nasal alar oxygen sensor|Application of a nasal alar oxygen sensor
1580219|NCT02382107|Other|Observational|TB suspects, who present themselves to the pulmonary ambulance at the Marius Nasta Instiute
1580220|NCT02382094|Drug|Bicalutamide|
1580221|NCT02382081|Procedure|Patient-initiated shared care|
1580222|NCT02382068|Drug|Dexamethasone|Given via intratympanic injection
1580223|NCT02382068|Other|Placebo|Given via intratympanic injection
1580224|NCT02382068|Drug|Cisplatin|"Standard of care treatment with the following treatment course criteria:
Dose: > 50 mg/m2
Frequency: q3 -q4 weeks
Cycles: 7 maximum"
1580225|NCT02382055|Behavioral|REACH|REACH is a 12-session intervention, delivered 2-3 times per week for 45 minutes. The treatment focuses on identifying and changing behaviors and routines that have become entrenched and help perpetuate the illness.
1580226|NCT02382055|Behavioral|Supportive Psychotherapy|The Supportive Psychotherapy is based on the Specialist Supportive Care (McIntosh et al, 2005), and modified for the current research procedures. Supportive Psychotherapy is a 12-session intervention, delivered 2-3 times per week as 45 minute sessions, focusing on symptoms of anorexia nervosa during the transition to the inpatient unit.
1580227|NCT02382055|Behavioral|Inpatient Behavioral Treatment|Inpatient treatment at the NYSPI is a behaviorally-based treatment program for anorexia nervosa. This is a non-research, clinical intervention for individuals with anorexia nervosa.
1580228|NCT02382042|Behavioral|Intensive Referral Intervention|
1580229|NCT02382029|Drug|Clonazepam|Active medical treatment for burning mouth syndrome
1580230|NCT02382029|Other|acupuncture|Traditional chinese acupuncture
1580231|NCT02382016|Drug|Macitentan|Macitentan film-coated tablet 10 mg once daily.
1580232|NCT02382016|Other|Placebo|Matching placebo tablet once daily.
2008577|NCT03328936|Other|Laboratory Biomarker Analysis|Correlative studies
2008578|NCT03328936|Drug|Melphalan Hydrochloride|Given personalized dose IV for predicted 3-day duration of severe neutropenia
2008579|NCT03328936|Drug|Melphalan Hydrochloride|Given personalized dose IV for predicted 5-day duration of severe neutropenia
1580286|NCT02381535|Drug|Cisplatin|Given IV
1580287|NCT02381535|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
2008580|NCT03328936|Other|Pharmacological Study|Correlative studies
2008581|NCT03328923|Dietary Supplement|250mg brown seaweed powder|
2008582|NCT03328923|Dietary Supplement|Placebo|
2008583|NCT03328910|Device|SPI monitor (GE Healthcare, Helsinki, Finland)|The SPI is derived from pulse rate and pulse wave amplitude measured with photoplethysmography, obtained from the CARESCAPE B650 monitor (GE Healthcare, Finland) with a scale from 1 to 100.
2008584|NCT03328897|Drug|Omalizumab|injection of 150 or 300 mg
2008585|NCT03328884|Drug|Irinotecan Hydrochloride|"nal-IRI (nanoliposomal irinotecan, also known as MM-398 and PEP02) is irinotecan hydrochloride, (also known as CPT-11) a topoisomerase 1 inhibitor, encapsulated in a liposome drug delivery system.
nal-IRI will be administered with a fixed dose of 60 mg/m2 on D1 of a 14-day cycle in monotherapy."
1580237|NCT02381990|Procedure|FUSE IMAGE MRI GUIDED PROSTATE CRYOTHERAPY|"Biopsy proven Prostate Cancer is delimited and defined by MP-MRI. The MRI study is fused with transrectal ultrasound in realtime. The cryogenic cryoprobes/devices are employed to freeze and all circuled or noted cancer lesions. Two freeze 8 min/ thaw 10 min clycles are performed. Thermocouples are used to monitor treatment areas and safety margins"
1580238|NCT02381977|Other|No intervention|
1580239|NCT02381964|Dietary Supplement|Supradyn® (1RDA+CoQ10)|
1580240|NCT02381964|Dietary Supplement|Supradyn® (3RDA)|
1580241|NCT02381964|Dietary Supplement|Placebo|
1580242|NCT02381951|Device|spinal cord stimulation (St Jude Medical)|implantation of a spinal cord neurostimulation system : St Jude Medical Octrode 3183 (R) peridural lead connected to a St Jude Medical EonC (R) primary cell IPG
1580243|NCT02381938|Behavioral|Healthy Lifestyles|6-month intervention to increase physical activity and improve other health related behaviors
1580244|NCT02381938|Other|Healthy Finances|6-month intervention to educate and improve financial health
1580245|NCT02381912|Other|EORTC QLQ-C30 and EORTC BLS-24 questionnaire|Questionnaires answered at baseline and 4 months follow up.
1580246|NCT02381899|Drug|Bendamustine and Rituximab|Patients receive bendamustine and rituximab. Treatment repeats every 28 days for 6 courses in the absence of disease progression or unacceptable toxicity.
1580247|NCT02381886|Drug|IDH305|
1580248|NCT02381860|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
1580249|NCT02381860|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
1580250|NCT02381847|Procedure|intraperitoneal chemoperfusion|HIPEC with cisplatin at the time of D2 radical surgery
1580251|NCT02381834|Procedure|Bladder stimulation technique|
1580252|NCT02381821|Other|ultrasound examination|All patients will undergo 3D transvaginal ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
1580253|NCT02381795|Drug|Nasal Carbon Dioxide|
1580254|NCT02381769|Dietary Supplement|Soybean based lipid emulsion|
1580255|NCT02381756|Device|Ultrasound|Cardiac echocardiography to determin the left ventricular ejection fraction by the biplane modified Simpson rule and by the calculation of the Strain Longitudinal Global by 2-D speckle tracking strain echocardiography
1580256|NCT02381743|Behavioral|Group 2 intervention daily SMS bullet point|Group 2 subjects receive a daily SMS bullet point, summarizing a key clinical point pertinent to the CBPA's daily work.
1580257|NCT02381743|Behavioral|Group 3 intervention daily SMS bullet point|Group 3 subjects receive a c phrased as a multiple choice question. The content mirrors that of group 2, but is presented as a question to render it interactive
1580258|NCT02381730|Drug|Intravitreal aflibercept|Patient receive one intravitreal injection of 2mg aflibercept (as currently recommended in the treatment of AMD)
1580259|NCT02381717|Other|ultra-sound guide|Patients randomized to this arm will have the femoral nerve block with the guidance of a bedside ultrasound
1580260|NCT02381717|Drug|bupivacaine|
1580261|NCT02381717|Drug|morphine|
1580262|NCT02381691|Other|maternal breast milk odor|
1580263|NCT02381691|Other|no odor|
1580264|NCT02381678|Device|Perimount 2900/6900 Heart Valve|This is a retrospective study which ask the subjects implanted with Perimount Heart Valve during 2001 to 2007 back hospital for follow up visit.
1580265|NCT02381665|Device|Flexstim IF|Patient enrolled will receive a device for effective interferential current stimulation
1580266|NCT02381665|Device|Flexstim IF faked|Patient enrolled will receive a sham device.
1580267|NCT02381652|Device|Cingal®|Injection into the knee
1580268|NCT02381639|Behavioral|One interview of 90 minutes with a part of cognitive assessment and a part of self-assessment|The content of the assessment will be the same for all subjects and will consist of a part of cognitive assessment (National Reading Test, Rey Osterreich Complex Figure, Hayling Sentence Completion Task, verbal memory, digit sequencing, token motor task, verbal fluencies, symbol coding, tower of London) and self-assessment (Mini International Neuropsychiatric Interview, Beck Depression Inventory, State Trait Anxiety Inventory, Wender Utah Rating Scale, Adult Self-Report Scale Symptom Checklist, UPPS Impulsive Behavior Scale)
1580269|NCT02381626|Device|HEPA air purifier|air purifiers to remove PM and volatile organic compounds will be placed in drivers cars
1580270|NCT02381626|Behavioral|questionnaires|
1580271|NCT02381626|Other|Log-book|PM and biological measurements
1580272|NCT02381626|Other|Urine sample|PAH (Polycyclic Aromatic Hydrocarbon) will be assessed via urine sample collection of Urinary 1 hydroxy pyrene and particulate matter collected via Polyurethane Foam Filter (PUF) sampler
1580273|NCT02381613|Other|Baked beef|A meal based on baked beef
1580274|NCT02381613|Other|Baked herring|A meal based on baked herring
1580275|NCT02381613|Other|Pickled herring|A meal based on pickled herring
1580276|NCT02381600|Drug|Vitamin D|"Experimental :
Patients will undergo clinical and functional assessment as well as evaluation using the Montreal Cognitive Assessment (MoCA) screening test, the modified 15-item Geriatric Depression Scale, and the Neurotrax (®Mindstreams) computerised cognitive assessment battery.
Patients will receive a supplemental monthly oral dose of 60000 units Vitamin D administered by a nurse for a period of 3 months Patients will undergo a repeat blood test to examine the level of vitamin D at the end of 3 months of follow-up.
At 3-month follow-up atients will be asked to complete the 15-item GDS and the Neurotrax (®Mindstreams) computerised cognitive assessment battery."
1580277|NCT02381587|Other|Retrospective study|no interventional study - Retrospective study that valuate The effect of HCQ treatment in cardiovascular AVENTS IN patients with primary sjogren syndrome
1580278|NCT02381561|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1580279|NCT02381561|Other|Laboratory Biomarker Analysis|Correlative studies
1580280|NCT02381561|Other|Pharmacological Study|Correlative studies
1580281|NCT02381561|Drug|Ropidoxuridine|Given PO
1580288|NCT02381535|Other|Laboratory Biomarker Analysis|Correlative studies
1580289|NCT02381535|Drug|Onalespib|Given IV
1580290|NCT02381535|Other|Pharmacological Study|Correlative studies
1580291|NCT02381522|Other|Remote Ischemic Pre-conditioning|
1580292|NCT02381522|Other|Sham RIPC|
1580293|NCT02381509|Device|IVC Filter|
1580294|NCT02381496|Drug|ACT-453859 1 mg|Capsule
1580295|NCT02381496|Drug|ACT-453859 3 mg|Capsule
1580296|NCT02381496|Drug|ACT-453859 10 mg|Capsule
1580297|NCT02381496|Drug|ACT-453859 30mg|Capsule
1580298|NCT02381496|Drug|ACT-453859 100 mg|Capsule
1580299|NCT02381496|Drug|ACT-453859 300 mg|Capsule
1580300|NCT02381496|Drug|ACT-453859 800 mg|Capsule
1580301|NCT02381496|Other|Placebo|Matching ACT-453859 placebo capsule
1580302|NCT02381496|Drug|Setipiprant 500 mg|Capsule
1580303|NCT02381496|Drug|Setipiprant 1000 mg|Capsule
1580304|NCT02381483|Other|Cold exposure|
1580305|NCT02381470|Drug|Faropenem|400mg Faropenem
1580306|NCT02381470|Drug|Amoxicillin/clavulanic acid|500mg Amoxicillin/ 125mg clavulanic acid
1580307|NCT02381470|Drug|Pyrazinamide|2g pyrazinamide
1580308|NCT02381470|Drug|Isoniazid|300mg isoniazid
1580309|NCT02381431|Device|FLIR ONE|
1580310|NCT02381418|Biological|Trivalent influenza subunit vaccine Influvac|"3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1 "
1580311|NCT02381405|Dietary Supplement|Enterade beverage|
1580312|NCT02381392|Device|Accuvein AV400|This device is FDA approved for assistance with intravenous access. It has been shown to cause no harm to patients. The device utilizes infrared technology to provide a visible map of the subject's blood vessels where the light is shone.
1580313|NCT02381379|Drug|Peginterferon-α-2a|Subcutaneous peginterferon-α-2a (PEGASYS®) starting at 180µg weekly for one year.
1580314|NCT02381366|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|"Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells:
Dose A: 10 million cells per kg / Dose B: 20 million cells per kg"
1580315|NCT02381353|Drug|Bupivacaine|Intraoperative orbital injection of local pain medication
1580316|NCT02381340|Device|ACE stapling procedure|Endoscopic trans-oral gastroplication
1580317|NCT02381327|Device|Mandometer|Mandometer is an eating disorder conditioning tool, class 2 device cleared by the FDA for the treatment of eating disorders. Mandometer offers on-line, real-time feedback on how much food to eat and how quickly to eat during a meal.
1580318|NCT02381314|Biological|enoblituzumab plus ipilimumab|enoblituzumab is administered by IV infusion once per week. Ipilimumab is administered by IV infusion every 3 weeks for up to 4 doses.
1580319|NCT02381301|Biological|Venous blood sampling prior to CCTA.|
1580320|NCT02381288|Drug|TAK-448|TAK-448 solution for subcutaneous injection
1580321|NCT02381288|Drug|TAK-448 Placebo|TAK-448 placebo-matching solution for subcutaneous injection
1580322|NCT02381275|Drug|Tenofovir Disoproxil Fumarate|Observe long-term outcomes of patients using Tenofovir based antiretroviral therapy at the Lighthouse Clinics
1580323|NCT02381262|Behavioral|Fitbit|The Fitbit is a wrist based wearable technology device designed to monitor physical activity by tracking steps, distance and calories burned as well as sleep patterns and heart rate. It has wireless capabilities to sync with smart devices and summarize data for the user or export for synchronize with electronic health records.
1580324|NCT02381249|Drug|Octreotide|Single dose 100mcg octreotide acetate (1mL), subcutaneously to the lower abdomen
1580325|NCT02381249|Drug|Placebo|Single dose 0.9% saline (1mL), subcutaneously to the lower abdomen
1580326|NCT02381236|Drug|G-202|G-202 administered by intravenous infusion on Days 1, 2 and 3 of each 28-day cycle for up to 3 cycles
1580327|NCT02381210|Device|Congo Red Dot Test|The Congo Red Dot test is a simple test has been developed to detect unfolded or misfolded proteins in urine.
1580328|NCT02381197|Device|Congo Red Dot test|The Congo Red Dot test is a simple dye test that detects unfolded or misfolded proteins
1580329|NCT02381184|Drug|clomiphene citrate|receive100 mg of clomiphene citrate (Clomid®; Hoechst Marion Russel, Cairo, Egypt) daily starting on day 3 of spontaneous or progestin induced cycle for 10 days.
1580330|NCT02381184|Procedure|laparoscopic ovarian drilling (LOD)|Laparoscopy was performed under general anesthesia, using three-puncture technique
1580331|NCT02381171|Device|Active rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) 10Hz (1600 pulses)
1580332|NCT02381171|Device|Sham rTMS|Repetitive Transcranial Magnetic Stimulation (rTMS) with Placebo coil
1580333|NCT02381171|Device|Active Neuroacupuncture|Neurofunctional electrical acupuncture 1Hz, continuous, 10mA current for 20 minutes.
1580334|NCT02381171|Device|Sham Neuroacupuncture|Neurofunctional electrical acupuncture without needles
1580335|NCT02381158|Drug|Nebulized beclomethasone dipropionate|Nebulized beclomethasone dipropionate applied for 12 weeks with a dose of 400 µg twice a day (total dose 800 µg)
1580336|NCT02381145|Dietary Supplement|EGCG+RSV-supplementation|Teavigo (~300mg/d) Resveratrol (~80mg/d)
1580337|NCT02381132|Drug|Norco 7.5mg/325|
1580338|NCT02381132|Drug|MNK155|
1580339|NCT02381119|Behavioral|Personalized Dietary Advice Services|"This Personalized Dietary Advice is based on markers for nutrition status and SNPs (single nucleotide polymorphisms).
This advice is given via Personalized Dietary Advice Services, in which health data of the client can be entered and will be translated into advice on intake of specific nutrients or food categories."
1580340|NCT02381119|Behavioral|Regular care|The control group will receive usual advice for diabetes type 2 from the dietician. However, after the end of the study participants in the control group will be offered the opportunity to receive the Personalized Dietary Advice from their dietician, as based on the parameters measured during the study.
1580341|NCT02381093|Other|Modified BLS course|BLS using CI
1580342|NCT02381093|Other|Standard BLS Course|Usual BLS teaching
1580343|NCT02381080|Drug|Ibrutinib|Ibrutinib capsule (at dose level of 140 or 420 or 560 mg) will be taken orally QD up to six, 28-days cycles.
1580344|NCT02381080|Drug|Erythromycin|Erythromycin 500 mg tablet will be taken orally TID (Part1 Cycle 1: on Days 5-10 and morning dose on Day 11; Part2 Cycle 1: on Days 5-17 and morning dose on Day 18).
1580411|NCT02380599|Other|Spinal Manipulation|Mid-thoracic spinal manipulation to T3-5 region
1580345|NCT02381080|Drug|Voriconazole|Voriconazole 200 mg tablet will be taken orally BD (Part1 Cycle 1: on Days 19-25; Part2 Cycle 1: on Days 5-17).
1580346|NCT02381067|Other|NuCel with Allograft Bone|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Allograft bone is bone that comes another patient. NuCel and Allograft bone will be combined for this treatment.
1580347|NCT02381028|Other|Human milk and emollient: Apobase creme® (Actavis Norway AS)|Topical application of human milk followed by emollient
1580348|NCT02381028|Other|Emollient: Apobase creme® (Actavis Norway AS)|Topical application of emollient
2008586|NCT03328871|Device|Fractional CO2 Laser|Fractional Carbon Dioxide Laser will be treated once every three months for 2 times.
2008587|NCT03328871|Procedure|Nanofat grafting|Nanofat grafting will be applied once every three months for 2 times.
2008588|NCT03328871|Procedure|Platelet-rich plasma (PRP) Injection|PRP Injection will be applied once a month for 6 times.
2008589|NCT03328858|Other|Ketogenic Diet|Once tolerance to the diet has been assessed, participants will be placed in the ketogenic diet, followed-up every three months until the one year completion.
1580353|NCT02381002|Other|Weight reduction program|Overweight and obese children (6-12 years old) from patient group accepting enrollment were assigned to weight reduction program for 6 months with monthly follow up. The program comprise: 1) Diet regimen: Healthy balanced diet was prescribed. The amount of calories was determined according to 24-hour recall then 250-500 calories were subtracted from total intake which decrease weight by 0.25-0.5 kg/week. 2) Exercise:were instructed to practice walking for at least 30 minutes 3-4 times per week.
1580354|NCT02380989|Device|Ayurveda|Ayurveda combinations in the form of gel and patches were applied on acute pain site.
1580355|NCT02380989|Device|Placebo|
1580356|NCT02380976|Drug|combination drug: DW330SR, DW1030|
1580357|NCT02380976|Drug|DW340|
1580358|NCT02380963|Dietary Supplement|Colorado Diet with soy protein foods.|"Phase 1 (week 1-2): Participants will be given soy protein powder and asked to consume 3 protein shakes per day.
Phase 2 (week 3-8): Participants will be given both protein powder and soy patties designed to be similar to other phase 2 acceptable foods and will be asked to consume 2 soy protein shakes and 1 soy patty per day.
Phase 3 (week 9-16): Participants will be given protein powder, soy patties, and protein bars designed to be similar to other phase 3 acceptable foods and will be asked to consume 1 soy protein shake, 1 soy patty and 1 soy protein bar per day.
Maintenance Phase (month 5-12): Participants will continue to receive study food products (protein powder, patties and protein bars)"
1580359|NCT02380963|Behavioral|Colorado Diet with monetary payments|"Phase 1 (week 1-2): Participants will be given monetary stipend and asked to consume 3 non-soy protein shakes per day.
Phase 2 (week 3-8): Participants will be given monetary stipends and asked to consume 2 non-soy protein shakes per day.
Phase 3 (week 9-16): Participants will be given monetary stipend and asked to consume 1 non-soy protein shake and 1 non-soy protein bar per day.
Maintenance Phase (month 5-12): Participants will continue to receive monetary stipend."
1580360|NCT02380950|Behavioral|250 ml alcohol consumption|"Each participant had to drink 250 ml white wine. Directly before, 10-30 min after and 45-65 min after wine consumption cognitive functions were tested by test battery for attentional performance (TAP) from Zimmermann and Fimm. During the whole examination breath-alcohol-contents (BACs) were measured every 5 minutes with breathalyser Dräger Alcotest 7510."
1580361|NCT02380937|Procedure|ablation for typical atrial flutter|ablation for typical atrial flutter
1580362|NCT02380937|Device|Vision Ablation Catheter|
1580363|NCT02380924|Drug|DSP loaded RBC using EryDex System|Intravenous infusion of 10 mg DSP encapsulated in autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
1580364|NCT02380924|Drug|Sham treated RBC using the EryDex System|Intravenous infusion of sham treated autologous erythrocytes. Peripheral blood samples are taken over 49 days to determine the 24-hour recovery and survival (T50) of the infused RBC.
1580365|NCT02380911|Other|Educational Intervention|"Physicians belonging to the PCC randomized to the intervention group receive a 3-component intervention: education workshop, Educational Outreach Visits and a mHealth application uploaded to their smartphones.
In addition, 2 intervention support tools are used at the intervention clinics:
A web-based platform that is tailored to send SMS messages for lifestyle modification, and prompts and reminders for clinic appointments are used to improve medication adherence for patients.
On-site training to pharmacist assistants at the first EOV is given by physician trainers focused on counseling to improve medication adherence among patients initiating statin therapy and at each patient visit to the clinic to refill drug prescriptions."
1580366|NCT02380898|Drug|Ketorolac|30 mg ketorolac immediately before induction of anesthesia
1580367|NCT02380898|Drug|Normal saline|4 mL normal saline 0.9% immediately before induction of anesthesia
1580368|NCT02380885|Behavioral|SCIT|psychosocial group intervention
1580369|NCT02380885|Behavioral|TAFT|psychosocial group intervention
1580370|NCT02380872|Procedure|Connective tissue graft|gingival recession treated with connective tissue graft
1580371|NCT02380872|Procedure|Platelet Rich Fibrin|gingival recession treated with platelet rich fibrin
1580372|NCT02380859|Device|Goggles with fitted lenses that distort vision|These distortions include but are not limited to restricting the visual field to only a narrow window and fogging the vision
1580373|NCT02380846|Other|White rice|Control - white rice
1580374|NCT02380846|Other|Rice with chicken breast|Treatment 1 - steamed white rice with steamed chicken breast
1580375|NCT02380846|Other|Rice with fish|Treatment 2 - steamed white rice with steamed fish
1580376|NCT02380846|Other|Rice with egg white|Treatment 3 - steamed white rice with egg white
1580377|NCT02380846|Other|Rice with beancurd|Treatment 4 - steamed white rice with steamed beancurd
1580378|NCT02380833|Behavioral|MyPlate|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations for eight weeks.
1580412|NCT02380599|Other|Spinal Mobilization|Mid-thoracic spinal mobilization to T3-5 region
2008590|NCT03328845|Drug|Toujeo SoloStar|
2008591|NCT03328845|Drug|Tresiba|
2008592|NCT03328845|Drug|Humalog Kwikpen|
2008593|NCT03328845|Drug|NovoRapid|
2008594|NCT03328845|Drug|Apidra|
1580379|NCT02380833|Behavioral|MyPlate + Exercise|To consume a weight maintenance diet based on the United States Department of Agriculture MyPlate nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
1580380|NCT02380833|Behavioral|Paleolithic|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations for eight weeks.
1580381|NCT02380833|Behavioral|Paleolithic + Exercise|To consume a weight maintenance diet based on alternative (Paleolithic based) nutrition recommendations and aerobic and resistance training four days per week for eight weeks.
1580382|NCT02380820|Device|Airsoft Duo mattress|A multi-layer mattress for pressure sore prevention. Made by NAUER FOAMPARTNER AG et OBA AG (Germany).
1580383|NCT02380820|Device|Softform Premier mattress (in static mode)|A multi-layer mattress for pressure sore prevention. Made by INVACARE MSS (United Kingdom).
1580384|NCT02380807|Device|Dry Needling|"Dry needling is the use of either solid filiform needles or hollow-core hypodermic needles for therapy of muscle pain, sometimes also known as intramuscular stimulation (IMS). Although dry needling originally utilized only hypodermic needles due to the concern that solid filiform needles had neither the strength or tactile feedback that hypodermic needles provided and that the solid filiform needle could be deflected by dense contraction knots."
1580385|NCT02380807|Other|Cross Tape Therapy|The tape consists of cross bands or strips mesh cross, nonelastic and without any medication, forming a grid-shaped patch. The cross tape will be applied on trigger points.
1580386|NCT02380794|Drug|Danshen Gegen Capsule|"Danshen can dilate blood vessels, reduce the number of angina attacks and significantly improve endothelial function in patients with Coronary Angina Pectoris.
Gegen is also effective in dilating cardiovascular and cerebrovascular of the brain, and improving blood circulation. The main active ingredient of Gegen isoflavones is effective in dilating the coronary arteries, improving metabolism in normal and ischemic myocardium and reducing blood pressure, heart rate and myocardial oxygen consumption."
1580387|NCT02380794|Drug|Placebo|
1580388|NCT02380781|Behavioral|Information in the form of a video|see intervention description
1580389|NCT02380768|Device|Ambu AuraGain (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
1580390|NCT02380768|Device|LMA Supreme (size 1.5 or size 2.0)|The device will be inserted and timed. A leak pressure test will be performed after successful insertion and after 10 minutes. The larynx will be visualized by placing a fiberoptic bronchoscope through the device. A gastric tube will be inserted through the device and timed.
1580391|NCT02380755|Drug|Clomiphene Citrate|50 mg orally daily during 12 weeks
1580392|NCT02380755|Drug|Placebo|1 pill orally daily during 12 weeks
1580393|NCT02380742|Drug|lidocaine-prilocaine cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of EMLA cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
1580394|NCT02380742|Drug|Placebo cream|The patient will then be positioned in dorsal lithotomy position with the use of stirrups. Two mL of placebo cream will be placed into the vagina and 2 mL will be spread on the perineum. The cream placed into the vagina will be introduced to the level of the pessary with the practitioners' finger. Once application is completed, a timer will be set for five minutes. After five minutes, the patient will again be placed into dorsal lithotomy position with the use of stirrups. The pessary will be removed per practitioners' usual practice. The patient will be asked to mark her pain score for at this point
1580395|NCT02380729|Genetic|Gene Panel Sequencing|Enrichment for and panel sequencing of 2942 disease genes listed in the Online Mendelian Inheritance of Man (OMIM) database.
1580396|NCT02380729|Genetic|Whole Genome Sequencing (WGS)|Whole Genome Sequencing of the index case and of both parents in the event that Gene Panel Sequencing did not identify a disease-causing mutation.
1580397|NCT02380703|Behavioral|Aggression Prevention Training (APT)|
1580398|NCT02380703|Other|Enhanced Usual Primary Care (EU-PC)|
1580399|NCT02380690|Behavioral|Peer Coach Assignment|Veterans will be assigned a peer coach to meet with for 6 months to discuss pain self-management.
1580400|NCT02380677|Drug|CRLX301|
1580401|NCT02380664|Device|Whole-body vibration (Powerplate®)|Swimmers will perform a 15 minute whole-body vibration training 3 times per week. This intervention will be performed with a Powerplate®. The vibration protocol will be progressive starting with 30 Hz and an amplitude op 4 mm reaching at the end of the protocol 38 Hz and 4 mm amplitude.
1580402|NCT02380664|Behavioral|Jumping intervention|Swimmers will perform a jumping intervention, 15 minutes 3 times per week. Jumps will include drop jumps, one leg jumps, squat jumps and countermovement jumps.
1580403|NCT02380651|Procedure|Limb salvage|Local or free flaps
1580404|NCT02380638|Device|Whole-body vibration training (Power Plate®) on bone mass and bone metabolism in adolescents with and without Down syndrome.|
1580405|NCT02380625|Drug|Azithromycin|Adults (>18 yrs): 3 x 500mg tablets daily for 5 days; Children (6 months to <18 yrs): 30mg/kg (oral suspension) daily for 5 days
1580406|NCT02380625|Drug|Sunitinib and Erlotinib|Sunitinib - Adults (>18 yrs): 1 x 50mg tablet daily for 7 days; Children (6 months to <18 yrs): 0.83 mg/kg (oral suspension) daily for 7 days. Erlotinib - Adults (>18 yrs): 1 x 150mg tablet daily for 7 days; Children (8kg to <20kg): 3.5 mg/kg daily for 7 days; Children (>20kg to <30kg): 3.0 mg/kg daily for 7 days; Children (>30kg to < 18 yrs): 25 mg/kg daily for 7 days
1580407|NCT02380625|Drug|Atorvastatin and Irbesartan|Atorvastatin - Adults (>18 yrs): 1 x 40mg tablet daily until discharge; Children (6 years to <18 yrs): 1 x 40mg tablet daily until discharge; Irbesartan - Adults (>18 yrs): 1 x 150mg tablets daily until discharge; Children (6 years to <18 yrs): 1 x 75mg tablet daily until discharge.
1580408|NCT02380625|Other|IV fluids and laboratory testing|All arms will receive aggressive IV fluid rehydration and frequent laboratory tests to assist with medical management as indicated.
1580409|NCT02380612|Device|ReCell Treatment|
1580410|NCT02380612|Procedure|Skin Graft|
1580413|NCT02380599|Other|Sham Ultrasound|Sham ultrasound to T3-5 region
1580414|NCT02380586|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
1580415|NCT02380573|Drug|Methylene Blue|
1580416|NCT02380573|Drug|FD&C Blue # 2|
1580417|NCT02380573|Drug|Phenazopyridine hydrochloride|
1580418|NCT02380560|Device|Ultrasonographic examination|"An abdominal ultrasound for: Estimation of gestational age, biophysical profile (BPP), Detection of any fetal gross anomalies, Assessment of fetal growth measurement of the Amniotic Fluid Index (AFI), Detection of any abnormal placental insertion and/or uterine structural abnormalities as septate or bicornuate uterus, measuring The myometrial thickness at 4 different sites:
a) The lower uterine segment (LUS): 2cm above the reflection of the full urinary bladder (b)The anterior wall: 1cm above the maternal umbilicus. (c)Fundus: by placing the scan probe perpendicularly above the uterine fundus so that the entire curvature of the uterus is visualized.
(d)The posterior wall: through using the maternal abdominal aortic pulsation as an anatomic marker."
1580419|NCT02380547|Other|Sonographic diaphragmatic measurements|
1580420|NCT02380534|Procedure|H.E.L.P. apheresis|High cardiovascular risk patients will undergo H.E.L.P. apheresis procedure every 3 weeks for 1 year.
1580421|NCT02380521|Drug|Exenatide once weekly (BYDUREON™)|"Exenatide is considered investigational medicinal product (IMP) and will be prescribed to enrolled patients in accordance with local requirements.
Exenatide will be available at a fixed dose of 2 mg and supplied as a kit. Exenatide should be injected subcutaneously (SC) in the thigh, upper arm (deltoid region) or abdomen. The injection site does not have to be consistent throughout the study. Injection can be done at any time of the day irrespective of meals. It is recommended that the time of injection is consistent throughout the study. Subjects will be instructed to perform an air shot before the first injection.
Subjects will follow a fixed dose of 2 mg"
1580422|NCT02380508|Drug|BCG SSI|Intradermal injection
1580423|NCT02380508|Other|No vaccination|
1580424|NCT02380508|Drug|BCG Sii|intradermal injection
1580425|NCT02380495|Other|Data Collection|
1580426|NCT02380482|Other|Transthoracic echocardiography on TBI patients|Two Dimensional and speckle trackingTransthoracic echocardiography on TBI patients within 24 hours of trauma
1580427|NCT02380482|Other|Transthoracic echocardiography on control patients|Two Dimensional and speckle trackingTransthoracic echocardiography on control patients while intubated-ventilated
1580428|NCT02380469|Behavioral|Identification and provision of lacking information|The intervention consists of an interview about the caregiver's responses (baseline measurement) to a list about 'lack of information' within 13 areas. For each area, the patient's nurse will enquire about what information is requested by the caregiver and the patient. Subsequently, the nurse provides the requested information. She may involve the doctor and arrange follow-up visits or phone calls until the need is covered
1580429|NCT02380443|Biological|AlloStim|AlloStim is an activated living CD4+ Th1 memory cell derived from the blood of normal blood donors and intentionally mismatched to the recipient. AlloStim is bioengineered to express high levels of Type 1 inflammatory cytokines (such as interferon-gamma, TNF-alpha, GM-CSF) and immunomodulatory molecules such as CD40L. AlloStim has CD3/CD28-coated microbeads attached to assure activation upon infusion.
1580430|NCT02380443|Procedure|Cryoablation|Percutaneous partial cryoablation of a single metastatic tumor lesion in the liver. The procedure is conducted under CT or ultrasound image-guidance
1580431|NCT02380430|Other|ambulatory surgery description|Medical questionnaire. Nausea and vomiting, pain, thromboprophylaxis description
1580432|NCT02380417|Procedure|paravertebral catheter placement|a thoracic paravertebral catheter was placed and connected to an elastomeric pump with a continuous infusion of 0.2% ropivacaine
1580433|NCT02380417|Drug|0.2% ropivacaine|0.2% ropivacaine was infused through the elastomeric device
1580434|NCT02380417|Device|Elastomeric pump|An elastomeric pump was connected to the paravertebral catheter
1580435|NCT02380404|Procedure|Implants-supported locators placement|Antibiotics will be prescribed 1 day before surgery and continued for 5 days. Three calibrated surgeons will place 4 NN or RN Roxolid tissue level implants. Two implants have to be placed in the ANT region (lateral or canine) and 2 implants in the POST region (as distal as possible). Angulated implant and placement of implant in the tuberosity region can be considered.
1580436|NCT02380365|Device|Electrocardiography|"Duration of intervention per patient/subject:
5 min, observation 6 months"
1580437|NCT02380352|Drug|Amoxicillin|
1580438|NCT02380352|Drug|Placebo|Experimental arm must receive 5 days placebo after 5 days amoxicillin to preserve blinding.
1580439|NCT02380339|Behavioral|Psych-Educational session and virtual reality|
1580440|NCT02380339|Behavioral|Psych-Educational and BF sessions|
1580441|NCT02380326|Procedure|Advanced endoscopic imaging modalities|Virtual bronchoscopic navigation, confocal laser endomicroscopy, micro CT
1580442|NCT02380313|Drug|Afuresertib|White of off-white round immediate release tablet for oral administration with unit dose strength of 50 mg and 75 mg to achieve the dosage level of 100 mg, 125 mg, 150 mg or 200 mg once daily.
1580443|NCT02380313|Drug|Enzalutamide|Opaque white to off-white capsule for oral administration with unit dose strength of 40mg to achieve dose level of 160 mg once daily.
1580444|NCT02380313|Drug|Abiraterone|White to off-white tablet for oral administration with unit dose strength 250 mg to achieve dose level of 1000 mg once daily.
1580445|NCT02380313|Drug|Prednisone|Continuous twice daily co administration of prednisone 5 mg as per labelled recommendation from United State Prescribing Information.
1580446|NCT02380287|Drug|humanized monoclonal antibody against human IL-17|
1580447|NCT02380261|Other|Systane® Lid Wipes|Commercially-marketed, individually-packaged, pre-moistened eyelid wipe for daily cleaning
1580448|NCT02380248|Other|Polyethylene Glycol, 0.4%, Propylene Glycol, 0.3% eye drops|
1580449|NCT02380235|Biological|PEG-somatropin|0.20mg/kg/w
1580450|NCT02380235|Biological|PEG-somatropin|0.12mg/kg/w
1580451|NCT02380222|Other|Interview|Single interview lasting approximately one hour
1580452|NCT02380209|Other|CEST MRI|CEST MRI will be performed on patients prior to surgical resection of their tumor
1580453|NCT02380183|Device|Civco Needle Guidance Device|Needle guidance device will be used while nerve block is performed.
1580454|NCT02380157|Drug|Kaleorid, 750mg (trade name), Potassium chloride (active substance)|4 weeks treatment with Kaleorid, 750mg, 3 tablets 3 times daily.
1580455|NCT02380157|Drug|Placebo|4 weeks treatment with Placebo tablets, 3 tablets 3 times daily.
1580456|NCT02380144|Other|Fresh orange fruit and pasteurized fruit juice|
1580457|NCT02380131|Drug|Oxaliplatin plus Capecitabine|A cycle: Oxaliplatin 130 mg/m2 D1 q3wk.E Capecitabine 2000mg/m2 D1-D14 q3wk、valuation for every two cycles.
1580458|NCT02380131|Drug|Herceptin|Herceptin 8mg/kg D1 q3wk for the first time,after Herceptin 6mg/kg D1 q3wk.Evaluation for every two cycles.Each of preoperative and postoperative chemotherapy was 3 cycles.
2008595|NCT03328832|Drug|Topical tranexamic acid|Intraarticular application of tranexamic acid 3g in 60 ml normal saline into knee joint after closure of the joint capsule
1580462|NCT02380105|Behavioral|Counseling|Patients were informed of their condition and possible etiological factors contributing to the pathology. They were also educated about the postural rest position of the mandible and instructed to perform bilateral chewing and not overload the temporomandibular joint and masticatory muscles. Techniques to relieve pain and tension were taught to correct postural habits, food and sleep irregularities. The patients received written instructions for future reference, as a way of reinforcing the information provided during the initial consultation.
1580463|NCT02380105|Device|Interocclusal Appliances|Patients were treated using interocclusal appliances
1580464|NCT02380092|Device|LEGION™ Primary TKS with VERILAST™ Bearing Surface|All study subjects will be treated with LEGION™ Primary TKS with VERILAST™ Bearing Surface as per standard clinical practice.
1580465|NCT02380079|Drug|SCD-101|Administered as gelatin capsules
1580466|NCT02380066|Drug|Anyu Peibo|
1580467|NCT02380053|Drug|Bisoprolol|2 weeks of Bisoprolol 2.5mg daily then 2 weeks Bisoprolol 5mg daily
1580468|NCT02380053|Drug|Celiprolol|2 weeks of Celiprolol 200mg daily then 2 weeks Celiprolol 400mg daily
1580469|NCT02380040|Device|PPG|A PPG device will be applied to subjects in the right hand, left hand and one of the legs. Data will be recorded into a computer software
1580470|NCT02380027|Device|MRI|This will be a multi-parametric MRI of the prostate
1580471|NCT02380027|Procedure|MRI-targeted biopsy|This will be a biopsy targeted to suspicious areas on the MRI
1580472|NCT02380027|Procedure|TRUS-biopsy|This will be a standard 12 core trans-rectal prostate biopsy
1580473|NCT02378922|Biological|Gene-Modified HIV-Protected Hematopoietic Stem Cells|Receive LVsh5/C46 (Cal-1) transduced CD34+ HSPC IV
1580474|NCT02378922|Other|Laboratory Biomarker Analysis|Correlative studies
1580475|NCT02378922|Other|Transplant Conditioning|Undergo high-dose chemotherapy or chemoradiotherapy
1580476|NCT02378909|Device|Electrical stimulation device.|In the intervention group, all participants will receive Geko device which will produce electrical stimulation to enhance wound healing. This is the non- invasive device, self adhesive, light and does not restrict the patient's movement. Wound will be measured at the beginning of the study (before the device is applied) and after the study is complete. Blood and wound tissue samples will also be taken pre and post electrical stimulation to observe the effect of electrical stimulation on wound healing in people with diabetes.
1580477|NCT02378896|Behavioral|Personalized Computer Program|Training with a personalized computerized inhibitory training program
1580478|NCT02378896|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT), consisting of Exposure and Ritual Prevention Therapy
1580479|NCT02378883|Device|Apollo™ Onyx™ Delivery Micro Catheter|
1580480|NCT02378870|Drug|Osteodex|Osteodex 3.0 mg/kg given every two week, maximum 13 times.
1580481|NCT02378870|Drug|Placebo|
1580482|NCT02380001|Drug|Dexketoprofen trometamol|White round pill containing 25mg of Dexketoprofen will be administered either prior/after to third molar surgery.
1580483|NCT02380001|Drug|Preoperative control|white round pill containing 25mg of placebo will be administered prior/after to third molar surgery. The placebo pill is identical to active dexketoprofen, in size and color
1580484|NCT02379988|Radiation|Verify radiation dose to heart and lung|This is a pilot study to determine whether the addition of inspiratory hold (breath holding) can decrease the radiation dose that the heart and lung receives for patients being treated for left sided breast cancer.
1580485|NCT02379975|Procedure|Non-surgical Periodontal Therapy|
1580486|NCT02379962|Other|no intervention|
1580487|NCT02379949|Behavioral|Virtual Reality Exposure Therapy|During virtual reality exposure therapy, a person encounters a feared stimulus (public speaking) in a computer-generated environment.
1580488|NCT02379949|Behavioral|Exposure Group Therapy|Exposure Group Therapy a behavioral treatment for social phobia. Participants face their fears by giving speeches to other group members.
1580489|NCT02379936|Device|The Neo Hilda|"This is a procedure that measures Lactate dehydrogenase in a fast and reliable way from only 10 microliter of blood. Using a small point of care card and a Smartphone for analysis.
Point of care method"
1580490|NCT02379936|Procedure|Traditional evaluation|Traditional way of evaluation
1580491|NCT02379936|Device|iPhone 4S|
1580492|NCT02379923|Device|Revascularization of Coronary Artery Chronic Total Occlusion (Corsair, Gaia, Asahi Guide Wires)|"Standard angiographic procedures will be followed for this study. The primary objective of this trial is to evaluate confirmation of placement of any guidewire beyond the chronic total occlusion (CTO) in the true vessel lumen in patients in which at least one Asahi series of guidewires and/or Corsair microcatheter were used.
Procedure success will be defined as angiographic visualization of any guidewire in a position either distal or proximal to the occlusion depending on the route of access and the absence of in-hospital MACE."
1580493|NCT02379910|Drug|AM1030-CREAM or placebo|
1580494|NCT02379897|Other|Diet|
1580495|NCT02379871|Other|Experimental Group|Supine mid-thoracic spinal manipulation to the T4/5 region
1580496|NCT02379871|Other|Sham Group|Subject will be positioned in supine identical to the experimental group, but no spinal manipulation will be delivered.
1580497|NCT02379858|Drug|Alvimopan|Alvimopan, 12mg, capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 after NGT removal until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
1580498|NCT02379858|Drug|Placebo|Placebo (sugar pill-will be the same size and color as the Alvimopan capsule), 12mg capsule. One 30 to 90 minutes before the scheduled start of surgery on Day 0, and twice daily beginning on POD 1 until hospital discharge or for a maximum of 7 days (up to 15 doses) of postoperative treatment. First post-operative dose begins after NGT removal.
1580499|NCT02379845|Device|NBTXR3|One intratumor implantation by injection
1580500|NCT02379845|Device|Radiation therapy|5 weeks/50 Gy (5 x 2 Gy by week)
1580501|NCT02379819|Device|Nucleus Hybrid L24 Implant|
1580502|NCT02379806|Drug|Enoxaparin|
1580503|NCT02379806|Drug|Placebo|
1580504|NCT02379793|Drug|LEO 80185 gel, vehicle, liquid paraffin|Each subject has all 3 treatments applied at the same time. Each treatment is applied once to 2 locations on the subject.
1580505|NCT02379780|Procedure|USG guided Subcostal TAP block|"Ultrasonography Assisted Subcostal TAP blockage: In plane technique was applied and 22 G needle (BRAUN Stimuplex D Plus 0,71*50 mm 22G*2) was used. Intravascular injection was eliminated after the passage of rectus sheath by negative aspiration. 0,5-1 ml local anesthetic was applied directly to confirm the right place. 10 cc bupivacain ( 0,5 % Marcain flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site. The same procedure was applied to the opposite site.
we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
1580506|NCT02379780|Procedure|USG guided Paravertebral Block|"Ultrasonoraphy assisted Thoracic Paravertebral blockage application: In-plane or out-of-plane technique was used with stimuplex needle (BRAUN Stimuplec D Plus 0,71*50 mm 22 G* 2'', 15°). Popping sensation that was felt by the penetration of the internal intercostal membrane, guided to paravertebral space. Intravascular injection was eliminated by negative aspiration. 0,5 - 1 ml local anesthetic injection was administered to show the displacement of pleura downward that confirmed the place of the needle in the right place. Then 10 cc bupivacain (% 0.5 Marcaine® flacon, Astra Zeneca, Sweeden) and 5 cc lidocaine was injected to the site.
we investigated amount of TIVA during the operation, postoperative Visual Analog Scores and the time that the pain free time."
1580507|NCT02379767|Device|Electroconvulsive therapy|
1580508|NCT02379767|Other|Positron emission tomography of the brain using [11C]harmine|
1580509|NCT02379767|Other|Structural magnetic resonance imaging|
1580510|NCT02379754|Drug|Gentamicins|Intratympanic installation of gentamicin 2-4 times depending on the efficacy of vestibular deafferentation
1580511|NCT02379741|Biological|ADC-1013|Agonistic human monoclonal IgG1 anti-CD40 antibody
1580512|NCT02379728|Device|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back during sleep, it is expected to significantly decrease the amount of time she spends in this position via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.
The PrenaBelt is worn at the level of the waist or thorax. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back of the user when she lies on her back, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back."
1580513|NCT02379728|Device|Body Position Sensor|The Body Position Sensor (BPS) is for research purposes only. The BPS can be securely integrated into a pocket on the PrenaBelt (PrenaBelt with BPS Arm) or sham-PrenaBelt (Control with BPS Arm). The BPS is a small, electronic data acquisition device. The BPS uses a three axes accelerometer to detect orientation of the PrenaBelt, and thus the user (right, left, prone, supine), in three-dimensional space. The accelerometer data is collected continually with time stamping and stored on the BPS hard drive and can be accessed via connecting it to a computer. The BPS is not expected to affect the body position of the user.
1580514|NCT02379728|Device|sham-PrenaBelt|The PrenaBelt can be easily converted into a sham-PrenaBelt for research purposes by removing the hard balls from its pockets or exchanging these hard balls for soft balls so it cannot provide pressure points, i.e., positional therapy function. The sham-PrenaBelt looks, fits, and feels like the PrenaBelt but cannot provide positional therapy.
1580515|NCT02379715|Drug|Remifentanil|
1580516|NCT02379715|Drug|Desflurane|
1580517|NCT02379702|Other|Metabolic Syndrome|This study will provide important information on the social and economic dimensions of metabolic syndrome
1580518|NCT02379689|Drug|Injectable placental tissue extract called BioDGenesis (Active Product)|
1580519|NCT02379689|Drug|Placebo|
1580520|NCT02379676|Drug|Ticagrelor|Ticagrelor 90mg twice daily for 30 days
1580521|NCT02379676|Drug|Clopidogrel|Clopidogrel 75mg once daily for 30 days
1580522|NCT02379663|Drug|Rivaroxaban|Rivaroxaban was taken orally in a dosage of 10mg once daily
1580523|NCT02379663|Drug|Enoxaparin|Enoxaparin was injected subcutaneously in a dosage of 40mg once daily
1580524|NCT02379663|Other|Normal saline|subcutaneous injection of 1 cc of normal saline once daily
1580525|NCT02379650|Drug|Hydroxychloroquine (HCQ)|
1580526|NCT02379650|Drug|Placebo|
1580527|NCT02379637|Drug|N-acetylcysteine|
1580528|NCT02379637|Drug|Placebo|
1580529|NCT02379624|Drug|pectin|Pectin, a representative diety fibre, is a gelatinous substance derived from the cell walls of fruits and some plants and contains galacturonan, consisting of mostly long-chain D-galacturonic acids combined into units by α-1,4 linkages. As a kind of soluble dietary fiber, pectin has been proved of controlling glucose and blood lipids. It slows rapid infusion of the liquid meal into the gut by delaying gastric emptying.
1580530|NCT02379611|Procedure|fNIRS (Functional Near Infrared Spectroscopy)|fNIRS is a non-invasive imaging method involving the quantification of chromophore concentration resolved from the measurement of near infrared (NIR) light attenuation, temporal or phasic changes. NIR spectrum light takes advantage of the optical window in which skin, tissue, and bone are mostly transparent to NIR light in the spectrum of 700-900 nm, while hemoglobin (Hb) and deoxygenated-hemoglobin (deoxy-Hb) are stronger absorbers of light. Differences in the absorption spectra of deoxy-Hb and oxy-Hb allow the measurement of relative changes in hemoglobin concentration through the use of light attenuation at multiple wavelengths.
1580531|NCT02379598|Dietary Supplement|Aminoacid based formula|Formula based on aminoacid
1580532|NCT02379598|Dietary Supplement|Hydrolyzed whey formula|Formula based on hydrolyzed whey protein
2008596|NCT03328832|Drug|Floseal®|Floseal® (Hemostatic matrix, 10ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 10 mL vial containing the active product (Floseal®) was used. The HM remained in place for 3 minutes and was then gently rinsed from the knee as recommended by the manufacturer (Baxter)
2008597|NCT03328832|Drug|rivaroxaban (10mg)|Oral rivaroxaban (10mg) QD on PostOp Day 1 to 14.
2008598|NCT03328819|Other|Acupuncture|Acupuncture is a form of alternative medicine in which thin needles are inserted into the body. It is a key component of traditional Chinese medicine (TCM). TCM theory and practice are not based upon scientific knowledge, and acupuncture is a pseudoscience. There are a diverse range of acupuncture theories based on different philosophies, and techniques vary depending on the country. The method used in TCM is likely the most widespread in the US. It is most often used for pain relief, though it is also used for a wide range of other conditions.
2008599|NCT03328793|Behavioral|Mood Assessment|Prior to and after the session, the patients will be asked to fill a VAMS (Visual Analog Mood Scale).
2008600|NCT03328793|Behavioral|Emotion Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the Observed Emotional Rating Scale (OERS), the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
2008601|NCT03328793|Behavioral|Communication Assessment|During the sessions, the patients will be videotaped and the videotapes will be reviewed by 2 independent research assistants. With the use of the CODEM Scale, the research assistants will be able to assess the patients's emotions at the beginning and at the end of the session (they will analyse the first 10 and the last 10 minutes of the sessions).
1580539|NCT02379572|Device|iMRI-guided surgery|For iMRI-guided glioma resections the surgery can be paused and a direct intraoperative resection control is possible by performing an intraoperative MRI scan. If residual tumor is found, the resection might be continued.
1580540|NCT02379572|Drug|5-ALA-guided surgery|For 5-ALA guided glioma resections patients have to drink 100ml of a solution with 5-Aminolevulinic acid 4-6 hours before surgery. Intraoperatively the light source of the surgical microscope can be switched to a certain wave length to enable fluorescence of the glioma cells, which helps resecting the tumor as radical as possible.
1580541|NCT02379559|Behavioral|Exercise|For the first 12-weeks, participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise. Exercise duration will increase from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, men will maintain 150 min/wk of moderate-intensity physical activity.
1580542|NCT02379559|Behavioral|Attention Control|We will provide weekly healthy lifestyle tips via text messages, and will include tips such as managing stressors in life and getting better sleep.
1580543|NCT02379546|Drug|Desflurane|Desflurane will be used to maintain the anesthesia and the dose of desflurane will be adjusted according to the Bispectral İndex Monitoring
1580544|NCT02379546|Device|Bispectral index monitoring|Bispectral index monitoring (BIS XP, A-2000, VERSİON 3.31, Aspect Medical Systems, Newton, Mass, USA)will be used to determine the depth of anesthesia
1580545|NCT02379533|Other|Aerobic exercise|
1580546|NCT02379520|Genetic|HPV Specific T Cells|"This is a dose escalation study. Three dose levels are being evaluated, namely DL1-1×10^7 cells/m2, DL2-3×10^7 cells/m2, and DL3-1×10^8 cells/m2.
Group A will receive HPVST cells alone. Group B will receive both lymphodepletion and nivolumab in addition to HPVST cells.
First, treatment in Group A will be completed for DL1 and DL2. Only if DL2 in Group A proves safe, Group B will be treated on DL2 and DL3.
Patients in Group A will be treated at DL3 only if there is excessive toxicity in the cohorts treated with lymphodepletion.
HPVSTs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line on day 0.
If the patient has had apparent clinical benefit (as determined by symptoms, physical exam or radiological studies) and no significant toxicities, he or she may receive up to 5 repeat infusions (for a max total of 6 infusions) of HPVSTs at or below the same dose level."
1580547|NCT02379520|Drug|Cytoxan|500mg/m^2/day x 3 days (on days -4, -3 and -2)
1580548|NCT02379520|Drug|Fludarabine|30mg/m^2/day x 3 days (on days -4, -3, and -2)
1580549|NCT02379520|Biological|Nivolumab|240mg every 2 weeks (+/- 3 days) starting on day -1
1580550|NCT02379507|Other|DEC033 Study Product|Apply twice daily
1580551|NCT02379481|Dietary Supplement|NS 550mg|
1580552|NCT02379481|Dietary Supplement|NS 1100mg|
1580553|NCT02379481|Dietary Supplement|placebo|
1580554|NCT02379468|Drug|Pedyphar Ointment|
1580555|NCT02379468|Drug|Panthenol|Ointment
1580556|NCT02379455|Other|Comprehensive drug review|1) Geriatric assessment including medical history, physical examination, supplementary tests. The geriatric work-up will be aimed at evaluating whether current medications are indicated, whether the relevant conditions are satisfactorily compensated, whether the dosages are appropriate, whether the patient has symptoms that may in reality be adverse drug effects, and whether drug-drug interactions or drug-disease interactions are likely to occur. 2) Conference with common drug review. The project physician and the family physician will discuss the patient's drug list systematically. 3) Individualized clinical follow-up depending on the medication changes that have been done.
2008602|NCT03328793|Other|Mobility assessment|If deemed to be safe, the patients will undergo a gait speed assessment as well as a TUG (timed-up-and-go) prior to and after the sessions
1580598|NCT02379156|Other|Cool Temperature|Subjects will be exposed to a routinely encountered cool temperature (64° F) for up to to 2 hours depending on the vital signs (BP, HR, Tcore) and tolerance (comfort).
2008603|NCT03328793|Other|Music Intervention|The participants will listen to a 30 minute live music sessions which will be given by musicians (who is a volunteer)
2008604|NCT03328793|Other|Documentary watching|The patients will watch a documentary for 30 minutes in the presence of a volunteer
2008605|NCT03328780|Device|Hemocue and Rad-67 measurement|Measurement of the hemoglobin level
2008606|NCT03328767|Behavioral|Early activity and Mobilisation intervention|The early activity and mobilisation intervention is comprised of exercises based on a reproducible, physiological approach using both strength and functional activities
2008607|NCT03328754|Device|Powerscope placed bilaterally for class II correction|Powerscope placed bilaterally for class II correction
1580559|NCT02379390|Drug|Cabazitaxel XRP6258|
1580560|NCT02379390|Drug|Ezalutamide|
1580561|NCT02379390|Drug|Abiraterone acetate|
1580562|NCT02379390|Drug|Prednisone|
1580563|NCT02379377|Radiation|Fluorine F 18 L-glutamate Derivative BAY94-9392|Undergo 18F-FSPG PET scan
1580564|NCT02379377|Radiation|Carbon-11 Acetate|Undergo 11C-acetate PET scan
1580565|NCT02379377|Device|Positron Emission Tomography|Undergo 18F-FSPG PET
1580566|NCT02379377|Procedure|Positron Emission Tomography|Undergo 11C-acetate PET
1580567|NCT02379377|Other|Laboratory Biomarker Analysis|Correlative studies
1580568|NCT02379364|Device|Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non invasive physiotherapeutic technique applied by means a set of metallic hooks having the advantage of allowing a deeper and more precise application, which could not be achieved manually
1580569|NCT02379351|Device|In-Home Non-Stress Test Device|Airstrip® Sense4Baby™
1580570|NCT02379338|Drug|[18F]Fluortriopride|All subjects will receive a [18F]Fluortriopride PET/CT scan
1580571|NCT02379325|Behavioral|Lets Quit|"Five tracks were created including Not Ready, Beginner, Advance, Relapse, and Distraction. The Distraction track was combined with all of the other remaining 4 tracks. It was aimed as a distraction (as the name indicated) method to lighten the participants mood. It consisted of general information such as sports, fashion, dining, movies, and travelling."
1580572|NCT02379325|Behavioral|pamphlets material|Given pamphlets material on smoking and complication
1580573|NCT02379312|Dietary Supplement|Very low energy aerated beverage|
1580574|NCT02379312|Dietary Supplement|Normal energy aerated beverage 1|
1580575|NCT02379312|Dietary Supplement|Normal energy aerated beverage 2|
1580576|NCT02379312|Dietary Supplement|Normal energy aerated beverage 3|
1580577|NCT02379299|Device|DiaCon dual-hormone closed-loop glucose control algorithm|Dual-hormone closed-loop glucose control
1580578|NCT02379299|Device|DiaCon single-hormone closed-loop glucose control algorithm|Single-hormone closed-loop glucose control
1580579|NCT02379286|Other|Investigation|Investigation of relationships between French teenagers' attitudes and beliefs towards alcohol and tobacco products and the degree to which they watch and relate to television series and music videos
2008608|NCT03328754|Device|Group 2 Forsus|Forsus placed bilaterally for class II correction
1580581|NCT02379260|Other|Interview with a sociologist|
1580584|NCT02379234|Other|simulation|Nurses received, in addition to the conventional formation (as in the control arm), a set of 3 high-fidelity simulation sessions. Each session lasted 1 to 2 hours, used high fidelity mannequin and CVVH generator and took place in an ICU room environment. For each session, a specific scenario was designed, the session began with a briefing and ended with a debriefing, based on video recording.
2008609|NCT03328741|Behavioral|Online Osteoarthritis treatment|6 week online-program
2008610|NCT03328741|Behavioral|Face-to-face osteoarthritis treatment|3 months face-to-face program
1580587|NCT02379195|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg are administered i.v on day -7 and -6
1580588|NCT02379195|Drug|Fludarabine|Fludarabine 25 mg/m2 are administered i.v on day -5 to -1
1580589|NCT02379195|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 min on day 0
1580590|NCT02379195|Drug|Interleukin-2|Interleukin-2 are administered as a continuous i.v. infusion in a decrescendo regimen (18 MIU/m2 IL-2 over 6 hours, 18 MIU/m2 IL-2 over 12 hours, 18 MIU IL-2 over 24 hours followed by 4.5 MIU/m2 IL-2 over another 24 hours for three days)
1580591|NCT02379195|Drug|Peginterferon alfa-2b|Peginterferon alpha-2b, 3 microgram/kg are administered as subcutaneous injection on day -2, day 7 and day 14.
1580592|NCT02379182|Behavioral|standard clinical care|adaptation of fluids, diet and oral hygiene recommendations, and postural and swallowing maneuvers training if necessary
1580593|NCT02379182|Device|transcutaneous electrical stimulation at sensory level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to 75% of motor threshold and electrode placement, thyro-hyoid (placement 3a described in the VitalStim Certification Program). The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
1580594|NCT02379182|Device|transcutaneous electrical stimulation at motor level|The treatment procedure will consist of the application, at rest, of 80 Hz of transcutaneous electrical stimulus (biphasic, 700 µs) using VitalStim device (Chattanooga Group, Hixson, TN, USA), 2 sessions of 1 hour per day the first week, and 1 hour per day the next week. Sessions will be applied from Monday to Friday for two weeks. Treatment intensity will be set to the motor threshold and electrode placement, supra-hyoid. The motor threshold will be determined by triplicate, as the intensity level at which the patient reports a grabbing or pulling sensation and confirmed by the clinician. Every 10 min, the patient will be asked if the initial sensation is maintained and, if necessary, treatment intensity will be re-adjusted.
1580595|NCT02379169|Dietary Supplement|Sea buckthorn oil & lutein|Standardised sea buckthorn seed and pulp oil complemented with lutein
1580596|NCT02379169|Dietary Supplement|Placebo|Triglycerides of medium chain fatty acids
1580597|NCT02379156|Drug|Midodrine Hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the vascular-constricting effects of this drug will help keep warm blood closer to the body's core and improve the ability to maintain Tcore in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only (Visit 2).
1580643|NCT02378779|Other|Help to verbalize|Help for the patient to speak about premature ejaculation
1580599|NCT02379143|Other|interview method: self report form|the responses about participants perception, behavior pattern and attitude were recorded on the self report form
1580600|NCT02379130|Behavioral|Family Nurture Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period the child will sit on the mother's lap. The pair will be asked to talk and play with each other as they customarily do. If the child becomes restless the mother will be coached by the nurture specialist to further engage the child with soothing and calming; the mother will be helped to bring the child back into a calm state through sustained physical contact, comfort touch, soothing words, and eye contact. The mother will also be helped to verbally express her feelings toward her child and to tolerate her child's full range of feeling.
1580601|NCT02379130|Behavioral|Play and Nutrition Intervention|The intervention begins with Block play. The child will be asked to play blocks with the mother during a eight minute video acquisition which will be coded for mother child interaction analysis. At the end of the video period, the child and mother will play nutrition-focused games using the Healthy Habits for Life program designed by Michelle Obama.
1580602|NCT02379104|Device|ROTEM sigma|Group Healthy Volunteers: a blood sample is tested with ROTEM sigma Group Patients with expected coagulopathy: a blood sample is tested with ROTEM sigma and ROTEM delta in parallel
1580603|NCT02379091|Drug|Namilumab|Namilumab subcutaneous injection
1580604|NCT02379091|Drug|Placebo|Namilumab placebo-matching subcutaneous injection
1580605|NCT02379091|Drug|Methotrexate|Methotrexate tablets
1580606|NCT02379091|Drug|Folic/folinic acid|Folic/folinic acid tablets
1580607|NCT02379078|Other|Shared decision-making aid|The IP-SDM toolkit consists of an online shared decision-making aid, 1-page provider enabler, a provider training video,1-page patient enabler, and a patient training video.
1580608|NCT02379078|Other|Generic hard copy diabetes resources|A hard copy of the executive summary of the CDA CPG and postcard outlining online resources, CDA patient education pamphlet
1580609|NCT02379078|Other|Generic online diabetes resources|Provider- and patient-directed guideline dissemination tools (not incorporating SDM) publicly accessible from the CDA website
1580610|NCT02379065|Device|The Aerogen Aeroneb Solo©|
1580611|NCT02379065|Device|Phillips Respironic© mask|
1580614|NCT02379026|Dietary Supplement|Protein Drink/Diet|1.2 - 1.5 g of protein per kilogram bodyweight will be consumed per day. One milk-based beverage high in dairy protein (50g of protein per 500ml bottle) will be consumed every day (post-workout on exercise days, before bed on non-exercise days). A 500kcal deficit diet will be prescribed based on the individual characteristics (eg weight, age, physical activity levels) of each participant.
1580615|NCT02379026|Behavioral|Exercise|Participants will enrol in a multimodal exercise program (with balance, flexibility, resistance and aerobic elements) 3 times a week, each lasting 1 hour.
1580616|NCT02379026|Dietary Supplement|Vitamin D3|1 tablet of Vitamin D3 (25 micrograms) will be taken on 3 non-consecutive days/ week to achieve a weekly intake of 75 micrograms.
1580617|NCT02379013|Procedure|Volunteer with MRI|functional MRI
1580618|NCT02379000|Drug|Triamcinolone Acetonide|Under sterile conditions an intravitreal injection of trimcinolone acetonide 4 mg was performed.
1580619|NCT02379000|Procedure|Transpupillary thermotherapy|We delivered TTT with an infrared diode laser adapted to a slit-lamp biomicroscope at a wavelength of 810 nm and beam diameters of 0.5, 0.8, 1.2, 2.0, or 3.0 mm using a contact lens and through a dilated pupil. Each TTT spot was applied for a duration of about 1 minute to achieve a grayish-white color on the surface of the tumor.
1580620|NCT02378974|Biological|Cordstem-ST|
1580621|NCT02378974|Biological|Placebo|
1580622|NCT02378961|Drug|VOX|100 mg tablet(s) administered orally once daily with food
1580623|NCT02378961|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily with food
1580624|NCT02378948|Dietary Supplement|Liquid oral feeding|Liquid oral feeding (water, soup, porridge, nutritional supplements etc.)
1580628|NCT02378844|Device|gammaCore®-R|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
1580629|NCT02378844|Device|gammaCore®-R Sham|Subjects will be instructed to treat three times per day, 2 consecutive bilateral stimulations, upon waking, six to eight hours following the first daily treatment, and six to eight hours following the second daily treatment (one stimulation on the right side immediately followed by a second stimulation on the left side).
1580631|NCT02378805|Drug|ACE-inhibitor|observational study!
1580632|NCT02378805|Drug|AT1-inhibitor|observational study!
1580633|NCT02378805|Drug|HMG-Coenzyme inhibitor (statin)|observational study!
1580634|NCT02378805|Drug|Spironolactone|observational study!
1580635|NCT02378805|Drug|Paricalcitol|observational study!
1580636|NCT02378792|Device|Vagus Nerve Stimulation|Vagus Nerve Stimulator
1580637|NCT02378779|Other|Questionary SF12 and PEDT|12 questions are asking to the patients 5 questions are asking to the patients
1580638|NCT02378779|Other|Total attention|Total attention of the GP to approach the subject of premature ejaculation during all the consultation
1580639|NCT02378779|Other|Humour|Use the humour to approach the subject of premature ejaculation
1580640|NCT02378779|Other|Take the drama out|Take the drama out to approach the subject of premature ejaculation
1580641|NCT02378779|Other|Question about premature ejaculation|Question about premature ejaculation during the GP consultation
1580642|NCT02378779|Other|Symptoms of premature ejaculation|GP's observation about signs of premature ejaculation
1580644|NCT02378766|Behavioral|Website A|"Patients assigned to this arm will be invited to complete a web-based tailored intervention called TAVIE en santé (TAVIE : Traitement, Assistance Virtuelle Infirmière et Enseignement).
TAVIE en santé is a web-based tailored multicomponent intervention addressing smoking cessation, physical activity and healthy eating. Each component consists of seven interactive computer sessions lasting 5-10 minutes. The sessions, hosted by a virtual nurse, aims to develop and strengthen skills required for behavior change."
1580645|NCT02378766|Other|Website B|Patients assigned to this arm will be invited to consult a validated list of five predetermined websites offering information about the health behavior they chose: being physically active, following a healthy diet or quitting smoking. These websites offers reliable information and their content were validated by experts.
1580647|NCT02378740|Drug|Saline|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:
0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
1580648|NCT02378740|Drug|Ketamine|"The study drug (either ketamine or saline) will be administered from the beginning of anesthesia through the commencement of wound closure to provide the following dose of ketamine:
0.5 mg/kg loading dose 8.3 mcg/kg/min (0.5 mg/kg/hr) infusion"
1580649|NCT02378727|Device|Active: Comparator Loss Of Resistance Syringe|Lumbar epidural procedure utilizing Loss of Resistance Syringe
1580650|NCT02378727|Device|Experimental: CompuFlo® Epidural System|CompuFlo® Epidural is intended for use with an epidural needle for the verification of needle tip placement in the lumbar epidural space
1580651|NCT02378714|Drug|Varenicline|Participants will be randomly assigned to 12 weeks of either placebo or varenicline medication (1mg twice daily). Participants and research personnel will be blind to treatment assignment.
1580652|NCT02378714|Behavioral|BASC|"The goal of behavioral activation therapy is to increase engagement in rewarding activities, a problem for smokers with depression who find smoking especially rewarding and prefer it over many other traditionally rewarding activities, by reducing patterns of behavioral avoidance, withdrawal, and inactivity. In this study, behavioral activation will be integrated with standard behavioral smoking cessation treatment.
Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions."
1580653|NCT02378714|Behavioral|Standard treatment|Standard behavioral smoking cessation treatment is an effective treatment for nicotine dependence. Treatment focuses on self-monitoring of smoking behavior, identifying smoking triggers and alternative trigger management strategies, relaxation, social support for non-smoking, and relapse prevention. Treatment will be delivered in eight 45-minute sessions over 12 weeks occurring weekly for the first four sessions and biweekly for the final four sessions.
1580654|NCT02378701|Behavioral|QUALMS-1 Questionnaire|Participants complete the QUALMS-1 during first treatment visit, and after 4th cycle of treatment or when treatment stops.
1580655|NCT02378701|Behavioral|FACT-An Questionnaire|Participants complete the FACT-An during first treatment visit, and after 4th cycle of treatment or when treatment stops.
1580656|NCT02378688|Drug|MT-1303|
1580657|NCT02378688|Drug|Placebo|
1580658|NCT02378675|Other|Blood draw|During the routine blood sampling, a 10ml plasma sample as well as a 10ml serum sample will be obtained, spinned and stored at -80°C until the final assessment of adipocytokines.
1580660|NCT02378649|Drug|Sildenafil|Sildenafil administration in the cardiac ICU following Mitral Valve Surgery concomitant with best practice usual care
1580661|NCT02378649|Drug|Placebo|Placebo comparator concomitant with best practice usual care
1580662|NCT02378636|Device|600S|Monofocal Aspheric Intraocular Lens (IOL)
1580663|NCT02378623|Drug|Apixaban|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
1580664|NCT02378623|Drug|Placebo|Patients who meet the study eligibility criteria and consent for enrollment will be randomized in a 1:1 ratio to intervention with apixaban or control group with placebo. The randomization will be performed by a computer generated block randomization protocol. Randomization will be stratified according to pre-existing CIED (≥6 months) vs. new implantation (<6 months from date of implant), in order to ensure at least 25% of patients have longstanding lead placement.
1580665|NCT02378610|Other|Observation|Observation of the gut bacterial flora in high- and low-stressed individuals
1580666|NCT02378597|Behavioral|Behavioral: Resiliency Intervention|4 hour behavioral session including education in the relaxation response, education about stress and allostatic load, cognitive skills building, review of difficult encounters with patients.
1580667|NCT02378584|Other|embryo transfer|healthy blastocyst transfer in natural and hormonal cycle
1580668|NCT02378571|Behavioral|Medication adherence telemonitoring|The member of the study team will respond to adherence data using clinical judgment as they would if the information was obtained during clinical care. Specifically, when contacting nonadherent participants, the member of the study team will provide participants with feedback on their electronic adherence; will inquire about potential consequences of missed doses; and will assess and respond to reasons for missed doses.
1580669|NCT02378558|Device|MagneMarker|The MagneMarker system includes a magnetic clip the MagneMarker, a clip placement device the MagneJector, and a magnetic field detecting probe the MagneProbe. The MagneMarker and MagneJector are used by a radiologist during a breast localization procedure. The MagneProbe is used by a surgeon to locate the MagneMarker during breast excision.
1580670|NCT02378545|Drug|Oxygen|"On the Hyperoxia arm: Oxygen will be administered using a non-re-breathe oxygen mask applied over the face and nose.
On the Normoxia arm: In many cases oxygen will not be administered. If required the minimum percentage required to reach the target saturations will be administered. In a majority of cases this will be via a venturi mask."
1580671|NCT02378532|Drug|Chloroquine|Three cohorts of 3 patients will receive chloroquine in escalating doses (3 dose levels: 200 mg up to 600 mg daily) during standard treatment (radiotherapy and temozolomide) for newly diagnosed GBM. Extra patients can be added to a cohort in case of dose limiting toxicity, resulting in a maximum of 6 patients per dose level.
1580672|NCT02378532|Radiation|Radiotherapy|Patients will receive megavoltage radiotherapy in a conventionally fractionated regimen of 59.4 Gy in 33 fractions in 6.5 weeks, using modern computer-based treatment planning and delivery techniques. Treatment should start within 6 weeks of surgery.
1580673|NCT02378532|Drug|Temozolomide|Patients will take TMZ 75 mg/m² po qd during the course of radiotherapy six adjuvant cycles of TMZ. After a 4 week break, patients will receive up to six cycles of adjuvant oral TMZ 150 - 200 mg/m² po qd for 5 days every 28 days. The starting dose is 150 mg/m² po qd. At the start of cycle 2 the dose will be escalated to 200mg/m2, if the CTC non-hematologic toxicity for cycle 1 is grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count is ≥1.5 x 109/L and the platelet count ≥ 100 x 109/L.
1580674|NCT02378519|Behavioral|Web-prog, followed by CBT + PT|This arm of the single system experimental design starts with a baseline phase of 8 weeks where the subjects are introduced into to the interactive web-based self-help program. The baseline-period is followed by the intervention period which consists of a continued use of the interactive web-based self-help program, now with with cognitive behavioral therapy coaching in combination with individually tailored physiotherapy according to the person's needs for 16 weeks.
1580675|NCT02378519|Behavioral|Base, followed by Web + CBT + PT|The intervention consists of a interactive web-based selfadministrated program with cognitive behavioral therapy coaching in combination with tailored physiotherapy according to the person's needs for 16 weeks.
1580676|NCT02378506|Biological|etanercept|50mg subcutaneous, once weekly, 24 weeks
1580677|NCT02378493|Biological|Antibiofilmogramme|An Antibiofilmogramme (BioFilm Control) evaluates the capacity of a series of antibiotics to inhibit the growth of bacterial biofilms for a given bacterial isolate.
1580678|NCT02378480|Drug|Omadacycline|Injection for IV dosing; Tablets for oral dosing
1580679|NCT02378480|Drug|Linezolid|Infusion solution for IV dosing; Tablets for oral dosing
1580680|NCT02378467|Drug|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
1580681|NCT02378467|Drug|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Vios® compressor.
1580682|NCT02378454|Device|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
1580683|NCT02378441|Drug|Atorvastatin 20mg and Metformin SR 750mg|co-administration of Atorvastatin 20mg and Metformin SR 750mg
1580684|NCT02378441|Drug|CJ-30056 20/750mg|fixed-dosed combination of Atorvastatin 20mg and Metformin SR 750mg
1580685|NCT02378428|Drug|MIBG|
1580686|NCT02378415|Drug|Ketamine|IV Bolus dose of ketamine dosed at 0.2mg/kg infused over 1-2 minutes.
1580687|NCT02378415|Drug|Placebo|Normal Saline Infusion
1580688|NCT02378402|Other|Proton (1H-) magnetic resonance (MR) spectroscopy|PRESS localized 1D MRS sequence was used on a 3-T MR system. The lipid resonances will be analyzed using the LC-Model algorithm, and a Cramer-Rao lower bound (CRLB) threshold of 50% was used as quality control. Resonances of fatty acid (FA, lipid resonances δ 0.9, 1.3 and 1.6 ppm) and polyunsaturated fatty acid (PUFA, lipid resonance δ 2.1 and 2.3, 2.8, 5.3 ppm) will be evaluated on MRS, with ratios normalized with total TG value.
1580689|NCT02378389|Drug|Pyrotinib/Pyrotinib with Docetaxel|Pyrotinib oral daily, 240 mg, 320 mg, 400 mg.... Docetaxel i.v. once every 21 days.
1580690|NCT02378376|Dietary Supplement|Arabinoxylan oligosaccharides|
1580691|NCT02378376|Dietary Supplement|Dietary fiber enriched bran|
1580692|NCT02378363|Other|Write, draw and interview|Child should write, draw cancer signifiance and after, they were interview by a school nurse about cancer signifiance.
1580695|NCT02378337|Other|Image quantify|Will be observed all patients who perform PET / CT examinations, independent of clinical indication, in nuclear medicine at Hospital Sao Rafael. Those who show interest in participating in the study, will be provided free and informed consent form (ICF) for your appreciation. This evaluation will serve for analysis and quantification of PET-CT images.
1580696|NCT02378324|Other|Screening without fee|All women in three districts in Gothenburg, Sweden, that were eligible for invitation in the regular screening program were individually randomized by computer program in two parallel arms 1:1.
1580697|NCT02378298|Drug|Rituximab|Rituximab (RTX) is a mouse-human chimeric antibody designed towards (CD20) pre B and mature B lymphocytes and that blocks B-cells activation without affecting the regenerating of B cells from stem cells or the plasma cells immunoglobulin production. Rituximab is used in the treatment of hematologic malignancies (B cells lymphoma, chronic lymphatic leukaemia, Waldenströms macroglobulinemia) and autoimmune diseases with B-cell involvement such as rheumatoid arthritis, thrombocytopenic purpura, SLE).
1580698|NCT02378298|Drug|Iv Methylprednisolone|Solumedrol is an intravenous glucocorticoid that are the gold standard in TAO. All patients start with 500 mg/weeks for 4 weeks. The response is evaluated and patients are randomised to non-responders or responders. The responders continues with the gold standard treatment that is another 500 mg solumedrol/ week in 2 weeks and then 250 mg/ week in 6 weeks.
1580699|NCT02378298|Drug|peroral methylprednisolone and Methotrexate|Peroral GC (starting with 30 mg and tapering down) is combined with 15-20 mg MTX /week to reduce the needed dose of steroids
1580700|NCT02378285|Device|ACP|ACP is prepared using the Autologous Conditioned Plasma (ACP®) device from Arthrex (Naples, Florida, USA), following the supplier instructions. 2 mL of ACP are transferred in a standard 2 mL injection syringe by a nurse. The standard 2 mL injection syringe is then given to the physician.The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
1580743|NCT02377934|Radiation|Cardiac Magnetic Resonance Imaging (MRI)|
1580744|NCT02377921|Drug|Sialic Acid Tablets|
1580701|NCT02378285|Other|Saline solution|2 mL of saline solution are placed in a standard injection syringe by a nurse. The syringe is then given to the physician. The patient is installed on a table with his arm in supine position. A local subcutaneous anesthesia (2 ml of 1% lidocaine) is done just before the infiltration by the physician. The infiltration is then done guided by ultrasound.
1580702|NCT02378272|Other|care manager for depression|District nurse (care manager for depression) providing clinical services ( in cooperation with GP) as patient information and education on patient's preferred treatment, development of care plan, assessment of patient's depressive symptoms and regular telephone contacts.
1580703|NCT02378259|Procedure|Laparoscopic Roux-en-Y gastric bypass|Bariatric surgery with Roux-en-Y gastric bypass as preferred option, possible laparoscopic Vertical Sleeve Gastrectomy
1580704|NCT02378259|Procedure|Intense conservative treatment|Intense medical treatment for obesity (behavioral treatment, dietary intervention, exercise, medication etc) 8 week period of Low Calorie Diet. Treatment intensity about 1 visit a month over 2 years
1580705|NCT02378246|Dietary Supplement|Iodine|We use multivitamin tablets one with 150 microgram iodine for Active comparator and one without iodine as placebo
1580706|NCT02378246|Dietary Supplement|Placebo|multivitamin tablets without iodine
1580707|NCT02378233|Dietary Supplement|iodine|The intervention is to give a multivitamin pill including 150 microgram iodine and compare with a multivitamin pill that is not including iodine.
1580708|NCT02378233|Dietary Supplement|Placebo|Patients are given a non-iodine containing multivitamin tablet
2008611|NCT03328728|Device|Cellular Matrix / A-CP HA Kit|Treatment with a single intra-articular injection in the knee of Cellular Matrix / A-CP HA Kit; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
1580710|NCT02378207|Biological|H4:IC31|
1580711|NCT02378207|Biological|H56:IC31|
1580712|NCT02378207|Biological|BCG|
1580713|NCT02378207|Biological|Control Sodium Chloride 0.9%|
1580714|NCT02378194|Drug|Placebo|24 weeks, once daily oral administration
1580715|NCT02378194|Drug|HD-003 (800mg/day)|24 weeks, once daily oral administration
1580716|NCT02378194|Drug|HD-003 (1600mg/day)|24 weeks, once daily oral administration
1580717|NCT02378181|Behavioral|Health Education Toolkit|An existing evidence-based toolkit intervention will be adapted and redesigned by a patient and provider team into an engaging, narrative graphic novel curriculum. The proven behavioral interventions will be augmented with health education material focused on MAT and HIV risk reduction. Together, these materials will comprise the Health Education Toolkit. The Health Education Toolkit (TK) will employ a shared decision making model to encourage 1) increased recovery engagement by patients, and 2) patient engagement in deciding whether to initiate and adhere to MAT.
1580718|NCT02378181|Behavioral|Treatment-as-usual|Treatment-as-usual will consist of the same number of counseling sessions as the experimental TK condition, but the counselors working with patients in this condition will not be equipped with the TK materials.
1580719|NCT02378168|Other|no intervention; retrospective study|
1580720|NCT02378155|Device|SenSmart Model X-100, Nonin Medical|Device to measure cerebral tissue oxygen saturation
1580721|NCT02378142|Drug|Pazopanib|
1580722|NCT02378129|Drug|Resin-modified glass ionomer cement Clinpro XT|Clinpro XT (3M ESPE, Minnesota, USA)
1580723|NCT02378129|Drug|Glass Ionomer cement Vidrion R|Vidrion R (SS White, Gloucester, UK)
1580724|NCT02378116|Procedure|Surgical closure of the left atrial appendage|When patients are randomized to surgical closure, the surgeon is informed to close the left appendage. Closure is documented by a member of the research group at the site.
1580725|NCT02378077|Procedure|Fat biopsy during scheduled abdominal surgery|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Fat tissue biopsy during a scheduled abdominal surgery.
1580726|NCT02378077|Procedure|Fat Aspiration|Physical exam including blood work, an EKG and bioimpedance testing. An oral glucose tolerance test. Insulin infusion. Subcutaneous fat tissue biopsy.
1580727|NCT02378077|Dietary Supplement|Fish Oil Supplement|Fish Oil supplementation for three months.
1580728|NCT02378064|Drug|6-month treatment|
1580729|NCT02378051|Behavioral|Staying Strong with Schools Intervention|"On-Site Training to Raise Awareness about the Stress of Parental Deployment and Review Resources Helpful in Promoting military-connected children (MCC)'s Resilience. A 60-minute training will be delivered by our Liaison Trainer on-site to school professionals at the beginning of the school year.
Training and supervision of the Resilience Support Liaison (RSL). In each school receiving the Staying Strong with Schools intervention, we will train the guidance counselor to take on the role of a RSL. The RSL will develop for each MCC an individual resilience support plan that will outline the specific intervention components that will be applied for him/her."
1580730|NCT02378051|Other|Waitlist Control|Receipt of an educational pamphlet outlining resources useful to support military-connected children distributed to all educators at the beginning of the school year.
1580731|NCT02378038|Drug|PNT2258|
1580732|NCT02378025|Behavioral|Yoga Group|A 10-week yoga course designed to treat pain.
1580733|NCT02378025|Behavioral|Pain Management Wellness Group|A 10-week behavioral therapy course designed to treat pain.
1580734|NCT02378012|Other|Computer-Assisted Intervention|Receive access to Netflix, Spotify, and Skype applications
1580735|NCT02378012|Other|Computer-Assisted Intervention|Receive iPad and instruction manuals.
1580736|NCT02378012|Other|Questionnaire Administration|Ancillary studies
1580737|NCT02377999|Drug|Picato|
1580738|NCT02377986|Behavioral|BIT+in-home decluterring|BIT Workshop + In-home decluttering practice
1580739|NCT02377986|Behavioral|In-Home Decluttering|In-home decluttering practice
1580745|NCT02377921|Drug|Placebo Tablets|
1580746|NCT02377908|Other|Online Survey|Online questionaire submitted to experts in geriatrics in different European countries. 12-item survey.
1580747|NCT02377895|Drug|Nasapaque Nasal Solution|
1580748|NCT02377895|Drug|Placebo Saline Nasal Solution|
1580749|NCT02377869|Other|No intervantion|
1580750|NCT02377856|Drug|pegylated interferon alpha 2a, ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
1580751|NCT02377843|Behavioral|Participatory|"The participatory intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:
Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine
Skills building on how to recommend HPV vaccine using a participatory communication strategy based in shared decision making
Practice using the communication strategy via role play
Discussion on applying the communication strategy to medical practice"
1580752|NCT02377843|Behavioral|Efficient|"The efficient intervention is a 1-hour training to help clinicians improve their ability to make strong and effective recommendations for HPV vaccine, and address parental concerns regarding HPV vaccination. The training includes four components:
Review of information on HPV vaccine, including effectiveness, safety, rationale for targeting adolescents ages 11-12, and low HPV vaccine coverage rates compared to Tdap and meningococcal vaccine
Skills building on how to recommend HPV vaccine using an efficient communication strategy based on first announcing the child is due for 3 vaccines
Practice using the communication strategy via role play
Discussion on applying the communication strategy to medical practice"
1580753|NCT02377830|Device|In-bed cycle ergometer (Restorative Therapies RT300 Supine)|
1580754|NCT02377830|Other|Routine physiotherapy|activities to assist with optimizing airway clearance and respiratory function, and, based on the patient's alertness and medical stability, activities to maintain or increase limb range of motion and strength, in- and out of bed mobility, and ambulation
1580755|NCT02377817|Device|PrenaBelt|"The PrenaBelt is a belt-like, positional therapy (PT) device designed specifically for pregnant women. While the PrenaBelt does not prevent the user from lying on her back or right side during sleep, it is expected to significantly decrease the amount of time she spends in these two positions via the mechanism of PT. PT is a simple, non-invasive, inexpensive, long-established, safe, and effective intervention for preventing people with positional-dependent snoring or obstructive sleep apnea from sleeping on their back - a position that exacerbates their condition.
The PrenaBelt is worn at the level of the waist. By virtue of its design and position on the user's body, the PrenaBelt affects subtle pressure points on the back and right side of the user when she lies on her back or right side, respectively, activating her body's natural mechanism to spontaneously reposition itself to relieve discomfort, thereby reducing the amount of time she remains on her back or right side."
1580756|NCT02377817|Device|Sham PrenaBelt|The Sham PrenaBelt and PrenaBelt are the same device except the plastic balls are removed from the Sham PrenaBelt so it cannot provide pressure points.
1580757|NCT02377804|Other|Dry needling|Patients will receive deep dry needling with disposable stainless steel needles (0.3mm x 50mm) that will be inserted into the skin over taut bands of the spastic musculature of the shoulder area: upper trapezius, subscapularis, infraspinatus, and pect
1580758|NCT02377804|Other|Physical Therapy|Patients will receive 3 sessions, one per week, of 45min of physical therapy including mobilizations of the scapular region, manual therapies targeted to decrease muscle tone, neuromodulatory techniques for spasticity and proprioceptive exercises for the upper extremity
1580759|NCT02377804|Device|stainless steel needles (0.3mm x 50mm)|
1580760|NCT02377791|Genetic|SNP: CYP3A5 gene polymorphisms|Evaluate impact of CYP3A5*1/*1 vs CYP3A5*1/*3 or CYP3A5*3/*3
1580761|NCT02377778|Drug|Propofol|Propofol intravenous infusion for introduction and maintance of anaesthesia at doses 3-5mg depending on the total time needed for completion of oocyte retrieval
1580762|NCT02377778|Drug|Thiopental|Patients will receive thiopental in addition to fentanyl for introduction and maintanance of anaesthesia at doses 7mg. IF required patients will receive a repeat dose of 1-3mg of thiopental depending on the totla time needed to complete oocyte retrieval
1580763|NCT02377765|Device|Transcutaneous Stimulation|TPTNS through a TENS unit is a non-invasive technique, easily manageable by patients, which lacks some adverse side effects reported with the use of PTNS, such as bleeding and/or pain at the site of needle insertion. As the technique is self-administered, the associated costs might be substantially lower when compared to PTNS, which involves repeated Hospital appointments for maintenance therapy.
1580764|NCT02377765|Procedure|Percutaneus Stimulation|PTNS aims to stimulate the sacral nerve plexus (origin to the parasympathetic innervations to the bladder) through the afferent fibres of the posterior tibial nerve, a mixed nerve containing L5-S3 fibres (Slovak, Chapple and Barker, 2014). This is achieved by a needle electrode inserted above the medial malleolus. Interestingly, this anatomical area is known as acupuncture point Spleen6 (Sp6).
1580765|NCT02377752|Biological|Olaratumab|Administered IV
1580766|NCT02377752|Drug|Doxorubicin|Administered IV
1580767|NCT02377739|Other|non-invasive ventilation|patients will undergo a nocturnal non-invasive ventilation
1580768|NCT02377726|Behavioral|Alkoholhjälpen counselor support|Users will have access to counselor support through secure comments at the end of every module they complete in the self help program.
1580769|NCT02377726|Behavioral|eChange Alkoholhjälpen|An internet based intervention program (iCBT) consisting of 5 modules. Fully automated self-help
1580770|NCT02377726|Behavioral|Alkoholhjälpen|A swedish, open access website that includes information on alcohol, on how to find treatment and an internet discussion forum
1580771|NCT02377713|Drug|KHK6640|Single ascending dose administration
1580772|NCT02377713|Drug|Placebo|Single ascending dose administration
1580773|NCT02377700|Device|Xeltis Vascular Patch, Model COR-VP-001|The intended use of the Xeltis Vascular Patch, Model COR-VP-001 is to augment pulmonary artery and thereby improve hemodynamics by increasing blood flow to the lungs in patients with congenital pulmonary artery obstructions as an initial part of the staged procedure of a bidirectional cava-pulmonary anastomosis
1580774|NCT02377687|Other|observational study|
1580775|NCT02377674|Device|Vascular Graft, Model COR-VG-001|The intended use of the Xeltis Vascular Graft, Model COR-VG-001 is to create an extracardiac total cavopulmonary connection (EC-TCPC) connection to divert the venous blood from the inferior vena cava to the pulmonary arteries without passing through the morphologic right ventricle reducing the volume load on the functional single ventricle and thereby improving hemodynamics by minimizing the deleterious effects of ventricular hypertrophy.
1580776|NCT02377661|Drug|Olmesartan medoxomil, amlodipine, hydrochlorothiazide|Up-titration of antihypertensive therapy with single pill combinations (comprising an angiotensin receptor blocker, calcium channel blocker and hydrochlorothiazide) in 4-week intervals if the target blood pressure of < 140/90 mmHg is not reached at the respective follow-up
1580777|NCT02377648|Device|Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)|Placement of bioresorbable vascular scaffold in presence of at least one critical angiographic de novo lesion (DS ≥70%) or a non-critical angiographic de novo lesion (50% ≤ DS <70%) associated with concomitant signs or symptoms of myocardial ischemia.
1580780|NCT02377622|Device|THERANOVA 400 dialyzer prototype AA|
1580781|NCT02377622|Device|THERANOVA 400 dialyzer prototype BB|
1580782|NCT02377622|Device|FX CorDiax 80 Dialyzer|
1580783|NCT02377622|Device|FX CorDiax 800 Dialyzer|
1580784|NCT02377609|Drug|Tacrolimus|oral
1580785|NCT02377570|Device|THERANOVA 400 dialyzer prototype AA|Hemodialysis
1580786|NCT02377570|Device|THERANOVA 400 dialyzer prototype BB|Hemodialysis
1580787|NCT02377570|Device|THERNOVA 400 dialyzer prototype CC|Hemodialysis
1580788|NCT02377570|Device|FX CorDiax 80 dialyzer|Hemodialysis
1580789|NCT02377557|Drug|Topical Steroids|
1580790|NCT02377544|Dietary Supplement|Probiotic|
1580791|NCT02377544|Other|Placebo|
1580792|NCT02377531|Other|Early glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 12 to 18 weeks of pregnancy instead of standard 24 to 28 weeks of pregnancy
1580793|NCT02377531|Other|Standard glucose screen group|Main intervention is randomization: half of the participants will be randomized to undergo a 50 gram oral glucose load with a 1 hour serum glucose measurement as a screen for Gestational Diabetes mellitus at 24 to 28 weeks of pregnancy
1580794|NCT02377518|Radiation|Single source dual energy compted tomography (CT750HD, General Electric, USA) with Krypton as a gaseous contrast media|
1580795|NCT02377505|Device|On-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is on"
1580796|NCT02377505|Device|Off-Stimulation|"The surgical electrode implanted in target 1 (mPFC) or target 2 (NAcc) by a pulse generating device (Kinetra, Medtronic Inc) is off"
1580797|NCT02377492|Drug|Vasopressins|Either paracervical and intramyometrial or intramyometrial alone at time of abdominal myomectomy.
1580798|NCT02377479|Drug|Clomiphene|Taken for controlled ovarian hyperstimulation.
1580799|NCT02377479|Drug|Letrozole|Taken for controlled ovarian hyperstimulation
1580803|NCT02377414|Drug|Retosiban solution for Infusion|Retosiban will be supplied as clear, colorless IV solution for infusion in 5 mL vial with a unit dose strength of 15 milligrams per milliliter (mg/mL) (each 5 mL vial contains 75 mg retosiban), dosed at up to 300 mg over 48 h infusion
1580804|NCT02377414|Drug|Placebo|Placebo will be supplied as a clear, colorless IV solution for infusion with a unit dose strength of 0.9% sodium chloride (NaCl) normal saline
1580805|NCT02377401|Drug|Zanamivir|Zanamivir will be supplied as 10 mg/mL sterile clear, colorless, aqueous solution in 20 mL clear glass vials, each containing 200 mg zanamivir. Intravenous solutions will be prepared with normal saline.
1580806|NCT02377388|Drug|saxagliptin|saxagliptin tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
1580807|NCT02377388|Drug|placebo|placebo tablets, 48(+-24) hours after the beginning of an AMI,and both arms in use of dual anti-platelet therapy (DAPT) .
1580808|NCT02377375|Procedure|Micro-assisted technique|Medtronic DBS lead 3391-28cm Medtronic electrode array microrecording 22670
1580809|NCT02377375|Procedure|Standard technique|Medtronic DBS lead 3391-28cm
1580810|NCT02377362|Drug|GLWL-01, Part A|Capsules administered orally, in 2 out of 3 periods
1580811|NCT02377362|Drug|Placebo, Part A|Capsules administered orally in 1 out of 3 periods
1580812|NCT02377362|Drug|GLWL-01, Part B|Capsules administered orally either once or twice daily for 27 days, with a single dose on Day 28
1580813|NCT02377362|Drug|Placebo, Part B|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
1580814|NCT02377362|Drug|GLWL-01, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
1580815|NCT02377362|Drug|Placebo, Part C|Capsules administered orally either once or twice daily for 27 days with a single dose on Day 28
1580818|NCT02377336|Drug|GS-6615|GS-6615 tablets administered orally
1580819|NCT02377336|Drug|Placebo|Placebo to match GS-6615 tablets administered orally
1580820|NCT02377323|Other|MACFIMS|Cognitive evaluation of 50 participants
1580821|NCT02377323|Other|MSQoL-54|Quality of life questionnaires
1580822|NCT02377297|Procedure|Restoration with Fuji IX|The cavities will be restored with Fuji IX (GC Europe, Leuven, BE).
1580823|NCT02377297|Procedure|Restoration with Vitro Molar|The cavities will be restored with Vitro Molar (DHL, Rio de Janeiro, BR).
1580824|NCT02377297|Procedure|Restoration with Maxxion R|The cavities will be restored with Maxxion R (FGM, Rio de Janeiro, BR).
1580825|NCT02377284|Other|Photograph|Add a photograph to a chef card.
1580826|NCT02377271|Drug|bosentan|treatment by bosentan or placebo is randomized , 125 mg twice a day
1580827|NCT02377271|Drug|placebo|treatment by bosentan or placebo is randomized
1580828|NCT02377258|Other|Non Interventional|
1580829|NCT02377232|Behavioral|Decision Aid for Colon Cancer Screening|Paper decision aid describing different screening options for colon cancer
1580830|NCT02377232|Behavioral|Usual Care Outreach for Colon Cancer Screening|Patients overdue for colon cancer screening are contacted and outreach is performed in an effort to schedule colonoscopy
1580832|NCT02377206|Other|ADAS-Cog evaluation|[18F]DPA-714 PET imaging
1580835|NCT02377180|Procedure|Intramuscular capsaicin injection|Intramuscular injection of capsaicin: 50 mcg/0.5 ml
1580836|NCT02377180|Procedure|Suprascapular nerve block|"Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus or trapezius muscle in randomized order, followed by suprascapular nerve block (ultrasound-guided) using Lidocaine 1%; nerve block is expected to be effective only in pain arising from the supraspinatus muscle. Trapezius pain serves as control condition.
Evaluates the diagnostic validity of suprascapular nerve block for muscle pain."
1580837|NCT02377180|Procedure|Local anesthetic infiltration|Injection of capsaicin 50 mcg/0.5 ml into the supraspinatus muscle in two different sessions; suprascapular nerve block in one session and intramuscular local anesthetic infiltration in one session (in randomized order) using Lidocaine 1%; the aim is to investigate which procedure provides faster and more efficient pain relief. Compares effectivity of suprascapular nerve block vs. intramuscular local anesthetic infiltration.
1580838|NCT02377167|Procedure|Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy with tracheostomy kit by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
1580839|NCT02377154|Device|Slit lamp|Examination of cornea
1580840|NCT02377154|Device|Autorefractor|Measurement of refraction
1580841|NCT02377154|Device|IOLMaster 500|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
1580842|NCT02377154|Device|Pentacam HR|Measurement of white-to-white distance; Keratometry
1580843|NCT02377154|Device|LenStar LS900|Measurement of axial length and white-to-white distance; Keratometry; IOL calculation
1580844|NCT02377154|Device|VERION Image Guided System|Measurement of white-to-white distance; Keratometry; IOL calculation with axial length value of IOLMaster 500
1580845|NCT02377141|Procedure|Endoscopic Variceal Band Ligation|Standard care: Endoscopic application of rubber bands to varices (swollen veins) in the oesophagus this is repeated on 4-5 occasions until the varices are eradicated.
1580846|NCT02377141|Procedure|Transjugular Intrahepatic Porto-Systemic Stent Shunt|Within 72 hours of the initial endoscopy to apply bands to the bleeding varices the patient undergoes a Transjugular Intrahepatic Porto-Systemic Stent Shunt (TIPSS) procedure. Under x-ray guidance a shunt is created in the liver between the hepatic vein and portal vein via a catheter introduced via the jugular vein. It may require a check once or twice per year to ensure it remains patent.
1580847|NCT02377128|Procedure|Bilateral salpingectomy|Surgical bilateral removal of fallopian tubes (not involving ovaries)
1580848|NCT02377128|Procedure|Tubal ligation|Bilateral ligation of fallopian tubes (not involving ovaries)
1580849|NCT02377115|Other|Tablet computer-based clinical screening tool.|Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing postoperative delirium.
1580850|NCT02377102|Procedure|Physical Therapy|12 weeks of supervised physical therapy.
1580851|NCT02377089|Device|Trigeminal Nerve Stimulation|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the active frequency of 120 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
1580852|NCT02377089|Device|Placebo|Subjects will be randomized to treatment with either active or sham TNS for a period of eight weeks. The programming will be set by an individual who has no contact with subjects to deliver TNS in a double-blind manner (n=37 in each group) at the sham frequency of 0 Hz. TNS will be performed for approximately 8 hours each night, a protocol that subjects found acceptable in the pilot work.
1580853|NCT02377076|Dietary Supplement|Dietary calcium supplementation|Dietary calcium supplementation as milk powder
1580854|NCT02377076|Dietary Supplement|Control|Control (Whey protein, vitamin D, sugar and salt)
1994185|NCT03055715|Radiation|Radiation|No intervention in this retrospective study
1580856|NCT02377050|Other|Higher Volume Feeding Goal|feeding volume goal of 180-200 ml/kg/day
1580857|NCT02377037|Other|Metabolic cost and HR associated with distinct postural behaviors|The order of the three conditions will be randomly assigned and all will be undertaken in laboratory settings. Before engaging in the experimental conditions participants will perform anthropometric and body composition assessments and also the resting EE evaluation. All evaluations will be performed at one time only, starting at 7:00 am in the morning after an overnight fast
1580858|NCT02377024|Dietary Supplement|TF 600mg|
1580859|NCT02377024|Dietary Supplement|TF 1200mg|
1994186|NCT03055507|Drug|Ibuprofen 400 mg|Addition of ibuprofen to standard pain regimen.
1994187|NCT03055507|Drug|Acetaminophen 650 mg|Standard analgesic provided post-operatively to patients undergoing sinus surgery
1994188|NCT03055507|Drug|OxyCODONE 5 Mg Oral Tablet|Standard PRN medication offered post-operatively for breakthrough pain
1580860|NCT02377024|Dietary Supplement|placebo|
1580861|NCT02377011|Behavioral|Problem solving cognitive behaviour therapy (PS CBT)|
1580862|NCT02376998|Device|Valiant™ endoluminal procedure|"Thoracic endovascular aortic repair with Endoluminal stent-graft placement (Valiant™ endoluminal stent-graft systems (Medtronic Inc., Santa Rosa, CA, USA) will be performed as follows:
The diameter of the stent graft will be calculated from the largest diameter of the proximal/distal neck with an oversizing factor of 10-20%. The procedures will be done with local or general anaesthesia in case of unstable pre-operative hemodynamic conditions.
After the procedure will be completed, a digital subtraction angiography and echocardiography with color-flow mapping were performed to verify the correct positioning of the stent and to detect any primary endoleak."
1580863|NCT02376985|Procedure|Oral management|
1580864|NCT02376985|Drug|Everolimus|
1580865|NCT02376972|Drug|RIFAXIMIN VAGINAL TABLET 25 MG|RIFAXIMIN VAGINAL TABLET 25 MG O.D./5 DAYS INTRAVAGINALLY
1580866|NCT02376972|Drug|RIFAXIMIN VAGINAL TABLET 100 MG|RIFAXIMIN VAGINAL TABLET 100 MG O.D./5 DAYS INTRAVAGINALLY
1580867|NCT02376972|Drug|PLACEBO VAGINAL TABLET|PLACEBO VAGINAL TABLET O.D./5 DAYS INTRAVAGINALLY
1580868|NCT02376972|Drug|METROGEL VAGINAL|METROGEL VAGINAL O.D./5 DAYS INTRAVAGINALLY
1580869|NCT02376959|Behavioral|"Spiritist passe"|"For a period of 5 min per week, the volunteers will remain in the supine position with their eyes closed, in a quiet environment with controlled light and temperature.
The applied intervention will consist of placing both hands in the classic Spiritist passe position for the stipulated 5-min period. Spiritist passe will be applied by volunteers with training and experience of more than two years with the technique."
1580870|NCT02376946|Device|ActiPatch(TM)|Assigned by randomization, this study group will be comprised of subjects that receive the PEMF ActiPatch(TM) treatment for postoperative management of pain and edema.
1580871|NCT02376946|Device|Placebo|Assigned by randomization, this control group will be comprised of the subjects that receive a placebo patch as treatment for postoperative management of pain and edema.
1580872|NCT02376933|Procedure|Vertebroplasty|Under imaging guidance, a fractured vertebral body is stabilized with injected bone cement.
1580873|NCT02376933|Radiation|Radiotherapy|Radiotherapy of metastatic lesions to the spine.
1580874|NCT02376907|Procedure|Biliary drainage|EUS-BD or ERCP
1580875|NCT02376881|Drug|Erythropoietin|20,000 IU epo IV infusion in 100 ml normal saline in 2 hr for 3 successive days
1580876|NCT02376881|Other|placebo|100 ml normal saline in 2 hr for 3 successive days
1580877|NCT02376868|Device|3D OCT-1 Maestro|OCT machines used for diagnostic purposes
1580878|NCT02376868|Device|iVue|OCT machines used for diagnostic purposes
1580879|NCT02376855|Other|eConsult|"An electronic consultation or eConsult is a secure message consult that allows specialists to provide advice on cases without seeing a patient face to face. They contain a reason for consult, any relevant tests, procedures or reports. The responsibility lies with the primary care provider to act, or not act on the advice as they deem fit."
1580880|NCT02376842|Behavioral|Severe sepsis early warning best practice alert|
1580881|NCT02376842|Behavioral|Standard care|
1580882|NCT02376829|Device|Invisalign System|The Invisalign® System is indicated for the alignment of teeth during orthodontic treatment of malocclusion
1580883|NCT02376816|Biological|rAAVrh74.MCK.micro-Dystrophin|"Recombinant adeno-associated virus carrying a truncated micro dystrophin transgene under control of a muscle specific MCK promoter."
1580885|NCT02376790|Drug|Etanercept + Oral Methotrexate|Etanercept 50 mg weekly by subcutaneous injection plus oral methotrexate 20 mg weekly.
1580886|NCT02376790|Drug|Etanercept + Placebo for Methotrexate|Etanercept 50 mg weekly by subcutaneous injection plus oral placebo for methotrexate.
1580887|NCT02376790|Drug|Oral Methotrexate + Placebo for Etanercept|Oral methotrexate 20 mg weekly plus placebo for etanercept.
1580888|NCT02376777|Other|Follow up|each three months during one year of follow up, general practioners will entered health data in database (hemorrhagic events, changes of medication, biological data...)
1580889|NCT02376764|Procedure|Blood drawing (venipuncture)|Patients with Deep Vein Thrombosis will undergo blood drawing in order to collect plasma samples.
1580890|NCT02376751|Drug|sebelipase alfa|
1580891|NCT02376725|Procedure|Phaco/IOL|Phaco/IOL refers to extracapsular cataract extraction (using phacoemulsification) and intraocular lens implantation
1580892|NCT02376725|Procedure|Phaco/IOL + goniosynechialysis|Phaco/IOL refers to extracapsular cataract ectraction (using phacoemulsification) and intraocular lens implantation. Goniosynechialysis refers to mechanical breaking of peripheral anterior synechiae using a spatula and goniolens to view the drainage angle structures.
1580895|NCT02376686|Other|Music intervention|Patient receives Music Intervention before going to sleep. It is composed Music which the Patient hear with maysound Music player.
1580896|NCT02376673|Other|Children's Book|A specially-designed, illustrated (full color) children's book written at a first-grade level, conveying American Academy of Pediatrics safe sleep guidelines through the story. Expanded guidelines are listed on the back cover, at a 4th grade reading level. This book will be exclusively used for safe sleep education at 3 study home visits: prenatal between 32 weeks and term, 1 week postnatal, and 2 months postnatal. The mother will be encouraged to share the book with her baby.
1580897|NCT02376673|Other|Standard Brochures|An assortment of standard safe sleep educational brochures provided by home visitors during prescribed home visits, covering various recommendations for safe sleep.
1580898|NCT02376660|Other|Oats|
1580931|NCT02376439|Other|Kool-aid|Participant drank two different types of kool-aid (sugar free and regular)
1580932|NCT02376426|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29, 57.
1580933|NCT02376426|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29, 57.
1580899|NCT02376647|Other|Driving pressure limited ventilation|"Investigators will use volume controlled (or pressure support ventilation) and adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). Investigators will not limit plateau pressure in this arm.
Once a daily the investigators will assess the target tidal volume that generates a driving pressure of 13cmH2O. The patient should be sedated and without spontaneous efforts during this assessment."
1580900|NCT02376647|Other|Conventional ventilation|Investigators will use volume controlled or pressure support ventilation, tidal volume ≤8 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 35 breathings per minute).
1580901|NCT02376634|Behavioral|Hypnosis|Patients will be taught self-hypnosis.
1580902|NCT02376621|Dietary Supplement|PronovaPure 150:500 triglycerides|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
1580903|NCT02376621|Dietary Supplement|Pronovum PRF-048|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
1580904|NCT02376621|Dietary Supplement|Pronovum PRF-037|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
1580905|NCT02376621|Dietary Supplement|PronovaPure 500:200 TG|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
1580906|NCT02376621|Dietary Supplement|Pronovum PRF-047|Subjects will receive 5 single doses with at least 4 treatment-free days between each treatment period. The order of treatments will be in accordance with the randomisation schedule. Using a Williams design, 2 subjects will be randomly assigned to receive 1 of the following 10 treatment sequences:ABECD,BCADE, CDBEA, DECAB, EADBC, DCEBA, EDACB, AEBDC, BACED, CBDAE
1580907|NCT02376608|Dietary Supplement|Pronova Pure 150:500 EE EU|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
1580908|NCT02376608|Dietary Supplement|Pronovum PRF-037|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
1580909|NCT02376608|Dietary Supplement|Pronovum PRF-041|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
1580910|NCT02376608|Dietary Supplement|Eskimo-3|Each subject will participate in 4 treatment periods. The subjects are randomized to one of the following treatment sequences ABCD, BDAC, CADB, DCBA. 4 treatment free days between each treatment period
1580911|NCT02376595|Drug|Rocuronium Bromide|Rocuronium 0,3 mg/kg in less than five seconds, followed by a saline bolus.
1580912|NCT02376582|Biological|DNA|DNA co-administered with protein at month 0, 1 and 6
1580913|NCT02376582|Biological|AIDSVAX B/E|Protein co-administered with DNA at month 0,1 and 6
1580914|NCT02376543|Device|19 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 19 gauge needle.
1580915|NCT02376543|Device|22 Gauge EUS FNA BNX|There will be fiducials placed in the pancreas according to facility policy and procedure utilizing the 22 gauge needle.
1580916|NCT02376530|Behavioral|Nutrient profiling|Nutrient profiling system will be present during shopping session.
1580917|NCT02376530|Behavioral|Price Changes|Price changes will be present during shopping session.
1580918|NCT02376517|Behavioral|Educational program|The educational program consists of a short (13 pages) read-along book in English and Spanish. This book presents sun protective practices at an appropriate level for 2-6 year old children to read with their parent or caregiver. A sun protective swim shirt, which provides a sun-protection factor (SPF) of over 50, for the child will be provided. Additionally, the parent will receive weekly text message reminders to practice sun protection.
1580919|NCT02376504|Behavioral|Active workplace|This is a 12-month, cluster-randomized trial with an intent-to-treat design to determine the effects of using treadmill and sit-to-stand workstations at the workplace on health variables in overweight office workers (N=66) with seated desk jobs and (2) to compare the efficacies of treadmill and sit-to-stand workstations in decreasing workplace sedentary behavior. The intervention will examine the effects of using these workstations on weight, cardiovascular and metabolic health variables , musculoskeletal discomfort, psychological affect and job stress. The study will also measure change in time spent sitting, standing and walking will be measured using wearable non-invasive acceleration sensors.
1580920|NCT02376491|Device|Transcranial magnetic stimulation|
1580921|NCT02376478|Drug|TNF-alpha inhibitors|therapy for at least 6 months
1580922|NCT02376478|Drug|Alternative/no medication|therapy for at least 6 months or no therapy
1580923|NCT02376478|Other|Alternative/no medication|phototherapy for at least 6 months
1580924|NCT02376478|Drug|Purine/folic acid analogues|therapy for at least 6 months
1580925|NCT02376465|Drug|BLI4600 bowel preparation|Oral bowel preparation for colonoscopy
1580926|NCT02376465|Drug|PEG based bowel preparation|Oral bowel preparation for colonoscopy
1580927|NCT02376452|Drug|Raltitrexed|2mg/m2 iv gtt, d1
1580928|NCT02376452|Drug|Irinotecan|180 mg/m2 iv gtt, d1
1580929|NCT02376452|Drug|5-fluorouracil|5-FU 400mg/m2 iv, 2400mg/m2 civ 46h
1580930|NCT02376452|Drug|Leucovorin|400mg/m2 iv gtt,d1
1580934|NCT02376426|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
1580935|NCT02376413|Procedure|Breast surgery|Traditional breast-conserving surgery, oncoplastic breast-conserving surgery or modified radical mastectomy
1580936|NCT02376413|Drug|Chemotherapy or endocrine therapy or Trastuzumab therapy|
1580937|NCT02376413|Radiation|Radiation therapy|
1580938|NCT02376400|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]) on Day 1, 29 or 57.
1580939|NCT02376400|Biological|Ad26.ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp) on Day 1, 29 or 57.
1580940|NCT02376400|Biological|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 or on Day 1 and 57.
1580941|NCT02376374|Other|Controlling vaccination rates in communities|Three communities will be in three arms, one per arm. From 150 randomly-selected households, 10% will receive OPV in one community, 30% in the second community, and 70% in the third community.
1994189|NCT03055195|Drug|Mepolizumab 100 mg|Mepolizumab is available as lyophilized powder in sterile vials for injection. The content is reconstituted with 1.2 milliliter (mL) Sterile Water just prior to use. Subjects will receive 1mL (100 mg/mL) bolus subcutaneous injections.
1580943|NCT02376348|Behavioral|A targeted demand creation Activities|Sites randomized to the intervention arm will receive all activities in the control arm, plus additional demand-creation communication messages that focus on the non-HIV benefits of VMMC and the voluntary nature of HIV testing prior to VMMC ii) use of already circumcised men from the community as auxiliary peer promoters, iii) separate waiting and group education areas for men aged 20 years and above during service delivery, iv) engagement of female partners in community-based demand creation and education and counselling about wound healing and post-circumcision abstinence.
1580944|NCT02376335|Biological|Rituximab|The Rituximab dosing regimen identified is that used in the proof of concept study, which is also the established treatment regimen for Rituximab use in rheumatoid arthritis. All interventions will be administered with a clinician present throughout the infusion in participants who have been encouraged to have adequate oral hydration in the 24 hours prior to attendance. Resuscitation equipment will be immediately available during the infusion period. Blood pressure, heart rate and temperature will be monitored during the infusion. Participants will continue to be observed in the Clinical Research Facility for at least 1 hour after the infusion.
1580945|NCT02376335|Other|Placebo|Participants will be randomised to Rituximab therapy (1000 mg IV on day 1 and 15) or placebo (0.9% Sodium Chloride 250 mls) control
1580946|NCT02376322|Radiation|Radiotherapy|Hypofractionated radiotherapy regimen, 16 Gy in 2 fractions in complicated bone metastases in patients with poor performance status
1580947|NCT02376309|Behavioral|Inactivity|Inactivity
1580948|NCT02376309|Drug|ND|1 nandrolone decanoate injection
1580949|NCT02376309|Dietary Supplement|Leu|Leucine supplements
1580950|NCT02376296|Drug|docetaxel|3-weekly docetaxel therapy (starting dose of 75 mg/m2)
1580951|NCT02376296|Other|Blood draws|Blood draws for determination of docetaxel plasma levels and exposure (AUC)
1580952|NCT02376283|Drug|Prasugrel|
1580953|NCT02376283|Drug|Clopidogrel|
1580954|NCT02376283|Drug|ticagrelor|
1580955|NCT02376270|Dietary Supplement|Pectin|This group will receive 7.5 grams of pectin supplements twice daily for four weeks.
1580956|NCT02376270|Dietary Supplement|Maltodextrin|This group will receive 7.5 grams of maltodextrin supplements twice daily for four weeks.
1580957|NCT02376257|Drug|250 mg DCS|Drug
1580958|NCT02376257|Drug|100 mg Modafinil|Drug
1580959|NCT02376257|Drug|Placebo|Drug
1580960|NCT02376244|Other|High intensity interval training (HIIT)|Standard care cardiac rehabilitation classes, delivered at a higher exercise intensity
1580961|NCT02376244|Other|Standard care|Standard care cardiac rehabilitation according to current guidelines
1580962|NCT02376231|Device|Surgery for EOC with trial (PJ) device (PlasmaJet)|Debulking surgery for EOC using PJ device
1580963|NCT02376218|Drug|Hypertonic 50% dextrose pleurodesis|Intrapleural administration of 180ml of hypertonic dextrose solution.
1580964|NCT02376205|Drug|bupivacaine hydrochloride 0.5% solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
1580965|NCT02376205|Drug|0.9% NaCl solution|10mL will be poured into the retropharyngeal space intraoperatively during anterior cervical discectomy and fusion procedure
1580966|NCT02376192|Device|Initial MicroScan® (Microvision Medical) SDF Measurement|Initial SDF measurements are recorded in the obstetric preoperative area within two hours prior to administration of spinal anesthesia.
1580967|NCT02376192|Drug|Spinal Anesthesia- Bupivacaine|The spinal anesthetic technique is standardized. In the operating room spinal anesthesia will be administered with the L2-L5 interspaces in the sitting position using 12 mg of hyperbaric bupivacaine with 15 mcg of fentanyl and 150 mcg of preservative free morphine.
1580968|NCT02376192|Device|Comparative MicroScan® (Microvision Medical) SDF Measurement|A second comparative SDF measurement be recorded within 10 minutes after induction of spinal anesthesia.
1580969|NCT02376192|Drug|Bolus Phenylephrine/Ephedrine Treatment|Participants who experience hypotension following induction of spinal anesthesia will be treated with a bolus of phenylephrine and/or ephedrine as needed.
1580970|NCT02376192|Drug|Phenylephrine Infusion|Participants will have an infusion of phenylephrine started immediately following the induction of spinal anesthesia for prevention of hypotension.
1580971|NCT02376179|Device|Cuff ETT|
1580973|NCT02376153|Device|ABS deployed and active|ABS is deployed onto surgical field and is turned on.
1580974|NCT02376153|Device|ABS deployed and NOT active|ABS is deployed onto surgical field and is NOT turned on.
1580975|NCT02376127|Procedure|Dynamic contrast enhancement MRI|
1581020|NCT02375763|Other|Software instruction|
1581021|NCT02375750|Device|GBO and GBG|Application of GBO and GBG to the defect fill after removal of chronic inflammatory tissue and decontamination of the surface of implant
1994190|NCT03055195|Drug|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution. Subjects will receive 1mL bolus subcutaneous injections.
1580976|NCT02376114|Drug|Ginkgo biloba|The Ginkgo biloba extract that was used contained 24% ginkgo flavone glycosides and 6% terpene lactones (Vitamin Research Products, Carson City, Nevada). Patients took 60 mg of Ginkgo or a placebo twice daily by mouth for two weeks. The placebo consisted of 40 mg of corn starch. Ginkgo and the placebo were encapsulated to ensure identical appearance.
1580977|NCT02376114|Drug|Placebo to Ginkgo biloba|
1580978|NCT02376101|Procedure|Surgery less than 60 minutes|
1580979|NCT02376088|Drug|Methimazole|All enrolled subjects with GD were treated with methimazole. The initial dose for the GA1 and GB1 sungroups were 30 mg/d (10 mg, tid), TH levels were tested every month, and the dose was titrated accordingly over a period of 2-3 months, the dose was then decreased to 15-20 mg/d and thyroid function was monitored periodically until it eventually reached the maintenance dose of 2.5 mg-5.0 mg/d. The dose and adjustment method for GA2 and GB2 were the same with GA1 and GB1, while the dose for GA3 and GB3 was gradually decreased to 2.5-5.0 mg/d. All subjects underwent a treatment course over a period of 6 months.
1580980|NCT02376075|Drug|Linagliptin|Intake of tablets containing 5 mg Linagliptin, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
1580981|NCT02376075|Drug|Placebo|Intake of Placebo, administered once daily as add on to pre-existing antihypertensive treatment for 6 weeks
1580982|NCT02376062|Behavioral|Online mental health modules|The authors have designed online educational modules to improve clinical capacity and competency about mental health for Nepali Primary Care Providers.
1580983|NCT02376049|Drug|Pimecrolimus cream|
1580984|NCT02376049|Drug|Betamethasone dipropionate cream|
1580985|NCT02376049|Drug|Clobetasol propionate cream|
1580986|NCT02376049|Drug|Glaxal Base cream vehicle|
1580987|NCT02376036|Drug|MGD010|MGD010 is a CD32B x CD79B bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART) molecule. MGD010 will be administered as a single agent.
1580988|NCT02376036|Drug|Placebo|Placebo comparator.
1580989|NCT02376036|Biological|Hepatitis A vaccine|Hepatitis A vaccine, inactivated
1580990|NCT02376023|Other|mHealth|Text and voice messages sent to study participants reminding them to schedule a PAP smear.
1580991|NCT02376010|Drug|rivaroxaban|
1580992|NCT02376010|Drug|Warfarin|
1580993|NCT02375997|Other|Palliative care|Early nutrition intervention and psychological intervention
1580994|NCT02375984|Biological|Tumor Infiltrating Lymphocytes (TIL)|Patients will receive an IV adoptive transfer of at least 10^9 tumor-reactive lymphocytes. An IV catheter in the patient's arm or upper chest will be used for cell infusion. The TIL will be administered over 20-30 minutes at room temperature using a standard infusion protocol or by hanging the infusion bag from a stand and allowing gravity to pull the cells down.
1580998|NCT02375958|Drug|PCA062|
1580999|NCT02375945|Device|New non-elastic compression kit|Comparison of new non-elastic bandage kit with the currently accepted method
1581000|NCT02375945|Device|current compression stocking Comprinet®|Comparison of new non-elastic bandage kit with the currently accepted method
1994191|NCT03054727|Other|Villalta phone score > or = to 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score > or = 5 will have a visit with clinical and CUS assessments of PTS/ venous insufficiency.
All patients will have self administered-questionnaires. For Grenoble Center, the 200 first patients with clinical follow-up will have an Echo-Doppler examination."
1994192|NCT03054727|Other|Villalta phone score < 5|"Follow up call. At the end of the follow-up, the patients who received an Utne and Sandset Villalta phone score < 5, will don't have a clinical follow up.
All patients will have self administered-questionnaires."
1581003|NCT02375919|Other|PERC based Strategy|work up for diagnosis of PE includes calculation of PERC
1581004|NCT02375893|Other|No intervention|Collecting blood and feces samples
1581005|NCT02375893|Other|Healthy subject|Collecting blood and feces samples
1581006|NCT02375880|Drug|DKN-01|Administration by intravenous (IV) infusion.
1581007|NCT02375880|Drug|gemcitabine|Administered by IV infusion.
1581008|NCT02375880|Drug|cisplatin|Administered by IV infusion
1581009|NCT02375867|Drug|prednisolone|Oral administration of 1 mg/Kg/day
1581010|NCT02375867|Drug|methylprednisolone|Intravenous injection of 0.8 mg/kg/day
1581011|NCT02375854|Other|Observation|
1581012|NCT02375841|Behavioral|psychometric tests, questionnaires and neurocognitive assessments|
1581013|NCT02375828|Drug|Glibenclamide|Glibenclamide pills will be administrated during one month at the previously used dosage. During the first month of the study we wwil record pharmacokinetic data, number of hypoglycaemia and the administration problems associated to this galenic form. At the end of the first month of enrolment, patients will be given oral solution of glibenclamide for the 4 remaining months. Pharmacocinetic data, number of hypoglycaemia and parents and children feeling about pratictability of administration will be then recorded.
1581014|NCT02375815|Other|Statin Choice Implementation|
1581015|NCT02375802|Biological|Adipose-derived stromal cells|Adipose-derived stromal cells contain stem cells which have been successful in enhancing wound healing. The product used as the carrier is a fibrin sealant called TISSEEL. Pre-pilot testing was done to verify viability of the stromal cells for up to 72 hours in the fibrin sealant.
1581016|NCT02375802|Drug|Placbo|
1581017|NCT02375789|Device|Active RhinoChill|"The device is intended for use for the reduction of temperature via the nasal cavity.
The RhinoChill® System is a British Standards Institution Kite-Marked device that is currently commercially available in Europe. The RhinoChill® device is intended for temperature reduction in patients via the nasal cavity."
1581018|NCT02375789|Device|Placebo RhinoChill|The placebo RhinoChill device looks and functions in an identical way to the active RhinoChill. All components are used, however through some minor changes in the design of the device it now provides a sufficient placebo treatment to the patient.
1581019|NCT02375776|Other|"CORA- Device:smartphones"|Participants will download and use Multi - modal mobile smartphone application (CORA -Device:smarthpones) designed for renal cell and prostate cancer patients taking anti-cancer medications
1994193|NCT03053544|Drug|Metformin|Participants will self‐administer 500mg metformin twice daily by mouth: 1) beginning 1-2 weeks prior to standard of care CRT, 2) during standard of care CRT and 3) until 30 days after the end of standard of care CRT.
1581022|NCT02375750|Other|Standard treatment|Removal of chronic inflammatory tissue using titanium curettes and a rotary titanium brush; Implant Surface decontamination and closure by suturing
1581023|NCT02375737|Behavioral|m-health|Patients will receive e-reminders via text message and email. A message library that allows us to disseminate constant and reliable information has been created. Messages will contain not only medication reminders, but information about issues related to self-management and medication adherence for CVD risk including messages on side-effects, risks/benefits of medication treatment, and barriers to medication adherence. In addition to these messages, patients will also receive tailored information via telephone by trained research staff.
1581024|NCT02375724|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg twice per day by Eklira Genuair Inhaler
1581025|NCT02375724|Drug|Placebo|Inhaled dose-matched placebo, twice per day by Eklira Genuair Inhaler
1581026|NCT02375711|Biological|Blood sample|A blood sample of 35 ml is achieved at 1 month to evaluate the anti-HBV cell response. Two other blood samples of 10 ml are scheduled 3 and 6 months after vaccination to assess humoral response to HBV vaccination.
1581027|NCT02375698|Biological|H56:IC31|H56:IC31 contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c).
1581028|NCT02375698|Biological|Placebo|The placebo consists of 10mM Tris and 169 mM NaCl pH 7.4.
1581030|NCT02375672|Drug|Pembrolizumab|Pembrolizumab (MK-3475) 200mg IV over 30 minutes every 3 weeks
1581031|NCT02375672|Drug|mFOLFOX6|"mFOLFOX6 Treatment D1 and D15 (Cycle = 28 days)
Oxaliplatin 85 mg/m^2 IV with
Leucovorin 400 mg/m^2 IV followed by
5FU 400 mg/m^2 bolus and then 2400 mg/m^2 via continuous infusion"
1581032|NCT02375646|Drug|Warfarin|
1581033|NCT02375646|Drug|LMW Heparin|
1581034|NCT02375633|Drug|DW-330SR2|
1581035|NCT02375633|Drug|Pelubiprofen|
1581036|NCT02375620|Biological|PEG-somatropin|
1581037|NCT02375607|Device|Algometer|Algometer performed patients
1581038|NCT02375594|Other|Exercise in park equipment|
1581039|NCT02375581|Drug|Icotinib|125mg, Po, TID during RT
1581040|NCT02375581|Radiation|Thoracic radiotherapy|involved-Field irradiaton without elective nodal irradiation
1581041|NCT02375568|Other|103024-F|mesenchymal stem cell isolation
1581042|NCT02375555|Drug|Lenalidomide|
1581043|NCT02375555|Drug|Elotuzumab|
1581044|NCT02375555|Drug|Bortezomib|
1581045|NCT02375555|Drug|Dexamethasone|
1581046|NCT02375555|Procedure|Stem Cell Mobilization|
1581047|NCT02375529|Procedure|Single Incision Laparoscopic Cholecystectomy (SILC)|A 2.5-cm incision is made through the everted umbilicus down to the midline fascia, and through the fascia and the peritoneum. The multichannel port (Olympus) is introduced. Carbon dioxide is insufflated (12 mmHg) and a 30 degree 10-mm laparoscope is introduced. The operating table is put in the reverse Trendelenburg position (20 degrees), left side down. A pre-curved grasper and the monopolar electrocautery are introduced through the other 2 ports of the trocar and the dissection of the gallbladder starts in a retrograde manner. The triangle of Calot is exposed, the cystic duct and artery are separately dissected and ligated with 5 mm clips. The monopolar electrocautery is used to remove the gallbladder from the liver bed. The gallbladder is removed along with the port system from the abdominal cavity. The fascia at the port site is closed and the umbilicus is inverted.
1581048|NCT02375529|Procedure|Four Ports Laparoscopic Cholecystectomy (4PLC)|"An 11-mm periumbilical port, a 10-mm left upper quadrant port , 5mm subxyphoid port, and 5-mm right lower quadrant port were used in 4-port LC. We adopted the single surgeon technique in the 4-port LC using 30-degree operating telescopes that was inserted into the umbilical port. Retraction of the gallbladder was done by the long grasping forceps through the 5-mm right lower quadrant port, whereas dissection was accomplished through the 10-mm left upper quadrant port. The cystic duct and cystic artery were clipped by a 5-mm multiple clip applicator. The gallbladder was retrieved through the umbilical port after the position of the operating telescope was changed.
Nontransparent surgical adhesive tape was applied to the standard 4-port sites at the end of the operation ."
1581049|NCT02375516|Behavioral|Prevention Program|Youths in the intervention-arm will interact online with the initial intervention program between pretest and posttest measurement occasions and will interact with booster sessions subsequent to 1- and 2-year follow-up measurement occasions. Owing to the expense associated with developing a treatment-as-usual intervention for computer delivery in the control arm, youths assigned to the control arm will receive no intervention.
1581050|NCT02375503|Dietary Supplement|Calcium/Vitamin D|Daily, calcium and vitamin D fortified snack bar
1581051|NCT02375503|Dietary Supplement|Placebo|
1581052|NCT02375490|Behavioral|Healthy Start|Healthy Start was designed to promote physical activity and healthy eating among 3-5 year old children. Specifically, Healthy Start attempts to influence factors at the intrapersonal (ex: eating and physical activity behaviour of children), interpersonal (ex: educators and parents), organizational (ex. child care centres), community (ex: community organization involvement), and physical environment and political levels (ex: built environment and policies). These levels of influence are targeted such that from an operational stand point, Healthy Start is composed of six interlinked components: 1) intersectoral partnerships that leads to promoting healthy weights in communities and ECC; 2) The Healthy Start guide for educators; 3) customized training, role modelling and monitoring; 4) an evidence-based resource for both families and educators; 5) supplementary resources from governmental partners; and 6) a knowledge development and exchange, and communication strategy.
1581053|NCT02375477|Other|Educational Intervention|Given educational presentation
1581054|NCT02375464|Drug|Gallium-68 DOTATOC|Imaging with Gallium-68 DOTATOC
1581055|NCT02375451|Other|Radioiodine|We will determine if prior radioiodine treatment in childhood impacts salivary function or symptoms. Radioiodine treatment will have been determined by the patient's medical condition and care (NOT assigned by this research study).
1581056|NCT02375425|Other|no intervention|no intervention-specimen collection study only
1581057|NCT02375412|Procedure|Pre-operative measurement of heart rate variability|Pre-operative measurement of heart rate variability in patients undergoing elective major abdominal surgery
1581058|NCT02375386|Procedure|Spinal manipulation|Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
1581059|NCT02375386|Procedure|Therapeutic touch|"Participants in this group will lie prone. The therapist will place both hands in contact with the participants' pelvis across the top of the posterior aspect of the sacrum and ilia and apply a downward force to keep the pelvis in contact with the table. This group accounts for effects of time and personal contact. The amount of hands-on contact will be equivalent between groups. Both groups will be given the same verbal instructions regarding the techniques performed. In addition, the following will be performed: Functional MRI, Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment."
1581060|NCT02375386|Procedure|fMRI|Both groups will receive an fMRI.
1581061|NCT02375386|Behavioral|Pain Sensitivity Testing|Both groups will receive an Pain Sensitivity Testing
1581062|NCT02375386|Other|Questionnaires|Both groups will receive Questionnaires
1581063|NCT02375386|Behavioral|Physical Impairment|Both groups will receive testing on physical impairment.
1581064|NCT02375373|Other|Observational Chickpea Diet|"Individuals encouraged to maintain increased legume intake and explore new recipes that allow them to maintain a diverse menu of legume based foods.
Fecal samples collected monthly."
1581065|NCT02375360|Other|Oral immunotherapy|
1581066|NCT02375347|Other|Chickpea Enhanced Diet (Short term)|"Dry Roasted Chickpeas, 21.26 gram serving size bags, by mouth five times per week.
Stool Samples collected at Day 1, Day 9, and Day 14."
1581067|NCT02375334|Other|Medical Chart Review|Medical chart review by the Cancer Center ORIS and EPIC based systems
1581068|NCT02375321|Behavioral|CPAP and Psychological support|Six sessions of psychological support with cognitive behavioural orientation lasting 1 hour every two weeks for 3 months
1581069|NCT02375308|Behavioral|HDT|20 sessions, individual psychotherapy
1581070|NCT02375308|Behavioral|ACDT|20 sessions, individual psychotherapy
1581071|NCT02375295|Drug|ciprofloxacin, cotrimoxazole-trimethoprim, macrodantin|Approved antibiotics used routinely will be given at the physician's discretion with the patient: ciprofloxacin, cotrimoxazole-trimethoprim, or macrodantin
1581072|NCT02375282|Procedure|Ambulation orderly|The responsibility of the ambulation orderly is to walk patients after having a cardiac surgery, such as a coronary artery bypass surgery or a valve surgery. Baystate Medical Center hired an ambulation orderly May 8, 2013. The ambulation orderly is generally a high school graduate with some training in safe lifting and exercise, but extensive training is not required. In general, the goal is to have 1 ambulation orderly present 7 days a week for 8 hr per day. When available, ambulation orderlies are responsible for walking the patients who have been cleared by the clinical exercise physiologist or nurse up to 4 times per day. The walking of the patients occurs through the halls of the 6th floor of the Mass Mutual wing of Baystate Medical Center.
1581073|NCT02375269|Device|RIPC with a tourniquet|
1581074|NCT02375256|Biological|AERAS-402|Live recombinant serotype 35 replication deficient adenovirus vector expressing a fusion protein of 3 Mycobacterium tuberculosis antigens (Ag85A, Ag85B, and TB10.4).
1581075|NCT02375256|Biological|Placebo|Identical buffer solution in which AERAS-402 is formulated.
1581076|NCT02375256|Biological|BCG (1-8 x105 cfu ID)|BCG given to all participants at day -84 prior to a boost with either Aeras-402 or placebo.
1581077|NCT02375243|Drug|dexmedetomidine|dexmedetomidine continous infusion 0.5 mcg/kg/h
1581078|NCT02375230|Procedure|Control group|Health care provider randomized to the control group will receive a copy of the NRP text pages discussing MR SOPA at every shift for self-study. They will be encouraged by the educator to study these pages for five minutes at every shift. The educator will be there to answer questions if they arise.
1581079|NCT02375230|Procedure|MR SOPA|"Health care provider randomized to the MR SOPA group will receive MR SOPA training provided by a qualified educator on every shift. This training will be five minutes long and will consist of each MR SOPA step. These corrective steps will be demonstrated and practiced on a low-fidelity neonatal mannequin. The alternative airway practice will be performed on an intubation mannequin in the DR also placed on the DR resuscitation unit. Each participant will receive five minutes of training at the start of each shift."
1581080|NCT02375217|Drug|Sugammadex|half dose
1581081|NCT02375217|Drug|Sugammadex|full dose
1581082|NCT02375217|Drug|Neostigmine|IV = 50mcg/kg
1581083|NCT02375217|Drug|glycopyrrolate|
1581084|NCT02375204|Drug|paclitaxel|IV
1581085|NCT02375204|Drug|ifosfamide|IV
1581086|NCT02375204|Drug|cisplatin|IV
1581087|NCT02375204|Drug|pegylated G-CSF|IV
1581088|NCT02375204|Drug|G-CSF|IV
1581089|NCT02375204|Drug|carboplatin|IV
1581090|NCT02375204|Drug|etoposide phosphate|IV
1581091|NCT02375204|Procedure|stem cell reinfusion|surgical procedure
1581092|NCT02375191|Drug|fentanyl|
1581093|NCT02375191|Drug|dexmedetomidine|
1581094|NCT02375191|Drug|Ropivacaine|
1581095|NCT02375178|Drug|chlorhexidine|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0.12% chlorhexidine solution. Samples of saliva will be collected immediately before the mouth wash and after 30, 60 and 180 minutes.
1581096|NCT02375178|Drug|Polyhexamethylene biguanide|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of an 0,07% solution Polyhexamethylene biguanide. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
1581097|NCT02375178|Drug|Sterile saline solution|The volunteers will be instructed to mouthwash with 10ml of a sterile saline solution for 30 seconds and than make the mouthwash with 10ml of a sterile saline solution. Samples of saliva will be collected before the mouth wash and after 30, 60 and 180 minutes.
1581098|NCT02375165|Procedure|tissue sampling|skin punch biopsy of affected and unaffected tissue (upper/lower limb) phlebotomy for collection of plasma and serum, ~30 cc
1581099|NCT02375152|Procedure|Anterior Capsulotomy|
1581100|NCT02375139|Drug|DA-1229_01|complex single administration
1581101|NCT02375139|Drug|E+M|co-administration of 2 drugs
1581102|NCT02375126|Procedure|Electroencephalography|Electroencephalography (EEG) is a relatively inexpensive measurement of basic brain activity. Traditional EEG techniques rely on the clinician to visually examine the electrical current waveforms to identify abnormal signal patterns and slowing. Abnormalities on EEG have been reported following CO poisoning, though the literature is scarce. While current EEG technologies record EEG signals digitally, rather than writing directly to paper, computer-assisted analysis of the data (quantitative EEG, or qEEG) has not been widely embraced, in part because clinicians are unsure what patterns revealed by computer-assisted analysis represent abnormal activity.
1581103|NCT02375113|Dietary Supplement|soy supplementation|"Isoflavones will be in the form of capsule (80 mg /capsule). Placebo capsule will be filled with cellulose. These capsules will be identical in size and color. Soy protein will be prepared in the form of powder, containing 25 g of soy protein per package. Placebo powder will contain 25 g whole milk protein. Both powders will be available in vanilla and chocolate flavors, and look and taste similar. They could be mixed with water, milk and other beverages. Subjects will be asked to consume 2 capsules and 1 powder packet daily, preferably at breakfast for 6 months.
Subjects failing to show up at the monthly visit for refilling supplement will be contacted by research staff via email or phone."
1581104|NCT02375100|Procedure|Spinal Anesthesia|All patients will be administered 3ml of %0.5 bupivacaine through L3-L4 interspace to acquire motor and sensory blockade
1581105|NCT02375100|Procedure|Transversus Abdominis Plane Block|Analgesic intervention which will be performed only to Transversus Abdominis Plane Block arm. It requires 20ml of %0.25 bupivacaine administration through a 22 G. x 4 in. (100 mm) Insulated Echogenic Needle with 30° Bevel from midaxillary line between costal margin and anterior superior iliac spine with ultrasound guidance
1581106|NCT02375100|Procedure|Ilioinguinal Nerve Block|Analgesic intervention which will be performed only to Ilioinguinal Nerve Block arm. It requires 10ml of %0.25 bupivacaine administration through a 22 G. x 3-1/8 in. (80 mm) Insulated Echogenic Needle with 30° Bevel between umbilicus and iliac crest where the nerve is detected with ultrasound guidance
1581107|NCT02375100|Drug|Bupivacaine %0.5 (hyperbaric)|
1581108|NCT02375100|Drug|Bupivacaine %0.25 (isobaric)|
1581109|NCT02375100|Device|25G Quincke needle|
1581110|NCT02375100|Device|Echogenic Needle with 30° bevel|
1581111|NCT02375100|Drug|Acetaminophen|Analgesic drug administration through iv and im route postoperatively. Patients are administered iv acetaminophen 1g twice a day routinely
1581112|NCT02375100|Drug|Tramadol|Patients will be administered tramadol in postoperative period when their pain score exceeds 4 points (moderate pain)
2008612|NCT03328728|Device|Synvisc-One|Treatment with a single intra-articular injection in the knee of Synvisc-One; Synvisc-One (hylan G-F 20) is a sterile, nonpyrogenic, elastoviscous fluid containing hylans. Hylans are derivatives of hyaluronans (sodium salt of hyaluronic acid). Hylan A has an average molecular weight of 6,000,000 daltons and hylan B is a hydrated gel. Hylan G-F 20 contains hylan A and hylan B (8.0 mg per ml) in buffered physiological sodium chloride solution.
1581115|NCT02375061|Behavioral|e-BPS|
1581116|NCT02375061|Behavioral|Daily Activities|
1581117|NCT02375048|Radiation|Hypofractionated WBI|Dose prescription was 40.5 Gy to PTVWB and 48.0 Gy to PTVboost in 15 fractions over 3 weeks, with simultaneous integrated boost delivering 2.7 and 3.2Gy/fraction for each PTV respectively. Daily image guided radiotherapy (IGRT) were generated before each treatment session in each patient to verify the set-up.
1581118|NCT02375048|Radiation|Accelerated Partial Breast Irradiation|APBI was delivered at a dose of 30 Gy in five 6-Gy/day fractions over 10 days (every other day) with IGRT at each treatment.
1581119|NCT02375035|Device|CAMPROBE|To assess patient's experience and complications of the CAMPROBE biopsy needle and compare the results with known published outcomes from standard transrectal biopsies
1581120|NCT02375022|Drug|Endostar and icotinib|Endostar and icotinib are used as combination therapy.
1581121|NCT02375009|Procedure|Selective laser trabeculoplasty|laser therapy to trabecular outflow pathway of the eye to lower intraocular pressure, delivered to 360 degrees of both eyes in a single session
1581122|NCT02374983|Other|Gamma knife radiosurgery re-planning with convolution algorithm|"The convolution algorithm, which uses the correlation between CT imaging density in Hounsfield units (HU) and electron density (ρe) of the tissues as input to predict dose distribution, can provide a better simulation of real delivered dose for GKR. By more accurately predicting the dose delivered, a better prediction of clinical effects can be made, increasing the potential clinical efficacy of treatment.
Convolution algorithm is now available in Leksell GammaPlan® 10 but there is not enough clinical data to support its use over TMR 10, which is the current clinical standard. Using convolution algorithm to recalculate the dose for the otherwise unaltered TMR 10 plan will provide valuable insight and understanding of the dosimetric differences between these planning algorithms."
1581123|NCT02374970|Other|Lumbar stability exercises|Four individualized learning sessions will be held during the same period of protocolized physiotherapy. Biofeedback training using the ultrasound machine will be performed in the first session, in order to show the specific contraction of the abdominal muscles with the stability exercises. The other three learning sessions will be performed without feedback, for the patient learn the exercises to make at home during the follow-up period.
1581124|NCT02374970|Other|Protocolized Physiotherapy|Therapeutic exercises and thermotherapy during 12 daily sessions
1581126|NCT02374944|Procedure|Hardware removal|
1581127|NCT02374931|Radiation|F-18 16 Alpha-Fluoroestradiol|Undergo 18F-FES PET/CT
1581128|NCT02374931|Procedure|Positron Emission Tomography|Undergo 18F-FES PET/CT
1581129|NCT02374931|Procedure|Computed Tomography|Undergo 18F-FES PET/CT
1581130|NCT02374931|Other|Laboratory Biomarker Analysis|Correlative studies
1581131|NCT02374918|Device|mTBI wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
1581132|NCT02374918|Device|mTBI wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
1581133|NCT02374918|Device|HC wavelength-1 bright light|30 minutes of light exposure
1581134|NCT02374918|Device|HC wavelength-2 bright light|30 minutes of light exposure
1581135|NCT02374905|Device|Drinksmeter|Web-based application delivering Identification and Brief Advice of Alcohol Use
1581136|NCT02374905|Behavioral|Brief Advice of Alcohol Use|Lifestyle counseling regarding alcohol intake and completion of Audit-10 questionnaire done chair-side with clinician
1581137|NCT02374892|Behavioral|CHAPTER III Study Intervention|This will involve a 60 minute interaction between the adolescent and a cardiology nurse. A MyHealth passport will be created covering the name of the adolescents' cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications will be discussed. The adolescent and nurse will watch videos on talking to various health professionals. The adolescent will be given a study email address and encouraged to contact the nurse by email or text messaging with follow-up
1581138|NCT02374879|Device|Blood Glucose Monitoring Systems.|In vitro diagnostic medical device.
1581139|NCT02374866|Other|closer monitoring|
1581140|NCT02374853|Drug|Vancomycin|Topical prophylactic antibiotic
1581141|NCT02374853|Other|No Vancomycin|Placebo: Sterile water. No Vancomycin.
1581142|NCT02374827|Procedure|Standard postpartum tubal ligation|Patients will undergo a standard postpartum tubal ligation by accepted documented surgical procedural methods (Modified Pomeroy or Parkland method)
1581143|NCT02374827|Procedure|Complete Salpingectomy|Patients will undergo a complete salpingectomy by a documented surgical protocol established by accepted surgical procedural methods.
1581144|NCT02374814|Drug|Rabies vaccine|Compare dose schedule and route of administration
1581145|NCT02374814|Drug|Placebo|Placebo
1581146|NCT02374801|Device|"SonR automatic optimization feature turned ON (AV+VV)."|
1581147|NCT02374788|Behavioral|Pedometer intervention|Intensive intervention with pedometer. The participants are instructed to set daily step goal and to record their daily steps on a website.
1581148|NCT02374788|Behavioral|Group meetings|Participants receive 12 group meetings over two years' time.
1581149|NCT02374788|Behavioral|Individual consultations|Participants receive 10 individual meetings with a diabetes specialist nurse. Physical activity on prescription is used to set individual goals and to highlight the importance of physical activity.
1581150|NCT02374749|Behavioral|self-assessment/self-management|Nurse led-program of self-assessment/ self-management of spondyloarthritis
1581151|NCT02374749|Behavioral|Comorbidities (detection/prevention)|Standardized assessment of comorbidities by nurses
1581152|NCT02374736|Drug|Privigen (Human normal immunoglobulin G (IgG > 98 % purity))|"Privigen (CSL Behring AG, Bern, Switzerland) 10% liquid human IgG for intravenous administration, 2 g/kg, given as 2 g/kg for 2 days/month for 6 months (maximum dose: 80 g/day).
Privigen will be provided in vials containing 10 g IgG in 100 mL."
1581153|NCT02374723|Device|NuCornea|Deep anterior lamellar corneal transplantation where the NuCornea is substituting a donor cornea
1581154|NCT02374723|Device|donated human corneas|Deep anterior lamellar corneal transplantation with a donated cornea as graft material.
1581155|NCT02374710|Procedure|ACL Reconstruction: Anterior Tunnel|ACL reconstruction with anterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
1581156|NCT02374710|Procedure|ACL Reconstruction: Posterior Tunnel|ACL reconstruction with posterior tibial tunnel placement in reference to a point measuring 35% of the anterior-posterior distance of the proximal tibia.
1581157|NCT02374697|Device|During tele-expertise|
1581158|NCT02374684|Drug|Methosulide|"Tolerability Study:
Period I:Single oral administration,dose-escalation of Methosulide(six dose groups:25mg-250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg ,group 2:depending on the adverse drug reaction,150mg/250mg)
Pharmacokinetic Study:
Period I:Single oral administration,dose-escalation of Methosulide(three dose groups:50mg,100mg,200mg/250mg) Period II:Repeated oral administration of Methosulide(group 1:MTD（maximum tolerated dose）/250mg
,group 2:depending on the adverse drug reaction,150mg/250mg)
Food Effect on the Pharmacokinetics:
single dose(100mg),two status(Feeding and fasting), washout period(7 days)"
1581159|NCT02374684|Drug|Placebo|Placebo to match with experimental groups
1581160|NCT02374671|Device|VisAbility Micro Insert|The VisAbility Micro Insert (Model SGP-046) is an injection molded curved scleral implant molded from PMMA (polymethylmethacrylate), a material with an extensive history of long-term implantation in the human eye, including intraocular lenses (IOLs). Four (4) VisAbility Micro Insert segments are placed in a single presbyopic eye to improve near vision.
1581161|NCT02374658|Behavioral|Living Through the Arts Intervetion|A weekly one-hour creative arts program that will engage participants in several different creative processes, including visual art, music, dance, drama, and creative writing.
1581162|NCT02374645|Drug|Volitinib|600mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
1581163|NCT02374645|Drug|gefitinib|250mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
1581164|NCT02374645|Drug|Volitinib|800mg QD: Patients may continue to receive the treatment as long as they are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
1581165|NCT02374632|Other|Meal tests after saline injection|Fixed breakfast meal and ad libitum lunch meal
1581166|NCT02374632|Other|Meal tests after octreotide injection|Fixed breakfast meal and ad libitum lunch meal
1581167|NCT02374632|Other|Sham feeding|
1581168|NCT02374619|Dietary Supplement|Iron supplement Resoferon Ferrous Sulfate|Oral supplementation with one tablet of iron supplement [Resoferon Ferrous Sulfate 125 (37) mg]
1581169|NCT02374619|Dietary Supplement|Placebo|
1994194|NCT03054506|Device|CSP01|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
1994195|NCT03054506|Device|Carboxymethylcellulose (CMC)|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
2008613|NCT03328715|Device|intraoperative OCT|before and after surgery intraoperative OCT is performed
2008614|NCT03328715|Device|stand-alone OCT|before and after surgery stand-alone OCT is performed
1994196|NCT03054506|Device|Placebo|Subjects will take three capsules in the morning before breakfast, and three capsules at night before dinner each day for three weeks.
1994197|NCT03054441|Other|Actigraph|Actigraphs worn on wrists
1994198|NCT03054428|Drug|Dupilumab|Dupilumab as per protocol
1994199|NCT03054428|Drug|Placebo|Matching placebo
2008615|NCT03328702|Device|Continuous Positive Airway Pressure|Apex XT Fit CPAP Machine
2008616|NCT03328689|Other|Physical activity program|This arm will begin with PT assessment. Following this, participants will meet with a specialist who will design an individualized physical activity program. Classes will include warm up, 40 minutes of individualized exercises and a cool down that will include back pain specific exercises including core strengthening. The first 4 weeks of exercise will include a 30-minute education program. Education comprise information on back pain, efficient use of the back during daily activities, self-management, self-efficacy and pain neurophysiology. Classes will run for a 12-week period. Participants will be encouraged to attend the exercise facility at least 3 times a week. An activity monitor will be provided to all participants. We will use group classes to facilitate the development of social support.
2008617|NCT03328689|Other|Control group standard care|"Participants from the control group will receive usual care which will often include recommendation to keep activity, home exercise programs and advice to engage in physical activity.
Participants in the control group will also receive and activity monitor for collection of physical activity data. This activity monitor may also be used for positive feedback and activity reinforcement"
1581269|NCT02374554|Device|Structured Light Plethysmography (Thora-3Di)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
1581270|NCT02374554|Device|BCI Capnograph 9004 (Smiths Medical)|Respiratory Rate measured by Structured Light Plethysmography Thora-3Di and Clinician Over-scored End Tidal C02 (COSC) during 1 randomised minute of a 5 minute measurement period
1581271|NCT02374541|Behavioral|Patient Navigation|The Autism Patient Navigator (APN) will interview families to determine system and individual barriers facing the family at each stage of the care process. The APN will help families to overcome any identified barriers through education, coaching, social support, interpretation or translation, linkage to resources (e.g., for obtaining insurance) or logistical support (e.g., scheduling appointments, providing reminders, arranging transportation), in order to ensure timely diagnostic evaluation / eligibility determination; educate the family about autism, tests and treatments; and offer psychosocial support.
1581272|NCT02374528|Procedure|Negative pressure wound therapy|Negative pressure wound therapy (NPWT) is the application of suction (negative pressure) to wounds with skin grafting.
1581273|NCT02374528|Procedure|standard pressure bolster dressing|This method is traditional used in skin grafting wound.
1581274|NCT02374515|Device|EndoCuff-assisted colonoscopy|Adenoma detection rate
1581275|NCT02374515|Device|Standard Colonoscopy|
1581276|NCT02374502|Behavioral|Brief Intervention|'Brief Intervention' is the term used to mean verbal advice, discussion, negotiation or encouragement, with or without written or other support or follow-up. 'Brief Interventions' provide a structured way to deliver advice and involve the provision of formal help and follow-up. They aim to equip people with tools to change attitudes and handle underlying problems.
1581277|NCT02374489|Drug|LDK378|LDK378 750 mg ( p.o.) daily, with 3 week as a treatment cycle.
1581278|NCT02374476|Device|Bipolar Ablation|Patients will undergo bipolar ablation if unipolar ablation unsuccessful
1581279|NCT02374463|Behavioral|MMBI|Multimodality Balance Intervention (MMBI): Our MMBI will be held 3-times a week for an hour and will consist of a group dynamic balance class (30 minutes), a supervised obstacle course (10 minutes), and lower extremity and core strengthening (20 minutes). The group exercise classes will focus on dynamic weight shifts with an emphasis on the lateral and diagonal directions. Over the 6 months of class, the exercises will gradually increase in difficulty to challenge balance. A skilled instructor will lead each class and 1-2 assistants will be present to assist with fall risk prevention. The supervised obstacle course will focus on obstacle negotiation, gait over challenging surfaces, and moving in lateral, diagonal, and backward directions. Finally, strength training of the lower extremities and core will focus on strengthening major muscles of the lower extremity and core utilizing commonly available gym equipment, ankle weights and body weight.
1581280|NCT02374463|Behavioral|Tai Chi|Tai Chi Intervention: The supervised Tai Chi class will be held 3-times a week for one hour. All Tai Chi classes will be taught in a group setting by an experienced instructor. The emphasis during the class will be on standing movements, body alignment, weight shift and changes of direction. Movements will be adapted as the class progresses to increase the difficulty of weight shift and change in direction over time so that participants balance is continually challenged throughout the 6 months. Chairs or hand rails will be available for the participants to use as needed for balance recovery.
1581281|NCT02374450|Procedure|Lumbar puncture|For all enrolled children, hospitalised and suspected of a neu-rological AESI or meningitis, where a cerebrospinal fluid (CSF) sample has been taken as part of routine practice, part of the CSF sample will be stored for this study (minimum 500 µL).
1581282|NCT02374450|Procedure|Venous blood sample|Approximately 5 mL of whole blood will be collected from all enrolled children, hospitalised and suspected of having an AESI or meningitis, and the serum will be stored.
1581283|NCT02374437|Drug|Aramchol|PART A: Subjects will receive single dose of 200 or 400 mg Aramchol PART B: Subjects will receive single dose of 600 mg Aramchol under fasting or fed conditions ( following a crossover between the groups) PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
1581284|NCT02374437|Drug|Placebo|PART C: subjects will be equally randomized to receive either 200 mg, 400 mg, 600 mg or placebo tablets for ten consecutive days.
1581285|NCT02374424|Drug|GA101_DHAP|"Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.
Scheme of treatment:
GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)
Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion
Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles
Dexamethasone 40 mg day 1-4 of every cycles
Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)
GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy"
1581286|NCT02374398|Drug|Tranexamic Acid|see arm/group descriptions
1581287|NCT02374398|Device|Aquamantys System|see arm/group descriptions
1581288|NCT02374398|Other|Control|Standard Electro-cautery and Saline
1581289|NCT02374385|Biological|BPSC-1001 (VSVΔG-ZEBOV)|Ebola vaccine candidate
1581290|NCT02374385|Other|Placebo|Normal saline
1581291|NCT02374372|Device|conventional hemodialysis|
1581292|NCT02374372|Device|hemodiafiltration On-line|
1581293|NCT02374359|Other|follow-up|
1581294|NCT02374333|Biological|huCART19|
1581295|NCT02374320|Drug|liposomal bupivacaine|injected as an axillary block
1581296|NCT02374307|Other|Exercise and education|Exercise according to the falls prevention programme. Information on motivation, the effectiveness of falls prevention and the importance of adherence.
1581297|NCT02374294|Device|Epiflo|"EPIFLO: Small, silent disposable, battery-operated oxygen concentrator capable of delivering 98% to 100% oxygen (balance moisture) for seven days at a rate of ~3.0 ml/hour; and 60 long sterile cannula (tube) that conveys the oxygen concentrator to the area beneath the bandage overlying the wound."
1581298|NCT02374281|Drug|Glucose sucking|
1581299|NCT02374281|Drug|Water sucking|
1581300|NCT02374281|Other|No sucking|
1581301|NCT02374268|Behavioral|Exercise program alone|
1581302|NCT02374268|Dietary Supplement|Combined exercise program and nutrition supplement|
1581303|NCT02374268|Other|Waitlist control group|
1581304|NCT02374255|Behavioral|GoC intervention|Training of oncologists using OncoTalk to conduct Goals of Care discussions and measure impact on patient satisfaction.
1581305|NCT02374242|Drug|Nivolumab|Nivolumab is a fully human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor PD‐1 (programmed death‐1 or programmed cell death‐1/PCD‐1) with immunopotentiation activity.
1581306|NCT02374242|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to the cytotoxic T lymphocyte‐associated antigen 4 (CTLA‐4). CTLA‐4 is a negative regulator of T‐cell activation. Ipilimumab binds to CTLA‐4 and blocks the interaction of CTLA‐4 with its ligands, CD80/CD86. Blockade of CTLA‐4 has been shown to augment T‐cell activation and proliferation. The mechanism of action of ipilimumab's effect in patients with melanoma is indirect, possibly through T‐cell mediated anti‐tumour immune responses.
1581307|NCT02374229|Procedure|Surgical ablation of ganglion plexus pulmonary artery.|Performed ablation zone pulmonary artery bifurcation, at 2mm proximal direction and a distal direction in the left and right branches of the pulmonary artery using the electrophysiological device Atricure.
1581308|NCT02374229|Procedure|mitral valve surgery|The standard procedure for mitral regurgitation or stenosis, the procedures will be a valve repair or mitral valve replacement, depending upon the particular morphological condition of the mitral valve.
1581309|NCT02374216|Procedure|Insertion of dental implants|Evaluation of the failure rate of all dental implants, of any brand, inserted between September 1st 2014 to August 31st 2017
1581310|NCT02374203|Dietary Supplement|high protein enteral nutrition|supply protein over 1.5 gm/kg body weight
1581311|NCT02374190|Other|Standard Hospital Care|Retrospective, observational analysis will be used to examine the relationship between pre‐admission patient characteristics (as available), acute clinical management and patient outcomes. Standard hospital care is here defined as interventional (e.g., primary angioplasty) and pharmaceutical (e.g., warfarin, beta-blockers) care provided to patients during index hospitalization for MI.
1581312|NCT02374164|Drug|Febuxostat XR|Febuxostat XR capsules
1581313|NCT02374151|Device|Electrohysterography|The EHG uses a Graphium electrode patch that is applied to the abdomen and records electrical activity non-invasively
1581314|NCT02374138|Behavioral|Parental stress management|"The intervention for this study is a multi-dimensional stress management program designed to be responsive to parent and other stakeholder preferences. The intervention will have two separate yet coordinated components: one-on-one stress management sessions and peer group sessions led by community wellness coaches."
1581315|NCT02374138|Other|Usual Care|IMPACT DC Asthma Clinic intervention of guideline-based clinical care, education, and short-term care coordination
1581316|NCT02374125|Device|Diacutaneous Fibrolysis|Applied only around teres major muscle.
1581317|NCT02374125|Other|Trigger Point Pressure Release|Applied only in teres major muscle trigger points.
1581318|NCT02374125|Other|Protocolized physiotherapy|Exercises, TENS and cryotherapy
1581319|NCT02374112|Dietary Supplement|Creatine|Creatine supplementation
1581320|NCT02374112|Other|Placebo|Placebo supplementation
1581321|NCT02374099|Drug|CC-486|Each cycle will be 28 days. CC-486 will be administered orally at a dose of 300 mg daily on days 1-21 of each 28-day cycle
1581322|NCT02374099|Drug|Fulvestrant|Fulvestrant will be administered by intramuscular (IM) injection at a dose of 500 mg on days 1 and 15 of cycle 1 and day 1 of subsequent cycles.
1581323|NCT02374086|Behavioral|Exercise training|
1581324|NCT02374073|Other|Functional Massage|The functional massage is a manual therapy technique, indicated in cases of painful muscle tightness that combines a rhythmical and non painful passive joint mobilization in the direction of muscle stretching together with compression/decompression of the muscle to be treated.
1581325|NCT02374073|Other|Protocolized physiotherapy|therapeutic exercises, analgesic electrotherapy and cryotherapy
1581326|NCT02374060|Drug|Periocular triamcinolone 40 mg|Periocular triamcinolone acetonide, 40 mg injection may be given either by posterior sub-Tenon's approach or by the orbital floor approach, as both appear to have similar efficacy; the approach to the periocular injection will be recorded for analysis if needed.
1581327|NCT02374060|Drug|Intravitreal triamcinolone 4 mg|Intravitreal triamcinolone acetonide, 4 mg injection procedures should be carried out under controlled aseptic conditions which include the use of sterile gloves and a sterile eyelid speculum (or equivalent). Adequate anesthesia and a broad-spectrum microbicide such as betadine, applied to the periocular skin, eyelid and ocular surface are required prior to an intravitreal injection.
1581328|NCT02374060|Drug|Dexamethasone intravitreal implant|• Standard preparation as described for intravitreal injections.
1581329|NCT02374047|Drug|CAT-2054|
1581330|NCT02374047|Drug|Placebo|
1581331|NCT02374047|Drug|CAT-2054-C|
1581332|NCT02374047|Drug|Atorvastatin|
1581377|NCT02373735|Other|lasix|Group B (SVV 10-20%): infuse lasix 5 mg if SVV is < 10%
1581378|NCT02373722|Procedure|Mohs Surgery|Undergo Mohs surgery
1581333|NCT02374034|Other|Corrective exercise|Participants were assigned to either the exercise group, which performed Egoscue corrective exercises for two weeks, or the control group, which did not receive any treatment for two weeks.
2008618|NCT03328676|Drug|Cannabis|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
2008619|NCT03328676|Drug|Placebo oil|Patients will receive study medication as drops applied under the tongue 3 times a day - morning, noon and evening, at a minimum of 4hr apart between administrations.
2008620|NCT03328663|Other|CARE|Promote effective coping and reduce caregiving burden.
1581339|NCT02374008|Drug|Ropivacaine|
1581340|NCT02373995|Biological|LAB4|Additional treatment with the specific LAB4 probiotic preparation
1581341|NCT02373956|Device|MELECTIS G|The experimental medical device (MELECTIS G) is an association of selected honey and pharmaceutical grade hyaluronic acid.
1581342|NCT02373956|Procedure|Usual care|Patients will receive usual care according to the current procedures at the Nîmes University Hospital (ICMD010 concerning pressure sore care and SCMD002 concerning referenced anti-pressure sore dressings).
1581343|NCT02373943|Other|β-carotene biofortified maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene fortified maize
1581344|NCT02373943|Other|β-carotene supplemented maize|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of β-carotene supplemented maize
1581345|NCT02373943|Other|Normal (non biofortified) maize without added β-carotene|Determination of all-trans retinol AUC values after the ingestion of 200 g porridge made with 50 g of flour of normal maize
1581346|NCT02373930|Drug|DTG 50 mg|Dolutegravir will be supplied as a white, film-coated, round tablet with a unit dose strength of 50 mg to be administered orally
1581347|NCT02373930|Drug|RPV 25 mg|Rilpivirine will be supplied as a white to off-white, film-coated, round biconvex tablet with a unit dose strength of 25 mg to be administered orally
1581348|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AS|DTG/RPV will be supplied as a pink, film coated, round biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
1581349|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AM|DTG/RPV will be supplied as a pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
1581350|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AQ|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
1581351|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AK|DTG/RPV will be supplied as pink, film coated, oval, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
1581352|NCT02373930|Drug|DTG/RPV 50 mg/25 mg: Product Code AR|DTG/RPV will be supplied as a pink, film coated, round, biconvex tablet with a unit dose strength of 50 mg DTG and 25 mg RPV to be administered orally
1581353|NCT02373904|Device|Photodynamic Bone Stabilization System|Treatment of impending and actual pathological fractures of the humerus
1581354|NCT02373891|Drug|Surfolase CR|T1: Surfolase CR (Acebrophylline 200mg) administration after fat intake Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
1581355|NCT02373891|Drug|Surfolase CR|T0: Surfolase CR(Acebrophylline 200mg) fasting administration Surfolase CR(Acebrophylline 200mg) administrated fasting or fat intake at D1 and D8 a.m. 8:00
1581356|NCT02373878|Behavioral|Telecoaching plus Plate|A wellness coach proactively contacted the participants every two weeks during treatment, using motivational interviewing. In addition, she provided a portion control plate.
1581357|NCT02373878|Behavioral|Usual Care|Subjects were provided with institutional pamphlets on healthy eating and exercise habits
1994566|NCT02974556|Procedure|Proactive management|Colon cancer patients (high-risk T3 and T4) without peritoneal or systemic metastases are resected for cure. Simultaneously patients will undergo infracolic omentectomy, appendectomy, exeresis of the liver round ligament and, in women, a bilateral oophorectomy. After positioning three in- and outflow catheters HIPEC perfusion starts with a minimum of 2 L isotonic dialysis fluid at a flow-rate of 1-2 l min and an inflow temperature of 42-43° C with a total of 30 minutes perfusion time. Before the beginning of HIPEC 5-fluouracil and leucovorin will be administrated intravenously to potentiate oxaliplatin activity.
1994567|NCT02974556|Drug|Standard adjuvant systemic chemotherapy|Adjuvant systemic chemotherapy (according CAPOX or FOLFOX regimens for a total of 6 months) will be reserved in patients with pT3 tumors with poor prognostic factors, in patients with pT4 tumors and when lymph-nodes metastases are present. Presence or absence of peritoneal recurrence will be evaluated by MDCT every six months for the first 24 months and later every year for the next three years in both study arms.
1581362|NCT02373852|Device|Saphenous vein graft (SVG) stenting|Opening and stenting of blocked SVG with the use of the WIRION embolic protection filter
1581363|NCT02373839|Other|Measurement of PlGF|If lower than 100 pg/mL labour will be inducted at the moment of diagnosis. Otherwise standard monitoring will be done with labour induction at 37 weeks
1581369|NCT02373787|Device|creos xenoprotect|Implant placement with simultaneous bone augmentation
1581370|NCT02373787|Device|Bio-Gide|resorbable collagen membrane
1581371|NCT02373774|Device|Ultrasound|Patients will receive an ultrasound prior to lumbar puncture procedure to help visualize and select spinal interspace.
1581372|NCT02373761|Device|Stryker Triathlon Tritanium primary knee|
1581373|NCT02373748|Device|BioGaming YuGo System|Subjects will perform a customized training program predefined in the BioGaming YuGo system.
1581374|NCT02373735|Other|crystalloid|Group A (SVV <10%): infuse crystalloid 6-10 ml/kg/hr during surgery. Group B (SVV 10-20%): infuse crystalloid 2-4 ml/kg/hr until cystectomy, 6-10 ml/kg/hr after cystectomy
1581375|NCT02373735|Other|colloid|Group A (SVV <10%): infuse colloid 200 ml if SVV is ≥ 10%. Group B (SVV 10-20%): infuse colloid 200 ml if SVV is > 20%
1581376|NCT02373735|Other|mannitol|Group B (SVV 10-20%): infuse mannitol 0.5 g/kg if SVV is < 10%
1581379|NCT02373722|Other|Internet-Based Intervention|Watch website application based educational video
1581380|NCT02373722|Behavioral|Telephone-Based Intervention|Receive text messages
1581381|NCT02373722|Other|Educational Intervention|Watch website application based educational video
1581382|NCT02373722|Behavioral|Exercise Intervention|Use Fitbit
1581383|NCT02373722|Other|Petrolatum-Mineral Oil-Lanolin-Ceresin Ointment|Applied to the wound area
1581384|NCT02373722|Other|Questionnaire Administration|Ancillary studies
1581385|NCT02373722|Other|Survey Administration|Ancillary studies
1581386|NCT02373683|Device|Vapotherm-Heliox|Following separation from mechanical ventilation, patient is placed on heliox (70% oxygen-30% helium) delivered with Vapotherm, a proprietary heated, humidified, high-flow nasal cannula delivery system.
1581387|NCT02373670|Behavioral|Promotion of positive deviance behaviors|Using locally derived positive deviance findings to inform a behavioral intervention
1581388|NCT02373670|Behavioral|Promotion of healthy behaviors|Using standardized healthy behavior education (EatPlayGrow curriculum from NHLBI)
1581389|NCT02373657|Behavioral|instruction in soap-making and hygiene education|
1581390|NCT02373644|Other|HVLA Thrust Manipulation and DN|HVLA thrust manipulation targeting primarily the lumbar articulations and sacroiliac joint. Up to 10 sessions over 6 weeks. At least one session of dry needling to the lumbo-pelvic muscles and peri-articular ligaments of the SI joint.
1581391|NCT02373644|Other|Conventional Physical Therapy|Therapeutic exercise and manual therapy, up to 10 sessions over 6 weeks. Patients may receive interferential current and moist heat.
1581392|NCT02373631|Other|Dry Needling, Conventional PT|Dry needling to the knee and conventional physical therapy (stretching, ROM, strengthening), 1-2 treatments per week X6 weeks (up to 10 sessions total)
1581393|NCT02373631|Other|Conventional PT|Conventional physical therapy to include knee stretching, range of motion, and strengthening exercises,1-2 treatments per week X6 weeks (up to 10 sessions total)
1581394|NCT02373618|Other|DN and conventional PT|Dry needling to the foot and lower leg. Up to 8 sessions over 4 weeks. Also conventional PT including: ultrasound, stretching, strengthening, cryotherapy and manual therapy to the foot and lower leg.
1581395|NCT02373618|Other|Conventional PT|Conventional physical therapy includes ultrasound, strengthening, cryotherapy, and manual therapy up to 8 sessions over 4 weeks.
1581396|NCT02373605|Other|Dry Needling,Thrust Manipulation|HVLA thrust manipulation to upper cervical and upper thoracic regions. Dry needling to cervicothoracic and craniofacial regions. Up to 8 treatment sessions over 4 weeks.
1581397|NCT02373605|Other|Exercise,Non-thrust Mobilization|Non-thrust mobilization and exercise to upper cervical and upper thoracic regions. Up to 8 treatment sessions over 4 weeks.
1581398|NCT02373592|Behavioral|SMS and voice messaging|"This group will receive reminders to use the TempStat (two messages) and promote foot care (six messages). The content of these eight messages have been developed and validated their delivery through both, SMS and voice messaging.
During the first two weeks of the intervention, only reminders to use the TempStat will be sent, daily, Monday to Friday, both via SMS and voice messaging.
Hereafter, for the remaining 76 weeks, patients will only receive two messages per week, one SMS and one voice message, alternating content (reminders to use TempStat and promotion of foot care)."
1581399|NCT02373592|Device|Thermometry|Subjects will be provided with a TempStat (foot thermometer), a device that captures a thermal image of feet. (See Detailed description)
1581400|NCT02373579|Drug|Omega-3 Fatty Acids|"study group, included standard risk ALL pediatric patients who were supplemented with oral omega-3 capsule (one capsule / day) .
Omega-3 was supplied as soft gelatin capsules in a dose of 1000 mg of omega-3 fatty acids/day ."
1581401|NCT02373579|Drug|Methotrexate|control group, included pediatric patients with standard risk acute lymphoblastic leukemia in maintenance phase day 0 and receiving oral Methotrexate (20 mg / m2) weekly without any supplementation .
1581402|NCT02373566|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
1581403|NCT02373553|Other|EXERCISES|The postural reeducation in a sitting position, in ventral and dorsal recumbency, including manual techniques, stretching the sternocleidomastoid and scalene muscles. Exercises for pelvic girdle positioning and stretching the hamstrings muscles tibial and sural triceps are associated with respiratory exercise. Twice a week during 3 months
1581404|NCT02373553|Other|HEALTH EDUCATION|Booklet contain many pictures demonstrating some exercises and an importance to do it.
1581405|NCT02373540|Device|Algovita Spinal Cord Stimulation system|
1581406|NCT02373527|Other|No Fasting prior to catheterization|No restriction for oral intake
1581407|NCT02373514|Drug|Paracetamol|1 gr paracetamol in 100 ml saline with rapid infusion
1581408|NCT02373514|Drug|Dexketoprofen|50 mg dexketoprofen in 100 ml saline with rapid infusion
1581409|NCT02373501|Procedure|Intra-abdominal repair|Intra abdominal repair of uterine incision
1581410|NCT02373501|Procedure|Extra-abdominal repair|Extra abdominal repair of uterine incision
1581411|NCT02373488|Other|lifestyle advice|lifestyle advices such as increasing fluid and fibre intake, improving physical activity level, and taking the ideal posture for defecation (squatting position) with a two-pages document.
1581412|NCT02373488|Other|connective tissue manipulation|CTM wil be applied five days per week, a total of 20 sessions for 4 weeks. Each session lasted around 15-20 minutes. While patients are in a sitting position, starting from the lumbosacral region, lower thoracic, scapular, inter-scapular and cervical regions will be included in the treatment, respectively.
1581413|NCT02373488|Other|abdominal massage|Abdominal massage will be applied five days a week for four weeks. Each session will last around 15-20 minutes.
1581414|NCT02373475|Other|Conventional ventilation|Conventional ventilation with TV of 10 mL/kg predicted body weight (PBW) without positive end-expiratory pressure (PEEP) during the surgery under general anesthesia
1581415|NCT02373475|Other|Protective lung ventilation|Protective lung ventilation with TV of 6 mL/kg PBW, PEEP of 6 cmH2O and recruitment maneuver during the surgery under general anesthesia
1581416|NCT02373462|Drug|Olmesartan|
1581417|NCT02373462|Drug|other anti-hypertensive drug|CCB, diuretics, alpha blocker, direct vasodilator, beta blocker
1581418|NCT02373449|Other|RS-fMRI|Resting State-functional Magnetic Resonance Imaging. Protocols involving BOLD (blood oxygen level-dependent) and non-BOLD techniques will be used.
1581419|NCT02373449|Drug|Ketamine|Part of standard care. To be performed over five consecutive days (Monday to Friday) for six hours per day. A therapeutic range of 0.5 to 2.0 mg/kg/hour is targeted.
1581420|NCT02373436|Other|Constraint Induced Therapy|"They will be instructed to remain with the mitt in UL less affected by 90% of the hours in which to stay awake beyond the training period.
The training will consist of 30 minutes for the transfer package, interview by items of MAL, and 2 hours and 30 minutes with four tasks of Shaping, and Task Practice.
The Transfer Package consists of a compromise agreement, held at the end of the first day of practice, in which the individual undertakes to complete:
The Shaping is a training method that makes it difficult gradually according to the motor capacity of each individual. It will be taken care of including tasks using all joints (shoulder, elbow, wrist and fingers), giving priority to the individual in need.
The individual will be instructed not to remove the trunk of the chair, and each task is repeated 10 times in no more than 45s.
The Task Practice promotes increased motor function during functional activities. For all individuals will be held the same function: meal."
1581421|NCT02373436|Other|Control|This group has no intervention. They will wear a mitt that don't limit the use of the fingers and wrist. This is only to ensure blinding of the measurer
1581422|NCT02373423|Other|Advocacy|See above for description
1581423|NCT02373410|Procedure|Umbilicus|"Depending on the height of the operating table, the insertion angle of the spinal needles would be vary. The investigators intend to find the optimal angle and the height of the table to provide that.
The height of the operating table which set at the needle insertion point of anesthetists; the level of umbilicus"
1581424|NCT02373410|Procedure|Lowest rib margin|The height of the operating table which set at the needle insertion point of anesthetists; the level of lowest rib margin
1581425|NCT02373410|Procedure|Xiphoid|The height of the operating table which set at the needle insertion point of anesthetists; the level of xiphoid
1581426|NCT02373410|Procedure|Nipple|The height of the operating table which set at the needle insertion point of anesthetists; the level of nipple
1581427|NCT02373410|Drug|Umbilicus Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
1581428|NCT02373410|Drug|Lowest rib margin Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
1581429|NCT02373410|Drug|Xiphoid Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
1581430|NCT02373410|Drug|Nipple Bupivacaine|If freely flowing of CSF is detected, appropriate dose of MARCAINE was injected in all interventional groups.
1581431|NCT02373397|Device|Cacicol20|Investigational device, regenerating agent, single-use doses, topical eye drops. Indicated for corneal wound healing.
1581432|NCT02373397|Device|Placebo|Vehicle only in identical packaging, with identical dosage and administration route.
1581433|NCT02373384|Drug|Oral alkalinization (Potassium citrate, Allopurinol)|"Eligible patients, who fulfilled the study criteria, will be instructed For; Oral alkalinization therapy
Potassium citrate 20 mEq three times daily
Hyperuricosuric patients (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will receive:
Allopurinol, a competitive inhibitor of xanthine oxidase, in a dose of 300 mg daily."
1581434|NCT02373384|Behavioral|Life style modification|"Eligible patients, who fulfilled the study criteria, will be also instructed for;
Adequate fluid intake in order to maintain urine volume between 2-3 L per day."
1581435|NCT02373384|Dietary Supplement|Dietary recommendations (decrease purine rich diet as red meat and fish, increase vegetables)|Eligible patients, who fulfilled the study criteria and they are hyperuricosuric (24-hours urine uric acid more than 750 mg/day in male and more than 650mg/day in females) will be also instructed for; Dietary modification will be advised in the form of decrease purine rich diet as red meat and fish, increase vegetables.
1581436|NCT02373371|Drug|Metvix®|
1581437|NCT02373371|Procedure|Photodynamic Therapy Blue light|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a blue light source to activate the applied drug
1581438|NCT02373371|Procedure|Photodynamic Therapy Daylight|Photodynamic therapy (PDT) is a medical treatment that utilizes a photosensitizing molecule (Metvix) and a the day light to activate the applied drug
1581439|NCT02373358|Behavioral|Group yoga intervention|Participants will participate in 6 90-minute yoga groups designed to promote themes related to trauma recovery (safety & boundaries, strength & power, assertiveness, intuition, trust, & community) using mindfulness, breath work, and physical yoga poses.
1581440|NCT02373332|Other|omega-3 and -6 fatty acids and their 12-LOX oxylipins|platelets from healthy subjects and T2DM patients will be isolated from their blood and treated with omega-3 and -6 fatty acids and their 12-LOX oxylipins of those fatty acids followed by assessment of protection from agonist-induced platelet activation and thrombosis
1581441|NCT02373319|Behavioral|CV-screening-1 plus personalized|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
1581442|NCT02373319|Behavioral|CV-screening-2 plus personalized|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Communication of personalized recommendations according to the health exam results for the control of cardiovascular risk factors
1581443|NCT02373319|Behavioral|CV-screening-1 plus standard|Cardiovascular risk screening supervised by health professional - 15 minutes wash-out - Self-screening of cardiovascular risk; Standard communication of the health exam results
1581444|NCT02373319|Behavioral|CV-screening-2 plus standard|Self-screening of cardiovascular risk - 15 minutes wash-out - Cardiovascular risk screening supervised by health professional; Standard communication of the health exam results
1581445|NCT02373306|Procedure|Sustained or hemodynamically unstable arrhythmia induction during non-invasive programmed stimulation|
2008621|NCT03328663|Other|Standard Transplant Care|Standard cared administered by the hospital.
1581493|NCT02373033|Other|Natural food folate|Consumed folate-rich foods (providing additional 250 μg/d folate).
2008622|NCT03328650|Procedure|Measurement of Bone Material Strength Using Osteoprobe|Participants who have elected to participate in the optional, interventional arm of this study will undergo routine proximal humeral plate fixation for their proximal humerus fracture. Once the participant has been anesthetized prior to stabilizing the fracture with a ALPS proximal humerus plate, the participant's arm will be secured and the orthopaedic surgeon will indent the proximal humeral metaphysis, distal to the site of the fracture, at 10 to 15 locations ((~2 mm apart) using the OsteoProbe-RPI. The indent size is approximately ~300 μm in diameter and ~300 μm in depth. All Osteoprobe measurements (bone materal strength and bone indentation distance) taken will be relayed from the Osteoprobe to a laptop which is connected to the instrument during the surgical case.
1581451|NCT02373267|Biological|Technozyme|determination of ADAMTS13 activity
1581452|NCT02373254|Drug|Ibuprofen|Ibuprofen 400 mg and 800 mg
1581453|NCT02373254|Drug|Acetaminophen/hydrocodone|Norco 5/325 mg and 10/325 mg
1581454|NCT02373241|Drug|Losartan|Standard dosing
1581455|NCT02373241|Drug|Losartan|Experimental dosing
1581457|NCT02373215|Drug|Nalbuphine HCL ER|Nalbuphine HCL extended release tablet
1581458|NCT02373202|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
1581459|NCT02373202|Drug|non-MTX DMARDs (e.g. sulfasalazine, leflunomide, bucillamine, tacrolimus, or mizoribin)|
1581460|NCT02373202|Drug|sulfasalazine|Pharmaceutical form: tablet Route of administration: oral
1581461|NCT02373202|Drug|leflunomide|Pharmaceutical form: tablet Route of administration: oral
1581462|NCT02373202|Drug|bucillamine|Pharmaceutical form: tablet Route of administration: oral
1581463|NCT02373202|Drug|tacrolimus|Pharmaceutical form: capsule Route of administration: oral
1581464|NCT02373202|Drug|mizoribin|Pharmaceutical form: tablet Route of administration: oral
1581465|NCT02373189|Device|Bright light|The purpose of this R34 Pilot and Feasibility study is to develop a morning bright light treatment to help manage chronic pain and improve PTSD symptoms, mood, and sleep in US veterans. Veterans will have 7 baseline days at home, followed by a baseline pain sensitivity assessment and baseline home circadian phase assessment (dim light melatonin onset). Following an instructional home visit, patients will then self-administer morning bright light treatment for 6 days, followed by reassessments of pain sensitivity and home circadian phase. This will be repeated after a further 7 days of morning bright light treatment. The Patient Reported Outcomes Measurement Information System (PROMIS) will also be administered at every lab visit. Additionally, pain and mood (electronic diaries) and sleep (wrist actigraphy) will be assessed daily throughout baseline and treatment. Pain, mood and sleep will also be self-reported daily during a 1 month follow up after cessation of light treatment.
1581466|NCT02373176|Drug|[14C]PRC 4016 (Icosabutate)|Single oral dose
1581467|NCT02373163|Drug|Hydrochlorothiazide|Arm: Active Comparator: Diuretic Therapy with hydrochlorothiazide (25 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Calcium-channel blocker Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM Arm: Active Comparator: Angiotensin Receptor Blocker Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
1581468|NCT02373163|Drug|Amlodipine|Therapy with amlodipine (10 mg daily) taken once daily between 6 and 8 AM
1581469|NCT02373163|Drug|Telmisartan|Therapy with Telmisartan (80 mg daily) taken once daily between 6 and 8 AM
1581470|NCT02373150|Drug|Imeglimin|
1581471|NCT02373150|Drug|Placebo|
1581472|NCT02373137|Procedure|DSAEK|
1581473|NCT02373137|Procedure|DMEK|
1581474|NCT02373137|Device|Endoserter|The Endoserter, a corneal endothelium device, is an approved FDA device. This will be used to insert and position the graft into the anterior chamber during endothelial replacement surgery. It is a sterile, single-use instrument.
1581475|NCT02373137|Drug|Prednisolone|Prednisolone is a corticosteroid used to alleviate swelling post-surgery.
1581476|NCT02373137|Drug|Ofloxacin|Ofloxacin is an antibiotic used to treat bacterial infections of the eye.
1581477|NCT02373137|Drug|Tropicamide|Tropicamide is a prescription drug used to dilate pupils during an eye exam.
1581478|NCT02373137|Drug|Phenylephrine|Phenylephrine is a prescription drug used to dilate pupils during an eye exam.
1581479|NCT02373137|Device|Jones Tube|The Jones Tube will be used to insert the graft into a 3.5 mm corneal incision during endothelial replacement surgery.
1581480|NCT02373124|Drug|infusion of NMDA antagonist|52 minute infusion
1581481|NCT02373111|Dietary Supplement|Isoflavone|
1581482|NCT02373111|Dietary Supplement|Astaxanthin|
1581483|NCT02373111|Dietary Supplement|Placebo|
1581484|NCT02373098|Drug|Fingolimod 0.5 mg|60 relapsing remitting MS (RRMS) patients will be recruited.Patients who meet all inclusion and none of the exclusion criteria will be treated by Fingolimod 0.5 mg
1581485|NCT02373085|Other|Antibiotic adjusted to antibiogram|A course of 3-14 days of antimicrobial treatment, according to the antibiogram results, will be prescribed for every episode of asymptomatic bacteriuria during the first 2 years after transplantation.
1581486|NCT02373072|Drug|PF-06649751|Subjects completing all three treatment periods will be administered two doses. Doses: 0.75mg, 1.5mg, 3mg, 6mg, 9mg. Tablets in the form of 0.25mg or 1 mg.
1581487|NCT02373072|Drug|Trimethobenzamide Hydrochloride|300mg TID, Capsules. Optional in both Cohorts.
1581488|NCT02373072|Drug|Placebo|Subjects completing all three treatment periods will be receiving placebo once.
1581489|NCT02373059|Other|Diabetes Issue Cards Decision Aids|
1581490|NCT02373059|Other|Usual Pharmaceutical Care|
1581491|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 1 × 400-mg tablet Day 1 or Day 9
1581492|NCT02373046|Drug|LX4211|Single dose of LX4211 400 mg as 2 × 200-mg tablets on Day 1 or Day 9
1581570|NCT02372409|Drug|Doxorubicin|
1581494|NCT02373033|Other|Folic acid|Received a folic acid supplement (providing additional 500 μg/d folic acid).
1581495|NCT02373033|Other|Apple juice|Received apple juice containing no folate or folic acid.
1581496|NCT02373020|Other|colonoscopic biopsies|
1581497|NCT02373007|Procedure|Scopinaro Surgery|Classic Scopinaro Technique is a bariactric surgery that proposes the stomach will be divide in two parts: a proximal part and a distal part for performing horizontal gastrectomy. Differently what will happen in the Modified Scopinaro Surgery that will divide the stomach in two parts: a proximal part and a distal part for performing gastroplasty.
1581498|NCT02372994|Other|Loop|Loop is a secure online communication system centered on the patient that assembles the patient's actual healthcare team for ongoing collaborative care. The patient and caregiver are integral members of the team. Loop is cross-organizational, cross-setting and interprofessional. It is for ongoing, interactive, contextual, team-based communication. Loop is explicitly for asynchronous communication, not instant messaging. The stream of messages is stored and can be sorted for ease of viewing. The tool was developed with user-centred design and requires no prior training.
1581499|NCT02372981|Device|mucopexy +/- Doppler-guided haemorrhoidal artery ligation|Mucopexy with or without DG-HAL is performed using a specific device consisting of a proctoscope equipped with a Doppler probe and a light source. The proctoscope model in our study has a sliding part comprising the operating window and Doppler probe for better proximal and distal movement without repositioning the proctoscope during mucopexy.
1581500|NCT02372968|Other|Full body composition and of plasma and urine metabolites|"Full body composition in lean, fat and bone mass will be assessed from DXA scans.
Plasma and urine metabolites will be measured using metabolomics"
1581501|NCT02372955|Drug|dapagliflozin|subjects will be randomly assigned to receive dapagliflozin 10 mg daily
1581502|NCT02372955|Drug|glimpiride|subjects will be randomly assigned to receive glimpiride 4 mg daily
1581503|NCT02372942|Drug|Lattoferrin|515 pregnant women using lattoferrin to prevent preterm delivery
1581504|NCT02372942|Drug|Progesterone|515 pregnant women using lattofferrin to preventf preterm delivery lattoferrin or progesterone
1581505|NCT02372929|Procedure|Endoscopic Ultrasound|Esophageal cancer patients will be staged by endoscopic ultrasound. All patients will undergo upper endoscopy prior to endoscopic ultrasound.
1581506|NCT02372916|Drug|Ranibizumab|The medication Ranibizumab is routine standard of care for patients with wet AMD, and this is not an aspect of the study that is considered novel intervention
1581507|NCT02372903|Drug|Administration of micronized Palmitoylethanolamide (PEA)- Transpolydatin|Palmitoylethanolamide 600 mg twice daily for 10 days sublingually and oral palmitoylethanolamide 400 mg and polydatin 40 mg, twice daily for 90 days
1581508|NCT02372877|Device|Amicus Red Cell Exchange in SCD patients|Each patient will be treated with one RBCx procedure using the AMICUS RBCx System
2008623|NCT03328650|Procedure|Measurement of Bone Indentation Distance Using Osteoprobe|Participants who have elected to participate in the optional, interventional arm of this study will undergo routine proximal humeral plate fixation for their proximal humerus fracture. Once the participant has been anesthetized prior to stabilizing the fracture with a ALPS proximal humerus plate, the participant's arm will be secured and the orthopaedic surgeon will indent the proximal humeral metaphysis, distal to the site of the fracture, at 10 to 15 locations ((~2 mm apart) using the OsteoProbe-RPI. The indent size is approximately ~300 μm in diameter and ~300 μm in depth. All Osteoprobe measurements (bone materal strength and bone indentation distance) taken will be relayed from the Osteoprobe to a laptop which is connected to the instrument during the surgical case.
1581510|NCT02372851|Device|Pureit As+ Filter|The Pureit As+ water filter has been developed to effectively remove arsenic (both arsenite and arsenate) from over 300 µg/L to less than 10 µg/L in addition to removing microbial contamination (Institution of Public Health Engineers, 2011). It has an end-of-life indicator and consumables that do not re-contaminate the environment when disposed (Institution of Public Health Engineers, 2011). The technology requires no electricity, but only the replacement of the battery after 1000 L of water filtered (approximately 100 days based on a family of five drinking 2 L/day).
1581511|NCT02372838|Procedure|Microvascular fibula bone transfer|Reconstructive surgery with a microvascular bone flap
1581512|NCT02372825|Procedure|Reconstructive surgery|Reconstructive surgery with the free iliac crest flap
1581513|NCT02372812|Drug|dexamethasone|12 mg of dexamethasone
1581514|NCT02372812|Drug|Placebo|
1581515|NCT02372799|Drug|Vilazodone|
1581516|NCT02372799|Drug|Placebo|
1581517|NCT02372799|Drug|Fluoxetine|
1581518|NCT02372786|Drug|2,5% lidocaine / 2,5% prilocaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thick layer of 2,5% lidocaine / 2,5% prilocaine cream will be applied on one side to the intact skin under plastic occlusion (average of 1,5-2g per 10 cm2) 60 minutes before laser treatment.
1581519|NCT02372786|Drug|7% lidocaine / 7% tetracaine cream|The treatment area will be divided in two equal parts with white markings. Between these two areas an area of 1 cm will be marked. This area will be left untreated, to avoid possible spill-over effects of the two anaesthetic creams. A thin layer of 7% lidocaine / 7% tetracaine cream (1mm) will be applied on the other side to the intact skin (average of 1,3g Pliaglis per 10 cm2) 60 minutes before laser treatment.
1581520|NCT02372786|Device|Neodymium-doped yttrium aluminium garnet (Nd:Yag) laser|Acne keloidalis nuchae: during this study a 1064 nm Nd:yag laser with a spot size of 7-10 mm, and a fluence of 35-60J/cm2, (depending on the effective and safe clinical response), a pulse duration of 20-35 ms and 2 passes will be used.
1581521|NCT02372786|Device|Q-switched nd Yag laser|Tattoo removal: we will use a 3 mm spotsize and a fluence depending on the absorption of the laser light, which is visible as skin whitening.
1581522|NCT02372760|Device|BA by spray catheter (Olympus PW-205V)|This group will be having the bronchoscopic anesthesia (lidocaine) injected through the spray catheter (Olympus PW-205V)
1581523|NCT02372760|Other|BA classic anesthesia|This group will have the bronchoscopic anesthesia (lidocaine) injected through the bronchoscope's working channel.
1581524|NCT02372760|Drug|Anesthesia|Both groups will receive lidocaine as the anesthesia for bronchoscopy
1581525|NCT02372747|Procedure|Delta-shaped anastomosis|The patients in DS group underwent Delta-shaped anastomosis after TLDG.
1581571|NCT02372409|Drug|Etoposide|
1581526|NCT02372747|Procedure|Billroth II anastomosis|The patients in B-II group underwent Billroth-II anastomosis after TLDG.
1581527|NCT02372734|Other|Pediatric Quality of Life (Peds QL) Survey|The subjects will be administered the Peds QL survey. Children will also have a parental section for parental response. This is NOT an interventional study.
1581528|NCT02372708|Drug|dinitrophenyl(DNP)|
1581529|NCT02372708|Radiation|Radiation|laser irradiation was carried out for 10 min, the power density of laser irradiation was 1W/cm2
1581530|NCT02372695|Drug|Paricalcitol|
1581531|NCT02372682|Device|Shear wave sonoelastography|Sonoelastography is to be performed on the liver.
1581532|NCT02372669|Device|Chitosan nerve tube in addition to gold standard therapy|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand with use of an chitosan nerve tube in addition. Clinical Follow-up will be performed after 3,6,12 and 24 months.
1581533|NCT02372669|Procedure|Gold standard Primary microsurgical repair|Primary microsurgical repair of traumatic lesion of sensory nerves of the hand. Clinical Follow-up will be performed after 3,6,12 and 24 months.
1581534|NCT02372656|Drug|Placebo gel|Placebo gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
1581535|NCT02372656|Drug|1% Metformin|1% Metformin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
1581536|NCT02372656|Drug|1.2% Simvastatin|1.2% Simvastatin gel to be delivered in intrabony sites of chronic periodontitis subjects at baseline, 3,6 and 9 months.
2008624|NCT03328637|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) consisting of weekly 12 sessions will focus on moderated and controlled use of smartphone instead of abstinence model.
1581538|NCT02372630|Drug|Linagliptin|
1581539|NCT02372630|Drug|Placebo|
1581540|NCT02372617|Procedure|periacetabular osteotomy|
1581541|NCT02372604|Drug|Levocetirizine (as levocetirizine dihydrochloride), 5mg ( then 20 mg) per day . Oral administration.|"Week 1 to week 5, every day : - the morning : 5 mg of levocetirizine (capsule)
the evening : placebo capsule
Week 6 to week 10, every day : - the morning : 10 mg of levocetirizine (capsule)
the evening : 10 mg of levocetirizine (capsule))"
1581542|NCT02372604|Drug|Levocetirizine, (as levocetirizine dihydrochloride) 20 mg ( then 5 mg) per day. Oral administration.|"Week 1 to week 5, every day : - the morning : 10 mg of levocetirizine (tablet)
the evening : 10 mg of levocetirizine(tablet)
Week 6 to week 10, every day : - the morning : 5 mg of levocetirizine (tablet)
the evening : placebo tablet"
1581543|NCT02372591|Drug|Buprenorphine|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
1581544|NCT02372591|Drug|Hydromorphone|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
1581545|NCT02372591|Drug|Placebo|Intravenous injection of approximately 10 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
1581546|NCT02372578|Drug|ASP3662|oral
1581547|NCT02372578|Drug|pregabalin|oral
1581548|NCT02372578|Drug|ASP3662 placebo|oral
1581549|NCT02372578|Drug|pregabalin placebo|oral
1581550|NCT02372565|Behavioral|Facebook and text Message|Culturally-relevant physical activity promotion program
1581551|NCT02372565|Behavioral|Standard Print-based Intervention|Non-culturally relevant physical activity promotion program
1581552|NCT02372552|Device|CROMA|Microwave coagulation of small blood vessels
1581553|NCT02372539|Other|Diabetes|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
1581554|NCT02372539|Other|Control Group|All patients enrolled in study will be given dexamethasone for prophylaxis of chemotherapy-induced nausea and vomiting. This will already be a part of their chemotherapy regimen and will not be prescribed by study investigators
1581555|NCT02372526|Other|Mealtest: High protein 200 kcal 200 ml liquid meal consumed during 10 minutes|
1581556|NCT02372526|Other|Mealtest: High fat 200 kcal 200 ml liquid meal consumed during 10 minutes|
1581557|NCT02372526|Other|Mealtest: High carbohydrate 200 kcal 200 ml liquid meal consumed during 10 minutes|
1581558|NCT02372526|Other|Mealtest: High fat 200 kcal 200 ml liquid meal with pancreatic lipase inhibitor consumed during 10 minutes|
1581559|NCT02372500|Dietary Supplement|Chewing gum|Sugar free chewing gum
1581560|NCT02372487|Drug|sildenafil citrate|sildenafil citrate 25 mg every 8 hours
1581561|NCT02372487|Dietary Supplement|fluid therapy|2 liters of fluid per day
1581562|NCT02372474|Biological|Stem cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
1581563|NCT02372461|Drug|Placebo|This is an non inferiority trial, the intervention is a placebo
1581564|NCT02372461|Drug|Amoxicillin|Amoxicillin Liquid
1581565|NCT02372448|Other|ALK analysis on CTCs detected by ISET|
1581566|NCT02372435|Procedure|Shortening of the interval of two-stage prosthesis exchange|The Intervention consist in shortening of the interval between Explantation and re-implantation in patients undergoing a two-stage prosthesis Exchange. Comparison between arms is performed between short and long interval before re-implantation.
1581567|NCT02372422|Other|Transvaginal ultrasound determination of cervical length|Transvaginal ultrasound was used to measure the length of the cervix from the internal to external os relying on a standard approach and clinicians caring for the patients were made aware of the results.
1581568|NCT02372422|Other|Routine care|Routine prenatal care of twins. Digital exams were permitted, but transvaginal ultrasound assessment of cervical length was not.
1581569|NCT02372409|Device|MRI-guided laser ablation|
1581572|NCT02372409|Device|Dynamic contrast-enhanced (DCE) MRI|
1581573|NCT02372409|Device|Dynamic susceptibility contrast (DSC) MRI|
1581576|NCT02372383|Drug|Ethambutol|Anti-mycobacterial oral drug
1581577|NCT02372383|Drug|Rifampin|Anti-mycobacterial oral drug
1581578|NCT02372383|Drug|Azithromycin|Anti-mycobacterial oral drug
1581579|NCT02372383|Drug|Pancrelipase|Pancreatic enzyme replacement therapy
1581580|NCT02372370|Procedure|Microneedle pretreatment + MAL-PDT|Interventions: microneedling of the skin using dermarollers prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
1581581|NCT02372370|Procedure|Sandpaper pretreatment + MAL-PDT|Interventions: abrasion of the skin using Abrasive Pads for Skin Preparation prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
1581582|NCT02372370|Procedure|Curettage pretreatment + MAL-PDT|Interventions: curettage of the skin using a curette prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
1581583|NCT02372370|Procedure|Ablative Fractional Laser (AFXL) pretreatment + MAL-PDT|Interventions: Ablative Fractional Laser (AFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
1581584|NCT02372370|Procedure|Non-Ablative Fractional Laser (NAFXL) pretreatment + MAL-PDT|Interventions: Non-Ablative Fractional Laser (NAFXL) resurfacing of the skin prior to topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)). Three settings are applied: mild, moderate and strong.
1581585|NCT02372370|Drug|MAL Control.|Intervention: Topical application of 125 microliter methyl aminolevulinate (MAL) cream followed by red light illumination after 3 hours incubation (i.e. photodynamic therapy (PDT)).
1581586|NCT02372370|Other|Untreated Control|Untreated control. No interventions.
1581587|NCT02372357|Drug|Posaconazole prophylaxis 120 mg/m² tid|Patients are receiving posaconazole to prevent invasive fungal infections in a dose of 120 mg/m² tid
1581588|NCT02372357|Procedure|Blood sampling|During steady state treatment with posaconazole (at least 7 days), 9 blood samples are taken via a central venous catheter to evaluate the pharmacokinetics of posaconazole.
1581589|NCT02372344|Drug|AZD0585|Following an overnight fast of at least 10 hours, a single dose of 4 g AZD0585 will be administered on 3 separate occasions (fasting, before meal, and after meal) in a randomized crossover fashion with different food restrictions.
1581590|NCT02372331|Other|ERAS perioperative management|"Preop Counseling
Preop biliary drainage (X) when Serum Total bilirubin < 14.62mg/dl and cholangitis (-)
Preop enteral nutrition
Oral bowel preparation (mechanical bowel preparation ) (X)
Preop fasting < 6 hours
Prevention of postoperative nausea and vomiting (PONV) (O)
Nasogastric intubation (X)
Near-zero fluid balance
Somatostatin analogues (X)
Postop routine artificial nutrition (X), soft diet at POD #2
Audit
Other items are same as conventional"
1581591|NCT02372318|Drug|Nalmefene|18mg of Nalmefen will be administered orally
1581592|NCT02372318|Drug|Placebo|Placebo tablet
1581593|NCT02372305|Biological|FlexHD|Patients will be randomized to receive FlexHD.
1581594|NCT02372305|Biological|Alloderm|Patient will be randomized to receive Alloderm.
1581595|NCT02372292|Drug|intravenous furosemide|Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion
1581596|NCT02372279|Other|Embryo observation|In EO group, conventional observations will be made.
1581597|NCT02372266|Other|Early Maternal-Newborn Infant Discharge|Discharge from the hospital between 12-24 hours of life
1581598|NCT02372266|Other|Routine discharge|Discharge of the mother and newborn 2 to 3 days after delivery
1581599|NCT02372253|Drug|Verapamil|
1581600|NCT02372253|Drug|Placebo|
1581601|NCT02372240|Drug|VLX1570 and dexamethasone|
1581602|NCT02372227|Drug|VS-5584 and VS-6063|Starting dose of VS-5584 will be 20mg taken once daily, 3x/week of each 21 day cycle. All subjects will also receive 2x/day treatment with 400mg VS-6063 in 21 day cycles. Number of Cycles: until progression or unacceptable toxicity develops.
1581603|NCT02372214|Procedure|Training|Patients will have their aneurysm impressed by a 3D printing. The senior vascular surgeon and the residents of this group will be able to practice the procedure in the model as many times as they wish before the surgery. After the training, the EVAR will be performed according to the routine of the hospital.
1581604|NCT02372201|Other|Hydro Colon Therapy plus probiotic|Probiotic intervention was done after 2-5 cycles of hydro colon therapy.
1581605|NCT02372188|Other|water|Control
1581606|NCT02372188|Dietary Supplement|caffeine|
1581607|NCT02372188|Dietary Supplement|caffein + homoeriodictyol sodium salt|
1581608|NCT02372188|Dietary Supplement|homoeriodictyol sodium salt|
1581610|NCT02372162|Other|Image Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a comprehensive Image Fingerprint that includes CT, MRI and PET diagnostics
1581611|NCT02372162|Other|Molecular Fingerprint|This is an observational study that uses in depth diagnostic procedures to characterize patients with a Molecular Fingerprint that includes next-generation sequencing
1581612|NCT02372149|Drug|10% intravenous immunoglobulin (IVIg)|
1581613|NCT02372149|Drug|0.9% sodium chloride|
1581614|NCT02372136|Dietary Supplement|Individualized Nutrition|"Intake of macronutrients (protein, fat, and carbohydrate) will be individualized every day by adding one or more macronutrients to human milk based on daily measurements using near-infrared analysis.
In patients receiving less milk than 140 ml x kg-1 x day-1 fortification of human milk will be adjusted to reach at least the average concentrations of protein, fat, and carbohydrate in donor's milk (Wojcik. J Am Diet Assoc. 2009 Jan;109:137-40) and 20 cal/oz as provided by the Mother's Milk Bank of North Texas.
In those receiving at least 140 ml x kg-1 x day-1 of milk at 24 cal/oz fortification will be adjusted to meet recent guidelines from the the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition (ESPGHAN) (Agostoni et al. J Pediatr Gastroenterol Nutr. 2010 Jan;50:85-91)."
1581615|NCT02372136|Dietary Supplement|Optimized nutrition|Milk fortification will be based on current recommendations and optimized by adjustment of nutrients once a week based on blood levels of urea nitrogen (corrected for serum creatinine level) and albumin and velocity of growth (weight and length).
1581616|NCT02372123|Other|lifestyle advice|Investigators will give lifestyle advice to patients such as exercising regularly, limiting caffeine, sugar and alcohol intake, reduction or cessation of smoking
1581617|NCT02372123|Other|connective tissue manipulation|Investigators will apply connective tissue manipulation on lumbosacral, lower thoracic, and anterior pelvic regions starting from the estimated time of ovulation until the next period begins
1581618|NCT02372110|Drug|HPA, ANS stimulation|Oral administration of Hydrocortisone will increase HPA axis activity. Oral administration of Caffeine will boost ANS activity
1581619|NCT02372110|Drug|Placebo|Two cellulose placebo capsules filled with acidophilus powder will be administered to subjects who are randomly assigned to the placebo condition
1581620|NCT02372097|Drug|SYR-472|SYR-472 25mg, 50mg
1581621|NCT02372084|Drug|osilodrostat|
1581622|NCT02372071|Device|BiliCare|Two measurements with the BiliCare device
1581623|NCT02372058|Device|BiliCare|"Three non invasive measurements of TcB:
Two measurements with the BiliCare device and one measurement with a competitive FDA approved device"
1581624|NCT02372032|Procedure|percutaneous lumbar discectomy|process percutaneous lumbar discectomy
1581625|NCT02372032|Procedure|ozone therapy|percutaneous intradiscal ozone injection
1581626|NCT02372019|Behavioral|CBM With Active Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 20 minutes afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. This training takes places during the memory reconsolidation window that opens after fear reactivation, during which time the fear memory is in a labile state and thus more amenable to rewriting."
1581627|NCT02372019|Behavioral|CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given CBM for interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving positively, 7 resolving negatively, and 7 resolving neutrally. Because this training takes places well outside of the memory reconsolidation window that opens shortly after fear reactivation, the reactivation is not expected to have any effect, and only serves as a control."
1581628|NCT02372019|Behavioral|Inert CBM With Inert Fear Reactivation|"Participants will undergo a fear reactivation trial, which involves giving a one-minute impromptu speech after only 30 seconds of preparation time. 12 to 36 hours afterwards, they will be given an inert form of CBM, which should not influence the direction of interpretation bias. Training will involve 84 social scenario vignettes, with 70 resolving neutrally, 7 resolving positively, and 7 resolving negatively. Because the CBM training takes places well outside of the memory reconsolidation window that opens after fear reactivation, the reactivation is not expected to have any effect, and the inert CBM training is not expected to have any effect either. This condition only serves as a control for the other two conditions."
2008625|NCT03328624|Device|Deep Vein Thrombosis (DVT) Cuff|Recovery Force's DVT II Cuff
1581630|NCT02371993|Dietary Supplement|Choline|
1581631|NCT02371993|Other|Placebo|
1581632|NCT02371980|Drug|Vortioxetine|Vortioxetine capsules
1581633|NCT02371980|Drug|Placebo|Vortioxetine placebo-matching capsules
1581634|NCT02371967|Drug|Vismodegib|Vismodegib therapy will be given in compliance with the physician's standard practice as per local label.
1581635|NCT02371954|Behavioral|Happy Older Latinos are Active|Health promotion intervention desgined to prevent anxiety and depression in at risk older Hispanics
1581636|NCT02371954|Other|Fotonovela|Comic book style informational booklet designed for people with low literacy to educate them on mental illness.
1581637|NCT02371941|Drug|oral cromolyn sodium|Oral cromolyn sodium
1581638|NCT02371941|Drug|Placebo|Saline
1581639|NCT02371928|Other|Neuromuscular exercise program|"Exercises can be individually progressed from basic to elite level.
Low load exercises are performed every day with 2 sets of 20-25 repetitions whereas high load exercises are performed three times per week with 2 sets of 8-12 repetitions.
Exercises are progressed using the following components: arm-position, load, speed, open/closed eyes, stable/unstable surfaces.
Patients have online access to instructions and video recordings of all exercises and progression levels. Patients are trained to continuously evaluate their own shoulder function and to adjust the exercise levels themselves at home.
Supervision will be given two times a week for the first two weeks and then once a week for the remaining period."
1581640|NCT02371928|Other|Standard home exercise program|"Strengthening of the rotator cuff muscles are performed with the use of elastic bands (shoulder internal and external rotation besides abduction in scapular plane) whereas mobility/strengthening exercise for the scapular muscles are performed through weight-bearing positions and movements of the upper extremity.
All exercises are performed three times a week with 2 sets of 10 repetitions."
1581641|NCT02371915|Other|Videoconference follow-up|Rheumatology visits to take place video videoconference with a physiotherapist present
1581642|NCT02371902|Device|MODULITH® SLK, STORZ MEDICAL AG, Switzerland|Three sessions were carried out, with the time interval between sessions spanning between 48 and 72 hours. In each session, 2400 pulses were administered with energy flux density (EDF) ranging from 0.14 and 0.20 mJ/mm2, depending on the maximum tolerated pain of each patient. Analgesics or local anaesthetics were not administered before, during or after treatment.
1581643|NCT02371902|Device|Cryoultrasound™, Medisport S.r.l., Italy|Cryo-US therapy was performed in a continuous emission modality, using an ultrasound emission power rating of 1,8 Watt/cm2, and a temperature of -2˚C, for a total of 12 sessions lasting 20 minutes each. The treatment was performed in 3 weeks (4 daily sessions per week).
1581644|NCT02371889|Drug|Topiramate|Max therapeutic dose of 200mg/day
1581645|NCT02371889|Behavioral|Medical Management|Medical Management (MM; Pettinati, 2004) will support subjects' efforts to reduce or stop their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The subject is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the subject's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 3 drinks 4 times per week; women will be advised to consume no more than 2 drinks 4 times per week.
1581646|NCT02371889|Drug|Inactive Placebo|In capsules indistinguishable from topiramate capsules and gradually increased to a maximum equivalent of 200 mg of topiramate/day
1581647|NCT02371876|Device|ONYX PLUS Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX PLUS Investigational Blood Glucose Monitoring System. All BG results were compared to reference method results obtained from subject capillary blood. Study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
1581648|NCT02371850|Drug|Nicoderm patch first, then Aveva patch|This is a single group assignment where each of 10 adult smokers completes 4 procedure days using a Nicoderm CQ nicotine patch (2 days) followed by the application of a generic Aveva patch (2 days). For each patch, heating is applied for one hour at hour 4 on the first procedure day and at hour 8 in the second procedure day (2 days per patch, or a total of 4 days per subject).
1581649|NCT02371837|Other|Pilates and fall prevention|A 2 days per week during 6 week Pilates practice will be performed in experimental group in order to check the effectiveness in fall prevention
1581650|NCT02371824|Other|MRI sequence|One supplementary MRI sequence Dynamic Contrast Enhancement (DCE) was added to the clinical protocol.
1581651|NCT02371811|Device|uterine manipulator (v care)|
1581652|NCT02371798|Drug|Gadopentetate dimeglumine|IV administration of 0.2 mmol/kg of Gd-DTPA
1581653|NCT02371785|Device|CorPath 200 System|Remote delivery of guide wires and balloon catheters for use in percutaneous vascular interventions (PVI).
1581654|NCT02371772|Other|Training|Patients were trained to monitor INR and dose warfarin
1581655|NCT02371759|Drug|L+C maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
1581656|NCT02371759|Drug|L+C mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + clonidine (15 mcg/ml)
1581657|NCT02371759|Drug|L+E maxillary anesthesia|Maxillary anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
1581658|NCT02371759|Drug|L+E mandibular anesthesia|Mandibular anesthesia obtained by 2% lidocaine + epinephrine (1:80 000)
1581659|NCT02371746|Drug|ENV515 Travoprost XR|
1581660|NCT02371746|Drug|TRAVATAN Z|
1581661|NCT02371746|Drug|Timolol maleate ophthalmic solution 0.5%|
1581662|NCT02371733|Other|Upper extremity aerobic exercise training|"Training group will receive upper extremity aerobic exercise training using arm ergometer at 50-80% of maximal heart rate and breathing exercises.
Training will exercise with arm ergometer 3days/week, for 6 weeks with the assistance of a physiotherapist. Training workload will be undercontrol both using target heart rate and Modified Borg dyspnea scale. Training group will also perform breathing exercises 120 times/day, 7 days/week, for 6 weeks."
1581663|NCT02371733|Other|Alternative upper extremity exercises|"Control group will receive alternative upper extremity exercises and breathing exercises. Control group will perform alternative upper extremity exercises 3days/week, for 6 weeks and also breathing exercises 120 times/day, 7 days/week, for 6 weeks.
Control group will be followed-up by telephone once a week."
1581664|NCT02371720|Behavioral|Mobile DOT|Daily reminders via text or email to send a video of themselves taking their Hydroxyurea, positive feedback, and be encouraged to contact the research coordinator with any questions, concerns, etc.
1581665|NCT02371707|Drug|Idalopirdine 60 mg formulation A (test)|Tablet for oral use, single dose
1581666|NCT02371707|Drug|Idalopirdine 60 mg formulation B (reference)|Tablet for oral use, single dose
1581667|NCT02371694|Other|Test drink|"The intervention is a drink taken 4 hours after the evening meal insulin injection, or 10PM, whichever is later. All drinks are 116-120g in weight and similar volume.
All drinks are served in a double blind fashion, apart from the 20g carbohydrate which is visibly different from other drinks in colour, texture and flavour."
2008626|NCT03328611|Device|Hip and Knee Joint Replacement|Hip and Knee Joint Replacement
2008627|NCT03328598|Behavioral|Positive psychology therapy group|This program is developed from a foreign group program based on positive psychology. The positive psychology therapy lasts 8 weeks, and has a group intervention in each week. The themes of each week are start-up, time gift, positive mind, three good things, a thankful heart, life train, active service, end-up.
1581674|NCT02371655|Procedure|Diet|A low-fibre diet for three days before the examination
1581675|NCT02371655|Drug|Faecal Tagging|Oral ingestion of iodinated contrast media (Gastrografin 60 ml) 3h before the examination
1581676|NCT02371655|Drug|Bowel cleansing|Oral ingestion of water solution (macrogol 100 mg, Sanipeg) the day before the examination
1581677|NCT02371655|Procedure|CT colonography|CT Examination of the colon aimed to detect polyps and cancer
1581678|NCT02371629|Drug|NVA237 (glycopyrronioum bromide)|NVA237 capsules for inhalation, delivered via a Single Dose Dry Powder Inhaler (SDDPI) called Concept1
1994576|NCT02971748|Drug|Pembrolizumab|Pembrolizumab 200 mg administered on day 1 of each 3-week cycle as approximately 30 minute IV infusion. Hormonal therapy at physicians' discretion including tamoxifen, exemestane, anastrozole, letrozole, LHRH agonist and combination with any of above and starts at the same time as pembrolizumab.
1581682|NCT02371603|Drug|GSK1278863 25 mg Tablet|A round, biconvex, white film coated tablet to be taken orally in the fasted state in the morning
1581683|NCT02371603|Drug|Pioglitazone 15 mg Tablet|"White to off-white, round, convex, non scored tablet with ACTOS on one side, and 15 on the other, to be taken orally in the fasted state in the morning"
1581684|NCT02371603|Drug|Rosuvastatin 10 mg Tablet|"Pink, round, biconvex, coated tablets. Debossed CRESTOR and 10 on one side, to be taken orally in the fasted state in the morning"
1581685|NCT02371603|Drug|Trimethoprim 100 mg Tablet|"White, round, scored, convex tablet, debossed 93 above the score and debossed 2159 below the score on one side and plain on the other, to be taken orally as two tablets once in the morning and once in the evening"
1581686|NCT02371590|Drug|Lenalidomide|"Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The starting dose for all patients is 5 mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, as tolerated.
The study consists of a 6 month treatment period with obinutuzumab and lenalidomide, and an indefinite period of treatment with lenalidomide for as long as it is helpful and tolerated by subject."
1581687|NCT02371590|Drug|Obinutuzumab|Obinutuzumab is administered as follows: Cycle 1: 100mg IV on day 1, 900 mg IV on day 2, 1000mg day 8, 1000 mg on day 15. Cycles 2-6: 1000mg IV on day 1.
1581688|NCT02371577|Drug|Lenalidomide|Lenalidomide is administered orally once daily on Days 8-28 of each 28 day cycle. The typical starting dose is 2.5mg PO daily. At the start of each cycle, there is intra-patient dose-escalation to a maximum of 25mg daily, in the absence of grade 2 or higher adverse events Duration of lenalidomide on the clinical trial is for up to 6 cycles, each of 28 day duration.
1581689|NCT02371564|Device|High flow humidified oxygen|
1581690|NCT02371564|Device|Standard flow humidified oxygen|
2008628|NCT03328598|Behavioral|Resilience promotion therapy group|The other one is developed from research team's previous research results. The resilience promotion therapy lasts 8 weeks, and also has a group intervention in each week. The themes of each week are start-up, mutual help, trust in yourself, thanksgiving feedback, care for yourself, emotional management, end-up.
2008629|NCT03328598|Other|Controlled routine activity|Conventional community activities is viewed as an active comparator for controlled group.
2008630|NCT03328585|Behavioral|CBT-I in person|6 weeks of CBT-I in person, one 1-hour long session per week
2008631|NCT03328585|Behavioral|CBT-I via Telemedicine|6 weeks of CBT-I via telemedicine, one 1-hour long session per week
1581695|NCT02371538|Biological|Donor Breastmilk|Donor breastmilk will be obtained from the Mother's Milk Bank of New England.
1581697|NCT02371512|Device|MitraClip system (Abbott Vascular, Menlo Park, USA)|Valve repair with the MitraClip system (Abbott Vascular, Menlo Park, USA) consists of a steerable guide through which a Clip Delivery System is advanced to the left atrium.
1581698|NCT02371512|Procedure|Mitral valve surgery|Mitral valve surgery or mitral valve replacement (technique and access at the discretion of the participating surgical center, MACE procedure and tricuspid annuloplasty possible)
1581699|NCT02371499|Dietary Supplement|Lactobacillus casei DG|the patients will receive 1 capsule of Lactobacillus casei DG (Enterolactis plus®) twice daily for 4 weeks
1581700|NCT02371499|Dietary Supplement|Placebo|the patients will receive 1 capsule of product without bacteria (Enterolactis placebo) twice daily for 4 weeks
1581701|NCT02371486|Procedure|hysteroscopic repair of cesarean section defect|Operative hysteroscopy for the repair of cesarean section defect is performed under general anesthesia. the cervix is dilated and the cesarean section defect opened. polypoid tissue is ablated
1581702|NCT02371486|Procedure|Diagnostic Hysteroscopy|Betthochi's method for diagnostic hysteroscopy: No anesthesia will be used. vaginoscopy will be performed, followed by diagnostic hysteroscopy. saline will be used as a distension media. 4.2 mm Storz hysteroscope will be used.
1581703|NCT02371486|Procedure|Ultrasound Scan|"Scanning the uterus with the ultrasound probe . Transvaginal ultrasound usually produces better and clearer images of the female pelvic organs, because the ultrasound probe lies closer to these structures.
The transvaginal ultrasound probe is thin, about 2cm diameter. The probe is covered with a disposable protective sheath. A small amount of ultrasound gel is placed on the end of this probe. The probe is then gently inserted a short distance into the vagina."
1581704|NCT02371486|Procedure|IVF Cycle|Controlled ovarian hyperstimulation, followed by Human chorionic Gonadotropin ( hCG) administration, Ovum Pickup and Embryo transfer
1581705|NCT02371473|Drug|Acetazolamide-placebo|The patients in this arm are given Acetazolamide mg for six days and after 2 weeks washout they are given placebo for six days.
1581706|NCT02371473|Drug|Placebo-acetazolamide|The patients in this arm are given placebo for six days and after 2 weeks washout they are given Acetazolamide for six days.
1581707|NCT02371460|Dietary Supplement|DHA-rich algal oil|Mothers will receive a DHA-rich algal oil treatment (400 mg DHA per capsule) three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
1581708|NCT02371460|Dietary Supplement|Placebo|Mothers will receive a placebo capsule three times a day before meals from randomization (<72 hours post-delivery) until the infant reaches 36 weeks PMA.
1581710|NCT02371434|Biological|autologous CD4+CD25+FoxP3+ natural regulat. T cells (nTregs)|autologous CD4+CD25+FoxP3+ natural regulatory T cells (nTregs). nTregs will be infused at escalating doses of 0.5 x 106, 1 x 106, and 3 x 106 cells/kg body weight in cohorts of three patients each.
1581711|NCT02371421|Drug|Allopurinol|
1581712|NCT02371408|Drug|ravidasvir hydrochloride|200 mg
1581713|NCT02371408|Drug|sofosbuvir|400 mg
1581714|NCT02371408|Drug|ribavirin|1000 mg - 1200 mg per day, weight-based dosing
1581716|NCT02371382|Device|Arthroplasty hip|Hip replacement
1994579|NCT02971540|Drug|Metamizol|in group A patients will receive pre-emptive analgesia using intravenous infusion of metamizol in a single dose of 1-1,25 gram with following intravenous infusion of 5 grams per day.
1994580|NCT02971540|Drug|Tramadol|in group A patients will receive pre-emptive analgesia using intravenous infusion of tramadol in a single dose of 2 mg per hg of body weight with following intravenous infusion of 400 mg per day.
1581721|NCT02371317|Behavioral|Mindfulness-Based Stress Reduction|Patients are randomized to an intervention
1581722|NCT02371317|Behavioral|Stress Management Education|Patients are randomized to an intervention
1581723|NCT02371317|Other|American Heart Association Recommended Self-Care|All Patients receive AHA Recommended Self-Care
1581724|NCT02371304|Radiation|Adjuvant chemoradiotherapy|Patients will receive capecitabine 825 mg/m2 twice a day for 5 weeks only on weekdays. This will be combined with 1.8 Gy in 25 fractions with a limited dose only on the mesorectum
1581725|NCT02371304|Procedure|Additional TME surgery|
1581726|NCT02371304|Drug|capecitabine|
1581727|NCT02371291|Behavioral|Memory Flexibility Training|As in experimental arm description.
1581728|NCT02371291|Behavioral|Psychoeducation|As in experimental arm description.
1581729|NCT02371278|Dietary Supplement|Leucine|5 g leucine with sucrose and maltodextrin
1581730|NCT02371278|Dietary Supplement|Placebo|5 g glycine with sucrose and maltodextrin
1581731|NCT02371265|Other|Adherence and retention package|"Based on formative research findings, the following core components of the B+ study intervention have been designed and will be stepped in at the study sites to improve early retention in care and adherence:
Workflow modification: 1) Redefinition of key roles of MCH nurses and task shifting to community health workers (CHW's), and 2) enhanced patient tracking via improved management of registries/charts;
Adherence and retention package: 1) Creation of Adherence Committees at each site to coordinate and systematize patient follow-up, 2) active patient follow-up and home visits by community health workers (CHWs or activistas), 3) use of text messaging to patients by MCH nurses, 4) improved and intensified counseling coordinated with active CHW and text follow-up, and 5) intensified and improved Option B+ training and supportive supervision."
1581732|NCT02371252|Drug|Generic alendronate|The patients will be given the generic alendronate 1 tablet per week for approximately 1 year after enrollment.
1581733|NCT02371239|Behavioral|Physical activity intervention|
1581734|NCT02371226|Drug|AGT-181 (HIRMAb-IDUA)|intravenous infusion over 3-4 hours
1581735|NCT02371213|Other|social networking on mobile phone|Audio-video media about serious complications such as labor pain, vaginal bleeding, water breaking and fewer fetal movement via social networking application on mobile phone to antenatal women from the first ANC visit four times every month and four times biweekly
1994581|NCT02971540|Drug|Bupivacaine|patients in group BF will receive local wound infiltration with a solution of 0,2% bupivacaine in a volume of 10 ml per segment of vertrebral columne.
1994582|NCT02971540|Drug|Ropivacaine|patients in group RF will receive local wound infiltration with a solution of 0,2% ropivacaine in a volume of 10 ml per segment of vertrebral columne.
1994583|NCT02971540|Other|control group|patients will receive no pre-emptive analgesia. intraoperatively standard dose of fentanyl will be used.
1581739|NCT02371161|Drug|R-DHAP/R-ICE|"R-DHAP/R-ICE 3 cycles every 21 days:
R-DHAP
Rituximab 375 mg/m2, e.v. day 1
Desamethasone 40 mg days 1-4
cis-Platino100 mg/m2, day 2 (if ≥70 years 75 mg/m2)
Aracytin 2000 mg/m2, e.v. day 3 (if ≥70 years 1500 mg/m2)
R-ICE
Rituximab 375 mg/m2, e.v. day 1
Etoposide 100 mg/mq, e.v. days 1,2,3 (if ≥70 years 75 mg/mq)
Ifosfamide with Mesna equidone 5000 mg/mq, day 2 (if ≥70 years 3750 mg/mq)
Carboplatino AUC=5, e.v. (max 800 mg/mq), day 2 (if ≥70 years AUC=4)
Conditioning BEAM or FEAM"
1581740|NCT02371148|Drug|Bortezomib-Rituximab-Bendamustine|"Bortezomib-Rituximab-Bendamustine Bortezomib: 1.3 mg/mq sc days 1, 8, 15, 22* Rituximab: 375 mg/sqm i.v. day 1** Bendamustine: 90 mg/sqm iv days 1-2 or days 2-3 according to institutional/physician choice Repeat cycles every 28 days for a total of 6 cycles *In case of toxicity is omitted
**In cycles 1, in order to avoid tumor lysis syndrome, Rituximab will be given on day 8"
1581741|NCT02371135|Genetic|colonic biopsies|
1581742|NCT02371135|Genetic|questionnaires|
1581743|NCT02371122|Device|Therapy Setting 1 (Medtronic)|RestoreSensor or RestoreUltra Setting 1
1581744|NCT02371122|Device|Therapy Setting 2 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 2
1581745|NCT02371122|Device|Therapy Setting 3 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 3
1581746|NCT02371122|Device|Therapy Setting 4 (Medtronic)|Medtronic RestoreSensor or RestoreUltra Setting 4
1581747|NCT02371109|Other|selftaken versus clinically taken swabs|
1581748|NCT02371096|Drug|MabThera (rituximab)|
1581749|NCT02371096|Drug|RGB-03|
1581750|NCT02371083|Other|Extended timing of pessary care|
1581751|NCT02371031|Drug|6-[F-18]-Fluoro-L-3,4,-dihydroxyphenylalanine|
1581752|NCT02371031|Device|PET/MRI|
1581753|NCT02371031|Procedure|Surgical resection (standard of care)|
1581754|NCT02371018|Dietary Supplement|Nepro|Patients will be asked to consume a single 8 oz can of Nepro
1581755|NCT02371005|Radiation|Cone Beam Computed Tomography (CBCT)|
1581756|NCT02370992|Radiation|I125 brachytherapy|I125 brachytherapy is a standard treatment and will be delivered using routine techniques involving a preimplant volume study followed by implantation of the I125 sources. This is undertaken as an inpatient or day case under general or spinal anaesthetic according to local practice
1581757|NCT02370979|Biological|Blood samples|
1581758|NCT02370966|Dietary Supplement|Berry powder|Berry and gingivitis trial
1581759|NCT02370953|Device|VERION for toric IOL alignment|The VERION Measurement Module is a diagnostic device which can make high resolution colour reference images of the patient's eye for position reference. The VERION Digital Marker is a medical device that assists the surgeon in planning and performing surgical procedures on the eye. The VERION tools use several reference points on the conjunctiva and limbus, and make an overlay between the preoperative achieved and live-surgery image. During surgery, this device projects the horizontal axis and the estimated placement axis of the toric IOL on the patient's eye, and therefore, the surgeon can accurately place the toric IOL to its preoperatively calculated angle.
1581806|NCT02370667|Other|Meditation Control (M)|A meditation program acting as a control will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
1581807|NCT02370654|Behavioral|Tai chi|
1581808|NCT02370654|Behavioral|Conventional exercise|
1581809|NCT02370641|Dietary Supplement|PomX|1000 mg POMx daily for 4 weeks
1581854|NCT02370342|Procedure|Robot-Assisted Laparoscopic Surgery|Undergo robot-assisted laparoscopic HIFU ablation
1581760|NCT02370953|Procedure|Conventional, manual ink-marking for toric IOL alignment|Several manually performed methods are used to align the toric IOL at the intended axis. Most of them use a 3-step procedure. First, the horizontal axis of the eye is temporarily marked with ink in a seated position to correct for cyclotorsion when changing into supine position. Three spots on the conjunctiva, close to the edge of the cornea, are applied at 0°, 90° and 180°, which may be done by using a bubblemarker or gravity marker with a calibrated horizontal position. Next, the desired alignment axis for the toric IOL is marked intra-operatively. The last step is to rotate the implanted toric IOL until the IOL markings agree with the alignment marks. After surgery is performed, the ink marks will disappear within a few hours.
1581761|NCT02370940|Other|High phytate intake|
1581762|NCT02370940|Other|Low phytate intake|
1581763|NCT02370927|Other|Control|Non pulse extruded cereal
1581764|NCT02370927|Other|Pea protein|Pulse extruded cereal
1581765|NCT02370927|Other|Pea Starch|Pulse extruded cereal
1581766|NCT02370927|Other|Pea fibre + pea starch|Pulse extruded cereal
1581767|NCT02370927|Other|Pea protein + pea starch|Pulse extruded cereal
1581768|NCT02370927|Other|Pea fibre + pea starch + pea protein|Pulse extruded cereal
1581769|NCT02370914|Device|Nautilus NeuroWaveTM System|Recording of subjects with Nautilus NeuroWave diagnostic device
1581770|NCT02370914|Behavioral|SCAT|A Neurocognitive evaluation of the patients to assess for concussion.
1581773|NCT02370888|Drug|Lenalidomide|Subjects will be enrolled in cohorts of three (3). Lenalidomide will be administered for 21 consecutive days in a 28 day cycle X 2 cycles. The starting dose will be 2.5 mg given orally every other day for 21 days.
1581774|NCT02370875|Device|Magstim RapidStim2|Application of repetitious transcranial magnetic stimulation (TMS) pulses using Magstim RapidStim2 to a specific brain target at predefined stimulation parameters.
1581775|NCT02370875|Device|Sham Magstim RapidStim2|Same procedure as real rTMS without stimulating the cerebral cortex.
1581776|NCT02370862|Drug|Neostigmine and Glycopyrrolate|
1581777|NCT02370849|Drug|nimotuzumab|nimotuzumab 200mg infusion on day 1,8,15 every 3 weeks
1581778|NCT02370849|Drug|cisplatin|cisplatin: 30 mg/m2 iv. infusion on day 1, 2 every 3 weeks
1581779|NCT02370849|Drug|S-1|S-1: 40 mg/m2 bid , 2 weeks on, 1 week off ；
1581780|NCT02370836|Other|Education|One 60 minute psycho-oncological educational session on stress management, late effects and fatigue.
1581781|NCT02370823|Procedure|Regenexx SD|stem cell treatment
1581782|NCT02370810|Behavioral|CBT-based internet-intervention for tinnitus|The intervention offered is a CTB-based internet intervention, providing an opportunity to learn about new ways of coping with tinnitus during everyday life. It is 8 week long e-learning intervention, with new modules introduced weekly and assignments given to practice techniques learnt.
1581783|NCT02370797|Radiation|Single Fraction IOeRT|A single dose of 21 Gy calculated such that the 90% isodose line encompasses the posterior of the tumor bed will be administered.
1581784|NCT02370784|Drug|atorvastatin|Atorvastatin is an oral cholesterol-lowering medication commonly referred to as statin therapy.
1581785|NCT02370784|Drug|Placebo|oral drug of similar appearance to atorvastatin
1581786|NCT02370771|Procedure|Biological sampling|Biological sampling to identify by label-free proteomic analysis of a combination of serum biomarkers in patients with Erosive and non erosive hand Osteoarthritis
1581787|NCT02370771|Device|Radiographic evaluation|Radiographic assessments using Bone Mineral Analyser and Hand MRI will be done in patients with Erosive and non erosive hand Osteoarthritis
1581788|NCT02370758|Drug|Valganciclovir or Ganciclovir|
1581789|NCT02370745|Drug|GLP-1|GLP-1 effects on skeletal muscle glucose and amino acid metabolism and microvascular blood flow will be scrutinised under the specified insulin concentrations. It will also be used to test the effect of intravenous feed on insulin secretion.
1581790|NCT02370745|Drug|Insulin Actrapid|Skeletal muscle metabolic and microvascular parameters will be tested under specified insulin concentrations with or without GLP-1
1581791|NCT02370745|Dietary Supplement|Oral amino acids|Oral amino acids containing 15 g of amino acids
1581792|NCT02370745|Drug|GIP|This will be co infused with GLP-1 and intravenous amino acids
1581793|NCT02370745|Drug|Intravenous amino acids|This will aim to deliver iso equivalent amount to the amino acids administered orally
1581794|NCT02370732|Other|Alcohol|A weight based dose of alcohol will be administered during each study day.
1581795|NCT02370719|Behavioral|Mobile application for diabetes self-management|
1994584|NCT02970942|Drug|Semaglutide|Once daily administration of semaglutide subcutaneously (s.c., under the skin) in three different doses (0.1 mg, 0.2 mg and 0.4 mg)
1581799|NCT02370693|Drug|Bortezomib|Bortezomib 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 48 weeks
1581800|NCT02370693|Drug|Placebo|Placebo (normal saline) 1.3 mg/m² subcutaneously (or IV push if unable to tolerate subcutaneous injection) once per week for the first two weeks per month for 48 weeks
1581801|NCT02370693|Drug|Mycophenolate mofetil|Mycophenolate mofetil 1.5 g twice a day orally for 48 weeks
1581802|NCT02370680|Drug|Aspirin|steady-state run-in prior to Durlaza treatment
1581803|NCT02370680|Drug|Durlaza™|comparison of different numbers of capsules
1581804|NCT02370667|Other|Biomechanical Exercise (BE)|A biomechanical exercise program shown to decrease joint loading will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
1581805|NCT02370667|Other|Traditional Exercise (TE)|A traditional exercise program for people with knee OA will be administered 3 times a week for 12 weeks. Outcomes will include mobility performance; pain; muscle and fat volumes, and cartilage morphology using MRI; strength; cardiovascular fitness; and gait analysis.
1581853|NCT02370355|Other|Laboratory Biomarker Analysis|Correlative studies
1581945|NCT02369666|Dietary Supplement|Placebo|Contains MCT oil.
1581810|NCT02370628|Procedure|Percutaneous vertebroplasty|"The procedure involves percutaneous application of bone cement (polymethylmethacrylate) into collapsed vertebrae, and has been used for treatment of patients with osteoporosis who have severe or prolonged pain following vertebral compression fracture, as well as those with painful, aggressive hemangiomas and osteolytic neoplasms.
In our trial, vertebroplasty shall be performed in two steps:
Step 1: facet block
Step 2: cement infusion
Therefore, patients in both arms will undergo Step 1 since our control intervention serves as a routine first part of our active intervention."
1581811|NCT02370628|Procedure|Facet block|"A long-acting local anesthetic agent and corticosteroids are injected in the spinal articular facets at the affected level.
All patients will undergo facet block since it serves as a routine first part to percutaneous vertebroplasty."
1581812|NCT02370615|Drug|TAK-272|TAK-272 tablet.
1581813|NCT02370615|Drug|Digoxin|Digoxin tablet.
1581814|NCT02370615|Drug|Itraconazole|Itraconazole oral solution
1581815|NCT02370615|Drug|Midazolam|Midazolam syrup.
1581816|NCT02370602|Drug|TAK-063|TAK-063 tablets
1581817|NCT02370602|Drug|[^11C]T-773|[^11C]T-773 IV solution
1581818|NCT02370589|Biological|Base Dose EBOV GP Vaccine|
1581819|NCT02370589|Biological|2x Base Dose EBOV GP Vaccine|
1581820|NCT02370589|Biological|4x Base Dose EBOV GP Vaccine|
1581821|NCT02370589|Biological|8x Base Dose EBOV GP Vaccine|
1581822|NCT02370589|Biological|Placebo|
1581823|NCT02370589|Biological|Matrix-M Adjuvant|
1581824|NCT02370576|Other|rating scale application|"Administration of validated PTSD, MDD and anxiety disorders rating scales immediately after birth and 1 month postpartum.
rating scale application"
1581825|NCT02370563|Drug|18F-FSPG|18F-FSPG is a novel F18-labelled, radiopharmaceutical agent for PET imaging. It is administered intravenously at a dose of 300 MBq (8.1mCi ± 10%).
1581826|NCT02370550|Drug|Cyclosporin A|CsA 2-3 mg/kg/d, BID PO
1581827|NCT02370550|Drug|Prednisone|Prednisone 0.5mg/kg/d QD PO starting at Week 0. After 2-4 weeks, the initial dose is gradually tapered by 2.5 mg each week until a maintenance dosage of 5-7.5 mg/d through week 52 (visit 6). The initial and maintenance doses are determined by the investigators of each center depending on the patients.
1581828|NCT02370550|Drug|Placebo|Placebo tablet 2-3 mg/kg/d, BID PO
1581829|NCT02370550|Drug|Calcium carbonate D|Calcium carbonate D 600 mg, QD PO
1581830|NCT02370537|Drug|Epanova® (omega-3 carboxylic acids)|4 g (administered orally as 4 x 1 g capsules)
1581831|NCT02370537|Drug|Omacor® (omega-3-acid ethyl esters)|4 g (administered orally as 4 x 1 g capsules)
1581832|NCT02370524|Drug|[18F]T807|All enrolled subjects will undergo an [18F]T807 PET imaging visit. In addition, subjects with AD and aged volunteers will have one PET scan with Amyvid (florbetapir F 18 injection) as part of the screening activities to measure Aβ in the brain.
1581833|NCT02370511|Device|Transcatheter Mitral Valve Replacement|Implantation of a balloon expandable Edwards SAPIEN XT or SAPIEN 3 transcatheter heart valve in the mitral position.
1581834|NCT02370498|Biological|pembroliziumab|IV infusion
1581835|NCT02370498|Drug|paclitaxel|IV infusion
1581836|NCT02370485|Drug|LY2801653|Administered orally
1581837|NCT02370472|Other|tool developed using cameras and a computer|cameras allowing subject to be able to visualize hand and needle movements as well s the position of the transducers along with the image from the ultrasound on a computer screen
1581838|NCT02370459|Other|AFIX in-person consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
1581839|NCT02370459|Other|AFIX webinar consultation|The adolescent AFIX (Assessment, Feedback, Incentives, and eXchange) Program is a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement. Relevant AFIX information will be communicated to vaccine providers using several intervention and quality improvement components.
1581840|NCT02370446|Other|personalized medication log|
1581841|NCT02370446|Other|standard of care|
1581842|NCT02370446|Behavioral|questionnaires|
1581843|NCT02370446|Behavioral|Cognitive Interview|
1581844|NCT02370433|Drug|Intravenous Neostigmine and Glycopyrrolate|
1581845|NCT02370433|Drug|Transdermal Neostigmine and Glycopyrrolate|
1994585|NCT02970942|Drug|Placebo|Once daily administration subcutaneously ( s.c., under the skin)
1994586|NCT02970435|Behavioral|Video Discharge Instructions|The video discharge instructions, will be provided to the patient at the time of surgical procedure.
1581848|NCT02370407|Device|a laparoscopic simulator (Fundamentals of Laparoscopic Surgery (FLS), VT Medical Inc, Waltham, MA)|10 repetitions of practice on laparoscopic simulator.
1581849|NCT02370407|Device|Mimic da Vinci robotic simulator|10 repetitions of practice on Mimic da Vinci robotic simulator.
1581850|NCT02370394|Behavioral|ROSE Program|The ROSE Program will be specifically tailored, innovative and relevant to diverse, racial and ethnic perinatal women in a number of ways including the images and content used in the intervention and coordinating study appointments with treatment visits. It will also be tailored on the current IPV risk assessment, pregnancy or postpartum status of each participant, will be designed to reach participants across levels of motivation for change. The content of ROSE will be theory-driven, consistent with the Motivational Interviewing model of behavior, and consistent with the literature on effective interventions that address IPV.
2008632|NCT03328585|Other|No intervention|Patients in this arm will receive no intervention but will receive CBT-I treatment after conclusion of the study
1581852|NCT02370355|Other|Cytology Specimen Collection Procedure|Undergo collection of blood samples
1581855|NCT02370342|Procedure|High-Intensity Focused Ultrasound Ablation|Undergo robot-assisted laparoscopic HIFU ablation
1581856|NCT02370342|Procedure|Therapeutic Laparoscopic Surgery|Undergo laparoscopic partial nephrectomy
1581857|NCT02370342|Device|Sonatherm 600i Ultrasonic Lesion Generating System|Device used for high-intensity focused ultrasound ablation
1581858|NCT02370329|Other|Laboratory Biomarker Analysis|Correlative studies
1581859|NCT02370329|Biological|PEG-Proline-Interferon Alfa-2b|Given SC
1581860|NCT02370329|Other|Quality-of-Life Assessment|Ancillary studies
1581861|NCT02370316|Behavioral|Metacognitive Interpersonal Therapy (MIT-SA)|MIT-SA consists of weekly individual therapy (1 year) and weekly group sessions (six months)
1581862|NCT02370316|Behavioral|Clinical Structured Treatment|structured case management and symptom-targeted medication
1581863|NCT02370290|Other|Medical Chart Review|Clinical and imaging information collected
1581864|NCT02370290|Other|Informational Intervention|Clinical and imaging data collected
1581865|NCT02370277|Other|Cytology Specimen Collection Procedure|Undergo collection of stool samples
1581866|NCT02370277|Other|Laboratory Biomarker Analysis|Correlative studies
1581867|NCT02370277|Other|Questionnaire Administration|Ancillary studies
1581868|NCT02370264|Procedure|Quality-of-Life Assessment|Ancillary studies
1581869|NCT02370264|Other|Questionnaire Administration|Ancillary studies
1581870|NCT02370264|Other|Medical Chart Review|Ancillary studies
1581871|NCT02370251|Drug|Omegaven|Once the direct bilirubin is 2 mg/dL or more x 2 weeks, Intralipid will be switched to Omegaven at 1 g/kg/day. The bilirubin level will be monitored to determine when resolution of cholestasis (DB <2 mg/dL) occurs.
1581872|NCT02370251|Drug|Omegaven + Intralipid|Infants who experience resolution of cholestasis and continue to require IV lipids will have Intralipid added back at a dose of 0.5 g/kg/day (if enteral intake is 50-99 ml/kg/day) or 1 g/kg/day (if enteral intake is 0-49 ml/kg/day) three times weekly. Essential fatty acid profiles will be monitored.
1581873|NCT02370238|Drug|paclitaxel|paclitaxel 80 mg/m2 i.v. (Days 1, 8, and 15)
1581874|NCT02370238|Drug|Reparixin|reparixin oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
1581875|NCT02370238|Drug|placebo|placebo oral tablets 1200 mg t.i.d. continuing from D 1 to Day 21 of 28-day cycle
1581876|NCT02370225|Other|aerobic exercise|"Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).
The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end."
1581877|NCT02370212|Dietary Supplement|Creatine|
1581878|NCT02370212|Dietary Supplement|Placebo|
1581879|NCT02370212|Other|High intensity interval training|
1581880|NCT02370199|Device|670 nm light|670 nm light emitting diode will be placed 1 cm above the gastrocnemius muscle. The diode will not be in direct contact with the skin. Subjects will be exposed to 75 mW/cm2.
1581881|NCT02370199|Drug|octafluropropane|Octofluoropropane will be administered as a continuous infusion prior to the initiation of 670 nm light in order to measure skeletal muscle blood flow.
1581882|NCT02370173|Device|PTSD wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning.
1581883|NCT02370173|Device|PTSD wavelength-2 bright light|6 weeks daily light exposure, 30 minutes per morning.
1581884|NCT02370160|Biological|DT2219ARL|DT2219ARL at assigned dose IV on day 1, 3, 5, 8 and day 15, 17, 19, and 22. Up to 2 additional courses of DT2219ARL may be given until disease progression and/or unacceptable toxicity.
1581885|NCT02370147|Behavioral|Smoking reduction intervention|Smokers was informed that many harmful effects were proved to be related with smoking, such as cancer, coronary heart disease, respiratory disease and many other health problems, and one out of two smokers will be killed by smoking. Smokers will be advised to reduce smoking consumption for at least half of their total consumption in the next month. Finally, all smokers were warned to keep in mind that the current attempt to reduce smoking is an intermediate step before the complete cessation.
1581886|NCT02370147|Behavioral|Exercise and diet advice control|Smokers will be asked to do regular activities for three or four times per week, and to have a healthy and balanced diet, having more fruit and vegetables which are rich in vitamins, high in nutrition yet low in calories. In the whole process, advises will not refer to smoking cessation or smoking reduction.
1581887|NCT02370134|Device|Parkinson's glove|Parkinson's glove had module for detection tremor by gyroscope/acceleroscope and suppression rest hand tremor with electrical muscle stimulation
1581888|NCT02370134|Device|sham glove|
1581889|NCT02370121|Drug|Placebo|Capsules of 300 mg two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
1581890|NCT02370121|Drug|Gymnema Sylvestre|Capsules of 300 mg of calcined magnesium two times per day before breakfast and dinner a total dose of 600 mg per day. During 90 days.
1581891|NCT02370108|Device|electrical muscle stimulation|electrical muscle stimulation at hand muscle for reduction tremor
1581892|NCT02370095|Drug|Treprostinil Inhalation Solution|Treprostinil inhalation solution administered as blinded marketed product
1581893|NCT02370095|Drug|Placebo|Supplied by the manufacturer and similar to the active drug but containing no Treprostinil
1581894|NCT02370082|Device|Localization of breast lesion|localization of breast lesion for removal
1581895|NCT02370069|Biological|Prevnar 13|One dose of 0.5 mL Prevnar 13 injected intramuscularly into the deltoid muscle on Day 0.
1581896|NCT02370056|Diagnostic Test|3-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 3D mode
1581897|NCT02370056|Diagnostic Test|2-dimensional visualization|Subjects are receiving Standard of Care Colectomy for Ulcerative Colitis visualized in 2D mode
1994587|NCT02970435|Behavioral|Telecommunication Reminders|Telecommunication reminders including text messages, email, or phone calls to remind participants how to access the video discharge instruction up to three times before follow-up
2008633|NCT03328572|Other|E-max Endocrown|Endocrown preparation
1581901|NCT02370030|Dietary Supplement|Citrulline malate|Active comparator: 10 g/day citrulline malate during 7 days
1581902|NCT02370017|Biological|ANKL(Ex vivo-expanded NK cell enriched lymphocytes)|add ANKL in 3rd and 4th course in case of stable response after two initial courses
2008634|NCT03328572|Other|Cerasmart Endocrown|Endocrown preparation
1581904|NCT02369991|Procedure|Reconstructive surgery|Patients were treated with free latissimus dorsi flap and bone transport technique
1581905|NCT02369978|Drug|Nifurtimox|Full dose: 8 mg/Kg/day, assuming an average weight of 60 Kg: 240 mg B.I.D Half-dose: 120 mg B.I.D
1581906|NCT02369978|Drug|Benznidazole|Full dose: 5 mg/Kg/day, assuming an average weight of 60 Kg: 150 mg B.I.D Half dose: 75 mg B.I.D
1581907|NCT02369978|Drug|Placebo|Two capsules of matching placebo (contaning Magnesium stearate and cellulose) B.I.D
1581908|NCT02369965|Drug|albuvirtide|albuvirtide 320mg administered intravenously once a week
1581909|NCT02369965|Drug|lopinavir-ritonavir|lopinavir-ritonavir 400/100mg administered orally twice daily
1581910|NCT02369965|Drug|tenofovir|tenofovir 300mg administered orally once daily
1581911|NCT02369965|Drug|lamivudine|lamivudine 300mg administered orally once daily
1581912|NCT02369939|Radiation|Irradiation|Radiotherapy 55,8 Gy - 59,4 Gy
1581913|NCT02369939|Drug|Mitomycin C|MMC w1, w5
1581914|NCT02369939|Drug|5-Fluorouracil|5-FU w1, w5
1581915|NCT02369939|Procedure|Hyperthermia|6x deep regional hyperthermia
2008635|NCT03328559|Diagnostic Test|ISET® - Isolation by Size of Tumor cells|early stage bronchial cancer patient will have a blood collection
2008636|NCT03328559|Diagnostic Test|ISET® - Isolation by Size of Tumor cells|advanced stage bronchial cancer patient will have a blood collection
1581918|NCT02369913|Other|Blood Drawn|Both groups will have 1 teaspoon of blood drawn for analysis.
1581919|NCT02369900|Drug|Esmolol|
1581920|NCT02369900|Other|Saline|
1581921|NCT02369874|Drug|MEDI4736|MEDI4736 Monotherapy
1581922|NCT02369874|Drug|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
1581923|NCT02369874|Drug|Standard of Care|Standard of Care
1581924|NCT02369861|Drug|ACCS|Topical ocular application 4 times per day
1581925|NCT02369861|Drug|Refresh Lubricant Eye Drops|Topical ocular application 4 timer per day
2008637|NCT03328546|Other|Dietary intake|Dietary intake converted into dietary pattern scores.
1581927|NCT02369835|Drug|Dakin's solution|Apply modified Dakin's solution (0.005%) topically
1581928|NCT02369835|Other|Placebo|Applied topically
1581929|NCT02369835|Other|Questionnaire Administration|Ancillary studies
1581930|NCT02369822|Dietary Supplement|Vitamin C|those who are 2-3 years will receive 400 mg/day, 4-8 years will receive 500 mg/day, those who are 9-13 years will receive 1000 mg/day, and from 14-16 years will receive 1500 mg/day
1581931|NCT02369809|Drug|Neovasculgen®|Treatment according to routine clinical practice at the discretion of the treating physician. Patients receive two local intramuscular injections of Neovasculgen® at a course dose of 2.4 mg according to the summary of product characteristics (SmPC).
1581932|NCT02369796|Drug|TAK-448|TAK-448 solution for subcutaneous injection
1581933|NCT02369783|Other|Questionnaire and interview|The aim is to detect social fragility.
1581934|NCT02369770|Device|IntelliStretch rehabilitation robot|A portable rehabilitation robot will be used to move the impaired joint back and forth and the subject is asked to relax during the movement. The subject will also be asked to move the joint back and forth with the robot.
1581935|NCT02369757|Behavioral|Navigator intervention|peers sharing common characteristics with the target population whose mission is to accompany towards OCCS
1581936|NCT02369744|Drug|Silodosin|8mg tablet, 1 tab PO daily for 2 weeks
1581937|NCT02369744|Drug|Tamsulosin|0.4 mg Tab, 1 tab PO daily for 2 weeks
1581938|NCT02369731|Drug|Translarna|
1581939|NCT02369718|Other|Listening to 12 Fournier's lists of words|Patients will listen to words from Fournier's lists of words in presence of noise presented at different Signal to Noise Ratio (SNR). 6 disyllable words Fournier's lists are presented to the implantees: SNRs ranged from 0 to 15 decibels (dBs) (0; 3; 6; 9; 12; 15) ; the subjects repeat orally the words. Then microphone is cleaned and, again, 6 Fournier's lists are presented.
1581940|NCT02369718|Other|Listening to 48 Fournier's lists of words|48 disyllable Fournier's lists of words are presented to the subjects (6 SNR*2 coding strategies*4 dirtying levels) and the subjects repeat orally the words. Dirtying levels will be simulated by sounds effects.
1581941|NCT02369692|Device|Magellan Robotic 6 Fr Catheter|The Hansen Medical Magellan™ Robotic Catheter 6 Fr (Magellan™)
1581942|NCT02369679|Device|Precast Adjustable Compression Wrap (Circaid)|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the precast adjustable compression wrap to the patient. The patient would maintain the precast adjustable compression wrap until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.
After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
1581943|NCT02369679|Device|Multilayer Compression Bandages|"A physiotherapist well trained in lymphedema treatment will apply a lymphatic drainage to the affected upper limb. Then the physiotherapist will apply the multilayer bandage to the patient. The patient would maintain the multilayer compression bandage until the next session of treatment. The first 10 sessions will be daily from Monday to Friday.
After the 10 first sessions, the treatment will be applied on alternate days (3 per week) until the patient receive a tailored compression garment (7-14 days)."
1581944|NCT02369666|Dietary Supplement|LycoRed (code 40051) product|Mixture of tomato lycopene and carotenoids.
2008638|NCT03328533|Drug|Phenylephrine|Phenylephrine variable infusion with a starting rate of 0.75 mcg/Kg/min.
2008639|NCT03328533|Drug|Norepinephrine|Norepinephrine variable infusion with a starting rate of 0.1 mcg/Kg/min.
2008640|NCT03328533|Drug|Bupivacaine|Bupivacaine will be injected in the subarachnoid space with a dose of 10 mg.
2008641|NCT03328520|Behavioral|WILD 5 Wellness Intervention|"Behaviors in 6 areas of wellness: Sleep, Social Connectedness, Exercise, Nutrition, Mindfulness and HERO (Happiness, Enthusiasm, Resilience, Optimism)"
2008642|NCT03328507|Drug|BLI4900|BLI4900 Bowel Preparation
1581948|NCT02369640|Procedure|Error-management training vs error-avoidance training. Defined by training instructions.|". Error-avoidance training: The participants are instructed to follow the simulator program step-by-step, to achieve the highest possible simulator metric scores by making as few errors as possible, and only to follow the task required in the training program.
Study group 2. Error-management training: The participants are required to complete the same training program as study group 1. The participants are instructed to experiment and explore on their own and to deliberately make errors during the task that they are instructed to perform. Participants are instructed to reflect on their errors based on the simulator metrics that they do not pass. Errors are framed as positive events and instructor comments may include statements such as the more errors you make, the more you learn! or you have made an error? Great! Because now you can learn something new!"
2008643|NCT03328507|Drug|PEG Control|Polyethylene glycol-based bowel preparation
2008644|NCT03328494|Drug|BOS172722|Oral capsules
2008645|NCT03328494|Drug|Paclitaxel|IV infusion
1581952|NCT02369614|Other|Active Comparator: 1 Hz rTMS|1 Hz rTMS
1581953|NCT02369614|Other|Active Comparator: 10 Hz rTMS|10 Hz rTMS
1581954|NCT02369614|Other|Sham Comparator:|Sham rTMS
1581955|NCT02369601|Other|non- intervention study|Study design is non-interventional. Patient therapy will not be affected by study participation.
1581956|NCT02369588|Other|Food portion size|
1581957|NCT02369575|Other|novel biomarkers of lung disease|we will be identifying molecular, genetic, and cellular markers of lung disease
1581958|NCT02369562|Procedure|Evaluation of the failure rate of dental implants|Evaluation of the failure rate of dental implants, from the time of implant insertion (any time between 1980 and August 31st 2014) until September 2015
1581959|NCT02369549|Drug|Micro-particle Curcumin|as described in Arm
1581960|NCT02369549|Drug|Placebo|Looks, smells, tastes and feels exactly like the Curcumin capsules.
1581961|NCT02369536|Dietary Supplement|nutraceutical mixture|Lifestyle counseling, administration of a nutraceutical mixture: fish oil 70% DHA (docosahexaenoic acid), phosphatidylcholine concentrated in sunflower oil, silymarin, choline bitartrate, curcumin, D-α-tocopherol; choline (82,5 mg, corresponding to 15% of the average intake of 550 mg per day in an adult man)
1581962|NCT02369536|Dietary Supplement|placebo|Lifestyle counseling, administration of a placebo, containing only choline, at the same low concentration of the active mixture
1581963|NCT02369523|Drug|Exparel|Mixture of 50 mL of 0.25% Bupivacaine with epinephrine, 40 mL of sterile saline and 20 mL of Exparel®.
1581964|NCT02369523|Drug|Ropivacaine cocktail (PIC)|400 mg Ropivacaine, 5 mg morphine, and 0.4 mg epinephrine in 100 cc solution
1581965|NCT02369523|Drug|Bupivacaine|"Continuous Femoral Nerve Block- 0.25% Bupivacaine at a rate of 5 ml/hour for 48 Hours.
Sciatic nerve block - 0.125% bupivacaine"
1581966|NCT02369510|Drug|Low-dose epinephrine|0.1ml of preservative-free saline and 0.1ml of 1:1000 epinephrine will be added to the standard spinal medications
1581967|NCT02369510|Drug|High-dose epinephrine|0.2ml of 1:1000 epinephrine will be added to the standard spinal medications
1581968|NCT02369510|Drug|No epinephrine|0.2ml of preservative-free saline will be added to the standard spinal medications
1581969|NCT02369497|Device|HRA|Humeral head resurfacing with the HRA device
1581970|NCT02369484|Drug|Afatinib|40mg p.o./ day until documented progression or unacceptable toxicity
1581971|NCT02369471|Drug|GWP42006|
1581972|NCT02369471|Drug|Placebo|
1581973|NCT02369458|Drug|Mitomycin-C|
1581974|NCT02369458|Drug|Pegfilgrastim|
2008646|NCT03328481|Procedure|Loss-of-resistance Quadratus lumborum block|"ِA blunted 22-G, 11 mm, short-bevel facet needle will be connected to a syringe. The needle will be introduced in the paravertebral line at the level of L3 or L4, in 30-45 degree to the skin directing it laterally. Once the skin barrier is breached, the needle will be withdrawn back so that the tip lies just under the skin. The needle will be advanced through the posterior thoracolumbar fascia and a first fast pop sensation will be felt when the needle pierced it. With further advancement of the needle, a second deep pop will be felt after it pierces the middle thoracolumbar fascia. At this point, the needle will be in the plane of the quadratus lumborum block type II. After careful aspiration, the 30 mLs of local anaesthetic will be injected."
1581978|NCT02369419|Other|Frailty|CRT device is implanted in all patients selected for the study. Frailty is evaluated before implant and defined as <14/17 points using the ONCODAGE score
1581979|NCT02369406|Drug|Nevirapine|
1581980|NCT02369406|Drug|Kaletra|
1581981|NCT02369406|Drug|Lamivudine|
1581982|NCT02369406|Drug|Zidovudine|
1581985|NCT02369380|Device|Hyaluronic acid|Injections of Hyaluronic acid under the metatarsal heads
1581986|NCT02369367|Drug|Irinotecan|200 mg/m^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
1581987|NCT02369367|Drug|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
1582064|NCT02368691|Drug|GTx-024|GTx-024 softgel capsules will be administered once-daily to a total dose of 18 mg
1582133|NCT02368080|Device|"Comparison of two MBWN2 devices : EasyOne Pro Lab versus Exhalyzer D"|Healthy and Cystic Fibrosis participants will perform the same day MBWN2 tests in duplicate with each device.
1994588|NCT02970435|Behavioral|Standard of Care|Standard of Care: verbal and written discharge instructions for patients after surgery
1994589|NCT02971033|Drug|20mg ezetimibe|Participants assigned to this intervention will receive 20mg per day of ezetimibe for 12 weeks.
1994590|NCT02971033|Drug|Placebo|Participants assigned to this intervention will receive placebo every day for 12 weeks
1994591|NCT02971033|Drug|40mg ezetimibe|Participants assigned to this intervention will receive 40mg per day of ezetimibe for 12 weeks.
1994592|NCT02970032|Drug|Real time heparin dose adjustment|Patients will have steady state anti-Xa levels drawn at least 6 hours after initiation of heparin infusion. Patients with out of range anti-Xa levels will receive real time heparin dose adjustment followed by repeat anti-Xa levels.
1994593|NCT02970032|Drug|Standard heparin dose|Patients will be placed on heparin infusions per their surgeon's discretion.
1994598|NCT02968420|Biological|Human Papillomavirus 9-valent Vaccine, Recombinant|All groups will receive a single dose of the Gardasil9 vaccine at Visit 1/Day 0 of the study.
1581988|NCT02369354|Behavioral|TALKS Social Worker Intervention|TALKS includes a video and book that describe patient and family experiences with talking about and considering live kidney transplantation. TALKS also includes a social worker meeting. Potential recipients meet with a transplant social worker for up to 60 minutes to identify potential barriers to considering or pursuing live donor kidney transplantation. They also are invited to have a second meeting with family and/or friends with the social worker for up to 60 minutes.
1581989|NCT02369354|Other|Financial Assistance Intervention|"The financial assistance intervention offers potential donors the ability to draw from a bank of $2100 to reimburse their costs related to being evaluated for live kidney donation or for donating a kidney. Costs include, but are not limited to: child care, travel, time off work, and other out of pocket expenses related to being evaluated to become a live kidney donor or to donating."
1581991|NCT02369328|Device|MULTIMODAL MRI|Multimodal MRI (including perfusion MRI, sodium MRI, resting-state functional MRI, high resolution anatomical MRI) will be carried on at the inclusion, after 24 hours, at 3 months and at 12 months and neurological clinical exam , rankin score, NIHSS
1581992|NCT02369315|Behavioral|Treatment (Invited entry 2012)|Entry to music program offered in September 2012
1581993|NCT02369315|Behavioral|Control (Invited entry 2013)|Entry to music program offered in September 2013
1581994|NCT02369302|Drug|DWC20141|Tablet
1581995|NCT02369302|Drug|DWC20142|Tablet
1581996|NCT02369302|Drug|DWC20141, DWC20142|Tablet
1581997|NCT02369289|Other|bone mineral density test|
1581998|NCT02369276|Other|ultrasonography and elastography|Evaluate the soft tissue of shoulder girdle with musculoskeletal ultrasonography and elastography, compare the finding in each group and the range of motion of their shoulder, the severity of wing scapula, visual pain analog scale and the score of The Disability of Arm, Shoulder and Hand
1581999|NCT02369250|Drug|Rosuvastatin|Rosuvastatin, is a statin group of drug.
1582000|NCT02369250|Biological|platelet rich fibrin|AUTOLOGUS PLATELET GROWTH FACTOR
1582001|NCT02369211|Drug|Acetaminophen (Ofirmev)|
1582002|NCT02369211|Drug|Placebo|
1582003|NCT02369198|Drug|TargomiRs|"TargomiRs are targeted minicells containing a microRNA mimic. They consist of three components: 1. A miR-16-based microRNA mimic. The miR-16 family has been implicated as a tumour suppressor in a range of cancer types. The mimic is a double-stranded, 23 base pair, synthetic RNA molecule. 2. Drug delivery vehicle - EDVs. EDVs are nonliving bacterial minicells (nanoparticles). They function as leak resistant micro-reservoir carriers that allow efficient packaging of a range of different drugs, proteins or nucleic acids. 3. Targeting moiety. The EDVs are targeted to EGFR-expressing cancer cells with an anti-EGFR bispecific antibody.
TargomiRs are IV injected."
1582004|NCT02369172|Drug|Bupropion|
1582005|NCT02369172|Drug|ASP2151|
1582006|NCT02369159|Drug|Peramivir|
1582007|NCT02369159|Drug|Oseltamivir|
1582009|NCT02369133|Drug|paracetamol|Drugs were given intravenously by a nurse unaware of the study 15 min before surgery. Patients in group P (n = 30) received 1 g iv paracetamol, patients in group S (n = 30) received 100 ml iv %0.9 NaCl
1582010|NCT02369133|Drug|Placebo|
1582011|NCT02369120|Other|Educational intervention|The internet platform will provide patients with customized tasks that allow them to use the metaphor of the journey (the narrative as a dynamic of the game) to feel that they manage their own path, which will change negative perceptions into positive perceptions about certain actions. At all times, the patients will be able to choose among different information sources, such as videos about the origin of chronic pain, 3D representations of different neurophysiological processes, and FAQs. Additionally, the patients will be able to contact a specialist in the neurophysiology of pain by email or videoconference. Furthermore, to reinforce patients' motivation and participation, gamification techniques will be implemented.
1582012|NCT02369120|Other|Normal care by GP|Patients will follow GP advice including NSAID medication if needed
1582013|NCT02369107|Other|Verum acupuncture and medicine|Participants will receive acupuncture therapy 1 hour prior to chemotherapy administration ，6 hours after chemotherapy administration，and once acupuncture therapy on the following day2,3,4,5. The stimulation points are RN12,LR13(bilaterally), RN6, ST25(bilaterally), PC6(bilaterally), ST36(bilaterally). The acupuncture needle in ST36 and auxiliary point will be connected to form a circuit containing a SDZ-V stimulator for 30 min with a frequency of 2/100 Hz. They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
1582014|NCT02369107|Other|Sham acupuncture and medicine|Participants will receive minimal acupuncture therapy at the same time as the intervention group .The stimulation points are not belong to traditional Chinese medicine.They will receive 8mg Ondansetron Intravenously twice a day during the chemotherapy administration period (5 days in total).
1582015|NCT02369094|Other|acupressure|A 15 minutes structured acupressure protocol with specific acupoints and applications technique will be performed on the elderly participants twice a week by the research team in YCHSS centers. The caregiver of the elderly will be trained and perform the same acupressure protocol on the elderly at 2 additional occasions during the week. The total trial period is 12 weeks.
1582016|NCT02369081|Drug|Spironolactone|Spironolactone 25mg tablet orally once daily for 6 weeks, followed by Spironolactone 50mg tablet orally once daily for a further 6 weeks.
1582017|NCT02369081|Drug|Bisoprolol|Bisoprolol 5mg tablet orally once each day for 6 weeks, followed by Bisoprolol 10mg tablet orally once each day for a further 6 weeks.
1582018|NCT02369081|Drug|Doxazosin|Doxazosin 4mg tablet orally once daily for 6 weeks, followed by Doxazosin 8mg tablet orally once daily for a further 6 weeks.
1582019|NCT02369081|Drug|Placebo|Placebo treatment for 12 weeks.
1582020|NCT02369068|Drug|Onabotulinumtoxin A|Intravaginal pelvic floor injection one series
1582021|NCT02369068|Drug|Kenalog|Intravaginal pelvic floor injection one series
1582134|NCT02368067|Procedure|Standard of Care Sentinal Node Dye|Delivery of sentinal node dye by different routes
1582136|NCT02368054|Drug|Bupivacaine|Infiltration anesthesia
1582022|NCT02369042|Device|Kyma Device u-Cor System|The Kyma uCor system externally measures thoracic fluid content, heart rate, respiratory rate, posture and movement. The system includes a flat antenna that is attached to the patient's torso with a bandage-like sticker. The antenna transmits radio waves and receives their reflections from the body for several seconds every few hours throughout the day.The data is recorded and collected then compared to traditional clinical parameters.
1582023|NCT02369029|Drug|BAY 1238097|Oral administration twice weekly. Starting dose will be 10 mg per week and dose will be escalated dependent on any dose limiting toxicities.
1582024|NCT02369016|Drug|Copanlisib (BAY 80-6946)|60 mg of experimental drug in solution administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle
1582025|NCT02369003|Procedure|Autologous Peripheral Nerve Graft|Implantation of Autologous Peripheral Nerve Graft into the substantia nigra pars compacta (SNpc) or basal forebrain of participants with PD undergoing deep brain stimulation (DBS) surgery.
1582026|NCT02368977|Device|Third Eye Panoramic device|A Third Eye Panoramic device will be attached to the tip of the colonoscope and will provide two additional views from laterally-oriented video cameras during the colonoscopy procedure.
1582027|NCT02368964|Drug|GnRH agonist 0.2 mg + hCG 250 mcg|Treatment for triggering
1582028|NCT02368964|Drug|high dose hCG 500 mcg|Treatment for triggering
1582029|NCT02368951|Drug|BAY1187982|A dose of 0.1 mg BAY 1187982 per kilogram (kg) body weight (BW) was chosen as the starting dose based on toxicology data. The investigational drug will be administered as a 1-hour IV infusion once every 21 days at the trial site (Day 1 of each 21-day Cycle). The maximum possible dose escalation will be 2-fold and not more than 0.5 mg/kg BW until maximum tolerated dose is selected
1582030|NCT02368925|Device|Ultherapy™ System|The Investigator will apply to the eligible subject the Study Device Ultherapy™ System with 200~260 lines of 3.0 and 4.5 probe respectively on the subject's neck.
1582031|NCT02368912|Drug|ASP1707 single dose of dose levels 1 -7|Oral, dose escalation
1582032|NCT02368912|Drug|Placebo single dose of dose levels 1-7|Oral, dose escalation, healthy young male
1582033|NCT02368912|Drug|ASP1707 single dose fasted|Oral, healthy young male
1582034|NCT02368912|Drug|ASP1707 single dose fed|Oral, healthy young male
1582035|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
1582036|NCT02368912|Drug|Placebo multiple dose of dose levels 1-4|Oral, multiple dose escalation, healthy elderly male
1582037|NCT02368912|Drug|ASP1707 multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
1582038|NCT02368912|Drug|Placebo multiple dose of dose levels 1-2|Oral, multiple dose escalation, healthy pre-menopausal female
1582039|NCT02368912|Drug|ASP1707 parallel multiple dose of dose levels 1-3|Oral, multiple dose, healthy pre-menopausal female
1582040|NCT02368912|Drug|Placebo parallel multiple dose|Oral, dose escalation, healthy pre-menopausal female
1582041|NCT02368899|Other|Computerized Alcohol Misuse Intervention|Interventionaire© is a computerized alcohol misuse intervention that includes a normative feedback component unique in its micro-targeting of alcohol use feedback based on participant demographic characteristics (race/ethnicity, gender, and age), drawing population normative data from the National Surveys on Drug Use and Health. This represents a novel use of epidemiological data to inform clinical services.
1582042|NCT02368899|Other|Attention Control (AC)|These products are designed for entertainment and educational purposes only. No medical claims are made for them and, the participant's interaction with them should be conceptually unrelated to alcohol use behavior.In order to avoid any carryover effect from comparing two active treatments, we have chosen to use a simple attention control condition that is not expected to exert any real intervention effect. In that way, the effect size estimate of the intervention can be readily calculated. No research data will be collected as part of the AC, beyond the amount of time spent on the program.
1582043|NCT02368886|Drug|Clobetasol Propionate|Given topically
1582044|NCT02368886|Other|Pharmacological Study|Correlative studies
1582045|NCT02368886|Other|Quality-of-Life Assessment|Ancillary studies
1582046|NCT02368886|Drug|Regorafenib|Given PO
1582047|NCT02368873|Procedure|Application of IPOM mesh|
1582048|NCT02368860|Drug|oxaliplatin, irinotecan, capecitabine|fixed doses of intravenous oxaliplatin 50 mg/m2, and intravenous irinotecan administered on days 1 and 8 in a 21 day-cycle while xeloda will be administered daily at around midnight from day 1 to day 14
1582049|NCT02368847|Device|Diagnostic tests|C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine C Reactive Protein level in the blood
1582050|NCT02368847|Device|Diagnostic tests|Uricult dipslide: Easy-to-perform bacterial culture test for dectecting urinary tract infections in point of care settings
1582051|NCT02368834|Behavioral|psychoeducation|The intervention included a presentation by a psychiatrist, with parent manual provided, and then two group sessions at the 2nd and 4th weeks to address further concerns of the parents
1582052|NCT02368808|Behavioral|Abangane Support Group|The Abangane support group program consists of 8 sessions for bereaved adolescents with standardized activities and discussion content based the Khululeka Grief Support Program in Cape Town, South Africa. The materials include a resource book that provides training and referral agencies for grief group facilitators as well as exercises and creative activities designed to stimulate group discussions that will help adolescents to deal with loss and grief.
1582053|NCT02368795|Device|Pancreatic Stent|A 5-Fr, 4-cm-long stent (Endoflex) with a single duodenal pigtail is used for pancreatic duct stenting
1582054|NCT02368795|Drug|Indomethacin|Indomethacin 100 mg suppository ten minutes before ERCP
1582055|NCT02368795|Drug|Isosorbide Dinitrate|Sublingual Isosorbide dinitrate 5 mg before ERCP
1582056|NCT02368795|Drug|Ringer's lactate|IV Ringer's lactate serum with a dose of 6 cc/kg/h during the procedure and 20 cc/kg after ERCP as a bolus dose and 3 cc/kg/h for the next 8 hours.
1582057|NCT02368769|Device|During Tele-expertise|
1582058|NCT02368756|Drug|Aflibercept|A 2mg dose of intravitreal Aflibercept given as needed with possible laser until end of protocol.
1582060|NCT02368730|Drug|desmopressin|
1582063|NCT02368704|Other|No intervention|
1582065|NCT02368678|Procedure|Scaling and Root Planning (SRP)|"Scaling and Root Planing (n=15): quadrant-wise scaling and root planing performed within four weekly session (30 min. per quadrant).
Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.
Oral hygiene instructions were given to all participants."
1582066|NCT02368678|Procedure|Full Mouth Scaling (FMS)|"Full Mouth Scaling (n=15): scaling and root planning was performed in a single stage (within 24 hours); two sessions (60 min. per session) in two consecutive days.
Oral malodor was measured by organoleptic test and Oral Chroma (Abilit, Osaka Japan) prior to the oral examination, at Baseline and also at 90 days after treatment. Clinical monitoring and tongue coating index were taken at these same times.
Oral hygiene instructions were given to all participants."
1582067|NCT02368665|Drug|Amlodipine 5mg|- Daily oral administration for 8 weeks
1582068|NCT02368665|Drug|Amlodipine 5mg, Candesartan cilexetil 16mg|- Daily oral administration Amlodipine 5mg for 8 weeks
1582069|NCT02368665|Drug|Amlodipine 10mg, Candesartan cilexetil 16mg|- After 8 weeks of administration, Amlodipine 10mg and Candesartan cilexetil 16mg once a day for 8 weeks
1582070|NCT02368652|Drug|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
1582071|NCT02368652|Drug|Amlodipine 10mg, Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
1582072|NCT02368639|Device|Fisher & Paykel Healthcare PAP Device|The device is a modified version of the Fisher & Paykel Icon continuous positive airway pressure (CPAP) device, which is a fully released product in New Zealand.
1582073|NCT02368626|Device|EndyMed Pro™ RF Micro-Needles|RF Micro-needles ablation treatments
1582074|NCT02368613|Drug|DW-3102|
1582075|NCT02368600|Behavioral|Lifestyle modification program|On top of the usual care, subjects in the intervention will receive a lifestyle intervention that will be delivered by experienced registered dietitian and exercise specialist. There will be 5 face-to-face dietitian consultations, 2 telephone dietitian consultations and at least one face-to-face exercise specialist consultation. The exercise consultation will be normally scheduled on the same day of the face-to-face dietitian consultation.
1582076|NCT02368587|Biological|WJMSCs Vs. placebo|WJMSCs Vs. placebo
1582077|NCT02368587|Biological|Placebo|WJMSCs Vs. placebo
1582078|NCT02368574|Procedure|Class II hysterectomy|Class II hysterectomy
1582079|NCT02368561|Drug|"Injection of Hyaluronic Acid - SYNVISC (hylan G-F 20)"|US guided weekly injection of sodium hyaluronate administered for 3 week in adult subjects with insertional achilles tendinopathy
1582080|NCT02368548|Other|Pharmaceutical Care Program|Intensive pharmaceutical care program, initiated in the emergency department, as described in its corresponding arm intervention description.
1582081|NCT02368548|Other|Standard Care|Standard pharmaceutical care process, initiated at the hospital admission, as described in its corresponding arm intervention description.
1582084|NCT02368496|Device|HR-pQCT|
1582085|NCT02368483|Other|Neuromuscular training|Neuromuscular training for the hip and lower limb muscles.The training program is divided into 3 phases, and includes specific exercises for improving the hip range of motion, muscle strength of the hip and lower limb muscles, as well as the trunk stability and coordination. The intervention lasts 12 weeks. Patients will train 2 times/week with a physical therapist and 2 times/weeks alone at home.
1582086|NCT02368470|Drug|Gemifloxacin-based triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and gemifloxacin (Factive®, LG Life Sciences, Ltd, Seoul, Korea) 320 mg once daily for 7 days
1582087|NCT02368470|Drug|Standard triple therapy|Rabeprazole (Rabiet®, ildong pharmaceutical Co. Ltd., Seoul, Korea) 20 mg twice daily, amoxicillin (Pamoxin®, Dongwha Co. Ltd., Seoul, Korea) 1 g twice daily, and clarithromycin (Klaricid®, Abbot Korea Co. Ltd., Seoul, Korea) 500 mg twice daily for 7 days
1582088|NCT02368457|Drug|Pentoxifylline and Tocopherol|pentoxifylline with tocopherol Pentoxifylline 800 mg/day, oral (1cp 400 mg twice a day) + Vitamin E (alfa-tocopherol) 1000 UI/day, oral (1cp 400UI twice a day + 1cp200UI once a day) during 24 months (maximum).
1582089|NCT02368444|Behavioral|Cognitive Behavioral Therapy and Yoga|Group Cognitive Behavioral Therapy Treatment and Yoga Program
1582092|NCT02368418|Procedure|PCP|PCP is short for the standard disease management program of individuals at high risk of cardiovascular disease delivered by Primary Care Providers (village doctors).
1582093|NCT02368418|Procedure|SRS|SRS is short for a community-based Salt Reduction program delivered by community health educators.
1582094|NCT02368405|Behavioral|Control|Participants in the control group will receive the standard nutrition lecture currently given at Carolinas Rehabilitation to all inpatients with spinal cord injuries. This one lecture is what is required by Commission on Accreditation for Rehabilitation Facilities (CARF)
1582095|NCT02368405|Behavioral|Eat Right, Live Better|Intervention participants will participate a series of six, 60-minute small group sessions of interactive nutrition education discussions led by a Registered Dietitian delivered over 3 weeks. They will also have one follow-up comprehensive nutrition education session approximately 3 months after receipt of the Eat Smart, Live Better curriculum. In order to help us assess the effectiveness of the nutrition education program, we will assess nutrition behavior and knowledge at this time as well. Community participants in the treatment group will attend the sessions at Carolinas Rehabilitation (CR). The control participants from the community will come to CR for the one standard nutrition lecture. Caregivers and spouses of all of the participants will be encouraged to attend the sessions.
1582096|NCT02368392|Other|Exposure for cardiac arrests|There is no particular intervention. This study merely observes the occurrence of cardiac arrests
1582097|NCT02368379|Other|Low dose (1 mcg) ACTH stimulation test|Subjects will have baseline cortisol and ACTH drawn followed by administration of 1 mcg/m2 (max 1 mcg) of cortrosyn. Blood will be drawn at 20 and 40 minutes post cortrosyn for peak cortisol assessment of central adrenal insufficiency.
1582135|NCT02368067|Procedure|Study Sentinal Node Dye|Patients will receive different types of dye by different routes of administration
1582098|NCT02368379|Other|Overnight metyrapone test|Subjects will receive metyrapone 30 mg/kg (max 3 grams) by mouth at midnight. Blood will be drawn at 0800 AM the following morning for ACTH, cortisol and 11 deoxycortisol for assessment of central adrenal insufficiency.
2008647|NCT03328481|Procedure|Ultrasound-guided Quadratus lumborum block|A broadband (5-8 MHz) convex transducer will be placed transversely in the abdominal flank above the iliac crest to identify the external oblique, internal oblique, transversus abdominis muscles and aponeurosis. Then the external oblique muscle will be followed posteriorly until its posterior border is visualized (hook sign), and the posterior aspect of the Quadratus lumborum muscle is confirmed. A 22-G, 11-mm, short-bevel facet needle will be advanced under direct ultrasound visualization in-plane from anterolateral to postero-medial. Then the 30 ml of local anesthetic (bupivacaine 0.25 %) will be injected into the lumbar inter-facial triangle (LIFT) behind the quadratus lumborum muscle using hydro-dissection.
2008648|NCT03328481|Procedure|General anesthesia|Patients will receive 2 mg of midazolam and 8 mg of dexamethasone IV; then, they will be transferred to the operating room to receive a standard general anesthetic. Perioperative monitoring will include ECG, non-invasive arterial blood pressure, and pulse oximetry (SpO2) and end-tidal carbon dioxide. Anesthesia will be induced by propofol 1.5-2.5 mg/kg, atracurium 0.5 mg/kg, and fentanyl 2 mcg/kg to facilitate the insertion of an endotracheal tube. Anesthesia will be maintained by isoflurane 1-2% end-tidal concentration to maintain systolic arterial blood pressure and heart rate within + 20% of the baseline values. Ventilation will be adjusted to maintain normocapnia.
2008649|NCT03328468|Other|Breathing Exercise|Breathing exercise for stroke patients
2008650|NCT03328299|Drug|Dexmedetomidine|20 ml of 0.5 % bupivacaine plus dexmedetomidine 1 μg•kg-1
2008651|NCT03328299|Drug|bupivacaine|20 ml of 0.5 % bupivacaine
1582104|NCT02368340|Other|Pulmonary function test|Pulmonary function testing performed
1582105|NCT02368340|Other|Chest CT|Chest CT scan to evaluate for pulmonary fibrosis
1582106|NCT02368340|Other|Sample collection|Blood and urine sample collections
1582107|NCT02368327|Biological|Fluad|
1582108|NCT02368327|Biological|Fendrix|
1582109|NCT02368327|Biological|Placebo|
1582110|NCT02368314|Drug|Sodium Enoxaparine|30 mg (0,3 ml), subcutaneously, twice a day (every 12 h).
1582111|NCT02368301|Drug|Elotuzumab in combination with Lenalidomide and Dexamethasone|
1582112|NCT02368288|Drug|entecavir|in this group, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 week.
1582113|NCT02368262|Other|Questionnaire and micturition and drinking diaries|"Questionnaire: ICCS parental questionnaire + extended history taking document, ROME III criteria, demographic information and/or PIN-Q.
Diaries: 24-hour voiding chart"
1582114|NCT02368262|Procedure|Uroflowmetry, pelvic floor EMG and bladderscan|Voiding variables, pelvic floor activity during micturition and postmictional residue.
1582115|NCT02368249|Drug|Terlipressin|Patients are receiving a post-operative intravenous terlipressin treatment in association with human albumin to preserve the renal function
1582116|NCT02368249|Drug|Placebo|Patients are receiving a post-operative intravenous Ringer's lactate solution
1582117|NCT02368236|Behavioral|Tailored Printout|The Cancer Risk Intake System (CRIS) is a tablet-based program through which patients answer detailed questions about their colorectal cancer risk prior to an appointment. Tailoring algorithms in CRIS generate printed information for patients and their physicians summarizing their risk factors and matching them with guideline-based screening options.
1582118|NCT02368223|Device|YouGrabber|2 weeks of home-based therapy with a virtual-reality enhanced upper limb training system
1582119|NCT02368210|Drug|122-0551 Foam|Topical Foam
1582120|NCT02368210|Drug|Vehicle Foam|Topical Foam
1582121|NCT02368197|Drug|paclitaxel (Cardionovum Legflow drug eluting balloon)|Elution of paclitaxel from inflated balloon catheter into vessel wall
1582122|NCT02368197|Device|Balloon angioplasty (Bard Dorado)|Dilatation of cephalic arch venous stenosis by radial force applied by a balloon catheter
1582123|NCT02368171|Other|measure exhaled carbon monoxide and nitric oxide|
1582124|NCT02368158|Other|Driving simulation with elevation of medical data in comparison to Lane Change Test plus automotive monitoring via contactless sensors|During a driving simulation medical data are elevated such as electrocardiography (ECG), heart rate breathing rate and oxygen saturation and compared to data of the performed Lane Change Test as a measurement for the quality of driving. Hereby the deviation of the lane from baseline during driving and ordered lane change via signs are determined also when performing cognitive and visual tasks. Also the simulation is simultaneously accompanied by monitoring via contactless camera usage in regard to possible determination of heart and breathing rate according to Eulerian Magnification Method
1582125|NCT02368132|Behavioral|Group Delivered TEP|All TEP modules will be in a group format. Each call will take 1.5-2 hours. Each group will be comprised of 5-8 CGs who will call into a teleconference line at a pre-specified time. Groups will include spouse/partner-only or adult child-only CGs. The content of the calls will mirror those in the individual TEP delivered program. In addition to the group calls, they will receive individual care management.
1582126|NCT02368132|Behavioral|Individual Delivered TEP|Two mandatory modules that cover the stages of dementia and provide a brief introduction to problem solving techniques, action plan development, and coping skills, plus a menu of additional modules covering various content areas evaluated during the course of the monthly assessments (e.g., communication skills, behavioral management techniques, stress management and coping skills, longterm planning, etc.). Each individual TEP session will begin with reviewing education related to the selected module. The remainder of each session will involve coaching the caregiver on emotion-focused and problem focused coping strategies. The care manager will also discuss problem solving with the CG to reinforce the action plan and the educational component of the intervention.
2008652|NCT03328442|Procedure|VISTA with PRF membrane|VISTA with PRF membrane includesTreatment of recession class I and II using autologous PRF membrane
2008653|NCT03328429|Other|Cystectomy|Bartholin cyst will be excised
2008654|NCT03328429|Other|Marsupialisation|Bartholin gland will be marsupialised
1582131|NCT02368106|Radiation|Radiation Therapy|targeted radiation treatment
1582132|NCT02368093|Drug|Dextromethorphan hydrobromide|120mg per day with once daily dose taken after breakfast for 6 months
1582137|NCT02368054|Drug|Adrenaline|Infiltration anesthesia
1582138|NCT02368041|Device|InSpectraTM StO2 monitor|InSpectraTM StO2 monitor manufactured by Hutchinson Technology INC. to measure the baseline StO2 level after applying the noninvasive probe to the thenar eminence. After a stable reading is obtained a blood pressure cuff will be inflated 40 mmHg above the obtained systolic pressure and the rate of desaturation (Rdes; % × sec-1) will be recorded. After 3 minutes or once the StO2 level comes to zero, whichever is earlier the cuff pressure will be released instantaneously and the rate of reperfusion (Rres; % × sec-1) will be measured. The measurement will be continued until the StO2 returns to the baseline value.
1582139|NCT02368028|Other|Oral Samples|Oral samples of saliva, dental plaque and DNA will be collected between the two groups.
1582140|NCT02368015|Other|Peripheral intravenous cannula (IVC)|Blood samples will be withdrawn prior, during and after the procedure using an additional peripheral intravenous cannula (IVC).
1582141|NCT02368015|Drug|cefazolin|
1582142|NCT02368002|Behavioral|Behavioral weight loss therapy|All participants start with behavioral weight loss therapy which consists of 20 weekly meetings wtih a weight loss coach. Session components will include weekly weigh-in, discussion of progress and challenges and discussion of scheduled session topic. Dietary goals and physical activity goals are set. After their first session, participants are randomized to have their weight assessed at either their 3rd session or their 7th session. Both the participant and their coach are blinded to the randomization. If the participant has lost the expected amount of weight, they continue with behavioral weight loss therapy for the full 20 session.
1582143|NCT02368002|Behavioral|Meal replacements|"Participants continue with behavioral weight loss therapy, but this is augmented with meal replacements (MR). Adherence to energy intake goals is facilitated by consuming pre-prepared meals specifically designed to meet caloric intake guidelines. MRs reduce individuals' motivationally- and self-regulatory-dependent planning and decision making around eating. MRs also serve as a teaching tool regarding the amount and type of food people should eat in order to produce weight loss."
1582144|NCT02368002|Behavioral|Enhanced behavioral weight loss therapy|Switching the therapeutic approach to an enhanced behavioral weight loss therapy teaching acceptance based behavioral skills theoretically addresses the root problem of many weight loss challenges and boosts long-term capacity for self-regulation. Acceptance based strategies are designed to help participants identify and internalize values and lasting commitment to behavior consistent with these values. The strategies focus on increasing people's ability to forgo more pleasurable options (e.g., hedonic pleasure of food) in favor of behavior that is distinctly less pleasurable or even aversive (remaining hungry, anxious, bored). The inability to tolerate such distress is directly associated with failure of self-regulation.
1582145|NCT02367989|Dietary Supplement|0g of barley β-glucan|Food containing no barley beta-glucan
1582146|NCT02367989|Dietary Supplement|2g of barley β-glucan|Food containing low amounts of barley beta-glucan
1582147|NCT02367989|Dietary Supplement|4g of barley β-glucan|Food containing high amounts of barley beta-glucan
1582148|NCT02367989|Dietary Supplement|8g of barley β-glucan|Food containing high amounts of barley beta-glucan
1582149|NCT02367976|Drug|rhprouk|rh-prouk will be administrated within 60 minutes after the patients eligibility confirmed
1582150|NCT02367963|Behavioral|Training period|Six workshops in which education on health habits and encouragement to reduce risk factors was promoted. Workshops addressed rigorous, accurate and effective technical information but were tailored to general public to ensure that subjects became aware of the importance of change in their overall health. Workshops led by experts dealt with the following relevant subjects: Motivation to Change; Physical Activity, Healthy Diet, Smoking Cessation; Stress Management and Self-control of Blood Pressure.
1582151|NCT02367963|Behavioral|Peer-group|The ultimate goal is to reinforce the self-accountability in the subjects and nurture their self-care. It is designed to make the subjects participate actively in their healthcare. Through the different activities subjects will begin to successfully make various changes that increase their confidence in the ability to manage risk factors and problems arising from unhealthy habits. Along the twelve sessions (60-90 minutes) subjects propose assumable health goals; learn to manage their emotions, to resolve problems, to control their diet, to increase their physical activity, to control their state of mind and how the acquisition or not of healthy habits influences their relationships.
1582152|NCT02367950|Behavioral|Exercise|10 exercise sessions with a personal trainer
1582153|NCT02367937|Drug|PRC-4016 (icosabutate)|"Midazolam, omeprazole, flurbiprofen and simvastatin interaction with PRC-4016. Detailed description under Study description"
1582154|NCT02367924|Drug|trabectedin|The administration of chemotherapy regimen with trabectedin (according to Summary of Product Characteristics (SmPC)) will be determined by the Investigator's discretion depending on the patients' conditions and previous chemotherapy.
1582155|NCT02367911|Drug|122-0551 Foam|122-0551 Foam applied twice daily to treat psoriasis
1582156|NCT02367911|Drug|Vehicle Foam|Vehicle Foam applied twice daily to treat psoriasis
1582157|NCT02367898|Other|Lumosity Cognitive Training|adaptive online cognitive training
1582158|NCT02367898|Other|Crossword Puzzles|timed online crossword puzzles
1582159|NCT02367885|Drug|TAK-850 0.5 mL injection|TAK-850 injection
1582160|NCT02367885|Drug|TAK-850 0.25 mL injection|TAK-850 intramuscular injection
1582161|NCT02367872|Drug|TAK-272|TAK-272 tablet
1582162|NCT02367859|Drug|Dabrafenib|Given PO
1582163|NCT02367859|Other|Laboratory Biomarker Analysis|Correlative studies
1582164|NCT02367846|Drug|Combined Oral Contraceptive (COC)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of COC use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive COC during either the first or second intervention period.
1582165|NCT02367846|Drug|Contraceptive Vaginal Ring (CVR)|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral vs. non-oral ethinyl estradiol on net bone calcium balance. A prospective crossover study with repeated measures and a simple random assignment will be used to test the effects of 49 days of CVR use on bone metabolism using 41Ca to determine net bone calcium balance. Subjects will be randomized to receive CVR during either the first or second intervention period.
1582166|NCT02367833|Drug|Combined Oral Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of combined oral contraceptive (Apri or Reclipsen) on the GH/IGF-1 axis.
1582167|NCT02367833|Drug|Transdermal Contraceptive|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of a transdermal contraceptive (Xulane) on the GH/IGF-1 axis.
1582168|NCT02367833|Drug|Contraceptive Vaginal Ring|The proposed study is a preclinical, multi-site trial comparing the short-term effects of oral and non-oral ethinyl estradiol on the GH/IGF-1 axis and bone metabolism. Using a prospective repeated measures design, we will test the effects of 2 cycles of vaginal ring contraceptive (Nuva Ring) on the GH/IGF-1 axis.
1582169|NCT02367820|Drug|NKTR-181 BID tablets|NKTR-181 tablets 100-600 mg twice daily (BID)
1582170|NCT02367807|Drug|Emtricitabine and tenofovir disoproxil fumarate|This study will enroll 50 subjects who are offered TDF/FTC for 48 weeks as part of a combined biomedical/behavioral intervention offered in a community-based setting serving high-risk youth in an urban setting.
1582171|NCT02367794|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (anti-PD-L1) antibody|Atezolizumab 1200 milligrams (mg) intravenous infusion (IV) on day 1 of each 21-day cycle.
1582172|NCT02367794|Drug|Carboplatin|Carboplatin area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles.
1582173|NCT02367794|Drug|Nab-Paclitaxel|Nab-paclitaxel 100 milligrams per meter squared (mg/m^2) IV on Day 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles.
1582174|NCT02367794|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 of each 21-day cycle for 4 or 6 cycles. Participants of Asian race/ethnicity will be administered paclitaxel 175 mg/m^2 IV.
1582179|NCT02367755|Drug|Propofol|Propofol use during therapeutic hypothermia
1582180|NCT02367755|Drug|Lorazepam|Lorazepam use during therapeutic hypothermia
1582183|NCT02367729|Device|Neurostimulator|Non-invasive, battery operated neurostimulator of the external ear worn for 5 days each week x 4 weeks.
1582184|NCT02367729|Device|Sham|Inactive neurostimulator device pre-programmed to be inactive. To be worn for 5 days each week x 4 weeks.
1582185|NCT02367716|Device|CRT|Quartet™ left heart leads or any newer St. Jude Medical quadripolar CRT systems including CRT-P systems that CFDA might approve in the future
1582186|NCT02367703|Procedure|laparoscopic hysterectomy|
1582187|NCT02367690|Drug|Selinexor|Topical gel
1582188|NCT02367690|Other|Standard-of-Care|Surgical debridement, sterile saline rinses, and dressing changes.
1582189|NCT02367690|Other|Vehicle Gel|Topical vehicle gel with no active ingredients.
1582190|NCT02367677|Other|Method comparison|
1582191|NCT02367664|Biological|0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
1582192|NCT02367664|Biological|0.5ml experimental vaccine on day 0,28 Vero cell-derived inactivated Japanese Encephalitis vaccine|Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 28 days interval, a booster dose 12 months after the first dose
1582193|NCT02367664|Biological|0.5ml active comparator vaccine on day 0,7 inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell)|inactivated freeze-dried Japanese Encephalitis vaccine(Vero cell) produced by Beijing Tiantan Biological Products Co., Ltd. /0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose
1582194|NCT02367651|Drug|Pazopanib 800 mg|Aqueous film-coated, oval-shaped, white tablets containing either 200 mg or 400 mg pazopanib
1582195|NCT02367651|Drug|Placebo|Tablets matching the 200 mg and 400 mg pazopanib tablets
1582196|NCT02367638|Biological|MG1111|Low, Medium, High Plaque-Forming Unit (PFU) of MG1111 in 0.5 mL dose is administered by subcutaneous injection
1582197|NCT02367638|Biological|VARIVAX|VARIVAX is administered by subcutaneous injection
1582198|NCT02367625|Device|CryoPop|The new CryoPop device will be compared to standard cryotherapy
1582199|NCT02367625|Device|MedGyn MGC 200|Standard cryotherapy
1582200|NCT02367612|Dietary Supplement|Fermented milk|Fermented milk with Lactobacillus paracasei CBA L74
1582201|NCT02367612|Dietary Supplement|Placebo|Maltodextrin
1582202|NCT02367599|Drug|Vitamin D Supplement|Subjects enrolled into this sub-study will be provided Vitamin D 4000IU/day for 24 Weeks.
1582203|NCT02367573|Procedure|2D laparoscopic TAPP inguinal hernia repair|
1582204|NCT02367573|Procedure|3D laparoscopic TAPP inguinal hernia repair|
1994602|NCT02966522|Drug|Thalidomide|
1994603|NCT02966522|Drug|Dexamethasone|
1994604|NCT02966184|Drug|preservative free albuterol|Preservative free albuterol for nebulization
1994605|NCT02966054|Behavioral|Print materials on exercise after cancer|
1994606|NCT02966054|Device|Fitbit Flex|
1994607|NCT02966054|Device|Text messages|
1994614|NCT02965404|Biological|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
1582205|NCT02367560|Procedure|Needle decompression|Direct manipulation of calcium deposits in the shoulder with a needle to fragment the deposit performed by a radiologist.
1582206|NCT02367560|Procedure|Shockwave therapy|A physiotherapist performs the shockwave therapy procedure. Treatment is completed in 4 weekly sessions. Treatment involves applying soundwaves directly to the affected shoulder area using an ultrasound device.
1582207|NCT02367560|Drug|Depo medrol|Subacromial steroid injection (40 mg depo medrol) is given to the patient to limit irritation following needle decompression.
1582208|NCT02367560|Device|Ultrasound device|Ultrasound device is applied directly to the shoulder at 0.2 mJ/mm2.
1582209|NCT02367547|Drug|Hexylaminolevulinate cream|The cream is mixed up by the Pharmacy Yliopiston Apteekki for the study and every set is analysed by mass spectrometry.
1582210|NCT02367547|Drug|Aminolevulinic Acid Nano Emulsion|In the study we use Ameluz.
1582211|NCT02367547|Drug|Methylaminolevulinate cream|In the study we use Metvix.
1582212|NCT02367534|Procedure|umbilical vein catheterization|A 7 cm incision was made in the middle-right of upper abdominal. The umbilical vein was identified located 4cm beyond umbilicus, which was then half dissected transversely and the atresic venous lumen was recanalized with a common duct probe (3mm-5mm, BAKES). A breakthrough feeling would be sensed after approaching forward for 10-14cm and the umbilical vein was successfully recanalized. The common duct probe was pulled out. A catheter (single lumen central venous catheter, 16-20G, TUOREN, China) was then cannulated for 15cm into left branch of portal vein through umbilical vein. The procedure was observed with Doppler ultrasound (LOGIQ S6, GE).
1582213|NCT02367521|Combination Product|Low Frequency Right sided repetitive transcranial magnetic stimulation (LFR rTMS)|"LFR rTMS will be delivered at the Brain Stimulation Program at The Johns Hopkins Hospital with a Magstim Super Rapid 2 stimulator with a focal double 70-mm air cooled coil. LFR rTMS will be administered to the Experimental Group.
Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength."
1582214|NCT02367521|Device|Sham Comparator: Sham Treatment|Control patients will receive treatment using an identically appearing coil that produces the same sound and is the same weight as the active coil, but has negligible magnetic field strength
1582215|NCT02367508|Behavioral|MODEL Care|The Mindfully Optimizing Delivery of End-of-Life Care (MODEL Care) intervention is two-pronged and mutually interactive with: (1) a patient and family caregiver group, and (2) an oncology provider group. Patients and family caregivers meet as a group for 6 weekly sessions of 2 hours each, for a total of 12 hours of class time. Oncology providers will have 5 class sessions for a total of 16 hours of class time. One class is held conjointly with patients, family caregivers, and providers to practice newly-learned skills. The course curriculum is generally based on mindfulness practices, group discussion, and didactic teaching with an emphasis on embodying interpersonal mindfulness in dialogue in daily life.
1582216|NCT02367495|Device|PCB|PCB with Citrate-based excipient
1582220|NCT02367443|Radiation|Radiation|Radiation: Accelerated Hypofractionated radiotherapy with full dose Chemotherapy
1582221|NCT02367430|Behavioral|Critical Time Intervention With Buried in Treasures included|Critical Time Intervention and BIT Workshop
1582222|NCT02367430|Behavioral|Buried in Treasures Workshop|
1582223|NCT02367404|Drug|Duloxetine|Duloxetine 60mg OD for 3 months
1582224|NCT02367404|Behavioral|Pelvic Floor Muscle Training|PMFT weekly for 3 months
1582225|NCT02367391|Behavioral|Motivational Text Messages|Usual care plus motivational text messages sent via Mobile Phone. All participants receive the active medication, Varenicline.
1582226|NCT02367391|Behavioral|Control|Usual Care. All participants receive the active medication, Varenicline.
1582227|NCT02367365|Other|No Intervention|No intervention
1582228|NCT02367365|Other|No Intervention|No intervention
1582229|NCT02367352|Drug|Alisertib|Alisertib tablets
1582230|NCT02367352|Drug|Paclitaxel|Paclitaxel intravenous solution
1582231|NCT02367339|Other|ESBL|Evaluation of the prevalence of ESBL-Enterobacteriaceae colonization among ICU staff
1582232|NCT02367326|Other|data collection|data collection will be carried out by the investigator during a standard hospitalization of the patient
1582233|NCT02367313|Drug|Vapendavir|Vapendavir 264 mg twice daily
1582234|NCT02367313|Drug|Vapendavir|Vapendavir 528 mg twice daily
1582235|NCT02367313|Drug|Placebo|Placebo twice daily
1582236|NCT02367300|Device|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
1582237|NCT02367274|Device|BrainScope Ahead 200|A single-use, proprietary headset containing pre-gelled electrodes will be placed on the subject's forehead according to the standard locations of the modified International 10/20 system. Subjects will undergo approximately 5 minutes of eyes closed brain electrical activity recording.
1582238|NCT02367261|Device|SPI implant|SPI implant - the original spiral implant
1582239|NCT02367248|Drug|deferoxamine|Deferoxamine mesylate(40 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
1582240|NCT02367248|Drug|Xingnaojing injection|Xingnaojing injection (20 ml/day) given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
1582241|NCT02367248|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 12 hours of ICH symptom onset.
1582242|NCT02367235|Procedure|Traditional vaginal positioning device|A vaginally placed endo-anal sizer will be used to position the vagina during surgery.
1582243|NCT02367235|Procedure|Colpassist vaginal positioning device|A vaginally placed Colpassist will be used to position the vagina during surgery.
1582244|NCT02367222|Other|Exposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..
1582245|NCT02367222|Other|Unexposed to Arepanrix™ Cohort|Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.
1582246|NCT02367196|Drug|CC-90002|
1582247|NCT02367196|Drug|Rituximab|
1582248|NCT02367183|Drug|GED-0301|
1582249|NCT02367183|Drug|Placebo|
1582250|NCT02367170|Procedure|Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressure|Pressure changes are recorded. The phrenic nerves are stimulated with bilateral magnetic stimulators over the neck. Measurements will be performed on day 1, every 7 days after and on last day of participation. The FiO2 will be increased (at least 20%) for at least 2 min. prior to measurement to maintain oxygen saturation >92%. Prior to activating the stimulator, the artificial airway will be occluded with a pneumatic valve to create a quasi-isometric diaphragm contraction. The airway will be occluded for 3 seconds or less for each stimulation. The procedure will be repeated up to a maximum of 5 times per testing day.
1582251|NCT02367170|Drug|Midazolam|In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
1582252|NCT02367170|Procedure|Volitional Measurement of Maximal Inspiratory Pressure (MIP)|MIP is tested on all subjects on day 1, every 7 days after and on the last day of participation. To measure MIP, a subject will be suctioned, disconnected from the ventilator, and instructed to take a few spontaneous breaths. A 1-way exhalation valve connected to a NICO respiratory monitor will be placed on the ET/tracheotomy tube. The subject will be instructed to inhale and exhale as forcefully as possible for 20 seconds, followed by at least 2 minutes of rest on full mechanical ventilation support. MIP trials will be repeated 3 times, and the greatest negative pressure recorded with a NICO respiratory monitor connected to a laptop computer, which will digitize airway pressure, flow and volume signals at 100Hz. This allows for analysis of the individual pressure waves, facilitating pre-post comparisons of MIP at specific time points during inspiration.
1582253|NCT02367170|Device|Inspiratory Muscle Strength Training (IMST)|"Occurs 5 days/wk using threshold IMST device-Respironics model 735. Prior to training, cuff pressure is assessed, FiO2 increased for 2 min. to keep O2 sats ≥92%. The ventilator circuit is disconnected, IMST device is attached to endotracheal or tracheotomy tube and subject is instructed to exhale then forcefully inhale for 10 breaths. The initial setting of device is set to -5cmH2O, subject must generate a negative inspiratory pressure more negative than -5cmH2O to open spring-loaded valve and receive inspiratory airflow. Pressure setting is made more negative/difficult to open by 2-5cm every few breaths until a setting is found where the patient has difficulty fully opening valve, resulting in valve flutter noise. Training pressure is then made more positive /easier by 2-4cm of H2O, so subject can fully open valve, and 4 sets of 6-10 breaths are completed. Training pressures advanced as rapidly as possible, provided the patient is able to open the valve withoutvalve flutternoise."
1582254|NCT02367170|Device|SHAM Inspiratory Muscle Strength Training (IMST)|Training will also be conducted 5 days/wk with an identical IMST device that has been modified by removing the valve leaflet, which essentially removes all inspiratory loading by the device. The modified SHAM IMST device makes a whistling sound during inspiration, which enhances the sham effect. For SHAM treatment, supplemental oxygen FiO2 will be increased for two minute prior to each bout. The ventilator will be disconnected and a SHAM device will be attached to the endotracheal or tracheostomy tube. The subject will be instructed to take 6-10 breaths with a normal tidal volume through the SHAM device and will be reconnected to the ventilator for a 2-minute rest period. The process will be repeated 3 more times for a total of 4 sets of 6-10 breaths.
1582255|NCT02367170|Procedure|Diaphragm thickness measurement|Ultrasound will be used to obtain measurements of the thickness of the right hemidiaphragm. Ultrasonography of the diaphragm will be performed upon enrollment, every 2-4 days during hospitalization and as long as the patient is hospitalized or up to 28 days of participation.
1582256|NCT02367170|Other|Blood and Urine samples|Peripheral blood and urine samples will be collected once upon study entry day (+/- 2 days), once every 2-4 days and once on final day of study participation (+/- 2days).
1582257|NCT02367157|Procedure|Kenzo Kase Method|
1582258|NCT02367157|Device|Kinesio Taping|
2008655|NCT03328416|Device|Augmented Reality|The neurointerventional radiologist will have imaging information projected on a headset in addition to on the conventional monitors that hang from the procedure suite ceiling.
1582260|NCT02367118|Drug|Prednisone|
1582261|NCT02367118|Drug|Placebo|
1582262|NCT02367105|Drug|Testosterone|Daily testosterone gel applied once daily in the morning to intact skin
1582263|NCT02367105|Other|Lifestyle Therapy|Weekly behavioral diet to induce ~10% weight loss in combination with supervised aerobic and exercise training three times a week
1582264|NCT02367105|Drug|Placebo|Placebo gel for testosterone
1582265|NCT02367092|Behavioral|Exercise Program|They will perform low-intensity, low-resistance exercise facilitated by a DVD video in their home. This exercise program lasts for 30 minutes at a time. Patients will be instructed to engage in this exercise program 3-4 times per week but not more often than 4 times per week. Pre-transplant patients will be asked to do the exercises from enrollment to transplant. Post-transplant patients will be asked to do the exercises for 6 months.
1582266|NCT02367079|Device|Diathermy|Sham diathermy vs switched on diathermy effect on pain where assessed
1582267|NCT02367066|Drug|AR-C165395XX|Oral dose of AR-C165395XX (tablets)
1582268|NCT02367066|Other|Placebo|Oral dose of placebo for AR-C165395XX (tablets)
1582269|NCT02367053|Drug|ZP4207|
1582270|NCT02367053|Drug|Glucagon|
2008656|NCT03328403|Device|Aspiration First|Use aspiration system (mainly Penumbra) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
2008657|NCT03328403|Device|Stent retriever first|Use one of the stent retrievers (Trevo / Solitaire) first, other devices would be used if the first device failed to open the occluded vessel satisfactorily, depending on clinical situation and the involved interventionists' preferences.
2008658|NCT03328390|Other|Quadratus lumborum block|15 ml of 0.5% isobaric bupivacaine + 10 ml saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
1582274|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension (dry powder) in fasted conditions.
1582275|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 20 mg oral suspension (dry powder) in fed conditions.
1582276|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg oral suspension in fasted conditions.
1582277|NCT02367027|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single dose of 10 mg tablet in fasted conditions.
1582278|NCT02367014|Drug|MTP-131|MTP-131 (low dose) administered as single day intravenous infusion over 2 hours for 5 days
1582279|NCT02367014|Drug|MTP-131|MTP-131 (intermediate dose) administered as single day intravenous infusion over 2 hours for 5 days
1582280|NCT02367014|Drug|MTP-131|MTP-131 (high dose) administered as single day intravenous infusion over 2 hours for 5 days
1582281|NCT02367014|Drug|Placebo|Placebo Comparator (at each dose cohort) administered as single day intravenous infusion over 2 hours for 5 days
1582282|NCT02367001|Other|Normal invitation|No modification and signed by the coordinating doctor as usual
1582283|NCT02367001|Other|revised invitation signed by the coordinating doctor|Invitation with revised text and layout and signed by the coordinating doctor as usual
1582284|NCT02367001|Other|Revised invitation signed by the attending physician|signature typed or typed + handwritten
1582285|NCT02366988|Device|Endoscopic Biliary Stenting|Endoscopic probe self-expandable metallic covered stent Biliary stent will be left in place for 6 months
1582286|NCT02366988|Procedure|Surgical treatment Bilio-enteric anastomosis|Bilio-enteric anastomosis including Whipple, Frey or Beger procedure, double or triple derivation
2008659|NCT03328390|Other|Transversus abdominis plane block|15 ml of 0.5% isobaric bupivacaine + 10 ml of saline + 50 micro gram dexmedetomidine + epinephrine (1:100,000) for each side.
1582289|NCT02366962|Biological|ASP7374|subcutaneous
1582292|NCT02366936|Device|Tortle Midliner|The Tortle Midliner is a breathable, knit beanie with two support rolls to help position the infant's head in midline while supine. It can also be worn sidelying or prone. The design includes Velcro adjustments and tabs for nasal cannula and feeding tubes. It is compatible with some ventilation devices, nasal CPAP, X-ray, and bilirubin shades. The beanie is designed to prevent dolichocephaly and provide passive stretch to cervical rotators if head preference has developed. It comes in three sizes and can fit preemies weighing 500 to 2500 g.
1582293|NCT02366923|Device|stenfilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
1582294|NCT02366923|Device|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
1582295|NCT02366910|Device|omafilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
1582296|NCT02366910|Device|delefilcon A|Each subject randomized to wear either the test or control in either the left of right eye.
1582297|NCT02366897|Device|Manus Sensor Pen|Manus Sensor Pen as made by Manus Neurodynamica Ltd
1582298|NCT02366884|Drug|Anti-Bacterial Agents|Doxycycline, Paramomycin, Clarithromycin, Clindamycin, Dapsone, Miltefosine
1582299|NCT02366884|Drug|Anti-Fungal Agents|Itraconazole, Amphotericin B liposomal, Fluconazole, Terbinafine, Voriconazole
1582300|NCT02366884|Drug|Anti-Protozoal Agents|Nitazoxanide, Chloroquine, Albendazole, Ivermectin, Mebendazole, Metronidazole, Praziquantel, Levamisole
1582303|NCT02366858|Procedure|19 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 19 gauge needle
1582304|NCT02366858|Procedure|22 gauge|Evaluate the ability to perform molecular marker or immunohistochemistry studies on tissue procured with a 22 gauge needle
1582345|NCT02366637|Drug|Placebo|Orally inhaled placebo twice a day (BID) for 4 weeks
1582346|NCT02366637|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 4 weeks
1583304|NCT02359175|Drug|Oral Paracetamol|Paracetamol to be given orally
1994615|NCT02965404|Biological|control live attenuated varicella vaccine|The control vaccine was manufactured by Shanghai Institute of Biological Products Co., Ltd. (SIBP)
1994616|NCT02965404|Biological|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology
1994617|NCT02964611|Behavioral|Observational Study|This is an observational study.
1994621|NCT02964247|Drug|liraglutide|Liraglutide given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
1994622|NCT02964247|Drug|placebo|Liraglutide placebo given s.c. once daily, gradually titrated to 1.8 mg/day as an add-on to the subject's stable pre-trial SGLT2 inhibitor ± metformin for 26 weeks
1582305|NCT02366845|Biological|Fresh Frozen Plasma|An INR dose-response curve with associated transfusion algorithm was generated for plasma in bleeding patients with chronic liver disease. In the intervention arm we will determine the plasma transfusion dose using the algorithm dosing table based on the pre-transfusion INR and the clinician chosen INR target. In the usual care group the dosing will be determined by the clinician.
1582306|NCT02366832|Procedure|Cryoablation|Subjects who respond to lidocaine nerve block will undergo CT guided cryoablation of the affected nerve stump with a 17g Galil Medical Ice Sphere cryoablation needle.
1582307|NCT02366832|Device|17g Galil Medical Ice Sphere cryoablation needle|Under CT guidance, the corresponding nerve will be targeted with a 17g probe. Two freeze-thaw cycles will be undertaken. The probe will be removed and a final scan obtained.
1582308|NCT02366819|Drug|Oxaliplatin|Given IV
1582309|NCT02366819|Drug|Leucovorin Calcium|Given IV
1582310|NCT02366819|Drug|Irinotecan Hydrochloride|Given IV
1582311|NCT02366819|Drug|Fluorouracil|Given IV
1582312|NCT02366819|Procedure|Conventional Surgery|Undergo surgery
1582313|NCT02366793|Other|Accessory joint mobilization|Three kinds of humeral head slides: anterior, posterior and caudal slides. Subjects remained in supine position during the whole treatment. The techniques were applied in a rhythmical way, with 2 seconds of slide/traction and then a 2-second break. Each technique was carried out for 2 minutes.
1582314|NCT02366793|Other|Nerve mobilization|Neural tissue longitudinal slide using the median neurodynamic test 1 (MNT1) that was described by Butler. The proximal parameters (scapular depression, abduction and humeral external rotation) were introduced with maximum neural tension. On the other hand, the distal parameters (supination, elbow extension, wrist and fingers extension) received the remaining tension that the neural tissue allowed. The parameters were introduced sequentially in the order exposed
1582315|NCT02366780|Procedure|Pump|Breast milk expression using manually or using an electric pump
1582316|NCT02366767|Device|Automatic closed-loop insulin delivery|Sensor transmit glucose data every 5 minutes to the control algorithm which adjusts insulin delivery every 5 minutes.
1582317|NCT02366767|Device|Control|Threshold suspend
1582318|NCT02366754|Device|rTMS|Repetitive TMS is a non-invasive neural stimulation technique achieved via electromagnetic induction. An insulated metal coil is placed on the scalp and short discharges of electric current are directed through the coil producing a magnetic field. This magnetic field is accompanied by an electric field that passes through the skull inducing currents in the tissue beneath the coil. If a cell beneath the coil is viable, then rTMS initiates or inhibits an action potential affecting ongoing neural activity. 30 sessions of active rTMS are provided.
1582319|NCT02366754|Device|Placebo rTMS|The placebo coil simulates magnetic stimulation, but does not actually emit a pulse. The placebo coil looks, sounds and feels like an active rTMS coil. The placebo coil, visually identical to the active coil, provides a slight sensory sensation and discharge noise (i.e., clicking) nearly identical to that of the active coil.
1582320|NCT02366741|Radiation|Whole brain radiotherapy with reduced dose to the hippocampi|VMAT plan to treat the whole brain while reducing the dose to the hippocampi.
1582321|NCT02366728|Biological|Unpulsed DCs|Patients in Group I will receive 1 x 10^6 autologous unpulsed DCs in saline administered to a single side of the groin intradermally 1 day before the fourth vaccine.
1582322|NCT02366728|Biological|Td|Patients in Groups II and III will receive a single dose of Td toxoid (1 flocculation unit, Lf, in 0.4 mLs) administered to a single side of the groin given intradermally 1 day before the fourth vaccine.
1582323|NCT02366728|Biological|Human CMV pp65-LAMP mRNA-pulsed autologous DCs|2x10^7 human CMV pp65-LAMP mRNA-pulsed autologous DCs are given intradermally and bilaterally at the groin site (divided equally to both inguinal regions). Patients will receive up to a total of 10 DC vaccines.
1582324|NCT02366728|Biological|111In-labeled DCs|111In-labeled DCs are 2 x 10^7 pp65-LAMP mRNA loaded mature DCs will be labeled with 111In (50 μCi / 5 x 10^7 DCs) and given i.d. as fourth vaccine for Groups I and II only.
1582325|NCT02366728|Drug|Temozolomide|Temozolomide is a standard chemotherapy given to all enrolled patients at a targeted dose of 150-200mg/m2/d for 5 days every 5 (± 1) weeks for a total of 6 to 12 cycles at the discretion of the treating oncologist.
1582326|NCT02366728|Drug|Saline|0.4mL of saline given in the opposite groin 1 day before the fourth vaccine in all groups
1582327|NCT02366728|Drug|Basiliximab|Group III will receive basiliximab infusions (20 mg I.V) 1 week before the first vaccine and 1 week before the second vaccine.
1582328|NCT02366715|Device|HeatedHumidifiedHighFlowNasalCannula|"We will enroll children 0-2 years old, diagnosed with Bronchiolitis in our ward (Pediatrics C) during the months of November-March 2014-2016. Children will be evaluated according to a Bronchiolitis Severity Score devised by Wang and Co. [3] which was successfully used in previous research. Children answering criteria for moderate or severe Bronchiolitis according to Wang and Co. will be enrolled pending written consent by both parents.
Our prediction is to enroll a total of 200 children during the 2 winter seasons during 2014-2016."
1582329|NCT02366702|Device|Lower Limb Powered Knee-Ankle Prosthesis|
1582330|NCT02366689|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (triclosan/fluoride) using Total 360 toothbrush for 1 minute, 2 times/day for 6 months (study duration).
1582331|NCT02366689|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 months (study duration).
1582332|NCT02366689|Drug|fluoride only toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 months (study duration). Immediately after each brushing, rinse whole mouth with 20 ml of Crest fluoride Mouthwash for 30 seconds.
1582333|NCT02366689|Drug|Cetylpyridinium chloride mouthwash|Immediately after each brushing with Crest Pro-Health toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health Mouthwash for 30 seconds.
1582334|NCT02366689|Drug|Fluoride only mouthwash|Immediately after each brushing with Crest Cavity Protection toothpaste, rinse whole mouth with 20 ml of Crest Pro-Health For Me mouthwash for 30 seconds.
1582335|NCT02366676|Drug|IALURIL|IALURIL Intravesical instillation with cystoscope ( 1st month: once a week, 2nd~5th month:once a month)
2008660|NCT03328377|Diagnostic Test|Metagenomic analysis of gut microbiota|All patients have rectal swaps/fecal samples subjected to metagenomic analysis
2008661|NCT03328364|Drug|enzalutamide|oral
1582347|NCT02366611|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS is a non-invasive brain neuromodulatory method that involves sending a weak electrical current to the brain. 2mA of tDCS will be applied for 20 minutes at each session and participants will undergo a total of 20 sessions over a 7-week period.
1582348|NCT02366598|Other|Hemp shake|Hemp protein shake
1582349|NCT02366598|Other|Soybean shake|Soybean protein shake
1582350|NCT02366598|Other|Control|Non-protein shake
1582351|NCT02366585|Drug|Ciclosporin|Ciclosporin gel applied to two periodontal pockets
1582352|NCT02366572|Other|Control|Non pulse extruded cereal
1582353|NCT02366572|Other|Pea protein|Pulse extruded cereal
1582354|NCT02366572|Other|Pea starch|Pulse extruded cereal
1582355|NCT02366572|Other|Pea fibre + pea starch|Pulse extruded cereal
1582356|NCT02366572|Other|Pea protein + pea starch|Pulse extruded cereal
1582357|NCT02366572|Other|Pea fibre + pea starch + pea protein|Pulse extruded cereal
1582358|NCT02366559|Device|Hyfrecator|
1582359|NCT02366559|Device|532 nm Q-switched Nd:YAG laser|
1582360|NCT02366546|Drug|TBI-1301|TBI-1301(5*10^8 or 5*10^9) is administered.
1582361|NCT02366546|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
1582362|NCT02366546|Drug|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1301 in combination with cyclophosphamide.
1582363|NCT02366520|Device|handheld mirror|The child may see the dental treatments that are conducted in his or her mouth by a handheld mirror.
1582364|NCT02366494|Drug|Bicalutamide|ANDROGEN BLOCKADE
1582365|NCT02366494|Drug|Leuprolide|ANDROGEN BLOCKADE
1582366|NCT02366494|Drug|Goserelin|ANDROGEN BLOCKADE
1582367|NCT02366494|Drug|Triptorelin|ANDROGEN BLOCKADE
1582368|NCT02366494|Drug|Docetaxel|Chemo hormonal therapy
1582369|NCT02366481|Dietary Supplement|Placebo|Two placebo softgel capsules (containing no vitamin K2) every day for 8 weeks.
1582370|NCT02366481|Dietary Supplement|Low-Dose Vitamin K2 Supplement (menaquinone-7; 90-mcg/d)|One 90-mcg vitamin K2 softgel capsules (containing no vitamin K2) and one placebo softgel capsule everyday for 8 weeks.
1582371|NCT02366481|Dietary Supplement|High-Dose Vitamin K2 Supplement (menaquinone-7; 180-mcg/d)|Two 90-mcg vitamin K2 softgel capsules every day for 8 weeks.
2008662|NCT03328364|Drug|docetaxel|intravenous infusion
1582374|NCT02366455|Procedure|Measurement of the length of the right main stem bronchus|Measurement of the length of the right main stem bronchus on CT-Scan
1582375|NCT02366455|Procedure|Measurement of the right upper lobe bronchus antero-posterior angulation|Measurement of the right upper lobe bronchus antero-posterior angulation on CT-Scan
1582376|NCT02366442|Other|Exploring relationships among balance performance, cognitive dysfunction, affective dysregulation, and community integration in Veterans with Traumatic Brain Injury (TBI).|
1582377|NCT02366429|Behavioral|ICBT for antenatal depression|Participants receives active therapist support via the internet to go through a 10-week self-help treatment on a secure web platform
1582378|NCT02366429|Other|TAU|Treatment as usual provided at antenatal clinics and other health care instances
1582379|NCT02366416|Behavioral|Exercise training|Physical activity
1582380|NCT02366403|Behavioral|SKY meditation|SKY (Sudarshan Kriya Yoga) meditation is a standardized, manual-based and replicable program that includes relaxation techniques as well as periods of discussion. The format is a 7-day intensive group class (2 1/2 hours/day intensive format) followed by five weeks of sessions twice per week (1hr/session). SKY meditation incorporates several types of breathing exercises involving arousal and attentional control. Initial breathing exercises are calming and focusing. Subsequent breathing exercises are more fully engaging energizing, allowing the practitioner to focus more fully in each moment.
1582381|NCT02366403|Behavioral|CPT-C|CPT-C (Cognitive Processing Therapy-cognitive only) is a standardized, manual-based treatment consisting of 12, 60-minute sessions which will be given twice per week. Sessions will focusing on specific issues, learning new therapeutic techniques and setting up homework for the following session including real-life application of learned CPT techniques.
1582382|NCT02366390|Behavioral|Psychoeducative intervention|Patient-education about feelings, cognitions, behaviors and bodily sensations related to management of dyspnea and associated anxiety
1582383|NCT02366377|Drug|SHR3824|
1582384|NCT02366377|Drug|Placebo|
1582385|NCT02366377|Drug|Metformin|
1582386|NCT02366364|Drug|Placebo|Single oral administration of placebo consumption on Day 1
1582387|NCT02366364|Drug|NRX-1074 375 mg|Single oral administration of 375 mg consumption on Day 1
1582388|NCT02366364|Drug|NRX-1074 500 mg|Single oral administration of 500 mg consumption on Day 1
1582389|NCT02366364|Drug|NRX-1074 750 mg|Single oral administration of 750 mg consumption on Day 1
1582390|NCT02366351|Drug|SHR3824|Once daily, 12 weeks
1582391|NCT02366351|Drug|Placebo|Once daily, 12 weeks
1582392|NCT02366325|Drug|EPO-018B|
1582393|NCT02366312|Drug|vismodegib|vismodegib is a synthetic, small molecule inhibitor of the sonic Hh pathway, which is involved in tumorigenesis, thus providing a strong rationale for its use in the treatment of a variety of cancers.
1582394|NCT02366299|Drug|Dexmedetomidine|Treatment of delirium by dexmedetomidine i.v. infusion
1582395|NCT02366299|Drug|Propofol|Treatment of delirium by Propofol i.v. infusion
1582396|NCT02366273|Other|PASI and HOMA index|
1582397|NCT02366247|Drug|PEG-Tα1|3.2mg/ml, once a week, taken subcutaneously
1582398|NCT02366247|Drug|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
1582399|NCT02366247|Drug|Adefovir|10 mg, once daily, taken orally for 48 weeks
1582400|NCT02366221|Other|60-minute visit to the outpatient clinic|An interview, an injury-specific physical exam and/or a set of xrays.
1582401|NCT02366221|Other|Phone Interview|If subject cannot return to office in Boston, researcher may conduct interview over the phone.
1582402|NCT02366208|Drug|PEG-Tα1|1.6 mg/ml, once a week, taken subcutaneously
1582403|NCT02366208|Drug|Placebo to match PEG-Tα1|1ml, once a week, taken subcutaneously
1582404|NCT02366208|Drug|Adefovir|10 mg, once daily, taken orally for 48 weeks
1582405|NCT02366195|Drug|Talimogene Laherparepvec|Open label Single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 10^6 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 10^8 PFU/mL.
1582406|NCT02366169|Device|Medigus Ultrasonic Surgical Endostapler (MUSE) Procedure|The procedure is performed transorally under general anesthesia. The physicians staples the fundus of the stomach to the esophagus approximately 3cm superior to the Z-line in 2 or more locations. The procedural result is anatomically and functionally similar to standard anterior fundoplication (Dor-Thal operation). The staples are standard, 4.8mm titanium surgical staples. Each application of the device fires a quintuplet of staples (5) in three staggered rows. Anti-retching medications at the time of the procedure are essential.
1582407|NCT02366156|Dietary Supplement|Placebo|Three placebo capsules consumed prior to breakfast each day for 4 weeks
1582408|NCT02366156|Dietary Supplement|Low Dose Grape Blend|Three low dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
1582409|NCT02366156|Dietary Supplement|High Dose Grape Blend|Three high dose grape blend capsules consumed prior to breakfast each day for 4 weeks.
2008663|NCT03328351|Other|manual therapy|"Manual therapy: One of the following techniques was used for the treatment group based on the patients' response (i.e centralization and reduction of symptoms).
Cervical postero-anterior vertebral mobilization glides:
a central posteranterior (PA) or unilateral PA oscillatory pressure of grade III on the patient's most symptomatic level for 2 minute and 3 sets .
Cervical lateral vertebral glides :at grade III for 1 minute and 3 sets.
Strengthening Exercises:
for deep neck flexor muscles for 10 seconds and repeating it for 10 times."
2008664|NCT03328351|Other|Superficial soft tissue massage|"1. Superficial soft tissue massage: The researcher applied a superficial effleurage massage without moving the deeper tissue for 2 minutes for 3 sets
Strengthening Exercises:
for deep neck flexor muscles for 10 seconds and repeating it for 10 times"
2008665|NCT03328325|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes and 2 influenza B subtypes.
2008666|NCT03328312|Drug|Sugammadex|Time period from administration of the reversal agent to recovery of TOFR >0.9
1582417|NCT02366117|Behavioral|Training|Adapted training on the patients active participation, rehabilitation, independence, rights and wellbeing.
1582418|NCT02366091|Drug|Methotrexate|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease
1582419|NCT02366091|Drug|Colchicine|Administered to determine the effect of anti-inflammatory agents on coronary and systemic endothelial function in patients with coronary artery disease.
1582420|NCT02366091|Drug|Placebo|Prepared by Johns Hopkins Investigational Drug Service to mimic methotrexate and colchicine.
1582421|NCT02366078|Behavioral|SMART|Paced breathing meditation with cognitive training
1582422|NCT02366065|Drug|Acetaminophen|Before treatment, study subjects will have their intraocular pressure measured at 8 am, 10 am, 12 pm and 4 pm. They will then take acetaminophen 650 mg qid for 7 days and the intraocular pressures again measured at 8 am, 10 am, 12 pm, and 4 pm. Subjects will then stop the acetaminophen and return one week later for one more set of intraocular pressure measurements at 8 am, 10 am, 12 pm, and 4 pm.
1582423|NCT02366052|Behavioral|Nutritional Counseling|Nutritional counseling by a trained nutritionist for 12 weeks.
1582424|NCT02366052|Dietary Supplement|Lactobacillus casei shirota (LCS)|The dietary supplement LCS (Yakult plus) will be given 2 times a day for 12 weeks in addition to dietary counseling every 3 weeks.
1582425|NCT02366052|Other|Nutritional Counseling and LCS|Nutritional counseling by a trained nutritionist in addition to the dietary supplement LCS (2 times a day) for 12 weeks.
1582426|NCT02366026|Biological|IR103|REMUNE HIV/AIDS Vaccine with two adjuvants IFA + Amplivax
1582427|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^8 vp|1 oral capsule, 1x10^8 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
1582428|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^9 vp|10 oral capsules, 1x10^8 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
1582429|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^10 vp|1 oral capsule, 1x10^10 vp/capsule or 1 placebo capsule; 5:1 vaccine:placebo
1582430|NCT02366013|Biological|rcAd26.MOS1.HIV-Env 1x10^11 vp|10 oral capsules, 1x10^10 vp/capsule or 10 placebo capsules; 5:1 vaccine:placebo
1582431|NCT02366000|Other|Brief Parental Training Intervention|The workshop was designed to assist parents to communicate with their children about issues in the prevention of health risk behaviours- alcohol, tobacco and other drug use (ATOD), by equipping them with the appropriate interaction skills and encouraging them to build relationships with their children.
1582432|NCT02365987|Dietary Supplement|Interesterified blend of palm kernal and plam stearin|50g fat provided as interesterified palm kernal and palm sterin blend in a single meal
1582433|NCT02365987|Dietary Supplement|Un-interesterified blend of palm kernal and plam stearin|50g fat provided as un-interesterified palm kernal and palm sterin blend in a single meal
1582434|NCT02365974|Device|Transcutaneous Electrical Stimulation|TENS will be applied in the cervicothoracic ganglion region located between the C7 and T4 vertebral processes for 40 minutes three times weekly for a total of four weeks. The intensity in milliamps will be adjusted depending on the sensitivity of each individual patient.
1582435|NCT02365974|Device|No Transcutaneous Electrical Stimulation|The sham group will be submitted to the procedure to fit the stimulation equipment. without be submitted to stimulation.
1582436|NCT02365961|Drug|ropivicaine|
1582437|NCT02365961|Drug|clonidine|
1582438|NCT02365961|Drug|Epinephrine|
1582439|NCT02365961|Drug|Noropin|
1582440|NCT02365948|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol
Pharmaceutical Form: Prefilled syringes
Concentration: 200 mg/mL
Route of Administration: Subcutaneous injection"
1582441|NCT02365948|Other|Placebo|"Active Substance: Placebo
Pharmaceutical Form: Prefilled syringes
Concentration: 0.9 % Saline
Route of Administration: Subcutaneous injection"
1582442|NCT02365935|Procedure|Group A adjuvant chemotherapy|In Group A, all patients received 4 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
1583305|NCT02359175|Drug|Oral NSAID|NSAID to be given orally
1582443|NCT02365935|Procedure|Group B adjuvant chemotherapy|In Group B, all patients received 6 cycles of adjuvant chemotherapy every three weeks according to the scheme Cisplatin 100 mg/mq and Paclitaxel 175 mg/mq.
1582444|NCT02365935|Drug|Cisplatin|
1582445|NCT02365935|Drug|Paclitaxel|
1582446|NCT02365909|Drug|0.5% bupivacaine|This group will receive 0.3 ml of 0.5% bupivacaine per nare, applied with the Tx360®
1582447|NCT02365909|Drug|normal saline|This group will receive 0.3 ml of normal saline per nare, applied with the Tx360®
1582448|NCT02365896|Procedure|TLDG or LADG|
1582449|NCT02365883|Device|Photoacoustic Imaging System|manufactured by Endra
1582450|NCT02365870|Drug|rotigotine transdermal patch|Participants will receive the dopamine agonist rotigotine in the form of a transdermal patch to be worn daily
1582451|NCT02365870|Drug|placebo|Participants will receive a placebo transdermal patch to be worn daily
1582452|NCT02365857|Drug|Dexmedetomidine & Bupivacaine.|Intrathecal injection of Dexmedetomidine & Bupivacaine.
1582453|NCT02365857|Drug|Bupivacaine Only.|Intrathecal injection of Bupivacaine only.
1582454|NCT02365831|Other|Observation of treatment management|Group/cohort
1582455|NCT02365818|Biological|CG0070|
1582456|NCT02365805|Drug|Epirubicin + Ciclofosfamide + Fluorouracil + Paclitaxel|Epirubicin 90 mg/m2 + Ciclofosfamide 600 mg/m2 + 5-Fluorouracil 600 mg/m2 intravenous infusion on day 1 every three weeks, for four cycles; followed by Paclitaxel 100 mg/m2 weekly for eight weeks.
1582457|NCT02365805|Drug|Epirubicin + Cisplatin + Fluorouracil|Epirubicin 60 mg/m2 + Cisplatin 60 mg/m2 intravenous infusion on day 1 every three weeks and 5-Fluorouracil 200 mg/m2/day for eight cycles.
1582458|NCT02365805|Drug|Docetaxel + Ciclofosfamide|Docetaxel 75 mg/m2 + Ciclofosfamide 600 mg/m2, intravenous infusion on day 1 every three weeks, for eight cycles.
1582459|NCT02365792|Procedure|Clinical Decision Support Tool for Prehospital Care|"A clinical decision support system (CDSS) is a health information technology system that is designed to assist physicians and other health professionals with clinical decision-making tasks. A working definition of the Centre for Health Evidence: Clinical Decision Support systems link health observations with health knowledge to influence health choices by clinicians for improved health care."
1582460|NCT02365779|Procedure|bilateral laparoscopic salpingectomy|Use of the confocal laser endomicroscopy Cellvizio® system during laparoscopy salpingectomy
1582461|NCT02365779|Device|endomicroscopy Cellvizio® system|
1582462|NCT02365766|Drug|Pembrolizumab|In this dose-finding cohort, pembrolizumab (MK-3475) will be administered (cisplatin-eligible patients only) at starting dose 200mg IV every 21 days for 4 cycles to determine RP2D. Once MTD is established in phase Ib, pembrolizumab will be administered on phase II cohorts I and II at RP2D every 21 days for 5 cycles.
1582463|NCT02365766|Drug|Gemcitabine|For cisplatin-eligible patients on phase Ib and phase II cohort 1, gemcitabine 1000mg/m2 IV, D1 and D8 every 21 days for 4 cycles. For cisplatin-ineligible patients on phase II cohort II, gemcitabine 1000mg/m2 will be administered D1, D8 and D15 every 28 days for 3 cycles.
1582464|NCT02365766|Drug|Cisplatin|For cisplatin-eligible patients, cisplatin 70mg/m2 IV will be administered D1 every 21 days for 4 cycles.
1582465|NCT02365766|Procedure|Consolidative Surgery|Following completion of treatment, subjects will then have surgery to remove their primary tumor within 2-7 weeks after their last dose of neoadjuvant therapy.
1582466|NCT02365753|Device|SofPulse|Pulsed Electomagnetic Field Therapy Device. Selectively inhibits cytokines to inhibit pain.
1582467|NCT02365740|Other|gastric emptying test|gastric emptying rate for solid will be determined using the 13C-OBT. Breath samples will be taken before the meal and then at 15-min intervals for a period of 240 min postprandially. The 13C content will be determined by on-line gas chromatographic purification-isotope ratio mass spectrometry (ABCA; Europe Scientific, Crewe, UK). The 13CO2 excretion curves will be analyzed and the half-emptying time (t½) and lag phase (tlag) calculated.
1582468|NCT02365740|Other|gut hormones determination|blood sampling at 0, 15, 30, 60, 90, 120, 180 min for determination of plasma, glucagon and GI hormones (Ghrelin, GLP-1, GIP)
1582469|NCT02365740|Other|Continuous Glucose Monitoring|7 days Continuous Glucose Monitoring
1582470|NCT02365740|Drug|Insulin single bolus|pre-prandial insulin administered as single bolus calculated on the basis of carbohydrate counting and each patient's insulin/glycaemic load
1582471|NCT02365740|Drug|Insulin double-wave bolus|pre-prandial insulin fractioned into a double-wave bolus
1582472|NCT02365727|Drug|Liposomal bupivacaine|
1582473|NCT02365727|Drug|Ropivacaine|
1582474|NCT02365727|Drug|Epinephrine|
1582475|NCT02365727|Drug|Clonidine|
1582476|NCT02365727|Drug|Saline|
1582477|NCT02365714|Radiation|CK Stereotactic Accelerated Partial Breast Irradiation|Adjuvant radiation therapy will be delivered to the region of the lumpectomy cavity once daily for 5 treatments over 5-10 days.
1582478|NCT02365701|Drug|Motilitone 30mg|30mg of Motilitone in tablet form, to be taken 3 times daily for 4 weeks
1582479|NCT02365701|Drug|Placebo|Placebo, in tablet form, to be taken 3 times daily for 4 weeks. The placebo is the same formulation as Motilitone except that it does not contain the active pharmaceutical ingredient.
1582480|NCT02365688|Procedure|Initial bolus pre-incision|Measured hemodynamic response to pre-incision bolus
1582481|NCT02365675|Device|Cotton gauze with petrolatum|
1582482|NCT02365675|Device|Cellulose acetate with petrolatum|
1582483|NCT02365675|Device|Nanocrystalline silver (Acticoat)|
1582484|NCT02365675|Device|Carboxymethylcellulose with ionic silver (Aquacel Ag)|
2008667|NCT03328312|Drug|neostigmine+atropine|Number and time of bradycardic episodes (HR<60 bpm) as well as that of tachycardic episodes (HR>100 bpm) before tracheal extubation
1582486|NCT02365649|Drug|ABT-494|Oral Dosing
1582487|NCT02365649|Drug|Placebo|Oral Dosing
1582488|NCT02365636|Drug|TV-45070|TV-45070 4%, 8%
1582489|NCT02365636|Drug|Placebo|
1582536|NCT02365285|Drug|Placebo Oral Capsule|Placebo oral capsule, acute intervention prior to the infusion of intralipids
1582537|NCT02365272|Drug|Amikacin|Amikacin administered in a single dose for critical care patients
1583306|NCT02359175|Drug|Oral opioids|Opioids to be given orally
2008668|NCT03328312|Drug|neostigmine+atropine+sugammadex|4. Time of extubation
1582490|NCT02365623|Drug|TMC207 (bedaquiline)|TMC207 (bedaquiline): Participants will receive TMC207 (bedaquiline) 400 milligram (mg) as 4*100 mg tablets once daily 2 weeks (14 days) followed by 200 mg (2 tablets) 3 times a week up to Week 24 along with background regimen (BR). Based on the discussion with the Pharmaceuticals and Medical Devices Agency (PMDA), the extension of 24-week TMC207 treatment with BR drugs may occur up to Week 48, under certain circumstances, such that many BR drugs which are susceptible at the beginning of the Treatment Phase show resistance during the Treatment Phase.
1582491|NCT02365623|Drug|Background Regimen (BR)|Participants will receive anti-bacterial tuberculosis drugs (pyrazinamide [PZA], ethambutol [EB, EMB], streptomycin [SM], kanamycin [KM, KAN], enviomycin [EVM], ethionamide [TH], cycloserine [CS], para-aminosalicylic acid [PAS], amikacin [AMK], levofloxacin [LVFX] and other fluoroquinolone. Other drugs are used less commonly, such as amoxicillin-clavulanate, linezolid and clofazimine based on Investigator's decision twice a week from Day 1 up to 78 weeks after conversion or 102 weeks after day 1 (what happens first).
1582492|NCT02365610|Drug|GWP42006|
1582493|NCT02365610|Drug|Placebo Control|
1582496|NCT02365571|Drug|LY3154207|Administered orally
1582497|NCT02365571|Drug|Placebo|Administered orally
1582498|NCT02365571|Drug|Itraconazole|Administered orally (twice daily on Day 3 and then once daily to Day 12) as a 10 mg/mL solution
1582499|NCT02365558|Drug|Evacetrapib|Administered orally
1582500|NCT02365558|Drug|Omeprazole|Administered orally
1582501|NCT02365532|Drug|GS-6615|GS-6615 tablets administered orally
1582502|NCT02365532|Drug|Placebo to match GS-6615|Placebo to match GS-6615 tablets administered orally
1582503|NCT02365532|Drug|Placebo to match dofetilide|Placebo to match dofetilide capsules administered orally
1582504|NCT02365532|Drug|Dofetilide|Dofetilide 500 μg capsules administered orally according to the current prescribing information
1582507|NCT02365506|Drug|Eleclazine|Eleclazine tablets administered orally
1582508|NCT02365506|Drug|Placebo|Placebo to match eleclazine tablets administered orally
1582509|NCT02365493|Drug|Beta-Lactam|
1582513|NCT02365467|Device|Valiant Mona LSA Thoracic Stent Graft System|
1582514|NCT02365454|Device|Stent Graft Placement (Nexus)|"The Nexus stent graft is introduced through a groin to the diseased location at the Aortic Arch. Depending on the patients anatomy and other medical considerations the physician may decide that blood flow to the sub-clavian artery and possibly also to the left carotid artery is required to be maintained via surgical bypass grafting, either immediately, or a few days, before the implantation. In addition to the incision for introducing the investigational stent graft, two smaller access sites are required, one at the groin on the opposite side and on into the Right Arm to the Brachial Artery.
This endovascular procedure will likely require full anesthesia. The entire procedure is assisted by an angiography imaging system."
1582515|NCT02365441|Drug|Regorafenib|
1582516|NCT02365441|Drug|imatinib|
1582517|NCT02365428|Behavioral|Physical activity text messages|
1582518|NCT02365415|Drug|Sirolimus|8 weeks oral sirolimus, following drug levels
1582519|NCT02365402|Drug|Entecavir|After enrolled, entecavir will added, and patients will receive treatment of PEG-IFN a-2a combine with entecavir for 48 weeks and 24 weeks of follow-up after treatment.
1582520|NCT02365389|Drug|MTZ vaginal gel|MTZ vaginal gel once daily for 5 days
1582521|NCT02365389|Drug|Conventional MTZ vaginal gel|Conventional MTZ vaginal gel (Tricho gel 0.8%, Sedico, Egypt) twice daily for 5 days
1582522|NCT02365363|Other|Control|Non pulse ingredient bagel
1582523|NCT02365363|Other|Pea flour|Pulse ingredient bagel
1582524|NCT02365363|Other|Pea fibre|Pulse ingredient bagel
1582525|NCT02365363|Other|Pea flour and pea fibre|Pulse ingredient bagel
1582526|NCT02365363|Other|Pea flour and pea protein|Pulse ingredient bagel
1582527|NCT02365363|Other|Pea flour + pea fibre + pea protein|Pulse ingredient bagel
1582528|NCT02365350|Procedure|STEINER-TAN Needle®|A purpose built new double lumen needle with little dead space.
1582529|NCT02365350|Procedure|17 G single lumen needle|A conventional single lumen IVF aspiration needle.
1582532|NCT02365311|Procedure|transesophageal echocardiography(TEE)|Transesophageal echocardiography examination will be performed TLV in supine and lateral position, 10, 20 and 30 min during OLV in left lateral decubitus position. By using the transesophageal echocardiography, we will evaluate the changes of pulmonary blood flow and cardiac function.
1582533|NCT02365298|Device|etafilcon A|etafilcon A soft contact lens
1582534|NCT02365298|Device|nelfilcon A|nelfilcon A
1582535|NCT02365285|Drug|Galantamine|16 mg po acute intervention prior to the infusion of intralipids
1582538|NCT02365259|Device|Phototherapy|Participants will be exposed to phototherapy according to the 2014 Guidelines issued by the American Academy of Dermatology 3 days per week over an 8-week period.
1582539|NCT02365246|Device|immunoadsorptions with an IgE-specific adsorption column|immunoadsorptions
2008669|NCT03327844|Drug|RET using antibiotics (Ciprofloxacin and Metronidazole)|RET using antibiotics Ciprofloxacin and Metronidazole. First Treatment Visit: Local analgesic, tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal drying using paper points. Delivery of mixture of Bi antibiotic paste (Ciprofloxacin and Metronidazole with sterile water). Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstriction, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
1582543|NCT02365220|Behavioral|No expectancy (control)|No expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)
1582544|NCT02365220|Behavioral|Prospective expectancy|"Prospective expectancy instruction (Training will have an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
1582545|NCT02365220|Behavioral|Retrospective expectancy|"Retrospective expectancy instruction (Training already had an effect on...) with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
1582546|NCT02365220|Behavioral|Prospective and retrospective expectancy|"Prospective (Training will have an effect on...) and retrospective (Training already had an effect on...) expectancy instruction with regard to the efficacy of the daily smartphone-based training (exposition to either mock sound or color)"
1582547|NCT02365207|Drug|BCG strain of Mycobacterium bovis|Invasive bladder cancer treated with 3-6 weeks of intravesical BCG
1582548|NCT02365194|Behavioral|Prehabilitation|information included in arm description
1582549|NCT02365194|Behavioral|Standard counseling|information included in arm description
1582550|NCT02365181|Procedure|intra-articular local anesthetic infiltration|intra-articular local anesthetic infiltration with 20 ml of Ropivacaine 2 % and catheter
1582551|NCT02365181|Procedure|inter-scalene block|inter-scalene block with 20 ml of Ropivacaine 2 % and catheter
1582552|NCT02365181|Drug|Ropivacaine 2 %|20 ml of Ropivacaine 2 %
1582553|NCT02365168|Other|Cod_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with cod in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
1582554|NCT02365168|Other|Salmon_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with salmon in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
1582555|NCT02365168|Other|Mackerel_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with mackerel in the following doses: 3µg, 600µg, 12 mg, 120 mg, and 1g covered in chocholate dessert over one day
1582556|NCT02365168|Other|Placebo_Double Blind Placebo Controlled Food Challenge|DBPCFC Food Challenge with placebo covered in chocholate dessert over one day
1582557|NCT02365155|Other|Multicomponent training intervention.|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including a physical part (endurance, strength, flexibility and balance).
1582558|NCT02365155|Other|Nutrition intervention|Both groups will be included in a program of quarterly monitoring receiving nutritional support: nutritional advice plus enteral supplementation should specify.
1582559|NCT02365155|Other|Cognitive intervention|Both groups will be included in a program of quarterly monitoring receiving cognitive support: detection and treatment of depression and delirium in medical consultation.
1582560|NCT02365155|Other|D-vitamin intervention|Both groups will be included in a program of quarterly monitoring receiving hormonal support: supplementation of vitamin D if required with adjustment for guides.
1582561|NCT02365155|Other|Occupational intervention|The intervention group will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary nursing intervention including occupational support.
1582562|NCT02365155|Other|Heart failure follow up.|Both groups will be included in a program specifically developed for this study based on the multidimensional continuous care of patients with heart failure and frailty diagnosis or prefrailty. A joint interdisciplinary medical intervention including and pharmacological treatment of heart failure and comorbidities adjusted according to recent clinical guidelines requirements.
1582565|NCT02365129|Other|Exercise training based on recommendations for adults (WHO)|The length of the trial will be 6 months. the total time of aerobic exercise in both moderate-intensity and vigorous-intensity groups will be 150 minutes/week, whereas the time needed to complete the resistance training exercises will be ≈15-30 minutes for both groups.
1582566|NCT02365116|Behavioral|Peer mentorship|Patients who are working with a peer specialist will have their sessions audio taped and reviewed by research staff for training purposes and to ensure that peer specialists are following protocol.
1582567|NCT02365116|Behavioral|Enhanced Usual Care|The enhancement to usual care will occur at the 3 and 6 month follow-up assessments, where participants will be assessed to determine whether they require any additional referral information for follow-up care. If referral information is indicated, the patient will be provided a list of mental health treatment providers in their area.
1582568|NCT02365103|Other|Test meal I (given with water)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
1582569|NCT02365103|Other|Test meal II (simultaneously with tea)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
1582650|NCT02364557|Other|Laboratory Biomarker Analysis|Correlative studies
1583307|NCT02359175|Drug|Placebo (for oral opioids)|Placebo tablets to be given instead of oral opioids
1582570|NCT02365103|Other|Test meal III (1 hour after test meal)|4 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled in the test meal administered in the study, enrichment in the system will take approximately 14 days post dosing
1582571|NCT02365103|Other|Reference iron dose|3 mg of the iron stable isotope, in a form of ferrous sulphate solution, extrinsically labelled and administered in the study, enrichment in the system will take approximately 14 days post dosing
1582572|NCT02365090|Other|patching|covering the sound eye with a patch to force use of the amblyopic eye
1582573|NCT02365090|Other|binocular games|playing iPad games 1 hour per day 5 days per week to allow the child to use the amblyopic eye and the sound eye together
1582574|NCT02365064|Device|AirCurve 10 ASV|Device is able to provide both ASV therapy and CPAP therapy modes.
1582575|NCT02365051|Behavioral|Care of Persons with Dementia in their Environments|In-home visits by occupational therapist and advanced practice nurse.
1582576|NCT02365038|Other|Driving pressure limited ventilation|We will use volume controlled ventilation or pressure support in the weaning phase. We will adjust tidal volume between 3 and 8 mL/Kg of predicted body weight in order to achieve a driving pressure of 13 cmH2O. The respiratory rate will be titrated to achieve a pH between 7.30 and 7.45 (maximum respiratory rate is 50 breathings per minute). We will not limit plateau pressure in this arm.
1582577|NCT02365038|Other|Conventional ventilation|ARDSNet Strategy: conventional mechanical ventilation strategy with tidal volume between 4 and 6 mL/kg of predicted body weight and plateau pressure limited to 30 cmH2O.
1582578|NCT02365025|Other|Meetings guides by experts in sleeping disorders.|meetings guides by experts in sleeping disorders. In those meeting the parents will be exposed to sleep disturbances, the importance of sleep habits and the influence of electronic media on sleep and learning.
1582579|NCT02365012|Drug|Midodrine|Crossover intervention comparing midodrine to placebo for subjects with orthostatic intolerance
2008670|NCT03327844|Drug|RET using non-setting Calcium Hydroxide|First Treatment Visit: Local analgesic, Tooth isolation, access, pulp extirpation and root canal irrigation with 1.5% sodium hypochlorite. Canal negotiation, canal drying using paper points. Delivery of the non-setting Calcium Hydroxide. Tooth access sealed with temporary dressing. Second Treatment Visit: Tooth analgesia using plain local analgesics without vasoconstrictor, isolation and re-access as described above. Irrigation of root canal system using sodium hypochlorite followed by paper point drying. Initiation of bleeding through insertion of a sterile k-file at a length of 2-3 mm beyond the working length into the periapical tissues. Access sealed using resorbable plug, Biodentine, followed by composite resin.
1582584|NCT02364986|Drug|Rebif®|Rebif® 44µg (day 1, 3, 5 and 8) s.c.
1582585|NCT02364986|Drug|Avonex|Avonex 30µg (day 1 and 8) i.m.
1582587|NCT02364947|Drug|Nalmefene hydrochloride|As-needed; tablets, orally
1582588|NCT02364947|Drug|Placebo|As-needed; tablets, orally
1582589|NCT02364934|Drug|Propofol|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and propoful anaesthesia.
1582590|NCT02364934|Drug|Sevoflurane|This study was designed to determine the dose requirements for rocuronium, administered by continuous infusion to maintain a stable 90-99% T1 depression (depression of the first twitch in the train-of-four, TOF) in adult, elderly and different sex patients under sufentanil and sevoflurane anaesthesia.
1582591|NCT02364921|Device|Two multilayer compression bandage|"Usual clinical practice in venous ulcer in wound care in assessing, cleaning, desinfection, debridement and topical treatment.
Compression therapy: a multilayer compression bandage with two layers, suitable for the treatment of venous leg ulcers and to reduce edema chronic venous be used. Apply one two seven days"
1582592|NCT02364921|Device|Crepe bandage|Crepe bandage: Usual clinical practice in venous ulcer in wound care. crepe bandage apply one to seven days
1582593|NCT02364908|Other|therapeutic education|This is the group sessions aimed to convey additional information to patients about their disease. The main objective is to learn how to better anticipate any medical problems and better manage daily life with the disease.
1582594|NCT02364895|Other|Males control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
1582595|NCT02364895|Other|Males Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
1582596|NCT02364895|Other|Males Group 2: New letter with neutral gender content|Unisex letter
1582597|NCT02364895|Other|Males Group 3: New letter with male-specific content|New letter tailored for men
1582598|NCT02364895|Other|Females control group: Deferred letter|This letter will be sent 6 months after index (mailing) date
1582599|NCT02364895|Other|Females Group 1: Current CCC invitation letter|This letter is currently used by the program in 50-54 year olds
1582600|NCT02364895|Other|Females Group 2: New letter with neutral gender content|Unisex letter
1582601|NCT02364882|Drug|Sildenafil|
1582602|NCT02364869|Dietary Supplement|Fructooligosaccharide|Patients will be evaluated at baseline, week 6 and 12.
1582603|NCT02364869|Dietary Supplement|Maltodextrin|Placebo Comparator. Patients will be evaluated at baseline, week 6 and 12.
1582604|NCT02364856|Device|Analgesia Nociception Index|"The Analgesia Nociception Index (ANI, MDoloris Medical Systems, Lille, France), based on Heart Rate Variability analysis, measures continuously and non-invasively the influence of Respiratory Sinus Arrhythmia on the heart rate. This 0-100 index indicates the proportion of paraS over sympathetic activity. In adults during surgery under general anesthesia, ANI decreases after painful stimulation and has been related to the balance between analgesia and nociception.
ANI is calculated from heart rate recording."
1582605|NCT02364843|Dietary Supplement|Amino Acid: Threonine|Each of the 18 infants will have a different intake of dietary amino acid threonine for a 24 period and by cross-over regression analysis a break-point or requirement will be established
1582606|NCT02364830|Drug|Anise-oil EC Capsule|Anise-oil EC Capsule,One Cap(187mg)/day for 4 Weeks
1582607|NCT02364830|Other|Placebo|One Placebo Capsule/Day for 4 Weeks
1582608|NCT02364830|Drug|Colpermin®|Colpermin® Capsule/Day for 4 Weeks
1582865|NCT02361619|Drug|Midazolam|probe
1582609|NCT02364817|Behavioral|cognitive and psychiatric assessment|"Administered at baseline:
Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar)
hyperactivity : Adult ADHD Self-Report Scale (ASRS), Wenders-Utah Rating Scale (WURS), Diagnostic Interview for Adult ADHD 2nd edition (DIVA 2.0)
psychiatric history : Mini International Neuropsychiatric Interview 5th edition (MINI 5.0), Personality Disorder Questionnaire for the DSM-IV (PDQ-4)
cognitive functions : Frontal Assessment Battery (FAB), Montreal Cognitive Assessment (MoCA)
impulsivity : Barratt's Impulsiveness scale 11th edition (BIS-11)
alcohol consumption: alcohol - timeline follow-back (A-TLFB) ,administered at baseline (month before hospitalization), week 4 visit, week 6 visit, and week 12 visit.
administered at week 12: ASRS"
1582610|NCT02364804|Drug|Aprepitant|The incidence and grade of chemotherapy-induced nausea and vomit (CINV) will be assessed in patients receiving Aprepitant for the prevention of CINV upon the combination chemotherapy of nedaplatin and docetaxel for NSCLC. These data will be compared with those surveyed retrospectively in patients who had received the combination chemotherapy with anti-emetic agents but Aprepitant.
1582611|NCT02364791|Device|standard techniques used to achieve air leak control|
1582612|NCT02364791|Device|Hemopatch|
1582613|NCT02364765|Drug|Remifentanil|Elective bimaxillary orthognathic surgery consisting of a unsegmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of mean remifentanil administration of 0.3 mg/kg/hour
1582614|NCT02364752|Procedure|Blood Draw|
1582615|NCT02364752|Procedure|Loop Diuretic Withdrawal/Salt Load|
1582616|NCT02364739|Other|Written information|Brochure
1582617|NCT02364739|Other|Written and oral information|Written information consists in a brochure with information about fertility, while oral information consists in a tailored oral explanation about the wrong answers to the pre-test (that is related to the brochure).
1582618|NCT02364726|Procedure|Acupuncture|Each treatment session will be approximately 40 minutes in duration, 10 minutes to insert needles, 30 minutes to leave needles in. Patients will receive one acupuncture treatment each week until the end of chemotherapy. Adverse effects related to the administration of acupuncture will be collected each week before and after each treatment by the acupuncturist or research study assistant. All Integrative Medicine Service acupuncturists are licensed, credentialed employees of MSK.
1582619|NCT02364726|Behavioral|Neuropathic Pain Scale (NPS) questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session before the last chemotherapy session.
1582620|NCT02364726|Behavioral|FACT/GOG-Ntx questionnaire|It will be collected weekly throughout the screening phase, as well as, at the time of intervention consent, weekly during the intervention, and then once again after the last acupuncture session but before the as the last chemotherapy session, and then once again 3 months (+/-2 weeks) after chemotherapy completion.
1582621|NCT02364713|Drug|Gemcitabine Hydrochloride|Given IV
1582622|NCT02364713|Other|Laboratory Biomarker Analysis|Correlative studies
1582623|NCT02364713|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
1582624|NCT02364713|Drug|Paclitaxel|Given IV
1582625|NCT02364713|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
1582626|NCT02364713|Other|Quality-of-Life Assessment|Ancillary studies
1582627|NCT02364713|Drug|Topotecan Hydrochloride|Given IV
1582628|NCT02364700|Device|Hand of Hope (HOH)|"Subjects will receive arm training 3x/week for 6 weeks, each session is anticipated to last approximately 60 minutes. Sessions will be scheduled for Monday, Wednesday, and Friday whenever possible to provide a rest period between sessions. Each session will consist of the following:
warm up-passive stretch of hand in flexion and extension (5 minutes);
setting the EMG threshold parameters for the device;
active practicing of opening the hand (Desperate Bee, Hungry Bird, Sun Archer games; 10 min)
active practice of closing then hand (UFO Catcher game; 10 min)
open and closing the hand (Ball and Basket game; 10 min)
open and closing the hand while incorporating reach ( for subjects with adequate ability to reach with shoulder/elbow; 10 min)
cool down-passive stretch of hand in flexion and extension (5 minutes)"
1582629|NCT02364687|Radiation|Computed tomography late enhancement imaging|
1582630|NCT02364674|Radiation|High Resolution Computed Tomography scan|"a HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.
An Upper Airway (UA) scan will be taken on visit 1."
1582631|NCT02364661|Behavioral|Over night starvation (fasting)|HBV viral load will be analyzed after over-night starvation versus following a morning meal
1582632|NCT02364648|Dietary Supplement|MitoQ|Mitochondria targeted antioxidant
1582633|NCT02364648|Dietary Supplement|Placebo|Placebo
1582634|NCT02364635|Drug|icosabutate|Single dose at each dose levet
1582635|NCT02364622|Device|Tranditional fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by tranditional fiberoptic bronchoscopy.
1582636|NCT02364622|Device|Modified fiberoptic bronchoscopy|The accurate placement of left-sided DLT into the left main bronchus was facilitated by modified fiberoptic bronchoscopy
1582637|NCT02364622|Device|Flexible Trachway intubating stylet|The accurate placement of left-sided DLT into the left main bronchus was faciliated by using flexible Trachway intubating stylet.
1582638|NCT02364609|Drug|Afatinib Dimaleate|Given PO
1582639|NCT02364609|Biological|Pembrolizumab|Given IV
1582640|NCT02364596|Biological|SA4Ag vaccine|Subjects receive 1 intramuscular injection (0.5 mL) of the SA4Ag vaccine.
1582641|NCT02364596|Procedure|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
1582642|NCT02364583|Drug|Primaquine|Primaquine treatment given in a step-wise manner; (a) 0.5 mg/kg total dose daily for 14 days (n=40), (b) 1.0 mg/kg total dose daily for 7 days (n=40), (c) 1.0 mg/kg twice daily for 3.5 days (n=40)
1582643|NCT02364570|Other|Glucose (100g)|Ingestion of glucose (100g)
1582644|NCT02364570|Other|Glucose (75g)|Ingestion of glucose (75g)
1582645|NCT02364570|Other|Whole Eggs|Ingestion of 1.5 whole eggs
1582646|NCT02364570|Other|Egg Whites|Ingestion of 7 egg whites
1582647|NCT02364570|Other|Egg Yolks|Ingestion of 2 egg yolks
1582648|NCT02364557|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
1582649|NCT02364557|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1582651|NCT02364544|Behavioral|Relapse Prevention Plan|brief, in-person, relapse prevention counseling with supplemental web-based learning modules,
1582652|NCT02364544|Behavioral|Daily Support Website|web-based program for patients and families that provides psychoeducation about schizophrenia and its treatments to improve knowledge, increase problem-solving skills and offer social support through the use of web-based therapist facilitated sessions
1582653|NCT02364544|Behavioral|Computer CBT for voices and paranoia|A ten-session CBT programs, one to address voices and the other for paranoia. The web-based programs incorporate the essential elements of CBT for psychosis such as normalizing behavior and offering behavioral coping strategies
1582654|NCT02364544|Behavioral|FOCUS|an interactive smart phone text-messaging application to support medication adherence, facilitate coping with symptoms and improve daily functioning in individuals with schizophrenia
1582655|NCT02364544|Other|Prescriber Decision Assistant|is a web-based prescriber decision support system that includes a brief patient-completed assessment describing symptoms and adverse events which prompts the prescriber to conduct a detailed clinical assessment. Embedded in the program are decision supports for medication choices based on best evidence-based practices regarding symptoms, side effects, information from laboratory tests and history of prior treatment response
2008671|NCT03328286|Behavioral|Weekly group meeting w/psychotherapist|Introduce a Psychotherapist in a work Integration program to further support Young adults in Job search and at the same time offering psychotherapeutic counselling. The participants will have a weekly meeting lasting 1.5 hour and additionally the can have 5 private counselling sessions with the psychotherapist if they wish
1582657|NCT02364518|Procedure|Snoreplasty|The procedure will be performed under local anesthesia in the examination chair. The subject's throat will be anesthetized with benzocaine spray followed by infiltration of the soft palate with 4-5 milliliters of 1% lidocaine with 1:100,000 epinephrine. The TranQuill suture will be inserted into the soft palate tissues using a predescribed pattern.
1582658|NCT02364505|Behavioral|Telemedicine mindfulness-based intervention|Comparison of telemedicine mindfulness intervention with telemedicine psycho-education control group
1582659|NCT02364505|Behavioral|Psycho-education intervention|Psycho-education control group, provided with a telemedicine approach. Subject in this group will use a similar software than the experimental intervention, with identical time efforts required. Software contents will be psycho-educative.
1582660|NCT02364492|Drug|MAG-TN3 + AS15|
1582661|NCT02364479|Drug|etanercept|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 50mg per week
1582662|NCT02364479|Drug|etanercept (half dose)|Recombinant Human Tumor Necrosis Factor-α Receptor Ⅱ IgG Fc Fusion Protein Injection, 25mg per week
1582663|NCT02364479|Drug|placebo|
1582664|NCT02364453|Drug|PACAP38|Giving doses of 4, 6 or 8 pg/kg/min on three separate trial days.
1582665|NCT02364440|Device|Ultherapy™ System|Subjects will receive 20 lines Ultherapy™ System Treatment over their right and left hand with 1.5 and 3.0 probe respectively
1582666|NCT02364427|Device|Arterial stiffness - Vicorder to measure pulse wave velocity|Pulse wave velocity (PWV)measures the stiffness of the arteries. This provides a simple and quick noninvasive method of obtaining the PWV for an arterial segment.
1582667|NCT02364414|Device|3Shape TRIOS (R)|Direct intra-oral scan of teeth and dentition
1582668|NCT02364401|Device|Ablation|Catheter ablation for atrial fibrillation
2008672|NCT03328273|Drug|AZD6738|An ATP competitive, orally bioavailable inhibitor of the Serine/Threonine protein kinase Ataxia Telangiectasia and Rad3 related (ATR).
1582670|NCT02364362|Drug|famitinib L + docetaxel|famitinib 15mg qd + docetaxel 60 mg/m^2
1582671|NCT02364362|Drug|famitinib M + docetaxel|famitinib 20mg qd + docetaxel 60 mg/m^2
1582672|NCT02364362|Drug|famitinib H + docetaxel|famitinib 25mg qd + docetaxel 60 mg/m^2
1582673|NCT02364349|Drug|Bee Venom (BV)|Raw Bee Venom
1582674|NCT02364349|Drug|Essential Bee Venom (e-BV)|Bee venom without Hyaluronidase, Lysophospholipase, α-D-glucosidase, PLA2, Adolapin
2008673|NCT03328273|Drug|acalabrutinib|A novel experimental anti-cancer drug and a 2nd generation Bruton's tyrosine kinase (BTK) inhibitor.
1582676|NCT02364323|Behavioral|Personalized Risk Counselling|Motivational message- towards lifestyle change, improved compliance and risk factors control Review overall control of clinical risk factors based on lab test results
1582677|NCT02364323|Other|Normal usual care|General education on diabetes and diabetic complications
1582678|NCT02364310|Device|Baroreceptor stimulation with Barostim Neo TM|
1582679|NCT02364297|Device|Early TIPS|TIPS (first 5 days)
2008674|NCT03328260|Device|HIFU|Transvaginal high intensity focused ultrasound to ablate uterine myoma
2008675|NCT03328247|Other|ASICA digital app|Participants in the intervention arm will be trained to use ASICA (in addition to completing routine follow-up) and participants within the control arm will continue to attend their usual structured melanoma follow-up only. The hypothesis is that the ASICA intervention will increase TSSE practice in those affected by melanoma without affecting psychological well-being and lead to earlier detection of recurrent and new primary melanoma.
2008676|NCT03328234|Radiation|SIB-IMRT|Patients receive radiotherapy once daily, 5 days a week for an average of 5.5 weeks. Radiotherapy is delivered to achieve a prophylactic dosage of 50.4Gy to PTV and 59.92Gy to PGTV in 28 fractions, respectively.
1582866|NCT02361619|Drug|Dabigatran|probe
2008677|NCT03328234|Drug|Paclitaxel|45 to 50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
2008678|NCT03328234|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
2008679|NCT03328234|Drug|Paclitaxel|150mg/m2 on day1,every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
2008680|NCT03328234|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 80mg/m2 on day1 (Lobaplatin,50mg on day1 ),every 3 weeks, 2 cycles, 1 month after completion of radiotherapy
2008681|NCT03328234|Other|Elective Nodal Irradiation (ENI)|CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and lymph node regions at high risk.
2008682|NCT03328234|Other|Involved Field Irradiation (IFI)|CTV was defined as GTV with a 3.0-5.0 cm craniocaudal margin and a 0.6-0.8 cm lateral margin and GTVnd with a 0.5-1.0 cm margin.
2008683|NCT03328208|Other|Comfort Talk® app|Test app
2008684|NCT03328208|Other|White Noise app|White Noise app built to mimic appearance of Comfort Talk® test app
2008685|NCT03328195|Device|Neuro RX Gamma|Twenty minute treatment, six days per week for 12 weeks
1582685|NCT02364258|Drug|Rosuvastatin|Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
1582686|NCT02364258|Drug|Atorvastatin|Atorvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
1582687|NCT02364245|Device|Kinect|Receive computer games training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
1582688|NCT02364245|Other|Traditional OT(30 Mins)|Receive Traditional Occupational Therapy training for 30 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
1582689|NCT02364245|Other|Traditional OT(60 Mins)|Receive Traditional Occupational Therapy training for 60 minutes. There are 3 sections for 1 week; the intervention period will be 8 weeks.
1582690|NCT02364232|Behavioral|bilateral training with and without mirror feedback|
1582691|NCT02364219|Other|Prewarming|Patients are treated according to standard operating procedures plus prewarming period of at least 30 minutes during induction of combined general and epidural anesthesia.
1582692|NCT02364219|Device|Microdialysis|71 High Cut-Off Brain MD Catheter Membrane cut-off: 100 kDa Membrane length 30 mm Shaft length: 60 mm Dialysis AB, Stockholm, Sweden
1582693|NCT02364206|Drug|LY2228820|
1582694|NCT02364206|Drug|Temozolomide|
1582695|NCT02364206|Radiation|radiotherapy|
1582696|NCT02364193|Device|MRI|"Cardiac MRI for LVEF and segmentation.
Phase-contrast MRI for CO in aorta and each pulmonary vein.
DCE-MRI for bolus kinetic parameter analysis."
1582697|NCT02364193|Drug|Gd-CA|Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
1582698|NCT02364193|Device|BIS ImpediMed™ SFB7|"BIS will be measured by Bio-impedance spectroscopy will be performed using ImpediMed™ SFB7 (ImpediMed Limited 2008).
Impedance will be measured continuously during the fluid challenge and for maximum 600 seconds before and after the fluid challenge.
Currents of different frequencies will be applied; the resulting voltage will be recorded, with a time resolution for the complete frequency span not lower than 2 seconds."
1582699|NCT02364193|Device|Autotransfusion Lympamat Digital Gradient system|Lympamat Digital Gradient system (Bosl, Aachen) inflatable leg compression trousers will induce an autotransfusion by compressing the legs with a maximum of 90 mmHg for a maximum of 300 seconds
1582700|NCT02364180|Diagnostic Test|Electromyography (EMG)|
1582701|NCT02364167|Drug|Standard therapy|Standard therapy includes pharmacologic treatment of postoperative pain according to the standards of our University hospital
1582702|NCT02364167|Device|Verum acupuncture|"Verum acupuncture will be performed using indwelling permanent acupuncture needles New Pyonex with 1,5 mm length, manufactured by Seirin Corp. Japan"
1582703|NCT02364167|Other|Placebo acupuncture|"Placebo acupuncture will be performed using the placebo New Pyonex adhesive tapes, mimicking the needles, manufactured by Seirin Corp. Japan"
1582704|NCT02364154|Other|Blood sampling|Determine the metabolic phenotype of blood plasma by NMR spectroscopy
1582705|NCT02364154|Other|Blood sampling|determine amount and type of free circulating miRNA in blood plasma
1582706|NCT02364141|Other|Trunk restraint therapy|"Reaching training with trunk restraint by a harness that limited the trunk movements.
Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks."
1582707|NCT02364141|Other|Trunk unrestraint therapy|"Unrestraint reaching training, only with verbal feedback to maintain the trunk right position.
Forty-five training minutes, twice a week, totaling twenty sessions, were performed. The training was based in the motor learning concepts including repetitive and task-specific practice. The training task consisted of grasping a cone (3.5 cm diameter base, 13 cm high) and fitting random targets as requested by the therapist in a training platform (54 cm length, 64 cm extent, 1.5 cm high) with 9 targets (6.5 cm diameter) placed 10-13 cm apart, along 3 lines. The targets that were ordered in a way that stimulated the complete range of motion of shoulder and elbow, had pictures, colors, letters and numbers on them yielding variability and feedback to the performing tasks"
1582708|NCT02364128|Behavioral|Decider Guider: Weight Loss|Decision aid tool about weight loss treatment
1582709|NCT02364115|Radiation|Stereotactic Body Radiotherapy|
1582710|NCT02364089|Procedure|Laparoscopic surgical removal of the adrenal tumor|
1582711|NCT02364089|Drug|Standardized medical treatment of hypertension by SAHR|"Standardized anti-hypertensive drug regimen has been established according to international recommendations and includes the following steps:
step 1: Angiotensin converting enzyme inhibitor (ACE-I) or angiotensin II receptor antagonist (ARBs) at half-dose (Ranipril 5mg or Ibesartan 150 mg )
step 2: CEI or ARA2 at full dose (Ranipril 10 mg or Ibesartan 300 mg)
step 3: Add-on of Amlodipine 10 mg or Diltiazem LP 300 mg
step 4: Add-on of Indapamide LP 1.5 mg
step 5: Add-on of Spironolactone 25 mg
step 6: Add-on of Bisoprolol 10 mg
step 7: Add-on of Prazosine LP 5mg/day."
2008686|NCT03328195|Device|Sham|Twenty minutes, six days per week for 12 weeks with sham device
1582713|NCT02364063|Other|urotherapy with or without pharmacotherapy|Individualized
2008687|NCT03328182|Device|New oral endotracheal tube holder|The single arm study product is designed to hold a standard or subglottic ET tube.
2008688|NCT03328169|Behavioral|Mindfulness-Based Therapy|Participants are taught relaxation and mindfulness techniques to practice. They also learn about various alternative medicine modalities to which they can apply mindfulness with the target of reducing insomnia. The group meets weekly for 2 hours for a duration of 9 weeks.
1582867|NCT02361619|Drug|Clarithromycin|perpetrator
1582868|NCT02362711|Drug|NPC-16 Standard Dosing Regimen Group|
2008689|NCT03328169|Behavioral|Cognitive Behavioral Therapy for Insomnia|A licensed psychologist is delivering Cognitive Behavioral Therapy for Insomnia to women for 90-120 minutes weekly for nine weeks. The Cognitive Behavioral Therapy for Insomnia protocol is well documented in published literature.
2008690|NCT03328143|Drug|Lavender (Lavandula angustifolia)|Lavender (Lavandula angustifolia) is an essential oil.
1582718|NCT02363985|Dietary Supplement|Mega-dose of vitamin A supplement|vitamin A supplementation normally given every six months for under five children in Ethiopia. In addition, there is also dietary intervention like orange flash sweet potato and promotion of other vitamin A rich foods to tackle vitamin A deficiency in Ethiopia.
1582719|NCT02363972|Device|Ellipsys Vascular Access Catheter|A one-time use vascular catheter used as a less invasive means of creating an AV fistula. Screening and follow-up assessments are standard of care for surgical AV fistulae.
1582720|NCT02363959|Drug|Hyperbaric Oxygen Therapy|2 hours of breathing >99% medical grade oxygen inside an air-pressurized chamber at 2 ATA once a day for 20 sessions. These sessions will be scheduled 3-5 times per week, depending on the availability of the patient and the hyperbaric medicine physician.
1582721|NCT02363959|Procedure|Endobronchial Biopsy of Airway Epithelium|During standard post-transplantation bronchoscopies, participants in this study will undergo an endobronchial biopsy of the airway epithelium for each donor lung.
1582724|NCT02363933|Drug|Perampanel|Perampanel is a highly selective non-competitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) type glutamate receptor antagonist that has shown efficacy in a randomized phase III study for refractory partial-onset seizures
1582725|NCT02363920|Device|HOF|the addition of high oxygen flow to patients breathing spontaneously
1582726|NCT02363920|Device|noninvasive mechanical ventilation (NIV)|the addition of a ventilatory support delivered with a oro-nasal interface
1582727|NCT02363855|Drug|BAY 1841788(ODM-201)|Cohort 1: Single dose 300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks Cohort 2: Single dose 2x300 mg BAY 1841788, followed by twice daily administration of the same dose for 12 weeks.
1582728|NCT02363842|Device|Skin IQ™ MCM Coverlet|Test article is the Skin IQ™ MCM, a Class II 510k exempt product. It is an overlay coverlet indicated to be used in conjunction with a pressure redistribution surface in order to aid in the prevention and treatment of skin breakdown and pressure ulcers for patients who require microclimate management of the skin.
1582729|NCT02363842|Other|Pressure redistribution surface|Standard of Care (SOC): pressure redistribution surface already in use at the participating institution to manage patients at risk for tissue breakdown
1582730|NCT02363829|Drug|Nelfinavir|
1582731|NCT02363829|Biological|Cisplatin|
1582732|NCT02363803|Drug|lidocaine|lidocaine is a sodium channel blocker/analgesic. It is approved for intravenous administration for cardiac arrhythmias.
1582733|NCT02363803|Drug|Placebo|Normal saline, approved for hypovolemia, and homeostasis.
1582734|NCT02363790|Procedure|LVHR PFC|Information included in arm description
1582735|NCT02363790|Procedure|Bridging LVHR|Information included in arm description
1582736|NCT02363777|Procedure|Epidural|A mid thoracic epidural is placed preoperatively and a local anesthetic and opioid infusion is run postoperatively
1582737|NCT02363777|Procedure|Paravertebral catheters|Bilateral paravertebral catheters are placed and a local anesthetic infusion via an elastomeric pump is run postoperatively
1582738|NCT02363764|Procedure|Nasal swab|"Will be obtained by the physiotherapist in:
Expectorating CF patients
Non-expectorating CF patients
Bronchoscopy CF patients"
1582739|NCT02363764|Procedure|Cough swab|"Will be obtained by the physiotherapist in:
Expectorating CF patients
Non-expectorating CF patients
Bronchoscopy CF patients"
1582740|NCT02363764|Procedure|Spontaneous expectorated sputum|"Will be obtained by the physiotherapist in:
- Expectorating CF patients"
1582741|NCT02363764|Procedure|Induced sputum|"Will be obtained by the physiotherapist in:
Non-expectorating CF patients
Bronchoscopy CF patients"
1582742|NCT02363764|Procedure|Bronchoalveolar lavage|"Will be obtained by the pulmonologist in:
- Bronchoscopy CF patients"
1582743|NCT02363764|Other|Questionnaire|Completing questionnaire on acceptability of different sampling methods by patients >6 years of age
1582745|NCT02363738|Drug|Infliximab|Intravenous infliximab (5mg/kg) at baseline, week 2 and 6 under clinical observation. Infliximab will be prescribed adjunctively to a conventional mood stabilizer or atypical antipsychotic agent.
1582746|NCT02363738|Other|Saline|Intravenous placebo (saline solution) at baseline, week 2 and 6 under clinical observation. Placebo will be matched to infliximab in color and consistency and will be administered adjunctively to conventional mood stabilizer or atypical antipsychotic agent.
1582747|NCT02363725|Drug|Colchimax®|
1582748|NCT02363725|Drug|Conventional treatment|
2008691|NCT03328130|Biological|AAV2/5-hPDE6B|Subretinal administration in one eye
2008692|NCT03328117|Drug|Imatinib|Over-encapsulated 100 mg imatinib mesilate tablets
1582751|NCT02363699|Drug|Lidocaine|Lidocaine was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure. Solution of 0,3% lidocaine was used, so that the infusion rate was equal to the weight of the patient.
1582752|NCT02363699|Drug|Saline solution|Saline solution was administered in bolus of 1.5 mg.kg-1 at the start of the procedure and maintained at a dose of 3 mg.kg-1.h-1 until one hour after the end of the procedure.
1582869|NCT02362711|Drug|NPC-16 Continuous Dosing Regimen Group|
1582870|NCT02362711|Drug|Placebo Group|
2008693|NCT03328117|Drug|Placebo oral capsule|Matching placebo oral capsule
2008694|NCT03328104|Drug|Everolimus|Given once daily orally via mouth or NG tube beginning at Dose Level (DL) 1 (4 mg/m2/day). Depending on safety and tolerability, dose levels will be escalated to DL2 (5 mg/m2/day). There is also a dose level de-escalation to DL0 (3 mg/m2/day) if toxicity is noted at DL1. Begins at Day 1 through 28.
1582753|NCT02363686|Procedure|FEES|A thin, flexible endoscope designed for assessment of laryngeal structures is passed through the nose to the oropharynx, visualizing the laryngeal structures, and the base of tongue and the pharynx. If needed 4% topical lidocaine and/or oxymetazoline (Afrin) will be administered. Swallowing will then be evaluated directly with six food boluses of 5 ml each. All patients will be allowed to swallow spontaneously without a verbal command to swallow. Video of the examinations will be recorded and presence of dysphagia will be designated independently by 3 different observers (one pulmonary physician and two speech language pathologists (SLPs)). This procedure will take 5-10 minutes. The camera will then be removed.
1582754|NCT02363686|Procedure|BSE|Following the FEES, a speech language pathologist (SLP) will perform a noninvasive bedside swallow evaluation (BSE). The SLP will be blinded to the results of the FEES, and the name of the SLP performing the BSE will not be recorded. No other identifying information will be collected regarding the SLP performing the test.
1582755|NCT02363673|Other|Individualised homoeopathic remedy in aqua distilla|Each participant is to receive an individualised homoeopathic remedy according to their symptoms and characteristic manifestations of their disorder.
1582756|NCT02363660|Biological|GINI|
1582757|NCT02363647|Other|Tumor Genomic Analysis|"Tumor mutations identified by deep DNA and RNA sequencing of individual tumors are screened for tumor drivers, which are then incorporated into the personal Drosophila model and tested against a library of FDA approved drugs. Fly mortality is used as a surrogate for toxicity and increased survival to adulthood; improvements in tumor mutation-linked eye and/or wing abnormalities serve to quantify efficacy. This allows rapid and parallel screening of FDA approved drugs and subsequent drug combinations. The most efficacious and least toxic combinations are tested in xenograft models and a multidisciplinary tumor board of experts select the best therapeutic option. The objective is to demonstrate that the personalized drosophila model approach is superior to the current standard. Patient will be offered an unique personalized single drug or combination of drugs, all FDA approved, based on the Drosophila drug screening process."
1582758|NCT02363634|Dietary Supplement|magnesium threonate|nutritional product
2008695|NCT03328104|Drug|Nelarabine|650 mg/m2 IV daily x Day 1-5
2008696|NCT03328104|Drug|Cyclophosphamide|440 mg/m2 IV x Day 1-5
1582761|NCT02363608|Other|standard post surgery care|
1582762|NCT02363608|Behavioral|Caring Canine program|The therapy dogs who visit at MSKCC. A visit by a therapy dog typically lasts about 10-15 minutes with the patient interacting with the therapy dog while the dog is supervised by the handler.
1582763|NCT02363608|Behavioral|baseline and post assessment|The baseline and post assessment will include the Professional Quality of Life Scale (ProQOL R-IV) (Stamm, 1997-2005) and qualitative questions.
1582764|NCT02363582|Other|formula|An infant formula contains prebiotics and lactoferrin
1582765|NCT02363556|Procedure|Misoprostol administered vaginally|
1582766|NCT02363556|Procedure|Misoprostol administered buccally|
1582767|NCT02363556|Procedure|Misoprostol administered vaginally with Dilapan|
1582768|NCT02363556|Procedure|Misoprostol administered buccally with Dilapan|
1582769|NCT02363543|Device|Hyalomatrix|
1582770|NCT02363543|Device|Integra|
1582771|NCT02363530|Device|Hydroxypropyl ethylcellulose (HPMC) 2% gel|We use the hydroxypropyl ethylcellulose (HPMC) 2% gel instead of the traditional balanced salt solution during the cataract surgery.
1582772|NCT02363530|Device|BSS|Balanced Salt Solution including normal saline and glucose
1582773|NCT02363517|Drug|Sofosbuvir/ledispasvir fixed dose combination (SOF + LDP)|SOF + LDV tablets contain 400mg of SOF and 90mg of LDV.
1582774|NCT02363504|Other|7 Tesla MRI with memory task and non-invasive neurostimulation|This is not an intervention, we investigate the neural mechanisms
1582775|NCT02363491|Drug|OPN-305|For the dose confirming part of the study, patients will receive a starting dose of 5 mg/kg OPN-305.
1582776|NCT02363478|Drug|buspirone|buspirone 10 mg X2 for 4 weeks
1582777|NCT02363465|Other|Echographic measurement of skin thickness|"(Epi)Dermal thickness at the proximal forearm and the deltoid region will be measured using imaging technology, more specifically high-frequency ultrasound (20-40 MHz) in B-mode (VEVO 2100®, Visual Sonics). This non-invasive measuring technique has already been proven to be accurate.
The echographic measurement will be performed on the left and right deltoid region and on two sides of the proximal forearm. Both the dorsal part and the volar/palmar part of the proximal forearm will be investigated. Ultrasound will be executed using gel (Aquasonic®) to optimize imaging."
1582778|NCT02363452|Drug|Reverse transcriptase inhibitors: Zidovudine, Lamivudine, Abacavir|Oral Solution (syrup) or Tablets
2008697|NCT03328104|Drug|Etoposide|100 mg/m2 IV x Day 1-5
1582780|NCT02363426|Device|INVOcell Culture Device|INVOcell is a vaginal culture device
1582781|NCT02363426|Device|IVF Incubation|IVF Incubator
1582782|NCT02363413|Other|IniVAH|Initiation of the NIV during a 3 days hospitalization as usual.
1582783|NCT02363413|Other|IniVAD|Initiation of the NIV at home. The first day, the kinesiologist and the technician start-up the NIV at home with the patient. The investigator will validate the adjustment settings proposed by the kinesiologist. No procedure during the second day as described by the HAS. The third day, the kinesiologist and the technician come back to the patient home so as to adjust the settings if needed and if validated by the investigator.
1582784|NCT02363400|Drug|MEP|Adjuvant Chemotherapy
2008698|NCT03328091|Other|Traditional pre-test genetic counseling|Participant meets with a genetic counselor at the Center for Cancer Genetics and Prevention and traditional pre-test cancer genetic counseling is provided
2008699|NCT03328091|Other|Pre-test video education|The video is designed to mirror the educational components of a traditional genetic counseling visit
1582915|NCT02362308|Drug|mineralocorticoid receptor antagonist|Subjects will be treated with a mineralocorticoid receptor antagonist according to standard of care
1582916|NCT02362295|Other|qualitative interview|some patient are interviewed.
2008700|NCT03328078|Drug|CA-4948|CA-4948
2008701|NCT03328065|Other|Interviews|Semi-directed interviews, recorded and transcribed for analysis
2008702|NCT03328065|Other|Questionnaires|economic and psycho-social questionnaires
1582787|NCT02363374|Drug|Induction Chemotherapy arm A|"Patients receive three induction chemotherapy cycles, starting on day 1, 15 and 29, consisting of:
Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv
After a break of two weeks, radiotherapy starts combined with:
5-FU: 250 mg/sqm per day, iv, on day 43-57, day 64-77 Oxaliplatin: 50 mg/sqm, day 43, 50, 64, and 71"
1582788|NCT02363374|Radiation|Radiation arm A|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 43 -80
1582789|NCT02363374|Radiation|Radiation arm B|Radiotherapy: 28 x 1.8 Gy (total: 50.4 Gy), 5 fractions per week on day 1- 38
1582790|NCT02363374|Drug|Chemotherapy arm B|"chemoradiotherapy is started according to the following schedule: 5-FU: 250 mg/sqm per day, iv, on day 1-14, day 22-35; Oxaliplatin: 50 mg/sqm, day 1, 8, 22, and 29.
After a break of two and a half weeks, patients receive three chemotherapy cycles, starting on day 57, 71 and 85, consisting of:
Folinic acid: 400 mg/sqm, 2h-iv; Oxaliplatin: 100 mg/sqm, 2h-iv; 5-FU: 2400 mg/sqm, 46h-iv"
1582791|NCT02363374|Procedure|Surgery|Surgery should be performed about 5 (arm B) or 6 (arm A) weeks after the last radiation or chemotherapy, i.e. around day 123
1582792|NCT02363361|Drug|Imatinib|Day 1. 800 mg, Day 2-14: 2 * 400 mg per day
1582793|NCT02363348|Dietary Supplement|L arginine|L arginine is a basic amino-acid precursor of nitric oxide main vasodilator.
1582794|NCT02363348|Other|Placebo|calcined magnesia
1582801|NCT02363283|Drug|Glembatumumab Vedotin|Given IV
1582802|NCT02363283|Other|Laboratory Biomarker Analysis|Correlative studies
1582803|NCT02363283|Other|Pharmacological Study|Correlative studies
1582804|NCT02363270|Procedure|Ketamine|IV Push or or IV Drip
1582805|NCT02363218|Radiation|CyberKnife|Patients will undergo a CT scan with and without contrast and MRI scan for radiation treatment planning and target delineation.SBRT will be delivered on the CyberKnife with Synchrony Respiratory Tracking capabilities. The tumor will be tracked with 3 implanted fiducial seeds for targeting. Treatment will be delivered in 3 fractions within a 7 day window at the discretion of the investigator.
1582806|NCT02363205|Behavioral|Tailored Internet-administrated CBT-Treatment|Guided internet-delivered CBT with chat sessions
1582807|NCT02363192|Behavioral|Pharmacist intervention and pharmacist support|Patients randomised to this group will undergo an asthma assessment to assess asthma control, adherence and inhaler technique, by an Advanced Clinical Pharmacist specialising in Respiratory Medicine.
1582808|NCT02363179|Behavioral|Live preferential music|Live preferential music will be performed for patients in the emergency department.
1582809|NCT02363166|Other|Acute Abscess Group|Samples collected for culture and sensitivity testing depending on acute abscess, or skin/soft tissue infection.
1582811|NCT02363140|Other|Will undergo a single MRI assessment with intravenous dye|
1582812|NCT02363140|Other|pre and post surgery MRI scan|
1582813|NCT02363127|Drug|subcutaneous progesterone|subcutaneous progesterone 25 mg/day
1582814|NCT02363127|Drug|vaginal progesterone|vaginal progesterone in capsules 200 mg/3 times a day
1582815|NCT02363088|Other|Neutral text message reminder|"Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
1582816|NCT02363088|Other|Messenger text message reminder|"<GP NAME>: Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
1582817|NCT02363088|Other|Social Norms A reminder|"Last year in Hillingdon 7 out of 10 women took part in cervical screening. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
1582818|NCT02363088|Other|Social Norms B reminder|"Last year 12000 women in Hillingdon took part in cervical screening. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
1582819|NCT02363088|Other|Framed Gain text reminder|"Cervical cancer screening saves 4500 lives in England every year. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
1582820|NCT02363088|Other|Framed Loss text reminder|"Failing to attend cervical screening could lead to 4500 avoidable deaths in England each year. Your cervical smear test is due. To book please call <xxxxxxxxxxx>"
1582821|NCT02363075|Drug|Dexamfetamine sulphate|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
1582822|NCT02363075|Drug|placebo|10mg/day per os for the first ten days, 20mg/day for the ten following days, 30mg/day until D90.
1582823|NCT02363049|Procedure|Colectomy|
1582824|NCT02363049|Drug|Chemotherapy|
1582825|NCT02363023|Procedure|Collect tracheal and pulmonary secretions|Collect tracheal and pulmonary secretions (endotracheal aspirate, bronchoscopic and non-bronchoscopic bronchoalveolar lavage)
1582826|NCT02363010|Behavioral|Gold Standard Behavior Therapy for Weight Loss|Group- based behavioral treatment for weight loss and weight loss maintenance, with a standard emphasis on diet (65% of session) and physical activity goals (25% of session). Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
1582827|NCT02363010|Behavioral|Behavior Therapy for Weight Loss with Physical Activity Emphasis|Group-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
1582828|NCT02363010|Behavioral|Acceptance-based Behavior Therapy for Weight Loss with PA emphasis|Group-based, acceptance-based behavioral treatment for weight loss and weight loss maintenance, with a larger emphasis on physical activity goals (65% of session) than eating-related goals (25% of session).Other weight loss behaviors such as self monitoring will be covered in the remaining time (10% of session).
1582829|NCT02362997|Drug|Pembrolizumab|Anti-PD-1 monoclonal antibody
1582992|NCT02361658|Other|Ultrasonographic of the optic nerve sheath diameter|On both eyes of all subjects in supine position by two investigators.
1582830|NCT02362984|Drug|Placebo|Placebo of DLBS1033 will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
1582831|NCT02362984|Drug|DLBS1033|DLBS1033 enteric-coated tablets will be given in addition to the standard therapy consisting of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, vitamin B complex 1 x 1 tablet daily, and citicholine injection 250 mg/2 mL twice daily
1582832|NCT02362958|Drug|lapatinib and capecitabine or vinorelbine|lapatinib 1250 mg qd and Capecitabine 1000 mg/m2 bid or Vinorelbine 25mg/m2(d1,d8)
1582833|NCT02362945|Drug|Intervention group:|Treatment with 1 gr hexakapron Intra-Venous (IV) after delivery of the fetus in addition to accepted treatment with oxytocin (10 units in 100ml NaCl 0.9% solution IV).
1582834|NCT02362932|Other|Sanitation|Shared sanitation
1582835|NCT02362906|Drug|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection
1582836|NCT02362906|Drug|wind-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
1582837|NCT02362906|Drug|phlegm-heat formula granules|children aged 6 months to 3-year old: 1/2 packet，orally taken two times daily or frequency; children aged 3 to 5-year old: 2/3 packet，orally taken two times daily or frequency; children aged 5 to 14-year old: 1 packet， orally taken two times daily or frequency
1582838|NCT02362906|Drug|Fu-xiong San|external application; 8-10 cm wide, 0.3-0.5 cm thick;10 mins for patient aged 1 to 3-year old; 15 mins for those aged 3 to 5-year old; once daily
1582839|NCT02362906|Drug|second generation cephalosporin|
1582840|NCT02362906|Drug|Erythromycin|ivd. 30 mg/(kg•d), plus 5% Glucose Injection, 80 to 500 ml, ivd. Once a day injection
1582841|NCT02362906|Drug|Azithromycin|ivd. 10 mg/(kg•d), plus 5% Glucose Injection, 100 to 500 ml, ivd. Once a day injection
1582842|NCT02362893|Other|Direct Observed Therapy|Patients allocated to the intervention group take their medication (from original blister packaged) in front of the invistigator who observe the patient swallowing the medication. To secure the principals of Direct Observed Therapy, the patient do not leave the clinic for two hours.
1582843|NCT02362880|Radiation|Florbetaben|single dose of Florbetaben followed by PET scan
1582844|NCT02362867|Device|Balanced Knee System|A multi-compartmental total knee replacement providing a system of components for primary posterior cruciate ligament substituting procedures. The system consists of femoral, tibial, and patellar components that allow the surgeon to select the most appropriate component combination to meet specific patient needs.
1582845|NCT02362854|Procedure|Conventional peri-implantitis treatment|Elimination of the bacterial plaque. Establishing optimal healing conditions. Detoxification of the affected environment.
1582846|NCT02362854|Device|DL application in peri-implantitis|Diode laser application in the diseased implants.
1582847|NCT02362815|Other|Apple juice|Intervention consists in allowing drinks during labour
1582850|NCT02362776|Other|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
1582851|NCT02362763|Procedure|Acupuncture|Patients randomized to the study group received five sessions of acupuncture in a series of points in the lower abdomen, lower back, hands, and feet. This combination of acupoints is believed to impact on the genital area, raise the pain threshold, and counteract inflammation. Control group patients received five sessions of acupuncture at acupoints that are believed to have no influence on the genital area, but are believed to have a general sedative effect.
1582852|NCT02362750|Other|Organizational Interview|Survivorship program leaders will participate in a phone-based organizational interview regarding the organization of the clinical survivorship care program.
1582853|NCT02362750|Other|Organizational Survey|Survivorship program leaders will participate in a brief web-based organizational survey regarding the organization of the clinical survivorship care program.
1582854|NCT02362750|Other|Survivor Survey (1): Pre-Visit Baseline|Survivors will participate in a baseline survey regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
1582855|NCT02362750|Other|Survivor Survey (2): Post-Visit|Survivors will participate in a survey within one week after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
1582856|NCT02362750|Other|Survivor Survey (3): 3 Month Post-Visit|Survivors will participate in a survey three months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
1582857|NCT02362750|Other|Survivor Survey (4): 6 Month Post-Visit|Survivors will participate in a survey six months after their survivorship visit regarding their satisfaction, health-related quality of life, ability to manage their cancer post-treatment and appropriate health care utilization.
1582858|NCT02362750|Other|Clinician Survey|Survivorship program clinicians will complete a survey for each survivor who enrolls in the study indicating services provided through the survivorship visit.
1582859|NCT02362737|Behavioral|Active and Healthy Brotherhood (AHB)|Participants will attend group sessions led by trained group facilitators. The group sessions will be ~16 weekly meetings of ~90 minutes duration for 4 months. AHB participants will also engage in experiential learning opportunities. Following the intensive intervention phase, during months 5 and 6, participants will receive three structured, individual phone calls with the group facilitator.
1582860|NCT02361632|Dietary Supplement|Coffee with or without milk|Intervention :30 participants were randomized to 3 Groups, 10 persons in each group. All participants fasted 6 hours for solid food before gastric volume was measured by Magnetic Resonance Imagining ( MRI). 2 hours before MRI examination, each participant ingested either 175 ml black coffee, 175 ml coffee with 20% milk or 175 ml coffee with 50% milk in the order defined for the group (arm).
1582861|NCT02361619|Drug|Caffeine|probe
1582862|NCT02361619|Drug|Diclofenac|probe
1582863|NCT02361619|Drug|Esomeprazole|probe
1582864|NCT02361619|Drug|Metoprolol|probe
1582871|NCT02362698|Other|electro-acupuncture|"13points were selected including he-gu(LI4), nei-guan(PC6), tai-chong(LR3) and san-yin-jiao(SP6) from both sides, bai-hui(GV20) and si-shen-cong(EX-HN1) from head.
HANS-200A acupoints stimulator, which had two output channels, was connected to some selected points. Dilatational wave was adopted in this research, the frequency of rarefaction wave was 2 hertz and condensation wave was 100 hertz, with a waviness width of 0.3ms. Switched the stimulator on after connected the poles to the needles, adjusted the intensity of output gradually from 0 milliampere to the extent of subject's maximum tolerance. Then needles would be remained on the body for half an hour."
1582872|NCT02362698|Other|psychological intervention|Cognitive behavioral therapy was adopted by national accredited professional psychologist, in the form of team work and individual counseling, aim to help IA participants to understand their deviant behaviors, correct unhealthy cognitive states and eventually retrieve normal life style.
1582873|NCT02362685|Device|functional test|subjects perform a metabolic exercise testing
1582874|NCT02362685|Genetic|matching genotype with phenotype|
2008703|NCT03328052|Device|MYnd Analytics PEER Online directed antidepressant therapy|"PEER Online is similar to a standard QEEG in that it uses QEEG output variables, but differs from a standard QEEG in that it references the QEEG to a normative and then symptomatic database. By comparing a given patient's QEEG to a database of QEEGs of subjects who have tried and responded to a specific medication, PEER Online can provide useful information regarding the response of neuro-physiologically similar patients to a wide number of medications. PEER Online may thus have the advantage of providing physicians with useful information as to medication outcomes before a medication regime is started. It has also been used to help select the medication that best matches the QEEG brainwave pattern, regardless of symptom clusters, currently used for diagnostic nomenclature. Patients will receive anti-depressant therapy guide by the results of the PEER Online algorithm."
2008704|NCT03328052|Other|Conventional antidepressant therapy|Anti-depressant therapy chosen based on physician best judgement.
1582877|NCT02362646|Biological|MPC Intramyocardial Injection|Intramyocardial injection of 150 million mesenchymal precursor cells at the time of LVAD implantation
1582878|NCT02362646|Drug|Control Solution|
1582879|NCT02362633|Device|real tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
1582880|NCT02362633|Device|sham tDCS|Sham tDCS will be delivered for 20 minutes. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
1582881|NCT02362607|Behavioral|Integrated Diabetes Management Protocol|
1582882|NCT02362607|Behavioral|Standard Diabetes Management Protocol|
1582883|NCT02362594|Biological|pembrolizumab|
1582884|NCT02362594|Other|placebo|Locally sourced placebo
1582885|NCT02362581|Other|prophylaxis treatment, on demand treatment|
1582886|NCT02362568|Procedure|Ultrasound cervical exploration|The cervical ultrasound exploration will consist in the ultrasound measurement of the length between the hyoid bone and the skin and the length between the thyroid cartilage and the skin. The ultrasound cervical exploration will be performed in all patients admitted in the postoperative room after a planned surgery performed under general anesthesia.
1582887|NCT02362555|Other|no intervention was used in this observational study|
1582888|NCT02362542|Device|tDCS|For active tDCS, a 2 mA current will be delivered for 20 minutes with 20 second up and down ramp times. The anodal electrode will be placed on the right DLPFC (F4; 10-20 EEG system), and the cathode electrode will be placed on the left DLPFC (F4;10-20 EEG system), which is known to be related to cognitive function. The electrodes used for tDCS are saline-soaked sponges (25 cm2).
1582889|NCT02362529|Drug|Minocycline|50 mg and 100 mg capsule, oral administration
1582890|NCT02362529|Drug|Placebo|Lactose monohydrate in identical gel capsules to minocycline, oral administration.
1582891|NCT02362529|Drug|Celecoxib|100 mg and 200 mg capsules, oral administration.
1582892|NCT02362516|Drug|BI 425809|
2008705|NCT03328039|Device|Garmin wearable device|Physiological data capture only
1582895|NCT02362490|Drug|peginterferon alpha 2a|in this group,patients will receive 180 ug of peginterferon alpha 2a injection weekly for 72 weeks
1582896|NCT02362477|Behavioral|Cognitive Processing Therapy in-person|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, in-person.
1582897|NCT02362477|Behavioral|Cognitive Processing Therapy through videoteleconference|Cognitive Processing Therapy is delivered to female veterans and civilians, who have been diagnosed with PTSD, through videoteleconference.
1582903|NCT02362412|Drug|FK949E|A tablet containing 50 mg or 150 mg of quetiapine taken orally.
1582904|NCT02362399|Drug|sildenafil citrate|single oral dose of 50 mg
1582905|NCT02362399|Other|placebo|single oral dose of placebo tablet
1582906|NCT02362386|Device|Celution Device|Non-interventional evaluation of Celution Device preparation of ADRCs from thermal burn eschar tissue that would normally be discarded.
1582907|NCT02362373|Drug|levonorgestrel IUS|placement of levonorgestrel intrauterine system
1582908|NCT02362360|Device|Coloplast Test Product|A new 2-piece ostomy appliance developed by Coloplast A/S
1582909|NCT02362360|Device|Comparator (Hollister)|Comparator is a Hollister FlexWear baseplate (ileostomy) or a Hollister SoftFlex baseplate (colostomy) both used with a Hollister open bag.
1582910|NCT02362347|Device|London Health Sciences Centre - Compression Vest|London Health Sciences Centre - Compression Vest
1582911|NCT02362347|Other|exercise|exercise
1582912|NCT02362321|Drug|Dexamethasone|Patients received a daily dosage of 12mg (4mg three times a day) of dexamethasone for three weeks. Corticosteroid treatment was then tapered off over the next week (8mg for 48 hrs, 4mg for 48 hrs, 2mg for 48 hrs and 1mg for 24 hrs).
1582913|NCT02362321|Other|Placebo|Identical oral capsules filled with lactose were administered to the control (placebo) group for 28 days.
1582914|NCT02362308|Other|Adrenalectomy|Adrenalectomy for treatment of primary aldosteronism, according to standard of care
2008706|NCT03328026|Biological|BriaVax|BriaVax™ inoculation intradermally in 4 sites on the upper back (x2) and thighs (x2).
2008707|NCT03328026|Biological|Pembrolizumab|Pembrolizumab will be given 200 mg intravenously either ~2 or ~4 days after BriaVax inoculation for up to 24 infusions. Cycles will be every 3 weeks.
2008708|NCT03328026|Biological|Ipilimumab|Ipilimumab will be given 3 mg/kg intravenously either ~2 or ~4 days after BriaVax inoculation for up to 4 infusions. Cycles will be every 3 weeks.
1582920|NCT02362269|Dietary Supplement|Vitamin D|Gelcaps containing 1000, 2500, and 4000 IU of vitamin D3 will be obtained from Tischon corporation (Westbury, NY). The gelcaps will be protected from light and not stored above 25° C. Participants will be instructed to take their vitamin D3 gelcaps with supper daily. Compliance with study supplementation will be documented by pill count at the time of each study visits.
1582921|NCT02362256|Drug|Naltrexone|
1582922|NCT02362256|Drug|Clonidine|
1582923|NCT02362256|Drug|Lorazepam|
2008709|NCT03328026|Drug|Low dose cyclophosphamide|Pretreatment with low dose cyclophosphamide 2-3 days prior to BriaVax™ inoculation.
2008710|NCT03328026|Biological|Interferon Inoculation|Post-inoculation low dose Interferon-alpha-2b into the vaccination sites ~2 and ~4 days after BriaVax™ inoculation.
1582926|NCT02362230|Drug|Icotinib|Icotinib 125 mg BID
1582927|NCT02362217|Biological|AdCh3NSmut1|Genetic vaccine against Hepatitis C virus infection
1582928|NCT02362217|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
1582929|NCT02362217|Biological|ChAdV63.HIVconsv|Genetic vaccine against HIV-1 infection
1582930|NCT02362217|Biological|MVA.HIVconsv|Genetic vaccine against HIV-1 infection
1582931|NCT02362204|Behavioral|therapeutic education and psychological support|Intervention consists of alternate face-to-face consultations (anticipated duration: 60-90 minutes) and telephone consultations (anticipated duration: 15-30 minutes). All interventions will include: i) a focused assessment of physical and psychological symptoms, ii) information about lung cancer (disease) and its treatment, iii) a review of disease-related and treatment-related side effects and strategies to manage these symptoms, and iv) printed listing and review of available support resources.
1582932|NCT02362191|Device|Alternating current stimulator|The stimulator used in this study was developed by the Frohlich lab and has been reviewed by the biomedical engineering department. The stimulator has multiple safety features and is considered to be non-significant risk.
1582933|NCT02362178|Procedure|Thromboelastography to guide blood products infusion|A TEG has been performed before invasive procedure and blood products infusion has been decided according to TEG parameters as follow: fresh frozen plasma (FFP 10 ml/kg) in case of r time>40 mm and/or platelets (PLTs 10 units/Kg) for MA<30 mm
1582934|NCT02362178|Procedure|Standard of care coagulation tests to guide blood products infusion|Patients received FFP (10 ml/kg) if INR>1.8 and/or PLTS (10 units/Kg) If PLTs count < 50000/μl
1582935|NCT02362165|Drug|Cyclophosphamide|500mg/d,once-weekly,per oral.
1582936|NCT02362165|Drug|Bortezomib|1.3mg/㎡,once-weekly,subcutaneous injection
1582937|NCT02362165|Drug|Dexamethasone|40mg/d,once-weekly,per oral
1582938|NCT02362165|Drug|Doxorubicin|9mg/㎡,d1-4
1582939|NCT02362152|Drug|Ingenol mebutate|Topical field treatment as prescribed by dermatologist
1582940|NCT02362152|Drug|5-fluorouracil|Topical field treatment as prescribed by dermatologist
1582941|NCT02362152|Drug|Imiquimod|Topical field treatment as prescribed by dermatologist
1582942|NCT02362152|Drug|Diclofenac|Topical field treatment as prescribed by dermatologist
1582943|NCT02362139|Drug|The study group|200 pregnant women, 18-45 years old, 37-41 weeks of gestation, in spontaneous labor, which were treated with 80 mg of Intra-muscular (IM) Papverine during the latent phase of labor (cervical dilatation<4cm).
1582944|NCT02362126|Device|Endoscopic full thickness resection (EFTR)|Patients undergo EFTR using the FTRD
1582945|NCT02362113|Other|GI/GL|GI and GL would be categorized as tertile. due to cross-sectional design of this study, intervention would not be applicable.
1582946|NCT02362100|Other|Non operative|non operative treatment
1582947|NCT02362100|Procedure|locking plate surgical fixation|
1582948|NCT02362087|Other|Quality of life and brief pain inventory|blood collection and quality of life questionnaires and a pain medication diary
1582949|NCT02362061|Radiation|3D ultrasound|ultrasound to measure the thickness of the junctional zone at day 21 of the cycle
1582950|NCT02362048|Drug|ACP-196|
1582951|NCT02362048|Drug|ACP-196 in combination with pembrolizumab|
1582952|NCT02362035|Drug|Acalabrutinib|oral
1582953|NCT02362035|Drug|Pembrolizumab|intravenous
1583048|NCT02361138|Drug|SHR3824|
2008711|NCT03328000|Radiation|CTU and MR urethrography|computed tomographic and Magnetic Resonance Urethrography.
2008712|NCT03327987|Biological|standard of care influenza vaccine|The standard of care annual 2017-2018 influenza vaccine will be used for this study.
2008713|NCT03327974|Other|DEPASSE Apllication|"Application DEPASSE in depressed patients. This application was developed by the laboratory SERVIER, by a scientific committee of psychologists and psychiatrists: Pr. Courtet, Dr Rimlinger and Pr. Swendsen.
Depasse is available for all on the App store and on Googleplay.
This application has several interests:
- The first is the daily monitoring of the symptoms allowing a regular evaluation throught smileys simulating a scale from 1 to 5. The 10 parameters evaluated are: mood, dark ideas, sleep, stress, concentration, social activities, energy, pleasure, motivation and libido.
There is the possibility to generate a graph representing the evolution of these parameters.
Tips adapted to the actual mood are provided related to the dysfunctional parameters."
2008714|NCT03327961|Device|scaffold|implantation of scaffold (eg Magmaris, Desolve, Others)
2008715|NCT03327935|Dietary Supplement|Nutrition|150 Faroese surgical patients randomized to one of the following three arms 1) Standard hospital procedure 2) oral nutritional supplements and advice and 3) oral nutritional supplements and exercise plan. Primary outcome is loss of lean body mass
2008716|NCT03327922|Device|Vicryl absorbable suture|Vicryl absorbable suture is a synthetic sterile surgical suture made up of a copolymer
2008717|NCT03327909|Behavioral|TAKE vs. HOLD|All participants will be told to take once daily antihypertensive medications at night. Timing of other antihypertensive medication administration will differ depending on whether the participant is randomized to the TAKE or HOLD arm.
1582954|NCT02362022|Drug|Morphine|Group Saline (Group S): Received i.v saline 0.9 % in 10 ml volume (n=30) Group Morphine 1 (Group M1): Received i.v morphine 0.1 mg kg-1 in 10 ml volume (n=30) Group Morphine 2 (Group M2): Received i.v morphine 0.2 mg kg-1 in 10 ml volume (n=30)
1582955|NCT02361983|Device|DLT versus bronchial blockers|Safety and efficacy of the double-lumen tubes (DLT) and bronchial blockers (BB) for lung isolation in patients undergoing thoracic surgery have been extensively studied and most of the results show similar rates of successful placement and lung collapse. DLT and BB are more frequently inserted by anesthetists who are expert in thoracic anesthesia, with dedicated but different training.
1582956|NCT02361957|Dietary Supplement|Ecologic 825|Multispecies probiotic product, 2.5 x10E9 colony forming units per gram, 6 grams a day
1582957|NCT02361957|Dietary Supplement|Placebo|Placebo
2008718|NCT03327896|Other|Charlson score and Community Social Deprivation|This is an observational study of the association of clinical comorbidity and neighborhood social deprivation characteristics with healthcare performance assessment.
1582959|NCT02361931|Drug|A formula with erythropoietin|
1582960|NCT02361931|Drug|Hydrogel|
1582961|NCT02361918|Procedure|Colon surgery|
1582962|NCT02361905|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
1582963|NCT02361905|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
1582964|NCT02361892|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle for two courses of 3 months each
1582965|NCT02361879|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later
1582966|NCT02361879|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24)
1582967|NCT02361866|Biological|GC1107|0.5 ml, Intramuscular, single dose(day0)
1582968|NCT02361866|Biological|Tetanus and Diphtheria(Td vaccine)|0.5ml, Intramuscular, single dose(day0) only applicable step1
1582969|NCT02361853|Other|Exposure: abundance of Immature Myeloid Cells counts in blood samples|
1582970|NCT02361853|Other|Exposure: abundance of Immature Dentritic Cells counts in blood samples|
1582971|NCT02361853|Other|Exposure: abundance of Immature monocytes counts in blood samples|
1582972|NCT02361853|Other|Exposure: abundance of Immature neutrophils counts in blood samples|
1582973|NCT02361827|Procedure|Embryo transfer|For patients in each group, they will have embryo transferred 3 or 5 days after oocyte retrieval.
1582974|NCT02361814|Procedure|The use of amnionic membrane allograft|After the conventional flexor tendon repair, the amniotic membrane will be wrapped around the tendons and its borders will be fixed to the remaining tendon sheath.
1582975|NCT02361801|Drug|Liberal dobutamine protocol|All patients will receive dobutamine at the cardiopulmonary bypass weaning.
1582976|NCT02361801|Drug|Restrictive dobutamine protocol|Patients will receive dobutamine during the first 8 hours after cardiopulmonary bypass weaning only if they have a cardiac index of ≤ 2.5L/min/m2 and at least one sign of tissue hypoperfusion: ScvO2 ≤ 70% and / or urine output < 2 mL/Kg/h despite adequate fluid replacement.
1582977|NCT02361775|Device|Paravertebral catheter|A catheter is placed ultrasound guided at the T5 paravertebral level
1582978|NCT02361775|Device|opioid iv pca|opioid pca consisting of hydromorphone
1582979|NCT02361775|Drug|Ropivacaine|0.2% ropivacaine infused through paravertebral catheter
1582980|NCT02361775|Device|Elastomeric Pump|Elastomeric pump connected to paravertebral catheter
1582981|NCT02361762|Behavioral|Computerized executive control training|"Children will play computerized training games designed to improve executive control skills. Each training activity is structured to achieve a particular type of training related to executive control and/or attention shifting.
Sessions last for 1 hour each and the intensity of intervention ranges from 5-10 hours. Children will receive training until all levels of all tasks have been passed or 10 hours, whichever happens first. All training exercises have a number of levels, and children progress to the next level by meeting specific criteria for accuracy and/or speed.
A trainer will be present during all sessions to help children comply with the training demands and to teach skills involved in completing challenging tasks."
1582982|NCT02361749|Drug|Botulinum Toxin|Injection of Botulinum toxin under general anesthesia. Four injections will be given into the anal sphincter into the four quadrants in one session.
1582983|NCT02361749|Procedure|Anal Myectomy|Longitudinal anal myectomy will be performed under general anesthesia as a day case.
1582984|NCT02361736|Drug|Hydroxyethyl Starch|6% Hydroxyethyl Starch(HES) is intravenously given 7.5ml/kg for the first hour of surgery
1582985|NCT02361736|Drug|Lactate Ringers|Lactate Ringers is intravenously administrated at a dose of 7.5ml/kg during the surgery
1582986|NCT02361723|Drug|BGB-290|The dose levels will be escalated following a modified 3+3 dose escalation scheme.
1582987|NCT02361710|Procedure|frozen embryo transfer|comparison of groups according to their serum vitamin D levels on frozen embryo transfer day
1582988|NCT02361697|Other|DTI-MRI|MRI of the brain with special DTI-sequences are performed in each child with multiple sclerosis or clinically isolated syndrome at timepoint of first manifestation and every 6 months in a longterm follow-up of 3 years
2008719|NCT03327857|Biological|AbGn-168H|AbGn-168H (Neihulizumab) is a humanized monoclonal antibody
1583049|NCT02361138|Drug|Placebo|
2008720|NCT03326128|Drug|Bupropion hydrochloride extended release|Antidepressant that is also effective in smoking cessation
2008721|NCT03327831|Drug|Aminolevulinic Acid|Topical application followed by activation by ambient sunlight
2008722|NCT03327818|Procedure|hysterectomy|
2008723|NCT03327818|Procedure|uterine conservative study|
2008724|NCT03327805|Dietary Supplement|Choline|Participants will consume 1000 mg of choline bitartrate (over-the-counter supplement) for 6 days. Subjects will be given 10 capsules (2x500mg) of choline bitartrate to take once a day in the morning five days prior to testing.
2008725|NCT03327805|Dietary Supplement|Placebo|Participants will consume 1000 mg of placebo for 6 days. Subjects will be given 10 capsules (2x500mg) of placebo to take once a day in the morning five days prior to testing.
2008726|NCT03327792|Drug|Mavoglurant|200 mg Mavoglurant
2008727|NCT03327792|Drug|Placebo|Placebo
1582993|NCT02361658|Other|RespirAct™|Carbon dioxide Manipulation by RespirAct™ sequential gas delivery breathing circuit at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia).
1582994|NCT02361658|Other|Neck collar|Internal jugular compression using a Neck collar will be applied at each CO2 levels (normocapnia, Hypercapnia I and II and hypocapnia) and ONSD measurements will be done before and after the collar.
1582995|NCT02361645|Drug|Ketorolac 0.5% eyedrops|
1582996|NCT02361645|Drug|Indomethacin 0.5% eyedrops|
1582997|NCT02361645|Drug|Bromfenac 0.09% eyedrops|
1582998|NCT02361645|Drug|Nepafenac 0.1% eyedrops|
1582999|NCT02361606|Behavioral|An Internet Cognitive-Behavioral Intervention|We developed a cognitive behavioral program for adolescents with type 1 Diabetes and their parents, that consists of six virtual sessions at https://minustress.com/diabetes/gate.asp.
1583002|NCT02361580|Other|Diary|Subject keeps diary of recovery
1583003|NCT02361567|Drug|Tramacet|Pain medication commonly used post-operatively
1583004|NCT02361567|Drug|Percocet|Pain medication commonly used post-operatively
1583005|NCT02361554|Device|Medtronic Activa Deep Brain Stimulation System|
1583006|NCT02361541|Procedure|HCV screening|HCV antibody screening, liver function tests, full blood count and HbsAg will performed. Additional blood samples will be taken for further HCV diagnostic work-out (polymerase chain reaction (PCR) and genotyping). For patients with current HCV infection, liver ultrasound, transient elastography - Firbroscan and further lab analysis will be performed.
1583007|NCT02361528|Drug|Sargramostim: Leukine (Genzyme USA)|Leukine: 125 µg/m² daily, subcutaneously, for 5 days.
1583008|NCT02361528|Drug|Placebo|placebo subcutaneously, for 5 days
1583009|NCT02361515|Radiation|Moderate hypofractionated radiotherapy|Moderate hypofractionated radiotherapy of 62Gy in 20 fraction of 3.1Gy.
1583010|NCT02361515|Radiation|Stereotactic radiotherapy|Stereotactic radiotherapy of 37.5Gy in 5 fraction of 7.5Gy.
1583011|NCT02361502|Drug|mirabegron|
1583012|NCT02361502|Drug|placebo|
1583013|NCT02361489|Device|V-Go|Initiation and titration of V-Go® using one of two dose titration algorithms to achieve improved A1C at 4 months.
1583014|NCT02361476|Drug|Clonidine|Injection - during surgery
1583015|NCT02361476|Drug|Placebo|Injection - during surgery
1583016|NCT02361463|Device|3D vision|Laparoscopic simulator training to proficiency under 3D conditions
1583017|NCT02361463|Device|2D vision|Laparoscopic simulator training to proficiency under 2D conditions
1583018|NCT02361450|Device|Retrograde Colonic Irrigation|
1583019|NCT02361450|Other|Usual Care|
1583020|NCT02361437|Dietary Supplement|Vasculera|Vasculera 630 mg b.i.d.
1583021|NCT02361424|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
1583022|NCT02361424|Drug|placebo|
1583023|NCT02361398|Other|the EIT guide the individualized PEEP Setting|the EIT guide the individualized PEEP Setting in the EIT group
1583025|NCT02361372|Other|Placebo|Placebo daily for 6 months
1583026|NCT02361372|Other|CaCO3|CaCO3 daily for 6 months
1583027|NCT02361372|Other|Kefir|Kefir daily for 6 months
1583028|NCT02361359|Other|Psychological questionnaires|
1583029|NCT02361346|Drug|MT-3724|Intravenous dosing M-W-F X 2 weeks; MT-3724 infusion over 2 hours on each dosing day over 4 week initial cycle and then 3 week repeat cycles for up to 5 total cycles.
1583030|NCT02361333|Behavioral|Teaching Intervention|Patients will be taught how to install and use a remote monitor
1583031|NCT02361320|Procedure|Computed Tomography (CT)|Participants to receive 2 CT scans. One scan performed before the start of chemotherapy, and the other at first restaging visit with oncologist.
1583032|NCT02361320|Behavioral|Questionnaire|Participant to complete the MD Anderson Symptom Inventory for Gastrointestinal cancer (MDASI-GI) questionnaire at baseline visit, and follow up visit. Questionnaires should take about 10 minutes to complete.
1583033|NCT02361307|Procedure|Seamless ADL training|The experimental group receive the seamless ADL training which occupational therapist and nurse work with effective communication and cooperate in dressing and bathing training
1583034|NCT02361307|Procedure|Conventional ADL training|The control group receive the conventional ADL training programme
1583035|NCT02361294|Other|Blood samples|
1583036|NCT02361268|Behavioral|Intradialysis-yoga|The experimental intervention in this study is intra-dialysis yoga. The intra-dialysis yoga protocol consists of yoga instruction and practice being offered three times a week for 12 weeks. Subjects will have the opportunity to participate in 15 to 60 minutes of yoga during dialysis.
1583037|NCT02361268|Behavioral|Educational program|The educational intervention in this study consists of 12 modules of an educational course, Kidney School, developed and maintained by the Medical Education Institute, Inc. Kidney School is a comprehensive, free, educational curriculum for people with kid
1583038|NCT02361255|Other|no intervention|
1583039|NCT02361242|Drug|PXT00864|PXT00864 is a fixed-dose combination of baclofen and acamprosate
1583040|NCT02361216|Drug|Ingenol Mebutate|
1583041|NCT02361216|Other|Vehicle|Vehicle gel
1583042|NCT02361203|Behavioral|Exercise|30 minutes of aerobic exercise on a treadmill at 80% of participant's heart rate reserve.
1583043|NCT02361190|Drug|Testosterone|Administration of 1ml aqueous nasal spray containing 7mg testosterone propionate
1583044|NCT02361190|Drug|Placebo|Administration of 1ml aqueous saline spray
1583045|NCT02361177|Drug|Oxytocin|Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
1583046|NCT02361151|Behavioral|TECH|Weekly newsletter with health information, mobile apps, and self-monitoring materials
1583047|NCT02361151|Behavioral|TECH+|Weekly newsletter with health information, mobile apps, and self-monitoring materials along with theory-based mobile web intervention
1583050|NCT02361125|Drug|Methylphenidate|5 mg tablet by mouth as needed every 2 hours for participant described significant fatigue. Participants to take a maximum of 20 mg/day, for total of 28 tablets for 7 days.
1583051|NCT02361125|Behavioral|Fatigue Evaluations|Participants to have evaluation of their fatigue, ability to sleep, and will answer a set of general symptom questions at baseline visit, daily while on study drug, and on seventh day of treatment.
1583052|NCT02361112|Drug|pyrotinib combined with capecitabine|
1583053|NCT02361099|Other|Monitoring by SENTINEL application|Patients will connect once a week to SENTINEL application to do a self-evaluation of several symptoms. A CT- scan will be scheduled only when there is an alert of the application
1583054|NCT02361086|Drug|VT-464: given orally once daily in 28 day cycles|VT-464: given orally once daily in 28 day cycles either 5 days or 7 days a week.
1583055|NCT02361060|Drug|Neostigmine|40mcg/kg
1583056|NCT02361060|Drug|Sugammadex|4mg/kg
1583057|NCT02361060|Drug|Atropine|10 mcg/kg
1583058|NCT02361047|Behavioral|Phone Coaching Program|Participants in this group will receive a 10-session nutrition and physical activity program delivered via phone by a health behavior coach to promote healthy lifestyle changes. Participants will also receive standard-of-care physician counseling regarding lifestyle recommendations to achieve/maintain a healthy weight trajectory after cancer treatment.
1583059|NCT02361034|Drug|GRC 27864|
1583060|NCT02361034|Drug|Placebo|
1583061|NCT02361021|Other|- Weaning from mechanical ventilation|
1583062|NCT02361008|Device|TEE-guided perventricular device closure without CBP|Perventricular device closure through minithoracotomy under the TEE-guidance without CBP.The device is an eccentric occluder made by Shanghai Shape Memory Alloy Co.,Ltd in Shanghai,China
1583063|NCT02361008|Procedure|Surgery repair with CBP|Traditional surgery repair under the CBP.
1583064|NCT02360995|Drug|Triclosan/fluoride toothpaste|Brush whole mouth with Total toothpaste (sold in the US), using a Total 360 toothbrush, 2 times/day for 6 weeks (study duration).
1583065|NCT02360995|Drug|stannous fluoride toothpaste|Brush whole mouth with Crest Pro-Health toothpaste using an Oral B Pro-Health toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
1583066|NCT02360995|Drug|fluoride toothpaste|Brush whole mouth with Crest Cavity Protection toothpaste using an Oral B Indicator toothbrush for 1 minute, 2 times/day for 6 weeks (study duration).
1583067|NCT02360995|Drug|Fluoride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest fluoride Mouthrinse for 30 seconds each time.
1583068|NCT02360995|Drug|cetylpyridinium chloride Mouthwash|Immediately after each toothbrushing rinse whole mouth with 20 ml of Crest Pro-Health Mouthrinse for 30 seconds each time.
1583069|NCT02360982|Behavioral|propofol and esmeron(rokuronyum)|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
1583070|NCT02360982|Behavioral|marcaine and fentanyl|All patients were evaluated at postoperative 24th and 72th hours with laboratory tests including hemoglobin, sodium, potassium, BUN, creatinine, total protein, albumin and glucose values in blood samples and delirium tests (CAM and DRS-R-98).
1583071|NCT02360969|Other|Examination of the eye|"Before planed surgery, an ophthalmologist measures the patient's visual acuity and realise an oculomotor examination. Measurement the refraction and the axial length of the eye is performed. Photographs wakefulness are performed.
During surgery, participation in this study does not involve any change in the course of anesthesia and surgery.
Pictures of the eye will be performed under general anesthesia.
Timing photos will be dictated by the values of BIS and train-of-four (TOF). Photos will be conducted at different times, with the top given by the anesthetist under the following conditions:
Deep anesthesia: BIS <50 Deep anesthesia and muscle relaxation: BIS <50 and TOF 0/4"
1583072|NCT02360956|Drug|Olmesartan medoxomil tablets|Dosage must be individualized. The usual recommended starting dose of Benicar is 20mg once daily when used as monotherapy in patients who are not volume-contracted.For patients requiring further reduction in blood pressure after 2 weeks of therapy, the dose of Benicar may be increased to 40 mg. Doses above 40 mg do not appear to have greater effect. Twice-daily dosing offers no advantage over the same total dose given once daily.
1583073|NCT02360956|Drug|Antihypertensive medication (per doctor suggestion)|Any antihypertensive medication alone or in combination.Calcium channel blockers (CCBs),diuretics, beta-blockers, or other antihypertensive medication except ACE inhibitors or ARBs.The drug dose must be individualed.Dosage must be individualized.The patients should take the antihypertensive drugs according to doctors'suggestion.
1583075|NCT02360917|Other|Emerging from the Haze|A 6 week psycho-educational class
1583076|NCT02360904|Other|Yoga|The intervention will consist of 12 weekly 60-minute yoga classes taught by a certified yoga instructor with cancer-specific yoga training. Classes will be conducted at the Beth Israel Comprehensive Cancer Center in a closed-group format, and will be offered twice a week. Yoga mats will be provided for each patient. The maximum number of patients attending each class will be 12. The classes will combine physical postures (asanas), breathing (pranayama), and deep relaxation (savasana). We would also encourage patient to practice yoga at home and keep a diary.
1583077|NCT02360891|Other|biomarkers (composite analysis)|biological, imaging, electrophysiological and anatomopathological examinations
1583078|NCT02360878|Device|EndoBarrier Gastrointestinal Liner|Implantation with the EndoBarrier
1583079|NCT02360865|Other|Exercise|
1583080|NCT02360852|Drug|A4250|A4250 once daily
1583081|NCT02360839|Device|EUS-guided fine needle biopsy sampling (EUS-FNB)|Dual sampling with EUS-FNA and EUS-FNB in a randomized order.
1583082|NCT02360826|Drug|Pravastatin|
1583083|NCT02360826|Drug|Simvastatin|
1583084|NCT02360813|Behavioral|Cognitive Remediation Therapy|Fifty-six sessions of principle driven cognitive remediation therapy. Three individual sessions and one group session each week for approximately fourteen weeks.
1583085|NCT02360813|Other|Treatment as usual|Keep getting usual care.
1583086|NCT02360800|Procedure|Spray Fibrin Sealant|Baxter Tisseel (Fibrin Sealant) is sprayed in the mediastinum at the end of the operation afetr routine chest hemostasis protocol has been completed, right before closing the chest.
1583445|NCT02358317|Behavioral|Sedentary Video Game Training|
1583087|NCT02360800|Procedure|Traditional Hemostasis and chest Closure Routine|Routine chest hemostasis and closure protocol (gauzes and inspection till satisfactory according to the surgeon)
1583088|NCT02360787|Behavioral|Energy restriction|
1583089|NCT02360787|Behavioral|Almonds (15% kcal/day)|
1583090|NCT02360774|Drug|Canagliflozin|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
1583091|NCT02360774|Drug|Placebo|Subjects will take one 300mg capsule of canagliflozin or identically dispensed placebo by mouth once daily, for 18 weeks.
1583092|NCT02360761|Procedure|VATS|Patients undergo lobectomy,wedge resection, or anatomical segmentectomy by thoracoscopic surgery or video assisted thoracoscopic surgery.
1583093|NCT02360761|Procedure|Thoracotomy|Patients undergo lobectomy, wedge resection, or anatomic segmentectomy by thoracotomy.
1583094|NCT02360748|Dietary Supplement|Plant based high protein food items|Patients will add high protein plant based food items to their diet
1583095|NCT02360735|Other|Manual Lymphatic Drainage|Manual Lymphatic Drainage (MLD) is a specialized massage technique utilized to decrease various forms of edema. This technique promotes reuptake of interstitial fluid along the pathways of the lymphatic system. This technique promotes healing, decrease swelling, and decrease pain.
1583096|NCT02360735|Other|Physical Therapy|All patients will participate in joint physical therapy classes during their inpatient stay.
1583097|NCT02360722|Other|Oral Nutritional Supplement|Will receive ONS twice a day for 6 months and two nutritional education at baseline and 3 months after intervention
1583098|NCT02360722|Other|Nutritional Education|Two nutritional education courses at baseline and 3 months after intervention
1583099|NCT02360709|Device|CRE8 sirolimus-eluting stent|The CRE8 stent system consists of a sirolimus eluting coronary stent firmly held on the distal end of a semicompliant balloon catheter. This stent is made of cobalt chromium alloy and is coated with a thin carbon film.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
1583100|NCT02360683|Other|patients with Parkinson's disease|
1583101|NCT02360670|Other|control imaging|
1583102|NCT02360670|Other|additional multimodal imaging|
1583103|NCT02360657|Drug|JNJ-54861911, 10 mg|JNJ-54861911, 10 mg (2*5 mg tablet) orally once daily for 4 weeks.
1583104|NCT02360657|Drug|JNJ-54861911, 50 mg|JNJ-54861911, 50 mg (2*25 mg tablet) orally once daily for 4 weeks.
1583105|NCT02360657|Drug|Placebo|Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
1583106|NCT02360644|Dietary Supplement|Cholecalciferol|Vitamin D deficient patients, in both Arms, will be administered Cholecalciferol 5,000 IU daily.
1583109|NCT02360618|Drug|Metformin|See Group Description
1583110|NCT02360618|Drug|Simvastatin|See Group Description
1583111|NCT02360605|Behavioral|automated telephone reminder|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT. ATR will remind the patient of the importance of completing and returning the FIT results and encourage screening completion. There will also be an option where the patient can request another FIT kit be mailed to them, one to hear information on common problems with FIT completion or how to call the clinic if they have questions. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up ATR calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
1583112|NCT02360605|Behavioral|prevention coordinator|The patients will be contacted at 4 weeks and again at 8 weeks if they have not returned the FIT by a prevention coordinator (PC). PC will call to encourage completion and ascertain any barriers to completion. The PCs will use Health Literacy and motivational interviewing techniques described in the training section to enhance understanding and confidence and reduce ambivalence to completing and returning the FIT. Years 2 and 3: 12 months after patients returned their initial FIT (or if they did not return the FIT, 12 months after enrollment) they will be mailed a friendly letter to remind them that it is time for their annual CRC screening and that a FIT kit will be mailed the following week. During the following week the patients will be mailed the FIT kit with addressed stamped envelope and the educational pamphlet they received at enrollment. For follow-up PC calls, we will use the same protocol as described for the initial screening. Same procedure for year 3.
1583113|NCT02360605|Behavioral|Health literacy appropriate education and demonstration|The Research Assistant (RA) will employ health literacy communication principles in providing a CRC recommendation and brief screening information using the CRC pamphlet and a FIT kit with simplified instructions and accompanying self-addressed, stamped envelope. A scripted message and illustrations will model what the patient needs to do to complete the FIT. The RA will appropriately demonstrate, using the kit, and will suggest patients show the pamphlet and FIT kit to their provider that day and talk to them about screening. Annual screening will be further emphasized at enrollment by giving patients an empowering message about the benefits of completing a FIT annually and telling them they will be mailed a reminder letter and FIT kit and receive outreach phone calls in 12 and 24 months for the next two years as well as a post survey and satisfaction interview over the phone at 6 months.
1583263|NCT02359370|Drug|Lidocaine|Lidocaine 2 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
1583119|NCT02360566|Behavioral|Participatory Video Intervention for Early Psychosis|The Participatory Video intervention consists of 12 semi-structured, 2 hour group workshops over the course of a 6-month time period. Through facilitated discussion, participants will learn how to effectively work collaboratively as a member of the video production team. Together, they will choose what story of their shared experience with psychosis they would like to tell through documentary-video and how they plan to share it. Participants will be trained to operate all equipment required to bring their vision to life. Individuals will also have the opportunity, during the Participatory Video process, to create and share their own video clips, independent of the group, allowing participants to share their own video-narrative with others (friends, family members, public) as a means of engaging in dialogue around their personal experience with psychosis.
1583120|NCT02360553|Behavioral|ObeseGO!|The intervention group were received the obeseGO! intervention which is an internet-based intervention. The participants and the parents who are randomly chosen to enroll in this intervention group were provided with the ObeseGO! website. The website was accessed at www.obesego.com. The website consists of various informations on healthy lifestyle, diet and ways to overcome obesity.
1583121|NCT02360553|Behavioral|Pamphlets material|The control group will be given pamphlets material on diet and physical activity.
1583122|NCT02360540|Other|Gestalt estimation|
1583123|NCT02360514|Drug|Hantavax injection|Intramuscular or hypodermic injection of 0.5ml per time twice at interval of 1 month for adults. For more immune, inoculate muscle or subcutaneous once mor 12 months after the completion of the initial immune
1583124|NCT02360501|Drug|Docetaxel|75mg/㎡,d1
1583125|NCT02360501|Drug|Cisplatin|25mg/㎡,d1-3
1583126|NCT02360501|Drug|Capecitabine|2000mg/㎡,d1-14
1583127|NCT02360488|Device|Telerehabilitation Therapy|18 days of supervised sessions via videoconference and 18 days of unsupervised sessions.
1583128|NCT02360488|Behavioral|In-Clinic Therapy|18 days of therapist supervised sessions and 18 days of unsupervised in home sessions.
1583129|NCT02360475|Biological|RSV vaccine GSK3003895A (formulation 1)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
1583130|NCT02360475|Biological|RSV vaccine GSK3003898A (formulation 2)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
1583131|NCT02360475|Biological|RSV vaccine GSK3003899A (formulation 3)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
1583132|NCT02360475|Biological|Boostrix|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
1583133|NCT02360462|Device|Active tDCS|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA (milliampere) current.
1583134|NCT02360462|Device|Sham tDCS|The sham tDCS consists in the same montage of the active tDCS, but the device is turned off 30 seconds after stimulation starts (without letting the patient notice it). The rest of the montage is kept identical to the active one during the 20 minutes session
1583135|NCT02360449|Behavioral|Social Initiation Motivation Intervention|The SIMI approach under investigation uses behavioral strategies based in Applied Behavior Analysis and Pivotal Response Treatment to motivate children with ASD to initiate to peers. The adult arranges the play environment in order to promote cooperation and facilitates frequent prompting and reinforcement from peers, thereby enhancing the reward value of peer interactions.
1583136|NCT02360423|Device|CRE8 sirolimus-eluting stent|The CRE8 stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium alloy and is coated with i-carbofilm.The outer surface of the stent has dedicated grooves for containing the pharmaceutical formulation, which is composed of the drug sirolimus and a mixture of long chain fatty acids.
1583137|NCT02360423|Device|RESOLUTE zotarolimus-eluting stent|The RESOLUTE stent is a flexible implantable device that can be expanded using a PTCA catheter. The stent is made of Cobalt chromium tungsten alloy. It has been approved by CFDA in 2009 and commercially available in Chinese market
1583138|NCT02360410|Behavioral|Check Yourself App with Feedback|
1583139|NCT02360397|Drug|ranolazine|Ranolazine 1000 mg tablet twice daily for 30 days
1583140|NCT02360384|Drug|Linaclotide|Linaclotide 290mcg po od in all patients with irritable bowel syndrome with constipation.
1583141|NCT02360384|Dietary Supplement|FODMAP diet|Patients with irritable bowel syndrome with alternating bowel habit will be commenced on the either the low FODMAP diet or a control healthy eating diet.
1583143|NCT02360358|Drug|Tiscover|two step procedure, week 0 and week1. Dosage depends on wound size.
1583144|NCT02360358|Other|AS210|two step procedure, week 0 and week1. Dosage depends on wound size.
1583145|NCT02360345|Drug|ONX-0801|
1583146|NCT02360332|Behavioral|Project SEARCH plus ASD Supports|Project SEARCH program (Rutkowski, Daston, Kuiken, and Riehle, 2006) is a work based learning model for high school transition that was developed at Cincinnati Children's Hospital Medical Center. The model provides complete immersion in the workplace. Students spend their entire school day at the workplace for a full school year. Consistent with principles of work based learning, Project SEARCH facilitates the development of a broad range of high-quality jobs within the employer organization and provides over 700 of supervised work experience. The model also relies on the intensive application of supported employments strategies (task analysis and customization, systematic instruction, ongoing support, etc.) to allow the participation of individuals with extensive support needs.
1583147|NCT02360319|Drug|Any FDA approved antipsychotic agent|Investigators are free to choose the most appropriate treatment for their clients
1583148|NCT02360319|Drug|aripiprazole long acting injectable formulation|
1583149|NCT02360306|Procedure|Endobronchial Ultrasound|Endobronchial ultrasound bronchoscopy with potential transbronchial needle aspiration, transbronchial forcep biopsy, brushing, or radial endobronchial ultrasound
1583150|NCT02360293|Behavioral|Stay Strong|Pts randomly placed in the Stay Strong group receive an app-mediated physical activity intervention. Pts are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly and will receive tailored push notifications. Each week the pt will receive a new automatically calculated personalized physical activity goal. Stay Strong coaches will call pts up to 3 times in the first 6-8 weeks of the study to help pts meet physical activity goals including problem solving support. Pts will also be reminded to follow-up with their healthcare provider as needed for the remainder of the 12-month program.
1583151|NCT02360293|Behavioral|Active Comparator|Pts randomly placed in the active comparator arm are asked to wear a physical activity monitoring device and weigh regularly using a Bluetooth scale while participating in the study. Pts will be asked to upload the device data at least weekly. Pts will have access to a standard app-mediated intervention that is linked to the wearable device.
1583152|NCT02360280|Drug|ketamine|sedative
1583153|NCT02360280|Drug|midazolam|sedative
1583154|NCT02360254|Drug|Insulin degludec|Once daily injection of insulin degludec
1583155|NCT02360241|Device|Robot|Use of the robot to locate the fictional needle
1583156|NCT02360228|Device|tACS (alpha)|
1583157|NCT02360228|Device|tDCS|
1583158|NCT02360215|Other|Cognitive Assessment|Ancillary studies
1583159|NCT02360215|Radiation|Intensity-Modulated Radiation Therapy|Undergo HA-WBRT using IMRT
1583160|NCT02360215|Drug|Memantine Hydrochloride|Given PO
1583161|NCT02360215|Other|Quality-of-Life Assessment|Ancillary studies
1583162|NCT02360215|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
1583163|NCT02360215|Radiation|Whole-Brain Radiotherapy|Undergo HA-WBRT using IMRT
1583164|NCT02360202|Procedure|Impedance analysis|"Impedance analysis in patient with Bullous pemphigoid disease treated with clobetasol propionate.
impedance analysis includes : fat measures, lean body mass, total body water, extracellular water phase angle"
1583165|NCT02360202|Drug|Clobetasol Propionate cream treatment|clobetasol propionate treatment initiated following French recommendations
1583166|NCT02360176|Procedure|Sleeve gastrectomy single port|Bariatric surgery: one incision of 2.5 to 3 cm
1583167|NCT02360176|Procedure|Sleeve gastrectomy multi trocar|Bariatric surgery: 4 to 7 incisions of 1 to 2 cm
1583168|NCT02360163|Procedure|Traditional Landmark Technique (TLT)|
1583169|NCT02360163|Device|ultrasound guided peripheral intravenous access (USGPIVA)|
1583170|NCT02360150|Radiation|second propeller arm scanner|The experimental procedure is to conduct a second helical scanner strictly centered on the heart, 10 minutes after the first helix without inject contrast medium, to assess late enhancement.
1583171|NCT02360124|Drug|silver diammine fluoride|topical application of the SDF solution onto tooth root surfaces
1583172|NCT02360124|Other|Water as placebo|topical application of water as a placebo in the control arm
1583173|NCT02360124|Other|saturated potassium iodide solution|topical application of SDF solution followed by KI solution onto tooth root surfaces
1583174|NCT02360111|Drug|Cyclophosphamide|
1583175|NCT02360098|Other|Emergence from Anesthesia|There are no study related interventions in this study and perioperative care of these patients will be as per our standard practice The only study related protocol would be collecting the data on the emergence from anesthesia. The data will be collected from the time of turning off the anesthetic agents till the discharge from recovery room. Data collected include, vital signs, Glasgow coma scale( GCS), and Riker agitation- sedation score.. The patients will be assessed every 5 minutes for the first 30 minutes and every 10 minutes for the next 60 minutes.
1583176|NCT02360059|Drug|Metformin|Metformin dose starts at 500 mg daily for 5 days, followed by 500 mg twice daily for 5 days, followed by 1,000 mg twice daily for 2 days. Participants reach required study medication dose of 2,000 mg daily 2 days prior to commencement of Paclitaxel therapy and continue this dose for remainder of intervention.
1583177|NCT02360059|Other|Placebo|Participants take placebo by mouth twice daily starting 12 days before, and 12 weeks during Paclitaxel treatment.
1583178|NCT02360059|Behavioral|Questionnaires|Questionnaires completed about numbness and/or symptoms about 2 weeks before start of Paclitaxel, 1 -2 days before Paclitaxel, every week while taking Paclitaxel, and at end of study visit. At week 12, questionnaire completed regarding satisfaction with Paclitaxel.
1583179|NCT02360059|Other|Sensory and Fine-Motor Tests|Three sensory and fine-motor tests completed 2 weeks before Paclitaxel, every 3 weeks while taking Paclitaxel, and at end of study visit.
1583180|NCT02360046|Drug|Hydrocortisone|Established Hydrocortisone replacement therapy plus Hydrocortisone (10mg/day)
1583181|NCT02360046|Drug|Placebo|Established Hydrocortisone replacement therapy plus Placebo (0mg Hydrocortisone)
1583182|NCT02360033|Behavioral|Systemic Therapy for Social Anxiety Disorder|
1583183|NCT02360033|Behavioral|Cognitive Behavioral Therapy for Social Anxiety Disorder|
1583184|NCT02360020|Device|XLimus|Techniques attempted for facilitating stent delivery in such a complex lesions are: maximize guide catheter support, optimize predilatation of the stenosis, use of a stiffer guidewire. Specific tricks include: a) buddy-wire; anchoring balloon; GuideLiner catheter. In case of severe calcification, rotational atherectomy was electively performed with the Rotablator® system (Boston Scientific Corporation, Natick, MA, U.S.A.). Following stent implantation, postdilatation is performed in all instances with a non-compliant balloon
1583185|NCT02360007|Drug|Interim Buprenorphine Treatment (IBT)|"The Interim Buprenorphine Treatment (IBT) includes:
Buprenorphine (BUP)
Computerized adherence monitoring (CAM): BUP will be dispensed via a portable device that makes each day's dose available only at a predetermined time.
Mobile health clinical support: An Interactive Voice Response (IVR) system to deliver clinical support
Urinalysis and adherence monitoring with participants contacted via IVR for random call-backs
HIV+Hepatitis Education delivered via iPad"
1583188|NCT02359981|Behavioral|MyBehavior|The intervention automatically provides personalized suggestions based on users behavior and user context. Suggestions relates to users life and how often they have done them in the past. Since the suggestions relate to users' lives, they are easy to follow.
1583189|NCT02359981|Behavioral|Generic suggestions|A nutritionist and an exercise trainer jointly created 45 food and exercise suggestions based on guidelines posted by the NIH. These suggestions ask users to walk for 30 minutes or eat healthier foods. These suggestions however doesn't personalize to users daily behavior into account.
1583190|NCT02359981|Device|Smartphone|An Android Smartphone with operating system version higher than 2.2
1583191|NCT02359968|Drug|FOLFOX|radiochemotherapy before surgery
1583192|NCT02359968|Drug|CarboP-pacliT|radiochemotherapy before surgery
1583193|NCT02359955|Device|zero degree teeth|zero degree teeth complete denture was first prescribed to patients in group 1 while patients in group 2 were treated with anatomic teeth complete denture
1583194|NCT02359955|Device|anatomic teeth|when anatomic teeth complete denture was prescribed to patients in group 1, patients in group 2 were treated with zero degree teeth complete denture
1583195|NCT02359942|Drug|Citric acid|Giving the citric acid (4g) solving in 200 ml of water before UBT
1583196|NCT02359929|Biological|Autologous mesenchymal stromal cells (MSCs)|Infusion of MSCs delivered to each patient will depend on their weight and assigned dose level. The maximal individual dose of MSCs any patient will receive is 2 x 1000000 cells/kg.
1583200|NCT02359903|Drug|Infliximab (BCD-055)|infliximab is a chimeric monoclonal antibody against tumor necrosis factor alpha
1583201|NCT02359903|Drug|Infliximab (Remicade)|
1583203|NCT02359877|Drug|BCD-054|
1583204|NCT02359877|Drug|Rebif|
1583205|NCT02359877|Drug|Avonex|
1583206|NCT02359864|Radiation|Whole Brain Irradiation to treat Alzheimer's Disease|
1583207|NCT02359851|Biological|Pembrolizumab|Given IV
1583208|NCT02359851|Other|Laboratory Biomarker Analysis|Correlative studies
1583211|NCT02359825|Drug|Polyethylene glycol (PEG)|For the control groups, epineural repair or interposition grafting will be undertaken in the standard end-to-end fashion using interrupted nylon suture after irrigation of the wound with normal saline as deemed necessary by the operating surgeon. For the experimental group, the nerve(s) will be repaired using standard suture neurorrhaphy techniques and a 149.25 mM (50%) solution of PEG 3.35 kD in sterile water will then be irrigated onto the neurorrhaphy site for one minute. Following this, the approximated nerve ends will be irrigated with sterile water gently for 2 minutes. All wounds will be closed in the fashion deemed appropriate by the operating surgeon.
1583212|NCT02359799|Device|Intelligent Stretcher|The impaired ankle of the participants are trained 3 sessions a week for 6 weeks in lab/at home. The participants use the portable robot in passive mode to increase range of motion (ROM), then subjects use their gained ROM immediately in the active movement to train their impaired ankle in controlling game play and improve motor control.
1583214|NCT02359747|Genetic|Polymerase Chain Reaction and Whole Genome Amplification|
1583215|NCT02359734|Other|Smart pump safety Intervention bundle for improving IV medication administration process with smart pump|Smart pump safety intervention bundle includes three components--1) eliminating unauthorized medications; implement standardized discontinuation policy of medications, implement standardized keep vein open rates and keep vein open rate order sets, and implement standardized verbal order practice. 2) Implement standardized intravenous(IV) labeling and IV tubing labels. 3) Implement standardized drug library lists and drug library use policies
1583217|NCT02359708|Procedure|Surgical hand disinfection.|Bacterial recolonization
1583218|NCT02359695|Drug|Growth Hormone|A dose of 0.5 IU of growth hormone will be administered daily from the first day of the agonist until the day of hCG administration
1583219|NCT02359682|Other|No intervention|No Intervention
1583220|NCT02359669|Behavioral|StimuLearn Intervention|"StimuLearn apps
Cognitive questionnaires"
1583221|NCT02359669|Behavioral|Without StimuLearn intervention|Cognitive Questionnaires
1583222|NCT02359656|Procedure|surgical treatment|C1-C1 arthrodesis
1583223|NCT02359656|Other|non operative treatment for odontoid non unions|specific non operative treatment protocol
1583224|NCT02359643|Drug|Aspirin|"This study was conduct to investigate the role of high dose aspirin in acute stage of KD via a multi-center randomized control trail, and we plan to achieve the followings in the coming 4 years:
Enroll 300 KD patients from multiple medical centers of Taiwan and China in 4 years. Randomize group patients as group 1: with high dose aspirin (more than 30/mg/kd/day) until fever subsided and shift to low dose aspirin (3-5mg/kg/day, N=150); and group 2: without high dose aspirin during acute febrile stage, only use low dose aspirin (N=150).
Compare data including fever days, admission duration, laboratory data (CBC/DC, GOT/GPT, BUN/Cr, Alb, ESR, CRP, 2D echo), IVIG treatment response and CAL formation rate (followed at least 1 year)."
1583225|NCT02359630|Device|EasyTube|Insertion for ventilation
1583226|NCT02359630|Device|Endotracheal tube|Insertion for ventilation
1583264|NCT02359370|Drug|Magnesium Sulphate|Magnesium Sulphate 30 mg/kg was administered through continuous infusion, immediately before induction of anesthesia
1583265|NCT02359357|Drug|FDL169|
1583227|NCT02359617|Drug|insulin delivery|Subcutaneous insulin (100 U/ml, NovoRapid®; Novo Nordisk, Bagsvaerd, Denmark) delivery with an insulin pump (Vibe-TM; Animas Corp., West Chester, PA, USA) and an insulin infusion cannula (SOF-SET MICRO QR 6mm; Medtronic MiniMed, USA) placed at the same site as the continuous glucose sensor.
1583228|NCT02359617|Device|glucose sensing|Glucose sensing with a continuous glucose sensor (Dexcom G4 Platinum Sensor; Dexcom Inc., San Diego, USA) placed at the site of subcutaneous insulin delivery.
1583229|NCT02359604|Drug|PPI therapy|"PPI therapy (medication has FDA approval) for 8 weeks in children with proven GERD.
The medication used (esomeprazole) in this trial is approved by the FDA"
1583230|NCT02359604|Procedure|Stool sample|Stool sample will be obtained before initiation of PPI (before PPI therapy)
1583231|NCT02359604|Procedure|Stool sample|Stool sample will be obtained 4 weeks after initiation of PPI (under PPI therapy)
1583232|NCT02359604|Procedure|Stool sample|Stool sample will be obtained 8 weeks after termination of PPI therapy (after PPI therapy).
1583233|NCT02359591|Other|text-based or multimedia|subjects fills in a questionnaire regarding whether the child meets the developmental milestones for his/her developmental age.
1583234|NCT02359578|Drug|Indocyanine Green|Subcutaneous injection of Indocyanine Green in the first interdigital space of the studied arm
2008728|NCT03327766|Diagnostic Test|4-Measurment of serum 25(OH)D3 using Vidas by ELFA meathod.|A specialized test of the 25(OH)D serum level was conducted and the blood samples were collected in the months of November to April. The winter months were chosen intentionally in order to limit the impact of the sun light upon 25(OH)D serum level.The test VIDAS® 25 OH Vitamin D Total was used-enzyme immunoassay with highly fluorescent measurement ELFA. According to the reference values of this method the 25(OH)D < 20 ng/ml serum levels are considered as deficiency and the serum levels between 20 - 30ng/ml are defined as insufficiency. It's sufficient if the level of 25(OH)D is 30 to 100 ng/ml.
1583243|NCT02359552|Drug|Rasagiline|
1583244|NCT02359552|Drug|Placebo|
1583245|NCT02359539|Procedure|Regenerative therapy|Periosteal pedicle, Platelets rich fibrin
1583246|NCT02359526|Drug|IlUVIEN|All patients will receive ILUVIEN 190 micrograms intravitreal implant in applicator with an initial release rate of 0.2 microgram per day. The implant will be administered by injection according to the method of administration defined in the SmPC (ILUVIEN SmPC). Only one eye of each patient will be treated with ILUVIEN.
1583249|NCT02359500|Drug|68Ga-DOTATOC PET|68Ga-DOTATOC as a diagnostic PET/CT imaging agent for the detection of NETs, mainly carcinoid tumors.
1583250|NCT02359487|Behavioral|Alcohol-HIV Risk Reduction Counseling|The intervention consists of a 1-hour individual counseling session relating to alcohol consumption and HIV sexual risk behaviors. Intervention counselors will assess alcohol-related sexual risk behaviors through the use of job aids that include a flip chart, guided scripts, activities, role plays, and a take home booklet. Counselors use motivational interviewing and interactive activities to discuss alcohol and HIV myths and facts, participants personal risk behaviors, and a decision-making activity that assists participants in weighing the pros and cons of engaging in risky behavior. Counselors also facilitate role plays to improve communication skills in risky situations, as well as a condom demonstration and skills session, and goal setting. In addition, men in the intervention arm will also receive two cell phone text messages 1-month and 4-months following enrollment to reiterate risk reduction messages.
1583251|NCT02359487|Behavioral|Placebo Intervention|Participants assigned to the control arm will be given a general alcohol information booklet and an alcohol abuse support services brochure. The alcohol information booklet contains information about responsible drinking, signs and symptoms of alcohol abuse, advice and guidance to reduce alcohol intake, and resources for assistance. The alcohol support services brochure contains times, dates, and locations of peer support and counseling services in the Windhoek region.
1583252|NCT02359474|Drug|Trabectedin|
1583253|NCT02359474|Genetic|DNA double-strand breaks|The rationale for combining Trabectedin and regional hyperthermia is that clinical hyperthermia might also prevent repair of DNA double-strand breaks (DSBs) which are induced by Trabectedin. Preclinical investigations show an enhanced anti-tumor efficacy of Trabectedin in different human STS cell lines by heat exposure (41.8°C). Using BRCA2 deficient cells or BRCA2 knock-down the thermal enhancement of Trabectedin efficacy seems to be related to DSB repair.
1583254|NCT02359461|Device|Combination pulsatile Stendo3|
1583255|NCT02359448|Drug|Melatonin|An open label clinical trial of sustained-release Melatonin 2mg once daily for 6 weeks.
1583256|NCT02359435|Drug|Reverse hybrid therapy|pantoprazole 40 mg b.d., amoxicillin 1 g b.d., clarithromycin 500 mg b.d. and metronidazole 500 mg b.d. for the first 7 days, followed by pantoprazole 40 mg b.d. and amoxicillin 1 g b.d. for another 5 days
1583257|NCT02359435|Drug|Standard triple therapy|pantoprazole 40 mg b.d., clarithromycin 500 mg b.d., and amoxicillin 1 g b.d. for 12 days
1583258|NCT02359422|Behavioral|Media Aware-Sexual Health|10-lesson middle school, comprehensive sexual health media literacy education program. Each lesson take approximately 50 minutes to teach and will be taught every school day for 2 weeks.
1583259|NCT02359409|Device|goggle balloon|Colonoscopy will be performed using the water immersion technique.
1583260|NCT02359409|Other|water immersion only|Colonoscopy will be performed using a goggle balloon at the tip of the scope with water immersion technique.
1583261|NCT02359396|Drug|MZRW|MZRWs is composed of Fructus Cannabis (HuoMaRen), Radix et Rhizoma Rhei (DaHuang), Radix Paeoniae Alba (BaiShao), Semen Armeniacae Amarum (KuXingRen), Fructus Aurantii Immaturus (ZhiShi) and Cortex Magnoliae Officinalis (HouPo). All MZRW granules will be prepared by PuraPharm International (H.K.) Limited. The entire manufacturing process, from authenticating the raw materials to the final products, is in strict compliance with the standards of Good Manufactory Practice (GMP) and Chinese Pharmacopoeia.
1583262|NCT02359383|Other|Chest physiotherapy|Depending on the location of the pleural effusion different techniques are performed: 1. Postural control techniques; 2. Secretions drainage techniques; 3. Thoracic expansion techniques; 4. Diaphragmatic mobility techniques.
1583266|NCT02359357|Drug|Placebo|
2008729|NCT03327753|Behavioral|Motor control exercises|The first stage of the treatment involves assessment of symptoms and implementation of a retraining program designed to improve activity of muscles assessed to have poor control and reducing activity of any muscle identified to be overactive. Participants are taught how to contract these muscles independently from the superficial trunk muscles and progress until the patient are able to maintain isolated contractions of the target muscles. During this stage exercises for breathing control, posture of spine and lower limb and movement are performed. The second stage of the treatment involved the progression of the exercises towards more functional activities. Throughout this process the recruitment of the trunk muscles, posture, movement pattern and breathing are assessed and corrected.
1583277|NCT02359318|Device|Icon|Resin infiltration as described in manufacture´s documentation prior bonding of new brackets
1583278|NCT02359318|Procedure|Debonding|debonding of brackest and bonding of new ones
1583280|NCT02359292|Drug|CHF 5993 HS 200/6/25 pMDI|
1583281|NCT02359292|Drug|CHF 5993 MS 100/6/25 pMDI|
1583282|NCT02359292|Drug|CHF 5993 HS 200/6/25 pMDI + Charcoal Block|
1583283|NCT02359292|Drug|CHF 5993 MS 100/6/25 pMDI + Charcoal Block|
1583284|NCT02359292|Drug|Placebo pMDI|
1583285|NCT02359279|Device|Sodium iodide|Comparison of control radiographs made before application of sodium iodide and test radiograph after application.
1583286|NCT02359266|Dietary Supplement|Vitamin D|Given to patients with existing vitamin D deficiency
1583287|NCT02359253|Other|Arm with Sham Stretching|During the hour of Active Training the subject will actively move their arm while supported in the IntelliArm to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance. Subjects will spend the 15 minutes prior to active training In the IntelliArm with it on and moving their arm only within ranges that produce no to very minimal forces.
1583288|NCT02359253|Other|Hand with Sham Stretching|During the hour of active training the subject will actively open and close their hand while participating in task oriented occupational therapy focused on grasp and release tasks. Subjects will spend the 15 minutes prior to active training with the X-Glove on and moving their hand only within ranges that produce no to very minimal forces.
1583289|NCT02359253|Other|Arm and Hand with Sham Stretching|"Each visit subject alternates between interventions (a) and (b):
During the hour of Active Training the subject will actively move their arm while supported in the IntelliArm to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance
During the hour of active training, the subject will actively open and close their hand while participating in task oriented occupational therapy focused on grasp and release tasks.
In both treatments A and B, subjects will spend 15 minutes prior to active training with the IntelliArm or X-Glove moving their arm or hand (respectively) only within ranges that produce no to very minimal forces."
1583290|NCT02359253|Other|Arm with Stretching|During the hour of Active Training the subject will actively move their arm while supported in the IntelliArm to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance.
1583291|NCT02359253|Other|Hand with Stretching|During the hour of active training the subject will actively open and close their hand while participating in task oriented occupational therapy focused on grasp and release tasks. Subjects will spend the 15 minutes prior to active training In the IntelliArm with it on and moving their arm within maximum tolerable ranges without pain or compensatory movements.
1583292|NCT02359253|Other|Arm and Hand with Stretching|"Each visit subject alternates between interventions (a) and (b):
During the hour of Active Training the subject will actively move their arm while supported in the IntelliArm to interact with virtual targets and objects. The IntelliArm may provide resistance or assistance
During the hour of active training, the subject will actively open and close their hand while participating in task oriented occupational therapy focused on grasp and release tasks.
In both treatments A and B, subjects will spend 15 minutes prior to active training with the IntelliArm or X-Glove moving their arm or hand within maximum tolerable ranges without pain or compensatory movements."
1583293|NCT02359240|Procedure|therapy according to SSC guidelines and muscle biopsy|Septic patients will be treated according to the international guidelines for management of severe sepsis and septic shock 2012. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
1583294|NCT02359240|Procedure|standard surgery for femoral fracture and muscle biopsy|Patients with femoral fracture will under standard surgery for fracture fixation. Percutaneous needle muscle biopsies will be performed. Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing.150-300 mg muscle (wet weight) was routinely obtained , which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein
1583295|NCT02359227|Drug|Cenderitide|Cenderitide is a dual receptor natriuretic peptide.
1583296|NCT02359214|Dietary Supplement|Vitamin D3|5000IU (125mcg) vitamin D3 tablet daily over 8 weeks (56 days).
1583297|NCT02359214|Other|Placebo|100% Lactose tablet daily over 8 weeks (56 days).
1583298|NCT02359201|Drug|V0018|Oromucosal - Single dose
1583299|NCT02359201|Drug|Placebo|Oromucosal - Single dose
1583300|NCT02359188|Device|Transcutaneous vagal nerve stimulation|4 hours of transcutaneous vagal nerve stimulation
1583301|NCT02359175|Drug|Bupivacaine in epidural catheter|Bupivacain to be given in epidural catheter
1583302|NCT02359175|Drug|Fentanyl in epidural catheter|Fentanyl to be given in epidural catheter
1583303|NCT02359175|Drug|Placebo (for Bupivacain and Fentanyl i epidural catheter)|Saline to be given in epidural catheter
2008730|NCT03327753|Behavioral|Graded activity|The program is based on activities that each patient identify as problematic and that they cannot perform or have difficulty performing because of their back pain. The activities in the program are progressed in a time-contingent manner from the baseline assessed ability to a target goal set jointly by patient and therapist. Patients receive daily quotas and are instructed to only perform the agreed amount, even when they feel they are capable of doing more. Cognitive-behavioural principles are used to help patients overcome the natural anxiety associated with pain and activities. Physiotherapists use positive reinforcement, explain pain mechanisms and addressed negative behaviours and pain-related anxiety. A plan for managing relapses is developed between therapists and patients.
2008731|NCT03327740|Drug|DTG based ARV regimen with ABC|ARV regimens containing DTG and ABC
2008732|NCT03327740|Drug|DTG based ARV regimen without ABC|DTG based ARV regimens that do not contain ABC
2008733|NCT03327740|Drug|RAL or EGV based ARV regimens with ABC|RAL or EGV based regimens containing ABC
2008734|NCT03327740|Drug|RAL or EGV based regimens without ABC|RAL or EGV based ARV regimens that do not contain ABC
2008735|NCT03327740|Drug|Any other DTG based ARV regimen as monotherapy|Any other DTG based ARV regimens including DTG as monotherapy or two-drug regimens.
2008736|NCT03327727|Drug|Investigational Agent: VL-2397|VL-2397
2008737|NCT03327727|Drug|Standard treatment: Voriconazole, Isavuconazole, or Liposomal amphotericin B|Voriconazole, Isavuconazole, or Liposomal amphotericin B
1583317|NCT02359149|Procedure|intravitreal injections given by a nurse|
1583318|NCT02359149|Procedure|intravitreal injections given by a physician|
1583319|NCT02359149|Procedure|Intravitreal injections|
1583320|NCT02359149|Drug|Anti-VEGF agents|
1583321|NCT02359136|Procedure|local infiltration anesthesia using Ropivacaine and Epinephrine|150 ml Ropivacaine 2mg/ml + 0,5 ml Epinephrine 1 mg/ml: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
1583322|NCT02359136|Procedure|local infiltration anesthesia using saline|150 ml 0,9% saline: The first 50 ml will be injected in the periacetabular tissue after insertion of the acetabular component. After insertion of the femoral component, 50 ml will be inserted in the gluteus muscles and the proximal part of the iliotibial tract. The last 50 ml will be inserted in the subcutaneous layer.
1583323|NCT02359136|Procedure|Multimodal analgesic regimen|All patients will be operated under spinal anaesthesia with 2.0-3.0 ml Bupivacaine 0.5 % plain, preferably at the L2/L3 alternatively the L3/L4 vertebral interspace. Propofol infusion will be administrated for sedation if needed. Postoperative morphine will be given as needed intravenously when needed. After transfer to a specialized hip arthroplasty unit with a well-defined and experienced program for multimodal rehabilitation, multimodal oral opioid-sparing analgesia will be given to all patients; NSAIDS and Acetaminophen will be given at regular intervals and Oxycodone as needed.
1583324|NCT02359123|Other|Cannabics capsules|Cannabis extract in an oil formulation
1583325|NCT02359110|Drug|Gabapentin|Patients will receive Gabapentin 300mg tab less than 1 hour before surgery.
1583326|NCT02359110|Other|Placebo|Patient will receive placebo tab less than 1 hour before surgery
1583327|NCT02359097|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo MRI including DSC or DCE-CBV mapping
1583328|NCT02359097|Drug|Ferumoxytol|Given IV
1583329|NCT02359097|Drug|Gadoteridol|Given IV
1583330|NCT02359097|Procedure|Magnetic Resonance Imaging|Undergo MRI including SS-CBV
1583331|NCT02359084|Behavioral|Family Navigation|
1583332|NCT02359084|Behavioral|Conventional Care Management|
1583333|NCT02359071|Other|handover duration, handover rate|To better analyze independent variables, we dichotomized the data. First, we dichotomized handover duration into two groups according to the median handoff time of 20 minutes. Second, we divided handover rates into two groups using the median rate of handovers per shift, which was 3.87%.
2008738|NCT03327714|Behavioral|Mindfulness and compassion|
2008739|NCT03327701|Drug|Benralizumab|Subjects will receive benralizumab 30 mg (subcutaneous) every 4 weeks for three doses followed by a fourth dose 8 weeks later.
2008740|NCT03327688|Diagnostic Test|Point-of-care ultrasound|Point-of-care ultrasound performed by an emergency physician
2008741|NCT03327675|Other|68Ga-PSMA (HBED-CC) PET|68Ga-PSMA PET/MR
2008742|NCT03327662|Other|Active CTC Assessment|CTC Counts used to guide treatment switch
1583339|NCT02359045|Drug|D1400147|Treatment A
1583340|NCT02359045|Drug|D14000136|Treatment B
1583341|NCT02359045|Drug|D14000137|Treatment C
1583342|NCT02359045|Drug|Epanova®|Treatment D
1583343|NCT02359032|Drug|ASP6858|Oral tablets
1583344|NCT02359032|Drug|Placebo|Oral tablets
1583345|NCT02359019|Biological|Pembrolizumab|Given IV
1583346|NCT02359019|Other|Laboratory Biomarker Analysis|Correlative studies
2008743|NCT03327649|Device|low level transcutaneous vagus nerve stimulation|Stimulation of the auricular branch of the vagus nerve
1583349|NCT02358993|Drug|methenamine hippurate|A urinary antiseptic used for prevention of UTI
1583350|NCT02358993|Drug|Ciprofloxacin|An antibiotic used for treatment and prevention of UTI
1583351|NCT02358980|Device|KIDNEY therapy|
1583352|NCT02358967|Dietary Supplement|TRF (Tocotrienol-rich-fraction)|2 x 150 mg capsules
1583353|NCT02358967|Dietary Supplement|Placebo|2 x 150 mg capsules
1583354|NCT02358954|Procedure|Quantitative sensory testing|Measurement of warm and cold detection and pain thresholds
1583355|NCT02358954|Procedure|CHEPS|Measurement of amplitude and latency of cortically evoked potentials
1583356|NCT02358954|Procedure|3D Turntable|
1583357|NCT02358954|Procedure|Vection stimulation|
1583360|NCT02358928|Other|Diet Intervention|
1583361|NCT02358915|Device|FastStart neuromuscular electrical stimulator|
1583362|NCT02358902|Device|tDCS|tDCS - DC stimulator, Neurocom, Germany
1583363|NCT02358902|Procedure|active intervention of aerobic exercise|different types of aerobic exercise
1583364|NCT02358902|Device|placebo tDCS|only 30 seconds of cortical stimulaion , with the power turned off for the remaining time (tDCS - DC stimulator, Neurocom, Germany)
1583365|NCT02358902|Procedure|placebo AE|the procedure was a training on the treadmill, but heart rate was maintained within 5% of the resting heart rate at the minimum speed on the treadmill
1583366|NCT02358889|Biological|hI-con1|Intravitreal injection of hI-con1 0.3 mg
1583367|NCT02358889|Biological|ranibizumab|Intravitreal injection of ranibizumab 0.5 mg
1583368|NCT02358889|Other|Sham injection|No injection is given, a needleless syringe is used to mimic an injection.
1583369|NCT02358863|Drug|Modified FOLFOX6|Oxaliplatin 85 mg/m2 IV Day 1 every 14 days Leucovorin 400 mg/m2 IV over 2 hours Day 1 5-FU 400 mg/m2 IV over 2 hours Day 1 5-FU 2400 mg/m2 IV over 46 hours Day 1
1583370|NCT02358863|Drug|Docetaxel/Capecitabine|Docetaxel 30 mg/m2 IV Days 1 and 8 Capecitabine 825 mg/m2 PO BID Days 1-14
1583371|NCT02358863|Drug|Cisplatin/Irinotecan|Cisplatin 30 mg/m2 IV Days 1 and 8 every 21 days Irinotecan 65 mg/m2 IV days 1 and 8 every 21 days
1583372|NCT02358863|Drug|Cisplatin/Docetaxel|Cisplatin 75 mg/m2 IV Day 1 every 21 days Docetaxel 75 mg/m2 IV Day 1
1583373|NCT02358863|Drug|IRI/EPI|Irinotecan IV over 90 minutes Days 1 and 8 every 28 days Epirubicin IV over 10-15 minutes Days 1 and 8 every 28 days
1583374|NCT02358863|Drug|EPI/Docetaxel|Docetaxel 75 mg/m2 Day 1 every 21 days Epirubicin 50 mg/m2 IV Day 2
1583375|NCT02358863|Drug|Irinotecan/Docetaxel|Irinotecan 120 mg/m2 Day 1 every 21 days Docetaxel 50 mg/m2 IV Day 1
1583376|NCT02358863|Drug|Docetaxel|Docetaxel 60-100 mg/m2 IV day 1 every 21 days
2008744|NCT03327636|Device|Echopulse|This is a machine to apply high intensity focused ultrasound to ablation the target zone. In this study, we would apply it to the papillary thyroid microcarcinoma.
2008745|NCT03327610|Other|VC-CMV20|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 20Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
1583381|NCT02358824|Drug|CKD-828|"Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
(1arm:2period and 4period, 2arm:1period and 3period)"
1583382|NCT02358824|Drug|Telmisartan|"- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
(1arm:1period and 3period, 2arm: 2period and 4period)"
1583383|NCT02358824|Drug|S-amlodipine|"- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
(1arm:1period and 3period, 2arm: 2period and 4period)"
1583384|NCT02358811|Device|Magnetic resonance imaging (MRI)|"The acquisition of the image will last 45 minutes with 6 sequences.
Before any examination, the manipulator will check the absence of contraindication to MRI.
During the fifth sequence, Gadolinium (Gadovist®) will be injected intravenously to the concentration 0.1 mmol / kg. For this, a venous catheter will be placed before the first sequence and then removed after the examination. This injection will be carried out according to the usual practice of MRI.
Throughout the examination, a physician will always be present."
1583385|NCT02358811|Behavioral|Cognitive assessment|"This cognitive assessment will include the following executive tests :
test of Stroop
left Trail Making Test A and B
verbal fluence test
test of memory of figures direct and inverse in order
completion of matrices
Paced Auditory Serial Addition Test (PASAT)"
1583386|NCT02358798|Other|3 years-assessment of respiratory function|
1583387|NCT02358785|Device|ECHELON FLEX™ Powered Plus Stapler|ECHELON FLEX™ Powered Plus Stapler using ENDOPATH ECHELON™ Reloads with Gripping Surface Technology (GST). The combination of stapler plus reload is referred to as the ECHELON FLEX™ GST System.
1583388|NCT02358772|Other|thrombolysis in a pre-hospital setting (STEMO concept)|
1583389|NCT02358759|Procedure|Correction of abnormally fertilized oocytes|Removing of extra developed nucleus from fertilized oocyte.
1583390|NCT02358746|Other|combined endo/epicardial approach|
1583391|NCT02358746|Other|stepwise approach|endocardial scar homogenization only at the first VT ablation procedure
1583392|NCT02358733|Procedure|Intra-cytoplasmic Sperm Injection|Selection of sperm at 400x for sperm injection
1583393|NCT02358733|Procedure|Intra-cytoplasmic Morphologically-selected Sperm Injection|Selection of sperm at 6000x for sperm injection
1583394|NCT02358720|Radiation|Arm A|1x24Gy high dose IMRT on spinal bone metastasis
1583395|NCT02358720|Radiation|Arm B|fractionated conformal RT 10 x 3 Gy on spinal bone metastasis
1583396|NCT02358707|Other|Ibuprofen phonophoresis|
1583397|NCT02358694|Dietary Supplement|Serum-Derived Bovine Immunoglobulin|Patients who weigh less than 40 Kg will receive Serum Derived Bovine Immunoglobulin -5 g daily (2.5 g PO BID) and patients who weigh 40 Kg or more will receive Serum Derived Bovine Immunoglobulin- 10 g daily (5 g PO BID)
1583398|NCT02358694|Other|Placebo|"Matching placebo packets will be supplied and will appear identical to SBI with respect to volume, appearance and taste.
Patients who weigh less than 40 Kg will take one-half packet BID (2.5 g BID) Patients who weigh 40 Kg or more will take one packet BID (5 g PO BID)."
1583399|NCT02358681|Drug|Ketorolac, intranasal|Ketorolac 1 mg/kg, maximum dose 30 mg. To be administered by intranasal route.
1583400|NCT02358681|Drug|Ketorolac, intravenous|Ketorolac 0.5 mg/kg, maximum dose 30 mg. To be administered by intravenous route.
1583401|NCT02358681|Drug|Placebo, intravenous|Placebo of equal volume to IV ketorolac, to be administered by intravenous route.
1583402|NCT02358681|Drug|Placebo, intranasal|Placebo of equal volume to IN ketorolac, to be administered by intranasal route.
1583403|NCT02358668|Drug|BTI320|BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.
1583404|NCT02358668|Drug|BTI320 matching placebo|Placebo
1583405|NCT02358655|Other|Retrospective review of OAC prescription|
1583406|NCT02358655|Other|Prescription of OAC in ED|
1583407|NCT02358655|Other|Community AF clinic|
1583408|NCT02358642|Drug|Angiotensin converting enzyme inhibitor (Lisinopril)|
1583409|NCT02358642|Drug|Placebo|
1583410|NCT02358629|Device|NovaCross™ microcatheter|successful delivery, crossing, and retrieval of the investigational device as identified by confirmation of guidewire placement in the distal true lumen confirmed by angiography
1583411|NCT02358590|Behavioral|HAPA menu-based mini-video|The intervention will be a multi-target menu-based mini-videos designed to deliver information about vitamin D adherence and its effect on osteoporosis
1583412|NCT02358590|Behavioral|Standard care|The treating physician will advice participants to take vitamin D
1583413|NCT02358577|Device|In-bed cycling|In-bed cycling will be applied using a cycle ergometer (RT300 Supine Cycle Ergometer) for 30 minutes per day in addition to Usual Care, until the physiotherapist deems that the patient is mobilizing well, or a maximum of 7 days (whichever comes first). This cycle ergometer is specifically designed for pediatric use, and can be applied to facilitate lower or upper limb cycling. The intervention will be applied by a trained physiotherapist and/or clinician. Pre-defined Safety Criteria for interrupting or aborting the intervention will be observed. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
1583414|NCT02358577|Other|Usual Care|Usual care physiotherapy will be applied to patients in the control arm, according to the unit specific guidelines for early mobilization. Qualitative interviews will be conducted with a health care provider, the patient where possible, and a family caregiver following the intervention period.
1583415|NCT02358564|Procedure|Gastrointestinal Permeability Test|This test will involve ingesting a solution followed by urinalysis
1583416|NCT02358564|Procedure|Upper Endoscopy|You will have an upper endoscopy
1583417|NCT02358564|Procedure|Rectal Barostat and Infusion of Fats|Feeding tube will be placed as well as a small balloon in the rectum
1583418|NCT02358551|Device|Placement of electrode lead through axillary vein puncture|
1583419|NCT02358551|Device|Placement of electrode lead through subclavian vein puncture|
1583420|NCT02358538|Drug|Ganaxolone|oral suspension or capsules
1583421|NCT02358525|Behavioral|multi-modality rehabilitation program for heart failure|rehabilitation consists of supervised exercise training, both endurance and strength, as well as gymnastics, diet and psychosocial education around living with heart failure
1583422|NCT02358512|Other|Enteral feeding|Bolus feeds or continuous feeds during a 10-day ICU stay
1583423|NCT02358499|Drug|Posaconazole|Posaconazole will be given as a one time intravenous (IV) dose. The dose will take ninety (90) minutes to be infused and will be based on weight at the time of the visit.
1583424|NCT02358486|Device|Acupuncture|"Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)
Needling details 2a) Number of needle insertions per subject per session: 13 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Pericardium(PC)3, Spleen(SP)4, Stomach(ST)34, Conception Vessel(CV)12, 2c) Depth: 5 ~ 30mm 2d) Response sought: 'De qi' sensation; 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 0.2 X 40 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
1583425|NCT02358486|Device|Sham acupuncture|The participants in sham acupuncture group are given sham acupuncture treatment at the same acupoints in the same times and method as acupuncture arm. The sham device would be a Streitberger device.
1583426|NCT02358473|Biological|mogamulizumab|Mogamulizumab will be administered by IV infusion.
1583427|NCT02358473|Drug|Docetaxel|Docetaxel will be administered by IV infusion.
1583428|NCT02358460|Device|Ventilation delivered by SLE5000 ventilator|"In pressure-limited ventilation arm, ventilator settings as required to maintain appropriate oxygenation and carbon-dioxide elimination.
In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
1583429|NCT02358447|Procedure|TKR|non-navigated versus computer-navigated total knee replacement
1583430|NCT02358434|Radiation|Observational use of fluoroscopy|
1583431|NCT02358408|Device|Blood glucose monitoring systems for self-testing|
1583432|NCT02358395|Drug|BBI608|Administered continuously twice daily with doses separated by 9-15 hours.
1583433|NCT02358395|Drug|Sorafenib|Sorafenib 400 mg twice daily (800 mg total daily dose).
1583434|NCT02358382|Drug|pH Stat|pH stat blood gas management - increased carbon dioxide content of administered gas mixture.
1583435|NCT02358369|Drug|Bimatoprost|Bimatoprost sustained release
1583436|NCT02358369|Drug|Timolol|BID drops OU, 0.5% ophthalmic solution
1583437|NCT02358356|Drug|octreotate|7.8GBq 177Lu Octreotate (Lutate) given intravenously (IV)
1583438|NCT02358356|Drug|Capecitabine|oral capecitabine 750mg/m2 b.i.d.
1583439|NCT02358356|Drug|Temozolomide|temozolomide 75mg/m2 b.i.d.
2008746|NCT03327610|Other|VC-CMV50|Application of a ventilator hyperinflation intervention with Volume Control Continuous Mandatory Ventilation (VC-CMV). The inspiratory flow was set at 50Lpm and the tidal volume was increased in steps of 200mL until the peak airway pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
2008747|NCT03327610|Other|PC-CMV1|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 1 second and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
2008748|NCT03327610|Other|PC-CMV3|Application of a ventilator hyperinflation intervention with Pressure Control Continuous Mandatory Ventilation (PC-CMV1). The inspiratory time was set at 3 seconds and the pressure control was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
1583444|NCT02358317|Behavioral|Video Game Motor Training|
2008749|NCT03327610|Other|PSV10|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 10% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
1583446|NCT02358304|Drug|nasal spray calcitonin|recurrence rate of aggressive CGCG will be recorded after the use of nasal spray calcitonin
1583447|NCT02358304|Drug|Placebo|
1583448|NCT02358291|Procedure|open discectomy|The open discectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
1583449|NCT02358291|Procedure|microendoscopic discectomy|Microendoscopic discectomy combines standard lumbar microsurgical techniques with endoscope, enabling surgeons to successfully address free-fragment disc pathologic factors and lateral recess stenosis.
1583450|NCT02358291|Procedure|transforaminal endoscopic lumbar discectomy|transforaminal endoscopic lumbar discectomy removes the intervertebral disc portion through the intervertebral foramen
1583451|NCT02358265|Drug|10 mg Rupatadine on demand|Group A1 (dose administered: 10 mg rupatadine on demand): one tablet of placebo once daily- one on-demand tablet of rupatadine 10 mg intake only if needed.
1583452|NCT02358265|Drug|10 mg Rupatadine|Group B1 (dose administered: 10 mg rupatadine continuously): one tablet of rupatadine 10 mg once daily, one on-demand tablet of placebo, intake only if needed.
1583453|NCT02358265|Drug|20 mg Rupatadine|Group B2 (dose administered: 10 mg rupatadine continuously): two tablets of rupatadine 10 mg daily- one on-demand tablet of placebo , intake only if needed.
1583454|NCT02358265|Drug|10 mg Rupatadine on demand (sham updosing to 20 mg)|Group A2 (dose administered: 10 mg rupatadine on demand): two tablets of placebo daily- one on-demand tablet of rupatadine 10 mg ,intake only if needed.
1583455|NCT02358239|Procedure|acupuncture|Experiment group received acupuncture at Zusanli (ST36) and Neiguan (PC6) acupuncture points
1583456|NCT02358226|Behavioral|Soccer League (SL)|Participants will be invited to attend soccer practice in the late afternoons, roughly 2-3 times per week. Competitive games will be held on Saturdays so that friends and family may attend. Using a mobile phone application, coaches will regularly record information on participants' arrival and departure times, sportsmanship, volunteering in the community, the results of saliva tests for drugs and alcohol. The SL intervention arm will last for one year.
1583457|NCT02358226|Behavioral|Soccer League/Vocational Training (SL-V)|In addition to the SL intervention, participants will gain access to vocational training. The Vocational Training will take place through the Learn to Earn program based in Khayelitsha for a period of 6 months. This program offers practical and market-related training in life skills, business skills and mentorship. The SL-V intervention arm will last for one year; with six months dedicated to soccer and six months dedicated to vocational training.
1583458|NCT02358213|Procedure|Ultrasound|Ultrasound examinations are done 5 times
1583459|NCT02358200|Drug|BMN-673|
1583460|NCT02358200|Drug|Carboplatin|
1583461|NCT02358200|Drug|Paclitaxel|
1583462|NCT02358187|Biological|Experimental: HLA-A2 Restricted Glioma Antigen-Peptides with Poly-ICLC|Poly-ICLC is administered intramuscularly (i.m.) using sterile technique, as supplied from the vial, and in the amount prescribed for the participant's weight. Patients should receive a dose of acetaminophen (15 mg/kg up to a max of 1000 mg) 30-60 minutes before each poly-ICLC administration. The poly-ICLC treatments will be administered immediately following the vaccine. Patients/parents will be asked to report any temperature elevations and side effects after each treatment.
1583463|NCT02358174|Procedure|Hemorrhoidectomy|"Grade III and IV patients were treated with surgery according to Milligan-Morgan (Milligan-Morgan laser optical fibers variant) procedure.
All patients will perform blood sampling for MMPs and NGAL plasma levels evaluation"
1583464|NCT02358174|Other|blood sampling|blood sampling for MMPs and NGAL plasma levels evaluation (ELISA test)
1583465|NCT02358174|Other|tissue sampling|tissue sampling for MMPs and NGAL tissue levels evaluation (Western Blot)
1583466|NCT02358161|Drug|gemcitabine and nab paclitaxel|DLT adn MTD of LED225 co-administered with fixed doses of gemcitabine and nab-paclitaxel in patients with advanced or metastasized pancreatic cancer
1583467|NCT02358135|Other|Collaborative Connected health, (CCH)|CCH is an asynchronous, secure online platform where patients can upload images of psoriasis lesions and submit assessments. Likewise, practitioners can request and/or initiate dermatology consultations, assume longitudinal care or communicate with patients directly.
1583468|NCT02358135|Other|Control|In-person care is the control group because it is currently considered the standard of care in delivering dermatologic services. The intervention includes regular visits to a physician, and may include such treatments as ointments, steroids or UV therapy at the discretion of a physician. In-person care is the major healthcare-delivery model for managing chronic skin diseases and a realistic, primary option that patients face. The patients in the in-person arm can seek psoriasis care from PCPs or dermatologists, just as they would in the real world.
1583469|NCT02358122|Other|Wholegrain rye|A variety of cereal foods providing >100g/day wholegrain from rye
1583470|NCT02358122|Other|Wholegrain wheat|A variety of cereal foods providing >100g/day wholegrain from wheat
1583471|NCT02358122|Other|Refined wheat|A variety of cereal foods providing 0g/day wholegrain
1583472|NCT02358109|Behavioral|exercise|The exercise intervention will be performed in groups of 20 participants which will train 3 days/week (60 min per session) for a 16-week period. Sessions will be designed and carefully supervised by exercise monitors, including a 15 minute warm-up period followed by 35 minute focused on aerobic exercises, developed progressively at intensity sufficient to achieve 50% (at the beginning of the intervention) and 80% (the last month of the intervention) of predicted maximum heart rate (209-0.73 × age) and resistance strength training.Monday sessions will involve resistance strength exercises. Wednesday sessions will include balance oriented activities and dancing aerobic exercises. Fridays will include aerobic, resistance strength and coordination using a circuit of different exercises.Sessions finish with a 10 minute cool-down period of stretching and relaxation exercises.
1583473|NCT02358096|Drug|ASP8232|oral capsule
1583474|NCT02358096|Drug|Placebo|oral capsule
1583475|NCT02358083|Behavioral|Provider Communication about Vaccination|There are 12 pairs of messages varying in target vaccination, discussion of relative safety of vaccination, and strength of provider recommendation for vaccination.
1583476|NCT02358057|Drug|Dexmedetomidine|
1583477|NCT02358057|Drug|Alfentanil|
1583478|NCT02358044|Drug|Sofosbuvir|400 mg tablets, taken orally (PO) every day (QD) for 12 weeks.
1583479|NCT02358044|Biological|PegIntron|PegIntron administered subcutaneously every week (QW) at 1.5 mcg/kg for 12 weeks.
1583480|NCT02358044|Drug|Ribavirin|Capsule and/or tablet administered PO twice daily (BID) based on weight (1000 - 1200 mg) for 12 weeks.
1583481|NCT02358044|Drug|Grazoprevir/Elbasvir (100 mg/50 mg) FDC|Grazoprevir/Elbasvir (100 mg/50 mg) FDC, taken PO QD for 12 weeks.
1583482|NCT02358031|Biological|Pembrolizumab|
1583483|NCT02358031|Drug|Cisplatin|
1583484|NCT02358031|Drug|Carboplatin|
1583485|NCT02358031|Drug|5-FU|
1583486|NCT02358031|Biological|Cetuximab|
1583487|NCT02358018|Drug|68Ga-DOTATOC PET/CT Scan|Study participants will undergo the 68Ga-DOTATOC PET/CT after informed consent. The nominal injected dose will be up 3-5.5 mCi containing approximately 10 - 50 microgram of 68Ga-DOTATOC and will be injected via IV access lines. CT scans will be performed with our standard oral contrast agent (typically Omnipaque and/or barium) in accordance with our standard FDG practice unless some contraindication is present. Uptake period following injection will be 0.75-1hour. Acquisition time will be approximately ~1 hour. In patients who may not be able to lie still, anesthesia will be provided as per routine standard clinical practice.
1583488|NCT02358005|Procedure|Extracorporeal shock wave therapy 60mj|
1583489|NCT02358005|Procedure|Extracorporeal shock wave therapy 120mj|
1583490|NCT02358005|Procedure|non extracorporeal shock wave therapy|
1583491|NCT02357992|Radiation|Stereotactic Body Radiotherapy (SABR)|SABR once a day for 3-4 days in a row, 50Gy in 4 fractions for central tumor, or 54Gy in 3 fractions for peripheral tumor.
1583492|NCT02357979|Device|Laser|CO2 - 9.3μm short-pulsed laser irradiation will occur on the occlusal enamel surface. This results in changes in crystal composition and structure, which increase the resistance of dental mineral to dissolution by acid and will work to better prevent dental caries in the occlusal surface of vital teeth when compared to fluoride therapy alone over 12 months.
1583493|NCT02357979|Other|Fluoride|The Fluoride varnish is painted on the occlusal surface of the tooth. Fluoride varnish makes enamel more acid resistant.
1583494|NCT02357966|Biological|514G3|True Human Monoclonal Antibody
1583495|NCT02357966|Drug|Placebo|Buffered saline solution
1583496|NCT02357966|Drug|Standard IV antibiotic therapy|standard antibiotic therapy will be determined by the attending physician and will be guided by the results of cultures with sensitivities.
1583497|NCT02357953|Other|Measurement of cardiac index|
1583498|NCT02357940|Drug|Experimental Product|1% Colloidal Oatmeal Balm
1583499|NCT02357927|Behavioral|Mini-AFTERc|20-30 minute structured conversation following guidelines and instruction within the Mini-AFTERc 20 page manual
1583500|NCT02357927|Behavioral|telephone call|this consists of a 20-30 minute conversation about the general well-being of the patient with no specific reference to recurrence fears unless raised by the patient explicitly themselves
1583501|NCT02357901|Drug|Sublingual Film buprenorphine|Sublingual film is used for induction therapy. Participants take sublingual film for 3 days according to the sublingual film prescribing information; they then complete a 4-to-11 day sublingual film dose adjustment at doses ranging from 8 mg to 24 mg sublingual film prior to randomization
1583502|NCT02357901|Drug|RBP-6000|Six injections administered subcutaneously every 28 days on alternate sides of participant's abdomen at either High dose or Low dose
1583503|NCT02357901|Drug|Placebo|Six injections of placebo administered subcutaneously every 28 days on alternate sides of participant's abdomen expect volumes matching the experimental drug at either the Low dose or High dose
1583504|NCT02357888|Drug|V0018|Oromucosal - Single dose
1583505|NCT02357888|Drug|Placebo|Oromucosal - Single dose
1583506|NCT02357862|Procedure|Mitral Valve Annuloplasty|Mitral valve annuloplasty by a rigid mitral ring, a semi-rigid ring, or a fully flexible band, at the surgeon's discretion
1583507|NCT02357849|Drug|Aripiprazole|see arm description
1583508|NCT02357849|Drug|Fluoxetine|see arm description
1583509|NCT02357836|Drug|Itraconazole|"Once on study, itraconazole will be taken twice daily for a total of 10-14 days. After being on itraconazole for 7-10 days, Post-treatment assessments will include a skin biopsy, blood draw for the PK analyses and the cytokine panel, and also MRI evaluations (anticipated to last 45-50 minutes). Toxicity assessments and laboratory checks will also be conducted during that time. Following these assessments, itraconazole will be continued until the day of surgery. At the time of surgical resection, a tissue sample (with adjacent normal tissue as per standard resection technique) will be obtained to complete the analysis. Following resection, subjects will be followed per standard post-operative procedure."
1583510|NCT02357823|Other|Evaluation of immunological response|Study of short and long term immunological response after different schedule of PCV13 or PPV23
1583511|NCT02357823|Other|Nasopharyngeal swabs analysis|Evaluation of pneumococcal nasopharyngeal colonization
1583512|NCT02357810|Drug|Pazopanib Hydrochloride|Given PO
1583513|NCT02357810|Drug|Oral Topotecan Hydrochloride|Given PO
1583514|NCT02357810|Other|Laboratory Biomarker Analysis|Correlative studies
1583515|NCT02357797|Drug|Vortioxetine|
1583516|NCT02357797|Other|Placebo|
1583517|NCT02357784|Device|Neurometer|The purpose of Current Perception Threshold (CPT) testing is to help physicians better understand how Sacral Neuromodulation affects the nerves of patients with dual incontinence. CPT Testing involves the use of a portable battery-operated machine which will stimulate the subject's nerves via an electrical stimulation. Electrodes will be placed via a catheter in to the subject's urethra and rectum, and the electrical current will be increased gradually until the subject feels the onset of tingling, buzzing, or warmth at the site of the electrode. The electrical current will then gradually decrease until no sensation of stimulation is felt. The procedure will then be repeated where the subject will be asked to hold the test button to increase the stimulus intensity above their sensory threshold (above the point where they can feel it) until the device automatically shuts off.
1583518|NCT02357771|Drug|Probiotic (L. brevis CD2 lozenges)|Each Lactobacillus brevis CD2 lozenge contains not less than 1 billion Colony Forming Unit of L. brevis CD2
1583519|NCT02357771|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
1583520|NCT02357758|Drug|Antibiotic Prophylaxis|
1583521|NCT02357745|Procedure|Non surgical periodontal therapy|scaling and root planing
1583522|NCT02357732|Drug|Nivolumab|
1583523|NCT02357732|Drug|Trametinib|
1583524|NCT02357732|Drug|Dabrafenib|
1583525|NCT02357719|Device|VistaO2 FLUX device|Full night VistaO2 FLUX device monitoring synchronized with the gold standard polysomnography.
2008750|NCT03327610|Other|PSV25|Application of a ventilator hyperinflation intervention with Pressure Support Ventilation (PSV). The cycling off was set at 25% of peak inspiratory flow and the pressure support was increased until a peak pressure of 40cmH2O was achieved. After achieving the target pressure, this ventilatory regimen lasted 15 minutes. Positive end expiratory pressure and the inspired oxygen fraction were not modified.
2008751|NCT03327597|Other|Clinical follow-up 1|Participants receive routine care outside the bounds of the trial. No further work-up.
1583528|NCT02357693|Drug|Aprepitant|Aprepitant or placebo will be administered to the patient before surgery
1583529|NCT02357680|Other|Diary|"The intervention is a notebook in which the relative will be asked to keep a diary of the time when the patient is critically ill in the ICU. At least two photos of the patient will be added to the diary upon full consent from the patient.
The diary contains a written description on how to use the diary during and after the patients stay in the ICU."
1583530|NCT02357654|Drug|GnRH|single shot of GnRH agonist
1583531|NCT02357654|Drug|placebo|placebo
1583532|NCT02357641|Other|retrospective echographic myocardial strain analysis refering to acute coronary syndrome|retrospective evaluation for cut off value of circumferential and radial echographic strain parameters corresponding to acute coronary disease
1583533|NCT02357628|Device|Wound treatment with RO-NPT|
1583534|NCT02357628|Device|Wound Irrigation|
1583535|NCT02357615|Drug|nifedipine CR tablets (Xin Ran)|
1583536|NCT02357615|Drug|Adalat|
1583537|NCT02357602|Drug|GS-7340|Medication is supplied in 10 or 25mg tablets, so subjects will receive either 1/2 or one tablet in a single dose.
1583538|NCT02357589|Procedure|2D laparoscopic cholecystectomy|
1583539|NCT02357589|Procedure|3D laparoscopic cholecystectomy|
1583540|NCT02357576|Drug|Intralipid 20% I.V. Fat Emulsion|
1583541|NCT02357563|Drug|ulipristal acetate|5 mg/day will be administered starting from day 1 of the cycle and up to three months later for two courses, with an interval between the courses of 1 month
1583542|NCT02357563|Drug|Leuprolide acetate|One dose of 11.25 GnRH analogue depot will be administered in the luteal phase of the menstrual cycle (days 21-24) and repeated 3 months later
1583543|NCT02357550|Drug|ketone|3-OHB is infused intravenously.
1583544|NCT02357550|Drug|placebo|Saline infusion.
2008752|NCT03327597|Other|QoL questionnaire|Participants receive an QoL questionnaire that will be answered electronically on the study website (www.blodskimun.is)
1583546|NCT02357524|Drug|Oritavancin|
1583547|NCT02357511|Device|Study Monitor used|
1583548|NCT02357498|Procedure|transsphenoidal surgery|
1583549|NCT02357485|Biological|ADSC|Single injection of ADSC
2008753|NCT03327597|Other|Standard follow-up or treatment.|Participants previously diagnosed as having MGUS or participants that have multiple myeloma or other lymphoproliferative diseases will receive standard clinical follow-up and treatment.
2008754|NCT03327597|Other|Clinical follow-up 2|Standard clinical follow-up according to International Myeloma Working Group (IMWG) guidelines.
2008755|NCT03327597|Other|Clinical follow-up 3|Intensive clinical follow-up with regular clinical assessment, laboratory testing and radiology imaging.
1583554|NCT02357433|Device|High Doses CPFA|
1583555|NCT02357420|Drug|RM-131|Double blind RM-131 given subcutaneously at three BID doses: 10, 30 and 100 μg for 12 weeks.
1583556|NCT02357420|Drug|Placebo|Placebo given subcutaneously for 12 weeks.
1583557|NCT02357407|Drug|Patients in intensive care : infection treated with ciprofloxacin IV|8-10 samples per patients on day-4 of their treatment
1583558|NCT02357407|Drug|Osteoarticular infected patients : infection treated with oral ofloxacin|8-10 samples per patients on day-4 of their treatment
1583559|NCT02357381|Device|eNeura SpringTMS|Single pulse magnetic stimulation for prevention and/or treatment of migraine headache with or without aura.
1583560|NCT02357368|Drug|Depot medroxyprogesterone acetate (DMPA)|DMPA will be administered every 12 weeks at the standard dose of 150 mg IM, beginning from week 3 of study enrollment and repeated at week 15.
1583561|NCT02357368|Device|Etonogestrel implant (Eng-Implant)|A standard nexplanon rod implant will be placed at study week 3 by a trained clinician.
1583562|NCT02357368|Device|Levonorgestrel intrauterine device (Lng-IUD)|A standard Mirena IUD will be placed at study week 3 by a trained clinician.
1583563|NCT02357368|Device|ParaGard® T 380A Intrauterine Copper Contraceptive|A standard ParaGuard IUD will be placed at study week 3 by a trained clinician.
1583564|NCT02357355|Device|UIHC Driving Simulator|This is a driving simulator located in the basement of the hospital. A car will be facing a large video screen of a driving simulation.
1583565|NCT02357342|Drug|Sirolimus|intravitreal injection
1583566|NCT02357342|Drug|Standard of Care intravitreal injections of anti-VEGF|intravitreal injections of anti-VEGF
1583567|NCT02357303|Drug|Simethicone|100mL of water plus 100mg Simethicone by mouth, 15 to 30 minutes before endoscopy
1583568|NCT02357303|Drug|Acetylcysteine|100mL of water plus 100mg Simethicone plus 600mg N-acetylcysteine by mouth, 15 to 30 minutes before endoscopy
1583569|NCT02357303|Other|Placebo|100mL of water
1583570|NCT02357290|Drug|Open-label Treatment with N-Acetylcysteine|
1583571|NCT02357277|Drug|Budesonide|inhaled glucocorticoid budesonide as dry powder inhaler
1583572|NCT02357277|Other|Placebo Inhaler|inhaled placebo
1583573|NCT02357264|Device|Ultrasound|Ultrasound of the chest for the detection of fluid in the lung
1583574|NCT02357251|Other|Enhanced recovery protocol|
1583575|NCT02357225|Drug|Pyridostigmine Bromide|Pyridostigmine is an acetylcholinesterase inhibitor, which increases the amount of acetylcholine at the neuromuscular junction. It will be taken orally, either as a tablet or as a syrup.
1583576|NCT02357212|Procedure|coronary angiography|invasive procedure performed to determine coronary anatomy
1583577|NCT02357212|Procedure|adenosine stress test|non-invasive procedure to determine area of cardiac ischemia
1583578|NCT02357199|Other|Intensive oral care & didactic training|Professional (dental hygienist) intensive oral care intervention and individual patient training/didactic instruction to promote patient compliance and patient capability of oral preventive measures in a long-term perspective.
2008756|NCT03327597|Other|Clinical follow-up control|Control clinical visit
2008757|NCT03327584|Procedure|Arthrocentesis|Athrocentesis
1583581|NCT02357160|Behavioral|Artwork|Prints by local artists that are hung on the walls of patient rooms.
1583582|NCT02357147|Drug|Placebo|"Combination Phase - Placebo will be administered IV (intravenous infusion) once weekly for six 21-day cycles.
Maintenance Phase - Placebo will be administered IV (intravenous infusion) once weekly until disease progression."
1583583|NCT02357147|Drug|Amatuximab|"Combination Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly for six 21-day cycles.
Maintenance Phase - Amatuximab 5mg/kg will be administered IV (intravenous infusion) once weekly until disease progression."
1583584|NCT02357147|Drug|Pemetrexed|Combination Phase - Pemetrexed 500 mg/m2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
1583585|NCT02357147|Drug|Cisplatin|Combination Phase - Cisplatin 75 mg/m2 will be administered IV on Day 1 of each 21-day cycle for 6 cycles.
1583586|NCT02357134|Other|Stationary Bicycle Test|All groups: After screening, participants perform a cycle test using a stationary bicycle. Participants pedal with no resistance for 60 seconds. Participants perform the cycle test without receiving any air or oxygen for as long as they can. After a 2 hour rest, participant performs the cycle test again using low-flow air for as long as they can.
1583587|NCT02357134|Behavioral|Questionnaires|Four symptom questionnaires completed at screening and after the second cycle test. This should take about 40 minutes to complete.
1583588|NCT02357134|Other|Structured Exercise with High Flow Oxygen|About 3 days after baseline cycle test, second cycle test performed using high flow oxygen.
1583589|NCT02357134|Other|Structured Exercise with High Flow Air|About 3 days after baseline cycle test, second cycle test performed using high flow air.
1583590|NCT02357134|Other|Structured Exercise with Low Flow Oxygen|About 3 days after baseline cycle test, second cycle test performed using low flow oxygen.
1583591|NCT02357134|Other|Structured Exercise with Low Flow Air|About 3 days after baseline cycle test, second cycle test performed using low flow air.
1583592|NCT02357121|Device|Focal Laser Ablation|Focal laser ablation of prostate tissue using laser interstitial thermal therapy (LITT) under MR/ultrasound fusion guidance
1583593|NCT02357108|Other|Video|Watch two short videos with a 4-minute interval between the two of them, estimate 8 minutes to watch both the videos.
1583594|NCT02357108|Behavioral|Survey|One set of surveys before first video and one set after each video played, estimate total of 30 minutes for all surveys.
1583595|NCT02357095|Procedure|monitoring|uterine artery chemo-embolization combined with suction curettage under different monitoring methods,such as hysteroscopic monitoring,ultrasonography monitoring and no monitoring
1583596|NCT02357082|Radiation|MRI Scan|MRI scan with Specific Absorption Rate (SAR) limit of 1.5 watts per kilogram of body weight
1583597|NCT02357069|Drug|Enbrel|Etanercept
1583598|NCT02357069|Drug|LBEC0101|Etanercept
1583599|NCT02357056|Other|Wet Lab|ITA dissection and Annuloplasty Sutures in porcine model.
1583600|NCT02357056|Other|Dry Lab|Camera and clutching, peg transferring, intracorporeal knot tying
1583601|NCT02357056|Other|Virtual Reality|daVinci Surgical Skills simulation
2008758|NCT03327558|Drug|Apriso 0.375G Extended-Release Capsule|extended release capsule
1583604|NCT02357030|Drug|Methyl-P plus GWI Nutrient Formula|"Week 1:
One tablet of Methyl-P (5mg) twice daily
Four tablets of GWI Nutrient Formula twice daily
Week 2 to Week 12 :
Two tablets of Methyl-P (10mg) twice daily
Four tablets of GWI Nutrient Formula twice daily"
1583605|NCT02357017|Dietary Supplement|NaCl tablets|
1583606|NCT02357004|Drug|Carvedilol|CR 40 mg daily in addition to normal BP medications
1583607|NCT02357004|Drug|Chlorthalidone|12.5 mg daily in addition to normal BP medications
1583608|NCT02356991|Drug|Famitinib|
1583609|NCT02356991|Drug|Placebo|
1583610|NCT02356978|Device|Arm1 homemade phototherapy treatment|"session of 10 or 12 hours phototherapy treatment using the homemade device during the first night and then the DRAP device during the next nights."
1583611|NCT02356978|Device|DRAP|
1583612|NCT02356965|Drug|Ketamine|Single dose of sublingual investigational medication administered when subjects develop moderate to severe pain after third molar extraction.
1583613|NCT02356965|Drug|Placebo (for Ketamine)|Sublingual sugar pill developed to mimic ketamine sublingual dose.
1583614|NCT02356952|Behavioral|Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
1583615|NCT02356952|Behavioral|Low Glycemic Index Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
1583616|NCT02356952|Behavioral|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods).
1583617|NCT02356939|Device|intraductal removable stent custom-made segment (2 cm) of a 8 French T-tube|": In the IST group, the surgeon will place the IST in the bile duct, which is a custom-made segment (2 cm) of a 8 French T-tube. The stent is inserted in the biliary duct without suture fixation.
In order to minimize bias and to homogenize the technique, a short technical explanatory movie was realized by the promoter's team and edited on internet.
In the IST group, an endoscopic retrograde cholangio-pancreatography (ERCP) with sphincterotomy will be planned between the 4th and the 6th month post-transplantation, requiring a short stay in hospital, a general anesthesia, clinical and biological tests including plasmatic lipase dosage at Day 1."
1583618|NCT02356939|Procedure|stent extraction by endoscopic retrograde cholangio-pancreatography (ERCP)|
1583619|NCT02356913|Drug|Nicotine gum|
1583620|NCT02356900|Procedure|Hyperoxic hyperbaric interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week while at 1.4 ATA of oxygen in a hyperbaric chamber.
1583621|NCT02356900|Procedure|Normoxic, normobaric, interval exercise training|Six 30-min high-intensity interval training sessions completed 3-times a week.
1583622|NCT02356900|Drug|Oxygen|Used in Hyperoxic hyperbaric interval exercise training intervention
1583623|NCT02356887|Other|IJV Flow in the sitting position|All volunteers will be fully awake throughout the study and be kept comfortable. A cross will be marked where the left and right IJV cross the level of C6. This is where all the measurements will be taken in 3 different conditions. The volunteers will be scanned initially in the sitting position at rest followed by the 2 conditions mimicking venous occlusion, one with internal jugular compression using neck collar and Valsalva maneuver.. At each conditions, the left and right IJV will be scanned with an ultrasound measuring the cross sectional area and Doppler velocity of the IJV. The least amount of pressure will be used to press on the ultrasound probe and the measurements will be obtained at end inspiration. The IJV flow is then calculated.
1583624|NCT02356874|Behavioral|Exercise|An exercise program for 40-60 minutes three times a week in 3 months. Twice a week the exercise sessions will be supervised by a physiotherapist and these sessions will consist of endurance and strength training. The endurance training will be high intensity interval training on a treadmill. And strength training with external load for the major muscle groups (individually adapted: six exercises, eight to ten repetitions maximum, two to three sets). Once a week the participants will exercise individually for a minimum of 40 minutes of endurance exercise.
1583625|NCT02356861|Device|Photomedex Sham Helmet with Red/Near-Infrared Light-Emitting Diodes (LEDs) that are not turned on|"The LED helmet from Photomedex, Montgomeryville, PA will be used.
18 LED pods are in the helmet. Each LED pod:
Pod size: 19 cm2 Power output: 692.5 mW Power density: 36.5 mW/cm2
20 NIR diodes, 830 nm and 4 red diodes, 633 nm.
1 J/cm2 = 30.4 sec"
1583626|NCT02356848|Behavioral|Tailored Intervention (TI)|Participants in this arm will receive a comprehensive intervention based on the Transtheoretical Model and Prospect Theory with the counseling being delivered by health counselors using MI principles.
1583627|NCT02356848|Behavioral|Current Practice (CP)|this group will receive calls and mailings focusing on providing education and prevention strategies for health conditions such as colorectal cancer, influenza, insomnia, vision, dementia, and oral disease.
1583628|NCT02356835|Device|APT001|APT001, is a portable device that uses plasma energy to deliver nitric oxide to the tissues.
1583629|NCT02356835|Device|SHAM|Portable device that uses warmed room air to mimic delivery of the APT001 treatment.
1583630|NCT02356822|Other|Patient registry|Oncology data registry
1583631|NCT02356809|Drug|Neovasculgen|Neovasculgen is an original gene construction that contains supercoiled plasmid DNA (1.2 mg) that encodes pCMV-vegf165 as the active substance. The drug will be supplied to the study centre as a sterile lyophilisate that will be then dissolved in 2 ml of water for injections immediately prior to administration. The drug will be administered intramuscularly (interosseous muscles of hand) at 4-5 injection sites in the dorsal surface of the hand.
1583632|NCT02356796|Other|Multidisciplinary group treatment|"Multidisciplinary group intervention at the University Hospital of North Norway. The group intervention is led by physiotherapists, with contributions from a gynecologist, nutritionist and a peer patient. The treatment consists of active exercises and theory lessons. The focus is to enhance the participants body awareness and to recognize the integration of mental and physical processes. The aim is to create change in patterns that influence the participants health negatively.
The treatment lasts one year. The first meeting has a duration of 10 days, then follow-up after 3, 6 and 12 months."
1583633|NCT02356796|Other|Standard physiotherapy treatment|Standard treatment in primary or secondary health care physiotherapy. Patients are referred to a physiotherapist with appropriate training/competence, as close to their home as possible.
1583634|NCT02356783|Device|Pedometer|Wireless pedometer
1583635|NCT02356770|Device|Collagen Matrix 10808|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Collagen Matrix 10808 will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
1583636|NCT02356770|Procedure|Connective tissue graft|At the day of the Intervention (day 0) sulcular incisions will be made around the neighbouring teeth and a straight incision from the lingual/palatal line angle of the distal tooth to the lingual/palatal line angle of the mesial tooth. A full thickness flap will be elevated on the lingual side, whereas a split flap will be made at the buccal aspect preparing a soft tissue pouch without the preparation of horizontal release incisions. The Connective tissue graft (Gold Standard) will then be positioned in the pouch under the elevated buccal flap. A horizontal mattress suture will be made to immobilize graft to the flap followed by four to five single sutures to close the wound.
1583637|NCT02356757|Behavioral|Personalized Behavioral Intervention|The PBI is based on self-regulation theory, the Transtheoretical Model and Prospect Theory, and will be delivered using Motivational Interviewing principles and the teach-back method. Participants will receive monthly calls targeting foot self-care, foot self-monitoring, diet, medication and physical activity for 6 months. Call/mailing frequency during the next 6 months will depend on adherence level to foot self-care and self-monitoring at 6 months.
1583638|NCT02356757|Behavioral|Current Best Practice|CBP will include monthly calls from a counselor focusing on preventing conditions like colorectal cancer, flu, insomnia, vision problems, memory loss and oral disease for the first 6 months. Frequency of calls and mailings from counselors during the next 6 months will be determined by level of adherence to preventive strategies during the first 6 months.
1583639|NCT02356744|Other|Ultrasound|Ultrasound assessment of fetal growth, anomalies , liqour and placenta
1583640|NCT02356718|Behavioral|Cognitive training activities|Training activities consist of computer tasks designed to improve memory and cognition. The intervention consists of 45-minute training sessions delivered regularly during inpatient treatment.
1583641|NCT02356718|Behavioral|Inpatient psychosocial therapy|Group psychosocial therapy delivered in an inpatient setting.
1583642|NCT02356705|Drug|Midazolam|midazolam 0.2 mg/kg given intranasally
1583643|NCT02356705|Drug|xylocaine|intransal xylocaine given in conjunction with intranasal midazolam
1583644|NCT02356705|Drug|saline placebo|intranasal saline given as placebo
1583645|NCT02356692|Device|enfilcon A|Daily disposable contact lens worn in a daily wear, daily disposable mode
1583646|NCT02356692|Device|senofilcon A|Daily disposable contact lens worn in a daily wear, daily disposable mode
1583647|NCT02356679|Drug|Eupasidin-s Tab|three times per day, 1 tab for each time, PO, during 2weeks
1583648|NCT02356679|Drug|Stillen Tab.|three times per day, 1 tab for each time, PO, during 2weeks
1583649|NCT02356653|Device|Transplant of stem cells with CD3+/CD19+ depletion (CliniMACs)|Processing of stem cells using the CliniMACs device to selectively deplete specific T cells to decrease risk of graft versus host disease when using donor stem cells which are not fully matched.
1583650|NCT02356640|Procedure|EUS-guided celiac ganglion neurolysis|EUS-CGN would be performed with a linear video echoendoscope (Olympus UM 2000; Olympus Co Ltd, Japan). The celiac ganglia are visualized under linear EUS and the injection would be applied directly into the ganglia. It is represented by small 2 to 3 mm hypoechoic nodules with hyperechoic foci in the center or a single elongated hypoechoic structure. IIf the ganglia are not identified by EUS, then injection would be performed as bilateral injections at the celiac vessel trunk. All procedures would be performed by a two experienced endosonographer.
1583651|NCT02356640|Procedure|Percutaneous celiac plexus neurolysis|Percutaneous fluoroscopy-guided CPN would be performed in the operation theatre with the transcural technique. A 22-gauge, 17 cm-long spinal needle (B-D Quincke Type Point, Becton Dickinson &Co., NJ 07417, USA) would be inserted and advanced just caudal to the margin of 12th rib and cephalad to the transverse process of L1 toward the anterolateral surface of the L1 vertebral body. Final needle position would be confirmed by radiographic contrast, layering over anterior surface of aorta. 10mL of levobupivacaine (0.25%), followed by 10mL of absolute alcohol would be injected on both sides using separate punctures.
1583652|NCT02356640|Device|Olympus UM 2000|
1583653|NCT02356640|Device|B-D Quincke Type Point|
1583654|NCT02356640|Drug|Levobupivacaine|
1583655|NCT02356627|Other|The Cancer Home Life Intervention|Adaptive interventions aiming at compensating for functional limitations.
1583656|NCT02356588|Drug|Sufentanil Tablet 30 mcg|
1583657|NCT02356588|Drug|Placebo Tablet|
2008759|NCT03327545|Device|Neural mobilization|Neural mobilization on the right side of the craniocervical region for a total of 12 minutes.
2008760|NCT03327545|Device|Soft tissue techniques and Stretching|Soft tissue techniques and Stretching on the right side of the craniocervical region for a total of 12 minutes
2008761|NCT03327545|Device|Control group|Did not receive any treatment.
2008762|NCT03327532|Procedure|Clinical examination centered on congestion|Clinical examination centered on congestion will be performed within 72 hours of admission and before discharge from hospital
1583664|NCT02356549|Behavioral|EMR Tailoring|Electronic Medical Records (EMR) data alone will be entered into the Michigan Tailoring System (MTS system) and their brochures will be prepared.
1583665|NCT02356549|Behavioral|Survey Tailoring|Survey that will use standardized, psycho-metrically sound measures to gather information about patients, including their levels of trust in medical research and preferences for information and decision involvement. The survey augmented by their EMR data will be used to develop a level of tailored messages.
1583666|NCT02356549|Behavioral|Physician Involvement|Prior to the consultation, physicians of patients will receive a summary of patients' tailored message brochure from the Research Assistant (RA) and included in the patient's notes. At the conclusion of the consultation, the RA will ask the oncologist whether or not a clinical trial was discussed and whether or not they read the patients brochure.
1583667|NCT02356536|Device|Agilitas|WCD trial
1583668|NCT02356510|Procedure|Primary PCI|
1583669|NCT02356471|Device|Management of Therapy Complications Fitbit Zip (portable pedometer device)|Use pedometer to monitor physical activity
1583670|NCT02356471|Other|Questionnaire Administration|Ancillary studies
1583671|NCT02356471|Other|Quality-of-Life Assessment|Ancillary studies
1583672|NCT02356458|Drug|Ibrutinib|"Combination therapy:
Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Ibrutinib: p.o daily; Phase I: according to DL; Phase II: RP2D established in phase I
Maintenance therapy:
p.o daily: 560 mg"
1583673|NCT02356458|Drug|bortezomib|"Combination therapy:
Trial treatment of ibrutinib in combination with bortezomib Cycles 1-6 (1 cycle = 21 days) Injection of Bortezomib (s.c.), dose of 1.3 mg/m2 on day 1, 4, 8, 11"
1583674|NCT02356445|Other|Cytotoxic drug|Observe patients versus treatment type
1583675|NCT02356419|Drug|Recombinant erythropoietin stimulating protein|Recombinant erythropoietin stimulating protein is a high glucose medium and long-acting recombinant protein products, containing 165 amino acids by adding 3 glycosylation sites
1583676|NCT02356406|Radiation|Celiac Plexus Radiosurgery|"5 fractions of SBRT (Stereotactic body radiation therapy). The target will always include the anterior-medial aspect aorta at T12-L2 (surrogate for celiac plexus). If there is adjacent tumor (e.g. pancreatic tumor that infiltrates the celiac plexus) this will be irradiated in addition.
It is expected that patients will be treated with a rapid-arc IMRT (Intensity modulation radiation therapy) dose-painting technique. Details of beam arrangement and energy used will be determined on an individual basis."
1583678|NCT02356367|Other|telemonitoring|
1583679|NCT02356354|Procedure|Skin biopsy|2 biopsies are done on the same patient : 20 cutaneous biopsies from post-burn scar and from healthy skin
1583680|NCT02356341|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
1583681|NCT02356328|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
1583682|NCT02356315|Other|Functional Magnetic Resonance Imaging|Functional magnetic resonance imaging will be performed to measure brain, brainstem, and spinal cord activity.
1583683|NCT02356302|Device|Vicriviroc (MK-4176) Intravaginal Ring (IVR)|Contains 182 mg vicriviroc (MK-4176).
1583684|NCT02356302|Device|MK-2048 IVR|Contains 30 mg MK-2048.
1583685|NCT02356302|Device|MK-2048A IVR|Contains 182 mg vicriviroc (MK-4176) and 30 mg MK-2048.
1583686|NCT02356302|Device|Placebo IVR|
1583687|NCT02356289|Drug|Placebo|
1583688|NCT02356289|Drug|MYK-461|
1583692|NCT02356237|Other|No episiotomy|Avoidance of episiotomy
1583693|NCT02356224|Drug|SHR3824|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of SHR3824 taken for single dose.
1583694|NCT02356224|Drug|Placebo|A tablet of 2.5 mg, 5 mg, 10 mg, 25 mg, 50mg, 100mg, 200 of Placebo taken for single dose.
2008763|NCT03327532|Procedure|Cardio-pulmonary and peritoneal ultrasound|Cardio-pulmonary and peritoneal ultrasound will be performed within 72 hours of admission and before discharge from hospital
2008764|NCT03327532|Biological|Blood sample retrieved for biological assessment and biobanking|Blood sample collection will be performed within 72 hours of admission and before discharge from hospital
2008765|NCT03327532|Other|Telephone interview|Telephone interview will be performed 3 months after discharge from hospital
2008766|NCT03327519|Behavioral|SHUTi|Sleep Healthy Using the Internet (SHUTi) is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of CBT-I: sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention.
2008767|NCT03327519|Behavioral|Emmi|The Emmi® program for insomnia contains educational information on physiological controls of sleep, sleep hygiene practices, healthy sleep behaviors (e.g., reduce time in bed, get up at the same time every day, go to bed only if sleepy, and do not stay in bed unless asleep), and sleep medications; assesses self-efficacy, and; allows patients to set individual goals.
2008768|NCT03327506|Drug|Alprazolam 0.5 mg|alprazolam 0,5 mg the eve and the morning of the surgery versus a preoperative hypnosis session
2008769|NCT03327493|Diagnostic Test|Biological|"We will assess in all patients under ECLS for the treatment of a cardiogenic shock at day 0 (ECLS initiation) day 3 and day ECLS weaning :
Biological assessment:
Adrenoreceptors α1, α2, β1, β2, β3 on monocytes and lymphocytes T helper by flow cytometry
Lymphocytes Th1/Th2 pattern by flow cytometry
Cytokines on plasma : IL4, IL 12, TNF α, INF γ , IL1, IL6, IL10
Clinical assessment:
Hemodynamic parameters
Cumulated doses of catecholamines
Cardiac output variation measured by echocardiography during a standardized weaning procedure of ECLS at a constant mean arterial pressure (only on day 3 and Day ECLS weaning"
2008770|NCT03327480|Other|orthosis|Group 1: neoprebe CMC orthosis Group2: thermoplastic CMC orthosis
2008771|NCT03327467|Biological|Cord Blood Infusion|IV infusion of umbilical cord infusion (sibling or autologous)
2008772|NCT03327454|Biological|Benepali|Administered as specified in the treatment arm.
2008773|NCT03327441|Other|Almonds|Almonds will be provided as 15% energy
1583706|NCT02356146|Drug|Tacrolimus C12|
1583707|NCT02356120|Other|Echocardiogram|Tricuspid annular plane systolic excursion will by measured by emergency physician performed echocardiogram
1583708|NCT02356107|Drug|5-hydroxytryptophan and Creatine monohydrate|
1583709|NCT02356094|Procedure|Pentacam|Corneal topography using Scheimpflug Pentacam examination
1583710|NCT02356081|Other|ASyMS intervention Group|ASyMS is a mobile phone-based remote-monitoring system that enables the 'real-time' monitoring of patients' symptoms through use of a patient-reported outcome measure (PROM)
1583711|NCT02356068|Other|ROTEM analysis|3 blood samples for ROTEM analysis
1583712|NCT02356055|Behavioral|STOMP (Skill-building through Task-Oriented Motor Practice)|The STOMP intervention is a package including family-centered goals, task-specific training delivered through motor learning and errorless learning principles. It is unique in the use of massed practice (high-dosage) therapy.
1583713|NCT02356042|Other|Geriatric inclusive art (GIA) activity|The frequency of GIA sessions in this study was from 1 to 2 per month. The time of a session was around 1 hour 30 minutes. Participants of intervention group benefited GIA activity during a 6-month follow-up period.
1583714|NCT02356016|Behavioral|WB-EMS Intervention|Supervised WB-EMS Intervention 18 min/session (one session/week) and monthly dietary counseling for 6 months
1583715|NCT02356016|Behavioral|WB-EMS-Intervention and dietary supplementation|Supervised WB-EMS Intervention and dietary supplementation and monthly dietary counseling for 6 months
1583716|NCT02356016|Other|control (dietary counseling)|Monthly dietary counseling only
2008774|NCT03327441|Other|Breakfast/snack bar|Breakfast/snack bars will be provided as 15% energy
1583718|NCT02355990|Procedure|Minimally Invasive Micro Sclerostomy|Creation of a drainage channel of 50 - 100 microns (diameter) at the sclera-corneal junction and extending from the anterior chamber to the interface between the sclera and the conjunctiva (subconjuctival space).
1583719|NCT02355977|Drug|minocycline|Periocline dental ointment
1583720|NCT02355977|Procedure|surface and root planning|surface and root planning
1583721|NCT02355964|Behavioral|Exercise|Aerobe exercise 3 times a week in 8 weeks
1583722|NCT02355964|Behavioral|Diet|Diet (a diet with an overall high protein content and a low glycemic index) in 8 weeks
1583723|NCT02355951|Other|blood draw|
1583724|NCT02355938|Drug|Fidaxomicin 200 mg|Fidaxomicin 200 mg every 12 hours
1583725|NCT02355938|Drug|Placebo|1 dose of placebo every 6 hours x 2 doses
1583726|NCT02355938|Drug|Vancomycin|Vancomycin 125 mg every 6 hours
1583727|NCT02355925|Drug|intrauterine injection of uhCG|40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) containing either 500 IU of hCG (Choriomon®, IBSA SA, Switzerland) is injected intrauterine, approximately 7 minutes before embryo transfer.
1583818|NCT02355236|Drug|Naproxen/Esomeprazol 500/20mg|Tablet, b.i.d.
1583819|NCT02355236|Drug|Celecoxib 200mg|Capsule, o.d.
2008775|NCT03327402|Drug|SHP465|SHP465 capsule will be administered at a dose of 6.25 mg, orally once daily for 4 weeks. SHP465 is comprised of sulfate salts of dextroamphetamine and amphetamine, with dextroamphetamine saccharate and amphetamine aspartate monohydrate, which provide a composite enantiomer ratio of 3:1 d-amphetamine to l-amphetamine.
2008776|NCT03327389|Drug|Dexmedetomidine|dexmedetomidine was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure.
2008777|NCT03327389|Drug|placebo|0.9% NaCl was infused at a rate of 0.4 μg/kg/h starting immediately after anesthetic induction and continued until skin closure
2008778|NCT03327376|Device|ultrasound-screening|Daily ultrasound-screening for CVC-related thrombosis (DUCT) by compression ultrasound and color doppler ultrasound.
1583728|NCT02355925|Drug|Placebo|only 40 μL of tissue culture medium (G.2plus ref. 10132, Vitrolife) is injected intrauterine, approximately 7 minutes before embryo transfer.
1583729|NCT02355925|Other|control|the embryonic transfer is done without the intrauterine hCG injection. The ET procedure is performed just like in the other two groups.
1583730|NCT02355912|Device|Powered knee and ankle prosthesis|A powered knee and ankle prosthesis developed by Vanderbilt University.
1583731|NCT02355899|Drug|PD P 506 A|PD P 506 A is a dermal patch of 4 cm² in size loaded with 2 mg 5-ALA (as 5-ALA HCl) per cm².
1583732|NCT02355886|Drug|Gabapentin|Given PO
1583733|NCT02355886|Other|Placebo|Given PO
1583734|NCT02355886|Other|Questionnaire Administration|Ancillary studies
1583735|NCT02355873|Device|AN69ST hemofilter|
1583736|NCT02355873|Device|AN69 hemofilter|
1583737|NCT02355860|Behavioral|assessment|assessment
1583738|NCT02355847|Other|Lectures|Lectures
1583739|NCT02355834|Other|IBD nurse intervention|Two IBD nurse specialists at each centre (8 in total) will deliver the IBD nurse intervention
1583740|NCT02355821|Drug|Moxonidine|0.4 mg moxonidine QD titration up to 0.6 mg moxonidine BID Other Names:perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
1583741|NCT02355821|Drug|Bisoprolol|5 mg Bisoprolol QD titration up to 7.5 mg Bisoprolol BID Other Names: perindopril 10 mg/day (optional); losartan 50 mg/day (optional); calcium carbonate; vitamin D
1583742|NCT02355808|Behavioral|Tailored Leaflet|
1583743|NCT02355808|Behavioral|GP visit|
1583744|NCT02355795|Behavioral|low-fat diet|Energy from total fat, protein and carbohydrates are 20%, 14% and 66%, respectively
1583745|NCT02355795|Behavioral|moderate-fat diet|Energy from total fat, protein and carbohydrates are 30%, 14% and 56%, respectively
1583746|NCT02355795|Behavioral|high-fat diet|Energy from total fat, protein and carbohydrates are 40%, 14% and 46%, respectively
1583747|NCT02355782|Biological|OMS721|Human IgG4 MASP-2 Monoclonal Antibody
1583748|NCT02355756|Drug|Maxadilan|
1583749|NCT02355756|Drug|Placebo|
1583750|NCT02355743|Drug|rtPA lock therapy|"rtPA 2 mg/2 ml, or 110% of the volume of the catheter lumen if less than 2 mL, administered locally in a volume to fill the lumen (dead space) of the CVAD, once weekly for a total of 24 weeks. rtPA will be given as research intervention as lock therapy in that it will dwell within the catheter of the CVAD for a specified duration of time and then be removed (aspirated); in this setting the medication is not given to the patient as a flush, i.e. in systemic fashion."
1583751|NCT02355730|Procedure|Venepuncture|Venepuncture to collect blood samples from Patients undergoing Warfarin Therapy.
1583752|NCT02355717|Other|Observational Study|
1583753|NCT02355704|Drug|Atorvastatin|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure controls were performed
1583754|NCT02355704|Drug|Placebo|Patients were assigned to two groups, one of them received oral atorvastatin (study group) and the other, homologated placebo (control group) for 4 weeks before a kidney transplantation. Previous surgical procedure were performed
1583755|NCT02355691|Device|PREVENA|The device is a sealed negative pressure wound therapy tool. The details of the device can be found at http://www.kci1.com/KCI1/prevena.
1583756|NCT02355678|Drug|dexamethasone|IV 0.5 mg/kg
1583757|NCT02355678|Drug|Local anesthetic infiltration|Using 25 G-3.5 cm curved needle
1583758|NCT02355678|Drug|General anesthesia|"Induction by intravenous fentanyl (1.5 µg kg-1) and propofol (2.5 mg kg-1) followed by endotracheal intubation facilitated by atracurium (0.5 mg kg-1).
Maintenance with sevoflurane 1-3%, fentanyl (1-2 µg kg-1), nitrous oxide 70% and oxygen 30%."
1583759|NCT02355678|Procedure|Tonsillectomy|Mono-polar electrocautery or cold dissection
1583760|NCT02355678|Procedure|gastric content suction|By orogastric tube
1583761|NCT02355678|Drug|Tramadol hydrochloride|If Visual Analogue Scale was greater than 5
1583762|NCT02355678|Drug|Propacetamol hydrochloride|If Visual Analogue Scale was between 4 and 5
1583763|NCT02355678|Drug|Paracetamol Suppository|If Visual Analogue Scale was less than 4
1583764|NCT02355665|Drug|Nicotine Spray|Nicotine Spray
1583765|NCT02355665|Drug|Placebo|Placebo to match nicotine spray
1583766|NCT02355652|Device|Surgical total knee replacement using cemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using cemented femoral and tibial prosthetic components.
1583767|NCT02355652|Device|Surgical total knee replacement using uncemented components|Each patient of this arm will go under a surgical procedure of total knee replacement (or total knee arthroplasty) using uncemented femoral and tibial prosthetic components.
1583768|NCT02355639|Drug|Clobetasol propionate 0.05 % ointment|
1583769|NCT02355639|Drug|Betamethasone dipropionate 0.064 % ointment|
1583770|NCT02355639|Drug|Petrolatum ointment|
1583771|NCT02355613|Radiation|Radiosurgery with Gamma Knife Perfexion|Gamma Knife Radiosurgery is a very precise form of therapeutic radiology. Even though it is called surgery, a Gamma Knife procedure does not involve actual surgery but it uses 192 isocentric beams of highly-focused gamma rays (60-Co) to treat small to medium size lesions. Minimum beam size is 4 mm. This procedure is frame based.
1583772|NCT02355613|Radiation|Linac-based Radiosurgery with EDGE|EDGE linear accelerator from Varian (Varian, Palo Alto, USA) is a C-arm machine specifically developed for radiosurgery frameless treatment. The characteristics of this linac are a high level of precision and the possibility to include multiple positioning systems for stereotactical treatments, among which Cone Beam CT (CBCT), the Optical Surface Monitoring System (OSMS), and Calypso.
1583773|NCT02355600|Other|Oocyte retrieval|Tamoxifen given at a fixed dose for invasive breast cancer adjuvant hormonotherapy or for breast cancer prophylaxis.
1583774|NCT02355561|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg formulation 1 of JNJ-54861911 tablet as Treatment A under fasted conditions in one of the treatment periods.
1583775|NCT02355561|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment B under fasted conditions in one of the treatment periods.
1583820|NCT02355236|Drug|Naxozol-Placebo|Tablet (which is identical to Naxozol), b.i.d.
1583776|NCT02355561|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg formulation 2 of JNJ-54861911 tablet as Treatment C under fed conditions in one of the treatment periods.
1583777|NCT02355548|Other|Outpatient Treatment of Pulmonary Embolism|Patients who participate in the study will be treated for their pulmonary embolism in an outpatient setting instead of being hospitalized.
1583779|NCT02355522|Drug|Intrauterine lidocaine|
1583780|NCT02355522|Drug|Lidocaine gel|
1583781|NCT02355522|Drug|KY jelly|
1583782|NCT02355522|Drug|Intrauterine normal saline|
1583783|NCT02355509|Drug|Acarbose|"Acarbose dose was progressively titrated (50 mg/day per week up to 150 mg/day) to reduce the known adverse effects of acarbose such as flatulence, bloating, diarrhea, abdominal pain.
The treatment for three months"
1583784|NCT02355509|Drug|Placebo|Placebo pills are given instead of acarbose in this group
1583785|NCT02355496|Other|Displaying medicare fee data|Using the computerized order entry system to make medicare fee data for a randomly selected inpatient laboratory tests transparent to providers at the time of order entry.
1583786|NCT02355483|Device|Unenhanced abdominal Computed Tomography|Systematic Unenhanced abdominal Computed tomography
1583787|NCT02355470|Behavioral|GIFTSS|Universal education and brief counseling regarding sexual violence
1583788|NCT02355470|Behavioral|Brief alcohol use intervention|Brief education and counseling intervention to promote safer alcohol use, reduce binge drinking
1583789|NCT02355444|Dietary Supplement|blackberry polyphenol enriched beverage|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
1583790|NCT02355444|Dietary Supplement|blackberry beverage with minimal polyphenol concentrations|Double-blind intervention study, cross-over design with one 250 mL bottle of high-dose blackberry polyphenol beverage per day or placebo (blackberry beverage with minimal polyphenol) in Phase one followed by cross-over in Phase two.
1583791|NCT02355431|Drug|INCB039110|tablets to be administered by mouth once daily at dose selected from safety run-in phase
1583792|NCT02355431|Drug|erlotinib|150 mg tablets administered by mouth once daily at total daily dose of 150 mg
1583793|NCT02355431|Drug|placebo|matching placebo tablets to be administered by mouth at dose selected from safety run-in phase
1583794|NCT02355418|Procedure|Mitral valve repair|Standard mitral valve repair surgery
1583795|NCT02355405|Device|lung ultrasound|lung ultrasound investigations were performed right before and after the surgical procedure.
1583796|NCT02355405|Radiation|thoracic computed tomography|thoracic CT were performed within one hour after the LUS investigation
1583797|NCT02355392|Other|Telemedical home blood pressure measurements|
1583798|NCT02355379|Drug|LV5FU2 or capectitabine|
1583799|NCT02355379|Drug|FOLFOX4 or XELOX|
1583800|NCT02355379|Other|Observation|
1583801|NCT02355379|Drug|LV5FU2 or capecitabine|
1583802|NCT02355366|Behavioral|Family-Focused Therapy|Family Focused Therapy is a manual-based, psycho-educational intervention which is designed to reduce intra-familial stress, conflict, and affective arousal by enhancing communication and problem solving skills among families who are affected by bipolar disorder (Miklowitz et al., 2013). It concentrates on skills relevant to managing the prodromal stages of bipolar disorder, such as mood monitoring, reducing family conflict, improving problem solving, stabilizing daily routines and regulating sleep/wake cycles (Miklowitz, 2012).
1583803|NCT02355366|Behavioral|Brief Educational Treatment|Brief Educational Treatment will consist of 1 - 2 sessions involving both parents and adolescents; it will consist of diagnostic feedback following the adolescent's baseline assessment. It will provide families with information and strategies on tracking and managing adolescent mood disorders. Additionally, ongoing medication management and crisis family sessions will be available if required.
1583804|NCT02355353|Other|Experimental: imaging arm|DWI-MRI scans at baseline, at 14 days after first administration of chemotherapy and after up to 6 cycles of chemotherapy
1583805|NCT02355340|Other|Dual energy x-ray absorptiometry (DXA)|Subjects will undergo DXA scan to assess total body (less head) and lumbar spine bone mineral density.
1583806|NCT02355340|Other|Peripheral quantitative computed tomography (pQCT)|Subjects will undergo pQCT assessment of radius and tibia.
1583807|NCT02355327|Device|Laselle Kegel Exerciser|Participants use a vibrating pelvic floor muscle training ball for 12 weeks. The ball is inserted into the vagina and left for 15 minutes daily in the first week, and if well tolerated 30 minutes daily from the second week onwards. To achieve the vibrating effect, the balls are worn while moving - performing everyday tasks or going for a walk.
1583808|NCT02355327|Behavioral|Pelvic floor muscle exercises|Participants get standard care after childbirth, which is the routine recommendation of pelvic floor muscle exercises. Participants will be asked to continue/start the pelvic floor muscle exercises they routinely were recommended by customary written instructions from their health professionals after birth. Intervention duration for this study is 12 weeks.
1583809|NCT02355314|Other|Doppler-based renal|Doppler-based renal : day 0 and day 3
1583810|NCT02355314|Biological|blood sample and urine sample|blood sample and urine sample : day 0 and day 3
1583812|NCT02355288|Procedure|Minimally Invasive Coronary Bypass|Bypass graft of the Left Anterior Descending (LAD) artery using minimally invasive cardiac surgery. MICS is a bypass surgery done with a small (4-6 cm) incision under the left breast, instead of the usual incision down the middle the chest.
1583813|NCT02355288|Procedure|Percutenous Coronary Intervention|Stenting of the Left Anterior Descending (LAD) artery using a drug-eluting stent.
1583814|NCT02355275|Procedure|Home Exercise Program|All patients will be provided with a Thera-Band® Loop and Band and handout describing home exercises to be performed 3 times a week for 4 weeks.
1583815|NCT02355262|Other|Informational Intervention|Receive CATCH-UP intervention
1583816|NCT02355249|Procedure|MIE|Minimally invasive thoracol-laparoscopic esophagectomy will be performed in this group.
1583817|NCT02355249|Procedure|OE|Patients will be treated with traditional three incisions esophagectomy.
1583821|NCT02355236|Drug|Comparator-Placebo|Capsule (which is identical to Celebrex), o.d.
1583822|NCT02355223|Other|FAST|See information in arm description
1583823|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1|packet containing 10^9 cells of Bifidobacteria adolescentis BD1
1583824|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12|packet containing 10^9 cells of Bifidobacteria animalis subsp. lactis BB-12
1583825|NCT02355210|Dietary Supplement|Bifidobacteria adolescentis BD1 and galactooligosaccharide|packet containing 10^9 cells Bifidobacteria adolescentis BD1 and 5 g galactooligosaccharide
1583826|NCT02355210|Dietary Supplement|Bifidobacteria animalis subsp. lactis BB-12 and galactooligosaccharide|packet containing 10^9 cells B animalis subsp. lactis BB-12 and 5 g galactooligosaccharide
1583827|NCT02355210|Dietary Supplement|galactooligosaccharide|5 g galactooligosaccharide
1583828|NCT02355210|Dietary Supplement|Placebo|lactose powder, 5 grams
1583829|NCT02355197|Drug|L-ascorbic acid|1 gram L-ascorbic acid (vitamin C …..) per day from the time of diagnosis until the time of delivery
1583830|NCT02355184|Drug|PRO 140 350mg weekly SQ injection.|CCR5 Antagonist
1583831|NCT02355158|Drug|clonidine hydrochloride topical gel, 0.1%|
1583832|NCT02355132|Other|Insurance Intervention|Random selection to apply for Medicaid coverage through Oregon Experiment drawings held between March and October 2008
1583833|NCT02355119|Drug|FOLFOXIRI|Combination of 5-Fluorouracil/Folinic Acid, Irinotecan, Oxaliplatin
1583834|NCT02355119|Drug|Gemcitabine|
1583835|NCT02355106|Device|PolarStart System|Atrial flutter Ablation
1583836|NCT02355093|Procedure|adductor canal block (ACB)|We performed an ultrasound survey at the medial part of the thigh，the needle is introduced in-plane and 2 to 3 mL of saline is used to ensure correct placement of the needle in the vicinity of the saphenous nerve in the adductor canal,the catheter is introduced and advanced 1 to 2 cm beyond the tip of the needle.The study medication is administered as an infusion of 0.2% ropivacaine at a rate of 5mL/h during the next 48 hours.
1583837|NCT02355093|Procedure|Femoral nerve block (FNB)|the catheter is inserted in-plane with the probe parallel to the inguinal crease, to obtain a short-axis view of the nerve. The correct needle placement is confirmed by injecting 2 to 3 mL of saline to cause tissue expansion below the iliac fascia, lateral to the femoral artery, and in the vicinity of the femoral nerve. The catheter is introduced 1 to 2 cm beyond the tip of the needle，an infusion of 0.2% ropivacaine at a rate of 5mL/h is administered during the next 48 hours.
1583838|NCT02355093|Drug|ropivacaine|
1583839|NCT02355080|Behavioral|On-site bundled rapid HIV/HCV testing|Participants will be offered bundled on-site rapid HIV and HCV testing with post-test counseling that addresses both sexual and drug use risk reduction, and linkage to care.
1583840|NCT02355080|Behavioral|Standard of care (SOC)|Participants will receive the SOC for HIV and HCV testing at the study sites.
1583841|NCT02355067|Behavioral|Social Media Intervention|These women will participate in the intervention through the online Facebook group.
1583842|NCT02355067|Behavioral|Traditional In-Person Intervention|These women will participate in the intervention through a traditional weekly meeting of a group in-person.
1583843|NCT02355054|Drug|C-11 Choline PET Imaging|Patients will receive IV injection of C-11 Choline followed by imaging from the base of the brain to the upper thigh on a PET/CT or a PET/MRI scanner
1583844|NCT02355041|Behavioral|Meal Replacement-based Weight Loss Diet|
1583845|NCT02355041|Behavioral|Educational Video|Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity through healthy lifestyle changes. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Potential community changes are further addressed with respect to schools by presenting particularly successful programs that have been implemented in some schools. Participants will stream it free on the web.
2008779|NCT03327363|Device|Feedback using ICT based monitoring system|In experimental group, the subjects the check their lung function using self FEV1 monitoring device (microlife PF-200). They send the information to central monitoring system(EDC systems). In case of decreased FEV1 compared with own average FEV1, the ICT based monitoring system send the feedback message to the subject and medical staffs.
2008780|NCT03327350|Device|WATCHMAN transplantation|WATCHMAN Left Atrial Appendage System is a novel device designed to prevent the embolization of thrombi that may form in the LAA. It is hypothesized that it may prevent ischemic stroke and systemic
1583849|NCT02355002|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation uses a rapidly changing magnetic field to induce current in brain tissue non-invasively. It is common procedure in both clinical and research settings, and it has well established guidelines for safe an ethical use which maximize safety for all subjects. See attached Rossi et. al. 2009 as a reference to safety guidelines for TMS.
1583850|NCT02354989|Device|Rate Response on first (VVI biventricular pacing)|Rate Response function is turned on in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned off and the patient performs a second 6 minute walking test.
1583851|NCT02354989|Device|Rate Response off first (VVI biventricular pacing)|Rate Response function is turned off in the device. The patients performs a 6 minute walking test. After a week Rate Response function is turned on and the patient performs a second 6 minute walking test.
1583856|NCT02354963|Procedure|In vitro fragmentation of the ovarian tissue|Unilateral ovarian cortex extraction, in vitro fragmentation and reimplantation.
1583858|NCT02354937|Drug|GSK1265744 30 mg|White to almost white coated oval tablets with unit dose strength of 30 mg for oral administrations.
1583859|NCT02354924|Device|Biofinity soft contact lens|Biofinity soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
1583860|NCT02354924|Device|Visco soft contact lens|Viso soft contact lens on two eyes and follow up for 3 months (90 days). It is necessary to remove contact lenses every day and replace after 30 days.
1584566|NCT02349737|Other|Exposure to BIA interference with the ICD|Exposure to BIA interference with the ICD
1583861|NCT02354911|Biological|Immunoregulatory Dendritic Cells|Autologous dendritic cells harvested by leukapheresis and engineered ex vivo via incubation with antisense DNA oligonucleotides targeting the primary transcripts of CD40, CD80 and CD86. The ex vivo engineered product is then administered via blinded intradermal injection in the peri-umbilical region of the abdomen given as 4 separate injections at 2-week intervals (~10 million cells/injection).
1583862|NCT02354911|Other|Placebo Comparator: Placebo Control|Blinded intradermal injections in the peri-umbical region of the abdomen given as 4 separate injections at 2-week intervals
1583863|NCT02354898|Drug|BBI503|
1583864|NCT02354898|Drug|Sorafenib|Sorafenib 400mg twice daily (800mg total daily dose)
1583865|NCT02354885|Drug|Tranexamic Acid|Coagulation Management / Efficiency
1583866|NCT02354872|Drug|Nicotine Mini-Lozenge|If randomized to only the Nicotine Mini-Lozenge condition: Participants randomized to this condition will receive up to a 12 month supply of 2 mg or 4 mg nicotine mini-lozenges. Mini-Lozenges will be given at the initial visit and over the course of the whole study. Participants will be instructed to use 9 pieces daily for the 12 months.
1583867|NCT02354872|Behavioral|Behavioral Reduction Counseling|We will deliver BR in 10 (10-15 minute) sessions over a 52-week period, with an in-person session at Visit 1 followed by nine phone counseling sessions. Sessions are front-loaded to enhance acquisition of new behaviors. BR Counseling will emphasize the development of smoking control skills via feasible, specific, and graded assignments of smoking reduction activities that will be tracked over time. BR will also emphasize competence and self-efficacy, both which will be directly linked to the practice of smoking reduction skills and success in smoking control. The health counselor will provide rationales for the reduction intervention, why reduction (e.g., eliminating smoking contexts) should help the smoker, and provide the participant with specific exercises and goals. The health counselor will explicitly address pragmatic issues such as work contexts, smoking policies, and habits that interfere with smoking reduction efforts.
1583868|NCT02354872|Behavioral|5Rs Motivation Counseling|"The 5Rs Motivation Counseling will be delivered in four (10-15 min) sessions over a 52-week period. Participants in the on condition will receive three brief phone sessions over the year to prompt processing of motives for smoking reduction or cessation. The health counselor and smoker will discuss: 1) Relevance of smoking to the individual; 2) Risks of continued heavy smoking; 3) Rewards of quitting and significant reduction; and 4) Roadblocks to success; and will do so on a 5) Repeated basis. The discussion will follow the general principles of MI: counselors will use strategies that are nonauthoritarian, nonconfrontational, supportive, and use open-ended questions."
1583869|NCT02354872|Behavioral|Behavioral Activation Counseling|The BA treatment will be delivered in 10 (10-15 minute) sessions over a 52-week period starting with Visit 1 followed by nine phone counseling sessions. This BA treatment will be modeled after Behavioral Activation for quitting smoking, but made relevant for smoking reduction. Treatment goals focus on helping participants engage in positively reinforcing activities while not smoking. The treatment includes: 1) a rationale for the BA exercises as they relate to smoking (e.g., engaging in non-smoking reinforcers will provide other sources of pleasure and assist with cutting down); 2) assessment of the participant's goals, values, and reinforcing value of current nonsmoking activities; 3) training in self-monitoring using an activity log; 4) ongoing assignments of activities that should significantly increase the participant's nonsmoking reinforcement and create broader lifestyle and cue exposure changes; and 5) problem-solving to address obstacles to goal attainment.
1583870|NCT02354872|Other|No Treatment|No Treatment
1583871|NCT02354859|Drug|Gallium nitrate|Study subjects will receive an infusion of either placebo or gallium nitrate.
1583872|NCT02354859|Drug|Normal Saline|Study subjects will receive an infusion of either placebo (normal saline) or gallium nitrate.
1583873|NCT02354833|Drug|Phenylephrine|
1583874|NCT02354833|Drug|Norepinephrine|
1583876|NCT02354807|Drug|Mirabegron|One-time dose of 100mg of Mirabegron
1583877|NCT02354807|Other|Cold exposure|Exposure of subjects to cold temperature to induce non-shivering thermogenesis
1583878|NCT02354794|Dietary Supplement|One form of arginine|3 capsules containing 0.5g of one form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 month
1583879|NCT02354794|Dietary Supplement|placebo|3 capsules containing 0.5g cellulose (non active product) 3 times daily (4.5g per day) for 1 month
1583880|NCT02354781|Biological|rAAV1.CMV.huFollistin344|Six DMD patients will receive rAAV1.CMV.huFollistatin344 to both limbs by multiple injections to gluteal muscles, quadriceps and tibialis anterior muscles.
1583881|NCT02354768|Drug|Effects of lanreotide with current anti-diarrheal treatments (diosmectite and loperamide)|
1583882|NCT02354768|Drug|Effects of current anti-diarrheal treatments (diosmectite and loperamide) alone|
1583883|NCT02354755|Device|Psychomotor vigilance test (PVT|The Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurements. The device measures the speed with which subject responds to visual stimulus (by pressing a response button).
1583884|NCT02354742|Other|Echo guided fluid resuscitation|Patients will have their fluid resuscitation care guided by measurements obtained during an echo.
1583885|NCT02354742|Other|EGDT fluid resuscitation|Patients will have their fluid resuscitation care guided by an EGDT protocol, which is currently used as standard of care.
1583886|NCT02354729|Other|Behavioral Economics|Use financial incentives to promote epinephrine-carrying.
1583887|NCT02354716|Device|EndoFLIP|The Endolumenal Functional Lumenal Imaging Probe Imaging System is a technology developed to measure the dimensions & function of a variety of hollow organs throughout the body. Since receiving FDA clearance for sale in the United States EndoFLIP has been used in a variety of clinical applications. We intend to investigate the potential clinical applications of EndoFLIP in the upper GI tract in patients with esophageal stenoses who require endoscopic therapy for benign esophageal strictures. The use of EndoFLIP to characterize a stricture pre- & post- dilation may offer insight in to the clinical and endoscopic predictors of successful stricture dilation, & what characteristics determine & predict refractory & recurrent strictures.
1583888|NCT02354703|Drug|Ondansetron|Ondansetron (0.33 mg) bid+ BBCET counseling
1583889|NCT02354703|Drug|Placebo|Placebo + BBCET counseling
1583890|NCT02354690|Drug|Vemurafenib|Vemurafenib is used to treat patients with BRAF mutated metastatic melanoma. Patients will start treatment in a dose of 960 BID 7 days before tumor harvest and ends at the day of admission (day -8).
1583891|NCT02354690|Drug|Lymphodepleting chemotherapy|First patients undergo lymphodepleting chemotherapy regimen consisting of cyclophosphamide 60 mg/kg for 2 days and fludarabine 25 mg/m2 for 5 days (constitutes day -7 to -1 of admission).
1583892|NCT02354690|Drug|TIL infusion|"7 days after start of vemurafenib treatment, patients undergo surgery to removal of a tumor in order to isolate, activate and expand tumor infiltrating lymphocytes (TIL) to high numbers. In vitro preparation usually takes 4-6 weeks using the young TIL method.
On day 0 patients receive an infusion of TIL (1x10e9-2x10e11 cells)."
1583893|NCT02354690|Drug|Interleukin-2|After infusion of TILs, patients will receive interleukin-2 infusions according to the decrescendo regimen (18 MIU/m2 for 6 hours, 18 MIU/m2 for 12 hours, 18 MIU/m2 for 24 hours followed by 4,5 MIU/m2 for another 3 x 24 hours)
1583894|NCT02354677|Other|In vitro experiments on bronchial epithelial cells|
2008781|NCT03327350|Drug|Oral anticoagulant drugs|This group will take oral anticoagulant drugs(warfarin or the new oral anticoagulant drugs like Dabigatran ).For patients taking warfarin,international normalizedratio (INR) monitoring wil be performed at least every 2 weeks for 6 months and at least monthly thereafter, targeting an INR between 2 and 3. Followup visits occurred twice annually after the first year,with neurological assessments at 12 months and yearly thereafter or whenever a neurological event is suspected.
2008782|NCT03327337|Procedure|Arthroscopic Assisted Balloon Tibioplasty|Under arthroscopy, the balloon supports the articular surface, with additional bone graft and necessary internal fixation
1583901|NCT02354651|Other|Pulmonary function testing|Measure the breathing muscles ability to move gases in and out
1583902|NCT02354651|Other|Resting breathing pattern|Record resting ventilatory flow and timing
1583903|NCT02354651|Other|Respiratory muscle endurance test|Subjects will maintain breathing rate with loaded breaths
1583904|NCT02354651|Other|Phrenic nerve stimulation|
1583905|NCT02354651|Other|Maximal inspiratory pressure|Measure the maximal airflow on inhalation
1583906|NCT02354651|Other|Forced expiratory testing|Measure the maximal airflow and volume of gas that can be exhaled with the subject breathing or coughing forcefully
1583907|NCT02354651|Other|EMG|Evaluate electrical activity of diaphragm via pacer
1583908|NCT02354638|Behavioral|Tobacco users|Various tobacco cessation interventions in the form of one to one counseling, focus group discussions, role plays, games etc. will be used in the tobacco users.
1583909|NCT02354638|Drug|Pharmacotherapy|"Pharmacotherapy will also be prescribed as per the need assessment consisting of:
Nicotine Chewing Gums:
Dose: 2 mg/4 mg, 10-15 pieces per day with maximum dose of 24 pieces/day depending on cravings.Total Duration: 12 weeks Duration of treatment: Higher dose for 4-6 weeks, with weaning till 2-3 months
Nicotine Transdermal patches:
Dose: 7 mg/10 mg/14 mg/21 mg -for 24-hours use. Total Duration: 12 weeks Duration of treatment: Higher strength patch for 2 weeks and depending on cravings will be gradually decreased till 4 weeks"
1583910|NCT02354625|Biological|Autologous human Schwann cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
1583911|NCT02354612|Drug|TRC105|
1583912|NCT02354612|Drug|Bevacizumab|companion therapy selection depends on companion therapy used in the parent study
1583913|NCT02354612|Drug|Axitinib|companion therapy selection depends on companion therapy used in the parent study
1583914|NCT02354612|Drug|Pazopanib|companion therapy selection depends on companion therapy used in the parent study
1583915|NCT02354612|Drug|Capecitabine|companion therapy selection depends on companion therapy used in the parent study
1583916|NCT02354599|Drug|MT203 80 mg or matching Placebo|MT203 80 mg or matching placebo injection
1583917|NCT02354599|Drug|MT203 150mg or matching Placebo|MT203 150mg or matching placebo injection
1583918|NCT02354599|Drug|MT203 300 mg or matching placebo|MT203 300 mg or matching placebo injection
1583919|NCT02354586|Drug|Niraparib|
1583920|NCT02354573|Drug|Ivabradine|All subjects will receive Ivabradine 7.5mg twice daily for 2 weeks in a double-blind randomized crossover design.
1583921|NCT02354560|Drug|Erythromycin|Oral Treatment with Erythromycin 250-500mg, twice daily, for 16 weeks.Exact dose is subjected to body weight and will be determined by the study's pediatrician.
1583922|NCT02354547|Genetic|SGT-53|The starting dose of SGT-53 will be 1.4 mg DNA/m² (dose level 1). If MTD is reached at dose level 1, subsequent cohort will be treated at 0.7 mg DNA/m² (dose level -1). If MTD is not reached at 2.1 mg DNA/m² (dose level 2), additional dose level(s) may be added. Intra-patient escalation is not allowed. Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, SGT-53 will be administered in combination with 0.6 mg/m² topotecan and 200 mg/m² cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan and cyclophosphamide will be escalated to 0.75 mg/m² and 250 mg/m², respectively. No further dose escalation is permitted. If DLT develops at the higher doses, the doses should be decreased back to those in cycle 2.
1583923|NCT02354547|Drug|Topotecan|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 0.6 mg/m² topotecan will be administered in combination with SGT-53 and cyclophosphamide IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, topotecan will be escalated to 0.75 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
1583924|NCT02354547|Drug|Cyclophosphamide|Topotecan/cyclophosphamide will not be administered in cycle 1. In cycle 2, 200 mg/m² cyclophosphamide will be administered in combination with topotecan and SGT-53 IV daily for 5 days. Beginning in cycle 3, if no DLTs in cycle 2, cyclophosphamide will be escalated to 250 mg/m². No further dose escalation is permitted. If DLT develops at the higher doses, the dose should be decreased back to those in cycle 2.
1583925|NCT02354534|Drug|Artesunate Suppositories|
1583926|NCT02354521|Other|NO INTERVENTIONS|
1583927|NCT02354508|Drug|Pasireotide LAR|Pasireotide 40 mg and 60 mg.
1583928|NCT02354495|Dietary Supplement|Changes in energy and protein intake|Energy intake will be based on accurate measurements of energy expenditure. Protein intake will be matched to age-based recommended values if necessary.
1584567|NCT02349724|Biological|Anti-CEA-CAR T|T cells modified with CEA targeted chimeric antigen receptor.
1583929|NCT02354482|Other|Transitional care services naturally implemented at participating hospitals|The transitional care strategies/services that participating hospitals implement to help patients and their caregivers transition from one site of health care (e.g. hospital) to another (e.g., nursing home or care at home).
1583930|NCT02354443|Biological|ProHema-CB Transplant|ProHema-CB, the cellular product, represents the cell populations contained within a human UCB unit after modulation on the day of transplantation by an ex vivo incubation process with the prostaglandin derivative, 16,16-dimethyl prostaglandin E2 (also referred to as FT1050). The cell populations include hematopoietic stem and progenitor cells.
1583931|NCT02354430|Behavioral|Water-exercise|"An instruction session at an indoor swimming pool, led by the research midwives and a specially trained coach. Participants is shown short movie clips of the six Aqua-Mama water-exercises and practical instructions by the coach while performing the exercises in water. The participants are encouraged to keep a training logbook during the project.
One training session consists of: eight laps (200 m) of swimming and AquaMama exercises. Each exercise is illustrated on a board and are performed twice
Unsupervised water-exercises (The six AquaMama exercises)
Motivating weekly emails during the 12 week training period.
Brush up sessions is held once every month for guidance in performing the exercises."
1583932|NCT02354417|Biological|Biological: ProHema-CB|Each subject will receive one administration of ProHema-CB unit transplant.
1583933|NCT02354404|Biological|cAd3-EBOZ|cAd3 vaccine vector expressing Ebola glycoprotein from the Zaire strain in single dose vials at 1x10(11) PU/mL.
1583934|NCT02354404|Biological|cAd3-EBO|1:1 ratio of cAd3 vaccine vectors expressing Ebola glycoprotein from the Zaire and Sudan strains filled into single dose vials at 1x10(11) PU/mL of each [2x10(11) PU/mL total].
1583935|NCT02354404|Biological|MVA-EbolaZ|MVA vaccine vector that expresses Ebola glycoprotein from the Zaire strain in single dose vials at 3.2 x 10(8) PFU/mL
1583936|NCT02354391|Drug|Ingenol mebutate Picato® and MAL PDT day 1, day 5|Treatment of ingenol mebutate, Picato® 0.015% topical gel applied on day 1 followed by MAL PDT on day 5
1583937|NCT02354391|Drug|Ingenol mebutate Picato® day 2, 3, 4|Full treatment course with Ingenol mebutate (Picato®) 0.015% topical gel, apply day 2,3 and 4
1583938|NCT02354391|Procedure|MAL PDT day 5|Methyl aminolevulate combined with Photodynamic therapy at day 5
1583939|NCT02354378|Drug|Dexmedetomidine|
1583940|NCT02354378|Other|Memory Test|
1583941|NCT02354365|Device|Transpulmonary Pressure measurement|Transpulmonary pressure measurements are done by placing a catheter (often combined with a feeding tube) into the esophagus of a patient. Intermittently, the esophageal pressure is measured by inflating a small balloon on this catheter. The resulting esophageal pressure is accepted as representing the pleural pressure. The difference between this pressure and the airway pressure is the transpulmonary pressure and PEEP is raised or lowered to make this value zero so that the forces distending the alveoli are just balanced with the natural elasticity of the lung which wants to collapse the alveoli.
1583942|NCT02354352|Drug|Eplerenone|26 Subjects will take Eplerenone, one 50mg capsule by mouth once daily for 12 months.
1583943|NCT02354352|Drug|Spironolactone|26 Subjects will take Spironolactone, one 50mg capsule by mouth once daily for 12 months.
1583944|NCT02354339|Dietary Supplement|Irvingia gabonensis|Intervention will be administered 30 minutes before meals
1583945|NCT02354339|Other|Placebo|Intervention will be administered 30 minutes before meals
1583946|NCT02354326|Radiation|virtual non-calcium dual-energy computed tomography|Undergo VNC DECT
1583947|NCT02354326|Radiation|computed tomography|Undergo CT without VNC
1583948|NCT02354313|Drug|Lenalidomide|"Treatment Phase: consisting in an induction phase (3 cycles of RCHOP, given every 21 days); consolidation phase: (high-dose cyclophosphamide (CTX), 2 cycles of high dose Ara-C, BEAM and ASCT).
Randomization and maintenance phase: Patients who have achieved complete or partial response will be randomized between maintenance with lenalidomide or observation."
1583949|NCT02354300|Device|TCD Ultrasound|Transcranial doppler ultrasound monitoring will occur during flow diverter placement.
1583950|NCT02354287|Procedure|Cold forceps polypectomy with pre lift|"Polyps ≤7mm will be included in the study if deemed appropriate by the colonoscopist..
These polyps will be resected with cold forceps after pre injection into the submucosa with a few millilitres of pre injection solution (19 ml gelofusine, 1ml 1:10000 adrenaline and 1ml indigo carmine). Polyps are grasped with the cold forceps and pulled away from the rest of the colonic mucosa. Attempt will be made to remove polyps with single attempt with the forceps however several grasps may be required for complete visual resection of the polyp.
The polypectomy site and a 5mm rim of normal appearing tissue will then be resected with endomucosal resection (EMR) using conventional snare method. This is to ascertain if there is any residual polyp tissue."
1583951|NCT02354274|Radiation|Escalated: Inhomogene dose plan|
1583952|NCT02354274|Radiation|Standard: Homogene dose plan|
1583953|NCT02354261|Drug|SUBA-Itraconazole|Subjects will receive an oral dose of 300 mg SUBA-Itraconazole daily.
1583954|NCT02354248|Procedure|Triple stimulation technique|Evoked motor potentials obtained by magnetic transcranial stimulation are usually used, in standard practice, to evaluate the corticospinal tract. This procedure combines two techniques: the magnetic stimulation and the electroneuromyography. It is based on the double collision principle between the descending central stimulation (magnetic) and the ascending peripheric stimulation, hereby suppressing the issue of desynchronisation of evoked motor potentials. The Triple stimulation technique allows a better quantification of the proportion of motor units activated by the transcranial stimulation.
1583955|NCT02354235|Drug|Teneligliptin|
1583956|NCT02354235|Drug|Canagliflozin|
1583957|NCT02354235|Drug|Placebo|
1583958|NCT02354222|Drug|Canagliflozin|
1583959|NCT02354222|Drug|Teneligliptin|
1583960|NCT02354222|Drug|Placebo|
1583961|NCT02354196|Procedure|CCTA|CT of heart to assess coronary disease
1583962|NCT02354183|Behavioral|DBT Skills Training|Based on Linehan's (1993) manualized DBT approach, the brief DBT skills training group covers will cover five skills: wise mind, TIP skills, distraction, mindfulness of the current emotion, and opposite to emotion action.
1583963|NCT02354170|Drug|Mifepristone|
1583964|NCT02354170|Drug|Placebo|
1583965|NCT02354157|Other|no intervention|no intervention
1584610|NCT02349386|Drug|BHR-200 (0.36% transdermal 17β-estradiol gel)|An absorptive hydroalcoholic gel preparation containing 17β-estradiol.
1583966|NCT02354144|Other|Carrageenan-based gel|Carrageenan is a non-toxic gelling agent safe in animals and humans as a potent HPV inhibitor. An anionic polymer derived from red algae, carrageenan has a long history of human use as a stabilizer and emulsifier in many industries. All three major classes of carrageenan act as extremely potent HPV inhibitors and block HPV infection by binding to the viral capsid, thus preventing attachment to the appropriate cell-surface heparan sulfate proteoglycans (HSPG) receptors.
1583967|NCT02354144|Other|Control gel|A gel not containing carrageenan
1583968|NCT02354131|Drug|Niraparib|Niraparib versus Bevacizumab-Niraparib combo
1583969|NCT02354131|Drug|Bevacizumab|
1583970|NCT02354118|Other|Heparinized saline catheter flush|The control group will have their port catheters flushed with 20mL saline + 5mL heparin 100 units/mL; q 3 months
1583971|NCT02354118|Other|Saline-only catheter flush|The intervention group will have their port catheters flushed with saline only.
1583972|NCT02354092|Procedure|Local anesthetic for tenaculum placement|2 mL of buffered Lidocaine injected superficially at anterior lip of cervix in 12 o'clock position Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
1583973|NCT02354092|Procedure|Sham|Over 60 seconds, without moving the tenaculum, a capped needle gently touches the vaginal sidewall at the level of the external os at 4 and 8 o'clock positions
1583974|NCT02354092|Procedure|Paracervical Block|18 mL of buffered Lidocaine is slowly injected into the vaginal fornices and equally distributed at 4 and 8 o'clock. The injection is continuous from superficial to deep (3cm) to superficial (injecting with insertion and withdrawal) Drug: 1% Lidocaine Hydrochloride, 8.4% Sodium Bicarbonate
1583975|NCT02354092|Procedure|Dilator Placement|"Osmotic dilators will be placed in the usual fashion with a combination of Dilapan-S and laminaria per clinician preference
Drugs:
Dilapan-S is a hygroscopic cervical dilator made of a patented hydrogel called AQUACRYL. It is a rigid hydrophilic stick that increases in volume by absorbing fluids and comfortably dilating the cervix.
Laminaria is an herbal medicine used to induce labor and abortion. The dried stem of Laminaria mechanically dilates the cervical opening by absorbing water and swelling to several times its original diameter."
1583976|NCT02354092|Behavioral|Post-procedural assessment|15 minutes after procedure, subjects will complete a questionnaire that collects information about pain, negative symptoms, and assessment of how effective their pain management was.
1583977|NCT02354092|Drug|Preprocedural pain control|800 mg Ibuprofen taken before dilator placement
1583978|NCT02354079|Genetic|hypobetalipoproteinemia genetic and genotypic screening|
1583979|NCT02354066|Device|Hallux valgus Shoe|Brake response measurement after surgery with this foot orthosis
1583980|NCT02354066|Device|Forefoot relief shoe|Brake response measurement after surgery with this foot orthosis
1583981|NCT02354066|Device|Retail Shoe|Brake response time measurement before surgery (control run)
1583982|NCT02354053|Drug|Switch to Triumeq|
1583983|NCT02354053|Behavioral|Adherence support + current ART|
1583984|NCT02354040|Behavioral|Talking Rx|For patients in the intervention group, the physician written prescription for anti-platelet and statin will be transferred on an OMR sheet and will be scanned. The information on the prescription (dose, name of the medication, duration, route or any other special instruction) will be sent to the patients via a text and a voice SMS (in Urdu language). The patients also receive an individualized code that helps them request for repeated reminders for their medication timings. However, a weekly medication reminder SMS will be sent to the patients in the intervention arm.
1583985|NCT02354027|Drug|SHR3824 metformin|"Two 500-mg tablets of metformin on Day 1 followed by 25 mg of SHR3824 once daily on Days 4 through 8 followed by two 500-mg tablets of metformin and 25 mg of SHR3824 on Day 8.
Drug: SHR3824 + Metformin"
1583986|NCT02354014|Drug|Bedaquiline (TMC207)|"Bedaquiline (TMC207) tablet formulation administered orally as 400 milligram (mg), once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 200 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 1. Cohort 2, 3 and 4 will receive the pediatric formulation which is a scored 20mg dispersible tablet.
Bedaquiline (TMC207) tablet administered orally as 200 mg, once daily, for the first 2 weeks, followed by bedaquiline (TMC207) 100 mg 3 times per week with intakes at least 2 days (48 hours) apart for 22 weeks in cohort 2. Dose administered in cohort 3 and 4 will depend upon the review of safety and pharmacokinetic data from Cohort 1 and 2 by internal safety monitoring group."
1583987|NCT02354014|Drug|Background Regimen (BR)|Background Regimen (BR) of Multidrug Resistant Tuberculosis (MDR-TB) medications will be dosed according to World Health Organization (WHO) guidelines, National Tuberculosis Program (NTP) guidelines and current standard of care at the site.
1583988|NCT02354001|Drug|Raloxifene hydrochloride|120mg daily- 1 capsule for 12 week trial
1583989|NCT02354001|Drug|Placebo|1 capsule daily for 12 week trial - lactose
1583990|NCT02353988|Drug|Bicalutamide|"Patients in experimental group are designated to take bicalutamide orally, 150mg on a continuous schedule. The investigator should pay attention to the patients' adverse event. Every month, the patients will be evaluated for the adverse event by the criterion National Cancer Institute Common Toxicity Criteria (NCI-CTC) version 3.0. Every 2 months, the patients will be evaluated for the clinical effects. If disease progressed, the patients would be ruled out.
Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance. A maximum of 2 dose reductions for grade >= 3 toxicity were allowed (100 and 50 mg). A maximum of 2 weeks was permitted for treatment delays due to toxicity."
1583991|NCT02353988|Other|Physician's Choice|"The comparator group, treatment of physician's choice (TPC), represented a mix of agents (both approved and non-approved for metastatic breast cancer) to mirror clinical practice at the time in this setting.
The 60 patients are enrolled in the study, before randomized to the two arms, each of them will be assessed for eligibility and then their proposed TPC.
Treatment continued until disease progression, unacceptable toxic effects, patient or physician request to discontinue, or serious protocol non-compliance."
1583992|NCT02353975|Drug|SHR3824|SHR3824 tablet,10mg, fasting conditions and high fat, high calorie breakfast.
1583993|NCT02353962|Other|Neglect Exergames|Exergames for rehabilitation of hemineglected stroke patients played with a haptic device on a computer. The intervention duration is three weeks. During this week the patients play daily a half hour on workdays. The treatening therapist will adjust the intensity according to the progress of the patient.
1583994|NCT02353949|Drug|Flutemetamol|PET-MR Scan using the radiotracer Flutemetamol for diagnostic purpose
1583995|NCT02353936|Drug|BIBW2992|"International Nonproprietary Name (INN): BIBW 2992 Pharmacological dosage form: Film-coated tablet Supplier: Boehringer Ingelheim Pharma GmbH & Co. KG Unit content: 40 mg, 30 mg, 20 mg film-coated tablet (BIBW 2992 content in film-coated tablet is related with equivalent free base BIBW 2992.) Daily dose: 40 mg Dosing period: To be successively administered once daily until a disease will develop, an unacceptable adverse event will occur, or another reason requiring discontinuation of the study will occur; For administration, study treatment consists of periods(each 4 weeks(28 days)).
Route of administration: Orally (Take by swallowing) Dosage: Once daily"
1583996|NCT02353923|Dietary Supplement|OcuStem Supplementation|2800 mg daily dosage of OcuStem, 2 capsules BID.
1583997|NCT02353910|Procedure|Ultrasound|
1583998|NCT02353871|Drug|Clostridium Botulinum Toxin Type A|A solution containing 50 U in 0.25 mL (200 U/mL). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL, containing 50 U of BTX-A-HAC NG (i.e. 10 U/0.05 mL) was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
1583999|NCT02353871|Drug|Placebo|A solution containing only the excipients of BTX-A-HAC NG (identical in appearance to the active product). Each vial contained 0.625 mL of deliverable volume of solution. A volume of 0.25 mL was withdrawn from the vial into a syringe for administration. The total treatment volume (0.25 mL) was divided into five injections (0.05 mL per injection), each of which was to be administered into predefined sites across the glabellar region (two injections into each corrugator muscle and one injection into the procerus muscle).
1584000|NCT02353858|Other|Deep regional hyperthermia|Deep regional hyperthermia of the pelvis, Total time 90 min, Target temperature 41-42°C.
1584001|NCT02353858|Radiation|Radiotherapy|Radiotherapy of the primary tumor and pelvis, 5 x 1,8 Gy per week, total Dose: 50,4 Gy.
1584002|NCT02353858|Drug|Chemotherapy (5-Fluorouracil)|5-Fluorouracil, continuous venous infusion week 1 and 5. 1000 mg per square meter of body-surface area per day.
1584003|NCT02353832|Device|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)|Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product
1584004|NCT02353819|Radiation|Stereotactic Ablative Radiotherapy|SABR x5 fractions CBCT based image-guidance prior to each fraction: localize based on prostate/seeds positions SCORE system
1584005|NCT02353806|Drug|Amlodipine besylate|Pregnant and postpartum women will continue taking amlodipine besylate 5 mg for treatment of chronic hypertension as prescribed by their clinician.
1584006|NCT02353793|Device|ReadyHeat® blanket|Using ReadyHeat® blanket for patient warming
1584007|NCT02353793|Device|Cotton wool blanket|Using cotton wool blanket for patient warming
1584008|NCT02353780|Drug|TNF Antagonist (enbrel, humire, remicade, cimzia, symponi)|TNF Antagonist; treating rheumatologist selects specifics for the therapy chosen.
1584009|NCT02353780|Drug|Abatacept|Abatacept; SQ; specifics to be determined by the treating rheumatologist.
1584010|NCT02353780|Drug|Tocilizumab|Tocilizumab; SQ; specifics determined by the treating rheumatologist.
1584011|NCT02353767|Procedure|Noninvasive evaluation of liver fibrosis and steatosis|Transient elastography (using the Fibroscan, CAP Fibroscan) and biomarker panels (FibroTest, Fibromètre, Hepascore, Steatotest, Nashtest)
1584012|NCT02353754|Drug|Intrathecal morphine injection|0.2 mg
1584013|NCT02353754|Drug|EXPAREL|266 mg
1584014|NCT02353741|Drug|EGFR-TKIs|Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.
1584015|NCT02353741|Radiation|thoracic radiotherapy|From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
1584016|NCT02353728|Drug|Nilotinib|
1584017|NCT02353715|Drug|Enzalutamide|
1584018|NCT02353715|Drug|Abiraterone acetate|
1584019|NCT02353715|Drug|Sipuleucel-T|
1584020|NCT02353702|Procedure|Sniff test|Evaluation of diaphragmatic function by sniff test after continuous parietal infusion of ropivacaine or placebo
1584021|NCT02353702|Drug|Infusion of Ropivacaine during 48 hours|"20 ml Bolus (7,5 mg/ml) then continuous administration of 10 ml per hour (2 mg/ml) during 48 hours of Ropivacaine.
20 ml Bolus (NaCl 0.9 %) then continuous administration of 10 ml per hour, during 48 hours of NaCl 0.9 %."
1584022|NCT02353702|Device|Continuous parietal infusion with parietal catheter|Continuous parietal infiltration of Ropivacaine or placebo
1584023|NCT02353702|Drug|Infusion of placebo during 48 hours|
1584024|NCT02353702|Drug|NaCl|
1584025|NCT02353689|Dietary Supplement|low FODMAP|consumed EN formula containing low FODMAPs (0.320g/can) during 14-day intervention
1584026|NCT02353689|Dietary Supplement|moderate FODMAP|consumed EN formula containing moderate FODMAPs (0.753g/can) during 14-day intervention
1584027|NCT02353689|Dietary Supplement|high FODMAP|consumed EN formula containing high FODMAPs (1.222g/can) during 14-day intervention
1584028|NCT02353676|Drug|Bupivacaine|1.5 ml of 0.55 bupivacaine solution to be used as postoperative anesthetic agent for prolonged analgesia
1584029|NCT02353676|Other|SALINE|1.5 ml of placebo (saline solution) to be injected into the opposite site postoperatively.
1584030|NCT02353663|Other|Echocardiography|Echocardiography examination
1584031|NCT02353650|Dietary Supplement|Q10|
1584032|NCT02353650|Dietary Supplement|placebo|
1584033|NCT02353637|Dietary Supplement|Partial Meal Replacements|The use of partial meal replacements will be utilized in conjunction with a high protein, restricted carbohydrate diet
1584034|NCT02353624|Behavioral|Cycling|Cycling distance of 2880 km in 14 days
1584035|NCT02353611|Other|peroxide hydrogen 6% compound catalyzed by titanium oxide nanoparticles and activated by blue hybrid light and an infrared laser|
1584036|NCT02353611|Other|35% peroxide gel tooth bleaching|conventional peroxide whitening compound acted like control
1584041|NCT02353572|Drug|Melphalan|Given IV
1584042|NCT02353572|Drug|Bortezomib|Given IV
1584043|NCT02353572|Drug|Dexamethasone|Given IV
1584044|NCT02353572|Procedure|Autologous Transplant|Undergo autologous hematopoietic stem cell transplant
1584045|NCT02353559|Behavioral|EASE|EASE includes psychotherapeutic (EASE-psy) and physical symptom control (EASE-phys) components.
1584046|NCT02353546|Behavioral|CALM|
1584047|NCT02353533|Device|over- the- scope full- thickness resection device (FTRD)|Endoscopic resection of adenomatous lesions of the colon using the over- the- scope full- thickness resection device
1584048|NCT02353533|Device|EMR|Standard endoscopic mucosal resection using a resection snare
1584049|NCT02353520|Other|motricity index strength assessment|
1584050|NCT02353507|Device|Opticell Ag+|
1584051|NCT02353507|Device|Aquacel Ag+|
1584052|NCT02353494|Drug|Dihydroartemisinin-Piperaquine|Treatment according to national guidelines with follow up.
1584053|NCT02353481|Other|Heart Failure Management|
1584054|NCT02353468|Drug|Bortezomib|Given IV
1584055|NCT02353468|Drug|Lenalidomide|Given PO
1584056|NCT02353468|Drug|Dexamethasone|Given PO or IV
1584057|NCT02353455|Procedure|Blood sampling|In each group a blood sample of approximately 50 mL will be obtained upon study inclusion.
1584058|NCT02353442|Other|Posterior shoulder mobilizations|A second investigator performed 5min of posterior capsule shoulder mobilization for the experimental group, 3times/week during 4 weeks.
1584059|NCT02353442|Other|External rotators strengthening|Individuals performed 3x10 repetitions of external rotators strengthening in sidelying position 3times/week during 4 weeks.
1584060|NCT02353442|Other|Placebo ultrasound|A second investigator performed 5min of placebo ultrassound for the control group, 3times/week during 4 weeks.
1584061|NCT02353442|Other|Scapular squeezing|Individuals performed 3x10 repetitions scapular squeezing exercise 3times/week during 4 weeks.
1584062|NCT02353442|Other|Upper trapezius stretching|Individuals performed 3x30s of upper trapezius stretching, 3times/week during 4 weeks.
1584063|NCT02353442|Other|Posterior Capsule Stretching|Individuals performed 3x30s of posterior capsule stretching, 3times/week during 4 weeks.
1584064|NCT02353429|Drug|Toremifene|Patients will receive 60 mg daily and then 180 daily in case of progression
1584065|NCT02353416|Behavioral|Low Glycemic Index Mediterranean Diet|Prescription of a Low Glycemic Index (less than 50) Mediterranean Diet with no more than 10% of total daily calories coming from saturated fats, high in monounsaturated fatty acids (MUFA) from olive oil and omega-3 polyunsaturated fatty acids (ω3PUFA), from both plant and marine sources
1584066|NCT02353416|Other|INRAM Guidelines' diet|Prescription of INRAM guidelines' diet
1584067|NCT02353403|Other|Sugar|A 210g chocolate dairy dessert made with 35g of dextrose.
1584068|NCT02353403|Other|FOS|A 210g chocolate dairy dessert made with 24g of dextrose and 11.2g of FOS.
1584069|NCT02353390|Other|Oral Water Hydration|Subjects in the hydration group will be allowed up to 15 minutes to drink up to 500 milliliters (mL) of water prior to the vaccines. Subjects will be encouraged to drink the entire 500 mL; however, they are free to drink as much as they want and can finish before the end of the 15-minute period. Subjects will be instructed not to share the water and to not otherwise empty the bottle. As with the control group, subjects will be instructed not to eat or drink anything else for the duration of the study, unless clinically indicated (e.g., as part of management of presyncope or syncope).
1584070|NCT02353364|Other|PGS|Embryos screened by the validated NGS technology CNV-Seq
1584071|NCT02353351|Device|atrial septal occluder|Single arm atrial septal defect closure with the AMPLATZER Septal Occluder
1584072|NCT02353338|Procedure|Surgical intervention|Surgical management of radial fracture
1584073|NCT02353338|Procedure|Conservative management|Immobilized/cast for 6 weeks
1584074|NCT02353338|Device|cast|
1584075|NCT02353325|Dietary Supplement|non-encapsulated FeSO4|
1584076|NCT02353325|Dietary Supplement|encapsulated FeSO4, before cooking|
1584077|NCT02353325|Dietary Supplement|encapsulated FeSO4, after cooking|
1584078|NCT02353325|Dietary Supplement|non-encapsulated FeSO4 + ascorbic acid|
1584079|NCT02353325|Dietary Supplement|encapsulated FeSO4 + ascorbic acid, before cooking|
1584080|NCT02353325|Dietary Supplement|encapsulated FeSO4 + ascorbic acid, after cooking|
1584081|NCT02353312|Drug|Kuvan|Kuvan® (sapropterin dihydrochloride) will be initiated at 10mg/kg/day with meals for one week. After telephone contact on day 7, assuming no adverse effects are noted, the patient will be instructed to increase their daily dose to 20mg/kg/day with meals for the remainder of the 3 months.
1584084|NCT02353273|Drug|WH-1 ointment|Each subject will be applied the one dose of WH-1 ointment on Day 1, and twice a day of WH-1 application from Day 2 to Day 13, then one dose for Day 14.
1584085|NCT02353260|Device|Ultrasound Hyperthermia|treated with Therapeutic Ultrasound device on the 1st,3rd,5th,7th,9th day of each 21 day cycle
1584086|NCT02353260|Drug|Docetaxel,Cisplatin,Fluorouracil|Squamous cell carcinoma of head and neck: Docetaxel(75mg/m²,d1/21d,2 cycles);Cisplatin(75mg/m²,d1/21d,2 cycles);Fluorouracil(750mg/m²/d,d1-5/21d, 2 cycles)
1584087|NCT02353247|Drug|Norethindrone acetate|
1584088|NCT02353234|Other|Bread|In each arm subjects consume bread
1584089|NCT02353208|Other|Sham Feeding of Bacon Bits|Bacon bits will be a commercially available produce which has been deemed safe for sale in Canada.
1584090|NCT02353208|Other|Placebo|Participants will not be asked to chew bacon bits
1584134|NCT02352909|Other|Education|Education on running training modifications depending on symptoms (decrease running speed, spread running volume throughout the week, run/walk intervals, avoid downhill and stairs running). Education about symptoms will also be provided.
1585559|NCT02342782|Biological|Yttrium Y 90 Basiliximab|Given IV
1584091|NCT02353195|Other|Radiofrequency|The equipment used, 35-mm diameter CAP and 30-mm diameter RES movable electrode was used on the affected site, and a planar electrode was used as a return electrode on the abdomen. The electricity was administered in the following manner: cream was applied to the site with the severest pain and its adjacent area, and the electrical output was increased by moving the movable electrode within the patient´s tolerance level, while monitoring the skin temperature tolerable to the patient.
1584092|NCT02353182|Drug|Dexmedetomidine|Loading dose:1 mcg/kg over 10 minutes. Infusion: Start 1-1.5 mcg/kg/hr. Titrate up or down within 50% of starting doses as needed.
1584093|NCT02353182|Drug|Remifentanil|Loading dose: 1 mcg/kg over 1-2 minutes. Infusion: Start at 0.2-0.5 mcg/kg/min. Titrate up or down (max 0.5 mcg/kg/min) as needed.
1584094|NCT02353182|Drug|Bupivacaine|Administered in caudal/epidural/field block: 0.175%-0.25% (dose at discretion of anaesthetist)
1584095|NCT02353182|Drug|Ropivacaine|Administered in caudal/epidural/field block: 0.2% (dose at discretion of anaesthetist)
1584096|NCT02353169|Drug|Dexmedetomidine|
1584097|NCT02353169|Other|normal saline solution|
1584098|NCT02353156|Other|Electronic bidet|electronic bidet after hemorrhoidectomy for relieving pain and inducing wound healing
1584099|NCT02353156|Other|Sitz bath|sitz bath after hemorrhoidectomy for relieving pain and inducing wound healing
1584100|NCT02353143|Drug|MEN1112|Intravenous infusion of MEN1112 pro/Kg body weight dose on days 1, 8, 15 of a 21-day cycle. Two induction cycles followed by a 3 week End of induction period. Post-induction/Maintenance Visits every 4 weeks with or without maintenance treatment administration, whilst clinical benefit is maintained as per Investigator's judgement. The individual treatment/observation period is six months (except for female patients of childbearing potential that will undergo monthly pregnancy test until 6 months from the last study drug administration).
1584101|NCT02353130|Drug|Memantine-XR|Participants will begin with 7mg Memantine XR® daily for a minimum of one week before increasing to an optimal dose of 14 mg daily. It is suggested that participants be titrated to the optimal dose by week 2 so that they may remain on 14mg for at least 6 weeks. Morning dosing is suggested, but can be flexible.
1584102|NCT02353117|Behavioral|Congenital Syphilis Intervention Group|
1584103|NCT02353104|Dietary Supplement|Onion-Pumpkin Extract|
1584104|NCT02353091|Device|Personal FM system|
2008783|NCT03327324|Diagnostic Test|Sleep Using Mentored Behavioral and Environmental Restructuring|SLUMBER is a non-pharmacological intervention program, delivered by providing mentoring to facility staff who work directly with residents. SLUMBER focuses on detecting sleep-disruptive factors including: nighttime noise and patient behaviors associated with poor sleep quality; disruptions caused by nighttime caregiving; daytime inactivity; and limited light exposure. In this model, staff-delivered interventions to improve these factors improve sleep quality thereby creating opportunities to test the impact of improving sleep quality (measured by actigraphy) on mood (depression and anxiety), pain, cognitive function, functional ability, and observed activity levels.
1584108|NCT02353065|Procedure|Ultrasound imaging|Point of care ultrasound of fracture site during and post-reduction
1584109|NCT02353065|Radiation|Bedside x-ray|Portable x-ray of fracture post-reduction
1584110|NCT02353052|Other|follow up|The patients were followed up for 3 years about their survival conditions and tumor status (eg. recurrence and metastasis).
1584111|NCT02353039|Drug|GC6101A 37.5mg|Administer 12.5mg of GC6101A t.i.d for 2 weeks.
1584112|NCT02353039|Drug|GC6101A 75mg|Administer 25mg of GC6101A t.i.d for 2 weeks.
1584113|NCT02353039|Drug|GC6101A 150mg|Administer 50mg of GC6101A t.i.d for 2 weeks.
1584114|NCT02353039|Drug|Placebo|Administer placebo t.i.d for 2 weeks
1584115|NCT02353026|Drug|Intravenous Artesunate|Intravenous Artesunate in escalating doses: 8, 12, 18, 25, 34, 45 mg/kg on days 1 and 8 of every 3 week cycles
1584116|NCT02353013|Dietary Supplement|Protein supplementation|Standard fortification of human milk may not have enough protein for optimal growth of premature infants. The investigators will add extra protein to this group to increase the protein consumed.
1584117|NCT02353013|Dietary Supplement|Standard fortification|Standard fortification of human milk involves adding a commercially available human milk fortifier to human milk in order to increase several nutrients.
1584118|NCT02353000|Radiation|Stereotactic Radiosurgery|Stereotactic Radiosurgery for patients with 4 up to 10 brain metastases
1584119|NCT02353000|Radiation|Whole Brain Radiotherapy|Whole Brain Radiotherapy for patients with 4 up to 10 brain metastases
1584120|NCT02352987|Drug|Neem plus propylene glycol plus salicylic acid|Leaf extract of neem plus propylene glycol (40%) plus salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
1584121|NCT02352987|Drug|Salicylic acid|salicylic acid (10%) will be applied on palmar keratotic lesion once daily at bedtime for 12 weeks
1584122|NCT02352974|Drug|GAD-Alum|
1584123|NCT02352974|Drug|Vitamin D|
1584124|NCT02352961|Other|Exclusive Intervention Strategy|"The Exclusive Intervention Strategy aimed at men aged 25 - 49 years and Active Follow-up strategy"
1584125|NCT02352948|Drug|MEDI4736|MEDI4736 treatment by intravenous infusion
1584126|NCT02352948|Drug|Vinorelbine|Vinorelbine by intravenous infusion. Administered at a dose of 30 mg/m2 iv on Days 1, 8, 15 and 22 of a 28-day cycle.
1584127|NCT02352948|Drug|Gemcitabine|Gemcitabine by intravenous infusion. Administered at a dose of 1000 mg/m2 iv over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
1584128|NCT02352948|Drug|Erlotinib|Erlotinib administered at a dose of 150 mg once daily as a tablet for oral administration
1584129|NCT02352948|Drug|MEDI4736 in combination with tremelimumab (anti-CTLA4)|MEDI4736 in combination with tremelimumab (anti-CTLA4) treatment by intravenous infusion
1584130|NCT02352948|Drug|tremelimumab (anti-CTLA4)|tremelimumab (anti-CTLA4) treatment by intravenous infusion
1584131|NCT02352935|Device|NanoKnife LEDC System|90 pulses of 70 microseconds each in duration will be administered per electrode pair
1584132|NCT02352922|Drug|Liposomal Bupivacaine|pre-incision infiltration with liposomal bupivacaine
1584133|NCT02352922|Drug|Bupivacaine HCl|pre-incision infiltration with bupivacaine HCl
1584484|NCT02350439|Drug|Adenosine infusion at 200μg/Kg/min|Assessment of fractional flow reserve (FFR) under high adenosine intravenous infusion dose (200mg/kg/min)
1584135|NCT02352909|Other|Exercise program|A home-based program including strengthening and motor control exercises will be prescribed. The program will include 4 different phases of 2 weeks.
1584136|NCT02352909|Other|Gait retraining|Running gait will be modified to reduce knee loading while running (step frequency, impact, foot strike pattern).
1584137|NCT02352896|Drug|EPI-743|EPI-743 is a quinone oxidation product of alpha tocotrienol
2008784|NCT03327311|Device|Bellafill|Bellafill injected into site of pre-planned surgery (i.e., mini-abdominoplasty or redundant abdominal tissue removal) at two depths (dermis & deep dermis).
2008785|NCT03327298|Procedure|pedicle screw fixation|One hundred forty four screws were placed in the lumbosacral pedicles of 32 patients using free hand technique depending on direct visualization of the pedicles, roots, and intervertebral disc ( IVD) after doing full laminectomy, then postoperative CT was done for evaluation of pedicle violation.
2008786|NCT03327285|Biological|C-CAR011|CBM.CD19-targeted chimeric antigen receptor T cells(C-CAR011)
2008787|NCT03327272|Drug|Methylprednisolone|Injection of 80mg Depomedrol injectable suspension at surgical site prior to incision closure
2008788|NCT03327272|Drug|Saline|Administration of saline at surgical site prior to incision closure
2008789|NCT03327259|Behavioral|Activity Planning|The therapist will work with the participant to select a challenging, yet rewarding or value-driven activity that he/she can engage in 5x and monitor daily over the upcoming week.
2008790|NCT03327259|Behavioral|Imaginal Exposure|The therapist will work with the participant to create a brief, 1st person, present tense, narrative of the target activity, including the anticipated negative emotions and outcome. The participant will then be recorded reading the narrative aloud and will subsequently listen to the recording repeatedly for 20 minutes.
1584148|NCT02352857|Other|Sugar|100g of sponge cakes made with 24g of dextrose.
1584149|NCT02352857|Other|FOS|100g of sponge cakes made with 19.4g of dextrose and 9.1g of FOS.
1584150|NCT02352844|Drug|Everolimus|
1584151|NCT02352831|Drug|Tosedostat|
1584152|NCT02352831|Drug|Capecitabine|
1584153|NCT02352831|Procedure|Fresh tissue biopsy|Patients who have a partial response at the end of cycle 2 will be required to undergo biopsy if deemed safe for the patient and tissue is feasible to obtain.
1584154|NCT02352818|Other|no study intervention|
1584155|NCT02352805|Device|ECLS/ECC|Extracorporeal circulation and mechanical circulatory support for heart or lung or renal failure during intensive care therapy or cardiac surgery
1584156|NCT02352792|Radiation|radiochemotherapy with 70 Gy|
1584157|NCT02352792|Radiation|radiochemotherapy with 77 Gy|
1584158|NCT02352779|Dietary Supplement|Omega-3 Fatty Acid|Given PO
1584159|NCT02352779|Other|Placebo|Given PO
1584160|NCT02352779|Other|Questionnaire Administration|Ancillary studies
1584161|NCT02352779|Other|Laboratory Biomarker Analysis|Correlative studies
1584163|NCT02352740|Dietary Supplement|A form Arginine|3 capsules containing 0.5g of A form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
1584164|NCT02352740|Dietary Supplement|B form Arginine|3 capsules containing 0.5g of B form of L-arginine (1.5g) 3 times daily (4.5g per day) for 1 week
1584167|NCT02352701|Drug|Noltec tab. 10mg|Ilaprazole 10mg BID dosage form : delayed release tablet
1584168|NCT02352701|Drug|Chongkundang Amoxicillin Cap. 500mg|Amoxicillin 1000mg, BID dosage form : capsule
1584169|NCT02352701|Drug|Cravit Tab. 500mg|Levofloxacin 500mg, BID dosage form : film coated tablet
1584170|NCT02352688|Procedure|Enhanced Colorectal Geriatric Care|
1584171|NCT02352675|Other|Intraoperative Blood Sample|Blood sample will be run using rotational thromboelastometry to determine the minimal concentration of TXA and EACA need to inhibit fibrinolysis
1584172|NCT02352662|Other|Perioperative blood samples collection|Collect blood samples at 3 different points intra-operatively. Each blood sample will be run using rotational thromboelastometry to assess intraoperative coagulation
1584173|NCT02352649|Drug|Neovasculgen|
1584174|NCT02352636|Other|magnetotherapy|The magnetic pellets will contain an average of ~200 gauss/pellet magnetic flux densities, with a diameter of 1.76 mm
1584175|NCT02352636|Device|laser auriculotherapy|A laser device (pointer pulse) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz, which is a common acceptable dosage for clinical use. This application belongs to a low-energy laser therapy (LLLT), in which the energy level emitted from the device is approximately comparable to a teaching pointer.
1584176|NCT02352636|Other|Placebo|"Subjects will serve as a placebo control, and will receive LAT at power off mode (i.e. deactivated laser) for acupoint stimulation before the application of plaster without magnetic pellets that mimic MAT treatment."
1584177|NCT02352623|Radiation|DXA scan|DXA scan
1584178|NCT02352623|Procedure|Clinical examination|Clinical examination
1584179|NCT02352610|Procedure|LRTI|
1584180|NCT02352610|Device|Biotenodesis Screw|
1584181|NCT02352597|Drug|phytoestrogen|20mg of cimifuga racemosa from day 1- 12
1584182|NCT02352597|Drug|estradiol valerate|2mg from cycle day 7 to day 11
1584183|NCT02352597|Drug|clomiphene citrate|50 mg orally every 8 hours started from cycle day 3 for 5 days
1584184|NCT02352584|Biological|GC3110A(Quadrivalent)|GC3110A(Quadrivalent), 0.5ml, intramuscular, a single dosing at Day 1
1584185|NCT02352584|Biological|GC Flu(Trivalent)|GC Flu Pre-filled Syringe Inj.(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
1584186|NCT02352584|Biological|GC3110A(Trivalent)|GC3110A(Trivalent), 0.5ml, intramuscular, a single dosing at Day 1
1584187|NCT02352571|Biological|GC1118|"For Part A, GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in the dose escalation cohorts, starting 0.3mg/kg until Maximum Tolerated Dose is defined.
For Part B, the defined MTD/RP2D of GC1118 will be administered by IV infusion once per week for 4 weeks (28-day cycles) in patients with stage IV of gastric cancer, colorectal cancer or other cancers.
For Part C, GC1118 will be administered by IV infusion once every 2 weeks for 4 weeks (28-day cycles) in patients with all stage IV advanced solid cancers.
Part A, Part B and Part C participants who qualify for subsequent cycles will receive continued GC1118 until evidence of progression of disease."
1584659|NCT02349048|Drug|Daclatasvir 60 mg|Daclatasvir 60 mg tablet orally once daily.
1584188|NCT02352558|Drug|BBI608|Patients will receive BBI608 orally twice daily, with doses separated by approximately 12 hours. The starting dose for all cohorts will be 240 mg twice daily. Subsequently, cohorts at alternate dose-levels (480 mg twice daily) may be enrolled as determined by the criteria for dose-escalation.
1584189|NCT02352558|Drug|Dexamethasone|Dexamethasone will be taken orally at a dose level of 40 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Patients over the age of 75 years are allowed to begin dexamethasone at a dose of 20 mg once weekly, on Days 1, 8, 15, and 22 of each Cycle. Dexamethasone should be taken with food or milk, and a minimum of 2 hours should separate a dose of dexamethasone from a dose of BBI608.
1584190|NCT02352558|Drug|Bortezomib|Bortezomib will be administered at 1.3 mg/m2/dose as a 3-5 second bolus intravenous (IV) injection or subcutaneous injection twice weekly for 2 weeks (Day 1, 4, 8, and 11) followed by a 10-day rest period (Day 12-21).
1584191|NCT02352558|Drug|Imatinib|Imatinib will be taken orally once daily with a meal and a large glass of water. For patients having difficulty swallowing, imatinib can be dissolved in water or apple juice for intake. The dose of imatinib is 400 mg for CML patients in the chronic phase and 600 mg for CML patients in the accelerated phase or in blast crisis. A minimum of 2 hours should separate a dose of imatinib from a dose of BBI608.
1584192|NCT02352558|Drug|Ibrutinib|Ibrutinib will be taken orally once daily with water. Do not open, break, or chew the capsules. The dose of ibrutinib is 420 mg for patients with normal liver function and is 140 mg for patients with mild liver impairment (Child-Pugh class A). A minimum of 2 hours should separate a dose of ibrutinib from a dose of BBI608.
1584193|NCT02352545|Drug|Montelukast|Patients in experimental treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) .
1584194|NCT02352532|Other|Dry Needling|"The dry-needling treatment will consist of inserting a sterile needle into needling the prone participant's lumbar multifidus and paraspinal muscles, 1-2 times each, in regions of local tenderness to palpation and/or regions with palpable trigger points. All needling treatment will be performed with FDA approved (FDA regulation # 880.5580) disposable 0.30 x 50-60 mm stainless steel Seirin J-type needles (Seirin, Japan). Each needle insertion will last approximately 5 seconds using a pistoning (in and out) technique."
1584195|NCT02352532|Other|Sham Needling|The sham dry-needling procedure will mimic the dry needling procedures by placing a sharp object in a needling guide tube against the skin (see figure). The sharp object will be rocked and twisted to simulate treatment, but will not pierce the skin. We have used this sham dry-needling technique in a previous study performed at AMEDDC&S and have found it to be indistinguishable from real dry needling by the great majority of participants.
1584196|NCT02352519|Procedure|UGBRSB|Under sterile conditions,the posterior rectus sheath will be identified by ultrasound, and an insulated 22 gauge 50 mm needle inserted till the tip is seen to be directly between the rectus abdominis muscle and the posterior rectus sheath. Bupivacaine 0.25% (0.2 ml/kg with maximum 5 ml in each side) will be injected observing the spread on the ultrasound image.
1584197|NCT02352519|Procedure|Local Infiltration|In those patients randomized to the LAI group, the surgeon will perform infiltration of 0.5 ml/kg of 0.25% bupivacaine (maximum, 10 ml) around the incision
1584198|NCT02352506|Other|Blood draw for measurement of MIF|Observational study, no intervention
1584199|NCT02352493|Drug|ALN-CC5|Single or multiple doses of ALN-CC5 by subcutaneous (sc) injection
1584200|NCT02352493|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
2008791|NCT03327246|Device|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
2008792|NCT03327233|Device|Connecare self managment system|The CONNECARE SMS will rely on a hybrid solution that, besides being autonomous (the patient may use the SMS to monitor and access to her/his data and information), has also a collaborative component (through the interaction with the SACM) to allow participation by clinicians and to provide feedback to them. In so doing, the patient may control her/his activity, receiving recommendations to improve the treatment and to be encouraged in following it.
2008793|NCT03327220|Device|iovera°|The iovera° device applies cold to a target nerve to cause a temporary peripheral nerve block based on a process called Wallerian degeneration (2nd degree axonotmesis) without disrupting connective nerve tissue.
1584204|NCT02352441|Other|Implementation Intentions(II)|"Implementation Intention training will include:
Demonstration and practice using examples and personal goals identified at first session. Worksheets will be provided to practice IF-THEN statements to set Implementation Intentions. Additionally, at the end of each session, the participant will be instructed to perform and event based or time based task. The objective is to see if those receiving II training are more likely to carry out the assigned task than those who do not receive II training. They will also be expected to practice II at least 5 days/week using personal goals."
1584205|NCT02352428|Other|Skin Cancer Screening Training|Topics of the 5.5-hour in-class course include: the screening test, types of skin cancer (signs and symptoms), case history taking, epidemiology of skin cancer, etiology, risk factors and risk groups, communicative aspects of primary and secondary preventive measures, and benefits and harms of cancer screenings.
1584206|NCT02352402|Drug|Ticagrelor|
1584207|NCT02352402|Drug|Placebo|
2008794|NCT03327207|Other|Non Interventional|Non Interventional
1584213|NCT02352376|Other|Conventional ventilator|A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
1584214|NCT02352376|Other|Specific ventilator|A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
1584219|NCT02352337|Drug|FOLFIRINOX|Perfusion :oxaliplatine, Irinotecan ,folinic acid, 5FU bolus and continue
1584220|NCT02352337|Drug|LV5FU2|Perfusion: Folinic Acid,5FU Bolus,5FU continue
1584221|NCT02352337|Drug|FOLFIRI.3|Perfusion :Irinotecan,Acide folinique ,5FU continue
1584222|NCT02352337|Drug|Gemcitabine|Gemcitabine perfusion
1585560|NCT02342782|Drug|Carmustine|Given IV
1584223|NCT02352324|Other|Fluid responsiveness tests|After the end of surgery in ICU the positive end-expiratory pressure (PEEP) test of 15 cm H2O for 300 seconds will be performed. Following PEEP test, the two-step fluid load test of 6 ml/kg balanced crystalloid solution will be performed sharing in two portions: Initial mini FLT (mFLT) of 1.5 ml/kg within 1 min (approximately 100 mL) followed by the registration of continuous CI and traditional fluid responsiveness parameters and the rest of standard FLT (4.5 mL/kg) within 5 minutes (approximately 350 mL) followed by transpulmonary thermodilution, registration of continuous cardiac index (CI) and classic fluid responsiveness parameters.
1584224|NCT02352311|Drug|DKF-313|Combination of dutasteride 0.5 mg and tadalafil 5 mg
1584225|NCT02352311|Drug|AVODART|Dutasteride 0.5 mg
1584226|NCT02352311|Drug|CIALIS|Tadalafil 5 mg
1584227|NCT02352298|Device|Dario Blood Glucose Monitoring System|Fingerstick to obtain blood sample for analysis with the Dario BGMS
1584228|NCT02352298|Device|YSI Analyzer|Fingerstick to obtain blood sample for analysis with YSI
1584229|NCT02352285|Drug|Tolvaptan|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
1584230|NCT02352285|Drug|Placebo|Start with 15mg to titrate upwards to 30mg to 60mg, once a daily
1584231|NCT02352272|Other|Total Sleep deprivation|Subject are submitted to 39 hours of continuous awaking in laboratory and a recovery night
1584232|NCT02352259|Procedure|Electrochemotherapy|Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin, within 8-30 min after administration of bleomycin application of electric pulses, removal of electrodes.
1584233|NCT02352259|Device|Cliniporator Vitae®|Positioning of electrodes, within 8-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
1584234|NCT02352259|Drug|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2), 8 minutes before application of electric pulses
1584235|NCT02352246|Procedure|Physical activity programs steady-state exercise (SSE) program|The aim of our study was to compare the effects of 16-week steady-state exercise (SSE) program with high intensity intermittent exercise (HIIE) program on total abdominal and visceral fat mass in T2D postmenopausal women.
1584236|NCT02352246|Procedure|Physical activity programs high intensity intermittent exercise (HIIE)|
1584237|NCT02352233|Procedure|RETROVIEW colonoscope|withdrawal in retro vision and forward vision was performed by segments (right, transverse, left, sigmoid colon and rectum). Retroflexed therapeutics procedures were executed when needed.
1584238|NCT02352207|Other|identification of a pulmonary malformation in the fetus|
1584239|NCT02352194|Other|Rehabilitation|Physiotherapy and physical activity
1584240|NCT02352181|Procedure|Conventional coagulation profile Analysis|"Transfusional protocol for Standard group Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if fibrinogen <1gram per liter
Platelet concentrate :
if platelets <50gram per liter before transfusion, at anhepatic phase, or in case of bleeding.
if platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding 2 Fresh frozen plasma if :
if prothrombin<40% before transfusion at anhepatic phase or in case of bleeding.
if prothrombin<30% at vascular unclamping time at the end of intervention or without bleeding Bolus Tranexamic acid 1g and 3g every 24 hours in case of fibrin degradation products.
Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose.
Analyses in S Group only: coagulation profile (PT, APTT, INR, fibrinogen, platelet count, soluble complexes, PDF)."
1584241|NCT02352181|Procedure|Rotem analysis|"Transfusional protocol for Rotem group. Red Blood cells concentrate if Hemoglobin <9 gram per liter Fibrinogen 3 gram, if A10 FIBTEM <8 mm
Platelet concentrate :
If MCF EXTEM <40mm or A10<35 mm and MCF or A10 FIBTEM >8mm.
If platelets <30gram per liter at vascular unclamping time at the end of intervention or without bleeding.
2 Fresh frozen plasma if CT EXTEM >100s.
Bolus Tranexamic acid 1g and 3g every 24 hours :
if fibrinolysis in EXTEM
Reduction of 15 % of clotting time or clot formation time and increase of maximum clot firmness in APTEM compared to EXTEM, or maximal lysis at 60 minutes >15%.
Analyses in R group only: blood sampling on citrated tube for ROTEM analysis (EXTEM, INTEM, FIBTEM, APTEM +/- HEPTEM), coagulation profile (same as that of the S Group, for emergency procedure).
Analyses common to both groups: NFS, chemistry panel with ionized serum calcium, blood gas with lactates, HemoCue ®, capillary blood glucose."
1584242|NCT02352168|Drug|Budesonide nasal spray|64mcg/1putt, 1 putt/nostril,b.i.d
1584243|NCT02352168|Drug|Placebo|1 putt/nostril,b.i.d
1584244|NCT02352155|Procedure|epinephrine injection or heater probe or hemoclips|Elective Second look endoscopy in the following morning with re-treatment to the bleeding vessel using epinephrine injection or heater probe or hemoclips
1584245|NCT02352155|Other|Observation only|Observation for rebleeding, unscheduled endoscopy only when rebleeding criteria fulfilled
1584246|NCT02352142|Other|Full Term EEG|Full-term infants assigned to this arm of the study will receive one sleep EEG (one hour in duration). These EEGs will be used as healthy control comparisons to those of premature infants at 40 weeks.
1584247|NCT02352142|Behavioral|Facilitated Infant Care|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
1584248|NCT02352129|Other|CMR using T1 mapping technique|the level of myocardial fibrosis for patient suffering of cardiomyopathy dilated will be quantified using CMR T1 mapping technique
1584249|NCT02352116|Other|Additional face-to-face education|Additional teaching regarding what to expect in terms of postoperative pain, how to properly identify pain in children, and instruction on the proper administration of analgesic medications
1584250|NCT02352116|Other|Standard of care management|Current standard of care at a major U.S. teaching hospital.
1584251|NCT02352103|Procedure|Retzius sparing radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Retzius sparing technique
1584252|NCT02352103|Procedure|Vattikuti Urology Institute radical prostatectomy|Robotic assisted laparoscopic radical prostatectomy based on Vattikuti Urology Institute technique
1585561|NCT02342782|Drug|Etoposide|Given IV
1584253|NCT02352103|Device|da Vinci Surgical System|The da Vinci Surgical System is a sophisticated robotic platform designed to expand the surgeon's capabilities and offer a state-of-the-art minimally invasive option for major surgery.
1584254|NCT02352090|Drug|Ethinyl estradiol / dienogest|One tablet orally for 9 weeks, continuous use
1584255|NCT02352090|Drug|Estradiol valerate / dienogest|One tablet orally for 9 weeks, continuous use
1584256|NCT02352090|Drug|Dienogest|One tablet orally for 9 weeks, continuous use
1584257|NCT02352077|Biological|NeuroRegen scaffold with BMMCs or MSCs transplantation|Patients with chronic SCI (ASIA grade A) will receive NeuroRegen Scaffold with bone marrow mononuclear cells (BMMCs) or mesenchymal stem cells (MSCs) transplantation after localized scars cleared and after surgery patients will undergo a comprehensive rehabilitation, psychological and nutritional measures.
1584258|NCT02352064|Procedure|PET (18-FDG)|Every patient will have a PET
1584259|NCT02352051|Drug|Atomoxetine|the drug was initiated at a dose of 0.5 mg/kg/day which was then gradually increased at 2-week intervals and it was attempted to titrate the dose to 1.2 mg/kg/day.
1584260|NCT02352051|Drug|methylphenidate|the drug was initiated at the lowest commercially available dose this was then increased at one-month intervals and it was attempted to titrate the dose to 1 mg/kg/day using daily doses of 36-54 mg
1584261|NCT02352038|Device|low-level laser therapy|The test teeth will receive LLLT using a 940 nanometer diode laser (EZLASE; BIOLASE Technology Inc., Irvine, CA, USA) with output power of 330 milliwatt. The experimental side was irradiated for 30 s in two sessions, delivering an energy density of 7 Joules per square centimeter.
1584262|NCT02352038|Other|orthodontic treatment|Orthodontic treatment will be carried out using preadjusted appliances with bonded 0.022×0.028-square inch brackets/buccal tubes and 0.014-inch NiTi archwires as the first archwires. The treatment or the major part of the treatment will be completed in 12 months.
1584263|NCT02352025|Drug|S-equol|S-equol should be administered orally, twice daily (12 hours apart), preferably on an empty stomach with a glass of water. Tablets should be swallowed whole.
1584264|NCT02352012|Other|Autologous blood|Autologous blood was perfused to the target pulmonary segment
1584265|NCT02352012|Device|Bronchial plug|Bronchial plug was placed to the target pulmonary segment
1584266|NCT02351999|Device|TSP Crosser Transseptal Access System|for transseptal puncture, left atrial access and catheter navigation.
1584267|NCT02351986|Procedure|physical therapy|A 20 minutes ice pack cryotherapy applied for 4 consecutive days
1584268|NCT02351986|Other|ice pack|
1584269|NCT02351973|Drug|Hydrochlorthiazide|"HCTZ 25mg to 50mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.
In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.
In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
1584270|NCT02351973|Drug|Amiloride|"Amiloride 10mg to 20mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.
In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.
In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
1584271|NCT02351973|Drug|Hydrochlorthiazide and Amiloride|"HCTZ 12.5 to 25mg & + Amiloride 5mg to 10mg All drugs will be provided in an acceptable container where the active agent is not identified on the drug label.
In Phase 1 (weeks 0-12) patients will have 1 tablet from each of 2 bottles. These will contain either a) HCTZ 12.5mg in both bottles; b) amiloride 5mg in both bottles; OR c) one bottle of each.
In Phase 2 (weeks13-24) patients will take 2 tablets from each of 2 bottles. These bottles will have the same contents as in Phase 1, except that the number of tablets will be twice as many."
1584272|NCT02351960|Drug|Dexlansoprazole|Dexlansoprazole capsules
1584273|NCT02351947|Other|upper limb rehabilitation for chronic stroke|subjects in this group will receive upper limb motor learning rehabilitation and undergo fMRI/EEG testing as well as testing of motor function (AMAT and FM).
1584274|NCT02351934|Drug|Furosemide|
1584275|NCT02351934|Drug|Celecoxib|Celecoxib is a nonsteroidal anti-inflammatory drug (NSAID) used to treat pain or inflammation.
1584276|NCT02351934|Drug|Gabapentin|Gabapentin is a oral drug used to treat seizures, postherpetic neuralgia, and restless legs syndrome.
1584277|NCT02351921|Device|Transcranial magnetic stimulation|Continuous theta-burst stimulation is a form of repetitive Transcranial magnetic stimulation. CTBS is a non-invasive, non-painful procedure being used worldwide to study brain function and promote short-term changes (~1 hour) in neural activity in the brain. The delivery of cTBS requires ~ 40 seconds in total.
1584278|NCT02351908|Drug|Stribild® (Tenofovir Disoproxil Fumarate, Elvitegravir, Cobicistat)|
1584279|NCT02351908|Drug|Isentress® (Raltegravir 400 mg)1 tablet twice a day + Truvada® (FTC & Tenofovir) 1 tablet|
1584280|NCT02351908|Drug|Tivicay® (Dolutegravir 50 mg) 1 tablet once a day + Truvada® (FTC & Tenofovir)|
1584281|NCT02351895|Other|Copper impregnated linen|Copper impregnated linen was used in place of regular linen on one ward (out of two) for each period of the study. Each study period lasted for 23 weeks. After the washout period (3 weeks) the wards were switched.
1584282|NCT02351882|Drug|Nabilone|Participants randomized to nabilone treatment arm, will undergo a one-week placebo washout, followed by 6 weeks of nabilone treatment (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of placebo treatment (weeks 8-14).
1584283|NCT02351882|Drug|Placebo|Participants randomized to placebo arm, will undergo a one-week placebo washout, followed by 6 weeks of drug matched placebo (weeks 1-6). Participants will then receive a one-week placebo washout (week 7), before receiving 6 weeks of nabilone treatment (weeks 8-14).
1584284|NCT02351869|Drug|Nitrous Oxide|
1584285|NCT02351869|Drug|Midazolam|
1584286|NCT02351856|Drug|ARRY-371797, p38 inhibitor, oral|multiple dose, single schedule
1584287|NCT02351843|Device|MECTA Spectrum 5000Q|
1584288|NCT02351830|Other|Birch Pollen|Participants will be exposed to birch pollen to activate their allergy symptoms therefore validating the unit.
1585562|NCT02342782|Drug|Cytarabine|Given IV
1584289|NCT02351830|Procedure|Nasal Brushing|To assess allergic biomarkers participants will provide a nasal sample which will be collected using a cytobrush. This procedure will be performed twice; once at screening and once following pollen exposure in the EEU.
1584290|NCT02351817|Device|Test A|Ostomy appliance
1584291|NCT02351817|Device|Test B|Ostomy appliance
1584292|NCT02351817|Device|Baseline|Ostomy appliance
1584293|NCT02351804|Drug|Ropivacaine + dexamethasone|Adductor canal block, single bolus
1584294|NCT02351804|Drug|Ropivacaine + placebo|Adductor canal block, single bolus
1584295|NCT02351791|Other|Patch 1, Center|
1584296|NCT02351791|Other|Patch 1, Leakage pocket|
1584297|NCT02351791|Other|Patch 1, Adhesive|
1584298|NCT02351791|Other|Patch 2, Center|
1584299|NCT02351791|Other|Patch 2, Leakage pocket|
1584300|NCT02351791|Other|Patch 2, Adhesive|
1584301|NCT02351791|Other|Patch 3, Center|
1584302|NCT02351791|Other|Patch 3, Leakage pocket|
1584303|NCT02351791|Other|Patch 3, Adhesive|
1584304|NCT02351791|Other|Patch 4, Center|
1584305|NCT02351791|Other|Patch 4, Leakage pocket|
1584306|NCT02351791|Other|Patch 4, Adhesive|
1584307|NCT02351791|Other|Patch 5, Center|
1584308|NCT02351791|Other|Patch 5, Leakage pocket|
1584309|NCT02351791|Other|Patch 5, Adhesive|
1584310|NCT02351791|Other|Patch 6, Center|
1584311|NCT02351791|Other|Patch 6, Leakage pocket|
1584312|NCT02351791|Other|Patch 6, Adhesive|
1584313|NCT02351765|Drug|Acelarin|First-in-class nucleotide analogue
1584314|NCT02351765|Drug|Cisplatin|Platinum-compound chemotherapy drug
1584315|NCT02351752|Drug|Hydroxychloroquine Sulfate|Hydroxychloroquine Sulfate: 0.1 Tid(eGFR 30-59);0.2 Bid (eGFR>60)
1584316|NCT02351739|Drug|pembrolizumab|
1584317|NCT02351739|Drug|ACP-196 in combination with pembrolizumab|
1584318|NCT02351726|Device|Mitroflow DL|Treatment with Mitroflow Pericardial Aortic Heart Valve with Phospholipid Reduction Therapy (Model DL)
1584319|NCT02351713|Other|Exercise|Continuous aerobic exercise prescribed according to two exercise intensity methods: threshold based method (i.e., ventilatory threshold) and relative percent method (i.e., heart rate reserve).
1584322|NCT02351687|Dietary Supplement|Lipid Nutrient Supplement|
1584323|NCT02351687|Drug|Sulfadoxine-pyrimethamine|
1584324|NCT02351687|Drug|Albendazole|
1584325|NCT02351687|Drug|Zinc|
1584326|NCT02351687|Other|Insecticide-treated bednet|
1584327|NCT02351661|Other|There was no intervention|observational study, no intervention
1584328|NCT02351648|Other|a transitional care model|"Intervention extend from transfer of care to the study team from the initial admission medical team through 90 days after discharge
Intervention in hospital includes the following. Comprehensive discharge planning based on the 6 principles. Discharge planning initially within 24 hours of recruitment Daily ward review of patients Weekly multi-disciplinary meeting Consolidation of medication and follow-up appointment before discharge Assessment of needs before discharge Comprehensive discharge summary and medication record at discharge
Intervention after discharge:
Work done mainly by integrated care nurse Review of patients within 48 hours after discharge via home visit or phone call Subsequent home visit as needed based on patient's needs At least weekly contact with pt or caregiver via telephone Telephone availability working weekday 8 AM to 5 PM Multi-disciplinary meeting for problematic cases Use chronic disease pathway for suitable patients"
1584329|NCT02351648|Other|Control|Patients receive usual standard of care from the internal medicine team
1584330|NCT02351635|Other|fecal calprotectin level|Stool sample collected by the subject, sent study laboratories where fecal calprotectin levels are quantified.
1584331|NCT02351622|Drug|Caffeic acid|Oral administration of caffeic acid tablet 0.3g three times per day for 1 year
1584332|NCT02351622|Drug|Dexamethasone|Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.
1584333|NCT02351622|Drug|Placebo|Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
1584334|NCT02351609|Behavioral|Intervention|"Intervention patients will be introduced to the patient navigator either in person or by telephone. The intervention patients will receive navigation from one of two trained navigators, based centrally in the Section of General Internal Medicine. The purpose of the patient navigation interactions is to 1) connect patients to existing yet underutilized smoking cessation resources and 2) increase patient commitment to follow through with existing treatment services.
Financial incentives: $250 for biochemically confirmed abstinence within six months after study enrollment, and $500 for biochemically confirmed abstinence for an additional six months after the initial cessation."
1584335|NCT02351609|Other|Enhanced Traditional Care control|List of smoking cessation resources and educational brochure.
1584336|NCT02351596|Other|Physiotherapy Core Stability Group Programme|"The aim of the intervention is to teach the participants active alignment and core stability, in order to influence their balance strategies. The exercises carried out will teach participants how and when to activate deep core stabilizing muscles. These exercises will be taught in a child-friendly way using imagery appropriate for the age of the participants. They will carry out activities like wall squats, 4-point kneeling, Transverses abdominis activation and gym ball sitting.
Participants will also be supplied with a Home Exercise Programme (HEP) sheet with explanations for exercises that they will be asked to carry out on their 'off' days over the 4 week period. They will be asked to keep a record of their compliance with this."
1584337|NCT02351596|Other|Control Group|The control group will partake in their usual physiotherapy care during the 4 week control period. They will not include core stability or balance specific exercises in their physiotherapy programme for the duration of the control period. If they are receiving active physiotherapy treatment during this time, the duration and frequency of this intervention is recorded
1585563|NCT02342782|Drug|Melphalan|Given IV
1584338|NCT02351583|Device|CytoCam|The side-stream darkfield camera ( CytoCam) will be put under the subjects tongue for 5-10 minutes. Multiple pictures of the small blood vessels will be taken.
1584339|NCT02351583|Device|NIRS Artinis PortaLite with OxySoft softwear|. The NIRS probe will be applied to one of the patient's thenar muscle and over the patient forehead and tissue oxygenation (TOI) will be recorded for 5 minutes.
1584340|NCT02351544|Drug|Botulinum Toxin Type A|
1584341|NCT02351544|Procedure|Surgery|
1584342|NCT02351544|Other|Daily headache diary|
1584343|NCT02351544|Other|Migraine Disability Assessment Test (MIDAS)|
1584344|NCT02351544|Other|Migraine Work and Productivity Loss Questionnaire (MWPLQ)|
1584345|NCT02351544|Other|Migraine-Specific Quality of Life Questionnaire (MSQ)|
1584346|NCT02351531|Dietary Supplement|Extensively Hydrolyzed formula|
1584347|NCT02351518|Other|No intervention|There will be no interventions in this study
1584348|NCT02351505|Drug|Selinexor|Given PO
1584349|NCT02351505|Other|Laboratory Biomarker Analysis|Correlative studies
1584350|NCT02351505|Other|Pharmacological Study|Correlative studies
2008795|NCT03327194|Device|ADHEAR Audio Processor|"ADHEAR Audio Processoris a non-invasive bone conduction hearing device which is retained on the patient's head with an adhesive adapter that is placed behind the auricle.
The ADHEAR Audio Processor transmits sounds to the mastoid by vibrating on the skull and stimulates the inner ear without any previous surgery.
ADHEAR Audio Processor is classified as a Class lla medical device and ADHEAR Adhesive Adapter is classified as a Class I medical device.
The ADHEAR Audio Processor has the CE mark."
2008796|NCT03327181|Dietary Supplement|short chain fatty acid tracers|stable tracer infusion of acetate, propionate, and butyrate
2008797|NCT03327168|Drug|Adenosine|Intravenous infusion of adenosine (0.14 mg/kg) is administered for 5 minutes during PET/CT scan.
2008798|NCT03327168|Other|Cold exposure|Controlled cold exposure is performed before and during PET/CT scan.
1584355|NCT02351479|Behavioral|Hula|
1584356|NCT02351466|Other|Observational|
1584357|NCT02351440|Drug|duloxetine|patients will be randomized to receive either duloxetine or placebo
1584358|NCT02351440|Drug|placebo|placebo
1584359|NCT02351427|Drug|Bortezomib|In one group, investigators administer bortezomib and steroid to manage acute cellular rejection in kidney transplantation, and compare the results with another group in which only steroid was administered.
1584360|NCT02351427|Drug|Steroid|Investigators administer steroid in both groups for conventional treatment of acute cellular rejection.
1584361|NCT02351414|Device|Total Knee Arthroplasty (EVOLUTION®)|
1584362|NCT02351401|Behavioral|Education using ultrasonography as feedback tool|Education using ultrasonography as feedback tool
1584363|NCT02351388|Device|Transcranial Direct Current Stimulation|
1584364|NCT02351388|Other|Sham Stimulation|
1584365|NCT02351375|Other|diet|A controlled diet will be provided to participants which consists of either high protein/low carbohydrate, or of low protein/high carbohydrate.
1584366|NCT02351375|Device|IntelliCap® system|
1584367|NCT02351362|Behavioral|Incentive Group|A one-time supermarket voucher of R50 (about $5.00) for participants who return for at least one postpartum visit at the study clinic within 10 weeks of delivery
1584368|NCT02351349|Other|multidisciplinary intervention|multidisciplinary intervention
1584369|NCT02351336|Device|Ultrasound imaging|"- Fetal adrenal gland volume calculation using 3D ultrasound ( in mm3)
- corrected adrenal gland volume calculation ( adrenal gland volume (mm3)/ estimated fetal weight (kg) )
- CL measurement using 2D ultrasound ( in cm)"
1584370|NCT02351323|Drug|Glutamine (Pharmacological doses)|30 grams/day of glutamine for 12-14 months
1584371|NCT02351323|Behavioral|Lifestyle change|Lifestyle change as recommended by Registered Dietitian
1584372|NCT02351310|Drug|Betamethasone|Course of ACS given intramuscularly (2 doses of 12 mg, 24 hours apart)
1584373|NCT02351310|Genetic|Placebo|Course of placebo drug given intramuscularly (2 doses of normal saline (of equal quantity) 24 hours apart).
1584374|NCT02351297|Dietary Supplement|casein supplementation|After the run-in period, volunteers will receive casein supplementation (15 % of energy intake) for 3 weeks.
1584375|NCT02351297|Dietary Supplement|soy protein supplementation|After the run-in period, volunteers will receive soy protein supplementation (15 % of energy intake) for 3 weeks.
1584376|NCT02351297|Dietary Supplement|maltodextrin supplementation|After the run-in period, volunteers will receive maltodextrin supplementation (15 % of energy intake) for 3 weeks.
1584377|NCT02351284|Other|Measurement|Measurement of vitamin D, PTH, and BMD changes in HIV-infected patients
2008799|NCT03327155|Drug|Tenofovir disoproxil fumarate (TDF)/emtricitabine (FTC)|One tablet, containing 300mg of TDF and 200mg of FTC once daily with food.
2008800|NCT03327142|Diagnostic Test|Endoscopic Ultrasound-Guided FNA|Endoscopic Ultrasound Guided Fine Needle Aspiration of Puncture of Adrenal Glands
1584380|NCT02351258|Device|70% isopropyl alcohol embedded caps|protective cap on central lines
2008801|NCT03327129|Drug|Buprenorphine|An fMRI scan will be conducted before and 60 minutes (peak plasma concentration) after receiving a single 0.4 mg sublingual dose of buprenorphine under single blind conditions.
1584382|NCT02351232|Drug|Liraglutide|
1584383|NCT02351232|Drug|Placebo|
1584384|NCT02351219|Drug|FOLFOXIRI|
1584385|NCT02351206|Radiation|x-ray, MRI|
1584386|NCT02351193|Other|transvaginal Ultrasound|
1584387|NCT02351180|Drug|Inhaled beclomethasone|Inhaled steroid that may decrease airway inflammation and the risk of chronic rejection
1584388|NCT02351180|Drug|Placebo|Placebo will serve as a control treatment
1584389|NCT02351167|Drug|Combination NRT (Nicotine patch, Nicotine lozenge)|
1584390|NCT02351167|Drug|Varenicline|
1584391|NCT02351167|Drug|Placebo|
1584392|NCT02351154|Other|Cellvizio Viewer software|permets to perform analysis of diameters in micrometers
1584485|NCT02350426|Other|Gadobutrol|Gadobutrol is a solution for intravenous (IV) injection in prefilled syringe/cartridge with a unit dose strength of 1.0 millimole (mmol)/mL solution, and will be administered at up to 0.1mmol/kg.
1584486|NCT02350426|Other|18F-FDG|18F-FDG is a solution for IV injection in multidose vial, maximum 10 mL with unit dose strength of 160 megabecquerel (MBq) at maximum.
1584393|NCT02351141|Other|Hyperpolarized Noble Gas MRI|"Hyperpolarized Helium-3 and/or Xenon-129. Noble gas magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces.
Noble gas MRI provides a complimentary and alternative method for evaluating lung disease and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function."
2008802|NCT03327116|Drug|Methotrexate|oral, 15 mg per week, 24 weeks
1584395|NCT02351115|Drug|Staccato® Alprazolam, 0.5 mg|
1584396|NCT02351115|Drug|Staccato® Alprazolam, 1 mg|
1584397|NCT02351115|Drug|Staccato® Alprazolam, 2 mg|
1584398|NCT02351115|Drug|Staccato® Placebo (a)|
1584399|NCT02351115|Drug|Staccato® Placebo (b)|
1584400|NCT02351102|Drug|Valacyclovir|
1584401|NCT02351102|Drug|Placebo|
1584402|NCT02351089|Dietary Supplement|Capsules placebo|Capsules
1584403|NCT02351089|Dietary Supplement|Capsules probiotic powder and corn starch|
1584404|NCT02351063|Drug|Changes of heart failure medications|Changes in dosage of existing medications or introduction of new medications to improve heart failure condition.
1584405|NCT02351050|Device|Sonolysis|continual transcranial Doppler monitoring of middle cerebral artery
1584406|NCT02351050|Other|Sham procedure|sham transcranial Doppler monitoring of middle cerebral artery
1584407|NCT02351037|Drug|Ibrutinib|Subjects will receive ibrutinib 560 mg once daily on a continuing basis.
1584408|NCT02351037|Drug|Ibrutinib + LD-AraC|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 2 days prior to first cytarabine dose (20 mg BID sc) for 10 days of a 28-day cycle.
1584409|NCT02351037|Drug|Ibrutinib+Azacitidine|Subjects will receive ibrutinib 560 mg once daily on a continuous basis starting 1 day prior to first azacitidine dose + azacitidine 75 mg/m2 IV once daily on Days 1-7 of a 28-day cycle (with an option to increase to 100 mg/m2 after 2 cycles).
1584410|NCT02351024|Drug|OXP005|
1584411|NCT02351024|Drug|Naprosyn®|
1584412|NCT02351011|Biological|1 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
1584413|NCT02351011|Biological|10 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
1584414|NCT02351011|Biological|50 x 10^6 MSCs|Autologous, bone-marrow derived MSCs
1584415|NCT02350998|Drug|OTO-201|
1584416|NCT02350985|Drug|Propranolol|Propranolol was given in a flexible dose between 40 mg to 160 mg with an escalating fashion starting at 40 mg PO AM for one week and followed by 40 mg AM and 40 mg PM for a total dose up to 160 mg daily
1584417|NCT02350985|Drug|Venlafaxine|Venlafaxine treatment was followed as: 37.5 mg qhs for two weeks and followed 75 mg qhs with an escalating dose with 2 weeks periods up to 150 mg daily
1584418|NCT02350972|Biological|Autologous cytokines|Sterile autologous cytokines were injected weekly into multiple metastatic nodules while other nodules in the patient were never injected and were monitored for the development of dense lymphocytic infiltrates as evidence of an induced immune response.
1584419|NCT02350959|Drug|Atorvastatin|in moderate dosea statin group, atorvastatin 10mg will be used and maintained until follow up angiography
1584420|NCT02350959|Drug|Atorvastatin|in high dose statin group, atorvastatin 40mg will be used and maintained until follow up angiography
1584421|NCT02350946|Drug|Oxytocin|
1584422|NCT02350946|Drug|Placebo|
1584423|NCT02350933|Procedure|Endoscopy|A rigid endoscopy of the larynx and the trachea until the carina is performed using a rigid 0° endoscope.
1584424|NCT02350920|Behavioral|Acceptance and Committment Therapy (ACT)|This intervention will run with 12-15 participants in each group for a duration of 8 weeks. Each group session will last 1-1.5 hours.
1584425|NCT02350881|Device|Primus FGTI (Flexible Great toe Implant)|Great toe arthroplasty consists of replacing the first Meta-Tarso-Phalangeal (MTP1) joint by a two hinged prosthesis made of silicone : the Primus FGT implant (FGTI). The Primus is designed with an axially offset hinge to align with the anatomy of the MTP joint. This results in less implant stresses and improved toe function.
1584426|NCT02350868|Drug|MPT0E028|The starting dose in the Dose Escalation Phase will be 50 mg/day.Dose escalation from the first cohort to the second cohort will be doubled; and from the second cohort to the fourth cohort will proceed at no more than 50% increments.
1584427|NCT02350855|Dietary Supplement|Improved Atta|Improved Atta is a multi macro- micronutrient bread mix. Patients were given 100 grams of Improved Atta (in the from of unleavened bread) everyday for consumption for six months.
1584428|NCT02350855|Other|Nutritional counseling|Dietary counseling for 30 minutes was imparted to all patients on every hospital visits by the researcher. Consumption of cereals, roots and tubers, vegetables, legumes, nuts, energy dense fruits, milk products (and eggs for non-vegetarians) was encouraged in their daily diets.
1584429|NCT02350855|Behavioral|Physical activity counseling|Depending on the physical status of the patients, low level of physical activity (walking and/or stairs), was encouraged daily during counseling sessions.
1584430|NCT02350842|Device|triple-site biventricular pacing with peri-operative echo guidance|placement of the third lead by peri-operative echo guidance.
1584431|NCT02350842|Device|standard biventricular pacing|standard biventricular pacing without optimization by echo guidance
1584432|NCT02350829|Other|Cardiac magnetic resonance sequence T1 mapping|Adding T1 mapping sequence to the clinical cardiac magnetic resonance scan Obtaining bloodwork for assessment of hematocrit and collagen biomarkers
1584433|NCT02350816|Drug|HGT-1410|HGT-1410 administered according to Patient Group assignment.
1584434|NCT02350803|Device|mini plate|in the intervention group, 4 L shaped titanium mini plates with 16 screws were fixed immediately after distraction phase and removal of distraction ossteogenesis to prevent the relapse after distraction
1584435|NCT02350790|Procedure|Robotic ablation|Robotic laparoscopic ablation of endometriosis with the argon beam coagulator (ABC)
1584436|NCT02350790|Procedure|Robotic excision|Robotic excision of endometriosis
1584487|NCT02350426|Other|18F-GE-180|18F-GE-180 solution for IV injection in 10mL glass vial. Patients will receive a maximum activity of 195 MBq in a maximum volume of 10 mL (bolus) of 18F-GE-180, containing not more than 2 microgram (mcg)/mL 18F-GE-180 (20 mcg for a 10 mL dose).
1584488|NCT02350413|Other|The Endometriosis Health Profile EPH-30|Self-reported questionnaires
1584489|NCT02350400|Device|DEBIRI|DEBIRI TACE
1584439|NCT02350764|Drug|nivolumab|
1584440|NCT02350764|Drug|pilimumab|
1584441|NCT02350751|Drug|MEDI8852|
1584442|NCT02350751|Drug|Placebo|
1584443|NCT02350738|Other|Period I MCET (8 wks)|MCET_Mock group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk) Mock_MCET group: mock-therapy (3 sessions/wk)
1584444|NCT02350738|Other|Washout (4 wks)|4 weeks wash-out period in both arms and cross-over
1584445|NCT02350738|Other|Period II MCET (8 wks)|MCET_Mock group: mock therapy (MCET) (3 sessions/wk) Mock_MCET group: Multimodal Cognitive Enhancement Therapy (MCET) (3 sessions/wk)
1584446|NCT02350725|Drug|Furosemide injection solution for subcutaneous administration (80 mg)|
1584447|NCT02350725|Drug|Oral Furosemide tablets (80 mg)|
1584448|NCT02350712|Drug|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes, followed in Cycle 2 and beyond with a maintenance dose of 9 mg/kg IV over 60 minutes (+/- 10 minutes) every 3 weeks. Infusion time can be extended to a maximum of 120 minutes for participants unable to tolerate the 60-minute infusion.
1584449|NCT02350712|Drug|Cetuximab|Cetuximab initial dose at 400 mg/m2 IV as a 2-hour infusion, followed by 250 mg/m2 IV over 60 minutes weekly.
1584450|NCT02350712|Drug|Cisplatin|Cisplatin is given as an IV infusion, over 1 hour, 1 hour after the cetuximab infusion, every 3 weeks up to a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
1584451|NCT02350712|Drug|Carboplatin|Carboplatin is given as an IV-bolus, over 30-60 minutes, every 3 weeks, for a maximum of 6 cycles (with standard pre- or post-treatment therapies at the investigator's discretion).
1584452|NCT02350699|Device|Nautilus BrainPulse|A noninvasive device to detect concussion utilizing headset and sensors
1584453|NCT02350686|Drug|capecitabine|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
1584454|NCT02350686|Drug|oxaliplatin|XELOX every 3 weeks will be continued until disease progression, patients' refusal or upto 8 cycles
2008803|NCT03327103|Behavioral|CHAMPION|An interactive mHealth decision aid that includes immediate and over time quality of life (QL) graphical summaries for advanced prostate cancer patients to enhance informed, shared decision making and will also be used to assess the CPNs' role in the decision-making process.
2008804|NCT03327090|Other|Kinesio Tape original brand (Kinesio® Tex GoldTM finger print, black, Georgia, Albuquerque).|Kinesio Tape: An elastic therapeutic tape, which mimics the skin's thickness. It is a cotton, porous fabric and acrylic adhesive, which is non-medicated and free of latex. The Kinesio Tape is applied in a specific manner to enhance muscle function, increase circulation, decrease pain and improve proprioception.
1584459|NCT02350647|Device|Suture Anchor HEALOCOIL|Rotator cuff tears will be repaired intraoperatively using suture anchors
1584460|NCT02350647|Device|Suture anchor Twinfix Ultra HA|
1584462|NCT02350621|Procedure|ACDF|
1584463|NCT02350621|Procedure|minimal invasive Posterior Cervical Foraminotomy|
1584464|NCT02350608|Device|Noninvasive monitor|A novel technique on noninvasive blood pressure monitoring.
1584465|NCT02350595|Other|Lean fish|
1584466|NCT02350595|Other|Fatty fish|
1584467|NCT02350582|Device|Telerehabilitation eCUIDATE system|Resistence and endurance exercise adapted to individual requeriment during chemotherapy
1584468|NCT02350569|Drug|LDV/SOF|90/400 mg FDC tablet administered orally
1584469|NCT02350556|Other|Dynamic Avoidance Task|
1584470|NCT02350556|Procedure|physical therapy|
1584471|NCT02350556|Device|3D motion on optoelectronic device|
1584472|NCT02350543|Drug|Aspirin|
1584473|NCT02350530|Drug|FOLFOXIRI + Bevacizumab|Bevacizumab 5mg/kg + irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
1584474|NCT02350530|Drug|FOLFOXIRI|Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
1584475|NCT02350517|Drug|Paclitaxel+Nedaplatin+Endostar|Patients will receive chemotherapy every 3 weeks: Paclitaxel 175mg/m2 IV over 3 hours on Day 4; Nedaplatin 80mg/m2 IV over 1 hours on Day 4; Endostar 3mg/day for 14 days continuous infusion from Day 1 to Day 14
1584476|NCT02350504|Behavioral|Full interactive instruction|This is a prospective randomized controlled trial in which the level of the child's exposure to instruction is controlled according to the group he is attributed to. The children are divided randomly, each Sunday (the day there is an available anesthesia staff) we change the extent of the instruction. In the intervention group, we use Full interactive instruction- which include an instructional booklet, a movie and a simulator's practice.
1584477|NCT02350491|Other|Collection of biological samples|
1584478|NCT02350478|Drug|Linagliptin|The subject will receive Linagliptin 5mg orally once daily for 12 weeks.
1584479|NCT02350478|Drug|Placebo|The subject will receive placebo orally once daily for 12 weeks.
1584480|NCT02350465|Behavioral|Eccentric Exercise|Submaximal progressive resistance exercise (PRE) using eccentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
1584481|NCT02350465|Behavioral|Concentric Exercise|Submaximal progressive resistance exercise (PRE) using concentric muscle actions for the knee extensors/flexors will be performed for 10 repetitions, 3 to 4 sets, twice per week for 12 weeks.
1584482|NCT02350452|Procedure|Diode laser coagulation|Diode laser coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
1584483|NCT02350452|Procedure|Bipolar coagulation|Bipolar coagulation of inner lining of ovarian endometrioma after laparoscopic cystectomy
1584490|NCT02350387|Procedure|High Intensity Short Duration Exercise|Participants randomized to this group will perform 4 sets of 8-15 repetitions of eccentric exercise using the Eccentron set at 50-80% of the participant's one repetition maximum.
1584491|NCT02350387|Procedure|Low intensity Long Duration Exercise|Participants randomized to this group will perform 5-20 minutes of continuous eccentric exercise using the Eccentron set at 50% of the participant's one repetition maximum.
1584492|NCT02350374|Other|carbohydrate counting|"patients must fill their logbook with the following data:
cho amount at breakfast, lunch, snack and dinner
insulin amount at breakfast, lunch, snack and dinner"
1584493|NCT02350361|Drug|Recombinant human endostatin|Recombinant human endostatin 7.5mg/m2
1584494|NCT02350361|Drug|Placebo|Placebo
1584495|NCT02350335|Drug|Nicotine (transdermal)|Application of transdermal nicotine replacement in smokers with acute aneurysmal hemorrhage
1584496|NCT02350322|Other|Schoolmeal with fatty fish|Schoolmeal with fatty fish three times a week for 12 weeks
1584497|NCT02350322|Other|Schoolmeal without fish|Schoolmeal with meat/cheese three times a week for 12 weeks
1584498|NCT02350322|Dietary Supplement|Supplement|Omega-3 capsules three times a week for 12 weeks
1584499|NCT02350309|Drug|E2006 5 mg|E2006 5 mg tablet
1584500|NCT02350309|Drug|E2006 10 mg|E2006 10 mg tablet
1584501|NCT02350309|Drug|E2006-matched placebo|E2006-matched placebo tablet
1584502|NCT02350309|Drug|Flurazepam 30 mg|Flurazepam 30 mg capsule
1584503|NCT02350296|Drug|KSL 40 mg|Ketoprofen lysine salt oral immediate release tablets 40 mg
1584504|NCT02350296|Drug|OKi® 80 mg|Ketoprofen lysine salt granules for oral solution 40 mg (half of a bipartite sachet)
1584505|NCT02350283|Device|Interventional treatment with Solitaire|Patients will be treated for mechanical recanalization with Solitaire within 12 hours after stroke onset plus standard medical management.
1584506|NCT02350270|Other|gait and cognitive testing|
1584507|NCT02350257|Behavioral|Internet-based CBT|12 weeks of internet-based CBT
1584508|NCT02350244|Behavioral|Computer program|Intervention consists in a computer program suggesting workers to take active breaks at given times of their working day, during one month.
1584509|NCT02350231|Drug|The progesterone vaginal pessary|Those patients will receive progesterone vaginal pessary for prevention of preterm delivery in twins pregnancy
1584510|NCT02350231|Drug|Tonics group|Those patients will receive only tonics
1584511|NCT02350218|Drug|Eglandin|Inject Eglandin 360㎍ or 720㎍ for 14 days in living donor liver transplanted patient
1584512|NCT02350205|Biological|Self assembled skin substitute (SASS)|Two site A / B, an area of about 50-100 cm2 are selected. The two sites are side by side and subjected to similar stresses. The type of graft (split thickness autograft or SASS) for the site A or B has been determined in advance.
1584513|NCT02350205|Procedure|Split-thickness autograft|Two site A / B, an area of about 50-100 cm2 are selected. The two sites are side by side and subjected to similar stresses. The type of graft (split thickness autograft or SASS) for the site A or B has been determined in advance.
1584514|NCT02350192|Behavioral|e-health educational intervention (eHEI)|The e-HEI link (e-health link http://ehealth.nur.cuhk.edu.hk) provides the content of culture-specific cognitive knowledge related to CVD and measures to modify risk factors. The member area and interactive platform of the e-HEI website allows the self-monitoring of individual health and exercise records. Members can view and retrieve their own exercise records daily, and health measures trend regularly.
1584515|NCT02350179|Drug|Tranexamic Acid|"This will be a prospective, randomized controlled trial that will be carried at Obstetrics and Gynecology Department, Ain Shams Maternity Hospital.
The study will include 100 pregnant women with singleton fetus 38 or more weeks gestation who will be divided in to two groups.
Study group will include 50 women and control group will include 50 women. Women assigned to the study group will receive 1 gr of TXA injection (Kapron, AMOUN Pharmaceutical co.) given slowly I.V over 10 minutes before the operation.
The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study."
1584516|NCT02350179|Drug|Glucose|The control group will receive 30ml of 5% glucose. Both provider and patient will be double-blinded until the conclusion of the study.
1584517|NCT02350166|Procedure|laparoscopic surgery|laparoscopic-assisted small-incision surgery
1584518|NCT02350140|Other|Text messaging from beginning|"Registered women will then receive up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.Participants at facilities receiving TextIT will have the option to call or send text messages to a designated clinic phone, to which a clinic nurse will respond. Participants will also have an option to request a call from the clinic by sending a free call back text message to the designated clinic phone at any time."
1584519|NCT02350140|Other|Text messaging after 6 months of control|After six months of standard care, women at control clinics will be registered to receive the text messaging intervention with up to 14 text messages as follows: weeks 28, 30, 32, 34, 36, 38, 39, and 40 during the third trimester of pregnancy; weeks 1, 2, 3, 4, 5, and 6 after delivery.
1584520|NCT02350127|Behavioral|Preventing Loss of Independence through Exercise (PLIE)|PLI is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
1584521|NCT02350127|Behavioral|Usual Care Control|Study participants who are randomized to the Usual Care (UC) control group will continue to participate in usual activities at the adult day center, which include a combination of daily physical, mental and social activities.
1584522|NCT02350114|Procedure|6 Minute Walk Test|Evaluation of walking distance on standardized 6 minute walk test
1584523|NCT02350101|Device|Rotational thromboelastometry|In bleeding patients point of care measurements are performed, in this case Rotational Thromboelastometry (ROTEM) to guide the use of blood products and coagulation factors.
1584524|NCT02350088|Drug|probiotics|probiotics
1584525|NCT02350088|Drug|placebo|placebo
1584526|NCT02350075|Procedure|Dental implants installation|Dental implants installation is a procedure to insert dental implants into alveolar bone.
1584527|NCT02350075|Device|Osteotome Sinus floor elevation|Osteotomes with different diameters are specially-designed device to vertically increase the bone volume in atrophic maxilla.
1584528|NCT02350036|Other|ultrasound monitoring|Uterine artery Doppler assessment
1584529|NCT02350023|Drug|Topical latanoprost 0.005%|Local application of the drug on affected skin/scalp
1584530|NCT02350023|Drug|Topical betamethasone 0.05%|Local application of the drug on affected skin/scalp
1584531|NCT02350010|Device|CT Angiography|"CTA Scan with the specified sequences below:
120 kVp, 360 mAs, 0.5 second/rotation, 0.75 mm thick with a pitch of 0.65. Coronal and sagittal multiplanar reconstructed images with 10.0-mm-thick images spaced by 3 mm.
Axial reformed images were 4 mm thick with 2-mm spacing. 90 mL of nonionic iodinated contrast (OPTIRAY 350) at 5 mL/s."
1584532|NCT02349997|Other|no interventions|This is an observational study and no intervention applied.
1584533|NCT02349971|Device|MR-HIFU|Magnetic Resonance guided High Intensity Focused Ultrasound (MR-HIFU) provides precise and controlled delivery of focused ultrasound energy inside a lesion using an external applicator, without the need for a scalpel or needle
1584534|NCT02349958|Device|HIPEC: MMC 30mg @ T0, 10mg @ T45min|MMC 30mg @ T0, 10mg @ T45min for Appendix, Psuedomyxoma, colorectal, small bowel
1584535|NCT02349958|Device|HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0|Gastric and Pancreato-biliary HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min
1584536|NCT02349958|Device|HIPEC: CDDP 75 mg/m2 @T0|Ovarian/peritoneal/fallopian tube, Uterine CDDP 75 mg/m2 @T0
1584537|NCT02349958|Device|HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0|CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0 Mesothelioma and Sarcoma
1584538|NCT02349945|Drug|follitropin alpha|"All subjects included in the study will receive recombinant FSH therapy (follitropin alpha: Gonal-f 150 I.U. s.c. every other day for 12 weeks). Follow up: 12 further weeks after end of treatment.
Previous studies included in the Cochrane meta-analysis used: hMG/hCG, 150 IU three times a week for 13 weeks; purified FSH, 150 IU/day for 12 weeks; rec hFSH, 150 IU/day for 12 weeks; rec hFSH, 100 IU on alternate days for 3 months. Therefore any dosage > 100 IU on alternate days is eligible. The duration of treatment is based on the duration of one spermatogenetic cycle."
1584539|NCT02349932|Other|Healthy Adults|The following samples will be collected: fecal, blood, and saliva. The samples will be tested for HBGA-reactive antigens using an immunoaffinity assay.
1584540|NCT02349919|Drug|Procaterol|Procaterol 25 micrograms/tablet, 1 tablet twice daily for 4 weeks
1584541|NCT02349919|Drug|Placebo|Placebo twice daily for 4 weeks
1584542|NCT02349906|Drug|Treosulfan|
1584543|NCT02349906|Drug|Busilvex|
1584544|NCT02349893|Device|RFA treatment|RFA treatment using CelonProSleep plus system
1584545|NCT02349880|Behavioral|shared decision making training|
2008805|NCT03327077|Other|Live Preferential Music|Trained musicians will play live preferential music to ED patients who consent to participate.
2008806|NCT03327064|Drug|UAB30|9cUAB30 promotes homodimer and heterodimer formation with retinoic acid receptors (RARs), and was shown to inhibit breast tumor development in the N-methyl-N-nitrosourea (MNU)-induced rat mammary gland carcinoma model. The compound has also shown efficacy in rodent models of skin cancer. Dose administration will be 160mg daily for 28 days.
2008807|NCT03327064|Drug|Placebo|This matches the UAB30 in appearance. Frequency of dosing will be daily for 28 days.
2008808|NCT03327051|Drug|Omeprazole|Proton pump inhibitor
2008809|NCT03327051|Dietary Supplement|VSL #3|Probiotic
2008810|NCT03327038|Behavioral|Web-Based Cognitive Behavioral Therapy|Patients will receive access to a 5-week web-based CBT program entitled 'Mood Gym'. The program is derived from traditional, therapist-directed cognitive behavioral therapy. The program consists of 5 modules, and patients will asked to complete 1 module per week over, during weeks 2-6 over their intervention period.
1584553|NCT02349854|Procedure|Biopsy|1 scalp biopsy will be done at the site of central sensitization testing, according to standard of care practices. First, the site will be anesthetized and within this area, 2 immediately adjacent (ie contiguous) punch biopsies will be taken-2mm & 3mm. Both will be closed simultaneously using either (i) non fast-absorbing gut sutures, requiring a 10-14 day follow-up visit for suture removal; (ii) fast absorbing gut sutures that will not require a subsequent suture removal visit, or (iii) gel foam without stitches that also does not require a suture removal visit. Wound care instruction will be discussed with patient. The patient will be instructed to apply petroleum jelly at least 3 times per day to the biopsy site, reflecting standard of care clinical care at BMC.
1584554|NCT02349841|Drug|Meropenem|To administer 2g daily 8 hourly for 14 days
1584555|NCT02349841|Drug|Faropenem|To adminster 600mg 8 hourly daily for 14 days
1584556|NCT02349841|Drug|Amoxycillin/clavulanic acid|To administer 625mg 8 hourly daily for 14 days together with the faropenem and meropenem
1584557|NCT02349841|Drug|Rifafour e275|To be taken as per the National TB treatment programme for 14 days
1584558|NCT02349828|Drug|Acyclovir|
1584560|NCT02349802|Drug|Auto-injector with exenatide suspension|A flexible study design to accommodate multiple cohorts.
1584561|NCT02349802|Drug|Syringe with exenatide suspension|A flexible study design to accommodate multiple cohorts.
1584562|NCT02349776|Other|Providing testimonies from survivors of transplants to patients|"Patients will be asked to complete one mood measure (the HADS), the Life Orientation Test (LOT), and a questionnaire about expectations of treatment in clinic once a decision to proceed to transplant has been made.
Patients will receive the testimonies upon admittance to the transplant unit and then receive the HADS and a structured interview within the first week of being admitted to the transplant ward (just prior to receiving the transplant) and within the first two weeks following the transplant."
1584563|NCT02349763|Drug|Intravenous Dexamethasone|Lactose (Placebo) 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and dexamethasone 20 mg (5mg/ml) given intravenously at 30 minutes before paclitaxel infusion
1584564|NCT02349763|Drug|Oral Dexamethasone|Dexamethasone 20 mg (4 mg/tablet) or 5 tablets given orally at 12 and 6 hours before paclitaxel infusion and 0.9% NaCL (Placebo) 4 ml given intravenously at 30 minutes before paclitaxel infusion
1584565|NCT02349750|Procedure|endometrial scratch injury|ESI using No.8 neonatal feeding tube
1584568|NCT02349711|Dietary Supplement|Probiotic mixture|A 350 mg capsule containing a mixture of Lactobacillus gasseri, Bifidobacterium bifidum, and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration) will be taken twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Inactive ingredients include gelatin, potato starch, and silica.
1584569|NCT02349711|Dietary Supplement|Placebo|Placebo will be taken as a capsule twice daily for 8 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded). Supplement contains 348.25 mg of potato starch.
1584570|NCT02349698|Biological|Chimeric Antigen Receptor Modified T cells Targeting CD19|T cells modified with CD19 targeted chimeric antigen receptor.
1584571|NCT02349685|Procedure|H. pylori culture and antimicrobial susceptibility test|Antral and body biopsy specimens were evaluated separately. Organisms were identified as H. pylori by Gram staining, colony morphology, and positive oxidase, catalase, and urease reactions. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin (Sigma Chemical Co., St. Louis, Mo.), clarithromycin (Abbott Laboratories, Abbott Park, Ill.), metronidazole (Sigma), tetracycline (Sigma) and moxifloxacin (Sigma) for the H. pylori isolates were examined by use of the serial twofold agar dilution method and the reference of susceptibility testing was according to the recommendations of the Clinical and Laboratory Standards Institute [amoxicillin (AMC), MIC ≥ 0.5 μg / ml; clarithromycin (CLA), MIC > 1.0 μ g / ml; metronidazole (MET), MIC > 8 μ g / ml; tetracycline (TC), MIC > 4 μ g / ml; and moxifloxacin (MOX), MIC > 1 μ g / ml).
1584572|NCT02349685|Drug|14 day PBMT group|Rescue therapy using 14 day PBMT regimen [Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d]
1584573|NCT02349685|Drug|14 day MEA group|Rescue therapy using 14 day MEA regimen (PPI regular dose b.i.d., moxifloxacin 400 mg q.d., and amoxicillin 1g b.i.d.)
1584574|NCT02349672|Procedure|blood sample|Blood will be collected to test for concentrations of UCH-L1 and GFAP.
1584575|NCT02349659|Device|Implantation with the commercially available Axium neurostimulator|
2008811|NCT03327038|Other|Short Questionnaires|Patients will receive emails to complete bi-weekly, web-based questionnaires at weeks 2, 4, and 6 of their intervention period. The short questionnaires will ask to patients to self-report their Depression (PHQ-9) and Anxiety (GDA-7) symptoms; along with their Crohn's Disease activity (PRO-2) or Ulcerative Colitis Disease Activity (MAYO-6).
1584578|NCT02349620|Biological|PRF|implant stability was measured by RFA and implant resorption was measured by IOPA after surface treatment by PRF
1584579|NCT02349607|Drug|PF-05089771 300mg|PF-05089771 300 mg
1584580|NCT02349607|Drug|PF-05089771 300 mg + pregabalin 300 mg|PF-05089771 300 mg + pregabalin 300 mg
1584581|NCT02349607|Drug|Placebo|Placeco
1584582|NCT02349607|Drug|pregabalin 300 mg|pregabalin 300 mg
1584583|NCT02349607|Drug|ibuprofen 600 mg|ibuprofen 600 mg
1584584|NCT02349594|Drug|Omegaven 10%|intravenous administration 10% (w/v) fish oil emulsion (Omegaven) for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
1584585|NCT02349594|Drug|Intralipid 20%|intravenous administration of 20% (w/v) lipid-control (Intralipid®), for 1 hour on three consecutive days at a dose of 0.2 g/kg bodyweight/hr.
1584586|NCT02349581|Procedure|PECS block|Ultrasound guided delivery of local anesthetic between the pectoral muscles
1584587|NCT02349581|Drug|Bupivacaine|
1584588|NCT02349568|Procedure|High risk group|Patients with high risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. All patients even if negative EUS examination of CBD stone were underwent ERCP in the same session. The ERCPs were performed in standard manner. All patients were contacted by phone on day 1, 3 and 30 after the procedure.
1584589|NCT02349568|Procedure|Intermediate risk group|Patients with intermediate risk underwent EUS examination under conscious sedation. EUS was examined from second part of duodenum up to duodenal bulb. ERCPs were done at the discretion of the attending physicians. The ERCPs were performed in standard manner. The patients without ERCP done were contacted at 3 months interval to assess symptoms and LFT for 12 months.
1584590|NCT02349555|Dietary Supplement|Nutritional Supplement Blend|It is to be taken orally at a dose of 4 capsules per day, 2 capsules with breakfast and 2 capsules with dinner.
1584591|NCT02349542|Drug|Liposomal bupivacaine|One (1) 20 mL vial of 266 mg liposomal bupivacaine (3% (~8mg free bupivacaine)) will be injected into each surgical (knee) site following simultaneous bilateral total knee arthroplasty. In addition, 30 mL of 0.25% bupivacaine (75 mg free bupivacaine) will be injected into each surgical (knee) site for a total of 83 mg free bupivacaine injected into each surgical (knee) site.
1584592|NCT02349529|Behavioral|Psychosocial Intervention Group|6 group sessions
1584593|NCT02349529|Other|Waiting list control|Treatment as usual
1584594|NCT02349516|Drug|Squalamine Lactate Ophthalmic Solution 0.2%|Squalamine Lactate Ophthalmic Solution 0.2% eye drop to be administered to study eye either BID or QID for 52 weeks
1584595|NCT02349503|Drug|NBI-77860|
1584596|NCT02349503|Drug|NBI-77860|
1584597|NCT02349503|Drug|NBI-77860|
1584598|NCT02349490|Device|Seraseal / Fastact Hemostatic agent (combined activated factors IIa, VIIa, IXa, Xa )|Following endoscopic confirmation of a bleeding, 2,5-5ml of liquid Seraseal / Fastact, is topically applied to the bleeding site via catheter
1584599|NCT02349477|Drug|Gabapentin|gaba potentiating medication
1584600|NCT02349477|Drug|Placebo|a pill that looks exactly like the active medication but does not contain medication
1584601|NCT02349464|Other|Specialized Preterm Infant/Mother Dyad Lactation Support|Mother will receive home equipment and pediatric clinic lactation support.
1584602|NCT02349451|Biological|adalimumab|
1584603|NCT02349451|Biological|ABT-122|
1584604|NCT02349438|Device|senofilcon A|A soft spherical contact lens
1584605|NCT02349438|Device|lotrafilcon B|
1584606|NCT02349425|Drug|Gefapixant|
1584607|NCT02349425|Drug|Placebo (for gefapixant)|
1584608|NCT02349412|Other|Early palliative care|
1584609|NCT02349399|Drug|Cyproterone / Ethinylestradiol (Diane-35, BAY86-5264) and its Generics|Hormonal Contraceptive: Cyproterone Acetate 2 mg / Ethinylestradiol 35 μg
1585749|NCT02341508|Biological|20 mg/kg Lpathomab|
1584611|NCT02349386|Drug|Placebo|An absorptive hydroalcoholic gel preparation gel of the same ingredients as BHR-200, but without 17β-estradiol.
1584612|NCT02349373|Behavioral|An 8 week preconditioning period|Receipt of a weekly running schedule through an online training diary.
1584613|NCT02349373|Behavioral|16 week training period|Receipt of a weekly running schedule through an online training diary.
1584614|NCT02349360|Biological|L. johnsonii N6.2|L. johnsonii N6.2 10^10 CFU in capsule form administered for 8 weeks (n=15)
1584615|NCT02349360|Biological|Placebo|Encapsulated starch placebo administered for 8 weeks (n=15)
1584616|NCT02349347|Drug|Melphalan|
1584617|NCT02349347|Drug|Lenograstim|
1584618|NCT02349334|Device|Percutaneous Tibial Nerve Stimulation|
1584619|NCT02349321|Behavioral|Skhokho Supporting Success for Schools|All information describing each facet of the intervention are included in the arm/group descriptions.
1584620|NCT02349321|Behavioral|Skhokho Supporting Success for Families|All information describing each facet of the intervention are included in the arm/group descriptions.
1584621|NCT02349308|Device|CentrosFLO Long Term Hemodialysis Catheter|
1584624|NCT02349282|Dietary Supplement|Calcifediol 10ug/day|
1584625|NCT02349282|Dietary Supplement|Vitamin D3 20ug/day|
1584626|NCT02349282|Dietary Supplement|Placebo|
1584627|NCT02349243|Drug|Entacapone|200 mg entacapone, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
1584628|NCT02349243|Drug|Placebo|200 mg placebo, oral intake, 4 times per day (after breakfast, lunch, supper and before sleep at night), for 6 six months
1584629|NCT02349230|Other|Astym treatment|Astym is a manual therapy technique applied by a certified therapist with advanced training in the technique. The technique is applied to a limb or body segment with specialized instruments in a specific sequential protocol that incorporates the muscle groups and joints of the entire kinetic chain.
1584630|NCT02349217|Behavioral|Mindfulness-Based Relationship Enhancement (MBRE)|Participant and partner take part in an 8-week Mindfulness-Based Relationship Enhancement (MBRE) intervention course. MBRE course consists of meditation and yoga techniques and handouts.
1584631|NCT02349217|Behavioral|Self-Help Materials|Participants and partner receive self-help materials.
1584632|NCT02349217|Behavioral|Pain Assessment|Pain assessment administered at baseline and at follow up visit. Pain assessment involves submerging hand in cold water.
1584633|NCT02349217|Behavioral|Questionnaires|Questionnaires completed at baseline and at follow up visit. Questionnaires ask about fatigue, mood, stress, social support, marital satisfaction, depression, and general demographics (age, race and so on). It should take about 1½ hours total to complete the questionnaires.
1584634|NCT02349217|Behavioral|Neurocognitive Tests|Neurocognitive tests administered at baseline and at follow up visit. Tests to check memory and thinking abilities.
1584635|NCT02349217|Procedure|Cortisol Tests|Cortisol testing performed after baseline visit and at follow up visit. Participants asked to collect saliva samples for cortisol assays immediately, 30, 45, and 60 minutes after awakening (representing the cortisol awakening response) and at noon, 4 P.M. and 8 P.M.
1584636|NCT02349217|Behavioral|Interviews|Interviews conducted after follow up visit. These interviews are audio-taped and transcribed.
1584637|NCT02349204|Behavioral|Music - Mozart's sonata for 2 pianos in D-440|
1584638|NCT02349191|Procedure|Omental transposition for mild Alzheimers disease|An omental pedicle is brought from the abdomen underneath the skin and sewn to the dura matter of the brain via a craniotomy.
1584639|NCT02349178|Drug|Clofarabine|Days 1-5 receive Clofarabine 20 mg/m2 IV over 2 hours
1584640|NCT02349178|Drug|Cyclophosphamide|Days 1-5 receive Cyclophosphamide 300 mg/m2 IV as a 30-60 minute infusion
1584641|NCT02349178|Drug|Etoposide|Days 1-5 receive Etoposide 100 mg/m2 IV over 2 hours
1584642|NCT02349165|Procedure|Transepithelial versus epithelium-off CXL|A comparison of the CXL procedure with and without epithelium removal
1584643|NCT02349165|Drug|Ricrolin TE|Ricrolin TE was instilled during 30 minutes before ultraviolet-A irradiation
1584644|NCT02349165|Drug|Isotonic riboflavin|After epithelium removal, isotonic riboflavin was instilled during 30 minutes before ultraviolet-A irradiation
1584645|NCT02349152|Drug|Remifentanil|Subjects in the experimental group will receive remifentanil infusion 0.1-0.4ug/kg/minute before induction of anesthesia and continued until skin closure. During cardiopulmonary bypass, remifentanil infusion will be increased to 0.5-1 ug/kg/min as hemodynamically tolerated.
1584646|NCT02349152|Drug|Fentanyl|Subjects in the control group will initially receive intermittent boluses of Fentanyl in the range of 50-250 ug. Additional fentanyl can be given titrated to hemodynamic parameters throughout surgery.
1584647|NCT02349139|Drug|ASN001: Escalating dose Part A|Androgen inhibitor
1584648|NCT02349126|Drug|ARC-520 Injection|ARC-520 Injection is a liver-targeted antiviral therapeutic designed to treat chronic hepatitis B virus (HBV) infection via an RNA interference (RNAi) mechanism.
1584649|NCT02349113|Drug|Estrogens (Climara)|Treatment with estrogens: Estradiol dermal patch 0.1mg/d transdermally
1584650|NCT02349100|Device|Nellix Endoprosthesis|Implantation of Nellix
1584651|NCT02349087|Device|Acute EEG with fast applicable EEG electrode|
1584652|NCT02349074|Procedure|Digestive endoscopy|Performed a systematic œsophago-gastro-duodenoscopy between 2 and 4 days after out-of-hospital cardiac arrest
1584653|NCT02349061|Drug|Ustekinumab IV|Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
1584654|NCT02349061|Drug|Placebo Infusion|Placebo intravenously at Week 0.
1584655|NCT02349061|Drug|Placebo SC|Placebo subcutaneously at Weeks 8 and 16.
1584656|NCT02349061|Drug|Ustekinumab SC|Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
1584657|NCT02349061|Other|Concomitant Medication|Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
1584658|NCT02349048|Drug|Simeprevir 150 mg|Simeprevir 150 mg capsule orally once daily.
1584660|NCT02349048|Drug|Sofosbuvir 400 mg|Sofosbuvir 400 mg tablet orally once daily.
1584661|NCT02349035|Device|Compare control of multifunction transradial prosthesis|Subjects practice control methods using a VR system. EMG data and virtual games are used and provide data to assess control methods without prosthesis. Subjects are fit with commercially available multifunctional hand system. They receive 1-3 days of training for conventional or pattern recognition control. They return home for an 8 week trial. They use the prosthesis for 2 hours a day across the 8 week trial. They keep a log of use and check with a therapist about usage and performance. After the 8 week trial, data from the prosthesis is downloaded. The subject will complete 1-3 days of outcomes testing. They perform a series of tests and data is recorded. The subject will repeat the 1-3 days of training, 8 week home trial, and 1-3 days of outcomes testing with either type of control.
1584662|NCT02349035|Procedure|Perform TMR surgery and evaluate transradial TMR pattern recognition control of multifunctional prostheses.|Subject has Targeted Muscle Reinnervation surgery. The surgery transfers median nerve to flexor digitorum superficialis muscle and ulnar nerve to flexor carpi ulnaris muscle. Two weeks after surgery, exercises start for muscle recovery. Then return to prosthesis from Phase 1 for 6 months. If they have pattern recognition control, usage and performance will be tracked for 6 months. If they return to conventional control, they will not complete tests, track usage, or performance. Six months after surgery, they return to pattern recognition control. Receive 1-3 days of training. Take prosthesis home for 8 week trial. Log use of device, note issues, and follow up with therapist. After home trial, 1-3 days of outcomes testing are completed and usage data downloaded. Continue using their prostheses for an additional 3-4 months. At 12 months after surgery, a final round of 1-3 days of testing and data are downloaded.
1584663|NCT02349022|Radiation|[89Zr]Df-IAB2M|
1584664|NCT02349009|Drug|C-82 Topical Gel, 1%|active
1584665|NCT02349009|Drug|C-82 Topical Gel, Placebo|placebo
1584666|NCT02348996|Other|Bioimpedance|status of overhydration determine by BCM once a week to determine dry weight
1584667|NCT02348996|Other|Clinical evaluation|Doctors or nurses will evaluate patients on a daily basis and determine dry weight
1584668|NCT02348983|Behavioral|Health Coaching via Telephone|Health coaching arm to assess feasibility of intervention among truck driving population. Coaching will be weekly with emphasis on both diet and physical activity. No medication or treatment devices are administered.
1584669|NCT02348970|Device|ONIRIS®|sleeping test
1584670|NCT02348970|Device|TALI|sleeping test
1584671|NCT02348944|Other|serum and urine sample|Serum and urine samples will be collected at baseline, weeks2, 16, 52 and 68 to assess intra-individual biological variability of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 / FIB3-1 and FIB3-2.
1584672|NCT02348931|Device|Use of customized nasal brace (Nasella) for nose deformities|
1584673|NCT02348931|Procedure|corrective surgery|
1584674|NCT02348918|Drug|Luminate 1.0mg|
1584675|NCT02348918|Drug|Luminate 2.0mg|
1584676|NCT02348918|Drug|Luminate 3.0mg|
1584677|NCT02348918|Drug|Avastin|
1584678|NCT02348918|Device|Focal laser photocoagulation|
1584679|NCT02348905|Drug|ACTHAR Gel 40 units twice weekly|ACTHAR Gel (adrenocorticotropic hormone) 40 units twice weekly between Baseline and week 12.
1584680|NCT02348905|Drug|ACTHAR Gel 80 units twice weekly.|ACTHAR Gel (adrenocorticotropic hormone) 80 units twice weekly between Baseline and week 12.
1584681|NCT02348892|Other|Coordinator|Patients in complex situation taken care by coordinator
1584682|NCT02348892|Other|Classic plan|Patients in complex situation taken care by classic plan
1584683|NCT02348879|Drug|AMG 403|AMG 403 is for treatment of subjects with chronic pain
1584684|NCT02348879|Drug|Placebo|contains no active drug
1584685|NCT02348866|Other|method of laundering and donning scrubs|
1584686|NCT02348853|Behavioral|Healthy Weight for Living (HWL)|
1584687|NCT02348853|Behavioral|Current Best Practice (CBP)|
1584688|NCT02348840|Device|mHealth|A cell phone that can capture data measurements from devices on blood pressure, oxygen level, the heart rate of pregnant women, and the heart rate of the baby.
1584689|NCT02348827|Behavioral|Family psychoeducation|
1584690|NCT02348827|Behavioral|Social support group|
1584691|NCT02348801|Behavioral|Weight loss and Exercise|"Group behavior therapy sessions designed to acquire positive weight-control skills and attitudes, and practice weight-maintenance skills. A balanced diet will be prescribed to provide a deficit of 500-750 kcal/day from daily energy requirement.
Exercise sessions of ~90 min duration 15 min warm-up of flexibility exercise, followed by ~30 min of aerobic exercise, and, after a brief rest period, ~30 min of resistance training, and finally ~15 min balance exercise) conducted three times weekly supervised at our exercise facility for first six months, and regular exercises continued at community-fitness centers and at home for the following six months."
1584692|NCT02348801|Behavioral|Healthy lifestyle|Diabetes support and education
1584693|NCT02348788|Drug|Artemether-lumefantrine + Primaquine|
1584694|NCT02348788|Drug|Chloroquine + Primaquine|
1584695|NCT02348775|Dietary Supplement|Cysteine (as n-acetylcysteine) and glycine|HIV patients will be studied before and after receiving cysteine and glycine
1584696|NCT02348762|Dietary Supplement|Cysteine (as n-acetylcysteine) and Glycine|Older subjects will be studied before and after receiving cysteine and glycine
1584697|NCT02348749|Radiation|18F-MFBG (meta-fluoro benzylguanidine)|Adult patients: about 8-12 mCi of 18F-MFBG will be administered intravenously. Pediatric patients: 12 mCi/1.7m2 IV (up to a maximum of 12mCi).
1584698|NCT02348749|Device|Positron emission tomography (PET) imaging|Dynamic imaging for the first 30 min over the chest and Whole body (WB) PET-CT scan. Imaging 2 (~1.0 - 2 hours post dose): Whole body (vertex to feet) PET-CT scan. Imaging 3 (~3-4 hours post dose): Whole body (vertex to feet) PET-CT scan.
1584699|NCT02348749|Other|Blood draws|Blood samples to be collected: at baseline, 5, 15, 30, 60, 90, 120 and 180 mins post injection on the day of administration. (Phase I only)
1584700|NCT02348736|Device|Time for tracheal intubation|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
1585564|NCT02342782|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
1584703|NCT02348710|Behavioral|Exercise OE workbook|The workbook will aim to make participants aware of the breadth and depth of OEs by first providing a global overview of the many and diverse positive outcomes breast cancer survivors may experience. Participants will then be asked to focus on the three OEs they would most like to experience. Each section of the OE guide contains activities to target specific OE dimensions. Importance will be increased through elaboration of why outcomes are important to the participant; and certainty will be increased by narrative messages from other breast cancer survivors and an oncologist. Accessibility will be increased by having the participant think about the association between exercise and its outcomes
1584704|NCT02348710|Behavioral|Diet workbook|The workbook will contain the same activities as the intervention workbook but be focused on diet instead of exercise.
1584705|NCT02348697|Biological|NOVOCART 3D|Autologous Chondrocyte Implantation
1584706|NCT02348684|Radiation|Radiation therapy groups|Radiation Therapy treatment between 2000 and 2007.
1584707|NCT02348671|Other|shear- force|19 Newton shear- force and 3,9 kPa pressure for half an hour
1584708|NCT02348658|Drug|TAK-536TCH|TAK-536TCH tablets
1584709|NCT02348645|Procedure|Spinal fusion|
1584710|NCT02348645|Procedure|Spinal decompression|
1584711|NCT02348632|Drug|JZP-110|
2008812|NCT03327038|Behavioral|Nurse Monitoring|Patient responses to the short questionnaires will be monitored by an IBD advanced practice nurse. The IBD nurse will determine if there are elevations in anxiety, depression, and disease activity over the intervention period. Based on patient responses to the short questionnaires, the nurse will follow-up with patients via email or telephone to address patient symptoms. If there are clinically important changes in the patients' disease activity the nurse may also arrange for the patients to receive expedited outpatient follow-up with their gastroenterologist.
1584715|NCT02348580|Behavioral|Child centered teaching of life-skills|The intervention includes five core components: (1) personal understanding and exploration, (2) rights and responsibilities, (3) savings and spending, (4) planning and budgeting, and (5) social and financial enterprise. The training and curriculum are both manualized. The curriculum is in English and is regionally specific (for Anglophone Africa) and has been contextualized for Rwanda. The minimum hours required by Aflatoun's fidelity guide is 20 hours which includes 10 hours of curriculum lesson and 10 hours of learning activities (savings groups, social and financial projects, club activities etc).
1584716|NCT02348567|Other|Unannounced hospital surveys|This is a cluster-randomised controlled trial performed at hospital level. We hypothesise that unannounced surveys produce less successful assessments of patient safety compared to announced surveys (conventional/control). This study defines less successful as less compliance with the included standards and performance indicators.
1584717|NCT02348567|Other|announced hospital surveys|
1584718|NCT02348554|Behavioral|Controlled conditions|The 13 volunteers in controlled conditions performed each of the nine activities several times according to the activity scenario: sitting, slow, normal and brisk walking, climbing and descending stairs (eight floors), standing, slow running and taking public transportation (tramway). The duration of each activity varied from 2 to 20 minutes.
1584719|NCT02348554|Behavioral|Free-living conditions|The spontaneous activities of 30 volunteers were recorded in the free-living conditions for a full day selected either during the week or the weekend.
1584720|NCT02348541|Device|CollaGUARD|
1584721|NCT02348528|Drug|Lenalidomide|
1584722|NCT02348528|Drug|Dexamethasone|
1584728|NCT02348489|Drug|SGI-110 (guadecitabine)|Investigational Medicinal Product
1584729|NCT02348489|Drug|Treatment Choice|Choice of one: cytarabine, decitabine, or azacitidine
1584730|NCT02348476|Other|No Intervention|No study drug is administered in this study.
1584731|NCT02348463|Drug|Clindamycin-2-phosphate|how many women will deliver before the 37th week of gestation
1584732|NCT02348450|Drug|Irinotecan|40mg
1584733|NCT02348450|Drug|Etoposide|5ml：0.1g
1584734|NCT02348450|Drug|Cisplatin|6ml：30mg
1584735|NCT02348437|Procedure|Repair|An on-going suture technique with minimum four stitches.
1584736|NCT02348437|Procedure|Non-repair|The PQ muscle will be placed so it covers the volar plate. No suture.
1584737|NCT02348424|Drug|Solithromycin|Cohorts 1 and 2 will receive a single 1000mg dose of solithromycin after a 12 hour overnight fast (water permitted). Solithromycin is a fluoroketolide antibiotic under investigation for oral and parenteral use and will be administered orally.
1584738|NCT02348411|Device|ExAblate|
1584739|NCT02348398|Drug|Pazopanib|600 mg by mouth daily in a 28 day cycle.
1584740|NCT02348398|Drug|Topotecan|0.25 mg by mouth daily for 21 days of a 28 day cycle.
1584741|NCT02348398|Behavioral|Phone Call|During follow up if disease gets worse, participant called by study staff every 3 months. Each call should last about 5 minutes.
1584742|NCT02348385|Drug|Amphetamine|Subjects will have 2 PET scans on the same day. Up to 3 hours before the second PET Scan, amphetamine (0.4mg/kg, orally) will be administered.
1584743|NCT02348372|Drug|GSK1278863A Placebo|Matching size, shape and color
1584744|NCT02348372|Drug|GSK1278863A|A round, biconvex, white film coated tablet
1584745|NCT02348359|Drug|X-82|
1584746|NCT02348359|Drug|Anti-VEGF|
1584747|NCT02348359|Drug|Placebo|
1584748|NCT02348346|Other|MVX (titanium dioxide)|The investigators have designed a prospective pre-post evaluation time-based pilot study addressing the microbial colonization of surfaces in four rooms of the ICU before and after coating with titanium dioxide (MVX). During a pre-intervention period cultures will be taken every 7 days from 10 prespecified and marked sites per room for a total duration of 4 weeks (sink, wall, floor, bed rail, door handle, ceiling, keyboard patient room, nurse call button, bedside table and monitor arm). After coating of the rooms with MVX another 4 weeks observation period will be used to gather samples in the post-intervention period.
1584749|NCT02348333|Drug|FYU-981, (Oral daily dosing for 7 days)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
1585565|NCT02342782|Other|Laboratory Biomarker Analysis|Correlative studies
1584750|NCT02348333|Drug|Placebo, (Oral daily dosing for 7 days)|Subjects randomized to the placebo arm receive placebo.
1584751|NCT02348320|Biological|Personalized polyepitope DNA vaccine|
1584752|NCT02348307|Drug|FYU-981, (Oral single dosing)|Subjects randomized to the FYU-981 arm receive active drug, FYU-981.
1584753|NCT02348307|Drug|Placebo, (Oral single dosing)|Subjects randomized to the placebo arm receive placebo.
1584754|NCT02348294|Other|Shear- force 19 newton and 3,9 kpa pressure for half an hour|
1584755|NCT02348281|Drug|Bicalutamide|150mg, po, qd, d1-28
1584756|NCT02348268|Other|Manual Therapy|The manual therapy techniques included: (i) anterior-posterior and side-shift of the cervical spine; (ii) muscle energy technique involving side-bending of cervical spine; (iii) neuromuscular technique for restricted C1-C2 rotation; (iv) inhibitive occipital distraction; and (v) cervical stretching: post-isometric relaxation for the upper trapezius, scalene and sternocleidomastoid muscles.
1584757|NCT02348268|Other|Myofascial Release Therapy|The myofascial release therapy techniques included: (i) cranial base release, adjusting the relation of the rectus capitis posterior muscles to the dura mater; (ii) gross release of the sternocleidomastoid muscle; (iii) release of the suprahyoid and infrahyoid muscles; and (iv) release of the retrohyoid fascia.
1584758|NCT02348268|Device|Analgesic therapy|Analgesic therapy consisted of superficial thermotherapy by an infrared lamp (Infra 2000, Enraf Nonius) and TENS (TENSMED 911, Enraf Nonius). The 250-watts infrared lamp was focused at a distance of 50 cm on the cervical area for 15 minutes. TENS employed 80 Hz frequency, 150 µs pulse duration, with 50x50 mm electrodes (Gel-Trode, Enraf Nonius) placed on the painful or metamers areas for 20 minutes.
1584759|NCT02348255|Procedure|Electric Field Therapy|Undergo NovoTTF-100A
1584760|NCT02348255|Biological|Bevacizumab|Given IV
1584761|NCT02348255|Drug|Carmustine|Given IV
1584762|NCT02348255|Other|Quality-of-Life Assessment|Ancillary studies
1584763|NCT02348242|Device|Aqueous Gel|1 drop of Dexpanthenol® 0.2% aqueous gel in the eye every 6 hours
1584764|NCT02348242|Device|Eyelid Occlusion Dressing|Eyelid occlusion using pro-ophta® eyelid occlusion dressing, dressing to be verified every 6 hours and replaced daily
1584765|NCT02348242|Device|Artificial Tears|1 drop of Phylarm® artificial tears in the eye every 6 hours
1584766|NCT02348229|Procedure|ERAS protocols|Normal meal allowed until 6 h before surgery and Carbohydrate drink until 2 h before surgery
1584767|NCT02348229|Procedure|ERAS protocols|No bowel preparation
1584768|NCT02348229|Procedure|ERAS protocols|No nasogastric placement; if used, remove on the 1st postoperative day
1584769|NCT02348229|Procedure|ERAS protocols|Vasoactive drugs used if need be
1584770|NCT02348229|Procedure|ERAS protocols|Temperature management
1584771|NCT02348229|Procedure|ERAS protocols|Intra-abdominal drains not to be used
1584772|NCT02348229|Procedure|ERAS protocols|Intraperitoneal Ropivicaine infusion
1584773|NCT02348229|Procedure|ERAS protocols|"On the 1st postoperative day Nasogastric catheter removed /Urinary catheter removed.
Oral non‐opioid analgesia/Drinking 0.5L liquid. Active mobilisation"
1584774|NCT02348229|Procedure|ERAS protocols|On the 2nd postoperative day：Drains removed Oral diet was initiated
1584775|NCT02348229|Procedure|ERAS protocols|3-4th postoperative day： Stop oral non opioid analgesia
1584776|NCT02348229|Procedure|ERAS protocols|On the5-6th postoperative day Check discharge criteria
1584777|NCT02348229|Procedure|conventional pathway group|No solid foods at dinner before surgery and no liquids 12 h before surgery. Routine bowel preparation Nasogastric placement on the morning of surgery
1584778|NCT02348229|Procedure|conventional pathway group|Routine use of anesthesia medicine. Standard 5-trocar laparoscopy-assisted procedure. I.V. fluids not restricted (Ringer's lactate 20 ml/kg in the first hour, then at the rate of 10-12 ml/kg/h) Routine use of abdominal drainage tubes and placement of catheters.
1584779|NCT02348229|Procedure|conventional pathway group|1st postoperative day: Keep Nasogastric catheter Removal of urinary catheter Opioid analgesic by intramuscular injection Parenteral nutrition until flatus. I.V. fluids not restricted Mobilization in bed
1584780|NCT02348229|Procedure|conventional pathway group|2nd postoperative day Patient is advised to get out of bed until 24-48h after surgery
1584781|NCT02348229|Procedure|conventional pathway group|3-4th postoperative day： Remove nasogastric tube after flatus Oral liquids started. Encouraged to walk in the ward.
1584782|NCT02348229|Procedure|conventional pathway group|"5-6th postoperative day：Oral diet was changed from liquids to semi-fluids and normal food.
Drains removed"
1584783|NCT02348216|Biological|KTE-C19|
1584784|NCT02348203|Drug|Aspirin|Given PO
1584785|NCT02348203|Other|Laboratory Biomarker Analysis|Correlative studies
1584786|NCT02348203|Other|Placebo|Given aspirin placebo PO
1584787|NCT02348203|Other|Placebo|Given zileuton placebo PO
1584788|NCT02348203|Drug|Zileuton|Given PO
1584789|NCT02348190|Other|Lipid/heparin|"32 healthy volunteers will undergo euglycemic - hyperinsulinemic clamping without radioactive isotopes and with (n=16) and without (n=16) lipid/heparin co-infusion for 8 hours.
Serial (at 0, 1, 2 and 4 h) muscle and fat biopsies and serial blood samples (q' 1 h) will be obtained. The following measurements will be obtained in muscle biopsies and T-cell extracts: PKC-βI and II and PKC-δ, IKK, IκB-α, NFκB, IRS-1 tyrosine phosphorylation, IRS-1 associated PI3- kinase, ICAM, VCAM and e-selectin mRNAs."
1584790|NCT02348177|Drug|lopinavir with ritonavir in 1:1 ratio|During co-treatment of rifampicin containing tuberculosis treatment and lopinavir/ritonavir (4:1) based therapy, additional ritonavir is given to make lopinavir/ritonavir 1:1 ratio
1584791|NCT02348177|Drug|Lopinavir/ritonavir 4:1|This is the conventional dosing of LPV/r 4:1 for HIV when TB treatment has not been started or has been stopped
1584792|NCT02348164|Other|Pink grapefruit first followed by tangerines two weeks later|A 504 gram serving of pink grapefruit was fed as a single meal followed by 234 grams tangerines two weeks later
1584793|NCT02348164|Other|Tangerines first followed by pink grapefruit two weeks later|A 234 gram serving of tangerines was fed as a single meal followed by 504 grams pink grapefruit two weeks later
1584794|NCT02348151|Other|Treadmill|The volunteers will perform the shuttle walk test on the treadmill
1584795|NCT02348151|Other|Corridor|The volunteers will perform the shuttle walk test on the corridor
1585566|NCT02342782|Other|Pharmacological Study|Correlative studies
1584796|NCT02348138|Other|Isometric handgrip training|The two experimental groups (HBT and ST) will receive intervention with isometric handgrip exercise for 12 weeks, and the HBT group without daily supervision.
1584797|NCT02348125|Drug|Mitochondrial Cocktail|
1584798|NCT02348112|Device|Altis Sling|Altis is a minimally invasive, adjustable incontinence sling that is placed through a single incision in the vaginal wall and anchored inside the body. The sling has an integrated tensioning system eliminating the need for additional skin exits.
1584799|NCT02348112|Device|Transobturator or Retropubic Sling|Both transobturator and retropubic slings are a hammock-like mesh placed underneath the urethra to provide support. A single incision is made in the vaginal wall and two incisions in the abdomen. Tensioning of the sling is achieved by pulling the sling through the abdominal incisions.
1584800|NCT02348099|Other|Ultrasound|Abdomen scanned with portable ultrasound to determine presence of subclinical lipohypertrophy.
1584801|NCT02348073|Drug|Vayarin®, supplementation of n-3 PUFA|"Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
At the end of this period, active product will be continued, at the same dose, for a 12 week-open label period. All patients will be administered the active product."
1584802|NCT02348073|Drug|PLACEBO|Two capsules will be swallowed twice daily, 20 to 30 minutes prior to breakfast and dinner, during 12 weeks, between visit 1 and visit 2.
1584803|NCT02348047|Device|Hamilton T1|
1584804|NCT02348034|Device|Prevena Dressing|Prevena dressing will be applied to the closed surgical wound after the elective colorectal surgery to evaluate its ability to reduce surgical site infections.
1584805|NCT02348021|Procedure|Percutaneous coronary intervention (PCI)|
1584806|NCT02348021|Drug|Dual Anti Platelet Therapy|All patients will receive Dual Anti Platelet Therapy for one month
1584807|NCT02348008|Drug|MK-3475|Arm A: Phase 1b Cohort 1: 200mg IV; Arm A: Phase 1b Cohort 2: 200mg IV
1584808|NCT02348008|Drug|Bevacizumab|Arm A: Phase 1b Cohort 1: 10mg IV; Arm A: Phase 1b Cohort 2: 15mg IV
1584809|NCT02348008|Drug|MK-3475|Arm B: Phase II Treatment: 200mg IV
1584810|NCT02348008|Drug|Bevacizumab|Arm B: Phase II Treatment: administered at the maximum safe dose of 5mg or 10mg as established in the Phase 1b dose escalation cohort study.
1584811|NCT02347995|Other|Protein|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl. This group will drink a beverage containing protein after each training session.
1584812|NCT02347995|Other|Placebo|This training is designed to target the major muscle groups of the leg. Resistance training will be completed through a combination of lower extremity machines and complemented by whole body exercises such as squatting. The lower extremity machines include leg press, leg extension, and leg curl.This group will drink a placebo beverage after each training session.
1584813|NCT02347969|Dietary Supplement|X34|Dietary supplement named X34
1584814|NCT02347956|Procedure|Reduced port robotic distal gastrectomy|
1584815|NCT02347930|Other|kidney ultrasound|kidney ultrasound
1584816|NCT02347917|Drug|BBI608|480 mg orally twice daily (960 mg total daily dose)
1584817|NCT02347917|Drug|Pemetrexed|500 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for cycle 1, in which Pemetrexed will be given on Day 3).
1584818|NCT02347917|Drug|Cisplatin|75 mg/m2 I.V. infusion on Day 1 of each treatment cycle (except for Cycle 1, in which Cisplatin will be given on Day 3).
1584819|NCT02347904|Drug|S-1 and Oxaliplatin|Six courses of oxaliplatin (130 mg/m2) intravenously on day 1 and S-1 (25 mg/m2 b.i.d.) orally from day 1 to 14 every 3 weeks, starting within 12 weeks after esophagectomy
1584820|NCT02347891|Drug|Belimumab|Randomized phase: Week 0 - Week 36
1584821|NCT02347891|Drug|Placebo|Randomized phase: Week 0 - Week 36
1584822|NCT02347878|Drug|Aprepitant|use aprepitant 1 hour before lumbar puncture and intrathecal treatment
1584825|NCT02347852|Drug|Regorafenib (Stivarga, BAY73-4506)|Stivarga is available as tablets (40 mg). It is taken in four-week treatment cycles at a recommended starting dose of 160 mg once every day for three weeks, followed by a week off.
1584827|NCT02347813|Drug|Pioglitazone|15 mg of pioglitazone orally for 2 weeks, and if well tolerated, 30 mg pioglitazone orally for 5 1/2 months.
1584828|NCT02347787|Behavioral|IMPaCT|"The IMPaCT intervention has three stages:
Goal-setting: CHWs will help patients to deconstruct the chronic disease management goal they set with their PCP into patient-driven short-term goals and action plans.
Tailored Support: CHWs will conduct weekly follow-up for 6 months through either telephone or home visit in order to support the achievement of patients' short-term goals.
Connection with longitudinal support: IMPaCT CHWs will also facilitate a weekly patient support group."
1584829|NCT02347787|Other|Usual care|
1584830|NCT02347774|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow (R) Closed System (CS) nebulizer
1584831|NCT02347774|Drug|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg BID eFlow (R) Closed System (CS) nebulizer
1584832|NCT02347774|Drug|Placebo eFlow (CS) nebulizer|Placebo BID eFlow (R) Closed System (CS) nebulizer
1584833|NCT02347761|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 50 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
1584834|NCT02347761|Drug|SUN-101 25 mcg BID eFlow (CS) nebulizer|SUN-101 25 mcg twice daily (BID) eFlow Closed System (CS) nebulizer
1584835|NCT02347761|Drug|Placebo BID eFlow Closed System (CS) nebulizer|Placebo twice daily (BID) eFlow Closed System (CS) nebulizer
1584836|NCT02347748|Behavioral|Reading pre-procedure script|Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area
1584837|NCT02347748|Behavioral|Reading pre-extubation script|Patients will be read a comfort talk script before extubation
1584838|NCT02347748|Behavioral|Reading 2 scripts|"Patients will be read a pre-procedure comfort talk script in the pre-procedure work-up area.
Patients will be read a comfort talk script before extubation"
1584839|NCT02347735|Other|No interventions, only data collection|Only data is collected from the subjects in both groups.
1584840|NCT02347709|Procedure|Diabetic Foot Ulcer Biopsy|Specimens from both the wound edge and a distal area of skin of patients will be obtained via 3 mm punch biopsy in the Winthrop University Hospital Wound Care Center. Biopsies will be collected from the wound edge prior to routine debridement using the following standard procedures, including the use of anesthetic if needed.
1584841|NCT02347709|Other|Survey|Study subjects from all three groups will be asked to complete a one-page Focused Neuropathy Evaluation. Providers will complete a one-page Focused Neuropathy Evaluation and a complete neurological examination and sensation assessment.
1584842|NCT02347709|Other|Comprehensive Neuropathy Assessment|Standard Monofilament Exam, Vibration Assessment, and Temperature Assessment will be performed on all patients in all study groups.
1584843|NCT02347709|Other|Wound Photography|Digital photographs and wound measurements for patients in Study Group 1 will be obtained per standard protocol at baseline and all subsequent visits.
1584844|NCT02347696|Behavioral|Control|Subjects will follow a diet based on INRAN guidelines without doing any physical activity.
1584845|NCT02347696|Behavioral|LGIMD|Subjects will follow a Low Glycemic Index Mediterranean Diet (LGIMD) without doing any physical activity.
1584846|NCT02347696|Behavioral|Endurance Activity (EA)|"Subject will follow a program of endurance activity as follows:
Frequency: 3 times/week Duration: 60 minutes
Intensity:
weeks 1-4: 14.2 kcal*kg-1*week-1;
weeks 5-8: 18.9 kcal*kg-1*week-1;
weeks 9-12: 23.6 kcal*kg-1*week-1."
1584847|NCT02347696|Behavioral|EA+Resistance Training (RT)|"Subject will follow a program of endurance activity as follows:
Frequency: 3 times/week Duration: 60 minutes
Intensity (for Endurance activity):
weeks 1-4: 14.2 kcal*kg-1*week-1;
weeks 5-8: 18.9 kcal*kg-1*week-1;
weeks 9-12: 23.6 kcal*kg-1*week-1.
Resistance activity:
Muscolation: Training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutes and legs);
Progression: increase of 1-2.5 kg*week-1
Training of all muscle groups in the same session"
1584848|NCT02347696|Behavioral|LGIMD+EA|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of endurance activity.
1584849|NCT02347696|Behavioral|LGIMD+EA/RT|Subjects will follow a Low Glycemic Index Mediterranean Diet together with a program of both endurance activity and resistance training.
1584850|NCT02347670|Behavioral|Efficacy-patient navigator to improve follow-up adherence|Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day. With assistance from the patient navigator, participants will receive assistance with scheduling appointments, arranging transportation, reminder letters, and referral s for ocular care.
1584851|NCT02347670|Behavioral|Office-Based Usual Care|"Over the course of 1 year, a 6-person team comprised of one attending physician ; ophthalmic technicians, project managers/community health educators , and patient navigators will complete a baseline eye examination visit, baseline assessment, and 2-3 follow-up visits. The equipment will occupy a designated location at each site for 1 to 2 days, from 9 a.m. to 3 p.m., with at least 15 eye examinations performed each day.
This intervention group will receive a phone number to schedule an appointment. Participants in the usual-care group who have scheduled an appointment will receive an automated phone call similar to the standard appointment-reminding procedure used at the Wills Eye Hospital."
1584852|NCT02347657|Drug|VX-661/ ivacaftor|
1584853|NCT02347657|Drug|ivacaftor|
1584854|NCT02347657|Drug|VX-661/ ivacaftor placebo|
1584855|NCT02347657|Drug|ivacaftor placebo|
1584856|NCT02347644|Behavioral|Brief Motivational Interview|"Motivational interviewing is a technique which aims to be both non-judgmental and non-confrontational. Its success depends largely on the presentation of objective feedback based on information provided by an individual. The technique involves acknowledgement that individuals who attend a counselling session, assessment or prevention program may be at different levels of readiness to change their alcohol consumption patterns, including:
No perception of any alcohol consumption problem
Realization of alcohol consumption problem with no corresponding action"
1584857|NCT02347631|Device|Soft Contact Lens - Daily Disposable Alcon Dailies Total 1|Soft contact lens - Daily wear disposable to correct myopia in subjects who are nearsighted. Comparison of Alcon Dailies Total 1 versus Acuvue TruEye when worn as daily disposables over a two month period. This is a cross-over project where both lenses will be worn by participant over the course of the study. The order of randomization will differ for each participant. There is a washout period in between earch contact lens wearing schedule.
1584858|NCT02347631|Device|Acuvue TruEye|
1584859|NCT02347618|Radiation|Preoperative SBRT|This will be a Phase 2, single center, prospective, single arm feasibility study of the use of stereotactic body radiotherapy (SBRT) for the preoperative treatment of surgically resectable pancreatic adenocarcinoma.
1584862|NCT02347592|Device|Self-locating Catheter|Procedure/Surgery necessary if obstruction occurs
1584863|NCT02347592|Device|straight Tenckhoff|Procedure/Surgery necessary if obstruction occurs
1584864|NCT02347566|Behavioral|Physical activity enhancing programme|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor with set targets and feedback. They will have access to a web coaching programme. Their physical activity targets will be updated on a weekly basis in order to enhance their physical activity.
1584865|NCT02347566|Other|Usual care|COPD patients performing pulmonary rehabilitation will wear the DirectLife activity monitor without set targets and/or feedback. They will not have access to a web coaching programme.
1584866|NCT02347553|Other|This is not an interventional study|Participants will act as their own controls and will undergo the study procedure once in a hypoglycaemic state and once in a euglycaemic state. Therefore there is no intervention being studied as such.
1584867|NCT02347527|Behavioral|Active Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of positive or negative valence.
1584868|NCT02347527|Behavioral|Control Implicit Priming|A 10-minute implicit priming intervention, associating food images with images of neutral valence.
1584869|NCT02347514|Behavioral|Diabetes group visit|
1584870|NCT02347501|Drug|Sitagliptin (Januvia)|Sitagliptin 100mg tablet once daily (or 50mg once daily for participants with moderate kidney disease) for twenty four weeks in patients due to undergo NBUVB light therapy.
1584871|NCT02347488|Device|Haider ETT Tube Holder and Bite Guard|Surgery patients will have endotracheal tubes secured with a novel combined endotracheal tube holder and bite guard change in ETT tip position caused by traction up to 15N was measured prior to surgery.
1584872|NCT02347488|Procedure|Tape|Surgery patients will have endotracheal tubes secured with adhesive tape, as the current clinical procedure; change in ETT tip position caused by traction up to 15N measured prior to re-securing the ETT with the Haider device.
1584873|NCT02347475|Other|Observational Study|Ultrasound and NIRS
1584874|NCT02347462|Device|Bilevel Positive Airway Pressure (BiPAP) (Trilogy BiPAP, Philips Respironics)|Children in the intervention group will receive BiPAP (Trilogy, Philips Respironics; spontaneous trigger mode) via a nasal or full face mask. End expiratory positive airway pressure (EPAP) will be set at 5cm H20. Inspiratory positive airway pressure (IPAP) will be titrated to achieve a tidal volume of 6 - 9 ml/kg. These settings will remain unchanged throughout the study period.
1584875|NCT02347462|Other|Standard care|Standard care according to the hospital severe asthma protocol
1584876|NCT02347449|Other|Questionnaires, Oncotype Dx Assay|"Physician pre-assay questionnaire
Patient pre-assay questionnaire
Oncotype DX® Assay
Physician post- assay questionnaire
Patient post-assay questionnaire"
1584877|NCT02347436|Procedure|24-hr ambulatory blood pressure measurement|
1584878|NCT02347423|Biological|Primary series of immunisation comprised by 3 vaccinations IPV-Al SSI|
1584879|NCT02347423|Biological|IPV Vaccine SSI|
1584880|NCT02347410|Device|SIFS graft containment device|The SIFS mesh is a graft containment and reinforcement device. Following conventional thorough discectomy, the disc space is entered through a small portal in the annulus, the SIFS mesh is introduced, deployed and then filled with bone graft. Bilateral commercially available posterior lumbar fixation is applied.
1584881|NCT02347397|Device|SS Bipolar Head + SL-TWIN Stem|Subject will undergo hemiarthroplasty surgery with SS Bipolar Head & SL-TWIN Stem
1584882|NCT02347397|Device|Bipolar Head + SL-PLUS Stem|Subject will undergo hemiarthroplasty surgery with Bipolar Head & SL-PLUS Stem
1584883|NCT02347384|Device|Delta PLUS Femoral Head + SL-TWIN Stem|Subject will undergo total hip arthroplasty with Delta PLUS Femoral Head & SL-TWIN Stem
1584884|NCT02347384|Device|BIOLOX forte ball head + SL-PLUS Stem|Subject will undergo total hip arthroplasty with BIOLOX forte ball head & SL-PLUS Stem
1584885|NCT02347358|Device|JRecanTM blood FR device|JRecanTM blood flow recanalisation device
1584886|NCT02347358|Drug|IV r-tPA|intravenous recombinant human tissue plasminogen activator
1584887|NCT02347345|Drug|Harvoni (Fixed dose combination ledipasvir/sofosbuvir)|Harvoni, one pill daily x 12 weeks
1584888|NCT02347332|Drug|vinflunine|
1584889|NCT02347332|Drug|Methotrexate|
1584890|NCT02347319|Drug|Pennel|Pennel 2 Tablet, Legalon Placebo 1 tablet, Tid
1584891|NCT02347319|Drug|Legalon|Pennel Placebo 2 Tablet, Legalon 1 tablet, Tid
1584892|NCT02347319|Drug|Placebo|Pennel Placebo 2 Tablet, Legalon Placebo 1 tablet, Tid
1584893|NCT02347306|Other|Telephone interview|
1584894|NCT02347293|Other|High levels of indigestible carbohydrates|
1584895|NCT02347293|Other|Low levels of indigestible carbohydrates|
1584896|NCT02347280|Procedure|Loop Ileostomy with colonic lavage|creation of a loop ileostomy, intraoperative colonic lavage with warmed polyethylene glycol via the ileostomy and postoperative antegrade instillation of vancomycin flushes into the diseased colon via the ileostomy
1584897|NCT02347280|Procedure|Total Abdominal Colectomy with end ileostomy|Removal of entire colon with preservation of rectal stump and construction of end ileostomy
1584898|NCT02347267|Behavioral|Caloric and non-caloric SSBS reduction|Isocaloric individualized diet and sweetened caloric and non-caloric beverages restriction
1584899|NCT02347267|Behavioral|Caloric SSBS reduction|Isocaloric individualized diet and caloric SSBS restriction
1584900|NCT02347254|Device|Transcranial ExAblate|Transcranial ExAblate MRgFUS
1584901|NCT02347241|Other|Educational intervention|Educational Debriefings and High frequency training and team reflection
1584902|NCT02347228|Drug|OB318 capsule|Oral qd, at least 30 minutes before breakfast
1584903|NCT02347215|Other|Quality of Life assessment|Seattle Angina Questionnaire and other questionnaires.
1584904|NCT02347215|Procedure|Stress imaging|Stress imaging
1584905|NCT02347202|Other|Online counseling via Zoom teleconferencing|
1584906|NCT02347202|Other|Telephone support as needed|
1584908|NCT02347176|Other|Placebo|Subcutaneous injection with placebo
1584909|NCT02347176|Biological|Tralokinumab Dose 1|Subcutaneous injection with tralokinumab
1584910|NCT02347176|Biological|Tralokinumab Dose 2|Subcutaneous injection with tralokinumab
1584911|NCT02347176|Biological|Tralokinumab Dose 3|Subcutaneous injection with tralokinumab
1584912|NCT02347163|Drug|Zoledronate|Patients fulfilling the eligibility criteria will be registered using a centralized system and will receive a pre-operative, single administration of zol (4mg i.v.), 7 days before definitive breast surgery .
1584913|NCT02347137|Other|step-reduction|reduce daily physical activity to less than 1500 steps per day
1584914|NCT02347137|Other|step-reduction plus resistance exercise|reduce physical activity to less than 1500 steps per day with thrice weekly low-load, high effort resistance exercise
1584915|NCT02347124|Behavioral|Usual Care Control|Standard quitline counseling and other treatment materials provided through each participating state quitline program + a series of text messages with general health promotion tips.
1584916|NCT02347124|Behavioral|Enhanced Intervention|Standard quitline counseling and other materials provided through each participating state quitline program + oral health-focused counseling + oral health focused text messages + access to additional oral health educational content (website and written materials) + oral health tools (toothbrush, dental floss)
1584917|NCT02347111|Drug|Flecainide|flecainide up to 150mg twice daily for the control of atrial fibrillation
1584918|NCT02347111|Drug|Sotalol|sotalol up to 120mg twice daily for the control of atrial fibrillation
1585621|NCT02342366|Drug|GHB 35 mg/kg p.o.|GHB 35 mg/kg p.o.
1584919|NCT02347098|Procedure|Percutaneous coronary intervention|Widening of coronary arteries using balloons or stents.
1584920|NCT02347098|Procedure|Intravascular ultrasound with virtual histology|IVUS-VH allows for the identification of discrete plaque components using radiofrequency backscatter data. The technology can visualize the coronary artery wall and measure atherosclerosis volume.
1584921|NCT02347098|Drug|Atorvastatin or other equivalent dose statin|40-80mg oral daily dose of Atorvastatin or other equivalent dose statin to lower LDL in blood.
1584922|NCT02347098|Device|LDL-apheresis|The device used in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. A filter separates plasma from whole blood, the Liposorber -columns remove LDL from the plasma. The system recombines plasma and blood cells and returns them into the patient's body. This procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
1584923|NCT02347085|Drug|GFF MDI (PT003)|
1584924|NCT02347085|Drug|Placebo MDI|
1584925|NCT02347072|Drug|GFF MDI (PT003)|
1584926|NCT02347072|Drug|Placebo MDI|
1584927|NCT02347072|Drug|Spiriva® Respimat® (Tiotropium Bromide)|Tiotropium Bromide Inhalation Solution; Spiriva® Respimat® (Spiriva)
1584928|NCT02347059|Drug|L-dopa|Antiparkinsonian medication
1584929|NCT02347059|Drug|Dopamine Agonists (pramipexole, ropirinole)|Antiparkinsonian medication
1584930|NCT02347046|Drug|FYU-981, (Oral single dosing)|FYU-981, (Oral single dosing)
1584931|NCT02347033|Drug|Sertraline|"Sertraline will be prescribed by the patients' GP, starting at 25mg daily for 1-2 weeks and increasing to 50mg daily if tolerated. The GP should review the patient within the first 2 weeks, checking for acceptability, concordance and any side-effects, with further reviews at 6 and 12 weeks. We expect the usual treatment dose to be 50 to 100mg daily, although some may require 150mg.
We will suggest that the GPs use their usual procedures to review the patient's progress, asking about and noting functional change as well as clinical improvement. Minimal improvement after 12 weeks at a maximal tolerated dose should prompt consideration of change of treatment. If there has been an adequate therapeutic benefit there should be further review at 26 and 52 weeks."
1584932|NCT02347033|Behavioral|Cognitive Behavioural Therapy|"CBT will consist of 14 (+ / - 2) weekly 50-minute sessions and will cover 6 treatment modules: psychoeducation and worry awareness training; re-evaluation of the usefulness of worry; uncertainty recognition and behavioural exposure; problem-solving training; written exposure; and relapse prevention.
Sessions will be digitally recorded and a random 10% assessed for quality (fidelity to the manual and therapist competence) by an independent external assessor according to pre-specified criteria. Patient consent for this will be obtained as part of obtaining informed consent."
1584933|NCT02347020|Behavioral|Normal Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0000-0800 h, with meals at 1, 5, 11, and 12.5 (snack) h after awakening every day for 5 days. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
1584934|NCT02347020|Behavioral|Normal Sleep/ Late Meal|The subject will be inpatient for 5 days and sleep between the hours of 0000-0800 h,with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
1584935|NCT02347020|Behavioral|Late Sleep/ Normal Meal|The subject will be inpatient for 5 days, and sleep between the hours of 0330-1130 h, with controlled meals at 1, 5, 11, and 12.5 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
1584936|NCT02347020|Behavioral|Late Sleep/ Late Meal|The subject will be inpatient for 5 days, and sleep between the hours o 0330-1130 h, with controlled meals at 4.5, 8.5, 14.5, and 16 (snack) h after awakening. On night 3, we will insert a catheter in the participant's arm to facilitate multiple blood sampling overnight and the next day. On d 4, at the scheduled breakfast time, a frequently sampled i.v. glucose tolerance test (FSIVGTT) will be performed. A MTT will be performed at the scheduled lunch. At 1 h before dinner, participants will undergo fMRI scanning to assess neuronal responses to food stimuli and to examine functional connectivity with reward circuitry. On d 5, participants will be allowed to determine their own food intake at the scheduled meal and snack times. Participants will be discharged upon awakening on day 6.
1584937|NCT02347007|Dietary Supplement|Almond|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from almonds daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily almond supplement as a mid-afternoon snack and the rest at a meal of their choice.
1584938|NCT02347007|Dietary Supplement|Cereal Bar|Participants will be randomized to consume approximately 17.5% of their estimated energy requirements from cereal bars daily for 24 weeks. Prescribed energy requirements will be determined for each participant individually using the Mifflin St Jeor Equation equation with an activity factor of 1.3. Participants will be asked to consume half of their daily cereal bar supplement as a mid-afternoon snack and the rest at a meal of their choice.
1585622|NCT02342366|Drug|GHB 20 mg/kg p.o.|GHB 20 mg/kg p.o.
1584939|NCT02346994|Dietary Supplement|Melt Test Blend 3.2|Participant will be given a standard breakfast (containing 20 g of fat from test blend 3.2) to consume over a 10-min period. Test blend 3.2 will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
1584940|NCT02346994|Dietary Supplement|Corn Oil|Participant will be given a standard breakfast (containing 20 g of fat from corn oil) to consume over a 10-min period. Corn oil will be provided in test muffins. The test breakfast will provide 35% of the participant's daily energy requirements, estimated using the Schofield equation. The muffin will provide 450 kcal, and the rest of the energy will be in the form of fat free yogurt, up to 140 kcal, and applesauce.
1584941|NCT02346981|Behavioral|Resistance training|Supervised resistance training program was performed on three nonconsecutive days per week at morning period for 12 weeks. The resistance training program included eight exercises in two consecutive sets of 10-15 repetitions until moderate fatigue, except for crunch exercise which was performed on 20 to 30 repetitions without overload. The participants were instructed to perform repetitions at a ratio of 1:2 (concentric and eccentric phases, respectively). Subjects rested for 60- to 90-s between each set and for 2- to 3-min between each exercise. Each subject was individually supervised. Increases of 2-5 % for the upper limb exercises and 5-10 % for the lower limb exercises every time that subjects were able to complete 15 repetitions in both sets.
1584943|NCT02346955|Biological|CM-24 (MK-6018)|humanized IgG4 (kappa) isotype monoclonal antibody against CEACAM1 by intravenous (IV) infusion
1584944|NCT02346955|Biological|Pembrolizumab (MK-3475)|200 mg of Pembrolizumab by IV infusion
1584945|NCT02346929|Other|ultrasound guide|Patients randomized to this arm will have the hematoma block of the distal radial fracture with the guidance of a bedside ultrasound
1584946|NCT02346916|Drug|Capsaicin|1 inch ribbon of Capzasin-HP 0.1% will be applied to the forearm for 30 minutes
1584947|NCT02346903|Drug|Capsaicin|one inch ribbon of Capzasin -HP applied to forearm for 30 minutes
1584948|NCT02346890|Drug|AZD1722|
1584949|NCT02346890|Drug|Renvela|
1584950|NCT02346877|Behavioral|Personalized Patient Counselling|In the interventional cohort participants enrolled on the study will receive personalized patient counselling using the IMS-model based on the baseline BMQ results through a patient assistance program for patients on Enbrel (Etanercept) therapy.
1584951|NCT02346864|Behavioral|Three-stair-position|Infants in the TSP group received three-stair-prone position. Implementation steps were as following: 1) produced pad of three-stair-prone position the total height of which should be the same height as the head elevated 15 °. 2) Placed the infants on the pad with head on the highest ladder, chest on the second step and leg on the third step, bending the knees to the chest
1584952|NCT02346864|Behavioral|Head elevated tilt position group|Infants in the HETP group were allowed head up 15 ° prone position using a protractor with head to one side, arms against the sides of the body naturally bending, knees bent to the chest.
1584953|NCT02346851|Procedure|Functional Electrical Stimulation (FES) treatment|This study is randomized controlled trial performed by Random permuted blocks. This study has 2 experimental groups and 1 control group. Both experimental group receive FES treatment of their posterior deltoid and supraspinatus. Experimental group 1(Acceleration group) uses Novastim CU FS1 once a day for 30 minutes during 3 weeks. During treatment patient give a maximal effort for shoulder abduction. Experimental group 2 (Convention group) receive cyclic FES treatment for reducing shoulder subluxation. All patients have evaluation pre-intervention, post-intervention, 3 weeks after intervention and 9 weeks after intervention including physical examination and x-ray.
1584954|NCT02346838|Dietary Supplement|Inulin|The treatment will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
1584955|NCT02346838|Dietary Supplement|Placebo|The placebo will be mixed in orange juice or other beverage and will be consumed at breakfast each day in our metabolic kitchen.
1584956|NCT02346825|Behavioral|Neurorehabilitation therapy with cast|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing a full-arm cast on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
1584957|NCT02346825|Behavioral|Neurorehabilitation therapy with splint|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks while wearing part-time splint on their stronger arm and hand. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
1584958|NCT02346825|Behavioral|Neurorehabilitation bimanual|Children in this group will have 3 hours of daily therapy each weekday for 4 weeks will not wear a constraint. Parents will be required to do 45 minutes of daily therapy for which they will be trained.
1584959|NCT02346812|Other|Controlled diet without brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
1584960|NCT02346812|Other|Controlled diet with brassica vegetables|Participants will be fed a controlled diet containing foods of a typical American diet.
1584961|NCT02346799|Behavioral|Workout Window Reminders|Participants will receive emails at prespecified times reminding them to exercise, either during a specific two hour window or at any time during the day.
1584962|NCT02346799|Behavioral|Individual Workout Incentive Payment|Participants will be paid $3 or $7 for each workout completed during the appropriate times.
1584963|NCT02346799|Behavioral|Lump Incentive Payments|Participants will receive $20 payments for completing post treatment survey.
1584964|NCT02346799|Behavioral|Partner Assignment|"Participants will be required to have same workout window as partners."
1584965|NCT02346786|Dietary Supplement|eau minérale d'Aix-Les-Bains|Sodium 0.44 mg Magnésium 2.25 mg Phosphore 0.003 mg Potassium 0.08 mg Calcium 8.23 mg Manganèse 0.0001 mg Fer 0.001 mg Cuivre 0.0005 mg Zinc 0.0005 mg Sélénium 1 µg Iode 0 µg
1584966|NCT02346786|Dietary Supplement|tap water|
1585017|NCT02346357|Procedure|Obturator Nerve Block|Ultrasound-guided obturator nerve block with 20 mL of treatment drug (Ropivacaine 0.5% [local anesthetic]) 30 minutes prior to induction of anesthesia.
1585018|NCT02346357|Drug|Ropivacaine|
1585019|NCT02346357|Drug|Placebo Saline|
1585020|NCT02346331|Other|WHO algorithm of fluid boluses guided by physical examination|
1584967|NCT02346773|Dietary Supplement|ω-3 LC-PUFA|The intervention product was a full fat (80%) margarine.Participants were provided with one-month supply of the intervention product (including reserve products) at the onset of the intervention and received a new supply monthly. The intervention products were provided in neutral serving-sized cups, each containing 10 grams of margarine.The child's parents were instructed to have their child consume one complete portion pack (10 g) of margarine per day. The margarine had to be consumed as spread on sandwiches, crackers or bread rolls.The intervention product could be consumed on various periods over the day or all at one occasion. Every day a new portion pack had to be used, even if there was margarine left in the package of the previous day.
1584968|NCT02346773|Other|Placebo|The placebo product was a similar margarine with the same sensory properties, but with monounsaturated fatty acids (MUFA; refined plant oils) replacing EPA and DHA; total saturated fatty acids (SAFA) and ω-6 long chain polyunsaturated fatty acids (LC-PUFA) content were similar between the active and placebo products.
1584969|NCT02346760|Drug|UB-621|100 mg/ml, subcutaneous injection
1584970|NCT02346747|Biological|Vigil|bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy
1584971|NCT02346747|Biological|Placebo|"freeze media."
1584972|NCT02346734|Device|Multiple Sclerosis Home Automated Telemanagement (MS HAT) system|
1584973|NCT02346721|Drug|SOF/VEL|400/100 mg tablet administered orally once daily
1584974|NCT02346708|Device|Real TMS|real treatment
1584975|NCT02346708|Device|Sham TMS|placebo treatment
1584976|NCT02346682|Drug|venlafaxine|Venlafaxine dose was initiated at 75 mg/day and escalated to an optimal dose (150-225 mg/day in most cases) within 2 week, depending upon individual patient response, but the maximum dose could not exceed 300 mg/day during the next 4 weeks. Patients were prescribed a combination of venlafaxine and Benzodiazepines for sleep disturbance.
1584977|NCT02346669|Procedure|gastroscopy|as detailed in arm description
1584978|NCT02346669|Drug|Fecal Microbiota Transplantation|as detailed in arm description
1584979|NCT02346669|Other|high fat low fiber diet|as detailed in arm description
1584980|NCT02346669|Other|sham diet|as detailed in arm description
1584981|NCT02346669|Other|low fat high fiber diet|as detailed in arm description
1584982|NCT02346656|Device|Implantation with the commercially available Axium neurostimulator|
1584984|NCT02346630|Drug|Placebo|Placebo capsules daily for 3 weeks.
1584985|NCT02346630|Drug|Levodopa / Carbidopa|Levodopa / Carbidopa drug 100/25 mg once a day for 3 weeks.
1584986|NCT02346630|Device|Armeo|Armeo Robotic Assisted Intensive Upper Extremity Therapy every weekday for 3 weeks.
1584987|NCT02346617|Biological|IFN-γ positive selected T-cells|
1584988|NCT02346591|Behavioral|Jauntly|Mobile app designed to encourage positive emotion-enhancing and stress reduction activities.
1584989|NCT02346591|Behavioral|Online stress management information|Online educational information about stress management
1584990|NCT02346578|Drug|Enzalutamide|
1584991|NCT02346578|Drug|Flutamide|
1584992|NCT02346565|Procedure|Exercise ECG|
1584993|NCT02346565|Procedure|Stress Echocardiography|
1584994|NCT02346552|Device|AutoLap|
1584995|NCT02346539|Drug|Nicotine polacrilex|Single Acute dose
1584996|NCT02346526|Procedure|Blood Tests|Blood will be drawn for standard and nonstandard testing on day one, day 4, and weeks 5, 9, 13, 17, 21, 25, 37, and 93.
1584997|NCT02346526|Procedure|CT scan and bone scan|Standard CT and bone scans will be carried out prior to treatment, week 9, and week 25.
1584998|NCT02346526|Procedure|FACBC PET/MRI in a subset of participants|Approximately half of the study patients (n=10) will undergo experimental FACBC PET/MRI testing at 2 time points each: (1) prior to therapy, and (2) week 9.
1584999|NCT02346526|Drug|Radium-223 dichloride|Ra-223- Each treatment cycle lasts 4 weeks during which the patient receives Ra-223 at a dose of 50 kBq/kg body weight by intravenous infusion on day 1 only. Treatments are given every 4 weeks for a total of 6 treatments.
1585000|NCT02346513|Device|Ceramic on Metal Articulation|Patients have THA with ceramic on metal articulation
1585001|NCT02346513|Device|Non-Ceramic on Metal Articulation|Patients have THA with non-ceramic on metal articulation
1585002|NCT02346500|Device|Transrectal Ultrasound|The TRUS and TRUS-Robot will be used to record ultrasound images during PVP. The PVP procedure will be conducted as usual, without using the ultrasound for guiding the intervention.
1585003|NCT02346487|Drug|LPV/RTV pellets and AZT/3TC or ABC/3TC|"Drug: LPV/r pellets 40/10 mg: orally taken twice a day. Dosage according to patient's weight:
Between 3 and 5.9kg: 2 capsules twice a day
Between 6 and 9.9kg: 3 capsules twice a day
Between 10 and 13.9kg: 4 capsules twice a day
Between 14 and 19.9kg: 5 capsules twice a day
Between 20 and 24.9kg: 6 capsules twice a day
Drug: NRTIs (AZT/3TC 60/30mg tablet or ABC/3TC 60/30mg tablet). Dosage according to patient's weight:
Between 3 and 5.9kg: 1 tablet twice a day
Between 6 and 9.9kg: 1.5 tablets twice a day
Between 10 and 13.9kg: 2 tablets twice a day
Between 14 and 19.9kg: 2.5 tablets twice a day
Between 20 and 24.9kg: 3 tablets twice a day"
1585006|NCT02346448|Procedure|endoscopic sphincterotomy|sphincterotomy during ERCP
1585007|NCT02346448|Procedure|balloon dilatation for 3 minutes|balloon dilatation during ERCP using 10mm balloon
1585008|NCT02346448|Procedure|balloon dilatation for 6 minutes|balloon dilatation during ERCP using 10mm balloon
1585009|NCT02346422|Genetic|MYDICAR Phase 1|Single dose of MYDICAR
1585010|NCT02346422|Genetic|MYDICAR Phase 2|Single dose of MYDICAR
1585011|NCT02346422|Genetic|Placebo Phase 2 only|Single dose of placebo
1585012|NCT02346409|Device|tACS of the cerebellum|tACS of the cerebellum
1585013|NCT02346396|Device|tDCS (use at home)|During 4 weeks (every week : 20 minutes / day during 5 days)
1585014|NCT02346383|Device|preset program|Change to different present program using epidural and peripheral lead to cover pain
1585015|NCT02346370|Drug|PEGPH20|
1585016|NCT02346370|Drug|Docetaxel|
1585021|NCT02346331|Other|Frequent patient monitoring|Vital signs and physical exam every 30-60 minutes
1585623|NCT02342353|Drug|Pacritinib|
1585022|NCT02346331|Other|Early administration of empiric antibiotics|Clinician will be prompted to administer antibiotics within 60 minutes
1585023|NCT02346331|Other|Oxygen delivery|
1585024|NCT02346331|Other|Correction of hypoglycemia|If blood glucose is less than 3.0 mmol/L, IV dextrose will be administered
1585025|NCT02346331|Other|Correction of severe anemia|If hemoglobin is less than 7 mg/dL, clinician will be prompted to offer blood transfusion
1585026|NCT02346318|Drug|Compound Kushen Injection|Compound Kushen Injection 20ml i.v.drip qd, synchronize with radiotherapy, total dosage is 400ml.
1585027|NCT02346305|Device|Non-invasive ventilation|Home NIV installation
1585028|NCT02346279|Other|Questionnaires, EDSS, physical test|6 Meter timed walking test, Nine Hole Peg Test, Berg balance Scale, MSQPT, HAQUAMS, Transition Questionnaire for Patients, Transition Questionnaire for Therapists, EDSS, 6 Minute Walking Test
1585029|NCT02346266|Other|SMART Education|
1585030|NCT02346253|Radiation|Internal Radiation Therapy|Undergo high-dose-rate brachytherapy
1585031|NCT02346253|Drug|Bicalutamide|Given PO
1585032|NCT02346253|Drug|Leuprolide Acetate|Given IM or SC
1585033|NCT02346253|Drug|Goserelin Acetate|Given SC
1585034|NCT02346253|Drug|Triptorelin Pamoate|Given IM
1585035|NCT02346253|Drug|Degarelix|Given SC
1585036|NCT02346253|Other|Laboratory Biomarker Analysis|Correlative studies
1585037|NCT02346253|Other|Quality-of-Life Assessment|Ancillary studies
1585038|NCT02346240|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 200 mg/ mL
Route of Administration: Subcutaneous use"
1585039|NCT02346240|Biological|Etanercept|"Active Substance: Etanercept
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 50 mg / mL
Route of Administration: Subcutaneous use"
1585040|NCT02346240|Other|Placebo|"Active Substance: Placebo
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 0.9 % saline
Route of Administration: Subcutaneous use"
1585041|NCT02346227|Drug|AV2|"The virucide AV2 consists of a spray. It is a mixture of natural essential oil components (Carvone, Eugenol, Geraniol, Nerolidol) in equal volumes diluted 50% in olive oil (Olea europaea).
It is administered as a topical spray to the cervix while the subject is in the lithotomic position and fitted with a speculum. The manual spray applicator is positioned inside the anterior of the vagina and two pumps are applied. Each pump delivers 100 microliters of the solution."
1585042|NCT02346227|Drug|Placebo|"The placebo consists of 10% lemon (citrus limon) and 10% lime (citrus aurantifolia) in 80% olive oil.
It is administered as a one time (2 puffs) topical spray of 100 microliters on the cervix."
1585043|NCT02346201|Drug|Methylphenidate|Two 5mg methylphenidate over-encapsulated drug taken twice a day for 6 months (total of 20 mg methylphenidate per day), and psychosocial intervention
1585044|NCT02346201|Drug|Placebo|Two over-encapsulated placebo taken twice a day for 6 months and psychosocial intervention
1585045|NCT02346188|Dietary Supplement|Ferrous fumarate|Tablet formulated from 30 mg ferrous fumarate.
1585046|NCT02346188|Dietary Supplement|Zinc oxide|Tablet formulated from 30 mg zinc oxide
1585047|NCT02346188|Dietary Supplement|Placebo|
1585048|NCT02346175|Drug|SHR3824|
1585049|NCT02346175|Drug|Placebo|
1585050|NCT02346162|Behavioral|Weight management|Phone counseling for pre-pregnancy weight loss and weight maintenance when BMI </=25, and when pregnant, weight gain within IOM guidelines.
1585051|NCT02346162|Other|Usual Care Control|Usual care control participants receive general dietary advice as it relates to planning for a healthy pregnancy (e.g. folate requirements, prenatal vitamins, smoking cessation, alcohol cessation, and prenatal food safety).
1585052|NCT02346149|Other|glucose 20%|Intravenous infusion (0.75 ml / kg) over 1 min
1585053|NCT02346149|Device|Bold-MRI|performance of a renal MRI in both groups
1585054|NCT02346136|Behavioral|Tai Chi training|
1585055|NCT02346136|Behavioral|Educational Control|
1585056|NCT02346123|Genetic|Gathering of samples of genetic material|The samples will be obtained from peripheral blood mononuclear cells and the genotyping of the polymorphisms will be done by real time PCR.
1585057|NCT02346110|Drug|Bupivacaine-adrenaline|50 mg bupivacaine and 50 μg adrenalin
1585058|NCT02346110|Drug|Dexamethasone|4 mg
1585059|NCT02346110|Other|Sodium chloride|1 mL of sodium chloride solution as placebo
1585060|NCT02346097|Device|Cardiac Resynchronization Therapy (St. Jude Qaudripolar LV lead)|"Optimal electrical resynchronization vs. routine CRT strategy, imaging guided. For more details refer to Arm descriptions"
1585061|NCT02346084|Drug|Maraviroc 300 mg tablet (PO) and Maraviroc 1% gel (PR and PV)|"Tablets: daily 300 mg oral maraviroc, Selzentry®,(MVC) for 8 consecutive days Gel: daily rectally administered 1% MVC gel for 8 daily consecutive days Female Participants - will receive an additional third regimen of daily vaginally administered MVC 1% gel for 8 consecutive days.
Each treatment regimen will be followed by a washout period of 14 to 21 days.
Participants will also be randomized to a biopsy sampling schedule (i.e., D8, D9, or D10 sampling)."
1585062|NCT02346071|Behavioral|Acceptance and Commitment Therapy|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.
The ACT treatment is manualized and given in groups of 7-8 patients with 9 3-hour sessions (i.e. 27 hours in total) over a period of 3 months and one follow up meeting (3 hours) three months after end of treatment. The parents and other relevant close relatives (e.g. siblings, boy/girlfriends) to the patient participate in a workshop where ACT principles are applied. One individual consultation with the adolescent and parents will be offered at the end of 8 sessions of group therapy."
1585063|NCT02346071|Other|Enhanced Usual Care (EUC)|"All patients will have a thorough clinical psychiatric and somatic assessment in order to determine eligibility and a psychiatric consultation (SPC) of 1-1½ hrs. duration approx. 2 weeks after randomization.
The consultation is according to a manual and includes psycho-education related to the diagnosis of multiorgan BDS, health promoting recommendations and counselling regarding existing medicine or other treatment. An individualized treatment plan will be sent to the patient's general practitioner, to optimize management in primary care and support by social services."
1585064|NCT02346058|Drug|Esarin Gel|
1585624|NCT02342353|Drug|Erlotinib|
1585065|NCT02346045|Procedure|Renal sympathetic denervation|"In the experimental arm, Intervention is renal sympathetic denervation using Symplicity® system (Medtronic Ardian Inc, Mountain View, CA, USA) and antihypertensive medications previously prescribed
After femoral puncture guiding catheter is engaged in renal artery
Symplicity radiofrequency ablation catheter is inserted into renal artery and by circular sequence, from distal to proximal portion, ablation energy is applied to the wall of renal artery
4-5 ablations are applied in each renal artery.
In the sham comparator, intervention is renal angiogram and continue antihypertensive medications previuosly decribed"
1585066|NCT02346032|Drug|refametinib|Refametinib will be administered orally at the starting dose of 50 mg twice daily on a continuous daily dosing schedule.
1585067|NCT02346019|Procedure|Medial thighplasty with or without thigh liposuction|Perform a standard medial thighplasty with or without additional thigh liposuction on up to three obese transfemoral amputee subjects. The subjects will be transfemoral amputees who are successful ambulators and have a body mass index (BMI) of 30 or greater with excessive adipose tissue in their residual limb. The surgery will consist of medial excision of excess adipose and cutaneous tissue with circumferential liposuction.
1585068|NCT02346006|Behavioral|More physical activity.|Subjects receiving more physical activity in school.
1585069|NCT02345993|Drug|Extra fine Formoterol/Beclomethasone|"standard treatment consisting in: Albuterol 2.5 mg via nebulizer at baseline (0), 20, 40 minutes + Systemic steroid (methylprednisolone 60 mg) at the moment of evaluation
+ formoterol/beclomethasone, 3 puffs administered via aerochamber at baseline (0), 20, 40, 60 minutes"
1585070|NCT02345980|Drug|Sildenafil|
1585071|NCT02345980|Drug|Placebo|
1585072|NCT02345967|Device|Model 100 Sensor|One Model 100 Sensor to be implanted per subject.
1585073|NCT02345954|Procedure|Laparoscopic Supracervical Hysterectomy and Sacropexy|Laparoscopic supracervical hysterectomy and laparoscopic sacrocolpopexy
1585074|NCT02345954|Procedure|Laparoscopic Hysteropexy|Laparoscopic hysteropexy
1585075|NCT02345941|Other|Parent Action Report|Parent Action Report will be displayed after the baseline assessment and contain educational safety messages.
1585076|NCT02345941|Other|Parent Portal|Parents will have access to the Parent Portal, and they will be encouraged to visit it at any time.
1585077|NCT02345928|Drug|Part 1: CNTO 7160|Participants will receive Drug CNTO7160 administered IV infusion at escalating doses (with a starting dose of 0.001 mg/kg).
1585078|NCT02345928|Drug|Part 2 (Asthma): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
1585079|NCT02345928|Drug|Part 2 (Atopic Dermatitis): CNTO 7160|Participants will receive Drug CNTO 7160 administered IV infusions (3 dose administrations over 4 weeks).
1585080|NCT02345928|Drug|Part 1 and Part 2: Placebo|Participants will receive single IV infusion of placebo matched to CNTO 7160.
1585081|NCT02345915|Other|Blood sample|
1585082|NCT02345915|Other|Electrocardiogram|
1585083|NCT02345902|Drug|Haloperidol|haloperidol 1.25 mg P.O q.d
1585084|NCT02345902|Other|Placebo|placebo 1.25 mg P.O q.d
1585085|NCT02345902|Other|non-pharmacologic measures|A. Reorientation (i.e., calendar, clocks, familiar objects) B. Glasses and hearing devices for the particular patients needing such aids C. Avoidance of physical restraints D. Limitation of excessive personnel shifts or hospital room E. A tranquil and comfortable environment, especially at night, to avoid interruptions (i.e., dim light, low levels of noise) F. Adequate schedules for medication administration and to take vital signs or medical procedures G. Sleep hygiene (light in the room and movement during the day) H. Avoidance of dehydration I. Avoidance of medications use which are associated with delirium (e.g., psychoactive medications)
1585086|NCT02345889|Device|Colonoscopy with EndoCuff™|colonoscopy performed with an EndoCuff™ device at the tip of a standard colonoscope
1585087|NCT02345889|Device|FUSE® Colonoscopy|colonoscopy performed with the FUSE® (full spectrum endoscopy) system
1585088|NCT02345889|Device|Colonoscopy with EndoRings™|colonoscopy performed with an EndoRings™ device at the tip of a standard colonoscope
1585089|NCT02345889|Device|Standard Colonoscopy|Current standard of care colonoscopy
1585090|NCT02345876|Other|no intervention|
1585091|NCT02345863|Drug|Bendamustine|"Debulking:
2 cycles of Bendamustine (70 mg/m² iv) will be administered before induction unless a contraindication is existing or it is not clinically indicated."
1585092|NCT02345863|Drug|GA101|"Induction
GA101 iv infusion:
Cycle 1: Day 1 100 mg Day 1 (or 2) 900 mg Day 8 1000 mg Day 15 1000 mg Cycle 2-6: Day 1 1000 mg
Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.
GA101: Cycle 1-8 Day 1 1000 mg"
1585093|NCT02345863|Drug|Ibrutinib|"Ibrutinib will be administered as a daily oral dosage of 420 mg starting on cycle 2 day 1.
Cycle 2-6: Day 1 420 mg daily
Maintenance After the induction ibrutinib po 420 mg daily and GA101 iv 1000 mg every three months will be continued.
Ibrutinib: Cycle 1-8 420 mg daily"
1585094|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Tacrolimus/Methotrexate|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
1585095|NCT02345850|Procedure|Mobilized CD34-selected Peripheral Blood Stem Cell graft|Mobilized CD34-selected PBSC grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
1585096|NCT02345850|Procedure|Unmanipulated Bone Marrow Graft with Cyclophosphamide|Unmanipulated BM grafts will be administered on Day 0 to all patients according to individual institutional guidelines after appropriate processing and quantification has been performed by the local laboratory. Stem cells are administered through an indwelling central venous catheter. If infusion occurs over two days, Day 0 is the first day the infusion is initiated.
1585137|NCT02345720|Device|etafilcon - PVP (multi-focal)|The investigational contact lens must be worn at least six hours daily.
1585138|NCT02345707|Drug|Cabotegravir 30 mg current formulation|Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg
1585625|NCT02342340|Other|Navy Beans (cooked)|One time consumption of 3/4 cup of cooked navy beans.
1585097|NCT02345850|Drug|Cyclophosphamide|"Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.
Cyclophosphamide 50 mg/kg will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
1585098|NCT02345850|Drug|Tacrolimus|Tacrolimus will be given orally or intravenously per institutional standards starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels, with a target of 5-15 ng/ml. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
1585099|NCT02345850|Drug|Methotrexate|Methotrexate will be administered at the doses of 15 mg/m^2 IV bolus on Day +1, and 10 mg/m^2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate should be given at least 24 hours after the hematopoietic stem cell infusion. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices. Leucovorin rescue is allowed according to institutional practices.
1585100|NCT02345837|Device|endometrial sampling|injury to the endometrium
1585101|NCT02345837|Drug|clomiphene citrate|ovulation induction by 100mg clomiphene citrate
1585102|NCT02345824|Drug|Ribociclib|CDK4/6 INHIBITOR
1585103|NCT02344719|Drug|Taurin 6g per day per oral for 28 days|Taurin 6g per day per oral for 28 days
1585104|NCT02344719|Procedure|HVPG Measurement baseline|On day 1 (baseline) and day 28 HVPG measurement will be performed
1585105|NCT02344719|Procedure|HVPG Measurement day 28|On day 1 (baseline) and day 28 HVPG measurement will be performed
1585106|NCT02344719|Drug|Placebo 6g per day per oral for 28 days|Placebo to Taurin 6g per day per oral for 28 days
1585107|NCT02344706|Device|Registration of EEG|EEG is registered for study purposes. No interventions to patient care is done at this stage. Acquisition is done without harming the patient.
1585108|NCT02344680|Drug|Anti-HIV Agents|
1585109|NCT02344667|Radiation|Stereotactic Body Radiotherapy|
1585110|NCT02344654|Drug|Indocyanine green|
1585111|NCT02344654|Device|Near-infrared illumination|To see the fluorescence from indocyanine green
1585112|NCT02344654|Drug|Urografin|
1585113|NCT02344654|Radiation|X-ray|
1585114|NCT02344641|Drug|Exenatide|
1585115|NCT02344628|Drug|Azithromycin|Comparison of two different dosing strategies for the treatment of yaws
1585116|NCT02344615|Procedure|NS-guided infraclavicular block|Patients received a standard single injection infraclavicular block using the lateral sagittal approach of Klaastad. The infraclavicular brachial plexus is identified using an insulated needle connected to a nerve stimulator. Placement of the needle is considered adequate if motor response of radial nerve in the hand or wrist is still present at 0.2 - 0.5mA. Ropivacaine 0.5% 35ml is used.
1585117|NCT02344615|Procedure|US-guided infraclavicular block|Infraclavicular block is performed under ultrasound guidance. Linear probe is placed in a parasagittal positon below the clavicle medial to the coracoid process and adjusted to achieve a cross-sectional image of the axillary artery. Using in-plane technique, an 22-gauge insulated needle is advanced caudally and posteriorly to the axillary artery. Subsequently, 35 ml of 0.5% ropivacaine is incrementally injected.
1585118|NCT02344602|Drug|Febuxostat|Oral tablet, 80mg, OD, 8 weeks
1585119|NCT02344589|Drug|Lidocaine|used for the active blocks
1585120|NCT02344589|Drug|Saline|used for the placebo-block
1585122|NCT02345798|Procedure|Standard Follow-Up Care|Undergo usual care
1585123|NCT02345798|Other|Caregiver-Related Intervention or Procedure|Undergo video-assisted intervention
1585124|NCT02345798|Other|Educational Intervention|Undergo video-assisted intervention
1585125|NCT02345798|Other|Quality-of-Life Assessment|Undergo quality of life assessment
1585126|NCT02345798|Other|Questionnaire Administration|Undergo questionnaire administration
1585127|NCT02345785|Other|urologic surgery and caudal block|
1994736|NCT02931552|Behavioral|Nuevo Amancer-II Stress Management Program|Participant meets weekly with a trained interventionist called a Compañera (a peer who has had breast cancer) to complete a structured 10-week program designed to develop cognitive and behavioral skills to manage stress and distress, improve communication with family and clinicians, and increase knowledge of self-management after breast cancer.
1994737|NCT02932579|Other|Pharmacogenomic Testing|Saliva collection (5mL)
1994738|NCT02932579|Drug|Ibuprofen|400 mg
1585132|NCT02345746|Drug|Oxaliplatin|infusion over 12 hours via HAI
1585133|NCT02345746|Drug|Folinic Acid|as a 2-hour infusion via HAI on day 2
1585134|NCT02345746|Drug|5-Fluorouracil|Following Folinic Acid as a continuous infusion over 48 hours on days 2, 3
1585135|NCT02345733|Other|Ulcerative Colitis Diet|we have postulated that a diet that we developed that reduces exposure to dietary ingredients that allow sulfide reducing bacteria to thrive, or that impair the mucous layer, coupled with dietary products that enhance butyrate production, could induce remission in UC without involving additional immune suppression.
1585136|NCT02345733|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
1994739|NCT02932579|Drug|hydroxycontin/acetominophen|hydroxycontin 2.5 mg, acetominophen 325 mg
1994740|NCT02932579|Drug|acetominophen|650 mg
1994741|NCT02932579|Drug|Oxycontin/acetominophen|5mg Oxycontin, 325 mg acetominophen. This will be a rescue medication is the other three pain medications do not work.
1585139|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 500 M|Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg
1585140|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 500 U|Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg
1585141|NCT02345707|Drug|Cabotegravir 30 mg micronized new formulation 650 M|Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg
1585142|NCT02345707|Drug|Cabotegravir 30 mg unmicronized new formulation 650 U|Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg
1585143|NCT02345694|Device|Effective CPAP|Effective Continuous Positive Airway Pressure auto-regulated, worn all night long during 8 weeks
1585144|NCT02345694|Device|Sub-therapeutic CPAP|Sub-therapeutic Continuous Positive Airway Pressure (Sham-CPAP) worn all night long during 8 weeks
1585145|NCT02345681|Drug|Furosemide|
1585146|NCT02345668|Behavioral|Emotion Regulation Protocol|Emotion Regulation Protocol is an Internet-based Self-administered Protocol for emotional disorders, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in twelve modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
1585147|NCT02345668|Drug|Treatment as Usual (Pharmacological Treatment)|The Pharmacological Treatment provided by a psychiatrist in the mental health unit.
1585148|NCT02345668|Behavioral|Treatment as Usual (Psychological Treatment)|The Psychological Treatment provided by a clinical psychologist in the mental health unit.
1585149|NCT02345655|Procedure|urine drug testing|Performed a OS-UDT test in general practice on patients starting buprenorphine
1585150|NCT02345655|Other|no test|normal procedure decided by the general practitioner
1994742|NCT02932241|Behavioral|Computerized Dialectical Behavior Therapy Skills Training|8, 50 minute skill training sessions made available to participants each week
1994744|NCT02931539|Drug|Maribavir|Maribavir 2X200 mg two times per day
1994745|NCT02931539|Drug|Investigator-Assigned Treatment|Active Comparator: anti-CMV agent
1585155|NCT02345629|Procedure|Cordotomy|Radiologist performs a spinal tap to inject a contrast drug into the spinal fluid. A 20G spinal needle guided by real-time CT scan to the C1-C2 level opposite to participant's pain. A radiofrequency electrode inserted through the spinal needle into the spinal cord, to the anatomic location of the spinothalamic tract. Once ideal position of the electrode is confirmed, 1 or 2 radiofrequency ablations performed at 70C-80C for 60 seconds. The procedure will take 1-2 hours.
1585156|NCT02345629|Behavioral|Pain/Symptom Questionnaire|Pain and symptom questionnaire completed at baseline, by phone during first week of study, and once each month by phone during 6 month follow up.
1585157|NCT02345629|Procedure|Sharpness Sensory Testing|Sharpness detection determined using 8, 10, 16, 20, 32, 64, and 128g weighted needle devices. Each stimulus applied for about 1 second in ascending order. Participants asked to rate each stimulus as producing the sensation of touch, pressure, sharp, or pain. The sharpness detection threshold defined as the mean force of the stimuli deemed ''sharp'' or ''painful'' from 3 trials separated by an average interval of 30 to 90 seconds.
1585158|NCT02345629|Procedure|Heat Pain Sensory Testing|Thermal ramps will applied using a 3.6 x 3.6 cm Peltier thermode (Medoc Inc.) from a baseline temperature set at 32C. Skin heated at a rate of 0.30C/s, and participants asked to signal when the stimulus is perceived as first becoming warmer and then painfully hot.
1585159|NCT02345616|Drug|Nitric oxide|
1585160|NCT02345603|Procedure|Cryo-therapy|Cryo-therapy for about 60 seconds applied circumpherentially to each renal artery
1585161|NCT02345590|Drug|Eplerenone|25mg of eplerenone
1585164|NCT02345564|Device|implantation of MaioRegen fleece into osteochondral lesion|arthroscopic localization of lesion, arthroscopic guided mini-arthrotomy and implantation of defect sized MaioRegen fleece
1585165|NCT02345551|Behavioral|Exercise|Moderate-vigorous aerobic activity in line with published guidelines for cancer prevention
1585166|NCT02345525|Behavioral|mCIMT|"This intervention is based on 3 main aspects:
intensive training of functional tasks with the affected arm (massed practice)
constraint of the un-affected hand through a mitt
shaping techniques designed to transfer gains to the real world activities
The 2 hours massed practice will be performed in a outpatient clinic with a supervision of PT."
1585167|NCT02345525|Behavioral|hCIMT|"This intervention is based on 3 main aspects:
intensive training of functional tasks with the affected arm (massed practice)
constraint of the un-affected hand through a mitt
shaping techniques designed to transfer gains to the real world activities
In this group, a comprehensive set of the material necessary to perform the training at home and a booklet containing an explanation of the exercises that can be done will be provided to subjects.
In addition, 2 hospital visits will be scheduled to instruct subjects and caregivers on the training and to update activities (1 visit at the beginning + 1 visit after 1 week)."
1585169|NCT02345499|Procedure|Laparoscopic radical cystectomy with open urinary diversion|Laparoscopic surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
1585170|NCT02345499|Procedure|Open radical cystectomy with open urinary diversion|Open surgical procedure in which the bladder is removed because of bladder cancer and a urinary diversion is performed
1585171|NCT02345486|Other|0.9% sodium chloride|
1585172|NCT02345486|Other|Physiologically balanced fluid|
1585228|NCT02345174|Drug|GSK2849330|GSK2849330 solution (100 mg/mL) for infusion diluted in 0.9% sodium chloride to the appropriate concentration for the dose.
1585627|NCT02342340|Other|Pinto Beans (cooked|One time consumption of 3/4 cup of cooked pinto beans.
1585173|NCT02345473|Genetic|Detection of circulating tumor cells in blood samples|Ficoll based isolation of mononuclear cells from the peripheral blood of patients undergoing radical cystectomy, nucleic acids extraction and, finally, PCR based detection of sequences specific to cytokeratins.
1585174|NCT02345460|Drug|Irinotecan Hydrochloride|Given IV
1585175|NCT02345460|Drug|Oxaliplatin|Given IV
1585176|NCT02345460|Drug|Leucovorin Calcium|Given IV
1585177|NCT02345460|Drug|Fluorouracil|Given IV
1585178|NCT02345460|Other|Laboratory Biomarker Analysis|Correlative studies
1585179|NCT02345447|Drug|Herbal-based medication|Aconitum napellus, Capsicum annuum; Chamomilla recutita; Echinacea purpurea; Hydrargyrum bicyanatum; Hydrastis canadensis; Iodum; Natrium tetraboracicum; Sambucus nigra; Sanguinaria canadensis
1585180|NCT02345447|Drug|Placebo|Aqueous ethanol solution non-distinguishable from verum
1585181|NCT02345434|Other|Informative letter|The intervention is a letter that describes the Schedule II prescribing activity of the individual in comparison to a peer group of similar prescribers. It highlights the fact that the prescriber's activity is highly unlike her peers.
2008813|NCT03327038|Other|Detailed Questionnaires|Patients will complete a detailed questionnaires at enrollment (i.e. week 1 of enrollment) and also at post-intervention (i.e. week 8 of enrollment). The enrollment questionnaire will query the patients Ulcerative Colitis Disease Activity (MAYO-6) or Crohn's Disease Activity (PRO-2); Quality of Life (SIBDQ); and Patient Satisfaction with Health Care in IBD (CAHCE). The post-intervention questionnaire will query the same information as the enrollment questionnaire but will also ask patients to self-report their depression (PHQ-9) and anxiety (GDA-7) symptoms.
1585183|NCT02345395|Procedure|Aneurysm Clipping|All Patients will be submitted to a surgical intervention in order to clip their unruptured brain aneurysm
1585184|NCT02345382|Drug|BAY1143572|The starting dose will be 20 mg BAY 1143572. Maximum dose escalation between dose levels will be 2 fold.The dose-escalation part of each dosing schedule may be followed by an expansion part.
1585185|NCT02345382|Drug|BAY1143572|"As soon as the MTD has been determined for the once-daily continuous dosing schedule (i.e. Study Arm 1), Study Arm 2 will be opened, testing a 3 days on / 4 days off dosing schedule. The starting dose for Study Arm 2 will be the MTD of BAY1143572 determined in Study Arm 1.
Maximum dose escalation between dose levels will be 2 fold. The dose-escalation part of each dosing schedule may be followed by an expansion part."
1585186|NCT02345369|Device|Locked Set Screw|Fixation of hip fracture with intramedullary hip screw with locking of the set screw
1585187|NCT02345369|Device|Unlocked Set Screw|Fixation of hip fracture with intramedullary hip screw without locking of the set screw
1585188|NCT02345356|Genetic|Genotype-guided|Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm
1585189|NCT02345356|Other|Standard-of-Care|Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
1585190|NCT02345343|Drug|Apixaban|
1585191|NCT02345330|Biological|Plasmid interleukin-12|Patients will receive intratumoral injection(s) of pIL-12.
1585192|NCT02345330|Device|Intratumoral electroporation|Immediately following intratumoral injection of pIL-12, electroporation will follow by electrical discharge around the tumor site using the OMS system.
1585193|NCT02345304|Drug|Omeprazole|
1585194|NCT02345304|Drug|Warfarin|
1585195|NCT02345304|Drug|BI 1181181|
1585196|NCT02345304|Drug|Midazolam|
1585197|NCT02345304|Drug|Omeprazole|
1585198|NCT02345304|Drug|BI 1181181|
1585199|NCT02345304|Drug|Midazolam|
1585200|NCT02345304|Drug|Midazolam|
1585201|NCT02345304|Drug|Warfarin|
1585202|NCT02345304|Drug|BI 1181181|
1585203|NCT02345304|Drug|Digoxin|
1585204|NCT02345304|Drug|Digoxin|
2008814|NCT03327038|Other|Screening Form|Patients will complete a screening form at routine IBD outpatient visits to Mount Sinai Hospital to self-report their depression and generalized anxiety symptoms on the 9-item Patient Health Questionnaire (PHQ-9) and 7-item Generalized Anxiety Disorder Questionnaire (GDA-7). Patients who self-report scores of moderate depression AND/OR moderate anxiety will be eligible to participate in this study.
2008815|NCT03327025|Behavioral|Health education counseling|Health education counseling
1585207|NCT02345278|Drug|SUBLIVAC FIX Mite mixture|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
1585208|NCT02345278|Other|Placebo|Study medication will be taken sublingually once a day. Patients will start with one drop and increase the dose by one drop each consecutive day until the maintenance dose (5 drops/day) is reached. Drops should be kept under the tongue for 2-3 minutes before swallowing. After reaching the maintenance dose patients will be treated up to 1 month.
2008816|NCT03327012|Drug|Treatment of Panlongqi Tablet|Panlongqi Tablet:1.2g,3times a day, oral, for 4 weeks.
2008817|NCT03327012|Drug|Treatment of Panlongqi placebo|Panlongqi placebo:1.2g,3times a day, oral, for 4 weeks.
2008818|NCT03326999|Drug|Obturator nerve regional block|Obturator nerve regional block involves the injection of a local anesthetic called bupivacaine into the upper thigh.
1585217|NCT02345239|Drug|Pantoprazole|proton pump inhibitor
1585222|NCT02345213|Drug|E2020|E2020 tablets will be orally administered once daily after breakfast
1585223|NCT02345213|Drug|Placebo|Matching placebo tablets will be orally administered once daily after breakfast
1585224|NCT02345200|Procedure|bioelectrical impedance analysis|electrophysical measurement that allows to determine the exact composition of single body compartments by producing a magnetic field and detecting the potential difference through the body
1585225|NCT02345200|Procedure|blood draw|blood samples are taken at 8 am in order to pay attention to the circadian rhythmicity to get a detailed hormonal status
1585226|NCT02345187|Dietary Supplement|Beverage powder fortified with Bacopa Monnieri Extract and Multiple Micronutrient supplementation|The study product (fortified beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
1585227|NCT02345187|Dietary Supplement|Non-fortified isocaloric beverage powder|The study product (non-fortified isocaloric beverage powder reconstituted with 180 mL lukewarm water) will be administered twice daily for 17 weeks
1585229|NCT02345174|Drug|89Zr-GSK2849330|89Zr-GSK2849330 solution for intravenous administration diluted with GSK2849330 Solution for Infusion (unlabelled GSK2849330) with a target radioactivity of 37MBq and a total antibody concentration of 0.4 mg/mL or 1.2 mg/mL.
2008819|NCT03326999|Drug|Adductor canal regional block|Adductor canal regional block, which involves injecting numbing medication in the thigh region for pain control.
2008820|NCT03326999|Drug|Saline|Saline as placebo comparator
2008821|NCT03326986|Drug|MK-7252|1 mg/mL or 20 mg/mL oral suspension in water volume to bring to a total of 240 mL
2008822|NCT03326986|Drug|Placebo|Water volume of 240 mL
2008823|NCT03326973|Behavioral|EuroQoL EQ-5D-3L|Overall QOL
1585235|NCT02345148|Drug|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray at 0, 5 and 10 minutes on Day 1.
1585236|NCT02345135|Procedure|Blood collection|In all patients with Ataxia telangiectasia blood was collected at each visit date to determine blood count, lymphocyte subpopulation count and immunoglobulin levels in serum (IgA, IgG, IgM, IgE), as well as alpha feto protein (AFP).
1585237|NCT02345135|Procedure|Lung function measurement|In all patients - Ataxia telangiectasia and healthy controls - a lung function measurement was done to determine vital capacity (VC), forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF) and Tiffenau index.
1585238|NCT02345135|Behavioral|Symptom diary|All patients - Ataxia telangiectasia and healthy controls - were requested to keep a symptom diary for the months September to March of the years 2012/2013 and 2013/2014 to determine days with symptoms as coughing during day and night, cold and fever, as well missing days at kindergarten/school/work, intake of medication (especially antibiotic treatment) and hospitalisations.
1585239|NCT02345122|Behavioral|Intervention: Mental Health Technician|In addition to structured assessments at baseline, four, eight and twelve months (the results will be shared with their Primary Care Provider), subjects will receive psychoeducation regarding their depression, anxiety, and alcohol use disorder or at-risk drinking; symptom monitoring; and medication adherence support. Their Primary Care Provider will also be provided evidence-based recommendations regarding their treatment.
1585240|NCT02345122|Other|Enhanced Usual Care|Subjects will receive structured, quantitative assessments at baseline, four, eight and twelve months. The results will be shared with their Primary Care Provider.
1585241|NCT02345109|Device|Transtek DUT|"Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie.
Measure each participants by Transtek DUT."
1585242|NCT02345109|Device|Reference|Measuring weight, total body water, body fat, muscle mass, bone mass, BMI, visceral fat, and calorie. Measure each participants by Reference.
1585243|NCT02345096|Dietary Supplement|Saccharomyces cerevisiae|
1585244|NCT02345096|Dietary Supplement|Placebo|
1585245|NCT02345070|Drug|SAR156597|Pharmaceutical form:solution Route of administration: subcutaneous
1585246|NCT02345070|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
1585247|NCT02345057|Drug|CS-3150|
1585248|NCT02345057|Drug|placebo|
1585249|NCT02345044|Drug|CS-3150|
1585250|NCT02345044|Drug|placebo|
1585251|NCT02345044|Drug|eplerenone|
1585252|NCT02345031|Drug|AUT00063|600 mg, orally, once a day, for 4 weeks
1585253|NCT02345031|Drug|Placebo|orally, once a day, for 4 weeks
2008824|NCT03326973|Behavioral|EORTC QLQ-C30|General symptoms; physical, role, emotional, cognitive, and social functioning scales; fatigue, nausea/vomiting , and pain scales
2008825|NCT03326973|Other|PRO-CTCAE|Additional potential immune-specific symptoms
1585256|NCT02344992|Drug|BioChaperone insulin lispro|Single dose of 0.2 U/kg body weight injected subcutaneously
1585257|NCT02344992|Drug|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
1585258|NCT02344940|Drug|Toremifene|patients will take toremifene 60 mg qd.
1585259|NCT02344940|Drug|Tamoxifen|patients will take tamoxifen 10 mg bid.
1585260|NCT02344927|Other|Non-Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care
1585261|NCT02344927|Other|Clinically Assisted Hydration arm|Best supportive care. Continuance of oral intake (if appropriate) and regular mouth care, and clinically assisted hydration.
1585262|NCT02344914|Device|receive Laboraide|"After giving consent, randomization will be carried out using sealed envelopes. After randomization women will be offered to withdraw consent. Women assigned to the study group will receive a sealed Laboraide™ package.
Labor follow up will be documented regularly including outcome. The use of the DSD will not affect the regular management of labor according to the routine standards of the delivery suite. Following delivery, patients will be asked to complete a satisfaction questionnaire."
1585263|NCT02344888|Drug|Clomiphene citrate and Prednisolone|Women will receive clomiphene citrate (150 mg/day for 5 consecutive days from day 2 of cycle) and prednisolone (5 mg/day for 10 consecutive days from day 2 of cycle)
1585264|NCT02344888|Drug|Clomiphene citrate|Women will receive clomiphene citrate alone (150 mg/day for 5 consecutive days from day 2 of cycle)
1585265|NCT02344875|Drug|FYU-981, (Oral single dosing)|
1585266|NCT02344862|Drug|FYU-981 High dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 High dose arm receive active drug, FYU-981 High dose.
1585267|NCT02344862|Drug|FYU-981 Middle dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Middle dose arm receive active drug, FYU-981 Middle dose.
1585268|NCT02344862|Drug|FYU-981 Low dose, (Oral daily dosing for 8 weeks)|Subjects randomized to the FYU-981 Low dose arm receive active drug, FYU-981 Low dose.
1585269|NCT02344862|Drug|Placebo, (Oral daily dosing for 8 weeks)|Subjects randomized to the placebo arm receive placebo.
2008826|NCT03326973|Behavioral|Fatigue severity score questionnaire|Fatigue severity
2008827|NCT03326973|Behavioral|The COST|Financial toxicity; satisfaction with ability to work
2008828|NCT03326960|Drug|Sevoflurane|Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
2008829|NCT03326960|Drug|Propofol|Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
1585270|NCT02344849|Drug|mesenchymal stem cell (Cellgram-ED)|Patients will receive single injection of Cellgram-ED( 30,000,000 MSC) intracavernously.
1585271|NCT02344836|Behavioral|Podcast + mobile diet app|Use of a mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
1585272|NCT02344836|Behavioral|Podcast + theory-based mobile diet app|Use of a theory-based mobile app to track behaviors related to weight loss as well as receive study-related weight loss information via podcast.
1585273|NCT02344823|Drug|Vardenafil|per oral intake of 10mg Vardenafil once daily
1585274|NCT02344823|Procedure|HVPG (Hepatic venous pressure measurement) baseline|HVPG measurement day 1
1585275|NCT02344823|Procedure|HVPG (Hepatic venous pressure measurement) day 7|HVPG measurement day 7
1585276|NCT02344823|Behavioral|IIEF 5 (International Index of Erectile Function) questionaire baseline|IIEF 5 questionaire to define level of erectile dysfunction at baseline
1585277|NCT02344823|Behavioral|IIEF 5 (International Index of Erectile Function) questionnaire at study phase end|IIEF 5 questionaire to define level of erectile dysfunction at end of study phase
1585278|NCT02344823|Drug|Placebo intake once daily|
2008830|NCT03326947|Drug|docetaxel, cisplatin and 5-fluorouracil|"Drug: TPF induction chemotherapy TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.
Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy, for high risk factors, concurrent chemotherapy with cisplatin of 80mg/m2.
Other Names:
TPF protocol group Procedure/Surgery: surgery In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
Radiation: radiotherapy"
2008831|NCT03326934|Dietary Supplement|Dark chocolate|Trader Joe's 72% Cacao Dark Chocolate bar, 47g, 34g cacao, total flavanols: 316.3 mg.
2008832|NCT03326934|Dietary Supplement|Milk Chocolate|Trader Joe's Crispy Rice Milk Chocolate bar: 40g, 12.4g milk chocolate cocoa; total flavanols: 40 mg.
2008833|NCT03326921|Drug|Fludarabine Phosphate|Given IV
2008834|NCT03326921|Biological|Immunotherapy|Given CD4+ and CD8+ HA-1 TCR T cells IV
1585287|NCT02344784|Device|SR-HLAB EMG|Prepulse inhibition test using SR-HLAB EMG device will record the acoustic startle response for each participant: with and without Methylphenidate treatment
1585288|NCT02344784|Drug|Methylphenidate|The regular daily dose of P.O methylphenidate of each participant will be given directly after the first prepulse inhibition test
1585289|NCT02344771|Procedure|Elective colon cancer surgery|
1585290|NCT02344758|Device|Non-invasive lateral flow test for monitoring gluten intake|
1585291|NCT02344758|Behavioral|gluten-free diet (GFD)|
1585292|NCT02344758|Behavioral|gluten-containing diet|
1585293|NCT02344745|Other|Lavandula angustifolia essential oil (Aura Cacia)|The participants will be instructed to take a deep breath while holding the towel with two drops of essential oil 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
1585294|NCT02344745|Other|Distilled water|The participants will be instructed to take a deep breath while holding the towel with two drops of distilled water 3 inches from her face before the start of the procedure and will be instructed to continue to take normal breaths subsequently during the procedure.
1585295|NCT02344732|Drug|Dexamethasone 0.1%, Neomycin Sulfate and Polymyxin B Sulfate topical eye drops four times daily|
1585296|NCT02344732|Drug|Homatropine 2% eye drops thrice daily|
1585297|NCT02344732|Drug|Oxygen gas|
1585298|NCT02344563|Drug|Meropem|
1585299|NCT02344563|Drug|Mepem|
1585300|NCT02344550|Drug|Everolimus(afinitor)|Everolimus 10mg p.o. daily
1585301|NCT02344550|Drug|Letrozole|Letrozole 2.5 mg p.o. daily
1585302|NCT02344550|Drug|Leuprolide(Lorelin Depot)|Leuprorelin (Lorelin Depot)3.75 mg SC in every 4 weeks
1585303|NCT02344537|Behavioral|Kundalini Yoga|Kundalini Yoga incorporates mindfulness practice with a triad of stretching, breathing, and meditation. The three components of treatment consist of muscular relaxation/stretching exercises, a meditation period characterized by a directed breathing exercise, and then a guided meditation.
1585304|NCT02344524|Device|Intercostal drainage|Small bore chest drains are inserted by modified Seldinger's technique. Large bore chest drains are inserted by blunt dissection technique.
1585305|NCT02344511|Drug|Dalbavancin|Drug
1585306|NCT02344511|Drug|cefazolin, nafcillin, oxacillin or vancomycin|Standard of Care
1585307|NCT02344498|Drug|Tenofovir disoproxil|
1585309|NCT02344472|Drug|pertuzumab|HER2 targeted Therapy
1585310|NCT02344472|Drug|Trastuzumab|HER2 targeted Therapy
1585311|NCT02344472|Drug|Capecitabine|Chemotherapy
1585312|NCT02344472|Drug|Paclitaxel|Chemotherapy
1585313|NCT02344472|Drug|Vinorelbine|Chemotherapy
1585314|NCT02344472|Drug|Docetaxel|Chemotherapy
1585315|NCT02344472|Drug|Exemestane|endocrine therapy
1585316|NCT02344472|Drug|Letrozole|endocrine therapy
1585317|NCT02344472|Drug|Anastrozole|endocrine therapy
1585318|NCT02344472|Drug|Fulvestrant|endocrine therapy
1585319|NCT02344472|Drug|Tamoxifen|endocrine therapy
1585320|NCT02344459|Device|mechanical pre-induction cervical ripening|The balloon catheters have been used to provide mechanical dilation to the cervix as a method of pre-induction cervical ripening.
1585321|NCT02344446|Other|Skilled Therapy|Active physical therapy treatment
1585322|NCT02344433|Behavioral|VICKY|Relational agent/virtual counselor
1585323|NCT02344433|Behavioral|MFHP|US Surgeon General's family history tool
2008835|NCT03326921|Other|Laboratory Biomarker Analysis|Correlative studies
2008836|NCT03326908|Device|Spectral Domain Optical Coherence Tomography|Five SD-OCTs will be performed with various conditions of enlightenment.
2008837|NCT03326895|Device|Left-sided colon resection|Left-sided colon resection with manual circular stapler
1585328|NCT02344407|Biological|VSVG-ZEBOV|The VSVdeltaG-ZEBOV vaccine is comprised of a single recombinant (vesicular stomatitis virus) VSV isolate (11481 nt) modified to replace the gene encoding the G envelope glycoprotein with the gene encoding the envelope glycoprotein from the Ebola virus Zaire strain (ZEBOV)
1585329|NCT02344407|Biological|ChAd3-EBO Z|The ChAd3-EBO Z vaccine is comprised of a ChAd3 vector with a DNA fragment insert that encodes the Ebola virus glycoprotein, which is expressed on the virion surface and is critical for attachment to host cells and catalysis of membrane fusion.
1585330|NCT02344407|Biological|Placebo|
1585331|NCT02344394|Device|Medtronic Cryoballoon|For endocardial pulmonary vein Isolation, an Arctic Front Advance Cardiac CryoAblation catheter (Medtronic, Mounds view, MN, USA) will be used.
1585332|NCT02344394|Device|Thermocool Catheter|For mapping and ablation from endocardium a 3.5 mm irrigated tip catheter (Navistar Thermocool SmartTouch Unidirectional Navigation Catheter, Biosense Webster, Diamond Bar, CA, USA) will be used.
1585333|NCT02344394|Device|nContact|For Epicardial Ablation (the surgical portion of the Hybrid procedure), we will use the VisiTrax cardiac ablation device (nContact, Morrisville, NC, USA).
1585334|NCT02344381|Dietary Supplement|Sucrose|
1585335|NCT02344381|Dietary Supplement|Glucose|
1585336|NCT02344368|Other|0.2 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
1585337|NCT02344368|Other|0.5 ml sucrose 25%|Administered on the tongue by a syringe, a half dose two minutes before blood sampling and the other half dose immediately before sampling
1585338|NCT02344355|Drug|Temozolomide|"oral temozolomide (75 mg/m2), given 7 days per week, for a maximum of 49 days during radiation therapy.
Starting 1 month after radiation therapy, additional temozolomide will be given as chemotherapy cycles. Each cycle is 28 days.
For the first cycle, temozolomide will be administered (150 mg/m2) once per day for 5 days.
If the subject tolerates the first cycle well, temozolomide will be prescribed at 200 mg/m2 for cycles 2 through 6. Each cycle is 28 days."
1585339|NCT02344355|Radiation|radiation therapy|Conformal radiation administered daily, M-F, to a total dose of 61.2 Gray in 34 fractions.
1585340|NCT02344355|Drug|Ascorbic Acid|"Intravenous infusions of 87.5g of ascorbate administered three times weekly during radiation.
After radiation, ascorbate is administered twice weekly through the end of cycle 6 of temozolomide."
1585341|NCT02344342|Device|Telemonitoring|The Health Buddy web management system allows the patient to enter self-care data through a study provided tablet computer.
1585342|NCT02344342|Other|Flexible Diuretic Regimen|Patients will have a prescribed diuretic regimen specified by specific weight ranges.
1585343|NCT02344329|Device|Topical wound dressing|Topical Wound Dressing
1585344|NCT02344329|Biological|Human Amnion Allograft|Change dressing every two to three weeks and TCC-EZ is changed weekly for 12 or until healed.
1585345|NCT02344329|Other|usual wound care|assessment, wound cleansing, debridement, moist wound environment, and off-loading
2008838|NCT03326895|Device|Left-sided colon resection|Left-sided colon resection with powered stapler
2008839|NCT03326882|Device|Endotracheal intubation|
1585348|NCT02344303|Drug|TRV130|
1585349|NCT02344303|Drug|Moxifloxacin|
1585350|NCT02344303|Drug|Placebo|
2008840|NCT03326869|Device|Raindrop Near Vision Inlay|The Raindrop Near Vision Inlay was approved by the US FDA in June of 2016 for the improvement of near vision in presbyopic emmetropes. Raindrop is a clear device made of a hydrogel material and resembles a microscopic contact lens; it is the first implantable device that changes the shape of the cornea to correct the refractive errors that cause near vision problems.
2008841|NCT03326856|Biological|botulinum toxin, Type A|topical liniment
1585353|NCT02344277|Device|S-ICD System (implantable defibrillator)|"The subjects will be symptomatic or asymptomatic Brugada patients with Indication for ICD replacement. Patients should be follow first at 1 month and then every 6 months according to the recent ACC/AHA/HRS guidelines60, for a period of 5 years until remote monitoring became available for S-ICD.
Visit to 4 week post-implantation: Vital status, Clinical assessment data: weight; height; blood pressure; NYHA class, Exercise test will be performed to control sensing vectors during exercise, Electrocardiogram, Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form. Visit every 6 months post-implantation to 5 years follow-up visit: Vital status, Clinical status (e.g.NYHA) , Electrocardiogram , Current cardiac medication, Device interrogation, Device programming, Save to USB pen drive data + Printouts Adverse events, Life quality evaluation form, Current status of S-ICD system."
1585354|NCT02344264|Drug|Ropivacaine|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).
Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
1585355|NCT02344264|Drug|Saline|"Arm RP is receiving 8 ml of ropivacaine 7,5 mg/ml at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with placebo (saline 8ml).
Arm PR is receiving 8 ml of placebo (saline) at first blockade (NCFL) and after 45 minutes another blockade (NCFL) with ropivacaine 8 ml."
1585356|NCT02344251|Device|MEMS Cap|MEMS Track Cap records when the medication bottle is opened and closed
1585357|NCT02344251|Device|ID-Cap|ID-Cap Tag is an ingestible medical device for detecting the presence of an ingested capsule inside the gastrointestinal (GI) tract.
1585358|NCT02344251|Dietary Supplement|Riboflavin|50 mg
1585359|NCT02344238|Other|ID Cap|Capsule-encased computer chip
1585360|NCT02344238|Dietary Supplement|Riboflavin|50mg
1585361|NCT02344238|Behavioral|Prompts|Reminder calls and/or text messages to ingest the study medication if a signal is not sent to the study team within one hour of the scheduled medication administration time.
1585445|NCT02343536|Drug|Oral Azacitidine|
2008842|NCT03326856|Biological|Vehicle|Vehicle Formulation
2008843|NCT03326843|Drug|Avatrombopag 60 mg|Oral avatrombopag administered once daily for 5 days prior to procedure.
1585362|NCT02344225|Drug|Caffeine citrate|Caffeine citrate IV (20 mg/kg loading dose, 5 mg/kg/day maintenance dose)
1585363|NCT02344225|Drug|Ibuprofen|Ibuprofen (10 mg/kg loading dose followed by low dose ibuprofen 2.5 mg/kg/day) for 5 days
1585364|NCT02344225|Drug|Ketorolac|Ketorolac (Acuvail) eye drops (one drop two times a day) for 14 days
1585365|NCT02344212|Behavioral|ESENCIAL Para Vivir: a weight loss program for Latinas|Overweight or obese Latina immigrant women were recruited to participate an 8-week weight loss program to reduce or delay their risk of developing diabetes. Data was collected at baseline, program completion, and six months.
1585366|NCT02344186|Drug|Liraglutide|Crossover design - 24 weeks on active drug and 12 weeks daily placebo
1585367|NCT02344160|Other|Phlebotomy|Phlebotomy will be performed at study follow up visits to obtain blood for metal ion analysis which will monitor levels for safety outcome measures
1585368|NCT02344134|Biological|NBP607|0.5 mL, intramuscular, a single dose
1585369|NCT02344134|Biological|Agrippal S1|0.5 mL, intramuscular, a single dose
1585370|NCT02344121|Radiation|Radiation Therapy|Radiation therapy plans for cancer patients who have completed treatment.
1585371|NCT02344108|Device|Inspire® Upper Airway Simulation System, Model 3024 IPG, and any subsequent iteration thereof that are approved under P130008 for the treatment of obstructive sleep apnea|Subjects will be implanted with a hypoglossal nerve stimulator. Safety and efficacy of implantation will be evaluated.
1585372|NCT02344095|Drug|weekly paclitaxel|Patients are treated with weekly paclitaxel 70mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks
1585373|NCT02344095|Drug|weekly cisplatin|Patients are treated with weekly cisplatin 40mg/m2 (IV) on day 1, 8, and 15 at an intervals of 4 weeks.
1585374|NCT02344095|Device|oncothermia|"Thermotherapy is performed by applying oncothermia (EHY 2000) probe on the part of body where tumor is located and delivering energy. It is performed on day 1, 4, 8, 11, 15, 18, 21, and 24 (8 times in total every cycle). Oncothermia can be performed a day earlier than scheduled day or a day later than scheduled day. With tumors at multiple sites, oncothermia is performed several times changing sites that apply probe and type of probes.
- It takes 60 minutes to treat a site for oncothermia. Energy is gradually increased from 60W to 140W."
1585375|NCT02344082|Other|Telemedicine|The intervention arm will receive pharmacy clinic visits plus additional telephone follow-up.
1585376|NCT02344069|Drug|Fibrinogen|Human fibrinogen concentrate as a injection
1585377|NCT02344069|Drug|Placebo|Saline 0.9% as a injection
1585378|NCT02344056|Other|Having lunch/skipping lunch|Lunch ad libitum on test day 1 and no lunch on test day 2. Water at libitum was constantly available on both days.
1585379|NCT02344056|Other|Skipping lunch/having lunch|No lunch on test day 1 and lunch ad libitum on test day 2. Water at libitum was constantly available on both days.
1585380|NCT02344043|Device|Near infrared spectroscopy|This device uses near infrared spectroscopy to measure tissue oxygen levels (0-100%). The sensors are placed on the subjects' forehead to measure brain tissue oxygenation
1585381|NCT02344030|Device|channeled blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
1585382|NCT02344030|Device|standard blade|In a randomised trial we measure the time for ventilation by means of endtidale CO2 Curve
1585383|NCT02344017|Drug|ODM-204|co-administered with prednisone, orally daily
1585384|NCT02344017|Drug|Prednisone|ODM-204 is co-administered with oral prednisone
1585385|NCT02344004|Drug|Liposomal Amikacin for Inhalation|
1585386|NCT02343991|Device|Transcranial ExABlate|MR Guided Focused Ultrasound
1585387|NCT02343978|Drug|KWA-0711|
1585388|NCT02343965|Other|Touch-massage|
1585389|NCT02343952|Drug|Pembrolizumab|Pembrolizumab, 200 mg IV every 3 weeks (until PD, unacceptable toxicity, or after 12 months of therapy with pembrolizumab.
1990756|NCT01832233|Procedure|Renal Denervation|The Symplicity Renal Denervation System is indicated for the delivery of low-level radiofrequency energy through the wall of the renal artery to denervate the kidney and reduce blood pressure in adult patients with refractory hypertension. The Symplicity Generator delivers controlled relatively low power radiofrequency energy (approximately 8 watts for 2 minutes). The Symplicity System selectively denervates the kidney by delivering radiofrequency from the generator via the electrode of the catheter through the renal artery wall from the intra-luminal side to ablate the renal sympathetic efferent and afferent nerves and reduce overall sympathetic nervous system activity.
1585396|NCT02343926|Drug|GEMIGLIPTIN LS15-0444|"Pharmaceutical form:tablet
Route of administration: oral"
1585397|NCT02343926|Drug|vildagliptin|"Pharmaceutical form:tablet
Route of administration: oral"
1585398|NCT02343926|Drug|metformin|"Pharmaceutical form:tablet
Route of administration: oral"
1585399|NCT02343913|Device|PAC checklist|
1585400|NCT02343887|Other|neuropsychological tests|
1585401|NCT02343887|Other|STAI-Y scale for anxiety|
1585402|NCT02343887|Other|Beck scale for depression|
1585403|NCT02343887|Other|without intervention|
1585404|NCT02343874|Other|No intervention|No intervention will be done. The exposure of interest in this study is alcohol consumption in patients attended in primary health.
1585405|NCT02343861|Behavioral|Tailored leaflet group|Parents in intervention group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients. In addition to general information, parents in intervention group will also receive the tailored leaflet including the estimated amount of emollients based on the body surface area.
1585406|NCT02343861|Behavioral|Control group|Participants (parents of children with atopic dermatitis) in control group will receive an patient education leaflet and watch an educational video about lifestyle recommendations, and the use of emollients.
1585407|NCT02343848|Device|smart bracelet.|Physical activity will be evaluated using smart bracelet.
1585408|NCT02343835|Device|NanoKnife LEDC System|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels and bile ducts. With IRE, multiple electrical pulses are applied to tumorous tissue. These pulses alter the existing transmembrane potential of the cell membranes, and create 'nanopores', after which the cell dies through loss of homeostasis.
1585446|NCT02343536|Drug|Rituximab|
1585447|NCT02343536|Drug|cyclophosphamide|
1585409|NCT02343822|Other|Platelet Rich Plasma Injection|"Plasma component of blood rich in growth factors
-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
1585410|NCT02343822|Other|Saline Injection|"Saline
-during the injection, 5 needle fenestrations will be done to help stimulate blood flow to the area for healing"
1585411|NCT02343809|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. The hook is deeply applied following the intermuscular septum between the muscles with an anatomical of functional relationship with the painful structure in order to release adherences between musculoskeletal structures.
1585412|NCT02343809|Other|Sham Diacutaneous Fibrolysis|Sham Diacutaneous Fibrolysis is applied at a superficial level. A pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
1585413|NCT02343809|Other|Protocolized Physiotherapy|Protocolized physiotherapeutic treatment: Three weeks fo daily stretching exercises, ultrasound and analgesic electrotherapy
1585414|NCT02343796|Other|Fibreglass reinforced composite restoration-everStick|For those subjects with space availability on interocclusal distance, composite resin restorations with fibreglass reinforcement will be applied without any tooth preparation by using adhesive techniques.
1585415|NCT02343796|Device|everStick|GC, Belgium
1585416|NCT02343783|Other|Allergic Skin Reaction (ASR) Testing and Skin Blister Induction|Participants will not receive any intervention in this study. Healthy participants will be enrolled in order to allow for training on the overall skin blister induction and fluid aspiration process. The cell populations and inflammatory mediator responses in suction skin blister fluid after allergic skin reaction (ASR) in participants with atopic dermatitis (AD) or allergic asthma (AA) will be observed.
1585417|NCT02343770|Other|blood sample for identifying biomarkers|
1585418|NCT02343757|Device|PET/MRI|
1585419|NCT02343744|Drug|Guselkumab|"Participants will receive 50 milligram (mg) guselkumab subcutaneously at Weeks 0, 4 and 12. At Week 16 through the study end (Week 52) participants who are defined Very much improved or Much improved in Clinical Global Impression (CGI) will continue to receive guselkumab 50 mg every 8 weeks from Week 20 to the study end (Week 52). At each visit timing from Week 20, participants who are defined No change or Worsened in CGI will receive guselkumab 100 mg and continue 100 mg every 8 weeks dosing until the study end (Week 52). Participants who are defined Minimally improved in CGI will also receive guselkumab 100 mg only if the investigator considers that it is necessary."
1585420|NCT02343731|Other|Introduction of a dog into the home|Participants will foster dogs from the HSSA for three months while they are in the study.
1585423|NCT02343705|Device|Latella Knee Implant System|
1585424|NCT02343692|Procedure|EUS guided RFA of cystic tumours of the pancreas|Endoscopic ultrasound guided radiofrequency ablation of pancreatic cysts
1585425|NCT02343679|Drug|ceritinib|Ceritinib will be administered to ALK + hematologic malignancies orally at the 750mg/day dose that has been calculated as the maximum tolerated dose in prior phase I trials in lung cancer patients. Intra patient dose reductions will be allowed for toxicities. Subjects with stable disease or better will be allowed to continue study drug until disease progression or until intolerable adverse events or patient or physician choice.
1585426|NCT02343666|Biological|C46/CCR5/P140K Lentiviral Vector-transduced Autologous HSPCs|Given IV
1585427|NCT02343666|Drug|Carmustine|Given IV
1585428|NCT02343666|Biological|Filgrastim|Given SC
1585429|NCT02343666|Other|Laboratory Biomarker Analysis|Correlative studies
1585430|NCT02343666|Drug|O6-Benzylguanine|Given IV
1585431|NCT02343666|Drug|Plerixafor|Given SC
1585432|NCT02343653|Behavioral|Nutrition and strength training|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:
Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered.
The intervention group will receive supervised training."
1585433|NCT02343653|Behavioral|Nutrition|"All participants will receive professional dietary guidance and a protein supplement. At the beginning and end of the intervention every participant will be part of a program consisting of:
Test of muscle strength, blood samples, assessment of nutritional status, MRi scan, test of Quality of life by questionnaire and test of the ammonium metabolism. After one year readmissions will by registered."
1585434|NCT02343627|Drug|NVXT Solution|NVXT Solution, applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
1585435|NCT02343627|Drug|Vehicle of test product|Vehicle of test product applied to infected toe nails and 0.5 mm of adjacent skin once daily for 60 days.
1585436|NCT02343614|Drug|Celecoxib|
1585437|NCT02343601|Device|Photoplethysmography|Use Photoplethysmography for hemodynamic optimization during colorectal perioperative period
1585438|NCT02343588|Behavioral|The Health Lifestyles Interventions|"Creating supportive school and family environment, whole intervention periods;
Health lifestyles educational strategies, 30min/week for education lessons and six times education activities;
Instruct and promote school physical education, whole intervention periods;
The monitoring and instruction of obesity related behaviors, once a week for physical activity and dietary behavioral log and once a month for parental monitor"
1585439|NCT02343575|Drug|Valproic Acid|"1.
Start:
VPA PO/NGT 500 mg BID
2.
If need to increase in 24 or more hours:
VPA 500 mg PO/NGT q am, 1000 mg PO/NGT QHS
3.
If need to increase in 24 or more hours:
VPA 500 mg PO/NGT q am, 1500 mg PO/NGT QHS
4.If need to increase in 24 or more hours:
VPA 500 mg PO/NGT Q am, 2000 mg PO/NGT QHS"
1585440|NCT02343575|Drug|Placebo|Placebo 500 mg matched to VPA BID PO/NGT
1585441|NCT02343575|Drug|Haloperidol|Both arms (intervention VPA and placebo) will receive flexible as needed haloperidol: Rescue: HAL IV 2-5 mg Q4hr PRN
1585442|NCT02343562|Dietary Supplement|Probiotics|Probiotics in the form of sachet will be given twice daily for a period of at least 6 months during the trial period.
1585443|NCT02343562|Dietary Supplement|Placebo|Multivitamin off-the-counter.
1585444|NCT02343549|Device|bevacizumab, NovoTTF100A, temozolomide|
1585450|NCT02343510|Other|PCR for chlamydia DNA in primary tubal cancer|PCR for presence of chlamydia DNA in paraffin blocks retrieved for tubal and ovarian tissues in all groups
1585451|NCT02343497|Dietary Supplement|Astaxanthin|
1585452|NCT02343497|Dietary Supplement|Placebo|
1585453|NCT02343484|Drug|Gelified ethanol combined to pulsed radiofrequency|Gelified ethanol (Discogel) is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally. Pulsed radiofrequency treatment is performed intradiscally for the management of chronic discogenic low back pain. The intradiscal pulsed radiofrequency is first applied and then combined to gelified ethanol injection via the same radiofrequency needle.
1585454|NCT02343484|Drug|Gelified ethanol|Gelified ethanol is a sterile, implantable medical solution which is administered within the affected intervertebral disc nucleus pulposus, via a fine needle which is guided into the center of the disc, transdermally.
1585455|NCT02343471|Dietary Supplement|20 g whey protein|
1585456|NCT02343458|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI; PT003); Glycopyrronium and Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
1585457|NCT02343458|Drug|FF MDI (PT005)|Formoterol Fumarate Metered Dose Inhaler (FF MDI; PT005); Formoterol Fumarate Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
1585458|NCT02343458|Drug|GP MDI (PT001)|Glycopyrronium Metered Dose Inhaler (GP MDI; PT001); Glycopyrronium Inhalation Aerosol administered as 2 inhalations twice-daily (BID)
1585459|NCT02343458|Drug|Placebo MDI|Placebo (matching) for GFF MDI, FF MDI, and GP MDI administered as 2 inhalations twice-daily (BID)
1585460|NCT02343445|Drug|P-1037|P-1037 is a novel ENaC inhibitor
1585461|NCT02343445|Drug|Hypertonic Saline|4.2% saline solution
1585462|NCT02343445|Drug|Saline|0.17% saline solution
2008844|NCT03326830|Device|High-flow nasal oxygen|oxygen therapy will be delivered through a dedicated system, the Airvo2™ (Fisher&Paykel, New-Zealand).
1585466|NCT02343419|Other|Methacholine Challenge Test|"Forced oscillation technique test, plethysmography, interrupter technique test and spirometry will be performed in a row before any intervention and after inhalation of aerosols - normal saline, followed by increasing concentrations of methacholine: 0.03 mg/ml; 0.06 mg/ml; 0.125 mg/ml; 0.25 mg/ml, 0.5 mg/ml, 1 mg/ml, 2 mg/ml, 4 mg/ml, 8 mg/ml, 16 mg/ml.
In case of FEV1 decrease of ≥ 20% of the initial value methacholine challenge test will be ceased and patient will be administered 200 µg of salbutamol in inhalation. Then, pulmonary function tests will be performed after 15 minutes."
1585467|NCT02343406|Drug|ABT-414|ABT-414 will be administered by intravenous infusion over approximately 30-40 minutes.
1585468|NCT02343406|Drug|Lomustine|Lomustine will be administered orally.
1585469|NCT02343406|Drug|Temozolomide|Temozolomide (TMZ) will be administered orally.
1585470|NCT02343393|Drug|Hydralazine|
1585471|NCT02343393|Drug|Isosorbide Dinitrate|
1585472|NCT02343380|Other|calorimetric exam after a standard meal|The calorimetric and metabolic responses to identical meals (a high-protein, low-carbohydrates meal) consumed in the morning (8:00 am) and in the evening (8:00 pm) are measured in healthy volunteers, after standardizing diet, physical activity level, duration of fast and resting
1585473|NCT02343367|Behavioral|behavioral counseling|Pediatrician trained in motivational interviewing techniques provides brief lifestyle behavioral counseling to child and parent using a Healthy Lifestyle Prescription
1585474|NCT02343367|Other|Education Materials|Health education materials about healthy eating and physical activity and a community resource guide
1585475|NCT02343367|Behavioral|Face to face counseling session|30 minute face-to-face family-centered behavioral counseling session delivered by a health educator
1585476|NCT02343367|Behavioral|Text messages|regularly scheduled cell phone text messages for 12 months
1585477|NCT02343367|Behavioral|Telephone Counseling|14 telephone counseling sessions delivered by a health educator using motivational interviewing techniques. Two sessions per month for the first two months followed by one session per month for 10 months
1585478|NCT02343367|Behavioral|Newsletters|12 monthly newsletters mailed to participant homes
1585479|NCT02343354|Behavioral|Nutrition/physical activity intervention|Please see arm description
1585480|NCT02343341|Behavioral|Preschool Health Promotion Education Program|
1585481|NCT02343328|Biological|Fecal Microbiota Transplant|
1585482|NCT02343328|Biological|Placebo|
1585483|NCT02343315|Device|TENS|"Six treatment sessions will be given over two weeks. Total duration of the treatment session may last from 40 - 60 minutes.
Equipment- TENS (CEFAR Basic TENS Machine)
Electrodes- Four channel electrode to cover the site of pain
Site of electrode placement- will be decided by the physical therapist to best suit or cover the area of pain based on complaints of patient based on the body chart.
Intensity- the intensity will be increased progressively until maximum tolerable intensity is reached. This stimulation may cause visible muscle contraction. This type of current is also referred to as Motor-level TENS, which is effective for chronic pain. The intensity will not be increased beyond 25 milli Amperes if no sensation is perceived by the patient.
Frequency- 5 Hertz
Duration- 30 minutes"
1585484|NCT02343315|Other|SMCE|"Six sessions of supervised Motor control exercises will be provided over the period of two weeks. Exercises will be provided in order to target the function of core muscles of the spine. Each participant in the SMCE group will be trained by a physical therapist to recruit the deep muscles of the spine and reduce the activity of superficial muscles.
Initially participants will be taught how to contract the transversus abdominis and multiﬁdus muscles in isolation from the more superﬁcial trunk muscles, but in conjunction with the pelvic ﬂoor muscles. Pressure biofeedback will be used in order to provide feedback about muscle recruitment to the participant. Exercises will be provided to the participants in the progressive manner. Later, movement of limbs will be incorporated with the contraction of the core muscles. Finally, these core muscle activation will be emphasized during the functional activities."
1585526|NCT02343029|Other|Individualised aerobic exercise training|During the first 4 weeks of intervention two of the three weekly training sessions are offered as group training supervised by the respective qualified exercise physiologist of the Department of Sports Medicine. After 4 weeks, participants' physical performance is reassessed at the Department of Sports Medicine. If necessary, workload is readjusted to achieve the initially defined exercise intensity.
1585485|NCT02343315|Other|UHEP|"All the participants will receive the following treatments:
Unsupervised home exercise program- which includes series of motor control exercises along with specific exercises including stretching exercises based on impairments.
Education in terms of body mechanics, ergonomics advises and educational leaflet in the form of Nepali version of Back book which includes, evidence based advises about back pain self-management, advice to remain active. Treating physical therapist will educate all the participants in the first intervention session.
Participants will not be asked to not take the over the counter analgesics including Acetaminophen or Non-inflammatory anti-inflammatory drugs (ibuprofen)."
1585486|NCT02343302|Device|Suctioning Drainage|"A closed suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled suction drain"
1585487|NCT02343302|Device|Non-suctioning drainage|"A closed non-suctioning drain will be placed at the time of surgery. Patients in both arm A and arm B will receive this intervention. The patients that receive this treatment will be the ones whose envelope, selected on the basis of the texture of the gland, contains a card labelled gravity drain"
1585488|NCT02343289|Drug|Esketamine|28 mg of esketamine as a single, 40-minute, intravenous infusion on Day 1 of Period 1, 84 mg of esketamine solution as a single, oral dose on Day 1 of Period 2, 84 mg of intranasal esketamine on Day 1 of Period 3 and on Day 1 of Period 4.
1585489|NCT02343289|Drug|Clarithromycin|500 mg of clarithromycin twice daily on Days -3, -2, -1, 1, and 2 of Period 4.
1585490|NCT02343276|Drug|Nitroglycerin|Nitroglycerin (200 micrograms) + saline solution 10 ml in radial artery after sheath insertion
1585491|NCT02343276|Other|Placebo|Placebo (saline solution 10 ml) in radial artery after sheath insertion
1585492|NCT02343263|Drug|Bupivacaine|1 milliliter (mL) of 0.75% Bupivacaine Hydrochloride will be infused into 4mL of fibrin sealant (diluting the Bupivacaine HCl to 0.15%). The bupivacaine-infused fibrin sealant will then be applied to the tonsillectomy (or adenotonsillectomy) wound bed.
1585493|NCT02343263|Biological|Fibrin Sealant|Fibrin sealant will be applied to the wound bed topically as per product instructions.
1585494|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
1585495|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
1585496|NCT02343250|Drug|Cilnidipine/Valsartan|Cilnidipine 10mg/Valsartan 160mg oral on day1 of 14day cycle
1585497|NCT02343250|Drug|Cilnidipine+Valsartan|Cinidipine 10mg+Valsartan 160mg oral on day1 of 14day cycle
1585498|NCT02343237|Procedure|Osteopathic treatment|osteopathic sessions of 20 minutes
1585499|NCT02343237|Procedure|Factitious osteopathic treatment|6 factitious osteopathic sessions of 20 minutes
1585500|NCT02343224|Drug|Pegylated interferon alpha-2b|PEG-Intron 1mcg/kg/dose weekly through an injection under the skin on the same day each week
1585501|NCT02343211|Drug|Immunoglobulin|
1585502|NCT02343198|Device|Custom-built research muscle stimulator|Muscle stimulator
1585503|NCT02343185|Other|manual therapy with diaphragmatic treatment|Subjects receive five sesions of manual therapy for low back pain combined with diaphragmatic treatment.
1585504|NCT02343185|Other|Placebo treatment|Subjects receive five sesions of manual therapy for low back pain combined with a sham diaphragmatic treatment.
1585505|NCT02343172|Drug|HDM201|
1585506|NCT02343172|Drug|LEE011|
1585507|NCT02343159|Drug|dimethyl fumarate|120 mg and 240 mg delayed release capsules
1585508|NCT02343159|Device|Medication Event Monitoring System (MEMS)|The MEMS automatically compiles drug dosing history data by electronically recording the date and time of each opening of the medication container
1585509|NCT02343159|Behavioral|Adherence counseling|A telephone call to discuss adherence and individualized strategies based on data collected via smart device (i.e., LCD reader)
1585510|NCT02343146|Behavioral|Type One Training (TOT)|The intervention is comprised of a number of modes of delivery including in person, use of parent peer consultant, telephone intervention, and text messaging. The intervention is based on Social Cognitive Theory and previous work of the investigators.The focus of the intervention is on working with parents to improve child eating and physical activity behaviors as a means of improving glycemic control in very young children with type 1 diabetes.
1585511|NCT02343133|Biological|HemaMax|Recombinant human interleukin-12 [rHuIL-12]
1585512|NCT02343133|Biological|Placebo|Placebo
1585513|NCT02343120|Drug|BGB-3111|"In the dose-escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
In the safety, schedule and efficacy expansion part, patients will be assigned to different cohorts based on histology type."
1585514|NCT02343107|Behavioral|e-coaching|connexion to a website and interaction with an automatizes system which delivers tailored recommendations over a 4 month period.
1585515|NCT02343094|Drug|PBA 7,5g/d|Treatment for 14 days with PBA
1585516|NCT02343094|Drug|PBA 15g/d|Treatment for 14 days with PBA
1585517|NCT02343081|Drug|Temozolomide|
1585518|NCT02343081|Drug|Temozolomide|
1585519|NCT02343055|Other|Case Management and Self-Management Education|A Certified Respiratory Educator (CRE) will obtain a detailed COPD history, provide general and self-management education, and confirm a management plan with the primary care physician. Specific elements of evidence-based management are targetted for intervention. Subjects will return for a follow-up visit in-person with the interdisciplinary care team including a CRE to review their health status including COPD symptoms, exacerbation diary, symptoms, MRC scale, etc as a minimum at 3 and 12 months. Telephone follow up will occur at a minimum at 6 and 9 months.
1585520|NCT02343042|Drug|Selinexor|Tablets
1585521|NCT02343042|Drug|Dexamethasone|Oral tablets in a multi-dose vial.
1585522|NCT02343042|Drug|Lenalidomide|25mg Oral capsule
1585523|NCT02343042|Drug|Pomalidomide|4 mg oral tablets
1585524|NCT02343042|Drug|Bortezomib|3.5mg for injection supplied as lyophilized powder in single-use viles for subcutaneous injection.
1585525|NCT02343042|Drug|Daratumumab|16mg/kg Intravenous
1585527|NCT02343029|Other|Waiting Control|After waiting for 12 weeks with normal daily activity, patients are allocated to a individualised aerobic exercise training, too.
1585626|NCT02342340|Other|Red Kidney Beans (cooked)|One time consumption of 3/4 cup of cooked red kidney beans.
1585528|NCT02343016|Device|Near-InfraRed Spectroscopy (NIRS)|NIRS is a non invasive monitoring system that enables assessment of tissue oxygenation through a quantitative estimation of haemoglobin oxygen-saturation within tissues.
2008845|NCT03326830|Device|Standard oxygen therapy|Oxygen therapy will be delivered using standard devices such as nasal canula or face mask with or without rebreathing bag
2008846|NCT03326817|Other|Control Group|Patients receive standard care
1585531|NCT02342990|Other|Cluster B CogMed: an home-based and computer-based solution to improve working memory deficit|CogMed: an home-based and computer-based solution to improve working memory deficit
1585532|NCT02342990|Other|Cluster A No training. Delay start of CogMed|No training will be provided after T1 time point. Cluster A will start the CogMed training after the assessment at the T2 time point
1585533|NCT02342977|Drug|Placebo|Patients will randomly receive placebo
1585534|NCT02342977|Drug|Lacosamide|Patients will randomly receive lacosamide
1585535|NCT02342964|Other|Measure of hepatic elasticity|"Measure of hepatic elasticity by four non-invasive methods:
Fibroscan, Fibrotest, SWE, MRE."
1585536|NCT02342951|Other|Lung clearance index determination|Lung clearance index determination
1585537|NCT02342938|Procedure|MEG or fMRI And INtracranial EEG|
1585538|NCT02342938|Procedure|fMRI|
1585539|NCT02342925|Other|Omnipaque 300|647 mg/mL of iohexol, equivalent to 300 mg/mL of iodine, used for assessment of glomerular function and other measure of renal function
1585540|NCT02342925|Drug|RG1662|Oral administration twice daily
1585541|NCT02342925|Drug|metformin|Single 850 mg dose of metformin
1585542|NCT02342912|Behavioral|Social Media Treatments|Each of the three intervention groups offers information that has been shown to be important for college students to have a healthy body weight. All three groups provide information on topics that we know are related to having a healthy body weight, like managing stress, keeping track of how you spend your time, and increasing self-awareness of certain health behaviors. Two of the three programs are focused on weight loss for a healthy body. The third group focuses on having a healthy mind, body and having energy during college.
1585543|NCT02342899|Device|Outpatient NIV Set Up using AVAPS AE (Manufactured by Philips-Respironics)|Intervention set ups will follow a standard protocol for the automated device (A40 AVAPS-AE machine;Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) and patients will be discharged with the machine and a full face mask or nasal interface. Patients will then undergo a 1-2 night home oximetry study to ensure adequate control of overnight oxygenation. Patients will be reviewed clinically as an outpatient at 6 weeks and adherence to non-invasive ventilation will be evaluated and an arterial blood gas measurement will be undertaken. A full clinical review and optimisation of NIV and interface will be performed at this visit. Patients will be reviewed at 3 months as an inpatient where overnight transcutaneous carbon dioxide level and SpO2 studies will be performed. All other patient-centred, physician-centred and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
1585544|NCT02342899|Device|Inpatient NIV Set Up using spontaneous/timed (S/T) mode pressure support ventilation (Manufactured by Philips-Respironics)|The patient will follow a specialist nurse-led protocolised set up of spontaneous/timed (S/T) mode pressure support ventilation (A40 AVAPS-AE machine; Manufactured by Philips-Respironics, Murraysville, Pittsburgh, US) using limited respiratory polygraphy, including overnight TcCO2 (Trascutaneous Carbon Dioxide) and SpO2 (Oxygen Saturation) studies. Following the inpatient set-up, patients will be reviewed as an outpatient at 6 weeks and adherence with non-invasive ventilation will be evaluated and arterial blood gas measurements will be performed. Patients will then be reviewed at 3 months as an inpatient where overnight respiratory polygraphy, TcCO2 and SpO2 studies will be repeated. All other patient-centred, physician-centred measurements and healthcare utilisation measurements will be assessed at baseline, 6 weeks and 3 months.
1585545|NCT02342886|Drug|Moxifloxacin|Oral
1585546|NCT02342886|Drug|PA-824|Oral
1585547|NCT02342886|Drug|Pyrazinamide|Oral
1585548|NCT02342886|Drug|HRZE (Rifampicin, Isoniazid, Pyrazinamide, and Ethambutol combination tablet)|Oral
1585549|NCT02342886|Drug|HR (rifampicin plus isoniazid combination tablets)|Oral
1585550|NCT02342873|Procedure|NS-guided interscalene block|Patients received a standard single injection interscalene block using the modified lateral approach of Borgeat. The interscalene brachial plexus was identified using an insulated needle connected to a nerve stimulator. An insulated needle attached to a nerve stimulator was used to identify the brachial plexus. Placement of the needle was considered adequate if the deltoid, triceps, pectoralis, or biceps muscle motor response was still present at 0.2 - 0.5mA. Ropivacine 0.75% 20ml was used.
1585551|NCT02342873|Procedure|US-guided interscalene block|Interscalene block is performed under ultrasound guidance. Linear probe is placed on the ipsilateral interscalene groove visualizing the brachial plexus located between anterior and middle scalene muscles. Using in-plane technique, an insulated needle is advanced into the brachial plexus sheath, into which 20 ml of 0.75% ropivacaine is injected
1585552|NCT02342860|Other|WASH in Schools (WinS) programme|"The intervention group will receive the UNICEF/DFAT-supported WinS programme, which consists of the following intervention package:
Hardware: water supply system, handwashing station for group handwashing, and gender-segregated toilets with one facility accessible to students with physical disabilities;
Software: operations and maintenance (O&M) training for teachers, hygiene training, and basic hygiene package."
1585553|NCT02342847|Other|N/A (non-interventional study)|
1585554|NCT02342834|Dietary Supplement|Small mixed protein and lipid meal|Ingestion of a small mixed protein and lipid meal 30 minutes before glucose
1585555|NCT02342808|Behavioral|Structured center-based lifestyle intervention|Participants will meet with interventionists weekly for 16 weeks and receive instruction on the DASH diet with caloric and sodium restriction and will exercise three times per week at one of the designated CR facilities, under the supervision of medically trained staff, 3 times per week for 16 weeks.
1585556|NCT02342808|Behavioral|Standard education and physician advice|Participants will receive routine medical care provided by the participants' primary care physician(s) supplemented by an educational session on hypertension management. Participants will receive a dietary consultation from the study nutritionist and an individualized exercise prescription from an exercise physiologist, but not participate in a structured program. Participants will be free to engage in diet and exercise for the 16-week intervention.
1585567|NCT02342769|Drug|Dolutegravir/Abacavir/Lamivudin|Prospective, non-interventional observational study on the use of TRIUMEQ and the respective monitoring measures in the practice of HIV care in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
1585568|NCT02342756|Device|Targeting transpulmonary pressure to avoid VILI|Set different values of PEEP (CMV) and mPaw (HFOV) to obtain determined values of transpulmonary pressure (0 and 15 centimeters of water) and to determine the impact of ventilation on VILI
1585569|NCT02342743|Device|CEFALY|
1585570|NCT02342730|Behavioral|Weight Loss Specialist|Referred to a weight loss specialist
1585571|NCT02342730|Other|Quality-of-Life Assessment|Complete EORTC-QLQ questionnaires
1585572|NCT02342730|Other|Medical Chart Review|Chart reviews are performed
1585573|NCT02342717|Drug|BI 425809|single dose BI 425809 tablet
1585574|NCT02342717|Drug|Itraconazole|multiple doses of Itraconazole capsules
1585575|NCT02342717|Drug|BI 425809|single dose BI 425809 tablet
1585576|NCT02342704|Drug|natalizumab|Administered as specified in the treatment arm
1585577|NCT02342704|Drug|fingolimod|Administered as specified in the treatment arm
1585578|NCT02342691|Drug|BLXA4|BLXA4-ME is a member of a new class of chemically and metabolically stable lipoxin analogs featuring a replacement of the tetraene unit of native lipoxin-A4 (LXA4) with a substituted benzo-fused ring system. The full chemical name of the BLXA4-ME drug substance is (5S, 6R, E)-methyl 5,6-dihydroxy-8-(2-((R,E)-3-hydroxyoct-1-enyl) phenyl) oct-7-enoate.
1585579|NCT02342691|Drug|Placebo oral rinse|The placebo preparation will consist of formulated oral rinse without BLXA4-ME and will be identical to the test rinse in color, appearance and taste
1585580|NCT02342678|Behavioral|Yoga Therapy|
1585581|NCT02342678|Behavioral|Physical Conditioning|
2008847|NCT03326817|Device|Soft Robotic Glove Group|This group will receive standard care and soft robotic therapy (continuous passive motion device developed by National University of Singapore).
1585583|NCT02342652|Drug|ASLAN003|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
1585584|NCT02342652|Drug|Matched Placebo|Healthy subject will be randomised to receive either ASLAN003 (N-aryl substituted aminoaryloic acid derivative), which is a DHODH inhibitor developed with the aim of improving several features of teriflunomide or the matching placebo as a negative control for each dose of ASLAN003 administered.
1585585|NCT02342639|Drug|Rifaximin|550mg pills
1585586|NCT02342639|Drug|Placebo|Placebo pill
2008848|NCT03326804|Device|H1 Hip Resurfacing Arthroplasty|A non-porous non-cemented ceramic-on-ceramic hip resurfacing arthroplasty device
1585588|NCT02342613|Biological|Activated PTCy-MILs|
2008849|NCT03326791|Drug|Acetylsalicylic acid|Trombyl 160 mg once daily
2008850|NCT03326791|Drug|Placebo Oral Tablet|Placebo one tablet daily
1585591|NCT02342587|Drug|Lapatinib|Patients will be treated with oral lapatinib 1250mg once daily for 21 days.
1585592|NCT02342574|Drug|F901318|Administration of active compound
1585593|NCT02342574|Drug|Placebo|Administration of placebo
1585594|NCT02342561|Device|Ioban 2 incision drape, 3M|The anterior knee of the patient is covered with an Ioban 2 drape for 75 minutes. The drape is applied and removed in accordance with product instructions.
1585595|NCT02342548|Drug|20 mg BID of PF-02545920|All subject who completed A8241021 will receive 20 mg BID (with or without titration)
1585596|NCT02342535|Behavioral|Physical Activity|Culturally tailored physical activity intervention for South Asian women and their children.
1585597|NCT02342522|Device|Remote ischemic conditioning|An automated autoRIC™ cuff will be placed on the upper arm and inflated to 200mmHg for 5 minutes and then deflated for 5 minutes, a cycle which will be undertaken 4 times in total. For patients presenting with a systolic blood pressure (SBP)≥175mmHg, a manual blood pressure cuff will be used and inflated to 25 mmHg above systolic blood pressure.
1585598|NCT02342522|Device|Sham control|An automated autoRIC™ cuff will be placed on the upper arm and a simulated inflation and deflation protocol will be applied.
1585599|NCT02342509|Drug|Desflurane|Group A: Desflurane 5.0-6.0 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
1585600|NCT02342509|Drug|Sevoflurane|Group B: Sevoflurane 1.4-2.1 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
1585601|NCT02342509|Drug|Isoflurane|Group C: Isoflurane 0.9-1.2 Vol% (1.0 MAC) in Oxygen (FiO2 0.8-0.95)
1585602|NCT02342496|Dietary Supplement|Placebo|Powder
1585603|NCT02342496|Dietary Supplement|Active, only probiotics|Powder
1585604|NCT02342496|Dietary Supplement|Active, blend of berries and probiotics|Powder
1585605|NCT02342483|Dietary Supplement|MSM|
1585606|NCT02342470|Drug|Placebo|Drug : Placebo
1585607|NCT02342470|Drug|PMK-S005 1|Drug : PMK-S005 1 (50mg)
1585608|NCT02342470|Drug|PMK-S005 2|Drug : PMK-S005 2 (100mg)
1585609|NCT02342470|Drug|PMK-S005 3|Drug : PMK-S005 3 (150mg)
1585610|NCT02342457|Device|Child suspected of Hirschsprung disease|Children admitted for rectal biopsy, due to chronic constipation and suspected of Hirschsprungs disease, will undergo electrophysiological reading from the rectal inner wall, at thechosen site for biopsy before biopsy is performed. Histopathology and readings will be analyzed for corelation
1585611|NCT02342444|Drug|Enoxaparin Sodium Injection 30 mg BID|
1585612|NCT02342444|Drug|Enoxaparin Sodium Injection 40 mg QD|
1585613|NCT02342431|Device|Forced air warming compressible|Warming with a compressible forced air mattress
1585614|NCT02342431|Device|Forced air non-compressible|Warming with a non-compressible forced air mattress
1585615|NCT02342418|Drug|Tedizolid phosphate|Each group will receive a single dose of tedizolid phosphate 200 mg through a peripheral intravenous catheter.
1585616|NCT02342405|Other|80% oxygen|
1585617|NCT02342405|Other|30% oxygen|
1585618|NCT02342392|Drug|ranibizumab|Intralesional ranibizumab 0.3 mg/0.03mL injected 1 week before pterygium excision surgery.
2008851|NCT03326778|Procedure|AVR and CABG|Combined AVR with CABG
1585628|NCT02342340|Other|Black Beans (cooked)|One time consumption of 3/4 cup of cooked black beans.
1585629|NCT02342340|Other|Lentils (cooked)|One time consumption of 3/4 cup of cooked lentils.
1585630|NCT02342340|Other|White Rice|One time consumption of 3/4 cup of cooked white rice.
1585631|NCT02342327|Other|switch to non-menthol cigarettes prior to cessation attempt|
1585632|NCT02342327|Other|continue smoking menthol cigarettes prior to cessation attempt|
1585633|NCT02342314|Drug|LY3143753 (Part A)|Administered via SC injection
1585634|NCT02342314|Drug|LY3185643 (Part B)|Administered via SC injection
1585635|NCT02342314|Drug|Normal Saline|Administered via SC injection
1585636|NCT02342301|Behavioral|Standing Desk|Participants will be provided with a standing desk for 3 months
1585637|NCT02342301|Behavioral|Traditional Desk|Participants will use a traditional seated desk for 3 months
1585638|NCT02342288|Procedure|Head raised 10 degrees|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. Head was raised to 10 degrees. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
1585639|NCT02342288|Procedure|Head in neutral position|Baseline measurement in seated position; anesthetization in the supine position. Prior to turning into the prone position, another measurement was taken. Five minutes after turning prone, a third IOP measurement was obtained. After 5 minutes a fourth IOP measurement was performed. Repeat measurements were taken every 15 minutes until three sequential measurements were within plus or minus 3 mmHg of one another; thereafter, measurements were obtained every hour until end of case. A final measurement was taken after turning the patient supine and 5 minutes elapsed for equilibration.
1585640|NCT02342275|Drug|Propranolol|Initiated at a dosage of 1 mg/kg per day divided 3 times daily for 1 week, and then increased to 2 mg/kg per day divided 3 times daily from weeks 2 to 24.
1585641|NCT02342275|Drug|Atenolol|Initiated at a dosage of 0.5 mg/kg per day in a single dose for 1 week, and then increased to 1 mg/kg per day in a single dose from weeks 2 to 24.
1585642|NCT02342262|Dietary Supplement|EcologicBarrier|multispecies probiotic product, 2x10-9 cfu/gram
1585643|NCT02342262|Other|Placebo|similar appearance as the probiotic product, but without bacteria
1585644|NCT02342249|Drug|VX-787 300 mg|A oral dose of 300 mg VX-787 tablet will be administered over 5-6 days.
1585645|NCT02342249|Drug|VX-787 600 mg|A oral dose of VX-787 600 mg (formulated as 2*300 mg tablets) will be administered over 5-6 days.
1585646|NCT02342249|Drug|Oseltamivir 75 mg|A oral dose of 75 mg Oseltamivir capsule will be administered over 5-6 days.
1585647|NCT02342249|Drug|Placebo|Subjects will receive matching placebo of Oseltamivir
1585648|NCT02342236|Device|cemented or cementless type of hip prothesis|
1585649|NCT02342223|Device|Voluma|
1585650|NCT02342210|Behavioral|Mindfulness Ambassador Council for Early Psychosis (MAC-EP)|MAC is a 12-week facilitated group mindfulness intervention promoting the development of social-emotional competence in youth created by Mindfulness Without Borders (MWB; www.mwb.org). A meditative practice, mindfulness focuses one's awareness on the present, acknowledging and accepting without judging one's feelings, thoughts, or bodily sensations. Each session has a unique focus (e.g., paying attention, practicing gratitude) and consists of facilitated group learning, discussion and mindfulness skills practice. Home assignments to help reinforce specific lesson are also assigned. Although MAC has demonstrated acceptability, feasibility, and promising beneficial effects in schools, it has yet to be implemented and/or evaluated in a clinical population. Its youth-focus and emphasis on building social and emotional competencies through mindfulness, in addition to teaching core mindfulness skills make it a promising intervention for youth recovering from their first episode of psychosis.
1585651|NCT02342197|Drug|Decapeptyl|half the dose of Gn agonist
1585652|NCT02342184|Drug|GB-0998|
1585653|NCT02342171|Other|Convalescent Plasma|Patients will be treated with plasma from recovered EVD patients.
1585654|NCT02342158|Procedure|biopsy or surgical sampling|
1585655|NCT02342158|Other|blood sampling|
1585656|NCT02342145|Drug|Basiliximab,|Basiliximab was used 10mg each time on 0d(after transplantation) and +4 d .
1585657|NCT02342145|Drug|cyclosporine A|Specifically cyclosporine A was used by intravenous drip infusion on 2mg/kg dosage from -1d and change to 5mg/kg twice oral when gastrointestinal function recovers. The blood concentrations of cyclosporine A was maintained 150-250ng/ml.
1585658|NCT02342145|Drug|Methotrexate|Methotrexate was used 15mg/m2 on +1d and 10mg/m2 on +3,+6,+11d by intravenous for prevention of graft-versus-host-disease.
1585659|NCT02342145|Drug|Mycophenolate mofetil|Mycophenolate mofetil was used 0.25g qd from 0d to 3 months for prevention of graft-versus-host-disease.
1585660|NCT02342132|Device|Non-invasive bipap ventilator|The non-invasive bipap ventilator will be used in the following respiratory treatment: bipap assisted inspiratory breaths (BAIB). The patient will be encouraged to take deep breaths at least 1.5 times greater than resting tidal volume. The pressure assistance provided by the bipap starts at 10cm H2O. Patients already on bipap will use their home settings. Starting pressure is then increased as necessary to meet the maximal inspiratory goal volume in steps of 2 up to a maximum 20cm H2O. Once the ideal pressure of support levels are established, the child will perform 3 cycles of 5 deep breaths. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
1585661|NCT02342132|Device|Mechanical insufflator-exsufflator|A commercial mechanical insufflator-exsufflator will be used in the following treatment: Mechanical insufflation-exsufflation (MI-E). The pressure will be administered by a face mask. The optimal pressure for the test will start at 10 cm H2O and will in crease in steps of 5 to a maximum of 25 cm H2O. The insufflation phase will take 3 seconds followed by a 2 second exsufflation phase. Three cycles of treatment will be used. Between each cycle the subject will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
1585701|NCT02341794|Drug|Rosuvastatin|Rosuvastatin (5mg) will be orally administrated once daily. Dose of rosuvastatin will be adjusted to control serum LDL-c level under 1.8 mmol/L.
1585750|NCT02341508|Other|Saline solution for intravenous infusion|
1585662|NCT02342132|Device|High frequency percussive oscillator|A commercial high frequency percussive oscillator will be used in the following treatment: combined oscillation and nebulisation. Pressures will be delivered by a face mask. At higher oscillation frequencies it is usually necessary to support the cheeks. Pressure will be gradually be increased to accustom the child to a maximum of 25cm H2O. This standard maximal pressure will ideally be used for every child. A treatment cycle will consist of 3 minutes at a frequency of 2 Hz and pressure of 15cm H2O followed by 3 minutes of 4 Hz at 20cm H2O, then 3 minutes of 5 Hz at 25cm H2O. Throughout each cycle, the patient will receive nebulized saline through the machine. After each cycle the patient will pause and perform huffing and assisted coughing. The patient will be suctioned as necessary.
1585663|NCT02342119|Other|Talking About Living Kidney Donation|TALK participants receive a culturally sensitive educational booklet and video. A study interventionist encourages participants to share the materials with their family members or friends. Materials provide information to encourage patient and families shared and informed consideration of LDKT, including: 1) information about eligibility for LDKT, 2) the clinical evaluation required for LDKT, 3) the donor selection process, 4) surgical procedures for transplantation and donation, 5), and concerns brought forth about these factors, identified through structured group interviews.
1585664|NCT02342119|Other|Kidney Transplant Fast Track|KTFT is a one-day streamlined transplant evaluation process. Every patient who is evaluated at the University of Pittsburgh Starzl Transplant Center receives the KTFT. This approach involves completion of most or all testing on the same day that patients arrive for their first pre-transplant clinic appointment, rather than providing them with a list of tests they complete on their own with their referring physician. If patients are unable to be scheduled the same day, the transplant clinic scheduler secures appointment times and preparatory material for all testing to be completed within a 2 week period.
1585665|NCT02342093|Drug|30EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (30EE+DRSP), 1 pill once a day with a pause of seven days between the blisters for 6 months
1585666|NCT02342093|Drug|20EE+DRSP|Combined oral contraceptive containing 30 mcg of ethinylestradiol + 3 mg of drospirenone (20EE+DRSP), 1 pill once a day with a pause of four days between the blisters for 6 months
1585667|NCT02342080|Other|Training sessions|A group with spinal cord injury will be trained in a 30-minute session 5 times weekly for 6 weeks. Each session will be supervised by qualified staff. Patients will undergo training with gradual increase in load and speed, according to the tolerance of each patient. The body weight support progression will start at 50 % of the patient body weight. It will be changed every 2 weeks and the load will decrease 10%. The progression of speed may be accompanied during the training period.
1585668|NCT02342080|Device|Lokomat system (Hocoma AG Switzerland)|For the robot locomotion therapy, the Lokomat system (Hocoma AG Switzerland) will be used.
1585669|NCT02342067|Drug|Cenicriviroc|CVC 150 mg QD on Days 1-10, washout on Days 11-20, PGZ 45 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
1585670|NCT02342067|Drug|Pioglitazone|PGZ 45 mg QD on Days 1-10, washout on Days 11-20, CVC 150 mg QD on Days 21-30, and CVC 150 mg QD + PGZ 45 mg QD on Days 31-40
1585671|NCT02342054|Radiation|MRI-TRUS fusion guided Single Frac HDR|
1585672|NCT02342041|Drug|SUVN-G3031|
1585673|NCT02342041|Drug|Placebo|
1585674|NCT02342028|Biological|OSA|This study aims to compare the difference in the number and function of regulatory T cells between OSA patients and controls. The investigators will draw peripheral venous blood samples from both groups and measure the number and function of their regulatory T cells. However, some, NOT ALL, of OSA patients may receive continuous positive airway pressure (CPAP) treatment-the standard therapy for severe-to-moderate OSA. Use of CPAP is based on physician's suggestion and patients' decision, but not for this study. The devices are provided by patients themselves and its type/brand is not limited or prespecified. For those with CPAP therapy, their blood sample will be re-collected 26 weeks later to repeat measurement for subgroup analysis.
1585675|NCT02342015|Drug|Atorvastatin|Atorvastatina 40mg/day for three months
1585676|NCT02342002|Drug|Mifepristone|Mifepristone for treatment of missed abortion
1585677|NCT02342002|Drug|Misoprostol|Misoprostol for treatment of missed abortion
2008852|NCT03326765|Other|Questionnaires|"Epworth sleepiness scale
Pittsburgh sleep quality Index (PSQI)
EQ-5D Adults
Pediatric Daytime Sleepiness scale (PDSS)
Sleep disturbance Scale for Children (SDSC
EQ-5D Children
Sleaping diary"
1585680|NCT02341976|Other|Vibratory platform exercises|Different positions on vibratory platform with different frequencies
1585681|NCT02341963|Drug|Oral Ketamine|Oral ketamine (Ketamine HCL injection, 100 mg/ml, USP, Hospira)
1585683|NCT02341937|Other|Diagnostic tests for suspected deep vein thrombosis|Pre-test clinical probability (Wells score), D-dimer, compression ultrasonography
1585684|NCT02341924|Other|Portfolio of functional foods|
1585685|NCT02341924|Other|Control foods|
1585686|NCT02341911|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
1585687|NCT02341911|Drug|Gemcitabine,carboplatin|Gemcitabine 1000 mg/m2, IV drip 30 minutes, D1, D8 Carboplatin AUC 2, IV drip 120 minutes, D1
1585688|NCT02341898|Other|Educational programme for all nurses|
1585689|NCT02341898|Other|Training and structured support for nominated key nurses|
1585690|NCT02341898|Other|Facultative train-the-trainer module for key nurses|
1585691|NCT02341898|Other|Printed study material|
1585692|NCT02341898|Other|Supportive material (poster, mugs etc.)|
1585693|NCT02341872|Other|Clinpro White Varnish (fluoride + calcium varnish)|Clinpro White Varnish will be applied to the teeth with brush.
1585694|NCT02341872|Other|Curodont Repair|Curodont Repair solution be applied to the teeth in the form of drops
1585695|NCT02341859|Device|stenfilcon A|contact lens
1585696|NCT02341859|Device|delefilcon A|contact lens
1585697|NCT02341859|Device|narafilcon A|contact lens
1585698|NCT02341846|Other|Qualitative interviews|
1585699|NCT02341833|Drug|Sevoflurane|In the sevoflurane group, the anesthetic agent has to be administered immediately after arrival in the operating room to reach an end-expiratory target concentration of 2%. This concentration of sevoflurane should be maintained until the procedural cardiac arrest and for at least 15 min.
1585700|NCT02341807|Biological|AAV2-hCHM|Comparison of different dosages of AAV2-hCHM
1585702|NCT02341768|Device|ICD|ICD single, dual or triple chamber, upgrade, replacement or primo implant
1585703|NCT02341742|Device|multiple examinations|biological,clinical, X-ray, DXA, accelerometry assessment
1585704|NCT02341729|Drug|ticagrelor|crushed tablets and non-crushed tablets
1585705|NCT02341716|Procedure|WA|Walk advice with Nordic Poles and best medical treatment
1585706|NCT02341716|Procedure|SET|Walk advice with Nordic Poles, best medical treatment and hospital-based supervised exercise therapy
1585707|NCT02341716|Procedure|HET|Walk advice with Nordic Poles, best medical treatment and home-based supervised exercise therapy
1585708|NCT02341703|Drug|letrozole-metformin|letrozole 2.5 mg will be given daily from day 3 of the cycle for 5 days + metformin 500 mg three times daily continuously for 3 months unless pregnancy occurred
1585709|NCT02341703|Drug|letrozole-metformin-pioglitazone|letrozole will be given daily from day 3 of the cycle for 5 days + (metformin 850 mg + pioglitazone 15 mg) from the first day of the cycle for 10 days.
1585710|NCT02341703|Radiation|transvaginal ultrasound|transvaginal ultrasound will be done from day 10 of the cycle and every other day for monitoring of follicular enlargement.
1585711|NCT02341703|Other|laboratory investigations|day 3: FSH, LH, TSH, and total testosterone day 12 serum E2 day 21 serum progesterone
1585712|NCT02341690|Other|Interval walking training|"Interval Walking Training with the InterWalk Application An Interval-walking bout will consist of repeated cycles of 3 minutes of fast and 3 minutes of slow walking at 70% and 40% of the smart-phone assessed peak VO2-rate, respectively.
IWT is conducted for at least 60 minutes per day, three days per week. Compliance is monitored continuously using the on-board accelerometer logger"
1585713|NCT02341690|Other|control|Standard care at the promotion centre in the municipality
1585714|NCT02341677|Procedure|SmartTarget - Biopsy|MRI to ultrasound fusion guided prostate biopsy
1585715|NCT02341651|Other|Multicomponent intervention|Multicomponent intervention is a combination of the following 1) community health worker (CHW)- led blood pressure (BP) screening and referral to provider, plus 2) home health education (HHE) adapted to the local diet by trained CHW plus 3) trained primary health center mid-level providers (MLP) and physicians using evidence-based treatment algorithm of BP lowering in all and lipid lowering for high risk, plus 4) process-based incentives
1585716|NCT02341638|Drug|BMS-986141|
1585717|NCT02341638|Drug|Placebo|
1585718|NCT02341638|Drug|Aspirin|
1585719|NCT02341638|Drug|Itraconazole|
1585722|NCT02341612|Other|single exposure at 5°C in CWI|The subjects of this group performed cold water immersion immediately after exercise-induced muscle damage (EIMD) a single exposure at 5°C for 20 minutes.
1585723|NCT02341612|Other|single exposure at 15°C in CWI|The subjects of this group performed CWI immediately after EIMD a single exposure at 15°C for 20 minutes.
1585724|NCT02341612|Other|multiple exposures at 10°C in CWI|The subjects of this group performed CWI immediately, 24h, 48h and 72h after EIMD (once a day) for 20 minutes.
1585725|NCT02341612|Other|whole body cryotherapy (WBC)|The whole body criotherapy (WBC) group remained in the cabin immediately after EIMD for 3 minutes.
1585726|NCT02341612|Other|passive recovery|The control group was exposed to treatment after the EIMD protocol.
1585727|NCT02341599|Drug|CB-238,618 Group A|Subjects in Group A will participate in one treatment period and will receive a single IV dose of 1000 mg CB-238,618.
1585728|NCT02341599|Drug|CB-238,618 Group B|Subjects in Group B will participate in one treatment period and will receive a single IV dose of 1000 mg CB-238,618.
1585729|NCT02341599|Drug|CB-238,618 Group C|Subjects in Group C will participate in one treatment period and will receive a single IV dose of 500 mg CB-238,618.
1585730|NCT02341599|Drug|CB-238,618 Group D|Subjects in Group D will participate in one treatment period and will receive a single IV dose of 500 mg CB-238,618.
1585731|NCT02341599|Drug|CB-238,618 Group E|Subjects in Group E will participate in two treatment periods, Treatment Period 1 and Treatment Period 2. These patients will receive a single IV dose of 250 mg CB-238,618 per treatment period, once before the hemodialysis (HD) session and once following the HD session.
1585732|NCT02341586|Other|Lucky Iron Fish - home fortification system|The Lucky Iron Fish (LIF) is an ingot used during cooking as an in-home fortification system of iron. The LIF works on the same principle as cast iron pots and pans by increasing dietary intake of iron but is small and lightweight. The LIF was designed in collaboration with village elders and community members to ensure it would be accepted in Cambodia. The iron ingot resembles a local fish believed to be lucky among villages in Cambodia, contributing to the acceptability of the ingot.
1585733|NCT02341586|Dietary Supplement|18 mg elemental iron|This dose of iron is the recommend dietary allowance (RDA) for iron for this cohort. Women will receive one-on-one instructions on how best to consume their tablet (for example, with food).
1585734|NCT02341586|Other|Nutrition Education|This group will receive education containing key messages around anemia, malaria, iron intake, and dietary diversity.
1585735|NCT02341573|Drug|experienced chinese herbal formulas|At the acute stage of asthma :Shegan mixture ; At the remission stage:Huangqi Bushen mixture; 10-30 mL , 2 times a day, for 3 months.
1585736|NCT02341573|Drug|leukotriene receptor antagonist and bronchial relaxant|At the acute stage of asthma : etinoline,twice a day for 7 days; At the remission stage: Singulair, once daily for 3 months.
1585737|NCT02341560|Drug|QPI-1007 Injection - single low dose|QPI-1007 Injection, single low dose
1585738|NCT02341560|Drug|QPI-1007 Injection - single high dose|QPI-1007 Injection, single high dose
1585739|NCT02341560|Drug|QPI-1007 Injection - multiple low dose|QPI-1007 Injection, multiple low dose
1585740|NCT02341560|Drug|QPI-1007 Injection - multiple high dose|QPI-1007 Injection, multiple high low dose
1585741|NCT02341560|Other|Sham Injection Procedure|Sham Procedure
1585742|NCT02341547|Drug|a Biosimilar Epoetin Alfa|End Stage Renal Failure patients stable on Eprex switched to Binocrit
1585743|NCT02341534|Device|BioMonitor|Patients will be implanted with the BioMonitor + standard of care
1585744|NCT02341521|Drug|OC000459|Taken orally for 8 days
1585745|NCT02341508|Biological|0.5 mg/kg Lpathomab|
1585746|NCT02341508|Biological|1.0 mg/kg Lpathomab|
1585747|NCT02341508|Biological|3.0 mg/kg Lpathomab|
1585748|NCT02341508|Biological|10 mg/kg Lpathomab|
1585751|NCT02341495|Drug|Deferasirox|Deferasirox (20mg/kg/day)on days 1-7 of protocol every 4 wks for 8 cycles PO
1585752|NCT02341495|Drug|Cholecalciferol|Cholecalciferol(4,000 units/day) on days 1-7 of protocol every 4 wks for 8 cycles PO
1585753|NCT02341495|Drug|Azacitidine|Azacitidine (75mg/m2 subcutaneous or IV administration) on days 1-7 of protocol 28 days for 32 wks
1585754|NCT02341482|Drug|PF-04958242|PF-04958242 will be provided in a capsule. subjects will receive a 0.10 mg loading dose of PF-04958242 twice daily (BID) on Day 1 then 0.025 mg BID on Day 2-Day 16, with the last dose occurring in the morning on Day 17.
1585755|NCT02341482|Drug|Itraconazole|Itraconazole will be provided as a solution starting on Day 4. On Day 4, a 200 mg dose of itraconazole will be administered approximately 1 hour before PF-04958242 morning administration and for 13 additional days (Day 4-Day 17).
1585756|NCT02341469|Other|integrated ediagnostic approach (IeDA)|"IeDA is a package of several interventions with the objective of improving the quality of child health care in health centres to ultimately decrease child morbidity and mortality. The components of IedA are described as follows:
REC: the IMCI protocol translated into a computer-based tool that aims to guide nurses during consultations.
The training of nurses on IMCI and REC.
A quality assurance mechanism through which each district and health centre is encouraged to find appropriate solutions in response to their local needs.
A supervision system conducted implemented by district managers to provide support and guidance to health centres.
A health information system based on data collected through the REC and fed back to the district managers and Heads of health centres."
1585757|NCT02341456|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Gemcitabine is a nucleoside analog used as chemotherapy.
1585758|NCT02341456|Drug|Paclitaxel|Paclitaxel is a mitotic inhibitor used in cancer chemotherapy ; it and docetaxel represent the taxane family of drugs.
1585759|NCT02341456|Drug|carboplatin|Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
1585760|NCT02341443|Procedure|Implants|"Experimental arm: Rigid
Surgical treatment using arch bars and according to the following fixation:
Rigid fixation on one side (most anterior fracture) and non-rigid fixation on the other (most posterior fracture).
Active comparator: Non-rigid
Surgical treatment using arch bars and according to the following fixation:
Non-rigid fixation on both fracture sides.
Whereas non-rigid fixation is defined as a single miniplate of ≤1.00 mm thickness, and rigid fixation is defined as a single plate of ≥1.25 mm thickness, a combination of 2 plates or a 3D geometric plate."
1585761|NCT02341430|Device|Symbotex™ Composite Mesh|Repair of a Grade I or II ventral hernia according to VHWG classification system with Symbotex™ Composite Mesh
1585762|NCT02341417|Drug|Cinacalcet|Subjects will receive cinacalcet daily for up to 28 weeks in addition to standard therapy. Sites to receive 5mg capsules and 30mg tablets. Protocol specified doses: 1, 2.5, 5, 7.5, 10, 15, 30, 60, 90, 120, 180mg. Subjects completing treatment/reaching study termination in 20130356 and up to week 26/study termination in 20110100 will be eligible. For subjects enrolling from 20130356, the maximum dose of cinacalcet at any time during the study will be 2.5 mg/kg/day based on baseline dry weight/ 180 mg daily, whichever is lower. For subjects enrolling from 20100100, the maximum dose of cinacalcet at any time will be 2.5 mg/kg/day based on baseline dry weight/ 60 mg daily, whichever is lower.
1585763|NCT02341404|Drug|2-hydroxyflutamide (2-HOF)|Two components are mixed, transferred to a syringe and administered with injection into the prostate
1585764|NCT02341391|Biological|TissueGene-C(Low dose)|3.0 x 10^6 cells
1585765|NCT02341391|Biological|TissueGene-C(Medium dose)|1.0 x 10^6 cells
1585766|NCT02341391|Biological|TissueGene-C(High dose)|3.0 x 10^7 cells
1585767|NCT02341378|Biological|TissueGene-C(Low dose)|TissueGene-C at 6.0x10^6 cells
1585768|NCT02341378|Biological|TissueGene-C(High dose)|TissueGene-C at 1.8x10^7 cells
1585769|NCT02341365|Other|vitamin D,AMH, AFC, reproductive outcome egg recipients|observational study of 269 donnors
2008853|NCT03326765|Procedure|electroencephalogram (EEG)|is an electrophysiological monitoring method to record electrical activity of the brain
1990766|NCT01825512|Drug|Deferiprone|Deferiprone 80 mg/mL oral solution
1990767|NCT01825512|Drug|Deferasirox|Deferasirox is used at the following dosage strengths: 125 mg, 250 mg and 500 mg
1585773|NCT02341339|Procedure|Laparoscopic Surgery (Biopsies of fallopian tube lumen) using a laparoscopic brush/biopsy device|
1585774|NCT02341300|Device|Cast Iron Pot|Cast iron pot
1585775|NCT02341300|Device|Alumnium Pot|Aluminum Skillet
1585776|NCT02341287|Device|Warming hydrogel device|Patients will wear a warming hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.
1585777|NCT02341287|Device|Non thermal hydrogel device|Patients will wear a hydrogel glove in the second two week period. Also a actigraph to monitor sleep latency.
1585778|NCT02341274|Drug|Tacrolimus|Bioequivalence study
1585779|NCT02341261|Behavioral|Standard Care Counseling|
1585780|NCT02341261|Behavioral|Supervised Exercise and Counseling|
1585781|NCT02341248|Other|Exclusive Enteral Nutrition (EEN)|8 week standard course of treatment with EEN
1585782|NCT02341235|Behavioral|Game intervention|The game will target motivation via narrative and game mechanics. It will also encourage self-regulation by providing monitoring and feedback of activity. Counseling will be adapted to specifically reference concepts related to narrative and games.
1585783|NCT02341235|Behavioral|Standard intervention|The electronic activity monitor will monitor steps, and the mobile device will provide basic feedback on progress toward goals. Counseling will be standard and concentrate on self-regulatory skill-building.
2008854|NCT03326765|Procedure|polysomnography|type of sleep study, is a multi-parametric test used in the study of sleep and as a diagnostic tool in sleep medicine
1585848|NCT02340689|Other|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic analysis.
2008855|NCT03326765|Procedure|Actigraphy|type of sleep study based on bracelet around the wrist
1585784|NCT02341222|Device|BP self-standing felt device|BP device will be implanted under fascia group-A, operated subjects. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats will receive 2x2cm2 samples of BP (Buckypaper) in a pocket created between muscular fascia and large muscles. The rough opaque surface will face the muscle surface and the smooth brilliant surface will face the lower muscular fascia surface, without fixation with stitches. Then the scar will be sutured with absorbable stitches on the fascia incision edge and not absorbable stitches on the skin.
1585785|NCT02341222|Device|PR Parietene mesh device|Fifteen rats (hereafter defined as BPR16-BPR30 B-group control subjects) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. A lumbar 4-5 cm incision will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, with a blunt dissection the fascia will be separated from muscles. Fifteen rats (hereafter defined as BPR16-BPR30) will receive 2x2cm2 samples of PP (polypropylene) in a pocket created between muscular fascia and large muscles. The polypropylene prosthesis will be fixed to the muscle with absorbable sutures surface and then the muscular fascia will be sutured over the prosthesis, with absorbable stitches on the fascia. Not absorbable stitches will be sutured on the skin.
1585786|NCT02341209|Drug|Doxycycline monohydrate|Doxycycline will be administered in either tablets or capsules for either five months or a year depending on response.
1585787|NCT02341196|Procedure|CEA|Patients in both groups received an intra-operative angiography
1585788|NCT02341183|Device|tPAD|7% NaCl administered continuously for 8 hours, overnight, via the tPAD device
1585789|NCT02341183|Device|7% hypertonic saline (510K approved as a device)|Subjects will receive overnight treatments of 7% HS via the tPAD device in both comparators, but in a randomly assigned order as described.
1585790|NCT02341170|Radiation|HS-PCI|Hippocampal-sparing prophylactic cranial irradiation with 25 Gy in 10 fractions
1585791|NCT02341144|Procedure|Pre-op percutaneous rectus sheath block|After induction of anesthesia, the attending anesthesiologist will use a portable ultrasound probe to locate the rectus sheath. A 22 gauge needle will be used to inject a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally). The analgesic will be injected percutaneously using ultrasound guidance between the rectus abdominis muscle and the posterior rectus sheath at the lateral border bilaterally.
1585792|NCT02341144|Procedure|Intra-operative rectus sheath block|After the completion of the umbilical hernia repair, after fascial closure, but prior to skin closure, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10c, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon.
1585793|NCT02341144|Drug|Ropivacaine|
1585794|NCT02341131|Behavioral|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
1585795|NCT02341131|Behavioral|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
1585796|NCT02341118|Genetic|BRCA genetic data|Two blood samples will be taken which is part of the standard of care. Tumor samples will be obtained from previous biopsy or surgery prior to this study for DNA testing
1585797|NCT02341105|Procedure|Catheter ablation|Pulmonary vein isolation by catheter ablation
1585798|NCT02341105|Drug|Amiodarone|antiarrhythmic therapy using Amiodarone
1585799|NCT02341092|Behavioral|Traumatic brain injury|Collection of the use of expertise relatives of victims of traumatic brain injury
1585800|NCT02341079|Drug|Bupivacaine Liposome Injection|Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
1585801|NCT02341079|Drug|Indwelling femoral nerve block|Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
1585802|NCT02341066|Device|Endothelial Dysfunction evaluation by EndoPAT|Endothelial dysfunction will be measured assessing reactive hyperemia of digital arteries by using Endo-PAT2000 (Itamar, Israel).
1585803|NCT02341053|Other|Assisted Standing Treatment Program|Assisted Standing Treatment Program - Assisted standing treatment program will be gradually increase duration of standing by up to 75% after baseline.
1585804|NCT02341027|Device|Jadelle|within 5 days of delivery and before discharge from hospital
1585805|NCT02341027|Device|Jadelle|6-8 weeks (42-56 days) postpartum
1585806|NCT02341014|Drug|Carfilzomib|The initial dose of carfilzomib (cycle 1, day 1) given to any patient regardless of dose level must be 20mg/m2 . All subsequent doses of carfilzomib will be based on the patient's dose level.
1585807|NCT02341014|Drug|Romidepsin|
1585808|NCT02341014|Drug|Lenalidomide|
2008856|NCT03326752|Drug|DV281|- Dose Escalation will be the preliminary dose finding phase of the study. Subjects will be enrolled to available Dosing Cohorts.
1585810|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin|Oritavancin will be administered as a single IV infusion simultaneously with Warfarin. The infusion will last approximately 3 hours.
1585811|NCT02340988|Drug|Single-Dose IV Oritavancin Diphosphate and Warfarin 24 hour post dose|Oritavancin will be administered as a single IV infusion and 24 hours post dose subjects will receive 25mg of Warfarin. The infusion will last approximately 3 hours.
2008857|NCT03326752|Device|Breath Actuated Nebulizer|Breath-actuated, electronic system designed to aerosolize liquid medication.
2008858|NCT03326752|Drug|DV281 (RP2D)|- Dose Expansion will be enrolled into 2 groups, specifically, anti-PD-1/L1 treatment naïve and anti-PD-1/L1 treatment experienced.
2008859|NCT03326752|Device|Breath Actuated Nebulizer|Breath-actuated, electronic system designed to aerosolize liquid medication.
1585847|NCT02340702|Other|COPD|COPD as diagnosed clinically or based on pulmonary function test showing post-bronchodilator forced expiratory volume in one second to forced vital capacity ratio of <0.7.
1586294|NCT02337478|Other|Laboratory Biomarker Analysis|Correlative studies
2008860|NCT03326115|Behavioral|Peer Visitation Program|The Amputee Coalition's Peer Visitation Program (PVP) trains amputee peer supporters to properly navigate a new or less-experienced amputee through the process of rehabilitation. Peer support plays an important role, following the amputation of a limb, by allowing patients to meet other amputees and discuss lifestyle changes post-amputation. Subjects randomized to the PVP group will receive the intervention (visitation by a Certified Peer Visitor) immediately at amputation. Subjects randomized to the non-PVP group will not receive CPV visits immediately at amputation. Rather, they will receive delayed PVP intervention beginning 60 days after amputation and lasting a total of 60 days (or at 120 days post-amputation).
2008861|NCT03326726|Drug|2% CHG|Chlorhexidine Gluconate
1585820|NCT02340949|Drug|Aflibercept|Administered I.V. at doses of 4 mg/Kg on Day 1 every 14 days. It will be supplied to sites by Sponsor as 4 ml vials at a concentration of 25 mg/ml
1585821|NCT02340949|Drug|5-Fluoruracil|Once every 14 days. Day 1: 400 mg/m2 I.V. bolus and a 46 h infusion of 5-FU 2400 mg/m2
1585822|NCT02340949|Drug|Oxaliplatin|Once every 14 days. Day 1: 85 mg/m2 I.V. infusión in 250-500 mL, over two hours, followed by 5-FU
1585823|NCT02340949|Drug|Leucovorin|Once every 14 days. Day 1: 200 mg/m2 I.V., over two hours, followed by 5-FU
1585824|NCT02340936|Drug|LR-ESHAP (lenalidomide 5 mg)|3 cycles of lenalidomide 5mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
1585825|NCT02340936|Drug|LR-ESHAP (lenalidomide 10 mg)|3 cycles of lenalidomide 10mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
1585826|NCT02340936|Drug|LR-ESHAP (lenalidomide 15 mg)|3 cycles of lenalidomide 15mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
1585827|NCT02340936|Drug|LR-ESHAP (lenalidomide 20 mg)|3 cycles of lenalidomide 20mg, etoposide, methylprednisolone, cisplatin, cytarabine and rituximab every 3 weeks.
1585828|NCT02340910|Other|Short Duration|During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 6 minutes of WBV at a frequency of 50 Hz.
1585829|NCT02340910|Other|Long Duration|"During each WBV repetition, subjects will stand on the vibration platform of the WBV device with knees slightly bent (approximately 30 degrees flexion). The subject will hold the handrails for balance and the WBV device will be turned on. The subject will receive a total of 12 minutes of WBV at a frequency of 50 Hz.
Interventions will occur for 5 days a week for 4 weeks ."
1585830|NCT02340884|Behavioral|Promoting Resilience In Stress Management (PRISM)|"The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding."
1585831|NCT02340871|Genetic|Genetic testing|Patients suspected of harboring a genetic neurological disease will be summoned to take a blood test. DNA will be extracted from the blood and sent to the collaborating hospital labs for next generation sequencing.
1585832|NCT02340858|Device|NanoKnife LEDC System|Irreversible electroporation (IRE) is a method to induce irreversible disruption of cell membrane integrity (loss of cell homeostasis) resulting in cell death without the need for additional pharmacological injury. Because IRE is a non-thermal technique, changes associated with perfusion-mediated tissue cooling (or heating) are not relevant. While cells in the ablation region are destroyed, the underlying extracellular matrix is not damaged thus allowing tissues in the ablation zone to heal normally.
2008862|NCT03326713|Behavioral|Telephone Counseling & Navigation (TCN)|A health coach will conduct a 15-30 minute telephone counseling session with participants. Prior to the telephone session, participants will receive the same brochure that the TP arm receives. After the phone call, participants will receive a tailored follow-up letter which will include images tailored to the individual's age, self-identified ethnicity, and family composition.
1585834|NCT02340819|Drug|Teduglutide|0.05 mg/kg/day administered by subcutaneous injection over a 24-week period.
1585835|NCT02340806|Device|CADD-Solis pump (Smiths Medical)|The maintenance epidural solution for both groups will be bupivacaine 0.625 mg/mL with fentanyl 1.95 mcg/mL. The intermittent bolus volume will be 10 mL administered every 60 minutes. The first bolus will be given 30 minutes after intrathecal injection. The bolus rate will be 300 mL/h in the high-rate bolus group, and 100 mL/h in the low-rate bolus group. In addition to the programmed boluses, patients will be able to administer patient-controlled epidural analgesia (PCEA) boluses of 5 mL every 10 minutes to a maximum of 15 mL (three PCEA boluses in a one hour period).
1585836|NCT02340793|Dietary Supplement|Counterweight Plus|A non-surgical, nutritionally replete weight management programme comprising a Total Diet Replacement Plan (TDR) of 800+ calories/day to produce a weight loss of >15kg over 12-20 weeks; followed by a structured Food Reintroduction phase for 6-8 weeks and a Weight Loss Maintenance phase; total intervention period 2 years.
1585837|NCT02340780|Drug|Buparlisib|
1585838|NCT02340767|Device|Spectra Device|Spectra Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
1585839|NCT02340767|Device|DIAGNOdent|DIAGNOdent Caries detection device is used for study data collection recording the results of the dental examination and recording results of dental treatment.
1585840|NCT02340754|Behavioral|Mindfulness-based Stress Reduction|
1585841|NCT02340754|Behavioral|MS Education Control|
1585842|NCT02340741|Procedure|conventional prophylaxis of aeroembolism|167 patients will be enrolled. Will perform standard way of aeroembolism prevention
1585843|NCT02340741|Procedure|conventional prophylaxis plus CO2 insufflation|167 patients will be enrolled. Will perform standard way of aeroembolism prevention and insufflation of carbon dioxide
1585844|NCT02340741|Procedure|cardiac surgery with opening of heart chambers|Patients with different clinical diagnoses, which is planned to cardiac surgery with the opening heart cavities
1585845|NCT02340728|Device|ERCP with SEMS plus radiofrequency ablation|
1585846|NCT02340728|Device|ERCP with SEMS alone (standard of care)|
1585849|NCT02340676|Procedure|Extracorporeal Photopheresis (ECP)|Participants receive ECP treatment twice a week for 16 weeks
1585850|NCT02340676|Drug|Interleukin-2|Participants receive daily IL-2 injections starting Week 8 of study and ending at Week 16
1585851|NCT02340663|Device|SOVA Bite Splint|Over-the-counter thermoplastic bite splint blank, heated, molded to fit.
1585852|NCT02340663|Device|Michigan Bite Splint|Heat-cured acrylic bite splint fabricated by dentist/dental technician to fit
1585853|NCT02340650|Device|High Resolution Microendoscope|
2008863|NCT03326713|Behavioral|Mailed Targeted Print (TP)|Participants will be mailed an educational brochure within two weeks of completing the baseline survey that addresses important evidence-based theoretical targets: CGRA guideline (knowledge), threat appraisal (to validate or raise risk perceptions, HBOC seriousness), response efficacy (benefits and expectations about CGRA), self-efficacy messages (CGRA resources, insurance reimbursement, and assistance for those with financial challenges) and possible actions to take (make an appointment and discuss with provider). Both the targeted print and tailored intervention materials were developed using formative community engaged research methods.
2008864|NCT03326713|Other|Usual Care (UC)|A usual care arm is included to assess CGRA uptake in the absence of intervention as well as priming from the surveys for the primary outcome analysis.
1585856|NCT02340624|Behavioral|Referral to SmokeFreeMoms, Quitline or Brief intervention|"SmokeFreeMom is a mobile text messaging service designed for pregnant women across the United States to help them quit smoking. The program provides 24/7 encouragement, advice, and tips to help pregnant women and mothers quit smoking and stay quit.
The 1-800 QuitLine provides smoking cessation services to Michigan residents who want to quit using tobacco. The Quit Line offers a personal health coach and participant toolkits to help tobacco users gain confidence and motivation they need to quit for good.
Computer-delivered 5As (CD-5As) brief intervention The software platform to be used for this study features an interactive three-dimensional narrator, clear and relevant graphics, and aura;Participants use headphones for privacy while working with the computer."
1585859|NCT02340598|Other|cold vest|The lowering of body temperature increases basal metabolic rate
1585860|NCT02340585|Device|Next Generation Neuroform Stent System|The Next Generation Neuroform Stent System is pre-loaded on a stent delivery wire and protected by a transfer sheath. An accessory pouch containing an optional stabilizer may be attached to the proximal end of the stent delivery wire to facilitate handling and stabilization.
1585861|NCT02340572|Drug|PRS-080#022-DP|hepcidin antagonist
1585862|NCT02340572|Drug|PRS-080-Placebo#001|Placebo treatment
1585863|NCT02340559|Behavioral|Meta-cognitive Training|
1585864|NCT02340559|Behavioral|Psychoeducational group|
1585865|NCT02340546|Device|cardiac resynchronization therapy|cardiac resynchronization by means of biventricular pacing via left ventricular pace from coronary sinus veins combined with conventional any-site right ventricular pace
1585866|NCT02340533|Procedure|hysteroscopic endo-myometrial biopsy|
1585867|NCT02340533|Device|ultrasound|two dimensional trans-vaginal ultrasonography
1585868|NCT02340520|Drug|Theophylline. Roflumilast|Oral
1585869|NCT02340507|Other|Rice and bread (high GI)|Rice is a high glycaemic index glutinous rice. Bread is a high glycaemic index white bread.
1585870|NCT02340507|Other|Rice and bread (low GI)|Rice is a low glycaemic index parboiled basmati rice. Bread is a low glycaemic index multigrain bread.
1585871|NCT02340494|Behavioral|Online Enhanced Education Tool|The website resource will be credible, comprehensive, relevant and engaging information that young women with breast cancer will use intensively for self-management and education.
1585872|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable tablet|Each tablet contains 2 milligram (mg) of loperamide hydrochloride and 125 mg of simethicone.
1585873|NCT02340481|Drug|Loperamide hydrochloride|Each capsule contains 2 mg of loperamide hydrochloride
1585874|NCT02340481|Drug|Loperamide hydrochloride + simethicone chewable placebo tablet|Placebo matched to loperamide hydrochloride and simethicone chewable tablet.
1585875|NCT02340481|Drug|Loperamide hydrochloride placebo capsule|Placebo matched to loperamide hydrochloride capsule.
1585876|NCT02340468|Device|diffuse optical spectroscopy|diffuse optical spectroscopy
1585877|NCT02340455|Drug|Pregabalin_male|Pregabalin 150mg bid 1day Men
1585878|NCT02340455|Drug|Pregabalin_female|Pregabalin 150mg bid 1day Women
1585879|NCT02340455|Drug|Placebo_Men|Placebo durg
1585880|NCT02340455|Drug|Placebo_Women|Placebo_Women
1585881|NCT02340442|Other|Obstetrical care parameters|
1585882|NCT02340442|Other|DVA measurements|
1585883|NCT02340442|Other|Fundus photographs|
1585884|NCT02340429|Device|DE500 Digital Video Otoscope|
1585885|NCT02340416|Device|Transcranial Doppler Ultrasound, DWL Doppler BoxX|
1585886|NCT02340403|Procedure|NMR Spectroscopy|
1585887|NCT02340390|Device|G7|The Biomet G7™ Acetabular System has been designed to provide more options to surgeons for treatment of patients needing total hip arthroplasty, while concurrently simplifying the surgical process with well-designed, modular components and corresponding instruments. The G7™ Acetabular System includes three liner types; ArComXL highly-crosslinked or E-1 Vitamin E-infused polyethylnene and a Biolox Delta (Ceramtec, Plochingen, Germany) ceramic liner.
1585888|NCT02340390|Device|Exceed ABT|The Exceed ABT Acetabular System has been designed for cementless fixation and consists of an acetabular shell and an acetabular insert. The acetabular insert/bearing includes a tapered outer geometry that matches the inner geometry of the acetabular shell and an inner hemispherical geometry to suit the varying modular head diameters. Inserts/bearings are inserted into the acetabular shell intra-operatively and are available in varying sizes to match the acetabular shell diameters. The insert/bearings are available in Biolox Delta ceramic (CeramTec AG).
1585889|NCT02340377|Device|ELITE 3 HQ|The pill is about the size of a multivitamin, is coated with special medical plastic, and is easy to swallow. The pill sends radio signals to a small recording device that participants wear that send a signal to a monitor and records the participant's internal body temperature. The pill will exit the participant's body in one of his/her bowel movements approximately 1-5 days after ingestion. Pills are not reused.
1585890|NCT02340364|Behavioral|Education + Patient Navigation|208 patients randomized to self-care Education+ Patient Navigation-delivered self-care plan.
1585891|NCT02340364|Behavioral|Self-care Education|208 patients randomized to self-care education alone.
2008865|NCT03326700|Procedure|Inguinal Hernia Repair|Inguinal hernia repair is surgery to repair a hernia in the groin. A hernia is tissue that bulges out of a weak spot in the abdominal wall. The intestine may bulge out through this weakened area. During surgery to repair the hernia, the bulging tissue is pushed back in. The abdominal wall is strengthened and supported with sutures (stitches), and sometimes mesh. This repair can be done with open or laparoscopic surgery.
2008866|NCT03326687|Behavioral|Treatment|Participants will receive anomia treatment in isolation and in combination with a physical endurance task during different phases of the research.
1585894|NCT02340338|Biological|rTSST-1 Variant Candidate Vaccine|"In the absence of adverse events classified as clinically relevant, interval between dose escalations 1 week. Immunization to be repeated at the same dose level 1 - 2 months later. If immunogenicity can be shown after the second administration of 1 µg, the sample size will be increased from 3 + 1 to 9 + 3. Otherwise, the sample size of 3 + 1 will continue until immunogenicity is seen at a higher dose level. If there is no immune response in any dose group after the second immunization, a third injection will be given 4 -8 weeks thereafter in dose groups of 1 µg and above.
Immunogenicity is defined by seroconversion from a TSST-1 Ab titer of < 20 to > 40 or a 4-fold increase in TSST-1 Ab titer .
Patients 3 µg or more will be randomized."
1585895|NCT02340325|Drug|Acute Application of kynurenic acid cream|Pouches containing 0.00% (placebo), 0.15%, 0.25%, 0.4% and 0.5% of FS2 will be randomly applied to an occlusive, transparent dressing (Tegaderm) and applied to each test area. The pouch order will be random, generated by the www.random.org list generator each application. The study team member applying the cream will randomly choose the application sites of different concentrations of the FS2 creams and mark the corresponding cream code name on a separate sheet. This study member will not be evaluating the results and the evaluating study member will be blinded to the randomization. Patients will be evaluated at 24 hours post application for skin reactions and adverse reactions by a blinded observer recorded. Before and after photographs will be taken.
1585896|NCT02340325|Drug|Chronic application of kynurenic acid cream|Volunteers will be educated how to apply a pouch of cream to an occlusive, transparent dressing (Tegaderm) and place it on the test site every 24 hours for 30 days. The date and time of first application will be recorded. Baseline urine and serum measurements of drug concentration (presumed absent), as well as complete blood count, liver enzymes, blood urea nitrogen, and creatinine will be taken on Day 0 (the initial enrollment of each part). The volunteers will be seen in follow-up at day 1, day 5, day 15, and day 30
1585897|NCT02340312|Procedure|EGD|In this study patients are being scoped(EGD) as standard of care and being asked to allow .5 aggregate of tissue biopsy to be taken for research purposes.
1585898|NCT02340312|Other|Collection of Stool Specimens|We will be collecting stool samples from each participant for research purposes. Within two weeks after EGD tissue collection.
1585899|NCT02340299|Device|nHFOV|Extubation to ventilator-derived nHFOV using binasal prongs
1585900|NCT02340299|Device|nCPAP|Extubation to ventilator-derived nCPAP using binasal prongs
1585901|NCT02340273|Device|Therapeutic ultrasound|Patients receive therapeutic ultrasound daily for 4 hours of continuous therapy at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
1585902|NCT02340273|Device|Placebo therapeutic ultrasound|"Patients receive sham therapeutic ultrasound daily for 4 hours."
1585903|NCT02340260|Behavioral|High intensity interval training|High intensity exercise during 12 weeks with three weekly training sessions
1585904|NCT02340260|Behavioral|Sprint interval training|Sprint interval exercise during 12 weeks with three weekly training sessions
1585905|NCT02340247|Other|Water|
1585906|NCT02340247|Drug|Ursodeoxycholic Acid|
1585907|NCT02340247|Drug|Chenodeoxycholic Acid|
1585908|NCT02340234|Drug|Lebrikizumab|Lebrikizumab will be administered SC as per the schedule specified in the respective arms.
1585909|NCT02340234|Drug|Placebo|Placebo matching to lebrikizumab will be administered as per the schedule specified in the respective arms.
1585910|NCT02340234|Drug|TCS Cream|TCS cream (triamcenolone acetonide 0.1% or hydrocortisone 2.5% cream) twice daily
1585911|NCT02340221|Drug|Taselisib|Taselisib 4 mg will be administered as two tablets of 2 mg each as per the schedule specified in the respective arm.
1585912|NCT02340221|Drug|Placebo|Placebo matching to taselisib will be administered as per the schedule specified in the respective arm.
1585913|NCT02340221|Drug|Fulvestrant|Fulvestrant 500 mg will be administered as two IM injections of 250 mg each as per the schedule specified in the respective arms.
1585914|NCT02340208|Drug|L-DOS47|A treatment cycle will be 21 days with patients receiving L-DOS47 on cycle Days 1 and 8.
1585915|NCT02340195|Drug|Idalopirdine (Lu AE58054) 60 mg|encapsulated film-coated tablets for oral use once daily for 10 days
1585916|NCT02340182|Drug|Vancomycin|250mg 3dd2
1585917|NCT02340182|Drug|Ciprofloxacin|500mg 2dd1
1585918|NCT02340182|Drug|Metronidazole|500mg 3dd1
1585919|NCT02340169|Drug|Topicort® (desoximetasone) Topical Spray, 0.25%|Topicort® (desoximetasone) Topical Spray, 0.25% applied to affected areas twice a day for 28 days
1585920|NCT02340156|Genetic|SGT-53|SGT-53, at 3.6 mg DNA per infusion, will be administered twice per week for 3 weeks (on Day 1, 4, 8, 11, 15 and 18 of each cycle) for 3 cycles. If SGT-53-related toxicity occurs, the dose of SGT-53 will be de-escalated to 2.4 or 1.2 mg DNA/infusion when appropriate.
1585921|NCT02340156|Drug|Temozolomide|TMZ will be administered orally on days 9-13 of each cycle. In cycle 1, the dose of TMZ will be 150 mg/m². If the TMZ-related toxicities are tolerated in cycle 1, the dose of TMZ will be escalated to 200 mg/m² for cycle 2 and beyond. If TMZ-related toxicity occurs, the dose if TMZ will be de-escalated to 125 mg/m² (dose level -1), 100 mg/m² (dose level -2) or 75 mg/m² (dose level -3) when appropriate.
1585922|NCT02340143|Other|Control|Marketed partially hydrolyzed cow's milk protein infant formula
1585923|NCT02340143|Other|Investigational|Partially hydrolyzed cow's milk protein infant formula with a probiotic
1585924|NCT02340130|Biological|DP/MG/14-1|The administration regimen will consist of a rush build-up régimen and a follow up period
1585925|NCT02340130|Biological|DP/MG/14-2|The administration regimen will consist of a rush build-up régimen and a follow up period
2008867|NCT03326674|Drug|Tesetaxel and Capecitabine|Tesetaxel plus reduced dose of Capecitabine vs. approved dose of Capecitabine
2008868|NCT03326674|Drug|Capecitabine|Capecitabine alone at approved dose
1585926|NCT02340117|Genetic|SGT-53|The starting dose of SGT-53 in week 1 will be 2.4 mg DNA/infusion. If the combination therapy of SGT-53 and gemcitabine/nab-paclitaxel is tolerated, starting in week 2, the dose of SGT-53 will be escalated to 3.6 mg DNA/infusion. If necessary, the dose of SGT-53 can be de-escalated to 1.2 mg DNA/infusion (dose level -1) or 0.6 mg DNA/infusion (dose level -2) in the event that increased toxicity probably or definitely related to SGT-53 is observed with the combination.
1585927|NCT02340117|Drug|nab-paclitaxel|The dose of nab-paclitaxel will be 125 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7. If increased toxicities related to administration of nab-paclitaxel is observed, the dose of nab-paclitaxel can be reduced to 75 or 100 mg/m² when appropriate.
1585928|NCT02340117|Drug|Gemcitabine|The dose of gemcitabine will be 1000 mg/m² and will be administered once weekly (day 3) in weeks 1, 2, 3, 5, 6 and 7, after the administration of nab-paclitaxel. If increased toxicities related to administration of gemcitabine is observed, the dose of gemcitabine can be reduced to 750 mg/m² when appropriate.
1585929|NCT02340104|Drug|Baricitinib|4 milligrams (mg) administered orally
1585930|NCT02340104|Drug|[^13C4D3^15N]-baricitinib|4 micrograms (μg) administered intravenously (IV)
2008869|NCT03326661|Procedure|Aspiration|Needle aspiration of pus from the peritonsilar abscess
2008870|NCT03326661|Procedure|Tonsillectomy a chaud|Removal of tonsil(s) due to peritonsillar abscess
2008871|NCT03326661|Drug|Penicillin V + metronidazol (Penicillin allergy: Clindamycin alone)|patients treated with aspiration will receive antibiotic treatment
2008872|NCT03326648|Other|Strength training|Heavy load strength training performed twice a week for 10 weeks.
1585935|NCT02340065|Procedure|standard colonoscopy|examination of the colon with a conventional colonoscope
1585936|NCT02340065|Procedure|Endocuff-assisted colonoscopy|examination of the colon with Endocuff-assisted colonoscopy
1585937|NCT02340052|Drug|Pain treatment|Registration af actual analgesic treatment and outcomes
1585938|NCT02340039|Dietary Supplement|Polyphenols|Drinks will be delivered in random order at 3 separate study visits immediately before a high-carbohydrate meal. Seven days wash-out period will be required between study days.
1585939|NCT02340026|Other|Dynamic Supported Mobility|Dynamic weight support; Child-directed; No assistive devices, limited use of orthoses, no treadmill; Encourage high degree of error with reduced physical assistance; Encourage frequent variability in motor tasks (no redirection when moving from one activity to another); Physical therapist expertise is focused on designing a salient and challenging environment for the child's specific interests and ability level to encourage engagement, variability, challenge, and error experience, and on determining the appropriate amount of weight assistance
1585940|NCT02340026|Other|Conventional Therapy|"No or static weight support; Therapist-directed (therapist initiates); Traditional early gait training methods: use of assistive devices/orthoses and may use treadmill; Focus on producing typical movement patterns with extensive manual guidance/correction from therapist, prevention of falls; Therapy activities grouped into blocks of practice (i.e. repeated floor to stand practice followed by gait training); Physical therapist expertise is focused on designing and directing the specific practice activities each session, tailored to the individual child"
1585941|NCT02340013|Drug|Medroxyprogesterone acetate|Women in this arm of the study will be assigned to start medroxyprogesterone acetate 10mg per os x 10 days. This will be followed by vaginal bleeding. On the 3rd day of vaginal bleeding, women will start clomiphene citrate 50mg per os x 5 days for ovulation induction.
1585942|NCT02340000|Drug|standard dose amoxicillin/clavulanate|amoxicillin/clavulanate 875/125 + placebo bid x 7 days
1585943|NCT02340000|Drug|high dose amoxicillin/clavulanate|Time Period I: extended-release amoxicillin/clavulanate 1000/62.5 two tablets bid x 7 days Time Period 2: immediate-release amoxicillin/clavulanate 875/125 plus amoxicllin 875 bid x 7 days
1585944|NCT02339974|Device|Heterotopic Implantation Of the Edwards-Sapien XT Transcatheter Valve in the Inferior VEna Cava|
1585945|NCT02339961|Radiation|Ultrasound radiation|Recording Doppler ultrasound noninvasively from the right chest wall
1585946|NCT02339948|Radiation|SBRT|8.0 Gy per fraction for 5 fractions for a total of 40 Gy
1585947|NCT02339935|Behavioral|Brief Analogue Functional Analysis|The Brief AFA seeks to identify the function of the challenging behavior by creating controlled test conditions in which specific responses are provided for challenging behavior (e.g., attention, escape from task demands, access to tangible - including variants of each as needed), as well as a control condition in which continual access to attention and preferred items is provided. It consists of a 30-90-minute abbreviated analysis comprised of a single exposure to 2-5-minute test and control conditions, along with replication of applicable test conditions and a treatment probe, which provides evidence of challenging behavior function faster than other methods.
1585948|NCT02339935|Other|No Brief AFA|These participants will receive typical standard of care procedures while hospitalized, but will not receive the additional behavioral intervention
1585949|NCT02339922|Drug|Ixazomib Citrate|Given PO
1585950|NCT02339922|Other|Laboratory Biomarker Analysis|Correlative studies
1585951|NCT02339922|Biological|Rituximab|Given IV
2008873|NCT03326648|Dietary Supplement|Protein supplementation|Dietary protein supplement (protein-enriched milk with 0,2 % fat). 0,33 l each day for 10 weeks.
2008874|NCT03326635|Other|Frailty in elderly (≥70 y) patients in ICU|Determine the prevalence of frailty in elderly patients (≥ 70 year old) in a group of French ICUs. The frailty is measured by a score (Fried score) at the admission of the patient
1585955|NCT02339896|Biological|rabies vaccine|rabies vaccine 0.1 ml intradermal two site for 4 times
1585956|NCT02339870|Other|Psychosocial Support for Caregiver|Complete expressive disclosure writing
1585957|NCT02339870|Other|Psychosocial Support for Caregiver|Complete benefit finding writing
1585958|NCT02339870|Other|Questionnaire Administration|Ancillary studies
1585959|NCT02339870|Other|Sham Intervention|Complete writing on an emotionally neutral topic
1585960|NCT02339857|Procedure|No-touch harvesting technique|The saphenous vein is harvested with a pedicle of surrounding tissue.
1585961|NCT02339844|Drug|Aripiprazole|6 weeks of individual doses of aripiprazole
1585962|NCT02339831|Device|CAMOPED|Camoped given after surgery
1585963|NCT02339831|Device|CPM passive motion device|passive motion device given after surgery
1585964|NCT02339805|Other|next generation sequencing|DNA from plasma, peripheral blood mononuclear cell and bone marrow will be sequenced by NGS for a panel of 34 genes.
1585965|NCT02339805|Device|Fluorine-18 fluorodeoxyglucose positron emission tomography (18F-FDG-PET)|tumor Assessment tool during the study
1585966|NCT02339792|Other|E-learning|e-learning program of medical education, focused on teaching and implementing Comprehensive Geriatric Assessment (CGA) added to geriatric pharmacological notions (GPNs)
1585967|NCT02339779|Procedure|autologous fat transfer|"Each procedure consists of the transfer of syringe-aspirated fat (form the abdomen, thighs, flanks) to the breast by injection in the subcutaneous planes.
Typically three separate procedures are needed for a complete breast reconstruction:
First session comprises of sub- and intrapectoral fat transfer during the primary mastectomy surgery, providing volume to the deep tissue planes.
Second session is preceeded by wearing an external pre-expansion device to prepare the recipient site for grafting. It aims to give the breast its shape and initial volume.
Third session is also preceded by external pre-expansion and aims to provide extra volume of the breast to achieve symmetry with the healthy breast."
1585968|NCT02339779|Procedure|breast implant|"Implant-based reconstruction typically will occur as follows:
During the primary mastectomy surgery, a tissue expander will be implanted subpectorally.
The tissue expander will be gradually filled with sterile saline during outpatient clinic visits.
When the desired volume is achieved, a second operation will be planned, to exchange the tissue expanded with the definite breast implant.
(Note: in patients who are receiving encapsulectomy and implant exchange, the first 2 steps are skipped.)"
1585969|NCT02339766|Procedure|Quadratus Lumborum Block|Quadratus Lumborum Block with Ropivacaine 0.5% will be done.
1585970|NCT02339766|Procedure|Sham Block|Sham block of Quadratus Lumborum will be done with Saline.
1585971|NCT02339766|Drug|Intrathecal Morphine|Intrathecal Morphine 150 mcg will be co-administered with the spinal anesthetic.
1585972|NCT02339766|Drug|Intrathecal Saline|Intrathecal Saline 0.15 mL will be co-administered with the spinal anesthetic.
1585973|NCT02339753|Drug|Carboplatin|Blood sampling will be done at the time before administration (0hr pre-dose), 1hr, 2hr, 5hr for pharmacokinetic study.
1585974|NCT02339740|Drug|Arsenic Trioxide|Given IV
1585975|NCT02339740|Drug|Cytarabine|Given IV
1585976|NCT02339740|Drug|Dexamethasone|Given PO or IV
1585977|NCT02339740|Drug|Idarubicin|Given IV
1585978|NCT02339740|Other|Laboratory Biomarker Analysis|Correlative studies
1585979|NCT02339740|Drug|Mitoxantrone Hydrochloride|Given IV
1585980|NCT02339740|Other|Questionnaire Administration|Ancillary studies
1585981|NCT02339740|Drug|Tretinoin|Given PO
1585982|NCT02339727|Dietary Supplement|Preterm infants formula|The group 1 of children will receive a preterm infants formula supplemented with DHA and ARA with a relationship omega 6/omega 3 = 2/1 during the first 3 months of life. And group 2 will receive other Preterm infants formula very similar, but with a ratio of DHA and AA=1/1 also during the first 3 months of life.
1585983|NCT02339714|Other|acupuncture combined moxibustion|"Points: Hegu(LI4),Yingxiang(LI20),Chize(LU5),Sibai(ST2), Yintang(EX-HN3),Shangyingxiang(EX-HN8),Shangxing(GV23),Dazhui(Du14).
Pierced the skin, needles are inserted 0.5 to 2cm into the acupoints. Each needle are roated until the participants and the practitioner felt de-qi sensation. After that, moxibustion is applied to Dazhui(Du14). A 1cm long moxa cone is putted on the top of the needle at the acupoint, then ignite moxa cone until the cone is burn. The needles are left in place for 30 minutes. once every two days, 3 times in a week for consecutive 4 weeks, 12 times altogether."
1585984|NCT02339714|Drug|Loratadine|Loratadine will be taken orally at the dose of 10mg/day in the morning. Each treatment cycle will be given for continuous 4 weeks.
1585985|NCT02339701|Radiation|IMRT|
1585986|NCT02339701|Radiation|SBRT|
1585987|NCT02339688|Other|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
1585988|NCT02339675|Other|conventional MS rehabilitation|assessment pre and post conventional MS rehabilitation
1585989|NCT02339662|Drug|Gabapentin|muscles pain treatment
1585990|NCT02339662|Drug|Amitriptyline|muscles pain treatment
1585991|NCT02339649|Procedure|Blood Sample|Blood Sample
1585992|NCT02339649|Behavioral|Neurocognitive Assessment|Neurocognitive Assessment
1585993|NCT02339649|Other|Resting State EEG|10-20 Minutes of Resting State EEG
1585994|NCT02339649|Procedure|Lumbar Puncture|Lumbar Puncture
1585995|NCT02339649|Other|MRI|60 Minutes MRI
1585996|NCT02339636|Other|PDUS examination|
1585997|NCT02339623|Device|Ultrasound imaging|"- Fetal adrenal gland volume calculation using 3D ultrasound
- Assessment of the fetal central adrenal zone enlargement by 3D ultrasound
- CL measurement using 2D ultrasound"
1585998|NCT02339610|Device|ATTUNE Primary, Cemented Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four implant configurations of the ATTUNE knee ( CR FB, CR RP, PS FB, PS RP).
1585999|NCT02339597|Procedure|Automatic Positive Airway Pressure (APAP) initiation|
1586000|NCT02339584|Drug|Brinzolamide 10 mg/mL / Brimonidine 2 mg/mL fixed combination eye drops, suspension|
1586001|NCT02339584|Drug|Brinzolamide 10 mg/mL eye drops, suspension|
1586002|NCT02339584|Drug|Brimonidine 2 mg/mL eye drops, solution|
1586003|NCT02339584|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
2008875|NCT03326622|Other|standard care|A standard care program based on American Academy of Neurology guidelines (Range Of Motion (ROM) exercises, gait and balance training )at home or another rehabilitation units without intensity control.
1586009|NCT02339558|Other|Laboratory Biomarker Analysis|Correlative studies
1586010|NCT02339558|Biological|Nivolumab|Given IV
1586011|NCT02339545|Device|Volcano FloWire|Following successful revascularization, Coronary Flow Reserve will be measured for all subjects.
1586012|NCT02339532|Drug|FEC100|"3 cycles of FEC 100 administered IV q3w
5-Fluorouracil (5-FU) 500 mg/m2
Epirubicin 100 mg/m2
Cyclophosphamide 500 mg/m2"
1586013|NCT02339532|Drug|Docetaxel|TOP2A amplified : DOCETAXEL 75 mg/m2 IV escalading at 100 mg/m2 IV as tolerated q3w TOP2A not amplified : DOCETAXEL 75 mg/m2 IV
1586053|NCT02339246|Drug|Prograf vs Envarsus XR vs Astagraf XL|prograf vs Envarsus XR vs Astagraf XL
1586014|NCT02339532|Drug|Trastuzumab|Trastuzumab 8 mg/kg loading dose administered intravenously (IV) followed by 6 mg/kg IV q3w in subsequent cycles.
1586015|NCT02339532|Drug|Pertuzumab|Pertuzumab 840 mg loading dose administered IV followed by 420 mg IV q3w in subsequent cycles.
1586016|NCT02339532|Drug|Carboplatin|CARBOPLATIN AUC 6 IV q3w
1586017|NCT02339519|Device|LMA CLASSIC|Classic LMA consists of a mask with a surrounding inflatable bag compatible to the shape of the hypopharynx and a tube that has a 30° angle with a mask.
1586018|NCT02339519|Device|LMA FASTRACH|Fastrach LMA has similar features to the LMA Classic, but it is designed to provide upper airway during intubation via blind intubation or fiberoptic assistance. It has a rigid handle that allows one-handed insertion, removal or adjustment.
1586019|NCT02339519|Device|LMA SUPREME|Supreme LMA is a novel, sterile, single use, new generation supraglottic airway device which provides more rapid and higher volume gas passage through airway and can be inserted in a rapid and safe manner.
2008876|NCT03326622|Other|moderate exercise|A moderate exercise protocol two times per week in a treadmill in the lower range of the training zone determined by Cardiopulmonary Exercise Testing, monitored by continuous pulse oximetry evaluation.
2008877|NCT03326609|Drug|Ropivacaine|Perineural injection using a peripheral nerve block catheter and a constant infusion rate (10mL/h)
1586022|NCT02339493|Other|Computer Electronic Alert|A computer program that will issue an on-screen electronic alert notifying the responsible provider that his or her patient is high-risk for stroke due to AF or atrial flutter and that the patient is not ordered to receive anticoagulant therapy. The alert will provide options for anticoagulation for stroke prevention in AF as well as additional information in the form of suggested reading.
1586023|NCT02339480|Other|Massage therapy|Healthy volunteers do not accept treatment, just to be a control group to compare with obesity group
1586024|NCT02339467|Other|GO-OUT program|Participants attend the walking workshop followed by a 3-month outdoor walking group intervention, twice weekly for 60-minutes. Each session includes a 10-minute warm-up and cool down, and a planned walk in an outdoor community environment. Continuous walking exercise will gradually increase from 10 to 60 minutes, as well increase difficulty. Balance exercises will be included in the warmup and walk. There will be a variety of surfaces and environmental factors to challenge the participants, e.g., carrying objects, diverting the walker's attention, crossing at a light, walking up and down curbs, slopes, and level or uneven surfaces. Supervision will be on a 1:3 facilitator-to-participant ratio to allow for assistance and individualization of the intervention where necessary.
1586025|NCT02339467|Other|Task-oriented outdoor walking workshop|The 1-day workshop will be 5 hours with breaks. Participants will complete a series of stations learning information, strategies and skills related to safely walking outdoors. Stations include: pedometer use; walking pole use; footwear; footcare; fall prevention; balance exercises; proper use of walking aids; correct posture; self-management of exercise intensity; goal setting; and walking safely outdoors. Participants will receive a workbook with Canadian Physical Activity Guidelines, benefits of outdoor walking, information for each workshop station and a pedometer. Participants will use the workbook as an information resource and to record their community ambulation goals, planning routes, and walking time. All participants will be encouraged to walk outside with a partner, for safety.
1586026|NCT02339454|Device|Active treatment group|Energy Density - 0.09 mJ/mm2 Device: Active Applicator
1586027|NCT02339454|Device|Placebo group|Placebo Applicator
1586028|NCT02339441|Drug|Methotrexate|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, either oral or subcutaneous with a target dose of 20-25mg weekly.
1586029|NCT02339441|Drug|Mycophenolate mofetil|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study,recommended dose 500 mg twice daily for 2 weeks increasing to 1gm twice daily.
1586030|NCT02339441|Drug|Cyclophosphamide|Immunosuppressant agent. Patients treated with Methotrexate at the entry of the study, recommend use (i) IV. Minimum monthly dose 500mg/m2 with a recommended duration of 6-12 months. (ii) Oral. 1-2mg/day with a recommended duration of 12 months.
1586031|NCT02339428|Drug|diclophenac sodium|Patients will be given 100mg p.o. diclophenac sodium tablets
1586032|NCT02339428|Drug|Placebo|Inactive pill manufactured to mimic diclofenac tablet
1586033|NCT02339415|Drug|Edoxaban 30mg daily|
1586034|NCT02339415|Drug|Matching placebo|
2008878|NCT03326596|Drug|Tranexamic Acid 1000 mg/10ml normal saline infusion|Infusion of Tranexamic Acid (Cyklokapron) to all consented women with the delivery of the anterior shoulder of the infant
1586036|NCT02339376|Device|Low-frequency repetitive transcranial magnetic stimulation|
1586037|NCT02339376|Device|High-frequency repetitive transcranial magnetic stimulation|
1586038|NCT02339376|Device|Sham repetitive transcranial magnetic stimulation|
1586039|NCT02339363|Behavioral|Sitting Meditation|4 weeks Sitting Meditation
1586040|NCT02339363|Behavioral|Hatha yoga|4 weeks of Hatha yoga
1586041|NCT02339350|Drug|high dose methotrexate|HD-MTX IV 5,000 mg/m2 I.V. over 4hr on day 0, 14, 28, 42 of SER interim maintenance schedule
1586042|NCT02339350|Drug|Intrathecal triple chemotherapy|Intrathecal triple chemotherapy for SEG group instead of radiotherapy
1586043|NCT02339337|Other|Abbreviation of treatment duration|
1586044|NCT02339324|Drug|Pembrolizumab and high dose interferon alfa-2b (HDI)|Pembrolizumab and HDI will be given concurrently during the induction phase of the study for up to 6 weeks from treatment initiation. This is followed by surgery. After recovery from surgery, pembrolizumab and HDI will be reinitiated as maintenance therapy during the maintenance phase of the study.
1586045|NCT02339311|Other|Educational intervention of Lifestyle and patient activation in diabetics|Participants underwent a one hour group didactic session led by Community Health Representatives (CHRs) who subsequently carried out monthly home-based educational interventions to encourage healthy lifestyles, including diet, exercise, and alcohol and cigarette avoidance until follow up at 6 months, when clinical phenotyping and the PAM survey were repeated.
1586046|NCT02339298|Other|music application|music is applied during anaesthesia using headphones
1586047|NCT02339298|Other|only headphones|music is not applied, only headphones are placed
1586048|NCT02339298|Drug|a caudal block|
1586049|NCT02339285|Device|tACS (alpha)|
1586050|NCT02339285|Device|tACS (gamma)|
1586051|NCT02339272|Other|non interventional|
1586052|NCT02339259|Other|Observation|
1586054|NCT02339246|Drug|Prograf vs Astagraf XL vs Envarsus XR|Prograf vs Astagraf XL vs Envarsus XR
1586055|NCT02339233|Biological|Locomotor Training|Standing and Stepping in a body weight support (BWS) harness on a treadmill with/out EMG evaluation
1586056|NCT02339220|Behavioral|Constraint-Induced Movement Therapy (CIMT)|Constraint-Induced Movement Therapy (CIMT) is a form of physical rehabilitation based on basic research in behavioral psychology and behavioral neuroscience. The therapy will be given on an outpatient basis for 3.5 hours/day for 10 consecutive weekdays. This treatment has four components: 1. intensive training in use of the more-affected arm; 2. organization of this training following shaping principles, which involve frequent positive feedback and progressively increasing the demand of the task in small increments; 3. discouraging use of the less-affected arm by placing the hand in a padded safety mitt, and 4. a set of behavioral procedures, known as the Transfer Package, for transferring gains from the treatment to real-world setting. In this study, two forms of the Transfer Package, standard and enhanced, will be used and form a separate factor (see below).
1586057|NCT02339220|Behavioral|Lakeshore Enriched Fitness Training (LEFT)|This treatment will given on an outpatient basis for 3.5 hours per day for 10 consecutive weekdays. It will consist of the following components: general fitness exercises (largely lower extremity), sports and recreation (land and water-based); adapted Yoga; breathing exercises and postural control, movement to music, massage therapy, meditation and Progressive Muscle Relaxation (PMR).
1586058|NCT02339220|Behavioral|standard Transfer Package (sTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. The sTP is a set of behavioral procedures for transferring gains from the treatment setting to real-world. The procedures when the sTP is applied to CIMT include negotiating a behavioral contract with the patient and caregiver, when available, about use of each arm during the treatment period, keeping a daily diary on arm use, completing a structured interview about use of the more-affected arm in daily, problem solving about perceived barriers to use of the more-affected arm outside the treatment setting during treatment, and four weekly follow-up phone calls to assess use of the more-affected arm and problem solve about any remaining barriers perceived to its use. The sTP when applied to the LEFT intervention will have parallel components that target engagement in fitness activities and overcoming perceived barriers to fitness in the home.
1586059|NCT02339220|Behavioral|enhanced Transfer Package (eTP)|This intervention will take, on average, 30 minutes out of the 3.5 hour daily planned for treatment. It is an enhanced form of the sTP. The enhancements include a computerized version of the daily diary, cues to be placed in patients' homes to prompt engagement in desired activities, and additional follow-up phone calls.
1586062|NCT02339194|Procedure|Denture fabrication technique|"Both arm groups are composed by patients present severely resorbed mandibular alveolar bones who will receive complete dentures fabricated by means of a simpler techinique previously proved to be effective. Although for the traditional protocol group a second more complex impression step will be performed in order to evaluate if the simpler approach for this anatomical condition could be safely applied."
1586063|NCT02339168|Drug|Enzalutamide|Given PO
1586064|NCT02339168|Drug|Metformin Hydrochloride|Given PO
1586065|NCT02339155|Biological|AVA|Sterile, milky-white suspension with dosage level of 0.5 mL for SC administration
1586066|NCT02339155|Biological|Raxibacumab|Sterile, liquid formulation with unit dose strength of 40 mg/ kg for IV administration
1586067|NCT02339155|Drug|Diphenhydramine|Depending upon the labelling of the specific product chosen, 25 - 50 mg will be administered orally or IV
1586068|NCT02339142|Radiation|External beam radiotherapy|100 Rads to each lateral orbit x 10 doses
1586069|NCT02339142|Drug|intravenous corticosteroids (methylprednisolone)|Intravenous methylprednisolone (iv MP) 500 mg weekly x 6 weeks, then iv MP 250 mg x 6 weeks
1586070|NCT02339129|Drug|SST-0225|SST-0225 is a cream formulation for topical application. Each 5.4 g dose is formulated to topically deliver 400 mg of ibuprofen. The cream contains sodium ibuprofen and various salts.
1586071|NCT02339129|Drug|Placebo|Placebo IP will be the same vehicle as SST-0225 vehicle without the active ingredient, ibuprofen. It will be matched in appearance, smell, consistency, and color to SST-0225 topical ibuprofen cream.
1586072|NCT02339116|Drug|fluoruracil|
1586073|NCT02339116|Drug|Oxaliplatin|
1586074|NCT02339116|Drug|Irinotecan|
1586075|NCT02339116|Drug|Bevacizumab|
2008879|NCT03326583|Drug|Patiromer|Patiromer will be orally self-administered by participants.
2008880|NCT03326570|Behavioral|Medical Data Collection|Medical information collected after bronchoscopy for up to 2 years.
2008881|NCT03326557|Procedure|Membrane Sweeping versus Transcervical Foley Catheter for Induction of Labour in Women with Previous Caesarean Delivery|Subjects undergoing induction of labour (IOL) will be randomly assigned to two interventional arms (Group 1: membrane sweeping or Group 2: transcervical Foley catheter insertion). Before IOL, modified Bishop score will be assessed for cervical favourability. After 24 hours of IOL, improvement of modified Bishop score will be reassessed. If the cervix is favourable, amniotomy will be performed followed by augmentation with intravenous oxytocin. If the cervix is still unfavourable and amniotomy is impossible, membrane sweeping will be continued for one more day in Group 1 whereas conservative management will be undertaken for one day in Group 2. Suitability for amniotomy will be reassessed on the next day. After amniotomy, subsequent intrapartum management will be based on the hospital protocol. If amniotomy is still impossible after 2 days of IOL, the ward Obstetrician will discuss with women regarding option of Caesarean section.
2008882|NCT03326544|Other|Saphenous nerve block group|Patients will receive ultrasound-guided intervention treatment with a sub-sartorial approach for a saphenous nerve block with 8 mL of bupivacaine 0.5% plus dexamethasone 4 mg
1586081|NCT02339051|Behavioral|Jumping on one leg|
1586082|NCT02339038|Drug|Ledipasvir 90 mg and Sofosbuvir 400 mg|Ledipasvir 90 mg and Sofosbuvir 400 mg fixed dose combination as per standard of care treatment guidelines
1586087|NCT02338960|Drug|Bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
1586088|NCT02338960|Drug|Placebo|Placebo
1586233|NCT02337933|Drug|Ursolic acid|Ursolic acid capsules of 150 mg extracted from rosemary, once a day before breakfast
2008883|NCT03326544|Other|Platelet rich plasma group|Patients will receive intra-articular ultrasound-guided injection of 5 mL of autologous Platelet rich plasma
1586091|NCT02338934|Drug|Combination Cinacalcet with Vitamin D analogue|Depending on the iPTH level and the serum calcium level they will be started on Cinacalcet 25mg OD and active Vitamin D will be adjusted. If Serum Cal <2.4 mmol/L - Start Cinacalcet 25mg OD & Increase active Vit D by 1 mcg/dose 3x/week Increase active Vit D by 1 mcg/dose 3x/week or Serum Ca 2.4-2.54 mmol/L- Start Cinacalcet 25mg OD and Maintain active Vit D dose OR if >2.54 mmol/L - Start Cinacalcet 25mg OD & Maintain active Vit D dose. Then they will go to maintenance phase.
2008884|NCT03326531|Other|Not applicable for this study|Not applicable for this study
2008885|NCT03326518|Diagnostic Test|Lumentin® 44|Contrast agent
2008886|NCT03326518|Diagnostic Test|Diluted Omnipaque®|Contrast agent
2008887|NCT03326518|Diagnostic Test|Movprep®|Contrast agent
2008888|NCT03326505|Biological|Umbilical cord derived Mesenchymal Stem Cells|Allogenic umbilical cord derived stem cells which are to be injected intrathecally as a treatment option for consenting MS patients
1586097|NCT02338908|Other|exercise program|Patients will be asked to perform an eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles, to be performed on an individual basis twice every day. The therapeutic protocol will be applied for 5 weeks.
1586098|NCT02338908|Other|TrP-DN|In addition, within the second and fourth sessions, they will receive TrP-DN over active TrPs in the shoulder muscles
1586099|NCT02338895|Device|Ultrasound|Ultrasound of inferior vena cava and kidneys
1586100|NCT02338882|Device|Bi flex M multifocal intraocular lens|Multifocal intraocular lens
1586101|NCT02338882|Device|Bi flex 1.8 monofocal intraocular lens|Standard monofocal intraocular lens
1586102|NCT02338869|Behavioral|Dialogue-based psychosocial rehabilitation|
1586103|NCT02338856|Drug|MB12066 200mg|100mg bid (multiple dose, day 8)
1586104|NCT02338856|Drug|Placebo|100mg bid (multiple dose, day 8)
1586105|NCT02338843|Drug|LJPC-501|Treatment arm
1586106|NCT02338843|Drug|Placebo|PBO
1586107|NCT02338830|Drug|Progesterone|Women received vaginal progesterone suppositories (Cyclogest®, Actavis, Barnstaple, EX32 8NS, United Kingdom) in a dose of 400 mg daily beginning at 20-24 weeks gestational age
1586108|NCT02338817|Device|Diabetes Sentry|The Diabetes Sentry device will be monitored for alarms for possible hypoglycemic. A blood sample will be taken to confirm blood glucose levels, lactate, and ketone values.
1586109|NCT02338804|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
1586110|NCT02338804|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
1586111|NCT02338791|Device|Manual Mobilization|Stabilization of the glenoid fossa with movement of the humerus using varying degrees of force as applied by a physical therapist. Subject is positioned with the shoulder in 55 degrees of abduction and 30 degrees of horizontal adduction. Manual force is applied by a physical therapist on the proximal humeral head moving the humeral head posterior, inferior or lateral (distraction). An ultrasound transducer placed over the anterior shoulder joint provides imaging of the humeral head and the glenoid fossa. This manual intervention is repeated three times in each direction on each arm.
1586112|NCT02338778|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
1586113|NCT02338778|Other|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
1586114|NCT02338765|Behavioral|mHealth Physical Activity|
1586115|NCT02338765|Behavioral|Buddy-partnered exercise|
1586116|NCT02338752|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
1586117|NCT02338752|Other|Standard Treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
1586118|NCT02338739|Behavioral|REC; Outreach if Failure|Routine education and counseling (REC) services, delivered per Kenya Ministry of Health Guidelines; followed by standard of care (SOC) outreach to encourage return to clinic for patients 14 days late for a scheduled visit in year 1.
1586119|NCT02338739|Behavioral|REC; SMS + Voucher if Failure|Routine education and counseling services, delivered per Kenya Ministry of Health (MOH) Guidelines; followed by SMS text messages for patients and reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
1586234|NCT02337933|Drug|Placebo|Calcined magnesia capsules of 150 mg, once a day before breakfast
1586235|NCT02337907|Drug|Placebo|for blinding purposes
2008889|NCT03326505|Other|Supervised physical therapy|A combined physical therapy program of Balance, strengthening and endurance exercises
1586120|NCT02338739|Behavioral|REC; Navigator if Failure|REC services, delivered per Kenya MOH Guidelines; followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
1586121|NCT02338739|Behavioral|SMS; Outreach if Failure|SMS text messages for patients; followed by SOC outreach for patients 14 days late for a scheduled visit
1586122|NCT02338739|Behavioral|SMS; Outreach if Failure; Stop SMS if Success|SMS text messages for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
1586123|NCT02338739|Behavioral|SMS; SMS+Voucher if Failure|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1.
1586124|NCT02338739|Behavioral|SMS; SMS+Voucher if Failure; Stop SMS if Success|SMS text messages for patients, followed by reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit in year 1, and discontinuation of SMS text messages if never 14 days late
1586125|NCT02338739|Behavioral|SMS; Navigator if Failure|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
1586126|NCT02338739|Behavioral|SMS; Navigator if Failure; Stop SMS if Success|SMS text messages for patents, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of SMS text messages if never 14 days late
1586127|NCT02338739|Behavioral|Voucher; Outreach if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit
1586128|NCT02338739|Behavioral|Voucher; Outreach if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SOC outreach for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
1586129|NCT02338739|Behavioral|Voucher; SMS+Voucher if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit
1586130|NCT02338739|Behavioral|Voucher; SMS+Voucher if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by SMS text message and reimbursement (KSH 400) for transport to the clinic for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
1586131|NCT02338739|Behavioral|Voucher; Navigator if Failure|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit
1586132|NCT02338739|Behavioral|Voucher; Navigator if Failure; Stop Voucher if Success|Reimbursement at a fixed amount (KSH 400) for transport to the clinic for patients, followed by Peer Navigator (tailored outreach and support) for patients 14 days late for a scheduled visit, and discontinuation of voucher for patients if never 14 days late
1586133|NCT02338726|Other|Gynecological examination|Comparison of questionnaires and gynecological examination
1586134|NCT02338713|Drug|Calcichew D3|Calcium 500 mg and vitamin D3 1000 IU chewable tablets
1586135|NCT02338713|Drug|Noncarbonated Water|Noncarbonated water 200 mL
1586136|NCT02338700|Biological|MV|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for
1586137|NCT02338700|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
1586138|NCT02338687|Dietary Supplement|calcium|one chewable tablet daily, at bedtime, containing 500 mg elemental calcium (1250 mg calcium carbonate)
1586139|NCT02338687|Behavioral|Educational sessions|Women will participate in at least 2 interactive group educational sessions lasting 30 minutes each. Session content: importance of calcium during pregnancy and how to modify their diets to include calcium-rich foods that are available locally
1586140|NCT02338674|Drug|Telbivudine and Tenofovir|Telbivudine and Tenofovir administered at least 48 weeks
1586141|NCT02338661|Device|SBG hip stem|
1586142|NCT02338648|Drug|SUN-131 1.5% TDS|Active transdermal patch
1586143|NCT02338648|Drug|Placebo TDS|Placebo transdermal patch for blinding
1586144|NCT02338635|Drug|Ursodeoxycholic Acid|Inhibition of ER stress (Ursodeoxycholic Acid)
1586145|NCT02338622|Drug|olaparib|olaparib BD
1586146|NCT02338622|Drug|AZD5363|AZD5363 BD
1586147|NCT02338609|Drug|Everolimus|Blood sample and Tanner Stage assessment
1586148|NCT02338609|Drug|Envirolimus drug class as prescribed by Physician|At the discretion of the investigator, patients may be treated with commercially available everolimus, as per local product information/ standard of care.
1586149|NCT02338596|Procedure|Total hip replacement|"Simultaneous bilateral sequential total hip arthroplasties under the same anesthetic.
Randomization to treatment with an ultra-short or a convnetional cementless stem was accomplished with use of study numbers in sealed envelope, which were opened in the operating room before the skin incision was made.
The pore size was 250㎛. A 28-mm-diameter Biolox forte ceramic femoral head (CeramTec AG, Polchingen, Germany) ) was used in all hips. A cementless cup and a 28mm internal-diameter Biolox forte ceramic liner was used in all hips in both groups."
1586150|NCT02338583|Device|Echelon Flex™ 45 and 60 Powered ENDOPATH® Stapler Articulating Endoscopic Linear Cutter|
1586151|NCT02338570|Drug|Everolimus|Patients will start study treatment on day 1 and will be treated with daily doses of everolimus (10 mg daily tablets).
1586152|NCT02338557|Device|motor relearning programme|MRP exercises for training of Wrist Extensors, Extension of wrist and holding objects, training of supination of forearm, opposition of thumb, cupping of hand and training of manipulation of the objects
1586230|NCT02337959|Radiation|Radiation|Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
1586153|NCT02338557|Device|MIRROR THERAPY|Mirror therapy in which patient was seated close to the table in front of mirror (35x35 cm). The involved hand was placed behind the mirror. : the practice consisted of intransitive exercises as Hand opening, Wrist extension and flexion, Forearm pronation and supination, Hand sliding on a flat surface. During the session patient were asked to try to do the same movement with the paretic hand while they were moving the non-paretic hand.In both the groups total treatment was given for 1 hour/day for 6 days/week
1586154|NCT02338544|Drug|0.1% Adapalene / 2.5% Benzoyl peroxide|Epiduo® gel containing 0.1% adapalene + 2.5% benzoyl peroxide dispensed from a pump.
1586155|NCT02338531|Drug|PF-03084014|
1586156|NCT02338531|Procedure|Breast cancer surgery|
1586157|NCT02338518|Drug|oxaliplatin|"oxaliplatin 100 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group and SOX group.
Intravenous oxaliplatin 130 mg/m2 was administered on day 1 of every cycle in SOX group."
1586158|NCT02338518|Drug|etoposide|etoposide 80 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
1586159|NCT02338518|Drug|pharmorubicin|pharmorubicin 30 mg/m2 was administered from the celiac artery on day 1 of every cycle in SEEOX group.
1586160|NCT02338518|Drug|S-1|80 mg of oral S-1 per square meter of body-surface area per day was given for 2 weeks in both SEEOX and SOX groups.
1586161|NCT02338505|Device|Telelap ALF-X|"Patients placed in the dorsal lithotomic position with both legs supported in Allen stirrups with a Trendelenburg tilt. After achieving pneumoperitoneum (12mmHg) through a trans umbilical open access technique, intra-abdominal visualization was obtained with a 10mm 0° HD 3D telescope. During the trocar placement the operative room nurses supported the surgeon in the docking procedures approaching the robotic arms to the operative table, in places established for pelvic surgery. The cockpit is located in one corner of our square shape room; the operative table is surrounded by the three robotic arms unit.
Through the teleassisted operative ports we could make use of several type of instruments. Movements of both instruments and optic were completely carried out by the surgeon from the cockpit according to the needs of the procedure."
1586162|NCT02338492|Device|Photodynamic Bone Stabilization System (PBSS)|Treatment of impending and actual pathological fractures of the humerus
1586163|NCT02338466|Drug|rt-PA|0,9 mg/kg of rt-PA is infused intravenously 60 minutes, with 10% of the total dose administered as an initial intravenous bolus.
1586164|NCT02338466|Drug|tenecteplase|"Tenecteplase is under the form of powder and solvent for solution for injection.
The maximum duration of this treatment is 15 seconds by a single bolus intravenous injection (0, 25 mg/kg)."
1586165|NCT02338453|Behavioral|Active Attention Bias Modification Treatment|Attention bias is modified using a dot-probe task. Each trial begins with a fixation cross presented in the center of the screen for 500 ms. Next, participants are presented with two stimuli depicting two faces of the same individual for 500 ms, either of two neutral faces or with one neutral face and one disgust face (i.e., the socially-threatening stimulus). Then, one of two optional probes appears in the location former occupied by one of the faces. Participants are instructed to discriminate as fast as possible between the two variants of the probe, without compromising accuracy, by pressing on two corresponding keys. The probe remains on the screen until the participant responds, after which the next trial commences. This protocol is designed to divert attention away from socially-threatening stimuli as in 80% of trials the probe appears in the location formerly occupied by the neutral face. The remaining 20% of trials include two neutral faces, with no predictive value
1586166|NCT02338453|Behavioral|Placebo Attention Bias Modification Treatment|the Placebo ABMT is similar to the active ABMT except that this protocol is not designed to divert attention away from or toward socially-threatening stimuli as in 40% of trials the probe appears in the location formerly occupied by the neutral face and in 40% it appears in the location formally occupied by the threatening face. The remaining 20% of trials include two neutral faces
1586167|NCT02338440|Drug|lipoprostaglandin E1|Blood sampling before administration (baseline), between 1 hour to 72 hours from administration (plateau 1), 72 hours after engraftment (plateau 2), when the clinician determine to do blood sampling because of change of kidney/liver function change (optional 1), 72 hours from the change of lipoprostaglandin E1 concentration change (optional 2)
1586168|NCT02338427|Other|Immunohistochemistry|
1586169|NCT02338427|Other|Proteomic analysis|
1586170|NCT02338414|Drug|Romiplostim|Subcutaneous Romiplostim (weekly injection) -> if titrated with maintaining PLT count between 50-200 x 10^9/L -> Subcutaneous Romiplostim (biweekly injection)
1586171|NCT02338401|Dietary Supplement|Omega-3 Complete|Fish Oil Capsules
1586172|NCT02338401|Dietary Supplement|Placebo Pill|Olive Oil Capsules
1586173|NCT02338388|Procedure|cesarean section technique|Comparing three different types of suturing the uterus at Cesarea section
1586174|NCT02338375|Biological|Cartistem|Cartistem is allogenic umbilical cord blood-derived stem cell product. Cartistem is 500uL/cm2 applied according to the lesion.
1586177|NCT02338349|Drug|RAD1901|
1586178|NCT02338336|Drug|Nowarta110|Nowarta110 contains fig extract as the main drug substance, and colloidal silver is used as a medium for penetration of fig extract into the wart lesion. Liquid for topical administration.
1586179|NCT02338336|Drug|Placebo|Matching placebo liquid for topic administration.
1586180|NCT02338323|Drug|Febuxostat|It acts as an inhibitor of xanthine oxidase, thus lowering urate concentrations in the body
1586181|NCT02338323|Drug|Benzbromarone|It is structurally related to the antiarrhythmic amiodarone, and it is a uricosuric agent and non-competitive inhibitor of xanthine oxidase
1586182|NCT02338310|Drug|Aromatase Inhibitors|Choice of AI is according to centre policy; any brand can be used
1586183|NCT02338297|Procedure|TACE|Transarterial chemoembolisation (TACE)
1586184|NCT02338297|Drug|EGM|Occlude arterioportal shunts(APS) with ethanol/gelfoam mixture(EGM)
1586185|NCT02338297|Drug|PVA|Occlude arterioportal shunts(APS) with PVA
1586231|NCT02337946|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|oxaliplatin (OXA), levofolinate calcium (l-LV), panitumumab: intra-venous infusion 5-FU: bolus and continuous intra-venous infusion
1586232|NCT02337946|Drug|oxaliplatin (OXA), levofolinate calcium (l-LV), 5-FU, panitumumab|
1586236|NCT02337907|Drug|Placebo|
1586237|NCT02337907|Drug|BI 409306|
1586186|NCT02338284|Other|ultrasound of globe|"A high resolution 7.5 -10 MHz linear array ultrasound transducer probe will be used. A large amount of standard water-soluble ultrasound transmission gel will be applied to the patient's closed eyelid. The globe will be scanned in the transverse plane.• The ONSD will be measured at a predefined point 3 mm posterior to the globe in both eyes. • Measurement of the ONSD for both eyes will be done and the average the two measurements will be taken.
A value > 58mm (from reference 1) will be considered as indicative of increased ICP and the primary ICU team will be informed for rapid measures to decrease ICP or urgent imaging of the CNS."
1586187|NCT02338271|Other|autologous adipose derived mesenchymal stem cell|autologous adipose derived mesenchymal stem cell (2 x 10^7 cells/mL /vial or 4 x 10^7 cells/mL /vial) and Tissuefill (hyaluronic acid derivatives) 1mL/syringe
1586188|NCT02338258|Device|Anti-rotational plate|
1586189|NCT02338258|Device|Exchanged Intramedullary nailing|
1586193|NCT02338232|Drug|Telmisartan|
1586194|NCT02338219|Other|postpartum female pelvic floor muscle affection|"transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
1586195|NCT02338219|Other|postpartum sexual function in Egyptian women.|answering of the validated female sexual function index (F.S.F.I) three months postpartum period for same cases submitted to ultrasound.
1586196|NCT02338206|Drug|Growth hormone|
1586197|NCT02338193|Drug|DAPA/MET XR|final dose- 5 mg dapagliflozin/1000 mg glucophage XR BID for 20-24 weeks
1586198|NCT02338193|Drug|DAPA|10 mg dapagliflozin QD for 20-24 weeks
1586199|NCT02338193|Drug|MET XR|1000 mg Metformin XR BID for 20-24 weeks
1586200|NCT02338180|Other|proximal preventive sealants|On sound mesial surfaces of first permanent molars adjacent to a caries active lesion of second primary molar, after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
1586201|NCT02338180|Other|proximal therapeutic sealant|On mesial surfaces of first permanent molars with caries active lesion adjacent to a caries active lesion of second primary molar , after 4-6 days with an orthodontic separating rubber ring around the approximal contact area. The test site was isolated with cotton rolls or a rubber dam. The surface of 6m was etched with 35% phosphoric acid for 20 sec, washed with water and then air-dried. The sealant (Concise Sealant; 3M ESPE) was applied and light-cured for 20 sec each on the occlusal, buccal and lingual sides. After polymerization, the sealant was inspected for complete coverage.
1586202|NCT02338167|Procedure|Blood sampling|A blood sample will be taken during a routine blood draw
1586203|NCT02338141|Device|Portable colposcopy (Cerviscope)|HPV-positive women will be evaluated with portable colposcopy (with a novel portable colposcope known as the Cerviscope) after visual inspection with acetic acid and prior to biopsy in the experimental group.
1586204|NCT02338141|Device|Conventional colposcopy (Wallach Zoomscope)|HPV-positive women will be evaluated with conventional colposcopy (with the Wallach Zoomscope) after visual inspection with acetic acid and prior to biopsy per usual standard of care.
1586205|NCT02338115|Drug|Paclitaxel 80mg/m2 weekly x 12 weeks|
1586206|NCT02338102|Other|Saline mixture|premeasured salt packets mixed with distilled water
1586207|NCT02338089|Drug|Oxytocin|Oxytocin, 100 micromolar solution
1586208|NCT02338076|Drug|Petrolatum application under occlusion|"Day 0 study patients will have 1 patch applied to either back or thighs ( containing 2 wells)
1 well will be empty and the other well will contain petrolatum
Day 3 patches will be removed and 3 skin biopsies will be performed 1 biopsy from normal skin at a distance from the patch
1 biopsy each from under the 2 wells of the patch ( so 1 biopsy from skin that was occluded with petrolatum and 1 biopsy from skin that was occluded without petrolatum)"
1586209|NCT02338063|Behavioral|Virtual Reality|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using 3-D goggles for some activities.
1586210|NCT02338063|Behavioral|Health Promotion|4-session group intervention including affect management training as well as sexual health skills training to prevent the transmission of HIV. Group will practice skills using traditional role-plays for some activities.
1586211|NCT02338050|Biological|Moxetumomab Pasudotox|
1586212|NCT02338037|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection
1586213|NCT02338037|Procedure|Biopsy|Undergo biopsy
1586214|NCT02338037|Drug|Eribulin Mesylate|Given IV
1586215|NCT02338037|Procedure|Microdialysis|Undergo intracerebral microdialysis
1586216|NCT02338037|Other|Pharmacological Study|Correlative studies
1586217|NCT02338024|Behavioral|Modified Antiretroviral Treatment Access Study intervention|
1586218|NCT02338011|Drug|Gefitinib|Gefitinib was given 250mg per day. Dose reduction was allowed for intolerable adverse effects such as rash(grade 4)、diarrhea(grade 3-4) or non hematological toxicity(grade 3-4) from 250mg per day to 250mg every other day then to 250mg every three days if needed.
1586219|NCT02338011|Radiation|WBRT|WBRT was delivered in 3.0 Gy fractions once per day 5 days per week to a total dose of 30Gy (10 fractions).
1586220|NCT02337998|Other|load carriage|
1586221|NCT02337985|Drug|Prednisone|Given PO
1586222|NCT02337985|Biological|Rituximab|Given IV
1586223|NCT02337985|Drug|Etoposide|Given IV
1586224|NCT02337985|Drug|Doxorubicin Hydrochloride|Given IV
1586225|NCT02337985|Drug|Vincristine Sulfate|Given IV
1586226|NCT02337985|Drug|Cyclophosphamide|Given IV
1586227|NCT02337985|Biological|Filgrastim|Given SC
1586228|NCT02337985|Biological|Lentivirus Vector rHIV7-shI-TAR-CCR5RZ-transduced Hematopoietic Stem/Progenitor Cells|Given IV
1586229|NCT02337972|Drug|povidone-iodine 4%|Prior to each injection and before the use of povidone-iodine drops, a conjunctival culture will be taken
1586239|NCT02337894|Dietary Supplement|Essential amino acids plus arginine|Flavored drink containing essential amino acids plus arginine.
1586240|NCT02337894|Dietary Supplement|Placebo|Flavored drink without essential amino acids plus arginine.
1586241|NCT02337881|Drug|nifedipen|The protocol for nifedipen in our units consists of 20 mg orally stat, followed by 10 mg orally every 6-8 hours for 48 to 72 hours as needed
1586242|NCT02337881|Drug|Sildenafil|sildenafil citrate will be administered vaginally in a dose of 25mg at 8 hourly intervals and both medications will be continued for 48-72 hours as indicated.
1586243|NCT02337868|Biological|HydroVax-001|HydroVax-001 West Nile Virus inactivated vaccine, alum-adsorbed given at doses of 1 mcg (low dose) and 4 mcg (high dose) IM on days 1 and 29
1586244|NCT02337868|Other|Placebo|0.9% Sodium Chloride Injection diluent will be given IM on days 1 and 29
1586245|NCT02337855|Other|Placebo|Placebo: normal saline for parenteral administration. Group C. Group F, and Group I: single dose intramuscular (IM) Placebo (normal saline (0.9% NaCl) on Day 1, 57 and 113.
1586246|NCT02337855|Biological|Sm-TSP-2/Alhydrogel|Sm-TSP-2/Alhydrogel. Group A: single dose IM 10mcg Sm-TSP-2/Alhydrogel® on Day1, 57 and 113. Group D: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113. Group G: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel® on Day 1, 57 and 113.
1586247|NCT02337855|Biological|Sm-TSP-2/Alhydrogel/GLA-AF|Sm-TSP-2/Alhydrogel/GLA-AF. Group B: single dose intramuscular (IM) 10mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group E: single dose intramuscular (IM) 30mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113. Group H: single dose intramuscular (IM) 100mcg Sm-TSP-2/Alhydrogel®/GLA-AF on Day 1, 57 and 113.
1586248|NCT02337842|Biological|Norovirus GII.4 Challenge Pool CIN-1|Norovirus Challenge GII.4 Strain 031693. Cohort 1: receive single oral dose of GII.4 CIN-1 at 10^3 RT-PCR units. Cohort 2: single oral dose of GII.4 CIN-1 either at 10^2 or 5x10^3 RT-PCR units. Cohort 3: single oral dose of GII.4 CIN-1 at either 10^4, 10^3, 5x10^2 or 5x10^1 RT-PCR units. Cohort 4: single oral dose of GII.4 CIN-1 at either 5x10^4 or 5x10^3 or 10^3 or 10^2 or 10^4 or 5x10^2 or 5x10^1RT-PCR units.
1586249|NCT02337842|Other|Placebo|Placebo: 80 ml of sterile water for oral administration
1586250|NCT02337829|Drug|acalabrutinib|Patients undergo lymph node biopsies
1586251|NCT02337829|Drug|acalabrutinib|Patients undergo bone marrow biopsies
1586252|NCT02337816|Procedure|laparoscopic surgery, obtainment of biological samples|
2008890|NCT03326492|Drug|Antivenom serum Inoserp Pan-Africa® injection|Participation to the study does not change usual follow-up of patients. All medical procedures will be performed and products will be used in a routine manner. Antivenom serum Inoserp Pan-Africa® injection will be decided according to the clinical evaluation of the patient.
2008891|NCT03326479|Diagnostic Test|Caris Molecular Intelligence Profile|A comprehensive biomarker testing
2008892|NCT03326453|Device|Mini dental implant|titanium mini dental implant which diameter less than 3 mm
1586256|NCT02337751|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
2008893|NCT03326440|Other|VERT system|3D images of radiotherapy planning and administration using the VERT (Virtual Environment Radiotherapy) system is shown either prior to Radiotherapy (study arm) or post Radiotherapy (control arm)
2008894|NCT03326427|Behavioral|Skill Training Group of the Dialectical Behavior Therapy|A 12 session version of the Skill Training Group of the Dialectical Behavior Therapy, adapted for treatment of ADHD.
2008895|NCT03326427|Other|Treatment as Usual|Conventional protocol using only medication (including drug adherence).
2008896|NCT03326414|Procedure|Constant PEEP - low tidal volume|The respirator is set according to study protocol
2008897|NCT03326414|Procedure|Constant PEEP - high tidal volume|The respirator is set according to study protocol
1586262|NCT02337712|Radiation|q.d. RT|65 Gy in 26 fractions
1586263|NCT02337712|Radiation|b.i.d.RT|45 Gy in 30 fractions
1586264|NCT02337699|Device|Implantation with the commercially available Axium neurostimulator|
1586265|NCT02337699|Procedure|QST Testing|
1586266|NCT02337686|Drug|Pembrolizumab|Up to 2 doses of 200 mg IV prior to surgery (Day -21 and Day -1, prior to the surgery on Day 0); continued after recovery from surgery (approximately 2-3 weeks) every 3 weeks until disease progression or development of unacceptable toxicities.
1586267|NCT02337686|Procedure|Surgery|Routine care surgery (reoperation) performed Day 0 for tumor progression.
1586268|NCT02337660|Procedure|Liver biopsy|One ultrasound guided liver biopsy
1586269|NCT02337660|Other|Pancreatic clamp|I.v. infusions of somatostatin and insulin (basal rate) for will be adminstered for 3 hours. Glucagon will administered for 3 hours in total with infusion rates at a basal and a high physiological rate for 1.5 hours each.
1586270|NCT02337647|Other|DCDC App|The DCDC app is an experimental software that allows users to map their visual distortions on a tablet computer.
1586273|NCT02337621|Other|No intervention|
1586274|NCT02337608|Drug|GLPG1205|GLPG1205 daily dosing in the morning for 12 weeks
1586275|NCT02337608|Drug|Placebo|placebo daily dosing in the morning daily for 12 weeks
1586276|NCT02337595|Biological|CD45RA-depleted peripheral blood mononuclear cells|Infusion of escalating doses of CD45RA-depleted donor-derived allogeneic peripheral blood mononuclear cells
1586277|NCT02337582|Other|Opportunistic Breast cancer screening|Opportunistic breast screening offered to women attending clinics for non-breast health issues
1586278|NCT02337582|Other|Usual Care|No breast screening was explicitly offered to women attending clinics for non-breast health issues, unless the health care provider felt that it was appropriate
1586279|NCT02337569|Drug|NPC-02|
1586280|NCT02337556|Other|Peptamen Bariatric|Commercially available enteral diet
1586281|NCT02337556|Other|Replete|Commercially available enteral diet
1586282|NCT02337543|Drug|NEO6860|NEO6860 is an NCE acting as a TRPV1 antagonist
1586283|NCT02337543|Drug|Placebo|Placebo
1586288|NCT02337517|Other|Laboratory Biomarker Analysis|Correlative studies
1586289|NCT02337517|Drug|Vismodegib|Given PO
1586290|NCT02337504|Other|community-based care|Will receive HIV care in the community and not in the clinic which is the normal standard of care
1586291|NCT02337491|Drug|Pembrolizumab|Administered intravenously
1586292|NCT02337491|Drug|Bevacizumab|Administered Intravenously
1586293|NCT02337478|Drug|Vincristine Sulfate Liposome|Given via injection
1586295|NCT02337465|Device|Cone-Beam Computed Tomography|Undergo kilo-voltage cone beam computed tomography
1586296|NCT02337465|Radiation|3-Dimensional Ultrasound-Guided Radiation Therapy|Undergo ultrasound-guided radiation therapy
1586297|NCT02337452|Behavioral|Family History Questionnaire|Participants complete a family history questionnaire online or hardcopy, which should take about 20 minutes to complete.
1586298|NCT02337452|Behavioral|Web-Based Family Outreach Registry|Participants taught how to use the Web-Based Family Outreach Registry. They will be given a secure log-in username and password for the web site.
1586299|NCT02337439|Behavioral|Sensory Information Processing Training|Computer exercises requiring identification of visual stimuli on computer screen and response with keyboard
1586300|NCT02337439|Behavioral|Active Control Training|Commercially available educational software
1586301|NCT02337426|Drug|Dimethyl Fumarate|Given PO
1586302|NCT02337426|Drug|Temozolomide|Given PO
1586303|NCT02337426|Radiation|Radiation Therapy|Undergo radiation therapy
1586304|NCT02337413|Drug|Polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and then will be stepped down to 0.8gr/kg subsequently and tapered accoriding to stool consistency and frequency.
1586305|NCT02337413|Behavioral|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavioral therapy including active sitting on the toilet to attempt defaction following meals.
1586306|NCT02337413|Behavioral|Urotherapy|Patients will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
1586307|NCT02337400|Behavioral|"Cognitive behavioral smoking reduction program Smoke_less"|Duration: 5 weeks, 4 sessions over 2,5 hours and 2 phone calls
1586308|NCT02337400|Behavioral|15 minute counseling interview|
2008898|NCT03326414|Procedure|constant tidal volume - low PEEP|The respirator is set according to study protocol
2008899|NCT03326414|Procedure|constant tidal volume - high PEEP|The respirator is set according to study protocol
1586311|NCT02337374|Device|Midurethral sling mesh|
1586312|NCT02337361|Behavioral|Electronic SBI|"Bilingual (English and Spanish) e-SBI with four key components:
1) Beverage-specific drink size assessment; 2) Individualized feedback on the woman's drink sizes and on discrepancies between her drink size and the standard size for each beverage; 3) A personalized plan for reducing consumption which includes goal setting; and 4) an analysis of high risk situations for drinking alcohol, and suggested coping strategies."
2008900|NCT03326388|Drug|Selumetinib|Selumetinib Intermittent Dosing
2008901|NCT03326375|Radiation|SBRT|Maximum dose : 60Gray (Gy) Fraction : 2 to 5
1586315|NCT02337322|Drug|Dolutegravir|
1586316|NCT02337322|Drug|Darunavir/r|
1586317|NCT02337309|Drug|SF1126|SF1126 in IV form with be given to patients on this study.
1586318|NCT02337296|Behavioral|ADHERE|"ADHERE entails a face-to-face 30 minute session during week 1 while in the clinic/office and three subsequent ADHERE phone calls for 10 minutes each, weekly during weeks 2-4 to promote symptom management and adherence to their oral agent regimen. The face-to-face intervention and phone interactions will consist of Motivational Interviewing and Cognitive Behavioral Therapy interaction strategies. Each patient will be given a Medication Management and Symptoms Management Toolkit, to assist with symptom management at home.
All patients (intervention and control) receive weekly assessments of symptom severity and oral agent adherence (weeks 2-7). At exit (week 8), all patients receive an assessment of depressive symptoms, self-efficacy, beliefs, motivation, symptom severity, and adherence."
1586319|NCT02337283|Drug|BI 425809|Tablets
1586320|NCT02337283|Drug|Placebo|Tablets
1586321|NCT02337270|Biological|Ad5Ag85A|Aerosol administration of Ad5Ag85A
2008902|NCT03326362|Other|Resistance training|Comparison between high and low intensities trainings described in arms
1586324|NCT02337244|Device|Zimmer Persona Total Knee System|No Intervention
1586325|NCT02337231|Dietary Supplement|soybean oil and borage oil|Compare the capacity of humans with GG, GT and TT genotypes at rs174537 taking soybean and borage oils to metabolize medium chain PUFAs.
1586326|NCT02337218|Device|SENSUS Pain Management System|An electrical stimulation device worn on a band around the leg. This device was determined to be non-significant risk by the FDA.
1586327|NCT02337205|Drug|KX2-391 Ointment|KX2-391 Ointment will be applied at a predetermined concentration to the treatment area for a predetermined time period.
1586328|NCT02337192|Drug|Curcumin|
1586329|NCT02337192|Device|LED|
1586330|NCT02337192|Drug|Surfactant|
1586331|NCT02337192|Drug|DMSO + water|
1586332|NCT02337192|Drug|Chlorhexidine gluconate|
1586333|NCT02337179|Procedure|Voluntary medical male circumcision|Male Circumcision Under Local Anesthesia using the Forceps Guided Method
1586334|NCT02337166|Device|a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate|0.2ml of a gel containing 4mg/ml rhFGF-2 in sodium hyaluronate MW 1.3 x 106
1586335|NCT02337166|Procedure|Periodontal flap surgery|
1586336|NCT02337140|Device|Pacemaker SORIN Group KORA DR|
1586337|NCT02337140|Procedure|transcatheter aortic valve implantation (TAVI)|
1586338|NCT02337127|Drug|Lamivudine|Lamivudine, 100mg/day, per os
1586339|NCT02337114|Behavioral|Acceptance and Commitment Therapy|A psychotherapeutic intervention that aims to enhance individuals' willingness to have difficult experiences but persist with behaviours that reflect what is important to them.
1586340|NCT02337114|Behavioral|Treatment as Usual|A client-centred goal planning system linked to community reintegration and based on a holistic rehabilitation model including counselling, medical management, cognitive behavioural therapy and pharmacotherapy.
1586341|NCT02337101|Other|Enhanced Usual Care (EUC)|All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
1586379|NCT02336841|Other|Treatment as usual + Recovery MANTRA|Participants in this group will receive the guided self-help intervention including video-clips, a workbook, and guidance from peer mentors, and treatment as usual.
1586380|NCT02336841|Other|Treatment as usual + feedback|Participants in this group will receive treatment as usual and feedback on their eating disorder symptoms.
1586342|NCT02337101|Behavioral|EUC + Early intervention programme|"All patients will have a brief clinical psychiatric and neurological assessment in order to determine eligibility, and will be provided with information and advice about typical post-concussional symptoms, the typical recovery process and the use of pain medication.
The early intervention programme will be interdisciplinary and will mainly be provided by an occupational therapist and a physiotherapist under supervision of a neuropsychologist. It will be based on psychoeducation and principles from Cognitive Behavioral Therapy and Graded Exercise Therapy and targeted to patients' individual goals.
Patients will receive 8 weekly treatment sessions (3 group based and 5 individual sessions). Intervention will start approximately 4-5 months after the concussion."
1586343|NCT02337088|Procedure|Delayed cord clamping at 30 seconds|For subjects enrolled in the 30 second arm, the umbilical cord will be clamped at exactly 30 seconds after delivery
1586344|NCT02337088|Procedure|Delayed cord clamping at 60 seconds|For subjects enrolled in the 60 second arm, the umbilical cord will be clamped at exactly 60 seconds after delivery
1586345|NCT02337075|Behavioral|PATH program|A brief education session, use of a wearable physical activity tracker, and physical activity mentoring by an Activity Mentor every 2 weeks.
1586346|NCT02337075|Device|Activity Mentor|
1586347|NCT02337062|Drug|APD421|
1586348|NCT02337062|Drug|Placebo|
1586349|NCT02337036|Other|Pharmacokinetic|Taking blood samples for an Pharmacokinetic of tacrolimus in Paediatric Liver Transplant Patients treated with tacrolimus
1586350|NCT02337036|Other|Pharmacogenetic|Pharmacogenetic study
1586351|NCT02337036|Drug|Tacrolimus|These Patients are treated with tacrolimus after the Liver Transplantation
1586352|NCT02337023|Radiation|Brain scintigraphy with injection of Neurolite® (ECD)|Brain scintigraphy with injection of Neurolite® (ECD) 1 injection
1586353|NCT02337010|Device|CeVOX|Central venous saturation was continuously monitored by using a CeVOX monitor (Pulsion Medical Systems, Munich, Germany). The CeVOX probe (PV2022-37; Pulsion Medical Systems, Munich, Germany) was inserted into the internal jugular central venous catheter as described in the user's manual.
1586354|NCT02337010|Device|CVP|Central venous pressure was continuously monitored by using a central venous catheter. The probe was inserted into the internal jugular central vein as described in the user's manual.
1586355|NCT02337010|Drug|Fluid bolus|If hypovolaemia was suspected fluid bolus was given in the form of 250 ml hydroxyethyl starch solution (HES, 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride, Voluven, Fresenius Kabi, Germany) over 15 minutes.
1586356|NCT02337010|Drug|Vasopressor|If hypotension was present it was treated with vasopressor as 10 mcg bolus or continuous infusion of norepinephrine (Arterenol® Sanofi, Germany).
1586357|NCT02336997|Procedure|FAT-GRAFT|Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
1586358|NCT02336997|Procedure|SVF-TRANSPLANTATION|Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1*10e6 cells/cm2.
1586359|NCT02336997|Procedure|PLACEBO|Saline will be injected into expanded skin.
1586360|NCT02336984|Biological|HER-2 pulsed DC1|Vaccine administered weekly, with no more than 4 weeks delay over the course of 6 vaccines.
1586361|NCT02336984|Drug|trastuzumab|The loading dose of Trastuzumab will be 8 mg/kg and the maintenance dose given week 4 will be 6 mg/kg, both standard doses of trastuzumab.
1586362|NCT02336984|Drug|pertuzumab|Pertuzumab 420 mg IV will be given at the same time as trastuzumab.
1586363|NCT02336971|Behavioral|CBCT for PTSD|CBCT consists of three phases of treatment: Phase 1: treatment orientation and education about PTSD and its related intimate relationship problems Phase 2: behavioral communication skills training Phase 3: cognitive interventions based on Cognitive Processing Therapy (CPT)
1586364|NCT02336971|Behavioral|Prolonged Exposure|PE consists of: psychoeducation and some limited distress management training, but emphasizes the role of imaginal and in vivo exposure in treating PTSD.
1586365|NCT02336958|Drug|intermediate cervical plexus block ropivacaine|20ml ultrasound guided intermediate cervical plexus block.
1586366|NCT02336958|Drug|pericarotidal infiltration (active comparator) ropivacaine|5ml ropivacaine 0.75% (active comparator): pericarotidal infiltration.
1586367|NCT02336958|Drug|jugular infiltration prilocaine|5ml prilocaine 1% jugular infiltration for wound drainage.
1586368|NCT02336958|Drug|pericarotidal infiltration (placebo comparator) saline|5ml saline 0.9% (placebo comparator): pericarotidal infiltration.
1586369|NCT02336945|Device|Abbott Sensor Based Glucose Monitoring System-Professional|Subjects will wear 2 glucose sensors while going about daily activities and adhering to establish diabetes treatment plan. This is not a treatment study.
1586370|NCT02336919|Behavioral|Txt2Prevent|A 60-day text messaging program called Txt2Prevent (see description in the arm description).
1586371|NCT02336906|Drug|polyethylene glycol 3350|Patients will initially receive three days of high dose PEG3350 treatment (1.5gr/kg up to 100gr maximum) and the stepped down to 0.8gr/kg subsequently tapered according to stool consistency and frequency.
1586372|NCT02336906|Behavioral|Constipation behavioral therapy|Patients in the active group will receive dietary instruction as to fiber content, as well as behavior therapy including active sitting on the toilet to attempt defacation following meals.
1586373|NCT02336906|Behavioral|Urotherapy|The children will be guided for appropriate drinking and toilet habits, and will start with timed voiding.
1586374|NCT02336893|Behavioral|Training|The final training was provided to a group of 34 residents --from internal medicine, anesthesiology, gynecology, and intensive care-- in charge of giving information to the patient's family members in the ICU. They were trained in the semi-structured interview PACIENTE (Present oneself and greet, Attend and listen, Call diagnosis, Inform treatment, Expose prognosis, Name introductory phrases to bad news, Take time to provide empathetic comfort, Explain an action plan involving the family) conjointly while participating in simulated difficult clinical cases with family members-actors. Four training programs were performed from February to September 2014.
1586375|NCT02336880|Behavioral|Internet-delivered cognitive behavioural therapy|
1586376|NCT02336867|Device|Closure clip (OTSC® Proctology)|
1586377|NCT02336854|Drug|Tacrobell tab. 2mg|
1586378|NCT02336854|Drug|Prograf cap. 2mg|
1586381|NCT02336815|Drug|Selinexor|Fixed oral dose of 80 mg twice weekly (e.g., Monday and Wednesday or Tuesday and Thursday, etc.)
1586382|NCT02336815|Drug|Dexamethasone|20 mg will be given with each dose of Selinexor.
1586383|NCT02336802|Behavioral|Avoidance experiment|Participants complete an avoidance task
1586384|NCT02336789|Other|fecal material|. All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
1586385|NCT02336789|Other|normal saline|All patients will undergo a screening colonoscopy and will be allocated to receive either 250 ml of diluted fecal material prepared from a screened donor, or an equivalent volume of normal saline (sham transplantation).
1586386|NCT02336776|Other|Functional electrical stimulation|"Functional electrical stimulation will be applied through self adhesive electrodes on the quadriceps muscle of both thighs, and these will be positioned at 60° of flexion and contained by a band for that exercise happen isometric form.
Parameter settings in the electrical stimulator are as follows: 80 Hz frequency, 0.4 ms pulse, 10 s time on, 50-20 s time off, intensity according to the patient's tolerance but enough to cause visible muscle contraction. The total time of each session starts at twenty minutes and is increased every week a total thirty-four minutes at the end of the eighth week. Intervention will be held three times a week for eight weeks and during hemodialysis session."
1586387|NCT02336763|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
1586388|NCT02336763|Other|Laboratory Biomarker Analysis|Correlative studies
1586389|NCT02336750|Drug|Aprepitant|125mg D1, 80mg D2-3
1586390|NCT02336750|Drug|Mirtazapine|15mg D2-4
1586391|NCT02336737|Device|SiennaXP|Sub-cutaneous injection of SiennaXP magnetic marker, followed by lymph node localization using the SentiMag handheld magnetic probe
1586392|NCT02336737|Drug|Technetium Tc99m Sulfur Colloid|Injection of a single dose of radioisotope (Technetium Tc99m Sulfur Colloid)
1586393|NCT02336737|Drug|Isosulfan blue dye|Injection of a single dose of isosulfan blue dye
1586394|NCT02336724|Drug|Famitinib|
1586395|NCT02336711|Radiation|dose escalation|molecular imaging based radiotherapy dose escalation
1586396|NCT02336698|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
1586397|NCT02336698|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
1586398|NCT02336698|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
1586399|NCT02336685|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
1586400|NCT02336685|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
1586401|NCT02336685|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
1586402|NCT02336685|Drug|Opioid|Opioids will be administered as standard of care for osteoarthritis (OA) pain therapy during the double-blind treatment phase as per investigator discretion.
1586403|NCT02336672|Device|Cryothermal ablation|"The procedures will be performed in the Endoscopic Room. Patients will be sedated by the anaesthesiologist. Device settings and application times will be set and recorded on a computer that will analyze the changes of the properties of the tissue.
The setting of the maximal application time will be based on the results of the described ex-vivo and in-vivo studies and will be adjusted to the size of the tumour. This ensures a reduction of HybridTherm related complications which may occur if the applica-tion time would not be limited. The application of Power Doppler will make the procedure safer.
The probe will be guided under real time EUS into the tumour. The success of the placement of the HTP into the tumour will be an index of the feasibility of the treatment. The system will analyse the effects on the tissue, and EUS will record the changes of the tissues, the growing edema around the treated area, and tissue devita-lisation, with attention to the complications."
1586404|NCT02336659|Drug|exendin 9-39|Exendin 9-39 is a specific GLP-1 receptor antagonist
1586405|NCT02336659|Drug|sitagliptin|DPP-4 Inhibition
1586406|NCT02336659|Other|Placebo|Saline
1586407|NCT02336646|Drug|Allogenic MSC|Hypoxia-cultured human bone marrow derived mesenchymal stem cells
1586408|NCT02336646|Drug|Normal saline|
1586409|NCT02336633|Dietary Supplement|Resveratrol|2 capsules of 20mg in the morning and in the evening (4 capsules in total/day = 80mg/day) every day during 1 year
1586410|NCT02336633|Other|Placebo|
1586411|NCT02336620|Drug|Ringer acetate|Ringer acetate 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
1586412|NCT02336620|Drug|Normal saline|NSS 10-20 ml/kg IV bolus in 15-30 min,repeat bolus as needed by patient status
1586413|NCT02336607|Drug|Felodipine tablet (Plendil) alone|Felodipine sustained release tablet single drug therapy (1st week- 2nd week) Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks. If blood pressure is controlled after 2 weeks, then the subjects will continue the treatment until the end of primary therapy stage (14th week).
1586414|NCT02336607|Drug|Felodipine tablet (Plendil)+Hydrochlorothiazide|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.
If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with hydrochlorothiazide 12.5mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
1586459|NCT02336282|Device|transcranial Direct Current Stimulation (tDCS)|transcranial Direct Current Stimulation (tDCS) involves modulation of cerebral cortex excitability by the application of weak direct current to the scalp. tDCS is a technique that applies safe, low level direct current through large pads on the scalp to stimulate the underlying brain region, with current level < 0.10 C/cm2. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
1586874|NCT02333188|Drug|Fluorouracil|Given IV
1586415|NCT02336607|Drug|Felodipine tablet (Plendil)+Metoprolol tablet (Betaloc ZOK)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.
If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with metoprolol succinate prolonged-release tablet (Betaloc ZOK) 47.5mg , once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
1586416|NCT02336607|Drug|Felodipine tablets (Plendil)+Lisinopril (Zestril)|"Step 1: Eligible subjects will first take felodipine tablet 5mg, once daily, orally for 2 weeks.
If blood pressure is not controlled after 2 weeks, then the subjects will go to Step 2: Felodipine sustained release tablet 5mg once daily combined with Lisinopril (Zestril) 10mg, once daily. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 3: The dosage of felodipine sustained release tablet will be escalated to 10mg, once daily, while the dosage of the combined drug remains the same. If blood pressure is not controlled after 4 weeks, then the subjects will go to Step 4: The dosage of felodipine sustained release tablet keeps 10mg, once daily, while the dosage of different combined drug is doubled."
1586419|NCT02336581|Behavioral|Acceptance and Commitment Therapy (ACT)|individual + group + follow-up phone contacts
1586420|NCT02336581|Behavioral|Enhanced Treatment as Usual (eTAU)|individual + group + follow-up phone contacts
1586421|NCT02336568|Drug|Oxytoine|In the first week 24 IU * 2/day. in the 2nd & 3rd 40 IU * 2/day
1586422|NCT02336568|Drug|PLACEBO|In the first week 24 IU * 2/day. in the 2nd & 3rd 40 IU * 2/day
1586423|NCT02336555|Drug|MK-8291|MK-8291 10 mg tablet orally, once daily, on days 1,2 and 28; and twice daily, on days 3 to 27
1586424|NCT02336555|Drug|Placebo|Placebo for MK-8291 tablet orally, once daily on days 1,2, and 28; and twice daily, on days 3 to 27
1586425|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
1586426|NCT02336542|Biological|5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 5μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
1586427|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same person and different arm.
1586428|NCT02336542|Biological|10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm|TB subjects and non-TB subjects with lung disease inject 10μg/ml ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same person and different arm.
1586429|NCT02336529|Drug|Bupivacaine|
1586430|NCT02336529|Drug|NaCl|
1586431|NCT02336516|Drug|Azithromycin|ZITHROMAX ® 40mg/ml solution. DCI : Azithromycin . Pfizer ® 20mg/kg dose with a maximum dose of 500mg per day for three days
1586432|NCT02336516|Drug|Placebo (glucose solution 10%)|
1586433|NCT02336503|Drug|BBI-4000 Low Concentration|BBI-4000 Low Dose
1586434|NCT02336503|Drug|BBI-4000 Middle Concentration|BBI-4000 Middle Dose
1586435|NCT02336503|Drug|BBI-4000 High Concentration|BBI-4000 High Dose
1586436|NCT02336503|Drug|Placebo|Vehicle
1586437|NCT02336490|Other|Discharge Medication Delivery Service|hospital-owned outpatient pharmacy fills and delivers discharge medications to patients in their rooms prior to discharge
1586438|NCT02336477|Drug|Mexiletine|"Blisters of 10 capsules of 200 mg mexiletine hydrochloride.
Patients will receive gradual dose of the treatment as it would be done in clinical practice.
Mexiletine will be started at 200 mg / day (1 capsule to be taken at the beginning of the meal) and will be increased by 200mg every 3 days to reach a maximum of 600mg / day in 3 taken in 1 week.
The duration of each treatment period is 18 days minimum (maximum 22 days)."
1586439|NCT02336477|Drug|placebo|
1586441|NCT02336438|Dietary Supplement|glucomannan|Glucomannan is a natural, odorless soluble fiber that is found in the konjac plant. It will be given during the Intervention Phase in conjunction with the MMTT and then for 5 days at home with meals.
1586442|NCT02336425|Drug|QGE031|QGE031 120 mg per 1 mL liquid in vial
1586443|NCT02336425|Drug|Placebo|Placebo to QGE031 0 mg per 1 mL liquid in vial
1586444|NCT02336412|Other|SMS reminder|Daily SMS medication reminder
1586445|NCT02336386|Drug|CDD|Chemotherapy
1586446|NCT02336386|Drug|CDD Plus Bortezomib|Chemotherapy plus Proteasome Inhibitors
1586447|NCT02336373|Drug|hydroxyurea|Treat symptomatic HbSC patients to MTD on hydroxyurea, and assess for clinical improvement using the PedsQL™ Sickle Cell Disease Module version 3.0 after 6 months at MTD, compared to entrance scores
1586448|NCT02336360|Drug|18F-AV-1451|370 megabecquerel (MBq) (10 millicurie [mCi]) administered in a separate Avid-sponsored study. No drug will be administered in this study.
1586449|NCT02336347|Drug|AVP-786|
1586450|NCT02336347|Drug|AVP-923|
1586451|NCT02336334|Device|Positioning measurement|Logging of posturing informations
1586452|NCT02336334|Device|Patient feedback|Evaluation of patients questionary
1586453|NCT02336334|Procedure|Usefulness of a sketch|Helping the patients to understand posturing positions by randomized allocation of sketches
1586454|NCT02336334|Device|Closure rate of macular holes|closure rates of macular holes in the group with macular holes. Measurement using SD-OCT (spectral domain optical coherence tomography=
1586455|NCT02336321|Device|BNCI controlled hand exoskeleton|The BNCI system fuses and translates bio-signals related to user intention into control signals of an assistive device performing grasping motions
1586456|NCT02336308|Drug|Ketamine|
1586457|NCT02336308|Drug|Placebo, Normal Saline|
1586458|NCT02336295|Other|Food Frequency Questionnaires|filling a Food Frequency Questionnaires
1586460|NCT02336282|Device|Sham|The sham intervention will be used in both arms with one arm receiving the sham intervention on day 1 and the other receiving the sham intervention on day 2. The sham procedure provides the same small current during ramp up to imitate the intervention, but the current is discontinued after ramp up and no intervention is provided. Direct current is transferred by a pair of saline-soaked sponges from the anode to the cathode.
1586461|NCT02336282|Other|Cognitive Assessment|"Three tests will be used to evaluate cognitive function: Dimensional Change Card Sort Test, Flanker Inhibitory Control and Attention Test, and List Sorting Working Memory Test. These measures have a computerized format and are nationally standardized.
The Gray Oral Reading Test measures reading comprehension. Participants are asked to read a set of passages and recall specific details from the stories.
The Woodcock Johnson Understanding Directions measures listening comprehension. Participants listen to a series of complex instructions, then follow the directions by pointing to various objects in a colored picture."
1586462|NCT02336282|Other|Brain Games Stimulation|Cognitive exercises using the Lumosity Brain Games program will be used simultaneously with the tDCS intervention. Participants will be asked to engage in training for 20 minutes a day, two days per week over 5 weeks. This program involves cognitive exercises designed to enhance executive function and processing speed.
1586463|NCT02336256|Procedure|Procedures of hernia repair.|We use two procedure: single incision laparoscopic surgery (SILS) and totally extra-peritoneal repair (TEP). SILS procedure used one approche - 10mm (experimental). TEP procedure used three approaches 2x5mm and 1x10mm (active comparator).
1586464|NCT02336243|Dietary Supplement|Docosahexaenoic acid (DHA)|Docosahexaenoic acid (DHA), 600 mg per day. Each woman will take three DHA capsules per day (200 mg each), as early in gestation as possible and until the end of pregnancy.
1586465|NCT02336243|Dietary Supplement|Placebo (for Docosahexaenoic acid (DHA))|Each women allocated to the placebo group, will receive three placebo capsules per day. The placebo capsules will have same size, aspect and flavor than the DHA capsules.
1586466|NCT02336230|Drug|remestemcel-L|Subjects will be treated with intravenous (IV) remestemcel-L at a dose of 2 x 10e6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart and no more than 5 days apart for any infusion.
1586467|NCT02336217|Other|Experimental Group instructions for glucose management via App|The Experimental Group receives individually calculated instructions for glucose management management via the App.
1586468|NCT02336217|Other|Placebo Comparator general instructions|The Placebo Comparator Group receives general instructions but not the complete management algorithm
1586469|NCT02336191|Procedure|living donor liver transplantation|living donor liver transplantation
1586470|NCT02336178|Drug|Benefix|"Subjects will be treated by the investigator according to usual care in China and in accord with the China BeneFIX Package Insert.
The treatment duration is approximately 6 months (±7 days) or approximately 50 Exposure Days (EDs) (±5 EDs) (see protocol definition on EDs) whichever occurs first."
1586471|NCT02336165|Drug|MEDI4736|Anti-PD-L1
1586472|NCT02336165|Radiation|Radiotherapy|
1586473|NCT02336165|Biological|Bevacizumab|
1586474|NCT02336152|Device|Anaesthesia, Teles Pro, Body suit|
1586475|NCT02336139|Drug|Sofosbuvir (SOF)/GS-5816|12 weeks of Sofosbuvir (SOF)/GS-5816 (400mg/100mg) in an oral once-daily fixed dose
1586476|NCT02336126|Behavioral|Biopsychological intervention|
2008903|NCT03326349|Other|Guttmann, NeuroPersonalTrainer|Guttmann NeuroPersonalTrainer (GNPT) is a telerehabilitation platform. GNPT consists of a set of computerized cognitive exercises covering different cognitive functions and subfunctions. Every task has been specifically based on cognitive paradigms to address specific cognitive subfunction. The rehabilitation process starts by assigning a patient to a therapist responsible for the treatment. The therapist has then to perform the initial neuropsychological assessment, consisting of a set of validated tests used to attention, memory and executive functions prior to the treatment. The results of these tests will be stored in GNPT system. Then, the cognitive profile is calculated using these results, and taking into account the patient's age and study level. Using this profile, the program assigns a set of computerized tasks to a certain day, configuring the input parameters of each task in order to personalize treatments.
1586478|NCT02336100|Device|Endoscopy (FICE and pCLE)|FICE is Flexible Spectral Imaging Color Enhancement and pCLE is probe-based Confocal Lase Endomicroscopy
1586479|NCT02336087|Drug|Gemcitabine Hydrochloride|Given IV
1586480|NCT02336087|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1586481|NCT02336087|Drug|Metformin Hydrochloride|Given PO
1586482|NCT02336087|Dietary Supplement|Therapeutic Dietary Intervention|Given PO
1586483|NCT02336087|Other|Laboratory Biomarker Analysis|Correlative studies
1586484|NCT02336087|Other|Quality-of-Life Assessment|Ancillary studies
1586485|NCT02336074|Drug|Combination Antiretroviral Therapy (cART)|Likely consisting of an Nucleoside reverse-transcriptase inhibitor (NRTI) backbone i.e. Truvada plus a ritonavir-boosted protease inhibitor (PI) e.g. Darunavir + ritonavir. Prescribed at week 0 for the duration of the study.
1586486|NCT02336074|Drug|Raltegravir|All participants will be dispensed sufficient supplies of Raltegravir to ensure they have sufficient medication to last to the next study visit. Raltegravir is supplied in marketed pack with 30 tablets per bottle.
1586487|NCT02336074|Drug|Vorinostat|"Vorinostat (suberoylanilide hydroxamic acid abbreviated to SAHA) inhibits the histone deacetylases HDAC1, HDAC2, HDAC3 (Class I) and HDAC6 (Class II).
Vorinostat is supplied as capsules containing 100mg vorinostat and the following inactive ingredients: microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
1586488|NCT02336074|Biological|ChAdV63.HIVconsv (ChAd)|Dosage: 5x1010vp .This dose is obtained by injecting 0.37ml of the vaccine at 1.35x1011vp/ml without dilution. This prime vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 00.
1586489|NCT02336074|Biological|MVA.HIVconsv (MVA)|Dosage: 2x108pfu Administration: This dose is obtained by injecting 0.23 ml of the vaccine IM at 8.6x108pfu/ml without dilution. This boost vaccination is administered intramuscularly (IM) into the deltoid muscle of the non-dominant arm at post-randomisation week 08 Day 1 (2 prior to start of vorinostat)
1586490|NCT02336061|Behavioral|Evaluation of gender differences on the psychosocial and economic impact.|
1586575|NCT02335281|Drug|Mesalazine|2g Po perday
2008904|NCT03326349|Other|Ictus.online|"An online domain which provides a daily session of one hour of duration. Each session consists of four ten-minute videos. After each video, the participant must complete a three-question quiz about the contents of the video (for example, What animal appears in in the video?). The difficulty level is minimal, and does not vary depending on the execution of the participant."
2008905|NCT03326336|Combination Product|Gene therapy: GS030-DP AND Medical device: GS030-MD|GS030-Drug Product (GS030-DP) - Recombinant adeno-associated viral vector, derived from serotype 2 (rAAV2.7m8), containing the optimized channelrhodopsin ChrimsonR-tdTomato gene under the control of the ubiquitous CAG promoter (rAAV2.7m8-CAG-ChrimsonR-tdTomato) GS030-Medical Device (GS030-MD) - Visual Interface Stimulating Glasses (that amplify the external visual stimulus to the optogenetically engineered retina)
1586496|NCT02336035|Procedure|Volar plate|Flexor carpi radialis (FCR)-approach. Standard surgical procedure with a volar locking plate
1586497|NCT02336022|Device|Respiratory Motion Inc|
1586498|NCT02336009|Device|total wrist arthroplasty, Trimed|A new total wrist arthroplasty design. A pilot study.
1586499|NCT02335996|Biological|Blood samples for measuring adiponectin, leptin and omentin plasma|
1586500|NCT02335996|Device|MRI at 3 Tesla|Evaluation by MRI at 3 Tesla of the amount of ectopic fat heart, liver and pancréas and bone marrow.
1586501|NCT02335983|Drug|Carfilzomib|
1586502|NCT02335983|Drug|Lenalidomide|
1586503|NCT02335983|Drug|Dexamethasone|
1586504|NCT02335970|Other|Training group|"After 1 week
Chest expansions
Static thoracic extension in prone
Lateral flexion of the spine in standing
Bilateral shoulder flexion
Shoulder external rotation of shoulders
Rotation of the thoracic spine in sitting
Static back extensor strength in prone
After 1 month
Thoracic extension, rotation and flexion abduction
Hand in neck and in back
Bilateral active flexion abduction
Strength training of leg muscles
Static back extensor strength
After 2 months
Strength training of legs and back muscles
Push-ups against a wall
Thoracic extension in sitting and standing
Thoracic rotation in lying
Stretching of mm. pectoralis Training was performed daily with 10 rep of each exercise"
1586505|NCT02335957|Radiation|Irradiation|Intentional versus incidental irradiation of lymphatic node areas, administered using a lineal accelerator, after 3D delimitation of the supraclavicular and axillary levels I, II and III. In both treatment arms, further tumoral bed boost will be allowed according to the investigator criteria, whether dose contribution to the nodal areas can be calculated. Due to its nature, interventions cannot be asked.
2008906|NCT03326323|Procedure|Acute Normovolemic Hemodilution|Collection and reinfusion of a patients own blood during coronary artery bypass graft surgery.
1586509|NCT02335905|Drug|Ceftaroline Fosamil|IV Ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour) for children 2 years of age - 17 years of age (inclusive). IV Ceftarloine Fosamil 10 mg/kg infused 120 (± 10) minutes q8h (± 1 hour) for children 1 years of age - less than 2 years of age (inclusive).
1586510|NCT02335879|Biological|Gonal-F|
1586511|NCT02335866|Procedure|test groups|At the test sites, the previously prepared PRF was positioned over the recession defects, the coronal margin of the PRF was placed at the CEJ
1586512|NCT02335866|Procedure|Control groups|Split-full-split thickness flap incisions were performed in a coronal-apical direction. The papillae adjacent to the involved tooth were de-epithelialized to create a connective tissue bed. The gingival flap was repositioned without tension, with its margin located on the enamel, on the test and control sides. It was held in that position with 5-0 resoble sutures
1586513|NCT02335840|Other|CAF-1|In this intervention the volunteers ingested one dose of caffeinated coffee containing 144 mg of caffeine
1586514|NCT02335840|Other|CAF-2|In this intervention the volunteers ingested two doses of caffeinated coffee containing 288 mg of caffeine
1586515|NCT02335840|Other|CAF-3|In this intervention the volunteers ingested three doses of caffeinated coffee containing 432mg of caffeine
1586516|NCT02335840|Other|DESC|In this intervention the volunteers ingested one dose of decaffeinated coffee containing 108 mg of caffeine
1586517|NCT02335827|Procedure|irreversible electroporation|Percutaneous (CT-guided and/or US-guided) or open IRE with voltage in level B for renal tumors
1586518|NCT02335814|Drug|FLX925|
1586519|NCT02335788|Device|The EMBA Peripheral Embolization Device|arterial and venous embolization in the peripheral vasculature
1586520|NCT02335749|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
1586521|NCT02335736|Drug|Gonadotropins releasing hormone antagonist|
1586522|NCT02335723|Device|Alteco LPS Adsorber|"Alteco® LPS Adsorber is a Class IIa medical device developed in accordance with existing international standards. Alteco® LPS Adsorber does not contain any pharmaceutical or toxic components.
Alteco® LPS Adsorber is used for the adsorption of LPS as endotoxins. The capturing component is a specially designed synthetic peptide developed for adsorption of endotoxin. The capturing component has high affinity to Lipid A, i.e. a constant component in the endotoxin molecule, which ensures efficient reduction of endotoxins from different bacterial species."
1586523|NCT02335723|Device|Placebo|Exactly the same as Alteco LPS Adsorber but no peptide component has been attached to the matrix (i.e. there is no adsorber functionality)
1586524|NCT02335710|Device|Journey II BCS TKA|
1586525|NCT02335697|Behavioral|Attitude change towards female circumcision|The intervention comprises of a series of meetings between newly arrived Somalis and established Somalis. At each meeting, a pre-determined topic relating to FC will be discussed. The topics include culture, religion, health, children's rights, and Swedish laws. Different experts, chosen to match the specific topic of the meeting will be invited to each meeting to facilitate the interactive discussions between the participants. Somalis who are both familiar with the Swedish and Somali culture will facilitate the meetings. The intervention spans over a time period of six months. The intervention meetings will be held during the first five months of the intervention period; one meeting scheduled per month. Thereafter, there will be a 'wash-out' period of one month to allow for reflections and to minimize the risk of courtesy bias.
1586526|NCT02335697|Other|No intervention|
1586527|NCT02335684|Other|CF-LVAD pump speed baseline.|Submaximal exercise test with baseline pump speed.
1586528|NCT02335684|Other|CF-LVAD pump speed increased.|Submaximal exercise test with increased pump speed (+800RPM).
1586529|NCT02335671|Procedure|Intra-operative Magnetic Resonance Imaging (MRI)|
1586530|NCT02335671|Other|Mass Spectrometer Analysis of Tissue Sample|Analysis of Tissue Sample
1586531|NCT02335658|Drug|DSP-5423P|40-80mg/day
1586532|NCT02335645|Other|Body Weight Supported Treadmill Use of Patients with ACL Reconstruction|"Standard ACL protocol will be followed throughout the treatment of each patient. The only variance from treatment will be using body weight supported treadmill and video gait analysis to help guide treatment.
The first analysis will be performed at week 6 after surgery. Motion capture sensors will be placed on the patient at different anatomical positions. The patient will then run in a body weight supported treadmill. During this run, video capture will be performed and later analyzed to determine biomechanical kinematics.
Based on findings of video gait analysis, exercise progression will be altered to improve deficits found. This process will be repeated at week 8 of rehabilitation in the body weight supported treadmill.
At week 10 and 12, the patient will shift treatment from the body weight supported treadmill, to a standard treadmill. The process will be repeated using the same anatomical landmarks and video capture."
2008907|NCT03326310|Drug|Azacitidine|"Patients will receive azacitidine 75 mg/m2 as a subcutaneous injection on days 1-7. The dose of azacitidine 75 mg/m2 will remain unchanged, unless a dose reduction is required based on toxicities (dose level -1 = selumetinib 50 mg PO twice daily and azacitidine 50 mg/m2).
Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression"
2008908|NCT03326310|Drug|Selumetinib|"Patients will receive selumetinib administered by mouth on days 8-21. The starting dose cohort (dose level 1) will receive selumetinib 50 mg PO twice daily on days 8-21. Subsequent planned doses include selumetinib 75 mg PO twice daily (dose level 2) and selumetinib 100 mg PO twice daily (dose level 3). Subsequent dose levels will only be given once the prior dose level has shown acceptable safety.
Subjects will continue on this schedule in cycles of 28 days duration in the absence of disease progression."
1586535|NCT02335619|Behavioral|Early pain and symptom/palliative care referral|
1586536|NCT02335593|Dietary Supplement|Zinc Sulphate|Zinc Sulphate Hard Gel capsules 110mg
1586537|NCT02335593|Other|Corn Starch filled Hard Gel Capsules|Corn Starch filled Hard Gel Capsules
1586538|NCT02335593|Drug|Epoetin alfa 2000-4000 IU solution for injection|Epoetin alfa 2000-4000 IU solution for injection
1586539|NCT02335593|Drug|Iron Hydroxide Saccharate Complex Solution for injection|Iron Hydroxide Saccharate Complex Solution for injection
1586540|NCT02335580|Drug|Somatostatin and its analogs|
1586541|NCT02335580|Procedure|Endoscopic sclerotherapy, endoscopic variceal ligation, endoscopic tissue glue injection|
1586542|NCT02335567|Other|there is no intervention|
1586543|NCT02335554|Behavioral|MoodHacker|Mobile-web app to educate users about depression and promote daily mood and positive activity monitoring.
1586544|NCT02335554|Behavioral|Alternative Care|Online information about depression from government and other trusted sources to educate users about depression.
1586545|NCT02335528|Behavioral|SimCoach|
1586546|NCT02335515|Device|Soctec|Gastroretentive Drug Delivery System
1586547|NCT02335502|Device|Implantation with the commercially available Axium neurostimulator|
1586548|NCT02335489|Device|Implantation with the commercially available Axium neurostimulator|
1586549|NCT02335450|Behavioral|Motivational Interviewing|The participant will describe their unique physical activity challenges and their physical activity goals with the physical therapist. Using the technique of motivational interviewing, the physical therapist will work with the participant to help identify potential solutions to challenges and set realistic activity goals for the next week. Each week, the participant and the physical therapist will review the previous week's activity data, and the participant's reports of any challenges or problems they encountered in meeting their physical activity goals the previous week. The participant will identify new activity goals for the next week.
1586550|NCT02335450|Device|Wristband physical activity monitor|The participant will wear a Fitbit wristband which will track the participant's daily steps and minutes of physical activity.
1586556|NCT02335398|Drug|Methadone|The starting methadone dose for naïve-opioid patients was 2.5-5 mg every 8-12 hours. In patients who required opioid rotation, the conversion ratios, morphine:methadone, were 4:1, 8:1, and 12:1 for patients receiving less than 90 mg of morphine, receiving 90-300 mg of morphine, and receiving more than 300 mg of morphine , respectively. A fixed dose ratio of 1:20 was applied for changing from transdermal fentanyl to oral methadone. Then, the daily calculated methadone dose was divided into 8-12 hourly dosing. Calculated rescue dose was estimated to be 10-15% of total daily dose of methadone which there was switched to be morphine syrup in the ratio of 1:4.
1586557|NCT02335385|Procedure|single incision laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a single transumbilical flexible SILS port.
1586558|NCT02335385|Procedure|conventional transperitoneal laparoscopic varicocelectomy|bilateral and unilateral varicocelectomy was performed through a conventional 3-ports transperitoneal varicoceletomy
1586559|NCT02335372|Procedure|Wide-Field White Light Imaging|Initial wide-field white light images acquired of cervix in unpolarized and cross-polarized modes during cervical colposcopy.
1586560|NCT02335372|Drug|Acetic Acid|3-6% acetic acid applied to cervix after wide-field while light imaging during colposcopy.
1586561|NCT02335372|Drug|Proflavine Solution|Topical application of 0.01% proflavine solution applied for 1 minute to cervix after sites for biopsy have been identified during colposcopy.
1586562|NCT02335372|Procedure|Wide-Field Fluorescence Imaging|Wide-field imaging in fluorescence mode performed during cervical colposcopy after topical proflavine solution applied.
1586563|NCT02335359|Drug|tranexamic acid diluted in 100 ml of saline solution (loading dose)|
1586564|NCT02335359|Drug|tranexamic acid undiluted (continous infusion)|
1586565|NCT02335359|Drug|Placebo|Saline
1586567|NCT02335333|Other|No treatment|
1586571|NCT02335294|Drug|TRV130|Rescue: Ibuprofen, oxycodone
1586572|NCT02335294|Drug|Morphine|Rescue: Ibuprofen, oxycodone
1586573|NCT02335294|Drug|Placebo|Rescue: Ibuprofen, oxycodone
1586574|NCT02335281|Procedure|FMT|Standardized FMT once
1586576|NCT02335268|Drug|N-Plate / romiplostim|medical intervention in 3 patient groups (MDS patients with IPSS Low/Int-1) that are stratified according to their baseline TPO-Level and previous transfusions
1586577|NCT02335255|Drug|Naftifine Hydrochloride Gel 2%|Naftifine Hydrochloride Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
1586578|NCT02335255|Drug|Naftin® Gel 2%|Naftin® Gel 2% applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
1586579|NCT02335255|Drug|Placebo Topical Gel|Placebo Topical Gel applied once daily for fourteen consecutive days to affected areas plus a 1/2 inch margin of healthy surrounding skin.
1586580|NCT02335242|Drug|Sildenafil 20 mg tablets|
1586581|NCT02335242|Other|Placebo tablets (resembling Revatio)|
1994746|NCT02930447|Device|Autologous glue|Patients will undergo abdominoplasty according to the procedure routinely used in the Department of Plastic, Reconstructive and Aesthetic Surgery of HUG. At the end of the procedure, patients assigned to the experimental group will be additionally treated with an application of autologous glue prepared with RegenKit®-Surgery in the undermining region space between fascia and skin, just before closure of the surgical wound.
1994747|NCT02929394|Drug|Trabectedin|Trabectedin 1.2 mg/m² through a central venous catheter as an IV infusion over 24 hours every 4 weeks until disease progression (RECIST 1.1) or unacceptable toxicity
1586586|NCT02335190|Procedure|Radiofrequency ablation|RF ablation will be performed using 2 Nimbus multitined electrodes in a bipolar configuration. The electrodes will be placed along the lateral crest using a leap-frogging technique from the inferomedial aspect of the PSIS to the third transverse sacral tubercle at 1.5-2 cm intervals at the skin surface. A radiofrequency current will be passed for 120 seconds per site resulting in thermal coagulation of the plexus. Prior to performing the thermal lesion, electrical stimulation at 2 Hz and 2.0 V will be administered.
1586587|NCT02335190|Procedure|Sensory block|Participants will undergo a lidocaine block of the PSN at the lateral crest under ultrasound guidance. 0.5 mL of 2% lidocaine will be injected from the inferomedial border of the PSIS to the third transverse sacral tubercle at approximately 1.5 cm intervals along the skin surface.
1586588|NCT02335190|Drug|Lidocaine|
1586589|NCT02335177|Behavioral|Interventional arm|At home patients have both technologies for autonomy (walkers, treadmill) and tailored physical activity program performed with the help of the home carer. Intervention takes 3 months. Assessment at hospital discharge et at 3 months.
1586590|NCT02335164|Biological|recombinant influenza hemagglutinin|recombinant influenza hemagglutinin
1586591|NCT02335164|Biological|Advax1|Delta inulin adjuvant formulation 1
1586592|NCT02335164|Biological|Advax2|Delta inulin adjuvant formulation 2
1586593|NCT02335151|Drug|Desflurane|Apply desflurane as anesthetic
1586594|NCT02335138|Behavioral|Couples HIV Testing and Counseling|Male couples randomized to the experimental group (Couples HIV Testing and Counseling) will receive HIV counseling and testing as a couple via an online, HIPPA-compliant videoconferencing service. The dyad-centered session will last less than one hour and focus on couples agreement, prevention strategies, and/or linkage to HIV care, depending on each couple's test results. Participants will complete follow-up surveys at 3 and 6 months post-testing.
1586595|NCT02335138|Behavioral|at-home test kit|Male couples in the control group will receive test kits, but will not receive any testing intervention. Once individual results are reported,participants will be contacted via phone by study staff with options for referrals to services for the reactive partner(s). Participants will complete follow-up surveys at 3 and 6 months post-testing.
1586596|NCT02335125|Behavioral|Motivational Interviewing|
1586597|NCT02335125|Behavioral|Cognitive Behavioral Therapy Elements|
1586598|NCT02335125|Drug|Psychotropic Drugs|
1586599|NCT02335125|Other|Care Management|
1586600|NCT02335112|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Head and Neck Neoplasms guide with ultrasound or/and CT.
1586601|NCT02335112|Device|NanoKnife|
1586604|NCT02335073|Other|Venous blood|
1586605|NCT02335060|Drug|Delta-9-THC|Active Delta-9-THC (0.036mg/Kg) given intravenously.
1586606|NCT02335060|Drug|N-acetylcysteine|A pill given orally.
1586607|NCT02335060|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously.
1586608|NCT02335060|Drug|Placebo|"Placebo sugar pill given orally with no N-acetylcysteine."
1586609|NCT02335047|Other|Impaired passivity test|Description of the test: the subject lies in the supine position on an exercise mat with his/her feet together. The subject is told to let his/her arms rest loosely by his/her side (as if they were ropes) and to keep the head aligned with the back. The examiner pulls the subject into the sitting position by pulling on the subject's wrists, with passive flexion of the trunk until the hip joint is fully flexed..
1586610|NCT02335034|Behavioral|Study Group Educational courses, DVD, print material of lectures|2 Educational courses (two months apart). Receive DVD and printed material of the lectures.
1586611|NCT02335034|Behavioral|Control Group only make evaluations / consultations with all professional teams|"Evaluations and consultations with all professional teams without classes for 2 years.
At two years: two days of lectures two months apart with DVD and printed material of the lectures. Will be followed by two more years."
1586612|NCT02335021|Dietary Supplement|Sucralose|2 packets per 12 fl oz
1586613|NCT02335021|Dietary Supplement|Sucrose|equisweet to sucralose
1586614|NCT02335021|Dietary Supplement|Sucralose + maltodextrin|sucralose plus equicaloric (to sucrose) maltodextrin
1586615|NCT02335021|Dietary Supplement|Sucralose + Sucrose|half the amount of sucralose plus equicaloric sucrose
1586616|NCT02335008|Dietary Supplement|Sucralose|2 packets per 12 fl oz
1586617|NCT02335008|Dietary Supplement|Sucrose|equisweet to sucralose
1586618|NCT02334982|Drug|TAK-137|TAK-137 tablets
1586619|NCT02334982|Drug|Placebo|TAK-137 placebo-matching tablets
1586620|NCT02334969|Drug|Naoxintong Capsule|This is Naoxintong capsule,which is composed of Huangqi,Chishao,Danshen,Danggui, Chuanxiong,Taoren,Honghua,Ruxiang,Moyao,Jixueteng,Niuxi,Guizhi,Sangzhi,Dilong,Quanxie,etal.
1586700|NCT02334319|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1586621|NCT02334969|Drug|Placebo|placebo capsule has the same as Naoxintong capsule in the appearance, shape,colour and content tinct.
1586622|NCT02334956|Other|Brain MRI|
1586623|NCT02334943|Biological|Blood test|Blood test
1586624|NCT02334930|Other|Biopsy|
1586625|NCT02334917|Procedure|Surgical wound closure with superficial absorbable sutures|Different superficial absorbable sutures will be used in the closure of skin wounds after Mohs surgery. No drugs or devices are being compared, only the two different absorbable sutures (Vicryl Rapide and Fast Absorbing Gut).
1586626|NCT02334904|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study)
1586627|NCT02334904|Drug|Risperidone|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
1586628|NCT02334891|Other|Standard|Standard management
1586629|NCT02334878|Biological|Stem Cells,Mesenchymal|The patient will be placed in lithotomy position. A Foley's catheter (size 18) will be inserted in the urethra, then under local anaesthesia; retrieved cells (total 20- 30 million cells per patient in 10cc syringe) will be injected into the submucosal tissue at the level of the proximal urethra just distal to the bladder neck (guided by stretch on the Foley's catheter), at 3,9,12 o'clock, injecting around 3.5 cc in each site.
1586630|NCT02334878|Procedure|surgery (TVT)|A small midurethral incision will be made in the vaginal mucosa, then a polypropylene 40*1cm mesh tape attached to two curved trocars will be passed lateral to the urethra & through the endopelvic fascia into the retropubic space. The trocar will then be passed along the back of the pubic bone, through the rectus fascia, in two small suprapubic skin incisions, then the tension on the tape adjusted & the remaining tape cut off at the level of the skin.
1586631|NCT02334865|Biological|Incomplete Freund's Adjuvant|Given SC
1586632|NCT02334865|Other|Laboratory Biomarker Analysis|Correlative studies
1586633|NCT02334865|Drug|Lenalidomide|Given PO
1586634|NCT02334865|Biological|Sargramostim|Given SC
1586635|NCT02334865|Biological|SVN53-67/M57-KLH Peptide Vaccine|Given SC
1586636|NCT02334839|Other|Observational only|Endothelial function will be assessed using ENDO-PAT (Itamar medical LTD, Caesarea, Israel) device, which evaluates the change in peripheral vascular tone in reaction to temporal ischemia in a process called Reactive Hyperemia (RH) .The RH-PAT is a blood pressure measurement-like cuff which is placed on the non-dominant arm. A pneumatic probe is placed on the index finger bilaterally (one serves as a control). After a baseline assessment for a 5 minutes period, the cuff is inflated to a 60mm Hg pressure above the systolic pressure in order to occlude the arterial flow distal to the brachial artery. After 5 minutes of occlusion, a prompt deflation of the cuff results in a RH response and vasodilatation in the distal arteries including those monitored in the index finger. The sensor translates the change in vascular tone and the ENDO-PAT V3.0.4 device analyzes the data automatically. The results are given in a RH index scale that reflects the level of reactive hyperemia.
1586637|NCT02334826|Procedure|PCI -BVS|All patients in the PCI arm will be treated with bioresorbable scaffolds (Absorb). Lesions in native coronary arteries ≥2.25 mm to ≤4.0 mm in diameter (by visual estimate) will be treated after confirmation of functional significance with iFR/FFR.
1586638|NCT02334826|Procedure|CABG|In the CABG arm the surgery will be carried out according to the routine practice, with the intention of complete revascularization and frequent use of arterial grafts.
1586639|NCT02334813|Drug|Prednisone|Continuous daily therapy
1586640|NCT02334813|Drug|Dexamethasone|4-day pulses every 3 weeks
1586642|NCT02334787|Drug|0.3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 0.3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 0.3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
1586643|NCT02334787|Drug|1% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 1 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 1% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose
1586644|NCT02334787|Drug|3% OPA-15406 Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration period, subjects were treated with assigned 3 % OPA-15406 ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned 3% OPA-15406 ointment twice daily for 14 days and assessed until 48 hours post dose.
1586645|NCT02334787|Drug|Placebo Ointment|32 subjects were randomly allocated to 4 treatment groups (8 subjects per dose). In a single administration periodriod, subjects were treated with assigned placebo ointment assessed until 48 hours postdose. In the multiple administration period, same subjects were treated with assigned placebo ointment twice daily for 14 days and assessed until 48 hours post dose.
1586646|NCT02334774|Procedure|Oral Swallowing Care Program|An Oral Swallowing Care Program involves moisturizing and cleansing oral cavity, massaging salivary gland, oral motor exercise daily, and intake education as needed.
1586647|NCT02334748|Drug|canakinumab|canakinumab
1586648|NCT02334735|Biological|DC Vaccine|"DCs pulsed with 100µg/mL peptide (NY-ESO-1 and Melan-A/MART-1)
10 to 15 x 106 DCs per peptide antigen (NY-ESO-1 and Melan-A/MART-1) (total not to exceed 50 x 106 cells)"
1586649|NCT02334735|Biological|Montanide Vaccine|250 µg peptide (NY-ESO-1 and Melan-A/MART-1) and 1.1 mL Montanide ISA-51 VG
1586650|NCT02334735|Biological|Poly-ICLC|1.4 mg
1586652|NCT02334709|Radiation|Stereotactic body radiotherapy|A first line TKI will be administered according to the standard dosing of the drug for metastatic RCC during a 1-week run-in period after which SBRT will be delivered to the largest metastatic lesion concurrently with the TKI. The SBRT dose will be escalated in 3 dose levels, starting at 24Gy (8 Gy per fraction), followed by 30 Gy (10 Gy per fraction) and 36 Gy (12 Gy per fraction).
1586701|NCT02334319|Other|Laboratory Biomarker Analysis|Correlative studies
1586795|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 20 mcg|25(OH)D3 (Calcifediol Hy.D)
1994750|NCT02929004|Device|Vibrasens|Transcutaneous vibrations are used. This device allows vibrations from 25 to 150 Hz with an amplitude of 1 mm. In our study the frequency used is 50 Hz.
2008909|NCT03326297|Other|Osteopathy manual therapy|Technique for the treatment of parasympathetic innervation, Techniques for the treatment of sympathetic innervation of the digestive system, Functional visceral techniques.
2008910|NCT03326297|Behavioral|Measures to support and education to the family|Pedagogical intervention in parents and health education
1586655|NCT02334670|Drug|Fluconazole|HIV-infected patients with CD4 ≤100 cells/μL who present for HIV care at outpatient clinics (OPCs) in Vietnam where CrAg screening is offered will be recruited into the study. Study participants will be screened for cryptococcal antigen using the Lateral Flow Assay (LFA). Those who are CrAg-positive, but have no features of central nervous system (CNS) disease, will be treated with high-dose fluconazole.
1586656|NCT02334657|Other|SF-36|postal questionnaire consisting a short-form health survey with 36 simple questions (SF-36)
1586657|NCT02334644|Dietary Supplement|Probiotic Formula (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175)|2 sachets/day x 12 weeks
1586658|NCT02334644|Dietary Supplement|Placebo|2 sachets/day x 12 weeks
1586659|NCT02334631|Drug|High Volume Simethicone|High volume simethicone is defined as 1125 mg simethicone in 750 ml of water (1.5 mg/ml).
1586660|NCT02334631|Drug|Standard Volume Simethicone|Standard volume simethicone is defined as 300 mg simethicone in 200 ml of water (1.5 mg/ml).
1586661|NCT02334605|Other|cold dry air|"Patients will be asked to acclimatize to room temperature for 20 minutes prior to exposure to cold dry air.
Through a nasal cannula, compressed dry air for medical use will be delivered for 15 minutes (25L/minute). Patients will be instructed to breathe through the nose only. The temperature of the air reaching the nose will be approximately -10°C and the relative humidity less than 10-15%."
1586662|NCT02334605|Device|hyperosmolar discs|A small paper disc (5-6mm of diameter) previously loaded with 50µl NaCl 5,13M will be applied on the right nasal septum for 1 minute and then be discarded.
1586663|NCT02334605|Device|capsaicin nasal spray|1 puff of a nasal spray with a solution of capsaicin 0,0001mM will be sprayed in each nostril of the subject and subjects will be asked to score visual analogue scale for irritation of the nasal mucosa immediately after the adminitration.
1586664|NCT02334592|Radiation|Sunbed tanning|Invention groups undergo a 12-week tanning protocol that follows Health Canada's RED Act
1586665|NCT02334579|Radiation|CyberKnife Stereotactic Radiosurgery|Five treatments given over about one week.
1586666|NCT02334566|Behavioral|NET TX|Intervention procedures are a behavioral intervention (NET & KIDNET) with 8-12 sessions administered on a weekly basis.
1586667|NCT02334553|Drug|S1226(8%)|The drug S1226(8%), consists of Perflubron (PFOB) and 8% CO2 delivered as an aerosol/vapour/gas mixture with a Circulaire nebulizer. The drug is administered as a single dose during the early phase asthmatic response for 2 minutes.
1586668|NCT02334553|Drug|Placebo|Normal saline nebulized with compressed medical air for 2 minutes during the early phase asthmatic response
1586669|NCT02334540|Dietary Supplement|purses|food intake
1586670|NCT02334540|Dietary Supplement|a calorie/protein matched smoothie|
2008911|NCT03326284|Other|15 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 15 g of protein
1586672|NCT02334501|Drug|Lansoprazole|
1586673|NCT02334501|Drug|Neratinib|
1586674|NCT02334488|Drug|Everolimus|Active Comparator
1586675|NCT02334488|Drug|Tacrolimus|Active Comparator
1586676|NCT02334488|Drug|Mycophenolate sodium|Experimental Arm
1586677|NCT02334475|Biological|Platelet Rich Plasma|single intraarticular injection of 3 ml of leukocyte free platelet rich plasma with 0.5 ml of calcium chloride(total volume 3.5 ml)
1586678|NCT02334475|Biological|methylprednisolone|single injection 1.5 ml of methylprednisolone (40mg/ml) and 1.5 ml of 2% lidocaine (20mg/ml) with 0.5 ml of saline (total volume 3.5 ml)
2008912|NCT03326284|Other|35 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 35 g of protein
2008913|NCT03326284|Other|60 g protein hypocaloric|Following a 5 day hypocaloric diet one group of 10 women will ingest 60 g of protein
1586683|NCT02334449|Drug|LML134|LML134 will be administered first as single doses and then as multiple doses
1586684|NCT02334449|Drug|Placebo|All study cohorts (except food effect cohort) are placebo controlled
1586685|NCT02334436|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
1586686|NCT02334436|Other|0.9% sterile, unpreserved saline|Placebo Comparator Arm
1586687|NCT02334423|Biological|Botulinum toxin, Type A|Botulinum toxin, Type A
1586688|NCT02334423|Other|0.9% sterile, unpreserved saline|Placebo
1586689|NCT02334410|Device|Whole body vibration (WBV)|Side-alternating WBV
1586690|NCT02334397|Behavioral|Total Control Program|Women will be enrolled in Total Control, which is a fitness and education program.
1586691|NCT02334384|Biological|Antimicrobial TheraGauze|"In the intervention arm: Antimicrobial TheraGauze, tobramycin impregnated TheraGauze, will be used to pack the wound cavity after incision and drainage of the skin abscess.
In the comparator arm: Standard wound packing, plain cotton wick or iodoform gauze - at the discretion of the provider will be used to pack the wound cavity after incision and drainage of the skin abscess."
1586692|NCT02334371|Radiation|MR-PET|The MR-PET will be performed with the Biograph mMR system (Siemens Healthcare, Erlangen, Germany). This system integrates a 3Tesla MRI and PET scan which makes simultaneous acquisition of whole-body MRI and PET images possible. The Biograph mMR holds the CE mark and was FDA approved in June 2011. The Biograph mMR is intended to be used in the Academical hospita! Maastricht for standard patient care. The radiotracer that will be used is 18F-Iabeled fluorodeoxyglucose (18F-FDG), according to standard PET -protocol.
1586693|NCT02334358|Device|YVOIRE Classic s|
1586694|NCT02334345|Drug|Evoskin|Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
1586695|NCT02334345|Drug|Trixiera|Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
1586696|NCT02334332|Other|Educational Intervention|Receive educational brochure
1586697|NCT02334332|Procedure|Standard Follow-Up Care|Receive standard post-operative care
1586698|NCT02334332|Procedure|Quality-of-Life Assessment|Ancillary studies
1586699|NCT02334319|Drug|Ganetespib|Given IV
1586875|NCT02333188|Other|Laboratory Biomarker Analysis|Correlative studies
1586702|NCT02334306|Biological|AMG 557/MEDI5872|Fixed subcutaneous (SC) dose of AMG 557/MEDI5872 every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85). Beginning on Day 99, all subjects (n = 42) will receive a fixed SC dose of AMG 557/MEDI5872 every week (Days 99 to 113) and every 2 weeks (Days 127 to 183) for an additional 12 weeks.
1586703|NCT02334306|Other|Placebo|Fixed SC dose of placebo every week for 3 weeks (Days 1 to 15) and then every 2 weeks for 9 weeks (Days 29 to 85). Beginning on Day 99, all subjects (n = 42) will receive a fixed SC dose of AMG 557/MEDI5872 every week (Days 99 to 113) and every 2 weeks (Days 127 to 183) for an additional 12 weeks.
1586704|NCT02334293|Drug|Omegaven|Omegaven® fat emulsion will be used as a Compassionate Use treatment for critically ill infants with PN associated liver injury.
1586705|NCT02334280|Behavioral|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
1586706|NCT02334267|Device|Group 1: GranuFlo|Study subjects will be randomized to undergo dialysis treatments using GranuFlo, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using NaturaLyte, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
1586707|NCT02334267|Device|Group 2: NaturaLyte|Study subjects will be randomized to undergo dialysis treatments using NaturaLyte, a commercially available acid dialysate concentrations for one weekly hemodialysis treatment. This will be followed by dialysis treatments using GranuFlo, a commercially available acid dialysate concentration for a second weekly hemodialysis treatment. Intervention: blood and dialysate samples will be obtained at specific time points during the dialysis treatments.
1586708|NCT02334254|Drug|rivaroxaban and ticagrel therapy|Antiplatelet therapy are mandatory at least 1 month after bare metal stent implantation, and 6 months after drug-eluting stent implantation.
1586709|NCT02334254|Drug|triple antithrombotic regimen with warfarin, asipirin and clopidogrel|
1586710|NCT02334241|Device|Sorbact®|Sorbact® is available in many types and sizes. These different presentations are available allowing management of quite all types of wounds of various anatomical locations, sizes or depths. Application of any of these presentations is allowed and may change during study course according to wound evolution.
1586711|NCT02334241|Device|Best local cares|Participating centers will provide a list of dressings they planned to use in the best local cares arm. This list must be validated by the study Steering Committee members
1586712|NCT02334228|Behavioral|In SHAPE Lifestyles|In SHAPE Lifestyles is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
1586713|NCT02334228|Behavioral|Health Club Membership and Education|Fitness club membership with education in using the exercise equipment.
1586714|NCT02334215|Drug|Methadone|Interim methadone treatment (methadone without routine counseling) will be provided in jail. Methadone treatment with counseling will be continued in the community.
1586715|NCT02334215|Behavioral|Patient Navigation|A patient navigator will assist the participant for the first three months after release from jail to enter and remain in methadone treatment in the community.
1586716|NCT02334215|Behavioral|Enhanced Treatment as Usual (ETAU)|Participants will receive methadone detoxification, drug abuse and overdose prevention information, drug treatment and overdose prevention referral in the community.
1586717|NCT02334202|Behavioral|Interpersonal Psychotherapy-Weight Gain|Participants will have 1 individual pre-group session when each participant meets with the group leaders so that they can learn about each girl's significant relationships, set goals for the program, and so each girl can learn about group participation and format. Participants then will begin IPT-WG which is designed to decrease excessive weight gain among adolescents ages 12-17 years who are at risk for adult obesity. The IPT-WG program has been adapted to be appropriate for military dependents. The IPT-WG group meets for 12 consecutive, weekly group meetings and involves developing strategies for dealing with the problems girls struggle with that may lead to increased eating. At the 6th week of the group, the group leaders meet with each participant to review their progress and goals.
1586718|NCT02334202|Other|Health Education|"The health education group will follow the HEY-Durham health program designed by researchers at Duke University. This program, designed to be delivered to youth attending community high schools, was adapted to a 12-week program (each with a 90 minute session). Girls will come in for a 1.5-hour group meeting once a week for 12 weeks (12 times total). Before beginning the group, girls will meet with group leaders to review each adolescent's family health history. The curriculum includes focus on various health topics, including avoiding alcohol, drug and tobacco use, nutrition and body image, nonviolent conflict resolution, sun safety, exercise, and domestic violence."
1586719|NCT02334189|Behavioral|Letter|Patients receive an information letter following an avoidable visit to the Emergency Department.
1586720|NCT02334176|Procedure|Ultrasound guided axillary plexus block with 1 injection|The needle will be advanced until the tip is positioned just dorsal to the artery and 35ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
1586721|NCT02334176|Procedure|Ultrasound guided axillary plexus block with 2 injections|The needle will be initially advanced toward musculocutaneous nerve and 7 ml of LA (lidocaine 1.5% with epinephrine 5µg/ml) is deposited around the nerve. The needle will be then advanced until the tip is positioned just dorsal to the artery and 28 ml of (lidocaine 1.5% with epinephrine 5µg/ml) is deposited in this location.
1586722|NCT02334176|Drug|lidocaine 1.5% with epinephrine 5µg/ml|35 ml of lidocaine 1.5% with epinephrine 5µg/ml will be used to perform the axillary plexus block
1586723|NCT02334163|Drug|Nitazoxanide|500 mg nitazoxanide tablets twice daily
1586724|NCT02334163|Drug|Oral lactulose|Oral lactulose (65%)
1586725|NCT02334163|Drug|Metronidazole|250 mg metronidazole tablets every 8 hours
1586726|NCT02334163|Drug|Rifaximine|Two 200 mg rifaximine tablets every 8 hours
1586796|NCT02333682|Dietary Supplement|Vitamin D3 (Cholecalciferol) 20 mcg|Vitamin D3 (Cholecalciferol)
1586797|NCT02333669|Other|no intervention|no intervention
1586922|NCT02332876|Behavioral|Control|
1586727|NCT02334150|Drug|CSEA (ropivocaine and sufentanil)|Women in the CSEA group received CSEA during labor. An intravenous line was established when the uterine opening measured 1-2 cm. Then sufentanil (5-7 μg) was injected intrathecally. When the visual analogue pain score was 3 or higher, a mixture of ropivocaine (0.143%) and sufentanil (0.3 μg/ml) was continuously infused into the epidural space using an analgesia pump until the cervix was fully dilated. Load capacity was 5 ml. The analgesic plane was controlled under T10.
1586728|NCT02334137|Behavioral|iPad app|"Provided by the Patient Education Institute, the X-plain iPad app includes modules on healthy eating for diabetics, eye complications, foot care, and others."
1586729|NCT02334137|Behavioral|Educator sessions|A certified diabetes educator and/or registered dietitian will meet with patients for 30-60 minutes prior to their ophthalmology visits, when scheduling permits.
1586730|NCT02334137|Behavioral|Retinal photos|A resident ophthalmologist will spend approximately 5 minutes showing patient their own retinal photos, compared to a normal retina, and explaining the pathology present (if applicable).
1586731|NCT02334124|Other|Home|The main intervention is for children with uncomplicated cellulitis to remain at home throughout the period of intravenous treatment but as it is not feasible to administer flucloxacillin four times a day by the Hospital-In-The-Home team, once daily ceftriaxone is the most ideal antibiotic to be given to this group
1586732|NCT02334124|Other|Ward|Admission to a hospital based ward
1586733|NCT02334124|Drug|ceftriaxone|50mg/kg once daily
1586734|NCT02334124|Drug|flucloxacillin|50mg/kg 6 hourly
1586735|NCT02334111|Behavioral|RESPECT-Plus|A RESPECT-Plus family specialist (FS) will deliver the intervention to subjects (mothers in treatment for opiate use disorder) recruited during their third trimester of pregnancy and randomized into the study's intervention arm post-delivery. During their infant's hospital stay, the FS will schedule a convenient time to meet the subjects (mothers) to educate them on infant soothing techniques. With permission from the mother, the FS will join the subjects during their infant's routine well-child visits at the pediatric primary site. Optional home visiting provides another meeting opportunity between the subjects and FS.
1586736|NCT02334098|Dietary Supplement|Omega-3 supplemented drink|"The drink has apple/ pear/ pomegranate taste which is well accepted by children and adolescents, is rich in natural antioxidants to help prevent oxidation of omega-3. The drink can be taken at any time during the day.
1/3 of the participants will be assigned to the omega-3 group after randomization. They are going to take the treatment for 6 months. They will be assessed at baseline, end of treatment and 6 months post-treatment."
1586737|NCT02334098|Dietary Supplement|Smartfish|Treatment duration is 6 months. They will be assessed at baseline (0 months), end of treatment (6 months) and 6 months post-treatment (12 months).
1586738|NCT02334072|Device|Laryngeal mask classical application|Laryngeal mask classical application will be done following induction of anesthesia and anesthesia will be conducted by this device.
1586739|NCT02334072|Device|I-gel laryngeal mask application|I-gel laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
1586740|NCT02334072|Device|Cobra laryngeal mask application|Cobra laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
1586741|NCT02334072|Device|Supreme laryngeal mask application|Supreme laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
1586742|NCT02334072|Device|Proseal laryngeal mask application|Proseal laryngeal mask application will be done following induction of anesthesia and anesthesia will be conducted by this device.
1586743|NCT02334059|Drug|Ketamine|Ketamine infusion plus placebo infusion of normal saline
1586744|NCT02334059|Drug|Ketamine plus magnesium|Ketamine plus magnesium infusion
1586745|NCT02334059|Other|Placebo|2 placebo infusions
1586746|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in elderly patients (65-80 years) .
1586747|NCT02334046|Drug|Remifentanil|Remifentanil was maintained at predetermined effect-site concentration during the periextubation period (initial concentration: 1.8 ng/ml) in adult patients (20-60 years) .
1586748|NCT02334046|Drug|Sevoflurane|Anesthesia was maintained with sevoflurane with 1.5-2.0 vol% in air/50%oxygen mixture, and sevoflurane was adjusted to about 1.0 vol% 10 min before end of surgery.
1586749|NCT02334033|Other|other|
1586750|NCT02334020|Other|Mental Health First-aid|2 days training course providing information on severe mental illness, in order to make people able to support in situations of crisis
1586751|NCT02334007|Drug|LMWH: Dalteparin|Dalteparin is a low-molecular weight heparin. The dosage used will be 5000 units once daily (administered as a subcutaneous injection). This is an established prophylactic dose used to prevent the incidence of VTE after surgery.
1586752|NCT02334007|Other|Placebo|Upon hospital discharge, half of the patients will be assigned to receive saline placebo injections for up to 35 days after surgery. These injections will have no effect.
1586753|NCT02333994|Device|GROUP A education programme as well as balance training exercises|Group A received education programme as well as balance training exercises.The intervention group attended one-hour training classes once a week for 6 consecutive weeks. The classes involved both lectures and discussions and were guided through with handouts and worksheets. Each session began by giving a summary of the previous session and continued with the main topic of the session. The intervention program also engaged the participants in discussions about their concerns regarding falling and on topics pertaining to identifying and reducing the risk factors of falls, including environmental hazards in and out of the house
1586754|NCT02333994|Other|GROUP B on-platform training|on-platform training was performed while standing and while sitting on a 22-inch therapeutic ball, 1 eyes open or closed 2 normal or reduced area of foot support 3 on foam or floor 4 with or without manual p
1586792|NCT02333695|Device|Spinal Magnetic Stimulation|Spinal Magnetic Stimulation (SMS) is a relatively new way to use magnetism to affect the spinal cord. It is non-invasive, meaning that the procedure does not require any type of surgery; rather, it is conducted by transmitting magnetic pulses through the Spinal Cord by pressing a machine against the back.
1586793|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 10 mcg|25(OH)D3 (Calcifediol Hy.D)
1586794|NCT02333682|Dietary Supplement|25(OH)D3 (Calcifediol Hy.D) 15 mcg|25(OH)D3 (Calcifediol Hy.D)
1994751|NCT02928913|Other|No intervention|
1586755|NCT02333981|Device|passive oral motor therapy for drooling|7 subjects aged 7-19 yrs were taken . All subjects received passive treatment which included light touch, stroking, vibration with (mechanical vibrator), tapping, pressure and stretch. All the techniques have been proved to be effective in treating drooling. Relative sterility and hygiene was maintained throughout the procedure as sterilized gloves and napkins were used. The measurement protocol was designed to check effectiveness on drooling in children. The protocol was given for 4 weeks with treatment sessions given 3 times per week and the treatment duration was 30min.12 sessions of oral motor stimulation therapy given during the 4 weeks..
1586756|NCT02333968|Behavioral|Self-management support|The 12-week intervention consists of an iPad application for patients that is connected to a web application for nurses. Every morning and evening patients register pain and related symptoms by use of a pain diary. Patients are also requested to register medication intake. Graphical feedback is provided based on registered pain scores and medication intakes. Patients receive education on causes and treatment of pain, symptoms that require action, and methods to better control pain. Patients communicate with nurses via text message functionality within the application. Specialized nurses remotely monitor and analyze the patients' situation once every workday. Nurses have the opportunity to collaborate with the treating physician, pain specialist or multidisciplinary team.
1586757|NCT02333955|Drug|GCS-100|3 mg GCS-100 IV push. All doses of study drug will be administered least once monthly for a total of 1 year with a follow-up 4 weeks after the last dose is administered.
1586758|NCT02333942|Device|Nautilus NeuroWaveTM System|A noninvasive device to detect dementia utilizing headset and sensors
1586759|NCT02333929|Device|STA- Rivaroxaban Calibrator&Control|One sample blood collected per patient the day of the treatment (drawn soon after the the drug intake)
1586760|NCT02333916|Other|overfeeding + exercise pre-training|
1586761|NCT02333916|Behavioral|fitness training|
1586762|NCT02333916|Other|overfeeding + exercise post-training|
1586763|NCT02333903|Other|Personalized Physical Activity|"1.5 hours physical training sessions, twice a week for 1 year, under the supervision of a dedicated coach specialized in supporting overweighted patients.
Typical training session organized for small groups (5 patients) will consist of aerobic exercises, muscular strengthening (4 peripheral members and abdominal muscular belt), followed by stretching exercises."
1586764|NCT02333890|Drug|Chloroquine|chloroquine 500 mg daily as an oral capsule during the wait time to surgery.
1586765|NCT02333890|Drug|Placebo|
1586766|NCT02333877|Other|Skinlink|suture using Skinlink
1586767|NCT02333877|Other|Nylon|conventional suture using nylon
1586768|NCT02333864|Device|POGO® BGMS|SMBG
1586769|NCT02333851|Drug|Mixtard 30:70 Novonordisk® twice daily|Premixed insulin twice daily before breakfast and before dinner
1586770|NCT02333851|Drug|Lantus® once daily and Apidra® before meals|Injection of Lantus® insulin once daily and rapid insulin Apidra® before breakfast, lunch and dinner
1586771|NCT02333838|Drug|IV Thiotepa|IV Thiotepa (5 mg/Kg/day for 2 days) (Day -7 and -6)
1586772|NCT02333838|Drug|IV Fludarabine|IV fludarabine (40 mg/m²/day for 4 days) (from Day-5 to day -2)
1586773|NCT02333838|Drug|IV Busulfan|(Busilvex 3.2 mg/kg/day for 3 days) (Day-5, -4 and -3)
1586774|NCT02333838|Drug|IV Anti-thymocyte globuline|(Thymogobuline®, 2.5 mg/kg/day for 2 days) (Day-3 and -2)
1586775|NCT02333825|Procedure|Medial patellofemoral ligament reconstruction surgery|Medial patellofemoral ligament reconstruction surgery using hamstring autograft
1586776|NCT02333825|Other|Physical therapy and rehabilitation|A standardized physical therapy and rehabilitation program to be administered and guided by rehab specialists
1586777|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
1586778|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
1586779|NCT02333812|Other|Stroboscopic nasopharyngeal laryngoscopy|
1586780|NCT02333799|Drug|Bedaquiline|100mg tablets
1586781|NCT02333799|Drug|PA-824|200mg tablets
1586782|NCT02333799|Drug|Linezolid|Scored 600mg tablets
1586783|NCT02333786|Other|Long-axis/in-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant of a preschool child putting the 24 gauge needle parallel to the ultrasound transducer.
1586784|NCT02333786|Other|Short-axis/out-of-plane US-guided arterial catheterization|Cannulate the radial artery or posterior tibial artery of an infant or a preschool child putting the 24 gauge needle perpendicular to the ultrasound transducer.
1586785|NCT02333773|Procedure|Irreversible electroporation (IRE)|Irreversible Electroportion For Unresectable Portal venous tumor emboli guide with ultrasound or/and CT.
1586786|NCT02333760|Genetic|Autologous CD34+ cells transduced with WASP lentiviral vector|Follow up of ex vivo gene therapy transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WASP gene
1586787|NCT02333747|Device|the Hans electronic acupuncture apparatus|TEAS was performed with a dense-disperse frequency of 2/10 Hz and an intensity of 6-9 mA for 30 min using the Hans electronic acupuncture apparatus (HANS-100A, Nanjing Jisheng Medical Technology Company, Nanjing, China).
1586788|NCT02333734|Other|Physical training|Performed supervised high intensity interval training 3 times a week over 8 weeks on a bicycle ergometer (with watt meter). During the training period, the trainee individually established program, each time with 10 × 60 sec. workout (interspersed with 60 sec. break) corresponding to a force which during the test cycle induces ~ 90% of the maximum heart rate. The time spent per session is expected to last ~ 25 minutes.
1586789|NCT02333721|Procedure|D2 lymphadenectomy including No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy including spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
1586790|NCT02333721|Procedure|D2 lymphadenectomy excluding No. 10|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, Laparoscopic total gastrectomy with D2 lymphadenectomy excluding spleen-Preserving No. 10 Lymph Node Dissection will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy
1586791|NCT02333708|Other|Blood sample|
1586873|NCT02333188|Drug|Irinotecan Hydrochloride|Given IV
1586798|NCT02333656|Other|New OA model|"The general practitioners and the physiotherapists will attend an inter-active workshop and deliver osteoarthritis care in line with international recommendations for osteoarthritis treatment. The general practitioner will refer eligible patients to treatment by physiotherapists at Healthy Living Center or by physiotherapists in private practice. This treatment will include a standardized patient education program followed by structured exercise program with individual adjustments. The general practitioner will schedule a follow-up after the 12-week treatment and will receive a treatment report from the physiotherapist."
1586799|NCT02333643|Drug|CLS003|
1586800|NCT02333643|Drug|Furosemide|
1586801|NCT02333643|Drug|Digoxin|
1586802|NCT02333643|Drug|Vehicle topical|
1586803|NCT02333630|Other|AsthmaCare mobile health application|Personalized, interactive mobile health application designed to send daily medication reminders and assist with self management
1586804|NCT02333630|Other|Asthma education|A website with links to written asthma education and videos
1586805|NCT02333617|Other|Dry Needling|Dry Needling will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will use the appropriate needle based upon patient's size and location of trigger point [No. 5 (0.25 x 40mm), No. 8 (0.30 x 50mm), or No. 11 (0.30 x 75mm)]. They will target trigger points identified in the ipsilateral gluteus medius. Once the needling is inserted into the trigger point the needle will be moved in multiple directions until the first local twitch response is noted. Once the first local twitch response is obtained, the needling will be performed in an up-and-down fashion, performing 2- to 3-mm vertical motions with no rotations (fast-in and fast-out technique), at approximately 1 Hz for 25 to 30 seconds, with the aim of eliciting local twitch responses. The treating therapist can dry needle each trigger point identified in the gluteus medius with a maximum treatment time of 5 minutes.
1586806|NCT02333617|Other|Soft Tissue Mobilization|Soft tissue mobilization will be performed on the patient's ipsilateral gluteus medius muscle with the patient in sidelying. The treating therapist will apply firm pressure with the palm and side of their hand. The treating therapist will mobilize the gluteus medius muscle in 4 separate directions (Proximal-Distal, Distal-Proximal, Medial-Lateral, and Lateral-Medial). The treating therapist will apply the pressure to reach the upper limit of the patient's tolerable discomfort. At any point in time the patient can request for the therapist to decrease the pressure applied. The treating therapist will perform soft tissue mobilization for 20 mobilizing strokes in each of the 4 directions.
1586807|NCT02333617|Other|Placebo Control|Treating therapist will place hands on the patient's gluteus medius muscle and gently rub, but not apply enough pressure to treat the muscles trigger point. This placebo control is designed to account for hands on time from therapist in the 2 other treatment groups, as well as blinding patient to treatment group.
1586808|NCT02333617|Other|Hip and core strengthening exercises|Patient will perform standardized hip and core exercises using body weight, and elastic bands for resistance. Exercises will take approximately 40 minutes to complete.
1586809|NCT02333591|Drug|GlucagonLikePeptide-1 (7-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
1586810|NCT02333591|Drug|GlucagonLikePeptide-1 (9-36)|Diluted in saline and human serum albumin, then infused intravenously for 2,5 hours.
1586811|NCT02333591|Drug|Saline|Infused intravenously for 2,5 hours.
1586812|NCT02333578|Procedure|Convalescent Plasma Treatment|This pilot trial will treat subjects in the ECP Group with ECP derived from two donors. ECP will be provided as ECPSDU each comprising 90 - 110mL of plasma from two individual ABO-compatible donors. Two ECPSDU will be administered as immediately sequential infusions. Subjects may receive up to three doses of ECP not less than 48 hours apart. ECP will be provided as Plasma Frozen Within 24 Hours After Phlebotomy (PF24).
1586813|NCT02333565|Drug|Everolimus|
1586814|NCT02333565|Drug|Octreotide|
1586815|NCT02333539|Behavioral|Adherence behaviors and recommendations for improvement.|
1586816|NCT02333539|Behavioral|Adherence behavior that needs improvement is targeted|
1586817|NCT02333513|Drug|Lomustine/Vincristine/Procarbazine|
1586818|NCT02333500|Other|olfactory workshop|olfactory workshop
1586819|NCT02333500|Other|other workshop|other workshop: discussion group, dance and body Expression
1586820|NCT02333500|Other|No intervention|control group
1586821|NCT02333487|Drug|Lu AF35700|5 mg tablets for oral administration once daily, up to 21 days. Dose will be established based on receptor occupancy, safety, tolerability and PK data from previous cohorts. Starting at 10 mg/day and not more than 20 mg/ day
1586822|NCT02333474|Biological|MV mix vaccine|MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), BCG (Bacille Calmette-Guerin vaccine), measles, Serratia and pneumococcus. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.
1586823|NCT02333474|Other|standard treatment|Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
1586824|NCT02333461|Dietary Supplement|Placebo|Participants were randomly assigned to receive one of four botanical interventions or placebo.
1586825|NCT02333461|Dietary Supplement|Apple|Participants were randomly assigned to receive one of four botanical interventions or placebo.
1586826|NCT02333461|Dietary Supplement|Grape|Participants were randomly assigned to receive one of four botanical interventions or placebo.
1586827|NCT02333461|Dietary Supplement|Raspberry|Participants were randomly assigned to receive one of four botanical interventions or placebo.
1586828|NCT02333461|Dietary Supplement|Apricot/Nectarine|Participants were randomly assigned to receive one of four botanical interventions or placebo.
1586829|NCT02333448|Biological|Blood sample taken on the day the treatment is initiated|
1586830|NCT02333448|Biological|Blood sample taken on day 3 after initiation of treatment|
1586831|NCT02333448|Biological|Blood sample taken on day 5 after initiation of|
1586832|NCT02333448|Biological|Blood sample taken on day 7 after initiation of treatment|
1586833|NCT02333448|Biological|Blood sample taken on day 10 after initiation of treatment|
1586834|NCT02333435|Dietary Supplement|EPA|3g/day of purified EPA , capsules, taken once daily, for 14 months
1586835|NCT02333435|Dietary Supplement|Placebo|3g/day of placebo (high oleic sunflower oil) , capsules, taken once daily, for 14 months
1586836|NCT02333422|Other|NIRS Neurofeedback|The sensor will be placed on 4 specific regions defined by the International 10/20 System for Electrode Placement. F7, Fp1, Fp2 and F8. Each region will be initially trained for 4 minutes, with the eyes open, gradually increasing training time throughout the sessions to a maximum of 10 minutes. Training will amount to 24 sessions, occurring 2 times per week over a period of 3 moths. The procedure will be interrupted at any time, should the subject demonstrate the desire to stop.
1586837|NCT02333409|Procedure|Electroacupuncture|Electroacupuncture (EA) has been used as a part of Traditional Chinese Medicine (TCM) and the benefits and success of EA as a viable treatment option for acute and chronic pain of various origins have been well-recognised.electro-acupuncture (EA) is taken place as to give out the stimulation with fixed frequency, pulse width and current to acupuncture needle for further promotion of analgesics effects.
1586838|NCT02333396|Other|PICU Supports|The PICU Supports intervention includes navigator activities and ancillary tools. The Navigator activities include: initial visits with the healthcare team members (HTMs) and parents; weekday visits with the parents and feedback to the HTMs as needed; coordination of weekly family meetings between the parents and HTMs; and support during transitions out of the unit. The ancillary tools include: a PICU handbook; a place for parents to keep track of events and their goals; a provider sheet to inform PICU HTMs about important parental issues, concerns or goals; a bedside communication log so parents know which non-PICU HTMs have visited; an end-of-life checklist; a bereavement packet for those whose child dies; and informational resources.
1586839|NCT02333396|Other|Educational Brochure|Parents will receive a short educational brochure with information about the pediatric intensive care unit.
1586840|NCT02333370|Drug|LEE011|LEE011 as 50 mg and 200 mg hard gelatin oral capsules as individual patient supply packaged in bottles. LEE011 will be taken QD - days 1-21 of each 28 days cycle.
1586841|NCT02333370|Drug|Letrozole|25mg
1586842|NCT02333370|Drug|Tamoxifen|20 mg
1586843|NCT02333370|Drug|Fulvestrant|500 mg
1586844|NCT02333370|Drug|goserelin|
1586845|NCT02333357|Behavioral|Multimedia 12-Step Toolkit|The Multimedia 12-Step Toolkit includes counselor written guides, posters, client worksheets, engagement activities, and videos designed to be shown during group treatment sessions to explain and encourage 12-step participation.
1586846|NCT02333357|Behavioral|Treatment as Usual|Treatment as Usual is defined as five standard 12-step facilitation group sessions as counselors would normally conduct with their clients.
1586847|NCT02333344|Drug|Zoledronic acid 5mg|two-year Zoledronic acid 5mg infusion treatment
1586848|NCT02333331|Drug|bimagrumab|Bimagrumab will be administered as an intravenous infusion starting on Day 1 until week 21.
1586849|NCT02333331|Other|placebo|Placebo will be administered as an intravenous infusion starting on Day 1 until week 21.
1586850|NCT02333318|Drug|VVZ-149 injection|Colorless, transparent liquid in water for injection
1586851|NCT02333318|Other|Placebo|water for injection
1586852|NCT02333305|Dietary Supplement|CoQ10|• 2 dosages according to patient weight: Weight < 50kg : 20 drops 3 times a day (150 mg / d) Weight ≥ 50 kg : 40 drops 3 times a day (300 mg / d)
1586853|NCT02333305|Other|Sanomit Placebo|• according to patient weight: Weight < 50kg : 20 drops 3 times a day Weight ≥ 50 kg : 40 drops 3 times a day
1586854|NCT02333292|Drug|Telaprevir|Initiation of a regimen containing TVR
1586855|NCT02333292|Drug|Boceprevir|Initiation of a regimen containing BOC
1586856|NCT02333292|Drug|Sofosbuvir|Initiation of a regimen containing SOF
1586857|NCT02333292|Drug|Simeprevir|Initiation of a regimen containing SMV
1586858|NCT02333292|Drug|Daclatasvir|Initiation of a regimen containing DCV
1586859|NCT02333292|Drug|Ledipasvir|Initiation of a regimen containing LDV
1586860|NCT02333292|Drug|ritonavir-boosted Paritaprevir/ Ombitasvir|Initiation of a drug combination of PTV/OTV
1586861|NCT02333292|Drug|Dasabuvir|Initiation of a regimen containing DBV
1586862|NCT02333292|Drug|Velpatasvir|Initiation of a regimen containing VPV
1586863|NCT02333292|Drug|Elbasvir|Initiation of a regimen containing EBV
1586864|NCT02333292|Drug|Grazoprevir|Initiation of a regimen containing GZR
1586865|NCT02333266|Other|Candidemia|
1586866|NCT02333253|Drug|cetrotide|0.25 cetrotide S.c was added on when leading follicle reach >12 mm
1586867|NCT02333240|Other|Self-management of postnatal anti-hypertensive treatment|Daily use of a validated home blood pressure monitor in conjunction with an individualised medication adjustment schedule to adjust anti-hypertensive medications in line with blood pressure readings.
1586868|NCT02333227|Dietary Supplement|Xylitol gum|This is a cluster randomized trial, whereby 4 sites will receive the intervention of xylitol gum in the prepregnancy and early pregnancy interval.
1586869|NCT02333214|Other|Exergames and conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group exercises that are best accomplished using virtual scenarios, such as dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed using video games.
1586870|NCT02333214|Other|Conventional physiotherapy|The protocol of conventional physiotherapy will be customized and will include exercises to improve strength and muscle power, flexibility, mobility, balance, and aerobic conditioning exercises. In particular cases, when necessary analgesia will be used to relive pain. The progression of the exercises will be individualized according to the treatment plan established in the initial functional assessment and will be target to meet patient's improvement during treatment. Conventional physiotherapy will be conducted in pairs. In this group dual task exercises, anticipatory adjustments exercises and inter limb coordination exercises will be performed without the virtual environment.
1586871|NCT02333188|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1586872|NCT02333188|Drug|Leucovorin Calcium|Given IV
1586876|NCT02333175|Other|Specialist review|Specialist review with individually tailored treatment strategies suggested by specialist
1586877|NCT02333162|Drug|Fludarabine Phosphate|Given IV
1586878|NCT02333162|Drug|Melphalan|Given IV
1586879|NCT02333162|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMTMI
1586880|NCT02333162|Radiation|Total Marrow Irradiation|Undergo IMTMI
1586881|NCT02333162|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
1586882|NCT02333162|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
1586883|NCT02333162|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
1586884|NCT02333162|Drug|Tacrolimus|Given IV or PO
1586885|NCT02333162|Drug|Mycophenolate Mofetil|Given IV or PO
1586886|NCT02333162|Other|Laboratory Biomarker Analysis|Correlative studies
2008914|NCT03326284|Other|35 g protein energy balance|Following a 5 day energy balanced diet one group of 10 women will ingest 35 g of protein
2008915|NCT03326271|Procedure|Exeter stem|Patients treated with an total or hemiarthroplasty using a Exeter stem for a displaced femoral neck fracture
1586889|NCT02333136|Device|raman spectroscopy (LighTouch)|near infrared light will be shone upon a fingerbed capillary and light scatter measured using in vivo raman spectroscpy
1586890|NCT02333123|Drug|Aspirin|Each 300mg aspirin capsule will contain over-encapsulated 4 x Aspirin 75mg tablets.
1586891|NCT02333123|Drug|Placebo (for Aspirin)|Each placebo capsule will contain a lactose and magnesium stearate blend, and will appear identical in weight, colour and size to the matched aspirin capsules.
1586892|NCT02333110|Radiation|spatially fractionated radiation therapy|A single dose of 15-20Gys of spatially fractionated radiation therapy
1586893|NCT02333084|Dietary Supplement|PRN Joint Health Formula|
1586894|NCT02333084|Dietary Supplement|placebo|
1586895|NCT02333084|Dietary Supplement|PRN Flex Omega Benefits® combination|
1586896|NCT02333071|Drug|bremelanotide|A melanocortin agonist and synthetic peptide analog of the naturally occurring hormone alpha-MSH (melanocyte-stimulating hormone)
1586897|NCT02333071|Other|Placebo|Placebo
1586898|NCT02333058|Drug|Treosulfan|"Treosulfan dose per day is to be calculated by using BSA:
One dose of Treosulfan per day on three consecutive days (day -6, day -5 and day -4) as intravenous (i.v.) infusion, given over 2 hours.
Two background conditioning regimens with Treosulfan are allowed: One regimen consists of a standardised Fludarabine-containing regimen (regimen A) and the other consists of an intensified regimen with Fludarabine and ThioTEPA (regimen B). The investigator decides for each individual patient whether to treat the patient with regimen A or with regimen B.
Treosulfan: i.v., BSA adapted: 10, 12 or 14 g/m²/day within 120 min to be administered prior to Fludarabine; Fludarabine: i.v., 30 mg/m2/day on days from -7 to -3 prior to HSCT; ThioTEPA (Regimen B): i.v., 2 x 5mg/kg/day on day -2."
1586899|NCT02333045|Drug|Truvada qd|Truvada 1 tablet PO daily for 7 days
1586900|NCT02333045|Drug|Maraviroc 300 qd|Maraviroc 300 mg PO daily for 7 days
1586901|NCT02333032|Other|Inclined treadmill training|
1586902|NCT02333019|Behavioral|Let's Talk About Sex|Multimedia web site to build parental skills in communicating with their pre-adolescnet child sex and relationships, pregnancy prevention, and risk of sexually transmitted infections.
1586903|NCT02333019|Behavioral|Websites; preventing teen pregnancy|Two general web sites with information about preventing teen pregnancy
1586904|NCT02333006|Other|Questionnaires|Traumatic brain injury patients and participant without neurological deficits will answer to questionnaires about Anosognosia
1586905|NCT02332993|Dietary Supplement|FPP|Made from Carica papaya and represents a sweet and granular substance available over the counter. FPP possesses antioxidant properties that can provide benefit against age-related complications..
1586906|NCT02332980|Drug|Ibrutinib|Given PO
1586907|NCT02332980|Drug|Idelalisib|Given PO
1586908|NCT02332980|Other|Laboratory Biomarker Analysis|Correlative studies
1586909|NCT02332980|Biological|Pembrolizumab|Given IV
1586910|NCT02332967|Other|Whey predominant starter formula|Milk powder product given to babies between 1 week and 4 months
1586911|NCT02332967|Other|Whey predominant starter formula + 40% palmitic acid|Milk powder product containing 40% of palmitic acid
1586912|NCT02332967|Other|Whey predominant starter formula + 50% palmitic acid|Milk powder product containing 50% of palmitic acid
1586913|NCT02332954|Drug|vortioxetine|The starting and recommended dose of vortioxetine is 10 mg once daily; film-coated 10 mg tablets for oral use once daily for 52 weeks.Depending on individual patient response, the dose may be increased to a maximum of 20 mg daily.
1586914|NCT02332941|Drug|Rituximab|The purpose of this study is to determine if treatment of Age Related Macular Degeneration (AMD) with a new medication,rituximab is effective.
1586915|NCT02332928|Drug|Melatonin|Melatonin + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
1586916|NCT02332928|Drug|Placebo|Placebo + RT (as clinically indicated) (Subjects will receive 20-mg oral melatonin or placebo the night before their first RT treatment, each night throughout the course of RT treatment, and for 2 weeks following the completion of RT).
1586917|NCT02332915|Behavioral|Sound Production Treatment (SPT)|SPT is a behavioral treatment for acquired apraxia of speech. It involves verbal modeling of target words by the clinician, simultaneous productions, articulatory placement instructions, and repeated practice. Treatment is administered in the context of an hierarchy.
1586918|NCT02332902|Drug|Everolimus|Everyone in the study will receive Everolimus at a starting dose of 10 mg daily and will be adjusted up or down by 2.5 mg at 2 week intervals to attain a trough concentration of 5-15 ng/ml
1586919|NCT02332889|Biological|Vaccine (autologous dendritic cells)|Prior to vaccination, DC will be thawed, washed once with normal saline containing 1% human serum albumin, and viability will be checked (must be > 70%). Peptide pulsed DC will be placed in 1 ml tuberculin syringe(s) and transferred to the study physician for vaccination
1586920|NCT02332889|Drug|Decitabine and Hiltonol|Patients will receive DAC at a dose of 10 mg/m2/d intravenously (IV) over one hour on days 1-5 of week 1. Hiltonol will be given intramuscularly at the same site immediately following vaccine
1586921|NCT02332876|Behavioral|Exercise|
1586923|NCT02332863|Device|Back-loaded Needle (Device)|"Fiducial marker placement via a traditional 22G back-loaded needle will be performed with multiple endpoints recorded:
total length of procedure
how many markers are successfully deployed
technical success
Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
1586924|NCT02332863|Device|Preloaded Needle (Device)|"Fiducial marker placement via a novel 22G preloaded needle will be performed with multiple endpoints recorded:
total length of procedure
how many markers are successfully deployed
technical success
Fiducial marker location will be confirmed via fluoroscopy at time of placement and on 4D treatment planning CT ordered by the radiation oncologist for simulation."
1586925|NCT02332850|Drug|SAR650984|
1586926|NCT02332850|Drug|Carfilzomib|
1586927|NCT02332837|Behavioral|Intervention A: Questionnaire accuracy|Participants will be tested by questionnaire to measure how well consent is understood
1586928|NCT02332837|Behavioral|Intervention B: Questionnaire speed of completion|Time to complete questionnaire from time of presentation
1586929|NCT02332837|Behavioral|Intervention C: Questionnaire Completion rate|Number of participants who complete the questionnaire
2008916|NCT03326271|Procedure|Lubinus SP2 stem|Patients treated with an total or hemiarthroplasty using a SP2stem for a displaced femoral neck fracture
2008917|NCT03326258|Drug|Glembatumumab Vedotin|Given IV
2008918|NCT03326258|Biological|Ipilimumab|Given IV
1586933|NCT02332811|Drug|sevelamer carbonate 800mg|"Pharmaceutical form:tablet
Route of administration: oral"
1586934|NCT02332811|Drug|sevelamer carbonate 2.4 g|"Pharmaceutical form:powder
Route of administration: oral"
1586935|NCT02332798|Drug|PF-04958242|Oral capsule, 0.20 mg, twice a day dosing for 14 days
1586936|NCT02332798|Drug|Placebo|Oral capsule, placebo, twice a day dosing for 14 days
1586937|NCT02332798|Drug|PF-04958242|Oral capsule, 0.35 mg, twice a day dosing for 14 days
1586938|NCT02332798|Drug|Placebo|Oral capsule, placebo, twice a day dosing for 14 days
1586939|NCT02332785|Other|Data Collection|Data collection of endoscopy procedure reports of participants with serrated polyps at MD Anderson Cancer Center in Houston, Texas.
1586940|NCT02332772|Other|Data Collection|Data collected from endoscopy procedures.
1586941|NCT02332759|Device|Materna Medical|
1586942|NCT02332733|Biological|TV003|10^3 plaque forming units (PFU) of rDEN1 delta 30, 10^3 PFU of rDEN2/4 delta 30(ME), 10^3 PFU of rDEN3 delta 30/31-7164, and 10^3 PFU of rDEN4 delta 30 to be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
1586943|NCT02332733|Biological|Placebo for TV003|To be administered as 0.5 mL by subcutaneous injection in the deltoid region of the upper arm or the thigh in pediatric participants
2008919|NCT03326258|Other|Laboratory Biomarker Analysis|Correlative studies
2008920|NCT03326258|Biological|Nivolumab|Given IV
2008921|NCT03326258|Other|Pharmacological Study|Correlative studies
2008922|NCT03326245|Drug|Oral Methylphenidate|dynamic changes in D2R
2008923|NCT03326245|Drug|IV Methylphenidate|dynamic changes in D2R occupancy
2008924|NCT03326245|Other|Oral Placebo|Dynamic changes in D2R
1586950|NCT02332707|Drug|Grazoprevir|One grazoprevir 100 mg tablet (Part A), or two uprifosbuvir (+) grazoprevir (+) ruzasvir tablets each containing grazoprevir 50 mg (Part B), taken once daily by mouth.
1586951|NCT02332707|Drug|Uprifosbuvir|Two or three uprifosbuvir 150 mg (300 mg and 450 mg total daily dose) tablets (Part A), or two uprifosbuvir (+) grazoprevir (+) ruzasvir tablets each containing uprifosbuvir 225 mg (Part B), taken once daily by mouth.
1586952|NCT02332707|Drug|Elbasvir|One elbasvir 50 mg tablet (Part A), taken once daily by mouth.
1586953|NCT02332707|Drug|Ruzasvir|Six ruzasvir 10 mg (60 mg total daily dose) capsules (Part A), or two uprifosbuvir (+) grazoprevir (+) ruzasvir tablets each containing ruzasvir 30 mg (Part B), taken once daily by mouth.
1586954|NCT02332707|Drug|Uprifosbuvir (+) Grazoprevir (+) Ruzasvir|Two FDC tablets, each containing grazoprevir 50 mg + uprifosbuvir 225 mg + ruzasvir 30 mg (Part B), taken once daily by mouth.
1586955|NCT02332707|Drug|Ribavirin|Ribavirin (RBV) 200 mg capsules taken twice-daily at a total daily dose of 800-1400 mg based on participant body weight.
1586956|NCT02332694|Device|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
1586957|NCT02332668|Biological|Pembrolizumab|IV infusion
1586958|NCT02332655|Drug|Cannabidiol|"Initiation of treatment will begin with 2mg/kg/day. The dose will be increased by 3 mg/kg/day after seven days and then by 5 mg/kg/day every seven days up to a maximum dose of 25 mg/kg/day given.
The dose of concomitant antiepileptic drugs will remain unchanged during the first 12 weeks of CBD treatment (or until 8 weeks after steady state at final dose), unless symptoms of toxicity and/or significant changes in blood levels are observed."
1586959|NCT02332642|Other|Immuno-monitoring|
1586960|NCT02332629|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
1586961|NCT02332629|Drug|Isotonic Sodium Chloride|Placebo
1586962|NCT02332616|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
1586963|NCT02332616|Drug|Isotonic Sodium Chloride|Placebo
1586964|NCT02332603|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride
1586965|NCT02332603|Drug|Isotonic Sodium Chloride|Placebo
2008925|NCT03326245|Other|IV Placebo|Dynamic changes in D2R
2008926|NCT03326232|Device|Continuous glucose monitoring|The blinded CGM group the investigators will be using the Medtronic iPro2 system (Enlite sensor + transmitter). The real-time CGM group we will be using the 530g system (iPro2 (Enlite sensor + transmitter) + inactivated 530g pump set only to display glucose values, no insulin will be administered).
1586966|NCT02332590|Drug|Sarilumab|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
1586967|NCT02332590|Drug|Adalimumab|Pharmaceutical form:solution for injection in pre-filled syringe; Route of administration: SC
1586968|NCT02332590|Drug|Placebo (for sarilumab)|Pharmaceutical form: solution for injection in pre-filled syringe; Route of administration: SC
1586969|NCT02332590|Drug|Placebo (for adalimumab)|Pharmaceutical form:solution for injection in pre-filled syringe; Route of administration: SC
1586970|NCT02332577|Drug|PRISTINAMYCIN XRP7263|Pharmaceutical form:tablet 500 mg Route of administration: oral
1586971|NCT02332577|Drug|Amoxicillin|Pharmaceutical form:capsule 500 mg Route of administration: oral
1586972|NCT02332577|Drug|Amoxicillin Placebo|Pharmaceutical form: capsule Route of administration: oral
1586973|NCT02332577|Drug|PRISTINAMYCIN Placebo|Pharmaceutical form:Tablet Route of administration: Oral
1586974|NCT02332564|Other|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index|Coronary Artery Balloon Occlusion for Determination of Collateral Flow Index
1586975|NCT02332551|Device|NanoKnife|Irreversible electroporation (IRE) is a new, minima-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and the gallbladder .
1586976|NCT02332538|Procedure|532nm-laser photoselective vapo-enucleation of the prostate)|using Greenlight (532nm-laser) modified vaporization technique, PVEP (photoselective vapo-enucleation of the prostate)
1586977|NCT02332538|Procedure|Holmium laser enucleation of prostate|Holmium-Yag laser enucleation of the prsotate
1586978|NCT02332538|Procedure|Bipolar TURP|Bipolar transurethral resection of the prostate in saline
1586979|NCT02332525|Device|Oral Vibrational Stimulation|"Oral application of vibratory stimulus
: With the oral equipment, which is similar to the device generally used to prevent teeth grinding in dental clinics, 15-second vibratory and 15-second non-vibratory stimulus are given repeatedly for about 5 minutes using a vibrator that has a strength less than or equal to the vibratory stimulus of a smartphone (3.3V, 166Hz, maximum 180Hz). A stimulus of two times for 5 minutes, a total of at least 10 minutes is conducted for 10 days in a hospital or designated place."
1586980|NCT02332512|Drug|Apatinib|
1586981|NCT02332512|Drug|Placebo|
1586982|NCT02332499|Drug|Anlotinib|Anlotinib p.o. qd
1586983|NCT02332499|Drug|Placebo|Placebo p.o. qd
1586984|NCT02332486|Drug|Qingxuan Decoction|In Qingxuan Decoction, there are a bag of Chinese honeylocust spine，Glehnia littoralis and Smilax china L,and two bags of Silktree albizia bark, Kadsura interior,Cortex dictamni, Lilium brownii var, Silkworm larva,Forsythia suspensa and Rhizoma polygonati preparata, and three bags of viridulumArisaema erubescens and Poria cocos Wolf. All drugs are made by Jiangyin Tianjiang company in China.
1586985|NCT02332473|Drug|Ypeginterferon alfa-2b|
1586986|NCT02332473|Drug|Granulocyte-macrophage colony stimulating factor|
1586987|NCT02332447|Drug|naloxone|"A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.
The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
1586988|NCT02332447|Drug|Placebo|"Placebo will be isotonic sodium chloride which preparation in 1 ml vials will be centralized by the pharmaceutical department of Edouard Herriot Hospital to ensure its indistinguishability from naloxone A single dose of 1 ml of naloxone (i.e 0.4 mg) or placebo will be administered by the supervising nurse or physician, using direct intravenous injection with a 5 ml syringe through peripheral venous catheter of which all patients will be equipped throughout the video-EEG.
The evolution from a partial seizure to a GTCS being gradual, and the total duration of the seizure ranging from 2 to 3 minutes, the injection will be prepared during the course of the seizure. Given the assumptions about the role of endogenous opioids release in the spontaneous termination of seizures, naloxone will be administrated immediately after the end of the GTCS and not before. Specifically, treatment administration will be performed within the 2 minutes following the end of the GTCS."
1586989|NCT02332434|Other|stable isotope enrichment methodology (5,5,5-D3-L-Leucine)|
1586990|NCT02332421|Device|modified dentoalveolar distractor|Here, the modified distractor is going to be used when retracting the canine.
1586991|NCT02332408|Radiation|Cybernetic microradiosurgery|Cybernetic microradiosurgery (6MV) using tracking to TD 25Gy given in five fraction (5Gy p fr) two or three days a week, during 2 weeks
1586992|NCT02332408|Radiation|Conventional radiotherapy|Conventionally fractionated linac based external beam radiation therapy - EBRT, (conformal or dynamic) to the TD of 36 Gy, in 2.0 Gy per fraction 5 days a week over the period of 3.5 weeks)
1586993|NCT02332369|Device|Capsular Tension Ring|
1586994|NCT02332356|Drug|azathioprine or adalimumab and infliximab|
1586995|NCT02332343|Other|No intervention - Natural history study|
1586996|NCT02332330|Device|VEST|
1586997|NCT02332317|Behavioral|Palliative rehabilitation|12-week individually customized, specialized palliative rehabilitation program
1586998|NCT02332304|Procedure|Preterm fetus|A sample of amniotic fluid was taken before the birth of fetus between 26 and 36 6/7 weeks of pregnancy.
1586999|NCT02332291|Drug|Escitalopram|Escitalopram 10-20mg daily
1587000|NCT02332291|Drug|Bupropion XL|Bupropion XL 150-450mg daily
1587001|NCT02332278|Procedure|Early feeding|Fluid diet four hours after cesarean section
1587002|NCT02332278|Procedure|Late feeding|Fluid diet 12 hours after cesarean section
1587030|NCT02332083|Device|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
1587031|NCT02332083|Device|Exergame|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
1587032|NCT02332083|Other|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1
1587033|NCT02332083|Device|Aktiv Tramp|Participants will undergo a training program set from the 5 to 8 week, three times a week over 4 minutes.
1587003|NCT02332265|Other|Support to Able-Bodied Vulnerable groups to Achieve Food Security (SAFE)|The SAFE program was developed & implemented from Jan. 2008-Dec. 2010 by CARE-Malawi, a country office of CARE International, a large NGO. SAFE participants were selected by CARE-Malawi. SAFE was designed to address intertwined structural issues contributing to HIV susceptibility: food insecurity, poverty, gender inequity and ineffective governance. SAFE was implemented in 3 geographic subdivisions (Njombwa, Kaomba, & Mwase) of Kasungu District, located in west-central Malawi. It was funded primarily by the European Commission & partially by the Austrian Development Cooperation. SAFE had 4 main components: 1) improving farming practices & sustainable agriculture through Farmer Field Schools, 2) increasing access to savings and investment through Village Savings & Loans Groups, 3) building capacity of local governance structures & 4) integrating HIV education & gender empowerment into programs through training & education. Details: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4082534/.
1587004|NCT02332252|Device|Scalpel|Skin incision performed with a scalpel during cesarean section.
1587005|NCT02332252|Device|Electrocautery|Skin incision performed with an electrocautery during cesarean section.
1587006|NCT02332252|Procedure|Skin incision|
2008927|NCT03326219|Procedure|Clarivein|The Clarivein technique uses mechanical damage to the endothelium of the vein wall through a rotating tip of the catheter. At the same time a sclerosans is injected, causing occlusion of the vein. No heating is used in this technique .
2008928|NCT03326206|Other|COPE Program|The COPE Program is a programmatic model that is designed to support to providers, Community Health Representatives, and patients/family members. Patients are referred to the COPE Program under program auspices. COPE referral and participation is part of routine care at all service units in Navajo Area Indian Health Services, and enrollment is not influenced by study participation. Patients receive the same health care services in the same manner and intensity, whether or not they are not enrolled in this observational study.
1587009|NCT02332226|Behavioral|Representational approach|Representational approach to patient education
1587010|NCT02332213|Procedure|Breath sampling for volatile marker detection|Acquisition of two exhaled breath samples of alveolar air to be analysed by GCMS and nanosensor technology
1587011|NCT02332213|Procedure|Upper endoscopy with biopsies|Upper endoscopy with proper biopsy work-up will be used for identification and stratification of gastric lesions as well as acquisition of biopsies for microbiota testing
1587012|NCT02332213|Procedure|Colonoscopy with biopsies or lesion removal when required|Colonoscopy with proper biopsy or polypectomy material work-up will be used for identification and stratification of colorectal lesions as well as acquisition of biopsies for microbiota testing
1587013|NCT02332213|Procedure|Plasma/serum sampling|Plasma/serum sampling will be used to obtain information for group stratification, e.g. H.pylori status determination
1587014|NCT02332213|Procedure|Faecal sample acquisition|Faecal samples will be obtained for faecal occult blood testing as well as microbiota analysis
1587015|NCT02332213|Procedure|Histological evaluation of the surgery material|The material obtained during surgery (stomach or colorectal) will be used for confirmation of the diagnosis in cancer groups. Surgery itself will be performed according to the clinical indications, and will not be extended (i.e. cannot be considered a study intervention)
1587016|NCT02332200|Other|Physical Therapy|Physical therapy will consist of standard physical therapy care for spondylolysis or spondylolisthesis.
1587017|NCT02332187|Device|Active electrical stimulation using an All Stim stimulator|This is an FDA approved stimulator that is used for strengthening the quadriceps muscle.
1587018|NCT02332187|Device|Sham electrical stimulation using an All Stim stimulator|With this intervention the All Stim unit is turned off and no electrical stimulation is provided.
1587019|NCT02332174|Drug|rufinamide|comparison of different doses, sex and medication conditions
1587020|NCT02332161|Other|surveys, evaluative tests for leg function|See outcome measures
1587021|NCT02332148|Drug|3VM1001|3VM1001 topical cream for treatment of osteoarthritis of the knee
1587022|NCT02332148|Drug|Placebo for 3VM1001|Topical cream placebo for 3VM1001; cream without 3VM1001
2008929|NCT03326193|Drug|Niraparib|niraparib by mouth once daily continuously during 21 day cycle
2008930|NCT03326193|Biological|Bevacizumab|bevacizumab intravenously D1 of every cycle for up to 15 months, including total duration of frontline use
1587025|NCT02332122|Procedure|Sputum induction|Patients will have to puff 200µg of salbutamol (metered-dose inhaler with spacer device). After 10 minutes FEV1 will be measured with MIR spirobank. If FEV1 is >= 30% we can safely proceed with sputum induction. An ultrasonic nebulizer will be used to induce sputum. 4% sodiumchloride will be inhaled. Induction will be performed at 5-min intervals until a sample of good quality is obtained. Sodiumchloride of 5% will be used if no good sample is obtained after two intervals with the 4% solution. Maximal time of induction will be 20 minutes. Subjects will spit saliva into one container and rinse the mouth thoroughly with water before coughing sputum into another sterile container. Samples will be refrigerated at 4°C and processed within 24 hours of collection.
1587026|NCT02332122|Procedure|Skin prick test|Skin Prick Test is a reliable method to diagnose IgE-mediated allergic disease. It is minimally invasive and results are immediately available. Interpretation utilizes the presence and degree of cutaneous reactivity as a surrogate marker for sensitization. A positive control, a negative control and Aspergillus fumigatus will be tested. Location will be Protocol version 1 3/11/2014 marked on the volar aspect of the forearm and drops of each solution will be placed (>= 2cm between drops). A single-head metal lancet will be pressed through the drop of allergen extract and held against the skin for at least 1 second. A new lancet will be utilized for each drop. A wheal diameter of >= 3mm is a positive result.
1587027|NCT02332122|Other|Questionnaires|MRC: Medical Research Council Scale CAT: COPD Assessment Test SGRQ: Saint George's respiratory questionnaire
1587028|NCT02332109|Device|ODM 5|ODM 5 is a CE-certified, preservative-free, hyperosmolar ophthalmological solution containing 5% sodium chloride and 0.15% sodium hyaluronate recommended for the reduction of corneal edema. The patient will use ODM 5 on a daily basis in accordance with the instructions for use and as recommended by the investigator over a period of 8 weeks.
1587029|NCT02332096|Device|Home Sleep Testing Device|Patients will undergo obstructive sleep apnea screening with a FDA approved home sleep testing device.
2008931|NCT03326180|Drug|Liposomal bupivacaine|266mg/20ml vial of EXPAREL
2008932|NCT03326180|Drug|Bupivacaine hydrochloride|100mg/20ml 0.5% bupivacaine hydrochloride. Branded or generic, must be plain (cannot contain adrenaline/epinephrine)
1587034|NCT02332070|Procedure|cardiac surgery|coronary artery bypass surgery and or cardiac valve surgery with cardiopulmonary bypass
1587035|NCT02332057|Drug|Diclofenac plus lidocaine|The study nurse will instruct the patients to swallow diclofenac tablets (100 mg) 1 hour before IUD insertion. Three millilitres of the lidocaine gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the lidocaine gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
1587036|NCT02332057|Drug|Placebo|The study nurse will instruct the patients to swallow placebo tablets 1 hour before IUD insertion. Three millilitres of the placebo gel will be placed on the anterior lip of the cervix . A cotton swab socked in 3 ml of the placebo gel will be introduced in the cervical canal till the level of internal os. The cotton swab will be left in place for three minutes. The IUD will be inserted by experienced gynecologists according to the recommendations of manufacture.
1587037|NCT02332044|Drug|Erdos|capsule, 300mg
1587038|NCT02332044|Drug|Talion|tablet, 10mg
1587039|NCT02332044|Drug|Erdos, Talion|capsule 300mg and tablet 10mg
1587040|NCT02332031|Drug|Sorafenib (Nexavar, BAY43-9006)|Single dose of 400 mg orally on Period 1 Day 1 and Period 2 Day 11
1587041|NCT02332031|Drug|Levothyroxine|Single dose of 300 mcq orally from Period 2 Day 1 to Period 2 Day 14
1587042|NCT02332018|Radiation|Biplanar x-ray images|biplanar x-ray images with microdose and low-dose protocol
1587043|NCT02332005|Drug|diepalrestat choline|aldose reductase inhibitor
1587044|NCT02332005|Drug|Placebo|Placebo
1587046|NCT02331979|Device|Electromagnetic Neuromodulation|Electromagnetic stimulation to neuromodulate the spinal cord in the context of spinal cord injury.
1587047|NCT02331940|Drug|tiotropium|Comparison of the effect of tiotropium delivered by the Respimat Soft Mist Inhaler versus the HandiHaler on sleeping oxygen saturation and sleep quality in patients with COPD.
1587048|NCT02331940|Device|Handihaler|Inhalation via the HandiHaler once daily
1587049|NCT02331940|Device|Respimat|Inhalation via the Respimat once daily
1587050|NCT02331927|Biological|Aflibercept|"Early marker-driven switch of antiangiogenic treatment (bevacizumab to aflibercept) maintaining the chemotherapy backbone until definite radiological progression.
compared to a conventional treatment approach of changing chemotherapy and antiangiogenic agent at time of radiologic progression."
1587051|NCT02331914|Procedure|Vena puncture for blood collection|GIST patients will be asked to provide 40ml blood that will be collected in four Na-EDTA 10ml blood collection tubes at every routine outpatient visit.
1587052|NCT02331914|Procedure|Tumor biopsy|Tumor biopsy after disease progression
1587053|NCT02331888|Device|Scalp electrode, fetal doppler and EUM|the parturient will be connected to the routine fetal Doppler and to the EUM. and When necessary to the scalp electrode will be connected. Tracings will be recorded simultaneously from all three devices until delivery. three separate outputs will be processed Output of the scalp electrode recording. Output of the fetal doppler. Output of the EUM. Three noncontinuous segments of 30 minutes each with two segments occurring during the first stage of labor and the third occurring during the second stage of labor, will be randomly picked from the scalp electrode recording with 3 matching segments in time from the EUM100pro and the fetal doppler.
1587054|NCT02331875|Drug|IPH2201|The first 6 patients will receive IPH2201, IV, at a dose of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
1587055|NCT02331875|Procedure|Standard Surgery|After the end of treatment with IPH2201, according to standard recommendations in the relevant country .
1587056|NCT02331875|Radiation|Postsurgical Adjuvant Therapy|After the standard surgery, according to standard recommendations in the relevant country
1587057|NCT02331862|Drug|Methylprednisolone|Add methylprednisolone in addition to the experience antibiotics in children with urinary tract infection to see if the frequency of the renal scar formation could be decreased
1587058|NCT02331849|Device|High resolution manometry (HRM)|High resolution manometry of the esophagus
1587059|NCT02331836|Device|Arc Endocuff (AEC 110, 120, 130, 140)|
1587060|NCT02331836|Device|Cap|Olympus Disposable distal attachment 15mm diameter, 4mm depth
1587061|NCT02331836|Device|Standard colonoscope|
1587062|NCT02331823|Drug|Isoniazid Aminosalicylate Tablets|a regimen consists of 5 anti-TB drugs (Isoniazid Aminosalicylate Tablets+pyrazinamide tablets+ethambutol tablets+rifabutin capsules+moxifloxacin tablets)to treat retreatment pulmonary tuberculosis patients. The total treatment course is 5 months.
1587063|NCT02331823|Drug|Streptomycin injectable|standardized regimen 2 months of streptomycin injectable + isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules or 3 months of isoniazid tablets + ethambutol tablets + rifampicin capsules + pyrazinamide tablets and 6 months of isoniazid tablets + ethambutol tablets + rifampicin capsules to treat Arm B patients as a control to arm A.The treatment course is 8-9 months.
1587064|NCT02331810|Drug|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1587065|NCT02331810|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1587066|NCT02331797|Device|Endoscopic Technique|Endoscopic Technique; endoscopic transcanal lateral graft tympanoplasty using An endoscope (Karl Storz, Tuttlingen, Germany) and A microdrill (Skeeter Otologic Drill System; Medtronic Xom ed Surgical Products, Inc., Jacksonville, FL, USA)
1587067|NCT02331797|Device|Microscopic Technique|Microsopic surgical approach using a Zeiss Opmi 111 (Carl Zeiss, Jena, Germany) operating microscope
1587068|NCT02331784|Behavioral|Computerized Plasticity-based Software|Participants will be asked to use their assigned training program for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
1587069|NCT02331784|Behavioral|Commercially available Video Game|Participants will be asked to use their assigned video games for forty minutes per session, up to five sessions per week, over 10 weeks (50 total sessions).
1587070|NCT02331771|Drug|Donepezil|Donepezil 5 mg once daily 2 days before ECT and continuing through the last ECT procedure.
1587071|NCT02331771|Drug|Placebo|Placebo capsule once daily 2 days before ECT and continuing through the last ECT procedure.
1587072|NCT02331758|Behavioral|Lifestyle Counseling|The investigators do lifestyle counseling for PCOS patients and monitor the factors to normal level, like BMI, serum index etc.
1587073|NCT02331745|Drug|Granulocyte colony-stimulating factor|Granulocyte colony-stimulating factor(G-CSF) was given 5 ug/kg subcutaneously qd for 6 doses,then qod for other 6 doses(total 12 doses).
1587074|NCT02331745|Drug|standard treatment|Standard treatment includes reduced glutathione, glycyrrhizin, ademetionine,polyene phosphatidylcholine, alprostadil, and human serum albumin) on the day of admission. HBV associated ACLF patients receive entecavir at the same time
1587075|NCT02331732|Behavioral|Virtually Observed Treatment|
1587076|NCT02331732|Other|Directly Observed Treatment|
1587077|NCT02331706|Drug|Interferon alpha-2B (IFN-α) 3 million units (MU) subcutaneous daily|
1587078|NCT02331693|Biological|anti-EGFR CAR T|
1587079|NCT02331680|Drug|OPC-41061|
1587080|NCT02331680|Drug|OPC-41061|
1587081|NCT02331680|Drug|Placebo|
1587082|NCT02331667|Other|Seafood|The aim is to investigate the effect of meals consisting of mackrel and herring on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
1587083|NCT02331667|Other|Non-seafood|The aim is to investigate the effect of meals consisting of meat on learning abilities by using a two-armed individually randomized non-blinded intervention trial.
1587084|NCT02331654|Other|Experimental treatment|Anodal DC stimulation (2 mA, 20 min) will be delivered by a constant direct current electrical stimulator connected to a pair of electrodes
1587085|NCT02331654|Other|Placebo treatment|Electrodes will be placed as for active stimulation, but the stimulator will automatically turn off after 10 s
1587086|NCT02331641|Procedure|Hepatectomy|Removal of a part of the liver
1587087|NCT02331628|Device|ESWT - Extracorporeal Shockwave Therapy|"Patients will receive:
Four applications of EWST to be delivered to the affected hip and /or knee over a period of eight weeks : starting week 8\52 from baseline until and including week 14\52, one dose every two weeks ± 3 days), administered by the principal investigator.
Dosage will be calculated for each participant, by the manufacturer, according to the size of NHO as recorded on X-ray.
The energy flux density (EFD) will be 'high level'
All participants will be supplied with headphones to reduce the noise level emitted by the machine."
1587088|NCT02331615|Device|neuroConn_CE_DC-STIMULATOR|right frontal anodal stimulation
1587089|NCT02331615|Device|neuroConn_CE_DC-STIMULATOR|left frontal anodal stimulation
1587090|NCT02331615|Device|SHAM|no meaningful stimulation will be given
1587091|NCT02331602|Drug|Rivaroxaban|Patients are assigned to receive rivaroxaban 15mg once daily for 12 months. Patients with creatinine clearance 30-49 mL/min receive rivaroxaban 10mg once daily.
1587092|NCT02331602|Drug|Dabigatran|Patients are assigned to receive dabigatran 150mg twice daily for 12 months. Patients at a high risk of bleeding receive dabigatran 110mg twice daily.
1587093|NCT02331589|Drug|KRG (Korea Red ginseng)|3 weeks of KRG capsule (3,000 mg/day)
1587094|NCT02331589|Drug|Placebo (for KRG)|Placebos with same shape and size were manufactured and at Korea Ginseng Corporation
1587095|NCT02331576|Drug|rocaine|
1587096|NCT02331576|Drug|Fentanyl|
1587097|NCT02331563|Drug|Dexmedetomidine|ultrasound guided transvers abdominis plane block
1587098|NCT02331563|Drug|0.25 % bupivacaine|ultrasound guided transvers abdominis plane block
1587099|NCT02331550|Procedure|Ablative treatment|Use of an ablative treatment (cryotherapy) for the management of Low-Grade Squamous Intraepithelial Lesions of the cervix.
1587100|NCT02331550|Procedure|Expectant management|Patients diagnosed with Low-Grade Squamous Intraepithelial Lesions were managed with observation and evaluation at 6 and 12 months after diagnosis.
1587101|NCT02331537|Behavioral|Internet-based cognitive-behavior therapy|Internet-based cognitive-behavior therapy on a safe internet platform. Treatment is divided into seven modules, each containing homework assignments . The participants will be assigned a therapist that they can contact through a message system in the platform and expect answer within 24 hours.
1587102|NCT02331524|Behavioral|Activity Feedback and Encouragement|"The Daily Activity Feedback/ Encouragement group will receive weekly feedback and encouragement regarding daily activity using the Fitbit Zip® for 3 months. Visual feedback and verbal encouragement will be provided. Visual feedback will provide graphics showing current and historical daily activity trends since the start of the intervention period. Subjects in the Feedback group will also receive standardized verbal feedback based upon the Fitbit Zip data. For example, subjects demonstrating a trend of increasing daily activity will be encouraged to Continue what you are doing. You are doing great!"
1587103|NCT02331524|Other|Health Coaching/Home Exercise|The Health Coaching/Home Exercise group will receive 12 weekly health coaching and physical therapy visits for 3 months. Health coaching will be provided by a trained, highly experienced health and wellness coach. In-home health coaching sessions will be provided monthly (total of 3) with the remaining 9 sessions provided telephonically. Initial health coaching sessions will include the utilization of motivational interviewing to establish individualized, three-month goals related to symptoms, function, and/or daily activity, with subsequent sessions celebrating successes in and/or identifying barriers to achieving these goals.
1587104|NCT02331511|Drug|placebo|placebo administration for 3 months after device(PPM,ICD,CRT) implantation
1587105|NCT02331511|Drug|Aspirin 80 mg daily|Aspirin 80 mg daily administration for 3 months after device(PPM,ICD,CRT) implantation
1587106|NCT02331511|Drug|Clopidogrel 75 mg daily|Clopidogrel administration for 3 months after device(PPM,ICD,CRT) implantation
1587107|NCT02331498|Drug|Pazopanib|Study drug Pazopanib will be administered once tumoral evaluation has been performed and after Stupp Protocol (TMZ + Radiation) realisation.
1587108|NCT02331485|Device|PICO + Acticoat group|Comparison between Pico and Acticoat dressing change after 3 and 7 days with standard Mepor dressing change on daily basis.
1587109|NCT02331459|Other|Multicomponent training intervention|"Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)
Legend:
min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching"
1587110|NCT02331459|Other|Nutritional intervention|"Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.
Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.
Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)"
1587111|NCT02331446|Behavioral|Physical exercise intervention|
1587112|NCT02331433|Drug|APN1125|APN1125 orally at ascending doses
1587113|NCT02331433|Drug|Placebo|Matching Placebo
1587114|NCT02331420|Procedure|Gastric bypass|A subcardial gastric pouch with a 30±10 ml capacity will be created by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastro-enterostomy.
1587115|NCT02331420|Behavioral|Medical therapy|"Assessment and treatment by a multidisciplinary team (diabetologist, dietitian, nurse);
Planned visits at baseline and at 1, 3, 6, 9, 12, and 24 months after study entry;
Oral hypoglycemic agents and insulin doses optimized on an individual basis with the aim of reaching a glycated hemoglobin level of less than 7%;
Programs for diet and lifestyle modification, including reduced overall energy and fat intake (<30% total fat, <10% saturated fat, and high fiber content) and increased physical exercise (≥30 minutes of brisk walking every day, possibly associated with moderate-intensity aerobic activity twice a week);
low-calorie diet (every day: 50% carbohydrate, 30% protein and 20% lipids)."
1587116|NCT02331407|Device|Robotic arm therapy|Training with the ReoGo device
1587117|NCT02331394|Dietary Supplement|Chinese herbs formula: Shu Yu Wan|The patients will be offered the choice of taking the CH formula in capsules or sachets and given instructions about recommendations to improve palatability. The formula should be taken with meals 3 times a day (each dose is either 1 sachet or 4 capsules) for six-weeks.
1587118|NCT02331381|Device|Magnetic resonance imaging|
1587119|NCT02331368|Procedure|Autologous Stem Cell Transplant|
1587120|NCT02331368|Drug|Melphalan|140-200 mg/m^2
1587121|NCT02331368|Drug|Lenalidomide|5-15 mg/day starting 45-90 days post-transplant
1587122|NCT02331368|Drug|MK-3475|200 mg/day every 3 weeks starting day +14 post-transplant for a total of 9 doses.
1587123|NCT02331342|Device|NICOM cardiac output measurement|
1587124|NCT02331342|Device|Innocor cardiac output measurement|
1587125|NCT02331329|Device|NICOM cardiac output measurement|
1587126|NCT02331329|Device|Cardiac MRT cardiac output measurement|
1587127|NCT02331316|Other|Daily extra water intake|"Intervention-A: Timing of assigned daily extra water intake specified
Intervention-B: Daily extra water assigned at any time during 24 hour period"
1587128|NCT02331303|Other|Radium-223 dichloride (Xofigo, BAY88-8223)|Xofigo was approved in the US and EU for the following indication: Xofigo is indicated for the treatment of adults with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastases. Xofigo is contraindicated in women who are or may become pregnant.
1587129|NCT02331277|Drug|BI 655064|subcutaneous injection
1587130|NCT02331277|Drug|Placebo|Placebo
1587131|NCT02331264|Other|Exposure to metal debris|The 3 groups are defined by the patients exposure to metal debris from a hip implant. This is either elevated metal ions in those with poorly functioning metal on metal hip implants, or low metal ion levels in those with well functioning metal hip implants, and a second control group of patients with non melt bearing hip implants.
1587132|NCT02331251|Drug|Pembrolizumab|
1587133|NCT02331251|Drug|Gemcitabine|
1587134|NCT02331251|Drug|Docetaxel|
1587135|NCT02331251|Drug|Nab-paclitaxel|
1587136|NCT02331251|Drug|Vinorelbine|
1587137|NCT02331251|Drug|Irinotecan|
1587138|NCT02331251|Drug|Liposomal Doxorubicin|
1587139|NCT02331238|Behavioral|"Coaching Boys into Men program"|"Coaching Boys into Men program consists of 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rational for Coaching Boys into Men and the Coaching Boys into Men Coaches Kit. The coaches use this Coaching Boys into Men toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth."
1587140|NCT02331225|Other|No intervention given|There is no intervention for this study
1587141|NCT02331212|Other|Cytology Specimen Collection Procedure|Correlative studies
1587142|NCT02331212|Other|Laboratory Biomarker Analysis|Correlative studies
1587143|NCT02331199|Device|Amniotic fluid lamellar body count|The LBC (the unit of measurement is number of lamellar bodies counted per microliter of amniotic fluid) will be determined using the platelet channels on the Hematology Flow Cytometer.
1587144|NCT02331199|Device|Fetal pulmonary artery Doppler|A fetal pulmonary artery Doppler will be performed using color Doppler ultrasound. Doppler flow velocity measurements, including systolic/diastolic ratio, pulsatility index, resistance index, and acceleration-time/ejection-time ratio using spectral Doppler ultrasound.
1587145|NCT02331186|Procedure|bariatric surgery|bariatric surgery for obese women
1587147|NCT02331160|Behavioral|Rebozo|Shaking of the maternal pelvis by the midwife to increase the spontaneous cephalic version rate in breech presentation.
1587148|NCT02331147|Other|Offloading|Patient will be offloaded in a diabetic camboot after treatment
1587149|NCT02331147|Other|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
1587151|NCT02331121|Behavioral|Family First Aid Online Training|Web-based interactive multimedia program comprised of videos, interactive animations and text information designed to teach parents of children aged birth to 12 years old basic first-aid and CPR skills, including the option to practice skills as needed.
1587152|NCT02331121|Behavioral|Text-only Online Training|Online text created from the American Heart Association's 2010 guidelines for CPR training via a computer, depicting infant, child and adult CPR skills and choking relief.
1587153|NCT02331108|Drug|Selection of anesthetic induction technique|Standard anesthesia care will be provided after induction based on randomization. Temperatures will be monitored every 15 minutes
1587154|NCT02331095|Drug|Atorvastatin|"Atorvastatin belongs to the statin class of drugs, and is routinely used for prevention of cardiovascular diseases and/or reduction of cholesterol levels. It has been shown to decrease the risk of first venous thromboembolism in an otherwise healthy population with elevated high-sensitivity C-reactive protein (hs-CRP)."
1587155|NCT02331095|Drug|Warfarin|Warfarin is a standard anticoagulation in the treatment for venous thromboembolism. The dose will be adjusted to goal INR of 2-3.
1587156|NCT02331082|Other|Structured Quality Improvement|For structured quality improvement, trained healthcare providers (primarily doctors from referral hospital) will serve as mentors to mid-level providers. The mentors will facilitate on-site trainings of primary care with mid-level providers at the district hospital. Mentors will also travel monthly to the healthcare facilities themselves to provide training both in the direct context of clinical care and to provide feedback based upon surveillance and monitoring data. The focus will be on the techniques from the Institute for Healthcare Improvement's Model for Improvement, including Plan-Do-Study-Act cycles, run charts, and root cause analyses. Finally, they will work with the clinical healthcare staff to identify resource needs from the local government for maintenance, water, electricity, and supplies. These resource needs will be addressed through an integrated supply chain management system across the tiers of the healthcare system.
1587157|NCT02331082|Other|Chronic Care Model|Senior physicians trained in mentorship of non-physician mid-level providers will provide decision support for mid-level providers in the current district healthcare system with specific protocols for target conditions. We will add the following elements: focus on mid-level, non-physician providers as the primary clinicians within the intervention; intensive Community Health Worker (CHW) outreach for detection, screening, follow-up of patients, and encouragement of patient self-care and behavior change; and focused effort on the seamless care coordination of patients across the tiers of the system. Through trainings of CHWs, much of patient self-management comes in the form of home visits that reinforce clinic and hospital counseling, including risk management and prevention. CHWs will be trained in the counseling of each target condition, with counseling largely occurring in the patients' homes, where much of the challenges of chronic disease management and behavior change lie.
1587158|NCT02331082|Device|Integrated Electronic Medical Record|Clinical information systems. We are developing a system for tracking patients that integrates across each of the tiers using an electronic medical record. This is a key technology in supporting each of the above delivery system design elements.
1587159|NCT02331082|Device|Solar-powered electrical supply|As a component of our comprehensive healthcare systems strengthening intervention, we are installing solar panels at community-level clinics to ensure continuous electrical supply for medical devices and technology.
1587160|NCT02331082|Behavioral|Performance-based financing|As part of our healthcare systems strengthening intervention, we have established a performance-based financing agreement with the Government of Nepal that conditionally funds healthcare delivery based on population-level health outcomes and quality healthcare service delivery. In this arrangement, the Government serves as a regulator of healthcare delivery rather than a primary provider of healthcare services.
1587161|NCT02331082|Other|Existing healthcare system|This is the current rural, district-level public sector healthcare infrastructure of rural Nepal that is not strengthened during the study.
1587162|NCT02331069|Drug|Dextrose 5% (D5W)|0,1,2, and 3 week injection sessions consisting of injection of 2 ml of D5W into the D-T groove at the point of maximal pain at 1-2 cm depth, followed by subcutaneous injection of D5W at 4 cm intervals along the course of the PACN if tenderness is present.
1587163|NCT02331069|Other|Physical therapy|Three times weekly X 3 week sessions to include myofascial release, exercise, and one modality.
1587164|NCT02331056|Other|fluid loading|"Fluid loading at defined period
500ml colloid solution infusion at 20min after thorax open for 30min. 500ml colloid administration is a kind of routine procedure during pulmonary lobectomy in our hospital. We just control the fluid loading timing for hemodynamic parameter records."
1587165|NCT02331056|Procedure|thoracoscopic pulmonary lobectomy|the patient group for scheduled thoracoscopic pulmonary lobectomy
1587166|NCT02331056|Procedure|thoracotomy|the patient group for scheduled open pulmonary lobectomy
1587167|NCT02331043|Dietary Supplement|Plant stanol ester|
1587168|NCT02331043|Dietary Supplement|Placebo|
1587169|NCT02331030|Procedure|Supraclavicular|Ultrasound-guided supraclavicular brachial plexus block
1587170|NCT02331030|Procedure|Pecs II block|Ultrasound guided interfascial plane block between pectoralis minor and serratus anterior
1587171|NCT02331030|Procedure|Sham block (Grade 1)|Sham block -- with skin preparation, ultrasound scanning of pecs II block area, but no actual needle injection
1587172|NCT02331030|Drug|Ropivacaine 0.5% 20ml|Local anaesthetic solution administered for supraclavicular block
1587173|NCT02331030|Drug|Ropivacaine 0.5% 10ml|Local anaesthetic solution administered for pecs II block
1587174|NCT02331017|Behavioral|Speech perception tests and self-rating questionnaire|Speech perception test results and self-rating questionnaire scores will be analyzed by means of non-parametric statistical tests. The statistical tests will be chosen in accordance with the number and type of variables in each test. Correlation between audiological variables (aided and unaided hearing thresholds in the non implanted ear, aided speech perception abilities in the HA-alone condition) and the bilateral-bimodal benefit will be examined. Moreover, possible relationship between self-rating questionnaire scores and speech perception test results will be assessed.
1587175|NCT02331004|Other|Intervention for fine motor skills|Implementation of an well known activity to improve the function of upper extremities
1587176|NCT02331004|Other|Support to activities of daily living|Participants are supported and orientated when they are performing some activity of daily living scheduled by the institution
1587177|NCT02330991|Drug|Temozolomide|
1587178|NCT02330978|Procedure|Intravitreal transplantation of mesenchymal stem cell|
1587179|NCT02330978|Biological|Culture and isolation of autologous bone-marrow mesenchymal stem cells|
1587180|NCT02330965|Procedure|Blood Draw|Blood draws (65 mLs [~4 tablespoons] per blood draw) at 4 time points: Prior to study medication initiation, and at +6, +12 and+24 months post treatment initiation.
1587181|NCT02330965|Procedure|CSF collection by lumbar puncture (Optional)|For participants who volunteer to donate CSF samples: up to 25 mLs (<2 tablespoons): prior to study medication initiation, and at month 24 post treatment initiation.
1587182|NCT02330952|Drug|Prednisone|40mg/day per os for 5 days
1587183|NCT02330952|Drug|Placebo|40mg/day per os for 5 days
1587184|NCT02330939|Other|Low fat- Low glycemic index meal|
1587185|NCT02330939|Other|MUFA- Low glycemic index meal|
1587186|NCT02330939|Other|SAFA- Low glycemic index meal|
1587187|NCT02330939|Other|Low fat- High glycemic index meal|
1587188|NCT02330939|Other|MUFA- High glycemic index meal|
1587189|NCT02330939|Other|SAFA- High glycemic index meal|
1587190|NCT02330926|Other|standard care|
1587191|NCT02330926|Other|nutritional supplements and advice|
1587192|NCT02330926|Other|home-based self-assisted exercise program|
1587193|NCT02330926|Drug|Ibuprofen|
1587194|NCT02330913|Procedure|Intracorporeal esophagojejunostomy|Under laparoscopic view, esophagojejunostomy was pereformed with 60mm linear stapler on right side of distal esophagus like as functional end-to-end fashion before esophageal and jejunal resection. Then, three procedures of esophageal resection, common entry hole closure and jejunal resection was performed with a single use of 60mm stapler. Also, jejunojejunostomy was also performed via already made staple entry hole.
1587195|NCT02330900|Other|Study group|Exposure to cell phone interference of the ICD
1587196|NCT02330887|Other|Group Antenatal Care|The group antenatal care intervention will match pregnant women by gestational age in the intervention village clusters and assign them to peer group sessions facilitated by local healthcare clinic staff.
1587197|NCT02330887|Other|Individual Antenatal Care|Pregnant women in control village clusters will have individual antenatal care sessions with their healthcare provider.
1587198|NCT02330861|Device|combowire and IVUS|
1587199|NCT02330848|Dietary Supplement|Walnut Ad libitum diet|Participants will be provided 392 grams of walnuts per week (56g or 2 oz/day) to include in their diet. Their calorie intake will not be subsequently monitored or regulated, and thus will be allowed to float ad libitum
1587200|NCT02330848|Dietary Supplement|Walnut Calorie controlled|The intervention group participants will meet with a registered dietitian and receive instructions and recipes for inclusion of 392 grams of walnuts per week (56g or 2 oz/day) in their meal plan for 6 months.
1587201|NCT02330835|Behavioral|In the Drivers Seat|Multimedia student behavior management program for school bus drivers and school administrators
1587202|NCT02330835|Behavioral|School bus driver training videos|Basic bus driving safety videos
1587203|NCT02330822|Drug|Hyaluronic Acid|This material is going to be injected into the extraction socket in order to promote bone healing.
1587204|NCT02330809|Other|Daily extra water intake|Amount of extra daily water intake to consume
1587205|NCT02330809|Other|Timing of daily extra water intake|Intervention-A: Timing of daily extra water intake specified Intervention-B: at any time during 24 hour period
1587206|NCT02330796|Drug|Bucillamine|Bucillamine Tablets
1587207|NCT02330796|Drug|Colchicine|
1587208|NCT02330783|Drug|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
1587209|NCT02330783|Drug|Sorafenib|400mg twice daily by oral of each 4-week cycle
1587210|NCT02330770|Drug|GnRHa and HCG|Final oocyte maturation will be triggered by dual administration of 0.2 mg of GnRHa preparation (Triptorelin) SC and 1500 IU of HCG preparation IM
1587211|NCT02330770|Drug|GnRHa then HCG|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then a single IM bolus of 1500 IU HCG will be administered 35-37 hours after GnRHa trigger (1 hour after oocyte retrieval)
1587212|NCT02330770|Drug|GnRHa then HCG|Final oocyte maturation will be triggered by administration of 0.2 mg Triptorelin SC then 3 IM boluses of 500 IU HCG will be administered day 1, day 4 and day 7 after oocyte retrieval
1587213|NCT02330757|Drug|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
1587214|NCT02330757|Drug|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
1587215|NCT02330744|Behavioral|Approach-positive AAT|One session of approach-positive AAT (Aim 1 and 2) followed by 4 sessions of approach-positive AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
1587216|NCT02330744|Behavioral|Control AAT|One session of control-AAT (Aim 1 and 2) followed by 4 sessions of control-AAT over 2 weeks concurrent with a brief computer-delivered behavioral activation treatment for depression (Aim 3).
1587217|NCT02330731|Procedure|injection sclerotherapy for gastric varices|The intravariceal technique of injection
1587218|NCT02330718|Other|No intervention|
1587219|NCT02330705|Drug|HCG|Women will be given HCG before IUI
1587220|NCT02330692|Other|No intervention|
1587221|NCT02330679|Drug|Desvenlafaxine|The intervention will consist of a 2-week single-blind placebo run-in phase followed by a 12-week open-label trial with desvenlafaxine (a SNRI medication)
1587222|NCT02330679|Drug|Placebo|
1587311|NCT02330029|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
1587223|NCT02330666|Behavioral|Mission Possible: Parents & Kids Who Listen|MP is a 12-hour, 6-session, manualized skills training program with 2 boosters. Behavioral strategies teach adults and youth to communicate with one another emphasizing youth's need for flexible family boundaries, emotional closeness, and adults as resources. Dyads attend together. Sessions begin with relaxation exercises, review of the prior week's lessons and homework, and examination of success and failure in trying communication techniques. New concepts are introduced using didactic videotaped presentations. Lively, interactive, developmentally appropriate group exercises follow reflective of ethnic diversity that are reinforced with handouts and encouragement to try them at home. Week-by-week content covers: Developmental Changes; Self-Esteem; Communicating What You Want; Listening to What the Other Wants; Solving Conflicts; and Letting Go. The booster sessions are 2 hours in length and update developmental concepts; 5 basic listening skills; and 6 conflict resolution steps.
1587224|NCT02330653|Biological|Fecal Microbiota Transplant|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standards by the Microbiome Health Research Institute Inc. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
1587225|NCT02330653|Biological|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
1587226|NCT02330640|Drug|ticagrelor|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
1587227|NCT02330640|Drug|clopidogrel|After the operation, the subjects will be randomized into two groups according to the proportion of 1:1; and receive the treatment of aspirin 100mg qd+ticagrelor 90mg bid or the treatment of aspirin 100mg qd+ clopidogrel 75mg qd. The study will plan to enroll 140 subjects in 12 months and the treatment will last for 30 days.
1587228|NCT02330640|Drug|asprin|All patients will be given asprin 100mg Qd within 24hours after operation,and will continue taking aspirin at the end of the study
1587229|NCT02330627|Behavioral|Positive Valence System Treatment|Clinician-administered one-hour treatment sessions focused on presenting rationale and instructions for completing positive activity exercises (e.g., gratitude, acts of kindness) between sessions.
1994752|NCT02928627|Other|Analysis of microRNA expression|sample analysis
1587232|NCT02330601|Procedure|endoscopic papillary large balloon dilation|For the patients in EPLBD group, a CRE balloon (diameter 10, 11, 12, 13.5, 15 mm; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast. When the waist disappeared, the balloon was kept inflated for 120s. The stones were then retrieved by a basket or a retrieval balloon.Mechanical lithotripsy was used if necessary
1587233|NCT02330588|Behavioral|Eat It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.
*Two brief questions about children's grain portion sizes and sugar sweetened beverage intake were presented."
1587234|NCT02330588|Behavioral|Move It|"The SBIRT (Screening, Brief Intervention, Referral to Treatment), called RIPPLE (Resource Information Program for Parents on Lifestyle Education) was delivered on a study-designated tablet and designed to (1) screen children's weight status, (2) deliver a brief intervention*, and (3) provide parents with the opportunity select resources and services to help prevent obesity in children.
*Two brief questions about children's moderate-to-vigorous physical activity (MVPA) and screen time were presented."
1587235|NCT02330588|Behavioral|eHealth Control|The eHealth Control group (1) screened children's weight status, and (2) provided parents with the opportunity select resources and services to help prevent obesity in children.
1587236|NCT02330575|Behavioral|Exercise|The participant exercise sessions will be conducted in small groups of 5 to 10 participants under the direct supervision of the community-based exercise specialist. Participants will have the choice between taking part in a bridging exercise class (e.g., Beauty program and Bridging to Fitness - Cancer) or group-based supervised fitness centre exercise training.
1587237|NCT02330575|Behavioral|Education|Participants allocated to the standard care group will receive standard advice and counseling on physical activity and will serve as the 'control group' for a 16-week period.
1587238|NCT02330562|Drug|MRZ|"MRZ dosing in Phase 1 to range from 0.55 to 0.8 mg/m2.
Dose Escalation: MRZ dose-escalation will occur using a standard 3+3 study design.
The RP2D of MRZ (0.8.mg/m2) will be used in a two stage design, with fifteen response-evaluable patients entered in the first stage. If 1 or more responses are observed at the MRZ RP2D, then the second stage will be implemented with an additional 15 response-evaluable patients treated."
1587239|NCT02330562|Drug|BEV|BEV 10 mg/kg IV infusion administered for all cohorts in Phase 1 only.
1587240|NCT02330549|Drug|Cenicriviroc 150 mg|CVC 150 mg, administered orally once daily and taken every morning with food
1587241|NCT02330549|Drug|Matching placebo|Matching placebo administered orally once daily and taken every morning with food
1587242|NCT02330536|Device|Insufflation of carbon dioxide (CO2)|After patients were positioned, CO2 was insufflated into right pleural cavity at eight or sixteen L/min. during video-assisted thoracoscopic surgery, thoracic pressure, hemodynamic and respiratory parameters were recorded.
1587243|NCT02330523|Device|allograft + x-link collagen membrane|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Allograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. X-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
1587312|NCT02330029|Drug|Radix curcumae|Radix curcumae (~10g)
1587313|NCT02330029|Drug|Fingered citron|Fingered citron (~10g)
1587314|NCT02330029|Drug|Tuckahoe|Tuckahoe (15g)
1587244|NCT02330523|Device|xenograft + non-x-link collagen|Following resolution of any periodontal issues in the region of study and administration of pre-surgical antibiotic, minimally traumatic extraction with periotomes and flap reflection will be performed. Xenograft will be placed according to randomization schedule and in quantity to fill the extraction socket and mimic surrounding ridge dimension. Non-x-link collagen membrane will be trimmed to extend at least 2 mm beyond the margins of the defect, and soft tissue flaps will be re-approximated using resorbable Vicryl® 6-0.
1587245|NCT02330497|Procedure|Radiofrequency Ablation under EUS|Pancreatic radiofrequency ablation under endoscopic ultrasonography guidance Procedure under general anesthesia Punction of the pancreatic lesion and aspiration of the liquid if present / then thermal ablation with a 18G needle (50 W during 10 secondes) - only one session
1587246|NCT02330484|Behavioral|Give incentives to patients based on their own HbA1c improvement|Give incentives to patients based on their own HbA1c improvement
1587247|NCT02330484|Behavioral|Give incentives to physician based on their patient's HbA1c improvement|Give incentives to physician based on their patient's HbA1c improvement
1587248|NCT02330471|Procedure|Spray|surgical method to achieve intraoperative hemostasis by a superficial electrocoagulation of 80 Watt voltage
1587249|NCT02330471|Procedure|Forced|surgical method to achieve intraoperative hemostasis by a deep tissue electrocoagulation of 80 Watt voltage
1587250|NCT02330458|Procedure|Small bowel ultrasound|Small Bowel Ultrasound will be performed by a single radiologist using an Acuson S2000 machine with 6 MHz convex and 9 MHz linear array transducers (Siemens, Germany). Participants will be asked to not eat for at least 8 hours prior to the ultrasound, and to drink 500ml of a fluid of their choice just prior to the SBUS, for bowel distension and better visualization. Bowel wall thickness (BWT), the length of any segment of thickened bowel wall >3mm, hyperemia using doppler, and the presence of free fluid, stricture, intestinal dilation, or enlarged lymph nodes will be documented
1587251|NCT02330445|Drug|PRTX-100|6 micrograms PRTX-100 per kilogram of body weight administered via infusion
1587252|NCT02330432|Biological|Mycobacterium w|Single daily dose of 0.3 mL of Mw (heat-inactivated Mw [0.5 × 10^9]; Immuvac, Cadila Pharma, Ahmedabad, India) in the deltoid region for 3 consecutive days
1587253|NCT02330432|Other|Best standard care|Antibiotics as early as possible; Norepinephrine > vasopressin > epinephrine for hypotension; Blood glucose 140-180 mg/dL; DVT and stress ulcer prophylaxis; Low tidal volume mechanical ventilation; Standard VAP, CLABSI prevention bundles
1587254|NCT02330419|Drug|Placebo|
1587255|NCT02330419|Drug|Naltrexone|
1587256|NCT02330406|Drug|Anagliptin|Suiny 100 mg
1587257|NCT02330406|Drug|Sitagliptin|Januvia 50 mg Glactiv 50 mg
1587265|NCT02330367|Drug|AC0010|"Stage 1: AC0010 will be administered in escalating dosages in a period of 28-day cycles.
Stage 2: AC0010 will be administered twice-daily at RP2D."
1587266|NCT02330354|Behavioral|Healthy Me, Healthy We|The intervention - Healthy Me, Healthy We - is a 7-month social marketing campaign designed to improve preschool children's (3-4 years) diet and physical activity behaviors.
1587267|NCT02330341|Dietary Supplement|Artemisia dracunculus|
1587268|NCT02330341|Other|Placebo|
1587269|NCT02330328|Other|No Telemetry Monitoring|
1587270|NCT02330328|Device|Telemetry Monitoring|
1587271|NCT02330315|Device|transcranial direct current stimulation (tDCS)|Subjects will receive 20 minutes of either active or sham tDCS at intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. In the sham group, the tDCS device will not be active for the full 20 minutes.
1587272|NCT02330315|Device|transcranial ultrasound (TUS)|Subjects will receive 20 minutes of either active or sham TUS. During active stimulation the ultrasound will be active for the full 20 minutes- however, during sham stimulation the ultrasound will not be active for the full 20 minutes.
1587273|NCT02330302|Drug|Ropivacaine|Ultrasound-guided femoral nerve block with Ropivacaine 0.5% 30mls
1587274|NCT02330302|Drug|Ropivacaine|Ultrasound-guided suprainguinal approach to fascia iliaca block with Ropivacaine 0.5% 30mls
1587275|NCT02330289|Behavioral|Normative report card|Personalized visual report card describing physician's laboratory ordering pattern for prior week relative to peers as well as a link to a website tracking lab ordering for the team in real time compared to peer teams.
1587276|NCT02330276|Drug|(+)-Epicatechin|The drug to be tested is (+)-epicatechin, synthesized under GMP standards. Subjects will be given a single oral dose of (+)- epicatechin and followed on an inpatient basis over 24 hours. Three (3) different dose levels will be tested in a randomized, double-blind design: (+)- epicatechin 10 mg, 30 mg, or 100 mg. As this is a pilot study, a placebo arm will not be included.
1587277|NCT02330263|Dietary Supplement|carbohydrate beverage|400ml of 12.8 g/100 ml carbohydrate beverage
1587278|NCT02330250|Other|Pharmaceutical Care|"The patients assigned for the intervention group will receive guidance from a pharmacist (pharmaceutical consultation) in addition to the medical care habitually delivered by the hospital.
The pharmacist will review the drug therapy, identifying current and potential problems related to the drug prescription, making a systematic assessment of the need, effectiveness and safety of all medications and their adequacy to the patient's life routine. A care plan will then be designed along with the patient that may include interventions and/or referral to other practitioners."
1587315|NCT02330029|Drug|Placebo|Placebo is blindly given to patients.
1587316|NCT02330016|Device|Voluma XC|Voluma XC
1587317|NCT02330003|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ.|Second vaccination (only for the test group) of IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL
1587279|NCT02330250|Other|Control|The patients assigned to the control group will receive the medical care habitually provided by the hospital and will be attended by a non-pharmacist professional, who will provide hygiene/nutritional counseling and risk reduction, such as smoking cessation advice; use of estrogen-based contraceptive drugs; exposure to sunlight, proper use of sunscreen and clothes; nutritional guidance on the intake of low saturated-fat food. As usual, information about the use of medication will be provided by the attending physician.
1587280|NCT02330237|Drug|natural gels|whole fruits and vegetables
1587281|NCT02330237|Drug|Placebo|
1587282|NCT02330224|Other|Hypertension Management Intervention|"The multifaceted intervention consists of three main components:
Structured treatment algorithm with fixed dose antihypertensives for high cardiovascular disease risk patients
Motivational conversation by nurses and nurse practitioners for high risk patients at baseline
Telephone based follow-up for all patients by nurses"
1587283|NCT02330211|Biological|Fecal Microbiota Transplant|The study intervention consists of frozen, bottled or encapsulated fecal microbiota preparations that have been screened and prepared to a uniform and rigorous standards by the Microbiome Health Research Institute Inc. FMT is performed by patients receiving a retention enema and swallowing capsules, introducing stool from a healthy donor into their intestinal tract.
1587284|NCT02330211|Biological|Placebo|Placebo administration will consist of both a placebo retention enema and placebo capsules.
1587285|NCT02330185|Device|ultrasonography|spinal anesthesia guided with ultrasonography
1587286|NCT02330172|Other|Injection of neostigmine or sugammadex|"At anesthetic induction, rocuronium 0.45 to rocuronium 0.45 - neostigmine group or rocuronium 0.9 mg/kg to rocuronium 0.9 - sugammadex group will be injected for muscle relaxation.
During surgical procedure, we will monitor train of four (TOF) using nerve stimulator. After operation, neostigmine 50 mcg/kg or sugammadex 4 mg/kgl be injected."
1587287|NCT02330159|Procedure|Novel Wound Healing Protocol|All patients will undergo surgical excision of the pilonidal disease and application of the novel wound healing protocol. After excision, MatriStem MicroMatrix powder will be applied to the wound bed. A MatriStem Multilayer Wound Matrix sheet will then be placed over the MatriStem MicroMatrix, secured in place, then covered with surface dressings. The wound should be left undisturbed for 10-14 days (until the 1st follow-up visit). At the 1st postoperative visit, the wound will reassessed, and a second application of the MicroMatrix to the wound bed may be performed. At subsequent follow-up visits at 1, 3, and 6 months, the wound bed will be measured, photo documentation will be captured, and patients will complete a survey to assess quality of life.
1587288|NCT02330146|Drug|RCT-01|
1587289|NCT02330146|Drug|Placebo|
1587290|NCT02330133|Behavioral|Women's Reproductive Health|Targeted text and video information on website for women aged 25-55 to avoid unplanned pregnancy and sexually transmitted infections
1587291|NCT02330133|Behavioral|Online sexual health content|Online general text-based information about reproductive health issues and strategies for preventing sexually transmitted infections
1587292|NCT02330120|Drug|propofol|
1587293|NCT02330120|Drug|dexmedetomidine|
1587294|NCT02330107|Other|MAT & LAT|"For MAT, the magnetic pellets will have ~200 gauss/pellet magnetic flux densities on average, with a diameter of 1.76 mm, to be put on the 6 selected acupoints of the ear.
For LAT, a laser device (Pointer Pulse™) will be used in this study. This device has a wavelength of 650 nm, an average output power of 2.5 mW, an energy density of 1 minute with 0.54 J/cm2, and a pulse of 10 Hz. A 1-minute treatment using the continuous mode of the device will be directly applied to the reactive region of each of the six selected acupoints on the ear."
1587298|NCT02330068|Drug|citalopram|Cases
1587299|NCT02330055|Procedure|Forty-five degrees elevated upper body position|
1587300|NCT02330055|Procedure|non-elevated upper body position|
1587301|NCT02330055|Device|Noninvasive wrist pulse oximeter (WristOx Model 3150)|The noninvasive wrist pulse oximeter (WristOx Model 3150) is used to measure the SpO2 and the pulse rate of the patient in the first night after delivery.
1587302|NCT02330055|Other|Stop-Bang questionnaire|"The Stop-Bang questionnaire is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient. The STOP Bang questionnaire includes snoring, tiredness, observed apneas, blood pressure, Body Mass Index, age, neck circumference and gender.
The investigators will ask the patient to answer the questionnaire and measure the neck circumference."
1587303|NCT02330055|Other|Epworth Sleepiness Scale|"The Epworth Sleepiness Scale is a well-established clinical tool to quantify daytime sleepiness. It is clinically used for the diagnosis of sleep disorders.
The investigators will ask the patient to complete the questionnaire and will specify that the questionnaire pertains to the patient's pre-admission condition."
1587304|NCT02330055|Other|P-SAP Score|"The P-SAP Score is a well-established clinical tool to quantify the risk factors of Obstructive Sleep Apnea, which can lead to desaturation in the patient.
The investigators will ask the patient to answer the questionnaire and will assess the Mallampati Score. The investigators will also measure the neck circumference and the Thyromental distance."
1587305|NCT02330055|Other|self-reported pain|A verbal numerical rating scale is used to asses the pain during the study-night.
1587306|NCT02330029|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
1587307|NCT02330029|Device|Atractylodes|Atractylodes (~10-15g)
1587308|NCT02330029|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
1587309|NCT02330029|Device|Tangerine Peel|Tangerine Peel (~10g)
1587310|NCT02330029|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
1994766|NCT02927301|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be given as 1200 milligrams (mg) via intravenous (IV) infusion on Day 1 of each 21-day cycle.
1587318|NCT02330003|Biological|Fluarix Prefilled Syringe|Fluarix Prefilled Syringe 0.5mL
1587319|NCT02329990|Dietary Supplement|phosphorus|phosphorus supplement
1587320|NCT02329977|Other|standard barium meal examination|All eligible patients received standard barium meal examination, MRCP and enhanced abdominal CT.
1587321|NCT02329964|Drug|Sugammadex|Sugammadex 2mg/kg was injected to patients to R-S group, as reversal of neuromuscular blockade.
1587322|NCT02329964|Drug|Neostigmine|Neostigmine (pyridostigmine) 0.2 mg/kg mg was injected to patients to S-C-N group, as reversal of neuromuscular blockade.
1587323|NCT02329951|Procedure|Injection|Injection of steroids and local anesthetic / radiofrequency denervation for those with a positive facet block
1587324|NCT02329938|Procedure|Lichtenstein tension free reair|a mesh is apllied on the posterior wall of the inguinal canal and sutured to the inguinal ligament below, to the internal oblique muscle above , and to rectus sheath medially.
1587325|NCT02329938|Procedure|Desarda's repair|the repair is done using a flap of the external oblique aponeurosis sutured to the inguinal ligament below and to the aponeurotic part of the internal oblique muscle above.
1587326|NCT02329925|Device|Tongue Stabilizing Device (TSD)|Tongue Stabilizing Device (TSD) is a preformed appliance for OSA that protrudes the tongue and improves upper airway structure and function during sleep.
1587327|NCT02329912|Device|SmartPill|Application of the SmartPill at the end of surgery
1587328|NCT02329899|Other|Second step of investigations|"Second step according to results of the first step:
exploration of coagulation factors;
factor XIII and fibrinolysis investigations;
investigation of platelet function;
investigation of thrombocytopenia."
1587329|NCT02329873|Behavioral|Respiratory rehabilitation exercise training|The respiratory rehabilitation exercise training package was conducted twice a day and 10-30 minutes per session for 4 days: (a) disease awareness, (b) sputum clearance treatments, (c) pursed lip breathing training, (d) upper-limb exercise with breathing pranayama, (e) walking training with breathing pranayama, and (f) assign a pulmonary rehabilitation program coordinator.
1587330|NCT02329860|Drug|Apatinib|
1587331|NCT02329860|Drug|Placebo|
2008933|NCT03326167|Other|Myocardial Perfusion Imaging by Single Photon Emission Computed Tomography (MPI SPECT)|Evaluation of the improvement of the sensitivity, in tri-truncular patients, provided by the estimation of the coronal reserve by territory, during the realization of a myocardial perfusion tomoscintigraphy on CZT camera dedicated to cardiology (Discovery NM 530 ).
2008934|NCT03326154|Other|No intervention, observational|Observation
1587334|NCT02329834|Drug|Fursemide Injection Solution for subcutaneous administration (80 mg)|Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)
1587335|NCT02329834|Drug|Furosemide Injection, USP|Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.
1587336|NCT02329821|Other|hartmann solution|hartmann solution infusion in patients for hepatic resection
1587337|NCT02329808|Procedure|blood drawing|The association between conventional venous sampling and finger prick dried blood spot (DBS) will be associated by drawing blood in both ways.
1587340|NCT02329782|Behavioral|Adherence Readiness Program|The ARP consists of pre-treatment (including practice trials to determine readiness for and timing of ART initiation), early-treatment, and ongoing maintenance training (using a performance-based, dose regulation mechanism to tailor the amount and intensity) phases
1587341|NCT02329769|Drug|PRO044 SC 6 mg/kg|
1587342|NCT02329769|Drug|PRO044 IV 6 mg/kg|
1587343|NCT02329769|Drug|PRO044 IV 9 mg/kg|
1587344|NCT02329756|Drug|Tranexamic Acid (TXA)|1g Tranexamic acid will be given at the time of delivery. If in 30 minutes, heavy bleeding continues, a 2nd dose will be administered.
1587345|NCT02329756|Drug|Sodium Chloride 0.9%|"Dose 1: 1 gram - to be administered by intravenous injection at an approximate rate of 1 mL/minute to all randomized women approximately 10 minutes prior to induction of anesthesia
Dose 2: 1 gram - If 30 minutes after beginning the cesarean section there is significant bleeding as defined by the need for the transfusion of 4 or more units of blood products, or if there is a rebleed within the 24 hours after the first dose, a second dose may be given. To be administered by intravenous injection at an approximate rate of 1 mL/minute.
The trial treatment injections should not be mixed with blood for transfusion, or infusion solutions containing penicillin or mannitol."
1587346|NCT02329743|Drug|RX-10045|topical therapy
1587347|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
1587348|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
1587349|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10g/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
1587350|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and tuberculin purified protein derivative|Left arm intradermal injection of 0.1ml TB-PPD(50IU/ml) by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 Allergen and TB-PPD only one time in the healthy subjects and the first part of tuberculosis subjects respectively.
1587351|NCT02329730|Biological|1μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 1μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 1μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
1587511|NCT02328469|Drug|Acyclovir|Patients will be treated with intravenous acyclovir 10 mg per kg three times daily for 14 to 21 days.
1587352|NCT02329730|Biological|5μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 5μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 5μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
1587353|NCT02329730|Biological|10μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 10μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 10μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
1587354|NCT02329730|Biological|20μg/ml ESAT6-CFP10 and placebo|Left arm intradermal injection of the placebo of 20μg/ml ESAT6-CFP10 by a syringe(1ml).Observe 30 minutes , if without obvious adverse reaction then right arm intradermal injection 20μg/ml ESAT6-CFP10 by a syringe(1ml). Inject ESAT6-CFP10 and placebo only one time in the second part of tuberculosis subjects.
1587355|NCT02329717|Drug|PBI 05204|PBI 05204 daily dosing
1587356|NCT02329704|Procedure|Diff-Quik staining for morphology evaluation|"Papanicolaou stain (haematoxylin, orange G6, and EA50) gives a clear difference between basophilic and acidophilic cell constituents and thereby enables a detailed examination of chromatin pattern, which is useful in the evaluation of sperm morphology and assessment of presence of immature spermatozoa. Cytoplasmic staining can vary between red and green dependent on ionic strength, pH, and composition of the cell department and the stain (OG6 and EA50).
Morphological assessment for processed portions of semen. As separation process has to minimize the morphological abnormal sperm."
1587357|NCT02329704|Procedure|Motility Evaluation for grade A and B|"The better separation method will insure more progressive sperms after processing.
Grading using A and B scale scored by (WHO 2010) references."
1587358|NCT02329704|Procedure|Concentration (mil/ml)|count of isolated sperms Using Makler chamber for count of sperm for each portion post processing.
1587359|NCT02329704|Procedure|24 H half life|"percentage of active motile to non motile sperms.
Microscopic examination for each sample after 24 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
1587360|NCT02329704|Procedure|48 H half life|"percentage of active motile to non motile sperms.
Microscopic examination for each sample after 48 hours incubation, to evaluate the progressively motile sperm and those non progressive or non motile."
1587361|NCT02329704|Procedure|HBA Testing|"The Hyaluronic Binding Assay (HBA®) is an important diagnostic tool for suspected male infertility in the analysis of semen. In a matter of minutes the HBA® slide provides an answer to the proportion of mature binding spermatozoa in the sample (The HBA® score %).
By using HBA slide we can count the physiologically active sperms at each sample and calculate percentage of active sperms with reference to post processing count from 3rd investigating arm."
1587362|NCT02329704|Biological|Bacterial contamination|Routine bacterial culture using Blood Agar culture plates for 10 micron finally washed samples, to confirm presence of any bacteria contamination caused by carry over during processing.
1587363|NCT02329678|Procedure|Peripical surgery|Thirty patients meeting inclusion criteria were selected and allocated randomly into two groups: collagen membrane group and control group. Clinical and radiographic measurements were recorded during follow up at regular intervals of 0, 3, 6, 9, and 12 months after surgery. The criteria for success included the absence of clinical signs and symptoms, and complete or incomplete radiographic healing.
1587364|NCT02329665|Device|NeedleWays™ System|A total of 50 consecutive subjects scheduled for clinically indicated CT guided needle intervention procedure will be invited to enroll in the study.
1587365|NCT02329652|Device|Networked Neuroprosthetic System for Grasp and Trunk|Receive implanted networked neuroprosthesis
1587367|NCT02329626|Device|PET CT 18 FDG|"Positron emission tomography with 2-deoxy-2-[fluorine-18]fluoro- D-glucose integrated with computed tomography.
This intervention is required for the observational needs of the study."
1587368|NCT02329613|Other|Standard evening meals.|Patients will receive usual evening meals.
1587369|NCT02329613|Other|Improved evening meal|Patients will receive improved evening meals. Improved meals will include enriched soup (with starches, butter, cheese or sour cream), a semi-liquid dairy dessert, fruit or a fruit dessert.
1587370|NCT02329600|Drug|green tea tablets (Green tea extract 5:1) 200 mg|Green tea is a product made from the Camellia sinensis plant. The fresh leaves are used to make medicine. the green tea extract is presented in a form of tablets 200 mg and is taken orally.
1587371|NCT02329600|Drug|Triamcinolone Acetonide|topical corticosteroids (Kenalog in orabase: Bristol-Myers, Squibb, Spain) applied topically 4 times a day i.e. following each meal and at bed time for one month
1587372|NCT02329587|Other|ERP plus tDCS|Participants in the ERP plus tDCS arm will receive an 11-session program, including 10 sessions which include both tDCS and ERP. During these sessions, 20 minutes of anodal tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
1587373|NCT02329587|Other|ERP plus sham tDCS|Participants in the ERP plus sham tDCS arm will receive an 11-session program, including 10 sessions which include both sham tDCS and ERP. During these sessions, 20 minutes of sham tDCS will be delivered over right inferior frontal gyrus prior to the ERP exercise.
1587374|NCT02329561|Drug|Tramadol extended release 200 mg|Tramadol extended release 200 mg: Administration of a single 200mg tramadol extended-release tablet
1587375|NCT02329561|Behavioral|CP/T|Subjects were evaluated for perception and tolerance of electrical current. An experimentally induced pain model utilizing electrical stimulation from the FDA approved Neurometer, as the painful stimulus was used to assess Current Perception Threshold and Pain Tolerance Threshold (CP/T) in young and elderly subjects following administration of tramadol and of placebo.
1587376|NCT02329561|Drug|Placebo|Administration of a single placebo tablet identical in appearance to a 200mg tramadol extended-release tablet
1587377|NCT02329548|Other|Alizarin Red|An Alizarin Red mixture will be applied to all exposed skin below the angle of the mandible. Once applied the patient will be tilted to 70 degrees. Serial photos will be taken once sweat begins and until conclusion of the test.
1587378|NCT02329535|Drug|Micronized progesterone|vaginal caps 400 mg daily up to 36 weeks of gestation
1587517|NCT02328417|Other|Consecutive radical cystectomies|Pre-, intra- and post-operative clinical measures during radical cystectomy clinical process
1587379|NCT02329522|Device|Ultrasonic Cardiac Output Monitor|"An Ultrasonic Cardiac Output Monitor (USCOM; USCOM Pty Ltd, NSW, Australia) is a non-invasive Doppler ultrasonography. It is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD).
USCOM scans will be performed on patients to measure direct and derived haemodynamic variables, which will be performed in the supine position wherever possible. A transducer will be placed on the chest in either the suprasternal position to measure trans-aortic blood flow, or the left parasternal position to measure transpulmonary blood flow."
1587380|NCT02329522|Device|Spirometry|Spirometry assesses lung function through measuring the amount (volume) and/or speed (flow) of air that can be inhaled and exhaled. Patients are regarded as COPD if their Forced expiratory volume in 1 second (FEV1) to Forced vital capacity (FVC) ratio are smaller than 70%. Patients were required to perform three blowing manoeuvres, and post-bronchodilator test results were obtained within 20 minutes to 4 hours after inhaling 400 mg of salbultamol.
1587381|NCT02329509|Procedure|two stage palate surgical repair|two stage palate surgical repair with a hard palate closure at 3 to 4 years old
1587382|NCT02329509|Procedure|One stage Palate Surgical repair|One stage palate repair at the age of 9 to 24 months old
1587383|NCT02329496|Device|Lotus Valve and LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System with the Next Generation Delivery System and LOTUS Edge Valve System, with either the Lotus Introducer or iSleeve Introducer Sets
1587384|NCT02329470|Procedure|Withdrawal of CPAP treatment|Withdrawal of CPAP treatment
1587385|NCT02329457|Biological|Zostavax|varicella zoster vaccine
1587386|NCT02329457|Biological|Normal Saline|normal saline placebo vaccine
1587387|NCT02329444|Procedure|Remote ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 200mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
1587388|NCT02329444|Procedure|Sham ischemic preconditioning|Appropriately sized sphygmomanometer cuff placed around right upper arm; where contraindicated, left arm, with inflation of the cuff up to 50mmHg for 5 minutes, followed by deflation of 5 minutes to allow reperfusion with cycle repeated 3 times.
1587389|NCT02329431|Behavioral|activation curriculum|psychosocial activation curriculum
1587390|NCT02329431|Behavioral|support group|parent directed support group
1587391|NCT02329418|Other|Explaining withholding and withdrawing life-sustaining therapies along with a written document|The document describes the law and the role of family members and medical team in the decision.
1587392|NCT02329418|Other|Explaining withholding and withdrawing life-sustaining therapies following standard procedure|
1587395|NCT02329379|Drug|Levothyroxine|
1587396|NCT02329366|Other|Specimen Collection|. In this study, diabetic patients undergoing DFU debridement under the standard of care will be asked for their permission to collect the debrided tissue for use in scientific research.
1587397|NCT02329353|Drug|Lactobacillus brevis CD2 Lozenges|Each lozenge contains not less than 1 billion Colony forming unit of Lactobacillus brevis CD2
1587398|NCT02329340|Behavioral|Am Academy of Pediatrics print materials|Print materials of injury prevention content.
1587399|NCT02329340|Behavioral|Family safety 1-2-3|Theoretically based school-aged childhood injury prevention videos for families
1587400|NCT02329327|Biological|Andexanet|
1587401|NCT02329301|Drug|MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
1587402|NCT02329301|Drug|Focal MDA with DHAp (Eurartesim)|Eurartesim is the brand name.
1587403|NCT02329288|Drug|Triamcinolone Acetonide|
1587404|NCT02329288|Drug|placebo|
1587405|NCT02329275|Procedure|Testicular biopsy|
1587408|NCT02329249|Behavioral|Smokefree Partners: 21 Days to Freedom|Treatment subjects, who chose a quit date, were given 21 sessions to be viewed one session (i..e, one day) at a time, and an in-person smoking cessation coach to support them through their quit process via tailored email or phone coaching messages. Treatment users were encouraged to use pharmacological aids in their quit attempt, but smoking cessation aids were not provided.
1587409|NCT02329249|Other|Wait-List Control|Subjects randomized to the control condition were placed on a wait-list and given access to the smoking cessation program after 120 days and completion of the 120-day follow-up assessment.
1587410|NCT02329223|Biological|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
1587411|NCT02329223|Other|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
1587412|NCT02329197|Drug|Human Chorionic Gonadotropin (HCG)|intrauterine injection of HCG prior to embryo transfer in an IVF cycle
1587413|NCT02329184|Drug|MYK-461|
1587414|NCT02329171|Drug|Imiquimod|Imiquimod 5% cream will be administered in a vaginal applicator, containing 12,5 mg of imiquimod (one sachet). The cream will be self-administered three times per week, by use of a vaginal applicator.
1587415|NCT02329171|Procedure|LLETZ|Standard treatment consists of a LLETZ procedure, in which excision of the transformation zone and macroscopic lesions is performed by a monopolar loop electrode, under local anaesthesia. The excision is usually performed in two or three steps, depending on the size of the lesions.
1587416|NCT02329158|Drug|6% hydroxyethyl starch|
1587417|NCT02329145|Procedure|renal denervation|
1587418|NCT02329132|Drug|Ranibizumab|Each eye will be treated with three initial monthly injections of intravitreal ranibizumab 0.5 mg (Lucentis), followed by retreatment as needed, guided by monthly clinical examinations including biomicroscopy, VA measurement, and optical coherence tomography (OCT) examination.
1587419|NCT02329119|Other|electrophysiological recordings|
1587518|NCT02328404|Drug|50,000 IU vitamin D3|Film-coated tablet Biodal 50,000 IU containing cholecalciferol 50,000 IU
1587420|NCT02329106|Device|Irreversible electroporation (IRE)|Irreversible electroporation (IRE) is a new, minimal-invasive image-guided treatment method for tumors not amenable for surgical resection or thermal ablation, due to vicinity near vital structures such as vessels,bile ducts and diaphragmatic dome.
1587422|NCT02329080|Drug|Methotrexate|methotrexate 3.5 g/m2 on day 1 courses 1, 2,3 of MATRIX regimen
1587423|NCT02329080|Drug|Rituximab|Rituximab 375 mg/m2 as conventional IV infusion on day 0 courses 1, 2,3 (MATRIX regimen) and on day 1 courses 4,5,6 (R-ICE)
1587424|NCT02329080|Drug|Cytarabine|Cytarabine 2 g/m2 every 12 hours, in 3-hr infusion on days 2,3 courses 1, 2,3 (MATRIX regimen)
1587425|NCT02329080|Drug|Thiotepa|Thiotepa 30 mg/m2 in 30 minutes infusion on day 4 courses 1, 2,3 (MATRIX regimen) and 5 mg/kg in 250 ml of saline sol. in 2-hrs infusion every 12 hours on day -5 and -4 of conditioning and ASCT
1587426|NCT02329080|Drug|liposomial cytarabine|Intrathecal liposomial cytarabine 50 mg on day 5 courses 1, 2,3 (MATRIX regimen) and on day 4 courses 4,5,6 (R-ICE)
1587427|NCT02329080|Drug|Etoposide|Etoposide 100 mg/m2/d in 500 mL saline sol. in 30 minutes on day 1-2-3 courses 4,5,6 (R-ICE)
1587428|NCT02329080|Drug|Ifosfamide|Ifosfamide 5 g/m2 in 1.000 mL saline sol. in 24-hour infusion on day 2 courses 4,5,6 (R-ICE)
1587429|NCT02329080|Drug|Carmustine|BCNU (carmustine) 400 mg/m2 in 500 mL glucose 5% sol. in 1-hr infusion on day-6 of conditioning and ASCT
1587430|NCT02329080|Radiation|whole brain radiotherapy|whole-brain irradiation 36 Gy + tumor- bed boost 10 Gy in patients with residual disease in the parenchymal brain/cerebellum.
1587431|NCT02329067|Other|walnuts|consumption of 43 g walnuts per day
1587432|NCT02329054|Drug|Favipiravir|"Group A1: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.
Group A2: Day-0 (inclusion), h0: 2400 mg; h8: 2400 mg; h16: 1200 mg. Day-1 to Day-9: 1200 mg bid.
Group C: daily dosages will be adapted to their body weight."
1587433|NCT02329041|Device|McGrath Series 5|one kind of videolaryngoscopes, which are widely used in airway management.
1587434|NCT02329041|Device|Airtraq|another kind of videolaryngoscopes, which are also widely used in airway management.
1587435|NCT02329028|Device|Prehospital mini-EEG|Observational
1587436|NCT02329015|Behavioral|Yoga-informed Health and Wellness Program|The HWP will be comprised of physical postures, breathing exercises, a period of sitting in stillness (meditation) and relaxation provided two times per week, 45 minutes per session, for the entire school year (Sept. - June).
1587437|NCT02329015|Behavioral|Physical Education Class|Standard physical education
1587438|NCT02329002|Device|Magnetic resonance imaging|MR imaging protocol should include a thin-slice (3-4 mm) short TI inversion recovery (STIR) sequence or fat-saturated T2-weighted images in axial direction. Furthermore, a 3D-T1 weighted sequence with isotropic voxels will be obtained, with reconstruction in 3 directions. If suspicious lesions are detected, additional MR imaging has to be performed, including contrast-enhanced images.
1587439|NCT02328989|Device|Pessary|The device will be placed in the vagina during the consultation. It is rinsed in sterile water for lubrification and left in place until delivery or remove at 36 weeks in case of no delivery before. There is no need to use any analgesia. The good position of the pessary is checking in the same time than the placement with digital examination.
1587440|NCT02328976|Other|functional Magnetic Resonance Imaging (fMRI)|both chronic and episodic patients with migraine have a specific functional Magnetic Resonance Imaging (fMRI)
1587441|NCT02328963|Drug|Everolimus|"Everolimus : 0.75 bid, targeted to 3-8 ng/ml
Cyclosporin A :
CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.
Corticosteroids :
Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study
Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
1587442|NCT02328963|Drug|mycophenolic acid|"Mycophenolic acid :
1080 mg bid for one month, then 720 mg bid
Cyclosporin A :
CsA target ranges for Arm 1 will be 100-200 ng/mL from Day 3 to Month 2, decreasing to 75-150 ng/mL from Month 2 to Month 4 and 25-50 ng/mL from Months 6 to 12.
Corticosteroids :
Méthylprednisolone: 500 mg at Day 0, 120 mg à Day 1. Prednisone or equivalent: 20 mg/d from Day 3. Corticosteroid dosing will be tapered according to center standard practice but to not less than 5 mg per day for the duration of the 12-month study
Basiliximab :Day 0: 20 mg ; Day 4: 20 mg"
1587443|NCT02328950|Drug|Fludarabine and Cytarabine followed by IV busulfan and cyclophosphamide|Fludarabine (F) 30 mg/m²/day for 5 days (day -12 to day-8) Cytarabine (A) 2g/m²/day for 5 days (day -12 to day-8) Bulsufan (Bu) 0.8mg/kg/day for 3 days (day -7 to day-5) Cyclophosphamide(Cy) 1.8g/m²/day for 3 days (day -4 to day-3)
1587444|NCT02328937|Device|etafilcon A|spherical hydrophilic soft contact lens worn in a daily wear modality
1587445|NCT02328937|Device|lotrafilcon B|
1587446|NCT02328937|Device|comfilcon A|
1587447|NCT02328924|Other|LH value|analyzed LH value in the the arms of the study, fixed and flexible protocols
1587448|NCT02328911|Device|Laser treatment|Laser energy will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits therapeutic dual-wavelength infrared laser energy as well as red visible light.
1587449|NCT02328911|Device|Sham treatment|A sham treatment will be applied to the skin of the back and feet manually by physician though a device with a movable head, in contact with the skin, that emits only red visible light.
1587450|NCT02328898|Device|Cre8 Stent|Comparison of the Resolute Integrity stent with the Cre8 stent.
1587451|NCT02328898|Device|Resolute Integrity stent|
1587452|NCT02328885|Other|DLI of the 20 fraction of the UCBT|Administration of 20 fraction of the UCBT
1587453|NCT02328872|Device|Molecular testing for HPV|Molecular testing for HPV with a test allowing partial genotyping for separate identification of types 16/18 from cervical samples. The technology used in this trial will be approved by the Therapeutic Goods Administration (TGA) Australia. It will identify the major HPV oncogenic genotypes in a pool and separately identify HPV 16 and 18. It will also satisfy performance criteria for relative sensitivity and specificity compared to Hybrid Capture 2 (HC2 ) as articulated by Meijer et al, 2009, Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older.
1587591|NCT02327832|Drug|bone marrow-derived mesenchymal stem cells|
1587454|NCT02328872|Device|Liquid Based Cytology|The liquid based cytology (LBC) used in this trial will be will be approved by the Therapeutic Goods Administration (TGA) Australia for LBC and appropriately validated and (TGA approved) to perform human papillomavirus testing from a cytology sample.
1587455|NCT02328859|Other|Virtual Reality Gait Training|A Virtual Gait Retraining System (VGRS) will be used to train amputees for six weeks. the system consists of an actuated treadmill, a virtual environment and an avatar
1587456|NCT02328859|Other|Treadmill Gait Training|A conventional treadmill with no visual display will be used to gait train amputees for a period of six weeks.
1587457|NCT02328833|Other|Experimental strategies of guidelines implementation|Experimental strategies of Depression Guidelines implementation in Primary Care Centers. The active process includes the establishment of local implementation teams, seminars, regular feedback and follow-up visits for four months.
1587460|NCT02328807|Procedure|Radio-Frequency Ablation (RFA)|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
1587461|NCT02328794|Behavioral|E-cigarette free access|Participants in this arn will be given free access to e-cigarettes to help quit smoking
1587462|NCT02328794|Behavioral|E-cigarette/NRT/Zyban/Chantix Choice|Participants in this arn will be given free access to cessation aids to help quit smoking
1587463|NCT02328794|Behavioral|Outcome Incentive arm|Participants in this arm will be earn incentives across 6 months for verified abstinence.
1587464|NCT02328794|Behavioral|Loss framing incentive arm|Participants in this arm will be told they have a pre-funded account with money that is theirs if they quit smoking.
1587465|NCT02328794|Behavioral|Control|Participants will have access to information and advice on quitting smoking. This is a control and no actual intervention will be applied.
1587466|NCT02328781|Device|Drug-eluting stent|
1587467|NCT02328768|Drug|Omegaven|
1587468|NCT02328755|Drug|peg-IFN-α|
1587469|NCT02328755|Procedure|Hematopoietic Cell Transplant (HCT)|
1587470|NCT02328755|Drug|Calcineurin Inhibitor|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
1587471|NCT02328755|Drug|Methotrexate|Administered along with HCT for Graft Versus Host Disease (GVHD) prophylaxis.
1587472|NCT02328742|Biological|Hysteroscopy + endometrial biopsy|"The day of the first diagnostic hysteroscopy an endometrial biopsy is performed (biopsy A1). These biopsies will be used for the evaluation of TGFbeta, Activin A and inhibin.
This intervention is required for the observational needs of this study."
1587473|NCT02328742|Other|Telephone call|"Patients will be contacted via telephone 6 months after first hysteroscopy.
This intervention is required for the observational needs of this study."
1587474|NCT02328742|Biological|Resection + endometrial biopsy|"If patients are found to have synechia or another intracavitary pathology, resection is scheduled 1-2 months later. A second endometrial biopsy is performed at this time.
This intervention is required for the observational needs of this study."
1587475|NCT02328742|Biological|Follow-up hysteroscopy + endometrial biopsy|"For patients having had resection, a follow-up hysteroscopy is performed 1 to 3 months later. An endometrial biopsy will be performed at this time.
This intervention is required for the observational needs of this study."
1587476|NCT02328729|Procedure|mandibular block with Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
1587477|NCT02328729|Procedure|C-CLAD-IL with Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
1587478|NCT02328729|Procedure|Infiltration with Epinephrine|Delivery of infiltration anesthesia for dental treatment with Lidocaine HCl 2% with 1:100,000 Epineprine
1587479|NCT02328729|Procedure|Mandibular block without Epinephrine|Delivery of mandibular block anesthesia for dental treatment with Mepivacaine 3% without Epineprine
1587480|NCT02328729|Procedure|C-CLAD-IL without Epinephrine|Delivery of C-CLAD-ILanesthesia for dental treatment with Mepivacaine 3% without Epineprine
1587481|NCT02328729|Procedure|nfiltration without Epinephrine|Delivery of infiltration anesthesia for dental treatment with Mepivacaine 3% without Epineprine
1587482|NCT02328716|Procedure|Cytoreduction|Cytoreduction
1587483|NCT02328716|Drug|Hipec with Cisplatin|Intraoperative Intraperitoneal Hyperthermic Chemotherapy (Hipec)+Cisplatin
1587484|NCT02328703|Other|Reiki Therapy|Reiki is a biofield energy therapy that is based on the idea that there is a universal energy that supports the body's innate healing abilities. A trained Reiki Master uses their hands as a conduit of the energy that goes naturally to any area of the recipient's body where it is needed. This provides a means for life force energy to recharge and rebalance the human energy fields, creating optimal conditions needed by the body's natural healing system.
1587485|NCT02328690|Other|Binaural Beat Technology|A phenomenon when two nearly similar frequencies (between 30-1000 hertz [Hz]) are presented to each ear and the brain detects the difference between the two sounds. These two sounds are processed in the superior olivary nucleus of each hemisphere of the brain. This integration of brain hemispheres produces a frequency that in turn affects the reticular activating system which alters the electrical potentials of the thalamus and cerebral cortex changing brainwave frequency.
1587486|NCT02328664|Procedure|Flexible sigmoidoscopy or colonoscopy|Depending on the localization of the scar of the malignant polyp, either a flexible sigmoidoscopy or colonoscopy will be done to take biopsies from the polypectomy scar.
1587512|NCT02328456|Other|SMS and free eye drops|The SMS reminder message will sent to the SMS associated with free eye drops group patients 1 week and 1 day before there appointment to remind them the exact time and address of the revisit appointment.The eye drops will be offered free to the the SMS associated with free eye drops group patients when they revisit on time.
1587513|NCT02328443|Drug|Midazolam|
1587514|NCT02328443|Drug|itraconazole|
1587515|NCT02328443|Drug|rifampicin|
1587516|NCT02328430|Device|Kinnect 3 camera|comparison of Kinnect 3 measures of chest wall movement during standard spirometry
1587487|NCT02328651|Drug|Ribavirin plus Xiao'er jiebiao oral liquid|"For mild (Phase I) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, ivgg, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.
For moderate (Phase II) patients:
recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2~5ml/kg,iv, Bid~tid）"
1587488|NCT02328651|Drug|Ribavirin|"For mild (PhaseI) patients : recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip.
For moderate (PhaseII) patients: recommended treatment according to naitonal guildeline for treatment of mouth-foot-hand diseases 2010, including ①treatment for control symptoms ② ribavirin 15mg/kg/d（ diluted in 100ml 5%GS），qd, intravenous drip, in combination using of Xiaoer jiebiao oral liquid 5 ml, bid for children aged 1-2 years, tid for children aged 3-5 years.③anti-intracranial pressure treatment: mannitol 2~5ml/kg, iv, Bid~tid）"
1587489|NCT02328638|Behavioral|Parent Education Program|The PEP intervention consists of didactic sessions regarding basic information about Autism Spectrum Disorders.
1587490|NCT02328638|Behavioral|Manual-based Behavioral Treatment|The Manual-based Interdisciplinary Behavioral Treatment consists of nutritional and behavioral interventions to improve dietary intake (increase water, decrease sweetened beverages and snack foods, improve balanced diet), increase exercise, and teach behavioral strategies to address barriers to these goals.
1587491|NCT02328612|Other|Intravenous infusion of cells|"The treatment administration will be infused intravenously to the subjects after randomization:
An hour after the end of the eASCs administration, all subjects will be given an intravenous dose of LPS. Subjects will be allowed to leave in the evening once deemed clinically stable by the investigator."
1587492|NCT02328599|Procedure|Bariatric surgery involving Roux-en-Y gastric bypass|Subjects previously underwent Bariatric surgery involving Roux-en-Y gastric bypass (RYGB) surgery at one of the 4 participating sites and will be followed prospectively.
1587493|NCT02328599|Procedure|Bariatric surgery involving Laparoscopic adjustable gastric banding|Subjects previously underwent Bariatric surgery involving laparoscopic adjustable gastric banding (LAGB) surgery at one of the 4 participating sites and will be followed prospectively.
1587494|NCT02328599|Procedure|Bariatric surgery involving Laparoscopic sleeve gastrectomy|Subjects previously underwent Bariatric surgery involving laparoscopic sleeve gastrectomy (LSG) surgery at one of the 4 participating sites and will be followed prospectively.
1587495|NCT02328586|Other|Group Acupuncture|
1587496|NCT02328573|Behavioral|Communal singing|
1587497|NCT02328547|Drug|Fecal microbiota transplantation capsules|Fecal microbiota transplantation capsules contain extensively screened donor stool and are prepared by OpenBiome, Medford, MA.
1587498|NCT02328547|Drug|Placebo capsules|Placebo capsules prepared by OpenBiome, Medford, MA
1587499|NCT02328534|Behavioral|Blastocyst Formation Rate|"Embryos developed at Day3 cultures, are continued for Day5 culture tho reach blastocyst stage. The percentage of blastocyst produced from cleaved embryos to be evaluated ar rate.
The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
1587500|NCT02328534|Procedure|Blastocyst Rate|"Day 5 embryo transfer achieved pregnancy are compared with total embryo transfer cases at Day5.
The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time.
Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam."
1587501|NCT02328534|Procedure|Pregnancy Rate|"All pregnancy achieved from all ET. Pregnancy confirmed with day 12 after Et and repeated with 48 hours after 1st exam.
The evaluation with doe one time using Density Gradient semen one time and Swimming down semen another time."
1587502|NCT02328521|Drug|Nicorandil|Nicorandil is given once before PCI and given 3 times daily for 30 days after PCI.
1587503|NCT02328521|Drug|nicorandil placebo|Nicorandil placebo is given once before PCI and given 3 times daily for 30 days after PCI.
1587504|NCT02328508|Device|Hyperbaric oxygen therapy|HBOT was carried out in a hyperbaric chamber for 120-min per session, five days a week for four consecutive weeks (20 treatment sessions).
1587505|NCT02328495|Drug|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.
Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
1587506|NCT02328495|Other|Bladder Filling|"Patients in bladder filling group will be instructed to drink one liter of water and to avoid urination during the one and half hour period before office hysteroscopy procedure..A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach . All the procedures will be diagnostic.
Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used."
1587507|NCT02328482|Drug|Cabaletta 30gr|Cabaletta 30 g for IV infusion administered every week over an additional 52 weeks
1587508|NCT02328469|Drug|symptomatic therapy|patients will receive symptomatic therapy with antipyretics, analgetics, antiemetics and parenteral hydration: metamizole, paracetamol, thiethylperazine, saline
1587509|NCT02328469|Drug|Ceftriaxone or Doxycycline|beside symptomatic therapy (metamizole, paracetamol, thiethylperazine, saline), patients with proven or probable Lyme neuroborreliosis will be treated with ceftriaxone 2 g intravenously once daily for 14 days OR doxycycline 100 mg orally twice daily for 14 days
1587510|NCT02328469|Other|questionnaire|Control subjects will be asked to answer a questionnaire asking about the presence and frequency of nonspecific symptoms.
1587519|NCT02328404|Drug|Placebo|Placebo film-coated tablet of Biodal 50,000 IU
1587520|NCT02328378|Procedure|Quadratus Lumborum block|Patients will receive a bilateral Quadratus Lumborum block using 0.125% Bupivacaine in a dose of 0.2ml/kg body weight, after the end of surgery.
1587521|NCT02328365|Other|Structured medical follow-up after operation|Patients in the intervention arm are seen by a physician on the 4th or 5th postoperative day before discharge to pick up and manage any medical problems, and are furthermore seen in the cardiology clinic 1 month after operation, and in the pulmonary medicine clinic 1 and 3 months after operation
1587522|NCT02328352|Procedure|BP selfstanding felt|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. Ten rabbits (hereafter defined as BPR1-BPR10) will receive 2x2cm2 samples of BP selfstanding felt in a pocket created between muscular fascia and large muscles of the abdominal wall.
1587523|NCT02328352|Procedure|PP mesh|intervention of laparotomy with the incision of 10 cm navel-pubis will be performed, splaying of the skin and subcutaneous layers, then will be incised the fascia plane, and muscles. A 2x2cm2 sample of PR (polypropylene) prosthesis was implanted without stitches into a pocket between large abdominal muscle and abdominal fascia
1587524|NCT02328352|Procedure|BP intraperitoneal mesh|Laparotomy on the linea alba carried out deeply for entering into the abdominal cavity, a 2x2cm2 BP sample implantation with the rough side facing the parietal peritoneum surface and the smooth and brilliant surface facing to the visceral peritoneum and gut
1587525|NCT02328352|Procedure|control group|observational intervention in 5 rabbits with the same body weight and the same age will be observed and will be feeded in the same way of the BP device intraperitoneal implanted group
1587526|NCT02328339|Other|Tea|Black tea infusion equivalent to approximately 530 mg total polyphenols expressed as gallic acid equivalents
1587527|NCT02328339|Other|Placebo|Placebo matched to tea with respect to taste and appearance
1587528|NCT02328326|Other|CO-IMPACT|Primary care-integrated activation and social support intervention that provides tools and training in patient activation and effective support techniques for patients and their family supporter
1587529|NCT02328326|Other|PACT|participants will receive PACT care for high-risk diabetes, which includes (at primary care team discretion): nurse care manager visits, diabetes education classes, chronic disease self-management groups, telehealth, clinical pharmacist visits
1587530|NCT02328313|Behavioral|Walk with Ease Program|The Walk With Ease Program sets a goal for participants to walk 30 minutes a day five times a week and gives helpful hints on how to achieve this goal.
1587531|NCT02328300|Drug|FLT PET/MR|Each participant will be injected with FLT, a common PET radiotracer for brain tumors and lesions, and then will complete one (1) PET/MR scan.
1587532|NCT02328287|Drug|ALLOB®|Each patient will undergo a single administration of ALLOB® into the failed fusion lumbar level under anesthesia.
1587533|NCT02328274|Procedure|A Modified Technique for Laparoscopic Subtotal Hysterectomy|incorporation of two methods of vessels ligation and laparoscopic in situ morcellation
1587534|NCT02328261|Drug|Icotinib|Icotinib (125 mg tablet) is orally administered three times daily until disease progression or unaccepted toxicity.
1587535|NCT02328248|Procedure|Biological patch|Use biological patch as opposed to plastic patch to repair hiatal hernia laparoscopically
1587536|NCT02328235|Other|High Saturated Fat Diet|"Prior to the high fat diet and after baseline testing, subjects will be asked to eat a standard diet to lead-in to the high fat diet condition. The diet will contain 55% of calories as carbohydrate, 30% as fat, and 15% as protein. The high fat diet will contain 50-60% of calories as fat, 20-30% as carbohydrate, and 10-20% as protein. Subjects will be provided with all of their meals throughout the study."
1587537|NCT02328222|Drug|ESW group|CORTICOSTEDORID TREATMENT WAS AS FOLLOWS: day zero post-transplantation (DP 0), 500 mg/day of MPD; (DP 1), 250 mg MPD; (DP 2), 125 mg MPD; (DP 3), 60 mg MPD; (DP 4), 30 mg MPD; and (DP 5), PREDNISONE AS DOSES 1 MG/KG (1 MONTH) AND A REDUCTION TO ACHIEVE 0.1 MG/KG IN THE 3rd MONTH.
1587538|NCT02328209|Drug|ranibizumab|0.5mg/0.05ml, intravitreal injection, frequency: each 8 or 12 weeks
1587539|NCT02328196|Behavioral|The Danish McGill Ingestive Skills Assessment (MISA-DK)|The MISA measures the performance of dysphagic patients during the patient's usual mealtime routine.
1587540|NCT02328183|Drug|Polymyxin B|administrate drug by 0.75-1.25 mg/kg/dose intravenously q 12 hrs both saline and dextrose solution can be dissolved duration 7-14 days
1587541|NCT02328170|Other|EUROIMMUN Allergy|Immunoblot assay
1587542|NCT02328170|Other|ImmunoCap|Fluoroallergosorbent test
1587543|NCT02328157|Device|Vitrectomy with cataract surgery and toric IOL|
1587544|NCT02328157|Device|Vitrectomy with cataract surgery and common IOL|
1587545|NCT02328144|Drug|Metronidazole|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days
1587546|NCT02328144|Drug|Placebo|Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.
1587547|NCT02328118|Drug|Ranibizumab|A week before 25-gauge vitrectomy, all subjects in Ranibizumab group will receive Ranibizumab 0.5mg/0.05 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
1587548|NCT02328118|Drug|Triamcinolone Acetonide|A week before 25-gauge vitrectomy, all subjects in Triamcinolone Acetone group will receive Triamcinolone Acetone 4mg/0.1 ml intravitreal injection. All patients in this group will receive Triamcinolone Acetonide(4mg/0.1ml) during operation.
1587549|NCT02328105|Drug|carboplatin plus abraxane|
1587550|NCT02328092|Device|rSMS in treatment of Nocturnal Enuresis|Real rSMS (15 Hz at 50% of maximum stimulator output (10 seconds on and 30 seconds off) with a total of 1500 pulses and the hand of the coil upword. The stimulation was repeated for 10 sessions, 5 sessions per week and 2 days off. Sham rSMS received stimulation using the same coil, the same session frequency, in the same setting, but the coil was tilted 90.
1587592|NCT02327819|Dietary Supplement|Branched-chain amoni acids (BCAA)|
1587593|NCT02327819|Dietary Supplement|non-BCAA protein supplement|
1587594|NCT02327806|Device|pulsed electromagnetic field therapy|
1587551|NCT02328079|Drug|Steroids (Prednisolone) and Steroids plus Antiviral (Prednisolone + acyclovir)|Group allocations: First group (prednisolone 60 mg /day IM /IV), second group (Prednisolone IM/ IV 60 mg /day + IV acyclovir 500 mg three time /day for 6 consecutive days) then reduced by 10 mg /day (for a total treatment time for 12 days) were placed in serially-numbered opaque closed envelopes. Each patient was placed in the appropriate group after opening the corresponding sealed envelope.
1587552|NCT02328066|Device|NBI used by trained endoscopists|Examination of colon lesions, using NBI and NICE classification, by endoscopists who previously performed an easy learning program. The learning program consists on the reading of two reference articles and a tutorial explaining the NICE classification. This tutorial shows several lesions and describes the characteristic features in which the classifications focus on.
1587553|NCT02328053|Procedure|collagen crosslinking group|collagen crosslinking with riboflavin and Ultraviolet A
1587554|NCT02328053|Drug|Topical anti-fungal therapy|topical antifungal medications like natamycin eye drops and voriconazole eye drops
1587555|NCT02328040|Drug|Sitagliptin and insulin/novolog via CL Part B|In the treatment arm the participant receives a single dose of sitagliptin with closed loop with insulin/novolog (Sitagliptin and insulin/novolog via CL), Part B
1587556|NCT02328040|Drug|placebo and insulin/novolog via CL Part A|In the control arm patient receives a placebo pill with the closed loop with insulin/novolog (placebo and insulin/novolog via CL), Part A
1587558|NCT02328014|Drug|ACP-196 and ACP-319|Dose escalation
1587559|NCT02328014|Drug|ACP-196 and ACP-319|Dose expansion
1587560|NCT02328001|Behavioral|Debriefing endoscopists of the procedure accessory costs|Informing endoscopists of the number of accessories used and the dollar value of the accessories
1587561|NCT02327988|Other|Cryotherapy|
1587562|NCT02327988|Device|Laser therapy|
1587563|NCT02327975|Other|Training group|"The main part of the session included a whole-body strength training, which incorporated chest press, shoulder press, lateral pull-down, seated row, shoulder flexion, chest pulley, hammer curl, biceps curl, triceps curl, triceps pushdown, leg extension, leg curl, lunge, squat, abdominal crunch. To control and equate the intensity between the TG and MG, a method based on the combined use of the prescribed number of repetitions and the OMNI Resistance Scale for the active muscles was used. Previous studies have described the method used for controlling exercise intensity (Colado et al., 2012; Colado et al., 2014).
During 1-3 weeks subjects performed 25 min of exercise at 60% maximum heart rate (HRmax), during weeks 4-6 subjects performed 30 min of exercise at 70% HRmax and during weeks 7-10 subjects performed 35 min of exercise at 80% HRmax."
1587564|NCT02327975|Other|Mobile group|The subjects in this group received the same intervention that trainning group but through a mobile application (whatsapp).
1587565|NCT02327975|Other|Control group|No received intervention.
1587566|NCT02327949|Device|W-Shaped Angular Plate|Treatment of posterior wall fracture of the acetabulum with a W-Shaped Angular Plate
1587567|NCT02327949|Device|Reconstruction Plate|Treatment of posterior wall fracture of the acetabulum with a Reconstruction Plate
1587568|NCT02327936|Drug|Fesoterodine|Administer medication to patients with overactive bladder
1587569|NCT02327936|Drug|Oxybutynin XL|Administer medication to patients with overactive bladder
1587570|NCT02327923|Drug|Lidocaine|Lidocaine intravenous 1.5mg/kg IV bolus at the time of induction followed by IV infusion @ 1.5 mg/kg/hr till the last suture.
1587571|NCT02327923|Drug|Esmolol|Esmolol intravenous bolus 0.5 mg/kg at the time of induction followed by infusion @ 5-15 microgram/kg/min till the last suture.
1587572|NCT02327923|Drug|Paracetamol|Inj. Paracetamol 1 gm IV at the time of induction
1587573|NCT02327923|Drug|Lidocaine|Inj. Xylocaine 2% 3 ml will be infiltrated in skin in all port sites prior to incision.
1587574|NCT02327923|Drug|Propofol|Inj. Propofol 2- 2.5 mg/kg will be given for induction
1587575|NCT02327923|Drug|Fentanyl|Inj fentanyl 1.5mg/kg will be given at the time of induction.
1587576|NCT02327923|Drug|Vecuronium|Inj Veccuronium 0.1mg/kg will be given at induction and for maintenance.
1587577|NCT02327923|Drug|Atropine|Inj Atropine 0.4 mg IV will be given for bradcardia (HR < 50/min)
1587578|NCT02327923|Drug|Ephedrine|
1587579|NCT02327923|Drug|Morphine|
1587580|NCT02327923|Drug|Ketorolac|
1587581|NCT02327923|Drug|Ondansetron|
1587582|NCT02327923|Drug|Bupivacaine|Inj. Bupivacaine 0.25% 10 ml will be infiltrated at incision site after closure.
1587583|NCT02327923|Drug|Tramadol|Inj tramadol 50 mg IV will be given on SOS basis in ward.
1587584|NCT02327923|Drug|Neostigmine|50 mcg/kg for reversal of residual neuromuscular blockade
1587585|NCT02327923|Drug|Glycopyrrolate|10 mcg/kg with neostigmine
1587586|NCT02327910|Other|TOF unit TcPCO2 group|The patients of U group were extubated when TOF ratio greater than 0.9 and TcPCO2 recovery to preoprative(±5mmHg)
1587587|NCT02327910|Other|TOF group|The patients of T group were extubated when TOF ratio greater than 0.9.
1587588|NCT02327871|Device|Esophageal cooling device (and usual standard procedure)|Standard treatments for resuscitation after CA will follow local, national, and international guidelines. Core temperature is measured using urinary Foley catheters and/or arterial temperature monitoring if available. During TH, sedation and analgesia is performed in routine. Neuromuscular blockade is induced to favor cooling and prevent shivering if necessary. Circulatory function is monitored by arterial catheter if necessary and blood pressure is maintained as usually. Hypotension is treated with dobutamine catecholamines titrated according cardiac output monitored using echocardiogram, or PiCCO® systems. Fluid management is left at the discretion of the attending physician. Prognostication after CA uses serial clinical examinations, biomarkers, transcranial Doppler, Electro-Encephalo-Gram, cerebral CT-scan or MRI, and/or Somato-Sensory-Evoked-Potential.
1587589|NCT02327858|Other|Supportive text messages|Patients in all the intervention groups will receive twice daily supportive SMS text messages for 3 months. The messages will be tailored towards improving mood, compliance with medication or targeting abstinence from alcohol in accordance with the primary aims of our study. As far as possible, the majority of the text messages will reflect lessons patients usually learn during CBT and addiction counselling sessions.
1587590|NCT02327832|Procedure|Autologous BMSCs|Cultured autologous bone marrow-derived mesenchymal stem cells
1587598|NCT02327767|Device|Resonating Arm Exerciser|Participants in the exercise group will exercise using the device for 8 exercise sessions for 45 minutes per session for 3 consecutive weeks.
1587599|NCT02327754|Drug|Topiroxostat BID, (Oral daily dosing for 28 weeks)|The dose of topiroxostat is increased up to 160 mg/day in a stepwise manner.
1587600|NCT02327754|Drug|Placebo BID, (Oral daily dosing for 28 weeks)|Subjects randomized to the placebo arm will receive placebo.
1587601|NCT02327741|Drug|plavix|taking plavix more than 12 months
1587602|NCT02327741|Drug|plavix|taking plavix less than 12 months
1587603|NCT02327728|Procedure|Botulinum toxin A injection (5 sites: 12.5U)|
1587604|NCT02327728|Procedure|Botulinum toxin A injection (4 sites: 10U)|
1587605|NCT02327728|Drug|Botulinum toxin A 12.5U|
1587606|NCT02327728|Drug|Botulinum toxin A 10U|
1587607|NCT02327715|Drug|Emtricitabine|emtricitabine were given to each patients from week 28 pregnancy to 24 weeks after delivery
1587608|NCT02327702|Drug|Emtricitabine|emtricitabine were given to each patients at baseline till 48 weeks after delivery
1587609|NCT02327689|Drug|Emtricitabine plus adefovir dipivoxil|emtricitabine plus adefovir dipivoxil were given to each patients for 96 weeks
1587610|NCT02327676|Drug|Emtricitabine|emtricitabine were given to each patients for 48 weeks
1587611|NCT02327663|Drug|Emtricitabine|emtricitabine were given to each patients at baseline and respoonse guided therapy was adopted according HBV DNA level at week 24
1587613|NCT02327637|Behavioral|Moderate Activity|Ambulation 150 feet, two times per day
1587614|NCT02327624|Drug|Clopidogrel|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
1587615|NCT02327624|Drug|Ticagrelor 60|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
1587616|NCT02327624|Drug|Ticagrelor 90|Compare Clopidogrel to two doses of Ticagrelor 60 and 90
1587617|NCT02327611|Drug|Custodiol|
1587618|NCT02327611|Drug|Enriched Ringer's lactate solution|
1587619|NCT02327585|Behavioral|A randomized controlled study of Executive Function training for children with ADHD|Children diagnosis of ADHD are randomized to the experimental condition(Executive Function therapy) or waiting group experimental:participants will receive 12 sessions of executive function therapy weekly no intervention :waiting participants will not be treated with executive function therapy and keep waiting for 12 weeks for comparison
1587620|NCT02327559|Behavioral|Mind in Labor (MIL): Working with Pain in Childbirth|The Mind in Labor (MIL) mindfulness intervention for pregnant women and their partners integrates mindfulness strategies for coping with labor pain and fear and formal mindfulness meditation with traditional childbirth education. The MIL intervention is held over 3 consecutive weekend days (Friday - Sunday) for a total of 16 hours of mindfulness skills training for childbirth preparation and labor pain management. Mindfulness strategies for coping with labor-related pain and fear are taught in an interactive, experiential format, with periods of didactic instruction.
1587621|NCT02327559|Behavioral|Treatment as usual (TAU)|"The treatment as usual TAU active comparison condition includes participation in a standard care childbirth education course, chosen by participants in the TAU arm from a pre-approved list of hospital- and community-based childbirth education courses comparable in length and quality to MIL, but without any mindfulness meditation, mindful movement/yoga, or other core mind/body component (e.g., hypnosis)."
1587622|NCT02327546|Drug|AKB-6548|
1587623|NCT02327546|Drug|Ferrous Sulfate|
1587624|NCT02327520|Other|Colitis with CDI treatment|All patients will be treated with standard treatment
1587625|NCT02327507|Behavioral|Toothpaste & Telephone Support|Mailed toothpaste, messages and telephone support.
1587626|NCT02327494|Drug|neuromuscular blockade|to determine the influence on oxygantion saturation parameters of the administration of neuromuscular blockade drug, rocuronio, to provide intense neuromuscular blockade during laparoscopic colorectal surgery
1587627|NCT02327481|Procedure|3D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,3D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
1587628|NCT02327481|Procedure|2D Laparoscopic Surgery|After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy,2D laparoscopic gastrectomy will be performed with curative treated intent. The type of reconstruction will be selected according to the surgeon's experience.
1587629|NCT02327455|Procedure|Stress Dobutamine Echocardiographic using 4DE System|
1587630|NCT02327442|Radiation|68Ga-NOTA-NFB|In this investigation, 68Ga-NOTA-NFB is employed to a preclinical trial, including radiation dosimetry study in healthy volunteers and the first application in glioma patients, to assess the safety, dosimetry property and evaluate the CXCR4 expression in glioma patients and breast cancer patients.
1587631|NCT02327429|Behavioral|A Chinese menu plan for type 2 diabetes|The intervention is a menu plan, recipes and tips on healthy eating delivered one-on-one between the participant and the facilitator. There will be 4 such one-on-one meetings. The goal is to facilitate behaviour change that results in a healthier diet.
1587632|NCT02327416|Drug|Y peginterferon alfa-2b|In arm 2 and 3, Y peginterferon alfa-2b is used for 96 weeks
1587633|NCT02327416|Drug|Granulocyte-macrophage colony stimulating factor|In arm 3, Granulocyte-macrophage colony stimulating factor is used for 48 weeks intermittently
1587634|NCT02327416|Drug|Entecavir and or adefovir dipivoxil|In arm 1, Entecavir and or adefovir dipivoxil are used for 96 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir and or adefovir dipivoxil are used for 48 weeks.
1587635|NCT02327403|Drug|Belatacept|Conversion from calcineurin-inhibitor to Belatacept maintenance immunosuppression.
1587636|NCT02327390|Procedure|lymph node|Undergo surgery to remove a melanoma-draining lymph node for generation of X-ACT cells in the laboratory
1587637|NCT02327390|Biological|X-ACT|Administered as an IV infusion
1587638|NCT02327377|Behavioral|Online Cognitive Behavior Therapy|
1587639|NCT02327377|Behavioral|Online Education|
1587640|NCT02327351|Other|Biological: TCR alfa beta T cell depletion|
1587641|NCT02327338|Device|thermacare heat wraps|off the shelf thermacare continuous heat wraps made by thermacare to produce low level heat on the neck
1587642|NCT02327338|Drug|Ibuprofen|1200 mg ibuprofen administered 400mg at 4 hour intervals
1587643|NCT02327325|Behavioral|Physical Activity|12-week home-based physical activity program with telephone support. Delivered by a physical therapist and exercise counselor. Comprehensive program including stretching, strengthening and aerobic activity.
1587644|NCT02327325|Behavioral|Cognitive Behavioral Therapy|Telephone-based training in multiple skills for managing low back pain.
1587645|NCT02327312|Device|Stents|Two Trabecular meshwork Micro-Bypass stents into the study eye
1587646|NCT02327312|Procedure|Laser|Laser Trabeculoplasty
1587647|NCT02327312|Device|Laser Trabeculoplasty|
1587648|NCT02327299|Dietary Supplement|Bouillon fortified with FePP|
1587649|NCT02327299|Dietary Supplement|Bouillon fortified with FePP + Stabilizer|
1587650|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4|
1587651|NCT02327299|Dietary Supplement|Bouillon fortified with FeSO4 + Stabilizer|
1587652|NCT02327286|Behavioral|Promote and support healthy behaviors|"Exclusive breastfeeding for 6 months and partial breastfeeding for at least 3 additional months.
Personally monitored weight loss and maintenance with goal: return to pre-pregnancy weight and, if overweight pre-pregnancy, loss of an additional 5% of body weight.
Healthy eating: avoidance of ultra-processed foods, limited intake of oils, sugars and processed foods, increased intake of foodstuffs in their natural state, regular intake of water, dairy products, unsweetened coffee and tea.
A progressive increase in physical activity of at least 150 minutes of moderate or vigorous physical activity/week (7500 steps/day) and reduction of sedentary behavior with monitoring by personally worn devices."
1587653|NCT02327273|Drug|BMS-963272|
1587654|NCT02327273|Drug|Placebo|
1587655|NCT02327260|Behavioral|Video + Motivational interview for CR participation|Patients will be shown a 9 minute video that highlights actual CR patients discussing barriers they overcame to participate in CR, and introductions to the CR staff. The brief, phone-based motivational interview will focus on increasing motivation to participate in CR.
1587656|NCT02327260|Behavioral|Motivational interview for medication adherence|The brief, phone-based motivational interview will focus on increasing motivation to adhere to prescribed cardioprotective medications.
1587657|NCT02327247|Drug|Felodipine|Extended Release Tablets, 10mg
1587658|NCT02327247|Drug|PLENDIL®|Extended Release Tablets, 10mg
1587659|NCT02327234|Drug|ibuprofen|2x 200mg ibuprofen, single dose, blinded in 00 capsules
1587660|NCT02327234|Drug|Placebo|lactose filled 00 capsules to match appearance of ibuprofen intervention
1587661|NCT02327221|Drug|Ovasave|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
1587662|NCT02327221|Drug|Placebo|During CATS29-Double blind phase, two intravenous administrations of study drug will be administered, one at week 0 and another one at week 8.
1587663|NCT02327208|Dietary Supplement|Control|
1587664|NCT02327208|Dietary Supplement|Protein|
1587665|NCT02327208|Dietary Supplement|Carbohydrate|
1587666|NCT02327195|Drug|Methylphenidate HCl|Subjects will be randomly assigned to either the Methylphenidate or the Placebo arm, and be given a 20 mg dose (of Methylphenidate or Placebo) in liquid form (4 mL)
1587667|NCT02327195|Drug|Placebo|20 mg of placebo (PO) will be given 2 hours prior to surgery
1587668|NCT02327182|Drug|MT-4666|
1587669|NCT02327169|Drug|MLN2480|MLN2480
1587670|NCT02327169|Drug|MLN0128|MLN0128
1587671|NCT02327169|Drug|Alisertib|Alisertib
1587672|NCT02327169|Drug|Paclitaxel|Paclitaxel
1587673|NCT02327169|Drug|Cetuximab|Cetuximab
1587674|NCT02327169|Drug|Irinotecan|Irinotecan
1994767|NCT02927210|Drug|Dimethandrolone Undecanoate|Single doses of DMAU in castor oil/benzyl benzoate injections intramuscularly (IM) (80 mg, 240 mg, 480 mg, and 800 mg) or administered subcutaneously (SC) (50 mg, 100 mg and 200 mg).
1587678|NCT02327130|Device|Isomark Canary™|Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™, that is intended to determine the breath delta value of breath samples collected from critically ill patients.
1587679|NCT02327117|Drug|Tranexamic Acid|
1587680|NCT02327117|Drug|Normal saline|
1587681|NCT02327104|Behavioral|Mindfulness Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems, and to prevent relapses.
1587682|NCT02327104|Other|Brazilian Ministry of Health Protocol|The control group will receive maintenance sessions based on the Ministry of Health protocol after the four sessions of cognitive-behavioral approach.
1587683|NCT02327091|Drug|alfacalcidol|One group of 47 subjects received alfacalcidol 0.5 mcg/day and the other group received placebo
1587684|NCT02327078|Drug|Nivolumab (Phase 1)|specified dose and dosing schedule
1587685|NCT02327078|Drug|Epacadostat (Phase 1)|oral twice daily continuous at the protocol-defined dose
1587686|NCT02327078|Drug|Chemotherapy (Phase 1)|Specified dose on specified days
1587687|NCT02327078|Drug|Nivolumab (Phase 2)|specified dose and dosing schedule
1587688|NCT02327078|Drug|Epacadostat (Phase 2)|oral twice daily continuous at the protocol-defined dose
1587689|NCT02327065|Device|EUS-FNA (EchoTip Ultra)|FNA,Fine needle aspiration
1587690|NCT02327065|Device|EUS-FNB (EchoTip ProCore)|FNB,Fine needle biopsy
1587692|NCT02327039|Drug|Dapagliflozin|Sodium glucose cotransporter-2 inhibitor
1587693|NCT02327039|Drug|Placebo|Tables of Dapagliflozin placebo
1587694|NCT02327026|Procedure|bag-valve-mask ventilation|Airway management including initial bag-valve-mask ventilation by the medical team during OHCA. When standard bag-valve-mask ventilation is possible, the patient will be intubated in case of a return of spontaneous circulation. When standard bag-valve-mask ventilation is impossible or in case of massive regurgitation of gastric content (after randomisation), intubation of patient is the preferred alternative.
1587695|NCT02327026|Procedure|tracheal intubation|Tracheal intubation during OHCA by the medical team: The standard intubation procedure is to use a non-styletted tube and no sedation. When standard laryngoscopy-assisted intubation is not possible, an alternate procedure will be used based on the French consensus conference guidelines on difficult airway management
1587699|NCT02327000|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
1587700|NCT02327000|Drug|Pregabalin 300mg|GLA5PR GLARS-NF1 tablet 300mg/day(Pregabalin 300mg once a day)
1587701|NCT02326987|Drug|Pregabalin 150mg|GLA5PR GLARS-NF1 tablet 150mg/day(Pregabalin 150mg once a day)
1587702|NCT02326987|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day)
1587703|NCT02326974|Drug|T-DM1|Participants will receive Trastuzumab emtansine (T-DM1) by IV every 3 weeks for 6 doses; for a total of 18 weeks of treatment.
1587704|NCT02326974|Drug|Pertuzumab|Participants will receive a loading dose of pertuzumab by IV on Cycle 1 Day 1 followed by maintenance dose of pertuzumab by IV every 3 weeks for a total of 6 doses; for a total of 18 weeks of treatment.
1587705|NCT02326974|Procedure|Excision of tumor/mastectomy|Definitive breast cancer surgery (excision or mastectomy) marks the end of protocol mandated therapy.
1587706|NCT02326961|Device|Celution Device|ADRCs Prepared using the Celution Device
1587707|NCT02326961|Other|Placebo|Inactive Placebo
1587708|NCT02326935|Biological|Autologous adipose derived mesenchymal cells|Autologous adipose derived mesenchymal cells, 150M cells deployed via two (2) treatments via intravenous injection.
1587709|NCT02326922|Device|Metraplant-E levonorgestrel-releasing intrauterine device|Metraplant-E insertion and follow up for 6 months
1587710|NCT02326909|Device|Optical Coherence Tomography|Single Optical Coherence Tomography measurement of upper urinary tract tumour taken during ureterorenoscopy
1587711|NCT02326909|Device|Optical Coherence Tomography|A single 1300 nm OCT measurement will be performed during ureterorenoscopy in patients with upper urinary tract tumour(s)
1994768|NCT02927210|Drug|Placebo|Placebo injections that look like the DMAU injections but with no active ingredients
1994769|NCT02926339|Behavioral|Teens Against Tobacco Use presentation|Students receive a series of 3 anti-tobacco presentations delivered by older peers
1587715|NCT02326870|Device|AutoLap|
1587716|NCT02326844|Drug|BMN 673 (talazoparib)|1 mg by mouth (p.o.) once daily on 28-day cycles until disease progression
1587720|NCT02326805|Other|Laboratory Biomarker Analysis|Correlative studies
1587721|NCT02326805|Other|Placebo|Given SC
1587722|NCT02326805|Biological|Rilimogene Galvacirepvec|Given SC
1587723|NCT02326792|Other|Exercise|The groups will perform the trunk extensor exercise on a roman chair by 2 x week, for a total of 10 weeks of training (20 sessions). The load will be progressive and tested to each 14 days with regard to the number of repetition reached by the participant. The exercise is safe and will be supervised by a health sport professional.
1587724|NCT02326779|Drug|Acetylsalicylic acid|Acetylsalicylic acid (Aspirin) 100 mg OD for 3 years
1587725|NCT02326766|Dietary Supplement|KRG|5g Korea red ginseng (KRG)
1587726|NCT02326766|Dietary Supplement|Placebo|5g placebo
1587727|NCT02326753|Device|No. 7 oral airway|the use of 7 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
1587728|NCT02326753|Device|No. 8 oral airway|the use of 8 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
1587729|NCT02326753|Device|No. 9 oral airway|the use of 9 cm sized-oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC)
1587730|NCT02326740|Drug|gevokizumab|
1587731|NCT02326740|Drug|Placebo|
1587732|NCT02326740|Drug|gevokizumab open-label|
1587733|NCT02326727|Drug|Ropivacaine|Epidural analgesia
1587734|NCT02326727|Drug|Fentanyl|General Anesthesia
1587735|NCT02326727|Drug|Propofol|General Anesthesia
1587736|NCT02326727|Drug|Isoflurane|General Anesthesia
1587737|NCT02326727|Drug|Nitrous Oxide|General Anesthesia
1587738|NCT02326714|Other|Auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were asked to massage the points for 5 minutes, 30 minutes before three meals and sleep.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
1587739|NCT02326714|Other|Placebo auricular acupressure|The magnetic beads were taped to the auricular acupressure points, by the same acupuncture specialist on one ear approximately after skin sterilization, and the subjects were not asked to massage the points.The magnetic beads were left in situ, but replaced with new ones once every week in the other ear.
1587740|NCT02326688|Other|Kinematic analysis of trunk compensation|
1587741|NCT02326675|Other|Ice|This group will receive cryotherapy, saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
1587742|NCT02326675|Other|Normal Saline Solution|This group will receive saline rinses, an oral care diary will be completed by the subject, and a daily oral assessment will be performed by the investigators as part of their participation.
1587743|NCT02326662|Biological|Autologous Stem Cell Transplantation|Autologous neural stem cell transplantation Stem Cell Transplantation by intraspinal and intrathecal injection with 3D matrix as needed
1587744|NCT02326649|Device|Physioflow|impedance cardiography instrument that measures cardiac output non-invasively
1587745|NCT02326636|Biological|Fecal Microbial Transplantation|Participants with refractory Clostridium difficile infection will be given healthy donor stool administered by colonoscopy or enema.
1587746|NCT02326623|Other|distraction|distraction using an iPad with a selection of child-appropriate games
1587747|NCT02326623|Other|topical anesthetic cream|standard care is to use a topical anesthetic cream at the site of planning IV access
1587748|NCT02326610|Drug|Human growth hormone,ZOMACTON® (somatropin)|The initial dose will be 30µg/kg/day. The maximal dose will be 40µg/kg/day. The dose will be adjusted by monitoring the serum IGF-I level. Growth hormone will be delivered by injection.
1587751|NCT02326584|Drug|Standard dose cytarabine for induction|100 mg/m2/day Days 1-7
1587752|NCT02326584|Drug|SGN-CD33A|Given intravenously Day 1 or Days 1 and 4 of each cycle
1587753|NCT02326584|Drug|Daunorubicin|60 mg/m2/day Days 1-3
1587754|NCT02326584|Drug|High dose cytarabine for consolidation|3g/m2 on Days 1, 3, and 5 of each cycle
1587755|NCT02326558|Procedure|laparoscopic microwave ablation-assisted enucleation|
1587756|NCT02326558|Procedure|conventional laparoscopic partial nephrectomy|
1994775|NCT02922985|Drug|Intravenous acetominophen|One dose if 1 gram intravenous to be given pre-surgery
1587759|NCT02326532|Other|PRO data utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is provided to the treating physician.
1587760|NCT02326532|Other|PRO data not utilized|Data collected from a patient-completed MDHAQ/RAPID3 questionnaire is not provided to the treating physician.
1587761|NCT02326519|Other|Intracardiac electrode catheter|All patient in the study will have the same data collected using the Steerable intracardiac electrode catheter
1587762|NCT02326506|Device|VA-ELS pump speed variations|Small variations in the pump speed of the veno-arterial extracorporeal life support (VA-ELS) pump
1587763|NCT02326493|Device|Cardiac Resynchronization Therapy|A CRT device will be implanted while performing extra hemodynamic (LV dP/dtmax) and electrical (LVLED, VCG, and D-VCG) measurements. Devices and leads from various vendors will be used.
1587764|NCT02326480|Other|Identification of genetic causes of obesity|A blood test will be performed to the child and his/her parents with the aim of identifying genetic causes of obesity. Different analysis will be as follows: caryotypes, Raindance, whole exome, in order to find potential mutations or new genes associated to this condition
1587765|NCT02326467|Drug|Chlorhexidine gluconate|Bi-weekly chlorhexidine baths
1587766|NCT02326454|Drug|talaporfin sodium|1 mg/kg
1587767|NCT02326454|Drug|Saline|
1587768|NCT02326454|Device|Drug Activator 100 J/cm|Light Dose: 100 J/cm
1587769|NCT02326454|Device|Drug Activator 200 J/cm|Light Dose: 200 J/cm
1587771|NCT02326428|Device|Stent retriever endovascular device for thrombectomy|Thrombectomy by selected stent retrievers (TREVO, Solitaire, preSET, in special cases all stent retrievers) as additional therapy in major artery occlusion in patients fulfilling criteria for and receiving intravenous thrombolysis
1587772|NCT02326428|Drug|Intravenous thrombolysis by alteplase (Actilyse)|Stroke thrombolysis with Alteplase (Boeringer-Ingelheim, ATC-code B01AD02; a fibrinolytic drug) according to conventional guidelines (0.9 mg/kg, not exceeding 90 mg, given intravenously)
1587773|NCT02326415|Other|"Clinical Pathway with Fast-Track"|Care described in the critical pathway during postoperative like the moment when the patients can eat, can move or are discharged.
1587774|NCT02326415|Other|Postoperative Usual Protocol|Cares step by step as sugery responsable thinks are the best for patients until discharge.
1587775|NCT02326402|Device|TandemHeart System|Percutaneous insertion of TandemHeart System
1587776|NCT02326389|Behavioral|Exercise|The exercise intervention is a 10-week program involving 40 minutes of aerobic exercise targeting 60-75% of maximum heart rate on 3 days each week, with an additional 5-minute stretching warm up and cool down.
1587777|NCT02326389|Behavioral|Cognitive Remediation|Participants will be engaged in 30 hours of computer-based cognitive exercises with a standardized, widely used software package (Cogpack, Version 7.0, Marker Software), shown to improve cognitive functioning in multiple studies. One-hour sessions will be conducted 3 times per week for 10 weeks.
1587778|NCT02326376|Drug|anakinra (Kineret)|
1587779|NCT02326363|Behavioral|Mindfulness Based Relapse Prevention (MBRP)|Each session has a central theme/topic and consists of in-session experiential practice, discussions and homework assignments. Sessions begin with a check-in followed by a 20-30 minute meditation (i.e. body scan). The therapist reviews homework assignments, discusses challenges and participants are taught a variety of MM practices such as breath meditation, urge surfing, walking or movement meditation.
1587780|NCT02326363|Behavioral|Twelve-Step Facilitation Intervention (TSF)|"The primary goal is to promote abstinence by facilitating the patient's acceptance and surrender of addiction. Sessions begin with a check-in during which participants introduce themselves, report on meeting attendance and participation in related activities, any alcohol/drug use or craving to use. The remainder of the session focuses on discussion of the topic content followed by a take home summary and homework assignment."
1587781|NCT02326350|Drug|Aspirin 75mg|Active treatment
1587782|NCT02326350|Drug|Lactose powder|Placebo
1587783|NCT02326337|Device|TWO2 Device|Application of the Topical Wound Oxygen (TWO2) device that supplies cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
1587784|NCT02326337|Device|Placebo Device|Application of placebo device that does not supply cyclical oxygen pressure directly to the wound site within a sealed and humidified environment for 90 minutes, 5 times a week with AMWT dressings.
1587785|NCT02326311|Drug|imatinib|Tyrosin kinase inhibitor
1587786|NCT02326311|Drug|nilotinib|Tyrosin kinase inhibitor
1587787|NCT02326311|Drug|dasatinib|Tyrosin kinase inhibitor
1587836|NCT02325934|Drug|Stribild|Elvitegravir, cobicistat, emtricitabine, tenofovir disoproxil
1994776|NCT02922985|Drug|Ketorolac, intramuscular|One dose of 60 mg Intramuscular to be given at time of skin closure
1994777|NCT02922985|Drug|Bupivacaine, subcutaneous|Inject 20 mL of 0.25% bupivacaine at the site of anticipated skin incision.
1994778|NCT02922985|Drug|Normal saline|Normal saline will be given intravenously, intra-muscularly, and subcutaneously in the same volume as the study drugs for the patients in the placebo group.
1994779|NCT02921269|Drug|Atezolizumab|Given IV
1994780|NCT02921269|Biological|Bevacizumab|Given IV
1994781|NCT02921269|Other|Laboratory Biomarker Analysis|Correlative studies
1587788|NCT02326298|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 200 mg/mL
Route of Administration: Subcutaneous use"
1587789|NCT02326298|Other|Placebo|"Active Substance: Placebo
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 0.9 % saline
Route of Administration: Subcutaneous use"
1587790|NCT02326285|Drug|Gefitinib|Patients will be treated for 12 days with gefitinib 250 mg/day p.o. (d -12 to -1) and induced with chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3). Surgery is planned in the 4th week after d1 of the last cycle.
1587791|NCT02326285|Drug|docetaxel|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
1587792|NCT02326285|Drug|cisplatin|chemotherapy docetaxel 75 mg/m2 and cisplatin 50 mg/m2 d1+2 and intercalated gefitinib 250 mg/day d4-20 (cycle 1 and 2) and d4-17 (for cycle3).
1587793|NCT02326285|Procedure|Surgery|Surgery should be performed in the 4th or at the latest 5th week after d1 of the last cycle of chemotherapy (d64 to 78).
1587794|NCT02326272|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 200 mg/mL
Route of Administration: Subcutaneous use"
1587795|NCT02326272|Other|Placebo|"Active Substance: Placebo
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 0.9 % saline
Route of Administration: Subcutaneous use"
1587796|NCT02326259|Other|Initiation of treatment of diabetes|Treatment of diabetes according to the standard of care.
1587797|NCT02326246|Other|multi-parametic MRI|
1587798|NCT02326233|Biological|Pen of SB5|
1587799|NCT02326233|Biological|PFS of SB5|
1587800|NCT02326220|Drug|Alirocumab|
1587801|NCT02326220|Drug|Placebo|
1587802|NCT02326207|Device|Infant Ventilator Circuit Dual Heated with Autofeed Chamber|
1587803|NCT02326194|Biological|Low dose Ebola Zaire vaccine (Ad5-EBOV)|one dose, Low dose Ebola Zaire vaccine (Ad5-EBOV)
1587804|NCT02326194|Biological|High dose Ebola Zaire vaccine (Ad5-EBOV)|two doses, High dose Ebola Zaire vaccine (Ad5-EBOV), with one dose to each arm at a same time.
1587805|NCT02326194|Biological|placebo (one dose)|placebo, one doses
1587806|NCT02326194|Biological|placebo (two doses)|placebo, two doses, with one dose to each arm at a same time.
1587807|NCT02326181|Device|inspiratory pressure training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) .
1587808|NCT02326181|Device|mixed training group|The respiratory pressure load device can be provided different loads to perform inspiratory and expiratory pressure training.In the study,pressure-threshold respiratory trainers were calibrated to provide different loads against inspiration (IMST) and expiration(EMST).
1587809|NCT02326168|Drug|Bacillus Calmette-Guerin (BCG)|Intravesical instillation for non-muscle invasive bladder cancer
1587810|NCT02326142|Drug|OBE001|OBE001 dispersible tablets for a single oral dose a day for up to 7 days.
1587811|NCT02326142|Drug|Placebo|Placebo dispersible tablets for a single oral dose a day for up to 7 days.
1587812|NCT02326116|Other|Trachael Preparation Education|
1587813|NCT02326103|Drug|Ciprofloxacin|Comparison of ciprofloxacin with placebo in alcoholic hepatitis
1587814|NCT02326103|Drug|Placebo|
1587815|NCT02326090|Drug|cis-UCA ophthalmic solution 1.0%|
1587816|NCT02326090|Drug|cis-UCA ophthalmic solution 2.5%|
1587817|NCT02326090|Drug|Placebo ophthalmic solution|
1587818|NCT02326077|Other|Ultrasound|Monitoring of the mechanism of labor
1587819|NCT02326077|Other|Acceptability of ultrasound monitoring of labor|Evaluation of the acceptability of intrapartum ultrasound monitoring - the rate of uptake ultrasound protocol during labor
1587820|NCT02326077|Other|Patients' experience regarding intrapartum ultrasound|The day after birth, consenting women are invited to take part in a questionnaire survey. Questionnaires contained no identifying information other than a code number and contains features regarding the patient's impression about the ultrasound monitoring scans during labor. The final questions concerned the willingness of having again another such protocol for labor monitoring in the future.
1587821|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously once positive pregnancy test is established and the therapy will continue until termination of pregnancy
1587822|NCT02326051|Drug|Enoxaparin|Women will start Enoxaparin therapy in a dose of 40 mg/day subcutaneously after sonographic confirmation of fetal cardiac pulsation and the therapy will continue until termination of pregnancy
1587823|NCT02326038|Drug|Methylphenidate|single oral administration of 20 mg tablet
1587826|NCT02326012|Behavioral|Emotion Regulation Individual Therapy for Adolescents|
1587827|NCT02325999|Procedure|ESD AND LRLD|A new therapy for gastric cancer : Endoscopic Submucosal Dissection combine with Laparoscopic Regional Lymph node Dissection.
1587828|NCT02325986|Drug|fluorouracil|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
1587829|NCT02325986|Drug|Cisplatin|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
1587830|NCT02325986|Radiation|Intensity-modulated radiation therapy|cisplatin 25mg/m2 on day 1, fluorouracil 1176mg/m2 on day 1-3，repeated weekly for 4 weeks concurrently with IMRT radiotherapy (60Gy/28fr)
1587831|NCT02325973|Device|PressureWire Certus guidewire|Assessment of IMR index in coronaries through PressureWire Certus guidewire
1587832|NCT02325960|Drug|exenatide|5 μg BID for the first 4 weeks of treatment and 10 μg thereafter.
1587833|NCT02325960|Drug|Insulin glargine|≥8 IU QD, and titrate based on a dosing algorithm targeting FPG <6.1 mmol/L. Titration is only allowed in first 4 weeks.
1587834|NCT02325947|Device|hand exoskeleton, brain-computer interface (BCI),|Hand exoskeleton, brain-computer interface (BCI) 10 sessions of 45-minutes
1587835|NCT02325947|Device|hand exoskeleton, sham BCI|Hand exoskeleton, sham BCI 10 sessions of 45-minutes (BCI imitation)
1587837|NCT02325934|Drug|Stribild, crushed|Crushed Stribild tablet
1587838|NCT02325921|Device|Magnetic Resonance Imaging|One MRI examination, diagnostic scanning protocol as used for renal tumours with additional diffusion weighted sequences (including diffusion tensor imaging), but without contrast enhancement.
1587839|NCT02325895|Other|Dried Plum|Three doses of dried plum (0 g, 50 g and 100g) were used as intervention.
1587840|NCT02325882|Drug|Dexmedetomidine|Dexmedetomidine mixed fentanyl based intravenous PCA
1587841|NCT02325882|Drug|Fentanyl 1|conventional fentanyl-based epidural PCA
1587842|NCT02325882|Drug|Fentanyl 2|conventional fentanyl based intravenous PCA
1587843|NCT02325869|Device|Bell Balloon Catheter|An angioplasty procedure to open the blockage in blood vessels will be performed. Standard angioplasty procedure includes local analgesia of the groin area and a small cut through which the procedure will be performed. An introducer sheath (thin tube) will be inserted. The Bell Balloon dilatation will then be inserted. The Bell Balloon works in fashion similar to standard balloon with the same physical and behavioral characteristics. Upon deflation, debris from the blockage is withdrawn into the cavity formed between the deflated balloon and its outer capsule. Then balloon is retracted and retrieved through the guiding catheter, together with the captured debris and trap it between the outer surface of the balloon and the inner surface of the membrane.
1587844|NCT02325856|Device|Bioimpedance Spectroscopy|Bioimpedance Spectroscopy is a safe tool to evaluate the fluid status in hemodialysis patients.
1587845|NCT02325856|Behavioral|Clinical judgement|
1587846|NCT02325843|Other|human bone marrow MSC|the arms of active comparator :human bone marrow MSC subconjunctival injection once per week,adminstered for 4 weeks
1587847|NCT02325830|Device|CARILLON Mitral Contour System|Percutaneous mitral valve repair
1587848|NCT02325817|Device|Drug-eluting balloon|Treat the side branch of bifurcation lesion with drug-eluting balloon
1587849|NCT02325817|Device|Uncoated ballloon|Treat the side branch of bifurcation lesion with uncoated balloon
1587850|NCT02325804|Behavioral|Lifestyle Counseling|In both arms life style counseling: Low calorie diet- 30% reduction of weight maintenance calories (TDEE); and recommended moderate exercise 3 times per week 45 minutes.
1587851|NCT02325791|Drug|REGN2222|
1587852|NCT02325791|Drug|Placebo|
1587853|NCT02325778|Procedure|CTI ablation Timing|The timing of when the CTI ablation is performed. There are no other relevant interventions used in the procedure.
1587854|NCT02325752|Other|Intervention|"A multidisciplinary team delivered the transitional care program.
Our transitional care program focused on four key areas:
Post discharge surveillance of the patient to ensure adherence to care plans.
Coordination of follow-up visits with specialist care providers.
Patent education and care giver training.
Activation of community and social services.
Upon recruitment, the patients were interviewed and assessed by the team nurse prior to their discharge. Intervention starts upon discharge from the hospital. The duration of the intervention program was 3 months. A follow-up by telephone was made within 72 hours after discharge to assess patient's condition and adherence to treatment plan. Home visits were made within 2 weeks after discharge."
1587855|NCT02325739|Drug|FGF401|FGF401 is a FGFR4 inhibitor.
1587856|NCT02325739|Biological|PDR001|PDR001 is a humanized anti-PD1 IgG4 antibody that blocks the binding of PD-L1 and PD-L2
1587857|NCT02325726|Procedure|Renal Resistive Index compared with NephroCheckTM|
1587858|NCT02325713|Drug|Oral dispersible tablet of praziquantel (ODT-PZQ)|Treatment A (test): ODT-PZQ (MSC1028703A) at a single dose of 40 milligram per kilogram (mg/kg) orally dispersed in water after meal.
1587859|NCT02325713|Drug|Cysticide|Treatment B (reference): Cysticide tablet at a single dose of 40 mg/kg will be given with water orally after a meal.
1587860|NCT02325713|Drug|ODT-PZQ|Treatment C1 (test): ODT-PZQ (MSC1028703A) at a single dose of 20 mg/kg orally dispersed in water after a meal.
1587861|NCT02325713|Drug|ODT-PZQ|Treatment C2 (test): ODT-PZQ (MSC1028703A) at a single dose of 60 mg/kg orally dispersed in water after a meal.
1587862|NCT02325713|Drug|ODT-PZQ|Treatment D1 (test): ODT-PZQ (MSC1028703A) at a single dose of 40 mg/kg orally dispersed in water without a meal.
1587863|NCT02325713|Drug|Cysticide|Treatment D2 (reference): Cysticide crushed tablets at a single dose of 40 mg/kg will be given with water orally after a meal.
1587864|NCT02325700|Procedure|Aortic repair|Aortic bypass
1587865|NCT02325687|Procedure|Lumbar Puncture (Standard-of-Care)|All study patients will have previously consented to undergo either spinal or spinal-epidural anesthesia. Patients will undergo their planned spinal or combined spinal-epidural placement in the OR. At the time of confirmation of placement of the spinal needle (positive CSF flow), 5 mL CSF will be collected and stored. CSF will be drawn using a standard 25g or 27g needle commonly used for anesthesia. The volume of CSF removed will be replaced with 4 cc local anesthetic (1.5% mepivacaine for spinal anesthesia).
1587866|NCT02325661|Other|cognitive interviewing|"For the individual cognitive interviews we are using the two techniques to think aloud and the verbal probing. To think aloud means, that the patients are asked to express precisely what comes to their mind when reading the single questions. This means, the interviewer is interested in the line of thoughts, which arise when reading the question. Thereby, the problems which appear in the usually covert process of answering a question should be revealed. In a second step, we are using the verbal probing technique to identify possible misunderstandings of the questions or difficulties with single phrases. The interviewer asks further questions that target the patients' interpretation."
1587867|NCT02325648|Drug|HIPEC cytoreductive surgery|At least 30 minutes prior to the prospective conclusion of the surgery, 1 μg/kg of fentanyl is administered for postoperative analgesia and 0.075mg of palonosetron is IV-infused for the prevention of nausea and vomiting. Desflurane and remifentanil administration is ceased after the surgery is concluded, muscle relaxation is evaluated by train of four (TOP) monitoring using a nerve stimulator, and the neuromuscular blockade is reversed with 0.2 mg of glycopyrrolate and 1 mg of neostigmine. When the patient recovers consciousness and begins spontaneous respiration, extubation is performed and the patient is transferred to the ICU with monitoring of their vital signs.
1587868|NCT02325635|Other|Educational Training|Intervention/Training offered to endoscopists only.
1587869|NCT02325596|Genetic|miRNA mimics or inhibitors|DCs are transfected by the miRNA mimics or inhibitors after they are separated from peripheral blood mononuclear cells in CRS patients
1587870|NCT02325583|Drug|30% Glucose|ORAL 30% GLUCOSE 0,5-2 ML
1587871|NCT02325583|Drug|Midazolam|INTRAVENOUS 0.1 MG/KG MIDAZOLAM
1587872|NCT02325570|Device|KLOX BioPhotonic OraLum Gel|Klox BioPhotonic OraLum Gel will be used with a LED curing lamp as an adjunct to conventional non-surgical periodontal treatment (SRP).
1587873|NCT02325570|Procedure|Scaling and Root Planing (SRP)|Scaling and Root Planing (SRP) is the conventional non-surgical treatment of chronic periodontitis.
1587874|NCT02325557|Drug|ADXS31-142|starting at 1x10^9 cfu IV
1587875|NCT02325557|Drug|ADXS31-142 + Pembrolizumab (MK-3475)|starting at dose from Part A + 200mg of Pembrolizumab
1587876|NCT02325544|Behavioral|Cognitive Behavioral Therapy|"12 sessions of CBT (over 4-5 months) +1 booster session. Guided by a therapy manual and patient handouts; will involve setting homework tasks. Although treatment is manualised, it allows treatment to be formulation-based i.e. tailored to the person.
Standardised medical as described in other intervention."
1587877|NCT02325544|Behavioral|Standardized Medical Care|Delivered by neurologists/ psychiatrists - both will be involved in discussing diagnosis. It will Include an information sheet about dissociative seizures and direction to self-help websites, general information provision about management of DS and support, consideration of psychiatric comorbidities / associated drug treatment and general review but no CBT techniques.
1587878|NCT02325531|Other|ALL|"The ALL Initiative ('ALL') is a population-level management program developed at Kaiser Permanente (KP). It seeks to decrease cardiovascular disease (CVD) morbidity and mortality in patients with diabetes by improving rates of prescribing for guideline-concordant cardioprotective medications.
For SPREAD-NET, we propose to compare the effectiveness of 3 support strategies for optimizing the sustainable implementation of the evidence-based ALL intervention. To do so, we will randomize 30 CHCs to receive 1 of 3 implementation support strategies: Low support (toolkit only), Medium (toolkit, staff training), High (toolkit, training, on-site facilitation). Using a mixed methods approach, we will assess how effectively each strategy supports sustainable implementation of ALL at the practice- and patient-levels, and we will identify clinic characteristics associated with success at each level of support. We will also conduct a cost analysis to compare costs per patient in each study arm."
1587879|NCT02325518|Drug|Brinzolamide 1%/Timolol maleate 0.5% fixed combination ophthalmic suspension|
1587880|NCT02325518|Drug|Dorzolamide hydrochloride 1%/Timolol maleate 0.5% ophthalmic solution|
1587881|NCT02325518|Drug|Subject's habitual PGA monotherapy|
1587882|NCT02325492|Drug|Aramchol|
1587883|NCT02325492|Drug|Placebo|
1587884|NCT02325492|Device|Ultrasound|
1587885|NCT02325479|Drug|Enaoxaprin sodium|intrauterine administration after oocyte pickup as the main experimental intervention
1587886|NCT02325479|Drug|tissue culture media|intrauterine administration after oocyte pickup as placebo
1587887|NCT02325466|Drug|Aspirin|Aspirin 81mg
1587888|NCT02325466|Drug|Ticagrelor|ticagrelor 90 mg
1587889|NCT02325466|Drug|Aspirin Placebo|
1587890|NCT02325466|Drug|Ticagrelor Placebo|
1587891|NCT02325453|Procedure|Robotic Surgery|Surgical procedure performed with a robotic system.
1587892|NCT02325453|Procedure|Laparoscopic Surgery|Surgical procedure performed with laparoscopic techniques.
1587893|NCT02325453|Procedure|Open Surgery|Traditional approach for gastric cancer.
1587894|NCT02325440|Drug|Fingolimod|Fingolimod: 0.5 mg p.o. (o.i.d)
1587895|NCT02325440|Drug|Natalizumab|Natalizumab: 300 mg i.v. (once at baseline);
1587896|NCT02325427|Device|tDCS|tDCS could deliver either real or sham stimulation.
1587897|NCT02325414|Drug|Zoledronic acid|Intravenous infusion of zoledronic acid 5 mg.
1587898|NCT02325414|Drug|Placebo|Placebo infusion to match zoledronic acid
1587903|NCT02325375|Procedure|lumbar puncture for spinal fluid and blood sample|lumbar puncture for spinal fluid and blood sample
1587904|NCT02325362|Drug|Miglustat ; placebo|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Miglustat during the first period (2 weeks), following by a wash out period(14 days (up to 4 weeks)), then Placebo during the second period (2 weeks). 30 days follow-up will be carried out after end-of-treatment of the second period.
1587905|NCT02325362|Drug|Placebo ; Miglustat|For this 2 x 2 (2 periods /2 treatments) crossover design each patient will receive Placebo during the first period (2 weeks), following by wash out period (14 days (up to 4 weeks)), then Miglustat during the second period (2 weeks). 30 days follow-up will be carried out after end of treatment of the second period.
1587906|NCT02325349|Drug|radiopharmaceutical (Flotegatide (18F) or RGD (68Ga)|PET/CT after intravenous administration of 2-4MBq/kg of body weight of Flotegatide (18F) or RGD (68Ga) performed prior and after 2 cycles of chemotherapy including an agent with antiangiogenic effect (two examinations in each patient)
1587907|NCT02325336|Device|BCMA (bar-code-assisted medication administration)|"Implementation of ADIM system (Aide a la Distribution Informatisee des Medicaments) which consists of 2 machines with photographic reconnaissance and readers: one for preparation assistance that can be placed at the pharmacy or in the clinical service and one to assist the administration by the nurse in the clinical service.
In case of discrepancy with the prescription, there is a visual alert. However, the alert can be override by the nurse if she/he gives a justification."
1587908|NCT02325310|Biological|Combined measles-mumps-rubella (MMR) vaccine - PRIORIX®|One dose of 0.5 mL vaccine will be administered (intra-muscularly or subcutaneous) in post-partum (before the exit of the maternity) during visit V0. A second dose will be administered at week 8(+/-15 days) during visit V1.
1587909|NCT02325297|Other|Letter of condolence|
1587910|NCT02325284|Device|Pressure Algometer Testing|
1587911|NCT02325271|Other|Frequent blood and urine sampling and blood pressure measurement|Blood and urine sampling for the determination of VEGF and biomarkers
1587912|NCT02325258|Other|Telephone call|Aug-Dec 2012. Prospective study in patients who had blood cultures drawn and sent to the Microbiology Lab during the morning shift (9 am to 3 pm, Mon- Fri) to evaluate sepsis recognition. The investigators allocated 300 patients to 2 groups of 150 patients each, by opportunity sampling: patients whose clinical history number ended in odd numbers were assigned to group A (intervention) and those whose clinical history number ended in even numbers were assigned to group B (no intervention, control group). For patients in group A, the investigators attempted a telephone contact with the physician and/or nurse in charge and an interview, issuing recommendations regarding the convenience of further biochemical, microbiological or extra radiologic tests, and management and antimicrobial therapy.
1994790|NCT02920112|Behavioral|Telephone based Cognitive Behavioral Therapy|6 sessions of Telephone based Cognitive Behavioral Therapy over the telephone, lasting approximately 60 minutes each.
1994791|NCT02920853|Behavioral|Biofeedback Training (BT-CPR)|Participants will receive biofeedback training (which will include electric stimulations) to reduce arousal and pain
1587915|NCT02325232|Device|Capsule endoscopy, double balloon enteroscopy sequential use|Small bowel capsule endoscopy followed by double-balloon enteroscopy with histological sampling in case of mucosal alterations
1587916|NCT02325219|Drug|CNTO 1959 50 mg|Participants will receive subcutaneous injection of CNTO 1959 50 mg.
1587917|NCT02325219|Drug|CTNO 1959 100 mg|Participants will receive subcutaneous injection of CNTO 1959 100 mg.
1587918|NCT02325219|Drug|Placebo 50 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 50 mg.
1587919|NCT02325219|Drug|Placebo 100 mg|Participants will receive subcutaneous injection of Placebo matched to CNTO 1959 100 mg.
1587920|NCT02325206|Drug|dapagliflozin|one administration in the morning
1587921|NCT02325206|Drug|Placebo|one administration in the morning
1587922|NCT02325193|Device|Minimed®640G system|Sensor augmented insulin therapy with and without use of Predictive low glucose management (PLGM)
1587923|NCT02325180|Drug|Dihydroartemisinin-Piperaquine|
1587924|NCT02325180|Drug|Artemether-lumefantrine|
1587925|NCT02325167|Behavioral|EBT|participants assigned to the intervention arm will receive 2 manualised therapy sessions with focus on mindfulness and activating resources delivered by trained therapists at the Clinic of Palliative Care
1587926|NCT02325167|Behavioral|treatment-as-usual|participants assigned to the treatment-as-usual arm will receive 2 supportive sessions delivered by trained therapists at the Clinic of Palliative Care
1587927|NCT02325154|Device|Cerebral Oximeter|Use of cerebral oximeter to monitor cerebral oxygenation for occurence of desaturation events.
1587928|NCT02325141|Procedure|laparoscopic sleeve gastrectomy|creation of a gastric tube of 100cc using a stapler.
1587929|NCT02325128|Behavioral|Sleep-enhancement of extinction memory|Recent reports show that sleep promotes memory consolidation. The investigators' preliminary findings suggest sleep may enhance the therapeutic extinction memories acquired during exposure therapy. For sleep-enhancement of extinction memory, the current intervention uses post-exposure naps as a means to provide sleep in close temporal proximity to the encoding of memory for the extinction social exposure fears in individuals with severe social anxiety symptoms.
1587930|NCT02325102|Other|No intervention|As this is an observational study, no intervention was conducted.
1587931|NCT02325089|Device|Mandibular advancement device|Use of a mandibular advancement device every night during one year. Device will be titrated to reduce or - if possible - eliminate snoring and sleep apnea.
1587932|NCT02325089|Device|Placebo|Placebo oral appliance will be identical to the mandibular advancement device without, however, the attachemnt to allow mandibular advancement. It will be used every night during one year.
1587933|NCT02325076|Device|Spirodoc|A device to detect the physical condition of the lungs
1587934|NCT02325063|Drug|PRP-L Injection|Patients will be treated with an injection of leukocyte and platelet rich plasma.
1587935|NCT02325063|Drug|Botox injection|Patients will be treated with an injection of Type A Botulinum toxin.
1587936|NCT02325063|Drug|Corticoid injection|Patients will be treated with an injection of Corticoids.
1587937|NCT02325050|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 1*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
1587938|NCT02325050|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 5*10^10 viral particles (vp).
1587939|NCT02325050|Biological|MVA-BN-Filo|One 0.5 milliliter (ml) intramuscular (IM) injection of 4.4*10^8, (50%Tissue Culture Infectious Dose [TCID50]).
1587940|NCT02325050|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 1*10^11 viral particles (vp).
1587941|NCT02325050|Other|Placebo|One 0.5 mL IM injection of 0.9% saline.
1587942|NCT02325037|Drug|GLPG1837 single ascending doses|Single dose, oral suspension
1587943|NCT02325037|Drug|Placebo single dose|Single dose, oral suspension matching placebo
1587944|NCT02325037|Drug|GLPG1837 multiple ascending doses|Multiple doses, daily for 14 days, oral suspension
1587945|NCT02325037|Drug|Placebo multiple doses|Multiple doses, daily for 14 days, oral suspension, matching placebo
1587946|NCT02325024|Drug|Sativex|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
1587947|NCT02325011|Drug|Sativex® (Treatment A)|Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
1587948|NCT02325011|Drug|Sativex® and fluconazole concomitantly (Treatment B)|"Each 100 uL actuation (spray) of Sativex contains 27 mg/mL THC and 25 mg/mL CBD plus peppermint flavouring. The study dosage of 10.8 mg THC and 10 mg CBD is delivered as four sprays to the oral mucosa.
Fluconazole 200 mg twice daily (BID) for two days, will be administered at the following time points relative to the Day 1 Sativex dose: 1 hour pre-dose, and approximately 11, 24, and 36 hours post-dose."
1587949|NCT02324998|Drug|Olaparib|PARP Inhibitor
1587950|NCT02324998|Drug|Degarelix|Gonadotrophin releasing hormone blocker
1587951|NCT02324985|Drug|S-Ibuprofen Topical Gel 5%|S-Ibuprofen Topical Gel 5% applied every 6 hours
1587952|NCT02324985|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied every 6 hours
1994792|NCT02920853|Behavioral|Biofeedback Training|Participants will receive biofeedback training to reduce arousal and pain
1994793|NCT02920216|Drug|indocyanine green|intravenous injection of Indocyanine Green (0,25mg/kg) before surgery.
1587955|NCT02324959|Device|RehaCom|The computer-based neurorehabilitation program is intended for patients with acquired cognitive deficits after brain damage, e.g. after stroke. The RehaCom software has five different therapeutic groups aimed at restoration of attention, memory, executive functions, and visual field, respectively. Each group has one to four different modules to choose from for each therapy session. Only attention will be trained in this study.
1587956|NCT02324959|Device|Acupuncture|"The affected meridian group is treated by needling on Baihui (GV20|DU20) and Shenting (GV24|DU24) - both acupoints of the Governor Vessel. Baihui is 5 cun (1cun=3.33 cm) superior to the anterior hairline on the anterior median line (midpoint of the connecting line between the auricular apices)."
1587957|NCT02324946|Other|Mass Screening|Preoperative screening with STOP-BANG and DES-OSA scores and postoperative comparison with difficult intubation / ventilation scores.
1587958|NCT02324933|Drug|Fentanyl|Fentanyl Patient Controlled Analgesia for post-operative pain management
1587959|NCT02324920|Device|DDD-CLS|
1587960|NCT02324920|Device|ODO|
1587961|NCT02324907|Device|Procedure/Surgery|Tibiotalocalcaneal (TTC) arthrodesis with a novel dynamic compression intramedullary nail. The assignment of the device is at the discretion of the standard of care provider, not the study investigator.
1587962|NCT02324894|Procedure|MRI screening|Diagnostic screening. The normal eligible screening population will first undergo a mammography, then an echography screening followed by a fast MRI screening.
1587963|NCT02324881|Behavioral|Telephone-Based Intervention|Use PSMA
1587964|NCT02324881|Other|Questionnaire Administration|Ancillary studies
1587965|NCT02324868|Device|Shower patch IV catheter protection|Shower patch will be available for the patient for bathing activities
1587966|NCT02324868|Device|Conventional IV catheter protection|No Shower patch will be provided during study period
1587967|NCT02324855|Other|Chest physiotherapy plus usual care|Subjects will perform daily chest physiotherapy during at least 30 minutes. Patients will perform a slow expiratory airway clearance technique combined with positive expiratory pressure device (Acapella device, Murray et al.) Each patient will receive 12 supervised professional sessions (once a month).
1587968|NCT02324842|Drug|Canagliflozin|Canagliflozin is a sodium-glucose co-transporter 2 (SGLT2) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus (1)
1587969|NCT02324842|Drug|Liraglutide|Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
1587970|NCT02324816|Device|The Zeltiq System|CoolSculpting treatment.
1587972|NCT02324790|Device|iNAP® Sleep Therapy System|The iNAP® Sleep Therapy System provides pressure gradient within the oral cavity to pull the tongue toward upper palate and the soft palate forward, which aims to maintain better upper airway patency near the pharynx to prevent sleep-disordered breathing.
1587973|NCT02324777|Drug|Cannabis|Cannabis sativa L. subsp. indica, variety indica blends of flowering heads that have been air-dried, milled, destemmed and fine ground, stored in glass vials with aluminum caps in 100 mg dose size.
1587974|NCT02324777|Device|Volcano® Medic Vapourizer|"Volcano® Medic vapourizer is licensed for medical administration of cannabis in Canada March 2010 (Licence No. 82405).
The contents of a vial of drug product formulation will be transferred to the Volcano® Medic's filling chamber (sample-holder) equipped top and bottom with fine wire mesh to retain the finely ground material. The filling chamber will be placed atop the main body of the unit and then have a, 12.5 L, heat-resistant Medic Valve balloon affixed. Active components are vapourized at 190 °C. The ensuing vapour is captured in the balloon and inhaled by the study subject using a standardized inhalation technique."
1587975|NCT02324764|Device|Glidesheath Slender|testing the efficacy and safety of the new transradial sheath in comparison to the standard 6 french sheath.
1587976|NCT02324764|Device|standard 6- French radial sheath|
1587977|NCT02324751|Biological|Vi-TCV|Each 0.5mL vaccine dose contains 25μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain) conjugated to non-toxic tetanus toxoid. The vaccine will be administered 28 days prior to typhoid challenge
1587978|NCT02324751|Biological|Vi-PS Vaccine|Each 0.5 mL vaccine dose contains 25 μg of purified Vi capsular polysaccharide (S. Typhi Ty2 strain). The vaccine will be administered 28 days prior to typhoid challenge
1587979|NCT02324751|Biological|Control (Men ACWY)|Each vaccine dose contains N. meningitidis oligosaccharides (10μg MenA oligosaccharide, 5μg of each of MenC, Men Y and MenW-135 oligosaccharides) conjugated to 32.7 μg to 64.1μg Diphtheria CRM197 protein with residual formaldehyde dose less than 0.30μg. The vaccine will be administered 28 days prior to typhoid challenge
1587980|NCT02324738|Drug|Mefloquine and Dihydroartemisinin-piperaquine|2 tablets of mefloquine and 3 tablets of dihydroartemisinin-piperaquine single dose
1587981|NCT02324738|Other|Wash-out period|
1587982|NCT02324738|Drug|Mefloquine|2 tablets of Mefloquine single dose
1587983|NCT02324725|Drug|Naltrexone|Up to three monthly injections of 380 mg of naltrexone suspended in dissolvable polymer microspheres and administered intramuscularly
1587984|NCT02324712|Device|Acupuncture|Acupuncture using standard stainless steel acupuncture needles inserted into intramuscular tissue for 20 minutes
1587985|NCT02324712|Device|Sham Acupuncture|Acupuncture using non-penetrating Park Sham Needles for 20 minutes
1587986|NCT02324699|Drug|Prednisone|
1587987|NCT02324699|Drug|Placebo|
1587988|NCT02324699|Drug|Vedolizumab|300mg IV over 30 minutes. Both arms will receive vedolizumab at weeks 0, 2, and 6.
1587989|NCT02324686|Drug|vitamin K1|Vitamin K1 400 mcg orally three times a week on dialysis days for four months
1587990|NCT02324673|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
1587991|NCT02324660|Other|screening test|screening test with peak expiratory flow and respiratory health screening questionnaire to discriminate patients at risk for COPD
1588059|NCT02324114|Device|Hsp90|Detect plasma Hsp90α concentration
1588060|NCT02324101|Device|Hsp90|Detect plasma Hsp90α concentration
1588061|NCT02324088|Drug|Docetaxel|
1588062|NCT02324088|Drug|Cyclophosphamide|
1587992|NCT02324634|Device|NeuroTrac Rehab dual channel device|ES intervention twice a day, 5 days a week, for 3 months applied to the wrist extensors and wrist flexors. The therapist will identify the motor points for the forearm flexors and the extensors, and will place an electrode on these motor points using sticky pads. They will then connect the electrodes to the respective channels in the electrical stimulator. The ES will be set to deliver a 450μs pulse at a frequency of 40-60Hz (as per patient convenience). The intensity of the current will be increased to produce an alternating contraction of the flexors and extensors using a flex-hold-extend-hold pattern. A single stimulation and hold cycle will last 20 seconds and this will be cyclically repeated for 30 minutes after which the device can be removed.
1587993|NCT02324621|Drug|Oral ONC201|Given PO
1587994|NCT02324621|Other|pharmacological study|Correlative studies
1587995|NCT02324621|Other|laboratory biomarker analysis|Correlative studies
1587996|NCT02324608|Biological|cetuximab|Given IV
1587997|NCT02324608|Other|laboratory biomarker analysis|Correlative studies
1587998|NCT02324595|Procedure|Laparoscopic interval debulking surgery|"Diagnostic laparoscopy with a careful exploration of peritoneal cavity: if available a 5 mm flexible tip videolaparoscope will be used to explore all peritoneal recesses.For eligible patients,will be placed 3 5mm trocar in standard position for pelvic surgery:cytoreduction will consist in total/radical hysterectomy,bilateral salpingo-oophorectomy,radical omentectomy.If needed pelvic/upper peritonectomy will be performed:in these cases additional trocar can be placed in right or left subcostal spaces. All surgical procedure requested will have be carried out by laparoscopy/robotic or by laparotomy,in case of increased surgical risk or technical impossibility:the case will be registered as laparotomic conversion.At the end of surgical procedures residual tumor will be registered"
1587999|NCT02324582|Drug|Intravenous MK-3475/ Intravesical BCG|6 cycles (each cycle is 21 days) of pembrolizumab will be given over 9 weeks in combination with BCG. BCG treatment will begin on Day 1 of cycle 3 of pembroluzimab.
1588000|NCT02324569|Drug|SYR-472|SYR-472 tablets
1588001|NCT02324569|Drug|Placebo|Placebo tablets
1588002|NCT02324543|Drug|Gemcitabine|IV over 40 minutes; Days 4 and 11 of a 21 day cycle
1588003|NCT02324543|Drug|Taxotere|IV over 60 minutes; Days 4 and 11 of a 21 day cycle
1588004|NCT02324543|Drug|Xeloda|orally, twice daily; Days 1 through 14 of a 21 day cycle
1588005|NCT02324543|Drug|Cisplatin|IV over 60 minutes; Days 4 and 11 of a 21 day cycle
1588006|NCT02324543|Drug|Irinotecan|IV over 60 minutes; Days 4 and 11 of a 21 day cycle
1588007|NCT02324530|Device|Continuous positive airway pressure (CPAP)|CT simulation with and without CPAP
1588008|NCT02324504|Device|C3 Wave ECG-based PICC Tip Confirmation System|The C3 Wave PICC tip detection system will be used to identify catheter tip location during the procedural placement of the catheter. This system includes an ECG monitor that will connected to the guidewire used for catheter placement. The changes in the ECG tracing will guide correct catheter placement.
1588009|NCT02324504|Radiation|Chest radiograph|Chest radiograph will be performed as a second measure to confirm catheter tip placement.
1588010|NCT02324491|Drug|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 52 weeks.
1588011|NCT02324491|Drug|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 52 weeks.
1588012|NCT02324478|Procedure|autonomic nervous system analysis|electrocardiographic and pulse-photoplethysmographic waves of patients under general anesthesia for laparoscopic cholecystectomy will be recorded on a laptop pc for offline analysis of autonomic nervous system modulation a three main time point: 1) at baseline, before general anesthesia induction, 2) five min after tracheal tube placement, 3) five min after pneumoperitoneum insufflation.
1588013|NCT02324465|Device|King Vision Video Laryngoscope|Intubation via King Vision Video Laryngoscope
1588014|NCT02324465|Device|Glidescope Video Laryngoscope|Intubation via Glidescope Video Laryngoscope
1588015|NCT02324452|Drug|Fluoropyrimidine (capecitabine or 5-fluorouracil)|Patient that are a heterozygous carrier of a DPYD variant will receive a reduced dosage of capecitabine or 5-fluorouracil (25-50% reduction, depending on which SNP is identified). The dose will be titrated in subsequent cycles, to achieve maximal safe exposure. Patients that are wild type (not carrying any of the for DPYD variants) will receive a normal (full) dose.
1588016|NCT02324439|Drug|Omega Nutrition cold-milled flaxseeds|Patients who are currently in clinical remission will receive a daily 20g dose of cold milled flaxseed as a dietary supplement to determine if this intervention prolongs clinical remission.
1588017|NCT02324426|Drug|Reduced Glutathione|200 mg GSH delivered in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
1588018|NCT02324413|Drug|Clonidine|Comparison between placebo and 2 different concentrations of clonidine
1588019|NCT02324413|Drug|Placebo|
1588020|NCT02324400|Device|RenaSense Stimulation|RenaSense Catheter, Electrical Stimulation of the Urinary Bladder Wall
1588021|NCT02324400|Device|RenaSense Sham Control|RenaSense Catheter,no delivery of stimulation
1588022|NCT02324387|Procedure|Molecular Breast Imaging (MBI)|Participants undergo 3 MBI scans with injections of injection of Tc99m sestamibi before each scan. First scan is 7 days before scheduled neoadjuvant chemotherapy (NAC) treatment, after 2 cycles of chemotherapy, and after completion of chemotherapy treatment.
1588023|NCT02324387|Drug|Tc99m sestamibi|8 mCi of 99mTc sestamibi by vein before each molecular breast imaging (MBI).
1588024|NCT02324374|Procedure|Endocystoscopy During Colonoscopy|Colonoscopies will be performed as per routine practice. When a colorectal lesion is found that would normally require biopsy or polypectomy; the lesion will be evaluated by chromoendoscopy with the application of 10 ml 1% methylene blue followed by the inspection with the endocytoscope at both magnifications (450X and 1100X). The endocytoscopic images of the abnormal area will be recorded prior to biopsy or removal of the suspicious tissue. For each lesion, a matching endocytoscopy image from normal adjacent tissue will also be obtained, at least 5cm away from the suspect site, but within the same segment of intestine (e.g. ascending colon). No biopsy will be obtained from normal tissue, and this will be assumed to be normal. Following image acquisition, the lesion will be biopsied or removed as per standard clinical care.
1588063|NCT02324088|Drug|Epirubicin|
1588064|NCT02324075|Behavioral|Behavior change|Non governmental organization delivers communication intervention with facilitating hardware, a waste bin and bucket
1588025|NCT02324374|Device|Endocytoscope|The endocytoscopes, prototype I and prototype II will be used during the study along with the standard colonoscopes. The endocytoscope is a soft catheter type endoscope, with an outside diameter of 3.4 mm at the distal end and 3.2 at the shaft, and total length of 380 cm (working length of 250 cm) which uses a lens system for magnification. The Prototype 1 endocytoscope (low resolution type) has a magnification capability of x 450, depth of field of 50 um, field of view of 300X 300 um with a spatial resolution of 1.7 um. The Prototype 2 (high resolution) has a magnification capability of x1125, depth of field of 5um, field of view of 120X 120 um, and a spatial resolution of 4.2 um, The ECS system can be passed through the working channel of a standard colonoscope.
1994794|NCT02921048|Dietary Supplement|omega-3 fatty acids|
1588028|NCT02324348|Procedure|Deferred coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In deferred stenting group, second stage procedure (stent implantation) will be done at 5 to 7 days after TIMI Ⅲ flow has achieved.
1588029|NCT02324348|Procedure|Immediate coronary stenting|Abciximab (0.25㎎/㎏) intracoronary injection will be performed to all possible patients after guidewire has passed culprit lesion. Additional manual thrombus aspiration or balloon angioplasty can be performed by operator to achieve TIMI Ⅲ flow. When TIMI Ⅲ flow is achieved after these procedures, patient will be randomized to immediate stenting or deferred stenting group. In immediate stenting group, stenting will be done immediate after achieving TIMI III flow during initial procedure.
1588030|NCT02324335|Drug|Brilacidin|Oral Rinse used 3 times daily for 7 weeks
1588031|NCT02324335|Other|Placebo|
1588032|NCT02324322|Device|Exoskeleton Training|Exoskeleton Training (100 sessions - 1 hour, 4 - 5 sessions per week for 20 weeks) to enhance functional ambulation for persons with a spinal cord injury. To examine the effectiveness of exoskeleton assisted overground walking to induce positive changes in muscle volume and structure of the lower limbs for non-ambulatory persons with SCI.
1588033|NCT02324322|Other|Muscle Biopsies|"Needle Biopsies for Quadricep Muscles will be performed to define changes in BMD and Bone structure with intensive exoskeleton assisted walking. This procedure includes having a trained physician make a small skin incision, after numbing the area over the muscle, and then removing a tiny sliver of muscle to study under the microscope. Three separate biopsies for one incision will be obtained. The biopsies will be performed at baseline, 7 days, and after the intervention.
To define changes in biochemical markers of bone metabolism with intensive exoskeleton-assisted walking."
1588034|NCT02324322|Other|MRI|MRI's will provide accurate assessments of muscle CSA of each lower limb (from above the origin of the iliopsoas to the insertion of the achilles tendon) to determine individual's muscle thigh and shank volume.
1588035|NCT02324309|Drug|BIOD-531|
1588036|NCT02324309|Drug|Humalog Mix 75/25|
1588037|NCT02324309|Drug|Humulin R U-500|
1588038|NCT02324309|Drug|BIOD-531|
1588039|NCT02324296|Drug|ifosfamide|PEI regimen may be a possible therapeutic option, with high activity and an acceptable toxicity profile.
1588040|NCT02324283|Drug|desflurane|"Desflurane group: this group of patients receives desflurane as the main anesthetic agent during one-lung anesthesia.
Propofol group: this group of patients receives propofol as the main anesthetic agnet during on-lung anesthesia."
1588041|NCT02324283|Drug|propofol|Propofol group:this group of patients receives propofol as the main anesthetic agent during one-lung anesthesia.
1588042|NCT02324270|Drug|Diclofenac epolamine|Diclofenac epolamine in a topical patch formulation; applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
1588043|NCT02324270|Other|Placebo|Topical patch not containing diclofenac epolamine applied to the area of sprained ankle; to treat pain associated with a mild ankle sprain
1588046|NCT02324231|Other|39.0°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
1588047|NCT02324231|Other|38.5°C temperature limit defining fever|Diagnosis of FN, correspondingly hospitalization and start of empirical intravenous broad-spectrum antimicrobial therapy. Further treatment according to treating physician.
1588048|NCT02324218|Other|Data collection|Data extraction from CPRD database of UK.
1588049|NCT02324205|Device|Digital Breast Tomosynthesis|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
1588050|NCT02324205|Device|Full-field digital mammogram|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
1588051|NCT02324192|Other|Ultrasonography|imaging findings
1588052|NCT02324166|Drug|Cefazolin|cephalosporin antibiotic
1588053|NCT02324166|Drug|Lidocaine|local anesthetic
1588054|NCT02324153|Drug|Ramelteon|1 pre-operative and 2 nightly postoperative doses of Ramelteon/placebo will be administered
1588055|NCT02324153|Drug|Microcrystalline Cellulose|Placebo Comparator
1588056|NCT02324153|Drug|Riboflavin 100 mg|Riboflavin will be added to both placebo and active intervention capsules in order to track adherence to dose while taken as an outpatient (i.e. only the first preoperative dose)
1588057|NCT02324140|Other|Whole blood analysis|In all fours groups of patients we investigate inflammatory and antiinflammatory response to the surgical and interventional treatment by analyzing changes in the concentration of interleukins, C-reactive protein, soluble CD62L and HLA-DR.
1588058|NCT02324127|Device|hsp90|Detect plasma Hsp90α concentration of lung cancer patients
1994797|NCT02918279|Drug|Liraglutide|Administered once daily subcutaneously (s.c., under the skin)
1994798|NCT02918279|Drug|Placebo|Administered once daily subcutaneously (s.c., under the skin)
1994799|NCT02915848|Device|PC+S group|PC+S group: participants in the study will also receive a specific stimulation device (Activa PC+S, Medtronic) that is capable of recording the local field potentials (LFP). Approximately 10 participants are expected to take part in this study at UHN.
1588065|NCT02324062|Other|Questionnaires|These participants will be asked to complete questionnaires for the duration of the study (up to 60 months after enrollment) at 3 months, 6 months, 12 months, 24 months, 36 months, 48 months, and 60 months.
1588066|NCT02324062|Other|Blood Draw and Baseline Questionnaire|Participants will have their blood drawn for the study and complete a baseline questionnaire about their current cancer screening practices and concern regarding cancer.
1588068|NCT02324036|Device|EMPATHy Toolkit|Software-based toolkit to help patients identify and prioritize barriers to medication adherence; community health worker provides participation training to patient
1588069|NCT02324036|Behavioral|Coached Care|Community health worker provides participation training to patient
1588070|NCT02324023|Device|Endoscopic ultrasound|All patients will be evaluated by EUS and CE-EUS, using radial EUS instruments. The EUS scope will be inserted under direct vision, passed by the tumour and examination should begin during withdrawal at 7.5 MHz. The tumour will be characterized describing its echogenicity, echo structure, size, extent into the bowel wall and surrounding structures, and it will be staged using the modification of the TNM classification, based on a five-layer intestinal wall model. The presence/absence of power Doppler signals will be noted. For CE-EUS parameters for objective measurement of tumour perfusion will include maximum intensity of enhancement, mean transit time, time to peak (wash-in time), wash-in slope, area under the curve, representing indirectly blood flow or blood volume in CRC patients.
1588071|NCT02324010|Drug|Sitagliptin|100mg mane for 2 days
1588072|NCT02324010|Drug|Placebo|Inactive drug (Placebo)
1588073|NCT02323984|Other|miRNA Testing, Microemboli Monitoring, Delirium Assessment|Delirium assessment questionnaire and blood testing for miRNA will be done for all patients postoperatively, as well as BIS monitoring during surgery. The three arms of the study indicate the allocation of each patient based on their delirium presentation (hypoactive, hyperactive, or none).
1588074|NCT02323971|Drug|Ticagrelor|
1588075|NCT02323958|Other|acupoint stimulation|stimulation is given at acupoints
1588076|NCT02323958|Other|non-acupoint stimulation|stimulation is given at acupoints
1588077|NCT02323958|Other|electrode attached|electrodes are attached to skin
1588078|NCT02323958|Device|electrical stimulation|electrical stimulation is given through electrodes attached to th skin
1588079|NCT02323945|Other|AIH|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia). Participants will receive treatment on 5 consecutive days.
1588080|NCT02323945|Other|SHAM|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment on 5 consecutive days.
1588081|NCT02323945|Other|Walk|30 minutes of walking practice consisting of 5 repetitions of 6-minute walks
1588082|NCT02323945|Other|Strength|30 minutes of isometric ankle plantar flexion torque practice broken into 3 sets of 10 repetitions
1588083|NCT02323932|Behavioral|Perception of correct intonation identification|The amount of change in the fundamental frequency that was required in order to identify a question
1588084|NCT02323919|Behavioral|SystemCHANGE|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
1588085|NCT02323919|Behavioral|CHANGE+|consists of a series of five small-group (six to eight people) education sessions provided in three 1.5 -hour sessions once a week during the last three weeks of the CRP and in two sessions held at one and two months following completion of their CRP. An experienced cardiac nurse or exercise physiologist trained in the intervention protocol taught each of the sessions. In a series of structured activities, participants were taught to use behavior change strategies consistent with the respective intervention models. A series of three monthly booster calls were made during months four, five and six following the last intervention class and individuals were coached in the use of strategies consistent with the respective interventions.
1588086|NCT02323919|Behavioral|Usual Care|Participants will receive only the routine care provided to CRP patients. This care consists of assessment of exercise capacity, graduated exercise training (consisting of exercising three times a week at the cardiac rehabilitation center on treadmill or cycle, counseling about safe exercise {warm-up procedures, pulse taking, attending to body cues for exertion levels} and advisement to exercise on days between CRP sessions). At the end of the CRP, individuals are given an exercise prescription that includes their target heart rate and they are counseled to exercise at least 5 times a week for 30 minutes. This information is provided by the CRP personnel, usually in the form of individual informal conversations during exercise at the CRP.
1588087|NCT02323906|Drug|CC-122|Investigational new drug
1588088|NCT02323906|Drug|Sorafenib|Kinase inhibitor
1588089|NCT02323893|Drug|[18F]F-AraG|
1588090|NCT02323880|Other|Pharmacological Study|Correlative studies
1588091|NCT02323880|Drug|Selinexor|Given PO
1588092|NCT02323867|Device|Alpha Beta T cell depletion|
1588093|NCT02323854|Procedure|Ablation and Surgical Resection|"Percutaneous antenna will be placed into the target tumor under CT image guidance. Target tumor will be ablated.
The antenna will be removed and the planned surgical resection will be conducted as scheduled."
1588094|NCT02323841|Procedure|conservative treatment|we performed pelvic lymphadenectomy before neoadjuvant chemotherapy and conization as conservative treatments
1588095|NCT02323828|Dietary Supplement|High RS cookies|High RS cookies ingestion in healthy young adults
1588096|NCT02323828|Dietary Supplement|Placebo|Placebo cookies ingestion in healthy young adults
1588175|NCT02323230|Drug|Cyclophosphamide|Low dose cyclophosphamide will be taken by mouth
1588178|NCT02323217|Drug|Isocarboxazid|Isocarboxazid block of [11C]BU99008
1588097|NCT02323815|Dietary Supplement|Small-Quantity Lipid-based nutrient supplement|A monthly dose of SQ-LNS (31 sachets of 20g) will be distributed to mothers attending counselling sessions
1588098|NCT02323815|Behavioral|Child's health and nutrition topics|Monthly group counselling meetings organized at village level. Caregivers of participating children are invited to attend monthly counselling meetings that treat topics on child nutrition, health, hygiene and good sanitary practices. During these visits children are also screened for acute malnutrition measuring arm circumference.
1588099|NCT02323802|Behavioral|educational group intervention|
1588100|NCT02323802|Behavioral|prescriptive diet|
1588101|NCT02323789|Drug|Mesenchymal stromal cells|TC-MSC: a cell product containing mesenchymal stromal cells. Mesenchymal stromal cells are adherent non-haematopoietic multipotent cells that are expanded from bone marrow from healthy donors, using platelet lysate as source of growth factor.
1588102|NCT02323776|Other|Trimodality protocol|neoadjuvant chemoradiotherapy followed by surgery
1588103|NCT02323763|Other|fMRI Scanning|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes. fMRI will be used to determine brain activation and differences in intertemporal discounting.
1588104|NCT02323737|Drug|Irinotecan and cisplatin|
1588105|NCT02323737|Drug|Etoposide and cisplatin|
1588106|NCT02323724|Genetic|BRAF V600E mutation by pyrosequencing technique|
1588107|NCT02323711|Device|2-octyl cyanoacrylate|If the subject is allocated to the experimental group, they would receive 2-octyl cyanoacrylate in place of a primary dressing consisting of their non-adherent composite dressing (Tefla) and a secondary dressing of Army Battle Dressing (ABD).
1588108|NCT02323698|Dietary Supplement|Caffeine|Subjects will ingest capsules containing caffeine (up to 6mg/kg). Experiments will begin 60min after consumption to approximately coincide with peak plasma concentrations.Throughout the 60min wait time and experimentation, blood pressure and heart rate will be monitored.
1588109|NCT02323698|Other|AIH|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia).
1588110|NCT02323698|Other|SHAM|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia).
1588111|NCT02323698|Dietary Supplement|Placebo|This is a placebo counterpart to the caffeine drug. Subjects will ingest capsules containing dextrose. Experiments will begin 60min after consumption to mimic the caffeine drug protocol.Throughout the 60min wait time and experimentation, blood pressure and heart rate will be monitored.
1588112|NCT02323685|Biological|SANGUINATE™|Single infusion of SANGUINATE (pegylated carboxyhemogloblin)
1588113|NCT02323659|Drug|Methotrexate|Methotrexate 20mg per dose, administered orally, once every week
1588114|NCT02323659|Drug|Interferon Alfa-2b|Interferon Alfa-2b 3 million international units (MIU), administered 3 times per week
1588115|NCT02323646|Drug|Placebo Comparator|Safety and efficacy comparison of 6 mg and 12 mg for 2, 18 week courses of treatment for uterine fibroids
1588116|NCT02323646|Drug|Proellex 6 mg|Safety and efficacy comparison of 6 mg and 12 mg for 2, 18 week courses of treatment for uterine fibroids
1588117|NCT02323646|Drug|Proellex 12 mg|Safety and efficacy comparison of 6 mg and 12 mg for 2, 18 week courses of treatment for uterine fibroids
1588118|NCT02323633|Device|Braingear Brainbuds Pulsed Current stimulation device|Transcranial Pulsed Current stimulation (tPCS) at random noise oscillating frequencies for a duration of 20 minutues
1588119|NCT02323633|Device|Sham|No transcranial Pulsed Current Stimulation (tPCS)
1588120|NCT02323620|Procedure|Intracoronary infusion of BM-MC|Bone marrow-derived progenitor cells are obtained from 60ml bone marrow aspirated from the iliac crest. Intracoronary infusion of the autologous cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique.
1588121|NCT02323607|Drug|Pacritinib|Given PO
1588122|NCT02323607|Drug|Cytarabine|Given IV
1588123|NCT02323607|Drug|Daunorubicin Hydrochloride|Given IV
1588124|NCT02323607|Drug|Decitabine|Given IV
1588125|NCT02323607|Other|Laboratory Biomarker Analysis|Correlative studies
1588126|NCT02323607|Other|Pharmacological Study|Correlative studies
1588127|NCT02323594|Drug|Daclatasvir|Treatment A= single oral dose of Daclatasvir (DCV) tablet and Treatment B= single oral dose of DCV pediatric chewable tablet
1588128|NCT02323594|Drug|Daclatasvir|Treatment C= single oral dose of Daclatasvir (DCV) pediatric chewable tablet and Treatment D= single oral dose of DCV pediatric chewable tablet
1588129|NCT02323594|Drug|Asunaprevir|Treatment E= single oral dose of Asunaprevir (ASV) tablet and Treatment F= single oral dose of ASV pediatric chewable tablet and Treatment G= single oral dose of of ASV pediatric chewable tablet
1588130|NCT02323594|Drug|Daclatasvir|Treatment H= single oral dose of Daclatasvir (DCV) tablet and Treatment I= single oral dose of DCV tablets
1588131|NCT02323581|Device|Endovascular treatment of Thoracoabdominal Aortic Aneurysm|"A TAAA is an abnormal enlargement (ballooning out) of the main artery (the aorta) and involves all or part of the aorta in your chest as well as all or part of the aorta in the abdomen. It also involves the part of the aorta where the arteries that bring blood to the liver, stomach and intestines and kidneys are attached.
This investigational procedure that is being studied uses stent-grafts (cylindrical fabric tubes (grafts), with metal springs (stents) attached). The stent-grafts are placed inside the aneurysmal (weakened) area of the aorta to re-line it. These customized stent-grafts have special branches attached to them or openings (called fenestrations) that are used to keep blood flowing to the arteries that supply the liver, stomach, intestines and kidneys. The investigational stent graft will be designed and custom-made specifically for your aneurysm."
1588132|NCT02323568|Other|Gynecological consultation|
1588133|NCT02323555|Other|Paramedic telephone consultation|
1588134|NCT02323542|Other|Nutrition intervention with cereal products|acute evaluation of the effect of ingestion of cereal products differing by their Slowly Digestible Starch content
1588176|NCT02323217|Radiation|[11C]BU99008|Baseline Scan, Test-ReTest or Dosimetry
1588177|NCT02323217|Drug|Idazoxan|Idazoxan block of [11C]BU99008
1588258|NCT02322580|Drug|etanercept|
1588135|NCT02323529|Drug|Nitisinone|All patients in the study will first be put on twice daily dosing of nitisinone for 4 weeks. This will then be followed by once daily dosing of nitisinone for 4 weeks. The dose of nitisinone in the study will be the same as the one prescribed at completed screening visit. Dose will be 1-2 mg/kg body weight.
1588136|NCT02323516|Drug|Acetylsalicylic acid + loperamide|In case of inefficiency in one month, according to predefined criteria, acetylsalicylic acid will be stopped and replaced by diosmectite.
1588137|NCT02323516|Drug|diosmectite + loperamide|In case of inefficiency in one month, according to predefined criteria, diosmectite will be stopped and replaced by acetylsalicylic acid.
2008935|NCT03326141|Behavioral|Otago Exercise Program|The program has been adapted for groups and includes 5 flexibility movements (e.g., back extension and ankle, head, neck, trunk movements), 5 leg strengthening exercises (knee extensor, knee flexor, hip abductor, ankle plantar flexes, ankle dorsiflexes), 12 balance movements (knee bends, backwards walking, walking and turning, sideways walking, tandem stance, tandem walk, one leg stand, heel walking, toe walking, heel-toe walking backwards, sit to stand, stair walking), and a walking plan. The number, intensity and duration of movements are individualized according to preference and ability and they are gradually progressed.
1588139|NCT02323490|Procedure|with microfractures|following meniscal repair, microfractures will be created on the intercondylar and outer part of femoral condyle (outside of joint surface), lateral or medial, respectively
1588140|NCT02323490|Procedure|without microfractures|standard procedure meniscal repair without augmentation.
1588141|NCT02323477|Biological|stem cell transplantation|Human allogeneic umbilical cord MSC or autologous BM-MNC transplantation
1588142|NCT02323464|Procedure|Surgery for colorectal cancer|We are investigating patients before and after planned surgery for colorectal cancer.
1588143|NCT02323451|Device|Medical Chitosan|intra-articular injection
1588144|NCT02323451|Drug|Sodium Hyaluronate Injection|intra-articular injection
1588145|NCT02323438|Other|Usual Brand Cigarette|Combustible cigarette brand style smoked most frequently by subject
1588146|NCT02323438|Other|Electronic Cigarette #1|Electronic cigarette
1588147|NCT02323438|Other|Electronic Cigarette #2|Electronic cigarette
1588148|NCT02323438|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
1588149|NCT02323425|Device|Remote ischemic postconditioning|Remote ischemic postconditioning（RIPC）treatment was performed by the inflating a cuff around bilateral arms to 180 mmHg with 5 cycles of 3 min inflation and 5 min relax alternation automatically.
1588150|NCT02323412|Drug|Amoxicillin (Amoksicillintrihydrat)|Amoxicillin tablets 750 mg 1x3 for 100 days (oral intake).
1588151|NCT02323412|Drug|Placebo|Placebo tablets 1x3 for 100 days (oral intake).
1588152|NCT02323399|Drug|Phenylephrine|one of six initial treatments Phenylephrine Hydrochloride Injection (PHI) will be initially administered to approximately 50 subjects as an intravenous bolus (IV-B) at Low (1 μg/kg), Med (3 μg/kg), or High (5 μg/kg) level; PHI will be initially administered to approximately 50 subjects as a continuous intravenous infusion (IV-I) at Low (0.25 μg/kg/min), Med (0.75 μg/kg/min), or High (1.25 μg/kg/min) level]; each initial treatment group will have two PK sampling schedules.
1588153|NCT02323386|Device|Primary Total Knee Arthroplasty (ATTUNE Knee System)|"The patient will undergo primary Total Knee ArthroplastY use ATTUNE Knee System. During surgery a navigation system will be used to record preoperative joint kinematics under different tests. During the test the 6 degrees of freedom (DOF) of the joint will be computed and shown to the surgeon; these are the femoral rotation and translation pattern against flexion ranges. Navigation system will be also used to monitor the implant positioning and possible surgical bias. Dynamic RSA will be used to analyze the in vivo kinematics of the prosthesis at 6 months follow-up.
The above mentioned motion tests will be performed 3 times. The first 2 will be executed to gain comfort with the experimental set-up with no X-ray exposure. During the last data is collected."
1588154|NCT02323373|Drug|Tranexamic Acid - topical|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this study arm, the drug is administered topically on the wound.
1588155|NCT02323373|Drug|Placebo|100 ml of saline solution administered with anesthesia during 10 minutes
1588156|NCT02323373|Drug|Tranexamic Acid - intravenous|Tranexamic acid is an antifibrinolytic agent that decreases perioperative blood loss, because it inhibits fibrinolysis by competing with lysine molecule in coupling sites in fibrinogen. In this arm, the drug is administered intravenously.
1588157|NCT02323360|Radiation|SBRT|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to stereotactic radiotherapy in 3 or 6 daily fractions
1588158|NCT02323360|Procedure|TACE|Patients with single nodule no more 5 cm or 1- 3 nodules no more 3 cm in diameter after incomplete TAE or TACE, are randomized to a new cycle of TAE or TACE
1588159|NCT02323347|Other|Progesterone|Progesterone level
1588160|NCT02323334|Drug|LY3202626|administered orally
1588161|NCT02323334|Drug|Placebo (Part A, B, C)|administered orally
1588162|NCT02323334|Drug|Itraconazole|administered orally
1588163|NCT02323321|Device|Preservation of Hearts for Transplantation|Preserving and Assessing Expanded Criteria Donor Hearts for Transplantation
1588164|NCT02323308|Other|blood sampling|
1588165|NCT02323295|Radiation|Radiation|For surgical candidates, the standard treatment includes pre-operative radiation of 50.4 Gy, followed by a recovery period of approximately 4 to 5 weeks. After this surgery will take place. After approximately 6 weeks of recovery, to allow the surgical incision to heal, the patient is treated with another 19.8 Gy up to 27 Gy of radiation postoperatively depending on the final margin status (higher for gross residual disease) Non-surgical candidates receive 72 up to 77.14 Gy of radiation depending on the histology (72 Gy for osteosarcoma and chondrosarcoma and 77.4 Gy for chordoma)
1588166|NCT02323295|Procedure|Malignant Tumor Surgery|Surgery involves removing the malignant tumor in the sacrum in one piece, preferably with a cuff of normal tissue around the tumor
1588167|NCT02323282|Drug|ropivacaine|
1588168|NCT02323269|Drug|dimethyl fumarate|administered according to the local product label (i.e., Canadian Product Monograph).
1588173|NCT02323243|Device|"Allium  Bulbar Urethral Stent  (BUS) system"|
1588174|NCT02323230|Biological|DPX-Survivac|Immunotherapeutic vaccine targeting survivin antigen will be administered subcutaneously
1588179|NCT02323204|Behavioral|Link for Injured Kids|Psychological First Aid
1588180|NCT02323204|Other|So you've been in an accident|Educational materials
1588181|NCT02323191|Drug|Atezolizumab|Participants will receive atezolizumab intravenously at a fixed dose of 1200 milligram (mg) q3w.
1588182|NCT02323191|Drug|Emactuzumab|Participants will receive emactuzumab intravenously in ascending dose levels with a starting dose of 500 mg.
1588183|NCT02323178|Drug|eltrombopag|initial dose of 100 mg once daily, then the dose can be sequentially increased every 2 weeks by 100 mg steps up to a maximum dose of 300mg/day
1588184|NCT02323165|Other|Molecular Detection of Bacteria in the Bloodstream|Extracted nucleic acid will be tested by Polymerase Chain Reaction (PCR) with universal bacterial 16 S amplifiers from known 16 S sequences that routinely contaminate reagents. Polymerase Chain Reaction (PCR) will be performed with both TaqMan assays to provide quantitative copy numbers, as well as traditional PCR that can produce products that can be sequenced to confirm bacterial species identification.
1588185|NCT02323152|Behavioral|psychoeducation|Usual treatment + psychoteraphy focused on problem solving (6 sessions). The psychoeducational programme consists of 6 sessions of 60 minutes, one per week.
1588186|NCT02323152|Other|Standard care|Puerperal control with their doctor. This group will also be interviewed with the same frecuency of the experimental group but will not receive a psichologycal treatment
1588187|NCT02323139|Drug|Azacitidine and LDE255|Azacitidine at maximum tolerated dose. LDE255 at dose escalation (200, 400 or 800 mg)
1588188|NCT02323126|Drug|EGF816|
1588189|NCT02323126|Drug|INC280|
1588190|NCT02323126|Drug|Nivolumab|
1588191|NCT02323113|Drug|TAK-659|TAK-659 tablets taken orally once daily.
1588192|NCT02323100|Drug|Ravicti low dose|8 am, 4pm and midnight
1588193|NCT02323100|Drug|Ravicti high dose|8 am, 4pm and midnight
1588194|NCT02323100|Drug|Placebo|8 am, 4pm and midnight
1588195|NCT02323087|Device|FLEXICULT™ SSI-Urinary Kit|Urine culture and sensitivity testing will be performed on the intervention group by means of a POCT, the FLEXICULT™ SSI-Urinary Kit. The kit is designed as an ordinary Petri dish but with higher sides. The Petri dish is divided into 6 compartments: 1 large one for quantitative analysis and 5 smaller ones for susceptibility testing (Fig. 1). The agar in each of the smaller compartments contains 1 of 5 antimicrobials: trimethoprim, sulfamethoxazole, ampicillin, nitrofurantoin and mecillinam. The agar plate is flooded with the urine specimen for a couple of seconds and then incubated at 35°C over night. The following day the plate is read. When reading the compartment for quantitative analysis the lower limit is:103 colony-forming units (cfu) per milliliter.
1588196|NCT02323087|Device|ID FlexicultTM|Point of care culture will be performed using ID FlexicultTM,which is a chromogenic agar plate for identification and quantitation of urinary tract pathogens. The agar plate is for cultivation of urine, which makes it possible to identify the bacteria and quantitate the amount of bacteria. Based on bacterial colony color and size can be determined which bacteria are involved. For example, an E. coli bacteria will grow with big red colonies, and Enterobacter sp. will grow with large dark blue / purple colonies. The sample is seeded with a 10 uL inoculation needle, the lid is applied and the agar plate incubated with the lid down at 35 0C overnight. The plate is read the next day
1588197|NCT02323074|Procedure|Brain Computer Interface|
1588198|NCT02323061|Procedure|BCI using EEG signals|A robot hand will be used and controlled by the system in real time based on EEG pattern for identification of motion intention for hand movements in the cortex.
1994800|NCT02915822|Procedure|Minimally Invasive Chevron/Akin osteotomy|Minimally invasive technique for hallux valgus correction
1994801|NCT02915822|Procedure|Open Scarf/Akin osteotomy|Open technique for Hallux Valgus correction
1588201|NCT02323035|Device|Headgear|Investigative Headgear with CPAP Mask.
1588202|NCT02323022|Drug|IAC regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Cladribine 5mg/msq/d (d1-5), Ara-C 100mg/msq/d(d1-7) and IDA 8mg/msq/d (d1-3)
1588203|NCT02323022|Drug|High-dose IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 12mg/msq/d (d1-3)
1588204|NCT02323022|Drug|Intermediate-dose IA regimen|Induction treatment for initially diagnosed AML with IAC regimen, including Ara-C 100mg/msq/d (d1-7) and IDA 10mg/msq/d (d1-3)
1588205|NCT02323009|Device|Esophageal Balloon|Esophageal balloon was used to measure esophageal pressure (Paux) which was used as an estimate of pleural pressure. Transpulmonary pressure (Ptp) was calculated as the difference between airway pressure (Pao) and Paux. Applied PEEP was then adjusted to overcome negative Ptp which we maintained between 0 to 10 cm H20. All measurements were made at end-expiration.
1588206|NCT02323009|Other|Cstat|PEEP was adjusted to achieve the best CStat in this group of patients
1588207|NCT02322996|Other|questionnaires|The deep phenotyping of acute pain will be conducted using the oral surgery model. Before surgery, subjects will undergo QST and answer short-form questionnaires related to pain and activities of daily living.
1588208|NCT02322983|Behavioral|Control of Stress|To control stress were measured (at different times: T1, T2, T3 and T4) Venham's Score, Heart Rate, Respiratory Rate, and the titration of gases.
1588209|NCT02322970|Device|transcranial Doppler|Comparison of non invasive intracranial pressure (through use of transcranial Doppler ) vs invasive monitoring (through insertion of intracerebral catheters) with the purpose of comparing these two techniques in terms of specificity and sensitivity.
1588210|NCT02322957|Drug|FV-100|Subjects will be randomized to one of two treatment sequences: AB or BA.
1588211|NCT02322944|Behavioral|Quality improvement strategies and tools|Training in standardized treatment pattern; building quality management team and determining improvement goals; tools (a wristband in order to remind all medical staff involved in the treatment process; workflow posters and cards; a CRF including a flowchart to inform the management steps); periodical quality feedback report and regular quality meeting; study website serving as the communication platform.
1588212|NCT02322944|Behavioral|Process optimization|Examining local hospitals' workflow to determine the key link affecting the rate of reperfusion therapy and its timeliness (such as thrombolytic drug preparation, cardiac catheterization laboratory preparation, transferring from the ER to the cath lab, interventional medical team gathering, etc.) and systems (such as pre-paid policy for thrombolysis or PPCI)
1588259|NCT02322567|Other|medical records|review of medical records
1588213|NCT02322931|Procedure|Intra-operative C-arm CT imaging|"Two intra-operative C-arm 3D reconstruction scans with the Ziehm Vision FD Vario 3D immediately after treatment implantation, once with the TRUS probe inserted and once with the TRUS probe removed. This involves approximately 10 fluoroscopy snapshots of the prostate.
Two TRUS Sagittal B-mode sweeps and two TRUS axial B-mode sweeps, once mid-way, i.e. after implanting a sub-set of the seeds, and once at the end of the implantation procedure.
One Cine loop C-arm scan in the sagittal plane while retracting the probe.
One 3D C-arm scan immediately after the treatment, with the TRUS probe removed and the patient in the supine position (i.e. legs down)."
1588214|NCT02322918|Genetic|Blood samples for whole genomic/transcriptomic sequencing|Participant will receive one blood draw whereby two samples will be extracted. If the participant wishes to participate in the study but is fearful of needles, they may be given the option to provide a saliva sample. A retrospective medical chart review will be performed after participant is discharged from BCPP in order to obtain a full phenotype. Genotyping of BDNF and COMT will be performed. Protein levels of BDNF will be determined. The remaining blood or saliva samples will be stored over the long-term in a biorepository at the BC Mental Health and Addictions Research Institute. A retrospective medical chart review will be completed after the participant is discharged.
1588215|NCT02322905|Behavioral|Emotion Regulation Therapy|8 sessions of ERT
1588216|NCT02322892|Drug|Thiamine|200 mg thiamine in 50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
1588217|NCT02322892|Drug|Normal saline solution|50 mL normal saline once immediately before surgery and once immediately after (at arrival in the intensive care unit)
1588218|NCT02322879|Drug|First Treatment Period|(duration: 14 days) Subjects will be randomized to receive either of the 2 interventions (4 grams of solid acetaminophen formulation for two weeks vs. 4 grams of solid acetaminophen formulation + 70 mg/kg/day of liquid propylene glycol)
1588219|NCT02322879|Other|Washout|(duration: 14 days) At the end of the First intervention period all participants will enter a washout period.
1588220|NCT02322879|Drug|Second Treatment Period|(duration: 14 days) At the end of the washout period, participants will receive the alternative intervention.
1588221|NCT02322866|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day, 1 hour prior to eating or 2 hours after eating
1588222|NCT02322866|Drug|Placebo|Dose-matched placebo, taken orally at the same time each day, 1 hour prior to eating or 2 hours after eating
1588223|NCT02322853|Drug|Tamoxifen|hormonotherapy
1588224|NCT02322853|Drug|Ralimetinib (LY2228820 dimesylate)|
1588225|NCT02322814|Drug|Cobimetinib|Cobimetinib will be administered orally at a dose of 60 milligrams (mg) per day, once a day, on Day 3 through Day 23 of each 28-day treatment cycle.
1588226|NCT02322814|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 mg/m^2 by IV infusion on Day 1, Day 8, and Day 15 of each 28-day cycle according to prescribing information.
1588227|NCT02322814|Drug|Placebo|Cobimetinib placebo will be administered orally, once a day, on Day 3 through Day 23 of each 28 day treatment cycle.
1588228|NCT02322814|Drug|Atezolizumab|Atezolizumab will be administered to Cohorts II and III at a dose of 840 milligrams (mg) intravenously (IV) every 2 weeks on Days 1 and 15 of each 28-day treatment cycle.
1588229|NCT02322814|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered to Cohort III according to the local prescribing information at a starting dose of 100 millimeters per square meters (mg/m^2) by IV infusion on Days 1, 8, and 15 of each 28 day cycle.
1588230|NCT02322788|Drug|Terbutaline sulphate|Bricanyl Turbuhaler M2
1588231|NCT02322788|Drug|Terbutaline sulphate|Bricanyl Turbuhaler M3
1588232|NCT02322788|Drug|Placebo for terbutaline sulphate|Placebo Turbuhaler M2
1588233|NCT02322788|Drug|Placebo for terbutaline sulphate|Placebo Turbuhaler M3
1588234|NCT02322775|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
1588235|NCT02322775|Biological|Placebo|Placebo administered subcutaneously every 4 weeks
1588236|NCT02322749|Drug|selumetinib 75mg single dose|3 blue capsules of 25 mg given as a single dose
1588237|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
1588238|NCT02322749|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
1588241|NCT02322697|Drug|Intravenous administration of L-carnitine|Chronic intravenous administration of L-carnitine (1000mg on each dialysis session) for 1 year in hemodialysis patients
1588242|NCT02322684|Device|Air-Q|Air-Q/Intubating Laryngeal Airway (air-Q/ILA, Cookgas LLC, St. Louis, MO, USA) is an extra glottis airway (EGA) used as a primary airway device or as an adjunct to tracheal intubation. The air-Q/ILA is available as a disposable (air-Q) or nondisposable (ILA) device
1588243|NCT02322671|Drug|Reference Montelukast|It is available as pink, round, bi-convex-shaped chewable tablet of reference 5 mg montelukast sodium (innovator product). that has to be placed on the tongue and chewed immediately.
1588244|NCT02322671|Drug|Test 1 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 1: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
1588245|NCT02322671|Drug|Test 2 Montelukast|It will be provided as pink, round, bi-convex-shaped chewable tablet of test formulation 2: 5mg montelukast sodium (GW483100) that has to be placed on the tongue and chewed immediately.
1588246|NCT02322658|Drug|Eszopiclone Tablets 3 mg|
1588247|NCT02322645|Drug|Eszopiclone Tablets 3 mg|
1588248|NCT02322632|Drug|Paricalcitol Capsules, 4 mcg|Paricalcitol Capsules, 4 mcg of Dr. Reddy's Laboratories Limited
1588249|NCT02322619|Drug|Moxifloxacin Tablets 400 mg|Moxifloxacin Tablets 400 mg of Dr. Reddy's Laboratories Limited
1588250|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
1588251|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
1588252|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet or TAK-137 0.5 mg tablet, TAK-137 placebo tablet|
1588253|NCT02322606|Drug|TAK-137 5mg tablet, TAK-137 placebo tablet|
1588254|NCT02322606|Drug|TAK-137 5 mg tablet, TAK-137 placebo tablet|
1588255|NCT02322606|Drug|TAK-137 5mg tablet, TAK-137 placebo tablet|
1588256|NCT02322593|Drug|TAS-118 plus Oxaliplatin|
1588257|NCT02322593|Drug|S-1 plus Cisplatin|
1588260|NCT02322554|Biological|Cellular and tissue based products|Procedure: Application of device or biological to wounds
1588261|NCT02322541|Other|Garlic Intervention|Participants will consume an Allium-free controlled diet for 3 days. On the 4th day, they will consume a test meal containing garlic followed by blood and urine collections for 10 hours. On the 5th day, participants will have a fasting blood and urine collection.
1588262|NCT02322528|Drug|Administration of Lotemax|An FDA approved drug (Lotemax) will be administered to induce an inflammatory mediated response in both eyes.
1588263|NCT02322515|Other|Intervention taping|A rigid patellar taping will be used for the correction in lateralization of the patella and more stabilization of the knee.
1588264|NCT02322515|Other|Placebo Taping|A rigid patellar taping will be used in the vertical position and without no correction in lateralization of the patella and/or stabilization of the knee.
1588265|NCT02322502|Drug|Desflurane|inhalation with laryngeal mask to maintain anaesthesia
1588266|NCT02322502|Drug|Sevoflurane|inhalation with laryngeal mask to maintain anaesthesia
1588267|NCT02322502|Drug|propofol|intravenous injection to maintain anaesthesia
1588268|NCT02322489|Device|Microcurrent Therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started and lasts for one hour.
1588269|NCT02322489|Device|Sham microcurrent therapy|Several electrodes are placed over the muscles involved in the provocative task. The microcurrent therapy is then started but lasts only for five seconds.
1588270|NCT02322476|Other|No intervention will be performed|No intervention will be performed
1588271|NCT02322463|Drug|Arab children|Treatment with Oxycodone
1588272|NCT02322450|Drug|QGC001|
1588273|NCT02322450|Drug|Placebo|
1588274|NCT02322437|Other|Home treatment|Patients are treated at home whenever possible and appropriate
1588275|NCT02322437|Other|Treatment As Usual|Patients are treated at a mental hospital
1588276|NCT02322424|Procedure|pancreaticoduodenectomy|
1588279|NCT02322398|Drug|rFSH plus rLH|150-300 IU/d rFSH plus 75-150 IU/d rLH in 2:1 ratio
1588280|NCT02322398|Drug|hMG|150-300 IU/d hMG
1588281|NCT02322372|Drug|Femoral blockade|Spinal anesthesia with heavy bupivacaine combined with femoral blockade with bupivacaine
1588282|NCT02322372|Drug|Intrathecal anesthesia|Spinal anesthesia with heavy bupivacaine
1588283|NCT02322346|Other|Group S|"Peritonsillar infiltration with saline Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.
During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
1588284|NCT02322346|Drug|Group LL|"Peritonsillar infiltration with low-dose of levobupivacaine 0.25%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.
During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
1588285|NCT02322346|Drug|Group HL|"Peritonsillar infiltration with high dose of levobupivacaine 0.5%. Additional remifentanil 1 µgr kg-1 IV was administered to the patients if HR was increased by 25 % of the basal value.
During postoperative period, symptoms such as pain, fever and dysphagia, adverse affects such as nausea and vomiting and hemorrhage were evaluated. Pain was evaluated by FLACC (Faces, leg, activity, cry, consolability), FPRS (Faces pain rating scale) ve Wong-Baker facies scales at postoperative 0, 30 and 60 minutes and 2, 6, 12 and 24 hours. Total analgesic consumption during the postoperative period were recorded. If the patients had no complication, they were discharged at the postoperative 24th hour."
1588286|NCT02322333|Drug|MLD10|
1588287|NCT02322333|Drug|Placebo|
1588288|NCT02322320|Drug|Lenalidomide|In BMT CTN 0702, maintenance therapy with lenalidomide started at 10 mg daily for three months and increased to 15 mg daily. The duration of maintenance was three years in all treatment arms. Lenalidomide will be administered initially at the patient's last documented dose prior to discontinuation of BMT CTN 0702 lenalidomide maintenance therapy. Cycle duration is 28 days. Patients will continue lenalidomide until disease progression, or discontinuation due to toxicity, death, or withdrawal from the study.
1588289|NCT02322307|Other|HealthPROMISE users|"Patients using HealthPROMISE will be asked to use the application once every two weeks at a minimum to provide updates on health information. Providers can use the data entered by patients in real time. Patients will get alerts requesting them to contact their providers if their quality of life scores fall below a certain threshold or their symptoms scores are worrisome. Both patients and physicians are also sent regular notifications with data about their own health or health of their patient panel respectively. Both patients and providers are encouraged to use existing communication tools (phone, office visits, personal health records) since direct patient-physician messaging is not provided in the HealthPROMISE platform. Reminders through app, email and SMS will be used to facilitate patient engagement.
Physicians will also be encouraged to check the physician panel to see how patients are doing through weekly updates and monthly quality improvement meetings."
1588290|NCT02322307|Other|Control Group|In order to eliminate a placebo effect, patients in both groups will get an app customized for IBD. Physician and rest of care team will not be blinded since they will use HealthPROMISE dashboard to get alerts and notifications.
1588291|NCT02322294|Dietary Supplement|Glucodia™|
1588292|NCT02322294|Other|Placebo|
1588293|NCT02322281|Drug|Rociletinib|
1588294|NCT02322281|Drug|Pemetrexed or gemcitabine or paclitaxel or docetaxel|
1588375|NCT02321579|Dietary Supplement|vitamin B-6|50 mg/d
1588295|NCT02322268|Dietary Supplement|Cosmos Caudatus|15g of Cosmos caudatus consumed with lunch or dinner
1588296|NCT02322242|Drug|Systemic Dexamethasone|Intravenous infusion of dexamethasone (4mg)
1588297|NCT02322242|Drug|Perineural dexamethasone|Perinerual administration of dexamethasone (4mg)
1994802|NCT02915575|Other|Risk guided follow-up|Participant will be stratified for risk of CKD in three groups: Low (<20% risk of CKD), medium (20-50% risk of CKD) and high (>50% risk of CKD). Specific follow-up will be guided by risk status
1588299|NCT02322216|Drug|Olopatadine Hydrochloride Ophthalmic Solution 0.2%|
1588300|NCT02322216|Drug|Olopatadine Hydrochloride Ophthalmic Solution 0.1%|
1588301|NCT02322216|Drug|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
1994803|NCT02915575|Other|Usual Care|Participants will be discharged as per usual ward discharge protocols.
1588305|NCT02322138|Other|Experimental 1 Infant Formula|Ready to feed infant formula to be fed ad-libitum
1588306|NCT02322138|Other|Experimental 2 Infant Formula|Ready to feed infant formula to be fed ad-libitum
1588307|NCT02322138|Other|Reference Group|Breast fed ad libitum
1588308|NCT02322125|Device|ReWalk|Intensive training with the ReWalk to negotiate smooth ground, rough terrain indoors and outdoors, ascending and descending slopes and steps, in a home setting and in the community.
1588309|NCT02322112|Other|Microcrystalline Cellulose Supplementation|Fifty overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of MCC (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
1588310|NCT02322112|Other|Acacia Gum Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of AG (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
1588311|NCT02322112|Other|Resistant Starch Type 4 Supplementation|Seventy five overweight and mildly obese subjects will supplement their normal dietary intake with a significant yet tolerable amount of RS4 (Females: 25 g; Males: 35 g) daily for six consecutive weeks.
1588312|NCT02322099|Drug|Alendronate|alendronate 70 mg tablets to be administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART initiation
1588313|NCT02322099|Drug|Placebo|Sugar pill manufactured to mimic alendronate 70 mg tablet administered weekly for a total of 14 weeks, commencing 2 weeks prior to ART
1588314|NCT02322099|Dietary Supplement|calcium carbonate and colecalciferol|Calcium carbonate 1250 mg (equivalent to 500 mg of elemental calcium) and colecalciferol 400 iu (equivalent to 10 micrograms of vitamin D3) tablets administered twice daily for a total of 14 weeks, commencing 2 weeks prior to ART initiation
1588315|NCT02322099|Drug|Tenofovir disoproxil|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label) commencing 2 weeks after alendronate initiation and continuing for 48 weeks
1588316|NCT02322086|Drug|Topical Rose Bengal, 0.005%|Subjects will apply PH-10 vehicle daily for 28 consecutive days followed by active PH-10 daily for 28 consecutive days to their plaque psoriasis areas on the trunk or extremities (excluding palms, soles, scalp, facial and intertriginous sites).
1588317|NCT02322073|Procedure|Laparoscopic surgery|Roux-en-Y gastric bypass or other benign laparoscopic surgery
1588318|NCT02322060|Procedure|Ovariotomy|Remove one ovary (maybe both ovaries depending on the condition) by laparoscopic surgery or by laparotomy in some cases.
1588319|NCT02322060|Procedure|Activate dormant follicles|Cut ovary into small cubes, which are then cultured with medium containing BPV(pic), a PTEN inhibitor, and 740YP, an activator of phosphoinositol 3 kinase, to activate dormant follicles for 2 days before transplantation.
1588320|NCT02322060|Procedure|Ovary tissue transplantation|After extensive washing to remove drugs, the ovary cubes are transplanted beneath the membrane of both Fallopian tubes and the remaining ovary under laparoscopic surgery.
1588321|NCT02322047|Drug|Prazosin|Prazosin Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 15-49: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
1588322|NCT02322047|Drug|Naltrexone|Naltrexone Dosing Days 1-49: 50mg @ 9PM
1588323|NCT02322047|Drug|Placebo|Placebo Dosing Days 1-2: 1 mg @ 9PM Days 3-4: 1 mg @ 9AM, 3PM, 9PM Days 5-7: 2 mg @ 9AM, 3PM, 9PM Days 8-10: 2mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 11-14: 4mg @ 9 AM, 3 PM; 6mg @ 9 PM Days 15-49: 4mg @ 9 AM, 3 PM; 8mg @ 9 PM
1588324|NCT02322047|Drug|Placebo|Placebo Dosing Days 1-49: 50mg @ 9PM
1588325|NCT02322034|Other|Interval Training|Exercise training protocol (high intensity, interval training) is followed by the enrolled patients on hospital outpatient-based regimen 3 times/week for 24 weeks. The high intensity group will perform interval cycling for 4 minutes with 1-minute rest between intervals. High intensity exercise will be 90-95% peak heart rate. The exercise intensity will be established, and maintained throughout the 24-week exercise training period, by calculating the heart rate range as a percentage of maximum (90-95%) as obtained from the most recent cardiopulmonary exercise test. Every 4 weeks during the training program, the exercise intensity will be titrated to the same relative percentage of maximum (90-95%) as it is assumed most patients will become fitter over the training period.
1588328|NCT02322008|Biological|infliximab and adalimumab|In this retrospective, observational study, no interventions were undertaken by the researchers.
1588329|NCT02321982|Other|Same-day preoperative consultation|Preoperative consultation occurs on the same day as Mohs surgery
1588376|NCT02321579|Dietary Supplement|Glutathione|500 mg/d
1588377|NCT02321579|Dietary Supplement|Dextrins|50 mg/d
1994804|NCT02914340|Device|Spiration Valve System|
1994806|NCT02914665|Drug|elamipretide|20 mg elamipretide administered intravenously once daily for 7 consecutive days
1994807|NCT02914665|Drug|Placebo|Placebo administered intravenously once daily for 7 consecutive days
1588330|NCT02321969|Dietary Supplement|GTE (green tea extract)|6 GTE tablets per day. Daily dose is equivalent of 9 cup-of-green tea per day (0.9 g/day GTE, 0.6 g/day epigallocatechin gallate [EGCG]).
1588331|NCT02321956|Diagnostic Test|Ultrasound|Using ultrasound to determine the size of endotracheal tube
2008936|NCT03326141|Device|PAM|We will use Fitbit Charge 2 (or an equivalent). Features essential for this research include built-in accelerometers that accurately measure steps and physical activity (PA) duration.Participants will have a brief orientation to these during baseline data collection and have the opportunity to return demonstrate. In addition, RAs will be available to help participants troubleshoot, as needed, via telephone and in person, after intervention meetings. Intervention meetings include discussions about the PAMs, but topics vary according to assigned study condition.
1588333|NCT02321917|Device|MECC system with rheoparin coating|MECC system for extracorporeal circulation equipped with rheoparin coating.
2008937|NCT03326141|Behavioral|Interpersonal Behavior Change Strategies|The interpersonal content will include facilitated discussed about including PA into social routines, identifying and problem-solving social and environmental barriers to PA, social support for exercise, and friendly social comparisons about practicing PA outside the small group setting and interpreting/ sharing data.
2008938|NCT03326141|Behavioral|Intrapersonal Behavior Change Strategies|The intrapersonal content will include encouragement and guidance to identify baseline PA patterns, develop and refine personally meaningful goals and plans, identify and problem solve personal barriers to staying physically active, integrate PA into personal routines, and monitor goal outcomes
1588339|NCT02321891|Device|NeuroConn DC Stimulator Plus, tDCS|transcranial electrical stimulation intervention with two experimental protocols
1588340|NCT02321878|Drug|liraglutide|"Liraglutide (Victoza®) will be prescribed by the physician under normal clinical practice conditions.
No treatment given."
1588341|NCT02321865|Drug|NPC-02|
1588342|NCT02321852|Drug|Triflusal|Once daily oral administration of 600 mg triflusal Disgren® for 7 days.
1588343|NCT02321852|Drug|Placebo|Once daily oral administration of placebo mannitol for 7 days
1588344|NCT02321839|Drug|Intraviteal Ranibizumab 0.5mg|Intraviteal Ranibizumab 0.5mg
1588345|NCT02321826|Behavioral|Music|Participants choice among 4 genres of music matched on music characteristics
1588346|NCT02321826|Behavioral|Audiobook|Participants choice among 4 types of audiobooks
1588347|NCT02321813|Behavioral|quality of life pathway|Quality of life measurement, diagnosis and tailored therapy (pain therapy, psychotherapy, social support, nutrition, stoma care, physiotherapy, fitness)
1588348|NCT02321813|Other|placebo control|Quality of life measurement
1588349|NCT02321800|Drug|S-649266|2000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function and body weight)
1588350|NCT02321800|Drug|Imipenem/cilastatin|1000 mg intravenously every 8 hours for a period of 7 to 14 days (dosage adjustment is necessary based on renal function and body weight)
1588351|NCT02321787|Procedure|Ultrasound for confirmation of successful caudal block|Use of ultrasound for confirmation of successful caudal block
1588352|NCT02321761|Drug|Amantadine hydrochloride|Drug dosages: day 0-14 no drug will be given Days 15-21 100 mg Days 22-28 200 mg Days 29-42 400 mg Days 43-56 200 day 57-70 no drug will be given
1588353|NCT02321748|Drug|Montelukast|
1588354|NCT02321748|Drug|ASP2151|
1588355|NCT02321735|Behavioral|Quality of life questionaire|Patients will participate in a QOL questionaire followed by a phone interview
1588356|NCT02321709|Drug|SAR113244|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1588357|NCT02321709|Drug|placebo|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1588358|NCT02321696|Device|Acupuncture|
1588359|NCT02321696|Other|Physiotherapy and eccentric exercise|
1588360|NCT02321696|Other|Watchful waiting and eccentric exercise|
1588361|NCT02321696|Other|eccentric exercise|
1588362|NCT02321683|Device|Taperloc|Femoral stem with electrochemical deposition of hydroxyapatite
1588363|NCT02321670|Procedure|End-to-end|Excision of the stricture and end-to-end anastomosis of the urethra.
1588364|NCT02321670|Procedure|Graft|Incision of stricture and grafting procedure with buccal mucosa where the corpus spongiosum is not divided
1588365|NCT02321657|Other|iPad app containing art, music and games|An iPad app that takes demographic information on a child and suggests suitable art, music and games for use by the anaesthetist and nurse to distract them during anaesthetics
1588366|NCT02321657|Other|Toys, books and games|Games, books and toys used to distract
1588367|NCT02321644|Drug|CC-90001|CC-90001 Active-ingredient-in-capsule and formulated tablet
1588368|NCT02321631|Dietary Supplement|EPA-enriched supplement|EPA-enriched supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement composes of 2.2 gm of EPA and 630 kcal daily.
1588369|NCT02321631|Dietary Supplement|standard formula supplement|The standard formula supplement is given to the patients for 3 weeks (1 week prior to surgery and 2 weeks post surgery). The supplement is 630 kcal daily without EPA.
1588370|NCT02321618|Behavioral|BP measurement & pharmacy|Blood pressure monitoring by barber, blood pressure medication management by pharmacist, role model posters encouraging program participation
1588371|NCT02321618|Behavioral|BP educational materials|Exposure to hypertension educational materials
1588372|NCT02321605|Behavioral|e-BPS|"Participants are asked to write and imagine about a future in which they have reached all their goals and they have developed all their potentialities in four different domains: personal, professional, social and health domain.
They carry out the exercise in a Positive Technology System called the Book of Life, which has shown efficacy in the enhancement of positive mood (Baños, Etchemendy, Farfallini, García-Palacios, Quero & Botella, 2014). This application looks like a personal diary, where participants can write all that they want and these essays are supported by multimedia content (pictures, songs and videos). Additionally, they can continue doing the exercise in a web platform in which they can visualize all the content they had developed previously."
1588373|NCT02321605|Behavioral|Daily Activities|Participants are asked to think and write about all that they have done the last 24 hours. They carry out the exercise in a powerpoint document, where they can record all the activities, situations and thoughts.
1588374|NCT02321592|Drug|AFM13|
1588378|NCT02321566|Device|Epidural Motor Cortex Stimulation|
1588379|NCT02321553|Other|Brown rice|brown rice cake
1588380|NCT02321553|Other|White rice|white rice cake
1588381|NCT02321540|Drug|Ibrutinib|"Part 1 Starting level of Ibrutinib: 560 mg by mouth daily in a 28 day cycle.
Part 2 Starting level of Ibrutinib: Maximum tolerated dose from Part 1 or 840 mg daily."
1588382|NCT02321527|Drug|Perflutren Protein-Type A Microspheres Injectable Suspension|Participants receive a subdermal periareolar injection of 0.2 - 0.5 cc of microbubble contrast Perflutren Protein-Type A Microspheres Injectable Suspension (OPTISON™) before breast ultrasound.
1588383|NCT02321527|Device|Contrast-Enhanced Ultrasound (CEUS)|Ultrasound images of breast and videos of tumor and lymph nodes in underarm area taken after Perflutren Protein-Type A Microspheres Injectable Suspension injection.
1588384|NCT02321527|Procedure|Biopsy + Radioactive Seed Placement|Biopsy of sentinel lymph node that was identified in ultrasound performed, and a titanium clip marker inserted into the node. After biopsy, a radioactive seed may be inserted into the node to allow surgeon to find and remove it during surgery.
1588385|NCT02321527|Behavioral|Phone Call|Participant called by phone 30 days after seed is removed to check for any side effects. This phone call should take about 10 minutes.
1588387|NCT02321501|Drug|Ceritinib (LDK378)|"Dose Escalation Phase Starting Dose of Ceritinib (LDK378) - No ALK Status: 450 mg by mouth once a day in a 28 day cycle.
Dose Expansion Phase Starting Dose of Ceritinib (LDK378) - No ALK Status: MTD from Dose Escalation Phase.
Dose Expansion Phase participants with non small cell lung cancer (NSCLC), with anaplastic lymphoma kinase (ALK+) expression on IHC who have progressed, treated with Ceritinib (LDK378) at MTD from Dose Escalation Phase."
1588388|NCT02321501|Drug|Ceritinib (LDK378) 750 mg|Dose Expansion Phase of Non small cell lung cancer (NSCLC) participants with anaplastic lymphoma kinase (ALK+) expression on IHC receive single agent Ceritinib (LDK378) at 750 mg by mouth once a day for a 28 day cycle.
1588389|NCT02321501|Drug|Everolimus|"Dose Escalation Phase Starting Dose of Everolimus: 5 mg by mouth once a day in a 28 day cycle.
Dose Expansion Phase Starting Dose of Everolimus: MTD from Dose Escalation Phase.
Dose Expansion Phase participants with non small cell lung cancer (NSCLC), with anaplastic lymphoma kinase (ALK+) expression on IHC who have progressed, treated with Everolimus at MTD from Dose Escalation Phase."
1588390|NCT02321475|Drug|EGb761®|
1588391|NCT02321462|Drug|Eziclen|Eziclen solution administered orally as split-dose the day before and on the day of colonoscopy.
1588392|NCT02321462|Drug|Fortrans®|Fortrans® solution administered orally as split-dose the day before and on the day of colonoscopy.
1588393|NCT02321436|Drug|BotulinumtoxinA|Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.
1588394|NCT02321436|Drug|Placebo|Placebo administered intramuscularly in the targeted upper limb.
1588395|NCT02321410|Other|Contrast enhanced ultrasound of the carotid plaque|visual grading of neovessel
1588396|NCT02321410|Other|Dynamic contrast-enhanced carotid plaque MRI|quantitative analysis of gadolinium enchantment in a region of interest
1588397|NCT02321397|Drug|Oxycodone|
1588398|NCT02321397|Drug|Naloxone|Prolonged Release Tablets
1588399|NCT02321384|Drug|Placebo|Placebo matched to RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
1588400|NCT02321384|Drug|RO6889678|RO6889678 will be administered orally as a single dose on Day 1 in SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in MAD cohorts.
1588401|NCT02321384|Drug|Midazolam|Single dose of 100 mcg midazolam solution will be administered orally, before (Day -1) and after (Day 14) the treatment with RO6889678 or matching placebo.
1588402|NCT02321384|Drug|Ritonavir|RTV will be administered orally as a single dose on Day 1 in RTV-boosted SAD cohorts and multiple doses BID from Day 1 to Day 14 (no second BID dose on Day 14) in RTV-boosted MAD cohorts.
1588403|NCT02321371|Drug|Lactulose + Rifaximin|Lactulose + addition of Rifaximin 400 mg 8th hourly through enteral route
1588404|NCT02321371|Drug|Lactulose|Continuation of Lactulose therapy for further 48 hours.
1588405|NCT02321358|Behavioral|Two-time implementation intention|Will be given intervention and booster at six weeks
1588406|NCT02321358|Behavioral|One-time implementation intention|Will only be given the intervention once
1588407|NCT02321358|Behavioral|Sham Comparator|Canada's Food Guide for Healthy Eating will be provided. This contains a small amount of physical activity information.
1588408|NCT02321358|Behavioral|Physical Activity Materials|Thera-Bands, instructional DVD and exercise handout, instructional stretching handout, CSEP Physical activity guidelines.
1588409|NCT02321345|Other|Palliative Care Support|Palliative care meetings Quality of Life Assessments
1588410|NCT02321332|Procedure|bilateral simultaneous endoscopic thoracic symapthectomy|Patients underwent bilateral simultaneous T2-T3 ganglionectomy using thoracoscopic approach.
1588411|NCT02321332|Procedure|unilateral sequential endoscopic thoracic symapthectomy.|Patients underwent unilateral T2-T3 ganglionectomy of the dominant side followed by T2-T3 ganglionectomy of the other side after 2 months interval.
1588412|NCT02321319|Drug|Hydromorphone HCl ER Tablets|
1588413|NCT02321306|Drug|LUM001|LUM001 administered orally once each day.
1588414|NCT02321293|Dietary Supplement|CurcuVIVA™|80 mg PO daily for 8 weeks with an option to reduce the dose based on individual tolerability
1588415|NCT02321293|Drug|Tyrosine Kinase Inhibitor gefitinib (Iressa)|250 mg PO daily until progression
1588416|NCT02321293|Drug|Tyrosine Kinase Inhibitor erlotinib (Tarceva)|150 mg PO daily until progression
1588417|NCT02321280|Drug|Denosumab|Single dose subcutaneous administration
1588418|NCT02321267|Drug|ranibizumab, aflibercept, pegaptanib, verteporphin|ranibizumab, intravitreal injections, 0.5mg, monthly or less aflibercept,intravitreal injections, 2.0mg, monthly or less pegaptanib, intravitreal injections, 0.3mg, every 6-week pars plana vitrectomy, once verteporphin, iv, 6mg/㎡
1588419|NCT02321254|Device|The RehaARM-Robot|Robot therapy by using a 3-Degrees-Of-Freedom (3DOFs) robot to train the shoulder.
1588420|NCT02321254|Behavioral|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities.
1589542|NCT02312544|Drug|Timolol|Timolol drops and placebo punctum plug
1588421|NCT02321241|Drug|Aflibercept (EYLEA, BAY-86-5321)|"st year: 3 monthly injections followed by 1 injection every two months
nd year and following: injection according the visual and anatomical results observed the 1st year"
1588422|NCT02321228|Procedure|Salpingectomy with delayed oophorectomy|Early salpingectomy upon completions of childbearing with postponement of oophorectomy until between 40 and 45 in BRCA1 mutation carriers and between age 45 and 50 in BRCA2 mutation carriers.
1588423|NCT02321228|Procedure|Risk-reducing salpingo-oophorectomy|This is the current guideline procedure, usually performed between age 35 and 40 in BRCA1 mutation carriers and between age 40 and 45 in BRCA2 mutation carriers.
1588424|NCT02321215|Other|Introductory Disease Education|This intervention will consist of two one-on-one education sessions, each lasting 30 minutes.
1588425|NCT02321202|Drug|Omega-3 Fatty Acid-Based Parenteral Nutrition|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 fatty acid [FA] mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
1588426|NCT02321202|Drug|Structolipid|"Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively."
1588427|NCT02321189|Drug|LONGEVINEX|let everyone of the participants oral 1 capsule containing 100 mg LONGEVINEX
1588428|NCT02321189|Drug|placebo|let everyone of the participants oral 1 capsule containing 100 mg placebo
1588429|NCT02321176|Drug|trans-resveratrol|"patients received 100mg Longevinex everyday,total of three days
1 capsule daily for one day containing 100 mg of trans resveratrol active ingredient"
1588430|NCT02321163|Device|NMES new paradigm|stimulation frequency: 2 Hz; intensity: low amplitude; duration: 3 hours, 2 times per day for 8 weeks
1588431|NCT02321163|Device|NMES conventional|stimulation frequency: 50 Hz; intensity: maximally tolerated; duration: 30 min per day for 8 weeks
1588432|NCT02321163|Device|NMES no stimulation|Placebo, electrode pad on, no stimulation
1588435|NCT02321137|Procedure|Surgical closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease. The operation as well as the pre and post-operative care will be performed according to local surgical policies.
1588436|NCT02321137|Procedure|No closure of left atrial appendage|aortic valve replacement with bioprosthesis according to indications in the current guidelines for the management of valvular heart disease.
1588437|NCT02321124|Other|connective tissue manipulation|We will apply connective tissue manipulation 5 days a week for four weeks.
1588438|NCT02321124|Behavioral|life style advice|We will apply life style advice for four weeks.
1588439|NCT02321111|Drug|Eritoran|Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.
1588440|NCT02321111|Drug|D5W (5% Dextrose in water)|D5W = 5% Dextrose Water Vehicle
1588441|NCT02321098|Drug|Loceryl Nail Lacquer|Once weekly application of Loceryl Nail Lacquer during 3 months (12 applications) in combination with cosmetic varnish
1588442|NCT02321098|Drug|Loceryl Nail Lacquer|Once weekly application of Loceryl Nail Lacquer during 3 months (12 applications)
1588443|NCT02321098|Drug|Loceryl Nail Lacquer follow up period|Once weekly application of Loceryl Nail Lacquer during 15 additional months
1588444|NCT02321098|Other|Cosmetic varnish|Once weekly application of cosmetic varnish during 3 months (12 applications) in combination with Loceryl Nail Lacquer
1588445|NCT02321085|Procedure|Sinus Rhythm control|
1588446|NCT02321085|Procedure|Pulse Rate control|
1588447|NCT02321072|Drug|Oxygen|
1588448|NCT02321059|Device|Measurement of abdominal wall strength|Test-retest examination of the reliability of the Goodstrength trunk dynamometer
1588449|NCT02321033|Dietary Supplement|soft drinks|soft drinks with palatinose and maltodextrin
1588450|NCT02321020|Procedure|Radiofrequency maze procedure|Radiofrequency energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In the first 70 patients a monopolar technology was employed (Cardioblate Surgical Ablation Pen, Medtronic Inc, Minneapolis, MN, USA - cooled tip cardioblate pen, power ranging from 25 to 35 W), while in the subset of patients who underwent surgery after July 2005 a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System, Medtronic Inc, Minneapolis, MN, USA). The tip of both types of RF probe was irrigated with saline at room temperature at a flow rate of 4-6 ml/min.
1588451|NCT02321020|Procedure|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography by the same cardiologist at 3,6,12 and 24 months in order to specifically monitor left atrial contractility presence.
1588452|NCT02320981|Diagnostic Test|Standard of Care esophagogastroduodenoscopy (EGD) with measurement of mucosal impedance|
1588453|NCT02320968|Other|MedclineTM Sleep Assist Pillow|The pillow is designed so that the sleeper can have proper upper-body elevation while sleeping on his or her left side without the need for placing blocks under the head of the bed and bothering anyone else who may be sleeping in the bed. The pillow supports the patient's head, back and body to provide comfort while reducing or relieving acid reflux symptoms during sleep.
1588504|NCT02320630|Drug|Entanercept|Both Entanercept and MTX were given to patients for 60weeks (Week0-Week60).
1588454|NCT02320955|Procedure|Reimplantation of cryoconserved bone flap|A bone flap, which was explanted for decompression of a swollen brain or following severe head trauma and which was cryoconserved in the meantime is reimplanted. This procedure is the gold-standard therapy after decompressive hemicraniectomy and is routinely performed.
1588455|NCT02320942|Other|Exercise Intervention|The semi-supervised intervention is a progressive program with a goal of three aerobic and two resistance exercise sessions per week. Aerobic exercise will consist of 20-40 minutes of bicycling using a stationary bike located on CP6 (supervised or un-supervised) or brisk walking at home. Resistance exercise will include exercise for the upper and lower extremities with stretch bands. Patients will complete at least one supervised aerobic and resistance session per week with the exercise trainer and complete a daily log of their exercise, including adherence, adverse events and symptoms.
1588456|NCT02320929|Procedure|Intraoperative flexor tendon sheath irrigation|
1588457|NCT02320929|Procedure|Postoperative flexor tendon sheath irrigation|
1588458|NCT02320916|Procedure|23Gauge|Arterial puncture will be made using a 23Gauge needle
1588459|NCT02320916|Procedure|25Gauge|Arterial puncture will be made using a 25Gauge needle
1588461|NCT02320890|Device|YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left(anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
1588462|NCT02320890|Device|sham-YBand (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
1588463|NCT02320877|Device|Mandibular Advancement Device (Somnomed Flex)|The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature
1588464|NCT02320864|Procedure|Total knee replacement surgery|The surgeon removes damaged cartilage and bone from the surface of the knee joint and replaces them with a man-made surface of metal and plastic.
1588465|NCT02320851|Behavioral|SVD-tailored Integrative Psychotherapy (IPT)|(see description of corresponding study arm)
1588466|NCT02320851|Behavioral|Self-help group (SHG)|(see description of corresponding study arm)
1588467|NCT02320838|Device|5 KHz|5 KHz transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1588468|NCT02320838|Device|TENS|TENS transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1588469|NCT02320838|Device|Sham stimulation|Sham transcutaneous electrical stimulation over superficial radial nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft, Netherlands)
1588470|NCT02320825|Radiation|single-fraction SRS|
1588471|NCT02320825|Radiation|high-dose hypofractionated SRS|
1588472|NCT02320825|Behavioral|Quality of Life Measures|
1588473|NCT02320812|Biological|human retinal progenitor cells|single intravitreal injection of 0.5 - 3.0 million human retinal progenitor cells (hRPC)
1588474|NCT02320799|Behavioral|interpersonal psychotherapy|Interpersonal psychotherapy is an evidence based, structured, brief psychotherapy which improves relationships in order to improve mood and reduce anxiety
1588475|NCT02320799|Behavioral|treatment as usual|Clinic psychosocial treatment as usual
1588476|NCT02320786|Behavioral|CoPILOT|Participants in both groups will receive twelve hours of training in a standard powered wheelchair however the CoPILOT groups will use remote control technology we have developed. The technology provides the trainer with remote control of wheelchair speed and direction allowing the trainer to override the participant's actions as needed to ensure safe error-free shared controlled wheelchair training. The CoPILOT approach will accommodate varied learning needs, as per adult learning principles, while decreasing trainer input until the participant can complete tasks independently.
1588477|NCT02320773|Drug|Betmiga®|Oral
1588478|NCT02320760|Behavioral|Physical activity on prescription|
1588479|NCT02320747|Other|Tai Chi|
1588480|NCT02320734|Drug|Rocuronium|Rocuronium given continuously to reach deep neuromuscular block
1588481|NCT02320721|Drug|Insulin Glargine (HOE901 - U300)|Self-administered by subcutaneous (SC) injection in the evening using a pre-filled pen. Dose titration to achieve fasting self-monitored plasma glucose (SMPG) from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
1588482|NCT02320721|Drug|Insulin Glargine (HOE901 - U100)|Self-administered by SC injection in the evening using a pre-filled pen. Dose titration to achieve fasting SMPG from 90 to 130 mg/dL (5.0 to 7.2 mmol/L).
1588483|NCT02320721|Drug|Background therapy|Non-insulin anti-diabetic drugs with the exception of thiazolidinediones.
1588484|NCT02320708|Drug|Acetaminophen (ACE) (1000 mg)|2 Test ACE 500 mg tablets taken orally one time
1588485|NCT02320708|Drug|Commercial ACE (1000 mg)|2 ACE 500 mg caplets taken orally one time
1588486|NCT02320708|Drug|Commercial Ibuprofen (IBU) (400 mg)|2 IBU 200 mg soft-gels taken orally one time
1588487|NCT02320708|Drug|Placebo|2 placebo caplets for acetaminophen taken orally one time
1588488|NCT02320708|Drug|Placebo|2 placebo soft-gels for ibuprofen taken orally one time
1588489|NCT02320708|Drug|Placebo|2 placebo tablets for Test acetaminophen taken orally one time
1588490|NCT02320695|Drug|Saline|
1588491|NCT02320695|Drug|Isopropyl Alcohol|
1588492|NCT02320695|Drug|Pain Relieving Cream|
1588493|NCT02320695|Drug|Antibiotic/Pain Relieving Ointment|
1588494|NCT02320695|Drug|Original Ointment|
1588495|NCT02320695|Drug|Pain Relief Ointment|
1588497|NCT02320669|Drug|Triostat|Bolus of Triiodothyronine followed by infusion for 48 hours
1588498|NCT02320669|Drug|Placebo|Bolus of Placebo followed by infusion for 48 hours
1588499|NCT02320656|Other|Blood sampling|Longitudinal (3 stages of the disease)
1588500|NCT02320656|Other|Bone marrow aspirate|Longitudinal (3 stages of the disease)
1588501|NCT02320656|Other|Skin biopsy|Single biopsy (optional)
1588502|NCT02320656|Other|Buccal swab|Single sampling.
1588503|NCT02320643|Device|Seratom® PA mesh|Partially absorbable mesh
1588505|NCT02320630|Drug|HCQ|Combination of HCQ+SSZ+MTX were given to patients for 60weeks (Week0-Week60).Entanercept was given to patients for 12 weeks (Week0-Week12).
1588506|NCT02320630|Drug|MTX|MTX was given to patients for 60weeks (Week0-Week60). Entanercept was given to patients for 12 weeks (Week0-Week12).
1588507|NCT02320617|Procedure|Diffusion Magnetic Resonance Imaging|Diffusion weighted imaging (DWI) is a form of magnetic resonance imaging based upon measuring the random Brownian motion of water molecules within a voxel of tissue. The relationship between histology and diffusion is complex, however generally densely cellular tissues or those with cellular swelling exhibit lower diffusion coefficients, and thus diffusion is particularly useful in tumour characterisation
1588508|NCT02320604|Drug|Administration of study drug|i.v. administration of Ambisome in two different dossages
1588509|NCT02320591|Other|care management fee|for each Medicare beneficiary attributed to the practice, the practice received a monthly care management fee
1588510|NCT02320591|Other|feedback reports|Each participating practice received quarterly reports showing the practice's trend in key outcomes during the pre-intervention and intervention periods. The risk adjusted average Medicare expenditures of their patients were also shown in relation to all of the other CPC practices in their region, and to those with a similar average risk profile. Unadjusted hospitalization rates and emergency room visits were also plotted over time and compared to those of other CPC practices in the region
1588511|NCT02320591|Other|technical assistance|CPC practices could ask for technical assistance on transformation activities from a regional learning faculty (RLF). The RLF also provided seminars and other learning activities, as well as provided a forum for participating practices to share lessons they had learned.
1588512|NCT02320578|Procedure|3D Laparoscopy|3D Laparoscopy approach
1588513|NCT02320578|Procedure|Standard Laparoscopy|Standard laparoscopy approach
1588514|NCT02320565|Procedure|3D Laparoscopy|3D Laparoscopy approach
1588515|NCT02320565|Procedure|Standard Laparoscopy|Standard laparoscopy approach
1588516|NCT02320552|Other|No intervention|no intervention
1588517|NCT02320526|Behavioral|Control|
1588518|NCT02320526|Behavioral|Continuous walking|
1588519|NCT02320526|Behavioral|Interval walking|
1588520|NCT02320513|Other|Wearing activty monitoring device (Fitbit Flex)|
1588521|NCT02320513|Device|Fitbit Flex|
1588522|NCT02320500|Behavioral|Standard Physiotherapy|standard of care physiotherapy once every 2 weeks for 8 weeks
1588523|NCT02320500|Behavioral|Myofascial-specific therapy|Once every 2 weeks for 8 weeks (includes trigger point injections if deemed 'necessary' by chronic pain physician)
2008939|NCT03326141|Other|Information about Health and Wellness|Information about health and wellness varies in dose, according to time spent in each condition that addresses behavior change. Topics in condition 1 include sleep, vaccinations, supplements, fall risk factors, memory, hearing and pain guided by information for older adults available on the NIA and CDC websites. Topics in conditions 2 and 3 include fall risk factors and sleep. Topics in condition 4 include fall risk factors.
2008940|NCT03326739|Procedure|Arterial Line Placement|arterial line placement
1588526|NCT02320474|Drug|Aflibercept|
1588527|NCT02320448|Drug|PIPAC|
1588529|NCT02320422|Behavioral|Behavioral Telehealth|The telemetric intervention (administered via telephone, or interactive video chat applications such as FaceTime ® or Skype ®) will enable the intervention team (IT) to address non-adherence from a remote location, using a structured, tailored approach
1588530|NCT02320409|Drug|Sufatinib|250mg Sufatinib ,single dose,oral
1588531|NCT02320396|Drug|Desloratadine 5 mg|Desloratadine 5 mg tablets
1588532|NCT02320396|Drug|Placebo|Placebo tablets
1588533|NCT02320383|Biological|GA101 (Obinutuzumab)|"Induction
Cycle 1: d1 - 100 mg, (d1 or) d2 - 900 mg, d8+15 - 1000 mg i.v., q28d
Cycle 2 - 6: d1 - 1000 mg i.v., q28d
Maintenance
GA101 iv 1000 mg (flat dose): every 84 days"
1588534|NCT02320383|Drug|Bendamustine|"Induction
Cycle 1: d3+4 (or d2+3) - 70 mg/m² i.v., q28d
Cycle 2 - 6: d2+3 - 70 mg/m i.v., q28d"
1588535|NCT02320370|Device|NeuroConn DC Stimulator Plus tDCS|transcranial electrical stimulation intervention with two experimental protocols
2008941|NCT03326102|Drug|DHP107|DHP107 200mg/m2 orally twice daily on Days 1, 8 and 15 every 28 days
2008942|NCT03326102|Drug|IV Paclitaxel|IV Paclitaxel 80 mg/m2 QW (3 weeks on/1 week off)
2008943|NCT03326089|Procedure|Pulmonary rehabilitation|Endurance training for 30 minutes, 3 times/week for 2 months followed by resistance training
1588539|NCT02320318|Drug|Ibodutant 10 mg|Oral tablet, once daily.
1588540|NCT02320318|Drug|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablet), once daily.
1588541|NCT02320305|Biological|MART-1 Antigen|Given IM
1588542|NCT02320305|Drug|TLR4 Agonist GLA-SE|Given IM
1588543|NCT02320305|Other|Laboratory Biomarker Analysis|Correlative studies
1588544|NCT02320292|Other|Laboratory Biomarker Analysis|Correlative studies
1588545|NCT02320292|Other|Quality-of-Life Assessment|Ancillary studies
1588546|NCT02320292|Biological|Rituximab|Given IV
1588547|NCT02320292|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
1994818|NCT02912962|Behavioral|Self-Regulation Intervention adapted from the Alert Program ®|
2008944|NCT03326076|Diagnostic Test|Donor-derived cell-free DNA (AlloSure®)|Patients will receive donor-derived cell-free DNA testing for surveillance and for-cause. The planned surveillance will occur at months 1, 2, 3, 4, 6, 9, and 12 post-transplant and quarterly in year 2 and year 3.
2008945|NCT03326076|Other|Standard care|Current standard methods for monitoring of renal allograft recipients for rejection (e.g. donor-specific antibodies, serum creatinine, proteinuria, renal allograft biopsy)
1588548|NCT02320279|Device|Fetal Heart Rate Monitor|Use of a system that monitors fetal heart rate through use of fetal EKG read using abdominal electrodes
1588549|NCT02320253|Behavioral|In Person Group (IP)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via in-person groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success.
1588550|NCT02320253|Behavioral|Telephone Conference Call Group (TCC)|The goals of the diabetes lifestyle intervention program are weight loss of 5-10% of initial body weight and increased activity levels to 175 minutes/week of moderate intensity physical activity. Dietitians will deliver the adapted Look AHEAD lifestyle intervention via telephone conference call groups combined with 2-3 individual sessions per year. The program curriculum focuses on nutrition, activity, and behavioral topics and incorporates the use of meal replacements for the first 4-16 weeks to enhance weight loss success. Dietitians will deliver the adapted Look AHEAD lifestyle intervention.
1588551|NCT02320253|Behavioral|Medical Nutrition Therapy (MNT)|Participants are referred to meet with a registered dietitian for individual medical nutrition therapy sessions up to 3-4 times per year.
1588552|NCT02320240|Drug|Duloxetine|Current exposure to Duloxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
1588553|NCT02320240|Drug|Venlafaxine|Current exposure to Venlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
1588554|NCT02320240|Drug|Desvenlafaxine|Current exposure to Desvenlafaxine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
1588555|NCT02320240|Drug|Citalopram|Current exposure to Citalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
1588556|NCT02320240|Drug|Escitalopram|Current exposure to Escitalopram will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
1588557|NCT02320240|Drug|Fluoxetine|Current exposure to Fluoxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
1588558|NCT02320240|Drug|Fluvoxamine|Current exposure to Fluvoxamine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
1588559|NCT02320240|Drug|Paroxetine|Current exposure to Paroxetine will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
1588560|NCT02320240|Drug|Sertraline|Current exposure to Sertraline will be defined as a prescription lasting until the index date or dispensed in the 60 days before the index date.
1588561|NCT02320227|Device|Miami w/o frag Personal lubricant|
1588562|NCT02320214|Device|Miami w/ frag Personal lubricant|
1588563|NCT02320201|Device|Transcutaneous Electrical Nerve Stimulator (TENS)|Electrical stimulation will be applied to the foot via skin surface electrodes for a minimum of 2 hours per day for 1 week to 20 subjects.
1588564|NCT02320188|Other|Eccentric exercise|This study aimed to determine the muscle effects of ECC training, with the primary outcome being the knee extensor strength gain at 3 months.
1588565|NCT02320188|Other|Concentric exercise|The purpose of the study is to determine in a randomized controlled trial (RCT), the efficacy of eccentric exercise training in restoring muscle mass and function in patients with rheumatoid cachexia.
1588566|NCT02320175|Behavioral|Communication Bundle|Communication bundle to improve patient and family experience and patient safety
1588567|NCT02320162|Behavioral|Experiential learning oral health education|
1588568|NCT02320149|Drug|Sarecycline|1.5 mg/kg/day taken orally at the same time each day, 1 hour prior to eating or 2 hours after eating
1588569|NCT02320149|Drug|Placebo|Dose-matched placebo taken orally at the same time each day, 1 hour prior to eating or 2 hours after eating.
1588570|NCT02320136|Behavioral|cognitive testing|patients perform simple tasks like watching a video or memorizing items
2008946|NCT03326063|Drug|Ifetroban|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
1588572|NCT02320097|Other|Foot pressure measurement|"Description of the foot pressure measurement:
The subject stands on the platform, with the heels and buttocks touching a vertical plane and the head held freely. The subject then moves his/her head backwards so that it touches the vertical plane. Next, he/she turns the head to the right and then towards the left. Each of these positions is maintained for 2 minutes.
The platform's sensors measure the anteroposterior foot pressure distribution during the various acquisitions."
1588573|NCT02320084|Drug|Nitisinone|Nitisinone according to prescription
1588574|NCT02320071|Other|Examination of abdominal wall strength changes over time|
1588577|NCT02320045|Drug|ITCA 650 (Exenatide in osmotic mini pump)|
1588578|NCT02320032|Drug|Aripiprazole Lauroxil|Gluteal IM injection, given once every 4 to 8 weeks
1588579|NCT02320019|Drug|Placebo|Placebo matching YH14618
1588580|NCT02320019|Drug|YH14618|
1588581|NCT02320006|Other|acupuncture|For RN4、CV6 CV3 and EX-CA1, needles will be inserted vertically to the abdominal muscles. The acupuncturist can feel resistance from the tip of the needle when touching the muscles and continues to insert it to a depth of 2-3 mm and stops. For ST36 and SP6, needles will be inserted vertically to a depth of 25 mm. The needles will be manipulated with an even lifting and twisting method three times to achieve the sensation of deqi.
1588582|NCT02319993|Drug|TIAN WANG BU XIN DAN|assigned to TWBXD (n =48) and were instructed to take 6 gm 2 times per day of TWBXD for a period of 4 weeks.
1588583|NCT02319993|Drug|Suan Tzao Ren Tang|assigned to SZRT (n = 48) and were instructed to take 6 gm 2 times per day of SZRT for a period of 4 weeks.
1588584|NCT02319993|Drug|Placebo|1/10 TIAN WANG BU XIN DAN assigned to placebo (n =32) and were instructed to take 6 gm 2 times per day of placebo for a period of 4 weeks.
1994819|NCT02912663|Drug|Verapamil and Magnesium Sulfate|Single dose strategy will be used
1994820|NCT02912663|Other|Placebo|Single matching dosing strategy will be used
1994821|NCT02913079|Behavioral|Sit-stand desk|
1588585|NCT02319980|Procedure|Extracranial-intracranial bypass surgery|All participants in this group will undergo combined cerebral revascularization surgery,namely superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis(EDMS)
1588586|NCT02319967|Behavioral|CAPE|Structured patient-centered ED discharge template completed prior to ED discharge.
1588587|NCT02319967|Behavioral|Home|Home visits led by community-health workers to reinforce CAPE and guide environmental remediation.
1588588|NCT02319954|Procedure|Direct compression|Direct compression by the surgeon with their hands on the nasal sidewall
1588589|NCT02319941|Drug|ticagrelor|
1588590|NCT02319941|Drug|clopidogrel|
1588591|NCT02319928|Procedure|Colonoscopy|
1588592|NCT02319915|Drug|Tranexamic Acid|
1588593|NCT02319915|Drug|Adrenalin|
1588594|NCT02319902|Device|Standard cold carbon dioxide gas|Use of standard cold carbon dioxide gas in laparoscopic gynaecological surgery.
1588595|NCT02319902|Device|Heated humidified carbon dioxide gas|Use of the Fischer and Paykel heated humidification system for laparoscopic gynaecological surgery.
1588596|NCT02319889|Radiation|Stereotactic Body Radiotherapy|Undergo SBRT
1588597|NCT02319889|Drug|Carboplatin|Given IV
1588598|NCT02319889|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1588599|NCT02319863|Procedure|hepatectomy (conventional method)|A Simple Technique of Rapid Ligating the Corresponding Inflow and Outflow Vessels Without Hilus Dissection During Hepatectomy
1588600|NCT02319863|Procedure|hepatectomy (rapid ligating)|
1588601|NCT02319850|Radiation|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
1588605|NCT02319824|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
1588606|NCT02319824|Other|Laboratory Biomarker Analysis|Correlative studies
1588607|NCT02319824|Radiation|Palliative Radiation Therapy|Undergo palliative radiation therapy
1588608|NCT02319811|Procedure|Cryopreserved meniscus transplants|Lateral or medial cryopreserved meniscus transplants implanted into appropriately indicated patients.
1588609|NCT02319798|Other|telephone consultations|Those randomized to telephone consultation will be told to expect a call from the gastroenterology doctor at the time of their appointment.
1588610|NCT02319798|Other|face-to-face consultations|Those randomized to face-to-face follow up will attend their appointments in hospital
1588611|NCT02319785|Behavioral|RAT-NMES|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive neuromuscular electrical stimulation (NMES) concurrently with RAT.
1588612|NCT02319785|Behavioral|RAT-MT|This combined RAT- treatment involves the same protocol as the RAT regimen except that patients receive mirror therapy instead of functional activities training after RAT.
1588613|NCT02319785|Behavioral|Mirror therapy|This protocol includes mirror therapy and functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
1588614|NCT02319785|Behavioral|Unilateral RAT|"This protocol includes warm-up, unilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.
The unilateral RAT session uses the robot-assisted arm trainer, InMotion Isokinetic Testing and Evaluation System."
1588615|NCT02319785|Behavioral|Bilateral RAT|"This protocol includes warm-up, bilateral RAT, and functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks.
The unilateral RAT session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany)."
1588616|NCT02319785|Behavioral|Conventional rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RAT and MT groups.
1588617|NCT02319772|Drug|BCX4430|
1588618|NCT02319772|Drug|Placebo|
1588619|NCT02319759|Drug|Guselkumab|In the guselkumab group, Guselkumab 100 mg subcutaneous injection will be administered at Weeks 0, 4, 12, 20, 28, 36 and 44. In the placebo group, guselkumab 100 mg subcutaneous injection will be administered at Weeks 24, 28, 36 and 44 for participants remaining on placebo at Week 24.
1588620|NCT02319759|Drug|Ustekinumab|In both placebo and guselkumab groups, if the participants qualify for early escape, they will switch to receive ustekinumab 45 mg or 90 mg subcutaneous injection at Weeks 16, 20, 32, and 44 based on the approved dosage in the particular country of the study.
1588621|NCT02319759|Drug|Placebo|In placebo group, Placebo subcutaneous injection will be administered at Weeks 0, 4, 12, and 20. In guselkumab group, placebo subcutaneous injection will be administered at Week 24 to maintain the blind.
1588622|NCT02319746|Behavioral|Cognitive-behavioral therapy program to first-episode psychosis patients and cannabis abuse|The intervention program is focused on reducing the cannabis use, improving awareness of illness, adherence to treatment, identification of prodromes, psychosocial functioning improvement and relapse prevention.
1588623|NCT02319746|Behavioral|Psychoeducation|The aim of psychoeducation is that the patient understands and be able to manage the disease providing the tools and skills to symptoms management, to avoid relapse and contribute to their wellbeing.
1588624|NCT02319733|Device|Bioresorbable vascular scaffold|Implantation of Bioresorbable vascular scaffold in vulnerable plaques
1588625|NCT02319720|Biological|Bone Marrow Aspirate|Fresh bone marrow aspirate administered to the wound at the time the bone marrow is taken.
1588626|NCT02319720|Biological|Cultured Bone Marrow Cells|The bone marrow aspirate will be sent to the laboratory to be grown in tissue culture. Once the cell cultures have matured (within 8 weeks) they will be checked for sterility and frozen until applied to the subject's wound.
1588701|NCT02319161|Drug|Calcium channel blocker and beta blocker|The patients in which systolic blood pressure increased to 150 mmHg and above following tourniquet inflation and in which a bolus dose of calcium channel blocker 10 mg (Diltizem, Mustafa Nevzat İlaç Sanayi Aş) (Group I) or beta blocker 0.5mg/kg (Brevibloc, Eczacıbaşı İlaç Sanayi Aş) (Group II) were administered intravenously constituted the study groups.
1588627|NCT02319720|Procedure|Control|The subjects in this group will receive currently approved treatments for their wound. These treatments will include debridement and dressing changes. Wound dressings allowed will include gauze, foam dressings, occlusive films, and non-stick pads. More advanced dressing materials such as Hydrocolloids, alginates, silver containing dressings, and biomaterials can also be used. Compression will be utilized for lower extremity wounds.
1588628|NCT02319707|Drug|Oxytocin|"The study group: divided into two groups:
• Intramuscular treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin during the third stage of labor.
• Combined treatment: pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IM Oxytocin together with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor."
1588629|NCT02319707|Drug|Oxytocin in 100 ml NaCl 0.9%|"The control group:
pregnant women, 34-41 weeks of gestation, which were treated with 10 IU of IV Oxytocin in 100 ml NaCl 0.9% during the third stage of labor. (this is the routine practice in our department)."
1588630|NCT02319681|Behavioral|Simple Reminiscence (SR)|SR is a 30-minute psychoeducational activity administered by a trained RA at 4 home visits (week 2, week 3, week 7, and week 19). SR has a didactic component using the SR manual that the couple retains, viewing one of the brief video-vignettes illustrating the application of reminiscence techniques (a different video-vignette will be viewed at each visit), and facilitation of caregiver practice in applying the techniques, using a recent example of anxiety-linked experience of the person with EAD.
1588631|NCT02319681|Behavioral|Attention Control (AC)|AC is a 30-minute in which the person with EAD, the caregiver and the RA review and discuss the day's newspaper headlines. The RA will use communication techniques specifically designed to keep the conversation present focused at 4 home visits (week 2, week 3, week 7, and week 19).
1588632|NCT02319668|Drug|0.2% w/v Chlorhexidine digluconate|Participants will brush their teeth with the reference product (toothpaste) and thoroughly rinse their mouth with water and wait 5 timed minutes before using 10 ml of the 0.2% w/v Chlorhexidine digluconate mouthwash, except when using at site, where no brushing will take place prior to using the mouthrinse.
1588633|NCT02319668|Drug|Sodium fluoride toothpaste (Aquafresh Mild & Minty)|Participants will apply a strip of toothpaste to cover the head of the toothbrush and will brush in their usual manner for two timed minutes twice daily. They will then rinse their mouth thoroughly with water after brushing
1588636|NCT02319642|Drug|Certolizumab Pegol|Active Substance: Certolizumab Pegol Pharmaceutical form: Prefilled syringes Concentration: 200 mg/ ml Route of Administration: Subcutaneous injection
1588637|NCT02319629|Drug|URSODIOL|preventive treatment with Ursolit to reduce the incidence of gallstones formation after bariatric surgery
1588638|NCT02319629|Drug|Placebo|
1588639|NCT02319616|Drug|Clobetasol 0.05% ointment|Blinded, daily application to one arm for a period of fourteen (14) days
1588640|NCT02319616|Drug|Placebo|Blinded, daily application to one arm for a period of fourteen (14) days
1588641|NCT02319603|Drug|Low dose WenXin keli|Low dose WenXin keli (the original quantity Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 5 g+ Wenxin keli simulation agent 5g.
1588642|NCT02319603|Drug|High dose WenXin keli|High dose WenXin keli(2 times the amount of Wenxin keli): specification 10g /bag, Wenxin keli (no sugar) 10 g.
1588643|NCT02319577|Drug|oral vinorelbine|Anti-neoplastic drug (PO chemotherapeutical agent, vinka alkaloid)
1588644|NCT02319577|Drug|Gefitinib|EGFR tyrosine kinase inhibitor
1588645|NCT02319564|Drug|Beclomethasone|
1588646|NCT02319564|Drug|Beclomethasone and Salbutamol|
1588647|NCT02319564|Drug|Placebo|
1588648|NCT02319564|Device|Aerochamber Max®|
1588649|NCT02319538|Procedure|Absolute total thyroidectomy performed|Surgery combined with standard thyroxine treatment
1588650|NCT02319538|Drug|medical hormone treatment (Thyroxine)|Medical hormon treatment with individual dosage
1588651|NCT02319525|Other|Computerized patient decision-aid|The decision-aid contained information regarding lupus and lupus nephritis, its impact on patient lives and benefits and harms of lupus nephritis treatments, focused on immunosuppressive medications compared to each other. The content of the decision-aid allowed individualization based on patient preference for details on certain aspects, as well as the desire to view additional, optional sections of the decision-aid.
1588652|NCT02319525|Other|Usual care (lupus pamphlet)|Patient received the standard handout/pamphlet from a non-profit organization (American College of Rheumatology [ACR]) regarding lupus and its treatments, that explained risks and benefits of various treatments
1588653|NCT02319512|Other|Chewing gum|ChiczaTM organic chewing gum 6 pieces a day
1588654|NCT02319512|Other|Glucose|12ml glucose solution (13,6g) per day
1588655|NCT02319499|Dietary Supplement|Zinc Alone|Zn-alone group received 10 mg/day of elemental zinc (as zinc sulphate)
1588656|NCT02319499|Dietary Supplement|Iron and Zinc|Zn+Fe group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate)
1588657|NCT02319499|Dietary Supplement|Iron, Zinc and Vitamin A|Zn+Fe+vit.A group received 10 mg/day of elemental zinc (as zinc sulphate) and 10 mg/day of elemental iron (as ferrous sulphate), plus 1,000 IU/day of vitamin A
1588658|NCT02319499|Other|Placebo|Placebo group received no minerals/vitamin
1588659|NCT02319486|Drug|carboplatin periocular injection|chemotherapy together with/without 20mg/2ml carboplatin periocular injection
1588660|NCT02319486|Drug|CEV chemotherapy|vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2
1588661|NCT02319473|Other|JAC Registry|patients who received acute reperfusion therapy
1994822|NCT02913079|Behavioral|Sitting desk|
1994823|NCT02911766|Drug|Chlorhexidine 0.2% Mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
1588702|NCT02319148|Drug|itraconazole|itraconazole dosed at 200 mg
1588703|NCT02319148|Drug|diltiazem|diltiazem dosed at 240 mg
1588704|NCT02319148|Drug|SR verapamil|SR verapamil dosed at 240 mg
1588705|NCT02319148|Drug|PF-00489791|PF-00489791 20 mg single dose administration
1588706|NCT02319135|Drug|Azacitadine|
1588707|NCT02319135|Drug|Fludarabine|
1588708|NCT02319135|Drug|Cytarabine|
1588664|NCT02319447|Behavioral|Additional education|"Our Intervention includes a 60-90 minute educational seminar, entitled Destination: Transplant, featuring live speakers, delivered to small groups of Black kidney transplant candidates and their family and friends. Topics include: 1) basic facts about Chronic Kidney Disease (CKD), transplant, and the waiting list; 2) the experience of receiving a LDKT transplant (by a Black LDKT recipient); 3) the experience of serving as a living kidney donor (by a Black living kidney donor); and 4) strategies to increase the chances of getting a transplant sooner. Participants receive monthly mailed, written information for 9 months and a follow-up phone call from a transplant educator, 3 months after attending the seminar."
1588665|NCT02319434|Device|Ostom-i Alert Sensor|Sensor on ostomy bag.
1588666|NCT02319421|Other|Alarm Reduction Script|The intervention will consist of a script to facilitate the discussion of the alarm data that will take place on weekday mornings. The script will be used by huddle participants as a structured outline to rapidly discuss the high alarm low acuity patients eligible for intervention. The patients who are identified will have further discussion on rounds to determine if there are appropriate ways to reduce the alarm rates of individual patients through the safe adjustment of physiologic monitor parameters.
1588668|NCT02319395|Genetic|Blood Sampling and DNA collection|"One blood sampling during the study. A small number (1 to 5) of markers type tag SNPs or coding SNP  (single nucleotide polymorphism, SNP) will be selected for each of the selected genes, for a total of 50 markers (representing 20 to 25 genes). Non-silent coding SNP, that may have a functional effect, will be included as a priority. Genotyping is carried out by the method of genotyping VeraCode Goldengate."
1588669|NCT02319382|Radiation|PET with the tracer 18F-DPA-714|
1588670|NCT02319382|Radiation|PET with the tracer 11C-PE2I|
1588671|NCT02319382|Other|MRI|Magnetic field
1588673|NCT02319356|Dietary Supplement|Beetroot juice|(BRJ, containing NO3-, 6.2 mmol/day, administered as 500ml Beet it Sport Shots, James White drinks, Ipswich uk)
1588674|NCT02319356|Dietary Supplement|Placebo beetroot juice|(PL, NO3-depleted beetroot juice, administered as 500ml Placebo Beet it Sport Shots, James White drinks, Ipswich uk)
1588675|NCT02319343|Drug|Methylprednisolone|Comparison of preoperative single high dose of Methylprednisolone 125 mg iv. and isotonic Sodium Chloride (placebo)
1588676|NCT02319343|Drug|Isotonic Sodium Chloride|Placebo
1588677|NCT02319330|Behavioral|Nurse-delivered mobile phone counseling intervention|Multi-dimensional, patient-centered counseling approach used to build patient-provider rapport, establish sources of support, and enable and empower problem solving to address inter-related, multi-tiered barriers to care.
1588678|NCT02319330|Behavioral|Treatment as Usual|Routine HIV clinic-based counseling
1588679|NCT02319317|Behavioral|Risky driving prevention|The web-based intervention to prevent risky driving targets knowledge, attitudes, perceived control and norms about driver inattention, with strategies to keep attention on the roadway.
1588680|NCT02319317|Behavioral|Control group general health promotion|The control group will receive a web-based intervention for general health promotion and is designed to enhance participants' knowledge and ability to reduce their risk of adverse health conditions including, obesity and heart disease.
1588681|NCT02319304|Drug|FOLFOX {5-fluorouracil (5-FU), leucovorin, and oxaliplatin}|see arm description
1588682|NCT02319304|Radiation|Low dose fractionated radiation therapy (LDFRT)|see arm description
1588683|NCT02319291|Device|P.F.C. Sigma PS150 RP Total Knee System|Total Knee Arthroplasty - surgical procedure to replace knee with metal implant
1588684|NCT02319278|Drug|Ferumoxytol|Infusion following between paired MRI scans
1588685|NCT02319265|Drug|Melatonin|Oral liquid
1588686|NCT02319252|Device|Gastric tube (Nutricia Flocare® Pur Tube Enlock)|Nutricia Flocare® Pur Tube Enlock, Ch. 12
1588687|NCT02319252|Device|Jejunal tube (Nutricia Flocare® Bengmark®)|Nutricia Flocare® Bengmark®, Ch. 10
1588688|NCT02319239|Radiation|Fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 15/39 fractions. DW-MRI at baseline, 3 months and 12 months.
1588689|NCT02319239|Radiation|hypofractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 10/20 fractions. DW-MRI at baseline, 3 months and 12 months
1588690|NCT02319239|Radiation|stereotactic fractionation|During a radiotherapy period the prostate movement will be monitored by temporary implanted electromagnetic detector. Rectum fixation at 5/5 fractions. DW-MRI at baseline, 3 months and 12 months
1588691|NCT02319226|Other|Transplantation from an HLA-identical sibling donor|The study will include a cohort of 60 patients transplanted from an HLA-identical sibling donor.
1588692|NCT02319213|Other|Intraocular pressure measurement with 9 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
1588693|NCT02319213|Other|Intraocular pressure measurement with 12 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
1588694|NCT02319213|Other|Intraocular pressure measurement with 15 mmHg insufflation|Comparison of intraocular pressure levels at different abdominal pressure
1588695|NCT02319200|Drug|Metformin|"1000 mg (2x500 mg) at morning and 1000 mg (2x500 mg) at afternoon (2000 mg per day)
Metformin daily during 36 months"
1588696|NCT02319200|Drug|placebo tablet|4 tablets per day for 36 months
1588697|NCT02319187|Drug|S1|S1 80mg to 120 mg per day on Days 1-14, every 21 days
1588698|NCT02319187|Drug|S-1|S1 80mg to 120 mg per day on Days 1-10, every 14 days;
1588699|NCT02319187|Drug|irinotecan|irinotecan 160mg/m2 d1, every 14 days
1994824|NCT02911766|Drug|Chlorhexidine 0.12% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
1588709|NCT02319135|Drug|Lenograstim|
1588710|NCT02319135|Drug|Filgastrim|
1588711|NCT02319122|Other|High Intensity Interval Training|See arm description
1588712|NCT02319122|Other|Progressive Resistance Training|See arm description
1589573|NCT02312271|Other|enteral formula|standard tube feeding formulas
1994825|NCT02911766|Drug|Chlorhexidine 0.06% mouthrinse|Intervention; Rinsing 60 sec with Comparator solution twice daily for 21 days
1588714|NCT02319083|Procedure|Coronary artery bypass surgery|Patients will undergo coronary artery bypass grafting
1588715|NCT02319070|Other|Survey|Recombinant antihemophilic factor VIII (FVIII) on Secondary Prophylaxis treatment scheduled according to daily routine
1588716|NCT02319070|Other|Survey|Recombinant antihemophilic factor VIII (FVIII) On Demand treatment scheduled according to daily routine
1588717|NCT02319057|Drug|ORM-12741 MR A|Modified release formulation of ORM-12741
1588718|NCT02319057|Drug|ORM-12741 IR|Immediate release formulation of ORM-12741
1588719|NCT02319057|Drug|ORM-12741 MR B|Modified release formulation of ORM-12741
1588720|NCT02319044|Drug|MEDI4736|MEDI4736 monotherapy
1588721|NCT02319044|Drug|Tremelimumab|Tremelimumab monotherapy
1588722|NCT02319044|Drug|MEDI4736 + Tremelimumab|MEDI4736 + Tremelimumab combination therapy
1588723|NCT02319031|Drug|Daclatasvir|
1588724|NCT02319031|Drug|Sofosbuvir|
1588725|NCT02319031|Drug|Ribavirin|
1588726|NCT02319018|Drug|Alisertib|Given PO
1588727|NCT02319018|Drug|Fluorouracil|Given IV
1588728|NCT02319018|Other|Laboratory Biomarker Analysis|Correlative studies
1588729|NCT02319018|Drug|Leucovorin Calcium|Given IV
1588730|NCT02319018|Drug|Oxaliplatin|Given IV
1588731|NCT02319005|Drug|Revusiran (ALN-TTRSC)|
1588732|NCT02319005|Drug|Sterile Normal Saline (0.9% NaCl)|
1588733|NCT02318992|Biological|Fecal Microbiota|Fecal Microbiota will be delivered via colonoscopy.
1588734|NCT02318979|Device|Otto Bock prosthesis|Participants will run using the Otto Bock prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
1588735|NCT02318979|Device|Ossur prosthesis|Participants will run using the Ossur prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
1588736|NCT02318979|Device|Freedom Innovations prosthesis|Participants will run using the Freedom Innovations prosthesis at a recommended stiffness and height, one category stiffer than recommended at the recommended height, one category softter than recommended at the recommended height, at the optimal stiffness and 2 cm taller, and at the optimal stiffness and 2 cm shorter.
1588737|NCT02318966|Dietary Supplement|Medical Food - Glycosade|double blind randomised crossover of 2 starches - glycosade and UCCS
1588738|NCT02318953|Device|Mobile app follow-up care|The mobile app follow-up care is an application that can be loaded on to a smartphone. It allows the patient to submit photos of their surgical site, VAS pain scores, and QoR9 scores. The information collected is transmitted to members of the surgical team (i.e. the primary surgeon) and used to monitor recovery over the first 30-days following surgery.
1588739|NCT02318953|Other|Conventional, in-person follow-up care|This includes a typical in-person visit with the operating surgeon at one- and four-weeks after surgery.
1588740|NCT02318940|Device|central venous catheter|installation of Central venous catheter ultrasound guided
1588741|NCT02318940|Device|central venous catheter|installation of Central venous catheter landmark guided
2008947|NCT03326063|Drug|Placebo|4-week, double-blind, placebo-controlled parallel-design trial of oral ifetroban (a TP receptor antagonist) in patients with AERD
1588743|NCT02318914|Drug|gevokizumab|
1588744|NCT02318901|Drug|Pembrolizumab|
1588745|NCT02318901|Drug|Trastuzumab|
1588746|NCT02318901|Drug|ado-trastuzumab emtansine|
1588747|NCT02318901|Drug|Cetuximab|
1588748|NCT02318888|Procedure|Surgery|
1588749|NCT02318888|Drug|Icodextrin|
1588750|NCT02318875|Dietary Supplement|Kritech administration|300mg/day (1 capsule) during 12 weeks; oral ingestion
1588751|NCT02318875|Other|Placebo adminstration|1 placebo capsule per day during 12 weeks; oral ingestion
1588752|NCT02318862|Procedure|Standard of Care esophagogastroduodenoscopy (EGD) with mucosal impedance testing|
1588753|NCT02318849|Behavioral|Web intervention|interactive website using social media and gamification
2008948|NCT03326050|Drug|Gemifloxacin|Gemifloxacin 320Mg Oral Tablet once daily
1588755|NCT02318823|Other|Beer (alcoholic)|Beer (individually calculated amount aiming to achieve a blood-alcohol-centration of 0.4g/kg)
1588756|NCT02318823|Other|Placebo (non-alcoholic beer)|Non-alcoholic beer serves as Placebo.
1588757|NCT02318810|Drug|Rocuronium 0.3 mg/kg|Patients receive rocuronium 0.3 mg/kg
1588758|NCT02318810|Drug|Rocuronium 0.6 mg/kg|Patients receive rocuronium 0.6 mg/kg
1588759|NCT02318810|Drug|Rocuronium 0.9 mg/kg|Patients receive rocuronium 0.9 mg/kg
1588760|NCT02318810|Drug|Placebo|Patients receive saline
2008949|NCT03326050|Drug|Ciprofloxacin|cipro 750 tablet twice daily
2008950|NCT03326050|Drug|Rifampicin|Rifampicin 150Mg Capsule twice daily
1588763|NCT02318784|Drug|Carfilzomib|
2008951|NCT03326037|Genetic|Genotyping of the NPHS2 variant rs61747728|Genotyping of the NPHS2 variant rs61747728 will be performed by Real-time TaqMan Allelic Discrimination Assay (Life technologies, CA, USA) according to standard manufacturer protocols. Allelic discrimination analysis will be performed and analyzed using ABI 7500 Fast Real-time PCR system SDS software (Life technologies, CA, USA)
2008952|NCT03326011|Device|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
1588766|NCT02318758|Drug|UT-15C|sustained release oral treprostinil
1588767|NCT02318758|Other|ethanol|Absolut 100 vodka
2008953|NCT03325998|Device|Samsung Hip Assist v1|All subjects receive gait training 3 times per week for 8 weeks for 24 training sessions. Each session is directed by a licensed physical therapist and lasted 60 min including rest period of 10 min. Brain activity and gait assessment is performed at visits 0 (baseline), 24 (post-test), and at 3 months (follow-up) after training.
2008954|NCT03325985|Behavioral|Nurse-led telephonic case management|nurse led telephonic interviews
1588768|NCT02318745|Behavioral|Culturally Informed Family Treatment for Adolescents|Family Therapy, Psycho-educational Modules, Individual therapy sessions
1588769|NCT02318745|Behavioral|Individual Treatment|Cognitive Behavior Therapy, Interpersonal psychotherapy, social skills training, anger control training, problem solving skills, assertiveness training, and the Empty chair technique from Gestalt therapy
1588770|NCT02318732|Behavioral|APPS intervention|Contact with and recovery of firearms from individuals who are prohibited from possessing them
1588771|NCT02318719|Drug|Placebo|Placebo
1588772|NCT02318719|Drug|DS-5565|
1588773|NCT02318706|Drug|DS-5565|
1588774|NCT02318706|Drug|placebo|
1588775|NCT02318693|Drug|Sitagliptin|Sitagliptin 50 mg orally once a day before breakfast for 14 days
1588776|NCT02318693|Drug|Glibenclamide|Glibenclamide 1.25 mg orally twice a day (2.5 mg/day) before breakfast and dinner for 14 days
1588777|NCT02318680|Other|Review of follow home visits after discharge from Nykøbing Falster Hospital|The intervention is follow home visits which is randomized and is an intervention that is assigned by the investigator.
1588778|NCT02318667|Biological|Golimumab|Golimumab is a fully human anti-TNFalpha monoclonal antibody that will be administered SC.
1588779|NCT02318654|Other|Ice Pack|Subjects will have 600 grams of ice in clear plastic bag size 18 x 23 cm applied to the randomized axilla for 10 minutes. After 10 minutes, the ice pack will be removed and laser hair treatment will be performed.
1588780|NCT02318654|Drug|Topical EMLA cream|Topical EMLA will be applied approximately 2 mm thick to the randomized axilla with a wooden tongue depressor wrapped with impermeable plastic occlusion dressing for 60 minutes. After 60 minutes, the drug will be removed with regular gauze and saline and laser hair treatment will be performed.
1588781|NCT02318641|Device|oximetry|Retinal oximetry will be performed with Oxymap.
1588782|NCT02318628|Device|Cardio Ankle Vascular Index (CAVI) of the Vasera system VS1500N|"CAVI will be measured using the Vasera device (VS1500 n - Fukuda Denshi co, Japan). This device is easy to use and calculates automatically the CAVI.
CAVI measurements will be performed according to the manufacturer Measurements will be performed after five to ten minute - period of rest in order to obtain a steady hemodynamic state and to limit measurements variability."
1588783|NCT02318615|Procedure|Immediate Axillary Plasty|Immediate Axillary Plasty would be performed to reduce the formation of scar in the axilla.
1588784|NCT02318602|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
2008955|NCT03325985|Behavioral|Facilitated,outpatient specialty palliative care|Physician led follow up interviews
1588786|NCT02318576|Other|Cognitive Training|Computerized Cognitive Training: The online computer training program will be administered on the participants' home computer. The training program will consist of a total of 36 sessions (3 times/week for 12 weeks). Each session will last no more than 60 minutes and consist of five different cognitive exercises designed to improve cognitive processing speed, memory and executive function. All exercises will involve visual stimuli and a motor response (key or button press). Exercises will be adaptive to participants' individual ability and start with minimal difficulty.
1588787|NCT02318563|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)
1588788|NCT02318563|Drug|Placebo Solution|A matching oral solution containing no cannabidiol
1588789|NCT02318550|Other|MRI Scan|"The MRI will be performed with a 1.5 T scanner utilizing institutional protocols and the following settings:
Normal operating mode
SAR ≤ 2.0 W/kg per patient."
1588790|NCT02318537|Drug|Cannabidiol Oral Solution|An oral solution containing pharmaceutical grade cannabidiol (nonplant-based).
1588791|NCT02318537|Drug|Placebo Solution|A matching oral solution containing no cannabidiol.
1588792|NCT02318511|Procedure|Knee injection|Injection into knee for the treatment of Osteoarthritis
1588793|NCT02318511|Device|ReNu amniotic allograft|
1588794|NCT02318511|Device|placebo saline|
1588795|NCT02318511|Device|Hyaluronic Acid|
1588796|NCT02318498|Procedure|CMR|Intervention performed 2-4 days after admission to hospital with the latest CMR technique including sensitive oedema sequences using T1 mapping
1588797|NCT02318485|Biological|Limbal epithelial stem cell graft|
1588798|NCT02318472|Device|VACOped orthosis|Weight-bearing orthosis with adjustable range of motion of the ankle
1588799|NCT02318472|Device|Plaster cast|Lower limb plaster cast
1588800|NCT02318459|Other|high intensity interval training-HIIT|HIIT 4 times a week, 30 minutes duration
1588801|NCT02318459|Other|Traditionnal group rehabilitation|Traditionnal group rehabilitation, 3 times a week, 1 hour duration
1588802|NCT02318446|Drug|Folic Acid|Test group(n= 24) Existing Anti-epileptic Drugs + Oral Folic acid 1mg tablet daily for 1month
1588803|NCT02318446|Drug|Saccharine|Placebo group(n=12) Existing Anti-epileptic Drugs + Oral saccharine 10 mg tablet daily for 1month
1588804|NCT02318433|Drug|Dexamethasone|Data demonstrates that low doses of dexamethasone preserves chondrocyte viability, protects collagen, and maintains proteoglycan synthesis in cartilage subjected to injurious compression.
1588805|NCT02318433|Drug|Saline|
1588806|NCT02318420|Other|The PartoMa intervention|WHO partogram, locally developed and achievable labour management guidelines (PartoMa guidelines), continual in-house training
1588807|NCT02318407|Drug|AMG 403|AMG 403 for the treatment of subjects with osteoarthritis
1588808|NCT02318407|Drug|Placebo|contains no active drug
1588809|NCT02318394|Biological|MEDI0562|Subjects will receive MEDI0562 until unacceptable toxicity, confirmed disease progression or other reason for treatment discontinuation develops.
1588810|NCT02318381|Procedure|Dissection of the superior transverse scapular ligament|After treatment of the rotator cuff tear, the arthroscopic procedure will also proceed with the dissection of the superior transverse scapular ligament, in order to release pressure from the suprascapular nerve.
1588811|NCT02318368|Drug|Ficlatuzumab|
1588812|NCT02318368|Drug|Erlotinib|
1588813|NCT02318368|Drug|placebo|
1588814|NCT02318355|Other|normal saline|Crystalloid intravenous solution
1588815|NCT02318355|Other|lactated ringers|Crystalloid intravenous solution
2008956|NCT03325972|Drug|Dexmedetomidine|The drug will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
1588816|NCT02318342|Drug|Warfarin|Patients with prosthetic valve abnormalities suggestive of thrombus will be administered anticoagulation therapy with Vitamin K antagonists (Warfarin) for 3 months with goal INR 2-3, followed by repeat contrast CT of the chest and transthoracic imaging. Repeat imaging following 3 months of anticoagulation therapy is performed to evaluate the response to anticoagulation therapy.
1588817|NCT02318329|Drug|FPA144|FPA144 will be administered by IV infusion over approximately 30 minutes every 2 weeks.
1588818|NCT02318316|Other|Exhaled breath condensate|Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
1588819|NCT02318303|Drug|GSP 301-1 NS (QD)|GSP 301-1 NS (665 μg olopatadine hydrochloride/50 μg mometasone furoate) administered as 2 sprays/nostril
1588820|NCT02318303|Drug|GSP 301-2 NS (BID)|GSP 301-2 NS (665 μg olopatadine hydrochloride/25 μg mometasone furoate) administered as 2 sprays/nostril
1588821|NCT02318303|Drug|GSP 301 Placebo NS|GSP 301 placebo NS administered as 2 sprays/nostril
1588822|NCT02318303|Drug|Olopatadine HCl-1 NS (QD)|Olopatadine HCl-1 NS (665 μg) administered as 2 sprays/nostril
1588823|NCT02318303|Drug|Olopatadine HCl-2 NS (BID)|Olopatadine HCl-2 NS (665 μg) administered as 2 sprays/nostril
1588824|NCT02318303|Drug|Mometasone Furoate-1 NS (QD)|Mometasone furoate -1 NS (50 μg) administered as 2 sprays/nostril
1588825|NCT02318303|Drug|Mometasone Furoate-2 NS (BID)|Mometasone furoate-2 NS (25 μg) administered as 2 sprays/nostril
1588826|NCT02318290|Drug|Opiates|Mechanically ventilated patients receiving opiates for more than 96 hours will be evaluated for withdrawal symptoms upon weaning of the opiates
1588827|NCT02318277|Drug|MEDI4736|MEDI4736 administered intravenously (IV) every two weeks (q2w)
1588828|NCT02318277|Drug|INCB024360|INCB024360: Oral daily dosing
1588829|NCT02318264|Device|Kinesio Tape|Elastic tape placed over the skin
1588830|NCT02318251|Other|Involuntary muscle contractions|Physiotherapy program focusing on involuntary pelvic floor muscle fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day). This program includes the standard physiotherapy.
1588831|NCT02318251|Other|Voluntary muscle contractions|Physiotherapy program (physiotherapy standard program) focusing on voluntary fast contractions: 9 individual physiotherapies taking place within 16 weeks. During these 16 weeks the participants will perform a home program 3x/week (3x/day) during week 1-5 and 3x/week (1x/day) in week 6-16. In the following 6 months they will perform the home program 3x/week (1x/day).
1588832|NCT02318238|Other|6 minutes walking test|
1588833|NCT02318238|Other|6 minutes step test|
1588834|NCT02318238|Other|4 meters gait speed|
1588835|NCT02318225|Drug|Misoprostol|"Misoprostol (400µg) will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.
Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
1588836|NCT02318225|Drug|Placebo|"Placebo will be administered vaginally 12 hours before office hysteroscopy. A rigid 2.9 mm hysteroscope with 30° forward oblique lens will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997 . All the procedures will be diagnostic.
Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain)."
1588837|NCT02318212|Device|Dilapan-S|Synthetic osmotic dilators Dilapan-S or Dilasoft for cervical priming prior to induced abortion
1588838|NCT02318199|Procedure|Anesthesia recovery after intracranial surgery|Intracranial surgery for brain tumor, traumatic brain injury, intracranial hemorrhage, subarachnoid hemorrhage and infection.
1588839|NCT02318173|Device|Dilapan-S|Synthetic osmotic dilators Dilapan-S, Dilasoft for cervical ripening prior to induction of labor in women with unfavourable cervix
1588840|NCT02318160|Other|measurement of oxidant status in AIT|measurement of thyroid-stimulating hormone (TSH) and free thyroxin (FT4), as well as anti-thyroid peroxidase antibodies (TPOAb) and anti-thyroglobulin antibody (TgAb) were done in addition to assessment of malondialdehyde (MDA) and total antioxidant capacity (TAC) levels as an oxidative stress markers
2008957|NCT03325972|Other|Placebo Saline|Placebo will be administered with a loading dose of 0.5 mcg/kg given over 20 min followed by an infusion at 0.6 mcg/kg/hr. The infusion will be stopped during closure of the fascia.
2008958|NCT03325959|Device|Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen
1588843|NCT02318134|Procedure|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
1588844|NCT02318134|Other|The traditional treatment|the traditional treatments according to associated guidelines
1588845|NCT02318121|Procedure|Amniotomy first|rupture of membranes to augment labor
1588846|NCT02318121|Procedure|Oxytocin first|Administration of oxytocin to augment labor
1588847|NCT02318121|Procedure|Amniotomy and oxytocin|Rupture of membranes and administration of oxytocin to augment labor
1588848|NCT02318121|Drug|Oxytocin|
2008959|NCT03325959|Drug|Cymbalta / lyrica|one of the two medications currently licensed for the treatment of FMS in Israel, i.e. Cymbalta and Lyrica.
2008960|NCT03325959|Device|Crossover Hyperbaric oxygen therapy|60 HBOT sessions at 2 ATA 100% oxygen after crossover
1588994|NCT02316964|Biological|aldesleukin|Given SC
2008961|NCT03325946|Behavioral|ACQUIRE Therapy|Intensive therapy services combined with operant conditioning during treatment delivered by trained OT or PTs
2008962|NCT03325933|Other|High Load/Low Rep Resistance Training|Participants will be prescribed High Load/Low Rep resistance training.
2008963|NCT03325933|Other|Low Load/High Rep Resistance Training|Participants will be prescribed Low Load/High Rep resistance training.
2008964|NCT03325920|Device|DIABRUX|All participants receive an individually fabricated diagnostic plate, viz the DIABRUX, for the upper or lower jaw to be worn for five consecutive nights. After use a newly developed analyzing software quantifies the abrasion on the diagnostic plate, thus resulting in a score, viz the Pixel score. This represents a quantitative measure of sleep bruxism activity.
1588855|NCT02318082|Drug|Interleukin-2|
1588856|NCT02318069|Biological|FSME-immune|0.5 ml im as scheduled in the 5 arms
1588857|NCT02318056|Other|Aquacel® Ag Burn Glove|burn dressing
1588858|NCT02318056|Other|Mepilex® Transfer Ag|burn dressing
1588859|NCT02318056|Drug|antibiotic|antibiotic burn dressing
1588860|NCT02318043|Drug|inhaled corticosteroids (usually budesonide/fomorterol 160/4.5mcg; fluticasone/salmeterol 250/50mcg)|Patients with uncontrolled and partly controlled asthma, following accomplishment of study 1, were invited to participate in observational study (study 2), which sought to determine usefulness of both BPTs in reflecting improvement of asthmatic symptoms following 3 and 6 months of moderate-dose ICSs treatment (400~800μg budesonide or equivalent). Patient continued to administer their original ICS during follow-up. During two follow-up visits (3 months apart), AMP-BPT, His-BPT and Hogg's symptom scores were reassessed.
2008965|NCT03325907|Device|navigational template|The navigational template was created based on computed tomography data using three-dimensional technology.
2008966|NCT03325894|Drug|SHP465|SHP465 capsule will be administered in a dose of 6.25 mg orally once daily for 360 days.
1588863|NCT02318004|Other|Home Monitoring|Non invasive nocturnal monitoring of heart and respiratory rate and subjects movement out of bed.
1588864|NCT02317991|Drug|nab-paclitaxel|nab-paclitaxel 125 mg/m^2 IV
1588865|NCT02317991|Biological|ramucirumab|Ramucirumab 8 mg/kg IV
1588866|NCT02317978|Procedure|ICSI|records of women who had ICSI will be reviewed and analysed for determining FSI
1588867|NCT02317965|Other|Maternal Blood Draw|Maternal Blood Draw
1588868|NCT02317952|Other|Experimental Extensively Hydrolyzed Formula|
1588869|NCT02317952|Other|Active Comparator Formula|
1588870|NCT02317939|Other|instruction|online instruction tutorials at followup visits
1588871|NCT02317939|Other|standard baseline instruction|self-guidance at followup visits
1588872|NCT02317926|Drug|Levothyroxine|
1588873|NCT02317926|Drug|Levothyroxine Plus Liothyronine|
1588874|NCT02317926|Drug|Desiccated Thyroid Extract|
1588875|NCT02317900|Biological|TV005|TV005 is a live attenuated recombinant tetravalent dengue virus vaccine. It will be administered as a 0.5 mL dose containing 10^3 plaque forming units (PFUs) of each component (10^3.3 PFUs/mL of rDEN1∆30, 10^4.3 PFU/mL of rDEN2/4∆30(ME), 10^3.3 PFU/mL of rDEN3∆30/31-7164 and 10^3.3 PFU/mL of rDEN4∆30). It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
1588876|NCT02317900|Biological|Placebo|The placebo vaccine will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
1588877|NCT02317900|Biological|rDEN2∆30-7169|rDEN2∆30-7169 is a live recombinant attenuated DENV-2 candidate vaccine virus. It will be administered as a 0.5 mL dose containing 10^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
2008967|NCT03325881|Drug|SHP465|SHP465 capsule 6.25 mg orally once daily for 4 weeks
1588879|NCT02317874|Drug|Carboplatin|Given IV
1588880|NCT02317874|Other|Laboratory Biomarker Analysis|Correlative studies
1588881|NCT02317874|Drug|Paclitaxel|Given IV
1588882|NCT02317874|Other|Pharmacological Study|Correlative studies
1588883|NCT02317874|Drug|Talazoparib|Given PO
2008968|NCT03325881|Drug|Placebo|Placebo matching to SHP465 capsule orally once daily for 4 weeks
1588887|NCT02317848|Other|polygraphy and ECG|polygraphy and ECG during hospitalisation for acute heart failure to see Persistence of the severity of SAS after 2 months
1588888|NCT02317835|Device|DFUPS|The DFUPS device is a two-camera instrument for capturing images of feet
1588889|NCT02317809|Drug|Liquid pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH solution (Liquid Pergoveris) as subcutaneous injection using a disposable pen-injector on Day 1 in either first intervention period or second intervention period.
1588890|NCT02317809|Drug|Freeze-dried pergoveris|All subjects will be administered with 900 IU of r-hFSH and 450 IU of r-hLH freeze-dried powder (Freeze-dried Pergoveris) as subcutaneous injection on Day 1 in either first intervention period or second intervention period.
1588891|NCT02317796|Drug|MLR-1023|Each subject will receive an oral dose of placebo or MLR-1023 once before breakfast and either placebo (placebo and q.d. dose groups) or a second dose of MLR-1023 (b.i.d. dose groups) before dinner for 4 weeks.
1588892|NCT02317783|Drug|FDG-PET, [18F]Flutemetamol|
1588893|NCT02317770|Drug|Lidocaine Spray|5 puffs of 10% Lidocaine spray is administered every 5 minutes for 4 times. Then the patient is undergone procedure 5 minutes later.
1588894|NCT02317770|Drug|Nebulized Lidocaine|The patient receives 2.5 mL of 10% lidocaine is used by nebulizer under oxygen flow 6-7 LPM for 15 minutes prior the procedure.
1588897|NCT02317731|Other|Straw|Bowel preparation ingestion with a straw
1588898|NCT02317718|Other|monitor reproductive outcome|
1588899|NCT02317705|Drug|OTL38|
1588901|NCT02317679|Drug|Bosentan|Patients with PWS resistant to PDL treatment will be included. The treatment by Bosentan (twice daily :2 mg/kg and maximum 62,5 mg) will be given 1 day before the PDL irradiation (maximum area treated 100 cm2) and continued for 14 days. The clinical improvement of the lesions will be evaluated by comparing standardized pictures, 14 days after the end of the treatment by Bosentan which corresponds to 1 month after the laser PDL irradiation. The evaluation will be realized by 2 independent physicians blinded to the area treated or not. Hemoglobin and SGOT/SGPT will be controlled before and after the treatment by Bosentan.
1588995|NCT02316964|Other|laboratory biomarker analysis|Correlative studies
1588902|NCT02317679|Device|Pulsed dye laser (PDL)|A test area of the PWS will be treated by pulsed dye laser (PDL) (λ= 595 nm, 7 mm spot diameter, τp= 1.5 ms, same energy density used at the last session for each subject).
1588903|NCT02317666|Procedure|Medication Review|A structured 5-step multidisciplinary medication review (STRIP method) as described in the multidisciplinary guidelines by the Nederlands Huisartsen Genootschap (2013) including the objective to reduce the DBI, performed by the pharmacist in collaboration with the general practitioner
1588904|NCT02317640|Drug|Testosterone Gel applied by a pump|After being diagnosed with low testosterone levels the participant will be given a 30-day supply of the Testosterone/placebo gel (40.5 mg/day). The gel is to be applied every morning on clean and dry area of skin of the upper arms and shoulders.
1588905|NCT02317640|Other|Stand Training|Stand training with BWST with manual assistance. Participant is placed on treadmill in an upright position and suspended in a harness by an overhead cable. A trainer will aid the participant in pelvis and trunk stabilization, by applying anterior forces at the pelvis and/or posterior forces at the shoulders and ensure that the trunk and pelvis are not flexed or hyper-extended.
1588906|NCT02317640|Device|Electrical Stimulation|Electrical Stimulation (ES) will be applied via bifurcated leads and self-adhesive reusable surface electrodes. The electrodes will be applied over the motor points of both legs. Two electrodes will be used for contracting each muscle.
1588907|NCT02317627|Drug|KD025|
1588908|NCT02317614|Behavioral|SteadyRx|The proposed intervention consists of four core elements. The intervention will include a Smartphone application that allows direct interaction with the SteadyRx system, as well as automatic events controlled via a central server. The CONSULT element will facilitate patient-provider communication with links to care providers and other care resources. The REMIND element will provide telephonic reminders for late doses. The OBSERVE element will feature electronically observed dosing through time-stamped video recordings made on the Smartphone and sent securely to a central server. The REWARD element will feature monetary incentives designed to reinforce short- and long-term medication adherence and promote reductions in viral load.
1588909|NCT02317601|Drug|methylprednisolone sodium succinate|Single dose Intravenous
1588910|NCT02317601|Drug|placebo saline|
1588911|NCT02317588|Dietary Supplement|Flax Oil|Participants will consume capsules containing flax oil at a dose of 4 grams of ALA per day (8 capsules a day) with a meal for 28 days (4 weeks).
1588912|NCT02317588|Dietary Supplement|Fish Oil|Participants will consume capsules containing fish oil at a dose of 4 grams DHA + 0.8 grams EPA per day (8 capsules) for 28 days (4 weeks).
1588913|NCT02317575|Biological|LY900014|Administered SC
1588914|NCT02317575|Biological|Insulin Lispro|Administered SC
1588915|NCT02317562|Drug|I10E|Patients who met all eligibility criteria will receive 0.5 g/kg of IMP every 3 weeks during 45 weeks.
1588918|NCT02317536|Dietary Supplement|Carnipure Product 1|
1588919|NCT02317536|Dietary Supplement|Carnipure Product 2|
1588920|NCT02317536|Other|Placebo|Placebo
1588921|NCT02317523|Behavioral|Behavioral Activation|Six face-to-face sessions (60 minutes each) of Behavioral Activation (BA) therapy
1588922|NCT02317523|Behavioral|Information and Support|Six face-to-face sessions (60 minutes each) of Supportive Therapy
1588923|NCT02317510|Procedure|combined anesthesia|Combined Spinal Epidural Anesthesia for laparoscopic cholecystectomy
1588924|NCT02317510|Procedure|general anesthesia|General anesthesia for laparoscopic cholecystectomy
1588925|NCT02317497|Other|Intensive Care Sedation (depth, level)|As far as sedation is concerned, this will be adapted to all patients before randomization in the first 3 days according to what the diagnosis and acute treatment of the underlying disease demands. This will be deep sedation or even general anesthesia (for operative procedures) in most cases. After 72h at the sedation level of the respective randomization result, both groups will tried to be weaned from sedation with the goal of awakening, weaning from ventilation, overall de-escalation and transfer to rehabilitation as far as the course of the disease and the occurrence of complications allows. This reduction of sedation will follow individual regimes at he discretion of the treating physician. However, if cessation of sedation violates safety-limits (see below, Tab. 2) or is not feasible for other reasons, return to the level the patient was initially randomized for (or even below that) is mandatory with a re-assessment of safety for sedation weaning after 12h aimed for.
1588926|NCT02317497|Drug|Vasopressors to maintain normal blood pressure values, if needed|
1588927|NCT02317497|Drug|Osmotherapeutics to lowr intracranial pressure, if needed|
1588928|NCT02317497|Procedure|Endovascular stroke care to treat brain vessel occlusions, if needed|
1588929|NCT02317497|Procedure|Decompressive neurosurgery, if needed|
1588930|NCT02317484|Drug|Ipragliflozin (SGLT2 inhibitor)|
1588931|NCT02317471|Biological|autologous gp96 vaccination|"Vaccination of gp96 derived from autologous tumor tissue. Treatment will be started between 3-6 weeks after the surgery.
gp96 of 25ug in 1mL normal saline s.c. on days 1 of each cycle, up to a maximum of 10 doses (1 cycle= 7 days). 200-400mg cyclophosphamide i.v. 1-3 days before each gp96 infusion."
1588932|NCT02317471|Drug|Oxaliplatin+S-1|"Treatment will be start at the 5th week after the surgery.
S-1: 40~60mg bid，d1~14 q3W; oxaliplatin:130mg/m2，iv drip for 2h，d1,q3W 6 cycles."
1588933|NCT02317458|Biological|Experimental|One active arm with standard of car and treatment with C3BR-CQR-1 using intramyocardial injection
1588934|NCT02317458|Biological|Sham comparator|One arm with standard of care undergoing a sham procedure
1588935|NCT02317432|Behavioral|Comparison of a combined CBT + exercise intervention and enhanced usual care|
1588936|NCT02317419|Drug|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 21-day treatment cycle (QOD x 3).
1588937|NCT02317419|Drug|RO6927005|RO6927005 administered intravenously on Days 1, 3, and 5 of each 28-day treatment cycle (QOD x 3).
1588938|NCT02317419|Drug|gemcitabine|gemcitabine administered according to local label on Days 1, 8, and 15 of each 28-day cycle.
1588939|NCT02317419|Drug|nab-paclitaxel|nab-paclitaxel administered according to the local label on Days 1, 8, and 15 of each 28-day cycle.
1588940|NCT02317406|Drug|Biostime probiotics sachet children's formula|Biostime probiotics sachet children's formula,1.5g Oral Single dose
1588941|NCT02317406|Drug|Biostime probiotics sachet children's formula（placebo）|Biostime probiotics sachet children's formula（placebo）,1.5g Oral Single dose
2008969|NCT03325868|Drug|Ulipristal Acetate|Ulipristal 5mg daily by mouth for 12 weeks
2008970|NCT03325855|Other|None - Observational|None - Observational
2008971|NCT03325842|Diagnostic Test|ASKp|30 items questionnaire
2008972|NCT03325816|Drug|Nivolumab|Nivolumab is administered intravenously
2008973|NCT03325816|Radiation|177Lu-DOTA0-Tyr3-Octreotate|"177Lu-DOTA0-Tyr3-Octreotate will be administered every 8 weeks. The first dose of 177Lu-DOTA0-Tyr3-Octreotate will be given two weeks after the first administration of nivolumab. Each dose is infused over 30 minutes. On the day of 177Lu-DOTA0-Tyr3-Octreotate infusion, an intravenous bolus of anti-emetics will be given (suggested options: ondansetron (8 mg), granisetron (3 mg), or tropisetron (5 mg)). Administration of 177Lu-DOTA0-Tyr3-Octreotate may be given one day earlier or delayed up to 1 week due to holidays, inclement weather, conflicts, or similar reasons.
Concurrent amino acids are given with each dose of 177Lu-DOTA0-Tyr3-Octreotate since co-infusion of amino acids leads to a significant reduction (47%) in the mean radiation dose to the kidneys. The amino acid solution and 177Lu-DOTA0-Tyr3-Octreotate are administered in parallel by peripheral vein infusion"
2008974|NCT03325803|Drug|lidocaine/prilocaine (5%) application|For AFL pre-treatment, lidocaine/prilocaine (5%) cream (EMLA; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area under occlusion for 30 min
1588949|NCT02317302|Device|FDG-PET/MR|
1588950|NCT02317302|Device|FDG-PET/CT|
1588951|NCT02317289|Device|Detection of freezing|single wireless inertial sensor placed on the patients's lower limbs to detect freezing of gaitin Parkinsonian patients
1588952|NCT02317276|Drug|Triamcinolone 0.1%|Topical ointment
1588953|NCT02317263|Drug|testosterone|
1588954|NCT02317263|Drug|placebo gel|
1588957|NCT02317237|Procedure|Local anesthesia|Conscious sedation
1588958|NCT02317224|Procedure|"3-Hole subxiphorid and subcostal approach"|"3-Hole subxiphorid and subcostal approach anterior mediastinum tumor resection"
1588959|NCT02317224|Procedure|Trans sternal approach|Trans sternal approach anterior mediastinum tumor resection
1588960|NCT02317224|Procedure|VATS approach|Video-assisted thoracoscope anterior mediastinum tumor resection
1588961|NCT02317211|Dietary Supplement|Anthocyanin|Extract of blueberry and huckleberry （MEDOX，http://www.medox.no/english）
1588962|NCT02317211|Dietary Supplement|placebo|starch
1588963|NCT02317198|Drug|Clopidogrel|
1588964|NCT02317198|Drug|Ticagrelor or Prasugrel|
1588965|NCT02317185|Device|genex bone graft with bone graft|
1588966|NCT02317185|Other|autogenous bone graft|
1588967|NCT02317172|Other|Gel-based artificial saliva|Gel-based artificial saliva is a novel gel-like, edible moisturizing gel designed to relieve dry mouth.
1588968|NCT02317159|Drug|Imatinib|400mg imatinib qd PO
1588969|NCT02317146|Drug|Magnesium Sulfate|Magnesium sulfate is the drug used as prophylaxis to eclampsia in women with severe preeclampsia
1588970|NCT02317133|Biological|Blood samples|Compared to routine practice, 3 additional tubes of blood will be drawn for the observational needs of this study.
1588971|NCT02317133|Biological|Stool samples|Stool samples will be collected for the observational needs of this study (and are not part of routine practice).
1588972|NCT02317120|Genetic|NGS BRCA 1 and BRCA 2 full sequencing|
1588973|NCT02317120|Genetic|Multiplex ligation-dependent probe amplification (MPLA) BRCA1 BRCA2|Firstly many pairs of probes, containing: a universal primer sequence, a specific hybridisation target sequence and a stuffer DNA region to vary the size of the resulting product, are hybridised adjacent to each other on the target DNA strand .The two adjacent probe sequences are ligated to form a continuous section of DNA.The ligated probes are then amplified using PCR. The amplified fragments are analysed by capillary electrophoresis to detect the different fragment lengths. These data can be analysed to show the relative copy number of each fragment that is present in the sample.
1588974|NCT02317094|Other|Blood-flow restricted training|The intervention consists of low-intensity blood-flow restricted training involving 5 lower extremity exercises performed uni lateral in four sets to concentric failure with an intensity of approximately 25 repetition maximum (25RM).
1588975|NCT02317094|Drug|Care as usual|The intervention consists of various DMARDs, which are given to the patients depending on their physical state and the disease activity.
1588976|NCT02317081|Device|Axetis Inert Coronary Stents|de novo coronary artery stenosis in native vessels
1588977|NCT02317068|Device|HBR|
1588978|NCT02317068|Device|DD|
1588979|NCT02317055|Other|imaging|
2008975|NCT03325803|Device|2940-nm Er:YAG AFL pretreatment|After the anaesthetic cream was removed, AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 150 µm ablation depth, level 1 coagulation, 22% treatment density and a single pulse
1588981|NCT02317029|Device|Cardioversion with a pulsed biphasic waveform|Cardioversion will be performed by a pulsed biphasic (Multipulse Biowave®) waveform (Schiller Defigard 5000) with an energy setting of 90J, 120J, 150J, 200J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
1588982|NCT02317029|Procedure|Normoxia during cardioversion|Patients will be treated with room air with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal room air with a flow of 3 L/minute for 30 minutes following cardioversion
1588983|NCT02317029|Device|Cardioversion with a biphasic truncated exponential waveform|Cardioversion will be performed by a biphasic truncated exponential waveform (LIFEPAK 20), with a energy setting of 100J, 150J, 200J, 250J. Primary endpoint: The proportion of patients in sinus rhythm four hours post cardioversion.
1588984|NCT02317029|Procedure|Hyperoxia during cardioversion|Patients will be treated with 100% oxygen with a flow of 10-15 L/minute for 3 minutes prior to cardioversion and nasal 100% oxygen with a flow of 3 L/minute for 30 minutes following cardioversion
1588990|NCT02317003|Behavioral|Intervention PPIL|
1588991|NCT02317003|Behavioral|Control OR|
1588992|NCT02316964|Drug|decitabine|20 mg/m2 Given IV (intravenous) for 5 days over 60 minutes
1588993|NCT02316964|Biological|natural killer cell therapy|Undergo infusion of allogeneic NK cells on day 0
1588996|NCT02316951|Device|single-arm study group|Study participants will wear a small motion detection device and a regular Webcam will be placed near the wall facing the bed in each patient's hospital room. Study participants will be questioned about their sociodemographic, pain, and health history.
1588997|NCT02316938|Drug|Everolimus and reduced CNI|MTORi inhibitor, given as part of the core CRAD001A2433 study.
1588998|NCT02316938|Drug|Calcineurin Inhibitor and MPA|Will either be cyclosporine or tacrolimus. Used as standard of care in this patient population, but at a lower dose in the everolimus arm and at a standard dose in the comparator arm. Treatment given as part of the core CRAD001A2433 stud.
1588999|NCT02316925|Dietary Supplement|Setria glutathione supplement|500 mg/day capsule taken in the morning
1589000|NCT02316925|Dietary Supplement|Crystalline Cellulose|500 mg/day capsule taken in the morning
1589001|NCT02316912|Drug|ATX2417|Randomised double blind parallel group ascending dose assessment
1589002|NCT02316912|Drug|Placebo|Randomised double blind parallel group ascending dose assessment
1589003|NCT02316899|Drug|ASP0456|Oral administration once daily
1589004|NCT02316899|Drug|Placebo|Oral administration once daily
1589005|NCT02316886|Device|Coronary intervention|Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment
1589006|NCT02316886|Drug|Optimal Medical treatment|
1589007|NCT02316873|Behavioral|Music training|This program was based on the Kodaly and Orff pedagogy and adapted to focus on rhythm and temporal processing.
1589008|NCT02316873|Behavioral|Visual arts|This program emphasized visual-spatial and hand skills as well as creativity.
2008976|NCT03325803|Drug|MAL application|Immediately after AFL treatment, an approximately 1- mm-thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. Incubation time is 3 hours
1589010|NCT02316847|Drug|diazepam nasal spray|
1589011|NCT02316834|Drug|BMN 673|1 mg by mouth once daily.
2008977|NCT03325803|Other|Measurements of the fluorescence intensity|After 3 hours of application with MAL, saline wash was performed and fluorescence imaging analysis was performed with ultraviolet examination light (model 31602,356 nm; Burton Medical Products Crop.) at 10 cm height above the base of each lesion. The red fluorescence (610 nm-700 nm) was separated and extracted by Matlab program and then used to measure the amount of 633 nm fluorescence of protoporphyrin IX.
1589014|NCT02316808|Dietary Supplement|Plant stanol ester|Smoothie that contains plant stanol ester
1589015|NCT02316808|Dietary Supplement|placebo|Smoothie that contains placebo
1589016|NCT02316795|Procedure|Sentinel lymph node biopsy|
1589017|NCT02316795|Device|Goggle-based device with light-emitting diodes (LED)|
1589018|NCT02316795|Drug|Indocynanine Green|This is a infrared fluorescence imaging contrast agent
1589019|NCT02316782|Device|Blinded IVUS assessment|Only the angiogram is used for stent placement
1589020|NCT02316782|Device|Nonblinded IVUS|Angiogram, Grayscale IVUS and VH IVUS used for stent placement pre and post intervention
1589021|NCT02316769|Procedure|King Vision video laryngoscope|Patient intubated with the King Vision Video Laryngoscope
1589022|NCT02316769|Procedure|McGrath MAC video laryngoscope|Intubation with the McGrath MAC video laryngoscope
1589023|NCT02316756|Drug|PF-06648671|Experimental Pfizer compound which will be dosed as oral suspension
1589024|NCT02316756|Drug|Placebo|Placebo which will be given as oral suspension
1589025|NCT02316743|Drug|Levothyroxine supplementation|T4 supplementation for heart failure patients with subclinical hypothyroidism.
1589026|NCT02316730|Drug|Sanchi-Tongshu Capsule (Enteric coated pellets)|Take 0.7g (2 Capsules) of test preparation orally.
1589027|NCT02316730|Drug|Sanchi-Tongshu Capsule|Take 0.4g (2 Capsules) of reference preparation orally.
1589028|NCT02316717|Biological|IMM-124E|IMM-124E
1589029|NCT02316717|Other|Placebo|Matched placebo
1589030|NCT02316704|Device|THA with G7 PPS coted acetabular component|
1589031|NCT02316704|Device|THA with G7 OsseoTi coted acetabular component|
1589032|NCT02316678|Other|No intervention|There is no intervention
1589033|NCT02316665|Device|continuous positive airway pressure|continuous positive airway pressure treatment during three months with adherence recording
1589034|NCT02316665|Device|Sham-continuous positive airway pressure|Sham-continuous positive airway pressure during three months with adherence recording
1589035|NCT02316652|Procedure|Scaling and root planing|Mechanical instrumentation
1589036|NCT02316652|Procedure|Scaling and root planing with solution|Mechanical instrumentation with sodium hypochlorite disinfective solution
1589037|NCT02316639|Other|Neuromuscular Training|The established Neuromuscular Training (NMT) protocol is supervised, progressive program in which the patient maintains balance on three different support surfaces while a clinician administers purposeful manipulations of the support system.1 The patient maintains a single-leg stance on the rollerboard and tiltboard surfaces, and a two-leg stance with one foot on a roller board while the other is on a platform. Participants will complete two training sessions per week, for five weeks for a total of 10 training sessions.
1589038|NCT02316626|Drug|Subcutaneous progesterone|25 mg daily for 14 days
1589039|NCT02316626|Drug|Vaginal progesterone|90 mg daily for 14 days
1589040|NCT02316613|Drug|Rituximab|
1589041|NCT02316600|Device|smart insole|smart insole to encourage the frail elderly person's physical activity and to monitor key parameters of frailty
1589043|NCT02316561|Radiation|Single dose ablative radiotherapy|A single dose ablative radiotherapy will be delivered prior to surgery
1589044|NCT02316548|Other|No radiation|No radiation is received by the patient.
1589045|NCT02316548|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiotherapy (IMRT)
1589046|NCT02316535|Drug|Capecitabine|adjuvant chemotherapy;
1589048|NCT02316496|Drug|cetuximab|cetuximab 500mg/m²/ IV infusion, (q2w)
1589049|NCT02316496|Drug|Irinotecan|Irinotecan 180mg/m², in 500ml NaCl 0.9% solution, 90 min IV infusion (q2w)
1589050|NCT02316470|Biological|VLA84|a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B
1589051|NCT02316470|Biological|Placebo|phosphate buffered saline (PBS) solution
2008978|NCT03325803|Device|irradiation with red light-emitting diode lamp|After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface, and a total light dose of 37 J/cm-2. All patients wore protective goggles during illumination.
1589054|NCT02316444|Biological|Hepatitis B vaccine|An eligible participant will receive 3 doses of hepatitis B vaccine ( 20mcg in the deltoid intramuscular). Then their immune response will be assessed. Non responders will receive 3 additional vaccine doses then their response will be re-assessed.
1589055|NCT02316418|Device|Hairstetics™ anchoring system|"Overall, up to 360 prosthetic hair implants will be set in the scalp. The procedure will be performed in accordance with the instructions in the device Instructions for Use. Training and certification of operators by the Sponsor is a prerequisite for use of the study device by the former.
Hair extensions will be attached to the fibers four weeks after the implantation."
1589056|NCT02316405|Other|Arm and Leg Cycling Exercise for Walking after Stroke|
1589057|NCT02316392|Drug|Hyperpolarized Helium-3 MRI|Subjects will inhale Hyperpolarized Helium-3 gas during the MRI. This gas enhances images and the data collected will be used to determine if it can be used to detect BOS earlier than current standard of care.
1589058|NCT02316379|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
1589059|NCT02316379|Device|MRI|
1589060|NCT02316366|Device|Astoflo Plus fluid warmer|A fluid warmer (the Astoflo Plus warmer) was used to warm fluid to body temperature 37.5 degrees Celsius
1589065|NCT02316327|Drug|gemcitabine, cisplatin and bevacizumab|Therapeutic
1589066|NCT02316314|Procedure|Cardiac magnetic resonance imaging (CMR)|"CMR is a non-invasive way to take a high-resolution image of the heart and vessels. CMR uses powerful magnets and radio waves to obtain the image. During the CMR, you will have a substance injected into your vein called contrast to get a better picture of the heart."
1589067|NCT02316314|Procedure|Exercise-stress test|You will be asked to pedal on a bicycle with your arms to see how much work you can do and how far you can go.
1589068|NCT02316314|Procedure|Echocardiogram (ECHO)|An echocardiogram is an ultrasound of the heart done at rest.
1589069|NCT02316314|Procedure|Cardiac-related blood studies|The blood test involves drawing blood from a vein in the arm by placing a needle in it. The total amount of blood to be drawn for a single visit will be up to 57 mL (12 teaspoons).
1589070|NCT02316301|Drug|Long interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
1589071|NCT02316301|Drug|Short interval misoprostol|A rigid 2.9 mm hysteroscope with 30° forward oblique lens and outer sheath diameter of 5 mm will be used in the procedure. The uterine cavity will be distended by warm saline at a pressure between 60-80 mmHg. All the procedures will be performed during the proliferative phase using the vaginoscopic approach as described by Betocchi and Selvaggi in 1997. All the procedures will be diagnostic.Pain intensity will be assessed by visual analogue scale during the examination and 30 minutes after the procedure. A visual analogue scale ranging from 0 to 10 will be used (zero indicates no pain and 10 indicates the worst possible experienced pain).
1589072|NCT02316288|Behavioral|Mindfulness and Acceptance Therapy|Couples will learn psychological flexibility skills including mindfulness, acceptance, and values-based action as well as relational flexibility skills including empathic listening and responding during weekly 1.5-hour long sessions over the course of this 6-week intervention.
1589073|NCT02316288|Behavioral|Health Education|Couples will learn about chronic pain including causes, consequences, and how to talk with their health care professionals about their pain during weekly 1.5-hour long sessions over the course of this 6-week program.
1589074|NCT02316275|Other|No post-operative activity restrictions|Patients are to resume regular activity immediately after mid-urethral sling surgery. The investigators will determine the impact of unrestricted post-operative activity on continence outcomes of mid-urethral sling surgery in women with stress urinary incontinence (SUI). Investigators will measure the effect of unrestricted post-operative activity on early health-related quality of life (HRQOL). A Productivity Loss form for cost-effective analysis will be asked of the patient.
1589075|NCT02316275|Other|Standard post-operative activity restriction|
1589076|NCT02316262|Procedure|Targeted Muscle Reinnervation|Targeted reinnervation (TR) is a surgical procedure originally designed to provide intuitive control of upper limb prostheses through transfers of residual nerves to otherwise redundant target muscle. Native motor innervation of the target muscle is cut, and the residual nerves—after excision of end-neuromas—are coapted to the motor end point of the motor nerve, close to its point of entry into the muscle. The central principle underlying the nerve transfers in TR surgery is to reestablish the function of the amputated nerve and allow intuitive, seamless prosthesis control.
1589077|NCT02316249|Drug|Estradiol|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
1589078|NCT02316249|Other|placebo|Patients will be instructed to digitally apply 0.5mg of cream inside vagina every night for 2 weeks. After 2 weeks they will switch to 2 nights weekly.
1589079|NCT02316236|Drug|dexmedetomidine|an alpha-2 receptor agonist
1589080|NCT02316236|Other|loading dose|0.8ug/kg of dexmedetomidine is given in 10 minutes
1589081|NCT02316236|Other|sustaining dose|0.4ug/kg/min of dexmedetomidine is given
1589117|NCT02315872|Drug|ACTH|ACTH injections twice weekly for 28 weeks.
1589118|NCT02315872|Drug|Placebo|Placebo injections twice weekly for 28 weeks.
1589119|NCT02315833|Drug|Acetium|Capsule for oral administration contains L-cysteine 100mg
1589120|NCT02315833|Drug|Placebo|A placebo capsule matching Acetium for oral administration.
1589574|NCT02312258|Drug|Ixazomib|Ixazomib capsules
1589082|NCT02316223|Behavioral|Supporting Asthma Management Behaviors in Aging Adults (SAMBA)|The SAMBA program will be led by an asthma care coach (ACC) and the home program by a community health worker (CHW). All interventions, including usual care, will include EMR-based asthma self-management and decision support tools for clinicians in all practice sites. The ACC and CHW will provide education, goal setting, and general self-management support with assigned patients and coordinate with PCPs through in-person and phone contacts over 12 months. Outcomes will be measured through interviews, EMR chart abstractions, and from the Statewide Planning and Research Cooperative System (SPARCS) dataset to identify all ED visits and hospitalizations to any New York State facility.
1589083|NCT02316210|Device|electrical stimulation|
2008979|NCT03325790|Drug|200mg SPI-1005 BID|Active: low dose
1589085|NCT02316184|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered method of exploring individual's interest in making behavioral changes. In this study, the targeted behavior is alcohol use.
1589086|NCT02316184|Behavioral|Brief Advice|
1589087|NCT02316171|Biological|CAVATAK|CAVATAK is a purified preparation of CVA21
1589088|NCT02316171|Drug|Mitomycin C|Chemotherapy
1589089|NCT02316158|Other|Web-based support|Comparison between the efficacy between webb-based support and informational support
1589090|NCT02316145|Behavioral|Habilitation (Internet-based support and coaching)|Support and coaching with therapist (psychologist or educational therapist) by using chat and e-mail
1589091|NCT02316132|Drug|Stress|Corticotropin-Releasing Hormone
1589092|NCT02316132|Drug|Control|Saline 0.9%
1589093|NCT02316106|Drug|daratumumab|16 mg/kg administered by intravenous (IV) infusion once every week in Cycle 1, every other week in Cycle 2 and Cycle 3, every 4 weeks in Cycle 4 to Cycle 7, and from Cycle 8 to Cycle 20 on Day 1 of each cycle. Treatment cycles are 8 weeks in length.
1589094|NCT02316106|Drug|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1, and then on Day 1 of each cycle from Cycle 2 to Cycle 20. Treatment cycles are 8 weeks in length.
1589095|NCT02316106|Drug|daratumumab|16 mg/kg administered by IV infusion once every week in Cycle 1 only. Treatment cycles are 8 weeks in length.
1589096|NCT02316093|Other|Procedure: Gingival Crevicular Fluid, Saliva and Blood Sampling|
1589097|NCT02316080|Other|Dental bleaching|Home-use or in-office dental bleaching was performed in patients that received different types od desensitizing therapy
1589098|NCT02316080|Other|Desensitizing therapy|Participants (in T1 and T2) used domestic-use (DU) or in office (IO) desensitizers (D): Control Group; (DU)- experimental dentifrice with 7,5% of Biosilicate micro-particles-(D1); Sensodyne® dentifrice-(D2); (DU)-Odontis RX Sensiblock® dentifrice-(D3); (IO)-Biosilicate micro-particles paste, 1:1-(D4); (IO)-bioglass type 45S5 paste, 1:1 (D6); (IO)-Desensebilize Nano P-(D6).
1589099|NCT02316067|Other|Rehabilitation|The CHORDATA® Method (16 sessions; 50 minutes each; twice a week) consisted of three exercises: (1) anterior pendulum, with the patient seated on a chair, upper limb suspended by springs and straps, and actively moving the trunk forward; (2) posterior pendulum exercise, on a similar position as exercise (1) but now moving the trunk backwards and recruiting the abdominal wall muscles during a posterior pelvic tilt motion; and (3) stand-up and sit-down exercise, patient with knees fixed anteriorly, initiating the standing-up movement by pulling back and down the springs, trying to maintain the standing position for as long as possible, balancing the trunk and transferring the supporting force from the upper limbs to the lower limbs.
1589100|NCT02316054|Device|MPHI|addictive value of MPHI to management of high risk cardiovascular type 2 diabetes
1589101|NCT02316041|Procedure|Small incision lenticule extraction|The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.
1589102|NCT02316041|Device|ReLEx® (SMILE)|
2008980|NCT03325790|Drug|400mg SPI-1005 BID|Active: high dose
1589104|NCT02316015|Dietary Supplement|Infatrini® or Infatrini Peptisorb®|
1589105|NCT02316002|Drug|Pembrolizumab 200 mg every 3 weeks|
1589106|NCT02315989|Radiation|proton therapy|proton therapy
2008981|NCT03325790|Other|Placebo|Placebo Comparator
1589108|NCT02315963|Other|Performance Feedback|Performance Feedback regarding the patients efforts and accomplishments during the patients stay in the rehabilitation clinic, an expected average of 6 weeks. The data available about the patients progress will be analysed and processed to create a visual illustration shown to the patient on a daily bases.
1589109|NCT02315950|Other|Botulinum toxin and cineMRI-UDS|The investigators will be testing the capability of cineMRI combined with simultaneous urodynamics in the context of OAB in this proposal and expect to reveal a new understanding of diseased lower urinary tract physiology. Participants will receive an injection of intravesical botulinum toxin after filling out validated questionnaires and receiving a pre-treatment cineMRI-UDS.
1589110|NCT02315937|Procedure|transthoracic echocardiography|measurement of inferior vena cava diameter during inspiration and expiration using transthoracic echocardiography
1589111|NCT02315924|Other|simultaneous coronary and cerebral intervention|Simultaneous strategy is considered that coronary and cerebral intervention will be performed via the same access and within the same day.
1589112|NCT02315924|Other|staged coronary and cerebral intervention|Staged strategy was intended that coronary or cerebral intervention will be performed within 7 days from the first procedure.
1589113|NCT02315911|Procedure|ATE|surgical removal of adenoids and tonsils
1589114|NCT02315911|Procedure|APP|surgical removal of adenoids and tonsils and suturing of palatal pillars
1589115|NCT02315898|Drug|Inhaled tissue plasminogen activator (tPA)|Enrolled patients with acute plastic bronchitis (fibrin airway casts) will receive inhaled tPA treatment
1589116|NCT02315885|Other|Alcohol administration|
1589121|NCT02315820|Procedure|Induction of labor group (Group I)|Women at 38-40+3 weeks with estimated fetal weight 3800-4500 will be offered ripening and IOL.
1589122|NCT02315807|Device|transcranial direct current stimulation|
1589123|NCT02315794|Device|SPI®ART|implant prothetic restoration using a yttrium oxide stabilized zirconia abutment
1589124|NCT02315794|Device|SPI®EASY|implant prosthetic restoration using a commercially pure titanium grade 4 abutment
1589125|NCT02315781|Device|active tDCS|transcranial direct current stimulation (tDCS), is a type of electrical stimulation for the brain
1589126|NCT02315781|Device|Sham tDCS|Sham tDCS will appear exactly the same as active tDCS, but no stimulation will be administered.
1589127|NCT02315768|Drug|GA101|
1589128|NCT02315768|Drug|ibrutinib|
1589129|NCT02315742|Behavioral|Let's Move Program|Patients will walk 5 times per week for 12 weeks for a minimum of 30 minutes while using a heart rate monitor. After the first two weeks of walking, patients will attend four consecutive group meetings which a research team member will look at walking logs and download data from heart rate monitor to focus on progress. Patient will receive weekly phone calls to monitor progress and to change walking duration or intensity level.
1589130|NCT02315716|Procedure|Autologous Stem Cell Transplant (ASCT)|Randomisation to melphalan conditioned autologous stem cell transplant
1589131|NCT02315716|Drug|Consolidation with 4 cycles of CarCyDex|Randomisation to 4 further cycles of Carfilzomib, Cyclophosphamide and Dexamethasone for responding patients following 4 cycles of induction chemotherapy
1589132|NCT02315703|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelop (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
1589133|NCT02315703|Biological|MVA-Mosaic|Recombinant live attenuated MVA virus-vectored vaccine that has been genetically engineered to express 2 mosaic Gag, Pol, and Env sequences (Mosaic 1 and Mosaic 2). Total dose is 10^8 plaque-forming unit per 0.5 mL injection administered intramuscularly.
1589134|NCT02315703|Biological|gp140 DP Low-dose|The gp140 DP vaccine containing 50 mcg of total protein, mixed with aluminum phosphate adjuvant (0.425 mg aluminum), per 0.5 mL injection administered intramuscularly.
1589135|NCT02315703|Biological|gp140 DP High-dose|The gp140 DP vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
1589136|NCT02315703|Drug|Placebo|Normal saline, 0.5 mL injection administered intramuscularly.
1589139|NCT02315677|Device|Nasal Intubation with nasal RAE endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the standard nasal RAE endotracheal tube with bevel facing leftward.
1589140|NCT02315677|Device|Nasal Intubation with Parker Flex-Tip endotracheal tube|A single experienced operator with at least 5 years of clinical anesthetic experience will intubate using the Parker Flex-Tip endotracheal tube with the bevel facing posteriorly.
1589141|NCT02315664|Behavioral|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker called Fitbit Flex, and remote counseling by a PT. Intervention will be received immediately.
1589142|NCT02315664|Behavioral|Same intervention with a 2 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 2 month delay.
1589143|NCT02315651|Dietary Supplement|Coenzyme Q10|A snack containing 60 mg of Coenzyme Q10. The snack contains also dried fruits and nuts, and their content are identical to this of placebo.
1589144|NCT02315651|Dietary Supplement|Placebo|A snack identical to the trial snack, but without Coenzyme Q10. The snack contains also dried fruits and nuts.
1589149|NCT02315573|Procedure|Wrist block anesthesia|The carpal tunnel release surgery will be performed under wrist block anesthesia. Group 1 will have the wrist block performed with Lidocaine and epinephrine, while Group 2 with Bupivacaine and epinephrine.
1589150|NCT02315560|Device|TRANSCUTANEOUS ELECTRICAL NERVE STIMULATOR (TENS|electrical stimulation of the nerves in the foot on the incidence of nocturnal enuresis (bedwetting) in children
1589151|NCT02315547|Drug|Antibiotics|Patients will be given antibiotics based on sputum microbiology during steady-state bronchiectasis. The methodology has been described in the British Thoracic Society guideline [16]. Briefly, for first-line therapy, patients isolated with Hemophilus influenzae, Hemophilus parainfluenzae, Streptoccus pneumoniae and Moraxella catarrhalis at baseline will be treated with amoxicillin clavulanate potassium (625mg bid); patients isolated with Klebsela pneumonae or Pseudomonas aeruginosa at baseline will be treated with fluoroquinolones. Levofloxacin (500mg qd) will be empirically employed for antibiotic treatment in those who tested negative to sputum microbiology. Severe BEs could be prescribed with intravenous antibiotics therapy at the discretion of study investigators, either in the out-patient department or hospitalized for intensive systemic treatment. Hospitalized patients will not be included in the exacerbation cohort.
1589152|NCT02315534|Drug|BBI608|"In arm A, BBI608 will be administered at the RP2D twice daily for 7(±2) days prior to planned surgical resection or biopsy of recurrent GBM. Upon the clinical recovery of the patient and at a time between 15-28 days after surgery, BBI608 will be administered orally, daily, each day of a 28 day cycle in combination with temozolomide.
In arm B, patients who are not candidates for surgical resection will receive BBI608 administered orally, daily, each day of a 28 day cycle at the RP2D in combination with temozolomide."
1589153|NCT02315534|Drug|Temozolomide|Temozolomide (TMZ) will be administered orally, once daily, at a dose of 150 mg/m^2 daily on days 1 through 5 of each 28-day study cycle. The dose of temozolomide can be increased to 200 mg/m^2 as per standard TMZ dosing guidelines for patients who complete at least one cycle at 150 mg/m^2.
1589154|NCT02315521|Procedure|Fetal Intervention for LUTO|"Fetal vesico-amniotic shunting placement consists in placing a shunt (stent) percutaneously from fetal bladder to the amniotic cavity under ultrasound guidance.
Fetal cystoscopy will be performed using a thin scope that will be introduced to the fetal bladder for evaluation of the cause of the obstruction and ablation of the posterior urethral valves."
1589155|NCT02315508|Drug|AUT00063|800 mg orally, once a day, for 4 weeks
1589156|NCT02315508|Drug|Placebo|orally, once a day, for 4 weeks
1589157|NCT02315495|Drug|Saxagliptin|
1589158|NCT02315495|Drug|Acarbose|
1589159|NCT02315482|Procedure|pneumoperitoneum insufflation and steep trendelenburg|the sequence of pneumoperitoneum insufflation and steep trendelenburg positioning is randomized
1589160|NCT02315469|Other|Comprehensive Geriatric Assessment|Complete pre-operative geriatric assessment
1589161|NCT02315469|Other|Questionnaire Administration|Ancillary studies
1589162|NCT02315456|Procedure|capsulorhexis|
2008982|NCT03325777|Behavioral|Approach Bias Retraining|The Approach Avoidance Task (AAT) used for this experiment is an implicit, computerized paradigm in which participants respond to visually presented pictures on a computer screen displaying either 1) smoking-related images or 2) positive images, by pulling a joystick either towards their body (approach movement) or pushing it away from their body (avoidance movement). By pulling the joystick towards their body, the picture grows in size; by pushing the joystick away, the picture shrinks and then disappears from the screen. Participants are instructed to pull upon seeing an image tilted to the right and to push upon seeing a left-tilt image, while ignoring the image content and responding as quickly and as accurately as possible.
2008983|NCT03325777|Behavioral|SHAM Training|SHAM Training
1589167|NCT02315417|Drug|gevokizumab|
1589168|NCT02315417|Drug|Placebo|
1589169|NCT02315417|Drug|gevokizumab open-label|
1589170|NCT02315404|Procedure|CAP|CAP fitted to the end of the endoscope
1589171|NCT02315391|Dietary Supplement|isolated whey protein|isolated whey protein
1589172|NCT02315391|Dietary Supplement|micellar whey protein|micellar whey protein
1589173|NCT02315391|Dietary Supplement|glycine|glycine
1589174|NCT02315391|Dietary Supplement|citrulline|citrulline
1589175|NCT02315378|Behavioral|TAU|Treatment as Usual for patients presenting after accidents and assaults as it pertains to mental health, is a brief intervention that varies in length depending on the patient's needs. If the patient is highly distressed, the social worked will provide brief crisis management support. The social worker also performs case management functions such as attempting to get in touch with family, contacting shelter or hotel if the patient is homeless, contacting other social service agencies if needed, and providing the patient referrals for mental health services in the community. A psychiatrist will also be called to assess the patient only if he or she appears to be a threat to self (suicidal) or others, and exclusion criteria for this study.
1589176|NCT02315378|Behavioral|ARTAT|A one-session intervention targeting at-risk individuals (those continuing to experience peritraumatic panic following a trauma) and designed to reduce peritraumatic anxiety and enhance self-efficacy.
1589177|NCT02315352|Drug|L-PZQ ODT|L-PZQ ODT (MSC2499550A) tablet at a dose of 150 milligram (mg) put and disintegrated in the mouth without water
1589178|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg put and disintegrated in the mouth without water
1589179|NCT02315352|Drug|L-PZQ ODT|L-PZQ (MSC2499550A) tablet at a dose of 150 mg dispersed in water
1589180|NCT02315352|Drug|Rac-PZQ ODT|Rac-PZQ ODT (MSC1028703A) tablet at a dose of 150 mg dispersed in water
1589181|NCT02315352|Drug|Cesol®|Cesol® tablet at a dose of 150 mg crushed in water
1589182|NCT02315326|Drug|Ibrutinib|"Arm A: Ibrutinib will be given once daily. The starting dose cohort (level 1) will receive 560 mg/day (4 x 140 mg capsules). During the dose escalation period of the study, the 3+3 design will be applied (see Table 3). Participants will be assigned to cohorts of increasing oral daily doses of ibrutinib (560mg, 840mg) until disease progression, intolerable toxicity or death. Three patients with recurrent/refractory PCNSL or recurrent/refractory SCNSL will be treated with daily oral ibrutinib for a 28-day cycle starting at dose level 1 and observed for toxicities during cycle 1. Arm B: Ibrutinib will be given at the MTD defined in Arm A."
1589183|NCT02315326|Drug|HD- Methotrexate (MTX)|Arm C1: HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a total of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments.The starting dose of ibrutinib is 560 mg/day (4x140mg capsules)
1589184|NCT02315326|Drug|Rituximab + HD- Methotrexate (MTX)|Arm C2: Intravenous rituximab (500mg/m2) will be given on day 0, 14, and 28 of cycle 1 and day 14 and 28 of all following cycles. HD-MTX at 3.5g/m2 (standard hydration/leucovorin support) will be given on day 1 and 15 of each 28-day cycle for a maximum of 4 cycles totaling 8 HD-MTX administrations. Ibrutinib will be given between days 5 and 14 as well as days 19 and 28 of each cycle and continued daily after completion of HD-MTX treatments. The starting dose of ibrutinib is 560 mg/day (4x140mg capsules; dose level 1) (see Table 4). Filgrastim will be given at days 7-11 and 22-26.
1589185|NCT02315300|Device|medilog® DARWIN FD12|
1589186|NCT02315300|Device|Continuous Glucose Monitoring|
1589187|NCT02315287|Drug|Pioglitazone|Comparison of two different thiazolidinediones
1589188|NCT02315287|Drug|Lobeglitazone|Comparison of two different thiazolidinediones
1589189|NCT02315274|Other|Frequent remote contact between clinic visits.|Subjects will upload diabetes device data onto websites. Website data will be reviewed by study team who will provide feedback to patients without clinic visits.
1589191|NCT02315248|Radiation|Quantitative computed tomography scan for bone density analysis|A low radiation dose quantitative computed tomography (QCT) of the spine (L1 and L2) and the hips will be performed to measure bone density in the spine and hips.
1589192|NCT02315235|Biological|Normal saline|Normal saline is injected in one leg of patient.
1589193|NCT02315235|Biological|stem-cell|"Granulocyte colony-stimulating factor (G-CSF) is injected into subcutaneous for three days prior to the blood collection (D-3 to D-1). Peripheral mononuclear stem-cell is collected by Cobe spectra apheresis system in D-day.
The stem-cell (mononuclear cell) is injected into the muscle in the other side leg of patient."
1589194|NCT02315222|Dietary Supplement|Regenium|
1589195|NCT02315222|Dietary Supplement|Placebo|
1589196|NCT02315222|Procedure|Full Mouth Disinfection|
1589197|NCT02315209|Device|UHS, UPP, Comfort Plug|only Repairs with 3D Devices (UPP,UHS,Comfort Plug)
1589198|NCT02315196|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
1589199|NCT02315196|Drug|epirubicin hydrochloride|Given IV
1589200|NCT02315196|Drug|carboplatin|Given IV
1589201|NCT02315196|Procedure|therapeutic conventional surgery|Undergo definitive surgery
1589202|NCT02315196|Drug|paclitaxel|Given IV
1589203|NCT02315196|Other|laboratory biomarker analysis|Correlative studies
1589204|NCT02315196|Other|quality-of-life assessment|Ancillary studies
1589205|NCT02315183|Other|This is an observational Study|THis study has no intervention
1589206|NCT02315170|Device|intraocular injection guide|The device is 35mm long with tapered edges for an easy grip and it aligns with the curvature of the cornea to ensure that needle entry takes place at the optimal distance for injection
1589207|NCT02315170|Device|standard lid speculum|standard wire lid speculum
1589208|NCT02315157|Drug|Bendamustine|Given IV
1589209|NCT02315144|Drug|TV48108|TV48108 15, 60, 120 μg
1589210|NCT02315144|Drug|Placebo|Placebo Comparator
1589211|NCT02315131|Drug|TV46017|TV46017 15, 60, 120, and 240 μg; 4 ascending doses of inhaled TV46017 with an ipratropium bromide reference to evaluate the single administration of 4 ascending doses of inhaled TV46017 in COPD patients.
1589212|NCT02315131|Drug|Placebo|Placebo Comparator
1589213|NCT02315118|Drug|T-cell therapy + Rituximab + IL-2|"T cells collection
T cells expansion and modification in the laboratory
T cells infusion back to the patients"
1589214|NCT02315105|Procedure|Laparoscopic Greater Curvature Plication|LGCP is a procedure in which the stomach is folded inwards to that its capacity to hold amount of food is decreased dramatically. This is done under general anesthesia. The operation takes about 1 hour and is done laparoscopically. The attachments of the stomach to the spleen are feed up and the outside is folded inside and stitched up to keep it from folding in. To ensure that the surgeon has not obstructed the passage in or out of the stomach, a tube ( Bougie) is placed in the stomach at the time of the creation of the fold and checked again at the end of the procedure with a camera in the stomach which is placed through the mouth (EGD- upper endoscopy) to ensure the desired outcome is achieved.
1589215|NCT02315092|Device|Fluorescence Imaging|Wounds will be imaged using violet light (405 nm) illumination to locate areas with bacterial presence to guide swabbing.
1589216|NCT02315079|Other|Eye inflammation|This group will have a regular eye exam with the collection of tears. In addition, a the Ocular Surface Disability Index Survey of National Eye Institute Visual Functioning Questionnaire- 25 may be administered.
1589217|NCT02315079|Other|Without eye inflammation|This group will have a regular eye exam with the collection of tears.
1589218|NCT02315066|Drug|PF-04518600|Part A1 - PF-04518600 will be administered intravenously every 14 days in cohorts of 2 or more patients starting at a dose of 0.01 mg/kg. Increases in dose will continue until MTD is determined
1589219|NCT02315066|Drug|PF-04518600|Part A2 - patients with hepatocellular carcinoma will be treated at dose levels based on the optimal biologic dose (OBD) and maximum tolerated dose (MTD) tested in Part A1.
1589220|NCT02315066|Drug|PF-04518600 plus PF-05082566|Part B1 -In cohorts of 2 or more patients, PF-04518600 will be administered intravenously every 2 weeks starting at a dose of 0.1 mg/kg and PF-05082566 will be administered intravenously 4 weeks starting at a dose of 20 mg. Increases in dose will continue until MTD is determined.
1589221|NCT02315066|Drug|PF-04518600 plus PF-05082566|Part B2 - patients with select tumor types (head and neck squamous cell carcinoma and non small cell lung cancer) will be treated at dose levels based on the OBD selected in Part 1.
2008984|NCT03325764|Other|functional assessment|assessment of functional capacity, habitual physical, cardiorespiratory fitness, muscle power and postural stability and gait parameters
1589223|NCT02315040|Device|EVIE|EVIE is a small, mechanical, single use pump that mimics natural fertilization by introducing sperm into the uterus over a period of 4 hours, rather than all at once as in conventional IUI
1589224|NCT02315040|Other|Standard Intrauterine Insemination|standard intrauterine insemination procedure
1589225|NCT02315027|Biological|autologous mesenchymal stem cells|"There will be three treatment groups of up to 8 patients each. Groups 1 will receive a single dose of cells. Groups 2 and 3 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:
Group 1: single intrathecal dose of 1 x 107 cells.
Group 2: one intrathecal dose of 5 x 107 cells followed one month (+/- 4 days) later by a second intrathecal dose of 5 x 107 cells.
Group 3: one intrathecal dose of 1 x 108 cells followed one month (+/- 4 days) later by a second intrathecal dose of 1 x 108 cells."
1589226|NCT02315014|Other|whey protein|whey protein.
1589227|NCT02315014|Other|placebo|placebo.
1589228|NCT02315001|Drug|Liraglutide|GLP-1 receptor agonist administered via subcutaneous injection
1589229|NCT02315001|Other|Placebo|Volume-matched normal saline placebo administered via subcutaneous injection
1589230|NCT02314988|Drug|Tranexamic Acid|"3.0 grams of tranexamic acid will be poured in the surgical field and left in contact for five minutes. Subsequently, excess study solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.
TXA solution will be prepared using a dose of 3 grams of tranexamic acid combined with 70 mL of sterile normal saline, for a total volume of 100 mL."
1589231|NCT02314988|Drug|Placebo|"Placebo will be poured in the surgical field and left in contact for five minutes. Subsequently, excess solution will be suctioned away without touching the surrounding tissue surfaces and then the would closed without irrigation or manipulation.
The placebo solution will be 100 mL of sterile normal saline."
2008985|NCT03325751|Diagnostic Test|Visual field testing|Standard Automated Perimetry using a perimeter is one of the most commonly used techniques for measuring perceived visual ability of a subject. For a given eye, it provides quantitative measurements of visual function represented as a 2D spatial visual field map. It is of great clinical importance for diagnosing and monitoring glaucoma and detecting neurological conditions.
1589235|NCT02314949|Procedure|intestinal transplantation|
2008986|NCT03325725|Device|NewBreez LD intra-laryngeal implant|NewBreez LD intra-laryngeal implantation
1589240|NCT02314923|Biological|BPSC-1001 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^3, 3x10^4, 3x10^5, 3x10^6, 9x10^6, 2x10^7, or 1x10^8 pfu.
1589241|NCT02314923|Other|Placebo|0.9% Saline
1589242|NCT02314910|Other|Sample histology|
1589243|NCT02314897|Device|LV pacing|Left ventricular pacing lead implanted via the coronary sinus.
1589244|NCT02314897|Device|RV pacing|Conventional right ventricular pacing.
1589245|NCT02314884|Drug|Cafusertib Hydrochloride|
1589246|NCT02314871|Other|Epidural analgesia|see Arm/group description
1589247|NCT02314871|Drug|Piritramide|see Arm/group description
1589248|NCT02314871|Drug|Morphine|see Arm/group description
1589249|NCT02314858|Behavioral|Brief Personalized Video (BPV)|The BPV group will view a portion of their own sleep study that took place during their overnight sleep study.
1589250|NCT02314858|Behavioral|Non-Personalized Video (NPV)|The NPV group will see a stock video of someone with OSA.
1589251|NCT02314858|Behavioral|Treatment as Usual (TAU)|The TAU group will not watch a video.
1589252|NCT02314845|Other|Optimal PEEP|"Optimal PEEP determined by EIT during a PEEP titration procedure."
1589253|NCT02314845|Other|Low PEEP|Use of PEEP of 4 cmH2O during intraoperative period
1589254|NCT02314832|Procedure|adductor canal block|ultrasound guided saphenous nerve block in the adductor canal
1589255|NCT02314832|Procedure|femoral nerve block|ultrasound guided femoral nerve block
1589256|NCT02314819|Drug|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
1589257|NCT02314819|Drug|placebo|fruquintinib placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
1589258|NCT02314806|Drug|Irrigation with gentamicin solution|The surgical bed is irrigated with a gentamicin solution
1589259|NCT02314806|Drug|Irrigation with Clindamycin solution|The surgical bed is irrigated with a clindamycin solution
1589260|NCT02314806|Drug|Irrigation with Normal saline|The surgical bed is irrigated with normal saline
1589261|NCT02314793|Drug|ASP2205|oral
1589262|NCT02314793|Drug|Placebo|oral
1589263|NCT02314780|Drug|heme arginate 1mg/kg|
1589264|NCT02314780|Drug|heme arginate 3mg/kg|
1589265|NCT02314780|Drug|placebo|
1589266|NCT02314767|Behavioral|Interpersonal Psychotherapy|Patients were treated with IPT method, which was an active comparator vs treatment as usual
1589267|NCT02314767|Behavioral|Psychoeducational Group Therapy|Patients were treated with PeGt method which was an active comparatos vs treatment as usual
1589268|NCT02314754|Drug|Mifepristone followed by misoprostol 24-48 hours later|200mg oral mifepristone and 800mcg buccal misoprostol 24-48 hours after mifepristone
1589269|NCT02314741|Procedure|POEM Procedure|The procedure is performed under anesthesia.The procedure involves endoscopic electrosurgical dissection with an Olympus triangular tip knife.The myotomy is usually ~6cm long & averages 8-10cm. After the myotomy is performed the scope is withdrawn & inserted into the lumen to inspect the mucosa, ensure mucosal integrity & confirm easy passage of the endoscope through the LES consistent with an adequate myotomy. The mucosal entry site is usually 2-3cm long, & is closed with 5-10 endoscopic clips. Patients are hospitalized after procedure for observation.The patient is given IV-nutrition until post-operative day 1. An esophagram is obtained. If no loss of mucosal integrity or leak is noted, a liquid diet is started, which is continued for several days before initiating a solid diet.
1589270|NCT02314728|Drug|Misoprostol|Patients who are randomized to receive misoprostol will have 25mcg placed vaginally. Repeated dosing of misoprostol is based on clinical exam and clinical judgment of the provider.
1589271|NCT02314728|Drug|Oxytocin|Patients who are randomized to receive oxytocin alone will receive intravenous administration of oxytocin as designated by the hospital protocol. Protocol begins with 2 milliunits of oxytocin that is then titrated over time. Titration is based on clinical exam and clinical judgment of the provider and is continued until there are adequate uterine contractions.
1589272|NCT02314702|Device|PROFEMUR® L Revision Femoral Stem|Revision Total Hip Arthroplasty
1589273|NCT02314689|Drug|Intravenous (IV) citrulline|
1589274|NCT02314676|Biological|PEG-somatropin|
1589275|NCT02314663|Device|"COMBINED STRATEGY"|"Participants in the intervention group will be supplied with: a) printed matter containing information on the disease and its management (this will be handed out at each of the follow-up visits); b) mobile-telephone text messages containing guideline summaries, reminders of forthcoming appointments and/or arrangements for making new appointments in the event of non-attendance (in the periods between visits); and, c) self-report cards to check compliance with recommendations (across the entire follow-up)."
1589276|NCT02314650|Other|acupoint stimulation|stimulation was given at acupoints
1589277|NCT02314650|Other|non-acupoint stimulation|stimulation was given at non-acupoints
1589278|NCT02314650|Other|electrodes attached|electrode were attached to skin
1589279|NCT02314637|Drug|Teneligliptin|Teneligliptin for 52 weeks
1589280|NCT02314637|Drug|Teneligliptin + Sulfonylurea|Teneligliptin for 52 weeks in combination with sulfonylurea
1589281|NCT02314624|Behavioral|Behavioral Activation for Depression, Cognitive Behavior Therapy for Insomnia, Collaborative Assessment and Management of Suicidality|Evidence-based interventions for treating depression and concurrent problems
1589282|NCT02314624|Behavioral|Care-as-Usual Psychotherapy|Usual care psychotherapy for depression and concurrent problems
1589283|NCT02314611|Device|PROFEMUR® Gladiator HA Coated Modular Femoral Stem|Total Hip Arthroplasty (THA) using PROFEMUR® Gladiator HA Coated Modular Femoral Stem
1589284|NCT02314598|Other|No treatment|
1589324|NCT02314325|Drug|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 1 prior patients will be dosed as per body weight 20-40 IU/kg 5-7 infusions per fortnight
1589285|NCT02314585|Other|Exercise|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
1589286|NCT02314585|Other|Education|Participants will partake in three, six month phases. In the second phase, either an education or exercise program will be implemented. Assessments will follow each phase with the addition of an initial assessment for baseline data.
1589287|NCT02314572|Device|Binocular cataract surgery with phacoemulsification and implantation of multifocal intraocular lenses|Binocular implantation of the combination of AcrySof® IQ ReSTOR® multifocal intraocular lenses with an addition of +2.5 D in the distance-dominant eye and +3.0 D in the fellow eye.
1589288|NCT02314559|Procedure|Manual titration|One group will be sedated with a manual titration technique: here the titration of propofol is done manually by the anesthetist. Dosages may range between 50 and 400mg, given by boluses of 20-50mg.
1589289|NCT02314559|Procedure|Target controlled infusion|The other group will be sedated with a target controlled infusion technique (pump, marsh or Schneider). The anesthetist can titrate indirectly by adjusting the target controlled infusion to achieve adequate sedation. The concentrations of propofol may vary between 2 and 6 µg/ml, achieved by increments of 0.5-1.5 µg/ml.
1589290|NCT02314546|Drug|Midazolam|"Study participants will be randomly assigned to one of three treatment groups:
Group 1 - Placebo - Control patients will receive intranasal saline.
Group 2 - Nasal Midazolam Only - Patients will receive 0.2 mg/kg of intranasal midazolam.
Group 3 - Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam."
1589291|NCT02314546|Drug|xylocaine|Midazolam Plus Xylocaine - Patients will receive 0.2 mg/kg intranasal midazolam plus xylocaine 4% in a dose based on 25% of the volume of the midazolam.
1589292|NCT02314546|Drug|saline placebo|Placebo - Control patients will receive intranasal saline.
1589293|NCT02314533|Drug|fenofibrate|Fenofibrate (Lipanthyl®) 200mg capsule will be administered orally with breakfast once daily
1589294|NCT02314520|Device|peripherally inserted central catheter|Any complication associated with central access
1589295|NCT02314520|Device|centrally inserted central catheter|Central access not associated with any complication
1589296|NCT02314507|Other|Gua sha|A smooth, rounded-edged Gua sha tool will be press-stroked into the flesh enough to contact the fascial layer start at the midline of the subject's back. A stroke line is typically 4 to 6 inches long. Press-stroking will be repeated in one direction until the petechiae raises on that stroke line, typically 8 to 12 strokes. Gua sha will then be continued at the next stroke line directly adjacent to the one before, until the area covered the lower one third of the back.
1589297|NCT02314507|Other|Hot pack|A hydrocollator pack will be used and it will be stored at 42-43oC in the hydrocollator. 6 layers of towel will be used to cover the hydrocollator pack when applying to the back of the subjects.
1589298|NCT02314494|Behavioral|ProAsk|The intervention is a computer programme ProActive Assessment of Overweight Risk to identify infants at risk of developing childhood overweight and obesity. Parents of infants identified as at risk will be offered strategies for prevention by UK health visitors (public health nurses)
1589299|NCT02314481|Drug|MPDL3280A|Intravenous (IV) infusion
1589300|NCT02314481|Drug|Vemurafenib|Film coated tablet
1589301|NCT02314481|Drug|Alectinib|capsule
1589302|NCT02314481|Drug|Trastuzumab emtansine|Powder for concentrate for solution for infusion
1589303|NCT02314468|Procedure|Negative pressure wound therapy|NPWT changed twice a week.
1589304|NCT02314468|Procedure|Glycerol Preserved Allografts (GPA)|GPA changed every 7 to 10 days.
1589305|NCT02314455|Other|D-xylose|There will be four patient groups analyzed. Ten patients each, 10 with active eosinophilic esophagitis defined by consensus guidelines, 20 patients in histologic remission (10 by steroids and 10 by diet) and 10 control volunteers will be studied. Patients who have consented to the trial will be scheduled at the Clinical Research Unit (CRU) Patients will report to Charlton 7 the CRU, having their height, weight, blood pressure and temperature recorded. Subjects can choose to either have a saline lock IV placed or have their bloods drawn 3 separate times. They will receive 25 grams of D-xylose orally. The D-xylose will be mixed in 10 cc of water with 2 teaspoons of honey. D-xylose serum levels will be drawn at 5 and 10 and 60 minutes.
1589306|NCT02314442|Drug|ALN-PCSSC|Single or multiple doses of ALN-PCSSC by subcutaneous (sc) injection
1589307|NCT02314442|Drug|Sterile Normal Saline (0.9% NaCl)|calculated volume to match active comparator
1589308|NCT02314429|Device|Vaginal ring releasing lactic acid (racemic mixture)|
1589309|NCT02314416|Biological|Amniotic Stem Cells and Collagen Matrix|Nucel will be applied in between two pieces of collagen matrix`. The NuCel-impregnated collagen matrix will be placed over a clean, debrided wound.
1589310|NCT02314403|Drug|Belatacept|A selective T-cell (lymphocyte) costimulation blocker
1589311|NCT02314403|Drug|ATG|A T-Cell Depleting Agent
1589312|NCT02314403|Drug|Rituximab|B-Cell Depleting Agent
1589313|NCT02314403|Radiation|Total Body Irradiation|
1589314|NCT02314403|Radiation|Thymic Irradiation|
1589315|NCT02314403|Procedure|Combined Bone Marrow/Kidney Transplantation|
1589316|NCT02314390|Behavioral|Group-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered in a group and will last 2 1/2 hours.
1589317|NCT02314390|Behavioral|Individual-Mindfulness-Based Cognitive Therapy|The intervention consists of 8 weekly sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
1589318|NCT02314377|Drug|Bevacizumab|Bevacizumab dosing of 5mg/kg q 2 weeks for 12 weeks (2.5 mg/week).
1589319|NCT02314364|Radiation|SBRT with protons or photons|
1589320|NCT02314351|Drug|Metoclopramide 10 mg|Intravenous form of metoclopramide is in the same appearance with placebo
1589321|NCT02314351|Drug|Placebo|Intravenous form of metoclopramide is in the same appearance with placebo
1589322|NCT02314351|Drug|Fentanyl|Intravenous fentanyl (1 mcg/kg), if pain persists at 30th minute
1589323|NCT02314338|Other|Pulmonary rehabilitation|In-patient pulmonary rehabilitation including individualized exercise prescription, group based exercise training, education, individual sessions with a multi professional health care team
2008987|NCT03325712|Drug|BI 705564|Film-coated tablet
2008988|NCT03325712|Drug|Placebo|Film-coated tablet
1589325|NCT02314325|Drug|ADVATE [Antihemophilic Factor (Recombinant)]|In Arm 2 patients who have completed arm 1 will cross over onto an individualised PK tailored alternate day dosing regimen
1589326|NCT02314312|Drug|Everolimus + low dose cyclosporin A + prednisolone|
1589327|NCT02314312|Drug|Standard immunosupressive regimen|
1589328|NCT02314299|Drug|MTP-131|
1589329|NCT02314286|Drug|Rosuvastatin|Rosuvastatin is a hydrophilic statin, short treatment (hours to days) with this type of statin improved the outcome of patients during acute myocardial infarction, sepsis, contrast-induced nephropathy, hepatic ischemia/reperfusion injury, emphasizing its preferential pleiotropic effects. Currently, the FDA classiﬁes all statins as pregnancy category X and discourages their use during pregnancy due to higher abortion rate and teratogenicity that were observed in animals exposed to hydrophobic statins during pregnancy. Since the use of statins after delivery is allowed, the present study will aim to evaluate whether Rosuvastatin may accelerates preeclampsia resolution following delivery and potentially reduce postpartum preeclampsia complications.
1589330|NCT02314286|Drug|Placebo|
1589331|NCT02314273|Drug|rhIL-11|patients receive rhIL-11(50 mcg/kg，subcutaneously)after standard chemotherapy，once a day for 10 days or until platelet count ≥80000/mL
1589332|NCT02314260|Other|bishop score calculation|Assessment of bishop score by vaginal examination
1589333|NCT02314260|Other|Trans-vaginal ultrasound|trans-vaginal ultrasound assessment of cervical length.
1589334|NCT02314260|Other|Modified bishop score calculation|using the cervical length and the original bishop score to calculate modified bishop score
1589335|NCT02314260|Procedure|labour induction|Induction of labor was carried out as per our hospital's standard protocol.
1589336|NCT02314247|Drug|Selinexor|20 mg oral tablets: Oral 60 mg dose on Days 1 and 3 of Weeks 1-4 of each 4-week cycle. Number of Cycles: up to 12 but there is no maximal duration for treatment.
1589337|NCT02314234|Drug|sugammadex (Bridion)|single dose of sugammadex at skin incision
1589338|NCT02314221|Device|Exoskeletal-assisted walking (ReWalk, Ekso)|The WALK arm will consist of supervised exoskeletal-assisted walking training, three sessions per week (4-6 h/week) for 36 sessions (12 weeks) and usual activities for their second 12-week period.
1589339|NCT02314208|Drug|Xenbilox|
1589340|NCT02314208|Dietary Supplement|Resveratrol|
1589341|NCT02314208|Drug|Tahor|
1589342|NCT02314195|Drug|Selective serotonin re-uptake inhibitor|A medication of selective serotonin re-uptake inhibitor (SSRI) family, Behavioral. The type and dosage of the medication was decided by the treating psychiatrist.
1589343|NCT02314195|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for obsessive compulsive disorder carried out by a psychologist.
1589344|NCT02314195|Other|Music therapy|12 sessions of 30-minute individual-based receptive music therapy, supervised by the treating psychiatrist.
1589345|NCT02314182|Procedure|Primary tumor resection + chemotherapy|"Step 1: Primary Tumor (PT) resection
Within 3 weeks after randomization
Immunonutrition given 7 days prior to PT resection
Mechanical bowel preparation performed before surgery according to the local practices
Performed by laparoscopy (recommended) or by laparotomy (at the investigator's discretion)
Step 2: postoperative CT-scan
Must be performed within 4 weeks after surgery
CT-scan/MRI with the same criteria as pre-treatment evaluation
Step 3: Chemotherapy +/- target therapy
Within 4 weeks after the surgery
Chemotherapy administered according to the usual scheme for the chosen protocol
All validated and/or registered perioperative rectal cancer treatments authorized
The duration of one treatment cycle depending on the type of treatment administered
Radiotherapy is allowed after randomization if indicated"
1589346|NCT02314182|Drug|Oxaliplatin/irinotecan + capecitabine, 5-FUI ± bevacizumab|"Treatment will start within 3 weeks after randomization; Chemotherapy will be administered according to the regimen in the chosen protocol and validated by the MDOC of each center.
If complications occur, emergency surgery can be performed according to the local practices of each investigator center.
Radiotherapy is allowed after randomization if indicated (MDOC)."
1589347|NCT02314169|Other|Laboratory Biomarker Analysis|Correlative studies
1589348|NCT02314169|Biological|Nivolumab|Given IV
1589349|NCT02314156|Drug|Telapristone Acetate|Given transdermally
1589350|NCT02314156|Other|Placebo|Given PO
1589351|NCT02314156|Drug|Telapristone Acetate|Given PO
1589352|NCT02314156|Other|Placebo|Given transdermally
1589353|NCT02314156|Other|Laboratory Biomarker Analysis|Correlative studies
1589354|NCT02314156|Other|Questionnaire Administration|Ancillary studies
1589355|NCT02314143|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules.
1589356|NCT02314143|Drug|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets.
1589357|NCT02314130|Dietary Supplement|Dietary therapy|A enteral diet formulation was developed to meet dietary requirements of adult patients. The formulation was standarized in household measures so that caregivers would prepare it and delivered it at the patients' home. Anthropometric measurements and blood samples were taken at baseline and at the end of the intervention which lasted four months.
1589358|NCT02314117|Drug|Ramucirumab|Administered IV
1589359|NCT02314117|Drug|Capecitabine|Administered orally
1589360|NCT02314117|Drug|Cisplatin|Administered IV
1589361|NCT02314117|Drug|Placebo|Administered IV
1589362|NCT02314117|Drug|Fluorouracil|Administered IV
1589363|NCT02314104|Drug|ropivacaine|Treatment local injection was 2 mL of 0.5% ropivacaine at each port site. Treatment TAP was 30 mL of 0.5% ropivacaine bilaterally.
1589364|NCT02314091|Procedure|onlay mesh hernioplasty|
1589365|NCT02314065|Behavioral|CBT, exposure and response prevention (Face-to-face)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.
Treatment is delivered in a conventional manner. Participants are physically meeting with a therapist once a week."
1589366|NCT02314065|Behavioral|CBT, exposure and response prevention (Internet-based)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.
Treatment is delivered via the Internet. Participants are guided by a therapist using an email-like communication system."
1589443|NCT02313337|Drug|Anesthesia maintenance(midazolam,fentanyl,propofol,atracurium)|All cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
1589572|NCT02312297|Drug|Minocycline hydrochloride|extended release tablets 135 mg
1589367|NCT02314052|Drug|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.
Starting dose: 0.125mg/kg/dose
Number of cycles: until progression or unacceptable toxicity develops.
PHASE 1b Dose escalation: 50% or 25% increase in subsequent cohorts depending upon toxicity until maximum tolerated dose (MTD) is identified.
PHASE 2 Cohort expansion at the MTD: Additional patients to be treated at the highest dose tolerated to assess efficacy and further assess safety"
1589368|NCT02314026|Device|Suspected NASH BreathID test with 13C-Octanoate|Subject will have breath measured before and after ingestion of solution of 100 mg 13C Octanoate dissolved in 150 cc of water
1589369|NCT02314026|Device|Suspected NASH Breath test with 13C Methacetin|Subject will have breath measured before and after ingestion of solution of 75 mg 13C Methacetin dissolved in 150 cc of water
1589370|NCT02314013|Drug|Cephalosporin + Metronidazole|intravenous antibiotics injection (3rd generation cephalosporin + metronidazole)and then change to oral antibiotics (3rd generation cephalosporin+ metronidazole) (an expected average 10 days)
1589371|NCT02314000|Device|Precision Spinal Cord Stimulator System|
1589372|NCT02313974|Procedure|Renal Biopsy|
1589373|NCT02313961|Other|Remote ischaemic conditioning|Remote ischaemic conditioning is induced by 3 cycles of manual inflation of a blood pressure cuff placed on the left lower limb to 200 mmHg for 5 minutes and then deflation to 0 mmHg for another 5 minutes.
1589374|NCT02313935|Other|LLM|LLM training Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
1589375|NCT02313935|Other|FFA|PTC training Participants use the FitForAll exergaming computer platform as the physical training component (PTC)
1589376|NCT02313935|Other|Brain Fitness|CTC training Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
1589377|NCT02313935|Other|VideoGrade|Active cognitive training by use of the VideoGrade software by AUTH.
1589378|NCT02313922|Drug|etanercept combined with methotrexate or etanercept combined with placebo|
1589383|NCT02313896|Behavioral|Phone calls|Phone calls from medical staff assess confusion of the patient, and recommend immediate changes to dosage of lactulose.
1589384|NCT02313883|Drug|PerioSept(r)|Taurolidine is derived from the amino acid taurine and has antimicrobial and immune modulating properties
1589385|NCT02313870|Drug|clobetasol propionate + Methotrexate|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, associated with methotrexate (MTX) received either orally or subcutaneously at a dose of 12.5 mg / week in patients weighing less than 60 kg and with creatinine clearance greater than 50 ml / min (planned dose reduction to 10 mg / week in patients less than 60 kg or with a creatinine clearance less than 50 ml / min) for four weeks followed by oral or subcutaneous methotrexate alone at the same dose during following 8 months
1589386|NCT02313870|Drug|clobetasol propionate alone|daily applications of topical clobetasol propionate at a dose of 10 to 30 g / day depending on the patient's weight and the initial number of new blisters per day, up to 14 days after control of the disease followed by 1 application every 2 days at the same dose for 4 weeks then an application twice a week for 4 weeks then once application a week until the end of the 9th month of treatment
1589387|NCT02313857|Biological|Viralym-C|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-C infusion. If a patient has multiple Viralym-C infusions the schedule resets again at the beginning so follow up relates to the last Viralym-C infusion.
Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
1589388|NCT02313844|Biological|Viralym-B|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-B infusion. If a patient has multiple Viralym-B infusions the schedule resets again at the beginning so follow up relates to the last Viralym-B infusion.
Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
1589389|NCT02313831|Other|Interval training|Patients of this group will be submitted to an interval training program
1589390|NCT02313818|Behavioral|Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for 4-24 sessions; each session is 60 minutes.
1589391|NCT02313805|Other|Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are on the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
1589392|NCT02313792|Drug|Palifermin|
1589393|NCT02313779|Behavioral|Lovingkindness Meditation (LKM)|Compassionate behavior training (REVISE)
1589394|NCT02313779|Behavioral|Mindfulness Meditation|
1589395|NCT02313766|Other|PPV : positive pressure ventilation|Inspiratory pressure support ventilation (12 cmH2O) without PEEP
1589396|NCT02313766|Other|PEEP : PPV + PEEP|Inspiratory pressure support ventilation (12 cmH2O) with PEEP (6 cmH2O)
1589399|NCT02313740|Biological|Butantan Fragmented Inactivated Trivalent Influenza Vaccine|Subjects participating in the study are exposed to Butantan´s Fragmented Inactivated Trivalent Influenza Vaccine during vaccination campaign, and will have immunogenicity and safety related to the vaccine evaluated (observational study).
1589400|NCT02313727|Drug|Pamidronate|intravenous infusion of pamidronate 60 mg
1589401|NCT02313727|Other|Placebo (NaCl 0.9%)|intravenous infusion of NaCl 0.9% 500 ml
1589402|NCT02313714|Device|stimulation wave (2.5 kHz, burst at 50Hz, on/off: 3/9 sec),|All patients in the treatment arm will receive electric muscular stimulation with a Russian current protocol twice a week for 7 weeks.
1589403|NCT02313714|Device|Sham|very low electric muscular stimulation
1589404|NCT02313701|Other|Standardized visual presentation|Visual presentations will address what type of procedure they will undergo, the risks and benefits of the procedure (i.e. injury to nearby organs, risks of infection and bleeding, risk of re-operation), alternative treatments to the procedure, what to expect during the pre-operative period, and what to expect in the post-operative period (i.e. urinary catheter, constipation, pain management, hospital stay).
1589405|NCT02313688|Procedure|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 3±0.5 cm lengthen proximal resection margin.
1589406|NCT02313688|Procedure|gastrectomy|Transabdominal (include transhiatal) D2 gastrectomy according JGCA gastric cancer treatment guidelines (2010, ver.3) and with 5±0.5 cm lengthen proximal resection margin.
1589407|NCT02313675|Drug|Acetaminophen|
1589408|NCT02313675|Drug|Ketorolac Tromethamine|
1589409|NCT02313675|Drug|Saline|
1589410|NCT02313662|Device|NBI and PDD|
1589411|NCT02313623|Procedure|Prostate Fusion Biopsy|For subjects with scheduled fusion biopsies, we propose a research plan to acquire additional biopsy cores for research purposes without impacting clinical protocol. After acquiring clinically-necessary biopsies, we propose taking an additional research biopsy to establish a matched-pair of clinical and research samples.
1589412|NCT02313610|Drug|Qinbudan|Contains three kinds of traditional Chinese medicine radix scutellariae, radix stemona, liquorice
1589413|NCT02313610|Drug|Qinbudan Placebo|Qinbudan Placebo was the same as therapeutic drug in package,shape,size.
1589414|NCT02313597|Procedure|VAAFT|Video assisted Anal fistula Treatment is minimal invasive method of treatment of complex and high anal fistulas.
1589415|NCT02313584|Drug|dabigatran|
1589416|NCT02313584|Drug|placebo|
1589417|NCT02313558|Drug|Dentifrice Containing Ilex Rotunda Thunb|Use the dentifrice to brush teeth twice a day for 12 weeks
1589418|NCT02313558|Drug|Control dentifrice|Use the dentifrice to brush teeth twice a day for 12 weeks
1589419|NCT02313545|Drug|IZN-6NVS Cream|"IZN-6NVS, a hydrocream containing three herbal extracts, is a polymolecular agent derived from botanical sources. It is composed of a blend of three herbal extracts, Centella asiatica, Echinacea purpurea, and Sambucus nigra.
Cream concentration: 5%"
1589420|NCT02313519|Dietary Supplement|Probiotics|Probiotics are prepared in capsule form
1589421|NCT02313519|Dietary Supplement|Placebo|Glucose powder
2008989|NCT03325699|Device|SMART4MD Health Application|"SMART4MD is a general health application which has been adapted specifically for people with mild dementia through a structured process. The application is intended to be used daily at home, mainly by the participants themselves, with the help of their informal carers. The application is optimized for tablet devices running on Android operating system (OS). Participants will be provided with a tablet with the SMART4MD health application.
The core functionalities of the application are based on reminders (medication, appointments with healthcare providers), brain supporting activities (clock, calendar, brain games, photos) and optional status and health information sharing with family and informal carers (including daily feeling status, specific health problems, and quality of life). An important feature of SMART4MD is its personalization facility: main users (PWD and informal carers) will be able to switch off/on various features and information sharing possibilities."
2008990|NCT03325686|Dietary Supplement|vitamin D supplement|D; received 50,000 IU of vitamin D supplement weekly
1589424|NCT02313493|Behavioral|Baby Triple P|
1589425|NCT02313480|Other|massage|Swedish massage was included in one arm of the study and not the other. Administered by a trained therapist as part of the usual 30 minute treatment time. Amount of massage administered dependant on Therapist's clinical reasoning
1589426|NCT02313467|Drug|Topical application of 1.5% Butenyl ALA|
1589427|NCT02313467|Drug|Topical application of sham control|
1589428|NCT02313441|Other|Remote Ischemic Pre-Conditioning|The blood pressure cuff was inflated to a pressure of 200 mm Hg for 5 minutes, followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated 3 times by the resident doctors in the pre-cath room
1589429|NCT02313428|Device|Topical Oxygen Chamber for Extremities|Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
2008991|NCT03325686|Other|Placebo|placebo
1589431|NCT02313402|Device|EOL (Eye On Line)|the intervention consists in training program allowing a gradual acquisition of the eye-writing
1589432|NCT02313389|Drug|Rituximab, Methotrexate, Temozolomide|Seven monthly R-MT cycles including high dose MTX (3.5g/m2, D1), TMZ, rituximab.
1589433|NCT02313376|Biological|GAP3KO|GAP3KO administered via the bite of 150-200 GAP3KO-infected A. stephensi mosquitoes under controlled conditions.
1589434|NCT02313363|Device|patient-centered smartphone-based diabetes care system|patient-centered smartphone-based diabetes care system (PSDCS) is composed of 4 modules such as glucose module, diet module, physical activity module, and SNS module. Participants were instructed to use the PSDCS and to measure blood glucose levels with a Bluetooth glucometer, input daily food intake, and wear an activity tracker.
1589435|NCT02313350|Device|Chemonucleolysis with Discogel|
1589436|NCT02313350|Procedure|open discectomy|
1589437|NCT02313337|Other|Oral administration|Premedicate--Oral administration of a mixture at preoperative 30 minutes: ketamine 3 mg/kg, midazolam 0.5 mg/kg and atropine 0.02 mg/kg, plus 50% glucose solution to 0.5ml /kg.
1589438|NCT02313337|Other|Intramuscular injection|Premedicate--At preoperative 30 minutes intramuscular injection of atropine 0.02 mg/kg, 5 minutes before entering the operation room, intramuscular injection of ketamine 5 mg/kg.
1589439|NCT02313337|Other|Rectal perfusion|Premedicate--At preoperative 30 minutes rectal infusion of midazolam 0.5mg/kg
1589440|NCT02313337|Other|Dripping nose|Premedicate--At preoperative 30 minutes dripping nose of Imidazole valium 0.2 mg/kg
1589441|NCT02313337|Drug|Anesthesia induction(midazolam,fentanyl,propofol,atracurium)|After entering the operation room ,all cases intravenous midazolam 0.05 mg/kg, fentanyl 3μg/kg, closed-loop target controlled infusion propofol and atracurium .
1589442|NCT02313337|Procedure|Intubation|Intubation when the trachea-oesophageal fistula（TOF） value fell 15%, BIS value dropped to 40.
1589538|NCT02312557|Drug|Enzalutamide|Given PO
1589444|NCT02313324|Device|Extracorporeal shock wave therapy (ESWT)|The patients received 2000 shots of extracorporeal shock wave therapy in the coccyx area per session for four sessions (one session a week for 4 consecutive weeks). The frequency used was 5 Hz and the pressure was 3-4 bar.
1589445|NCT02313324|Device|SWD combined IFC|The shortwave diathermy (SWD) was the inductive mode with a coil at a frequency of approximately 27.12 MHz. The shortwave diathermy applicator was placed over the sacrococcygeal area. The treatment duration was 20 minutes. After completing the SWD treatments, the patients received the interferential current (IFC) treatment. IFC provides deeper electrical stimulation. The electrical current was applied to the gluteal area using four electrodes from 2 channels of the stimulator. The four electrodes were set on the gluteal area. The carrier frequency, typically 4000 Hz and 4100 Hz and designed to interfere with each other, resulted in a beat frequency of 100 Hz within the treated area. The treatment duration was 20 minutes. The protocol was set as 3 times per week for a period of 4 weeks.
1589446|NCT02313311|Other|time-lapse imaging|Embryos are observed using time-lapse imaging (Primo Vision®). It is an incubator with a compact, sealed, and digitally inverted camera unit which can automatically acquire images.The system can record the actual developmental stage of the embryos, all the recorded images can be saved to be analyzed later using a special software program.
1589447|NCT02313298|Radiation|Stereotactic Body Radiotherapy|IMRT or similar techniques that use inverse treatment planning
1589448|NCT02313272|Radiation|Hypofractionated Stereotactic Irradiation (HFSRT)|Radiation therapy treatment (FSRT) which will be given to participants over 5 days.
1589449|NCT02313272|Drug|Pembrolizumab|"Dose Escalation: The dose of pembrolizumab will be escalated per schema in a 3+3 fashion. The starting dose (i.e., dose level 1) will be 100 mg.
Dose Expansion: The pembrolizumab dose used in the dose expansion cohort will be maximum tolerated dose (MTD) determined from the dose escalation phase."
1589450|NCT02313272|Drug|Bevacizumab|Initial cycle of bevacizumab must start within 10 days of registering to the trial. It will be given concurrent with radiation therapy. Bevacizumab will be administered intravenously at a dose of 10 mg/kg every 2 weeks. Doses will be adjusted if there is a > 10% change in weight.
1589451|NCT02313259|Other|Speed discrimination test|"The participant has to stare in the middle of two screens, i.e the reference screen and the test screen. Dots are moving from the center to the edge of the screens at different speeds. The participant is forced to determine if the dots of the test screen are moving faster or slower than the reference screen.
The test is designed in Psychtoolbox3. Data analyses performed using MATLAB. Two-alternative forced choice paradigm."
1589452|NCT02313259|Behavioral|Driving simulation|"25 km simulated car driving session. The participant is seated in the driver compartment of a real car featuring all the actual components (steering wheel, pedals regulating speed and brakes). He is instructed to respect road regulations as well as safety rules and must perform some driving manoeuvres, such has turning at intersections, stopping when necessary, passing another car, etc.
Software Drive 3.0 by Systems Technology Inc., Hawthorne, California, USA. Magnetic head tracker (Flock of Birds, Ascension Technology Corporation, Burlington, Vermont, USA).
A fixed-base driving simulator. 2 driving scenarios: a practice (10 minutes) and a main scenario including rural and urban sections (35 minutes)."
1589453|NCT02313246|Behavioral|Group Cognitive Behaviour Therapy|This 11-week group treatment will cover the following topics: psychoeducation about IBS and the role of stress in exacerbating IBS symptoms, progressive muscle relaxation, stress management, problem solving, identifying and modifying maladaptive thinking patterns, decreasing behavioural avoidance, and exposure to feared physical sensations.
1589454|NCT02313233|Dietary Supplement|Umooze|Umooze is consisted of Astragalus radix extracts and soy extracts. Astragalus radix (AR) is the dried root of Astragalus membranaceus Bge. Var. mongholicus and is used as a tonic in the traditional Chinese medicine. According to the reports submitted by the National Cancer institute of American, people who eat soybean products can reduce the incidence rate for prostate cancer. The composition of Umooze is invented by Golden Biotechnology Corp. against prostatic hyperplasia.
1589455|NCT02313233|Dietary Supplement|Placebo|Placebo is consisted of cornstarch and is provided by by Golden Biotechnology Corp.
1589456|NCT02313220|Drug|Dapagliflozin|Oral use
1589457|NCT02313220|Drug|Exenatide|Powder and solvent for suspension for injection, prolonged release suspension. Subcutaneous use.
1589458|NCT02313220|Drug|Placebo|Oral and Subcutaneous use.
1589459|NCT02313207|Dietary Supplement|FODMAP|patients will undergo a specific FODMAP diet for a period of 2 weeks.
1589460|NCT02313194|Device|Epidural Stimulation|Determine if epidural stimulation can improve motor function
1589461|NCT02313181|Other|Early Limited Formula|10 milliliters (mL) Nutramigen fed to baby by syringe after each breastfeeding and discontinued at the start of mature milk production
1589462|NCT02313181|Other|Standard Care|Continue exclusive breastfeeding unless otherwise directed by a health care provider
1589463|NCT02313168|Other|observation, inspection|
1589464|NCT02313155|Drug|Subcutaneous injection of TAK-850|TAK-850 0.5 mL, Subcutaneous injection
1589465|NCT02313155|Drug|Intramuscular injection of TAK-850|TAK-850 0.5 mL, Intramuscular injection
1589466|NCT02313142|Behavioral|Leg exercises|
1589467|NCT02313116|Device|Interferometric Synthetic Aperture Microscopy|Optical coherence tomography with interferometric synthetic aperture microscopy will be used to image ex vivo breast tissue specimens.
1589469|NCT02313090|Other|Welltang|The intervention group installed Welltang (downloaded from www.welltang.com for free) designed by Shanghai Geping Information and Technique Company Ltd (Shanghai, China) on their cell phones. Welltang is a cell phone- based diabetes management application that consists of three main parts: knowledge, self-management, communication between patients and clinicians
1589470|NCT02313077|Biological|MVA-BN-filo|One 0.5 mL intramuscular (IM) injection of 1E8 (50%Tissue Culture Infectious Dose [TCID50]) on Day 1 (Groups 1 and 2), or on Day 29 (Group 3), or on Day 57 (Group 4), or on Day 15 (Group 5).
1589471|NCT02313077|Biological|Ad26. ZEBOV|One 0.5 mL IM injection of 5E10 viral particles (vp) on Day 1 (Groups 3, 4 and 5), or on Day 29 (Group 1), or on Day 57 (Group 2).
1589472|NCT02313077|Other|Placebo|One 0.5 mL IM injection of 0.9% saline on Day 1 and 29 (Groups 1 and 3), or on Day 1 and 57 (Groups 2 and 4).
1589539|NCT02312557|Other|Laboratory Biomarker Analysis|Correlative studies
1589540|NCT02312557|Biological|Pembrolizumab|Given IV
1589541|NCT02312544|Drug|OTX-TP|OTX-TP and placebo drops
1589473|NCT02313064|Drug|CXA-10|Part A has sequential single ascending doses will be administered in up to 5 cohorts of subjects. Each cohort of subjects will be randomized to receive a single dose of CXA-10 or placebo in, a fasted state. Part B has 2 periods and subjects will receive two doses of the selected dose of CXA-10.
1589474|NCT02313064|Drug|CXA-10 placebo|
1589475|NCT02313051|Drug|Everolimus|mTOR inhibitor
1589476|NCT02313051|Drug|Goserelin|
1589477|NCT02313051|Drug|Letrozole|
1589478|NCT02313025|Other|speech sound intervention|"An intervention that stimulates speech sound perception and production in four-year-olds.
Each day at preschool the children receive a 15 to 20 minutes intervention, for 12 weeks"
1589479|NCT02313025|Other|World-project|An intervention that stimulates vocabulary development in four-year-olds. Each day at preschool the children receive a 120 minutes intervention, for 10 weeks
1589480|NCT02313012|Drug|CC-90003|CC-90003 PO once daily
1589481|NCT02312999|Drug|Plasmalyte|
1589482|NCT02312999|Drug|Volulyte|
1589483|NCT02312986|Biological|Fecal microbiota transplantation (FMT)|Prospective pilot study to examine whether fecal microbiota transplantation (FMT) is able to suppress or reverse gastrointestinal carriage of multi-drug resistant organisms.
1589484|NCT02312973|Drug|Molidustat(BAY85-3934)|Two single oral doses of 75 mg molidustat tablet in subjects on hemodialysis and peritoneal dialysis
1589485|NCT02312973|Drug|Molidustat(BAY85-3934)|One single oral dose of 75 mg molidustat in healthy subjects
1589486|NCT02312960|Other|Data Collection|No study treatment will be provided in this long term follow up study.
1589487|NCT02312947|Device|coblation (COBLATION II surgery system ,CE8001-01)|comparison of two methods of operation : coblation and cold dissection
1589488|NCT02312947|Device|cold dissection adenoidectomy|comparison of two methods of operation : coblation and cold dissectionby currete
1589489|NCT02312934|Drug|Transdermal nicotine|Nicotine patches are currently FDA approved for smoking cessation. Nicotine has effects that have been well studied for many years. Studies have shown that nicotine by itself does not appear by itself to be cancer causing. The use of the nicotine patch is not expected to increase risk of breast cancer recurrence.
1589490|NCT02312934|Other|Placebo Transdermal Patch|
1589491|NCT02312921|Other|PREDICT|Allied dental personnel provide screening and preventive services in community settings and case managers serve as patient navigators to arrange referrals of children who need dentist services. The intervention is paired with a compensation system for high performance (pay-for-performance) with efficient performance monitoring. PREDICT focuses on: 1) identifying eligible children and gaining caregiver consent for services in community settings (e.g., schools); 2) providing risk-based preventive and caries stabilization services efficiently at these settings; 3) providing curative care in dental clinics; and 4) incentivizing local delivery teams to meet performance benchmarks.
1589492|NCT02312908|Drug|Clonazepam|For experimental treatment of RBD
1589493|NCT02312908|Drug|Placebo|Placebo pill manufactured to mask clonazepam 0.5mg tablet
1589494|NCT02312895|Other|Manual therapy|The therapist will locate the involved segment using passive accessory intervertebral movements. The segment will be localized to the level, which provokes the patient's symptoms most easily, and this segment will be determined to be the involved level. Once this level has been identified, the therapist will compare central glides over the spinous process or a unilateral glide over the facet joint to determine which is more provocative. Whichever is most provocative will be the location of the treatment. The therapist will provide 3 bouts lasting 45 seconds just easing into the patient's symptoms at the most provocative level with approximately 45 seconds rest between each bout.
1589495|NCT02312895|Other|Dry needling|Dry needling involves inserting a dry, acupuncture needle through the skin and into a taut-band of muscle known as a myofascial trigger point (MTrP). The two-inch needles will be placed in all MTrPs identified by the treating physical therapist. Following initial penetration into the skin over the MTrP, the therapist carefully advances the needle into the muscle tissue below the skin. After the needle has reached the desired depth, the therapist will insert the subsequent needles. Needles will be placed along the segmental levels of the lumbar spine above and below the MTrP identified and into the lower extremity in areas that correlate with a peripheral nerve map. Needles will remain in the muscle for up to 5 minutes, removed, and appropriately disposed of.
1589496|NCT02312895|Other|Home Exercise Program|A home exercise program will be given to each subject to be completed in the clinic and at home 3x/day. The exercises will consist of active range of motion exercises and core stabilization exercises. The program is standardized for all subjects.
1589498|NCT02312869|Other|No intervention|not applicable, observational study
1589499|NCT02312856|Device|PulseRider|Adjunctive device for endovascular embolization of intracranial aneurysms
1589500|NCT02312843|Behavioral|Exercise/Aerobic|
1589501|NCT02312843|Behavioral|Exercise/Stretching|
1589502|NCT02312817|Other|Mailed Outreach Invitation|"Individuals randomized to Group 2 will receive:
Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.
Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion. Up to three attempts will be made. All communications will use standard English or Spanish scripts.
Centralized process to promote guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
1589503|NCT02312817|Other|Mailed Outreach Invitation and Patient Navigation|"Individuals randomized to Group 3 will receive:
Mailed outreach invitation to complete HCC screening ultrasound and alpha-fetoprotein (AFP) blood test.
Live phone calls 2 to 4 weeks after the mailed invitation to facilitate HCC screening completion and address patients' self-reported barriers to HCC screening (e.g., it does not apply to me). Up to three attempts will be made. All communications will use standard English or Spanish scripts.
Centralized navigation to promote screening completion (i.e., appointment reminder phone calls from patient navigator) and guideline-appropriate follow up testing with CT or MRI or referral to GI Clinic."
1589504|NCT02312804|Drug|BGJ398|BGJ398 will be administered orally once daily on each day of the 21 day cycle.
1589505|NCT02312804|Drug|Carboplatin|Carboplatin will be administered in combination with paclitaxel intravenously on the first day of each 21-day cycle.
1589506|NCT02312804|Drug|Paclitaxel|Paclitaxel will be administered in combination with carboplatin intravenously on the first day of each 21-day cycle.
1589507|NCT02312778|Other|HVLA Manipulation|Intervention Group who receives a high velocity and low amplitude (HVLA) lumbar manipulation. A manual procedure also known as high velocity and low amplitude lumbar spinal manipulation are delivered for the subjects in the side lying position. The lumbar segment more restrict (mobility restriction) will be the target region for the manipulative procedure.
1589508|NCT02312765|Behavioral|AirCare App|Tablet software to encourage adherence and support
1589509|NCT02312752|Device|Intra-epidermal stimulation electrode|"A small piece of plastic with a tiny sharp protruding tip (the intra-epidermal stimulation electrode) will be applied to the foot and hand. Small sticker electrodes will be placed over nerves on the forearm or ankle. A stimulus will be applied to the electrode for intra-epidermal stimulation. The stimulus will be gradually increased from no stimulus to a stimulus that is barely felt as a pin-prick type of sensation. Thereafter, the stimulus will be applied 5-15 times per second for 10 periods of 40-60 seconds."
1589510|NCT02312739|Procedure|In-office Transcervical Sterilization (Essure®)|The standard transcervical sterilization procedure is not being evaluated in this study, and will be performed in the same manner in the two study arms. The procedure includes a standardized paracervical block with 1% lidocaine. A 5mm operative hysteroscope is passed through the cervix and into the uterine cavity using normal saline for uterine distention. Each tubal ostium is identified, followed by deployment of the device into each fallopian tube. A confirmatory test, hysterosalpingogram, is required at 90 days post procedure to demonstrate successful sterilization.
1589511|NCT02312739|Drug|Standard Oral pain medications|one 5/325mg hydrocodone/acetaminophen (Vicodin) tablet and one 1mg Lorazepam tablet given to patients randomized to the active comparator arm at least 30 minutes before the procedure
1589512|NCT02312739|Drug|Intramuscular Ketorolac|30mg of intramuscular ketorolac given to all patients at least 30 minutes before the procedure
1589513|NCT02312739|Drug|Placebo pills|Two placebo bills given to patients randomized to the experimental arm at least 30 minutes prior to the procedure
1589514|NCT02312739|Other|Oxygen|Oxygen at 5L/min given to patients randomized to the active comparator arm
1589515|NCT02312739|Other|Nitrous Oxide|Nitrous oxide with a maximum titration of up to 70% given to patients randomized to the experimental arm
1589516|NCT02312726|Procedure|Postplacental IUD insertion|Postplacental IUD insertion using the standardized ring forceps technique (Speroff and Mishell 2008) under ultrasound guidance, within 10-30 minutes of vaginal delivery.
2008992|NCT03325673|Device|TrueTear|TrueTear Device should be used intranasally on contact lens (CL) wear days; it may also be used on non-CL wear days if participant chooses. The number of applications is determined by participant.
2008993|NCT03325673|Device|TrueTear Sham Control|TrueTear sham device, which is not electrically active, should be used intranasally on contact lens (CL) wear days; it may also be used on non-CL wear days if participant chooses. The number of applications is determined by participant.
1589519|NCT02312700|Behavioral|Interactive empowerment tool|
1589520|NCT02312687|Drug|KRN23|KRN23 is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).
1589521|NCT02312674|Dietary Supplement|Oral nutritional supplement|Beginning with the start of palliative therapy, depending on the nutritional status, one, two, or three cans per day are ingested during a period of three months.
1589522|NCT02312661|Drug|Metformin|Metformin in increasing doses will be added to carboplatin/paclitaxel chemotherapy
1589523|NCT02312661|Drug|Carboplatin|Intravenous carboplatin chemotherapy in three-weekly cycles, for a maximum of 6 cycles
1589524|NCT02312661|Drug|Paclitaxel|Intravenous paclitaxel chemotherapy in three-weekly cycles, for a maximum of 6 cycles
1589525|NCT02312648|Other|Interventional Group|Respiratory exercises will be performed and subsequently active upper limb exercises will be conducted (flexion-extension and adduction-abduction) of large joints (shoulder, elbow and wrist) Associated with upper limb exercises, patients will undergo a series of exercises ergometer with lower limb (LL). The mobilization will be conducted on a cycle ergometer in an active, lasting 20 minutes, divided into three steps: heat 5 minutes; 10 minutes of low intensity exercise, with a speed of 30 revolutions per minute (rpm); and 5 minutes recovery. The patient remains in the supine position with the head of the bed elevated to 45 degrees, while the lower limbs will remain planned. After positioning the patient, the ergometer is adjusted.
1589526|NCT02312648|Other|Control group|The patients will oriented to maintain sitting position and perform deep breaths (3 sets of 10 repetitions) in each session. They will receive the intervention once a day, for 30 minutes until 7th postoperative day. In addition, non invasive ventilation will be installed after orotracheal extubation for 30 to 60 minutes.
1589527|NCT02312635|Drug|D-Cycloserine|Half of the participants will be randomly chosen to receive the medication D-cycloserine in addition to the working memory program, while the other group will receive an inactive pill (placebo).
1589528|NCT02312635|Behavioral|Cogmed Working Memory Training|Both arms of the study will receive Cogmed working memory training for 6 weeks, M-F.
1589529|NCT02312622|Drug|pegylated irinotecan NKTR 102|Given IV
1589530|NCT02312622|Other|laboratory biomarker analysis|Correlative studies
1589531|NCT02312609|Drug|Minocycline hydrochloride|extended release tablets 135 mg
1589532|NCT02312596|Device|Eclipse PRP™ Wound Biomatrix|Application of Eclipse PRP™ Wound Biomatrix in addition to usual and customary practice
1589533|NCT02312596|Other|Usual and Customary Practice|Usual and customary care for non-healing wounds
1589534|NCT02312583|Behavioral|Psychoeducational online information|Psychoeducational online information. During 7 weeks as a complement to the usual treatment. Participants will have access to online psychoeducational material for depression.
1589535|NCT02312583|Behavioral|iFightDepression online programme|"iFightDepression online programme. During 7 weeks as a complement to the usual treatment.
Participants will complete the modules of a structured online programme for depression"
1589536|NCT02312570|Device|Eclipse PRP™ Wound Biomatrix|Administration of Eclipse PRP™ Wound Biomatrix to wound in addition to usual and customary care
1589537|NCT02312570|Other|Usual and Customary Practice|Ussual and customary care of non-healing pressure wounds
2008994|NCT03325660|Other|whole body vibration|pelvic floor exercises
1589543|NCT02312531|Drug|Hepatitis B immunoglobulin|Hepatitis B immunoglobulin 200 IU injection at gestational week 20, 24, 28, 32, 34, 36, 38, 39, and 40 in HBIG group mothers.
1589544|NCT02312518|Device|Eclipse PRP™ Wound Biomatrix|Eclipse PRP™ Wound Biomatrix in addition to usual and customary practice
1589545|NCT02312518|Other|Usual and Customary Practice|Usual and Customary Practice for non-healing venous leg ulcers
1589546|NCT02312505|Device|COPFX|cardiac Output by semi-invasive pulse contour analysis
1589547|NCT02312492|Other|Oleic Diet|The 18:1 (oleic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (oleic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
1589548|NCT02312492|Other|Palmitic Diet|The 16:0 (palmitic) diet will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oils (palmitic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
1589549|NCT02312492|Other|Stearic Diet|The 18:0 diet (stearic) will contain 55%E carbohydrate, 15%E protein, 30%E fat, 100 mg cholesterol/1000 kcal and 15 g fiber/1000 kcal. The vegetable oils and/or fats (henceforth collectively referred to as experimental oils) that will be used to formulate the diets were selected not only take into account the fatty acid of interest but also the fatty acid displaced within the context of an unchanged total fat content. This was accomplished by formulating a diet containing 10%E fat and then adding the experimental oil (stearic) to 30%E total fat by incorporating them into various food items intended for consumption throughout the day. The actual food items comprising the 3 diets will be similar, only differing in the experimental oils.
1589550|NCT02312479|Device|Nyxoah SAT system|The Nyxoah SAT system is comprised of an implantable nerve stimulator implanted over one of the tongue muscles via a minimally invasive procedure. Stimulation of the Hypoglossal nerves causes the tongue muscles to contract, thus maintaining an open airway during sleep.
1589551|NCT02312453|Procedure|Posterior approach|We adopted the technique as described by Hebbard et al.
1589552|NCT02312440|Drug|0.9% sodium chloride|The normal saline solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
1589553|NCT02312440|Drug|tranexamic acid|The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the scrub nurse. The contents (60 ml) will be emptied in a sterile surgical bowl and the nurse will ask the surgeon to apply the solution before wound closure.The dosage and applying route can also be looked up in doctor's order sheet.
1589554|NCT02312440|Drug|tranexamic acid|"The Tranexamic Acid solution will be prepared under sterile conditions. In the operation room the sterile bag containing the solution will be given to the circuit nurse and the circuit nurse will ask the anesthetist to apply the solution intravenously before tourniquet deflation. The dosage and applying route can also be looked up in doctor's order sheet.
60 Milliliters（ml） by irrigation for 3 minutes before wound closure."
1589555|NCT02312427|Drug|Suspending DPP-4 inhibitor, in outpatient service|After baseline data collection, DPP-4 inhibitor (sitagliptin, vildagliptin, alogliptin, linagliptin, teneligliptin, anagliptin or saxagliptin) will be suspended for one month and serum BNP will be measured. The DPP-4 inhibitor will be resumed and after another month, serum BNP will be measured again.
1589556|NCT02312427|Drug|Starting DPP-4 inhibitor after treatment of heart failure|After hospitalization, medication for diabetes will be suspended. During the treatment for heart failure, drugs other than DPP-4 inhibitor will be resumed when required. After the stabilization of heart failure, DPP-4 inhibitor will be resumed (or administered if it was not prescribed before hospitalization) and serum BNP before and after the initiation of DPP-4 inhibitor will be measured.
1589557|NCT02312414|Drug|L-Canitine|Carnitine is a quaternary ammonium compound biosynthesized from the amino acids lysine and methionine, it is essential for the transport of fatty acids from the intermembraneous space in the mitochondria, into the mitochondrial matrix during the breakdown of lipids (fats) for the generation of metabolic energy
1589558|NCT02312401|Device|multi-parametric MRI(MP-MRI)|
1589559|NCT02312401|Device|dynamic contrast-enhanced MRI (DCE)|
1589560|NCT02312401|Procedure|biopsy|
1589561|NCT02312388|Other|catheter-over-the-needle technique|using a 22 G Angiocath Plus™ catheter
1589562|NCT02312388|Other|Thin-wall needle technique|using 18 - 21 G introducer needle
1589563|NCT02312375|Drug|Fimasartan|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
1589564|NCT02312375|Drug|Amlodipine|16 weeks of fimasartan vs. amlodipine followed by 2 weeks of wash-out period, then crossover
1589565|NCT02312362|Procedure|Combined sclerotomy ab interno and phaco|
1589566|NCT02312362|Procedure|Phacoemulsification with IOL implantation|
1589567|NCT02312336|Other|Cohort A - Room temperature coronary perfusate|Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution at room temperature (Cohort A). The research intervention is the infusion of room temperature Hartmans solution.
1589568|NCT02312336|Other|Cohort B - Cooled coronary perfusate|"Patients recruited into the study will receive standard PPCI and in addition a transcoronary infusion of Hartmans solution cooled at 15 degrees (Cohort B).
The research intervention is the infusion of Hartmans solution cooled to 15 degrees."
1589569|NCT02312323|Device|Definitive 65 HPT contact lenses|
1589570|NCT02312323|Device|Definitive 65 contact lenses|
1589575|NCT02312258|Drug|Placebo|Ixazomib placebo-matching capsules
1589576|NCT02312245|Biological|Bevacizumab|Given IV
1589577|NCT02312245|Drug|Gemcitabine Hydrochloride|Given IV
1589578|NCT02312245|Drug|Paclitaxel|Given IV
1589579|NCT02312245|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
1589580|NCT02312245|Drug|Topotecan Hydrochloride|Given IV
1589581|NCT02312232|Drug|levodopa, carbidopa, ODM-104|
1589582|NCT02312219|Drug|Folic Acid|1 mg folic acid once daily
1589583|NCT02312219|Drug|Placebo|placebo once weekly
1589584|NCT02312219|Drug|Low Dose Methotrexate|An anti-inflammatory drug
1589585|NCT02312206|Drug|NEOD001|NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
1589586|NCT02312206|Other|Placebo|Placebo
1589587|NCT02312180|Biological|Plasminogen (Human) Intravenous|Plasma-derived purified plasminogen formulated for intravenous administration
1589588|NCT02312167|Device|confocal laser endomicroscopy|probe-based and needle-based confocal laser endomicroscopy
1589589|NCT02312154|Device|Restylane Vital|stabilized hyaluronic acid (HA)-based gel of nonanimal origin
1589590|NCT02312128|Other|Questionnaire|DASH Score, PRWE Score, Mayo Wrist Score
1589591|NCT02312128|Radiation|X- Ray|X-ray exposures in two planes 6., 9., 12. postoperative week, half and one year after surgery
1589592|NCT02312128|Other|Grip Strength|Grip strength measurement
1589593|NCT02312128|Other|VAS Score|Measurement pain according to the visual analogue scale (VAS)
1589594|NCT02312128|Other|Range of Motion measurement|Angle measurement of the active range of motion in the wrist
1589595|NCT02312115|Drug|Furosemide|Diuretic
1589596|NCT02312115|Drug|Placebo|Saline
1589599|NCT02312089|Drug|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
1589600|NCT02312076|Drug|Triptorelin|Luteal phase support will be continued by the same regimen started on the day of oocytes retrieval until 2 weeks after embryo transfer (ET) with subcutaneous administration of a single dose (0.2 mg) of GnRHa (Triptorelin) 6 days after oocyte retrieval
1589601|NCT02312063|Drug|Sitagliptin|
1589602|NCT02312063|Drug|Glimepiride|
1589603|NCT02312050|Drug|GCS-100|1 mg, 3 mg, or 9 mg IV push injections
1589604|NCT02312050|Drug|Placebo|
1589606|NCT02312024|Device|Use of CytoSorb adsorber|Use of CytoSorb adsorber either in patients with severe sepsis/septic shock or with cardiac surgery with CPB or in other patients.
1589607|NCT02312011|Drug|IONIS-DMPKRx|Drug
1589608|NCT02312011|Drug|Placebo|Placebo
1589609|NCT02311998|Drug|Bosutinib|"Phase I Dose Escalation - Starting dose of Bosutinib at 300 mg by mouth once daily in a 28 day cycle.
Phase II Dose Expansion - Starting dose of Bosutinib is maximum tolerated dose from Phase I Dose Escalation."
1589610|NCT02311998|Drug|Inotuzumab Ozogamicin|Phase I Dose Escalation and Phase II Dose Expansion - Inotuzumab Ozogamicin given by vein on a weekly schedule 0.8 mg/m2 by vein Day 1, 0.5 mg/m2 Day 8, and 0.5 mg/m2 Day 15 in a 28 day cycle.
1589611|NCT02311998|Behavioral|Phone Call|After end of treatment visit, participants called 1 time about every 12 weeks for up to 1 year, and asked about any anti-cancer therapy they may have started. This call will last about 5 minutes.
1589612|NCT02311985|Other|Coagulogram-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on international normalised ratio (INR), partial thromboplastin time (PTT), platelet count and/or fibrinogen. If INR >1.5 or PTT >50 sec., fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets <50,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or fibrinogen <150 mg/dL, cryoprecipitate is administered (dose: 01 unit/Kg).
1589613|NCT02311985|Other|Thromboelastometry-based protocol|The interventions for this protocol include transfusion of fresh frozen plasma, platelets (random or aphaeresis) and/or cryoprecipitate, based on rotational thromboelastometry (ROTEM(R)). If CTex <80 sec. and A10ex >40 mm, then no blood transfusion is performed; when CTex >80s, then fresh frozen plasma is administered (dose: 10 mL/Kg); and/or A10ex <40 mm or A10fib >10 mm, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis); and/or A10ex <40 mm or A10fib <10 mm, cryoprecipitate is administered (dose: 01 unit/Kg).
1589614|NCT02311985|Other|Restrictive strategy|The interventions for this protocol include transfusion of fresh frozen plasma and/or platelets (random or aphaeresis), based on INR and platelet count. If INR >5, fresh frozen plasma is administered (dose: 10 mL/Kg); and/or platelets <25,000/microliter, random or aphaeresis platelets are administered (01 unit/Kg or 01 aphaeresis).
1589615|NCT02311972|Device|Philips InnerSense Esophageal Temperature Sensor/Feeding Tube|
1589616|NCT02311972|Device|Standard of care feeding tube|
1589618|NCT02311946|Drug|Palbociclib Alone|In Period 1 of each Cohort, a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
1589619|NCT02311946|Drug|Palbociclib + Rabeprazole|In Period 2 of each Cohort, subjects will receive daily 40 mg oral doses of the proton pump inhibitor rabeprazole on 7 consecutive days. Approximately 4 hours after the last rabeprazole dose a single 125 mg dose of palbociclib will be administered alone in a fasted state, and subjects will undergo serial pharmacokinetic blood sampling for up to 120 hours post-dose.
1589628|NCT02311907|Drug|Carboplatin|Given IV, over 30 minutes per planned chemotherapy regimen
1589629|NCT02311907|Drug|Glutathione|Given IV, over 15 minutes, immediately before chemotherapy administration
1589630|NCT02311907|Other|Laboratory Biomarker Analysis|Correlative studies
1589631|NCT02311907|Drug|Paclitaxel|Given IV, over 1 or 3 hours, per planned chemotherapy regimen
1589632|NCT02311907|Other|Placebo|Given IV
1589633|NCT02311907|Other|Quality-of-Life Assessment|Ancillary studies
1589634|NCT02311894|Drug|Somatropin|Somatropin will be administered as SC injections at a dose of up to 0.043 mg/kg/day. The dose may be adjusted for a change in body weight of at least (plus [+]/minus [-]) 2 kilograms (kg) from baseline at the Month 6 study visit or for a change in insulin-growth factor-1 (IGF-1), as per investigator assessment.
1589635|NCT02311881|Drug|Paracetamol 1000 mg SR tablets|Two paracetamol 1000 mg SR tablets administered orally two times a day plus two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day for 12 weeks.
1589636|NCT02311881|Drug|Paracetamol 665 mg SR tablets|Two paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
1589637|NCT02311881|Drug|Placebo|Two placebo-matched paracetamol 665 mg SR tablets administered orally three times a day plus two placebo-matched paracetamol 1000 mg SR tablets administered orally two times a day for 12 weeks.
1589638|NCT02311868|Dietary Supplement|SYNBIOTIC (Probinul neutro®)|Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
1589639|NCT02311868|Dietary Supplement|PLACEBO|Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water.
1589640|NCT02311855|Biological|Influenza vaccine|"Each participant will have a blood draw to measure the antibody titres influenza strains covered by the 2014-2015 influenza vaccine at three different time points:
Visit 1- Baseline/prior to vaccination Visit 2- 4-6 weeks post-vaccination Visit 3- end of influenza season (April-May)
At Visit 1, after the baseline blood draw, all participants will be vaccinated by Research staff in order to standardize the time from Baseline blood draw to vaccination. Participants aged 65 and older will be offered the extra strength version of the vaccine, which is usual care. Participants under the age of 65 will be given the usual strength vaccine. All patients will be given the intramuscular (IM) vaccine."
1589641|NCT02311829|Other|Telephone follow-up device|For patients in the DST group only: Phone calls by clinical psychologist at J 15 at 2, then every 2 months until M12.
1589642|NCT02311803|Procedure|Preservation of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery without excision of Denonvilliers Fascia
1589643|NCT02311803|Procedure|Excision of Denonvilliers Fascia|In this group, patients accepte L-PANP surgery with excision of Denonvilliers Fascia
1589644|NCT02311790|Dietary Supplement|Trans-C16:1 supplement|Each volunteer will consume 3 escalating doses (120 mg/day, 240 mg/day and 480 mg/day) of trans-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each [9 weeks total]
1589645|NCT02311790|Dietary Supplement|Cis-C16:1 supplement|Each volunteer will consume 3 escalating doses (380 mg/day, 760 mg/day and 1520 mg/day) of cis-C16:1 enriched vegetable oil for 3 weeks each (3 doses x 3 weeks each [9 weeks total]
1589646|NCT02311777|Drug|Pregabalin|Pregabalin will be given orally during preoperative period
1589647|NCT02311777|Drug|Ketamine|Ketamine will be given on the surgery day before the anesthesia induction
1589648|NCT02311777|Drug|Placebo|Placebo will be given orally during preoperative period
1589649|NCT02311764|Drug|Carboplatin|Carboplatin will be administered weekly
1589650|NCT02311751|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
1589651|NCT02311738|Other|Training intensity intervention|High intensity training group describes the group performing high intensity exercise intervention. Moderate intensity training group describes the the group performing moderate exercise intervention
1589652|NCT02311725|Behavioral|aTAU + sTVi|Antidepressant treatment as usual provided by participants' primary care physician plus narrative communication, video-based intervention for improving depression in primary care patients.
1589653|NCT02311725|Behavioral|aTAU + Attention Control Videos|Antidepressant treatment as usual provided by participants' primary care physician plus videos about general mental health and well-being on the same dose and frequency as the experimental intervention.
1589654|NCT02311712|Device|Capsule sponge|Capsule sponge cytology examination coupled with H&E staining analysed for the presence of atypia and p53 immunohistochemistry
1589655|NCT02311699|Behavioral|Intervention to reduce IPV and HIV|The Ethiopian traditional coffee ceremony will be used as an entry point for a community based intervention to provide information, change behaviour around IPV and improve gender equity and intra-couple relations. The coffee ceremony is a culturally established forum for community discussion and conflict resolution and an integral part of Ethiopian life. The intervention will involve regular coffee ceremonies, during which approximately 20 members of the community will participate in education and discussions centred on gender issues, sexuality, communication and conflict resolution, HIV/AIDS and its link with violence, as well as HIV/AIDS prevention. Each coffee ceremony will be moderated by a female or male facilitator trained in participatory learning, moderation, HIV/AIDS prevention, counselling, and gender issues. The intervention will involve 14 two‐hour session per group of participants.
1589656|NCT02311686|Dietary Supplement|10 g ethanol|Alcohol single oral dose
1589657|NCT02311686|Dietary Supplement|20 g ethanol|Alcohol single oral dose
1589658|NCT02311686|Dietary Supplement|40 g ethanol|Alcohol single oral dose
1589659|NCT02311686|Dietary Supplement|60 g ethanol|Alcohol single oral dose
1589660|NCT02311686|Dietary Supplement|80 g ethanol|Alcohol single oral dose
1589661|NCT02311673|Drug|RM-493|subcutaneous injection
1589662|NCT02311673|Drug|Placebo|subcutaneous injection
1589663|NCT02311660|Device|Vagus Nerve Stimulation Device|Cyberonics VNS System
1589664|NCT02311634|Device|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
1589665|NCT02311634|Device|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
1589666|NCT02311621|Biological|Patient Derived CD171 specific CAR T cells expressing EGFRt (2nd generation T cells)|Intravenous infusion of autologous T cells transduced to express 4-1BB:zeta CD171CAR and EGFRt (2nd generation T cells)
1589667|NCT02311621|Biological|Patient Derived CD171 specific CAR T cells expressing EGFRt (3rd generation T cells)|Intravenous infusion of autologous T cells transduced to express CD28:4-1BB:zeta CD171CAR and EGFRt
1589668|NCT02311608|Drug|Terlipressin|administered as a first-line medicine or as salvage
1589669|NCT02311608|Drug|Usual Dose Somatostatin/Octreotide|administered as a first-line medicine or as salvage
1589670|NCT02311608|Drug|High Dose Somatostatin/Octreotide|administered as salvage
1589671|NCT02311595|Procedure|reduced port laparoscopic distal gastrectomy|
2008995|NCT03325647|Drug|Testosterone Cypionate 200 Milligram/Milliliter Injectable Solution|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
2008996|NCT03325647|Drug|Placebo injectable saline|Subjects in one arm will be randomized to receive testosterone cypionate 200 mg/ml intramuscularly every 4 weeks for a total of three doses after visit 1, and receive placebo injectable saline for the same duration starting at visit 2. Subjects in the other arm will be randomized to receive placebo injectable saline every 4 weeks for a total of 3 doses after visit 1, and testosterone cypionate 200 mg/ml intramuscularly for the same duration starting at visit 2.
2008997|NCT03325634|Other|Laboratory Biomarker Analysis|Correlative studies
2008998|NCT03325634|Other|Quality-of-Life Assessment|Ancillary studies
2008999|NCT03325634|Other|Questionnaire Administration|Ancillary studies
2009000|NCT03325634|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1589678|NCT02311569|Drug|Mirabegron|25 mg daily during the first week followed by 50 mg Mirabegron daily during the remaining treatment period.
1589679|NCT02311556|Device|dynamic susceptibility-weighted contrast-enhanced perfusion magnetic resonance imaging|
1589680|NCT02311543|Drug|TachoSil® patches|TachoSil® is a sterile, ready-to-use, absorbable surgical patch and consists of an equine collagen sponge coated with human fibrinogen and human thrombin.
1589681|NCT02311530|Drug|Felodipine|Extended Release Tablets, 10mg
1589682|NCT02311530|Drug|Felodipine (Plendil®)|
1589683|NCT02311517|Drug|Ropivacaine|90 patients are randomly allocated into two groups: ropivacaine group (n=45), saline group (n=40). In the ropivacaine group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg of 0.375% ropivacaine after induction of anesthesia. In the saline group, ultrasound-guided serratus anterior plane block is performed with 0.4 ml/kg saline after induction of anesthesia.
1589684|NCT02311517|Drug|Normal Saline|
1589685|NCT02311504|Device|OCT examination|
1589686|NCT02311491|Device|Ceramic coated orthodontic archwire|Hard ceramic coatings will reduce the sliding resistance of archwires in their brackets during orthodontic treatment procedures. The new coated archwire is expected to reduce treatment time.
2009001|NCT03325621|Biological|PRS-080#022-DP|Biological/Vaccine: PRS-080#022-DP Hepcidin antagonism to mobilize iron and to treat anemia
1589688|NCT02311465|Other|Palliative Care|"Components of the palliative care service intervention are expected to include:
Establishment of a palliative care plan
Care coordination by palliative care team
Informational, patient friendly materials supporting Palliative Care
Communication by palliative care team to all providers and teams involved in patient's care
Systematic collection of information, including identification of surrogate or health care proxy and advance care planning
Questionnaires capturing health related quality of life at regular intervals throughout the intervention period"
1589689|NCT02311452|Device|Peripherally Inserted Central Catheter (PICC)|Post-discharge antibiotics delivered via a PICC line.
1589690|NCT02311439|Drug|FOLFIRINOX + CRT|"Induction 4 times chemotherapy, FOLFIRINOX regimen, consisted of Oxaliplatin at a dose of 85 mg/m2 D1, 2-hour I.V + Irinotecan 180 mg/m2 D1 90-minute I.V. + Leucovorin 200 mg/m2 2- hour I.V, D1,2 + (5-FU) dosed at 400 mg/m2, administered as an intravenous bolus on day 1 and day 2, followed by a continuous intravenous infusion of 600 /m2 over a 20- hours period on day 1 and day 2. Treatment will be administered every 2 weeks. G-CSF will be administrated according to the need.
In non-progressed cases, will be followed by consolidation concurrent radiotherapy with capecitabine 625 mg/m2 BID.
Radiotherapy :
A fractionated dose of 50.4Gy /28 fractions/15 MeV photon energy generated by Dual-energetic Linear Accelerator."
1589691|NCT02311426|Other|Observational study|
2009002|NCT03325621|Biological|PRS-080-Placebo#001|Placebo Comparator
1589698|NCT02311309|Other|Control|Control patients were defined as either transfusion using only pre ordered packed red blood cells or peroperative hemoglobin concentration >8 g/dL.
1591406|NCT02298179|Biological|Placebo-Sterile Saline|Sterile Saline
1589699|NCT02311309|Other|Unanticipated bleeding|Unanticipated bleeding was defined as either transfusion above the pre ordered packed red blood cells or peroperative hemoglobin concentration < 8 g/dL.
1589700|NCT02311231|Drug|bivalirudin|Will be administered as an intravenous bolus of 0.75 mg per kilogram, followed by an infusion of 1.75 mg per kilogram per hour). Bivalirudin will be administered alone or with a low dose of heparin up to 3000U heparin in lab or up to 5000 U given pre-hospital according to local practice.
1589701|NCT02311231|Drug|Heparin|Treatment with unfractionated Heparin 5000 IU/ml i.v. ,Leo Pharma, Sweden, (the control group). Heparin in the control group is administered as an intravenous or intra-arterial bolus according to local practice. A dose of 70-100 U/kg is recommended
1589702|NCT02311218|Dietary Supplement|Lactobacillus reuteri DSM 17938 and PTA 5289|Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening
1589703|NCT02311218|Dietary Supplement|Placebo|Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
1589704|NCT02311205|Procedure|Conventional Transarterial Chemoembolization (TACE)|On demand conventional TACE will be performed in all the patients after enrollment and can be continued until intrahepatic CR, TACE failure or consent withdrawal. Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
1589705|NCT02311205|Drug|sorafenib|Sorafenib will be started 3-7 days after the first and each subsequent TACE and stopped one day before next TACE and will be continued until sorafenib failure, consent withdrawal or condition worsening by clinical decision.
1589706|NCT02311192|Device|Ultrasonography B-scan|The patient's eye will be anesthetized. The ultrasound probe will then be used to obtain images by keeping the probe in light contact with the eye.
1589707|NCT02311179|Device|Prosthesis, BoneMaster-Exceed cup (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
1589708|NCT02311179|Device|Prosthesis Exceed cup without HA (Biomet)|Patients will be randomized preoperatively to 1) Exceed cup coated with hydroxyapatite deposited electrochemically (BoneMaster) or 2) Exceed cup coated without hydroxyapatite coating.
1589711|NCT02311140|Other|nasal lavage (routine diagnostic procedure in our centre), assessment of symptoms|
1589712|NCT02311127|Device|SecurAcath|Devices secures PICC subcutaneously and remains in place during the complete dwell time of the PICC
1589713|NCT02311127|Device|StatLock|Device secures PICC however, device has to be changed weekly
1589714|NCT02311114|Other|In Depth interview|In Depth interview will be conducted for 30-60 min using semi-structured questionnaire to assess participants experience with telehomecare program.
1589715|NCT02311114|Other|Observational fieldwork|Observational fieldwork will conducted to observe everyday routine activities related to telehomecare. May last up to 1h per observation.
1589716|NCT02311114|Other|Survey|Surveys with participants will be conducted using validated survey tools.
1589717|NCT02311101|Drug|Mitomycin C|Given intravesically
1589718|NCT02311088|Drug|Caffeine|
1589719|NCT02311088|Drug|Placebo|
1589720|NCT02311075|Biological|Blood samples|Blood samples will be performed at baseline and during endothelial stimulation by hand skin heating to quantify metabolites of NO, EETs, ET-1 and ROS
1589721|NCT02311062|Other|Eccentric hamstring exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
1589722|NCT02311062|Other|Unistable exercises|Three exercises: 3 sets of 8 repetitions with 1 minute of rest between sets and 2 minutes of rest between exercises
1589723|NCT02311062|Other|Control|Only soccer training
1589724|NCT02311049|Radiation|Hypofractionation|
1589725|NCT02311036|Other|Comprehensive Rehabilitation|Comprehensive rehabilitation programs including PT, OT or ST will be done for two hour each every day and 5 days per week for 6-12 weeks. Initial assessment will be done within 3 days and the following assessment will be done 6 weeks or 12 weeks after rehabilitation intervention by physician and well-trained therapists.
1589726|NCT02311023|Other|Intermittent fasting|
1589727|NCT02311010|Drug|Advagraf|daily dose adapted according to Cyp 3A5 polymorphism
1589728|NCT02310997|Other|Umbilical Cord Blood Transplant|
1589729|NCT02310997|Drug|Cyclophosphamide|
1589730|NCT02310997|Radiation|Total body irradiation|
1589731|NCT02310997|Drug|Busulfan|
1589732|NCT02310997|Drug|Melphalan|
1589733|NCT02310997|Drug|Fludarabine|
1589734|NCT02310971|Biological|CVac|Cvac will be administered via intradermal injection, every 4 weeks for the first 3 doses and thereafter every 12 weeks for 3 additional doses for a total of 6
1589735|NCT02310958|Procedure|Laparoscopic surgical hernia repair|Laparoscopic surgical hernia repair in children
1589736|NCT02310945|Other|Physiotherapy|Individualised programme for each patient in line with current clinical guidelines. May include education, exercise (strengthening, range of motion exercise, aerobic), lifestyle advice and manual therapy
1589737|NCT02310932|Behavioral|Healthy Living Intervention|"Patients in the intervention groups will receive integrated collaborative clinic care by their physicians, a nurse case manager and consulting psychiatrists. They will also participate in 12-month community-based Healthy Living groups, in which cognitive and behavioral strategies are used to target health promoting behaviors, such as increased activity, improved diet, adherence to medical regimens, as well as problem-solving skills, coping skills, and social support."
1589738|NCT02310919|Drug|Low dose hCG plus FSH co-trigger|Low dose hCG (1,500 IU) plus FSH (450 IU) co-trigger
1589739|NCT02310919|Drug|Standard dose of hCG|Standard dose of hCG (10,000 or 5,000 IU) trigger
1589740|NCT02310906|Drug|Placebo|
1589741|NCT02310906|Drug|SRP-4053|
1589742|NCT02310893|Behavioral|Combined Contingency Management and Peer Navigation|
1589743|NCT02310893|Behavioral|Contingency Management|
1589744|NCT02310893|Behavioral|Peer Navigation|
1589745|NCT02310867|Drug|Belatacept|This study will also test a new immunosuppressant drug called Nulojix® (belatacept) to see if it is able to prevent rejection in a hand transplant. Nulojix® (belatacept) is approved by the FDA for use in kidney transplants; however, it is investigational in this study.
1589746|NCT02310867|Procedure|Hand transplant|The purpose of this study is to see if a surgical procedure for transplantation of a hand from a deceased donor can help subjects perform daily living activities better than they are currently able to do.
1589747|NCT02310854|Procedure|ACL Repair|augmented suture of acute ACL rupture (<3 weeks after injury)
1589748|NCT02310854|Procedure|ACL reconstruction|reconstruction hamstring autograft
1589749|NCT02310841|Device|ANGELAA|Different control strategies with transfemoral prosthesis prototype ANGELAA, developed at the Sensory-Motor Systems Lab, ETH Zurich, not commercially available, only 1 device exists
1589750|NCT02310828|Drug|Acetium|Capsule for oral administration contains L-cysteine 100mg
1589751|NCT02310828|Drug|Placebo|A placebo capsule matching Acetium for oral administration.
1589752|NCT02310815|Device|ReSure Sealant|
2009003|NCT03325608|Other|POISED Care|Using information collected, a propose plan of care and tailored interventions to the patients. Patients will understand natural history, and the prognosis of dementia; care protocols will be implemented.
2009004|NCT03325608|Other|Usual Care|Usual care group will not receive the POISED structured assessment, attention to chronic disease management, or RCA related to the ED visit.
2009005|NCT03325595|Drug|AEF0117|0.2, 0.6, 2, or 6mg of AEF0117
2009006|NCT03325595|Drug|Placebo|Matching capsule placebo
1589757|NCT02310789|Drug|Ivacaftor|150mg Q12 p.o. Protocol describes Ivacaftor treatment to be given in two-week intervals. The patient will serve as their own controls. Diagnostic procedures to be performed on and off Ivacaftor.
1589758|NCT02310776|Device|Supine automated breast ultrasound scanner|Automated wide-field-of-view breast ultrasound volume scan performed by a sonographer and interpreted by a breast imaging radiologist.
1589759|NCT02310776|Device|High-resolution handheld breast ultrasound|Standard of care, small field-of-view 2D breast ultrasound performed and interpreted by a breast imaging radiologist
1589760|NCT02310763|Biological|PF-06252616|PF-06252616 IV Infusion, 3 dose levels (5mg/kg, 20 mg/kg and 40 mg/kg) will be investigated within each subject
1589761|NCT02310763|Drug|Placebo|
1589762|NCT02310750|Drug|PF-06700841 oral solution/suspension|Oral solution or suspension of study drug PF-06700841 (once daily or twice daily during multiple dosing periods)
1589763|NCT02310750|Other|Placebo|Matching placebo given during the single ascending and multiple dose periods
1589764|NCT02310750|Drug|PF-06700841 tablet|PF-06700841 tablet formulation administered during the bioavailability / food effect investigation
1589765|NCT02310737|Procedure|sharp incision|The fascia will be opened with a sharp scissors in cesarean section
1589766|NCT02310737|Procedure|blunt incision|Fascia distracted from the muscle tissue with a blunt maneuver in cesarean section
1589767|NCT02310724|Other|TODAY cohort|This protocol is observation only and involves no intervention, care, treatment, or management.
1589768|NCT02310711|Other|Standard of Care|"Standard of care for early stage breast cancer is breast conserving therapy at this center.
Other concomitant standard of care treatment • Radiation therapy to the whole breast
o 45-50 Gy delivered over 25-28 fractions with a boost to the tumor bed of 10-16 Gy delivered over 5-8 fractions"
1589769|NCT02310698|Device|contrast enhanced digital mammography (CEDM)|
1589770|NCT02310698|Device|whole breast screening ultrasound (WBUS)|
1589771|NCT02310685|Other|Comprehensive e-health wellness program|"Participants randomized to this arm will have complete access to the myhealthcheckup website equipped with online tools including health assessments with coaching modules, educational material with quizzes, exercise challenges and motivational tips. The subject will meet with the pharmacist on 4 occasions (initial, 3, 6, 12 months) to update the cardiovascular risk profile, BP, weight, waist circumference and lipid profile. All interventions that were prespecified to be administered as part of the protocol, even if a particular intervention is not of interest."
1589772|NCT02310672|Drug|Macitentan|All patients take open-label macitentan 10mg o.d.
1589773|NCT02310659|Other|No intervention|No intervention
1589774|NCT02310646|Drug|LEO 90100 Aerosol Foam|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Aerosol Foam 60 g per can, applied once daily for one week
1589775|NCT02310646|Drug|Daivobet® gel|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate) Gel 60 g per bottle, applied once daily for one week.
2009007|NCT03325569|Diagnostic Test|oral glucose tolerance test|GLP1 response to oral glucose load during oral glucose tolerance test was assessed.
2009008|NCT03325556|Drug|Placebo|Placebo, tablets, once daily by mouth
2009009|NCT03325556|Drug|Pimavanserin 34 mg|Pimavanserin 34 mg total daily dose, tablets, once daily by mouth
1589779|NCT02310620|Behavioral|Cognitive training|regular playing with the logic games developed in the framework of the M3W (Mental Wellness Toolset) project (https://m3w-project.eu/)
1589780|NCT02310607|Other|Not an interventional study|Not an interventional study
1589781|NCT02310594|Other|cytology specimen collection procedure|Undergo blood sample collection
1589782|NCT02310594|Other|laboratory biomarker analysis|Correlative studies
1589783|NCT02310581|Drug|Buprenorphine Sublingual Spray|Buprenorphine sublingual spray delivered via single 100 μL spray
1589784|NCT02310581|Drug|Placebo|Placebo-matching buprenorphine sublingual spray delivered via single 100 μL spray
1589785|NCT02310568|Drug|PF-06372865.|Blinded PF 06372865 and matching placebo will be provided as tablets for oral administration.
1589786|NCT02310555|Procedure|Gastric bypass|
1589787|NCT02310555|Procedure|Modified gastric bypass.|
1589788|NCT02310555|Procedure|Slevee Gastrectomy|
1589789|NCT02310542|Device|MARS albumin dialysis system|
1589790|NCT02310542|Device|SPAD albumin dialysis system|
2009010|NCT03325556|Drug|Pimavanserin 20 mg|Pimavanserin 20 mg total daily dose, tablets, once daily by mouth
1589791|NCT02310529|Behavioral|Interpersonal Psychotherapy|"Interpersonal Psychotherapy will be delivered to Intervention group. The intervention group will be further divided into 3 groups (8 depressed mothers in each group).IPT is 12-16 week treatment, contains a supportive element, an educational element, parenting element and an interpersonal relationship element. Its goals include helping mothers feel supportive, empowered and confident about their parenting abilities, which will directly influence in reducing their depressive symptoms as well as resolution of interpersonal conflicts. Groups will assist people who have become withdrawn, isolated and disconnected.
Intervention will be delivered by trained clinical psychologists."
1589792|NCT02310516|Device|preoperative adequate explanations about awake surgery|
1589793|NCT02310516|Other|no preoperative explanation|
1589794|NCT02310503|Procedure|Mohs surgery|A surgical technique used primarily in the treatment of skin neoplasms, especially basal cell or squamous cell carcinoma of the skin. This procedure is a microscopically controlled excision of cutaneous tumors either after fixation in vivo or after freezing the tissue. Serial examinations of fresh tissue specimens are most frequently done.
1589795|NCT02310490|Device|DermaVeil right with left side Sculptra left side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
1589796|NCT02310490|Device|DermaVeil left with left side Sculptra right side|The treatment phase will consist of one to three visits at 3 week intervals during which eligible subjects will receive bilateral injections of study material in the left and right nasolabial fold wrinkles, including visits at weeks 3 and 6 for touch ups if needed
1589797|NCT02310477|Drug|regorafenib|regorafenib for all groups
1589798|NCT02310464|Drug|OBI-833/OBI-821|
1589799|NCT02310451|Biological|blood test|blood test to J0-M3-M6-M12
1589800|NCT02310438|Other|Therapeutic Instrumental Music Performance|The same instruments are selected and used with each participant. They are spatially arranged for them to play in their home in a way that addresses the target movement, for example elbow flexion and extension. The music therapist plays specific musical patterns live on a guitar for each exercise whilst the participant plays specific patterns on the instruments.
1589801|NCT02310425|Drug|S. boulardii|50 mg/kg twice daily
1589802|NCT02310425|Drug|Placebo|he control group (group C) did not receive S. boulardii (nor other probiotics)
1589803|NCT02310412|Biological|INTERCEPT treated platelets|
1589805|NCT02310386|Device|BEMER electromagnetic field therapy|To study the effects of three months electromagnetic field therapy on pain in women with fibromyalgia.
1589806|NCT02310373|Other|Nicotine free hookah smoking|Subjects will smoke waterpipe in a controlled research environment
1589807|NCT02310360|Radiation|Fallypride|
1589808|NCT02310347|Drug|dronabinol|
1589809|NCT02310347|Drug|Placebo|
1589810|NCT02310334|Other|Guided Exercise Session|Participants will be provided a pace based upon their current (estimated) physiological strain index (PSI) - a measure of thermal work strain, the time, and the distance completed already.
1589811|NCT02310334|Other|Unguided Exercise Session|Participants will be instructed to complete 5 miles within 60 minutes and finish in as cool (lower body temperature) a state as possible.
1589812|NCT02310321|Drug|gilteritinib|Once-daily repeated oral administration in every period
1589813|NCT02310321|Drug|Idarubicin|Induction period: Once-daily intravenous injection of 12 mg/m2 idarubicin on 3 consecutive days.
1589814|NCT02310321|Drug|Cytarabine|Induction period: Once-daily intravenous injection of 100 mg/m2 cytarabine on 7 consecutive days. Consolidation period: Twice-daily intravenous injection of 1.5 g/m2 cytarabine at 12-hour intervals on Days 1, 3, and 5.
1589815|NCT02310308|Dietary Supplement|Chewing gum administration|Intervention chewing gum Each subject will be instructed to chew 1 or 2 pellets for 5 min 3 times a day (2 in the morning, 2 after the midday meal and 1 in the afternoon). Thus, the total daily intake of magnolol and honokiol in MX group will be 11.9 mg/day. The daily use of the two different chewing gums will be carried out for 12 months.
1589816|NCT02310295|Device|Laser|focal macular laser therapy
1589817|NCT02310295|Drug|Bevacizumab|Intravitreal injection of Bevacizumab
1589818|NCT02310295|Drug|Triamcinolone Acetonide|Intravitreal injection of Triamcinolone Acetonide
1589819|NCT02310282|Device|Telemedicine|In-hospital telemedicine
1589820|NCT02310269|Drug|SOM230|
1589821|NCT02310256|Other|Five plus exercise training|calf raise exercise
1589822|NCT02310243|Drug|Palbociclib|oral, once daily (125mg, 100mg or 75mg) for 21 days
1589824|NCT02310204|Behavioral|multidisciplinary education program|both individual and group education sessions over a 6-month period in addition to standard psoriasis care
1589825|NCT02310204|Other|standard psoriasis care alone|
1589826|NCT02310191|Procedure|Carotid stenting|Procedures will be carried out via the femoral approach following a Seldinger technique. All patients will be on long-term aspirin (100 mg/day) and a 525-mg loading dose of clopidogrel. A dose of 10 000 units unfractionated heparin will be administered at the beginning of the intervention. A cerebral protection device (FilterWire EZ™; Boston Scientific, Natick, Massachusetts, USA) will be use in all patients if possible. The type of covered stent and other specific intervention strategies will be left to the discretion of the interventional radiologists. After predilatation of the stenosis (if needed), an appropriate stent for each stenosis will be implanted and then dilated using a balloon catheter.
1589827|NCT02310178|Procedure|Bariatric surgery|all of the current bariatric surgeries are allowed in this prospective cohort study
1589828|NCT02310165|Procedure|Z-tract Insertion Technique|
1589829|NCT02310165|Procedure|Coaxial Insertion Technique|
1589830|NCT02310152|Behavioral|Parent-Based Treatment of Child and Adolescent Anxiety Disorders|Supportive Parenting for Anxious Childhood Emotions
1589831|NCT02310152|Behavioral|CBT|Cognitive Behavioral Therapy
1589832|NCT02310139|Procedure|Colonoscopy|
1589833|NCT02310126|Device|etafilcon A (multi-focal)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
1589834|NCT02310126|Device|etafilcon A (sphere)|Each subject will wear the soft contact lenses for 15 minutes then remove the lenses.
1589835|NCT02310113|Other|NIRS|Measurment of skeletal muscle oxygenation by near-infrared spectroscopy
1589836|NCT02310100|Device|TactiCath Quartz treatment|
1589837|NCT02310087|Dietary Supplement|astaxanthin with vitamin E|Four tablets of 4 mg astaxanthin with 10 mg vitamin E daily, taken at once. Daily dose is 16 mg astaxanthin with 40 mg vitamin E. Continuously for three months.
1589838|NCT02310087|Other|Placebo|Four tablets of placebo daily, taken at once. Continuously for three months.
1589839|NCT02310074|Drug|Pulsatile Gonadotropin Releasing Hormone|
1589840|NCT02310074|Drug|Human chorionic gonadotropin|Human chorionic gonadotropin (hCG)
1589841|NCT02310074|Drug|Urinary Follicle-Stimulating Hormone|Urinary Follicle-Stimulating Hormone (uFSH)
1589842|NCT02310061|Procedure|Extra-vascular lung water measurements by ultrasound (LW-US)|It is widely agreed that the high prevalence of patients with LV dysfunction and heart failure and the lack of simple, non-expensive, bedside techniques that may serve to estimate and monitor parameters of central hemodynamics for guiding the prescription of ultrafiltration (UF) and drug treatment is a factor of major clinical relevance. So,in patients allocated to the active arm, nephrologists register pre- and post-dialysis US-B lines whenever considered useful for volume monitoring.
1589843|NCT02310061|Other|Standard protocol of fluid management in hemodialysis|The intervention consists in applying a standard clinical approach for monitoring/tailoring fluid excess in HD patients.
1589844|NCT02310048|Drug|MT-1303-FormA|
1589845|NCT02310048|Drug|MT-1303-FormB|
1589846|NCT02310022|Drug|Drug Omega 3|4 g (4 capsules) once a day, administered with food
1589847|NCT02310022|Drug|Drug Omega-3 Comparator|4 g (4 capsules) once a day, administered with food
1589848|NCT02310009|Drug|Anakinra (AN)|
1589849|NCT02310009|Behavioral|Exercise (EX)|
1589850|NCT02310009|Behavioral|Control (CON)|
1589851|NCT02309996|Behavioral|Supervisor Training Program|
1589852|NCT02309983|Other|Electrical Stimulation|Electrical stimulation is a rehabilitative approach that generates muscle activity by alternating leg extension and flexion even in individuals who are unable to stand or step independently. Electrical stimulation will be applied to multiple muscles of the lower limb.
1589853|NCT02309983|Other|Stand Retraining with Body Weight Support (BWS)|Locomotor training consists of (step training and stand retraining) on the treadmill, over ground training, and community ambulation. BWS will be given when a subject can not maintain his/her body weight while executing limb locomotion.
1589854|NCT02309970|Drug|acetylsalicylic acid, clopidogrel bisulfate and/or warfarin, Apixaban, Rivaroxaban, Dabigatran|subject in this group will receive oral treatment with anti platelet drug
1589855|NCT02309970|Drug|alteplase|subject in this group will receive intravenous tPA
1589856|NCT02309970|Procedure|endovascular|
1589857|NCT02309957|Device|BioMatrix CRD|
2009011|NCT03325543|Other|Verbal instruction and Vaginal palpation|The experimental group will receive verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques and vaginal palpation to learn the correct PFMs contraction. The control group will receive only verbal instructions on the anatomy and function of PFMs associated with the use of body awareness techniques.
2009012|NCT03325530|Behavioral|Focus Group with Participants|Focus groups with leaders (18+) to investigate tolerance to healthy initiatives
1589860|NCT02309931|Procedure|antiperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy + antiperistaltic side-to-side ileocecal anastomosis
1589861|NCT02309931|Procedure|isoperistaltic side-to-side ileocecal anastomosis|Right laparoscopic hemicolectomy+isoperistaltic side-to-side ileocecal anastomosis
1589862|NCT02309918|Drug|LDV/SOF FDC|Ledipasvir/Sofosbuvir fixed dose combination (FDC) tablet (LDV 90 mg/SOF 400 mg) once daily
1589863|NCT02309905|Device|Telemedicine|Inmates of prisons having telemedicine after implementation of telemedicine
1589864|NCT02309892|Drug|L-DOS47|A treatment cycle will be 21 days, with patients receiving L DOS47 on cycle Days 1, 8, and 15 and pemetrexed/carboplatin on Day 1 of each treatment cycle.
1589865|NCT02309879|Drug|Remifentanil infusion|Patients in Remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
1589866|NCT02309879|Drug|Lidocaine infusion|Patients in Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
1589867|NCT02309879|Drug|Magnesium sulphate infusion|Patients in Magnesium group received an intravenous bolus injection of 50 mg/kg magnesium sulphate plus an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous magnesium sulphate infusion of 15 mg/kg/hr.
1589868|NCT02309879|Drug|Magnesium sulphate and Lidocaine infusion|Patients in Magnesium and Lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine plus 50 mg/kg magnesium sulphate followed by a continuous lidocaine infusion of 3 mg/kg/hr plus 15 mg/kg/hr magnesium sulphate
1589869|NCT02309866|Genetic|Genetic testing|Genetic testing for mutations in known and novel genes underlying RP and allied diseases
1589870|NCT02309853|Other|Visual and tactile scanning training|"20 Sessions of 30 minutes with a visual and tactile scanning training in the personal, peripersonal and extrapersonal space and trunk rotation. The intervention includes visual or tactile scanning training in three different spaces and will be individually adapted to the needs of the patients.
Visual or tactile scanning in the personal space
Visual or tactile scanning and trunk rotation in the peripersonal space
Visual scanning and trunk rotation in the extrapersonal space"
1589871|NCT02309853|Other|Uni-modal visual scanning training|20 sessions of 30 minutes with traditional uni-modal visual scanning training in the peripersonal space.
1589872|NCT02309840|Behavioral|choice architecture|"Place vegetables at the beginning of the lunch line.
Place fruits in attractive bowls or trays lined with appealing fabric, and place other fruit options next to the cash registers.
Promote fruits and vegetables with prominently displayed signage and images.
Place white milk selection in front of sugar-sweetened milk (e.g. chocolate milk) or at eye-level."
1589873|NCT02309840|Other|Chef-enhanced meals|meals prepared by a professional chef with enhanced palatability
2009013|NCT03325504|Biological|Cultured Mesenchymal Cells|Cultured Mesenchymal Cells obtained from expanded bone marrow
1589874|NCT02309827|Drug|PF-06651600 or Placebo|PF-06651600 or placebo will be administered as an extemporaneously prepared solution in each cohort.
1589875|NCT02309814|Device|eyelid motion sensor device (Hall-probe)|all volunteers will wear the eyelid motion sensor device (Hall-probe) (including the tiny magnets on the upper eyelid). a 10 minutes movie will be screened on 40 inch television screen in a 3 meters distance
1589876|NCT02309801|Dietary Supplement|Daidzin|Super-Absorbable Soy Isoflavones, LifeExtension, USA. Single oral dose of 4 capsules (containing 80 mg of daidzin-daidzein).
1589877|NCT02309801|Dietary Supplement|Alcohol|Alcohol single oral dose
1589878|NCT02309775|Other|Auriculotherapy|First cleaning of the ear is made with 70% alcohol. The seed will be stuck in the ear with an adhesive (Micropore 3M) tape. The placement, points according to Souza (1997), were: Shen Men, Sympathetic, Kidney, Subcortex, Adrenal and Cerebral. As sessions will held twice a week for a total of 10 sessions.
1589879|NCT02309762|Drug|FB825|FB825 will be supplied at a concentration of 20 mg/mL for a single dose IV injection
1589880|NCT02309762|Drug|Placebo|Solution containing no active ingredients
1589881|NCT02309749|Other|CAP|
1589882|NCT02309736|Device|ReSure Sealant|
1589883|NCT02309723|Device|Beta amyloid imaging|
1589884|NCT02309710|Device|ShangRing|ShangRing administered to males seeking medical male circumcision
1589885|NCT02309671|Drug|FE 999049|
1589886|NCT02309671|Drug|follitropin beta|
1589887|NCT02309658|Drug|gemcitabine|Patients received intravenous 500-1000 ml normal saline and antiemetic medication before chemotherapy. Treatment consisted of intravenous gemcitabine at a dose of 1000 mg/m2 diluted in 500 ml of normal saline administered over 30 minutes mg/m2 diluted in 500 ml of normal saline administered over 30 minutes on days 1 and 8, followed by cisplatin 35 mg/m2 administered over 2 hours on day 1 and 8.
1589888|NCT02309658|Drug|cisplatin|35 mg/m2 administered over 2 hours on day 1 and 8.
1589889|NCT02309658|Radiation|chemoradiation|external beam radiotherapy concomitant with weekly cisplatin 40mg/m2
1589890|NCT02309645|Biological|EVICEL® Fibrin Sealant|Subjects randomized to receive EVICEL® Fibrin Sealant (Human), a thin layer will be applied to the entire length of the suture line and the adjacent area to at least 5mm away, including all suture holes.
1589891|NCT02309645|Other|Sutures Only|Subjects randomized to Control (Additional Sutures) will receive additional dural repair sutures applied immediately to the dural suture line after randomization as deemed necessary by the surgeon.
1589892|NCT02309632|Other|Pancreatic Cancer Screening Pathway 1|Screening with imaging and biomarker testing
1589893|NCT02309632|Other|Pancreatic Cancer Screening Pathway 2|Screening with biomarker testing only
1589894|NCT02309619|Procedure|lifting of the gastric tube to the neck for gastro-esophageal anastomosis through trans-substernal or trans-esophageal bed path.|Patients with esophageal cancer (EC) will undergo minimally invasive esophagectomy and be classified into two groups according to the last step of the procedure. The gastric tube will be lifted to the neck for gastro-esophageal anastomosis through trans-substernal path in the trans-substernal group, and through trans-esophageal bed path in the trans-esophageal bed group.
1589895|NCT02309606|Other|PET scan with 5-HT receptor ligands|Interictal episodic migraine patients and healthy controls will be scanned with a 5-HT1B and a 5-HT4 receptor radioligand. Episodic migraine patients will further be scanned during a cilostazol induced migraine attack and after treatment with sumatriptan. Chronic migraine patients will be scanned with only the 5-HT4 receptor radioligand.
1589896|NCT02309593|Device|PROFEMUR® Xm Femoral Stems|THA using PROFEMUR® Xm Femoral Stems
1589897|NCT02309580|Drug|Ibrutinib|Ibrutinib will be administered once daily continuously until disease progression (confirmed by two assessments for CTCL patients only) or intolerance. The dose levels for the Phase 1 portion of the study. Either 560 mg (4 X 140 mg capsules) or 840 mg (6 X 140 mg capsules) doses will be administered. After the recommended expansion dose is established, an expansion cohort of 12 additional patients will be treated at the recommended expansion dose to further characterize the safety at that dose and to further assess preliminary efficacy
1589898|NCT02309567|Other|Blood Collection|
1589899|NCT02309554|Other|SILCS diaphragm used with ContraGel|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. ContraGel is a clear, water soluble greaseless gel packed in a metal tube.
1589900|NCT02309554|Other|SILCS diaphragm used with 3% Nonoxynol-9|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring. 3% Nonoxynol-9 (branded as Gynol II) is clear, unscented water soluble greaseless gel packed in plastic tubes with a vaginal applicator.
1589901|NCT02309554|Other|SILCS diaphragm|SILCS Diaphragm (branded as CAYA countoured diaphragm) is a single-size vaginal barrier method of contraception used with each sex act, made of silicone membrane with a nylon spring
2009014|NCT03325504|Procedure|Autologous iliac crest graft|Autologous iliac crest grafting
1589903|NCT02309528|Other|Educational computerized digital stories|computerized digital stories made by American Indians
1589904|NCT02309515|Other|Laboratory Biomarker Analysis|Correlative studies
1589905|NCT02309515|Drug|Lenalidomide|Given PO
1589906|NCT02309515|Biological|Pneumococcal 13-valent Conjugate Vaccine|Given IM
1589907|NCT02309502|Device|Green Pascal|"Single-session Barely Visible Pascal 532nm 3,000 burns 20ms Multi-spot, single session
Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: 100%
Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
1589908|NCT02309502|Device|Yellow Pascal|": Single-session P-RPhS; Pascal 577nm 3000 burns 20ms Endpoint Management: 70% Number of burns: 3,000 Spot size: 400micron Duration: 0.02seconds Exposure: A barely visible burn will be aimed at for the pattern landmark burns and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-width apart Total number of burns: 3,000 Distribution: From the vascular arcades towards the periphery and in the four quadrants"
1589909|NCT02309489|Behavioral|Partner involvement|Partner is involved in maternity care
1591608|NCT02296671|Genetic|Germline genotyping analyses for TSER|
1589910|NCT02309476|Device|PASCAL Laser, Green Laser 0.75|"Barely Visible Pascal laser grid using 532nm green wavelength, 0.75 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
1589911|NCT02309476|Device|PASCAL Laser, Green Laser 1|"Barely Visible Pascal laser grid using 532nm green wavelength, 1 burn-widths-apart. Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: barely visible burn Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
1589912|NCT02309476|Device|PASCAL Laser, 70% Yellow Laser 0.75|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
1589913|NCT02309476|Device|PASCAL Laser, 70% Yellow Laser 1|"Pascal EM at 70% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 70% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 1 burn-widths-apart Distribution: Grid"
1589914|NCT02309476|Device|PASCAL Laser, 40% Yellow Laser 0.75|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
1589915|NCT02309476|Device|PASCAL Laser, 40% Yellow Laser 1|"Pascal EM at 40% 577nm yellow laser grid, 0.75 burn-widths-apart Intervention: macular laser grid Number of burns: Full grid 112 burns Spot size: 100micron Duration: 10 ms Exposure: A barely visible burn will be aimed at for the Landmark burn and EndPoint Management will be set at 740% to achieve non-visible burns Average power: 100 to 1000 mW Spot spacing: 0.75 burn-widths-apart Distribution: Grid"
1589916|NCT02309463|Drug|Endothelin receptor antagonist therapy|
1589917|NCT02309450|Drug|.Asunaprevir, Daclatasvir and BMS - 791325|All patients will receive an all-oral HCV tritherapy with Asunaprevir (200mg), Daclatasvir (30mg) and BMS-791325 (75mg) in a fixed-dose combination (FDC) tablet, twice a day (1 tablet in the morning and 1 tablet in the evening) for 12 weeks.
1589918|NCT02309437|Drug|Oxycodone|Use oxycodone to treat patients with mild pain caused by radiation mucositis.
1589919|NCT02309437|Drug|Oxycodone|Use oxycodone to treat patients with moderate/severe pain caused by radiation mucositis.
1589920|NCT02309424|Dietary Supplement|Vinegar|0,50mmol vinegar (6% acetic acid)
1589921|NCT02309424|Other|Placebo|50 ml water
1589922|NCT02309411|Drug|Rivaroxaban(Xarelto,BAY59-7939)|With age and body-weight adjusted twice daily dosing of rivaroxaban as Oral Suspension to achieve a similar exposure as that observed in adults treated with 20 mg rivaroxaban once daily, and no other anticoagulant
1589923|NCT02309385|Drug|8% Dexamethasone Sodium Phosphate - Visulex|
1589924|NCT02309385|Drug|15% Dexamethasone Sodium Phosphate - Visulex|
1589925|NCT02309385|Drug|Prednisolone Acetate (1%) Eye Drops|
1589926|NCT02309372|Behavioral|Beating the Blues|Computerized depression treatment intervention
1589927|NCT02309359|Biological|ALX-0061|
1589928|NCT02309359|Other|Placebo|
1589929|NCT02309359|Drug|Methotrexate|Stable background dose of commercially available methotrexate (not provided by the Sponsor).
1589930|NCT02309346|Drug|Clindamycin|Use of Clindamycin 2700mg+gentamicin 240mg+ 250ml sterile saline solution i.v. once a day or Gentamcin 240mg i.v once a day, plus clindamycin 900mg i.v. 8/8 h diluted in 250ml of sterile saline solution
1589931|NCT02309320|Biological|ALX-0171|
1589932|NCT02309320|Other|Placebo|
1589933|NCT02309307|Device|Tissue Repair Device (VergenixTM STR)|Administration of Soft Tissue Repair Device
1589934|NCT02309294|Device|Novel lubricant Miami w/ fragrance|0.2 ml aliquot on occlusive patch
1589935|NCT02309294|Device|Novel lubricant Miami no fragrance|0.2 ml aliquot on occlusive patch
1589936|NCT02309294|Device|KY Liquid lubricant|0.2 ml aliquot on occlusive patch
1589937|NCT02309294|Device|Astroglide Gel lubricant|0.2 ml aliquot on occlusive patch
1589938|NCT02309294|Device|Wet Platinum lubricant|0.2 ml aliquot on occlusive patch
1589939|NCT02309281|Drug|aflibercept 2mg|Aflibercept 2mg (Eylea) is intravitreally applied. The first treatment interval with aflibercept will be 4 weeks and corresponding to the treat and extend regime intervals will be increased in 2-weeks-steps.
1589940|NCT02309255|Other|no intervention|
1589941|NCT02309242|Behavioral|Neuropsychological assessment, MRI|All subjects will be imaged (MRI) on the same 3T Philips scanner with a 32-channel phased-array head coil, located in the radiology department at UZ Leuven. For the neuropsychological assessment we will implement an extended neuropsychological assessment battery: ANT, CMS, Rey, BRIEF, WISC III, PedsQL, STAI, BDi, achenbach questionnaires
1589942|NCT02309216|Other|Whol-Body MRI scan|
1589943|NCT02309203|Device|FRED|Flow Re-Direction Endoluminal Device
1589944|NCT02309177|Drug|nab-Paclitaxel|
1589945|NCT02309177|Drug|Nivolumab|
1589946|NCT02309177|Drug|Gemcitabine|
1589947|NCT02309177|Drug|Carboplatin|
1589948|NCT02309164|Procedure|Acupuncture|10 acupuncture sessions of 30 minutes each, twice a week
1589949|NCT02309164|Behavioral|Orientation group|medical management guidelines for foot / hands care, sensory desensitization, risk prevention guidelines, proper ergonomics and orthoses when necessary.
1589950|NCT02309151|Procedure|Acute coronary angiography|Acute coronary angiography for patients with out of hospital cardiac arrest with no signs of ST elevation in ECG
1589951|NCT02309151|Other|Routine care ICU|Routine care at ICU for out of hospital cardiac arrest patients with with no signs of ST elevation in ECG.
1589952|NCT02309151|Other|Routine care STEMI|Routine care with acute coronary angiography for STEMI patients.
2009015|NCT03325491|Dietary Supplement|Acipimox|Acipimox plus exercise training: Oral supplement containing Acipimox 250mgs as the active ingredient in blinded label tablet form.
2009016|NCT03325491|Dietary Supplement|Placebo|Alternate unilateral resistance and aerobic exercise training will also be performed 5 times per week for 6 weeks.
1589955|NCT02309125|Procedure|immediate progressive loading using gingival formers|"Implant placement will be 1 mm subcrestally, and it will receive transmucosal healing using gingival former.
The gingival former will be replaced every 2 weeks by consequent larger size gingival former (at surgery time group A will receive 2 mm height gingival former which will be swapped by,3 mm, 4 mm and the last is 5 mm)."
1589956|NCT02309125|Procedure|submerged healing|the implant placement will be 1 mm subcrestally, and it will receive unloaded healing.(submerged healing)
1589957|NCT02309112|Other|Yoga|A mind-body therapy that includes specified breathing, meditation and physical postures.
1589958|NCT02309099|Device|Cochlear Implant|Cochlear implantation used a treatment for single-sided deafness resultant of labyrinthectomy or a translabyrinthine surgical approach
1589960|NCT02309060|Behavioral|Storytelling Video Intervention (sTVi)|Narrative communication, video-based intervention for depressed primary care patients.
1589961|NCT02309034|Behavioral|Jump exercise|Land Group / Jump (LG): Will hold weekly classes of nutritional guidance and three weekly sessions of jump, for 12 weeks, divided into warm up, main aerobics and relaxation.
1589962|NCT02309034|Behavioral|Aquatic exercise|Group Water / Water aerobics (WG): Will hold weekly classes of nutritional guidance and three weekly sessions of water, for 12 weeks, divided into warm up, main aerobics and relaxation.
1589963|NCT02309034|Other|Nutritional guidance|Control Group (CG): take part only of weekly classes of nutritional guidance, in addition to a closed group on Facebook in order to encourage them and increase attention to the group.
1589964|NCT02309021|Other|Sport|
1589965|NCT02309021|Other|Non-sport activities|
1589966|NCT02309008|Drug|PAC-14028|Participants will receive PAC-14028 cream applied topically once a day for 9 days
1589967|NCT02309008|Other|Vehicle|Participants will receive vehicle cream applied topically once a day for 9 days
1589968|NCT02308995|Procedure|Cystectomy using barbed sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using V-Loc (Covidien, Mansfield, MA).
1589969|NCT02308995|Procedure|Cystectomy using conventional sutures|A sharp transverse cortical incision was made over the endometroma using unipolar hook and a cleavage plane was developed by sharp dissection. After the identification of the cleavage plane, the entire cyst will be enucleated by means of adequate traction with a strong grasper and counter-traction maneuvers with another grasping forceps . The ovarian edges will be re-approximated by using polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ) .
1589970|NCT02308995|Device|V-Loc (Covidien, Mansfield, MA)|
1589971|NCT02308995|Device|polyglactin 910 suture(VICRYL™, Ethicon Inc, Sommerville, NJ)|
1589974|NCT02308969|Drug|LSD|100ug per os, single dose
1589975|NCT02308969|Drug|Placebo|Capsules containing mannitol looking identical to LSD
1589978|NCT02308930|Dietary Supplement|Vitamins + DHA supplement (Vitamins A,D, E and algal oil)|
1589979|NCT02308930|Dietary Supplement|Vitamins supplement (Vitamins A,D, E and corn oil)|
1589980|NCT02308904|Other|Blood Draw/Semen Exam|"Females:
1. Obtain levels of LH/FSH, Estradiol, and AMH in all enrolled women. Males: We expect to enroll approximately 15 males ages 12 years and older.
Levels of FSH/LH and testosterone will be obtained. In addition, we will examine the association of the hormone inhibin B with mean fertility measures. Inhibin B levels were shown to correlate with azospermia and could demonstrate better prediction of reproductive potential.
Semen exam for determination of volume, sperm count, motility and sperm DNA integrity will be determined for interested adult thalassemia males (age ≥18 years and older)."
1589981|NCT02308904|Other|Retrospective data/Chart Review/Relevant Clinical Results|"1. Documentation of liver iron from SQUID or MRI. 2. Transfusion data on age at onset of regular transfusions, transfusion frequency over the previous five years, and years of chronic transfusion therapy (defined as 8 or more per year). 3. Data on cardiac iron as indicated by T2* MRI. 4. Ferritin levels.
NTBI will be accessed using a mobilizer ligand to collect NTBI from all pools as Fe-NTA which is then measured by HPLC.
1. Age at onset of chelation 2. Estimated periods of known or recalled non-compliance with regular chelation. 3. Listing of all chelation drugs previously used including dose and time period.
1. Vitamins E and C, at time closest to obtaining reproductive hormone levels. 2. Measuring the ratio of reduced gluthatione (GSH) to oxidized gluthatione (GSSG).
Assessment of time for pubertal development, assessment of menstrual history and need for treatment with gonadal hormone replacement."
1589982|NCT02308904|Other|Pituitary MRI|"MRI has been shown to demonstrate well the changes related to iron toxicity in the pituitary gland. An MRI protocol was optimized at Children's Hospital and Research Center Oakland (CHRCO) and Texas Children's Hospital. Utilizing 1.5 T clinical scanner to evaluate the iron accumulation in the anterior pituitary. The total data acquisition time is approximately 32 minutes. No sedation will be given.
MRI data will be sent to Dr. Wang, department of Radiology, Children's Medical Center, University of Texas Southwestern Medical Center, Dallas, Texas. Quantification of R2, pituitary height and volume will be conducted."
1589983|NCT02308891|Drug|lactated Ringer's solution (vigorous hydration arm)|"Initial bolus of lactated Ringer's solution at 10mL/kg over 1 hour prior to ERCP
Intravenous lactated Ringer's solution at a rate of 3mL/kg/h during the procedure and continued for 8 hours.
At the end of ERCP, post-procedure bolus of lactated Ringer's solution at 10mL/Kg over 1hour"
1589984|NCT02308891|Drug|lactated Ringer's solution (standard hydration arm)|- Patients will receive lactated Ringer's solution at the start of the ERCP and the fluids will be administered at a rate of 1.5ml/kg/h during the procedure and for 8hours after ERCP.
1589985|NCT02308891|Device|endoscopic retrograde cholangiopancreatography (ERCP)|endoscopic retrograde cholangiopancreatography
1589986|NCT02308878|Behavioral|Mobile health cognitive stimulation|
1589987|NCT02308865|Other|multi disciplinary palliative care monthly consultations|multi disciplinary palliative care consultations with a doctor, a nurse, a psychologist and posibility of a physical therapist and a worship person.The primary consultation within 3 weeks inclusion and then every month at the same time that consultations onco-respiratory
1589988|NCT02308852|Device|tDCS|
1589989|NCT02308839|Device|GORE® EXCLUDER® Endoprosthesis|Endovascular therapy to treat abdominal aortic aneurysms
1589990|NCT02308826|Behavioral|Turtle Program|
1589991|NCT02308826|Behavioral|Cool Little Kids|
1589992|NCT02308813|Other|Braking and functionality|
1589993|NCT02308800|Device|Quantum™ Therapy - NPWT with Prontosan|Negative pressure wound therapy with Prontosan irrigation.
1589994|NCT02308800|Device|Quantum™ Therapy|Negative pressure wound therapy without irrigation.
1589995|NCT02308787|Device|Spectra Optia Apheresis System|Platelet Depletion
1589997|NCT02308748|Drug|Dofetilide|"8 am: Placebo
12 pm (noon): 250 µg
5:30 pm: 250 µg"
1589998|NCT02308748|Drug|Mexiletine|"8 am: weight x 4 mg/kg
12 pm (noon): Same as at 8 am
5:30 pm: Same as at 8 am"
1589999|NCT02308748|Drug|Lidocaine|"9 am : 30 µg/min per kg (loading) for 60 minutes and 10 µg/min per kg (maintenance) for 30 minutes
2 pm: 55 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes
7:30 pm: 52 µg/min per kg (loading) for 60 minutes and 20 µg/min per kg (maintenance) for 30 minutes"
1590000|NCT02308748|Drug|Moxifloxacin|"9 am: 5.63 mg/h per kg (loading) for 1 hour and 0.26 mg/h per kg (maintenance for 30 minutes)
2 pm: 6.14 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)
7:30 pm: 2.23 mg/h per kg (loading) for 1 hour and 0.49 mg/h per kg (maintenance for 30 minutes)"
1590001|NCT02308748|Drug|Diltiazem|• 7:30 pm: 330 µg/h per kg (loading) for 60 minutes and 61 µg/h per kg (maintenance) for 30 minutes
1590002|NCT02308748|Drug|Placebo|Placebo (#2 Gelcap or IV saline)
1590003|NCT02308735|Other|N/A - No intervention|
1590004|NCT02308722|Radiation|5-fraction stereotactic body radiation therapy|"The investigators expect to need a maximum of 3 dose levels investigating dose to the area at risk of involved resection lines and to the tumour bed to assess the tolerability of SBRT in this setting.
Patient entry will commence at level 1. There is the option to de-escalate to Level -1 should 2 or more DLTs be observed at the starting level. SBRT will not be escalated above level 3.
Level -1:
Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 8Gy/# (total dose 40Gy)
Level 1:
Tumour (PTV) 6Gy/# (total dose 30Gy). Area at risk of R1 (PTV_R) 9Gy/# (total dose 45Gy)
Level 2:
Tumour (PTV) 6.5Gy/# (total dose 32.5Gy). Area at risk of R1 (PTV_R) 9.5Gy/# (total dose 47.5Gy)
Level 3:
Tumour (PTV) 7Gy/# (total dose 35Gy). Area at risk of R1 (PTV_R) 10Gy/# (total dose 50Gy)"
1590005|NCT02308709|Radiation|Ventilation image-guided radiotherapy|Patient's treatment plan will be created and optimized to minimize the dose to highly-functional lung regions
1590006|NCT02308696|Behavioral|Peer-to-Peer Support|All three data collection sites run peer-to-peer community support programs. Core program elements include the same program objective, standard definition of who qualifies for peer-to-peer support, the mechanism by which older adults are referred for consideration for peer-support, core elements of training programs for the older adults who volunteer to provide the peer support, and monthly in-service trainings for all volunteers once trained, weekly hours that volunteers spend providing support, and provision of small stipends for volunteers.As they find their role very rewarding, there is very little peer turn-over; the vast majority of peers volunteer for years in this role, until they themselves start requiring services.
1590007|NCT02308696|Behavioral|Standard Community Services|All three data collection sites will continue to provide standard community services to the older adults that are not enrolled in the peer-to-peer support program
1590008|NCT02308683|Dietary Supplement|Moringa oleifera|12 weeks supplementation
1590009|NCT02308644|Drug|intravitreal bevacizumab injection(1.25mg)|intravitreal bevacizumab injection(1.25mg) / Sham injection
1590010|NCT02308631|Procedure|ENDOSCOPICALLY ASSISTED COLOSTOMY WITH COLOPEXY|The endoscope was manipulated until the light approached the pre-set for the use of transillumination site and puncture with the Loop Fixture II gastropexy kit
1590011|NCT02308618|Other|Traditional Immobilization|"After surgery subjects were immobilized in a plaster cast, with the ankle positioned in gravitational equinus; weight bearing was not allowed. Two weeks post-operatively, the cast was removed and the patient was immobilized with a new plaster cast, with the ankle in the same position. Four weeks post-operatively, the ankle was plastered in neutral position (i.e. with the sole of the foot perpendicular to the shank), and weight bearing was encouraged. Six weeks post-operatively, the plaster cast was removed
The home exercise program consisted of active exercises and stretches to improve ankle range of motion, and resistance and balance exercises"
1590012|NCT02308618|Other|Early Mobilization|The physical therapy started two weeks after the surgery and lasted six weeks, during which a removable brace was used. Therapy sessions, three times per week in the six-week period, included one to two hours of exercises for regaining range of motion and muscular endurance.
1590013|NCT02308605|Device|SMARTCap|The Sarissa Biomedical SMARTCap biosensor array. This is an array of biosensors and electrodes in a simple moulded device that will fit into a vacutainer blood tube and will enable the rapid measurement of purines in freshly drawn blood. Therefore, this is not an intervention as such as the device is an In-Vitro Diagnostic Medical Device.
1590014|NCT02308592|Behavioral|Electronic Patient Decision Aid|"The electronic Patient Decision Aid (PDA) is an interactive website with 3 main sections:
Evidence-based information on (a) depression in pregnancy, (b) each treatment option and procedure;
(a) Evidence-based information on the risks and benefits of both untreated depression and antidepressant treatment, (b) exercises to help women determine which risks and benefits are most important to them; and
A summary section that outlines the information reviewed and which benefits and risks they deemed most important."
1590103|NCT02307981|Other|Training with vision teacher (visual rehabilitation)|Individually adapted training With vision teacher
1590015|NCT02308592|Behavioral|Standard Resource Sheet|"Women allocated to the control intervention will login to the study website and receive a printable PDF containing references to standard published information on antidepressant use in pregnancy. This ensures women have access to accurate information on the benefits and risks of antidepressant medication in pregnancy (even though they will not receive the PDA).
Women who are assigned the control condition AND who are not receiving care from Women's College Hospital Reproductive Life Stages Program will receive waitlisted access to the intervention after data collected at 4 weeks post-randomization."
1590016|NCT02308566|Procedure|Minimized Extracorporeal Circulation (MECC)|This group of patients receives surgical aortic valve replacement using MECC.
1590017|NCT02308566|Procedure|Conventional Extracorporeal Circulation (CECC)|This group of patients receives surgical aortic valve replacement using CECC.
1590018|NCT02308553|Drug|Nintedanib|Nintedanib (150 mg or 200 mg BID)
1590019|NCT02308553|Drug|Nintedanib-Placebo|Placebo (150 mg or 200 mg BID)
1590020|NCT02308553|Drug|Paclitaxel|Paclitaxel as 90mg/mw infusion day 1, 8, 15 q28 (6 cycles)
1590021|NCT02308540|Biological|SIILPCV10|10-valent Pneumococcal Conjugate Vaccine (SIILPCV10) at a dosage of 2 µg for each serotype polysaccharide, except 4 µg for 6B serotype, conjugated to a carrier protein (CRM197), with adjuvant (aluminum phosphate [alum]) and preservative (thiomersal).
1590022|NCT02308540|Biological|Pneumovax 23|23-valent Pneumococcal Polysaccharide Vaccine (Pneumovax 23; MSD Pharmaceuticals) for the adult cohort.
1590023|NCT02308540|Biological|Prevenar 13|13-valent Pneumococcal Conjugate Vaccine (Prevenar 13; Pfizer-Wyeth) for the toddler and infant cohorts
1590024|NCT02308527|Drug|Bevacizumab|10mg/kg IV (in the vein) on Days 1 and 15 of a 4 week cycle, for 6 cycles or until progression
1590025|NCT02308527|Drug|Temozolomide|200mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
1590026|NCT02308527|Drug|Temozolomide|100mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
1590027|NCT02308527|Drug|Irinotecan|50mg/m2/d IV (in the vein) on Days 1 to 5 of a 3 week cycle, for 6 cycles or until progression
1590028|NCT02308527|Drug|Bevacizumab|15mg/kg IV (in the vein) on Day 1 of a 3 week cycle, for 6 cycles or until progression
1590029|NCT02308527|Drug|Topotecan|0.75mg/m2/d IV (in the vein) on Days 1-5 of a 4 week cycle, for 6 cycles or until progression
1590030|NCT02308527|Drug|Temozolomide|150mg/m2/d PO (capsule taken orally) on Days 1 to 5 of a 4 week cycle, for 6 cycles or until progression
1590031|NCT02308514|Device|cryostimulation|pressurized cold air (-70 celsius degree) is blown on the skin surface surrounding the lateral epicondyle, creating a rapid decrease in ski temperature. In a 30-40 sec exposition, skin temperature can drop to 4 celsius degree. this rapid decrease is presumed to have a positive healing effect.
1590032|NCT02308514|Other|conservative care|manual treatment of localized tender and painful myofascial areas in the muscles surrounding the forearm and mobilization of the radial head.
1590033|NCT02308501|Drug|Lastacaft ®|
1590034|NCT02308501|Drug|Tears Naturale ®|
1590035|NCT02308488|Radiation|Radiation|Whole breast/chest wall, level 1- III (includes Cohort A) and SCV nodes IMRT at 2.7 Gy x 15 fractions. The treatment will consist of 15 fractions, with one fraction daily for five days a week, for 3 consecutive weeks.
1590036|NCT02308475|Device|Somatom Force CT Scanner|Dynamic CT perfusion of the heart
1590037|NCT02308462|Behavioral|CHIMPS intervention|"CHIMPs intervention (Family-Intervention composed of 8 Topic-related sessions over a period of 6 month, based on the evaluated manual: a preliminary talk with the family, two sessions with the parents, one session with each child, three sessions with the family).
The sessions are semi-structured and cover the topics illness and coping, education, family relationships and trusting attachement figures, social network and support of the Family. A detailed description of the procedure is found in the Manual (Wiegand-Grefe, Halverscheid & Plass, 2011)."
1590038|NCT02308449|Drug|Ferric carboxymaltose|Infusion of 15 mg/kg (up to maximum 1000 mg) ferric carboxymaltose in 250 mL 0.9% sodium chloride
1590039|NCT02308449|Drug|Sodium chloride (placebo)|Infusion of 250 mL 0.9% sodium chloride
1590040|NCT02308436|Device|Candida Mouthwash with Curolox™ Peptide|Prophylaxis - protection and care of teeth against caries & acidic challenges
1590041|NCT02308423|Radiation|XR of shoulder|Radiologic examination: Axial view, Axillary view and Anterior posterior view- to evaluate the level of osteoarthritis by Kellgren Lawrence score and Samilson score.
1590042|NCT02308410|Procedure|Tourniquet application during surgery|Both groups received usual care according to the orthopedic surgeons surgical preferences. One group received no tourniquet during surgery (non-tourniquet group) and the other group received a pneumatic tourniquet during surgery (tourniquet-group).
1590047|NCT02308384|Behavioral|Intervention|CME, Start-package and status mail
1590048|NCT02308371|Device|Automated Pulse Pressure Variation|Based on standard of care, the physician will give fluid as needed based on standard clinical data (heart rate, central venous pressure if available, blood pressure, urine output, physical exam, lactate level) and pulse pressure variation. PPV should be elevated consistently greater than 15 minutes before giving fluid without other symptoms of patient instability (low blood pressure, elevated lactate, tachycardia). Pulse pressure variation will be followed for 48 hours.
1590049|NCT02308345|Other|Pre-chemotherapy visit summary Video|
1590051|NCT02308319|Drug|Tenofovir disoproxil fumarate|300mg q.d. per oral
1590052|NCT02308293|Behavioral|High intensity exercise|3x30 seconds 'all out' sprints
1590053|NCT02308293|Behavioral|Lay down comfortably|rest
1590104|NCT02307968|Other|insulin injection site|insulin injected site between inner thigh and out thigh
1590105|NCT02307955|Device|firefly|
1590054|NCT02308280|Drug|Bortezomib following nonmyeloablative allogeneic transplant|Bortezomib 1,3 mg/m2 subcutaneously every 2 weeks for 1 year (26 injections) starting on day +120 from a non myeloablative sibling or 10/10 unrelated allogeneic transplantation
1590055|NCT02308267|Other|Lung explants|Lung explants from end-stage CF, which were obtained for a reason independent from the study in the Paris (Prof Burgel) and Leuven (Prof Dupont) centres will be analysed for pIgR and IgA expression as well as for Pseudomonas aeruginosa colonization. Some lung explants from control patients will also be obtained from the Leuven centre.
1590056|NCT02308267|Other|Sputum, nasal fluid and serum|Sputum, nasal (fluid) and serum samples from CF patients and controls patients will be collected (Leuven, Paris, Torino, Verona and Saint-Luc Brussels) for S-IgA and microbiological assays. Spontaneous sputum will be collected, while nasal fluid will be sampled through nasal lavage. Control subjects will consist of COPD patients and healthy subjects (smokers or not).
1590057|NCT02308267|Procedure|Bronchoscopy|Endobronchial biopsies (EBB) and broncho-alveolar lavage (BAL) will be sampled at the KULeuven centre (Prof Dupont) in some CF patients (homozygous for the DF508 mutation) and colonized or not with Pseudomonas aeruginosa and who must have a general anaesthesia for a reason independent from the study. In these patients, a bronchial endoscopy will be performed during narcosis to take EBB (n=8) and BAL (2x50mL). If possible, nasal and rectal biopsies will also be performed in some patients. Samples will be assessed for pIgR and IgA expression and for primary broncho-epithelial cultures (carried out at the UCL centre, Pr Pilette). Control subjects will be patients without CF and without evidence of lung disease and who are undergoing narcosis for an independent reason at the KULeuven centre.
1590058|NCT02308254|Drug|Lixisenatide|Abdominal administration
1590059|NCT02308254|Drug|Placebo|Abdominal administration
1590060|NCT02308241|Drug|Ribavirin|self-administer ribavirin 1400 mg PO BID (total dose, 2800 mg/day)
1590061|NCT02308228|Behavioral|Progressive Resistance Training|Participants will complete 14 weeks (42 sessions, 3x/week) of progressive resistance training which will consist of 8 constant load movements to train all major muscle groups bilaterally.
1590062|NCT02308228|Drug|Metformin|Participants will be randomized to receive metformin in conjunction with their strength training program.
1590063|NCT02308202|Drug|doxazosin|
1590064|NCT02308202|Drug|Perindopril|
1590065|NCT02308202|Drug|Placebo|
1590066|NCT02308189|Behavioral|Exercise with blood flow restriction|Low load resistance exercise performed with an external pressure cuff applied over both legs or both arms during respective leg and arm exercises.
1590067|NCT02308189|Behavioral|Exercise|Low load resistance exercise performed with no external pressure cuff applied to the appendicular limbs.
1590068|NCT02308176|Behavioral|APP + health advice|health advice and reinforcement to it
1590069|NCT02308176|Behavioral|health advice|health advice
2009017|NCT03325478|Other|"Over the phone interviews on the BCI Stay in Contact"|"This study used phone call interviews on a BCI Stay in Contact, 6 months after suicide attempt behavior.The questionnaire used for the interview of included suicide attempters was pilot tested to assess acceptability and feasibility of the study. It included 24 questions, which were based on literature's data.They covered seeking care and help items and assess the subjective quality appreciation of medical care in the PED and on the BCI.Closed-ended and multiple-choice questions were mixed. Included patients were informed that the questionnaire was anonymous and that seeking their views and feedbacks would help adjusting the implementation of follow-up interventions closer to their needs.The baseline interviews were conducted on the phone, on weekdays, during a mean time of 10 to 15minutes by a trained resident in psychiatry as the only interviewer."
1590073|NCT02308150|Device|transcatheter aortic valve replacement|
1590075|NCT02308124|Drug|Midodrine|
1590076|NCT02308124|Drug|Pyridostigmine Bromide|
1590077|NCT02308124|Drug|Midodrine + pyridostigmine|
1590080|NCT02308098|Drug|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
1590081|NCT02308098|Drug|Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
1590082|NCT02308098|Drug|Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
1590083|NCT02308098|Drug|Symbicort Turbuhaler 320/9 ug/inhalation 1inh|
1590084|NCT02308098|Drug|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 4 inh|
1590085|NCT02308098|Drug|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 4 inh|
1590086|NCT02308098|Drug|Placebo Budesonide/Formoterol Easyhaler 320/9 ug/inhalation 1 inh|
1590087|NCT02308098|Drug|Placebo Symbicort Turbuhaler 320/9 ug/inhalation 1 inh|
1590088|NCT02308085|Other|Endocrine therapy interruption|"3 months wash-out between treatment interruption and pregnancy attempt. Up to 2 years interruption to allow pregnancy, delivery, breastfeeding or failure to conceive.
Endocrine therapy resumption. Completion of full duration of endocrine therapy according to individual risk, institutional policy or patient's preference."
1590089|NCT02308072|Drug|Olaparib|50 mg, 100 mg, 150 mg or 200 mg taken twice daily (depending on dose under investigation at time of registration) on days 1-3, 1-4 or 1-5 (depending on allocation of treatment schedule) of each week of treatment.
1590090|NCT02308072|Drug|Cisplatin|35 mg/m^2 IV on day 1 of each week of treatment during radiotherapy for a total of 7 weeks (total overall dose 245 mg/m^2)
1590091|NCT02308072|Radiation|IMRT|2 Gy delivered in 35 fractions, on days 1-3, 1-4 or 1-5 each week for up to 7 weeks (total overall dose delivered 70 Gy)
1590092|NCT02308059|Other|Ultrasonographic evaluation of nerves in diabetic patients|Ultrasonographic evaluation of peripheral nerves in patients with diabetes mellitus which have peripheral neuropathy
1590093|NCT02308059|Other|Ultrasonographic evaluation of nerves of healthy volunteers|evaluation of peripheral nerves and correlated with group I
1590094|NCT02308046|Drug|Terconazole|
1590095|NCT02308046|Drug|Placebo|
1590096|NCT02308033|Drug|Metronidazole|
1590097|NCT02308033|Drug|Gel vehicle|
1590098|NCT02308020|Drug|Abemaciclib|Administered orally
1590099|NCT02308007|Drug|Terconazole|
1590100|NCT02308007|Drug|Metronidazole|
1590101|NCT02308007|Drug|Terconazole/metronidazole|
1590102|NCT02307994|Drug|75IU uFSH|
1590106|NCT02307955|Other|Standard of care|
1590107|NCT02307942|Procedure|Gastric banding|The bariatric procedure is a gastric banding under general anesthesia with all the centres using the same surgical procedure (harmonized by group meetings). The laparoscopic surgical procedure has been described. The ERAS protocol will be applied in each centre. The inflation of the band will follow the procedures described by 0'Brien. The patients will attend a group education session before surgery, during which the eating behaviour with a band will be explained and practiced. Then after surgery, the routine procedure is applied.
1590108|NCT02307916|Drug|FGF-2|The FGF-2 method of use comprises a pledget of gelatin foam with human fibroblast growth factor-2 (FGF-2) added to the pledget just before topical application to the tympanic membrane, and the use of Tisseel, a fibrin glue used for applications in ear surgery.
1590109|NCT02307916|Other|Placebo|Placebo comparator using a sterile saline solution.
1590110|NCT02307864|Drug|Tramadol HCl|Tramadol HCl 50 mg immediate release (IR) tablet administered orally.
1590111|NCT02307864|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg tablet administered orally.
1590112|NCT02307864|Drug|Tramadol HCl Placebo|Placebo matched to tramadol HCl IR tablet administered orally.
1590113|NCT02307864|Drug|Moxifloxacin Placebo|Placebo matched to Moxifloxacin 400 mg tablet administered orally.
1590114|NCT02307851|Biological|Quadrivalent VLP Vaccine|
1590115|NCT02307851|Biological|Comparator TIV|
1590116|NCT02307838|Other|Assessments arm|Protocol required assessments not provided in standard of care
1590117|NCT02307825|Drug|Azithromycin|The drug will be taken three times a week for four months.
1590118|NCT02307825|Drug|Placebo|The placebo will be taken three times a week for four months.
1590119|NCT02307812|Drug|Ramucirumab|Administered intravenously (IV)
1590120|NCT02307812|Drug|Paclitaxel|Administered IV
1590121|NCT02307773|Drug|Case Group|Consecutively, all the participants were assigned to case group with additional 2 puffs of the 10% lidocaine spray on the tip of endoscope, same medication which was used for prior pharyngeal anesthesia, or to control group with conventional pharyngeal anesthesia without further treatment. Then we compared the primary outcome measures, such as, frequency of belching and retching of two groups.
1590122|NCT02307760|Other|Human Milk Fortifier A|Acidified concentrated liquid human milk fortifier
1590123|NCT02307760|Other|Human Milk Fortifier B|Non-acidified concentrated liquid human milk fortifier
1590124|NCT02307747|Other|blood samples|Blood samples will be collected every 4 hours during 24 h
2009018|NCT03325465|Drug|Pembrolizumab|Patients will receive pembrolizumab alone or pembrolizumab in combination with epacadostat. Pembrolizumab will be administered at 200 mg IV every 3 weeks for up to 3 doses for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
2009019|NCT03325465|Drug|Epacadostat|Patients will receive epacadostat in combination with pembrolizumab. Epacadostat will be administered orally at a dose of 100 mg twice a day starting on day 1 for the duration of pembrolizumab treatment. Patients will continue on this combination for no longer than 8 weeks prior to surgery. After surgery, patients will continue pembrolizumab plus epacadostat every 3 weeks for 12 months.
1590127|NCT02307721|Drug|Intranasal naloxone|Administer 0,1 ml 8 mg/ml naloxone intranasally, dose = 0,8 mg naloxone
1590128|NCT02307721|Drug|Intramuscular naloxone|Administer 2 mL, dose intramuscular naloxone 0,8 mg
1590129|NCT02307721|Drug|Remifentanil|Administer remifentanil intravenously by way of Target Control Infusion, Minto model at a target of 2,5 ng/ml. This to achieve a state of safe and predictable opioid influence to assess pharmacodynamic response to naloxone. After treatment of 4 participants protocol amended 22. january 2015 to reduce remifentanil target to 1,25 ng/ml in the next 4. In the last 4 participants the dose will be decided later, but not exceed 2,5 ng/ml.
1590130|NCT02307721|Device|Aptar Unidose|This is the spray device chosen, and its function in this setting (spray up side down) will be assessed by weighing the device before and after administration.
1590131|NCT02307708|Device|8° incline shoe|"Wearing inclined shoes for 6 weeks, walking 15 minutes (2 times/day).
The shoe is inclined from front to back and from top to bottom of 8 °. This causes a controlled and an eccentric contraction during the passage.
During the walk we will have:
In support tardigrade : an ankle dorsiflexion with a stretching the Achilles tendon (eccentric contractions).
In support digitigrade: plantar flexion of ankle with a muscle contraction of triceps surae (concentric contraction)."
1590132|NCT02307708|Other|kinesitherapy|Daily eccentric contraction at home and once per week for 6 weeks with the physiotherapist
1590133|NCT02307695|Drug|Saxagliptin|saxagliptin 5 mg p.o. qd, 24 week
1590134|NCT02307695|Drug|Insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
1590135|NCT02307682|Drug|RTH258 solution for IVT injection|
1590136|NCT02307682|Drug|Aflibercept solution for IVT injection|Administered as a 2 mg/50 µL dose
1590137|NCT02307669|Behavioral|INCA feedback|The study team have developed a device which is attached to inhalers that makes an audio recording of the inhaler being used. Analysis of this audio data provides objective evidence of the time of inhaler use, technique of use and the peak inspiratory flow the patient makes each time they use their inhaler. Our preliminary experiences with the information obtained from this device indicate that adherence is poor in patients with severe asthma due to any one the following issues poor time of use, errors in handling and low peak inspiratory flow rates.
2009020|NCT03325452|Biological|venous lactate|value of venous lactate
1590141|NCT02307643|Drug|MT-1303 Low dose|
1590142|NCT02307643|Drug|MT-1303 High dose|
1590143|NCT02307630|Biological|124I-Humanized 3F8|
1590144|NCT02307604|Genetic|Tumour markers testing|
1590269|NCT02306798|Drug|TP05|One radio-labelled tablet given to subject after a high fat and a rich in calories breakfast
1590270|NCT02306785|Drug|TP05 Coating D|One radio-labelled tablet given to subjects
1590271|NCT02306785|Drug|TP05 Coating E|One radio-labelled tablet given to subjects
1590145|NCT02307591|Drug|Best Supportive Care|Dehydration Ringer's lactate solution or normal saline intravenously Electrolytes should be monitored at regular intervals and corrected as long as vomiting and/or diarrhoea persist Fever intravenous Paracetamol Antimicrobial treatment Prophylactic 5-days course with Ampicillin should be used Pain Paracetamol,Tramadol or Pentazocine Central nervous system disturbances If a patient is restless or confused, prescribe a light sedation utilizing Midazolam, Propofol or Ketamine, preferably in association with Diazepam or Midazolam Seizures Diazepam Vomiting antiemetic medications may provide some relief and facilitate the rehydration Dyspepsia in adults, Omeprazole Diarrhoea in adults, Loperamide Acute bleeding leading to signs of haemorrhagic shock should be treated with whole blood transfusion and supportive care. Patients haemodynamically stable should not be transfused if the Hb level is >7 mg% Septic shock intensive support care Malaria in case of positive initial test, Artesunate
1590146|NCT02307591|Drug|Best Supportive Care + Amiodarone|"This treatment will be provided to patients in the experimental arm only in addition to best supportive care scheme .
During the first 3 days of treatment, the drug must be administered in Glucose 5% solution. Deliver through the largest possible vein inserting a long catheter (if possible a CVP line).
Day 1. Dose: 20 mg/kg/die i.v. deliver a loading dose of 5mg/kg in the 1st hour, followed by continuous infusion during the remaining 23 hours.
Example: 20 mg /kg of Amiodarone in 500 cc of Glucose 5%. Deliver 125 ml during the 1st hour followed by 16 ml/hour for the remaining 23 hours.
Day 2 - Day 3. Dose: 20 mg/kg/die i.v. Continuous infusion over 24 hrs. Example: Glucose 5% 500 ml containing 20 mg/kg of Amiodarone (infusion speed = 21 ml/hour).
Day 4 to Day 10. If no significant diarrhea and/or vomiting, shift to oral intake of Amiodarone as follows:
Adults: 200 mg tablets, 3 times a day, according to the body weight (30mg/Kg)
Children < 29 kg: 5 mg/kg 3 times a day"
1590147|NCT02307578|Drug|Perampanel|Perampanel will be available in 2-mg and 4-mg tablets. Subjects will start this EAP with the dose that they were receiving at the end of their participation in Study 332. Doses of perampanel can be adjusted based on clinical judgment.
1590148|NCT02307565|Drug|Midodrine|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
1590149|NCT02307565|Drug|Placebo|Each arm (2) will last 30 days with a 14 day washout in between each arm. Subjects nor the investigators will know which drug (midodrine or placebo) is administered to the subject for the first arm (30 days) and the second arm (30 days). The subjects will take a pill three times a day. Each subject will return home with a blood pressure monitor and will be asked to report his/her blood pressure at least 3 times a day and complete questionnaires based on how he/she is feeling.
1590150|NCT02307552|Device|UreScan|The TUUS Foley/catheter will be inserted into the urethra via the ultrasound visualization onto the apex prostate, and the ultrasound extended through the urethra until the bladder neck and stopped. This is recorded twice automatically, and this should take 5-10 minutes for completion, and the prostate ultrasound data stored in memory. The ultrasound/subject interaction is now complete, and the study should add 30-60 minutes to the preoperative visit. No local or general anesthesia is used. The subject will be given 500 mg of Ciprofloxacin as a preventative measure against a urinary tract infection.
1590151|NCT02307539|Procedure|Psychosocial Assessment and Care|Undergo PCPI
1590152|NCT02307539|Other|Palliative Therapy|Undergo PCPI
1590153|NCT02307539|Other|Quality-of-Life Assessment|Undergo QOL assessment
1590154|NCT02307539|Other|Questionnaire Administration|Undergo questionnaire administration
1590155|NCT02307526|Drug|Pyridostigmine Bromide|After being transferred onto a tilt table, subject will lie in a rested, supine position in which the study drug, pyridostigmine bromide will be administered at the 30 minute time point. Following the administration of the study drug, the subject will remain in the supine position for an additional 30 minutes until the tilting protocol commences.
1590156|NCT02307526|Device|Tilt table test|After 60 minutes in supine resting position, a progressive head-up tilt will be utilized in which the table will be adjusted to 15°, 25°, 35° for 5 minutes at each angle and then maintained at 45° for 45 minutes or until the subjects experiences symptoms of compromised cerebral blood flow, which include, but are not limited to, light headedness, blurry vision, dizziness and nausea.
1590157|NCT02307513|Drug|Apremilast (CC-10004)|
1590158|NCT02307513|Drug|Placebo|
1590159|NCT02307500|Drug|Regorafenib|oral therapy
1590160|NCT02307487|Drug|120 mg MMC in 90ml gel|120 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
1590161|NCT02307487|Drug|140 mg MMC in 90ml gel|140 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
1590162|NCT02307487|Drug|160 mg MMC in 90ml gel|160 mg of Mitomycin C mixed with 90 ml UroGen's TC-3 gel
1590163|NCT02307487|Drug|120 mg MMC in 60ml gel|120 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
1590164|NCT02307487|Drug|140 mg MMC in 60ml gel|140 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
1590165|NCT02307487|Drug|160 mg MMC in 60ml gel|160 mg of Mitomycin C mixed with 60 ml UroGen's TC-3 gel
1590166|NCT02307474|Radiation|Stereotactic Radiosurgery|3 fractions of 16 Gy per fraction to a total dose of 48 Gy on non-consecutive day within a 10 day time span
1590167|NCT02307474|Drug|Pazopanib Hydrochloride|Given PO starting at 800mg to be systematically altered following drug related toxicities.
1590168|NCT02307461|Drug|IPI-145 (duvelisib)|High single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) high single oral dose
1590169|NCT02307461|Drug|IPI-145|Low single oral dose capsule IPI-145 test formulation and IPI-145 reference formulation (capsule) low single oral dose
1590170|NCT02307461|Drug|IPI-145|High single oral dose IPI-145 test formulation (capsule) with a high-fat meal and without food
1590171|NCT02307448|Procedure|Platelet Rich Plasma|Patients will receive weekly PRP treatments with standard of care.
1590172|NCT02307448|Procedure|Standard of Care|Patients will receive weekly standard of care.
1590173|NCT02307435|Biological|MSC|subjects are implanted with allogenic mesenchymal stem cells from umbilical cord/ bone marrow/ adipose
1590272|NCT02306785|Drug|TP05 Coating H|One radio-labelled tablet given to subjects
1590273|NCT02306772|Drug|TP05 Coating A|One radio-labelled tablet given to subjects
1590274|NCT02306772|Drug|TP05 Coating B|One radio-labelled tablet given to subjects
1590174|NCT02307422|Genetic|IL-1 Genotypes, other SNPs associated with CAD|Genotyping will be carried out by a CLIA-certified genotyping facility at ILI, Waltham MA. DNA concentrations will be adjusted to a range compatible with multiple PCR conditions. Genotyping will be accomplished by performing multiplex polymerase chain reactions (PCR) specifically targeting the surrounding sequences for the SNPs being studied. A single base extension assay will be hybridized to a 48-plex microarray plate and read on a SNPstream Genotyping System (Beckman-Coulter).
1590175|NCT02307409|Other|Sonoclot/TEG test|The Sonoclot/TEG test will be done at the study time points. Within 12 hours of presentation in the emergency department, at 72 hours, and at 7 days, or when the patient meets the study criteria for suspected or proven sepsis
1590176|NCT02307396|Drug|Olanzapine|
1590177|NCT02307396|Drug|Amisulpride|
1590178|NCT02307396|Drug|Risperidone|
1590179|NCT02307396|Drug|Haloperidol|
1590180|NCT02307396|Drug|Quetiapine|
1590181|NCT02307396|Drug|Perphenazine|
1590182|NCT02307396|Drug|Sulpiride|
1590183|NCT02307396|Drug|bromperidol|
1590184|NCT02307396|Drug|Zuclopenthixol|
1590185|NCT02307396|Drug|Thioridazine|
1590186|NCT02307396|Drug|Paliperidone|
1590187|NCT02307396|Drug|Ziprasidone|
1590188|NCT02307396|Drug|Benperidol|
1590189|NCT02307396|Drug|Fluspirilene|
1590190|NCT02307396|Drug|Pimozide|
1590191|NCT02307396|Drug|Perazine|
1590192|NCT02307396|Drug|Fluphenazine|
1590193|NCT02307396|Drug|Flupentixole|
1590194|NCT02307396|Drug|Sertindole|
1590195|NCT02307383|Drug|Lactitol|
1590196|NCT02307383|Drug|Lactobacillus|
1590197|NCT02307370|Device|Turbo-Elite Laser Catheter|Application of laser energy to remove blockage
1590198|NCT02307357|Behavioral|physical fitness tests|the subjects will perform 6 different tests to evaluate their physical fitness
1590199|NCT02307344|Dietary Supplement|Nigella Sativa|
1590200|NCT02307344|Dietary Supplement|Placebo|Capsules that contain a placebo but look like the Nigella Sativa capsules
1590201|NCT02307331|Device|Optivac|A vacuum mixing system for cement with mixing and collection under vacuum but open initial mixture of powder and monomer. Has been used since 1993 with excellent results
1590202|NCT02307331|Device|Optipac|A vacuum mixing system for cement with mixing and collection under vacuum but with a pre-packed mixing system allowing for an all closed system minimizing exposure for monomer fumes. This is a relatively new mixing system
1590203|NCT02307331|Device|Arcom (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The first is the 'classic', long term proven ArCom, a conventional polyethylene
1590204|NCT02307331|Device|E1 (Exceed cup)|The Exceed cup is available in two type of advanced bearing polyethylene material: The new is a highly cross linked polyethylene with infusion of vitamin E1 to remove free radicals in order to reduce wear.
1590205|NCT02307331|Device|Sirius stem|A polished tapered stem
1590206|NCT02307318|Device|SoftSeal Hemostatic Pad|Use of SoftSeal hemostatic device at a transradial access site with a 4 French system with with manual pressure by compression of the ulnar artery.
1590207|NCT02307305|Drug|Duloxetine|"Phase I (preemptive): 2 hour before surgery (30mg for 1 day)
Phase II (titration): POD#1~6 (30mg for another 6 days)
Phase III (maintenance): POD#7~13(60mg for 7 days)
Phase IV (tapering-1): POD#14~20 (30mg for 7 days)
Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)"
1590208|NCT02307305|Drug|celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone|Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
1590209|NCT02307292|Device|POLARIS Peripheral Vascular Self Expanding Stent System|
1590210|NCT02307279|Device|Gelesis100|
1590211|NCT02307279|Device|placebo|
1590212|NCT02307266|Behavioral|Standard of care + supplementary education|
1590213|NCT02307266|Behavioral|Standard of care + additional visits|
1590214|NCT02307266|Behavioral|Standard of care|
1590215|NCT02307253|Device|Expect™19Flex needle (Boston Scientific Corp.,Natick,MA,USA)|EUS-guided fine needle biopsy performed through the duodenum with the Expect™ 19 Flex needle
1590216|NCT02307240|Drug|CUDC-907|CUDC-907 oral with meals.
1590217|NCT02307227|Drug|Trastuzumab|
1590218|NCT02307227|Drug|Paclitaxel|
1590219|NCT02307227|Drug|Epirubicin|
1590220|NCT02307227|Drug|Docetaxel|
1590221|NCT02307214|Other|BaroReflex Sensitivity, endothelial function measurement|no other
1590222|NCT02307201|Drug|Magnesium Sulfate|The patient will receive magnesium sulfate for 24 hours postpartum
1590223|NCT02307188|Device|Constellation Full Contact Mapping Catheter|64-electrode intracardiac mapping catheter.
1590224|NCT02307162|Drug|RPL554|Phosphodiesterase 3 and 4 Inhibitor
1590225|NCT02307162|Drug|Placebo|Dummy solution
1590226|NCT02307149|Biological|CAVATAK|CAVATAK is a preparation of CVA21
1590227|NCT02307149|Drug|Ipilimumab|Ipilimumab is a human cytotoxic T-lymphocyte antigen (CTLA-4)-blocking antibody indicated for the treatment of unresectable or metastatic melanoma
1590228|NCT02307123|Procedure|Intubation|HEMS physician prehospital intubation
1590229|NCT02307110|Other|cross-sectional observation|cross-sectional opthalmic examination
1590233|NCT02307084|Procedure|Ultrasound imaging of the long saphenous vein|Ultrasound imaging of the long saphenous vein from the ankle to the saphenofemoral junction. This will allow assessment of vein calibre, branches and bifurcations, presence of thrombophlebitis and distribution. The presence of a proximal deep vein thrombosis will also be assessed.
1590234|NCT02307071|Device|Cefaly Kit Arnold|Occipital neurostimulation can have a therapeutic effect in chronic migraine treatment, thus representing a possible therapeutic option in patients that do not respond to any medication.
1590275|NCT02306759|Drug|Ketamine|Ketamine 0.3mg/kg in 50ml normal saline, administered over 15 minutes
1590276|NCT02306759|Drug|Placebo|Normal saline 50ml, administered over 15 minutes
1590235|NCT02307058|Radiation|LEAD RT|LEAD RT: Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 39 fractions over ~8 weeks. The multiparametric-MRI (MP-MRI) defined gross tumor volume (GTV) will receive 12-14 Gy on the first day of treatment and then the prostate plus proximal seminal vesicles (SVs, usually 7-10 mm and/or <= 50%, whichever is less), the CTV1, will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full IMRT dose of 76 Gy, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
1590236|NCT02307058|Radiation|HEIGHT RT|HEIGHT RT: Radiotherapy will begin within two months of fiducial marker placement. The therapy will consist of 38 fractions over ~7.5 weeks. The MRI defined GTV will receive a higher dose per day than the clinical tumor volume (CTV) by dose painting. The GTV will receive an absolute dose of 91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 98.5 Gy in 2.0 Gy fractions. The prostate plus proximal seminal vesicles CTV1 will receive 76 Gy in 38 fractions (Fxs) at 2.0 Gy per Fx. For High Risk patients, the distal SVs (CTV2) may be treated to 56 Gy in 38 Fxs or full IMRT dose of 76 Gy, and the pelvic lymph nodes (CTV3) may be treated to 56 Gy in 38 Fxs.
1590237|NCT02307058|Behavioral|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) will be administered pretreatment, at the end of treatment and at each follow-up visit.
1590238|NCT02307058|Behavioral|Memorial Anxiety Scale for Prostate Cancer patients|Memorial Anxiety Scale for Prostate Cancer (MAX-PC) Quality of Life questionnaire - Recommended after enrollment and prior to fiducial marker placement, as well as during the last week of treatment, and post-RT at 3 mo, 9 mo and then yearly to 5.25 years.
1590239|NCT02307058|Behavioral|Expanded Prostate Cancer Index Composite-Short Form 12|Expanded Prostate Cancer Index Composite-Short Form 12 (EPIC SF-12) Quality of Life questionnaire - Recommended after enrollment and prior to fiducial marker placement, as well as during the last week of treatment, and post-RT at 3 mo, 9 mo and then yearly to 5.25 years.
1590240|NCT02307045|Drug|Varenicline|Stimulation of nicotinic receptors by varenicline (Champix) 1,0 mg po
1590241|NCT02307045|Drug|nicotine|Nicotine replacement therapy with transdermal patches and/or chewing gums
1590242|NCT02307019|Other|Program on specific prevention of health|The intervention will be centered in provide effective tools to manage each situation presented while a caregiver cares for patients poststroke with upper limb apraxia. Moreover, the workshops will be focused on the balance between the assistance provided by the caregiver and the improvement and the increase the autonomy and independence of the patients. Finally, we will provide skills and strategies to the caregiver for enhancing the environment adaptation of the patients.
1590243|NCT02307019|Other|Program on general prevention of health|The general health educative program will consist in an educational workshop for caregivers where they are taught the habitual guidelines to caring for patients in situation of dependency.
1590244|NCT02307006|Drug|Ceftaroline|Surgical prophylaxis
1590245|NCT02307006|Drug|Cefazolin / Vancomycin|Standard of care surgical prophylaxis
1590246|NCT02306993|Other|Healthy volunteers without SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
1590247|NCT02306993|Other|Healthy volunteers with SCT|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
1590248|NCT02306993|Other|Volunteers with SCD|Subjects will undergo bone density evaluation via dual energy x-ray absorptiometry (DEXA) scanning. Subjects will provide a sample of for testing of bone turnover markers, complete blood count, and hemoglobin electrophoresis. Subjects will provide information about their dietary calcium intake and pain burden.
1590249|NCT02306980|Other|Colostrum|Mother's own colostrum (0.2 ml) will be administered into the mouth of the infant every 2 hours for 48 hours.
1590252|NCT02306954|Biological|High Dose IL-2|High Dose IL-2 is approved by the FDA for the treatment of renal cell cancer.
1590253|NCT02306954|Radiation|SBRT|Patients assigned to SBRT arm will receive two doses of SBRT at 20 Gy on the Wednesday and Friday before the Monday on which IL-2 starts.
1590254|NCT02306941|Behavioral|Internet-delivered CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, adapted for adolescents with FAP/FD and their parents. Main component in the treatment is exposure for symptoms. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children as well as how to support exposure. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
1590255|NCT02306928|Other|Blood draw|
1590256|NCT02306915|Drug|lipegfilgrastim|lipegfilgrastim 30 μg/kg, 60 μg/kg, 100 μg/kg
1590257|NCT02306902|Drug|fenofibrate|130mg, Capsules
1590258|NCT02306902|Drug|ANTARA® (fenofibrate)|130mg, Capsules
1590259|NCT02306889|Drug|Fenofibrate|130mg Capsules
1590260|NCT02306889|Drug|ANTARA® (fenofibrate)|130mg Capsules
1590261|NCT02306876|Drug|PF-06412562 3mg BID|PF-06412562
1590262|NCT02306876|Drug|PF-06412562 15mg BID|PF-06412562
1590263|NCT02306876|Other|Placebo|Placebo
1590264|NCT02306863|Device|vibrating chair|vibration provided via physioacoustic method
1590265|NCT02306863|Device|sham treatment|simulated whole-body vibration
1590266|NCT02306850|Drug|Pembrolizumab|At the Treatment Initiation Visit (Baseline/Day 1), subjects will begin treatment with IV pembrolizumab 200 mg infusions every 3 weeks. As in previous pembrolizumab trials, eligible subjects will receive at least 24 weeks of therapy and may receive up to 2 years of pembrolizumab therapy depending on response to treatment.
1590267|NCT02306837|Drug|Bu-CY-E|mini Bu-Cy-E as consolidation chemotherapy after autologous HSCT
1590268|NCT02306811|Drug|Vatelizumab|"Pharmaceutical form:solution for infusion
Route of administration: intravenous"
1590279|NCT02306733|Drug|Ergometrine|100 women with atonic PPH will receive Ergometrine 400µgm (Methergin® Novartis, Switzerland) slowly intravenous (iv).
1590280|NCT02306733|Drug|Oxytocin|100 women with atonic PPH will receive Oxytocin 10 IU(Syntocinon® Novartis, Switzerland) slowly intravenous. iv and group 2 will receive oxytocin
1590281|NCT02306707|Procedure|Endoscopic Mucosal Resection|
1590282|NCT02306694|Drug|Advate|Patients who are currently taking Advate as their factor replacement will be eligible for the 5-day study.
1590283|NCT02306681|Other|No treatment given|This study comprises of a two-part SAQ (Self-Assessment Questionnaire). Paired responses to SAQ1 and SAQ2 will be used to estimate the differences in the frequency of hypoglycaemic episodes between the retrospective and prospective periods.
1590284|NCT02306629|Biological|Epratuzumab sc|Active substance: Epratuzumab, Pharmaceutical form: Solution for injection, Route of Administration: Subcutaneous,
1590285|NCT02306629|Biological|Epratuzumab iv|Active substance: Epratuzumab, Pharmaceutical form: Solution for Infusion, Route of Administration: Intravenous,
1590286|NCT02306603|Procedure|Endoscopic Mucosal Resection|
1590287|NCT02306590|Dietary Supplement|Calogen|
1590288|NCT02306590|Dietary Supplement|Placebo|
1590289|NCT02306577|Drug|STRIBILD|Taking oral 1 STRIBILD tablet once a day for 48 weeks
1590290|NCT02306564|Drug|Cabergoline|given to patients at high risk for OHSS
1590291|NCT02306551|Other|Biological and psycho-social risk and resilience factors|Naturalistic study, no active intervention or exposure is administered
1590292|NCT02306525|Procedure|Arthroscopic surgery of the hip joint|Arthroscopic treatment of Femoroacetabular Impingement
1590293|NCT02306512|Procedure|H&E|Sample will be stained with H&E according to standard procedures
1590294|NCT02306512|Procedure|IHC MART-1|Samples will be stained with immunohistochemistry antibody: MART-1 according to standard procedures.
1590295|NCT02306512|Procedure|IF MART-1|Samples will be stained with immunofluorescence antibody: MART-1 according to standard procedures.
1590296|NCT02306512|Procedure|IF cocktail|The fluorescent primary antibodies may include HMB-45, SOX10, Ki-67 and MART-1. However other markers will be considered to make the most visually remarkable cocktail; these may include S-100, MiTF, lamin and nestin. Primary antibodies will be tagged with secondary antibodies labeled with fluorescent signals. A fluorescent organelle stain and/or 4',6-diamidine-2-phenylindol (DAPI) may also be used to enhance cellular architecture.
1590297|NCT02306499|Procedure|ICSI|Intracytoplasmic Sperm Injection
1590298|NCT02306486|Other|with 0,5% oxalic acid (Desenssiv SSWhite)|with 0,5% oxalic acid (Desenssiv SSWhite) , desensitizer for sensivity cervical lesions on tooth
1590299|NCT02306473|Drug|Mannitol|Subjects will be challenged with inhaled mannitol according to already approved protocols.
1590300|NCT02306447|Device|rPMS and rTMS|"rPMS Stimulation of the neck muscles in five medial-lateral movements starting from the neck: left and right trapezius and deltoid muscle, trapezius and lattissimus dorsi muslce, and over the backbone. 20 stimuli per movement with 2s inter-train interval; four repetitions for each of the five movements; the first 20 trains with a frequency of 5Hz, the second 20 trains at 20Hz; stimulation at individual comfortable level (20-30% stimulator output); round coil.
rTMS 20Hz stimulation with 2000 stimuli over the left dorso-lateral prefrontal cortex at 110% motor threshold; followed by 1Hz stimulation with 2000 stimuli over the left temporo-parietal cortex; stimulation intensity 110% motor threshold; butterfly coil.
For stimulation we use MagPro X100 (Medtronic, Denmark)."
1590301|NCT02306434|Behavioral|Therapy by iCBT|Internet Cognitive behavioral therapy (iCBT) is given by a psychologist in the U-CARE platform. The intervention will focus on management of childbirth related fear. This means that the participants read texts and do homework assignments instructed from an internet page. Additional resources such as pictures, animations, videos and sounds will be a part of the treatment program. A psychologist will communicate with the participants through internal text-messages and will give feed back on their home work assignments. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment.
1590302|NCT02306434|Other|Standard care-counselling|Standard care (Counselling by midwives)
1590303|NCT02306421|Procedure|RPH with the simplified Milligan-Morgan|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation. The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer, anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids. Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
1590304|NCT02306421|Procedure|PPH with the simplified Milligan-Morgan|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position.Simplified Milligan-Morgan is a surgical option which was improved and developed by Professor He,well-known traditional Chinese doctor from Hunan province, based on Milligan-Morgan in 1971.The operation method is simple, the operation time is shortened.
1590305|NCT02306421|Procedure|RPH|RPH is a new therapy for hemorrhoid following the improvement of rubber band ligation.The treatment principle is: shrinkage of mucous membrane after the ligation, lift of anal cushion, the local inflammatory response resulting in adhesion of mucosa and submucosa and shallow muscle layer , anal cushion fixing to a higher position, at the same time by using the elastic contraction of automatic elastic line partly blocking blood supply of Internal hemorrhoids or reducing venous stasis, decreasing congestion hypertrophy of hemorrhoids , making hemorrhoidal lump shrink, thus eliminating bleeding and prolapse symptoms of hemorrhoid.It is suitable for internal hemorrhoids in every period and internal hemorrhoids part of mixed hemorrhoid.
1590306|NCT02306421|Procedure|PPH|According to anal cushion down theory of the formation of hemorrhoids, the Italy scholar Longo pioneered a new method for the treatment of circular prolapsed internal hemorrhoids In 1998.Its principle is resection of lower rectal mucosa and submucosa of the intestinal wall tissue in the ring above the hemorrhoids through surgical staples,anastomosis of the proximal and distal mucosa , lifting and fixing down anal cushion, recovering to the normal anatomical position
1590307|NCT02306421|Procedure|Milligan-Morgan|Milligan-Morgan surgery ,created in 1937 by Milligan etc,whose essence is to excise hemorrhoids of increasing prolapse in anatomy has good curative effect, low recurrence.It is currently the most common clinical surgery.
1590308|NCT02306395|Procedure|Endometrial local injury|The way of intervention is to scratch the uterine cavity two cycles by a small spatula in the first 3-5 days after menstrual period.
1590309|NCT02306382|Procedure|Perianal abscess drainage|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
1590310|NCT02306382|Device|3D ultrasonography|The patientens will be randomly selected and after they have taken part and said yes to the study, half the group will undergo examination with ultrasound and half without. After this random selection all the patients abscess will be drained.
1590311|NCT02306369|Behavioral|Internetdelivered exposure-based CBT|The Internet-delivered exposure treatment is based on the well-established internet-delivered CBT-treatment for IBS in adults, and adapted for adolescents and their parents. The feasibility of the treatment were tested in a pilot study during 2012. Components in the treatment are exposure for symptoms and parent training. The purpose of the treatment is to reduce fearful and anxious responses to symptoms and lessen avoidance of symptoms in the adolescents, and to teach the parents how parental behavior can influence symptoms in children. Detailed behaviour analysis is made for each individual and instruction is given on how to gradually expose to symptoms to lessen fear for symptoms and widen the behavioral repertoire.
1590312|NCT02306356|Behavioral|Internet-delivered Cognitive Behavior Therapy|
1590313|NCT02306343|Device|InsuPad|The InsuPad device is composed of a disposable heating pad and a reusable control unit. The heating pad is intended for one day use. The user would attach the InsuPad device to a site where insulin can be injected. When there is a need for insulin bolus injection the user would inject the insulin to a location designate for that. The device would start heating the area around the injection site without over heating the insulin. At the end of the day the subject would remove the device, dispose of the disposable unit and put the reusable unit for recharging.
1590314|NCT02306330|Device|Malditof|Malditof MS system is applied for Malditof group for identifying pathogens. It takes 20 minutes to give the results.
1590315|NCT02306330|Other|Routine clinical microbiology|Pathogens will be identified by the routine clinical microbiology of the hospital.
1590316|NCT02306317|Other|Standard procedure|FiO2 manually controlled by nursing
1590317|NCT02306317|Other|Experimental procedure|FiO2 manually controlled by parents, after training.
1590318|NCT02306304|Other|Duplex ultra sound screening for abdominal aortic aneurysms|Duplex ultra sound screening for abdominal aortic aneurysms in Israeli Arab men, smokers or past smokers at the age of 60-80 years.
2009021|NCT03325439|Drug|Brivaracetam (BRV) iv|"Exploratory Cohort:
Subsequent to one or multiple therapeutic doses of midazolam ([MDZ], dose and dosing frequency of MDZ is at the discretion of the investigator), a low dose of Brivaracetam (BRV) intravenous (iv) solution for injection will be administered. At the discretion of the Investigator, 3 additional iv BRV doses, up to a total of 4 iv BRV doses (0.5mg/kg twice daily [bid]), can be administered during the 48-hour Evaluation Period.
Confirmatory Cohort:
During the Evaluation Period, subjects are expected to receive intravenous (iv) BRV bid. The dose and dosing frequency of BRV will be adjusted for the Confirmatory Cohorts based on the analysis of the data collected for the Exploratory Cohort."
2009022|NCT03325439|Drug|Brivaracetam (BRV) oral|Subjects can switch from intravenous (iv) to oral brivaracetam (BRV) at any time during the BRV Extension Period
1590324|NCT02306265|Device|Full-Field Digital Mammogram|2D imaging of the breast using Full-Field Digital Mammography (FFDM) device
1590325|NCT02306265|Device|Digital Breast Tomosynthesis|3D imaging of the breast using Digital Breast Tomosynthesis (DBT) device
1590326|NCT02306252|Other|Occupational and Physical Therapy|OT and PT will be arranged for the subject and conducted in a manner as determined by the therapist.
1590327|NCT02306239|Drug|Terlipressin|
1590328|NCT02306239|Drug|Norepinephrine|
1590329|NCT02306213|Drug|Hydroxyethylstarch 6% 130/0.4|Use of Hydroxyethylstarch intraoperatively, for cardiopulmonary bypass use and postoperatively in the intensive care unit
1590330|NCT02306213|Other|standard volume therapy|
1590331|NCT02306187|Drug|Edirol|Edirol 0.5 or 0.75ug once every day oral treatment for at least 1 year after initial visit.
1590332|NCT02306174|Behavioral|Cognitive Rehabilitation and Exposure-based Class for Compulsive Hoarding|
1590344|NCT02306148|Other|Foot and ankle strengthening|Group will be trained during 2 months at the university by a physiotherapist and at home with a training software for foot and ankle strengthening.
1590345|NCT02306135|Other|n/a- this is an observational study|
1590346|NCT02306122|Behavioral|Pharmacist calls patient unless physician cancels call|
1590347|NCT02306122|Behavioral|Patient nonadherence information sent to physician|
1590348|NCT02306122|Behavioral|Pharmacist calls patient if physician requests call|
1590349|NCT02306122|Behavioral|Patient HMO/PPO status revealed to physician|
1590350|NCT02306109|Procedure|Standard motor rehabilitation treatment|Standard treatment: 2 sessions/week of motor rehabilitation treatment (45 minutes each one) for 10 weeks for a total of 20 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 20 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
1590445|NCT02305303|Procedure|Diary|A diary written prospectively during the ICU stay by the staff and relatives
1590446|NCT02305290|Procedure|Endoscopic Mucosal Resection|
1590351|NCT02306109|Procedure|Intensive motor rehabilitation treatment|Intensive treatment is characterized by an increased exercises volume: 5 sessions/week)(45 minutes each one) for 10 weeks for a total of 50 sessions, including exercises for aerobic endurance, reinforcement at low load and stretching. At the end of the 50 sessions, patient and caregiver are going to continue motor activity with therapist supervision through regular follow up
1590352|NCT02306083|Drug|Placebo three times a day|
1590353|NCT02306083|Drug|glucosamine sulfate 1500 mg three times a day|
1590354|NCT02306070|Drug|Metformin|
1590355|NCT02306070|Other|No treatment|
1590356|NCT02306057|Procedure|Pre BCPC|Routine catheterization before surgical procedure Bidirectional CavoPulmonary Connection
1590357|NCT02306057|Procedure|Pre TCPC|Routine catheterization before surgical procedure Total CavoPulmonary Connection
1590358|NCT02306057|Procedure|BCPC surgery|Surgical procedure Bidirectional CavoPulmonary Connection
1590359|NCT02306057|Procedure|TCPC|Surgical procedure Total CavoPulmonary Connection
1590360|NCT02306031|Drug|Prescribe ARTIFICIAL TEAR|From one week before surgery, and control group received artificial tear (Sina Darou Laboratories Company, Tehran, Iran) as a placebo every 6 hours. Theses drops continued up to 6 weeks with the same dose after operations
1590361|NCT02306031|Drug|Prescribe diclofenac sodium drop 0.1%|From one week before surgery, case group received diclofenac sodium drop 0.1% (Sina Darou Laboratories Company, Tehran, Iran) every 6 hours.Theses drops continued up to 6 weeks with the same dose after operations
1590362|NCT02306018|Device|EV1000™/volumeView™|
1590363|NCT02305992|Procedure|Axillary Block with 0.5% Ropivicaine|Axillary blocks are regional anesthesia techniques that are sometimes employed as an alternative to general anesthesia for surgery of the shoulder, arm, forearm, wrist and hand. In this case, ultra-sound technique will be used.
1590364|NCT02305992|Procedure|Stellate ganglion block with 0.2% Ropivicaine|A stellate ganglion block is an injection of local anesthetic in the sympathetic nerve tissue of the neck. These nerves are a part of the sympathetic nervous system. The nerves are located on either side of the voice box, in the neck
1590365|NCT02305992|Procedure|Local anesthetic infiltration with 0.25% Bupivicaine|Patients will receive local anesthetic infiltration of 0.25% Bupivicaine at the surgical site which will last approximately 6 hours.
1590366|NCT02305979|Drug|Loratadine|
1590367|NCT02305966|Procedure|surgery|All patients will receive a Delta XTEND reverse shoulder implant
1590368|NCT02305966|Device|0.8 mm diameter Tantalum marker beads|At the time of surgery, 0.8 mm diameter Tantalum marker beads will be injected into the bone surrounding the implant,
1590369|NCT02305940|Drug|Doxycycline|An oral dose of 100 mg of Doxycycline once daily, for a total duration of 52 weeks.
1590370|NCT02305940|Drug|Placebo|An oral dose of one capsule of placebo once daily, for a total duration of 52 weeks
2009023|NCT03325426|Device|FitBit|Daily use of physical activity tracker coupled with weekly provider telemonitoring and feedback for 3 months
2009024|NCT03325413|Behavioral|Systematic inclusion of family members|Systematic inclusion of family members/ reference person in the perioperative process
1590373|NCT02305901|Drug|repaglinide|single dose on day 1 of visits 2 and 3
1590374|NCT02305901|Drug|BI 187004 tablet|multiple doses on days 8-13 of visit 2 and days 1-7 of visit 3
1590375|NCT02305901|Drug|bupropion extended release tablet|single dose on day 3 of visits 2 and 3
1590376|NCT02305888|Drug|LEO 43204|Treatment of actinic keratosis
1590377|NCT02305875|Other|MCN scoring|Mcn's distance from top of the humeral head. Mcn's distance to the catheters insertion point. Mcn's distance and position in relationship to the axillary artery.
1590378|NCT02305862|Drug|Rosuvastatin 5mg|drug intervention
1590379|NCT02305862|Drug|Rosuvastatin 20mg|drug intervention
2009025|NCT03325413|Behavioral|Preoperative information|Detailed preoperative information about delirium prevention and procedures
2009026|NCT03325413|Behavioral|Physical and breathing exercises|Preoperative execution of physical and breathing exercises if necessary
1590382|NCT02305836|Procedure|acupuncture|"For GV16, the needle in length of 25mm will be inserted obliquely and downward towards mandibular direction slowly to a depth of 0.5. And the needle will be pulled out after de qi without being retained. For Shang Yintang, GV20 and GV24, the needle will be inserted with a 30°angle to a depth of about 0.5 cun to the subperiosteum until the patients have a strong sense that the needle is being heavily pressed. For EX-HN5 and KI 4 in both sides, the needle will be outward and obliquely inserted to the same depth of 1 cun and the needle will be manipulated with an even lifting and thrusting method to make the patients feel soreness and distention. The electric stimulator will be put on GV20, GV24 and EX-HN5 in both sides with a spare-dense wave, 10/50 Hz, 0.5-5.0 mA. The current intensity will be increased until the patients can not stand."
1590383|NCT02305836|Drug|donepezil|cholinesterase inhibitors (ChE-Is)
1590384|NCT02305823|Drug|Aripiprazole|
1590385|NCT02305823|Drug|Quetiapine|
1590386|NCT02305823|Drug|Ziprasidone|
1590387|NCT02305810|Drug|Everolimus 10 mg daily|everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors
1590388|NCT02305797|Drug|EDG004|EDG004
1590389|NCT02305797|Drug|Placebo|Placebo
1590390|NCT02305771|Device|Electroencephalography|
1590391|NCT02305771|Device|MRI|
1590392|NCT02305758|Drug|Veliparib|Veliparib will be given for 7 days of the 14 day cycle. One treatment of FOLFIRI with or without bevacizumab will be given during the 14 day cycle.
1590393|NCT02305758|Drug|Placebo|Placebo will be given for 7 days of the 14 day cycle. One treatment of FOLFIRI with or without bevacizumab will be given during the 14 day cycle.
1590394|NCT02305745|Other|Observational|
2009027|NCT03325413|Dietary Supplement|Dietary supplements|Dietary supplements if necessary
1590396|NCT02305706|Procedure|starting position in colonoscopy|
1590397|NCT02305693|Drug|Letrozole|
1590398|NCT02305693|Procedure|Laparoscopic ovarian drilling|
1590399|NCT02305667|Device|Macintosh|double lumen tube intubation using the Macintosh laryngoscope
1590447|NCT02305277|Drug|BIA 9-1067 (clinical micronized, CM)|
1590448|NCT02305277|Drug|BIA 9-1067 (to-be-marketed, TBM)|
2009028|NCT03325413|Other|Evaluation of long-term medication|Avoidance of unsuitable drugs for elderly if possible
1590400|NCT02305667|Device|Glidescope®|double lumen tube intubation using the Glidescope® videolaryngoscope. The distal portion of a left-sided DLT will be angulated to the right concealing the distal orifice of the tracheal lumen. The DLT will be advanced directly through the vocal cords after initial 90° clockwise rotation, the stylet will be removed, and then the DLT will be advanced gently while rotating in a 180° couterclockwise direction
1590401|NCT02305667|Device|Airtraq®|double lumen tube intubation using the Airtraq® videolaryngoscope.
1590402|NCT02305667|Device|King Vision™|double lumen tube intubation using the King Vision™ videolaryngoscope. the distal 21 cm of the left-sided DLT will be bended to replicate the curve of the non-channeled blade and the proximal curve of the DLT remains directed to the right side. Then, after initial 90° clockwise rotation, the bronchial cuff passes through the vocal cords, the stylet of the DLT will be withdrawn and the DLT will be rotated 180°counterclockwise while advancing the DLT to the desired depth.
1590403|NCT02305654|Procedure|ILND - Inguinal Lymph Node Dissection|
1590404|NCT02305654|Drug|Paclitaxel|Dose 175mg/m2 as part of TIP regimen.
1590405|NCT02305654|Drug|Ifosfamide|Dose 900mg/m2 as part of TIP regimen.
1590406|NCT02305654|Drug|Cisplatin|Dose 15mg/m2 as part of TIP regimen (neoadjuvant chemotherapy arm) Dose 40mg/m2 for use concurrently with raditotherapy (chemoradiotherapy arm)
1590407|NCT02305654|Radiation|Intensity modulated radiation treatment (IMRT)|
1590408|NCT02305654|Procedure|Prophylactic PLND - pelvic lymph node dissection|
1590409|NCT02305602|Biological|VentriGel|VentriGel will be injected via MyoStar catheter after NOGA mapping
1590410|NCT02305589|Drug|Sugammadex|Muscle relax reversing agent
2009029|NCT03325413|Procedure|Regional anesthesia|Regional anesthesia whenever possible
1590413|NCT02305550|Device|electrical pulsed plasma discharge synthesis of nitric oxide|An NO generator was designed and developed by electrical pulsed plasma discharge nitric oxide from atmospheric nitrogen and oxygen. This generator has been fabricated by the investigators and it is not commercially available.
1590414|NCT02305537|Behavioral|McLean Anxiety Mastery Program|Cognitive-Behavioral Therapy with Exposure and Response Prevention
1590415|NCT02305524|Device|ETView VivaSight SL|Intubation using ETView VivaSight SL
1590416|NCT02305524|Device|Macintosh laryngoscope|intubation with macintosh laryngoscope with conventional tube
1590417|NCT02305511|Device|Peripheral venous catheterization|Cannulation using standard method
1590418|NCT02305511|Device|Jamshidi|intraosseous access using the Jamshidi device
1590419|NCT02305511|Device|BIG|intraosseous access using the BIG device
1590420|NCT02305511|Device|Cook|intraosseous access using the Cook device
1590421|NCT02305511|Device|EZIO|intraosseous access using the EZIO device
1590422|NCT02305498|Other|Vigorous yoga practice|
1590423|NCT02305498|Other|Restorative (gentle) yoga practice|
1590424|NCT02305485|Device|NeoVas BCS|Subjects receiving NeoVas BCS
1590425|NCT02305485|Device|XIENCE PRIME EECSS|Subjects receiving XIENCE PRIME EECSS
1590426|NCT02305472|Device|NeoVas BCS|Subjects receiving NeoVas BCS
1590427|NCT02305459|Device|Yttrium-90 loaded SIR-Spheres microspheres|Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
1590428|NCT02305459|Behavioral|QLQ-C30 with HCC module|In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.
1590429|NCT02305446|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|One dose (0.5 mL) vaccine administered by intramuscular (IM) injection in the deltoid area of the non-dominant arm.
1590430|NCT02305433|Other|Home-based physiotherapy|Each physiotherapy session includes muscle strength and endurance training (especially for lower limbs), balance and coordination training and functional training. Functional training includes walking exercises and ADL (activities of daily living) exercises. In addition the physiotherapist gives counseling on nutrition.
1590431|NCT02305420|Device|EmbryoGen/ BlastGen media|Embryos will be cultured in media containing Gm-CSF (EmbryoGen/BlastGen)
1590432|NCT02305420|Device|Standard Cook sequential media|Standard Cook IVF media will be used in the control arm
1590433|NCT02305407|Procedure|Surgical Revascularization|Most patients in this group will be performed combined procedures of superficial temporal to middle cerebral artery bypass (STA-MCA) and encephalo-duro-myo-synangiosis (EDMS). Patients not suitable for combined procedures will be performed EDMS.
1590434|NCT02305407|Other|Conservative treatment|Patients will be medically treated with antiplatelets, antiepileptics, antihypertensives and vasodilators depending on the presentation.
1590435|NCT02305394|Drug|ketamine and propofol|propofol 1.5 mg/kg and ketamine 0.3 mg/kg will be administered to participants separately by intravenous infusion.
1590436|NCT02305394|Drug|propofol and normal saline|propofol 1.5 mg/kg and normal saline [weight(kg)×0.3÷10]ml will be administered to participants separately by intravenous infusion.
1590437|NCT02305381|Drug|semaglutide|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
1590438|NCT02305381|Drug|placebo|Injected subcutaneously (s.c. under the skin) once-weekly. As add-on to the pre-trial background medication.
1590439|NCT02305368|Other|Chimio-oncogramme|Cells fragment are cultured for 7 days. The effects of chemotherapy are studied on these cells through chimio-oncogramme.
1590440|NCT02305355|Drug|Omega-3-acids ethylesters 90 4g|
1590441|NCT02305355|Drug|Pravastatin, Simvastatin, Atorvastatin, Rosuvastatin|
1590442|NCT02305329|Drug|BIA 9-1067|
1590443|NCT02305316|Drug|BIA 9-1067 non-micronized|
1590444|NCT02305316|Drug|BIA 9-1067 micronized|
1590449|NCT02305264|Drug|18F-DPA-714 and 18F-FDG|"Positron emission tomography (PET) imaging following the injection of 2 radiotracers (here considered as the drugs): 1) 18F-DPA-714 ii) 18F-FDG. PET -18F-DPA-714, dose 5mCi (185MBq), will be injected via an arm intravenous catheter.
18F-FDG , dose 5mci(185MBq), will be injected via an arm intravenous catheter."
1590450|NCT02305251|Other|Survey|Standard Gamble Survey
1590451|NCT02305238|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Aflibercept 2mg is intravitreally injected.
1590452|NCT02305225|Behavioral|Sleep Deprivation|
1590453|NCT02305212|Behavioral|Cogmed|
1590454|NCT02305199|Drug|Hartmann's solution|Hartmann's solution containing 200 mg/L of calcium chloride, 300 mg/L of potassium chloride, 6 g/L of Sodium chloride, 3.1 g/L of Sodium lactate.
1590455|NCT02305199|Drug|Normal saline|Fluid containing Sodium chloride 9 g/L
1590456|NCT02305186|Drug|Pembrolizumab|Pembrolizumab administered at a dose of 200 mg IV every 3 weeks on days 1, 22, and 43 during concurrent neoadjuvant chemoradiation treatment
1590457|NCT02305186|Radiation|Neoadjuvant Chemoradiation|Chemoradiation with capecitabine (825 mg/m2 orally twice daily, Monday through Friday, on days of radiation only) and radiation (50.4 Gy in 28 fractions over 28 days)
1590458|NCT02305173|Drug|Intravenous Dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before surgery.
1590459|NCT02305173|Drug|intravenous salin water|Patients of the control group received homologated placebo 60 minutes before surgery.
1590460|NCT02305160|Drug|Butantan|Use of Butantan surfactant 100 mg/kg, IT, maximum of 3 doses
1590461|NCT02305160|Drug|Control|The pulmonary surfactants commercially available in Brazil Survanta or Curosurf: 100 mg/kg, IT, maximum of 3 doses.
1590462|NCT02305147|Other|Clinical, biological and imaging followup|Assessment of motor and non motor signs every 12 months. Imaging and blood, cerebral fluid, stools and skin samples for identification of biomarkers of disease phenotype and progression.
1590463|NCT02305134|Drug|Tipepidine Hibenzate|
1590464|NCT02305134|Drug|Placebo|
1590465|NCT02305121|Device|TFNA|All investigated procedures are part of the standard of care treatment. Only the parker mobility score is study-specific. All patients included are followed up from the time point of enrollment until three months after surgery
1590466|NCT02305108|Other|fascial manipulation|"Recruited patients in study's group will be treated with the standard treatment and fascial manipulation.
Specific points of fascial tissue will be treated with a deep friction to improve elasticity.
The number of point treated will be refered to a specific evaluation for each patient.
Fascial manipulation provide 3 session treatment (one treatment for week)."
1590467|NCT02305108|Other|standard treatment|"Before surgery, standard physiotherapy treatment provides an education session about the rehabilitation program tha is going to be execute after surgery.
After surgery 2 daily physiotherapy treatment are implemented: bed exercise as active and passive flex-extension of lower limb, movements for postural change to reach sitting and standing position, walking training."
1590468|NCT02305095|Drug|FDC I/H|All subjects in both groups will be initiated on drug, FDC I/H with dose titrated up to target doses based on clinical guidelines
1590469|NCT02305082|Other|Fast-track group|Enhanced recovery after surgery pathway. Postoperatively, a set of well-defined discharge criteria will be assessed daily at 9:00 and 15:00, as well as pain, nausea, time to flatus, saturation and drain production.
1590470|NCT02305069|Drug|Pioglitazone|Described elsewhere
1590471|NCT02305069|Drug|Insulin|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
1590472|NCT02305069|Drug|Octreotide|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
1590473|NCT02305069|Drug|Glucose|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
1590474|NCT02305069|Drug|Mixed Amino Acids|Administered to simulate the feeding response in study visits. Description of amount administered provided elsewhere.
1590475|NCT02305069|Other|[2H5]phenylalanine|Administered to allow the determination of leg protein breakdown rates in study visits. Description of amount administered provided elsewhere.
1590476|NCT02305069|Other|[1-13C]leucine|Administered to allow the determination of muscle protein synthesis rates in study visits. Description of amount administered provided elsewhere.
1590477|NCT02305056|Drug|C13 N15 Valine|C13 N15 Valine administration
1590478|NCT02305043|Other|non-interventional|non-interventional
1590481|NCT02305017|Drug|BIA 9-1067|BIA 9-1067 50 mg
1590482|NCT02305017|Drug|Paracetamol|Paracetamol 1g
1590483|NCT02304991|Drug|Liquid Peanut Extract|5000mcg/ml peanut protein
1590484|NCT02304991|Drug|Placebo Glycerin SLIT|pure glycerinated saline solution with caramel coloring to match color
1590485|NCT02304978|Biological|Group CRC|blood samples
1590486|NCT02304978|Biological|Group control|Blood samples
1590487|NCT02304965|Behavioral|Daily physical activity|A combination of walking (> 10.000 steps per day) and cycling on a stationary bicycle at home at an individual intensity. For the activity walking patients need to walk at a certain speed (e.g. 3 km/h) in order to be in the range of pulsatility as obtained from their pre-training treadmill test. For cycling a defined power in watt and duration will be given to each patient as defined from the pre-training cycling test.
1590488|NCT02304952|Procedure|Radiofrequency microtenotomy|For the minimally invasive surgery will Arthrocare Topaz MicroDebrider device be used. A small incision will be made and the tip of the device is placed on surface of the tendon to structure and activated for 0.5 second, at 5 mm distance intervals on the tendon creating a grid-like pattern.
1590489|NCT02304952|Other|Eccentric exercise|Eccentric exercise for 3 months. The exercise will be performed once a day with 3 set and 5 reps, women start with 0.5 and men 1.0 kilo with a 10 % increase every week.
1590490|NCT02304952|Device|Arthrocare Topaz MicroDebrider|
1590491|NCT02304939|Procedure|changeover|
1590492|NCT02304939|Device|use of automatic infusion pump|
1590493|NCT02304939|Behavioral|datas collection|
1590494|NCT02304926|Drug|Simvastatin|simvastatin (40 mg/day) for 4 weeks
1590495|NCT02304926|Drug|Ezetimibe|ezetimibe (10 mg/day) for 4 weeks
1591781|NCT02295540|Other|laboratory biomarker analysis|Correlative studies
1590496|NCT02304926|Drug|Simvastatin + Ezetimibe|combined therapy simvastatin (40 mg/day) + ezetimibe (10 mg/day) for 4-week period
1590497|NCT02304913|Other|Hypoglossal acupuncture|
1590498|NCT02304913|Other|Sham acupuncture|
1590499|NCT02304913|Behavioral|Dietary recommendations|
1590500|NCT02304900|Other|white implant|"st intervention (in the month following the inclusion): Randomization of the color of the implant
nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
1590501|NCT02304900|Other|yellow implant|"st intervention (in the month following the inclusion): Randomization of the color of the implant
nd operation (1 to 3 months after the first surgery): Installation of a same color as the first implant operated eye"
1590502|NCT02304887|Drug|Bis, SERM Teriparatide, Denosumab|Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
1590503|NCT02304874|Other|Phlebotomy|
1590504|NCT02304861|Procedure|Viscoat|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision 3% Sodium Hyaluronate, 4% Chondroitin Sulfate (Viscoat, Alcon, Greece) was injected in the anterior chamber
1590505|NCT02304861|Procedure|Visthesia|Cataract extraction surgery performed with the Alcon Infiniti VisionSystem platform. Pupils were dilated with Tropicamide 0.5% (Tropixal, Demo, Greece) and Phenylephrine Hydrochloride 5% (Phenylephrine, Cooper, Greece). Periorbital skin and the lids were cleaned and the conjuctival cul-de-sac was irrigated with povidone iodine (Betadine). Patients received topical anesthesia with propacaine hydrochloride 0.5% drops (3 drops prior to surgery). By means of a 2.75mm, superior-temporal (eleven o'clock), self-sealing, clear-cornea incision sodium hyaluronate 1.5% and lidocaine hydrochloride 1% ophthalmic viscosurgical device (OVD) (Visthesia, Carl Zeiss, Germany) was injected in the anterior chamber
1590506|NCT02304848|Other|DBS (Deep Brain Stimulation)|Applying low frequency and high frequency deep brain stimulation to subthalamic nucleus.
1590507|NCT02304822|Drug|Multiple-dose of Ciprofloxacin prophylaxis|Multiple-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery and within 12 hours after surgery additionally
1590508|NCT02304822|Drug|Single-dose of Ciprofloxacin prophylaxis|Single-dose prophylactic antibiotic of 200mg intravenous ciprofloxacin, 30 minutes before surgery only.
1590509|NCT02304822|Drug|Zero-dose of Ciprofloxacin prophylaxis|Zero-dose of ciprofloxacin prophylaxis with none intravenous ciprofloxacin either preoperatively or postoperatively
1590510|NCT02304809|Drug|Vemurafenib|Vemurafenib is a low molecular weight, orally available, inhibitor of BRAF serine-threonine kinase. Mutations in the BRAF gene which substitute the valine at amino acid position 600 result in constitutively activated BRAF proteins, which can cause cell proliferation in the absence of growth factors that would normally be required for proliferation
1590511|NCT02304796|Behavioral|Unified Cognitive-Behavioral Therapy|"20 weekly sessions (1.5-2 hours each), based on the principles of the Unified Protocol for Trans-diagnostic Treatment of Emotional Disorders (Barlow et al., 2011) adapted for a group format.
The treatment will include 8 different modules of varying length: motivation enhancement, understanding emotions, identifying and monitoring emotions, emotional awareness training, cognitive appraisal and reappraisal, emotional avoidance, emotion driven behaviors, awareness and tolerance of bodily sensations, relapse prevention."
1590512|NCT02304796|Behavioral|Combined Cognitive-Behavioral and Dance/Movement Therapy|20 weekly sessions (1.5-2 hours each), based on combined cognitive-behavioral techniques (psychoeducation, awareness and tolerance of emotions, interoceptive exposures, in-vivo exposures, cognitive flexibility) and dance/movement techniques.
1590513|NCT02304783|Drug|Piroxicam|Patients allocated to this arm received, as a second line treatment of renal colics, a five days treatment with 20 mg piroxicam per day and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
1590514|NCT02304783|Drug|Placebo|Patients allocated to this arm received a five days treatment with Placebo and were contacted at the seventh day by telephone call to investigate the efficacity and the side effects of the treatment.
1590515|NCT02304770|Drug|Aminolaevulinic acid photodynamic therapy|Aminolaevulinic acid mediated photodynamic therapy
1590516|NCT02304757|Drug|99Tc-MDP|99Tc-MDP, H20000218
1590517|NCT02304757|Drug|fosamax|H20080172
1590518|NCT02304757|Drug|Caltrate|Calcium 600 mg and vitamine D3 125iu.
1590519|NCT02304744|Other|Observational study, no intervention.|Observational study, no intervention.
1590520|NCT02304731|Other|Physical Exercise|Incremental running
1590521|NCT02304718|Behavioral|Stationary bike|
1590522|NCT02304705|Drug|Sildenafil|20 mg TID PO for 90 days
1590523|NCT02304705|Drug|Placebo|One capsule TID PO for 90 days
1590524|NCT02304692|Device|Bone anchored hearing aid|
1590525|NCT02304679|Other|Pre-inclusion questionnaires|"(Month -2)
During this visit, the investigator will:
Validate the patient's inclusion and exclusion criteria;
Obtain informed consent from the patient;
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
Prescribe 1 month of PDE5i treatment.
The next visit will be scheduled"
1590526|NCT02304679|Drug|1 month of PDE5i treatment|5 mg Tadalafil per day for 1 month
1590527|NCT02304679|Other|PDE5i follow-up questionnaires|"(Month -1)
During this visit the investigator will:
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Remind the patient that over the next 4 weeks he is not to take any treatments for his condition (wash-out period).
The next visit will be scheduled"
1590551|NCT02304523|Drug|CDFR0613|Preparation 500mL is a mixture of CDFR0613 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
1590696|NCT02303457|Procedure|Open Surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
1590528|NCT02304679|Other|Inclusion questionnaires|"(Day 0)
During this visit the investigator will:
Verify inclusion and exclusion criteria, and proceed with final inclusion
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope in order to respect patient confidentiality.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
Randomize the patient at the end of the visit
The patient will go home with a calendar specifying the time and place of the various visits. The patient should have four weekly LIESWT or sham sessions within the next month. The first session may take place the same day and immediately after the present visit."
1590529|NCT02304679|Device|4 weekly LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
1590530|NCT02304679|Device|4 weekly sham LIESWT (Wave 1) with the RENOVA device|Following final inclusion, patients will have weekly sham LIESWT sessions (one session per week for four weeks). Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
1590531|NCT02304679|Other|Follow-up questionnaires 1 month after Wave 1|"(Month 2)
During this visit the investigator will:
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
1590532|NCT02304679|Other|Follow-up questionnaires 3 months after Wave 1|"(Month 4)
During this visit the investigator will:
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events.
The patient should have four weekly LIESWT sessions within the next month. The first session may take place the same day and immediately after the present visit."
1590533|NCT02304679|Device|8 bi-weekly LIESWT (Wave 2) with the RENOVA device|During the 5th month following final inclusion, all patients will have bi-weekly LIESWT sessions. These will occur twice per week for four consecutive weeks. Particular attention is given to the recording of complications/adverse events. At the end of each session, the patient is asked to evaluate the level of pain that occurred during the session using a visual analog scale.
1590534|NCT02304679|Other|Follow-up questionnaires 1 month after Wave 2|"(Month 6)
During this visit the investigator will:
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
1590535|NCT02304679|Other|Questionnaires via postal mail|Eight, 11, and 14 months after final inclusion, corresponding to 3, 6 and 9 months following Wave 2, the IIEF, SEP2, SEP3, GAQ and EHS questionnaires will be sent to patients via postal mail.
1590536|NCT02304679|Other|Final follow-up questionnaires 12 months after Wave 2|"(Month 17)
During this visit the investigator will:
Have the patient fill out the IIEF, SEP-2, SEP-3, EHS and GAQ questionnaires. Responses are place and sealed in a specifically provided envelope.
Perform a clinical exam; particular attention is given to the recording of complications / adverse events."
1590537|NCT02304666|Procedure|Colonoscopy for biopsies samples|
1590538|NCT02304653|Other|Clinical descision making|Chage in diagnosis before and after the presentation of the reults of CRP and Leucocytes
1590539|NCT02304627|Drug|insulin 338 (GIPET I)|Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
1590540|NCT02304614|Other|3D surface imaging using a non portable and portable camera|The participant will have 3D surface imaging taken of their breasts (the face will not be shown)
1590541|NCT02304614|Other|Patient reported outcome measure (PROM): BREAST-Q|The participant will answer the BREAST-Q questionnaire. This is a patient reported outcome measurement of satisfaction and quality of life after BCT
1590542|NCT02304614|Other|2D photography|The participant will have standard medical photography of their breasts (the face will not be shown)
1590543|NCT02304614|Other|Applanation Tonometry|A small 300g disc is placed on the breast to measure the surface area of contact with the breast to measure compressibility
1590544|NCT02304588|Biological|Mesenchymal stem cells|10-20 x 10^6 cells/20mL
2009030|NCT03325413|Other|Personal aids|Personal orientation aids until anesthesia induction
2009031|NCT03325413|Device|Temperature management|Perioperative warming
1590547|NCT02304562|Biological|UCB Mesenchymal Stem Cells treatment|reduce skin injury
1590548|NCT02304536|Drug|FSH|70 women will receive urinary purified FSH (Fostimon® IBSA, Switzerland) 75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days. The cycle will be cancelled if no follicles exceed 9mm 4 weeks after starting FSH. This was combined with oral metformin (Cidophage® CID, Egypt) 500 mg three times per day
1590549|NCT02304536|Procedure|Laparoscopic ovarian drilling|70 women will have LOD in which the ovaries will be stabilised by grasping the ovarian ligament and monopolar diathermy will be used to do 4-10 punctures in each ovary. The number of punctures will be individualised according to the size of the ovary. Serial vaginal ultrasound scans were done starting from the 10th day of menstruation, the frequency of monitoring will be individualized according to the women's response.
1590550|NCT02304523|Drug|CDFR0612|Preparation 500mL is a mixture of CDFR0612 150mL and water 350mL. A total of 2L (Preparation 1L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
1590744|NCT02303080|Other|MC 50|16.7% maltodextrin, 15.0% fat, 68.2% (50 g) MC
2009032|NCT03325413|Device|Neurmonitoring|Using Bispectral index (BIS) to measure the depth of anesthesia
2009033|NCT03325413|Procedure|Pain catheter|A pain catheter will be used as postoperative pain therapy if possible
1590552|NCT02304523|Drug|Coolprep Powder|Preparation 500mL is a water solution of Coolprep Powder A and B. A total of 3L (Preparation 2L and additional water 1L) will be administrated divided into two in evening before and in early morning at that day of colonoscopy.
1590553|NCT02304497|Other|Platelet Rich Fibrin|Procedure: Platelet Rich Fibrin obtained
1590554|NCT02304484|Biological|Evolocumab|All subjects will receive open-label evolocumab for approximately 2 years (or until the investigator's recommendation of discontinuation, Amgen's recommendation of discontinuation, the subject's decision to discontinue for any reason, or until an administrative decision is made to end the study).
1590559|NCT02304445|Procedure|Transarterial Chemoembolization (TACE)|TACE is a treatment modality where local delivery of an anti-neoplastic agent is performed through the feeding artery of the tumor followed by end embolization of the artery. The goal of TACE is to cause tumor necrosis and tumor control via acute arterial occlusion while preserving as much functional liver tissue as possible.
1590560|NCT02304445|Radiation|TACE+Stereotactic Body Radiotherapy|This intervention adds Stereotactic Body Radiation (SBRT) to TACE therapy. SBRT is the precise administration of large doses of radiotherapy delivered over 1-5 treatments to extra-cranial tumors.
1590561|NCT02304432|Drug|D-cycloserine|Both participants received open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
1590562|NCT02304432|Drug|DCS or placebo|Double-blind placebo-controlled exposures to DCS or placebo x 6 weeks. One participant received exposure to DCS x 6 weeks and then received placebo dosing x 6 weeks. The other participant received exposure to placebo dosing x 6 weeks and then DCS x 6 weeks.
1590563|NCT02304432|Drug|D-cycloserine|Both participants received second open label D-cycloserine (seromycin), 50 mg/d capsule, x 8 weeks.
1590564|NCT02304419|Drug|Galunisertib|Administered orally.
1590565|NCT02304393|Drug|Atezolizumab|Atezolizumab will be administered at fixed dose of 1200 mg intravenously.
1590566|NCT02304393|Drug|RO7009789|RO7009789 will be administered in IA, IB, II and III following dose-escalations as long as the participant experiences clinical benefit in the opinion of the investigator or until unacceptable toxicity.
1590567|NCT02304367|Drug|KRN23|KRN23 is a recombinant fully human immunoglobulin G1 (IgG1) monoclonal antibody (mAb) that binds to and inhibits the activity of fibroblast growth factor 23 (FGF23).
1590569|NCT02304328|Other|Clinical assessment|Patients will be clinically assessed whether they present clinical signs of brain herniation syndromes
1590570|NCT02304315|Biological|GC1102 50,000 IU|a recombinant hepatitis B immunoglobulin
1590571|NCT02304315|Biological|GC1102 80,000 IU|a recombinant hepatitis B immunoglobulin
1590572|NCT02304302|Drug|Memantine|Encapsulated Namenda 10 mg bid (after four week dose escalation protocol)
1590573|NCT02304302|Drug|Placebo|Identically looking placebo capsules bid (after a four-week regimen designed to mimic dose escalation protocol)
1590574|NCT02304289|Drug|Artesunate|Oral Artesunate once-daily for 14 days, dose-escalation
1590577|NCT02304263|Drug|iohexol|5mL bolus of 300 mg/ml iohexol (Omnipaque) over 2 minutes
1590578|NCT02304250|Drug|Dexamethasone|dexamethasone 1ml (5mg)
1590579|NCT02304250|Drug|saline|saline 1ml
1590580|NCT02304237|Drug|Vaginal progesterone|micronized progesterone 200mg/day till 36 weeks 6 days of gestation or premature rupture of membranes
1590581|NCT02304237|Drug|Intramuscular progesterone|hydroxyprogesterone caproate 250mg/ml/week till 36 weeks 6 days of gestation or premature rupture of membranes
1590582|NCT02304224|Other|eye masks|eye masks from 21:00 to 6:00 each night during admission
1590583|NCT02304211|Drug|Insulin|Insulin will be administered either into the radial artery (microdose intervention) or IV (systemic intervention).
1590584|NCT02304198|Drug|Udenafil|Udenafil 50mg tablet
1590585|NCT02304185|Biological|gp140, 50 mcg|Glycoprotein 140 (gp140) vaccine containing 50 microgram (mcg) total protein will be administered intramuscularly on Day 1 and Day 29.
1590586|NCT02304185|Biological|gp140, 50 mcg + Adjuvant|The gp140 vaccine containing 50 mcg total protein mixed with 0.425 milligram (mg) aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
1590587|NCT02304185|Biological|gp140, 250 mcg|The gp140 vaccine containing 250 mcg total protein will be administered intramuscularly on Day 1 and Day 29.
1590588|NCT02304185|Biological|gp140, 250 mcg + Adjuvant|The gp140 vaccine containing 250 mcg total protein mixed with 0.425 mg aluminum phosphate adjuvant will be administered intramuscularly on Day 1 and Day 29.
1590589|NCT02304185|Drug|Placebo|Placebo matched to gp 140 vaccine drug product will be administered intramuscularly on Day 1 and Day 29.
1590590|NCT02304172|Device|Thunderbeat (Group A)|hemostatic device utilized intraoperatively
1590591|NCT02304172|Device|Harmonic (Group B)|hemostatic device utilized intraoperatively
1590592|NCT02304159|Drug|daclatasvir|
1590593|NCT02304159|Drug|Sofosbuvir, Sovaldi|
1590594|NCT02304159|Drug|Ribavirin|
1590595|NCT02304133|Other|Education|
1590596|NCT02304120|Other|Proprioceptive postural training|
1590597|NCT02304120|Other|Treadmill training|
1590655|NCT02303743|Device|Written instructions with visual aids|written instructions with visual aids explaining the procedure and when to begin self-administration of the bowel solution (control group).
1590656|NCT02303730|Drug|Exenatide|The starting dose of exenatide is 5 ug bid, subcutaneously, for 4 weeks, followed by 10 ug bid, subcutaneously, for 20 weeks. If hypoglycaemia (blood glucose<2.9 mmol/l or < 3.9 mmol/l at least 2 times) or serious intolerance occurs, the dose will be adjusted to 5 ug bid, subcutaneously.
1590598|NCT02304120|Other|Conventional physiotherapy|All participating patients will attend usual care according to their treatment plan (taking part in the study does not affect the treatment plan). A physiotherapy referral requests 9 treatments, each of which takes 30 minutes. These will take place twice a week for 4.5 weeks. The study protocol does not dictate the content of the physiotherapy sessions themselves, but detailed documentation of provided treatments is required (therapy documentation sheet). Additionally, the aim of the physiotherapy sessions should always include reduction of muscular imbalances and optimisation of posture.
1590599|NCT02304107|Drug|FSH|75IU daily for 7 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding. If the follicle does not exceed 9mm the dose will be increased by 37.5IU every 7 days
1590600|NCT02304107|Drug|Letrozole|70 women will receive Letrozole (Femara®, Novartis, Switzerland) 2.5mg twice daily for 5 days starting from the 3rd day of menstruation or progesterone withdrawal bleeding.
1590601|NCT02304094|Drug|methylprednisolone|the steroid group shall receive a single injection of 1 mL methylprednisolone [40 mg] and 1 mL 2% lignocaine
1590602|NCT02304094|Other|Manual manipulation|the manipulation group shall have the lesser MTPJs of the affected foot manually manipulated using a high velocity, low amplitude thrust technique
1590603|NCT02304081|Drug|Saxagliptin|competitive inhibitor of human dipepitdylpeptidase (DPP)-IV
1590604|NCT02304081|Drug|Placebo for Saxagliptin|
1590605|NCT02304068|Other|Home monitoring|
1590606|NCT02304068|Other|Hospital assessment|
1590607|NCT02304055|Drug|Carbetocin|100 women with atonic PPH will receive Carbetocin 100 µgm slowly iv.
1590608|NCT02304055|Drug|Oxytocin|100 women with atonic PPH will receive Oxytocin 5IU slowly iv.
1590609|NCT02304042|Drug|Carbetocin|Carbetocin will be given slowly iv after delivery of the anterior shoulder.
1590610|NCT02304042|Drug|Oxytocin|Oxytocin will be given slowly iv after delivery of the anterior shoulder.
1590611|NCT02304029|Device|MRI|
1590612|NCT02304016|Behavioral|Pelvic floor physical therapy|Patients in this arm will be receiving pelvic floor physical therapy
1590613|NCT02304003|Other|Structured Physiotherapy Regimen|Experimental group will be treated with heavy-slow resistance exercises targeted at the rotator cuff tendons, and exercises to improve scapular stability and strength. Glenohumeral mobilisation techniques and and stretching of glenohumeral capsule and pectoralis minor. Rotator cuff tendons and glenohumeral synovia will be irradiated with low level laser according to WALT dosage recommendations . Intervention period is 12 weeks. Three weekly treatment sessions at 0-3 weeks. 4-12 weeks one treatment session weekly , and two days of home-exercise per week.
1590614|NCT02304003|Other|Standard Care|Standard follow up in primary care.
1590615|NCT02303990|Drug|Pembrolizumab|
1590616|NCT02303990|Radiation|Radiotherapy|
1590617|NCT02303977|Drug|Abraxane|
1590618|NCT02303977|Drug|Gemcitabine|
1590619|NCT02303964|Biological|Plasma|Type A thawed plasma (up to 2 units) will be administered to polytrauma subjects randomized to plasma arm of study
1590620|NCT02303964|Drug|Normal saline|Normal saline will be administered to polytrauma subjects randomized to normal saline arm of study
1590622|NCT02303938|Behavioral|physical exercise|Patients in the intervention group will undergo a 6-month home-based exercise intervention. Patients will exercise (e.g., running, biking, swimming) three times per week for 6 months. Session duration will vary between 20 minutes and 45 minutes.
1590623|NCT02303925|Device|NESTER COILS|
1590624|NCT02303912|Drug|Nuc-1031 and Carboplatin|Nuc-1031 IV injection on day 1 and day 8 repeated every 21 days Carboplatin IV infusion on day 1 repeated every 21 days (Total 6 cycles)
1590625|NCT02303899|Drug|Gemcitabine|infusion drug
1590626|NCT02303899|Drug|Imatinib mesylate|oral drug
1590627|NCT02303886|Drug|Methylene blue|In NaCL0.9% 100 ml
1590628|NCT02303886|Drug|Methylene blue|in NaCl 0.9% 100 ml
1590630|NCT02303860|Drug|ORM-12741 MR A|Modified release formulation of ORM-12741
1590631|NCT02303860|Drug|ORM-12741 MR B|Modified release formulation of ORM-12741
1590632|NCT02303860|Drug|ORM-12741 IR|Immediately release formulation of ORM-12741
1590633|NCT02303847|Drug|Ketamine|ultra-low dose oral ketamine twice daily in two different doses over a 2 week period.
1590634|NCT02303834|Device|Continuous Positive Airway Pressure Ventilation (CPAP)|A mask worn over the nose that delivers air under slight pressure.
1590635|NCT02303821|Drug|Carfilzomib|
1590636|NCT02303821|Drug|Dexamethasone|
1590637|NCT02303821|Drug|Mitoxantrone|
1590638|NCT02303821|Drug|PEG-asparaginase|
1590639|NCT02303821|Drug|Vincristine|
1590640|NCT02303821|Drug|Intrathecal (IT) Methotrexate|
1590641|NCT02303821|Drug|Intrathecal Triple Therapy (Intrathecal Cytarabine, Hydrocortisone, and Methotrexate)|
1590642|NCT02303821|Drug|6-Mercaptopurine|
1590643|NCT02303821|Drug|Cyclophosphamide|
1590644|NCT02303821|Drug|Cytarabine|
1590645|NCT02303821|Drug|Daunorubicin|
1590646|NCT02303808|Device|INHALATION WITH PEP DEVICE (Acapella Duet)|Intervention will be performed during 5 consecutive days. The performance order of both arms will be randomized.
1590647|NCT02303795|Drug|Rivaroxaban|Patients assigned to rivaroxaban will receive oral rivaroxaban, 20 mg od. Patients with a calculated creatinine clearance of 30 to 49 mL/min per 1.73 m2 received a reduced dose of rivaroxaban of 15 mg od.
1590648|NCT02303795|Drug|Warfarin|"Patients will take the warfarin once daily (q.d.). The individual doses will be titrated as needed to maintain a target INR of 2.0-3.0.
Patients with 65 > years old, should take warfarin (2,5mg/day) and all others patients should take 5mg/day."
1590649|NCT02303782|Drug|OTX015|
1590650|NCT02303782|Drug|Vidaza (azacitidine)|
1590651|NCT02303769|Drug|Tamsulosin HCL 0.4mg|Tamsulosin HCL 0.4mg once a day
1590652|NCT02303769|Drug|Tamsulosin HCL 0.2mg|Tamsulosin HCL 0.2mg once a day
1590653|NCT02303756|Device|Pillcam® COLON Capsule|colonoscopy
1590654|NCT02303743|Device|Smart Phone Application|Bowel preparation was evaluated using the Harefield Cleansing Scale (HCS). The scale was the primary outcome measure
1590657|NCT02303730|Drug|insulin glargine|"The starting dose of insulin glargine will depend upon the HbA1c level at screening(HbA1c <8% use 0.1 -0.2 U/kg per day;HbA1c >8% use 0.2 -0.3 U/kg per day).
Dose adjustment protocol for insulin glargine (at least 3 determinations of fasting blood glucose per week):
fasting blood glucose(FBG) > 180 mg/dL(10 mmol/l): add 4 U; FBG 140-180 mg/dL(7.8-10 mmol/l): add 2 U; FBG 126-139 mg/dL(7.0-7.8 mmol/l): add 1 U.
If hypoglycemia, reduce insulin glargine by:
blood glucose <70mg/dl（3.9mmol/l）: 10%-20%; blood glucose <40mg/dl（2.2mmol/l）: 20%-40%."
1590658|NCT02303717|Device|Percutaneous coronary intervention|Percutaneous coronary stent implantation
1590659|NCT02303717|Drug|Dual antiplatelet therapy|Dual antiplatelet therapy with aspirin and either clopidogrel, prasugrel or ticagrelor will be recommended for 12 months duration in the Xience stent arm but only 4 months duration in the Synergy stent arm.
1590660|NCT02303704|Procedure|multiport antegrade cardioplegia|Cold blood cardioplegia was used for myocardial protection and just before the removal of the aortic cross-clamp, warm blood shot (normo-kalemic) was started through multi-perfusion set attached to cardioplegia cannula in the aortic root and vein grafts.As contraction of heart started the multiport limb attached to cardioplegia cannula was off and cross clamp was removed .The warm perfusion through the vein grafts was continued at controlled pressures of about 50-70 mmHg, flow rate of 10-30ml/min/graft and temperature of 35-37 oC
1590661|NCT02303704|Procedure|Aortic root antegrade cardioplegia|only cold blood cardioplegia was used for myocardial protection without hotshot.
1590662|NCT02303691|Behavioral|Attention Bias Modification|Excessive attention to threat is theorized to be a critical contributor to chronic anxiety symptoms and related negative health consequences. Attention Bias Modification, which directly targets this mechanism, is a highly cost-effective intervention with growing empirical support for its potential efficacy in clinically anxious populations.
1590663|NCT02303691|Behavioral|Neutral Training|A control version of computerized attention training.
1590664|NCT02303678|Drug|D2C7-IT|D2C7-IT is a single-chain fragment variable (scFv) monoclonal antibody (Mab) fragment immunotoxin with high binding affinity for both EGFRwt- and EGFRvIII-expressing glioblastoma multiforme (GBM) cells.
1590665|NCT02303665|Other|The dual therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction +auricular acupoint therapy
1590666|NCT02303665|Other|The triple therapy|TCM prescriptionⅡof cultivated emotion and assisted reproduction + auricular acupoint therapy+ retention enema of TCM
1590667|NCT02303652|Procedure|Radiofrequency maze procedure|RF energy was used to create continous endocardial and epicardial lesions mimicking most of the left atrial incisions set as described in the Cox Maze III procedure. In all patients a bipolar device was used (Cardioblate BP2 Irrigated RF Surgical Ablation System®, Medtronic Inc, Minneapolis, MN, USA).
1590668|NCT02303652|Procedure|Transthoracic echocardiography|Contemporary to clinical follow up, all patients were evaluated with 2-dimensional transthoracic echocardiography (Philips ultrasound system (iE33®, Andover, MA, USA)) at 3,6,12,24 months in order to specifically monitor the evolution of cardiac chambers dimensions and systolic performance and to record left and right atrial contractility presence.
1590669|NCT02303639|Procedure|Radiofrequency catheter ablation|Catheter ablation with an open-irrigated tip ablation catheter and 3D electroanatomical mapping
1590670|NCT02303639|Drug|Antiarrhythmic drug therapy|Amiodarone (or sotalol) for prevention of VT/VF relapses
1590673|NCT02303613|Other|Mapping|Mapping of current triage situation regarding 30 days mortality
1590674|NCT02303600|Drug|Montelukast|Patients in biomarker guided positive treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.). Patients in biomarker guided negative treatment arm were given placebo tablets . Patients in standard treatment arm were given Montelukast Sodium Tablets (p.o., 10mg, q.d.) . All treatment regimens lasted for 10 days and no other antitussive/decongestant or bronchodilators are given to any patients.
1590675|NCT02303600|Other|Placebo|Patients in biomarker guided negative treatment arm were given placebo tablets (main excipient lactose monohydrate) (p.o., 10mg, q.d.) .
1590676|NCT02303587|Drug|methylprednisolone|
1590679|NCT02303561|Behavioral|CHAMP|Families assigned to this arm will receive tailored asthma education and behavioral skills focused on improving asthma and weight management.
1590680|NCT02303561|Behavioral|Health education|Families assigned to this arm will receive tailored asthma education and general health education on a variety of topics.
1590681|NCT02303548|Drug|Sodium bicarbonate|Administer Sodium bicarbonate 50 mEq IV over 2 minutes
1590682|NCT02303548|Drug|Normal saline|Placebo
1590683|NCT02303535|Procedure|Cardiac Surgery|All patients with congential and acquired heart disease treated by cardiac surgery procedures.
1590684|NCT02303535|Procedure|Therapeutic cardiac catheterisations procedures|All patients with congential and acquired heart disease treated by therapeutic cardiac catheterisations procedures .
1590685|NCT02303522|Other|Other: not applicable - observational study|No intervention exists as this is a retrospective observational study
1590686|NCT02303509|Drug|UCB5857 Part 1|"Active substance: UCB5857
Pharmaceutical form: Capsule
Concentration: 1 mg, 5 mg, 10 mg or 15 mg
Route of administration: Oral"
1590687|NCT02303509|Drug|UCB5857 Part 2|"Active substance: UCB5857
Pharmaceutical form: Capsule
Concentration: 5 mg, 8 mg, 15 mg
Route of administration: Oral"
1590688|NCT02303509|Other|Placebo|"Active substance: Placebo
Pharmaceutical form: Capsule
Concentration: Avicel PH 102, 50 mg
Route of administration: Oral"
1590689|NCT02303496|Biological|Platelet Rich Plasma Cream|Cream Containing Platelet Rich Plasma and Oleaginous Base
1590690|NCT02303496|Biological|Placebo - Sterile Water Cream|Cream Containing Sterile Water and Oleaginous Base
1590691|NCT02303483|Dietary Supplement|Nicotinamide riboside (NIAGEN TM, ChromaDex, CA, USA )|
1590692|NCT02303483|Dietary Supplement|Placebo|
1590693|NCT02303470|Behavioral|Vigorous Exercise|High-intensity interval training alternates 30 seconds of vigorous exercise with 30 seconds of low-intensity recovery for a total of 15 minutes.
1590694|NCT02303470|Behavioral|Moderate Exercise|
1590695|NCT02303457|Procedure|CO2 Laser surgery|Patients were randomly assigned to CO2 laser surgery group and open Surgery group.
1590701|NCT02303418|Drug|Carbetocin|Carbetocin will be given slowly iv after delivery of the baby
1590702|NCT02303418|Drug|Oxytocin|Oxytocin will be given slowly iv after delivery of the baby
1590703|NCT02303405|Drug|Hydroxychloroquine|Anti-inflammatory and anti-malarial agent
1590704|NCT02303405|Drug|Pioglitazone|Anti-hyperglycemic agent
1590705|NCT02303392|Drug|Selinexor|Given PO
1590706|NCT02303392|Drug|Ibrutinib|Given PO
1590707|NCT02303392|Other|Pharmacological Study|Correlative studies
1590708|NCT02303392|Other|Laboratory Biomarker Analysis|Correlative studies
1590709|NCT02303379|Other|Continuous Endurance Training|Endurance training with constant work load 31min at 65-75% Hrmax
1590710|NCT02303379|Other|Pyramid Training|One pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block of 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
1590711|NCT02303379|Other|High-intensity interval training|HIT: 4x4 min intervals at85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min.
1590714|NCT02303340|Radiation|Dual Energy X-ray Absorptiometry|
1590715|NCT02303327|Radiation|EBRT + HDR brachytherapy boost|Standard radiotherapy (EBRT, 23 fractions) with the addition of High Dose-Rate (HDR) brachytherapy boost within 3 weeks of beginning or finishing the EBRT.
1590716|NCT02303327|Radiation|Hypofractionated Dose Escalation Radiotherapy|Radiation therapy (higher radiation dose per treatment) will be given once a day, five days a week, over approximately 5 weeks.
1590717|NCT02303327|Drug|Androgen deprivation therapy|28 months of androgen deprivation therapy (injections every 4 months for a total of 28 months)
1590718|NCT02303314|Drug|Trigonella Foenum-graecum Seed Extract|
1590719|NCT02303314|Drug|Drug: Placebo|
1590720|NCT02303301|Dietary Supplement|Probiotics|Cultures from the oropharynx
1590721|NCT02303301|Dietary Supplement|Placebo|Cultures from the oropharynx
1590722|NCT02303288|Device|Argus II Retinal Prosthesis System|The Argus II System is designed to provide visual function to individuals with severe to profound vision loss due to outer retinal degeneration. It consists of implanted and external components. The implant is an epiretinal prosthesis that is surgically implanted in and around the eye. The external equipment includes glasses and a video processing unit (VPU). The glasses include a miniature video camera, which captures video images, and a coil that sends data and stimulation commands to the implant. The VPU converts the video images into stimulation commands and is body-worn. The Argus II System operates by converting video images into electrical energy that activates retinal cells, delivering the signal through the optic nerve to the brain where it is perceived as light.
1590723|NCT02303275|Behavioral|Lifestyle Change|"Intervention: Lifestyles Change Program (LCP)
The LCP is a 12-week multi-disciplinary program that incorporates a holistic approach to chronic disease management, which will be tailored to our study population, patients with chronic heart failure. The core of the LCP includes:
Clinician, Dietician, Exercise physiologist, Counselor, Nurse Case Manager Medical oversight by board-certified Cardiologist, Exercise prescription, Stress management classes (yoga, meditation, guided imagery), Group support, lifestyle change lectures, body composition analyses, grocery store tour, cooking classes, Music Wellness, and resiliency classes."
1590724|NCT02303275|Behavioral|Lifestyle Change|The lifestyle change program consists of classes conducted three times a week for 12 weeks at the Scripps Center for Integrative Medicine. Each day participants will spend about four to five hours in a variety of classes such as monitored exercise, group support, mindful-yoga and meditation, vegetarian cooking classes, music-centered wellness, mind-body lectures, and resiliency training.
1590725|NCT02303262|Drug|Mocetinostat|
1590726|NCT02303262|Drug|Gemcitabine|
1590727|NCT02303249|Other|Review of discharges and cross-sectoral video conferencing immediately after discharge|The intervention is video conference which is randomized and is an intervention that is assigned by the investigator.
1590728|NCT02303223|Drug|Propofol|
1590729|NCT02303210|Device|hearing aid NaidaUP|Standard Power Hearing instruments including different frequency lowering techniques
1590730|NCT02303210|Device|hearing aid NaidaSP|Standard Power Hearing instruments including different frequency lowering techniques
1590731|NCT02303197|Drug|ChiNing decoction|ChiNing decotion was reformed by Liangge San that was stemed from Prescriptions of the Bureau of Taiping People.
1590732|NCT02303184|Drug|suprachoroidal CLS-TA + IVT aflibercept|suprachoroidal injection of CLS-TA following a 2 mg intravitreal injection of aflibercept
1590733|NCT02303184|Drug|suprachoroidal sham + IVT aflibercept|suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
1590734|NCT02303171|Drug|Enoxaparin|Women will be given Enoxaparin throughout pregnancy in a dose of 40 mg/day subcutaneously (SC)
1590735|NCT02303171|Drug|Warfarin|Women will be given Enoxaparin (40 mg/day SC) in the first trimester then Warfarin (3-5 mg/day) after the first trimester until termination of pregnancy
1590736|NCT02303132|Other|Ussing experiment|fresh colon mucosa (biopsy) of all participants will be mounted in an Ussing chamber and exposed to NSAIDs / PPI / control.
1590737|NCT02303119|Drug|Rituximab IV|intra-venous, 375 mg/m²
1590738|NCT02303119|Drug|Rituximab SC|sub-cutaneous, 1400 mg
1590739|NCT02303106|Drug|Lamotrigine|
1590740|NCT02303093|Biological|Octagam IVIG 5% or 10%|
1590741|NCT02303080|Other|Control (WPM 0)|85.0 % maltodextrin,15.0% fat, 0% WPM
1590742|NCT02303080|Other|WPM 30|43.7% maltodextrin, 15.2% fat, 41.1% (30 g) WPM
1590743|NCT02303080|Other|WPM 50|16.3% maltodextrin, 15.2% fat, 68.5% (50 g) WPM
2009034|NCT03325400|Other|Toothpaste non-fluoride and fluoride|"Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm).
Participants have used toothpaste for four months. The first two months they used non-fluoride toothpaste, after which, for the next two months, they used toothpaste containing fluoride of the same manufacturer and similar composition. The tested kinds of toothpaste were applied twice a day, in the morning and evening, for three minutes in the amount of 1 g (≈2 cm). Contemporary, participants did not use other agents for oral hygiene such as mouthwash or topical fluoridation."
2009035|NCT03325387|Drug|LY3305677|Administered SC
1590747|NCT02303041|Drug|Buparlisib|Given PO
1590748|NCT02303041|Drug|Sonidegib|Given PO
1590749|NCT02303028|Drug|Topotecan and Pazopanib|Dose escalation of low-dose metronomic Topotecan with a fixed dose of Pazopanib
1590750|NCT02303002|Biological|Botulinum Toxin Type A|Intramuscular injection (IM)
1590751|NCT02303002|Biological|Active Comparator botulinum toxin|IM injection
1590752|NCT02303002|Biological|Placebo Comparator|IM injection
1590753|NCT02302989|Drug|Ranibizumab 0.5mg|
1590754|NCT02302976|Drug|cocaine hydrochloride|
1590755|NCT02302976|Drug|exenatide|
1590756|NCT02302976|Drug|placebo|
1590757|NCT02302963|Device|AP System (DiAs or inControl) with USS Virginia|Subject will participate in two 24-hour study insulin pump and AP System training sessions. At the conclusion of each training session, subject will wear the equipment at home for a total of 5 weeks.
1590758|NCT02302963|Device|Sensor-Augmented Pump Therapy (placebo)|Subject will participate in 5 weeks use of CGM and personal insulin pump at home.
1590759|NCT02302950|Drug|raltegravir|HIV therapy component
1590760|NCT02302937|Procedure|Group A will undergo laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm )|laparoscopic TEP inguinal hernia repair with 3 ports (10 mm , and 2 ports of 5 mm ).
1590761|NCT02302937|Procedure|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port|Group B will undergo laparoscopic TEP inguinal hernia repair with a single port LESS (12 to 15 mm transumbilical).
1590762|NCT02302911|Behavioral|Early intensive behavioral intervention|at least 10 hours a week of early intensive behavioral intervention
1590763|NCT02302911|Behavioral|Early intensive eclectic intervention|at least 10 hours a week of early intensive eclectic intervention
1590764|NCT02302911|Other|Treatment as usual|receipt of any Intervention that is less intensive than 10 hours a week
1590765|NCT02302898|Behavioral|Eating Behavior Evaluation|Scores will be measured on binge eating behaviors and an increased craving for sweets.
1590766|NCT02302898|Other|Measurement of Functional gastric volume|The functional gastric volume is the amount of food or liquid that can be consumed to a feeling of comfortably full in one meal.
1590767|NCT02302898|Other|Measurement of gastric pouch and GJ size|Anatomical dimensions of the gastric pouch and GJ will be determined by using an articulated measuring tool during upper GI tract endoscopy.
1590768|NCT02302885|Other|Blood collection|Blood Collection
1590769|NCT02302872|Device|ARTO System|
2009036|NCT03325387|Drug|Placebo|Administered SC
2009037|NCT03325374|Other|Questionnaires and examination|None this is an observational study only
2009038|NCT03325361|Other|Tube drain insertion|A de-Pezzer catheter was placed transanally after the creation of the anastomosis, secured to the buttocks, and connected to a urine bag to allow monitoring the amount and the color of the drainage. The catheter was removed on the 3rd day postoperative if the volume collected was insignificant.
2009039|NCT03325348|Drug|Nifedipine 10 mg|Nifedipine 10mg oral tablet with 1 ml 0.9% n/saline will be given to patients every 15 min uptil one hour
2009040|NCT03325348|Drug|Labetalol|IV labetalol 20 mg & mint tablet will be given to patients every 15 min until one hour
2009041|NCT03325335|Drug|Midazolam premedication|Patients in Group P received midazolam (0.05 mg/kg, intramuscular injection) 30 minutes before induction of general anesthesia.
1590776|NCT02302846|Drug|Ixazomib|4 mg by mouth on Days 1, 8 and 15 of each 28-day cycle.
1590777|NCT02302833|Drug|Cabozantinib|60 mg by mouth once daily.
1590778|NCT02302833|Behavioral|Questionnaire|Questionnaire completion regarding symptoms completed at baseline, 4 days before starting Cabozantinib, and weekly while taking the drug.
1590779|NCT02302820|Other|Advance Care Planning Intervention|"ACP Intervention The ACP intervention involves structured discussions between patients and NCCs using 1 of 4 decision aids in order to clarify patient's values, goals and preferences for living well and sharing goals with family, SDM/HCA, and the health care team. Because the time needed for reflective thinking, decision making and discussions with family are important components of the ACP process, the intervention is designed to occur in at least 3 NCC/patient visits over approximately 4 weeks. The NCC will assist patients in the ACP process following scripts specific to each of the decision aids."
1590780|NCT02302807|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab will be administered intravenously at a fixed dose of 1200 mg on Day 1 of each 21-day cycle.
1590781|NCT02302807|Drug|Docetaxel|Docetaxel 75 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
1590782|NCT02302807|Drug|Paclitaxel|Paclitaxel 175 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
1590783|NCT02302807|Drug|Vinflunine|Vinflunine 320 mg/m^2 will be administered intravenously on Day 1 of each 21-day cycle.
1590784|NCT02302794|Procedure|open surgery|Patients in this arm undergo radical resection of gastric cancer in open surgery.Open surgery is a conventional technique for gastric cancer patients.
1590785|NCT02302794|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for gastric cancer patients.
1590786|NCT02302781|Other|Questionnaires|Several validated questionnaires, depending on moment in fertility work up or treatment.
1590787|NCT02302768|Dietary Supplement|Selenomethionine|
1590788|NCT02302768|Other|Placebo|
1590928|NCT02301650|Drug|Tenofovir|mothers use Tenofovir in late pregnancy
1590789|NCT02302755|Drug|TP10|All patients will be enrolled through the University of Iowa. This study will follow a patient-specific dose-escalation scheme during the Induction Period and subsequent TP10 dose adjustments based on complement levels during the Maintenance Period.
1590790|NCT02302729|Dietary Supplement|Micronutrients|Nutrient Quantity Nutrient Quantity Zinc 9 mg Copper 0.3 mg Iron 12.5 mg Vitamin D3 5 mg Folic Acid 160 mcg Vitamin E 5 mg Iodine 90 mcg Calcium 200 mg Vitamin A 250 mg Phosphorus 150 mg Vitamin C 40 mg Magnesium 40 mg Vitamin B12 0.9 mcg Selenium 17 mcg Thiamine 0.5 mg Manganese 0.17 mg Niacin 0.5 mg Biotin 8 mg Riboflavin 6 mg Vitamin B5 1.8 mg Vitamin B6 0.5 mg
1590791|NCT02302729|Behavioral|Responsive feeding|"Strategy
Mother ensures that feeding area is set up with infant and mother able to see one another.
Mother mirrors the infant's facial expressions to attract the infant's attention.
Mother interprets infant's behavior with a positive voice, Oh, you like the spinach. Mother extends infant's behavior by saying, Oh the cereal is all gone and doing a consistent hand signal Mother models eating, makes positive comments in a nurturing tone. Mother offers finger food or use of utensil"
1590792|NCT02302729|Dietary Supplement|Placebo|Riboflavin Vitamin B2
1590796|NCT02302703|Other|low FODMAP diet vs Gluten free diet|
1590797|NCT02302690|Biological|Blood sample for immunology|
1590798|NCT02302664|Procedure|PRP Injection into Achilles tendon rupture gap|PRP injection delivered into the tendon rupture gap Intervention - PRP Injection: The injection is the intervention. A blood sample is withdrawn from patient. Away from patient part of sample is spun down in centrifuge to produce 'Platelet Rich Plasma' (PRP). Patient returns to treatment area and their own PRP is then injected into tendon rupture gap. This is carried out by a surgeon or extended scope physiotherapist, generally in the outpatient clinic, after a local anaesthetic has been applied. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Remaining blood sample sent for analysis.
1590799|NCT02302664|Procedure|Imitation Injection into Achilles tendon rupture gap|Imitation injection delivered into the tendon rupture gap Sham - Imitation Injection: The injection is the intervention. A blood sample is withdrawn from patient. Treatment is prepared. Patient returns to treatment area and a needle (no syringe) is inserted and held into tendon rupture gap to mimic injection (after local anaesthetic has been applied). No active ingredient given. Carried out by surgeon or extended scope physiotherapist, generally in the outpatient clinic. Patient is lying face down during procedure, unaware of treatment given to tendon at back of leg. Blood sample sent for analysis.
1590800|NCT02302651|Device|MR guided High Intensity focused ultrasound|High Intensity Focused Ultrasound is a totally non-invasive procedure that can destroy tumors transcutaneously; safety and efficacy profile are dramatically increased by the MRI guidance
1590801|NCT02302638|Other|embryo culture in different single-step media|Half of each patient's oocytes will be randomly allocated to be cultured either in Sage 1-step medium (Origio) or in CSC medium (Irvine Scientific) for up to six days following oocyte retrieval.
1590802|NCT02302625|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy based on exposure and response prevention. The treatment also incorporates mindfulness training as a means to increasing tolerance for aversive thoughts and emotions associated with AD. The treatment is delivered by a licensed psychologist and comprises 10 individual weekly sessions.
1590803|NCT02302612|Behavioral|CREATE Wellness|Patients allocated to the intervention arm will receive three group sessions with between visit contacts designed to increase activation and engagement with their care plans. They will also continue to be enrolled in the KP PHASE program
1590804|NCT02302612|Other|Usual Care Control|Patients allocated to the control arm will continue to receive usual care, including disease management within the KP PHASE program.
1590805|NCT02302599|Biological|Umbilical cord mesenchymal stem cells|Infusion treatment
1590806|NCT02302599|Biological|Controlled suspension liquid|Infusion treatment
1590807|NCT02302586|Drug|Thoracic paravertebral block (TPVB)|Thoracic paravertebral block (TPVB) is being performed by injecting 5 mL of Bupivacaine 0.5% to 4 consecutive level of paravertebral spaces between T4 and T8 by using landmark technique
1590808|NCT02302586|Drug|Patient Controlled Analgesia (IV PCA)|IV morphine patient controlled analgesia (PCA) is being used in the postoperative period for 48 hours. Basal infusion: 0.3 mg/kg/h, Bolus: 1 mg, Lock-out time: 20 min, 4-h limit: 10-12,5 mg
1590809|NCT02302573|Drug|contast-enhanced ultrasound with sonovue|contast-enhanced ultrasound with sonovue
1590810|NCT02302547|Drug|triple therapy|Dosage treatment and usual prescription
1590811|NCT02302547|Drug|dual therapy|1 tablet (200mg/245mg) daily for 48 weeks
1590812|NCT02302534|Device|MRI|MRI
1590813|NCT02302521|Device|Multiplex Sensitivity Encoding (MUSE)|It is an algorithm for MRI post-processing/image reconstruction (see reference: Chen).
1590814|NCT02302508|Drug|Clopidogrel, Prasugrel, Ticagrelor|PK and PD parameters will be compared between groups and comparison will be performed between antiplatelet agents
1590815|NCT02302495|Drug|Carfilzomib|"DOSING REGIMEN.
The regimen will have 2 parts:
Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².
In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.
Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study."
1590816|NCT02302482|Other|The Lawton Instrumental Activities of Daily Living score (IADL), and the disability assessment of dementia score (DAD-6|
1590817|NCT02302469|Drug|Revlimid|Three cohorts of subjects will be successively exposed to escalating doses of Lenalidomide (15, 20 and 25mg once daily on days 1-21 of a 28 day cycle).
1590818|NCT02302456|Drug|Tranexamic Acid|Intravenous administration of a 10 mL solution containing 1g of tranexamic acid within 2 minutes of birth and routine prophylactic IV injection of oxytocin
1590819|NCT02302456|Drug|Placebo|Intravenous administration of 10 mL of 0.9% sodium chloride solution within 2 minutes of birth and routine prophylactic IV injection of oxytocin
1590820|NCT02302443|Biological|HM12470|Single dose subcutaneous administration ranging from a very low dose to high dose
1590821|NCT02302443|Biological|Active comparator|Single dose subcutaneous administration of active comparator
1590822|NCT02302430|Drug|Oxytocin|20 International Units Intranasal Oxytocin
1590823|NCT02302430|Other|Placebo comparator|Saline nasal spray
2009042|NCT03325335|Drug|Remifentanil infusion|Target controlled infusion of remifentanil (4ng/ml) was used for induction of anesthesia based on the pharmacological models of Minto. After intubation, remifentanil (2 ng/ml) was infused until incision time. (Both groups)
2009043|NCT03325335|Drug|Propofol infusion|Target controlled infusion of propofol (4.0 μg/ml) was used for induction of anesthesia based on the pharmacological models of Marsh. After intubation, propofol (3.0μg/ml) was infused until incision time. (Both groups)
1590826|NCT02302404|Drug|GSK2982772 solution|Clear, colorless solution containing GSK2982772 in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
1590827|NCT02302404|Drug|GSK2982772 capsule|Size 00 White Opaque capsule containing GSK2982772 as white to almost white solid. Administered orally with water for dosing from 5 to 120 mg
1590828|NCT02302404|Drug|Placebo solution|Clear, colorless solution containing placebo in water with 5% ethanol (0.1mg/mL). Administered orally in required volumes for dosing less than 5mg
1590829|NCT02302404|Drug|Placebo capsule|Size 00 White Opaque capsule containing Placebo as white to almost white solid
1590830|NCT02302391|Other|PK analysis|Quantification of Serum Levels and subsequent pharmacokinetic (PK) modelling.
1590831|NCT02302378|Procedure|Lumbar paramedian approach at L3-L4 interspace|Spinal anesthesia will be performed via a lumbar paramedian approach at L3-L4 interspace using 12.5mg 0.5% Bupivacaine (preservative free)
1590832|NCT02302378|Procedure|Taylor's approach (paramedian approach at L5-S1 interspace)|Spinal anesthesia will be performed via Taylor's approach (paramedian approach at L5-61 interspace) using 12.5mg 0.5% Bupivacaine (preservative free)
1590833|NCT02302365|Device|Spectra Optia® Apheresis System|White Blood Cell Depletion
1590834|NCT02302352|Other|Probiotic|Probiotic 1g once a day by mouth for 8 weeks
1590835|NCT02302352|Other|Placebo|Maltodextrin 1g, manufactured to mimic the probiotic, once a day by mounth for 8 weeks
1590836|NCT02302339|Drug|glembatumumab vedotin|
1590837|NCT02302339|Drug|glembatumumab vedotin and varlilumab|
1590838|NCT02302339|Drug|glembatumumab vedotin and PD-1 targeted checkpoint inhibitor (nivolumab OR pembrolizumab)|
1590839|NCT02302326|Drug|Metformin|Dose: metformin (1700 mg / day) for 12 weeks
1590840|NCT02302326|Dietary Supplement|Myo-inositol + folic acid|Dose: Ovusitol® (4 g myo-inositol plus 400 micrograms of folic acid/day) for 12 weeks
1590841|NCT02302313|Device|CO2 laser and ANI monitor|Painful skin stimuli of variable intensity will be delivered by a CO2 laser used at the power of 0.3 W for each stimulation (6/phases) and this for each of the 3 phases (critical consciousness or hypnosis). During each stimulation, ANI values will be identified by the Physiodoloris ® monitor, through 3 standard ECG electrodes placed on the thorax of the subject.
1590842|NCT02302300|Device|Manufacturer STELLAR 150|5 days of non-invasive ventilation at two levels of pressure from it pre-operative, followed by 5 days in post-operative.
1590843|NCT02302287|Dietary Supplement|Ketoacids diet|Ketoacids diet for 6 months: protein 0,3-0,5 g/bw/day (animal protein 0 g/day, plant protein 30-40 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 0,6-0,8 g/day; sodium 6 g/day, potassium 2-4 g/day; mixture of essential aminoacids and ketoacids 0,05 g/kg ideal bw/day
1590844|NCT02302287|Other|Mediterranean diet|Mediterranean diet for 6 months: protein 0,7-0,8 g/bw/day (animal protein 30-40 g/day, plant protein 40-50 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 2,5-3 g/day, potassium 2-4 g/day
1590845|NCT02302287|Other|Free diet|Free diet for 3 months: protein 1 g/body weight/day (animal protein 50-70 g/day, plant protein 15-20 g/day); energy 30-35 kcal/bw/day; Calcium 1,1-1,3 g, phosphate 1,2-1,5 g/day; sodium 6 g/day, potassium 2-4 g/day;
1590846|NCT02302274|Drug|flecainide iv|infusion over 10 min
1590847|NCT02302248|Behavioral|Crowdsourcing reappraisal intervention|3 week access to a web-based crowdsourcing reappraisal platform.
1590848|NCT02302248|Behavioral|Expressive writing intervention|3 week access to a web-based expressive writing platform.
1590849|NCT02302235|Other|Ketogenic Diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction.
1590850|NCT02302235|Other|Standardized Diet|Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
1590851|NCT02302222|Device|Customizable Dressing with ActiV.A.C. Therapy Unit|
1590852|NCT02302222|Device|Standard of Care Dressing|
1590853|NCT02302209|Drug|Oxytocin|
1590854|NCT02302209|Other|Placebo Comparator|
1590855|NCT02302196|Procedure|Autologous Fat Grafting of the Breast|In fat grafting, fat tissue is removed from other parts of the body; usually thighs, belly, and buttocks by liposuction. The tissue is then processed and injected into the breast area to reconstruct or recreate the breast. The fat will be removed from by a narrow surgical instrument (cannula) through a small incision. Then the fat will be prepared in a specific way before being replaced back in the body. This preparation may include washing, filtering, and centrifugation (spinning) of the fat. The fat is then placed into the desired area of the breast using either a smaller cannula or needle.
1590856|NCT02302196|Other|Control Arm|Retrospective chart review for women who have undergone standard breast reconstruction for lumpectomy.
1590857|NCT02302183|Device|FreeO2 v2.0 automatic adjustment|
1590858|NCT02302183|Device|FreeO2 v2.0 data collecting|
1590859|NCT02302170|Biological|H. pylori vaccine|
1590860|NCT02302170|Biological|placebo|
2009044|NCT03325309|Other|Home-based cycling|A single outpatient supervised session followed by a 3-month home-based cycling program tailored to patients' preferences
2009045|NCT03325296|Drug|LEO 124249|Ointment containing LEO 124249
2009046|NCT03325296|Other|Ointment vehicle|Ointment without active ingredients
2009047|NCT03325283|Device|ProtEmbo Cerebral Protection System|A catheter-based embolic deflection device will be positioned in the arch of the aorta to prevent debris liberated during the TAVR procedure from entering the three major vessels of the aortic arch.
1590862|NCT02302144|Behavioral|Balance & Strengthening Exercises|Progressive balance and strengthening exercises conducted in a group format yet tailored to each individual
1590863|NCT02302131|Other|SAPIEN XT|Patients that have undergone percutaneous implantation of an Edwards SAPIEN XT Transcatheter Heart Valve in the pulmonic position at the time of data collection
1590864|NCT02302118|Procedure|Esophagogastrectomy|Esophagogastrectomy
1590865|NCT02302105|Radiation|IGRT|Image Guided RT to the prostate
2009048|NCT03325270|Dietary Supplement|labeled ferrous fumarate|labeled iron as Ferrous Fumarate
2009049|NCT03325270|Dietary Supplement|labeled ferrous fumarate + prebiotics|labeled iron as Ferrous Fumarate + galacto-oligosaccharides
1590868|NCT02302079|Drug|ASP8232|oral capsule
1590869|NCT02302079|Drug|ranibizumab|intravitreal (IVT) injection
1590870|NCT02302079|Drug|Placebo|oral capsule
1590871|NCT02302079|Other|Sham intravitreal (IVT) injection|intravitreal (IVT) injection
1590872|NCT02302066|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
1590873|NCT02302066|Drug|TDV Placebo|Takeda's tetravalent dengue placebo-matching vaccine
1590874|NCT02302053|Dietary Supplement|New Viviscal Professional Supplement|The key ingredient is AminoMar C™ marine complex, an organic form of silica derived from Equisetum sp. (horsetail), vitamin C derived from Malpighia emarginata (acerola cherry), microcrystalline cellulose (E460), natural orange flavor, magnesium stearate, hypromellose, and glycerol. The AminoMar C ™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
1590875|NCT02302053|Dietary Supplement|Placebo tablets|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
1590876|NCT02302040|Behavioral|AIM2ACT|AIM2ACT is a mobile health tool that is designed to facilitate collaborative asthma management between early adolescents and their caregivers.
1590877|NCT02302040|Behavioral|Self-guided|Paper feedback and collaborative asthma management strategies are provided to early adolescents and caregivers.
1590878|NCT02302027|Device|platinium IRC9LXO2AWQ|high flow concentrator delivering normobaric oxygen after extraction, 9 liter per minute dimensions: 46 * 67 * 36 cm
1590879|NCT02302014|Other|Palliative Care Intervention|Baseline interview with trial cardiologist and trial nurse lasting for up to 1 hour Creation of a Future Care Plan (FCP) document following this baseline interview Sharing of FCP document with primary care and unscheduled care organisations 6 week interview with trial nurse lasting for up to 1 hour to review FCP 12 week interview with trial nurse lasting for up to 1 hour to review FCP Continuous access to trial nurse by mobile telephone 9am - 5pm Monday-Friday for 12 weeks Trial nurse will - ensure FCP is appropriately shared with primary and secondary care, patient is registered on primary care palliative care register and will liaise with specialist PC services and the general practitioner as needed.
1590880|NCT02302001|Device|Silicone Implant|
1590881|NCT02301988|Drug|Ipatasertib|Ipatasertib will be administered at a dose of 400 milligrams (mg) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
1590882|NCT02301988|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 80 milligrams per square meter (mg/m^2) as IV infusion QW for 3 cycles.
1590883|NCT02301988|Drug|Placebo|Participants will receive placebo (matching to ipatasertib) orally daily on Days 1-21 of each 28-day cycle for 3 cycles.
1590889|NCT02301962|Drug|Panitumumab|Panitumumab is available as a concentrate for solution for infusion (sterile concentrate). It is a colorless solution that may contain, translucent to white, visible amorphous, proteinaceous panitumumab particles. Each milliliter (mL) of concentrate contains 20 mg panitumumab. Each vial contains 100 mg of panitumumab in 5 mL.
1590890|NCT02301949|Drug|Thalidomide|Patients are randomly assigned to receive a second course of four-month treatment of thalidomide (Pharmaceutical Co., Ltd. of ChangZhou, China). Medications are taken orally 25mg four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
1590891|NCT02301949|Other|Placebo|Patients are randomly assigned to receive placebo tablets (Pharmaceutical Co., Ltd. of ChangZhou, China) four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
1590892|NCT02301936|Drug|LDV/SOF|90/400 mg fixed dose combination (FDC) tablet administered orally once daily
1590893|NCT02301910|Drug|Recombinant staphylokinase|15 mg of drug reconstituted in 15 ml of 0.9% solution of NaCl given as single i.v. bolus over 5 - 10 seconds
1590894|NCT02301910|Drug|Tenecteplase|"50 mg of drug reconstituted in 10 ml sterile water for injection given as single weight-adjusted i.v. bolus over 5 - 10 seconds Weight (kg) Dose (mg) Dose (ml)
55 to <60 30 mg 6 ml
60 to <70 35 mg 7 ml
70 to <80 40 mg 8 ml"
1590895|NCT02301897|Drug|Telapristone Acetate|Evaluate the safety and efficacy of 6 and 12 mg Proellex in the treatment of Premenopausal Women with confirmed symptomatic uterine fibroids
1590896|NCT02301897|Drug|Placebo|
1590897|NCT02301884|Biological|Allergen extract|Causal allergen extract such as D. farinae, D. pteronyssinus, cat hair, dog hair/dander, or combination of those
1590898|NCT02301871|Device|Dr. Gene's Health and Wellness|The device is used to perfom deep neck flexors muscles traning. These low load craniocervical flexion exercise are even in early stages of rehabilitation when pain or pathology might preclude high load exercises and thus gradually reduces the symptoms.
1591402|NCT02298179|Biological|RSV F subunit vaccine-Medium dosage; with MF59|Medium dosage; with MF59
2009050|NCT03325270|Dietary Supplement|labeled ferrous sulfate + prebiotics|labeled iron as Ferrous Sulfate + galacto-oligosaccharides
2009051|NCT03325257|Other|Routine care|This study is an observational one - there is no change to the routine care. Patients received the Nivolumab independently of the study. Only data will be collected during this project.
2009052|NCT03325244|Other|EEG monitor|sleep patterns will be monitored using EEG monitor
2009053|NCT03325244|Other|FitBit|activity levels will be monitored
2009054|NCT03325231|Other|Reconstructive surgery following bladder removal.|Investigating patient experience of bladder reconstructions.
2009055|NCT03325205|Other|Anodal tDCS|Anodal Transcranial direct current stimulation (tDCS) is a non- invasive brain stimulation technique. Low intensity current (1-2 mA) is induced to increase excitability, stimulate plasticity and enhance cognitive functions.
1590899|NCT02301871|Procedure|Muscle Energy Technique|MET was applied to Upper trapezius, Levator scapulae and Scalene Following the 7-10 seconds isometric contraction and complete relaxation of all elements, the stretch is maintained for 30 seconds. The effort and the counter-pressure should be modest (20% of available strength) and painless. The process is repeated 3-5 times.
1590900|NCT02301871|Procedure|Static stretching and Cervical non thrust manipulation|conventional treatment for 5 days per week for 2 weeks such as MHP (Moist Heat Pack) for 20 minutes, Static Stretching exercises for upper trapezius, levator scapulae and scalene muscle which is held for 10-30 seconds- repeated 3-5 times, Cervical spine non-thrust mobilization (Grade 3) was given to each segment from C2-C7 was oscillated for 10 repetitions, followed by a 10 seconds rest between segments, Cervical spine active ROM (Range of Motion) exercises with 10 repetitions- 2-3 times a day and Postural exercises were given as home programme.
1590901|NCT02301858|Genetic|Genome analysis of tissue samples.|Genome analysis of tissue samples.
1590902|NCT02301845|Drug|Diatoms Shells|Instillation of suspended diatom shells - 10 mg q12h
1590903|NCT02301819|Device|Veno-arterial extracorporeal membrane oxygenation (ECMO)|Veno-arterial extracorporeal membrane oxygenation (ECMO) will be ineserted as soon as possible and set to achieve adequate organ and tissue perfusion.
1590904|NCT02301819|Other|Early conservative therapy according to standard practice|Standard therapy including inotropes and vasopressors will be used to achieve hemodynamic stabilization and adequate tissue perfusion.
1590905|NCT02301806|Other|dieting|
1590906|NCT02301806|Drug|Sitagliptin|sitagliptin 50 mg tablet by mouth 12 weeks
1590907|NCT02301806|Drug|Glimepiride|glimepiride 1 mg tablet by mouth 12 weeks
2009056|NCT03325205|Other|Sham tDCS|The electrodes are placed over the same areas as in the anodal tDCS condition. Participants will receive sham tDCS instead of anodal tDCS
1590910|NCT02301780|Drug|Aspirin|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.
The maximum duration for aspirin or placebo intake will be 180 days."
1590911|NCT02301780|Drug|Placebo|"Participants who are screened with a high-risk of developing PET will be randomised into one of 2 arms of the trial (on the same day as screening or within 1 week of the screening visit). Randomised participants will be advised to start 150mg of Aspirin/Placebo once per night within 24 hours of randomisation until 36 weeks' gestation or when signs of labour commence.
The maximum duration for aspirin or placebo intake will be 180 days."
1590912|NCT02301754|Biological|INVAC-1|intradermal injection combined with electroporation
1590913|NCT02301741|Behavioral|Game|We will assess the influence of participation in a computer game of virtual dodge ball that requires whole-body reaching movements to manipulate an on-screen avatar. We will gradually reduce the gain of lumbar spine motion of the participant's on-screen avatar across the three game sessions such that participants will need to produce progressively larger excursions of the lumbar spine to manipulate their avatar's spinal motion. Specifically, in game session 1, the spine motion of the avatar is equal to that of the participant (gain=1); in session 2 spine motion of the avatar is 5% less than the participant (gain=0.95); in session 3 spine motion of the avatar is 10% less than the participant (gain=0.90).
1590914|NCT02301728|Other|sampling of breast milk, obtaining information about the maternal diet|take samples of 3 ml breast milk and 3-days diet diaries
1590915|NCT02301715|Drug|Oxytocin|OT spray will be performed by the research pharmacy at the University Regional Hospital Pharmacy of Besançon. The placebo contained all inactive ingredients except for the neuropeptide. Placebo and OT spray containers will be prepared to look identical and will be counterbalance to be randomly assigned by the pharmacy as well. Double blinding and randomization of patients in the two groups will also be carried out by the pharmacy service. Researchers, as well as participants, will be blinded to the content of the spray. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
1590916|NCT02301715|Drug|Placebo|The placebo contained all inactive ingredients except for the neuropeptide. Participants will be instructed to sit and take one puff every 30 seconds, alternating nostrils. Participant will take each dose in front of the clinician to assure correct administration and tolerability.
1590917|NCT02301702|Biological|Tdap|Commercially available, U.S. and Guatemala licensed, 0.5mL intramuscular injection combination tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine
1590918|NCT02301702|Biological|Td|The tetanus toxoid and reduced diphtheria toxoid vaccine (Td) used for this study will be the same preparation used by the National Immunization Program of Guatemala
1590919|NCT02301676|Behavioral|Korean version of telephone interview for cognitive status|The telephone interview for cognitive status (TICS), developed by Brandt et al. (1988), is one of the most popular telephone interview-based screening instruments. Especially, the Korean version of TICS is translated more suitable for Korean culture with the permission of the authors of the original version. The Korean version of TICS consists of 11 items, total score is 41.
1590920|NCT02301676|Drug|Sevoflurane|Sevoflurane is one of the most commonly used volatile anesthetic agents, particularly for outpatient anesthesia, and including in anesthesia of children and infants, and in veterinary medicine.
1590921|NCT02301676|Drug|propofol|Propofol is highly protein-bound in vivo and is metabolized by conjugation in the liver. The half-life of elimination of propofol has been estimated to be between 2 and 24 hours.
1590922|NCT02301676|Device|dexmedetomidine|Dexmedetomidine is a sedative medication used by intensive care units and anesthesiologists. It is relatively unusual in its ability to provide sedation without causing respiratory depression.
1590923|NCT02301663|Other|Handgrip|Subjects will be asked to squeeze and handgrip dynamometer to increase cardiac metabolic demand
1590924|NCT02301663|Other|Altitude simulation|Subjects will breathe a lower concentration of oxygen to simulate the effects of altitude.
1590925|NCT02301663|Other|Leg exercise|Subjects will perform leg exercise to increase metabolic demand.
1590926|NCT02301650|Drug|Lamivudine|mothers use Lamivudine in late pregnancy
1590927|NCT02301650|Drug|Telbivudine|mothers use Telbivudine in late pregnancy
1590929|NCT02301637|Device|Eeva™ Test|The Eeva System is indicated to provide adjunctive information on events occurring during the first two days of development that may predict further development to the blastocyst stage on Day 5 of development. This adjunctive information aids in the selection of embryo(s) for transfer on Day 3 when, following morphological assessment on Day 3, there are multiple embryos deemed suitable for transfer or freezing.
1590930|NCT02301624|Biological|Eculizumab|Open-Label eculizumab 1200mg IV every 2 weeks
1590933|NCT02301598|Procedure|FS-ALK (Femtolaser-assisted anterior lamellar keratoplasty)|The procedure was a non-penetrating transplantation of 80% thickness corneal graft
1590934|NCT02301585|Procedure|Passive Leg Raising Test|Before decision on fluid administration a passive leg raising test is performed. The results are interpreted according to a treatment protocol. If the test indicates fluid irresponsiveness optimization of circulation will be done with vasopressors or inotropes.
1590935|NCT02301585|Procedure|Standard of care|Patients are treated according to Surviving Sepsis Guidelines
1590936|NCT02301559|Behavioral|Pilates exercises|Pilates exercises with emphasis on pelvic region
1590937|NCT02301546|Behavioral|computerized cognitive exercises|Each group will perform computerized cognitive exercises, 1 hour per day, 3 - 5 days per week, for 13 weeks. The experimental group will use exercises shown to improve cognition, whereas the comparator group will use exercises without clear beneficial findings.
1590938|NCT02301533|Behavioral|Shikamana Intervention|See arm description
1590939|NCT02301533|Behavioral|Standard Care|See arm description
1590940|NCT02301507|Behavioral|cell phone SMS text messaging|This study will utilize mobile texting services to send text messages to enrolled subjects on a weekly basis. The text would convey messages that promote better awareness and knowledge on HIV and its treatment, reminders for medication adherence and clinic appointments. The text content would also be customized based on individual subject requirements. English will be used in texting. We would also assess the subjects for traditional demographic items (e.g., age, marital status, education, number/age of other children, employment, and religion), and potential environmental barriers (e.g., transportation and childcare).
1590941|NCT02301494|Drug|3.75% Imiquimod Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
1590942|NCT02301494|Drug|0.1% Fluocinonide Cream|CTCL specific assessments to measure response in lesions will be done at each visit. Therapy initiates at day 1 followed by a visit at day 15. Visits will then be once a month for four months with a follow up at 6 and 12 months.
1590943|NCT02301481|Radiation|SIB-IMRT|45.1Gy and 40.04Gy in 22 fractions using intensity-modulated radiotherapy with a simultaneous integrated boost (SIB-IMRT) to primary tumor
1590944|NCT02301481|Drug|S-1|40mg/m2, orally twice daily every weekday concurrently with radiotherapy treatment
1590945|NCT02301481|Procedure|Surgery|Surgery, preferred D2 lymphadenectomy
1590946|NCT02301481|Drug|SOX|SOX (S-1: 40~60mg, orally twice daily on days 1 to 14, oxaliplatin 130mg/m2 intravenously on day 1, 21 days per cycle)
1590947|NCT02301468|Other|Dry Needling|(experimental- physiotherapy intervention) - will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). The same 4 trigger points will be treated during the 4 weeks. DN will be performed by locating the taut band and the trigger point. Once the trigger point is located, the overlying skin will be cleaned with alcohol. A certified and experienced therapist will penetrate the needle through the skin 10-15mm. into the TrP until the local twitch response will be obtained.
1590948|NCT02301468|Other|Ischemic Compression|(experimental - physiotherapy intervention) will be performed during 4 weeks (1 treatment/week) on the 4 most painful trigger points (determined/selected at the first session - see above). IC will be performed by applying a pressure with a wooden stick on the 4 individually determined most painful trigger points. The duration of the pressure will be about 60s, (increase of pressure 10N/s) until the highest tolerable pressure will be reached and this pressure will be held even when the pain is decreasing during the intervention. The subject will always be treated by the same clinician.
1590949|NCT02301455|Behavioral|Text messaging|persistently hypertensive participants will be randomized to receive these tailored, motivational text messages
1590950|NCT02301442|Behavioral|Exercise + behaviour change intervention|In addition to the same exercise intervention as the control group, this group will receive a behaviour change intervention. This will be delivered after each exercise session and will incorporate the elements: self-efficacy, outcome expectations, impediments and goal-setting. On the weeks when the participants do not attend group sessions, they will receive telephone calls from physiotherapists. This will consist of guided conversations that consider content delivered in previous sessions.
1590951|NCT02301442|Behavioral|Exercise + control education|The control group will receive exercise and education components. The exercise intervention includes aerobic & strengthening components and are in line with MS exercise guidelines (Latimer-Cheung et al 2013). The aerobic activity is walking, measured using pedometers & exercise logs. The strengthening programme consists of 10 exercises targeting major muscle groups for the upper and lower extremities using elastic resistance band. Over the 10-week programme participants will attend 6 group exercise class, supplemented with telephone calls in the weeks without classes. After each group exercise class this group will receive an education session about the following: diet, vitamin D, sleep, temperature and hydration, and immunisations and vaccinations.
1590952|NCT02301429|Device|Model 20105|implant and follow-up of study device
1590953|NCT02301416|Drug|Phentermine/topiramate|Minimum of 3 months on Qsymia (7.5/46 mg) prior to scheduled weight loss surgery and continuance of up to 24 months of Qsymia after scheduled weight loss surgery.
1590954|NCT02301403|Drug|Nicotine patch|8 weeks of nicotine patch
1590955|NCT02301403|Behavioral|in-person counseling and quitline counseling|a single brief, in-person counseling session plus a faxed referral to the Wisconsin Tobacco Quit Line (WTQL), for counseling, including the QUITNOW app and the Website
1590956|NCT02301403|Drug|Preparation Nicotine Mini-Lozenges|Nicotine lozenge prior to attempting to quit smoking
1590957|NCT02301403|Drug|Combination NRT (nicotine patch + nicotine mini-lozenges)|26 weeks of combination NRT as part of a quit smoking attempt
1590958|NCT02301403|Behavioral|Intensive In-Person Cessation Counseling|three 20-min In-person Cessation Counseling sessions
1590959|NCT02301403|Behavioral|Extended Maintenance Counseling Calls|8 Maintenance-phase smoking cessation counseling sessions
1590960|NCT02301403|Behavioral|Automated Adherence Calls|11 brief, automated calls reminding them to use their medications properly
1590961|NCT02301390|Drug|Amiodarone|Amiodarone is a Class III antiarrhythmic agent.
1590962|NCT02301390|Device|Catheter Ablation|The ablation procedure uses radiofrequency energy to destroy cardiac tissue at the origin of the arrhythmia.
1590963|NCT02301377|Device|Spiro PD personal spirometer|
2009057|NCT03325192|Drug|Rapid pleurodesis protocol|"The pleural space will be evacuated completely through the newly placed IPC
20mL of 10% iodopovidone and 80mL of normal saline will be instilled into the pleural space
The patient will be transferred to the recovery unit
Two hours after instillation the pleural space will be drained
After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged
Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
1590967|NCT02301338|Other|Usual care|
1590968|NCT02301338|Other|Phone Calls|
1590970|NCT02301312|Device|POSS-PCU vascular graft|
1590971|NCT02301299|Behavioral|Community-based Stroke Awareness Program|A culturally-adapted stroke awareness and action program will be delivered by trained Stroke Promoters in the targeted neighborhoods in the south side of Chicago. Community Stroke Promoters will be trained on 1) the benefits of early recognition and EMS utilization for stroke (i.e. stroke centers, tPA), 2) culturally-adapted solutions to current barriers (i.e. misperceptions about vulnerability, severity, mistrust, costs), and 3) cues to aid in stroke recognition and immediate action. The intervention will take place at community settings throughout a 1-year period.
1590972|NCT02301286|Drug|Acetylsalicylic acid|
1590973|NCT02301286|Drug|Placebo Acetylsalicylic acid|
1590974|NCT02301273|Other|Usual Physiotherapy|o Patients will receive the usual physiotherapy treatment in ICU in Iceland from day 5 after intubation, which adheres to international standards of practice, including the potential for no treatment. Usual physiotherapy once daily for 20 minutes.
1590975|NCT02301273|Other|Enhanced Physiotherapy|o Patients will receive the intervention physiotherapy treatment consisting of exercises and a progressive upright positioning and mobilization (20 minutes) twice daily from day 3 (>48 hours) after intubation including the potential for no treatment, if they are stable, even though they are not completely alert, Total treatment time of 40 minutes.
1590976|NCT02301260|Behavioral|Speed of Processing Training (SPT)|
1590977|NCT02301260|Behavioral|Placebo Control|Placebo control exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
1590978|NCT02301247|Behavioral|Memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
1590979|NCT02301247|Behavioral|Placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
1590980|NCT02301234|Drug|Placebo|Placebo will be administered once every 4 weeks with or without adjunctive therapy for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
1590981|NCT02301234|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
1590982|NCT02301234|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks with or without adjunctive therapy for up to 16 weeks by SC injection into the thigh or abdomen.
1590983|NCT02301234|Drug|Celecoxib 100 mg|Double-blind capsules taken twice daily for up to 16 weeks.
1590984|NCT02301234|Drug|Celecoxib 100 mg Matching Placebo|Double-blind capsules taken twice daily for up to 16 weeks.
1590985|NCT02301221|Procedure|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
1590986|NCT02301221|Drug|Vancomycin and bowel lavage|An initial vancomycin regimen (500 mg orally two times per day for 3 days), followed by bowel lavage before the infusion of a solution of donor fecal microbiota.
1590987|NCT02301208|Drug|Nedaplatin|Nedaplatin combine with IMRT
1590988|NCT02301208|Drug|Cisplatin|Cisplatin combine with IMRT
1590989|NCT02301195|Other|Therapeutic horseback riding|Inclusion of horses as part of the therapeutic experience
1590990|NCT02301195|Other|Barn Activity Intervention|Equine-focused educational activities in small group setting without horses
1590991|NCT02301182|Device|ADM X3-MoP Cup|
1590992|NCT02301182|Device|CoC Cup|
1590993|NCT02301169|Behavioral|Heat pain stimuli A|
1590994|NCT02301169|Behavioral|Video A|
1590995|NCT02301169|Drug|Administration of T4P1001 capsules|This treatment is given as add on therapy to patients' regular analgesic
1590996|NCT02301169|Behavioral|Heat pain stimuli B|
1590997|NCT02301169|Behavioral|Video B|
1590998|NCT02301169|Drug|Administration of placebo capsules|This treatment is given as add on therapy to patients' regular analgesic
1590999|NCT02301156|Drug|Ublituximab|Ublituximab IV infusion
1591000|NCT02301156|Drug|ibrutinib|Ibrutinib oral daily dose
1591001|NCT02301143|Drug|nab-Paclitaxel|
1591002|NCT02301143|Drug|Gemcitabine|
1591003|NCT02301143|Drug|Chemoradiation|
1591004|NCT02301143|Drug|Capecitabine|
1591005|NCT02301143|Procedure|Surgery|Surgical intervention
1591009|NCT02301117|Drug|TAS-102|
1591010|NCT02301104|Drug|TAS-102|
1591011|NCT02301091|Procedure|TACE|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mixed with pirarubicin,mitomycin and lobaplatin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
1591012|NCT02301091|Procedure|RFA|For RFA, we used two commercially available system (Cool-Tip, Valleylab，USA) and (Octopus RF Systema，Starmed,Korea）with needle electrode with a 17-gauge internally cooled electrode.
1591013|NCT02301091|Drug|pirarubicin,mitomycin and lobaplatin|They were cytotoxic drugs used in the TACE procedure.
1591014|NCT02301078|Procedure|Percutaneous Needle Aponeurotomy|single procedure (day 0)
1591015|NCT02301078|Drug|Collagenase clostridium histolyticum|Xiaflex injection into palpable cords (day 0), physical manipulation (day 7)
1591016|NCT02301052|Drug|Leek topical cream|Leek (Allium Ampeloprasum Spp.Iranicum) topical cream 2 cc twice daily for 3 weeks
1591017|NCT02301052|Drug|placebo topical cream|placebo topical cream 2 cc twice daily for 3 weeks
1591018|NCT02301052|Drug|Anti-hemorrhoid topical cream|Anti hemorrhoid topical cream 2 cc twice daily for 3 weeks(This cream consists of lidocaine (5% w/w), hydrocortisone acetate (7.5% w/w), aluminium sub-acetate (3.5% w/w), and zinc oxide (18% w/w). 30 g )
1591019|NCT02301039|Drug|Pembrolizumab|
1591020|NCT02301026|Drug|5% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
1591021|NCT02301013|Procedure|Urinary incontience surgery|Surgery for stress or mixed urinary incontience
1591022|NCT02301013|Drug|300 cc saline|
1591023|NCT02301000|Biological|Intestinal microbiota therapy|60 ml of ACHIM suspension will be administered through a rectal tube
1591024|NCT02301000|Drug|Metronidazole|Peroral Metronidazole 500 mg t.i.d. for ten days
1591025|NCT02300987|Drug|LEE011|
1591026|NCT02300987|Drug|LEE011 Placebo|
1591027|NCT02300961|Behavioral|Cognitive rehabilitation program|
1591028|NCT02300948|Drug|PregVit® contains 1.1 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
1591029|NCT02300948|Drug|PregVit-folic 5® contains 5 mg of folic acid|Participants are randomly allocated to one of two groups: PregVit-Folic 5® (group1) contains 5 mg folic acid or PregVit® (group 2) contains 1.1 mg folic acid.Both supplements are taken as 2 tablets daily, one tablet in the morning (am) and one tablet in the evening (pm). Both multivitamins are appropriate for periconceptional, prenatal, and post-partum supplementation. The total volume of blood that will be taken is approximately 20 mL (4 teaspoons). Each appointment will be scheduled according to when participants are available. To monitor adherence, the PregVit-Folic 5® blister packs should be returned among with a diary of pill intake (will be provided). To document dietary folate, telephone interviews regarding the diet will be conducted.
1591030|NCT02300935|Drug|trametinib|
1591031|NCT02300935|Drug|nab-paclitaxel|
1591032|NCT02300922|Drug|Antibody TF2|injection of a recombinant antibody CEA specific. Three injections. Each injection are separate by one week
1591033|NCT02300922|Drug|90-Y-IMP-288|Injection of the peptide 90-Y-IMP-288, 24 Hours after injection of TF2. 2 injections by patients separated by one week (week 2 and week 3)
1591034|NCT02300922|Drug|111-In-IMP-288|Injection of the peptide 111-In-IMP-288, 24 Hours after the first injection of TF2 (week 1)
1591035|NCT02300909|Procedure|Lumbar Decompression Surgery|Lumbar Decompression Surgery
1591036|NCT02300909|Procedure|Microdiscectomy Surgery|Microdiscectomy Surgery
1591037|NCT02300909|Other|Dehydrated Human Amnion/Chorion Membrane (dHACM)|Application of Dehydrated Human Amnion/Chorion Membrane (dHACM)
1591038|NCT02300896|Other|Group-based exercise training during hospitalization|Exercise training. Individual program training 5 days a week during hospitalization
1591039|NCT02300870|Drug|Optison|Echocardiogram with IV contrast
1591040|NCT02300857|Behavioral|Low carbohydrate diet|Feeding study. Composition (by proportion of calories): 20% carbohydrate, 60% fat, 20% protein
1591041|NCT02300857|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
1591042|NCT02300857|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
1591043|NCT02300844|Drug|NNC0174-0833|"Subjects will receive a single s.c. (subcutaneous/under the skin) dose of NNC0174-0833.
Up to nine dose levels of single s.c. doses of NNC0174-0833 are planned to be investigated."
1591044|NCT02300844|Drug|placebo|Subjects will receive a single s.c. (subcutaneousl/under the skin) dose.
1591045|NCT02300831|Other|Data Collection|Non interventional prospective data collection
1591046|NCT02300818|Device|Pulsed Electromagnetic Field Therapy|Pulsed Electromagnetic Field Therapy widely termed as (PEMF) is a reparative technique used for treatment of eye therapy has proved to be a beneficial treatment for those suffering from glaucoma. This therapy helps in increased blood flow and show positive results on latent, initial and advanced glaucoma with ten sessions of seven minutes' each.
1591047|NCT02300818|Drug|Seawater eyedrops|Eye-drops daily 1 time a day for 12 weeks
1591048|NCT02300792|Dietary Supplement|honey|Each patient in the intervention group (group 1) took oral honey in a dose of 5 ml/kg/day (with a maximum dose of 150 ml/day) for four weeks.
1591049|NCT02300792|Dietary Supplement|molasses|Each patient in the molasses (placebo) group took 5 ml molasses/kg/day for four weeks, with a maximum of 150 ml/day
1591050|NCT02300779|Dietary Supplement|Low-residue diet|"Subjects will be instructed by members of the research team to follow a low-residue diet for 4 days.
Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.
Fasting will be required from 2 hours after the bowel cleansing is complete. Their usual treatment for diabetes (whether insulin or an oral agent) will be adjusted."
1591130|NCT02300155|Drug|Pregvit®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing -twice daily for '35 mg' group
1591403|NCT02298179|Biological|RSV F subunit vaccine-High dosage; with MF59|High dosage; with MF59
1591051|NCT02300779|Dietary Supplement|Usual care|"Subjects will be instructed by members of the research team to follow a low-residue diet for 3 days followed by a liquid-only diet for an additional day.
Bowel cleansing will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure.
Fasting will be required from 2 hours after the bowel cleansing is complete. No modifications in their usual treatment will be made."
1591052|NCT02300753|Drug|EPI-743|EPI-743 is a quinone oxidation product of alpha-tocotrienol
1591053|NCT02300740|Dietary Supplement|Nicotinamide riboside|NIAGEN, ChromaDex
1591054|NCT02300727|Drug|Curcumin-MTD|0.33g-3g by ingested mouth wash three times per day for 4-6 weeks until unacceptable toxicity develops- to determine the maximum tolerated does (MTD).
1591055|NCT02300727|Drug|Mouthwash-standard pharmacy preparation|"Standard mouth wash preparation administered by ingested mouth rinse three times per day.
The standard mouth rinse contains 40% Benadryl, 40% Maalox, and 20% of 1% Viscous Lidocaine."
1591056|NCT02300727|Drug|Curcumin|After maximum tolerated dose (MTD) is determined, MTD by ingested mouth wash three times per day for 4-6 weeks until mucositis is resolved, disease progression, or unacceptable toxicity develops.
1591057|NCT02300714|Procedure|oblique view approach|
1591058|NCT02300701|Drug|Xolair|According to manufacturer's instructions
1591059|NCT02300701|Drug|Placebo|Placebo
1591060|NCT02300688|Drug|Treatment A|administration of 1 time administration of the test drug (Treatment A)
1591061|NCT02300688|Drug|Treatment B|administration of 1 time administration of the reference drug (Treatment B)
1591062|NCT02300675|Behavioral|therapeutic education program|
1591063|NCT02300662|Device|Cycle Ergometer|Passive movement of the cycle ergometer will execute alternate flexions and extensions of the patients' knee and hips bilaterally for 20 minutes consecutively.
1591064|NCT02300662|Other|Conventional physiotherapy|Manual bronchial hygiene exercises: vibrocompression, manoeuvres with a manual resuscitator (bag squeezing) and aspiration of secretions where necessary.
1591065|NCT02300649|Drug|Dexmedetomidine, Transesophageal echocardiography(TEE)|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for 10 minutes; resulting in a loading dose of 1 mcg/kg, followed by an infusion of 0.5 μg/kg/hr for 50 minutes.
1591066|NCT02300649|Drug|Saline will be infused for 60 minutes at the same rates as dexmedetomidine group.|
1591067|NCT02300636|Other|Training|Co-contraction training at 60 knee flexion angle by using isokinetic dynamometer
1591068|NCT02300636|Other|Training|Co-contraction training at 60 knee flexion angle by using leg press machine
1591069|NCT02300636|Other|Training|Standard ACL rehabilitation
1591070|NCT02300623|Drug|Antiretroviral therapy plus Interleukin-2|Daily s.c. IL-2: 750,000 UI/m2/day for 6 months
1591071|NCT02300623|Drug|Antiretroviral therapy alone|Standard antiretroviral therapy
1591072|NCT02300610|Drug|Enzalutamide|Enzalutamide orally once a day. Dose Escalation Level 1: 80 mg; Level 2: 160 mg. Dose Expansion at recommended dose level, after dose escalation.
1591073|NCT02300610|Drug|Cisplatin|Cisplatin at 70 mg/m^2 IV on day 1, repeated every 21 days for total of 6 cycles.
1591074|NCT02300610|Drug|Gemcitabine|Gemcitabine at 1000 mg/m^2 IV on days 1, 8, repeated every 21 days for total of 6 cycles.
1591075|NCT02300597|Other|Internet based support and coaching|Young people between age 15 and 25 with ADHD and/or autism spectrum disorders are offered internet-based support and coaching during eight weeks (chat and e-mail). Data is collected before and after the intervention and six months after end of treatment using self-report questionnaires pertaining to sense of coherence, self-esteem, quality of life, depressive and anxiety symptoms and socioeconomic status. Parents complete an assessment scale for the next of kin. After treatment the young people are interviewed regarding the quality of the intervention.
1591076|NCT02300584|Behavioral|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each)
1591077|NCT02300584|Behavioral|Tele-Savvy|as a program delivered on an iPad with daily instructional video segments (8-12 minutes each). Videos may be modified after feedback from Prototype arm.
1591078|NCT02300584|Other|iPad|a tablet computer with an internet connection
1591079|NCT02300558|Drug|Eleclazine|Eleclazine tablet administered orally
1591080|NCT02300558|Drug|Eleclazine placebo|Eleclazine placebo tablet administered orally
1591081|NCT02300545|Drug|Pazopanib|
1591082|NCT02300532|Other|No intervention|
1591083|NCT02300519|Other|blood sampling|Samplings will be taken on 4 citrated S-monovette tubes, 3 citrated tubes and 1 EDTA tube, namely 36.5 ml for each volunteer
1591084|NCT02300506|Other|No intervention|
1591085|NCT02300493|Behavioral|Experimental|Asked to weigh themselves
1591086|NCT02300480|Procedure|CTB group|CTB: A single injection of 1.0% 10ml ropivacaine by bile duct needle in calot's triangle when before surgical dissection.After surgery,participants in this group will also receive PCIA.
1591087|NCT02300480|Procedure|PCIA group|The formula of the PCIA included tramadol 800 mg, flurbiprofen axetil 100mg with saline added up to a volume of 80 ml in total. The PCIA pump was set up with a 5 ml loading dose, a 2 ml bolus dose, a 15 min lockout interval and background infusion at a rate of 1 ml/h.
1591088|NCT02300467|Drug|NOV120401|5 to 45 mg/day PO for 5 consecutive days and 2 days off
1591089|NCT02300454|Device|Non-slip element balloon (NSE)|Lacrosse® NSE and SeQuent® Please drug coated balloon (DCB)
1591090|NCT02300454|Device|Balloon|Non-compliant balloon and SeQuent® Please drug coated balloon (DCB)
1591091|NCT02300441|Other|ECG, blood pressure and oximetry|
1591092|NCT02300428|Dietary Supplement|oral iron|BNF code for section 9.1.1.1 (Oral iron preparations for iron-deficiency anaemias)
1591093|NCT02300415|Biological|blood sample|Dosage of presepsine
1591094|NCT02300389|Radiation|Hypofractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with hypofractionated dose of 7.5 Gy in two fractions (II phase) to the total dose of 61 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
1591095|NCT02300389|Radiation|Conventional Fractionated IMRT boost radiotherapy|All patients included into this arm are irradiated to 46 Gy a 2 Gy fraction to the whole pelvis and seminal vesicles and prostate gland (I phase) and than the boost dose is limited to the prostate gland with some part of seminal vesicles with conventional fractionated dose of 2 Gy in 15 fractions (II phase) to the total dose of 76 Gy. Additionally all patients received neoadjuvant Androgen Deprivation Therapy (3-4 months prior starting radiotherapy) and during radiotherapy and during the follow-up up to 24 months.
1591096|NCT02300376|Drug|Dosage of Calcium edetate de sodium|There is no medical data for the use of Calcium edetate de sodium as a tracer to assess GFR. Calcium edetate de sodium is a treatment for lead intoxication. The extension of use as a tracer comes from its exclusive elimination by glomerular filtration. Plasma and renal clearance of Calcium edetate de sodium and Inulin will be measured for every included patient during a hospital day care (V1). For transplanted patients, plasma clearance of Calcium edetate de sodium will be repeated within one week (more or less 48hours) during annual medical check-up of renal transplantation.
1591097|NCT02300363|Drug|Treatment A (rosuvastatin)|10 mg rosuvastatin administered on Day 1 and Day 13
1591098|NCT02300363|Drug|Treatment B (LX4211)|400 mg LX4211 administered on Day 7 through Day 13
1591099|NCT02300363|Drug|Treatment C (rosuvastatin + 400 mg LX4211 administered concomitantly)|10 mg rosuvastatin + 400 mg LX4211 administered concomitantly on Day 13
1591100|NCT02300350|Drug|Treatment A digoxin|0.5 mg digoxin administered on Day 1 and Day 20
1591101|NCT02300350|Drug|Treatment B LX4211|400 mg LX4211 administered daily on Day 14 through Day 25
1591102|NCT02300350|Drug|Treatment C Digoxin + 400 mg LX4211 administered concomitantly|0.5 mg Digoxin + 400 mg LX4211 administered concomitantly on Day 20
1591103|NCT02300337|Device|Reduce Cuff pressure|We reduce the Cuff Pressure from the LTS-D (Laryngeal Tube suction) from 60 to 50 to 40 to 30cmH2O and measure the Delta from Inspiration to Expiration Tidalvolume (Delta Vt). The Delta Vt shows the actual leakage.
1591104|NCT02300324|Dietary Supplement|Standard broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
1591105|NCT02300324|Dietary Supplement|Beneforte broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
1591106|NCT02300324|Dietary Supplement|Beneforte Extra broccoli and stilton soup|Participants will be randomised to eat one portion (300g) of broccoli soup for each phase.
1591107|NCT02300311|Drug|nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area approximately 20 x 20 cm2 up to 3 times in a 24 hour period
1591108|NCT02300311|Drug|placebo matching nonivamide + nicoboxil (Finalgon cream)|2 cm cream line for a skin area of approximately 20 x 20 cm2 up to 3 times in a 24h period
2009058|NCT03325192|Other|Placebo|"The pleural space will be evacuated completely through the newly placed IPC
Only placebo (normal saline) will be instilled into the pleural space
The patient will be transferred to the recovery unit
Two hours after instillation the pleural space will be drained
After recovery from anesthesia and complete drainage of the pleurodesis mix, the subject will be discharged
Subjects will be asked to drain their effusion on a daily basis for the next 7 days and then on an every other day basis."
2009059|NCT03325179|Other|Thread-embedding Therapy|
1591111|NCT02300285|Device|Continuous Glucose Monitoring|Continuous glucose monitors (CGM) will be used to monitor blood sugar levels in enrolled subjects. CGMs measure blood sugar in the tissue just under the skin every few seconds and report average blood sugar every 5 minutes. In our study, the CGMs will function as monitoring systems. In the CGM protocol group the CGM will let the medical team know if there is a concerning blood sugar level, so that the medical team can then check a blood sugar level by the standard way (usually in a small drop of blood) and then decide if they need to give any medical treatment. In the Standard of Care group the CGM data will not be visible to the medical but the medical team will be informed by the researchers if there are multiple unrecognized episodes of severe hypoglycemia.
1591112|NCT02300272|Device|Polysomnograph|Participants will be screened for sleep disorders other than chronic insomnia with an in-home overnight sleep monitoring. Monitoring will consist of six electroencephalography (EEG) measures, two electrooculography (EOG), and chin electromyography (EMG) according to standard placements. Other channels will include oxygen saturation level, bilateral anterior tibialis EMG, heart rate (EKG), thoracic strain gauge, and a nasal/oral thermistor. A single night of polysomnography will be collected during the 2 weeks of assessment.
1591113|NCT02300272|Device|Actiwatch|This device will be worn on the wrist for 14 continuous days to measure limb movements and ambient light.
1591114|NCT02300259|Drug|LY2623091|Administered orally
1591115|NCT02300259|Drug|Itraconazole|Administered orally
1591116|NCT02300259|Drug|Simvastatin|Administered orally
1591117|NCT02300259|Drug|Tadalafil|Administered orally
1591118|NCT02300259|Drug|Diltiazem|Administered orally
1591119|NCT02300246|Procedure|Platelet-Rich Fibrin|Alveolar socket preservation with Platelet-Rich Plasma
1591120|NCT02300233|Drug|volanesorsen|300 mg volanesorsen administered subcutaneously once-weekly for 26 weeks
1591121|NCT02300233|Drug|Placebo|Placebo administered subcutaneously once-weekly for 26 weeks
1591122|NCT02300220|Drug|Ciprofloxacin|500 mg, twice daily for 1 week (oral)
1591123|NCT02300220|Drug|Placebo|One capsule, twice daily for 1 week
2009060|NCT03325166|Drug|Ferumoxytol|Given IV
1591125|NCT02300194|Drug|Topic Morphine|Topical application of a 0.1% morphine gel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
1591126|NCT02300194|Drug|Placebo|Topical application of a placebo hydrogel in patients undergo a procedure. It will be applied 30 minutes before the procedure and the first day every 4 hours. General basic sedation and systemic analgesia will give for all the patients. Efficacy of treatment will be measured with FLACC scale.
1591127|NCT02300181|Dietary Supplement|Placebo|
1591128|NCT02300181|Dietary Supplement|Bacillus subtilis var natto DC-15|
2009061|NCT03325166|Other|Laboratory Biomarker Analysis|Correlative studies
1591404|NCT02298179|Biological|Placebo-Sterile Saline|Sterile Saline
2009062|NCT03325166|Procedure|Magnetic Resonance Imaging|Undergo MRI
2009063|NCT03325166|Biological|Pembrolizumab|Given IV
1591131|NCT02300155|Drug|Orifer F®|Women were randomized to one of two groups. An information package was mailed to each woman, instructing her to commence supplementation with her assigned prenatal multivitamin, according to the product's standard dosing-once daily for '60 mg' group
1591134|NCT02300129|Drug|CD07805/47, CD07805/47+Placebo, Placebo, CD07805/47, Placebo|"Period 1:
1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.
500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.
Period 2:
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.
1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
1591135|NCT02300129|Drug|Placebo, CD07805/47+Placebo, CD07805/47, CD07805/47, Placebo|"Period 1:
1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.
500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.
Period 2:
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week for 2 weeks.
1g of Placebo Gel on full face once daily 7 days per week the 2 following weeks."
1591136|NCT02300129|Drug|CD07805/47, CD07805/47+Placebo, Placebo, Placebo, CD07805/47|"Period 1:
1g of CD07805/47 0.5% Gel on full face on Day 1 and 500mg on a half-face on Day 3.
500mg of Placebo Gel on a half-face on Day 3 and 1g on full face on Day 5.
Period 2:
1g of Placebo on full face once daily 7 days per week for 2 weeks.
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
1591137|NCT02300129|Drug|Placebo, CD07805/47+Placebo, CD07805/47, Placebo, CD07805/47|"Period 1:
1g of Placebo Gel on full face on Day 1 and 500mg on a half-face on Day 3.
500mg of CD07805/47 0.5% Gel on a half-face on Day 3 and 1g on full face on Day 5.
Period 2:
1g of Placebo on full face once daily 7 days per week for 2 weeks.
1g of CD07805/47 0.5% Gel on full face once daily 7 days per week the 2 following weeks."
1591138|NCT02300103|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
1591139|NCT02300103|Drug|RBV|Tablet (s) administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1591142|NCT02300077|Drug|methadone|Escalating dose of methadone up to .3mg/kg.
1591143|NCT02300077|Drug|Control (Intra-operative administration of opioids, other than methadone)|Intra-operative administration of opioids, other than methadone
1591144|NCT02300064|Other|Knee-extensor exercise test|Steady-state, single leg knee-extensor exercise at 20 Watts for 10 minutes
1591145|NCT02300064|Other|Exercise test with restricting/releasing blood flow|10 minute submaximal (20 Watts) single leg knee-extensor exercise with blood flow clamped 10-15% lower by arterial infustion of phenylephrine; 10 minute passive single leg knee-extensor exercise with blood flow matched to the 20 Watt work rate level by arterial adenosine infusion; 10 minute seated rest with blood flow matched to the 20 Watt work rate level by adenosine infusion. Each test separated by at least 30 minutes rest.
1591146|NCT02300064|Other|Exercise test with variable oxygen concentration and MRI|Two bouts of single leg knee-extensor exercise to maximal effort breathing regular air (21% oxygen) or 100% oxygen through a mouthpiece, with a 90 minute rest period between each bout. The same experiment performed again on a separate day in an magnetic resonance imaging (MRI) machine
1591147|NCT02300064|Other|Exercise test with oral antioxidant or placebo cocktail|Antioxidants (Vitamin E - 400 international units, Vitamin C - 1000 milligrams and Alpha lipoic acid - 600 milligrams) or matching placebo capsules administered orally followed by femoral nerve stimulation and single leg knee-extensor exercise for 30 minutes at 50% maximum effort
1591148|NCT02300051|Behavioral|STPGP and RPGT|
1591149|NCT02300051|Drug|TAU|
1994854|NCT02905799|Drug|oral resveratrol|Resveratrol will be administered orally, at the dose of 40 mg (2 caplets) twice a day for one week, then at the dose of 20 mg (1 caplet) twice a day, for a total duration of 6 months.
1591152|NCT02300025|Drug|cobimetinib|single oral 10-mg dose of cobimetinib
1591153|NCT02300012|Procedure|Surgeons knowledge of pre-operative PBIs|Surgeon performing ACL repair will have prior knowledge of patients pre-operative PBIs to inform surgical practice
1591154|NCT02299999|Drug|AZD2014|Target: m-TOR
1591155|NCT02299999|Drug|AZD4547|Target: EGFR
1591156|NCT02299999|Drug|AZD5363|Target: AKT
1591157|NCT02299999|Drug|AZD8931|Target: HER2, EGFR
1591158|NCT02299999|Drug|Selumetinib|Target: MEK
1591159|NCT02299999|Drug|Vandetanib|Target: VEGF, EGFR
1591160|NCT02299999|Drug|Bicalutamide|target: Androgen receptor
1591161|NCT02299999|Drug|Olaparib|Target: PARP
1591162|NCT02299999|Drug|Anthracyclines|DNA intercalation
1591163|NCT02299999|Drug|Taxanes|Target: mitotic tubulin and microtubules
1591164|NCT02299999|Drug|cyclophosphamide|Alkylating agents
1591165|NCT02299999|Drug|DNA intercalators|DNA intercalators
1591166|NCT02299999|Drug|Methotrexate|DNA intercalators
1591167|NCT02299999|Drug|vinca alkaloids|Target: mitotic tubulin and microtubules
1591168|NCT02299999|Drug|Platinum based chemotherapies|Platinum based chemotherapies
1591169|NCT02299999|Drug|Bevacizumab|Target: VEGF
1591170|NCT02299999|Drug|Mitomycine C|Alkylating agents
1591171|NCT02299999|Drug|Eribuline|Microtubule modulator
1591172|NCT02299999|Drug|MEDI4736|Target: PD-L1
1591173|NCT02299986|Other|Ultrasound measurement|Thickness measurement through ultrasound. The investigators will perform daily ultrasound measurements to assess the evolution in thickness during mechanical ventilation
1591174|NCT02299973|Procedure|FMT with donor stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from a healthy pool of donors and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the treatment group
1591175|NCT02299973|Procedure|FMT with own stool|fecal microbiota transplantation by means of colonoscopy with deliverance of the transplant in the right colon and terminal ileum. Transplants will be collected prior to the start of the study from the patients and will be frozen at -80 degrees celsius after thorough screening for infectious diseases. At the time of transplantation samples will be frozen and administrated to the patients in the control group
1591176|NCT02299960|Device|Endo-PAT|Analysis of endothelial function through pulse-amplitude-tonometry
1591177|NCT02299960|Device|NICOM|Non-invasive measurement of cardiac output
1591178|NCT02299947|Drug|Haemocomplettan P|
1591179|NCT02299947|Drug|Placebo|
1591180|NCT02299934|Diagnostic Test|Magnetic Resonance Imaging (MRI)|MRI sequences for visualisation of the blood supply of liver without contrast agent.
1591181|NCT02299934|Diagnostic Test|Compurtized Tomgraphy (CT)|CT including CT Angiography (CTA) for the evaluation of hepatic vasculature.
1591182|NCT02299921|Other|Characterize alcohol and drug use|Characterize alcohol and drug use in patients newly admitted to the medical ICU service, who are expected to stay in the ICU for greater than 48 hours. The investigators will collect blood, exhaled breath condensate, urine and hair samples over the first 10 days of hospitalization. A select subset of subjects will have bronchoalveolar lavage (BAL) obtained.
1591183|NCT02299908|Drug|TAP block with Bupivacaine at 0.25%|Application of 20 mL of local anesthetic bupivacaine at 0.25% in the transverse abdominis plane (TAP) under ultrasound guidance. This area (TAP) is between the anterior fascia of the transverse abdominal muscle and the posterior fascia of the internal oblique muscle, through which the thoracic nerve fibers and a portion of the first lumbar pass. This intervention will be done 10 minutes before conducting the ipsilateral inguinal herniorrhaphy in a single application.
1591184|NCT02299908|Drug|Placebo saline solution|Application of 20 mL of saline solution in the transverse abdominis plane (TAP).
1591185|NCT02299882|Drug|Vancomycin|Patient will be randomized to either vancomycin or no vancomycin. This treatment will take place prior to the closure of the incision from back surgery.
1591186|NCT02299869|Device|Verde (Competitor-control)|contact lens
1591187|NCT02299869|Device|Green (CVI-test)|contact lens
1591188|NCT02299869|Device|Cinza (Competitor-control)|contact lens
1591189|NCT02299869|Device|Grey (CVI-test)|contact lens
1591190|NCT02299869|Device|Esmeralda (Competitor-control)|contact lens
1591191|NCT02299869|Device|Jade (CVI-test)|contact lens
1591192|NCT02299869|Device|Azul (Competitor-control)|contact lens
1591193|NCT02299869|Device|Blue (CVI-test)|contact lens
1591194|NCT02299856|Other|Cardiac magnetic resonance scan|
1591195|NCT02299843|Procedure|RALPPS|Using radiofrequency ablation assisted ALPPS（RALPPS）instead of in-situ split of liver to form a coagulation band in stage I.Habib 4X was used in RFA.
1591196|NCT02299843|Procedure|ALPPS|Treat the hepatocellular carcinoma with ALPPS.
1591197|NCT02299830|Procedure|cryotherapy|use cryotherapy to delete soft neoplasm tissue in the airway
1591198|NCT02299830|Procedure|argon plasma coagulation|use argon plasma coagulation to delete hard neoplasm tissue in the airway
1591199|NCT02299830|Procedure|stent placement|use stent placement to open the airway compressed by out neoplasm
1591200|NCT02299830|Procedure|deletion tumor tissue by snare|use snare to delete polypoid neoplasm tissue in the airway
1591201|NCT02299817|Drug|Denosumab|"Prolia is used to treat osteoporosis (a disease that makes bones fragile) in women who have been through the menopause and in men who have an increased risk of fracture (broken bones). In women who have been through the menopause Prolia reduces the risk of fractures in the spine and elsewhere in the body, including in the hip.
Prolia is also used to treat bone loss in men receiving treatment for prostate cancer that increases their risk of fracture. Prolia reduces the risk of fractures in the spine.
Recently denosumab was found to be effective in preventing osteoporosis related fractures in post-menopausal women by blocking RANKL and thereby inhibiting the development and activity of osteoclast."
1591202|NCT02299817|Drug|Placebo|Placebo
1591203|NCT02299804|Drug|Levophencynonate Hydrochloric|this drug is M receptor inhibitor
1591204|NCT02299804|Drug|Placebo|No active ingredient
1591205|NCT02299791|Other|ALL|"This clinic-level intervention involves a toolkit of decision support tools. These tools are listed below.
EHR tools to expedite identification
a. EHR automated point-of-care alerts (Best Practice Alerts)
EHR tools to expedite prescribing
EHR order sets
EHR text shortcuts for notation
patient education materials (handout, poster)
EHR-based outreach support tools a. EHR registries"
1591206|NCT02299791|Other|ALL|These clinics got the same exact intervention, but one year later, as this was a staggered randomized trial.
1591207|NCT02299778|Dietary Supplement|13C6-p-aminobenzoic acid|
1591208|NCT02299765|Drug|Gefitinib|patients in arm A will be given gefitinib as target therapy
1591209|NCT02299765|Drug|gemcitabine|patients in arm A will be given gemcitabine chemotherapy
1591210|NCT02299765|Drug|carboplatin|patients in arm A will be given carboplatin chemotherapy
1591211|NCT02299752|Procedure|single-gloving system|single-gloving system was used during Catheterization
1591212|NCT02299752|Procedure|double-gloving system|double-gloving system was used during Catheterization. inner and outer gloves were the same size
1591213|NCT02299739|Drug|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
1591214|NCT02299739|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
1591215|NCT02299739|Procedure|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
1591216|NCT02299739|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
1591217|NCT02299739|Procedure|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
1591218|NCT02299726|Drug|Spironolactone|
1591219|NCT02299726|Other|Placebo|Matching placebo
1591220|NCT02299713|Device|Electroacupuncture|Electro acupuncture is a relatively new method of treatment in Chinese Medicine. Just as in a regular acupuncture treatment, needles are inserted into acupuncture points but small crocodile clips are then attached to the ends of needles to connect them to an electro-acupuncture device. In traditional acupuncture the inserted needles are manually vibrated to induce a response whilst in electro-acupuncture the bi-phasic current results in a constant (controlled) vibration of the needles and a direct electrical stimulation. The device allows the practitioner to adjust the frequency and intensity of the electric stimulation in a consistent manner which is not operator dependant.
2009064|NCT03325127|Drug|radium Ra 223 dichloride (Xofigo, BAY88-8223)|Radium-223, 55kBq (1.49 microcurie) per kg body weight given at 4 week intervals for 6 injections
1591222|NCT02299687|Drug|Omeprazole|
1591223|NCT02299674|Other|Level overground ambulation|
1591224|NCT02299661|Drug|DS-1093a|DS-1093a, single oral doses up to 50 mg
1591225|NCT02299648|Other|Molecular profiling|molecular profiling, patient derived cells, fresh or FFPE
1591226|NCT02299635|Drug|PF-03084014|Tablet, 10 mg, twice a day.
1591227|NCT02299635|Drug|PF-03084014|Tablet, 50 mg, twice a day
1591228|NCT02299635|Drug|PF-03084014|Tablet, 100 mg, twice a day
1591229|NCT02299622|Genetic|Genetic test|Next-generation sequencing (AmpliSeq) & fusion analysis
1591230|NCT02299609|Other|Ultrasound beams Philips HD11 XE®|Ultrasound beams used during standard echocardiography
1591231|NCT02299596|Other|Physical activity|The intervention will take place both pre- and postoperatively. During the hospital stay both groups will be treated in the same manner.
1591232|NCT02299583|Other|Preventive intervention trauma-informed early intervention|Every department appoints 2-4 health care professionals as child welfare officers (CWOs) who will be responsible for carrying out the intervention at the department. Whenever a child or adolescent is present in the department a CWO will be send for. The intervention consists of four distinct elements: 1) A standardized plan of action for the appointed health care CWOs on how to conduct trauma-informed health care for children and their families shortly after exposure to a PTE, 2) a training program for CWOs on trauma-informed support and communication with children and their families, 3) a supervision program for the CWOs, and 4) three psychoeducational booklets for young children, older children, and parents. The booklets will be given to the families by the CWOs.
1591233|NCT02299570|Biological|RBX2660 (microbiota suspension)|A suspension of intestinal microbes
1591234|NCT02299570|Other|Placebo|A suspension of saline and cryoprotectant
1591235|NCT02299557|Drug|Oxymetazoline gel|Oxymetazoline gel applied intra-anally once daily
1591236|NCT02299557|Drug|Placebo gel|Placebo gel applied intra-anally once daily
1591237|NCT02299544|Device|BlueWind Medical system|The BlueWind Medical System is intended for the treatment of patients with overactive bladder (OAB) including urinary urgency frequency and urge incontinence.
1591238|NCT02299531|Other|Varying meal energy density and portion size|
1591239|NCT02299518|Drug|mitoxantrone hydrochloride|Given IV
1591240|NCT02299518|Drug|etoposide|Given IV and PO
1591241|NCT02299518|Drug|cytarabine|Given IV
1591242|NCT02299518|Drug|selinexor|Given PO
1591243|NCT02299518|Other|laboratory biomarker analysis|Correlative studies
1591244|NCT02299518|Other|pharmacological study|Correlative studies
1591245|NCT02299505|Drug|ceritinib|
1591246|NCT02299492|Other|Person Centered Care Planning|PCCP is a manualized provider-based intervention that maximizes consumer choice for adults receiving mental health services. PCCP focuses on engagement and individualized care, thereby enhancing the impact of existing evidence based practices.
1591247|NCT02299479|Device|Dexcom G4 Platinum|Blood glucose levels will be monitored using continuous glucose monitors (CGMs). Participants will be asked to verify CGM low blood sugars using their home glucometer. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
1591248|NCT02299479|Device|Activity Monitor|Patients will be asked to wear an activity monitor so that we may assess their daily activity level. Insulin dose adjustments will be made if there is concern that nocturnal hypoglycemia is occurring in relation to high daytime activity.
1591249|NCT02299453|Behavioral|IPT|Nine sessions of telephone-administered interpersonal psychotherapy (IPT)
1591286|NCT02299193|Behavioral|Healthy Sleep Habits|6 weekly, 20 minute online sessions about healthy sleep practices
1591287|NCT02299180|Behavioral|ACP|
1591257|NCT02299427|Behavioral|dog safety|use of dog safety website at home for about 2 weeks
1591258|NCT02299427|Behavioral|transportation safety|use of transportation safety website at home for about 2 weeks
1591261|NCT02299401|Drug|Misoprostol|Women will receive three 800 mcg doses of misoprostol.
1591262|NCT02299401|Device|Semi-quantitative pregnancy test|All women will be given a semi-quantitative pregnancy test (SQPT) for at-home follow-up.
1591263|NCT02299388|Drug|Liraglutide or Placebo|All subjects will be advised a low sodium diet. Eligible patients will have ABPM measurements and laboratory blood collection at baseline (prior to initiation of Liraglutide or Placebo), at 4 and 8 weeks of therapy. Patients will return 24 hours following ABPM placement for device and data retrieval.
2009065|NCT03325127|Drug|Zytiga|Abiraterone 1000 mg per day orally
2009066|NCT03325127|Drug|Xtandi|Enzalutamide 160 mg per day orally
1591266|NCT02299349|Drug|bupivacaine liposome suspension|bupivacaine liposome suspension periarticular injection
1591267|NCT02299349|Drug|concentrated multi drug Ketorlac, Morphine PF, Epinephrine, Ropivicaine, 0.9% NaCL|Ketorolac 30 mg, Morphine PF 5 mg, Epinephrine 0.6 mg, Ropivacaine 400 mg, QS to 100ml with 0.9% NaCl
1591268|NCT02299336|Drug|Aflibercept|pro re nata (PRN)
1591269|NCT02299336|Procedure|Focal Laser|Focal laser administered based on pre-specified criteria
1591270|NCT02299323|Device|INDEPENDENCE|Lumbar Integrated plate and spacer, with percutaneous screws and rods.
1591271|NCT02299310|Drug|Valsartan|Valsartan 80mg/tablet, 1 tablet once daily (crossover)
1591272|NCT02299310|Drug|Perindopril|Perindopril 4mg/tablet, 1 tablet once daily (crossover)
1591273|NCT02299297|Drug|Tofacitinib|Dosage/Frequency: 5mg - 10mg, oral, twice daily
1591274|NCT02299284|Other|Intensive Home-based Bimanual and Lower-limb Training in Young Children With Hemiplegia|
1591275|NCT02299271|Drug|Ropivacaine|0.375% ropivacaine as a one-time, 60 milliliter injection
1591276|NCT02299271|Drug|Saline|Saline as a one-time, 60 milliliter injection.
1591277|NCT02299258|Device|Standard stents MTN-CG-s-20/100|The ends of the stents were semi-spherical with diameters of 28 mm and length of 20 mm. The length of the stents was 100 mm
1591278|NCT02299258|Device|Tailored stents MTN-WE-20/100-A|cup-shaped or funnel-shaped, according to the shapes of the proximal GOOs.
1591279|NCT02299245|Drug|rosuvastatin|different dose of rosuvastatin treatment
2009067|NCT03325114|Drug|Chlorthalidone|Chlorthalidone 12.5-5 mg by mouth daily for 4 weeks
1591281|NCT02299219|Behavioral|Taking Charge: Managing Cancer Online|"n addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing Cancer Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol that consists of Cancer-specific education, self-management strategies, and social support that is available in English and French."
1591282|NCT02299219|Behavioral|Standard Medical Care and Cancer Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about Cancer (Cancer Resource Centre) and online assessments."
1591283|NCT02299206|Drug|CeraVe Baby Diaper Rash Cream|Parents/caregivers of subjects will administer CeraVe Baby Diaper Rash Cream (ingredients: Zinc oxide 10mg in 1g (1%) and dimethicone 10mg in 1g) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
1591284|NCT02299206|Drug|Desitin Maximum Strength Original Paste|Parents/caregivers of subjects will administer Desitin Maximum Strength Original Paste (ingredients: Zinc Oxide 40%) with each diaper change throughout the course of the study period. The product can be applied liberally as needed. Diapers and skin cleansing interventions will stay constant throughout the treatment period.
1591285|NCT02299193|Behavioral|Cognitive Behavioral Therapy|6 weekly, 20 minute online sessions about how thoughts and behaviors can affect sleep
1591327|NCT02298751|Behavioral|Cue Exposure Treatment|
2009068|NCT03325101|Procedure|Cryosurgery|Undergo cryosurgery
2009069|NCT03325101|Biological|Pembrolizumab|Given IV
2009070|NCT03325101|Procedure|Pheresis|Undergo apheresis
2009071|NCT03325101|Biological|Therapeutic Autologous Dendritic Cells|Given IT
2009072|NCT03325088|Procedure|Bronchial endoscopy|Bronchial endoscopy will be performed after clinical examination and pulmonary function tests
2009073|NCT03325088|Procedure|Bronchial biopsies|5 biopsies will be done and analysed at the end of recruiting to assess monomeric GTP Rac1 protein expression and activity on bronchial biopsies
1591288|NCT02299167|Drug|Dixon's up-and-down method|using a modified Dixon's up-and-down method (using 0.5 mg as a step size) (16). The first patient was tested at a dose 1.5 mg bupivacaine, if patient responded with failed block then the next patient received an increment of 0.5mg bupivacaine, if patient responded with successful block, then the next patient received a decrement of 0.5mg bupivacaine. The research continued until we obtained seven crossover midpoints.
1591289|NCT02299154|Behavioral|Psychological questionnaires|Psychological questionnaires about memory problems perceptions, anxiety, depression, quality of life and coping
1591290|NCT02299141|Drug|Nintedanib|
1591291|NCT02299128|Other|Physical Therapy Treatment|
1591292|NCT02299115|Drug|Prednisolone|Corticosteroid
1591293|NCT02299115|Drug|Vigabatrin|Antiepileptic
1591294|NCT02299102|Device|Jamshidi Manual Standard Device|Jamshidi Manual Standard Device
1591295|NCT02299102|Device|OnControl Powered Ported Device|OnControl Powered Ported Device
2009074|NCT03325088|Procedure|Bronchial alveolar enema|For participants who had signed ancillary research consent
1591297|NCT02299076|Behavioral|Behavioral economics incentives|Behavioral economics-informed incentives to promote engagement and outcomes in a smoking cessation intervention.
1591298|NCT02299076|Other|Minimal incentives|Minimal financial incentives to promote engagement and outcomes in a smoking cessation intervention.
1591299|NCT02299063|Drug|Dexmedetomidine|A bolus dose of 0.5 mcg/kg infused over 10 minutes will be administered, followed by a continuous infusion for the duration of the surgery at 0.6 mcg/kg/hr.
1591300|NCT02299063|Drug|0.9% NaCl|
1591301|NCT02299050|Drug|Cycloset|Bromocriptine QR 0.8 mg tablet 0.8 mg/day with dose increased to a maximum of 3.2 mg/day or as tolerated to a minimum of 2.4 mg/day Other names: Cycloset, B-QR
1591302|NCT02299024|Behavioral|Additional Opioid Information|Patients receiving this intervention are given additional information about the opioid pain medication that they are receiving in the form of a one page handout. The hand out was written in a health-literacy appropriate manner. A research assistant read the handout to them out loud, and they were given a copy to take home with them.
1591303|NCT02299011|Device|Orsiro drug eluting stent|Orsiro Hybrid drug eluting stent
1591304|NCT02299011|Drug|Biomatrix drug eluting stent|Biomatrix Flex drug eluting stent
1591305|NCT02298998|Other|EAU surveillance|Patients randomized into the intervention group will follow the EAU surveillance guidelines for cystoscopy follow-ups during bladder cancer surveillance.
1591306|NCT02298985|Drug|Curcumin|3 g/day (3 capsules/day) for 6 months
1591307|NCT02298985|Drug|placebo|3 g/day (3 capsules/day) for 6 months
1591308|NCT02298972|Behavioral|Nurse support and selfmanagement intervention|
1591309|NCT02298959|Other|Laboratory Biomarker Analysis|Correlative studies
1591310|NCT02298959|Biological|Pembrolizumab|Given IV
1591311|NCT02298959|Biological|Ziv-Aflibercept|Given IV
2009075|NCT03325075|Biological|VAL-181388|Escalating dose levels
2009076|NCT03325075|Other|Placebo|Saline
2009077|NCT03325062|Behavioral|MOVE|The MOVE program emphasizes movement pattern retraining in conjunction with contemporary rehabilitation. More specifically, the MOVE program promotes symmetry in functional knee motion and loading without postural compensation. Intervention uses pressure-sensing shoe insoles to deliver real-time visual biofeedback during activity performance.
1591316|NCT02298920|Drug|AZD0914|Radiolabelled AZD0914 for study of absorption, disposition, metabolism, and excretion in healthy volunteers.
1591317|NCT02298868|Drug|Baclofen|
1591318|NCT02298855|Behavioral|Individualised follow-up|Patients allocated to gynaecological cancer nurse specialist at the end of primary treatment. Follow-up is negotiated to suit their individual situation. Type of contact is flexible, primarily by telephone although some women may opt for face-to-face appointments. Patients will be assessed using a holistic guide to identify signs of disease progression, symptoms warranting intervention, and psychological issues. The nurses delivering the intervention are expert in the management of ovarian cancer and will work to a model of health promoting interactions oriented towards improving self-efficacy. The nurses will provide information and support to assist patients to manage troublesome symptoms and live with psychological discomfort.
1591319|NCT02298842|Device|Platelets stored in InterSol|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. Following each blood collection, Platelet Additive Solution (PAS), InterSol, will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
1591320|NCT02298842|Device|Platelets stored in Plasma|A platelet apheresis procedure involves connecting the blood in the donor's vein through tubing to a machine that separates the blood components. After the separation, the desired component of the blood is removed (platelets and plasma), while the remainder of the blood components are reinfused back into the patient. To prevent clotting, an anticoagulant (ACDA) is used throughout the procedure. During the collection, plasma collected from the donor will be added to the platelet product to prepare the final product for 7 day storage. The entire procedure is painless and should take 90 to 120 minutes and the subjects will have two collections within 6-8 days of each other.
1591323|NCT02298790|Behavioral|Meal schedule|
1591324|NCT02298777|Procedure|- Skin biopsy - Urine sample - Blood sample|
1591325|NCT02298764|Other|Standard back pain treatment|Standard back pain treatment
1591326|NCT02298764|Other|Standard back pain treatment + 10 psychotherapeutic sessions|"Standard back pain treatment plus 10 psychotherapeutic session, that will include the shock-trauma method somatic experiencing."
1994855|NCT02905799|Drug|oral placebo|Placebo will be administered orally : 2 caplets twice a day for one week, then 1 caplet twice a day, for a total duration of 6 months
1591328|NCT02298725|Other|DGA Diet Plan|A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with food group recommendations set in the 2010 Dietary Guidelines for Americans.
1591329|NCT02298725|Other|NHANES Diet Plan|"A nutrient-adequate, balanced diet providing energy to maintain body weight, and macronutrient composition falling within the acceptable range, as recommended by the Institute of Medicine. The foods provided in this diet will be closely aligned with the NHANES What we eat in America report."
1591330|NCT02298660|Drug|BOTOX|"BOTOX® Total dose OR units/kg (per patient): 200U Number of cycles:1 cycle
200 units of BOTOX will be injected per procedure. BOTOX will be diluted in 15mL saline to 20U/mL. BOTOX injections will be performed with a normal 22 FF rigid cystoscopy or flexible 6Fr injection needle. BOTOX will be injected into the detrusor muscle at 20 sites (10U per site), sparing the trigone. A local anaesthesia with instillation of 50 ml lidocaine 2% into the bladder will be done prior to the procedure to avoid autonomic dysreflexia."
1591331|NCT02298621|Other|pomegranate juice|Randomized clinical trial or RCT
1591332|NCT02298621|Other|placebo|Randomized clinical trial or RCT
1591333|NCT02298608|Device|Nano Knife|Percutaneous, CT guided, ablation of renal mass
1591334|NCT02298595|Drug|cisplatin|75 mg/m2 IV day 1 of each cycle
1591335|NCT02298595|Drug|Cetuximab|XXXX day 1, 8, and 15 of each cycle
1591336|NCT02298595|Drug|BYL719|200, 250, 300, or 350 mg/day by mouth every day
2009078|NCT03325062|Behavioral|Control|The contemporary progressive rehabilitation program consists of progressive resistive exercise to key lower extremity muscle groups, knee range of motion exercise, weight-bearing exercise, as well as education on symptom management strategies.
1591338|NCT02298569|Behavioral|multi-pronged program to improve early postpartum discharge|"Better team integration and changes to promote interprofessional collaboration and communication between healthcare providers involved in pre- and post-natal care in a perinatal network.
Transition optimization: all involved healthcare professionals will complete a specific form during pregnancy and hospitalization to coordinate support safe process, and to improve quality transitions to outpatient midwives and pediatrician. A check-list will be completed by the mother to assess whether she agrees to early discharge and that she is aware of its conditions Implementation of best practices about early discharge after delivery to improve safety of early discharge particularly for neonates at risk (jaundice and dehydration)."
1591339|NCT02298543|Other|coronary spasm|
1591340|NCT02298530|Other|Combination of caffeine and theanine|Beverage containing caffeine and theanine
1591341|NCT02298530|Other|Caffeine|Beverage containing caffeine
1591342|NCT02298517|Procedure|incentive spirometry|Incentive spirometry to flow and incentive spirometry to volume
1591343|NCT02298517|Procedure|inspiratory load equipment|Threshold and Power breathe
1591344|NCT02298504|Drug|Mineral Trioxide Aggregate|
1591345|NCT02298504|Drug|Biodentin|
1591346|NCT02298504|Drug|Vitrebond|
1591347|NCT02298491|Drug|H.P. Acthar Gel|80 IU subcutaneously daily for 10 days then followed by 80 IU subcutaneously three times per week through Month 12
1591348|NCT02298478|Behavioral|NO-FEAR Airlines|"NO-FEAR Airlines is a computer program that allows people who are afraid to fly to be exposed to images and sounds related to their phobic fears on a standard personal computer. The treatment can be totally self-applied.
NO-FEAR Airlines divides the flight process into six sequential stages: (1) flight preparation, (2) a series of activities immediately prior to flying on the day of the flight, (3) boarding and taking off, (4) the central part of the flight, (5) the airplane's descent, approach to the runway and landing, (6) sequence with images and auditory stimuli related to plane crashes."
1591349|NCT02298465|Procedure|Supine ESWL|ESWL to distal ureteric stone is performed in the supine position with the shockwave generator placed in the patient's buttock area. The aim is to direct the shockwaves through the greater and lesser sciatic foramina to reach the distal ureter.
1591350|NCT02298465|Procedure|Prone ESWL|ESWL to the distal ureteric stone is performed in the traditional prone position. The shockwave generator is placed on the patient's abdomen
1591351|NCT02298465|Device|Extracorporeal Shockwave Lithotripsy (ESWL)|The ESWL machine we use is the Dornier S2 lithotriptor. ESWL is performed without any sedation or anesthesia under fluoroscopy. Painkillers are given upon request.
1591352|NCT02298452|Device|Hearing aid.|The hearing aid will be fitted to the individual hearing loss of the subject.
1591353|NCT02298426|Behavioral|Health Management|We provide large scales of weight management information included recipes according to people's constitution. Information is provide through both face to face meeting and telephones. Materials are also given to participants.
1591354|NCT02298426|Behavioral|General Management|We provide general information about health. Information is provided through telephones and materials.
1591355|NCT02298426|Other|Placebo|We use placebo to replace the health product.
1591356|NCT02298426|Dietary Supplement|SCHSANDRA PLUS, YI RUI CAPSULE, Gest Aid Plus: INFINITUS®|We use dietary supplement products to help balance the constitution of participants. Each participant got one of the three dietary supplement products. SCHSANDRA PLUS, INFINITUS® is a health product made of Schisandra, ginseng, Ginseng, Radix and other plant materials which can help enhance the body's antioxidant capacity. YI RUI CAPSULE , INFINITUS® is a health product made of salvia, hawthorn, alisma, perilla oil microcapsules, panax powder, ginkgo biloba and other plant materials which can assist lower the blood lipid level. Gest Aid Plus, INFINITUS® is a health product made of yam, codonopsis, poria, white beans, dried tangerine peel and other plant materials which can help regulate intestinal flora.
1591357|NCT02298413|Device|PCI with Absorb scaffold|Implantation of biovascular scaffold during PCI
1591358|NCT02298400|Device|Acuvue® Oasys® Lenses (senofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
1591359|NCT02298400|Device|30-Day Bausch + Lomb PureVision (balafilcon A)|Contact lenses placed in each eye during the day for about 8 hours
1591360|NCT02298400|Device|Clariti® 1-Day (Somofilcon A)|Contact lenses placed in each eye during the day for about 8 hours
2009079|NCT03325049|Behavioral|The health-promoting conversations|The health-promoting conversations
1591362|NCT02298374|Other|Homecare reablement|
1591363|NCT02298374|Other|usual care|
1591405|NCT02298179|Biological|Placebo-Sterile Saline|Sterile Saline
1591364|NCT02298361|Other|Health insurance outreach IT tools|"IT tools that support Community Health Centers in children's health insurance outreach efforts (insurance outreach IT tools), adapted from tools proven to support chronic disease management."
1591365|NCT02298348|Drug|Sorafenib|Sorafenib -100-200mg/m2/dose (dose escalation), Orally BID continuously Days 1 thru 28 Cyclophosphamide - 250 mg/m2/day IV x 5 days - day 1 thru day 5 Topotecan - 0.75 mg/m2/day IV x 5 days - day 1 thru day 5
1591366|NCT02298348|Drug|Cyclophosphamide|250mg/m2/day IV x5 days (Day 1 through Day 5 of each course)
1591367|NCT02298348|Drug|Topotecan|0.75mg/m2.day IV x5 days (Day 1 through Day 5 of each course)
1591368|NCT02298335|Drug|prednisone|Full-dose induction period: Prednisone 1mg/kg.day, maximum 60mg/day, orally, divided into 3 times; Protracted tapering period: orally, no ask for fract. dos.
1591369|NCT02298322|Device|CoolSculpting System|
1591370|NCT02298309|Other|Test-and-Treat TB|
1591371|NCT02298283|Drug|brentuximab vedotin|is 1.8 mg/kg administrated by IV infusion
1591372|NCT02298283|Drug|Cyclophosphamide|1250 mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
1591373|NCT02298283|Drug|Adriamycin|35mg/m², IV, part of the BEACOPP chemiotherapy, D1 of 2 BEACOPP cycles, every 3 weeks
1591374|NCT02298283|Drug|Oncovin|1.4 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
1591375|NCT02298283|Drug|Bleomycin|10 mg/m², IV, part of the BEACOPP chemiotherapy, D8 of 2 BEACOPP cycles, every 3 weeks
1591376|NCT02298283|Drug|Etoposide|200 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D3 of 2 BEACOPP cycles, every 3 weeks
1591377|NCT02298283|Drug|Procarbazine|100 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
1591378|NCT02298283|Drug|Prednisone|40 mg/m², IV, part of the BEACOPP chemiotherapy, D1 to D7 of 2 BEACOPP cycles, every 3 weeks
1591379|NCT02298283|Drug|G-CSF|5 µg/kg/j, SC, D9 until GB 1.0x109/L
1591380|NCT02298283|Radiation|30 Grays|30 Gy radiation of sites initially diagnoses + 6Gy for residual sites, 3 to 4 weeks after D1 of BEACOPP cycle 2.
1591381|NCT02298270|Behavioral|The Relaxation Response Resiliency Program (3RP) via Skype|8-week group intervention, delivered via Skype, teaching relaxation and psychological resiliency enhancing skills. Topics include the relaxation response, meditation, and yoga.
1591382|NCT02298257|Drug|brentuximab vedotin|given IV
1591383|NCT02298257|Drug|Doxorubicin Hydrochloride|Given IV
1591384|NCT02298257|Drug|Vinblastine|Given IV
1591385|NCT02298257|Drug|Dacarbazine|Given IV
1591386|NCT02298244|Procedure|PV isolation + GP Ablation|In real time builds the 3D card LA using nonfluoroscopic navigation system.Left and right PVs encircle in 1 lesion line by circumferential PV isolation.Radiofrequency energy delivered at 43◦C,35 W,0.5 cm away from the PV ostia at the anterior wall,and reduced to 43◦C,30 W,1 cm away from the PV ostia at the posterior wall,with a saline irrigation speed of 17 ml/min.Each lesion of ablation continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds.The endpoint of circumferential PV isolation is PV isolation;this confirm when Lasso mapping show the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.To accomplish ganglionated plexi ablation,LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter HFS.Rectangular electrical stimuli were delivered at a frequency of 50 Hz,output amplitude 15V and pulse duration of 10 ms,for 5 sec
1591387|NCT02298244|Procedure|PV isolation + GP ablation + Pulmonary GP ablation|"The procedure of AF ablation is the same like in the circumferential PV isolation + GP Ablation.
8-Fr sheath is carried through the right heart into the pulmonary artery trunk. Using ablation electrode constructed 3D map of the pulmonary artery trunk and the right and left main branches. Further HFS performed with the tip ablation electrode at the bifurcation of the pulmonary artery and in the ostium of the left and right pulmonary arteries (less than 2 mm distal to the bifurcation) 20 Hz, duration of each stimulus 10 ms. A positive response would be considered an increase in the RR interval of more than 50% of baseline within 10 seconds. In areas with a positive response to HFS, will be performed RFA Efficiency criterion: no previously described responses to HFS in the ablation area. Parameters RFA: 8-10 watts for 60 seconds duration at one point, the irrigation speed of 5 ml / min."
1591388|NCT02298231|Other|Standard of Care Balance Intervention|Standard balance therapy as performed by a physical therapist
1591389|NCT02298231|Other|Mystic Isle Balance Intervention|Balance therapy using virtual reality
1591390|NCT02298231|Other|Mystic Isle Balance Intervention with Dual Task|Balance therapy using virtual reality and performing cognitive tasks
1591391|NCT02298218|Drug|Meloxicam|The intervention drug, meloxicam is safe medicine which is used to treat pain or inflammation caused by osteoarthritis or rheumatoid arthritis in adults and children who are at least 2 years old. It may also be used for purposes not listed in the medication guide. It will be taken once a daily with a dose of 0.125 mg/kg/day (high-dose group) or 0.06 mg/kg/day (low-dose group). After 6 months of medication, the maintenance will be decided by the comparison of liver stiffness score before and after the intervention.
1591392|NCT02298205|Other|Asthma controller medication (Beclomethasone) adjustment strategy|The participant will adjust the dose of Beclomethasone based on symptoms
1591393|NCT02298205|Other|Provider-based adjustment|The provider will adjust the dose of Beclomethasone based on the participant's asthma control at their encounter with them
1591394|NCT02298192|Drug|insulin degludec/liraglutide|For subcutaneous (s.c., under the skin) injection, once daily. Subjects will be instructed to continue with the same dose of OADs (metformin alone or in combination with pioglitazone), as prior to the trial.
1591395|NCT02298179|Biological|RSV F subunit vaccine-Low dosage; no adjuvant|Low dosage; no adjuvant
1591396|NCT02298179|Biological|RSV F subunit vaccine-Medium dosage; no adjuvant|Medium dosage; no adjuvant
1591397|NCT02298179|Biological|RSV F subunit vaccine-High dosage; no adjuvant|High dosage; no adjuvant
1591398|NCT02298179|Biological|RSV F subunit vaccine-Low dosage; with aluminum hydroxide|Low dosage; with aluminum hydroxide
1591399|NCT02298179|Biological|RSV F subunit vaccine-Medium dosage; with aluminum hydroxide|Medium dosage; with aluminum hydroxide
1591400|NCT02298179|Biological|RSV F subunit vaccine-High dosage; with aluminum hydroxide|High dosage; with aluminum hydroxide
1591401|NCT02298179|Biological|RSV F subunit vaccine-Low dosage; with MF59|Low dosage; with MF59
1591407|NCT02298166|Drug|chemotherapy (Mitoxantrone, Cytarabine)|"Induction therapy:
Mitoxantrone 10 mg/m² IV, push (8 mg/m² for patients > 60 years of age and/or previous allogeneic HCT) d 1-3
Cytarabine 1000 mg/m² IV (500 mg/m² for patients > 60 years of age and/or previous allogeneic HCT), over 3 hours, d 1-6
Consolidation therapy:
Younger adult patients (18 to 60 yrs):
Cytarabine 1500 mg/m² by i.v infusion over 3 hours BID on days 1-3 (total dose 9000 mg/m²).
Older patients (> 60 yrs) and or previous allogeneic HCT:
Cytarabine 1000 mg/m² by i.v. infusion over 3 hours BID on days 1-3 (total dose 6000 mg/m²)."
1591408|NCT02298166|Drug|Placebo|"Induction therapy:
Placebo to be given as p.o. TID starting d 7+, given continuously thereafter until 48 hours prior to the next chemotherapy.
Consolidation therapy:
Placebo will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.
Maintenance therapy with placebo is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.
Maintenance with placebo will be given at the same dose tolerated during induction therapy."
1591409|NCT02298166|Drug|Crenolanib|"Induction therapy:
Crenolanib to be given as p.o. TID starting d 7+, given continuously until 48 hours prior to the next chemotherapy.
Consolidation therapy:
Crenolanib will start on day 4, thereafter with continuous dosing until 48h before start of subsequent consolidation chemotherapy.
Maintenance therapy with Crenolanib is intended in all patients after allogeneic HCT or intermediate-dose cytarabine consolidation therapy. Maintenance therapy will be given for 364 days (equivalent to 13 cycles à 28 days) after recovery from allogeneic HCT or IDAC.
Maintenance with Crenolanib will be given at the same dose tolerated during induction therapy."
1591410|NCT02298166|Other|Allogeneic stem cell transplantation|"In patients achieving a CR or CRi after salvage-reinduction chemotherapy allogeneic HCT from a matched related or unrelated donor is the preferred form of consolidation. Preferred source of allogeneic HSC are mobilized peripheral blood stem cells. Other forms of allogeneic transplantation (haploidentical donor; cord blood) are allowed.
Allogeneic HCT should be conducted at the earliest time point after the start of the last chemotherapy but no later than after 56 days. A delay of transplant beyond this time window need to be discussed with the Coordinating Investigator. Patients can receive allogeneic HCT directly after salvage re-induction chemotherapy with MC, but also later on following consolidation with IDAC."
1591411|NCT02298153|Drug|atezolizumab|atezolizumab: administered intravenously (IV) every three weeks (q3w)
1591412|NCT02298153|Drug|epacadostat|epacadostat: Oral daily dosing
1591413|NCT02298140|Other|SMS reminders|Text-message reminders about malaria case management will be prepared and distributed to all health workers seeing outpatients in the selected health facilities through their personal mobile phones and facility phones. These messages will reflect ACT recommendations from Tanzania's national guidelines for the diagnosis and treatment of malaria and training manuals. The intervention will run for three months, two text message a day will be send to all identified health workers during regular working hours (i.e. between 8 am to 3 pm), three times a week. To avoid health worker's fatigue of receiving these messages, the messages will also contain some non-malaria humorous, inspirational, motivational and educative contents.
1591414|NCT02298127|Other|Auricular acupressure|For each auricular acupressure weekly session, magnetic ears tacks will be will be applied by certified traditional Chinese medicine practitioners according to the allocated group assignment, for a duration of one month.
1591415|NCT02298114|Device|NEUROMUSCULAR ELECTRICAL STIMULATION|Neuromuscular electrical stimulation will be applied Functional Electrical Stimulation (FES) machine.
1591416|NCT02298114|Other|Conventional physiotherapy|The control group will receive conventional physiotherapy associated the placebo electrical stimulation
1591417|NCT02298101|Drug|Technetium-99m - Diethylenetriaminepentaacetic acid|Solution placed on the nebulizer reservoir
1591418|NCT02298101|Device|Aeroneb Solo Adapter|Nebulizer
1591419|NCT02298101|Device|Opti-Mist Plus Nebulizer|Standard jet nebulizer
1591420|NCT02298101|Other|Planar scintigraphy|Imaging technique to investigate whole lung deposition
1591421|NCT02298101|Other|Single photon emission computed tomography|Imaging technique to investigate regional pulmonary deposition
1591422|NCT02298101|Other|Spirometry|FEV1, FVC assessment
1591423|NCT02298088|Drug|Ticagrelor 180 mg|Ticagrelor, 180 mg as early as possible after the index event and not >24 h post event followed by 90 mg twice daily for 12 months.
1591424|NCT02298088|Drug|Clopidogrel|"300 mg clopidogrel as early as possible after the index event and not > 24h post event, followed by 75mg/day for 12 months.
For patients with > 75 years the recommended load dose is 75 mg instead 300 mg."
2009080|NCT03325049|Other|Usual Care|Usual Care
2009081|NCT03325036|Diagnostic Test|Serum levels of immunologic profiles|Serum levels of immunologic profiles before and after chemoradiotherapy
1591427|NCT02298062|Drug|Infliximab|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
1591428|NCT02298062|Drug|IVIG|The treatment-resistant children will be randomly assigned to either the infliximab or IVIG group in a 1:1 ratio and receive either infliximab (5 mg/kg at 1 mg/mL intravenously over 2 h) or IVIG (2g/kg). The primary outcome measure is change in absolute cell counts, concentrations of C-reactive protein, alanine transaminase,IL-1,IL-6,TNF-a,STNFR-I,STNFR-2; number of fever days (24 h period with a temperature of at least 38•0°C) from enrolment; duration and cost of hospital stay.The secondary 0utcome Measure is the incidence of coronary artery abnormalities
1591429|NCT02298049|Other|Satiated / Pre-meal|All participants were scanned before and after not being fed (pre-meal), and before and after being given a satiating lunch (satiated).
1591430|NCT02298049|Device|MRI|
2009082|NCT03325023|Dietary Supplement|Dietary and life style modification and probiotic Sanprobi Super Formula|Sanprobi Super Formula consisting of: Bifidobacterium lactis, Lactobacillus acidophilus, Lactobacillus paracasei, Lactobacillus plantarum, Lactobacillus salivarius, Lactobacillus lactis, Fructooligosacharide, Inulin.
2009083|NCT03325023|Other|Placebo|Placebo
2009084|NCT03325010|Drug|Valbenazine|vesicular monoamine transporter 2 (VMAT2) inhibitor
1591431|NCT02298036|Behavioral|(Remote) Cognitive Behaviour Therapy|Randomised controlled trial of 6-10 sessions of CBT for health anxiety delivered remotely via video calling or the telephone versus treatment as usual. Treatment as usual will be that decided by the patient with their general practitioner and other health providers they consult for unscheduled/urgent care.
1591432|NCT02298023|Biological|allogenic adipose stem cell treatment|Intervention will be done with stem cell injection, 0.5cc (Total: 10 million cells), fibrin glue injection 0.5cc and range of motion exercise.
1591433|NCT02298010|Drug|Capecitabine, oxaliplatin|
1591434|NCT02297997|Drug|cetylpyridinium chloride|Four study groups take cetylpyridinium chloride of 1.5mg, 3mg, 4.5mg and 6mg daily for two weeks.
1591435|NCT02297997|Drug|Placebo|Control group takes the placebo for the same period.
1591436|NCT02297945|Drug|metyrapone|Single arm study
1591437|NCT02297932|Behavioral|Strength training|Participants will engage in a home-based strength training program.
1591438|NCT02297932|Behavioral|Stretching|Participants will engage in a home-based stretching training program
1591439|NCT02297919|Behavioral|Effectiveness of Internet Based Obesity Control Programme|
1591440|NCT02297906|Drug|Ketorolac|Non-steroidal anti-inflammatory drug
1591441|NCT02297893|Behavioral|Dexterity training program (HOMEDEXT)|The dexterity training program contains 7 exercises which focus on improving fine motor skills.
1591442|NCT02297893|Behavioral|Theraband training program|The Theraband training program contains 7 exercises which focus on improving upper limb strength
1591443|NCT02297880|Other|Beverage containing low calorie sweeteners|Beverage containing low calorie sweeteners
1591444|NCT02297880|Other|Still water|Still water (no flavour)
1591445|NCT02297867|Drug|ADSCs|autologous ADSCs
1591446|NCT02297854|Drug|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
1591447|NCT02297841|Device|Experimental: Novel lubricant Miami Fragrance|
1591448|NCT02297841|Device|Experimental: Novel lubricant Miami no Fragrance|
1591449|NCT02297841|Device|KY Liquid lubricant|
1591450|NCT02297841|Device|Astroglide Gel lubricant|
1591451|NCT02297828|Device|Boussignac CPAP|Boussignac CPAP with a 50% FiO2 (adjusted in a piece adapted to the system) and a pressure of 5cmH2O (measured with a manometer) is applied immediately after extubation and mantained for two hours after extubation in the post anesthesia care unit (PACU).
1591452|NCT02297828|Device|Venturi face mask|Venturi mask with a 50% FiO2 is used immediately after extubation and mantained for two hours in the post anesthesia care unit (PACU).
2009085|NCT03325010|Drug|Placebo oral capsule|non-active dosage form
2009086|NCT03324997|Drug|Restylane Silk|Restylane Silk is a temporary hyaluronic acid filler currently approved for the lips and fine lines around the mouth.
2009087|NCT03324997|Drug|Saline|Saline as placebo
2009088|NCT03324997|Device|Optical Coherence Tomography|An FDA-cleared non-invasive imaging device
2009089|NCT03324984|Drug|2-chloroprocaine|Since 2004, 2-Chloroprocaine-PF has been used off label for spinal anesthesia and there have been very few incidence of TNS noted. The concern prior to 2004, was the the vials of Chloroprocaine had preservative sodium metabisulfite and methylparaben in them so they were not used for spinal because of incidence of transient neurologic symptoms (TNS).
1591459|NCT02297802|Drug|PD-0325901|
1591460|NCT02297789|Device|Investigative Full Face Mask with Headgear|
1591461|NCT02297763|Drug|quetiapine|"patient body weight <50kg : quetiapine 12.5mg patient body weight >=50kg : quetiapine 25mg
quetiapine 12.5mg (bwt <50kg ) or 25mg (bwt>= 50kg) study medicine is pulverized to power and melted in 10cc tepid water. The study medicine(quetiapine) will be provided as liquid form.
The study medicine(quetiapine) was provided as liquid form (medicine was pulverized and melted in 10cc water)."
1591462|NCT02297763|Drug|placebo|The placebo is made of 100mg of corn starch which is melted in 10cc water.
1591463|NCT02297750|Procedure|double-wire technique in patients undergoing ERCP with biliary cannulation|
1591464|NCT02297750|Procedure|single-wire technique in patients undergoing ERCP with biliary cannulation|
1591465|NCT02297737|Behavioral|Tai Chi|
1591466|NCT02297737|Other|Health Education|
1591467|NCT02297724|Other|Oxygen|Administration of oxygen will last for no more than 10 min, with flow rate 15L/min via non-rebreather facial mask. Each subject will have once of the administration per scan.
1591468|NCT02297711|Procedure|Total ExtraPeritoneal|This is a keyhole operation which will use one small incision at the 'belly button' followed by two small incisions of approximately 5mm in diameter below the 'belly button' . A lightweight mesh is then placed over the inguinal ligament to reinforce the weakness. This approach is keyhole in nature with visualisation of the inguinal canal from behind - posteriorly.
1591469|NCT02297711|Procedure|Open minimal suture repair|This is best described as open minimal repair and involves a small incision into the groin of the affected side. Once the inguinal canal is exposed the back wall is repaired using a simple suture to reinforce the weakness. This approach is open surgery in nature with visualisation of the inguinal canal from in front - anteriorly.
1591611|NCT02296645|Drug|ZuraPrep|Apply topically.
1591612|NCT02296645|Drug|ChloraPrep|Apply topically.
1591614|NCT02296619|Procedure|TAP block|Using real time ultrasound imaging, bilateral, 20 ml 0,25% bupivacaine inject into the area between the internal oblique and transverse abdominis muscle
1591473|NCT02297685|Device|Sham Transcutaneous nerve stimulation|The group with sham transcutaneous nerve stimulation (TENS) did not receive any electrical treatment. We placed 4 surface electrodes (5x5 cm Prim-Trode, Spain) over the L1 and L5 transverse processes with respect to the spine but we did not delivery any current. The patients were informed that they may or may not feel any sensation at the application site of the electrodes.
1591474|NCT02297685|Device|Transcutaneous nerve stimulation|The group with transcutaneous nerve stimulation (TENS) received electrical stimulation for 12 sessions at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was delivered by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) placed over the L1 and L5 transverse processes with respect to the spine. The current intensity was set 3 times during each session according to each patient's sensitivity.
1591475|NCT02297685|Device|Interferential currents|The group with IC received a base frequency of 4000 Hz with AMF = 65 Hz, sweep = 95 Hz and slope of 1/1 in tetrapolar mode (Endomed 492 Enraf-nonius, Netherlands). The current was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: were symmetrically placed over the L1 and L5 transverse processes with respect to the spine; the current intensity was set 3 times during each session according to each patient's sensitivity.
1591476|NCT02297672|Radiation|Stranded palladium seed interstitial implant|Interstitial implantation of stranded palladium 103 seeds in seroma with a margin
1591477|NCT02297672|Device|3 dimensional breast ultrasound|guidance of placement of interstitial needles in breast
1591478|NCT02297672|Device|Computerized tomography (CT)|Breast CT for planning and assessing interstitial implantation of radioactive seeds
1591479|NCT02297659|Procedure|Primary Fascial Closure|Abdominal wall closure following damage control laparotomy.
1591480|NCT02297659|Device|wound vac dressing application|temporary abdominal wall closure with this device after damage control laparotomy
1591481|NCT02297646|Behavioral|Endurance Training|
1591482|NCT02297620|Drug|Suglat®|oral
1591483|NCT02297607|Dietary Supplement|Tube Feeding|
1591484|NCT02297594|Drug|AK0529|AK0529 capsule for oral administration
1591485|NCT02297594|Drug|Placebo|Sugar placebo capsule for oral administration
1591486|NCT02297568|Drug|Calciferol|Comparison 25OHD levels between calciferol and placebo
1591487|NCT02297568|Drug|placebo|
1591488|NCT02297555|Device|ENDOBARRIER®|This medical device consists of a tube (impermeable fluoropolymer) inserted endoscopically and secured by hooks in the wall of the duodenal bulb. From the anchor site, this duodeno-jejunal sheath covers 60 cm in the small intestine. It thus limits the contact of nutrients with digestive juices (bile and pancreatic juice) and initial absorption, at least in part mimicking duodenal exclusion of the gastric bypass, one of the techniques of bariatric surgery.
1591489|NCT02297542|Biological|Flu Vaccine|
1591490|NCT02297529|Drug|Talimogene Laherparepvec|Open label single arm study. The initial dose of talimogene laherparepvec is up to 4.0 mL of 106 PFU/mL. Subsequent doses of talimogene laherparepvec are up to 4.0 mL of 108 PFU/mL.
1591491|NCT02297516|Drug|Azzalure or Dysport|Glabellar lines
1591492|NCT02297516|Device|Restylane or Emervel filler|Facial tissue augmentation
1591493|NCT02297516|Device|Restylane Skinbooster|Facial skin rejuvenation
1591494|NCT02297503|Drug|Azzalure|Glabellar lines
1591495|NCT02297503|Device|Restylane/Emervel filler|Facial tissue augmentation
1591496|NCT02297503|Device|Restylane Skinbooster|Facial skin rejuvenation
1591497|NCT02297490|Drug|Placebo|Placebo treatment is identical to the active treatment schedule. The placebo-preparation used is identical to the active solution but without any allergen substance in it.
1591498|NCT02297490|Biological|Allergovit 6-grasses|Immunotherapy will be performed for approx. 5 months. 7 injections will be administered at weekly intervals to reach the maintenance dose. However, dosing must be individualised.
1591499|NCT02297477|Drug|atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg respectively)
1591500|NCT02297477|Drug|artesunate-atovaquone-proguanil|A daily fixed dose combination of 4 tablets containing atovaquone 250mg and proguanil hydrochloride 100mg (total 1000mg/400mg daily respectively) in addition to 4 tablets containing 50mg artesunate (200mg daily)
1591501|NCT02297464|Other|Eggs - 2 per day for breakfast|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
1591502|NCT02297464|Other|1 packet of oatmeal per day|11-week crossover study in which participants consumed 2 eggs or 1 packet of oatmeal per day daily for 4 weeks, separated by a 3-week washout period.
1591503|NCT02297451|Procedure|Proximal radial/ulnar artery as inflow|Proximal radial/ulnar artery used as inflow
1591508|NCT02297425|Drug|PF-06459988|The study will evaluate PF-06459988 PO (tablets) continuous daily dosing in 21 day cycles. The starting dose for PF-06459988 will be 50 mg PO daily. The escalation/de-escalation rules will follow the modified toxicity probability interval method with adjustments using the DLT rate and maximum size per dose level of 10 patients
1591509|NCT02297412|Drug|Minocycline Hydrochloride|Given PO
1591510|NCT02297412|Other|Placebo|Given PO
1591511|NCT02297412|Other|Quality-of-Life Assessment|Ancillary studies
1591512|NCT02297412|Other|Questionnaire Administration|Ancillary studies
1591615|NCT02296619|Procedure|Control|A sham band-aid will be applied to the abdomen of subjects
1592086|NCT02293226|Device|Intubrite|Video-laryngoscopy 3
1591513|NCT02297399|Drug|PEG-ascorbate 2L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.
Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 2 sachets (labelled A and B) of the investigational product and take their contents diluted in 1 liter of water. Two other sachets, also labelled A and B, will be taken diluted in 1 liter of water 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
1591514|NCT02297399|Drug|PEG 4L|"Subjects will be asked to proceed to colonic cleansing with the interventional agents as per summary of product characteristics and specific instructions from members of the research team.
Participants will be required to be on a low residue diet for 4 days before the procedure. The preparation will begin at 9:00 pm on the evening before the colonoscopy is scheduled. Participants will take 8 sachets of the investigational product and take their contents diluted in 2 liters of water. Eight other sachets, also diluted in 2 liters of water will be taken 4 to 5 hours before the procedure. Fasting will be required from 2 hours after the investigational product has been taken."
1591515|NCT02297386|Drug|[18F] DIHYDRO-TESTOSTERONE|
1591516|NCT02297386|Device|PET scan|
1591517|NCT02297386|Device|MRI|
1591518|NCT02297386|Other|Blood draw|
1591519|NCT02297360|Dietary Supplement|Viviscal Extra-Strength Supplement|The key ingredient of Viviscal Extra-Strength Supplement is AminoMar C™ marine complex, Equisetum arvense sp. (horsetail), containing a naturally occurring form of silica), Malpighia glabra (acerola cherry) which contains Vitamin C, Biotin and Zinc. The AminoMar C™ is an active ingredient which has been trademarked and comprises of a proprietary blend of shark powder and mollusc powder. It is derived from sustainable marine sources. Viviscal provides essential nutrients to nourish hair naturally from within. The Viviscal supplement is compared to the placebo tablet which contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
1591520|NCT02297360|Other|Placebo tablet|The placebo tablet contains no active ingredients. One tablet is taken by mouth in the morning and evening with food.
1591521|NCT02297334|Device|CytoSorb device|In 20 patients the CytoSorb device will be installed into the extra corporeal circuit. A blood flow of 400ml/min is provided by an roller pump of the heart lung machine in a parallel stream to the main circulation.
1591522|NCT02297321|Device|Describe patch|Application of Describe patch over tattoo for approximately 5 minutes during Q-switched laser treatment
1591523|NCT02297295|Other|Physiotherapy|Physiotherapy three times a week for 8 weeks according to a well-defined protocol
1591524|NCT02297282|Behavioral|Behavioural Activation (BA)|Behavioural activation is a therapy, which has been shown to be quite effective in the treatment of depression. Originally a component of cognitive therapy, behavioural activation is the use of strategies such as activity scheduling, master/pleasure ratings, and graded task assignments to change one's perception of specific situations. It involves the use of activities to improve life situations or depressed mood.
1591525|NCT02297269|Device|laparoscopic surgery|the method of surgery is conducted by laparoscope with proper pressure of pneumoperitoneum instead of opening the abdomen.
1591526|NCT02297269|Device|open surgery|the method of surgery is conducted by surgical instruments to open the abdomen.
1591527|NCT02297256|Biological|BMAC & Allograft|Use of Allograft infused with adult stem cells from the bone marrow aspirate harvested from the iliac crest during posterior lumbar/lumbosacral spinal fusion.
1591528|NCT02297256|Biological|Iliac Crest Bone Graft|Use of iliac crest bone grafts (ICBG) during posterior lumbar/lumbosacral spinal fusion.
1591529|NCT02297243|Device|Sinopsys Lacrimal Stent|The Sinopsys Lacrimal Stent is indicated for use to create a transcaruncular ethmoid sinus access.
2009090|NCT03324984|Drug|0.75% bupivacaine|Bupivacaine is used on label
2009091|NCT03324971|Other|Medications review|"Medications review. Elimination of all unnecessary prescription to cut down the number of medications to the least possible number.
This is in line with the best practice guidelines."
2009092|NCT03324958|Device|Virtual reality Helmet|The virtual reality helmet will be installed by a radiotherapist or a radiotherapy manipulator, just before the intra vaginal applicator. The virtual reality headset will be connected to a dedicated computer. The virtual reality program will run for 10 minutes which will cover the entire procedure for setting up the brachytherapy device. In order to optimize the distractive potential of virtual reality, four different virtual reality programs will be offered to patients during each brachytherapy fraction. These programs will be contemplative so as not to compromise the immobility of the patients during the installation of the brachytherapy applicator.
2009093|NCT03324958|Other|No Virtual Reality Helmet|The radiotherapists can freely dialogue with the patients during the brachytherapy applicator' seating up, as in current practice.
1591534|NCT02297217|Drug|Carboplatin and Taxol (paclitaxel)|patients will receive receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on days 1, 8. Patients are seen weekly during concurrent chemoradiation then every 4 weeks until 6 months after enrollment.
1591535|NCT02297217|Radiation|External Beam Radiation|Patients will receive external beam radiation therapy of 30Gy/10 fractions over two weeks and receive carboplatin (AUC 2) and paclitaxel (50 mg/m2) intravenously on days 1, 8. Treatment will be delivered using 3D radiotherapy planning to encompass the primary tumor and surrounding clinical target volume. Preparation and administration of chemotherapy will be according to local site standard operating procedures. Patients are seen weekly during concurrent chemoradiation then every 4 weeks until 6 months after enrollment.
1591613|NCT02296632|Behavioral|Motion sensors and daily online assessments|Patients will be asked to wear motion sensors during their waking hours and complete daily Patient Reported Outcomes online assessments.
1591653|NCT02296385|Dietary Supplement|Triple Strength Fish Oil|Triple Strength Fish Oil
2009094|NCT03324945|Behavioral|Neurocognitive assessments|Baseline and post-chemotherapy neurocognitive testing. A sequentially-assigned subset of participants also receive baseline and post-chemotherapy neuroimaging (FMRI)
2009095|NCT03324932|Drug|Denosumab Injection|AI intake + denosumab injection per 6 months VS only AI intake
2009096|NCT03324919|Behavioral|HRQL|Intervention of patient centered care situation and health-related quality of life of patients with Psoriasis, Urticaria or Lupus erythematodes from non-urban practices vs urban practises. Identification of relevant health-related quality of life parameters of these patients.
1591536|NCT02297204|Procedure|Focal Laser Treatment|All subjects receiving PRN IVT aflibercept injections will be evaluated for focal laser treatment beginning at week 12 through the end of the study. If the subject meets any of the criteria for focal laser treatment (FLT), fluorescein angiography (FA) will be performed to guide the focal laser treatment. Focal laser treatment and focal laser re-treatment will be administered no more than once every 90 days.
1591537|NCT02297204|Drug|aflibercept 2.0 mg|If a subject has recurrent CR-DME they will receive an IVT aflibercept injection
2009097|NCT03324906|Device|tDCS|The anode will be placed in the left side of DLPFC (F3) of the International Electrode Placement System 10-20 and cathode will be placed in the same region of the contralateral cortex, corresponding to the area F4. The stimulation current will be 2mA (for individuals aged 14-35 years) and 1mA (for individuals aged 11 to 13 years, maintaining this intensity until the end of the stimulation), will last for thirty seconds, and the ramp will exit fifteen seconds. The stimulation will last for up to 20 minutes, for a total of 10 sessions, one a day for twice a week with a weekend break.
2009098|NCT03324893|Diagnostic Test|[F-18]-FCH PET/MRI|Subjects will undergo the [F-18]-FCH PET/MRI within three months prior to scheduled parathyroidectomy.
1591540|NCT02297178|Procedure|Cystoscopy only|Cystoscopy performed for investigation and treatment of OAB and voiding dysfunction
1591541|NCT02297178|Procedure|Cystoscopy and Urethral dilatation|Cystoscopy and urethral dilatation performed for investigation and treatment of OAB and voiding dysfunction
1591542|NCT02297165|Behavioral|olfactory stimulation program|"8 individual sessions of olfactory stimulation at the rate of 2 sessions per week. 3 semi-directed interviews will be help (one at the beginning of the trial, the second 5 weeks later and the third at 6 month).
For each session, patients have to smell two different odors (previously selected from a panel presented to the patient during first visits) and then they are invited to evoke memories and feelings related to each odor."
2009099|NCT03324880|Biological|rhPTH(1-84)|rhPTH(1-84) 25, 50, 75, and 100 mcg QD SC injection will be administered
2009100|NCT03324880|Biological|Placebo|Placebo QD SC injection will be administered
1591545|NCT02297126|Device|Pharmacogenetic Intervention Arm (pharmacogenetic testing)|In the design of this trial, pharmacogenetic testing will be triggered by the incident prescription of one or more of the targeted medications listed in the control arm. The pharmacogenetic array to be used incorporates 51 genetic variants for the following 16 genes/transporters: ATP-binding cassette sub-family C member 2, ATP-binding cassette, sub-family C, member 4, Cytochrome P450 2B6, Cytochrome P450 2C19, Cytochrome P450 2C9, Cytochrome P450 2D6, Cytochrome P450 3A4/3A5, Cytochrome P450 4F2, Dihydropyrimidine dehydrogenase, Glucose-6-Phosphate Dehydrogenase, Human Leukocyte antigen-B, I interleukin-28B, Inosine Triphosphatase, Solute Carrier Organic Anion Transporter Family, Member 1B, Thiopurine methyltransferase and V vitamin K epoxide reductase complex, subunit 1.
1591546|NCT02297113|Device|Macintosh blade|conventional endotracheal intubation
1591547|NCT02297113|Device|C-MAC videolaryngoscope|
1591548|NCT02297100|Drug|Onabotulinumtoxin A|100 units of botox spread out among 10 separate injections
1591549|NCT02297100|Procedure|injections upper aspect of trigone of urinary bladder|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
1591550|NCT02297100|Procedure|injections on posterior bladder wall excluding the trigone|We hypothesize that injections into the trigone should be more effective in the treatment of IC than injections elsewhere in the bladder.
1591551|NCT02297087|Genetic|Standard of care based on target(s) identified via GWS.|
1591552|NCT02297074|Other|Ordinary white bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.
After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
1591553|NCT02297074|Other|Precooked-Frozen White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.
After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
1591554|NCT02297074|Other|Candeal-flour White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.
After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
1591598|NCT02296697|Other|Wound dressing with saline solution|Wound dressing will be done daily on patients from the three groups during the study period. On patients who will receive laser therapy and high frequency, the pressure ulcer will be sanitized with worm saline solution in order to clean the wound. This cleaning will be done before and after the interventions.
1591599|NCT02296684|Biological|MK-3475|
1591600|NCT02296684|Procedure|Surgery|
1591601|NCT02296684|Radiation|Intensity modulated radiation therapy|
1591602|NCT02296684|Radiation|Image-guided radiation therapy|
1591603|NCT02296684|Drug|Cisplatin|
2009101|NCT03324867|Drug|Regular insulin|40 IU of Humulin-R to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery.
1591555|NCT02297074|Other|Alfacar White Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.
After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
1591556|NCT02297074|Other|Wholemeal Bread|"The evening before the test day, subjects consumed a standardised dinner. Volunteers arrived in a 12-h fasting state. A fasting blood sample was acquired after the resting time, and appetite feelings were assessed by using visual analogue The subjects were instructed to consume the tested bread or 50 g of glucose. The subjects immediately completed two VAS, one on appetite feelings and another on bread palatability. The appetite feeling VAS were repeated every 30 min until a total of 180 min had passed. The subjects were not allowed to eat or drink anything else during the 180 min of the intervention.
After the last blood extraction (3 h), an ad libitum lunch and 300 ml of water was provided. Volunteers ate until comfortably satisfied and the amount of food intake was registered"
1591557|NCT02297074|Other|Glucose|50 g of glucose were administered as a reference
1591558|NCT02297061|Biological|Thrombelastography analysis (TEG)|TEG analysis is performed on admission
1591559|NCT02297048|Dietary Supplement|Potassium depletion|Healthy subjects will be submitted twice at 15-30 day interval, to a low potassium diet (20mmol/day)
1591560|NCT02297035|Behavioral|Behavioural testing|
1591561|NCT02297035|Other|Brain imaging|MRI, PET
1591562|NCT02297035|Genetic|Genetic screening|APOE, Progranulin
1591563|NCT02297022|Device|Deep Brain Stimulation|Deep Brain Stimulation hypothalamic surgery in patients with Prader-Willi syndrome
1591564|NCT02297009|Procedure|Buccal swab|Buccal swabs will be taken from the volunteers
1591565|NCT02296996|Drug|Dabrafenib + Trametinib|
1591566|NCT02296983|Biological|VSV-ZEBOV|VSV-ZEBOV
1591567|NCT02296970|Procedure|Deep shave removal using a blue surgical blade|Removal of a skin lesion with 2mm margins and an adequate amount of tissue deeper than the clinical appearance of the lesion using a blue surgical blade
1591568|NCT02296957|Procedure|Hypnosedative discontinuation|Intervention towards hospital physicians to promote hypnosedative discontinuation in patients initiated during the hospital stay, intervention towards patients and their general practitioners to heighten awareness about the hypnosedative-related risks.
1591569|NCT02296944|Other|Collection of anatomical and functional results in the appearance of the tympanic membrane after surgery|
1591570|NCT02296931|Other|Saline|Standard IV Saline Fluids
1591571|NCT02296931|Drug|Magnesium Sulfate|The standard drug used to prevent and treat convulsions for women with pre-eclampsia and eclampsia is magnesium sulfate (MgSO4)
1591572|NCT02296918|Drug|acalabrutinib in combination with obinutuzumab|Patients with R/R CLL
1591573|NCT02296918|Drug|acalabrutinib in combination with obinutuzumab|Patients with treatment-naive CLL
1591574|NCT02296905|Drug|ABT-493|Up to 2 single doses of ABT-493 will be given orally in combination with ABT-530.
1591575|NCT02296905|Drug|ABT-530|Up to 3 single doses of ABT-530 will be given orally alone or in combination with ABT-493.
1591576|NCT02296892|Drug|Remimazolam|For induction and maintenance of sedation
1591577|NCT02296892|Drug|Placebo|For induction and maintenance of sedation
1591578|NCT02296892|Drug|Midazolam|For induction and maintenance of sedation
1591579|NCT02296879|Genetic|SAIT301|The treatment period will consist of 21-day cycles. On Day 1 of each cycle, SAIT301 will be administered as an intravenous (IV) infusion.
1591580|NCT02296853|Drug|TAF|Tenofovir alafenamide (TAF) 25 mg tablet administered orally
1591581|NCT02296840|Drug|Ibuprofen|Ibuprofen 10mg/kg/day every 6-8 hours
1591582|NCT02296840|Drug|Hydrocodone-Acetaminophen|Hydrocodone-Acetaminophen 0.15mg/kg/day every 4-6 hours
1591583|NCT02296814|Drug|Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
1591584|NCT02296814|Drug|Placebo for Sinusitis Hevert SL Tablet|1st week: 6 times daily 2 tablets and 2nd week: 4 times daily 2 tablets
1591585|NCT02296801|Drug|Letrozole|
1591586|NCT02296801|Drug|palbociclib|
1591587|NCT02296788|Behavioral|Aerobic Exercise|The exercise expenditure goals were calculated by multiplying the participants' body weight by the exercise dose (8 or 20 KKW) divided by the number of sessions (3-5 sessions/wk). The speed and grade were monitored and documented to keep participant heart rate at 65-85% of tested VO2 peak and entered into ACSM equations for energy expenditure.
1591588|NCT02296775|Biological|DRL_RI|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
1591589|NCT02296775|Biological|Rituxan|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
1591590|NCT02296775|Biological|MabThera|Two 1000 mg intravenous infusions, one each on Day 1 and Day 15
1591591|NCT02296762|Drug|Sirolimus|Sirolimus tablets 2 mg
1591592|NCT02296749|Drug|Sirolimus|Sirolimus tablets 2 mg
1591593|NCT02296736|Radiation|Computerised tomography (CT) scan|Retrospective review of CT scans
1591594|NCT02296723|Drug|Valganciclovir Hydrochloride|Valganciclovir Hydrochloride Tablets 450 mg
1591595|NCT02296710|Procedure|Echocardiographic and sleep apnea test|Echocardiographic evaluation (Vivid 7, GE) of systolic and diastolic function of both ventricles as well as evaluation of apnea-hypopnea index and type of apnea (ApneaLink®)
1591596|NCT02296697|Device|Low-level laser therapy AlGaInP|Pressure ulcers will be treated with AlGaInP 660 nm laser, wich will be used once a day, five days per week, dosed with 6 J/cm2. Laser therapy is applied punctually in each 1cm2 of the ulcer.
1591597|NCT02296697|Device|High-frequency therapy with O3 formation|High-frequency laser therapy will be applied with spherical electrode, wich contains neon gas inside, from a short distance from the pressure ulcer. The application will last 15 minutes, with increasing intensity from 80 to 100% for ozone formation, once a day, five days per week.
1591604|NCT02296671|Drug|Pemetrexed|
1591605|NCT02296671|Drug|Oxaliplatin|
1591606|NCT02296671|Drug|Leucovorin|
1591616|NCT02296593|Device|comparison of blood lactate and glucose levels|comparison of blood lactate and glucose levels with the reference method (co oxymetry) and a new central veinous catheter microdialysis system provided by MAQUET. (Critical Care AB, Solna, Sweden.)
2009102|NCT03324867|Drug|Normal Saline Flush, 0.9% Injectable Solution|Placebo: Normal Saline to be administered via nose using metered nasal dispenser prior to surgery, and up to 7 days after surgery
1591618|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
1591619|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care.
1591620|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care.
1591621|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care.
1591622|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal Bevacizumab as part of their routine medical care
1591623|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
1591624|NCT02296567|Drug|Ranibizumab|Drug: Ranibizumab Subjects will receive intravitreal Ranibizumab as part of their routine medical care
1591625|NCT02296567|Drug|Bevacizumab|Drug: Bevacizumab Subjects will receive intravitreal bevacizumab as part of their routine medical care
1591626|NCT02296567|Drug|Aflibercept|Drug: Aflibercept Subjects will receive intravitreal Aflibercept as part of their routine medical care
1591627|NCT02296567|Other|Control Group|Control group Subjects will no previous anti-VEGF treatment
1591628|NCT02296554|Procedure|SLAP Repair|SLAP repair for SLAP tear
1591629|NCT02296554|Procedure|Biceps Tenodesis|Biceps tenodesis for SLAP tear
1591630|NCT02296541|Biological|DNA Nat-B env|4 mg to be administered as 1 mL intramuscularly (IM) by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
1591631|NCT02296541|Biological|DNA CON-S env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
1591632|NCT02296541|Biological|DNA Mosaic env|4 mg to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
1591633|NCT02296541|Biological|MVA-CMDR|1×10^8 plaque forming units (pfu) to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
1591634|NCT02296541|Biological|Placebo for DNA Nat-B env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
1591635|NCT02296541|Biological|Placebo for DNA CON-S env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
1591636|NCT02296541|Biological|Placebo for DNA Mosaic env|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM by Biojector 2000® or with a needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
1591637|NCT02296541|Biological|Placebo for MVA-CMDR|Sodium Chloride for Injection, 0.9% to be administered as 1 mL IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated)
1591638|NCT02296528|Device|Swallowing Expansion Device|"SED looks like the letter T and has a plate and a post. The plate is like the top part of the T or smooth part of the tack. The plate is attached to the cartilage or flexible connective tissue of the throat. The SED post is like the bottom part of the T with a small ring. The post permanently sticks out from the throat, like a skin piercing. The SED is made out of titanium because this metal is extremely strong and commonly used in medical devices put into the body, such as hip joints or bone plates."
1591639|NCT02296515|Procedure|Intrathecal pump refill:|Two different experienced clinicians will perform one time the blind technique andTwo different experienced clinicians will perform one time the blind technique andtwo times the ultrasound-guided technique on all patients.
2009103|NCT03324854|Procedure|Rives technique|Open ventral hernia repair followed by the placement of the mesh.
1591641|NCT02296489|Device|Capnostream20p|The device will be used to monitor respiratory co2 values during the methacholine challenge, a well known diagnostic procedure
1591642|NCT02296476|Drug|OTX015|OTX015 is to be administered per os daily in a fasted state just before breakfast (around 8 a.m. [±2h]), without a rest period. A treatment cycle will be 4-weeks (Day 1= Day 29). Dosing not performed at the same time (±2h) as on other days will be omitted. Patients are to be instructed that if they vomit or omit their dose in that time frame, it is not to be replaced.
1591643|NCT02296463|Biological|RSV F Vaccine with adjuvant (0.5mL injection)|
1591644|NCT02296463|Biological|RSV F Vaccine (0.5mL injection)|
1591645|NCT02296463|Biological|Hepatitis A Vaccine (0.5mL injection)|
1591646|NCT02296463|Biological|Placebo (0.5mL injection)|
1591647|NCT02296450|Behavioral|Quality of Life (QoL) Assessment|Per physician's discretion, the patient (or, if applicable, patient's family member/ spouse/ caregiver for FDLQI) will complete one or more of the following dermatology-specific QoL instruments: Skindex-16, Skindex-29 DLQI (Dermatology Life Quality Index), FDLQI (Family DLQI) - for patient's family member/spouse/caregiver ONLY, CDLQI (Children's DLQI;Cartoon version) - for patient's under the age of 18 ONLY, FACT-G (Functional Assessment of Cancer Thearpy-General), FACT-Melanoma (Functional Assessment of Cancer Therapy-Melanoma), SCI (Skin Cancer Index) Face-Q Skin Cancer FACT-EGFRI-18 (Functional Assessment of Cancer Therapy-Epidermal Growth Factor Receptor Inhibitor-18), HFS-14 (Hand-Foot Syndrome) OMWQ (Oral Mucositis Weekly Questionnaire), ESTEEM, Hairdex , Skindex-29 modified for hair loss, Itchy QoL,CADS (Chemotherapy-induced alopecia distress scale), ONYCHO (Nail-specific QoL questionnaire), Scalpdex
1591649|NCT02296424|Drug|ACZ885 150 mg (Canakinumab)|Active canakinumab in individual 2 mL glass vials, each containing 150 mg canakinumab liquid in vial.
1591650|NCT02296411|Drug|CHF 5259 12.5 µg|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
1591651|NCT02296411|Drug|CHF 5259 placebo|comparison of CHF5259 versus placebo over 2 treatment periods of 6 weeks
1591652|NCT02296398|Drug|Romidepsin|Received romidepsin per standard of care or through a clinical trial for more than one cycle
1591654|NCT02296372|Device|Continuous glucose monitoring|"Continuous glucose monitoring by subcutaneous or intravasal device for 72 hours.
In use MEDTRONIC SENTRINO® and Edwards GlucoClear® systems."
1591655|NCT02296359|Biological|Influenza Vaccination|The individuals will be followed to observe their immune system activation, following their vaccination with the standard influenza vaccine approved for the year by the FDA.
1591656|NCT02296346|Drug|SoluMedrol|Infusion of drug subcutaneously, once a month.
1591657|NCT02296346|Device|Extracorporeal Photopheresis|This intervention is the placement of up to two IV's to extract your blood as a set volume, separate out the white cells and return the red cells to your body. Then the white cells are treated with a drug called UVADEX (methoxsalen), excited by a UV light and returned to your body. Once IV is to withdraw your blood and the other is to return your blood to your body.
1591658|NCT02296333|Drug|ondansetron|8 mg intravenous in the skin closure
1591659|NCT02296333|Drug|isotonic|8 mg intravenous in the skin closure
2009104|NCT03324854|Procedure|Drainage|Placement of active-close drainage in surgical site.
2009105|NCT03324854|Drug|Prophylactic|Prophylactic antibiotic 1gm of cefalotin was administered 30 minutes before the incisión.
1591662|NCT02296307|Other|Blood test: CA-125 biomarker|"CA-125 biomarker blood test at visit 1, day 1.
CA-125 biomarker blood test at visit 2, week 6."
1591663|NCT02296307|Other|Second Test: Transvaginal Ultrasound|-Transvaginal Ultrasound at visit 1, day 1.
1591664|NCT02296307|Other|Follow-up phone call|Phone call 6 months after last visit to verify continued health.
1591665|NCT02296294|Drug|Elo-mel® (Fresenius Kabi Austria)|an iv isotonic crystalloid fluid therapy at a rate of 0,50ml/kg/min for one hour.
1591666|NCT02296294|Device|Body Composition Monitoring|BCM measurements every 10 minutes for 6 hours.
1591667|NCT02296281|Drug|Pirfenidone|
1591668|NCT02296268|Behavioral|Aerobic Exercise Screening and Prescription Clinic|Patients will be referred to the Clinic by their physiotherapist to be assessed regarding their safety and readiness to participate in aerobic training. If they are deemed to be safe and ready, an aerobic exercise prescription will be written to guide the implementation of a safe and effective training protocol. Patients deemed to be at moderate to high risk will need to be cleared for testing by a physician on the stroke service. A cardiologist will be consulted about specific concerns re cardiac status.
1591669|NCT02296255|Biological|Cervarix®, GlaxoSmithKline|3 doses (0,1,6 months) of Cervarix®, GlaxoSmithKline
1591670|NCT02296242|Drug|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
1591671|NCT02296229|Radiation|stereotactic body radiation therapy|Undergo SBRT
1591672|NCT02296229|Other|quality-of-life assessment|Ancillary studies
1591673|NCT02296229|Other|laboratory biomarker analysis|Correlative studies
1591674|NCT02296229|Drug|androgen deprivation therapy|up to 9 months at the discretion of the treating physician
1591675|NCT02296216|Device|Gamma Knife radiosurgery|To determine potential long-term (superior to 10 years) extra-pituitary side-effects of Gamma Knife radiosurgery in patients treated for Acromegaly
1591676|NCT02296203|Drug|cetuximab|
1591677|NCT02296203|Drug|irinotecan|
1591678|NCT02296190|Drug|Etripamil|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
1591679|NCT02296190|Drug|Placebo|intranasal administration via 4 prefilled Aptar Pharma Unit-Dose Spray devices
1591680|NCT02296177|Behavioral|Peace of Mind Program|The Peace of Mind Program (PMP) is a telephone counseling program based on the Transtheoretical Model of Change, with messages matched to readiness (assessed with a stage of change question)and barriers identified by women who are non-adherent to mammography. The program telephone protocol guides counselors to assess a woman's readiness to be screened and counsel her through barriers to increase appointment keeping.
1591681|NCT02296164|Drug|Valchlor|Valchlor gel 0.016%
1591682|NCT02296151|Other|Gluteus medius strengthening|Hip abductor, gluteus medius strengthening
1591683|NCT02296151|Other|iliotibial band stretches|Iliotibial band stretches
1591684|NCT02296138|Drug|olodaterol|fixed dose combination
1591685|NCT02296138|Drug|tiotropium|fixed dose combination
1591686|NCT02296138|Drug|tiotropium|
2009106|NCT03324841|Diagnostic Test|Caris MI Profiling|Customized comprehensive biomarker testing
2009107|NCT03324828|Drug|Hydroxyzine|Hydroxyzine solution
2009108|NCT03324828|Other|Clowns intervention|Clowns intervention
2009109|NCT03324815|Drug|Morphine|Pain Treatment
2009110|NCT03324815|Drug|Methadone|Pain Treatment
1591772|NCT02295592|Procedure|PPH|PPH is short fo procedure for prolapsed hemorrhoids .Patients in group B with severe prolapsed hemorrhoids will undergo PPH operation.
1591773|NCT02295579|Other|lactobacillus (EcoVag)|Probiotic human lactobacillus (L. gasseri and L rahmnosus)
1591774|NCT02295566|Drug|Nitric Oxide|Not required
2009111|NCT03324802|Radiation|Hypofractionated Radiation Therapy|Undergo hypofractionated radiation therapy
2009112|NCT03324802|Other|Quality-of-Life Assessment|Ancillary studies
2009113|NCT03324802|Radiation|Radiation Therapy|hypofractionated radiation therapy
2009114|NCT03324789|Other|Single Implant Partial Over-denture|Single Implant Retained Partial Over-denture will be as follows; two rests on principle abutments and lingual plate major connector, single implant in the symphyseal region.
2009115|NCT03324789|Other|Conventional Partial Denture|patients will receive conventional partial denture with double Aker clasp on mandibular second premolar and first molar, with no indirect retention and lingual plate as major connector .
2009116|NCT03324776|Drug|Afrezza Inhalant Product|Mealtime Ultra-Rapid Acting Insulin
2009117|NCT03324763|Other|stool sampling|A stool sample will be collected to perform the H. pylori antigen test
2009118|NCT03324737|Device|Interactive Smartphone App|"There are six main components to the APP.
Goal Setting: personalizes diet, activity, and weight loss goals for patients based on their starting point.
Food choices and recommendations: App has an automated and immediate recommendation of foods if the choice selected from food database is not optimal. It has a calorie and nutrients tracker to enable patients to track their food intake.
Activity and steps tracker: App has a pedometer to count physical activity and steps to enable patients to track their progress towards goals.
Interactive video lessons: App has video lessons pushed weekly to the patient according to her needs. The videos encompass aspects of diet, lifestyle and behavior management.
Healthcare Professionals Support: App has a chat channel to enable interaction between participants and healthcare professionals."
1591693|NCT02296112|Drug|trametinib|Given PO
1591694|NCT02296112|Other|laboratory biomarker analysis|Correlative studies
1591695|NCT02296112|Other|pharmacological study|Correlative studies
1591696|NCT02296099|Drug|liposomal bupivacaine|Liposomal bupivacaine 20 mL diluted with 10 mL normal saline. Ten mL of solution to be injected into the vaginal epithelium in the mid-urethral area and 10 mL injected into each of the trocar paths through the suprapubic incisions bilaterally.
1591697|NCT02296099|Drug|Placebo|Normal saline 30 mL total injected. Ten mL injected into the vaginal epithelium in the mid-urethral area and 10 mL will be injected into each of the trocar paths through the suprapubic incisions bilaterally.
1591698|NCT02296073|Drug|Midazolam|midazolam 3～5μg/kg•min for maintenance of sedation.
1591699|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.5μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
1591700|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.25μg/kg intravenous bump for 15 min，then 0.2～1.4μg/(kg.h) for maintenance of sedation；
1591701|NCT02296073|Drug|Dexmedetomidine|Dexmedetomidine 0.2～1.4μg/(kg.h) for maintenance of sedation；
1591702|NCT02296073|Drug|Fentanyl|Fentanyl 0.5～4 μg/(kg.h) for maintenance of analgesia
1591703|NCT02296073|Other|assessment|Ramsay score for sedation assessment, Facial expression, leg movement, activity, cry, and consolability score (FLACC) for analgesia assessment.
1591704|NCT02296060|Procedure|6 minutes walking test|
1591705|NCT02296047|Drug|Placebo|physiological saline
1591706|NCT02296047|Drug|ipratropium bromide|80 µg inhalation once
1591707|NCT02296047|Drug|salbutamol|400 µg inhalation once
1591708|NCT02296021|Drug|Berberine|Berberine-containing quadruple therapy group: given for 14 days at a dose of berberine 100 mg 5 tablets BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
1591709|NCT02296021|Drug|Bismuth|Bismuth-containing quadruple therapy group: given for 14 days at a dose of colloidal bismuth tartrate capsule 55 mg 4 capsules BID, esomeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID.
1591710|NCT02296021|Drug|esomeprazole|Esmeprazole 20mg 1tablet BID plus amoxicillin 500 mg 2 capsules BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
1591711|NCT02296021|Drug|amoxicillin|Amoxicillin 500 mg 2 capsules BID plus esmeprazole 20mg 1tablet BID, clarithromycin 500 mg 1 tablet BID, and colloidal bismuth tartrate capsule 55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
1591712|NCT02296021|Drug|clarithromycin|Clarithromycin 500 mg 1 tablet BID plus amoxicillin 500 mg 2 capsules BID, esmeprazole 20mg 1tablet BID, and colloidal bismuth tartrate capsule55 mg 4 capsules BID or berberine 100 mg 5 tablets BID as a dose given for bismuth-containing quadruple therapy or berberine-containing quadruple therapy.
1591713|NCT02296008|Device|3D high resolution anorectal manometry|"Procedure will take about 15 minutes. During procedure resting, squeeze, bear down maneuver, cough, ano-anal and rectoanal inhibitory reflex will be obtained, if possible.
3D picture of pressures of anorectal will be recorded."
1591715|NCT02295982|Procedure|Hand assisted laparoscopic nephrectomy|patients with renal cancer will undergo hans assisted laparoscopic nephrectomy
1591716|NCT02295969|Drug|Oralair|Observational study, Oralair is used as prescribed by the prescriber phycisian.
1591717|NCT02295956|Behavioral|Questionnaires|Series of physical and quality of life assessments administered to participants, taking about 20 minutes to complete.
1591718|NCT02295956|Other|Exercise|Participants instructed to perform resistance/strengthening exercises for 30 minutes two times each week. Participants to walk 20-30 minutes at least 3 times a week. Participants issued a set of 3 resistance exercise bands with which the exercises can be performed.
1591719|NCT02295956|Other|Nutrition Counseling|Within 7 days after being enrolled on study, participant meets with a dietitian to discuss nutrition.
1591720|NCT02295956|Behavioral|Phone Calls|Participants receive phone calls from study staff every 2 weeks for 6 weeks to check for adherence, and if they are having any side effects from the exercise.
1591721|NCT02295956|Other|Booklet|Exercise instructional booklet given to all participants describing all exercises.
1591722|NCT02295943|Other|Positioning measuring device|Vitrectomy, intraocular gas fill. The supine time during the first postoperative day is measured
1591723|NCT02295930|Other|folfoxiri+cetuximab+surgery+cetuximab|"Induction FOLFOXIRI plus cetuximab will consist of:
CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by
IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by
OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with
l-LV 200 mg/sqm IV over 2-h, day 1 followed by
5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.
Surgical revaluation will be performed after the induction phase (8 cycles).
Patients deemed unsuitable for surgery will received maintenance treatment as follows:
•CETUXIMAB 500 mg/sqm IV over 60-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
1591775|NCT02295566|Drug|Control|Not required
1591776|NCT02295553|Drug|Ketamine|
1591777|NCT02295553|Drug|Propofol|
1591778|NCT02295540|Radiation|hypofractionated radiation therapy|Undergo hypofractionated IMRT
1591779|NCT02295540|Radiation|intensity-modulated radiation therapy|Undergo hypofractionated IMRT
1591780|NCT02295540|Procedure|therapeutic conventional surgery|Undergo surgery
1591724|NCT02295930|Other|folfoxiri+cetuximab+surgery+bevacizumab|"Induction FOLFOXIRI plus cetuximab will consist of:
CETUXIMAB 500 mg/sqm IV over 1-h* , day 1 followed by
IRINOTECAN 130 mg/sqm IV over 1-h, day 1 followed by
OXALIPLATIN 85 mg/sqm IV over 2-h, day 1 concomitantly with
l-LV 200 mg/sqm IV over 2-h, day 1 followed by
5-FLUOROURACIL 2400 mg/sqm IV 48-h continuous infusion, starting on day 1 repeated every 2 weeks for 8 cycles.
Surgical revaluation will be performed after the induction phase (8 cycles).
Patients deemed unsuitable for surgery will received maintenance treatment as follows:
•BEVACIZUMAB 5 mg/kg IV over 30-min, day 1 repeated every 2 weeks until PD, patient's refusal, unacceptable toxicity or consent withdrawal."
1591725|NCT02295917|Device|Transvaginal sonography|Transvaginal sonography
1591726|NCT02295891|Device|MiraDry ®|Non-invasive thermolytic technology which utilizes a microwave energy-based mechanism targeted for eccrine gland reduction at the dermal-fat interface
1591727|NCT02295878|Dietary Supplement|Treatment capsule containing seaweed extract (treatment)|400mg capsule containing seaweed extract (treatment)
1591728|NCT02295878|Dietary Supplement|Placebo|
1591729|NCT02295865|Drug|JNJ-38518168 60 mg|Two tablets of JNJ-38518168, 30 milligram (mg) each for a total of 60 mg, orally, once daily.
1591730|NCT02295865|Drug|JNJ-38518168 30 mg|One tablet of JNJ-38518168, 30 mg, orally, once daily.
1591731|NCT02295865|Drug|JNJ-38518168 3 mg|One tablet of JNJ-38518168, 3 mg, orally, once daily.
1591732|NCT02295865|Drug|Placebo|Matching Placebo either 30 mg tablet or 3 mg tablet will be administered orally.
1591733|NCT02295852|Dietary Supplement|LOW-SODIUM LOW LIPID CALCIUM RICH DIET|1.Composition of the diet: Proteins 17%, Total lipids 28%, Saturated Fatty Acids 7%, Carbohydrates 54%, Fibers 42 g, Sodium 1377 mg, potassium 4067mg, Calcium 1211 mg
1591734|NCT02295852|Dietary Supplement|LOW-SODIUM LOW LIPID DIET|2. Composition of the diet: Proteins 17%, Total lipids 27%, Saturated Fatty Acids 7%, Carbohydrates 56%, Fibers 39 g, Sodium 1397 mg, potassium 3973 mg, Calcium 650 mg
1591735|NCT02295839|Behavioral|Sleep Hygiene and Relaxation Education|Intervention group participants receive a nurse-led, one-hour 1:1 educational session including education about sleep in children and a description of what is known about sleep and fatigue issues in children with cancer. The session also includes strategies to improve sleep hygiene in children. Information about relaxation to promote sleep is outlined and two children's books designed to promote relaxation using the principles of deep breathing are given to the parent(s). A handout containing all the information covered is given to the parent(s).
1591736|NCT02295826|Drug|Dabigatran|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
1591737|NCT02295826|Drug|Acetylsalicylic acid|participants randomized to ASA therapy will be loaded with 325 mg of ASA, followed by 81 mg/day
1591738|NCT02295813|Biological|FBF001|
1591739|NCT02295813|Drug|Placebo|
1591740|NCT02295800|Other|Standard of care|
1591741|NCT02295800|Other|Semi-structured interviews|
1591742|NCT02295787|Drug|Ketamine|Intranasal ketamine for late-life depression and suicidal ideation.
1591743|NCT02295787|Drug|Placebo|
1591744|NCT02295774|Procedure|standard white light colonoscopy-equivalent to placebo|standard white light colonoscopy
1591745|NCT02295774|Drug|Methylene Blue MMX tablets|8x25mg methylene blue MMX tablets administered before a colonoscopy
1591746|NCT02295761|Behavioral|Lifestyle counseling (Fb)|Facebook-delivered lifestyle counseling
1591747|NCT02295761|Behavioral|Lifestyle counseling + activity monitor (Fb+Act)|Facebook-delivered lifestyle counseling and self-monitoring physical activity using Polar activity monitor
1591748|NCT02295748|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized rapidly to the active drug 21-desacetyldeflazacort.
1591749|NCT02295735|Device|Mepilex® Border Sacrum and Mepilex® Border Heel|
1591750|NCT02295722|Drug|Gemcitabine|gemcitabine 1.5 g/m2 INFUSED
1591751|NCT02295722|Drug|Melphalan|200 mg/m2
1591752|NCT02295722|Other|ASCT|Day 0 - Stem cell infusion
1591753|NCT02295709|Procedure|SNR steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal nerve root with the guidance of ultrasound.
Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
1591754|NCT02295709|Procedure|CTF steroid (dexamethasone) injection|"deliver steroids (dexamethasone) into spinal epidural space with the guidance of ultrasound.
Device: Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)"
1591755|NCT02295709|Drug|Dexamethasone|One of the most efficient steroids
1591756|NCT02295709|Device|Ultrasound|Ultrasound (S-Nerve; SonoSite, Bothell, Wash), Probe 9L (6 MHz, SonoSite, Bothell, Wash)
1591757|NCT02295709|Radiation|C arm|the needle position will be re-confirmed by C arm C arm (Philips Healthcare, Best, the Netherlands）
1591758|NCT02295696|Behavioral|EMMA|Consultations using dialogue tools
1591759|NCT02295683|Device|Renal Denervation|
1591760|NCT02295670|Device|Vividtrac|video-laryngoscopy
1591761|NCT02295670|Device|MIL|direct-laryngoscopy
1591762|NCT02295657|Device|standard double-lumen tube|intubation using standard double-lumen tube
1591763|NCT02295657|Device|VivaSight Double Lumen Tube|intubation using VivaSight Double Lumen Tube
1591764|NCT02295644|Device|Ultrasound Sonicator 740|Therapeutic ultrasound (Ultrasound Sonicator 740) used on masseter muscle, 1MHz, 5 minutes
1591765|NCT02295631|Device|Standard tracheal tube|ETI with standard tracheal tube and Macintosh laryngoscope
1591766|NCT02295631|Device|ETView VivaSight SL|ETI with ETView VivaSight SL
1591767|NCT02295618|Device|Standard tracheal tube|Intubation using Macintosh laryngoscope and standard tracheal tube
1591768|NCT02295618|Device|ETView VivaSight SL|Intubation using ETView VivaSight SL
1591769|NCT02295605|Other|water-based exercises|water-based exercise strengthening protocol for lower limb muscles
1591770|NCT02295605|Other|land-based exercises|land-based exercise strengthening protocol for lower limb muscles
1591771|NCT02295592|Procedure|TSTstarr+|"TSTstarr+ : a kind of modified STARR（stapled transanal rectal resection ） operation, compared to the traditional STARR operation, it does not need two staplers but with a larger diameter stapler,  + means better . Patients in group A with severe prolapsed hemorrhoids will undergo TSTstarr+ operation ."
1591782|NCT02295527|Other|Home-based physical exercise intervention|Progressive strengthening of muscle groups ankle dorsi flexors, knee extensors and hip abductors and progressive balance training according to individual capacity:weight-bearing, limits of stability, change of position/direction, maintenance of static and dynamic stability, anticipatory adjustments using different bases of support and different sensory conditions. Dynamic exercises involving spin on its own axis, sitting and standing, up and down stairs, functional reach, steps in different directions and walk training. In the first session the physiotherapist will choose two exercises that best address the participant function goals and will add more exercises each week according to the level of participants' ability and motivation. Participants will receive a detailed booklet, containing photos and instructions of the12 exercises.Visits to follow up exercises will be conducted by the physiotherapists to progress the exercises.
1591783|NCT02295527|Other|Control Group Usual Care|This group will receive usual care and will not have any disadvantage in participating in the study. We understand that usual care is what participant receives based on the network of health care in which he/she is inserted. The participants will receive at baseline assessment a diary falls logbook and a guidance booklet containing information about prevention of falls, fractures and bone health that will be explained at the moment.
1591784|NCT02295514|Biological|PTP1B dosage|PTP1B sampled and dosed during sepsis
1591785|NCT02295501|Biological|INTERCEPT Plasma|Plasma will be collected from eligible volunteer donors who have recovered from acute EVD (see EBOV convalescent donor inclusion criteria). This donor plasma will be collected by apheresis donation (approximately 650-1300 mL per donation at physician discretion) and treated with the IBS for plasma.
1591786|NCT02295488|Procedure|biological sampling|blood intake for biological sampling during validated desensitization protocol (Alyostall®)
1591787|NCT02295488|Biological|Desensitization protocol (Alyostall®)|Validated desensitization protocol using Alyostall® performed
1591788|NCT02295475|Drug|Apixaban|Study subjects will be randomized to receive Apixaban.
1591789|NCT02295475|Drug|Warfarin|Study subjects will be randomized to receive Warfarin.
1591790|NCT02295462|Other|Person-centered Care|Medication Review + Person-centered Care
1591791|NCT02295462|Other|Optimised Treatment|Medication Review only
1591792|NCT02295449|Device|biopsy sample performed after the SonoVue® injection|
1591793|NCT02295436|Drug|minodronic acid|comparison of different doses, ages and medication conditions
1591794|NCT02295410|Behavioral|CPT|
1591795|NCT02295397|Other|food|food provocation, skin testing, blood sampling
1591796|NCT02295384|Other|Retrospective Audit|Retrospective Audit
1591797|NCT02295345|Other|Cognitive Behavioural Therapy for Insomnia|
1591798|NCT02295332|Drug|Placebo|Matching oral placebo capsules to RG7625, according to treatment schedule
1591799|NCT02295332|Drug|RG7625|oral administration, capsules, single ascending dose according to treatment schedule
1591800|NCT02295319|Other|Individual discharge|"See previous description in Arms"
1591801|NCT02295306|Device|Respiratory Volume Monitor (RVM, ExSpiron)|Connecting patient to the ExSpiron monitor and continuous ExSpiron data collection during the patient's polysomnography (PSG)
1591802|NCT02295293|Drug|Rhus Coriaria L. (Rhus)|500 mg of Rhus Coriaria L. (Rhus) powder in capsule: 1 capsule twice daily for 6 weeks
1591803|NCT02295293|Drug|Placebo|Placebo capsule: 1 capsule twice daily for 6 weeks
2009119|NCT03324724|Behavioral|Integrative cognitive-affective therapy for adolescents (ICAT-A)|Participants will receive a 21-session individual psychotherapy approach with 4 phases. In addition, there will be 7-13 additional conjoint parent sessions.
1591807|NCT02295267|Other|walnut allergy provocation|double blind placebo controlled food challenge
1591808|NCT02295254|Other|feces sample|The travelers will give feces sample before and after the travel. The sample microorganisms will be analyzed.
1591809|NCT02295241|Other|No intervention|This is an observational trial, no interventions are being used.
1591810|NCT02295228|Other|No intervention|There are no interventions. This is an observational trial.
1591811|NCT02295215|Other|Exercise|Exercise Training for 4 months
1591812|NCT02295202|Device|CPAP (REMstar System One Plus - Philips Medical Systems)|Standard device for treating obstructive sleep apnea.
1591813|NCT02295202|Device|Nasal strips|
1591816|NCT02295176|Dietary Supplement|Armolipid Plus|
1591817|NCT02295176|Dietary Supplement|Placebo|
1591818|NCT02295163|Procedure|Stellate ganglion block|7 ml of 0.5% bupivacaine will subsequently be injected next to the stellate ganglion to produce a sympathetic block.
1591819|NCT02295163|Procedure|Sham procedure|7 ml of 0.9 % sodium chloride will subsequently be injected next to the stellate ganglion
1591820|NCT02295150|Drug|Nadroparin|Patients receive before surgery 3 days 2850 IU nadroparin. anti-Xa levels will be measured. After surgery they receive 5700 IU for 4 weeks as standard care in our hospital. 3 days and 4 weeks after surgery anti-Xa levels will be measured again.
1591821|NCT02295137|Procedure|Using pre-procedural CTA to guide advanced EVAR procedure|
1591822|NCT02295124|Drug|Oxycodone|Patients will receive oxycodone 10mg (5mg if > 65) every 2 hours based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
1591823|NCT02295124|Drug|Hydromorphone|Patients will receive an initial dose of hydromorphone 2mg (1mg if > 65) every 2 hours as needed based on an equianalgesic dose calculation. As per routine practice, the dose will be titrated according to the patient's pain at the discretion of the Acute Pain Service physician who will not be blinded to group allocation.
1591824|NCT02295111|Device|EA treatment|Electro acupuncture and traditional Chinese Medicine Health consult
1591825|NCT02295111|Behavioral|TCM health consult|Traditional Chinese Medicine Health Consult without needling
1591826|NCT02295111|Other|Usual Care|Standard NHS care
1591827|NCT02295098|Other|Thoracic epidural catheter placement|Thoracic epidurals work by delivering local anesthetics and narcotics to the epidural space, which then diffuse into the spinal nerve roots and block the transmission of pain from the chest wall to the spinal cord and brain.
1591870|NCT02294773|Drug|Letrozole|Patient is to take letrozole during cycle days 3-7.
1591828|NCT02295098|Other|Paracostal catheter placement|Paracostal catheters run along the outer surface of the chest wall and act by delivering local anesthetics to the intercostal nerves as traverse the lower border of the ribs.
2009120|NCT03324711|Diagnostic Test|"Antillanisée Mini Mental State Examination (MMSEa)"|"Antillanisée version of the Mini Mental State Examination (MMSEa), is a version adaptated to the French West Indies creole culture."
1591830|NCT02295059|Dietary Supplement|omega 3 fatty acids|supplied as soft gelatin capsules for oral administration
1591831|NCT02295046|Drug|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
1591832|NCT02295033|Radiation|Boost irradiation|
1591833|NCT02295020|Drug|Standard treatment only|Standard treatment such as NSAIDs and injections
1591834|NCT02295020|Device|Standard treatment plus Bioskin Ten-7 knee brace|Standard treatment such as NSAIDs and injections plus Bioskin Ten-7 knee brace.
1591835|NCT02295007|Behavioral|text message|
1591836|NCT02294994|Drug|tirofiban|
1591837|NCT02294981|Device|Excimer laser phototherapy|Excimer laser phototherapy is a type of ultraviolet light that is applied to psoriatic plaques. It is administered using a laser in a targeted way so that only the plaques are treated (normal skin is not treated).
1591838|NCT02294968|Other|Family Startup (in Danish: Familieiværksætterne)|Manualized parenting support program; see Center for Socialt Ansvar (2013)
1591839|NCT02294955|Device|Catheterablation|Pulmonary vein isolation using either Arctic Front™ Cardiac CryoAblation or irrigated radiofrequency catheter ablation. A linear lesion, a left atrial roof line, is optional for patients with AF recurrence after a first procedure or primarily for patients with persistent AF.
1591840|NCT02294955|Drug|Amiodarone|Dosage orally 600 mg once daily for 7-10 days, and 100-200 mg once daily thereafter.
1591841|NCT02294955|Drug|Sotalol|Dosage orally 80-160 mg twice daily
1591842|NCT02294955|Drug|Flecainide|Dosage orally 100 to 150 mg twice daily or the entire dose as slow-release formula once daily
1591843|NCT02294955|Drug|Propafenone|Dosage orally 300 mg twice daily
1591844|NCT02294955|Drug|Disopyramide|Dosage orally 250-375 mg twice Daily
1591845|NCT02294955|Drug|Dronedarone|Dosage orally 400 mg twice daily
1591846|NCT02294942|Drug|RANCAD|Extended-Release RANCAD
1591847|NCT02294929|Procedure|Atrial fibrillation ablation|Atrial fibrillation ablation using the Arctic Front™ Advance Cardiac CryoAblation Catheter in two balloon sizes (23mm and 28mm) for pulmonary vein isolation
1591848|NCT02294916|Device|AWS|Video-laryngoscopy 1
1591849|NCT02294916|Device|Intubrite|Video-laryngoscopy 2
1591850|NCT02294916|Device|AirTraq|Optical-laryngoscopy
1591851|NCT02294916|Device|MIL|Direct-laryngoscopy
2009121|NCT03324685|Drug|BIIB074|BIIB074 is administered as specified in the treatment arm.
1591853|NCT02294890|Procedure|Total knee arthroplasty|
1591854|NCT02294877|Drug|Vimizim® (elosulfase alfa)|Recombinant human N acetylgalactosamine 6 sulfatase (rhGALNS)
1591855|NCT02294864|Device|Percutaneous Pulsed Radiofrequency|Pulsed Radiofrequency
1591856|NCT02294864|Procedure|Physical Therapy|
1591857|NCT02294851|Drug|BMS-986168|
1591858|NCT02294851|Drug|BMS-986168 Placebo|
1591859|NCT02294838|Device|MRI|Participants will undergo MR imaging of the parotid gland pre and post stimulation. Perfusion images will be acquired using a time-resolved, spoiled GE sequence with 1×1×2 mm spatial resolution, approximately one second 3D temporal resolution, and image technique/contrast parameters TR = 2.8 ms and TE = 0.9 ms.
1591860|NCT02294838|Other|Citric acid|5 mls of 2% citric Acid will be delivered to the oral cavity via a syringe and Tygon tubing at two separate time intervals in order to stimulate the parotid gland during the MRI scanning process.
1591861|NCT02294838|Other|Gadovist|Upon commencement of the scan, 0.05 ml/kg of Gadovist (at 4 ml/s) and 20 ml of saline flush (also at 4 ml/s) will be administered.
1591862|NCT02294825|Procedure|various surgical procedures in endometriosis|Shaving, disc excision and colorectal resection; ureterolysis or ureter resection; bladder resection; ablation of endometriomas using plasma energy; excision and ablation of deep and superficial lesions
1591863|NCT02294812|Behavioral|Cognitive training|"Participants will engage in eight weeks of training that focuses on improving various cognitive abilities. For example, short term memory.
Cognitive training will take place 30 minutes per day, five days per week, for eight weeks. Training will be done in the participant's own home using web-based software. Participants will be randomly assigned to either the active control group, the control cognitive training group, or the experimental cognitive training group following the second study visit.
After eight weeks, participants will no longer partake in training."
1591864|NCT02294799|Procedure|Intervention Group|Grade 1, Nonspecific Mandibular Mobilization. 3 times a week during 4 weeks.
1591865|NCT02294786|Drug|Lapatinib|Lapatinib is supplied as 250mg tablets that are oval, biconvex, and orange film-coated with one side plain and the opposite side debossed, or as 250mg tablets that are oval, biconvex, and yellow film-coated with one side plain and the opposite side debossed. Each tablet contains 405mg of Lapatinib ditosylate monohydrate, equivalent to 250mg Lapatinib free base
1591866|NCT02294786|Drug|Capecitabine|Capecitabine (Xeloda™) is supplied as a biconvex, oblong, light peach or peach colored film-coated tablet for oral administration. Each light peach colored tablet contains 150mg Capecitabine and each peach colored tablet contains 500mg Capecitabine.Generic versions of capecitabine may be used within the study if Xeloda cannot be provided. XELODA™ is a trademark of Hoffmann-La Roche AG.
1591867|NCT02294786|Drug|Octreotide|Octreotide (Sandostatin LAR™) is supplied as sterile 5milliliter (mL) vials delivering 20mg Octreotide as the free peptide. When mixed with diluent (approximately 2mL or 2.5 mL) it becomes a suspension that is given as an intramuscular injection. Two 20mg intramuscular injections are given to deliver a total dose of 40mg. The Octreotide is uniformly distributed within the microspheres which are made of a biodegradable glucose star polymer, D,L-lactic and glycolic acids copolymer. Sterile mannitol is added to the microspheres to improve suspendability
1591868|NCT02294773|Procedure|Intrauterine Insemination|Intrauterine insemination is either performed on the day the home ovulation predictor kit first turns positive or the day after the first positive.
1591869|NCT02294773|Drug|Clomiphene|Patient is to take clomiphene citrate during cycle days 3-7.
1592087|NCT02293226|Device|Vividtrack|video-laryngoscopy 4
1591871|NCT02294760|Device|Subsensory|The stimulation is set to 90% of the sensory threshold.
1591872|NCT02294760|Device|OFF|The stimulation is turned OFF.
1591873|NCT02294747|Device|Sliding Hip Screw with Trochanteric Stabilization Plate|
1591874|NCT02294747|Device|Sliding Hip Screw without Trochanteric Stabilization Plate|
1591875|NCT02294734|Drug|GSK2269557|Dry powder for inhalation via DISKUS 'device' with unit dose strength of 500 micrograms (mcg) per actuation with total dose of 1000 mcg daily
1591876|NCT02294734|Drug|Placebo|Dry powder for inhalation via DISKUS 'device'
1591877|NCT02294721|Device|Standard BLS|Resuscitation without feedback devices, standard manual standard basic life support
1591878|NCT02294721|Device|The CPREazy|feedback device-1
1591879|NCT02294721|Device|TrueCPR|feedback device -2
1591880|NCT02294721|Device|The CPR PRO APP|feedback device -3
1591881|NCT02294721|Device|The CardioPump|feedback device- 4
1591882|NCT02294708|Behavioral|postoperative postures|two postoperative postures: supine and temporal-lateral
1591883|NCT02294682|Drug|GSK2140944|Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
1591884|NCT02294669|Device|Turris Facet Fuser|Study participants will have a Turris Facet Fuser inserted into the contralateral facet joint, instead of a state of the art contralateral pedicle screw system.
1591885|NCT02294656|Drug|Ranibizumab,|Intravitreal injection of Ranibizumab as treatment for acute pseudophakic cystoid macular edema. Ranibizumab patients will receive three monthly Ranibizumab 0.5 mg/0.05 mL injections, followed by PRN dosing, as treatment for acute pseudophakic cystoid macular edema.
1591886|NCT02294656|Drug|Triamcinolone acetonide|Intravitreal injection of Triamcinolone acetonide as treatment for acute pseudophakic cystoid macular edema. Triamcinolone acetonide patients will receive PRN Triamcinolone acetonide 4 mg/0.1 mL injections, every 3 months, as treatment for acute pseudophakic cystoid macular edema.
1591887|NCT02294643|Drug|Sarpogrelate|
1591888|NCT02294643|Drug|Aspirin|
1591889|NCT02294643|Drug|Clopidogrel|
1591890|NCT02294643|Drug|Placebo (for Sarpogrelate)|
2009122|NCT03324685|Drug|OC (ethinyl estradiol and levonorgestrel)|OC is administered as specified in the treatment arm.
1591892|NCT02294617|Other|Electronic Cigarette|Subject will use electronic cigarette for 3 days.
1591893|NCT02294617|Other|Nicotrol Inhaler|Subjects will use the Nicotrol Inhaler for 3 days.
1591894|NCT02294604|Device|ethyl alcochol, chlorhexidine and moisturizers|
1591895|NCT02294604|Device|chlorhexidine|
1591896|NCT02294604|Device|povidone-iodine|
1591897|NCT02294591|Drug|N-acetylcysteine|Add-on treatment of NAC
1591898|NCT02294591|Drug|Placebo|Add-on treatment of placebo
1591899|NCT02294565|Drug|VST-1001|Single-dose injection (peritumoral, periareolar, and/or intradermal) of VST-1001 administered pre-SLNB procedure; VST-1001 is used with medical devices (blue-light LED illuminator and blue-light filtering eyewear) for lymphatic mapping and localization of lymph nodes during a SLNB procedure.
1591900|NCT02294565|Drug|99mTc-labeled sulfur colloid|Single-dose injection (peritumoral, periareolar, intradermal, and/or subdermal) of 99mTc-labeled sulfur colloid administered per standard of care; the radioactivity of the radioactive colloid is detected with a gamma probe per standard of care.
1591901|NCT02294552|Drug|Cyclophosphamide|
1591902|NCT02294552|Drug|Busulfan|
1591903|NCT02294552|Drug|Fludarabine monophosphate|
1591904|NCT02294552|Drug|Tacrolimus|
1591905|NCT02294552|Drug|Mycophenolate mofetil|
1591906|NCT02294552|Procedure|Allogeneic hematopoietic stem cell transplantation|
1591907|NCT02294539|Drug|Losartan 50mg/amlodipine 5mg|once daily, 1T, PO medication
1591908|NCT02294539|Drug|Losartan 100mg/amlodipine 5mg|once daily, 1T, PO medication
1591909|NCT02294539|Drug|Losartan 50mg/Hydrochlorothiazide 12.5mg|once daily, 1T, PO medication
1591910|NCT02294539|Drug|Losartan 100mg/Hydrochlorothiazide 25mg|once daily, 1T, PO medication
1591911|NCT02294526|Other|Sardine diet|Diet rich in sardine: 100g/day of sardine 5 times a week
1591912|NCT02294513|Device|Standard audiologic rehabilitation (incl. HI)|The intervention consists of standard audiologic rehabilitation in which participants are fit with at least one hearing instrument (HI).
1591913|NCT02294474|Drug|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
1591914|NCT02294474|Drug|Humalog|Pharmaceutical form:solution Route of administration: subcutaneous
1591915|NCT02294474|Drug|insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
2009123|NCT03324672|Procedure|TRIGGER|only TRIGGER point will be included for the manual therapy
2009124|NCT03324672|Procedure|TRIGGER+CURETAPE|TRIGGER point will be included for the manual therapy with kinesio-taping
1591918|NCT02294448|Drug|Qishe Pill|Qishe Pill is a thin 0.15 g film-coated pill, composed of processed Radix Astragali, Muscone, Szechuan Lovage Rhizome, Radix Stephaniae Tetrandrae, Ovientvine, and Calculus Bovis Artifactus, which should be taken orally with water (240mL) after a minimum 10-hour fast
1591919|NCT02294435|Device|Visceral Manifold and Thoracic Bifurcation|Endovascular stent graft system
1591920|NCT02294435|Device|Unitary Manifold|Endovascular stent graft system
1591921|NCT02294422|Device|PBP|the pilot balloon is continuously palpated o felt for adequate pressure as its being inflated.
1591922|NCT02294422|Device|LOR|
1591923|NCT02294422|Device|Aneroid manometer|The pilot balloon is attached onto the manometer and cuff pressures are raed off from the gauge.
1591953|NCT02294227|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
1591954|NCT02294227|Biological|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
1591955|NCT02294214|Device|Spatial Repellent product with active ingredient|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
1591956|NCT02294214|Device|Active ingredient|Transfluthrin (Active ingredient)
1591924|NCT02294409|Behavioral|Manualized group Cognitive-behavioral therapy (CBT) for social anxiety in first episode psychosis|All CBT sessions will be conducted in English or French by trained clinicians with the aid of a group CBT script that we have developed over the last two years. The script will provide a general outline for each session, remind the therapist about relevant CBT principles, and provide examples of topics and homework that may be useful in each session. This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring; iii) Exposure component; iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia. The latter module specifically examines stigmatization and self-stigmatization that are contributing factors to social anxiety. Each of the 13 group sessions consisting of 6-8 participants on average, will last for 1.5 hour each. One session per week will be provided for the 13-week period.
1591925|NCT02294409|Behavioral|Group Computer assisted cognitive remediation therapy|This group intervention has been developed by Dr. Bowie a co-applicant on the current proposal. This intervention involves completing cognitive training activities on a computer, documenting and attempting new strategies for solving problems, and doing 'bridging activities'. The target domains of cognition to be trained are processing speed, attention, memory and executive functions. The investigators will perform 13 weekly sessions of 1.5 hours. The software Brain Training Pro (http://www.scientificbraintrainingpro.fr), which has been used extensively in the field of schizophrenia, will be used. Each 1.5 hour session will be conducted with groups of 6-8 participants. The therapist's interventions, while minimal, are meant to emphasize the link between activities in the CACRT sessions and day-to-day activities that people do.
1591926|NCT02294396|Drug|Mirabegron tablet|orally administered at a dose of 1 tablet once daily after breakfast
1591927|NCT02294396|Drug|Solifenacin tablet|orally administered at a dose of 1 tablet once daily after breakfast (may be increased to 2 tablets)
1591928|NCT02294396|Drug|Propiverine tablet|orally administered at a dose of 1 tablet once daily after breakfast (may be increased to 1 tablet twice daily after breakfast and after dinner)
1591929|NCT02294396|Drug|Imidafenacin tablet|orally administered at a dose of 1 tablet (0.1 mg tablet) twice daily after breakfast and after dinner (may be increased to 2 tablets twice daily after breakfast and after dinner)
1591930|NCT02294396|Drug|Tolterodine capsule|orally administered at a dose of 1 capsule once daily after breakfast (must not be increased)
1591931|NCT02294357|Drug|Carfilzomib|
1591932|NCT02294357|Drug|Dexamethasone|If the patient was receiving steroids at the equivalent of > 8 mg of dexamethasone weekly either intravenously (IV) or Per Orem (PO) in combination with carfilzomib, the same drug(s), dose(s) and schedule(s) of steroids will be continued. If the patient was not receiving steroids or was receiving less than the equivalent of 8 mg of dexamethasone weekly, then he/she will be given 8 mg of dexamethasone (IV or PO) prior to each carfilzomib administration.
1591933|NCT02294357|Drug|Prednisone|f the patient was receiving prednisone, at the equivalent of > 8 mg of dexamethasone weekly PO in combination with carfilzomib, he/she will continue to receive prednisone at the same dose and schedule.
1591934|NCT02294357|Drug|Methylprednisolone|If the patient was receiving methylprednisolone at the equivalent of > 8 mg of dexamethasone weekly either IV or PO in combination with carfilzomib, he/she will continue to receive methylprednisolone at the same dose and schedule.
1591935|NCT02294344|Other|DFPP&CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.
Then double volume of plasma was processed during each DFPP session every two day. A fraction plasma separator(Asahi Kasei Medical, surface area 2.0 m2,pore size 0.03 mm)and another fraction plasma separator (Asahi Kasei Medical, surface area 2.0 m2, pore size 0.01 mm)were used as first and second filter for plasma fractionation, respectively. 1.5 volume of plasma was processed, and 35~45g human albumin and blood plasma was supplemented during each session. The patients were treated with DFPP every two days for at least 3 times. After DFPP, 300-500ml blood plasma was supplemented."
1591936|NCT02294344|Drug|CTX|"First,patients received methylprednisolone pulse therapy followed by oral prednisone and intravenous cyclophosphamide (IV-CTX) pulse therapy.
After three months therapy, if the renal function was not recover, the patient would be withdrawn from the study. The other patients after CTX pulse therapy for 6 months and achieve remission to receive oral maintenance therapy with azathioprine (AZA).
The dosage of AZA was 1.0-2.0mg/kg/d(more than 50mg/d) and adjusted by white cell count and liver enzyme. If white cell count ＜3×109/L or an increase in liver enzyme to more than twice the normal upper limit, the dosage of AZA should be reduced. If white cell count ＜3×109/L or liver enzyme increased repeatedly, the patient would be withdrawn from the study."
1591937|NCT02294318|Behavioral|HealthCall+Motivational Interviewing (MI)|HealthCall is a technology-based enhancement to brief MI to improve behavior outcomes. It is introduced to patients by the study counselor at the end of the MI session.
1591938|NCT02294318|Behavioral|Motivational Interviewing|Motivational Interviewing is a client-centered counseling approach for eliciting behavior change.
1591941|NCT02294292|Drug|Carvedilol|Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.
1591942|NCT02294292|Drug|Ivabradine|"Carvedilol started to achieve target HR (heart rate) reduction to 60/min, to a lowest permissible 50-55/ min ; provided Systolic Blood Pressure> 90 mmHg.
If carvedilol is not tolerated,Ivabradine is added in a dose starting 2.5 mg BD to a maximum of 15 mg/day to ensure targeted heart rate reduction"
1591943|NCT02294292|Procedure|Endoscopic Variceal Ligation|
1591944|NCT02294279|Drug|Qvar (100 mcg)|2 puffs twice daily; 400 mcg daily over 4 weeks treatment period
1591945|NCT02294266|Drug|Mephedrone and alcohol|"Single oral dose mephedrone
Single oral dose alcohol"
1591946|NCT02294266|Drug|Mephedrone|Single oral dose mephedrone
1591947|NCT02294266|Drug|Alcohol|Single oral dose alcohol
1591948|NCT02294266|Drug|Placebo|Single oral dose placebo
1591949|NCT02294253|Drug|Buprenorphine/naloxone|30 day oral Buprenorphine/naloxone
1591950|NCT02294240|Dietary Supplement|Energy dense biscuits|Energy dense biscuits will be provided
1591951|NCT02294240|Other|Wheat Flour, oil, iron & Folic acid|Wheat flour, oil, iron and folic acid will be provided
1591952|NCT02294227|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
1591957|NCT02294214|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
1591958|NCT02294201|Device|Spatial Repellent product with active ingredient|Spatial Repellent product
1591959|NCT02294201|Device|Active ingredient|Transfluthrin (Active ingredient)
1591960|NCT02294201|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
1591961|NCT02294188|Device|Spatial Repellent product with active ingredient (SHIELD)|Spatial Repellent Product
1591962|NCT02294188|Device|Active ingredient|Transfluthrin (Active ingredient)
1591963|NCT02294188|Device|Spatial Repellent product without active ingredient (SHIELD)|Spatial Repellent Product - Passive Emanator. The name of the product is SHIELD from SCJohnson
1591964|NCT02294175|Device|Larval Debridement Therapy|small sterile mesh bags containing live maggots placed into an open chronic wound to remove necrotic tissue and bacterial biofilm
1591965|NCT02294175|Procedure|Bedside Sharp Debridement|The use of a sharp clinical instrument (currette, scalpel, scissors, forceps) by a qualified clinician to remove necrotic tissue and bacterial biofilm from an open chronic wound
1591966|NCT02294162|Drug|Ketamine i.v|
1591967|NCT02294149|Drug|mammalian Omega 3 Fatty acids|A mammalian oil derived Omega 3 FA that is a further concentrated and purified supplement as compared to the regular fish oil derived Omega 3 FA supplement.
1591968|NCT02294149|Drug|placebo|
1591969|NCT02294136|Behavioral|Prep-C|PREP-C is a web-based structured clinical interview that healthcare providers of diverse disciplines can be trained to administer. It provides an assessment of a client's psychosocial readiness to begin HCV treatment and identifies domains of functioning which require tailored intervention to improve treatment readiness.
1591970|NCT02294136|Behavioral|Educational Control|Attention Control
1591971|NCT02294123|Other|3 tortillas and white bread|Type crossover clinical trial in adults 20-69 years. Three groups of participants were included for each category (n = 27 in each group): 1) adults with diabetes, b) adults with overweight c) clinically healthy adults. The glycemic and insulinemic index was measured for each group of participants given in random order the 3 types of Tortilla and white bread
1591972|NCT02294110|Other|spinal anesthesia|non diabetes mellitus
1591973|NCT02294097|Procedure|Surveillance protocol kidney allograft biopsy|Surveillance protocol biopsy under ultrasound-guided will perform at post-operative day 7, month 3, month 6, month 12, and month 24
1591974|NCT02294084|Drug|Sitagliptin|Each subject will be randomized to receive either Sitagliptin or placebo for 12 weeks. The compounds will be packed so that the subject nor the investigator will know which compound is administered (double blind)
1591975|NCT02294084|Drug|placebo|
1591976|NCT02294071|Drug|Ibuprofen|oral liquid ibuprofen 10mg/kg (maximum 600 mg)
1591977|NCT02294071|Drug|Acetaminophen|oral liquid acetaminophen 15mg/kg (max 975mg)
1591978|NCT02294058|Drug|RPC1063|
1591979|NCT02294058|Drug|Beta interferon|
1591980|NCT02294032|Drug|Immunosuppressive Agents|standard of care for patients post-transplant
1591981|NCT02294019|Drug|Ibuprofen 400 mg caplet|400 milligram (mg) caplet according to Drug Facts label
1591982|NCT02294006|Drug|Everolimus plus Octreotide LAR plus Metformin|
1591983|NCT02293993|Drug|SGI-110|
1591984|NCT02293980|Drug|PART 1: PT2385 Tablets|PT2385 inhibits HIF-2α and is a novel approach to treatment for this patient population.
1591985|NCT02293980|Drug|PART 2: PT2385 Tablets in combination with nivolumab|PT2385 inhibits HIF-2α and in combination with nivolumab is a novel approach to treatment for this patient population.
1591986|NCT02293980|Drug|PART 3: PT2385 Tablets in combination with cabozantinib|PT2385 inhibits HIF-2α an upstream regulator of VEGF activation. In combination with the VEGF inhibitor cabozantinib tablets, this is a novel approach to treatment for this patient population.
1591987|NCT02293967|Drug|MT-1303|
1591993|NCT02293941|Drug|JKB-122|Participants were randomized to receive JKB-122 5mg/15mg/35mg/placebo for 12 weeks
1591994|NCT02293941|Drug|Placebo|Participants were randomized to receive JKB-122 5mg/15mg/35mg/placebo for 12 weeks
1591995|NCT02293928|Procedure|Hybrid coronary revascularization|Hybrid coronary revascularization with standard double antiplatelet therapy
1591996|NCT02293915|Drug|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
1591997|NCT02293915|Drug|Placebo|simulant of sodium oligo-mannurarate capsule
1592002|NCT02293889|Dietary Supplement|Vitamin D3 2000IU/daily 3 months|Vitamin D will be provided in the form of a daily capsule over 3 months containing 2000IU of Vitamin D3 suspended in oil (manufactured and provided by DSM) with the aim of raising 25OHD levels to sufficiency (>50nmol/L) by 3 months.
1592003|NCT02293889|Behavioral|PA intervention People with Osteoarthritis Walking Programme|The PA intervention will aim to increase levels of PA safely in our defined population. Participant are given a pedometer at the start of the intervention and encouraged to record their daily step counts and set step goals using the online system provided (POW: People with osteoarthritis walking programme).
1592004|NCT02293889|Other|Placebo capsule (Vitamin D): edible oil|Placebo capsules will be administered over 3 months, as daily capsules (identical to Vitamin D capsules) containing edible oil (manufactured and provided by DSM)
1592005|NCT02293876|Device|LACRIBELL®|Hypromellose and dextran based eyedrop, used in the treatment of dry eye.
1592006|NCT02293876|Device|LIPOSIC®|Carbomer and Sorbitol based gel, used in the treatment of dry eye.
1592007|NCT02293876|Device|Glad wrap|A clear plastic wrap occluding eye and orbital area, turning the space into a moisture chamber.
1592008|NCT02293863|Drug|MHAA4549A|Participants will receive a single dose of MHAA4549A by IV infusion on Day 1
1592009|NCT02293863|Drug|Oseltamivir|Participants will receive oseltamivir capsule either 75 mg or 150 mg BID orally for minimum of 5 days. Dosage and administration should follow local prescribing information for oseltamivir.
1592010|NCT02293863|Drug|Placebo|Participants will receive a single IV dose of placebo matched to MHAA4549A on Day 1
1592011|NCT02293850|Biological|OBP-301|"In phase I part, a range of dose levels is investigated and the starting dose is 1x1010 VP/tumor. Dose administration will be conducted through a dose-escalating scheme from 1x1010 VP/tumor to 1x1011 VP/tumor, 1x1012 VP/tumor, 3x1011 VP/tumor and 3x1012 VP/tumor.
After assessing the clinical safety profiles by escalating doses of OBP-301 in patients with hepatocellular carcinoma, the phase II study to determine the response rate will be performed."
1592012|NCT02293837|Drug|Tocilizumab (TCZ)|Subjects assigned to this group will receive tocilizumab intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
1592013|NCT02293837|Drug|Placebo|Subjects assigned to this group will receive placebo intravenous (IV) infusions of either 8.0 mg/kg (body weight ≥ 30kg) or 10.0 mg/kg (body weight <30kg) every 4 weeks for 24 weeks.
1592014|NCT02293824|Drug|Caffeine|Given per standard of care.
1592015|NCT02293811|Other|Analysis|"An additional blood sample (10ml) will be taken on the day of hospitalization to achieve the genomic studies in search of mutations in constitutional DNA of circulating lymphocytes and acquired mutations of DNA circulating.
We will use the technique of tissue-microarray to analyze the expression level of P2RX7 both in epithelial cells than in stromal cells inflammatory.
Genotyping will be conducted partly on colonic biopsies and also on blood samples (to demonstrate the feasibility of this technique much less debilitating)."
1592016|NCT02293798|Device|silk surgical scaffold|surgical implant
1592017|NCT02293785|Drug|Oxycodone-Naloxone|
1592018|NCT02293772|Other|Hypoxic ambulatory|21 days confinement in normobaric hypoxic (FiO2 = 14%) environment
1592019|NCT02293772|Other|Hypoxic Bedrest|21 days supine bedrest in normobaric hypoxic (FiO2 = 14%) environment
1592020|NCT02293772|Other|Normoxic Bedrest|21 days supine bedrest in normobaric normoxic (FiO2 = 21%) environment
1592021|NCT02293759|Procedure|HoLEP|Holmium laser enucleation of the prsotate
1592022|NCT02293759|Procedure|Greenlight laser PVP|Greenlight laser (532nm) Photoslective vaporization of the prostate
1592023|NCT02293746|Device|Inspire® Upper Airway Stimulation (UAS) System|This is a single-arm study; all participants will be implanted with the Inspire® Upper Airway Stimulation (UAS) System is a permanent, implantable therapy device, which consists of three implantable components: an IPG, a stimulation lead, and a sensing lead. In addition, the patient receives a remove to activate the therapy.
1592024|NCT02293720|Device|EndoBarrier|The EndoBarrier is indicated as an adjunct to diet and exercise to achieve weight loss and improve glycemic control in obese adults with type 2 diabetes whose anti-diabetes medications have not achieved adequate glycemic control.
1592025|NCT02293707|Biological|GX301|"GX301 therapy consists of four human telomerase reverse transcriptase (hTERT) peptides and two adjuvants.
Peptides are hTERT (540-548) Acetate, hTERT (611-626) Acetate, hTERT (672-686) Acetate and hTERT (766-780) Acetate. Adjuvants are Montanide ISA 51 VG and imiquimod 5% cream (Aldara).
Each GX301 administration will consist of four intradermal injections - one injection for each hTERT peptide - given at the same time and followed by topical application of imiquimod. Each intradermal injection will consist of a fixed hTERT peptide dose, 500 µg, reconstituted as a solution and mixed with Montanide ISA 51 VG."
1592026|NCT02293694|Drug|Sayana Press|Sayana® Press is a subcutaneous formulation of depot medroxyprogesterone acetate (DMPA) in a prefilled, auto-disabled injection system called Uniject
1592030|NCT02293668|Drug|FSH 225IU and hMG 225IU|
1592031|NCT02293668|Drug|FSH 150IU and hMG 150IU|
1592032|NCT02293668|Drug|Letrozole 5mg and hMG 150IU|
1592033|NCT02293655|Drug|OROS-Methylphenidate (MPH)|OROS-methylphenidate will be taken orally once daily at doses that have been approved for the study age group by the U.S. FDA.
1592034|NCT02293629|Drug|BMS-986147|
1592035|NCT02293629|Drug|Placebo matching BMS-986147|
2009125|NCT03324659|Behavioral|Exercise and Meditation|The Exercise and Meditation group will listen to recorded meditations (15 minutes) that are based on mindfulness. They will then walk on a treadmill for 30 minutes at a moderate intensity. The intervention is completed five days per week for four weeks.
2009126|NCT03324659|Behavioral|Control|The Control group will listen to a recorded audio book for 15 minutes, five days per week for four weeks.
1592038|NCT02293603|Biological|Allogeneic Cardiosphere-Derived Cells (CDCs)|Intracoronary delivery of CAP-1002 or placebo
1592039|NCT02293590|Drug|Certolizumab Pegol|
1592040|NCT02293577|Device|continuous glucose monitor|In this study all subjects will wear a continuous glucose monitor for 5 days.
1592041|NCT02293564|Drug|gevokizumab|Solution for subcutaneous injection
1592042|NCT02293551|Drug|Lispro|Administered SC
1592043|NCT02293538|Drug|FID 114657 eye drops (10 ml)|Lubricating eye drop for temporary relief of burning and irritation due to dryness of the eye
1592044|NCT02293538|Drug|Saline control eye drops (15 ml)|Saline eye drops (15 ml)
1592045|NCT02293538|Device|Habitual contact lenses|Commercially marketed biweekly or monthly replacement soft contact lenses as prescribed by eye care practitioner, brand and power
1592046|NCT02293525|Device|ReLeaf catheter|Continuous infusion rate 10ml/hr (5ml/side)
1592047|NCT02293525|Drug|Ropivacaine|
1592048|NCT02293525|Drug|Saline|
1592049|NCT02293525|Drug|Morphine|Patient-controlled analgesia (PCA) at 1mg every 6 minutes with a 4 hour lock out after 30mg
1592050|NCT02293525|Drug|Oxycodone|10mg every 4-6 hours
1592084|NCT02293226|Device|CoopDech|Video-laryngoscopy 1
1592085|NCT02293226|Device|CoPilot|video-laryngoscopy 2
2009127|NCT03325322|Dietary Supplement|Fisetin|Flavonoid family
2009128|NCT03325322|Drug|Placebo oral capsule|Placebo
1592054|NCT02293499|Behavioral|PLASMA|"A structured asthma self-management manual (Let's Talk about Asthma [LTAA],developed by the study team will be utilized in a camp like setting and administered by either peers or adults medical professionals. The manual adheres to the 2007 NAEPP Guidelines Training strategies will involve didactic sessions, discussion, demonstrations, and role-play. Group learning activities will closely align with the program manual (LTAA) that consists of three sessions. Participants will also learn and practice skills in using the peak flow meter, spacer and inhaler, daily symptom diary and asthma action plan. Besides instructional activities, participants will engage in recreational activities that each camp site."
1592055|NCT02293486|Dietary Supplement|Pomegranate juice|Intake of 200 ml of pomegranate juice or pomegranate juice dilution during 21 days after exercise.
1592056|NCT02293473|Device|LiDCO Rapid|LiDCO Rapid haemodynamic monitor
1592057|NCT02293473|Device|BIS-Bispectral Index Monitor|Depth of anaesthesia
1592058|NCT02293473|Device|INVOS-Cerebral Oxygenation Monitor|regional brain tissue oxygenation
1592059|NCT02293473|Other|Standard of care|Using standard of care
1592060|NCT02293460|Drug|I10E|"Patients who meet all eligibility criteria will receive one dose of IMP at 2g/kg over 2-5 days followed by 7 doses of IMP at 1g/kg over 1-2 day(s), every 3 weeks.
Duration of treatment period: 21 weeks +/- 7 days."
1592061|NCT02293447|Drug|Lidocaine per-embolization|10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.
1592062|NCT02293447|Drug|Lidocaine post-embolization|10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
1592063|NCT02293421|Other|Obstructive sleep apnea|
2009129|NCT03324594|Device|(1) WONDALEAF-CAP, (2) WONDALEAF-ON-MEN, (3) durex-TOGETHER (active comparator)|"WONDALEAF-ON-MEN (WLM) is a polyurethane pouch with outstretching adhesive shield. The pouch covers the penis in man user; while the adhesive shield covers the groin regions to provide extra protection for the couples. The pouch is equivalent to marketed polyurethane male; while the adhesive shield is equivalent to marketed polyurethane wound dressing. WLM integrally joined with an adhesive wound dressing, both made of the same polyurethane material.
WONDALEAF-CAP (WLC) is a miniature form of WLM: the pouch covers glans penis and the adhesive shield wraps around the shaft of the penis only, thereby emulating the configuration of a donned regular condom on the penis. Because of the adhesive coating, WLC overcomes the problems of slippage when the penis is flaccid.
The durex-TOGETHER serves as the active comparator in this study. It is a transparent natural rubber latex male condom which is commercially available."
2009130|NCT03324516|Procedure|Re-Suspension of the temporal muscle after a craniotomy.|The temporal muscle cuff will be used to re-suspend the temporal muscle after a traditional craniotomy.
2009131|NCT03324516|Procedure|Traditional re-suspension of the temporal muscle|The temporal muscle will be re-suspended to the bone plate that is used to fixate the temporal bone that is removed for the craniotomy.
2009132|NCT03324399|Dietary Supplement|probiotic|a proprietary probiotic formulation
1592068|NCT02293369|Procedure|Cuff closure via vaginal route|Vaginal cuff will be closed via vaginal route during total laparoscopic hysterectomy.
1592069|NCT02293369|Procedure|Cuff closure via laparoscopic route|Vaginal cuff will be closed via laparoscopic route during total laparoscopic hysterectomy.
1592070|NCT02293356|Drug|Nimotuzumab Injection|patients receive nimotuzumab injection for 200mg/w,intravenous infusion over 60 minutes.Doctor adjust the dosage of nimotuzumab and choose other treatment options according to the actual situation of patients.
1592071|NCT02293343|Other|blood profile|
1592072|NCT02293330|Drug|continuous infusion of levobupivacaine|continuous infusion of levobupivacaine 0,125% at 5 ml/h , bolus dose 6 ml, lock out 30 minutes 4 hours limit: 60 ml/h
1592073|NCT02293330|Drug|Intermittent bolus infusion of levobupivacaine|Intermittent bolus of levobupivacaine 0,125%: 0.1 ml /h and 9,8 ml bolus every two hours. Optional patient controlled bolus dose 6 ml, lock out 30 minutes, 4 hours limit: 60 ml/h
1592074|NCT02293317|Biological|M-001|A recombinant epitope based universal vaccine against seasonal and pandemic influenza
1592075|NCT02293317|Drug|TIV|HA based seasonal influenza vaccine, for 2014/15 seson
1592076|NCT02293317|Other|Saline|Placebo
2009133|NCT03324386|Behavioral|Experimental: Individual Orientation|This approach may be individual orientation with by an embracement strategy (relational strategies) may be making 7 nursing visits at 20-day intervals, for 4 month.
1592079|NCT02293291|Dietary Supplement|Lithium Water|"To empirically test the effects of Lithium water in violence prevention program on rates of violent attitudes and behavioral inclinations in populations whose drinking water supplies contain little or no lithium.
To utilize an experimental design to establish statistical support for the impact of community habits related variables (protective factors) on violent attitudes and behavioral inclinations among at-risk communities To demonstrate the effect of drinking water variables (protective factors) to existing evidence-based factors (risk factors) that have proven effective in GWI"
1592080|NCT02293278|Behavioral|Physical Activity Intervention|The intervention consists of 2, 3-hour workshops conducted by a master trainer with experience in promoting PA in preschoolers. The workshops focus on the importance of PA and movement skills for preschool-aged children, understanding structured and unstructured play, practical activities related to movement skills, how to overcome barriers in facilitating PA, and using everyday materials to facilitate PA and active play. Each provider in the intervention group is given the Healthy Opportunities for Preschoolers resource training manual, suggested implementation, and a starter kit of equipment. Master Trainers facilitated biweekly PA sessions throughout the intervention. The intervention is based on NASPE (2002) guidelines of not having children sedentary more than 60 mins at a time, having children accumulate 60 mins in structured and unstructured PA (active play) each day at MVPA, as well as 180 mins of total PA as recommended by the Canadian PA Guidelines for preschoolers.
1592082|NCT02293252|Device|Remote patient monitoring (Motiva)|interactive bi-directional home telemonitoring system that provides remote monitoring
1592083|NCT02293239|Other|Whole-Body Electromyostimulation (WB-EMS)|WB-EMS training is performed 2x/week for 12 weeks; Stimulation protocol: Frequency of 85 Hz, pulse duration of 0.35 ms, stimulation period of 6 sec, resting period of 4 sec; supervised by certified training instructors/physiotherapists participants perform simple exercises during the stimulation period following a video tutorial
1592088|NCT02293213|Behavioral|EMR Referral|EMR referral to California Teratogen Information Services (CTIS) for use of category D or X medication.
1592089|NCT02293213|Behavioral|CTIS Counseling|Counseling from MotherToBaby teratogen information specialist.
1592090|NCT02293213|Behavioral|Baseline Questionnaire|Baseline Questionnaire capturing contraceptive use immediately after counseling with MotherToBaby
1592091|NCT02293213|Behavioral|Contraception Provision Appointment|Appointment with contraception provider to discuss contraception options.
1592092|NCT02293213|Behavioral|3 Month Follow Up Questionnaire|Questionnaire 3 months after CTIS counseling to assess contraception use and plans
1592093|NCT02293213|Behavioral|6 Month Follow Up Questionnaire|Questionnaire 6 months after CTIS counseling to assess contraception use and plans
1592094|NCT02293200|Device|Standard BLS|basic life support without any feedback device
1592095|NCT02293200|Device|TrueCPR|CPR with feedback device
1592096|NCT02293187|Dietary Supplement|vitamin D3|Dose for intervention arm is 800 IU/day for first 4 months. At 4 months, if vitamin D level <70 nmol/L, a second 800 IU capsule will be added to regimen (total of 1600 IU/d) for remainder of study.
1592097|NCT02293187|Other|Placebo|Those in the placebo group will receive 1 capsule for first 4 months. At 4 month visit, one capsule will be added to regimen to be taken throughout the remainder of the study.
1592098|NCT02293174|Device|Topcon TRC-NW400|Retinal Fundus Camera
1592099|NCT02293174|Device|TRC-NW8|Retinal Fundus Camera
1592100|NCT02293174|Device|TRC-NW400|Retinal Fundus Camera
1592101|NCT02293174|Device|Canon-CR2|Retinal Fundus Camera
1592102|NCT02293174|Device|Zeiss Visucam PRO|Retinal Fundus Camera
1592103|NCT02293161|Drug|GSK2618960|GSK2618960 will be provided as 100 mg/mL solution for injection to be administered as single dose IV infusion that has to be diluted at the study site with placebo
1592104|NCT02293161|Drug|Placebo|It is Sodium Chloride Intravenous Infusion
1592105|NCT02293148|Drug|GSK1278863 75 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
1592106|NCT02293148|Drug|GSK1278863 500 mg|A round, biconvex, white film coated tablet available in two doses (25 and 100 mg)
1592107|NCT02293148|Drug|Moxifloxacin 400 mg|Oblong, dull red, film-coated, convex tablets with M400 on one side
1592108|NCT02293148|Drug|Placebo matching GSK1278863|A round, biconvex, white film coated tablet as matching placebo for GSK1278863
1592109|NCT02293148|Drug|Placebo matching Moxifloxacin|Capsule shaped white film coated tablet as matching placebo for Moxifloxacin
1592110|NCT02293135|Device|Verum Stendo session on V1 and Phantom Stendo session on V2|On the firt V1 visit, the patient will receive the verum Stendo session ; then on V2 visit ((V1 + 13 days +/- 2), the patient will receive the verum Stendo session On the firt visit, V1 the patient will have a phantom Stendo session (no pressure will be applied)
1592111|NCT02293135|Device|Phantom Stendo session on V1 and Verum Stendo session on V2|On the firt V1 visit, the patient will have a phantom Stendo session (no pressure will be applied) ; then on V2 visit ((V1 + 13 dayx +/- 2), the patient will receive the verum Stendo session
1592112|NCT02293122|Other|Observational|Intervention is observational to two different diagnostic devices for which comparative readings of the corneal endothelium are being measured; the test device- the EM-3000 Specular Microscope against the Konan Robo-pachy F&A Specular Microscope.
1592113|NCT02293109|Drug|carfilzomib|Given IV
1592114|NCT02293109|Drug|cyclophosphamide|Given IV
1592115|NCT02293109|Drug|vincristine sulfate|Given IV
1592116|NCT02293109|Drug|doxorubicin hydrochloride|Given IV
1592117|NCT02293109|Drug|dexamethasone|Given PO
1592118|NCT02293109|Drug|methotrexate|Given IV
1592119|NCT02293109|Drug|cytarabine|Given IV
1592120|NCT02293109|Drug|leucovorin calcium|Given IV or PO
1592121|NCT02293109|Drug|methylprednisolone|Given IV
1592122|NCT02293109|Biological|rituximab|
1592123|NCT02293109|Other|laboratory biomarker analysis|Correlative studies
1592124|NCT02293096|Drug|metoprolol succinate|
1592125|NCT02293096|Genetic|Genotyping|CYP2D6 only clinically pertinent pathway of metoprolol metabolism and polymorphisms have been associated with altered levels of metoprolol. ADRB1 is the drug target and polymorphism in this receptor has been associated with variable drug response. Genotyping will occur after the treatment phase is complete. Thus the investigator, the subject, and the outcomes investigator will be blind to the intervention.
1592126|NCT02293096|Procedure|CYP2D6 Phenotyping|Phenotype can be discordant from what is predicted by genotype due to variability in absorption, hepatic blood flow, drug interaction and drug elimination. These factors can be accounted for by utilizing a phenotyping assay that determines area under the curve of the probe since the probe is affected by the same variables dictating metabolism phenotype of the therapeutic drug. Investigators will be blind to the patient blood pressure outcome for this intervention.
1592127|NCT02293083|Drug|trigger point injection|
1592128|NCT02293070|Other|Delayed Enhanced Cardiac Magnetic Resonance Imaging|Subjects in this study get a Delayed Enhanced Cardiac Magnetic Resonance Imaging 2-6 weeks after they undergo cryoablation for atrial fibrillation. This MRI is compared to the pre-procedure cardiac MRI to determine if it possible to visualize the cryoablation lesions.
1592129|NCT02293070|Procedure|Cryoablation|All subjects in this study undergo a cryoballoon ablation procedure to achieve pulmonary vein isolation for the purposes of treatment of atrial fibrillation
1592130|NCT02293057|Behavioral|VOICES Group|VOICES: A program of self-discovery and empowerment includes four modules: Self (A), Connecting with others (B), Healthy living (C), and the Journey Ahead (D). All sessions are 90 minutes long and include required and optional activities.
1592131|NCT02293057|Behavioral|Girl Health Group|The Girl Health group comparison condition includes adolescent groups matched for time and attention to VOICES groups. Intervention take a psychoeducational/didactic approach and content focuses on a range of health behaviors, including substance use, exercise, nutrition and sleep.
1592132|NCT02293044|Device|Crest® Sensi-Stop™ Strips|
1592133|NCT02293031|Device|"Gene-activated matrix Nucleostim"|"Gene-activated matrix Nucleostim is bone graft substitute consisting of collagen-hydroxyapatite composite scaffold and DNA plasmids with gene encoding vascular endothelial grothw factor (VEGF-A165) in concentration 100-120 ng/mg which is an active substance of gene-therapeutic drug Neovasculgen®."
1592134|NCT02293018|Drug|0.75% (w/w) MTC896 Gel Once Daily|
1592135|NCT02293018|Drug|0.75% (w/w) MTC896 Gel Twice Daily|
1592136|NCT02293018|Drug|1.5% (w/w) MTC896 Gel Once Daily|
1592137|NCT02293005|Drug|Alisertib|50 mg twice a day on Days 1-7 of each 21-day study cycle.
1592138|NCT02292992|Device|Nasal Pillow CPAP|Nasal Pillow CPAP in extubated patients
1592139|NCT02292979|Drug|Doxorubicin|25mg/m2
1592140|NCT02292979|Drug|Bleomycin|10mg/m2
1592141|NCT02292979|Drug|Vinblastine|6mg/m2
1592142|NCT02292979|Drug|Dacarbazine|375mg/m2
1592143|NCT02292979|Drug|Brentuximab Vedotin|1.2 mg/kg
1592144|NCT02292966|Drug|DCV/ASV/BCV|Each participant will each receive daclatasvir (30mg), asunaprevir (200mg) and beclabuvir (75mg) in a fixed-dose combination oral tablet for twice daily administration with food.
2009134|NCT03324386|Behavioral|Experimental: VLE for Distance Learning|Experimental: This approach may be associated with the use of educational technology (E-Care of Hypertension) in a virtual learning environment(VLE) for distance learning (DL) consultation with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
2009135|NCT03324386|Behavioral|Experimental: E-blended Lerarning|This approach may be associated with the use of educational technology (E-Care of Hypertension) in the blended e-learning mode associated with face-to-face with the health professional and making 7 nursing visits at 20-day intervals, for 4 months
1592147|NCT02292914|Procedure|Robot-assisted surgery|Robot-assisted esophagectomy; Robot-assisted subtotal gastrectomy; Robot-assisted pancreatectomy;Robot-assisted rectal resection; Robot-assisted radical cistectomy;Robot-assisted prostatectomy;Robot-assisted Partial Nephrectomy; Robot-assisted hysterectomy;Robot-assisted Resection of malignant tumors of the mouth and orofaringolaringe; Robot-assisted lung lobectomy
1592148|NCT02292914|Procedure|Conventional Surgery|Thoracoscopic Esophagectomy; Open rectal resection and rectal laparoscopy resection; Open radical cistectomy; Open prostatectomy; Open Partial Nephrectomy; Laparoscopic hysterectomy; Laparoscopic lung lobectomy
1592149|NCT02292901|Device|Macintosh laryngoscope|
1592150|NCT02292901|Device|McGrath Mac videolaryngoscope|
1592151|NCT02292888|Other|Passive Leg Raising (PLR) test|Passive Leg Raising (PLR) test
1592152|NCT02292862|Procedure|Lymph node and blood sampling|"By bipolar dissection 1 portal and 1 mesenteric lymph node are removed from the infant.
Blood (1ml) is taken from mother and infant."
1592153|NCT02292849|Behavioral|Peer to Peer|12 weekly sessions of peer-delivered behavioral activation
1592154|NCT02292849|Other|Standard Mental Health Referral|Standard mental health referral to a community agency
1592155|NCT02292836|Other|Questionnaire testing|Questionnaire testing on rosacea and non-rosacea dermatology outpatients
1592156|NCT02292823|Device|MGuard™ Prime Embolic Protection Stent System|
1592157|NCT02292810|Device|Inspiratory muscle exercise|For inspiratory muscle exercise patients will breathe with a high load of 60% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) until task failure. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by continuous glucose monitoring system.
1592158|NCT02292810|Device|Inspiratory muscle exercise placebo|For inspiratory muscle exercise patients will breathe with a very low load of 2% of MIP using a respiratory frequency of 15 breaths min and a prolonged duty cycle (TI/TTOT =0.7) for 10 minute. The blood flow, conductance and resistance arterial will be measured in the calf using plethysmography device. Arterial blood pressure and heart rate will be monitored continuously at the finger on a beat-by-beat basis by biopac equipment and the glucose levels will be captured by using the continuous glucose monitoring system.
1592159|NCT02292797|Other|Prevalence assessment|Assessment of the prevalence of rosacea in the general population per country using subject questionnaire and dermatologist diagnosis
2009136|NCT03324386|Other|Conventional Therapy - Control Group|This approach may be individual orientation with conventional therapy may be making 2 nursing visits at baseline and 1 after 120 days,
2009137|NCT03324334|Diagnostic Test|Thyroid antibodies|Thyroid antibodies: Antithyroperoxidase(Anti-TPO), Anti-thyroglobulin (anti-TG) to detect graves disease in study and control groups
2009138|NCT03324334|Diagnostic Test|Thyroid sonography|Thyroid sonography to detect anatomical changes in thyroid
2009139|NCT03324321|Other|Hypocapnia via Hyperventilation Protocol|90 seconds of hyperventilation using a metronome to lower levels of -5mmHg and -10mmHg below baseline EtCO2
2009140|NCT03324269|Device|NOL|"After tracheal intubation, a Tetanus test (60 mAmp,100 Hz) is done during 30 sec at remifentanil level Ce of 4 ng/ml (with starting NOL value <10). According to the NOL response: increment of 1 ng/ml of RemiCe if NOL gradient ≥ 10 / decrement of 1 ng/ml of remifentanil Ce NOL gradient < 10. During the testing period propofol Ce is fixed at the concentration associated with BIS levels between 45-60 during the first calibration.
Upon the incision and 10 minutes after skin incision and sternotomy, Propofol TCI (Schnider model) is adjusted to BIS between 45-60 and remifentanil Ce at which the variation of NOL index variation is less than10 units at a NOL starting value <10. MAP (mean arterial pressure), HR (heart rhythm) and NIBP (non-invasive blood pressure) will be measured."
1592172|NCT02292745|Radiation|stereotactic radiotherapy|
1592173|NCT02292732|Drug|Trametinib 0.5 mg|Each tablet will contain GSK1120212B equivalent to 0.5 mg of Trametinib. Tablets are yellow, oval, biconvex, film-coated (4.85 x 8.86 millimeter [mm]) to be taken orally and once daily
1592174|NCT02292732|Drug|Trametinib 2 mg|Each tablet will contain GSK1120212B equivalent to 2 mg Trametinib. Tablets are pink, round, biconvex and film-coated tablets (7.5 mm in diameter) to be taken orally and once daily.
1592175|NCT02292732|Drug|ORTHO-NOVUM® tablet 1/35|Each peach tablet will contain 1 mg of NE and 0.035 mg of EE. Other inactive ingredients will include lactose, magnesium stearate and pregelatinized corn starch
1592176|NCT02292732|Drug|Placebo|Each green tablet will contain only inert ingredients: D&C yellow No. 10 Aluminum Lake, FD&C Blue No. 2 Aluminum Lake, lactose, magnesium stearate, microcrystalline cellulose, and pregelatinized cornstarch. The tablets are to be taken orally and once daily
1592177|NCT02292719|Drug|Ombitasvir/ABT-450/r|Tablet
1592178|NCT02292719|Drug|Sofosbuvir|Tablet
1592179|NCT02292719|Drug|Ribavirin (RBV)|Tablet
1592180|NCT02292706|Drug|Sofosbuvir|Exposure of interest for participants who received a sofosbuvir-based regimen in a previous Gilead study for chronic hepatitis C virus infection.
1592181|NCT02292693|Device|MIL|Direct laryngoscopy. Laryngoscopy with Miller blade
1592182|NCT02292693|Device|MAC|Direct laryngoscopy. Laryngoscopy with Macintosh blade
1592183|NCT02292693|Device|McCoy|Direct laryngoscopy. Laryngoscopy with McCoy blade
1592184|NCT02292667|Procedure|TAP block|The aim of the Transversus Abdominis Plane (TAP) Block is to deposit local anesthetic in the plane between the internal oblique and the transversus abdominis muscles targeting the spinal nerves in this plane. The local anesthetic used in the ETAP study is Ropivacaine 0.375%. 2 ultrasound-guided injections of 10 ml will be performed on each side of the abdominal wall: 1 subcostal injection and 1 supra-iliac injection.
1592185|NCT02292667|Drug|PCA with Chlorhydrate of Morphine|Doses of 1 mg of Chlorhydrate of Morphine will be delivered intravenously by the Patient Controlled Analgesia (PCA) pump. The PCA pump is a computerized pump which contains a syringe of 1 mg/ml of Chlorhydrate of Morphine as prescribed by the physician in charge of the patient, and connected directly to a patient's intravenous line. Doses of Chlorhydrate of Morphine can be self-administered by the patient as needed by the having the patient press a button.
1592186|NCT02292667|Drug|Acetaminophen|1 g of Acetaminophen will be given intravenously each 6 h during 48 hours after the surgical procedure.
2009141|NCT03324217|Other|Mental Practise|They made a mental task to produce a neurophysiological activation of the brain areas related to the planning and execution of voluntary movement in a manner that resembles how the action is performed in reality in combination with real exercises.
1592188|NCT02292641|Procedure|New Radiological Staging Classification system for patients with advanced and recurrent colorectal cancer undergoing pelvic exenterative surgery|Currently there are no validated criteria or guidelines for judging whether advanced primary or recurrent colorectal cancer can be successfully removed and for selecting which patients should undergo this form of more radical surgery as is exenterative surgery. We are proposing that by validating the detailed evaluation of imaging of the tumour distribution within the pelvis using a new radiological staging classification, this will enable clear selection criteria to be established and will improve surgical planning.
1592189|NCT02292628|Drug|Infusion of mesenchymal stem cells from adipose tissue|
1592190|NCT02292628|Other|Infusion of placebo|
1592191|NCT02292615|Other|Medical Imaging|
1592192|NCT02292602|Behavioral|Family-Based Weight Control|Families randomized to the intervention condition will receive a 4-month, 14-session behavioral weight control intervention targeting obesity reduction in preschoolers and caregivers. Within the program, 9 sessions will be group-based and held at WIC and 5 sessions will be individual visits (4 home-based and 1 at a food market where the family shops). The intervention includes teaching behavioral weight loss, child behavior management, and life skills (e.g., budgeting and time management ) via experiential learning to assist families with implementing diet and activity recommendations for pediatric and adult weight management.
1592193|NCT02292589|Device|Frontal Stimulation|The patient will receive anodal tDCS on left dorsolateral prefrontal cortex with an intensity of 1.5 mA for 20 minutes.
1592194|NCT02292589|Device|Temporal Stimulation|The patient will receive anodal tDCS on left temporal cortex with an intensity of 1.5 mA for 20 minutes.
1592195|NCT02292589|Device|Sham Stimulation|The patient will receive anodal tDCS over the occipital area for 30 seconds only and then it will be turned off without the patient's knowledge.
1592196|NCT02292576|Other|Cocoa Pure|Cocoa Pure.
1592197|NCT02292576|Other|Placebo|Placebo.
1592198|NCT02292563|Procedure|Colonoscopist only|Only Colonosopist Observe during Colonoscopy (single observer)
1592199|NCT02292563|Procedure|Experienced Endoscopy Nurse Participation|Experienced Endoscopy Nurse Participation Observation during Colonoscopy (Both endoscopist and endoscopic nurse observe)
2009142|NCT03323944|Biological|huCART-meso cells|Intravenous administration of permanently modified CAR T cells that target mesothelin, given as single agent or in combination with a lymphodepleting dose of cyclophosphamide.
1592204|NCT02292524|Other|Commercially-available tomato food product|Each of the three tomato food products (juice, soup, sauce) provided 25-35 mg lycopene/day.
1592205|NCT02292511|Behavioral|Square-stepping exercise|In a group setting, an instructor will demonstrate walking patterns on a gridded mat to the participants and the participants must memorize and repeat the patterns on their own. This program has over 200 patterns that increase in difficulty from beginner to advanced. Eighty percent of the group must successfully complete the patterns to move onto the next pattern. Social engagement is encouraged.
1592206|NCT02292498|Device|FLIR ONE|
1592207|NCT02292485|Behavioral|Survey|Physicians complete survey to better understand their readiness to implement lung cancer screening programs in their practice settings. Surveys administered to physicians attending the TAFP education events in Houston, Texas, October 17-19, 2014 and in Dallas, Texas, November 7-9, 2014.
1592208|NCT02292472|Drug|Botulinum Toxin Type A|Inject intramuscularly once in visit 2
1592209|NCT02292459|Drug|Polyethylene Glycol 3350 Powder for Solution (PEG 3350)|
1592210|NCT02292459|Drug|Polyethylene Glycol 4000 Powder for Solution (PEG 4000)|
1592212|NCT02292433|Drug|PF-04937319 high dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 7 days
1592213|NCT02292433|Drug|PF-04937319 low dose|tablets, 50 mg with breakfast plus 50 mg with lunch, 7 days
1592214|NCT02292433|Drug|Placebo|tablets, breakfast plus lunch, 7 days
1592215|NCT02292407|Device|LigaSure Precise instrument|LigaSure Precise instrument is used during Axillary Lymph Node Dissection Technique: Dead space closure Technique: Omission of postoperative drain
1592216|NCT02292394|Behavioral|Multicomponent Cognitive Behavioral Telephone Intervention|
1592217|NCT02292394|Behavioral|Telephone Intervention Pleasant Activities|
1592218|NCT02292381|Other|Isometric exercise|
1592265|NCT02292082|Drug|Dexamethasone|
1592266|NCT02292082|Device|8 MHz. Chiba needle, 22 G / 4 inches|
1592267|NCT02292069|Drug|Amlodipine besylate/Atorvastatin calcium|Amlodipine besylate/Atorvastatin calcium 10/80 mg
1592219|NCT02292368|Behavioral|Questionnaires|At each acupuncture session, 3 questionnaires completed before each session that ask about dry mouth, any other symptoms, and treatment expectations. It should take about 5 minutes total to complete these questionnaires. Participants also complete another brief questionnaire about dry mouth after each session. It should take about 1 minute to complete this questionnaire.
1592220|NCT02292368|Procedure|Acupuncture|Acupuncture treatments given within 3 to 7 days of each other during Weeks 3-5 of regularly scheduled radiotherapy visits. It should take about 20 minutes to complete the acupuncture session each time.
1592221|NCT02292368|Procedure|Electroencephalogram (EEG)|Participants have an EEG at each acupuncture treatment. EEG recorded 5 minutes before acupuncture, during acupuncture, and for 5 minutes after acupuncture. Total visit time will last about 45-60 minutes.
1592222|NCT02292355|Other|Pilates|The intervention group will perform Pilates exercises for 15 weeks with frequency of twice weekly
1592223|NCT02292342|Dietary Supplement|Water|Control
1592224|NCT02292342|Dietary Supplement|Epicatechin 0.1 mg/kg|EC 0.1 mg/kg
1592225|NCT02292342|Dietary Supplement|Epicatechin 0.5 mg/kg|EC 0.5
1592226|NCT02292342|Dietary Supplement|Epicatechin 1.0 mg/kg|EC 1.0
1592227|NCT02292329|Dietary Supplement|Acai puree, frozen blended it with banana|150g of acai fruit, frozen blended it with banana.
1592228|NCT02292329|Dietary Supplement|Control Macronutrient matched|Macronutrient matched control in water and also prepared with banana.
1592229|NCT02292316|Behavioral|gait and cognitive assessments|several tests are given in each domain
1592230|NCT02292316|Biological|blood sample|routine analyses in rheumatology such blood count and 25OH-D
1592231|NCT02292316|Other|osteodensitometry|Looking for osteoporosis
1592232|NCT02292303|Dietary Supplement|zinc-enriched yeast|
1592233|NCT02292303|Dietary Supplement|Zinc references|
1592234|NCT02292290|Drug|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response
1592235|NCT02292290|Drug|Liraglutide|4 week lead-in 0.6mg Liraglutide OD up to 1.2mg after two weeks if poor response.
1592236|NCT02292290|Drug|Sulfonylurea or Pioglitazone|Addition to Metformin
1592237|NCT02292290|Drug|Maintain dual therapy (Sulf/Pio) as comparator to Liraglutide|As per clinical guidelines for prescription
1592238|NCT02292277|Drug|Ticagrelor|Oral loading dose of 180 mg ticagrelor.
1592239|NCT02292251|Behavioral|Device-assisted therapy|
1592240|NCT02292251|Behavioral|Therapy-based occupational therapy|
1592241|NCT02292238|Drug|Benfotiamine|"To test whether increasing brain thiamine by administering 600 mg per day (300 mg/morning and 300 mg/evening) of benfotiamine for one year can slow cognitive decline in these patients as measured with the Alzheimer's Disease Assessment Scale (ADAS-COG).
To determine whether increasing brain thiamine availability with 600 mg (300 mg/morning and 300 mg/evening) per day of benfotiamine for one year can slow the decline in brain glucose metabolism in these patients as measured with Fluorodeoxyglucose Positron Emission Tomography(FGPET) in the posterior cingulate."
1592242|NCT02292225|Drug|IPI-145 (duvelisib)|25mg and/or 5mg oral capsule
1592243|NCT02292225|Drug|Obinutuzumab|1000mg/40mL single-use vials
1592244|NCT02292212|Device|ViE-21|The subjects will be undergone three times KUF measurement sessions and three times blood sampling sessions during study period.
1592245|NCT02292199|Device|TENS High Frequency|TENS high frequency (100 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
1592246|NCT02292199|Device|TENS Low Frequency|TENS low frequency (4 Hz / 200μs) was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The intensity of the current was delivered at sensory-level intensity, adjusted every 5 minutes by the sensory threshold, during the 30 minutes as tolerated by each subject, but without motor contraction or pain reported by the subject.
1592247|NCT02292199|Device|TENS Placebo|TENS was applied in bilateral paravertebral region of the T1 segment of the thoracic spine at L2 lumbar spine. The placebo group received an active current for 30 seconds, and then gradually decreased for 15 seconds to not pass any current. This approach aims at masking the investigator and subject (RAKEL et al., 2010).
1592248|NCT02292186|Drug|Revusiran (ALN-TTRSC)|
1592249|NCT02292173|Drug|Trametinib|"Dose Escalation:
Level 1: 1 mg daily. Level 2: 1.5 mg daily. Level 3: 1.5 mg daily. Level 4: 2 mg daily.
Dose Expansion:
Maximum Tolerated Dose (MTD)"
1592250|NCT02292173|Drug|Sorafenib|"Dose Escalation:
Level 1: 200 mg twice daily. Level 2: 200 mg twice daily. Level 3: 400 mg twice daily. Level 4: 400 mg twice daily.
Dose Expansion:
Maximum Tolerated Dose (MTD)"
1592251|NCT02292134|Device|earplug and sleep mask|Individual protection against light and noise using earplugs and a sleep mask from 2 hrs to 8 hrs
1592252|NCT02292121|Procedure|Intestinal permeability|5h-intestinal permeability test 10-hour overnight fasting subject who first emptied his bladder drinks a solution of mannitol and lactitol. 2 hours after, the subject drinks 500mL of water in less than 30 minutes. All urine samples are collected during the 5h-test for measurement of lactitol and mannitol.
1592253|NCT02292121|Other|a solution of mannitol and lactitol|
1592254|NCT02292108|Behavioral|dietetic counselling|
1592255|NCT02292108|Behavioral|Hypnosis and self-hypnosis|Erickson's hypnosis and self-hypnosis
1592256|NCT02292095|Procedure|TAPB group|transverse abdominis plane block will be conducted by ultrasound and a single-injection of 20ml 0.75% ropivacaine will be conducted for nerve block at the end of surgery.After surgery,participants in this group will also receive patient controlled intravenous analgesia.
1592257|NCT02292095|Procedure|PCIA group|The formula of patient controlled intravenous analgesia included tramadol 800 mg, flurbiprofenaxetil 100 mg, and dexamethasone 5 mg with saline added up to a volume of 80 ml in total, they received a loading dose of 2 ml followed by an infusion rate of 1 ml/h with bolus of 2 ml, the lock time was set at 15 min
1592258|NCT02292082|Drug|Bupivacaine|
1592259|NCT02292082|Drug|Morphine|
1592260|NCT02292082|Drug|Methylprednisolone|
1592261|NCT02292082|Drug|Cefazolin|
1592262|NCT02292082|Drug|Normal saline|
1592263|NCT02292082|Drug|Midazolam|
1592264|NCT02292082|Drug|Propofol|
1592268|NCT02292056|Behavioral|1-on-1 counseling|"Precounseling questionnaire collecting demographic information, contraception information, and reasons for choosing contraceptive method
Precounseling quiz: assess baseline level of knowledge regarding medication safety and contraceptive option.
Counseling: completed by MotherToBaby counselor about the safety of their medications for use in pregnancy.
10 minute video entitled The Contraceptive Choice Project: Which Birth Control Method is Right for You? by Washington University in St. Louis.
Post-Counseling Quiz to assess whether specialized training impacted their understanding of medication safety and contraceptive options.
Post-Counseling Questionnaire: assess contraceptive plans and satisfaction with counseling"
1592269|NCT02292043|Drug|HTEA|HTEA
1592270|NCT02292030|Drug|HTEA|usually high thoracic epidural anesthesia
1592271|NCT02292017|Device|Embolization of intracranial aneurysm|Cerebral angiogram will be performed, target aneurysm measurements are performed including dome height, width, and depth as well as the neck length. Aneurysm volume will be calculated. During the embolization, framing, filling, and finishing should be done with Target Coils. In the event of aneurysms with a wide neck a Neuroform Stent may be used to ensure the best clinical and angiographic outcome. Immediate post procedure angiography is performed using the same pre-treatment views to assess results and complications.
1592272|NCT02292004|Device|ACL Repair with MIACH Scaffold|Surgical insertion of the MIACH scaffold to promote ACL healing/repair
1592273|NCT02292004|Procedure|Standard ACL Reconstruction|Standard surgical reconstruction of the ACL with autograft hamstring tendon
1592274|NCT02291991|Drug|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
1592275|NCT02291991|Drug|GX-E2|Investigational drug(GX-E2 or Placebo) will be administered to healthy volunteers by the intravenous route.
1592276|NCT02291978|Device|ExAblate 2100|The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.
1592277|NCT02291952|Behavioral|Meal schedule|
1592278|NCT02291939|Procedure|Parotidectomy|Surgical Intervention with the FMwand Surgical System
1592279|NCT02291926|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will be implanted to patients by intra-articular injection, and repeated every month for four times.
1592280|NCT02291913|Drug|Everolimus|
1592281|NCT02291913|Drug|Exemestane|Anti-estrogen therapy
1592282|NCT02291913|Drug|Tamoxifen|Anti-estrogen therapy
1592283|NCT02291913|Drug|Fulvestrant|Anti-estrogen therapy
1592284|NCT02291913|Drug|Anastrozole|Anti-estrogen therapy
1592285|NCT02291913|Drug|Letrozole|Anti-estrogen therapy
1592286|NCT02291913|Drug|Toremifine|Anti-estrogen therapy
1592287|NCT02291900|Procedure|core decompression|retrograd drilling of the avascular talar necrosis, followed by osseous autograft
1592288|NCT02291887|Drug|Ranibizumab|Intravitreal injection of Ranibizumab
1592289|NCT02291887|Drug|Aflibercept|Intravitreal injection of Aflibercept
1592290|NCT02291874|Drug|Ipragliflozin|oral
1592291|NCT02291861|Drug|SD-809|SD-809 tablets dose titrated for 4 weeks until target randomized dose is reached. The dose is maintained for an additional 8 weeks.
1592292|NCT02291861|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks
1592293|NCT02291848|Biological|TAA-specific CTLs|"Each patient will receive 2 infusions at the same dose, 14 days apart, according to the following dosing schedules:
Dose Level One:
Day 0: 5 x 10^6 cells/m2 and Day 14: 5 x 10^6 cells/m2
Dose Level Two:
Day 0: 1 x 10^7 cells/m2 and Day 14: 1 x 10^7 cells/m2
Dose Level Three:
Day 0 2 x 10^7 cells/m2 and Day 14 2 x 10^7 cells/m2
Dose Level Four:
Day 0 4 x 10^7 cells/m2 and Day 14 4 x 10^7 cells/m2
If patients without measurable disease remain in complete remission or those patients with measurable active disease at the time of infusion have stable disease or a partial response by the International Working Group (IWG) criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number or less (if there is not enough product available for the subject's original dose) than their second infusion."
1592294|NCT02291822|Drug|Gadobenate Dimeglumine|gadolinium contrast agent
1592295|NCT02291809|Biological|REMUNE|Inoculation of HIV-1 Virus via Vaccination of Whole Killed GP120 Depleted P24 Antigen Vaccine
1592296|NCT02291796|Drug|Bezafibrate|Patients with ST elevation acute myocardial infarction (STEAMI) and with fibrinogen concentration >500 mg/dl at 72 h of evolution, were randomly assigned to bezafibrate 400 mg/day or just conventional therapy
1592297|NCT02291783|Drug|HTL0009936|Single dose
1592298|NCT02291783|Drug|HTL0009936 placebo|Placebo single dose
1592299|NCT02291770|Biological|Mesenchymal Stromal Cells|Mesenchymal stem cell(MSC). Patients with newly diagnosed cGvHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
1592300|NCT02291757|Dietary Supplement|NEM Eggshell Membrane|
1592301|NCT02291744|Procedure|resection of primary lesion|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle, and resection of primary lesion with metastatic colon cancer
1592302|NCT02291744|Drug|XELOX|Oxaliplatin 130mg/m2 ivgtt d1 and capecitabine 1000mg/m2,bid,po,d1-d14,every three weeks for a cycle,
1592303|NCT02291731|Drug|Continuous use of topical autologous serum|Silicone-hydrogel SCLs combined with 20% (v/v) autologous serum eye drops were used until complete re-epithelialization. SCLs were removed after total re-epithelialization and patients were subsequently randomized divided into two groups: (1) with and (2) without continuous use of topical autologous serum for an additional 2 weeks after SCLs removal.
1592304|NCT02291718|Drug|Isovue|iodine contrast
1592305|NCT02291705|Procedure|rectus sheath block|ultrasound-guided rectus sheath block with 0.25% 0.2 ml/kg levobupivacaine
1592306|NCT02291705|Drug|Tramadol|tramadol 1 mg/kg iv
1592307|NCT02291692|Procedure|paravertebral blockade|ultrasound guided thoracic paravertebral block with 0.5 ml/kg bupivacaine %0.5
1592308|NCT02291679|Drug|Linaclotide|
1592309|NCT02291679|Drug|Matching Placebo|
1592310|NCT02291666|Drug|CRCHUM-MT cocktail|
1592311|NCT02291653|Device|McGrath|video-laryngoscopy
1592312|NCT02291653|Device|MIL|direct-laryngoscopy
1592313|NCT02291640|Device|MIL|direct laryngoscopy
1592314|NCT02291640|Device|CoPilot|video laryngoscopy
1592315|NCT02291627|Device|MAC|direct laryngoscopy
1592316|NCT02291627|Device|Coopdech|Video laryngoscopy
1592317|NCT02291627|Device|AirTraq|optical laryngoscopy
1592318|NCT02291614|Drug|AMG 211|200-12,800 µg/day cIV infusion in cycles from 7 to 28 days
2009143|NCT03323840|Other|Incentivized Care|Patients will receive a $10 gift card for every blood pressure measurement (up to 2 times/month)
1592322|NCT02291588|Drug|AMG 811|A single dose of AMG 811 or placebo will be adminstered.
1592323|NCT02291588|Drug|Placebo|contains no active drug
1592324|NCT02291575|Other|Training|(please see Arm Description)
1592325|NCT02291575|Other|Control|This group will not receive any training from the Liver Foundation; they will simply be evaluated at baseline and endline.
1592326|NCT02291562|Drug|Tetrahydrocannabinol|10 mg Tetrahydrocannabinol (capsule, once) oral intake
1592327|NCT02291562|Drug|Cannabidiol|600 mg Cannabidiol (capsule, once) oral intake
1592328|NCT02291562|Drug|placebo|placebo (capsule, once) oral intake
1592329|NCT02291549|Drug|S8 Sinus Implant|Bilateral in-office placement of the S8 Sinus Implant (mometasone furoate, 1350 mcg) in the ethmoid sinuses
1592330|NCT02291549|Drug|Nasonex steroid nasal spray|topical nasal steroid spray 200mcg once daily
1592331|NCT02291536|Drug|tetrahydrocannabinol|
1592332|NCT02291536|Drug|cannabidiol|
1592333|NCT02291536|Other|placebo|
1592334|NCT02291523|Biological|Fecal Microbial Transplant|Fecal Transplant via Colonoscopy.
1592335|NCT02291510|Drug|Met DR|metformin delayed-release tablets
1592336|NCT02291510|Drug|Met XR|metformin extended-release tablets
1592337|NCT02291510|Drug|Met IR|metformin immediate-release tablets
1592338|NCT02291484|Device|Cardiac CT scan|CT-guided management
1592339|NCT02291471|Drug|T0001，10mg|
1592340|NCT02291471|Drug|T0001，20mg|
1592341|NCT02291471|Drug|T0001，35mg|
1592342|NCT02291471|Drug|T0001，50mg|
1592343|NCT02291471|Drug|T0001，65mg|
1592344|NCT02291471|Drug|T0001，75mg|
1592345|NCT02291458|Drug|L-arginine|9 gram L-arginine / day for 6 weeks
1592346|NCT02291458|Drug|Placebo|9 gram placebo / day for 6 weeks
1592347|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (enteric coated capsule)|Peppermint oil capsule available as an over the counter prescription drug on the Dutch market.
1592348|NCT02291445|Drug|Menthae piperitae aetheroleum/peppermint oil (colon-targeted-delivery capsule)|Peppermint oil capsule with a coating developed according to the ColoPulse® technology, ensuring a pulsatile and therefore slower release in a lower part of the intestinal tract compared to Tempocol, namely in the (ileo-)colonic region.
1592349|NCT02291432|Biological|autologous muscle-derived cells (AMDC)|Cell treatment
1592350|NCT02291419|Drug|ticagrelor|ticagrelor 90 mg bid
1592351|NCT02291419|Drug|aspirin|aspirin 81 mg daily
1592352|NCT02291406|Procedure|Abdominal hysterectomy|Standard extrafascial abdominal total hysterectomy through a low transverse abdominal wall incision.
1592353|NCT02291406|Procedure|Robot assisted laparoscopic hysterectomy|Robotic assisted total laparoscopic hysterectomy.
1592354|NCT02291393|Device|80 lead ECG|
1592355|NCT02291380|Drug|Botulinum Toxin Type A for Injection|In these studies ,patients received a minimum intramuscular (IM) dose of 155 U of Botulinum Toxin Type A（HengLi®）administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 5 U in 0.1 mL). In addition, up to 40 U Botulinum Toxin Type A,administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. Thus, the minimum dose was 155 U and the maximum dose was 195 U. In the core phase, two doses of HengLi® will be injected.In the extension phase, three doses of HengLi® will be injected.
1592356|NCT02291380|Drug|Placebo|In these studies, patients received placebo administered to 31 injection sites across 7 head and neck muscles using a fixed-site, fixed-dose injection paradigm (each injection was 0.1 mL). In addition, up to 0.8 mL placebo, administered IM to 8 additional injection sites across 3 head and neck muscles, was allowed, using a follow-the-pain approach. In the core phase, two doses of placebo will be injected.
1592357|NCT02291367|Drug|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
1592358|NCT02291367|Drug|Cymbalta®|60 mg capsule of Eli Lilly and Company
1592359|NCT02291354|Drug|Pectin|Patients allocated to experiment group will receive 12 g pectin each day for 12 weeks.
1592360|NCT02291354|Other|Placebo|Patients allocated to experiment group will receive 12 g maltodextrin each day for 12 weeks.
1592361|NCT02291354|Procedure|Fecal microbiota transplantation (FMT)|Standardized Frozen Fecal Microbiota will be infused via nasointestinal tube.
1592362|NCT02291341|Drug|Duloxetine|Duloxetine Delayed-Release Capsules 60 mg
1592363|NCT02291341|Drug|Cymbalta®|60 mg capsule of Eli Lilly and Company
1592364|NCT02291328|Other|High Brassica|Participants consume a minimum of one portion of a Brassica food (84g frozen broccoli, 84g frozen cauliflower, or 300g frozen broccoli and sweet potato soup) each day for 14 consecutive days at their homes.
1592365|NCT02291328|Other|Low Brassica|Participants consume one portion of a Brassica vegetable (84g frozen broccoli, or 84g frozen cauliflower) each week for two weeks at their homes.
1592366|NCT02291302|Other|integrated pest management|integrated pest management and environmental strategy
1592367|NCT02291302|Other|air purifier|air purifiers
1592368|NCT02291302|Other|No intervention (control)|no integrated pest management and sham air purifier
1592369|NCT02291289|Drug|Cetuximab|500 mg/m^2 via IV infusion on Day 1 of every 2-week cycle
1592370|NCT02291289|Drug|FOLFOX induction regimen|Administered per the Investigator's discretion in accordance with locally approved prescribing information.
1592371|NCT02291289|Drug|Fluoropyrimidine (5-FU/LV or capecitabine)|Per Investigator's discretion: 1600-2400 mg/m^2 administered via 46-hour IV infusion on Day 1 of every 2-week cycle and LV 400 mg/m^2 administered via a 2-hour infusion on Day 1 every 2 weeks or 1000 mg/m^2 twice-daily capecitabine (BID) by mouth given days 1-14 every 2 weeks. The chosen fluoropyrimidine should be administered in accordance with local prescribing information.
1592372|NCT02291289|Drug|Atezolizumab|800 mg atezolizumab via 60-minute IV infusion on Day 1 of every 2-week cycle, or a fixed dose of 840 mg
1592373|NCT02291289|Drug|Vemurafenib|960 mg vermurafenib BID by mouth
1592374|NCT02291289|Drug|Bevacizumab|5 mg/kg bevacizumab via 15-30 minute IV infusion on Day 1 of every 2-week cycle per local prescribing information
1592375|NCT02291289|Drug|Trastuzumab|Initial loading dose of 8 mg/kg followed by 6 mg/kg for subsequent doses by IV infusion on Day 1 of every 3-week treatment cycle
1592376|NCT02291289|Drug|Pertuzumab|Initial fixed loading dose of 840 mg followed by 420 mg for subsequent doses by IV infusion on Day 1 of each 3-week treatment cycle
1592377|NCT02291289|Drug|Cobimetinib|60 mg orally once daily for 3 weeks followed by a 1-week treatment break
1592378|NCT02291289|Drug|5-FU/LV|1600-2400 mg/m^2 5-FU via 46-hour IV infusion in combination with 400 mg/m^2 LV via 2-hour infusion on Day 1 of every 2-week cycle until disease progression per the Investigator's assessment using modified Response Evaluation Criteria in Solid Tumors or death from any cause, whichever occurs first.
1592379|NCT02291263|Biological|bOPV/IPV (6 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 weeks of age
1592380|NCT02291263|Biological|bOPV/IPV (14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 14 weeks of age
1592381|NCT02291263|Biological|bOPV/IPV (6 & 14 weeks)|bOPV at 6, 10 and 14 weeks of age IPV at 6 and14 weeks of age
2009144|NCT03323814|Device|Slow-wave optimization|employing sensory stimulation to enhance slow waves
2009145|NCT03323775|Diagnostic Test|Suprathreshold stimulation|Intraoperatively, radiofrequency needles will be placed on specific nerves targeted using parallel needle placement technique under image guidance. These nerves will have identified by the diagnostic injections carried out previously. The nerves will be located using 50 Hz sensory stimulation. The targeted medial branches (dorsal ramus in the case of L5) will be stimulated using suprathreshold stimulation (up to three times the sensory detection threshold) to identify the pain referral area. Motor stimulation of 2 Hz will be used to identify the multifidus muscle as well as to evaluate the close proximity to major spinal nerve to improve the safety of the procedure.
2009146|NCT03323463|Diagnostic Test|F-FMISO PET/CT Scan|Every participant will undergo a pre-treatment F-FMISO scan PET/CT scan pretreatment
2009147|NCT03323463|Radiation|30 Gy over 3 weeks|Treatment will be delivered as one fraction per day on a standard 5 day per week schedule (excluding weekends and holidays), total of 30 Gy over 3 weeks at 2 Gy per fraction each day. The gross nodes, the postoperative bed, all subclinical areas at risk for disease will receive the same dose at 30Gy.
1592386|NCT02291237|Drug|Eleclazine|Eleclazine tablets administered orally once daily
1592387|NCT02291237|Drug|Placebo|Placebo to match eleclazine administered orally once daily
1592388|NCT02291224|Behavioral|Interactive multimedia platform|An interactive platform that includes video vignettes of young women who are choosing dual protection strategies (based on a synthesis of focus group data from members of the TSC patient population), as well as true/false questions to build knowledge about dual protection and dispel common myths about contraceptive strategies. There will also be reflection questions that encourage participants to consider values and priorities in their own lives that may influence their dual protection strategy selection.
1592389|NCT02291224|Behavioral|Intervention arm counseling|Counseling for the intervention group will follow carefully developed guides and incorporate the participants' answers to the reflection questions in the interactive multi-media component. This counseling has a set structure (set forth in separate counseling guides for health care providers and nurse educators), incorporates motivational interviewing techniques, includes multiple opportunities for role play, and is designed to be patient-centered.
1592390|NCT02291224|Behavioral|Standard of care counseling|Standard of care counseling is provided by health care providers and health educators at TSC. It incorporates extensive counseling on methods to prevent both unintended pregnancy and sexually transmitted infections, however the structure of the counseling and techniques used are dependent on the standard practice of each provider or educator. This counseling does not incorporate answers to reflection questions from the multi-media platform because control arm participants will not view this content.
1592391|NCT02291211|Drug|S-1 plus cisplatin HIPEC|Using cisplatin in HIPEC plus oral S-1
1592392|NCT02291198|Device|NK Vue: NK cell activity in stimulated whole blood|One mL of blood is collected from each subject, on the day of colonoscopy, using NK Vue Promoca Tubes blood collection tubes containing a proprietary stimulating cytokine. After incubation, NK cell activity is measured in the collected plasma using an ELISA.
1592393|NCT02291172|Behavioral|Intervention JEP|A blend of JASP-EMT using SGDs with parent training intervention with the addition of individualized DTT to teach receptive language, imitation, and joint attention when children lack these skills at entry.
1592394|NCT02291159|Device|DNHS ® (Dry Needling for Hypertonia and Spasticity)|Dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
1592395|NCT02291159|Device|Sham Dry Needling|Sham dry needling of Myofascial Trigger Points. 2 sessions, one per week, in biceps brachii, brachialis, flexor digitorum superficialis nad profundus, adductor pollicis and first dorsal interossei
1592396|NCT02291146|Behavioral|LA Sprouts intervention|see arm 1 description
1592431|NCT02290873|Drug|Placebo|For induction and maintenance of sedation
1592582|NCT02289768|Drug|5-fluorouracil/salicylic acid|
2009148|NCT03323463|Drug|Cisplatin|Cycle 1 (week 1): At the start of week 1 of IMRT, subjects will receive cisplatin 100 mg/m2 intravenously. They may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 1 and 2, or as a single dose, typically on day 1.
2009149|NCT03323463|Drug|Carboplatin|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. Carboplatin will be given at a dose of AUC 1.25 intravenously daily x 4 days starting on day 1 of the cycle (total dose of AUC 5). Cycle 2 (Week 4): After the three weeks of radiation at week 4 when the subject no longer is receiving radiation therapy, subjects will receive cisplatin 100 mg/m2 intravenously. The may be given for 2 consecutive days (50 mg/m2 each day for a total dose 100 mg/m2), typically on days 22 and 23, or as a single dose, typically on day 22.
1592397|NCT02291133|Procedure|Electrochemotherapy|Exploration, anesthesia, adhesiolysis, mobilization of liver, intra-operative US or CT, bleomycin administration, electroporation
1592398|NCT02291133|Device|Cliniporator Vitae®|"Positioning of electrodes, 8-28 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 8 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
The maximum duration of procedure is 90 minutes, after liver mobilization."
1592399|NCT02291133|Drug|Bleomycin PHC 15 e. (United States Pharmacopeia - USP)|Intravenous in bolus administration of bleomycin (15 mg/m2)
1592400|NCT02291120|Procedure|Pulpotomy|
1592401|NCT02291107|Device|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assisted Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
1592402|NCT02291107|Other|Conventional Physiotherapy|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
1592403|NCT02291094|Drug|Lidocaine|Patients in intravenous lidocaine group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous lidocaine infusion of 3 mg/kg/hr.
1592404|NCT02291094|Drug|Remifentanil|Patients in remifentanil group received an intravenous bolus injection of 2 mg/kg lidocaine followed by a continuous remifentanil infusion of 0,1 mcg/kg/min.
1592405|NCT02291081|Other|Comprehensive non invasive cardiovascular examination|"Comprehensive non invasive cardiovascular examination
Anamnesis with the participants
File recherche,Physical examination
Documentation of the cardiovascular and antiretroviral medical therapy
Electrocardiogram
Transthoracic echocardiography
Exercise electrocardiogram
Exercise Montreal Cognitive Assessment test
Exercise the Grooved Pegboard test
Blood collection
Questionnaire to quality of life and health economics"
1592406|NCT02291068|Behavioral|psychotherapy treatment|3 months long (12 sessions) dynamic psychotherapy. The dynamic psychotherapeutic technique which will be applied in the current research is derived from Malan's focused, brief psychodynamic psychotherapy (Malan 1976) and from the literature specifying psychodynamic psychotherapies distinctive techniques (Shedler 2010). The principle of this treatment is a time limited intervention in which the primary objective is to enhance the patient's insights regarding repetitive conflicts. As psychodynamic psychotherapy is suitable for all kinds of adjustment disorders, no special adjustment in the course of therapy was made for the different subtypes (Cabaniss et al. 2011).
1592407|NCT02291055|Drug|ADXS11-001|
1592408|NCT02291055|Drug|Medi4736|
1592409|NCT02291042|Drug|B+O Suppository|
1592410|NCT02291029|Drug|CFZ533 active - Cohort 1|multiple doses of CFZ533 s.c. injection
1592411|NCT02291029|Drug|CFZ533 placebo- Cohort 1|multiple doses of placebo s.c. injection
1592412|NCT02291029|Drug|CFZ533 active - Cohort 2|multiple doses of CFZ533 intravenous infusion
1592413|NCT02291029|Drug|CFZ533 placebo - Cohort 2|multiple doses of placebo intravenous infusion
1592414|NCT02291016|Drug|Formoterol|Comparison of dosage administered via a nebulizer versus dosage administered via a dry powder inhaler. 12 µg Formoterol with the dry powder inhaler and 20 µg (solution form) of Formoterol with the nebulizer. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
1592415|NCT02291016|Other|Placebo|Comparison of drug administered via a nebulizer versus a dry powder inhaler. The placebo used will be sterile, preservative free, normal saline for inhalation for the nebulizer and a matched capsule without active drug for the dry powder inhaler. All patients will receive 2 ml of normal saline with the nebulizer to match the volume of nebulized formoterol solution. Patients will receive formoterol and placebo at both study visit #1 and visit #2.
1592416|NCT02290990|Behavioral|"Imaginative Distention technique"|ID is an Imaginative relaxation technique which combines physical and mental relaxation. ID technique reaches physical relaxation through planned alternated movements taken from Jacobson PMRT which consist of specific muscle contractions and subsequent relaxations, with a precise temporal scanning. Psychological relaxation is achieved thanks to mental imagery (motor imagery, body scan, imagination).
1592417|NCT02290977|Radiation|Scheduled interval TACE - RT|RT will be administered at 2 weeks after TACE in HCC combined PVTT
1592418|NCT02290964|Procedure|ANH|After general anesthesia is applied, blood was taken through the cubital vein and collected into standard blood bags containing CPDA anti-coagulant. The blood obtained is then stored at temperature of 23 - 25 Celsius degree and given back to patients in the operating room after the bleeding stopped and as soon as there are indications of transfusion.
1592419|NCT02290951|Drug|REGN1979 multiple dose levels|
1592420|NCT02290938|Behavioral|MICUNAY|MICUNAY is a three session workshop focused on discussions about how to make healthy choices using motivational interviewing, and providing a cultural activity.
1592421|NCT02290938|Other|Community Wellness Gathering|a monthly gathering focused on making healthy choices and learning about Native American culture
1592422|NCT02290925|Drug|Kothala Himbutu Biscuit|Kothala Himbutu biscuit (Salacia reticulata). This herb has been used by traditional physicians to control blood sugar.
1592423|NCT02290925|Dietary Supplement|Placebo Biscuit|Placebo biscuit without the herbal extract of Kothala Himbutu (Salacia reticulate)
1592424|NCT02290912|Behavioral|Health education program|"The intervention is a health education program including: informational website, experiential classes, custom smart phone or smart table application, wearable activity monitor, and informal coaching by student researchers to provide moral support for lifestyle behavioral change goals. Participants are not placed on any specific behavioral regimen but instead are encouraged to adopt healthier lifestyle behaviors per the evidence-based health education program, and to attend the experiential classes cafeteria style (i.e. based on their individual preferences)."
1592425|NCT02290886|Other|Intravenous administration of placebo|
1592426|NCT02290886|Drug|Intravenous administration of 1 million of MSC|
1592427|NCT02290886|Drug|Intravenous administration of 2 million of MSC|
1592428|NCT02290886|Drug|Intravenous administration of 4 million of MSC|
1592429|NCT02290873|Drug|Remimazolam|For induction and maintenance of sedation
1592430|NCT02290873|Drug|Midazolam|For induction of maintenance and sedation
1592432|NCT02290860|Procedure|Type 2 diabetes diagnosis test|Participants will perform type 2 diabetes diagnosis test the day of hospital discharge after delivery and the same test around 8 weeks later.
1592433|NCT02290847|Behavioral|Cognitive Processing Therapy (cognitive only version; CPT-C)|CPT is a cognitive behavioral treatment for PTSD consisting of 12 one-hour sessions (Resick, Monson, & Chard, 2008; Resick & Schnicke, 1993). CPT is delivered in three phases: education, processing, and challenging. The manualized treatment focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world.
1592434|NCT02290834|Other|Cognitive, functional and subjective assessments|Cognitive and functional assessments
1592435|NCT02290834|Device|MRI|Magnetic Resonance Imaging (MRI) Scan
1592436|NCT02290834|Radiation|PET Scan|Positron Emission Tomography (PET) Scan
1592437|NCT02290821|Drug|placebo|
1592438|NCT02290821|Drug|Placebos|
2009150|NCT03323463|Drug|5Fluorouracil|If cisplatin cannot be given at 100 mg/m2 for either cycle 1 or cycle 2, the investigator may use a regimen with carboplatin and 5-Fluorouracil in its place. 5-Fluorouracil will be given at a dose of 600 mg/m2 intravenous infusion over 24 hours daily x 4 days (total dose of 2400 mg/m2 intravenous infusion over 96 hours).
1592440|NCT02290795|Other|OCT imaging/HRT imaging|Standard follow up protocol with Optical coherence Tomography (OCT) imaging and Heidelberg Retinal Tomograph (HRT) imaging for glaucoma patients and patients scheduled for Ocriplasmin treatment In case of healthy controls the same investigations will be performed.
2009151|NCT03323658|Drug|Bexarotene|Given topically
1592442|NCT02290769|Device|Short guide wire rapid exchange|Use of short guide wire rapid exchange to guide the cannulation during primary ERCP
1592443|NCT02290769|Device|Long guide wire|Use of long wire to guide the cannulation during primary ERCP
1592444|NCT02290756|Behavioral|Parenting Program|The parenting program is an early childhood stimulation program aimed at newborns from their neonatal period till infancy. The implementation of the parenting program will be conducted through the link workers and parents of the newborns.
1592445|NCT02290756|Behavioral|Low cost evidence based toolkit|"The aim of providing the toolkit is to ensure that all pregnant women in the project are provided the requisite care needed from the antenatal period till delivery to limit complications and insults (both mother and especially the neonate) that can occur during pregnancy, delivery and post partum in both the mother and child. The contents of the toolkit will include:
Clean delivery kit, aspiration bulb, bag and mask, Chlorhexidine, Misoprostol, Nutritional supplements (Iron and folic acid, awareness about breastfeeding) and IEC materials
Trainings for Birth Attendants and Link workers on aspiration and hypothermia management techniques, use of bag and mask APGAR (also to parents), cord care, basic pregnancy and newborn care information"
1592446|NCT02290743|Other|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the quadriceps femoris in a stretched position. The tape can be divided into several tails to cover the whole muscle from origin to insertion.
1592447|NCT02290730|Other|Kinesio tape|Application of one Kinesio tape with 0-30 % tension over the muscle fibers of the lower trapezius in a stretched position. The tape can be divided into one, two or three tails to cover the whole muscle from origin to insertion
1592448|NCT02290717|Device|Fractional CO2 laser|
1592449|NCT02290717|Other|NB-UVB therapy|NB-UVB therapy (according to the standard treatment protocol of the SNIP, which the patient is already been treated with) will be continued for both treated and control sites during 6 months.
1592450|NCT02290717|Drug|Fluticasone Propionate Cream 0.05%|4 times a week (standard IPD protocol)
2009152|NCT03323658|Other|Laboratory Biomarker Analysis|Correlative studies
1592452|NCT02290678|Behavioral|Adventure-based Programming|
1592453|NCT02290665|Drug|Thermosensitive gel rectal formulation|
1592454|NCT02290665|Drug|Saline enema|
1592455|NCT02290652|Other|Prospective - Factors affecting sexual function pre-THR|"A prospective assessment of factors affecting sexual function in patients whom are awaiting a total hip replacement.
Patients will carry out a prospective 23 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Pre-operative' with validated questionnaire Female Sexual Function Index (FSFI), before their operation.
Then at 6 months and 12 months post-operatively they will fill out a retrospective 30 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Post-operative', again with FSFI."
1592456|NCT02290652|Other|Retrospective- Factors affecting sexual function post-THR|"A retrospective assessment of factors affecting sexual function in patients whom have undergone a total hip replacement (THR) in the preceding year.
Patients will carry out a retrospective 30 question questionnaire: 'Arthroplasty & Sexual Function Questionnaire (ASFQ) - Post-operative' with validated questionnaire Female Sexual Function Index (FSFI), at 6 months and/or 12 months (wherever possible).
Maximum retrospective collection of data 12 months."
1592457|NCT02290639|Behavioral|Brief Cognitive Behavioral Treatment|Cognitive-behavioral therapy (CBT) protocol designed specifically for use by behavioral health consultants (BHC) working in an integrated primary care setting. The treatment will be provided by a BHC in four 30-minute appointments scheduled approximately once a week in primary care over a one month period. Treatment content was largely drawn from a Prolonged Exposure model, but also includes elements of Cognitive Processing Therapy.
1592458|NCT02290639|Behavioral|Minimal Contact|Participants assigned to minimal contact (MC) will be asked to not work with another therapist or seek additional treatment for trauma-related difficulties during the 6-week MC period. They will be called once per week by the Behavioral Health Consultant (BHC) in order to monitor their status and to provide support as needed. The calls will be limited to 5-10 minutes.
1592459|NCT02290626|Drug|Elmental diet|elemental diet is administered using PEG.
1592460|NCT02290626|Drug|Semi-solid diet|Semi-solid diet is administered using PEG.
1592528|NCT02290132|Drug|Rabbit Anti－human Thymocyte Globulin (ATG)|The conditioning regimen in this study consisted of Rabbit antithymocyte globulin (ATG 2.5 mg/kg×4 days) , total-body irradiation (10 Gy in five fractions), cyclophosphamide (60 mg/kg×2 days) and etoposide or teniposide (30-40mg/kg) .
1592530|NCT02290119|Procedure|Control - Without the use of Verasense|Patients in this cohort will undergo manual total knee replacement without the use of Verasense
2009153|NCT03323658|Other|Questionnaire Administration|Ancillary studies
2009154|NCT03323567|Drug|MD Muscle GUNA collagen|intramusclular injections of MD Muscle collagen
2009155|NCT03323567|Drug|Lidocaine 2% Injectable Solution|intramuscular Lidocaine 2% injection
1592461|NCT02290613|Drug|Ambrisentan|"Titration:
As common practice of the clinic, the patient will adapt the dose from 5 mg to 10 mg after 1 to 4 weeks according to tolerability and after consultation (by phone or personally) with one of the investigators.
Additionally, at each study visit the investigator needs to decide, based on the patient's well-being, patients´ assessment, safety parameters, and tolerance of ambrisentan, if the study medication should be modified. The respective decision (increase, maintain or decrease dose) must be documented.
Maximum dose allowed: not to exceed 10 mg/die.
Administration:
Ambrisentan and placebo will be administered orally with or without food intake."
1592462|NCT02290613|Drug|Placebo|Placebo tablet (one to two tablets corresponding to one to two verum tablets)
1592463|NCT02290600|Device|Continuous Glucose Monitor|CGM sensor calibration individualization
1592464|NCT02290587|Other|Brain MRI - Clinical and cognitive evaluation|"Neuropsychological evaluation :
Questionnaire for depression and anxiety
Evaluation of executive functions
Evaluation of attention, information processing speed, verbal memory and working memory
Theory of mind evaluation
Clinical Evaluation
MRI Evaluation :
morphological MRI
functional MRI with two tasks of theory of mind : eyes test and test of attribution of intention"
1592465|NCT02290587|Device|MRI|
1592466|NCT02290574|Radiation|Hyperthermia with concurrent chemo-radiation therapy|
1592467|NCT02290561|Procedure|SmartTarget Therapy|MRI to Ultrasound fusion directed HIFU
1592468|NCT02290561|Device|MRI|
1592469|NCT02290561|Device|high intensity focused ultrasound (HIFU)|
1592470|NCT02290548|Device|high flow nasal cannula|High flow nasal cannula used in postextubation patients
1592471|NCT02290535|Procedure|patients|The 16-electrode belt will be applied to patient's chest. Following vital signs will be recorded: respiratory rate at rest breathing, heart rate, transcutaneous oxygen saturation. Then impulse oscillometry (IOS) will be performed in a sitting position. After that, subjects with cooperation willingness will get a body plethysmography. A spirometry / forced breathing maneuvers will be performed. All patients will receive 2 strokes salbutamol inhaler for bronchospasmolysis. Please note that inhalation of salbutamol is not study related. It is used in the clinical routine to examine the reversibility of the bronchial obstruction in patients with obstructive lung disease in course of the lung function test. Ten minutes later measurements described above will be repeated.
1592472|NCT02290535|Procedure|probands|Probands will receive the same treatment as patients, but without bronchospasmolysis.
1592473|NCT02290522|Procedure|Tumor biopsy|Biopsy of lesion for molecular characterization
1592474|NCT02290509|Biological|Flublok Quadrivalent|Intramuscular injection of study vaccine
1592475|NCT02290509|Biological|Inactivated Influenza Vaccine (IIV4)|Intramuscular injection of study vaccine
1592476|NCT02290496|Behavioral|CBT for Insomnia (CBT-I)|Cognitive behavior therapy for insomnia (CBT-I) comprising stimulus control, sleep restriction, and sleep-focused cognitive therapy. The CBT-I consists of in-person sessions and homework assignments and includes stimulus control and sleep restriction to regularize the sleep-wake cycle; cognitive therapy to address dysfunctional sleep beliefs and bedtime rumination; motivational interviewing to help youth make important health changes; and parental involvement. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
1592477|NCT02290496|Behavioral|Sleep Hygiene (SH)|Attention placebo control focusing on sleep hygiene, consisting of in-person sessions and homework assignments. The sleep hygiene sessions address sleep-related topics such as limiting pre-sleep caffeine intake, sleep-promoting activities, and the impacts of insufficient sleep. In addition, participants will continue treatment as usual (TAU) SSRI antidepressants delivered by a usual care provider.
1592478|NCT02290470|Drug|Olanzapine|"Drug: Olanzapine 10 mg oral
Drug: Chemotherapy (carboplatin and paclitaxel). Patients will receive carboplatin and paclitaxel.
Drug: Anti-emetic treatment (palonosetron; plus dexamethasone). Palonosetron (0.25 mg IV) on the day of chemotherapy plus dexamethasone (16 mg IV on the day of chemotherapy and 8 or 4 mg (depending on the experimental arm) oral on days 2 and 3 post-chemotherapy)."
1592479|NCT02290470|Drug|Palonosetron, Dexamethasone, Carboplatin, Paclitaxel, Olanzapine|all patients enrolled in the study will receive Palonosetron, Dexamethasone, Carboplatin, Paclitaxel and olanzapine On day 1
1592480|NCT02290457|Behavioral|core strength training|"Both training programs will last 6 weeks and comprise 2 training sessions per week with a total of 12 training sessions for each intervention group. Each training session will last 30 min, starting with a brief warm-up program mainly consisting of core strength exercises at moderate intensities and ending with a cool-down program (i.e., dynamic stretching). During the main part of training, both groups mainly conduct the big 3 exercises as described by McGill. These will include the curl-up, side bridge, and quadruped position. In other words, every single training session will consist of frontal, dorsal, and lateral core exercises. The only difference between the 2 intervention groups is that the CSTU protocol comprise core exercises that will be conducted on unstable elements (e.g., TOGU© DYNAIR PRO, THERA-BAND© STABILITY TRAINER), whereas the CSTS program will contain the same exercises on stable surface only."
1592481|NCT02290444|Drug|Adrenocorticotropic Hormone|Acthar Gel will be administered in accordance with the recommendations set forth in the package insert. The dosage may be individualized according to the medical condition of each patient. Frequency and dose of the drug may be determined by considering the severity of the disease and the initial response of the patient.
2009156|NCT03323567|Drug|Saline Solution, Hypertonic|intramuscular Saline injection
1592485|NCT02290418|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Gastric Bypass performed with two anastomoses (gastro-enteral and entero- enteral), two limbs (Alimentary limb of length 150cm and Biliary limb of length 75-100cm) and sewing of mesenteric defect.
1592486|NCT02290418|Procedure|Omega-Loop Gastric Bypass|Laparoscopic Gastric Bypass performed with single anastomosis (gastro-enteral) connecting a long gastric pouch to small bowel with Afferent limb of length 200cm.
1592529|NCT02290119|Device|Sensor-assisted TKR (Verasense)|Verasense is a single use, disposable device embedded with microelectronics into a standard tibial trial to provide dynamic, intraoperative feedback regarding limb alignment, tibiofermoral position and quantitative pressure at peak contact points in the medial and lateral compartments during total knee replacement surgery. Utilizing sensor-derived data, the surgeon can now evaluate intercompartmental loading throughout the range of motion, and correct for soft-tissue abnormalities while receiving real-time feedback regarding joint balance.
1592487|NCT02290405|Behavioral|Multiple Sleep Latency Test (MSLT)|The daytime protocol will include a 4-trial Multiple Sleep Latency Test (MSLT) along with 4-trials of a computer -administered battery of reaction time tasks. The assessment protocol will start two to three hours after participants' respective morning rising times and will begin with a battery of the neuro-cognitive testing followed by an MSLT nap. Per standard MSLT procedures, the daytime testing will be scheduled so the four performance testing and sleepiness assessment trials occur two hours apart. All daytime testing will be conducted under the supervision of trained laboratory technologists.
1592488|NCT02290379|Drug|TNX-201 35 mg|Drug: TNX-201 35 mg
1592489|NCT02290379|Drug|TNX-201 70 mg|Drug: TNX-201 70 mg
1592490|NCT02290379|Drug|TNX-201 140 mg|Drug: TNX-201 140 mg
1592491|NCT02290379|Drug|Racemic isometheptene 70 mg|Active Comparator: Racemic isometheptene 70 mg
1592492|NCT02290379|Drug|Placebo|Drug: Placebo
1592493|NCT02290366|Radiation|Focal prostate brachytherapy with Cesium-131|
1592494|NCT02290353|Device|FEATHERS|"FEATHERS Device includes a camera (PS3 Eye), 2 modified PS3 Move controllers, and a computer [2]. A software is designed to search through the camera feed to find the glowing balls attached to PS3 Move controllers, and changes the position of the computer's mouse cursor based on the balls' position. The participants play simple Facebook games that involve point-and-click by using the Move controllers and moving their arms in space to control the cursor and play games.
During the 8 weeks of intervention, we ask the participants to use the FEATHERS device to play online games (and thus do exercise) on the FEATHERS Facebook app at least 5 days/week, and at least 30 minutes/day. We are interested in seeing how this type of exercise changes the functional clinical scores of the participants."
1592497|NCT02290327|Drug|Pantoprazole|Proton pump inhibitor
1592498|NCT02290327|Drug|Placebo|50 ml of 0.9% normal saline
1592499|NCT02290314|Procedure|minimally invasive MID-line Lumbar Fusion (MIDLF)|
1592500|NCT02290314|Procedure|Posterior lumbar interbody fusion (PLIF)|
1592501|NCT02290301|Drug|gemigliptin|
1592502|NCT02290288|Procedure|vaginal surgery|
1592503|NCT02290288|Procedure|laparoscopic surgery|
1592504|NCT02290275|Dietary Supplement|Creatine|Subjects will supplement their regular diet with 20 grams of creatine for 1 week and then 5 grams of creatine for the following 11 weeks.
1592505|NCT02290275|Other|Walking Exercise|Subjects will walk on a specialized treadmill that lowers the impact of walking by taking up to 80% of their body weight away. The subjects will exercise by walking on this treadmill at 3.1 mph, 3 days per week for 30 minutes per day for 12 weeks.
1592506|NCT02290275|Dietary Supplement|placebo (maltodextrin)|Subjects will supplement their regular diet with 20 grams of maltodextrin for 1 week and then 5 grams of maltodextrin for the following 11 weeks.
1592507|NCT02290262|Other|Comprehensive phase one rehabilitation|"Patients allocated to the experimental group receive a rehabilitation programme consisting of physical exercise and psycho-education.
The physical exercises consist of; breathing exercises with and without using incentive spirometry with expiratory positive pressure airway, walking and cycling exercises and neck/shoulder exercises during hospitalisation and an exercise programme running from discharge until 4 weeks following surgery. The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse."
1592510|NCT02290236|Device|Pulseoximetry|Peripheral saturation will be recorded continuously
1592511|NCT02290223|Behavioral|Behavioral Based Treatment Model|The experimental procedure is a behavioral based treatment model, structured in the form of four group sessions, one meeting per week.
1592512|NCT02290210|Drug|URC102 0.25mg|
1592513|NCT02290210|Drug|URC102 0.5mg|
1592514|NCT02290210|Drug|URC102 1.0mg|
1592515|NCT02290210|Drug|URC102 2.0mg|
1592516|NCT02290210|Drug|placebo|
1592517|NCT02290197|Procedure|Surgery|Surgical reconstruction of all injured ligaments.
1592518|NCT02290197|Device|Hinged External Fixator|Hinged external fixator is used postoperatively for 6 weeks. Early joint mobility in the sagittal plane is encouraged.
1592519|NCT02290197|Device|Cast Immobilization|Cast is used postoperatively for 3 weeks. After this period we use a removable bracing and initiate rehabilitation with physical therapy.
1592521|NCT02290171|Behavioral|Activity groups|Children attend to activity groups weekly during the intervention periode.
1592522|NCT02290171|Behavioral|Group based dietary counselling|Parents attend to four sessions of group based dietary counselling
1592523|NCT02290171|Behavioral|Individual counselling|Parents attend to individual counselling focusing on parental skills and family structure
1592524|NCT02290158|Other|Finishing Protocol|Students education, cast models and Panoramic X-ray assessment, brackets reposition and frequent clinical evaluation.
1592525|NCT02290145|Drug|TPF group|"The patients in the experimental group received the TPF induction chemotherapy for 2 cycles followed by radical surgery and post-operative radiotherapy.
docetaxel:75mg/m2 cisplatin：75 mg/m2 5-Fu：750 mg/m2/day"
1592526|NCT02290145|Procedure|surgery group|The patients in the control group received the radical surgery and post-operative radiotherapy.
1592527|NCT02290145|Radiation|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
1592531|NCT02290106|Drug|pitavastatin|
1592532|NCT02290106|Other|PLACEBO|
1994861|NCT02899650|Other|exercise|acute downhill running
1592533|NCT02290093|Drug|Standard full-volume PEG|Subjects will be asked to take 4L of PEG-3350 solution the day prior to procedure.
1592534|NCT02290093|Drug|Split-dose full-volume PEG|Subjects will be asked to take 2L of PEG-3350 solution the day prior to procedure, followed by another 2L of PEG-3350 solution on the day of the procedure.
1592535|NCT02290093|Drug|Split-dose low-volume PEG|Subjects will be asked to take 1L of PEG-3350 containing ascorbic acid solution the day prior to procedure, followed by another 1L of PEG-3350 containing ascorbic acid solution on the day of the procedure.
1592536|NCT02290080|Drug|Oxygen|see arm description
1592537|NCT02290067|Device|Blood glucose monitoring system (Omnitest 3)|
1592538|NCT02290067|Device|Blood glucose monitoring system (Omnitest 5)|
1592539|NCT02290067|Device|Blood glucose monitoring system (Omnitest 5D)|
1592540|NCT02290054|Procedure|Control|Implementation of adhesive pads on the ears is performed while the patient is sleeping but before thoracic incision.
1592541|NCT02290054|Procedure|Treated|Auriculotherapy uses semi-permanent needles and implementation of adhesive pads to mask the needles.
1592542|NCT02290054|Procedure|Intra-venous anesthesia|
1592543|NCT02290041|Drug|Infusion of MSC|Intravenous infusion of 4 doses of allogenic adult mesenchymal stem cells from adipose tissue
1592544|NCT02290041|Drug|Infusion of placebo|Infusion of placebo
1592546|NCT02290015|Other|Acupuncture|All treatments were performed by the same acupuncturist, who is a medical doctor with more than eight years of clinical and research experience in ACP for tinnitus. Acupoints described as being effective for tinnitus were selected according to TCM theory. Basic points that are manipulated in ACP include GV 20 (Baihui), TE 17 (Yifeng), GB 8 (Shuaigu), SI 19 (Tinggong), GB 2 (Tinghui), TE 21 (Ermen), VC 23 (Lianquan), GB 20 (Fengchi), TE 2 (Yemen), TE 5 (Waiguan), SI 2 (Qiangu), GB 43 (Xiaxi) and GB 41 (Zulinqi). However, several secondary (accessory) acupoints were also added according to TCM and the etiological diagnosis of tinnitus: GV 4 (Mingmen), KI 3 (Taixi), BL 23 (Shenshu), BL 19 (Danshu), BL 18 (Ganshu) and CV 4 (Guanyuan).
1592547|NCT02290002|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
1592548|NCT02290002|Other|coasting|In group B, coasting (withholding gonadotrophins while maintaining pituitary suppression) for 3 days then either giving triggering or cycle cancellation is done
1592549|NCT02289989|Drug|Oregano extract cream|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
1592550|NCT02289989|Drug|Hydrocortisone|An experimental cream will be applied to one of the arms of the patient which will be an oregano extract and will be compared to the standard treatment which will be hydrocortisone 1% ointment
1592551|NCT02289976|Procedure|core decompression|Drilling of the avascular necrosis of the talus by 10mm drill under x-ray control
1592552|NCT02289963|Drug|Placebo (for Alirocumab)|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
1592553|NCT02289963|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen with a disposable auto-injector.
1592554|NCT02289963|Drug|Lipid-Modifying Therapy (LMT)|Statins (Rosuvastatin, Simvastatin or Atorvastatin) at stable dose with or without other LMT as clinically indicated.
1592555|NCT02289950|Drug|Farletuzumab|Farletuzumab will be administered intravenously (IV) weekly
1592556|NCT02289950|Drug|Placebo|Placebo will be administered intravenously (IV) weekly
1592557|NCT02289937|Drug|Ropivacaine|
1592558|NCT02289937|Drug|Placebo|
1592559|NCT02289937|Device|An ultrasound-guided Nervus cutaneous femoral lateralis blockade will be given postoperatively|
1592560|NCT02289924|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
1592561|NCT02289911|Other|Didactic training in the FAST|Participants in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
1592566|NCT02289885|Device|SonoScape|Ultrasonography device
1592567|NCT02289872|Device|Macintosh Laryngoscope|Direct-Laryngoscopy
1592568|NCT02289872|Device|TruView PCD Video laryngoscope|Video-Laryngoscopy
1592569|NCT02289859|Procedure|Wound Closure with Undermining|The side assigned to undermining will have undermining performed prior to wound closure in the subcutaneous plane. The amount of undermining will range from 1 cm for wounds with low tension to 2 cm for those with moderate tension. Since wound diameter will be 3 cm or less and exclude the scalp, high tension wounds are not anticipated.
1592570|NCT02289859|Procedure|Wound Closure without Undermining|One side of the wound will remain un-undermined.
1592571|NCT02289846|Drug|IW-9179|
1592572|NCT02289846|Drug|Matching Placebo|
1994862|NCT02899936|Drug|3 drug dose - IDA|Lymphatic Filariasis Mass Drug Administration (MDA) with triple drug therapy of ivermectin, diethylcarbamazine, and albendazole (IDA)
1994863|NCT02899936|Drug|2 drug dose - DA|Lymphatic Filariasis Mass Drug Administration (MDA) with the currently used standard of care combination drug therapy of diethylcarbamazine, and albendazole (DA)
1592577|NCT02289807|Drug|Cisplatin|concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles during IMRT
1592578|NCT02289807|Radiation|IMRT|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor
1592579|NCT02289794|Biological|E.coli bioconjugate vaccine|Single dose, intramuscular injection (0.5 mL)
1592580|NCT02289794|Biological|Placebo|Single dose, intramuscular injection (0.5 mL)
1592581|NCT02289781|Device|posterior crowns|teeth will be prepared to receive posterior crown made of either zirconia or metal-ceramic material
1592584|NCT02289755|Drug|ALLN-177|ALLN-177 is orally administered oxalate decarboxylase (OxDc). The goal of oral therapy with ALLN-177 is to enzymatically degrade both dietary oxalate and endogenously produced oxalate secreted in the gastrointestinal tract resulting in decreased absorption and reduced urinary oxalate excretion.
1592585|NCT02289742|Device|Nelfilcon A multifocal contact lenses|
1592586|NCT02289742|Device|Nelfilcon A toric contact lenses|
1592587|NCT02289742|Device|Nelfilcon A sphere contact lenses|
1592588|NCT02289716|Drug|Placebo|Placebo will be administered once every 4 weeks for 16 weeks by subcutaneous (SC) injection (injection under the skin) into the thigh or abdomen.
1592589|NCT02289716|Drug|Fulranumab 1 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
1592590|NCT02289716|Drug|Fulranumab 3 mg|Fulranumab will be administered once every 4 weeks for up to 16 weeks by SC injection into the thigh or abdomen.
1592591|NCT02289703|Drug|Rivaroxaban 15 mg|Single oral dose of rivaroxaban 15-mg tablet on Day 1 of each of the treatment periods.
1994870|NCT02899689|Device|Dilapan|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, synthetic osmotic dilators (Dilapan-S) are inserted into the cervical canal with special attention to cross through the internal os.
1592595|NCT02289677|Device|ATMOS Scope|Video-laryngoscopy 1
1592596|NCT02289677|Device|COOPDECH|Video-laryngoscopy-1
1592597|NCT02289677|Device|AirTraq|Optical-laryngoscopy
1592598|NCT02289664|Device|MAC|Direct-Laryngoscopy
1592599|NCT02289664|Device|Coopdech|Video-Laryngoscopy -1
1592600|NCT02289664|Device|CoPilot|Video-Laryngoscopy -2
1592601|NCT02289664|Device|Intubrite|Video-Laryngoscopy -3
1592602|NCT02289651|Device|Venner|Video-laryngoscopy
1592603|NCT02289651|Device|Miller|Direct-Laryngoscopy
1592604|NCT02289638|Device|Intubrite|Video-Laryngoscopy
1592605|NCT02289638|Device|MIL|Direct-Laryngoscopy
1592606|NCT02289625|Other|Exercise Training|six month of Exercise training will be conducted in individuals with moderate to severe sleep apnea. The training include aerobic exercise, resistance exercise, flexibility.
1592607|NCT02289612|Other|Yellow Mustard Gum Fibre|
1592608|NCT02289612|Other|Soluble Flaxseed Gum Fibre|
1592609|NCT02289612|Other|Fenugreek Gum Fibre|
1592610|NCT02289599|Drug|E2307|
1592611|NCT02289599|Drug|E2307 Matching Placebo|
1592612|NCT02289586|Procedure|invasive ventilation|
1592613|NCT02289586|Procedure|interventional bronchoscopy|
1592614|NCT02289586|Device|noninvasive ventilation|
1592615|NCT02289586|Drug|sedation(dezocine and midazolam)|
1592616|NCT02289586|Drug|general anesthesia(midazolam, fentanyl，rocuronium，propofol and Remifentanil）|
1592617|NCT02289573|Device|NAVA and PSV|change ventilation modes(NAVA and PSV) with different support levels
1592618|NCT02289560|Device|Transcranial ExAblate|Transcranial ExAblate
1592619|NCT02289547|Drug|Capecitabine|maintenance capecitabine therapy after six cycles of XELOX
1592620|NCT02289521|Device|Transcranial Direct Current Stimulation|"We will use a non-invasive, reversible transcranial direct current stimulation (tDCS) using a low-intensity electrical current. We will use Anodal and Sham tDCS.
Anodal: Active anodal electrode over F3 (EEG system) and return electrode over right supraorbital area. A 1.5mA current will flow between the electrodes for 20min. To decrease current-induced injuries, at the beginning, the current reaches from 0 to 1.5mA during 30 seconds (fade-in), and decreases from 1.5mA to 0 in 15 seconds at the end (fade-out).
Sham: The parameters mimics the A-tDCS (i.e. electrode placement, fade-in and current intensity), except the duration of stimulation: the current will reach to 1.5mA in 30 seconds (fade-in) and lasts only for 30 seconds (to give the initial sensation of stimulation)."
1592621|NCT02289508|Device|Ultrasonic cardiac output monitor|An Ultrasonic Cardiac Output Monitor, a non-invasive Doppler ultrasonography, is capable of measuring haemodynamic parameters non-invasively and appears to be simple and rapid to use, portable, relatively inexpensive and has less potential complications compared with the standard technique, pulmonary artery thermodilution (PATD). It has been compared favorably with a wide range of standard techniques, including PATD, with good interobserver reliability. USCOM may help on monitoring HF and suggesting proper treatment in order to reduce the mortality of adHF.
1592622|NCT02289508|Device|Echocardiography|2D-echo is a conventional standard-of-care tool for non-invasive hemodynamic assessments in adults. The use of 2D-echo requires highly trained personnel, and assessments may take anywhere between 30-45 minutes. It is used to find out the ejection fraction and to compare the haemodynamic parameters with USCOM in this study.
1592623|NCT02289495|Drug|GSK2838232|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20 and 50 mg which is to be administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
1592624|NCT02289495|Drug|Placebo|Matching placebo of Suspension to active dose, administered orally QD for 8 days (Part A) or 11 days (Part B), morning dose, following an overnight fast of at least 10 hours
1592625|NCT02289495|Drug|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg to be administer orally, QD
1592626|NCT02289482|Drug|GSK2838232 PIB (SDD)|GSK2838232 will be available as oral suspension dispersion in hydromellulose acetate succinate bulk powder/10, 20, 50, 200 and 500 mg in part A, while 100 mg in Part B. GSK2838232 will be administered orally once daily (QD) as single doses in the morning following an overnight fast of at least 10 hours.
1592627|NCT02289482|Drug|GSK2838232 PIB (API)|GSK2838232 will be available as oral suspension bulk powder/100 mg in Part B. GSK2838232 will be administered orally QD as single doses in the Morning following an overnight fast of at least 10 hours.
1592628|NCT02289482|Drug|Placebo|Matching placebo of Suspension to active dose, administered orally QD as single doses in the morning following an overnight fast of at least 10 hours.
1592629|NCT02289482|Drug|Ritonavir|Ritonavir will be available as white film-coated ovaloid tablets of 100 mg tablet/100mg. Ritonavir will be administered orally, once daily in Part A, Period 3 Days 1-14 and Period 4 from Days 1-12 and will be administer orally once daily in Part B for 9 days prior to dosing in Period 3 and on Days 10-14 of Period 3.
1592907|NCT02287636|Procedure|positron emission tomography|Undergo PET/MRI
1592630|NCT02289469|Other|PictureRx medication history platform|Tablet PC-based tool to take more complete and accurate medication history
2009157|NCT03323541|Drug|Filgrastim Prefilled Syringe [Zarxio]|Daily subcutaneous injection of Zarxio post ASCT, from day 5 until bone marrow recovery (neutrophils >1 giga/l)
1592633|NCT02289443|Other|complete denture|Comparison of different procedures
1592634|NCT02289430|Drug|Crestor+Ezetrol|rosuvastatin+ezetimibe
1592635|NCT02289430|Drug|Ezetrol|ezetimibe
1592636|NCT02289430|Drug|Crestor|rosuvastatin
1592637|NCT02289417|Drug|Apremilast|
1592638|NCT02289417|Drug|Placebo|
1592639|NCT02289404|Drug|NVP-1203(Fed)|fed
1592640|NCT02289404|Drug|NVP-1203(Fasting)|fasting
1592641|NCT02289391|Drug|Anesthesia induction|-Intravenous injection midazolam 0.05 mg/Kg,fentanyl 4μg/Kg,etomidate 0.2 mg/Kg,cisatracurium 0.15 mg/Kg in proper order.
1592642|NCT02289391|Drug|Anesthesia maintenance|"Continuous intravenous remifentanil O.2μg/(kg•h) and propofol 3~8mg/(kg•h).
Intermittent intravenous atracurium 0.05mg/kg. Maintain partial pressure of carbon dioxide(PETCO2) to 30~40 mmHg and bispectral index (BIS) to 45~60."
1592643|NCT02289391|Drug|Assisted anesthesia|Intervention 'Assisted anesthesia' has been included in Arm Descriptions.
1592644|NCT02289378|Drug|Docetaxel, Oxaliplatin and 5-Fu|To investigate the triplet regimen in the first-line therapy of advanced chemotherapy
1592645|NCT02289365|Drug|2000 mg of JBM-TC4 per day|2 capsules of 500 mg JBM-TC4 plus 1 capsule of 500 mg PEG-400, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
1592646|NCT02289365|Drug|3000 mg of JBM-TC4 per day|3 capsules of 500 mg JBM-TC4, oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
1592647|NCT02289365|Drug|3000 mg of PEG-400 per day|3 capsules of 500 mg polyethylene glycol 400 (PEG-400), oral route per time twice a day in Day (-7) prior to radiotherapy and continue through the radiotherapy period for additional 11 weeks.
1592648|NCT02289352|Drug|Brimonidine|
1592649|NCT02289352|Drug|placebo|
1592650|NCT02289339|Device|aortic valve prostheses|balloon-expandable and self-expandable aortic valve prostheses
1592652|NCT02289300|Drug|DCB-BO1202|"The assignment will be as follows:
(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)
DCB-BO1202: 4 DCB-BO1202 300mg capsules, t.i.d., orally.
Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
1592653|NCT02289300|Drug|Placebo|"The assignment will be as follows:
Placebo: 4 matched placebo, t.i.d., orally.
Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
1592654|NCT02289300|Drug|DCB-BO1202+Placebo|"The assignment will be as follows:
(Each DCB-BO1202 300mg capsule contains 150mg active ingredient)
DCB-BO1202+Placebo: 2 DCB-BO1202 300mg capsules plus 2 matched placebo, t.i.d., orally.
Duration of Administration: 96 weeks ((11 treatment weeks + 1 observation week) * 8 cycles)"
1592655|NCT02289287|Behavioral|Self-Management group-intervention|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). The group-intervention (SM program) will begin after enrollment of at least 4 participants to the intervention group, and within no longer than 5 weeks since enrollment. The intervention will include 12 weekly sessions, each session 2.5 hour long, and will be based on well-known SM interventions that were found effective for stroke patients in the U.S. Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
1592656|NCT02289287|Behavioral|Standard Care|At enrollment eligible patients will be randomized to Intervention + Standard Care or Standard Care group. Within 3 weeks after enrollment all participants will undergo baseline assessment using a predefined set of scales and questionnaires (intervention group will additionally undergo a semi-structured interview). Standard care will include 'one-on-one' sessions in each paramedical discipline as given regularly in this setting (average of 15-20 sessions per patient). Follow-up assessments will be done at 12 and 36 week to examine long term effectiveness.
1592657|NCT02289274|Drug|NVP-1203|NVP-1203(eperisone SR + aceclofenac)
1592658|NCT02289274|Drug|Eperisone SR tab. + and Airtal tab.|Eperisone SR and aceclofenac
1592659|NCT02289261|Drug|Morphine|Morphine, 0.02 mg/kg PCA bolus dose with 10 minutes lock-out interval
1592660|NCT02289261|Drug|Morphine plus dexmedetomidine|Morphine 0.02 mg/kg plus dexmedetomidine 0.1 microgram/kg PCA bolus dose with 10 minutes lock-out interval
1592661|NCT02289248|Drug|Ketamine|Subjects will undergo a twice weekly two week course of IV infusions of ketamine
1592662|NCT02289248|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects will undergo twice weekly CBT for a total of 8 weeks
1592663|NCT02289235|Drug|Ginger|Ginger powder capsule 500 mg daily for 3 months
1592664|NCT02289235|Drug|Placebo|Placebo powder 1 capsule daily for 3 months
1592665|NCT02289222|Drug|MK-3475|Anti PD-1 (MD 3475) will be given as an intravenous infusion at 200 mg every 2 weeks.
1592666|NCT02289222|Drug|Pomalidomide|Pomalidomide is given at standard dose of 4 mg daily orally for 21 days
1592667|NCT02289222|Drug|Dexamethasone|Dexamethasone is given at 40 mg orally weekly
1592668|NCT02289209|Radiation|Reirradiation|Reirradiation 1.2 GY BID 5 days a week for 5 weeks.
1592669|NCT02289209|Drug|MK-3475|MK-3475 will be given at 200mg intravenous every 3 weeks starting day one of reirradiation and will be continued once every 3 weeks until 3 months post completion of reirradiation. Further continuation of MK-3475 will be determined by response evaluation at 3 months post completion of reirradiation
1592670|NCT02289196|Drug|Vx-006: 0,5mg|
1592671|NCT02289196|Drug|Vx-006: 1mg|
1592672|NCT02289196|Drug|Vx-006: 5mg|
1592673|NCT02289196|Drug|Vx-006: 10mg|
1592674|NCT02289183|Procedure|Totally laparoscopic distal gastrectomy|Totally laparoscopic distal gastrectomy with modified delta-shaped gastroduodenostomy
1592675|NCT02289183|Procedure|Laparoscopy-assisted distal gastrectomy|Laparoscopy-assisted distal gastrectomy with Billroth-I anastomosis
1592735|NCT02288663|Device|Dual X-ray absorptiometry (DXA)|measurement of lean body mass by whole-body DXA
1592676|NCT02289170|Device|Heating and cooling combination therapy|The treatment was applied 10 times for 4 weeks. Most painful 2 points in 8 acupuncture points(both side of Bladder meridian23 (BL23), BL24, BL25, BL26) were used for all the patients assigned to this group.
1592677|NCT02289170|Device|Sham heating and cooling therapy|The treatment was applied 10 times for 4 weeks. The sham heating and cooling combination therapy was applied on the 2 of 8 same acupuncture points as in the treatment group.
1592678|NCT02289157|Device|Negative pressure wound therapy|Single use negative pressure wound therapy systems are composed of a pressure pump and dressing kit. The pump creates a negative pressure of 125 mmHg (+/- 20 mgHg) and the dressing directly covers surgical incision. The system is battery-powered and designed to be used for a minimum of two days and a maximum of seven days of continuous use. The investigators hypothesize that negative pressure wound therapy will decrease the wound complications in these patients. The investigators will be using Prevena Incision Management System as the negative pressure device in our study.
1592679|NCT02289144|Drug|Ceritinib|750 mg orally daily on day 1. Continue every 4 weeks and every 2 cycles (1 Cycle is 28 days long) : until progression, new recurrence or distant metastasis, as well as enlargment of an existing metastasis on radiological Imaging.
1592680|NCT02289131|Procedure|Tooth Brushing Protocol|A 2-minute tooth brushing protocol, followed by a mouthwash rinse and application of moisturizer for a total of approximately 15 minutes.
1592681|NCT02289118|Drug|[18F]-T807 imaging tracer|Tau Imaging tracer
1592682|NCT02289105|Behavioral|Mandatory active choice|the mandatory active choice group, will be presented two forms at the same time. The first form will be a legally valid AD. The second form will be a declination form. Participants in the intervention arm will be required to complete, and submit either of the two forms the task.
1592683|NCT02289092|Behavioral|Family Check-Up|Parents fill out questionnaires about their child and families and then participate in a videotaped interaction with their child. Clinicians then observe the video and analyze the questionnaires to establish family needs based on supports, stress, parenting, values, and strengths. Therapists then use this information to inform the intervention process and provide feedback to families with the use of motivational interviewing. parents identify goals for parenting and/or child behavior and to connect them with resources when needed. Feedback includes a discussion of goal attainment and plans to achieve goals. Goal achievement includes options such as (a) periodic follow-up and support, (b) brief support for change on a specific topic, and (c) community referral (e.g., substance abuse referral; domestic violence referral; referral for individual therapy for depression; referral for family therapy and support for families in conflict).
1592684|NCT02289079|Drug|Bupivacaine|
1592685|NCT02289079|Drug|liposomal bupivacaine|
1592686|NCT02289040|Procedure|cardiac surgery|cardiac surgery with extracorporeal circulation for congenital heart disease
1592687|NCT02289027|Biological|cAd3-EBOZ vaccine|
1592688|NCT02289027|Biological|Placebo (for cAd3-EBOZ vaccine)|Diluent
1592689|NCT02289014|Other|online stress Management program|Active treatment group
1592690|NCT02289001|Behavioral|Education on SBAR worksheet|The intervention group will receive one hour of training in teamwork skills, distribution of roles and use of the SBAR worksheet before participating in the simulated scenario using a human patient simulator (HPS).
1592691|NCT02288988|Procedure|Antireflux Surgery|Collis gasytroplasty Nissen antireflux fundoplication
1592692|NCT02288975|Device|CytoSorb 300ml device (3804606CE01)|
1592693|NCT02288962|Drug|cabergoline|
1592694|NCT02288949|Other|stratification|Patients will be stratified based on the values of relevant demographics, pulmonary and systemic variables in relation to mortality in the intensive care unit.
1592696|NCT02288923|Procedure|Femoral nerve block|"Supine position
If using peripheral nerve stimulator for localisation of the femoral nerve:
50 mm insulated needle Peripheral nerve stimulator set at 2 Hz with pulse width 100μs When quadriceps muscle twitch is present with a stimulated current between 0.2 and 0.5mA, inject 20ml 0.375% (3.75mg/ml) Levo- bupivacaine
If using ultrasound for localisation of the femoral nerve:
High frequency linear array probe Short bevelled nerve-block needle, using in or out of plane technique Inject 20ml 0.375% (3.75mg/ml) Levo-bupivacaine underneath fascia iliaca ensuring adequate spread of local anaesthetic"
1592697|NCT02288923|Procedure|Local Infiltration Analgesia|"Local infiltration analgesia to be administered by surgeon towards the end of operation:
40ml of bupivacaine 0.25% with adrenaline 1:200 000, diluted to 150ml with saline 0.9%. This is then divided into thirds; 50ml into the posterior capsule before cementing, 50ml into the medial and lateral capsules and 50ml into subcutaneous tissues and in and around the vastus medialis and sartorius muscles (where it may block the saphenous nerve)."
1592698|NCT02288923|Procedure|Sub arachnoid analgesia|Patients in both arms of the trial will be given sub arachnoid anasthesia of 2.5-3.0ml of plain bupivacaine 0.5% using a 25G Whitacre needle. Patients may have 0-4mg midazolam and/or 0-1mcg/kg fentanyl and/or 0-4mcg/ml propofol sedation using the Marsh protocol if required for this procedure as deemed appropriate by the anaesthetist.
1592699|NCT02288923|Procedure|Sedation or general anaesthesia|After insertion of the sub arachnoid anaesthesia the patient may choose to be fully asleep or sedated. If they choose to be fully asleep, they may have up to 2mcg/kg fentanyl in total (including any given at time of subarachnoid injection), muscle relaxation as indicated for facilitation of intubation where needed, airway control using LMA or tracheal tube where needed, and general anaesthesia maintained using inspired oxygen concentration of 0.3-0.7 with propofol up to 5mcg/kg (Marsh protocol) or isoflurane or sevoflurane. If the patient chooses to have sedation they may have additional midazolam up to a total dose of 4mg and/or a propofol infusion (Marsh protocol) of 0-4mcg/ml.
1592700|NCT02288923|Drug|Pre-medication|All patients will receive 1g paracetamol pre-operatively. Those on non steroidal anti inflammatory drugs may continue to take them. Apart from these, no other pain relieving pre-medications are to be used. Patients may be given anxiolysis using temazepam 10-20mg or diazepam 2-5mg by mouth if required. Antacid premedication is permitted using ranitidine, metoclopramide or proton pump inhibitors.
1592736|NCT02288663|Device|Bioelectric Impedance Spectroscopy (BIS)|measurement of lean body mass by BIS
1592737|NCT02288663|Biological|51Cr-EDTA plasma clearance|measurement of 51Cr-EDTA plasma clearance to determine GFR
1592738|NCT02288650|Other|early refeeding|
1592739|NCT02288650|Other|refeeding only in the recovery room (usual practice).|
1592701|NCT02288923|Drug|Intra-operative medication|If paracetamol has not been given pre-operatively, it will be given intraoperatively 1g IV. Where 2 or more of the following risk factors are present; female, non smoker, previous post operative nausea or vomiting, intra operative opiates, the patients will be given 4mg dexamethasone and or 4mg ondansetron IV. Vasopressor drugs may be given at the anaesthetist's discretion to maintain an appropriate blood pressure. Intraoperative fluid infusion is at the discretion of the anaesthetist. Antibiotic prophylaxis is as per the hospital protocol (currently 6mg/kg Teicoplanin IV and 3mg/kg gentamicin pre induction). Tranexamic acid will be given as per unit protocol, (currently 1g pre-operatively IV and 500mg orally at 8 hours post op. unless contraindicated by a high risk of thrombosis.)
1592702|NCT02288923|Drug|Post-operative analgesia - morphine|Patients will all be given a morphine pump which will give 1mg every 5 minutes. This is to be discontinued after 48 hours and changed to oral morphine 10-20mg if weight 50-70kg, 20-30mg if weight >70kg 2 hourly.
1592703|NCT02288923|Drug|Post-operative analgesia - ibuprofen and paracetamol|All patients will be given 1g paracetamol 6 hourly and 400mg ibuprofen 8 hourly unless there are contraindications. If patients are on an alternative non-steroidal anti inflammatory drug then this may be substituted for ibuprofen.
1592704|NCT02288923|Drug|Regular anti emetics|All patients will receive 4mg ondansetron regularly for 2 days. They will be prescribed 50mg cyclizine as an addition to this if needed.
1592707|NCT02288884|Device|Acticoat PostOp|
1592708|NCT02288884|Device|OpSite PostOp|
1592709|NCT02288871|Radiation|Cardiac CT-scan|"ECG gated CT angiography of the heart will be performed on a 128-slice dual-source and two Stellar detectors CT system with retrospective ECG-gating (Siemens/SOMATOM Definition Flash - Siemens, Germany, 100kV, 395.75 mAs).
In details, multi-phase images will be acquired to reconstruct between 10 and 100% of the cardiac cycle (10% increments) with a slice thickness of 1 mm. Examination will include left ventricular outflow tract, aortic root, coronary sinus, ascending aorta together with the prosthetic valves."
1592710|NCT02288858|Dietary Supplement|Viviscal Oral Supplement Tablets|Tablet (512 mg)
1592711|NCT02288845|Drug|ITI-007|
1592712|NCT02288832|Other|-self-collected vaginal samples|
1592713|NCT02288832|Drug|zithromax|
1592714|NCT02288832|Other|usual practices|
2009158|NCT03323762|Device|Remote Ischaemic Conditioning (RIC)|The CellAegis auto RIC (automated blood pressure cuff) will be placed on the upper arm and inflated to 200 mmHg for 5 minutes followed by 5 minutes of deflation. The programmed cycle is repeated 4 times in total, summing up to a total treatment length of 35 minutes
2009159|NCT03322748|Other|Usual physical therapy+ strengthening of lower limbs muscles|Experimental group will perform usual physical therapy plus 3 series of isometric contractions of ankle plantarflexor and Hamstring muscles bilaterally, each lasting 5 seconds.
1592717|NCT02288793|Other|Survey|Survey about Knowledge and Attitude About Focused Assessment With Sonography in Trauma
1592718|NCT02288767|Device|Conventional arterial blood pressure monitoring|
1592719|NCT02288767|Device|Stroke volume variation monitoring with arterial blood pressure monitoring|
1592720|NCT02288754|Diagnostic Test|Blood test|No intervention except to collect blood for diagnostic test development
1592721|NCT02288741|Drug|Anthracycline/dexamethasone-based induction chemotherapy|4 cycles of anthracycline/dexamethasone-based chemotherapy
1592722|NCT02288741|Drug|Dexamethasone for control of symptoms|2 x 4 days of dexamethasone (day 1-4 and day 8-11: 40mg)
1592723|NCT02288741|Drug|Tumor-reduction chemotherapy and stem cell mobilization|Ifosfamide (day 1-3: 1.900mg/m² iv), epirubicin (day 1: 75 mg/m² iv), etoposide (day 1-3: 120 mg/m² iv) and G-CSF (day 5 until end of apheresis: 5µg/kg sc)
1592724|NCT02288741|Procedure|Stem cell apheresis|stem cell apheresis in peripheral blood, sought amount of CD34-cells: 6 * 10E6/kg
1592725|NCT02288741|Drug|Tandem high-dose chemotherapy (melphalan)|Two cycles of high-dose melphalan (day -3 and day -2: 70mg/m²)
1592726|NCT02288741|Procedure|Autologous peripheral blood stem cell transplantation|Two infusions of collected stem cells (day 0: 2*10E6 CD34-cell/kg per transplantation)
1592727|NCT02288728|Procedure|Gastric tube anastomosis|"In the gastric tube group, the lesser curvature of the gastric remnant approximately 3 cm proximal to the pylorus was removed first by a linear stapling device. An approximately 5-cm-wide tubular stomach was then constructed with preserved right gastric vessels. The length of the tube was consistent with the greater curvature of the residual stomach. The reconstructed gastric tube was lastly anastomosed with the proximal esophageal end.
(Reference: Chen XF, Zhang B, Chen ZX, Hu JK, Dai B, Wang F, Yang HX, Chen JP. Gastric tube reconstruction reduces postoperative gastroesophageal reflux in adenocarcinoma of esophagogastric junction. Dig Dis Sci. 2012;57(3):738-745.)"
1592728|NCT02288728|Procedure|Double-track anastomosis|"Double-track anastomosis group: First, cut off the jejunum about 15-20 cm away from the Treitz ligament; Second, Roux-en-Y esophagojejunostomy (E-J stomy, first anastomosis) was perform by 25mm circular stapler device; Third, from 30-40cm to the E-J stomy, perform the side-to-side gastrojejunostomy (G-J stomy, second anastomosis). Forth, from 25-30cm to the G-J stomy, perform the jejunojejunostomy (J-J stomy, third anastomosis).
(Reference: Ahn SH, Jung do H, Son SY, Lee CM, Park do J, Kim HH. Laparoscopic double-tract proximal gastrectomy for proximal early gastric cancer. Gastric Cancer. 2014;17(3):562-70.)"
1592729|NCT02288715|Other|no interventions|
1592730|NCT02288702|Device|monitoring BIS in both groups|We will be monitoring BIS in both groups. A BIS monitor may be placed prior to induction or immmeditaely afterwards for monitoring BIS. All patients will receive general anesthesia. A standard inhalation induction agent such as sevoflurane and oxygen will be administered via face mask with or without an oral airway. An inhalation agent will be administered for the duration of the procedure. The MAC goal for inhalation agents will be 1. If the patient moves, the MAC goal will be increased to 1.5 and this change will be recorded.
1592731|NCT02288689|Device|Acuuvix SonoAce UGEO|Ultrasonographic vaginal examination
1592732|NCT02288663|Other|measurement of morphological parameters|measurement of morphological parameters : thigh perimeter, leg perimeter, arm perimeter.
1592733|NCT02288663|Biological|a blood sample|One single blood sample to assay SCr (enzymatic), BUN (blood urea nitrogen), cystatin C, CRP, Na, K, Cl, albuminemia.
1592734|NCT02288663|Biological|albumin or blood in urine|dipstick analysis for albumin or blood in urine
1592740|NCT02288637|Other|Olyset Plus LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin and the synergist piperonyl butoxide PBO as the active ingredients (AI).The LLIN can withstand repeated washing and retains efficacy over years of use
1592741|NCT02288637|Other|Conventional Olyset LLIN|Olyset Plus is a LLIN containing the pyrethroid permethrin. The LLIN can withstand repeated washing and retains efficacy over years of use.
1592742|NCT02288637|Other|IRS|Actellic CS (Syngenta), is a microcapsule formulation of the organophosphate insecticide, pirimiphos-methyl. Microencapsulation greatly extends the compound's residual life when applied to interior walls and ceilings. Evaluation by LSHTM in experimental huts in Tanzania showed residual activity of more than a year. Parallel trials in Benin against pyrethroid-resistant mosquitoes killed more than 80% of An. gambiae for up to 10 months.
1592743|NCT02288624|Dietary Supplement|Processed orange juice|3 different formulation of edible orange drinks
1592744|NCT02288611|Dietary Supplement|Date fruit - Ajwa variety|Twenty-two healthy human individuals were randomly assigned to consume 7 date fruits (approx. 50g). Each arm was 21 days in duration, separated by a 14 days washout period.
1592745|NCT02288611|Dietary Supplement|Maltodextrin/Dextrose|Twenty-two healthy human individuals were randomly assigned to consume Maltodextrin/dextrose , 40.2g. Each arm was 21 days in duration, separated by a 14 days washout period.
1592746|NCT02288598|Device|Anodal TDCS|20 minutes 1mA anodal stimulation to left inferior frontal cortex. Cathode positioned on right supra-orbital ridge.
1592747|NCT02288598|Behavioral|Fluency Training|Speech tasks will be completed using fluency-enhancing techniques: metronome-timed speech and auditory choral speech.
1592748|NCT02288585|Dietary Supplement|Plant sterols|Plant sterols
1592749|NCT02288585|Dietary Supplement|Placebo product|Placebo product
1592750|NCT02288572|Dietary Supplement|Lactobacillus plantarum PCS 26|Taking dietary supplement on a daily basis which corresponds to 1.000.000.000 CFU of Lactobacillus plantarum PCS 26 per day for 3 months.
1592751|NCT02288572|Dietary Supplement|Placebo|Taking dietary supplement on a daily basis for 3 months.
1592752|NCT02288559|Other|Sham|Sham injection will be administered as a matching intravitreal injection of lampalizumab.
1592753|NCT02288559|Drug|Lampalizumab|10 mg dose of lampalizumab administered intravitreally
1592754|NCT02288533|Device|real-tDCS|Participants will receive tDCS over the primary motor cortex bilaterally (M1). The excitability-enhancing anode electrode (saline-soaked sponge electrode - 16cm2) will be placed over the primary motor cortex, C3 and C4 (10/20 international EEG system). The excitability-diminishing cathode electrode will be placed over the supraorbital area. We will use the following stimulation parameters: intensity of 2 milliampere and for 40 minutes (10 consecutive sessions).
2009160|NCT03322748|Other|Usual physical therapy|Usual physical therapy
2009161|NCT03323073|Other|Resting state fMRI|One single fMRI which is used to characterize a uni or a bipolar major depressive episode (MDE).
1592757|NCT02288494|Other|stewart approach|Prospective study, for ICU patient with severe hypoalbuminemia < 20g/L, determining biological parameters from Stewart approach for acid base disorders (pH, SIDe, SIDa, SIG, Atot, PaCO2) before, and at 1hour, 2hours and 24 hours after a 200mL 20% human al Clinical parameters (respiratory, haemodynamic, neurologic) were also collected at the same times.
1592758|NCT02288481|Drug|TBA-354|TBA-354 supplied as a 20 mg /mL suspension and matching placebo suspension for oral administration.
1592759|NCT02288481|Other|Placebo|Placebo Suspension
1592760|NCT02288468|Device|Vercise™ Deep Brain Stimulation System|"The Vercise™ DBS System includes a Stimulator with DBS Leads for unilateral or bilateral stimulation. There are also DBS Extensions that allow the DBS Leads mounted in the skull to be extended to reach the Stimulator implanted near the clavicle.
The rechargeable Vercise DBS System utilizes current steering across eight contacts per DBS Lead to provide precise positioning of stimulation. The Stimulator is controlled by a handheld Remote Control, and can be interfaced with a Clinician's Programmer using the Bionic Navigator™ Software. Periodically, the Stimulator battery must be replenished with an RF (radiofrequency) charging device provided in the Patient DBS Charging Kit."
1592761|NCT02288455|Device|GTU Artificial Urinary Sphincter|A totally implantable Artificial Urinary Sphincter (AUS) for the treatment of male Stress Urinary Incontinence (SUI)
1592762|NCT02288442|Other|exercise|Exercise training for 8 weeks (aerobic exercise, resistance training and inspiratory muscle training thrice a week)
1592763|NCT02288429|Drug|colistimethate sodium|
1592764|NCT02288416|Other|educational intervention|Undergo video-based intervention
1592765|NCT02288416|Other|questionnaire administration|Ancillary studies
1592766|NCT02288416|Other|quality-of-life assessment|Ancillary studies
1592767|NCT02288416|Other|Best Practice|
1592768|NCT02288403|Behavioral|Aerobic interval training|
1592769|NCT02288403|Behavioral|Continuous training|
2009162|NCT03323008|Other|Prototype|Usability testing and System Usability Scale
1592771|NCT02288377|Drug|lanreotide|Patients will receive lanreotide 120 mg every 28 days until disease progression
1592772|NCT02288377|Drug|Placebo|
1592773|NCT02288364|Drug|1% Lidocaine|
1592774|NCT02288364|Drug|1% Lidocaine plus sodium bicarbonate|
1592775|NCT02288351|Other|Mix Nutrient Meal|Before Surgery: Subjects will have a visit where they will have a mixed nutrient stimulation test. They will be asked to fast for 12 hours prior to this visit (except water). During the visit they will drink an 8 ounce mixed nutrient liquid meal in 5 minute intervals over 20 minutes. During this visit a catheter will be placed in a vein in their arm for blood sample collections. A total of 50 ml of blood will be collected, (10 ml before drinking the mixed nutrient drink, at 30 minutes, at 60 minutes, at 90 minutes and 120 minutes after the mixed nutrient drink).
1592776|NCT02288351|Other|labs|Fasting Plasma Glucose (FPG) and insulin will be added to the standard pre-operative labs.
1592777|NCT02288351|Other|Biopsy|Intra-operatively: Subjects will undergo a standard laparoscopic Roux-en-Y Gastric Bypass (RYGB). During the surgery a 2cm tissue sample of the Roux limb will be taken by the doctor and frozen.
1592778|NCT02288351|Other|Second Mix Nutrient Meal|2 months post-operatively a second mixed nutrient stimulation test will be performed following the same process used pre-operatively.
1592779|NCT02288351|Other|Second biopsy|. Patients will also be scheduled to undergo a second upper endoscopy and a 2cm biopsy of the Roux limb will be taken by the doctor and frozen in liquid nitrogen.
1592780|NCT02288351|Device|PET/CT|Lastly, subjects will have a positron emission tomography/computed tomography (PET/CT) scan with Fluorodeoxyglucose (FDG) to evaluate the glucose in the Roux limb after surgery.
1592781|NCT02288338|Drug|1 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
1592782|NCT02288338|Drug|1 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592783|NCT02288338|Drug|1 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592784|NCT02288338|Drug|2 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592785|NCT02288338|Drug|2(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592786|NCT02288338|Drug|2 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
1592787|NCT02288338|Drug|3(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592788|NCT02288338|Drug|3 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
1592789|NCT02288338|Drug|3 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592790|NCT02288338|Drug|4 (Lipitor®)|atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
1592791|NCT02288338|Drug|4(Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592792|NCT02288338|Drug|4 (Ezetrol®)|After 11day withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592793|NCT02288338|Drug|5 (Ezetrol®)|ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592794|NCT02288338|Drug|5 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
1592795|NCT02288338|Drug|5 (Lipitor®, Ezetrol®)|After 11days withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592796|NCT02288338|Drug|6(Lipitor®, Ezetrol®)|atorvastatin calcium 40mg, Lipitor® 40mg and ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592797|NCT02288338|Drug|6 (Ezetrol®)|After 11days withdrawal period, ezetimibe 10mg, Ezetrol® 10mg will be administered to healthy volunteers during 7days
1592798|NCT02288338|Drug|6 (Lipitor®)|After 11day withdrawal period, atorvastatin calcium 40mg, Lipitor® 40mg will be administered to healthy volunteers during 7days
1592799|NCT02288325|Drug|Levomilnacipran ER|Once daily, oral administration
1592800|NCT02288325|Drug|Placebo|Once daily, oral administration
1592801|NCT02288312|Drug|BIA 2-093|
1592802|NCT02288299|Device|non invasive mechanical ventilation|instrumental increase of inspiratory capacity and cough
1592803|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
1592804|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
1592805|NCT02288286|Biological|2.5IU/ml rabies vaccine(MRC-5 cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(MRC-5 cell) of 2.5IU/ml, 5 doses, 4 weeks interval
1592806|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 10-20 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
1592807|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 21-50 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
1592808|NCT02288286|Biological|2.5IU/ml rabies vaccine(vero cell) in humans aged 51-60 years old|freeze-dried rabies vaccine(vero cell) of 2.5IU/ml, 5 doses, 4 weeks interval
1592809|NCT02288273|Drug|Bydureon|Once weekly injection of 2mg bydureon (extended release exenatide) for 10 weeks.
1592810|NCT02288273|Drug|Placebo|Placebo
1592815|NCT02288221|Other|Patient's answer with non pharmacological therapeutic|"Installation at patient's home of :
aromatherapy
music therapy
cognitive training in multimedia application offering cognitive games"
1592816|NCT02288221|Other|Patient's answer without non pharmacological therapeutic|No installation at patient's home
1592817|NCT02288208|Drug|Antiviral Therapy (tenofovir or entecavir)|
1592818|NCT02288208|Drug|Birinapant|
1592819|NCT02288208|Drug|Placebo (for birinapant)|
1592820|NCT02288195|Drug|Oxaliplatin|130 mg/m² iv drip over 2 hours on day 1, repeated every 21 days.
1592821|NCT02288195|Drug|capecitabine|"825 mg/m² twice daily administered orally and concurrently with radiation therapy for 5 days per week.
1000 mg/m² po twice daily on days 1- 14 repeated every 21 days in Group A and adjuvant chemotherapy in Group B."
1592822|NCT02288195|Radiation|Radiation|The total dosage was 46Gy consisted of 23 fractions of 2 Gy to clinical target volume without a boost dose and with the boost 4 Gy consisted of 2 fractions of 2 Gy to gross tumor volume by IMRT or 3D-CRT.
1592902|NCT02287662|Other|Vancouver 3M Clinical Pathway|
1592904|NCT02287636|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
1592905|NCT02287636|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
2009163|NCT03322878|Drug|Magnesium SO4|The intravenous solutions (magnesium 10% for group IV or saline 0.9% for group CA and P) will be started then caudal block will be performed by the same anesthetist. Under complete aseptic conditions a caudal puncture with 5 cm short beveled 22 G caudal needle will be used in the lateral decubitus position. After identifying the space using the loss of resistance technique with saline, the study solutions will be injected slowly with repetitive intermittent aspiration.
2009164|NCT03322800|Drug|AK0529|Active Substance: AK0529, Pharmaceutical Form: Capsule, Route of Administration: Oral
1592827|NCT02288156|Drug|Capsaicin|via nasal spray
1592828|NCT02288156|Drug|placebo|via nasal spray
1592829|NCT02288143|Drug|COOL-COS|"Controlled ovarian stimulation will start on the second or third day of a menstrual cycle:
Oral clomiphene citrate: 100 mg/day until the day of the triggering.
Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.
hMG: 150 IU every other day beginning on the day 6 of the controlled ovarian stimulation.
The triggering will be performed using urinary hCG (5,000 IU subcutaneous).
1-2 days after the identification of one follicle ≥ 17 mm
0-1 days after the identification of one follicle ≥ 19 mm."
1592830|NCT02288130|Drug|GnRHa|
1592831|NCT02288130|Drug|Ulipristal|
1592832|NCT02288104|Device|needle based confocal endomicroscopy|real time imaging of living tissue at microscopic scale, through a needle.
1592833|NCT02288091|Drug|Inosine|Twenty-five eligible subjects will receive inosine for 12 weeks (administered in the form of 500 mg capsules, 1 to 6 capsules a day for a total daily dose of up to 3 gm). The dose of inosine will be titrated to target urate levels of 7-8 mg/dL based on urate level measurement that will occur at Week 2, Week 4, Week 6, and Week 9 after Baseline.
1592834|NCT02288078|Other|General condition|Eastern Cooperative Oncology Group (ECOG) performance status (PS), height and body weight
1592835|NCT02288078|Other|Blood pressure|systolic blood pressure (SBP)/diastolic blood pressure (DBP)
1592836|NCT02288078|Other|Patient Reported Outcome|Incidence of fatigue or malaise (All grade of CTCAE ver. 4), anorexia, Brief fatigue inventory (BFI), FACT-C.
1592837|NCT02288078|Other|Clinical findings|"Blood and lymphatic system disorders: febrile neutropenia
Gastrointestinal disorders: constipation, diarrhea, oral mucositis, nausea, and vomiting
General disorders and administration site conditions: fatigue and malaise
Immune system disorders: allergic reaction
Metabolism and nutrition disorders: anorexia
Nervous system disorders: dysgeusia and peripheral sensory neuropathy
Respiratory, thoracic and mediastinal disorders: hoarseness (change of voice)
Skin and subcutaneous tissue disorders: alopecia, skin hyperpigmentation, urticaria, and palmar-plantar erythrodysesthesia syndrome
Vascular disorders: hypertension
Symptomatic pancreatitis"
1592838|NCT02288078|Other|Hematology/blood chemistry|White blood cell count, absolute neutrophil count (stab + segmented), hemoglobin, platelet count, albumin, total bilirubin, aspartate aminotransferase(AST) (GOT), alanine aminotransferase (ALT) (GPT), serum creatinine, Na, K
1592839|NCT02288078|Other|Coagulation and fibrinolysis system|international normalized ratio (INR)
1592840|NCT02288078|Other|Urinalysis|Proteinuria (qualitative)
1592841|NCT02288078|Other|Medication check|Medicine taking situation (regorafenib, dexamethasone and placebo) determined by subject's diary at every courses
1592842|NCT02288078|Other|Adverse event|CTCAE ver.4.0
1592843|NCT02288078|Other|Thyroid function test|Thyroid-stimulating hormone (TSH), T4, and T3
1592844|NCT02288078|Other|Contrast-enhanced torso CT|It is recommended that CT images should be taken every 4 weeks (if possible) or at least every 8 weeks (allowable time window: ± 2 weeks), with the treatment phase taken into consideration.
1592845|NCT02288078|Other|Brain MRI|If any symptom of brain metastasis is suspected
1592846|NCT02288078|Drug|Dexamethasone|Capsule filled with dexamethasone and lactose
1592847|NCT02288078|Drug|Regorafenib|Film-coating tablet contains 40 mg of regorafenib
1592848|NCT02288078|Drug|Placebo|Capsule filled with lactose
1592849|NCT02288078|Drug|Proton pump inhibitor|PPIs (omeprazole, lansoprazole, etc, as not specified) for prevention of peptic ulcer
1592850|NCT02288065|Drug|sterile talc pleurodesis|medical thoracoscopy and talc pleurodesis. No specific device is studied.
1592851|NCT02288052|Behavioral|Writing program|6 weeks of at-home training (5days/week, 30minutes/day) using both pen-and-paper exercises and exercises on a writing tablet.
1592852|NCT02288052|Behavioral|Stretch & Relaxation program|6 weeks of at-home training (5days/week, 30minutes/day) using a DVD with exercises.
1592853|NCT02288039|Other|Social Identity goal-based Intervention|Phase 1: collaborative group discussion in order to establish what group members want to achieve by the end of their 8-week pulmonary rehabilitation programme. Phase 2: further collaborative group discussion with the emphasis on evaluating, monitoring, and providing feedback on goal attainment. Phase 3: focus group interviews with an emphasis on reviewing the goal setting process that patients have engaged with.
1592854|NCT02288013|Procedure|Closure of uterine incision at C section|Closure of uterine incision at Cesarean section
1592855|NCT02288000|Drug|Memantine|Memantine will be administered OS as of 10 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
1592856|NCT02288000|Drug|Placebo|the placebo will be administered OS as of 10 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
1592857|NCT02287987|Procedure|Clamp Robotic partial nephrectomy|Renal artery clamping during partial nephrectomy
1592858|NCT02287987|Procedure|Clampless Robotic partial nephrectomy|Robotic partial nephrectomy without renal artery clamping
1592859|NCT02287974|Drug|Stem cell infusion|Unique stem cell infusion of the randomized group
1592860|NCT02287961|Procedure|Standard proctologic examination|(with digital rectal examination and 2 anal swabs) at initial inclusion visit, M12 and M24 follow-up visits and if applicable M6 and M18 control visits
1592861|NCT02287961|Procedure|High resolution anoscopy|at initial inclusion visit, Month 12 and Month 24 follow-up visits and if applicable Month 6 and Month 18 control visits
1592862|NCT02287961|Procedure|Biopsy(ies) during High Resolution Anoscopy|only if lesion suggestive of AIN detected during High Resolution Anoscopy
1592863|NCT02287961|Procedure|High Resolution Anoscopy biannually|Only if high-grade lesion (ASC-H, HSIL ou AIN2/3)
1592906|NCT02287636|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
2009165|NCT03322800|Other|Placebo|Active Substance: Placebo, Pharmaceutical Form: Capsule, Route of Administration: Oral
1592864|NCT02287948|Device|Nintendo Wii Fit Balance Board|"Clinical and instrumental evaluations carry out on the same day.
1) Instrumental evaluations
All subjects (healthy + MS) will ask to perform the following tasks both on force platform and Wii Fit Balance Board:
Open eyes, monopodalic balance for 20 seconds
Closed eyes, monopodalic balance for 20 seconds
Open eyes, balance on both feet for 60 seconds
Closed eyes, balance on both feet for 60 seconds
During trials subjects can leave arms in the most comfortable position they prefere
Subjects will perform every task for 5 times; they can rest for 30 seconds between every trials."
1592865|NCT02287935|Procedure|Limberg flap|Patients were divided into two groups, group 1 were treated with Limberg flap technique (n= 37) . Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
1592866|NCT02287935|Procedure|Karydakis procedure|Patients were divided into two groups, group 2 were treated with Karydakis flap (n= 34). Two groups were compared with a statistical in terms of fluid collection, wound infection, flap edema, hematoma, partial wound separation, return to daily activities, pain score, completes healing time, painless seating and patient satisfactions
1592867|NCT02287922|Biological|ALX-0061|
1592868|NCT02287922|Biological|Placebo|
1592869|NCT02287922|Biological|Tocilizumab|
2009166|NCT03322787|Device|HFO|Training will be done using the HFO device. Air-flow will set at the highest value tolerated by the patients, until a maximum value of 60 l/min permitted and FiO2 set during the run-in. The HFO will be administered using the AIRVO2® (Fisher&Paykel- NewZealand). Afterwards, the oxygen flow provided into the system will be progressively increased until the pre-fixed FiO2 will be reached, as displayed by the AIRVO2 monitor.
1592872|NCT02287896|Drug|ROLEDUMAB|See Arm description
1592876|NCT02287857|Drug|Domestic Tenofovir Disoproxil Fumarate Tablets|1 Domestic Tenofovir Disoproxil Fumarate Tablets and 1 blank Tenofovir Disoproxil Fumarate Tablets of Gilead
1592877|NCT02287857|Drug|Tenofovir Disoproxil Fumarate Tablets of Gilead|1 blank Domestic Tenofovir Disoproxil Fumarate Tablets and 1Tenofovir Disoproxil Fumarate Tablets of Gilead
1592878|NCT02287844|Other|XOS|5 g of XOS everyday for 4 weeks.
1592879|NCT02287844|Other|INU-XOS|1 g of XOS and 3 g of inulin everyday for 4 weeks.
1592880|NCT02287844|Other|Placebo|6.64 g of maltodextrins everyday for 4 weeks.
1592881|NCT02287831|Biological|umbilical cord mesenchymal stem cells|patients were divided into 3 dose treatment groups (6.29 × 107,9.43 × 107 and 14.15 × 107 cells/m2). After 4 and 8 weeks, patients were injected the same number of cells.
1592882|NCT02287818|Drug|Placebo|Placebo twice daily from Day 1 to Week 12
1592883|NCT02287818|Drug|AC-201|AC-201 CR tablet 100 mg twice daily from Day 1 to Week 12
1592884|NCT02287818|Drug|Febuxostat|Febuxostat 40 mg once daily from Week 4 to Week 16; titration to 80 mg once daily at Week 8 as needed to achieve serum uric acid concentration <6 mg/dL
1592885|NCT02287805|Other|qualitative survey|
1592886|NCT02287805|Other|quantitative survey|
1592887|NCT02287792|Procedure|18-FDG PET/CT scan|Whole body 18-FDG PET/CT to assess cardiac and extracardiac complications in infective endocarditis
1592888|NCT02287779|Drug|SHP626|
1592889|NCT02287779|Drug|Placebo|
1592890|NCT02287753|Other|vascular occlusion test using Pediatric SomaSensor for INVOS 5100C|Pediatric SomaSensor for INVOS 5100C is attached at calf muscle and non-invasive blood pressure cuff is applied to ipsilateral thigh. VOT is performed as: after baseline oxygen saturation value is recorded, cuff pressure is rapidly increased to 30 mmHg over than systolic blood pressure. After 3 minutes of ischemic time, cuff pressure is rapidly decreased. It is performed at 3 time periods : before start of operation, during cardiopulmonary bypass, and after weaning from cardiopulmonary bypass.
1592891|NCT02287740|Behavioral|Tai Ji Quan: Moving for Better Balance|The protocol involves a core 8-form routine training with built-in variations and a subroutine of integrated therapeutic movements.
1592892|NCT02287740|Behavioral|Multimodal Exercise|The protocol involves a multi-modality program that involves aerobic, strength, balance, and flexibility exercises.
1592893|NCT02287740|Behavioral|Stretching|The protocol represents a minimum standard of practice for exercises for older adults with activities consisting primarily of seated exercises accompanied by breathing, stretching, and relaxation.
1592894|NCT02287727|Other|Laboratory Biomarker Analysis|Correlative studies
1592895|NCT02287727|Drug|Regorafenib|Given PO
1592896|NCT02287714|Procedure|Instep without gastrocnemius recession|Patient will receive an instep plantar fascial release without gastrocnemius recession.
1592897|NCT02287714|Procedure|Instep with gastrocnemius recession|Patient will receive an instep plantar fascial release as well as gastrocnemius recession.
1592898|NCT02287701|Procedure|PET/MRI|Simultaneous PET/MRI (3T system)
1592899|NCT02287688|Biological|Meningococcal quadrivalent CRM-197 conjugate vaccine|This study is strictly observational. Decisions of vaccination are made by health care providers.
1592900|NCT02287675|Drug|Lymphoseek|Subjects will receive a single intradermal injection of Lymphoseek followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. Lymphoseek positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
1592901|NCT02287675|Drug|Sulfur Colloid|Subjects will receive a single intradermal injection of 99mTc-SC followed by SPECT imaging conducted in two phases: initial sequential planar imaging at 30 to 60 second intervals for the first 60 minutes and repeated at 90 minutes and 120 minutes, as indicated, for identification of the SLN followed by SPECT/CT for higher resolution imaging in transaxial, coronal, and sagittal planes. Subjects will then proceed to surgery for lymphatic mapping. 99mTc-SC positivity will be based upon radioactivity counts derived from the application of the handheld gamma probe ex vivo. Tumor resection or mastectomy will be performed according to standard procedures.
1592908|NCT02287636|Procedure|magnetic resonance imaging|Undergo PET/MRI
1592909|NCT02287623|Drug|liposomal bupivacaine|patients will receive a tap with liposomal bupivacaine
1592910|NCT02287623|Drug|bupivacaine|patients will receive a tap with bupivacaine
1592911|NCT02287610|Drug|RAYOS (delayed-release prednisone)|Physicians may prescribe any dosage of RAYOS based on what is appropriate for the treatment of the patient's condition as determined by performing standard of care assessments.
1592912|NCT02287584|Drug|DSP-5423P 40mg|
1592913|NCT02287584|Drug|DSP-5423P 80mg|
1592914|NCT02287584|Drug|DSP-5423P Placebo|
1592915|NCT02287571|Device|Derotation splint|This group is the actual intervention group.
1592916|NCT02287571|Device|elastic bandage|This group is the routine treatment (control) valid in the clinical practice.
1592917|NCT02287558|Drug|Pomalidomide|
1592918|NCT02287545|Procedure|trabeculectomy|Standard trabeculectomy with the use of antimetabolites (mitomycin C) for glaucoma patients with insufficient intraocular pressure (IOP) control taking maximally tolerated IOP-reducing medication, visual field progression despite maximally tolerated IOP-reducing medication, adverse events because of maximally tolerated IOP-reducing medication or nono.compliance.
1592919|NCT02287532|Device|DIABEO software|DIABEO is an electronic diary system incorporating an immediate automatic aid to calculating the insulin dose according to the prescription given by the doctor, and a data processing, automated analysis message and secure internet data transfer system. DIABEO software could be combined with remote paramedical monitoring of data (telemonitoring)
1592920|NCT02287519|Behavioral|Group Session|
1592921|NCT02287519|Behavioral|Telephone Coaching Session|
1592922|NCT02287519|Behavioral|Webinar|
1592923|NCT02287506|Other|Optimised Diagnostic Strategy|(ODS) based on integrating Clinical information (a validated clinical probability model), Biomarkers (GAD, IA2 and ZnT8 autoantibodies) and Genetic testing for MODY
1592924|NCT02287493|Other|Pharmacokinetic Analysis|
1592925|NCT02287480|Biological|VSV-ZEBOV|See arm/group descriptions.
1592926|NCT02287467|Biological|Intravenous hyperimmune immunoglobulin (IVIG)|Administered intravenously (IV) at a dose of 0.25 g/kg (up to a maximum of 24.75 g, corresponding to approximately 100 kg actual body weight)
1592927|NCT02287467|Biological|Placebo for IVIG|Administered IV as 500 mL of normal saline
1592928|NCT02287454|Other|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with MS patients consisted of: four weeks training attention (sustained, selective, alternating and divided attention); three weeks focused on learning and memory (the stimulation of verbal and visual memory was combined with learning and compensatory strategies, working memory was also trained); three weeks exercising executive functioning (development, planning and attainment of objectives); three weeks focused on language (verbal fluency, syntax, grammar, vocabulary and comprehension); and one week training social cognition (social reasoning, theory of mind and moral dilemmas).
1592929|NCT02287441|Other|Tomato|Tomato Products (tomato)
1592930|NCT02287441|Other|Raw|Vegetables Prepared Raw (raw).
1592931|NCT02287428|Radiation|Radiation Therapy|Standard radiotherapy (approximately 60 Gy over 6 weeks)
1592932|NCT02287428|Biological|Personalized NeoAntigen Vaccine|NeoVax will be administered on an individual basis using a dosing schedule that incorporates both priming and boost phases.
1592933|NCT02287415|Drug|BIA 2-093|
1592934|NCT02287415|Drug|Warfarin|
1592935|NCT02287402|Drug|AO-128|AO-128 tablet
1592936|NCT02287389|Device|balloon dilation|
1592937|NCT02287389|Procedure|cryotherapy|
1592938|NCT02287389|Procedure|spiculiform electrosurgery|
1592939|NCT02287389|Drug|mitomycin C|
1592940|NCT02287376|Drug|Diclofenac Potassium for Oral Solution|NSAID
1592941|NCT02287363|Other|No intervention involved|No interventions will be involved since it is an observational study
1592942|NCT02287350|Drug|diclofenac potassium oral solution|Administration of diclofenac potassium oral solution, taken by mouth, as needed for mild to moderate acute pain.
1592943|NCT02287337|Procedure|Manipulation|High velocity low amplitude thrust joint manipulation to cervical spine facet joints
1592944|NCT02287337|Procedure|Exercise|Therapeutic exercises to the cervical, thoracic and scapular musculature
1592945|NCT02287324|Procedure|Manipulation|
1592946|NCT02287324|Procedure|Manual Contact|
1592947|NCT02287311|Biological|MABEL CTLs|"Dose escalation:
Dose Level One: 2 x 10^7 cells/m2 + 2 x 10^7 cells/m2
Dose Level Two: 2 x 10^7 cells/m2 + 5 x 10^7 cells/m2
Dose Level Three: 5 x 10^7 cells/m2 + 1 x 10^8 cells/m2
All doses are based on total CD3+ cells/m2
If patients with active disease have apparent clinical benefit (as determined by symptoms, physical exam, or radiological studies) at their 8 week post 1st infusion (6 weeks after 2nd infusion) or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at intervals at least 6 weeks apart each of which will consist of the same cell number as their second injection or below the original dose if there is not enough product available for the original dose. Patients may receive lymphodepleting chemotherapy (Cy/Flu) prior to additional infusions. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
1592948|NCT02287311|Drug|Cyclophosphamide|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide (Cytoxan) and Fludarabine before s/he receives MABEL CTLs.
3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
1592949|NCT02287311|Drug|Fludarabine|"If the patient's level of circulating T cells is relatively high, s/he may require treatment with cyclophosphamide and fludarabine before s/he receives MABEL CTLs.
3 daily doses of cyclophosphamide (Cy: 500 mg/m2/day) together with fludarabine (Flu: 30 mg/m2) to induce lymphopenia, finishing at least 24 hours before CTL infusion."
1592950|NCT02287298|Procedure|TRIPLE COMBINATION THERAPY|TREATMENT WITH BEVACIZUMAB, DEXAMETHASONE AND PHOTODYNAMIC THERAPY
1592951|NCT02287285|Drug|Exendin9|Dosed at 600 pmol/kg/min for 210 minutes.
1592952|NCT02287272|Drug|CHF 5993 pMDI|4 inhalations of CHF 5993 pMDI (BDP/FF/GB 100/6/25 micrograms per actuation) giving a total dose of 400, 24, 100 micrograms of BDP, FF, GB
1593031|NCT02286661|Procedure|Casting (long arm)|Casting using plaster of paris after closed reduction of distal radius fracture
1592953|NCT02287272|Drug|Cimetidine plus CHF5993 pMDI|Cimetidine 800 milligrams twice daily for 6 days. On the fourth day, in addition, 4 inhalations of CHF5993 pMDI (BDP/FF/GB total dose 400/24/100 micrograms)
1592954|NCT02287259|Drug|olanzapine|
1592955|NCT02287259|Drug|lithium|
1592956|NCT02287246|Drug|Extended-Release liposomal bupivacaine (Exparel)|20mL
1592957|NCT02287246|Drug|Normal saline|20mL
2009167|NCT03322371|Device|2-lead limited electroencephalography recording|The EEG recording device will be placed in conjunction with the standard formal polysomnography (PSG). The EEG device will remain in place as long as PSG leads are connected to the subject and PSG machine.
2009168|NCT03322709|Procedure|kidney transplant|Transplantation of a kidney either by open surgery or robotic assisted laparoscopic surgery.
1592960|NCT02287220|Device|Non-Contact Oximetry|Video Record subject when subjected to small amounts of near infrared light
1592961|NCT02287207|Device|transcranial direct current stimulation (tDCS)|
1592962|NCT02287194|Device|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
1592963|NCT02287181|Drug|Remifentanil|short acting opiate
1592964|NCT02287181|Drug|Propofol|hypnotic drug
1592965|NCT02287181|Other|Bispectral index|electroencephalograph
1592966|NCT02287168|Procedure|pre-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid before gastrectomy
1592967|NCT02287168|Procedure|post-gastrectomy peritoneal washing cytology|sampling of peritoneal washing fluid after gastrectomy
1592968|NCT02287168|Procedure|post-lavage peritoneal washing cytology|sampling of peritoneal washing fluid after peritoneal lavage
1592969|NCT02287155|Behavioral|occupation based health promotion|"The description of the intervention is provided in the detailed description of the study."
1592970|NCT02287142|Procedure|Brachial plexus nerve block|All arms of the study comparing the three different blocks are receiving the same single injection bolus of ropivacaine 0.5% prior to surgery. We will then record and compare pain scores in PACU and opioid requirement.
1592971|NCT02287129|Drug|Oxaliplatin|130 mg/m2
1592972|NCT02287129|Drug|Epirubicin|50 mg/m2
1592973|NCT02287129|Drug|Capecitabine|625 mg/m2
1592974|NCT02287129|Drug|5-FU|200 mg/m2
1592975|NCT02287129|Drug|Carboplatin|2 mg/ml min
1592976|NCT02287129|Drug|Paclitaxel|50 mg/m2
1592977|NCT02287129|Radiation|radiation|total dosage 41,4 Gy
1592978|NCT02287129|Procedure|Biopsy|translational analysis
1592979|NCT02287116|Device|Easy Flow system and INCA® nasal cannulae set|
1592980|NCT02287103|Other|Skipping Breakfast|NoB: The patients will omit the breakfast, will continue the overnight fast until lunch, then will eat only lunch and dinner.
1592981|NCT02287103|Other|Eating Breakfast|YesB: will eat all three meals
1592982|NCT02287090|Other|Observational Cohort|
1592983|NCT02287077|Procedure|Umbilical Cord Milking|At birth, neonate will be held below the level of placenta and umbilical cord will be milked 3 times before clamping the cord.
1592984|NCT02287064|Drug|Intravenous Immune Globulin (IVIG)|"IVIG will be infused over a course of five days in the form of GAMMAGARD LIQUID 10% solution, available from Baxter. For neurological and autoimmune diseases 2 grams per kilogram of body weight is implemented for three months over a five day course once a month.
There is very limited reliable dose ranging data for IVIG in the treatment of any condition, and most dosing has been empiric. In our experience, we have empirically observed a more potent immunomodulatory effect from induction dose IVIG (2 g/kg) continued each month, than with the booster dose maintenance dose of 1gm/kg. Though there is no category one evidence to support this practice, neither is there such evidence to refute it. Additionally, results from previous trials of IVIG in SCAs show this dosage to be relatively safe and effective at this rate of infusion"
2009169|NCT03322657|Drug|Neostigmine|Neostigmine injection
1592986|NCT02287012|Other|Time/Motion evaluation of actual apheresis|The actual apheresis events will be measured in consecutive patients scheduled to be candidates for peripheral blood stem mobilization in the apheresis area of the hospital. Each apheresis will be considered as one event . Should the patient receive more than 1 apheresis, each apheresis will be considered as one different event.
1592989|NCT02286986|Drug|Cannabidiol|
1592990|NCT02286973|Drug|Tranexamic Acid|
2009170|NCT03322657|Drug|Glycopyrrolate|Glycopyrrolate injection
2009171|NCT03322657|Drug|Sugammadex|Sugammadex injection
1592993|NCT02286947|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
1592994|NCT02286934|Drug|Carvedilol|"Day 1 to 3 : Carvedilol 12.5 mg qd
Day 4 to 8 : Carvedilol 25 mg qd
Day 9 to 11 : Carvedilol 12.5 mg qd"
1592995|NCT02286934|Other|Isoproterenol Sensitivity Test|Day 0, 1, 8 : Isoproterenol Sensitivity Test
1592996|NCT02286921|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
1592997|NCT02286921|Drug|Enzalutamide|Enzalutamide is a white crystalline non-hygroscopic solid. It is practically insoluble in water. Enzalutamide is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides. The inactive ingredients are caprylocaproyl polyoxylglycerides, butylated hydroxyanisole, butylated hydroxytoluene, gelatin, sorbitol sorbitan solution, glycerin, purified water, titanium dioxide, and black iron oxide.
1593032|NCT02286661|Procedure|Casting (short arm)|
1593033|NCT02286648|Drug|Formocresol|pulpotomy with formocresol
1593034|NCT02286648|Drug|Mineral Trioxide Aggregate|pulpotomy with MTA
1592998|NCT02286921|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
1592999|NCT02286895|Biological|pentavalent rotavirus vaccine (PRV)|At enrollment, infants will be randomized 1:1 to receive one dose of 2.0ml orally
1593000|NCT02286895|Biological|measles vaccine (MV)|At enrollment, all infants will receive one dose of 0.5ml subcutaneously
1593001|NCT02286895|Biological|yellow fever vaccine (YFV)|At enrollment, all infants will receive one dose of 0.5ml intramuscularly
1593002|NCT02286895|Biological|meningitis conjugate vaccine (PsA-TT-5μg)|At enrollment, all infants will receive one dose of 0.5ml intramuscularly
1593003|NCT02286882|Drug|PF-06409577 or Placebo|PF-06409577or placebo will be administered as an extemporaneously prepared suspension once in each cohort
1593004|NCT02286869|Procedure|Three different mechanical ventilation modes|patients are randomly assigned to every arm. Baseline is the period immediatly before the study phase. The study phase is the sequence of three consecutive trials of different modes of mechanical ventilation. Every trial lasts 30 min plus 10 min of acclimation.
1593005|NCT02286856|Behavioral|diet intervention|The dietary intervention implies optimizing the diet based on individually calculated energy and protein requirements, while for remaining nutrients advise in line with recommended daily amounts (RDA) will be provided. This nutrients will be translated to food products and lifestyle advice is added. Individual diet counseling will be part of the intervention to improve compliance.
1593006|NCT02286843|Radiation|89Zr-trastuzumab|
1593007|NCT02286843|Device|PET/CT scan|
1593008|NCT02286843|Radiation|89Zr-pertuzumab|
2009172|NCT03322085|Procedure|radiofrequency ablation or cryoballoon|Patients in radiofrequency ablation group receive circumferential pulmonary vein isolation,and no additional ablation is performed in the extrapulmonary sites unless the patient is diagnosed with atrial flutter before the operation. And Cryoablation is performed using a single cryoballoon. The diameter of the cryoballoon is determined as 28 mm or 23 mm according to pulmonary venography results.
1593010|NCT02286817|Drug|NFC-1|Single-dose, open label administration to assess safety, tolerability, and pharmacokinetics in adolescents with ADHD and continuous daily administration for four weeks with weekly escalation to evaluate safety, tolerability, and impact on ADHD severity.
1593011|NCT02286804|Device|Ultherapy|Micro-focused ultrasound energy delivered below the surface of the skin
1593012|NCT02286791|Behavioral|Mindful Awareness Program|For Mindful Awareness Program, 40-minutes weekly sessions for 12 weeks, followed by 40-minutes monthly for 6 months. The mindful awareness practice techniques to be taught to the elderly include: (1) mindfulness of the senses practice; (2) the body scan practice; (3) walking meditation practice; (4) 'movement nature meant' practice; and (5) visuo-motor limb tasks
1593013|NCT02286791|Behavioral|Health Education Program|"For the Health Education Program, weekly sessions of 40 minutes for 12 weeks, followed by monthly sessions of 40 minutes for 6 months.
Week 1: Diabetes Mellitus Week 2: Hypertension Week 3: Home Safety Week 4: Medications Week 5: Diet Week 6: Depression Week 7: Dementia Week 8: Anxiety Week 9: Sleep Week 10: Exercise Week 11: Coping with bereavement Week 12: Social support"
1593014|NCT02286778|Dietary Supplement|Acetogenins|Acetogenins BID for 12 months
1593015|NCT02286778|Dietary Supplement|Placebo|
1593016|NCT02286765|Device|Ulthera System treatment|Micro-focused ultrasound energy delivered below the surface of the skin
1593017|NCT02286752|Drug|Neostigmine|for reversal of neuromuscular block: 0,05 mg kg-1 neostigmine + 0,025 mg kg-1 atropine
1593018|NCT02286752|Drug|sugammadex|for reversal of neuromuscular block: sugammadex 2 mg kg-1
1593019|NCT02286739|Device|"TKA with Verasense"|VERASENSE replaces the standard tibial trial inserts and is embedded with microelectronics and sensors to provide surgeons with real-time knee kinetic data. The data is wirelessly transmitted to a graphic display (VERASENSE Knee Application), allowing surgeons to quantify and assess soft tissue intercompartmental loads throughout the range of motion. The VERASENSE sensor is not an investigational device. OrthoSensor, Inc., received FDA 510K clearance in 2009. The indication for use is a tool for adjustment of the femoral knee implant to reduce instability from flexion gap asymmetry. The VERASENSE sensor is sterile and single patient use.
1593020|NCT02286739|Procedure|"TKA without Verasense"|TKA will be performed manually without the use of Verasense
2009173|NCT03321097|Device|condensed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.
Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 4 sessions per week, for 6 weeks.
During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
2009174|NCT03321097|Device|distributed RT group|"BoNT-A injections Botox brand BoNT-A Purified Neurotoxin Complex, (Allergan Pharmaceuticals, Irvine, CA) will be prepared by diluting lyophilized toxin with 0.9% saline to a concentration of 33-100 U/ml. depending on the size of the target muscle. Location of the targeted muscle will be confirmed by using echo guide.
Training procedures There are total 24 training sessions following one week after injection. Participants in the condensed practice group will receive 2 sessions per week, for 12 weeks.
During each practice session, participants first receive 40 minutes of repetitive RT with the InMotion 3.0 robot (Interactive Motion Technologies Inc., Watertown, MA), followed by 40 minutes of transition-to-task practice."
1593026|NCT02286700|Drug|Desonide Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
1593027|NCT02286700|Other|Amino Acid Moisturizing Cream|Study cream randomized and distributed to subjects, applied twice daily for 3 weeks and evaluated ability to reduce atopic dermatitis symptoms.
1593028|NCT02286687|Drug|Talazoparib Tosylate|Participants receive Talazoparib tosylate at 1 mg by mouth daily.
1593029|NCT02286687|Behavioral|Phone Call|Study staff calls participant after completion of the treatment.
1593030|NCT02286674|Other|Tablet (Audio/Visual Device)|Subjects will be given a tablet to use before surgery
1593035|NCT02286635|Drug|Deflazacort and rifampin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21-desacetyldeflazacort (21 desacetyl-DFZ). The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone. Rifampin is a potent inducer of drug metabolism by inducing a variety of hepatic and intestinal CYP enzymes, especially CYP3A4. Rifampin is a semi-synthetic antibiotic.
1593036|NCT02286635|Drug|Deflazacort and Clarithromycin|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects. It is an inactive pro-drug which is metabolized completely and rapidly to the active drug 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone. Clarithromycin is a semi-synthetic macrolide antibiotic. Clarithromycin is active in vitro against a variety of aerobic and anaerobic gram-positive and gram-negative bacteria as well as most mycobacterium avium complex (MAC) bacteria. Additionally, the 14-OH clarithromycin metabolite also has clinically significant antimicrobial activity. Clarithromycin is indicated for the treatment of mild to moderate infections such as pharyngitis/tonsillitis.
1593037|NCT02286622|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite 21-desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone
1593038|NCT02286609|Drug|Deflazacort|Deflazacort, a glucocorticoid with anti-inflammatory and immunosuppressive effects, is used in treating a variety of diseases. Pharmacologically it is an inactive pro-drug which is metabolized immediately to the active metabolite, 21 desacetyl-DFZ. The elimination of this metabolite is primarily via the urine in humans. Its potency is approximately 70 to 90% of prednisone and 6 mg of deflazacort has approximately the same anti-inflammatory potency as 5 mg of prednisolone or prednisone.
1593039|NCT02286596|Device|heparin-induced extracorporeal LDL precipitation|Lipid apheresis for 3 hours
1593040|NCT02286596|Device|dextran sulfate adsorption|Lipid apheresis for 3 hours
1593041|NCT02286583|Device|Microwave Thermography RTM-01-RES|Divide the breast into 3 circles start from the nipple with 1 cm increase in the circle diameter. Divide this circle into 8 points. This makes us detect 24 points in addition to the nipple as fixed point and the tail of the breast as separate point giving total of 26 points.
1593045|NCT02286557|Drug|Methelphenidate|All participants will undergo 4 weeks of treatment with Methelphenidate and 4 weeks of placebo
1593046|NCT02286557|Drug|Placebo|
1593047|NCT02286544|Biological|Salmonella typhi vaccine (Typhim Vi®)|A peripheral venous catheter will be inserted. This catheter will be used to collect blood sample during the study day. In addition, peripheral oxygen saturation will be measured by pulse oximetry. After baseline venous blood samples have been collected, all study participants will receive 0.5 mL of the Salmonella typhi vaccine as an intramuscular injection (Typhim Vi®, Sanofi Pasteur MSD, injection solution 25 microgram/0.5 mL) Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
1593048|NCT02286544|Drug|Oxygen (Oxymask®)|"As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry.
Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended."
1593049|NCT02286544|Drug|Atorvastatin|As in arm 1. Half an hour after vaccination is administered, oxygen treatment will be initiated at 6 L/min via Oxymask® and continued for 6 hours. During oxygen treatment peripheral oxygen saturation will be measured by pulsoximetry. A single dose of Atorvastatin 80 mg will be given immediately prior to start of oxygen. Venous blood samples will be collected at 3, 6 and 8 hours after baseline. After the 8-hour blood sampling, the peripheral venous catheter will be removed and the study day ended.
1593050|NCT02286531|Drug|O-(2[18F]FLUOROETHYL)-L-TYROSINE|Patient 0.1 mCi / kg (maximum 185 MBq) of FET will be injected through the venous catheter. At the same time, will trigger a PET 3D dynamic acquisition of 60 minutes (5 pictures 1 minute and 11 images of 5 minutes)
1593051|NCT02286518|Drug|TAK-114 10 mg capsule|
1593052|NCT02286518|Drug|TAK-114 matched placebo|
1593053|NCT02286505|Device|Brain Morphometry|Quantitative, automated reading of hippocampal volume from MRI scans, complemented by a general measure of brain atrophy, in addition to standard neuroradiological report.
1593054|NCT02286505|Other|Standard radiological assessment|Standard neuroradiological report produced by qualitative examination of structural MRI scan by trained neuroradiologist.
1593055|NCT02286492|Drug|TAS-102|At a dose of 35 mg/m2 administered orally twice daily for 5 days a week with 2 days rest for 14 days, followed by a 14-day rest (1 treatment cycle)
1593056|NCT02286479|Procedure|Incision and Drainage|In the incision and drainage group, the abscesses are incised, irrigated by sterile solutions and drained conventionally.
1593057|NCT02286479|Procedure|Loop drainage|In the loop drainage group, two small incision are made on each side of abscess. The pus are drained and septations are seperated by a forceps. Abscess cavitary irrigated by sterile solution. Sterile, non-powder, non-latex surgical gloves cuff is inserted in one incision and taken out from the other insicion. Then two tips of cuff are tied loosely.
1593087|NCT02286245|Other|Usual practice|The physician will decide for the same disease (isolated fever and/or symptoms of gastroenteritis) the need of telephone advice with or without drug prescription, home visit by a doctor, emergency department services with or without EMS system.
2009175|NCT03321214|Device|Gluten Sensor Device|"Gluten Sensor Device Dose-Finding Intervention Nima is a small portable sensor that detects gluten in a small amount of liquid and solid foods in about three minutes.
Nima combines an electronic sensor with antibody-based detection in a disposable capsule. Nima displays a smiley face if the food or beverage is < 20 ppm or a wheat icon for > 20 ppm (low or high gluten).
Each of the 30 participants will receive a Nima along with 3 months of disposable capsules. Ten participants will be randomized to receive 24 capsules per month; ten participants will be randomized to receive 12 capsules per month; and ten participants will be randomized to receive 12 capsules every other month. At the baseline visit, research staff will provide participants with the Nima and capsules and review instructions on how to properly use the device with all participants."
2009176|NCT03321136|Drug|LSD|0.025 mg LSD per os, single dose
1593060|NCT02286453|Drug|Benjakul recipe|Benjakul recipe capsule at dose of 100 mg three times a day after meal daily for 28 days
1593061|NCT02286453|Drug|diclofenac|diclofenac capsule at dose of 25 mg three times a day after meal daily for 28 days
1593062|NCT02286440|Other|AssureRx GeneSight genotyping results|
1593063|NCT02286440|Other|Treatment as usual|
1593064|NCT02286427|Device|Amniotic Membrane|
1593065|NCT02286414|Drug|Direct oral antocoagulant: dabigatran, rivaroxaban, apixaban|Exposure to direct oral antocoagulants
1593066|NCT02286414|Drug|Vitamin K antagonist: warfarin, fluindione, acenocoumarol|Exposure to vitamin K antagonist
1593067|NCT02286388|Procedure|A one-step partial caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:
Soprolife® (Acteon, La Ciotat, France) dental imaging device to detect dentinal infection status. The green-black light indicates infected dentin, red indicates infected/affected dentin and green indicates healthy dentinal tissue.
Sterile round bur under water spray coolant followed by final excavation with hand instruments The clinician will remove the superficial necrotic and demineralized dentin with complete excavation of the peripheral demineralized dentin, avoiding excavation close to the pulp.
Hand instruments will be used for final excavation following clinical criteria guidelines (color of residual dentin and probe resistance) and taking in to consideration the color data obtained by the Soprolife® camera.
The operator will stop excavating when the dentin close to the pulp appears red (for infected dentin)."
1593068|NCT02286388|Procedure|A complete caries removal procedure for the treatment of deep carious lesions in posterior permanent teeth.|"Instruments and procedures:
Idem partial excavation arm.
In the complete excavation arm, the operator will stop excavating when the dentin close to the pulp appears green (for healthy dentin tissue) using the Soprolife® camera, leaving no infected or affected dentin."
1593069|NCT02286388|Device|The application of an antibacterial dental adhesive (ClearfilTM SE Protect, Kuraray Dental).|"Enamel and dentin will be conditioned according to the manufacturer's instructions. Both antibacterial and conventional adhesives are two-steps bonding systems.
The first step consists of the application of a primer to the enamel and dentin for 20 seconds (which allows the completion of etching and priming procedures). The second step consists of the application of the antibacterial adhesive and its light curing for 10 seconds."
1593070|NCT02286388|Device|The application of a conventional dental adhesive (ClearfilTM SE Bond, Kuraray Dental)|Idem antibacterial dental adhesive arm. A conventional dental adhesive will be used instead of an antibacterial.
1593071|NCT02286375|Behavioral|Intervention group|A structured assessment is conducted using the Omaha system. Problems will be identified in the four domains which include environment, psychosocial, physiological and health-related behavior. According to the identified problems, the nurse case manager and older adults will set contract goals and formulate an individual care plan. The nurse case manager will provide information on the basic knowledge of participants' own chronic illnesses; recognition, measurement and management of the early signs and symptoms of a deterioration or exacerbation of diseases; and the importance of health-promoting and self-care activities. A booklet will be given to them for easy reference and act as a reminder to consolidate the knowledge in case the important concepts are forgotten.
1593072|NCT02286349|Device|Transcranial magnetic stimulation (Neurosoft®)|Repetitive transcranial magnetic stimulation
1593073|NCT02286349|Device|Transcranial direct current stimulation (Soterix, USA)|Transcranial direct current stimulation
1593074|NCT02286336|Other|brachial plexus block|brachial plexus block with ropivacaine 40ml
1593075|NCT02286323|Device|Bonfils|Bonfils Intubation Fiberoscope
1593076|NCT02286323|Device|Macintosh|Direct laryngoscopy using Macintosh Laryngoscope
1593077|NCT02286310|Other|Kinetic Chain Exercises|Exercises include kinetic chain segments.
1593078|NCT02286310|Other|Traditional Exercises|Stretching, strengthening exercises.
1593079|NCT02286297|Device|McGRATH® MAC|video-laryngoscopy-1
1593080|NCT02286297|Device|AirTraq|video-laryngoscopy-2
1593081|NCT02286297|Device|GlideScope|video-laryngoscopy-3
1593082|NCT02286297|Device|Miller|Direct laryngoscopy
1593083|NCT02286284|Device|Apheresis for extracorporal removal of sFlt-1|
1593084|NCT02286258|Drug|Calcium EDTA|"Calcium EDTA for equilibrium GFR measurement : bolus injection 30 mg/kg, then 10 mg/min perfusion for estimated renal clearance 100 mL /min for 4 hours.
Calcium EDTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
1593085|NCT02286258|Drug|Gd-DOTA|"Gd-DOTA for equilibrium GFR measurement : bolus injection 56 ng/kg, then 28 ng/min perfusion for estimated renal clearance 100 mL /min for 4 hours.
Gd-DOTA for single injection GFR measurement : bolus injection depending on the estimated GFR"
1593086|NCT02286245|Other|focused Telephonic Medical Advice|The physician will implement a protocol of care to each patient call for an isolated fever and/or symptoms of gastroenteritis: medical advice, drug prescription by phone and supervisory board
1593272|NCT02284711|Device|ultrasound energy|Coagulation during salpingectomy using UltraCision HARMONIC ACE® ultrasound energy
2009177|NCT03321136|Drug|LSD|0.05 mg LSD per os, single dose
2009178|NCT03321136|Drug|LSD|0.1 mg LSD per os, single dose
2009179|NCT03321136|Drug|LSD|0.2 mg LSD per os, single dose
2009180|NCT03321136|Drug|LSD|0.2 mg LSD plus 40 mg ketanserin per os, single doses each
2009181|NCT03321136|Drug|Placebo|Capsules containing mannitol looking identical to the other drugs.
2009182|NCT03320876|Drug|filgotinib|one filgotinib oral tablet once daily.
2009183|NCT03320746|Device|Activity tracker|Daily activity goal
1593088|NCT02286232|Behavioral|Stretching exercise|This program begins with 10 stretches/exercises over 15 minutes on the initial class and incrementally increases by 1 stretch/exercise each session for a total of 21 stretches/exercises over 30 minutes on the 12th session. The program is designed to stretch/exercise the major muscle groups, emphasizing the neck and arms, trunk, and legs. In addition to the stretches, each class will include breathing exercises and guided imagery for relaxation. Classes will be taught by Physical Therapists who are trained to lead classes through the protocol.
1593089|NCT02286232|Behavioral|Self-care book|The Back Pain Helpbook which provides information on the causes of back pain and advice on exercising, making appropriate lifestyle modifications, and managing flare-ups.
1593090|NCT02286219|Drug|FS102|Experimental
1593091|NCT02286206|Drug|Clozapine|One-half baseline dose po bid (or one-third baseline dose po qam and two-thirds baseline dose po qhs at the discretion of the treating clinicians and principal investigator)
1593092|NCT02286193|Behavioral|Patient clinical encounters with Community Resource Specialist (CRS)|CRS will work with patients to create goals, develop action plans and link to community resources to support goals
1593094|NCT02286154|Drug|Hydroxyurea|For New Cohort participants, PK/PD data will be used to predict the most effective maximum tolerated dose. Old Cohort participants will receive hydroxyurea escalated to MTD as per local clinical guidelines.
1593095|NCT02286115|Behavioral|Life-Stress Interview|A life-stress interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms, b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations
1593096|NCT02286102|Device|OrthoPAT|OrthoPAT drain to collect and retransfuse postoperative blood loss. Drains will be removed 48 hours postoperatively
1593097|NCT02286102|Device|Constavac|Constavac drain to collect postoperative blood loss. Drains will be removed 48 hours postoperatively
1593098|NCT02286089|Biological|OpRegen|Targeted dose of 50,000 - 500,000 cells will be delivered into the subretinal space following vitrectomy procedure
1593099|NCT02286063|Drug|Ambulatory Oxygen|"The IMP investigated in this study is medical oxygen (PL 15929/005), manufactured by Air Liquide Ltd. UK. Oxygen is a colourless, odourless gas with molecular weight 32, a boiling point of 183.1°C (at 1 bar) and a density of 1.355 kg/m3 (at 15°C and 1013mb).
Oxygen is present in the atmosphere at 21% and is an absolute necessity for life. Each of the four oxygen companies across the UK provide a light and a standard weight oxygen cylinder. Ambulatory Oxygen will be given to the Oxygen arm."
1593100|NCT02286050|Other|CF Nursing Program|
1593101|NCT02286011|Biological|MNC (Mononuclear cells)|"The cells are infused into the TA muscle of the lower limb randomized as Group A (experimental) intramuscularly. The infusion is made with a needle, 26 gauge, at 4 points of the TA muscle a specific depth given by the neurophysiological study. The total volume infused will be 2 ml, 0.5 ml at each point.
For infusion is as painless as possible for the patient to comply exactly with stereotactic indications of neurophysiology, the infusion was made at a uniform controlled rate and for this, the syringe is placed on a Yesargil arm, equipped with a microinjector and controlled infusion device."
1593102|NCT02286011|Other|Saline|The placebo, 2ml of saline, will be infused like in the experimental arm.
2009184|NCT03320200|Other|CNS-focused treatment|The CNS-focused treatment will last for 10 weeks, conducted in 60-minute sessions on a weekly basis. In addition, participants in this group will complete a home treatment program for 30 minutes, five times a week.
2009185|NCT03320200|Other|Standard Care Treatment|The standard physiotherapy group will receive a 10-session treatment program that will include one corticosteroid infiltration provided in the early acute stage followed by a multimodal physiotherapy program including analgesic modalities (e.g. TENS, cryotherapy) and exercise and manual therapy techniques addressing the specific mobility deficits of each patient. This program also include a home treatment based on conventional physiotherapy that involves a training load comparable to that in the CNS-focused group.
1593107|NCT02285972|Drug|saline|before the anesthesia induction, 2mL saline iv injection
1593108|NCT02285972|Drug|dexketoprofen|before the anesthesia induction, 50 mg (2mL) iv dexketoprofen
1593109|NCT02285972|Drug|tenoxicam|before the anesthesia induction, 20 mg (2mL) iv tenoxicam
1593110|NCT02285959|Drug|Bevacizumab|
1593111|NCT02285946|Procedure|major spine surgery|
1593112|NCT02285933|Other|virtual reality training|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Exercises challenge sitting balance control, reaching and shifting the base of support; for example, controlling a ball as it rolls down a maze or reaching to put dishes away in a virtual kitchen. The difficulty of the games is monitored to maintain a challenge to sitting balance. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre of pressure to ensure that the participant is adequately challenged during the VRT.
1593113|NCT02285933|Other|control|Each participant will engage in 10-12 sessions of 30-50 minutes each of virtual reality training (VRT) using Jintronix Rehabilitation Software and three-dimensional motion capture technology. A camera captures the movements of the participant and allows him or her to control an avatar, which interacts with the game. Control group exercises require limited hand and arm movements; for example, using an arm to move a fish along a simple pathway or using the arms to pop balloons without reaching. Control group participants are strapped into their chair to minimize trunk movement. The participant sits on a CONFORMat pressure mat which continuously monitors his or her centre during the VRT.
1593114|NCT02285920|Drug|Spironolactone|The trial will be conducted in 2 phases ‒ a dose escalation phase (6 weeks) and a treatment phase (30 weeks). At the end of the dose escalation phase, participants will continue treatment based on the randomized dose assignment for an additional 30 weeks (treatment phase) such that the total duration of study medication is 36 weeks.
1593273|NCT02284698|Other|Health Education|Heath education will be given through awareness creation & pamphlet distribution
1593368|NCT02283905|Drug|voriconazole|intravenously or orally administered
2009186|NCT03320122|Other|Telemedicine|Medical direction will be provided to MTUs through a video-based conferencing unit. Each telemedicine unit includes a Rubbermaid medical grade cart with a Polycom RealPresence 500 Series high-resolution video-conferencing unit flat screen to display video. Each cart also comes with an Uninterrupted Power Supply (UPS) to make the unit mobile if needed or to properly shut it down in the event of power failure.
2009187|NCT03320122|Other|In-Person Pediatric Physiatrist|UC Davis pediatric physiatrists will drive out to the school-based MTUs to provide medical direction in person.
1593119|NCT02285894|Other|Inspiratory hold|Sustainment of the ventilators inspiratory pressure for 10 seconds at a time
1593120|NCT02285881|Behavioral|Shared decision making|In the intervention practices the SDM process is used. In the SDM proces the patient and GP use a decision aid to discuss the pros and cons of two evidence based treatment possibilities, according to the Dutch College of General Practitioners (NHG) versus the ADDITION guideline, and the patients' preferences for either of these treatments. Together they choose one of these treatments, and set the five treatment targets (blood pressure, cholesterol, HbA1c, smoking status and weight) in order of priority. Subsequent treatment will take place according to the priorities of these OPTIMAL treatment targets. The priorities will be evaluated every 12 months.
1593121|NCT02285855|Drug|Metformin|Metformin treatment given at a dose of 2000 mg by mouth in divided dose daily (500 mg am, 1000 mg noon, 500 mg pm). To reduce GI toxicity, participants start Metformin at 1000 mg daily in a divided dose (500mg am, 500 mg pm) for 1 week.
1593122|NCT02285855|Other|Placebo|Placebo treatment given 3 weeks prior to SBRT treatment and for 1 week during SBRT treatment. Placebo administered by mouth three times a day.
1593123|NCT02285855|Radiation|Stereotactic body Radiotherapy (SBRT)|SBRT delivered per standard of care practice as determined by participant's physician.
1593124|NCT02285842|Device|Primary hip resurfacing device|CONSERVE® Press-Fit Femoral Components
1593125|NCT02285829|Drug|Rocuronium Bromide, Cisatracurium Besylate|Both Rocuronium Bromide and Cisatracurium Besylate are administered intravenously following induction of anesthesia initially by bolus, and subsequently re-bolused or administered in continuous infusion as clinically indicated to maintain muscle relaxation. Initial doses of Rocuronium range from 0.45 to 1.2 mg/kg IV, and doses for continuous infusion range from 0.01-0.012 mg/kg/min IV. Initial doses of Cisatracurium range from 0.15 to 0.2 mg/kg, and doses for continuous infusion range from 0.5 to 3 µg/kg/min. Following recovery and baseline screw stimulation at TOF >0.9, the dosing regimen for this study will rely on restarting a continuous infusion, and adjusting the infusion until the desired TOF ratios are reached. Following screw stimulations and data collection, the infusion will be terminated, and neuromuscular blockade allowed to recover.
2009188|NCT03320122|Other|In-Person Non-Pediatric Physiatrist|A contracted physician (i.e., a non pediatric physiatrist) would provide medical direction in person.
2009189|NCT03320057|Drug|Mifepristone|Patients will receive Mifeprex® (mifepristone) by pharmacy rather than standard care at clinic visit
1593128|NCT02285803|Device|transcranial direct current stimulation (tDCS)|
1593129|NCT02285790|Device|Reflectance confocal microscopy|
1593130|NCT02285790|Procedure|Punch biopsy|
1593131|NCT02285790|Procedure|Surgical excision|Excision of the suspected basal cell carcinoma lesion under local anesthetics
2009190|NCT03318536|Drug|Granisetron Hydrochloride|Patients received Granisetron.
1593134|NCT02285764|Other|Nutritional Supplement|Modified carbohydrate
1593135|NCT02285764|Other|Standard of Care|As determined by the study site
1593136|NCT02285751|Drug|acetylsalicylic acid|
1593137|NCT02285751|Drug|clopidogrel|
1593138|NCT02285751|Drug|prasugrel|
1593139|NCT02285751|Drug|ticagrelor|
1593140|NCT02285738|Drug|Aspirin|81mg/day for 4 weeks
1593141|NCT02285738|Drug|Simvastatin|Daily dose of Simvastatin for 4 weeks
1593142|NCT02285738|Other|Observation|participants will be observed for thrombotic evens for 4 weeks
1593143|NCT02285725|Procedure|Microdrilling Surgery|All patients will undergo an arthroscopic surgical procedure in which small holes are drilled throughout the areas of damaged cartilage (standard of care)
1593144|NCT02285725|Biological|Injections of BMAC + PRP + HA|All patients will receive up to 12 post-operative intra-articular knee injections of BMAC (derived from iliac crest), PRP (derived from peripheral blood) and HA (Supartz)
1593145|NCT02285712|Device|Vascular ultrasound system|
1593146|NCT02285699|Drug|SSRIs|12-weeks of standard SSRi treatment for those interested in Phase II of the study.
1593147|NCT02285673|Biological|Umbilical Cord Mesenchymal Stem Cell|
1593148|NCT02285660|Procedure|4D PET-CT Scan|
1593149|NCT02285660|Other|No intervention|
1593150|NCT02285647|Drug|Rolapitant - Oral|Oral Treatment A Investigational Product: Rolapitant Dose: 200 mg (4 x 50 mg) Route of Administration: Oral Dosage Form: Capsule Dosing Condition: Fasted (10 hours overnight)
1593151|NCT02285647|Drug|Rolapitant - IV|IV Treatment B Investigational Product: Rolapitant Dose: 185 mg Route of Administration: IV (30 minutes) Dosage Form: 2 mg/mL solution Dosing Condition: Fasted (10 hours overnight)
1593152|NCT02285634|Drug|Oxymetazoline 0.05%|sterile gauze soaked in 5mL of Oxymetazoline 0.05% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
1593153|NCT02285634|Drug|Phenylephrine 0.25%|sterile gauze soaked in 5mL of Phenylephrine 0.25% into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
1593154|NCT02285634|Drug|Lidocaine 1% plus epinephrine 1:100,000|sterile gauze soaked in 5mL of Lidocaine 1% plus epinephrine 1:100,000 into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
1593155|NCT02285634|Drug|Bacteriostatic 0.9% NaCL|sterile gauze soaked in 5mL of Bacteriostatic 0.9% NaCL into one nostril and placement of a nasal clamp. The nasal clamp and medication will be removed after 15 minutes.
1593186|NCT02285387|Procedure|Rate control|"No AAD, just anticoagulation
HR control between 60~110bpm (with beta blocker, calcium channel blocker, digoxin)
Without the treatment about antiarrhythmia and rhythm control, deification of rate control, the subject will be drop out for study."
1593274|NCT02284685|Behavioral|Promoting Eating Disorder Treatment among College Students|Online intervention designed to identify and increase help-seeking among undergraduates with previously undiagnosed/untreated eating disorders
1593156|NCT02285621|Other|Optimized brace versus conventional Boston brace|Surface topography using Inspeck cameras allows production of a 3D reconstruction of the patient's trunk, this reconstruction will help to produce the optimized brace. Radiographic and patient-reported data will be gathered and analyzed to observe changes between time points. All radiographs will be taken with an EOS imaging system to allow 3D reconstructions. The SRS-22r will be collected at all clinical visits. Study questions will be aligned as much as possible with other prospective scoliosis protocols so as to minimize patient and surgeon response burden. The study protocol requires no additional visits or radiographs beyond standard of care. Ibuttons are installed in each brace and used to measure the compliance of the patient.
1593157|NCT02285608|Other|PIMM/SAM|The PIMM program will include education to improve patients' knowledge regarding their medication's purpose, dosage, benefits, and side effects. The program will also include tools like a checklist or alarm clock to remind patients of when and how to take their medication. Furthermore, the program will contain an interactive listening period where healthcare professionals involved in medication dispensing will listen to patients' concerns, questions and thoughts regarding their medications.
1593158|NCT02285595|Device|Sonendo GentleWave™ System|
1593159|NCT02285582|Other|Registry study|No intervention.
1593160|NCT02285556|Behavioral|psychological rehabilitation training|The main content is self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training and so on.
1593161|NCT02285556|Behavioral|physical and neurological rehabilitation training|The main content is drug rehabilitation exercise and functional physical training. Rehabilitation led by the discipline cadres , practice once a day, each lasting about 15 minutes .
1593162|NCT02285556|Radiation|rTMS 10HZ high frequency stimulation|Stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
1593163|NCT02285556|Radiation|fake rTMS 10HZ high frequency stimulation|Fake stimulate the dorsolateral prefrontal and parietal lower part , 4 weeks of therapeutic intervention (5 times / week).
1593164|NCT02285543|Drug|TPF induction chemotherapy|"TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle. 2 weeks later, surgery.
Surgery: radical resection and full neck dissection with reconstruction. Radiotherapy: 4-6 weeks after surgery, 1.8-2Gy/day, 5 days/week for 6 weeks, and totally 54-60Gy"
1593165|NCT02285543|Procedure|surgery|In the TPF group,surgery was performed at least 2 weeks after completion of induction chemotherapy.Surgery group includes radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
1593166|NCT02285543|Radiation|radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery.Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed, and the dose was 1.8-2 Gy(gray)/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
1593167|NCT02285530|Drug|TPF induction chemotherapy|TPF induction chemotherapy: 2 cycles; docetaxel(75mg/m^2), cisplatin(75 mg/m^2), 5-Fu(750 mg/m^2/day) for 5 days; 16 days later, the 2nd cycle.
1593168|NCT02285530|Procedure|surgery group|Radical resection of the primary lesion and full neck dissection(functional or radical) with proper reconstruction(pedicle or free flap) were performed.
1593169|NCT02285530|Radiation|Post-operative radiotherapy|Radiotherapy was arranged 4 to 6 weeks after surgery. Routine external beam radiotherapy, such as conformal or intensity modulated radiotherapy was performed and the dose was 1.8-2 Gy/day, 5 days/week for 6 weeks, and totally 54-60 Gy.
1593170|NCT02285517|Procedure|modified Meek skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and modified Meek skin grating technique is used to treat them and then the results of the procedure are compared to mesh skin grafting technique results by measuring the square centimeters of healed areas related to the technique
1593171|NCT02285517|Procedure|mesh skin grafting technique|patients with third degree of burns and without infected wounds are entered to the study and mesh skin grating technique is used to treat them and then the results of the procedure are compared to modified Meek skin grafting technique results by measuring the square centimeters of healed areas related to the technique
1593172|NCT02285504|Drug|SAGE-547|Intravenous
1593173|NCT02285491|Drug|10ml of bupivacaine 0.5%|This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs
1593174|NCT02285491|Drug|Placebo|10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
1593175|NCT02285465|Drug|ASP3700|Oral
1593176|NCT02285465|Drug|Placebo|Oral
1593177|NCT02285452|Drug|Zingiberis Rhizoma plv.|
1593178|NCT02285452|Drug|Sinapis nigrea semen|
1593179|NCT02285452|Drug|Placebo|
1593180|NCT02285439|Drug|MEK162|• MEK162 is currently supplied as film-coated tablets in dose strength of 15 mg. The film-coated tablets consist of MEK162 drug substance, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, croscarmellose sodium, magnesium stearate, and a commercial film coating. The original tablets are yellow to dark yellow capsule-shaped
1593181|NCT02285426|Device|Pentax EB-1990i HD-bronchoscope guided biopsy|"3 different types of bronchoscopy image settings will be used investigating the entire bronchial tree.
When sites with abnormal or suspicious vascular patterns are detected meeting the criteria of abnormality [visual scale adapted from Herth 2009 and Zaric 2013] the investigator will change to a normal bronchoscope and take biopsies from each site and a biopsy from a normal secondary carina on the contralateral site as control."
1593182|NCT02285413|Biological|DC vaccination|DC vaccination without cisplatinum
1593183|NCT02285413|Biological|DC vaccination with cisplatinum|DC vaccination with cisplatinum
1593184|NCT02285400|Procedure|CPAP level|CPAP level ranges between 4 and 12 cm water column (cmH2O), each pressure increment for 1 cmH2O.
1593185|NCT02285387|Procedure|Rhythm control|"Start AAD right after evaluating for LA size, EF, LA thrombus, and presence of CAD during anticoagulation
Cardioversion after 1 month
Rhythm FU schedule (2012 ACC/AHA/ESC guidelines)
If AF recur, RFCA"
1593271|NCT02284711|Device|Bipolar electric energy|Coagulation during salpingectomy using conventional bipolar electric energy
1593187|NCT02285374|Drug|Dolutegravir, efavirenz, efavirenz/emtricitabine/tenofovir|Arm 1: Switch efavirenz to dolutegravir immediately (at baseline) for 12 weeks Arm 2: Continue on pre-study regimen (unchanged) for 4 weeks and then switch efavirenz to dolutegravir for 12 weeks
2009191|NCT03318536|Drug|No Granisetron|Patients who did not receive Granisetron.
2009192|NCT03319576|Other|Feeding at 4 hours|Patients will be fed 4 hours after their gastrostomy tube placement procedure.
2009193|NCT03319563|Drug|Local anesthetic-epinephrine|"Bupivacaine 0.5% (Astra Zeneca) 2 mg/Kg.
Lidocaine 5 mg/Kg.
Epinephrine 5 mcg/ml of the total volume.
Add normal saline to a total volume of 100 ml/10 cm of the wound length."
1593191|NCT02285348|Procedure|Lumbar puncture|Lumbar puncture is done according to general practice
1593192|NCT02285335|Dietary Supplement|GINST|The study is designed with using GINST either 500mg/capsule or 1000mg/capsule, two capsules at once, three times a day for 12 weeks.
1593193|NCT02285309|Procedure|Cardiac Surgery and enoximone|Does diastolic function change with cardiac surgery +/- enoximone
1593194|NCT02285296|Other|personalized support program|"interview of the primary caregivers to identify their needs and expectations, the implementation of a personalized support program, including telephone follow-up"
1593195|NCT02285283|Drug|Itraconazole|
1593196|NCT02285283|Drug|Placebo|
1593197|NCT02285270|Device|FDG PET/CT|PET/CT is a hybrid imaging modality that allows imaging positron emitting isotopes such as F-18 along with anatomic imaging using x-rays. The physiologic information from the PET component is co-registered with the anatomic information from the CT component, permitting accurate localization and quantification of physiologic processes. The most common clinically used positron emitting radiopharmaceutical is F-18 fluorodeoxyglucose (FDG). It is a glucose analog which is taken up by glucose transporters and phosphorylated to FDG-6P by hexokinase. FDG PET/CT gives a map of relative amount of glucose uptake and phosphorylation over the interval from injection to scan.
1593198|NCT02285244|Drug|sotrastaurin acetate|Given PO
1593199|NCT02285244|Other|pharmacological study|Correlative studies
1593200|NCT02285244|Other|laboratory biomarker analysis|Correlative studies
1593201|NCT02285231|Dietary Supplement|Arginyl-fructose|
1593202|NCT02285231|Dietary Supplement|Placebo|
1593203|NCT02285218|Other|serum blood sampling|
1593204|NCT02285205|Drug|Oral administration of Lobeglitazone|Lobeglitazone 0.5mg/tablet, orally, 1 tablet once daily for 24 weeks
1593205|NCT02285192|Radiation|18F-Fluorodeoxyglucose (18F-FDG)|
1593206|NCT02285192|Device|PET/CT imaging|
1593207|NCT02285179|Drug|GDC-0032|Dose of GDC-0032 given orally, once daily (total daily dose) level -1: 2 mg Q.O.D GDC-0032 level 1: (starting) 2 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd level 2: 4 mg QD for 21 days, 7 days off and tamoxifen 20 mg qd
1593208|NCT02285179|Drug|Tamoxifen|daily dose of 20 mg
1593209|NCT02285166|Drug|Omega-3-acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
1593210|NCT02285166|Drug|Standard antihyperlipidemic therapy other than administration of omega-3 fatty acid ethyl esters (Lotriga).|
1593211|NCT02285153|Drug|Acetylsalicylic acid lysinate|100mg intravenously administered Acetylsalicylic Acid lysinate per day
1593212|NCT02285153|Drug|0.9% sodium-chloride solution|Placebo, intravenously administered, daily
1593213|NCT02285140|Drug|Cefazolin|administration as outlined
1593214|NCT02285140|Drug|Vancomycin|administration as outlined
1593215|NCT02285127|Procedure|Short versus long cephalomedullary Intramedullary nail|Biomet Affixus Short and Long hip fracture nail. Stryker Gamma Short and Long hip fracture nail.
2009194|NCT03319563|Drug|Saline|normal saline 100 ml/10 cm of the wound length
1593218|NCT02285101|Biological|PEG-BCT-100|
1593219|NCT02285088|Drug|GBT440|GBT440 will be administered as oral capsules
1593220|NCT02285088|Drug|Placebo|Matching placebo will be administered as oral capsules
1593221|NCT02285075|Drug|temocillin PK/PD in haemodialysis|Pharmacokinetic study measuring total and free temocillin concentrations just before, and at 0.5, 3, 6, 12, 20 (before dialysis) and 24 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 1-day interval; just before and at 0.5, 3, 6, 12, 24, 36, 44 (before dialysis) and 48 (at the end of dialysis) hours after start of the infusion when patients were dialysed with a 2-day interval, and just before and at 0.5, 3, 6, 12, 24, 36, 48, 68 (before dialysis) and 72 (at the end of dialysis) hours after start of the infusion if patients were dialysed with a 3-day interval in order to determine basic PK and PD parameters in patients treated with intermittent haemodialysis and temocillin (Vd, T1/2, protein binding, clearance, reduction rate and T > MIC of 8 and 16 mg/L).
1593222|NCT02285062|Drug|lenalidomide|
1593223|NCT02285062|Drug|Placebo|
1593224|NCT02285062|Drug|Rituximab|
1593225|NCT02285062|Drug|Cyclophosphamide|
1593226|NCT02285062|Drug|Doxorubicin|
1593227|NCT02285062|Drug|prednisone|
1593228|NCT02285062|Drug|vincristine|
1593229|NCT02285049|Other|Urticaria Control Test|"The patients get the 1st UAS28 form and four-week appointment to follow up.
Collect completed UAS28 assessment, Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS)
Then patients fill the 1st UCT and DLQI questionnaire by themselves.
The patients get the 2nd UAS28 form and four-week appointment to follow up.
At the 2nd visit, collect completed UAS28 assessment. Assessment the severity of chronic urticaria symptoms by Patient's global assessment of disease severity (PatGA-LS) and Physician's global assessment of disease control (PhyGA-LS). The patients fill the UCT and DLQI and questionnaire by themselves."
1593230|NCT02285036|Biological|vaccination PPV23|All eligible participants were stratified into four age strata namely, 2 to 6 years, 7 to 17 years, 18 to 59 years and more than 60 years. Stratified, block randomization with a size of eight was applied. Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1. Blood samples were obtained from each subject at baseline, day 30-35 after injection, to evaluate immunogenicity.
1593231|NCT02285036|Biological|vaccination PNEUMOVAX 23|Vaccination of single dose of either treatment vaccine or control vaccine intramuscularly was performed in a ratio of 1:1.
1593275|NCT02284672|Drug|Dexmedetomidine|
1593276|NCT02284672|Drug|Normal saline|
2009195|NCT03318939|Drug|Poziotinib|The poziotinib drug substance is a hydrochloride salt of poziotinib and is formulated as a tablet for oral administration.
2009196|NCT03316950|Device|ThermiVA|ThermiVA is a radiofrequency vaginal rejuvenation device FDA approved for use in dermatological and general surgical procedures for electrocoagulation and hemostasis. The hand piece is a disposable monopolar applicator that is used to apply energy internally and externally.
2009197|NCT03316950|Device|DiVA|DiVA device utilizes a hybrid fractional laser technology in a wand hand piece. The hand piece is covered by a single use strengthened quartz dilator that allows the hand piece to rotate and provide treatment in a uniform manner.
1593235|NCT02284997|Device|MGDRx® EyeBag|Class 1 Medical Device, registered with the Medicines and Healthcare products Regulatory Agency. UK Patent: GB2421687B. The EyeBag is made of silk and 100% brushed black cotton and filled with flax / linseed. When heated, this device is intended to warm the eyelids. This melts the meibum and clears the meibum obstruction of the MGs.
1593236|NCT02284984|Drug|Rituximab with belimumab|Rituximab treatment on dag 0 and 14, 1000mg iv Belimumab 10mg/kg on day 28, day 42 and day 56. Thereafter, patients will receive Belimumab 10mg/kg every 4 weeks through 72 weeks.
1593237|NCT02284971|Biological|CDX1127|
1593238|NCT02284971|Radiation|SBRT|
1593239|NCT02284958|Behavioral|Standard|Back care advice
1593240|NCT02284958|Behavioral|Walking|Back care advice, individualized 12 week pedometer-driven walking program
1593241|NCT02284945|Procedure|Open fixation|
1593242|NCT02284945|Procedure|Keyhole surgery|
1593243|NCT02284932|Other|No specific intervention for this study|No specific intervention for this study
1593244|NCT02284919|Drug|[18F]ISO-1|[18F]ISO-1 PET/CT scan
1593245|NCT02284906|Drug|Pioglitazone|Pioglitazone tablets
1593246|NCT02284906|Drug|Placebo|Pioglitazone placebo-matching tablets
2009198|NCT03318094|Drug|Phentolamine|Intrabrachial phentolamine will be given on the blocked day
2009199|NCT03318094|Other|Saline|Intrabrachial saline will be given this day
2009200|NCT03317847|Drug|Bromfenac 0.09 % Ophthalmic Solution|Patients will self-administer 1 drop of Bromfenac twice daily to the affected eye beginning 1 day after cataract surgery and then continuing through the first 14 days of the postoperative period.
2009201|NCT03317847|Drug|Dexamethasone 0.1% ophthalmic suspension|Patients will self-administer 1 drop of Dexamethasone to the study eye beginning 1 day after cataract surgery 4 times daily during the first postoperative week and 2 times daily in the second postoperative week.
2009202|NCT03317769|Other|Computerized Plasticity-Based Adaptive Cognitive Training|Training on computerized exercises that targets social cognition for 2 hours per week.
2009203|NCT03317769|Other|Commercially available computerized training|Training on computerized, casual video games for 2 hours per week.
1593253|NCT02284880|Drug|BIA 2-093|MF - Marketed formulation
1593254|NCT02284880|Drug|BIA 2-093|TBM - to-be-marketed
1593255|NCT02284867|Other|immunohistochemistry study|After taking informed written consent,a placental sample will be taken either the patient delivered preterm or at term (term patients will be either control term group or patients with successful treatment of preterm labor). The placental sample taken should have part of the decidua and then the sample will be fixed in 10% neutral-buffered formalin for 24-48 h, routinely processed, embedded in paraffin wax, sectioned at 3 μm thickness, and mounted on 3-aminopropyl-triethoxysilane -coated slides. Serial sections will be immunostained for CD 16 and CD56 . immunohistochemistry study will be done at Ain Shams Maternity Hospital Histopathology department.
1593256|NCT02284854|Drug|BIA 2-093|
1593257|NCT02284854|Drug|Carbamazepine|
1593258|NCT02284841|Device|Hilotherm cooling face mask|Hilotherapy - use of an external cooling device; a facial mask through which water circulates at a controlled temperature, allowing continuous cooling of the face, and is thought to reduce post-operative swelling and pain.
1593259|NCT02284828|Drug|BIA 2-093|
1593260|NCT02284815|Dietary Supplement|Glutenfree diet|Newly diagnosed children could choose glutenfree diet
1593261|NCT02284802|Procedure|Confocal endomicroscopy|Confocal endomicroscopy examination during endoscopy
1593262|NCT02284789|Other|Colorado Adult Joint Assessment Evaluation|Physical evaluation of 6 joints, ankles, knees and elbows
1593263|NCT02284776|Behavioral|Therapeutic education|People in hydrotherapeutic cure are following a program of Therapeutic Education. This program includes dietary advice, physical activities, behavior advice in order to change the lifestyle of the obese people.
1593264|NCT02284763|Other|EtCO2|Initial data collection during BCP was performed following three conditions were satisfied: after start of surgery; at least 15 min after BCP (for stabilization of MAP); after ventilation frequency was adjusted to produce EtCO2 of 27-29 mmHg with tidal volume of 8 ml/kg. Data was collected every 3 min after decreasing ventilation frequency by 1-2 breaths/min to increase EtCO2 until 42-45 mmHg. Once the value of EtCO2 42-45 mmHg was reached, ventilator frequency was increased in the same way to decrease EtCO2 until 27-29 mmHg. Fraction of inspired oxygen of 50% was maintained and end-tidal desflurane concentration was adjusted to achieve bispectral index values of 40-55 during data collection.
1593265|NCT02284750|Procedure|Percutaneous coronary intervention|
1593266|NCT02284737|Procedure|PADN|Contrast pulmonary artery angiography is performed to localize the pulmonary artery bifurcation level and to calculate the PA diameter. Once the anatomy is deemed acceptable, the radiofrequency ablation catheter is introduced into the distal bifurcation area of the main PA. The catheter is then maneuvered within the PA to allow energy delivery to ensure that the electrodes are tightly in contact with the endovascular surface. Two to three ablations at 1-15 W for 120 seconds at each point were performed in the distal bifurcation area of the main PA.
1593267|NCT02284737|Procedure|sham PADN|The radiofrequency ablation catheter placed, no ablations for patients in the sham PADN group.
1593268|NCT02284737|Drug|Sildenafil|Participants initially received 5 mg tadalafil for the first 2 weeks in the two groups. The tadalafil dose may have been up titrated to 40 mg after 2 weeks, with maximum effects being obtained. The up titrated of tadalafil to 40 mg was not mandatory if the investigator decided for tolerability reasons the participants should remain on 5 mg.
1593269|NCT02284724|Procedure|Dry Needling|
1593270|NCT02284724|Procedure|Sham Needling|
1593279|NCT02284646|Other|Personalized physical training program|9-week personalized physical training program (ergometric bicycle)
1593280|NCT02284620|Procedure|CFNB group|CFNB :A single injection of ropivacaine 30ml for femoral nerve block pre-operatively +0.15% ropivacaine 300ml for continuous femoral nerve block post-operatively guided by ultrasound and nerve stimulator.
1593281|NCT02284620|Procedure|LWI group|LWI: 48 ml of 0.8% ropivacaine with 2 ml of 40mg methylprednisolone for intra-articular and peri-articular wound infiltration intra-operatively in combination with intravenous patient controlled analgesia post-operatively.
1593282|NCT02284607|Drug|MHAA4549A|MHAA4549A single, intravenous dose administration, lower dose level
1593283|NCT02284607|Drug|MHAA4549A|MHAA4549A single, intravenous dose administration, higher dose level
1593284|NCT02284607|Drug|Placebo|Matching placebo to MHAA4549A administration
1593285|NCT02284594|Behavioral|text message|series of text messages regarding influenza vaccination
1593286|NCT02284568|Drug|Laquinimod|Laquinimod 0.6 mg, 1.5 mg
1593287|NCT02284568|Drug|Placebo|Placebo
1593288|NCT02284555|Drug|Mupirocin|Mupirocin (Bactroban 2% Nasal Ointment) will be administered twice daily for five days in accordance with the SmPC.
2009204|NCT03317769|Other|Optimized social skills training|Group-video calls with Specialist for 1 hour per week where participants can interact with Specialist individually or as a group. Specialist will provide guidance, support and feedback, and send links and articles about information and topics discussed during the video calls.
2009205|NCT03317769|Other|Unstructured support group sessions|Unstructured support group-video calls for 1 hour per week. The Specialist will not engage with participants (eg. providing participants with links to articles and additional support) or provide guidance for the group discussion.
1593291|NCT02284529|Drug|Orectalip|Oxaliplatin 85mg/m2 in D5W 250 ml IV drip 2hrs on D1, Leucovorin 100mg/m2 in N/S 100ml IV drip 2hrs on D1, follow by 5-FU 2400mg/m2 IV infusion 24hrs on D1
1593292|NCT02284516|Drug|Lifitegrast|Lifitegrast Ophthalmic Solution 5%, BID for 84 days
1593293|NCT02284516|Drug|Placebo|Placebo to match active treatment, BID for 84 days
1593294|NCT02284503|Drug|Rosuvastatin|The subjects will receive intensive Rosuvastatin before and after PCI
1593295|NCT02284490|Drug|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
1593296|NCT02284477|Other|non- PVC containing packing materials|Beverage which was stored in glass bottle for 24 hours in 4 ℃.
1593297|NCT02284477|Other|PVC containing packing materials|Beverage which was stored in PVC blood bag for 24 hours in 4 ℃.
1593298|NCT02284464|Drug|Prednisone withdrawal|Withdrawal of steroids
1593299|NCT02284464|Drug|Prednisone continuation|Continuation of steroids
1593300|NCT02284451|Other|Video or Pictorial Brochure|Participants will receive HIV/AIDS and HIV testing information by video or by pictorial brochure according to patient health literacy level (lower or higher) and language (English or Spanish).
1593301|NCT02284438|Device|Endotracheal tube|Three endotracheal tubes with different surfaces will be used
1593302|NCT02284425|Drug|REGN1193|
1593303|NCT02284425|Drug|Placebo|
1593304|NCT02284412|Drug|Neostigmine|At a train-of-four (TOF) ratio of 0.5: administration of neostigmine 0.06 mg/kg for reversal of neuromuscular blockade.
1593305|NCT02284412|Drug|Sugammadex|At a train-of-four (TOF) ratio of 0.5: administration of sugammadex 15 mg/kg for reversal of neuromuscular blockade.
1593306|NCT02284412|Drug|Water for injection|At a train-of-four (TOF) ratio of 0.5: administration of placebo for spontaneous recovery of neuromuscular blockade.
1593307|NCT02284399|Other|non-invasive prenatal testing|Noninvasive Prenatal Testing (NIPT) of fetal cell free DNA in maternal circulation
1593308|NCT02284386|Drug|Bupivacaine SNB|SNB with a single 1.6 mL dose of bupivacaine HCl 7.5 mg/mL within 2 hours prior to the surgical procedure.
1593309|NCT02284386|Drug|EXPAREL Infiltration|Local infiltration of EXPAREL 266 mg into the surgical site at the end of the surgery just prior to wound closure.
2009206|NCT03317730|Drug|Xtampza ER|Xtampza ER is a wax microsphere formulation of oxycodone that results in a nearly identical pharmacokinetic profile regardless of whether the capsule is intact when ingested or if ingested via enteral feeding tube as opposed to by mouth.
2009207|NCT03317496|Drug|Avelumab in combination with pemetrexed / carboplatin|Avelumab Pemetrexed Carboplatin
1593313|NCT02284360|Drug|APOSEC™ for cutaneous use|"On day 0, a blinded and randomized test treatment with Verum and Placebo is performed on intact skin. If the subject does not reveal any adverse events, the actual treatment phase is initiated 24h later.
Following baseline evaluation on day 1, two punch biopsies (4mm) on the inner upper side of the non-dominant arm are set under local anesthesia. One wound on the upper arm (proximal or distal) will be treated with placebo and the second wound will be treated with the allocated concentration of Verum according to previous randomization scheme set for test treatment. Approximately 1ml of Verum vs. placebo will be applied on the artificial wounds.
From day 2 to 6, artificial wounds will be cleaned with 0.9 % NaCl and then allocated treatment will be administered. Wound dressing will be done daily and will cover the whole area of application.
On day 7 the treatment is terminated and the wound is evaluated with respect the extension of wound closure."
1593314|NCT02284347|Device|Electromagnetic Sinus Dilation System (NuVent™)|NuVent navigation-guided balloon system may be used to locate and move tissue, bone or cartilaginous tissue obstructing the drainage pathways of the frontal, maxillary, and sphenoid sinuses that is scarred, granulated or previously surgically-altered to facilitate dilation of the sinus ostia.
1593315|NCT02284334|Other|test meal|low- or high-glycemic index test meal, administered during mixed meal tolerance test
1593316|NCT02284308|Other|Blood withdrawal|An extra withdrawal of blood, during a routine blood withdrawal. This is an optional inverventions for patients.
1593317|NCT02284295|Other|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
1593318|NCT02284295|Other|exposure to aromatic hydrocarbons|history of exposure to aromatic hydrocarbons due to job
1593319|NCT02284282|Drug|Spinal injection bupivacaine/morphine|Spinal injection bupivacaine/morphine in laparoscopic surgery
1593320|NCT02284282|Drug|subcutaneum injection lidocaine|placebo injection
1990341|NCT02077166|Drug|Ibrutinib|
1990342|NCT02077166|Drug|Lenalidomide|
1990343|NCT02077166|Drug|Rituximab|
1593321|NCT02284269|Drug|SGLT2 Inhibitors|Ipragliflozin (Suglat®), Dapaglilozin (Forxiga®), Tofogliflozin (Deberza® / Apleway®), Luseogliflozin (Lusefi®), Canagliflozin (Canaglu®), Empagliflozin (Jardiance®)
1593322|NCT02284256|Drug|Fibrocaps|
1593323|NCT02284256|Drug|TachoSil|
1593324|NCT02284243|Drug|Intranasal Dexmedetomidine|
1593325|NCT02284243|Drug|Intranasal Placebo|
1593326|NCT02284230|Drug|Liraglutide|
1593327|NCT02284230|Drug|Placebo|
1593328|NCT02284217|Device|EVD|ICP monitoring will be done in parallel for both HS-1000 and ICP monitoring via an EVD device (per clinical protocol without any change in the patient's management). HS-1000 ICP monitoring intervals will last from 30 minutes to 6 hours, continuously depending on the patient's clinical condition. Each such interval may occur three times a day or more depending on the clinical condition of the patient.
1593329|NCT02284204|Drug|Midazolam, Ketamine and Sevoflurane|The combination of these three drugs were administered for the children of the intervention group in a attempt to improve the behavioral control. Midazolam and ketamine orally, sevoflurane inhaled.
1593330|NCT02284204|Drug|Midazolam and Ketamine|The combination of these two drugs were administered orally for the children of the control group.
1593331|NCT02284191|Radiation|CT Coronary Angiogram|Completion of a CT Coronary Angiogram
2009208|NCT03317496|Drug|Avelumab in combination with gemcitabine / cisplatin.|Avelumab Gemcitabine Cisplatin
2009209|NCT03316911|Behavioral|MKit|MKit is a web-based application that uses a life-skills approach to address healthy relationships and sexual violence. It includes 14 tiles which incorporate information, goal setting, and resources.
1593334|NCT02284165|Other|retrospective analysis|Analysis of data for patients hospitalized in 2006-2008 with acute ischemic stroke, and successfully linked with Medicare claims through 2009
1593335|NCT02284152|Behavioral|infant-led feeding|mothers' feeding practices and infant intakes were compared between a typical feeding condition and an infant-led feeding condition, where the experimenter ensured the feeding was in response to infant hunger and fullness cues.
1593336|NCT02284139|Drug|Arm 1|EGF Ointment (Arm1 drug) evenly apply to skin lesion every 12 hr/ day
1593337|NCT02284139|Drug|Arm 2|EGF Ointment 20 (Arm 2 drug) evenly apply to skin lesion every 12 hr/ day
1593338|NCT02284126|Drug|Vancomycin|Topically applied powder and paste to surgical site at time of closure.
1593339|NCT02284113|Device|iovera°|Use of iovera° device to administer treatment Focused Cold Therapy
1593340|NCT02284113|Device|iovera° Sham|iovera° device used for sham treatment
1593341|NCT02284100|Behavioral|animal assisted therapy|"For the AAT session, a 7 year old Golden Retriever was employed as the therapy animal. Prior to the study, the dog underwent rigorous screening although she had previous experience in Animal Assisted Interventions and was already trained and prepared prior for this type of work. The dog was fully vaccinated, bathed regularly, screened for enteric pathogens, and treated for internal and external parasites on a monthly basis. The dog and handler met hospital policy for participating in animal-assisted therapy, including documentation of the dog's current vaccinations, controllability and temperament.
The welfare of the dog was monitored and certificated by a dedicated veterinary during and at the end of the all sessions."
1593342|NCT02284087|Device|PAS|
1593343|NCT02284074|Other|Nasal LPS spray|LPS solution (250µl) will be prepared at 10, 100, 300 and 1000µg/ml, 100µl is administered to each nostril, both nostrils will be sprayed. The dose per nostril corresponds to 1, 10, 30 and 100µg.
1593344|NCT02284061|Other|physical activities adapted to children|
1593345|NCT02284048|Drug|ticagrelor|compare the effect of ticagrelor and control on the Coronary Flow Reserve in patients with microvessel angian
2009210|NCT03315208|Behavioral|Unified Protocol (UP)|The Unified Protocol for Transdiagnostic Treatment of Emotional Disorders (UP) is an evidence-based psychological intervention designed to be applied across anxiety, depressive, and other disorders in which emotion dysregulation is central. The UP targets shared temperamental vulnerabilities to emotional disorders through emotion-focused CBT strategies.
2009211|NCT03315208|Other|Treatment as Usual (TAU)|Treatment as Usual consists of some combination of group therapy, individual therapy, and/or psychopharmacology appointments at an existing comprehensive outpatient program for adolescents and young adults with substance use disorders.
1593355|NCT02284022|Device|Brain computer interface|Recording the P300 Testing the device Using the device with a speller
1593356|NCT02284009|Biological|Albiglutide weekly injection|Albiglutide will be provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a subcutaneous (SC) injection in the abdomen, thigh or upper arm region. The pen will deliver either 30 mg of albiglutide, 50 mg of albiglutide in a 0.5-mL injection volume. It may be administered at any time of day without regard to meals. It will be administered once a week on the same day each week
1593357|NCT02284009|Biological|Placebo weekly injection|Placebo provided as a fixed-dose, fully disposable pen injector system having a prefilled dual chamber glass cartridge. To be self-administered as a SC injection in the abdomen, thigh or upper arm region. It may be administered at any time of day, once a week on the same day each week, without regard to meals.
1593358|NCT02284009|Biological|Insulin|Commercially available basal/bolus insulin regimen, self administered by the subject, in accordance to the prescription of the physician and as per the package insert
1593359|NCT02283996|Other|Physical Therapy|"The following link contains the protocol for physical therapy that will be used in the study. There are no other ancillary devices or drugs used in this study aside from the depot methylprednisolone listed under interventions.
Brigham and Women's/Massachusetts General Standard of Care Guidelines for Physical Therapy in Treatment of Adhesive Capsulitis:
http://www.brighamandwomens.org/Patients_Visitors/pcs/rehabilitationservices/Physical%20Therapy%20Standards%20of%20Care%20and%20Protocols/Shoulder%20-%20Adhesive%20capsulitis.pdf"
1593360|NCT02283996|Drug|Depot Methylprednisolone|40 mg of depot methylprednisolone in solution with 2 cc of 1% lidocaine
1593361|NCT02283983|Other|mittens and booties|
1593362|NCT02283983|Other|cooling helmet|
1593363|NCT02283957|Drug|CNTX-4975|
1593364|NCT02283957|Other|Placebo|
1593365|NCT02283944|Device|TMS|Pulsed non-invasive brain stimulation using electromagnets
1593366|NCT02283931|Device|TTE / NICOM|
1593367|NCT02283905|Drug|amphotericin-B|continuously infused
1593369|NCT02283892|Other|Checklist|3 page checklist with suggestions of possible diagnosis according to clinical presentation of patients presenting with dyspnea or cough; also suggests diagnostic tests that are likely to be useful in each situation.
1593370|NCT02283892|Other|Conventional evaluation|Physician evaluation without the use of checklists
1593371|NCT02283879|Biological|Human umbilical cord mesenchymal stem cells|A single dose of 2×107 hUC-MSC will treated to patients, IV, Repeat every weeks for four times.
1593372|NCT02283866|Drug|Administering desflurane according to the patient's BIS value|Administering desflurane according to the patient's BIS value
1593373|NCT02283866|Drug|Administering desflurane at 1 MAC|Administering desflurane at 1 MAC
1593374|NCT02283853|Drug|dimethyl fumarate|administered orally
1593375|NCT02283853|Drug|Interferon β-1a|administered by intramuscular injection
1593376|NCT02283840|Drug|BIA 2-093|
1593377|NCT02283827|Drug|BIA 2-093|
1593378|NCT02283827|Drug|Phenytoin|
1593379|NCT02283814|Drug|BIA 2-093|
1593380|NCT02283814|Drug|Topamax|
1593383|NCT02283788|Drug|BIA 2-093|
1593384|NCT02283788|Drug|Moxifloxacin|
1593385|NCT02283788|Drug|Placebo|
1593386|NCT02283775|Drug|isatuximab SAR650984|Pharmaceutical form:solution for infusion Route of administration: intravenous
1593387|NCT02283775|Drug|Pomalidomide|Pharmaceutical form:capsules Route of administration: oral
1593388|NCT02283775|Drug|Dexamethasone|Pharmaceutical form:tablets or solution for infusion Route of administration: oral or intravenous
1593389|NCT02283762|Drug|Riociguat (Adempas, BAY63-2521)|Starting dose 0.5 mg TID, increase by 0.5mg very 2 weeks until highest possible dose of 2.5 mg TID
1593390|NCT02283762|Drug|Placebo|Sham-titration
1593391|NCT02283749|Biological|Xofigo|This is a radio-isotope
1593392|NCT02283736|Other|Lactobacillus rhamnosus SP1|Tablet containing Lactobacillus rhamnosus SP1
1593393|NCT02283736|Other|Talc powder|Tablet containing talc powder
1593394|NCT02283736|Procedure|Periodontal treatment|Scaling and root planning
1593395|NCT02283723|Other|TAPESTRY Intervention|The patient will receive in-home visits from trained volunteers to assess overall health and wellness and discover any health goals patient might have. This information will be electronically communicated back to interprofessional healthcare team and used to create informed care plan, link to relevant community services and allow the patient to age optimally.
1593396|NCT02283723|Other|Usual care|While waiting for the TAPESTRY intervention, the control group will receive usual care from their healthcare providers.
1593397|NCT02283710|Drug|Pentoxifylline|Pentoxifylline 600 mg BD
1593398|NCT02283710|Behavioral|Lifestyle modification|obtaining ideal body weight by calorie restriction diet and programmed physical activity.
1593399|NCT02283697|Behavioral|Dietary Counseling|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician AND an additional one on one (family members allowed) one hour long counseling by certified dietician who will assess the patient's dietary habits, endorse and describe the DASH diet, and will establish four weekly half an hour follow ups by telephone to address compliance and any question raised by patient and family members.
1593400|NCT02283697|Other|Control: Standard Care|a standard endorsement of low salt diet and other non-pharmacological interventions such as moderation of alcohol intake, optimal body weight, daily exercise by hypertension nurse and physician
1593401|NCT02283684|Procedure|Greenlight laser PVP|Vaporization of the prostate adenoma using 532nm laser with 180W XPS system using Moxy fiber
1593402|NCT02283684|Procedure|Bipolar PKVP|Bipolar energy is used for generation of plasma that ends up by vaporization of the prostate adenoma
1593404|NCT02283658|Drug|Everolimus|Given PO
1593405|NCT02283658|Other|Laboratory Biomarker Analysis|Correlative studies
1593406|NCT02283658|Drug|Letrozole|Given PO
1593407|NCT02283645|Drug|3 % minoxidil lotion|
1593408|NCT02283645|Drug|Placebo|
1593409|NCT02283632|Procedure|Jejunal Diversion|The jejuno-jejunostomy surgical procedure is a well-known general surgical operation performed for multiple acute and chronic conditions including Crohn's disease, ovarian cancer, and small bowel obstruction. The jejunal diversion procedure is an adaptation of a jejuno-jejunostomy. The proximal end of the anastomosis is approximately 100 cm distal from the ligament of Treitz. The distal end of the anastomosis is approximately 250 cm proximal from the ileocecal junction.
1593410|NCT02283619|Other|None - no intervention, observational study|No intervention, observational study
1593411|NCT02283606|Device|Accuvix SnonAce UGEO|vaginal ultrasonography
1593412|NCT02283593|Behavioral|eChange.se|7 modules: 1. Making a decisional balance 2. Setting a goal for alcohol consumption 3. Learning self control skills 4. Identifying risk situations 5. Dealing with urges 6. Dealing with emotions and with social pressure 7. Developing a crisis plan
1593413|NCT02283580|Other|Single limb|"Low load, high-repetitive resistance training.
single limb at a time (e.g., one arm or one leg)
elastic bands
8 weeks
3 times/week,
each session 60 minutes
seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension
maximal number of repetitions (RM) * 3 sets in each exercise."
1593414|NCT02283580|Other|Two limb|"Low load, high-repetitive resistance training.
two limbs at a time (e.g., both arms or both legs)
elastic bands
8 weeks
3 times/week,
each session 60 minutes
seven resistance exercises: Latissimus row, leg curl, elbow flexion, chestpress, plantar flexion, shoulder flexion and knee extension
maximal number of repetitions (RM) * 3 sets in each exercise."
1593415|NCT02283554|Procedure|open flap debridement (OFD)|
1593416|NCT02283554|Other|Platelet rich fibrin (PRF)|
1593417|NCT02283554|Drug|Metformin|
1593418|NCT02283541|Behavioral|Automatic self-transcending meditation|ASTM is a category of meditation that helps quiet the mind and induce physiological and mental relaxation while the eyes are shut. It utilizes relaxed attention to a specific sound value (mantra) according to specific criteria, in order to draw attention inward.
1593419|NCT02283528|Device|Stryker Hybrid|Place Hybrid arch bars
1593420|NCT02283528|Device|Erich|Control group is Erich arch bars
1593421|NCT02283515|Drug|Rosuvastatin|Rosuvastatin (RSV) is one of new synthetic, second-generation, sulfur-containing, hydrophilic statin, a highly efficient competitive inhibitors of HMG CoA Reductase having important role in reducing serum cholesterol concentrations and lowers the risk of cardiovascular disease.
1593422|NCT02283502|Device|MRgHIFU system|Magnetic resonance-guided high-intensity focused ultrasound (MRgHIFU) system for the noninvasive treatment of uterine fibroids
1593423|NCT02283489|Drug|recombinant human endostatin adenovirus|"Specification: 1mL/division, 1.0×1012 virus particle (VP). ESD01 preparation: Thaw at room temperature, dilute with normal saline to required volume (no more than 2 mL).
Method of administration: Intratumor injection, once a week for 2 weeks, every 3 weeks for one cycle. Select only one target lesion even when lesions are present. The target lesion is the largest and easiest to inject. This will be fixed during the study."
1593424|NCT02283489|Drug|Cisplatin injection|Specification: 2ml: 10mg. Usage: 25mg/m2, days 1 to 3, according to instruction.
1593425|NCT02283489|Drug|Paclitaxel injection|Specification: 5ml: 30mg. Usage: 160mg/m2 intravenously on day 1, according to instruction.
1593426|NCT02283476|Drug|Endostar continuous intravenous infusion|Endostar,7.5mg/m2, continuous intravenous infusion for 14 days each cycle, 21 days as one cycle, 4 cycles in total.
1593427|NCT02283476|Drug|Endostar routine intravenous infusion|Endostar,7.5mg/m2, routine intravenous infusion 3-4 hours daily each cycle,21 days as one cycle, 4 cycles in total
1593428|NCT02283476|Drug|Gemcitabine|Gemcitabine,1000-1250mg/m2,i.v d1,d8 in each cycle,21 days as one cycle, 4 cycles in total
1593429|NCT02283476|Drug|Cisplatin|Cisplatin,75mg/m2,i.v d1 or d1-3 in each cycle,21 days as one cycle, 4 cycles in total
1593430|NCT02283463|Device|Intrauterine device (IUD) insertion|
1593431|NCT02283463|Procedure|Endometrial biopsy|
1593432|NCT02283450|Drug|Qiliqiangxin Capsule|
1593433|NCT02283437|Behavioral|Problem-solving Based Bibliotherapy Program|The PSBBP will complete the bibliotherapy (self-help) and problem-solving manual developed by the research team for caregivers of people with schizophrenia spectrum disorders.
1593434|NCT02283437|Behavioral|Psychoeducation Group Program|Two trained advanced practice psychiatric nurses who are experienced in psychiatric rehabilitation and group programs will lead the psychoeducation group, which is guided by a validated treatment protocol based on the research team's (Chien and Wong, 2007) and McFarlane et al.'s (2001) psychoeducation programs for schizophrenia.
1593435|NCT02283424|Drug|Icotinib|compared with chemotherapy,which is better for lung adenocarcinoma patients with epidermal growth factor receptor gene mutation after surgery
1593436|NCT02283424|Drug|chemotherapy (Carboplatin and Docetaxel)|as control group,compared with Icotinib
2009212|NCT03316716|Procedure|active warming|Women randomised to the intervention group will be administrated warm IV fluids (39°C) consisting of Hartman's solution with the use of the theatre's Hotline™ device. The Hotline™ device is set to 39°C in which the Hartman's solution bags will be infused to the women peri-operatively.
1593438|NCT02283398|Other|without RIPC|the cuff will be placed around the left arm without being inflated
1593439|NCT02283398|Procedure|RIPC|RIPC will be induced with three cycles of inflation of a blood-pressure cuff on the left arm to 200 mm Hg for 5 min, followed by 5 min of reperfusion while cuff deflated
1593440|NCT02283385|Behavioral|PROTECT|8-session weekly psychotherapy intervention that combines problem-solving therapy, anxiety management and psycho education developed specifically for this population
2009213|NCT03316573|Drug|Pembrolizumab|The study drug is an antibody that targets a molecule called PD-1. Blocking PD-1 allow the immune system to attack the cancer more effectively.
2009214|NCT03315936|Drug|BI 894416|single-rising dose
2009215|NCT03315936|Drug|Placebo|single-rising dose
1593444|NCT02283359|Drug|Selinexor|Selinexor is a potent slowly reversible covalent Selective Inhibitor of Nuclear Export (SINE) that specifically blocks the karyopherin protein Exportin 1 or XPO1.
1593445|NCT02283359|Drug|Irinotecan|Irinotecan is a topoisomerase inhibitor and is approved by FDA to treat colorectal cancer. It is administered intravenously.
1593446|NCT02283346|Radiation|HDR brachytherapy + hypofractionated EBRT|"Single Fraction High Dose Rate (HDR) Brachytherapy One fraction with 10-15 Gray (Gy) (depending on normal tissues constraints).
+ Hypofractionated External Beam Radiotherapy (EBRT) The treatment will be held with fractions 2.5 Gy per day, with a final dose between 25 and 50 Gy (depending on normal tissues constraints)."
1593447|NCT02283333|Behavioral|BATE-G|Behavioral Activation and Therapeutic Exposure - Grief therapy are delivered in 7 weekly sessions to the participant.
1593448|NCT02283333|Behavioral|Standard Treatment|Cognitive Restructuring and Supportive Grief Counseling are delivered in 7 weekly sessions to the participant.
1593449|NCT02283320|Drug|BIND-014 (Docetaxel Nanoparticles for Injectable Suspension)|
1593450|NCT02283307|Other|Reduced contrast DECT scan|Subjects will undergo a dual energy CT scan with reduced contrast
1593451|NCT02283307|Other|Standard contrast SECT scan|Subjects will undergo standard of care single energy CT scan with a standard dose of contrast. (control)
1593452|NCT02283294|Drug|Apixaban|
1593453|NCT02283294|Drug|Warfarin|
1593454|NCT02283281|Drug|Tetrahydrocannabinol|1:1 THC to CBD standardized extract from cannabis plant
1593455|NCT02283281|Drug|Acetaminophen|50 ml intravenous vial
1593456|NCT02283281|Drug|Midazolam|2 ml prefilled syringe
1593457|NCT02283281|Drug|Dummy oromucosal spray|Oromucosal spray containing only alcohol vehicle without the active compound (i.e.: without nabiximols)
2009216|NCT03315871|Biological|PROSTVAC-V|Recombinant vaccinia virus vector vaccine of the genus Orthopoxvirus. Administered by subcutaneous injection.
1593459|NCT02283255|Other|Physical Activity|Physical Activity, Exercise training: aerobic and respiratory exercise with POWERbreathe device
1593460|NCT02283242|Drug|Galantamine|Oral use for 12 weeks
1593461|NCT02283242|Drug|Placebo (for galantamine)|Oral use for 12 weeks
1593462|NCT02283229|Behavioral|Newborns with preventive caring advices|Advices to prevent head molding
1593463|NCT02283229|Other|Newborns with normal caring advices|Normal handling
1593464|NCT02283216|Device|noise sound stimulation (Tucker-Davis Technologies)|Band-limited white noise stimulus, comfortable loudness level, presented via headphones or earphones with Tucker-Davis Technologies device.
1593465|NCT02283216|Device|body electrical stimulation (Digitimer device)|Single pulse electrical stimulation on different body regions, comfortable current level, presented via surface pads or clips with Digitimer device.
1593466|NCT02283216|Device|transcranial magnetic stimulation (Magstim)|Single pulse magnetic stimulation over frontal cortex, comfortable level at 110% resting motor threshold, presented via magnetic coil with Magstim device.
1593467|NCT02283203|Drug|APOTEL max|The study drug is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein.
1593468|NCT02283203|Drug|Placebo|Placebo is provided in a form of bag with 100ml final volume and it is directly connected to the infusion device that leads to a catheter already cannulated in one antecubital vein. Placebo contains water for injection and inactive vehicles.
1593469|NCT02283190|Drug|Erwinase|Six doses of Erwinase, given Monday-Wednesday-Friday for 2 weeks. Dosage levels to be used are: 20,000 IU/ m2 /day, 25,000 IU/ m2 /day, 30,000 IU/ m2 /day.
1593470|NCT02283177|Drug|crenolanib|
1593471|NCT02283177|Drug|cytarabine|
1593472|NCT02283177|Drug|daunorubicin|
1593473|NCT02283177|Drug|idarubicin|
1593474|NCT02283164|Behavioral|Hazardous materials online education and study feedback|Participants will receive a 45-minute educational webinar on hazardous materials handing best practices at the beginning of the intervention period. Subsequently they will receive quarterly feedback of interim study results.
1593475|NCT02283151|Dietary Supplement|diet nutrition bar|The experimental group was given individual instructions on how to follow the VLCD (very low carbohydrate diet). Energy intake was restricted to less than 800kcal/day (3349kJ/d) (carbohydrate intake < 20g/d). All daily meals were replaced as follows: a cup of soybean milk (200 mL) and a boiled egg at breakfast; a diet nutrition bar(Nutriease Health Technology Co., Ltd., Hangzhou, China), nonstarchy vegetables (<200 kcal), and 50 g protein from meat at lunch and dinner. Supplementation of multivitamins and minerals was provided per day.
1593476|NCT02283151|Other|energy-restricted diet|The control group was given an energy-restricted diet (ER diet). Energy-restricted diet was designed in the traditional Chinese style with an initial target for a total energy intake of 1200 kcal/d (5021 kJ/d).
1593477|NCT02283112|Other|antivirals, antimicrobials, oral contraceptive, erectile dysfunction agents|
1593478|NCT02283099|Biological|rVSVΔ-ZEBOV-GP|single dose of rVSVΔ-ZEBOV-GP (3x10^6 pfu, 2x10^7 pfu or 3x10^5)
1593479|NCT02283086|Behavioral|Physician Feedback Reporting|The performance feedback reports displayed both individual physicians' statistics as well as their performance compared to anonymized results for the entire group of emergency physicians.
1593480|NCT02283060|Drug|Stribild|To be administered orally, once daily with food.
1593481|NCT02283060|Drug|Atripla|To be administered orally, once daily at bedtime on an empty stomach
1593482|NCT02283047|Behavioral|DIET|Lifestyle intervention through hypocaloric diet
1593483|NCT02283047|Behavioral|DIET & MODERATE CONTINUOUS TRAINING|Lifestyle intervention through hypocaloric diet and exercise at moderate intensity (60-80%peakHR) continuous mode, and high volume (45 min).
1593484|NCT02283047|Behavioral|DIET & HIGH VOLUME HIIT|Lifestyle intervention through hypocaloric diet and exercise at high intensity (80-95%peakHR) interval mode, and high volume (45 min).
1593485|NCT02283047|Behavioral|DIET & LOW VOLUME HIIT|Lifestyle intervention through diet and exercise at high intensity (80-95%peakHR) interval mode, and low volume (20 min).
1593486|NCT02283034|Device|The CPRmeter|Feedback device - 1
1593487|NCT02283034|Device|The PocketCPR|Feedback device - 2
1593488|NCT02283034|Device|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
1593489|NCT02283034|Device|The CPREazy|Feedback device - 3
1593490|NCT02283034|Device|The CPR PRO APP|Feedback device - 4
1593491|NCT02283034|Device|The CardioPump|Feedback devices - 5
1593492|NCT02283034|Device|Standard BLS|Chest compressions without CPR feedback device (manual resuscitation)
1593493|NCT02283021|Other|A biopsy sample|Sample tissue will be obtained from the routine biopsy taken for pathological evaluation. A pathologist will determine which part of the tissue will be forwarded for this study, to avoid any interference with the pathological evaluation.
1593494|NCT02283008|Behavioral|Assessment of inhaler technique pre and 6 weeks post training|Assessment of inhaler technique on day one. Education package and training on inhaler use at week 2. Final assessment to establish maintenance of inhaler competence at week 8
1593495|NCT02282969|Behavioral|Interviews|Interviews performed by study staff encompassing lung cancer screening and patient decision aids.
1593496|NCT02282969|Behavioral|Questionnaires|Questionnaires completed after viewing patient decision aid video. Questionnaires also completed regarding lung cancer screening knowledge at first visit, then again in one month.
1593497|NCT02282956|Drug|Ropivacaine 0,75%|Ropivacaine injection
1593498|NCT02282956|Procedure|posterior tibial nerve block|ultrasound guided posterior tibal nerve block
1593499|NCT02282956|Drug|morphine and droperidol|i.v PCA
1593500|NCT02282943|Device|Laser|Vapourisation/excision of endometriosis AFS stages I-III using CO2 laser
1593501|NCT02282943|Device|Harmonic scalpel|Excision of endometriosis using Harmonic scalpel
2009217|NCT03315871|Biological|PROSTVAC-F|Recombinant fowlpox virus vector vaccine of the genus Avipoxvirus. Administered by subcutaneous injection.
1593503|NCT02282917|Drug|AR-42|AR-42 will be administered in a total of ten oral doses, +/- 1 dose, at 40 mg/dose, will be self-administered by study participants at approximately 8:00pm (+/- 1 hour) for 3 weeks pre-operatively, with the last dose being administered the night before surgery. The treating surgeon will perform the clinically indicated surgical procedure 3 weeks post-initial dose of medication as well as the specimen collection.
2009218|NCT03315871|Drug|MSB0011359C (M7824)|Fully human bi-functional fusion protein that combines lgG1 anti-PD-L1 and TGFbetaRII as a monoclonal antibody administered visa IV infusion over 1 hour.
2009219|NCT03315871|Biological|CV301|Recombinant vaccinia virus vaccine of the genus Avipoxvirus. Administered subcutaneously.
2009220|NCT03314116|Other|Guidance on auditory protection|by video or medic
2009221|NCT03314805|Drug|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), 3 days via i.v. infusion per chemotherapy cycle
1593508|NCT02282891|Drug|Propofol|Induction of general anesthesia using propofol 2mg/kg
1593509|NCT02282891|Drug|Propofol-Ketamine|Induction of general anesthesia using a mixture of 1.5 mg/kg:0.75 mg/kg propofol/ketamine
2009222|NCT03314805|Drug|Placebo|500 ml saline, 3 days via i.v. infusion per chemotherapy cycle
1593511|NCT02282852|Device|Wireless Capsule Endoscopy|
1593512|NCT02282852|Device|Magnetically steerable capsule endoscopy|
1593513|NCT02282839|Dietary Supplement|Glutamine|Powder that soluble in water for drinking, 10g TID (total 30 g per day)
1593514|NCT02282839|Dietary Supplement|Placebo|Powder that provided by manufacturer with the same ingredients yet without glutamine, TID use
1593515|NCT02282826|Drug|GZ402668|Pharmaceutical form:solution Route of administration: intravenous
1593516|NCT02282826|Drug|placebo|Pharmaceutical form:solution Route of administration: intravenous
1593517|NCT02282826|Drug|GZ402668|Pharmaceutical form:solution Route of administration: subcutaneous
1593518|NCT02282826|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
1593519|NCT02282826|Drug|acyclovir|Pharmaceutical form:tablet Route of administration: oral
1593520|NCT02282813|Drug|CTAP101 Capsules|At week 12, eligible subjects will continue to take 1-2 capsules (30 mcg each capsule) CTAP101 daily
1593521|NCT02282813|Drug|Calcitriol|At week 12, eligible subjects will be randomized to also take calcitriol 0.25 mcg dose one capsule daily
1593522|NCT02282813|Drug|Doxercalciferol|At week 12, eligible subjects will be randomized to also take doxercalciferol 0.5 mcg one capsule daily
1593523|NCT02282813|Drug|Paricalcitol|At week 12, eligible subjects will be randomized to also take paricalcitol 1 mcg one capsule daily
1593524|NCT02282800|Genetic|Vitamin D receptor|50-100mg gingival tissue samples were collected from both test and control group for immunohistochemical staining to assess the number of vitamin D receptors in nucleus as well cytoplasm and also for RNA isolation to check the presence of VDR gene.
1593525|NCT02282787|Drug|DEXMEDETOMIDINE|Does adding 5 or 10 micron of DEXMEDETOMIDINE to peribulbar anesthesia is any different from regular peribulbar anesthesia practice?
1593526|NCT02282774|Drug|2% lidocaine and 0.5% bupivacaine|Under general anesthesia and the operating microscope, a Lieberman lid speculum was placed and the conjunctiva was cleaned with 4% povidone iodine solution. The surgeon then created a fornix-based incision through conjunctiva and tenon's tissue inferonasally midway between the insertions of the medial and inferior rectus muscles, with blunt Wescott scissors to expose the scleral surface before tunneling posteriorly with curved Stevens scissors to create a small channel to the posterior subtenon space. A blunt-tipped subtenon cannula was then inserted into the posterior subtenon space, 4mL of 2% lidocaine and 0.5% bupivacaine (50:50) mixture versus saline was introduced and the drug solution was injected slowly into the subtenon space. After administration of local anesthetic mixture, the eyelid was gently taped down, and no ocular massage was performed
1593527|NCT02282774|Drug|Sham subtenon block|
1593528|NCT02282761|Drug|ITI-007|
1593529|NCT02282761|Drug|Placebo|
1593530|NCT02282748|Other|No intervention|
2009223|NCT03314805|Procedure|EC Chemotherapy|Epirubicin plus Cyclophosphamide every 21 days
2009224|NCT03314064|Drug|DTG 50 mg|DTG is an integrase inhibitor that has been developed for ART of HIV-infection in combination with other antiretrovirals. DTG will be available as 50 mg tablets to be administered once daily.
1593533|NCT02282709|Drug|Daclatasvir|60 mg once daily
1593534|NCT02282709|Drug|asunaprevir|100 mg BID
1593535|NCT02282696|Other|Questionnaire, focus group participation|participants of the quantitative part of the study are asked to fill in a questionnaire, participants of the qualitative part are asked to participate in a focus group interview.
1593536|NCT02282683|Drug|prednisone|Prednisone (10 to 20 mg/day, orally) combined with maximum tolerated guideline-directed medical therapy for at least 12 months
2009225|NCT03313804|Drug|Immune checkpoint inhibitor|Standard of care immune checkpoint inhibitor
1593539|NCT02282657|Device|ECCO2R will be initiated during the 2-hour run-in time|"A single (15.5 to 19 Fr) veno-venous ECCO2R catheter will be inserted percutaneously (jugular vein strongly suggested).
Catheters should be rinsed with heparinized saline solution before insertion Once the catheter has been inserted each line will be filled with an heparinized saline solution before its connection to the extracorporeal circuit The ECCO2R circuit will be connected to the catheter and blood flow set, depending on the device, up to 1000 mL/min.
Initially, sweep gas flow through the ECCO2R device will be set at zero (0 LPM) such as to not initiate CO2 removal through the device.
Anticoagulation will be maintained with unfractionated heparin to a target aPTT of 1.5 - 2.0X baseline. A bolus of heparin is suggested at the time of cannulation."
1593540|NCT02282657|Other|Neuromuscular blocking agents (NMBA)|Patients will receive NMBA starting in the run-in period and continued for the first 24 hours and thereafter will be directed by the attending physician
1593541|NCT02282657|Device|Ventilation|Following the 2-hour run-in time, VT will be reduced gradually to 5 mL/kg. Sweep gas initiated then VT decreased to 4.5 then 4 mL/kg and PEEP adjusted to reach 23 ≤ Pplat ≤ 25 cm H2O.
1593542|NCT02282657|Other|Level of carbon dioxide released at the end of expiration|EtCO2 will be monitored for safety purposes. Blood gases will be analyzed 20-30 minutes after each VT reduction
1593543|NCT02282657|Other|Respiratory Rate|RR will be kept what it was at baseline
1593544|NCT02282657|Other|Sweep gas flow|Sweep gas flow will be adapted to maintain the same EtCO2
1593545|NCT02282657|Other|Ventilation will be adapted|If PaCO2> 75 mmHg and/or pH < 7.2, despite respiratory rate of 35/min and optimized ECCO2R, VT will be increased to the last previously tolerated VT.
1593546|NCT02282657|Other|Respiratory rate will be adapted|If PaCO2 remains within the target range, respiratory rate will be progressively decreased to a minimum of 15/ min and facilitated by increases in sweep flow.
1593547|NCT02282644|Biological|Bone marrow sampling|
1593548|NCT02282631|Behavioral|Incentive scheme|Children who actively travel to school, full or partway, enter a weekly £5 voucher draw, whereby chances of winning are proportional to the number of trips as reported by the parent.
1593549|NCT02282618|Device|Cardiac Sympathetic Blockade|
1593550|NCT02282605|Drug|XF-73 nasal gel|
1593551|NCT02282605|Drug|Placebo nasal gel|
1593552|NCT02282605|Other|Chlorhexidine gluconate 2% topical cloths|
1593553|NCT02282592|Other|Observation about the presence of metabolic syndrome|
1593554|NCT02282579|Drug|Pazopanib|Non interventional study
1593555|NCT02282566|Other|Protein-nutrition beverage|Intervention involves consumption of one protein-nutrition beverage after exercise bout and 2 times per day for 5 days thereafter
1593556|NCT02282553|Device|Magnetically steerable pill camera (Microcam Navi, Intromedic Ltd, Seoul, Korea)|Capsule endoscopy uses a swallowable pill camera which passes through the GI tract by the action of peristalsis. The procedure utilizes a battery powered wireless capsule to transmit images of the gastrointestinal tract as it passes through the small intestine. The images are later downloaded to a computer and reviewed by a trained physician. Magnetically steerable gastric capsule endoscopy uses a pill camera containing a small amount of magnetic material, that can be manoeuvred in the gut and intestine by the physician using a handheld magnet.
1593557|NCT02282553|Device|Flexible endoscope|The current standard for investigation of upper gastrointestinal disorders is flexible endoscopy; oesophagogastroduodenoscopy (OGD), also known as gastroscopy.
1593558|NCT02282540|Procedure|Iodixanol to the Eustachian tube|Application of iodixanol to the middle ear for imaging of the ET.
1593559|NCT02282527|Biological|Liquid Alpha₁-PI|Liquid Alpha₁-PI, 60 mg/kg, 8 weekly intravenous infusions
1593560|NCT02282527|Biological|Prolastin-C|Prolastin-C, 60 mg/kg, 8 weekly intravenous infusions
1593561|NCT02282514|Biological|Autologous Hematopoietic Stem Cell Transplantation|The stem cells will be collected from patient's blood during mobilization. Then the patient will be given high dose chemotherapy in accordance with approved recommendations for use in conditioning regimens for stem cell transplant in autoimmune diseases. Autologous Hematopoietic Stem Cell Transplantation is to re-infuse immature cells that can re-establish blood production and patient's immune system.
1593562|NCT02282501|Other|enteral feeding by nasogastric tube.|method of administration enteral feeding by nasogastric tube.
1593563|NCT02282488|Other|Low protein formula|
1593564|NCT02282488|Other|High protein formula|
2009226|NCT03313804|Radiation|Radiation Therapy|Stereotactic Body Radiation Therapy OR Fractionated radiation therapy
2009227|NCT03313336|Drug|EMLA test patch|EMLA® Test Patch containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc. The source of cellulose for the cellulose disc will be provided from a new supplier in this test patch.
2009228|NCT03313336|Drug|EMLA current reference patch|EMLA current Reference Patch, containing the active ingredients lidocaine base 25 mg/g and prilocaine base 25 mg/g in an oil-in-water emulsion saturating the absorbent cellulose disc.
1593571|NCT02282449|Device|Power Injectable Port (AngioDynamics Smart Port CT Mini)|The subjects will all receive power injectable port.
1593572|NCT02282449|Device|Non-Power Injectable Port (Cook Vital Mini Port)|The subjects will all receive non-power injectable port.
1593573|NCT02282436|Other|No specific intervention for this study|No specific intervention for this study
1593574|NCT02282423|Behavioral|Pre-study dietary and exercise instruction.|All subjects will be instructed to continue their normal diet during the three days prior to study, to not consume alcohol the day before study, and to not engage in exercise for 48 hours before all studies.
1593575|NCT02282423|Procedure|Screening examination and oral glucose tolerance test|All subjects will have screening exam and OGTT at the Clinical Studies Infusion Unit at Mayo Clinic in Arizona at 7-8 am after having eaten nothing after 10 PM the night before, and have a screening examination and 75 g OGTT, as described
1593576|NCT02282423|Procedure|Euglycemic clamp|On a separate day, subjects will have a two-hour euglycemic clamp ((80 mU insulin/(m2.min)) at the Clinical Studies Unit at Mayo Clinic Arizona at 7-8 am after an overnight fast. A muscle biopsy will be taken before the insulin infusion, to serve as the resting biopsy (3). Biopsy specimens (150-300 mg) will be frozen immediately in liquid nitrogen and stored in liquid nitrogen until they are processed
1593577|NCT02282423|Procedure|VO2max.|VO2max.
1593578|NCT02282423|Behavioral|Acute exercise bout|The single acute exercise bout will be performed as described (3). It consists of 4 sets of 12 min each (8 min @ 70% VO2max, 2 min @ 90%, 2 min rest, repeat X 4). Biopsies are taken 30 min and 24 hr after end of exercise. Resting biopsies are taken on the glucose clamp day
1593579|NCT02282423|Procedure|Percutaneous needle muscle biopsies|Skeletal muscle biopsies, blotted free from blood, are frozen within 30 seconds in liquid nitrogen, and stored in liquid nitrogen until processing. We routinely obtain 150-300 mg muscle (wet weight), which is more than sufficient for the analyses proposed, with some muscle remaining for any additional validation assays that may arise during the course of the research. Muscle will be processed either for isolation of mRNA/microRNA or protein, as described (2, 3, 12).
1593580|NCT02282410|Drug|ADVATE|The baseline ABR will be assessed from bleeding log and clinic records from preceding year. Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2-3 times one week with ADVATE for 1 year.
1593581|NCT02282397|Device|Continuous Glucose Monitor|RT-CGM are adjunctive devices with glucose trend graphs and user-configurable low and high glucose alerts.
1593582|NCT02282384|Drug|oseltamivir|They will be assessed for eligibility at the clinics and those randomized to the intervention will receive oseltamivir 75 mg orally twice daily for 5 days within 72 hours of symptom onset. Participants randomized to the control group will receive calcium carbonate placebo pills twice daily for five days within 72 hours of symptom onset. For patients with a known creatinine clearance < 10 ml/min, the recommended dose of 75mg orally daily for 5 days of either intervention or placebo will be administered.
1593583|NCT02282371|Drug|Cetuximab|
1593584|NCT02282371|Drug|BYL719|
1593585|NCT02282371|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|
1593586|NCT02282358|Drug|Mocetinostat|
1593587|NCT02282345|Drug|Talazoparib|1 mg by mouth daily for 6, 28 day cycles.
1593588|NCT02282332|Drug|Ticagrelor|
1593589|NCT02282319|Drug|spinal dexmedetomidine 0.5 mcg|Administration of dexmedetomidine 0.5 mcg
1593590|NCT02282319|Other|spinal chloroprocaine 40 mg|spinal anesthesia with chloroprocaine 40 mg
1593591|NCT02282319|Drug|IV dexmedetomidine 0.5 mcg/kg|intravenous administration of dexmedetomidine 0.5 mcg/kg
1593628|NCT02281981|Dietary Supplement|Placebo|OAHTCUR005-2014
1593986|NCT02279407|Drug|Dapagliflozin|10 mg administered as 10 mg tablet
1593592|NCT02282306|Behavioral|TTIP-PRO|The peer-delivered TTIP-PRO intervention is designed to: 1). increase the patient's knowledge of risk factors for OOD, with a particular emphasis on the patient's personal risk factors. This aim is one of harm reduction and is intended to help patients who continue to abuse opioids to use in a safer manner and 2).For patients who are open to considering treatment, to encourage the patient to get treatment for his/her opioid use disorder. This goal is based on research findings that effective treatment reduces the risk of OOD.
1593593|NCT02282293|Drug|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
1593594|NCT02282293|Drug|Monthly dihydroartemisinin-piperaquine (DP) for infants|
1593595|NCT02282293|Drug|Placebo|
1593596|NCT02282280|Drug|Prilocaine Chlorhydrate|Use of prilocaine in spinal anesthesia
1593597|NCT02282267|Drug|Gefitinib|Iressa 250mg oral daily
1593598|NCT02282254|Other|Overnight intervention|Subjects will be admitted at the research facility at 19:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. On dual-hormone closed-loop visits, glucagon will be reconstituted according to the manufacturer's instructions and a MiniMed® Paradigm® Veo™ pump containing the glucagon solution will be installed. At 20:30, a snack containing 20g of carbohydrate will be given. Closed-loop strategy will start at 20:00 until 7:00 next morning. A glucose sensor reading will be entered manually in a tablet every 10 minutes. The tablet will generate a recommendation for the basal rates of insulin delivery and glucagon mini-boluses (glucagon recommendations will only be generated during the dual hormone closed-loop visits). Pumps' parameters will then be changed manually to implement the tablet generated recommendations.
1593599|NCT02282241|Drug|Melatonin|
1593600|NCT02282241|Other|Placebo|
1593601|NCT02282228|Device|Medfield Strokefinder MD100|Measurement with Medfield Strokefinder MD100.
1593602|NCT02282215|Biological|CLT-008|Single intravenous infusion
1593603|NCT02282215|Biological|G-CSF|Daily subcutaneous injections
1593604|NCT02282202|Device|Oscillating Positive Expiratory Pressure (Aerobika ®)|"The oPEP system (Aerobika ®) combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy (Aerobika ®) enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
There is only one intervention for this study. Subjects are on treatment for three weeks and off for the alternate three weeks."
1593605|NCT02282189|Device|Oscillating Positive Expiratory Pressure (Aerobika ®)|The oPEP system combines positive expiratory pressure therapy and airway vibrations to help mobilize pulmonary secretions. oPEP therapy enforces a resistance to exhalation at the mouth, while the airway vibration technology transmits movements upstream during exhalation so that airway walls may become free from mucous. Subjects will take home the device and use four times daily during the active part of the study.
1593606|NCT02282176|Drug|Azithromycin|Azithromycin IV 10mg/kg daily for 10 days
1593607|NCT02282176|Drug|Placebo|Azithromycin placebo (5% Dextrose) daily for 10 days
1593608|NCT02282163|Drug|sulphur hexafluoride lipid-type A microspheres|Ultrasound imaging contrast agent
1593609|NCT02282150|Drug|Hydrocortisone|Usual hydrocortisone dosage regimen; 10-40 mg hydrocortisone administered twice or thrice daily for 5 weeks
1593610|NCT02282150|Drug|Plenadren|10-40 mg modified-release hydrocortisone in tablets, once a day for 16 weeks
1593611|NCT02282137|Drug|68Ga-PSMA|Patients with suspected prostate cancer recurrence and non-informative bone scintigraphy, computerized tomography (CT) or magnetic resonance imaging (MRI). Suspected prostate recurrence is based upon elevated blood prostate specific antigen (PSA) levels following initial therapy.
1593614|NCT02282111|Device|22-gauge Procore needle (ProCore, Cook Medical Inc., Winston-Salem, NC)|A core-needle will be used to take a biopsy from the subepithelial lesion
1593615|NCT02282111|Device|conventional needle-knife sphincterotome (Microknife XL; Boston Scientific Inc, Natick, Mass)|Needle knife sphincterotome will be used to take a biopsy of the subepithelial lesion
1593616|NCT02282098|Drug|Colchicine|Colchicine 0.6mg twice daily
1593617|NCT02282098|Drug|Placebo|Placebo Colchicine
1593618|NCT02282085|Drug|Aripiprazole Once-Monthly|
1593619|NCT02282085|Drug|Oral Antipsychotic (i.e. aripiprazole, risperidone, lurasidone, quetiapine, olanzapine, ziprasidone, etc)|Oral antipsychotic medication
1593620|NCT02282072|Device|Deep brain stimulation：PINS Stimulation System|
1593622|NCT02282033|Device|The Moderato System|The BackBeat Moderato System incorporates traditional pacing modes and algorithms to provide pacing support to patients with all conditions currently indicated for dual chamber pacing. In addition, a special pacing algorithm was developed to reduce blood pressure.
2009229|NCT03313336|Drug|Placebo Patch|Placebo Patch, based on the EMLA Test Patch (incorporating the absorbent cellulose disc with cellulose from the current supplier), where the absorbent disc will be saturated with a placebo oil-in-water emulsion, where the eutectic mixture of lidocaine and prilocaine is replaced with fractionated coconut oil and chlorhexidine digluconate 20%, with identical appearance to the active EMLA patches.
2009230|NCT03313180|Drug|Nintedanib|Administered twice daily
1593625|NCT02282007|Behavioral|Individual NPMP to the participants|The participants in the intervention group will receive NPMP individually adjusted for six months. NPMP is not a standardized treatment approach, but individually adjusted to the individual patient according to their individual problems.
2009231|NCT03312400|Drug|Danazol|"Adult: 200 mg daily versus 400 mg daily;
Pediatric: 4 mg/kg/day divided in twice daily dose (max 400 mg daily) for 6 months or 2 mg/kg/day divided in twice daily dose (max 200 mg daily) for 6 months."
1593627|NCT02281981|Dietary Supplement|Curcumin|333mg CurcuWin OAHTCUR002-2014
1593629|NCT02281968|Drug|Naproxen|Standing regimen of naproxen in experimental group to reduce need for narcotic to control pain
1593630|NCT02281968|Drug|Placebo|
1593631|NCT02281955|Radiation|Intensity Modulated Radiotherapy (IMRT)|All patients will receive Intensity Modulated Radiotherapy Treatments (IMRT). Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day respectively. The PTV-HR will include the gross tumor and the PTV-SR will include areas at risk for harboring subclinical microscopic disease.
1593632|NCT02281955|Drug|Cisplatin (or alternative)|Cisplatin is the preferred mandated first choice chemotherapy, however alternative weekly regimens are permissible. Justification for not using cisplatin must be documented. Chemotherapy will be given intravenously weekly during IMRT. 6 total doses will be given. It is preferred that the doses be administered on days 1, 8, 15, 22, 29, and 36; however, this is not mandatory. Chemotherapy will not be given to patients with T0-2 N0-1 disease, ≤ 10 pack years smoking history.
1593633|NCT02281955|Procedure|Assessment for surgical evaluation|Decisions for surgical evaluation will be based on the results of the PET/CT 10 to 16 weeks after CRT and clinical exam (including fiberoptic laryngoscopy) at that time. Other optional imaging studies may be performed. Patients with a positive PET/CT scan will undergo surgical evaluation at the discretion of the surgeon, with the goal being to remove any suspected residual tumor with a negative resection margin while maintaining organ preservation. This may include biopsies and/or oncological resections of the primary tumor and lymph node metastases. Patients with a negative PET/CT scan will be observed.
1593634|NCT02281942|Behavioral|Yoga|
1593635|NCT02281942|Behavioral|Education|
1593636|NCT02281929|Drug|Amoxicillin|Amoxicillin+clavulanic acid at a daily dose of 3 gram / 375 mg in three daily doses of 1g/125mg, during 30 days
1593637|NCT02281929|Drug|Placebo|Placebo in three daily doses during 30 days
1593638|NCT02281929|Drug|Prednisolone|Prednisolone at 40 mg/j in a single daily dose in the morning, during 30 days
1593639|NCT02281916|Drug|P28GST|3 injections of 100 µg of P28GST within 3 months (one injection per month)
1593640|NCT02281903|Device|The TrueCPR feedback device|feedback devices
1593641|NCT02281903|Device|Standard BLS|Standard basic life support = chest compressions without any feedback device (manual resuscitation)
1593642|NCT02281890|Other|Proven sepsis|Exposure is proven sepsis
1593643|NCT02281877|Procedure|Neuromuscular electrical stimulation (NMES)|4x/day for 15 minutes/session
1593644|NCT02281877|Behavioral|Standard Rehabilitation Protocol|Standard physical therapy after TKA
1593645|NCT02281864|Behavioral|Smoking Cessation Intervention Bundle|Receipt of the smoke cessation/reduction intervention bundle followed by referral to the Quitline.
1593646|NCT02281864|Other|Control Group: Quitline|Referral to the Quitline
1593647|NCT02281838|Drug|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
1593648|NCT02281812|Procedure|Radiofrequency ablation|After tumor ablation and excision of the tumor, the pathologist performed a macroscopic study of the specimen,measuring the distance between the tumor and the margin in order to indicate if extensions are mandatory. Secondly and delayed, margins will be evaluated microscopically by H&E stain. Furthermore, the tumoral viability in the ablation zone will be evaluated by NADH-diaphorase, COX and tunnel.
2009232|NCT03311152|Diagnostic Test|"Epi proColon 2.0 CE test from Epigenomics, Inc (Berlin, Germany)"|The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.
1593650|NCT02281786|Drug|Placebo|Matching placebo to RO6926496
1593651|NCT02281786|Drug|RO6926496|single, ascending dose, intravenous administration
2009233|NCT03310606|Other|Dosage of serum and peritoneal of the B lactam used for antibiotic treatment|Dosage of serum and peritoneal of the B lactam used B lactam concerning are : CEFTRIAXONE, CEFOTAXIME, PIPERACILLINE/TAZOBACTAM, IMIPENEM
2009234|NCT03310242|Behavioral|Sunlight Exposure|"Everyday sunlight exposure around noon for 20-30 minutes for 8 weeks
Completing a Sun Diary after sunlight exposure"
2009235|NCT03310242|Dietary Supplement|Vitamin D Supplementation|- Supplementation of vitamin D3 500 IU/day for 8 weeks
2009236|NCT03310242|Other|Placebo|- Intake of placebo for 8 weeks
2009237|NCT03311009|Drug|GLPG1972 cohort 1|GLPG1972 dose 1 provided as oral tablets q.d.
2009238|NCT03311009|Drug|GLPG1972 cohort 2|GLPG1972 dose 2 provided as oral tablets q.d.
2009239|NCT03311009|Drug|GLPG1972 cohort 3|GLPG1972 dose 3 provided as oral tablets q.d.
1593659|NCT02281721|Device|Surpass Flow Diverter(s)|Endovascular placement of a Surpass Flow Diverter(s) for the treatment of an intracranial aneurysm(s)
1593660|NCT02281708|Drug|vinorelbine plus cisplatin|"Drugs will be administered for 4 cycles, and should be administered at scheduled day +/- 3 days
vinorelbine 25mg/m2 IV (Day 1, 8) q 3wks cisplatin 75mg/m2 IV (Day 1) q 3wks"
1593661|NCT02281695|Other|PEEP adjusment during the Weaning process|The PEEP will be adjusted after an previously established algorithm and the differences in the arterial blood oxygen partial pressure will be compared.
1593666|NCT02281669|Drug|Pentostam|Intralesional injection of Pentostam
1593667|NCT02281656|Procedure|Surgery:ulnar nerve transposition with AIN to ulnar nerve transfer|
1593668|NCT02281656|Procedure|Surgery:ulnar nerve subcutaneous transposition without AIN to ulnar nerve transfer.|
1593669|NCT02281643|Drug|Doxycycline|200mg oral doxycycline will be administered immediately (early) in the experimental arm or delayed in the comparator arm
1593670|NCT02281630|Drug|KWA-0711|
2009240|NCT03311009|Drug|Placebo|Matching placebo provided as oral tablets q.d.
2009241|NCT03309072|Device|tDCS|active tDCS
1593672|NCT02281617|Behavioral|Smart-device apps as memory aids|Patients will be taught to use software running on smartphones and smart tablets to help compensate for memory difficulties
1593673|NCT02281591|Drug|BIA 2-093|Tablets containing 900 mg
1593674|NCT02281591|Drug|S-licarbazepine|capsules containing 225 mg
1593675|NCT02281591|Drug|R-licarbazepine|capsules containing 225 mg
1593676|NCT02281578|Behavioral|Community-based combination HIV prevention intervention|The combination package will include integrated biomedical, behavioral and structural components: (1) mobile HIV testing and risk reduction counseling; (2) service navigation to facilitate access to treatment and retention in care; (3) sensitivity training for HIV clinical care providers; (4) SMS text messages to promote adherence to care and ART; (5) venue-based peer education and condom distribution; and (6) a community drop-in-center to promote cohesion and collective action to reduce stigma and discrimination.
1593677|NCT02281578|Behavioral|Standard of care HIV services|Locally available standard of care HIV prevention, treatment and care services
1593678|NCT02281565|Behavioral|survey|Survey about Knowledge, Attitude and Practice About Blood Donation
1593679|NCT02281552|Drug|Tofacitinib|tofacitinib modified release 11 mg tablet administered once time a day for 12 weeks
1593680|NCT02281552|Drug|Tofacitinib|tofacitinib immediate release 5 mg tablet administered twice a day for 12 weeks
1593681|NCT02281539|Device|Neuromotus|
1593682|NCT02281526|Drug|BIA 2-093|
1593683|NCT02281513|Other|Smartphone Application|Is a self-monitoring tool to document fruit and vegetable consumption, sleep quantity and quality, and physical activity
1593684|NCT02281513|Other|Fitbit Activity Monitor|Is connected to this smartphone application so that participants who wear this monitor have data that automatically populates the smartphone application for physical activity.
1593685|NCT02281513|Other|Coaching Sessions|Using motivational interviewing (a counseling style used in helping persons change their behavior) at baseline after completion of all baseline assessments and at follow up after completion of all follow up assessments. Coaching session includes discussion of facilitators and barriers to increasing physical activity, fruit and vegetable consumption and sleep, as well as setting goals to work towards at next meeting. The coach will monitor the information that the participant enters into the smartphone application and will provide feedback on a weekly basis to the participant.
1593686|NCT02281500|Biological|Human Plasma-Derived Fibrinogen Concentrate|A sterile freeze-dried fibrinogen concentrate filled in vials containing 1 g of FIB Grifols. FIB Grifols contains 20mg/ml of active substance fibrinogen when reconstituted.
1593687|NCT02281487|Procedure|Hysterectomy plus Tubectomy|hysterectomy with tubectomy
1593688|NCT02281487|Procedure|Hysterectomy|standard hysterectomy
1593689|NCT02281487|Device|light microscopy|analysis of the incidence of dysplastic lesions (defined as: nuclear atypia, pilling of epithelial cells, multiple mitosis), if any, in the removed Fallopian tubes by light microscopy (Leica DM4000)
2009242|NCT03309072|Device|sham tDCS|sham tDCS
1593691|NCT02281461|Device|Male circumcision using a non-surgical device|Male Circumcision
1593692|NCT02281448|Drug|BIA 2-093|
1593693|NCT02281448|Drug|Contraceptives, Oral, Combined|
1593694|NCT02281435|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures, but in this study the procedure consist an incision on to the foreskin.
1593695|NCT02281422|Drug|BIA 2-093|
1593696|NCT02281409|Biological|Mogamulizumab (KW-0761)|
1593697|NCT02281396|Biological|2.5IU/ml in rabies vaccine （MRC-5 Cell) humans aged 10-20 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
1593698|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans aged 21-60 years old|Freeze-dried Rabies Vaccine（MRC-5 Cell) of 2.5IU/ml,5 doses,4 weeks interval
1593699|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 10-20 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
1593700|NCT02281396|Biological|2.5IU/ml rabies vaccine （MRC-5 Cell) in humans(from 21-60 years old)|Freeze-dried Rabies Vaccine（vero Cell) of 2.5IU/ml,5 doses,4 weeks interval
1593701|NCT02281383|Biological|Bacillus Calmette-Guérin (BCG)|
1593702|NCT02281370|Drug|Eltrombopag|White to off white bi-convex round tablets containing eltrombopag 50 mg for oral administration
1593703|NCT02281370|Drug|Cyclosporine|Soft gelatine capsule containing cyclosporine 100 mg for oral administration. Cyclosporine will be administered at the doses of 200 mg (2 x 100 mg capsules) or 600 mg (6 x 100 mg capsules)
1593704|NCT02281357|Biological|Tralokinumab|Tralokinumab dose
1593705|NCT02281357|Other|Placebo|Placebo dose
1593706|NCT02281344|Drug|MMV390048 20mg|Supplied as a powder to be prepared as a suspension for oral use
1593707|NCT02281344|Drug|MMV390048 x mg|Supplied as a powder to be prepared as a suspension for oral use
1593708|NCT02281344|Drug|MMV390048 y mg|Supplied as a powder to be prepared as a suspension for oral use
1593709|NCT02281331|Dietary Supplement|Supplement|supplement/placebo plus exercise training
1593710|NCT02281318|Biological|Mepolizumab|Humanised Immunoglobulin G (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with sterile water for injection, just prior to use
1593711|NCT02281318|Drug|Placebo|Sterile 0.9% sodium chloride solution
1593712|NCT02281318|Drug|SOC|Standard of Care (SOC) will differ by participants, however it will include high dose ICS with at least one other controller, e.g. LABA, with or without maintenance OCS
1593713|NCT02281305|Drug|Colchicine|
1593714|NCT02281292|Biological|LKA651 ophthalmic solution|
1593715|NCT02281292|Biological|Ranibizumab ophthalmic solution|
1593716|NCT02281292|Biological|Sham injection|Mock injection administered as an empty hub without needle
1593717|NCT02281279|Biological|rituximab|Given IV
1593718|NCT02281279|Drug|lenalidomide|Given PO
1593719|NCT02281279|Drug|romidepsin|Given IV
1593720|NCT02281279|Other|laboratory biomarker analysis|Correlative studies
1593721|NCT02281266|Procedure|curative resection|
1593722|NCT02281266|Drug|thymalfasin|1.6mg twice a week, 12 months
1593723|NCT02281266|Drug|nucleoside analog (suggest to use entecavir)|
1593724|NCT02281253|Dietary Supplement|dietary fibre plus L-carnitine bread|"The enriched bread consisted of a mix of wheat flour, vegetable flour, rye flour, wheat gluten, soy protein, soluble and insoluble dietary fibre, inulin, guar gum, L-carnitine salt, diacetyl tartaric, enzymes, ascorbic acid, water and yeast.
Patients were recommended to consume the bread twice per day with main meals."
1593725|NCT02281253|Dietary Supplement|Placebo bread|The placebo group received commercially available bread with a similar macronutrient composition and energy intake to that consumed by the enriched bread group but without L-carnitine and dietary fibre. Patients were recommended to consume the bread twice per day with main meals.
1593726|NCT02281240|Drug|thrombopoietin, interleukin-11, heparin,|The hemostatic and antithrombotic (thrombopoietin, interleukin-11, heparin) measures during HSCT.
1593727|NCT02281227|Procedure|skin compression|skin compression with an indicator for determination of needle entry point
1593728|NCT02281214|Other|blood sample, biopsy|Blood samples and tumor biopsies will taken from patients before treatment and when tumor progression on therapy for Next Generation Sequencing (NGS) mutation analysis
1593729|NCT02281201|Biological|BE1116 (Prothrombin Complex Concentrate)|
1593730|NCT02281175|Behavioral|Psychosocial intervention|Based on a cognitive-behavioral approach, the psychosocial intervention (PASSE-65+) is specifically designed to help older BZD users to better manage their withdrawal symptoms, to stop their medication, and to improve their general psychological well-being
1593731|NCT02281175|Behavioral|a weekly physician intervention|Informative document + 12 meetings (once a week; 30 minutes) with a physician who will supervise the gradual withdrawal
1593732|NCT02281162|Other|Blood Draw|Blood Draw
1593733|NCT02281136|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
1593734|NCT02281136|Device|BLU-U|10 J/cm2 of 417 nm blue light delivered at 10 mW/cm2
1593735|NCT02281123|Other|SF36 (QQoL)|use of quality of life questionnaire (SF 36) ( at enrollment visit, at 3 month, at 6 month and at12 month for the following visits)
1593736|NCT02281110|Device|iFR/FFR|• The Volcano iFR®-FFR option, which is a measurement modality for the Volcano system that provides the capability to make FFR and instantaneous wave-Free Ratio™ (iFR®) measurements (CE-Marked). iFR® is a pressure-derived, hyperemia-free index for the assessment of coronary stenosis relevance. This option consists of an FFR-iFR® specific patient interface module (PIM-FFR) which can be connected to the Volcano system - VOLCANO s5 or s5i™ platform equipped with iFR® option. This PIM-FFR is compatible with all Volcano pressure measurement guide wires.
1593737|NCT02281097|Other|Stimulation|Application of current to skin above auricular branch of vagal nerve to modulate heart rate and symptoms
1593738|NCT02281097|Other|Placebo|Application of low intensive current or frequency to skin above auricular branch of vagal nerve as sham intervention
1593739|NCT02281084|Drug|CC-486 (ORAL AZACITIDINE)|200 mg CC-486 (Oral Azacitidine) will be given for the first 21 days of each 28-day treatment cycle
1593740|NCT02281084|Drug|Durvalumab|
1593741|NCT02281071|Procedure|laterally moved coronally advanced flap with microsurgical instruments and x2.5 loupe|The recipient area for the laterally moved flap was prepared. When the flap was moved in the distal-mesial direction another short horizontal incision was performed at the most apical extension of this vertical incision. Once the mucogingival line was reached, flap elevation was continued split-thickness. Flap elevation was terminated when it was possible to passively move the flap laterally above the exposed root. Flap was sutured.
1593742|NCT02281058|Drug|Abatacept|self-injected subcutaneous biologic medication
1593743|NCT02281045|Device|EVODIAL dialyzer and Selectbag citrate|Evodial is a trademark of Hospal-Gambro.
1593744|NCT02281045|Device|Regional citrate anticoagulation|Regional citrate anticoagulation is performed according to local practice, using a calcium-containing dialysate
1593745|NCT02281032|Other|interRAI PC|"PREPARATORY PHASE
Step 0: Introductory information
Step 1: Training on the interRAI PC and the BelRAI webapplication
Step 2: Introduction on the interRAI PC and the BelRAI webapplication in the organization
IMPLEMENTATION PHASE
Step 3: Identification of residents with palliative care needs, based on the surprise question
Step 4: Informed consent signature requirements
Step 5: Login to the BelRAI webapplication
Step 6: Definitions of roles and functions
Step 7: Completion of the interRAI PC
Step 8: Interpretation of results
Step 9: Use of results"
1593746|NCT02281019|Procedure|ERCP (Endoscopic Retrograde Cholangiopancreatography)|ERCP procedure will be performed to visualize bile ducts.
1593747|NCT02281019|Device|SpyGlass DVS and SpyGlass DS|Cholangioscopy using SpyGlass™ DVS or SpyGlass DS will be performed post ERCP for direct viewing of the bile ducts. What is seen during the procedure will determine a course of treatment. Among the options are biopsies taken, stones treated/removed, or a stent placed
1593748|NCT02281006|Drug|Trans-tympanic injection of a sodium thiosulfate gel|A sodium thiosulfate hyaluronate gel will be prepared by mixing 0.55 ml of a 25% solution of sodium thiosulfate pentahydrate (Seacalphyx, DIN 02386666, Seaford Pharmaceuticals Inc.) and 0.55 ml of a hyaluronate gel (Healon 10 mg, Abbott Medical Optics Inc.). On the day before each Cisplatin treatment an otologist will deposit 0.1 ml of the gel exactly on the round window of the middle ear.
1593749|NCT02280993|Drug|DHAP|DHAP
1593750|NCT02280993|Drug|Brentuximab Vedotin|Brentuximab Vedotin
1593751|NCT02280993|Other|Autologous Peripheral Blood Stem Cell Transplantation|Autologous Peripheral Blood Stem Cell Transplantation
1593752|NCT02280980|Other|Oculomotor and Gaze Stability Exercises|Daily oculomotor and gaze stability exercises, twice a day, for three weeks
1593753|NCT02280967|Behavioral|Education about HPV by school nurse|Information about prevention of HPV among adolescents aged 16 at time for the regular health interview with the school nurse.
1593754|NCT02280954|Drug|Indocyanine Green (ICG)|
1593755|NCT02280941|Other|single photon emission computed tomography|Single photon emission computed tomography (SPECT) imaging will be done.
1593756|NCT02280928|Other|Balance exercise|Balance activities, using a task-oriented approach, progress participants from body stability, to body stability plus hand manipulation, then body transport, and finally body transport plus hand manipulation.
1593757|NCT02280928|Other|Cognitive training|Cognitive training involves executive function, attention, and working memory. Examples of cognitive training include finding the exit to a maze, calculation, visual-spatial skills, Sudoku, Stroop color-word task, word search, spot the differences, visual discrimination, and memory scanning skills.
1593758|NCT02280928|Other|Dual-task cognitive-cognitive training|The Dual-task cognitive-cognitive training involves applying two cognitive tasks at the same time.
1593759|NCT02280915|Other|Savoury food product|
1593760|NCT02280902|Biological|Blood samples|Systematic follow-up (M3, M6, M12, M18, M24, M30) will be implemented to complete epidemiologic, clinical, therapeutic and biological data during a 30 months period. Specific measure of immune cells, markers of immune activation, immunoglobulins as described above will be performed at M3, M6, M12 and M24. A biologic collection (serum and cells) will be performed at the same time points for future prognostic studies.
1593761|NCT02280876|Drug|1 - Andrographis paniculata p/st extract|"Andrographis paniculata Extract (ApE), Oral tablets 650 mg, with 170 mg. of andrographolides active principles, three times per day, during a total of 365 continuous days.
Other Names:
• ApE tablets, EUROMED Specific. Santiago Chile."
1593762|NCT02280876|Drug|2 - Excipients|"Placebo 650mg tabs, 2/day, 365 days continuously.
Other Names:
• Excipients tablets EUROMED Specific. Santiago Chile"
1593763|NCT02280863|Device|Hybrid Closed Loop|Research staff will be remotely monitoring subjects at all times. If their sensor reads <70 mg/dl or >300 mg/dl, a health care member will intervene if no response from pt. or monitor within 5 and 10 minutes respectively. Treatment will be given as per the treatment interventions in the MM JDRF Hotel Studies Protocol (Table 2-1- Hypoglycemia and Hyperglycemia Monitoring and Treatment Procedures). At night a bedtime glucose, 3 AM glucose and a morning glucose will be obtained. During the day meter readings will be obtained before all meals and exercise.
1593764|NCT02280850|Drug|Guanxin Shutong Capsule|3 capsules three times a day; Duration: 4 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
1593765|NCT02280850|Drug|Placebo Capsule|3 capsules three times a day; Duration: 4 weeks.
1593766|NCT02280850|Drug|nitroglycerine|"Adults: 0.25mg-0.5mg (half pill or 1 pill) once, sub-lingual. One more pill per 5 minutes untill pain relief. If total dose is 3 pills in 15 minutes and the pain is still in, please seek medical advice urgently.
The participators in both arms who have agina symptom will take Nitroglycerine. So the accumulated consumption of participators is the one of the maesuremnts."
1593767|NCT02280837|Other|Determination of plasma GLP-1 level|Determination of GLP-1 level in samples of oral glucose tolerance tests
2009243|NCT03308552|Radiation|SIB-IMRT|PTV:50.4Gy/28f, PGTV:59.92Gy/28f
1593769|NCT02280811|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m^2/day for 5 days.
1593770|NCT02280811|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day x 2 days
1593771|NCT02280811|Biological|E6 TCR|On day 0, cells will be infused intravenously (IV) over 20-30 minute (between 1 and 4 days after the last dose of fludarabine)
1593772|NCT02280811|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
2009244|NCT03308552|Drug|Paclitaxel|45 to 50 mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
1593774|NCT02280785|Drug|Brentuximab vedotin|Brentuximab vedotin must not be administered as an IV push or bolus. It must be administered in 100ml-250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
2009245|NCT03308552|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 20-25mg/m2, once a week, concurrent with radiotherapy for 5-6weeks
2009246|NCT03308552|Drug|Paclitaxel|150mg/m2 on day1,every 3 weeks, 4 cycles, 1-3 months after completion of radiotherapy
1593777|NCT02280759|Drug|Gelatin Tannate|
1593778|NCT02280759|Drug|Placebo|Placebo consists of an identical formulation, except active substance
1593779|NCT02280746|Other|Gluten challenge|Intervention will be continued for at least 6 months
1593780|NCT02280733|Other|Usual care|advanced dressings, off-loading, venous ulcer compression, arterial screening
1593781|NCT02280720|Procedure|Stenting using Optimax™|
1593782|NCT02280720|Procedure|Stenting using PROMUS Element™ Plus|
1593783|NCT02280707|Other|Grab a Cup, Fill it Up|The intervention involved installing promotional posters encouraging students to drink water as well as cup dispensers stocked with disposable 5 ounce cups near water fountains in school lunchrooms.
1593784|NCT02280694|Drug|Capecitabine|
1593785|NCT02280694|Drug|Cyclophosphamide|
1593786|NCT02280694|Drug|Methotrexate|
1593787|NCT02280694|Drug|Celecoxib|
1593788|NCT02280681|Other|No intervention, only questionnaire|No intervention, only questionnaire containing a discrete choice experiment identifying the importance of treatment aspects for deciding between current treatments and possible future treatments with artificial gametes
2009247|NCT03308552|Drug|Platinum-Based Drug|Nedaplatin or Lobaplatin or Cisplatin, 80mg/m2 on day1 (Lobaplatin 50mg on day 1),every 3 weeks, 4 cycles, 1 month after completion of radiotherapy
2009248|NCT03307642|Other|Text message notification|Three text messages will be sent to 50% of the parents, scheduled around the standard methods of communication
1593791|NCT02280655|Biological|Storage-aged red blood cells (saRBCs) units|Packed RBCs units stored for greater than 21 days, with a mean storage duration of 29.6 ± 4.9 days (mean ± SD)
1593792|NCT02280655|Biological|Fresh red blood cells units|Packed RBCs units stored for less than 14 days, with a mean storage duration of 9.6 ± 3.9 days (mean ± SD)
1593793|NCT02280642|Biological|Both 2nd and 3rd doses on time|
1593794|NCT02280642|Biological|2nd dose late and 3rd dose on time|
1593795|NCT02280642|Biological|2nd dose on time and 3rd dose late|
1593796|NCT02280642|Biological|Both doses late|
1593797|NCT02280629|Drug|LT-02|LT-02 1.6g twice daily AND mesalamine PLACEBO three-times daily
1593798|NCT02280629|Drug|Placebo|LT-02 PLACEBO twice daily AND mesalamine PLACEBO three-times daily
1593799|NCT02280629|Drug|Mesalamine|LT-02 PLACEBO twice daily AND mesalamine 500mg three-times daily
1593800|NCT02280616|Drug|low dose budesonide tablet|1mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
1593801|NCT02280616|Drug|high dose budesonide tablet|2mg budesonide tablet twice daily AND 5ml placebo suspension twice daily
1593802|NCT02280616|Drug|high dose budesonide suspension|placebo tablet twice daily AND 5ml [0.4mg budesonide/ml] suspension twice daily
1593803|NCT02280616|Drug|Placebo|placebo tablet twice daily AND 5ml placebo suspension twice daily
1593804|NCT02280603|Drug|DA-4001C|1ml by topical application twice a day
1593805|NCT02280603|Drug|5% minoxidil|1ml by topical application twice a day
1593806|NCT02280590|Drug|Rosuvastatin(Cresnon®)|10mg
1593807|NCT02280590|Drug|Rosuvastatin(Crestor®)|10mg
1593808|NCT02280564|Behavioral|health coaching with technology support|Intensive behavior change support. Engaging participants to take an active role in their diabetes care using motivational interviewing, technology, family communication, problem solving skills.
1593809|NCT02280538|Device|Intra-Articular Hyaluronic Acid|
1593810|NCT02280538|Device|Placebo|
1593811|NCT02280525|Drug|Lenalidomide|2.5 mg by mouth daily on Day -2 to Day +14.
1593812|NCT02280525|Drug|Rituximab|375 mg/m2 by vein on Day -5 for participants with B-cell cancer.
1593813|NCT02280525|Drug|Fludarabine|"Lymphodepleting Chemotherapy Option #1: Fludarabine 25 mg/m2 by vein on Days -5 to -3.
Lymphodepleting Chemotherapy Option #2: Fludarabine 25 mg/m2 by vein over 1 hour on Day -6 to -2.
Lymphodepleting Chemotherapy Option #3: Fludarabine 30 mg/m2 by vein over 1 hour on Days -6 to -2"
1593814|NCT02280525|Drug|Cyclophosphamide|"Lymphodepleting Chemotherapy Option #1: Cyclophosphamide 200 mg/m2 by vein on Days -5 to -3.
Lymphodepleting Chemotherapy Option #2: Cyclophosphamide 60 mg/kg by vein over 3 hours on Days -5 and -4."
1593815|NCT02280525|Procedure|NK Cells|"Participant assigned to a dose level of NK cells based on when joined study. Starting dose level of NK cells 1 x 10^7 NK cells/kg given by vein on Day 0.
NK Cell Infusion Expansion Phase: Maximum tolerated dose of NK cells from Induction Phase."
1593816|NCT02280525|Drug|Cytarabine|Cytarabine 2 mg/m2 by vein on Days -6 to -2.
1593817|NCT02280512|Device|elderly with fractures|hemodynamic monitoring with NICOM and tissue perfusion monitoring with NIRS
1593818|NCT02280499|Device|standard PROMOS prosthesis|
1593819|NCT02280486|Drug|Saxagliptin|5 mg qd
1593820|NCT02280486|Drug|Glimepiride|1mg/d, up titrated 1mg if FPG ＞6.1 mmol/L (110mg/dL) till 6 mg
1593821|NCT02280473|Drug|Refresh Optive® Gel Drops|Refresh Optive® Gel Drops; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
1593822|NCT02280473|Drug|REFRESH LIQUIGEL®|REFRESH LIQUIGEL®; 1-2 drops in each eye as needed at least 2 times daily for 30 days.
1593823|NCT02280447|Biological|1/3 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
1593824|NCT02280447|Biological|1/5 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
1593825|NCT02280447|Biological|1/10 IPV-Al SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
1593826|NCT02280447|Biological|IPV SSI, manufactured by SSI, Denmark|Intramuscular injection of 0.5 mL vaccine into deltoid muscle
1593827|NCT02280434|Drug|CBP-307|
1593828|NCT02280434|Drug|Placebo|
1593829|NCT02280421|Drug|ASP2151 400mg + 100mg ciclosporin|
1593830|NCT02280421|Drug|ASP2151 1200mg + 100mg ciclosporin|
1593831|NCT02280408|Other|Placebo|Normal saline placebo.
1593832|NCT02280408|Biological|BPSC-1001 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.
1593833|NCT02280395|Drug|RUT058-60|Prior to closure of the abdomen at the end of the surgical repair, each subject will undergo lavage with approximately 900 mL of RUT058-60 administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
1593834|NCT02280395|Drug|Sterile saline for irrigation|Prior to closure of the abdomen, each subject will undergo lavage with approximately 900 mL of sterile saline administered as two 400 mL intra-abdominal (peritoneal) lavages and one 100 mL lavage above the fascia.
1593835|NCT02280382|Device|Femmeze®|Femmeze will be used by women in the intervention group for 8 weeks These women will be measuring against their usual care in a linear design; measurement will include validated questionnaires
1593836|NCT02280369|Device|Automated abdominal binder|Inflatable abdominal binder
1593837|NCT02280356|Radiation|external beam radiation therapy|
1593838|NCT02280356|Radiation|brachytherapy|
1593839|NCT02280356|Behavioral|questionnaires|
1593840|NCT02280343|Other|evaluated lung function|lung function tests
1593841|NCT02280330|Dietary Supplement|MNP group|MNP contains 15 vitamins an minerals, including Vitamin ADEC, B1, B2, B6, B12, Niacin, Folic Acid, Iron, Zine, Copper, Selenium and Iodine. There is 90 microgram of iodine per sachet of one gram of MNP.
1593842|NCT02280330|Other|Placebo group|The placebo is maltodextrin which is prepared as a white powder with similar physical characteristics and taste as MNP.
1593843|NCT02280317|Drug|VAL201|VAL201-001 Sub-cutaneous injection.
1593844|NCT02280304|Behavioral|Inner Resources for Veterans (IRV)|Meditation therapy which utilizes mindfulness, techniques that encourage non-judgmental attention to oneself in the present moment
1593845|NCT02280304|Behavioral|PTSD and mTBI education|Participants will learn about symptoms and triggers of PTSD and mTBI
2009249|NCT03306277|Biological|AVXS-101|Non-replicating recombinant AAV9 containing the complimentary deoxyribonucleic acid (cDNA) of the human SMN gene under the control of the cytomegalovirus (CMV) enhancer/chicken-β-actin-hybrid promoter (CB). The AAV inverted terminal repeat (ITR) has been modified to promote intramolecular annealing of the transgene, thus forming a double-stranded transgene ready for transcription.
2009250|NCT03306186|Device|HemoSpec|Blood sampling for analysis
2009251|NCT03305432|Combination Product|sleeve + preoperative PPI|sleeve + preoperative PPI
2009252|NCT03305432|Combination Product|sleeve + preoperative Placebo|sleeve + preoperative Placebo
1593854|NCT02280278|Procedure|Radical surgery|
1593855|NCT02280278|Drug|Adjuvant chemotherapy|
1593856|NCT02280278|Biological|Cytokine-induced killer cell immunotherapy|
1593857|NCT02280265|Drug|Recombinant Human Coagulation Factor VIII for injection|Subjects will initially be treated standard prophylaxis(20 - 40 IU/Kg body weight 2 times one week) with ADVATE for 1 year.
2009253|NCT03306043|Drug|Mepolizumab|Mepolizumab will be available as 100 mg vial for injection. Subjects will receive three 100 mg SC injections for every 4 Weeks for a total of 5 doses during 20 Week treatment period.
2009254|NCT03305549|Other|Conservative dialysis strategy|"Participants will receive RRT only when meeting 1 of the following indications (patterned after the AKIKI trial's delayed RRT initiation arm):
Blood urea nitrogen >112 mg/dL (40 mmol/L)
Serum potassium concentration >6 mmol/L
Serum potassium concentration >5.5 mmol/L despite medical treatment (e.g., bicarbonate, glucose-insulin infusion, albuterol, diuretics, sodium polystyrene sulfonate)
Arterial blood gas pH <7.15 in a context of pure metabolic acidosis (PaCO2 <35 mmHg) or in a context of mixed acidosis with PaCO2 50 mmHg despite medical treatment to reverse respiratory acidosis (e.g., naloxone), or in the absence of an available arterial blood gas, serum bicarbonate <12 mmol/L
Acute pulmonary edema due to fluid overload, responsible for hypoxemia requiring oxygen flow rate >5 L/min to maintain SpO2 >95% or requiring FiO2 >50% in patients already on invasive or non-invasive mechanical ventilation and despite diuretic therapy"
2009255|NCT03305549|Other|TIW dialysis strategy|Thrice-weekly acute intermittent hemodialysis schedule.
2009256|NCT03304613|Behavioral|Web-based Cognitive Behavioral Therapy (e-CBT) Self-Management|Already noted.
1593863|NCT02280213|Device|MIL|Direct laryngoscopy 1
1593864|NCT02280213|Device|MAC|Direct laryngoscopy 2
1593865|NCT02280213|Device|WIS|Direct laryngoscopy 3
1593866|NCT02280213|Device|PHIL|Direct laryngoscopy 4
1593867|NCT02280200|Device|AFO to improve outcomes|Ankle foot orthoses (AFO) are light-weight, low profile carbon fiber devices that store and release energy during ambulation. The AFO, in combination with standard of care advice to walk more, will be used to determine if there is any improvement in PAD patient outcomes.
1593868|NCT02280187|Procedure|Spine Fusion|All patients have been treated with a spinal fusion procedure with InductOs (rhBMP-2/ACS) following standard practice in each center.
1593869|NCT02280174|Drug|linagliptin|linagliptin 5 mg/d for12 weeks
1593870|NCT02280161|Other|cytology specimen collection procedure|Correlative studies
1593871|NCT02280148|Procedure|Endoscopy of Intravenous Anesthesia|The dose of intravenous anesthesia drug and time was controlled by the anesthesiologist,endoscopists were responsible for gastroscopy or colonoscopy , nurses assisted endoscopists with biopsy.Each subject's initial dose of propofol were set at 2mg / kg, and were added properly by anesthesiologists additional according to the subjects' intraoperative sedation or surgical time.
1593872|NCT02280148|Device|Driving Simulator|
1593873|NCT02280148|Drug|Propofol|2mg / kg
1593874|NCT02280135|Biological|Intravitreal injection of Autologous bone marrow Stem Cell|"We will proceed to the injection of 0.1 ml of the suspension with the autologous MNC of BM avoiding coincide with conjunctival and scleral hole and perpendicular to the sclera.
After the injection, a dry, sterile dressing will be placed to prevent reflux. Immediately, the perception of light, the movement of the central retinal artery, the venous pulse and the color of the papilla will be evaluated. If necessary, anterior chamber paracentesis will be performed.
After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
1593875|NCT02280135|Other|Subconjunctival injection of saline|"In the control eye, will make a subconjunctival injection of 0.1 ml saline. To realize contralateral injection gloves and all surgical materials will change, trying extreme measures of sterility.
After injection, the patient will remain with closed eyes and sitting, waiting for cells will be deposited on the bottom of the eyeball and for 3 days will instill tropicamide collyrium every 12 hours."
1593876|NCT02280122|Other|no intervention provided|No Intervention was rendered but the aMMP-8 test was made
1593877|NCT02280109|Drug|Tenofovir Gel|single dose of 1% tenofovir gel (equivalent to 40 mg in 4ml's of gel)
1593878|NCT02280109|Drug|Tenofovir Film|single dose of 1.3% tenofovir film (equivalent to 40 mg)
1593881|NCT02280083|Drug|Botulinum Toxin Type A for Injection|"HengLi002(Botulinum Toxin Type A for Injection,also known as HengLi®)"
1593882|NCT02280083|Drug|placebo|placebo
1593883|NCT02280070|Other|Laboratory test|Leukocyte, neutrophil (ANC ：stab + seg), hemoglobin, platlet, albumin, total birrilubin, AST, ALT, LDH, Creatinine, Na, K, CRP, fast blood sugar
1593884|NCT02280070|Other|Medical history and physical examination|medical history and physical examination
1593885|NCT02280070|Other|BW and height|Body weight (kg) and height (cm)
1593886|NCT02280070|Other|Performance status|ECOG performance status, 0: Fully active, able to carry on all pre-disease performance without restriction, 1: Restricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work, 2: Ambulatory and capable of all selfcare but unable to carry out any work activities. Up and about more than 50% of waking hours, 3: Capable of only limited selfcare, confined to bed or chair more than 50% of waking hours, 4: Completely disabled. Cannot carry on any selfcare. Totally confined to bed or chair, 5: Dead
1593887|NCT02280070|Other|Creatinine clearance|Creatinine clearance (CCr, mL/min) was estimated by Cockcroft & Gault method using serum creatinine (mg/dL), age and body weight (kg).
1593888|NCT02280070|Other|Biomarker|Carcinoembryonic antigen and carbohydrate antigen 19-9
1593889|NCT02280070|Radiation|Contrasting CT|Computed tomography
1593890|NCT02280070|Other|Adverse event|AE was evaluated using Common Terminology Criteria for Adverse Events (CTCAE v4.0).
1593891|NCT02280070|Other|HBs antigen and HCV antibody|check for exclusion criteria
1593892|NCT02280070|Other|Endoscopy|Endoscopy for lower digestive tract
1593893|NCT02280070|Other|HBs antibody and HBc antibody|Check according to hepatitis B guideline
1593894|NCT02280070|Drug|S-1|S-1 (80 mg/m2, p.o.) is administered at day 1 -14 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
1593895|NCT02280070|Drug|L-OHP (130mg/m2)|L-OHP (130mg/m2 intravenously) is administered at day 1 of the course and repeated every 3 weeks until 4 courses or meet discontinuation criteria.
1593896|NCT02280070|Drug|L-OHP (85 mg/m2)|L-OHP (85mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
1593897|NCT02280070|Drug|l-LV|l-LV (200 mg/m2) is administered by IV infusion drip for 2hr at day 1 of the course and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
1593898|NCT02280070|Drug|5-FU|5-FU (400 mg/m2) by bolus IV administration just after the L-OHP and l-LV administration. 5-FU (2,400 mg/m2) by IV continuous infusion for 46 hours using infuser pump afterwards and repeated every 2 weeks until 6 courses or meet discontinuation criteria.
1593899|NCT02280057|Drug|Metformin|Metformin 1500 mg (=2 pills) per day in six months
1593900|NCT02280057|Drug|Placebo|2 pills per day in six months; pills look like metformin pills
2009257|NCT03304613|Behavioral|Promoting Resilience through Innovative Self-Management|Already noted.
1593902|NCT02280031|Drug|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
1593903|NCT02280031|Drug|Placebo|Capsule containing placebo pill with lactose
1593904|NCT02280018|Drug|JNJ-49122944, 5 milligram (mg)|Participants will receive single dose of 5 mg JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
1593905|NCT02280018|Drug|Placebo|Participants will receive placebo matched to JNJ-49122944, administered as a 22.2 mL IV infusion over 45 minutes on Day 1.
1593906|NCT02280005|Device|WAK Treatment|Hemodialysis with WAK device.
1593907|NCT02279992|Drug|Vardenafil|
1593908|NCT02279992|Drug|Carboplatin|
1593909|NCT02279979|Device|HeartMate PHP|The HeartMate PHP system is a catheter-based heart pump and console designed to provide hemodynamic left ventricular support for up to 3 days to stabilize patients by maintaining adequate systemic cardiac output.
1593910|NCT02279966|Drug|Vortioxetine 10 mg|
1593911|NCT02279966|Drug|Paroxetine 20 mg|
1593912|NCT02279966|Drug|Placebo|
1593913|NCT02279953|Drug|Vortioxetine 10-20 mg|
1593914|NCT02279953|Drug|Placebo|
1593915|NCT02279953|Drug|SSRI|escitalopram, citalopram or sertraline
1593916|NCT02279927|Device|Ureteroscopy|Ureteroscopy with laser stone fragmentation
1593917|NCT02279914|Drug|Misoprostol 400 mcg 3 hours prior to procedure|
1593918|NCT02279914|Drug|Misoprostol 600 mcg 90 minutes prior to procedure|
1593919|NCT02279901|Behavioral|Telemedicine Education|"Emmi Solutions produces Web-based, simple to understand, healthcare related educational programs. These programs are interactive sessions that last about 15 minutes, educating patients on the risk of OSA and assisting in preparing patients for procedures. Two such programs will be sent to patients at preset intervals over the duration of the study:
OSA program
CPAP program
Links to each of these programs are emailed to the patient and date of birth needs to be verified before the program will start. The programs ask the patient for feedback at regular intervals and provide opportunities throughout to make notes or write down questions that can be later printed. These programs are already approved for clinical use within Kaiser Permanente which has a contract with the vendor."
1593920|NCT02279901|Behavioral|IVR|"Interactive Voice Response (IVR) is a protocol in which automated messages are delivered via e-mail, text or phone to patients to provide feedback regarding their CPAP use, intended to improve therapy adherence. The basic protocol involves the use of CPAP devices that wirelessly send usage data to a cloud platform. Automated algorithms will assess the usage data and send messages to the patient when there is suboptimal usage or excessive leak, or to provide encouragement for successful use.
Specifically, we will use CPAP devices with built-in modems which will send usage data via cellular network to cloud-based platforms that will automatically analyze the usage data and send the automated messages. Patients also can track their own therapy information through the platform."
2009258|NCT03302650|Drug|Angiotensin II|Patients will receive angiotensin-II at a starting dose of 20 ng/Kg/min.
1593922|NCT02279875|Drug|Linezolid|
1593923|NCT02279875|Drug|HRZE (isoniazid rifampicin,pyrazinamide,ethambutol)|isoniazid (H) 75 mg plus rifampicin (R) 150 mg plus pyrazinamide (Z) 400 mg plus ethambutol (E) 275 mg
1593924|NCT02279862|Drug|Ipilimumab|
1593925|NCT02279849|Other|Communications|Communication materials were used to promote healthier items to consumers in corner stores.
1593926|NCT02279849|Other|Pricing|The pricing incentives were used to help promote sales of healthier food items.
1593927|NCT02279849|Other|Combined (Communications & Pricing)|Communications with Pricing incentives were used to promote the sale/consumption of healthier foods.
1593928|NCT02279836|Device|SC20 Colonoscope|Single Arm Post-Marketing Study of SC20 Colonoscope
1593929|NCT02279823|Drug|CB-03-01 solution|Investigational drug solution
1593930|NCT02279823|Drug|Minoxidil Solution 5%|FDA approved marketed product
1593931|NCT02279823|Drug|Placebo solution|Vehicle solution
1593932|NCT02279810|Behavioral|survey|Survey
1593933|NCT02279797|Behavioral|survey|Survey about Knowledge, Attitude and Practice About bone marrow donation
1593934|NCT02279784|Device|Freeway PTA|angioplasty with Freeway drug-eluting balloon
1593935|NCT02279784|Device|Lutonix PTA|angioplasty with Lutonix drug-eluting balloon
1593936|NCT02279771|Procedure|transanal anastomotic reinforcement|"a circular anal dilator (CAD) of 34mm in diameter will be introduced into the anus to facilitate the transanal introduction of the 29-31 circular stapler. The stapler shaft will be introduced trying to avoid the stapler line and connected with the anvil of the prepared proximal colon and then fired.
Patients selected on the TAR-LAR arm will have the stapled suture reinforced by 6 supplemental full thickness stitches in vycril 3/0 placed transanally with the aid of a semicircular valve introduced into the CAD (Epo Flier, SapiMed SPA, Alessandria, Italy), at hours 2-4-6-8-10-12."
1593937|NCT02279771|Procedure|protective ileostomy group|S-LAR patients will had a standard lateral protective ileostomy in the right iliac region or a colostomy in the left region.
1593938|NCT02279771|Device|a circular anal dilator (CAD)|Epo Flier, SapiMed SPA, Alessandria, Italy
1593939|NCT02279758|Drug|Metformin|
1593940|NCT02279745|Drug|APD811|
2009259|NCT03302650|Drug|Normal saline|Patients will receive normal saline.
2009260|NCT03302650|Drug|Norepinephrine|patients will receive norepinephrine infusion adjusted according to blood pressure
1593945|NCT02279719|Drug|BBI608|BBI608 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
1593946|NCT02279719|Drug|BBI503|BBI503 will be administered in combination with sorafenib at the RP2D determined during the phase 1 dose-escalation portion of study.
1593987|NCT02279407|Drug|Placebo|Placebo matching to dapagliflozin 10 mg
1593988|NCT02279394|Drug|Elotuzumab|10 mg/kg IV; Days 1, 8,15, 22 Cycles 1-2 10 mg/kg IV; Days 1 & 15 Cycles 3-8
1593947|NCT02279719|Drug|Sorafenib|Sorafenib will be administered at a fixed dose of 400 mg twice daily (800 mg total daily dose). Sorafenib should be taken on an empty stomach, one hour prior to or two hours after meals. Sorafenib should not be taken with study drug, and at least 2 hours should separate a dose of sorafenib from a dose of study drug.
1593948|NCT02279706|Other|questionnaire|Check the Korean version of rhinitis controlled assessment tests, the total non-symptom scores (total nasal symptoms score, TNSS), rhinitis-related quality of life (RQLQ), rhinitis controlled degree, severity, and after study enrollment and 4 weeks treatment.
1593949|NCT02279693|Other|CBCT|10 participants will receive a cone beam computed tomography (CBCT) repositioning
1593950|NCT02279693|Other|fiducial marker (kV imaging)|10 participants will receive a kV imaging of fiducial marker repositioning.
1593951|NCT02279693|Radiation|IGRT Associated With IMRT|
1593952|NCT02279680|Device|Electroencephalography|
1593953|NCT02279680|Behavioral|Neuropsychological assesments|
1593954|NCT02279667|Drug|BIA 2-093|oral suspension 50 mg/mL
1593955|NCT02279667|Drug|BIA 2-093|200 mg tablet
1593956|NCT02279667|Drug|BIA 2-093|800 mg tablet
1593957|NCT02279654|Drug|Lenalidomide|Lenalidomide as prescribed in routine clinical practice for low to intermediate-1 risk MDS
2009261|NCT03303170|Device|Sebacia Microparticles|Topical microparticle suspension
2009262|NCT03303170|Device|Nd:Yag Laser|Laser delivering 1064 nm wavelength light
1593960|NCT02279628|Drug|Ropivacaine|Ropivicaine (0.2%) bolus of 10ml will be injected through the catheter after surgery and continuously infused during the postoperative period (8ml/H)
1593961|NCT02279628|Drug|Morphine|Morphine will be injected intrathecally (100µg) and oral morphine will be given during the postoperative period
1593962|NCT02279615|Drug|Mirabegron|50mg of mirabegron per day will be given.
1593963|NCT02279615|Drug|Tamsulosin|0.4mg of flomax per day.
1593964|NCT02279602|Drug|fosbretabulin|fosbretabullin, 60 mg/m2 weekly for up to 1 year
1593965|NCT02279589|Biological|Pneumo 23® 0,5|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at full dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
1593966|NCT02279589|Biological|Pneumo 23® 0,1|Polysaccharide vaccine Pneumo 23® (Sanofi Pasteur MSD), containing 23 valencies Pneumococcus (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, 33F) administered by intramuscular route. (Deltoid) at a 1/5 of the dose. One dose contains: 0, 5 mL of 25 μg of polysaccharide of the 23 serotypes pneumococcus.
1593967|NCT02279589|Biological|Prevenar13® 0,5|"The conjugate vaccine Prevenar13® (Pfizer) containing 13 valencies Pneumoccocus (4, 6B, 9V, 14, 18C, 19F, 23F), conjugated with diphtheria anatoxin (CRM 197) administered by intramuscular route (deltoid).
One dose contains: 0, 5 ml of 2 - 4μg of polysaccharide of the13 serotypes pneumococcus which 12 are shared with Pneumo 23® vaccine conjugated to diphtheria toxoid (CRM 197)."
1593968|NCT02279576|Drug|Pazopanib|Pazopanib 800mg/day continuously administered.
1593969|NCT02279576|Drug|Paclitaxel|Paclitaxel 65 mg/m2 in weekly administration 3 administrations (D1, D8 and D15) every 4 weeks period.
1593970|NCT02279563|Drug|Azelastine HCl and Fluticasone Propionate Nasal Spray, 137 µg/50 µg per spray|"During the placebo lead-in period, the placebo nasal spray was administered via nasal inhalation with one spray in each nostril twice daily for 7days.
During the randomized treatment period, the investigational products (experimental, active comparator and placebo nasal spray) were administered via nasal inhalation with one spray in each nostril twice daily for 14 days"
1593971|NCT02279563|Drug|Dymista™ Nasal Spray|
1593972|NCT02279563|Drug|Placebo|
1593973|NCT02279537|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
1593974|NCT02279524|Drug|Aramchol|"Subjects will be administered Aramchol as follows:
One tablet of Aramchol 400 mg and one tablet of matching placebo for Aramchol.
One tablet of Aramchol 400 mg and one tablet of Aramchol 200 mg.
Two tablet of Aramchol matching placebo. The tablets should be taken orally in the morning within 30 min after breakfast with a glass of water (250 ml).
Subjects are allowed to omit study drugs up to 3 consecutive days during the study."
1593975|NCT02279511|Drug|ADENOSINE TRIPHOSPHATE|Infusion of 2.5g of ATP in 500 mL of saline solution. (IV)
1593976|NCT02279511|Drug|PLACEBO|Infusion of 500 mL of saline solution. (IV)
1593977|NCT02279498|Drug|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
1593978|NCT02279498|Drug|porcine (pig) PERT|oral, enterically-coated, pancreatic replacement enzymes prepared from a porcine source
1593979|NCT02279485|Drug|Perampanel|
1593980|NCT02279472|Procedure|Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia|All the patients will be achieved with pilocarpine 1% for pupil constriction, laser peripheral iridotomy(LPI) is performed using the ophthalmic neodymium: yttrium aluminium garnet laser (Laserex Tango Nd:YAG, Ellex-SuperQ Medical, Australia) and an VOLK iridotomy contact lens. After LPI, patients will be given topical prednisolone acetate 0.1% for 7 days.
1593981|NCT02279446|Other|Intermediate Visual acuity (IVA) assessment|Intermediate visual acuity (IVA) will be assessed with the Intermediate Visual acuity chart which is similar to the prevalent Jaeger chart. It consists of short blocks of text in various type sizes.The computer screen is set at a specific reading distance (1 meter) and the patient is asked to read the passage with the smallest type he/she can see. According to the smallest text he/she can read, IVA is classified from IVA1 (which is considered the equivalent of 20/20 distance visual acuity) to IVA5
1593982|NCT02279433|Drug|DS6051b|DS-6051b 50 mg and 200 mg capsules for oral administration
1593983|NCT02279420|Device|g-Cath EZ™ Suture Anchor Delivery Catheter|This is a multicenter, un-blinded, open label, pivotal supplemental study to G130163 intended to evaluate the safety and efficacy of treating previous sham subjects in the Essential pivotal trial (IDE#G130163) with the active treatment (the placement of g-Cath EZ suture anchors along with diet and exercise). Compliant sham subjects (those who attended all primary IDE follow-up visits AND who continue to meet eligibility criteria as described in this protocol) will be offered this active treatment after their 12 month unblinding visit in the Essential pivotal trial.
1593984|NCT02279407|Drug|placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
1593985|NCT02279407|Drug|Omega-3 carboxylic acids|4 g administered as 4 x 1 g capsules
1593989|NCT02279394|Drug|Lenalidomide|25 mg Oral; Days 1-21 days Cycles 1-24
1593990|NCT02279394|Drug|Dexamethasone|40 mg Oral; Days 1, 8, 15, 22 Cycles 1-2 40 mg Oral; Days 1, 8, 15 Cycles 3-8
1593991|NCT02279381|Drug|Chlorhexidine|4% chlorhexidine will be applied to the umbilical stump from day 1 to day 10
1593992|NCT02279381|Other|Kangaroo Mother Care|Skin to Skin Care which is Kangaroo mother care will be carried out by mother from Day 1 till the study completion
1593993|NCT02279381|Other|Essential Neonatal Care|Essential Neonatal Care ensures delayed bathing, use of colostrum, exclusive breast feeding, skin to skin care for hypothermia, dry cord care, eye care and immunization for the newborn
1593994|NCT02279368|Behavioral|Family Counselling and safeguarding|
1593995|NCT02279342|Drug|Febuxostat|The starting dose of the febuxostat will be 10mg /day. The dose will be increased to 20 mg/day at week 4 and finally titrated to 40 mg/day at week 8.
1593996|NCT02279329|Other|Hyperpolarized Helium MRI|Hyperpolarized helium-3 (3He) magnetic resonance imaging (MRI) has recently emerged as another research approach for the non-invasive measurement of lung structure and function, including conduction of gas through airways and into airspaces. Preliminary studies suggest that 3He MRI may be ideally suited for longitudinal COPD research, which is a likely target application of this novel technology. 3He MRI provides a complementary and alternative method for evaluating COPD and may be superior to CT because it allows simultaneous visualization of both airway and airspace structure and function.
1593997|NCT02279316|Drug|Vi-De 3|All participants receive a dose of 800 IU vitamin D3 per day as a standard of care. 800 IU Vitamin D is the dose that is currently recommended by the Swiss Health Department (Bundesamt für Gesundheit) for seniors over 60.
1593998|NCT02279316|Other|Jaques-Dalcroze eurhythmics|The Jaques-Dalcroze eurhythmics method includes different courses of motion (multi-task exercises) that are conducted to the rhythm of improvised piano music. A session starts with a short warm-up that includes simple exercises to get body and mind prepared for the rest of the exercise session. The complexity of the exercises increases gradually during the session: starting with single tasks and then combining them into a multi-task exercise gradually increasing complexity.
1593999|NCT02279316|Other|Home exercise program|The home exercise program is a strengthening program that will consist of five simple exercises.
1594000|NCT02279303|Behavioral|Dietary Intervention|Participants will receive individualized anti-inflammatory dietary prescriptions with six monthly workshops (culinary demonstrations, recipes and meal planning) and behavior change cures reinforced through evidence- and theory-based patient navigation, motivational interviewing, and tailored newsletters personalized to individual readiness for change.
1594001|NCT02279303|Behavioral|Dietary Control|Control participants will receive minimal nutritional information at baseline, monthly American Cancer Society survivorship brochures, and two telephone calls prior to assessment appointments.
1594002|NCT02279290|Behavioral|Healthy Mind Intervention (HMI)|Healthy Mind Intervention (HMI) is a flexible cognitive-behavioral resilience building program. Participants will receive 8 weekly, 60-minute individual sessions of HMI. In HMI, participants will be able to select 3 areas of resilience that they want to work on.
1594003|NCT02279290|Behavioral|Healthy Body Intervention (HBI)|The 8 weekly, 60-minute individual sessions will include the following topics: the mind-body connection, nutrition, exercise, unhealthy substances, sleep, preventing illness, and preventive care. Each session is spent providing didactic information on these topics and strategies for how to engage in behavior change in these areas.
1594004|NCT02279277|Behavioral|Supervised physical therapy program prior to total knee replacement surgery|
1594005|NCT02279264|Device|RightSpot Infant pH Indicator|pH indicator
1594006|NCT02279251|Behavioral|VÅG|Low-intensity CBT intervention
1594007|NCT02279251|Behavioral|CHILLED|Evidence based CBT intervention
2009263|NCT03302936|Drug|Phenazopyridine|to be given preoperatively
1594009|NCT02279225|Radiation|Group Phototherapy|
1594010|NCT02279225|Radiation|Phototherapy + Physical activity|
1594011|NCT02279225|Other|Physical activity|
1594012|NCT02279225|Other|Placebo|
1594013|NCT02279186|Drug|Tranexamic Acid|Intravenous Injection
1594014|NCT02279173|Drug|Romiplostim|Romiplostim subcutaneous weekly injection
1594015|NCT02279160|Drug|APD811|
1594016|NCT02279160|Drug|Placebo|
1594017|NCT02279147|Drug|neostigmine methylsulfate，raceanisodamine hydrochloride|The patients receive immediately raceanisodamine hydrochloride(10mg) by intramuscular injection after operation .From that date, for three consecutive days, the patients will be receive 50mg raceanisodamine hydrochloride and 0.15mg neostigmine methylsulfate in the 24h by slow injection of vein.
1594018|NCT02279134|Radiation|Adjuvant Chemoradiation|Patients receive Paclitaxel 135-150mg/m2 (D1 and D29) and Cisplatin or Nedaplatin 50-75mg/m2 (D1 and D29) every 4 weeks, concurrent with radiotherapy. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity.
1594019|NCT02279134|Radiation|Adjuvant Radiation|Patients undergo radiotherapy once daily 5 days a week for an average of 5.5 weeks within 12 weeks after surgery in the absence of disease progression or unacceptable toxicity.
1594020|NCT02279134|Drug|Paclitaxel|135-150mg/m2 (D1 and D29)
1594021|NCT02279134|Drug|Cisplatin or Nedaplatin|50-75mg/m2 (D1 and D29)
1594022|NCT02279121|Device|Taurolock|At the beginning of each course of IV anti-tumor treatment, a nurse removes the lock TauroLock ™ and makes rinsing the CVC. At the end of each course, she rinses again the CVC and instills TauroLock ™ solution. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
2009264|NCT03300921|Drug|Paricalcitol|"Product: Paricalcitol
Dose/Route/Regimen:
Arm A: 50mcg IV weekly Arm B: 12mcg PO daily"
2009265|NCT03302039|Drug|Single shot phenylephrine|A single shot of phenylephrine (1.5 mcg/Kg) will be administrated intravenously.
2009266|NCT03302039|Drug|Fixed infusion phenylephrine.|Fixed infusion of phenylephrine will be administrated at a rate of 0.75 mcg/Kg/min
2009267|NCT03302039|Drug|Variable infusion phenylephrine.|Variable infusion of phenylephrine will be administrated at a starting rate of 0.75 mcg/Kg/min.
2009268|NCT03302039|Drug|Bupivacaine|Bupivacaine will be administrated in the subarachnoid space for spinal anesthesia.
2009269|NCT03301987|Other|Therapeutic exercise|30 minutes per day of therapeutic exercise
1594023|NCT02279121|Drug|saline solution|At the beginning of each course of IV anti-tumor treatment, a nurse makes rinsing the CVC. At the end of each course, she rinses again the CVC. Patients will be followed for each treatment, according to the same rhythm of their anti-tumor treatment program up to the end of the study
2009270|NCT03301363|Device|CRT|Subjects scheduled to be implanted for CRT by a Quadripolar Pacing System
2009271|NCT03301207|Drug|Ibrutinib|Ibrutinib capsule (at dose of 420 or 560 mg) will be taken orally QD.
2009272|NCT03301207|Drug|OC: Ethinylestradiol (EE) 30 mcg and Levonorgestrel (LN) 150 mcg|Single dose of oral contraceptives (OC) (1 tablet containing 30 mcg EE and 150 mcg LN) will be taken orally on Study Days 1 and 22.
2009273|NCT03301207|Drug|Bupropion|Bupropion 75 mg tablet as a part of CYP cocktail will be taken on Study Days 3 and 24.
2009274|NCT03301207|Drug|Midazolam|Midazolam 2 mg (1 milliliter [mL]) oral solution will be taken on Study Days 3 and 24 (as a part of CYP cocktail) and on Study Day 8 (alone).
2009275|NCT03300843|Biological|Peptide loaded dendritic cell vaccine|Cells for intravenous injection (IV) will be infused on the In-Patient Care Unit or 3SE Day Hospital over 20 to 30 minutes. Cells for subcutaneous injection will be administered in a total of 1.0mL into the deep subcutaneous tissue of a proximal extremity.
2009276|NCT03300362|Drug|Seasonal influenza vaccine|Seasonal influenza vaccine
1594031|NCT02279069|Device|4-roll canne|
2009277|NCT03300362|Drug|MVA-NP+M1|Trial vaccine
2009278|NCT03300362|Drug|Sodium chloride|Saline placebo
1594034|NCT02279043|Behavioral|Birth Control Connect (intervention)|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for eleven days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. Half of participants in Birth Control Connect intervention groups will be current IUC users."
1594035|NCT02279043|Behavioral|Birth Control Connect (control)|"Birth Control Connect is an online community where women will be invited to share their personal experiences with birth control. Birth Control Connect group sessions will last for twelve days. Each day, participants will be prompted to respond to questions in the group (e.g. If you're using a birth control method right now, how did you choose it?). Participants will also be able to pose questions to other members of the group and respond to other members' questions. No participants in Birth Control Connect control groups will be current IUC users."
2009279|NCT03299972|Dietary Supplement|Whey Protein|25 g of whey protein supplementation twice daily (breakfast and lunch)
1594037|NCT02279017|Behavioral|mHealth Texting for Weight Loss|
1594039|NCT02278978|Drug|BIBF1120|BIBF1120 200 mg two times per day orally
1594040|NCT02278965|Drug|Metformin|Metformin 850mg, oral, twice a day for 12 months
1594041|NCT02278965|Drug|Omega-3 fatty acids|Omega-3 fatty acids 2 capsules (560 mg each) oral, twice a day for 12 months
1594042|NCT02278939|Behavioral|Filipinos Fit and Trim Weight Loss Program|This 3-month pilot RCT with wait-list control Fit and Trim lifestyle intervention is designed to reduce weight by increasing physical activity, and health eating to improve fasting glucose and hemoglobin A1c. This intervention will use a mobile phone health app diary to self-monitor weight, physical activity, and diet to improve health outcomes to reduce type 2 diabetes risks in Filipino Americans. Program goals are to lose 5% body weight, increase and maintain steps to 12,000 steps/day (20% increase in step-counts each week), reduce total daily fat intake (25% of total calories from fat), and sugar-sweetened beverages over 3 months.
1594043|NCT02278926|Other|Ultrasound|Ultrasound measurements
1594044|NCT02278926|Other|Tapping and body inspection to define the area of insulin injection|Obese patients with a thickening fat subcutaneous tissue that could have interfered with the interpreting and analyzing of the data are left out of this first study. In the control group we manage to define the lypo-hypertrophic area by tapping and body inspection
1594045|NCT02278913|Drug|Basal Bolus (Glargine and Glulisine)|Glargine daily + Glulisine before meals
1594046|NCT02278913|Drug|Human Insulin|NPH twice a day + Regular insulin before meals
1594047|NCT02278900|Other|Communication aids|Question Prompt list Audiofile
1594048|NCT02278887|Procedure|Translational research|Before during and at progression/regression biopsies and blood will be taken for translational research
1594049|NCT02278887|Drug|Cyclophosphamide|The patient receives 2 days cyclophosphamide via IV to deplete T-cells.
1594050|NCT02278887|Drug|Fludarabine|The patient receives 5 days fludarabine via IV to deplete T-cells.
1594051|NCT02278887|Drug|Interleukin-2|After infusion of the TIL, the patient receives IL-2 to keep the TIL active.
1594052|NCT02278887|Drug|Ipilimumab infusion|In arm A patients will be treated with 4 infusion of ipilimumab
1594053|NCT02278861|Drug|Oral isotretinoin|Oral isotretinoin - 10mg/day (one pill) after lunch for six months
1594054|NCT02278861|Drug|Tretinoin 0,05% cream|Topical tretinoin 0,05% cream - applied every other night in the face and forearms for six months
1594055|NCT02278861|Drug|Sunscreen FPS 60|Sunscreen FPS 60 applied on sun exposed areas every 3 hours daily
1594056|NCT02278848|Other|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)|Diagnosis of ICAH using new investigative techniques (computerised gait analysis, ultrasound, MRI flow, urinary incontinence scale)
1594057|NCT02278835|Other|breathing exercises|3 sets of 10 repetitions of deep breathing exercises
1594058|NCT02278835|Device|incentive spirometry|3 sets of 10 repetitions of deep breathing exercises with incentive spirometry
1594059|NCT02278835|Device|Intermittent positive pressure breathing|20 minutes breathing with intermittent positive pressure
1594060|NCT02278835|Device|Continuous positive airway pressure|20 minutes breathing with continuous positive airway pressure
1594061|NCT02278822|Other|Low dose oral liposomal glutathione supplementation|Low dose oral liposomal glutathione supplementation
1594062|NCT02278822|Other|High dose oral liposomal glutathione supplementation|High dose oral liposomal glutathione supplementation
1594089|NCT02278614|Drug|Xalacom|Xalacom® 0.01% eye drop solution is supplied in 2.5 ml multidose container.
1594385|NCT02276443|Procedure|Ultrasound|Ultrasound performed at baseline, and after 2 and 4 cycles of chemotherapy.
1594063|NCT02278809|Behavioral|Movie Models|"The intervention group got acces to a private website for 4 weeks on which the online videos were placed (Week 1: fruit + water, week 2: vegetables + breakfast + supermarket, week 3: PA, week 4: SB)
After each week, parents received a link for an online process evaluation questionnaire in which we asked how many times they watched each video, if they discussed the videos with other people, if they found them interesting, boring…"
1594066|NCT02278783|Drug|regorafenib|Patients will be treated with Regorafenib 160 mg (4 x 40 mg tablets) daily for 21 days of a 28 day cycle (three weeks on drug, one week off) until disease progression or adverse effects prohibit further treatment
1594067|NCT02278757|Other|High protein diet|Group received a diet with higher protein content (1.34gr/kg body weight). Meal replacements (drinks and bars) and individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. Participants consumed two, protein-enriched drinks, contributing to the daily protein intake along with conventional foods and two low-fat bars. For both groups (intervention and control), the calorie density had a restriction of 500kcal/day calories less than the resting metabolic rate (RMR) and were equivalent in the type of carbohydrate. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week).
1594068|NCT02278757|Other|Low protein diet|Control group received a diet with a lower protein content (0.8gr/kg body weight). Conventional foods (such as fish, meet, vegetables, fruits, nutrs, beans, etc) were prescribed. Individualized menus, controlling the content of calories, protein, carbohydrates, and fat, had more control over the total amount of protein consumed daily. The calorie density had a restriction of 500kcal/day. Recommendations for exercise (e.g., walking, biking or jogging at least 30 minutes/day, 5 days per week)
1594069|NCT02278744|Radiation|single-fraction radiation|Patients enrolled on this study will be registered into a dose tier and undergo 1 session of image-guided SRS using techniques previously. Three escalating SRS spinal cord/cauda maximum dose (Dmax) levels (14 Gy, 16 Gy, and 18 Gy) will be evaluated to determine the safety of this approach. A minimum of three patients will be treated per dose tier. Toxicity based on NCI CTCAE (v4). Post treatment followup at 2 and 4 months (+/- 2 weeks) post-treatment, at 6 months (+/- 4 weeks) and then every 3 months until 2 years (± 4 weeks). Followup schedule based on last day of treatment. No schedule adjustments based on early or delayed visits.
1594070|NCT02278744|Device|MRI and/or CT|
1594071|NCT02278731|Other|training program|Participants were randomly allocated to 1 of 3 groups: Pilates group (n=20), which underwent one-month (three times per week) training program with the Pilates method; PNF group (n=20), that underwent one-month (three times per week) training program using the PNF method; and Control group (n=18), that received no intervention during that one month and continued with their daily activities.
1594074|NCT02278705|Other|BMI screened/interpreted|Provider identified and interpreted BMI percentile.
1594075|NCT02278705|Other|Provider addressed weight and weight-related disease risk|Provider addressed high weight status, including completing assessment of weight-related disease risk (indicated labs completed)
1594076|NCT02278705|Other|Provider reassessed high weight status|Provider and patient completed one or more interim visits to reassess progress or patient completed referral to nutrition, weight-management program, or relevant specialist
1594077|NCT02278705|Other|No weight-status assessment|There is no indication that the provider assessed the child as overweight, including evidence of addressing weight, weight-related disease risk, scheduling an interim visit to readdress weight management
1594078|NCT02278692|Dietary Supplement|Vitamin K|Oral vitamin K
1594079|NCT02278692|Other|Placebo|Oral placebo tablet
1594080|NCT02278679|Procedure|Digital Rectal Exam|The DRE digital rectal exam is an essential component of physical examination, but physicians enter their residency having neither been appropriately exposed nor trained in performing DREs. , the attending physician, resident physician(s), and medical student(s) will each perform a digital rectal exam on the subject, and independently document their examination on the DiRECT instrument.
1594081|NCT02278666|Procedure|aortic valve replacement|aortic valve replacement with either biological prosthetic valve or mechanical valve
1594082|NCT02278666|Device|biological prosthetic valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
1594083|NCT02278666|Device|Mechanical valve|aortic valve replacement with either biological prosthetic valve or mechanical valve
1594084|NCT02278653|Other|Questionnaires for the evaluation of Quality of Life|"European Organisation for Research and Treatment of Cancer (EORTC) QLQ-30 questionnaire, version 3.0, Global Quality of Life Score
Short Form (36) health survey
EORTC CR38
Vaizey score
Low Anterior Resection Syndrome (LARS) score
International Index of Erectile Function for men
International Prostate Symptom Score for men
Female Sexual Function Index for women"
1594085|NCT02278653|Other|Manometry|Manometry is a tool to measure the anal sphincter function. Patients do not need any bowel preparation before this procedure. During the examination a catheter tip will be positioned in the rectum above the sphincter and a small balloon will be inflated. This balloon is connected to a device that registers the measurements. Patients will receive instructions; e.g. squeeze, push, and cough. The procedure takes approximately 10 minutes and is not experienced as painful. Several parameters will be measured: the mean basal pressure, the maximum squeeze pressure, first sensation, first urge to defecate and the maximum tolerable volume. The manometric measurement will take place on the same day as the endoscopy and MRI (standard follow-up).
1594086|NCT02278640|Device|Harmonic ACE®+7 Shears|Vessel/pedicle sealing performance assessed for transection and sealing of the of the uterine vasculature.
1594087|NCT02278627|Other|manual lymphatic drainage|
1594088|NCT02278614|Drug|T2347|T2347 eye drop solution is presented in SDU. It is supplied in 0.20 ml single use polyethylene containers.
1594140|NCT02278250|Drug|Carboplatin|
1594090|NCT02278601|Device|epidural delivery system|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
1594091|NCT02278601|Drug|Ropivacaine|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
1594092|NCT02278601|Drug|Fentanyl|epidural delivery system for maintenance of labour epidural analgesia using 0.1% ropivacaine (amide local anaesthetic) with 2mcg/ml fentanyl (opioid) as maintenance solution
1594093|NCT02278588|Drug|Rasagiline|
1594094|NCT02278575|Drug|Atenativ|intravenous transfusion
1594095|NCT02278562|Drug|anakinra|100 mg in syringes; administered subcutaneously 3 times a week for 12 weeks (3 months)
1594096|NCT02278562|Drug|actos|30 mg capsules; administered orally 1 capsule per day for 12 weeks (3 months)
1594097|NCT02278562|Other|placebo|placebo capsules and injection
1594098|NCT02278523|Device|Threshold IMT®|A device used to offer threshold load to inspiratory muscle
1594099|NCT02278510|Drug|Topotecan|Topotecan is a chemotherapy that is approved by the FDA to treat cancers. It is normally given by an intravenous injection, and not directly into a tumor. That is why it is considered to be an investigational drug for this study
1594100|NCT02278510|Drug|Gadolinium DTPA|Gadolinium DTPA is a contrast agent which will be added to topotecan to allow the investigators to observe where topotecan goes in tumors. Gadolinium DTPA is approved by the FDA for intravenous injection during an MRI scan. It is not approved by the FDA for administration directly into a tumor.
1594101|NCT02278510|Device|Cleveland Multiport Catheter|The Cleveland Multiport Catheter is a device that is not approved by the FDA and so it is classified as an investigational device. It has been designed to deliver drugs and other agents intended to treat cancers directly into the affected tissues. The Cleveland Multiport Catheter can be placed into a brain tumor only in the operating room. It is placed during an operation to perform a biopsy of brain tumors. Following the biopsy, a surgeon will place two catheters into the tumor with use of an image guided navigation system. Once each catheter has been placed, it will be secured into the scalp and the incision will be closed. The Cleveland Multiport Catheter will be left in place until the completion of the topotecan treatment.
1594102|NCT02278497|Other|ASSESSMENT OF CORONARY FLOW RESERVE BY PET-H215O AND FFR|
1594103|NCT02278484|Device|XprESS device and PathAssist confirmation tools|
1594104|NCT02278471|Drug|Polypill (atorvastatin, amlodipine, losartan, and hydrochlorothiazide)|
1594105|NCT02278458|Drug|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
1594106|NCT02278458|Drug|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
1594107|NCT02278445|Radiation|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
1594108|NCT02278445|Device|Transthoracic Parametric Doppler (TPD) (Echosense Ltd., Haifa, Israel)|
1594109|NCT02278419|Drug|Simeprevir|Simeprevir 150 mg capsule orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
1594110|NCT02278419|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally, once daily for 8 weeks in Group A1, 12 weeks in Group A2 and Group B.
1594111|NCT02278406|Other|Deep brain stimulator|We will measure brain oxygen levels with a non-invasive near infrared spectroscopy device.
1594112|NCT02278393|Other|1-Fermented Dairy Product with Phytosterols (test)|1- 3 bottles of test product/day
1594113|NCT02278393|Other|2-Fermented dairy Product with No Phytosterols (control)|2-3 bottles of control product/day
1594114|NCT02278380|Other|Low GI Standard Breakfast|Low GI Standard Breakfast
1594115|NCT02278380|Other|Medium GI Standard Breakfast|Medium GI Standard Breakfast
1594116|NCT02278380|Other|Enfamama A+|Nutritional pregnant milk supplement
1594117|NCT02278380|Other|Glucerna Triple Care|Nutritional product for diabetics
1594118|NCT02278380|Other|Dumex Precima|Pregnant and lactation women milk powder
1594119|NCT02278380|Other|Diasip|Nutritional drinks for diabetics
1594120|NCT02278380|Other|Test product|Test product not patented yet
1594121|NCT02278367|Drug|18F-AV-1451|370 megabecquerel (MBq) (10 millicurie [mCi])
1594122|NCT02278354|Drug|18F-AV-1451|
2009280|NCT03299972|Dietary Supplement|Placebo|23.75 g of placebo powder twice daily (breakfast and lunch)
2009281|NCT03299972|Other|Resistance Exercise|60 minutes of resistance exercise twice a week
1990346|NCT02074306|Device|UROSHIELD®|An active UROSHIELD® device (low energy acustic wave generator) will be connected to an intratracheal tube externally. The device will transform low energy ultrasound waves on to the tube. These waves will by assumption lower the formation of bacterial growth and resistance to antibiotics.
1594126|NCT02278328|Drug|STX209|A randomized acute dose-response design will be employed with a total study duration of 3 weeks. At each visit, baseline MEG will be obtained followed by acute single-dose drug/placebo administration, followed 60 minutes later by repeat MEG. Each participant will receive a single dose of placebo in random order and a single dose of STX209 from smallest to largest (15mg, and 30mg). MRI and MRS will be performed immediately following MEG to provide an anatomic basis for source localization as well as to assess acute effects of STX209 administration on MRS estimates of GABA and glutamate.
1594127|NCT02278328|Drug|placebo|
1594128|NCT02278315|Drug|I-131-CLR1404|Single IV dose of I-131-CLR1404, increased/decreased by cohort
1594129|NCT02278315|Drug|dexamethasone|40 mg dexamethasone orally once weekly for up to 12 weeks
1594130|NCT02278302|Drug|Aggrenox®|
1594131|NCT02278302|Drug|Placebo|
1594132|NCT02278302|Other|Ethanol|
1990347|NCT02074306|Device|SHAM UROSHIELD®|SHAM UROSHIELD® will be connected to endotracheal tubes unable to transform any waves.
1594135|NCT02278276|Drug|sodium polysulthionate|Bioavailable composition of α-sulfur
1594136|NCT02278276|Drug|Placebo|400 mg capsules containing placebo
1594139|NCT02278250|Drug|VX-803|
1594144|NCT02278224|Behavioral|Group based rumination focused CBT|The RFCBT is a group trans-diagnostic manual based psychotherapy for depression and anxiety. RFCBT focuses on increasing effective behaviour - i.e., not stopping rumination but making it functional. It's grounded within the core principles and techniques of CBT for depression with two adaptations: (1) a functional-analytical perspective using Behavioural Activation (BA) approaches, (2) an explicit focus on shifting processing style via imagery and experiential approaches.
1594145|NCT02278224|Behavioral|Group based CBT|The control group is gold standard group based CBT based on Becks manual for CBT for depression.
1594146|NCT02278198|Drug|rhTSH|Intramuscular injections of rhTSH (Thyrogen) will be given on days 1 and 2.
2009282|NCT03299049|Drug|Cabotegravir Tablets|CAB tablets are white to almost white oval shaped film coated 30 mg tablets for oral administration. CAB tablets are to be stored up to 30 degree Celsius and protected from moisture.
2009283|NCT03299049|Drug|Rilpivirine Tablets|"RPV tablets are 25 mg tablets that are off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. RPV tablets should be stored at 25 degree Celsius (excursions permitted to 15 degree-30 degree Celsius) and protected from light."
1594153|NCT02278172|Dietary Supplement|Vitamin D|3000IU (75 μg) vitamin D in a commercially available oral spray solution
1594154|NCT02278172|Dietary Supplement|Placebo|Placebo oral spray solution manufactured to mimic the vitamin D oral spray
1594155|NCT02278159|Procedure|Peritoneal dialysis|
1594156|NCT02278159|Procedure|Home hemodialysis|
1594157|NCT02278146|Device|ParaPatch|A device for the treatment of urinary incontinence
1594161|NCT02278120|Drug|LEE011|LEE011 600 mg daily oral
1594162|NCT02278120|Drug|Tamoxifen|tamoxifen 20 mg daily oral
1594163|NCT02278120|Drug|Letrozole|letrozole 2.5 mg daily oral
1594164|NCT02278120|Drug|Anastrozole|anastrozole 1 mg daily oral
1594165|NCT02278120|Drug|Goserelin|Goserelin 3.6 mg subcutaneous injection
1594166|NCT02278120|Drug|LEE011 Placebo|LEE011 placebo 600 mg daily oral
1594167|NCT02278107|Device|Tidal Assist Ventilator System|Tidal volume augmentation with supplemental oxygen. Source gas options: cylinder, concentrator, wall.
1594168|NCT02278107|Device|Nasal Cannula Oxygen|Standard oxygen therapy delivered by nasal cannula at 2-5 lpm based on patient requirements. Source gas options: cylinder, concentrator, wall.
1594169|NCT02278094|Device|Tongue Muscle Trainer (TMT)|Subject will be instructed to compress the Iowa Oral Performance Instrument (IOPI) IOPI's bulb using tongue in three directions (anterior and both lateral sides). Then, hold 30-35 seconds each time. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
1594170|NCT02278094|Device|Threshold Inspiratory Muscle Trainer (TIMT)|Resistance of the TIMT devices will be set from 30% of the maximum inspiratory pressure. Nose clip follow by normal breathing. Seal the mouth to the device's mouth piece then inhale through the device. Subjects will be encouraged to do 60 minutes of exercise daily then continue three to five times a week for a total of 3 months.
1594171|NCT02278094|Procedure|Walking Exercise|Subjects will be encouraged to perform walking exercise in the field 10000 steps/ 60 minutes daily then continue three to five times a week during first months. Followed by 12500 steps and 15000steps per day during the second and third months.
1594172|NCT02278094|Device|Continuous Positive Airway Pressure (CPAP)|CPAP regular therapy per day (use ≥ 4 h/day) then continue three to five times a week for a total of 3 months.
1594173|NCT02278081|Drug|lansoprazole|the lansoprazole will be taken orally.
1594174|NCT02278081|Drug|placebo|the lansoprazole placebo will be taken orally.
1594175|NCT02278068|Device|Metabolic Neuromodulation System (MNS)|Prospective, First-in-Human (FIH), multi-center, non-randomized trial to evaluate the initial safety and performance of hepatic sympathetic denervation to aid in glycemic control.
1594176|NCT02278055|Drug|Radium-223|
1594177|NCT02278042|Other|Beverage Consumption|
1594178|NCT02278003|Other|memory test|
1594179|NCT02278003|Drug|Propofol|
1594181|NCT02277977|Other|Contrast enhanced ultrasound|Contrat enhanced ultrasound during septic shock
1594182|NCT02277951|Device|The Bonfils Intubation Fibrescope|Effectiveness and time to successful intubation will be measured.
1594183|NCT02277951|Device|The Video Rigid Flexing Laryngoscope|Effectiveness and time to successful intubation will be measured.
1594184|NCT02277951|Device|The C-MAC® S Video Laryngoscope|Effectiveness and time to successful intubation will be measured.
1594185|NCT02277951|Device|The Macintosh Laryngoscope|Effectiveness and time to successful intubation will be measured.
1594186|NCT02277938|Drug|Amantadine|Amantadine is a drug that has been on the market for several years and is currently approved for the treatment of Parkinson's disease and for prevention against influenza A infection. Amantadine may be of value in detecting the presence of cancer.
1594187|NCT02277925|Device|polytetrafluoroethylene, Gore-Tex permanent suture|polytetrafluoroethylene, Gore-Tex permanent suture
1594188|NCT02277925|Device|2-0 polydioxanone, PDS delayed absorbable monofilament suture|2-0 polydioxanone, PDS delayed absorbable monofilament suture
1594189|NCT02277912|Device|navigated repetitive Transcranial Magnetic Stimulation|Navigated repetitive transcranial magnetic stimulation of the motor cortex ( 10 Hz ) ,5 daily sessions per week for two weeks.
1594190|NCT02277912|Device|navigated repetitive Transcranial Magnetic Stimulation|Navigated repetitive transcranial magnetic stimulation of the secondary somatosensory cortex ( 10 Hz ), 5 daily sessions per week for two weeks
1594191|NCT02277912|Device|SHAM repetitive Transcranial Magnetic Stimulation|Repetitive SHAM transcranial magnetic stimulation of the motor cortex ( 10Hz) 5 daily sessions per week for two weeks.
1594192|NCT02277899|Other|Communication regarding overweight status|Pediatrician-patient/parent communication regarding child's high weight status
1594193|NCT02277899|Other|Risk-factor assessment and counseling|Counseling regarding cardiovascular risk factor assessments/results.
1594194|NCT02277899|Other|Lifestyle behavior assessment and counseling|Counseling regarding diet and lifestyle changes to improve weight status.
1594306|NCT02277067|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
1594195|NCT02277899|Other|Interval follow-up to readdress weight|Interval follow-up to readdress weight, prior to the next well-child visit one year later. Follow-up could include ongoing care through nutrition and/or an intensive weight-management program.
1594196|NCT02277899|Other|Patient-centered communication|Patient-centered communication will be scored as the ratio of patient to doctor-centered communication regarding weight topics. Means will be calculated for total and weight-communication-specific pediatrician, child, and parent-talk time, and patient, doctor, and the ratio of patient/doctor-centered communication scores. For the primary hypothesis, biomedical information-giving (for example, risk-factor communication) will be treated as patient-centered because the principal investigator's focus groups suggest that parents want this information, and prior research suggests that including biomedical-information giving improves the correlation of Roter's patient-centeredness measure with patient health status and satisfaction scores.
1594197|NCT02277886|Drug|sodium alginate|oral suspension, 50mg/ml, 20ml once at bed time
1594198|NCT02277886|Drug|esomeprazole|40mg/tablet, one tablet once before breakfast
1594199|NCT02277873|Behavioral|pregnancy|Observational study in order to establish relationship between moon and births
1594200|NCT02277860|Behavioral|Exercise|Aerobic and strength training using the Wii Fit for ≥ 30 min, ≥3 days/week, for 12 weeks, at a moderate intensity (Borg CR10 3-5).
1594201|NCT02277847|Drug|Idarubicin(8mg/m2) and cytosine arabinoside|IDA 8mg/M2 per day, D1-3. iv injection in 10 minutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
1594202|NCT02277847|Drug|Idarubicin(10mg/m2), cytosine arabinoside|IDA 10mg/M2 per day, D1-3. iv. injection in 10mimutes;Ara-C：100-200mg/M2 per day, D1-7. administration advice: at first, 25 mg/M2 of Ara-C is given by fast intravenous injection, then 100 mg/M2 of Ara-C is given by continuous iv drip for 24 hours for successive 7 days.
1594203|NCT02277821|Device|Stendo pulsating suit System|The Stendo system, a multilayer pulsatile inflatable suit is applied to the lower limbs and the abdomen. This device induces a sequential compartmentalized compression synchronized with each diastolic phase of the cardiac cycle, each phase evolving centripetally (lower limbs to abdomen).
1594204|NCT02277808|Drug|500mg Amikacine (Amukin®) diluted in 4mL NaCl (0,9%)|
1594205|NCT02277808|Device|Respirgard II|
1594206|NCT02277808|Device|Isoneb®|
1594207|NCT02277795|Device|AccuCirc|Circumcision with the use of the AccuCirc device.
1594208|NCT02277782|Drug|Hydromorphone|
1594209|NCT02277782|Drug|Hyperbaric bupivacaine|
1594210|NCT02277782|Drug|Fentanyl|
2009284|NCT03299049|Drug|Cabotegravir Injectable Suspension|CAB LA injectable suspension is a sterile white to slightly pink suspension containing 200 mg/mL of GSK1265744 as free acid for administration by IM injection. CAB LA injectable suspension is to be stored at up to 30 degree Celsius and should not be freezed.
2009285|NCT03299049|Drug|Rilpivirine Injectable Suspension|RPV LA injectable suspension is a sterile white suspension containing 300 mg/mL of RPV as the free base for administration by IM injection. RPV LA injectable suspension should be kept in the outer package and stored at 2-8 degree Celsius and should not be freezed. RPV LA should also be protected from light.
1594216|NCT02277730|Device|vasopressor delivery automated system|vasopressor delivery using phenylephrine and ephedrine
1594217|NCT02277730|Drug|phenylephrine|
1594218|NCT02277730|Drug|ephedrine|
1594219|NCT02277730|Device|manual vasopressor delivery|
1594220|NCT02277717|Drug|SYD985 (trastuzumab vc-seco-DUBA)|IV (in the vein) infusion every three weeks. Number of Cycles: until cancer progression or unacceptable toxicity develops. Different doses.
1594223|NCT02277691|Drug|TAK-536TCH tablet|TAK-536TCH tablets
1594224|NCT02277691|Drug|TAK-536CCB tablet|TAK-536CCB tablets
1594225|NCT02277691|Drug|HCTZ 12.5 mg tablet|HCTZ tablets
1594226|NCT02277678|Drug|Opioid administration oxycodone|Epidural administration single dose through epidural catheter
1594227|NCT02277678|Drug|Opioid administration morphine|
1594228|NCT02277665|Behavioral|CUD Treatment|
1594229|NCT02277665|Behavioral|Tobacco Treatment|
1594230|NCT02277652|Device|The Miller Laryngoscope|Direct laryngoscopy
1594231|NCT02277652|Device|The Bonfils intubation fibrescope|Optical laryngoscopy
1594232|NCT02277652|Device|The GlideScope Ranger|Videolaryngoscopy
1594233|NCT02277652|Device|The Supraglottic Airway Laryngopharyngeal Tube (SALT)|Blind intubation
1594235|NCT02277626|Device|Electro Flo 5000|Airway clearance device
1594236|NCT02277626|Device|Incourage Vest System|Airway Clearance Device
1594237|NCT02277613|Biological|AMI MultiStem cells|AMI MultiStem cells administration in coronary artery with a micro-infusion catheter.
1594238|NCT02277613|Other|Sham|Sham procedure using Micro-Infusion Catheter in coronary artery without injection.
1594239|NCT02277600|Drug|BMS-663068|BMS-663068
1594240|NCT02277600|Drug|Darunavir|Darunavir
1594241|NCT02277600|Drug|Cobicistat|Cobicistat
1594242|NCT02277587|Drug|Plenadren|Oral Tablets: 20-25-30 mg
1594243|NCT02277587|Drug|Conventional glucocorticoid therapy|Oral Tablets: 20-25-30- 37.5 mg
1594244|NCT02277574|Biological|AMP-110|2, 5, or 10 mg/kg
1594245|NCT02277574|Other|Placebo|Placebo
1594246|NCT02277561|Procedure|diffusion tensor imaging|Undergo VB-DTI
1594247|NCT02277561|Radiation|whole-brain radiation therapy|Undergo WBRT
1594248|NCT02277561|Radiation|stereotactic radiosurgery|Undergo SRS
1594249|NCT02277561|Procedure|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced MRI
1594250|NCT02277561|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW MRI
1594251|NCT02277548|Drug|Lyrica 300 mg|Lyrica 300 mg per day
1594252|NCT02277535|Other|Feedback/Reminder email.|
1594253|NCT02277522|Biological|RNA anti-CD19 CAR T cells|intravenously administered, RNA electroporated autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCRζ and 4-1BB (TCR /4-1BB) costimulatory domains (referred to as RNA CART19)
1594254|NCT02277509|Behavioral|Chinese DPP|The Chinese DPP intervention will include core curriculum, stress reduction, physical activity sessions, and self-monitor diet and physical activity.
1594255|NCT02277509|Behavioral|Minimal Intervention Control|Patients will receive printed diabetes prevention materials in Chinese. Materials will be from primary from the National Diabetes Education Program and from the New York City Department off Health and Mental Hygiene. Patients will receive an educational packet at randomization and quarterly thereafter.
1594256|NCT02277496|Behavioral|Toolkit Intervention|The toolkit intervention consists of strategies and activities to engage students (student toolkit) and school wellness councils (school toolkit) in addressing the six targeted behaviors of the 2010 Dietary Guidelines based on the principles of participatory action research. The intervention will promote goal setting and school-based food and physical promotion activities led by students as well as school wellness network development.
1594257|NCT02277483|Drug|LAIS®|10 X 1,000 / twice a week
1594258|NCT02277457|Radiation|PET-Adaptive RT|All patients will be treated with response-driven PET-adaptive RT. The radiation dose will be delivered in greater than or equal to 2.2 Gy per daily fraction to FDG-PET/CT-guided target volumes with the treatment duration limited to 30 fractions and total radiation dose limited to 66-80.4 Gy.
1594259|NCT02277457|Drug|Erlotinib|150 mg once daily
1594260|NCT02277457|Drug|Crizotinib|250 mg twice daily
1594261|NCT02277444|Drug|Golimumab|Golimumab 80 mg/m^2 IV infusion at Weeks 0, 4, and every 8 weeks through Week 244.
1594262|NCT02277444|Drug|Methotrexate|Methotrexate BSA-based dose (10 to 30 mg/m^2 per week for participants with BSA <1.67 m^2, or minimum of 15 mg/week for participants with BSA >=1.67 m^2) weekly at least through Week 28.
1594263|NCT02277431|Dietary Supplement|Probiotic dietary supplement (Trenev Trio®)|"Trenev Trio® (healthcare professional line)/Healthy Trinity® (consumer line) is a dietary supplement that contains probiotics microenrobed in an oil matrix in a two-piece hard gel capsule. One capsule will be taken twice per day (am & pm) offering a total daily serving of:
Lactobacillus acidophilus NAS super strain (10 billion Colony Forming Units [CFU])
Bifidobacterium bifidum Malyoth super strain (40 billion CFU)
Lactobacillus delbrueckii subspecies bulgaricus LB-51 super strain (10 billion CFU)"
1594264|NCT02277431|Dietary Supplement|placebo|
1594265|NCT02277418|Device|VAVL|Videolaryngoscope
1594266|NCT02277418|Device|MIL|Direct laryngoscopy
1594267|NCT02277405|Device|Shikani Optical Stylet|Optical intubation
1594268|NCT02277405|Device|Endoeye Flexible Intubation (LF-V)|endoscopy intubation
1594269|NCT02277392|Biological|Vaccine--‐primed, CD3/CD28--‐costimulated autologous peripheral blood T--‐cells|
1594270|NCT02277392|Biological|SB--‐485232 (Human recombinant Interleukin--‐18)|
1594271|NCT02277366|Procedure|Fluorescence Bronchoscopy/Narrow Band Bronchoscopy|Fluorescence Bronchoscopy and Narrow Band Bronchoscopy are used in the Fluorescence/Narrow Band Bronchoscopy group to make a diagnosis of lung cancer.
1594272|NCT02277353|Other|Fluid loading to evaluate fluid responsiveness|loading of hydroxyethyl starch 6ml/kg over 10-15min to all patients
1594273|NCT02277340|Procedure|EAPA|Under sedation and local anesthesia, a pit of pilonidal disease is widened, hair and debris removed and cavity first ablated by endoscopy assisted diathermy the filled with crystallized phenol. The remaining pits were also fulgurated.
2009286|NCT03298165|Device|diode laser|diode laser has antibacterial effect so can disinfect deep cavity and decrease the count of bacteria present after stepwise excavation
2009287|NCT03297021|Drug|Ondansetron 4 MG|dose as per arm selection
1594276|NCT02277314|Procedure|Manual Small Incision Cataract Surgery|This cost-effective solution for removing cataracts, also known as Manual Small Incision Cataract Surgery (MSICS), is a positive alternative when Phaco is not an option due to costs. The procedure takes approximately 30 minutes and involves a mid-size incision and an intraocular lens (IOL), or artificial lens, replacing the natural lens. Following the procedure, patients may need glasses, and most will need bifocals, but overall vision will be significantly improved.
1594277|NCT02277301|Behavioral|Mellow Babies|Mellow Babies is an intervention designed for mothers with substantial problems in their relationships with their infants. Typically, participating mothers have mental health difficulties, problem drug use, learning difficulties, forensic issues or they may have children already looked after by the local authority.
1594278|NCT02277288|Other|Filled bladder arm|Bladder to be instilled with 200 cc fluid during cystoscopy and no catheter for all mid-urethral sling procedures.
1594279|NCT02277275|Dietary Supplement|BCAA|Branched chain amino acid(BCAA) pills will be provided to subjects 0.15g/kg of body weight per day for six months
1594280|NCT02277275|Dietary Supplement|Placebo|Placebo will be provided to the other two arms for six months
1594281|NCT02277262|Device|Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention|The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
1594282|NCT02277262|Procedure|Direct suture of the anterior abdominal wall fascia|Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
1594283|NCT02277249|Drug|Digoxin (transvaginal administration)|"Transvaginal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
1594284|NCT02277249|Drug|Digoxin (transabdominal administration)|"Transabdominal digoxin administration prior to second-trimester abortion. This is only listed as a Procedure/Surgery type intervention because the mode of digoxin administration (transvaginal versus transabdominal) is what is being studied."
1594386|NCT02276430|Other|Vena punction|Once 90 ml
2009288|NCT03297021|Drug|Ondansetron 8mg|dose as per arm selection
1594285|NCT02277236|Radiation|DXA scanning|Exposure: Participants will undergo DXA scanning in the supine position per manufacturer guidelines to estimate absolute and percentage of total lean body mass (LBM) and body fat (BF).
1594286|NCT02277236|Radiation|CT imaging|Exposure: Estimates of intramuscular adipose tissue (IMAT) will be obtained with CT imaging. This measure will be restricted to a single leg (dominant side) in the mid-femur region, using a single 10mm axial image slice (120 kVp, 200 to 250 mA).
1594287|NCT02277223|Dietary Supplement|Curcumin|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.
Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
1594288|NCT02277223|Drug|Placebo|"Eligible patients will be randomized to either intervention of placebo groups. Randomization will be performed separately for patients receiving corticosteroids for induction in-order to ensure similar heterogeneity within groups. Induction: oral prednisone 1mg/kg up to 40 mg once daily for 2 weeks and then tapered down by 5 mg per week or 5-ASA 75 mg/kg/day divided to two doses. Maintenance: 5-ASA 75 mg/kg/day divided to two doses.
Patients receiving corticosteroids for induction, whose PUCAI is >35 points at 2 weeks will be regarded as treatment failure. Patients receiving 5-ASA for induction with induction treatment failure will be re-randomized to receive oral corticosteroids induction with or without curcumin."
1594289|NCT02277210|Other|Flushing|aspiration of follicles that are larger than 10 mm on both sides followed by follicular flushing for up to 4 times. Follicular fluid and flushing will be examined by the embryologists to identify any oocytes.
1594290|NCT02277197|Drug|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.
Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.
Ficlatuzumab is to be stored under refrigerated conditions (2o C- 8oC)"
1594291|NCT02277197|Drug|Cetuximab|"Cetuximab is supplied as a 50-mL, single-use vial containing 100 mg of cetuximab at a concentration of 2 mg/mL in phosphate buffered saline. The solution should be clear and colorless and may contain a small amount of easily visible white amorphous cetuximab particulates. Cetuximab can be administered via infusion pump or syringe pump, it must not be administered as an IV push or bolus. Cetuximab must be administered with the use of a low protein binding 0.22-micrometer in-line filter. Maximum infusion rate should not exceed 5 mL/min.
Store vials under refrigeration at 2C to 8C (36F to 46F). DO NOT FREEZE. Following the cetuximab infusion, a one-hour observation period is recommended."
1594292|NCT02277184|Drug|Ficlatuzumab|"Ficlatuzumab Concentrate for Injection, 20 mg/mL, is formulated in 10 mM histidine buffer pH 5.8. The formulation also includes 142 mM arginine (for isotonicity) and 0.01% polysorbate 80. The product is sterile filtered and aseptically filled into washed and depyrogenated 5 mL glass vials.The product is a clear to slightly opalescent, colorless to slightly yellow, solution.
Ficlatuzumab Concentrate for Injection is to be administered by IV infusion as an admixture with normal saline solution. The admixture solution in an IV bag is connected to an infusion set containing a 0.22 µm low protein-binding in line filter. The filtered admixture solution is clear to slightly opalescent.
Ficlatuzumab is to be stored under refrigerated conditions (2C - 8C)"
1594293|NCT02277184|Drug|Cisplatin|"Each vial contains 10 mg of DDP, 19 mg of sodium chloride, 100 mg of mannitol, and hydrochloric acid for pH adjustment. One vial is reconstituted with 10 ml of sterile water. The pH range will be 3.5 to 4.5.
Cisplatin will be given as a bolus, infused over 1-2 hours along with appropriate hydration and anti-emetics.
Reconstituted solution of cisplatin is stable for 20 hours when stored at 27°C and should be protected from light if not used within 6 hours. The vials and injection should not be refrigerated. Cisplatin has been shown to react with aluminum needles, producing a black precipitate within 30 minutes."
1594294|NCT02277184|Radiation|Intensity Modulated Radiotherapy (IMRT)|"Immobilization should be performed to ensure daily reproducibility of setup.Treatment planning CT scans will be required to define tumor, clinical and planning target volumes.The treatment planning CT scan should be performed with IV contrast. All tissues to be irradiated must be included in the CT scan.
Targets are defined as primary (requiring a higher dose) and secondary (targets at lower risk requiring a lower dose). The primary target is the PTV3 of the primary tumor and lymph nodes containing clinical or radiographic evidence of metastases. The secondary target is the PTVs consist of an area at intermediate risk (PTV2) and that containing the lowest risk of lymph node involvement (PTV2).
The treatment plan will be based on an analysis of the volumetric dose, including dose volume histogram (DVH) analyses of the PTV and critical normal structures. Inverse planning will be utilized to deliver optimal dose to the PTVs while excluding noninvolved normal tissue."
1594295|NCT02277171|Device|Nitric Oxide impregnated catheter|Patients undergoing radical prostatectomy will be catheterized for 7-14 days with Nitric Oxide impregnated Foley catheters
1594296|NCT02277158|Drug|Chemoradiotherapy|S-1 CCRT
1594297|NCT02277145|Biological|clinical grade umbilical cord mesenchymal stem cells|10^6 (1 million) /Kg/person cells of clinical grade umbilical cord MSCs will be injected after fully lavage of the localized lesions
1594298|NCT02277132|Drug|Sildenafil|Sildenafil 25 mg three times daily orally from randomization until delivery
1594299|NCT02277132|Drug|Placebo|Placebo tablets three times daily orally from randomization until delivery
1594300|NCT02277119|Device|Maestro|OCT machines used for diagnostic purposes
1594301|NCT02277119|Device|iVue|OCT machines used for diagnostic purposes
1594302|NCT02277106|Drug|SAGE-547|
1594303|NCT02277106|Drug|Placebo|
1594304|NCT02277093|Drug|Pacritinib|
1594305|NCT02277067|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
1594307|NCT02277054|Device|Collagen-MPC cornea|Patients will undergo surgery using conventional anterior lamellar keratoplasty technique: diseased cornea will be trephined to approximately 50-90% of corneal thickness (depending on corneal ulcer or scar depth) and then a lamellar dissection will be created. Trephine diameter will depend on ulcer or leukoma maximal size. Alternatively a femtosecond laser may be used to create the dissection. A collagen-phosphorylcholine cornea 250-500 microns thick and equal or 0.25 mm larger diameter is placed and sutured. The sutures are superimposed and the implant and the sutures covered with a bandage contact lens. The sutures and bandage lens will be removed later after the initial healing period of 4 weeks or as determined by physician depending on the implant epithelial coverage.
1594308|NCT02277041|Drug|Carbetocin|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute
1594309|NCT02277041|Drug|Misoprostol|600 micro gram of misoprostol which is a prostaglandin E1 will be given per rectum for patients immediately postoperative.
1594310|NCT02277028|Behavioral|priming and task specific training|This task specific training protocol has been used in several clinical trials.
1594311|NCT02277015|Device|Miller Laryngoscope|Direct Laryngoscopy
1594312|NCT02277015|Device|The Berci-Kaplan DCI|Videolaryngoscope-1
1594313|NCT02277015|Device|The AirTraq|Videolaryngoscope-2
1594314|NCT02277015|Device|GlideScope GVL|Videolaryngoscope-3
1594315|NCT02277015|Device|The Pentax AWS|Videolaryngoscope-4
1594316|NCT02277002|Device|Cabin Air Filtration|
1594317|NCT02277002|Other|Placebo|No Cabin Air Filtration
1594318|NCT02276989|Drug|acetazolamide|"On evening of Day 0, subjects will arrive at the session previously stabilized on buprenorphine and pregabalin. Pregabalin titration = 6 days prior to Day 0, during which time they will receive 100mg/day x 2 days, 200mg/day x2 days, and 300mg/day x 2 days, with the subjects receiving the full dose of 400mg/day beginning Day 0.
On Day 1, pregabalin PK measures will be collected.
On the mornings (8am) of Days 1 - 5, PGB compounded with the first tracer, ACZ will be administered.
On Day 5, subjects will again undergo PK testing on PGB + ACZ tracer.
On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.
On the mornings of Days 7-8 subjects will receive their PGB dose only."
1594319|NCT02276989|Drug|Quinine|"On the morning of Days 8-11, subjects will be administered the same dose of PGB, now compounded with the QUIN.
On Day 11, PK testing of QUIN and PGB will be repeated.
On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected.
On Day 13 patients will be discharged with take-home doses of PGB that will taper to zero over the period of one week."
1594320|NCT02276989|Drug|Riboflavin|"All subjects will receive riboflavin on the following days of the study:
On Day 6, subjects will be administered PGB and ACZ compounded with RIBO, and PK measures again collected.
On Day 12, subjects will be administered PGB and QUIN compounded with RIBO, and PK measures again collected."
1594321|NCT02276963|Drug|Ublituximab|Monoclonal antibody that specifically binds to the trans-membrane antigen CD20, which induces immune response that causes lysis of B cells.
1594322|NCT02276950|Procedure|Coronary artery bypass surgery|Primary isolated coronary artery bypass surgery with or without use of cardio-pulmonary bypass
1594323|NCT02276950|Procedure|Heart valve surgery|Heart valve surgery, aortic valve replacement or other heart valve procedures
1594324|NCT02276937|Drug|DVC1-0101|The investigational product will be drawn into a disposable 1 mL syringe using a 23G needle. A total of 0.5 mL of investigational product will be injected intramuscularly into each administration site. After administration, the administration sites will be wrapped with dressings.
1594325|NCT02276924|Device|Laser confocal microscopy|Patients undergoing a reno-ureteroscopy for diagnosis or treatment indication will receive an intra-vesical instillation of fluorescein (0.1%) for 5 minutes, followed by the laser confocal microscopy procedure.
1594326|NCT02276911|Drug|Ibuprofen|
1594327|NCT02276911|Other|normal saline|
1594328|NCT02276898|Drug|Hypertonic Saline 7%|PARI Hyper-Sal™ Sodium Chloride Solution - 7%
1594329|NCT02276898|Drug|Isotonic Saline 0.9% (Placebo)|
1594330|NCT02276885|Radiation|PBI Radiotherapy 6 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 6 Gy x 5, over 5 consecutive days
1594331|NCT02276885|Radiation|PBI Radiotherapy 8 Gy|Patients will receive 3D-Conformal or Intensity Modulated Radiation Therapy (IMRT) of 8 Gy x 3, over 5 days, every other day
1594332|NCT02276872|Drug|oral treprostinil|
1594333|NCT02276859|Drug|insulin aspart|A kind of study bolus insulin will be insulin aspart if participant used insulin aspart before entering the trial
1594334|NCT02276859|Drug|insulin lispro|A kind of study bolus insulin will be insulin lispro if participant used insulin lispro before entering the trial
1594335|NCT02276859|Drug|insulin glulisine|A kind of study bolus insulin will be insulin glulisine if participant used insulin glulisine before entering the trial
1594336|NCT02276846|Device|Paclitaxel-Eluting Balloon|
1594337|NCT02276833|Other|intra-articular space injection of SVF|intra-articular injection of autologous adipose SVF derived in the same surgical procedure
1594338|NCT02276820|Biological|Viralym-A|"Follow-up Assessments: The timing of follow-up visits is based on the date of Viralym-A infusion. If a patient has multiple Viralym-A infusions the schedule resets again at the beginning so follow up relates to the last Viralym-A infusion.
Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
1594339|NCT02276807|Behavioral|Brief Behavioral Activation|This is a 4-session individual workshop using behavioral activation techniques.
1594340|NCT02276807|Other|Usual Care|Primary care patients will be referred to the integrated behavioral health provider to receive brief treatment in primary care.
1594341|NCT02276794|Other|Thrust Manipulation|After positioning patients in right side-lying, a rotational TM technique will be addressed at the L4-L5 lumbar segments. The treating therapist will have up to two attempts to apply the TM.
1594342|NCT02276794|Other|Non-thrust manipulation (NTM)|A grade III rotational non-thrust manipulation will be addressed at the L4-L5 lumbar segments. Thirty oscilations will be performed.
1594343|NCT02276768|Drug|GIC-1001 375 mg TID|GIC-1001 375 mg TID mid-dose, oral tablet, white-coated, to be taken with water
1594344|NCT02276768|Drug|GIC-1001 500 mg TID|GIC-1001 500 mg TID high-dose, oral tablet, white-coated, to be taken with water
1594476|NCT02275806|Drug|Cisplatin|
1594345|NCT02276768|Drug|GIC-1002 345 mg TID (equimolar to GIC-1001 375 mg TID)|GIC-1002 345 mg TID mid-dose, oral tablet, white-coated, to be taken with water
1594346|NCT02276768|Drug|GIC-1002 460 mg (equimolar to GIC-1001 500 mg)|GIC-1002 460 mg TID high-dose, oral tablet, white-coated, to be taken with water
1594347|NCT02276768|Other|Placebo|Placebo identical and matching active drugs GIC-1001 and GIC-1001
1594348|NCT02276755|Dietary Supplement|cholecalciferol (vitamin D)|14000 IU vitamin D3 weekly Experimental group will receive vitamin D supplement (Tishcon, USA).
1594349|NCT02276755|Other|Placebo|Placebo group will receive placebo (Tishcon, USA) weekly.
1594350|NCT02276742|Behavioral|Social Cognitive Theory|focuses on the role played by self-referent thought in the maintenance of behavior change. Self- efficacy (e.g., the participant's confidence in their ability to engage in healthier behavior) is derived from four major sources of information: mastery experiences, social modeling, verbal persuasion, and physiological states
1594351|NCT02276742|Other|Monitoring|Technology-based self-monitoring reduces information processing demands by making relevant nutritional information readily available. Technology-based self-monitoring also can be used by interventionists to reduce information processing burden by using it for targeted counseling. For example, simultaneous consideration of all pertinent dietary recommendations would likely be overwhelming for an obese person with diabetes and CKD. By using an electronic log accessible to the interventionist, such a person could initially focus on calorie restrictions, with the interventionist stepping-in when problematic behaviors become evident.
1594352|NCT02276729|Other|Mirror Box Therapy|Mirror box therapy (MBT) is a relatively new therapeutic intervention that is gaining recognition within OT for the potential it offers in rehabilitation of upper limb function in stroke patients. It is postulated that mirror visual feedback can stimulate neural recovery in the brain using mirrored movements of the non-affected upper limb. It is thought that visual feedback helps recruit dormant motor pathways that replace the damaged pathways and encourage the return of movement to improve upper limb function.
1594353|NCT02276716|Drug|Phosphatidylserine|Phosphatidylserine will be titrated starting at 300mg/day dose for two months to 600mg/day dose for 2 months, then 800 mg/day dose for a final 2 month period.
1594354|NCT02276703|Device|Skin Conductance Monitor|monitors skin conductance values
1594355|NCT02276690|Biological|hepcidin|"In order to assess iron deficiency by innovative method (dosage of Hepcidin), an additional collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.
Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to hepcidin levels"
1594356|NCT02276690|Biological|ferritin and transferrin saturation|"In order to assess iron deficiency by using usual biomarkers (ferritin and transferrin saturation), collection of blood will be done at day 0 (and weekly until Intensive Care Unit discharge) and at Day 15 after Intensive Care Unit discharge.
Treatement of Iron deficiency anaemia and anaemia of chronic disease using intravenous iron (± erythropoietin) will be encouraged (or not) according to ferritin levels."
1594357|NCT02276677|Drug|Oxytocin|Single dose, intranasal
1594358|NCT02276677|Drug|Placebo|Single dose, intranasal
2009289|NCT03297983|Drug|M7583|Subject will receive either M7583 PiC or M7583 tablet formulation orally under fasted conditions in part 1 followed by M7583 tablet formulation under fed condition in part 2 of the study.
2009290|NCT03297658|Device|electro-acupuncture (EA)|stimulation of acupuncture points related to congenital heart surgery for comfort heart and renal health
2009291|NCT03297658|Device|sham|Micro electrodes will be placed but there will be no stimulation
2009292|NCT03295877|Drug|RO7171009|Patients will receive RO7171009 via ITV injection.
1594363|NCT02276625|Biological|rabies vaccine|Compare ID administration to IM administration. 1 visit schedule.
2009293|NCT03296800|Drug|Bexagliflozin|Bexagliflozin 20 mg, tablet; qd
1594366|NCT02276586|Procedure|Horizontal Tooth preparation|Round parallel chamfer diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
1594367|NCT02276586|Procedure|Vertical Tooth preparation|Long flame diamond burs were used for teeth preparation; coarse first (151 micron) and extra-fine after (25 micron)
1594368|NCT02276573|Biological|buccal cavity sample|
1594369|NCT02276560|Drug|Neoadjuvant Cisplatin, nab-paclitaxel|Cisplatin (75mg/m2) D1, nab-paclitaxel 125 mg/m2) D1, 8, 15; repeat each 28 D cycle x 2 then surgery
1594370|NCT02276560|Drug|Adjuvant Cisplatin,nab-paclitaxel|Cisplatin 75mg/m2 D1,nab-paclitaxel 125mg/m2 D1, 8, 15, repeat each 28D cycle x 2
1594371|NCT02276560|Drug|Adjuvant cisplatin+pemetrexed or cisplatin+gemcitabine|Cisplatin 75mg/m2 D1 + pemetrexed 500mg/m2 D1 or Gemcitabine 1000 mg/m2 D1, 8 (if SqCC) repeat each 21 D Cycle x 4
1594373|NCT02276534|Behavioral|SENSE Theatre|A peer-mediated, theatre-based intervention.
1594374|NCT02276534|Behavioral|Delayed Intervention|
1594375|NCT02276521|Biological|Cervarix®|All groups will received one dose of Cervarix® vaccine
1594376|NCT02276508|Drug|E. coli Nissle 1917|Participants will all take E. coli Nissle 1917 orally administered medication for 30 days
1594377|NCT02276495|Other|ACB Control - 20 ml saline injection for ACB|Adductor Canal Block Control (20 ml saline injection)
1594378|NCT02276495|Drug|ACB Study - 20 ml 0.5% Ropivacaine for Adductor Canal Block|Adductor Canal Block Study (20 ml 0.5% Ropivacaine)
1594379|NCT02276495|Drug|Local infiltration - 100 mLs of a solution containing: Ropivacaine + Epinephrine + Ketorolac + Clonidine + 0.9% Normal saline|"100 mLs of a solution containing:
Ropivacaine 2 mg/mL (49.25 mL) + Epinephrine 1 mg/mL (0.5 mL) + Ketorolac 30mg/mL (1mL) + Clonidine 100 mcg/mL (0.8 mL) + 0.9% Normal saline (48.45 mL)"
1990352|NCT02071563|Dietary Supplement|CSB14|
1990353|NCT02071563|Dietary Supplement|RUSF1|
1594382|NCT02276469|Behavioral|peer support|peer support is delivered by persons with a severe mental illness after the experience of recovery and after absolving a one year education to support others on their way to recovery
1594383|NCT02276456|Behavioral|Follow-up Appointment- early vs standard|Patient will undergo early follow-up (within 7 days of discharge) of discharge
1594384|NCT02276443|Drug|Anthracycline Based Chemotherapy|Participants receive standard-of-care chemotherapy for 4 cycles. A cycle of treatment may be given once every 2 or 3 weeks depending upon doctor's decision.
1990354|NCT02071563|Dietary Supplement|SC+|
1594387|NCT02276417|Other|Blood collection|Blood will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Blood will also be collected at the one year appointment.
1594388|NCT02276417|Other|Urine collection|Urine will be collected from patient at baseline, day 1, day 4, day 7 and weekly until week 6 as long as the patient is still hospitalized. Urine will also be collected at the one year appointment.
1594389|NCT02276417|Other|Bioimpedance Analysis|The bioimpedance analysis will be performed at baseline, day 14 or discharge from hospitalization, month 3, month 6, and month 12.
1594390|NCT02276417|Other|Cognitive Function Tests|Cognitive function tests will be administered at 3, 6 and 12 months.
1594391|NCT02276417|Other|Quality-of-life Questionnaires|Quality-of-life questionnaires will be administered at baseline, 3, 6 and 12 months.
1594392|NCT02276417|Other|Physical Function Tests|Physical function tests will be administered at baseline, day 14 or discharge from hospital 3, 6 and 12 months.
1594393|NCT02276417|Other|Blood Collection|The healthy volunteer participants will donate a blood sample. These controls will allow the investigators to determine if the values obtained are accurate, reliable, and repeatable.
1594394|NCT02276404|Behavioral|relaxation training|"The relaxation sessions comprise an introduction in 3 relaxation techniques conducted by a mind-body therapist: Body Scan, mindfulness meditation and imagination. Patients also receive a CD with different relaxation exercises and the instruction to exercise daily at home for at least 15 minutes."
1594395|NCT02276404|Other|acupuncture|The acupuncture treatment comprises needling of 6 standardized acupoints: Pericardium 6, Stomach 36, Large intestine 4, Spleen/Pancreas 10, Dumai 20, Liver 3, Shenmen. Additional points can be chosen individual.
1594396|NCT02276391|Drug|Telmisartan/HCTZ combination|
1594397|NCT02276391|Drug|Telmisartan|
1594398|NCT02276378|Drug|Telmisartan low|
1594399|NCT02276378|Drug|Telmisartan high|
1594400|NCT02276378|Drug|Hydrochlorothiazide (HCTZ)|
1594401|NCT02276378|Other|Japanese meal|
1594402|NCT02276365|Drug|BI 10773|
1594403|NCT02276365|Drug|Pioglitazone|
1594404|NCT02276352|Drug|Treatment 1|
1594405|NCT02276352|Drug|Treatment 2|
1594406|NCT02276352|Drug|Treatment 3|
1594407|NCT02276339|Other|Exercise|The exercise intervention will consist of an individual home-based progressive eccentric-concentric strengthening programme. Patients will be reviewed every two weeks during their rehabilitation; exercises will be progressed accordingly by their physiotherapist.
1594408|NCT02276326|Dietary Supplement|VSL#3 sachets|4 sachets a day for 4 months
1594409|NCT02276313|Device|Passeo-18 Lux|Endovascular Therapy
1594410|NCT02276300|Drug|Cyclophosphamide|Treatment of mild Endoxan application three days before Her2 vaccination
1594411|NCT02276300|Drug|Sargramostim|Sargramostim is part of Her2 vaccination
1594412|NCT02276300|Drug|HER2-Peptid-Vakzine|Her2 vaccination is supplemented by Sargramostim and Aldara Creme application
1594413|NCT02276300|Drug|Imiquimod|Imiquimod is part of Her2 vaccination
1594414|NCT02276274|Drug|SYR-322-MET|Oral administration of SYR-322-MET
1594415|NCT02276261|Procedure|Vaginal cuff closure - vertical|Vaginal cuff is closed vertically.
1594416|NCT02276261|Procedure|Vaginal cuff closure - horizontal|Vaginal cuff is closed horizontally.
1594417|NCT02276248|Radiation|Intensity-modulated radiation therapy|total dose: 50 to 56 grays per fraction: 2 grays
1594418|NCT02276248|Drug|GDP chemotherapy|gemcitabine (1000mg/m2 intravenously over 30 minutes on days 1 and 8), cisplatin (25mg/m2 intravenously over 60 minutes on days 1-3), and dexamethasone (20mg/d orally on days 1-4 and days 11-14), which was administered every 21 days.
1594419|NCT02276235|Device|Catgut embedding group|"An extensive form of acupuncture that involves weekly infixing self-absorptive chromic catgut sutures into acupoints with a specialised needle under antiseptic precautions. The catgut then stimulate those points over a long period. The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger with chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.
Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
1594420|NCT02276235|Device|sham catgut embedding group|"The stainless-steel acupuncture needles (3.8cm long) was inserted into 23 gouge needle as plunger without chromic catgut in front of the syringe needle. Catgut will be embedding in acupoints as below.
Acupoints: Qihai (REN-6), Shuifen (REN-9), bilateral Shuidao (ST-28),bilateral Siman (K-14) ,zusanli(ST-26)"
1594421|NCT02276222|Drug|SUN-101 50 mcg BID eFlow (CS) nebulizer|SUN-101 (Glycopyrrolate) 50 mcg twice daily (BID) via eFlow Closed System (CS) nebulizer
1594422|NCT02276222|Drug|Spiriva® 18 mcg QD Handihaler|Spiriva (tiotropium) 18 mcg once daily (QD) via Handihaler
1594423|NCT02276209|Drug|Dasotraline|Dasotraline 4 mg once daily
1594424|NCT02276209|Drug|Dasotraline|Dasotraline 6 mg once daily
1594425|NCT02276209|Other|Placebo|Placebo once daily
1594426|NCT02276196|Drug|Lixisenatide|GLP-1 receptor agonist
1594427|NCT02276196|Drug|Insulin glulisine|Insulin analogue
1594428|NCT02276183|Dietary Supplement|Nutrition intervention, test formula|
1594429|NCT02276183|Behavioral|progressive physical activity|Tai Chi; dynamic strength training (knee extension, knee flexion, hip extension, side leg raise, plantar flexion); flexibility warm up and cool down (shoulder and upper arm stretch, hamstrings stretch, calf stretch, ankle stretch); aerobic fitness training(walking on even flat ground); balance training(standing on one foot; heel-to-toe walk; toe stand)
1594430|NCT02276144|Other|Liver ultrasound|For evaluate whether fatty liver is exist or not
1594431|NCT02276131|Device|Vigilant Diabetes Management Application|Human factors and usability assessment of the device in the hands of diabetes subjects and caregivers
1594432|NCT02276118|Device|device: e.motion PS Pro|patients will undergo total knee arthroplasty with e.motion PS Pro implant
1594433|NCT02276118|Device|device : Genesis II|patients will undergo total knee arthroplasty with Genesis II implant
1594434|NCT02276105|Other|Questionnaires|On three time-points (Baseline, Retest, Follow-Up), each participant has to fill out the questionnaires: Michigan Hand Questionnaire, EuroQol EQ-5D-5L and the Short Form SF-12 Health Survey
1594477|NCT02275780|Drug|Doravirine|Doravirine 100 mg tablet administered orally once daily
1594435|NCT02276092|Other|antimicrobial stewardship|A member of the antimicrobial stewardship program will prospectively review the patient's medical record and make recommendations to the most responsible physician in the care of that patient
1594436|NCT02276079|Behavioral|Aerobic Exercise|Aerobic exercise will consist of riding a stationary bicycle at moderate intensity for 2 consecutive, 20-minute periods with a 5-minute break in between. Moderate intensity is defined as maintaining 65-75% of estimated maximum heart rate based on the calculation (HRmax = 208 − 0.7 × age).
1594437|NCT02276079|Behavioral|Non-Aerobic Exercise|Non-Aerobic exercise will consist of very low-intensity movements including static stretching and toning exercises.Participants will complete 2 consecutive, 20-minute periods with a 5-minute break in between, mirroring the aerobic exercise condition. Heart rate will be monitored by research staff to ensure that it remains below 50% of estimated maximum heart rate.
1594438|NCT02276066|Drug|Iohexol|Both groups of sepsis participants will receive a normal saline dilution of Iohexol 0.5-1 ml given by IV push. Blood or urine will be collected prior to the injection and at approximately 1, 2, 3, and 4 hours after the injection for glomerular filtration rate measurements. This test will be repeated in one year.
1594439|NCT02276066|Other|Urine Collection|Both groups of sepsis participants will have urine collected for at least 4 hours to as long as 24 hours or more. The urine volume determined and a sample sent to the lab for determination of creatinine and urea concentration.
1594440|NCT02276066|Other|Blood samples|Both groups of sepsis participants will provide peripheral blood samples to the research staff. The samples will be sent to the laboratory for serum creatinine and cystatin C results.
2009294|NCT03296800|Drug|Probenecid|Probenecid tablets, 500 mg; bid
1594442|NCT02276027|Drug|BYL719|BYL719 will be dosed as 350 mg once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take BYL719 exactly as prescribed.
1594443|NCT02276027|Drug|INC280|INC280 will be dosed as 600 mg (tablet) or 400mg(Capsule) twice daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to takeINC280 exactly as prescribed.
1594444|NCT02276027|Drug|LDK378|LDK378 will be dosed as 750 mg once daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take LDK378 exactly as prescribed.
1594445|NCT02276027|Drug|MEK162|MEK162 will be dosed as 45 mg twice daily. On the first day of each cycle, patient will receive a prescription of adequate drug supply for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take MEK162 exactly as prescribed.
1594446|NCT02276014|Dietary Supplement|Beta-carotene|
1594447|NCT02276001|Drug|K-877|
1594448|NCT02276001|Drug|Cyclosporine|
1594449|NCT02275988|Drug|K-877|
1594450|NCT02275988|Drug|Clarithromycin|
1594451|NCT02275975|Drug|K-877|
1594452|NCT02275975|Drug|Fluconazole|
1594453|NCT02275962|Drug|K-877|
1594454|NCT02275962|Drug|Rifampin|
1594455|NCT02275949|Device|acupuncture|Acupuncture needles are inserted at the acupoints Zusanli(ST 36), Neiguan(PC 6), Gongsun(SP 4), and Xiangu(ST 43) bilaterally.
1594456|NCT02275949|Device|Electroacupuncture|The electric stimulator will be connected to the handles of each needles on the ST 36 and PC 6 bilaterally with 5Hz.
1594457|NCT02275949|Device|Intradermal acupuncture|Intradermal acupuncture needles with tape are inserted on the ST36, PC6, SP4, ST43 bilaterally and maintained until the next session.
1594458|NCT02275949|Device|Mock transcutaneous electrical nerve stimulation|Electrical insulator are attached on the ST36 and PC6 bilaterally, the same electric stimulator will be connected on the points with the same parameters as the study group, but without current intensity.
1594459|NCT02275949|Device|sham intradermal acupuncture|Intradermal acupuncture needles are put over the tape not penetrating the skin.
1594460|NCT02275936|Drug|N91115|S Nitrosoglutathione Reductase Inhibitor
1990359|NCT02069431|Drug|Intranasal Oxytocin spray|Intranasal OT (24 IUs) self-administration will take place twice a day over a 28-day period.
1594462|NCT02275910|Drug|E7090|
1594463|NCT02275897|Procedure|Slow Speed of spinal injection|Speed of injection over 60 seconds
1594464|NCT02275897|Procedure|Fast Speed of spinal injection|Speed of injection over 15 seconds
1594465|NCT02275884|Dietary Supplement|Dark chocolate (85% cocoa)|
1594466|NCT02275884|Dietary Supplement|White chocolate (0% cocoa)|
1594467|NCT02275871|Other|MRI|High risk screening MRI will be performed as part of the patient's routine care.
1594468|NCT02275871|Other|CESM|After the MRI is complete, the patient will be brought to the mammography department for the contrast enhanced mammogram. The contrast enhanced mammogram will be independently interpreted by two study radiologists (randomly assigned) who are blinded to the MRI. They will then compare to the MRI to determine clinical follow-up. Any finding seen on MRI will be followed according to the MR protocol. Any finding seen on CESM only, will have a diagnostic work-up with mammography and ultrasound. If this work-up is negative, then follow-up CESM exams will be performed. Each patient will be followed for 2 years to determine sensitivity and specificity for both modalities.
1594469|NCT02275858|Device|Stiffening wire|Stiffening wire
1594470|NCT02275858|Device|Placebo wire|Placebo wire
1594471|NCT02275845|Drug|Metformin|Metformin twice daily 500 mg for the first week, after that twice daily 1000 mg (from 14 weeks pregnancy untill delivery)
1594472|NCT02275845|Other|control diet|2000 calories/day diet, with an adequate distribution of carbohydrates during the day
1594473|NCT02275832|Drug|3 % Minoxidil lotion|
1594474|NCT02275832|Drug|Placebo|
1594475|NCT02275806|Drug|Irinotecan|
1990360|NCT02069431|Other|Intranasal Placebo spray|placebo (containing all of the inert ingredients except for the oxytocin) self-administration will take place twice a day over a 28-day period.
2009295|NCT03296800|Drug|Rifampin|Rifampin, 600 mg (2 x 300 mg capsules); qd
1990363|NCT02065479|Drug|Prasugrel|Comparison of platelet reactivity between prasugrel and ticagrelor
1990364|NCT02065479|Drug|Ticagrelor|Comparison of platelet reactivity between prasugrel and ticagrelor
1594478|NCT02275780|Drug|Darunavir|Darunavir 800 mg tablet administered orally once daily
1594479|NCT02275780|Drug|Ritonavir|Ritonavir 100 mg tablet administered orally once daily
1594480|NCT02275780|Drug|TRUVADA™ or EPZICOM™/KIVEXA™|The investigator selects either TRUVADA™, a tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate, or EPZICOM™/KIVEXA™, a tablet containing 600 mg abacavir sulfate and 300 mg lamivudine. Either tablet can be administered orally once daily, or TRUVADA™, can be administered once every 2 days.
1594481|NCT02275767|Device|50% cortical/50% cancellous FDBA|Ridge preservation after tooth extraction using 50% cortical/50% cancellous FDBA
1594482|NCT02275767|Device|100% cortical FDBA|Ridge preservation after tooth extraction using 100% cortical FDBA
1594483|NCT02275767|Device|100% cancellous FDBA|Ridge preservation after tooth extraction using 100% cancellous FDBA
1594484|NCT02275754|Behavioral|PN+LCNC|Patient Navigation plus LIVESTRONG Cancer Navigation Center (PN+LCNC): Participants assigned to this group will be assisted by the patient navigator with their health-related needs. The patient navigator will call the study participant on a weekly basis for the first three months of their participation in the study, and on a monthly basis thereafter to see if study participant needs anything pertaining to their cancer care.
1594485|NCT02275754|Behavioral|PN Only|Participants will be navigated by PN on request
1594486|NCT02275741|Biological|prophylactic vaccine (tetanus, diphtheria, pertussis, poliomyelitis, influenza, hepatitis A, hepatitis B, tick-borne encephalitis, meningococcal, pneumococcal)|Publically recommended protective vaccines in MS patients, vaccination applied according to the manufacturers description
1594487|NCT02275728|Other|Pelvic floor muscle training|assessment and intervention group with a training of the pelvic floor muscles, another group with training of the pelvic floor muscles and electromyographic biofeedback and a control group will be held. All groups respond to a questionnaire of quality of life. At the end, all groups will be reassessed and compare the effectiveness of interventions between groups.
1594488|NCT02275728|Other|Eletromyography Biofeedback|
1594489|NCT02275715|Behavioral|Parent Training Program|An 11-session manualized behavioral parent training program for the treatment of feeding problems teaching parents to use a range of behavioral procedures to address a variety of common feeding problems.
1594490|NCT02275702|Drug|Dexamethasone IV|It will be administered at the induction of the anesthesia
1594491|NCT02275702|Drug|Saline solution|
1594492|NCT02275689|Procedure|Arthroscopic acromioplasty|Surgical intervention With arthroscopic acromion resection
1594493|NCT02275689|Procedure|Microtenotomy|Arthroscopic radiofrequency microtenotomy of rotator cuff tendon
1594494|NCT02275676|Other|bioelectrical impedance analysis|
1594495|NCT02275676|Other|indirect calorimetry|
1594496|NCT02275663|Drug|Azacytidine|
1594497|NCT02275663|Drug|Fludarabine|
1594498|NCT02275663|Drug|Cytarabine|
1594499|NCT02275663|Drug|Filgrastim|G-CSF
1594500|NCT02275650|Radiation|nbUVB|2 SED nbUVB exposure will be given every other week
1594501|NCT02275637|Device|implantable cardioverter defibrillator|
1594502|NCT02275611|Drug|intranasal oxytocin spray|Administration of oxytocin in a nasal spray
1594503|NCT02275611|Drug|Intranasal Placebo Spray|Intranasal Placebo Spray
1594504|NCT02275598|Drug|Brentuximab vedotin|1.8 mg/kg, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 2
1594505|NCT02275598|Drug|ABVD|Doxorubicin 25 mg/m2 IV, Bleomycin 10,000 units/m2 IV, Vinblastine 6 mg/m2 IV, Dacarbazine 375 mg/m2 IV on days 1-15 of each 28 day cycle. Number of Cycles: 3 or 6 according to initial disease stage.
1594506|NCT02275585|Other|Event of portal vein thrombosis|There is no intervention over patients. They are followed during 3 years to look after any event of portal vein thrombosis
1594507|NCT02275572|Procedure|Pharmacist Intervention|
1594508|NCT02275559|Behavioral|Mindfulness Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) program consists of 8 weekly classes plus an all-day class to train participants in mindfulness and its application, including addressing challenges arising from chronic diseases and life stresses.
1594509|NCT02275559|Behavioral|Healthy Living Course (HLC)|The Healthy Living Course (HLC) consists of 8 weekly classes plus an all-day class providing lectures and discussions about health-related topics. The purpose of the HLC is to match the MBSR for time, attention and group support
1594510|NCT02275546|Drug|Placebo vaginal ring|Drug-free placebo vaginal ring
1594511|NCT02275546|Device|Single-use, non-sterile applicator|Single-use, non-sterile, plastic applicator for insertion of vaginal ring.
2009296|NCT03296800|Drug|Verapamil|Verapamil hydrochloride tablet, 120 mg; qd
2009297|NCT03296176|Biological|blood sample|blood sample for metabolome analyse
1594515|NCT02275520|Device|NIO Adult device|IO access-1
1594516|NCT02275520|Device|Bone Iniection Gun|IO access-2
1594517|NCT02275520|Device|EZ-IO|IO access-3
1594518|NCT02275520|Device|Jamshidi Intraosseous Needle|IO access-4
1594519|NCT02275520|Device|Cook Intraosseous Needle|IO access-5
1594520|NCT02275507|Device|Masimo Rainbow Sensor|Non-Invasive Hemoglobin Measurement
1594521|NCT02275494|Procedure|Total hip arthroplasty|Cemented or uncemented total hip arthroplasty. No other intervention than observing patients operated according to routine practise at an orthopaedic department.
1594522|NCT02275481|Drug|Arformoterol tartrate inhalation solution|Arformoterol tartrate inhalation solution 15 mcg (BROVANA) will be administered BID (morning and evening, approximately 12 hours between doses) using a standard jet nebulizer with a face mask or mouthpiece connected to an air compressor
1594523|NCT02275481|Drug|Tiotropium|Tiotropium 18 mcg (SPIRIVA) will be administered QD (morning) via the HandiHaler®.
1594524|NCT02275468|Drug|Fu-zheng-qu-zhuo (FZQZ) oral liquid|FZQZ oral liquid is a herbal medicine, composed of astragalus, angelica root, rhubarb, etc, with the effect of reinforcing Qi and activating blood, dissolving dampness and downbearing turbid.
1594562|NCT02275130|Device|Radiesse Voice (Calcium Hydroxyapatite)|
1594563|NCT02275117|Biological|ALD403|
1594564|NCT02275117|Biological|Placebo|
1594597|NCT02274883|Dietary Supplement|Protein Fractions|Protein fractions
1594833|NCT02272998|Other|laboratory biomarker analysis|Correlative studies
1594525|NCT02275455|Behavioral|real life situations|Four phases will be carried out on autism participants and aged-marched controls: 1) 24-hour baseline pre-experiment (physical activity, sleep), 2) 2-hour in real life situation, 3) 30-minute in a quiet environment, interrupted by a few seconds stressful sound, 4) an interview to get comments and feelings about events that triggered anxiety. Autism and control participants will be together for phases 2 and 3, revealing different physiological responses to the same situations, and thus identifying potentially problematic events.
1594526|NCT02275442|Other|EPICES scale|
1594527|NCT02275429|Procedure|Blood test|blood will be drawn the day before the race (day 0), upon completion of the race (between 27 and 67 hours after departure), and on days 7 and 28
1594528|NCT02275416|Drug|Ipilimumab|
1594529|NCT02275416|Biological|UV1 vaccine|
1594530|NCT02275416|Biological|GM-CSF|
1594531|NCT02275403|Procedure|Acupuncture|10 x weekly sessions (40 minutes per session) of acupuncture by a trained therapist.
1594532|NCT02275403|Other|Medication taken to manage the symptom burden of CIPN|Standard of care medication to manage CIPN symptoms, as determined by a clinician in accordance with local trust policy. The standard care for CIPN includes a variety of oral medications to manage the altered sensations caused by damage to the peripheral nerves. These oral medications include, but are not limited to; Gabapentin, Amitriptyline and Pregabalin. In addition, medicated creams and gels may be used.
1594533|NCT02275390|Behavioral|Nurse-led Psycho-education|The program was modified from the psycho-educational, motivation-driven and emotionally supportive programs developed and previously tested by the research team in Chinese people with different kinds of serious mental illness, mainly including schizophrenia spectrum disorders and mood disorders by Chien and his colleagues in 2012, and adherence therapy for people with psychotic disorders by Gray et al. (2010).
1594534|NCT02275390|Behavioral|Usual Psychiatric Outpatient Care|These services consisted of medical consultation and treatment by the attending psychiatrist (i.e., around every four weeks), brief education sessions (i.e., 3 or 4 one-hour sessions) on mental illness and treatment received by psychiatric nurses, and advices and referrals for community mental health and social welfare services available and/or family counseling by a psychiatric nurse or medical social worker in each clinic.
1594535|NCT02275377|Other|Inspiratory muscle training (IMT)|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min. Inspiratory load will be set at 40% of maximum static inspiratory pressure, and weekly training loads will be adjusted to maintain 40% of MIP. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
1594536|NCT02275377|Other|Sham IMT|Participants will receive IMT for 30 min, 7 times per week for 8 weeks using Inspiratory muscle trainer device (PowerBreathe). During training, participants will be instructed to maintain diaphragmatic breathing with a breathing rate of 15-20 cycles/min, but without a load generating resistance. Each week, six training sessions will be held at home and a training session will be supervised in the research center.
1594537|NCT02275364|Device|Test strip|Class I device for the application to the nose to facilitate better air flow through the nose
1594538|NCT02275364|Device|Placebo strip|Placebo strip
1594539|NCT02275364|Other|Nasal spray|Nasal decongestant to be used on a single occasion (one spray per nostril), 20 minutes prior to commencing the third MRI scanning sessions.
1594540|NCT02275351|Drug|SM04554|Topical solution, applied once a day
1594541|NCT02275351|Drug|Vehicle|Topical solution, applied once a day
1594543|NCT02275325|Other|Preoperative vestibular rehabilitation|12 one-hour sessions with exercises of balance on unstable conditions (foam, tilt of the platform, biofeedback)
1594544|NCT02275299|Drug|Iguratimod|Iguratimod 25 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
1594545|NCT02275299|Drug|Leflunomide|Leflunomide 10 mg/tablet, taken orally, 2 tablets/day (bid),52 weeks
1594546|NCT02275299|Drug|Methotrexate|Methotrexate 2.5 mg/tablet, taken orally once a week, 4 tablets/week,52 weeks
1594547|NCT02275286|Drug|Trabectedin|Escalating dose of 1.3 or 1.5mg/m2, i.v 24h, once every 3 weeks. Cohort A: unlimited cycles Cohort B: 3 cycles
1594548|NCT02275286|Radiation|Radiotherapy|3D conformal radiotherapy (3D-CRT) or intensity modulated radiotherapy (IMRT) providing: Cohort A: 30Gy in 10 fractions (3Gy/fraction) Cohort B: 45Gy in 25 fractions (1.8Gy/fraction)
2009298|NCT03296033|Drug|Enoxaparin|The intervention is the implementation of a 36-hour time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing.
2009299|NCT03296033|Drug|Enoxaparin|This is the historical control arm. 24 hours removed from their last dose (time period from the last dose of treatment dose Enoxaparin to the blood sampling for anti-Xa testing)
2009300|NCT03294382|Drug|Botulinum toxin type A|5U botulinum toxin in 0.1 mL normal saline, injected in two points at one side, 2.5U per point, local injection
1594552|NCT02275247|Drug|Stellate Ganglion Block|stellate ganglion block will be administered using either 6-8mL saline (Group 1) or 0.25% ropivacaine 6-8mL (Group 2)
1594553|NCT02275234|Other|Psychological intervention|Psychological support via clinic visit, helpline and telephone calls
1594554|NCT02275208|Procedure|SIPS the stomach, intestinal, pylorus, sparing procedure|Bariatric Procedure
1594555|NCT02275182|Drug|Dexmedetomidine|0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
1594556|NCT02275182|Drug|Saline|0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/min and stopped 30 minutes before the surgery over.
1594557|NCT02275169|Drug|Urofollitropin|Urofollitropin 75 IU 2 ampoules three times a week for three months
1594558|NCT02275169|Other|Placebo|Placebo ampoules administered three times a week for three months
1594559|NCT02275156|Biological|Evolocumab|Administered by subcutaneous injection
1594560|NCT02275143|Radiation|CT TAP Scan|Modification of chest CT protocol in the routine CT TAP: The Research CT of Thorax will be acquired as per the routinely performed CTCA with inclusion of the lung apices. Therefore the study will be acquired axially with prospective gating.
1594561|NCT02275130|Procedure|Calcium Hydroxyapatite|Surgical augmentation of the vocal cords with injection of calcium hydroxyapatite
1594565|NCT02275104|Device|Contrast-enhanced ECG-gated multi-detector computed tomography|Depending on potential contra-indications to iodine-enhanced computed tomography. It will be performed using the usual method on a 64-slice dual energy scanner. Data will be acquired after the injection of 120 mL iodine contrast media. Contrast will be injected at the rate of 4 mL/s without additional saline flush in order to obtain homogeneous enhancement of the 4 cardiac chambers, there by simplifying subsequent segmentation. The objective will be to obtain a 3-dimensional imaging of cardiac structures
1594566|NCT02275104|Device|Magnetic resonance imaging|Depending on potential contra-indications to gadolinium-enhanced magnetic resonance. It will be performed on the 1.5 Tesla clinical device associated to MUSIC equipment (Magnetom Avanto, Siemens, Erlangen, Germany). Myocardial fibrosis will be imaged using a free-breathing delayed-enhancement method initially developed for atrial imaging. The method uses a 3-dimensional, inversion recovery-prepared, ECG-gated and respiratory-navigated Turbo Fast Low Angle Shot sequence with fat saturation. Acquisition will be initiated 15 minutes after the injection of a double-dose of gadolinium-based contrast media.
1594567|NCT02275104|Device|Positron emission tomography|Only in patients with a contra-indication to magnetic resonance imaging. It will be performed on a PET/CT 600 device. Acquisition will be preceded by a standard metabolic preparation for 18 fluoro-deoxy-glucose viability imaging. The objective will be to obtain a 3-dimensional imaging of ventricular scar.
1594568|NCT02275104|Device|Body surface mapping|It will be obtained using a 252-electrode vest. The position of each electrode with respect to epicardium will be assessed at multi-detector computed tomography prior to mapping. In patients referred for ventricular arrhythmia, body surface mapping will aim at recording the clinical arrhythmia whenever possible. In patients referred for atrial arrhythmia, body surface mapping will aim at recording atrial fibrillation.
1594569|NCT02275104|Procedure|Cardiac ablation procedure|Ventricular procedures will be performed endocardially using trans-septal or retro-aortic approach, potentially combined with sub-xiphoid epicardial access. Atrial procedures will be performed endocardially using trans-septal approach to access the left atrium. Bi-atrial bipolar contact mapping will be performed at high density during atrial fibrillation prior to ablation.
1594570|NCT02275078|Behavioral|COPD self-management using an action plan|"Behavioral: Self-management education on the use of a self-administered prescription for exacerbation.
Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription."
1594571|NCT02275078|Device|Telesystem-Phone self-assessment/reporting system|Phone Self-Assessment/Reporting System. The second component of the intervention is the use of a computer-linked interactive phone assessment/reporting system that can assess respiratory status and notify the nurse case manager as needed
1594572|NCT02275078|Other|Nurse case manager support|Support:Nurse Case Manager Phone Support . The nurse case manager will call patients under two conditions. The first is to provide regularly scheduled follow-up education and support.The nurse case manager will also phone patients in response to answers they have provided to the phone system. i.e Worsening COPD status
1594573|NCT02275065|Drug|GS-9883|GS-9883 tablet(s) administered orally once daily
1594574|NCT02275065|Drug|GS-9883 Placebo|Placebo to match GS-9883 administered orally once daily
2009301|NCT03294382|Drug|Placebo|0.1 mL normal saline, injected in two points at one side, 0.05 mL per point, local injection
2009302|NCT03295448|Other|Low carbohydrate diet|Diet low in carbohydrates (38%E), but higher in total and saturated fat.
1990366|NCT02060500|Procedure|Cardiaplication|
1594578|NCT02275039|Biological|modified vaccinia virus ankara vaccine expressing p53|Given SC
1594579|NCT02275039|Drug|gemcitabine hydrochloride|Given IV
1594580|NCT02275039|Other|laboratory biomarker analysis|Correlative studies
1594581|NCT02275026|Procedure|Functional magnetic resonance imaging|Diffusion tensor imaging
1594582|NCT02275013|Drug|Levosimendan|
1594583|NCT02275000|Other|5 Day Physiotherapy Programme|The experimental group will complete a 5 day physiotherapy programme consisting of education, movement retraining and a self management plan.
1594584|NCT02275000|Other|Physiotherapy|Treatment as usual physiotherapy. The participant will be referred to their closest NHS outpatient neuro-physiotherapy service.
1594585|NCT02274987|Other|Specialized tumor board recommendation|A combination of up to four FDA approved drugs based on the molecular profile of the patient's tumor as determined by gene expression analysis, WES and predictive modeling.
1594586|NCT02274987|Radiation|Standard radiation therapy|Initial therapy will consist of standard radiation therapy per institutional guidelines followed by molecular based therapy with FDA approved drugs.
1594587|NCT02274974|Drug|Lidocaine|•The wound of C.Swill be infiltrated before closure of the skin, with 20 ml of 2% lidocaine.
1594588|NCT02274974|Drug|lidocaine and Epinephrine|The wound of C.S will be infiltrated before closure of the skin, with 20 ml of 2% lidocaine and epinephrine in related dose manner 1:200.000.
1594589|NCT02274961|Drug|S-pantoprazole 10mg|
1594590|NCT02274961|Drug|Placebo|
1594591|NCT02274948|Drug|Metformin|Metformin in the form of 500mg tablets were administer to the Metformin group
1594592|NCT02274948|Drug|Placebo|A Placebo tablet physically and chemically similar to Metformin tablets except for the absence of the active ingredient was used
1594593|NCT02274935|Other|Exercise|Balance and gait exercise twice a week for an hour
1594594|NCT02274909|Other|TRAINING PROGRAM|Sixty healthy elderly women were randomly divided into 3 groups: Pilates group (PG), PNF group (PNFG) and Control group (CG). Pilates and PNF groups underwent one-month training program with Pilates and PNF methods, respectively. CG received no intervention along the one month.
1594595|NCT02274896|Device|PD Catheter group|PD catheter
1594596|NCT02274883|Dietary Supplement|Enriched Protein Fractions|Enriched protein fractions
2009303|NCT03295448|Other|High carbohydrate, high sugar diet|Diet high in carbohydrates (53%E) and sugars, but low in wholegrain, rye and wheat fibre.
2009304|NCT03295448|Other|High carbohydrate, low sugar diet|Diet high in carbohydrates (53%E), wholegrain, rye and wheat fibre, but low in sugars.
2009305|NCT03295396|Drug|ONC201|ONC201 is an oral, small molecule selective antagonist of DRD2 that induces tumor cell death.
2009306|NCT03294460|Drug|Alcohol (Oral)|Oral Self-administration
2009307|NCT03294460|Drug|Alcohol (IV)|IV Self-administration
1594598|NCT02274870|Drug|Liposome Bupivacaine|Administered via local tissue infiltration around the knee joint
1594599|NCT02274870|Drug|Bupivacaine HCl|Administered via CFNB
1594600|NCT02274857|Procedure|Standard PVI Ablation|Standard PVI procedure without FIRMap.
1594601|NCT02274857|Procedure|FIRM-Guided Procedure and PVI|FIRM-guided procedure followed by conventional ablation including PVI.
1594602|NCT02274844|Behavioral|Living Well with Diabetes Program|The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
1594603|NCT02274831|Other|Email Reminder of need to follow up with primary physician|
1594604|NCT02274818|Behavioral|Flexible Duty Hour Schedule|"IM programs randomized to intervention will be allowed to construct flexible duty hour schedules that comply with 3 rules:
No more than 80 hours of work per week (when averaged over 4 weeks)
1 day off in 7 (when averaged over 4 weeks)
In-house call no more frequently than every 3rd night (when averaged over 4 weeks)"
1594605|NCT02274805|Procedure|Adults presenting for surgery in the neck area|
1594606|NCT02274792|Drug|Etanercept|Etanercept produced using the serum free process (SFP)2 was supplied in a single-use 1 mL prefilled syringe for subcutaneous injection.
1594607|NCT02274779|Drug|ELIGARD|"Hormone therapy is recommended Eligard 45 mg acting for 6 months. It will be ideally administered the day of start of radiation therapy or within 3 months before the first day of radiotherapy.
Nevertheless, free prescription is left to investigators. When using other hormonal strategies (anti-androgen agonists, LHRH antagonists or LHRH), an administration for six months will be critical."
2009308|NCT03294460|Drug|Alcohol (Ethanol)|IV and Oral Self-administration
2009309|NCT03292809|Drug|CyclASol topical ocular, eye drops|Cyclosporine A solution in vehicle
1594610|NCT02274740|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
1594611|NCT02274740|Drug|metformin|Pharmaceutical form:tablet Route of administration: oral
1594612|NCT02274714|Other|Questionnaire Only|Subjects will have an interview with a study coordinator to fill out questionnaires for the study
1594613|NCT02274701|Other|Holistic Needs Assessment|An assessment completed by the patient in cancer care. It is recommended that this assessment is completed at key points in the care pathway, such as at diagnosis, post treatment and beginning of end of life care. The aim of this assessment is to allow the patient to discuss their most important needs as identified by them. The clinician will take any appropriate action. This may range from listening to the patient to referring to another member of the multi-disciplinary team.
1594614|NCT02274688|Behavioral|Stepped Care Management|Case management, information technology/mHealth innovations, stepped-up psychopharmacology and psychotherapy elements.
1594615|NCT02274675|Device|Robot-assisted therapy for wrist and forearm|Robot therapy by using a single degree reconfigurable robot to train for wrist and forearm rehabilitation training.
1594616|NCT02274675|Other|Standard rehabilitation therapy|Standard therapy of stroke rehabilitation including speech, physical, occupational therapies and group activities
1594617|NCT02274662|Biological|Thymus Transplantation|"Subjects receive thymus transplantation. Subjects may receive pre and/or post-transplantation immunosuppression.
Potential thymus recipient subjects are screened for eligibility. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Thymus transplantation is done under general anesthesia in the operating room. Thymus tissue is transplanted into the subject's quadriceps. Two to three months post-transplantation, if medically stable, the subject undergoes allograft biopsy. At the time of transplantation and biopsy, skin biopsy conducted. Subjects undergo laboratory testing for approximately one year post-transplantation. At year 2 post-transplantation, subjects are contacted for data collection."
1594618|NCT02274662|Procedure|Blood Draw|Biological Parent of Thymus Recipients may be asked to participate in the study and undergo phlebotomy to allow for testing of T cell identity in the thymus recipient subjects. If blood is not obtainable, then a buccal swab may be done.
1594619|NCT02274662|Drug|Rabbit Anti-Thymocyte Globulin and Cyclosporine or Tacrolimus|RATGAM and Cyclosporine or Tacrolimus may be given, depending on the patient. The doses, timing, and trough levels will vary depending on the patient's clinical condition.
2009310|NCT03292809|Drug|Vehicle topical ocular, eye drops|Vehicle
2009311|NCT03293992|Drug|0.01% RO7058584|Once daily morning administration for 7 days
1594622|NCT02274636|Dietary Supplement|Xylitol|A comparison between discs and gel
1594623|NCT02274623|Drug|CTAP101 Capsules|escalating doses
1594624|NCT02274610|Drug|Docetaxel-PNP|Docetaxel Polymeric Nanoparticle Formulation
1594625|NCT02274610|Drug|Taxotere|Docetaxel
1594626|NCT02274597|Device|metraux epitympanic thermometer|accuracy of epitympanic temperature measurement in different environmental settings
1594627|NCT02274584|Genetic|Anti-CD30 CAR T cells|Autologous 4th generation withdrawal lentiviral-transduced anti-CD30 CAR T cells
1594628|NCT02274571|Drug|TSEC (Tissue-selective estrogen complexes)|Duavee™, combination of CE(conjugated equine estrogens) and BZA (bazedoxifene)
1594629|NCT02274571|Other|Placebo|non active
1594630|NCT02274558|Drug|NBI-98854|NBI-98854 40 mg capsules
1594631|NCT02274558|Drug|Placebo|NBI-98854 placebo capsules
1594632|NCT02274545|Biological|H7N9 Anhui 2013/AA ca|10^7.0 fluorescent focus units (FFU); 0.5 mL of vaccine will be delivered as a nasal spray by an Accuspray device (0.25 mL per nostril)
1594633|NCT02274545|Biological|Inactivated subvirion H7N9 vaccine|30 mcg
1594634|NCT02274532|Device|SoftHand|Biomechanical, ADL, and functional testing.
2009312|NCT03293992|Drug|0.1% RO7058584|Once daily morning administration for 7 days
2009313|NCT03293992|Drug|1% RO7058584|Once daily morning administration for 7 days
1594637|NCT02274506|Drug|Cyclophosphamide|60 mg/kg by vein on Days -8 and -7.
1594638|NCT02274506|Drug|Fludarabine|25 mg/m2 by vein on Days -6 to -2.
1594639|NCT02274506|Procedure|T-Cell Infusion|T-cells infused no sooner than 48 hours and no later than 1 week post completion of chemotherapy on Day 0.
1594640|NCT02274493|Device|da Vinci® Robotic Surgical System|Da Vinci Robotic Surgical system to be used in procedures that harvest the latissimus dorsi muscle for reconstructive procedures
2009314|NCT03293992|Drug|Matching Placebo|Once daily morning administration for 7 days
1594641|NCT02274493|Procedure|LD muscle flap harvest procedure|Latissimus dorsi muscle flap harvest procedure using da Vinci® Robotic Surgical System for use in reconstructive surgery.
1594642|NCT02274493|Procedure|Reconstructive surgery|Reconstructive surgery is considered to be standard of care.
1594643|NCT02274493|Behavioral|Questionnaires|Questionnaire about pain, as well as participant's shoulder, arm, and hand range of motion completed at baseline, and at follow up visits 3-6.
1594644|NCT02274480|Device|cardiac MRI with DWI|
1594645|NCT02274467|Device|Trans-catheter electric stimulation test|
1594646|NCT02274454|Drug|Oxytocin|Experiments will be conducted with some myometrial strips pretreated with oxytocin, and others without any oxytocin pretreatment
1594647|NCT02274454|Drug|Calcium|Calcium will be applied to the myometrial strips in 3 concentrations; 1.25mM (low), 2.5mM (normal) and 5.0mM (high). Myometrial strips will be either oxytocin pretreated, or non-oxytocin pretreated.
1594648|NCT02274428|Drug|pneumostem|human umbilical cord blood derived mesenchymal stem cells
2009315|NCT03293992|Drug|Latanoprost 0.005%|Once daily morning or evening dosing
1594651|NCT02274402|Biological|blood sampling|Blood sample of 4 ml at enrolment and then at two following visits
1594652|NCT02274389|Drug|No Intervention|This is an observational study and participants did not receive any intervention in this study. Participants initiating bedaquiline (BDQ) treatment as decided by healthcare provider, will be prospectively observed.
1594653|NCT02274363|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic plaque type psoriasis will be assessed at a single time point, primarily for severity of plaque‐type psoriasis Participants will not be followed over time. Data will be collected from the medical consultation notes, medical records and during interviews.
1594654|NCT02274350|Radiation|radiation therapy|Radiation therapy either in the form of external beam radiation or radioactive gold seeds planted directly in the prostate.
1594655|NCT02274337|Drug|AC0010|patients take avitinib orally once per day at different dose
1594656|NCT02274324|Dietary Supplement|different diets|3 different diets: A\B\C
1594658|NCT02274298|Behavioral|CKD feedback and tools|people in the intervention arm will receive feedback on ckd quality indicators and tools to help in the detection and management of ckd
1594659|NCT02274285|Biological|DTaP-IPV/Hib Combined vaccine|0.5 mL, Subcutaneously. 3 times, each given 3 to 8 weeks apart
1594660|NCT02274285|Biological|DTaP-IPV vaccine and Hib vaccine|0.5 mL each, Subcutaneously, 3 times, each given 3 to 8 weeks apart
1594661|NCT02274285|Biological|DTaP-IPV/Hib Combined vaccine|0.5 mL, Intramuscularly. 3 times, each given 4 to 8 weeks apart
1594665|NCT02274259|Drug|Aflibercept|Aflibercept injection is given at every visit. Time to next treatment according to presence of macular edema
1594666|NCT02274259|Drug|Ranibizumab|Ranibizumab injection is given at every visit. Time to next treatment according to presence of macular edema
1594667|NCT02274246|Drug|gadobutrol|Gadobutrol administration in healthy volunteers
1594668|NCT02274233|Drug|SP-420|
1594669|NCT02274220|Dietary Supplement|Rapid advancement of feeds|Feeding is initiated on first postoperative day. Bolus feeds are started at 1 mL/kg every three hours and up-titrated by 1 mL/kg every feed (Q 3 hours) to a goal of 10 mL/kg/feed (equivalent to approximately 50 kcal/kg/day). Feeding volume will exceed 20 mL/kg/day by 6 hours following protocol initiation and reach target feeds by 27 hours of protocol initiation.
1594670|NCT02274207|Device|NPWT application|NPWT mode is cyclic mode : -125~-50 mmHg
1594671|NCT02274194|Other|Nasal CPAP|use of nasal mask to titrate CPAP - after titration 30 days of nasal CPAP
1594672|NCT02274194|Other|Oronasal CPAP|use of oronasal mask to titrate CPAP - after titration 30 days of nasal CPAP
1594673|NCT02274181|Drug|Androxal|
1594674|NCT02274168|Procedure|Conventional RF catheter ablation|RF catheter ablation will be performed as usually done by each center. No ICD EGMs will be obtained and used during the ablation procedure (do not place the programming head over the ICD generator).
1594675|NCT02274168|Procedure|Investigational RF Catheter Ablation using ICD-EG information|RF ablation procedure will be performed with the programming head over the ICD generator. ICD EGMs will be registered every time VT is induced and during ventricular pacing. ICD EGMs obtained during ablation procedure will be compared with the EGMs of the registered spontaneus VT and used to locate appropriate ablation sites.
1594676|NCT02274155|Drug|Anti-OX40 antibody administration|Anti-OX40 antibody administration at 0.4 mg/kg IV x 3 doses given on Days 1, 3 or 4, and 5 or 6 of study
1594677|NCT02274155|Procedure|Surgical Resection|Surgical Resection of Tumor
1594678|NCT02274142|Procedure|ART with powder-liquid material|restoration with powder liquid glass ionomer cement
1594679|NCT02274142|Procedure|ART with Encapsulated material|restoration with encapsulated ionomer cement
1594680|NCT02274142|Device|Encapsulated glass ionomer cement (EQUIA - GC Corp).|
1594681|NCT02274142|Device|powder-liquid glass ionomer cement (Fuji IX - GC Corp)|
1594682|NCT02274129|Device|Healing cap II|Healing cap II is used instead of the traditional healing cap as part of the surgical dressing after bone anchored hearing aid implant surgery
1594683|NCT02274116|Other|SHAM - Intermittent Room Air - room air mixture|Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment 3 times per week for 4 weeks.
1594684|NCT02274116|Other|AIH - Intermittent Hypoxia - hypoxia air mixture|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia). Participants will receive treatment 3 times per week for 4 weeks.
1594685|NCT02274103|Behavioral|BFST|Family-based skills training.
1594785|NCT02273362|Other|Quality-of-Life Assessment|Ancillary studies
1990375|NCT02051972|Device|Implanted with a Nanostim leadless pacemaker system|
1594686|NCT02274090|Drug|Placebo gel|Placebo gel consist of drug without the active component.
1594687|NCT02274090|Drug|1% Metformin gel|Metformin gel consist of active component.
1594688|NCT02274077|Drug|EXPAREL|
1594689|NCT02274077|Drug|Normal Saline|
1594690|NCT02274064|Behavioral|Motivational Interview and Implementation Intention|Telephone call that includes motivational interviewing techniques and develops an implementation intention plan.
1594691|NCT02274051|Dietary Supplement|Kinetin|Titration of Kinetin to maximum individualized dose, then steady state over a 3 year period once daily dose.
1594692|NCT02274038|Drug|Baseline 18F-thymidine (FLT) PET/CT|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This baseline scan will be used to compare post-therapy FLT-PET/CT in order to assess change in tumor accumulation of FLT.
1594693|NCT02274038|Drug|"Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced tumor FLT flare"|"FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed on the day of starting pemetrexed therapy (within 24hrs of starting pemetrexed) and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for early pemetrexed induced changes in tumor accumulation of FLT known as FLT flare."
1594694|NCT02274038|Drug|Post-therapy 18F-thymidine (FLT) PET/CT to assess for pemetrexed induced changes in tumor proliferation|FLT is a fluoro-labelled thymidine analog used as a radiotracer of tumor proliferation in PET/CT imaging. This scan will be performed 2-4 weeks after starting pemetrexed therapy and used to compare to baseline FLT-PET/CT in order to assess change in tumor accumulation of FLT. The objective is to assess for pemetrexed induced changes in tumor accumulation of FLT as a surrogate measure of tumor proliferation.
1594695|NCT02274012|Drug|Afatinib|Afatinib 40mg/PO daily will be administered in combination to standard of care paclitaxel.
1594696|NCT02274012|Drug|Paclitaxel|On the day of the first dose of afatinib, paclitaxel will be administered at a dose of 80 mg/m2 intravenously over 60 minutes on days 1, 8 and 15 of a 28-day cycle.
1594697|NCT02273999|Device|RecoveryRx™|Appliance of the device after surgery
1594698|NCT02273986|Drug|Digoxin|
1594699|NCT02273986|Drug|K-877|
1594700|NCT02273973|Drug|Letrozole|Letrozole tablets will be administered orally at 2.5 mg QD for 16 weeks.
1594701|NCT02273973|Other|Placebo|Placebo tablets matched to taselisib formulation will be administered orally daily on 5 days-on/2 days-off schedule for up to 16 weeks.
1594702|NCT02273973|Drug|Taselisib|Taselisib will be administered orally at 4 mg (two 2 mg tablets) daily.
1594704|NCT02273947|Drug|BMS-955176|Single dose by mouth for each treatment specified
1594705|NCT02273934|Behavioral|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
1594706|NCT02273934|Behavioral|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
1594707|NCT02273921|Other|EEG recording|EEG is recorded once for each participant
1594708|NCT02273908|Other|No intervention|The study is observational
1594709|NCT02273895|Drug|Scopolamine|0.3 mg/mL, intravenously, once
1594710|NCT02273843|Drug|High-dose vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 800 IU from the time of diagnosis of sepsis until discharge from the NICU
1594711|NCT02273843|Drug|Conventional-Dose Vitamin D 3|Will receive oral cholecalciferol (vitamin D3) in a single daily dose of 400 IU from the time of diagnosis of sepsis until discharge from the NICU
1594712|NCT02273830|Drug|oxygen|Oxygen administered after adjustment during a waking test or at 3L/min
1594713|NCT02273817|Drug|Ciclesonide nasal spray, 50 μg per actuation.|"During placebo lead-in period: patients received placebo nasal spray, two actuations in each nostril once daily for 7 days.
During treatment period: subjects were then assigned to one of the following three treatments according to the randomization scheme:
Ciclesonide nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.
Omnaris™ nasal spray: 50 μg per actuation, two actuations in each nostril once daily (200 μg per day) for 14 days.
Placebo nasal spray: 0 μg per actuation, two actuations in each nostril once daily for 14 days."
1594714|NCT02273804|Drug|Topiramate|Topiramate for 9 months treatment, and then 27 months of follow-up Dose regimen will be determined according to theoretical weight (taken orally), escalated every 15 days. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose.
1594715|NCT02273804|Drug|Placebo|Placebo will be taken orally following to the same dose regimen according to theoretical weight
1594716|NCT02273791|Drug|Estradiol valerate|Women will be given estradiol valerate 4 mg daily from day 2 to day 12 of the cycle then the endometrial thickness will be assessed on day 13 by transvaginal sonography (TVS). If the endometrium is ≥ 8 mm and of moderate echogenicity, luteal phase support (using progesterone supplements) will be started but if the endometrium is < 8 mm, estradiol valerate will be continued until reaching appropriate endometrial thickness and echogenicity then the luteal phase support will be started.
1594717|NCT02273791|Drug|Sequential Clomiphene citrate and Gonadotropin|Women will be given clomiphene citrate in dose of 100-150 mg daily for 5 days (from day 2 to day 6 of the cycle) then switched to low dose gonadotropin (75-150 IU daily) followed by monitoring of the follicular growth (folliculometry) ); starting from day 10 of the stimulation cycle and repeated every 2 days. Final oocyte maturation will be induced by administration of human chorionic gonadotropin (HCG) when there will be at least one leading follicle > 18 mm in diameter followed by luteal phase support (using progesterone supplements) after 48 hours.
1594718|NCT02273778|Procedure|MRI Scan|
1594719|NCT02273778|Procedure|PET-CT Scan|
1594720|NCT02273778|Other|No intervention|
1594721|NCT02273765|Drug|Tenofovir + lamivudine + raltegravir|"In this arm, patients will receive the following medications :
Tenofovir disoproxil fumarate (TDF) 300 mg / Lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)
Raltegravir (RAL) 400 mg (Isentress®): twice daily (1 tablet bid), with food
In countries where TDF/3TC FDC is not available, the following separate drugs will be used:
Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)
Lamivudine (3TC) : 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)
Raltegravir (RAL) 400 mg (Insentress®): twice daily (1 tablet bid), with food"
1594832|NCT02272998|Drug|ponatinib hydrochloride|Given PO
1594722|NCT02273765|Drug|Tenofovir + lamivudine + efavirenz|"In this arm, patients will receive the following medications, in accordance with treatment guidelines in all countries:
Tenofovir disoproxil fumarate (TDF) 300 mg / lamivudine (3TC) 300 mg FDC once a day (1 tablet qd)
Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd)
OR:
• Tenofovir disoproxil fumarate (TDF) 245 300 mg / lamivudine (3TC) 300 mg / efavirenz (EFV) 600 mg: once a day (1 tablet qd), at night, if possible without food
In countries where TDF/3TC FDC is not available, the following separate drugs will be used:
Tenofovir disoproxil fumarate (TDF) 300 mg (Viread® 245 mg): once a day (1 tablet qd)
Lamivudine (3TC): 300 mg once a day (300 mg, 1 tablet qd or 150 mg 2 tablets qd)
Efavirenz (EFV) 600 mg: once a day, at night (1 tablet qd), if possible without food. The dose will not be adapted to the patient's body weight."
1594723|NCT02273752|Drug|Everolimus|Given PO
1594724|NCT02273739|Drug|AG-221|AG-221 administered orally on every day of 28 day cycles until disease progression or unacceptable toxicities. Multiple doses.
1594725|NCT02273726|Drug|Epoetin Alfa|Epoetin alfa will be dosed intravenously three times a week.
1594726|NCT02273726|Drug|FG-4592|Roxadustat will be dosed orally three times a week.
1594727|NCT02273713|Drug|Nab-paclitaxel|Nab-paclitaxel added to first line treatment oxaliplatin and capecitabine
1594728|NCT02273700|Drug|Rivaroxaban|Patients are observed during their first month of Rivaroxaban (Xarelto®) treatment, which is part of their routine care.
1594729|NCT02273687|Device|Vivid S6 GE Ultrasound|"Diaphragmatic ultrasound will be performed by the physician supporting the patient on arrival and also at 4 hours later in the beginning of therapeutic management. The patient will be monitored for 24 hours following inclusion.
The exams will all be done with the same ultrasound system (Vivid S6 GE Ultrasound) and a phased array probe, also called a cardiac probe."
1594730|NCT02273674|Device|Left rTMS 5 Hz|The subjects will receive transcranial magnetic stimulation (5 Hz of frequency over left dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
1594731|NCT02273674|Device|Right r TMS 1 Hz|The subjects will receive transcranial magnetic stimulation (1 Hz of frequency over right dorsolateral prefrontal cortex . Once a day on monday to friday. Until receive 15 sessions. After this the subjects, will be received 8 more sessions of TMS, one session at week for next eight weeks
1594734|NCT02273648|Device|Drug Eluting Stent (DES)|
1594735|NCT02273635|Drug|Andrographolides|140 mg andrographolides coated tablets twice a day orally administered for 24 months.
1594736|NCT02273635|Drug|placebo|140 mg excipients coated tablets twice a day orally administered for 24 months
1594737|NCT02273622|Dietary Supplement|hydroxytyrosol|Pilot study with 20 participants, each participant will alternately by the two arms of the study (hydroxytyrosol 5 mg and 20 mg) and control, during 6 weeks.
1594738|NCT02273622|Dietary Supplement|placebo|
1594739|NCT02273609|Drug|Vitamin K antagonists (acenocoumarol or warfarin)|"INR values of patients treated with acenocoumarol or warfarin in the last 12 months will be recorded according to clinical practice of each center.
No specific recommendation about treatment will be provided by sponsor."
1594740|NCT02273596|Drug|WTX101|Dosage Form: 15 mg Tablets
1594741|NCT02273583|Drug|continuous oral cyclophosphamide and methotrexate|
1594742|NCT02273570|Drug|standard care|Standard care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion) to obtain a iPTH of 300-540 pg/ml.
1594743|NCT02273570|Drug|Optimal (I. iPTH control: Zemplar®,Mimpara®; phosphorous control: Renvela®, Phoslo®, Osvaren®, Foznol®,Maalox®; calcium control: calcium and vitamin D|Optimal care. Patients allocated to this study arm will be treated with all drugs available for PTH control (at the investigator discretion - see therapeutic algorithm) to obtain a iPTH of less than 300 pg/ml.
1594744|NCT02273557|Drug|Asasantin ER (new formulation I - low)|
1594745|NCT02273557|Drug|Asasantin ER (new formulation III - medium)|
1594746|NCT02273557|Drug|Asasantin ER (new formulation II - high)|
1594747|NCT02273557|Drug|Asasantin ER (present commercial formulation)|
1594748|NCT02273544|Drug|Asasantin ER (new formulation - low)|
1594749|NCT02273544|Drug|Asasantin ER (new formulation - medium)|
1594750|NCT02273544|Drug|Asasantin ER (new formulation - high)|
1594751|NCT02273544|Drug|Asasantin ER - commercial formulation|
1594752|NCT02273531|Drug|Asasantin ER, new formulation|
1594753|NCT02273531|Drug|Asasantin ER, present commercial formulation|
1594754|NCT02273518|Drug|Asasantin ER, new formulation I|
1594755|NCT02273518|Drug|Asasantin ER, new formulation II|
1594756|NCT02273518|Drug|Asasantin ER, present commercial formulation|
1594757|NCT02273505|Drug|Asasantin (ER)|
1594758|NCT02273505|Drug|Persantin|
1594759|NCT02273505|Drug|Acetyl salicylic acid (ASA)|
1594760|NCT02273492|Drug|Asasantin ER|
1594761|NCT02273492|Other|Standardized breakfast|
1594762|NCT02273479|Drug|Asasantin®|Asasantin® extended release (RAD-SP)
1594763|NCT02273479|Drug|Placebo|
1594764|NCT02273466|Drug|Desipramine tablet|
1594765|NCT02273466|Drug|Crobenetine infusion|
1594766|NCT02273466|Drug|Placebo infusion|
1594767|NCT02273453|Drug|Songha® Night|
1594768|NCT02273453|Drug|Oxazepam|
1594769|NCT02273453|Drug|Placebo|
1594770|NCT02273440|Drug|BIIL 284 BS|
1594771|NCT02273440|Drug|Theophylline|
1594772|NCT02273440|Drug|Placebo|
1594773|NCT02273427|Drug|BIIL 284 BS|
1594774|NCT02273427|Other|high fat meal|
1594775|NCT02273427|Other|low fat meal|
1594776|NCT02273414|Drug|BIIL 284 BS - rising dose|
1594777|NCT02273414|Drug|Placebo|
1594778|NCT02273401|Drug|BI 11054 CL|
1594779|NCT02273401|Drug|Placebo|
1594780|NCT02273388|Drug|BI 6727|
1594783|NCT02273362|Drug|Erlotinib Hydrochloride|Given PO
1594784|NCT02273362|Other|Laboratory Biomarker Analysis|Correlative studies
1594786|NCT02273349|Device|Lung Volume Reduction Coil (PneumrX Inc.)|Endoscopic Lung Volume Reduction
1594787|NCT02273336|Other|cytology specimen collection procedure|Undergo tissue and blood sample collection
1594788|NCT02273336|Other|laboratory biomarker analysis|Correlative studies
1594789|NCT02273323|Other|Tea|Single dose of black tea infusion containing approximately 400 mg flavonoids (expressed as gallic acid equivalents) with added sugar.
1594790|NCT02273323|Other|Placebo|Placebo: tea flavour, colouring and sugar
1594791|NCT02273310|Behavioral|Problem-Solving Skills Training for Disease Management|Children and caregivers participated in a multi-family group to learn problem-solving skills as applied to disease management and school functioning in the context of sickle cell disease.
1594792|NCT02273297|Other|Maternal factors|
1594793|NCT02273284|Device|Buzzy|The Buzzy will be applied for 30 seconds over the area that is going to be injected, then during the actual injection the Buzzy will be moved rostrally and continuously used during the injection. When the injection is completed the Buzzy is positioned in the same way over the next injection site.
1594794|NCT02273271|Other|18F-FLT-PET/CT and DWI-MRI|Patients with NSCLC will undergo 18F-FLT-PET/CT and DWI-MRI scans on three separate occasions. Dedicated in-house developed software will be used to quantify 18F-FLT SUV and ADC to assess tumor characteristics and response to therapy.
1594795|NCT02273258|Drug|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
1594796|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
1594797|NCT02273258|Drug|Insulin Lispro|Pharmaceutical form:solution Route of administration: subcutaneous
1594798|NCT02273245|Radiation|Thoracic aortogram CT|With and without contrast dye
1594799|NCT02273232|Other|Remote Ischemic Preconditioning|Blood pressure cuff will be inflated to 200 mmhg for 5 minuets and release for 5 minuets to total of 4 cycles
1594800|NCT02273232|Other|Supervised Exercise|constructed extra excessive for peripheral vascular diastase patients
1594801|NCT02273232|Other|Standard Care|Standard Care for peripheral vascular disease patients including advises regarding exercises
1594802|NCT02273219|Drug|AEB071|Oral, 100-400 mg twice daily A potent, oral, selective inhibitor of the classical Protein Kinase C (PKC)
1594803|NCT02273219|Drug|BYL719|Oral, 200-350 mg daily An oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds
1594804|NCT02273206|Behavioral|Preventive Care Management for Depression|
1594805|NCT02273206|Behavioral|Preventive Care Management for Cancer Screening|
1594806|NCT02273180|Drug|SAR342434|Pharmaceutical form:solution Route of administration: subcutaneous
1594807|NCT02273180|Drug|Humalog|Pharmaceutical form:solution Route of administration: subcutaneous
1594808|NCT02273180|Drug|insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
1594809|NCT02273167|Drug|NER1006, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
1594810|NCT02273167|Drug|NER1006,1-Day Morning Split-Dosing|"The subject will self-administer the first dose of the investigational product on the morning of the colonoscopy and take mandatory additional clear fluid.
After a 1-2 hour break the subject will self-administer the second dose plus additional clear mandatory fluid."
1594811|NCT02273167|Drug|MOVIPREP, 2-Day Split-Dosing|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take recommended additional clear fluid. Subject will take the second dose together with recommended additional clear fluids on the morning of the colonoscopy.
1594812|NCT02273154|Drug|Buspirone|MDD patients with anxiety disorder take paroxetine (20-60mg/d), combining with buspirone (initial dose is 5mg tid, then increase the dose to 10mg tid on 4th day)
1594813|NCT02273154|Drug|Paroxetine|MDD patients with anxiety disorder take paroxetine (20-60mg/d)
1594814|NCT02273141|Drug|NER1006, Day Before-Only Dosing|The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
1594815|NCT02273141|Drug|SP+MS, Day Before-Only Dosing|The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
1594816|NCT02273128|Genetic|CTR Gene|2ml blood sample collected from patients to extract DNA for Assessment of CTR Gene polymorphism
1594817|NCT02273115|Drug|Oxytocin|
1594818|NCT02273115|Device|Transcervical Foley catheter|
1594819|NCT02273102|Drug|Tranylcypromine|Tranylcypromine (TCP) to be administered orally twice a day (12 hours apart) for up to 16 cycles of 21 days each.
1594820|NCT02273102|Drug|Tretinoin|45 mg/m2 of ATRA to be administered orally twice a day (12 hours apart), beginning on day 4 for up to 16 cycles of 21 days each.
1594821|NCT02273089|Device|CPAP (ResMed S9 AutoSet)|nocturnal CPAP for three months
1594822|NCT02273076|Device|Spatial Frequency Domain Imaging|Spatial Frequency Domain Imaging
1594823|NCT02273063|Device|Transcranial Magnetic Stimulation|Stimulating DLPFC at 5 Hz for up to 40 treatment sessions overall. 35 sessions delivered over 7 weeks, and final 5 treatments delivered in taper over 3 weeks. There will be a post treatment assessment 72 hours after final treatment, and then again 1 month after the final treatment.
2009316|NCT03293576|Behavioral|Volitional Help Sheet|"This brief intervention will last around 20 minutes. The participants and the researcher will read through the list of real-life solutions the participants might find applicable to them. They will then read through the list of situations one by one. The participant will draw a coloured line between the situation and the solution which seems more appropriate to them. The volitional help sheet helps create implementation intentions, which are self-regulatory strategies taking the form of if-then plans (i.e. situation-solution plan)."
2009317|NCT03293004|Dietary Supplement|Hydrolyzed collagen|Escalating dose of Hydrolyzed collagen
2009318|NCT03293004|Dietary Supplement|Vitamin C|Escalating dose of Vitamin C
1594830|NCT02273024|Behavioral|Exercise|
1594831|NCT02273011|Procedure|caesarean section|elective caesarean section under regional anesthesia
2009319|NCT03293004|Dietary Supplement|Optimized Hydrolyzed Collagen and Vitamin C|combination of optimized doses of Hydrolyzed Collagen and Vitamin C
2009320|NCT03293004|Dietary Supplement|Gummy Placebo|Gummy placebo
1594836|NCT02272972|Other|Application of knowledge|Educational Intervention has been performed at the treating surgeon (video and poster). The surgeons applies the achieved knowledge when performing the intraoperative fluoroscopy in patients with pertrochanteric fractures.
1594837|NCT02272959|Behavioral|Attention bias modification treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns using threat and neutral stimuli.
1594838|NCT02272959|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns using only neutral stimuli.
1594839|NCT02272946|Drug|Canakinumab|150mg Canakinumab received subcutaneously
1594840|NCT02272946|Drug|Placebo|150mg Placebo received subcutaneously
1594841|NCT02272933|Device|Smart Slipper|The shoe measures foot pressure and motion allowing gait to be quantified.
1594842|NCT02272933|Device|Belt-Clip Sensor|The sensor measures acceleration of the body allowing falls to be detected.
1594843|NCT02272920|Procedure|Renal denervation|Medtronic Symplicity Flex, Medtronic Symplicity Spyral, or St Jude EnligHTN.
1594844|NCT02272907|Other|Injection of saline solution into specimen to test bursting pressure.|A 1 cm gastrotomy will be made with a purse-string suture placed around the defect. A fluid-instillation catheter will be inserted into the specimen via the gastrotomy. The purse-string suture will then be secured around the catheter. The catheter will be fenestrated with a flange to prevent leakage from the gastrotomy site. The catheter will be attached to a Biopac pressure-monitoring device to monitor pressure within the lumen of the specimen. The specimen will then be suspended in a water bath and methylene blue saline solution will be injected into the specimen to a pressure reading of 0. This will be time zero for our experiment. Methylene blue saline solution will then be injected steadily in incremental levels. During this process, the study team will observe for any obvious blue dye leaks at the staple line or drop in pressure on the monitor.
1594845|NCT02272894|Procedure|Dissection of the Superior Mesenteric Vein Lymph Node|14v lymph node dissection
1594846|NCT02272881|Procedure|surgical reconstruction|Patients randomized to surgical flap closure will undergo reconstructive plastic surgery to close an intended pressure ulcer at the earliest date after selection. Our group's co-investigator and staff plastic and reconstructive surgeon will decide on the optimal technical repair. Given the lack of retrospective evidence to support a superior surgical repair (myocutaneous, fasciocutaneous, local flap arrangement versus free microvascular tissue transfer) we will defer to our physician staff preference on a per patient basis. The time from enrollment to surgical intervention will be tracked, and no patient will be dropped from the study should this time exceed the two-week ideal.
1594847|NCT02272881|Procedure|wound management|Patients selected to the supportive wound care arm will be managed by the Center for Wound Care at Cottage Health System, a certified wound care center. They will receive standard of care conservative wound care including: debridement, dressing changes, wound checks, physical therapy, occupational therapy, antibiotic treatment, nutritional support and close follow-up over the study period.
1594848|NCT02272868|Biological|Fecal Microbial transplant|Pretransplant regimen(rifaxamin+omeprazole+miralax) + Donor feces transplant
1594849|NCT02272868|Drug|Normal Saline|Pretransplant regimen(rifaximin+omeprazole+miralax) +Normal Saline
1594850|NCT02272868|Drug|rifaximin+omeprazole+miralax|
1594851|NCT02272855|Biological|HF10 plus Ipilimumab|Patients will receive the dose of 1 x 10^7 TCID50/mL HF10 (for a total of 6 injections; the first 4 injections at 1-week intervals; the remaining 2 injections at 3-week intervals) and ipilimumab at 3 mg/kg ipilimumab (for a total of 4 intravenous infusions, each administered at 3-week intervals).
1594852|NCT02272842|Dietary Supplement|Vitamin B12|Vitamin B12 in a multivitamin paste.
1594853|NCT02272829|Behavioral|Choacot: Behavioral Intervention for Chronic Opioid Use|This is an intervention for individuals who use opioid medication for chronic pain, and targets the collaboration between the participant and his/her PCP.
1594854|NCT02272829|Other|Health Education|
1594855|NCT02272816|Drug|Carboplatin AUC-10|"Carboplatin will be administered as a day case and doses will be calculated using the Calvert formula as below:
Dose (mg) = (GFR + 25) x 10
Treatment will be repeated every 3 weeks for 3 or 4 cycles depending on the metabolic response after cycle 1 (assessed by PET-CT scan). Patients who display complete response after cycle 1 will have 3 cycles in total. Those who display partial response will have 4 cycles in total. Patients who display no response after cycle 1 but do display a response after cycle 2 will have 4 cycles in total. Those who display no response after cycle 2 will be withdrawn."
1594856|NCT02272803|Drug|Lenalidomide|
1594857|NCT02272803|Drug|Dexamethasone|
1594858|NCT02272803|Biological|Elotuzumab (BMS-901608)|
1594859|NCT02272790|Drug|AZD1775 + carboplatin|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Carboplatin is a chemotherapy drug used against some forms of cancer (mainly ovarian carcinoma, lung, head and neck cancers as well as endometrial, esophageal, bladder, breast and cervical; central nervous system or germ cell tumors; osteogenic sarcoma, and as preparation for a stem cell or bone marrow transplant.).
1594860|NCT02272790|Drug|AZD1775 + paclitaxel|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small-molecule inhibitor of the WEE1 kinase that sensitizes tumour cells to cytotoxic agents and is being developed for the treatment of advanced solid tumours and p53 pathway deficient malignancies. Chemotherapy is a category of cancer treatment that uses chemical substances, especially one or more anti-cancer drugs (chemotherapeutic agents) that are given as part of a standardized chemotherapy regimen.
1594861|NCT02272777|Drug|Imatinib|Imatinib 400mg QD，300mg QD or 600mg QD
1594862|NCT02272777|Drug|Nilotinib|Nilotinib 300mg BID or 400mg QD
1594863|NCT02272764|Drug|Itraconazole|Administered orally in a crossover design
1594864|NCT02272764|Drug|ALKS 5461|Administered sublingually in a crossover design
1594865|NCT02272751|Behavioral|Exercise|The Exercise intervention will consist of aerobic activity followed by upper and lower limb resistance training using Therabands and some core exercises.
1594866|NCT02272751|Behavioral|Relaxation|The Relaxation intervention will consist of a chair-based program incorporating breathing exercises, meditation, visualisation and progressive muscle relaxation.
1594867|NCT02272738|Drug|Gemcitabine|Gemcitabine is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
1594868|NCT02272738|Drug|Nab-Paclitaxel|Nab-Paclitaxel is administered with 30 min intravenous infusion on day 1,8 and 15 every 4 weeks.
1594869|NCT02272725|Drug|Ibuprofen|Ibuprofen
1594870|NCT02272725|Drug|Placebo|Tasteless and inert visually identical (to ibuprofen) pills
1594871|NCT02272712|Behavioral|Cognitive Behavioural Therapy|psychoeducation about insomnia, relaxation training, sleep restriction, stimulus control, hypnotic tapering under direction of a physician, cognitive therapy, sleep hygiene
1594872|NCT02272699|Drug|Nimotuzumab|Nimotuzumab 200mg per week for 6 weeks.
1594873|NCT02272699|Drug|Paclitaxel|Paclitaxel 175mg per square metre on day 1, repeated every 3 weeks for 2 cycles.
1594874|NCT02272699|Drug|Cisplatin|Cisplatin 30mg per square metre on day 1 and day 2, repeated every 3 weeks for 2 cycles.
1594875|NCT02272699|Radiation|Radiation|IMRT of primary tumor and local lymph nodes with 95% PTV of 41.4 Gy/23f. Nimotuzumab 200mg per week for 6 weeks.
1594876|NCT02272699|Procedure|Surgery|Esophagectomy
1594877|NCT02272686|Drug|Ibrutinib|560 mg by mouth daily.
1594878|NCT02272673|Dietary Supplement|Honey|The subjects in the I/C group consumed 2 ml (2.5 g) honey/kg body weight/dose twice weekly in the first 12-week period (period 1), while the subjects in the C/I group did not receive honey as a control in the period 1. After period 1, the subjects of each group exchanged their protocol for the following 12-week period (period 2).
1594879|NCT02272660|Drug|Parecoxib sodium|The patients in the parecoxib group received a single 40mg dose of parecoxib sodium 30 minutes before incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
1594880|NCT02272660|Drug|Normal saline injection|The patients in the control group received 2 mL normal saline injection 30 minutes before Normal saline injection incision, 9:00 pm on the operation day as well as 9:00 am and 9:00 pm for the next two days after the operation, along with PCIA morphine.
2009321|NCT03290573|Device|short peripheral venous catheter|short peripheral venous catheter for infusion therapy in adult patients
2009322|NCT03291067|Drug|MT-8554 Low dose|MT-8554 Low dose QD, oral, 12 weeks
2009323|NCT03291067|Drug|MT-8554 Medium dose|MT-8554 Medium dose QD, oral, 12 weeks
2009324|NCT03291067|Drug|MT-8554 High dose|MT-8554 High dose QD, oral, 12 weeks
2009325|NCT03291067|Drug|Placebo|Placebo QD, oral, 12 weeks
2009326|NCT03290794|Drug|Aflibercept (Eylea, BAY86-5321)|Intravitreal Aflibercept as prescribed by the treating Physician
1594890|NCT02272634|Drug|YPL-001 low dose|twice daily [BID]
1594891|NCT02272634|Drug|YPL-001 high dose|twice daily [BID]
1594892|NCT02272634|Drug|placebo|twice daily [BID]
1594893|NCT02272621|Procedure|Minimally invasive aortic valve replacement|
1594894|NCT02272621|Procedure|Full sternotomy aortic valve replacement|
1594895|NCT02272608|Other|Evaluation of Sleep Apnea Related Inflammation with CRP, ESR and Neutrophil toLymphocyte Ratio|CRP, ESR and Neutrophil toLymphocyte Ratio values of sleep apnea patients were evaluated with respect to apnea- hypopnea scores.
1594896|NCT02272595|Other|Treatment Based on Genetic Mutation|Participant's molecular profile shows that they have a gene mutation that may benefit from study drugs that are believed to target their gene mutation. Participant assigned to Arm A and will receive these targeted drugs.
1594897|NCT02272595|Other|Treatment Based on No Genetic Mutation|Participant's molecular profile shows that they do not have a gene mutation. Participant assigned to Arm B in which doctor chooses a therapy based on other studies rather than gene mutation.
1594898|NCT02272582|Device|SOMVC001 Vascular Conduit Solution|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
1594899|NCT02272582|Other|Standard of care Heparin-dosed saline|SV harvesting will be uniformly performed using an open or endoscopic vein harvesting technique. Once harvested, the SV will be divided into segments and these vein segments from each patient to be immersed in one of two blinded solutions: SOMVC001 or heparin dosed saline. The patients will then be randomized and SVG segment allocations will be defined and grafted to the assigned target regions.
1594900|NCT02272569|Device|STARflo Glaucoma Implant|Implantation of the STARflo Glaucoma Implant following surgical technique described in European labelling. Procedure does not require the use of anti-fibrotics.
1594901|NCT02272556|Other|Brain MRS during hyperglycemic clamp|All patients will undergo brain MRS at baseline and following 2 and 4 hours of hyperglycemia using the clamp technique
1594902|NCT02272556|Other|Analysis of Metabolites in cerebrospinal fluid|All patients will have the option to undergo a lumbar puncture for analysis of metabolites in cerebrospinal fluid
1594903|NCT02272543|Dietary Supplement|Fish surimi peptide|
1594904|NCT02272517|Drug|Vortioxetine 10-20 mg|
1594905|NCT02272517|Drug|Escitalopram 10-20 mg|
1594906|NCT02272491|Device|ZrO2 (Straumann CARES)|"Straumann CARES Variobase Abutment RN
Straumann CARES Full Contour Zerion HT The monolithic zircona crown (2) will be bonded to the titanium base (1)"
1594907|NCT02272491|Device|PFM crown (Straumann Gold)|Porcelain-fused-to-metal crown consisting of a gold abutment, a gold core, and veneering ceramic
1594908|NCT02272478|Drug|Arm A Mylotarg|
1594909|NCT02272478|Drug|Arm D Cladribine|Arm D - DAC Therapy
1594910|NCT02272478|Drug|AC220|Small molecule comparison
1594911|NCT02272478|Drug|Ganetespib|Small molecule comparison
1594912|NCT02272465|Other|No intervention|Observational study
1594913|NCT02272452|Device|High-Resolution Magic-Angle Spinning Nuclear Magnetic Resonance spectroscopy|
1594914|NCT02272426|Behavioral|CARET|Combined Aerobic and Resistance Exercise Training
1594915|NCT02272426|Behavioral|CTI|Cognitive Training Intervention
1594916|NCT02272426|Behavioral|Sham CARET|Sham Combined Aerobic and Resistance Exercise Training
1594917|NCT02272426|Behavioral|Sham CTI|Sham Cognitive Training Intervention
2009327|NCT03289923|Other|TMS+SST|Transcranial Magnetic Stimulation (TMS) with Self System Therapy (SST)
2009328|NCT03289923|Other|Sham TMS + Sham Therapy|Sham Transcranial Magnetic Stimulation (TMS) + Sham Therapy
2009329|NCT03289923|Device|TMS|Transcranial Magnetic Stimulation (TMS)
2009330|NCT03289923|Behavioral|Cogntive Therapy|Self-Systems Therapy (SST)
1594922|NCT02272400|Other|IGRT for prone partial breast irradiation (PBI)|IGRT for prone partial breast irradiation (PBI): All patients will be treated prone with 6 Gy/fraction delivered in 5 fractions over a 1-week period for a total dose of 30 Gy. Simulation and treatment will be started within 50 days from surgery in order to maximize the chances of optimal lumpectomy cavity visualization on the planning and cone beam CT scans. All patients will be followed monthly for the first 90 days then q3 months for the first year, then yearly for the next 10 years.
1594923|NCT02272387|Dietary Supplement|Vitamin D3 (Cholecalciferol)|
1594924|NCT02272387|Other|Placebo|
1594925|NCT02272374|Procedure|AVF creation|
1594926|NCT02272374|Procedure|TCC placement|
1594927|NCT02272374|Procedure|AVG creation|
1594928|NCT02272361|Other|laparoscopic sacrocolpopexy|
1594929|NCT02272361|Other|vaginal mesh surgery|
1594930|NCT02272348|Other|Training course to functional insulin therapy|Carbohydrate counting, carbohydrate/insulin ratio, sensitivity to insulin factor
1594931|NCT02272348|Other|Usual diabetes management.|
1594932|NCT02272335|Behavioral|Group Sessions|"10 weekly sessions:
CBSM - 10 consecutive weekly sessions (and consists of a roughly 30-minute relaxation component, 45-minute cognitive-behavioral stress management component, and a 15-minute break). Groups include an average of 4-9 women and a female African American interventionist. Participants in CBSM receive a workbook that summarizes the rationale for each module, techniques learned within each module, a short out-of-session exercise to practice and the content of the CW condition as well.
CW/EE - roughly 90 minutes in duration. Each session focuses on an important aspect of recovery from breast cancer. Modules were derived from products in the public domain"
1594933|NCT02272322|Device|cystocele repair with biomesh soft prolaps and endofast reliant|
1594934|NCT02272309|Procedure|EEG and EP measurement|
1594935|NCT02272296|Device|jet injector|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
1594936|NCT02272296|Device|Conventional pen (NovoPen IV)|1 administration of insulin in a dose of 0.2 units per kg body weight subcutaneously in the abdomen, 1 empty administration
1594937|NCT02272283|Device|Percutaneous coronary intervention with Nobori biolimus-eluting stent implantation|The third-generation biodegradable polymer Nobori biolimus-eluting stent is implanted in all patients
1594938|NCT02272270|Drug|Minocycline with chemoradiation (temozolomide and radiation therapy)|Patients receive minocycline in conjunction with standard chemoradiation and then they receive minocycline with standard chemotherapy.
2009331|NCT03290261|Other|Hypnosis|3 hypnosis sessions performed at 4 - 6 weeks apart
2009332|NCT03289533|Drug|Avelumab (MSB0010718C)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
1594941|NCT02272244|Behavioral|Decision Support & Navigation|
1594942|NCT02272244|Behavioral|Standard|
2009333|NCT03289533|Drug|Axitinib (AG-013736)|Patients will receive avelumab 10 mg/kg Q2W in combination with axitinib 5 mg BID.
1594944|NCT02272205|Other|Retrospective analysis of records|
1594945|NCT02272192|Behavioral|Play-based|The Early Start Denver Model (ESDM) is a comprehensive behavioral early intervention approach for children with autism, ages 12 to 48 months. The program encompasses a developmental curriculum that defines the skills to be taught at any given time and a set of teaching procedures used to deliver this content. The teaching format focuses on natural activities involving play or daily routines, though structure is added for children who need more structure to progress well. Progress data is collected throughout each session and used to make decisions about teaching approaches. Discrete Trial Teaching is not used in this group.
1594946|NCT02272192|Behavioral|Discrete Trial Teaching|Discrete trial training (DTT) is a one-to-one instructional approach used to teach skills in a planned, controlled, and systematic manner. Each trial or teaching opportunity has a definite beginning and end, thus the descriptor discrete trial. Within DTT, the use of antecedents and consequences is carefully planned and implemented. Positive praise and/or tangible rewards are used to reinforce desired skills or behaviors. Data collection is an important part of DTT and supports decision making by providing teachers/practitioners with information about beginning skill level, progress and challenges, skill acquisition and maintenance, and generalization of learned skills or behaviors.
1594947|NCT02272179|Behavioral|As Safe As Possible|The ASAP (As Safe As Possible) treatment is a brief, intensive intervention to be initiated during inpatient care and transitioning to outpatient care. The intervention focuses on 1) using motivational interviewing (MI) strategies throughout care; 2) developing a safety plan, including adapting the plan to an interactive safety plan phone app, My Safety Space (MSS); and 3) using treatment modules to target specific risk factors that are selected based on individual need.
1594948|NCT02272179|Behavioral|MySafety Space|MySafetSpace (MSS) is a HIPAA-compliant web-based application designed to provide the participants with guidance, social support, and convenient access to their safety plan via the patients' phone.
1594949|NCT02272179|Behavioral|Treatment as Usual|Participants will receive usual treatment for suicidal adolescents as they transition from inpatient hospitalization to outpatient therapy, which will include a paper safety plan.
1594950|NCT02272166|Drug|propofol|
1594951|NCT02272166|Drug|Sevoflurane|
1594952|NCT02272153|Other|Egg refined grain|
1594953|NCT02272153|Other|Egg Whole Grain|
1594954|NCT02272153|Other|Cereal Refined grain|
1594955|NCT02272127|Drug|icotinib|
1594956|NCT02272101|Dietary Supplement|Vitamin D versus placebo|Cross-over design
1594957|NCT02272088|Behavioral|physical activity-moderate|cross -over of moderate and intense physical activity
1594958|NCT02272088|Behavioral|Intense physical activity|cross -over of moderate and intense physical activity
1594959|NCT02272075|Device|Mobile OCT M3 scope|
1595040|NCT02271503|Drug|IPX203 270 mg|IPX203 containing 67.5 mg carbidopa and 270 mg levodopa
2009334|NCT03289143|Drug|RO7105705|Participants will receive RO7105705 intravenously (IV).
1594960|NCT02272062|Other|Decision-making tool for coronary artery disease treatment|A brief internet-based tool will provide education about coronary artery disease and assess patient preferences regarding treatment options (medical management, percutaneous coronary intervention, or coronary artery bypass graft). This information will be provided to the treating interventional cardiologist at the time of coronary angiography in the treatment group.
1594961|NCT02272049|Drug|Hyperpolarized 129 Xenon|During the scans, subject will inhale hyperpolarized Xenon gas for up to 16 seconds per scan, for up to 4 separate MR scans
1594962|NCT02272036|Procedure|Colonoscopy|Colonoscopy is performed in both study arm as standard examination
1594963|NCT02272036|Device|mobile phone|SMS received by mobile phone
1594964|NCT02272023|Behavioral|Intensive Motivational Interviewing|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
1594965|NCT02272023|Behavioral|Single session of Motivational Interviewing|
1594966|NCT02272010|Other|Experimental Diet|Altered n-6 (linoleic acid) and n-3 (eicosapentaenic acid (EPA) + docosahexaenoic acid (DHA)) diet.
1594967|NCT02272010|Other|Comparator Diet|Diet standardized to the usual American distribution of n-6 (7%) and n-3 EPA+DHA (150 mg per day).
1594968|NCT02271997|Drug|Ferrous fumarate|treatment with ferrous fumarate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
1594969|NCT02271997|Drug|Ferrous gluconate|treatment with ferrous gluconate during 1 year and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
1594970|NCT02271997|Drug|Iron(III)carboxymaltose|treatment with Iron(III)carboxymaltose and 6,12,26 and 52 weeks after starting treatment iron spectrum will be measured
2009335|NCT03289143|Drug|Placebo|Matching placebo doses of RO7105705 given intravenously (IV).
2009336|NCT03289143|Drug|[18F]GTP1|[18F]GTP1 will be administered as a solution for intravenous (IV) use, as part of positron emission tomography (PET) imaging.
2009337|NCT03288077|Other|Tryptophan|Beverage including tryptophan
2009338|NCT03287271|Drug|VS-6063|"Phase 1:
First 3 patient cohort: VS-6063 200 mg PO twice daily
IF TOLERATED, Second 3 patient cohort: VS-6063 400 mg PO twice daily,
Phase 2:
VS-6063 400 mg PO twice daily of a 28 day cycle until disease progression or unacceptable toxicity."
2009339|NCT03287271|Drug|Paclitaxel|"Phase 1:
First 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.
IF TOLERATED, Second 3 patient cohort: paclitaxel 80 mg/m2 infused IV continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle.
Phase 2:
Paclitaxel 80 mg/m2 infused continuously over 1 hour on days 1, 8, and 15 of a 28 day cycle until disease progression or unacceptable toxicity."
1594977|NCT02271971|Dietary Supplement|Vitamin D3|A daily 5.000 IU vitamin D3 capsule during 6 weeks.
1594978|NCT02271971|Dietary Supplement|Placebo|A daily placebo capsule during 6 weeks.
1594979|NCT02271958|Drug|Mifepristone|
1594980|NCT02271958|Drug|PLACEBO|
1594981|NCT02271945|Drug|MEDI-551 and MEDI0680 (AMP-514)|"3 to 6 subjects with relapsed or refractory aggressive B-cell lymphomas will be enrolled per cohort in the dose-escalation portion, starting with a MEDI0680 (AMP-514) medium dose every 2 weeks for 12 months of therapy (thirteen 28-day cycles). If a patient experiences PD after completing first year therapy, combination treatment may be resumed for up to 12 additional months.
Provided the MTD is not exceeded at the starting dose level, MEDI0680 (AMP-514) dosing will also be explored at a higher dose level. Subjects will receive MEDI0680 (AMP-514) on Days 2 and 15 of Cycle 1 and Days 1 and 15 of each subsequent 28-day cycle. Subjects will receive medium dose of MEDI-551 on Days 1 and 8 of Cycle 1 and on Day 1 of all subsequent 28-day cycles. Once an MTD is identified is reached, 20 additional subjects with DLBCL will be enrolled and treated at the selected dose of MEDI-551 in combination with MEDI0680 (AMP-514)"
1594982|NCT02271932|Other|Non-operative|Patients will receive only antibiotics and will not undergo appendectomy unless they do not improve or their appendicitis recurs
1594983|NCT02271919|Drug|Varenicline|"Phase I (VAR) Group Weeks 1 - 6: Varenicline dosing follows recommended dosing schedule (i.e., 0.5 mg/day Varenicline for days 1-3; 0.5 mg twice a day for days 4-7; and 1 mg twice a day thereafter).
Phase II Weeks 7 - 12 Group 3: If participant previously on Varenicline, will continue same dosage and schedule. Group 4: If participant previously on Placebo, will now start Varenicline. Group 5: If participant previously taking Varenicline in Phase I, will now continue same regimen, but take 1 extra dose in the evening."
1594984|NCT02271919|Other|Placebo Patch|"Phase I (VAR) Group Weeks 1 - 6: Placebo patch placed daily.
Phase II - Assigned Groups: Placebo patch per physicians instruction."
1594985|NCT02271919|Drug|Nicotine Patch|"Phase I - (NPL) Group: Nicotine 21 mg patch applied to upper arm starting on Day 12.
Phase 2 Assigned Groups: Nicotine patch applied per physician's instruction."
1594986|NCT02271919|Other|Placebo Lozenges|"Phase I (VAR) Group: Placebo lozenge used as needed.
Phase II Assigned Groups: Placebo lozenge used as needed."
1594987|NCT02271919|Drug|Nicotine Lozenge|"Phase I (NPL) Group: Nicotine 2 mg lozenge used as needed.
Phase II Assigned Group: Nicotine 2 mg lozenge used as needed."
1594988|NCT02271919|Behavioral|Questionnaires|Questionnaire completion at baseline, and on Days 8, 17, 24, 38, 52, 59, 73, and 94. Questionnaires also completed at follow up visit 9 and 10.
1594989|NCT02271919|Behavioral|Counseling|Counseling about quitting smoking conducted on Days 8, 17, 24, 38, 52, 59, 73, and 94. Some sessions may be audio/video recorded.
1594990|NCT02271919|Behavioral|Phone Calls|"Study staff conducts visits over the phone for Visits 2, 3, 4, 6, and 7 (on Days 17, 24, 38, 69, and 73). Each call should take about 25-45 minutes.
Study staff calls participant 1 day before quit date and 3 days after quit date to check on participant's progress in quitting smoking. Each call should take about 10-15 minutes."
1594991|NCT02271906|Drug|BIBW 2992|40 mg by mouth daily for a minimum of 14 days, and until the day of surgery.
1594992|NCT02271893|Drug|Dextromethorphan|The aim of this study is to assess if dextromethorphan administered during 4 weeks induces a decrease of pain intensity in breast cancer patients suffering from chemotherapy-induced peripheral neuropathy compared to placebo group.
1594995|NCT02271867|Procedure|Interscalene block|An ultrasound guided ISB was performed with injection aimed to block the C5-root
1594996|NCT02271854|Drug|Diclofenac sodium gel 1%|Diclofenac sodium gel 1% four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
1594997|NCT02271854|Drug|Placebo|Placebo gel four times daily (This study is a within-subject design i.e. active drug applied to one leg and placebo to the other leg at the same time. Therefore the study design is not a cross-over).
1594998|NCT02271841|Device|PVI|Pleth Variability Index
1594999|NCT02271828|Procedure|Sentinel lymph node procedure|Sentinel lymph node procedure according to the Dutch breast cancer guideline
1595000|NCT02271815|Other|Oral Hygiene|Oral Hygiene
1595001|NCT02271802|Dietary Supplement|Sodium butyrate|Patients recieved an enema containing butyrate or a placebo during upper abdominal surgery.
1595002|NCT02271802|Dietary Supplement|NaCl|
1595003|NCT02271789|Other|problematic tooth|problematic tooth
1595004|NCT02271776|Dietary Supplement|Galactooligosaccharide|The dietary fiber GOS will be supplemented in powder form to regular daily food intake three times per day for 12 weeks
1595005|NCT02271776|Dietary Supplement|maltodextrin|
1595006|NCT02271763|Other|ultrasound|subjects' neck will be scanned using ultrasound
1595007|NCT02271750|Procedure|lumbar puncture|for spinal fluid
1595008|NCT02271737|Behavioral|Training HC/VHSG, Health Education, and Supportive Supervision|1. Improve infection control Practice at health centers; 2) improve knowledge on newborn danger signs among HC staff, VHSG, and the mothers; 3) improve care coordination between community and health facilities, e.g. improve referral of sick newborns
1595009|NCT02271724|Procedure|Lumbar puncture|Lumbar puncture for spinal fluid
1595010|NCT02271724|Procedure|Blood sample|Blood sample
1595011|NCT02271711|Biological|Natural Killer (NK) Cells|Starting dose level of NK-cell number per infusion is 10^6/m^2. Infusions given through ommaya reservoir catheter. Participants receive the NK cells 3 times a week (at least 1 day apart) for the first 3 weeks in each 4-week cycle.
1595012|NCT02271698|Drug|Dexamethasone|Intravenous dexamethasone at incision and 24h after incision will be compared in 3 doses and placebo administered in a fourth group
1595013|NCT02271698|Other|Placebo|Placebo injection of saline at surgical incision and a repeat placebo saline injection 24h after incision.
1595014|NCT02271685|Other|Instructions about Overestimates|Participants are told that overestimating the duration of sounds are associated with low disease risk.
1595015|NCT02271685|Other|Instructions about Parkinson's|Participants are told that the task is about risk of Parkinson's disease.
1595016|NCT02271685|Other|Instructions about Underestimates|Participants are told that underestimating the duration of sounds are associated with low disease risk.
1595017|NCT02271685|Other|Instructions about Alzheimers|Participants are told that the task is about risk of Alzheimers disease.
1595018|NCT02271672|Device|XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
1595019|NCT02271672|Device|sham XP1000 RF|Treatment of adipose tissue within the fat layer with XP1000 RF.
1595020|NCT02271659|Radiation|Brachytherapy boost with external beam radiotherapy|Bras A: External beam radiotherapy of 46 Gy delivered with a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with a brachytherapy boost (of iodine-125 seeds from Bard (110Gy) or high dose rate (14Gy) with a iridium-192 source) only to the prostate. Each center will choose the appropriate brachytherapy technique. The number of seeds or needles will depend on the prostate's volume.
1595021|NCT02271659|Radiation|Exclusive external beam radiotherapy|Bras B: External beam radiotherapy of 46 Gy delivered with photons and a linear accelerator (Varian) to the prostate and the first centimeter of the seminal vesicles with an external beam radiotherapy of 80 Gy to the prostate alone.
1595022|NCT02271646|Drug|0.5% marcaine 20ml|3 levels ultrasound guided thoracic paravertebral block at T5-6, T7-8 and T9-10 (total 0.5% marcaine 20ml)
1595023|NCT02271633|Dietary Supplement|Sodium nitrate|
1595024|NCT02271633|Dietary Supplement|Beetroot juice|
1595025|NCT02271633|Dietary Supplement|Spinach|
1595026|NCT02271633|Dietary Supplement|Rocket salad|
1595027|NCT02271620|Procedure|nasal allergen provocation test|nasal allergen provocation test
1595028|NCT02271607|Device|moxibustion|The treatment schedule is three times per week for four weeks. Indirect moxa pillars and indirect-container moxibustion will be used.
2009340|NCT03287271|Drug|Carboplatin|"Phase 1:
First 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.
IF TOLERATED, Second 3 patient cohort: carboplatin (AUC of 5 mg/mL/min) IV infused continuously over 1 hour on day 1 of a 28 day cycle.
Phase 2: carboplatin (AUC of 5 mg/mL/min) infused continuously over 1 hour on day 1 of a 28 day cycle until disease progression or unacceptable toxicity."
1595030|NCT02271568|Procedure|Bariatric surgery|Laparoscopic or Robot R-Y gastric bypass
1595031|NCT02271568|Other|Intensive medical therapy|intensive medical therapy according to published guidelines by ADA and EASD
1595032|NCT02271555|Drug|Sevoflurane|Anesthetic induction will be achieved via 8% sevoflurane
1595033|NCT02271555|Drug|Remifentanil|After the loss of consciousness remifentanil will be administered to Group sevoflurane-remifentanil in the form of a 1 µg/kg intravenous bolus.
1595034|NCT02271555|Drug|Saline|After the loss of consciousness saline will be administered to Group sevoflurane-saline intravenous bolus.
2009341|NCT03286426|Diagnostic Test|Vision/Eye screening|The back of each eye will be imaged with Pictor. Visual acuity and color vision will be checked if patient able to cooperate with exam.
1595036|NCT02271529|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
1595037|NCT02271516|Radiation|188Re-BMEDA-liposome|EKG at baseline and in 24hours after administration
1595038|NCT02271503|Drug|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
1595039|NCT02271503|Drug|IPX203 180 mg|IPX203 containing 45 mg carbidopa and180 mg levodopa
2009342|NCT03286400|Device|CTAG Device with ACTIVE CONTROL|Intent to treat with the CTAG Device with ACTIVE CONTROL in the treatment of aortic diseases as part of routine clinical practice.
2009343|NCT03285438|Drug|Reduced dose of DOAC|The patient will receive apixaban 2.5 mg twice daily or rivaroxaban 10 mg once daily during a mean follow-up period of 24 months (12 to 48 months)
1595041|NCT02271503|Drug|Rytary 195 mg|Rytary 48.75Mg-195Mg Extended-Release Capsule
1595042|NCT02271503|Drug|Rytary 145 mg|Rytary 36.25Mg-145Mg Extended-Release Capsule
1595043|NCT02271490|Other|Acrosome Reaction induction|
1595044|NCT02271490|Other|capacitation in incubation medium prior to ICSI|
1595045|NCT02271477|Device|Ultrasound-guided volemic repletion|After echocardiography analysis of Inferior Vena Cava, patient is repleted with a pre-established bolus of fluid (500 ml of crystalloid). After this repletion, patient is analyzed till the exam reach signal of non-responsiveness, previously defined as a reduction of Inferior Vena Cava diameter less than 36% from baseline level during normal breath
1595046|NCT02271464|Drug|Maintenance:BEVACIZUMAB|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:
BEVACIZUMAB 5 mg/kg over 30 minutes, day 1
IRINOTECAN 165 mg/sqm IV over 1-h, day 1
OXALIPLATIN 85 mg/sqm IV over 2-h, day 1
L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1
5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1
with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):
- BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks)"
1595047|NCT02271464|Drug|Maintenance:BEVACIZUMAB+CAPECITABINE+CYCLOPHOSPHAMIDE|"Patients will be randomly assigned to receive induction chemotherapy with the G.O.N.O. FOLFOXIRI regimen plus bevacizumab:
BEVACIZUMAB 5 mg/kg over 30 minutes, day 1
IRINOTECAN 165 mg/sqm IV over 1-h, day 1
OXALIPLATIN 85 mg/sqm IV over 2-h, day 1
L-LEUCOVORIN 200 mg/sqm IV over 2-h, day 1
5-FLUOROURACIL 3200 mg/sqm IV 48-h continuous infusion, starting on day 1
with cycles repeated every 2 weeks for 4 months (8 cycles), followed after 2 weeks by (if no progression occurs):
BEVACIZUMAB 7.5 mg/kg over 30 minutes, day 1 (every three weeks),
CAPECITABINE 500 mg/tid orally, continuously,
CYCLOPHOSPHAMIDE 50 mg/day orally, continuously."
1595049|NCT02271438|Drug|Ibrutinib|Participants will receive a single oral dose of 12 capsules (12*140 mg capsules) of ibrutinib in Treatment A and 6 capsules (4 6*140 mg capsules) of ibrutinib in Treatment B.
1595050|NCT02271438|Drug|Moxifloxacin|Participants will receive a single oral dose of 1 moxifloxacin capsule (400 mg) in Treatment D.
1595051|NCT02271438|Drug|Ibrutinib-matching placebo|Participants will receive a single oral dose of 12 ibrutinib-matching placebo capsules in Treatment B and 6 ibrutinib-matching placebo capsules in Treatment C and D.
1595052|NCT02271438|Drug|Moxifloxacin-matching placebo|Participants will receive a single oral dose of 1 moxifloxacin-matching placebo capsule in Treatment A, B, and C.
1595053|NCT02271425|Drug|Evacetrapib Tablet|Oral administration
1595054|NCT02271425|Drug|Evacetrapib Intravenous|Intravenous administration
1595055|NCT02271412|Drug|LY03005|LY03005 is a new investigational pro-drug of desvenlafaxine formulated as extended-release oral tablets for the treatment of major depressive disorder.
1595056|NCT02271412|Drug|Placebo|Placebo
1595057|NCT02271399|Drug|acetylsalicylic acid|300 mg aspirin(acetylsalicylic acid, AA, Bayer)/day was given orally for 10 days postoperatively.
1595058|NCT02271399|Drug|rivaroxaban|xarelto 10mg(rivaroxaban, AA, Bayer)/day was given orally for 10 days postoperatively
1595060|NCT02271373|Behavioral|increasing time spent outdoors|The intervention group undertook interventions by increasing time spent outdoors. The interventions composed of performing two additional recess program lasting 30 minutes outside the classroom that encouraged children to go outside for outdoor activities during recess in both the morning and afternoon during school days within a intervention period of 1 school year.
1595061|NCT02271360|Drug|Calcium Dobesilate|1 cap / 8 hs Calcium Dobesilate ( 500mg) will be given at day of HCG injection and for 21 days
1595062|NCT02271360|Drug|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
1595063|NCT02271347|Drug|CMX001|CMX001 administered as initial dose of 200mg then 100mg BIW for a total of 5 doses.
1595064|NCT02271334|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
1595065|NCT02271334|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
1595066|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
1595067|NCT02271334|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
1595068|NCT02271321|Other|White noise|White noise is a simple, convenient, non-invasive and effective intervention. it sounds like the sound of running water, ocean or fan operation sounds. In this study, Subjects will receive 20 minute white noise of the ocean and the sound of running water at 16:00 to 17:00 for four weeks periods.
1595069|NCT02271308|Behavioral|Low-resistance elastic band training|The residents in experimental group will receive a low-resistance elastic band training (30 minutes), including warm-up and cold-down period, three times per week for 12 weeks.
1595070|NCT02271295|Drug|Enoxaparine|Enoxaparine 4000UI/day during 24 months
1595071|NCT02271282|Drug|Toremifene|
1595072|NCT02271282|Drug|Placebo|
1595073|NCT02271282|Drug|GHRH/Ghrelin combined Injection|
1595074|NCT02271269|Behavioral|Value Pricing Subsidies|"Usual care for glaucoma
Subsidies granted to adherent patients for their glaucoma medications and physician visits, lowering the costs of treatment and providing a financial incentive for patients to take their medicines as prescribed.
Subsidy (25 / 50%) granted based on meeting dose-rate adherence percentage targets (75 / 90%) at the month 3 and 6 assessment points."
1595075|NCT02271256|Device|Functional Intimate Apparel|The design of functional intimate apparel will incorporate different mechanisms, such as a) compression and pulling forces through a close fit of the intimate apparel, b) lumbar flexion by using a supporting belt, c) transverse forces applied by inserting pads inside the pocket lining by using the principle of the 3-point pressure system, d) axial rotation or coupled motion by using a system with uneven straps, and e) an active mechanism that aims to shift the trunk away from areas of pressure.
1595076|NCT02271230|Drug|Vitamin D and fish oil|2000 IU vitamin D and 1g/d fish oil
1595077|NCT02271230|Dietary Supplement|Fish oil (EPA/DHA) alone|1 g/d fish oil
1595078|NCT02271230|Drug|Vitamin D alone|2000 IU vitamin D
1595079|NCT02271230|Other|Placebo|Vitamin D placebo and fish oil placebo
2009344|NCT03285438|Drug|Full dose of DOAC|The patient will receive apixaban 5 mg twice daily or Rivaroxaban 20 mg once daily during a mean follow-up period of 24 months (12 to 48 months)
2009345|NCT03284255|Device|study group|study group in which patient will accept the treatment of Bioresorbable Coronary Stent
2009346|NCT03284255|Device|control group|control group in which patient will accept the treatment of Drug Eluting Stent of Abbott's XIENCE PRIME™ or XIENCE V®
1595083|NCT02271204|Drug|Ibandronic acid|As prescribed by physician
1595084|NCT02271191|Drug|Nicardipine|nicardipine 1-5 ug/kg/min and remifentanil 0.05 ug/kg/min during deliberate hypotension in spine surgery
1595085|NCT02271178|Other|Combined capsule|Combined capsule containing ramipril (5 to 10 mg), atenolol (50 to 100 mg), 100 mg aspirin, 40 mg simvastatin. In follow-up visits doses of atenolol and ramipril capsules may be adjusted according to blood pressure and heart rate.
1595086|NCT02271178|Other|Conventional therapy|Usual therapy
1595087|NCT02271165|Drug|Immunoglobulin (Hizentra)|
1595088|NCT02271152|Procedure|FAST mapping and ablation|
1595089|NCT02271152|Procedure|PVI|
1595090|NCT02271139|Drug|Alectinib|Alectinib 600 mg administered orally with food.
1595091|NCT02271126|Device|TEG monitoring|anticoagulation monitoring during ECMO will be according to TEG
1595092|NCT02271126|Device|APTT monitoring|anticoagulation monitoring during ECMO will be according to aPTT
1595093|NCT02271126|Drug|Heparin|Anticoagulation provided to patients in ECMO
1595094|NCT02271113|Drug|GMI-1271|
1595095|NCT02271113|Drug|Placebo|
1595096|NCT02271113|Drug|Enoxaparin Sodium (Lovenox®)|
1595097|NCT02271100|Device|ultrasound guidance|use of ultrasound for entry position estimation
1595098|NCT02271100|Device|palpation guidance|use of palpation for position estimation
1595099|NCT02271074|Other|Point of care CD4 testing|Participants in this arm will receive POC CD4 testing using the PIMA™ CD4 test system. Results will be made available to the participant within 20 to 25 minutes, before the participant leaves the HCT room. Participants will be given a copy of their results, which will be affixed to their referral letter, and they will be educated on the meaning of the CD4 results in relation to their health. This session will only be performed once at the time of issuing POC CD4 results.
1595100|NCT02271074|Behavioral|Care Facilitation|The goal of this intervention is to provide on-going counselling using a combination of motivational and strengths-based counselling approaches.This is a time limited intervention with a maximum of 5 client sessions over a 90-day period. Participants will also be transitioned out of the intervention upon successful entry into HIV care. Sessions will be done using both face-to-face and telephonic approaches, although the former is more preferred.
1595101|NCT02271074|Other|Transport support|The goal of this intervention is to address one of the most frequently noted structural barrier to entry-into-care in resource constrained settings: prohibitive distance or transport cost to reach a health facility.This is a time limited intervention with a maximum of 3 transport assists for healthcare visits over a 90-day period. Transport assistance is provided in the form of reimbursements to claims submitted by the participant after a self-reported HIV care clinic visits. Participants in this arm, receive their transport support through in-person collection or via cell phone transfer. Transport support amounts are standardised according to geographical area.
2009347|NCT03283982|Device|Robotic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the da Vinci robotic platform
2009348|NCT03283982|Device|Laparoscopic Ventral Hernia Repair with IPOM|Minimally invasive ventral hernia repair with intraperitoneal mesh placement, using the laparoscopic platform
1595104|NCT02271048|Device|Remote ultrasonography interpretation using the smartphone|The reviewers interpreted the ultrasonography images on the smartphone transmitted from the ultrasound machine in real time
1595105|NCT02271035|Drug|Deflux|Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
1595106|NCT02271035|Drug|Vantris|vantris will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
1595108|NCT02271009|Drug|AllerT|Ultrafast immunotherapy
1595109|NCT02271009|Drug|Placebo|placebo control
1595110|NCT02270996|Other|Antimicrobial Stewardship Program|Twice weekly meeting with Infectious Disease and Pediatric Surgery team members to audit antibiotics prescribed and suggest role for discontinuation.
1595111|NCT02270983|Drug|Linaclotide 145 micrograms|
1595112|NCT02270983|Drug|Linaclotide 290 micrograms|
1595113|NCT02270983|Drug|Placebo|Matching placebo
1595114|NCT02270970|Biological|belimumab|belimumab will be given at 10 mg/kg intravenously at Week 1, Week 2, Week 4 and monthly after that as was done in Phase III trials and approved in the FDA label
1595115|NCT02270957|Biological|Abatacept|
1595116|NCT02270957|Other|Placebo|
1595117|NCT02270944|Biological|GBS Vaccine|Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
1595118|NCT02270944|Biological|GBS Vaccine|Lyophilized formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus
1595119|NCT02270931|Device|CA 15-3 Assay|Physicians use the CA 15-3 test result to manage their patients
1595120|NCT02270918|Drug|Kcentra|IV infusion
1595121|NCT02270918|Drug|Apixaban|
1595122|NCT02270918|Drug|Placebo|
2009349|NCT03284684|Other|Blood test|plasma concentration of circulating DNA of specific genes
2009350|NCT03284723|Drug|PF-06804103|Dose Escalation Phase - Part 1
2009351|NCT03284723|Drug|PF-06804103|Dose Expansion Phase - Part 2
1595124|NCT02270892|Device|Ulthera treatment|Focused ultrasound energy delivered below the surface of the skin
1595125|NCT02270879|Procedure|Phacoemulsification cataract surgery|Phacoemulsification of cataract (opacified lens) using clear corneal approach. Implantation of a intra-ocular lens in the capsular bag
1595126|NCT02270866|Device|TNM(trademark) - thermoneuromodulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
1595127|NCT02270853|Device|sleep apnea screening with ApneaLinkTM|ApneaLink is sleep-screening tool that objectively identifies patients with sleep apnea
1595128|NCT02270840|Device|CRT-D|Biventricular upgrade. Subjects meeting the inclusion criteria (and if exclusion criteria are not present) patients will be randomized to CRT-D upgrade or ICD only (either continued ICD therapy in patients currently implanted with a defibrillator or implantation of a defibrillator in eligible patients who are currently implanted with pacemaker-only).
1595129|NCT02270827|Drug|Aminophylline|intravenous medication
1595130|NCT02270827|Drug|Hydrocortisone|Intravenous medication
1595131|NCT02270814|Drug|nab-paclitaxel|
1595132|NCT02270814|Drug|Cisplatin|
1595133|NCT02270814|Drug|Carboplatin|
1595134|NCT02270814|Biological|Cetuximab|
1595135|NCT02270801|Drug|rhTPO|rhTPO will be given intravenously at a dose of 300U/kg every day. Dose will be tapered to 300U/kg every other day when platelet count rise over 50×10^9/L. Maintenance will be continued after delivery and the dose will be further reduced to 300U/kg per week.
1595136|NCT02270788|Drug|Crenolanib|"Day 1 of Course 1: once followed by pharmacokinetic analysis. Days 2-28 of cycle 1: 3 times per day Crenolanib dose will not be adjusted unless the participant experiences side effects.
All subsequent courses: 3 times per day on Days 1-28. At least 50% of participants in each dose level must be ≤ 18 years old."
1595137|NCT02270788|Drug|Sorafenib|"Days 8-28 of course 1: given orally once each day.
All subsequent courses: given orally on days 1-28 once per day
This is a dose-finding study for the use of sorafenib in combination with crenolanib. Different doses will be given to several participants, with the first participants receiving a lower dose than typically used in children as a single agent. If the drug does not cause serious side effects, it will be given to other study participants at a higher dose. If side effects occur, the dose will be lowered."
1595138|NCT02270788|Drug|methotrexate, hydrocortisone and cytarabine with leucovorin|Triple IT therapy includes methotrexate, hydrocortisone and cytarabine with leucovorin rescue given on day 8. All participants will receive one IT chemotherapy on Day 8 of the first cycle. If they do not have leukemia cells in their spinal fluid, they will receive only one IT chemotherapy per cycle. If leukemia cells are present in their spinal fluid, they will receive IT chemotherapy weekly during the course. Triple IT therapy will be repeated on Day 1 of Cycle 2 and with each subsequent cycle in all participants.
1595139|NCT02270762|Other|Rest in bed|
1595140|NCT02270762|Other|Passive verticalization|
1595141|NCT02270762|Other|Rest in bed|
1595142|NCT02270749|Drug|Hydroxocobalamin|patients are treated for 6 months with hydroxocobalamin. Patients will be treated with once a dose of 2000ug, after that treatment will be continued with a dose of 1000ug per 2 months. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
1595143|NCT02270749|Drug|FitForMe vitamin B12|patients are treated for 6 months with a daily dose of 1000ug vitamin B12 tablets. At timepoint 0, 2, 4 and 6 months after treatment vitamin B12 will be measured. At timepoint 0 and 6 also homocystein and methylmalonic acid will be measured.
2009352|NCT03283878|Drug|Cefazolin|"Cefazolin will be administered intravenously within 30-60 minutes prior to skin incision in elective TKA for Group 1.
Cefazolin will be administered intravenously 30-60 minutes prior to skin incision in elective TKA and will be administered two (every 8 hours) weight based doses for 24 hours postoperatively for Group 2."
2009353|NCT03282552|Device|Nasal Cannula High Flow Oxygen|Nasal Cannula High Flow Oxygenation will be implemented at these study groups . (1st study group, and 2nd study group)
1595146|NCT02270723|Drug|"5% Human Albumin  Behring"|Intravenous infusion of 5% Human Albumin during major surgery
1595147|NCT02270723|Drug|Lactated Ringer|Intravenous infusion of Lactated Ringer during major surgery
1595148|NCT02270697|Device|Array|Applications of oligonucleotide array in diagnosis.
1595149|NCT02270684|Device|StepRite|The StepRite device uses an insole to monitor motion, and relays this information to the physical therapist via a smart phone app and web link. Set exercises can be programmed into the app for the participant to complete
1595152|NCT02270658|Device|CPAP|
1595153|NCT02270645|Device|595/1064 multiplex laser|595/1064 multiplex laser will be used 3 times spaced by a four week interval (+/- 3 days), it will be administered in an outpatient clinic setting.
1595154|NCT02270632|Drug|F8IL10|F8IL10 will be administered once a week for 8 weeks (or until withdrawn from the study).
1595155|NCT02270632|Drug|MTX|All patients enrolled in the study will receive as concomitant therapy MTX at stable dose (10-25 mg/week), and the corresponding fixed dose of folic acid.
1595156|NCT02270632|Drug|Placebo|Placebo will be administered once a week for 8 weeks (or until withdrawn from the study).
1595157|NCT02270619|Biological|Endotoxin|Low dose endotoxin (0.8 ng/kg of body weight) as IV bolus
1595158|NCT02270619|Behavioral|Partial sleep deprivation|Partial night sleep deprivation by staying awake from 23:00 to 03:00
1595159|NCT02270619|Other|Placebo|0.9% saline as IV bolus
1595160|NCT02270619|Other|Uninterrupted sleep|Uninterrupted sleep from 23:00 to 07:00
1595161|NCT02270606|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1595162|NCT02270606|Drug|fluorouracil|Given IV
1595163|NCT02270606|Drug|oxaliplatin|Given IV
1595164|NCT02270606|Drug|leucovorin calcium|Given IV
1595165|NCT02270606|Procedure|therapeutic conventional surgery|Undergo total mesorectal excision
1595166|NCT02270580|Behavioral|PN+|"we will evaluate the efficacy of a culturally tailored PN program (PN+) on improving quality of life (QoL), screening practices and treatment follow-up compliance among breast HL survivors"
1595167|NCT02270580|Behavioral|PN usual|participants will receive information brochures on breast cancer survivorship and have a minimum of 1 contact with the patient navigator
1595168|NCT02270567|Device|NETest|Non-invasive blood test
1595169|NCT02270554|Device|Endo GIA Reinforced Reload with Tri-Staple technology|Device:Endo GIA Reinforced Reload with Tri-Staple technology
1595170|NCT02270541|Other|Telemedicine|In-ambulance telemedicine
1595171|NCT02270528|Behavioral|Exercise|10 seconds of sprinting on a bicycle ergometer against a resistance equivalent to 5.5% of a participant's body weight, followed by 20 seconds of rest, repeated 10 times. (~5 minutes)
1595172|NCT02270528|Behavioral|Cognitive Task|The Wisconsin Card Sorting Task (WCST) is a measure of Executive Function.
1595173|NCT02270515|Other|Patient-Centered Medical Home for Kidney Disease (PCMH-KD)|A PCMH-KD enhances the usual dialysis care team by adding a primary care doctor, pharmacist, nurse coordinator and community health worker to the care team.
2009354|NCT03281928|Dietary Supplement|Sodium and Potassium Citrate|Sodium and potassium citrate levels will be altered in diet and renal mineral handling will be measured as compared to placebo.
2009355|NCT03281928|Dietary Supplement|Placebo|Sodium without Potassium Citrate
2009356|NCT03281200|Drug|L - Antineoplastic and immunomodulating agents|L - Antineoplastic and immunomodulating agents
1595177|NCT02270489|Biological|AFFITOPE® PD01A + Adjuvant|s.c. injection
1595178|NCT02270489|Biological|AFFITOPE® PD03A + Adjuvant|s.c. injection
1595179|NCT02270489|Biological|Adjuvant without active component|s.c. injection
1595180|NCT02270463|Drug|SL-401|
1595181|NCT02270450|Procedure|therapeutic conventional surgery|Undergo abdominal surgery
1595182|NCT02270450|Procedure|gastrointestinal complications management/prevention|Undergo non-surgical management
1595183|NCT02270450|Other|quality-of-life assessment|Ancillary studies
1595184|NCT02270437|Drug|ropivacaine, fentanyl, adrenaline|The patients in the cocktail analgesia group received an injection of 200mg ropivacaine, 100ug fentanyl, and 0.25mg adrenaline into knee collateral ligaments, posterior aspect of the capsule, quadriceps tendon, patellar tendon, fat pad, periosteum, and synovium, along with PCIA morphine postoperatively.
1595185|NCT02270424|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2013 GOLD, Salmeterol / fluticasone was used to severe and very severe COPD patients for 52weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
1595186|NCT02270424|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
1595187|NCT02270424|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
1595188|NCT02270424|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
1595189|NCT02270424|Drug|Placebo Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmono-splenic qi will be given placebo Bufeijianpi granule, twice daily for 52 weeks for lower dosage.
1595190|NCT02270424|Drug|Placebo Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given placebo Bufeiyishen granule, twice daily for 52 weeks for lower dosage.
1595191|NCT02270424|Drug|Placebo Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given placebo Yiqizishen granule granule, twice daily for 52 weeks for lower dosage.
1595192|NCT02270398|Behavioral|Dual-task training group|Balance and gait exercises while simultaneously engaging in a secondary cognitive task.
1595193|NCT02270398|Behavioral|Single-task training group|Balance/gait exercises and cognitive exercises done separately.
1595194|NCT02270398|Behavioral|Flexibility and strength training group|Whole-body flexibility exercises, upper limb strengthening exercises.
1595195|NCT02270385|Behavioral|PU prevention programme|The PU prevention programme consists of two major components which are an intensive training course(a 2-hour lecture and two skill training sessions) and a PU prevention protocol.
1595196|NCT02270385|Behavioral|Usual PU prevention care|Usual PU prevention care that is a series of basic nursing care activities: repositioning of residents, moisturization , change of napkins to keep buttock dry.
1595197|NCT02270372|Biological|ONT-10, Varlilumab combination|"ONT-10 a liposomal synthetic glycopolypeptide MUC1 targeted antigen formulated with PET Lipid A adjuvant.
Varlilumab is a recombinant, fully human mAb of the IgG1κ isotype that specifically binds human CD27."
1595198|NCT02270359|Device|OCT|Optical coherence tomography (OCT): Intracoronary imaging for amount and type of plaque as well as plaque rupture, ulceration, dissection and/or thrombosis.
1595199|NCT02270359|Procedure|CMR|Cardiac magnetic resonance imaging (CMR): MRI of the heart to identify areas of infarction (damage) and/or edema (smelling)
1595200|NCT02270359|Drug|contrast agent, Gadolinium|Gadolinium contrast will be administered during CMR
1595201|NCT02270346|Device|Inspiratory muscle training|"Treatment group received inspiratory muscle training using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).
The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.
The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
1595236|NCT02270034|Drug|Crizotinib|Crizotinib is added to Stupp method
1595375|NCT02269150|Other|No fecal microbiota transplantation (FMT), routine management|
2009357|NCT03281200|Drug|L01 - Antineoplastic agents|L01 - Antineoplastic agents
2009358|NCT03281200|Drug|L01X - Other antineoplastic agents|L01X - Other antineoplastic agents
2009359|NCT03281200|Drug|L01XE - Protein kinase inhibitors|L01XE - Protein kinase inhibitors
2009360|NCT03281200|Drug|L01XE31 - Nintedanib|L01XE31 - Nintedanib
2009361|NCT03280797|Procedure|Blood sample|2ml blood taken into TruCulture tube
2009362|NCT03278665|Drug|4SC-202 in combination with Pembrolizumab|4SC-202 in combination with Pembrolizumab
2009363|NCT03280303|Other|non-interventional|
1595202|NCT02270346|Device|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training using threshold loading device (POWERbreathe Classic IMT Technologies Ltd. Birmingham, England) at fixed workload, 5% of MIP.
The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
1595203|NCT02270333|Device|Inspiratory muscle training|"Treatment group received inspiratory muscle training (IMT) using threshold loading device (POWERbreathe Classic, IMT Technologies Ltd. Birmingham, England) at 40% of maximal inspiratory pressure (MIP).
The MIP was measured at supervised session each week, and 40% of measured MIP value was the new training workload.
The treatment group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
1595204|NCT02270333|Device|Sham inspiratory muscle training|"Control group received sham inspiratory muscle training (IMT) at fixed workload, 5% of MIP using threshold loading device (POWERbreathe Classic device IMT Technologies Ltd. Birmingham, England).
The control group trained for 30 min-per/day, 7 days/week, for 6 weeks. Six sessions at home and 1 session were performed at department."
1595205|NCT02270320|Behavioral|Physical activity|The training is 24 forms Yang-style Tai Chi Chuan exercise, which will perform a 60-minute exercise program, three times per week for 12 weeks.
1595206|NCT02270307|Drug|Cyclophosphamide|Dose 50 mg/kg at day +3,+4 once daily
1595207|NCT02270307|Biological|Mesenchymal stromal cells|Dose 1 million per kg, at day of recovery once
1595208|NCT02270294|Other|Thai traditional massage|Thai traditional massage treatment based on original Thai traditional massage at Wat Po was use in this study. The participants will be assigned to receive one time of Thai traditional massage one time. Thai traditional massage techniques consists of petrissage, friction, and passive stretching on head, neck, shoulders, arms, back and legs for 60 minutes.
1595209|NCT02270294|Other|No massage|The participants will be asked to lie down in relaxant position on bed without sleep for 60 minutes.
1595210|NCT02270281|Drug|Dexmedetomidine|CIF 0.3 and 0.6 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
1595211|NCT02270268|Dietary Supplement|Pectin|Pectin （Andeli Ltd. Yantai, China）, 24g/d for six weeks
1595212|NCT02270268|Dietary Supplement|maltodextrin|
1595213|NCT02270255|Procedure|Superior hypogastric nerve block|21g Chiba needle advanced into the superior hypogastric plexus via an anterior infraumbilical approach using the arterial catheter as a fluoroscopic landmark to target the vertebral body below.
1595214|NCT02270255|Drug|0.75% Ropivacaine|20 ml of 0.75% Ropivacaine
1595215|NCT02270255|Procedure|Subcutaneous injection|Injection into subcutaneous tissues in periumbilical region
1595216|NCT02270255|Drug|1% Xylocaine|5ml of 1% Xylocaine
1595217|NCT02270242|Drug|Aspirin|
1595218|NCT02270242|Drug|Placebo|
1595219|NCT02270242|Drug|ticagrelor|
1595220|NCT02270216|Procedure|static hand grip exercise|The static exercise pressor response will be tested using isometric handgrip of the left hand. The forearm will be supported on an arm rest with elbow flexed. The maximum voluntary contraction force will be measured as the best of three attempts. After 2 minute rest, subjects will perform 2 minute of isometric hand grip contraction at 30% MVC. Circulatory occlusion(50 mmHg supra-systolic pressure) will start at 1.30 min and continued for 2 minute after the end of the isometric handgrip exercise. Following release of the cuff there will be a further 2 minutes recovery. The blood pressure and heart rate will be measured at the end of each minute during rest, isometric handgrip, circulatory occlusion and recovery. Subjects will be instructed to breathe normally during the test and avoid any Valsalva maneuver; breathing frequency will be monitored during the handgrip pressor test using capnography.
1595221|NCT02270216|Procedure|cycling exercise|"The dynamic exercise will be with the subject sitting on a cycle ergometer (Monark 828 E). Resting heart rate will be measured for 2 minutes before the start of exercise. The exercise level will be limited to 50% of the estimated maximum heart rate reserve. Maximum heart rate will be estimated as 207-0.7*age and heart rate reserve (HRR) as maximum minus resting heart rate. Subjects will pedal at 50 rpm for 1 min with no load and then 3 minutes against a load of 0.5 Kp (25W) increasing to a load of 1 Kp for the next 3 minutes and to 1.5 Kp, if necessary, for a further 3 minutes until the target heart rate of 50% HRR is reached.
Subjects will be asked about their level of perception of dyspnea using a visual analog scale every 3 minutes at the end of each load. At the end of the exercise, the subjects will sit for ten minutes."
1595223|NCT02270190|Device|Percutaneous Tibial Nerve Stimulation (PTNS)|
1595224|NCT02270177|Other|Telemedicine, videoconsultation|We are investigating the use of videoconsultations (through telemedicine technology) in patients with primary headaches.
1595225|NCT02270164|Dietary Supplement|Artichoke Leaf Extract|Capsule
1595226|NCT02270164|Other|Placebo|Capsule
1595227|NCT02270151|Device|MyDiagnostick|Diagnostick strategy with MyDiagnostick
1595228|NCT02270138|Behavioral|Movement-to-music video program|Three separate movement-to-music video programs will be utilized. Genres of the songs are Children's rock, latin and folk. Range of the tempo is 64-124 beats per minute. The use of movement-to-music video program will be instructed 10-30 minutes every other day.
1595229|NCT02270125|Procedure|Mucotomy|Surgical removal of hypertrophic mucosa of the inferior nasal turbinate by cold-steel instruments under endoscopic control, under general anaesthesia
1595230|NCT02270112|Device|ECG|Patients receive a 5 Minute ECG recording and have their pulse recorded by an iPhone.
1595231|NCT02270073|Behavioral|Cognitive behavior therapy of trainee therapists|In all three treatment arms, trainee therapists perform a cognitive behavior therapy (CBT) under conditions of the German health care system. This treatment is not a manualized intervention, but rather based on individualized treatment plans that have been developed together with expert supervisors during a five session diagnostic stage. Treatment duration is 25 sessions, while on average every fourth is supervized by an CBT expert therapist.
1595232|NCT02270060|Other|Music Therapy|Patient receives a single 20-minute music therapy session with a music therapist. Patient will interact with specially composed music tailored to the patient's preferences using an iPad.
1595233|NCT02270060|Other|Music Listening|Patient listens to his/her preferred music on an iPod touch for 20 minutes without the presence of a music therapist.
1595234|NCT02270047|Dietary Supplement|Orange nectar|Orange nectar
1595235|NCT02270047|Dietary Supplement|Orange Nectar with fibre|
1595237|NCT02270021|Device|Mobile Application (APP)|Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition.
1595238|NCT02270021|Device|Patient-Centered Approach (PCA) + APP|"Patient-Centered Approach (PCA): A patient educational tool (mobile tablet) will educate women on cervical cancer screening and treatment. Patients' self-assessment using a tablet at the time of clinic check-in will help them to understand current guidelines and their choices for treatment if they have abnormal cytology. It will allow them to assess the risks and benefits of screening intervals and of treatment choices.
APP: Mobile phone application to maneuver clinicians through the cervical cancer screening and treatment guidelines based on patient age and condition."
1595239|NCT02270008|Other|Pelvic floor training|Baseline muscle strength will be measured with the modified Oxford scale. The intervention group will undergo an in-person standardized pelvic strength training session by a trained nurse practitioner.
1595240|NCT02269995|Device|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
1595241|NCT02269982|Device|AR-v7 assays|
1595242|NCT02269969|Drug|Tobramycin|
1595243|NCT02269956|Behavioral|12 week feasibility study|: At baseline, weeks 6 and 12, dementia feeding skills knowledge and self-efficacy tests will be administered, meal observations of nursing staff assisting PWD with meals will be video recorded for three meals over two days, and a medical record review will be conducted to ascertain technical and adaptive interventions also in place for the PWD (e. g., high density protein supplements, appetite stimulant medications, weighing, diet texture modifications). After baseline data is collected, the training program will delivered in five weekly modules with group coaching sessions completed the same week
1595244|NCT02269943|Drug|CC-486|
1595245|NCT02269930|Drug|peginterferon beta-1a|Administered as subcutaneous injection
1595246|NCT02269930|Drug|Rebif|Administered as subcutaneous injection
2009364|NCT03279328|Drug|Topical Steroid Ointment|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
2009365|NCT03279328|Other|Vaseline|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
1595250|NCT02269904|Drug|Fluorouracil Implants|Fluorouracil Implants: 800mg, implanted in the abdominal cavity during operation.
1595251|NCT02269904|Drug|Xelox regimes|Xelox regimes: Capecitabine,1000 mg/m2，PO.BID, from D1 to D14; Oxaliplatin, 130 mg/m2，IV, D1 in each cycle. The cycle will repeated every 21 days till 6 cycles finished.
1595252|NCT02269891|Dietary Supplement|Nu Femme|Combination product of Labisia pumila and Eurycoma longifolia extracts
1595253|NCT02269891|Other|Placebo|
1595254|NCT02269852|Biological|trivalent seasonal influenza vaccine|"Infants: 0.25 ml/ dose;
Adults: 0.5 ml/ dose;
Seniors: 0.5 ml/ dose;"
1595255|NCT02269839|Device|rTMS|Active treatment will consist of sessions of continuous theta-burst rTMS on consecutive days for 5 days. This will be delivered with a circular coil to the temporal scalp region overlying the auditory cortex, contralateral to the symptomatic side in unilateral tinnitus and to the left side in bilateral tinnitus. The treatment protocol will consist of treatment at 80% of individual motor threshold (established at the first treatment session) for 600 pulses of 40 seconds duration, which will be repeated after 15 minutes. Each patient will receive 1200 pulses per day.
1595256|NCT02269826|Device|Vagisan® Moisturising Cream|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
1595257|NCT02269826|Device|Gynomunal® vaginal gel|Once in the evenings before going to bed, intravaginally with the help of the applicator included (approximately 2.5 g per application) and perivaginally one fingertip unit (approximately 0.5 g per application).
1595258|NCT02269813|Other|MammaPrint|
1595259|NCT02269813|Other|BluePrint|
1595260|NCT02269813|Other|TargetPrint|
1595261|NCT02269800|Drug|Benzalkonium chloride solution|Tid, 7 days
1595262|NCT02269800|Drug|Normal saline|Tid, 7 days
1595263|NCT02269787|Behavioral|Enhanced Telephone Monitoring|Detox inpatients in the ETM condition will be expected to complete one session while in detox and one 15-minute telephone call per week for 12 weeks (plus usual care).
1595264|NCT02269774|Procedure|Standard pulmonary vein isolation|The MM will be carried out during a elective standard pulmonary vein isolation procedure. The MM will be performed using an occluded mouthpiece with a small air leak to prevent complete closure of the glottis during inspiration and thus assure negative pressure throughout the entire airway. After expiration, inspiration with a target negative intrathoracic pressure of -40mmHg will be carried out against the mouthpiece.
1595265|NCT02269761|Device|Nuvis Diagnostic Ultrasound System|Ultrasound of the chest
1595266|NCT02269748|Procedure|Tunnel technique with subepithelial connective tissue|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival tunnel prepared over the donor site.
1595267|NCT02269748|Procedure|Coronally advanced flap|After harvesting a connective tissue graft from the palate, the graft is placed under a gingival flap which is repositioned coronally
1595268|NCT02269748|Drug|Analgesic Therapy|Ibuprofen 600 mg TID
1595269|NCT02269735|Drug|MK-2640|MK-2640 intravenous infusion administered to participant in a fasted state
1595270|NCT02269735|Biological|Regular Human Insulin (RHI)|RHI 100 units/mL intravenous infusion to maintain target glycemic level
1595271|NCT02269735|Drug|Dextrose|Dextrose 20% or 50% intravenous infusion for approximately 9 or 7 hours, as appropriate to attain a target glycemic level
1595272|NCT02269735|Biological|Insulin aspart|Insulin aspart subcutaneous injection or intravenous infusion the evening before each period in Parts II and III to achieve/maintain glycemic target.
1595273|NCT02269735|Drug|Rescue medication|Rescue medication may be administered for hypotension or mild to moderate infusion reaction. Rescue medication may include epinephrine, antihistamines, steroids, or acetaminophen/paracetamol.
1595274|NCT02269722|Device|Vascular compression device- RADAR TM-Short clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
1595275|NCT02269722|Device|Vascular compression device RADAR TM-Long clamp time|A clamp is placed on the radial artery following cardiac catheterization for 20 minutes
1595276|NCT02269709|Device|ARFI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI), a new ultrasound technology in which unique sound waves create the images/pictures of the liver beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
1595277|NCT02269696|Drug|Metoprolol|Intraoperative metoprolol infusion.
1595278|NCT02269696|Drug|Normal saline|Equal of volume compared to metoprolol.
1595279|NCT02269683|Procedure|Robot-assisted distal pancreatectomy|
1595280|NCT02269683|Procedure|Laparoscopic distal pancreatectomy|
1595281|NCT02269670|Drug|everolimus|Given PO
1595282|NCT02269670|Drug|anastrozole|Given PO
1595283|NCT02269670|Drug|letrozole|Given PO
1595284|NCT02269670|Drug|tamoxifen citrate|Given PO
1595285|NCT02269670|Drug|fulvestrant|Given IM or PO
1595286|NCT02269670|Drug|megestrol acetate|Given PO
1595287|NCT02269657|Device|EOS® imaging system|The EOS® imaging system is a low dose, 3-dimensional imaging system that provides weight bearing images which provide visual information with respect to the interaction between the joints and the rest of the musculoskeletal system, particularly the spine, hips and legs. The imaging system is used for clinical purposes with additional images captured as part of this study to collect data from subjects in two different arm positions during imaging.
1595288|NCT02269644|Drug|Dalbavancin|dalbavancin 1500 mg IV over 30 minutes on Day 1
1595289|NCT02269644|Drug|Linezolid|linezolid 600 mg every 12 hours for a minimum of 10 days and a maximum of 14 days
1595290|NCT02269644|Drug|Linezolid Placebo|Dalbavancin randomized subjects after Day 1, 1st dose will receive linezolid placebo every 12 hours for a minimum of 10 days and a maximum of 14 days
1595291|NCT02269644|Drug|Azithromycin|Dalbavancin and linezolid randomized subjects on Day 1, 1st dose receive 500 mg of IV azithromycin
1595292|NCT02269631|Behavioral|Legume diet group|about 1 1/2 cups of legumes included in lunch and dinner meals
1595293|NCT02269631|Behavioral|Control diet group|no legumes in lunch or dinner meals
1595294|NCT02269631|Device|Smartpill|to assess how long food takes to pass through the digestive system
1595295|NCT02269631|Other|legumes|about 1 1/2 cups of legumes included in lunch and dinner meals
1595296|NCT02269618|Other|Home-based telehealth program|"Home-based telehealth program
Scheduled calls initiated by nurse performed weekly; the nurse carried out a standardized interview on general clinical condition of the patients.
Unscheduled calls initiated by patients or caregivers through the service centre(24h/24h) to report any clinical problems. in case of signs or symptoms
Telemonitoring: during calls, patients can transmit via landline or mobile phone the recordings from the 1-lead ECG to a service centre, and talk to the nurse or doctor
Home visit performed by therapist seven days after hospital discharge by setting the daily physical activity and other home visits in case of need
Scheduled calls initiated by therapist performed weekly aimed at increasing workload and evaluating the proper execution of exercises."
1595297|NCT02269618|Other|Home-based rehabilitation|"Home-based rehabilitation Individual rehabilitative program including at least 3 sessions/week of mini-ergometer and exercises and 2 sessions/week of walking with pedometer
Mini-ergometer: The personalized protocol will be structured at the beginning on the basis of data obtained from the assessment of the baseline exercise test, trying to get a training activity to the maximum value of around a Borg dyspnoea and motor equal to 6 (according to the protocol of Maltais)
Walking: The patient will be encouraged to walk every day. Will be given a pedometer and will be asked to try to increase the amount of steps up to the maximal for the patient."
1595298|NCT02269618|Other|Usual care|Usual care All patients will be followed also in usual care manner by their GPs.
1595299|NCT02269605|Other|Placebo|Group 1: Placebo (sodium chloride 0.8 %) at single dose
1595300|NCT02269605|Drug|Bryostatin 1 (10ug/m2)|Group 2: Bryostatin 1 (10ug/m2) at single dose
1595301|NCT02269605|Drug|Bryostatin 1 (20ug/m2)|Group 3: Bryostatin 1 (20ug/m2) at single dose
1595302|NCT02269579|Drug|CPX-351|
1595303|NCT02269566|Drug|HollisterStier|0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node
1595304|NCT02269566|Drug|Normal saline|0.1 ml of normal saline 3 injections into an inguinal lymph node
1595305|NCT02269553|Device|TMJ(TM) NextGeneration|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts.
1595306|NCT02269553|Device|Standard Hard TMJD Splint|The occlusal splint to be used in this study will be a hard, full-arch splint with at least one occlusal contact on each tooth of the opposing arch.
1595307|NCT02269540|Drug|Sertraline|selective serotonin reuptake inhibitor
1595308|NCT02269540|Drug|Citalopram|selective serotonin reuptake inhibitor
1595309|NCT02269540|Drug|N-acetylcysteine (NAC)|natural health product
1595310|NCT02269540|Drug|Existing depression medication treatment|Continuation of depression medication treatment already taken prior to study enrollment except for drugs with affinity for MAO-A or potentially influencing MAO-A levels, including phenelzine, tranylcypromine, moclobemide, cytomel and lithium
1595311|NCT02269527|Other|Live music|Providing 1-hour live music 5 days/ week.
1595312|NCT02269514|Other|Own Brand Cigarette|combustible cigarette brand style smoked most frequently by subject
1595313|NCT02269514|Other|Electronic Cigarette #1|VUSE® Digital Vapor Cigarette (original flavor, 14mg nicotine)
1595314|NCT02269514|Other|Electronic Cigarette #2|VUSE® Digital Vapor Cigarette (original flavor, 29mg nicotine)
1595315|NCT02269514|Other|Electronic Cigarette #3|VUSE® Digital Vapor Cigarette (original flavor, 36mg nicotine)
1595316|NCT02269514|Other|Leading U.S. Nicotine Gum|4 mg nicotine polacrilex gum
1595317|NCT02269501|Other|Exercise treatment|
1595318|NCT02269488|Drug|MEDI3250|MEDI3250
1595319|NCT02269475|Drug|MEDI3250|MEDI3250
1595320|NCT02269475|Drug|Placebo|Placebo
1595321|NCT02269462|Drug|Efavirenz|600 mg once daily in combination with other drugs (e.g. tenofovir and emtricitabine)
1595322|NCT02269462|Drug|Nevirapine|200 mg twice daily in combination with other drugs (e.g. tenofovir and emtricitabine)
1595374|NCT02269150|Biological|fecal microbiota transplantation (FMT)|
1595323|NCT02269449|Device|6Fr Glidesheath Slender sheath|6Fr sheath (Glidesheath slender: GSS), which is characterized with the same inner lumen diameter with contemporary 6Fr sheath as well as the sheath outer diameter similar with contemporary 5Fr sheath.
1595324|NCT02269449|Device|5Fr sheath|5Fr Hydrophilic coating sheath from Terumo.
1595325|NCT02269449|Procedure|Hemostasis with TR band|Hemostasis is achieved using TR band (TERUMO) Patent hemostasis.
1595326|NCT02269449|Procedure|Any hemostasis procedure|Hemostasis is achieved by any hemostasis of each hospital's routine procedure.
1595327|NCT02269436|Drug|sNN0029 infusion solution|4 µg/day, continuous i.c.v administration
1595328|NCT02269423|Biological|BPSC-1001 Vaccine|Vesicular Stomatitis Virus (VSV)-based vaccine 1-mL injection containing 3x10^6, 2x10^7, or 1x10^8 pfu.
1595329|NCT02269423|Other|Placebo|Normal saline placebo.
1595330|NCT02269410|Dietary Supplement|GBP-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
1595331|NCT02269410|Dietary Supplement|GBP-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
1595332|NCT02269410|Dietary Supplement|VSG-SPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
1595333|NCT02269410|Dietary Supplement|VSG-HPS|Protein powder supplementation will be given to participants to add to regular foods during the dietary intervention phase until reach protein objectives based on randomization and during 12 weeks after Bariatric Surgery.
1595334|NCT02269384|Procedure|Experimental Noxious Stimulus|Localized manual pressure will be placed up predetermined points on the lower extremity until maximum pain tolerance levels are reached.
1595335|NCT02269384|Behavioral|Memory of Experimental Noxious Stimulus|Subjects will be asked to visualize previously experience experimental noxious stimulus
1595336|NCT02269384|Behavioral|Memory of Prior Significant Injury|Subjects will visual prior significant injury or a predetermined lower extremity region in control subjects.
1595337|NCT02269384|Procedure|Mental Challenge Test|Subjects will count backwards from 100 by specified amounts as rapidly as possible
2009366|NCT03279328|Drug|Skin Barrier Moisturier|Based on randomization, the subject will either apply Topical Steroid Ointment, Vaseline or skin barrier repair moisturizer to one side of the face for seven days.
1595340|NCT02269358|Drug|METHOTREXATE|Infliximab therapy after escalation. SC methotrexate at 15 mg/m2 , not to exceed 25 mg/m2 per week for 4 weeks. Patients in remission after 4 weeks reduce their dose by halve. patients not in remission will continue the full dose until 12 weeks.
1595341|NCT02269345|Other|Battlefield Acupuncture|Battlefield Acupuncture at points cingulate gyrus, thalamus, omega 2, shen-men, point zero
1595342|NCT02269345|Other|Standard Treatment|Standard Treatment alone.
1595343|NCT02269332|Other|Screening Colonoscopy|we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
1595344|NCT02269319|Drug|MRX-I|Oral MRX-I 800mg given twice a day for 10 days
1595345|NCT02269319|Drug|Linezolid|Oral linezolid 600mg given twice a day for 10 days
1595346|NCT02269306|Drug|clomiphen citrate|The study was carried out on 150 patients with PCOS. Initial clomiphen citrate (CC) doses were 50 mg daily for 5 days starting on cycle day 3. In the case of an absent response, doses were increased to 100 and 150 mg daily in subsequent cycles. First ovulation with CC was used as the end point.
1595347|NCT02269293|Drug|Paclitaxel|
1595348|NCT02269293|Drug|Carboplatin|
1595349|NCT02269293|Drug|Selinexor|
1595350|NCT02269280|Drug|Azacitidine (AZA) Days 1 - 3|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 3 days (days 1-3) approximately every 28 days.
1595351|NCT02269280|Drug|Decitabine (DAC)|Decitabine 20 mg/m2 by vein for 3 days (days 1-3) approximately every 28 days.
1595352|NCT02269280|Other|Best Supportive Care (BSC)|Participants receive standard of care as chosen by study doctor. Best supportive care for transfusion-independent participants only.
1595353|NCT02269280|Drug|Azacitidine (AZA) Days 1 - 5|Azacitidine 75 mg/m2 by vein or subcutaneously daily for 5 days (days 1-5) approximately every 28 days.
1595354|NCT02269267|Other|Stopping their TKI|Patients with CML patients who are on imatinib, dasatinib, nilotinib, or bosutinib and have had deep molecular response is defined as BCR-ABL < 0.01%, (> MR4 i.e. > 4 log reduction) by PCR for at least 2 years will stop their TKI. Concurrently, the study will assess a wide range of PROs before stopping TKIs and after discontinuation in conjunction with PCR testing, though at fewer time points, utilizing online and/or phone questionnaires.
1595355|NCT02269254|Device|Persona PS Knee Prosthesis by Zimmer|Total Knee Replacement with Persona PS Knee Prosthesis by Zimmer
1595356|NCT02269254|Device|NexGen PS Knee Prosthesis by Zimmer|Total Knee Replacement with NexGen PS Knee Prosthesis by Zimmer
1595357|NCT02269241|Drug|LF111 (drospirenone)|One LF111 tablet once per day for 24 days followed by 4 placebo tablets for 4 days equals one cycle.
1595358|NCT02269228|Drug|Asasantin ER|
1595359|NCT02269228|Drug|Placebo|
1595360|NCT02269215|Drug|BIII 890 CL|
1595361|NCT02269215|Drug|Placebo|
1595362|NCT02269202|Drug|Midazolam, tablet|
1595363|NCT02269202|Drug|Crobenetine, i.v. infusion|
1595364|NCT02269202|Drug|Placebo|
1595365|NCT02269189|Drug|BIIL 284 BS, high dose|
1595366|NCT02269189|Drug|BIIL 284 BS, low dose|
1595367|NCT02269189|Drug|Placebo|
1595368|NCT02269176|Drug|Low dose of telmisartan|
1595369|NCT02269176|Drug|High dose of telmisartan|
1595370|NCT02269176|Drug|Low dose of losartan|
1595371|NCT02269176|Drug|High dose of losartan|
1595372|NCT02269163|Biological|Immune Globulin (Human) Intravenous|ProMetic BioTherapeutics Immune Globulin Intravenous is a 10% liquid formulation of human IgG in 50 mL vials containing 100 mg/mL of IgG.
1595373|NCT02269163|Biological|Commercial Immune Globulin Intravenous|
1595376|NCT02269124|Device|Hearing aid|The subject will wear a hearing aid at all times for a 3-month period. At school, he/she will wear this hearing aid in addition to using conventional measures (FM system and preferential seating).
1595381|NCT02269098|Other|Diabetes medication management|As above plus- Follow-up intervention visits were at 24-72 hrs, 2 and 4 weeks. During each, further DSME was provided, BG logs reviewed, and diabetes medications adjusted as needed by the CDE. Meter and insulin injections skills were reinforced as needed. Outpatient navigation included securing a primary care appointment no later than 4 weeks after study completion. Final contact was via telephone at 90 days. The MMS© (Morisky Medication Adherence Survey) was taken at 2 and 4 weeks and during the final telephone visit. Interim return visits to the ED or admissions to the hospital were queried at each visit. A follow up HbA1C was obtained at week 4 using the POC A1CNow+ ®, and a venous HbA1C was drawn if the POC result was above 13% .
1595382|NCT02269085|Drug|Ibrutinib|"Phase I Starting Dose: 420 mg by mouth daily on Days 1 - 28 of a 28-day cycle.
Phase II Starting Dose: MTD from Phase I."
1595383|NCT02269085|Drug|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8 ,9, 15 and 16 in Cycles 1 - 12, and Days 1,2 and 15,16 of Cycle 13 and beyond.
Phase II Starting Dose: MTD from Phase I."
1595384|NCT02269085|Behavioral|Phone Calls|Study staff calls participant after end-of-dosing visit every 6 months for 5 years. These calls should take about 2-3 minutes.
2009367|NCT03280420|Procedure|Early catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 3 days.
After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
2009368|NCT03280420|Procedure|Late catheter removal|"Patients will receive selective alpha blocker ( tamsulosin 0.4mg ) once daily and the catheter will be removed after 7 days.
After catheter removal, patients will be allowed to void and will be discharged home who will have a successful void more than 200 cc of urine. Patients who will fail to void will be re-catheterized and will be prepared for prostatectomy."
1595390|NCT02269059|Drug|MK-7680|MK-7680 10 mg and 100 mg capsules
1595391|NCT02269046|Other|acupuncture and moxibustion|Warm needling acupuncture on Fenglong (ST40, bilateral), Zusanli (ST36, bilateral), Sanyinjiao (SP6, bilateral) and Cake-seperated moxibustion on Juque (RN14), Tianshu (ST25, bilateral), Pishu (BL20, bilateral), Xinshu (BL15, bilateral), Ganshu (BL18, bilateral), Shenshu (BL23, bilateral)
1595392|NCT02269046|Drug|Simvastatin|10mg/d,p.o,12 weeks.
1595393|NCT02269046|Other|Therapeutic Lifestyle Change|"Reduced intakes of saturated fats (<7% of total calories) and cholesterol (<200 mg per day)
Therapeutic options for enhancing LDL lowering
Weight reduction
Increased physical activity"
1595394|NCT02269033|Behavioral|Patient Navigated Latinas|Patient navigators provided culturally sensitive support and guidance to Latina women who presented radiologic abnormalities categorized as BI-RADS 3, 4 and 5. Patient Navigators also collected clinical information from the patients' medical charts.
1595395|NCT02269033|Behavioral|Non Navigated Latinas|A convenience sampling approach was used to recruit non navigated Latinas. Eligibility criteria targeted self-identified Latinas at community-based health clinics, aged > 18 years with an abnormal breast screening mammogram resulting in BI-RADS 3, 4 or 5. Controls were chosen by determining eligibility consecutively backwards from the study start date.
1595396|NCT02269020|Procedure|Neck Dissection|Unilateral Selective Neck Dissection at Lymph Node Levels IIa, III and IV Using a Robot-assisted Transaxillary Approach. The robotic system used is the da Vinci system.
1595397|NCT02269007|Biological|inactivated quadrivalent influenza vaccine (split virion)|0.5ml inactivated quadrivalent influenza vaccine (split virion) for each subject, one dose
1595398|NCT02268994|Drug|ferric citrate|1 gr ferric citrate containing approximately 210 mg of ferric iron
1595399|NCT02268994|Drug|Placebo|Matching placebo
1595400|NCT02268981|Device|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with CNC
1595401|NCT02268981|Device|Oxymizer® compared to CNC|Oxygen Saturation measurement for 12 h with Oxymizer®
1595402|NCT02268981|Device|Oxymizer® compared to CNC|Saturation measurement for 12 h with Oxymizer® by reduced flow rate (-1l/min)
1595403|NCT02268968|Drug|Lidocaine 2% Gel|Lidocaine 2% gel will be applied to nostrils and nasal CPAP prong 5 minutes prior to application of nasal CPAP
1595404|NCT02268955|Drug|IV Ibuprofen|Intravenous ibuprofen will be administered for treatment of pain in adults presenting to the ED with biliary colic
1595405|NCT02268955|Drug|Saline|Saline will be administered to the placebo group
1595407|NCT02268929|Device|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
1595408|NCT02268929|Device|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out from blood glucose meter devices
1595409|NCT02268916|Behavioral|Counseling|OT led counseling
1595410|NCT02268916|Behavioral|Usual education|At the end of the study, will receive OT-led counseling
1595413|NCT02268890|Drug|Bortezomib|Participants will receive a 1.3 milligram per square meter per dose (mg/m^2/dose) of bortezomib intravenously on Days 1, 4, 8, and 11.
1595414|NCT02268877|Other|Emergency Medicine Physician Ultrasound|An ultrasound will be performed by an emergency medicine resident or attending physician
1595415|NCT02268877|Device|Ultrasound|An ultrasound will be performed by a radiology department technician
1595416|NCT02268864|Drug|Simeprevir|Simeprevir 150 mg oral capsule will be administered once daily for 12 or 24 weeks.
1595417|NCT02268864|Drug|Daclatasvir|Daclatasvir 60 mg oral tablet will be administered once daily for 12 or 24 weeks.
1595418|NCT02268851|Drug|TGR-1202|Capsules taken whole daily with water and with food
1595419|NCT02268851|Drug|Ibrutinib|Capsules taken whole with water- Do not consume fish oil, vitamin E, grapefruit, or Seville oranges
1595420|NCT02268838|Drug|E6007|
1595421|NCT02268838|Drug|E6007 matching placebo|
1595422|NCT02268825|Drug|MK-3475|"MK-3475 in combination with mFOLFOX6 in a 14 day cycle
Phase 1 and safety expansion Phased Regimen mFOLFOX6 Administered Day 1 of each cycle Leucovorin 400 mg/m2 IV 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hrs Oxaliplatin (Eloxatin) 85 mg/m2 IV
MK-3475 IV to be administered before mFOLFOX6 starting with Cycle 3 (after 28 days of chemotherapy alone); day 1 of each cycle (q 2 weeks)
Phase 1: 2 dose levels of MK-3475 Level -1: 50mg IV q 2 weeks Level 1: 75mg IV q 2 weeks Level 2: 200mg IV q 2 weeks
Safety Expansion: MK-3475 at highest tolerated dose"
1595423|NCT02268786|Other|Preimplantation Genetic Screening by NGS|The VeriSeq PGS takes advantage of next-generation sequencing (NGS) technology to provide comprehensive, accurate screening of all 24 chromosomes for selection of euploid embryos.
1595424|NCT02268773|Drug|Asasantin®|
1595425|NCT02268773|Drug|Acetylsalicylic acid low dose|
1595426|NCT02268773|Drug|Acetylsalicylic acid high dose|
1595427|NCT02268760|Drug|BILN 2061 ZW single rising doses|
1595428|NCT02268760|Drug|Placebo|
1595429|NCT02268760|Drug|BILN 2061 ZW fixed dose|
1595430|NCT02268760|Other|Standardized breakfast|
1595431|NCT02268747|Drug|Dacomitinib|"The patients will assume Dacomitinib 30 mg daily for the first 2 weeks. If the highest skin toxicity will be of grade <2, then the patients will start dacomitinib at 45 mg once daily and they will be clinically assessed every cycle (i.e. every 28 days).
If the highest skin toxicity will be grade >2, then the patient will interrupt the treatment following the criteria for dose reduction."
1595432|NCT02268721|Device|Tablet computer|Patients receive a tablet computer upon discharge. The tablet can be used for ordering food for delivery three times a week from the hospital kitchen.
1595433|NCT02268708|Procedure|Oncological pulmonary resection|Respiratory evaluation before sugery Oncological pulmonary resection with general anesthesia. Hospitalization for post operative care
1595434|NCT02268695|Drug|Cisplatin|
1595435|NCT02268695|Drug|5-Fluorouracile|
1595436|NCT02268695|Drug|Docetaxel|
1595437|NCT02268695|Drug|Cetuximab|
1595438|NCT02268695|Drug|granulocyte colony-stimulating factor (G-CSF)|
1595439|NCT02268682|Other|Patient-Guided|"The Explore Transplant education program was designed to increase patient informed decision-making and knowledge and is based on the theoretical tenets of the Transtheoretical Model of Behavior Change. The program helps patients think about what might motivate them to pursue transplant, addresses commonly held concerns about transplant and involving a living donor, and shares real-life transplant stories of donors and recipients. The ET materials were written for patients with low health literacy. Already developed for the Explore Transplant program are brochures, videos, and factsheets. ET at Home is an expansion of the ET program. Newly designed postcards and text messages have added to the list of transplant education resources for this program."
1595440|NCT02268682|Other|Educator-Guided|The Transplant Educator supports the Explore Transplant at Home materials by facilitating a conversation about the content of the materials. The role of the Educator is filled by an experienced dialysis healthcare provider who can support a patient as they learn about their treatment options. The program is split into a series of four modules and the Educator conversations are guided by a Transplant Educator Guide and Patient Tracking Tool. This tool is intended to provide direct talking points for the Educator and is also a place where the patients' responses, questions, or concerns can be documented.
1595441|NCT02268669|Other|Reperfusion strategies|Two different reperfusion strategies in STEMI will be compared: primary angioplasty vs. post-thrombolysis angioplasty
1595442|NCT02268656|Drug|propofol|First subjects start from effect site concentraion of 5ug/ml propofol, after insertion of i-gel, determine the next subjects' effect site concentraion would be increae or decrease 0.5 ug/ml as up and down method
1595443|NCT02268643|Other|ultrasound plus clinical breast examination|all the participants will be required to fill risk factor questionaires and then be screened with ultrasound plus physical examination every year
1595444|NCT02268617|Other|Treadmill Walking|Following instructions and familiarization with the treadmill, participants will walk on the treadmill for 20 minutes total with rest periods as needed. Treadmill speed will be set at each participant's overground comfortable walking speed for the first 5 minutes, provided that they can walk safely. If necessary the speed will be lowered until a safe gait is achieved. After 5 minutes the speed will be incrementally increased by10% each 5 minutes (3 times) as long as a safe gait (i.e., no abnormal vital signs, excessive effort, or loss of balance occurrences) can be maintained. If the gait pattern becomes unsafe or more abnormal the speed will revert to the previous safe speed and be maintained at this level until the end of training session.
1595445|NCT02268604|Drug|BIIB 722 CL|
1595446|NCT02268604|Drug|Placebo|
1595447|NCT02268591|Device|Transcranial Stimulator|A non invasive brain stimulation which delivers low amplitude current through scalp electrodes by a Transcranial Stimulator
1595448|NCT02268578|Device|Transcranial Direct Current Stimulation|2mA tDCS
1595449|NCT02268578|Procedure|Sham Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation is administered but at 0mA
1595450|NCT02268565|Drug|Aspirin|81mg aspirin daily at bedtime over a 2 week period
1595451|NCT02268565|Drug|Placebo|pill that looks like aspirin without the effects of aspirin
1595453|NCT02268539|Procedure|ablation|Ablation ranging from 20-25 watts / 30-45 seconds
1595454|NCT02268526|Biological|CSJ148|
1595455|NCT02268526|Drug|Placebo|
1595456|NCT02268500|Biological|Influenza vaccine|Influenza vaccine
1595457|NCT02268487|Drug|Sertraline|Treatment
1595458|NCT02268474|Device|Excel V 532nm (KTP) Laser or 595nm Pulse Dye Laser|Each subject's face will be divided in half and labeled as A (Right Side of the Face) or B (Left Side of Face). The allocation of treatment (532nm KTP laser) and active control treatment (595nm PDL) arms will be determined by randomization.
1595459|NCT02268461|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|The treatment arm will consist of 3 daily treatment sessions. One treatment session in this study with real rTMS will consist of 600 pulses of 1Hertz rTMS at an intensity of 90% of resting motor threshold (duration 10 minutes) applied to the primary motor area of the contralesional hemisphere.
1595508|NCT02268071|Drug|Antihypertensive treatment will be stopped for 1 year unless hypertension recurrence|For patients with average of HBPM values <135/85mmHg at baseline, the antihypertensive treatment will be stopped for 1 year (half dose for 3 days then interruption)
1595460|NCT02268461|Device|Sham repetitive Transcranial Magnetic Stimulation|Sham rTMS utilizes a coil that produces identical noise and tactile sensation to the real coil, but does not emit a magnetic field (0% intensity). Duration and frequency of auditory and tactile stimulation will be identical to the real intervention.
1595461|NCT02268448|Drug|Clonidine|
1595462|NCT02268448|Drug|Naltrexone|
1595463|NCT02268435|Drug|dovitinib plus imatinib|Dovitinib once daily on a 5 days on/2 days off dosing schedule, and imatinib once daily on a continuous dosing schedule
1595464|NCT02268422|Drug|Buprenorphine|7 day patch
1595465|NCT02268409|Drug|ACE-536|ACE-536 0.8 mg/kg once every 3 weeks by SC injection
1595466|NCT02268396|Drug|Glycopyrronium and Formoterol Fumarate Metered-dose Inhaler|GFF MDI administered as 2 inhalations BID
1595467|NCT02268383|Drug|ACE-536|ACE-536 1.0 mg/kg once every 3 weeks by subcutaneous injection
1595468|NCT02268370|Drug|Dasatinib|
1595469|NCT02268357|Drug|Propranolol|Oral propranolol capsules
1595470|NCT02268344|Device|Grass SD9 Stimulator|Electrical stimulation will be applied to the nerve using the Grass SD9 Stimulator at a frequency of 20Hz, 10-15V, for 60 minutes during the surgery. This will occur after the neck dissection has been completed, and the remainder of the surgery will continue during stimulation. The stimulation will be applied using the Grass SD9 Stimulator and the current will be conducted to the nerve using a sterile wire electrode that will be encircled around the nerve at its most proximally-exposed portion (skull base). The wire will be removed after 60 minutes of stimulation has been applied.
2009369|NCT03278080|Other|Road-tracking test|Driving with simulator program for SDLP measurement
2009370|NCT03278080|Other|Car-following test|Driving with simulator program for DCV measurement
1595473|NCT02268318|Other|1-Fermented Dairy Product with Phytosterols (test)|1- 1 bottle of test product/day
1595474|NCT02268318|Other|2-Fermented dairy Product with No Phytosterols (control)|2-1 bottle of control product/day
1595475|NCT02268305|Drug|MSM 1000mg twice a day (6000 mgs)|MSM is believed to have anti-inflammatory properties. MSM is a largely tasteless, odorless, white, crystalline solid which is water soluble. It occurs naturally in the environment and is synthesized in the human body as a byproduct of dietary DMSO.
1595476|NCT02268305|Other|Placebo capsules twice a day|Placebo is a capsule filled with rice flour.
1595477|NCT02268292|Behavioral|bicycle exercise|All enrolled subjects received a scheduled twelve-week exercise program. A commercially available bicycle (Giant CS800, Taichung, Taiwan) with an indoor bicycle stand (Giant Cyclotron Mag, Taichung, Taiwan) was used as the home exercise training modality.
1595478|NCT02268279|Drug|solithromycin|
1595479|NCT02268266|Device|Erigo|The control of cardiovascular parameters within suitable ranges for healthy and neurological patients using verticalization, leg mobilization and electrical stimulation
1595480|NCT02268253|Drug|SL-401|
1595481|NCT02268240|Behavioral|Stepped Care|Intervention will include : 1) care management; 2) cognitive-behavioral therapy (CBT); 3) psychiatric medication consultation in addition too receiving standard care through their medical team. Care management will include initial consultation to determine participants' and families' concerns and areas of difficulty, followed by brief interventions to connect them with care providers as needed . If participants do not show adequate symptom reduction, they will be engaged in structured CBT. CBT will be delivered in 4 to 12 structured sessions, each ranging from 30-60 minutes in length. Psychiatric medication consultation will be offered on an as-needed basis for participants not adequately responding to prior stepped care interventions. MD providers with expertise in psychopharmacological treatment of youth will provide consultation for participants' primary care provider regarding the prescription of psychiatric medications.
1595482|NCT02268214|Drug|Dapagliflozin|Tablets
1595483|NCT02268214|Drug|Placebo for dapagliflozin|Tablets
1595484|NCT02268201|Drug|Advagraf|oral
1595485|NCT02268201|Drug|Prograf|oral
1595486|NCT02268188|Other|educational intervention|Undergo Harvesting Health program
1595487|NCT02268188|Other|nutritional intervention|Undergo Harvesting Health program
1595488|NCT02268188|Behavioral|exercise intervention|Undergo Harvesting Health program
1595489|NCT02268188|Other|questionnaire administration|Ancillary studies
1595490|NCT02268188|Other|laboratory biomarker analysis|Correlative studies
1595491|NCT02268188|Other|quality-of-life assessment|Ancillary studies
1595492|NCT02268175|Drug|Enzalutamide|160 mg (four 40 mg capsules), oral, once daily, 28 days (4 weeks) 6 cycles maximum. Can be taken with or without food.
1595493|NCT02268175|Drug|Abiraterone Acetate|1000 mg (four 250 mg tablets), oral, once daily, 28 days (4 weeks) 6 cycles maximum. No food should be consumed for at least two hours before the dose and for at least one hour after the dose.
1595494|NCT02268175|Drug|Prednisone|5 mg, oral, once daily, 28 days (4 weeks) 6 cycles maximum.Take with food, preferred to be taken in the morning .
1595495|NCT02268175|Drug|Leuprolide Acetate|Either 7.5 mg monthly or 22.5 mg every three months, Intramuscular, monthly or every three months.
1595496|NCT02268162|Procedure|guiding equipments|The guiding equipments including VBN, EBUS-GS and fluoroscopy guide a bronchoscope along the bronchial route to a peripheral pulmonary lesion.
1595497|NCT02268149|Drug|BIIL 284 BS|
1595498|NCT02268149|Drug|Prednisone|
1595499|NCT02268149|Drug|Placebo|
1595500|NCT02268136|Drug|BIII 890 CL|
1595501|NCT02268136|Drug|Placebo|
2009371|NCT03278080|Other|Harsh-braking test|Driving with simulator program for BRT measurement
1595504|NCT02268097|Procedure|Patellar resurfacing with freehand technique|Preparing patellar resurfacing during total knee arthroplasty with freehand
1595505|NCT02268097|Procedure|Patellar resurfacing with resection guide technique|Preparing patellar resurfacing during total knee arthroplasty with a resection guide
1595506|NCT02268084|Device|EEG,ECG-guided Transcranial Magnetic Stimulation|A coil delivers a pulsed magnetic field to the cortex of the brain
1595507|NCT02268084|Device|Sham|Sham coil simulates behavior of the intervention magnetic coil without applying the magnetic field
1595509|NCT02268058|Drug|Acetaminophen|routine administration of medication for a 72 hour period
1595510|NCT02268058|Drug|Ibuprofen|routine administration of medication for a 72 hour period
1595511|NCT02268045|Biological|RTXM83|Rituximab biosimilar (RTXM83) will be administered in combination with CHOP chemotherapy regimen (Cyclophosphamide 750 mg/m2, Doxorubicin 50 mg/m2 and Vincristine 1.4 mg/m2 up to a maximum of 2 mg on Day 1 plus Prednisone 40 mg/m2 or 100 mg per day from Day 1 to 5) at a dose of 375 mg/m2 on Day 1 of each 3 week cycle, for 6 cycles, although the administration of 2 additional cycles may be allowed.
1595512|NCT02268032|Drug|DHEA|
1595513|NCT02268032|Drug|Another Androgenic Agent (VRaA)|
1595514|NCT02268032|Drug|Fixed combination of 2 androgenic agents (VR2A)|
1595515|NCT02268019|Procedure|tourniquet application|
1595516|NCT02268019|Drug|epinephrine injection|
1595517|NCT02268006|Radiation|IMRT-SIB|
1595518|NCT02268006|Drug|Capecitabine|
1595519|NCT02268006|Procedure|Surgery|
1595520|NCT02267993|Drug|recombinant human thrombopoietin|Patients received subcutaneous injection of recombinant human thrombopoietin at a dose of 300 U/kg body weight once daily at a platelet count of < 50×109/L, and recombinant human thrombopoietin treatment ceased at a platelet count of ≥20×109/L if platelet is not transfused.
1595521|NCT02267980|Drug|Sevoflurane|Inhalation anesthetic agent
1595522|NCT02267980|Drug|Ketamine|Intravenous anesthetic agent
1595523|NCT02267980|Drug|Saline|Isotonic solution for placebo group
1595524|NCT02267967|Drug|Sulfatinib|Sulfatinib 300 mg once a day (QD) will be orally administrated on a 28-day cycle.
1595525|NCT02267954|Other|Menu edited|The menu is edited to change price label to 50% of actual value and calorie label to 50% of the actual value, along with other changes.
1595526|NCT02267941|Other|observation|Data were collected by a disigned form. Statistic software was used to analyze clinical data.
1595527|NCT02267928|Other|Check Symptoms|"Symptoms are Checked"
1595528|NCT02267928|Other|Uncheck Symptoms|"Symptoms are Un-checked"
1595529|NCT02267928|Other|Experienced|Focus of instructions is on symptoms the participant has experienced
1595530|NCT02267928|Other|Not Experienced|Focus of instructions is on symptoms the participant has NOT experienced
1595531|NCT02267915|Drug|subcutaneous Rituximab|MabThera 1400 mg solution for subcutaneous injection
1595532|NCT02267902|Drug|DA-1229|
1595533|NCT02267889|Procedure|Image guided GP ablation|3D imaging data from the D-SPECT system will be used to visualise the GP and guide the location of catheter ablation sites during the electrophysiology procedure.
1595534|NCT02267889|Device|D-SPECT dedicated cardiac nuclear camera|
1595535|NCT02267876|Device|BD HPV Assay on Viper LT|The BD HPV specimen will be tested with the BD HPV Assay on the Viper LT instrument.
1595536|NCT02267876|Procedure|Colposcopy|The colposcopy will be performed on subjects that have abnormal cytology. At the third year visit all subjects will have an exit colposcopy.
1595537|NCT02267863|Drug|APTO-253 HCl|APTO-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate dose is reached. Patients will be treated on APTO-253 HCl for at least 1 cycle (28 days) for safety evaluation.
1595538|NCT02267850|Other|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
1595539|NCT02267850|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
1595540|NCT02267850|Device|Non-Functional OrthoPulse™|Patients carry out daily sham-OrthoPulse™ treatments at home. This is a non-functional device so patients do not receive photobiomodulation therapy.
1595541|NCT02267837|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
1595542|NCT02267824|Device|Extraoral OrthoPulse® PBM|Patients carry out daily extraoral OrthoPulse® PBM treatments at home.
1595543|NCT02267824|Other|Fixed Orthodontic Appliance Treatment|Patients are treated for full mouth fixed orthodontic appliance treatment by the qualified Principal Investigator (PI). Orthodontic treatment procedures carried out per the traditional practices of the PI and dental office.
1595544|NCT02267811|Other|Orthodontic Treatment|Patients are treated for orthodontic treatment by the qualified Principal Investigator (PI). Treatment and follow-up appointments per the traditional practices of the PI and dental office.
1595545|NCT02267811|Device|OrthoPulse™|Patients carry out daily OrthoPulse™ treatments at home.
1595546|NCT02267798|Other|conventional therapy|"The conventional rehabilitation program will consist of physiotherapy sessions (100 min/day) following an individualized approach. The program aims at the restoration of mobility and daily living competence. Specific exercises for the affected upper limb will include, bilateral tasks and facilitation techniques.
The amount of treatment will to be comparable between control and experimental groups in order to avoid possible confounding factors."
1595547|NCT02267798|Device|arm training combined with FES|"Arm training protocol Training sessions will last for 60 minutes. The Reo Therapy System is robot-assisted therapy; during the session the subject's affected hand is placed on or strapped onto a robotic arm and the subject is instructed to either actively reach predefined reach points, or to be guided while the robotic arm leads the arm towards these reach points.
Functional electrical stimulation protocol Experimental group will receive up to 40 minutes of FES after arm training. The device consists is a stimulator containing 5 electrodes positioned to provide reliable activation of the following muscles: extensor digitatum communis and extensor pollices brevis, flexor pollices longus, flexor digitatum superficialis, and thenar muscles."
1595548|NCT02267785|Other|Skill-Based Exercise|The skill-based exercise program is designed to improve skilled function, fine and gross- motor body coordination. The intervention will be focused on acquisition and improvement of complex movements for the whole body and include the following general categories of activities: (1) balance, (2) eye-hand coordination, (3) leg-arm coordination; 4) reaction time to moving objects/persons; (5) dynamic gait and 6) functional activity performance. The treating therapist will direct both general principles of progression and progression specific to each category.
1595590|NCT02267460|Biological|AA4500|
1595591|NCT02267460|Device|ErecAid® Esteem® Manual Vacuum Therapy System|
1595592|NCT02267460|Procedure|Investigator Modeling|
1595593|NCT02267434|Biological|Low dose AFFITOPE® PD03A + Adjuvant|s.c. injection
1595594|NCT02267434|Biological|High dose AFFITOPE® PD03A + Adjuvant|s.c. injection
1595595|NCT02267434|Biological|Adjuvant without active component|s.c. injection
1595549|NCT02267785|Other|Aerobic Exercise|The aerobic cardiovascular exercise will consist of 36 1-hour sessions performed 3 times weekly over 12 weeks. Aerobic exercise will consist of cycling on a recumbent stationary bicycle. Each session will begin and end with gentle stretching. Continuous cycling will be performed for 45-50 minutes, with the first and last 5 minutes designated as warm-up and cool-down periods. The intensity of the middle 30 minutes of cycling will be increased progressively from an initial target of 50% maximum heart rate (HR) during week 1 to 75% of maximum HR by week 12. The initial intensity will be set at 50% of maximum HR. Participants will be encouraged to cycle as fast as they can, with a goal of maintaining 90 revolutions per minute (RPM) throughout the middle 30-minute period. Pedaling resistance will be kept low throughout all sessions. Measures of heart rate via heart rate monitors, blood pressure, RPM, and rate of perceived exertion will be recorded at 5-minute intervals.
1595550|NCT02267785|Other|Social Contact|The control Social Contact group will consist of an equal amount of social contact as the exercise group. Subjects will have weekly visits at the University of Southern California with the study coordinator. The goal is for 3 hours of social contact every week for a total of 36 hours over 12 weeks. Activities scheduled for the social contact visits will include: (1) support group interactions and (2) social outings such as a trip to a museum, local café for lunch or dinner; (3) book club; (4) sports event. Support group interaction can include discussions among patients and caregivers, presentations from experts in various aspects of PD. They will be instructed to continue with their usual level of activity but refrain from beginning new exercise activities during the study period.
1595551|NCT02267772|Drug|IV Acetaminophen|IV Acetaminophen
1595552|NCT02267772|Drug|IV Morphine|IV Morphine
1595553|NCT02267759|Device|McGrath videolaryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, McGrath videolaryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
1595554|NCT02267759|Device|Macintosh laryngoscopy|After the softened nasotracheal tube was inserted into the nares until its tip passed through the posterior nares, Macintosh laryngoscope was introduced into the mouth and the nasotracheal tube was advanced.
1595555|NCT02267746|Drug|Tazarotene (Fabior™)|
1595556|NCT02267746|Drug|Tazarotene (Actavis)|
1595557|NCT02267746|Drug|Vehicle foam|
1595558|NCT02267733|Drug|Fluzone|Fluzone High-Dose will be administered with a planned booster at 30 days post initial administration
1595559|NCT02267720|Procedure|Occlusal-proximal ART restorations - Ketac Molar|Occlusal-proximal ART restorations - Ketac Molar
1595560|NCT02267720|Procedure|Occlusal-proximal ART restorations - Vitro Molar|Occlusal-proximal ART restorations - Vitro Molar
1595561|NCT02267707|Drug|nab-paclitaxel|Subjects will receive nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
1595562|NCT02267707|Drug|Gemcitabine|Gemcitabine will be administered immediately after nab-paclitaxel as an intravenous infusion over approximately 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
1595563|NCT02267694|Drug|Freeze-dried black raspberry powder|
1595564|NCT02267681|Drug|Fentanyl|Intravenous fentanyl for sedation/analgesia
1595565|NCT02267681|Drug|Alfentanil|Intravenous alfentanyl for sedation/analgesia
1595566|NCT02267681|Drug|Propofol|Intravenous propofol for sedation
1595567|NCT02267668|Behavioral|STEP|Physical therapists guide participants through novel set of assigned exercises
1595568|NCT02267668|Behavioral|Control|Participants self-guide through standard exercises
1595569|NCT02267655|Drug|inhaled Nitric Oxide - 30 mcg/kg IBW/hr|inhaled Nitric Oxide in 30 mcg/kg IBW/hr doses Part 1
1595570|NCT02267655|Drug|inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr|inhaled inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr dose titration
1595571|NCT02267655|Drug|inhaled nitric oxide 75 mcg/kg IBW/hr|inhaled nitric oxide 75 mcg/kg IBW/hr -Part 2b
1595572|NCT02267642|Biological|AbGn-168H|monoclonal antibody
1595573|NCT02267629|Drug|Rapastinel (formerly GLYX-13)|10 mg/kg IV Rapastinel (formerly GLYX-13)
1595574|NCT02267616|Device|Etonogestrel Implant|Subdermal arm implant
2009372|NCT03277521|Other|Intermittent theta burst stimulation|Intermittent theta burst stimulation (iTBS) is a non-invasive brain stimulation technique that can increase corticomotor excitability.
2009373|NCT03277482|Drug|Durvalumab|Durvalumab is given by intravenous infusion every 4 weeks for a maximum of 13 doses over 52 weeks. One cycle is defined as every 4 weeks. Each infusion will take approximately 1 hour.
2009374|NCT03277482|Drug|Tremelimumab|Tremelimumab is given by intravenous infusion every 4 weeks for a maximum of 4 doses over 16 weeks. One cycle is defined as every 4 weeks. If receiving both durvalumab and tremelimumab for the first 4 cycles, they will be given on the same day. Each infusion will take approximately 1 hour
1595578|NCT02267564|Procedure|MPFL reconstruction|to correct patellar dislocation with medial patellofemoral ligament reconstruction
1595579|NCT02267564|Procedure|tibial tubercle transfer|to correct patellar dislocation with tibial tubercle medial transfer
1595580|NCT02267551|Other|Mimic dv-Trainer|
1595581|NCT02267551|Other|daVinci Skills Simulator|
2009375|NCT03277482|Radiation|Radiation Therapy|Radiation treatment will begin on the same day as the first immunotherapy infusion or on the following day. The radiation treatment course is either 1 day or 5 days.
2009376|NCT03277469|Device|MRI|Medical imaging technique used in radiology to form pictures of the anatomy and the physiological processes of the body
1595584|NCT02267525|Drug|Velusetrag|
1595585|NCT02267525|Drug|Placebo|
1595586|NCT02267512|Drug|ATG-F|Intravenous (IV)
1595587|NCT02267499|Other|LLM training|Participants use the FitForAll exergaming computer platform as the physical training component (PTC); Participants use the language adapted Version of the BrainFitness Program as the cognitive training component (CTC)
1595588|NCT02267486|Other|Standard therapy of Alzheimer Dementia (AD)|
1595589|NCT02267486|Other|Observation|
2009377|NCT03277469|Radiation|Brachytherapy|Radiation therapy that is delivered by inserting radioactive sources directly into a tumor
2009378|NCT03277469|Device|MRI Tracker|The MR tracking device consists of a series of radiofrequency (RF) microcoils that are embedded into brachytherapy catheter stylet. The RF microcoils allows for accurate spatial localization of an individual brachytherapy catheter.
1595596|NCT02267421|Behavioral|Home based Aerobic exercise training|
1595597|NCT02267408|Other|Warfarin adjustment using the Fearon algorithm|All available historical data will be used to calculate with the Fearon algorithm the individual sensitivity to warfarin and to dose changes as well as lag time until a dose adjustment reaches full effect. Based on this a personal dosing nomogram will be developed and provided to the investigator and to the patients. This nomogram will be used during 6 month but override is possible if the investigator feels that the suggestion from the nomogram is unsafe.
1595598|NCT02267408|Other|Warfarin adjustment using standard dosing|Patients will receive warfarin dosing instructions from a trained nurse using fixed nomograms and computer-based dosing suggestion.
1595599|NCT02267395|Other|(1) cranio-cervical flexion test;|Test to determine level of strength for Deep Neck Flexor muscles
1595600|NCT02267395|Other|(2) scapular dyskinesis test|Test to determine scapular control
1595601|NCT02267395|Other|(3) deep neck flexor endurance test.|Test do determine endurance for the deep neck flexor muscle group.
1595602|NCT02267382|Drug|VT-1161|
1595603|NCT02267382|Drug|Placebo|
1595604|NCT02267369|Behavioral|Media-assisted fitness program|Participants can register workshops online, track program participation, and receive promotional health messages online.
1595605|NCT02267369|Behavioral|Social network-assisted fitness program|Participants can register workshops online and track program participation. Participants are put into anonymous online social networks and receive real-time activity updates from 4-6 peers.
1595606|NCT02267369|Behavioral|Basic fitness program|Participants can register workshops online and track program participation.
1595607|NCT02267356|Drug|VT-1161|
1595608|NCT02267356|Drug|Placebo|
1595609|NCT02267343|Drug|ONO-4538|
1595610|NCT02267343|Drug|Placebo|
1595611|NCT02267330|Procedure|Exposure Recording|Patient undergoing fracture surgery will have radiation exposure recorded
1595612|NCT02267317|Drug|Eritoran|Pharmacologic inhibitor of TLR4 receptors.
1595613|NCT02267317|Other|D5W|5% Dextrose Water = Vehicle
1595614|NCT02267304|Drug|50 mL of sodium chloride (0,9%)|
1595615|NCT02267304|Drug|Morphine 0,05mg/kg|
1595616|NCT02267304|Drug|Naloxone 10mg|
1595617|NCT02267291|Other|Non-invasive positive pressure ventilation|Ventilatory support to alter intrathoracic pressure
1595618|NCT02267278|Drug|Ruxolitinib|Ruxolitinib taken by mouth 2 times each day in a 28-day cycle. Patients receive Ruxolitinib alone for first 3 months, and then Pracinostat added. Starting dose of Ruxolitinib based on patients' platelet count. Dose of Ruxolitinib may be increased or decreased at discretion of treating physician prior to initiation of Pracinostat.
1595619|NCT02267278|Drug|Pracinostat|Starting dose of Pracinostat 60 mg by mouth 1 time each day for 3 alternating days every 3 weeks starting on Day 1 of Cycle 4.
1595620|NCT02267278|Behavioral|Questionnaire|Questionnaire regarding quality of life completed at baseline, within 3 days before Day 1 of Cycles 1 - 6, and then every 3 cycles after that.
1595621|NCT02267265|Other|TMW-Newborn Intervention video|This is an educational video intervention developed by the Thirty Million Words® Initiative Lab.
1595622|NCT02267265|Other|Safe Sleep for your Baby (SIDS) educational video|It is an educational video developed by the National Institute of Child Health and Development (NICHD) promoting the prevention of Sudden Infant Death Syndrome.
1595623|NCT02267252|Other|Antibody-sperm binding|
1595624|NCT02267239|Drug|essential oils, immersion|A single, 30-second immersion in 1 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson & Johnson, Madrid, Spain) (I-EO).
1595625|NCT02267239|Drug|Chlorhexidine, immersion|A single, 30-second immersion in 1 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (I-0.2% CHX).
1595626|NCT02267239|Drug|essential oils, mouthwash|A single, 30-second mouthwash with 20 mL of essential oils in a hydroalcoholic solution (Listerine Mentol, Listerine®, Johnson & Johnson, Madrid, Spain) (M-EO).
1595627|NCT02267239|Drug|chlorhexidine, mouthwash|A single, 30-second mouthwash with 10 mL of 0.2% chlorhexidine (Oraldine Perio®, Johnson and Johnson, Madrid, Spain) (M-0.2% CHX).
1595628|NCT02267239|Procedure|professional oral cleaning|scaling and polishing teeth of the volunteers
1595629|NCT02267239|Procedure|Plaster cast|Taking a plaster cast of the volunteers' mouth
1595630|NCT02267239|Device|IDODS|Specific intraoral device which carries six glass disks
1595632|NCT02267213|Drug|Administer 40mg Lipotecan at D1, D8, D15 of each cycle.|
1595633|NCT02267187|Procedure|Fat Grafting|Fat Grafting is a procedure that involves moving a person's own fat from an area of the body where it is less needed to another area of the body to improve its appearance. The fat is usually taken from the thighs or abdomen with a small liposuction tube and then moved to an area that has lost volume or fullness due to aging, trauma, surgery, birth defects, or other causes.
1595634|NCT02267187|Drug|General Anesthesia|A medicine that will relax and assist the subject in keeping unconscious (in a sleep like state) during the entire procedure.
1595635|NCT02267187|Device|Coleman Cannulas|The plastic surgeon, will use small narrow tube-like instruments called cannulas, will remove fat from various places throughout the body (commonly the abdomen and thighs). The plastic surgeon will then use the Coleman cannulas (specialized smaller cannulas with varied shapes and tip sizes specifically made to deliver smaller amounts of fat) to fill the desired area.
1595636|NCT02267187|Other|Tefla non-adherent gauze pad|The processing of the fat graft material is done using a Tefla non-adherent gauze pad in a rolling technique that separates the aqueous and oil layers from the injected component.
1595637|NCT02267174|Behavioral|Standardized handoff|A standardized handoff will be implemented that consists of choreographed handoffs utilizing a structured handoff tool to facilitate information exchange.
1595638|NCT02267161|Other|Psychometric scales for infants at 3 years of age|WPPSI-III, VINELAND, CBCL, NEPSY
1595665|NCT02266953|Behavioral|Treatment as usual|The public health nurses at child health centres in control municipalities are performing consultations at the child health centres as usual and without using the particular communication tool about diet.
1595666|NCT02266940|Drug|DS-1971a suspension|DS 1971a will be supplied as a powder or crystals and prepared at the study site for administration as an oral suspension with a taste masking agent.
1595669|NCT02266927|Drug|OPTINOSE™ FLUTICASONE|
2009379|NCT03274752|Drug|Paroxetine|Paroxetine (Deroxat) will be administered in a dosage of 20mg q.d. per os continuously for 12 weeks after primary PCI. In week 13, Paroxetine (Deroxat) will be administered in a dosage of 10mg q.d. per os.
2009380|NCT03274752|Drug|Placebo oral capsule|Placebo will be given q.d. per os continuously for 12 weeks after primary PCI. In addition, a placebo will be given q.d. per os in week 13 as well.
1595641|NCT02267122|Procedure|ionic silver-containing dressing|After placing the staples, a ionic silver-containing dressing was placed covering the wound
1595642|NCT02267122|Procedure|Mupirocin ointment application|After placing the staples, Mupirocin ointment application over the wound was performed
1595645|NCT02267096|Behavioral|Telephone Counseling|The TC arm includes a stepped care approach, 3-6 phone sessions, depending on each participant's needs. Within 1-2 days post-T1 assessment, the intervention will begin. Sessions 1-3 (15 min each) will occur approximately weekly over 3-4 weeks, scheduled at participants' convenience and at strategic therapeutic times (e.g., shortly pre/post-quit date). Continuing smokers or newly quit former smokers who would benefit from relapse prevention sessions will receive up to 3 additional sessions, to be completed within 3-4 weeks. The provision of 3-6 sessions is more intensive than several other telephone counseling interventions. A dose response relationship between quitting and number of sessions has been shown in non-volunteer smokers, and based on our pilot data, the investigators expect that a more intensive intervention will be needed for some participants.
1595646|NCT02267096|Behavioral|Minimal Treatment|A list of self-help materials (print-, web-, phone-based), the national telephone quitline phone number, and local in person cessation resources will be given to all participants.
2009381|NCT03275389|Biological|D-SUIV Formulation 1|1 Primary dose or 1 Booster dose will be administered intramuscularly (IM) in the deltoid region of non-dominant arm.
1595648|NCT02267070|Behavioral|Case management and supportive psychotherapy|An individual therapist will provide weekly case management and therapy targeting the individual psychological problems and everyday functioning needs of the patient
1595649|NCT02267070|Behavioral|Family psychoeducation|All immediate family members will be invited to family psychoeducation sessions.
1595650|NCT02267070|Behavioral|Cognitive training|The Cognitive Training and Exercise intervention involves 24 weeks of systematic computerized cognitive training, 4 hours per week, plus aerobic exercise, four 30 minute sessions per week. The first 12 weeks involves neurocognitive training, using auditory training exercises from Posit Science Brain HQ. The second 12 weeks involves social cognitive training, using the Posit Science SocialVille modules. A weekly one-hour Bridging Skills Group with other members of the treatment condition is designed to aid generalization of training to everyday life situations.
1595651|NCT02267070|Behavioral|Aerobic exercise|Aerobic exercise occurs as two 30-minute sessions at the clinic and two at home weekly. Intensity of aerobic exercise is tailored to maintain an individualized target heart rate zone and is monitored by a heart rate recorder.
1595652|NCT02267057|Drug|Paracetamol|Paracetamol granulate supplied by Weifa (Paracet) and 1 g paracetamol tablets produced by Kragerø tablettproduksjon for blinding purposes.
1595653|NCT02267057|Drug|Buprenorphine|Buprenorphine 5 micrograms/hour and 10 micrograms/hour transdermal system produced by Mundipharma, identical to placebo transdermal system.
1595654|NCT02267057|Drug|Paracetamol placebo|Paracetamol placebo tablets produced by Kragerø tablettproduksjon.
1595655|NCT02267057|Drug|Buprenorphine placebo|Buprenorphine transdermal system placebo produced by Mundipharma.
1595656|NCT02267044|Drug|Ropivacaine|The drug used for the interscalene blocks
1595657|NCT02267031|Procedure|mechanical ventilation|"Patients subjected to scheduled laparoscopic cholecystectomy were enrolled to the ongoing prospective study and randomized into four groups: 1) normoxia and normocapnia (nO2-nCO2), 2) hyperoxia and normocapnia (hO2-nCO2), 3) normoxia and hypocapnia (nO2-lCO2), and 4) hyperoxia-hypocapnia (hO2-lCO2).
Normoxia PaO2 was referred to PaO2 of 70-140 mm Hg, hyperoxia 150-300 mm Hg, normocapnia PaCO2 of 35-48 mmHg and hypocapnia PaCO2 of 25-35 mmHg."
1595658|NCT02267018|Device|Drager VN500 Ventilator|This ventilator is capable of providing both nCPAP and NIHFV support.
1595659|NCT02267005|Dietary Supplement|Creapure|Patients will be prescribed a creapure supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
1595660|NCT02267005|Dietary Supplement|Glucose Tablet|Patients will be prescribed the placebo supplement by weight, to be taken 3x/day for the duration of the trial. They will be randomized to an active product start time using a multiple baseline design.
1595661|NCT02266992|Biological|Live attenuated Vaccine- Fluenz Tretra|Intra-nasal administration of 0.2ml (0.1ml in each nostril).
1595662|NCT02266966|Drug|F2695|
1595663|NCT02266966|Drug|Placebo|
1595664|NCT02266953|Behavioral|Use of communication tool about diet|The experimental intervention comprise the public health nurse's use of an image based communication tool in her dialogue with the family. This is in order to act in a patient centered way to facilitate participation by the parents and focus on relevant food and feeding practices from the parents' point of view.
1595667|NCT02266940|Drug|DS-1971a tablet|A 200 mg DS 1971a tablet for oral administration
2009382|NCT03275389|Biological|D-SUIV Formulation 2|1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
2009383|NCT03275389|Biological|D-SUIV Formulation 3|1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
2009384|NCT03275389|Biological|D-SUIV Formulation 4|1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm.
2009385|NCT03275389|Biological|D-SUIV Formulation 5|1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
2009386|NCT03275389|Biological|D-SUIV Formulation 6|1 Booster dose will be administered IM in the deltoid region of non-dominant arm
2009387|NCT03275389|Biological|D-SUIV Formulation 7|1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
2009388|NCT03275389|Biological|D-SUIV Formulation 8|1 Primary dose or 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
1595670|NCT02266914|Device|Magnetic Resonance Elastography driver|A driver is required for MRE. The driver utilizes sound waves to produce vibrations. Images of these vibrations are captured with Magnetic Resonance scanner to produce images that indicate stiffness in an organ.
1595671|NCT02266901|Procedure|endoscopic drainage|Endoscopic percutaneous access was obtained through surgical drains or after ultrasound-guided percutaneous drainage with a thin scope , and transluminal procedures with large scopes through the leak hole. All the procedures were performed under general anesthesia and carbon dioxide insufflation. Debridement was done by pus aspiration and irrigation.
1595672|NCT02266888|Biological|Rituximab (Rituxan®)|2 Doses: 375 mg/m^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/‐2 days).
1595673|NCT02266888|Biological|Placebo|Placebo for Rituximab (Rituxan®). 2 Doses: 375 mg/m^2 on Day 0 (within 12 hours of return to ICU following transplant) and Day 12 (+/‐2 days).
2009389|NCT03275389|Biological|D-SUIV Formulation 9|1 Booster dose will be administered IM in the deltoid region of non-dominant arm
2009390|NCT03275389|Biological|Placebo|1 dose will be administered IM in the deltoid region of non-dominant arm
1595676|NCT02266862|Radiation|Study group|Patients will receive an additional CT sequence (end-expiration) at the time of their standard CT imaging before and after the repair.
1595677|NCT02266849|Drug|Loperamide|12 mg Loperamide each day for three days
1595678|NCT02266849|Drug|Placebo|6 tablets daily for three days
1595679|NCT02266836|Device|MyndMove|During a MyndMove therapy session, the patient is instructed to attempt to execute a task voluntarily. As the patient is attempting to perform the designated task, specific muscles in the arm are stimulated to generate contractions that produce the desired movement. After a brief interval of the patient attempting to initiate a movement the therapist activates the MyndMove stimulation protocol, which generates bursts of short electrical pulses, using surface electrodes, to produce muscle contractions enabling the patient to complete the desired/instructed task. Proper sequencing of the muscle contractions as per the MyndMove protocols are tailored to achieve a wide range of reaching and grasping functions. The technique stimulates non‐damaged pathways of the central nervous system.
1595680|NCT02266823|Behavioral|Social Cognitive Theory|The intervention, which combines behavioral counseling with mobile self-monitoring, will be based on SCT which focuses on the role played by self-referent thought in the maintenance of behavior change. Within SCT, behavior change and maintenance are influenced strongly by the individual's perceived self-efficacy.
1595681|NCT02266810|Device|PROPEL Mini Sinus Implant.|Placement of sinus implant following frontal sinus surgery
1595682|NCT02266810|Procedure|Sinus Surgery alone|Sinus surgery only, without implant placement
1595683|NCT02266810|Device|Propel Nova Sinus Implant|Placement of sinus implant following frontal sinus surgery
1595684|NCT02266797|Drug|Dexamethasone|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose. Dexamethasone doses will be 0.3 mg/kg for the first dose and 0.15 mg/kg for each subsequent dose.
1595685|NCT02266797|Other|Saline|The first dose will be given before the incision and the subsequent doses will be given 8 and 16 hours after the first dose.
1595686|NCT02266784|Behavioral|Contingency Management (CM)|
1595687|NCT02266784|Drug|Transdermal nicotine skin patches (i.e. Habitrol)|
1595688|NCT02266784|Other|Supportive Counseling|
1595689|NCT02266771|Device|NPWT with Instillation|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System with V.A.C. VeraFlo Instillation
1595690|NCT02266771|Device|NPWT|Kinetic Concepts Inc. V.A.C Ulta Negative Pressure Wound Therapy System
1595691|NCT02266758|Other|GDM Screening Methods|
1595692|NCT02266745|Drug|PT-112 Injection|
1595693|NCT02266732|Device|Stimuplex HNS 12|
1595694|NCT02266719|Device|CMD|"The CMD that will be used in this IDE is structurally the same as the commercially available Zenith Fenestrated AAA Endovascular Graft, except as noted below.
In general, the Zenith® Fenestrated AAA Endovascular Graft is a modular system constructed of full- thickness woven polyster fabric sewn to self-expanding stainless steel z-stents with braided polyster and monofilament polypropylene sutures. In this study, fenestrated grafts with usually up to 4 fenestrations may be used. Only in rare situations in which large accessory renal arteries or separate visceral arteries may exist, the device may include more than 4 fenestrations to accommodate these additional vessels.
Device implantation will be performed using standardized endosvacular techniques used in the treatment of abdominal aortic aneurysms."
1595695|NCT02266706|Drug|Ceftolozane/Tazobactam 1.5 g|1.5 g fixed dose combination (FDC) of 1000 mg ceftolozane and 500 mg tazobactam as a 60 minute infusion.
1595696|NCT02266706|Drug|Ceftolozane/Tazobactam 27 mg/kg|A FDC of 18 mg/kg of ceftolozane and 9 mg/kg of tazobactam as a 60 minute infusion.
1595697|NCT02266706|Drug|Ceftolozane/Tazobactam 18 mg/kg|A FDC of 12 mg/kg of ceftolozane and 6 mg/kg of tazobactam as a 60 minute infusion.
2009391|NCT03275389|Biological|FLU-D-QIV|1 Primary dose and 1 Booster dose will be administered IM in the deltoid region of non-dominant arm
1595699|NCT02266680|Behavioral|Yoga Treatment Group|The breathing focused yoga intervention is a manualized yoga protocol developed at CAMH by the Mood and Anxiety Disorders group, with yoga teacher, Ms. Tiffany Garfinkel, as the lead. BFY incorporates postures and meditation, but there is a special focus on controlled breathing at different rates, including Ujjaji or slow inhalation, exhalation and holding of breath; Bhastrika or Kapalabhati, two types of vigorous breathing with forced exhalation; and cyclical breathing or a repeated pattern of slow, moderate and fast breathing.
1595700|NCT02266667|Device|2 NEMOST rods : bilateral vertebral-pelvic implantation|Implantation of two NEMOST rods (bilateral vertebral-pelvic implantation)
1595701|NCT02266667|Device|1 NEMOST rod :unilateral vertebral-pelvic implantation|Implantation of one NEMOST rod (unilateral vertebral-pelvic implantation)
1595702|NCT02266654|Other|IV fluids|Normal Saline 0.9%
1595703|NCT02266654|Other|Hospital Notification|Prehospital providers will notify the receiving hospital over the radio or telephone that they are transporting a patient who meets Sepsis Criteria
1595704|NCT02266641|Behavioral|nutrition counseling|Pregnancy diet (include one-carbon nutrients)
2009392|NCT03274856|Drug|GLWL-01|Oral administration of 3 capsules, twice a day
2009393|NCT03274856|Drug|Placebo|Oral administration of 3 capsules, twice a day
1595705|NCT02266641|Dietary Supplement|multivitamin supplement|
1595706|NCT02266628|Biological|RSV-F Vaccine|
1595707|NCT02266628|Biological|Saline Placebo|
1595708|NCT02266615|Genetic|Biobanking of biomaterial for future genetic research.|
1595709|NCT02266602|Radiation|Intraoperative Radiation Therapy|Intraoperative radiation therapy at the time of partial mastectomy in early stage breast cancer
1595710|NCT02266589|Drug|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
1595711|NCT02266576|Behavioral|Standard DPP|The Standard Diabetes Prevention Program (DPP) delivered by the Indian Health Center is the Group Lifestyle Balance DPP, which has previously been tailored for the urban American Indian/Alaskan Natives (AIAN). The Standard DPP consists of 16 group classes, 4 visits with a lifestyle coach, and individual meetings with a registered dietician and fitness coordinator. The intervention will occur over the course of 20 weeks.
1595712|NCT02266576|Behavioral|Enhanced DPP|The Enhanced Diabetes Prevention Program (DPP) will include all components of the Standard DPP [16 group classes, 4 visits with a lifestyle coach, and individual meetings with a registered dietician and fitness coordinator] delivered by the Indian Health Center and additional components to address psychosocial issues. The Enhanced DPP components include 4 visits with a mental health counselor, active referrals to mental health services, and traditional healing workshops, such as the use of talking circles to address specific psychosocial issues that are a result of historical trauma, stress, and grief. The intervention will occur over the course of 20 weeks.
1595713|NCT02266563|Drug|Amyvid PET Scan|A thin line will be inserted into a vein in one arm for the injection of the tracer. Subjects will begin the Amyvid PET scan 50-60 minutes after the injection of the tracer, and scanned for about 20 minutes.
1595714|NCT02266563|Drug|T807 PET scan|Scanning will begin 80 minutes after the injection of the tracer, and last for about 20 minutes.
1595715|NCT02266550|Drug|[14C] BILL 284 BS|
1595716|NCT02266537|Drug|Tamsulosin|
1595717|NCT02266537|Drug|Alfuzosin|
1595718|NCT02266537|Drug|Doxazosin|
1595719|NCT02266537|Drug|Placebo|
1595720|NCT02266524|Drug|Tamsulosin hydrochloride, very low dose|
1595721|NCT02266524|Drug|Tamsulosin hydrochloride, low dose|
1595722|NCT02266524|Drug|Tamsulosin hydrochloride, medium dose|
1595723|NCT02266524|Drug|Tamsulosin hydrochloride, high dose|
1595724|NCT02266511|Drug|Flomax®, Norman II facility|
1595725|NCT02266511|Drug|Flomax®, Nishine facility|
1595726|NCT02266498|Drug|BIBB 515 BS|
1595727|NCT02266498|Other|Standard breakfast (40 g fat)|
1595728|NCT02266485|Drug|BIBB 515 BS|
1595729|NCT02266485|Drug|Pravastatin|
1595730|NCT02266485|Drug|Placebo|
1595731|NCT02266472|Drug|metformin|single dose of metformin given as tablets
1595732|NCT02266472|Drug|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
1595733|NCT02266472|Drug|empagliflozin|single dose of empagliflozin given as tablet
1595734|NCT02266459|Device|Microwave technology (Medfield Diagnostics)|A microwave measurement will be performed. The procedure will take approximately 15 minutes (the duration of the actual measurements is < 1 minute) and will not interfere with the patient's standard of care at the Stroke Unit.
1595735|NCT02266446|Behavioral|Attention & Interpretation Modification|
1595736|NCT02266433|Drug|Ketorolac|"The proposed use of ketorolac in this study is outside of the FDA-approved indication and is the investigational agent in this study
Ketorolac is a non-steroidal anti-inflammatory drug (NSAID). The approved indication for Ketorolac is for the short-term (≤5 days) management of moderately severe, acute pain that requires analgesia at the opioid level, usually in a postoperative setting. It is highly protein bound (99%) and is largely metabolized by the liver. In it's approved indication it is contraindicated for those with renal impairment, active peptic ulcer disease, pregnant or nursing females, individuals with NSAID hypersensitivity, or individuals at high risk for bleeding/clotting disorders."
1595737|NCT02266433|Drug|Dexamethasone|"Dexamethasone is a synthetic corticosteroid and possesses glucocorticoid activity, and will be used within its labeled indication for this study: intra-articular or soft tissue injection for: synovitis of osteoarthritis, epicondylitis, acute nonspecific tenosynovitis. It is the active comparator in this study.
In its approved indication there use limitations for immunocompromised individuals, pregnant females, persons with allergy to steroids, individuals with systemic fungal infections, and individuals with cerebral malaria. It is contra-indicated in systemic fungal infections, and hypersensitivity to any component of this product, including sulfites."
2009394|NCT03274804|Biological|Pembrolizumab|Eligible subjects will receive pembrolizumab beginning on Day 1 of each 3-week dosing cycle (d1, qd22)
1595739|NCT02266407|Procedure|Aquamantys System|The use of the saline-coupled bipolar sealing technology (Aquamantys® System, Medtronic Advanced Energy, LLC, Portsmouth, NH, USA) uses bipolar radiofrequency energy combined with a continuous-flow saline at the electrode tip to prevent tissue temperatures from exceeding 100 °C thus minimizing tissue charring. The temperature achieved is sufficient to induce a process called Transcollation(TM) which shrinks the collagen fibers in the walls of blood vessels, effectively sealing the blood vessels up to 1mm in diameter, resulting in the reduction of bleeding from soft tissue.
1595740|NCT02266394|Drug|Mesenchymal stem cell|Intra-arterial infusion of the single-dose MSC
1595741|NCT02266394|Procedure|Mesenchymal stem cell delivery with stent placement|Intra-arterial stent placement after Mesenchymal stem cell infusion
1595742|NCT02266381|Procedure|US-guided renal access|Patients undergo MPCNL using only US-guided renal access.
1595743|NCT02266381|Procedure|Fluoroscopy-guided renal access|Patients undergo MPCNL using only fluoroscopy-guided renal access.
1595744|NCT02266381|Procedure|US combined with fluoroscopy-guided renal access|Patients undergo MPCNL using US combined with fluoroscopy-guided renal access
1595745|NCT02266368|Device|Antimicrobeal coated stents|Patients in the intervention arm will undergo placement of (Silver Sulphdiazine) antimicrobeal coated stents
1595746|NCT02266355|Drug|Omalizumab|Omalizumab 300 mg SQ every 2 weeks
1595747|NCT02266342|Device|GORE® TAG® Thoracic Endoprostheses|Endovascular therapy to treat thoracic disease
1596264|NCT02262598|Drug|Hydrochlorthiazide (HCTZ)|
2009395|NCT03274804|Drug|Maraviroc|Maraviroc will be administered perorally on day 1 to 21 of each cycle (d1-21; qd22)
1595748|NCT02266329|Drug|prazosin hydrochloride|Prazosin as oral capsules titrated to the maximum dose or the maximum tolerated dose based on a dosing algorithm. The maximum dose to be used in this trial is 5mg in the morning and 20 mg at bedtime.
1595749|NCT02266329|Drug|placebo|Oral capsules of placebo identical in appearance to prazosin capsules titrated in the same manner as prazosin.
1595750|NCT02266316|Device|Air warming mask|Mask that warms air at the mouth
1595751|NCT02266303|Other|Insulin Start-up Checklist|The checklist is a simple A4 size, two sided, document. Eleven checklist items covering twenty-one key educational points are of the front. Images illustrating the process of using a syringe to draw up insulin from a vial as well as injection sites (for children, adults and pregnant women) are on the back.
1595752|NCT02266290|Procedure|taping of ankle sprain|All participants were taped for a lateral ankle sprain. The individual is in supine position keeping the foot and ankle in a neutral position. The strip (I) is applied with not stretch in the outside of the leg just above the ankle, and then the rest of the strip is applied on the outside of the ankle and under the heel.
1595753|NCT02266290|Device|Sport tex® kinesiotape|
1595754|NCT02266290|Device|Pretape Cramer®|
1595755|NCT02266277|Other|Arm 1: E-portal message with IVR call|Active electronic patient portal users will be randomized to receive an e-portal message and IVR calls. Both methods of outreach will provide patients with educational information about influenza vaccination, notify patients of local flu clinic schedules and elicit patient response to vaccination status and barriers.
1595756|NCT02266277|Other|Arm 2: E-portal message with no IVR call|Active electronic patient portal users will be randomized to receive only an e-portal message. The e-portal message will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
1595757|NCT02266277|Other|Arm 3: No e-portal message with IVR call|Active electronic patient portal users will be randomized to receive an IVR call. The IVR call will provide patients with educational information about influenza vaccination, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
1595758|NCT02266277|Other|Arm 5: IVR call|Non electronic patient portal users will be randomized to receive an IVR call with educational information about influenza vaccines, notification of local flu clinic schedules and elicit patient response to vaccination status and barriers.
1595759|NCT02266264|Drug|Hydrocortisone|Subjects will be divided into two groups by randomization. The intervention-group will be received 100 milligrams per day of hydrocortisone and the control-group will be received 200 milligrams per day of hydrocortisone in the first three days after enrollment.
1595760|NCT02266238|Device|DSA guided percutaneous balloon dilatation|Under the guidance of DSA, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
1595761|NCT02266238|Device|Ultrasound guided percutaneous balloon dilatation|Under the guidance of ultrasound, balloon is introduced into the stenosis area, proper pressure is given to achieve balloon dilatation to expand the narrow AVF lumen.
1595762|NCT02266238|Procedure|Surgical reconstruction|Direct surgery to reconstruction the AVF lumen.
1595763|NCT02266225|Other|Lifestyle-integrated Functional Exercise|Lifestyle-integrated functional exercise- one individual and four group-based sessions led by a physiotherapist over two months, and two phone calls one week and one month following final group-based exercise session.
1595764|NCT02266212|Procedure|5 ml arterial blood|A sample of 5 ml arterial blood will be withdraw to test the arterial blood oxygen saturation, CO2 content, carbon monoxide (CO) content and carboxyhemoglobin (COHg).
1595765|NCT02266186|Behavioral|Traditional Cognitive behavioural therapy|Therapist supported live therapy
1595766|NCT02266186|Behavioral|Internet based Cognitive behavioural therapy|Internetbased CBTwith limited therapist support
2009396|NCT03272217|Drug|Atezolizumab|Atezolizumab 1200 mg (flat dose) IV every 21 days
1595768|NCT02266160|Drug|EMLA cream 5%|"the interventional group will spread 2 grams (2 ml) of EMLA cream over the post auricular area. after 4 hours the patient will wash away the cream. the treatment will last 4 days."
1595769|NCT02266160|Other|cetomacrogol cream (lotion cream)|lotion cream that does not contain active drug. has no contraindications
1595770|NCT02266147|Drug|SD-101|
1595771|NCT02266147|Radiation|Radiation therapy|
1595772|NCT02266134|Behavioral|Tailored Implementation of Measurement Based Care|measurement based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire, the implementation of measurement based care will be tailored based on clinic specific barriers and facilitators
1595773|NCT02266134|Behavioral|Standard Implementation of Measurement Based Care|measurement based care in this study is the practice of basing psychotherapeutic services on the results of the Patient Health Questionnaire (PHQ-9), the implementation of measurement based care will be standardized such that clinicians will be encouraged to administer the PHQ-9 to depressed clients before each session
1595774|NCT02266121|Device|tDCS|Device: transcranial direct current stimulation tDCS tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
1595775|NCT02266108|Behavioral|ESTIMA Intervention|This study involves the evaluation of ESTIMA, a microfinance and gender equity intervention among women working as sex workers in Tijuana, Mexico.
1595776|NCT02266095|Device|Oval-8 Splint|Splinting with Oval-8
1595777|NCT02266095|Device|Tee Pee Splint|Splinting with Tee Pee
1595778|NCT02266095|Device|Forearm Based Splint|Splinting with Forearm based
1595779|NCT02266082|Other|No intervention|There is no intervention in this study.
1595780|NCT02266069|Other|Care Pathway for Primary Palliative Care|Early identification of palliative care patients, anticipatory care planning, systematic symptom assessment, interdisciplinary collaboration, rigorous follow-up of the functional status of the patient and giving attention to the informal care givers.
1595781|NCT02266056|Drug|Deep neuromuscular block using rocuronium and reversal with suggamadex|Deep neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
1595782|NCT02266056|Drug|Moderate neuromuscular block using rocuronium and reversal with suggamadex|Moderate neuromuscular block and moderate neuromuscular block with Esmerone and reversal with bridion
1596265|NCT02262598|Drug|Telmisartan/HCTZ fixed dose|
2009397|NCT03272217|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
1595783|NCT02266043|Device|Pre-epiglottic baton plate (PEBP)|"modified acrylic palatal plate in which a velar extension resembling a spur or baton shifts the base of the tongue forward.
This treatment is the standard care for infants with Pierre-Robin-Like Phenotype in the participating study centers and not assigned by protocol."
2009398|NCT03271632|Biological|CAR T cells|Infusion of multi-CAR T cells
1595786|NCT02266017|Behavioral|Pain Coping Skills Training|
1595787|NCT02266004|Device|Transcranial Direct Current Stimulation (tDCS)|anodal Transcranial Direct Current Stimulation (tDCS will be applied for 20 minutes at 2mA with IOMED Phoresor.
1595788|NCT02266004|Other|locomotor training|An individualized training exercise for patients with Parkinson's disease.
1595789|NCT02266004|Other|sham-tDCS|this is sham Transcranial Direct Current Stimulation (tDCS)
1595790|NCT02265991|Procedure|Fibula Explantation|surgical harvest of an osteomyocutaenous transplant consisting of a part of the fibula and surrounding soft tissues
1595791|NCT02265978|Device|CopeSmart|Participants will use the CopeSmart app at least once per day for four weeks
1595792|NCT02265965|Drug|intravenous nitroglycerin|Infusion at started at time of hysterotomy and stopped at neonate delivery
1595793|NCT02265952|Drug|REGN1500|
1595794|NCT02265939|Drug|NPO-13|
1595795|NCT02265926|Device|N95 mask|N95 mask material used to cover aperture of Hans Rudolph mask
1595796|NCT02265913|Drug|Acyclovir 5 percent (Perrigo)|
1595797|NCT02265913|Drug|Acyclovir 5 percent (Reference)|
1595798|NCT02265913|Drug|Placebo cream|
1595799|NCT02265900|Other|Exercise|Vigorous exercise
1595800|NCT02265900|Other|Exercise|Light exercise
1595801|NCT02265887|Other|standard of care|No intervention, this a patient registry and is purely an observational study
1595802|NCT02265874|Drug|Habitrol|Patch used daily for 28 weeks
1595803|NCT02265874|Drug|Placebo to Habitrol|
1595804|NCT02265861|Drug|HCG|
1595805|NCT02265848|Other|High frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver high frequency stimulation for pain relief. For our purposes, high frequency stimulation will be defined as 1000 hertz.
1595806|NCT02265848|Other|Low frequency stimulation|Implanted pulse generator of a spinal cord stimulator will programmed to deliver low frequency stimulation for pain relief. Low frequency stimulation will be defined as conventional stimulation pulse generator programming.
1595807|NCT02265835|Other|no intervention|no intervention
1595810|NCT02265809|Drug|Aldesleukin|
1595813|NCT02265783|Device|Nellcor USB Pulse Oximeter Monitor Interface Cable|Volunteers are subjected to certain simulated, sensor removal conditions known to represent challenges to the sensor-off feature. Such conditions include exposing the sensor to an ambient light source, sensor slipping off the finger with the light emitter and detector facing each other or a sensor slipping off under a blanket.
1595814|NCT02265770|Drug|16 weeks of VEC + CDDP|Days 1-36-71-106: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-36-38-71-73-106-108: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-36-71-106: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 22-57-92: Cisplatin: 80 mg/m² over 4 hours + Vincristine:1.5 mg/m² (maximal dose 2 mg) i.v.
1595815|NCT02265770|Drug|VEC + HD-MTX|Days 1-22-43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; Days 1-3-22-24-43-45: Etoposide: 100 mg/m² infused over 60 minutes; Days 1-22-43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; Days 15-36-57: Administer methotrexate at 8000 mg/m² as a 24 hour IV infusion on days 15-36-57. 10% of the dose should be given over the first hour and 90% over the remaining 23 hours. The infusion must finish at 24 hours even if it has not been completed.
1595816|NCT02265770|Drug|Chemotherapy + Valproate|"Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
Valproate: initial dose 30 mg/kg/day for two weeks in 2 divided doses (BID 15 mg/kg). Increasing weekly up to 40 - 50 - 60 mg/kg/day in 2 divided doses."
1595817|NCT02265770|Radiation|Conformal radiotherapy|Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
1595818|NCT02265770|Drug|VEC|D1: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D1-D3: Etoposide: 100 mg/m² infused over 60 minutes; D1: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D22: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D22-D24: Etoposide: 100 mg/m² infused over 60 minutes; D22: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes; D43: Vincristine: 1.5 mg/m² (maximal dose 2 mg) i.v.; D43-D45: Etoposide: 100 mg/m² infused over 60 minutes; D43: Cyclophosphamide: 3000 mg/m² in 3 divided infusions (1000 mg/m²/infusion) infused over 60 minutes
1595819|NCT02265770|Drug|Chemotherapy|Days 1-57-113-169-225-281-337: Vincristine and Carboplatin; Days 15-71-127-183-239-295-351: Vincristine and Methotrexate; Days 29-85-141-197-253-309-365: Vincristine and Cyclophosphamide; Days 43-44-99-100-154-155-211-212-267-268-323-324-379-380: Cisplatin 2-day continuous infusion.
1595820|NCT02265770|Radiation|conformal radiotherapy +/- boost|"Conformal radiotherapy: 59.4Gy (children <18 months or with risk factors: 54Gy). Daily fraction 1.8 Gy, 5 fractions / week.
In case of persistent residue : Boost of radiation 8 Gy in 2 equivalent fractions"
1595821|NCT02265757|Behavioral|Cognitive Rehabilitation|"Will provide each couple with memory compensation training 5 days per week for 2 weeks, with initial and ending adherence sessions. All sessions will involve 45- 60 minutes of training. The curriculum is described briefly here.
Learning phases. three training stages from learning theory: 1) an acquisition phase in which use of the memory compensation system is learned, 2) an application phase in which a participant is taught to apply to his/her daily life, and 3) an adaptation phase in which a participant practices incorporating into his/her daily life so as to make its use habitual."
1994871|NCT02899689|Device|Foley Catheter|Using a sterile speculum, the cervix is visualized and cleaned with iodine. Under direct visualization, a Foley catheter is inserted into the cervix and the balloon is filled with 60 ml of sterile 0.9% NaCl.
1994872|NCT02900209|Other|Influenza Vaccination|
1595822|NCT02265757|Behavioral|Computer Brain Fitness Training|Will use the commercially available Posit Science product BrainHQ™ (www.brainhq.com) on tablets (e.g. iPads). Participants will complete 45-60 minutes of training daily in the program and will be encouraged to maintain 250 minutes of computerized brain training per week for 18 months post program. Each participant's adherence and progress will be tracked through the clinician portal provided by Posit Science both during HABIT and for 18 months post-program.
1595823|NCT02265757|Behavioral|Support Group (patient and partner)|Patient: The patient support group will meet for 45-60 minutes daily. It will use the LifeBio Memory Journal© as a basis for reminiscence-focused group sessions. Partner: The care partner support group meets separately from the patient group for 45-60 minutes daily.
1595824|NCT02265757|Behavioral|Wellness Education|The education component will involve daily 60-minute group sessions with topics including Introduction to the Program, Living with MCI, Changes in Roles, Communication and Relationships, Sleep Hygiene, Steps to Healthy Brain Aging, Preventing Dementia, MCI and Depression, Nutrition and Exercise, Safety and Assistive Technologies, and Participating in Research, Community Resources, Meaning and Purpose, and Joy.
1595825|NCT02265757|Behavioral|Physical Exercise|The HABIT physical exercise intervention is intended to initiate and sustain a schedule rather than a type of physical activity. HABIT will provide a customized DVD as a supplement for continued use and practice after the program to those that opt to continue yoga. Will use an activity log completed by the partner to track activity level of the participants during the 18 month follow-up period.
1595826|NCT02265744|Drug|BMS-931699|
1595827|NCT02265744|Drug|Placebo matching BMS-931699|
1595832|NCT02265718|Drug|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
1595833|NCT02265718|Drug|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
1595834|NCT02265718|Drug|Ritalin|1 - 20 mg tablet taken once on Day 0 and taken once on Day 28
1595835|NCT02265718|Drug|Placebo|1 - matching tablet taken once on Day 0 and once on Day 28
1595836|NCT02265705|Drug|Baricitinib|Administered orally
1595837|NCT02265705|Drug|Placebo|Administered orally
1595838|NCT02265679|Drug|BIIL 284 BS, low dose, pediatric patients|
1595839|NCT02265679|Drug|BIIL 284 BS, medium dose, pediatric patients|
1595840|NCT02265679|Drug|BIIL 284 BS, high dose, pediatric patients|
1595841|NCT02265679|Drug|BIIL 284 BS, low dose, adult patients|
1595842|NCT02265679|Drug|BIIL 284 BS, medium dose, adult patients|
1595843|NCT02265679|Drug|BIIL 284 BS, high dose, adult patients|
1595844|NCT02265679|Drug|Placebo|
1595845|NCT02265666|Drug|BIIL 284 BS Tablet FF|
1595846|NCT02265666|Drug|BIIL 284 BS tablet C|
1595847|NCT02265666|Other|standard breakfast|
1595848|NCT02265653|Drug|BIIL 284 BS tablet C|
1595849|NCT02265653|Drug|BIIL 284 BS tablet D|
1595850|NCT02265653|Drug|BIIL 284 BS WIF tablet|
1595851|NCT02265640|Drug|BIIL 284 BS boli|
1595852|NCT02265640|Drug|BIIL 284 BS tablet C|
1595853|NCT02265640|Other|standard breakfast|
1595854|NCT02265627|Drug|BIIL 284 BS|
1595855|NCT02265614|Genetic|PGS|
1595856|NCT02265601|Other|computer-based decision aid|Offers tailored education, values clarification exercises, and a sophisticated decision aid that translates an individual's goals and preferences into a specific medical plan that can be implemented by a health care team.
1595857|NCT02265601|Other|standard care|paper/pencil living will form
1595858|NCT02265588|Behavioral|Cognitive behavioral therapy|A disease specific cognitive behavioral therapy program called PASCET-PI: The PASCET-PI model focuses on behavioral activation, cognitive restructuring and problem solving skills to change maladaptive behaviors, cognitions and coping strategies specific for IBD.
1595859|NCT02265575|Drug|Hyaluronic Acid|rehydration using hyaluronidase-assisted subcutaneous infusion
1595860|NCT02265562|Drug|Misoprostol|60 minutes before the surgery 400 μg of misoprostol (2 tablets of 200 μg) inserted rectally
1595861|NCT02265562|Drug|Placebo|60 minutes before the surgery 2 tablet of placebo inserted rectally
1595863|NCT02265523|Other|Cycle ergometer|The Viscus V1.5 is a kinetic flywheel cycle ergometer that will allow participants' pedal revolutions to be tracked as well as time of use.
1595864|NCT02265510|Drug|INCB052793|Initial cohort dose of INCB052793 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria.
1595865|NCT02265510|Drug|gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency.
1595866|NCT02265510|Drug|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency.
1595867|NCT02265510|Drug|dexamethasone|Dexamethasone administered orally at the protocol-specified dose and frequency.
1595868|NCT02265510|Drug|Carfilzomib|Carfilzomib administered intravenously at the protocol-specified dose and frequency.
1595869|NCT02265510|Drug|bortezomib|Bortezomib administered intravenously or subcutaneously at the protocol-specified dose and frequency.
1595870|NCT02265510|Drug|lenalidomide|Lenalidomide administered orally at the protocol-specified dose and frequency.
1595871|NCT02265510|Drug|azacitidine|Azacitidine administered subcutaneously at the protocol-specified dose and frequency.
1595872|NCT02265510|Drug|INCB052793|INCB052793 tablets administered orally at the protocol specified dose strength and frequency.
1595873|NCT02265510|Drug|pomalidomide|Pomalidomide administered orally at the protocol-specified dose and frequency.
1595874|NCT02265510|Drug|INCB050465|INCB050465 tablets administered orally at the protocol specified dose strength and frequency.
1595875|NCT02265510|Drug|INCB039110|INCB039110 tablets administered orally at the protocol specified dose strength and frequency.
1595876|NCT02265484|Drug|Lactulose+Rifaximin +Bromocriptine|
1596266|NCT02262585|Drug|BIBR 277 tablet|
1595877|NCT02265458|Behavioral|Musical intervention and sensory isolation|30 minutes musical intervention during NIV will be administrated, along with sensory isolation (mask obscuring the eyes)
1595878|NCT02265445|Drug|Deescalation therapy|Intravenous therapy Switch for a narrow spectrum beta-lactam active on the causative ESBL-PE.
1595879|NCT02265445|Drug|Maintaining carbapenem therapy|Intravenous therapy, Maintaining carbapenem therapy
1595880|NCT02265432|Behavioral|General physical activity educational materials|
1595881|NCT02265432|Device|Wearable activity tracking devices (fitbit)|
1595882|NCT02265432|Other|online map|
1595883|NCT02265432|Other|Personalized text messages|
1595884|NCT02265419|Device|Extracorporeal treatment with the Cytosorb adsorber|The extracorporeal treatment with the Cytosorb-Adsorber will be started 6 hours after heart surgery operation, the extracorporeal treatment duration will be 24 hours and the observation time 90 days.
2009399|NCT03270462|Drug|Envarsus XR|Pilot study documenting the neurotoxic side effects including tremors in patients with stable graft who are receiving Tacrolimus (Envarsus XR) following kidney transplantation. Standardized questionnaire will be used to document these symptoms.
2009400|NCT03269669|Drug|Cyclophosphamide|Given IV
1595887|NCT02265393|Drug|OTO-104|
1595888|NCT02265393|Drug|Placebo|
1595889|NCT02265380|Device|Placement of IV catheter|
1595890|NCT02265367|Drug|Levomilnacipran|
1595891|NCT02265367|Drug|Placebo|
1595892|NCT02265354|Behavioral|Collective-Intelligence computer tailored health communication|
1595893|NCT02265354|Behavioral|Rule-based computer tailored health communication|
1595894|NCT02265341|Other|Laboratory Biomarker Analysis|Correlative studies
1595895|NCT02265341|Drug|Ponatinib Hydrochloride|Given PO
1595896|NCT02265341|Other|Quality-of-Life Assessment|Ancillary studies
1595897|NCT02265328|Dietary Supplement|Bovine colostrum|Oral Bovine colostrum 200 ml (20 gram) TDS × 2 months
1595898|NCT02265328|Dietary Supplement|Enteral Nutrition|Enteral nutrition: Protein 1.5 gm/kg/day, energy (kcal) 40/kg/day, carbohydrate 67-80%, Fat 20-33%.
1595899|NCT02265328|Other|prednisolone|Oral prednisolone 40mg/day × 4 weeks and tapered to <40mg/day for next 4 weeks. (If Lilli score > 0.45 after 7 days, then prednisolone would be stopped)
1595900|NCT02265315|Other|Transcranial Magnetic Stimulation|Treament adjuvant applied to accelerate vocal motor learning and overall voice improvement
1595901|NCT02265315|Behavioral|Lee Silverman Voice Treatment|Time intensive behavioral treatment for Parkinson's hypophonia
1595902|NCT02265302|Drug|BIIL 284 oral solution|
1595903|NCT02265302|Drug|BIIL 284 wetability improved formulation (WIF) tablets|
1595904|NCT02265302|Drug|Placebo|
1595905|NCT02265289|Drug|Lefradafiban|
1595906|NCT02265289|Drug|Clopidogrel|
1595907|NCT02265276|Drug|Saroglitazar|Tab Saroglitazar 4 mg oral daily for 24 weeks
1595908|NCT02265276|Drug|Pioglitazone|Tab Pioglitazone 30 mg oral daily for 24 weeks
1595909|NCT02265250|Other|MRI|Noncontrast T1- and T2-weighted 3.0 T MRI of the bilateral carotid, coronary, and superficial femoral arteries
1595910|NCT02265250|Other|PET/MRI|Simultaneous 18F-NaF PET/MRI of the bilateral carotid, coronary, and superficial femoral arteries
1595911|NCT02265250|Other|Laboratory blood test|Cardiovascular biomarkers
1595912|NCT02265237|Drug|ombitasvir/paritaprevir/ritonavir|tablets
1595913|NCT02265237|Drug|ribavirin|tablets
1595914|NCT02265224|Drug|Acetylcysteine|
1595915|NCT02265211|Behavioral|Self-Help App|
1595916|NCT02265172|Procedure|Physiotherapy screening|Physiotherapy screening.
1595917|NCT02265172|Procedure|Standard practice|Orthopaedic surgeon assessment
1595918|NCT02265159|Procedure|Focal Therapy Using High Intensity Focused Ultrasound|
1595919|NCT02265120|Behavioral|Questionnaire|The Questionnaire aims to evaluate based on the responses if providers don't uniformly agree with the new guidelines, if they can't interpret them correctly, and or if they have personal biases towards the older guidelines based upon prior training, personal experience, financial incentives, etc.
1595920|NCT02265107|Other|exercise training|The program of exercise training (ET) was employed for 6 consecutive months with 3 sessions per week. The training of physical activity consisted of a combination of aerobic and resistance exercises for upper and lower limbs. Each session included: (1) 5-minute warm-up, (2) 30 minutes of aerobic exercise (performed in treadmills and stationary bikes); (3) 20 minutes of resistance exercises with dumbbells for upper limbs and ankle support for lower limbs (exercises preformed in diagonals) that consisted of 6 sets of 10 resistance exercises repeated for upper limbs, and the same number of sets for lower limbs; and (4) 5-minute cool-down, totaling ninety minutes of session per day (90min/day) and, two hundred and seventy minutes per week (270min/week).
1595921|NCT02265094|Other|Electroencephalography|EEG recordings during memory tests
1595922|NCT02265094|Behavioral|Neuropsychological assessment|patterns of eye gaze during cognitive tests
1595923|NCT02265081|Procedure|ultrasound|pelvic floor ultrasound
1595924|NCT02265081|Procedure|uroflow-meter|uroflow meter: measurement of passed urine volume
1595925|NCT02265068|Drug|Ticagrelor|Treatment of ACS patients with Ticagrelor
1595926|NCT02265055|Procedure|transfer early cleavage embryos|transfer early cleavage embryos
1595927|NCT02265055|Procedure|transfer non early cleavage embryo|
1595928|NCT02265042|Device|Stimulette|electrical stimulation device by Dr. Schuhfried Medizintechnik GmbH, Vienna, Austria
1595929|NCT02265029|Other|Immediate spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
1595930|NCT02265029|Other|Late spa treatment|spa treatment in rheumatology with sedative and antalgique techniques and mobilizing techniques (rehabilitation in pool)
2009401|NCT03269669|Drug|Doxorubicin Hydrochloride|Given IV
1595936|NCT02264977|Device|Branched TAG® Device|
1595937|NCT02264964|Device|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in femoral vein.
1595938|NCT02264964|Procedure|Arteriovenous fistula creation|500 patients will undergo AVF creation in either arm for femoral vein catheterization group.
1595939|NCT02264964|Device|GamCath®|Using non-cuff GamCath® catheter in patients with chronic renal failure requiring hemodialysis to building short-term vascular access in right internal jugular vein.
1595940|NCT02264964|Procedure|Arteriovenous fistula creation|900 patients will undergo AVF creation in left arm for internal jugular vein catheterization group.
1595941|NCT02264951|Dietary Supplement|Tributyrin|a triglyceride containing three C4-acids
1595942|NCT02264951|Dietary Supplement|C8-diet oil|a triglyceride containing 2 C8-fatty acids and one oleic acid at sn-2 position
1595943|NCT02264951|Dietary Supplement|Olive oil|a triglyceride containing mostly three oleic acids
1595944|NCT02264951|Dietary Supplement|Carrot|mainly water and glucose
1595945|NCT02264938|Dietary Supplement|Antioxidant|Oral supplemmentation with antioxidants
1595946|NCT02264925|Device|Deep Brain Stimulation with Medtronic Activa PC+S systems|Deep Brain Stimulation of VIM.
1595947|NCT02264912|Drug|antiplatelet drugs - P2Y12 antagonists|
1595948|NCT02264899|Other|in Memento-VASCOD|"Pulse wave velocity assessment
Cerebral MRI including Arterial Spin Labeling (ASL) and Magnetic Resonance Angiography (MRA) sequences
Ophthalmological exams: Spectral Domain-Optical Coherence Tomography (SD-OCT), colour photographs of the retina, visual acuity and axial lenght measurement
Neuropsychological testing and behaviorial and mood scales
Urinary albumin excretion measurement"
1595949|NCT02264886|Radiation|MRI-guided stereotactive body radiation therapy|
1595950|NCT02264873|Drug|Decitabine|Dose escalation starting at 5 mg, and increasing by 2.5 mg to a Dose Level of 12.5 mg qd x 3 days.
2009402|NCT03269669|Other|Laboratory Biomarker Analysis|Correlative studies
1595952|NCT02264847|Drug|Human chorionic gonadotrophin|Once a follicle reached more than 18 mm in size,women assigned to group (1) received 5,000 IU hCG trigger in the morning between 9 and 10 a.m. and the couple were advised to have intercourse the following night, about 36 hours later.
1595953|NCT02264847|Drug|clomiphene citrate alone|clomiphene citrate alone without hCG trigger
1595954|NCT02264834|Drug|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml|Levobupivacaine 0.1% + Sufentanil 0.2µg/ml
1595955|NCT02264834|Drug|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml|Levobupivacaine 0.07% + Sufentanil 0.3µg/ml
1595956|NCT02264834|Procedure|Lumbar epidural analgesia|Introduction of a catheter in lumbar epidural space
1595957|NCT02264821|Drug|ropivacaine infiltration|wound infiltration
1595958|NCT02264821|Drug|intrathecal morphine|100 µg added to the spinal anaesthesia
1595959|NCT02264821|Drug|placebo|placebo in spinal anaesthesia and in wound infiltration
1595960|NCT02264808|Other|Developmental Outcomes|A Bayley-III developmental assessment will be performed study subjects at age 18-20 months
1595961|NCT02264795|Drug|Lidocaine|Lidocaine 2% with epinephrine 5mcg/ml
1595962|NCT02264795|Drug|Placebo|0.9% Sodium Chloride Solution
1595963|NCT02264782|Behavioral|PreView, the Video Doctor Plus Provider Alert|"PRE-VIEW is a multimedia program utilizing laptop computers to assess whether or not primary care patients are up to date with cancer screening, assess their stage of change and personal barriers to screening. The Video Doctor, portrayed by an actor, delivers brief, individually tailored stage and barrier specific messages that simulate the ideal physician-patient cancer screening conversation, using a library of digital video clips and complex branching logic. The program then provides the individualized information to the patient's physician in the form of a cue sheet or Provider Alert."
1595964|NCT02264782|Behavioral|Healthy Lifestyles|Individuals in the Control Group will watch a video about healthy lifestyles, including information about exercise and healthy eating. This video was obtained from the Patient Education Institute. There will be no Provider Alert generated for participants in the control group.
1595965|NCT02264769|Drug|Carbetocin|
1595966|NCT02264756|Other|ASP review|patients admitted to hospital with a diagnosis of community-acquired pneumonia will be reviewed by team members of antimicrobial stewardship program and subsequently feedback to attending physicians will be offered in the form of recommendations for antibiotic management
1595967|NCT02264743|Drug|Femoston Conti|Ultra-low-dose oral E2/D [Oestradiol 17β 0.5mg/dydrogesterone 2.5 mg] oral Femoston Conti 0.5mg Estradiol&Dydrogesterone vs Oestradiol&Norethisterone acetate
1595968|NCT02264743|Drug|EVOREL® CONTI|Trans-dermal Estradiol 25mcg/norethisterone acetate 85 mcg 1/2 an Evorel Conti patch
1595969|NCT02264730|Drug|ClotFoam|Patient has not received blood products between screenings
1595970|NCT02264717|Procedure|SPECT|Patients are randomized to either SPECT or Cardiac MRI
1595971|NCT02264717|Procedure|Cardiac MRI|Patients are randomized to either SPECT or Cardiac MR
1595972|NCT02264704|Other|High intensity exericse|Participants will exercise at high intensity (70% VO2 peak) intermittently (30 seconds on, 30 seconds off) for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
1595973|NCT02264704|Other|Moderate intensity exericse|Participants exercise at moderate intensity (35% VO2 peak) continuously for 15 minutes, twice weekly for 15 weeks. Workload may increase as the study progresses based on heart rate response.
2009403|NCT03269669|Drug|Lenalidomide|Given PO
2009404|NCT03269669|Biological|Obinutuzumab|Given IV
2009405|NCT03269669|Drug|PI3K-delta Inhibitor TGR-1202|Given PO
1596267|NCT02262585|Drug|BIBR 277 capsule|
1596268|NCT02262572|Drug|Telmisartan /HCTZ - compression tablet (DC)|
2009406|NCT03269669|Drug|Prednisone|Given PO
2009407|NCT03269669|Drug|Vincristine Sulfate|Given IV
2009408|NCT03269136|Drug|PF-06863135|PF 06863135 will be administered intravenously. Increases in dose will continue until MTD is determined.
2009409|NCT03267576|Drug|Canagliflozin 300 mg|Participants will receive canagliflozin 300 mg oral tablet once-daily for 28 days.
2009410|NCT03267576|Drug|Sitagliptin 100 mg|Participants will receive sitagliptin 100 mg oral tablet once-daily for 28 days.
2009411|NCT03267576|Drug|Metformin|Participants will receive metformin at a stable dose of >= 1500 mg/day throughout the study including the washout period between each intervention.
2009412|NCT03267498|Drug|Nivolumab|Dosage 240mg of Nivolumab will be given intravenously over 60 minutes, every 14 days.
2009413|NCT03267498|Drug|Cisplatin|Dosage 40 mg/m2 of cisplatin will be given intravenously over 30-60 minutes, every 7 days.
2009414|NCT03267498|Radiation|Radiation Therapy|2.12 Gy/fraction x 33 fractions of radiation therapy will be given, daily Monday - Friday
2009415|NCT03266588|Drug|Rimegepant|75 mg oral tablet
1595978|NCT02264665|Drug|sunitinib|sunitinib 37.5mg/d orally
1595979|NCT02264665|Drug|everolimus|everolimus 10mg/d orally
1595980|NCT02264665|Drug|chemotherapies recommended in france|depends on the chemotherapy prescribed (IV)
1595981|NCT02264652|Device|HD Transcranial Direct Stimulation|Genuine cathodal HD-tDCS will be delivered through High Definition electrodes that will be arranged on the skull according to a 4x1 ring configuration.
1595982|NCT02264639|Drug|APL-2|
1595983|NCT02264626|Drug|Remifentanil|infusion at a rate by 0.025 μg kg-1 min-1 every minute to a maximum of 0.15 μg kg-1 min-1.
1595984|NCT02264613|Drug|ALRN-6924|ALRN-6924 will be administered as an IV infusion
1595985|NCT02264587|Drug|Mosapride|Mosapride 5mg by mouth ,3 times one day for 1 4days.
1595986|NCT02264587|Drug|domperidone|Domperidone 10mg by mouth ,3 times one day for 1 4days.
1595987|NCT02264574|Drug|Ibrutinib|Ibrutinib will be supplied as 140 mg hard gelatin capsules for oral (PO) administration.
1595988|NCT02264574|Drug|Obinutuzumab|Obinutuzumab will be supplied as 1000 mg/40 mL solution in a single-use vial for intravenous (IV) administration
1595989|NCT02264574|Drug|Chlorambucil|Chlorambucil will be supplied as 2 mg film-coated tablets for oral (PO) administration
1595990|NCT02264561|Other|Food|Active group
1595991|NCT02264561|Other|Food|Control group
1595992|NCT02264548|Radiation|Radio-Ablation|Level I 20Gy/5 Level II 25Gy/5 Level III 30Gy/5 Level IV 35Gy/5 Level V 40Gy/5
1595993|NCT02264535|Drug|0.1mg/ml Ginkgolides Meglumine Injection|
1595994|NCT02264535|Drug|1mg/ml Ginkgolides Meglumine Injection|
1595995|NCT02264535|Drug|5mg/ml Ginkgolides Meglumine Injection|
1595996|NCT02264522|Other|Place dialysis chair into position 3.|Upon device notification event 1, place patient in dialysis chair position 3.
1595997|NCT02264522|Other|Decrease dialysate temperature.|Upon device notification event 2, decrease dialysate temperature by 0.5 degree centigrade.
1595998|NCT02264522|Other|Decrease ultrafiltration rate by 25%.|Upon device notification event 3, decrease ultrafiltration rate by 25% from baseline ultrafiltration rate.
1595999|NCT02264522|Other|Decrease ultrafiltration rate by 50%.|Upon device notification event 4, decrease ultrafiltration rate by 50% from baseline ultrafiltration rate.
1596000|NCT02264509|Procedure|Ankle-Brachial index|The only procedure to be performed is the measurement of ABI for the diagnosis of arterial insufficiency.
1596001|NCT02264496|Behavioral|Exercise|
1596002|NCT02264470|Other|Not relevant|Not relevant
1596003|NCT02264457|Device|T-flex Aspheric Toric IOL|
1596004|NCT02264457|Device|AT TORBI toric IOL|
1596005|NCT02264444|Other|Cholecystectomy visualization|Patients undergo a standard removal of the gallbladder through a single incision at the umbilicus will have their operation recorded and graded according to a scale that is established for this study.
1596006|NCT02264418|Drug|ODM 203|ODM 203
1596007|NCT02264418|Drug|ODM 203|ODM 203
1596008|NCT02264405|Procedure|Autologous HSCT|1st AHSCT
1596009|NCT02264392|Procedure|Ultrasound Guided Incision and Drainage|Ultrasound guidance of the abscess drainage
1596010|NCT02264392|Procedure|Blind Incision and Drainage|Incision and drainage of abscess guided by physical exam alone
1596011|NCT02264379|Radiation|normal fractionated irradiation|25*2 Gy (once a day, 5 days a week)
1596012|NCT02264379|Radiation|hypo fractionated irradiation|3*10 Gy (once a day, 2-3 days a week)
1596013|NCT02264366|Behavioral|Motivational Communication for Health Behavior management|"An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006)."
1596016|NCT02264340|Behavioral|Relaxation technique Autogenic Training|Autogenic Training
1596017|NCT02264340|Behavioral|Combined treatment Autogenic Training + Cervical exercises and postural correction|Autogenic Training + Cervical exercises and postural correction
2009416|NCT03265249|Device|BRIDGE device|an externally placed, FDA-cleared device that delivers percutaneous electrical stimulation with alternating frequencies to branches of cranial nerves (V, VII, IX, and X) through the external ear via a field effect
2009417|NCT03263858|Device|Stent|Implantation of coronary stent in de novo coronary artery lesions
1994875|NCT02898506|Drug|Victoza®|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
1994876|NCT02898506|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months and thereafter follow-up of 6 months.
1994877|NCT02898584|Other|BP Track|
1994878|NCT02897739|Procedure|Magnetic resonance imaging|Cardiac MRI and short MRI following USPIO infusion
1994879|NCT02897739|Biological|Acute Inflammatory Activation study|Blood sampling for exploration of type and level of inflammatory response
1994880|NCT02897739|Radiation|PET CT|PET study for metabolic pathway study
1994881|NCT02897739|Behavioral|Psychological assessment|Assessment by a psychologist
1994882|NCT02898454|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution
Route of administration: Subcutaneous"
1994883|NCT02898454|Drug|Placebo|"Pharmaceutical form: Solution
Route of administration: Subcutaneous"
2009418|NCT03263338|Behavioral|Mobile Sleep and Growth Study|The intervention is designed to test if sleep tips delivered by text messages can aid with reaching time in bed targets. And if additional motivational text messages can further aide with reaching time in bed targets.
1596021|NCT02264314|Behavioral|Active Communication Education Program|A behavioral intervention aimed to improve the adherence to the hearing aid in older adults with hearing loss
1596022|NCT02264314|Other|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
1596023|NCT02264301|Drug|Puerarin injection 400 mg|
1596024|NCT02264301|Drug|Qingkailing injection 40 ml|
1596025|NCT02264288|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
1596026|NCT02264288|Biological|10 x 10^6 cells|10 x 10^6 Human Placenta Derived cells (PDA-002) administered on Study Days 1 and 8
1596027|NCT02264288|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
1596028|NCT02264288|Other|Placebo|Identical matching placebo administered IM on Study Days 1 and 8
1596029|NCT02264275|Behavioral|Aerobic Exercise Training|The aerobic exercise training uses a television attached to a Nintendo Wii videogame console with a dance game to be played by participants on 5 days per week using a ramped-duration schedule (from 10-30 minutes of moderate physical activity daily).
1596030|NCT02264262|Other|Physiologic maneuvers|Subjects will perform cold pressor test, valsalva maneuver, hand grip and post-exercise occlusion in a controlled research environment
1596031|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy split dose prep|"Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive the Split dose colonoscopy prep
split dose colonoscopy preparation- ½ evening before and ½ early AM (4L volume or 2L volume bowel preparation)"
1596032|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy Evening before colonoscopy prep|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Evening before (4L, 2L or miralax bowel preparation)
1596033|NCT02264249|Other|Esophagogastroduodenoscopy and colonoscopy Same day prep colonoscopy preparation|Patients undergoing a combined EGD (esophagogastroduodenoscopy) and a colonoscopy receive Same day prep (4L volume or 2L volume or Miralax bowel preparation)
1596034|NCT02264236|Biological|P10s-PADRE vaccine|P10s-PADRE vaccine combined with MONTANIDE™ ISA 51 VG Subcutaneous injection at weeks 1, 2, 3, and 8
1596035|NCT02264236|Biological|Placebo|Subcutaneous injection at weeks 1, 2, 3, and 8
1596036|NCT02264223|Dietary Supplement|Fermented red clover isoflavones in aglycone form|Fermented isoflavones in aglycone form
1596037|NCT02264223|Dietary Supplement|Unfermented glycosides (as aglycone equivalents)|Unfermented aglycone equivalents in glycoside form
2009419|NCT03261167|Drug|Botulinum toxin A (GSK1358820)|GSK1358820 is sterile, purified type A botulinum neurotoxin complex. GSK1358820 injection will contain botulinum toxin A (100 units), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). It will be available with doses of 400 units and 240 units.
1596039|NCT02264197|Drug|BIBX 245 CL - fed|
1596040|NCT02264197|Drug|BIBX 245 CL- fasted|
1596041|NCT02264184|Drug|Tamsulosin|
1596042|NCT02264184|Drug|Paroxetine|
1596043|NCT02264171|Drug|Tamsulosin HCl|
1596044|NCT02264171|Drug|Ketoconazole|
1596045|NCT02264158|Drug|Telmisartan high|
1596046|NCT02264158|Drug|Telmisartan low|
1596047|NCT02264158|Drug|Lacidipine high|
1596048|NCT02264158|Drug|Lacidipine low|
1596049|NCT02264158|Drug|Placebo|
1596050|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - low|
1596051|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - medium|
1596052|NCT02264145|Drug|Ethanolic Solution From HFA134a-MDI - high|
1596053|NCT02264145|Drug|Ethanolic Solution From Respimat®|
1596054|NCT02264132|Drug|Pramipexole ER tablet|
1596055|NCT02264132|Drug|Pramipexole IR tablet|
1596056|NCT02264119|Drug|Lefradafiban tablet|
1596057|NCT02264119|Drug|Pantoprazole tablet|
1596058|NCT02264119|Device|Lefradafiban double chamber sachet|
1596059|NCT02264106|Drug|Lefradafiban tablet|
1596060|NCT02264106|Drug|Lefradafiban double chamber sachet|
1596061|NCT02264106|Drug|Pantoprazole|
1596062|NCT02264093|Drug|Propranolol|
1596063|NCT02264093|Drug|Talsaclidine|
1596064|NCT02264080|Drug|WAL2014|
1596065|NCT02264080|Drug|Placebo|
1596066|NCT02264067|Drug|Talsaclidine|
1596067|NCT02264067|Drug|Placebo|
1596068|NCT02264054|Drug|[14C]talsaclidine, oral|
1596069|NCT02264054|Drug|[14C]talsaclidine, iv|
1596070|NCT02264041|Drug|Cilobradine, low dose|
1596071|NCT02264041|Drug|Cilobradine, high dose|
1596072|NCT02264041|Drug|Itraconazole|
1596073|NCT02264028|Drug|[14C]-DK-AH 269 CL, solution for infusion|
1596074|NCT02264028|Drug|[14C]-DK-AH 269 CL, drinking solution|
1596075|NCT02264015|Drug|Cilobradine, low, film-coated tablets|
1596076|NCT02264015|Drug|Cilobradine, high, film-coated tablets|
1596077|NCT02264015|Drug|Placebo, film-coated tablets|
1596078|NCT02264015|Drug|Moxifloxacin, film-coated tablets|
1596079|NCT02264002|Drug|Cilobradine low dose 1|
1596080|NCT02264002|Drug|Cilobradine low dose 2|
1596081|NCT02264002|Drug|Cilobradine medium dose|
1596082|NCT02264002|Drug|Cilobradine high dose 1|
1596083|NCT02264002|Drug|Cilobradine high dose 2|
1596084|NCT02264002|Drug|Metoprolol succinate tablets|
1596085|NCT02264002|Drug|Placebo|
1596086|NCT02263989|Drug|Telmisartan film coated tablet|
1596087|NCT02263989|Drug|Telmisartan conventional tablet|
1596088|NCT02263976|Drug|BEA 2180 BR|
1596089|NCT02263976|Drug|Placebo|
1596090|NCT02263976|Device|Respimat® A 4|
1596091|NCT02263976|Drug|Methacholine Chloride|methacholine challenge test
1596092|NCT02263976|Drug|Spiriva|
1596095|NCT02263950|Drug|Artemether|Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
1596096|NCT02263937|Procedure|Bilateral Nucleus Basalis Meynert DBS|Low frequency stimulation applied using standard Deep brain stimualtion hardware.
1596097|NCT02263937|Procedure|Sham Nucleus Basalis Meynert DBS|DBS system switched off.
1596098|NCT02263924|Dietary Supplement|Tocotrienol|Subjects in the intervention arm will take one capsule of 200mg tocotrienol twice daily for 6 months
1596099|NCT02263924|Dietary Supplement|Placebo capsules|Subjects in the placebo arm will take one capsule of placebo twice daily for 6 months
1596100|NCT02263911|Drug|Baricitinib|Administered orally
1596101|NCT02263898|Drug|Raf kinase inhibitor LGX818|Given PO
1596102|NCT02263898|Drug|binimetinib|Given PO
1596103|NCT02263898|Other|laboratory biomarker analysis|Correlative studies
1596104|NCT02263885|Device|ExAblate Transcranial System|Transcranial MRgFUS
1596105|NCT02263872|Drug|Minocycline|Minocycline 200mg perday
1596106|NCT02263859|Device|aura6000 System|The aura6000 System is intended to unilaterally stimulate the hypoglossal nerve which innervates the muscles of the tongue. The aura6000 System stimulates the hypoglossal nerve cyclically and continuously during sleep to maintain muscle tone of the tongue and upper airway during sleep. Stimulation is generated by a programmable, multi-current source, implantable neurostimulator (IPG) and delivered to the hypoglossal nerve by a lead with multi-contact cuff electrode (lead).
1596107|NCT02263833|Drug|Mircera|Participants received Mircera according to individualized physician-prescribed regimen.
1596108|NCT02263807|Procedure|Arthroscopy and MPFL-surgery|MPFL reconstruction or standard treatment follewed by physiotherapy
1596109|NCT02263807|Procedure|Rehabilitation|Arthroscopy followed by active rehabilitation
1596110|NCT02263794|Procedure|Conventional Bronchial Thermoplasty|Conventional bronchial thermoplasty is performed during three bronchoscopy sessions each separated by approximately three weeks.
1596111|NCT02263794|Procedure|Image Guided Bronchial Thermoplasty|Patient-specific bronchial thermoplasty based on imaging data will be performed during one bronchoscopy session.
1596112|NCT02263781|Procedure|Blood draw|Blood draw
1596113|NCT02263781|Procedure|muscle biopsy|Muscle biopsy during planned anesthesia/surgery
1596114|NCT02263768|Procedure|Oral clinical conditions|Caries incidence assessment dental anxiety assessment oral health related quality of life assessment time and costs assessment
1596115|NCT02263742|Behavioral|Peer whole health intervention|Provide wraparound peer support, education, and navigation to individuals
1596116|NCT02263742|Behavioral|EBPs at Wellness Center|four EBPs: a) on-site primary care; b) screening of clients for modifiable risk factors and medical conditions; c) care coordination; and d) peer health navigation
1596117|NCT02263729|Drug|Losartan|
1596118|NCT02263729|Drug|placebo|
1596119|NCT02263703|Biological|Quadrivalent HPV vaccine|Three 0.5 mL doses will be given at time 0, 2 months after the 1st dose and then 6 months after the initial dose. For kidney transplant recipients the first dose will be at least 6 months post-transplant.
1596120|NCT02263690|Procedure|Group Drops|The patients in the group Drops received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. The patients in the group Drops received a second drop of proparacaine 0.5% 5 minutes after the drop of povidone iodide 5%
1596121|NCT02263690|Procedure|Group SC|The patients in the group SC received a drop of proparacaine 0.5% before receiving a peri-ocular drop of povidone iodide 5%. In the patients in the group SC, a subconjunctival bleb of anesthesia was created by injecting 0,4 mL of lidocaine 1% into the subconjunctival space 4 mm posterior to the superotemporal limbus with a 30-gauge, 1/2-inch needle attached to a 1-mL syringe.
1596122|NCT02263690|Procedure|Group gel|For the patients in group gel, the gel was placed on the eye before receiving the peri-ocular drop of povidone iodide 5%.
1596123|NCT02263677|Drug|Sitagliptin|60 day supply of 100mg Sitagliptin. The investigators will use an MRS (a non invasive method using magnets) to evaluate liver fat before and after subjects take a diabetes medication. The investigators will also collect a small amount of blood to measure liver, kidney and hormone functions. This will be done 4 times. Also, at the time of the subject gets their first dose of medication they will have a DEXA (low exposure x-ray often used in clinical practice to measure bone density and body composition).
1596124|NCT02263651|Procedure|Quilting suture without drainage|"In an attempt to obliterate the dead space, the skin flaps are sutured to the underlying pectoralis major with multiple parallel rows of 0/0 vicryl (or equivalent). Running sutures at periodic intervals (<2cm) are placed from the skin flaps to the underlying muscle. Minor dimpling is considered acceptable and is expected to resolve. If severe dimpling is observed, stitches are removed and replaced.
Efficiency of quilting suture relies on a rigorous repartition of the sutures with a special attention taken to the obliteration of the largest potential dead spaces and the empty axillary apex.
The skin edges are sutured as stated before for the control group. Closed suction will not be used for draining the pectoral area."
1596125|NCT02263651|Procedure|Conventional closure with drainage|"The skin flaps are not fixed subcutaneously but sutured at the edges, a closed suction drain is inserted under the flaps in the dead space created by the dissection at the pectoral area. The drain is stitched to the skin.
The skin is closed in two layers with absorbable sutures, a deep layer of 2.0 or 3.0 vicryl sutures or equivalent, and a subcuticular closure with absorbable 3.0 or 4.0 Monocryl sutures or equivalent."
1596126|NCT02263638|Drug|Anakinra|One daily subcutaneous injection of a fixed dose of 100 mg will be administered at a fixed time during a five day period
1596127|NCT02263586|Behavioral|Education in nutrition|Athletes were given a 45 min lesson on the proper diet and fluid intake to prevent hyponatremia in long-distance triathlon.
1596128|NCT02263573|Other|PEP'C-R|"Preliminary session of calibration and tolerance: Test of Borg: determination of VT1 for 10 minutes, 3 min pedaling at 25 W and then 20 minutes pedaling on VT1 determined during the exercise test (ET) -10%.
Session 1: 30 min of pedaling at constant load VT1 determined during exercise testing (EE) - 10%.
Session 2 Session 17: increase in the burden of BASE (5 BASE * 5 min: 25 min) by 10% and decrease in relation to the load of the PIC (5 PIC * 1 min: 5 min) to get a cumulative charge of the same session. Changes in heart rate (HR) determine the evolution of sustained loads: a decrease of 10 bpm in heart rate leads to an increase by 10% in the intensity of the base (PIC load remains constant).
Session 18 = Session 1."
1596167|NCT02263287|Other|LeSCoD scale|LeSCoD is a clinical scale
1596269|NCT02262572|Drug|Telmisartan /HCTZ - dry granulation tablet (DG)|
1596129|NCT02263573|Other|Control group usual activities|Participants in the control group will not follow the intervention PEP'C-R. They will continue their usual activities for 9.5 weeks and will be assessed before and after this period. After the study, they will be offered the benefit of the conventional program of the PEP'C.
2009420|NCT03261167|Drug|Placebo|Placebo injection will contain sodium chloride (0.9 mg).
1596133|NCT02263534|Procedure|single incision minisling|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) in the retropubic direction with its end grasped with an artery forceps till level of perineal membrane closure of the vagina 2 sham incisions if the skin only will be made at suprapubic to maintain blindness posterior colpoperneorraphy will be carried out if needed
1596134|NCT02263534|Procedure|tension free vaginal tape|midline incision of the vagina at midurethral level dissection of the vagina from perivesical fascia insertion of the tape (polypropylene macropore mesh tape) with the applicators in the retropubic direction and 2 skin incision will be made supra pubic through which the applicators will be passed and removed and the tape will be cut at level just below the skin closure of the vagina posterior colpoperneorraphy will be carried out if needed
1596135|NCT02263521|Other|No intervention employed. Study is based on a cross-sectional observational design.|
2009421|NCT03259958|Drug|Donepezil TDS|Donepezil Hydrochloride Transdermal Delivery System
2009422|NCT03259958|Drug|Aricept|Aricept Tablet
2009423|NCT03258827|Procedure|Exercise with a towel|Exercise program composes with warm-up, strengthening exercise, cold-down, 60 minutes/time, 3 times/week. A towel is an important tool for exercise. Total duration of the program is 3 months.
2009424|NCT03258827|Procedure|Home-based exercise|Home-based program focuses on walking activity at fast speed, 3 times/week, 60 minutes/times. The total duration is 3 months.
1596145|NCT02263469|Biological|Replenine®-VF (High Purity Factor IX)|
1596146|NCT02263456|Biological|Replenine®-VF (High Purity Factor IX)|
1596147|NCT02263443|Procedure|Soap suds enema (S.S.E.)|Patients in S.S.E. group will bowel preparation by soap suds enema until clear at night before surgery.
1596148|NCT02263443|Procedure|sodium chloride enema|Patients in unison enema group will Unison enema 100 ml per rectal at night before surgery
1596149|NCT02263443|Procedure|No enema|Patients NPO groups will NPO and no bowel preparation.
1596150|NCT02263430|Device|Deep Brain Stimulation|
1596151|NCT02263417|Device|Deep Brain Stimulation (DBS) of Gpi|
1596152|NCT02263417|Device|Deep Brain Stimulation (DBS) of STN|
1596153|NCT02263404|Device|Deep Brain Stimulation|DBS Implant Stimulation
1596154|NCT02263391|Behavioral|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
1596155|NCT02263391|Behavioral|Focus Group|Study participants will be invited to participate in a focus group discussion.
1596156|NCT02263378|Drug|ellagic acid + annona muricata|pills
1596158|NCT02263352|Drug|Lycored soft gels Jagsonpal Pharma, Systemic 8mgms/day|Lycopene 8mgms taken orally ,one per day for two months.
1596159|NCT02263352|Device|Scaling and root planing|Scaling and root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or deep cleaning, is the process of removing or eliminating the etiologic agents - dental plaque, its products, and calculus
1596160|NCT02263339|Behavioral|Aerobic Exercise|Each subject will exercise 30 minutes per session, four times per week for 8 weeks at the OHSU Human Performance Laboratory (HPL). Choice of treadmill or cycle ergometer for each subject will be made based on subject ability by the HPL staff and maintained for the duration of the study. Exercise intensity will be determined by training heart rate to be provided to the subject based on the anaerobic threshold during initial stress test. Throughout the study, patients will be instructed not to alter their diet or baseline level of activity.
1596161|NCT02263339|Behavioral|Stretching|Each subject will follow a self-guided stretching program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
1596162|NCT02263339|Behavioral|Aerobic Exercise- Healthy Subjects|Each subject will follow a self-guided aerobic exercise program 30 minutes per session, four times per week for 8 weeks. The initial session will be supervised at the OHSU Human Performance Laboratory (HPL) and additional supervised sessions will occur every 2 weeks to support compliance with the program. Throughout the study patients will be instructed not to alter their diet or baseline level of activity.
1596163|NCT02263326|Drug|dolutegravir|50 mg tablet by mouth once daily for 48 weeks
1596164|NCT02263326|Drug|lamivudine|300 mg tablet by mouth once daily for 48 weeks
1596165|NCT02263326|Drug|Continue current antiretroviral regimen|Continue current DHHS recommended or alternative three-drug antiretroviral regimen
1596166|NCT02263313|Other|EGO-COMBO group|Assess the safety and effectiveness of Combo stent
1994884|NCT02898454|Drug|Mometasone furoate nasal spray|"Pharmaceutical form: Suspension
Route of administration: Intranasal"
1994885|NCT02898376|Other|skin-oriented spa care|"standardized procedure : 72 care sessions over 18 days of treatment
+/- Additional care according to the specificity of each spa"
1994886|NCT02898376|Drug|Pentoxifylline|400 mg bid during at least 6 months
1994887|NCT02898376|Drug|Tocopherol acetate|500 mg bid during at least 6 months
1994892|NCT02897934|Drug|Bupivacaine continuous infusion|The use of continuous wound infusion of bupivacaine
1994893|NCT02898025|Device|Active Interferential Current|Involves the application of medium frequency alternating currents
1994894|NCT02898025|Device|Active Laser|Involves the application of low level laser over the knee
1994895|NCT02898025|Device|Placebo Interferential Current|It is a sham interferential therapy
1994896|NCT02898025|Device|Placebo Laser|It is a sham laser therapy
1994897|NCT02896075|Other|30 Minute Comedy Video|The intervention is a 30 minute video of a comedy
1994898|NCT02896075|Other|30 Minute Documentary Video|The intervention is a 30 minute video of an uninteresting documentary
1596168|NCT02263274|Device|Transcranial Direct Current Stimulation (TDCS)|Conventional tDCS and low-frequency tACS are commonly administered at a current intensity of 2 mA or less
1596169|NCT02263261|Other|Flex HD Pliable Perforated HADM|Human Acellular Dermal Matrix
1596170|NCT02263248|Drug|venlafaxine|slow titration to a maximum of 300 mg per day. will remain on venlafaxine XR for upto 32 weeks.
1596171|NCT02263248|Drug|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg qd/ to 1.2 mg qd
1596172|NCT02263248|Drug|placebo|patients will remain on venlafaxine XR and be randomzied to receive either placebo or buprenorphine for 8 weeks. at the end of 8 weeks those who did not receive buprenorphine will be given an opportunity to try it.
1596173|NCT02263235|Biological|administration of stable isotope-labelled leucine-|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
1596174|NCT02263235|Other|collection of CSF, blood, urine, saliva|- administration of stable isotope-labelled leucine : by drip, for group 2A and group 2B. Group 1 (control group) : 1 collection of CSF. Group 2B : 4 collections of CSF, 24 hours after administration of stable isotope-labelled leucin. Group 2A (patients with brain trauma, acute hydrocephaly) : continuous collection of CSF, for 24 to 36 hours
1596175|NCT02263222|Drug|MDT-10013|
1596176|NCT02263209|Device|Bioguard Group|Patients randomised to receive the study investigative device will receive a Bioguard implant
1596177|NCT02263209|Device|Control Group|Patients randomised to receive the control device will receive a Exceed Taperlock implant
1596178|NCT02263196|Other|Alcohol and povidone iodine|using from Alcohol and povidone iodine for prevention of inflammation
1596179|NCT02263196|Other|combination of alcohol and betadin|using from combination Alcohol and povidone iodine for prevention of inflammation
1596180|NCT02263183|Dietary Supplement|Red Palm Olein|Red Palm Olein contains corresponding fatty acids like Palm Olein except having more phytonutrients (carotenoids and vitamin E)
1596181|NCT02263183|Dietary Supplement|Palm Olein|Palm Olein contains corresponding fatty acids like Red Palm Olein except having less phytonutrients (no carotenoids and less vitamin E)
1596182|NCT02263170|Other|MRI (magnetic resonance imaging)|Assessment of the sphincter morphology
1596183|NCT02263170|Other|US (ultra sound)|Assessment of the sphincter morphology
1596184|NCT02263170|Other|FLIP (functional luminal imaging probe)|Assessment of the biomechanical properties of the sphincter region
1596185|NCT02263170|Other|HRAM (high resolution anal manometry)|Assessment of the biomechanical properties of the sphincter region
1596186|NCT02263144|Procedure|virtual chromo-endoscopy using FICE Fujifilm Technology|For each polyps, any observer will use virtual chromo-endoscopy with FICE Fujifilm Technology
1596187|NCT02263131|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ.|IL-YANG FLU Vaccine Prefilled Syringe INJ.0.5mL or 0.25mL
1596188|NCT02263131|Biological|VAXIGRIP Prefilled Syringe INJ.|VAXIGRIP Prefilled Syringe INJ.0.5mL or 0.25mL
1596189|NCT02263118|Other|Uni-directional SMS|Exposure to breastfeeding promoting SMSs
1596190|NCT02263118|Device|Feature phone|Participants were given a feature phone.
1596191|NCT02263118|Other|Virtual communities|Exposure to virtual community communication via SMS
1596192|NCT02263118|Other|Hybrid setup|Exposure to virtual community and access to communications with health professional via SMS
1596193|NCT02263105|Drug|CDDP|
1596194|NCT02263105|Drug|Temozolomide|If hematologic and nonhematologic toxicity assessed according to the Common Terminology Criteria for Adverse Events (CTCAE; version 4.0) from the previous cycle had been grade 0 or 1, then TMZ dose escalation to was allowed to the maximum of 150 mg/m2. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity had occurred, then TMZ dose was reduced in 25 mg/m2 steps. If grade 4 nonhematologic toxicity occurred, patient treatment was halted. If grade 4 hematologic toxicity or grade 3 nonhematologic toxicity continued when TMZ dose was in the minimum of 75 mg/m2, patient treatment was halted.
2009425|NCT03258710|Drug|Tenofovir Disoproxil Fumarate|Tenofovir Disoproxil Fumarate is a nucleos(t)ide analogue that inhibits HBV growth. All subjects will receive one tablet of TDF 300 mg once daily orally for 96 weeks.
2009426|NCT03258567|Drug|Nivolumab|3mg/kg via IV infusion over 30 minutes every 2 weeks for up to 1 year in subjects without unacceptable toxicity who achieve complete remission; and up to 2 years in subjects with partial response (PR) or stable disease (SD) with clinical benefit if they are tolerating nivolumab
2009427|NCT03258593|Drug|Durvalumab|Durvalab 1500mg is administered intravenously (IV) once every 4 weeks for 12 months (total of 24 months) provided that patient is tolerating therapy and remains free of recurrent high grade NMIBC (see Treatment Period below). The dose of durvalumab is 1500mg will be administered intravenously once every 3 months to provide an immune boost.
1596198|NCT02263079|Drug|Entecavir|Participants will receive entecavir, either as a film-coated tablet or oral solution, once daily at a dose of 0.015 milligrams per kilogram (mg/kg) (maximum daily dose of 0.5 mg).
1596199|NCT02263079|Drug|Lamivudine|Participants will receive lamivudine, either as a film-coated tablet or oral solution, once daily at a dose of 3 mg/kg (maximum daily dose of 100 mg).
1596200|NCT02263079|Drug|Pegylated Interferon Alfa-2A|Participants will receive pegylated interferon-alfa-2A at a body surface area (BSA) based dose of 180 micrograms per 1.73 square meter (mcg/1.73m^2) BSA.
1596201|NCT02263066|Biological|BAY14-2222_Kogenate-FS FVIII|Depends on Doctor's decision
1596202|NCT02263053|Procedure|POSTERIOR MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower lateral incisors and canines. Applies a force previous distraction grade III and performs oscillating for 1 minute.
1596262|NCT02262611|Drug|MicardisPlus®|
2009428|NCT03258593|Drug|Vicinium|Vicinium is administered in a 12 week Induction Phase followed by a Maintenance Phase for at least one year with an option for a total of up to 2 years of treatment. During the Maintenance Phase, Vincinium is administered every other week. The dose of Vincinium 30mg in 50 mL of saline.
1596203|NCT02263053|Procedure|CAUDAL MOBILIZATION|Patient supine on the gurney, previously trained physiotherapist with disposable gloves, one hand place your thumb on the lower molars of patients. Apply simultaneous flow and force the previous direction, and performs the degree of oscillation III for 1 minute.
2009429|NCT03258476|Drug|Guanfacine Extended Release|Intuniv (guanfacine) is a prescription medicine used to treat attention deficit hyperactivity disorder (ADHD) in children who are at least 6 years old. An open-label trail of guanfacine extended release (GXR 1-4 mg/daily; Intuniv™) suggested benefits in improving behavioral and emotional regulation in children and adolescents with symptoms of traumatic stress. However, to date no controlled clinical trial has been completed assessing the effects of GXR on traumatic stress symptoms in youths
2009430|NCT03258476|Behavioral|Mindfulness Skills Therapy|Mindfulness is a therapy for anxiety and stress. Mindfulness forms of therapy involve regulation of attention, maintaining it in immediate experience, regardless of the valence and desirability of the experience. To reduce anxiety, Mindfulness encourages observing and accepting anxiety-related thoughts
1596206|NCT02263027|Biological|Vaccine|Licensed trivalent inactivated influenza vaccine
2009431|NCT03258476|Drug|Placebo|Placebo oral capsule
1596208|NCT02263001|Other|Auricular acupuncture|Auricular therapy for treatment of musculoskeletal pain
1596209|NCT02263001|Other|Usual Care|Usual care therapy consists of over-the-counter and prescribed pharmacotherapy
1596210|NCT02262988|Procedure|Autologous cells and total knee arthroplasty|
1596211|NCT02262988|Procedure|Standard total knee arthroplasty surgery|
1596212|NCT02262962|Other|Redesigned Well-Child Care|The Well-Child Visits will be enhanced using a newly-designed model of care. Parents will have access to Parent Coach during child's routine well visits, Well Baby Help Line, Well-Visit Planner, and HealthyTxt Messaging service.
1596213|NCT02262949|Device|LifeStent Vascular Stent|PTA followed by implantation of the LifeStent Vascular Stent (stent length 250 mm) in the SFA or popliteal artery.
1596214|NCT02262936|Drug|Desmopressin|
1596215|NCT02262936|Drug|Fesoterodine|
1596216|NCT02262923|Drug|metoclopramide|
1596217|NCT02262910|Biological|MOR209/ES414|MOR209/ES414 is a novel humanized bispecific antibody which is designed to treat mCRPC by redirecting T-cell cytotoxicity against prostate cancer cells expressing prostate-specific membrane antigen (PSMA).
1596218|NCT02262897|Drug|Nab-paclitaxel|Nab-paclitaxel weekly chemotherapy 130mg/m2, d1,8,15,every 4 week or Nab-paclitaxel chemotherapy once a time with a dose of 230 mg/m2 every 3 weeks
1596219|NCT02262884|Device|SurgiQuest AirSeal Insufflation System (AIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
1596220|NCT02262884|Device|Conventional Insufflation System (CIS)|Comparison between Conventional Insufflation System (CIS) and the SurgiQuest AirSeal Insufflation System (AIS) at similar pressures (15mmHg) and the SurgiQuest AirSeal at 12mmHg.
1596221|NCT02262871|Device|High flow nasal oxygen cannula|HFN will be set with an inspiratory flow rate at 45-55 L/min (maximal tolerated flow), temperature at 37°C or 34°C if perceived as too warm, and fraction on inspired oxygen (FiO2) will be adjusted to achieve an oxygen saturation (SpO2) of at least 92%.
1596222|NCT02262871|Device|Noninvasive ventilation|The setting of NIV will be appropriately adjusted, based on the clinical assessment of the respiratory therapist in charge and will not be modified during the test.
1596223|NCT02262858|Drug|Telmisartan and HCTZ|
1596224|NCT02262858|Drug|Telmisartan|
1596225|NCT02262858|Drug|HCTZ|
1596226|NCT02262845|Device|The Advanix™ Pancreatic Stent and NaviFlex RX Pancreatic Delivery System and Pushers|Used to drain pancreatic ducts
1596230|NCT02262793|Drug|telmisartan|
1596231|NCT02262793|Drug|ASA/ER-DP|
1596232|NCT02262780|Drug|Low dose of telmisartan|
1596233|NCT02262780|Drug|High dose of telmisartan|
1596234|NCT02262780|Drug|HCTZ|
1596235|NCT02262767|Drug|PF-06649751|Experimental Pfizer compound.
1596236|NCT02262767|Drug|Trimethobenzamide Hydrochloride|Trimethobenzamide Hydrochloride is indicated for the treatment of postoperative nausea and vomiting and for nausea associated with gastroenteritis.
1596237|NCT02262754|Drug|PF-06372865|Dose level 1 daily dosing BID for 1 week followed by dose level 2 daily BID for 3 weeks
1596238|NCT02262754|Drug|Placebo|Placebo for PF-06372865 and placebo for naproxen daily
1596239|NCT02262754|Drug|Naproxen|500 mg BID for 4 weeks
1596242|NCT02262728|Drug|Simeprevir|Simeprevir 150 milligram (mg) capsule orally once daily for 12 weeks
1596243|NCT02262728|Drug|Daclatasvir|Daclatasvir 60 mg tablet orally once daily for 12 weeks
1596244|NCT02262728|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet orally once daily for 12 weeks
1596245|NCT02262715|Drug|VX-787|Participants will receive VX-787, 600 mg either two times a day or once a day in either of the Part.
1596246|NCT02262715|Drug|Oseltamivir|Participants will receive Oseltamivir 75 mg either two times a day or once a day in either of the Part.
1596247|NCT02262715|Other|Placebo|Participants will receive placebo matching to VX-787 either two times a day or or once a day.
1596248|NCT02262702|Drug|Paracetamol 665 mg|Paracetamol 665 mg tablet
1596249|NCT02262702|Drug|Paracetamol 500 mg|Paracetamol 500 mg tablet
1596250|NCT02262689|Drug|GSK2256294|GSK2256294 will be supplied as gelatin capsule to be administered orally with the unit dose 5 mg / dose level 15 mg
1596251|NCT02262689|Drug|Placebo|Matched Placebo will be supplied as gelatin capsule to be administered orally
1596252|NCT02262676|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients treated by Physicians under approved local prescriptions
1596253|NCT02262663|Drug|Vilaprisan (BAY1002670)|
1596254|NCT02262650|Drug|Telmisartan|
1596255|NCT02262650|Drug|Clopidogrel|
1596256|NCT02262637|Drug|Micardis®|
1596257|NCT02262637|Drug|MicardisPlus®|
1596258|NCT02262624|Drug|Telmisartan|
1596259|NCT02262624|Drug|Hydrochlorthiazide (HCTZ)|
1596260|NCT02262624|Drug|Telmisartan/HCTZ fixed combination|
1596261|NCT02262611|Drug|Micardis®|
1596270|NCT02262572|Drug|Telmisartan /HCTZ - present commercial formulation|
1596271|NCT02262559|Drug|BIBR 277 tablet|
1596272|NCT02262559|Drug|BIBR 277 capsule|
1596273|NCT02262546|Drug|Pramipexole extended-release (ER) tablets|
1596274|NCT02262546|Drug|Pramipexole immediate-release (IR) tablets|
1596275|NCT02262546|Drug|Moxifloxacin|
1596276|NCT02262546|Drug|Pramipexole Placebo|
1596277|NCT02262546|Drug|Moxifloxacin Placebo|
1596278|NCT02262533|Drug|Apixaban|
1596279|NCT02262533|Drug|Atenolol|
1596280|NCT02262520|Drug|Apixaban|
1596281|NCT02262520|Drug|Digoxin|
1596283|NCT02262494|Procedure|portable venous compression ultrasonography|venous compression ultrasonography performed using an ultra-portable ultrasound device (by emergency physician)
1596284|NCT02262494|Procedure|venous compress ultrasonography|venous compression ultrasonography performed using a classic ultrasound device (by exploratory specialist)
1596285|NCT02262494|Procedure|Doppler ultrasound of the lower limbs|Doppler ultrasound of the lower limbs (gold standard; by exploratory specialist)
1596286|NCT02262481|Drug|dydrogesterone|
1596287|NCT02262481|Drug|placebo|
1596288|NCT02262468|Radiation|x ray|
1596289|NCT02262455|Drug|STM 434|STM 434 will be administered by IV injection. There are five planned dose levels, from 0.25mg/kg to 4mg/kg, which is dependent on the cohort (group) a participant is assigned to.
1596290|NCT02262455|Drug|Liposomal doxorubicin|Liposomal doxorubicin (40 mg/m2) will be administered once every 28 days by IV infusion prior to STM 434 for those participants enrolled in Part 3 of the trial. Liposomal doxorubicin will be administered for a maximum of 6 cycles (each cycle being 28 days).
1596291|NCT02262442|Device|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the flexible bronchoscopy
1596292|NCT02262442|Device|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the flexible bronchoscopy
1596293|NCT02262429|Other|ONS QIP|Rapid comprehensive ONS, dietary consult, follow up phone calls
1596294|NCT02262429|Other|ONS Standard Feeding|Standard of care
1596295|NCT02262416|Drug|leuprolide|normal saline
1596296|NCT02262403|Other|Blood and feces sampling|Blood and feces samples will be examined after 14 days, 28 days, 3 months and 16 months. This will require blood and feces sampling. The study is therefore defined as 'interventional' rather than 'observational' as it includes acts outside the standard of care.
1596297|NCT02262390|Procedure|Partner Notification Reminders|"For all 3 arms, the following will be done:
All participants will have an antenatal clinic visit every 4 weeks until delivery.
All notification slips will be duplicate; one given to the mother and one held in the clinic. The study ID number will be documented on the slip. On partner return the slips will be matched and used to link mothers with male returning partners.
Partner participant test result will be linked to the patient using the participant ID number in the lab. Partners will be tested using a rapid treponemal antibody test."
1596298|NCT02262377|Behavioral|Integrative Medicine Group Visits|Patients with chronic pain and depression attend group medical visits and use website and virtual patient advocate as part of the curriculum.
1596299|NCT02262364|Biological|APS|See above
1596300|NCT02262351|Other|30 Second Pulse Check|To detect atrial fibrillation
1596301|NCT02262351|Device|Watch BP Home A|Blood pressure device that detects atrial fibrillation
1596302|NCT02262351|Device|HeartCheck Hand-held ECG device|To detect atrial fibrillation
1596303|NCT02262338|Drug|AGT-182|Recombinant HIRMAb-IDS
1596304|NCT02262325|Radiation|hypofractionated radiation therapy|Radiation boost in week 1 (days 1-5)
1596305|NCT02262325|Drug|cisplatin|Given IV
1596306|NCT02262325|Drug|etoposide|Given IV
1596307|NCT02262325|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
1596308|NCT02262325|Other|laboratory biomarker analysis|Correlative studies
1596309|NCT02262312|Other|Transient elastography|All patients will have a transient elastography performed as a measure of liver stiffness.
1596310|NCT02262299|Drug|Pirfenidone|Receive tablets with pirfenidone
1596311|NCT02262299|Drug|Placebo|Recieve tablets with placebo
1596312|NCT02262273|Other|Data Collection|Colleciton of data from medical records only
1596313|NCT02262260|Drug|Labeled regime arm|Treatment will be given monthly and will be continued until maximum visual acuity is achieved (the patient's visual acuity is stable for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter patients should be monitored monthly for visual acuity. Treatment will be resumed when monitoring indicates loss of visual acuity due to DME. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections). The interval between two doses should not be shorter than 1 month.
1596314|NCT02262260|Drug|Wait and Extend regime arm|Lucentis (ranibizumab) 0.5 mg will be injected subsequently at baseline, month 1 and 2. After the three initial loading doses, patients will be called for the control visits 1 month later. If the visual acuity has reached a stable level and there is no sign of edema on OCT, patients will not receive intravitreal injection and will be called to come back 6 weeks later. The interval is increased by 2 weeks until a maximum of 8 weeks as long as the patient presents as stable regarding visual acuity, central retinal thickness and clinical findings. If there is a negative change, the interval is shortened back to 4 weeks.
1596315|NCT02262234|Other|Education Program Type 1|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
1596316|NCT02262234|Other|Education Program Type 2|The first part of the education program involves four weeks of in-person classes (2 hours per class) given once per week with homework assignments of approximately 30 minutes per day for at least 5 days per week. The second part of the education program involves home-based activities only, performed approximately 30 minutes per day for at least 5 days per week.
1596317|NCT02262221|Other|Scheduled radiologic evaluations|Scheduled radiologic evaluations (CT or MRI scan) and PET scan in the case that patiets are ≥ 50 years old and with a smokink history ≥ 20 pack year
1596318|NCT02262208|Other|Aerobic Exercises|"Exercise intensity for each individual by a heart rate monitor (Polar F1 TM, Polar Electro Oy, Helsinki, Finland), and a Borg 0-10 scale used to register individuals' perceived exertion every 5 minutes throughout the experimental sessions.
Aerobic session will consist of 40 min of lower limb bicycle at 70% of the peak heart rate, as determined in the incremental exercise test."
1596319|NCT02262208|Other|Eccentric Exercise|Eccentric session will consist of 40 min of one lower -limb exercises (leg press) with 6 sets of 10 repetitions at 120% of 1-RM.
1596320|NCT02262208|Device|Continuous glucose monitoring system (Guardian, Medtronic, Northridge, USA)|Subjects will be admitted to the laboratory in the morning at approximately 9:00 a.m., 24 h before the exercise session, when the glucose sensor (Sof-SensorTM, Medtronic Mini-Med, Northridge, USA) will be inserted subcutaneously. The sensor is a glucose oxidase based platinum electrode that is inserted through a needle into the subcutaneous tissue of the anterior abdominal wall, using a spring-loaded device (Senserter, Medtronic, Northridge, USA). Glucose profiles will be collected the day before (day 1), the day of (day 2), and the day following (day 3) and 40 min of exercise. Each sensor will be used continuously for up to 72 h.
1596321|NCT02262195|Other|Elevated levels of carboxyhemoglobin|Comparison of pulse co-oximeters
1596322|NCT02262182|Other|KP group|
1596323|NCT02262182|Other|KM group|
1596324|NCT02262169|Drug|Omeprazole|2 Omeprazole capsules 20 mg, once daily
1596325|NCT02262169|Drug|Placebo caplet of DLBS2411|1 placebo caplet of DLBS2411, twice daily
1596326|NCT02262169|Drug|DLBS2411|1 DLBS2411 caplet 250 mg, twice daily
1596327|NCT02262169|Drug|Placebo capsule of Omeprazole|2 placebo capsules of Omeprazole, once daily
1596328|NCT02262156|Other|Cognitive behavioral therapy|"The CBT group will receive 12 weekly 90-minute sessions. Each session will be given in group form by one certified CBT therapist and one neuropsychiatrist in training on group therapy.
The CBT structure include psychoeducation, addressing dysfunctional thoughts and maladaptive behaviors; problem solving techniques, assertiveness, coping strategies and depression relapse prevention"
1596329|NCT02262156|Drug|SSRI|"Patients will receive the treatment as usual with a SSRI: sertraline or citalopram. In patients already taking antidepressants for more than 8 weeks before enrollment but still experiencing depressive symptoms, treatment could be optimized either by augmenting the dose of his antidepressant or by changing to one of the SSRI mentioned."
1596330|NCT02262143|Drug|Rosuvastatin|Rosuvastatin 10 mg, qd, po
1596331|NCT02262143|Drug|Fenofibrate|Fenofibrate 160mg, qd, po
1596333|NCT02262117|Other|standard care|No specific medical care
1596334|NCT02262117|Drug|specific treatment|Regarding the immune endometrial profiling, medical care (personalization of treatment) should follow a step by step decision tree.
1596335|NCT02262104|Behavioral|Intensive exercise|Arm 1: Intervention group. Intensive strength exercise (12RM) for lower limb and balance exercises twice a week for 1 hour. Groups of max 3 participants lead by physiotherapist
1596336|NCT02262104|Behavioral|Control|Arm 2: control. Social activity group with light exercise, reading, and games. Lead by occupational therapist or nursing staff
1596337|NCT02262091|Dietary Supplement|Food fibers|
1596338|NCT02262091|Dietary Supplement|Maltodextrin|
1596339|NCT02262091|Biological|Influenza vaccine (incl. criterion)|
1596340|NCT02262078|Drug|Sodium Nitrite Inhalation Solution|90mg of (nebulized) inhaled sodium nitrite will be administered (by inhalation) to participants prior to exercise.
1596341|NCT02262078|Other|Placebo|Normal saline will be administered (by inhalation) to participants prior to exercise.
1596342|NCT02262052|Other|MRDTI|MRDTI is primary diagnostic test for management of suspected ipsilateral DVT
1596343|NCT02262039|Device|Valveless recirculating insufflation (VTI)|10 mmHg target pressure
1596344|NCT02262039|Device|Conventional pressure|15 mmHg target pressure
1596345|NCT02262026|Drug|125 mg AZD0530|Randomized to receive 125 mg of AZD0530
1596346|NCT02262026|Drug|50 mg AZD0530|Randomized to receive 50 mg of AZD0530
1596347|NCT02262026|Drug|Placebo|Placebo
1596348|NCT02262013|Behavioral|Parents as Coaches|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parents as coaches (PAC) intervention.
1596349|NCT02262013|Behavioral|Parent Weight Loss|Adolescents will receive lifestyle intervention (TEENS) and parents will receive parent weight loss (PWL) intervention.
1596350|NCT02262000|Radiation|Image Guided Stereotatic Ablative Radiotherapy|
1596351|NCT02261987|Other|Autogenic drainage (AD)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
1596352|NCT02261987|Other|Resistive inspiratory manoeuvre (RIM)|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
1596353|NCT02261987|Other|Resistive inspiratory manoeuvre+autogenic drainage|It will be apply in one only session. The time spent during this bronchial drainage session will be 30 minutes All patients will perform all interventions in a randomized order.
1596356|NCT02261961|Biological|TDAP|Both arms will receive the tetanus, diptheria, and pertussis vaccination after two weeks of treatment with supplement or placebo
1596357|NCT02261961|Other|Acute Resistance Exercise|Both arms will receive a single bout of resistance exercise twice, before and after two weeks of treatment with supplement or placebo, and be evaluated for the response within blood and muscle
1596358|NCT02261961|Other|Resistance Exercise Training|Both arms will receive 36 sessions of progressive high-intensity resistance exercise training (thigh muscle) over the course of approximately 12 weeks.
1596359|NCT02261961|Other|Post-training Follow-up|Both arms will continue to receive treatment with supplement or placebo for approximately 26 weeks after completion of the exercise training. During this time subjects will not be allowed to perform resistance exercise.
1994904|NCT02894385|Drug|BAY1841788|600 mg single dose, administered as 2 x 300 mg tablets on Day 00.
1596360|NCT02261961|Dietary Supplement|Nutritional Supplement (Muscle Armor)|Subjects in the supplement group will consume orange-flavored Muscle Armor according to the manufacturer's directions: one serving (approximately 30g, i.e. one scoop provided with the product by its manufacturer), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
1596361|NCT02261961|Dietary Supplement|Placebo (Kool-Aid)|Subjects in the placebo group will consume orange-flavored Kool-Aid (Kraft Foods) according to the manufacturer's directions: one serving (approximately 13g, i.e. one scoop provided with the product by the pharmacy), twice daily mixed with 12 ounces (oz) of water beginning after all baseline assessments are performed including assessment of the response to acute exercise and continuing until the end of study participation.
1596362|NCT02261948|Drug|Levosimendan|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
1596363|NCT02261948|Drug|Placebo|Treatment should be initiated with a loading dose of 6-12 mcg / kg infused over 10 minutes followed by a continuous infusion of 0.1 mcg / kg / min.
1596364|NCT02261935|Other|Existing home care nursing practice|"Home care nurses in this comparator group will provide care as per usual to their patients and family caregivers. The family is seen as the unit of care but no formal assessment of the caregiver will be done."
1596365|NCT02261935|Other|Practice support tool intervention|"The intervention will be the routine use of the Carer Support Needs Assessment Tool (CSNAT) in the practice of home care nurses (once every 4 weeks with each family caregiver) to document, monitor and address family caregiver support needs.
The completed CSNAT tool will be kept in the patient chart and will be integrated into the care provided by the nurse.
Update - December 22, 2016 - In some offices only, the CSNAT will be administered by a separate study nurse. Findings will be communicated to the home care nurse to inform the documenting, monitoring and addressing of family caregiver support needs."
1596366|NCT02261922|Drug|ticagrelor|
1596367|NCT02261922|Drug|prasugrel|
1596368|NCT02261896|Drug|Placebo|Evaluate usefullness of antibiotic prophylaxis
1596369|NCT02261896|Drug|Ciprofloxacin|Ciprofloxacine 400 mg intravenous one dose followed by ciprofloxacine oral each 12 hours (complete 3 days)
1596372|NCT02261870|Device|MRI T2 quantification|MRI acquisitions will be performed according to the already described method based on conventional Fast Spin Echo sequences and with an additional calibration pad positioned on the patient thorax (dedicated pad made by the Nancy CIC-IT with stable and adapted T2). MRI will be performed if possible before the biopsy and otherwise the radiologist will be kept blinded of the biopsy results.
1596373|NCT02261857|Device|Personalized continuous positive airway pressure (CPAP) mask|Personalized CPAP mask manufactured for study subjects using a combination of patient-specific computer-aided design and three-dimensional printing
1596374|NCT02261844|Dietary Supplement|Resveratrol|Resveratrol 1 gm po x 10 days prior to liver resection
1596375|NCT02261844|Drug|Placebo|Placebo 1 pill daily X 10 days
1596376|NCT02261831|Other|obese patients|collection of blood sampling and biopsies
1596377|NCT02261831|Other|diabetic patients|collection of blood sampling and biopsies
1596378|NCT02261831|Other|patients free of obesity and diabetes|collection of blood sampling and biopsies
1596379|NCT02261831|Other|patients free type 2 diabetes|collection of blood sampling and biopsies
1596380|NCT02261818|Behavioral|Meetings with peer mentors|Peer mentors provide social support to address depressive symptoms
1596381|NCT02261805|Drug|Ganetespib and doxorubicin|IV ganetespib and doxorubicin
1596382|NCT02261792|Procedure|24 hours Trendelenburg position|Trendelenburg position
1596383|NCT02261792|Procedure|24 hours bed rest|24 hours bed rest after EBP
1596384|NCT02261792|Procedure|EBP|Autologous Epidural Blood Patch
1596385|NCT02261779|Drug|Tranylcypromine|
1596386|NCT02261779|Drug|Tretinoin|
1596387|NCT02261766|Device|Holter monitoring and Thumb ECG|5 days holtermonitoring and 30 days 30 seconds twice daily thumb ECG recording
1596388|NCT02261753|Dietary Supplement|Classical ketogenic diet|A high fat low carbohydrate, low protein diet.
1596389|NCT02261740|Behavioral|Yoga Therapy|"A 90-minute orientation session led by the yoga class instructors, followed by 90-minute group yoga classes twice weekly for 6 weeks. Classes will be led by an experienced instructor. Women will also be taught to avoid any habits that may worsen their genito-pelvic pain (e.g., straining their pelvic floor muscles).
Participants will also be asked to practice yoga at home an additional hour per week throughout the 6-week yoga therapy program. Participants will be given a detailed written manual to use for home practice."
1596390|NCT02261727|Drug|Theophylline|Theophylline is an oral methylxanthine which relaxes smooth muscle through its action as a phosphodiesterase inhibitor
1596391|NCT02261727|Drug|Prednisone|Prednisone is an oral glucocorticosteroid which has anti-inflammatory properties
1596392|NCT02261727|Drug|Placebo (for prednisone)|"Arm 1 : Theophylline Placebo 1 tab twice daily and Prednisone placebo 1 tab once daily
Arm 2 : Theophylline 100mg 1 tab twice daily and Prednisone placebo 1 tab once daily"
1596393|NCT02261727|Drug|Placebo (for Theophylline)|One tablet twice daily in arm 1 (theophylline placebo 1 BD + prednisone placebo 1 once daily)
2009432|NCT03257137|Other|Diet Quality|Diets matched for calorie intake and macronutrient distribution but differing by overall diet quality will be provided in a random order, cross-over design study.
1596427|NCT02261493|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
1596428|NCT02261480|Other|Blood draw|When possible, blood will be drawn as an extra aliquot utilizing the same needle stick procedure performed for standard of care.
1596396|NCT02261701|Other|Early mobilization|Early mobilization, collar´n cuff 4 weeks post surgery and after this light exercises start and no further bandage.
1596397|NCT02261701|Other|Post surgery shoulder lock|Post surgery: Shoulder lock with abduction cushion, additionally 3 weeks with collar´n cuff, and after this period light exercises are allowed and nu further bandage.
1596398|NCT02261688|Dietary Supplement|Low salt diet|Low salt diet, 10mmoL of sodium per day, for 6 days
1596399|NCT02261688|Dietary Supplement|Low salt diet + IV normal saline|Low salt diet, 10 mmoL of sodium per day, for 4 days with normal saline infusion x 12 hours per day for 200 mmoL of sodium chloride. Total daily sodium is 210 mmoL/day.
1596400|NCT02261688|Dietary Supplement|Liberal salt diet|Liberal salt diet targeting 200 mmoL of sodium per day x 7 days
1596401|NCT02261675|Drug|dexmedetomidine|children received intravenous infusion with a bolus dose dexmedetomidine and followed by a continuous infusion before induction. use sevoflurane for induction and a steady-state end-tidal sevoflurane concentration was maintained for at least 15 min before skin incision.
1596402|NCT02261662|Drug|Ribavirin|"A nucleoside antimetabolite antiviral agent that blocks nucleic acid synthesis and is used against both RNA and DNA viruses.
It will be used along with Topical steroids; Betamethasone"
1596403|NCT02261662|Drug|Betamethasone|Topical Steroids alone will be used; Betamethasone
1596404|NCT02261649|Device|Medoc Advanced Medical Systems PATHWAY Model ATS|30 minutes of sensory testing using a contact thermal stimulator will measure thresholds for heat and cool detection, and threshold for hot and cold pain.
1596405|NCT02261649|Procedure|Cold water bath|The next 15 minutes of sensory testing will measure tolerance to having right or left hand in a tub of cold water. The participant will place their hand in cold water and leave it there for as long they can, even if it is uncomfortable. The participant can take their arm out if it gets too uncomfortable to leave it in.
1596406|NCT02261649|Device|MRI scanner|An MRI will be used to collect anatomical and functional images from patients and subjects. These data will be collected within a 1 hour block.
1596407|NCT02261649|Other|Questionnaires|The surveys include questions about emotions, thoughts, and feelings. These surveys will be given before sensory testing and before the MRI scan. The parent or guardian will help to complete two surveys, and will complete one survey on his or her own. Questions can be skipped, and may be stopped at any time.
1596409|NCT02261623|Device|WallFlex™ Biliary RX Fully Covered Stent System RMV|For use in the palliative treatment of biliary strictures produced by malignant neoplasms, and for treatment of benign biliary strictures
1596410|NCT02261623|Device|WallFlex™ Biliary RX Partially Covered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
1596411|NCT02261623|Device|WallFlex™ Biliary RX Uncovered Stent System|For use in the palliative treatment of biliary strictures produced by malignant neoplasms.
1596412|NCT02261610|Procedure|Procalcitonin algorithm|Procalcitonin algorithm (usually used for lower respiratory tract) guide antibiotic therapy
1596413|NCT02261597|Behavioral|Cold Pressor Test|Repeated immersion of hand in ice-cold water
1596414|NCT02261584|Device|Microwave Thermal Coagulation|Microwave thermal coagulation of splenic parenchyma.
1596415|NCT02261584|Device|Partial Splenic Embolization|Femoral artery approach will be used for splenic artery catheterization with the tip of the catheter always well advanced selectively into the splenic artery. Embolizing agent will be injected in small increments. Arteriography in between divided doses will be done to document the extent of devascularization.
1596416|NCT02261571|Other|Moxibustion|"In the moxibustion treatment group, 3 moxibustion, 3 acupoints(CV12, CV8, CV54) will be heated with indirected moxibustion.
The moxibustion will be removed when the patient feel hotness and require remove them"
1596417|NCT02261558|Other|Clinical Improvisation Instrumental Music Therapy|Select an instrument of choice (and instruments for caregiver/s if applicable) Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Closure through verbal reflection and sharing (5 minutes)
1596418|NCT02261558|Other|Clinical Vocal Improvisation|* 5 minutes of warm up. Select a few favorite songs of choice. Play/improvise and expand playing 10 minutes, inclusive of clinical improvisation (melody, harmony, timbre, and rhythmic idioms) where musical communication will be fostered and therapeutic goals will be addressed by the therapist in the music. Identify themes and issues addressed and/or paralleled in the song and/or within the self Closure through verbal reflection and sharing (5 minutes)
1596419|NCT02261545|Dietary Supplement|n-3 Fatty Acid|n-3 Fatty Acid supplement, 3 × 1000 mg softgel daily (2700 mg EPA+DHA per day), 3 times a day, for 10 weeks.
1596420|NCT02261545|Dietary Supplement|Placebo|3 cap 1 g Placebo(paraffin) per day for 10 weeks. Control Group: n-3 Fatty Acid placebo softgel (Containing 3 g edible paraffin oil), 3 × 1000 mg softgel daily (3 g per day), 3 times a day, for 10 weeks.
1596421|NCT02261532|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
1596422|NCT02261519|Drug|NaBen®|500 mg twice daily (1000 mg total)
1596423|NCT02261519|Other|Placebo|0 mg twice daily (0 mg total)
1596424|NCT02261506|Other|7 days of adequate antibiotic treatment durations|We will not be randomizing patients to any specific antibiotic regimen. Patients will be randomized to fixed durations of adequate treatment: 7 versus 14 days. The selection of antibiotic(s) will be at the discretion of the treating team, although the research team will check to ensure that the selected antibiotics have an 'adequate' spectrum of coverage for the bacterial pathogen(s) isolated in the blood culture.
1596425|NCT02261506|Other|14 days of adequate antibiotic treatment durations|
1596426|NCT02261493|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
1596429|NCT02261480|Other|Nasopharyngeal wash|Nasopharyngeal washes are optional for Group A and Group B participants. Nasopharyngeal washes will be performed on all subjects in Group C. The technique used will be the same as used for regular standard of care per St. Jude guidelines.
1596430|NCT02261467|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the protocol-specified areas. Subjects will receive at least 1 and up to 3 treatments.
1596431|NCT02261467|Drug|Normal Saline|Placebo (normal saline) injected into the protocol-specified areas on Day 1.
1596432|NCT02261454|Other|Gum chewing|1 piece of sugarless gum three times daily to be chewed for 1 hour each time.
1596433|NCT02261441|Other|Observational and noninterventional study|No specific recommendations will be provide to physicians about treatments. As a result, treatments of patients will be prescribed, modified or withdrawn according only to physicians´ judgment.
1596434|NCT02261428|Device|Catheter Tiemann|We tested the ability of Tiemann catheter to access trachea in order to aspirate bronchial secretions in ICU patients
1596435|NCT02261428|Device|Suction catheter|We tested the ability of Suction catheter to access trachea in order to aspirate bronchial secretions in ICU patients
1596436|NCT02261415|Drug|Tranexamic acid (TXA)|1 g TXA bolus injection + 1 g TXA infusion from induction over 8 hours
1596437|NCT02261415|Drug|Normal saline|1 g saline bolus injection + 1 g saline infusion from induction over 8 hours
1596438|NCT02261402|Other|Medisinstart|"Medisinstart is a newly developed pharmacy service for patients about to start a new medicine for a chronic or long-term condition. It consists of two follow-up consultations with a pharmacist. The first at 1-2 weeks and the second at 3-5 weeks after start of the new medicine."
1596439|NCT02261389|Other|Arm B, tumor markers assessment|Tumor markers assessment every three months through the study or until disease recurrence
1596440|NCT02261376|Drug|DS-1971a|DS-1971a is supplied as a powder or crystals and will be given as an oral suspension with Bitrex® (taste masking agent). Each subject will receive a single oral dose of 200 mg DS 1971a .
1596441|NCT02261350|Dietary Supplement|Food fortification|
1596442|NCT02261350|Dietary Supplement|Oral Nutritional Supplements|
1596443|NCT02261311|Other|Quality of Life|All participants recruited will complete a questionnaire prior to their breast biopsy and then again approximately one week before their surgery. The questionnaire is focused on the level of anxiety patients experience during the wait time between diagnosis and surgery. Additional tissue will be collected at the time of the diagnostic biopsy.
1596444|NCT02261298|Drug|ONO-4538|
1596445|NCT02261285|Drug|ONO-4538|
1596446|NCT02261272|Behavioral|CBT for insomnia SHUTi|SHUTi
1596447|NCT02261272|Behavioral|passive patient education/sleep hygiene|
1596448|NCT02261259|Procedure|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
1596449|NCT02261246|Procedure|Spinal manipulation treatment|Up to 4 sessions of spinal manipulation treatment (once per week).
1596450|NCT02261233|Procedure|Osteopathic manipulative treatment|Up to 4 sessions of osteopathic manipulative treatment (once per week)
1596451|NCT02261220|Biological|MEDI4736|MEDI4736 is administered by IV infusion in combination with tremelimumab
1596452|NCT02261220|Biological|tremelimumab|Tremelimumab is administered by IV infusion in combination with MEDI4736
1596453|NCT02261207|Drug|Axitinib|Axitinib will be administered at the dose of 5mg twice a day, continuously. Treatment will be continued till evidence of progression, or toxicities or patient withdrawal.
1596454|NCT02261194|Behavioral|Self-Care Tools|
1596455|NCT02261181|Device|XONRID|The patients will be treated with XONRID + standard of care (SOC) preemptive treatment adopted during radiation treatment for head and neck cancer patients. Patients will be instructed to apply the study cream (XONRID) on the irradiated area two times daily, the first application 1-2 h after the morning radiotherapy session, the second in the evening, starting on the first day of irradiation and continuing until 2 weeks after the completion of the radiation treatments or the development of Grade 3 or 4 skin toxicity. When G3 toxicity will occur the patient will be discontinued from the study medication and the skin toxicity will be managed according to internal guidelines.
1596456|NCT02261168|Other|Standardized living protocol|Subjects stay at the research facility for 44 hours and adhere to a standard sleeping, eating and activity protocol. During this protocol, multiple measurements will be performed including skeletal muscle biopsies (m. vastus lateralis), blood draws, indirect calorimetry and MRS measurements.
1596457|NCT02261155|Procedure|Hypnosis|hypnotic Relaxation without specific analgesic suggestion
1596458|NCT02261142|Device|Multifocal TENS garment (Mollii®)|Multifocal transcutaneous electrical stimulation incorporated into a whole-body garment in combination with training
1596459|NCT02261129|Drug|Telmisartan film-coated tablet|
1596460|NCT02261129|Drug|Telmisartan uncoated tablet|
1596461|NCT02261116|Drug|Telmisartan|
1596462|NCT02261116|Drug|Candesartan|
1596463|NCT02261116|Drug|Placebo|
1596464|NCT02261103|Drug|Pramipexole ER tablets|
1596465|NCT02261103|Drug|Pramipexole IR tablets|
1596466|NCT02261103|Drug|Placebo matching Pramipexole ER tablets|
1596467|NCT02261103|Drug|Placebo matching Pramipexole IR tablets|
1596468|NCT02261103|Other|Standard high-fat breakfast|
1596469|NCT02261090|Drug|Formulation B: Pramipexole Slow release (SR) tablet|
1596470|NCT02261090|Drug|Formulation C: Pramipexole Slow release tablet|
1596471|NCT02261090|Drug|Formulation D: Pramipexole Slow release tablet|
1596472|NCT02261090|Drug|Formulation E: Pramipexole Slow release tablet|
1596473|NCT02261090|Drug|Formulation F: Pramipexole Slow release tablet|
1596474|NCT02261090|Drug|Formulation G: Pramipexole Slow release tablet|
1596475|NCT02261090|Drug|Formulation H: Pramipexole Slow release tablet|
1596476|NCT02261090|Drug|Pramipexole immediate release (IR) tablets|
1596477|NCT02261077|Drug|Hyoscine butylbromide|
1596478|NCT02261077|Drug|Placebo|
1596479|NCT02261064|Drug|Telmisartan/Amlodipine low dose|
1596480|NCT02261064|Drug|Telmisartan/Amlodipine high dose|
1596481|NCT02261064|Other|Japanese meal|
1596482|NCT02261051|Other|Standard of care|Patients will be cared for using current standard of care preceding the design and implementation of the LCCM model of care.
1596483|NCT02261038|Other|Kanekasu radiographs|No interventions are performed here. All patients undergo CT and special radiographs of the knee to assess femoral TKA rotation.
1596484|NCT02261025|Drug|acetylsalicylic acid|75-100mg,per day
1596487|NCT02260973|Dietary Supplement|Omega-3 (Triglyceride form)|
1596488|NCT02260960|Dietary Supplement|Omega-3 (Triglyceride form)|
1596489|NCT02260947|Drug|PF-06273340|PF-06273340 50 mg
1596490|NCT02260947|Drug|PF-06273340|PF-06273340 400 mg
1596491|NCT02260947|Drug|Pregabalin|Pregabalin 300 mg
1596492|NCT02260947|Drug|Ibuprofen|Ibuprofen 600 mg
1596493|NCT02260947|Drug|Placebo|Matching Placebo
1596494|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2
1596495|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
1596496|NCT02260934|Drug|Prednisone|"Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)
Continue prednisone 10 mg/day to week 96"
1596497|NCT02260934|Drug|Methylprednisolone|"Week 0 and Week 2:
Solumedrol (100 mg) IV"
1596498|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
1596499|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
1596500|NCT02260934|Biological|Rituximab|Rituximab 1000mg intravenously (IV) at week 0 and week 2.
1596501|NCT02260934|Drug|Cyclophosphamide|Cyclophosphamide (750 mg) intravenously (IV) at week 0 and week 2.
1596502|NCT02260934|Drug|Prednisone|"Week 0 and Week 2: Prednisone (40 mg/day; taper to 10 mg/day by week 12)
Continue prednisone 10 mg/day to week 96"
1596503|NCT02260934|Drug|Methylprednisolone|Week 0 and Week 2: Solumedrol (100 mg) IV
1596504|NCT02260934|Drug|Diphenhydramine|Diphenhydramine (50 mg, or equivalent dose of similar antihistamine) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
1596505|NCT02260934|Drug|Acetaminophen|Acetaminophen (650 mg) will be given orally 1 hour (plus or minus 15 minutes) before each infusion of rituximab.
1596506|NCT02260934|Biological|Belimumab|The RCB Group will receive IV belimumab 10mg/kg at weeks 4, 6, 8, and then every 4 weeks through week 48
1596507|NCT02260921|Device|iovera°|
1596508|NCT02260921|Device|Sham Comparator|
1596509|NCT02260908|Drug|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
1596510|NCT02260908|Other|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily for six doses, starting 36-48 hours post-traumatic injury.
1596511|NCT02260895|Dietary Supplement|Almond pre-test snack|unsalted, dry-roasted almonds, 1/2 oz (14 g), ingested 30 minutes prior to the start of a two-hour oral glucose tolerance test
1596512|NCT02260882|Biological|PNEUMOVAX™ 23|PNEUMOVAX™ 23 (23-Valent Pneumococcal Polysaccharide Vaccination, V110, PPV23)
1596513|NCT02260869|Procedure|Genicular nerve radiofrequency ablation|Radiofrequency ablation uses the electrical field generated by a radiofrequency probe inserted near a nerve responsible for pain. Chronic pain sensation in the knee is generated at the genicular nerves. The physician locates the affected genicular nerve by injecting an anesthetic (lidocaine) that produces a sensory nerve block (i.e. anesthetic pain relief). A radiofrequency probe is inserted percutaneously near the affected nerve using a cannula/introducer and is then connected to a radiofrequency generator. This is set to stimulate sensory and motor response, which allows the physician to adjust the probe position for effective and safe treatment. Then radiofrequency is applied to the tissue for a short time (up to 150 seconds) in order to generate a target temperature (no more than 80 degrees Celsius). The increase in the temperature of the tissue ablates the affected nerve producing pain relief.
1596514|NCT02260869|Device|Pain Management Radiofrequency Kit|The pain management radiofrequency consists of a radiofrequency generator, a radiofrequency probe and an introducer/cannula. The introducer cannula is used to percutaneously position the probe in the appropriate location for treatment. The radiofrequency probe is an electrode that delivers the electric field that heats up the tissue. In cooled radiofrequency the electrode is surrounded by a water jacket that cools it while heat is generated. The generator is the instrument that provides the radiofrequency according to a particular temperature and time program. Temperature, tissue impedance and radiofrequency power are lalso monitored by the generator.
1596515|NCT02260856|Device|Tantalum Beads & Injector|To measure growth at physis, four tantalum beads will be implanted per physis at baseline and take radiostereometric analysis measurements at all follow up timepoints. Tantalum beads have been used to make detailed three dimensional radiographic measurements in orthopedic and other specialties
1596516|NCT02260856|Procedure|Percutaneous Drill Epiphysiodesis|
1596517|NCT02260856|Procedure|Percutaneous Screw Epiphysiodesis|
1596518|NCT02260843|Other|Generic Fitness|Subjects in this groups will receive three fitness lessons in a weeks while each session last for 1 hour throughout the 12 weeks experimental period
1596519|NCT02260843|Other|Tai Chi Intervention|Subjects in this groups will receive three tai chi lessons in a weeks while each session last for 1 hour throughout the 12 weeks experimental period
1596520|NCT02260830|Drug|Lu AF11167|
1596521|NCT02260817|Drug|11C-choline Injection|"Choline C11 Injection for PET/CT Imaging Protocol:
15 - millicuries (mCi) 11C-choline IV Injection
PET images skull base to mid thigh with 3 min per bed position
Use of IV contrast based on American College of Radiology (ACR) IV contrast guidelines for a renal function screening protocol
Fusion of PET and CT images
Choline C11 Injection for PET/MRI Whole Body Imaging Protocol:
No IV contrast
High resolution axial T2 prostate bed, axial Diffusion Weighted Image (DWI) pelvis, coronal T2 skull base to mid thighs
Fusion of coronal and PET images"
1596522|NCT02260804|Biological|CT-P10|375mg/m2, IV on day1 of 4 cycles in induction period, and 12 cycles in maintenance period.
1596523|NCT02260804|Biological|Rituxan|375mg/m2, IV on day1 of 4 cycles in induction period, Rituxan for the first 6 cycles and CT-P10 for the last 6 cycles in maintenance period.
1596613|NCT02260167|Other|A mix of natural treatments and medications|
1596526|NCT02260778|Behavioral|Learning Collaborative|A learning collaborative is an established technique that uses the model for improvement to bridge the gap between what we know and what we do. Structured learning sessions and collaborative coaching are used to guide small cycles of change called Plan-Do-Study-Act (PDSA) cycles. This quality improvement intervention will help providers adopt treat-to-target practices through the structured learning collaborative.
1596527|NCT02260765|Device|dTMS|The Brainsway H-Coil TMS device is intended for the treatment of depressive episodes in patients suffering from Major Depressive Disorder (MDD). The device technology is based on the application of deep TMS by means of repetitive pulse trains at a determined frequency
1596528|NCT02260752|Procedure|hysterectomy|surgical removal of the uterus
1596529|NCT02260752|Procedure|Uterine arterial embolization|In uterine artery embolization, doctor uses a slender, flexible tube (catheter) to inject small particles (embolic agents) into the uterine arteries, which supply blood to your fibroids and uterus.the embolic agents are injected into these fibroid blood vessels. The goal is to block the fibroid vessels, starving the fibroids and causing them to shrink and die.
1596530|NCT02260752|Procedure|myomectomy|surgical procedure to remove uterine fibroids, but does not remove uterus
1596531|NCT02260752|Drug|Medical Therapy|treatment of uterine fibroids with only medications, no procedure or surgery is used
1596532|NCT02260752|Procedure|endometrial ablation|surgical procedure that destroys uterine lining via a telescope placed inside the uterus
1596533|NCT02260752|Procedure|magnetic resonance guided focused ultrasound|procedure that destroys fibroids while inside an MRI machine
1596534|NCT02260752|Procedure|radiofrequency ablation|procedure that uses heat to destroy uterine fibroids
1596535|NCT02260739|Other|Blood samples|
1596536|NCT02260726|Procedure|Magnetic resonance imaging|
1596537|NCT02260726|Procedure|Ultrasound|
1596538|NCT02260713|Biological|autologous bone marrow cell|Transplantation of 200 million cells in 1.8 ml of autologous plasma in a single sitting. In case of intralesional route, the cells were delivered in one sitting at six sites ( 2 above the lesion, 2 at the lesion and 2 below the lesion) as 0.3 ml aliquots each. In case of Intrathecal route, the cells were delivered as a single injection of 1.8ml via lumbar puncture.
1596539|NCT02260700|Drug|JNJ-54861911 (Treatment A)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment A (oral suspension formulation) under fasted conditions in one of the treatment periods.
1596540|NCT02260700|Drug|JNJ-54861911 (Treatment B)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment B (solid formulation) under fasted conditions in one of the treatment periods.
1596541|NCT02260700|Drug|JNJ-54861911 (Treatment C)|Participants will receive a single oral 25 mg dose of JNJ-54861911 as Treatment C (solid formulation) under fed conditions in one of the treatment periods.
1596543|NCT02260674|Drug|JNJ-54861911, 10 milligram (mg)|Participants will self-administer JNJ-54861911, two tablets of 5 mg each for a total of 10 mg, orally, once daily, from Day 1 until Month 6 in treatment group 1.
1596544|NCT02260674|Drug|JNJ-54861911, 50 mg|Participants will self-administer JNJ-54861911, two tablets of 25 mg each for a total of 50 mg, orally, once daily, from Day 1 until Month 6 in treatment group 2.
1596545|NCT02260674|Drug|Placebo|Placebo matched to JNJ-54861911, orally, once daily, from Day 1 until Month 6 in placebo group.
1596546|NCT02260661|Drug|AZD8835|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
1596547|NCT02260661|Drug|AZD8835|AZD 8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components
1596548|NCT02260661|Drug|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy.
1596549|NCT02260661|Drug|AZD8835 in combination with fulvestrant|AZD8835 is a small molecule that inhibits cancer progression by blocking PI3 kinase pathway components. Fulvestrant is approved for the treatment of postmenopausal women with ER+ locally advanced or metastatic breast cancer following progression of disease while receiving anti-estrogen therapy
1596550|NCT02260648|Drug|Evacetrapib|Administered orally
1596551|NCT02260648|Drug|Ezetimibe|Administered orally
1596552|NCT02260648|Drug|Atorvastatin|Administered orally
1596553|NCT02260648|Drug|Placebo|Administered orally
1596554|NCT02260635|Drug|Evacetrapib|Administered orally
1596555|NCT02260635|Drug|Placebo|Administered orally
1596556|NCT02260622|Drug|rivaroxaban plus aspirin|Rivaroxaban 2.5 mg twice daily for 90 days (rivaroxaban will be started 6 to 8 hours after the finalization of the procedure) and 81 mg of ASA daily for 90 days
1596557|NCT02260622|Drug|clopidogrel plus aspirin|Clopidogrel 75 mg daily for 90 days (with a loading dose of 300 mg clopidogrel following PTA) and 81 mg of ASA daily for 90 days
1596558|NCT02260609|Other|Grafix®|"The treatment indication is for complex diabetic foot wounds with exposed tendon and/or bone that can accommodate up to three 5cm x 5cm pieces of Grafix®.
Patients will be treated for up to 16 weeks.
Patients will be evaluated at screening and then weekly throughout the study or until wound closure."
1596559|NCT02260583|Device|extracorporeal CO2 device|An ECCO2R device based on a modified continuous venovenous hemofiltration system will be used
1596560|NCT02260570|Drug|Tolcapone|COMT Inhibitor
1596561|NCT02260570|Drug|Placebo|A pill that contains no active ingredient
1596562|NCT02260557|Drug|Selexipag|Film-coated tablets containing 200 μg of selexipag to be administered orally twice daily
1596563|NCT02260557|Drug|Placebo|Placebo matching selexipag 200 μg tablets to be administered orally twice daily
1596564|NCT02260544|Drug|Doxorubicin Hydrochloride Liposome Injection|50mg/m2, IV on Day 1 of each cycle, On Day 1 of Cycle 2 , patients will crossover to the alternate reference or test formulation , After completion of Cycle 2 ( Day 28) , patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome injection upto 4 more cycles if tolerance permits under guidance of their attending physicians.
1596565|NCT02260531|Drug|Cabozantinib|One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1596566|NCT02260531|Drug|Trastuzumab|For HER2-Positive participants only. Administered by IV on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1596567|NCT02260518|Behavioral|Lifestyle Intervention|During pregnancy, participants complete one face-to-face counseling session, receive 10 behavioral podcasts, and receive weekly phone calls until delivery. Participants will be asked to attend one group session on breastfeeding. Participants will have the opportunity to participate in a private Facebook group during pregnancy and postpartum. During postpartum, participants complete one face-to-face counseling session, receive 16 behavioral podcasts, receive brief weekly check-in telephone calls for six weeks, and receive up to 8 telephone counseling calls through 6 months after delivery.
1596568|NCT02260518|Behavioral|Standard Care|Women will receive standard nutrition counseling provided by physicians, nurses, nutritionists, and counselors from the Women, Infants, and Children (WIC) program (if applicable). They will receive a monthly study mailing that is educational in nature as well as podcasts related to a healthy pregnancy. During pregnancy, the mailings will focus on tips for a healthy pregnancy and on fetal development. During postpartum the mailings will focus on infant development and parenting. We will select a matched number of podcasts from Pea in the Podcast, commercially available podcasts. All mailings and podcasts will avoid discussion of weight, PA, or diet (except for foods to avoid in pregnancy for safety reasons).
1596569|NCT02260505|Drug|Imatinib maintenance|Either 300 or 400 mg/day in accordance with the last dose routinely taken by the patient in the 3-year period before randomization. The treatment will be orally taken at time of meal with a large glass of water
1596570|NCT02260492|Drug|OT329 (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Solis dry powder inhaler
1596571|NCT02260492|Drug|Advair Diskus (combination of fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered by Diskus dry powder inhaler
1596572|NCT02260492|Drug|Placebo|Placebo (lactose) administered via the Solis dry powder inhaler
1596573|NCT02260479|Procedure|Preheated|Skin disinfection solution is preheated in a warming cupboard
1596574|NCT02260466|Other|a basal LV septum biopsy|During surgery, a basal LV septum biopsy will be collected for determination and quantification of interstitial deposits using specific staining which will be performed in a blind fashion
1596575|NCT02260453|Other|Preoperative coronary angiography|If coronary disease is detected percutaneous intervention (PCI) or coronary artery bypass grafting (CABG) is applied
1596576|NCT02260453|Other|Standard cardiac workup|EKG, transthoracic cardiac echocardiogram
1596577|NCT02260440|Drug|Pembrolizumab|Pembrolizumab will be given at 200 mg every 21 days
1596578|NCT02260440|Drug|Azacitidine|Azacitidine will be given at 100 mg daily subcutaneous injection on days 1-5 every 21 days.
1596579|NCT02260427|Device|Insertion of the i-gel|After induction of general anesthesia, the i-gel will be inserted according to randomly allocated group.
1596580|NCT02260427|Device|Insertion of the air-Q sp|
1596581|NCT02260414|Drug|Tinzaparin|single subcutaneous injection of 4500 IU tinzaparin
1596582|NCT02260414|Other|Blood sample|blood sample taken at hours 0, 3, 8, 18 and 24 after subcutaneous injection of 4500 IU tinzaparin
1596583|NCT02260401|Other|Individualized report|Each patient will receive an individualized report that contains their own outcome data for the first years of the LESS trial (including pain and function following treatment with epidural injections)
1596584|NCT02260388|Drug|Nortriptyline|
1596585|NCT02260388|Drug|Duloxetine|
1596586|NCT02260388|Drug|Pregabalin|
1596587|NCT02260388|Drug|Mexiletine|
1596588|NCT02260375|Biological|Mesenchymal Stromal Cells|
1596589|NCT02260349|Drug|indocyanine green infusion|intravenous injection (0,25mg/kg) of the indocyanine green 24h before prostatic surgery.
1596590|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 1g|
1596591|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 5g|
1596592|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 10g|
1596593|NCT02260336|Dietary Supplement|Panax Notoginseng Powder 15g|
1596594|NCT02260336|Drug|Celecoxib Capsule 400 mg daily|
1596595|NCT02260323|Other|patient-tailored anti-arthritis herbs|patient use tailored anti-arthritis herbs
1596596|NCT02260323|Other|patient-tailored DMARDs|patient use tailored disease-modifying antirheumatic drugs
1596597|NCT02260310|Other|Weizhong and Huantiao|
1596598|NCT02260310|Other|A-shi point|
1596599|NCT02260297|Device|Wrist Actigraphy(motion sensors)with light sensors-Jawbone Up 2|
1596600|NCT02260284|Other|Acupotome(needle knife)|patients under the treatment of acupotome(needle knife)
1596601|NCT02260284|Other|Control|patients under the treatment of general acupuncture,but not acupotome (needle knife)
1596602|NCT02260271|Other|Database Entry/Biospecimen Collection|blood, urine, buccal samples and medical data collected
1596603|NCT02260258|Drug|Rocuronium|Neuromuscular Blockade
1596604|NCT02260258|Drug|Normal Saline|Normal Saline
1596605|NCT02260245|Behavioral|Team training using the TeamSTEPPS model|Two or three master trainers from each affiliate will be undergo train-the-trainer training to bring back to their affiliate.
1596606|NCT02260232|Other|exercise training|
1596607|NCT02260219|Procedure|Surgical Implant of Ahmed Glaucoma Drainage Device, model M4 and S2|Surgically Implant an Ahmed Glaucoma Drainage Device Models S2 and M4, evaluare IOP evolution, complications and need for medication to control IOP
1596608|NCT02260206|Drug|Colchicine|Impact of Colchicine therapy on arrhythmia Recurrence after Acute Pericardial Effusion following Catheter Ablation of Atrial Fibrillation
1596609|NCT02260193|Drug|AKB-6548|Starting dose 1. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
1596610|NCT02260193|Drug|AKB-6548|Starting dose 2. Oral dose administered once daily for 16 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
1596611|NCT02260193|Drug|AKB-6548|Starting dose 3. Oral dose administered three times weekly for 16 weeks. Dose adjustment based on hemoglobin levels as defined in the protocol.
1596612|NCT02260180|Drug|A-101|Topical Solution
1596614|NCT02260154|Drug|Mebeverine|Subjects treated by Duspatalin (mebeverine) 200 mg BID (bis in die = twice a day) upto 6 weeks in accordance with routine practice will be observed
1596615|NCT02260141|Dietary Supplement|d-ribose|giving ribose in those with a diagnosis of Alzheimer's and/or dementia
1596616|NCT02260128|Other|Chewing gum|The intervention group will receive chewing gum four times daily following surgery.
1596617|NCT02260115|Device|LABS™|hydrogel sprayed laparoscopically over all pelvic areas of surgical trauma
1596618|NCT02260115|Procedure|Surgical Control|Surgery only
1596619|NCT02260102|Drug|Temocillin|Venous blood will be drawn (as per the protocol) for assay of temocillin on day 1 and day 4 of treatment. This is not part of our standard of care and is, therefore, an intervention. Patients are enrolled only if receiving temocillin as part of their normal standard of care (and the drug will be administered based on current recommendations [no change due to enrollment in the study]).
1596620|NCT02260089|Drug|Low dose of telmisartan|
1596621|NCT02260089|Drug|High dose of telmisartan|
1596622|NCT02260089|Drug|Placebo|
1596623|NCT02260076|Drug|PEG 400|
1596624|NCT02260076|Drug|Placebo|
1596625|NCT02260063|Drug|Epinastine syrup|
1596626|NCT02260063|Drug|Epinastine tablets|
1596627|NCT02260050|Drug|WAL 801 CL dry syrup new formulation|
1596628|NCT02260050|Drug|WAL 801 CL dry syrup conventional formulation|
1596629|NCT02260037|Drug|Epinastine nasal|
1596630|NCT02260037|Drug|Placebo|
1596631|NCT02260024|Other|High fat, high caloric meal|
1596632|NCT02260024|Drug|Pramipexole IR tablets|
1596633|NCT02260024|Drug|Pramipexole SR C|
1596634|NCT02260024|Drug|Pramipexole SR C2|
1596635|NCT02260024|Drug|Pramipexole SR C2A|
1596636|NCT02260024|Drug|Pramipexole SR C2B|
1596637|NCT02260011|Drug|Ipratropium bromide HFA-134a inhalation aerosol|
1596638|NCT02260011|Drug|Atrovent® CFC inhalation aerosol|
1596639|NCT02260011|Drug|Placebo|
1596640|NCT02259998|Drug|Persantin® new formulation|
1596641|NCT02259998|Drug|Persantin® commercial formulation|
1596642|NCT02259985|Drug|Itasetron tablet|
1596643|NCT02259985|Drug|Itasetron infusion|
1596644|NCT02259985|Other|high fat breakfast|
1596645|NCT02259972|Drug|BI 113823 solution|
1596646|NCT02259972|Drug|BI 113823 tablet|
1596647|NCT02259972|Drug|Placebo|
1596648|NCT02259972|Other|High fat, high calorie breakfast|only for dose group 5
1596649|NCT02259959|Drug|Single rising doses of BI 1744 CL, solution for oral inhalation|
1596650|NCT02259959|Drug|Tiotropium, fixed dose, solution for oral inhalation|
1596651|NCT02259959|Drug|Placebo|
1596652|NCT02259946|Drug|BI 1744 CL|
1596653|NCT02259946|Drug|Placebo|
1596654|NCT02259946|Drug|Tiotropium bromide|
1596655|NCT02259933|Drug|KUC 7483 CL|
1596656|NCT02259933|Drug|Placebo|
1596657|NCT02259920|Drug|KUC 7483 CL, immediate release tablet|
1596658|NCT02259920|Drug|KUC 7483 CL, particulate formulation|
1596659|NCT02259920|Drug|KUC 7483 CL, solution formulation|
1596660|NCT02259920|Device|Enterion™ capsule|
1596661|NCT02259907|Drug|KUC 7483 CL|
1596662|NCT02259907|Drug|Placebo|
1596663|NCT02259907|Other|High fat meal|
1596664|NCT02259894|Drug|BIRT 2584 XX|
1596665|NCT02259894|Drug|Placebo|
1596666|NCT02259881|Drug|Low dose of BIBT 986 CL, per i.v. infusion|
1596667|NCT02259881|Drug|Medium dose of BIBT 986 CL, per i.v. infusion|
1596668|NCT02259881|Drug|High dose of BIBT 986 CL, per i.v. infusion|
1596669|NCT02259881|Drug|Placebo|
1596670|NCT02259881|Drug|Lipopolysaccharide (LPS), single i.v. bolus|Endotoxin derived from E. coli bacteria, used for activation of coagulation
1596671|NCT02259868|Drug|BILR 355 BS /1B, current low dose formulation|
1596672|NCT02259868|Drug|BILR 355 BS /1B, current high dose formulation|
1596673|NCT02259868|Drug|BILR 355 BS - Jet Milled (JM) + Sodium Dodecyl Sulfate (SDS) formulation|
1596674|NCT02259868|Drug|BILR 355 BS - Hammer Milled (HM) + Sodium Dodecyl Sulfate (SDS) formulation|
1596675|NCT02259868|Drug|BILR 355 BS - Suspension low dose|
1596676|NCT02259868|Drug|BILR 355 BS - Suspension high dose|
1596677|NCT02259868|Drug|Ritonavir|
1596678|NCT02259855|Drug|Tipranavir|
1596679|NCT02259855|Drug|Ritonavir|
1596680|NCT02259855|Drug|Pegylated interferon|
1596681|NCT02259855|Drug|Ribavirin|
1596682|NCT02259842|Drug|BI 34021 FU2 solution|
1596683|NCT02259842|Drug|BI 34021 FU2 tablet|dose group 4 only
1596684|NCT02259842|Drug|Placebo|
1596685|NCT02259842|Other|High fat, high calorie breakfast|only for dose groups 3 and 5
1596686|NCT02259829|Drug|Telmisartan/Amlodipine|Fixed dose combination tablet
1596687|NCT02259829|Drug|Telmisartan|
1596688|NCT02259829|Drug|Amlodipine|
1596689|NCT02259816|Drug|Telmisartan|
1596690|NCT02259816|Drug|Amlodipine|
1596691|NCT02259803|Drug|Telmisartan/amlodipine fixed-dose combination (FDC) tablet|
1596692|NCT02259803|Drug|Telmisartan|
1596693|NCT02259803|Drug|Amlodipine|
1596694|NCT02259790|Drug|Telmisartan/amlodipine fixed-dose combination tablet|
1596695|NCT02259790|Drug|Telmisartan|
1596696|NCT02259790|Drug|Amlodipine|
1596697|NCT02259777|Drug|Telmisartan/Amlodipine|Fixed dose combination tablet
1596698|NCT02259777|Other|high fat, high caloric meal|
1596699|NCT02259764|Drug|KUC 7483 CL - single rising dose|
1596700|NCT02259764|Drug|Placebo|
1596701|NCT02259764|Other|standardized high fat meal|
1596702|NCT02259751|Drug|KUC 7483 CL|
1596703|NCT02259751|Drug|Placebo|
1596704|NCT02259738|Drug|Human Urinary Kallidinogenase|
1596705|NCT02259738|Drug|Shuxuening injection|
1596706|NCT02259725|Drug|regorafenib|Given PO
1596707|NCT02259725|Other|laboratory biomarker analysis|Correlative studies
1596708|NCT02259712|Other|Hipopressive exercises|45 minutes treatment by hipopressive exercises 2 times per week during 8 weeks. They will be doing in different positions: standing, kneeling, sitting and lying. The patient will be teach a total of 30 exercises. In the week number 8 the women with the physical therapist will choose 3 exercises that will be done daily at home during 20 minutes.
1596709|NCT02259712|Behavioral|Therapeutic education.|"The therapeutic education will be doing during the 8 weeks of treatment. In the first day the knowledge and the briefs of the pelvic floor dysfunction will be assessed. Dietary and behavioral habits will also be discussed. In the second day anatomical and physiological explanation of the pelvic girdle will be the priority. In the third day will be explained the signs and symptoms of the different pelvic floor dysfunctions. In the four day will be analyzed the risk factors that may cause or worsen pelvic floor dysfunctions.
In the fifth day will be begun to correct the bad habits. In the last day will be reviewed the knowledge and new habits acquired during the treatment. In all treatment days will be discussed the doubts of the participant."
1596710|NCT02259712|Other|Pelviperineal physiotherapy|45 minutes physical therapy treatment 2 times per week during 8 weeks. There will be done specific exercises of the pelvic floor muscles and coordination exercises of the pelvic floor muscles with other muscles in different positions. Electrostimulation, biofeedbak, cones and dinamometric devices can be employed to improve the muscle performance.
1596711|NCT02259712|Other|Physical Therapy assessment|Pre-treatment, post-treatment, 3, 6 and 12 months after physical therapy treatment. Will be done a specific evaluation of pelvic floor muscles using the Modified Oxford Scale, superficial electromyography, perineometry and dynamometer. For the evaluation of the impact, the signs and the symptoms questionnaires will be completed by the participants.
1596713|NCT02259686|Drug|Apelin 1mg subcutaneous|single subcutaneous injection of Apelin 1mg subcutaneous
1596714|NCT02259686|Drug|Apelin 1mg intravenous|15 minute intravenous bolus of Apelin 1mg intravenous
1596715|NCT02259686|Drug|Apelin 5mg subcutaneous|single subcutaneous injection of Apelin 5mg subcutaneous
1596716|NCT02259686|Drug|Apelin 5mg intravenous|15 minute intravenous infusion of Apelin 5mg intravenous
1596717|NCT02259686|Drug|Apelin 10 mg subcutaneous|24 hour continuous subcutaneous infusion of Apelin 10 mg subcutaneous
1596718|NCT02259673|Other|Fun exercise|Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises (including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)
1596719|NCT02259673|Other|fun exercise|"Intervention group 3 times a week for 20 minutes during 2 months, fun physical exercises
(including activities carried out with the use of sports equipment such as beach ball, stretch, bird toys, etc)"
1596720|NCT02259660|Device|Respiratory muscle strength training|Inspiratory and expiratory muscle strength training occur when subjects are required to breath in (as with inspiratory training) or out (as with expiratory training) through a pressure threshold device. This device features a spring-loaded one way valve which will only open if the subject is able to generate sufficient air pressure to overcome a predetermined pressure threshold. This threshold is typically set at 75% of the subject's maximum capacity. Repeatedly overcoming this threshold during training produces a strengthening effect in most people.
1596721|NCT02259660|Device|Sham respiratory muscle strength training|The placebo / sham intervention will mimic the active intervention(s) in every respect except the devices used will be rendered neutral via removal of the pressure threshold spring inside the devices.
1596722|NCT02259647|Drug|Sorafenib 400mg twice daily + intravenous infusion ofVit K1|Sorafenib 400mg twice daily + intravenous infusion ofVit K1 50 mg/day with daily increase of dose by 50 mg for 6 days, followed by oral Vitamin K1 20mg twice daily for 3month
1596723|NCT02259647|Drug|Sorafenib 400 mg twice daily + Intravenousinfusion of placebo|Sorafenib 400 mg twice daily + Intravenousinfusion ofplacebo daily for 6 days, followed by oral placebo twice daily x 3month
1596724|NCT02259634|Behavioral|Patient Navigation|Motivational Interviewing
1596725|NCT02259621|Drug|Nivolumab|Anti-PD-1 Therapy
1596726|NCT02259621|Drug|Ipilimumab|Anti-PD-1 Therapy
1596727|NCT02259608|Biological|BCG vaccine SSI|BCG vaccination
1596728|NCT02259595|Drug|HPN-07|500-1,500 mg oral capsules administered in a single dose
1596729|NCT02259595|Drug|NAC|1,200mg NAC administered via oral capsule in single dose
1596730|NCT02259595|Drug|Placebo|placebo oral capsule
1596731|NCT02259582|Drug|Pemetrexed|
1596732|NCT02259582|Drug|Carboplatin|
1596733|NCT02259582|Drug|demcizumab|
1596734|NCT02259569|Other|Pressure-controlled ventilation|
1596735|NCT02259569|Other|Volume-controlled ventilation|
1596736|NCT02259556|Biological|CART30|Cells will be infused 1 day after the completion of conditioning regimen.
1596737|NCT02259543|Other|Root conditioning with citric acid+tetracycline solution|Application of a citric acid + tetracycline gel solution (1:1) for decontamination of root surfaces during the treatment of recession defects by subepithelial connective tissue graft
1596738|NCT02259530|Behavioral|Integrated Psychotherapeutic Intervention|Evidence-based standard tools for the treatment of PTSD and comorbid khat dependence: Community Reinforcement Approach, Relapse Prevention, Narrative Exposure Therapy
1596739|NCT02259517|Drug|Guanfacine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
1596740|NCT02259517|Drug|Lisdexamfetamine|Participants will meet with the study doctor on a weekly basis during the treatment phase of the study. In the first few weeks, the daily dose of the medication will be individually adjusted by the study doctor according to participants' clinical response to and tolerability of the medication. The optimal dose will then be maintained for the remainder of the treatment period.
1596741|NCT02259504|Device|HyperSoft® 3D|HyperSoft® 3D or any other bare metal coil but must finish the remainder of the aneurysm with HyperSoft® 3D and/or HyperSoft® helical coils
1597129|NCT02256813|Drug|Midazolam hydrochloride|
1596742|NCT02259491|Drug|Manuka Honey Dressing|After surgical resection and reconstruction the skin graft donor site (thigh) and the free flap donor site will be dressed with Medihoney surgical dressings. More specifically, a dressing of appropriate size will be applied to the anterior thigh and covered with tegaderm. For the STSG recipient site a Medihoney dressing will cover the skin graft, followed by dry gauze, kerlex and a cast.
1596743|NCT02259465|Behavioral|low FODMAP diet|Participants will attend a one-hour group session on how to follow the low FODMAP diet, run by a dietitian trained in the diet. They will be asked to follow the diet for 7 days while keeping a food diary.
1596744|NCT02259465|Dietary Supplement|Oligofructose|Participants will supplement their diet with 7 grams of OF twice daily for the week that they follow the low FODMAP diet.
1596745|NCT02259465|Dietary Supplement|Maltodextrin|Participants will supplement their diet with 7 grams of maltodextrin twice daily for the week that they follow the low FODMAP diet.
1596746|NCT02259452|Procedure|SPECT Lung Perfusion Scan|
1596747|NCT02259452|Procedure|SPECT Heart Perfusion Scan|
1596748|NCT02259452|Procedure|Pulmonary Function Tests|
1596749|NCT02259426|Drug|Dihydroartemisinin-piperaquine combination (Artekin)|
1596750|NCT02259426|Drug|Primaquine|Single-dose 0.25mg/kg
1596751|NCT02259413|Behavioral|Exercise Rehabilitation|This intervention will consist of lifestyle education, home-based resistance exercise and stationary cycling during hemodialysis sessions. Duration of the intervention will be 12 weeks.
1596752|NCT02259400|Device|NSIPPV|In N-SIPPV, the physician will set : an initial PEEP of 4-6 cmH20; a peak inspiratory pressure (PIP) of 15-20 cmH2O ; an inspiratory time (IT) of 0.3-0.4 seconds; a flow rate of 6-10 L/min and a respiratory rate (RR) of 40 bpm with the lowest FiO2 to maintain a oxygen saturation (SpO2) of 88-93%. Weaning from N-SIPPV will be performed with a reduction of the RR to 15 bpm with a PIP of 10-15 cmH2O and PEEP of 4 cmH2O and will be stopped when the baby will not show signs of RDS and with a fraction of inspired oxygen (FiO2)< 0.3.
1596753|NCT02259400|Device|BiPAP|In BiPAP, the physician will set : an initial low CPAP-level of 4-6 cmH20 and high CPAP-level of 8-9 cmH20; a time high of 1 second and a pressure exchange rate of 20 bpm, with the lowest FiO2 to maintain a SpO2 of 88-93%. Weaning will start with a progressive reduction of the set pressure exchange rate ( minimum 15 pressures exchange/min), followed by the reduction of the higher level-CPAP down to 6 cmH20 and lower level-CPAP down to 4 cmH20. BiPAP will be stopped when the baby will not show signs of RDS and with a FiO2 < 0.3.
1596754|NCT02259374|Procedure|TAP BLOCK 0.2% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.2% Ropivacaine for bilateral TAP block after hysterectomy
1596755|NCT02259374|Procedure|TAP BLOCK 0.4% ROPIVACAINE|Patients randomised to this group will receive 20 ml 0.4% Ropivacaine for bilateral TAP block after hysterectomy
1596756|NCT02259361|Drug|Sustained-release oral dalfampridine|One Sustained-release oral dalfampridine; 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
1596757|NCT02259361|Drug|Placebo|Placebo, 10 mg tablet, twice daily, taken 12 hours apart (one tablet in the morning and one tablet in the evening) taken for 14 consecutive days.
1596758|NCT02259348|Drug|Cyclophosphamide|Given intravenously (IV)
1596759|NCT02259348|Drug|Fludarabine|Given IV
1596760|NCT02259348|Biological|G-CSF|Given IV or subcutaneously (SQ)
1596761|NCT02259348|Biological|Interleukin-2|Given SQ
1596762|NCT02259348|Drug|Melphalan|Given IV
1596763|NCT02259348|Drug|Thiotepa|Given IV
1596764|NCT02259348|Drug|Rituximab|Given IV
1596765|NCT02259348|Biological|Natural killer cell therapy|Given IV
1596766|NCT02259348|Biological|T-cell depleted HPC transplant|T-cell depleted hematopoietic stem cells will be infused on day 0.
1596767|NCT02259348|Biological|CD45RA-depleted HPC transplant|CD45RA depleted stem cells will be infused on day 1.
1596768|NCT02259335|Device|Extracorporeal CO2 removal device|A device able to remove CO2 using a dedicated device connected to the patient via a double lumen catheter inserted in the femoral vein
1596769|NCT02259322|Behavioral|Standard-of-Care|Standard-of-Care with bariatric team. Participants will be encouraged to continue their care with their bariatric team.
1596770|NCT02259322|Behavioral|Behavioral Weight Loss Treatment|Biweekly individual guided self-help sessions for 3 months
1596771|NCT02259322|Behavioral|Cognitive Behavioral Therapy|Biweekly individual guided self-help sessions for 3 months
1596772|NCT02259309|Drug|Misoprostol - buccal|buccal administration
1596773|NCT02259309|Drug|Misoprostol - vaginal|vaginal administration
1596774|NCT02259296|Procedure|Lower eGFR for AVF construction|Lower eGFR patients (eGFR<10ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR<15ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
1596775|NCT02259296|Procedure|Higher eGFR for AVF construction|Higher eGFR patients (eGFR 10-15ml/min 1.73m2 for patients without diabetic kidney disease, and eGFR 15-20ml/min 1.73m2 for diabetic kidney disease) are proposed to undergo AVF construction
1596776|NCT02259283|Device|Hybrid Knife|POEM (Per oral endoscopic myotoymy) technique performed with the hybrid knife which combines injection and cutting in the same device.
1596777|NCT02259270|Other|Record review|Record review. No intervention with patient or physician. No effect on outcome.
1596778|NCT02259270|Other|AST-history|Checking history (period and number) of ambulatory dispensed AST from 1 year before till 1 year after hospitalisation. No intervention with patient or physician. No effect on outcome.
1596779|NCT02259244|Behavioral|Weight reduction program|
1596780|NCT02259231|Drug|Omaveloxolone Capsules (2.5 mg/capsule)|Capsules containing 2.5 mg of omaveloxolone per capsule to the dosage indicated in the Arm Label
1596781|NCT02259231|Drug|Ipilimumab (3 mg/kg)|Sterile solution containing ipilimumab to be delivered intravenously at 3mg/kg
1596782|NCT02259231|Drug|Nivolumab (240 mg)|Sterile solution containing nivolumab to be delivered intravenously at 240 mg
1596783|NCT02259218|Other|laboratory biomarker analysis|Correlative studies
1596784|NCT02259205|Other|Enriched Yogurt|150 g yogurt enriched with bioactive lipids extract from olive oil mill will be provided daily for 8 weeks
1596785|NCT02259205|Other|Plain Yogurt|150 g plain yogurt will be provided daily for 8 weeks
1596786|NCT02259192|Device|MED-EL Maestro Cochlear Implant|cochlear implant
1597130|NCT02256813|Drug|Vitamin K1|
1596787|NCT02259179|Drug|Reference naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
1596788|NCT02259179|Drug|Test naltrexone 8 mg SR/bupropion 90 mg SR combination trilayer tablets (2 tablets)|
1596789|NCT02259166|Other|EHFP+|Enhanced-homestead food production program including home gardening and poultry rearing + WASH interventions + SBCC around the essential nutrition actions and WASH/malaria prevention with a gender component.
1596790|NCT02259153|Behavioral|Changes in cholesterol metabolism|
1596791|NCT02259153|Other|Lean red meat diet|
1596792|NCT02259153|Other|Fat red meat diet|
1596793|NCT02259140|Procedure|Proximal Femoral Resection Arthroplasty|Drains will be placed at the surgeon's discretion. Patients will be placed in skin traction on the operative side. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
1596794|NCT02259140|Procedure|Subtrochanteric Valgus Osteotomy|Drains will be placed at the surgeon's discretion. Post-operative bracing or casting will be at the surgeon's discretion. All patients will receive standardized post-operative prophylactic radiation to minimize heterotopic ossification.
1596795|NCT02259127|Drug|DTG|
1596796|NCT02259114|Drug|OTX015/MK-8628|OTX105/MK-8628 10, 20 and/or 40 mg capsules
1596797|NCT02259101|Behavioral|CBT-I Treatment Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
1596798|NCT02259101|Behavioral|SH Comparison Condition|Each group will last approximately 1 hour and will involve completing surveys in order to track both the quantity and quality of sleep. Blood will be drawn twice in order to compare how the body responds to medical illnesses.
1596799|NCT02259088|Drug|ranibizumab|intravitreal injections for 3 months then as needed
1596800|NCT02259088|Procedure|laser|laser photocoagulation according to ETDRS guidelines
1596801|NCT02259075|Drug|Botulinum Toxin Type A|
1596802|NCT02259062|Other|Music with brief mindfulness intervention|Music listening with mindfulness therapy
1596803|NCT02259062|Other|Music listening alone|
1596804|NCT02259062|Other|Audiobook listening|
1596805|NCT02259049|Dietary Supplement|L-tyrosine|Each subject will receive 2,000 mg of L-tyrosine BID for 24 hours.
1596806|NCT02259049|Dietary Supplement|Sugar Pill|Each subject will receive a sugar pill BID for 24 hours.
1596807|NCT02259036|Other|Ecological Momentary Treatment Enhancement|Participants will be given a pre-programmed smartphone on which they will enter their responses to a series of questions about moods and daily experiences using an app developed for this study. The child will receive an electronic notification message once per day and will be prompted through a series of questions about what he/she is doing, who he/she is with, how he/she is feeling, worries or stressful events, and how he/she coped with these events. It should take the child approximately 5 minutes each time to complete the questions. Participant data will be sent to study therapists to be reviewed weekly. The therapist will integrate this information into treatment and provide customized feedback to the patient.
1596810|NCT02259010|Drug|Alisertib|Alisertib tablets
1596811|NCT02259010|Drug|Itraconazole|Itraconazole oral solution
1596812|NCT02258984|Device|Mespere Venus 1000 Non-Invasive CVP System|The Venus 1000 CVP System is a non-invasive central venous pressure measurement system that utilizes the proven science of NIRS. Approved by FDA, received Health Canada Medical Device Licence and CE Marked, the Venus 1000 has been proven to be clinically equivalent to measurements made via right heart catheterization.
1596813|NCT02258971|Drug|BEA 2180 BR oral|Oral solution
1596814|NCT02258971|Drug|BEA 2180 BR infusion|Solution for infusion to be reconstituted with isotonic saline
1596815|NCT02258919|Procedure|Decompressive craniectomy (DC) and best medical treatment|"Decompressive craniectomy:
All patients in the treatment group will receive DC of at least 12 cm according to institutional guidelines and a published surgical protocol.
Best medical treatment:
Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively."
1596816|NCT02258919|Procedure|Best medical treatment|Best medical treatment is based on American Heart Association/American Stroke Association (AHA/ASA) and European Stroke Organisation (ESO) as published in the current protocol from 2010 and 2014 respectively.
1596817|NCT02258906|Drug|ulinastatin|
1596818|NCT02258906|Drug|normal saline|
1596819|NCT02258893|Other|NO2 Scrubber|an NO2 scrubber that removes NO2 and particles
1596820|NCT02258893|Other|HEPA filter|a HEPA filter that removes 95% of suspended particles ≥ 0.003 μm in size (but does not remove NO2)
1596821|NCT02258893|Other|Control|"a control filter designed to be the same size and weight as the other two filters, but filters neither NO2 nor particles"
1596822|NCT02258880|Drug|SUN13837|
1596823|NCT02258880|Drug|placebo|
1596824|NCT02258867|Drug|Placebo|Solution for subcutaneous injection
1596825|NCT02258867|Drug|Gevokizumab|Solution for subcutaneous injection
1596826|NCT02258854|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
1596827|NCT02258841|Behavioral|Setting Priorities for Safety|Participants rate the importance of 5 priorities to decision-making about their unsafe relationship by comparing the relative importance of each pair of priorities. Weights for each priority are computed and provided to the woman, along with examples of safety strategies that fit with her top ranked priority.
1596828|NCT02258841|Behavioral|Danger Assessment|Participants complete a calendar to show episodes of physical and/or sexual violence they have experienced in the past 12, along with 20 questions assessing risk of serious or lethal violence. A standardized weighted score is provided, along with a brief explanation about her level of danger and appropriate actions she may take.
1596829|NCT02258841|Behavioral|Personalized Action Plan|Women create a tailored action plan for themselves by selecting strategies from 8 different groups, including those which are recommended to them based on their responses to previous questions.
1596830|NCT02258841|Behavioral|General risk and safety information|Participants receive general information about the importance of priorities in making safety decisions and risk factors for intimate partner violence.
1596831|NCT02258841|Behavioral|Basic Emergency Safety Plan|Participants are provided with a basic emergency plan including information about local DV resources. The information is not personalized but is consistent with online information which women could find on their own (usual care)
1596832|NCT02258828|Drug|Memantine|Subjects initially received memantine 5 mg once daily, which was increased weekly by 5 mg/day in divided doses to a dose of 20 mg/day
1596833|NCT02258815|Drug|ch14.18/CHO|"A six courses regimen consisting of a 8 hour infusion (ch14.18/CHOmAb 20 mg/m² ) for five consecutive days will be administered every 4 weeks.
Interleukin 2 will be added to cycles 4-6 at days 6,8,10 (1 x 106 IU/m²/d s.c.) Participants will be premedicated with an intravenous antihistamine and ranitidine within approximately 30 minutes prior and during the infusion of the study agent Pain as an anticipated side effect is managed by a standard pain prophylaxis with Morphium hydrochloride Disease status will be evaluated after 3 and 6 courses and after 1 year."
1596834|NCT02258802|Behavioral|Psychoeducational intervention|A mobile kitchen visits the 5 selected communities every 2 weeks for a period of 1 year. A 30 minute cooking lesson is given by a trained instructor, the recipes have been designed to be quick and easy to make, use local and inexpensive ingredients, contain mostly vegetables and have a good taste. During the lesson, healthy habit and cooking tips are mentioned. A printed version of the recipe is given to every participant. Every lesson a different participant is encouraged to help prepare the recipe. At the end of the lesson all the participants get to taste the meal and express their opinion.
1596835|NCT02258789|Other|VR-method|Neglect rehabilitation by intense scanning training and multi sensory stimuli using Virtual Reality
1596836|NCT02258776|Dietary Supplement|Pomegranate Extract|Pomegranate extract 1000mg will be taken 1/day for 12 weeks.
1596837|NCT02258776|Dietary Supplement|Pomegranate Juice|Pomegranate juice 8oz will be consumed 1/day for 12 weeks.
1596838|NCT02258776|Dietary Supplement|Placebo|Placebo will be taken 1/day for 12 weeks.
1596839|NCT02258763|Drug|Amoxicillin-Potassium Clavulanate Combination|Oral antibiotic for 10 days
1596840|NCT02258763|Drug|Placebo|Placebo made to look like the study drug-main ingredient sugar syrup made by the pharmacy department in the hospital In the placebo arm, patient will be given 3 days of antibiotic followed by 7 days of placebo
1596841|NCT02258750|Dietary Supplement|Polydextrose|High fibre polydextrose enriched tomato soup (matched for sensory and nutritional characteristics to control) and eaten one hour before an ad-libitum lunch on study days. A 410g pre-packaged portion will be provided which contains 6% polydextrose compared to control.
1596842|NCT02258750|Other|Control|Tomato soup (matched for sensory and nutritional characteristics to control) served in a 410g portion and eaten one hour before an ad-libitum lunch on study days.
1596843|NCT02258737|Behavioral|Transitional Case Management|The case management activity deals with organizational and clinical aspects. The objective is to focus on network's expectations during hospitalization and at discharge, and ensure contacts between hospital and patient' social network. The aim is to support patient during the transition phase following discharge
1596844|NCT02258737|Behavioral|Standard Care|Routine hospitalization care is broadly defined as the usual level of care in the context of the adult department of psychiatry of the CHUV (Centre Hospitalier Universitaire Vaudois).
1596845|NCT02258711|Device|SIMPLE 2.0|SIMPLE 2.0 psychoeducative and self-monitoring smart-phone application plus treatment as usual.
1596846|NCT02258698|Procedure|Cardiac surgery|Blood samples for assessing Insulin resistance by HOMA, QUICKI, HbA1c, ANGPTL2, CXCL5, visfatin and irisin are drawn during induction of anesthesia, upon arrival on the intensive care unit and on postoperative day 1 and 3. Thirty days after surgery adverse outcomes covering all-cause morbidity and mortality will be assessed.
1596847|NCT02258672|Other|Prehabilitation program|Progressive and individualized physical training aimed at improving core muscles strength and endurance as well as spinal stability.
1596848|NCT02258659|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1596849|NCT02258659|Drug|carboplatin|Given IV
1596850|NCT02258659|Radiation|radiation therapy|Undergo radiation therapy
1596851|NCT02258659|Drug|paclitaxel|Given IV
1596852|NCT02258659|Drug|fluorouracil|Given IV
1596853|NCT02258659|Drug|hydroxyurea|Given PO
1596854|NCT02258659|Drug|cisplatin|Given IV
1596855|NCT02258659|Other|laboratory biomarker analysis|Correlative studies
1596856|NCT02258659|Procedure|quality-of-life assessment|Ancillary studies
1596857|NCT02258646|Behavioral|Exercise training at home|
1596858|NCT02258646|Behavioral|Telemonitoring and education/self-management|
1596859|NCT02258633|Other|Interactive interview and tailored family centered seatbelt safety intervention|
1596860|NCT02258620|Drug|dinitrate isosorbide|dinitrate isosorbide (cedocard*) by continuous intra venous (1 to 5 mg/h) dinitrate isosorbide (cedocard*) 5 mg by intra arterial direct in the sheat
1596861|NCT02258620|Drug|nitroglycerine|nitroglycerine dermal patch 15 mg/24h : 67,2 mg/21 cm2
1596862|NCT02258607|Drug|MMB|Momelotinib (MMB) tablet(s) administered orally once or twice daily
1596863|NCT02258607|Drug|Trametinib|Trametinib tablet administered orally once daily
1596864|NCT02258594|Other|Web-Based Patient Centered Toolkit (PCTK)|"The PCTK provides patients/care partners tailored health information regarding conditions, test results, and medications presented at a consumer health literacy level, and the ability to communicate with care team members via patient-facing tools accessible from bedside tablet computers. The PCTK allows patients to post questions to their care team members via a patient-centered microblog. The microblog facilitates development of a collaborative patient plan of care. The provider-facing PCTK includes tools that engage care team members in 1) completing a safety checklist and viewing a safety dashboard; 2) viewing patient-inputted information (goals, preferences, concerns) regarding the plan of care; 3) identifying clinical problems, care team goals, and patient schedules for education and multidisciplinary communication; 4) messaging patients on the patient thread; and 5) discussing patient's plan of care with other providers via the provider thread."
1596896|NCT02258412|Drug|Alcohol hand sanitizer foam|Alcohol foam hand sanitizer applied with 1 pump into hands, spread over hands up to the wrist and rubbed until dry. Foam will be applied twice approximately 15-30 minutes apart on one day
1596865|NCT02258594|Behavioral|The Patient-SatisfActive® Model|The Patient-SatisfActive Model is a structured, pro-active, patient-centered care model that aims at improving patient satisfaction by enhancing the degree to which patients' needs, concerns and expectations are met and by preserving dignity and respect. The model comprises steps that enhance interpersonal communication between clinicians and patients, incorporates clinicians' efforts to ascertain, address and document patients' needs, concerns, expectations and perceptions throughout hospitalization, and includes elements that empower and engage patients in their care.
1596866|NCT02258581|Drug|GS-4774|Exposure of interest for participants who received GS-4774 (administered as a subcutaneous injection) in a previous Gilead study for chronic hepatitis B virus infection.
1596867|NCT02258581|Drug|GS-9620|Exposure of interest for participants who received GS-9620 (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
1596868|NCT02258581|Drug|Tenofovir disoproxil fumarate (TDF)|Exposure of interest for participants who received TDF (tablets administered orally) in a previous Gilead study for chronic hepatitis B virus infection.
1596869|NCT02258568|Behavioral|Smoking abstinence counseling|Telephone smoking abstinence counseling based on motivational interviewing concepts
1596870|NCT02258555|Drug|GS-9901|GS-9901 tablets administered orally
2009433|NCT03256890|Behavioral|MB-BP Intervention|MB-BP customizes Mindfulness-Based Stress Reduction (MBSR) to participants with hypertension. It consists of nine 2.5-hour weekly group sessions and a 7.5-hour one-day session. Content includes education on hypertension risk factors, hypertension health effects, and specific mindfulness modules focused on awareness of BP determinants such as diet, physical activity, anti-hypertensive medication adherence, alcohol consumption, and stress reactivity. Students learn a range of mindfulness skills including body scan exercises, meditation and yoga. Homework consists of practicing skills for ≥45 min/day, 6 days/week. Participants are given a home BP monitor. Participants with uncontrolled hypertension are offered to have their physicians notified, if not already overseen for uncontrolled hypertension; those without a physician are worked with to provide access within health insurance constraints.
1596873|NCT02258529|Drug|Idelalisib|150 tablets administered orally twice daily
1596874|NCT02258529|Biological|Rituximab|375 mg/m^2 administered intravenously (weekly for 4 weeks and then every 8 weeks from Week 12 up to Week 100)
1596875|NCT02258516|Behavioral|CHIME 3-M|behavioral intervention for self-management in heart failure
1596876|NCT02258516|Behavioral|attention control|patients will receive phone calls regarding health-related topics not associated with heart failure
1596877|NCT02258503|Other|pain in elderly patients|
1596878|NCT02258490|Biological|G-CSF mobilized CD34+ selected cells for transplantation|"Mobilization of Donor: Following screening and enrollment after informed consent, the donor will receive mobilization therapy with G-CSF (10 ug/Kg S/C daily x5-6 days) using the standard National Marrow Donor Program (NMDP) guidelines.
CD34+ selection with CliniMACS device: CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs). If the donor's plasma is not available, CliniMACS buffer will be used.
The Day of CD34+ cell infusion: Immediately after the release tests have been performed and the product passes the release criteria, the patient will receive the final product. No conditioning regimen will be administered prior to cell infusion."
1596879|NCT02258477|Dietary Supplement|Sequence 1|100 calorie beverage during week 1; 10 calorie beverage during week 2; control beverage beverage during week 3; 50 calorie beverage during week 4.
1596880|NCT02258477|Dietary Supplement|Sequence 2|Control beverage during week 1; 100 calorie beverage during week 2; 50 calorie beverage during week 3; 10 calorie beverage during week 4.
1596881|NCT02258477|Dietary Supplement|Sequence 3|50 calorie beverage during week 1; control beverage during week 2; 10 calorie beverage during week 3; 100 calorie beverage during week 4.
1596882|NCT02258477|Dietary Supplement|Sequence 4|10 calorie beverage during week 1; 50 calorie beverage during week 2; 100 calorie beverage during week 3; control beverage during week 4.
1596890|NCT02258438|Behavioral|Uninterrupted sitting|Subjects will be asked to refrain for two days from any structured activity and to reduce any daily life activity (walking, taking the stairs, biking, etc.) in their daily life. On day 3, subjects will remain seated all day in the room calorimeter, except to rise from the chair to void.
1596891|NCT02258438|Behavioral|Sitting + 1 bout of activity|Subjects will be asked to perform 45 minutes of moderate-exercise in the morning once per day for two days in their daily life. On day 3 they will remain seated all day in the room calorimeter, except to rise from the chair to void, and to perform one bout of 45-min moderate-intensity (defined below) walking on a treadmill at 1000.
1596892|NCT02258438|Behavioral|Sitting + microbursts of activity|Subjects will be asked to refrain from any structured exercise for two days but to walk for 5 minutes each hour between 1000 and 1800 in daily life. On day 3, subjects will rise from the seated position every hour for 9 hours from 1000 to 1800 to complete 5min moderate-intensity (defined below) walking on a treadmill, which represents a total of 45min.
1596893|NCT02258425|Behavioral|FEM-CARE|
1596894|NCT02258425|Behavioral|Health Promotion|
1596895|NCT02258412|Drug|hand antiseptic with CHG and alcohol|HCWs will be randomized to use one product on one day and the other product on another day at least 3 days apart. Each product will be applied using 1 pump from its dispenser and rubbed over the hands until dry. Gloves will be worn while the HCW is in the patient room. Upon exit from the room, HCW will washoout with that same product. One imprint will be made of the non-dominant hand onto media containing neutralizers. That hand will be gloved with a white cotton glove. The HCW will work in the common areas with timing recorded. Upon leaving the common area, the dominant ungloved hand will be imprinted onto a fresh media plate containing neutralizers.
1596897|NCT02258399|Behavioral|Exercise|Moderate intensity exercise
1596898|NCT02258399|Dietary Supplement|Breakfast|Breakfast consumption
1596899|NCT02258373|Device|CGM+BGM|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm + Abbot Precision Xtra Blood Glucose-Ketone Meter
1596900|NCT02258373|Device|CGM Only|Dexcom G4 Platinum Continuous Glucose Monitoring System with modified algorithm
1596901|NCT02258360|Other|Therapeutic hypothermia|Therapeutic hypothermia with a target temperature between 32-34°C.
1596902|NCT02258347|Device|Echopulse|
1596903|NCT02258334|Biological|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
1596904|NCT02258334|Biological|Fluzone I®ntradermal vaccine, 2014-2015 formulation|0.1 mL, Intradermal
1596905|NCT02258334|Biological|Fluzone® Quadrivalent vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
1596906|NCT02258334|Biological|Fluzone High Dose vaccine, 2014-2015 formulation|0.5 mL, Intramuscular
1596907|NCT02258321|Drug|PPI-668 tablet|
1596908|NCT02258321|Drug|PPI-668 capsule|
1596909|NCT02258308|Behavioral|CHW intervention|Home education and support for asthma self management
1596910|NCT02258295|Drug|Intragel|Intragel has an average molecular weight of 800-1200 kDaltons.
1596911|NCT02258295|Drug|Saline|Saline
1596912|NCT02258282|Drug|Etanercept|
1596913|NCT02258282|Drug|Control|
1596914|NCT02258269|Other|SQ|
1596915|NCT02258269|Other|Control|
1596917|NCT02258243|Drug|aminolevulinic acid hydrochloride|Applied topically
1596918|NCT02258243|Drug|photodynamic therapy|Undergo PDT using blue light on the left side of the body and red light on the right side of the body
1596919|NCT02258243|Drug|photodynamic therapy|Undergo PDT using blue light on the right side of the body and red light on the left side of the body
1596920|NCT02258243|Other|laboratory biomarker analysis|Correlative studies
1596921|NCT02258243|Other|questionnaire administration|Ancillary studies
1596922|NCT02258230|Device|3D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
1596923|NCT02258230|Device|2D mode of the 3D Laparoscopic Video System|Olympus 3DV-190 3D Visualization Unit. LTF-190-10-3D: ENDOEYE FLEX 3D Videoscope.
1596924|NCT02258217|Drug|Acthar|Is indicated for the treatment of acute exacerbations of multiple sclerosis in adults.
1596925|NCT02258204|Drug|Ketamine|Co-administration of subanesthetic dose of ketamine with tPA for thrombolysis in acute ischemic stroke.
1596926|NCT02258204|Drug|Placebo|
1596927|NCT02258191|Device|telemonitoring|
1596928|NCT02258191|Device|sham telemonitoring|
1596929|NCT02258178|Biological|Flucelvax (cTIV)|vaccine exposure in routine care (no vaccination per protocol)
1596930|NCT02258165|Device|PET/CT|"PET/CT (without respiratory gating) is performed on an ad-hoc basis in patients with advanced ovarian cancer in the lead up to surgery. The sensitivity of PET/CT for detecting low volume pleural disease is likely reduced by respiratory motion during the ten minute acquisition time over the chest. By freezing this respiratory motion with respiratory gating, we hope that gated PET/CT detection of pleural metastases will improve over non-gated PET images."
1596931|NCT02258152|Drug|SYN120|SYN120 Doses to be Administered: 20 mg QD (1 week titration), 50 mg QD (1 week titration), 100 mg QD (14 weeks of maintenance).
1596932|NCT02258152|Drug|Placebo|Placebo QD
1596933|NCT02258126|Other|Multidisciplinary intervention program|"Exercise group:
The intervention program includes an education program promoting healthy dietary habits and physical activity (nutritionist), supportive therapy and behavioral advice for the family to improve nutrition and physical activity (psychologist) (2 times/month, for children and parents) and supervised exercise (3 times/week, 90 mins) program for 6 months."
1596935|NCT02258100|Other|Electronic Medical Record|Advent of EMR use for documentation of anesthetic care
1596936|NCT02258087|Radiation|LDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with low-dose-rate or brachytherapy using transrectal ultrasound guidance. Radiation sources (iodine-125 isotopes) are implanted into the prostate through transperineal needle insertion. Real time dose planning is applied. The prescribed dose to the whole prostate is 145 Gy.
1596937|NCT02258087|Radiation|HDR Brachytherapy|In spinal anaesthesia patients' prostate are treated with one fraction of HDR brachytherapy. The prescribed dose to the whole prostate is 1x19 Gy. Ir-192 radioactive stepping source is used for the treatment with after-loading technique. Transperineal approach, rectal ultrasound guidance, inverse treatment planning, real time intraoperative needle position update and dose optimization is applied.
1596938|NCT02258074|Drug|Nicotinamide|
1596939|NCT02258074|Drug|Lanthanum Carbonate|
1596940|NCT02258074|Drug|Placebo (for Nicotinamide)|Sugar pill manufactured to mimic Nicotinamide 750 mg capsule
1596941|NCT02258074|Drug|Placebo (for lanthanum carbonate)|Sugar pill manufactured to mimic Lanthanum Carbonate 500 mg capsule
1596942|NCT02258061|Procedure|DDD-80|Basal pacing rate set to 80-bpm. Note:Patients have already pacemaker implanted before this study.
1596943|NCT02258061|Procedure|DDD-60|Basal pacing rate set to 60-bpm. Note:Patients have already pacemaker implanted before this study.
1596944|NCT02258035|Other|Blood draw|Sampling of 100-150 ml of blood
1596945|NCT02258022|Device|Isomark Canary™|Isomark, LLC is a Madison, Wisconsin-based company that has developed an investigational device, the Isomark Canary™ breath delta value analyzer, that is intended to determine the breath delta value of breath samples collected from critically ill patients. We will use the Isomark Canary™ to determine the breath delta value of breath samples collected during this study.
1596946|NCT02258009|Drug|Ranibizumab|0.5 mg intravitreal injections
1596947|NCT02258009|Drug|Aflibercept|2 mg intravitreal injections
1596948|NCT02257996|Behavioral|Online Systematic Brief Psychodynamic Psychotherapy|Systematic Adaptative Diagnosis System will be applied in both groups at two different times: pre-treatment and post-treatment
1596949|NCT02257983|Drug|EPI-743|EPI-743 (2 capsules 200 mg each) taken at a dose of 400 mg P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
1596950|NCT02257983|Drug|Placebo|2 Placebo capsules P.O. TID for 9 days with noise exposure for 4 hours on Day 8.
1596951|NCT02257970|Drug|oral anti-inflammatory drug|1 capsule, three times a day, for four months
1596952|NCT02257970|Drug|Placebo|1 capsule, three times a day, for four months
1596953|NCT02257957|Drug|PRP injection|
1596954|NCT02257957|Drug|Standard care Hyaluronic acid eye drops|: 15 patients with diagnosis of severe dry eye will receive standard of care treatment ( Hyaluronic acid eye drops 5 times per day). Objective measurements as corneal staining, Shirmer , BUT, and VA, will be determinate as subjective measurements as OSDI and treatment compliance will be evaluated at day 0-30,60 and 90
1596955|NCT02257944|Behavioral|Motivational Interviewing|Brief hospital-based intervention, rooted in motivational interviewing
1596956|NCT02257944|Other|Treatment as Usual|treatment as usual
1596957|NCT02257918|Drug|AZD0914|AZD0914 is an antimicrobial amorphous nonsterile powder. Group 1 receive 2000 mg; Group 2 receive 3000 mg. The drug name is also known as ETX0914.
1596958|NCT02257918|Drug|Ceftriaxone|Ceftriaxone is a broad-spectrum cephalosporin antibiotic with a very long half-life and high penetrability to meninges, eyes and inner ears. A white to yellowish orange crystalline powder. Group 3 receives 500 mg reconstituted with 1 ml Lidocaine HCL 1%, intramuscularly.
1596960|NCT02257827|Radiation|IMRT|"The IMRT plan consisted of five - seven fields to deliver the same dose prescribed at the isodose line covering 95% of PTV.
The 3DCRT plan consisted of six fields to deliver a total dose of 70 Gy/ 25 fractions of a single daily dose of 2.8 Gy."
1596961|NCT02257814|Behavioral|Incredible Years Teacher Training|
1596962|NCT02257814|Behavioral|Preschool PATHS|
1596963|NCT02257814|Behavioral|Tools of the Mind|
1596964|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 6mg lutein/day|2 beverages (each containing 3mg lutein) per day (total of 6mg lutein/day) for a total of 4 months
1596965|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 6mg lutein) per day (total 12mg lutein/day) for a total of 4 months
1596966|NCT02257801|Dietary Supplement|Nutritional beverage fortified with 12mg lutein/day|2 beverages (each containing 0mg lutein) per day (total 0mg lutein/day) for a total of 4 months
1596967|NCT02257788|Biological|PRO 140|Humanized monoclonal antibody to CCR5
1596968|NCT02257775|Genetic|n/a - observational|
1596969|NCT02257762|Dietary Supplement|LNS|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients
1596970|NCT02257762|Dietary Supplement|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
1596971|NCT02257762|Dietary Supplement|Sprinkles|Multiple micronutrient powder packaged in sachet.
1596972|NCT02257749|Other|Active Rehabilitation|The active rehabilitation intervention is a 6-week graded rehabilitation program, consisting of four components that are anchored in neuroscience evidence.The four components include: 1) aerobic exercise 2) coordination exercise 3) visualization 4) home program.
1596973|NCT02257749|Other|Comprehensive Education Intervention (Standard Care)|An initial education session will be provided by an occupational therapist related to general concussion information and outcomes, as well as strategies for symptom management following concussion.
1596974|NCT02257736|Drug|Apalutamide|Participants will receive 240 milligram (mg) tablet of apalutamide once daily until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
1596975|NCT02257736|Drug|Abiraterone acetate|Participants will receive 1000 mg (four 250 mg tablets) of abiraterone acetate (AA) once daily on an empty stomach until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
1596976|NCT02257736|Drug|Prednisone|Participants will receive 5 mg tablet prednisone twice daily until disease progression, unacceptable toxicity, or end of treatment, whichever occurs first.
1596977|NCT02257736|Drug|Placebo|Participants will receive matching placebo to apalutamide once daily until study drug discontinuation.
1596978|NCT02257723|Drug|Herbal medicine|Herbal medicine was taken 3 times daily in dried powder (2g) and water-base decoction form (120ml) (Ostericum koreanum, Eucommia ulmoides, Acanthopanax sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica).
1596979|NCT02257723|Procedure|Acupuncture|Acupuncture treatment was administered 1-2 times daily using mainly Ah-shi points and local acupuncture points.
1596980|NCT02257723|Procedure|Pharmacopuncture|Select ingredients similar to those included in the oral herbal medicine (Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, Cuscuta chinensis, and Atractylodes japonica) were freeze dried into powder form after decoction, then diluted in normal saline and adjusted for acidity and pH to be used in injections. The pharmacopuncture injections were injected once daily to the amount of 1 cc and Ah-shi points and local acupuncture points (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
1596981|NCT02257723|Procedure|Bee venom pharmacopuncture|Bee venom pharmacopuncture was applied after confirming a negative reaction to the hypersensitivity skin test. Diluted bee venom (saline:bee venom ratio, 10,000:1) was injected at 4-5 acupoints at the physician's discretion. Each acupuncture point was injected with approximately 0.2 cc to a total of 0.5-1 cc using disposable injection needles (CPL, 1 cc, 26G x 1.5 syringe, Shinchang medical co., Korea).
1596982|NCT02257723|Procedure|Chuna manipulation|Chuna was administered 3-5 times a week. Chuna is a Korean version of spinal manipulation that incorporates conventional spinal manipulation techniques for mobilization involving high-velocity, low amplitude thrusts to joints slightly beyond the passive range of motion and gentle force to joints within the passive range of movement.
1596983|NCT02257710|Device|Orsiro|
1596984|NCT02257697|Drug|Mizoribine (MZR)|
1596985|NCT02257697|Drug|Cyclophosphamide (CTX)|
1596986|NCT02257684|Drug|pegcrisantaspase|
1596987|NCT02257671|Drug|Oral contraceptive|Neovletta
1596988|NCT02257658|Drug|Doxycycyline|
1596989|NCT02257658|Behavioral|Incentive|
1596990|NCT02257632|Drug|Ranibizumab|0.5 mg intravitreal injections
1596991|NCT02257632|Drug|Aflibercept|2 mg intravitreal injections
1597059|NCT02257190|Behavioral|IW3|A one hour exercise bout with repeated cycles of 3 min of fast and 3 min of slow walking
1596992|NCT02257619|Drug|INCB039110|INCB039110 tablets administered orally at dose defined in the protocol for Part 1 of the study and the dose selected from Part 1 based on the data available for use in Part 2 of the study.
1596993|NCT02257619|Drug|Placebo|Matching placebo tablets to be administered by mouth at dose defined in the protocol for Part 1 of the study and the dose selected from Part 1 based on the data available for use in Part 2 of the study.
1596994|NCT02257619|Drug|docetaxel|Administered as an intravenous infusion in the clinic at the frequency defined in the protocol for Part 1 of the study and the dose selected from Part 1 based on the data available for use in Part 2 of the study.
1596995|NCT02257606|Other|I-TRAVLE training|
1596996|NCT02257593|Other|Dietary protein|"Persons were fed
Participants were randomized to one of three arms, each of which received 10%, 15% or 25% of total energy derived from protein"
1596997|NCT02257580|Drug|E-Aminocaproic acid|E-Aminocaproic acid (EACA) is a synthetic lysine analog that competitively inhibits the activation of plasminogen to plasmin and subsequently decreases the degree of fibrinolysis (Faraoni,2014} and is currently being used to decrease blood loss and transfusion requirements after orthopaedic procedures.(Eubanks,2010} Multiple meta analyses and retrospective and prospective studies have shown that EACA decreases blood loss and transfusion requirements after orthopaedic surgery{ McLeod,2013; Thompson, 2005; Thompson,2008; Gill,2008; Florentino-Pineda,2001}.Results from these studies also suggest that EACA will decreased post-operative morbidity, length of hospital stay, hospital costs, and complications.{Chimento,2013; Thompson,2005; Florentino-Pineda,2001}
1596998|NCT02257567|Drug|Bendamustine|Bendamustine 90 milligrams per meter-squared (mg/m^2) per day administered IV on Days 2 and 3 of Cycle 1, then on Days 1 and 2 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
1596999|NCT02257567|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV on Days 1, 8, and 15 of Cycle 1 and on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
1597000|NCT02257567|Drug|Polatuzumab vedotin|Polatuzumab vedotin 1.8 milligrams per kilogram (mg/kg) administered IV on Day 2 of Cycle 1, then on Day 1 of each subsequent cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
1597001|NCT02257567|Drug|Rituximab|Rituximab standard dose, 375 mg/m^2 IV on Day 1 of each cycle for up to 6 cycles (each cycle is 21 days in DLBCL and 28 days in FL).
1597002|NCT02257554|Behavioral|education|Discussion of surgical expectations with patients
1597003|NCT02257541|Drug|BGJ398|
1597004|NCT02257541|Drug|Imatinib Mesylate|
1597007|NCT02257502|Drug|aflibercept|The patients are followed on a monthly basis until 52 weeks. Intravitreal injections of aflibercept at a dosage of 2 mg are initiated with a TAE regimen until 20 weeks (3 mandatory injections at inclusion, week 8 and 20 with reinjection at week 4, 12 and 16 only in case of CNV activity). Then, a PRN regimen is considered until 52 weeks (reinjection in case of CNV activity). Therefore, each patient receives between 3 and 13 injections in the whole study.
1597008|NCT02257489|Drug|ACE-083|recombinant fusion protein
1597009|NCT02257476|Drug|Carfilzomib|Carfilzomib will be given as an IV infusion over 4 hours. Subjects will remain at the clinic under observation for at least 1 hour following each dose of carfilzomib in Cycle 1 and following the dose on Cycle 2 Day 1. During these observation times, post dose IV hydration may be given at physician's discretion.
1597010|NCT02257476|Drug|Dexamethasone|Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses.
1597011|NCT02257463|Drug|theophylline, long acting bronchodilators (LABD) or combined LABD and inhaled steroids according to GOLD recommendations|
1597012|NCT02257463|Other|peripheral muscles exercise training|
1597013|NCT02257463|Device|inspiratory muscle training|Patients started breathing at a resistance that required generation of 30% of their PImax for one week. The load was then increased incrementally, 5-10%, to reach generation of 60% of their PImax at the end of the first month. Specific IMT was then continued at 60% of their PImax adjusted weekly to the new PImax achieved.
1597014|NCT02257437|Dietary Supplement|LNS snack|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients.
1597015|NCT02257437|Dietary Supplement|Corn-soy blend ++ (CSB++)|Blended flour containing soy, corn, milk powder, oil, sugar and multiple micronutrients.
1597016|NCT02257437|Dietary Supplement|Sprinkles|Multiple micronutrient powder packaged in sachet added to borbor (traditional white rice porridge).
1597017|NCT02257437|Dietary Supplement|LNS + borbor|Compact, paste-filled wafer snack containing fish, rice, soy, mungbeans, oil, sugar and multiple micronutrients added to borbor (traditional white rice porridge).
1597018|NCT02257424|Drug|Trametinib 2mg daily|
1597019|NCT02257424|Drug|hydroxychloroquine (HCQ)|hydroxychloroquine (HCQ) is 600 mg orally every 12 hours
1597020|NCT02257411|Device|Ear-sized based|the sizes of the PLMA determined with the ear-based formula were compared with the sizes according to the manufacturer's weight-based formula
1597021|NCT02257398|Drug|GSK2140944|GSK2140944 is available in dose strength 1000 mg and 1800 mg for single IV dose over 2 hours administration as a pale yellow to greyish yellow cake for reconstitution
1597022|NCT02257398|Drug|GSK2140944 placebo|GSK2140944 placebo is 0.9% sodium chloride available for single IV dose over 2 hours administration.
1597023|NCT02257398|Drug|Moxifloxacin|Moxifloxacin is available as pinkish red tablet with dose strength 400 mg for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
1597024|NCT02257398|Drug|Moxifloxacin placebo|Moxifloxacin placebo is available as white, film-coated tablet. containing nonactive material for single oral dose to be administered in the morning in the fasted state with approximately 240 mL of water.
1597025|NCT02257385|Drug|UMEC/VI|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains Umeclidinium bromide (unit dose strengths 62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate 0.6% weight/weight (w/w) of total drug product and second strip contains Vilanterol (unit dose strengths 25 mcg per blister) blended with lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
1597057|NCT02257203|Behavioral|Reading Education|Parents randomized to control will receive a 25-minute educational module on the importance of reading to children with instruction in interactive reading techniques that are appropriate to the child's age
1597026|NCT02257385|Drug|UMEC/VI matching placebo|ELLIPTA DPI will be supplied with 30 doses (2 strips with 30 blisters per strip) where first strip contains lactose monohydrate and magnesium stearate 0.6% w/w of total drug product and second strip contains lactose monohydrate and magnesium stearate 1.0% w/w of total drug product
1597027|NCT02257385|Drug|Tiotropium|Tiotropium (as bromide monohydrate) inhalation capsules 18 mcg per dose will be supplied along with HANDIHALER inhalers manufactured by Boehringer Ingelheim
1597028|NCT02257385|Drug|Tiotropium matching placebo|Tiotropium matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with HANDIHALER inhalers
1597029|NCT02257385|Drug|Indacaterol|Indacaterol inhalation capsules 150 mcg per dose will be supplied by GSK along with BREEZHALER inhalers manufactured by Novartis
1597030|NCT02257385|Drug|Indacaterol matching placebo|Indacaterol matching placebo capsules manufactured by GSK, will contain lactose and will be supplied along with BREEZHALER inhalers manufactured by Novartis
1597031|NCT02257385|Drug|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules for as needed use will be issued throughout the study. Albuterol/salbutamol will be sourced from local commercial stock. If not available locally, GSK will source centrally
1597032|NCT02257372|Drug|UMEC DPI|The UMEC DPI will contain one blister strip which will have 30 blisters of UMEC as dry powder blended with lactose and magnesium stearate, with no companion strip. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously.
1597033|NCT02257372|Drug|Placebo DPI|The matching placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
1597034|NCT02257372|Drug|ICS/LABA medication|Participants will use ICS/LABA combinations that are approved for the treatment of COPD at approved doses and frequency including SERETIDE 500/50mcg twice daily, FSC 500/50 mcg twice daily generic products such as AIRFLUSAL FORSPIRO inhaler 500/50mcg twice daily or ROLENIUM ELPENHALER inhaler 500/50mcg twice daily and SYMBICORT TURBUHALER inhaler at doses of 200/6mcg twice daily and 400/12mcg twice daily. The ICS/LABA will be sourced from local commercial stock while on the study
1597035|NCT02257372|Drug|Albuterol/salbutamol Metered Dose Inhaler (MDI)|Albuterol/salbutamol MDI or nebules will be issued throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline.
1597036|NCT02257359|Drug|Epelsiban|Epelsiban will be supplied as a 25 mg white to off-white round direct compression oral tablet.
1597037|NCT02257346|Drug|Lidocaine|Lidocaine infusion will be administered immediately after delivery of the fetus and continue through 1 hour into recovery period.
1597038|NCT02257346|Drug|Normal Saline|Normal Saline will be administered as a placebo immediately after delivery of the fetus and continue through 1 hour into recovery period
1597039|NCT02257320|Device|TMJ NextGeneration(TM)|The TMJ NextGeneration(TM) device consists of a pair of small, hollow ear inserts. These ear inserts are custom-fit to each subject's ear canals. The devices rest in the outer third of the ear canal and have a small retraction post that allows for removal of the device from the ear. The devices conform to the shape of the ear canal when the jaw is in the open position and permit full passage of sound into each ear. The mechanisms of action of the inserts are to support the TMJ and associated secondary musculature to reduce strain in the TMJ area and to provide cognitive awareness to the wearer regarding para-functional habits, i.e., jaw clenching.
1597040|NCT02257307|Procedure|RetCam retinal imaging used for routine care|De-identified digital images of both eyes, obtained by a non-physician Certified ROP Imager (CRI) using the RetCam Shuttle, will be uploaded to the secure server for remote evaluation by a Trained Reader. The results of the Reader's evaluation will be reported to the Clinical Center.
1597043|NCT02257281|Device|Active Therapeutic Ultrasound|For Experimental Arm: The pulsed therapeutic ultrasound was applied each spot for several days.
1597044|NCT02257281|Device|Non-active Therapeutic Ultrasound|For Placebo group: The non-active therapeutic ultrasound was applied each spot for several days.
1597045|NCT02257268|Behavioral|VAMOS program - Active life improving health|All participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for 12 weeks. VAMOS is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by a weekly meeting, in group, lasting about 90 min. In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories. The participants of this group will receive an educational material and, in the middle of the program, they will earn a pedometer to aid in motivation and in the self-monitoring physical activity.
1597046|NCT02257255|Procedure|Pfannenstiel cesarean section|Pain scales ( VAS and McGill ) 6, 12 and 24 hours after cesarean to pain assessment
1597047|NCT02257255|Procedure|Misgav-Ladach cesarean section|Pain scales (VAS and McGill) 6, 12 and 24 hours ater cesarean to pain assessment
1597048|NCT02257242|Drug|Rituximab|375 mg/m2 I.V. on Day 1 of each cycle
1597049|NCT02257242|Drug|Bendamustine|90 mg/m2 I.V. on Day 1 and 2 of each cycle
1597050|NCT02257242|Drug|Vincristine sulfate liposome injection|Dose per dose escalation protocol, I.V. on Day 2 of each cycle
1597051|NCT02257229|Procedure|Surgical|Surgery only
1597052|NCT02257229|Procedure|Non-Surgical|non-surgical methods such as, casting, bracing, physical therapy, and other.
1597053|NCT02257229|Procedure|Non-surgical + surgical|Combination of non-surgical methods subsequently followed by surgery
1597054|NCT02257216|Other|Vayarin®|Medical Food
1597055|NCT02257216|Other|Placebo|Cellulose
1597056|NCT02257203|Behavioral|Sugar Sweetened Beverage Education|Parents will receive an educational module on beverage just after the conclusion of their child's well visit in a private room adjacent to the clinic
1597058|NCT02257190|Behavioral|Control|One hour of rest.
1597128|NCT02256813|Drug|Caffeine|
1597060|NCT02257190|Behavioral|IW1|A one hour exercise bout with repeated cycles of 1 min of fast and 1 min of slow walking
1597061|NCT02257177|Drug|Inhaled TD139|DPI Galectin-3 inhibitor
1597062|NCT02257177|Drug|Placebo|DPI placebo
1597063|NCT02257164|Procedure|Femoral nerve block|2 mg/ml
1597064|NCT02257164|Procedure|obturator nerve block|
1597065|NCT02257164|Procedure|intraarticular injection|
1597066|NCT02257151|Drug|BMS-986142|
1597067|NCT02257151|Drug|Placebo|
1597068|NCT02257138|Drug|Ruxolitinib|"Phase I starting dose of Ruxolitinib: 10 mg by mouth twice a day for a 28 day cycle.
Phase II starting dose of Ruxolitinib: MTD from Phase I."
1597069|NCT02257138|Drug|Decitabine|Phase I and II: Decitabine 20 mg/m^2 by vein on Days 1 - 5 of each 28 day cycle.
1597070|NCT02257125|Behavioral|high incentive|Subjects are required to use their arms in order to control a virtual arm on a computer screen to prevent meteors from destroying a planet. The game includes visual effects and monetary rewards.
1597071|NCT02257125|Behavioral|low incentive|"Subjects are required to use their arms in order to control a virtual hand on a computer screen to prevent objects from reaching the bottom. The game does not include visual effects or monetary rewards."
1597072|NCT02257112|Device|Multistage low-energy stimulation|The parameters of the Multistage waveform will be altered and the response of the atria will be recorded.
1597073|NCT02257073|Behavioral|Cognitive-behavioral treatment|
1597074|NCT02257073|Behavioral|Waiting List|
1597075|NCT02257060|Procedure|Endocardial Ablation|
1597076|NCT02257047|Dietary Supplement|Tea|
1597077|NCT02257047|Dietary Supplement|RYR|red yeast rice
1597078|NCT02257034|Other|Taichi|
1597079|NCT02257034|Other|Dance|
1597080|NCT02257021|Drug|BILR 355 BS|
1597081|NCT02257021|Drug|Tipranavir|
1597082|NCT02257021|Drug|Low dose of ritonavir|
1597083|NCT02257021|Drug|High dose of ritonavir|
1597084|NCT02257008|Drug|BILR 355 BS|
1597085|NCT02257008|Other|Grapefruit juice|
1597086|NCT02257008|Drug|Nelfinavir|
1597087|NCT02257008|Drug|Atazanavir|
1597088|NCT02257008|Drug|Ritonavir|
1597090|NCT02256982|Drug|Gemcitabine|
1597091|NCT02256982|Drug|Cisplatin|
1597092|NCT02256982|Procedure|Surgery|Surgical Resection and Lymphadenectomy
1597093|NCT02256982|Radiation|Radiation|Radiation Therapy
1597094|NCT02256969|Drug|Blephamide|
1597095|NCT02256969|Drug|GenTeal PM Night-Time|
1597096|NCT02256969|Procedure|Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. After obtaining adequate anesthesia, the solid stainless steel probes (Maskin® Meibomian Gland Intraductal Probes, Rhein Medical Inc.) were used to probe all the meibomian glands of upper lids of both eyes at the slit lamp. All patients were initially be probed with a 1-mm probe followed by a 2-mm probe for all glands.
1597097|NCT02256969|Procedure|Sham Meibomian Gland Probing|For anesthesia, topical 3.5% lidocaine hydrochloride jelly (Akron) was applied directly with sterile cotton-tipped applicator to the lid margin for 3 times every 10 minutes before the procedure. If necessary, 2% lidocaine was injected into the lid margin during the procedure to provide additional comfort. The patient's lid margin was touched with the probes without actual probing of the meibomian gland orifices.
1597098|NCT02256956|Drug|Amitriptyline|25 mg / day for 10 days
1597099|NCT02256956|Drug|Tolterodine|Placebo 1 mg / day for 10 days
1597100|NCT02256943|Drug|Amitriptyline|100 mg single dose
1597101|NCT02256943|Drug|Tolterodine|Placebo 1 mg single dose
1597102|NCT02256930|Drug|M518101|
1597103|NCT02256930|Drug|M518101 Vehicle|
1597104|NCT02256930|Other|Sodium lauryl sulfate|
1597105|NCT02256930|Other|Saline|
1597106|NCT02256917|Biological|Human cl rhFVIII|
1597107|NCT02256904|Procedure|Anatomical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan.The anatomical cutting blocks will be design to resurface the femoral and tibial bones to restore each patient's pre-arthritic anatomy within specific margins: maximum of 5 degrees valgus/varus tibial or femoral cut and overall lower limb alignment within +/-3 degrees of varus/valgus). GMK sphere TKA will be implanted using the manufactured cutting blocks.
1597108|NCT02256904|Procedure|Mechanical TKA|Personalized Medacta plastic cutting blocks will be manufactured according to patient Ct-scan. In the mechanical group, femoral and tibial cutting blocks will be designed for a 0-degree angle according to the mechanical axis. Femoral rotation will be aligned with the femoral trans-epicondylar axis. Tibial rotation will follow femoral rotation. GMK sphere TKA will be implanted using the manufactured cutting blocks.
1597109|NCT02256891|Device|PRFM|
1597110|NCT02256891|Procedure|Double Row|
1597111|NCT02256878|Drug|BIRT 2584 XX|
1597112|NCT02256878|Drug|Amitriptyline|
1597113|NCT02256865|Drug|Ketoconazole|Ketoconazole is taken 4 times a day
1597114|NCT02256865|Drug|Hydrocortisone|Hydrocortisone is taken 3 times a day
1597115|NCT02256865|Drug|Testosterone|Testosterone gel is applied once a day
1597116|NCT02256865|Drug|Placebo for ketoconazole|Placebo for ketoconazole
1597117|NCT02256865|Drug|Placebo for hydrocortisone|Placebo for hydrocortisone
1597118|NCT02256865|Drug|Placebo for testosterone|Placebo for testosterone
1597119|NCT02256852|Biological|QBKPN SSI|QBKPN SSI is administered subcutaneously for 12 weeks
1597120|NCT02256839|Device|CST_001|
1597121|NCT02256826|Drug|BILR 355 BS|
1597122|NCT02256826|Drug|Ritonavir (RTV)|NORVIR®
1597123|NCT02256826|Drug|Kaletra®|(lopinavir (LPV) and ritonavir (RTV))
1597124|NCT02256813|Drug|BIRT 2584 XX|
1597125|NCT02256813|Drug|Warfarin sodium|
1597126|NCT02256813|Drug|Omeprazole|
1597127|NCT02256813|Drug|Dextromethorphan hydrobromide|
1597131|NCT02256800|Genetic|UGT1A1 genotyping (6,6)|"The investigators will use the regimen as following:
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 260 mg/m2."
1597132|NCT02256800|Genetic|UGTIA1 genotyping (6,7)|"The investigators will use the regimen as following:
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 240 mg/m2."
1597133|NCT02256800|Genetic|UGTIA1 genotyping (7,7)|"The investigators will use the regimen as following:
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (120 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks.
After 2 cycles of each different dose of irinotecan, we will observe the adverse effects (AEs) of hematological / non-hematological. If the grade is under the grade 2, we will escalate the dose of 30 mg/m2 gradually. The estimated maximal dose of irinotecan is 180 mg/m2."
1597134|NCT02256800|Genetic|UGT1A1 non-genotyping|"The investigators will use the regimen as following:
Regimen for treatment consisted of bevacizumab (Avastin) 5mg/Kg (IV infusion) on day 1, follow by irinotecan (180 mg/m2 as a 120-min IV infusion), Leucovorin (400 mg/m2 IV infusion over 2 hours), and 5-FU (2800 mg/m2 IV infusion over a 46-hour period), repeated every 2 weeks."
1597135|NCT02256800|Drug|bevacizumab (Avastin)|
1597136|NCT02256800|Drug|irinotecan|
1597137|NCT02256800|Drug|Leucovorin|
1597138|NCT02256800|Drug|5-FU|
1597139|NCT02256787|Drug|BILB 1941 ZW - single rising dose part|
1597140|NCT02256787|Drug|Placebo|
1597141|NCT02256787|Drug|BILB 1941 ZW - solution|
1597142|NCT02256787|Drug|BILB 1941 ZW - tablet|
1597143|NCT02256787|Other|standardized breakfast|
1597144|NCT02256774|Drug|BILR 355 BS|
1597145|NCT02256774|Drug|Combivir®|
1597146|NCT02256774|Drug|Ritonavir|
1597147|NCT02256761|Drug|BIRT 2584 XX - multiple escalating dose|
1597148|NCT02256761|Drug|Placebo|
1597149|NCT02256761|Drug|BIRT 2584 XX - single dose|
1597150|NCT02256761|Other|high caloric meal|30 minutes prior to the second drug administration after a one week wash-out period, a standardised high fat, high caloric meal was served
1597151|NCT02256748|Drug|BIRT 2584 XX|
1597152|NCT02256748|Drug|Midazolam|
1597153|NCT02256735|Drug|Treatment A|Ritobegron Cl (KUC 7483 CL) tablets low dose
1597154|NCT02256735|Drug|Treatment B|
1597155|NCT02256735|Drug|Treatment C|
1597156|NCT02256735|Drug|Treatment D|
1597157|NCT02256735|Drug|Placebo|
1597158|NCT02256735|Drug|Moxifloxacin|
1597159|NCT02256722|Drug|KUC 7483 CL|
1597160|NCT02256722|Drug|Bisoprolol|
1597161|NCT02256722|Drug|Propranolol|
1597162|NCT02256722|Drug|Acipimox|
1597163|NCT02256722|Drug|Salmeterol|
1597164|NCT02256709|Drug|BIBP 5371 CL tablet|single rising daily doses
1597165|NCT02256709|Drug|BIBP 5371 CL solution|
1597166|NCT02256709|Other|High fat, high caloric breakfast|
1597167|NCT02256709|Drug|Placebo tablet|
1597168|NCT02256709|Drug|BIBP 5371 CL tablet high dose|
1597169|NCT02256709|Drug|Placebo drinking solution|
1597170|NCT02256709|Drug|BIBP 5371 CL tablet low dose|
1597171|NCT02256696|Drug|PA-824|200 mg QD
1597172|NCT02256696|Drug|Rifampin|600 mg QD
1597173|NCT02256696|Drug|Rifabutin|300 mg QD
1597174|NCT02256696|Drug|Pyrazinamide|25mg/kg QD
1597175|NCT02256696|Drug|Ethambutol|15mg/kg QD
1597176|NCT02256696|Drug|Isoniazid|300 mg QD
1597177|NCT02256683|Drug|Dabigatran etexilate|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
1597178|NCT02256683|Drug|Phenprocoumon|After inclusion of the patients with LAA thrombus, they are treated according to the randomization either with Pradaxa® (150 mg bid) or Marcumar® (INR 2-3) for at least three weeks. Thrombus resolution will be determined by transesophageal echocardiography (TEE) 3 weeks after start of treatment and subsequently at week 4 and 6 if necessary, i.e. LAA thrombus has not yet resolved. The study is terminated for each patient with the resolution of the LAA thrombus or after 6 weeks of study treatment.
1597179|NCT02256670|Behavioral|Text Message Application|Two-way text messaging application addressing adherence with adjuvant endocrine therapy
1597180|NCT02256657|Behavioral|Quality Improvement Toolkit|The quality improvement toolkit is comprised of standardized admission and discharge checklists, clinical pathways, an audit and feedback mechanism through electronic data capture, and a monthly report used in conjunction with root cause analysis meetings. Quality improvement toolkits are implemented by individual hospitals.
1597183|NCT02256618|Other|Autologous umbilical cord blood cells|Autologous non-cryopreserved volume- and red blood cell-reduced cord blood cells will be intravenously infused
1597271|NCT02255942|Other|Ferric Pyrophosphate|Rice fortified with Ferric Pyrophosphate
1597272|NCT02255929|Radiation|Gamma Knife Radiosurgery|
1597184|NCT02256605|Dietary Supplement|Vitamin D-3|Children with IBD, aged 5 to 17, who are vitamin D insufficient or deficient will be recruited at the time of a routine clinic visit or lab draw that included a 25(OH)D level as part of clinical practice/standard care. Once consent and assent are obtained, the children who are 25-hydroxyvitamin D [259OH)D] insufficient or deficient will be randomly assigned to a daily or weekly dosing regimen using block randomization to ensure equal group size.
1597185|NCT02256592|Drug|Fecal Microbiota|300 mL of fecal suspension from a healthy donor will be delivered during colonoscopy
1597186|NCT02256566|Behavioral|emotional memory training exercise|
1597187|NCT02256566|Behavioral|memory training exercise|
1597188|NCT02256553|Biological|MK-3641 12 Amb a 1-U (short ragweed extract)|12 units of Ambrosia artemisiifolia major allergen number 1 (Amb a 1-U) extract sublingual tablets
1597189|NCT02256553|Biological|MK-7243 2800 BAU (Timothy grass extract)|2800 bioequivalent allergen units (BAU) of Phleum pratense extract sublingual tablets
1597190|NCT02256553|Drug|Rescue Medication|Self-injectable epinephrine, to be administered for an anaphylactic reaction, including symptoms/signs of upper airway obstruction.
1597191|NCT02256540|Drug|Climara|
1597192|NCT02256540|Drug|Placebo patch|Placebo patch designed to match active Climara patches.
1597193|NCT02256540|Dietary Supplement|Resveratrol|
1597194|NCT02256540|Dietary Supplement|Placebo|Placebo tablets designed to match active resveratrol tablets.
1597195|NCT02256527|Other|Observational|compare data
1597196|NCT02256514|Biological|Daily oral dose of hepcortespenlisimut-L|Oral therapeutic vaccine, hepcortespenlisimut-L (V5) to be given once-per-day with monthly check-up
1597197|NCT02256501|Biological|Mono Nuclear Cell (MNC) transplantation|Intracoronary administration of autologous bone marrow derived mononuclear cells
1597198|NCT02256488|Biological|TIVc_LOT A|Single IM (Intramuscular) administration dose of 0.5 mL of TIVc
1597199|NCT02256488|Biological|TIVc_LOT B|Single IM administration dose of 0.5 mL of TIVc
1597200|NCT02256488|Biological|TIVc_LOT C|Single IM administration dose of 0.5 mL of TIVc
1597201|NCT02256488|Biological|TIVf|Single IM administration dose of 0.5 mL of TIVf
1597202|NCT02256475|Drug|NBI-98854|
1597203|NCT02256462|Drug|Adalimumab|Eligible patients are those who are planned to start Adalimumab (ADA). Patients will be randomized at the first screening visits to either group 1 (interventional) or group 2 (clinical). Eligible patients, will start induction treatment (weeks 0,2) with ADA (> 40kg 160/80/40 mg every 2 weeks or < 40 kg 100/50/25 mg for m2 body surface area every 2 weeks). Interventions will start from the 4th injection for responding patients only (based on levels taken prior to the third injection). Responding patients will continue to the maintenance phase in which they will receive ADA every 2 weeks, either 40 mg or 25 mg/m2. At screening, and every 2 months all patients will be examined and have height, weight, PCDAI performed as well as comprehensive laboratory examinations.
1597208|NCT02256423|Drug|REFERENCE 1: Nurofen® 200 mg tablet|
1597209|NCT02256423|Drug|REFERENCE 2: Ibuprofen 200 mg soft gel capsule|
1597210|NCT02256423|Drug|ibuprofen 200 mg soft gel capsule|
1597211|NCT02256410|Device|Stimulation|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief electric stimulation, thus targeting the treatment to specific peak pain regions. Preliminary evidence supports the effectiveness of this device in reducing pain and disability over 6 sessions
1597212|NCT02256410|Other|Sham|The Nervomatrix device first measures skin impedance, and then creates a digital pain matrix map of the back. Regions with low resistance are then selected for brief mechanical pressure.
1597213|NCT02256397|Other|Standard comprehensive care|Standard comprehensive care at High Risk Children's Clinic
1597214|NCT02256397|Other|enhanced comprehensive care|"standard comprehensive care at the High Risk Children's Clinic enhaced with new technologies:
If between 2 and 5 years old--> will receive Home-centered comprehensive care with the propeller
5 and above--> will receive home-centered comprehensive care with propeller and PIKO"
1597215|NCT02256384|Device|Respiratory Acoustic Monitor|Examine the reliability and accuracy of the respiratory acoustic monitor.
1597216|NCT02256371|Behavioral|Hypnosis sessions|1 session per week during 8 weeks
1597217|NCT02256371|Behavioral|Relaxation group|1 relaxation session per week during 8 weeks
1597218|NCT02256358|Drug|Midazolam|preoperatively injected intravenous 0.1 mg/kg midazolam
1597219|NCT02256358|Drug|Ketamine|Preoperatively injected intravenous 1mg/kg ketamine
1597220|NCT02256345|Drug|KNO3|Active Comparator
1597221|NCT02256345|Drug|KCl|Placebo Comparator
1597222|NCT02256332|Dietary Supplement|Low dose plant based ingredient|Reference food with low dose of plant based ingredient
1597223|NCT02256332|Dietary Supplement|High dose plant based ingredient|Reference food with high dose of plant based ingredient
1597224|NCT02256332|Dietary Supplement|Reference food format|Reference food without plant-based ingredient
1597225|NCT02256319|Drug|Dexmedetomidine|Patients will receive a loading dose of 1 µg/kg in 10 min before starting the surgery. The maintenance dose will be 0.2-1 µg/kg/h for a Ramsey Sedation Score of 3-4 during the surgery´s preparation. It will be reduced to 0.2 µg/kg/h 15 min before starting the microelectrode recording for a Ramsey Sedation Score of 2. After the placement of the deep brain stimulator we will record the local field potentials activity. In addition, the subscales of rigidity, tremor and bradykinesia of the Unified Parkinson's Disease Rating Scale (UPDRS-III) score will be evaluated. Once the deep brain stimulator recording and neurologic exploration will be over patients will receive a maintenance dose 0.2-1 µg/kg/h until the end of the surgery. It will be stopped to transfer the patient to the ICU.
1597226|NCT02256319|Drug|Propofol|The target doses are 0.5, 1, 1.5, 2 and 2.5 µg/kg. For its administration we will use the TCI (target controlled infusion) system. After programming each dose we will wait until the plasma and brain concentration of propofol are stabilized in this target and then we will record the local field potentials activity through the DBS. In addition, the subscales of rigidity, tremor and bradykinesia of the UPDRS-III score will be evaluated.
1597273|NCT02255916|Other|Music|live sound-bed music intervention
1597228|NCT02256293|Behavioral|Diabetes self-management group based on Acceptance and Commitment Therapy (ACT).|The group sessions will be lead by a clinician trained in Acceptance and Commitment Therapy and will meet at Duke Medical Center for 1 ½ hours once a week for a total of 8 weeks. During group sessions, participants will identify how avoidance of difficult thoughts and feelings about diabetes has interfered with diabetes management and learn alternative ways of coping with these experiences. The group sessions are intended to supplement regular medical treatment; thus it is important that subjects continue to have diabetes symptoms monitored by their current treatment provider.
1597229|NCT02256280|Drug|Sugammadex|"Sugammadex will be diluted in a saline water solution in a 10 mL syringe.
Administration will be according to the neuromuscular blockade:
If Post tetanic count = 1-15: 4 mg/kg
If at least 1 twitch at the Train-of-four stimulation: 2 mg/kg"
1597230|NCT02256280|Drug|Neostigmine|"Neostigmine will be diluted with atropine in a saline water solution in a 10 mL syringe.
Administration will be according to the neuromuscular blockade:
If Post tetanic count = 1-15: 0.07 mg/kg
If at least 1 twitch at the Train-of-four stimulation: 0.05 mg/kg Atropine will be administered at a 0.02 mg/kg dosage."
1597233|NCT02256254|Drug|Simvastatin|2 Simvastatin capsules of 20 mg every evening for 14 days
1597234|NCT02256254|Drug|Placebo|2 placebo capsules every evening for 14 days
1597235|NCT02256228|Drug|Ropivacaine|Active Group
1597236|NCT02256228|Drug|Saline|Placebo Comparator
1597237|NCT02256215|Drug|Vitamin D|
1597238|NCT02256202|Other|Interview|Monitoring interviews to show medical and economic advantages of given therapy
1597241|NCT02256150|Drug|Mizoribine (MZR)|
1597242|NCT02256150|Drug|Cyclophosphamide (CTX)|
1597243|NCT02256124|Drug|Lamotrigine|
1597244|NCT02256124|Drug|Placebo|
1597245|NCT02256111|Drug|Enzalutamide|
1597246|NCT02256111|Drug|Androgen deprivation therapy|
1597247|NCT02256111|Behavioral|Supervised exercise training|
1597248|NCT02256098|Device|ATTUNE™ Knee Prosthesis by DePuy|Total Knee Replacement (TKR) Surgery with ATTUNE™ Knee Prosthesis by DePuy
1597249|NCT02256098|Device|PFC Sigma Knee Prosthesis by DePuy|Total Knee Replacement Surgery with PFC Sigma Knee Prosthesis by DePuy
1597250|NCT02256085|Device|Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
1597251|NCT02256085|Device|Daily rTMS with Sham coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
1597252|NCT02256085|Device|Open Label Daily rTMS with Active coil|rTMS produces strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for six weeks
1597253|NCT02256072|Other|Plan Your Lifespan Website|Participants in the intervention arm will navigate the advance planning tool, Plan Your Lifespan, a Web-based planning tool that provides information for seniors related to advanced health planning for home services in specific content areas of: hospitalizations, falls, Alzheimer's, dementia, as well as communicating with others. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating this website.The Plan Your Lifespan website is also interactive in that it allows participants to enter their information and share it with others to facilitate conversations and decision-making.
1597254|NCT02256072|Other|Go4Life Website|Participants in the attention control arm will navigate an electronic educational session via a National Institute on Aging at NIH Website, Go4Life, a website about physical activity and exercise as it is a topic of interest to seniors. A minimum of 15 minutes and a maximum of 45 minutes will be allotted for navigating the website. The website is interactive and comparable to the intervention tool: http://go4life.nia.nih.gov/get-started).
1597255|NCT02256059|Procedure|Plate osteosynthesis|Plate osteosynthesis using LCP plate (Synthes)
1597256|NCT02256046|Device|Esophagogastroduodenoscope|Endoscopic therapies for varices aim to reduce variceal wall tension by obliteration of the varix. The two principal methods available for esophageal varices are endoscopic sclerotherapy (EST) and band ligation (EBL). Endoscopic therapy is a local treatment that has no effect on the pathophysiological mechanisms that lead to portal hypertension and variceal rupture. However, a spontaneous decrease in HVPG occurs in around 30% of patients treated with either EST or EBL to prevent variceal rebleeding.
1597257|NCT02256033|Drug|Istradefylline|One 40 mg-tablet administered on Day 1
1597258|NCT02256020|Other|Original lifestyle|Control group with 3 times of watching 50-minute television a week for 6 months.
1597259|NCT02256020|Other|Wheel-chair music aerobic exercise (WC-MAE)|Wheel-chair music aerobic exercise with 3 times of 50-minute session a week for 6 months.
1597260|NCT02255994|Device|UGYTEX|Patients in this arm received the UGYTEX mesh in the pro-cure 1 study (see NCT00153257)
1597261|NCT02255994|Procedure|No mesh.|Patients in this arm had subvesical plication without reinforcement.
1597262|NCT02255981|Other|Traditional Chinese Medicine (TCM) Acupuncture|Treatment consist in to put needles on specific points of skin one day each week initially, then with longer spaces of time according to improvement.
1597263|NCT02255968|Drug|EDP-788|EDP-788 Capsules. All interventions are given as multiple doses.
1597264|NCT02255968|Drug|Placebo|Matching placebo capsules. All interventions are given as multiple doses
1597265|NCT02255955|Drug|550 mg naproxen sodium and 30mg codeine|Postoperative contramal consumption, pain intensity, side effects
1597266|NCT02255955|Drug|300 mg paracetamol and 30 mg codeine|Postoperative contramal consumption, pain intensity, side effects
1597267|NCT02255955|Drug|placebo tablet|Postoperative contramal consumption, pain intensity, side effects
1597268|NCT02255942|Other|Ferric Pyrophosphate and Zinc Oxide|Rice fortified with Ferric Pyrophosphate and Zinc Oxide (ZnO)
1597269|NCT02255942|Other|Ferrous sulfate|Rice fortified with Ferrous Sulfate (ZnSO4)
1597270|NCT02255942|Other|Ferric Pyrophosphate and Zinc Sulfate|Rice fortified with Ferric Pyrophosphate and Zinc Sulfate
1597274|NCT02255903|Other|ultrasound and Doppler examination|ultrasound and Doppler examination: Trans-abdominal ultrasound examination will be peformed to all patienst while women in a slightly tilted position with the head of the bed raised 30 degrees and with a small pillow under the right lion
1597275|NCT02255877|Device|Zip Surgical Skin Closure|Non invasive skin closure device for closure of the skin layer for surgical incisions or laceration repair.
1597276|NCT02255877|Device|Steel Staples|Skin Closure device for the closure of the skin layer for surgical incisions.
1597277|NCT02255864|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
1597278|NCT02255851|Device|SENTINEL (Cerebral Protection System)|
1597279|NCT02255838|Device|Bronchoscope reusable (Storz 8402 2x)|Bronchoscopy and alveolar lavage
1597280|NCT02255838|Device|Bronchoscope disposable (aScope 3)|Bronchoscopy and alveolar lavage
1597281|NCT02255825|Genetic|Whole Genome Sequencing|Whole genome sequencing in a CLIA lab and return of results.
1597282|NCT02255825|Procedure|Amniocentesis|Note: this is being performed on all subjects as a clinical (not research) procedure
1597283|NCT02255825|Other|Psychosocial assessment|Use of EPDS and STAI for assessment of maternal and paternal mood
1597284|NCT02255812|Dietary Supplement|Single intragastric instillation of 200 mL tap water via nasogastric tube|
1597285|NCT02255812|Dietary Supplement|Single intragastric instillation of 2 g citric acid in 200 mL tap water via nasogastric tube|
1597286|NCT02255812|Dietary Supplement|Single intragastric instillation of 2 g salt in 200 mL tap water via nasogastric tube|
1597287|NCT02255812|Dietary Supplement|Single intragastric instillation of 0.017 g quinine in 200 mL tap water via nasogastric tube|
1597288|NCT02255812|Dietary Supplement|Single intragastric instillation of 1 g monosodium glutamate in 200 mL tap water via nasogastric tube|
1597289|NCT02255812|Dietary Supplement|Single intragastric instillation of 25 g glucose in 200 mL tap water via nasogastric tube|
1597290|NCT02255799|Drug|Donepezil|Donepezil 5 mg capsule daily for 14 days. Donepezil 10 mg capsule daily for 56 days.
1597291|NCT02255799|Drug|Placebo|Placebo capsule once daily for 70 days.
1597292|NCT02255786|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy (ACT) is an intervention that fosters acceptance of uncomfortable thoughts and emotions as a coping strategy, and encourages engagement in valued behavior in the presence of these emotions. ACT has been successfully applied to parents of children with a variety of mental health presentations.
1597293|NCT02255773|Behavioral|Computerized Tasks|3 computerized tasks completed to assess motivation, learning of goal-directed and habitual behavior, and flexibility in switching between behavior strategies. It should take about 60 minutes to complete all three tasks.
1597294|NCT02255773|Behavioral|Questionnaires|Completion of 8 questionnaires about mood, fatigue, sleep quality, and other symptoms. It should take about 30 minutes to complete these questionnaires.
1597297|NCT02255747|Drug|Lactulose|
1597298|NCT02255734|Drug|Acyclovir|
1597299|NCT02255721|Behavioral|SHIP (Sleep Health in Preschoolers)|SHIP (Sleep Health in Preschoolers) is a family-centered health behavior change intervention for child behavioral sleep problems delivered 1:1 to parents via a home visit and follow-up phone calls.
1597300|NCT02255721|Behavioral|SHIP Control Arm|Families will receive a family-centered health behavior change intervention for child health topics unrelated to sleep or outcome measures, delivered 1:1 to parents via a home visit and follow-up phone calls.
1597301|NCT02255708|Other|Proprioceptive Neuromuscular Facilitation - PNF|
1597302|NCT02255695|Other|School-based exercise program|The exercise program was applied, twice a week, for 8 weeks, with sessions of 50 minutes, in groups of 10 students. The exercise program was elaborate to restore muscular balance through flexibility, endurance and muscular strength. To promote flexibility stretching exercises for rotator neck muscles, lateral neck flexors, levator scapulae, upper trapezius, erector spinae, major and minor pectoralis, rhomboids, spinal lateral flexors, column rotators, piriformis, hamstrings, quadriceps, hip adductors and abductors were applied. Strengthening exercises were applied for the development of strength, endurance and control of deep flexor muscles of the cervical spine, stabilizers of the glenohumeral joint and scapula, abdominals, spine extensors and hip extensors.
1597303|NCT02255682|Drug|Simvastatin|
1597304|NCT02255682|Dietary Supplement|Q10|
1597305|NCT02255669|Device|partially covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
1597306|NCT02255669|Device|fully covered SEMS|Used for palliation of inoperable malignant distal bile duct obstruction.
1597307|NCT02255656|Drug|alemtuzumab GZ402673|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
1597308|NCT02255643|Device|Change of PMT setting|The patients current motor threshold is determined and the patient is set to a new PMT (= new treatment arm)
1597309|NCT02255630|Other|Cycling Exercise|
1597310|NCT02255617|Biological|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donors
1597311|NCT02255604|Drug|Alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|4
1597312|NCT02255604|Drug|alk (225) Phleum Pratense. 0.1 ml of 10,000 standard quantity units/ml.|3 injection into a lymphnode
1597313|NCT02255604|Drug|0.1 ml Isoton saline|4 injection into a lymphnode
1597314|NCT02255591|Drug|Lidocaine-adrenaline added gadolinium.|
1597315|NCT02255578|Device|Endobarrier treatment in PCOS|the effect of an EndoBarrier device on fertility and metabolic parameters in obese insulin resistant (IR) PCOS women
1597316|NCT02255578|Drug|clomiphene citrate treatment|
1597317|NCT02255565|Drug|Very Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 10mg dose
1597318|NCT02255565|Drug|Low Dose Quillivant XR|Oral suspension dose once a day increasing to a 20mg dose
1597319|NCT02255565|Drug|Moderate Dose Quillivant XR|Oral suspension dose once a day increasing to a 40mg dose
1597320|NCT02255552|Drug|eteplirsen|Eteplirsen 30 mg/kg will be administered as an IV infusion once a week for 96 weeks, followed by a safety extension (not to exceed 48 weeks).
1597321|NCT02254434|Drug|Eltrombopag|Eltrombopag 50 mg per tablet for oral route of administration will be sourced locally
1597322|NCT02254421|Drug|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
1597323|NCT02254421|Drug|Placebo|Placebo to match presatovir administered orally or via nasogastric tube
2009434|NCT03256890|Other|Enhanced Usual Care Control|"Control group participants receive an educational brochure from American Heart Association entitled Understanding and Controlling Your High Blood Pressure Brochure (product code 50-1639). Every participant is provided with a validated home blood pressure monitor (Omron, Model PB786N), that as an evidence-based approach to lower blood pressure, would be considered enhanced usual care at this time. All participants who have uncontrolled hypertension (blood pressure >140/90 mmHg) will be offered to have their physicians notified, if not already being overseen for uncontrolled hypertension. For participants with uncontrolled hypertension who do not have a physician, we work participants to provide access within constraints of their health insurance."
1597326|NCT02254395|Device|Deep Brain Stimulation|
1597327|NCT02254382|Device|Adaptive servo ventilation (ASV)|Non-invasive Ventilation used to control central and obstructive sleep apnea.
1597328|NCT02254369|Drug|GC021109|
1597329|NCT02254369|Other|Placebo|
1597330|NCT02254356|Device|Zilver Flex Bare Metal Stent|
1597331|NCT02254343|Device|proximal robot-assisted therapy|
1597332|NCT02254343|Device|distal robot-assisted therapy|
1597333|NCT02254343|Behavioral|individualized intensive therapy|
1597334|NCT02254317|Dietary Supplement|0 mg placebo|Not containing GSE (Placebo)
1597335|NCT02254317|Dietary Supplement|300 mg GSE|300 mg GSE
1597336|NCT02254317|Dietary Supplement|600 mg GSE|Containing 600 mg of GSE
1597337|NCT02254317|Dietary Supplement|900 mg GSE|Containing 900 mg of GSE
1597339|NCT02254291|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks). Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
1597340|NCT02254291|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg (4 weeks) followed by 0.5 mg for 4 weeks. Total duration of treatment is 30 weeks. Administered subcutaneously (s.c. under the skin).
1597341|NCT02254291|Drug|sitagliptin|Daily doses of 100 mg sitagliptin. Total duration of treatment is 30 weeks. Administered as oral tablets.
1597342|NCT02254278|Drug|Cisplatin|Given IV
1597343|NCT02254278|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1597344|NCT02254278|Other|Laboratory Biomarker Analysis|Correlative studies
1597345|NCT02254278|Other|Quality-of-Life Assessment|Ancillary studies
1597346|NCT02255526|Device|BodyGuardian|BodyGuardian (BG) device will be worn by all subjects to determine accuracy of respiration and activity levels monitored by BG
1597347|NCT02255513|Drug|HLD200|methylphenidate hydrochloride (MPH) Capsules
1597348|NCT02255513|Drug|Placebo|
1597351|NCT02255487|Device|IrriSept System|"The IrriSept system consists of two containers: Step1, a sterile bottle of 450 mL 0.05% Chlorhexidine Gluconate in 99.95% water and Step 2, a sterile bottle of 450 mL of sterile 0.9% Normal Saline. Step 1 and Step 2 are identical in shape and size, with a clear distinction in labeling between. Their unique design allows the solutions to be delivered under the ideal pressure as determined by the surgeon via manual compression for wound and surgical irrigation.
Subjects randomized to the IrriSept system will receive irrigation per the provided Instructions for use; those randomized to Standard of Care will receive routine care per discretion of the investigator and in accordance with the institution's guidelines, which may or may not include some other type of irrigation."
1597352|NCT02255487|Other|No Intervention - Standard of Care (SoC) only|Institution will provide routine Standard of Care (SoC) only surgical preparation for subjects with abdominal trauma or acute surgical abdomen.
1597353|NCT02255474|Device|Biofinity Multifocal D +1.50 add|This is a monthly disposable contact lens commercially available from CooperVision
1597354|NCT02255474|Device|Biofinity Multifocal D +2.50 add|This is a monthly disposable contact lens commercially available from CooperVision
1597355|NCT02255474|Device|Biofinity|This is a monthly disposable spherical contact lens commercially available from CooperVision
1597356|NCT02255461|Drug|palbociclib isethionate|Given PO
1597357|NCT02255461|Other|pharmacological study|Correlative studies
1597358|NCT02255461|Other|laboratory biomarker analysis|Correlative studies
1597359|NCT02255448|Device|Transthoracic echo and esCCO stroke volume|All participants will have their cardiac outputs measured using these two devices simultaneously. Cardiac output 1 will include measurements made using transthoracic echo and cardiac output 2 will be done using esCCO device.
1597360|NCT02255435|Drug|Omaveloxolone Capsules, 2.5 mg|
1597361|NCT02255435|Drug|Omaveloxolone Capsules, 5 mg|
1597362|NCT02255435|Drug|Omaveloxolone Capsules, 10 mg|
1597363|NCT02255435|Drug|Placebo|
1597364|NCT02255435|Drug|Omaveloxolone Capsules, 20 mg|
1597365|NCT02255435|Drug|Omaveloxolone Capsules, 40 mg|
1597366|NCT02255435|Drug|Omaveloxolone Capsules, 80 mg|
1597367|NCT02255435|Drug|Omaveloxolone Capsules, 160 mg|
1597368|NCT02255435|Drug|Omaveloxolone Capsules, 300 mg|
1597369|NCT02255435|Drug|Omaveloxolone Capsules, 150 mg|
1597370|NCT02255422|Drug|Omaveloxolone capsules, 2.5 mg|
1597371|NCT02255422|Drug|omaveloxolone capsules, 5 mg|
1597372|NCT02255422|Drug|omaveloxolone capsules, 10 mg|
1597373|NCT02255422|Drug|Placebo capsules|
1597374|NCT02255422|Drug|omaveloxolone capsules, 20 mg|
1597375|NCT02255422|Drug|omaveloxolone capsules, TBD mg|
1597376|NCT02255422|Drug|omaveloxolone capsules, 40 mg|
1597377|NCT02255422|Drug|omaveloxolone capsules, 80 mg|
1597378|NCT02255422|Drug|omaveloxolone capsules, 160 mg|
1597379|NCT02255409|Biological|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 dose 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
1597380|NCT02255409|Biological|non-adjuvanted Quadrivalent Influenza Vaccine (QIV)|1 dose 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
1597381|NCT02255396|Other|ESTRADIOL|
1597382|NCT02255383|Device|Zimmer Persona Total Knee System|Primary Total Knee Arthroplasty
1597383|NCT02255370|Drug|Curcumin|subjects will be randomized into two arms; they will be given either placebo or curcumin 3g/d per os plus thiopurines during 6 months in a double-blind manner. Rutggerts endoscopic score at 6 months will be the main judgment criteria
1597384|NCT02255357|Drug|Placebo|Solution containing only the excipients of the original solution without Oxytocin.
1597385|NCT02255357|Drug|Intranasal Oxytocin|solution containing Oxytocin 6 IU/0.1cc or per puff is used in this arm
1597386|NCT02255318|Device|Taurolock|
1597387|NCT02255318|Drug|Placebo|
1597388|NCT02255305|Biological|FMT|Patients in the FMT group will receive ~50 grams of fecal material suspended in bacteriostatic normal saline and glycerol.
1597389|NCT02255305|Drug|Antimicrobials|Patients randomized to the control group will receive antimicrobials targeting C. difficile.
1597390|NCT02255292|Drug|cannabidiol (CBD)|Patients with confirmed solid cancer, after progression of all the available standard therapy or unfit to standard therapy according to oncologist's view, measurable disease as determined by RECIST using CT, life expectancy of at least 6 months, Eastern Cooperative Oncology Group (ECOG) performance status < or = 2 and aged 18 years old and more will be included in the current study
1597391|NCT02255279|Biological|Adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29)|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of aTIV, a trivalent (surface antigen, formaldehyde-inactivated) influenza virus vaccine, adjuvanted with MF59C.1, administered at day 1 (for all subjects) and day 29 (for naïve subjects).
1597392|NCT02255279|Biological|Non-adjuvanted Trivalent Influenza Vaccine, 1 dose for non-naive subjects (day 1), two doses for naive subjects (day 1 and day 29).|A 0.25 mL (for children 6 to <36 months old) and 0.5 mL (for children ≥36 months to < 72 months old) dose of TIV , an egg-derived trivalent split influenza vaccine licensed in Mexico, administered at day 1 (for all subjects) and day 29 (for naïve subjects)
1597393|NCT02255266|Drug|liraglutide|No treatment given.
1597394|NCT02255253|Drug|Telmisartan|capsule,40mg per day,2 months
1597395|NCT02255253|Drug|Hydrochlorothiazide|tablet, 25mg per day, 2 months
1597396|NCT02255240|Behavioral|Physical activity intervention|Participants will receive counseling on self-regulatory skill building that has been adapted to complement the video games used. We anticipate that the games used will consist of fitness, sports, and dance games and will be played on a Wii U console. The games played will be chosen by each participant from a pool of potential appropriate games.
2009435|NCT03255018|Drug|Pembrolizumab|Administered intravenously (IV) at a fixed dose of 200 mg every 3 weeks until disease progression or unacceptable toxicity; treatment may continue indefinitely if clinical benefit with options for treatment interruption if responding disease and re-treatment upon relapse.
2009436|NCT03255993|Drug|SPH3127 50mg|SPH3127 50mg
1597399|NCT02255201|Dietary Supplement|Master Performance Blend Dose 1|Caffeine content: 200 mg
1597400|NCT02255201|Dietary Supplement|Master Performance Blend Dose 2|Caffeine content: 400 mg
1597401|NCT02255201|Dietary Supplement|Performance Energy Blend|Caffeine content: 175 mg
1597402|NCT02255201|Dietary Supplement|Energy Blend|Caffeine content: 200 mg
1597403|NCT02255201|Dietary Supplement|Placebo|Caffeine content: 0 mg
1597404|NCT02255188|Procedure|blood sampling procedure|30 ml of venous blood will be collected from all voluteers using a special vacuum tubes after informed consent. Blood sampling is carried out from an arm vein. All subsequent studies will be executed in the laboratory diagnostic division of Novosibirsk Research Institute of Circulation Pathology and the presence of the donors is unnecessary
1597405|NCT02255175|Drug|Estradiol|Participants will receive transdermal estradiol (100μg/day) for 3 weeks
1597406|NCT02255175|Drug|Progesterone|Participants will receive an additional week of combined estradiol and micronized progesterone (200 mg/day) at the end of the study to precipitate menstruation.
1597407|NCT02255162|Drug|Lenalidomide|Patients will receive lenalidomide starting on day 6 of each post-remission cycle, following conclusion of cytarabine post-remission therapy on days 1-5. Following count recovery in the third post-remission cycle, patients will then receive lenalidomide daily as a maintenance therapy.
1597408|NCT02255162|Genetic|HLA-mismatched stem-cell Microtransplantation|Patient will receive HLA-mismatched stem cell microtransplant infusion on day 6 of each post-remission cycle, following conclusion of course of cytarabine in each cycle.
1597409|NCT02255162|Drug|Cytarabine|Patients will receive cytarabine post-remission therapy for 3 cycles, on days 1-5 of each cycle.
1597410|NCT02255149|Device|Bone/Mesh|A titanium mesh (Ti-Mesh) that is more porous than other materials will be placed in order to hold a spot for the bone particles to grow.
1597411|NCT02255136|Other|Individualized homeopathic medicines|5 ml dose of indicated individualized homeopathic medicine in centesimal or 50 millesimal potencies as appropriate; twice daily for 1 year
1597412|NCT02255136|Other|Placebo|Placebo, in the form of a single drop of rectified spirit in 5 ml of distilled water
2009437|NCT03255993|Drug|SPH3127 100mg|SPH3127 100mg
2009438|NCT03255993|Drug|Placebo matching to SPH3127 50mg|Placebo matching to SPH3127 50mg
2009439|NCT03255993|Drug|Placebo matching to SPH3127 100mg|Placebo matching to SPH3127 100mg
1597416|NCT02255084|Behavioral|Group 1 remove self sample kit at gp consulting room or perform pap smear|"Selected general practitioners are briefly informed about the study and they receive a package of kits for vaginal self-sampling.
Selected women receive a mail inviting them either to remove a kit for vaginal self-sampling at their general practitioner's consulting room or to perform a pap smear. When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
1597417|NCT02255084|Behavioral|Group 2 perform self sample at home or pap smear|"Selected general practitioners are briefly informed about the study. Selected women receive a mail inviting them either to perform a vaginal self sampling at their home (with the kit provided) or to perform a pap smear.
When women choose the vaginal self-sampling, a HPV test is performed on the sample in a virology laboratory."
1597547|NCT02254109|Drug|BEA 2180 BR - rising dose|
1597548|NCT02254109|Drug|Placebo|
1597418|NCT02255071|Device|Acupressure wristband|A acupressure wristband over Neiguan (P6 point) and acupressure for seven days.
1597419|NCT02255071|Device|Sham wristband|A wristband over wrist but no acupressure for seven days.
1597420|NCT02255058|Other|No intervention|The study is a Prospective observational cohort study
1597421|NCT02255045|Drug|Meloxicam|meloxicam in vaginal ring
1597422|NCT02255045|Drug|Potassium Diclofenac|oral pill
1597423|NCT02255032|Drug|4 mg CLS-TA|4 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
1597424|NCT02255032|Drug|0.8 mg CLS-TA|0.8 mg/mL CLS-TA, Clearside's formulation of TA (CLS-TA, triamcinolone acetonide injectable suspension)
1597425|NCT02255006|Device|Active acupuncture|Active acupuncture treatment group receive electroacupuncture (EA). For EA treatment, unilateral acupuncture meridian point Pericardium5 (PC5), Pericardium6 (PC6), Stomach36 (ST36), and Stomach37 (ST37) are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2 Hertz continuous wave current. After FMD measurement, a pneumatic cuff placed above the upper arms is inflated to 200 mmHg for 15 minutes. The cuff is then deflated, and 15 minutes of reperfusion is allowed before FMD measurement again. Acupuncture is performed from after ten minutes of ischemia till end time of reperfusion
1597426|NCT02255006|Device|Sham acupuncture|"For sham intervention, nonacupuncture points are used. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
Volunteers undergo FMD measurement and acupuncture like above methods."
1597427|NCT02255006|Drug|Euglucon 5mg|8 healthy volunteers are administered 5 mg of glibenclamide (Euglucon, Roche Pharma) 3 hour before FMD measurement. This dosage has previously been shown to be able to completely inhibit forearm KATP channels. With the glibenclamide administration, a 10% dextrose infusion is started and titrated to maintain blood sugar levels between 80 and 120 mg/dL throughout the study period. 3 hours after glibenclamide administration, the subjects undergo FMD measurement before and after ischemia reperfusion injury. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method.
1597428|NCT02255006|Drug|Celebrex 200mg|8 healthy volunteers are administered celecoxib, a selective COX-2 inhibitor, 200 mg twice daily for 5 days. Last dose of celecoxib is administered at morning. Volunteers undergo FMD measurements before and after ischemia reperfusion injury in that morning of last dose of celecoxib. During ischemia reperfusion period, active acupuncture treatment is performed for 20 minutes like above method
1597429|NCT02254993|Drug|C16G2|antimicrobial peptide
1597430|NCT02254980|Device|Vitamin-E diffused polyethylene acetabular component|Patients will undergo total hip arthroplasty using a cemented acetabular component diffused with Vitamin-E
1597431|NCT02254980|Device|Standard polyethylene acetabular component|Patients will undergo total hip arthroplasty using a standard cemented acetabular component
1597432|NCT02254967|Drug|Fidaxomicin|oral tablets administered in an extended pulsed regimen
1597433|NCT02254967|Drug|Vancomycin|oral capsule
1597434|NCT02254954|Drug|Macitentan in combination with RT and TMZ|Escalating doses of macitentan in combination with RT and TMZ, and maintenance TMZ.
1597435|NCT02254941|Drug|Chemotherapy|Metastatic colon cancer, first line treatment with conventional chemotherapy
1597436|NCT02254941|Biological|Chemotherapy plus monoclonal antibody|Metastatic colon cancer, first line treatment with conventional chemotherapy plus monoclonal antibody
1597437|NCT02254928|Drug|Corifollitropin alfa|One dose of 150 μg of corifollitropin alfa will be administered at day 1 of stimulation. Stimulation will be continued with 250-300 IU/day of rFSH from day 8 forward.
1597438|NCT02254915|Device|Synergo + MMC|Synergo radiofrequency (RF)-Induced hyperthermia-chemotherapy with mitomycin C (RITE). Intravesical instillation of MMC utilizing the Synergo system.
1597439|NCT02254915|Drug|Bacillus Calmette-Guérin|Intravesical instillation of BCG.
1597440|NCT02254902|Behavioral|Physical Activity intervention|The Physical Activity intervention is a 3-month group-based program based on an efficacious physical activity intervention that has been culturally adapted for use with adult Somali women. The program targets increased physical activity through educational and experiential opportunities.
1597441|NCT02254889|Drug|proton pump inhibitor|). In the pre-ESD therapeutic group, a standard intravenous dose of PPI was given 2 hours before ESD. In the post-ESD therapeutic group, patients also received intravenous PPI in standard doses, once in the evening after ESD.
1597442|NCT02254876|Other|Standard physical therapy program|Standard physical therapy program in this study involves joint health and passive mobility at the level of the shoulder girdle and upper limb affected by Painful Shoulder Syndrome associated with the modulation of hypertonic muscle groups.
1597443|NCT02254876|Other|NeuroMuscular Taping (NMT)|"The NeuroMuscular Taping (NMT) consists of the application on the skin of an adhesive tape with a particular structure to elastic waves and with characteristics comparable to those cutaneous. Because of these characterises it allows activation of endogenous analgesic, structural and muscular support, vascular and lymphatic activation.
In this study the NMT is applied with decompressive mode on Pectoralis Major, Deltoids, Supraspinatus."
1597444|NCT02254863|Biological|DUOC-01|Intrathecal administration of DUOC-01
1597445|NCT02254850|Procedure|Flow Mediated Dilation|"Patients performed FMD by an high-resolution ultrasound linear probe in a supine decubitus and conditioned room.The probe was placed on humeral artery and connected to a mechanically arm. Then were performed several measurement s of the internal diameter of the vessel (edge to edge distance), on the R wave of the ECG, and software calculated the average value.The post-ischemic vasodilation was induced using a sphygmomanometer placed on the forearm, distal to the elbow crease, kept inflated to 250 mmHg for 5 minutes. The flow rate was recorded immediately after the desufflation; the diameter of the brachial artery was measured several times after desufflation (for 60-90 seconds). Nextly, the FMD was calculated as the percentage difference between the maximum diameter of the post-ischemic reached and the mean diameter of the vessel."
1597446|NCT02254850|Drug|Mesoglycan|The Patients firstly underwent to intramuscular administration of 1 vial only, containing: Mesoglycan 30mg/ml.
1597447|NCT02254850|Drug|Mesoglycan|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing: Mesoglycan 50 mg.
1597540|NCT02254148|Drug|BI 187004|multiple doses of BI 187004 given as tablets (day 7-12 of visit 2 and day 1-6 of visit 3)
1597448|NCT02254850|Drug|Placebo|The Patients firstly underwent to intramuscular administration only of 1 vial containing inactive ingredients: sodium chloride, chlorocresol, water for injections.
1597449|NCT02254850|Drug|Placebo|The patients underwent to oral treatment with 1 capsule, administered bis in die for a period of 90 days, containing inactive ingredients: lactose monohydrate, corn starch, croscarmellose sodium, magnesium stearate, gelatin, titanium dioxide, erythrosine.
1597450|NCT02254837|Device|Zilver PTX Drug-Eluting Stent|
1597451|NCT02254824|Drug|Xuezhikang|Xuezhikang
1597452|NCT02254824|Drug|Atorvastatin|Atorvastatin
1597453|NCT02254824|Behavioral|Lifestyle modification|Lifestyle modification
1597454|NCT02254811|Biological|Fecal Microbiota Transplant|transfer of healthy human gut bacteria to restore the microbiome
1597455|NCT02254798|Other|no intervention|this is a non interventional study
1597456|NCT02254785|Drug|cabazitaxel|Cabazitaxel 25mg/m2 intravenous every 3 weeks until disease progression
1597457|NCT02254785|Drug|Abiraterone|Abiraterone 1000mg daily (oral) until disease progression
1597458|NCT02254785|Drug|Enzalutamide 160mg daily (oral)|Enzalutamide 160mg daily (oral) until disease progression
1597459|NCT02254772|Biological|Ipilimumab|A dose of 10 mg in cohort 1 or 25mg in cohort 2 via intratumoral injection on day 2, week 1.
1597460|NCT02254772|Drug|SD-101|Started on day 2 week 1, then once every week x 4 successive weeks for a total of 5 injections.
1597461|NCT02254772|Radiation|Radiation therapy|Undergo low-dose radiation therapy to 1 site of disease
1597462|NCT02254759|Drug|Midazolam, IV|2 milligrams per milliliter (mg/mL) midazolam solution for IV administration. For a 1 mg dose, the midazolam solution (0.5 mL of 2 mg/mL) will be injected at 2 milligrams per minute (mg/min).
1597463|NCT02254759|Drug|Midazolam, oral|0.1 mg/mL midazolam for oral administration. For a 5 mg dose, participants will receive 50 mL of 0.1 mg/mL midazolam.
1597464|NCT02254759|Drug|RO5186582|RO5186582 120 mg film-coated release tablet.
1597465|NCT02254746|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
1597466|NCT02254733|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|CBSST integrates CBT and SST techniques and neurocognitive compensatory aids. The treatment manual includes a patient workbook that describes the skills and includes homework assignment forms. Cognitive therapy is combined with role play practice of communication skills and problem-solving training. The ACT-adapted, team-delivered individual CBSST intervention will be delivered in 3 6-session modules (Cognitive Skills, Social Skills, and Problem Solving Skills) for a total of 18 weekly individual therapy sessions, but with participants completing the sequence of 3 modules twice, for a total of 36 sessions (9 months).
1597467|NCT02254733|Other|Assertive Community Treatment (ACT)|Assertive Community Treatment model is a evidence based practice model. ACT teams are multi-disciplinary and provide comprehensive services to individuals in their natural setting with small staff to recipient ratio. ACT teams use assertive engagement to proactively engage individuals in treatment providing services and support directly to individuals that are tailored to meet their specific goals and needs.
1597468|NCT02254720|Drug|BEA 2180 BR solution for infusion|
1597469|NCT02254720|Drug|Placebo|Intravenous infusion
1597470|NCT02254720|Drug|BEA 2180 BR solution for inhalation|
1597471|NCT02254720|Device|Respimat®|
1597472|NCT02254707|Drug|BILB 1941 ZW|
1597473|NCT02254707|Drug|Placebo|
1597474|NCT02254694|Other|high heeled shoes|see detailed study description
1597475|NCT02254681|Drug|Gemcitabine|
1597476|NCT02254681|Drug|Cisplatin|
1597477|NCT02254681|Radiation|Low dose whole liver and portal lymph node basin radiotherapy|
1597478|NCT02254668|Other|Protocol with Everolimus (Certican®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITH Everolimus (Certican®).
1597479|NCT02254668|Other|Protocol with Mycophenolate mofetil (CellCept®)|Electronic (computer-assisted) randomization of an immunosuppressive protocol WITHOUT Everolimus (Certican®), instead administration of Mycophenolate mofetil (CellCept®).
1597480|NCT02254655|Drug|Puerarin injection 400 mg|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis.Furthermore, patients were administrated with 400 mg intravenously infused puerarin injection once a day.Each treatment course lasted for 2 weeks followed by a regular time interval of 15 days.
1597481|NCT02254655|Drug|Control|Patients receive treatment with oral anti-rheumatic agents and/or non-steroidal anti-inflammatory drugs, prednisone, aspirin, statins, bone metabolism regulators and gastric mucosal protective agents on as-needed basis
1597482|NCT02254642|Procedure|Ischemic preconditioning during aortic clamping|
1597483|NCT02254642|Procedure|Procedure/Surgery: usual surgery|
1597484|NCT02254629|Drug|Probiotic Clostridium Butyricum|probiotic:2 tablets/ times, 3 times / day for 2 weeks
1597485|NCT02254629|Drug|Laxative Polyethylene Glycol|laxative：2000 ml.
1597486|NCT02254616|Behavioral|Mirror Therapy with tDCS|The MTtDCS group will receive a 20-minute tDCS at 1.5 mA current intensity per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
1597487|NCT02254616|Behavioral|Mirror Therapy with sham-tDCS|The MTtDCS(m) group will receive a 20-minute sham-tDCS per session followed by a 40-minute mirror therapy and 30-minute functional training during the first two weeks. Sixty-minute pure mirror therapy during the last 2 weeks, and followed by a 30-minute functional training.
1597488|NCT02254616|Behavioral|Mirror Therapy|The MT group will receive a 60-minute MT per session followed by a 30-minute functional training.
1597489|NCT02254616|Behavioral|Control Intervention|The CI group will receive a 60-minute conventional stroke rehabilitation training followed by a 30-minute functional training.
1597490|NCT02254603|Device|Acupuncture|Acupuncture about 30 mins will be performed by a traditional Chinese physician three times a week for 3 months.
1597491|NCT02254603|Behavioral|Yoga exercise|Subject will receive regular 60-minutes yoga exercise three times a week for 3 months.
1597541|NCT02254148|Drug|metoprolol|single dose of metoprolol given as tablets (day 1 of visits 2 and 3)
1597542|NCT02254135|Drug|BEA 2180 BR - rising dose|
1597543|NCT02254135|Drug|Placebo|
1597492|NCT02254590|Procedure|Irrigation Endoscopic Decompressive Laminotomy|2 portals 0.5cm were used one for the endoscope and the other for instruments. For every additional level one portal is added. The endoscope and instruments are directly placed over the surface of lamina without any dissection and saline under pump pressure is used to open a potential working space. Unilateral laminotomy/laminectomy is performed according to the severity of stenosis, followed by bilateral decompression beneath the midline structures.
1597493|NCT02254577|Drug|Endometrin® plus Progesterone in Oil (PIO)|
1597494|NCT02254577|Drug|Progesterone in Oil (PIO) Only|
1597495|NCT02254551|Drug|LDE225|"Lead-In: LDE225 will be administered orally at three dose levels starting at 400mg. If acceptable tolerability is demonstrated, escalations may continue up to 800 mg. LDE225 will be administered orally as a single daily dose for 21 days in combination with a fixed dose of bortezomib to be given on Days 1, 4, 8, 11 of each 21 day cycle.
Dose Expansion: LDE225 will be given as a single oral daily dose for 21 days at the MTD determined in the lead-in phase.
Maintenance Therapy: Patients who complete 16 cycles of therapy with stable disease or better will be eligible for single agent maintenance therapy of LDE225 at the MTD orally for up to 2 years or until progressive disease or unacceptable toxicity."
1597496|NCT02254551|Drug|Bortezomib|In both the lead-in and dose expansion portions of the study, bortezomib, 1.3 mg/m2, will be administered by subcutaneous injection (SQ) on Days 1, 4, 8, 11 of each 21 day cycle.
1597497|NCT02254538|Drug|BILR 355 BS|
1597498|NCT02254538|Drug|PEG 400|
1597499|NCT02254525|Drug|Intravenous ibuprofen|"Treatment group: 800 mg IV ibuprofen, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.
All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
1597500|NCT02254525|Drug|Saline solution|"Placebo group: 200 ml of saline solution, starting at the moment of skin closure and every 6 hours up to 72 hours after the first dose.
All patients will receive morphine administered by patient controlled analgesia (PCA). Investigation treatment will be administered every 6 hours until 24 h in abdominal surgery, 48 h in hip surgery and 72 h in knee surgery."
1597501|NCT02254486|Drug|NER1006|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
1597502|NCT02254486|Drug|Trisulfate solution|The subject will self-administer the first dose of the assigned investigational product in the evening prior to the scheduled colonoscopy and take mandatory additional clear fluid. Subject will take the second dose together with mandatory additional clear fluids on the morning of the colonoscopy.
1597503|NCT02254473|Other|Wedge Insert|
1597504|NCT02254473|Other|Flat Insert|
1597505|NCT02254460|Dietary Supplement|Test|Experimental product: Micronutrient fortified beverage powder, packed as 27 g individual sachet, administered orally as a single serve.
1597506|NCT02254460|Other|Control|Energy equivalent beverage powder without micronutrient fortification, packed as 27 g individual sachets, administered orally as a single serve
1597507|NCT02254447|Drug|Candesartan Cilexetil in formulation 1|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
1597508|NCT02254447|Drug|Candesartan Cilexetil in formulation 2|Round, biconvex white tablets containing Candesartan cilexetil 16 mg for oral administration
1597509|NCT02254447|Drug|ATACAND|Round, biconvex pink tablets containing Candesartan cilexetil 16 mg for oral administration
1597510|NCT02254265|Drug|OTX-101 0.05%|OTX-101 0.05% Ophthalmic Solution
1597511|NCT02254265|Drug|OTX-101 0.09%|OTX-101 0.09% Ophthalmic Solution
1597512|NCT02254265|Drug|Vehicle|Vehicle of OTX-101 Ophthalmic Solution
1597513|NCT02254252|Drug|Nicorandil|nicorandil (10mg tablets, two times a day)
1597514|NCT02254252|Drug|Nitroglycerin|sustained-release glyceryl trinitrate (6.4mg tablets, two times a day)
1597515|NCT02254239|Drug|Brentuximab Vedotin|Given IV
1597516|NCT02254239|Drug|Everolimus|Given PO
1597517|NCT02254239|Other|Laboratory Biomarker Analysis|Correlative studies
1597518|NCT02254239|Other|Pharmacological Study|Correlative studies
1597519|NCT02254226|Drug|Salmeterol Diskus low|
1597520|NCT02254226|Drug|Salmeterol Diskus high|
1597521|NCT02254226|Drug|Salmeterol MDI low|
1597522|NCT02254226|Drug|Salmeterol MDI high|
1597523|NCT02254213|Other|EEG recording|A short EEG recording is performed 10 times over the span of three months.
1597524|NCT02254200|Other|Fatmax group|For the Fatmax group each session will consist of 40-50 min of continuous exercise with an intensity that corresponded to the individual Fatmax (moderate intensity)
1597525|NCT02254200|Other|HIIT group|For HIIT group, each session will consist of 10x60-s cycling intervals interspersed with 60-s of recovery. The workloads will be selected to elicit a heart rate of ~90% maximal heart rate during the intervals with a pedal rate of 90-100 revolutions.min-1, whereas during recovery, the participants will be allowed to pedal against a resistance of 50 W
1597526|NCT02254187|Drug|Salmeterol capsule - low|
1597527|NCT02254187|Drug|Salmeterol capsule - high|
1597528|NCT02254187|Drug|Salmeterol via Serevent® Diskus®|
1597529|NCT02254174|Drug|Tiotropium/Salmeterol|Fixed dose combination of tiotropium 7.5 μg and salmeterol 25 μg inhalation powder, PE capsule via HandiHaler®
1597530|NCT02254174|Drug|Serevent® Diskus®|
1597531|NCT02254174|Drug|Spiriva®|
1597532|NCT02254161|Drug|Matching placebo|Tablet
1597533|NCT02254161|Drug|BI 1181181 healthy elderly|Tablet
1597534|NCT02254161|Drug|BI 1181181 Healthy young|Tablet
1597535|NCT02254148|Drug|midazolam|single dose of midazolam given as oral solution (day 1 of visits 2 and 3)
1597536|NCT02254148|Drug|caffeine|single dose of caffeine given as tablets (day 1 of visits 2 and 3)
1597537|NCT02254148|Drug|digoxin|single dose of digoxin given as tablets (day 3 of visits 2 and 3)
1597538|NCT02254148|Drug|warfarin|single dose of warfarin given as tablets (day 1 of visits 2 and 3)
1597539|NCT02254148|Drug|omeprazole|single dose of omeprazole given as tablet (day 1 of visits 2 and 3)
1597544|NCT02254122|Drug|BEA 2180 BR|
1597551|NCT02254096|Other|Grapefruit juice (GFJ)|
1597552|NCT02254096|Other|High fat meal (HFM)|
1597553|NCT02254083|Drug|BIBT 986 BS - low|
1597554|NCT02254083|Drug|BIBT 986 BS - high|
1597555|NCT02254083|Drug|Placebo|
1597556|NCT02254070|Drug|BIBT 986 BS|
1597557|NCT02254057|Drug|BIBT 986 BS - single rising dose|
1597558|NCT02254057|Drug|Placebo|
1597559|NCT02254044|Drug|bivatuzumab mertansine|
1597560|NCT02254031|Drug|bivatuzumab mertansine|
1597561|NCT02254018|Drug|bivatuzumab mertansine|
1597562|NCT02254005|Drug|bivatuzumab mertansine|
1597565|NCT02253979|Device|Standard double lumen tube|Endotracheal left side double lumen tube
1597566|NCT02253979|Device|VivaSight double lumen tube|VivaSight double lumen endotracheal intubation
1597567|NCT02253966|Drug|Methylprednisoloneacetate|
1597568|NCT02253966|Drug|Lidocaine|
1597569|NCT02253966|Other|sodium chloride|
1597570|NCT02253953|Drug|BILR 355 BS, D1|
1597571|NCT02253953|Drug|BILR 355 BS, D2|
1597572|NCT02253953|Drug|BILR 355 BS, D3|
1597573|NCT02253953|Drug|BILR 355 BS, D4|
1597574|NCT02253953|Drug|BILR 355 BS, D5|
1597575|NCT02253953|Drug|BILR 355 BS, D6|
1597576|NCT02253953|Drug|BILR 355 BS, D7|
1597577|NCT02253953|Drug|BILR 355 BS, D8|
1597578|NCT02253953|Drug|BILR 355 BS, D10|
1597579|NCT02253953|Drug|Placebo|
1597580|NCT02253953|Other|high-fat breakfast|
1597581|NCT02253953|Drug|Ritonavir|
1597582|NCT02253940|Drug|BILR 355 - Treatment A (current tablet formulation)|
1597583|NCT02253940|Drug|BILR 355 - Treatment B (new tablet formulation)|
1597584|NCT02253940|Drug|BILR 355 - Treatment C (new capsule formulation)|
1597585|NCT02253940|Drug|BILR 355 - Treatment D (current tablet formulation)|
1597586|NCT02253940|Drug|BILR 355 - Treatment E (new capsule formulation)|
1597587|NCT02253940|Drug|Ritonavir|
1597588|NCT02253927|Drug|BILR 355 - D1|
1597589|NCT02253927|Drug|BILR 355 - D2|
1597590|NCT02253927|Drug|BILR 355 - D3|
1597591|NCT02253927|Drug|BILR 355 - D4|
1597592|NCT02253927|Drug|Ritonavir|
1597593|NCT02253927|Other|high fat breakfast|
1597594|NCT02253914|Drug|BILR 355 BS, solution|
1597595|NCT02253914|Drug|BILR 355 BS, tablet|
1597596|NCT02253914|Drug|Ritonavir|
1597597|NCT02253914|Drug|Placebo|
1597598|NCT02253901|Drug|BILR 355 BS|
1597599|NCT02253901|Drug|Ritonavir|
1597600|NCT02253901|Drug|TRUVADA|
1597601|NCT02253888|Drug|TPV - Room condition|
1597602|NCT02253888|Drug|TPV - Refrigerated conditions|
1597603|NCT02253888|Drug|Ritonavir (RTV)|
1597604|NCT02253875|Drug|Tipranavir (TPV)|
1597605|NCT02253875|Drug|Ritonavir|
1597606|NCT02253875|Drug|Omeprazole|
1597607|NCT02253862|Drug|Tadalafil|administered days 1, 8 and 16
1597608|NCT02253862|Drug|Tipranavir|administered days 8-18
1597609|NCT02253862|Drug|Ritonavir|administered days 8-18
1597610|NCT02253849|Drug|Carbamazepine|
1597611|NCT02253849|Drug|Tipranavir|
1597612|NCT02253849|Drug|Ritonavir|
1597613|NCT02253836|Drug|Tipranavir|TPV
1597614|NCT02253836|Drug|Ritonavir|RTV
1597615|NCT02253836|Drug|Atazanavir|TAZ
1597616|NCT02253823|Drug|EFV|
1597617|NCT02253823|Drug|TPV/RTV - low dose|
1597618|NCT02253823|Drug|TPV/RTV - high dose|
1597619|NCT02253810|Drug|Tranexamic Acid|
1597620|NCT02253810|Drug|Placebo|
1597621|NCT02253797|Drug|14C-Tipranavir|
1597622|NCT02253797|Drug|Tipranavir|
1597623|NCT02253797|Drug|Ritonavir|
1597626|NCT02253771|Device|shockwave therapy|Shockwave therapy with 2000 impulses/treatment at 12 Hz; 8 treatment over 4 weeks, twice a week
1597627|NCT02253758|Drug|Propofol|Propofol will be injected as a continuous infusion by TCI intravenously
1597628|NCT02253745|Drug|V81444|V81444 capsules for oral administration, 100 mg twice daily for 13 days and once on Day 14
1597629|NCT02253745|Drug|Placebo|Capsules to match V81444 twice daily for 13 days and once on Day 14
1597630|NCT02253732|Behavioral|3 months exercise intervention program|3 months exercise intervention program which is given 3-times per week, 60 min session duration, 65-75% repetition maximum or heart rate maximum, combined strength & aerobic exercises
1597631|NCT02253719|Procedure|cryotherapy, further biopsy, LEEP, surgery as indicated|These interventions and their outcomes are not part of this study. However, we will be offering at no charge appropriate treatment for neoplasia or cancer that is diagnosed.
1597632|NCT02253706|Device|High flow nasal oxygen supplementation|High-flow nasal ventilation: This will be carried out using the Precision Flow device (Opti-Flow, Auckland, New Zealand). This device is intended to add warm moisture to breathing gases from an external source. Flow rate via the nasal cannula will be kept at 50 Liters/min and fractional inspired oxygen concentration will be set at 0.35.
1597633|NCT02253706|Device|low flow nasal oxygen supplementation|Low-flow nasal ventilation: This will be carried out using a regular nasal cannula fed with oxygen at flow rates from 2 to 6 liters/minute.
1597634|NCT02253680|Procedure|Actico, short-stretch, inelastic dressing|Worn 24hr post-operatively
1597635|NCT02253667|Device|HFONC|
1597636|NCT02253667|Device|Conventional oxygen therapy|
1597637|NCT02253654|Drug|Epoetin alfa|Administered intravenously (IV) three times a week (TIW) by appropriately trained healthcare professionals during hemodialysis.
1597638|NCT02253641|Behavioral|Standard Weight Loss Intervention|14-session/6-month standard behavioral weight loss intervention
1597639|NCT02253641|Behavioral|Stress-Focused Weight Loss Intervention|14-session/6-month tailored behavioral weight loss intervention
1597835|NCT02252354|Drug|TAK-385 Tablets|TAK-385 tablets 2 X 40 mg
1597640|NCT02253628|Other|Cold espresso|Volunteers consumed cold espresso with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
1597641|NCT02253628|Other|Hot instant coffee|Volunteers consumed hot instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
1597642|NCT02253628|Other|Cold instant coffee|Volunteers consumed cold instant coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
1597643|NCT02253628|Other|Hot filter coffee|Volunteers consumed hot filter coffee with 160 mg caffeine. Salivary gastrin, alpha-amylase and cortisol and self-reported GI symptoms and stress were collected at fasting and postprandially.
1597644|NCT02253615|Other|Machines exercises|Resistance training in pneumatic machines.
1597645|NCT02253615|Other|Elastic exercises|Resistance training with elastic tubes.
1597646|NCT02253602|Drug|Ferumoxytol|maximum rate of administration 1 ml/sec
1597647|NCT02253589|Behavioral|modified ASSIST-linked Brief Intervention|Trained counsellors support participant's motivation to reduce or stop khat use in a 20 minute counselling session.
1597648|NCT02253576|Other|inhaled 7% hypertonic saline|Three consecutive doses of 4 ml of 7% hypertonic saline added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
1597649|NCT02253576|Other|inhaled nebulized normal saline|Three consecutive doses of 4 ml of 0.9% NaCl added to salbutamol, 0.15 mg/kg; 0.03 ml/kg of 0.5% salbutamol nebulizer solution over 1 hour
1597650|NCT02253563|Behavioral|Resistance Training|
1597651|NCT02253563|Behavioral|Balance Training|
1597652|NCT02253550|Drug|Simeprevir|Simeprevir is a Hepatitis C Virus (HCV) NS3/4A protease inhibitor approved in the United States, Canada and Japan for the treatment of chronic HCV infection.
1597653|NCT02253550|Drug|Sofosbuvir|Sofosbuvir is a nucleotide NS5B polymerase inhibitor developed by Gilead Sciences Inc. and approved for the treatment of chronic HCV infection.
1597654|NCT02253537|Device|CST001|
1597655|NCT02253524|Drug|Dimenhydrinate|50 mg Dramamine with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
1597656|NCT02253524|Drug|Metoclopramide|10 mg Metoclopramide with 5 cc syringe in 150 ml normal saline given as a slow intravenous infusion over 15 minutes
1597657|NCT02253511|Drug|Cidan capsule|
1597658|NCT02253498|Device|deep brain stimulation (DBS)|
1597659|NCT02253485|Drug|telbivudine|"in telbivudine treatment entire pregnancy group, mothers were treated with telbivudine during entire pregnancy for hepatitis B.
in telbivudine treatment in late pregnancy group, mothers with high serum HBV DNA load receive telbivudine treatment in late pregnancy for preventing MTCT of HBV."
1597660|NCT02253472|Device|Deep Brain Stimulation|
1597661|NCT02253459|Drug|UTD1 Injection plus capecitabine|
1597662|NCT02253459|Drug|Capecitabine|
1597663|NCT02253446|Drug|Piroxicam|20 mg of piroxicam (Feldene ampoule-Pfizer-France) intramuscularly (IM) was given 200 patients,
1597664|NCT02253446|Drug|Diclofenac Sodium|Second Group: Diclofenac sodium 75mg (Miyadren ampoule-bulb-Yavuz Istanbul) intramuscularly (IM) was given 200 patients.
1597665|NCT02253433|Other|Enhanced in-clinic care and intervention|This arm receives enhanced in-clinic care, as well as a customized home-based environmental exposure assessment and multicomponent exposure reduction and asthma control intervention (five home visits over approximately 12 months).
2009440|NCT03255031|Dietary Supplement|Ketogenic Diet (KD)|Ketogenic Diet (KD) Meals and Shakes: Participants will be randomized to a meal plan of a ketogenic diet (KD) at the time they sign the consent (day 1 or 2 of admission). For each meal at breakfast, lunch and dinner, the diets will consist of a KD meal depending on treatment randomization. Compliance tests are done daily with a urine test measuring ketone levels. To ensure that the diet is double blind in both the outpatient and inpatient phases, solid snacks are always ketogenic and shakes are KD.
2009441|NCT03255031|Dietary Supplement|Standard American (SA) Meals and Shakes|Standard American (SA) Meals and Shakes: Participants will be randomized to a meal plan of standard American (SA) diet at the time they sign the consent (day 1 or 2 of admission). For each meal at breakfast, lunch and dinner, the diet will consist of a SA meal (carbohydrate rich) depending on treatment randomization. Compliance tests are done daily with a urine test test measuring ketone levels. To ensure that the diet is double blind in both the outpatient and inpatient phases, solid snacks are always ketogenic and shakes are SA.
1597670|NCT02253407|Biological|MMR vaccine|
1597671|NCT02253394|Drug|Ambrisentan plus Spironolactone|Cardiopulmonary fitness
1597672|NCT02253394|Drug|Ambrisentan plus Placebo|Placebo is a sugar pill manufactured to resemble spironolactone 50 mg Cardiopulmonary fitness
1597673|NCT02253381|Procedure|Right|Right lateral decubitus position during spinal anesthesia
1597674|NCT02253381|Procedure|Left|Left lateral decubitus position during spinal anesthesia
1597675|NCT02253368|Other|sleep|
1597676|NCT02253355|Device|Deep Brain Stimulation|
1597677|NCT02253342|Drug|WCK-2349|Each subject will receive ten oral doses of 1000 mg WCK 2349 administered twice-daily starting on Day 1
1597678|NCT02253329|Procedure|Dietary protein plus NMES during the day|Neuromuscular electrical stimulation after a protein bolus, performed during the day
1597679|NCT02253329|Procedure|Dietary protein plus NMES prior to sleep|Neuromuscular electrical stimulation after a protein bolus, performed prior to sleep
1597683|NCT02253303|Other|midline incision or off-midline incision|Eligible patients are randomized to midline incision or off-midline incision group in laparoscopic colectomy
1597684|NCT02253277|Drug|Nilotinib|Nilotinib will be supplied by Novartis as 150 mg and 200 mg hard gelatin capsules. Nilotinib will not be dosed by weight or body surface area. Medication labels will be in German and comply with the legal requirements of Germany. They will include storage conditions for the drug but no information about the patient. The investigator must emphasize compliance and will instruct the patient to take nilotinib exactly as prescribed.
1597774|NCT02252796|Radiation|Hypofractionated Stereotactic Boost|An ablative dose of radiation is delivered to the primary tumor target over a week through Stereotactic Ablative Radiotherapy.
1597775|NCT02252796|Drug|Carboplatin|Given during chemo-radiation phase and optional consolidative phase.
1597685|NCT02253277|Drug|Ruxolitinib|Ruxolitinib will be supplied by Novartis as 5 mg, 15 mg, and 20 mg tablets. Medication labels will be in German and comply with the legal requirements of Germany. They will include storage conditions for the drug but no information about the patient. The investigator must emphasize compliance and will instruct the patient to take ruxolitinib exactly as prescribed.
1597686|NCT02253264|Drug|Rituximab|
1597687|NCT02253251|Genetic|KRAS-variant and microRNA binding site mutation testing|Participant in these studies will be tested for the KRAS-variant
1597688|NCT02253238|Behavioral|Quality of Life Survey|Quality of life survey completed at baseline, 7 days after radiation therapy (RT) and at 6 - 8 weeks after RT.
1597689|NCT02253238|Behavioral|Health Management Surveys|Confidence in health management survey; completed at baseline and 6 - 8 weeks after RT.
1597690|NCT02253238|Other|Monitoring Devices|Home use of CYCORE devices (blood pressure monitor, weight scale, electronic tablet, palm-sized plug-in computer)
1597691|NCT02253238|Behavioral|Symptoms Surveys|"Behavioral: Symptoms survey 1; completed at weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT.
Behaviorial: Symptoms survey 2; completed at baseline, weeks 1, 3, 5, and 7 days after RT, and at 6 - 8 weeks after RT."
1597692|NCT02253238|Behavioral|Device Usability Survey|Device usability survey; completed at weeks 1, 3, 5, and 7 days after RT.
1597693|NCT02253225|Other|Functional Magnetic Resonance Imaging (fMRI)|Imaging will be performed on a 3T Siemens Trio scanner. Each MRI scanning session will last no more than 90 minutes.
1597694|NCT02253212|Device|SonoCloud|SonoCloud : dose escalation
1597695|NCT02253212|Drug|Carboplatin|Carboplatin : 6 cycles - individual dose determination according to renal function and AUC
1597696|NCT02253199|Drug|intranasal dexmedetomidine|"Children who were not adequately sedated ( no evidence of adequate sedation within 30 min after administration of Initial dose of chloral hydrate) received a bolus of intranasal dexmedetomidine which adjusted by the Dixon up-and-down method for rescue sedation.
The first child received 0.8mcg/Kg of intranasal dexmedetomidine dose (100mcg/ml), and the dose interval was set at 0.1mcg/Kg."
1597697|NCT02253186|Device|Auto-Adjustable MOBIDERM Armsleeve|
1597698|NCT02253173|Drug|Estradiol|
1597699|NCT02253173|Drug|Placebo|
1597700|NCT02253160|Device|Spectra Optia CMNC|The Spectra Optia® Apheresis System is an automated centrifugal system that separates whole blood into its cellular and plasma components. The device is comprised of three major sub-systems, 1) the apheresis machine itself (centrifuge, centrifuge filler, pumps, valves, computerized safety and control systems, etc.), 2) a sterile, single-use, disposable blood tubing set, and 3) embedded software. The Spectra Optia system's investigational CMNC procedure will be used to collect MNC from the peripheral blood.
1597701|NCT02253160|Device|COBE Spectra MNC|It is also a centrifugal system that separates whole blood into its cellular and plasma components. The COBE Spectra MNC collection procedure is chosen as the comparator device because it is the reference after which design of the Spectra Optia CMNC collection procedure was modeled.
1597702|NCT02253160|Drug|Granulocyte-colony stimulating factor (G-CSF)|Each subject received an injection of the G-CSF approximately equivalent to 10 ug/kg body weight subcutaneous per day for 5 days prior to the MNC collection procedure.
1597703|NCT02252055|Biological|ATDC_Nantes|"ATDC treatment (1 x 106 cells/kg BW slow peripheral venous) occurs the day before transplantation into recipients also recipients of a living donor renal transplantation.
Recipients also receive prednisolone, Mycophenolate Mofetil and tacrolimus background immunosuppression ( as described in detail in the arm description)"
1597704|NCT02252042|Biological|pembrolizumab|
1597705|NCT02252042|Drug|methotrexate|
1597706|NCT02252042|Drug|docetaxel|
1597707|NCT02252042|Biological|cetuximab|
1597708|NCT02252016|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken once daily by mouth.
1597709|NCT02252016|Drug|Placebo|Placebo tablets matching grazoprevir + elbasvir FDC tablets taken once daily by mouth.
1597710|NCT02252003|Other|Pain scales testing|
2009442|NCT03253744|Drug|18F-DCFPyL|Subjects will receive 18F-DCFPyL at baseline and 6 months after radiation. The maximum amount of injected active drug will be less than 4.02 micrograms. The target administered activity will be 10 mCi.
1597713|NCT02251977|Drug|GM1|GM1 will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of GM1 for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
1597714|NCT02251977|Drug|placebo|Placebo will be delivered to patients through the day before the initiation of chemotherapy (Day0) to the completion of chemotherapy (Day4), and the dosages of placebo for patients who receive mFOLFOX6 or XELOX are 80mg or 120mg per day.
1597715|NCT02251977|Drug|mFOLFOX6 or XELOX|"mFOLFOX6: Patients will receive mFOLFOX6 every 14 days, Oxaliplatin 85mg/m2 IV over 3 hours on Day1; Calcium Folinate IV over 2h on Day 1(Leucovorin 200mg/m2 or CF 400 mg/m2); 5-Fluorouracil 400mg/m2 IV on Day1; followed by 5-Fluorouracil 2.4g/m2 for 46 hours continuous infusion on Day1.
XELOX: Patients will receive XELOX every 21 days, Oxaliplatin 130mg/m2 IV over 3 hours on Day1;followed by Capecitabine 1000mg/m2 oral twice daily for 14 days.
The optimum chemotherapy regimen is at the discretion of the investigators based on the condition of each patient."
1597716|NCT02251964|Drug|Rituximab|2 times 1000mg dose at 14 days interval treatment
1597717|NCT02251964|Radiation|Zr-89-rituximab immuno PET/CT|Immuno labeled PET/CT of the lungs
1597718|NCT02251951|Drug|nab-Paclitaxel|Abraxane: 150mg/m2 i.v weekly for 3 consecutive weeks followed by a week of rest (28d)
1597719|NCT02251938|Drug|DE-109|Medium Dose of DE-109
1597720|NCT02251925|Biological|frozen Embryo transfer|In this study all patients who will undergo frozen embryo transfer are randomly allocated to be prepared for transfer by using either natural cycle (with or without hCG for ovulation induction) or Hormonal cycle (with or without administration of GnRH-a).
1597721|NCT02251925|Drug|10,000U hCG injection|In natural cycle with hCG, after detection of mature follicles in ultrasound and endometrial thickness over 7mm, 10,000IU hCG is injected for ovulation and embryo transfer is performed 3-5 days later in cleavage stage.
1597776|NCT02252796|Drug|Paclitaxel|Given during chemo-radiation phase and optional consolidative phase.
1597777|NCT02252796|Radiation|Image-guided IMRT|Given during chemo-radiation phase
1597923|NCT02251678|Dietary Supplement|Elimune Capsules|2 capsules BID for 28 days
1597722|NCT02251925|Drug|GnRH agonist (Superfact)|In group 3, injection of GnRH agonist (Superfact) at a subcutaneous daily dose of 0.5 mg is started on the day 17-19 of the natural menstrual cycle. Once pituitary desensitization is confirmed, hormonal treatment is commenced with 4mg/day oral Estradiol valerate and after 7 days if endometrial thickness is adequate, Estradiol administration will be continued with the same dose and 100mg Progesterone is administered before embryo transfer, otherwise patients are candidates for higher dosage of Estradiol till favourable endometrial thickness is achieved.
1597723|NCT02251925|Drug|administration of 6 mg Estradiol valerate|In the hormonal group without GnRH-a, endometrial preparation will be started with daily administration of 6 mg Estradiol valerate from the 2nd day of the natural menstrual cycle for 6 days. Then treatment will be continued similar to the 3rd group.
1597724|NCT02253121|Drug|Dapagliflozin|Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD
1597725|NCT02253121|Drug|Sliding scale insulin|Sliding scale insulin with short acting insulin based on current glucose levels
1597726|NCT02253108|Device|Everolimus eluting bioresorbable polymer stent|
1597727|NCT02253108|Device|Biolimus eluting bioresorbable polymer stent|
1597728|NCT02253095|Drug|Albendazole|
1597729|NCT02253095|Dietary Supplement|Zinc|
1597730|NCT02253095|Dietary Supplement|Multiple Micronutrient Supplement|
1597731|NCT02253095|Drug|Placebo|
1597732|NCT02253082|Drug|OctaplasLG®|OctaplasLG® is an industrial donor plasma product pooled from approximately 400 single donor units. It possess' unique features when compared to standard FFP, such as having standardized concentrations of natural pro- and anti-coagulation factors, standardized volume and as being pathogen free. Very importantly, the manufacturing method of OctaplasLG® removes immune complexes and cells in several steps of microfiltration in addition to viral, bacterial and prion pathogen inactivation.
1597733|NCT02253082|Biological|Fresh frozen plasma|Standard FFP from the Blood Bank
1597734|NCT02253069|Device|Applying Prontosan antiseptic solution to tie-over dressings|Applying a PHMB-based antiseptic to tie-over dressings
1597735|NCT02253069|Device|Applying Placebo to tie-over dressings|Placebo control
1597736|NCT02253056|Other|Fasting / Caloric Restriction|
1597737|NCT02253056|Other|Healthy Diet|
1597738|NCT02253043|Device|Deep Brain Stimulation (Beijing PINS Medical Co., Ltd)|PINS Stimulator System
1597739|NCT02253030|Device|Optical Coherence Tomography|
1597740|NCT02253017|Other|Children operated on for cataract|Compilation of results of monitoring of children aged 8 to 10 months, 3 years, 5 years, 8 years
1597741|NCT02253004|Drug|Cilostazol|Single oral administration of active or placebo one week apart
1597742|NCT02253004|Drug|Placebo|
1597743|NCT02252991|Other|physical activity|Patients will realise physical activity either during their treatment, either after their treatment. They will have practise a physical activity three times per week.
1597744|NCT02252978|Drug|ciprofloxacin|Given PO
1597745|NCT02252978|Other|placebo|Given PO
1597746|NCT02252978|Other|quality-of-life assessment|Ancillary studies
1597747|NCT02252978|Other|laboratory biomarker analysis|Correlative studies
1597748|NCT02252965|Drug|Metformin IR|Subjects will receive Metformin Immediate Release (IR) tablets, orally once daily at a dose of 500 milligram (mg) for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
1597749|NCT02252965|Drug|Metformin XR|Subjects will receive Metformin Extended Release (XR) tablets, orally once daily at a dose of 500 mg for 1 week, and then dose will increase with increments of 500 mg every week in first 2 weeks to 1500 mg. After that dose will increase up to maximum dose of 2000 mg for the next 2 weeks and will be maintained at 2000 mg until Week 16.
1597750|NCT02252952|Other|Beverage Consumption|
1597752|NCT02252926|Drug|Bupivacaine|25 mg bupivacaine lozenge
1597753|NCT02252926|Drug|Standard treatment (lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin)|Standard treatment includes lidocaine viscous solution, morphine, paracetamol, NSAID, gabapentin
1597754|NCT02252913|Drug|Volitinib|oral administration
1597755|NCT02252913|Drug|Docetaxel|intravenous injection
1597756|NCT02252900|Other|Magnetic resonance imaging|All patients will undergo the diagnostic test specific to the study
1597757|NCT02252887|Drug|Gemcitabine|
1597758|NCT02252887|Drug|Trastuzumab|
1597759|NCT02252887|Drug|Pertuzumab|
1597760|NCT02252874|Behavioral|Slow-paced action video game|20 hours slow-paced action video games
1597761|NCT02252874|Behavioral|Fast-paced action video game|20 hours fast-paced action video games
1597762|NCT02252874|Behavioral|Control|20 hours leisure activities
1597763|NCT02252861|Other|Percutaneous Left Atrial Appendage Closure in routine care|The inclusion in the database induces no specific intervention. Percutaneous Left Atrial Appendage Closure is performed for patient care. No specific intervention is performed specifically for the database. Neither left atrial appendage closure procedure nor patient follow up are modified by patient inclusion in the database.
1597764|NCT02252848|Drug|Clonidine|Determining the maximum-tolerated dose (MTD) of clonidine and secondarily, explore the efficacy of clonidine for reducing shivering in infants who are undergoing therapeutic hypothermia for treatment of HIE
1597765|NCT02252848|Drug|Clonidine|Characterizing population PK/PD of clonidine using non-linear mixed effects analysis to estimate the exposure-response relationship of clonidine on changes in cardiovascular parameters (heart rate and blood pressure), core body temperature, and cerebrovascular autoregulation during the cooling and rewarming phases of therapeutic hypothermia.
1597766|NCT02252835|Drug|Arhalofenate|800 mg once daily orally for four weeks
1597767|NCT02252835|Drug|Febuxostat|40 mg once daily orally for 1 week then up-titrated to 80 mg once daily orally for another three weeks
1597768|NCT02252835|Drug|Arhalofenate|600 mg once daily orally for four weeks
1597769|NCT02252835|Drug|Febuxostat|80 mg once daily orally for 1 week then down-titrated to 40 mg once daily orally for another three weeks
1597770|NCT02252835|Drug|Colchicine|0.6 mg daily
1597771|NCT02252822|Behavioral|Overcoming Bulimia Online Programme|
1597772|NCT02252809|Drug|adalimumab|
1597778|NCT02252783|Drug|BFPET|Sterile study drug will be delivered in individual dosage vials labeled and calibrated to approximately 2 mCi (74MBq) for the rest imaging and up to 8 mCi (296 MBq) for the stress imaging at the time of injection. The drug will be administered intravenously by bolus injection over 10 seconds into a peripheral vein to which access has been secured followed by saline flush.
1597779|NCT02252770|Dietary Supplement|Nitric oxide supplement|Each active comparator supplement is an all natural nitric oxide supplement. Subjects will take one lozenge twice a day.
1597780|NCT02252770|Dietary Supplement|Placebo|Placebo will not contain nitric oxide supplement.
1597781|NCT02252757|Device|CoVa|
1597782|NCT02252744|Other|No intervention|
1597783|NCT02252731|Drug|Warfarin|Oral
1597784|NCT02252731|Drug|FG-4592|Oral
1597785|NCT02252718|Other|Stool Assessment|"After passing a stool by the child participating in the study, within a short-time interval (<5 min), the stool will be assessed independently by one of the parents and the medical doctor. At the same time a parent will take 2 photos with phone photographic camera. Then the photographs will be independently evaluated by another doctor who will be unaware of both the in vivo stool appraisal and child condition."
1597786|NCT02252692|Drug|Enalapril|oral administration
1597787|NCT02252666|Device|Neuromodulation Rehabilitation|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
1597788|NCT02252640|Biological|RTS,S/AS01B (50mcg of RTS,S and standard adult dose of AS01)|
1597789|NCT02252640|Biological|RTS,S/AS01B (10mcg of RTS,S and one fifth of the standard dose of AS01)|
1597790|NCT02252640|Biological|ChAd63 ME-TRAP (5 x 10^10 vp)|
1597791|NCT02252640|Biological|MVA ME-TRAP (2 x 10^8 pfu)|
1597792|NCT02252627|Drug|Administration of phenylephrine|Intravenous phenylephrine will be administered in 50-100 microgram increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 1mg has been administered.
1597793|NCT02252627|Other|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor
1597794|NCT02252627|Other|Contrast enhanced ultrasound scan|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan
1597795|NCT02252627|Drug|Administration of ephedrine|Intravenous ephedrine will be administered in 3-6mg increments until the mean arterial blood pressure has increased by 25% compared to baseline, or until a maximum dose of 30mg has been administered.
1597796|NCT02252614|Drug|naproxen sodium codein|Pain intensity, contramal consumption
1597797|NCT02252614|Drug|paracetamol codein|Pain intensity, contramal consumption
1597798|NCT02252614|Drug|Placebo|Pain intensity, contramal consumption
1597799|NCT02252601|Other|HFDT test|
1597800|NCT02252601|Other|Pure tone Audiogram|
1597801|NCT02252588|Drug|Chlorhexidine|Oral Rinse
1597802|NCT02252588|Other|Placebo|Oral Rinse
1597804|NCT02252562|Device|Sage Personal Hand Hygiene System|Utilization of a health care provider worn personal hand hygiene system during routine practice in the intra-operative setting with provider specific individual feedback.
1597805|NCT02252549|Device|SPIES+WLI assisted TURB|
1597806|NCT02252549|Device|WLI assisted TURB|
1597807|NCT02252536|Drug|gabapentin enacarbil|Horizant Extended Release Tablets, 600 mg, white to off-white, oval shaped tablets, taken 2 times per day
1597808|NCT02252536|Drug|Placebo|Placebo tablet, white to off-white, oval shaped tablets, taken 2 times per day
1597809|NCT02252523|Drug|Dexmedetomidine|
1597810|NCT02252510|Other|HALOSPERM|
1597811|NCT02252497|Drug|Active comparator : Tranexamic Acid (Exacyl)|"1g Exacyl Intra Venous, just before surgery
Then infusion of 1g of Exacyl over eight hours ."
1597812|NCT02252497|Drug|Placebo comparator : physiologic serum|"1g Intra Venous just before surgery
Then infusion of 1g of physiologic serum over eight hours"
1597813|NCT02252484|Other|Weight Loss Program|Program has four main components: diet, physical activity, coaching and diet and exercise monitoring. The program is tailored to each individual in the study.
1597814|NCT02252484|Other|Standard of Care|Standard of Care for this patient population.
1597815|NCT02252471|Behavioral|Choices-Teen|Choices-Teen participants in this condition will receive two brief motivational-interviewing-based counseling sessions, and one counseling session with a physician.
1597816|NCT02252458|Drug|Fentanyl|
1597817|NCT02252445|Drug|Propofol|Propofol will be administered.
1597818|NCT02252445|Drug|Sevoflurane|Sevoflurane will be administered.
1597819|NCT02252432|Drug|Ketamine|A bolus of intravenous (IV) ketamine during induction (0.5mg/kg), and an IV infusion of ketamine intraoperatively (5 mcg/kg/min)
1597820|NCT02252432|Drug|Methadone|A single dose of IV methadone (0.2 mg/kg) preinduction.
1597821|NCT02252432|Drug|Ketamine + methadone|Methadone (0.2 mg/kg) preinduction, a bolus of IV ketamine (0.5 mg/kg) during induction and IV ketamine infusion intraoperatively (5 mcg/kg/min)
1597822|NCT02252419|Drug|Dexamethasone|Dexamethasone will be administered.
1597823|NCT02252419|Drug|Paracetamol|Paracetamol will be administered.
2009443|NCT03253744|Radiation|Tumor Irradiation|SBRT will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy
2009444|NCT03253744|Radiation|Prostate radiation + tumor boost irradiation|SBRT will be delivered to areas of recurrent prostate cancer identified on imaging and biopsy; and a reduced dose will be delivered to the entire prostate
1597826|NCT02252393|Procedure|robot-assisted laparoscopic surgery|Undergo RARC with IUD
1597827|NCT02252393|Procedure|robot-assisted laparoscopic surgery|Undergo RARC with EUD
1597828|NCT02252393|Other|intraoperative complication management/prevention|Undergo RARC with IUD
1597829|NCT02252393|Other|intraoperative complication management/prevention|Undergo RARC with EUD
1597830|NCT02252393|Other|quality-of-life assessment|Ancillary studies
1597831|NCT02252380|Device|Transcranial ExAblate System|MR Guided Focused Ultrasound
1597834|NCT02252354|Drug|[14C]-TAK-385 Oral Solution|TAK-385 oral radiolabelled solution
1598150|NCT02250248|Biological|AttraX Putty|
1597836|NCT02252354|Drug|[14C]-TAK-385 Solution for Intravenous Infusion|TAK-385 intravenous (IV) radiolabelled solution
1597837|NCT02252341|Dietary Supplement|N-Acetyl-Cysteine|drug: N-Acetyl-cysteine N-Acetyl-cysteine 1800 mg a day for 12 weeks versus placebo for 12 weeks
2009445|NCT03252353|Drug|octreotide capsules|octreotide capsules 40mg/day, 60mg/day, 80 mg/day (individual dose titration)
2009446|NCT03252353|Drug|Matching placebo|Matching placebo capsules
1597840|NCT02252315|Other|Educational Brochure|Participants will receive written education materials about mild traumatic brain injury.
1597841|NCT02252315|Other|Verbal education module|A structured in-person education module about mild traumatic brain injury.
1597842|NCT02252302|Other|Rest (Sitting on chair)|Study participants will sit on a chair for 60min. This is to simulate physical resting condition.
1597843|NCT02252302|Other|Cycling exercise|Study participants will exercise on a cycle ergometer for 45min. Participants will start their 30-min long constant workload exercise test test 60-min after the drug intervention. The exercise test will be set to a resistance of 55% of the maximal wattage that was reached on the graded exercise test on the screening day. The cycling exercise intervention will follow the rest-intervention.
1597844|NCT02252302|Drug|Salbutamol inhalation|Study participants will be exposed to 400ug of salbutamol prior to entering the air pollution chamber.
1597845|NCT02252302|Drug|Placebo inhalation|Study participants will inhale a placebo (placebo for salbutamol) prior to entering the air pollution chamber
1597846|NCT02252302|Other|Diesel Exhaust Exposure|Participants will be exposed to PM2.5 of 300 μg/m3
1597847|NCT02252302|Other|Filtered air|Participants will be breathing filtered air
1597848|NCT02252276|Procedure|Experimental (proprioception exercises, muscle strengthening, joint mobilization)|The experimental group performed a combined protocol of proprioception (the patient doing exercises standing on an unstable plane)exercises and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle), and joint mobilization techniques of the ankle joint two session per week, during four weeks
1597849|NCT02252276|Procedure|Control (proprioception exercises, muscle strengthening)|The control group performed only proprioception exercises (the patient doing exercises standing on an unstable plane) and muscle strengthening (The patient performed eccentric exercises to work the movement inversion of ankle). Two sessión per week during four weeks
1597853|NCT02252250|Procedure|conventional laparoscopic total mesentery excision|conventional laparoscopic total mesentery excision
1597854|NCT02252250|Procedure|transanal hybrid-laparoscopic total mesentery excision|transanal laparoscopic total mesentery excision for rectal cancer. Mobilize the rectum from down- to-up. Then, set a single incision laparoscopic surgery (SILS) port at the right-low abdomen to resect the lymph nodes of IMA.
1597855|NCT02252237|Biological|Pharmacokinetic|Blood sample of 2 ml at enrolment and then at two following visits. Buccal cell collection swab
1597856|NCT02252211|Drug|89Zr-DS-8895a|"Cohort Number: 1; No. Pts: 3-6; Day 1 89Zr-DS8895a dose: 0.2 mg/kg
Cohort Number 2; No. Pts.: 3-6; Day 1 89Zr-DS8895a dose: 0.2 mg/kg
Cohort Number 3; No. Pts.: 3-6; Day 1 89Zr-DS8895a dose: 0.2 mg/kg
Cohort Number 4; No. Pts.: 3-6; Day 1 89Zr-DS8895a dose: 0.2 mg/kg"
1597857|NCT02252211|Drug|DS-8895a|"Cohort Number: 1; No. Pts: 3-6; DS-8895a dose rest of cycle: 1 mg/kg
Cohort Number 2; No. Pts.: 3-6; DS-8895a dose rest of cycle: 3 mg/kg
Cohort Number 3; No. Pts.: 3-6; DS-8895a dose rest of cycle: 10mg/kg
Cohort Number 4; No. Pts.: 3-6; DS-8895a dose rest of cycle: 20 mg/kg
Patients will receive an initial 89Zr trace labelled infusion of DS-8895a. DS-8895a will then be infused on Day 8, and second weekly infusions of DS-8895a, for a further two infusions, will subsequently occur. The day 36 infusion of DS-8895a will also be trace labelled with 89Zr, with subsequent PET imaging and pharmacokinetic sampling. Four dose levels (1, 3, 10 and 20mg/kg) will be evaluated, with 3-6 patients entered at each dose level."
1597858|NCT02252198|Other|Epistem Genedrive® and MolBio Truenat™|S1 will undergo direct smear and Epistem Genedrive® (optional for phase 2*) testing, before being homogenized with glass beads and split into three portions for testing with Epistem Genedrive®, MolBio Truenat™ and GeneXpert MTB/Rif® respectively. S2 and S3 will be randomized as to the order of testing using Epistem Genedrive® and MolBio Truenat™.
1597859|NCT02252185|Device|Johnson&Johnson Medical Suzhou made Spine Fusion System|interventional device is Spine Fusion System that is manufactured by Johnson & Johnson Medical Suzhou Ltd.
1597860|NCT02252185|Device|Imported EXPEDIUM screws and OPAL cage|Comparator in this study is active comparator.
2009447|NCT03252145|Device|PhysioTouch|The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.
1597865|NCT02252133|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 8.8 base curves) dispensed per manufacturer's guidelines for daily disposable wear
1597866|NCT02252133|Device|Narafilcon A contact lenses|Silicone hydrogel contact lenses (8.5 and 9.0 base curves) dispensed per manufacturer's guidelines for daily disposable wear
1597867|NCT02252120|Device|Supreme|
1597868|NCT02252120|Device|Laryngeal Tube|
1597869|NCT02252107|Drug|decitabine|Single arm study: the addition of 10 days (20 mg/m2) decitabine to the conditioning regimen prior to allogeneic hematopoietic transplantation.
1597870|NCT02252094|Device|Prismalung|Prism lung (Baxter Healthcare/Gambro Lund, Sweden) is an extracorporeal carbon dioxide removal device. It removes blood through a double lumen catheter and pumps it through a hollow fiber gas exchange cartridge which is impervious to fluid. Carbon dioxide diffuses out, down a concentration gradient which is maintained by sweep gas flowing through the centre of the hollow fibres. The decarboxylated blood is returned to the patient through the double lumen catheter.
1597871|NCT02252094|Other|Ultra-protective ventilation|Ventilation with </= 3ml/kg predicted body weight
1597872|NCT02252094|Other|Conventional Lung Protective Ventilation|Ventilation with 6ml/kg predicted body weight
1598151|NCT02250248|Other|Iliac Crest Bone Graft (ICBG)|
1597873|NCT02252081|Drug|metformin|500 to 1500 mg orally per day for 16 weeks if eGFR > 45 ml/min; 500 to 1000 mg orally per day for 16 weeks if eGFR =< 45 ml/min
1597874|NCT02252081|Drug|Placebo|placebo pill(s) orally per day for 16 weeks
1597875|NCT02252068|Behavioral|I-CBT|New cognitive behavioral therapy treatment manual developed to treat co-occurring anxiety and opioid dependency disorders.
1597876|NCT02252068|Behavioral|IDC|Individual Drug Counseling manual that has been demonstrated efficacy for the treatment of drug dependence.
1597877|NCT02251912|Drug|Intranasal Oxytocin|10 insufflations (40IU of oxytocin total) given 3 initially then 2 times daily for 12 weeks
1597878|NCT02251912|Drug|Placebo|10 insufflations (same solution as active treatment minus oxytocin) given 3 initially and then 2 times daily for 12 weeks
1597879|NCT02251899|Behavioral|Disease-Management intervention|The participants in the intervention group receive a nurse-managed disease-management intervention that is regularly delivered by telephone or, when necessary, in person
1597880|NCT02251886|Other|Moxibustion in primiparae|Number of primiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment
1597881|NCT02251886|Other|Moxibustion in multiparae|"Number of multiparae participants with Version of Fetal Breech Position to Cephalic Position up to 4 weeks after treatment"
1597882|NCT02251873|Drug|TPV + RTV (low dose)|
1597883|NCT02251873|Drug|TPV + RTV (high dose)|
1597884|NCT02251873|Drug|ddl|
1597885|NCT02251847|Drug|Rosuvastatin/Ezetimibe|Rosuvastatin 5mg
1597886|NCT02251834|Behavioral|Community Health Worker (CHW) home visits, coaching phone calls, group sessions .|The primary mechanism used by the Community Health Worker (CHW) for delivering interventions will be a) home visits b) phone based contacts c) group level activities d) mobile technology. Ideally, each subject will have, at a minimum, 4 home visits and ten phone calls during months 3-12. Group visits will held twice a month. The Community Health Worker (CHW) intervention will be highly individualized and tailored to unique circumstances of each patient and we expect home visits, calls, ProMobile usage and group visits to vary by patient.
1597887|NCT02251834|Other|usual care and health education brochures every 4 months.|Patients randomized to the control group will receive usual care.
1597888|NCT02251821|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplant
1597889|NCT02251821|Drug|Busulfan|Given IV
1597890|NCT02251821|Drug|Cyclophosphamide|Given IV
1597891|NCT02251821|Drug|Fludarabine Phosphate|Given IV
1597892|NCT02251821|Other|Laboratory Biomarker Analysis|Correlative studies
1597893|NCT02251821|Drug|Melphalan|Given IV
1597894|NCT02251821|Drug|Methotrexate|Given IV
1597895|NCT02251821|Drug|Momelotinib|Given PO
1597896|NCT02251821|Drug|Mycophenolate Mofetil|Given IV or PO
1597897|NCT02251821|Drug|Pacritinib|Given PO
1597898|NCT02251821|Drug|Ruxolitinib|Given PO
1597899|NCT02251821|Drug|Tacrolimus|Given IV or PO
1597900|NCT02251821|Radiation|Total-Body Irradiation|Undergo TBI
1597901|NCT02251821|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
1597902|NCT02251795|Drug|Tipranavir|
1597903|NCT02251795|Drug|Ritonavir|
1597904|NCT02251795|Drug|Darunavir|
1597905|NCT02251795|Drug|Aspirin|single dose on day 2
1597906|NCT02251782|Device|Epi proColon Test|Subjects assigned to the Epi proColon arm will receive information on the Epi proColon test outlined in a template script. They will then be offered a blood draw for Epi proColon testing. The blood draw can be fulfilled at the clinic or at a specified blood draw station, at the convenience of the patient. Epi proColon plasma samples will be sent to a central laboratory for testing. If no test result is recorded within 4 weeks, patients will be mailed a reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
1597907|NCT02251782|Device|Fecal Immunochemical Test (FIT)|Subjects assigned to the FIT arm will receive information on the FIT test outlined in a template script. They will then be provided a FIT kit to take home and asked to send a stool sample to the testing lab following the kit instructions. If no test result is recorded within 4 weeks, subjects will receive a mailed reminder to complete testing. If no result is recorded within 2 weeks of the mailed reminder, subjects will be recorded as non-adherent to screening. Subjects with negative test results will be mailed a notice of result and reminder to continue screening. Subjects with positive tests will be contacted and counseled to undergo colonoscopy.
1597908|NCT02251769|Drug|Tipranavir|
1597909|NCT02251769|Drug|Ritonavir|
1597910|NCT02251769|Drug|Clarithromycin|
1597911|NCT02251769|Other|High-Fat Test Meal|
1597912|NCT02251756|Device|Actinica, 0.8 mg/cm2, 1 application|
1597913|NCT02251756|Device|Actinica, 0.8 mg/cm2, 2 applications|
1597914|NCT02251756|Device|Actinica, 2 mg/cm2, 1 application|
1597915|NCT02251756|Device|Actinica, 2 mg/cm2, 2 applications|
1597916|NCT02251743|Device|Neurofeedback treatment|"Each session, the child participates in 5 training tasks. Each task lasts 5 minutes at the beginning and gradually increases to 9 minutes per task over the course of the neurofeedback as the child's attention span improves. We record four results for each of the 5 tasks:
The number of half-second periods that they met the reward parameters (i.e. theta mV below threshold; beta mV above threshold)
Average voltage of theta waves
Average voltage of beta
Average ratio of theta to beta power (TBR)"
1597917|NCT02251730|Behavioral|Smoking cessation|Refer for smoking cessation
2009448|NCT03252145|Other|Manual Lymph Drainage (MLD)|MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.
2009449|NCT03251170|Drug|Ketamine|Patients will receive :1 mg/Kg ketamine for induction of anesthesia
2009450|NCT03251170|Drug|Fentanyl|Patients will receive :2.5 mcg/Kg fentanyl for induction of anesthesia
1597921|NCT02251691|Drug|Advagraf|Compare the drug compliance between once daily or twice daily regimen
1597922|NCT02251691|Drug|Prograf|Compare the drug compliance between once daily or twice daily regimen
1597924|NCT02251665|Other|No intervention|a single-center prospective observational study
1597925|NCT02251652|Drug|Ingenol Mebutate|Ingenol mebutate 0.05% gel
1597926|NCT02251652|Procedure|Cryotherapy|1-2 sprays, 5 seconds each, with a 5 second interval
1597927|NCT02251639|Behavioral|Questionnaire|Participant completes a short questionnaire regarding their awareness of oral cancer and risk factors.
1597928|NCT02251639|Device|POS + PS2 + VELscope|Oral cavity examined with one or more of the widefield imaging devices, such as the VELscope and/or PS2 device.
1597929|NCT02251639|Procedure|Oral Brush Biopsy|If abnormal areas found, a small brush is pressed against an area inside mouth, and turned 5-10 times. The areas that could be biopsied include gums, tongue, roof of mouth, bottom of mouth, or the inside of cheeks.
1597930|NCT02251626|Dietary Supplement|coenzyme Q10|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
1597931|NCT02251626|Dietary Supplement|Placebo|It is a randomized and double blind study so patients or his/her doctor will not know which group s/he is in.
1597932|NCT02251613|Drug|Olopatadine HCl ophthalmic solution, 0.1%|
1597933|NCT02251613|Drug|Epinastine HCl ophthalmic solution, 0.05%|
1597934|NCT02251600|Drug|Deflazacort|Oral deflazacort administered once daily at 0.9 mg/kg for eight days
1597935|NCT02251587|Other|Standard Weight Management Program|Standard Diet program based on diet and exercise.
1597936|NCT02251587|Other|Sensible Weigh Program|Weight loss program designed for low income women.
1597937|NCT02251574|Other|Low Calorie Diet|Weight management program designed around a low calorie diet.
1597938|NCT02251574|Other|Very Low Calorie Diet|Weight management program designed around a very low calorie diet.
1597939|NCT02251574|Other|Standard Care|Care provided that would normally be given to people meeting eligibility criteria for this study.
1597940|NCT02251561|Device|FID 109182|Investigational multipurpose contact lens cleaning and disinfecting solution
1597941|NCT02251561|Device|Opti-Free Plus|Commercially available multipurpose contact lens cleaning and disinfecting solution
1597942|NCT02251561|Device|Senofilcon A contact lens|Commercially available silicone hydrogel contact lens
1597943|NCT02251548|Drug|Ibrutinib|Oral BTK inhibitor
1597944|NCT02251548|Drug|Fludarabine|IV purine analogue chemotherapy agent
1597945|NCT02251548|Drug|Cyclophosphamide|IV alkylator chemotherapy agent
1597946|NCT02251548|Drug|Rituximab|IV anti-CD20 monoclonal antibody
1597947|NCT02251535|Device|ATTUNE® Knee System|
1597948|NCT02251535|Device|PFC® SIGMA® Knee System|
1597949|NCT02251522|Device|ConforMIS Total Knee Replacement System|Total knee replacement system using a patient specific implant.
1597950|NCT02251522|Device|Off-the-Shelf Knee Replacement System|Total knee replacement system not using a patient specific implant.
1597951|NCT02251509|Drug|Carvedilol|
1597952|NCT02251509|Drug|Metoprolol tartrate|
1597953|NCT02251496|Other|In between meals snacks (Snacks-group)|In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
1597954|NCT02251496|Other|Oral nutrition supplement (ONS-group)|The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing ~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
1597955|NCT02251483|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|
1597956|NCT02251483|Other|Placebo|
1597957|NCT02251470|Other|HBE Wii (EG)|Wii-Fit Balance games (Soccer Heading, Ski Slalom, Table Tilt, Balance Bubble etc.)
1597958|NCT02251470|Other|HBE Control (CG)|Simple balance exercises with own body weight (Single limb stance, stepping, side sways etc.)
1597959|NCT02251457|Drug|Ranolazine|Ranexa is FDA approved for chronic angina
1597960|NCT02251444|Procedure|outpatient rehabilitation program|
1597961|NCT02251444|Procedure|physical therapy|
1597962|NCT02251431|Drug|BYDUREON|Exenatide-extended release
1597963|NCT02251431|Drug|Placebo|
1597964|NCT02251418|Device|Extracorporeal shockwave therapy|
1597965|NCT02251405|Behavioral|One bag, stainless container|
1597966|NCT02251392|Other|Chamomila recutita Gel|Gel formulated with active principles from Chamomilla recutita which dose is being determined in a dose-response curve
1597967|NCT02251392|Other|Chamomila recutita Infuse|chamomila infuse in a concentration of 2,5% already determined in a dose response curve
1597968|NCT02251392|Drug|Urea cream based|Urea is already using to treat radiodermatitis when it starts to occur, so it will be the usual care
1597969|NCT02251379|Drug|Flovent Diskus|Inhaled corticosteroids
1597970|NCT02251379|Other|Home Environmental Intervention|Mouse, Cockroach, Furry pets, Dust mites, Smoking, air purifiers, laundered bedding
1597971|NCT02251379|Drug|Advair Diskus|inhaled corticosteroids + long-acting beta agonist
1597972|NCT02251366|Procedure|Physician-guided diagnostic|NVAMD participants in the physician-guided diagnostic arm will have receive injections based on diagnostic imaging provided by optical coherence tomography and optional fluorescein angiography, those in this group will only receive retinal examinations at the 4- and 8-month clinic visits.
1597973|NCT02251353|Procedure|intervention|hepatic and/or pulmonary resection, radiofrequency ablation (RFA), transcatheter arterial chemoembolization, CyberKnife stereotactic radiosurgery
1597974|NCT02251353|Drug|systemic treatment|Systemic therapy
1597975|NCT02251340|Behavioral|Eczema Care Plan|
1597976|NCT02251327|Other|investigational Xpert DST test|The Xpert MTB/RIF cartridge detects M. tuberculosis as well as resistance to rifampin, and has been endorsed by the World Health Organization for use in settings of high HIV and/or drug-resistant tuberculosis prevalence.
1597977|NCT02251301|Dietary Supplement|Skim Milk|250 ml skim milk will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
1598152|NCT02250235|Other|Health risk information|
1598153|NCT02250222|Drug|LGD-6972|LGD-6972 sodium salt powder in Captisol ® (betadex [β-cyclodextrin] sulfobutylether sodium, NF)
1597978|NCT02251301|Behavioral|High intensity interval training|All participants will undergo a 12 week high intensity interval training program consisting of 3 supervised sessions a week of 4-10 x 1 min high intensity interval alternating with 1 min of recovery.
1597979|NCT02251301|Other|Placebo|250 mL water will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
1597980|NCT02251301|Dietary Supplement|Macronutrient isoenergetic control|250 mL of protein+cho matched drink will be consumed by participants immediately and 1 hour after each of the 36 sessions of high-intensity interval training over a 12 week period.
1597981|NCT02251288|Biological|Influenza Virus Vaccine, Live Attenuated H7N9 Anhui 2013/AA ca|MedImmune supplies pLAIV vaccines as a colorless to pale yellow and clear to slightly cloudy suspension in single, unit-dose, Becton-Dickinson Accuspray™ Nasal Spray Systems sprayer devices. Each filled sprayer device contains a 0.5 mL dose of 10^7FFU of H7N9 Anhui 2013/AA ca vaccine. Group I receives the IN dose on Day 29, Group 2 on Day 85, and Group 3 on Day 169.
1597982|NCT02251288|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Sanofi supplies the monovalent influenza A/H7N9 virus vaccine as a sterile, clear, and slightly opalescent suspension in single-dose vials containing 15 mcg HA per 0.5 mL. Group 1 through Group5 will receive the IM vaccine on Day 1
1597983|NCT02251288|Drug|MF59 adjuvant|Novartis supplies the MF59 adjuvant as an oil-in-water milky emulsion in single-use vials containing a fill volume of 0.7 mL. Group 1 through Group 5 will receive MF59 IM on Day 1.
1597984|NCT02251275|Drug|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
1597985|NCT02251262|Device|Whole-body 18FDG-PET-CT scan|18FDG-PET-CT exam will be performed in patients, with suspicion of pacing or defibrillation lead infection, hospitalized in cardiology unit.
1597986|NCT02251249|Drug|Paracetamol concentration time curve from 0 to 120 min|It consists in oral ingestion of 1.5g of paracetamol (Contents of 3 Doliprane® capsules 500 mg) and 60 mg prasugrel (6 tablets Efient ® 10 mg) or 180 mg ticagrelor ( 2 tablets Brilique ® 90 mg) with water. Then Paracetamol concentration is followed by the realization of the curve of concentration of paracetamol in plasma samples. These samples are taken at 15 min intervals during the first 2 hours.
1597987|NCT02251236|Drug|Stribild|To be administered orally, once daily with food.
1597988|NCT02251236|Drug|Genvoya|To be administered orally, once daily with food.
1597989|NCT02251223|Drug|Tipranavir low dose|
1597990|NCT02251223|Drug|Tipranavir medium dose|
1597991|NCT02251223|Drug|Tipranavir high dose|
1597992|NCT02251223|Drug|Ritonavir low dose|
1597993|NCT02251223|Drug|Ritonavir high dose|
1597994|NCT02251210|Drug|BIIL 284 BS low dose|
1597995|NCT02251210|Drug|BIIL 284 BS medium dose|
1597996|NCT02251210|Drug|BIIL 284 BS high dose|
1597997|NCT02251210|Drug|Placebo|
1597998|NCT02251197|Drug|BIII 890 CL|
1597999|NCT02251197|Drug|Placebo|
1598000|NCT02251184|Drug|Aggrenox|
1598001|NCT02251184|Drug|Dipyridamole|
1598002|NCT02251184|Drug|Aspirin|
1598003|NCT02251184|Drug|Lansoprazole|
1598004|NCT02251171|Drug|Tipranavir|
1598005|NCT02251171|Drug|Ritonavir|
1598006|NCT02251171|Drug|Rifabutin|
1598007|NCT02251158|Drug|Tipranavir oral solution|
1598008|NCT02251158|Drug|Tipranavir capsules|
1598009|NCT02251158|Drug|Ritonavir oral solution|
1598010|NCT02251158|Drug|Ritonavir soft gel capsules|
1598011|NCT02251158|Other|High fat breakfast|
1598012|NCT02251145|Drug|Tipranavir low dose|
1598013|NCT02251145|Drug|Tipranavir high dose|
1598014|NCT02251145|Drug|Ritonavir low dose|
1598015|NCT02251145|Drug|Ritonavir high dose|
1598016|NCT02251145|Drug|Tenofovir disoproxil fumarate|
1598017|NCT02251132|Drug|TPV low 1|
1598018|NCT02251132|Drug|TPV low 2|
1598019|NCT02251132|Drug|TPV medium|
1598020|NCT02251132|Drug|TPV high 1|
1598021|NCT02251132|Drug|TPV high 2|
1598022|NCT02251132|Drug|RTV low|
1598023|NCT02251132|Drug|Ritonavir high|
1598024|NCT02251132|Drug|Radiolabelled erythromycin|
1598025|NCT02251119|Drug|Tipranavir|
1598026|NCT02251119|Drug|Ritonavir|
1598027|NCT02251119|Drug|Loperamide|
1598029|NCT02251093|Drug|Lcr Regenerans|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
1598030|NCT02251093|Drug|Placebo|Dosage: 1 vaginal capsule per day Route of administration: intravaginal Treatment duration: One 21-day cycle
1598031|NCT02251067|Drug|VPI-2690B low dose|Comparison of different doses of study drug
1598032|NCT02251067|Drug|VPI-2690B medium dose|Comparison of different doses of study drug
1598033|NCT02251067|Drug|Placebo to match VPI-2690B|
1598034|NCT02251067|Drug|VPI-2690B high dose|Comparison of different doses of study drug
1598035|NCT02251054|Other|Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials with Avatars.
1598036|NCT02251054|Other|No Avatar group|We developed and tested the online program of three multimedia tutorials using the game development and rendering engine (Unity3D, Unity Technologies, San Francisco, CA). This arm saw the tutorials without Avatars.
1598037|NCT02251041|Drug|Antithrombin-III|
1598038|NCT02251041|Drug|Infliximab|
1598039|NCT02251041|Drug|Apotransferrin|
1598040|NCT02251041|Drug|Human recombinant erythropoietin|
1598041|NCT02251041|Drug|C1-Inhibitor|
1598042|NCT02251041|Drug|Glutathione|
1598043|NCT02251041|Drug|Alfa-tocopherol|
1598044|NCT02251041|Drug|Melatonin|
1598045|NCT02251041|Drug|Epoprostenol|
1598046|NCT02251041|Drug|Sodium chloride solution|
1598047|NCT02251028|Behavioral|Value-based cognitive-behavioral therapy|The intervention is a manualized program specifically tailored for prevention of disability and psychological distress after whiplash injuries. The intervention is delivered by two trained clinical psychologists og consists of 10 weekly one-hour individual sessions.
1598048|NCT02251015|Procedure|occlusal plate|"In the plate group arm, the patients used the occlusal splints for all night plus 4 hours during the day and they made therapeutic exercises 15 repetitions 3 times a day.
The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day."
1598049|NCT02251015|Procedure|therapeutic exercises|The orientation for therapeutic exercises seek to correctly position the jaw in the resting position (maxillary teeth approximately 2mm away from the mandibular teeth and the tip of the tongue accommodated on top of the incisive papilla on the hard palate, beyond an exercise that consisted of repeated opening and closing movements paying close attention to the position of the tongue, the point of which being accommodated on the incisive papilla during the exercises. The patient was instructed to perform 15 repetitions 3 times a day.
1598050|NCT02250976|Drug|Livasupril Cap.160/2mg|Fenofibrate pellet( as micronized fenofibrate 160mg) and Pitavastatin Ca 2mg
1598051|NCT02250976|Drug|Lipilfen cap. 160mg|Micronized fenofibrate 160mg
1598052|NCT02250976|Drug|Livaro tab. 2mg|Pitavastatin Ca 2mg
1598053|NCT02250950|Behavioral|MI and SDT Exercise Group|The intervention group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor trained in MI and SDT. This individual will lead group discussions and will have the participants exercise together.
1598054|NCT02250950|Behavioral|Non-MI and SDT Exercise Group|This group will participate in a group exercise class that will be held once a week for an hour. This class will be taught by an instructor who was not trained in MI and SDT. This individual will lead a regular exercise class.
1598055|NCT02250937|Drug|Busulfan|"Arm 1 - Busulfan 80 mg/m2 (PK Studies) on Day -13 and Day -12.
Arm 2 - Busulfan 80 mg/m2 (PK Studies) on Day - 20 and Day -13.
Both Arms - Busulfan administered after Cladribine at dose calculated to achieve a total (including first two doses) systemic exposure of 20,000 ± 12% µMol-min based on pharmacokinetic studies on Days -6 to -3."
1598056|NCT02250937|Drug|Fludarabine|Arm 1 and 2 - Fludarabine 10 mg/m2 on Days -6 through -3.
1598057|NCT02250937|Drug|Cladribine|Both Arms - Cladribine 10 mg/m2 administered after Fludarabine on Days -6 through -3.
1598058|NCT02250937|Procedure|Stem Cell Transplant|Both Arms - Stem cell transplant on Day 0.
1598059|NCT02250937|Drug|G-CSF|Both Arms - G-CSF 5 mcg/kg/day subcutaneously on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 109/L for 3 consecutive days.
1598060|NCT02250937|Drug|Methotrexate|Both Arms - Methotrexate 5 mg/m2 on Days +1, +3, +6, and +11 post bone marrow transplant.
1598061|NCT02250937|Drug|Cyclophosphamide|Both Arms - Cyclophosphamide 50 mg/kg on Day +3 and Day +4 post bone marrow transplant.
1598062|NCT02250924|Dietary Supplement|Caffeine|
1598063|NCT02250924|Other|Gum|Chewing gum
1598064|NCT02250924|Behavioral|wear silicone bracelet|Subjects will put on bracelet to correspond with times for chewing gum
1598065|NCT02250911|Other|webcasts|
1598066|NCT02250911|Behavioral|Assessments|
1598067|NCT02250911|Other|Usual care|
1598068|NCT02250898|Other|Myofascial Massage Therapy|Myofascial Massage Therapy is a manual massage therapy consisting of the following techniques: fascial stretch, circular friction, deep fascial restriction release, arm pull, side latissimus dorsi stretch, twisting, moist heat application, cold therapy, and lymphatic drainage.
1598069|NCT02250898|Other|Global Relaxation Massage|Global Relaxation Massage is a manual massage therapy consisting of a full body relaxation massage that includes light kneading and stroking in order to restore a sense of well- being
1598070|NCT02250885|Drug|Selinexor|Selective Inhibitor fo Nuclear Export (SINE)
1598071|NCT02250872|Drug|Gemigliptin|Gemigliptin 100mg in 2 divided doses plus cisplatin
1598072|NCT02250872|Drug|Placebo|100mg in 2 divided doses plus cisplatin
1598073|NCT02250872|Drug|Cisplatin|All patients will receive intravenous cisplatin
1598074|NCT02250859|Drug|FMX101, Minocycline 4% foam|FMX101, Minocycline 4% foam to be applied twice daily for 16 consecutive days
1598075|NCT02250846|Drug|EGFR-TKI|egfr-TKI treatment
1598076|NCT02250833|Drug|CKD-828|Telmisartan 80mg /S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
1598077|NCT02250833|Drug|Telmisartan|- Telmisartan 80mg tablet, Oral, Once Daily (Combination Therapy with S-amlodipine)
1598078|NCT02250833|Drug|S-amlodipine|- S-amlodipine 5mg tablet, Oral, Once Daily (combination Therapy with Telmisartan)
1598079|NCT02250820|Drug|Dexmedetomidine|Nasal administration
1598080|NCT02250820|Drug|Pentobarbital|Oral administration
1598081|NCT02250820|Other|Oral Placebo|Oral placebo will be cherry syrup
1598082|NCT02250820|Other|Nasal Placebo|Nasal placebo will be nasally atomized saline
1598083|NCT02250807|Drug|Simeprevir|Subjects will receive oral capsule of Simeprevir 150 mg, once a day from Day 1 up to Week 12.
1598084|NCT02250807|Drug|Sofosbuvir|Subjects will receive oral tablet of sofosbuvir 400 mg, once a day from Day 1 up to Week 12.
1598085|NCT02250794|Drug|metformin and sitagliptin|metformin 750 mg PO twice daily
1598086|NCT02250794|Drug|insulin glargine and insulin lispro|insulin glargine given once daily
1598087|NCT02250794|Drug|metformin and sitagliptin|sitagliptin 100 mg PO once daily
1598088|NCT02250794|Drug|insulin glargine and insulin lispro|insulin lispro given three times daily with meals
1598089|NCT02250781|Drug|Oral ONC201|Given PO
1598090|NCT02250768|Biological|GM-CSF|2ng/ml of GM-CSF supplemented into culture media
1598091|NCT02250755|Other|MRI T1 T2 sequences|MRI
1598154|NCT02250222|Drug|Placebo (Captisol ®)|betadex [β-cyclodextrin] sulfobutylether sodium, NF
1598155|NCT02250209|Drug|Trastuzumab|Trastuzumab is given by intravenous infusion at 440mg on day 0every 3 weeks. Number of cycles: 14~16 cycles.
1598092|NCT02250742|Other|dry needling|Dry needling uses traditional acupuncture needles without injecting any liquid. Dry needling is based on traditional Western medicine whereby the needle insertion sites are located in known anatomical landmarks such as skeletal muscles, fascia and occasionally joints, tendons and bone/tendon junctions.
1598093|NCT02250729|Other|intradermal pholcodine allergy test in cases|
1598094|NCT02250729|Other|Blood sampling|
1598095|NCT02250716|Procedure|cryotherapy|cryotherapy for cervical intraepithelial neoplasia in HIV infected women vs control arm of standard of care (repeat pap smear in 1 year)
1598096|NCT02250703|Drug|Midazolam|oral midazolam 0.5mg/kg upto maximum dose of 15mg
1598097|NCT02250703|Drug|Dexmedetomidine|intranasal dexmedetomidine 2mcg/kg upto maximum dose of 100mcg
1598098|NCT02250690|Device|experimental group - tDCS|
1598099|NCT02250690|Device|Control group (tDCS sham)|
1598100|NCT02250664|Other|Very low nicotine content cigarettes|Very low nicotine content cigarettes
1598101|NCT02250651|Drug|Bimatoprost sustained-release|Bimatoprost sustained-release (SR) administered in the study eye on Day 1, Week 16, and Week 32.
1598102|NCT02250651|Other|Sham|Sham administered on Day 1, Week 16, and Week 32, as per protocol.
1598103|NCT02250651|Drug|Timolol|Timolol administered once in the morning and once in the evening for up to 20 months, as per protocol.
1598104|NCT02250651|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months, as per protocol.
1598105|NCT02250638|Other|CA 19-9 Assay|Physicians use the CA 19-9 test results to manage their patients
1598106|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose A|
1598107|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose B|
1598108|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose C|
1598109|NCT02250612|Drug|1 drop of SYL040012 (bamosiran) Dose D|
1598110|NCT02250612|Drug|1 drop of timolol maleate|0.5 %
1598111|NCT02250599|Drug|Paclitaxel|Paclitaxel 175 mg/m2 IV Day 1 each 3-week cycle
1598112|NCT02250599|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg Day 1 each 3-week cycle
1598113|NCT02250599|Drug|Carboplatin|Carboplatin AUC 6 IV Day 1 each 3-week cycle
1598114|NCT02250586|Behavioral|CBT-CSO|Internet-delivered cognitive-behavioral therapy for CSO's of treatment refusing problem gamblers
1598115|NCT02250573|Biological|Replenine®-VF (High Purity Factor IX)|
1598116|NCT02250560|Biological|Replenine®-VF (High Purity Factor IX)|
1598117|NCT02250534|Other|Very low nicotine content cigarettes|
1598118|NCT02250521|Device|McGrath MAC enhanced direct laryngoscope|The McGRATH® MAC enhanced direct laryngoscope (EDL) combines the familiarity of direct larygnoscopy with an inline video camera for an enhanced view.
1598119|NCT02250508|Biological|Optivate® (Human Coagulation Factor VIII)|
1598120|NCT02250508|Biological|Haemate P® (Human Coagulation Factor VIII)|
1598121|NCT02250495|Device|Sympara Therapeutic System|Sympara Therapeutic System as a non-invasive, fully reversible alternative for the treatment of hypertension
1598122|NCT02250482|Biological|Optivate® (Human Coagulation Factor VIII)|
1598123|NCT02250469|Device|Treatment with the Axium SCS system|
1598124|NCT02250469|Device|Treatment with the Medtronic SCS System|
1598125|NCT02250456|Procedure|Echo doppler|vascular ultrasound explorations
1598127|NCT02250430|Drug|SB204|SB204 2% and 4% to left and right cheeks
1598129|NCT02250404|Other|cytology specimen collection procedure|Correlative studies
1598130|NCT02250404|Other|laboratory biomarker analysis|Correlative studies
1598131|NCT02250391|Drug|NPB-06|5 days continuous-infusion
1598132|NCT02250391|Drug|Placebo|5 days continuous-infusion
1598133|NCT02250378|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
1598134|NCT02250378|Procedure|therapeutic conventional surgery|Undergo wedge resection
1598135|NCT02250378|Other|laboratory biomarker analysis|Correlative studies
1598136|NCT02250378|Other|quality-of-life assessment|Ancillary studies
1598137|NCT02250365|Other|Continuous, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
1598138|NCT02250365|Other|Intermittent, suprasensory ESS|1 hour of ESS daily from Monday to Sunday during hospitalization, but no longer than 4th week post-stroke. The ESS will be applied immediately prior to OT/PT training which will include 15 minutes of repetitive, task-oriented upper limb training during the first 30 minutes after cessation of ESS.
1598139|NCT02250352|Other|cytology specimen collection procedure|Correlative studies
1598140|NCT02250339|Other|LAKU family program|Multi-systemic and multicomponent family-based intervention program
1598141|NCT02250339|Other|Etä-LAKU family program|Ecosystem-based intervention for families living in rural parts of Finland
1598142|NCT02250339|Other|Family therapy|Treatment as usual (TAU)
1598143|NCT02250326|Drug|nab-paclitaxel IV|nab-Paclitaxel intravenous (IV) infusion
1598144|NCT02250326|Drug|CC-486|Oral CC-486
1598145|NCT02250326|Drug|Duravalumab|
1598146|NCT02250300|Drug|MLN9708|
1598147|NCT02250274|Biological|LAIV|Licensed and approved Live Attenuated Influenza Vaccination (LAIV) will be preferentially given to all children aged 5-8 years old as recommended by Advisory Committee on Immunization Practices. A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given LAIV will be used. The rest of the children aged 9-17 years old will receive IIV.
1598148|NCT02250274|Biological|IIV|"A modified randomization scheme in which every other child aged 9-17 years enrolled in the study will be given IIV will be used. The rest of the children 9-17 years old will receive LAIV.
[Note: Although we do not anticipate exhausting the supply of LAIV, should this occur, children aged 5-8 will be offered IIV as it is also approved in this age group and should be used if LAIV is unavailable.]"
1598149|NCT02250261|Behavioral|KÄPY|
1598156|NCT02250209|Drug|Capecitabine|"Capecitabine 800~1000 mg/m² is given orally twice a day for 14 days followed by a 1-week rest.
Number of cycles: 8 cycles."
1598157|NCT02250209|Drug|Oxaliplatin|"Oxaliplatin is given by intravenous infusion at 130 mg/m2 on day 1 every 3 weeks.
Number of cycles: 8 cycles."
1598158|NCT02250196|Drug|PEG-Asc|received 1 L solution of PEG-Asc at 7 p.m the evening before colonoscopy and another 1 L solution of PEG-Asc at 5 hours before procedure
1598159|NCT02250196|Drug|SPMC 2|received one sachet of SPMC at 7 p.m the evening before colonoscopy and another sachet of SPMC at 5 hours before procedure
2009451|NCT03251170|Drug|Midazolam|Patients will receive 0.05 mg/Kg midazolam
2009452|NCT03251742|Device|Hayek RTX ventilator|Negative pressure ventilation in Fontan patients.
1598162|NCT02250170|Drug|OPB-111077|Tablet, Oral, 300mg/500mg/700mg/900mg 4 days-on & 3 days-off (21 days=1cycle)
1598163|NCT02250157|Drug|Oratecan|
1598164|NCT02250144|Device|Foot orthoses|
1598165|NCT02250131|Procedure|Perfusion targeted at oxygen delivery|Flow on cardiopulmonary bypass based on a target oxygen delivery > 280 mL/min/m2
1598166|NCT02250118|Drug|Bevacizumab|Intrapleural Bevacizumab
1598167|NCT02250105|Drug|ARI-3037MO|Lipid lowering
1598168|NCT02250105|Drug|Placebo|Inactive
1598169|NCT02250092|Device|Transcranial Direct Current Stimulation (tDCS)|10 tDCS/CIMT Sessions
1598170|NCT02250092|Device|Placebo Comparator|
1598171|NCT02250079|Device|polyethylene plastic bag|Inborn neonates with both a gestational age >29 weeks were randomized 1:1 to either a standard thermoregulation protocol or placement of a Poliethylene body bag since birth to 10 minutes after birth.
1598172|NCT02250079|Device|Conventional treatment|Infants randomized to the control group received standard hospital care newborn. This included immediate drying, skin-to-skin contact, early and exclusive breast feeding, postponed bathing, bundling, and radiant warmer. While waiting for criteria cord clamping, the environment humidity and temperature and segment and rectal temperature of the newborn were measure. It was repeated at 1-5- 10-60 and 120 minutes. After clamping, the newborn were positioned in a radiant warmer, and completed the drying process. Umbilical prophylaxis, vitamin K1 application, initial physical examination and ocular prophylaxis are performed. The infants were swaddled in blankets provided by the mother, the head was covered with a hat, and the infants were placed either in an open crib or under a radiant warmer as necessary and available. The same process was done in surgery room in case of cesarean.
1598173|NCT02250066|Other|Diet|Study group 1 received high monounsaturated fat diet Study group2 received high carbohydrate diet Control group was encouraged to follow the Food Guide Pyramid
1598174|NCT02250053|Other|Exercise|
1598175|NCT02250040|Other|Conventional physiotherapy|Physiotherapy techniques that included muscle training, stretching and endurance.
1598176|NCT02250040|Other|Techniques based on patients' functional level were added.|The added techniques aimed to improve balance and movement dissociation.
1598177|NCT02250027|Drug|HL301 300mg capsule|2 capsules at once, 3 times a day, for 7 days
1598178|NCT02250027|Drug|Placebo|2 capsules at once, 3 times a day, for 7 days
1598181|NCT02249988|Drug|ABX203 therapeutic Hepatitis B vaccine treatment arm|
1598182|NCT02249975|Device|C2 CryoBalloon Focal Ablation System|"The C2 Focal Cryoablation Device will be used for the treatment of islands of BE in real patient care. Ablation at 10 seconds will be tested and post-ablation symptoms related to the Cryoballoon Focal Ablation will be recorded. At 12 weeks, the patient will receive a follow-up endoscopy and biopsy samples will be taken.
Biopsy samples will be evaluated for the presence of residual Barrett's Esophagus. Through evaluation of the histological results, treatment parameters for the ablation of human esophageal epithelium will be better understood.
Evaluations include, but are not limited to the following:
Device malfunctions
Adverse events
Patient Pain
Histological evaluation of treatment zone at 12 weeks for presence of residual Barrett's Esophagus."
1598183|NCT02249949|Drug|efatutazone|Given PO
1598184|NCT02249936|Drug|AZD1722|
1598185|NCT02249936|Drug|Omeprazole|
1598186|NCT02249910|Drug|semaglutide|Oral administration of 5 mg daily for one week, then escalated to 10 mg daily for one week, followed by escalation to 20 mg daily for 41 days
1598187|NCT02249910|Drug|metformin|Oral administration of 850 mg twice daily for 3 days followed by 850 mg on day 4, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) and 3) co-administration with oral semaglutide.
1598188|NCT02249910|Drug|digoxin|Oral administration of 0.5 mg single dose, assessed in 3 dosing periods 1) alone, 2) co-administration with SNAC (sodium N-[8-(2-hydroxybenzoyl) amino] caprylate) and 3) co-administration with oral semaglutide.
1598189|NCT02249910|Drug|placebo|Oral administration of SNAC 300 mg. Will be administered with the morning dose of metformin (1st, 3rd, 5th and 7th dose). On Day 24, a single SNAC dose will be administered with digoxin.
1598191|NCT02249884|Drug|Urea Dose A|Urea cream for topical use.
1598192|NCT02249884|Drug|Urea Dose B|Urea cream for topical use.
1598193|NCT02249884|Drug|Urea Dose C|Urea cream for topical use.
1598194|NCT02249884|Drug|Chamomile Dose A|Chamomile gel for topical use.
1598195|NCT02249884|Drug|Chamomile Dose B|Chamomile gel for topical use.
1598196|NCT02249884|Drug|Chamomile Dose C|Chamomile gel for topical use.
1598336|NCT02248883|Drug|RTV|
1598705|NCT02246049|Drug|5-fluorouracil|Given IV
1994910|NCT02893514|Other|Screening Only (SO) condition|Patient and PCP are not presented with screening results. The PCP does not receive clinical decision support, or clinical reminders.
1995004|NCT02874547|Behavioral|Intervention|During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
1598197|NCT02249871|Drug|semaglutide|All subjects will be treated for 10 consecutive days including dose escalation, with 5 days on 5 mg oral semaglutide followed by 5 days on 10 mg oral semaglutide.
1598198|NCT02249871|Drug|Omeprazole|Will be given daily with oral semaglutide.
1995005|NCT02874456|Other|virus detection|Men will give semen, urine and blood specimens 7 days after the beginning of clinical signs and 11, 20, 30, 60 and 90 days after. ZIKV RNA will be detected in seminal plasma, native semen cells and processed spermatozoa.
1598201|NCT02249832|Device|MIT Anklebot|
1598202|NCT02249819|Device|transcranial direct current stimulation|Soterix 1x1 anodal tDCS
1598203|NCT02249806|Other|PH target therapy according to physician|Patients receiving PH target therapy
1598204|NCT02249780|Procedure|Postoperative parathyroid function test|Calcium and parathormone dosage at 24 hours and ten day after surgery
1598205|NCT02249780|Procedure|No postoperative parathyroid dosage and supplementation|The patients will be clinically followed for 24 hours after surgery and caclium and parathormone dosage will be done at ten days after surgery. No supplementation will be given.
1598206|NCT02249780|Procedure|ICG parathyroid angiography|Injection of 3,5 mL of indocyanine green intravenously and perform angiography of parathyroid glands after thyroid removal.
1598207|NCT02249780|Drug|Parathyroid supplementation|Supplementration with Calcimagon D3 Forte (1gr Calcium and 800 IU of 25-OH-vitamin D) from surgery day to up to 10 days afeter surgery.
1598208|NCT02249767|Drug|Tretinoin|Treatment of acne once daily in evening
1598209|NCT02249754|Behavioral|Nutrition education|This group will receive the nutrition education package. The package is composed of: 1) education and counselling of mothers when the child is aged 6 (baseline), 9 and 12 months; 2) training community-based nutrition counsellors at baseline and 12 months and monthly home visits, 3) supervision of community-based nutrition counsellors' work every 2 months, and 4) sensitisation meetings with family members and health staff responsible for child health at baseline and repeated at 12 months. In addition, the group will continue to attend routine health education given at health facilities every month.
1598210|NCT02249754|Behavioral|Routine health education|This group will receive routine health education every month. It is a standard government health service offered monthly in all health facilities by health staff. It is given to mothers of children below the age of five years during growth monitoring and immunisation contacts. The sessions take 10-15 minutes focusing on general health issues including child feeding, prevention of diseases such as malaria and importance of immunisations.
1598211|NCT02249741|Drug|Treated with Ibandronic acid as per protocol|treated with Ibandronic acid at a dose of 150 mg once a month for six months
1598212|NCT02249728|Drug|IV PBT2 microtracer and oral PBT2 single dose|
1598213|NCT02249728|Drug|oral 14C-PBT2|
1598214|NCT02249715|Device|Brainsway Multiway deep TMS device (two channels)|
1598215|NCT02249702|Drug|gemcitabine + docetaxel|
1598216|NCT02249702|Drug|trabectedin|
1598217|NCT02249689|Other|Definitive 65|
1598218|NCT02249689|Other|Definitive 74|
1598219|NCT02249676|Biological|Autologous mesenchymal stem cells|Autologous mesenchymal stem cells
1598220|NCT02249663|Drug|Azelastine hydrochloride and Fluticasone propionate|137/50 mcg Nasal Spray
1598221|NCT02249663|Drug|Dymista™|137/50 mcg Nasal Spray
1598222|NCT02249663|Other|Placebo|Nasal spray with no pharmaceutically active content
1598223|NCT02249650|Drug|TSB-9-W1|Product name: TSB-9-W1 Unit dose: 100 mg per capsule Dosage form: Capsule Treatment cycle: A treatment cycle consists of 2-day on-dose oral administering and followed by a 3-day off-dose.
1598224|NCT02249637|Procedure|Novel technique Circumcision Incision Orchidopexy|The novel technique starts with retraction of the prepucial skin off the glans penis and double incision circumcision done with mucosal sparing, then degloving of the penis on the side of the undescended testis. Dissection via Dartos' layer into the inguinal area until the palpable testicle was identified and extracted with mobilization of the spermatic cord. Hernia sac was then separated and suture ligated as high as the area of internal ring opening. Spematic cord lengthening was done until adequate length achieved for fixation into the inferior aspect of the scrotum. Then development of the Dartos' pouch via the circumcision site was done. A double or single suture testicular fixation using Vicryl 3-0 simple interrupted sutures on the everted Dartos' pouch inner surface was done. Subsequent placement of the testicle into the Dartos' pouch was done as the inner surface was inverted. The last step was the completion of the circumcision closure using Chromic 4-0 interrupted sutures.
1598225|NCT02249611|Device|Mobile physical activity promotion tool|"Mobile activity sensor
Smartphone with APP
Interactional webpage of internet
Evidence based health information
Individualized reminding messages according to the data from activity recording system
Personal counseling from professional personnel"
1598226|NCT02249611|Other|Standard care|Counseling on lifestyles with health education material
1598227|NCT02249598|Biological|lactamica|
1598228|NCT02249598|Biological|Placebo|
1598233|NCT02249572|Radiation|gamma knife radiosurgery|Leksell Perfection model gamma knife.
1598234|NCT02249546|Drug|N-acetylcysteine + PPI-amoxicillin-clarithromycin|
1598235|NCT02249546|Drug|PPI-amoxicillin-clarithromycin|Triple therapy
1598236|NCT02249533|Other|Spot Light Concussion App|Certified Athletic Trainers will report football injuries using High School RIO and will report possible concussions using the Spot Light concussion app.
1598237|NCT02249520|Other|PET-MR imaging on Biograph mMR scanner|Participants will undergo PET-MR imaging on the Biograph mMR scanner to evaluate the technical aspects of the total acquisition protocol directly post clinical administration of FDG, thus removing the requirement for additional radioisotope.
1598238|NCT02249520|Other|MR-only imaging on Biograph mMR scanner|Participants will undergo MR-only imaging to test the technical aspects of the MR-only protocol on the Biograph mMR scanner. No drug administered.
1598239|NCT02249507|Other|aerobic exercise|aerobic exercise (cycloergometer) at selected intensity (HRmax or equivalent)
1598240|NCT02249494|Other|telehealth|Use the call service offered by the Center for Telehealth Rio Grande do Sul to answer clinic questions with qualified staff and in real time. All physicians who work in Primary Health Care in Brazil can call when they have questions about diagnosis and management of their patients.
1598241|NCT02249494|Other|nutritional counseling|Performing routine nutritional counseling in their clinical practice
1598242|NCT02249494|Device|smartphone (mobile app)|Mobile app, designed to provide nutritional recommendations for hypertensive patients, will be use. The recommendations will be based on the DASH diet guidelines appropriate to the patient profile: consumption of whole grains, fruits, vegetables, milk or low fat dairy products, lean meats, poultry and fish, nuts, seeds and legumes, amount of fats, oils and sweets, as well as guidelines for salt intake and alcohol.
1598243|NCT02249481|Procedure|Adductor Canal catheter delivering 0.0625% L- Bupivacaine|Adductor canal catheter: Blockade at mid-thigh. Identify sartorius at mid thigh - find point where the femoral artery begins to descend from sartorius. In plane technique, hydro-dissect space between sartorius and femoral artery. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad). Bolus 20 mls via needle and 5 mls via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
1598244|NCT02249481|Procedure|Femoral nerve catheter delivering 0.0625% L- Bupivacaine|Femoral nerve catheter: Blockade at level of Femoral crease. Identify femoral nerve. In plane lateral approach. Bolus 20 mls via needle. Catheter threaded and 2-4cm left in situ (bevel orientated cephalad).and 5 mls injected via catheter to confirm spread under ultrasound guidance. Glue/Lockit dressing.
1598245|NCT02249455|Device|Acapella|Treatment time for 20 min twice daily
1598246|NCT02249455|Other|ELTGOL|ELTGOL technique 20 min twice daily
1598247|NCT02249455|Other|conventional physiotherapy|Conventional physiotherapy was given twice daily for 20 min
1598248|NCT02249442|Drug|Tipranavir (TPV)|
1598249|NCT02249442|Drug|Ritonavir (r)|
1598250|NCT02249429|Drug|PQR309|60 mg or 80 mg PQR309 per oral (p.o.) once daily or intermittent dosing (120mg,140mg and 160mg) until unacceptable AE, disease progression, patient's request for withdrawal, investigator judgement or death - whichever comes first.
1598251|NCT02249416|Drug|Tipranavir (TPV) low|
1598252|NCT02249416|Drug|Ritonavir (RTV) low|Norvir®
1598253|NCT02249416|Drug|Tipranavir (TPV) high|Retrovir®
1598254|NCT02249416|Drug|Ritonavir (RTV) high|
1598255|NCT02249416|Drug|Zidovudine|
1598256|NCT02249403|Drug|Talsaclidine 6 mg|
1598257|NCT02249403|Drug|Talsaclidine 12 mg|
1598258|NCT02249403|Drug|Talsaclidine 24 mg|
1598259|NCT02249403|Drug|Talsaclidine 36 mg|
1598260|NCT02249403|Drug|Placebo|
1598261|NCT02249377|Other|Platelets-Rich-Plasma|Platelet-Rich Plasma
1598262|NCT02249377|Drug|Corticosteroid|Corticosteroid
1598263|NCT02249364|Procedure|Control|Routine practice
1598264|NCT02249364|Procedure|Hypnosis|Hypnosis session before induction of anesthesia
1598265|NCT02249364|Drug|propofol|Closed-loop administration of propofol for anesthesia induction
1598266|NCT02249351|Drug|Talsaclidine|
1598267|NCT02249351|Drug|Placebo|
1598268|NCT02249338|Drug|BIIL 284 BS|
1598269|NCT02249338|Drug|Placebo|
1598270|NCT02249325|Dietary Supplement|Probiotic dietary supplement|Florajen3 is a commercially available probiotic supplement containing three bacteria of human origin (>7.5 x10^9 L. acidophilus, >6.0 x10^9 .B. lactis, and >1.5 x10^9 B .longum). Once capsule was administered daily by mouth from 28 through 36 weeks gestation.
1598271|NCT02249312|Drug|BIIL 284 BS|
1598272|NCT02249312|Drug|Placebo|
1598273|NCT02249299|Drug|Sativex Oromucosal Spray|Sativex Oromucosal Spray (GW Pharma Ltd, Salisbury. UK). Each 100 microlitre spray contains: 2.7 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD).
1598274|NCT02249299|Drug|Placebo|
1598275|NCT02249286|Behavioral|Child Centered Nutrition Counseling|The intervention comprises child-centered nutrition counseling for caretakers and support for 'developed' gardens and improved backyard poultry production; whereas the control will only receive the agriculture extension and the existing health and nutrition education in the area
1598276|NCT02249286|Other|no intervention|the control will only receive the agriculture extension and the existing health and nutrition education in the area
2009453|NCT03251495|Drug|Vaxchora|Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.
1598278|NCT02249260|Behavioral|High intensity interval training|Group-based high-intensity aerobic interval training and lifestyle counseling
1598279|NCT02249247|Drug|Low dose of BIIL 284 BS tablets|
1598280|NCT02249247|Drug|Medium dose of BIIL 284 BS tablets|
1598281|NCT02249247|Drug|High dose of BIIL 284 BS tablets|
1598282|NCT02249247|Drug|Placebo|
1598283|NCT02249234|Drug|Botox|
1598284|NCT02249234|Drug|Placebo|
1598285|NCT02249221|Biological|Quadrivalent cell-culture based influenza vaccin|GC3106, 0.5ml, intramuscular, a single dosing at Day 1
1598286|NCT02249221|Biological|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
1598287|NCT02249208|Device|Tc+blue dye|Sentinel Lymph Node (SLN) identification and resection using the standard technique of sub-areolar injection of technetium-99m (Tc-99m) and sub-areolar injection of vital blue dye before surgery
1598288|NCT02249208|Device|Tc+SPIO|Sentinel Lymph Node (SLN) identification and resection using isotope technique of sub-areolar injection of technetium-99m (Tc-99m) and the magnetic technique with the sub-areolar injection of SPIO (Sienna+®), before surgery
1598289|NCT02249208|Device|SPIO alone|Sentinel Lymph Node (SLN) identification and resection using the magnetic technique with the sub-areolar injection of SPIO (Sienna+®) before surgery
1598337|NCT02248870|Drug|Dexamethasone|Dexamethasone is added to Bupivacaine with Adrenaline for perineural injection
1598294|NCT02249156|Behavioral|Financial incentive for choosing a lower-cost provider|Employees of the intervention group receive money (either as a payment to their health savings account or directly as a check) if they obtain a radiology test or laboratory test from what a low-cost or rewards provider. The amount of money per test varies by the employer and type of test. A provider is identified as low-cost or rewards if their costs are in the lowest 10-20% among all providers in the community. Again there is a range because the relative cutoff has varied across the employers that have implemented this program.
1598295|NCT02249143|Device|CPAP and room air|Stable premature infants on CPAP and room air and meeting specific stability criteria will be randomized to stay on continuous positive airway pressure and room air for an additional two weeks or will be transitioned to room air alone.
1598296|NCT02249130|Drug|Tipranavir (TPV)|
1598297|NCT02249130|Drug|Ritonavir (RTV)|
1598298|NCT02249130|Drug|Delavirdine (DLV)|
1598299|NCT02249130|Drug|Zidovudine (ZDV)|
1598300|NCT02249130|Drug|Lamivudine (3TC)|
1598301|NCT02249130|Drug|Stavudine (d4T)|
1598302|NCT02249117|Drug|BIWH 3|
1598303|NCT02249117|Drug|Placebo|
1598304|NCT02249104|Drug|Adapalene/benzoyl peroxide gel, 0.1%/2.5%|Topical AV therapy
1598305|NCT02249104|Other|Cetaphil Acne Regimen|Cleanse, Moisturize, and Protect
1598306|NCT02249091|Drug|Selinexor|Patients receive Selinexor 40 mg/m2 twice weekly orally
1598307|NCT02249091|Drug|Idarubcin|infusion, iv, 10 mg/m2, on days 1,3,5 in cycle 1, on days 1,3 in cycle 2
1598308|NCT02249091|Drug|Cytarabine|Continuous infusion day 1 to 7, 100 mg/m2, iv,
1598309|NCT02249078|Drug|E6011|E6011 solution for injection
1598310|NCT02249078|Drug|Placebo|Placebo 2-mL vial solution for injection
1598312|NCT02249052|Drug|AA4500|Subjects must present with 2 lipomas; one to receive AA4500 and one to receive placebo simultaneously
1598313|NCT02249052|Drug|placebo|Placebo
1598314|NCT02249039|Drug|intermittent IV CLON|Mechanically ventilated infants and children receive intravenous intermittent Clonidine instead of dexmedetomidine
1598315|NCT02249026|Drug|BZDs + opiate exposure treated with BPN|These infants will have been exposed not only to opiates but also to BZDs during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
1598316|NCT02249026|Drug|Opiates exposure treated with BPN|These infants will have been exposed not only to opiates during pregnancy. Administration of Buprenorphine: The solution will be administered under the tongue followed by the insertion of a pacifier to reduce swallowing. Dose volumes greater than 0.5 mL will be given in 2 aliquots separated by 2 minutes allowing time for the drug to be absorbed. If the infant's withdrawal is not controlled, clonidine will be used as adjunct therapy. The initial dose of clonidine is 6 mcg/kg/day in 4 divided doses given every 6 hours. If signs of withdrawal are not controlled, the dose may be increased by 3mcg/kg/day to a maximum 12 mcg/kg/day divided q 6 hrs.
1598317|NCT02249013|Procedure|Cytoreductive Surgery (CRS)|CRS has been performed with standard peritonectomy procedures and visceral resections directed towards complete elimination of tumors from the abdominopelvic cavity.
1598318|NCT02249013|Procedure|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|HIPEC has been performed according to the closed-abdomen technique using cisplatin (25 mg/L of perfusate/m2, total limit of 240mg) for 30 minutes, with an intra-abdominal target temperature of 41-43°C. Perfusate (2L/m2, ranging from 3L to 6L) has been circulated using an extracorporeal circulation device (Performer HT; RAND, Medolla, Italy) at a flow rate of 700 ml/min.
1598319|NCT02249013|Drug|combination of carboplatin and paclitaxel|Systemic chemotherapy has included the standard combination of carboplatin and paclitaxel as neo-adjuvant plus adjuvant regimens.
1598320|NCT02249000|Device|BIOVALVE prosthesis|Transcatheter Aortic Valve Replacement (TAVR)
1598321|NCT02248987|Other|patients treated with antipsychotics|
1598323|NCT02248961|Drug|Fimasartan|"Starting dose of Kanarb (Fimasartan) is 60 mg, orally, once a day in the morning. The subjects will visit the clinical site every 4 weeks to measure Arterial blood pressure (ABP). The dose will be doubled in case if SBP ≥140 mmHg or DBP ≥90 mmHg at Visit 3 (Day 28) or at Visit 4 (Day 56).
If necessary, the dose of the study drug may be increased based on the assessment of patient's condition performed at the phone contact (Day14±3). Patient may be called for an unscheduled visit for treatment adjustment (decided individually, with possibility of dose titration as per investigator's judgment, indicated in source documents).
When possibilities are, the patient should be administrated by the study medication at the same time in the morning."
1598324|NCT02248961|Drug|Losartan|Cozaar® (Losartan), manufactured by MERCK SHARP & DOHME B.V., Netherlands, tablets 50/100 mg
1598325|NCT02248948|Dietary Supplement|Omega-3 Fatty Acids|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
1598326|NCT02248948|Dietary Supplement|Medium Chain Triglycerides|Patients will receive a daily dose calculated based on the child weight (≤28 kg=4ml; 29-40 kg= 6ml and ≥41 kg=8ml) and will be provided once a day for 6 months.
1598328|NCT02248896|Drug|Telmisartan|
1598329|NCT02248896|Drug|Other angiotensin-receptor blockers (ARBs)|
1598330|NCT02248896|Drug|Angiotensin-converting enzyme inhibitors (ACEIs)|
1598331|NCT02248896|Drug|Other major antihypertensive medication classes|e.g. beta-blockers, calcium channel blockers (CCBs), diuretics
1598332|NCT02248883|Drug|TPV low|
1598333|NCT02248883|Drug|Placebo|
1598334|NCT02248883|Drug|Moxifloxacin|
1598335|NCT02248883|Drug|TPV high|
1598338|NCT02248870|Drug|Saline|Saline is added as a placebo to Bupivacaine with adrenaline for perineural injection
1598339|NCT02248857|Other|UMS Strategy|Patients of providers randomized to the UMS arm will receive study-related educational tools at their primary care visit to support the understanding, regimen consolidation, and use of prescriptions.
1598340|NCT02248857|Other|SMS Texting Reminders|In addition to the components from the UMS strategy arm, patients will receive daily text reminders for 7 days, with the option of extending reminders, following a study medication prescription.
1598342|NCT02248831|Device|Recording Doppler ultrasound signals noninvasively|Using ultrasound noninvasively and recording Doppler signals from the right chest wall
1598343|NCT02248818|Drug|AZD8108|Drug: AZD8108 Single or Multiple doses administered orally as a solution.
1598344|NCT02248818|Drug|Placebo|Placebo to match AZD8108 Single or Multiple doses of matching placebo administered orally as a solution
1598346|NCT02248792|Drug|Methotrexate|
1598347|NCT02248766|Device|somofilcon A|somofilcon A lens
1598348|NCT02248753|Drug|Pharmacological cardioversion - Flecainide|
1598349|NCT02248753|Procedure|Electrical cardioversion|
1598350|NCT02248753|Drug|Metoprolol|
1598351|NCT02248753|Drug|Verapamil|
1598352|NCT02248753|Drug|Digoxin|
1598353|NCT02248753|Drug|Pharmacological cardioversion - Amiodarone|
1598354|NCT02248740|Procedure|Ablation of the incompetent small saphenous vein|For each patient, the Small Saphenous Vein (SSV) will be accessed from the midcalf. After liberal use of tumescent anesthesia, ablation of the incompetent small saphenous vein will be performed. Half the patients will have this procedure performed using the Laser Ablation device and half will be performed using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
1598355|NCT02248727|Device|somofilcon A|somofilcon A lens
1598356|NCT02248714|Dietary Supplement|Glucerna SR|Glucerna SR (Abbott Laboratories, Columbus, USA) is a nutritional product with lower glycemic response.
1598357|NCT02248701|Drug|testosterone enanthate, finasteride|Subjects receive testosterone (125 mg/week) by intramuscular injection and finasteride (5 mg/day) orally
1598358|NCT02248701|Drug|placebo|Subjects receive weekly placebo injection and placebo pill daily
1598359|NCT02248688|Device|BeadBlock 300 - 500 Micron|Beadblock will be used intraarterially to occlude the left gastric artery and its branches. The left gastric artery supplies the fundus of the stomach, where it is known that the hormone Ghrelin (one of the hormones responsible for appetite) is produced.
1598360|NCT02248688|Procedure|Left Gastric Artery Embolization|
1598361|NCT02248675|Behavioral|CBT-I|Cognitive Behavioral Therapy for Insomnia (CBT-I), an evidence-based insomnia treatment. In this study it will be delivered in four individual sessions.
1598362|NCT02248675|Other|TAU|Treatment as Usual: All participants will be encouraged to begin or continue treatment of co-occurring conditions as recommended by treatment providers. This may include treatment within the primary care teams, through behavioral telehealth, and/or specialty outpatient mental health. Participants randomized to TAU may receive pharmacotherapy for insomnia, though CBT-I will be precluded until after the post-treatment assessments.
1598365|NCT02248636|Drug|Cholinesterase inhibitor|This group receives a half-dose of their previous cholinesterase inhibitor medication (in overencapsulated form) for two weeks, then receives placebo.
1598366|NCT02248636|Drug|Sham discontinuation|This group receives their previous dose of cholinesterase inhibitor medication, but in overencapsulated form
1598367|NCT02248610|Other|Non-interventional study|
1598368|NCT02248597|Drug|fludarabine phosphate|Given IV
1598369|NCT02248597|Drug|busulfan|Given IV
1598370|NCT02248597|Drug|cyclophosphamide|Given IV
1598371|NCT02248597|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo myeloablative or reduced intensity allogeneic stem cell transplant
1598372|NCT02248597|Drug|tacrolimus|
1598373|NCT02248597|Drug|mycophenolate mofetil|
1598374|NCT02248584|Dietary Supplement|Vitamin C, E and Zinc|Capsule containing vitamin C (50 mg; CVS Quality, USA), vitamin E (60 mg; Nature´s Bounty, USA), and zinc (40 mg; CVS Quality, USA) per day for 60 days.
1598375|NCT02248571|Drug|Bevacizumab|administered as combined therapy with Capecitabine
1598376|NCT02248571|Drug|Capecitabine|administered as combined therapy with Bevacizumab
1598377|NCT02248571|Drug|Everolimus|administered as combined therapy with Exemestane
1598378|NCT02248571|Drug|Exemestane|administered as combined therapy with Everolimus
1598379|NCT02248571|Other|Patient questionaires|Patients will fill out questionaires at four specific time points during study treatment to assess patient reported outcome and patients' preference
1598380|NCT02248558|Behavioral|Conventional Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was created by a local CDC via direct CDC funding and internal guidance and development.
1598381|NCT02248558|Behavioral|Crowdsourced Video|Participants will watch a one minute video whose purpose is to increase HIV testing uptake. This video was the winner in a crowdsourced video contest hosted in China. CBOs all submitted their own independently designed and funded videos.
1598450|NCT02247921|Other|Rehabilitation|Patients recruited into the intervention arm will have their family-nominated caregivers trained by a trained nurse and guided by a culturally appropriate and easy-to-understand rehabilitation manual to be given to caregivers at the last session, shortly before hospital discharge to reduce contamination. The training sessions will take at least 90 minutes per day for 2 or 3 days.The nurse will call the patients and caregivers at 2, 4, and 8 weeks after hospital discharge to monitor progress and offer guidance on rehabilitation.Duration of the standardized yet individualized intervention by nurses will be 8 weeks; however, trained caregivers are expected to deliver the rehabilitation services to patients as long as they are needed.
1598382|NCT02248532|Biological|Stem cell therapy|Bone marrow cells will be mobilized into peripheral blood by daily subcutaneous injections of G-CSF (10 µg/kg daily) and collected by leukapheresis. Positive immunomagnetic selection of CD34+ cells will be performed. Electroanatomic mapping of the left ventricle will be performed using the Biosense NOGA system (Biosense-Webster®, Diamond Bar, CA). The target area for cell delivery will be defined as the myocardial segments with unipolar voltage potentials ≥8.3 mV, bipolar amplitudes >1.9 mV, and linear shortening <6%. Intramyocardial delivery of cell suspension will be performed with the MyoStar (BiosenseWebster®, Diamond Bar, CA) injection catheter. Each patient will receive 20 injections (0.3 mL each; total volume of 6 mL). All the procedures will be repeated 6 months after baseline.
1598383|NCT02248519|Procedure|Open Gastrectomy|Patients allocated to the 'Open Gastrectomy' group will receive distal or total gastrectomy via laparotomy. This group is considered the control group
1598384|NCT02248519|Procedure|Laparoscopic Gastrectomy|Patients allocated to the 'Laparoscopic Gastrectomy' group will undergo distal or total gastrectomy via laparoscopy. If laparoscopic resection does not seem feasible during surgery, the procedure may be converted to an open gastrectomy.
1598385|NCT02248506|Other|Clotrimazole|All patients receive standard antifungal treatment for this type of infections consisting Clotrimazole 500 Single dose (standard treatment).
1598386|NCT02248493|Drug|Paracetamol|
1598387|NCT02248493|Drug|Placebo (for paracetamol)|
1598388|NCT02248493|Drug|Ketoprofen|
1598389|NCT02248493|Drug|Tramadol|Administered on request as rescue medication in a dose 2 mg/kg IV up till 2 doses. No other opioid is given to these patients.
1598390|NCT02248493|Drug|Morphine|administered in patients receiving IV PCA with morphine postoperatively. No other opioid is given to these patients.
1598391|NCT02248480|Drug|Duloxetine|Administered orally
1598392|NCT02248480|Drug|Placebo|Administered orally
1598393|NCT02248454|Drug|Lispro|Increasing insulin doses
1598394|NCT02248441|Other|Daily ischemic conditioning treatment|RIC stimulus will be conducted as 4 x 5 minutes upper arm ischemia achieved by inflation of a blood pressure cuff to 200 mmHg and 5 minutes reperfusion between inflations. The procedure will be performed using the AutoRICTM (CellAegis Devices Inc., Toronto, Ontario, Canada).
1598395|NCT02248428|Drug|Clarithromycin|500mg orally daily on days 1-28,repeated every 28 days
1598396|NCT02248428|Drug|Thalidomide|Thalidomide 100-200mg orally per night on days 1-28,repeated every 28 days
1598397|NCT02248428|Drug|Cyclophosphamide|300mg/m^2 intravenously daily on day 1-3,repeated every 28 days
1598398|NCT02248428|Drug|Dexamethasone|40 mg orally weekly on days 1,8,15,22,repeated every 28 days
1598399|NCT02248415|Other|No pump|In the no pump group blood cardioplegia was delivered using the arterial line pressure, created by the arterial centrifugal pump of the cardiopulmonary bypass system. Blood cardioplegia flow depended on the difference between arterial line pressure and aortic root pressure.
1598400|NCT02248415|Other|Pump|In the pump group blood cardioplegia was delivered using a roller pump. The blood cardioplegia flow was given at 200 mL/min.
1598401|NCT02248415|Other|Blood sample collection: after induction of anaesthesia (T0)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
1598402|NCT02248415|Other|Blood sample collection: after arrival at the ICU (T1)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
1598403|NCT02248415|Other|Blood sample collection: 4 hours in ICU (T2)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
1598404|NCT02248415|Other|Blood sample collection: the first postoperative day (T3)|The following biomarkers were analysed: TnT-hs, H-FABP, NT-pro-BNP and CRP.
1598405|NCT02248402|Biological|Vax-DC/MM|
1598406|NCT02248389|Device|Sonatherm 600i ablation system|HIFU ablation of tumor.
1598407|NCT02248376|Drug|Gel|Patients aged of more than 18 years-old coming for a natural miscarriage who will have the stick gel application at the end of the scraping surgery.
1598408|NCT02248363|Other|Multimodal rehabilitation|Multimodal rehabilitation (MMR) distinguishes itself as an interdisciplinary-coordinated (e.g., physician, occupational therapist, physiotherapist, and psychologist) intervention using a bio-psycho-social view of chronic pain. The MMR continues over a lengthy period with a common goal and generally includes patient education, supervised physical activity, simulated work training, and cognitive behavioural therapy (CBT). The exact composition of these MMR components depends on initial evaluations of the patients health status and furhter follow-up testing. The MMR interventional components can act independently and interdependently, resulting in combined effects due to known and unknown mechanisms; the effects are intended to be greater than the sum of its components.
1598409|NCT02248350|Behavioral|Supervised and Home Based Exercise|Participants will come to our community based research office for up to 50 min/session, 3-days/week of supervised exercise for 8-weeks. The exercise intensity will be tailored between 60-80% of their VO2max, as determined during baseline testing and with a rating of perceived exertion (RPE) of 11-14 on the 20-point scale.
1598410|NCT02248350|Behavioral|Stretching Control Group|Participants randomized into the control group will be provided an informational booklet with stretching techniques and exercises and will be asked to stretch at least 20-minutes a day for the duration of the study.
1598411|NCT02248337|Drug|Colon preparation for colonoscopy|Colon cleansing prior to perform colonoscopy
1598412|NCT02248298|Drug|2h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 2 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
1598479|NCT02247726|Drug|RSV F vaccine (0.5mL injection)|
1598480|NCT02247687|Drug|Protease inhibitor|"Modification in the antiretroviral treatment
•Switch arm for protease inhibitor : intervention switch of current boosted protease inhibitor for Prezista® (darunavir)/ Norvir® (ritonavir) (switch for a drug with a higher genetic barrier) 600/100 mg two times a day (BID) with counseling."
1598413|NCT02248298|Drug|3h-AFL-PDT|AFL therapy was performed using a 2940-nm Er:YAG AFL (Joule; Sciton Inc., Palo Alto, CA, USA) at 300-550µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. In the 3h-MAL-PDT group, the above mentioned procedures were not performed. Immediately after AFL treatment, an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2
1598414|NCT02248298|Drug|3hr-MAL-PDT|an approximately 1-mm thick layer of MAL (Metvix, PhotoCure ASA, Oslo, Norway) was applied to the lesion and on 5 mm of surrounding normal tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, St. Paul, MN, USA). After incubation for 3 hours, the dressing and cream were removed, and the area was cleansed with saline. The area was irradiated with a red light-emitting diode lamp (Aktilite CL 128; PhotoCure ASA, Oslo, Norway) with peak emission at 632 nm, placed 5 cm away from the skin surface and total light dose of 37 J/cm-2.
1598416|NCT02248272|Other|Isocaloric diet with 3 meals|Isocaloric diet with 3 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
1598417|NCT02248272|Other|Isocaloric diet with 6 meals|Isocaloric diet with 6 meals in order to maintain volunteers' weight, tailored to individual energy needs, with the same macronutrient composition. The volunteers were free to choose the foods they used to consume before. However, in order to assist them to adapt to the different meal frequency, individualized instructions were given to all volunteers before their entry to the study. An example of a 7-day diet menu was prescribed for both diet programs and analytical food exchange lists of different food groups were also provided.
1598418|NCT02248259|Drug|BI 409306|Oral single dose of BI 409306
1598419|NCT02248259|Drug|Itraconazole|Oral dose, twice daily on Day -3, once daily on Day -2 to Day 2 of Itraconazole
1598420|NCT02248259|Drug|BI 409306|Oral single dose
1598421|NCT02248246|Device|Harmonic ACE®+7 Shears|"Vessel sealing performance assessed for transection and sealing of the following named vessels:
Inferior mesenteric artery (IMA)
Inferior mesenteric vein (IMV) (if identified)"
1598422|NCT02248233|Drug|Nimodipine|Jiangsu Jichuan Pharmaceutical Co., Ltd., Jiangsu Province, China
1598423|NCT02248233|Drug|Saline + citicoline|physiological saline + citicoline 2.0 g, once a day, via intravenous drip, for 10 consecutive days.
1598424|NCT02248220|Drug|Pramipexole|
1598425|NCT02248207|Drug|Pramipexole|
1598426|NCT02248194|Device|Tactile electrosurgical ablation probe|
1598427|NCT02248194|Device|Hysteroscopic endometrial ablation|
1598428|NCT02248181|Drug|Pramipexole|
1598429|NCT02248168|Drug|Pramipexole|
1598430|NCT02248155|Drug|Pramipexole|
1598431|NCT02248142|Drug|Pramipexole|
1598432|NCT02248129|Drug|Telmisartan and hydrochlorothiazide|
1598433|NCT02248116|Drug|Talsaclidine|
1598434|NCT02248103|Procedure|Periosteal pedicle graft|Autogenous pedicle graft harvested from the periosteum
1598435|NCT02248103|Biological|Bioresorbable collagen membrane|Biocollagen is a thin equine Achilles tendon collagen barrier membrane used for guided tissue regeneration
1598436|NCT02248090|Drug|AZD9496|AZD9496
1598437|NCT02248090|Drug|AZD9496|If initial dosing of AZD9496 is tolerated then subsequent cohorts will test increasing doses until a maximum tolerated dose or maximum feasible dose is defined
1598438|NCT02248077|Device|AutoloGel|
1598439|NCT02248077|Other|Usual and Customary Care (UCC)|
1598440|NCT02248064|Device|Auto-titrating oxygen system|The auto-titrating oxygen system contains a number of components working together to produce variable oxygen flow. An oximeter measures the oxygen saturation of a patient and via Bluetooth this is relayed to a control centre in a mobile phone. This in turn regulates a flow meter which adjust oxygen flow.
1598441|NCT02248051|Drug|CXA-10|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
1598442|NCT02248038|Procedure|open surgery|Patients in this arm undergo radical resection of colon cancer in open surgery.Open surgery is a conventional technique for colorectal cancer patients.
1598443|NCT02248038|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of colon cancer in laparoscopic surgery.Laparoscopic surgery is a new and minimum invasive technique for colorectal cancer patients.
1598444|NCT02248025|Other|Observational study: No special intervention will be made.|No special intervention will be made, only data will be collected before, and after a passive leg raising and a fluid challenge decided and performed by the attending physician.
1598445|NCT02248012|Drug|Everolimus , temozolomide|
1598446|NCT02247986|Drug|Methylphenidate Hydrochloride|Bold signal changes by methylphenidate on DBD
1598447|NCT02247973|Biological|mesenchymal stem cells|Intravenous administration of up to 1~2x10^6 MSCs per kg,for 2 times,d0 and d14
1598448|NCT02247973|Biological|mesenchymal stem cells|bone marrow derived mesenchymal stem cells from related donors.
1598449|NCT02247960|Drug|Ciprofloxacin|
1598451|NCT02247908|Other|Surgeon General's Warning|"Participants will be randomly assigned to receive warnings with one of the four Surgeon General's Warnings on their cigarette packs for 4 weeks:
SURGEON GENERAL'S WARNING: Smoking Causes Lung Cancer, Heart Disease, Emphysema, and May Complicate Pregnancy.
SURGEON GENERAL'S WARNING: Quitting Smoking Now Greatly Reduces Serious Risks to Your Health.
SURGEON GENERAL'S WARNING: Smoking by Pregnant Women May Result in Fetal Injury, Premature Birth, and Low Birth Weight.
SURGEON GENERAL'S WARNING: Cigarette Smoke Contains Carbon Monoxide."
1598452|NCT02247908|Other|Graphic Warning|"Participants will be randomly assigned to receive one of the following four graphic warnings on their cigarette packs for 4 weeks:
Text: WARNING: Cigarettes are addictive. Image: Man smoking through tracheotomy hole.
Text: WARNING: Cigarettes causes fatal lung disease. Image: Healthy lungs next to diseased lungs.
Text: WARNING: Cigarettes cause cancer. Image: Mouth with cancerous lesion on lip.
Text: WARNING: Smoking can kill you. Image: Woman dying from cancer."
1598453|NCT02247895|Device|Sham Treatment|Subjects will undergo the same protocol as the treatment group except no electrical stimulation will be applied.
1598454|NCT02247895|Device|Electrical stimulation|Two thirty minute sessions of neuromuscular electrical stimulation applied to both quadriceps for seven days for a total of 14 treatments
1598455|NCT02247882|Other|Patient Education|"The educational program will comprise a multidisciplinary team: doctor, pharmacist, nurse, nutritionist, psychologist, physiotherapist and physical educator. Classes will be weekly in groups for eight weeks, with a duration of two hours.
The education program will include the following items: guidelines about the disease and its complications, strategies for pain management (pharmacological and cognitive), physical exercise, nutrition and weight control, medication (type, interactions, current trends, side effects ), balance, proprioception, fall prevention, coping with chronic pain."
1598456|NCT02247882|Other|Aquatic Physical Therapy|The exercise protocol will consist of: five minutes of heating with walking and patellar mobilization; ten minutes stretching the muscles of the lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); ten minutes isometric and dynamic exercises with elastic (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings); twenty minutes away from aerobic exercise (stationary running deep running water); ten minutes in functional training step and proprioceptive exercises; and five minutes of cooling with stretching of muscles of lower limbs (quadriceps, gluteus, adductors and abductors of hip sural triceps and hamstrings).
1598457|NCT02247869|Drug|dose dense ABVD|"dose dense ABVD will be administered intravenously on day 1 and 8 every 21 days Chemotherapy regimen
Doxorubicin 25 mg/m2 i.v. day 1 and 8
Bleomycin 10 mg/m2 i.v. day 1 and 8
Vinblastine 6 mg/m2 i.v. day 1 and 8
Dacarbazine 375 mg/m2 i.v. day 1 and 8
Granulocyte colony-stimulating factor (G-CSF): days 9 to 14"
1598458|NCT02247856|Other|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure after a period of adaptation before beginning the procedure to avoid ventilator-patient asynchrony
1598459|NCT02247856|Device|Jet Nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min"
1598460|NCT02247856|Device|Vibrating Mesh Nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
1598462|NCT02247830|Other|Chamomilla recutita gel|Such intervention will be characterized by topical application of C. recutita gel, concomitantly to the initiation of radiotherapy, should be applied on the irradiated region three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
1598463|NCT02247830|Drug|Urea cream|Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
1598464|NCT02247817|Device|Hybrid CRT-D/P implantation|
1598465|NCT02247804|Drug|Bimatoprost sustained-release|Bimatoprost sustained-release (SR) administered in the study eye on Day 1, Week 16, and Week 32.
1598466|NCT02247804|Other|Sham|Sham administered on Day 1, Week 16, and Week 32, as per protocol.
1598467|NCT02247804|Drug|Timolol|Timolol administered once in the morning and once in the evening for up to 20 months, as per protocol.
1598468|NCT02247804|Drug|Timolol Vehicle (placebo)|Timolol vehicle administered once in the morning and once in the evening for up to 20 months, as per protocol.
1598469|NCT02247791|Procedure|Uncemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
1598470|NCT02247791|Procedure|Cemented femoral stem|All patients will be randomized to operation with either an uncemented femoral stem or a cemented femoral stem
1598471|NCT02247778|Procedure|conventional plate osteosynthesis|Standard incision
1598472|NCT02247778|Procedure|mini-incision-type osteosynthesis|Mini-incision
1598473|NCT02247765|Device|Arterial line|Arterial line is inserted to draw a CO-Oximeter value as it is the gold standard and as advised in ISO 80601
1598474|NCT02247765|Device|Motion|The subject is asked to move their hand by either rubbing or tapping their fingers at a specified frequency and amplitude during portions of the hypoxic procedure.
1598475|NCT02247752|Other|inactive carrier|"Yearly demographic, clinic, biologic and ultrasonic data collection realized during usual follow-up as recommended.
Yearly centralisation of a complementary biological analysis in Paul Brousse Hospital laboratory of virology."
1598478|NCT02247726|Drug|Saline Placebo (0.5mL injection)|
1598481|NCT02247687|Drug|Isentress® (raltegravir)|• Addition of Isentress® (raltegravir) arm :Isentress® (raltegravir) 400 mg two times a day (BID) added to current antiretroviral treatment with counseling
1598482|NCT02247687|Other|Counseling arm|No change of antiretroviral treatment but only counseling
1598483|NCT02247674|Procedure|Bilateral movement training|Exercise training of bilateral isometric handgrip force training group consisted of 60 minutes of bilateral isometric handgrip force training 3 days per week for 4 weeks (total 12 sessions)
1598484|NCT02247648|Drug|tramadol|Patients from tramadol group received tramadol 100 mg day one, 100 mg day 2, and 200 mg day 3
1598485|NCT02247648|Drug|Placebo|"Patients from control group received a shame tramadol pill on day one, two, and 3"
1598486|NCT02247635|Behavioral|Healthy lifestyle and adherence|"Behavioral intervention to improve adherence to treatment and 1) Maintain a caloric restriction of 500kcal in overweight adults, 2) Have a total fat intake <30% (including cholesterol and trans fat), 3) A total intake of complex carbohydrates for 50%, 3) 30g fiber, 4) Perform at least 30 minutes of moderate physical activity at least 5 days a week; 5) Maintain education and behavioral therapy changes in your lifestyle.
The model consists of monthly visits to the doctor, nutritionist and psychologist, for screening cardiometabolic risk factors, to know limitations on treatment adherence, to start intervention to evaluate reasons for success or failure, to evaluate and maintain motivation to adherence to diet, physical activity and medication and long-term care"
1598487|NCT02247609|Genetic|Anti-CD19 CAR T cells|Autologous 4th generation withdrawable lentiviral-transduced anti-CD19-CAR T cells
1598488|NCT02247596|Drug|Resveratrol|1g tds 2 weeks
1598489|NCT02247596|Drug|Placebo|Sugar pill 1g tds for 2 weeks
1598490|NCT02247570|Procedure|Vestibular Rehabilitation|Stimulation of the vestibular system by off axis rotational therapy, gaze stabilization, eye movement strategies, balance training
1598491|NCT02247557|Drug|Liposome encapsulated BoNT-A|Liposome encapsulated BoNT-A ( mixed BOTOX 200U/10ml in Liposome 80mg/40ml) in single intravesical instillation
1598492|NCT02247557|Drug|BOTOX 200U in normal saline|BOTOX 200U in normal saline (BoNT-A/NS) 50ml in single intravesical instillation
1598493|NCT02247557|Drug|Normal saline|Normal saline (N/S) 50ml in single intravesical instillation
1598494|NCT02247544|Drug|Trabectedin|Trabectedin administered at a dose of 1.5 mg/m2 - 1.3 mg/m2 (at investigator's discretion, with a top-dose of 2.6 total mg per cycle) as a 24-hour continuous infusion via a central venous access until progressive disease, major toxicity, patient's intolerance, unwillingness to continue treatment, or medical decision by the responsible physician
1598495|NCT02247531|Drug|Lampalizumab|10-mg dose of lampalizumab administered intravitreally.
1598496|NCT02247531|Other|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
1598497|NCT02247518|Drug|Cialis Tab. 5mg|
1598498|NCT02247518|Drug|Harnal-D Cap. 0.2mg|
1598499|NCT02247505|Drug|Harnal-D Cap. 0.2mg|
1598500|NCT02247505|Drug|Cialis Tab. 5mg|
1598501|NCT02247479|Drug|Lampalizumab|Participants will receive 10 mg dose of lampalizumab administered intravitreally.
1598502|NCT02247479|Other|Sham|A sham injection is a procedure that mimics an intravitreal injection of lampalizumab.
1598503|NCT02247466|Drug|Rocuronium and Sugammadex|
1598504|NCT02247453|Other|screening|"All subjects undergo baseline LDCT examination, spirometry and miRNA profiling. Individuals with negative miRNA profile repeat the plasma assay at 3 years. Individuals with low-risk miRNA profile repeat the plasma assay and LDCT at 2 years, without additional diagnostic examinations if not required by the screening protocol.
Individuals with high-risk miRNA profile undergo additional diagnostic examinations consisting in PET in case of concurrent suspicious or positive CT, or WB MRI +- needle aspiration biopsy in case of negative CT."
1598505|NCT02247440|Drug|Peg-interferon + ribavirin under HIV physician supervision|Peg-interferon + ribavirin under HIV physician supervision
2009454|NCT03249090|Other|Patient Reporting of Symptoms|"At baseline, CRAs will train patients to self-report symptoms and physical functioning weekly for up to a year, with a choice to do this online or via an automated telephone system (patient choice), and a choice of English, Spanish, or Mandarin Chinese.
Whenever a concerning symptom is reported, an automated email alert notification will be sent to the site CRA. The CRA will forward the email alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system).
A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit, and will be given to the oncologist and nurse caring for the patient."
2009455|NCT03249090|Other|Usual Care Delivery|Patients receive routine cancer care delivery with no additional systematic monitoring of symptoms
1598511|NCT02247401|Drug|2 DAA|ABT-450/r/ABT-267 tablets
1598512|NCT02247401|Drug|RBV|Ribavirin tablets
1598513|NCT02247388|Behavioral|Computerized Alcohol Screening|iPad based automated alcohol screening
1598514|NCT02247388|Behavioral|Brief Negotiated Interview|iPad based automated brief negotiated interview (BNI)
1598515|NCT02247375|Drug|Low dose of BIIL 284 BS tablets|
1598516|NCT02247375|Drug|High dose of BIIL 284 BS tablets|
1598517|NCT02247375|Drug|Placebo|
1598518|NCT02247362|Biological|VAX2012Q|Recombinant influenza HA vaccine consisting of two Influenza A subtypes and two Influenza B lineages and delivered IM
1598519|NCT02247362|Other|Placebo|Vaccine Diluent
1598522|NCT02247336|Behavioral|MeTree|Participants will enter their family health history information into MeTree, patients and providers will receive a decision support document and pedigree
1598523|NCT02247323|Other|Risk of malignancy index|Calculation of RMI before sugery.
1598524|NCT02247310|Drug|Betaferon, (BAY 86-5046)|Patients will be treated with Betaferon
1598525|NCT02247310|Device|BETACONNECT|Auto-injector device to support the injection of Betaferon
1598526|NCT02247297|Procedure|Blood collection|Diagnostic blood collection
1598527|NCT02247284|Device|RNFL and BMO-MRW SD-OCT|Masurement of peripapillary RNFL measurements with Heidelberg Spectralis SD-OCT (Heidelberg Engeneering GmbH, Heidelberg, Germany) old protocoll and in addition with the new Glaucoma Premium Module (software version 6.0) tocoll, which in addition to RNFL measurements include measurement of Bruch's Membrane Opening-based minimum rim width (BMO-MRW).
1598528|NCT02247271|Behavioral|Diabetes health coach support|Receives support from a trained peer health coach for a six month period
1598529|NCT02247258|Drug|Azathioprine|See arm/group descriptions
1598530|NCT02247258|Drug|Azathioprine in case of endoscopic recurrence|See arm/group descriptions
1598531|NCT02247258|Procedure|Ileocolonoscopy|See arm/group descriptions
1598532|NCT02247258|Procedure|Small bowel follow trough|See arm/group descriptions
1598533|NCT02247245|Drug|Ivabradine|Ivabradine 7.5mg
1598534|NCT02247245|Other|Atrial fibrillation|Pacemaker base rate alteration
1598535|NCT02247232|Drug|Z-100|
1598536|NCT02247232|Drug|Placebo|
1598537|NCT02247219|Behavioral|Counselling and education individually and in groups|The counselling method is based om Motivational Interviewing
1598538|NCT02247206|Behavioral|Behavior Therapy for Tics (CBIT)|CBIT is an 8-session 10-week behavioral treatment for chronic tic disorders, including Tourette Syndrome. The first two sessions are 90 minutes, with subsequent sessions lasting 60 minutes. The treatment consists of Habit Reversal Training (awareness training, competing response training, and social support), and function-based assessment to reduce the impact of environmental or other stimuli on tic severity. The treatment also consists of relaxation techniques to reduce tic-related stress and tension, and behavioral rewards to motivate treatment compliance.
1598539|NCT02247193|Drug|Botulinum Toxin Type A|Injection of toxin at the time of surgery at cleft lip repair site
1598540|NCT02247193|Drug|Normal Saline Injection|Injection of normal saline into cleft lip at time of surgical repair.
1598541|NCT02247180|Behavioral|cognitive rehabilitation|
1598542|NCT02247180|Behavioral|standardized cognitive training|
1598543|NCT02247167|Procedure|adenotonsillectomy|adenotonsillectomy in children with OSAS and adenotonsillar hypertrophy.
1598544|NCT02247154|Biological|Vigam® (Human Normal Immunoglobulin)|
1598545|NCT02247141|Biological|Subgam® (Human Normal Immunoglobulin Solution)|
1598546|NCT02247128|Drug|Aspirin + clopidogrel|
1598547|NCT02247128|Drug|Aspirin monotherapy|
1598548|NCT02247128|Drug|OAC + clopicogrel|
1598549|NCT02247128|Drug|OAC monotherapy|
1598550|NCT02247102|Dietary Supplement|Isomaltulose|"Each subject receives isomaltulose on Study Day 1. After having completed the wash-out period, each subject receives sucrose on Study Day 2.
Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
1598551|NCT02247102|Dietary Supplement|Sucrose|"Each subject receives sucrose on Study Day 1. After having completed the wash-out period, each subject receives isomaltulose on Study Day 2.
Dosage of 1 g/ kg body weight (rounded up to the nearest 0.5 kg)."
2009456|NCT03249090|Other|Standardized symptom management guidelines|"At baseline, the CRA will provide all participants with a symptom advice booklet, based on best available evidence, existing guidelines, and expert consensus.
Nurses involved with the clinical care of participants in this study will be provided with access to evidence-based symptom management pathways."
2009457|NCT03249922|Device|Spinal Cord Stimulation|Implantation of a spinal cord stimulator for the control of axial back or neuropathic pain.
1598554|NCT02247076|Behavioral|Grazing|
1598555|NCT02247076|Behavioral|Time-restricted feeding (early eating)|
1598556|NCT02247063|Device|High-Definition Transcranial Direct Current Stimulation (HD-tDCS)|HD-tDCS is a non-invasive brain neuromodulatory method for M1that involves sending a weak electrical current into your brain.
1598557|NCT02247050|Behavioral|Commitment invitation|Clinicians will be invited to commit to follow 3 Choosing Wisely recommendations. Those that choose to commit will also receive point-of-care commitment reminders, point-of-care Choosing Wisely patient education handouts, and weekly emails with decision support resources.
1598558|NCT02247037|Other|Chemotherapy|Patients are treated with neoadjuvant chemotherapy as according to the standard of care guidelines. Patients with metastatic disease are treated according to standard of care guidelines.
1598559|NCT02247011|Other|Questionaire survey|We used a questionnaireto collect clinical data of the subjects. The questionnaire includes basic data, menstruation and pregnancy, habits and customs, daily activity, common healthy situation, history of drugs and history of factures.
1598560|NCT02247011|Radiation|Bone mineral density examination|We use dual energy X-ray absorptiometry (DXA) to exam the BMD at lumbar spine (L2-4, LS) and hip.
1598561|NCT02247011|Radiation|Vertebral fracture assessment|X-ray of thoracic and lumbar spine was taken, and the pictures were read by radiological specialists. The diagnosis of vertebral fracture was executed according to Genant's semiquantitative technique.
1598562|NCT02247011|Other|Biochemical markers analysis|Fasting blood sample was collected for each subject. Common biochemical maerkers including serum calcium(Ca), serum phosphate(P), serum glucose(Glu), serum creatinine(Cr), alkaline phosphatase(ALP), alanine aminotransferase(ALT) were analyzed. Besides, we also detect bone speficific markers including 25-hydroxyl Vitamin D(25OHD), parathyroid hormone(PTH), β-isomerized C-terminal telopeptide of type I collagen(β-CTX), N-terminal procollagen of type 1 collagen(P1NP) and osteocalcin(OC).
2009458|NCT03249753|Drug|SPH3127 200mg Panel A|Participants who are in panel A will receive a single dose of a SPH3127 tablets 200mg when limosis, then fast 4h after dosing, and 72 hours later participants take the second dose of SPH3127 200mg after a high-fat breakfast.
2009459|NCT03249753|Drug|SPH3127 200mg Panel B|Participants who are in panel B will receive a single dose of a SPH3127 tablets 200mg after a high-fat breakfast, then 72 hours later participants take the second dose of SPH3127 200mg when limosis.
2009460|NCT03249402|Drug|Ethinyl Estradiol + Levonorgestrel|Participants will receive one OC tablet containing EE 0.03 mg and LN 0.15 mg once daily on Days 1 to 21 in cycles 1 and 2.
2009461|NCT03249402|Drug|JNJ‑42847922|Participants will receive 40 mg of JNJ‑42847922 once daily on Days 14 to 21 in cycle 2.
1598570|NCT02246985|Dietary Supplement|Control|The bread and mayonnaise in this meal does not have vegetable powders incorporated into them. Hence this meal does not contain carotenoids.
1598571|NCT02246985|Dietary Supplement|Vegetable bread only|A vegetable powder (carrot and tomato) containing bread portion will be served alone. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids.
1598608|NCT02246712|Genetic|CYP2B6 genotype|The single nucleotide polymorphism 516G>T in CYP2B6 gene was evaluated using polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP).
1598572|NCT02246985|Dietary Supplement|Plain bread with vegetable mayonnaise|Plain bread will be served with a vegetable powder (carrot and tomato) containing mayonnaise. The amount of vegetable powder in the mayonnaise will be standardised to contain a known amount of carotenoids.
1598573|NCT02246985|Dietary Supplement|Vegetable bread with plain mayonnaise|A vegetable powder (Carrot and tomato) containing bread portion will be served with plain mayonnaise. The amount of vegetable powder in the bread portion will be standardised to contain a known amount of carotenoids
1598574|NCT02246972|Behavioral|Virtual Reality Exposure Therapy (VRET)|6 to 12 90-minute individual treatment sessions. During VRET sessions patients will wear a head-mounted display with stereo earphones that will provide visual and audio cues consistent with Iraqi or Afghan military scenarios or other base-related scenarios as appropriate for the individual patient.
1598575|NCT02246959|Behavioral|Process Incentive|Daily sweepstake conditional on daily medication adherence
1598576|NCT02246959|Behavioral|Outcome Incentive|Incentives conditional on LDL cholesterol reduction
1598577|NCT02246946|Device|Positive Airway Pressure|To this group, Intermittent Positive Airway Pressure Breathing with 15 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
1598578|NCT02246946|Other|Conventional Chest Physiotherapy|To this group, routine physiotherapy exercises will be conducted plus Intermittent Positive Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
1598579|NCT02246946|Procedure|Control group|to this group, Airway Pressure Breathing with 4 mmHg by Muller Reanimatior (Engemed, Brazil) device with a rubber facial mask will be provide
1598580|NCT02246933|Other|PUFA Diet|The 7-day diet will consist of 50% carbohydrate, 15% protein, and 35% fat. 21% of total energy will be poly-unsaturated fatty acids, 9% mono-unsaturated fatty acids, and 5% saturated fatty acids.
1598581|NCT02246933|Other|Control Diet|The 7-day diet will consist of 50% carbohydrate, 35% fat, and 15% protein. Furthermore, 7% of total energy will be poly-unsaturated fatty acids, 15% of total energy will be mono-unsaturated fatty acids, and 13% of total energy will be saturated fatty acids.
1598582|NCT02246920|Drug|Fluticasone propionate|50 mcg/actuation Nasal Spray
1598583|NCT02246920|Drug|Flonase®|50 mcg/actuation Nasal Spray
1598584|NCT02246920|Drug|Placebo|Inactive Nasal Spray
1598585|NCT02246907|Other|Exercise|All intervention patients will participate in an individualized prescriptive exercise intervention 2 to 4 times per week for a period of the induction chemotherapy/in-hospital recovery. The exercise intervention will begin on week 1 of the study, the day after the first batteries of initial assessments are concluded. Each exercise session will be divided into two parts. One part will be administered in the morning and the second one late in the afternoon. There will be a period of rest of at least 36 hours between each exercise session.
1598586|NCT02246894|Biological|Optivate® (Human Coagulation Factor VIII)|
1598587|NCT02246881|Biological|Optivate® (Human Coagulation Factor VIII)|
1598588|NCT02246868|Biological|Optivate® (Human Coagulation Factor VIII)|
1598589|NCT02246855|Biological|Gammaplex® (Human Normal Immunoglobulin)|
1598590|NCT02246842|Biological|D-Gam® (human anti-D immunoglobulin)|
1598591|NCT02246842|Biological|Rhophylac® (human anti-D immunoglobulin)|
1598592|NCT02246829|Procedure|Intravitreal injection|2 mg intravitreal Aflibercept initiated with one injection every 4 weeks for three consecutive doses (loading dose) The duration of the follow-up is 12 weeks. This means 3 injections per patient should be given over the study period
1598593|NCT02246816|Drug|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)|0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
1598594|NCT02246803|Procedure|CABG+Pulmonary vein isolation procedure|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion. Concomitant pulmonary vein isolation in CBP prior to occlusion and CABG
1598595|NCT02246803|Procedure|Isolated CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CBP) and occlusion.
1598596|NCT02246790|Procedure|Biatrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant biatrial RFA during CPB.
1598597|NCT02246790|Procedure|Left atrial radiofrequency ablation and CABG|Coronary artery bypass (CABG) using cardio-pulmonary bypass (CPB) and occlusion. Concomitant left atrial RFA during CPB.
1598599|NCT02246764|Drug|Netarsudil (AR-13324) Ophthalmic Solution q.d.|1 drop daily
1598600|NCT02246764|Drug|Netarsudil (AR-13324) Ophthalmic Solution b.i.d.|1 drop twice daily
1598601|NCT02246764|Drug|Timolol maleate Ophthalmic Solution b.i.d.|1 drop twice daily
1598602|NCT02246751|Device|Targeted Training for trunk control|Orthotics Research and Locomotor Research Unit (ORLAU) standers will be custom fit to help the child train at the segmental level of the trunk where they begin to lose control of posture. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body. The researchers evaluate children every 8 weeks and adjust the stander to lower levels of support as the child gains control.
1598603|NCT02246738|Other|Blood Collection|
1598604|NCT02246725|Other|Contact with palliative care unit.|
1598605|NCT02246712|Drug|Single oral dose of 100 mg racemic tramadol|Serial blood samples were collected up to 24 h after drug administration; Pain was evaluated at the same time of blood sampling using visual analog scale
1598606|NCT02246712|Other|CYP2D6 phenotype|"Patients were phenotyped using metoprolol (100 mg, single oral dose). Urine was collected up to 8 hours after metoprolol administration. Urinary concentrations of metoprolol and alfa-hydroxymetoprolol were determined by high performance liquid chromatography (HPLC), using fluorescence detector.
CYP2D6 phenotyped was determined by alfa-hydroxymetoprolol/metoprolol urinary rato"
1598607|NCT02246712|Other|CYP3A phenotype|"A single oral dose of midazolam (15 mg) was administered to all patients. Serial blood samples were collected up to 6 hours after the administration of midazolam.
The concentration of midazolam was determined in plasma in order to calculate midazolam clearance.
The in vivo activity of CYP3A was evaluated by midazolam oral clearance."
1598609|NCT02246699|Device|KiOnutrime®-Cs|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules of 500mg, 3 times per day.
1598610|NCT02246699|Other|Placebo|The product will be taken orally within 15 minutes before main meals (breakfast, lunch and dinner) with a large glass of water. Subjects will have to take 2 capsules, 3 times per day.
1598611|NCT02246686|Drug|STW5-II (Iberogast N, BAY98-7410)|Application over 12 weeks 20 drops three time daily
1598612|NCT02246686|Drug|Placebo|Application over 12 weeks 20 drops three time daily
1598613|NCT02246673|Drug|RDEA3170 15 mg|
1598614|NCT02246673|Drug|RDEA3170 10 mg|
1598615|NCT02246673|Drug|RDEA3170 2.5|
1598616|NCT02246673|Drug|RDEA3170 5 mg|
1598617|NCT02246673|Drug|Febuxostat 40 mg|
1598618|NCT02246673|Drug|Febuxostat 80 mg|
1598619|NCT02246660|Drug|Resveratrol|"The dose of Resveratrol will be 500 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative.
OR
The dose of Resveratrol will be 125 mg daily for six months. Resveratrol is taken orally. Resveratrol is a natural plant derivative."
1598620|NCT02246660|Drug|Placebo|Placebo will be taken orally for 6 months.
1995009|NCT02873598|Drug|FOLFIRINOX or gemcitabine/abraxane|Patients will have received induction chemotherapy for 3+ months with either FOLFIRINOX or gemcitabine/abraxane with at least stable disease.
2009462|NCT03248661|Behavioral|Now I'm Telling You|Messages will be sent trough Facebook, Twitter, Instagram, e-mail, texting or other electronic/social media specified by study volunteers.
2009463|NCT03247829|Device|Hemodynamic management using CardioMEMS|Using the CardioMEMS HF system, clinicians will treat to target PA pressure ranges
1598625|NCT02246621|Drug|Abemaciclib|Administered orally
1598626|NCT02246621|Drug|Anastrozole|Administered orally
1598627|NCT02246621|Drug|Letrozole|Administered orally
1598628|NCT02246621|Drug|Placebo|Administered orally
1598629|NCT02246608|Device|Routine NPWT plus Oasis wound product|Oasis® is a porcine acellular small intestine submucosa material compatible with human tissue. It is a complex scaffold that provides optimal environment for restoration of tissue structure. It guides tissue growth and traps growth factors. Oasis Matrix indications include partial and full thickness wounds and skin loss injuries as well as second-degree burns.
1598630|NCT02246608|Device|Routine NPWT plus foam wound product|Specialized material, often foam, designed to protect the wound and promote healing during NPWT.
1598631|NCT02246595|Biological|CaCP29|
1598632|NCT02246595|Biological|Placebo|
1598633|NCT02246582|Device|Enlite 3|Use of Enlite 3 Sensor over 168 hours (7 days) when inserted in the abdomen & arm used with the Guardian Mobile App and 640G Pump in subjects aged 14-75 years who have had a diagnosis of type 1 or type 2 diabetes for at least one year.
1598634|NCT02246582|Device|Guardian Mobile App|
1598635|NCT02246582|Device|640G Insulin Pump|
1598636|NCT02246556|Device|Dichoptic therapy|Dichoptic virtual reality video game therapy with Diplopoia (TM) software developed for the Oculus Rift (R) gaming system
1598637|NCT02246556|Other|Patching therapy|Conventional patching therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
1598638|NCT02246556|Device|Dioptic (non-dichoptic) therapy|Dioptic (non-dichoptic) video game therapy followed by crossover to the dichoptic virtual reality video game therapy with Diplopia (TM) software
1598639|NCT02246543|Dietary Supplement|Control|Water, Toast & Egg (Yolk only) + 0.1g 13C Octanoic Acid
1598640|NCT02246543|Dietary Supplement|HPL|High Protein Smoothie (Liquid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
1598641|NCT02246543|Dietary Supplement|LPL|Low Protein Smoothie (Liquid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
1598642|NCT02246543|Dietary Supplement|HPS|High Protein Milk Jelly (Solid): 30% protein; 30% fat and 40% CHO + 0.1g 13C Octanoic Acid
1598643|NCT02246543|Dietary Supplement|LPS|Low Protein Milk Jelly (Solid): 15% protein; 30% fat and 55% CHO + 0.1g 13C Octanoic Acid
1598644|NCT02246530|Procedure|PRP injection into PTRCT|"Day of procedure, 60 cc blood draw will be taken for processing and isolation of PRP. PRP sample will be injected peri-tendinous / intra-tendinous area at location of the PTRCT under ultrasound guidance to ensure accurate placement at site of injury.
PRP is an autologous blood product that is being re-injected into the same patient and is considered a non-invasive interventional procedure. PRP is classified as a procedure and not a drug."
1598645|NCT02246530|Drug|Subacromial steroid bursal injection|Combination steroid (Celestone) and anesthetic drug (Lidocaine) will be injected into the patient's subacromial bursa via needle guidance of ultrasound
1598646|NCT02246517|Drug|N2O|
1598647|NCT02246517|Drug|Oxygen|
1598648|NCT02246504|Device|HIFU treatment|
1598649|NCT02246491|Other|with gene correction|
1598650|NCT02246491|Other|without gene correction|
1598651|NCT02246478|Drug|TAS-205|"Single-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step, single oral administration after meals
Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 5 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
1598652|NCT02246478|Drug|Placebo|"Single-dose phase: 3steps (low dose, middle dose or high dose group), 2 patients/step, single oral administration after meals
Multiple-dose phase: 3 steps (low dose, middle dose or high dose group), 2 patients/step (the same patients between single- and multiple-dose phases), repeated oral administration for 7 days, BID after meals"
1598653|NCT02246465|Drug|RXI-109|
1598654|NCT02246439|Drug|RHB-102|RHB-102, Bimodal Release Ondasetron Tablets
1598655|NCT02246426|Other|Computerized plasticity-based adaptive cognitive training|Computerized plasticity-based adaptive cognitive training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
1598656|NCT02246426|Other|Commercially available computerized training|Commercially available computerized training for a total maximum of 40 treatment sessions, 3-5 times weekly, 40-60 minutes per session.
1598657|NCT02246413|Behavioral|RAINBOW Intervention Program|Integrated lifestyle intervention with as-needed antidepressant pharmacotherapy to treat coexisting obesity and depression in adults in primary care
1598704|NCT02246049|Biological|Bevacizumab|Given IV
1598658|NCT02246400|Behavioral|eCMP|eCMP is a 6-month lifestyle intervention designed and led by a team of experienced health professionals, including physicians, researchers, dietitians, and registered nurses. The program consists of weekly home and class activities delivered through online or take-home videos, video conferencing, and/or in-person sessions.
1598659|NCT02246387|Procedure|Manchester Operation|A 3- compartment native tissue repair procedure for Pelvic Organ Prolapse.
1598660|NCT02246374|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
1598661|NCT02246361|Procedure|Patient Information Leaflet (PIL)|Patient Information Leaflet (PIL) about infectious colitis, diverticulitis, pneumonitis, prostatitis or either pyelonephritis is given to the patient related to his disease during the consultation
1598662|NCT02246348|Radiation|Doppler ultrasound|Recording Doppler ultrasound noninvasively from the right chest wall
1598663|NCT02246335|Device|Cemented total hip arthroplasty|
1598664|NCT02246335|Device|Cemented hemiarthroplasty|
1598665|NCT02246322|Device|25G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
1598666|NCT02246322|Device|22G needle|All consecutive patients that will be referred for solid masses to be aspirated will be randomized to be targeted in the 25G needle arm (A), or in the 22G needle arm (B).
1995010|NCT02873598|Radiation|SBRT|After completion of induction chemotherapy, stereotactic body radiation therapy (SBRT) will be administered in 3 fractions, every other day, on an outpatient basis. Dose escalation will start with dose level 1 (9 Gy x 3 fractions) and increase by 1 Gy per fraction at each dose level, dose level 2 will be 10 Gy x 3 fractions and dose level 3 will be 11 Gy x 3 fractions.
1995011|NCT02872974|Other|GDM|Exposure to GDM during fetal life
1598669|NCT02246296|Dietary Supplement|Standard F75 Milk|This is the standard F75 milk used worldwide (Control group)
1598670|NCT02246296|Dietary Supplement|Modified F75 Milk|This is the experimental group
2009464|NCT03246724|Drug|Triazolam|"This will be used for oral sedation. This capsule or a microcrystalline cellulose placebo capsule will be administered depending on the randomized treatment group.
Dose for BMI less than 35: 0.125 mg
Dose for BMI greater than or equal to 35: 0.25 mg"
1598673|NCT02246257|Other|Simvastatin|LDL > 2.5 is treated with 40 mg
1598674|NCT02246257|Other|Losartan|BT > 140/90 mmHg treated with 50 mg OD
1598675|NCT02246257|Other|Losartan|DM BT > 130/80 mmHg treated with 50 mg OD
1598676|NCT02246257|Other|Losartan|Microalbuminuria (urinary albumin creatinin ratio > 30 mg) treated with 100 mg OD
1598677|NCT02246257|Other|Metformin|HBA1C > 48 mmol/mol treated with 500 mg increased dose to 2,000 mg in 4 weeks
1598678|NCT02246257|Other|Outpatient rheumatology department|(4 times yearly)
1598679|NCT02246257|Other|Refered to general practice|
1598680|NCT02246244|Drug|Escitalopram|
1598681|NCT02246244|Other|Placebo|
1598682|NCT02246231|Device|MR imaging|
1598685|NCT02246192|Procedure|sinus pilonidal excision+ PRGF|open sinus pilonidal excision and plasma rich grow factor infiltration intra and postoperatively
1598686|NCT02246192|Procedure|sinus pilonidal excision and standard cares|sinus pilonidal excision and postoperative standard care with povidone daily
1598687|NCT02246179|Device|AFXL|Pretreatment at 2.5 mJ/microbeam and 5% density Pain stimulus at 35 mJ/microbeam and 5% density
1598688|NCT02246179|Drug|AHES|Topical application at test region 1 and 3 under occlusion for 10 minutes
1598689|NCT02246179|Drug|EMLA cream|Topical application at test region 2 and 4 under occlusion for 10 minutes
1598690|NCT02246166|Drug|Test tablet|The active tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
1598691|NCT02246166|Other|Placebo|The placebo tablet will be administered orally. Product administration will occur within 30mins of the baseline assessment of symptom severity
1598692|NCT02246153|Procedure|Laparoscopic gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.
The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
1598693|NCT02246153|Procedure|Open gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.
The type of reconstruction will be selected according to the surgeon's experience."
1598694|NCT02246140|Other|Cerebral MRI and MRA|
1598695|NCT02246127|Drug|Drug: Everolimus|10mg/daily, oral. Number of Cycles: until progression or unacceptable toxicity develops.
1598696|NCT02246127|Drug|STZ-5FU|"0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-5 every 6 weeks (Moertel) or 0,5g/m2 STZ on days 1-5 and 400mg/m2 5-FU on days 1-3, and then 1 day with 1g/m2 and 1 day 400mg/m2 5-FU every 3 weeks (Uppsala).
Number of Cycles: until progression or unacceptable toxicity develops."
1598697|NCT02246114|Device|piCO+ Smokerlyzer® monitor|
1598698|NCT02246114|Other|Text messages|
1598699|NCT02246088|Procedure|MT + NE|"Manual therapy will be applied using mobilization with movement (MWM) techniques. MWM will consist of a sustained manual glide of the tibia (either medial, lateral, anterior, posterior, or rotation) during active knee flexion and extension, depending on which are the limited/painful movements for each patient.
The content and pictures of the neuroscience education (NE) will be based on the text Explicando el dolor (Spanish version of Explain Pain)."
1598700|NCT02246088|Procedure|MT + E|Program of education based on the traditional biomedical model (i.e. through visualization of several videos related to anatomy, biomechanics and surgical procedure of the knee), plus the same manual treatment as per the MT+NE group
1598701|NCT02246075|Drug|EVP-6124|
1598702|NCT02246062|Behavioral|info|the relative received leaflet containing information about the anesthetic procedure one day before the surgery at ward.
1598703|NCT02246062|Behavioral|smartphone|the child received smartphone application immediately before entering the operating room
1995012|NCT02872597|Drug|Ipratropium|
1995013|NCT02872597|Drug|0.9% Sodium Chloride|
1995014|NCT02872597|Drug|Albuterol|"albuterol prescribed by the clinical team per our PICU's Asthma Carepath"
1598706|NCT02246049|Drug|Irinotecan hydrochloride|Given IV
1598707|NCT02246049|Drug|Leucovorin calcium|Given IV
1598708|NCT02246049|Drug|Oxaliplatin|Given IV
1598709|NCT02246036|Device|APD probe|The probe will be placed in the patient with an endoscopic procedure by a gastroenterologist (standard procedure for post-pyloric tubes placement).
1598710|NCT02246023|Device|Flexible bronchoscopy in moderate sedation|Flexible bronchoscopy for diagnosis of lung cancer, sarcoidosis or interstitial pneumonia in moderate sedation with propofol;
1598711|NCT02246023|Device|Oxygen saturation|Continuous measurement of oxygen saturation;
1598712|NCT02246023|Device|Blood pressure|Measurement of non-invasive blood pressure every 3 minutes
1598713|NCT02246023|Device|Propofol dosage|Report of dose adjustments und cumulative propofol dosage;
1598714|NCT02246023|Device|Recovery time after bronchoscopy|Recovery time after bronchoscopy from removal of bronchoscope to eye opening/answer to verbal stimuli (whatever comes first)
1598715|NCT02246010|Dietary Supplement|Lactose- free milk|Lactose- free milk
1598716|NCT02245997|Radiation|External beam radiotherapy|
1598717|NCT02245984|Other|paper based nursing process|for two weeks, students in paper based nursing group will be implemented paper nursing process for patients.
1598718|NCT02245984|Other|electronic nursing process|for each of the groups separately-training program aimed to education the nursing process and how to do it (including the definition of the nursing process, advantages and its implementation and how to collect data using patient assessment forms Gordon) in the form of workshops a day (5 hours) will be implemented. Nursing process education in the two groups will similar but two hours of the program in each groups is devoted to practical training on how to implement. After completing the training program, students learn about the nursing process will be determined in the same way. Then for two weeks, students in Group A and Group B will be implemented paper and electronic nursing process for patients.
1598719|NCT02245971|Procedure|Partial precutting|Partial precutting will be performed prior to dissection during the ESD.
1598720|NCT02245971|Procedure|Whole precutting|Whole precutting will be performed prior to dissection during the ESD.
1598721|NCT02245958|Other|No Intervention|No treatment (intervention) was administered.
1598722|NCT02245945|Drug|TFV 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
1598723|NCT02245945|Drug|HEC Placebo Gel|Placebo gel contains hydroxyethylcellulose (HEC) as the gel thickener, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4. Each pre-filled applicator will contain approximately 4 mL of placebo gel for delivery.
1598724|NCT02245932|Dietary Supplement|Resveratrol|4 weeks of 150 mg resveratrol (2 times 75mg/day)
1598725|NCT02245932|Dietary Supplement|Placebo|4 weeks of placebo supplementation (two doses per day)
1598726|NCT02245919|Other|Back on Track intervention|A biopsychosocial primary care intervention based on multidisciplinary pain rehabilitation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
1598727|NCT02245906|Dietary Supplement|Control drink|As a control, subjects are asked to consume 300 ml control drinks containing equal amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
1598728|NCT02245906|Dietary Supplement|Brazilian fruit peel flour|In this study, subjects are asked to consume 300 ml beverage drinks contain certain amounts of Brazilian fruit peel flour. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
1598729|NCT02245906|Dietary Supplement|Negative control drink|As a negative control, subjects are asked to consume 300 ml control drinks without containing amount of total fiber and pectine as Brazilian fruit drink. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
1598730|NCT02245893|Procedure|open reduction internal fixation (ORIF)|The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
1598731|NCT02245880|Device|Glidescope|videolaryngoscope
1598732|NCT02245880|Device|ILMA|handling of the device till the optimal ventilation achieved
1598733|NCT02245867|Drug|Chimeric Fibril-Reactive Monoclonal Anti-body 11-1F4|The antibody binds to the pathologic material and initiates a neutrophil/macrophage response
1598734|NCT02245854|Device|Exacto™|Cold snare polypectomy
1598735|NCT02245841|Drug|H.P. Acthar Gel|80 U (1 mL) of H.P. Acthar gel via subcutaneous injection twice weekly for 24 weeks
1598736|NCT02245828|Drug|QCC374|Single and multiple ascending doses of QCC374
1598737|NCT02245828|Drug|Placebo|Placebo comparator
1995015|NCT02872597|Drug|corticosteroids|systemic (IV or enteral) corticosteroid prescribed by the clinical team, typically methylprednisolone IV
1598740|NCT02245789|Procedure|Tracheal intubation|Tracheal intubation will be performed using a Macintosh laryngoscope or a McGrath Mac videolaryngoscope
1598793|NCT02245321|Dietary Supplement|Ferrous gluconate- 19 mg|Receive pills to take daily that contain 19 mg of iron (the typical amount in a multivitamin with iron).
1598931|NCT02244255|Drug|Ascending doses of HYTRIN® capsules|
1995016|NCT02872025|Drug|Pembrolizumab|
1995017|NCT02871479|Drug|SAN007 5% cream|5% EISO in a cream formulation applied twice a day for up to 28 days.
1995018|NCT02871479|Drug|Placebo|A placebo cream containing the same components as the vehicle for the active intervention arm
1995019|NCT02871479|Drug|SAN007 10% cream|10% EISO in a cream formulation applied twice a day for up to 28 days.
1995020|NCT02871219|Drug|Obinutuzumab|Obinutuzumab, 1000 mg on Days 1, 8, and 15 of Cycle 1, and Day 1 of cycles 2 through 6. Participants then receive 1000 mg of Obinutuzumab on Day 1 of cycle 8, 10, and 12. Participants then receive Obinutuzumab, 1000 mg on Day 1 of cycle 14, 16, 18, 20, 22, 24, 26, 28, and 30.
1598741|NCT02245789|Drug|Propofol and remifentanil anesthesia|The standardized anesthetic procedure used a closed-loop anesthesia system with bispectral index as control variable and with two proportional-differential control algorithms, one for propofol target-controlled infusion system and one for remifentanil target-controlled infusion system.
1598742|NCT02245776|Biological|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
1598743|NCT02245763|Device|Leaflet Clip|
1598744|NCT02245750|Device|Hysteroscopy|hysteroscopy and endometrial injury prior to the IVF/ICSI cycle
1598747|NCT02245724|Biological|Stem Cell|Autologous bone marrow mononuclear cell transplantation
1598748|NCT02245711|Biological|Stem Cell|
1598749|NCT02245698|Biological|Stem cell|Intrathecal autologous bone marrow mononuclear cell transplantation
1598750|NCT02245672|Drug|MGR001 (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the CRC749 inhaler device
1598751|NCT02245672|Drug|Advair (Fixed dose combination of Fluticasone propionate and salmeterol xinafoate)|Fluticasone propionate (100 mcg) and salmeterol xinafoate (50 mcg) administered via the Diskus inhaler device
1598752|NCT02245672|Drug|Placebo|Placebo administered via the CRC749 and Diskus devices
1598753|NCT02245659|Device|CPAP|Continuous Positive Airway Pressure
1598754|NCT02245659|Other|Nasal dilator strip|Nasal dilator strip to be worn nightly
1598755|NCT02245620|Drug|MTP-131 (Bendavia™)|MTP-131 (Bendavia™; 0.25 mg/kg/hour) administered as an intravenous infusion at the rate of 60 mL/hour for 2 hours
1598756|NCT02245620|Drug|Placebo|Placebo administered as intravenous infusion at a rate of 60 mL/hour for 2 hours
1598757|NCT02245607|Behavioral|Compensatory Cognitive Training|
1598758|NCT02245607|Behavioral|Recreational Therapy|
1598759|NCT02245581|Procedure|SVV-guided fluid management|
1598760|NCT02245581|Procedure|CVP-guided fluid management|
1598761|NCT02245568|Drug|TRx0237|All subjects will initially be given 200 mg/day of TRx0237 (one 100-mg tablet in the morning and one 100-mg tablet in the evening). Thereafter, dosing is flexible (100 mg/day to 300 mg/day).
1598762|NCT02245555|Drug|Tamsulosin|
1598763|NCT02245542|Drug|ALNA®OCAS®|
1598764|NCT02245529|Drug|Tamsulosin|
1598765|NCT02245516|Drug|KPI-121|KPI-121 drug product will be supplied in two strengths: 0.25% and 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
1598766|NCT02245503|Drug|Tamsulosin|
1598767|NCT02245490|Drug|Tamsulosin HCl controlled release capsules|
1598768|NCT02245490|Drug|Matching placebo capsule|
1598769|NCT02245477|Device|obstetric Ultrasound|Transabdominal ultrasound was performed to confirm foetal number, viability, gestational age, exclusion of congenital anomalies, and assessment of amniotic fluid index and localization of the placenta.
1598770|NCT02245477|Other|serum Vascular Endothelial Growth Factor|Maternal blood samples (10 cc) were taken from an antecubital vein. Plastic clean sterile tubes were used for collection of blood. Two cc of the blood sample were put in other clean sterile tubes containing ethylene diamine tetra-acetic acid (EDTA) to be used in measuring maternal hemoglobin concentrations and evaluating the complete blood count. The rest of maternal blood samples were centrifuged within 3 hours and sera collected equally in 2 suitable containers and stored at -80 degrees until assayed (first container for routine laboratory investigations and the second for VEGF assay).VEGF sample was allowed to clot for 30 minutes before centrifugation for 15 minutes. Serum is removed and assay immediately or sample was stored at -80 degrees
1598771|NCT02245464|Drug|Telmisartan|
1598772|NCT02245451|Drug|Tipranavir|
1598773|NCT02245451|Drug|Ritonavir|
1598774|NCT02245451|Drug|Methadone|
1598775|NCT02245438|Drug|Tipranavir low dose|
1598776|NCT02245438|Drug|Tipranavir high dose|
1598777|NCT02245438|Drug|Ritonavir low dose|
1598778|NCT02245438|Drug|Ritonavir high dose|
1598779|NCT02245438|Drug|Norethindrone-Ethinyl Estradiol|
1598780|NCT02245425|Other|Supine Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
1598781|NCT02245425|Other|Prone Thoracic Spine Manipulation|Position patient so that small amplitude quick stretch can be applied to the least mobile area of the thoracic spine that is identified during the spinal segmental mobility testing. The thoracic spine thrust manipulation will be applied at an appropriate range of motion as identified by the clinician.
1598782|NCT02245412|Biological|ALXN1007|8 IV doses of 10 mg/kg of ALXN1007 once weekly
1598783|NCT02245412|Biological|ALXN1007|8 IV doses of 20 mg/kg of ALXN1007 once weekly
1598784|NCT02245412|Biological|ALXN1007|16 IV doses of 20 mg/kg of ALXN1007 twice weekly
1598785|NCT02245399|Behavioral|A canola oil enriched mediterranean diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A high protein canola oil-enriched test bread will be provided as a supplement.
1598786|NCT02245399|Behavioral|A high wheat fiber diet|The diet will be provided at 60% of calories estimated for stable body weight to encourage weight loss. A whole wheat control bread will be provided as a supplement to participants
1598787|NCT02245386|Radiation|transperineal pelvic floor ultrasound|"Transperineal pelvic floor ultrasound applied for the submitted 120 women primiparae (40 women after normal vaginal delivery), (40 women after urgent cesarean section), (40 women after elective cesarean section), in early postpartum period (48 to 72) hours postpartum, to evaluate levator ani morphology."
1598788|NCT02245373|Drug|Antidepressants|
1598789|NCT02245373|Other|Active Monitoring|
1598790|NCT02245360|Drug|Phleum pratense grass pollen allergen extract|Allergy Immunotherapy grass tablet 75,000 SQ-T given once daily over 60 days
1598791|NCT02245360|Drug|placebo|placebo tablet given once daily over 60 days
1598792|NCT02245334|Drug|Povidone-Iodine|1 pill per biopsy
1598878|NCT02244632|Drug|Fluorouracil|IV injection every second week for 8 weeks.
1598794|NCT02245321|Dietary Supplement|Ferrous gluconate- 38 mg|Receive pills to take daily that contain 38 mg iron (the typical amount in an over-the-counter iron supplement).
1598795|NCT02245321|Other|Letter Group- Information Provided|Receive a letter informing them of their ferritin result at each visit, along with recommendations for blood donation.
1598796|NCT02245321|Other|Letter - No Information Provided|Receive a letter thanking the participant for their participation.
1598797|NCT02245321|Dietary Supplement|Placebo|Receive pills to take daily that contain 0 mg iron.
2009465|NCT03246724|Drug|Midazolam|"This will be used for intravenous sedation. This injection or sodium chloride 0.9% will be administered depending on the randomized treatment group.
Dose for BMI less than 35: 1.0 mg
Dose for BMI greater than or equal to 35: 2.0 mg"
2009466|NCT03246724|Drug|Microcrystalline Cellulose|"This will be used for the oral placebo. This capsule or a triazolam capsule will be administered depending on the randomized treatment group.
Dose for BMI less than 35: 1 capsule
Dose for BMI greater than or equal to 35: 2 capsule"
2009467|NCT03246724|Drug|Sodium chloride 0.9%|"This will be used for the intravenous placebo.This injection or midazolam will be administered depending on the randomized treatment group.
Dose for BMI less than 35: volume to match volume of active intravenous medication
Dose for BMI greater than or equal to 35: volume to match volume of active intravenous medication"
2009468|NCT03244384|Other|Clinical Observation|Undergo observation
2009469|NCT03244384|Other|Laboratory Biomarker Analysis|Correlative studies
1598803|NCT02245295|Procedure|Moderate Sedation for EBUS/TBNA|EBUS-TBNA was performed by one of the pulmonologists in moderate sedation (D.F., M.K.).
1598804|NCT02245295|Procedure|General anesthesia for EBUS/TBNA|EBUS-TBNA was performedin general anaesthesia by one of the thoracic surgeons (D.S., P.K.)
1598805|NCT02245269|Drug|Tipranavir|
1598806|NCT02245269|Drug|Ritonavir|
1598807|NCT02245269|Drug|Atorvastatin|
1598808|NCT02245269|Drug|Maalox|Aluminum Hydroxide; Magnesium Hydroxide; Simethicone
1598809|NCT02245256|Drug|Precedex|infusion of 0.1mcg/kg/hr of precedex
1598810|NCT02245256|Drug|placebo control|placebo
1598811|NCT02245243|Drug|Delafloxacin|Plasma pharmacokinetic parameters: AUC0-t, AUC0 inf, Cmax, Tmax, λz, t1/2, MRTinf, CL, CLnr, Vss, Vz
1598812|NCT02245230|Drug|Angiotensin (1-7)|Angiotensin (1-7) is a peptide produced by the body. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 20 ng/kg/min.
1598813|NCT02245230|Drug|Trimethaphan|Trimethaphan is a Nn-nicotinic receptor antagonist that blocks sympathetic and parasympathetic transmission at the level of the autonomic ganglia. It will be administered as an acute intravenous infusion with doses ranging from 0.5 to 5.0 mg/min.
1598814|NCT02245230|Drug|Phenylephrine|Phenylephrine is an alpha 1-adrenergic agonist. It will be administered as an acute intravenous infusion to restore blood pressure following trimethaphan with doses ranging from 0.1 to 0.5 ug/kg/min.
1598815|NCT02245217|Device|PET/CT scan to assess treatment efficacy|
1598816|NCT02245204|Drug|Chlorogenic acid|Chlorogenic acid for injection is polyphenols, micromolecular and un-endogenous substance. It might play the role of cancer treatment via balancing tumor micro-environmental immune status according to the stability and rationality of immunodeficiency and endogenous immune material expression around the tumor. Chlorogenic acid for injection is made from chlorogenic acid (purity≥98%) which is extracted from folium cortex eucommiae.Chlorogenic acid and its preparations have not been reported as chemical drug and marketed around the world.
1598817|NCT02245191|Drug|Ephedrine|5mg after Spinal Anesthesia
1598818|NCT02245191|Drug|Phenylephrine|100mcg after Spinal Anesthesia
1598819|NCT02245191|Drug|Metaraminol|200mcg Metaraminol after Spinal Anesthesia
1598820|NCT02245178|Procedure|Lung spirometry|measurement of pulmonary function pre- and post-bronchodilator
1598821|NCT02245178|Other|CT scan analysis|Analysis of existing year 25 thoracic CT scans for lung and intrathoracic vascular structure
1598822|NCT02245165|Biological|L-Nitro-Monomethyl-Arginine (LNMMA) 10 mg/kg IV|
1598823|NCT02245165|Biological|saline|
1598824|NCT02245152|Dietary Supplement|LNS|A monthly dose of LNS (31 sachets of 20g) will be distributed to mothers attending well-baby visits and participating in small group counseling
1598825|NCT02245152|Behavioral|Child's health and nutrition topics|"After the well-baby visit. Caregivers will be invited to participate in a small group counseling or BCC (2-3 caregivers at a time).
Every month a set of topics related to child's health and nutrition will be treated. These BCC sessions will be organized in an interactive way centering around the condition of the participating children."
1598826|NCT02245152|Behavioral|National policy well-baby visits|
1598827|NCT02245126|Drug|3-3-4 mix|the drug mix included lidocaine, bupivacaine and water for injection
1598828|NCT02245126|Drug|4-4-2|In this group (4-4-2 group) eligible men were receiving an injection of the 4-4-2 local anesthetic mix ( composed of 4cc of parental lignocaine 2%, 4cc of parental bupivacaine 0.5% and 2cc of water for injection). This mix is given once before commencement of the surgical procedure safe male circumcision.
1598829|NCT02245113|Other|diets|Feeding trial for 6 weeks (week 0 - baseline). The experimental diets are comprised of 30% kcal fat, 15% kcal protein and 55% kcal carbohydrate. Each of the test fat contributes to two-thirds of total dietary fat will be compared.
1598830|NCT02245100|Other|Cytology specimen|Correlative studies
1598831|NCT02245100|Other|Laboratory biomarker analysis|Correlative studies
1598832|NCT02245087|Drug|Atorvastatin|20 mg of atorvastatin daily
1598833|NCT02245074|Other|Sputum induction|The sputum induction will be performed by repeated nebulizations of 3% saline hypertonic solution. Cellularity and cell profiles were analysed as previously recommended.
1598834|NCT02245061|Other|paired pulses cortical electrical stimulation|
1598835|NCT02245048|Other|Carotid Intima-Media Thickness (CIMT)|
1598879|NCT02244632|Drug|Oxaliplatin|IV infusion every second week for 8 weeks.
1599021|NCT02243553|Drug|Digoxin tablet|
2009470|NCT03244384|Biological|Pembrolizumab|Given IV
2009471|NCT03244384|Other|Pharmacological Study|Correlative studies
2009472|NCT03244384|Other|Quality-of-Life Assessment|Ancillary studies
2009473|NCT03244384|Other|Questionnaire Administration|Ancillary studies
1598836|NCT02245022|Drug|Dolutegravir 50mg od|Patients randomised to receive either Dolutegravir 50mg od or standard of care (Efavirenz 600mg od) plus Lamivudine 300mg od/ Tenofovir 300mg od
1598837|NCT02245022|Drug|Standard of Care|Patients are randomised 1:1 to receive either Dolutegravir 50mg once daily in combination with Lamivudine 300mg od and tenofovir 300mg od or standard of care (Efavirenz 600mg plus Lamivudine 300mg od and tenofovir 300mg od)
1598838|NCT02245009|Procedure|Cardioversion|
1598839|NCT02244996|Dietary Supplement|Lycium Barbarum|Traditional Chinese Herbs
1598840|NCT02244996|Dietary Supplement|Placebo|Placebo
1598842|NCT02244970|Other|Mindfulness|Mindfulness is the awareness that emerges from paying attention to the present moment without judgment. In this study, subject in this arm will receive 7 weeks of MBI with a focus on tackling anxiety, depressed mood, and attention deficits among early psychosis participants. The elements of 7-week program included mindful-breathing, indoor and outdoor mindful-walking, mindful-eating, mindul-drawing, tree-of-life exercise and closing celebration.
1598843|NCT02244970|Other|Psychoeducation|Participants in the psychoeducation group will receive seven weeks of psychoeducation sessions which include basic knowledge related to 1) General mental health, 2) Knowledge of psychosis, 3) Treatment and community resources, 4) Recovery and relapse prevention, 5) Healthy lifestyle, 6) Social skills training, and finally a closing celebration at week 7.
1598844|NCT02244957|Device|Bi-level positive airway pressure (BPAP)|Overlap patients randomized to BPAP will be titrated as per American Academy of Sleep Medicine (AASM) guidelines and oxygen if needed based on saturations <88% while on stable bi-level settings.
1598845|NCT02244957|Drug|Nocturnal oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
1598847|NCT02244931|Device|Servomatic™ assisting device|Servomatic™ is an hand controlled motorized device assisting to propel the wheelchair .
1598848|NCT02244931|Device|E.Motion© assisting device|E.Motion© is an hand controlled motorized device assisting to propel the wheelchair .
1598849|NCT02244931|Device|Standard manual Wheelchair|Standard manual Wheelchair
1598850|NCT02244918|Drug|Nicotine Replacement Therapy|Participant has choice of from over-the-counter nicotine patch, nicotine gum or lozenge.
1598851|NCT02244918|Behavioral|Smoking Cessation Counseling|
1598852|NCT02244905|Behavioral|Positive Deviance|The recipients of the Positive Deviance intervention are the staff members of the three wards in the intervention arm, while the outcomes are measured among the patients receiving care in the three wards in the intervention arm. Key components of the intervention were invitation to participate voluntarily, open-ended dialogues with staff members to discover barriers and seek solutions to prevent HAI, discussion of outcomes, and encouragement to prioritize and implement the solutions generated.
1598853|NCT02244905|Other|Standard-of-Care Infection Control approach|Standard-of-Care Infection Control approach
1598854|NCT02244879|Dietary Supplement|resveratrol|arm resveratrol 500: 6 months of resveratrol 500 mg/day arm resveratrol 40: 6 months of resveratrol 40 mg/day
1598855|NCT02244866|Drug|Pergoveris (FSH and LH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
1598856|NCT02244866|Drug|Follitropin alpha (FSH)|Drugs are injected subcutaneously everyday until ovarian follicles reach 17mm in diameter.
1598857|NCT02244840|Device|Electronic bidet|commercial electronic bidet
1598858|NCT02244840|Device|Sitz bath|Conventional sitz bath
1598859|NCT02244827|Drug|WCK 2349|levonadifloxacin (active drug) and the sulfate metabolite
1598860|NCT02244814|Behavioral|Low Carbohydrate/Conventional|Lower-carbohydrate/conventional diet (usual care)
1598861|NCT02244814|Behavioral|Choosing Healthy Options in Carbohydrate Energy|Choosing Healthy Options in Carbohydrate Energy
1598862|NCT02244801|Drug|darTreg infusion|"The first subject in each dosing cohort will be monitored for 4 weeks after darTreg infusion. Following the 4 week observation period, the study team will conduct a thorough review of all available data to ensure that there are no safety signals and to make a determination about proceeding with additional patients. sBc production for darTreg manufacturing for the second subject in each cohort may be initiated but the second subject may not undergo leukapheresis until the safety review is complete.
Once the last subject in the first cohort reaches week 4 post-infusion, the DSMB will conduct a thorough review of all available data to make a determination about proceeding with additional patients at the lower dose or proceeding to the second dosing cohort. sBc production for darTreg manufacturing for the subsequent subject may be initiated but the patient may not undergo leukapheresis until the DSMB( Data Safety and Monitoring Board ) has approved enrollment of subsequent subjects."
1598863|NCT02244788|Device|SR™ PIP|
1598864|NCT02244775|Device|SR™MCP|
1598865|NCT02244762|Drug|20 mg HC-ER|1-72 hours
1598866|NCT02244762|Drug|20 mg HC-ER|1-72 hours
1598867|NCT02244762|Drug|20 mg HC-ER|1-72 hours
1598868|NCT02244749|Other|skin specimen|skin specimen
1598869|NCT02244723|Other|Lung ultrasound examination|Lung ultrasound (LUS) is increasingly being used at the bedside for assessing alveolar-interstitial syndrome, lung consolidation, pneumonia, pneumothorax, and pleural effusion. It could be an easily repeatable noninvasive tool for diagnosis of ventilator associated pneumonia
1598870|NCT02244710|Drug|Ticagrelor vs Clopidogrel|
1598871|NCT02244671|Procedure|fat, PRP, botulinum toxin|fat injection with platelet-rich-plasma (PRP) after immobilizing the extraocular muscles with botulinum toxin
1598872|NCT02244671|Drug|botulinum toxin|botulinum toxin used to immobilize extra-ocular muscles prior to fat injection.
1598873|NCT02244671|Device|PRP|autologous PRP is prepared with a dedicated centrifuge at the time of fat harvesting
1598874|NCT02244658|Drug|rhTPO|rhTPO 1.0 μg/kg·d subcutaneously for 7~14 consecutive days
1598875|NCT02244645|Behavioral|passive modality|Passive modality control group will receive regular 40-minutes rehabilitation twice a week for 3 months.
1598876|NCT02244645|Behavioral|Yoga treatment|Yoga treatment group will receive regular 60-minutes yoga classes twice a week for 4 months.
1598877|NCT02244632|Drug|Modufolin|IV injection every second week for 8 weeks.
1598929|NCT02244268|Drug|ALNA®|
1598880|NCT02244632|Drug|Irinotecan|IV infusion every second week for 8 weeks.
1598881|NCT02244632|Drug|Bevacizumab|IV infusion every second week for 8 weeks.
1598882|NCT02244619|Drug|Oral acetaminophen|Subjects randomized to the Oral acetaminophen arm will receive 2 Tylenol 500mg capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving Oral acetaminophen will also receive 100ml of IV Normal Saline similar to the delivery method of the IV acetaminophen arm. The Normal Saline IV placebo will be given not as an intervention but rather as a method to maintain study integrity.
1598883|NCT02244619|Drug|IV acetaminophen|Subjects randomized to the IV acetaminophen arm will receive Ofirmev 1000mg in 100ml Normal Saline IV plus 2 placebo capsules. In this study, one arm receives an oral form of active medication and one arm receives an IV form of active medication. To keep the subject and study personnel blinded, subjects receiving IV acetaminophen will also receive 2 placebo capsules similar to the delivery method of the oral acetaminophen arm. The placebo capsules will be given not as an intervention but rather as a method to maintain study integrity.
1598884|NCT02244606|Drug|SCY-078|
1598885|NCT02244606|Drug|Fluconazole|
1598886|NCT02244606|Drug|Micafungin|
1598887|NCT02244593|Other|FAST MRI and mammography screening|Patients in this group will receive Breast MRI and annual mammography. Participants will complete 4 questionnaires at 3 time points: enrollment; 2 weeks after they receive their mammogram; 6 months after their mammogram.
1598888|NCT02244580|Device|MammaTyper™|MammaTyper™ kit is a molecular in vitro diagnostic test for the quantitative detection of the ribonuclease acid (RNA) expression status of the genes for estrogen receptor (ESR1), progesterone receptor (PGR), human epidermal growth factor receptor 2 (HER2) and proliferation antigen KI 67.
1598889|NCT02244567|Drug|Metformin 850 mg twice daily for 3 months|This drug is insulin sensitizing agent which will be given twice daily orally for 3 months for PCOS patients.
1598890|NCT02244567|Procedure|Serum uc-oc|Serum uc-oc is a bone biomarker involved in incraesing insulin in pathophysiology of PCOS. It will be measured in serum of pcos patients before and after treatment with metformin for 3 months.
1598891|NCT02244567|Other|drug|This group of patients will receive any type of vitamin as a placebo to compare with effect of Metformin on serum UC-OC.
1598892|NCT02244554|Device|enLighten Laser|Picosecond pulse-duration or Nanosecond pulse-duration tattoo treatment with enLighten Q-switched Laser Treatment
1598893|NCT02244541|Drug|ANAVEX2-73 Oral|
1598894|NCT02244541|Drug|ANAVEX2-73 Intravenous|
1598895|NCT02244541|Drug|ANAVEX2-73 Oral|30 mg hard gelatin capsule
1598896|NCT02244541|Drug|ANAVEX2-73 Oral|50 mg hard gelatin capsule
2009474|NCT03244189|Behavioral|Fluid prescription|The additional amount of fluid that the participant will need to consume each day, using the smart water bottle, in order to meet the study-specified urine output. This fluid is in addition to any other sources of fluid (ex. cups of coffee, bottled sports drink) that the participant consumes each day.
1598898|NCT02244515|Drug|dexmedetomidine|dexmedetomidine 0.5μg•kg-1 diluted in 10 ml NaCI 0.9%
1598899|NCT02244502|Device|NovoTTF-100L(O)|Patients will be treated continuously with the NovoTTF-100L(O). NovoTTF-100L(O) treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
1598900|NCT02244502|Drug|Paclitaxel|Paclitaxel 80 mg/m2 over 1 hour infusion will be administered weekly for 8 weeks and then on days 1, 8, 15 of each subsequent 28 day cycle.
1598901|NCT02244489|Drug|MMB|Momelotinib (MMB) tablet(s) administered orally once or twice daily
1598902|NCT02244489|Drug|Capecitabine|Capecitabine tablet(s) administered orally twice daily for 14 days, followed by 7 days off, until the end of treatment
1598903|NCT02244489|Drug|Oxaliplatin|Oxaliplatin administered intravenously over 120 minutes or as per institutional standard of care on Day 1 of each 21-day cycle.
1598904|NCT02244463|Drug|MLN0128|This is a non-randomized phase II study to investigate efficacy of MLN0128 in metastatic anaplastic thyroid cancer cases.
1598905|NCT02244450|Biological|SCID screening|
1598906|NCT02244437|Drug|Ibuprofen|
1598907|NCT02244437|Drug|Acetaminophen|
2009475|NCT03244189|Behavioral|Financial incentive|Participants in the Intervention Arm who meet their fluid intake goal on randomly selected days will receive a small payment for that day.
1598909|NCT02244411|Behavioral|individual diet & physical activity counselor and website through Healthways at Hopkins|Phone and web-based weight loss intervention (via Healthways at Hopkins counselor and website) focused on increasing physical activity and adhering to a healthy diet. Participants will log diet, physical activity, and weight in web-hub. Counselors will have access to this information to direct participants to goals and achievements.
1598910|NCT02244411|Behavioral|self directed weight loss|Participants will be given information and links to CDC and American Cancer Society recommendations for healthy eating and physical activity.
1598911|NCT02244411|Behavioral|questionnaires|Participants will complete behavioral questionnaires as well as diet and physical activity assessments through CCSS-based study website as baseline, 12 and 24 months.
1598912|NCT02244411|Other|fasting blood draw, measurement of height, weight and waist circumference, and blood pressure|During three time periods, at baseline and at 12 and 24 months.
1598913|NCT02244398|Other|FP and HTC services|In this project, VHTs already providing family planning services are trained to offer HIV testing and counseling services (HTC).
1598914|NCT02244398|Other|FP services|VHTs in the control arm only provide family planning services
1598915|NCT02244385|Other|no intervention|
1598916|NCT02244372|Dietary Supplement|Cordyceps sinensis mycelium culture extract 0.76 g|
1598917|NCT02244372|Dietary Supplement|Cordyceps sinensis mycelium culture extract 1.15 g|
1598918|NCT02244372|Dietary Supplement|Placebo|
1598919|NCT02244359|Behavioral|Training|
1598920|NCT02244359|Behavioral|Usual care|
1598921|NCT02244346|Drug|Secotex®|
1598922|NCT02244333|Drug|ALNA®|
1598923|NCT02244320|Drug|Tamsulosin|
1598924|NCT02244307|Drug|alpha-adrenergic blocker|
1598925|NCT02244294|Drug|FLOMAX® capsules|
1598926|NCT02244294|Drug|Placebo capsules|
1598927|NCT02244281|Drug|tamsulosin hydrochloride|
1598928|NCT02244281|Drug|Placebo|
1598932|NCT02244242|Drug|Tamsulosin hydrochloride|
1598933|NCT02244229|Drug|Tamsulosin|
1598934|NCT02244229|Drug|Finasteride|
1598935|NCT02244229|Drug|Placebo|
1598936|NCT02244216|Drug|Berotec® N 100 µg Metered-dose Inhaler|
1598937|NCT02244203|Drug|BI 60732|
1598938|NCT02244203|Drug|Placebo|
1598939|NCT02244190|Drug|Tipranavir|New oral solution (back up) formulation
1598940|NCT02244190|Drug|Tipranavir|
1598941|NCT02244190|Drug|Ritonavir|
1598942|NCT02244164|Drug|Incretinomimetics|
1598943|NCT02244164|Drug|DPP-4 inhibitors|
1598944|NCT02244151|Drug|Decapeptyl® diario|Decapeptyl® daily administration (Triptorelin acetate) and follicular puncture at 24, 30, 36 or 40 after administration.
1598945|NCT02244151|Drug|Decapeptyl® daily|Decapeptyl® daily OPU 36 hrs after GnRH administration
1598946|NCT02244138|Behavioral|Adolescent CDSS|computer decision support system (CDSS) for health care providers of adolescents in primary care
1598947|NCT02244125|Drug|PCD|"STUDY TREATMENT PHASE: All patients
4x 28 days cycles of PCD
[Pomalidomide: 4mg/day oral route on 21 days per cycle]
[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]
[Dexamethasone: 40mg/day oral route on days 1, 2, 3, 4 and 15, 16, 17, 18 per cycle]
CONSOLIDATION PHASE: depends on previous IFM/DFCI 2009's arm:
Arm A:
Melphalan 200mg/m2 followed by Autologous Transplantation
2x 28 days cycles of PCD, three months post transplantation
Arm B:
5x 28 days cycles of PCD
[Pomalidomide: 4mg/day oral route on 21 days per cycle]
[Cyclophosphamide: 300mg/day oral route on days 1, 8, 15, 22 per cycle]
[Dexamethasone: 40mg/day oral route on days 1, 8, 15, 22 per cycle]
MAINTENANCE PHASE: All patients
- Until progression/relapse or discontinuation for any other reason
[Pomalidomide: 4mg/day oral route on 21 days per cycle]
[Dexamethasone: 20mg/day oral route on days 1, 8, 15, 22 per cycle]"
1598948|NCT02244125|Procedure|Autologous transplantation (ASCT)|"Arm A:
•Melphalan 200mg/m2 followed by Autologous Transplantation"
2009476|NCT03244189|Behavioral|Structured Problem Solving|Structure Problem Solving involves interactions with health coaches to help participants develop feasible solutions to overcoming personal barriers to maintaining the prescribed fluid intake.
2009477|NCT03242525|Diagnostic Test|POCT and central laboratory blood analysis|In every participant blood analysis will be performed by POCT and central laboratory investigating the time advantage.
1598951|NCT02244099|Other|Controlled Substance|Patients will be identified using the reporting workbench in the EMR if they have been prescribed a controlled substance, carisoprodol, or tramadol at least 3 times in the last 6 months by one of the consenting resident physicians from Martha Morehouse General Internal Medicine Resident Continuity Clinic. Once identified, a comprehensive chart review for other important parameters based on best practice recommendations as described in the research protocol will be conducted in order to characterize the patient population for which the recommendations are being made to the physicians. Improvement in controlled substance, carisoprodol, and tramadol prescribing and adherence to the CSTA by the resident physicians will be tracked using a pre/post intervention comparison.
1598952|NCT02244086|Drug|bupivacaine|At the beginning of the work of effective labor maneuver randomly be allocated ( using sealed envelopes) and an outsider to the study prepared the dosage to bupivacaine 0.125% or 0.25% to be administered by epidural catheter for an anesthesiologist to disown the concentration employed. It is measured vital signs, and visual analogue scale dilatation in minutes 0,15,30,60 and 90 after being applied analgesia.
1598953|NCT02244073|Drug|Human insulin - Insulin administration to control blood glucose level.|On ICU admission, the glycated hemoglobin level (A1c) is measured and insulin IV is possibly administered using a web based nurse driven insulin infusion protocol (https://extranet.chu-lyon.fr/cpg) to maintain blood glucose level below 10 mmol/l. Glycated hemoglobin result triggers patient randomization. Thereafter, during ICU stay, blood glucose level is maintained either below 1.59 × A1c - 1.59 (mmol/l) (Individualized blood glucose target group), or bellow 10 mmol/l (Conventional blood glucose target group).
1598954|NCT02244060|Other|Priming effect from vignette|In the arm of DCV, the self-assessed vision (PSAV) is listed after the vignette questions; however, in the arm of ICV, the self-assessment of vision (SAV) is listed before the vignette questions. Priming effect from vignette will be estimated by comparing those two randomized variables (i.e., SAV and PSAV).
1598957|NCT02244021|Drug|BRENTUXIMAB VEDOTIN|"Patients with FDG-PET positive after IGEV will be treated with brentuximab vedotin as followed: 1.8 mg/kg every 3 weeks as a 30-minute outpatient IV infusion for a total of 4 cycles of treatment
Growth factors may be used at the discretion of investigators but are not routinely advised.
Patients with FDG-PET negative after brentuximab vedotin treatment will be addressed to high dose chemotherapy followed by ASCT."
1598958|NCT02244008|Other|joint mobilization|The experimental group received joint mobilization (anteroposterior mobilization of the talus - Maitland grade III). During the mobilization cyclic movements were applied in an anteroposterior direction from the first tissue resistance barrier until the end of the accessory range of motion without any pain or discomfort. This mobilization maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
1598959|NCT02244008|Other|manual contact|The placebo group received only manual contact. This maneuver was performed in 30-second duration sets with a 30-second interval between each set. The interventions lasted two weeks with three sessions each, completing six sessions.
1598960|NCT02243995|Other|Physical training|
1598961|NCT02243995|Behavioral|Physical training|
1598962|NCT02243982|Other|[F18]-FDDNP|radiopharmaceutical tracer, intravenous, single dose, of 360+/- 20 megabecquerel
1598963|NCT02243969|Dietary Supplement|Flaxseed oil|The flaxseed oil will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
1598964|NCT02243969|Dietary Supplement|high oleic sunflower oil (HOSF)|The HOSF will be provided in vials containing 5 g of oil, and should be taken for twelve weeks during the experimental period twice a day
1598965|NCT02243956|Other|Flavanol rich food product|polyphenol rich test product
1598966|NCT02243943|Drug|Sugammadex|
1598967|NCT02243943|Drug|Neostigmine|
1598968|NCT02243930|Device|Disposable distal attachment|
1598969|NCT02243917|Drug|CB-5083|
1598970|NCT02243891|Procedure|Atrial fibrillation ablation|Percutaneous catheter ablation for Atrial fibrillation.
1599022|NCT02243553|Drug|Digoxin injection|
1598971|NCT02243891|Procedure|ROX Coupler insertion|The ROX Coupler is a CE-marked device designed to maintain an iliac arteriovenous fistula
1598972|NCT02243878|Radiation|Stereotactic radiotherapy (16 Gray or Sham)|Participants will be allocated in a 2:1 ratio to either 16 Gray SRT (IRay, Oraya, Newark,USA) delivered in a single session, or sham SRT.
1598973|NCT02243878|Drug|0.5 mg ranibizumab|Both arms will receive intravitreal injections of 0.5 mg ranibizumab at baseline, and then administered 'as required' (PRN) up to monthly, if predefined retreatment criteria are met.
2009478|NCT03242174|Other|Health Behavior Questionnaire Packet|Any pregnant woman offered the questionnaire at her prenatal appointment in the third trimester can complete
2009479|NCT03242668|Procedure|VATS|General anesthesia was induced with 2.0 mg/kg of propofol, 2.0 mg/kg of fentanyl, and 1.0 mg kg/1 of rocuronium and maintained with continuous infusion 6-12mg/kg/h of propofol,injected 2.0 mg/kg of fentanyl and 0.15 mg/ kg of rocuronium every 30 minutes . All patients were intubated with a double-lumen endobronchial tube for one-lung ventilation.The VATS (Video-Assisted Thoracic Surgery) was performed.
1598976|NCT02243852|Drug|Growth Hormone Replacement Therapy|An observational study of patients who are commencing GH replacement as part of their routine NHS clinical care to assess changes in serum FGF21 concentration and determine how these relate to changes in body composition.
1598977|NCT02243839|Drug|Thrombolytic Therapy|Thrombolytic therapy is performed to the patients with obstructive prosthetic valve thrombosis
1598978|NCT02243839|Procedure|Surgery|Redo valve surgery is performed for obstructive valve thrombosis
1598979|NCT02243826|Drug|50:50 mixture of nitrous oxide/oxygen|
1598981|NCT02243800|Other|cholecalciferol versus placebo|
1598982|NCT02243787|Drug|COVA322|
1598983|NCT02243787|Other|Placebo|
1598984|NCT02243774|Behavioral|Core letter signed by Surgeon General|The core letter provides information about influenza and the risks associated with it, incorporating a number of behavioral insights. All four letters evaluated in this study will contain the same tops and bodies that are included in the core letter, but the signature and P.S. tag region will differ among the various intervention groups. In this intervention, the core letter is signed by and includes a picture of the Surgeon General. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
1598985|NCT02243774|Behavioral|Core letter signed by the Director of the National Vaccine Program|The core letter is signed by and includes a picture of the Director of the National Vaccine Program. The letter ends after the signature line and the space beneath the signature line is left blank where a P.S. tag region could be appended.
1598986|NCT02243774|Behavioral|Core letter signed by Surgeon General + implementation prompt|The core letter is signed by and includes a picture of the Surgeon General. Below the signature line of the core letter, an implementation intention prompt is provided in the P.S. tag region that invites the recipient to write in the day of week, month, day, and time at which he or she plans to get vaccinated.
1598987|NCT02243774|Behavioral|Core letter signed by SG + enhanced implementation prompt|"The core letter is signed by and includes a picture of the Surgeon General (SG). Below the signature line of the core letter, an enhanced implementation intention prompt is provided in the P.S. tag region that prompts recipients to decide now - by checking one of two boxes - indicating they will or will not get vaccinated. The options use language that highlights the losses incumbent in refusing to vaccinate. In addition, an implementation intention prompt is embedded into the checkbox for indicating a choice to be vaccinated."
1598988|NCT02243761|Other|DBT Based Skills Groups for Families|12 weeks of Dialectical Behaviour Therapy skills training group for families (90-minute once-weekly sessions)
1598992|NCT02243735|Drug|Ferrous fumarate|Patients randomized to standard care with ferrous fumarate will receive three tablets of 200 mg daily from randomisation until day before surgery
1598993|NCT02243735|Drug|ferric(III)carboxymaltose|Patients randomized to intravenous iron (ferric(III)carboxymaltose) will be dosed according to Summary of Product Characteristics (SPC) depending on body weight and Hb value and administered in one or two infusions with one week in between. A maximum dose of 1000mg or 15mg/kg per week will be administered
1598994|NCT02243709|Drug|Mifepristone 600-mg/day or placebo for a week|600-mg of mifepristone for a week, compared to placebo for a week, in a stress-induced condition triggered by a single dose of 32.4 mg of yohimbine
1598995|NCT02243683|Drug|AX-024.HCl|
1598996|NCT02243683|Other|Placebo|
1598997|NCT02243670|Device|AiCure monitoring and intervention|Participants will use the AiCure app to monitor ingestion of all prescribed doses of Zubsolv®. If a participant misses a dose, takes an incorrect dose, or their data are flagged for suspicious activity, they will be contacted by research staff or the AiCure study team through automated SMS text or by phone.
1598998|NCT02243657|Drug|ASP3652|oral
1598999|NCT02243657|Drug|Placebo|oral
1599000|NCT02243644|Drug|7 days of albendazole 15 mg/kg/day|group A will receive 7 days of oral albendazole 15 mg/kg/day
1599001|NCT02243644|Drug|28 days of albendazole 15 mg/kg/day|group B will receive 28 days of oral albendazole 15 mg/kg/day
1599002|NCT02243631|Drug|Probenecid|Treatment
1599003|NCT02243618|Drug|Polaprezinc|Administration of pantoprazole 40 mg q.d. and polaprezinc 75 mg b.i.d. for 4 weeks after the ESD.
1599004|NCT02243618|Drug|Rebamipide|Administration of pantoprazole 40 mg q.d. and rebamipide 100 mg t.i.d. for 4 weeks after the ESD.
1599005|NCT02243605|Drug|Cabozantinib S-malate|Given PO
1599006|NCT02243605|Other|Laboratory Biomarker Analysis|Correlative studies
1599008|NCT02243579|Other|Laboratory Biomarker Analysis|Correlative studies
1599009|NCT02243579|Biological|Pembrolizumab|Given IV
1599010|NCT02243566|Drug|MicardisPlus®|
1599011|NCT02243553|Drug|Tipranavir capsule|
1599012|NCT02243553|Drug|Tipranavir solution|
1599013|NCT02243553|Drug|Ritonavir capsule|
1599014|NCT02243553|Drug|Caffeine|
1599015|NCT02243553|Drug|Warfarin sodium|
1599016|NCT02243553|Drug|Vitamin K|
1599017|NCT02243553|Drug|Omeprazole|
1599018|NCT02243553|Drug|Dextromethorphan hydrobromide|
1599019|NCT02243553|Drug|Midazolam injection|
1599020|NCT02243553|Drug|Midazolam oral solution|
1599023|NCT02243527|Other|Inspiratory Muscle Training|6-weeks of inspiratory muscle training
1599024|NCT02243527|Other|Sham Inspiratory Muscle Training|A sham training procedure that is meant to elicit no physiologic changes
1599025|NCT02243501|Behavioral|Intervention Group|The BNBD intervention for caregivers of children 1 to 10 years with insomnia is a self-guided program delivered online. The intervention is conceptually consistent across age groups. Interactive and personalized content and evidence-based strategies are incorporated: sleep education, positive routines, faded bedtime with response cost, sleep restriction, extinction/graduated extinction, stimulus fading, and scheduled awakenings. BNBD includes five sessions available sequentially: Sleep Information; Healthy Sleep Practices; Settling to Sleep; Going Back to Sleep; Looking Back and Ahead. The completion time of the intervention will range from 5-10 weeks.
1599026|NCT02243488|Device|Irise Easy Pad & Menstrual Health Education|Reusable manufactured sanitary pad produced by Irise Uganda Limited and education sessions provided by qualified menstrual health educators
1599027|NCT02243462|Device|Forced Air Warmer|"A forced air warmer device will be used to pre-warm patients for 10 minutes in holding bay before surgery. Air warming device is an electrically powered control unit, hose, and inflatable blanket. The control unit has an air filter and heater, which warms air entrained from the environment. The hose connects to a blanket."
1599028|NCT02243462|Other|No pre-op warming|No forced air warming of the patient prior to being taken in for surgery
2009480|NCT03242668|Procedure|PVB using PVC|At the end of the surgery, the upper edge of the spinous process of the thoracic vertebral body was recognized. With an epidural needle (Tuohy 22 G; Braun, Melsungen, Germany), the injection point was punctured 2 cm lateral to the midline. The paravertebral space was entered by advancing the Tuohy needle over the superior border of the transverse process. Once in the right place, the PVC was placed through the needle, checking the tip remained placed when removing the needle. The advance of the needle and the entering of the catheter into the paravertebral space were verified all the time by the surgeon using the camera. The PVC (Paravertebral Catheter ) was inserted at this point preversed at this area.
2009481|NCT03242668|Drug|PCA|PVC was inserted.Initiated dose of 0.3ml/kg of Bupivacaine Hydrochloride 1.25mg/ml and Fentanyl Citrate 2 micrograms/ml was administered then continued PCA (Perfusor space pump,Germany)with background rate 3ml/h, bolus dose 2ml was infused through PVC.
1599031|NCT02243436|Drug|Brentuximab Vedotin|Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
1599032|NCT02243436|Drug|Etoposide|Intravenose use, 40mg/m2/day, on days 1 to 4
1599033|NCT02243436|Drug|Soludomerin|Intravenous use, 250mg/day, on days 1 to 4
1599034|NCT02243436|Drug|Cisplatin|Intravenous use, 25mg/m2/day, on days 1 to 4
1599035|NCT02243436|Drug|Ara C|Intravenous use, 2g/m2, day 5
1599036|NCT02243423|Procedure|SUPINE|"Patients in the SUPINE group will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay supine horizontal on the surgical table.
A phenylephrine intravenous infusion will be titrated according to a set protocol, to maintain the systolic blood pressure at baseline."
1599037|NCT02243423|Procedure|TILT|"Patients will receive spinal anesthesia for cesarean section in the sitting position, after which they will lay on the surgical table, which will be tilted to the left by 15°.
A phenylephrine intravenous infusion will be titrated according to a set protocol to maintain the systolic blood pressure at baseline."
1599038|NCT02243384|Procedure|Laparoscopic Hepatectomy|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
1599039|NCT02243384|Procedure|Radiofrequency Ablation|A total of 110 patients with early HCC with nodular diameters of less than 3 cm and up to three nodules were randomly divided into LH (n=55) and RFA groups (n=55). Outcomes were carefully monitored and evaluated during the 3-year follow-up period
1599040|NCT02243371|Biological|CRS-207|1 × 10^9 CFU administered IV on Day 2 of Cycles 3-6 (Arm A) or Day 1 of Cycles 3-6 (Arm B)
1599041|NCT02243371|Biological|GVAX|5x10^8 cells administered in 6 intradermal injections on Day 2 of Cycles 1 and 2 (Arm A and B)
1599042|NCT02243371|Drug|nivolumab|3 mg/kg administered IV on Day 1 of Cycles 1-6 (Arm A only)
1599043|NCT02243371|Drug|CY|200 mg/m^2 administered IV on Day 1 of Cycles 1 and 2 (Arm A and B)
1599044|NCT02243358|Drug|Folfox6|
1599045|NCT02243358|Drug|Gemcitabine|
1599046|NCT02243358|Radiation|Radiation Therapy|
1599047|NCT02243358|Procedure|Pancreaticoduodenectomy with retroperitoneal lymphadenectomy|
1599048|NCT02243332|Device|KneeStim mobile rehabilitation assistance device|KneeStim is a neuromuscular electrical stimulation (NMES) device that integrates motion-tracking hardware like three-axis accelerometers and a real-time operating system to enable quadriceps muscle stimulation in time with user gait. It is a completely non-invasive device that looks like a light brace and fastens to the user's quadriceps and gastrocnemius muscles. The end goal of this device is to assist with muscle re-strengthening and re-education during a user's everyday activities.
1599049|NCT02243319|Drug|HGP1201|
1599050|NCT02243319|Drug|HGP0904|
1599051|NCT02243319|Drug|HGP0904 and HGP1201 co-administraion|
2009482|NCT03241641|Drug|Tenofovir Alafenamide|25mg, Daily Oral
1599053|NCT02243293|Drug|ABT-493|Tablet
1599054|NCT02243293|Drug|ABT-530|Tablet
1599055|NCT02243293|Drug|ribavirin (RBV)|Tablet
1599056|NCT02243293|Drug|ABT-493/ABT-530|Tablet; ABT-493 co-formulated ABT-530
1599057|NCT02243280|Drug|ABT-493|Tablet
1599058|NCT02243280|Drug|ABT-530|Tablet
1599059|NCT02243267|Other|sample collection|
1599060|NCT02243254|Drug|high dose remifentanil|high dose remifentanil
2009483|NCT03241641|Drug|Tenofovir Disoproxil Fumarate|300mg, Daily Oral
2009484|NCT03240523|Drug|Vilaprisan (BAY1002670)|Orally, 2 mg, once daily
2009485|NCT03240523|Other|Matching placebo to ulipristal|Orally, Dose not applicable, once daily
2009486|NCT03240523|Other|Matching placebo to vilaprisan|Orally, Dose not applicable, once daily
2009487|NCT03240523|Drug|Ulipristal (Esmya)|Orally, 5 mg, once daily
2009488|NCT03239483|Drug|Dapivirine gel|Dapivirine gel (0.05%); administered rectally
2009489|NCT03239483|Drug|Placebo gel|Universal HEC placebo gel; administered rectally
1599061|NCT02243254|Drug|Ibuprofen|intravenous ibuprofen
1599062|NCT02243254|Drug|low dose remifentanil|low dose remifentanil
1599063|NCT02243241|Drug|HYD|Hydrocodone bitartrate 80 mg (day 9), 120 mg (day 12), 160 mg [(1) 40 mg tablet + (1) 120 mg tablet] (day 15) extended-release tablets administered orally every 24 hours.
1599064|NCT02243241|Drug|Moxifloxacin|Moxifloxacin 400 mg tablets administered orally on the morning of day 9, day 12, and day 15 only.
1599065|NCT02243241|Drug|Placebo for HYD|Placebo to match HYD tablets administered orally every 24 hours.
1599066|NCT02243241|Drug|Placebo for moxifloxacin|Placebo to match moxifloxacin tablets administered orally on the mornings of day 9, day 12, and day 15 only.
1599067|NCT02243228|Drug|GM-CSF|
2009490|NCT03240107|Procedure|levator resection|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.
The aponeurosis was measured for the desired amount of resection and fixed to the exposed tarsal border with three point mattress sutures with 6-0 prolene then amount measured resect.
The skin incision closed by continuous suture with 6-0 prolene."
1599069|NCT02243202|Drug|Canagliflozin|300 mg capsule, taken once daily, orally for 26 weeks.
1599070|NCT02243202|Drug|Phentermine|15 mg capsule, taken once daily, orally for 26 weeks.
1599071|NCT02243202|Drug|Matching Placebo to Canagliflozin|Placebo capsules look like canagliflozin but do not contain any active drug, taken once daily, orally for 26 weeks.
1599072|NCT02243202|Drug|Matching Placebo to Phentermine|Placebo capsules look like phentermine but do not contain any active drug, taken once daily, orally for 26 weeks.
1599073|NCT02243189|Drug|JNJ-43260295|A single nasal dose of JNJ-43260295, 6400 microgram, will be given.
1599074|NCT02243189|Drug|Placebo|A single nasal dose of placebo matching to JNJ-43260295 will be given.
1599075|NCT02243189|Drug|Nasal Allergen Challenge|Participants will be challenged by the nasal route with an appropriate allergen based on skin test reactivity.
1599076|NCT02243176|Drug|Saxagliptin|The dose of saxaglitpin will be 5mg oral qd.
1599077|NCT02243176|Drug|Acarbose|Patients who take acarbose will begin with 50mg tid for 7 days then be titrated to 100mg tid till the end of the study. A call visit (V5) will be performed at Week 1 for adverse event and reminding patients the dose titration of acrabose.
1599078|NCT02243163|Behavioral|Yoga exercise|Subjects will receive regular 90-minutes yoga classes twice a week for 3 months.
1599079|NCT02243150|Drug|G1T28-1 (CDK 4/6 Inhibitor)|
1599080|NCT02243150|Drug|Placebo|
1599081|NCT02243137|Drug|acetylsalicylic acid|Administration: one dose of Acetylsalicylic Acid (300mg)
1599082|NCT02243137|Drug|prasugrel|Administration: one loading dose (60mg)
1599083|NCT02243137|Drug|lysine acetylsalicylate|Administration: one dose (450mg iv)
1599084|NCT02243124|Drug|cenersen|cenersen is a phosphorothioate antisense oligonucleotide that down-regulates the production of both wild-type and mutant p53, and has a RNase H-dependent mechanism of action
1599085|NCT02243124|Drug|Dexamethasone|Optionally, Dexamethasone 20 mg po weekly can be added after week 16 if stable disease but no HI is observed.
1599086|NCT02243111|Radiation|Doppler ultrasound|Detecting Doppler signals from the lungs on the right chest wall
1599087|NCT02243098|Drug|semaglutide|Administered as a subcutaneous injection (s.c., under the skin). Initiated with weekly semaglutide dosing of 0.25 mg in the first 4 weeks, 0.5 mg the next 4 weeks, and 1.0 mg in the third 4 week period.
1599088|NCT02243098|Drug|digoxin|Oral administration. Digoxin will be given as 2 single doses of 0.5 mg.
1599089|NCT02243098|Drug|atorvastatin|Oral administration. Atorvastatin will be given as 2 single doses of 40 mg.
1599090|NCT02243072|Behavioral|Fit Families plus Standard Medical Care|Adolescents will receive the Fit Families plus Standard Medical Care which consists of twice weekly home-based, family psychotherapy from a CHW for 6 months
1599091|NCT02243059|Drug|Gadofosveset trisodium (Ablavar™ )|
1599092|NCT02243059|Device|MRI|
1599093|NCT02243046|Drug|Control toothpaste|1450 ppm fluoride toothpaste control - Subjects will brush their whole mouth with the control toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
1599094|NCT02243046|Drug|Experimental toothpaste|1450 ppm sodium fluoride/zinc base toothpaste - Subjects will brush their whole mouth with a fluoride/zinc toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
1599095|NCT02243046|Drug|Active Comparator|1450 ppm sodium fluoride/triclosan toothpaste - Subjects will brush their whole mouth with this toothpaste 2 times/day for 1 minute each time and rinse with water after brushing. This daily brushing routine will continue for the six (6) month study.
1599096|NCT02243033|Device|MR-guided laser focal therapy|Placement of laser applicator under MRI guidance and real-time MR thermal imaging of tissue necrosis.
1599097|NCT02243020|Device|Vagus Nerve Stimulation (VNS)|
1599098|NCT02243007|Drug|FOLFIRINOX|
1599099|NCT02243007|Drug|Gemcitabine/nab-Paclitaxel|
1599100|NCT02243007|Radiation|Radiation therapy|
1599101|NCT02243007|Drug|Capecitabine|
1599102|NCT02242994|Device|Dynavox Maestro|Receives commercially available communication device Dynavox Maestro to test speed and quality of communication.
1599103|NCT02242994|Device|Experimental App|Participant receives experimental app to test speed and error rate of communication.
1599104|NCT02242981|Drug|LY2623091|Administered orally
1599105|NCT02242955|Drug|Diazepam|40 mg per day.
2009491|NCT03240107|Procedure|levator tucking|"The levator aponeurosis was dissected from the upper border of the tarsal plate and conjunctiva.
. The aponeurosis was measured for desired amount of tucking The skin incision closed by continuous suture with 7-0 prolene."
2009492|NCT03239899|Drug|Pembrolizumab|Participants will receive one dose of 2mg/kg of pembrolizumab IV at baseline.
2009493|NCT03236844|Drug|Gantenerumab|Gantenerumab HCLF manufactured by either G3 or G4 process will be administered on Day 1 (in the abdomen).
1599109|NCT02242929|Drug|Imiquimod 5% cream with prior curettage|
1599110|NCT02242929|Procedure|Standard surgical excision|
1599111|NCT02242916|Radiation|Photon therapy versus proton therapy|
2009494|NCT03236246|Drug|KRX-0502|Oral ferric citrate with meals
1599112|NCT02242916|Radiation|Photon therapy versus C-ion therapy|
1599113|NCT02242903|Drug|LY3079514|Administered SC
1599114|NCT02242903|Drug|LY3079514|Administered IV
1599115|NCT02242903|Drug|Placebo|Administered SC
1599116|NCT02242903|Drug|Placebo|Administered IV
1599117|NCT02242890|Behavioral|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths.
1599118|NCT02242877|Drug|Telmisartan|
1599119|NCT02242877|Drug|Telmisartan combined with hydrochlorothiazide|
1599120|NCT02242864|Drug|Micardis®|
1599121|NCT02242864|Drug|MicardisPlus®|
1599122|NCT02242851|Drug|Telmisartan|
1599123|NCT02242838|Drug|Telmisartan|
1599124|NCT02242825|Drug|Micardis®|
1599125|NCT02242825|Drug|MicardisPlus®|
1599126|NCT02242812|Drug|Telmisartan|
1599127|NCT02242812|Drug|Metoprolol succinate|
1599128|NCT02242812|Drug|Placebo|
1599129|NCT02242799|Drug|Dolutegravir 50mg od|Dolutegravir 50mg once daily will be given either alone or in combination, as specified
1599130|NCT02242799|Drug|Artemether-lumefantrine combination|Artemether-lumefantrine combination will be given both alone and in combination with Dolutegravir 50mg od in order to assess changes in PK
1599131|NCT02242799|Drug|Artesunate-amodiaquine|Artesunate-amodiaquine will be given alone or in combination with Dolutegravir 50mg od (in a parallel study design) in order to assess the potential interaction causing changes in PK parameters
1599132|NCT02242786|Radiation|External beam radiation therapy|
1599133|NCT02242773|Device|Multi-Parametric MRI|Multi-Parametric MRI
1599134|NCT02242773|Device|MRI-Guided Biopsy|MRI-Guided Biopsy
1599135|NCT02242773|Behavioral|Expanded Prostate Cancer Index Composite SF12 Questionnaire|Quality of Life Questionnaire administered to subjects at intervals defined by study protocol.
1599136|NCT02242773|Behavioral|Memory Anxiety Scale for Prostate Cancer patients|Quality of Life Questionnaire administered to subjects at intervals defined by study protocol.
1599137|NCT02242773|Behavioral|Food Frequency Questionnaire|Quality of Life Questionnaire administered at baseline
1599138|NCT02242760|Drug|SB204 2%|
1599139|NCT02242760|Drug|SB204 4%|
1599140|NCT02242760|Drug|Vehicle Gel|
1599141|NCT02242747|Drug|ingenol mebutate|an application a day for three consecutive days in a pre-determined area
1599142|NCT02242747|Drug|5% 5-FU|two applications a day for four weeks in a pre-determined area
1599143|NCT02242734|Drug|20 mg HC-ER|1-72 hours
1599144|NCT02242734|Drug|20 mg HC-ER|1-72 hours
1599145|NCT02242734|Drug|20 mg HC-ER|1-72 hours
1599146|NCT02242708|Behavioral|Alternative nostril breathing|The experimental groups will do alternative nostril breathing twice a week (20 minutes/time) for 3 months.
1599147|NCT02242695|Drug|Fluomizin vaginal tablets|One vaginal tablet for 6 days and 1 placebo tablet on day 7
1599148|NCT02242695|Drug|Canesten vaginal tablets|one vaginal tablet for 7 days
1599149|NCT02242682|Other|Child passenger safety video|
1599150|NCT02242656|Drug|Opium Tincture USP Deodorized|Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
1599151|NCT02242656|Drug|Opium Tincture USP Deodorized|Treatment B - 0.6 mL, MP-101, 1/12 dilution, (0.833 mg/mL, OT), USP (Deodorized) QID oral drops, followed by Treatment A - 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized) QID oral drops, followed by Treatment C - 0.6 mL, MP-101 (10 mg/mL Opium Tincture with reduced uncharacterized material) QID oral drops
1599152|NCT02242643|Biological|FluLaval™ Quadrivalent|1 or 2 doses administered intramusculary (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
1599153|NCT02242643|Biological|Fluzone® Quadrivalent|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively
1599154|NCT02242630|Drug|Methylprednisolone, 20 mg|Compared with intrabursal triamcinolone
1599155|NCT02242630|Drug|Methylprednisolone, 40 mg|Compared with intrabursal triamcinolone
1599156|NCT02242630|Drug|Triamcinolone, 20 mg|Compared with methylprednisolone
1599157|NCT02242630|Drug|Triamcinolone, 40 mg|Compared with methylprednisolone
1599158|NCT02242617|Device|Positive Airway Pressure (PAP)|Continuous or auto-adjusting positive airway pressure (i.e. CPAP, APAP, and described here as PAP): a device which consists of a face mask attached to a plastic tube and a machine that blows compressed air through a patient's airway during sleep to keep the airway open
1599159|NCT02242617|Device|Mandibular Advancement Splints (MAS)|Mandibular advancement splints (MAS): dental splints used to keep the mandible in an advanced position opening the upper airway during sleep
1599160|NCT02242604|Other|Multidimensional Geriatric Assessment (MGA)|"The MGA contains the following tests:
Barthel Katz Index (activity of daily living, ADL)
Mini Mental State Test (MMST)
DemTec (dementia detection test)
Clock Test
Geriatric Depression Scale (GDS)
Tinetti Test
TUG (timed up-and-go Test)
Esslinger Transfer Scale (ETS)
Handgrip Test
Mini Nutritional Assessment (MNA)"
1599161|NCT02242591|Drug|Ropivacaine 7,5 mg/ml|
1599162|NCT02242591|Drug|Saline|
2009495|NCT03235375|Drug|MEDI0382|MEDI0382 administered subcutaneously
2009496|NCT03235362|Drug|YHR1705|Subjects will receive multiple oral doses of YHR1705 QD for 5 consecutive days in each period.
1599165|NCT02242565|Device|ShangRing|ShangRing device for male circumcision
1599166|NCT02242539|Behavioral|Height measurement poster|Each household is provided with a poster which study personnel help to hang on the wall. The poster clearly indicates height-for-age benchmarks and stunting cut-offs for study-age children. Parents are provided training on how to measure their children at regular intervals, and interpret height readings to determine whether their child is developing normally or is stunted.
1599167|NCT02242539|Behavioral|Community-based monitoring|"Once every three months, villages are visited by study staff who measure children's heights and weights, and parents are informed if their children are below the reference measures established by the World Health Organization. If a child's weight is such that the child is classified as severely malnourished, the child is referred to the nearest health center for treatment. If the child is stunted (height-for-age z-score more than 2 standard deviations below the reference median), we provide parents with a supply of Yummy Soy powder, a fortified soy and maize mix popular among parents and widely available in local super markets. Parents are instructed to give one or two tea spoons of the mix to the child each day."
1599168|NCT02242526|Device|Parietex™ Composite Hiatal Mesh, North Haven, CT|Parietex™ Composite Hiatal Mesh (North Haven, CT) designed for hiatal hernia repair.
1599169|NCT02242526|Device|Biodesign™ Surgisis® Graft, Cook Medical, Bloomington|Biodesign™ Surgisis® Graft (Cook Medical, Bloomington) designed for hiatal hernia repair.
1599170|NCT02242513|Device|Pulsed radiofrequency (PRF)|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury.
1599171|NCT02242513|Drug|Xylocaine|
1599172|NCT02242500|Procedure|Coronally Advanced Flap|
1599173|NCT02242500|Device|Mucograft|
1599174|NCT02242487|Drug|CVT-301|
1599175|NCT02242474|Drug|Anti-TNF suspended perioperatively|
1599176|NCT02242474|Drug|Anti-TNFα continued perioperatively|
1599177|NCT02242461|Drug|Rhodiola placebo capsules|Corn starch
1599178|NCT02242461|Drug|Rhodiola Crenulata|Rhodiola Crenulata
1599179|NCT02242435|Biological|Ampion <5 kDa ultrafiltrate of 5% human serum albumin|4 mL intra-articular injection of Ampion
1599180|NCT02242409|Drug|Gemcitabine and Abraxane|Gemcitabine 1000 mg/m2 followed by abraxane 125 mg/m2 administered intravenously on days 1, 8, and 15 every 28 days
1599181|NCT02242396|Drug|Telmisartan|
1599182|NCT02242396|Drug|Telmisartan hydrochlorothiazide|
1599183|NCT02242383|Drug|Telmisartan|
1599184|NCT02242383|Drug|Telmisartan in combination with hydrochlorothiazide|
1599185|NCT02242370|Drug|Low dose of telmisartan|
1599186|NCT02242370|Drug|High dose of telmisartan|
1599187|NCT02242357|Drug|Micardis®|
1599188|NCT02242357|Drug|Micardis® Plus|
1599189|NCT02242344|Drug|Telmisartan|
1599190|NCT02242344|Drug|Placebo|
1599191|NCT02242331|Drug|Micardis®|
1599192|NCT02242318|Drug|Telmisartan|
1599193|NCT02242318|Drug|Valsartan|
1599194|NCT02242318|Drug|Placebo|
1599195|NCT02242305|Drug|Hyoscine Butylbromide - Tablet|
1599196|NCT02242305|Drug|Hyoscine Butylbromide - Capsule|
1599197|NCT02242305|Drug|Placebo|
1599198|NCT02242292|Drug|Hyoscine butylbromide|
1599199|NCT02242292|Drug|Placebo|
1599200|NCT02242279|Drug|BEA 2180 BR|
1599201|NCT02242279|Drug|Tiotropium|
1599202|NCT02242279|Drug|Placebo|
1599203|NCT02242266|Drug|Tiotropium low dose|inhalation powder, hard PE capsule
1599204|NCT02242266|Drug|Tiotropium medium dose|inhalation powder, hard PE capsule
1599205|NCT02242266|Drug|Spiriva® HandiHaler® high dose|Tiotropium inhalation powder, hard gelatine capsule
1599206|NCT02242266|Drug|Placebo via the blue HandiHaler®|oral inhalation via the blue HandiHaler®
1599207|NCT02242266|Drug|Placebo via the grey HandiHaler®|oral inhalation via the grey HandiHaler®
1599208|NCT02242253|Drug|Tiotropium|administered via HandiHaler®
1599209|NCT02242253|Drug|Salmeterol|administered via metered dose inhaler (MDI)
1599210|NCT02242253|Drug|Placebo-MDI|
1599211|NCT02242253|Drug|Placebo HandiHaler®|
1599212|NCT02242240|Drug|Formoterol twice daily|
1599213|NCT02242240|Drug|Formoterol once daily|
1599214|NCT02242240|Drug|Tiotropium once daily|
1599215|NCT02242240|Drug|Placebo|
1599216|NCT02242227|Drug|Salmeterol xinafoate|
1599217|NCT02242227|Drug|Serevent® Diskus®|
1599218|NCT02242227|Drug|Placebo (HandiHaler®)|
1599219|NCT02242227|Drug|Placebo (Diskus®)|
1599220|NCT02242214|Drug|Misoprostol|
1599221|NCT02242201|Drug|Posterior Lumbar Plexus Block with Bupivacaine|
1599222|NCT02242201|Drug|Intra articular injection with Ropivacaine|
1599223|NCT02242201|Drug|Intra articular injection with liposomal bupivacaine (Exparel)|
1599224|NCT02242188|Drug|Iron|"Ferric pyrophosphate (powder preparation in sachets: Actiferol, SunActive Fe, Sequoia, Poland) in a single daily dose. Three doses will be used: 7 mg for infants up to 7 kg of body weight, 10 mg for infants from 7 to 10 kg of body weight, and 15 mg for those exceeding the weight of 10 kg. Caregivers will be instructed to administer the daily dose at the same time of a day, after mixing the content of the sachet with a little amount of breastmilk or milk formula.
The intervention will last from 4 months to 9 months of age."
1599225|NCT02242188|Dietary Supplement|Placebo|Maltodextrin (packed in identical sachets as active products)
1599226|NCT02242175|Device|hydrogen breath test|Hydrogen breath test is the current gold standard for diagnosis of irritable bowel syndrome. Glucose is a sugar that will be broken down by bacteria if present in the small bowel with hydrogen or methane gas as a by-product. The breath sample will be analyzed for hydrogen or methane content to determine if you are able to properly break down the lactose, fructose or sucrose, or if you have bacterial overgrowth.
1599227|NCT02242162|Procedure|phrenic nerves magnetic stimulations|
1599228|NCT02242149|Drug|Diacerein|All subjects will be given diacerein with a starting dose of 50 mg in one tablet once daily for 2 weeks. After 2 weeks, they will be given diacerein 50 mg in one tablet twice daily for the duration of sudy.
1599229|NCT02242149|Drug|Placebo|Sugar pill manufactured to mimic Diacerein
1599230|NCT02242136|Behavioral|FORNET|
1599231|NCT02242110|Behavioral|ERRT-Bipolar Disorder|The nightmare treatment, called Exposure, Relaxation, and Rescripting Therapy for Bipolar disorder, is a weekly 5-session treatment aimed at reducing chronic trauma nightmares and sleep disturbances in adults diagnosed with bipolar disorder.
1599232|NCT02242097|Drug|ibrutinib|Given PO
1599233|NCT02242097|Other|laboratory biomarker analysis|Correlative studies
1599234|NCT02242084|Drug|Intravenuse Alteplase|
1599235|NCT02242071|Biological|Stem Cell|intrathecal autologous bone marrow mononuclear cell transplantation
1599236|NCT02242058|Other|Quantitative sensory testing|
2009497|NCT03235362|Drug|YHR1706|Subjects will receive multiple oral doses of YHR1706 QD for 5 consecutive days in each period.
2009498|NCT03235362|Drug|YHR1705+YHR1706|Subjects will receive multiple oral doses of YHR1705 + YHR1706 QD for 5 consecutive days in each period.
1599239|NCT02242032|Drug|P-321 Ophthalmic Solution|
1599240|NCT02242032|Drug|P-321 Ophthalmic Solution placebo|Placebo to match P-321 Ophthalmic Solution
1599241|NCT02242019|Device|Erchonia LUNULA|The Erchonia LUNULA is administered to the infected toes for 12 minutes per treatment for 4 treatments, each treatment one week apart.
1599242|NCT02242006|Other|serial serum sampling for quantification of drug concentration|
1599243|NCT02241980|Other|Patient survey|
1599244|NCT02241980|Other|Physician survey|
1599246|NCT02241954|Device|Synthes VEPTR (Vertical Expandable Prosthetic Titanium Rib)|
1599247|NCT02241941|Drug|Daptomycin|
1599248|NCT02241928|Biological|Stem Cell|Intrathecal Autologous bone marrow mononuclear cell transplantation
1599249|NCT02241915|Procedure|Open Colorectal Surgery|
1599250|NCT02241915|Procedure|Laparoscopic Surgery|
1599251|NCT02241889|Device|Insulin pump therapy|Subject's own insulin pump will be used to manage blood glucose.
1599252|NCT02241889|Device|Closed-loop Artificial Pancreas Controller|Closed-loop Artificial Pancreas Controller includes insulin and glucagon delivery algorithm implemented on a smart phone, utilizing sensor glucose values from a Dexcom G4 sensor and sending delivery commands to two Tandem t:slim insulin pumps, one filled with insulin and one with glucagon.
1599253|NCT02241876|Drug|N-acetylcysteine|
1599254|NCT02241863|Behavioral|Multifaceted intervention|Supportive intervention: care giver, health care providers, and patient's family members (including disease knowledge, treatment t of the disease, medication problems or adverse effects, the importance of medication adherence, supervision taking medications by the patients as prescribed). patient education: about the disease and treatment, consuming regularly the pills motivational intervening, self-monitoring planning. Patients will attend in five motivational interviewing sessions regularly to facilitating and engaging intrinsic motivation within the patients in order to change medication adherence behavior.
1599255|NCT02241863|Behavioral|Routine counseling|
1599256|NCT02241850|Other|High intensity training|9 weeks of supervised high intensity training
1599257|NCT02241824|Device|In-elastic lumbar brace|
1599258|NCT02241824|Device|Elastic abdominal binder|
1599259|NCT02241811|Drug|3% Sodium Pentaborate Pentahydrate|For the interventional group after wound dressing we applied hydrogel with 3% Sodium pentaborate pentahydrate everyday for two months. The same doctor observed and took photo of the wounds every week in the outpatients clinic.
1599260|NCT02241811|Drug|Placebo|Hydrogel without 3% Sodium Pentaborate Pentahydrate
1599261|NCT02241798|Other|oxygen|O2 by nasal prongs
1599262|NCT02241785|Drug|natalizumab|Administered as specified in the treatment arm
1599263|NCT02241772|Drug|TA-8995|
1599264|NCT02241772|Drug|Placebo|
1599265|NCT02241759|Drug|TA-8995|
1599266|NCT02241759|Drug|Moxifloxacin|
1599267|NCT02241759|Drug|Placebo|
1599268|NCT02241746|Other|no intervention|
1599269|NCT02241733|Behavioral|Breathing retraining plus exercise|Patients will participate in a 12-week exercise program with breathing retraining. They will also participate in an adherence program.
1599270|NCT02241733|Behavioral|Exercise only|Patients will participate in a 12-week exercise program . They will also participate in an adherence program.
1599272|NCT02241694|Other|No treatment given|No treatment given. Participants are to complete a questionnaire in the study.
1599273|NCT02241681|Dietary Supplement|Peptamen 1.5|Peptamen will be given twice at the dose of 250 mL, with an interval of 4 hours.
1599274|NCT02241668|Procedure|PET Scan|FLT Pet Scan performed about 60 minutes after 3'-Deoxy-3'-18f-Fluorothymidine solution injected.
1599275|NCT02241668|Drug|3'-Deoxy-3'-18f-Fluorothymidine|3'-Deoxy-3'-18f-Fluorothymidine solution injected through a central venous catheter after MRI scan. After solution injected into a vein, PET scanner takes pictures of the radioactive solution as it moves through the body and collects at various sites in the body. Entire procedure should last about 60-70 minutes.
1599276|NCT02241655|Device|a pragmatic EEG-guided anesthetic protocol|
1599277|NCT02241642|Device|VIVASURE CLOSURE DEVICE™|Large hole vascular closure device
1599278|NCT02241629|Drug|placebo|placebo of levo phencynonate hydrochloride
1599279|NCT02241629|Drug|levo phencynonate hydrochloride|levo phencynonate hydrochloride
1599280|NCT02241616|Drug|Entecavir+Fuzheng Huayu+TCM Granule|The subjects will be taking 1 Entecavir tablet per day, 4 Fuzheng Huayu tablets three times a day and specific Traditional Chinese Medicine granule for 48 weeks.
1599281|NCT02241603|Behavioral|Weight loss|Obese Veterans will undergo dietary education for weight loss or weight maintenance
1599282|NCT02241590|Drug|Entecavir + Placebo|The subjects will be taking 1 Entecavir tablet per day and 4 Placebo tablets three times a day for 48 weeks.
1599283|NCT02241590|Drug|Entecavir + Fuzheng Huayu Tablet|The subjects will be taking 1 Entecavir tablet per day and 4 Fuzheng Huayu tablets three times a day for 48 weeks.
1599284|NCT02241577|Procedure|Surgical treatment|Flap surgery around dental implant for scaling and disinfection of the titanium surface under local anesthesia
1599285|NCT02241577|Procedure|Non-surgical treatment|Non-surgical subgingival scaling and disinfection of the titanium surface of dental implant under local anesthesia
1599326|NCT02241187|Drug|Cetuximab|
1599290|NCT02241538|Device|Pilates 1|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 6 sessions of treatment over a period of 6 weeks (1 session/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
1599291|NCT02241538|Device|Pilates 2|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 12 sessions of treatment over a period of 6 weeks (2 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
1599292|NCT02241538|Device|Pilates 3|Combination of an educational booklet with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient´s needs (pragmatic treatment).
1599293|NCT02241538|Device|Control|Patients will receive an educational booklet containing information about the anatomy of the spine and pelvis and the low back pain and recommendations regarding posture and movements involved in activities of daily living. The participants in this group did not receive additional exercise.
1599294|NCT02241512|Drug|Ibuprofen|
1599295|NCT02241512|Drug|placebo|
1599296|NCT02241499|Radiation|Radiation therapy|Radiotherapy at a dose of 4 Gy will be given to a total dose of 20 Gy, treatment duration 5 days.
1599297|NCT02241499|Drug|Oxaliplatin and fluorouracil.|Oxaliplatin at a dose of 85 mg/m2 and will be given on day 1, infusion (44 hours) of fluorouracil will be given for 4 cycles, cycle length 14 days.
1599298|NCT02241486|Drug|Sublingual Fentanyl Spray|Patients with burn injuries will receive sublingual fentanyl spray (Subsys) for procedural pain (dressing changes/minor debridement).
1599299|NCT02241473|Other|Training|During 3 weeks (9 sessions; three sessions/wk), subject will performed 60 min walking at spontaneous walking speed in normoxic (continuous normoxic training; CNT) or hypoxic (continuous hypoxic training, CHT; simulated altitude of 3000 m) condition in a single‐blind fashion. Both CNT and CHT sessions will be performed in an hypoxic chamber (ATS Altitude, Sydney, Australia) built in our laboratory at an altitude of 380 m (Lausanne, Switzerland). In order to blind subjects to altitude, the system will also run for normoxic training groups with a normoxic airflow into the chamber.
1599300|NCT02241460|Drug|Placebo|During the Double-Blind Treatment Period, patients randomized to placebo will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg. During the Open-Label Treatment Period, the patient will receive four weeks of Promescent (active treatment) in one-week cycles: 30 mg, 50 mg, 70 mg, and patient's self-selected dose.
1599301|NCT02241460|Drug|Promescent Lidocaine Spray|During the Double-Blind Treatment Period, patients randomized to active treatment will receive three cycles of Promescent. The first and second cycle consists of three weeks of treatment using 30 mg and 50 mg, followed by one week of washout. The third cycle consists of three weeks of treatment using 70 mg, followed by four weeks of treatment during the Open-Label Treatment Period using patient's self-selected dose.
1599302|NCT02241447|Other|Early Information|Nurse based at echo facility will inform referring physician within one week that their Patient was diagnosed with severe aortic Stenosis. outcomes and Treatment decision will be documented.
1599303|NCT02241434|Biological|Stem Cell|Intrathecal autologous bone marrow mononuclear cell transplantation
1599304|NCT02241421|Drug|Amoxicillin|
1599305|NCT02241421|Drug|Vancomycin|
1599306|NCT02241395|Biological|Intrathecal autologous bone marrow mononuclear cell transplantation|
1599307|NCT02241382|Device|Internal Electrocardioversion|Cardioversion by internal shock application via the implanted ICD
1599308|NCT02241382|Device|External Electrocardioversion|Cardioversion by external shock application via a cardioverter/defibrillator.
1599309|NCT02241369|Biological|INO-3106, INO-9012|
1599312|NCT02241343|Device|Venous occlusion (leg tourniquet, made in-house)|Leg occlusion applied via a blood pressure cuff. Venous occlusion checked using duplex ultrasound
1599313|NCT02241330|Dietary Supplement|Biofortified wheat|Wheat was grown by foliar Zn application and is therefore biofortified
1599314|NCT02241330|Dietary Supplement|Fortification|Wheat flour is fortified before testmeal preparation
1599315|NCT02241330|Dietary Supplement|Control|wheat flour is used as control comparator.
1599316|NCT02241291|Procedure|Percutaneous coronary intervention|Non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. A deflated balloon or other device on a catheter is fed from an artery (such as the inguinal femoral artery or radial artery) up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery
1599317|NCT02241278|Drug|Ketamine|In the operating room, the anesthesiologist administered 0.5 mg/kg of ketamine chlorhydrate in 50 mL of 0.9 % saline intravenously to patients in the ketamine group 30 minutes before surgical incision (a single dose).
1599318|NCT02241265|Procedure|Bronchial Thermoplasty|Thermoplasty delivers thermal energy to the airways to reduce bronchial muscle mass and airway reactivity. Each application delivers the energy over 10 seconds to each bronchial segment.
1599319|NCT02241252|Device|iPhone ECG|Please see detailed description for additional information.
1599320|NCT02241226|Behavioral|Perfect Health Course|The Perfect Health course as taught at the Chopra Center for Wellbeing
1599321|NCT02241213|Device|Transcranial Magnetic Stimulation (TMS-r)|"10 sessions, each session of EMT-r will be low frequency (1 Hz for 20 minutes and a total of 1200 pulses) using a biphasic pulse stimulator, with active coil (coil-shaped focal or inactive coil placebo for 2 weeks from Monday to Friday, target: triangular portion - homologous to injury Inferior front Gyrus (GFI)."
1599322|NCT02241213|Device|Placebo Transcranial Magnetic Stimulation|10 sesions of Non- active coil, that will simulate the sound of the TMS, holding the coil on the scalp at an angle of 45 degrees in the selected area
1599323|NCT02241200|Drug|DA3880|
1599324|NCT02241200|Drug|Aranesp|
1599325|NCT02241187|Drug|PEGPH20|
1599328|NCT02241187|Other|blood draws|Blood samples will be drawn at various time points.
1599329|NCT02241174|Drug|Sodium Hypochlorite|The 0.005% sodium hypochlorite solutions will be prepared from the commercially available Clorox® at 6% solution. 0.83ml of the 6% sodium hypochlorite solution will be taken and incorporated to a-100ml absolute distilled water. This 100ml solution will be stored in an amber glass bottle at room temperature unexposed to light at a maximum of 23 months
1599330|NCT02241161|Other|plantaricin a - rejuvenating cream|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
1599331|NCT02241161|Other|plantaricin a - antioxidant serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
1599332|NCT02241161|Other|plantaricin a - rejuvenating serum|single application on an area of 17,5 cm2, on the forearm, after skin stripping, and left absorbing on the skin for at least 15 minutes
1599333|NCT02241148|Drug|Acetaminophen 500mg|500 mg, tablets every 8 hours
1599334|NCT02241148|Device|Kinesio taping|Taping will be changed every week.
1599335|NCT02241135|Biological|CV7201 mRNA|CV7201 is composed of 1 RNActive® mRNA that encodes the rabies virus glycoprotein.
1599336|NCT02241122|Procedure|prostate biopsy|
1599337|NCT02241109|Other|no intervention|progression monitoring by echocardiography
1599338|NCT02241096|Drug|Lidocaine|IV lidocaine bolus of 1.5mg/kg over 10 minutes followed by a 1mg/kg/hr IV lidocaine infusion.
1599339|NCT02241083|Drug|Dopamine|
1599340|NCT02241083|Drug|Norepinephrine|
1599341|NCT02241083|Other|no medication|
1599342|NCT02241070|Behavioral|mindulness-based intervention|"A number of mindfulness techniques, including both formal and informal practices with integration in the context of Mind/Body meditation, were explored in order to cultivate moment-by-moment present awareness with non-judgmental acceptance."
1599343|NCT02241057|Device|Investigational Air-Activated Adhesive-Backed Heat Patch (3-Cell)|
1599344|NCT02241057|Other|Temperature Probe|
1599345|NCT02241044|Device|Argon plasma coagulation|Argon plasma coagulation therapy was realized by an Olympus electrosurgical unit/APC unit (PSD-60/Endoplasma, Olympus Corporation, Tokyo, Japan), and its catheters were 2.3mm and 3.5 mm equipped with different endoscope channels.7 APC treatment used a coagulation mode at gas flow/power settings of 1.5L/min and 40 watt for duodenal ulcers and 40-60 watt for gastric ulcers.10 Operative distance between the probe and target bleeding ranged from 2 to 8 mm. Air warranted to be sucked frequently at endoscopy in an attempt at decrease of APC-induced smoke and gastric decompensation, with appropriate treatment of high-risk bleeding ulcers.
1599346|NCT02241044|Device|Distilled water|Distilled water was then applied in aliquots of 0.5-2.0 mL, at and around the site of target bleeding, up to 25.0 ml if necessary. Injection amount was determined by endoscopists according to ulcer or vessel size and its location.
1599347|NCT02241031|Biological|MPs|MPs are generated from cord blood using a combination of cytokines.
1599348|NCT02241031|Drug|thrombopoietin (TPO) and interleukin-11|Platelet stimulating factors include thrombopoietin (TPO) and interleukin-11 and so on.
1599349|NCT02241018|Drug|CD25 monoclonal antibody|
1599350|NCT02241018|Drug|calcineurin inhibitors|
1599351|NCT02241018|Biological|MSCs|
1599352|NCT02241005|Other|Theraworx™ bath wipes|Theraworx™ bath wipes will be supplied in packaging similar to the standard bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
1599353|NCT02241005|Other|Standard bath wipes|Standard bath wipes will be supplied in packaging similar to the Theraworx™ bath wipes used in this study. The bath wipes will be started on the day of admission, and used once daily for a period of 60 days post-HSCT.
1599354|NCT02240992|Biological|PBSC|
1599355|NCT02240992|Biological|MSCs|
1599356|NCT02240979|Device|cardiac MRI|cardiac MRI
1599357|NCT02240953|Drug|Warfarin|Only warfarin is given with a target INR level of 2.5-4 to the patients with prosthetic heart valve thrombosis
1599358|NCT02240953|Drug|Warfarin + ASA 100 mg + PPI|100 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
1599359|NCT02240953|Drug|Warfarin + ASA 300 mg + PPI|In the third arm 300 mg acetylsalicylic acid and a proton pump inhibitor are added to treatment in combination with warfarin for the patients with prosthetic heart valve thrombosis
1599360|NCT02240953|Drug|Observational Warfarin|This is an observational group of patients who do not have prosthetic heart valve thrombosis. These patients also are followed under only warfarin therapy with INR level of 2.5-4.
1599361|NCT02240940|Device|Parachute Implant|CardioKinetix's Parachute implant device is suitable for use in isolating the dysfunctional region of the left ventricle in patients with symptoms of heart failure due to ischemic heart disease. Potential benefits of the Parachute implant device are improvement in hemodynamics and the clinical symptoms of heart failure.
1599362|NCT02240927|Drug|Low Molecular Weight Heparine : Enoxaparine|During first trimester, warfarin is stopped and enoxaparine is started in 1mg/kg dose twice a day. Dose is adjusted according to Anti Factor Xa levels (between 0.7-1.2). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
1599363|NCT02240927|Drug|Enoxaparine and 2.5 mg Warfarin|If the patient's therapeutic warfarin dose is more than 5 mg before pregnancy, warfarin dose is decreased to 2.5 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4)
1599364|NCT02240927|Drug|Enoxaparine and 4mg Warfarin|If the patient's warfarin consumption dose is more than 5 mg before pregnancy, warfarin dose is decreased to 4 mg during the first trimester and combined with enoxaparine in 1mg/kg dose twice a day. Enoxaparine dose is adjusted according to anti-factor Xa levels (between 0.5-1). Full dose warfarin is continued after first trimester and dose is regulated according to INR level (between 2.5-4).
1599365|NCT02240927|Drug|Warfarin|If the patient's therapeutic warfarin dose is less than 5 mg before pregnancy, warfarin is continued in the same dose during all the pregnancy and the dose is adjusted according to INR level (between 2.5-4).
1599529|NCT02239874|Dietary Supplement|Vitamin D placebo and fish oil placebo|placebo
1599366|NCT02240901|Device|Laryngeal mask airway（LMA）|Laryngeal mask airway（LMA） is used to maintain mechanical ventilation during intra-operative
1599367|NCT02240901|Device|Endotracheal intubation（ETI）|Endotracheal intubation group（ETI）is used to maintain mechanical ventilation during intra-operative
1599368|NCT02240888|Biological|0,5 mg Prevenar i.m.|
1599369|NCT02240888|Biological|0,5 mg seasonal influenza vaccine i.m.|
1599370|NCT02240875|Biological|cAd3-EBO Z at 1 x 10^10 vp|Low dose cAd3-EBO Z
1599371|NCT02240875|Biological|cAd3-EBO Z at 2.5 x 10^10 vp|Medium dose cAd3-EBO Z
1599372|NCT02240875|Biological|cAd3-EBO Z at 5 x 10^10 vp|High dose cAd3-EBO Z
1599373|NCT02240875|Biological|4.4x10^8 TCID50s MVA-BN® Filo|High dose MVA-BN® Filo
1599374|NCT02240875|Biological|2.2x10^8 TCID50s MVA-BN® Filo|Low dose MVA-BN® Filo
1599375|NCT02240875|Biological|4.4 x 10^7 TCID50s MVA-BN® Filo|Very low dose MVA-BN® Filo
1599376|NCT02240862|Device|Carotid Artery Stent|Placement of a stent within the carotid artery
1599377|NCT02240849|Device|Functional pillow|streamlined shape for cervical lordosis memory foam pillow functional design considered several sleep position
1599378|NCT02240849|Device|Placebo general pillow|
1599379|NCT02240836|Other|Intervention. Exercise|Physical activity. Attendance in exercise groups 60 min. twice a week and exercise at home 120 min per week. Intervention for 12 months.
2009499|NCT03234465|Biological|AG013|AG013 is made up of genetically modified (GM) bacteria called Lactococcus lactis (L. lactis). Wild type L. lactis are commonly used to produce dairy products including cheeses and milk. To make AG013, the DNA of L. lactis has been changed in the laboratory to secrete a protein called human Trefoil Factor 1 (hTFF1). hTFF1 is normally secreted in saliva and intestines. Trefoil factors have been shown to be important in protecting and healing mucosal tissues, such as the tissue in the mouth, when these tissues are damaged by cancer therapies such as chemotherapy and radiation therapy.
1599382|NCT02240797|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
1599383|NCT02240771|Procedure|Transarterial chemotherapy|"Femoral artery would be punctured at the upper thigh using 18 gauge needle under local anesthesia. Catheterization of the hepatic artery feeding the tumor would be done and placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.
Mixture would be prepared by using Doxorubicin 50mg and Cisplatin 100mg. Hydrocortisone 100mg and augmenting dose of analgesic and sedative would be injected prior to the administration of the drug.
The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-leur lock syringes."
1599384|NCT02240771|Drug|Oral chemotherapy|"Drugs used would be Thalidomide and Capecitabine in the following dosage schedule- Thalidomide---50mg once a day (OD) for 7 days, increased to 100mg OD for 7 days, 200mgOD for 7 days further increased to 300 mg OD.
Capecitabine---- 500mg OD for 7 days, then 1000mg OD for next 7 days, increased to a maximum dose of 1500mg OD
Maintenance dose - Capecitabine 1500 mg - every alternate week Thalidomide - 300 mg OD. Total leucocyte count & Platelet count would be monitored every 15 days"
1599385|NCT02240758|Procedure|confocal endomicroscopy with the CELLVIZIO® system (Mauna Kea technology)|The CELLVIZIO® system (Mauna Kea technology) will be used for confocal endomicroscopy during a surgical procedure (either open surgical approach or stereotaxic biopsy). The probe dedicated to the CELLVIZIO® system will be positioned against the surface of the brain, sequences will be acquired, and finally compared with anatomapathology exams. Two specific medications will be used as contrast agent in the study: Fluorescein FAURE 500mg/5mL IV with a maximum of two doses per patient OR 5 amino-levulinic hydrochloride (GLIOLAN, MEDAC) orally at the dose of 20mg/kg of body weight.
1599386|NCT02240745|Other|Stress-echocardiography|Stress-echocardiography (incl dobutamin and atropin)
1599387|NCT02240719|Drug|everolimus|Given PO
1599388|NCT02240719|Drug|bendamustine hydrochloride|Given IV
1599391|NCT02240693|Drug|BI 409306|
1599392|NCT02240693|Drug|Placebo|
1599393|NCT02240693|Drug|BI 409306|
1599394|NCT02240693|Drug|Placebo|
1599395|NCT02240693|Drug|Placebo|
1599396|NCT02240693|Drug|BI 409306|
1599397|NCT02240693|Drug|BI 409306|
1599398|NCT02240693|Drug|Placebo|
1599399|NCT02240693|Drug|Placebo|
1599400|NCT02240680|Drug|placebo|placebo matching linagliptin 5 mg
1599401|NCT02240680|Drug|linagliptin|5 mg once a day
1599404|NCT02240641|Drug|Lacidipine|
1599405|NCT02240641|Drug|Diuretics|
1599406|NCT02240641|Drug|antihypertensive drugs|
1599407|NCT02240641|Drug|alpha blockers|
1599408|NCT02240641|Drug|Angiotensin-Converting Enzyme Inhibitors|
1599409|NCT02240641|Drug|beta blockers|
1599410|NCT02240628|Device|Lidocaine/tetracaine transdermal patch|All patients in arm 1 and arm 2 will receive the Synera Patch.
1599411|NCT02240628|Drug|Saline|Patients in arm 2 will receive Saline with the Propofol.
1599412|NCT02240628|Drug|Lidocaine|Patients in arm 1 will receive Lidocaine with the Propofol.
1599413|NCT02240615|Device|Sinopsys Lacrimal Stent|Procedural insertion of the Sinopsys Lacrimal Stent in patients with epiphora
1599414|NCT02240602|Drug|Oxycodone, 1.00 mg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 1.00 mg.
1599415|NCT02240602|Drug|Oxycodone, 0.03 mg/kg dose|Intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.03 mg/kg.
1599416|NCT02240602|Drug|Oxycodone, 0.02 mg/kg dose|intravenous oxycodone is provided as patient-controlled analgesia after surgery with bolus dose of 0.02 mg/kg.
1599417|NCT02240589|Drug|Memantine|Day 1 to 3: 10 mg bid memantine. Day 3 to 21: 20 mg bid memantine. Day 21 to 168: 10 mg bid memantine.
1599418|NCT02240589|Drug|Placebo|Day 1 to 3: 10 mg bid placebo. Day 3 to 21: 20 mg bid placebo. Day 21 to 168: 10 mg bid placebo.
1599419|NCT02240563|Procedure|Low-level laser therapy|
1599420|NCT02240563|Procedure|Non laser ordinary red light|
1599421|NCT02240550|Device|ProFlor Hernia Repair System|The 3-D hernia mesh will be used in the repair of your inguinal hernia.
1599422|NCT02240550|Device|Lichtenstein hernia repair|The standard Lichtenstein hernia repair with flat mesh will be used in the treatment of your inguinal hernia.
1599423|NCT02240537|Drug|Sargramostim|Drug: Sargramostim (GM-CSF) Other Names: Leukine Sargramostim (250 ug vial) is reconstituted with 0.5 ml of Sterile Water for Injection. Subjects will receive 0.5 ml intradermally (250 µg) near the arm pit or inside of thigh.
1599424|NCT02240537|Drug|BB-MPI-03|Other Names: Multi-peptide immunotherapy (MPI) is comprised of 3 cytotoxic T-cell epitopes derived from oncofetal antigen. There are 3 dose levels of study vaccine planned to be tested, starting at 0.25 mg each peptide (0.75 mg total peptide dose), then 0.5 mg of each peptide (1.5 mg total) and finally 1 mg each peptide (3 mg total). At the starting dose of 0.75 mg, the BB MPI 03-15 mg vial is used and 100 ul is administered; at the 1.5 mg dose, 200 ul of the BB MPI 03-15 mg vial is used; at the 3 mg dose, 200 ul of the BB MPI 03-30 mg is used.
1599425|NCT02240537|Drug|Montanide|"Drug: Montanide Other Names: mineral oil, USP BB-MPI-03 is emulsified with Montanide and administered intradermally (ID) within 1-2 cm of the 2 sargramostim injection sites 1-3 minutes after sargramostim administration.
Subjects and the injection sites are to be monitored for 1 hour after sargramostim and BB-MPI-03 emulsion administration."
1599426|NCT02240524|Procedure|D2 lymphadenectomy|The dissected lymph nodes were classified according to the Japanese Classification of Gastric Carcinoma, first English edition.
1599427|NCT02240524|Procedure|Systemic chemotherapy|
1599428|NCT02240524|Procedure|HIPEC|
1599429|NCT02240511|Dietary Supplement|RE and BCAA Supplementation|RE: Resistance Exercise BCAA: Branched Chain Aminoacids
1599430|NCT02240511|Other|Resistance Exercise|
1599431|NCT02240498|Drug|Methylene Blue|Administration of 1 mg/mL methylene blue to the abscess cavity, followed by a 10 minute incubation interval. After this incubation interval, the methylene blue solution will be aspirated from the cavity and flushed twice with sterile saline.
1599432|NCT02240498|Drug|20% I.V. Fat Emulsion|The abscess cavity will be filled with sterile 1% Intralipid solution to gently distend the cavity and, through efficient light scattering, to homogenize the light dose to the walls of the cavity. After laser illumination, the Intralipid will be aspirated from the cavity.
1599433|NCT02240498|Device|Insertion of optical fiber|A sterile, FDA-approved optical fiber will be advanced to the approximate center of the abscess cavity via the drainage catheter under image guidance. Following laser illumination, the fiber will be withdrawn.
1599434|NCT02240498|Device|Laser illumination, 5 minutes|Laser illumination will be delivered via the optical fiber for a duration of 5 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
1599435|NCT02240498|Device|Laser illumination, 10 minutes|Laser illumination will be delivered via the optical fiber for a duration of 10 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
1599436|NCT02240498|Device|Laser illumination, 15 minutes|Laser illumination will be delivered via the optical fiber for a duration of 15 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
1599437|NCT02240498|Device|Laser illumination, 20 minutes|Laser illumination will be delivered via the optical fiber for a duration of 20 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
1599438|NCT02240498|Device|Laser illumination, 25 minutes|Laser illumination will be delivered via the optical fiber for a duration of 25 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
1599439|NCT02240498|Device|Laser illumination, 30 minutes|Laser illumination will be delivered via the optical fiber for a duration of 30 minutes. The fluence rate will be set such that the maximum fluence rate at the abscess wall is 20 mW/cm2.
1599440|NCT02240485|Behavioral|Couple therapy|"The experimental couple treatment is offered over 8 to 12 sessions of 90 minutes. The couple treatment called (Integrative Couple Therapy for Pathological Gambling - ICT-PG) is inspired by the Alcohol Behavior Couple Therapy from Epstein and McCrady, to which the team added diverse components to adjust to gamblers. During the sessions, the focus is on a) reducing/stopping gambling behaviors, b) helping the partner to stop behaviors facilitating gambling habits and rise the frequency of behaviors imcompatibles with gambling habits and c) improve marital components (communication, sharing positive moments, negotiation, mutual support)."
1599441|NCT02240485|Behavioral|Usual individual/group treatment|The control group receive individual or group treatment as already offered by the specialized centers in addiction.Their partner can receive individual intervention if desired.
1599442|NCT02240472|Procedure|Omission of axillary clearance|The intervention is the omission of completion axillary clearance after the detection of sentinel node macrometastasis
1599443|NCT02240459|Drug|fesoterodine 4mg|7 days therapy followed by seven days washout. Each 4mg tablet is taken in the morning
1599444|NCT02240459|Drug|Oxybutynin|5mg IR oxybutynin taken bid, encapsulated into a form indistinguishable from placebo
1599445|NCT02240459|Drug|placebo|placebo capsule, one twice daily, and 2 placebo fesoterodine tablets taken each morning for masking and comparator purposes
1599446|NCT02240459|Drug|fesoterodine 8mg|2, 4mg fesoterodine capsules taken together in the morning
1599447|NCT02240446|Device|Active tDCS|2mA stimulation for 20 minutes twice a day for five consecutive days
1599448|NCT02240446|Device|Sham tDCS|2mA for 30 seconds twice a day for five consecutive days
1599449|NCT02240433|Drug|LY2157299|LY2157299 administered orally
1599450|NCT02240433|Drug|Sorafenib|Sorafenib administered orally
1599451|NCT02240420|Behavioral|Life Style Counseling (Star-Mama)|"Participants enrolled in the Star-Mama intervention group will receive 1. weekly automated phone calls with prevention-focused queries (e.g., diet, exercise, breastfeeding). 2. If a participant generates a value rated out of range, a health coach who receives daily electronic downloads of STAR-Mama responses will call the participant to coach her about the specific health issue. Participants also hear recorded narratives related to their out of range reply encouraging behavior change. 3. Call-backs enable coaches to engage patients in goals setting/action plans and providing information about community resources"
2009500|NCT03234465|Other|Placebo|Subjects assigned to the placebo group will receive appearance- and taste-matched placebo powder.
2009501|NCT03233724|Drug|Decitabine (DAC)|Administered orally at increasing frequency or dose from 3 - 5 times per week for 3 weeks
2009502|NCT03233724|Drug|Tetrahydrouridine (THU)|Administered orally at increasing frequency or dose from 3 - 5 times per week for 3 weeks
2009503|NCT03233724|Drug|Pembrolizumab|200 mg IV once a day every Wednesday or Thursday every 3 weeks.
2009504|NCT03232619|Biological|CD19 CART|Patients will get one course of CART treatment with the dose of 2*10~6/KgBW.
2009505|NCT03232580|Drug|rhAnnexin V-128|Patients will receive a single administration of 99mTc-rhAnnexin V-128 at Day 0
2009506|NCT03231709|Drug|Trelagliptin|Trelagliptin 100 mg tablets
2009507|NCT03231709|Drug|Alogliptin|Alogliptin 25 mg tablets
1599459|NCT02240381|Procedure|assessment of therapy complications|During OGTT 75gm of glucose will be given followed by phlebotomy
1599460|NCT02240381|Procedure|assessment of therapy complications|During clamp procedure tritiated glucose, D20, regular insulin will be given, followed by phlebotomy.
1599461|NCT02240381|Other|laboratory biomarker analysis|Correlative studies
1599462|NCT02240355|Drug|RO6885247|oral solution
1599463|NCT02240355|Drug|placebo|oral solution
1599464|NCT02240342|Drug|Bone marrow transplant into ovarian artery|Bone marrow progenitors mobilized to peripheral blood, obtained by plasmapheresis and infused into the ovarian artery
1599465|NCT02240329|Behavioral|Neuropsychological Testing and Measures of TBI severity|A brief cognitive assessment will be given to each participant when he or she presents for this project.
1599466|NCT02240329|Behavioral|Respiratory measures|We will collect measures of cough airflow and breathing strength.
1599467|NCT02240329|Drug|Capsaicin cough sensitivity testing|Subjects will inhale a saline vapor mixed with various concentrations of capsaicin powder in order to determine how sensitive his or her cough response is.
1599468|NCT02240303|Procedure|Quantitative Sensory Testing (QST)|Participants in both groups will have a sensory assessment called quantitative sensory testing or QST that will assess in detail your ability to feel sensations due to touch, vibration, and changes in temperature on the skin.
1599469|NCT02240303|Procedure|Physical Performance|Participants in both groups will have a Physical Performance test.
1599470|NCT02240303|Procedure|Magnetic Resonance Imaging (MRI)|Participants in both groups will have an magnetic resonance imaging (MRI).
1599471|NCT02240303|Procedure|Blood Sample|Participants in both groups will have blood samples taken.
1599472|NCT02240290|Drug|tozadenant tablet|Active substance: tozadenant Pharmaceutical form: Tablet Concentration: 240 mg Route of Administration: Oral administration
1599473|NCT02240290|Drug|C14-tozadenant capsule|Active substance: C14-tozadenant Pharmaceutical form: Capsule Concentration: 74 kBq (2 μCi) Route of administration: Oral administration
1599474|NCT02240264|Dietary Supplement|Krill oil capsules|1 year supplementation with Krill oil provided by Aker BioMarine Antarctic AS equalling almost the daily recommended amount of 450 mg of EPA/DHA intake per day.
1599475|NCT02240264|Dietary Supplement|Placebo|Capsules containing a fatty acid mixture that reflects the fatty acid composition of the average European diet.
1599476|NCT02240251|Other|Prospective Chart Review|The laser assisted IVC filter removal procedure itself is not part of this study. This is a prospective chart review for patients undergoing this procedure.
1599477|NCT02240238|Drug|NC-6004|NC-6004 - given at escalating doses of 60, 75, 90, 105, 120, 135, 150, 165, or 180 mg/m2 according to observations of dose-limiting toxicity.
1599478|NCT02240238|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 will be administered as a 30 minute intravenous infusion on Day 1 after the completion of the NC 6004 infusion and on Day 8 of each cycle.
1599479|NCT02240212|Drug|Afuresertib|The unit dose strength is 50mg/75mg tablet. Afuresertib will be taken orally once daily continuously during trail.
1599480|NCT02240212|Drug|Paclitaxel|Paclitaxel sourced locally will be administered IV
1599481|NCT02240199|Drug|Intraoperative Intravenous Lidocaine Infusion|Lidocaine 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
1599482|NCT02240199|Drug|Perioperative Pregabalin|Pregabalin 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
1599483|NCT02240199|Drug|Perioperative Pregabalin Placebo|Pregabalin placebo 300 mg preoperatively (e.g. 2 hours prior to the start of surgery) and 75 mg twice a day for 9 days after surgery.
1599484|NCT02240199|Drug|Intraoperative Intravenous Lidocaine Placebo Infusion|Lidocaine placebo 1.5 mg/kg bolus with anesthesia induction followed by 2 mg/kg/hr infusion before the start of surgical incision and stopped at surgical closure.
1996672|NCT02417402|Other|Control|The patients allocated to the Control group will be treated by physical therapists who did not carry out the training before treatment. The physical therapists will use their usual care for nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
1599487|NCT02240173|Dietary Supplement|Jobelyn|Jobelyn is a dietary supplement made from Sorghum bicolor
1599488|NCT02240173|Drug|Haloperidol|Conventional drug normally used for psychotic problems
1599489|NCT02240160|Drug|Sativex|Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
1599490|NCT02240147|Behavioral|home-based exercise training|During a 30 minute face-to-face motivational interview with an exercise specialist, the patient will be advised and coached about his exercise prescription, on how to implement it in his own daily life and on how to prevent relapse. Furthermore, the patients will receive instructions on how to monitor their exercise intensity and on recognizing adverse signals. During the following 12 weeks, patients will be asked to exercise 4.5 hours per week within the prescribed exercise intensity range according to the guidelines.
2009508|NCT03231345|Procedure|US guided IJ|IV catheter placement
1599525|NCT02239900|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"Treatment Group 1 and 3: SBRT 50 Gy in 4 fractions to 1 - 4 liver lesion(s) on Days 1 - 4 of Cycle 1.
Treatment Group 2 and 4: SBRT 50 Gy in 4 fractions to 1-4 liver lesion(s) on Days 29 - 33 of each 21 day cycle.
Treatment Group 5: SBRT 60 Gy in 10 fractions to 1 - 4 lung, liver, or adrenal lesion (s) on Days 1 - 5 and Days 9 - 12 of Cycle 1."
1599526|NCT02239887|Device|WaveCrest LAA occlusion device|Left Atrial Appendage Occlusion
2009509|NCT03231345|Device|Ultrasound|Ultrasound-guided Internal Jugular vein
2009510|NCT03231007|Other|Questionnaire|A structured questionnaire will be administered to maternity service users. Another structured questionnaire will be administered to maternity healthcare professionals, and another to Organisational Leads (e.g. Clinical Directors at each site).
2009511|NCT03229993|Diagnostic Test|OCT|OCT is used to assess whether PCI will be of benefit to the treatment of the borderline coronary artery lesions
2009512|NCT03229876|Biological|universal CD19-CART|Patients will get one course of CART treatment with a dose of 2*10~6/KgBW.
1599494|NCT02240121|Drug|Rifaximin DR|
1599495|NCT02240121|Drug|Placebo|
1599496|NCT02240108|Drug|Rifaximin DR|
1599497|NCT02240108|Drug|Placebo|
2009513|NCT03229408|Drug|Salsalate|Lean PCOS Arms: Salsalate 1.5 gm PO bid; Obese PCOS Arm: Salsalate 2.0 gm PO bid
2009514|NCT03229408|Other|Placebo|Appears identical to experimental drug
2009515|NCT03228394|Drug|Ganaxolone|Ganaxolone IV
1599501|NCT02240082|Behavioral|Web-Based COPing with Shiftwork Program|COPing with Shift Work is an interactive, web-based program designed specifically for law enforcement officers to assist with the management of health and lifestyle challenges associated with shift work. The program will contain modules on sleep, physical activity, and nutrition in order to improve the health and safety of law enforcement officers and reduce their risk of chronic diseases associated with shift work. These modules will contain interactive assessments and cutting-edge scientific information on sleep, nutrition, and physical activity. Based on user input, officers will receive personalized feedback, tools, and strategies
2009516|NCT03228394|Drug|Placebo|Placebo IV
2009517|NCT03227029|Biological|RSV ΔNS2/Δ1313/I1314L|10^6 plaque-forming units (PFU); administered as nose drops
2009518|NCT03227029|Biological|RSV 276|10^5 PFU; administered as nose drops
1599505|NCT02240043|Other|growth hormone secretion|The glucagon stimulation test (GST) was performed by intramuscular injection of 1 mg of glucagon (Glucagen® Hypokit, Novo Nordisk A/S, Denmark). The blood samples were collected at baseline and after 90 minutes, 120 minutes, 150 minutes and 180 minutes of glucagon injection for GH and cortisol measurements. The subjects were recumbent during the test, and a cannula was maintained in a vein in the arm or forearm with a saline solution slowly infused to avoid multiple punctures.
1599506|NCT02240030|Drug|CVT-301|
1599507|NCT02240017|Drug|Carboplatin|Carboplatin AUC (area under curve) 4,5 at day 1 of each cycle until 6 cycles.
1599508|NCT02240017|Drug|Fractionated Cisplatin|Cisplatin 35mg/m² at day 1 and day 8 of each cycle until 6 cycles.
1599509|NCT02240017|Drug|Gemcitabine|Gemcitabine 1000mg/m² at day 1 and day 8 of each cycle until 6 cycles.
1599510|NCT02240004|Device|SUPRA HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen
1599511|NCT02239991|Procedure|Thromboelastometry|Group of cirrhotic bleeding patients that are treated with a bed side, point of care protocol based on thromboelastometry to guide transfusion and manage coagulopathy
1599512|NCT02239978|Behavioral|Postural perturbation|Participants will undergo between 50 and 100 postural perturbations (quick movements of the support surface) in multiple directions. These perturbations will be between 9 and 24cm, and between 18 and 56 cm/s depending on participant tolerance.
1599513|NCT02239952|Drug|Sunitinib|50 mg once daily, oral use for 14 days
1599514|NCT02239952|Drug|vandetanib|300 mg, once daily, oral use for 14 days
1599515|NCT02239952|Drug|Erlotinib|150 mg, once daily, oral use for 14 days
2009519|NCT03227029|Biological|Placebo|Administered as nose drops
2009520|NCT03225729|Device|CRYOBEAUTY MAINS ET DECOLLETE|The intervention lasts up to 6.5 s. The device will be applied on spots <6 mm which are previously selected by the investigator team.
1599518|NCT02239926|Drug|Ranolazine|On January 31, 2006, ranolazine was approved for use in the United States by the Food and Drug Administration (FDA) for the treatment of chronic angina pectoris.
1599519|NCT02239926|Drug|Placebo|
1599520|NCT02239913|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and topiramate.
1599521|NCT02239913|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and topiramate.
1599522|NCT02239913|Drug|Phentermine|The pharmacodynamic effects of phentermine maintenance will be determined during maintenance on placebo and topiramate.
1599523|NCT02239913|Drug|Topiramate|The pharmacodynamic effects of chronic topiramate will be determined.
1599524|NCT02239900|Drug|Ipilimumab|"Treatment Group 1 and 3: Ipilimumab 3 mg/kg by vein on Day 1 of all 21 day cycles for a total of 4 doses.
Treatment Group 2 and 4: Ipilimumab 3 mg/kg by vein on Day 1 of Cycles 1 and 2. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 3 and 4.
Treatment Group 5: Ipilimumab 3 mg/kg by vein on Day 1 of Cycle 1. After SBRT treatment, Ipilimumab given on Day 1 of Cycles 2-4"
1599527|NCT02239874|Dietary Supplement|Vitamin D and fish oil placebo|Vitamin D3 (cholecalciferol), 2000 IU per day and fish oil placebo
1599528|NCT02239874|Dietary Supplement|Fish oil and vitamin D placebo|840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
2009521|NCT03225729|Device|Liquid nitrogen|The intervention lasts up to 3 s. The liquid is stored in well-isolated recipients. Each patient has his recipient to avoid contamination. The investigator applies on spots <6 mm a small amount of nitrogen liquid.
2009522|NCT03225170|Behavioral|Self Affirmation|Participants will be asked to rank artistic skills, athletics, business/money, creativity, independence, music, politics, relationships with friends and family, religious values, sense of humor, spontaneity from most important to least important. They will then be asked to write about the item that is most important to them and why it may be important to them. The control group will rank the same list and be asked to will write about the 9th ranked item and why it might be important to someone else. The treatment and control condition are consistent with interventions used in other SA intervention studies.
2009523|NCT03223610|Drug|Venetoclax|Administered orally, days 2-14, at varying doses of 200-800mg (based upon assigned dose level); every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
2009524|NCT03223610|Drug|Ibrutinib|Administered orally, days 1-14, at a dose of 560mg; every 21 days for up to 6 cycles, or unacceptable toxicity
2009525|NCT03223610|Drug|Prednisone|Administered orally, days 1-7, at a dose of 100mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
2009526|NCT03223610|Drug|Obinutuzumab|Administered intraveneously, days 1 and 2, at a dose of 1000 mg; every 21 days for up to 6 cycles, or until unacceptable toxicity
1599530|NCT02239874|Dietary Supplement|Vitamin D and fish oil|Vitamin D3 (cholecalciferol), 2000 IU per day and 840 mg of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
1599531|NCT02239861|Biological|TAA-Specific CTLs|"Patients may be pre-medicated with diphenhydramine (Benadryl) up to 1 mg/kg IV (max 50 mg) and acetaminophen (Tylenol) 10 mg/kg po (max 650 mg), though this is not mandatory.
Cell Administration: Tumor-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.
Patients with stable disease or better will receive up to 6 further doses of CTLs, as long as they continue to show disease stabilization or improvement by RECIST criteria at their 8 week or subsequent evaluations. Each dose will consist of the same number as their second injection or less (if there is not enough product available for the subject's original dose).
Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
1599532|NCT02239835|Drug|Tipranavir (TPV) low dose|
1599533|NCT02239835|Drug|Tipranavir (TPV) high dose|
1599534|NCT02239835|Drug|Ritonavir low dose|
1599535|NCT02239835|Drug|Ritonavir high dose|
1599536|NCT02239835|Drug|Saquinavir|
1599537|NCT02239822|Procedure|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.
After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.
Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.
The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks. the duration of the open label trial will be more 24 weeks."
1599538|NCT02239822|Procedure|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.
After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.
Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.
The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
1599539|NCT02239809|Procedure|Stimulation of the trigeminal nerve (active stimulation)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks.
After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.
Participants randomized to sham stimulation will be shifted to active stimulation and will be followed-up until completion of the study.
The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
1599540|NCT02239809|Procedure|Placebo stimulation of the trigeminal nerve (placebo)|"Participants will be randomized to active vs. sham stimulation during a period of 24 weeks with a one-way cross over at 12 weeks. Patients of the placebo group will be implanted with a lead in the V1 branch of the trigeminal nerve, but will not receive stimulation.
After 12 weeks, the participants receiving active electrical stimulation will continue under active stimulation until completion of the study.
Participants randomized to placebo stimulation will be shifted to active stimulation and will be followed-up until completion of the study.
The study will be unblinded after 6 months of randomized stimulation. The second part of the study will be an open label prospective trial for evaluate long-term follow-up. The duration of the open label trial will be more 24 weeks."
1599541|NCT02239796|Device|NeuroTrac continence stimulators|"Electrically stimulating the sacral nerve plexus modulates the L4-S3 nerve roots that control bladder function and urethral sphincter activity to eliminate inappropriate detrusor contractions while leaving the micturition reflex intact.
Transcutaneous posterior tibial nerve stimulation (TPTNS) is a technique of non-invasive retrograde electrical stimulation of the sacral plexus via the sciatic nerve. The posterior tibial nerve, a tributary of the sciatic nerve, is accessed using surface electrodes applied to the medial malleolar area. We are using NeuroTrac continence stimulators."
1599542|NCT02239796|Device|NeuroTrac continence stimulators|We are using NeuroTrac continence stimulators.
1599543|NCT02239783|Device|total hip arthroplasty implant|
1599544|NCT02239770|Drug|Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
1599545|NCT02239770|Drug|Placebo Nicotine Film|Nicotine orally dissolving films (ODF) are films containing nicotine (0, 2, or 4 mg). The active pharmaceutical ingredient in Nicotine ODF is nicotine polacrilex (20%, USP). The film used in Nicotine ODF has a muco-adhesive property, i.e. it can adhere to the oral mucosa and allow the drug to be absorbed through oral mucosa. After placement in the oral cavity, nicotine ODF dissolves over a 5-10 minute period.The unit-dose dosage is in the form of 1 in x 1 in square and weighs about 100 mg. Nicotine films are not available in the United States in a non-investigational setting.
1599546|NCT02239757|Procedure|Left radial approach|Primary PCI performed through left radial approach.
1599547|NCT02239757|Procedure|Right radial approach|Primary PCI performed through right radial approach.
1599548|NCT02239744|Behavioral|Air purifiers|The 10 dormitory rooms were randomized into two groups of 5 rooms each. One group used an air purifier placed in the center of the room for 48 hours corresponding to one weekend, followed by a 2-week washout period, and another 48 hours of using a sham air purifier under the same conditions. The other group simply reversed the order in which the real and sham air purifiers were used. All rooms used the same qualified air purifiers (model FAP04, 3M Filtrete), with the only difference being removal of the filter gauze in the sham purifiers. The air pollution auto-sensing feature of air purifiers was disabled in both groups. All participants and research staff were blinded to the group assignment. We requested all participants to stay in their dormitory room with the windows/doors closed throughout each 48-hour intervention period.
1599549|NCT02239731|Drug|FDX104 (4% Doxycycline)|FDX104 - 4% or Placebo to be applied twice twice daily during 5 weeks
1599550|NCT02239718|Procedure|2-unit cantilevered resin bonded bridge|Use one tooth as abutment tooth to replace one adjacent missing tooth
1599551|NCT02239718|Procedure|3-unit fixed movable resin bonded bridge|Use teeth from both side of the missing tooth space to replace a tooth. The prosthesis is cast in two piece and connected with a fixed-movable joint (semi-precision, allow degree of movement).
1599552|NCT02239692|Drug|PICOPREP|Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
1599553|NCT02239679|Drug|Aminolevulinic Acid|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
1599554|NCT02239679|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
1599555|NCT02239679|Device|BLU-U|10 J/cm2 blue light delivered at 10 mW/cm2
1599556|NCT02239679|Procedure|Cryotherapy|Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.
1599557|NCT02239666|Other|NIS|This is a non-interventional study (NIS) of usual care over the 12 months following initiation of biologic therapy.
1599558|NCT02239653|Behavioral|Physician communication|
1599559|NCT02239627|Drug|Epidural steroid|
1599560|NCT02239627|Drug|Clonidine|
2009527|NCT03223610|Drug|Revlimid (lenalidomide)|Administered orally, days 1-15, at a dose of 15mg; every 21 days for up to 6 cycles, or until disease progression or unacceptable toxicity
1599563|NCT02239601|Other|Physical Therapy|Physical therapy assessment and treatment for any positive signs of nerve entrapment prior to chemotherapy including nerve gliding exercises, education and splinting. A home program will be provided to continue throughout chemotherapy treatment
1599564|NCT02239588|Other|Oral consumption|"Daily oral consumption for 12 weeks:
Placebo;
Pure Canterbury;
Other infant formula milk powder:
Yashili Ambery Infant Formula Milk Powder (Stage 1 0-6 months)
Yashili Newwit Infant Formula Milk Powder (Stage 1 0-6 months)
Yashili α-golden stage Infant Formula Milk Powder (Stage 1 0-6 months)
Abbott Similac Infant Formula Milk Powder (Stage 1 0-6 months)
Wyeth S-26 SMA Gold Infant Formula Milk Powder (Stage 1 0-6 months)
Beingmate Love plus Infant Formula Milk Powder (Stage 1 0-6 months)"
1599565|NCT02239562|Drug|sPIF|
1599566|NCT02239562|Drug|Placebo|
1599567|NCT02239549|Device|Jumbo cold forceps polypectomy|The specific jumbo cold forceps used are the Olympus EndoJaw Biopsy Forceps (open jaw diameter 8.5 mm) and the Boston Scientific RJ4 Biopsy Forceps (open jaw diameter 8.8 mm).
1599568|NCT02239549|Device|Cold snare polypectomy|The specific cold snares used are the Boston Scientific Captiflex Extra Small Oval Flexible Snare (loop width 11 mm), the US Endoscopy Dsnare Dimunitive Polypectomy and Suction System (loop width 9 mm), or the Boston Scientific Sensation Short Throw Oval Flexible Snare (loop width of 13 mm, 27 mm, or 30 mm).
1599569|NCT02239536|Procedure|removal of eligible polyps using hot snare polypectomy technique|Snare polypectomy using a electrosurgical snare with application of electrocautery
1599570|NCT02239536|Procedure|removal of eligible polyps using hot snare polypectomy after saline injection technique|Snare polypectomy after saline injection, using a electrosurgical snare with application of electrocautery
1599571|NCT02239523|Procedure|Letter Group|At time of discharge from the hospital, patients will be sent home with a letter that includes standard recommendations for evaluation and treatment for osteoporosis. This will be asked to give the letter to their primary care physician.
1599572|NCT02239523|Procedure|Intervention Group|The orthopedic department will be responsible for arranging bone density testing (DEXA) and recommending specific medication after discharge. A research assistant will call monthly to encourage treatment.
1599573|NCT02239510|Drug|Senna|1 capsule (50 mg) Senna daily for 12 weeks
1599574|NCT02239510|Drug|Linzess|1 capsule (145 mcg) of Linzess once daily for 12 weeks
1599575|NCT02239497|Procedure|Femoral block by ultrasound and neurostimulation|
1599576|NCT02239497|Drug|Intravenous analgesia|Intravenous analgesia with ketoprofen, dipyrone and dexamethasone. IV morphine to rescue analgesia
1599577|NCT02239484|Drug|Tadalafil|
1599578|NCT02239484|Drug|Tamsulosin|
1599579|NCT02239484|Drug|Tadalafil + Tamsulosin|
1599580|NCT02239458|Drug|Saxagliptin|
1599581|NCT02239445|Drug|chloral hydrate Group|chloral hydrate 0.25 mg/kg oral solution diluted with oral syrup to 5 ml and 0.2 mL intranasal placebo (normal saline)
1599582|NCT02239445|Drug|low dose dexmedetomidine group|Group L received intranasal dexmedetomidine at 1mcg/kg and 5 ml oral syrup
1599583|NCT02239445|Drug|high dose dexmedetomidine group|Group H received intranasal dexmedetomidine at 2mcg/kg and 5 ml oral syrup
1599584|NCT02239419|Procedure|CO2-Enriched Tap Water (Carbothera)|Participants will undergo foot bathing with CO2-enriched tap water (CO2 concentration, 1000-1200 ppm) maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
1599585|NCT02239419|Procedure|Non-CO2-Enriched Tap Water|Participants will undergo foot bathing with non-CO2-enriched tap water maintained at a temperature of 37˚C with an immersion time of 15 mins, 3 times per week for 4 consecutive months. Participants will be rested on a chair for 15 min before foot bathing. If participant is undergoing hemodialysis, foot bathing will occur prior to their routine hemodialysis procedure.
1599586|NCT02239393|Biological|Mesenchymal Stem Cells|"Mesenchymal Stem Cells in Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% dimethylsulfoxide (DMSO, total volume of 5mL DMSO in final cell product) and autologous MSCs at a dose of 1 to 2 x 106 MSC/Kg participant's body weight at randomization.
Matching placebo Plasma-Lyte A (Baxter) suspension media, containing 5% Human Albumin and 10% DMSO (total volume of 5mL DMSO in final cell product)."
1599658|NCT02238691|Procedure|Mask ventilation with PEEP via a face mask device|"15 subjects will undergo anesthetic induction with an application of PEEP of 10 cm H2O during mask ventilation via a face mask.
15 subjects will undergo anesthetic induction without PEEP during mask ventilation via a face mask."
1599659|NCT02238665|Device|Endomicroscopy|
1599660|NCT02238652|Behavioral|Communication|A preparation process before the patient become incapable of participating in life prolonging decisions
1599587|NCT02239380|Drug|Lorazepam|"intravenous administration. Dosage for adult subjects (16 years aged and over): 4 mg Dosage for pediatric subjects (3 months to < 16 years): 0.05 mg/kg (but not exceeding 4 mg) Frequency: Intravenous administration of lorazepam. Subjects whose seizure does not stop or recurs within 10 minutes after the initial dose may receive the same amount of lorazepam injection no earlier than 10 minutes following the initial dose.
Also, subjects whose seizure stops within 10 minutes after the initial dose, but recurs thereafter (within 12 hours) may receive the same amount of lorazepam injection; a total of 2 doses will be permitted in this study."
1599588|NCT02239367|Behavioral|Depression Decision Aid|The Depression Decision Aid protocol, integrated into the Electronic Health Record (EHR), is a streamlined adaptation of an in-person Shared Decision-Making intervention.
1599589|NCT02239354|Device|VC-01™ Combination Product|Biologic and Device
1599590|NCT02239341|Other|Music Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones in bed.
1599591|NCT02239341|Other|Muscle Conditioning Intervention|Music will be about 120 beats per minute and the participants will listen to the music while wearing head-phones and also participate in the muscle conditioning program while in bed.
2009528|NCT03223662|Other|Chemoradiotherapy|Chemotherapy: Carboplatin (AUC=2)x5 and Paclitaxel (50 mg/m2)x5 for two cycles. Radiation: a total dose of 40.4 Gy will be given in 23 fractions of 1.8 Gy, 5 fractions per week, starting the first day of the first cycle of chemotherapy.
1599593|NCT02239289|Other|Biofeedback|Idem as described in the arm section (above)
1599594|NCT02239276|Drug|Stiripentol|The initial dose of Stiripentol will be determined by the prescribing neurologist and titrated up to an initial goal dose of 50 mg/kg/day divided into 2 to 3 doses per day. Further dose increases by 10-20 mg/kg/day increments up to a max of 100 mg/kg/day or 4000 mg total daily dose may be necessary for improved seizure control.
1599595|NCT02239250|Device|Water filter and cookstove|"The Vestergaard Frandsen Lifestraw Family™ 2.1 is a point-of-use water treatment system.Water is poured through a 20 micron pre-filter into a 6L influent water tank.This water then filters through a 0.20 micron hollow-fiber ultrafiltration membrane into a 5.5L storage container.Water is then poured through a plastic tap, which prevents re-contamination.This system filters up to 18,000L of water.The system exceeds the WHO's highly protective standard for household water treatment technologies.The EcoZoom™ Spartan stove concentrates the combustion process while channeling airflow to completely burn the fuel provided.The stove has a ceramic combustion chamber within a steel housing, which is topped with a cast iron stove.The stove includes a rack for placing firewood and a pot skirt that improves the thermal efficiency.The cookstoves and filters will be delivered together at no cost to participating households.Households will receive instructions on how to operate these devices."
1599596|NCT02239237|Drug|Compound Kuh-seng Injection|Compound Kuh-seng Injection is a kind of natural compound injection extracted from Chinese herbs Kuh-seng (Radix Sophorae Flavescentis) and Rhizoma Heterosmilacis Japonicae. The major bioactive ingredients include oxymatrine，sophocarpidine, matrine, flavonoid etc.
1599599|NCT02239211|Drug|BTT1023|IV (in the vein) Investigational Medicinal Product (IMP)
1599600|NCT02239198|Other|Nutrition bar|The nutrition bar has been formulated to help achieve balanced nutrition with a polyphenolic-rich whole food matrix with vitamins, minerals, omega-3 fatty acids, and fiber at generally physiologic doses intended not to replace but to supplement a typical diet.
1599601|NCT02239185|Procedure|Hernial sac ligation in continuity|Laparoscopic closure of hernia sac at internal inguinal ring in continuity using 3 - 0 non-absorbable purse-string suture. The spermatic vessels and vas deferens are well visualized and protected during the suture. In all cases, hydro dissection can be done by injection of saline to separate the peritoneum from cord structures. Two 3-mm.needle holders are used for intracorporeal insertion of purse string suture around the opened IIR with intracorporeal knot tying. The stitches included the peritoneum and the underlying muscular tissue lateral to the spermatic cord. The procedure is modified in children with a dilated internal ring.
1599602|NCT02239185|Procedure|Hernial sac disconnection|Circumferential incision on the peritoneum at IIR will be started to separate hernia sac from the peritoneum. Initial disconnection of the vas and vessels will be done and then the peritoneum posterior to the internal ring will be divided and then the anterior disconnection will be carried out. Saline can be injected to separate the peritoneum from cord structures (hydro dissection). Care is taken not to damage the vas and vessels by handling them. Then the proximal part of the sac will be sutured using non-absorbable 3-0 prolene on round body needle.
1599603|NCT02239172|Biological|PA83-FhCMB|
1599604|NCT02239159|Other|TES(transcutaneous electric stimulation)|Stimulation will be given through electrodes attached to the skin
1599605|NCT02239146|Drug|catridecacog|Single doses of rFXIII administered intravenously (i.v.) to eight subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
1599606|NCT02239146|Drug|placebo|Single doses of placebo administered intravenously (i.v.) to two subjects in each of the four dose groups (11.9, 25, 35 and 50 IU/kg).
1599607|NCT02239133|Device|ProVATE vaginal pessary|
2009529|NCT03223662|Procedure|Esophagectomy|Minimally-invasive esophagectomy (RAMIE)or traditional open approach if necessary.
2009530|NCT03224975|Other|fMRI|During fMRI, patients and control group will have to thought to seven painful memories, seven emotional memories not painful, seven neutral memories. At every memory there is control test. It is to count backwards.
2009531|NCT03222466|Other|Co-created PEM|A co-created PEM has been designed in collaboration with patients.
2009532|NCT03220659|Device|Multi-point pacing|Pacing from more than one pole from the left ventricular lead
2009533|NCT03220659|Device|Standard settings|Normal bipolar LV pacing
1599614|NCT02239107|Drug|N-Acetyl cysteine|
1599615|NCT02239107|Procedure|laparoscopic ovarian drilling|
1599617|NCT02239081|Drug|CTP-730|
1599618|NCT02239081|Drug|Placebo for CTP-730|
1997038|NCT02266693|Behavioral|iCBT|The iCBT program consists of weekly online lessons, weekly homework assignments, regular automatic email reminders about lessons and homework, weekly contact via phone or email with a CBT therapist, and access to a large online library of written resources about depression and anxiety and application of CBT skills. The CBT therapist contacts all participants once a week to review lessons, assist patients with treatment difficulties, reinforce progress and encourage continued engagement with the program. Therapist-patient contact is limited to 10 minutes per patient per week.
1599619|NCT02239042|Procedure|LLLT|The patients allocated for the test group received the following protocol for laser application: Five (5) points of irradiation were performed. The irradiation was performed with a ASGaAl diode laser that continuously emitted a wavelength of 660 nm. 30 mW was used for 20 seconds, and the total applied energy density (fluence) was 15 J/cm2 (3 J/cm2 per point and an application time of 4 seconds per point). The applications were performed using punctual contact (to reduce reflection) with the tip perpendicular to the gingival tissue. Laser therapy was initiated in the immediate postoperative period (just after sutures) and was followed by seven more applications performed every other day, with a total of 8 laser applications. The power of the equipment was calibrated prior to each application. The patients allocated to the control group received sham irradiation. For this, black rubber protection was placed at the tip of the laser device, which did not allow the light to reach the tissue
1599620|NCT02239029|Drug|platelet rich plasma|Platelet rich plasma (PRP) is a new and potential treatment for patients with kinds of musculoskeletal disorders.
1599621|NCT02239029|Drug|Normal saline|The normal salin as the placebo intervention was injection in the other side of knee.
1599622|NCT02239003|Drug|DAOIB|
1599623|NCT02239003|Drug|Placebo|
1599624|NCT02238977|Drug|Fluoxetine|Antidepressant
1599625|NCT02238977|Drug|Bupropion|Antidepressant
1599626|NCT02238964|Device|Strattice™ Reconstructive Tissue Matrix|The protocol preference is for the mesh to be placed intra-peritoneally fashion (i.e. below the peritoneum). Anchoring bites will be taken in four to six sites of peritoneum (e.g. using 2-0 PDS) and the mesh will be 'parachuted' into place. Once correctly placed, the fascia above will be closed using Prolene, PDS or Nylon (surgeon preference, but excluding Vicryl). Infiltration of up to 40ml 0.25% Marcaine for infiltration into the fascial layer is recommended. The remainder of the closure will be at the surgeon's discretion.
1599627|NCT02238964|Procedure|Standard Closure|The non-intervention arm for fascial closure will be the preferred technique of the surgeon without mesh reinforcement. The fascia should be closed with Prolene, PDS or nylon sutures; Vicryl should not be used for the fascia. The remainder of the closure will be at the surgeon's discretion.
1599628|NCT02238951|Other|Mobile Health (mHealth)|Participants receive care coordination throughout their chemotherapy treatment using mHealth technology
1599629|NCT02238951|Other|No mHealth|Participants receive the same evidence-based care coordination without mHealth technology
1599630|NCT02238938|Procedure|en-bloc resection|En- bloc resection after marking by use of different customary endoscopic knifes including combining devices as hybrid knife to cut down the lesion. After submucosal injection of liquid (saline or equivalent) to elevate the tissue it will be dissected and removed by a snare of adequate size solitarily.
1599631|NCT02238938|Procedure|piecemeal resection|"Piecemeal resection is done by snare after marking and submucosal injection of saline or equivalent liquids. Small leftover adenoma tissue will be resected thoroughly by snare or forceps.
After three months, an APC therapy will follow any piecemeal resection, if necessary, another resection of leftover adenoma will be done."
2009534|NCT03220282|Other|Donor milk|For late preterm newborns who are breastfeeding and whose mothers are not making enough breast milk yet to meet their nutritional needs, the study will compare the intervention of banked donor breast milk with the control of preterm infant formula.
1599633|NCT02238912|Drug|kandhaga rasayanam|KANDHAGA RASAYANAM is a siddha herbo mineral drug with sulphur as a sole mineral ingredient. It is chosen from the classic Siddha text Siddha Vaidhya Thirattu.
1599634|NCT02238886|Dietary Supplement|Parenteral nutrition. SMOFKABIVEN infusion in central vene. Fresenius Kabi|
1599635|NCT02238873|Drug|Pegfilgrastim|
1599636|NCT02238860|Drug|Entacavir|Entacavir-0.5 mg ,OD,for
1599637|NCT02238860|Drug|Tenofovir|Tenofovir ,300 mg,OD,for 48 weeks
1599639|NCT02238834|Drug|FP-025|Subjects will receive single doses of 200 to up to 800 mg of FP-025 (API-in-capsule) in a dose escalation format (cohorts 1-3). Subjects will receive single doses of 50 to up to 450 mg of FP-025 (ASD-in-capsule) in a dose escalation format (cohorts 4-8).
1599640|NCT02238834|Drug|Placebo|Subjects will receive single doses of FP-025 matching placebo (capsule) in a dose escalation format.
1599641|NCT02238834|Drug|FP-025|Subjects will receive doses of FP-025 (capsule) twice daily for 5 days.
1599642|NCT02238834|Drug|Placebo|Subjects will receive FP-025 matching placebo (capsule) twice daily for 5 days
1599643|NCT02238808|Drug|Estradiol|Eligible participants will take 2 mg Estradiol 3 times daily for 7-14 days pre-surgery.
1599644|NCT02238782|Drug|selumetinib 75mg single dose|3 capsules of 25 mg given as a single dose
1599645|NCT02238782|Other|[14C] selumetinib IV solution|single, radiolabeled, IV (infused), microdose (80 μg) of [14C] selumetinib, infused using a syringe pump as a 15-minute infusion, administered 1h 15 min after receiving the oral dose
1599646|NCT02238769|Device|18F-FluoroethylCholine PET|18F-FluoroethylCholine PET will be performed before any treatment of patients. 18F-FECH was prepared and provided by Nuclear Medical Center of our hospital.PET scan was performed using SIEMENS/CTI（index） EXACT HR（high resolution) +.
1599647|NCT02238756|Biological|CV8102|Subjects will receive 2 intramuscular doses of CV8102 given 21 days apart
1599648|NCT02238756|Biological|Rabipur|Subjects will receive 2 intramuscular doses of Rabipur given 21 days apart
1599649|NCT02238756|Biological|CV8102 + Rabipur|Subjects will receive 2 intramuscular doses of CV8102+Rabipur given 21 days apart
1599650|NCT02238730|Device|Ultrabrief Right Unilateral|The first six electroconvulsive therapy sessions using ultrabrief (0.25 ms) right unilateral electroconvulsive therapy
1599651|NCT02238730|Device|Brief Pulse Bitemporal|The first six electroconvulsive therapy sessions using brief pulse (0.5 ms) bitemporal electroconvulsive therapy
1599652|NCT02238717|Drug|PF-06372865 (65mg)|single oral dose (65 mg)
1599653|NCT02238717|Drug|PF-06372865 (15mg)|single oral dose (15mg)
1599654|NCT02238717|Drug|Pregabalin|single oral dose (300mg)
1599655|NCT02238717|Drug|Placebo|matching oral placebo
1599656|NCT02238704|Dietary Supplement|Regimen A calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
1599657|NCT02238704|Dietary Supplement|Regimen B calcium and iron/folic acid|Comparison of recommended administration schedule for calcium and iron/folic acid supplements in pregnant women
1599703|NCT02238353|Drug|azelastine + fluticasone|
1599704|NCT02238353|Drug|Placebo|
1599661|NCT02238652|Behavioral|Systematic Pain Assessment and Treatment|Assess pain with MOBID-2 Pain Scale and thereby improve pain management in dementia.
1599662|NCT02238652|Behavioral|Medication Review|An individual and systematic review of medication prescriptions to identify possible harmful drug effects and to reduce the use of psychotropic drugs.
1599663|NCT02238652|Behavioral|Occupational therapy|Increase individual activities, based on function, personal interest and personality by educating the staff on these elements.
1599664|NCT02238652|Behavioral|Safety|Focusing on developing a culture where staff has an active and constant awareness of how to prevent adverse events and a commitment to safety.
1599665|NCT02238639|Procedure|Diagnostic and therapeutic strategy: Highly sensitive D-dimer testing and, if positive, multidetector computed tomographic pulmonary angiography (MDCT).|"If MDCT is positive for pulmonary embolism, patients will receive anticoagulant treatment according to updated guidelines.
If MDCT is negative for pulmonary embolism, patients will receive standard management for their exacerbation."
2009535|NCT03220282|Other|Preterm infant formula|Preterm formula determined by clinical practice
2009536|NCT03220035|Other|Laboratory Biomarker Analysis|Correlative studies
1599668|NCT02238613|Device|radioactive stent|radioactive stent carrying seed iodine 125
1599669|NCT02238613|Device|plastic stent|common plastic stent without carrying seed iodine 125
1599670|NCT02238587|Other|Control group|In control group, only placebos are given for 6 weeks. The patients who are in control groups are switched to receive Ganoderma Spores Powder Capsules for 6 weeks.
1599671|NCT02238587|Dietary Supplement|Ganoderma Spores Powder Capsules|In experimental group, Ganoderma Spores Powder Capsules for 12 weeks.
1599672|NCT02238574|Procedure|surgery|excision or carbondioxide laser evaporation of the mucosal lesion of the oral cavity
1599673|NCT02238574|Other|follow up|Intensified outpatient follow up (16 visits in 5 years)
1599674|NCT02238548|Biological|Cholera vaccination|Oral cholera vaccination on day 0 and day 14
1599675|NCT02238548|Other|Raw milk|
1599676|NCT02238535|Drug|Ventavis|
1599677|NCT02238535|Drug|Warfarin|
1599678|NCT02238522|Drug|ZEN003365|
1599679|NCT02238509|Drug|Lapatinib|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
1599680|NCT02238509|Drug|Trastuzumab|ARM A: oral lapatinib 1,000 mg daily in combination with intravenous trastuzumab 6mg/kg q3wks (after the initial 8 mg/kg loading dose).
1599681|NCT02238496|Procedure|Cytoreductive surgery|Standard of care/routine cytoreductive glioma resection surgery. Arm B only.
1599682|NCT02238496|Drug|Perifosine|Perifosine is a pill that has not been approved by the FDA which blocks a messenger that tells cancer cells to grow.
1599683|NCT02238496|Drug|Temsirolimus|Temsirolimus is an intravenous drug approved by the FDA for treatment of other cancers (kidney cancer, certain types of lymphoma) but not for brain tumors.
2009537|NCT03220035|Drug|Vemurafenib|Given PO
2009538|NCT03219840|Drug|CPC|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
1599686|NCT02238470|Drug|oral anticoagulants|Comparison of patients receiving oral anticoagulants with or without microbleeds in magnetic resonance imaging
1599687|NCT02238457|Drug|Low dose losartan|25 mg losartan bid for 10 weeks
1599688|NCT02238457|Drug|High dose losartan|50 mg, 75 mg, or 100 mg bid for 10 weeks. Dose will be determined by the medical doctor depending on patients' tolerability
1599689|NCT02238444|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
1599690|NCT02238444|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
1599691|NCT02238444|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
1599692|NCT02238444|Drug|Low Molecular Weight Heparin|From postoperative day 3, Patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
1599693|NCT02238431|Drug|Lucrin depot|scheduling the start of the artificial cycle and hormone down regulation during the artificial cycle
1599694|NCT02238431|Drug|OCP|to schedule the start of the artificial cycle
1599695|NCT02238431|Other|Natural|to use the normal menstrual period to schedule treatment start
1599696|NCT02238418|Drug|Cholecalciferol vial (100 000 UI)|"VISIT 1:
Patient > 60 kg and initial 25OHD serum concentration < 25nmol/L : prescription of 4 vials to be taken every 2 weeks between 25 and 50 nmol/L: prescription of 3 vials to be taken every 2 weeks between 50 and 75 nmol/L: prescription of 2 vials to be taken every 2 weeks Patient between 20 and 60 kg and initial 25OHD serum concentration < 25nmol/L: prescription of 2 vials to be taken every month between 25 and 50 nmol/L: prescription of 2 vials to be taken every 6 weeks between 50 and 75 nmol/L: prescription of 1 single vial Patient < 20 kg and initial 25OHD serum concentration < 75 nmol/L: prescription of 1 single vial
A local lab will performed urinary dosage of calciuria and creatininuria:
at days 0, 1, 2, 3, 4 and 7 after the first intake of a 25OHD vial
at days 0, 2 and 4 after other intakes (when applicable)
VISIT 2:
25OHD serum concentration will then be dosed at month 2 after visit 1"
1599697|NCT02238405|Other|Intensive anti-smoking counseling|Study participants randomized to the intervention arm will receive intensive cessation support outside of the TB clinic setting, from a health worker trained in cessation counseling, during the course of their TB treatment. Behavioral elements will consist of follow up using unscheduled drop in or phone sessions, motivational interviewing, and counseling tailored to the needs and circumstances of the patient. Patients who are current smokers and are ready to commit to quit smoking will be supported to stop completely. Recent smokers will supported for having quit, and the counselor will discuss coping strategies to maintain abstinence.
1599698|NCT02238392|Procedure|Adenosine test|Testing dormant conduction after PVI
1599699|NCT02238392|Procedure|Termination of AF|Testing AF iducibility and ermination of
1599700|NCT02238379|Drug|Oxytocin|24 International Units of Oxytocin in a Nasal Spray
1599701|NCT02238379|Other|Placebo|Placebo will contain all ingredients except the active oxytocin in the Nasal Spray.
2009539|NCT03219840|Drug|Placebo|All subjects will be instructed to chew four times a day, for at least 60 seconds, after which they expectorated.
1599705|NCT02238340|Drug|Extended-release oxycodone|10 o 20 mgrs of extended-release oxycodone ,started 12 hours before orthopaedic surgery
1599706|NCT02238340|Drug|Extended- release Oxycodone|
1599707|NCT02238340|Drug|ketoprofen|
1599708|NCT02238340|Drug|dipirone|
1599709|NCT02238340|Drug|dexametasone|
1599710|NCT02238340|Drug|Morphine IV (rescue)|
1599711|NCT02238327|Procedure|blood draw|Blood will be drawn for plasma, serum, and PBMCs. Clinical labs drawn will be for hepatitis, CMV, hemoglobin and carboxyhemoglobin.
1599712|NCT02238327|Procedure|questionnaires|The following questionnaires are administered to participants by study personnel at each visit: LEAP questionnaire, St. George's, and MMRC.
1599713|NCT02238327|Procedure|Lung function testing|The routine lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured before and after bronchodilator administration (4 puffs of albuterol). The best of three reproducible forced expiratory attempts is used in analysis. Percent- predicted spirometric values are based on age, height, gender, and ethnicity. DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms to ATS standards. DLco will be adjusted for hemoglobin and carboxyhemoglobin.
1599714|NCT02238327|Procedure|Six-Minute walk test|Six-minute walk tests are performed in a 100 foot (30.48 m) segment of straight hallway marked at 10 foot (3 m) intervals. In addition to the usual ATS protocol, the patient is monitored, when available, with Bluetooth wireless pulse oximetry and the time and distance recorded after six minutes and if they desaturate to <88%. Dyspnea (Borg 0-10) and perceived exertion (Borg 6-20) scales are completed at the beginning and the end of test.
1599715|NCT02238327|Radiation|Quantitative CT scans|Subjects will undergo a standard chest CT. The CT scans will use a phantom shipped between sites to standardize results and capture contiguous volume scans acquired at slice thicknesses of 5.0 mm in the axial plane and reconstructed with 512 x 512 pixel matrices. CT examinations will encompass the entire thorax and be performed during a breath-hold at end-inspiration. We will measure % of lung tissue below a threshold for emphysema (i.e. -950 Hounsfield units). Measurements have been histologically-verified and give reproducible measurements. The data set is assembled and analyzed with the image data anonymized.
1599716|NCT02238327|Procedure|Nasal secretion and cell collection|Participants will be instructed to blow their nose to remove accumulated mucus. Two sprays of commercially available nasal saline will be instilled in each nostril. The participant will then be ask to exhale through the rinsed nostril into a specimen cup. We will repeat this up to 5 times on each side depending on the participants' tolerance to the procedure. Using an otoscope, a small curette will then be used to collect 3 to 5 samples of nasal cells from each nostril. These samples will be used immediately for analysis or banked for future study.
1599717|NCT02238327|Procedure|Echocardiogram|The cardiac ultrasound will use standard ultrasound techniques to image two-dimensional slices of the heart using 3D real-time imaging.
1599718|NCT02238314|Drug|Tipranavir low dose|
1599719|NCT02238314|Drug|Tipranavir high dose|
1599720|NCT02238314|Drug|Ritonavir|
1599721|NCT02238314|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|
1599722|NCT02238314|Drug|Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)|
1599723|NCT02238301|Other|Bold sequence patients test|Develop the hyperventilation protocol (speed, duration ...) and the choice of type of mask oxygenation better tolerated by patients. Sequences beginning with a low oxygen flow (2L/mn) then progressively increasing to obtain the BOLD effect required
1599724|NCT02238301|Other|Bold sequence|"A first sequence BOLD will be launched in ambient air. The second sequence is repeated BOLD 5 minutes after power maternal hyperventilation.
Sequences will focus on the fetus and placenta but will also include maternal liver to validate maternal hyperoxygenation."
1599725|NCT02238288|Drug|Aminocaproic acid|Crushed tablet in the dental socket
1599726|NCT02238288|Other|Routine dental care|Chompret´s manoeuver, suture, surgical wound compression with gauze for 20 minutes
1599727|NCT02238288|Drug|lidocaine and epinephrine|2%
1599728|NCT02238288|Drug|Paracetamol|750 mg
1599729|NCT02238275|Drug|Micardis® plus|
1599730|NCT02238262|Drug|Telmisartan|
1599731|NCT02238249|Drug|Alesion®|Dry Syrup
1599732|NCT02238236|Drug|Alesion®|Dry Syrup
1599733|NCT02238223|Drug|Alesion®|
1599734|NCT02238210|Drug|Atrovent®|
1599735|NCT02238197|Drug|Atrovent® Inhalation Solution|
1599736|NCT02238184|Drug|Atrovent®|
1599737|NCT02238184|Drug|Ventilat®|
1599738|NCT02238171|Drug|Atrovent® inhalets|
1599739|NCT02238158|Drug|Atrovent® inhalets|
1599740|NCT02238145|Drug|Atrovent® Inhaletten|
1599741|NCT02238132|Drug|ATROVENT® inhalets|
1599742|NCT02238119|Drug|Tiotropium + formoterol combination|
1599743|NCT02238119|Drug|Tiotropium|
1599744|NCT02238119|Drug|Formoterol|
1599745|NCT02238106|Drug|Salmeterol medium dose|
1599746|NCT02238106|Drug|Salmeterol low dose|
1599747|NCT02238106|Drug|Salmeterol high dose|
1599748|NCT02238106|Drug|Serevent® Diskus®|
1599749|NCT02238106|Drug|Placebo HandiHaler®|
1599750|NCT02238106|Drug|Placebo Diskus®|
1599751|NCT02238080|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered according to the usual standard of care and current best practice guidelines and will be observed during the study period.
1599752|NCT02238067|Drug|ESA|Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.
1599753|NCT02238067|Other|Satisfaction Survey Questionnaire|Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.
1599754|NCT02238041|Device|GlucoClear System|
1599755|NCT02238028|Behavioral|Wear respirator|Healthy adult subjects wore the particulate filtering respirators for continuous 48 hours as much as possible both indoor and outdoor.
1599756|NCT02238015|Procedure|cataract surgery|All patients underwent cataract surgery with 3.0 mm clear corneal incision at 11 o'clock in one eye
1599757|NCT02238002|Procedure|cataract surgery|The patients of both groups underwent cataract surgery
1599758|NCT02237989|Drug|paracetamol|1500 mg
1599759|NCT02237989|Drug|paracetamol+native collagen type 2|paracetamol (1500 mg) + native collagen type 2 (10mg)
1599760|NCT02237976|Behavioral|Self-hypnosis|
1599761|NCT02237976|Behavioral|Routine practice|
1599762|NCT02237963|Procedure|Posterolateral thoracotomy|
1599763|NCT02237963|Procedure|Axillary thoracotomy|
1599764|NCT02237950|Drug|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
1599765|NCT02237950|Drug|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
1599766|NCT02237950|Drug|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
1599767|NCT02237937|Drug|Paroxetine|
1599768|NCT02237937|Drug|Sertraline|
1599769|NCT02237937|Drug|Citalopram|
1599770|NCT02237937|Drug|Venlafaxine|
1599771|NCT02237937|Drug|Amitriptyline|
1599772|NCT02237937|Drug|Escitalopram|
1599773|NCT02237937|Drug|Amitriptylinoxide|
1599774|NCT02237937|Drug|Nortriptyline|
1599775|NCT02237937|Drug|Trimipramine|
1599776|NCT02237924|Drug|endostar|Endostar 7.5mg / m2, 2 cycles of intravenous infusion for ten days,and 2 cycles of maintenance therapy after radiotherapy
1599777|NCT02237924|Drug|DDP|DDP:80mg/m2 for 2-3 cycles
1599778|NCT02237924|Radiation|IMRT|IMRT:70-74Gy for 2-3 cycles
1599779|NCT02237911|Other|Clinic-based outpatient exercise group|Subjects will participate in supervised sessions (clinic-based) of exercise followed by a home exercise program 2 times per week during 3 months. Each exercise session will last about 60 minutes. Treatment sessions will utilize a pragmatic approach and will include the exercises designed to increase muscular strength, low impact cardiovascular exercise, range of movement, and activity for daily living skills.
1599780|NCT02237911|Other|Community-based exercise group|Subjects will attend to exercise classes (community-based) 2 times per week during 3 months. The exercise classes last approximately 60 minutes. The group exercise classes consists of a variety of exercises designed to increase general muscular strength, low impact aerobic exercise, range of movement, and activity for daily living.
1599781|NCT02237898|Behavioral|MoMba Live Long app & Sensordrone™ carbon-monoxide sensor|MoMba Live Long application & Sensordrone™ carbon-monoxide sensor to deliver contingency management remotely
1599782|NCT02237898|Behavioral|Office contingency management|A control group which will receive financial incentives at an in-person office/clinic visit based on expired CO levels obtained through the Sensodrone™ CO sensor.
1599783|NCT02237898|Device|Sensordrone™ carbon-monoxide sensor|
1599784|NCT02237898|Device|MoMba Live Long Smartphone application|
1599785|NCT02237885|Device|NeuroSky MindWave Mobile|
1599786|NCT02237859|Drug|Vancomycin|Vancomycin Group: Study participants started on a broad-spectrum antibiotic will be initiated on Vancomycin 125 mg PO QD within 48 hrs of the 1st dose of primary broad-spectrum antibiotic and continued to complete a 10 day course regardless of the duration of primary antibiotic. Dose of oral Vancomycin is 125 mg PO QD. Vancomycin liquid will be dissolved in fruit juice which is standard practice at Spectrum Health Hospitals. Both groups will continue in the study even if their broad spectrum antibiotic therapy is curtailed prior to 10 days.
1599787|NCT02237859|Dietary Supplement|fruit juice/placebo|Placebo Group: Will receive similar volume of fruit juice/placebo for 10 days.
1599788|NCT02237846|Biological|Human umbilical cord tissue-derived mesenchymal stem cells|
1599789|NCT02237820|Drug|Dexamethasone|6 mg/day of Oral Dexamethasone
1599790|NCT02237820|Drug|Prednisone|40 mg/day of Oral Prednisone
1599791|NCT02237807|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
1599792|NCT02237807|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
1599793|NCT02237781|Drug|Gonadotropins|The dose of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH will depend on the levels of E2 and FSH prior to ovarian stimulation .
1599794|NCT02237768|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
1599795|NCT02237768|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
1599796|NCT02237755|Drug|Clomiphene citrate|clomiphene citrate 100mg/day will be added to the standard gonadotropin regiment
1599797|NCT02237755|Drug|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
1599798|NCT02237742|Drug|PF-06427878|Intravenous, 100 micrograms, single dose, 30 minute infusion
1599799|NCT02237729|Biological|PF-06410293|PF-06410293 will be administered as a single 40 mg, subcutaneous dose
1599800|NCT02237729|Biological|Adalimumab-US|Adalimumab-US will be administered as a single 40 mg, subcutaneous dose
1599801|NCT02237729|Biological|Adalimumab-EU|Adalimumab-EU will be administered as a single 40 mg, subcutaneous dose
1599802|NCT02237703|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
1599803|NCT02237690|Drug|Doxorubicin hydrochloride liposome|50mg/m2,IV on day1 of each cycle,On Day 1 of Cycle 2, patients will crossover to the alternate reference or test formulation,After completion of Cycle 2 (Day 28), patients will be continued on the treatment of Doxorubicin Hydrochloride Liposome Injection up to 4 more cycles if tolerance permits under guidance of their attending physicians.
1599804|NCT02237677|Other|Positron emission tomography (PET) imaging|Positron emission tomography (PET) imaging
1599805|NCT02237664|Procedure|Continuous paravertebral analgesia (C-PVB)|Patients will receive continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1
1599806|NCT02237664|Procedure|Patient-controlled paravertebral analgesia (PC-PVB)|Patients will receive background continuous paravertebral infusion of bupivacaine 0.2% and fentanyl 2 μg mL-1 at rate of 8 mL h-1 with patient demand bolus dose of 3 mL and lockout time of 15 min with a 20 mL h-1 maximum dose, irrespective of their age
1599807|NCT02237651|Device|topical anesthesia multi-use device|
1599808|NCT02237651|Device|topical anesthesia Intranasal Mucosal Atomization|
2009540|NCT03221166|Drug|Thalidomide|Thalidomide is a immunomodulatory and antiangiogenetic drug with anti TNF alpha properties
1599809|NCT02237638|Biological|hVEGF26-104/RFASE|Three intramuscular injections on days 0, 14 and 28, followed by an observational period of 6 weeks. If hererafter VEGF is not (or no longer) neutralized in serum and there is no sign of disease progression, another booster vaccination can be given. This booster can be repeated until disease progression, death or withdrawal from the study.
1599810|NCT02237612|Procedure|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
1599811|NCT02237612|Other|laboratory biomarker analysis|Correlative studies
1599812|NCT02237586|Biological|PfSPZ Challenge|live, aseptic, cryopreserved P. falciparum sporozoites
1599813|NCT02237573|Other|Written medical report and standardized medical advices|"The intervention will include: 1) handing the patient at the end of the consultation a copy of the consultation report which will be composed of:
a detailed report of the consultation (motive, case history, clinical examination, conclusion)
written standardized medical advices from evidence published in the literature. Interventions will be designed by several general practitioners and tested by few patients."
1599814|NCT02237573|Other|Control|"Other:
Oral standardized medical advices from evidence published in the literature. Physicians will be trained by a single investigator."
1599815|NCT02237560|Behavioral|Cybercycle-Game|Exercising on a virtual-reality enhanced stationary recumbent bicycle while playing interactive 3D video-game for 6 months, 3-5x/week.
1599816|NCT02237560|Behavioral|Cybercyle-Tour|Exercising on virtual-reality enhanced stationary recumbent bicycle and pedaling through interactive 3D scenic bike tours for 6 months, 3-5x/week.
1599817|NCT02237560|Behavioral|Game Only|While seated on a stationary recumbent seat play interactive 3D video-game for 6 months, 3-5x/week (no pedaling).
1599818|NCT02237547|Biological|Intravenous and intrathecal human umbilical cord tissue-derived mesenchymal stem cells and bone marrow mononuclear cells|
1599819|NCT02237534|Drug|Lanthanum carbonate|
1599820|NCT02237534|Drug|Calcium Carbonate|
1599821|NCT02237521|Other|Eu- and hyperglycemic clamp|Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.
1599822|NCT02237521|Other|Arginine test|Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon
1599823|NCT02237508|Drug|Z7200|
1599824|NCT02237508|Drug|Symbicort Turbohaler|
1599825|NCT02237508|Drug|Z7200 with charcoal|
1599826|NCT02237508|Drug|Symbicort Turbohaler with charcoal|
1599827|NCT02237508|Drug|Symbicort Turbohaler replicate|
1599828|NCT02237495|Drug|dexmedetomidine|dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
1599829|NCT02237495|Drug|placebo|The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
1599830|NCT02237482|Device|Trilogy cup|
1599831|NCT02237482|Device|Trabecular metal cup (TM)|
1599832|NCT02237482|Device|ZCA cup|
1599833|NCT02237469|Radiation|Prone and supine simulation|Treatment planning in the two positions.
1599834|NCT02237456|Procedure|Comparison of OCT scans|
1599835|NCT02237456|Procedure|Comparison of Intra Vascular Optical Coherence Tomography Systems for Assessment of Coronary Tissue, Stents and Scaffolds - DOCTOR Compare|
1599836|NCT02237443|Drug|Rocuronium|Administration of a NMBD
1599837|NCT02237443|Drug|Vecuronium Bromide|Administration of a NMBD
1599838|NCT02237443|Drug|Succinylcholine|Administration of a NMBD
1599839|NCT02237430|Device|MynxGrip|Closure device for femoral artery access closure
1599840|NCT02237430|Other|Manual compression|Conventional manual compression
1599841|NCT02237417|Drug|Standard of Care Oral antipsychotics|A total of 15 to 20 subjects with schizophrenia will receive SOC oral antipsychotic medications (e.g., aripiprazole (Abilify®), risperidone (Risperdal®), lurasidone HCI (Latuda®), quetiapine fumarate (Seroquel®), olanzapine (Zyprexa®), and ziprasidone HCI(Geodon®)) or once monthly aripiprazole (Abilify®), PO daily, in accordance with their respective product labeling.
1599842|NCT02237417|Drug|IM aripiprazole once monthly|A total of 30 to 40 subjects with schizophrenia will receive aripiprazole (Abilify®) monthly, at a starting dose of 400 mg IM or an approved dose based on the investigator's judgment and in accordance with product labeling.
1599843|NCT02237417|Other|No Treatment|A total of 15 healthy controls will participate in the study and will not receive medication
1599844|NCT02237404|Device|Telemedicine System|Telemedicine System is used in remote monitoring group
1599845|NCT02237391|Other|CIPAP Program|The intervention will involve a pain specialist, a clinical health psychologist and a nurse. As needed, it may involve a social worker, an addiction specialist, and other specialists. The pain specialist will conduct an evaluation that includes: history of presenting illness, review of systems, review of pain treatments, medical history, surgical history, addiction history, medications and allergies, insurance for medication, psychosocial history, opioid risk assessment, physical examination, and review of tests and investigations. The psychologist will conduct an evaluation that includes: a structured diagnostic clinical interview, a review of coping strategies, and a review of the questionnaires completed prior to the assessment pertaining to mood, anxiety, trauma and beliefs about pain.
1599846|NCT02237391|Other|Treatment as Usual (TAU)|Control group
1599847|NCT02237378|Radiation|FDG PET scan|Following an overnight fast, subjects will be positioned in the Discovery 660 PET/VCT scanner. Following a scout scan to confirm patient positioning, low dose xray CT scan is performed for photon attenuation. A 20 minute dynamic PET scan is started simultaneously with 3 MBq/kg of N-13 ammonia to measure myocardial perfusion. Following N-13 decay,a 60 minute dynamic PET scan with 3 MBq/kg F-18- FDG to measure myocardial glucose uptake. Blood sampling for glucose and insulin will occur at pre specified time points throughout the scan.
1599848|NCT02237365|Drug|81mg aspirin|1 tablet of 81mg aspirin and 2 tablets of placebo (visually matched to 500mg aspirin) daily for 60 days
1599849|NCT02237365|Drug|1000mg aspirin|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg aspirin daily for 60 days
1599850|NCT02237365|Drug|Placebo|1 tablet of 81mg placebo (visually matched to 81mg aspirin) and 2 tablets of 500mg placebo (visually matched to 500mg aspirin) daily for 60 days
1599853|NCT02237326|Procedure|Visual Inspection with Acetic Acid|Visual Inspection with Acetic Acid is the application of acetic acid to a cervix, followed by examination with a light source. It is not a new drug or device, and has been used in resource-limited settings for several decades. The purpose of this trial is to compare the two screening techniques, which had not been done previously.
1599854|NCT02237326|Procedure|Visual Inspection with Lugol's Iodine|Visual Inspection with Lugol's Iodine is the application of lugol's iodine to a woman's cervix, followed by examination with a light source with the goal of detecting precancerous lesions. Like Visual Inspection with Acetic Acid, it is not a new drug or device.
1599855|NCT02237313|Behavioral|psychological support and therapeutic education program|
1599856|NCT02237300|Behavioral|VR based cue-exposure therapy|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
1599857|NCT02237300|Behavioral|Additional Cognitive-behavioral treatment|Comparison of VR based cue-exposure therapy sessions and additional Cognitive-behavioral treatment sessions
1599858|NCT02237287|Other|wound dressing with VAC and sNAG without antiaggregation|
1599859|NCT02237287|Procedure|wound dressing with VAC|
1599860|NCT02237287|Drug|wound dressing with VAC and sNAG under Antiaggregation|
1599861|NCT02237274|Other|High altitude exposition|High altitude exposition
1599862|NCT02237261|Drug|Bendamustine, Bortezomib, Prednisone|"Cycle 1 (d1-42) - Induction:
Bortezomib: 1.3 mg/m2 s.c.: d1, 4, 8, 11, 22, 25, 29, 32 Bendamustine: 90 mg/m2 iv, d1, 2 Prednison: : 60 mg/m2 po,, d1-4
Cycle 2-9 (d1-28) - Consolidation:
Bortezomib: 1.3 mg/m2 s.c.: d1, 8, 15, 22 Bendamustine: 90 mg/m2 iv: d1, 2 Prednison: 60 mg/m2 po: d1-4"
1599863|NCT02237235|Drug|MMFS-202-302|"Active ingredient: L-Threonic acid Magnesium salt.
1 g (2 pills) by mouth once daily in the evening for 9 weeks
Drug: MMFS-302 Active ingredient: L-Threonic Acid Magnesium Salt
1 g (2 pills) by mouth once daily in the morning for 9 weeks"
1599864|NCT02237235|Drug|Placebo|Two tablets by mouth in the morning, and two tablets by mouth in the evening, daily for 9 weeks.
1599865|NCT02237222|Other|Gait rehabilitation|
1599866|NCT02237209|Biological|RSV LID ΔM2-2 Vaccine|10^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
1599867|NCT02237209|Biological|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
2009541|NCT03221166|Drug|Infliximab|Infliximab is a chimeric monoclonal antibody against TNF alpha
2009542|NCT03219437|Drug|risankizumab|subcutaneous (SC) injection
2009543|NCT03219437|Drug|methotrexate|capsule
2009544|NCT03219333|Drug|Enfortumab vedotin|Intravenous (IV) infusion on days 1, 8 and 15 every 28 days
1997039|NCT02266420|Procedure|Blood samples of 10 mL|Blood samples of 10 mL will be collected at initial visit; serum samples will then be stored at the end of the study (-80°C) and may be used for the purpose of further scientific research.
1599877|NCT02237157|Drug|Gemcitabine, local delivery|Intra-arterial targeted drug delivery
1599878|NCT02237144|Other|Cash transfer|1500 taka ($18.75) per household distributed monthly
1599879|NCT02237144|Other|Food transfer|30 kg rice, 2 kg lentils, and 2 kg micro-nutrient fortified cooking oil per household distributed monthly
1599880|NCT02237144|Other|Food and cash transfer|15 kg of rice; 1 kg of lentils and 1 kg of micronutrient fortified cooking oil and 750 taka cash per household, distributed monthly
1599881|NCT02237144|Behavioral|Behavior Communication Change (BCC)|Weekly, one hour meetings on maternal and child nutrition, sanitation and health knowledge, attitudes and practice Occasional home visits
1599882|NCT02237131|Drug|Oral contraceptives cyclic|tables containing Ethinyl estradiol 0.03mg and drospirenone 3mg will be administered in a cyclic fashion 21 days on 7 days off pill for 6 cycles.
1599883|NCT02237131|Drug|Oral contraceptives continuous|Patients will be treated with oral contraceptives containing 0.03mg ethinyl estradiol and 3 mg drospirenone per day in a continuous fashion.
1599884|NCT02237118|Device|Mepitel One|
1599885|NCT02237118|Device|UrgoTul|
1599886|NCT02237105|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy
1599887|NCT02237092|Procedure|Measurement of IAP|The level of intra-abdominal pressure was measured via a Foley catheter through the urinary bladder. After the introduction of a 30 mL of warm saline. Measurement of the water column in the system was made from the zero level to the mid-axillary line, for 10 minutes, after quiet breathing pregnant at the time of expiration.
1599888|NCT02237079|Drug|Bazedoxifene/Conjugated Estrogens (BZA/CE)|Daily tablet containing conjugated estrogens 0.45 mg and bazedoxifene 20 mg.
1599889|NCT02237079|Drug|Placebo Oral Tablet|Daily placebo tablet
1599890|NCT02237066|Device|Chocolate PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using the Chocolate PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
1599891|NCT02237066|Device|Standard PTA Balloon Angioplasty|OCT imaging of diseased vessel is treated with an Angioplasty Procedure using a standard PTA Balloon Catheter followed by OCT imaging of the treated area immediately after balloon use and 10 minutes later
1599892|NCT02237053|Drug|Glucagon|
1599893|NCT02237053|Drug|Octreotide|
1599894|NCT02237053|Behavioral|Placebo|
1599895|NCT02237053|Drug|Insulin|
1599896|NCT02237040|Procedure|Mandibular manipulation technique|patients are treated with The mandibular manipulation technique reported by Farrar, which was an effective treatment method to reset the physiological positional relationship between condyle and disc.Then patients are told to persist in mouth opening training at home everyday. The mouth opening training is performed as follow: patients are told to try to close his mouth in intercuspal position at first, then open their mouth as wide as possible(the reference maximal mouth opening is as wide as the mouth opening after treatment in last time), then close back to the intercuspal position again.
1599978|NCT02236403|Drug|Ivermectin 0.1% Metronidazole 1%|
2009545|NCT03218995|Drug|Eteplirsen|"Eteplirsen will be administered once a week by IV infusion for up to 96 weeks.
The starting dose is 2 mg/kg eteplirsen, with escalation to 4, 10, 20, and 30 mg/kg over the course of the dose-titration period."
2009546|NCT03218176|Device|Proximal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
1599897|NCT02237027|Biological|TasP using ART regimen as per Benin guidelines|Administration of ART to HIV positive female sew workers in order to prevent HIV transmission.
1599898|NCT02237027|Biological|PrEP using Truvada|Administration of Truvada to HIV negative female sex workers in order to prevent HIV acquisition.
1599899|NCT02237001|Device|Suture-based meniscal repair|Suture-based meniscal repair
1599900|NCT02236988|Drug|Apremilast|
1599901|NCT02236975|Device|BuMA Supreme Biodegradable drug coating coronary stent system|
1599902|NCT02236975|Device|Resolute Integrity durable polymer stent system|
1599903|NCT02236962|Drug|Placebo|
1599904|NCT02236962|Drug|Ephedrine, pioglitazone|
1599905|NCT02236949|Behavioral|Pain Practice Change Booster Intervention|See experimental arm for a description of the intervention
1599906|NCT02236936|Dietary Supplement|Standard care of parenteral nutrition|Standard treatment according to the discretion of the center, any required nutritional support (enteral tube feeding by nasogastric tube or percutaneous endoscopic gastrostomy) when considered necessary is allowed
1599907|NCT02236936|Dietary Supplement|Parenteral over night nutrition|Patients in interventional Arm B will receive parenteral overnight nutrition with ZentroOLIMEL® 5.7% with electrolytes, vitamins (Cernevit®) and micronutrients (Addel Trace® or Nutryelt®) starting with 15 ml/kg body weight/day. In case of weight loss of more than 5%, dose of ZentroOLIMEL® has to be increased up to 25 ml/kg/body weight/day.
1599908|NCT02236936|Biological|Cetuximab|"Weekly during radiotherapy; not given if cisplatin is given during radiotherapy
Cetuximab 400 mg/m2 (saturation) Cetuximab 250mg/m2 (during radiotherapy; in total 7x)"
1599909|NCT02236936|Drug|Cisplatin|Cisplatin total dose of >200 mg administered weekly (40 mg/m2/week) or every three weeks (100 mg/m2 every three weeks) according to local standard; not given in combination with cetuximab
1599910|NCT02236936|Radiation|Radiotherapy|70 Gy / 5 fractions per week, over 7 weeks
1599911|NCT02236910|Other|Lu-DOTA-TATE|
1599912|NCT02236897|Other|PET Scanning|
1599913|NCT02236884|Procedure|no-scar transanal total mesorectal excision(TME)|
1599914|NCT02236871|Behavioral|2 servings|Participants will receive motivational counseling to help the improve milk and milk product intakes to 2 servings per day.
1599915|NCT02236871|Behavioral|4 servings|Participants will receive motivational counseling to help them increase their milk and milk product intake to 4 servings per day.
1599916|NCT02236858|Device|HEPA Air Cleaner|Air cleaners containing HEPA and carbon filters (Austin HealthMate HM400) and capable of removing PM and NO2 will be placed in the bedroom and room where the participant reports spending the most time.
1599917|NCT02236858|Device|Sham HEPA Air Cleaner|Homes in the control group will receive sham air cleaners that have the internal HEPA and carbon filters removed, but which will run normally, including similar noise, airflow and overall appearance compared to active air cleaners, thus blinding participants to filter status.
1599918|NCT02236845|Device|Lacrima Medical Device and sham comparator|
1599919|NCT02236832|Device|transcranial magnetic stimulation|
1599920|NCT02236832|Other|MRI imaging|
1599921|NCT02236832|Other|EEG recording|
1599922|NCT02236832|Behavioral|Neuropsychological examination|
1599923|NCT02236806|Drug|Bisoprolol|5 mg daily
1599924|NCT02236806|Drug|Ramipril|5 mg daily
1599925|NCT02236806|Drug|Placebo|1 capsule daily
1599926|NCT02236793|Drug|BioChaperone PDGF-BB|
1599927|NCT02236793|Other|Standard of Care|
1599928|NCT02236767|Device|Neurostar Transcranial Magnetic Stimulation Therapy System|Treatment will entail daily (5 days/week) sessions of repetitive transcranial magnetic stimulation for 6 weeks employing right-sided, low frequency stimulation (1 Hz, 900 pulses/session for 30 sessions, 27,000 total pulses, intensity at 90% of the passive motor threshold) to the dorsolateral prefrontal cortex (DLPFC).
1599929|NCT02236754|Drug|18F-FP-DTBZ|The drug, no carrier added [18F]-FP-DTBZ, is formulated in 5% (v/v) ethanol in 0.9% sterile saline solution to produce [18F]-FP-DTBZ for injection. Subjects will receive a single i.v. administration of no more than 7.6 mCi of [18F]-FP-DTBZ for injection immediately prior to imaging. The specific activity at time of injection will less than 1.0 mCi/microgram and thus for a 7.6 mCi dose the maximal mass dose will be less than 10 microgram.
1599930|NCT02236754|Radiation|PET Scanning|Individuals will be imaged continuously (i.e. dynamically) for 2 hours.
1599931|NCT02236741|Drug|Mirapexin® (Sifrol®)|
1599932|NCT02236728|Drug|Pramipexole|
1599933|NCT02236715|Drug|Atrovent®|
1599934|NCT02236702|Other|Positron Emission Tomography (PET) imaging|Positron Emission Tomography (PET) imaging
1599935|NCT02236689|Procedure|Non operative|no surgical intervention
1599936|NCT02236689|Procedure|Arthroscopic tennis elbow release|Patients randomized to Arthroscopic tennis elbow release (ATER) will receive arthroscopic release of the origin of the extensor carpi radialis brevis tendon through a standard, two-portal arthroscopic technique (medial and lateral).
1599937|NCT02236676|Behavioral|Nap after rehearsal trials|
1599938|NCT02236663|Behavioral|Usual Care Safety Planing App|The control group App will provide women and friends with basic safety planning information and a brief resource list of IPV resources. The resources will be targeted to college students age 18-24 years. The control group App safety plan is not personalized to woman/friend's safety priorities and danger in the relationship.
1599939|NCT02236663|Behavioral|Personalized App-Based Safety Decision Aid|"Setting of priorities for safety: participants will establish priorities by making pairwise comparisons of importance between 5 factors.
Danger Assessment: asks participants to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger and safety planning information and resources based on their level of danger.
Personalized action plan: Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented tailored to their level of danger and priority settings. The participant is given the option to print results and the personalized plan."
1599940|NCT02236650|Behavioral|Primary Care Stepping Stones Triple P (PC-SS Triple P)|PC-SS Triple P is a parenting and family support strategy that aims to prevent and treat behavioral problems in children by enhancing parental resilience.
1599941|NCT02236650|Other|Treatment as Usual|Treatment as Usual for 4 weeks
1599942|NCT02236624|Behavioral|Aerobic exercise|
2009547|NCT03218176|Device|Proximal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
1599945|NCT02236598|Drug|K+ supplement|
1599946|NCT02236598|Drug|Placebo|
1599947|NCT02236585|Procedure|Patient-controlled epidural analgesia|Patients will receive with patient controlled background infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl that will be set between 4-6 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm), intermittent bolus of 10 ml on demand by the women with lockout interval of 20 min with a four-hour maximum dose of 100 mL, irrespective of their age. The epidural infusions will be maintained for the first 24 postoperative hours
1599948|NCT02236585|Procedure|Continuous epidural analgesia|Patients will receive continuous epidural infusion of 0.125% bupivacaine plus 2 μg/ml fentanyl at rate of 6-15 ml/hour (to maintain visual analog scale (VAS) of ≥ 50 mm).
1599949|NCT02236572|Drug|Everolimus|"Aromatase inhibitor plus everolimus by mouth daily for 26 weeks. All patients will begin treatment on Cycle 1 Day 1 with both the standard dose of one of the following 3 aromatase inhibitors ( physician's choice) plus everolimus 10 mg by mouth daily:
Anastrozole 1 mg
Letrozole 2.5 mg
Exemestane 25 mg"
1599950|NCT02236559|Device|Noninvasive positive pressure ventilation (NIPPV)|"Patients will be fit with an oronasal mask using a fitting gauge that will be applied by a respiratory therapist or other clinician skilled in management of NIPPV. Initial pressures will be at low end of suggested range but can be increased as rapidly as necessary to alleviate respiratory distress. Targets should be to lower respiratory rate to the low 20s and achieve tidal volumes of 6-8 ml/kg ideal body weight. If patients find pressures uncomfortably high, they can be lowered as necessary by 1 to 2 cmH2O decrements to enhance tolerance. EPAP (PEEP) can also be adjusted upward as needed to reduce triggering effort (by counterbalancing auto-PEEP) or to improve oxygenation.
FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 with an EPAP (PEEP) of not more than 10 cm H2O to maintain a PaO2 > 88%."
1599951|NCT02236559|Device|Vapotherm|Patients will be fit with a Vapotherm adult nasal cannula that will be applied by a respiratory therapist or other clinician skilled in management of HFT. Initial flow will be set to 35 L/min but can be decreased or increased as rapidly as necessary to alleviate respiratory distress and optimize patient comfort. Targets should be to lower respiratory rate to the low 20s and with a HFT flow rate between 20 to 35 L/min. Starting temperature will be between 35 to 37 C; if patients find the gas temperature to be uncomfortable, it can be lowered as necessary down to 33 C to enhance tolerance. FIO2 will be 1.0 initially to assure adequate oxygenation, but should be adjusted promptly to maintain an FIO2 of no greater than 0.6 to maintain a PaO2 > 88%.
1599952|NCT02236546|Diagnostic Test|[18F]fluorodeoxyglucose|FDG is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
1599953|NCT02236546|Other|Molecular assays on biopsied tissue|Correlative studies
1599954|NCT02236546|Device|positron emission tomography|Undergo FDG-PET/CT
1599955|NCT02236546|Device|computed tomography|CT that is part of FDG-PET/CT is a low-milliampere, low-resolution scan that is used for anatomic localization and attenuation correction for PET images.
1599956|NCT02236533|Dietary Supplement|whole grain pasta|Volunteers were fed with probiotic fortified pasta or control pasta once a day for 12 weeks.
1599957|NCT02236520|Drug|Spironolactone|
1599958|NCT02236520|Drug|Chlorthalidone|
1599959|NCT02236520|Dietary Supplement|Diet|
1599960|NCT02236520|Drug|Placebo|
1599961|NCT02236507|Device|3D high resolution anorectal manometry|Procedure will take about 15 min. During procedure resting, voluntary squeeze, bear down maneuver, cough reflex, ano-anal reflex and Rectoanal Inhibitory Reflex will be obtained, if possible.
1599962|NCT02236494|Behavioral|Brief Negotiated Interview|As per arm
1599963|NCT02236494|Behavioral|General Health Information|As per arm (this is the active comparator)
1599964|NCT02236481|Drug|Anakinra|
1599965|NCT02236481|Drug|TNF alpha inhibitors|
1599966|NCT02236468|Other|Enhanced-Homestead Food Production Program (old)|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication since 2010
1599967|NCT02236468|Behavioral|WASH/malaria behavior change|WASH/malaria behavior change communication
1599968|NCT02236468|Dietary Supplement|LNS distribution|Distribution of Nutributter (Fanga Degue) for children
1599969|NCT02236468|Other|Enhanced-Homestead Food Production Program (new)|Participation in an enhanced-homestead food production program including home gardening, poultry rearing and nutrition and health behavior change communication since 2014
1599970|NCT02236455|Behavioral|Audio Relaxation Technique|Audio relaxation technique created by an Icelandic Registered Nurse.
1599971|NCT02236455|Behavioral|Medical Music Intervention|Audio recordings of non-lyrical relaxing music
1599972|NCT02236455|Behavioral|Nature Therapy without Music|Nature videos of the mountains, desert, Icelandic scenery, and ocean were provided via iPads for surgical patients
1599973|NCT02236455|Behavioral|Nature Therapy with Music|Nature videos of the mountains, forest, Icelandic landscape, and the ocean were provided via iPads for surgical patients
1599974|NCT02236442|Other|Recommendation to use global headache treatment protocol|"The global treatment protocol is :
Put the patient in a quiet spot, ideally an individual room. Avoid waiting in the corridor
Lay down the patient on the stretcher. Avoid waiting on a seat or a chair.
Provide a sound-proof helmet to the patient.
Provide a light-blocking google to the patient.
If judged necessary by the physician in charge of the patient, administer oxygen therapy, 15 liter per minute, during 15 minutes.
If judged necessary by the physician in charge of the patient, administer analgesic treatment adapted to the etiology of the cephalalgia as described :
Migraine : acetylsalicilyc acid + metoclopramide or nonsteroidal anti inflammatory or paracetamol or triptan.
Tension headache : nonsteroidal anti inflammatory or paracetamol. Avoid methylmorphine or tramadol if possible.
Cluster headache : Intravenous or nasal spray sumatriptan and oxygen therapy.
Other etiology : Treatment left at the discretion of the physician in charge of the patient."
1599975|NCT02236429|Biological|vaginal flora transplant|
1599976|NCT02236416|Behavioral|Intervention group|Supervised, multimodal physical activity including aerobic, resistance and stretching exercises
1599977|NCT02236416|Behavioral|Control group|Usual physical activity, generally consisting in long walks and/or stretching, toning and/or balance exercises, or posture education
1599979|NCT02236390|Behavioral|Exposure, Relaxation, and Rescripting Therapy|5 sessions that last approximately one hour addressing nightmares and sleep problems. Participants will log sleep events and associated symptoms
1599980|NCT02236390|Behavioral|Cognitive Processing Therapy - Cognitive|12 sessions cognitive behavioral treatment targeting posttraumatic stress symptoms.
1599981|NCT02236377|Behavioral|Exposure, Relaxation, and Rescripting Therapy|Brief cognitive behavioral treatment targeting trauma-related nightmares and sleep problems
1599982|NCT02236364|Device|Contour, Bayer Healthcare, LLC|Blood glucose measurement
1599983|NCT02236351|Device|Pinched Patch|
1599984|NCT02236338|Procedure|Ablation of the Incompetent Greater Saphenous Vein|For each patient, the Greater Saphenous Vein (GSV) will be accessed just below the knee. After liberal use of anesthesia, the patient will undergo an ablation of the GSV. Half the patients will have this procedure performed using the Laser Ablation device and half will be treated using the Radiofrequency Ablation device. They will be randomly assigned to treatment.
1599985|NCT02236338|Device|ClosureFAST radiofrequency catheter|
1599986|NCT02236338|Device|EVLT 980nm diode laser system|
1599987|NCT02236325|Behavioral|DBT Brief Suicide Intervention|Participants assigned to the DBT Brief Suicide Intervention are presented with a selection of coping strategies selected from the Dialectical Behavior Therapy (DBT) skills training curriculum. The strategies are 1) mindfulness, 2) mindfulness of current emotions, 3) opposite-to-emotion action, 4) distraction, and 5) changing your body chemistry.
1599988|NCT02236325|Behavioral|Relaxation Training|Participants assigned to the Relaxation Training condition receive instruction in a sensory awareness practice and are guided through the practice by the therapist.
1599989|NCT02236312|Drug|Botulinum Toxin Type A|
1599990|NCT02236312|Drug|Placebo|
1599991|NCT02236299|Procedure|Right Coronary Artery Percutaneous Coronary Intervention|
1599992|NCT02236299|Other|saline placebo infusion|30 minute placebo infusion used as a comparator to the GLP-1 infusion
1599993|NCT02236299|Other|GLP-1 Infusion|30 minute infusion GLP-1
1599994|NCT02236286|Behavioral|Exercise|Agility Boot Camp (ABC) exercise intervention consisting of 18 sessions of group exercise led by an exercise trainer.
1599995|NCT02236273|Behavioral|Conventional text message reminder|Receipt of conventional text message notifying when due for next dose
1599996|NCT02236273|Behavioral|Enhanced text message reminders|Receipt of enhanced text messages notifying when due for next dose coupled with educational information
1599997|NCT02236260|Procedure|Electroacupuncture|Acupuncture will be performed using an electrical stimulator (generating electrical stimulation) for electroacupuncture.
1599998|NCT02236260|Drug|Local Anesthesia (lidocaine hydrochloride)|All patients will receive injectable paracetamol for pain relief, a mix of nitrous oxide 50% and oxygen 50% for analgesia and lidocaine hydrochloride for local anesthesia.
1599999|NCT02236247|Drug|ivabradine|5 mg oral twice daily
1600000|NCT02236247|Drug|Placebo|A placebo pill (identical to ivabradine) will be administered twice daily
1600001|NCT02236234|Biological|HPV vaccine|HPV vaccine
1600002|NCT02236195|Drug|Mocetinostat|
1600003|NCT02236182|Drug|Ipratropium Bromide low dose|
1600004|NCT02236182|Drug|Placebo|
1600005|NCT02236182|Drug|Ipratropium Bromide high dose|
1600006|NCT02236169|Drug|Ipratropium bromide HFA-134a inhalation aerosol|
1600007|NCT02236169|Drug|Atrovent CFC inhalation aerosol|
1600008|NCT02236156|Drug|Metronidazole oral tablets 500mg|One tablet taken orally twice daily for seven consecutive days
1600009|NCT02236156|Drug|1% SPL7013 Gel|5g inserted in to the vaginal on alternate days (i.e. every other day) for 16 consecutive weeks.
1600010|NCT02236156|Drug|Placebo gel|5g inserted in to the vagina on alternate days (i.e. every other day) for 16 consecutive weeks
1600011|NCT02236130|Procedure|Regional block|Single shot peripheral nerve block
1600012|NCT02236130|Procedure|General Anesthesia|General Anesthesia with O2/N2O/Sevoflurane
1600013|NCT02236130|Drug|Local Anesthetic Ropivacaine|0.5% Ropivacaine
1600014|NCT02236130|Drug|Opioids Morphine|Morphine
1600015|NCT02236130|Drug|Oral pain medication Acetaminophen with Hydrocodone|Acetaminophen with Hydrocodone
1600016|NCT02236117|Other|Aerobic Training|Will be included 160 children, 80 in an experimental group and 80 in a control group of both genders. The experimental group will realize aerobic training during 10 weeks (3×40min week−1; intensity, >80% maximal aerobic velocity - MAV), while the control group will have involved with the physical education classes two times a week for 50 minutes each class. The aerobic protocol will be composed by 2 sessions of intermittent running and 1 session by continuous.
1600017|NCT02236104|Device|Plethysmography opto electronic|
1600018|NCT02236104|Procedure|respiratory parameters|
1600019|NCT02236078|Drug|Capreomycin|See arm Description
1600020|NCT02236078|Drug|High dose isoniazid|See arm description
1600021|NCT02236078|Drug|Rifampicin|see arm description
1600022|NCT02236078|Drug|Rifabutin|see arm description
1600023|NCT02236078|Drug|Moxifloxacin|see arm description
1600026|NCT02236052|Biological|Non-adjuvanted low dose of quadrivalent VLP vaccine|A single non-adjuvanted low dose of quadrivalent VLP vaccine
1600027|NCT02236052|Biological|Non-adjuvanted medium dose of quadrivalent VLP vaccine|A single non-adjuvanted medium dose of quadrivalent VLP vaccine
1600028|NCT02236052|Biological|Non-adjuvanted high dose of quadrivalent VLP vaccine|A single non-adjuvanted high dose of quadrivalent VLP vaccine
1600029|NCT02236052|Biological|Adjuvanted low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine mixed with Alhydrogel®
1600030|NCT02236052|Biological|Adjuvanted high dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine mixed with Alhydrogel®
1600031|NCT02236052|Biological|Placebo|A single dose of placebo
1600032|NCT02236039|Procedure|Bronchoscopy|Bronchoscopy with biopsy sampling, brushings and bronchoalveolar lavage (BAL) 24 hours post exposure.
1600033|NCT02236026|Drug|Supratherapuetic dose of Nestorone|
1600034|NCT02236026|Drug|Placebo|
1600035|NCT02236026|Drug|Moxifloxacin|
1600036|NCT02236013|Drug|Gilteritinib|Oral
1600037|NCT02236013|Drug|Idarubicin|lyophilized powder administered intravenously
1600038|NCT02236013|Drug|Cytarabine|solution administered intravenously
1600039|NCT02236000|Drug|Neratinib|"Dose-Escalation Phase (Part 1) - Neratinib Dose-escalation will proceed on the basis of DLT during Cycle 1 starting at 120 mg/day.
Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day
Dose-evaluation Phase (Part 2) - Patients will receive the highest dose of neratinib with T-DM1 found in Phase I as study therapy"
1600040|NCT02236000|Drug|T-DM1|"Dose-Escalation Phase (Part 1) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days.
Dose-evaluation Phase (Part 2) - Trastuzumab emtansine (T-DM1) will be given at 3.6 mg/kg IV Day 1 every 21 days."
1994972|NCT02881775|Device|rTMS and exercise|rTMS at 10 Hz (5 sec on, 55 sec off) and light quadriceps isometric exercise (5% MVIC)
1600044|NCT02235974|Behavioral|Early Intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 30 days of stroke onset.
1600045|NCT02235974|Behavioral|Sub-acute intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 2 to 3 months post stroke.
1600046|NCT02235974|Behavioral|Chronic intensive upper extremity motor training|Using a shaping therapy protocol, participants will receive a dose of 20 hours of intensive upper extremity therapy (in addition to their current therapy) beginning within 6 to 9 months post stroke.
1600047|NCT02235974|Behavioral|Control|Usual and Customary Care only. No additional therapy will be given during the 1-year study.
1600048|NCT02235961|Drug|NNC9204-0530|Administered as single subcutaneous (s.c., under the skin) injections.
1600049|NCT02235961|Drug|liraglutide|Administered as subcutaneous (s.c., under the skin) injections of 1.8 or 3.0 mg.
1600050|NCT02235961|Drug|placebo|Administered as single subcutaneous (s.c., under the skin) injections.
1600051|NCT02235948|Drug|folic acid supplementation|0.8mg folic acid/day
1600052|NCT02235922|Other|Dual task training|The dual task training consisted of individuals subjected to a multicomponent exercise program associated to cognitive tasks.
1600053|NCT02235922|Other|Conventional training|The conventional training consisted of individuals subjected to a multicomponent exercise program.
1600054|NCT02235909|Drug|Azilsartan Medoxomil|
1600055|NCT02235909|Drug|Losartan|
1600056|NCT02235909|Drug|Placebo for Azilsartan Medoxomil|
1600057|NCT02235909|Drug|Placebo for Losartan|
1600058|NCT02235896|Behavioral|Education/Behavior Modification|Education, lifestyle counseling, experiential cooking, exercise classes.
1994973|NCT02881775|Device|Sham rTMS and exercise|rTMS unit is on and running but mu metal is placed between the coil and the skull
1994974|NCT02881125|Drug|Nortriptyline Hydrochloride|Given PO
1994975|NCT02881125|Drug|Paclitaxel|Given IV
1600062|NCT02235857|Device|Liposorber® LA-15 System|Liposorber® LA-15 System is an extracorporeal blood purification system. Approximately 3 to 4 L of plasma is treated in a single treatment session and it takes 2 to 3 hours. Recommended frequency of the treatment is twice weekly for 3 weeks followed by once weekly for 6 weeks, thus it takes 9 weeks for a total of 12 treatment sessions.
1600063|NCT02235844|Biological|Umbilical Cord Mesenchymal Stem Cells|
1600064|NCT02235831|Device|Nelfilcon A MF contact lenses (DACP MF)|Multifocal contact lenses in Low, Medium, High Add
1600065|NCT02235831|Device|Nelfilcon A single vision contact lenses (DACP)|
1600066|NCT02235818|Device|Kinesiotape|Pre-cut kinesiotape for tennis elbow, spidertech.com, applied on wrist extensors starting above elbow and ending at distal one third of forearm
1600067|NCT02235818|Device|Counterforce elbow brace|Applied over the wrist extensor muscle mass, had velcro for adjustment, comfortable grip as reported by patient was used to adjust the brace
1600068|NCT02235805|Dietary Supplement|Magnesium Citrate|One capsule thrice daily that contains magnesium citrate (total daily dose: 350 mg elemental magnesium) at breakfast, lunch and dinner for 24 weeks
1600069|NCT02235805|Dietary Supplement|Placebo|One capsule thrice daily that contains placebo at breakfast, lunch and dinner for 24 weeks
1600070|NCT02235792|Device|Activa PC+S|The model 37604 Activa PC+S system is a multiprogrammable device that both delivers electrical stimulation and records bioelectric data through one or two leads implanted in the brain.
1600071|NCT02235779|Other|Transbronchial lung cryobiopsy|
1600072|NCT02235766|Other|Echocardiographic assessment|
1600073|NCT02235753|Behavioral|High-intensity aerobic interval training, short interval|The intensity of HIT-S sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 100% which will be the target intensity from 6 to 12 months. The protocol includes four 6 min sets consisting of 15 sec exercise followed by 15 sec passive recovery separated with 3 min passive recovery between sets. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 15 seconds exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-S patients with ECG monitoring and supervised by physician.
1600119|NCT02235402|Drug|Placebo|
1600120|NCT02235389|Drug|Alteplase (Actilyse)|
1600121|NCT02235389|Drug|Standard therapy|
1600122|NCT02235376|Other|weaning trial of mechanical ventilation|
1600191|NCT02234804|Device|Medtronic Resolute Integrity stent|
1600074|NCT02235753|Behavioral|High-intensity aerobic interval training, long interval|The intensity of HIT-L sessions (cycle ergometer) will be increased during 3 to 6 months from 60% of VO2peak to 90% which will be the target intensity from 6 to 12 months. The protocol includes four 3 min exercise bouts with a 4 min recovery (pedaling at 0 W) between bouts. Exercise session will last ca. 40 min, with 12 min of HIT, warm-up and recovery. The intensity of the 3 min exercise bouts will be based on VO2peak at baseline and after 6 months. Meanwhile, the estimated VO2peak from the submaximal test will be used to adjust the training intensity in HIT sessions. Training will be conducted in a group of 1-3 HIT-L patients with ECG monitoring and supervised by physician.
1600075|NCT02235740|Drug|Afuresertib|Afuresertib will be dosed orally in morning, and will be sourced as opaque, white, size 4, 25 mg capsule and size 1, 100 mg capsules.
1600076|NCT02235740|Drug|Carfilzomib|Intravenous (IV) Carfilzomib will be sourced in the US from commercial stock. It will be a single-use 60 mg vial as a sterile, white to off-white lyophilized cake or powder
1600077|NCT02235727|Drug|GBR 900|
1600078|NCT02235727|Drug|Placebo|
1600079|NCT02235701|Drug|aldoxorubicin|administered at 170 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
1600080|NCT02235701|Drug|aldoxorubicin|administered at 250 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
1600081|NCT02235701|Drug|aldoxorubicin|administered 350 mg/m2 plus 1 gm/m2/day ifosfamide by continuous intravenous infusion for up to 14 days on Day 1 every 28 days
1600082|NCT02235701|Drug|ifosfamide|
1600083|NCT02235688|Drug|aldoxorubicin|administered at 170 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
1600084|NCT02235688|Drug|aldoxorubicin|administered at 250 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
1600085|NCT02235688|Drug|aldoxorubicin|administered at 350 mg/m2 by intravenous infusion (IVI) on Day 1 every 21 days plus 900 mg/m2 gemcitabine on Days 1 and 8 every 21 days.
1600086|NCT02235688|Drug|gemcitabine|
1600087|NCT02235675|Device|Tack-It Endovascular System|Repair of post-PTA dissections using the Intact Vascular Tack-It implant.
1600088|NCT02235662|Drug|TFV IVR|
1600089|NCT02235662|Drug|TFV/LNG IVR|
1600090|NCT02235662|Other|Placebo IVR|
1600091|NCT02235649|Behavioral|Social Cognition therapy ( Psychological Therapy)|
1600092|NCT02235623|Procedure|Single-stage Fowler-Stephens orchidopexy (FSO)|
1600093|NCT02235623|Procedure|Two-stage Fowler-Stephens orchidopexy (FSO)|
1600094|NCT02235610|Procedure|EVLP Group|"EVLP technique (Lund Protocol): open left atrium, Steen solution mixed with red blood cells and perfusion 100% of the donor predicted cardiac output.
Lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice."
1600095|NCT02235584|Drug|Dexamethasone|Dexamethasone are given dexamethasone tablets of 2mg twice daily.
1600096|NCT02235571|Behavioral|iChoose Kidney Decision Aid|Providers will use a shared decision making tool with patients via iPhone, iPad, or web which explains predicted individualized risk of mortality on dialysis vs. transplant during the evaluation appointment for kidney transplant.
1600097|NCT02235558|Drug|Verapamil|Super-selective intra-arterial administration of 10mg verapamil in 20cc of normal saline will be administered over 20 minutes (1cc/minute) through the microcatheter and into the vessel previously obstructed by clot, immediately following successful intra-arterial thrombolysis. Half-life is 2.8-7.4 hrs.
1600098|NCT02235545|Device|St. Jude Medical Optisure Lead|Patients implanted with St. Jude Medical Optisure Lead
1600099|NCT02235532|Other|Foramen Herbal Aloe toothpaste|use of aloe-vera toothpaste for 30 days in the test group.
1600100|NCT02235532|Other|fluoride toothpaste|use of signal toothpaste once a day for 30 days in the control group.
1600101|NCT02235519|Drug|Azilsartan 40 mg.|Patients will take 40 mg of azilsartan during 12 weeks
1600102|NCT02235519|Drug|Azilsartan 80 mg|Patients will take 80 mg of azilsartan during 12 weeks
1600103|NCT02235506|Procedure|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
1600104|NCT02235506|Procedure|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
1600105|NCT02235506|Device|epidural infusion|Lumbar epidural catheter is placed at the L3-4 level using loss-ofresistance procedure. Fentayl 2mcg/ml and 0.2% ropivacaine are infused at a rate of 5ml/hr.
1600106|NCT02235506|Device|femoral sciatic|After femoral and sciatic nerve are identified using ultrasound, 0.2% ropivacaine 20 mL is injected. A catheter is inserted to femoral nerve and 0.2% ropivacaine is infused through the femoral catheter at a rate of 5ml/hr from the end of surgery.
1600107|NCT02235493|Biological|Retrospective Case Only|
1600108|NCT02235480|Drug|Experimental Tazarotene Gel|
1600109|NCT02235480|Drug|Placebo|
1600110|NCT02235467|Behavioral|ABA parent training|A parent training based on Applied Behavior Analysis that is going to be delivered by video modeling in 21 weeks
1600111|NCT02235454|Device|SDOCT-GMPE software|Noninvasive imaging of the optic nerve in patients with existing glaucoma
1600112|NCT02235441|Other|Cardiopulmonary Exercise Test (CPET)|All subjects will undergo a maximal cardiopulmonary exercise test and resting metabolic rate study. Prior to the exercise treadmill test, each subject will have a resting ECG and blood pressure to determine whether there are any abnormalities that would contraindicate exercise testing.This exercise test involves exercising on a treadmill to maximal exertion, during which the subject's breathing and oxygen consumption are measured. The subject will wear nose clips to prevent exhaling air through their nose and a mouth piece that will allow all exhaled air to be analyzed through the metabolic cart. The subject's electrocardiogram (ECG), blood pressure, and perceived exertion are monitored throughout the test by trained personnel.
1600113|NCT02235428|Drug|Ipratropium bromide|
1600114|NCT02235428|Drug|Placebo|
1600115|NCT02235428|Drug|Salbutamol|
1600116|NCT02235415|Drug|Motens® (lacidipine)|
1600117|NCT02235402|Drug|Lacidipine|
1600118|NCT02235402|Drug|Bendrofluazide|
1600123|NCT02235363|Procedure|thread lift|In facial rejuvenating surgery, the current trend calls for fewer and less noticeable scars with desired results. Especially to improve the jowls and nasolabial folds, the thread lift is a simple and inexpensive technique for patients who do not wish to undergo the typical facelift surgery, but the weak points of it are less effective and shorter duration than the conventional facelift.The investigators propose the new method of the thread lifting the subdermal and subcutaneous layer by use of the retaining ligaments with two fixation points on both temporal fascia and retaining ligaments.
1600124|NCT02235350|Other|Action Observation Treatment (AOT)|Participants will be asked to carefully observe at a computer screen videos depicting different daily actions. Each action will consist of 3 to 4 constituent motor acts. Each motor act will be presented for 3 minutes. As a whole, therefore, each video will be 12 minutes long. At the end of each motor act presentation, participants will be required to execute with the affected hand the observed motor sequence for 2 minutes. Each single rehabilitation session based on AOT will last 20 minutes. We will record ten daily actions for a total of ten video-clips. Participants will be presented with each video clips, twice a day, in order of complexity as judged by the experimenter. Participants will undergo 10 sessions a week, each lasting 20 minutes for 2 weeks.
1600125|NCT02235350|Other|Observation of videos with no motor content (MNO)|Participants will be asked to observe video clips with no specific motor content. Videos will concern scientific, geographical and historical issues. As for cases, video clips will be divided into three to four parts. At the end of each part, controls will execute the same actions as cases, in the same order. In this way cases and controls will undergo the same amount of motor practice and receive the same amount of visual stimulation, the only difference being the content of visual stimuli.
1600126|NCT02235337|Drug|Riboflavin 400mg daily|
1600127|NCT02235324|Biological|ziv-aflibercept|Given IV
1600128|NCT02235324|Drug|leucovorin calcium|Given IV
1600129|NCT02235324|Drug|fluorouracil|Given IV
1600130|NCT02235324|Other|laboratory biomarker analysis|Correlative studies
1600131|NCT02235311|Drug|Pantoprazole|Pantoprazole 40mg orally daily x 8 weeks after acute management of UGIB
1600132|NCT02235298|Drug|Dapagliflozin|Dapaglifozin causes a rapid and significant reduction of epicardial fat in type 2 diabetic patients
1600133|NCT02235298|Drug|Metformin|
1600134|NCT02235285|Procedure|primary breast augmentation|With the patient under sedative anesthesia, wide preparation and draping by using povidone-iodine are performed with using talc-free gloves and povidone-iodine gauze nipple shields. Tumescent solution is infiltrated in the precise plane. Pockets are developed precisely with blunt dissection with fingers and instruments under both direct and indirect visions simultaneously, if needed, with using endoscopy, while careful hemostasis done. After dissection, two pockets are irrigated with 300ml of single antibiotic solution without active evacuation of the irrigation. When re-draping and re-preparation by using povidone-iodine are performed before implant insertion, a new pair of talc-free gloves is used and cleansed with the single antibiotic solution.
1600135|NCT02235272|Drug|XG-102|Comparison of XG-102 versus placebo sub-conjunctival injection efficacy
1600136|NCT02235272|Drug|Placebo|comparison of XG-102 versus placebo sub-conjunctival injection efficacy
1600137|NCT02235259|Drug|XG-104|Comparison of XG-104 (3 concentrations) versus placebo eye drops efficacy
1600138|NCT02235259|Drug|Placebo|
1600139|NCT02235246|Drug|Magnesium Sulfate|magnesium sulfate 50 mg/kg will be administrated during 10 min before anesthetic induction in patients undergoing endoscopic submucosal dissection.
1600140|NCT02235246|Drug|Normal saline|Normal saline will be administrated during 10 min before anesethetic induction in patients undergoing endoscopic submucosal dissection.
1600141|NCT02235233|Drug|Technetium Tc 99M Mebrofenin|Each subject will be injected with ~2.5 mCi of Technetium Tc 99M Mebrofenin
1600142|NCT02235220|Other|Composite resin restoration|"Masticatory muscular activity is measured before and after treatment with additive composite resin fillings (Tetric EvoCeram, Ivoclar Vivadent, Schaan, Liechtenstein). A Grindcare (Medotech A/S, Herlev, Denmark) device is used for determination of muscular activity.
A first measurement is conducted, followed by 4 weeks without any intervention. A second measurement is then carried out before restoration of the canine cusps with composite fillings. A third measurement is conducted, again followed by 4 weeks without any intervention. At last a final measurement is conducted."
1600143|NCT02235207|Behavioral|Neuromuscular exercise|"Fustra20 Neck & Back is individually guided, graded neuromuscular exercise program which is conducted twice a week for 20 times. Each session lasts one hour. After 20 sessions participants are encouraged to continue exercising at home with a help of an individual home exercise plan including diary of compliance.
The main targets are to
improve movement control in different posture and movements of the neck and back
improve flexibility with active functional movements
improve pelvic, spine and shoulder-neck stability using co-contraction of several muscle groups, and thus enhancing gross movement of the whole kinetic chain
improve muscular endurance of shoulder neck area, trunk, pelvis and lower extremities"
1600144|NCT02235194|Dietary Supplement|Amino Acid and chromium-picolinate containing drink|Amino Acid and chromium - picolinate containg water ist taken with a test meal to study efects on glucose and insulin response.
1600145|NCT02235194|Dietary Supplement|Placebo Drink|Placebo drink ist taken with a test meal to study efects on glucose and insulin response.
1600146|NCT02235181|Device|Arabin Cervical Pessary|The Arabin pessary is CE-certified for preventing Spontaneous Preterm Birth (SPB) (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC) and is being used in this study as per the CE certification and manufacturer's guidance.
1600147|NCT02235168|Procedure|six minute walking test|
1600148|NCT02235142|Other|Blood sample|
1600149|NCT02235129|Other|breath-holding|
1600150|NCT02235116|Other|Survey|
1600151|NCT02235103|Other|Sperm Chromatin Dispersion Test|
1600152|NCT02235090|Other|Direct current stimulation of cervical spinal cord|10 minutes direct current stimulation of 0, 100 microamperes, 1 milliampere strengths applied through dermal electrodes to cervical spinal cord
1600153|NCT02235077|Drug|Spironolactone|"Patients receiving no MRA at home will receive spironolactone 100 mg (4x25 mg capsules) once daily for 96 hours.
Patients already receiving low-dose MRA at home will be randomized to receive spironolactone 25 mg (1x25 mg capsules) or 100 mg (4x25 mg capsules) in hospital for 96 hours. The patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
1600154|NCT02235077|Drug|Placebo|"Patients receiving no MRA at home will receive 100 mg placebo (4x25 mg capsules) once daily for 96 hours.
Patients who are randomized to 25 mg spironolactone will also receive 75 mg placebo (3x25 mg capsules) in order to maintain blinding."
1600155|NCT02235064|Drug|Sertraline|Capsule containing crushed sertraline 50 mg tablets mixed with identically colored cellulose, with 4 day 25 mg taper
1600156|NCT02235064|Drug|Placebo|Capsule containing cellulose powder of same color as experimental arm
1600157|NCT02235051|Behavioral|exercise intervention|Undergo Curves exercise program
1600158|NCT02235051|Other|laboratory biomarker analysis|Correlative studies
1600159|NCT02235051|Other|questionnaire administration|Ancillary studies
1600160|NCT02235051|Other|quality-of-life assessment|Ancillary studies
1600161|NCT02235038|Behavioral|Low carbohydrate diet|Composition (by proportion of calories) : 15% carbohydrate, 65% fat, 20% protein
1600162|NCT02235038|Behavioral|Moderate carbohydrate diet|Feeding study. Composition (by proportion of calories): 40% carbohydrate, 40% fat, 20% protein
1600163|NCT02235038|Behavioral|High carbohydrate diet|Feeding study. Composition (by proportion of calories): 60% carbohydrate, 20% fat, 20% protein
1600164|NCT02235025|Other|Cardio-pulmonary exercise testing|
2009548|NCT03218176|Device|Distal single upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
2009549|NCT03218176|Device|Distal staggered upper limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
1600167|NCT02234999|Drug|CC-122|3mg [14C]-CC-122 will be administered as a single dose
1600168|NCT02234986|Drug|ENMD-2076|250 mg oral dose, QD for 28 day cycles
1600169|NCT02234960|Drug|Tocilizumab|Tocilizumab will be given according to summary of product characteristics as per clinical practice.
1600170|NCT02234947|Procedure|MRI, US, and blood samples|All groups will have pancreatic volume assessment by ultrasonography (US), Magnetic Resonance Imaging (MRI) and blood samples. These test will be compared to the testing from the other groups.
1600171|NCT02234934|Biological|Lentiviral G1XCGD Gene Therapy|"The investigational product is patient-specific and corresponds to autologous CD34+ cells transduced ex vivo with the G1XCGD vector in their final suspension. The starting materials used for the production of the investigational product consist of the viral vector and the patient's CD34+ cells.
The G1XCGD vector is used to transduce autologous CD34+ cells ex vivo. These transduced cells are then infused into the patient. The cell/product dose will consist of at least 1 x 10^6 cells per kg of body weight transduced ex vivo with 1 x 10^8 IG/ml of lentiviral vector to achieve > 0.3 integrated copies per cell."
1600172|NCT02234921|Drug|Cyclophosphamide|A single dose of cyclophosphamide, 300 mg/m2, will be administered intravenously 3 Days prior to the first vaccine.
1600173|NCT02234921|Biological|DRibble Vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19 and 22. Eight vaccinations will be administered. Week 1 and 4 vaccines will be administered by intranodal injections performed using ultrasound guidance.
1600174|NCT02234921|Biological|HPV Vaccinations|Patients will receive a dose of 0.5-mL CERVARIX at week 1 (Day 4) and week 7 by intramuscular injection at a site distant from the DRibble vaccine.
1600175|NCT02234921|Drug|Imiquimod|Imiquimod cream (5%, 250 mg) will be self-applied topically for 5 consecutive days by patients to a 4 x 5-cm outlined area of healthy extremity skin starting on the day of the second vaccine and again during each additional vaccine cycle.
1994978|NCT02879799|Other|Implement Family Integrated Care|Specially trained FICare nurses will provide education and support for families to provide care for the baby while they are present in the NICU. Study mothers will meet with veteran parents for additional support. Families will keep a log of their activities and costs.
1994979|NCT02879669|Biological|ONCOS-102|
1600178|NCT02234895|Device|Lateral wedge|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
1600179|NCT02234895|Device|Lateral wedge plus medial arch support|This will be a randomized cross-over study where all participants will receive both orthoses over a six month period. Each intervention will last two months, separated by a two month washout period of no orthotics wear, and will be preceded and followed by a laboratory-based gait and pain assessment. Two months has been chosen as the ideal time frame to ensure maximum participant adherence, to observe clinically meaningful changes in symptoms, and to minimize degradation of the insoles.
1600180|NCT02234882|Drug|Rosuvastatin|
1600181|NCT02234882|Drug|BMS-663068|
1600182|NCT02234869|Drug|Interferon Beta|Subcutaneous injection
1600183|NCT02234869|Drug|BIIB017 (Peginterferon beta-1a)|Single-use, disposable, prefilled pen for subcutaneous injection
1600184|NCT02234856|Procedure|Laparoscopic Hysterectomy trainer|In order to increase comfort level amongst Gynecologists, we aim to identify verbal and non-verbal components of teaching TLH through interview and video recordings. Utilizing qualitative analysis of common themes, we will develop an educational video and web-based e-module to be used by Gynecology residents and surgeons. We will also use a combination of quantitative pre- and post-tests and qualitative surveys to assess the effectiveness of such a training tool. Ultimately, the project aims to create a robust tool that can be implemented in Gynecology residencies.
2009550|NCT03218176|Device|Proximal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
2009551|NCT03218176|Device|Proximal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
2009552|NCT03218176|Device|Distal single lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
1600188|NCT02234830|Device|Exoseal closure device|Closure device for femoral artery access closure
1600189|NCT02234830|Device|Angioseal closure device|Closure device for femoral artery access closure
1600190|NCT02234804|Device|Xience Prime Stent|
1994980|NCT02879669|Drug|Pemetrexed/cisplatin|
1994981|NCT02879669|Drug|Cyclophosphamide|
2009553|NCT03218176|Device|Distal staggered lower limb|Measurement of pain, pressure under tourniquet, feeling and abolition of pulse doppler and pulse oximetry
1600195|NCT02234765|Other|Primary Care-based management|Patients will be diagnosed and follow-up in Primary Care.
1600196|NCT02234765|Other|Standard management|Standard management according to Spanish Respiratory Society guidelines in Sleep Unit.
1600199|NCT02234739|Drug|Voriconazole|2-week long intravenous instillation of voriconazole
1600200|NCT02234726|Behavioral|Early Childhood Development Program|"A cadre of community-based health workers, Child Development Agents (CDAs), have four main tasks and responsibilities: 1) biweekly screening and management (including referral) of acute malnutrition in children; 2) encouragement of caregivers to utilize routine care services for children; 3) screening for symptoms of acute diseases and referral for diagnosis and treatment; and 4) organization and mentoring of weekly meetings for caregivers to discuss parenting issues and promote early childhood cognitive stimulation.
Amendment: during second year extension, CDAs are responsible for organizing and mentoring biweekly (i.e., fortnightly) caregiver meetings. They no longer conduct household visits."
1600201|NCT02234713|Behavioral|Motivational Interview|
1600202|NCT02234713|Other|Video Attention Control|
1600206|NCT02234674|Other|Current intensive CDP|"Standard Intensive CDP including
manual lymph drainage,
pressotherapy and
bandaging"
1600207|NCT02234674|Other|intensive CDP where Stendo pulsating suit replaces pressotherapy|The intervention consist to perform daily during 5 days an intensive CDP where pressotheray is replaced by Stndo pulsating suit sessions.
1600208|NCT02234661|Behavioral|CareerAdvance®|CareerAdvance® is a dual-generation program providing education, career coaching, and soft-skills training for parents while their children attend CAP Tulsa's Head Start programs.
1600209|NCT02234648|Dietary Supplement|60mL tart Montmorency cherry juice|One bolus of 60mL of tart Montmorency concentrate mixed with 100mL of water.
1600210|NCT02234648|Other|Placebo|One bolus of less than 5% fruit cordial mixed with water, maltodextrin and whey protein isolate to match for carbohydrate and calorie content of the juice.
1600211|NCT02234635|Other|Diffractive multifocal IOLs group|Diffractive IOLs are a type of multifocal (bifocal) IOL that are based on the Huygens-Fresnel principle. Specifically, a diffractive IOL has concentric rings in its posterior surface that form 2 primary focal points independent of pupil size. This optical behavior of the IOL can effectively restore far and near vision. However, it can also cause side effects, such as halos and glare and loss of contrast sensitivity.
1600212|NCT02234622|Behavioral|Holistic Yoga Program|The Holistic Yoga Program (HYP) (postures, breathing practices, deep muscle contraction practices, relaxation) is a 16 week, 90 minute weekly group intervention.
1600213|NCT02234622|Behavioral|Wellness Lifestyle Program|The Wellness Lifestyle Program (WLP) is a 16 week, 90 minute weekly group intervention consisting of low intensity physical activity with didactics about wellness topics.
1600214|NCT02234609|Device|modified ART class IV|Carious tissue was removed with an excavator until a sound probing was obtained. Restorations were performed using a mechanically improved glass-ionomer cement for ART. The modified class IV ART restoration was inserted into the cavity using a spatula. By these restoration technique, the cavity was (i) sealed to stop further caries progression. The cavity was (ii) capped to protect the vital dentin-pulp-complex from external stimuli. The modified class IV ART was aimed at conserving the carious incisor for prospective functional use and for prolonging tooth preservation rather than at anatomical reconstruction of the tooth form for cosmetic reasons.
1600215|NCT02234596|Drug|Nintedanib|Nintedanib 200mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days continuously, unless interrupted for intolerable toxicity.
1600216|NCT02234583|Drug|15mg DS-5565|
1600217|NCT02234570|Drug|Oxfendazole|A benzimidazole carbamate antiparasitic drug. Oral Dose levels of 0.5,1, 3, 7.5, 15, 30, and 60 mg/kg will be evaluated sequentially, the dose increasing with each new cohort Group 1 to Group 7.
1600218|NCT02234570|Other|Placebo|Normal Saline administered with an oral dosing syringe. Group 1- Group 6
1600219|NCT02234557|Behavioral|Tai Chi|"6-8 students will be enrolled in 8 weeks of Tai Chi instruction, with two 1-hour sessions per week. Students will be requested to practice from recorded materials at home three times a week for 15-30 minutes each session, and parents will be asked to keep a log of at-home practice.
Class sessions will consist of warm up (qi k'ong), postural and breathing exercises, Tai Chi form practice, and Tai Chi games (including push hands).
Practice will consist of warm up, followed by practice of selected pieces of the form.
Children on stimulant medications will remain on these medications during the training period (though they will be asked to stop medications one day prior to motor and cognitive testing pre-, mid- and postintervention)."
1600220|NCT02234544|Drug|Ezetimibe|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection [25(OH)D, PTH, calcium, albumin]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
1600221|NCT02234544|Drug|Cholecalciferol|All participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
1600222|NCT02234544|Other|Placebo|The groups will be randomized to ezetimibe 10 mg for 5 days or placebo. On the fifth day, they should came after an overnight fast for blood tests collection [25(OH)D, PTH, calcium, albumin]. Next, all participants will receive orally a cholecalciferol 50,000 IU capsule and a snack containing 15g of fat. Participants will return 14 days after that for a second blood test.
1600308|NCT02233803|Drug|NEUMOTEROL 400 (BFF 400/12 mcg) single capsule inhaler|Micronized 400 mcg budesonide+ 12 mcg formoterol fumarate along with micronized and crystalline lactose monohydrate (excipient), per capsule dispensed by single capsule inhaler, twice daily (administered once in the morning and once in the evening approximately 12 hours later).
1600223|NCT02234531|Device|EVER TEACHER|"The treatment will be performed in a darkened room, to avoid distraction provided by environmental stimuli. The patients will be seat on a standard chair in front of a wall screen handling a sensorized object with plegic hand. In case of grasping deficits the hand's surface will be used as end effector (i.e. sensorized glove worn by the patient). During the treatment a specific feedback called virtual teacher will be displayed. The Reinforced Feedback in Virtual Environment (RFVE) approach consists of performing different motor tasks moving the end effector simultaneously displayed in the virtual scenario. The Virtual Reality Rehabilitation System (VRRS®. Khymeia Group, Noventa Padovana. Italy) will be used as device to provide the artificial environment."
1600224|NCT02234531|Device|NEVER TEACHER|The patients allocated to NEVER TEACHER group, will be treated using the VRRS and the proceedings will be the same as described for experimental group. In this group, the patient will move the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the wall screen in accordance with the requested virtual task and without the 'virtual teacher' support.
1600225|NCT02234518|Other|High quantity fiber|The intervention type is food product
1600226|NCT02234518|Other|Low quantity fiber|The intervention type is food product
1600227|NCT02234518|Other|Placebo|
1600228|NCT02234505|Procedure|Prosthetic alignment perturbation|Prosthetic ankle plantar-flexion will be modified in different degrees, devices (prosthetic components) will not be modified from baseline condition
1600229|NCT02234492|Drug|Rosuvastatin|Comparison of rosuvastatin to no rosuvastatin
1600230|NCT02234479|Biological|Hydrophor (Group A)|"Rehydrates dry, chapped or chafed skin
May be used alone as a skin lubricant or protectant"
1600231|NCT02234479|Biological|MediHoney (Group B)|"It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:
Maintain a balanced environment for healing.
Aids in reducing dermatitis.
Reduce affected area pH.2-3"
1600232|NCT02234466|Drug|Oral dexamethasone|Patients will received their study drug ( or placebo) 2 hours pre-induction. Allowing for the shifting schedules of the OR with the possibility of the previous case finishing early or late, the allowable range is 90-200 minutes pre-induction.
1600233|NCT02234466|Drug|Ondansetron|Patients in both groups will receive 6mg IV ondansetron at time of skin closure as their standardized prophylaxis for postoperative nausea and vomiting.
1600234|NCT02234466|Other|Gelatin capsule|Gelatin capsule enclosing either dexamethasone tabs or second gelatin capsule
1600235|NCT02234453|Device|Minicare H-2000|Patients will use the Minicare H-2000 at home to measure their capillary blood count, temperature, record questionnaire results and transfer the results via the 3G network to the hospital team.
1600236|NCT02234440|Drug|Metformin|
1600237|NCT02234440|Drug|Insulin|
1600238|NCT02234427|Drug|Aspirin|2-week aspirin therapy (81mg/day)
1600239|NCT02234401|Device|Bi level pressure support|
1600240|NCT02234401|Other|Standard Care|
1600241|NCT02234388|Other|Observation|There are no interventions associated with this registry as it is purely observational.
1600242|NCT02234375|Drug|Gadolinium|agents will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agents to assess their feasibility as an alternative to Iodine based contrast agents
1600243|NCT02234362|Drug|vortioxetine|Eligible subjects will initiate the treatment with 5 mg/day for two days and then 10 mg/day starting on Day 3. The dosage may be increased from 10 mg/day to 15 mg/day at Visit 2 or Visit 3. At Visit 4, the dosage may again be increased from 10 to 15 mg/day or from 15 to 20 mg/day, based on patient response and tolerability.
1600244|NCT02234349|Procedure|pancreas kidney transplantation|
1600245|NCT02234349|Procedure|kidney transplantation|
1600246|NCT02234336|Procedure|Noncontrast echocardiography|
1600247|NCT02234336|Procedure|Contrast Echocardiography|
1600248|NCT02234336|Procedure|Cardiac magnetic resonance imaging|
1600251|NCT02234297|Drug|BLZ-100|
1600252|NCT02234284|Behavioral|Health Coaching|Patient COPD education; Correct use of inhalers and nebulizers; Red flags and when to seek medical care; Dyspnea management; Patient decision making and action plans around, exercise, smoking cessation; nutrition, exacerbations; Ensuring appropriate preventive services (pneumovax, flu); Depression screening; Reinforcing clinician education and use of treatment guidelines by primary care providers; Identifying gaps in care, areas where care not in line with care plan; Facilitating communication between patients, pulmonary specialists and primary care providers; Connecting with community resources; Access to psychosocial services; Working with pulmonary specialist to provide recommended exercise program; Working with patient family members and caregivers;
1600253|NCT02234271|Other|Mobile Health Application|Mobile Health application for contraception information
1600254|NCT02234271|Other|Health Educator Counseling|Counseling via health educator
1600255|NCT02234258|Behavioral|Cognitive behavioral social skills|
1600256|NCT02234258|Behavioral|Psychoeducation|
1600257|NCT02234245|Device|Telemedicine System|Telemedicine System is used in remote monitoring group
1600258|NCT02234232|Behavioral|Exercise|Each exercise will be performed during the first 2.5 hours of the participant's hemodialysis session. Exercises are semi supervised: the kinesiologist will supervise the initial three exercise sessions, any session that requires a change to the exercise prescription and on a minimum of a weekly basis.
1600259|NCT02234219|Drug|Probiotics|
1600260|NCT02234206|Drug|Chandrakanthi Choornam (CKC)|"12gm in milk - OD dose; Oral route; 3 Months ( 90days) - duration
Preparation from approved sastric book as per drugs & cosmetic act 1940"
1600309|NCT02233803|Drug|SYMBICORT forte (BFF 320/9mcg) TURBUHALER inhaler|Unit dose containing 320 mcg budesonide and 9 mcg formoterol fumarate (as dihidrate) along with lactose monohydrate as excipient. Administered as inhalation by TURBUHALER inhaler, twice daily (once in the morning and once in the evening approximately 12 hours later)
1600386|NCT02233179|Device|Irremovable cast walker|Offloading device that cannot be removed by patients.
1600261|NCT02234193|Device|Micro biopsy|This is a prospective, self-controlled study of the healing response after collecting micro skin biopsies of different sizes (from 200 µm to 2 mm in diameter) from up to seven 1.5 x 1.5 cm biopsy sites in pre-abdominoplasty skin areas that are scheduled for surgical removal. The collection procedure will be performed using similar techniques as standard skin biopsies: the skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, then micro biopsies of skin will be removed by biopsy punch/harvesting needle. No more than 10% of the skin area within each biopsy site will be collected. Tattoo ink as described will be applied to 4 micro-biopsies at the corners of each biopsy test site
1600262|NCT02234193|Procedure|Lidocaine with epinephrine|The skin area involved will be cleaned with alcohol pads, and 1% buffered lidocaine with epinephrine anesthesia will be administered locally, prior to the surgical procedure
1600263|NCT02234180|Other|Placebo|Given PO
1600264|NCT02234180|Drug|Regorafenib|Given PO
1600265|NCT02234167|Behavioral|Risk behaviour and infectious diseases|through counselling, testing vaccination
1600266|NCT02234154|Device|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
1600267|NCT02234141|Drug|Selonsertib|Tablet administered orally once daily
1600268|NCT02234141|Drug|Placebo|Tablets administered orally once daily
1600269|NCT02234128|Device|Toronto EVLP System™|Extending preservation and assessment time of donor lungs using the Toronto EVLP System
1600270|NCT02234115|Drug|Leuprolide Mesylate|Subcutaneous injection of 50mg Leuprolide Mesylate
1600271|NCT02234102|Device|Endoscopically guided laser ablation HeartLight system|
2009554|NCT03217747|Drug|Avelumab|"Arm A: Avelumab 10 mg/kg by vein every 2 weeks starting Cycle 3 Day 1.
Arm B: Avelumab 10 mg/kg by vein every 2 weeks starting Cycle 3 Day 1.
Arm C Phase I and II Starting Dose of Avelumab: 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 1.
Arm D Phase I and II Starting Dose of Avelumab: 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 1.
Arm E Phase I and II Starting Dose of Avelumab: 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 1.
Arm F Phase I and II Starting Dose of Avelumab: 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 1.
Arm G Phase I Starting Dose of Avelumab: 10 mg/kg by vein every 2 weeks starting Cycle 1 Day 1.
Arm G Phase II Starting Dose of Avelumab: MTD from Phase I."
1600274|NCT02234076|Behavioral|VRET|
1600275|NCT02234076|Behavioral|TAU|Treatment as usual offered by the participating mental health care organisations
1600276|NCT02234063|Other|Immediate Genetic Testing|Participants will receive the APOL1 genetic test. Trained research staff will meet with participants to communicate results and lifetime ESRD risk attributable to variations in the APOL1 gene. Primary care providers will receive APOL1 genetic risk information via a best practice alert in the participant's EMR upon commencement of a patient encounter and through results filed in the participant's genetics results section of their EMR.
1600277|NCT02234050|Drug|Trabectedin|Trabectedin will be given as a 24-hour infusion every 3 weeks at a starting dose of 1.5 mg/m2 body surface area (BSA), until one of the treatment withdrawal criteria has been met.
1600278|NCT02234050|Other|Local standard of care|Left to the discretion of the investigator
1600279|NCT02234037|Drug|Decitabine|Decitabine will be administered intravenously at dose of 20mg/m² on 5 consecutive days every 28 days (1 cycle = 28 days) for a total of 2 cycles according to standard practice. Cycle 2 will proceed on time despite cytopenias, given that patients are not expected to be in remission after only 1 cycle of decitabine.
1600280|NCT02234037|Behavioral|Exercise|Each patient will participate in 2-3 exercise sessions per week supervised by a physical therapist. Each exercise session will comprise > 10 minutes of muscle strengthening, > 10 minutes of aerobic exercise (treadmill walking or cycling), > 10 minutes of stretching/range of motion exercises, and up to 10 minutes of individualized functional exercise (determined based on patient's reported deficits/targets in activities of daily living).
1600281|NCT02234024|Dietary Supplement|Supplementation of dairy-derived concentrated gangliosides.|
1600282|NCT02234011|Drug|Ketamine|
1600283|NCT02234011|Drug|Placebo|
1600284|NCT02233998|Other|Mouth Rinse 1|
1600285|NCT02233998|Other|Mouth Rinse 2|
1600286|NCT02233998|Other|Mouth Rinse 3|
1600287|NCT02233985|Drug|0.9% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 0.9% saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
1600288|NCT02233985|Drug|3% Sodium Chloride|Salbutamol 100 micrograms / kg / dose administered 3 % saline solution (4ml) nebulized for 3 initial sessions lasting 20 minutes each and every 4 hours during the entire hospital stay.
1600289|NCT02233972|Drug|Midazolam|
1600290|NCT02233972|Drug|Ginkgolides Meglumine Injection|
1600291|NCT02233972|Drug|placebo|
1600292|NCT02233946|Behavioral|computer-facilitated brief intervention|Immediate feedback to patient of screening results and risk for substance use problem, followed by 11 pages of science and true-life stories about health risks of adolescent substance use. Screening results then go to provider who reviews them with patient and gives brief counseling, and refers to an online motivational enhancement therapy intervention for patients at moderate/high risk for substance use problems.
1600293|NCT02233933|Other|Hemospray|hemospray is used after argon coagulation to stop bleeding
1600294|NCT02233920|Drug|Ventilat® - metered dose inhaler|
1600295|NCT02233907|Drug|Ventilat® - metered dose inhaler|
1600296|NCT02233894|Drug|Atrovent® - inhalets|
1600297|NCT02233881|Drug|Atrovent® - inhalets|
1600301|NCT02233842|Behavioral|Participant interview|People with cancer and who have survived cancer will have a 1 hour interview about using cigarettes and other tobacco products.
1600304|NCT02233816|Biological|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
1600305|NCT02233816|Biological|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
1600306|NCT02233816|Biological|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
1600307|NCT02233816|Biological|Placebo|A single dose of placebo
1600310|NCT02233803|Drug|NEUMOTEX 400 (Budesonide 400 mcg)|Budesonide 400mcg will be administered to all the subjects twice daily, during the Run-in and Washout Periods
1600311|NCT02233803|Drug|Salbutamol 100 mcg pMDI|Salbutamol 100mcg will be administered as pMDI on demand, as rescue medication, throughout the entire study period until Visit 5
1600312|NCT02233790|Drug|Ticagrelor|a loading dose of 180mg pre-PCI, and then 90 mg twice daily for 1 Month within the study. Thereafter, the patients will take clopidogrel if Ticagrelor is not available on the market.
1600313|NCT02233790|Drug|Clopidogrel|Clopidogrel 75 mg once daily after a loading dose of 300 mg pre-PCI.
1600314|NCT02233777|Drug|Pregabalin capsules 150 mg of Dexa Medica|Each capsule contains 150 mg of pregabalin. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
1600315|NCT02233777|Drug|Pregabalin capsules 150 mg of Pfizer Manufacturing Deutschland|Each capsule contains 150 mg of pregabalin. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
1600316|NCT02233764|Other|FeZnPM|Iron and zinc biofortified pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
1600317|NCT02233764|Other|CtrlPM|Conventional pearl millet will be consumed three times per day, six days per week, for 9 months. Children are anticipated to consume 25-30 grams of the pearl millet at each feeding. The pearl millet will be prepared using a variety of recipes such as porridges, breads, and biscuits.
1600318|NCT02233751|Drug|Testosterone enanthate auto-injector|Randomization of Treatment A; or Treatment B
2009555|NCT03217747|Drug|Utomilumab|"Arm A: Utomilumab 100 mg by vein every 4 weeks starting Cycle 1 Day 1.
Arm C Phase I and II Starting Dose of Utomilumab: 100 mg by vein every 4 weeks starting Cycle 1 Day 1.
Arm D Phase I and II Starting Dose of Utomilumab: 100 mg by vein every 4 weeks starting Cycle 1 Day 1.
Arm F Phase I and II Starting Dose of Utomilumab: 100 mg by vein every 4 weeks starting Cycle 1 Day 1."
1600321|NCT02233725|Device|Definity Perflutren Injectable Suspension|a single dose of 10 μL/kg of the activated product by intravenous bolus injection over 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 μL/kg dose may be administered 5 minutes after the first injection to prolong contrast enhancement
1600322|NCT02233712|Biological|G17DT|
1600323|NCT02233699|Drug|XEN-D0501|
1600324|NCT02233699|Drug|Placebo|
1600325|NCT02233686|Drug|XEN-D0501|
1600326|NCT02233686|Drug|Placebo|
1600327|NCT02233673|Behavioral|Financial incentives|Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
1600328|NCT02233660|Other|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapies including maneuvers targeted to the areas anatomically related to the median nerve (i.e., cervical spine, shoulder, elbow and wrist) of 30min of duration, once per week.
1600329|NCT02233660|Procedure|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
1600330|NCT02233647|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and phendimetrazine.
1600331|NCT02233647|Drug|Placebo|The pharmacodynamic effects of placebo will be determined during maintenance on placebo and phendimetrazine.
1600332|NCT02233634|Drug|Oxygen|Oxygen is provided with a standard medical oxygen mask with reservoir (12L/min) for 3-5 min, assigned to both groups
1600333|NCT02233634|Other|Hyperventilation Breath-hold (HVBH)|1 Minute of Hyperventilation (25/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
1600334|NCT02233634|Other|HVBH with Oxygen|1 Minute of Hyperventilation (25/min) with an oxygen mask mounted (12L/min) is followed by a consecutive breath-hold for as long as the subject can comfortably tolerate. Both groups will perform this maneuver
1600335|NCT02233621|Other|[18F]FES (16α-[18F]Fluoro-17β-estradiol)|PET with [18F]FES before coelioscopy
1600337|NCT02233595|Radiation|Chemoradiation|
1600339|NCT02233569|Procedure|Intraperitoneal onlay mesh (IPOM) repair with the use of Phisiomesh implant and Securestrap fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Physiomesh (mesh implant) and Securestrap (fixation device)
1600340|NCT02233569|Procedure|Intraperitoneal onlay mesh (IPOM) repair with the use of Ventralight ST implant with SorbaFix fixation device.|Laparoscopic intraperitoneal onlay mesh repair for abdominal wall hernia with the use of specially designed mesh and fixation device systems: Ventralight ST (mesh implant) and SofbaFix (fixation device)
1600341|NCT02233569|Device|Ventralight ST implant|
1600342|NCT02233569|Device|ETHICON PHYSIOMESH®|
1600343|NCT02233556|Drug|Memantine|"Taking 20mg(2 capsules) of memantine, followed by Event related potential assessments as below:
Mismatch negativity(MMN)
P50"
1994985|NCT02879370|Procedure|Transanal Inspection and management of low ColoRectal Anastomosis|Low anterior resection with total mesorectal excision (TME), either performed open, laparoscopic or robotic Closure of the rectum with linear or curved stapler with transanal inspection Transanal placement of four 2-0 prolene sutures on the rectal stump, respectively 2 at the extremities of the suture line (left and right) and other two 1 cm medial to each of the previous two sutures Circular stapler is introduced, the 4 tails of the prolene stitches are introduced through the windows (2 in the left and 2 in the right side of the instrument) and gently pulled, to obtain a gradual and homogeneous traction of the tissue and elimination of both previous suture lines and doggy ears, then the stapler is fired The termino-terminal anastomosis is carefully inspected A leak test can be performed (if negative the protective stoma is not performed) An eventual leak can be transanally repaired
1600383|NCT02233205|Device|ultrasonic microbubbles|inject 1ml once and five times in 20min, locate the probe on the lesion at the same time
1600384|NCT02233205|Drug|platinum and gemcitabine|Chemotherapy drug of pancreatic carcinoma is gemcitabine. Chemotherapy drug of liver metastases is oxaliplatin and taxol.
1600385|NCT02233179|Device|Removable cast walker|Offloading device that can be removed by patients.
1600346|NCT02233530|Behavioral|CST intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
2009556|NCT03217747|Drug|PF-04518600|"Arm B: PF-04518600 0.3 mg/kg by vein every 2 weeks starting Cycle 1 Day 1. Arm C Phase I Starting Dose of PF-04518600: 0.1 mg/kg by vein every 2 weeks starting Cycle 1 Day 1.
Arm C Phase II Starting Dose of PF-04518600: Maximum tolerated dose (MTD) from Phase I.
Arm E Phase I and II Starting Dose of PF-04518600 to be determined, given by vein every 2 weeks starting Cycle 1 Day 1.
Arm F Phase I and II Starting Dose of PF-04518600: MTD from Arm C by vein every 2 weeks starting Cycle 1 Day 1."
1600349|NCT02233504|Drug|Exjade® (deferasirox, ICL670)|
1600352|NCT02233478|Dietary Supplement|Pomegranate Juice|Pomegranate Juice alone
1600353|NCT02233478|Dietary Supplement|Soybean Flour Protein|Soybean Flour Protein combined with Pomegranate Juice
1600354|NCT02233478|Dietary Supplement|Soy Isolate Protein|Soy Isolate Protein combined with Pomegranate Juice
1600355|NCT02233465|Procedure|IPOM Mesh-repair parastomal hernia|Safety study for mesh-repair of parastomal hernia
1600356|NCT02233452|Drug|Methadone|The solution of methadone was prepared by mixing 10 ml of methadone (10 mg/ml) and 90 ml of saline 0.9% (Baxter, São Paulo, Brazil)
1600357|NCT02233452|Drug|Ketamine|The solution of ketamine was prepared by mixing 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 80 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 10 mg/ml of ketamine.
1600358|NCT02233452|Drug|Methadone plus Ketamine|the solution of methadone, ketamine was prepared by mixing 10 ml of methadone hydrochloride (10 mg/ml, Cristália®, São Paulo, Brazil), 20 ml of S(+)-ketamine hydrochloride (50 mg/ml, Cristália®, São Paulo, Brazil) and 70 ml of saline 0.9% (Baxter, São Paulo, Brazil), obtaining a concentration of 1 mg/ml of methadone and 10 mg/ml of ketamine.
1600359|NCT02233439|Dietary Supplement|Herbal galactagogue|
1600360|NCT02233439|Dietary Supplement|Placebo|
1600361|NCT02233413|Device|Active LLLT helmet application|LED helmet applied with light activated
1600362|NCT02233413|Device|Non-active LLLT helmet application|LED helmet applied without light activated
1600363|NCT02233400|Drug|Acetaminophen|Group 1 (treatment) will receive IV acetaminophen (intervention drug) (1g in 100 ml of 0.9% normal saline IV Q 6hrs for 24 hours) plus IV narcotics (2-4 mg IV Q2hrs PRN) for the first 6 hours post-surgery followed by IV narcotics (2-4 mg IV Q2hrs PRN)/ PO narcotics (Oxycodone 5-10 ml PO Q4 hrs PRN) for the remaining 18 hours.
1600364|NCT02233387|Other|injection with [18F] HX4 and PET imaging|"A standard clinical [18F]FDG PET-CT will be performed for the radiotherapy planning.
After a minimum time interval of 24 hours, baseline [18F]HX4 PET scans will be performed:
Based on the phase I trial1 444 MBq (12 mCi) [18F]HX4 is administrated via a bolus IV injection.
The first image acquisition is started together with the administration of [18F]HX4 (30-40 min dynamic). Static scans are acquired at 90 min, 180 min and 240 min p.i"
1600365|NCT02233374|Other|Early MRI and PET/CT - 2 weeks after commencing chemo/RT|Patients will have an early MRI and PET/CT - 2 weeks after commencing chemo/RT. A limited range PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI & ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
1600366|NCT02233374|Other|Late MRI and PET/CT 6 weeks post chemo/RT|Patients will have late a MRI and PET/CT 6 weeks post chemo/RT. A whole body PET/CT will look at parameters: SUVmaxm PERCIST, RECIST 1.1, ΔSUV (PET1-2), ΔSUV (early -late), Glycolytic tumour volume (GTV). MRI T2 (1-3mm slice as per NS Radiology protocol and ESGAR guideline) will look at parameters: DWI & ADC value (preferably on a single camera with reproducible ADC value), Local Staging, MRF involvement, EMVI, nodal status, MR volumetry, and desmoplastic reaction.
1600367|NCT02233361|Behavioral|Counseling|A randomized controlled design will determine whether hearing aid users who are informed in advance of a follow-up appointment have a different pattern of hearing aid use than a control group that is not preinformed in advance.
1600368|NCT02233322|Dietary Supplement|Iron|All subjects will receive iron supplementation based on iron levels in the blood
1600369|NCT02233309|Other|Monitoring of pressures during caudal anesthesia|The caudal itself is a separate procedure not covered by this observational study. This study simply attaches a monitoring device to the needle used for the caudal to measure pressures. The caudal takes place whether the observation of pressures is agreed to or not, as per standard protocol.
1600370|NCT02233296|Drug|Lasmiditan|2 discrete doses separated by 6 days.
1600371|NCT02233283|Other|Clamp|Volunteers will be submitted to hyperinsulinemic, euglycemic clamp studies of 10 hours duration.
1600372|NCT02233283|Other|Hypercaloric diet|Hypercaloric diet will be conducted during one month, and designed to provide 30% excess in calories compared to daily requirements. It will consist in a high fat, high carbohydrates diet.
1600373|NCT02233283|Other|Basal|Keeping the volunteers in the fasting state overnight and for the entire duration of the experiment (10 hours)
1600374|NCT02233283|Other|Isocaloric diet|Isocaloric diet will conducted for one month, and designed to provide the calculated daily energy needs
1600375|NCT02233257|Drug|Lorenzo's Oil|Oral use of Lorenzo's oil to lower very long chain fatty acids
1600376|NCT02233244|Drug|CTX-4430|
1600377|NCT02233244|Drug|Midazolam|
1600378|NCT02233231|Drug|Varenicline|Varenicline 0,5 mg x 1 day 1-3 Varenicline 0,5 mg x 2 day 4-6 Varenicline 2 mg x 1 day 7 to week 12
1600379|NCT02233231|Drug|Placebo|
1600380|NCT02233218|Drug|Telmisartan|
1600381|NCT02233218|Drug|Amlodipine|
1600382|NCT02233218|Drug|Rosuvastatin|
2009557|NCT03217747|Radiation|Radiation|"Arm D Phase I Starting Dose of Radiation: 60 Gy in 6 Gy / fraction for 10 fractions on days 2-11 of Cycle 1.
Arm D Phase II Starting Dose of Radiation: MTD from Phase I.
Arm E Phase I Starting Dose of Radiation: 48 Gy in 6 Gy/ fraction for 8 fractions on days 2-11 of Cycle 1.
Arm E Phase II Starting Dose of Radiation: MTD from Phase I.
Arm F Phase I Starting Dose of Radiation: 60 Gy in 6 Gy / fraction for 10 fractions on Days 2-11 of Cycle 1.
Arm F Phase II Starting Dose of Radiation: MTD from Phase I.
Arm G Phase I and II Starting Dose of Radiation: 45 Gy in 1.8 Gy / fraction for 25 fractions on Days 1-5 for the first 5 weeks starting Cycle 1 Day 1."
1600388|NCT02233140|Device|Extra-corporeal pulsed-activated therapy or shockwave therapy|
1600389|NCT02233114|Other|Yogic exercises|Yogic exercises (YE) - 2 hours per week, 1h in each session
1600390|NCT02233114|Other|Physiotherapy|Physiotherapy (low intensity cardiovascular training and strength training) - 2 hours per week, 1 h in each session
1600391|NCT02233101|Drug|Oral Tranexamic Acid|patients will receive 1950mg of oral prior to surgery to help reduce blood loss during total joint replacement
1600392|NCT02233101|Drug|Intravenous Tranexamic Acid|Patients will receive 1950mg of intravenous Tranexamic Acid prior to total joint arthroplasty and blood loss or need for transfusion within 24 hours post operative
2009558|NCT03217747|Drug|Cisplatin|Arm G Phase I and II Starting Dose of Cisplatin: 40 mg/m2 by vein weekly for 6 weeks only.
1600396|NCT02233075|Drug|REP 2139-Ca + Pegasys (TM)|15 weeks of REP 2139-Ca (500mg QW IV) followed by: 15 weeks of REP 2139-Ca (250mg QW IV) + Pegasys(TM) (180 ug QW SC) followed by: 33 weeks of Pegasys(TM) (180 ug QW SC)
1600397|NCT02233062|Dietary Supplement|Exclusive Enteral Nutrition Therapy|
1600398|NCT02233049|Drug|Erlotinib|
1600399|NCT02233049|Drug|Everolimus|
1600400|NCT02233049|Drug|Dasatinib|
1600401|NCT02233023|Drug|Pramipexole|
1600402|NCT02233023|Drug|Bromocriptine and other dopamine agonists|
1600403|NCT02233010|Other|The level of NGAL after pre op,post op 4hr, post op 12hr|
1600404|NCT02232997|Other|Long Hydration|The hydration with sodium chloride was set 12 hours before the procedure (before contrast exposure during coronary angiography), continued for the duration of the procedure, and for 12 hours post-procedure at the speed of 1ml/kg/hr (0.5ml/kg/hr for patients with congestive heart failure, New York Heart Association class III or LVEF<35%). For patients who weighed more than 80 kg, the bolus and infusion rate were limited to those calculated for patients weighing 80 kg.
1600405|NCT02232997|Other|Short Hydration|The hydration with sodium chloride was set 1 hour before the procedure (before contrast exposure during coronary angiography), continued for the duration of the procedure, and for 4 hours post-procedure at the speed of 3ml/kg/hr (1.5ml/kg/hr for patients with congestive heart failure, New York Heart Association class III or LVEF<35%). For patients who weighed more than 80 kg, the bolus and infusion rate were limited to those calculated for patients weighing 80 kg.
1600406|NCT02232971|Drug|Glucagon|Glucagon is given in three different doses according to three research days.
1600407|NCT02232971|Other|Isotonic saline solution|Placebo
1600409|NCT02232945|Drug|placebo of oseltamivir phosphate|
1600410|NCT02232945|Drug|oseltamivir phosphate|
1600411|NCT02232945|Drug|Banlangen (Radix Isatidis) granules|
1600412|NCT02232945|Drug|placebo of Banlangen(Radix Isatidis) granules|
1600413|NCT02232932|Procedure|CAPECITABINE-Radiotherapy -Liver Transplantation|CAPECITABINE (800 mg/m2 twice a day during 5 weeks) + External Radiotherapy (50 grays during 5 weeks) then Liver transplantation
1600414|NCT02232932|Procedure|RESECTION|Intent-to-treat R0 liver resection
1600415|NCT02232919|Device|Deep Brain Stimulation|"If subjects qualify with respect to protocol requirements, the Medtronic Activa system will be implanted with the leads placed bilaterally in the VMH.
Adjustment of DBS parameters at the three months visit will be performed to improve efficacy when the goal of 3% body weight loss mark was not achieved during this period of continuous stimulation. Subjects will be seen monthly after discharge throughout the study period. At visits, safety will be assessed through blood/urine tests, blood pressure measurements, verbal interviews with the subjects and family, quarterly formal psychiatric tests as well as QOL scales.
The determination of efficacy will be the within-group percent change in weight at the end of the DBS treatment period compared to baseline."
1600416|NCT02232906|Drug|intravenous ferric carboxymaltose|Ferric carboxymaltose (FCM) dose of 1,000 mg iron, followed by a 6-month ESA/FCM maintenance regimen (target: Hemoglobin 120 g/L, transferrin saturation >20%)
1600417|NCT02232893|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 32 days.
1600418|NCT02232893|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 32 days.
1600419|NCT02232880|Drug|Abatacept|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
1600420|NCT02232880|Drug|Placebo|All subjects will be treated with chlorthalidone 25 mg/day, lisinopril 20 mg/day [Patients with a history of adverse reaction to lisinopril will be treated with losartan 50 mg/day], amlodipine 5 mg/day and spironolactone 25 mg bid as standardized treatment of hypertension prior to randomization and throughout the active treatment phase.
1600421|NCT02232867|Behavioral|Arm and Leg Cycling Exercise Program|Participants will perform arm and leg cycling training three times a week, with 30 minutes of aggregate exercise time per session. To evaluate the physiological cost of exercise, heart rate and a rating of perceived exertion will be collected. The progressive element of this training will include increasing the resistance of the ergometer over the six weeks in order to maintain the same relative exercise stress.
1600598|NCT02231515|Device|Selective laser trabeculoplasty (SLT)|Selective laser trabeculoplasty
2009559|NCT03217643|Drug|Brentuximab Vedotin|The first part of the treatment (induction) will evaluate BV-CHP. The second part of the treatment (consolidation) will use standard drugs for the treatment of lymphoma. HDT will consist of BEAM conditioning regimen (or BAM if carmustine is not available). Management of HDT/ASCT will be done according to standard practice.
1600423|NCT02232841|Device|Mechanical Ventilation|Subjects will receive mechanical ventilation as part of their standard of care, as specified in the enrollment criteria
1600424|NCT02232841|Device|CT Scan|Subjects will receive a CT scan as part of their standard of care, as specified in the enrollment criteria
1600425|NCT02232828|Procedure|Selective removal|Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
1600426|NCT02232828|Procedure|Stepwise removal|"Caries removal in the periphery including the enamel-dentinal junction will be performed using rose head burs and/or an excavator until hard, dry dentin remains. Pulpo-proximal caries will be removed until leathery, slightly moist and reasonably soft dentin remains. Operating dentists will be calibrated prior to study commencement regarding these criteria using extracted teeth. Moisture control will be performed using cotton rolls and continuous aspiration. Restoration will be performed adhesively, with a self-etching one-bottle adhesive (G-aenial bond, GC, Bad Homburg, Germany) and a compomer material (Dyract, Dentsply Detray, Konstanz, Germany) being used.
If allocated to stepwise excavation, the second excavation will now be performed as described until only hard, dry dentin remains. Restoration will again be provided adhesively as described."
1600427|NCT02232802|Drug|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
1600428|NCT02232802|Drug|Enoxaparin Sodium|comparison of bioavailability of generic Enoxaparin Sodium and Clexane
1600429|NCT02232789|Drug|Mephedrone|Single oral dose mephedrone
1600430|NCT02232789|Drug|3,4-methylenedioxymethamphetamine|Single oral dose MDMA
1600431|NCT02232789|Drug|Placebo|Single oal dose placebo
1600432|NCT02232776|Drug|Losartan|
1600433|NCT02232763|Drug|Losartan|12 weeks of losartan or placebo with crossover to the other
1600434|NCT02232763|Drug|Placebo|12 weeks of losartan or placebo with crossover to the other
1600435|NCT02232737|Other|Very low nicotine content cigarettes|
2009560|NCT03216512|Other|Use of Noise Cancelling Headphones|During the 2 experimental sessions, participants will complete study assessments using either a noise cancelling headphone first (session 1) and then sham control second ( session 2), or vice versa, in the presence of noise distractions.
1600437|NCT02232698|Device|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels.
All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
1600438|NCT02232698|Device|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 3 and 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study (Sensor glucose measurements not visible during this time).
All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation (Sensor glucose measurements not visible during this time)."
1600439|NCT02232685|Device|18F-Choline PET/CT|18F-Choline PET/CT
2009561|NCT03216200|Device|plasma treatment|application of cold atmospheric plasma to a fungal infected toenail
1600441|NCT02232659|Device|70cc TAH-t for Destination Therapy|Use of the approved SynCardia 70cc TAH-t for patients who are in biventricular failure (approved use), but who are ineligible for cardiac transplant (experimental use).
1600442|NCT02232646|Drug|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
1600443|NCT02232633|Drug|BBI503|
1600444|NCT02232620|Drug|BBI503|BBI503 will be administered orally, daily, in continuous 28-day cycles at a dose of 300 mg once daily.
1600445|NCT02232607|Drug|Lacidipine, low dose|
1600446|NCT02232607|Drug|Lacidipine, medium dose|
1600447|NCT02232607|Drug|Lacidipine, high dose|
1600448|NCT02232607|Drug|Placebo|
1600449|NCT02232594|Drug|Berodual®|
1600450|NCT02232581|Drug|Alovudine - low|
1600451|NCT02232581|Drug|Alovudine - medium|
1600452|NCT02232581|Drug|Alovudine - high|
1600453|NCT02232581|Drug|Placebo|
1600454|NCT02232568|Behavioral|Feedback|
1600455|NCT02232555|Drug|Duloxetine|
1600456|NCT02232555|Drug|Placebo|
1600457|NCT02232542|Drug|Duloxetine - low dose|
1600458|NCT02232542|Drug|Duloxetine - high dose|
1600459|NCT02232542|Drug|Placebo|
1600460|NCT02232529|Drug|MIN-101|
1600461|NCT02232529|Drug|Placebo|
1600462|NCT02232516|Drug|romidepsin|Given IV
1600463|NCT02232516|Drug|lenalidomide|Given PO
1600464|NCT02232516|Other|laboratory biomarker analysis|Correlative studies
1600465|NCT02232503|Genetic|Studied cohort|For the purpose of DNA isolation prior to genetic analysis of patients two samples of peripheral blood will be taken; first in the volume of 3.5 ml and second in the volume of 9 ml from each patient included into the study.
1600466|NCT02232490|Biological|hepcortespenlisimut-L|hepcortespenlisimut-L (V5) is given in experimental arm
1600467|NCT02232490|Biological|Placebo|
1600468|NCT02232477|Drug|Intrathecal recombinant human alpha iduronidase|Intrathecal recombinant human alpha iduronidase every 3 months
1600599|NCT02231515|Device|Pattern laser trabeculoplasty (PLT)|Pattern laser trabeculoplasty (PLT)
2009562|NCT03216746|Other|Oral health educational methods|An educational protocol including different methods of education will be evaluated through the knowledge score and periodontal indexes.
1600469|NCT02232451|Device|ERCP with loop tip wire|Endoscopic retrograde cholangio-pancreatography with guide wire (loop-tip) for CBD cannulation
1600470|NCT02232451|Device|ERCP for cannulation|Endoscopic retrograde cholangio-pancreatography with traditional technique for CBD cannulation
1600471|NCT02232438|Behavioral|Behavioral activation therapy|Behavioral activation therapy (BAT) is a brief, manualized therapy that has shown efficacy in the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in several controlled trials patients (see review in Dimidjan et al., Ann Rev Clin Psychol, 2010, and Chu, Brian C., et al. Cognitive and Behavioral Practice, 2009.), including adult cancer patients (Hopkoet al., 2009; Hopko et al., 2011).
1600472|NCT02232425|Drug|IX-01|
1600473|NCT02232425|Drug|Placebo|
1600474|NCT02232399|Drug|Levosimendan|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
1600475|NCT02232399|Drug|Milrinone|The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
1600476|NCT02232386|Drug|Ibrutinib|Ibrutinib (PCI-32765) 420 mg (3 x 140 mg capsules) will be administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis.
1600477|NCT02232386|Drug|Rituximab|Rituximab 375 mg/m2 iv. Month 1: day 1 of weeks 1, 2, 3, 4; months 2-6: day 1of week 1.
1600478|NCT02232373|Behavioral|low FODMAP dietary advice|An education session with a specialist dietitian, and provision of written advice, on how to follow the low FODMAP diet. Second session after one month on re-introduction of FODMAP containing foods.
1600479|NCT02232373|Dietary Supplement|Maltodextrin|Dietary supplementation with maltodextrin 5 grams twice daily for a month
1600480|NCT02232373|Dietary Supplement|Oligofructose|Dietary supplementation with oligofructose 5 grams twice daily for a month
1600481|NCT02232360|Drug|Rosuvastatin and fenofibrate|Combination therapy: rosuvastatin 10 mg and fenofibrate 160 mg per day
1600482|NCT02232360|Drug|Rosuvastatin alone|Rosuvastatin 10mg per day
1600483|NCT02232347|Drug|Ketamine|
1600484|NCT02232347|Drug|Sufentanil|
1600485|NCT02232334|Other|Global Osteopathic Manual Treatment|subtle manipulations of the body according to the methodology of osteopathic manual therapy will be the intervention on subjects in the study. The global treatments will take into consideration the past medical history of each subject as well as what is found on assessment. Focus is on the position, mobililty and quality of each subjects anatomy.
1600486|NCT02232321|Other|PsA MDA|
1600487|NCT02232308|Drug|Nizatidine|Nizatidine (150 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
1600488|NCT02232308|Drug|Lisinopril|Lisinopril (10 mg) will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
1600489|NCT02232308|Drug|Placebo|Placebo capsules to match active drug will be administered once daily for the first 3 days, then twice daily for days 4-9, and once on day 10.
1600490|NCT02232295|Device|Recognise [TM]|Recognise accurately measures to identify left and right body parts and movements, and to train left/right discrimination as part of a comprehensive GMI rehabilitation process.
1600491|NCT02232295|Device|Mirror Box|A resource used for many pain and disability states of the hands and feet.
1600492|NCT02232282|Device|standard acupuncture treatment|A standardized acupuncture treatment will be assigned, and both groups will receive 7 acupuncture treatments that follow a standardized protocol on classical acupuncture points, with or without mild electrical stimulation versus sham/minimal acupuncture. Acupuncture needles are single use, sterile and disposable. Standard acupuncture treatment protocol will include 4 gates plus GV 20 to reduce anxiety and help with relaxation and to assess acupuncture naïve patient's response to needles during their first acupuncture encounter. Subsequent visits would include administration of curious meridian Chong Mo paired with Yang Ming. 4 Hz low level electrical stimulation will be applied.
1600493|NCT02232282|Device|Control Sham/Minimal Acupuncture|"Control group will receive sham/minimal acupuncture with low level electrical stimulation. The sham intervention (also described as minimal intervention) will use superficial needle insertion at body locations not recognized as true acupoints. Patients will be explained that various acupuncture treatment protocols will be tested including minimal acupuncture, therefore, the control group will not be aware of receiving sham acupuncture. These described acupuncture treatments are well accepted treatment protocols for women with pelvic pain and bladder complaints."
2009563|NCT03215498|Drug|Faster-acting insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
1600498|NCT02232256|Drug|CALPXT96|Arm 1: intervention begins with CALPXT96 Arm 2: intervention begins with placebo
1600499|NCT02232243|Drug|Hydroxychloroquine|Hydroxychloroquine (400 mg/d, 800 mg/d or 1200 mg/d) will be given to subjects for up to 14 days prior to surgery
1600500|NCT02232230|Drug|Provenge|
1600501|NCT02232217|Behavioral|Cognitive Behavior Therapy Sleep|Children in this arm will receive instructions on the use of 'coping thoughts.' Common elements across the CBTcs sessions include reviewing progress, setting goals for change, problem solving to address challenges/barriers, and reinforcing progress
1600502|NCT02232217|Other|Education Control|Children in this arm will receive sleep and dietary education, as well as general coping strategies and controls for staff attention and seasonal effects that could influence changes in sleep and health outcomes.
1600503|NCT02232204|Behavioral|CBT for Insomnia in ICD Patients (CBT-I-ICD)|Participants will complete 4 weekly therapy sessions focused on improving sleep and reducing ICD-related stress. A multicomponent CBT-I-ICD (Cognitive Behavioral Therapy for Insomnia in ICD Patients) protocol will involve: sleep hygiene, stimulus control, sleep restriction, relaxation, cognitive restructuring, ICD education and recall information, shock planning, and quality of life-improvement recommendations.
1600504|NCT02232191|Biological|Pneumovax-23|
1600510|NCT02232152|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
1600511|NCT02232152|Drug|fluorouracil|Given IV
1600512|NCT02232152|Other|pharmacological study|Correlative studies
1600513|NCT02232152|Other|laboratory biomarker analysis|Correlative studies
1600514|NCT02232139|Drug|Midazolam|The participants receive the pharmacological premedication before the surgery anyway
1600515|NCT02232126|Other|SWIFT home intervention|1 in-home assessment performed by study social worker, another in-home visit performed if needed. Up to 4 telephone contacts performed by study social worker. A maximum of 6 contacts
2009564|NCT03215498|Drug|Insulin aspart|In a euglycaemic clamp setting each participant will receive a priming dose of 0.08 U/kg body weight, followed by a continuous basal rate of 0.02 U/kg body weight/h and finally a bolus dose of 0.15 U/kg body weight on top of the basal rate
1600517|NCT02232100|Behavioral|Attentional bias modification training (AMG)|Attentional bias modification, administered via an internet-delivered visual-probe task that trains attention away from pain-related information
1600518|NCT02232100|Behavioral|Attentional bias placebo (ACG)|Attentional bias placebo, administered via an internet-delivered visual-probe task that does not train attention either away or towards pain-related information
2009565|NCT03213847|Device|Superb microvascular imaging (SMI) (Toshiba)|to determine whether there is a correlation between the increased intraneural flow as measured using Doppler US and SMI methods and the severity of CTS as measured by nerve conduction studies, we designed this study
2009566|NCT03213691|Other|Laboratory Biomarker Analysis|Correlative studies
1600521|NCT02232074|Other|Patient navigation enhanced with legal support|
1600522|NCT02232061|Drug|Fingolimod|
1600523|NCT02232048|Other|Transthoracic Echocardiogram|
1600524|NCT02232035|Drug|normal saline/diazepam at the active phase of labor|A single dose intravenous injection of normal saline (2ml)/diazepam (10mg, 2ml) at the beginning of active phase of labor.
1600525|NCT02232022|Device|Reveal LINQ Insertable Cardiac Monitor|
1600526|NCT02232009|Device|Neonatal MRI Scanner|
1600527|NCT02231983|Genetic|gene sequencing|Amplify and identify exons from gene IL-2RG by PCR and agarose gel electrophoresis, and then followed by gene sequencing.
1600528|NCT02231970|Procedure|Endoscopic sleeve gastroplasty|To perform endoluminal gastric volume reduction by the Endoscopic sleeve gastroplasty
1600529|NCT02231957|Other|educational text message reminders|
1600530|NCT02231957|Other|conventional text message reminders|
1600531|NCT02231944|Biological|Replenine®-VF (High Purity Factor IX)|
1600532|NCT02231931|Drug|Digoxin|single dose, fasted
1600533|NCT02231931|Drug|Rosuvastatin|single dose, fasted
1600534|NCT02231931|Drug|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
1600535|NCT02231931|Drug|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
1600536|NCT02231931|Drug|Metformin hydrochloride|single dose, fasted
1600537|NCT02231931|Drug|Digoxin, Furosemide, Metformin hydrochloride, Rosuvastatin|fasted
1600538|NCT02231931|Drug|Furosemide|single dose, fasted
1600539|NCT02231918|Drug|MIRAPEX® - low|
1600540|NCT02231918|Drug|MIRAPEX® - medium|
1600541|NCT02231918|Drug|MIRAPEX® - high|
1600542|NCT02231905|Drug|BI-Sifrol®|
2009567|NCT03213691|Drug|Selumetinib|Given PO
2009568|NCT03213678|Other|Laboratory Biomarker Analysis|Correlative studies
2009569|NCT03213678|Other|Pharmacological Study|Correlative studies
1600546|NCT02231866|Biological|VRC-EBOADC069-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire + GP Sudan
1600547|NCT02231866|Biological|VRC-EBOADC076-00-VP|cAd3-EBO Ebola Chimpanzee Adenovirus Vector Vaccine GP Zaire
2009570|NCT03213678|Drug|PI3K/mTOR Inhibitor LY3023414|Given PO
2009571|NCT03213665|Other|Laboratory Biomarker Analysis|Correlative studies
1600550|NCT02231827|Other|Gait analysis|Subjects, barefoot and standing upright and motionless on a force plate, were instructed to walk for 10 m following a beep delivered by the experimenter. Two experimental conditions were tested: (i) the 'natural' gait condition where subjects walked normally and (ii) the 'fast' gait condition where subjects walked as fast as they could, taking large steps. Each subject performed 10 trials in each condition.
1600551|NCT02231814|Dietary Supplement|Crohns Disease Exclusion Diet + PEN|"Patients will use the CDED for a 24 week period, coupled with 1000 ml of polymeric formula (1 Kcal/mL) for the first 6 weeks. For weeks 7 to 24 patients will use the CDED coupled with 600 ml formula and a calcium supplement. The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase."
1600552|NCT02231814|Other|Crohns Disease Exclusion Diet|Crohn's Disease Exclusion Diet alone with a calcium supplement during the study (0-24). The CDED is divided into 3 stages: 0-6 weeks induction phase, weeks 7-12 step down phase, weeks 13-24 maintenance phase.
1600553|NCT02231801|Behavioral|Mother-Infant Dyad|Skin-to-skin holding of preterm infants by their mothers
1600554|NCT02231788|Drug|Telminuvo®Tab. 40/2.5mg|Telminuvo®Tab. 40/2.5mg, Once daily, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
1600600|NCT02231502|Other|Vegetable-based convenience food|
1600601|NCT02231502|Other|Vegetable meal|
2009572|NCT03213665|Drug|Tazemetostat|Given PO
2009573|NCT03213652|Drug|Ensartinib|Given PO
2009574|NCT03213652|Other|Laboratory Biomarker Analysis|Correlative studies
2009575|NCT03213652|Other|Pharmacological Study|Correlative studies
1994986|NCT02878447|Radiation|External beam radiotherapy|External beam radiotherapy will be prescribed to a central plane using mega-voltage radiation encompassing all the assessed affected lung tissue at 3.5Gy weekly for 5 fractions to a maximum of 17G
1994987|NCT02877849|Device|MRI: Brain Imaging data collection|This study has no intervention, it is observational. We will collect brain imaging data and behavioral assessments.
1600555|NCT02231788|Drug|Telmitrend®Tab. 80mg|Telmitrend®Tab. 80mg, Once daily, Per oral for 8weeks after 2~4weeks run-in period with Telmitrend®Tab. 40mg
1600556|NCT02231775|Drug|Dabrafenib|Starting Dose: 150 mg by mouth twice a day.
1600557|NCT02231775|Drug|Trametinib|Starting Dose: 2 mg by mouth once daily.
1600558|NCT02231775|Procedure|Surgery|Participant has MRI and/or CT scans of brain to check status of disease after taking study drugs for 8 weeks. Participant also has CT scans of the chest, abdomen, and pelvis. If scans show disease has not spread or grown, surgical resection of gross disease is scheduled.
1600559|NCT02231762|Drug|Lanreotide Autogel 120 mg|Lanreotide Autogel 120 mg subcutaneous (s.c) - injection, every 28 days (+/-2 days).
1600560|NCT02231762|Drug|Temozolomide (TMZ)|Temozolomide capsule (variable dose). 150 mg/m2 per day for 5 days in the first month. 200 mg/m2 per day for 5 days in months 2, 3, 4, 5 and 6.
2009576|NCT03212859|Behavioral|Coach2Move|"Coach2Move is a multicomponent physiotherapeutic approach in addition to usual care physiotherapy consisting of:
Extensive intake during which not only impairments and disabilities, but wishes, barriers and facilitators considering physical functioning are profoundly examined.
Motivational interviewing is used to find and deal with barriers for becoming physically active and shared-decision making in goal setting.
The approach is patient focused (tailor made) and goal-oriented: the physiotherapist coaches the patient and the environment in reaching and maintaining their own goals.
In consultation with the patient, a stratified intervention is chosen by picking the best fitting option out of three patient-tailored intervention profiles with a predefined number of intervention sessions."
2009577|NCT03212859|Behavioral|Usual Care|"Usual care physiotherapy among older adults:
Intake of 30 minutes consisting of examining medical history, physical functioning and functional exercises to assess the demand for care.
Use of treatment modalities to enhance physical functioning (strength, mobility, coordination, balance etc.)
Consultation and advisory role in relation to the functional status of geriatric patients and his/her relations.
Collaborate with other disciplines in a multidisciplinary context."
1600572|NCT02231710|Biological|BPX-501 and AP1903|Single administration of BPX-501 T cells post partially-mismatched, related T cell depleted HCT followed by AP1903 infusion on day 7
1600573|NCT02231697|Other|Non-interventional, retrospective medical chart review|Non-interventional, retrospective medical chart review
1600574|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL).
1600575|NCT02231684|Drug|semaglutide|Semaglutide administered subcutaneously (s.c. under the skin) in two out of three different strengths (1mg/mL, 3mg/mL and 10 mg/mL) or intravenously (i.v.) (1mg/mL).
1600578|NCT02231658|Drug|Liraglutide|
1600579|NCT02231658|Drug|Lixisenatide|
1600580|NCT02231645|Device|STN DBS|The DBS device is turned on and off by the physician.
1600581|NCT02231632|Biological|Live attenuated Poliomyelitis vaccine (Human Diploid Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
1600582|NCT02231632|Biological|Live attenuated Poliomyelitis vaccine (Monkey Kidney Cell)|6.15 lgCCID50 /Vial, 0.1ml/dose(10 dose /Vial) in babies aged 2-3 months, three dose(4 weeks'interval for each Intervention).
1600583|NCT02231619|Behavioral|Baseline verbal instruction on LSUPT|
1600584|NCT02231606|Other|Free Glasses|Provide free glasses
1600585|NCT02231606|Other|Upgrade Glasses 1|Provide optional purchase from range of spectacles, cheapest RMB100 (Mean price paid for glasses by Control families in Seeing is Learning I, subtracting one SD)
1600586|NCT02231606|Other|Upgrade Glasses 2|Provide optional purchase from range of spectacles, cheapest RMB200 (Mean price paid for glasses by Control families in Seeing is Learning I, adding one SD)
1600587|NCT02231593|Other|SAGIT|SAGIT is a Clinician-Reported Outcomes (ClinROs) tool
1600590|NCT02231567|Other|Neurocognitive Rehabilitation|The patients will be treated in inpatient clinic with a neurocognitive rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
1600591|NCT02231567|Other|Traditional Rehabilitation|The patients will be treated in inpatient clinic with a traditional rehabilitation approach. The frequency will be two times a day for six days a week for four consecutive weeks. Followed by outpatient treatment three times a week for four weeks. Each session lasts about one hour.
1600592|NCT02231554|Other|Feldenkrais Method|The program of Awareness Through Movement ® chosen for this study, teaches the basic movements of the column. The aim is to stimulate changes in the chronic pathological patterns and in the distorted kinesthetic perceptions that so often hinder the rehabilitation of chronic non-specific low back pain. The patients will be treated in outpatient with the Feldenkrais method. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
1600593|NCT02231554|Other|Back School|The rehabilitation program of Back School is divided into two parts: one theoretical and one practical. To obtain an effective action not only in reducing pain but also in preventing relapse, the Back School acts on the typical risk factors of chronic non-specific low back pain, such as incorrect postures and movements, psychological stress, poor physical fitness, overweight, obesity, smoking, and insufficient knowledge of the spine. The patients will be treated in outpatient with a Back School program. Each group will consist of four or five patients who carry out the rehabilitation treatment with a frequency of twice a week for five consecutive weeks for a total of 10 sessions, each lasting about one hour.
1600594|NCT02231541|Device|Very Low Frequency Magnetic Fields|The device is set to an analgesic program lasting about 30 minutes.
1600595|NCT02231541|Device|Very Low Frequency Magnetic Fields|The device is turned off.
1600596|NCT02231528|Device|Use of ultrasound with active GPS|CVC insertion with ultrasound with active GPS function and appropriate needles
1600597|NCT02231528|Device|Use of ultrasound with inactive GPS|CVC insertion with ultrasound with inactive GPS function and conventional needles
1600835|NCT02229786|Drug|Buscopan® plus|
1600602|NCT02231489|Drug|JNJ-42756493 Tablet|Participants will receive 10 mg of JNJ-42756493 tablet as single oral dose on Day 1 of each treatment period.
1600603|NCT02231489|Drug|JNJ-42756493 Capsule|Participants will receive 10 mg of JNJ-42756493 capsule as single oral dose on Day 1 of each treatment period.
1600604|NCT02231489|Drug|JNJ-61818549|Participants will JNJ-61818549, 100 microgram (mcg) intravenous infusion over 5 minutes, after 2 hours of administration of JNJ-42756493 tablet/capsule on Day 1 Treatment Period 1.
1600605|NCT02231463|Other|neutral positioning, PEEP 0 cm H2O|neutral positioning, PEEP 0 cm H2O
1600606|NCT02231463|Other|neutral positioning, PEEP 5cm H2O|neutral positioning, PEEP 5cm H2O
1600607|NCT02231463|Other|neutral positioning, PEEP 10cm H2O|neutral positioning, PEEP 10cm H2O
1600608|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 0 cmH2O|Trendelenburg positioning -20°, PEEP 0 cmH2O
1600609|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 5 cmH2O|Trendelenburg positioning -20°, PEEP 5 cmH2O
1600610|NCT02231463|Other|Trendelenburg positioning -20°, PEEP 10 cmH2O|Trendelenburg positioning -20°, PEEP 10 cmH2O
1600611|NCT02231450|Drug|Lu AE58054 encapsulated film-coated tablets|
1600612|NCT02231437|Drug|Berodual®|
1600613|NCT02231424|Drug|Drug: Berodual®|
1600614|NCT02231411|Procedure|V-DCC|Ventilation with CPAP 5 cm H2O between inflations and Delayed clamping of the umbilical cord for 60 seconds
1600615|NCT02231411|Procedure|Delayed cord clamping|Delayed clamping of the umbilical cord for 60 seconds
1600616|NCT02231411|Procedure|Dry and and if apneic initially can stimulate by gently rubbing the back for approximately 30 seconds with warm sterile towels|
1600617|NCT02231385|Drug|Acetic Acid|"Subjects in Group A (study group) will undergo a standard colonoscopy. Once the right colon has been fully examined, acetic acid 2% will be sprayed and the right colon re-examined from cecum to hepatic flexure with within a frame-time of two minutes.
Subjects in Group B (control group) will undergo a second examination of the right colon without acid acetic and within the same frame-time."
1600618|NCT02231372|Drug|Berodual® Respimat® solution for inhalation|
1600619|NCT02231359|Drug|Berodual® Respimat® solution for inhalation|
1600620|NCT02231346|Drug|Berodual® Respimat® - inhaler|
1600621|NCT02231333|Drug|S-adenosylmethionine (SAMe)|
1600622|NCT02231333|Drug|pentoxiphylline (PTX)|
1600623|NCT02231320|Drug|Berodual® Respimat® - inhaler|
1600624|NCT02231307|Drug|SUBLIVAC FIX Birch|
1600625|NCT02231294|Drug|Sifrol®|
1600626|NCT02231281|Drug|cART(TDF/AZT+3TC+LPV/r)|Standard antiretroviral therapy for HIV infection
1600627|NCT02231281|Procedure|CTL infusion|cART(TDF/AZT+3TC+LPV/r) plus autologous HIV-1 specific cytotoxic T lymphocyte (CTL) infusion
1600628|NCT02231268|Drug|Gladem|
1600629|NCT02231255|Drug|Sifrol®|
1600630|NCT02231242|Biological|Autologous Stem Cell Transplantation|"Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 3 consecutive days. Bone marrow will be harvested under sedation and, after being processed in the laboratory, the buffy coat (TNC) of 10 mL will be infused intrathecally.
Intrathecal Autologous Bone Marrow TNC"
1600631|NCT02231229|Other|PCR-based strategy|Treatment based on the results of detection of resistance to isoniazid and rifampicin using PCR (GenoType ® Mycobacterium Tuberculosis Drug Resistance (MTBDR)plus 2.0) in a smear positive patient with pulmonary tuberculosis: initiation of a 3 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA)) if no resistance is detected and treatment based on suspected resistance in case of INH and/or RIF resistant strain.
1600632|NCT02231229|Drug|conventional therapy|Initiation of a standard 4 drug combination (isoniazid (H / INH); rifampicin (R /RIF); pyrazinamide (Z / PZA); ethambutol (EMB or E)) until the results of DST are available.
1600633|NCT02231216|Procedure|Rhinoseptoplasty|Rhinoseptoplasty without turbinectomy procedure
1600634|NCT02231216|Procedure|Partial turbinectomy|After medial dislocation of the inferior turbinate, proceed partial resection of the inferior turbinate in all its inferior extension in range. Possible bleeding is cauterized.
1600635|NCT02231216|Procedure|Endoscopic partial turbinectomy|Endoscopy to medial dislocation of the inferior turbinate with instrument
1600636|NCT02231203|Drug|Omegaven|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
1600637|NCT02231203|Drug|Placebo|2 infusions, 2 ml/kg, one the night before operation and one the day after operation
1600638|NCT02231190|Drug|GSK1278863|GSK1278863 will be supplied as oral tablet of strength 100mg, 5mg(5mg if a low dose is elected for subjects enrolled after interim analysis) to be administered with 240 mL of water after end of eccentric exercise
1600639|NCT02231190|Drug|Placebo|GSK1278863 matching placebo will be supplied as oral tablets for administration with 240 mL of water after end of eccentric exercise
1600640|NCT02231177|Drug|BI 1744 CL|
1600641|NCT02231177|Drug|BI 1744 CL/Tiotropium FDC|
1600642|NCT02231177|Drug|Tiotropium|
1600643|NCT02231164|Drug|docetaxel|intravenous chemotherapy drug
1600644|NCT02231164|Drug|docetaxel|intravenous chemotherapy drug
1600645|NCT02231164|Drug|placebo|oral placebo
1600646|NCT02231164|Drug|nintedanib|oral experimental therapy
1600647|NCT02231151|Behavioral|The type of CPR error(s) shown to the individual|Participants will be randomly assigned 12 videos to watch and rate the CPR quality of each. Investigators will be blind to the identity of the participants.
1600648|NCT02231138|Drug|Abelmoschus manihot (AM)|Abelmoschus manihot (AM): Huanghui capsule (Jiangsu Suzhong Pharmaceutical Group Co., Ltd.), 0.5 g × 30 capsules/box. A huangkui capsule is a single plant drug extract of Flos Abelmoschus manihot.
1600649|NCT02231125|Drug|Losartan|Losartan potassium tablet 100mg/time, once /day plus Huangkui Capsule dummy 2.5g/time, thrice /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
1600650|NCT02231125|Drug|Abelmoschus manihot|Huangkui Capsule 2.5g/time, thrice /day plus Losartan potassium tablet dummy 100mg/time, once /day, all drug and dummy are taken orally every day for 48 weeks during the whole study process.
1600651|NCT02231112|Radiation|Whole breast RT on prone position|
1600652|NCT02231099|Procedure|Prolift + M|prolapse surgery with mesh
1600653|NCT02231099|Procedure|conventional vaginal prolapse surgery|conventional vaginal prolapse surgery;anterior colporrhaphy, posterior colporrhaphy
1600654|NCT02231086|Procedure|Adjuvant HIPEC (open/laparoscopic)|Adjuvant HIPEC procedure: access to the abdominal cavity by laparoscopy or laparotomy under general anaesthesia, adhesiolysis if necessary, complete staging of the intra-abdominal cavity, positioning of in- and outflow catheters, perfusion with a minimum of 2l isotonic dialysis fluid at a flow rate of 1-2l/min and an inflow temperature of 42-43˚C. Before the beginning of HIPEC, 5-fluorouracil 400 mg/m2 and leucovorin 20 mg/m2 will be administered intravenously to potentiate oxaliplatin activity. Oxaliplatin (460 mg/m2) is added to the perfusate after attaining at least 42 degrees inflow temperature with a total of 30 minutes perfusion time.
1600655|NCT02231086|Drug|Standard adjuvant systemic chemotherapy|Colon cancer patients with a high risk of developing PC, but do not have (yet) proven macroscopic peritoneal metastasis, are standardly treated with adjuvant systemic chemotherapy. Standard adjuvant systemic chemotherapy consists in the Netherlands of a capecitabine and oxaliplatin (CAPOX) or 5-FU and oxaliplatin (FOLFOX) for a total of 6 months.
1600656|NCT02231086|Procedure|Diagnostic laparoscopy|Presence or absence of peritoneal recurrence will be evaluated by laparoscopy in case of negative routine examination (CEA and CT thorax/abdomen) at 18 months postoperatively in both study arms.
1600657|NCT02231073|Behavioral|Exercise and Education for Parkinson's Disease|Exercise and Education for Parkinson's Disease for 6 week cross-over intervention.
1600658|NCT02231047|Dietary Supplement|64N Nutraceutical|40 mg/kg/day of powdered 64N mixed in 12 ounces of a warm drink for 1 week (7 days)
1600659|NCT02231047|Other|No 64N Nutraceutical|12 ounce warm drink daily for 1 week (7 days)
1600660|NCT02231021|Drug|alogliptin|alogliptin 25 mg add-on background medication metformin
1600661|NCT02231021|Drug|Pioglitazone|pioglitazone 30 mg add-on background medication metformin
1600662|NCT02231021|Drug|alogliptin + pioglitazone|alogliptin 25 mg and pioglitazone 30 mg add-on background medication metformin
1600663|NCT02231008|Drug|tasimelteon|
1600664|NCT02230995|Drug|metformin|single dose of metformin given as tablets
1600665|NCT02230995|Drug|empagliflozin/metformin|Single dose empagliflozin/metformin given as fixed-dose combination tablet
1600666|NCT02230995|Drug|empagliflozin|single dose of empagliflozin given as tablet
1600667|NCT02230982|Drug|nintedanib|soft gelatin capsule
1600668|NCT02230969|Drug|peginterferon beta-1a|Administered as specified in the treatment arm
1600669|NCT02230956|Biological|onabotulinumtoxinA|onabotulinumtoxinA (botulinum toxin Type A) injection into the intra-articular space of the study knee.
1600670|NCT02230956|Drug|Normal Saline|Normal Saline (placebo) injection into the intra-articular space of the study knee.
1600671|NCT02230930|Drug|Apomorphine 0.25% (2.5mg/ml)|Apomorphine 0.5% (5mg/ml) will be diluted to 0.25% (2.5mg/ml) by the addition of the same volume physiological saline (NaCl 0.9%).
1600672|NCT02230930|Device|Massage with a spiky ball|Each patient will massage skin reactions with a spiky ball 3 times a day for 2 minutes.
1600673|NCT02230930|Drug|Hydrocortisone cream 1%|Hydrocortisone cream 1% (1mg/g) will be administered on each nodule one time a day
1600674|NCT02230930|Drug|Subcutaneous hydrocortisone 10mg|Subcutaneous hydrocortisone 10mg will be administered previous to apomorphine infusion making use of the apomorphine infusion system
1600675|NCT02230917|Drug|Sotatercept|
1600676|NCT02230917|Drug|Placebo|
1600677|NCT02230904|Drug|Rotigotine (Test product PR 2.3.1)|"Pharmaceutical form: Transdermal patch
Concentration: 8 mg/24 hours
Route of administration: Transdermal"
1600678|NCT02230904|Drug|Rotigotine (Reference product PR 2.1.1)|"Pharmaceutical form: Transdermal patch
Concentration: 8 mg/24 hours
Route of administration: Transdermal"
1600679|NCT02230891|Drug|Carvedilol|Carvedilol is a non selective beta blocker
1600680|NCT02230891|Drug|Spironolactone|Spironolactone is an aldosterone antagonist and can lower blood pressure/ is used in heart failure
1600681|NCT02230878|Drug|JNJ-42847922 5 mg|Participants will receive 5 mg of JNJ-42847922, from Day 1 up to Day 10.
1600682|NCT02230878|Drug|JNJ-42847922 10 mg|Participants will receive 10 mg of JNJ-42847922, from Day 1 up to Day 10.
1600683|NCT02230878|Drug|JNJ-42847922 20 mg|Participants will receive 20 mg of JNJ-42847922, from Day 1 up to Day 10.
1600684|NCT02230878|Drug|JNJ-42847922 40 mg|Participants will receive 40 mg of JNJ-42847922, from Day 1 up to Day 10 .
1600685|NCT02230878|Drug|Placebo|Participants will receive matching placebo from Day 1 up to Day 10.
2009578|NCT03212586|Drug|BAY1902607|Escalating doses of BAY1902607; single dose administration; different dosage forms (redosing of BAY1902607 at dose group 4 with different formulations; redosing of BAY1902607 solid formulation at dose group 4 together with food)
2009579|NCT03212586|Drug|Placebo|Escalating doses of Placebo; single dose administration; different dosage forms (redosing of Placebo at dose group 4 with different formulations; redosing of Placebo solid formulation at dose group 4 together with food)
1600688|NCT02230800|Drug|Tocovid SupraBio plus pentoxifylline|
1600689|NCT02230800|Drug|Matching placebos|
1600690|NCT02230787|Device|Recession coverage without Emdogain|In the control group subjects the recession coverage surgery will be performed without Emdogain.
1600691|NCT02230787|Device|Recession coverage with Emdogain|In the test group subjects the recession coverage surgery will be performed with Emdogain.
1600692|NCT02230761|Drug|XOPH5 Ointment|
1600693|NCT02230761|Drug|Placebo|
1600694|NCT02230735|Drug|Bipivacaine 0.5% with epinephrine|Total of 14 ml of bupivacaine hydrochloride 0.5% with epinephrine 1:200,000, 7ml in right uterosacral ligament, 7ml in left uterosacral ligament
1600695|NCT02230735|Drug|Normal Saline|(placebo for bupivacaine)
1600696|NCT02230722|Behavioral|Motivational Interviewing|
1600697|NCT02230722|Behavioral|Attention Control|
1600698|NCT02230709|Other|Dry Needling|Needling with acupuncture needle in a myofascial trigger point.
1600699|NCT02230709|Other|"TENS and dry needling"|Application of TENS current after dry needling technique
2009580|NCT03212326|Drug|Perflutren Lipid Microsphere Intravenous Suspension [DEFINITY]|Perflutren 1.3mL diluted in 50 mL is infused intravenously, and intracardiac echo imaging is recorded to analyze for areas of possible myocardial scar, which is then compared with areas of abnormal electrical signal via direct catheter mapping which is performed during ablation of ventricular tachycardia.
2009581|NCT03213704|Other|Laboratory Biomarker Analysis|Correlative studies
1600700|NCT02230696|Drug|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
1600701|NCT02230696|Drug|Azelastine Hydrochloride/Fluticasone Propionate Nasal Spray|137 micro-grams Azelastine Hydrochloride, 50 micro-grams Fluticasone Propionate
1600702|NCT02230696|Drug|Placebo nasal spray|
1600703|NCT02230683|Drug|IDN-6556|25 mg BID
1600704|NCT02230670|Drug|IDN-6556|25 mg BID
1600705|NCT02230670|Drug|Placebo|
1600706|NCT02230657|Procedure|Same day discharge|
1600707|NCT02230657|Procedure|Next day discharge|
1600708|NCT02230644|Other|Enhanced clinical environment|Surgical booths containing artwork and calming background music.
1600709|NCT02230644|Other|Other distraction|Such as newspaper, magazine or the news on television
1600710|NCT02230631|Other|No treatment given|Two different questionnaires will be applied to patients during a regular clinical visit.
1600711|NCT02230618|Other|Insulin degludec, insulin aspart|Ryzodeg™ will be prescribed by the physician under normal clinical practice conditions and will be obtained/purchased from the chemist based on physician prescription. No treatment given.
1600712|NCT02230605|Other|Mini-Mental State Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
1600713|NCT02230605|Other|Self-Administered Gerocognitive Examination|To be completed at the Screening Visit and Post-Operative Day 7 Visit (or Discharge)
1600714|NCT02230605|Other|Geriatric Depression Scale|To be completed at the Screening Visit and at POD 90
1600715|NCT02230605|Other|Charlson Comorbidity Index|To be completed at the Screening Visit and at POD 90
1600716|NCT02230605|Other|Short Form 36 Health Survey|To be completed at the Screening Visit
1600717|NCT02230605|Other|Confusion Assessment Method|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:00 A.M. and 6:00 P.M. (or until hospital discharge)
1600718|NCT02230605|Other|Memorial Delirium Assessment Scale|To be completed at the Day 0 (Pre-Operative) Visit, Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:00 A.M. and 6:00 P.M. (or until hospital discharge)
1600719|NCT02230605|Other|Postoperative Quality of Recovery Scale|To be completed at Day 0 (Post-Operative) Visit, and Day 1-7 Visits at 6:00 A.M. and 6:00 P.M. (or until hospital discharge). Will be completed POD 7 over the phone if patient already discharged. Will be completed on POD 30 and POD 90.
1600729|NCT02230566|Drug|UX003|UX003 is a sterile liquid buffered saline formulation of rhGUS
1600730|NCT02230566|Other|Placebo|Placebo consisting of the UX003 formulation buffer (without rhGUS)
1600731|NCT02230553|Drug|Lapatinib|
1600732|NCT02230553|Drug|trametinib|
1600733|NCT02230540|Device|SelfCath (comparator)|Commercially available CE-marked catheter for urinary drainage.
1600734|NCT02230540|Device|Product A SelfCath and urine bag, Conveen Security+|SelfCath and urine bag, Conveen Security+ (both commercially available CE-marked devices).
1600735|NCT02230540|Device|Product B SelfCath and urine bag, Conveen Contour|SelfCath and urine bag, Conveen Contour (both commercially available CE-marked devices).
1600736|NCT02230527|Drug|Ticagrelor|90mg twice a day by mouth
1600737|NCT02230527|Drug|Clopidogrel|75mg once a day by mouth
1600738|NCT02230514|Drug|XCEL-MT-OSTEO-ALPHA|"ex-vivo expanded autologous mesenchymal stromal cells fixed in allogenic bone tissue in association with open surgery"
1600739|NCT02230514|Other|autologous iliac crest|Autologous iliac crest in association with surgery
1600740|NCT02230514|Procedure|Surgery|Standard surgery for non-union fractures
1600741|NCT02230501|Dietary Supplement|stringent diet regimen|
1600742|NCT02230501|Dietary Supplement|moderate diet regimen|
1600743|NCT02230488|Other|Intensive Diabetes Case Management|A diabetes team , led by an endocrinologist and CDE, will manage the patients diabetes while in the hospital and will assist with the patient's discharge Diabetes endocrine consult team will manage the patient's diabetes daily while in the hospital Discharge diabetes medication reconciliation per research team Research team will provide 30 day supply of diabetes medication/supplies at discharge Research Team will provide 30 day supply of glucose test strips at discharge Discharge telecommunication from endocrinologist to primary care provider Patient-centered discharge diabetes education per research CDE Post-discharge 48-72 hours continuity check per phone by a diabetes research team member/CDE
1600744|NCT02230462|Other|Viewing of cancer excision defect|Patients will be invited to view their cancer excision defect, with the aid of a mirror, prior to its reconstruction.
1600745|NCT02230436|Other|Early drain removal|Removing drain(s) on postoperative day 3
1600746|NCT02230436|Other|Late drain removal|Removing drain(s) on postoperative day 4 or later
1600747|NCT02230423|Procedure|Nasal surgery|
1600748|NCT02230410|Device|CryoBalloon Focal Ablation|
1600751|NCT02230384|Drug|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week
1600752|NCT02230384|Drug|Placebo Pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week
1600753|NCT02230371|Drug|Granisetron|If the patient does not have any pain after the first or second injection of granisetron (Kytril®; 1 mg/mL, Roche, Stockholm, Sweden), there will be no more injections but the patient will still come for the follow ups.
1600754|NCT02230371|Drug|Control (placebo)|If the patient does not have any pain after the first or second injection of granisetron (isotonic saline (NaCl); 0.9 mg/mL, Fresenius Kabi, Uppsala, Sweden), there will be no more injections but the patient will still come for the follow ups.
1600755|NCT02230358|Procedure|Regional anesthesia|Regional anesthesia
1600756|NCT02230358|Procedure|General anesthesia|General anesthesia
1600757|NCT02230358|Device|Transcranial Doppler ultrasonography|6x for 4 hours
1600758|NCT02230358|Procedure|blood gas analysis|6 x 3 ml blood withdrawal (18 ml) within 4 hours
1600759|NCT02230358|Procedure|invasive arterial blood pressure measurement|before operation, 8 hours, as done in clinical routine
1600760|NCT02230358|Procedure|arterial blood gas measurement|perioperative, 4-6 times within 8 hours, as done in clinical routine
1600761|NCT02230358|Behavioral|Neurological Control|perioperative, 2-3 days, as done in clinical routine
1600762|NCT02230358|Behavioral|NIRS monitoring|perioperative, for 5 hours, as done in clinical routine
1600763|NCT02230358|Device|oxygen supply (not invasive 'Vigileo')|perioperative for 5 hours, as done in clinical routine
1600764|NCT02230345|Dietary Supplement|Probiotic yogurt|Probiotic yogurt (fermented milk with Lactobacillus delbrueckii subsp. bulgaricus and Streptococcus thermophilus- YoFlex FD-DVS YC-X11 Fr, with the addition of Lactobacillus rhamnosus GG (LGG)- Culture Collection, University of Göteborg, Sweden CCUG 34291).
1600765|NCT02230345|Dietary Supplement|Acidified milk|Milk will consist in an isocaloric supplement (compared to probiotic yogurt) of unfermented milk
1600768|NCT02230319|Other|Cryotherapy|
1600769|NCT02230319|Drug|Paclitaxel|
1600772|NCT02230293|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
1600773|NCT02230293|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
1600774|NCT02230280|Other|Strengthening Community-Based Stroke Care: A Pilot Study of a Community Navigation and Rehabilitation Intervention that Includes a Mobile Health Solution|Participants will be offered regular in-home visits over the 6-month study period in addition to usual outpatient rehabilitation services. The health care providers will have access to a mobile health application (MYST) to share real-time information and access community resources and best practice guidelines.
1600775|NCT02230267|Other|High intensity exercise and balance training|
1600776|NCT02230267|Other|Usual care arm exercise|
1600777|NCT02230254|Device|Percutaneous coronary intervention PROMUS PREMIER|PROMUS PREMIER
1600778|NCT02230228|Drug|ALK-001 (No generic name)|Daily, oral administration of ALK-001 capsules.
1600779|NCT02230215|Device|Total Knee Arthroplasty with use of Visionaire Patient-Specific Instrumentation|The manufacturing of a patient-specific instrument to be used by the orthopaedic surgeon during the knee replacement surgery.
1600780|NCT02230202|Other|Flow-mediated dilation|Flow-mediated dilation used to measure vascular function. The test is minimally invasive, with only a slight discomfort due to the inflation of the arm cuff.
1600781|NCT02230202|Other|single blood draw|single blood draw of approximately 45 mL.
1600782|NCT02230189|Biological|Segmental airway allergen challenge|
1600783|NCT02230176|Drug|Sunitinib|
1600784|NCT02230176|Drug|177Lu-DOTA0-Tyr3-Octreotate|
1600785|NCT02230163|Biological|anti-CHIKV hyperimmune immunoglobulins|Anti-CHIKV immunoglobulins (CHIKVIg) were purified after the Tégéline manufacturing process from a pool of 583 plasma samples from donors in the convalescent phase of CHIKV infections. Anti-CHIKV hyper immune intravenous immunoglobulin (50 mg/ml) is prepared as a powder to be reconstituted. The therapeutic regimen will consist of 2 doses of 0.5 g/kg 12 hours apart.
1600786|NCT02230150|Behavioral|Adhesion-HF|The hypothesis that was investigated is whether the nursing consultation improves therapeutic strategies for membership, adherence to self-care, improved levels of NT-proBNP improves performance in 6-minute walk test, monitoring of biomarkers of laboratory tests (sodium , potassium, urea, creatinine and NT-proBNP) frequent occurrence of readmissions and mortality in patients with heart failure after 1 month.
1600787|NCT02230137|Behavioral|Text message arm|Text message sent before each injection of insulin
1600788|NCT02230124|Device|MRE|
1600789|NCT02230111|Behavioral|Energy restriction plus CDR|Subjects will receive a reduced-calorie low energy density diet which will provide 85% of their energy needs for a period of 4 weeks. In the condition in which an increase in CDR will be induced, women will be told at the beginning of the study and will be reminded throughout the 4-week duration of the experimental condition that they are on a low-calorie diet and that it is important not to eat more than what is provided and that they should strictly avoid non-study food if they want to lose weight and improve their blood pressure. Subjects will receive feedback about their weight trajectory. After the 4-week controlled intervention women will then receive further information and advices to pursue their weight loss on their own and keeping on with strategies relying on an increase in CDR.
1600836|NCT02229786|Drug|Buscopan®|
1600837|NCT02229786|Drug|Paracetamol|
1600838|NCT02229786|Drug|Placebo|
1600839|NCT02229773|Drug|BIBB 1464 MS low dose|
1600840|NCT02229773|Drug|Placebo|
1600841|NCT02229773|Drug|Pravastatin|
1600842|NCT02229773|Drug|BIBB 1464 MS medium dose|
1600843|NCT02229773|Drug|BIBB 1464 MS high dose|
1600844|NCT02229760|Drug|Tipranavir capsules|
1600845|NCT02229760|Drug|Ritonavir capsules|
1600846|NCT02229747|Drug|Meloxicam|
1600790|NCT02230111|Behavioral|Energy restriction without CDR|Subjects will receive the same low-calorie diet (85% of their energy needs) for 4 weeks but will not be told that they are on an energy-deficit diet. They will be told at the beginning of the study that the food provided cover all their nutrient needs and that they should eat until satiation. There will be no emphasis on body weight and subjects will be reminded that the aim of the intervention is to document the effects of a diet rich in vegetables and fruits on blood pressure. After the 4-week controlled diet, participants will be taught about the impact of a low energy density diet on satiation and satiety. They will receive further information and advices (with non-restrictive messages) to incorporate more vegetables and fruits in their usual diet.
1600791|NCT02230098|Other|Remote Ischemic Conditioning|
1600792|NCT02230085|Other|Administration of the questionnaire and monitoring of CPAP adherence|
1600793|NCT02230072|Device|fetoscopy|The fetoscopic arm is described above. All patients will have a laparotomy, exteriorization of the uterus, and a fetoscopic repair of the fetal open neural tube defect.
1600794|NCT02230059|Other|No Intervention|Medical charts of participants with metastatic castration-resistant prostate cancer will be observed.
1600795|NCT02230046|Drug|Abiraterone acetate (Treatment A)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment A (current commercial formulation, 4*250 mg uncoated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
1600796|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment B (current commercial formulation, 4*250 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
1600797|NCT02230046|Drug|Abiraterone acetate (Treatment B)|Participants will receive a single oral 1000 mg dose of abiraterone acetate as Treatment C (new composition, 2*500 mg coated tablets) under fasted conditions on Day 1 of period as specified in the protocol.
1600798|NCT02230033|Drug|JNJ-56021927|Single oral dose of JNJ-56021927 240 milligram (mg) capsule will be administered on Day 1 or Day 4 in any of the treatment.
1600799|NCT02230033|Drug|Itraconazole|Itraconazole 200 mg (2 capsules of 100 mg) will be administered once daily orally from Day 1 until Day 32.
1600800|NCT02230033|Drug|Gemfibrozil|Gemfibrozil 600 mg oral tablet will be administered twice daily from Day 1 until Day 32.
1600801|NCT02230020|Device|Nasal High Flow|
1600802|NCT02230007|Drug|MEOPA|3 sessions of reeducation using MEOPA
1600803|NCT02229994|Other|Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.|"Evaluation will be performed on a group of 200 patients deriving from 4 samples.
From these 200 patients, a sub-sample will be evaluated at 7 days (DYSLIM questionnaire only) for reproducibility (n = 50 patients: 10 patients with diffuse interstitial lung disease, 10 patients with cystic fibrosis, 10 patients with arterial pulmonary hypertension, 20 patients with COPD).
From these 200 patients, a sub-sample (COPD, n = 60) will be recruited among patients undergoing pulmonary rehabilitation at the beginning of the 6 months separating follow up visit and the initial assessment."
1600804|NCT02229981|Drug|ABC294640|
1600805|NCT02229968|Drug|Amicar (ε-aminocaproic acid)|
1600806|NCT02229968|Drug|normal saline|
1600807|NCT02229955|Drug|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
1600808|NCT02229942|Drug|Rituximab|"Induction with two infusions two weeks apart, rituximab 500 mg/m2 (max 1000 mg).
Maintenance with rituximab infusions (500 mg fixed dose) at 3, 6, 9 and 12 months."
1600809|NCT02229942|Drug|Placebo|Saline (NaCl 0,9%) added human albumin (Flexbumin) 0,4 mg/ml, two infusions two weeks apart. Maintenance infusions after 3,6, 9 and 12 months.
1600810|NCT02229929|Drug|Part A: Placebo|Part A: Single i.v. dose of Placebo administered after each dialysis session over a 1 week treatment period (3 times per week)
1600811|NCT02229929|Drug|Part A: CR845 0.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
1600812|NCT02229929|Drug|Part A: CR845 1.0 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
1600813|NCT02229929|Drug|Part A: CR845 2.5 mcg/kg|Part A: Single i.v. dose of CR845 administered after each dialysis session over a 1 week treatment period (3 times per week)
1600814|NCT02229929|Drug|Part B: Placebo|Part B: Single i.v. dose of Placebo administered after each dialysis session over a 2 week treatment period (3 times per week)
1600815|NCT02229929|Drug|Part B: CR845 1.0 mcg/kg|Part B: Single i.v. dose of CR845 administered after each dialysis session over a 2 week treatment period (3 times per week)
1600816|NCT02229903|Device|Active DTMS Treatment|H-coil Deep TMS 29 TMS treatments over 6 weeks.
1600817|NCT02229903|Device|Sham Treatment|29 treatments over 6 weeks.
1600818|NCT02229890|Drug|alteplase|
1600819|NCT02229877|Drug|Omeprazole|40 mg oral capsules administered twice daily for 8.5 days
1600820|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (25 mg administered as a divided 50 mg tablet) administered twice daily for 2 days
1600821|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (50 mg tablet) administered twice daily for 8 days
1600822|NCT02229877|Drug|Gefapixant|Gefapixant oral tablet (150 mg administered as three 50 mg tablets) administered twice daily for 8 days
1600823|NCT02229864|Device|Coronary artery stenting: Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm"
2009582|NCT03213704|Drug|Larotrectinib|Given PO or via nasogastric- or gastric-tube
2009583|NCT03213704|Other|Pharmacological Study|Correlative studies
2009584|NCT03211156|Drug|Amoxicillin|Amoxicillin is an aminopenicillin antibiotic
1600827|NCT02229838|Drug|BIBB 1464 MS tablet|
1600828|NCT02229838|Drug|BIBB 1464 MS solution|
1600829|NCT02229838|Drug|BIBB 1464 MS placebo|
1600830|NCT02229838|Other|Standard dinner|
1600831|NCT02229825|Drug|Duloxetine high|
1600832|NCT02229825|Drug|Duloxetine low|
1600833|NCT02229812|Drug|alteplase|
1600834|NCT02229799|Drug|Actilyse|
2009585|NCT03211156|Other|Placebo|Placebo
2009586|NCT03208231|Biological|VRC01|40 mg/kg of VRC01 will be administered by subcutaneous injection.
1600849|NCT02229734|Radiation|Radiation|Radiation: Radiotherapy 7 gray (Gy) per week over 5 weeks (35Gy)
1600850|NCT02229734|Drug|Androgen Suppression|Leuprolide 45mg every 6 months for a total of 18 months
1600851|NCT02229721|Drug|Syntocinon Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.
The recommended dose is four puffs per nostril, containing 32 IU of synthetic oxytocin, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
1600852|NCT02229721|Drug|Placebo Nasalspray|"Over 8 weeks, intranasal oxytocin (32 IE) or placebo will be self-administered by women prior to sexual intercourse. Following a washout period of 2 weeks, a cross-over will take place and patients switched to the alternate group for another 8 weeks.
The recommended dose is four puffs per nostril, administered up to 50 minutes prior to sexual activity. The maximal dose should not exceed four puffs per nostril per day; the minimum dose was twice weekly."
1600853|NCT02229708|Behavioral|Healthy Lifestyle Group|
1600854|NCT02229682|Radiation|Mild-dose IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 46.2 grays (Gy) in 22 fractions.
1600855|NCT02229669|Procedure|Horizontal incisions|Performed by using horizontal interdental incisions. An initial horizontal incision was made slightly coronal to the CEJ from the distal to the mesial papilla of the teeth with the recessions. A second incision, 1 to 2 mm apart and parallel to the first incision, was made apically. A sulcular incision was made to link the second incisions and the blade was inserted (2 to 3 mm) extending beyond the mucogingival junction (MGJ), to create a uniform split-thickness flap. The tissue between the two incisions was partially removed to obtain a uniform receptor site that permitted primary closure. Approximation sutures to place the edge of the flap at the base of the remaining papilla were performed. Passive closure of the wound margins without tension was achieved with interrupted coaptation.
1600856|NCT02229669|Procedure|Oblique incisions|Coronally advanced flap was performed by using oblique incisions in interdental areas, according to the technique proposed by Zucchelli & De Sanctis (2000). Oblique submarginal interdental incisions were performed and continued with the intrasulcular incisions at the recession defects, resulting in a envelop flap that was raised with a split-full-split approach in the coronal-apical direction. During coronal advancement, each surgical papilla was dislocated with respect to the de-epithelized anatomic papilla by the oblique incisions. Interrupted sutures were performed to stabilize single surgical papilla over the interdental connective tissue bed.
1600857|NCT02229656|Radiation|radiotherapy|Primary tumor and lymph nodes will receive 35 fractions of 2 Gy resulting in a total dose of 70 Gy. Elective fields will receive 35 fractions of 1.55 Gy resulting in a total dose of 54.25 Gy in case a SIB technique is used, or 23 fractions of 2 Gy resulting in a total dose of 46 Gy in case a sequential boost technique is used. The higher total prescribed physical dose to the elective fields in a SIB technique based RT plan compensates for the lower dose per fraction and results in an equal biological effective dose when compared with a sequential boost technique.
1600858|NCT02229656|Drug|Olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, and 300 mg BID
1600859|NCT02229630|Radiation|Pregnant women with intra-uterine growth restricted Foetuses|Diffusion-weighted cerebral MRI before 32 weeks of gestation
1600860|NCT02229617|Drug|Subcutaneous testosterone|
1600861|NCT02229604|Other|EA|For BL33, insert the needle to the third posterior sacral foramina to a depth of 80-100mm. For ST25, EX-CA1 and RN4, the needle will be inserted vertically and quickly through the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall (until the moment of resistance is sensed on the tip of the needle and the participant feels a sting). The electric stimulator will be put on the BL33 and EX-CA1 with a continuous wave, 20 Hz, 1.0-4.0 mA.
1600862|NCT02229604|Drug|HRT, DHEA and herb|HRT, dehydroepiandrosterone (DHEA) and herb decoction could be used for this group. Time frame of treatment is not fixed. Herb decoction will be given to participants based on the principle of syndrome differentiation (a diagnosing method in Traditional Chinese Medicine).
1600863|NCT02229578|Drug|Lidocaine|Subjects in this group will receive a nonpyrogenic solution of lidocaine 2% in isotonic saline (Solution A) sprayed on the donor site of the grafted skin prior to emergence from general anesthesia. A total maximum of 7mg/kg of lidocaine solution will be available for administration. Prior to spraying of the Solution A, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
1600864|NCT02229578|Drug|Placebo|Subjects in this group will receive a nonpyrogenic solution of isotonic saline (Solution B) sprayed over the donor site. Prior to spraying of the Solution B, the donor site will be soaked with epinephrine soaked towels as per routine burn care. The site will then be covered with TheraBond dressing as per standard burn care.
1600865|NCT02229565|Device|Biopsy or prostatectomy|
1600866|NCT02229539|Drug|doxepin hydrochloride oral solution|2.5 mL (25 mg) doxepin and 2.5 mL water administered orally
1600867|NCT02229539|Drug|DLA (diphenhydramine, lidocaine and antacids) rinse|5.0 mL administered orally
1600868|NCT02229539|Other|Placebo|2.5 mL placebo and 2.5 mL water administered orally
1600869|NCT02229526|Dietary Supplement|Low dose fish oil|Four 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 2.7 g n-3 fatty acids per day.
1600870|NCT02229526|Dietary Supplement|Low dose olive oil|Four 1 g capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
1600871|NCT02229526|Dietary Supplement|High dose fish oil|Nine 1g gelatine capsules with fish oil (Pikasol: 32 % eicosapentaenoic acid (20:5n-3), 23 % docosahexaenoic acid (22:6n-3) and 2 mg tocopherol/ml)) corresponding to 6.1 g n-3 fatty acids per day.
1600872|NCT02229526|Dietary Supplement|High dose olive oil|Nine 1g gelatine capsules with olive oil (72 % oleic acid (18:1n-9) and 12 % linoleic acid (18:2n-6)) per day.
1600957|NCT02228889|Other|Assess Surgical Site Occurrences at 1 year postoperatively|Assess Surgical Site Occurrences at 1 year postoperatively
1600958|NCT02228889|Other|Assess overall complications at 30 days postoperatively|
1600959|NCT02228889|Other|Assess overall complications at 1 year postoperatively|
1600962|NCT02228889|Device|XenMatrix|Xenmatrix mesh
1600873|NCT02229513|Procedure|Uterine Cooling|Immediately following delivery of the fetus the uterus will be externalized in the usual fashion and the body of the uterus cephalad to the hysterotomy incision will be wrapped in sterile surgical towels saturated in sterile, iced normal saline. These towels will come from a sterile cooling pot set to 30 degrees Fahrenheit. Iced saline-soaked towels will be kept in place for a minimum of 5 minutes and replaced at the discretion of the attending obstetrician until the hysterotomy is closed and the uterus is replaced into the patient's abdomen.
1600874|NCT02229500|Dietary Supplement|Inulin|
1600875|NCT02229500|Dietary Supplement|2.5 g of propionate|This system delivers approximately 2.5 g of propionate to the colon in a 10g dose.
1600876|NCT02229500|Dietary Supplement|5 g of propionate|This delivers approximately 5g of propionate to the colon per 10g dose
2009587|NCT03208231|Drug|Combination Antiretroviral Therapy (cART)|All infants will receive non-study provided cART. Each infant's cART regimen will be selected by his or her primary care provider and supplied through non-study sources (i.e., ARVs will not be provided through the study).
2009588|NCT03207906|Drug|VBP-926|Topical VBP-926 solution
1600879|NCT02229461|Drug|Naproxen Sodium (Aleve, BAY117031)|Naproxen sodium 220 mg qd or bid
1600880|NCT02229461|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|ASA 81 mg qd
1600881|NCT02229422|Drug|GA101/HDMP|"All subjects will receive GA101 - Obinutuzumab by IV infusion for up to 6 cycles (28-day cycles) as follow:
On Cycle 1, Day 1, 100 mg GA101-obinutuzumab will be administered.
On Cycle 1, Day 2, 900 mg of GA101-obinutuzumab will be administered.
On Cycle 1, Days 8 and 15, 1,000 mg of GA101-obinutuzumab will be administered.
On Cycles 2-6, Day 1, 1,000 mg of GA101-obinutuzumab will be administered.
All subjects will receive HDMP by IV infusion for up to 4 cycles (28-day cycles) as follow:
•On Cycle 1-4, Days 1 to 3, 1,000 mg/m2 Methylprednisolone will be administered."
1600882|NCT02229409|Behavioral|Walkadoo|Walkadoo is a MeYou Health, LLC product.
2009589|NCT03206086|Drug|Eltrombopag|"Daily dose Non-Asian (greater than or equal to 12): 150 mg Non-Asian (6-11): 75 mg Non-Asian (4-5): 2.5 mg/kg
East Asian, South East Asian (greater than or equal to 12):
75 mg East Asian, South East Asian (6- 11): 37.5 mg
East Asian, South East Asian (4-5):
1.25 mg/kg"
2009590|NCT03206073|Drug|Durvalumab|1500 mg of durvalumab via IV infusion on Day 1 of each cycle until patients meet off treatment criteria
1600888|NCT02229357|Biological|OrniFlu® inactivated vaccine|All subjects will receive a single dose of an H5 inactivated influenza vaccine after blood collection for immunology assays
1600889|NCT02229344|Other|No Intervention|Participants with newly diagnosed moderate to severe ulcerative colitis in a tertiary referral hospital within 4 weeks before prior to enrollment will be observed.
1600890|NCT02229331|Other|Gait analysis|
1600891|NCT02229318|Dietary Supplement|FruitiVits|Daily administration of FruitiVits dietary supplement
1600892|NCT02229305|Behavioral|Usual Care Treatment|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
1600893|NCT02229305|Behavioral|Modular Approach to Therapy for Children|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, Trauma, or Conduct Problems (MATCH-ADTC; Chorpita & Weisz, 2010).
1600894|NCT02229292|Drug|Tranexamic Acid|"Active group:
Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml tranexamic acid (100mg/ml) administered iv. prior to the onset of the surgical procedure."
1600895|NCT02229292|Drug|Saline|"Placebo group:
Undergoes elective bi-maxillary orthognathic surgery consisting of a (un)/segmented LeFort I osteotomy combined with a bilateral sagittal split osteotomy, under the influence of 10ml sodium chloride (9mg/ml) administered iv. prior to the onset of the surgical procedure."
1600896|NCT02229279|Device|Teleconsulting|
1600897|NCT02229266|Biological|NK cells|
1600898|NCT02229266|Drug|Cytarabine|1 cycle of consolidation chemotherapy with high-dose cytarabine
1600900|NCT02229240|Drug|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
1600901|NCT02229240|Drug|Matching albiglutide placebo|Matching albiglutide placebo will be provided as 0.5-mL injection, fully disposable pen injector system
1600902|NCT02229227|Drug|Albiglutide|Albiglutide is intended for self-administration as a SC injection. It is provided as a fixed dose of 30 mg of albiglutide or 50 mg of albiglutide in a 0.5 mL injection volume, fully disposable pen injector
1600903|NCT02229227|Drug|Insulin Glargine and Insulin Lispro|Insulin glargine and insulin lispro will be provided as injection pens for SC injection
1600904|NCT02229214|Drug|Qsymia|
1600905|NCT02229214|Drug|Placebo|
1600906|NCT02229201|Drug|Propofol|4-6 mg/kg/h during anaesthesia
1600907|NCT02229201|Drug|Sevoflurane|0.8 MAC
1600908|NCT02229188|Behavioral|Problem Solving Therapy|Problem solving therapy is an evidence based behavioral intervention for late life depression. It consist of 8 weekly session of talk therapy, whereby the therapist helps the patient solve problems that are thought to be causing depressive symptoms.
1600909|NCT02229188|Behavioral|Evolution|Evo is a video game that has therapeutic elements targeting the cognitive control network. Impairment in this neural network is associated with a specific subtype of late life depression that puts people at risk for poor response to SSRIs. Evo is built from a research grade training paradigm that has shown to induce improvements in this network in healthy older adults
1600910|NCT02229188|Behavioral|Words|Words is a cognitively challenging crossword/word search type of video game that will serve as the control condition for the second phase of this project
1600911|NCT02229175|Drug|bevacizumab|intravitreal injections of antibodies inhibiting vascular endothelial growth factor
1600912|NCT02229175|Device|PASCAL Endpoint Management (EpM) laser treatment|This is an algorithm that is included in the PASCAL 577 mm yellow laser system (Topcon, Santa Clara, CA). This is FDA-approved for treatment of diabetic retinopathy and diabetic macular edema.
1600960|NCT02228889|Procedure|Abdominal wall reconstruction with XenMatrix|Abdominal wall reconstruction with XenMatrix
1600961|NCT02228889|Device|Strattice|Strattice mesh
1600913|NCT02229149|Drug|Trastuzumab|"Treatment for all patients will consist of trastuzumab, given as a loading dose of 8 mg/kg IV on Day 1 followed by 6 mg/kg IV every 3 weeks thereafter.
Patients randomized to the chemotherapy plus trastuzumab arm (without pertuzumab) can receive trastuzumab 6 mg/kg IV every 3 weeks if they are receiving docetaxel or capecitabine on a 3-week cycle, or 4 mg/kg IV every 2 weeks if they are receiving vinorelbine, paclitaxel, or nab-paclitaxel on a 4-week cycle. The loading dose for all patients remains 8 mg/kg.
For patients randomized to the chemotherapy plus trastuzumab plus pertuzumab arm, both trastuzumab and pertuzumab need to be administered every 3 weeks regardless of which chemotherapy agent they are receiving."
1600914|NCT02229149|Drug|Pertuzumab|pertuzumab given as a loading dose of 840 mg IV on Day 1 followed by 420 mg IV every 3 weeks.
1600915|NCT02229149|Drug|Vinorelbine, Paclitaxel, Nab-Paclitaxel , Docetaxel, Capecitabine|"physician's choice of chemotherapy:
Vinorelbine 25 mg/m2 IV weekly times 3 with 1 week off; OR
Paclitaxel 80 mg/m2 IV weekly times 3 with 1 week off; OR
Nab-Paclitaxel 100 mg/m2 IV weekly times 3 with 1 week off; OR
Docetaxel 75 mg/m2 IV every 3 weeks; OR
Capecitabine 1500 mg by mouth twice a day (PO BID) 14 days on and then 7 days off."
1600916|NCT02229136|Drug|Miracle Mouthwash Plus Hydrocortisone|Miracle Mouthwash Plus Hydrocortisone (16 oz recipe/480 ml)
1600917|NCT02229136|Drug|Prednisolone|Prednisolone oral solution 15 mg/5 ml
1600918|NCT02229123|Drug|Intravenous Levetiracetam|Intravenous Levetiracetam 40 to 60 mg/kg loading dose. 7.5 to 15 mg/kg 8 hourly maintenance as determined by the dose escalation design
1600919|NCT02229110|Other|Signal|Automatic signal in the electronic medical record
1600920|NCT02229097|Drug|Normal bolus|"During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period"
1600921|NCT02229097|Drug|Coordinated bolus|The basal rate will be reduced at a rate of 0.1 U/h during the 3 h postprandial period. The insulin subtracted of the basal rate will be added to the normal bolus calculated for the meal and injected immediately.
1600922|NCT02229084|Biological|Chemovax|Timing of the vaccination relative to chemotherapy
1600923|NCT02229071|Drug|Donafenib(200mg)|Donafenib 200mg,bid,po
1600924|NCT02229071|Drug|Donafenib(300mg)|Donafenib 300mg,bid,po
1600925|NCT02229058|Drug|Albumin Bound Paclitaxel|120 mg/m2, D1,D8,every 3 weeks until disease progress or intolerable toxicity.
1600926|NCT02229058|Drug|S-1|40mg QD D1-D14,every 3 weeks,for BSA<1.25 m2, 50mg QD D1-D14,every 3 weeks,for BSA=1.25～1.5m2, 60mg QD D1-D14,every 3 weeks,for BSA>1.5m2,until disease progress or intolerable toxicity.
1600927|NCT02229045|Drug|Albumin Bound Paclitaxel|Albumin Bound Paclitaxel 150 mg/m2 (on day 1), every 2 weeks until disease progress or intolerable toxicity.
1600928|NCT02229045|Drug|5-FU|5-FU 400 mg/m2 iv d1, 2.4g/ m2 civ,d1-d3 every 2 weeks until disease progress or intolerable toxicity.
1600929|NCT02229019|Behavioral|Volunteer mealtime assistance|
1600930|NCT02229006|Radiation|18F-NaF PET-CT|
1600931|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.25 mL Intramuscular (2 doses given 28 days apart)
1600932|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
1600933|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
1600934|NCT02228980|Biological|Shenzhen trivalent influenza vaccine (split virion, inactivated) North Hemisphere (NH) formulation|0.5 mL Intramuscular
2009591|NCT03206073|Drug|Tremelimumab|75 mg of tremelimumab via IV infusion on Day 1 of cycles 1-4
1600936|NCT02228954|Procedure|Molecular imaging|
1600937|NCT02228928|Drug|CAPNP, 50 ug/cm2 capsaicin patch|
1600938|NCT02228928|Drug|CAPNP, 100 ug/cm2 capsaicin patch|
1600939|NCT02228928|Drug|0.075% capsaicin cream|
1600940|NCT02228928|Other|Placebo patch|
1600941|NCT02228902|Drug|Ferrous fumarate|one group receives ferrous fumarate (12 patients) and one group (12 patients) receives ferrous gluconate
1600942|NCT02228902|Drug|Ferrous gluconate|One group receives ferrous fumarate and one group receives ferrous fumarate.
1600943|NCT02228889|Procedure|Abdominal wall reconstruction with Strattice|Abdominal wall reconstruction using Strattice
1600944|NCT02228889|Other|Assess pain intensity at last office visit preoperatively|Assess patient pain intensity preoperatively using the PROMIS Pain Intensity survey (average of 1-3 weeks preoperatively)
1600945|NCT02228889|Other|Assess pain interference at last office visit preoperatively|Assess pain interference preoperatively using the PROMIS pain interference survey (average of 1-3 weeks preoperatively)
1600946|NCT02228889|Other|Assess physical functioning at last office visit preoperatively|Assess physical functioning preoperatively using the PROMIS physical functioning survey (average of 1-3 weeks preoperatively)
1600947|NCT02228889|Other|Assess patient quality of life at last office visit preoperatively|Assess patient quality of life preoperatively, using the HerQLes survey (average of 1-3 weeks preoperatively)
1600948|NCT02228889|Other|Assess patient pain intensity postoperatively|Assess patient pain intensity at 1 year postoperatively using the PROMIS Pain Intensity survey
1600949|NCT02228889|Other|Assess pain interference postoperatively|Assess pain interference at 1 year postoperatively using the PROMIS Pain Interference survey
1600950|NCT02228889|Other|Assess physical functioning postoperatively|Assess physical functioning at 1 year postoperatively using the PROMIS Physical Functioning Survey
1600951|NCT02228889|Other|Assess quality of life postoperatively|Assess quality of life at 1 year postoperatively using the HerQLes survey
1600952|NCT02228889|Other|Assess hernia recurrence at 30 days postoperatively|Assess hernia recurrence at 30 days
1600953|NCT02228889|Other|Assess bulge at 30 days postoperatively|Assess bulge at 30 days
1600954|NCT02228889|Other|Assess Surgical Site Occurrences at 30 days postoperatively|Assess Surgical Site Occurrences at 30 days
1600955|NCT02228889|Other|Assess hernia recurrence at 1 year postoperatively|Assess hernia recurrence at 1 year postoperatively
1600956|NCT02228889|Other|Assess bulge at 1 year postoperatively|Assess bulge at 1 year postoperatively
2009592|NCT03206073|Biological|Pexa-Vec|3 x 10E8 pfu (DL 1) or 1 x 10E9 pfu (DL 2) via IV infusion for 4 doses: Day 12, Day 2, Day 16 of Cycle 1 and Day 2 of Cycle 2.
1600963|NCT02228863|Other|Early Inmotion and Botox|Concomitant use of Inmotion and Botox from the baseline
1600964|NCT02228863|Other|Botox, then Inmotion|At baseline Botox injection and 4 weeks after Inmotion
1600965|NCT02228863|Other|Inmotion, then Botox|Inmotion from the baseline, then Botox injection at 4 weeks after baseline
1600966|NCT02228863|Other|Late Inmotion and Botox|No intervention until 4 weeks from the baseline. Then Inmotion and Botox injection
1600967|NCT02228850|Drug|Alprostadil|
1600968|NCT02228850|Other|Placebo|
1600969|NCT02228837|Dietary Supplement|Pear|
1600970|NCT02228837|Dietary Supplement|Placebo|
1600971|NCT02228824|Drug|Very low nicotine content cigarettes|0.07 mg nicotine delivery
1600972|NCT02228824|Drug|Normal nicotine content cigarettes|0.8 mg nicotine delivery
1600973|NCT02228811|Drug|DCC-2701 tablet|
1600974|NCT02228785|Biological|G17DT|
1600975|NCT02228772|Drug|MLN 9708|Patients will received standard chemotherapy as well as MLN 9708 in escalating doses.
1600976|NCT02228772|Drug|Vincristine|Standard chemotherapy dosage and duration
1600977|NCT02228772|Drug|Cytarabine|Standard chemotherapy dosage and duration
1600978|NCT02228772|Drug|Doxorubicin|Standard chemotherapy dosage and duration
1600979|NCT02228772|Drug|Mercaptopurine|Standard chemotherapy dosage and duration
1600980|NCT02228772|Drug|Cyclophosphamide|Standard chemotherapy dosage and duration
1600981|NCT02228772|Drug|Methotrexate|Standard chemotherapy dosage and duration
1600982|NCT02228759|Procedure|Adductor canal block|All patients will recieve fast tracking with reduced fasting times, multimodal analgesia and adductor canal block
1600983|NCT02228746|Dietary Supplement|Alpha-galacto-oligosaccharides|6g of alpha-galacto-oligosaccharides in a 100 mL flavored drink
1600984|NCT02228733|Drug|KBP-5074|Comparisons of different doses of study drug
1600985|NCT02228720|Device|Propel Nova Sinus Implant|Bioabsorbable, steroid-releasing sinus implant with 370 mcg of mometasone furoate released over 30 days
1600986|NCT02228707|Drug|BIIB061|Participants receive BIIB061
1600987|NCT02228707|Other|Placebo|Matched placebo
1600988|NCT02228681|Drug|Everolimus|10mg daily by mouth
1600989|NCT02228681|Drug|Tamoxifen|20 mg daily by mouth on alternating weeks (even numbered) weeks
1600990|NCT02228681|Drug|Letrozole|2.5mg twice a day by mouth
1600991|NCT02228681|Drug|Medroxyprogesterone Acetate|200 mg daily by mouth
1600992|NCT02228655|Drug|FMX-8|
1600993|NCT02228629|Device|CrocsRx Medical Silver cloud clogs|
1600994|NCT02228616|Drug|Prucalopride|During the 12-week treatment phase of the study, the daily dose of 1 tablet of 2-mg prucalopride will be administrated orally before breakfast.
1600995|NCT02228616|Drug|Polyethylene glycol (PEG)|Optimized dose of PEG will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
1600996|NCT02228616|Drug|Lactulose|Optimized dose of Lactulose will be administrated for 13 weeks (1 week run-in+12 weeks intervention).
1600997|NCT02228603|Behavioral|high-intensity exercise training|
1600998|NCT02228603|Behavioral|web-based follow-up program|
1600999|NCT02228603|Behavioral|usual care|
1601000|NCT02228590|Drug|APL-130277|Apomorphine Hydrochloride, Sublingual Thin Film
1601001|NCT02228564|Procedure|Percutaneous transluminal angioplasty (PTA)|"Percutaneous transluminal angioplasty (PTA) is a procedure that can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored."
1601002|NCT02228564|Device|LIFESTREAM™ covered stent|Implantation of the LIFESTREAM™ covered stent
1601003|NCT02228551|Other|Augmented renal clearance Point prevalence study|An 8-hour urine collection was carried out to determine the CrCl8h. Participants were asked to empty the bladder at the start of the collection. From then, patients were asked to collect urine in a recipient during the following 8 hours. If an indwelling transurethral or suprapubic urinary catheter was in situ, the collection bag was emptied at the start of the collection. After 8 hours, total urinary volumes (Uv8h) were measured with a measuring cup and urinary creatinine concentrations were determined by laboratory analysis. Midterm serum creatinine samples were obtained at 4 hours after the start of the urinary collection. Based on these values, CrCl8h was calculated according to the standard formulas and normalized to a body surface area (BSA) of 1.73m².
1601004|NCT02228538|Device|Total knee arthroplasty patients|ConforMIS iTotal (CR) knee implant system & off-the-shelf standard knee implant system from various manufacturers
1601006|NCT02228512|Drug|Pomalidomide|Part A: 5 mg po daily for 21 days (full course) Part A: 5 mg po daily for 4 days (short course) Part B: 5 mg po daily for 5 days (Phase I/II dose) Part C: Phase I/II dose) po daily Day 1-21 of 28 day cycle for up to 12 cycles.
1601007|NCT02228512|Drug|Rituximab|Part A: 375 mg/m2 day 22 (full course) Part A: 375 mg/m2 day 5 (short course) Part A: 375 mg/m2 day 1 (omit pomalidomode) Part B: 375 mg/m2 day 1
1601008|NCT02228512|Drug|Prednisone|Part B: 60 mg/m2/day po x 5 days (day 1-5
1601009|NCT02228512|Drug|Etoposide|Part B: 50 mg/m2/day CIVI over 24 hrs x 4 days
1601010|NCT02228512|Drug|Doxorubicin|Part B: 10 mg/m2/day CIVI over 24 hrs x 4 days
1601011|NCT02228512|Drug|Vincristine|Part B: 0.4 mg/m2/day CIVI over 24 hrs x 4 days
1601012|NCT02228512|Drug|Cyclophosphamide|Part B: 750 mg/m2 Day 5
1601013|NCT02228499|Other|Survey|We will be administering surveys about health, quality of life, and asking for final report cards for the 2013-2014 school year for each group.
1601014|NCT02228486|Device|tDCS|2 mA (verum group) over the left dorsolateral prefrontal cortex (F3, anodal), 15 min; 10 seconds ramp in verum and sham group (see also above)
1601015|NCT02228486|Behavioral|Cue Exposure Therapy|5 weeks (9 sessions) of cue-exposure therapy with preferred alcoholic beverage (see also above)
1601016|NCT02228473|Drug|Glycopyrrolate|Glycopyrrolate will be administered.
1601017|NCT02228473|Drug|Atropine|Atropine will be administered.
1601018|NCT02228460|Drug|GZ/SAR402671|Pharmaceutical form: Capsule; Route of administration: Oral
1601128|NCT02227615|Dietary Supplement|Sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
1601019|NCT02228447|Behavioral|Healthy Habits, Healthy Girls Group|The intervention group will receive a 6-month multicomponent intervention (i.e., enhanced physical education classes; interactive seminars; nutrition workshops; text messages; and parents newsletters) and materials (i.e., nutrition and PA handbooks; cooking books; Choreographies CDs and PA leadership handbook).
1601020|NCT02228434|Behavioral|Monitoring and Tailored prescription|
1601021|NCT02228434|Behavioral|Happy 10 program|
1601022|NCT02228434|Behavioral|Specified nutrition education|
1601023|NCT02228434|Behavioral|General Health Education|
1601024|NCT02228408|Drug|Hydralazine/Isorsorbide Dinitrate|"Hydralazine/Isorsorbide Dinitrate (ISD/HY) will be administered with a target dose of 40 mg of ISD and 75 mg of Hydralazine 3x/daily. Doses will be titrated between weeks 0-4 and may be decreased as necessary for treatment of adverse events.
Target Dose:
Hydralazine 75 mg 3x day Isorsorbide Dintrate 40 mg 3x/day
Allowable Dosage Forms:
ISD/HY 10 mg/10-3x/day ISD/HY 20 mg/35 mg-3x/day ISD/HY 40 mg/75 mg-3x/day
Dose Titration:
ISD/HY will be administered at a starting dose ISD/HY 10 mg/10-3x/day and titrated to ISD/HY 20 mg/35 mg-3x/day after 4 days and to ISD/HY 40 mg/75 mg-3x/day at 4 weeks. Dose will be decreased as necessary for dose-limiting side effects."
1601025|NCT02228408|Drug|Placebo|Placebo titration will mimic titration of active study arm
1601026|NCT02228395|Drug|PF-04958242|Oral capsule, single dose, 0.35 mg, 0.55 mg, 0.75 mg
1601027|NCT02228395|Drug|Placebo|Oral capsule, single placebo dose
1601028|NCT02228382|Drug|Bosutinib|100 mg and 500 mg tablets, once daily dosage up to 4 years duration
1601029|NCT02228369|Drug|AZD3759|Starting dose 50 mg, administered twice daily. If tolerated subsequent cohorts will test increasing doses of AZD3759, until a maximum tolerated dose or an effective dose is defined
1601030|NCT02228369|Drug|AZD9291|AZD9291 160mg once daily
1601031|NCT02228356|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy with either Dynamic Tumor Tracking/Internal Target Volume approach on the Vero machine, and/or Internal Target Volume approach on the Tomotherapy machine.
1601032|NCT02228343|Other|Ayurveda|Ayurveda includes meditation, yoga, breathing exercises, herbs
2009593|NCT03206840|Behavioral|"control, meditation, hypnosis."|"three instructions will be given to each participant: control, meditation, hypnosis. The order of meditation and hypnosis will be randomized amongst two groups to avoid order effects."
1601034|NCT02228317|Device|Telemedicine consultation|Telemedicine consultation done by telephone or video
1601035|NCT02228304|Drug|NT-503-3 ECT implantation|NT-503-3 ECT implantation is a biological sustained drug delivery device that could provide continuous delivery of an anti-VEGF therapy
1601036|NCT02228304|Drug|Eylea® injected intravitreally administered every 8 weeks|The first part, stage 1, Phase I is open label with the experimental treatment arm only. Eylea® injected intravitreally is only used as a comparator in the stage 2, Phase II, portion of the study.
1601037|NCT02228291|Dietary Supplement|Capsule containing citrus flavonoid|
1601038|NCT02228291|Dietary Supplement|Placebo|
1601039|NCT02228278|Behavioral|Group A|"Phase 1: Group A will receive the typical clinic visits plus daily text messages for 12 weeks.
Phase 2: Group A will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider and for those prescribed medication for a chronic condition, medication counseling by a healthcare provide) plus daily text messages in between visits for 3 months to support their health goals."
1601040|NCT02228278|Other|Group B|"Phase 1: Group B will receive current standard care - clinic visits every three months anthropometric assessments and counseling on physical activity and nutrition goals by a healthcare provider, typically with no patient-provider communication between visits.
Phase 2: Group B will initially act as the control and will receive the typical clinic visits (which includes anthropometric measures every three months, counseling on physical activity and nutrition goals by a healthcare provider, and for those prescribed medication for a chronic condition, medication counseling by a healthcare provider) with typically with no patient-provider communication between visits. After a 6-month delay, Group B will then receive the intervention which includes the typical clinic visits as stated previously plus daily text messages in between visits for 3 months to support their health goals."
1601041|NCT02228265|Other|Cytology Specimen Collection Procedure|Undergo blood and tissue collection
1601042|NCT02228265|Drug|Enzalutamide|Given PO
1601043|NCT02228265|Other|Laboratory Biomarker Analysis|Correlative studies
1601044|NCT02228252|Other|Whey protein|
1601045|NCT02228252|Other|Casein|
1601046|NCT02228252|Other|Gluten protein|
1601047|NCT02228239|Drug|Esketamine|Esketamine 84 milligram (mg) [3*1 of spray in each nostril] will be administered intranasally on Day 1 in one of the treatment periods.
1601048|NCT02228239|Drug|Mirtazapine|Mirtazapine 30 mg capsule will be administered orally on Day 1 in one of the treatment periods.
1601049|NCT02228239|Drug|Placebo (Matched to Esketamine)|Placebo [3*1 in each nostril] will be administered intranasally on Day 1 in one of the treatment periods.
1601050|NCT02228239|Drug|Placebo (Matched to Mirtazapine)|Placebo capsule will be administered orally on Day 1 in one of the treatment periods.
1601051|NCT02228213|Biological|MIS416|Intravenous administration weekly for 52 weeks
1601052|NCT02228213|Drug|Saline|Intravenous administration weekly for 52 weeks
1601053|NCT02228200|Behavioral|Nurse-led care|The nurse-led care consisted of a pre-chemotherapy nursing consultation and telephone follow-up sessions during chemotherapy. The nursing consultation was on the day of the first cycle before drug administration. It included: history review, overall status evaluation, need and problem assessment, information provision, psychological support, and referral. The telephone follow-up sessions were delivered within one week after the 1st, 2nd, 4th, and 6th, and 8th cycle. A telephone follow-up session included: (i) The overall status assessment and problem triage; (ii) Care delivery based on problem severity; (iii) Evaluation of the change of the problems on the following telephone call.
1601054|NCT02228200|Behavioral|Routine care|Routine care includes: (1) Brief education on possible side-effects and coping skills before chemotherapy; (2) Care on chemotherapy day: vital sign assessment, casual communication between nurses and patients, video about chemotherapy and side effects management. (3) Care in chemotherapy intervals: hotline for patients when they have health problems at home.
1601129|NCT02227602|Dietary Supplement|Mango polyphenolics|Frozen mango pack will be provided (200~400g per day).
1601055|NCT02228187|Device|Brain-Computer Interface|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
2009594|NCT03205137|Drug|subjects treated with telmisartan/hydrochlorothiazide|subjects treated with telmisartan/hydrochlorothiazide
1601057|NCT02228161|Behavioral|Yoga|Yoga group will receive regular 60-minutes yoga classes twice a week for 3 months.
2009595|NCT03205137|Drug|Subjects treated with Telmisartan and amlodipine|Subjects treated with Telmisartan and amlodipine
1601060|NCT02228135|Drug|Dexamethasone|
1601061|NCT02228122|Device|Aquacel® Ag+ Extra|Aquacel® Ag+ Extra dressing will be applied to wounds as per instructions for use, dressing to be changed at least one per week for 4 weeks.
1601062|NCT02228109|Device|Acuvue Oasys for Presbyopia|Acuvue Oasys for Presbyopia contact lenses worn
1601063|NCT02228109|Device|PureVision2 for Presbyopia|PureVision2 for Presbyopia contact lenses worn
1601064|NCT02228109|Device|Biofinity Multifocal|Biofinity Multifocal contact lenses worn
1601065|NCT02228096|Biological|CTL019 T-cells|A target dose of CTL019 transduced cells will consist of a single infusion of 2.0 to 5.0 x 10^6 CTL019 transduced cells per kg body weight (for patients ≤ 50 kg) and 1.0 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg). The following cell dose ranges may be infused if all other safety release criteria are met: 0.2 to 5.0 x 10^6 CTL019 transduced viable T cells per kg body weight (for patient ≤ 50 kg) and 0.1 to 2.5 x 10^8 CTL019 transduced viable T cells (for patients > 50 kg).
1601066|NCT02228083|Drug|Lidocaine with epinephrine|Lidocaine without vasoconstrictor , lidocaine with epinephrine 1:100,000
2009596|NCT03205137|Drug|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group|subjects treated with Telmisartan+hydrochlorothiazide double-pill combination group
1601068|NCT02228044|Behavioral|Prevention program|
1601069|NCT02228031|Drug|Oxytocin|The experimental oxytocin group will receive 24 international units (IU) of oxytocin using an intranasal administration (self-administered nasal spray) one time before the experimental session
1601070|NCT02228031|Other|Placebo|The placebo comparator group will receive sterile saline through intranasal administration, consisting of the same salt solution in which the hormone will be dissolved , but lacking the hormone itself.
1601071|NCT02228018|Device|CT-scan|CT-Scan will be taken at visit 1 on FRC and TLC breathing levels
1601072|NCT02228005|Drug|Sertraline|Protocolized titration from 50 to max 200mg based on response and tolerance.
1601073|NCT02227992|Biological|EVARREST™ Sealant Matrix|EVARREST® Fibrin Sealant Patch is a sterile, bio-absorbable combination product, comprised of two biological components (human plasma-derived fibrinogen and thrombin) embedded in a flexible composite patch component.
1601074|NCT02227992|Device|SURGICEL®|SURGICEL® Absorbable Hemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
1601075|NCT02227979|Behavioral|The Purple Cry Intervention|This intervention consists of an 11-page booklet and 12-minute DVD produced by the National Center on Shaken Infant Syndrome.
1601076|NCT02227979|Behavioral|Control Intervention|This intervention consist of 1 brochure and a DVD on infant safety excerpted from the Safe Start video on infant safety.
1601077|NCT02227966|Device|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
1601078|NCT02227966|Device|Sham-Yband (YDT-201N)|tDCS 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex
1601079|NCT02227953|Device|Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 30 min; 20 sec of ramp-up and -down; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
1601080|NCT02227953|Device|sham-Yband (YDT-201N)|transcranial Direct Current Stimulation (tDCS) 2mA for 20 sec; left (anode) and right (cathode) Dorsolateral prefrontal cortex (DLPFC)
1601081|NCT02227940|Drug|Ceritinib|Given PO
1601082|NCT02227940|Drug|Cisplatin|Given IV
1601083|NCT02227940|Drug|Gemcitabine Hydrochloride|Given IV
1601084|NCT02227940|Other|Laboratory Biomarker Analysis|Correlative studies
1601085|NCT02227940|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1601086|NCT02227940|Other|Pharmacological Study|Correlative studies
1601087|NCT02227927|Drug|Domperidone|10-30mg oral dose, four times daily.
1601088|NCT02227914|Drug|Oprozomib|Study subjects will receive oprozomib tablets once a day on Days 1, 2, 8, 9, 15, 16, 22 and 23 of a 28 day cycle
1601089|NCT02227914|Drug|Sorafenib|Study subjects will receive sorafenib tablets twice a day for Days 1-28
1601090|NCT02227901|Drug|Tipifarnib|Given PO
1601091|NCT02227901|Radiation|External Beam Radiation Therapy|Undergo EBRT
1601092|NCT02227901|Drug|Temozolomide|Given PO
1601093|NCT02227901|Other|Laboratory Biomarker Analysis|Correlative studies
1601094|NCT02227888|Drug|N91115|S nitrosoglutathione reductase inhibitor
1601095|NCT02227875|Drug|Mylan's insulin glargine|Patients who are randomized to receive Mylan's insulin glargine during the comparative phase will receive the same dose as the dose of Lantus® received during the screening period. The recommended starting dose of Mylan's insulin glargine or Lantus®, in patients with T2DM who are not currently treated with insulin is 10 units (or 0.2 Units/kg) once daily, which should subsequently be adjusted every week if essential.
1601096|NCT02227875|Drug|Lantus®|For patients who are randomized to receive Lantus® during the comparative phase the dose of Lantus® will be equal to the dose received during the screening period.
1601130|NCT02227602|Dietary Supplement|sugary beverage|15.7g sugar, 3.8g pectin and 0.05g citric acid was added in 100ml of the control beverage.
1601131|NCT02227589|Behavioral|MET/CBT-12|Two sessions of motivation enhancement therapy followed by 10 sessions of cognitive behavior therapy targeting alcohol or cannabis abuse. These 12 sessions will be delivered over 12 to 14 weeks.
1601097|NCT02227862|Drug|Mylan's insulin glargine|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period, and will continue on this for the complete trial. During the 6 week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
1601098|NCT02227862|Drug|Lantus®|All patients will be shifted from their current mealtime insulin to insulin lispro at the start of the run-in period; and will continue on this for the complete trial. During the 6week run-in period the doses of Lantus® and insulin lispro will be titrated (if required) to ensure diabetes control. After the run-in period, patients will be randomized to receive either Mylan's insulin glargine (in place of Lantus®), or to continue on Lantus®. During the period from 12 to 24 weeks dose titration will be kept to a minimum.
1601099|NCT02227849|Drug|Canagliflozin (TA-7284) ＋GLP-1 analogue|The patients will receive Canagliflozin orally for 52 weeks
1601100|NCT02227836|Device|Allergy Patch Testing|"Patient will undergo APT testing per the following protocol:
2g of dry foods will be placed in 2ml of isotonic saline solution. The mixtures will then be placed in aluminum cups (ie Finn chambers) measuring 6 or 12 mm in diameter and adhered to the patient's back.
Foods to be included will be milk, wheat, egg, soy, peanut, tree nut, fish, shellfish, beef, corn, chicken, potato, pork, legumes, barley, rye, tomato, rice, fruits
The patches will be removed at 48 hours, and results read at 72 hours after application.
Reactions will be classified as negative, + (erythema and scattered papules), ++ (erythema and papules), and +++ (erythema and vesicles)."
1601101|NCT02227823|Drug|Pyridostigmine Bromide|
1601102|NCT02227810|Other|electrical stimulation (high frequency)|Participants will receive muscular electrical stimulation (75Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days
1601103|NCT02227810|Other|electrical stimulation (low frequency)|Participants will receive muscular electrical stimulation (35Hz) on quadriceps muscle for 20 min/session, twice daily for 10 days.
1601104|NCT02227810|Other|sham group|Participants will receive similar electrical stimulation (ES) procedure as those in intervention group but with ES machine power off.
1601105|NCT02227797|Drug|Voriconazole|6 mg/kg to 12 mg/kg IV/PO every 12 hours depending on patient age and dose toleration of prior patients
1601106|NCT02227784|Drug|Evacetrapib|Administered orally
1601107|NCT02227784|Drug|Atorvastatin|Administered orally
1601108|NCT02227784|Drug|Ezetimibe|Administered orally
1601109|NCT02227784|Drug|Placebo|Administered orally
1601110|NCT02227771|Device|Percutaneous coronary intervention|
1601111|NCT02227745|Drug|Dorzolamide hydrochloride (2%)|"Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.
Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed"
1601112|NCT02227745|Drug|Placebo Sodium hyaluronate 4mg|"Intervention: Subsequently photocoagulation treatment was applied according to the guidelines of the ETDRS, reevaluate the patient at 4 weeks.
Patient 1 drop of topical drug in the treaty provided every 8 hours for 4 weeks eye and again 4 weeks after cited for evaluation will be placed."
1601113|NCT02227732|Device|New Indwelling Pleural Catheter|Placement of an indwelling catheter in the pleural space. Drainage of effusions until resolution.
1601114|NCT02227719|Device|CTI|CTI is the titanium mesh
1601115|NCT02227719|Device|Collagen membrane|
1601116|NCT02227706|Biological|EVICEL® Fibrin Sealant|EVICEL® is a human plasma-derived fibrin sealant. EVICEL® consists of two components: a concentrate of Human Clottable Protein (referred to as Biological Component 2; BAC2) and a solution of Human Thrombin. No material of animal origin is present in the product
1601117|NCT02227706|Device|SURGICEL® Absorbable Hemostat|SURGICEL® Absorbable Hemostat (oxidized regenerated cellulose) is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose.
1601118|NCT02227693|Drug|avatrombopag|E5501 (avatrombopag) 20-mg tablets
1601119|NCT02227693|Drug|Placebo|Placebo matching 20-mg tablets
1601120|NCT02227680|Other|Music Therapy|Each music therapy session will begin with a brief description of the protocol, a musical introduction, a discussion of music preferences, and an informal assessment of participant needs to determine target goals, e.g., management of pain, anxiety, and other symptoms; breath control; emotional support and regulation. After the initial visit, the music therapist will create a playlist, based on participant preferences, and burn it onto a CD for the participant. The participant will be encouraged to use the book and listen to the CDs as often as he/she would like. After the initial visit, follow up visits will include techniques like music-facilitated breathing, music and imagery, music and relaxation/meditation, song writing, improvisation, singing, lyric substitution, lyric analysis, musical reminiscence, passive listening. There will be the opportunity to create music and write songs across multiple sessions, if these activities are indicated.
1601121|NCT02227680|Other|Massage Therapy|Working with experts in hospital-based massage therapy, we have developed a semi-standardized inpatient massage protocol that utilizes Swedish techniques and acupressure. The protocol was adapted from our successful previous study of massage for perioperative care of patients undergoing implantation of permanent intravenous access devices. Massage therapists will focus on hands, feet, arms, and neck, as able, during the treatments.
1601122|NCT02227667|Drug|MEDI4736|Patients will be seen the day of administration of MEDI4736. A medical history, with particular reference to toxicities, including medication review, and physical examination will be conducted at each treatment visit.
1601123|NCT02227654|Procedure|Abnormal Ovarian Ultrasound|Ultrasound
1601124|NCT02227641|Biological|CMV/EBV specific T-cell|Peptide stimulated allogeneic T-cells with dual specificity for CMV and EBV
1601125|NCT02227628|Dietary Supplement|Acai polyphenolics|Acai beverage was obtained from the Sambazon (San Clemente, CA).
1601126|NCT02227628|Dietary Supplement|Sugary Beverage|An equal amount of placebo juice comprised of artificially colored water containing sugar (5%), citric acid (0.01% to adjust the pH 3.8), and artificial colors (FD&C Red 40 and Blue 1, Tetra Pak, Denten, TX) that was identical to the acai beverage.
1601127|NCT02227615|Dietary Supplement|Mango polyphenolics|Frozen Mango (Keitt) packs provided to subjects.
1601132|NCT02227589|Behavioral|CBT-D|CBT-D consists of seven weekly sessions of cognitive behavior therapy targeting depression.
1601133|NCT02227589|Other|D-TAU|D-TAU is treatment as usual in the community, targeting depression. It may consist of medication and/or behavioral intervention.
1601134|NCT02227576|Drug|Romiplostim|
1601135|NCT02227563|Device|Active tDCS|repetitive daily tDCS sessions for a period of one week
1601136|NCT02227563|Device|control|
2009597|NCT03205137|Drug|subjects treated with telmisartan+amlodipine double pill|subjects treated with telmisartan+amlodipine double pill
2009598|NCT03204812|Drug|Durvalumab|1500 mg intravenously (IV) every four weeks (q4w) in combination with Tremelimumab for up to 4 doses/cycles each followed by another matching dose of Durvalumab (1500 mg IV q4w) for up to a total of 8 months (9 additional doses/cycles)
1601139|NCT02227537|Device|Providence Nighttime Bracing System|Providence Nighttime Bracing System
1601140|NCT02227537|Device|Providence Nighttime Bracing System|The Providence brace is a polypropylene plastic, acrylic framed, system designed to apply corrective forces to scoliatic curves achieving correction or reduction of scoliosis.
1601141|NCT02227524|Other|No device|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
1601142|NCT02227524|Device|Single-point cane (SPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
1601143|NCT02227524|Device|Four-point cane (FPC)|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
1601144|NCT02227524|Device|Trekking pole (TP).|Compare walking function and ability in a sample of persons with MS under four different assistive device conditions: no device, single-point cane (SPC), four-point cane (FPC) and trekking pole (TP).
1601145|NCT02227511|Dietary Supplement|Fruits|Randomization to extra fruit or nuts as snacks
1601146|NCT02227511|Dietary Supplement|Nuts|
2009599|NCT03204812|Drug|Tremelimumab|75 mg IV q4w in combination with Durvalumab for up to 4 doses/cycles each
1601148|NCT02227485|Drug|Punica granatum Pleniflora (Golnaar) mouth rinse|"All the patient in intervention group use 10 ml of Golnaar mouth rinse for 2 minutes every night for 2 weeks."
1601149|NCT02227485|Drug|Chlorhexidine (0.2%)|All the patient in control group use 10 ml of chlorhexidine (0.2%) for 2 minutes every night for 2 weeks.
1601150|NCT02227485|Procedure|Tooth bleaching|Tooth bleaching for both groups one time after using mouth rinses.
1601154|NCT02227459|Drug|ND-L02-s0201 Injection|
1601155|NCT02227446|Drug|Vancomycin antibiotic powder|At the time of fracture fixation 1000 mg of Vancomycin powder placed into the wound during wound closure.
1601156|NCT02227433|Drug|Brentuximab Vedotin|
1601157|NCT02227420|Drug|Anakinra|Anakinra 100mg s.c. x 5
1601158|NCT02227407|Device|RGOs(reciprocating gait orthoses)|using additional apparatus combined with Hip-Knee-Ankle-Foot orthoses (HKAFO) to help paraplegia patients to present reciprocating gait pattern
1601159|NCT02227394|Drug|Z7200|"Total dose budesonide/formoterol is 160 mcg/4.5 mcg) to be administered only with the inhaler device (RS-01).
At visit 2 or 3 (cross-over design)"
1601160|NCT02227394|Drug|Symbicort® Turbohaler®|Total dose budesonide/formoterol is 320 mcg/9 mcg. At visit 2 or 3 (cross-over design)
1601161|NCT02227394|Drug|Placebo of Test product|"Single dose of 2 puffs
Z7200 inhalation powder placebo is filled in size 3 hydroxypropyl methylcellulose (HPMC) capsules.
At visit 2 or 3 (cross-over)
To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
1601162|NCT02227394|Drug|Placebo of Reference Drug|"Single dose of 2 puffs
Symbicort placebo does not contain any drug substances, (Budesonide and Formoterol fumarate), or excipients (Lactose monohydrate).
At visit 2 or 3 (cross-over)
To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
1601163|NCT02227394|Radiation|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose.
1601164|NCT02227368|Drug|Ticagrelor|Antiplatelet therapy approved for ACS. Antagonist of P2Y12 and inhibitor of adenosine diphosphate (ADP)-induced platelet aggregation.
1601165|NCT02227368|Drug|Comparator|Aspirin monotherapy anti-platelet treatment for PAD patients following EVR procedures
1601166|NCT02227342|Biological|Fecal Microbiota Transplant|serial FMT
2009600|NCT03205488|Drug|Cohort 1:Nilotinib Oral Capsules (150mg or 300mg)|2 capsules taken once daily
2009601|NCT03205488|Drug|Cohort 2: Nilotinib Oral Capsules (dose to be determined from Cohort 1)|2 capsules taken once daily
2009602|NCT03205488|Drug|Placebo|2 capsules taken once daily
1601170|NCT02227316|Drug|IV Ibuprofen|
1601171|NCT02227316|Drug|IV Acetaminophen|
1601172|NCT02227316|Drug|IV Placebo|
1601174|NCT02227290|Drug|Naftin Cream|
1601175|NCT02227290|Drug|Placebo Cream|
1601176|NCT02227277|Drug|Peg-IFN-α2b|"Arm 1: At week 4 of the treatment, ART will be interrupted. Viral load will be monitored every 2 weeks. ART will be resumed at the earlier of a) a single measurement of VL > 50 c/ml or b) 16 weeks of treatment, and subjects will be observed for the remaining 4 weeks (total of 20 weeks on treatment).
Arm 2: In week 4, participants in arm 2 will add peg-IFN-α-2b to their ART regimen for a period of 20 weeks."
1601177|NCT02227264|Drug|Cinacalcet|Cinacalcet, Mimpara® 30mgx1-2 for 4 weeks
1601178|NCT02227264|Procedure|parathyroid adenomectomy|surgical removal of pathologic parathyroid tissue
1601179|NCT02227251|Drug|Selinexor|Fixed milligram dose of 60 mg selinexor orally twice weekly.
2009603|NCT03203733|Device|Cooral™|An intraoral cooling device which is as effective as ice but with better patient comfort. The cooling device has the advantage that the water temperature can be modified. It enables that the unacceptable low temperatures that occur with ice cooling can be avoided.
2009604|NCT03203733|Other|cryotherapy|Oral cooling by ice chips or crushed ice or ice pop
2009605|NCT03201562|Drug|PRX-100|Ophthalmic Solution
1601183|NCT02227212|Drug|Insulin glargine U300 (new formulation of insulin glargine) HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1601184|NCT02227199|Drug|Brentuximab Vedotin|Given IV
1601185|NCT02227199|Drug|Carboplatin|Given IV
1601186|NCT02227199|Drug|Etoposide|Given IV
1601187|NCT02227199|Drug|Ifosfamide|Given IV
1601188|NCT02227199|Other|Laboratory Biomarker Analysis|Correlative studies
1601189|NCT02227186|Other|School-located Influenza Vaccination Clinic|Children in the intervention arm are enrolled in schools in Monroe County, NY that are offering school-located influenza vaccination clinics during school hours
1601190|NCT02227173|Drug|BMS-986020|
1601191|NCT02227173|Drug|Montelukast|
1601192|NCT02227173|Drug|Flurbiprofen|
1601193|NCT02227173|Drug|Digoxin|
1601194|NCT02227160|Behavioral|10 weekly group meetings|10 weekly group meetings with up to five other men and women at Grady Health System
1601195|NCT02227160|Behavioral|Outpatient counseling and support groups|Usual mental health care
1601196|NCT02227147|Drug|rhNGF 20µg/ml|
1601197|NCT02227147|Drug|Placebo Vehicle|
1601198|NCT02227134|Procedure|Ultrasound|Ultrasound to measure hyo-mental distance, tonsil size and width of the tongue.
1601199|NCT02227121|Device|Defibrillation following induction of VT/VF|Up to 10 VT/VF induction attempts followed by shock(s) delivered by an externally placed ICD and/or external defibrillator.
1601200|NCT02227108|Drug|Moxetumomab Pasudotox|Participants received 6 doses of moxetumomab pasudotox 40 microgram per kilogram (mcg/kg) intravenous infusion over 30 minutes every other day (Days 1, 3, 5, 7, 9, and 11) in 21-day treatment cycles until completion of a maximum of 6 cycles of therapy.
1601201|NCT02227095|Behavioral|Exercise|Heart rate monitors worn by each child at each session
1601202|NCT02227095|Behavioral|After-school program|Supervised recreational program with token economy
1601203|NCT02227082|Radiation|radiotherapy|The whole breast and regional lymph nodes will receive 23 x 2.03 Gy per fraction (total 46.69 Gy) At the macroscopic tumor a added SIB will be given of 23 x 0.63Gy . Total dose: 61.18 Gy
1601204|NCT02227082|Drug|olaparib|The pre-defined dose levels of olaparib are 25mg QD, 25, 50, 100, 200, 300 and 400 mg BID
1601205|NCT02227069|Drug|M518101|
1601206|NCT02227069|Drug|M518101 Vehicle|
1601207|NCT02227069|Other|sodium lauryl sulfate|
1601208|NCT02227069|Other|saline|
1601210|NCT02227030|Drug|BIIB 722 CL solution|
1601211|NCT02227030|Drug|BIIB 722 CL tablet|
1601212|NCT02227030|Drug|Placebo solution|
1601213|NCT02227030|Drug|Placebo tablet|
1601214|NCT02227017|Drug|TPV capsule|
1601215|NCT02227017|Drug|TPV solution|
1601216|NCT02227017|Drug|RTV capsule|
1601217|NCT02227017|Drug|RTV solution|
1601218|NCT02227017|Other|standard meal|
1601219|NCT02227004|Diagnostic Test|Perform MRI in patients with pacemaker or ICD|Perform MRI in patients with pacemaker or ICD
1601220|NCT02226991|Drug|Tipranavir|
1601221|NCT02226991|Drug|Ritonavir|
1601222|NCT02226991|Drug|Efavirenz|
1601223|NCT02226978|Drug|Tipranavir|
1601224|NCT02226978|Drug|Ritonavir|
1601225|NCT02226978|Drug|Valaciclovir|
1601226|NCT02226965|Drug|PNT2258|
1601227|NCT02226952|Drug|BILN 2061 W, low dose|
1601228|NCT02226952|Drug|BILN 2061 W, medium dose|
1601229|NCT02226952|Drug|BILN 2061 W, high dose|
1601230|NCT02226952|Drug|Placebo|
1601231|NCT02226939|Drug|BILN 2061 ZW|
1601232|NCT02226939|Drug|Placebo|
1601233|NCT02226926|Drug|Aggrenox|
1601234|NCT02226926|Drug|Persantin Retard|
1601235|NCT02226926|Drug|Acetylsalicylic acid|
1601236|NCT02226913|Drug|2% lidocaine with 1:80,000 epinephrine|2% lidocaine with 1:80,000 epinephrine
1601237|NCT02226913|Drug|sodium bicarbonate|8.4% sodium bicarbonate
1601238|NCT02226913|Drug|placebo|sterile distilled water (Samen Pharmaceutical Co, Iran)
1601239|NCT02226900|Procedure|Hybrid Revascularization|Off-pump LIMA connected to the left anterior descending artery followed by percutaneous coronary intervention with drug eluting stents to the other territories.
1601240|NCT02226900|Procedure|Conventional Coronary Artery Bypass Surgery|On pump coronary artery by-pass surgery
1601241|NCT02226887|Procedure|MESH|"Pre-operative :
It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .
Surgical technique:
Peristomal incision with electrocautery
Release the handle of ileum
Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).
Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.
We add the mesh between the edges of the defect during fascia closure.
The skin is sutured purse string style.
Post-Op
Hospital discharge after verification of normal digestive transit."
1601280|NCT02226497|Other|Quality-of-Life Assessment|Ancillary studies
1601281|NCT02226497|Other|Questionnaire Administration|Ancillary studies
1601282|NCT02226497|Procedure|Supportive Care|Receive standard outpatient supportive care
1601283|NCT02226484|Drug|Quercetin|Two 250 mg capsules of quercetin twice-a-day one hour before meals with a glass of water.
2009606|NCT03201562|Drug|PRX-100 Component #1|Ophthalmic Solution
2009607|NCT03201562|Drug|PRX-100 Vehicle|Ophthalmic Solution
1601242|NCT02226887|Procedure|NO MESH|"Pre-operative :
It was made by barium enema protocol and transanal endoscopy to rule out anastomotic leaks or strictures contraindicating stoma closure .
Surgical technique:
Peristomal incision with electrocautery
Release the handle of ileum
Anastomosis made the with the segment everted sutured by simple manual end to end 3/0 or mechanical side to side (surgeon's election).
Return the ileum into the abdominal cavity and the fascial defect is repaired with continuous polydioxanone 1/0 suture respecting 4:1 measurement rule.
The skin is sutured purse string style.
Post-Op
- Hospital discharge after verification of normal digestive transit"
1601243|NCT02226887|Radiation|Post-operative Imaging|Abdominal Tomography 1 year after ileostomy closure
1601244|NCT02226887|Radiation|Pre-operative Imaging|Contrast study is used to ensure the integrity of the distal anastomosis
1601245|NCT02226887|Other|Blood Test and C-reactive protein at 4th day|All patients undergo a Blood Test study of C-reactive protein on day 4 by protocol within the unit before discharge.
1601247|NCT02226848|Drug|Erythropoeitin|
1601248|NCT02226809|Device|Accelerometry|Application of TOF stimulus (40 mA, three to four times) and recording TOFr in the PACU
1601249|NCT02226796|Device|transcranial direct current stimulation|Transcranial direct current stimulation (tDCS) is a non-invasive neuromodulation tool that presents a low current that induces bi-directional polarity-dependent changes in the cortex to facilitate focal, prolonged shifts in cortical excitability at or around the time stimulation is provided. Anodal tDCS (a-tDCS), in which the positively charged electrode is placed over the targeted cortical region, has been shown to increase cortical excitability (upregulation), similar to long-term potentiation (LTP). Combining a-tDCS with behavioral-based approaches has been suggested to enhance the learning process and increase the likelihood of retention.
1601250|NCT02226796|Other|Non-Prime Condition|
1601251|NCT02226796|Behavioral|Traditional behavioral treatment|
1601252|NCT02226783|Drug|AZD1722 salt tablet|AZD1722 will be administered as 14 mg (salt tablet). tablet for oral use. Subjects will receive a 14 mg tablet in the morning and evening on Days 1 to 4 (Period 1), Days 7 to 10 (Period 2), and Days 13 to 16 (Period 3).
1601253|NCT02226783|Drug|AZD1722 free base tablet|AZD1722 will be given as four 14 mg free-base tablets (56mg) in the morning and evening on Days 1 to 4 (Period 1) and Days 10 to 13 (Period 2).
1601254|NCT02226783|Drug|AZD1722 free base tablet + Omeprazole|AZD1722 free base tablet administered 5 to 10 minutes before intake of breakfast and evening dose 5 to 10 minutes before start of intake of dinner; omeprazole was administered twice daily from Days -5 to -1 or Days 5 to 9 (depending on assigned treatment period), 1 hour before breakfast and dinner, and from Days 1 to 4 or Days 10 to 13, 1 hour prior to the administration of AZD1722
1601255|NCT02226770|Device|Implantable Cardioverter Defibrillator (ICD)|
1601256|NCT02226757|Drug|Paclitaxel-trastzumab|"Trastuzumab
Dose:
First dose: 4 mg/kg IV
Subsequent doses: 2 mg/kg every week IV.
The patient must be monitored for at least 6 hours after the start of the first infusion and for at least 2 hours after the start of subsequent infusions.
Paclitaxel
- Dose: 60 mg/m2 IV in 30 minutes, every week, after trastuzumab"
1601257|NCT02226744|Behavioral|Focused Breathing|
1601258|NCT02226731|Device|Early Belfort-Dildy Balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed in the 15 minutes after randomization at the same time as the second line uterotonic treatment.
1601259|NCT02226731|Device|Late Belfort-Dildy balloon|Intrauterine tamponade with the Belfort-Dildy balloon, performed if failure of second line uterotonic treatment, ie persisting bleeding 30 minutes after the beginning of this infusion.
1601260|NCT02226718|Other|Administration of questionnaire|
1601261|NCT02226705|Procedure|Multiple transnasal endoscopic surgeries|Transnasal endoscopic surgery extended to the skull base
1601262|NCT02226679|Device|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
1601263|NCT02226666|Drug|MRI with Multihance|Patients will have Multihance used as an IV contrast agent for their scan.
1601264|NCT02226666|Drug|MRI with Eovist|Patients will have Eovist used as an IV contrast agent for their scan.
1601265|NCT02226653|Drug|Evacetrapib|Administered orally
1601266|NCT02226614|Device|University of Edinburgh head cooling device|head cooling
1601267|NCT02226601|Drug|Aprepitant|3 days perioperative Aprepitant once a day
1601268|NCT02226601|Drug|Placebo|3 days perioperative Placebot once a day
1601269|NCT02226588|Drug|Misoprostol|
1601270|NCT02226575|Behavioral|A cognitive behavior therapy distress management program targeting wellbeing in patients with atrial fibrillation and their relatives|Controls only delivery standard care. Experimental group deliver standard care plus a distress management program (cognitive behavioral therapy) performed in groups by a nurse, a pedagogue and a cardiologist (all trained in the distress management program).
1601271|NCT02226562|Drug|Potassium nitrate and sodium fluoride|3.0% w/w potassium nitrate mouthwash with 0.02% sodium fluoride
1601272|NCT02226562|Drug|Standard fluoride dentifrice|Standard fluoride dentifrice containing 1000 ppm fluoride as SMFP
1601273|NCT02226549|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
1601274|NCT02226549|Drug|VDV|VDV 80 mg tablet administered orally once daily
1601275|NCT02226549|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1601276|NCT02226536|Behavioral|fractioned diet without glucose|Patients were divided into two groups: Diet Group was treated with placebo pills and glucose restrictive and fractionated diet. Control Group received only placebo pills. All individuals had their vestibular function evaluated by Computerized Dynamic Posturography and done visual analogue scale (VAS) in the first day and 30 days after diet intervention
1601277|NCT02226510|Drug|Metformin XL|In the active arm, the added therapy will be metformin XL in an initial dose of 1000mg/day . They will continue on Metformin XL 500mg x2/day for 2 weeks and after safety blood checks the metformin XL dose will be increased to 2000 mg/day. If the higher dose cannot be tolerated the dose will be reduced to 1000mg/day.
1601278|NCT02226510|Drug|Placebo|Placebo capsules (with an identical appearance to the active drug) containing only microcrystalline cellulose PhEur will be administered.
1601279|NCT02226497|Device|Health Telemonitoring|Use home telemonitoring device
1601285|NCT02226445|Other|Combined ADHD medication and psychosocial counseling|"The patients are offered as well ADHD medication as non-standardized psychosocial treatment, the latter including psychoeducation (i.e. information about ADHD aetiology and symptoms plus management of symptoms) and counselling regarding emotional-, family- and social rehabilitation-related problems.
ADHD medication:
First choice of medication is methylphenidate immediate release, initially 5 mg 2-3 times a day increasing with 10-20 mg per week up to stabilization of symptoms.
When stabilized a shift to extended release methylphenidate. Alternatively dexamphetamine, initially 2.5 mg 2-3 times a day increasing with 5-10 mg per week up to stabilization of symptoms.
If there is no adequate effect of central stimulants then a shift to atomoxetine, initially 18 mg a day, increasing during a period of 6-10 weeks up to max. 100 mg a day.
If the patients have a substance use, an anxiety problem or other contraindications then first choice of medication is atomoxetine."
2009608|NCT03201874|Behavioral|Pain self-management|The program is designed to enhance self-efficacy. The app will guide youth in setting structured and personalized goals aimed at improving their pain and functioning. The pain self-management skills will include personalized CBT-based coping skills including deep breathing, relaxation, and cognitive skills (e.g., staying positive). The app will provide in-the-moment access to pain coping strategies to promote positive changes in mood, behavior, and pain.
2009609|NCT03201874|Behavioral|Education|Education about sickle cell disease to increase disease knowledge
2009610|NCT03202303|Drug|Cannabidivarin (CBDV)|Weight-based dosing of 10 mg/kg/day of CBDV
1601289|NCT02226419|Dietary Supplement|Break in L-carnitine treatment|Levocarnitine oral tablet supplement at individual doses
1601290|NCT02226406|Other|A: Chair - Leg Cycle ergometer|
1601291|NCT02226406|Other|B: Chair - Arm Cycle ergometer|
1601292|NCT02226406|Other|C: Walk in place|
1601293|NCT02226393|Behavioral|Prolonged exposure|The PE treatment includes 12-15 60 minutes' sessions. The 2 main components of the treatment are psychoeducation about common reactions to trauma and in-vivo exposures (gradual exposure to trauma related situations and objects) and repeated recounting of the traumatic memory, Trauma memory recounting and in-vivo exposures are conducted during several successive sessions so the child learns that the exposures themselves pose no real harm to him, indicating that when one confronts what one is afraid of it becomes easier to manage.
1601294|NCT02226393|Behavioral|Child-parent Play Therapy|Is consisted of 12-15 weekly 60 minute sessions of parent-child centered therapy it focus on establishing a trusting, empowering, and validating therapeutic relationship. Participants are allowed to choose when, how, and whether or not to address their trauma memory. Therapists provide active listening, empathy,and encouragement to talk about feelings and express belief in the participants ability to cope. In sessions 4 and 8, participants are asked how they feel about their trauma. With this exception, participants direct the sessions.
1601295|NCT02226380|Drug|mFOLFOX6 regimen|oxaliplatin 85 mg/m2 and folinic acid 400 mg/m2 are administered intravenously for 2 hours on day 1 following by 5-FU at 2,400 mg/m2 by continuous infusion for 46hours every 2 weeks for 3 cycles before performing surgery
1601296|NCT02226367|Drug|prazosin hydrochloride|study drug arm prazosin
1601297|NCT02226367|Drug|placebo|study drug arm placebo
1601298|NCT02226354|Dietary Supplement|Ahiflower oil|9.73 ml per day for 28 days
1601299|NCT02226354|Dietary Supplement|Flaxseed oil|9.73ml per day for 28 days
1601300|NCT02226341|Drug|CellCept|"For both arms:
CellCept 3 grams daily, oral, from Week 0-24 CellCept 2 grams daily, oral, from Week 25-144"
1601301|NCT02226341|Drug|ACTHar gel|Arm 1: 80 U biw, subcutaneous, for 3 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
1601302|NCT02226341|Drug|ACTHar gel|Arm 2: 80 U qod, subcutaneous, for 1 month, then 80 U biw, subcutaneous, for 2 months. Optionally additional 3 months of 80 U biw if a patient has partial response.
1601303|NCT02226328|Drug|Propofol sedation|
1601304|NCT02226328|Drug|Midazolam and Fentanyl sedation|
1601305|NCT02226289|Drug|Bevacizumab|bevacizumab with the latest received cytotoxic regimen
1601306|NCT02226276|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET/CT
1601307|NCT02226276|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET/CT
1601308|NCT02226276|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET/CT
1601309|NCT02226276|Biological|trastuzumab|Given IV
1601310|NCT02226276|Radiation|copper Cu 64-DOTA-trastuzumab|Given IV
1601311|NCT02226276|Procedure|positron emission tomography|Undergo copper Cu-DOTA-trastuzumab PET
1601312|NCT02226276|Biological|ado-trastuzumab emtansine|Given IV
1601313|NCT02226276|Other|laboratory biomarker analysis|Correlative studies
2009611|NCT03202303|Drug|Matched Placebo|Weight-based dosing of 10 mg/kg/day of placebo
1601315|NCT02226250|Dietary Supplement|3 Placebo Beverages|Sugar beverage 2 hr before meal, with meal and 2 hr after meal
1601316|NCT02226237|Procedure|group of pelvic floor exercises|contraction of the pelvic floor muscles sustained for 5 seconds, hip adductors using pillow and elevation of the hip, 30 repetitions of each exercise
1601317|NCT02226237|Procedure|anal electrostimulation group|The anal electrical stimulation protocol was performed by a physical therapist for seven weeks, twice per week, using the apparatus Dualpex 961 Uro® Quark, with frequency of 35 Hz, and the intensity determined according to the tolerance of the patient, lasting 20 minutes.
1601340|NCT02226029|Other|Lipid emulsion|"2 isovolumetric (200 ml) and isocaloric (200 kcal) lipid emulsions with different acid and shear stability
Lipid emulsion 1: acid stable, particle size 0.6 µm
Lipid emulsion 2: acid unstable, redispersible by mechanical processes during antral contractions and passage through the pylorus, particle size 0.6 µm
13C-markers will be mixed with emulsions"
1601341|NCT02226016|Device|FG-5000A|a measuring device for the assessment of levator muscle strength
1601342|NCT02226003|Drug|Ertugliflozin|Ertugliflozin, 5 mg or 15 mg, administered orally, once daily for 26 weeks.
1601343|NCT02226003|Drug|Sitagliptin|Sitagliptin, 100 mg, administered orally, once daily for 26 weeks.
2009612|NCT03201445|Drug|Filgotinib|200 mg tablet administered orally once daily
2009613|NCT03201445|Drug|Placebo|Tablet administered orally once daily
2009614|NCT03201445|Drug|Standard of Care|Standard of care therapy
2009615|NCT03201393|Drug|ALLOD-2 Capsules|One capsule contains component A and one capsule contains component B taken together twice a day for 12 weeks.
1601318|NCT02226211|Device|Air-Q intubation laryngeal airway|"The size selection of the air-Q ILA will follow the manufacture guideline to be size 3.5 for females and size 4.5 for males After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.
After successful insertion of the air-Q, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.
After successful intubation, the device will be removed according to the manufactures guides using removal stylet ."
1601319|NCT02226211|Device|Ambu-Aura i laryngeal mask|"The size selection of the device will follow the manufacture guideline according to the patient weight, size 4 for (50-70kg), size 5 (70-100) and size 6 (> 100kg).
After induction of general anesthesia, the devices will be inserted by using midline insertion technique, then cuff will be inflated according to manufacture recommendations.
After successful insertion of the aura-i, the appropriate endoracheal tube (ETT) will be loaded over the fiberoptic bronchoscopy, and the connector will be removed too. The bronchoscope will be introduced and advanced throughout the airway tube to just proximal to ventilating orifice, a video image of the fiberoptic view will be recorded and saved on CD to be graded later by an independent observe. The fiberoptic then will be advanced and once the carina is seen, the ETT is will be slided into the trachea.
After successful intubation, the device will be removed according to the manufactures guides using another ETT."
1601320|NCT02226198|Drug|Rosuvastatin 20mg|Active drug will be taken taken orally, QD, either in the morning or in the evening
1601321|NCT02226198|Drug|Placebo|Will be taken taken orally, QD, either in the morning or in the evening
1601322|NCT02226185|Drug|Berberine hydrochloride|supplement of Berberine hydrochloride 0.3g two times per day for 3 years
1601325|NCT02226159|Drug|Lidocaine|
1601326|NCT02226159|Drug|Lidocaine with Dexamethasone|
1601327|NCT02226146|Biological|Bertilimumab|
1601328|NCT02226133|Device|LAAx, Inc. TigerPaw® System II|Exclusion of Left Atrial Appendage.
1601329|NCT02226120|Drug|LCZ696|Angiotensin receptor antagonist neprilysin inhibitor (ARNI) with target dose of 200 mg bid
1601330|NCT02226107|Behavioral|Peer-PN|Participants in the peer-PN group will also receive two navigation telephone calls: 1) to schedule the colonoscopy, and 2) a reminder call one week before the procedure. It is expected that these phone calls will be shortly longer than the Pro-PN calls by 5-7 minutes because of the additional focus on culture and peer modeling. Peers will remind the patient about the procedure and address concerns, but will provide culturally specific, identity-based navigation, in which they will speak specifically about Latino rates of CRC screening while also modeling self-efficacy by describing what their experience was like before, during and after the colonoscopy procedure.
1601331|NCT02226107|Behavioral|Pro-PN|Participants in the standard navigation group receive two phone calls: 1) to schedule the colonoscopy and 2) a reminder call one week before the procedure. The phone calls will each last approximately 15 minutes. During the second phone call, the patient will be reminded about the procedure and any concerns they may have will be addressed. Professional navigators will also be advised to not disclose their race or ethnicity or to discuss specific issues related to Latinos and CRC screening.
1601332|NCT02226094|Device|DWT device dose A|Deep Wave Trabeculoplasty (DWT) is an investigational device intended to reduce IOP in patients with POAG or OHT. The DWT device applies focal mechanical oscillation (low amplitude, sonic frequency) to the surface of the eye proximate the limbal region and anterior to the trabecular meshwork (TM). Mechanical oscillation of the TM by the DWT device is believed to initiate a physiological cascade to restore function of the TM, increase the outflow of aqueous humor and thereby decrease the IOP. DWT involves 24 spot treatments applied around the limbal region on the ocular surface. Dose A refers to 10 second spot treatments.
1601333|NCT02226094|Device|Ellex Tango SLT machine|Laser trabeculoplasty is the application of a laser beam to burn areas of the trabecular meshwork, located near the base of the iris, to increase fluid outflow. Selective laser trabeculoplasty (SLT) uses a Nd:YAG laser to target specific cells within the trabecular meshwork and create thermal damage.
1601334|NCT02226094|Device|DWT device dose B|Same as DWT device dose A except 20 second spot treatments.
1601335|NCT02226094|Device|DWT sham|Same as DWT device dose A except device not applied to ocular surface.
1601336|NCT02226068|Drug|Cyclosporine A (CsA)|3 mg/kg/day for 4 month
1601337|NCT02226068|Other|Extracorporeal photopheresis (ECP)|Administered two consecutive days twice a month for 4 month
1601339|NCT02226042|Behavioral|Mindfulness-based Cognitive Therapy|MBCT: Mindfulness-based Cognitive Therapy is an 8 week group-based programme consisting of approximately 12 participants per group. There is also a full one day of practice around week 6. MBCT was initially designed for individuals in remission from depression and at risk of relapsing. The intervention is a mix of mindfulness meditation, cognitive behavioural therapy exercises and psychoeducation. MBCT has been shown to be effective in reducing relapse risk over 12 months.
1601344|NCT02226003|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin administered orally, once daily for 26 weeks.
1601739|NCT02223091|Behavioral|Consultation by a trained physician|
1601345|NCT02226003|Drug|Placebo to Sitagliptin|Matching placebo to sitagliptin administered orally, once daily for 26 weeks.
1601346|NCT02226003|Drug|Glimepiride|Open-label glimepiride rescue therapy will be initiated at 1 or 2 mg/day and may be titrated to the maximum labeled dose or maximum tolerated dose (if lower than labeled dose), as considered appropriate by the investigator, based on blood glucose measurements and in accordance with the local, approved label.
2009616|NCT03201393|Drug|Placebo Capsules|One capsule contains placebo for component A and one capsule contains placebo for component B taken together twice a day for 12 weeks.
2009617|NCT03201133|Diagnostic Test|Neuromuscular evaluation|(1) Muscle trunk endurance test; (2) Hip isometric strength (abductor, lateral rotation, extension); (3) Knee extensor isometric strength; (4) unilateral squat; (5) navicular drop test; (6) muscle architecture at rest of gluteus medius, gluteus maximus,vastus lateralis, vastus medialis and rectus femoris; (7) muscle activation during unilateral squat (gluteus and quadriceps muscles); (8) pennation angle of obliques vastus medialis; (9) medial patellofemoral ligament length; (10) knee pain.
2009618|NCT03201120|Behavioral|Outdoor Sun Behavior|Participants will provide informed consent and complete a short background questionnaire about usual sun exposure and protection behaviors and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a computer monitor, keyboard and mouse setup. Each participant will view messages with different emotional appeals related to outdoor sun exposure (seeking shade, covering up, using sunscreen, and multiple behaviors). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
1601351|NCT02225977|Drug|Gilenya|
1601352|NCT02225951|Dietary Supplement|Nutritional product|
1601353|NCT02225951|Other|Standard breakfast according to ADA recommendations|
1601354|NCT02225925|Radiation|Brachytherapy|
1601355|NCT02225912|Other|PrevinC|
1601356|NCT02225886|Drug|Ascorbic Acid|300 mg of intravenous ascorbic acid will be given 3 times a week, postdialysis, in 100 mL saline solution, except for the dialysis sessions when iv iron is administered
1601357|NCT02225873|Other|motor control exercises|Will carry out intermuscular coordination exercises through cranio-cervical training, following Jull et al. and exercises to increase strength-endurance on the neck flexor muscles
1601358|NCT02225873|Other|muscle strength-endurance and proprioception|Will carry out proprioception exercises through articular repositioning training and exercises to increase strength-endurance on the neck flexor muscles. They will be performed in the same way as the experimental group protocol.
1601359|NCT02225860|Behavioral|Diet and water adjustment|The dietary intervention consisted of three elements: low sodium (1500 mg/day), low protein (daily protein dietary allowance of 0.8 gram/kg body weight), and low urea (avoidance of preservatives, food additives, bulking agents, and chewing gum). Protein was factored by measured body weight to mirror the estimated average requirement (EAR) of healthy adults which is set on a grams per kilogram basis
1601360|NCT02225847|Other|Gardening|The intervention consists of twice weekly group sessions of gardening activities of 60 minutes in duration that will take place in a greenhouse. A total of 12 gardening sessions administered over a period of six weeks will include planting seeds, bulbs and tubers, transplanting seedlings, vegetative propagation and sight, smell, taste and touch sensory based activities.
1601361|NCT02225847|Procedure|Functional Magnetic Resonance Imaging (fMRI)|Functional magnetic resonance imaging will be employed to assess whether engaging in gardening activities in a greenhouse does or does not alter the spatial patterns of brain network activation relative to changes that occur between the groups.
1601362|NCT02225847|Behavioral|psychometric assessments|The following assessments will be used: The SF-36 Health Survey assessment instrument (Ware and Sherbourne 1992; Hays et al 1993), the Beck Depression Inventory 2nd edition (BDI-II) (Beck et al 1988), The State Trait Anxiety Inventory (STAI) instrument (Form Y) (Spielberger et al 1983), the Profile of Mood States 2nd edition short form for adults instrument (POMS2-AS), and the Perceived Stress Scale (PSS) (Cohen et al 1983) for changes that occur in between the groups.
1601363|NCT02225834|Drug|Atorvastatin|treatment with atorvastatin 80 mg (once-daily) from admission day until discharge
1601364|NCT02225821|Drug|Cephalozin|1000 mg Cephalozin
1601365|NCT02225821|Other|Sodium chloride|10 cc of NaCl 0.9%
1601366|NCT02225808|Behavioral|CBT for anxiety in autism|
1601367|NCT02225795|Other|Hematopoietic stem cell transplantation|"Immuno-ablative regimen for HSCT:
Day Treatment
6 r-ATG 2 mg/kg
5 r-ATG3 2 mg/kg
4 r-ATG3 2 mg/kg
3 Cyclophosphamide with Mesna
2 Cyclophosphamide with Mesna
1 REST 0 PBSC infusion
3 Cyclophosphamide with Mesna
4 Cyclophosphamide with Mesna
6 Start GCSF"
1601368|NCT02225782|Drug|Alteplase|Alteplase is a fibrinolytic drug widely used to restore hemodialysis catheter patency.
1601369|NCT02225769|Other|Management of febrile children using e-POCT|Use of the e-POCT tool by study clinicians for the clinical management of febrile episodes. The e-POCT tool is an electronic algorithm that integrates key clinical elements with the results of malaria and host biomarkers point-of-care test results (including oximetry).
1601370|NCT02225769|Other|Management of febrile children using ALMANACH|Management of febrile children by study clinicians using ALMANACH. ALMANACH is an improved IMCI algorithm on mobile phone or tablet
1601371|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 1
1601372|NCT02225756|Drug|Cyclosporine A|Oral administration for a short time of cyclosporine A dose 2
1601373|NCT02225756|Drug|Placebo|Oral administration for a short time of placebo
1601374|NCT02225743|Other|Observation Of Temperature|Participants temperature will be recorded perioperatively.
1601375|NCT02225717|Procedure|Cervicovaginal swab|Sample of cervicovaginal secretions made by the surgical team using a sterile swab introduced directly into the posterior fornix of vagina for one minute during the insertion of the urinary catheter
1601376|NCT02225704|Drug|Radium-223 and enzalutamide|
1601378|NCT02225665|Genetic|SB-728mR-T|-SB-728mR-T infusions of 2 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
1601379|NCT02225665|Genetic|SB-728mR-T|- SB-728mR-T infusions of 3 equal doses 14 days apart (total of up to 40 billion ZFN modified T-cells)
1601380|NCT02225665|Drug|Cyclophosphamide|- IV cyclophosphamide 1 g/m2 two days prior to the first SB-728mR-T infusion
1601381|NCT02225652|Drug|FEC (Fluorouracil, Epirubicin, Cyclophosphamide) + filgrastim + paclitaxel|
1601382|NCT02225639|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
1601383|NCT02225639|Drug|Placebo|Oral placebo capsule
1601384|NCT02225639|Drug|PRC-063 35 mg|Oral 35 mg capsule - active
1601385|NCT02225639|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
1601386|NCT02225639|Drug|PRC-063 55 mg|Oral 55 mg capsule - active
1601387|NCT02225639|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
1601388|NCT02225639|Drug|PRC-063 85 mg|Oral 85 mg capsule - active
1601389|NCT02225639|Drug|PRC-063 100 mg|Oral 100 mg capsule - active
1601390|NCT02225626|Drug|BI 1060469|tablet, oral administration with 240 mL of water after an overnight fast of at least 10 h
1601391|NCT02225626|Drug|BI 1060469|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
1601392|NCT02225626|Drug|Other: standard breakfast|tablet, oral administration with 240 mL water 30 minutes after subject is served a standardised high-caloric high-fat administration
1601393|NCT02225613|Other|Usual protocol|
1601394|NCT02225613|Other|Spa protocol|
1601395|NCT02225600|Drug|40 IU Intranasal Oxytocin|40 IU intranasal oxytocin
1601396|NCT02225600|Drug|Placebo|Intranasal Placebo
1601397|NCT02225600|Drug|24 IU intranasal Oxytocin|
1601401|NCT02225574|Drug|MEK-162|"Phase 1: Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of MEK-162: 30 mg by mouth twice a day on starting on Day 1 of a 28 day cycle.
Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of MEK-162: MTD from Phase 1 to be taken by mouth twice a day starting on on Day 1 of a 28 day cycle.
Phase 1 Chronic Phase CML - Group 2 Starting dose of MEK-162: 30 mg by mouth twice a day of a 28 day cycle.
Phase 2 Chronic Phase CML - Group 2 Starting Dose of MEK-162: MTD from Phase 1 by mouth twice a day starting on Day 8 of a 28 day cycle."
1601402|NCT02225574|Drug|Nilotinib|"Phase 1 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting Dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.
Phase 2 Advanced CML + Philadelphia positive Acute Leukemia-Group 1 Starting dose of Nilotinib: MTD from Phase 1 to be taken by mouth twice a day starting on Day 2 of a 28 day cycle.
Phase 1 Chronic Phase CML - Group 2 Starting dose of Nilotinib: 400 mg by mouth twice a day of a 28 day cycle.
Phase 2 Chronic Phase CML - Group 2 Starting Dose of Nilotinib: MTD from Phase 1 by mouth twice a day starting on Day 1 of a 28 day cycle."
1601403|NCT02225574|Behavioral|Questionnaires|Questionnaires completed and the end of cycle 1, 2, 3, 6, 9, and 12.
1601404|NCT02225561|Procedure|pharmaco- mechanical optimization|"Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
As soon the peripheral intravenous or intraosseous line is set the intervention group will receive an injection of 2 mg of sodium nitroprusside. 4 minutes after the first injection, a second and last injection of 1 mg of sodium nitroprusside will be realized.- The preparation procedure of the sodium nitroprusside will be:
Using a pomping needle and the provided syringe 4 ml of the solvent (Water for Injections, WFI) will be take.
The 4 ml of WFI will be empty in the 50 mg vial of lyophilisate sodium nitroprusside to solubilize the product.
Always with the needle and 20 ml syringe, the 4 ml of this solution (50 mg in 4 ml) will be collect."
1601405|NCT02225561|Procedure|mechanical optimization only|Getting started as soon as possible cardiopulmonary resuscitation (CPR) mechanical ( LUCAS 2) with inspiratory impedance valve ( ResQPOD ) performed according to the 2015 recommendations of the European Resuscitation Council . It will be carried out continuously without a break for control pulse until the first defibrillation attempt.
1601406|NCT02225548|Drug|Selegiline|
1601407|NCT02225548|Drug|Tadalafil|
1601408|NCT02225535|Other|NP face to face management of Chronic Low Back Pain|usual NP management of chronic low back disorder
1601409|NCT02225535|Other|PT face to face management of Chronic Low Back Pain|Includes manual therapy, education, exercise
1601410|NCT02225535|Other|Interprofessional Videoconferencing for Chronic Low Back Pain|Includes manual therapy, education, exercise.
1601411|NCT02225522|Other|Rapid whole genome sequencing (StatSeq)|Patients in this arm will received standard genetic testing, the Perkins Elmer StepOne expanded newborn screen and the rapid whole genome sequencing (StatSeq). the receipt of the StatSeq testing is the different factor between arms. the standard genetic testing includes any testing that is clinically available to the attending physician that would normally be ordered for the patient if not enrolled in this study.
1601412|NCT02225509|Procedure|FNA biopsy for thyroid nodule(s)|"The study is intended for patients for whom a FNA biopsy of thyroid nodule/nodules is medically indicated for the detection of thyroid cancer. FNA biopsy should preferably be carried out under ultrasound guidance. The FNA samples will be collected either from the remaining material of FNA or there will be dedicated FNA sample in order to ensure an adequate quantity of material for molecular analysis. The patients will also be invited to take part in the mutation study in a separate consent form.
The samples of enrolled patients will be sent to the Diaxonhit Genomics Laboratory and analysed using Diaxonhit technology after checking the quantity and quality of the samples. Enrolled patients whose samples are inadequate in terms of quantity or quality for the various molecular tests will not be considered for the study. If necessary, mutation analyses can be carried out anonymously by an independent French laboratory and under the supervision of Diaxonhit."
1601459|NCT02225093|Drug|Enzalutamide Placebo to Match (PTM)|Oral
1601740|NCT02223091|Behavioral|Consultation by an untrained physician|
1601413|NCT02225496|Procedure|Transoral Robotic Surgery (TORS)|Transoral robotic surgery performed utilizing Intuitive Surgical da Vinci Surgical System. Utilizing robotic surgical system, tumor excised with wide surgical margins of 0.5-1 cm.
1601414|NCT02225496|Procedure|Modified Barium Swallow (MBS)|MBS performed at baseline and 1 - 4 weeks after surgery, and at 6 months, 12 months and 24 months.
1601415|NCT02225496|Behavioral|Questionnaires|Questionnaires about speech and swallowing function completed at baseline, 1 - 4 weeks after surgery, and at 6 months, 12 months, and at 24 months.
1601416|NCT02225470|Drug|E7389 (Eribulin Mesylate)|
1601417|NCT02225470|Drug|Vinorelbine injection|
1601418|NCT02225457|Other|Hypercaloric diet|"Hypercaloric diet will be designed to provide 50% excess in calories compared to daily requirements. It will consist in a snack type, high fat and high carbohydrates diet."
1601419|NCT02225457|Dietary Supplement|polyphenols|Administration of polyphenols will consist in the administration of 1 gram (5x200 mg) of the compound bid during the entire overfeeding period.
1601420|NCT02225457|Dietary Supplement|placebo (for polyphenols)|Placebo will consist in the administration of a number of placebo pills matching that of polyphenols, in a similar way (bid) for the duration of the overfeeding experiment.
1601421|NCT02225444|Other|OsteoAMP|OsteoAMP in posterolateral fusion procedure of the lumbosacral spine
1601422|NCT02225431|Drug|sodium chloride infusion|
1601423|NCT02225418|Drug|Ropivacaine|
1601424|NCT02225418|Drug|saline|
1601425|NCT02225405|Drug|Nintedanib|"Run-In Phase Starting Dose of Nintedanib: 150 mg by mouth twice a day every day from Day 2 of Cycle 1 through Day 7 of Cycle 3, except for the days that Cisplatin and Docetaxel given.
Expansion Phase: During expansion phase, participants receive priming therapy with Nintedanib single agent for 28 days (+/- 7 days) at the maximum tolerated dose from Run-In Phase. Then 3 cycles given with Cisplatin and Docetaxel followed by surgery."
1601426|NCT02225405|Drug|Cisplatin|"Run-In Phase: 75 mg/m2 by vein on Day 1. Cycles repeated every 21 days +7 days/-3 days for a maximum of 3 cycles.
Expansion Phase: Same dose as Run-In Phase."
1601427|NCT02225405|Drug|Docetaxel|"Run-In Phase: 75 mg/m2 by vein on Day 1. Cycles repeated every 21 days +7 days/-3 days for a maximum of 3 cycles.
Expansion Phase: Same dose as Run-In Phase."
1601428|NCT02225392|Procedure|Bronchial thermoplasty|Bronchial thermoplasty (BT) will be performed using the Alair system (Boston Scientific, USA). Patients will undergo 3 bronchoscopy procedures with BT at least 3 weeks apart. Treatment sessions are designed to address different lobes of the lung with the right lower lobe treated during the first bronchoscopy, the left lower lobe treated during the second bronchoscopy, and both the right and left upper lobes treated in the third and final bronchoscopy. The right middle lobe and proximal airways including RC2 are left untreated.
1601429|NCT02225392|Device|Alair system (Boston Scientific, USA)|The alair system consist of a controller and a bastket catheter.
1601430|NCT02225379|Device|Hypo-Sense (non invasive sensor)|Parallel measurements of capillary blood glucose using reference methods (both capillary glucometer and continuous sensor) and data generated by the non- invasive study device during approximately 4 hours, in which a hypoglycemic event will be induced.
1601431|NCT02225366|Biological|LL37|Starting dose 250 µg/tumor. The injections will be given every 7 days for up to 8 weeks.
1601432|NCT02225366|Other|Photographs|Tumors measured and photographed one week before receiving LL37, and again at 4 weeks after LL37. Then photographs of the LL37 injected sites taken at 8 weeks.
1601435|NCT02225327|Biological|Fluad alone|Fluad
1601436|NCT02225327|Biological|Fluad and PPV23 on the different arms|Fluad and Prodiax
1601437|NCT02225327|Biological|Fluad and PPV23 on the same arm|Fluad and Prodiax
1601438|NCT02225327|Biological|PPV23 alone|Prodiax
1601439|NCT02225314|Behavioral|Brain Fitness|Brain Fitness is a computer-based cognitive training programs that consists of six types of exercises that train auditory processing speed and accuracy.
1601440|NCT02225314|Behavioral|InSight|InSight is a computer-based cognitive training program that consists of five types of exercises that train visual processing and working memory.
1601441|NCT02225314|Behavioral|Active Control|The Active Control arm is a computerized learning program that consists of five programs (i.e., Wright Brothers, History of Britain, Sister Wendy's American Collection, In Search of Shakespeare, and View the Cosmos) designed to improve knowledge about literature, art, and history.
1601442|NCT02225301|Other|iLook Out for Child Abuse|The online learning module is an interactive, multi-media, self-paced intervention that takes 1.5-2 hours to complete.
1601443|NCT02225288|Drug|E2022|transdermal E2022 tape formulation (8.1 cm x 8.1 cm)
1601444|NCT02225275|Drug|Lenalidomide|5 mg by mouth per day from day 9 until day 56, and at 10 mg per day from day 57 until progression or excessive toxicity.
1601445|NCT02225275|Drug|Obinutuzumab|100 mg by vein on Day 1, 900 mg by vein on Day 2, and 1000 mg on Day 8 and Day 15 for the first cycle, then 1000 mg on Day 1 for cycles 2 - 6 in a 28 day cycle.
1601446|NCT02225262|Radiation|CyberKnife Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
1601447|NCT02225236|Behavioral|Classroom Intervention|
1601448|NCT02225223|Device|STAR™ Tumor Ablation System|Targeted-radiofrequency ablation (t-RFA)
1601449|NCT02225223|Device|StabiliT® Vertebral Augmentation System|Radiofrequency-targeted vertebral augmentation (RF-TVA)
1601450|NCT02225210|Drug|Dexmedetomidine|Loading dose:0.4μg.kg-1 Maintenance dose :0.2~0.7µg.kg-1 Sedation-Agitation Scale: maintain between 3 and 4.
1601451|NCT02225210|Drug|Midazolam|Loading dose of midazolam:0.1mg.kg-1 . Maintenance dose of midazolam :0.05~0.1mg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
1601452|NCT02225210|Drug|Fentanyl|Loading dose of fentanyl:1 μg.kg-1 . Maintenance dose of fentanyl: 0.5~1μg.kg-1.h-1 . Sedation-Agitation Scale: maintain between 3 and 4
1601453|NCT02225197|Radiation|CyberKnife Radiosurgery|25 Gy delivered in 5 fractions of 5 Gy per fraction
1601455|NCT02225106|Drug|Methylphenidate|
1601456|NCT02225093|Drug|Caffeine|Oral
1601457|NCT02225093|Drug|Dextromethorphan|Oral /.L
1601458|NCT02225093|Drug|Enzalutamide|Oral
1601460|NCT02225067|Drug|Calcium (13C)Carbonate|Visit 1 and Visit 2, 24-hour gastric pH monitoring and C13-CAC breath test containing 200 mg of Calcium (13C)Carbonate
1601461|NCT02225054|Drug|Dexmedetomidine|0.5 u/kg Dexmedetomidine diluted in saline to 1 mL (single interscalene injection) Dexmedetomidine 0.5 u/kg as a single IV bolus over 30 minutes following GA induction
1601462|NCT02225054|Drug|Ropivacaine|15 ml 0.5%
1601463|NCT02225054|Drug|Normal Saline|1 mL 0.9%
1601464|NCT02225028|Behavioral|Physical Activity Counseling|Participants in the physical activity counseling group will be mailed a home exercise toolkit that may include an activity monitor, exercise resistance bands, and exercise DVDs made for people with paraplegia or tetraplegia.
1601465|NCT02225015|Behavioral|Follow-up Telephone Genetic Counselling|Individualized theoretical genetic counselling among women with BRCA mutations to assess the impact it has on the uptake of cancer prevention strategies.
1601466|NCT02225002|Drug|CP-870,893|
1601467|NCT02224989|Behavioral|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 10 weeks.
1601468|NCT02224976|Behavioral|Intensified Training|Volunteers will increase exercise training by 30% from baseline
1601469|NCT02224963|Behavioral|Preventive Problem-Solving Training|Preventive Problem-solving Training is an adaptation of Problem-Solving Therapy that builds problem-solving skills and then focuses these skills on potential future problems. It aims to reduce avoidance of contemplation of future needs and enhance gathering information, decision-making, and concrete planning about future needs.
1601470|NCT02224963|Behavioral|Life and Health Review|Life and Health Review is an Enhanced Attention Control that provides classes and resource information modules, just as in intervention. It differs from the intervention in that we conduct an 8-session life and health review with subjects, in which they recount life experiences from childhood to the present.
1601471|NCT02224950|Device|Non-medicated Emollient plus Lyocell/Chitosan Sleeve|
1601472|NCT02224950|Other|Non-medicated Emollient plus Cotton Sleeve|
1601473|NCT02224950|Other|Placebo Sleeve|
1601474|NCT02224937|Drug|Melatonin|
1601475|NCT02224937|Drug|Placebo|
1601476|NCT02224924|Other|ABPI|If the patient was assigned to the ABPI group, a blood patch will be administered using the clotted blood in the syringe obtained at the beginning of the procedure. The guiding needle will be retracted up to 1.5-2 cm from the pleural surface, and the blood will be injected steadily and gently as the needle is pulled back out of the pleura. Injection will stop when the operator feels the needle is in subcutaneous tissues.
1601477|NCT02224924|Device|BioSentry (formerly known as Bio-Seal) hydrogel Tract Plug|If the patient is assigned to BioSentry group, using the manufacturer's deployment device the introducer needle is positioned so that the tip is at least 1.5 cm deep to the visceral pleura. The coaxial introducer needle hub will be prehydrated with a drop of saline, the BioSentry plug housing will be mated and locked to the hub and the plug will be deployed.
1601478|NCT02224911|Device|Laser Interstitial Thermal Therapy|
1601479|NCT02224898|Behavioral|Mobile Mindfulness Therapy|Subjects will be asked to complete 30 days of mobile mindfulness therapy, for 2-30 minutes daily.
1601480|NCT02224885|Device|CT-guided percutaneous biopsy or ablation|Standard interventional radiology procedure for a biopsy or ablation in the liver or in the lung
1601481|NCT02224872|Procedure|Bone marrow transplant|Day 0
1601482|NCT02224872|Drug|Thymoglobulin|0.5 mg/kg IV on Day -9 2 mg/kg IV on Days -8, -7
1601483|NCT02224872|Drug|Fludarabine|30 mg/M2 IV on days -6 to -2
1601484|NCT02224872|Drug|Cyclophosphamide|14.5 mg/kg IV on days -6, -5, 3, 4
1601485|NCT02224872|Radiation|TBI|200 cGy on day -1
1601486|NCT02224872|Drug|Mesna|40 mg/kg IV on days 3, 4
1601487|NCT02224872|Drug|Tacrolimus|For patients 18 years or older, tacrolimus will be given per institutional standards; may be increased or later changed to a PO BID schedule. Treatment to continue until Day 365 or longer if GVHD present
1601488|NCT02224872|Drug|Mycophenolic acid mofetil|15 mg/kg PO/IV TID beginning on day 5 through day 35
1601489|NCT02224859|Device|HCP will place the Invictus Cranial Support Device (CSD) on the patient|"There is no active therapeutic treatment (e.g., medication, stimulation, etc.) associated with this device or study. All supplies for this study will be supplied by the sponsor and returned to them upon completion of the trial.
The device used in this study is a soft gel based bonnet referred to as a Cranial Support Device (CSD). In this study, after obtaining written informed consent from the patient's parent(s) or guardian(s) and confirming that the patient meets all inclusion and no exclusion criteria, the study HCP will place the CSD on the selected patient."
1601490|NCT02224859|Other|human intervention|This study is designed to evaluate the safety of the Invictus Cranial Support Device (CSD) when worn by medically stable infants within a neonatal intensive care unit (NICU), to evaluate the form, fit, and ease of use/application of the CSD device (i.e., utility), as well as initial impressions of safety, by health care providers (HCPs) after placing the current CSD on infants for approximately six (6) hours in a NICU
1601492|NCT02224833|Behavioral|Pharmacist intervention|"Systematic review of treatments:
Identification of reasons for PPI.
Determination of recommended pharmacotherapeutic alternatives.
Issue recommendations for therapeutic appropriateness to the doctor (via registration on the EHR and verbal communication if deemed appropriate); that will be of 4 types: Add medicine, discontinue medicine, adjust dosage, replace medicine.
After the medical visit (the next day) New treatment review for: Checking acceptance or rejection of the recommendations issued, review potential new prescriptions made without pharmacist recommending, and whether these new drugs lead to PIP."
1601493|NCT02224820|Biological|IdeS|Doses are administered in ascending doses
1601494|NCT02224807|Behavioral|Active Comparator: Progressive Resistance Training (PRT) and a healthy diet|no additional information; see arm description
1601495|NCT02224807|Behavioral|Experimental: PRT and a healthy diet, plus weight loss|no additional information, see arm description
1601496|NCT02224794|Device|Ovation® Abdominal Stent Graft Platform|
1601504|NCT02224755|Device|HeartMate 3 LVAS|Implantation of HeartMate 3 LVAD to evaluate the safety and effectiveness of the HeartMate 3 LVAS by demonstrating non-inferiority to the HMII LVAS (HMII) when used for the treatment of advanced, refractory, left ventricular heart failure
1601505|NCT02224755|Device|HeartMate II LVAS|Implantation of the commercially approved HeartMate II LVAD which is the standard treatment for advanced heart failure
1601506|NCT02224742|Device|LeucoPatch|LeucoPatch® is prepared by centrifuging one or more 18mL aliquots of the participant's venous blood in the LeucoPatch device and bench-top centrifuge. The centrifugation yields a tough layer of fibrin, with viable white cells and platelets, and this is applied directly to the wound surface using sterile forceps. The wound is then covered with an inert primary dressing, secondary protective dressing and the ulcerated area protected with appropriate off-loading. The patch is prepared and applied each week for up to 20 weeks or until the wound is judged healed.
1601507|NCT02224742|Other|Usual care|"Usual wound care provided in a multidisciplinary foot care clinic , in accordance with international guidelines.
Components of usual wound care include:
Formal assessment of ulcer and surrounding skin
Provision of any necessary off-loading
Debridement (i) sharp, (ii) other as appropriate (but excluding the use of larvae)
Appropriate dressing products
Appropriate antibiotic therapy
Nutrition and self care
Optimal glycaemic control
Revascularisation if deemed clinically necessary
Continued close observation"
1601511|NCT02224703|Drug|GWP42003-P|
1601512|NCT02224703|Drug|Placebo Control|
1601513|NCT02224690|Drug|GWP42003-P|GWP42003-P oral solution
1601514|NCT02224690|Drug|Placebo Control|Placebo oral solution
1601515|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 5mg QD
1601516|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD
1601517|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 15 mg QD (slow titration with option to down titrate)
1601518|NCT02224664|Drug|PF-06649751|Oral daily doses titrated up to 25 mg QD
1601519|NCT02224651|Drug|PF-06650833|Subjects will receive sequential single escalating doses of 1-1000 mg of Immediate Release of PF-06650833 (as solution/suspension) under fed and / or fasted conditions.
1601520|NCT02224651|Drug|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as solution/suspension) under fed and/ or fasted conditions.
1601521|NCT02224651|Drug|PF-06650833|Subjects will receive sequential single escalating doses of 10-500 mg of Modified Release of PF-06650833 (as capsule) under fed and / or fasted conditions.
1601522|NCT02224651|Drug|Placebo|Subjects will receive sequential single escalating doses of PF-06650833 matching placebo (as capsule) under fed and/ or fasted conditions.
1601525|NCT02224625|Drug|2% CHG Cloth solution|Investigational CHG
1601526|NCT02224625|Device|Vehicle Cloth|Excipients from CHG cloth only
1601527|NCT02224625|Drug|Active Comparator|Active comparator
1601528|NCT02224625|Other|Saline|Negative control
1601529|NCT02224625|Other|SLS|Provides a slight irritation for a positive control
1601532|NCT02224599|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
1601533|NCT02224586|Device|light treatment|clinical routine treatment according to the doctor's advice
1601537|NCT02224547|Radiation|Radiotherapy (Fractionated stereotactic body radiation)|Radiation: Fractionated stereotactic body radiation therapy For centrally located T1 and T2 lesions 4 x 12 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 17Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
1601538|NCT02224534|Drug|Ticagrelor|Ticagrelor 180 mg as a loading dose and 90 mg twice daily as a maintenance dose
1601539|NCT02224534|Drug|Clopidogrel|Clopidogrel 600 mg as a loading dose and 75 mg once daily as a maintenance dose.
1601540|NCT02224521|Drug|GSK2190915 Solution.|Aqueous Solution, 10mg/mL.
1601541|NCT02224521|Drug|GSK2190915 Granule Capsule (A)|GSK2190915A granule filled in to Gelatin capsules
1601542|NCT02224521|Drug|GSK2190915 Semi-solid Lipid Capsule (B)|GSK2190915A dispersed in a lipid vehicle and filled in to HPMC capsules
1601543|NCT02224521|Drug|GSK2190915 Liquid Lipid Capsule (C)|GSK2190915A dissolved in lipid vehicle milled and filled in to Gelatin capsules
1601544|NCT02224521|Drug|GSK2190915 Milled Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
1601545|NCT02224521|Drug|GSK2190915 Micronised Tablet|GSK2190915A granule is blended, compressed into tablets and aqueous film coated
1601546|NCT02224495|Behavioral|Structured exercise training|
1601547|NCT02224482|Behavioral|PROGRESS|PROGRESS is a multimedia website designed to help prostate cancer survivors.
1601548|NCT02224469|Device|ECoG (electrocorticography) sensing|Implant electrodes and sensing device and use for control of Assistive Technology
1601549|NCT02224456|Drug|Tenofovir disoproxil fumarate|"White, almond-shaped, film-coated tablet containing 300 mg of TDF, debossed with GILEAD and 4331 on one side of the tablet."
1601550|NCT02224443|Drug|dexmedetomidine|Experimental: Group A, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.3µg.kg-1.h-1 until 30 minutes before end of operation
1601741|NCT02223078|Biological|G17DT|
1601742|NCT02223078|Biological|Placebo Comparator|
1601551|NCT02224443|Drug|dexmedetomidine|Group B, Continuous pump infusion dexmedetomidine with loading dose at 0.8µg.kg-1 over 10 minutes,followed continuous pump infusion dexmedetomidine at 0.5µg.kg-1.h-1 until 30 minutes before end of operation
1601552|NCT02224443|Drug|normal saline|Group C , Normal saline infusion will be given with the same infusion volume as group A and B
1601553|NCT02224443|Drug|midazolam,fentanyl,etomidate,Cisatracurium besylate|Anesthesia induction : 0.05 mg.kg-1 midazolam,4~5μg.kg-1 fentanyl,1.0~1.5mg.kg-1etomidate and 0.15 mg.kg-1Cisatracurium besylate
1601554|NCT02224443|Drug|cisatracurium besylate,propofol,remifentanil,sevoflurane|Maintenance of anesthesia :Continuous pump infusion 0.05~0.1mg.kg-1.h-1cisatracurium besylate,4~8mg.kg-1.h-1propofol,0.1~0.2μg.kg-1.min-1 remifentanil and sevoflurane inhalation with 0.6%~1.0%
1601555|NCT02224417|Behavioral|Diabetes Educational Program (DEP)|"Participants in this Arm will receive the Diabetes Educational Program (DEP), as required, which is part of usual care at the Polyclinic. It is delivered by a Health Counsellor at the point of diagnosis and focused education is provided during doctor visits for medication. The program at the Polyclinic comprises information on a series of diabetes-related issues.
The participant will receive the 2 or 3 study devices (patients will receive a glucometer if they do not already have one). The Site Study Coordinator will provide education on the use of the Fitbit Zip™ and the eCAP™. As part of usual care, patients who have difficulties with their glucometer will be referred to a Health Counsellor at the Polyclinic."
1601556|NCT02224417|Behavioral|DEP + Process Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for meeting specified goals:
SGD3.50 weekly for meeting Glucose testing goals: measuring blood glucose on three non-consecutive days each week.
SGD0.50 daily for Medication adherence: taking medications daily as prescribed, monitored by eCAP device. Assessed based on medication-taking times within specified time windows. Participants should be adherent at all specified mealtimes to be fully adherent for the day.
SGD1.00 daily for Regular Physical activity: taking 8,000 steps during the day as recorded by Fitbit."
1601557|NCT02224417|Behavioral|DEP + Outcome Incentive|"Participants will receive the DEP as required. In addition, participants will have the opportunity to earn financial incentives (in vouchers) for recording glucose readings within the normal range (i.e. between 4 to 7mmols/L two before a meal) on 3 non-consecutive days within the week using the glucometer.
SGD 2 weekly if one glucose readings falls within the normal range,
SGD 7 weekly if two glucose readings fall within the normal range,
SGD 14 weekly if all three glucose readings fall within the normal range."
1601558|NCT02224404|Device|Fast Gelling Dressing (Exufiber)|
1601559|NCT02224391|Behavioral|Smartphone Training|"ABM Group: Participants complete 13 days of attentional bias modification (ABM) training through a smartphone, designed to help in smoking cessation after first lab session.
Sham Group: Participants complete 13 days of smartphone training after first lab session."
1601560|NCT02224391|Behavioral|Questionnaires|Questionnaire completion regarding smoking history and behavior completed at baseline, Day 15, Day 70, and daily after Smartphone training.
1601561|NCT02224391|Other|Urine Collection|Urine collected at baseline, Day 15, and at Day 72 to check cotinine levels.
1601562|NCT02224391|Procedure|Electroencephalography (EEG)|Event-related potential (ERP) electroencephalography (EEG) performed at baseline, Day 15, and on Day 70.
1601563|NCT02224391|Drug|Nicotine Replacement Therapy|Nicotine Replacement Therapy given to participants on Day 15 consisting of 4 weeks of 21 mg, 2 weeks of 14 mg, and 2 weeks of 7 mg.
1601564|NCT02224391|Behavioral|Counseling Sessions|Participants attend counseling sessions on Day 15 in person, and on the phone on Days 28, 42, and 56.
1601565|NCT02224378|Procedure|peep induced CVP|
1601566|NCT02224378|Procedure|passive leg raising(PLR)|
1601567|NCT02224365|Dietary Supplement|Apple|12 weeks of 75 g dried apple powder taken in 480 ml per day.
1601568|NCT02224365|Dietary Supplement|Placebo|12 weeks of 75 g apple-flavored placebo powder taken in 480 ml per day.
1601569|NCT02224352|Device|Functional neuromuscular electrical stimulation|
1601570|NCT02224313|Drug|oral estradiol 0.5 mg|
1601571|NCT02224313|Drug|oral estradiol 1.0 mg|
1601572|NCT02224313|Drug|oral progesterone 100 mg|
2009619|NCT03201120|Behavioral|Indoor Tanning Behavior|Upon arrival, participants will provide informed consent and complete a short background questionnaire about usual indoor tanning, sun exposure and protection behaviors, and demographics. Next, each participant will be seated in a room to view the audio-visual media messages. Eye-tracking equipment running Paradigm (Perception Research Systems Incorporated) for stimuli presentation will be calibrated to the participant. Subjects will be seated at a desk in front of a typical computer monitor, keyboard and mouse setup. Each participant will view messages with each type of target behavior (freedom, health risk, appearance)). Messages will be shown in random order, with each message interspersed by a 30 second baseline screen consisting of black background and white, centered plus sign. The last 10 seconds of each preceding the 30-second baseline screen will be used to establish physiologic baseline to minimize carry-over effects of the preceding message.
1601574|NCT02224287|Procedure|Technologist control of fluoroscopy|Technologist control of fluoroscopy
1601575|NCT02224287|Procedure|Surgeon control of fluoroscopy|Surgeon control of fluoroscopy
2009620|NCT03201952|Drug|Ursodeoxycholic Acid|Ileostomy administration of 300mg UDCA once
2009621|NCT03201952|Drug|Placebos|Ileostomy administration of 5cc saline placebo once
1601578|NCT02224261|Other|Physical Therapy protocol|
1601579|NCT02224261|Other|Control|
1601580|NCT02224248|Behavioral|Health checks with fitness testing|Fitness testing as part of a preventive health check compose the intervention in this trial. Thus, the intervention group will receive preventive health checks with fitness testing.
1601581|NCT02224248|Behavioral|Health checks without fitness testing|The active comparator will not receive fitness testing as part of the preventive health checks. With the exception of fitness testing, the preventive health checks in the active comparator group and the intervention group are identical.
1601743|NCT02223065|Drug|Saxagliptin|
1601744|NCT02223065|Drug|Dapagliflozin|
1601746|NCT02223052|Drug|Vidaza|75mg/m^2 IV or SC daily x 7 days every 4 weeks for ≤ 6 (four-week) cycles
1601586|NCT02224209|Device|Abbott EPD systems (Accunet/Emboshield), a balloon, stent|"Standard method of endovascular interventional treatment:
Method of stage-1 angioplasty
The stent can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield) if distal filter cannot be used, balloon angioplasty can be performed under proximal protection device;
Use a balloon with diameter of 2mm × 2cm for stage-1 dilation until angiography shows residual stenosis <70%.
Method of stage-2:
The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);
Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation;
After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
1601587|NCT02224209|Device|a balloon, stent|"Routine stenting procedure:
The stent systems (Acculink/Xact) can be placed into the distal stenosis under Abbott EPD systems (Accunet/Emboshield);
Use an Abbott balloon (diameter of 4 ~ 6mm) for pre-dilation or post-dilation;
After the placement of stent, the angioplasty is a success when residual stenosis is <30%."
1601588|NCT02224196|Other|manual ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
1601589|NCT02224196|Other|pressure-controlled ventilation|Anesthesia will be induced by propofol 1mg/kg via intravenous line. Once loss of eyelash reflex occurred, ultrasonography of antral area will be started by same physician. After administration of muscle relaxant (rocuronium 0.2-0.4mg/kg), manual ventilation will be performed with respiratory rate 20 breathes/min, I:E ratio of 1:1 and tidal volume with 9-10mL/kg. The pop-off valve will be set at 15cmH2O at fixed gas flow of 500mL/min of oxygen. Pressure-controlled ventilation will be performed with respiratory rate 20 breaths/min, I:E ratio of 1:1 and peak airway pressure will be set to get a tidal volume of 9-10mL/kg. The peak airway pressure during facemask ventilation will be checked. Another physician will auscultate the epigastric area to detect gastric insufflation during facemask ventilation. Ultrasonography of antral area will be checked once again after 3 minutes of facemask ventilation.
1601590|NCT02224183|Behavioral|Education|Individuals randomized to the education group will receive The Back Pain Helpbook, an educational book with strategies for self-care including an exercise program, lifestyle modification, and tips for managing flare-ups. In addition, they will receive an assignment sheet outlining specific chapters to read over the course of the 12-weeks. In addition, participants receive at 3, 6, 9, and 12 weeks newsletters highlighting main points from the assigned chapters.
1601591|NCT02224183|Behavioral|Yoga|Weekly yoga classes will each be taught by two yoga instructors. Classes will be 75 minutes long. Mats and props will be provided. Yoga participants will be encouraged to practice for 30 minutes on days when they do not have class. They will be provided free of charge with a participant handbook, mat, block, and strap to aid home practice. Yoga home practice videos will be placed online for home practice and the website will track time spent using the videos for home practice. DVDs will be provided for those that do not have consistent access to the internet at home.
1601592|NCT02224170|Drug|Lidocaine|Lidocaine 2mg Kg-1 in normal saline (total volume 25mL) was infused after tracheal intubation, and lidocaine was infused at the rate of lidocaine 2mg Kg-1 h-1 (0.2 ml Kg-1 h-1, equivalent volume as normal saline in dexamethasone group) until the end of surgery (at the time of skin closure).
1601593|NCT02224170|Drug|Dexamethasone|Dexamethasone 8mg in normal saline (total volume 25mL) was infused after tracheal intubation, and normal saline was continuously infused at the rate of 0.2 ml Kg-1 h-1 until the end of surgery (at the time of skin closure).
1601594|NCT02224157|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
1601595|NCT02224157|Drug|budesonode bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
1601596|NCT02224144|Drug|Vitamin D3|Vitamin D3 1000 IU per day for 12 months
1601597|NCT02224144|Drug|Calcitriol|Calcitriol (Rocaltrol) 0.5 mcg per day for 12 months
1601598|NCT02224144|Drug|Placebo|Placebo (sugar pill) 1 pill per day for 12 months
1601599|NCT02224131|Drug|Aspirin and clopidogrel|modification of aspirin and clopidogrelmaintenance doses based on a biological assay Device:thrombelastography(TEG) point of care assay TEG(Haemoscope Corporation, Niles, IL)
1601600|NCT02224131|Drug|Aspirin and clopidogrel|aspirin and clopidogrel maintenance doses (according to international guidelines)
1601601|NCT02224118|Drug|CNTO 3649 10 mcg/kg|A single dose of 10 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
1601602|NCT02224118|Drug|CNT0 3649 30 mcg/kg|A single dose of 30 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 30 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
1601603|NCT02224118|Drug|CNTO 3649 100 mcg/kg|A single dose of 100 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men and multiple doses of 100 mcg/kg of CNTO 3649 will be administered to participants with type 2 diabetes mellitus as subcutaneous injections once weekly for 4 weeks.
1601604|NCT02224118|Drug|CNTO 3649 300 mcg/kg|A single dose of 300 mcg/kg of CNTO 3649 will be administered as subcutaneous injection to healthy adult Japanese men.
1601605|NCT02224118|Drug|Placebo|Matching Placebo to CNTO 3649 will be administered to both healthy volunteers and participants with type 2 diabetes mellitus.
1601606|NCT02224105|Drug|BI 653048 BS|
1601607|NCT02224105|Drug|Prednisolone low|
1601608|NCT02224105|Drug|Prednisolone high|
1601609|NCT02224105|Drug|Placebo|
1601610|NCT02224105|Drug|sodium chloride infusion|
1601611|NCT02224105|Drug|endotoxin escherichia coli (E. coli) lipopolysaccharide (LPS)|
1601612|NCT02224092|Dietary Supplement|multivitamin multimineral with phytonutrient supplementation|"The multivitamin multimineral with phytonutrient product consists of four tablets per dose, two Vitamin tablets, a Mineral tablet, and a Phytonutrient tablet. The placebo for this trial will be formulated to match the shape and color of all multivitamin multimineral with phytonutrient product tablets, e.g., a Vitamin Placebo, a Mineral Placebo and a Phytonutrient Placebo."
1601613|NCT02224079|Drug|BIIB 722 CL|
1601614|NCT02224079|Drug|Placebo|Hydroxypropyl-beta-cyclodextrin (HPβCD)
1601615|NCT02224066|Drug|Ticagrelor 90 mg twice per day during three months following TAVI|
1601616|NCT02224066|Drug|Aspirin 100 mg plus Clopidogrel 75 mg daily during three months following TAVI|
1601617|NCT02224053|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
1601618|NCT02224053|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken on Day 5 in Period 1 and Day 1 in Period 2.
1601619|NCT02224053|Drug|Omeprazole tablet dosing|Omeprzole taken from Days 1 to 5 in Period 1.
1601620|NCT02224053|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
1601621|NCT02224040|Drug|ceftriaxone|
1601622|NCT02224040|Drug|ceftriaxone and azithromycin|
1601623|NCT02224040|Drug|azithromycin|
1601624|NCT02224040|Drug|azithromycin and cefixime|
1601625|NCT02224027|Device|proceal laryngeal mask airway|In proceal laryngeal mask group, proceal laryngeal mask airway is inserted by novices.
1601626|NCT02224027|Device|tracheal tube|In tracheal tube group, tracheal tube is intubated by novices.
1601627|NCT02224027|Device|i-gel|In i-gel group, i-gel is inserted by novices.
1601628|NCT02224014|Drug|Lendormin D tablets|
1601629|NCT02224001|Procedure|The Flag Technique|"A New Concept in the Tip Plasty of Asian Rhinoplasty : The Flag Technique by Use of Only A Septal Cartilage without Septal Extension Grafts
The investigators propose the new technique, so called 'Flag Technique' by a tip-strut complex in a flag-like shape : using only the septal cartilage as an elongated columellar septal strut graft, a shield graft , bilateral mini-spreader grafts of the upper part in the elongated columellar septal strut graft without the septal extension graft to achieve the desired the result."
1601630|NCT02223988|Procedure|subglottic secretion removal|
1601631|NCT02223962|Behavioral|Physical activity|Counseling about physical activity will only be provided in the intervention group by 3 weekly telephone contacts. Based on the information the physiotherapist receives, he or she will adapt the goal (in agreement with the patient) and motivate the patient to reach the individual goal.
1601632|NCT02223949|Device|Cook double balloon catheter|
1601633|NCT02223949|Drug|PGE1 tablet|
1601634|NCT02223936|Other|group exposed|Assessment by Brunet Lezine scale
1601635|NCT02223936|Other|Control|Not exposed group
1601636|NCT02223923|Drug|AZD6738|
1601637|NCT02223923|Radiation|Palliative radiotherapy|
1601638|NCT02223910|Procedure|Neurofeedback training of functional connectivity|
1601639|NCT02223897|Drug|huc-MSCs|Received conventional treatment and huc-MSCs once per week for the first month and once per month for 6 months(9 times in total), at a dose of 1×106 huc-MSCs/kg body weight.
1601640|NCT02223897|Drug|Placebo|Received conventional treatment and 50 ml saline solution once per week for the first month and once per month for 6 months(9 times in total).
1601641|NCT02223884|Drug|docetaxel 35mg/m2|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
1601642|NCT02223884|Drug|Carboplatin AUC3|D1, 8 docetaxel 35 mg/m2 D1, 8 carboplatin AUC 3 every 3 weeks
1601643|NCT02223871|Drug|ACT-451840:|ACT-451840 500 mg was provided in 100 mL amber glass bottles formulated as a powder for oral suspension. The ACT-451840 suspension was prepared extemporaneously by addition of 25 mL of water and administered orally under fed condition.
1601644|NCT02223871|Other|Plasmodium falciparum-infected human erythrocytes:|Each participant was inoculated on Day 0 with approximately 1,800 viable Plasmodium falciparum-infected human erythrocytes administered intravenously.
1601645|NCT02223871|Drug|Artemether 20 mg and lumefantrine 120mg combination tablet:|Rescue treatment to ensure clearance of Plasmodium falciparum comprising six doses of four tablets (total course of 24 tablets) given over a period of 60 hours. Each dose of tablets administered orally was immediately followed by food or drinks rich in fat (e.g., milk).
1601646|NCT02223871|Drug|Primaquine:|Rescue treatment to ensure clearance of Plasmodium falciparum, to be taken as a single oral 45 mg dose with food only if gametocytes were identified after administration of Riamet® rescue medication.
1601647|NCT02223858|Behavioral|Positive Activities (PA) Program|This is a 6-week program consisting of at-home activities (1 completed per week) that have been shown to increase positivity. Activities will be delivered using a combination of activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist will orient participants to the booklets and review the first activity at the end of an in-person baseline visit. The booklet contains all instructions patients need to complete the full program. However, the interventionist will conduct weekly telephone calls to provide additional support patients may need. During these calls, the interventionist will assess whether participants completed the previous week's activity, review instructions for the next week's activity, and help participants trouble-shoot anticipated barriers to completing the next activity.
1601648|NCT02223858|Behavioral|Attention Control (AC) Program|This is a 6-week program consisting of at-home activities (1 completed per week) that are based on affectively neutral activities from control conditions in prior studies of positive activities interventions. Activities will be delivered using a combination of activity booklets and oral instructions provided during weekly telephone calls from trained interventionists. Interventionist will orient participants to the booklets and review the first activity at the end of an in-person baseline visit. The booklet contains all instructions patients need to complete the full program. However, the interventionist will conduct weekly telephone calls to provide additional support patients may need. During these calls, the interventionist will assess whether participants completed the previous week's activity, review instructions for the next week's activity, and help participants trouble-shoot anticipated barriers to completing the next activity.
1601649|NCT02223845|Other|Music|Self-selected music played via headphones
1601650|NCT02223832|Drug|ACT-128800|
1601747|NCT02223039|Biological|AbGn-168H|AbGn-168H monoclonal antibody
1601651|NCT02223819|Drug|Crizotinib|"An anti-cancer drug acting as an ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene 1) inhibitor, used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body and is caused by a defect in a gene called ALK.
Crizotinib will be provided as capsules containing 200 or 250 mg of study medication for oral administration."
1601652|NCT02223806|Behavioral|Uterine Tonus Assessment by Midwife|Uterine tonus assessment every 15 minutes for 2 hours.
1601653|NCT02223806|Behavioral|Patient self-assessment of uterine tonus|Uterine tonus assessment by patient every 15 minutes for 2 hours.
1601657|NCT02223780|Other|early palliative care|the patients will benefit from an early palliative care consultation
1601658|NCT02223767|Device|Experimental: Verum TMS|Intensity of 100 % of the resting motor threshold with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
1601659|NCT02223767|Device|Experimental: Sham TMS|Sham stimulation with 10 Hz and ITI of 26 s. 1560 pulse in 40 trains at all . One train lasts 4 s.
1601660|NCT02223754|Device|lotrafilcon B|Soft contact lens to be worn as daily wear, monthly replacement modality.
1601661|NCT02223754|Device|etafilcon A|Soft contact lens to be worn as daily wear, daily disposable modality.
1601662|NCT02223741|Other|Korean medical treatment|acupuncture and herbal drugs
1601663|NCT02223728|Behavioral|Lifestyle|
1601664|NCT02223728|Behavioral|Health Education|
1601665|NCT02223715|Other|CDI Pts|
2009622|NCT03200873|Device|repetitive transcranial magnetic stimulation|Each session of iTBS will apply3 trains of 600 pulses to the RDLPFC, with 20 2-second trains and an 8-second inter-train interval. Sham iTBS condition will be administered with the same methodology used for active iTBS condition with a sham coil mimicking noises and vibrations without delivery of magnetic pulses.
2009623|NCT03200327|Procedure|promontofixation|reconstruction of cystoceles using a subvesical prosthesis
2009624|NCT03200327|Procedure|sacrospinofixation|Utero-vaginal suspension by bilateral anterior prosthetic sacrospinofixation using the vaginal route
2009625|NCT03199586|Drug|NP-G2-044|capsule
1601670|NCT02223676|Procedure|Clinical pharmacists conduct medication history|pharmacists conduct medication history before the physician interviews the patient and does not spend time on conducting medical history
1601671|NCT02223650|Device|Overminus treatment|2.50D overminus spectacles
1601672|NCT02223650|Device|Non-overminus treatment|spectacles without overminus or no spectacles
2009626|NCT03198767|Drug|LIK066|LIK066 with added breakfast type and supplement
1601674|NCT02223624|Other|walking and light weights|
1601675|NCT02223624|Other|eccentric aerobic exercise|
1601676|NCT02223624|Other|concentric aerobic exercise|
1601677|NCT02223611|Drug|S1 capsule|Within four weeks after the completely resection, S-1 was administered orally twice a day, after meals on days 1 to 14. The actual dose of S-1 was selected as follows: in a patient with body surface area (BSA)＜1.25 m2 40mg twice a day, 1.25 m2≤BSA＜1.5 m2 50mg twice a day, and 1.5 m2≤BSA 60mg twice a day. Cisplatin (75 mg/m2) was administered intravenously on day 1 The treatment regimen was repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
1601678|NCT02223611|Drug|Vinorelbine|Vinorelbine (25 mg/m2) is administered intravenously on day 1, and day 8. Cisplatin (75 mg/m2) is administered intravenously on day 1. The treatment regimen is repeated every 3 weeks, totally 4 cycles unless disease progression or unacceptable toxicity occurred.
1601679|NCT02223598|Drug|CB-5083|
1601680|NCT02223598|Drug|Dexamethasone|
1601681|NCT02223585|Other|Animal-based protein diet|
1601682|NCT02223585|Other|Vegan-based protein diet|
1601683|NCT02223572|Radiation|hip Xray|
1601684|NCT02223533|Device|19Gx500-mm Pajunk InfiltraLong® catheter|Before completing the surgery, the surgical team inserted a 19Gx500-mm Pajunk InfiltraLong® catheter with multiple perforations in the last few centimeters before the tip to allow for local anesthetic administration.
1601685|NCT02223533|Drug|morphine|After the intervention patients had access to intravenous morphine via a patient-controlled analgesia
1601686|NCT02223520|Drug|Mupirocin and Chlorhexidine|
1601687|NCT02223520|Drug|Placebo ointment and placebo cloths|
1601688|NCT02223507|Drug|BIIR 561 CL|
1601689|NCT02223507|Drug|Placebo|
1601690|NCT02223494|Drug|Terbogrel|
1601691|NCT02223481|Drug|Terbogrel low dose|
1601692|NCT02223481|Drug|Terbogrel high dose|
1601693|NCT02223481|Drug|Placebo|
1601694|NCT02223455|Other|Hand Hygiene Compliance Signs|Hand hygiene signs will not be changed (control) or change weekly/monthly on wards/units randomized to each of these study arms. Signs will be posted by the hand hygiene sanitizer outside each patient room.
1601695|NCT02223429|Drug|Oxytocin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
1601696|NCT02223429|Drug|Vasopressin|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
1601697|NCT02223429|Drug|Placebo|1 ml solution in each nostril; five (5) sprays per each nostril, for a total of ten (10) sprays
1601698|NCT02223416|Drug|RGB-10|
1601699|NCT02223416|Drug|Teriparatide|
1601700|NCT02223403|Dietary Supplement|nitrate-rich beetroot juice|3 ounces of nitrate-rich beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
1601701|NCT02223403|Dietary Supplement|nitrate-deplete beetroot juice|3 ounces of nitrate-deplete beetroot juice ingested orally once 90 minutes before exercise interventions of steady state treadmill exercise followed 30 minutes later by six minute walk
2009627|NCT03197584|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
1601745|NCT02223052|Drug|CC-486|Arm 1: Two 150-mg tablets of CC-486 on Day 1 and 1 x 300 mg CC-486 on Day 2 Arm 2: 1 x 300mg tablet of CC 486 on Day 1 and 2 x 150mg CC-486 on Day 2
2009628|NCT03197584|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
2009629|NCT03197584|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
2009630|NCT03197584|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
2009631|NCT03197584|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
1601703|NCT02223377|Drug|Morphine|Participant to be asked for their pain score, and if it is more than 4 out of 10 (NAS): to receive the 1st dose within 5 minutes after coming to PACU: 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
1601704|NCT02223377|Drug|Hydromorphone|Participant to be asked for their pain score, and if it is more than 4 out of 10 (NAS): to receive the 1st dose within 5 minutes after coming to PACU: 0.04mg/kg morphine units (rounding off to the nearest 1 ml or 0.5 ml); with a maximum of 3 mg of morphine equivalents. Repeat doses: 0.02 mg/kg morphine units every 5-10 minutes to titrate for analgesia and side effects (rounding off to the nearest 1 ml or 0.5 ml)
1601705|NCT02223364|Drug|Peripheral nerve blocks with Bupivacaine|Subjects received Bupivacaine 0.5% preoperatively, then Bupivacaine 0.2% upon post anesthesia care unit (PACU) arrival via femoral nerve block, then Bupivacaine 0.25% via single-injection sciatic nerve.
1601706|NCT02223364|Drug|Intra articular injection with Ropivacaine|Subjects received an intra articular injection with Ropivacaine, a total volume of 120 milliliters (mL) injected in the periarticular structures by the surgeon. Ropivacaine dose depended upon body weight: 50-74.9 kg: 200 mg, 75-99.9 kg: 300 mg, 100-125 kg: 400 mg.
1601707|NCT02223364|Drug|Intra articular injection with liposomal bupivacaine|Subjects received an intra articular injection with liposomal bupivacaine, a total volume of 120 mL injected in the periarticular structures by the surgeon. Patients weighing 50-125 kg received 266mg of Liposomal Bupivacaine.
1601708|NCT02223351|Drug|ASP2151|
1601709|NCT02223351|Drug|ritonovir|
2009632|NCT03197584|Drug|Fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
2009633|NCT03197584|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
1601712|NCT02223312|Biological|TAPA-pulsed DC vaccine|A cycle of low-dose cyclophosphamide (100mg/day) by mouth for 5 days starting seven 7 days prior to the DC vaccine cycle to reduce Treg activity. Low-dose cyclophosphamide will be taken every 14 days for six 6 cycles. A total of 6 vaccines containing 1 x 10^7 TAPA-pulsed DC will be administered SQ every 14 days. The DC vaccine is given on Day 1 of the DCV cycle plus low-dose GM-CSF 50mcg/day SQ x 5 days (Day 1 to Day 4). GM-CSF is administered for 5 days to increase monocyte production and dendritic cell precursors to optimize immune responses.
1601713|NCT02223299|Dietary Supplement|L-tyrosine|6g/d daily for 30 days
1601714|NCT02223299|Dietary Supplement|L-Tryptophan|2g/d daily for 30 days
1601715|NCT02223299|Drug|deplin|15mg daily for 30 days
1601716|NCT02223299|Other|Placebo A|a sugar-pill that looks like a real medication
1601717|NCT02223299|Other|Placebo B|a sugar-pill that looks like a real medication
1601718|NCT02223273|Behavioral|Multifaceted Strategy|"Simulation Based Team Training
Case Manager: a trained person who works in the hospital and is responsible for ensuring the usage of all interventions
Reminders -
Check lists - decision support algorithm
Distribution of educational materials: guidelines and recommendations for best practices"
1601719|NCT02223260|Drug|dabigatran|Experimental dose chosen based on age and weight
1601720|NCT02223247|Drug|TVB-2640|
1601721|NCT02223234|Behavioral|Emails and 4 Home Visits|Weekly emails and 4 home visits with health educator
1601722|NCT02223234|Behavioral|Control|Monthly emails on child health
1601723|NCT02223234|Behavioral|Emails and 2 home visits|Weekly emails and 2 home visits with health educator
1601724|NCT02223221|Procedure|IVF/ICSI|In vitro fertilization or intracytoplasmic sperm injection.
1601725|NCT02223221|Genetic|PGS|Selection of embryos are based on SNP-array-based preimplantation genetic screening for the number of all chromosomes on the 5th day of IVF/ICSI.
1601726|NCT02223221|Other|Without PGS|Selection of embryos are based on morphology criteria on the 5th day of IVF/ICSI.
1601727|NCT02223208|Drug|Ro-CHOEP-21 (PHASE I)|"Romidepsin (dose escalation) Starting dose: 12mg/ms iv day +1 and +8
Dose modification according to toxicity:
14mg/ms day +1 and +8
10mg/ms day +1 and +8
8mg/ms day +1 and +8
CHOEP-21
Doxorubicin 50 mg/ms iv day +1,
Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1,
Cyclophosphamide 750 mg/ms iv day +1,
Etoposide 100mg/ms iv from day +1 to +3
Prednisone100 mg orally from days +1 to +5
PR or CR:Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)"
1601728|NCT02223208|Drug|Ro-CHOEP-21 (PHASE II)|"Ro-CHOEP-21 x 3 cycles
Romidepsin dose according to phase I iv day +1 and +8
Doxorubicin 50 mg/ms iv day +1,
Vincristin 1.4 mg/ms (maximum 2.0 mg total dose) iv day+1,
Cyclophosphamide 750 mg/ms iv day +1,
Etoposide 100mg/ms iv from day +1 to +3
Prednisone100 mg orally from days +1 to +5
PR or CR: Ro-CHOEP-21 for 3 additional cycles followed by stem cell mobilization and transplantation phase (CR --> AUTO-SCT, PR --> ALLO-SCT)"
1601729|NCT02223182|Biological|Viaskin Milk 150 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 150 mcg cow's milk proteins.
1601730|NCT02223182|Biological|Viaskin Milk 300 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 300 mcg cow's milk proteins.
1601731|NCT02223182|Biological|Viaskin Milk 500 mcg|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
1601732|NCT02223182|Biological|Viaskin Placebo|Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
1601733|NCT02223169|Dietary Supplement|Egg albumin-derived peptide|Double-blind intervention study cross-over design with one sachet containing 3g Egg albumin-derived peptide (Tensio-control) or placebo (maltodextrin) in Phase one followed by cross-over in Phase 2.
1601734|NCT02223130|Behavioral|Cognitive Behavioral Therapy techniques|Participants attend 9 weekly group sessions. Each of the weekly sessions is led by a mental health professional and a peer facilitator who use Cognitive Behavioral Therapy techniques to work with participants in tracking their cognitions, emotions and behaviors in response to stressful/discrimination experiences.
1601735|NCT02223117|Biological|Thrombosomes|Freeze-dried platelets
1601736|NCT02223117|Biological|Placebo|
1601737|NCT02223104|Device|Flexima Active|
2009634|NCT03197584|Drug|Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
1601748|NCT02223039|Biological|Placebo|Placebo of AbGn-168H
1601749|NCT02223026|Drug|Linagliptin/metformin FDC|
1601750|NCT02223026|Other|high-fat, high caloric meal|
1601751|NCT02223013|Drug|BIBV 308 SE solution|
1601752|NCT02223013|Drug|BIBV 308 SE capsule L|
1601753|NCT02223013|Drug|BIBV 308 SE capsule S|
1601754|NCT02223000|Drug|BIBV 308 SE solution|
1601755|NCT02223000|Drug|BIBV 308 SE capsule 1|
1601756|NCT02223000|Drug|BIBV 308 SE capsule 2|
1601757|NCT02222987|Drug|Terbogrel|
1601758|NCT02222987|Drug|Clopidogrel|
1601759|NCT02222974|Drug|BIIR 561 CL|
1601760|NCT02222974|Drug|Placebo|
1601761|NCT02222961|Drug|BIIR 561 CL|
1601762|NCT02222961|Drug|Placebo|
1601763|NCT02222948|Drug|Vatelizumab|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1601764|NCT02222948|Drug|Placebo (for Vatelizumab)|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1601765|NCT02222935|Behavioral|Balance Exercise Training|Balance exercise - 5 type (single leg squat, dead lift, step ups, forward reaches), 10 Repetition Maximum, 2 sets, five times a week and 2 weeks
1601766|NCT02222935|Behavioral|Routine Back exercise program|Back strengthening 5 exercises - pelvic bridges, prone plank, side plank, dead bug and prone lift ups, 10 Repetition Maximum, 2 sets, five times a week, 2 weeks
2009635|NCT03197584|Drug|omega-3 acid ethyl esters|omega-3 acid ethyl esters
2009636|NCT03197584|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
2009637|NCT03197584|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy (SBRT)
2009638|NCT03197584|Biological|ALT-803|Recombinant human super agonist IL-15 complex
1601774|NCT02222883|Genetic|Testing of BRCA status regarding germline and somatic mutation|
1601775|NCT02222870|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2014-2015 formulation)
1601776|NCT02222870|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2014-2015 formulation)
1601777|NCT02222844|Other|Preoperative MRI scan|Standard preoperative CT of abdomen, chest and pelvis plus interventional preoperative MRI scan.
1601778|NCT02222831|Procedure|Day 0 denudation and time lapse culture on IVF-oocytes.|
1601779|NCT02222818|Device|Conducted AF Response (CAFR)|The CAFR algorithm is currently available in the Medtronic market-released devices and intended to promote delivery of CRT pacing during conducted AT/AF episodes.
1601780|NCT02222818|Device|Conducted AF Response Plus (CAFRPlus)|The CAFRPlus algorithm is part of the CRTee feature set. This feature set has a diagnostic element that tracks the loss of effective CRT pacing that is occurring over time, both during normal sinus rhythm (NSR) and during AF. It also has an interventional element (i.e. CAFRPlus) that uses this evaluation of effective CRT pacing to adjust the pacing rate during AF to decrease loss of effective CRT pacing.
1601781|NCT02222805|Procedure|Early (≤30 seconds) cord clamping|Early (≤30 seconds) cord clamping of the umbilical cord after delivery.
1601782|NCT02222805|Procedure|Delayed (≤180 seconds) cord clamping|Delayed (≤180 seconds) cord clamping of the umbilical cord after delivery.
1601783|NCT02222766|Behavioral|Parents and Tots Together Program|Group-based parenting program, 9 sessions offered weekly
1601784|NCT02222766|Behavioral|Control|Minimal attention control- 9 weekly mailed information on general child development
1601785|NCT02222740|Drug|10 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
1601786|NCT02222740|Drug|20 mg of Hydrocodone Bitartrate Extended Release (HC-ER)|Schedule II Class
1601787|NCT02222727|Drug|Donepezil|Loading 20 mg dose of donepezil on first day of recruitment followed by once daily 5 mg dose for subsequent twenty days
1601788|NCT02222714|Biological|3K3A-APC|3K3A-APC, diluted in 0.9% sodium chloride in water, given as 100 mL IV infusion
1601789|NCT02222714|Drug|Placebo|Matching placebo, 0.9% sodium chloride in water, given as 100 mL IV infusion
1601790|NCT02222688|Drug|cirmtuzumab|
1601791|NCT02222675|Procedure|Sonography assisted breast surgery|
1601792|NCT02222675|Procedure|Conventional breast surgery|
1601793|NCT02222662|Other|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
1601794|NCT02222662|Other|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
1601795|NCT02222649|Dietary Supplement|Vitamin D3|High dose of 200,000 IU of cholecalciferol orally in a single dose
1601796|NCT02222649|Dietary Supplement|Placebo|Capsules of starch, no therapeutic action
1601797|NCT02222636|Drug|Normal saline,1 milliliter|Normal saline,1 milliliter, 20 minutes before anaesthetic induction
1601798|NCT02222636|Drug|Dexmedetomidine 1 μg.kg-1,1 milliliter|Dexmedetomidine 1 μg.kg-1,1 milliliter,20 minutes before anesthesia induction
1601799|NCT02222636|Drug|Dexmedetomidine 2μg.kg-1,1 milliliter|Dexmedetomidine 2μg.kg-1,1 milliliter,20 minutes before anesthesia induction
1601800|NCT02222636|Drug|Anesthesia induction, 8% sevoflurane|Inhalation induction with 8% sevoflurane
1601842|NCT02222324|Drug|Placebo|8 placebo tablets matching E2609
2009639|NCT03197584|Biological|ETBX-021|Ad5 [E1-, E2b-]-HER2 vaccine
2009640|NCT03197584|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
2009641|NCT03197584|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1 vaccine
2009642|NCT03197584|Biological|GI-4000|Heat-killed S. cerevisiae yeast expressing the mutated RAS oncoproteins
2009643|NCT03197584|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
2009644|NCT03197584|Biological|haNK®|NK-92 [CD16.158V, ER IL-2]
2009645|NCT03197571|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
1601801|NCT02222636|Drug|Anesthesia maintenance, 2%~3% sevoflurane,fentanyl|2%~3% sevoflurane,inhalation. fentanyl,2μg.kg-1.min-1,intravenous infusion
1601802|NCT02222623|Drug|Glargine|Glargine given as 100% total daily dose with breakfast. The initial dose will be calculated using the patient's weight or using their basal insulin doses prior to hospitalization.
1601803|NCT02222623|Drug|NPH|NPH 2/3 of the total daily dose given with breakfast, 1/3 of the total daily dose given at bedtime. The initial dose is calculated using the patient's weight or using the basal insulin dose prior to hospitalization.
1601804|NCT02222610|Drug|0.5 mg ranibizumab|
1601805|NCT02222610|Procedure|Targeted Retinal Photocoagulation (TRP)|TRP to areas of retinal ischemia
1601806|NCT02222597|Device|infrascanner|
1601807|NCT02222571|Behavioral|Parents and Tots Together Program|Group-based parenting program, 9 weeks delivered in a community setting
1601808|NCT02222571|Behavioral|Supervision for Safety|group-based safety intervention for parents
1601809|NCT02222558|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
1601810|NCT02222545|Biological|OMS721|
1601811|NCT02222532|Drug|Tetronine|Oral T3 was given 1 microgram/kgBW q6h since induction of anesthesia for 11 doses (for 60 hours)
1601812|NCT02222532|Drug|Placebo|Placebo was sacharum lactis, given q6h since induction of anesthesia for 11 doses (for 60 hours)
1601813|NCT02222519|Drug|Rocuronium|Rocuronium 0.6mg/kg iv single dose
1601814|NCT02222506|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 24 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for diabetic foot ulcers.
1601815|NCT02222493|Biological|PF-06438179|PF-06438179 will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
1601816|NCT02222493|Biological|Infliximab|Infliximab will be administered by intravenous infusion at an initial dose of 3 mg/kg at 0, 2 and 6 weeks, then every 8 weeks.
1601817|NCT02222480|Drug|Fimasartan|
1601818|NCT02222480|Drug|Hydrochlorothiazide|
1601819|NCT02222480|Drug|Placebo|
1601820|NCT02222467|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for venous leg ulcers.
1601821|NCT02222454|Device|KLOX BioPhotonic System|KLOX BioPhotonic System (Multi-LED Light and KLOX Photo Converter Wound Gel) will be administered until wound closure or for a maximum of 16 weeks, followed by a 8-week follow-up period, in association with Standard Of Care for pressure ulcers.
1601822|NCT02222441|Drug|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
1601823|NCT02222441|Drug|Palbociclib plus Modafinil|For Cohort 1, modafinil 200 mg once daily for 7 days, followed by 400 mg once daily for 25 days; on Day 28, a single oral 125 mg dose of palbociclib will be given with modafinil after a meal, followed by 120 hours of PK sample collection.
1601824|NCT02222441|Drug|Palbociclib alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection.
1601825|NCT02222441|Drug|Palbociclib plus pioglitazone|For Cohort 2, pioglitazone 45 mg once daily for a total of 19 days; On Day 15, a single oral 125 mg dose of palbociclib will be given with pioglitazone after a meal, followed by 120 hours of PK sample collection.
1601826|NCT02222428|Drug|BI 1744 CL/BI 54903 XX FDC|
1601827|NCT02222428|Drug|BI 54903 XX|
1601828|NCT02222428|Drug|BI 1744 CL|
1601829|NCT02222415|Dietary Supplement|Exercise + Protein drink|
1601830|NCT02222402|Behavioral|INTRA-DIALYTIC EXERCISE TRAINING|
1601831|NCT02222389|Behavioral|CM for Alcohol|"Escalating reinforcement for alcohol abstinence.
Alcohol-negative CM Participants draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
1601832|NCT02222389|Behavioral|CM for drugs|"Escalating reinforcement for drug abstinence.
Drug-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
1601833|NCT02222389|Behavioral|CM for both substances|"Escalating reinforcement for drug and alcohol abstinence.
Drug- and alcohol-negative participants will be invited to draw chips out of a bowl containing 500 chips. Fifty percent of the chips will say good job! or a similar encouraging phrase, 41.8% of the chips will result in a small prize, 8% will result in a large prize, and 0.2% will result in a jumbo prize."
1601834|NCT02222389|Behavioral|Non-Contingent group|Compensation for Non-Contingent control group participants is dependent only on providing urine samples, regardless of whether the urine tests are negative for alcohol and/or drugs.
1601835|NCT02222376|Drug|Pirfenidone|Twice a day topical application
1601836|NCT02222376|Procedure|Debridement|Weekly ulcer debridement
1601837|NCT02222363|Drug|VLX600|Patients will receive a dose of VLX600 by 4-hr intravenous infusion using a central venous catheter on Days 1, 8, and 15 of each 28-day treatment cycle. There are the following dose cohorts: 10, 20, 40, 80, 160, and 210 mg VLX600. It is anticipated that patients will receive 6 treatment cycles. In the absence of unacceptable toxicity and disease progression, patients have the option of continuing treatment beyond 6 cycles, if the investigator determines that the patient may benefit further from it.
1601838|NCT02222350|Drug|10mg DS-8500a tablet|
1601839|NCT02222350|Drug|75mg DS-8500a tablet|
1601840|NCT02222350|Drug|placebo|
2009646|NCT03197571|Biological|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
2009647|NCT03197571|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
2009648|NCT03197571|Drug|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
2009649|NCT03197571|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
2009650|NCT03197571|Drug|5Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
1601843|NCT02222324|Drug|E2609|E2609 will be administered as 8 tablets
1601844|NCT02222324|Drug|Moxifloxacin|Administered as 1 tablet with 7 tablets of placebo matching E2609
1601845|NCT02222311|Other|Blood Samples|
1601846|NCT02222298|Procedure|Video assisted ablation of pilonidal sinus|A 5-phases' technique. The 1st phase is to insert the endoscope through the external opening (orifice). In the patients that had more than one opening the lower pit is used for access. The 2nd phase is to identify the sinus cavity and its lateral tracks. The endoscope is advanced along the pathway using slow movements, left/right and up/down. These manoeuvres and the saline solution, used as distension medium, allow the sinus cavity to accommodate the endoscope. Additionally mechanical adhesiolysis with the forceps grasping could be useful. The 3rd phase is to identify the presence of hair and its removal. The 4th phase phase is to obtain complete ablation of sinus cavity. The sinus cavity and its lateral tracks are destroyed with the electrode under continuous direct vision. The 5th phase is to obtain the accurate cleaning of sinus cavity. The saline solution flow allows the elimination of any necrotic material. A Volkmann spoon could be useful to complete the cleaning.
1601847|NCT02222298|Procedure|Bascom Cleft lift procedure|
1601848|NCT02222285|Other|Medical Food : Vayarin_005|
1601849|NCT02222285|Other|Placebo|
1601850|NCT02222259|Procedure|GA and Integrated Care Plan|The intervention will consist of a Geriatric Assessment conducted by a multidisciplinary geriatric oncology team followed by an integrated care plan developed and implemented by the team for those issues identified in the assessment. The study intervention includes contact with the intervention team at 4 points in time during the study: at baseline (to conduct the assessment and develop the integrated care plan), 2-3 weeks by telephone after the clinic visit to evaluate if the plan needs adjustments, at 3 and 6 months (to evaluate the outcomes of the integrated care plan; i.e., did the patient follow all recommendations of the integrated care plan and did the plan lead to the desired outcomes for the problems identified?
1601851|NCT02222246|Drug|Hydromorphone (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
1601852|NCT02222246|Drug|Morphine Sulfate (Standardized, weight-based dosing)|Standardized analgesic management using a SCD specific standard protocol based on NHBLI guidelines (initial opioid dose weight-based).
1601853|NCT02222246|Drug|Hydromorphone (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
1601854|NCT02222246|Drug|Morphine Sulfate (Patient Specific dosing)|Patient specific analgesic management, with specific opioid dosage and frequency based on a protocol developed by a patient's healthcare team.
1601855|NCT02222233|Drug|BI 671800 HEA delayed release (enteric coated) tablet|
1601856|NCT02222233|Drug|BI 671800 HEA solution|
1601857|NCT02222233|Drug|BI 671800 HEA particulate|
1601858|NCT02222220|Drug|Metoclopramide|30 mg/day during 4 weeks
1601859|NCT02222220|Drug|placebo|
1601860|NCT02222207|Drug|Regorafenib, ophthalmic oily suspension (BAY73-4506)|Subjects receive Regorafenib as eye drops
1601861|NCT02222207|Procedure|Sham IVT|Sham injections
1601862|NCT02222207|Drug|Ranibizumab|Subjects receive Ranibizumab as intravitreal injection
1601863|NCT02222207|Drug|Placebo|Placebo eye drops
1601864|NCT02222181|Other|Pharmacotherapy Management|"assessment of patient characteristics as alcoholic, smoker, food, drugs
Pharmacotherapy follow-up
to evaluated medication adherence
Assessment of the individual clinical parameters each patient at baseline and after the educational or pharmacy intervention."
1601865|NCT02222168|Drug|BI 409306|medium dose, oral administration
1601866|NCT02222168|Drug|BI 409306|medium dose, oral administration
1601867|NCT02222168|Drug|BI 409306|medium dose, oral administration
1601868|NCT02222155|Drug|CCX168 low dose plus standard of care|
1601869|NCT02222155|Drug|CCX168 high dose plus standard of care|
1601870|NCT02222155|Other|Placebo BID plus standard of care|
1601871|NCT02222142|Drug|Isoflurane|Comparison between isoflurane and propofol, Retrospective study
1601872|NCT02222129|Drug|Bupivacaine|
1601873|NCT02222129|Drug|liposomal bupivacaine|
1601874|NCT02222116|Device|MGuard Prime|
1601875|NCT02222116|Device|Control BMS DES|
1601876|NCT02222064|Behavioral|Mindfulness|Mindfulness is a psychological intervention based on increasing skills of non-judgemental awareness using meditations. In this study a self-directed 8 week course of mindfulness will be used involving self-help materials in the form of a book and 8 guided meditations on audio files.
1601877|NCT02222051|Behavioral|Tai Chi|traditional chinese martial art meditative movement technique
1601878|NCT02222051|Behavioral|Neck exercises|group exercises for strengthening and stretching neck and back muslces to alleviate neck pain
1601879|NCT02222038|Other|skin biopsy|
1601880|NCT02222025|Other|Injury Prevention Programme|The injury prevention program will be included at the beginning of the usual football training by replacing the traditional warm-up. The programme will be conducted by the coaches at least two times a week (with exception of school holidays). The prevention programme contains seven exercises and lasts about 15 min after familiarisation. Three exercises focus on unilateral, dynamic stability of the lower extremities (hopping, jumping and landing). Further, three exercises emphasize whole body and trunk stability. The last exercise contains rolling movements to improve fall technique. The difficulty of each exercise can be progressively increased in five steps. Players start at the level of difficulty which corresponds to their current performance level. They will proceed to the next level when they perform the exercises with good control. This will be assessed by the coaches.
1601881|NCT02222012|Device|"single channel Multiway Coil®"|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks).
1601928|NCT02221635|Procedure|rTMS + risperidone|Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks,than 2 sessions per week for 2 months, repeat that for 12 months. Meanwhile,risperidone (2-4 mg) was took orally.
1601929|NCT02221635|Drug|Risperidone|Risperidone (2-4 mg) was took orally.
1601882|NCT02222012|Device|"Two channels Multiway stimulator coil® (Brainsway Ltd.)"|"During the two channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together.
10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
1 Hz protocol:
1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)."
1601883|NCT02221999|Drug|Paclitaxel|
1601884|NCT02221999|Drug|Cisplatin|
1601885|NCT02221999|Drug|Gonadotropin-releasing hormone agonist|Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m
1601886|NCT02221999|Drug|Letrozole|
1601887|NCT02221986|Behavioral|Interdisciplinary rehabilitation|
1601888|NCT02221973|Dietary Supplement|sterols and hawthorn powder|there are two dose level of sterols (1.2g/d; 1/8g/d)
1601889|NCT02221960|Biological|MEDI6383|Subjects will receive MEDI6383 until disease progression or adverse event.
1601890|NCT02221960|Biological|MEDI6383 and MEDI4736|Subjects will recieve MEDI6383 and MEDI4736 until disease progression or adverse event.
1601891|NCT02221947|Drug|Bryostatin 1|25 μg/m2 bryostatin 1, single dose via intravenous infusion over 1 hour.
1601892|NCT02221947|Drug|Placebo|Placebo, single dose via intravenous infusion over 1 hour.
1601893|NCT02221934|Device|Altius|Electrical signal
1601894|NCT02221921|Device|MicroPort's Transcatheter Aortic Valve and Delivery System|
1601895|NCT02221908|Device|Mespere Venus 1000 CVP System|
1601896|NCT02221895|Other|Postpartum follow up appointment 2-3 weeks after delivery|experimental arm
1601897|NCT02221895|Other|Postpartum follow up 6-8wk after delivery|control arm
1601898|NCT02221882|Drug|LY3164530|Administered IV.
1601899|NCT02221869|Drug|Xyrem|
1601900|NCT02221856|Procedure|Motion View|Motion View, a software we are using to place brackets virtually on a 3D rendition of a patients teeth, will be used to indirectly bond brackets onto patient's teeth with a 3D printed plastic transfer JIG in which the brackets will be precisely placed on the patients teeth according to the computer-guided software.
1601901|NCT02221856|Procedure|Conventional Orthodontic Treatment|orthodontic treatment using non-customized brackets and stock wires
1601902|NCT02221830|Drug|Oxytocin|Our intervention simply replaces the standardly given normal saline with treatment (normal saline + oxytocin)
1601903|NCT02221817|Procedure|Trochanter bursa injections|
1601904|NCT02221817|Device|Ultrasound|
1601905|NCT02221804|Behavioral|14 days of voluntary step count reduction to no more than 1500 steps/day.|
1601906|NCT02221791|Dietary Supplement|Pure Epicatechin|Participants will consume 100mg of epicatechin (capsule) + 70g white chocolate
1601907|NCT02221791|Dietary Supplement|High flavan-3-ol cocoa|Participants will consume 70g high flavan-3-ol cocoa (100mg epicatechin) + placebo capsule
1601908|NCT02221791|Dietary Supplement|Placebo|Participants will consume 70g white chocolate + placebo capsules
1601909|NCT02221778|Radiation|SBRT|"SBRT will be prescribed according to the Radiation Therapy Oncology Group (RTOG) 1112 protocol using Mean Liver Dose (MLD) as parameter. MLD will be calculated using Liver minus Gross Tumor Volume (GTV). Prescription dose will follow the scheme below:
Prescription dose(Gy) / (MLD) (Gy)
50 / 13
45 / 15
40 / 15
35 / 15.5
30 / 16
27.5 / 17
If the dose constraints cannot be met, prescription will be according to the level immediately bellow.
Treatment will be delivered in 5 fractions in consecutive working days"
1601910|NCT02221765|Drug|PP1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 8, 16, 32, 64 mg.
1601911|NCT02221765|Drug|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
1601912|NCT02221752|Dietary Supplement|Ferrous Sulfate + folic acid|Mothers randomized to receive 2 capsules per day: one with iron (300 mg ferrous sulfate [60 mg elemental iron]) and the other with 0.40 mg folic acid from enrollment to delivery.
1601913|NCT02221752|Dietary Supplement|Folic acid|Mothers randomized to receive 2 capsules per day: one with placebo and one with 0.40 mg folic acid from enrollment to delivery.
1601914|NCT02221739|Drug|Ipilimumab|
1601915|NCT02221739|Radiation|Radiotherapy (IMRT or 3-D CRT)|
1601916|NCT02221726|Drug|JNJ-35684-AAA-023: Size 1; small patch|Placebo (matched to Fentanyl transdermal delivery device system [TDDS]) JNJ-35685-AAA-G-023 TDDS, 5.5 centimeter square (cm^2) will be applied vertically to 1 side of the paraspinal region, replicated 3 times, and worn for 72 hours.
1601917|NCT02221726|Drug|JNJ-35684-AAA-023: Size 2; large patch|Placebo (matched to Fentanyl transdermal delivery device system [TDDS]) JNJ-35685-AAA-G-023 TDDS, 44 cm^2 (Size 1; small patch) will be applied vertically to other side of the paraspinal region, replicated 3 times, and worn for 72 hours.
1601918|NCT02221700|Other|Massage|"Two groups receive massage three times a week for 4 weeks.
Two groups receive massage two times a week for 6 weeks."
1601919|NCT02221700|Behavioral|Questionnaires|3 symptom questionnaires completed at baseline, at weeks 4, 6, 8, 10, and at follow up visit. Questionnaires take about 15-30 minutes to complete in total.
1601920|NCT02221700|Other|Leg Function and Balance Tests|Participants complete tasks such as walking and standing on 1 leg at baseline, at weeks 4, 6, 8, 10, and at follow up visit. Tests should take about 20 minutes to complete.
1601921|NCT02221687|Dietary Supplement|Synbiotic formula|Standard milk formula enriched with a prebiotic fiber and a probiotic strain
1601922|NCT02221687|Dietary Supplement|Control formula|Standard milk formula without pre and probiotic
2009651|NCT03197571|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
2009652|NCT03197571|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
1601926|NCT02221648|Drug|Placebo|Subjects will be randomization to receive either the study drug or the placebo group.
1601927|NCT02221648|Drug|AbobotulinumtoxinA Treatment|Subjects receive intervention injections with the study drug arbobotulinumtoxinA.
1601930|NCT02221622|Drug|Allopregnanolone injection (intravenous solution)|Allopregnanolone intravenous infusion
1601931|NCT02221622|Drug|Placebo injection (intravenous solution)|Placebo intravenous infusion
1601932|NCT02221609|Other|Treatment based on Movement System Impairment model|The analysis and modification of daily activities will be performed by identifying and analyzing the patients activities that provoke their symptoms. The patient will be taught on how to correct his posture and limit the movements that increase the amount of stress on the lumbar spine. The prescription of specific exercises is done based on the patient's classification into one of 5 categories of the MSI model. These exercises consist of practicing the movement tests performed at the initial assessment in a corrected form, emphasizing the control of the lumbar spine movement and increasing movement on the adjacent joints. Patients will also advised to repeat the exercises at home at least once a day. 12 treatment sessions are planned for each patient (2 sessions per week during the first 4 weeks and 1 session per week during the last 4 weeks). Each treatment session has an estimated duration of 45-60 minutes. Patients will register their home exercise in an exercise diary.
1601933|NCT02221609|Other|General exercise|The general exercise program consists of 12 treatment sessions with estimated duration between 45-60 minutes per session (2 sessions per week for the first 4 weeks and 1 session per week in last 4 weeks). Each session is also done individually by a trained physical therapist. The patients perform an exercise program that starts with a 5-minutes warm-up followed by stretching exercises. Those stretching exercises address the six directions of lumbar motion and the lower limbs muscles. The patient also performs strengthening exercises of the trunk muscles. Based on correct performance of the exercises, the subject may progress through increased load as tolerated. He is also advised to perform these exercises at home and receive figures of the exercises with written instructions. The exercise program will be adapted according to American College of Sports Medicine recommendations (Garber et al., 2011). Patients will register their home exercise in an exercise diary.
1601934|NCT02221596|Dietary Supplement|vitamin D|50,000IU/wk of vitamin D3
1601935|NCT02221596|Other|aerobic training|7 days of treadmill training during the 13th week of study
2009653|NCT03197571|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
2009654|NCT03197571|Drug|Lovaza|Omega-3-acid ethyl esters
2009655|NCT03197571|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
1601939|NCT02221570|Drug|Baclofen|Baclofen, a derivative of gamma-aminobutyric acid, is a muscle relaxant and an antispastic agent. It was introduced in 1966 as a possible treatment for spasticity due to corticospinal tract lesions. Baclofen was also tested with promising results in the treatment of other medical disorders such as cluster headaches, gastroesophageal reflux disease,chronic hiccups and cough.
1601940|NCT02221557|Device|easy-graft (beta-Tricalcium Phosphate)|
1601941|NCT02221544|Device|Low-frequency repetitive Transcranial Magnetic Stimulation|"Participants will receive treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions). In each session patient will receive repetitive Transcranial Magnetic Stimulation using a stimulation frequency of 10 Hz for half an hour.
The treatment is done by attaching an electromagnetic coil to the scalp using a special hat. Each patient has a personal hat which serves him throughout the entire process. The treatment is performed without anesthesia and patient fully conscious. During the treatment he sits comfortably on a chair, meanwhile the magnetic field passes through the skull into the brain."
1601942|NCT02221544|Device|rTMS maintenance|Same treatment as in rTMS treatment intervention, but only once a week for a month
1601943|NCT02221544|Device|Sham|Participants will receive sham treatment at a frequency of 3 sessions per week for 4 weeks (12 sessions total) for half an hour each session. The treatment is done by attaching an electromagnetic coil to the scalp but without turning on the magnetic field.
1601944|NCT02221544|Device|Sham maintenance|The same as Sham stimuli intervention, but once a week for a month
1601945|NCT02221531|Drug|Carbetocin Short-infusion|Short-infusion of Carbetocin 100 microgram as compared to bolus application of Carbetocin 100 microgram (double dummy method)
1601946|NCT02221531|Drug|Carbetocin Bolus application|Carbetocin 100 microgram given intravenously as a bolus application over about 15 seconds
1601947|NCT02221518|Behavioral|Exposure & Response Prevention (EX/RP)|Exposure and Response Prevention (EX/RP) is a type of Cognitive Behavioral Treatment for treating OCD.
1601948|NCT02221505|Drug|LOP628|
1601949|NCT02221492|Drug|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
1601950|NCT02221492|Drug|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
1601951|NCT02221479|Drug|plerixafor GZ316455|Pharmaceutical form:vial Route of administration: subcutaneous injection
1601952|NCT02221479|Drug|Filgrastim|Pharmaceutical form:vial Route of administration: subcutaneous injection
2009656|NCT03197571|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL-15N72D:IL-15RαSu/IgG1 Fc complex]
1601954|NCT02221440|Device|Low flow nasal oxygen|Oxygen will be administered by nasal catheter at a flow rate of 2 L/min. The therapy will continue until after delivery
1601955|NCT02221427|Other|Dynamic progression curve|Guideline which takes into account the dilatation of the cervix on admission and calculates the expected progression during the active phase of the first stage of labour based on this finding. Labour dystocia in the second stage of labour is diagnosed if lasting longer than two hours and 45 minutes, three hours and 30 minutes for women with epidurals or if the expulsion phase lasts longer than 60 minutes. This guideline is based on the labour progression curve by Zhang.
1601956|NCT02221427|Other|Static labour progression curve (F)|
1601957|NCT02221414|Drug|Linagliptin/Metformin FDC|
1601958|NCT02221414|Drug|Linagliptin|
2009657|NCT03197571|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
2009658|NCT03197571|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
2009659|NCT03197571|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
2009660|NCT03197571|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
2009661|NCT03197571|Biological|GI-4000|RAS yeast vaccine
2009662|NCT03197571|Biological|GI-6207|CEA yeast vaccine
2009663|NCT03197571|Biological|GI-6301|Brachyury yeast vaccine
2009664|NCT03197571|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)
2009665|NCT03197025|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg (based on total body weight) IV infused over 15 minutes approximately every 12 hours for a maximum of two doses.
1601960|NCT02221401|Drug|Linagliptin/Metformin FDC|
1601961|NCT02221401|Drug|Linagliptin|
1601962|NCT02221401|Drug|Metformin|
1601963|NCT02221388|Drug|BI 671800 HEA, 200 mg tablets|
1601964|NCT02221388|Drug|BI 671800 HEA EC, 200 mg tablets|
1601965|NCT02221388|Drug|BI 671800 HEA, 50 mg tablets|
1601966|NCT02221388|Drug|BI 671800 ED, 100 mg capsules|
1601967|NCT02221388|Other|Standard meal|
1601968|NCT02221375|Drug|BHT low|
1601969|NCT02221375|Drug|BHT medium|
1601970|NCT02221375|Drug|BHT high|
1601971|NCT02221375|Drug|BI 54903 XX low|
1601972|NCT02221375|Drug|BI 54903 XX medium 1|
1601973|NCT02221375|Drug|BI 54903 XX medium 2|
1601974|NCT02221375|Drug|BI 54903 XX high|
1601975|NCT02221375|Drug|Ciclesonide|
1601976|NCT02221349|Device|Potassium oxalate|Professionally applied (liquid) and self applied (gel)
1601977|NCT02221349|Drug|Sodium fluoride paste|Toothpaste used by subject
1601978|NCT02221349|Drug|Stannous fluoride paste|Toothpaste used by subject
1601979|NCT02221336|Device|The MONARCA II system|Daily electronic monitoring of subjective and objective smartphone measures including a feedback loop
1601980|NCT02221336|Device|Non-MONARCA II system|Daily use of smartphone for normal communicative purposes. No self-monitoring in the MONARCA II system.
1601981|NCT02221323|Drug|Insulin LISPRO|
1601982|NCT02221310|Drug|Gemtuzumab Ozogamicin|Gemtuzumab Ozogamicin 7.5 mg/m^2/dose given IV over 2 hours once during conditioning
1601983|NCT02221297|Dietary Supplement|Supplement product with plant stanol ester|2 grams plant stanols consumed with a meal daily for 3 to 4 weeks
1601984|NCT02221284|Drug|Alogliptin|Alogliptin tablets
1601985|NCT02221271|Drug|NPB-01|
1601986|NCT02221258|Biological|FURESTEM-RA Inj.|Patients will be treated FURESTEM-RA Inj.+DMARDs(Disease-Modifying antirheumatic drugs)
1601987|NCT02221245|Procedure|Tumor Biopsy via Ultrasound Endoscopy|The staging ultrasound endoscopy is performed on patients previously diagnosed with esophageal cancer via diagnostic biopsy. The staging ultrasound identifies affected lymph nodes and depth of tumor to the esophageal wall. The tumor sampling is via a biopsy forcep (one pass to obtain 100 cells).
1601988|NCT02221232|Drug|Chloraprep|Apply topically.
1601989|NCT02221232|Drug|ZuraPrep|Apply topically.
1601990|NCT02221232|Drug|ZuraPrep Vehicle|Apply topically.
1601991|NCT02221219|Drug|Indomethacin|indomethacin at standard dose for prevention of intraventricular hemorrhage in preterm infants
1601992|NCT02221219|Procedure|delay in umbilical cord clamp at birth|provision of a ~45 second delay of umbilical cord clamping at birth in preterm infants (recorded in delivery note)
1601993|NCT02221219|Drug|placebo infusion|saline infusion to match input of indomethacin treatment group (and serve as drug-dosing 'blinding' for bedside staff)
1601994|NCT02221219|Procedure|immediate cord clamp at birth|no delay in umbilical cord clamp; <10sec (recorded in delivery note)
1601995|NCT02221206|Device|Mini-Screw implant|Mini-screw implants (VectorTASTM8*1.4mm, Ormco Corporation, USA) were placed between maxillary first molar and second molar after local anesthetic on both sides
1601996|NCT02221193|Other|traditional mouth rinsing and site-specific mouth rinsing (crossover)|blinded prospective, descriptive correlational crossover cross-section clinical trial conduct during the month of Ramadan in the lunar Hajri year 1434 AH (10 July 2013-8 August 2013) in Albaha province in Saudi Arabia involving the application of Listerine® Cool Mint® mouth rinse by either the traditional panoral rinsing method or a site-specific disinfection method targeting the subgingival and supragingival plaque and the posterior third of the tongue dorsum while avoiding the remaining locations within the oral cavity
1601997|NCT02221180|Drug|Canagliflozin and Metformin Immediate Release (IR) Fixed Dose Combination [FDC]|Participants will receive 1 IR FDC tablet containing canagliflozin 150 mg and metformin 500 mg orally under fed or fasted condition in each treatment period as per treatment sequence.
1601998|NCT02221180|Drug|Canagliflozin|Participants will receive canagliflozin 150 mg (50 mg+100 mg oral tablet) under fed or fasted condition in each treatment period as per treatment sequence.
1601999|NCT02221180|Drug|Metformin|Participants will receive metformin 500 mg tablet orally under fed or fasted condition in each treatment period as per treatment sequence.
1602000|NCT02221167|Other|Donor Milk|"breastfeeding plus 10 ml of donor milk by syringe after each breastfeeding until mother's milk comes in."
1602001|NCT02221154|Dietary Supplement|Inofolic®|
1602002|NCT02221154|Other|Gonadotropins; Folic Acid|standard ovarian stimulation
1602003|NCT02221115|Device|Google Glass|The device is a wearable, voice-controlled Android device that resembles a pair of eyeglasses and displays information directly in the user's field of vision
1602004|NCT02221102|Drug|Aspirin|non-steroidal anti-inflammatory drugs
1602005|NCT02221102|Drug|edoxaban|orally active direct factor Xa inhibitor
1602006|NCT02221102|Drug|placebo|
1602007|NCT02221089|Drug|Escherichia coli Endotoxin|dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
1602008|NCT02221089|Dietary Supplement|Retaron®|Dosage 1 capsule Retaron® per day.: Lutein 10mg, Zeaxanthin 2mg, Fishoil 500mg (with 250 mg DHA, 30 mg EPA), Vitamin C 100mg, Zinc 10mg, Selen 25µg, Vitamin E 25mg, Taurin 50mg, Aroniaextract 50mg, administered for 14 days
1602009|NCT02221089|Other|Placebo|Placebo capsules identical in appearance to Retaron capsules
1602010|NCT02221076|Device|Confocal Laser Endomicroscopy (CLE)|Real-time microscopic imaging of living tissue during the standard procedure
1602011|NCT02221063|Other|Thiamin fortified fish sauce (low concentration)|Low concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
1602012|NCT02221063|Other|Thiamin fortified fish sauce (higher concentration)|Higher concentration thiamin fortified fish sauce will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
1602013|NCT02221063|Other|Placebo fish sauce|Fish sauce fortified only with iron, not thiamin, will be consumed ad libitum for 6 months, with biweekly monitoring and evaluation to assess fish sauce usage by household and to re-stock fish sauce within the home.
1602014|NCT02221037|Drug|GSK2862277|"It is available as 26 milligrams (mg) white to off-white, uniform lyophilized cake that will be reconstituted (using reconstitution fluid formulated with polysorbate 80 in Water for Injection) to 40 mg/vial of Lyophile for reconstitution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
1602015|NCT02221037|Drug|Placebo|"It is a clear, colorless to pale yellow liquid, will be administered in volume to match active dose as solution for inhalation with duration of nebulisation as approximately 3-5 min and will be administered using Pari eFlow with s30 mesh device."
1602016|NCT02221024|Procedure|Flushing with positive pressure|Placement of a sterile plug (MicroClave ICU Medica, a neutral displacement connector) on the needle cannula and flushing with positive pressure with saline solution (BD PosiFlush XS Syringes, filled with 3 ml of saline)
1602017|NCT02221024|Drug|Normal saline|
1602018|NCT02221024|Device|MicroClave ICU Medica|
1602019|NCT02221011|Device|Shock wave|"Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs) is conveyed by an appropriate generator to a specific target area with an energy density in the range of 0.003-0.890 mJ/mm2.
Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies, calcific tendinitis of the shoulder, lateral epicondylitis, plantar fasciitis, and several tendon diseases."
1602020|NCT02220998|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
1602021|NCT02220998|Drug|SOF|SOF 400 mg tablet administered orally once daily
1602022|NCT02220998|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
2009666|NCT03197025|Biological|E6 TCR|On day 0, the E6 TCR cells will be administered one time, intravenously over 20 to 30 minutes
2009667|NCT03198078|Drug|Brexpiprazole (OPC-34712)|Once-daily, tablets
2009668|NCT03198078|Drug|Aripiprazole|Once-daily, tablets
2009669|NCT03198078|Drug|Placebo|Once-daily, tablets
2009670|NCT03195348|Other|HBF Bed Rest|7 days of bed rest on hyper-buoyancy floatation (HBF)
2009671|NCT03196297|Drug|Concizumab|0.15 mg/kg (with potential stepwise dose administration to 0.25 mg/kg) administered daily s.c (subcutaneously, under the skin). Treatment duration is 24 weeks in the main phase, and 52 weeks in the extension phase
2009672|NCT03196297|Drug|Turoctocog alfa|Breakthrough bleeding episodes will be treated by the patients at home with turoctocog alfa at the discretion of the study doctor, who will also choose dose levels
2009673|NCT03195517|Other|Physical exercise|
2009674|NCT03194659|Dietary Supplement|Choline|Choline chloride is a water soluble choline salt that will be provided in a juice solution to participants to be consumed daily. The intervention will increase dietary choline intake by 500mg/day.
2009675|NCT03194555|Drug|ALLOD-2 Capsules|One capsule contains component A and one capsule contains component B taken together twice daily for 12 weeks.
1602034|NCT02220972|Drug|Perampanel|
1602035|NCT02220972|Drug|Placebo|
1602036|NCT02220959|Other|walk test|patients will be encouraged to walk a 60 meter distance under 1 minute and FVC will be measured before and after the walk test
1602037|NCT02220946|Device|Vaginal Electrical Stimulation|A vaginal probe inserted, and a medium frequency (50 Hz) alternating current was administered for 5 seconds on, 5 seconds off. the intensity of the current was started at 0 mA, and gradually increased until pelvic muscle contractions was observed, then increased according to patient tolerance. each patient received a 20 minute session once a week for total 8 session
1602038|NCT02220933|Drug|MD1003 100mg capsule|
1602039|NCT02220933|Drug|Placebo|
1602040|NCT02220920|Drug|Canagliflozin (TA-7284)|The patients will receive Canagliflozin orally for 16 weeks
1602041|NCT02220920|Drug|Placebo|The patients will receive Placebo orally for 16 weeks
1602042|NCT02220920|Drug|Insulin|
1602043|NCT02220907|Drug|Teneligliptin/Canagliflozin|Co-administration of Teneligliptin and Canagliflozin orally once daily for 52 weeks.
1602044|NCT02220894|Biological|pembrolizumab|
1602045|NCT02220894|Drug|carboplatin|
1602046|NCT02220894|Drug|paclitaxel|
1602047|NCT02220894|Drug|pemetrexed|
1602050|NCT02220868|Drug|Sofosbuvir, Ribavirin, and Stribild|
1602051|NCT02220855|Drug|BKM120|
1602052|NCT02220842|Drug|Atezolizumab|During safety evaluation stage, atezolizumab will be administered as 1200 milligrams (mg) intravenous (IV) infusion. During expansion stage, atezolizumab will be administered as either 1200 mg IV infusion or at dose decided from safety evaluation stage.
1602053|NCT02220842|Drug|Obinutuzumab|During safety evaluation stage, obinutuzumab will be administered as 1000 mg IV infusion. During expansion stage, obinutuzumab will be administered as either 1000 mg IV infusion or at dose decided from safety evaluation stage.
1602054|NCT02220842|Drug|Tazemetostat|Tazemetostat 800 mg will be administered orally, twice daily, on Days 1 to 21.
1602055|NCT02220829|Drug|Preventive administration of Rapaflo|Rapaflo treatment: 8 mg daily during 4 months and 8 mg every other day for 2 months.
1602056|NCT02220829|Drug|Standard Care|Administration of alpha-blocker Rapaflo only at onset of symptoms.
1602057|NCT02220816|Behavioral|Competitive training|30 sessions of competitive cognitive training; 3 - 5 sessions/week; duration 45 min
1602058|NCT02220816|Behavioral|Non-Competitive Training|30 sessions of non-competitive cognitive training; 3 - 5 sessions/week; duration 45 min
1602059|NCT02220803|Drug|Acetazolamide|Acetazolamide, 250mg tablets, will be administrated as multiple doses. Dosing of acetazolamide will be up-titrated during 3 days according to manufacturer instruction and titration scheme of the study. Maximum daily dosage is 750 mg (equivalent of 3 tablets/daily). Evening medication should be taken 2 hours before bedtime. The total length of Acetazolamide treatment will be 4 weeks (2x2) including 3 days of titration phase of the drug.
1602060|NCT02220803|Device|nasal Continuous Positive Airway Pressure (nCPAP)|
1602061|NCT02220777|Drug|ASP8477|oral
1602062|NCT02220777|Drug|omeprazole|oral
1602063|NCT02220777|Drug|Placebo|oral
1602064|NCT02220764|Device|Teeth abutment|
1602065|NCT02220764|Device|Implant abutments|
1602066|NCT02220751|Drug|non-surgical periodontal therapy + systemic doxycycline|"A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
Non-surgical periodontal therapy was associated with systemic doxycycline 100 mg/day, for two weeks after an initial dose of 200 mg, started on the day before the first scaling and root planning session. Patients of the PD group had no access to information about antibiotics administration to patients of the PD+DM group."
1602067|NCT02220751|Procedure|Non-surgical periodontal therapy|A program of plaque control with dental prophylaxis and oral hygiene instruction, and the scaling and root planning sessions were included in the non-surgical periodontal therapy. The scaling and root planning was performed by the same operator using curettes and an ultrasonic device, and it was inspected for a second operator. Oral hygiene was reviewed after a week and after a month of periodontal disinfection, followed by dental prophylaxis.
1602068|NCT02220738|Drug|ABT-957|ABT-957 administered twice-daily for 7 days
1602069|NCT02220738|Other|Placebo for ABT-957|Placebo for ABT-957 administered twice-daily for 7 days
1602070|NCT02220725|Biological|Andexanet|
1602071|NCT02220725|Other|Placebo|
1602072|NCT02220712|Drug|OPC-14597 IMD|Administration by injection into the deltoid muscle for a total of 5 doses of 400 mg in 4-week intervals
1602073|NCT02220686|Behavioral|Offer and Report Protocol|Physician advice to stop smoking, referral to state Quitline, and physician considers prescribing nicotine replacement therapy.
1602074|NCT02220673|Drug|BHT 0.1%|
1602075|NCT02220673|Drug|BHT 0.5%|
1602076|NCT02220673|Drug|Placebo for RMT-B|
1602077|NCT02220673|Drug|Placebo for HFA-MDI|
1602078|NCT02220660|Drug|BI 1744 CL|
1602079|NCT02220660|Drug|BI 54903 XX|
1602080|NCT02220660|Drug|BI 1744 CL + BI 54903 XX FDC|
1602081|NCT02220660|Drug|Placebo|
1602082|NCT02220647|Drug|Linagliptin/Metformin FDC|
1602083|NCT02220647|Drug|Linagliptin|
1602084|NCT02220647|Drug|Metformin|
1602085|NCT02220634|Drug|Regadenoson|Injection for intravenous administration
1602086|NCT02220621|Device|Crosslinked hyaluronic acid gel|After hysteroscopic adhesiolysis, MateRegen Gel IU is applied into the uterine cavity together with a Foley balloon catheter.
1602087|NCT02220621|Device|Foleys balloon catheter|After adhesivolysis, the Foleys balloon catheter is inserted into the uterine cavityand expanded with normal saline.
1602088|NCT02220608|Biological|Bortezomib|
1602089|NCT02220608|Drug|G-CSF|
1602090|NCT02220595|Procedure|Carotid endarterectomy vs. carotid stenting|
1602091|NCT02220582|Other|MRI|Magnetic Resonance Imaging
1602092|NCT02220556|Procedure|Blood sampling|
1602093|NCT02220543|Other|Back on Track intervention|Biopsychosocial primary care intervention based on multidisciplinary pain rehabiliation programs. The Back on Track intervention comprises 4 individual sessions and 8 group sessions.
1602094|NCT02220543|Other|Primary care as usual|Regular physical therapy in primary care. Physical therapists are recommended by their profession (the Royal Dutch Society for Physical Therapy) to work according to a profession-specific guideline for the treatment of patients with low back pain in primary care settings. Maximally 12 individual sessions (30 minutes each) for a maximum of 8 weeks.
1602095|NCT02220530|Drug|Conscious sedation with iv midazolam and fentanyl.|Sedation group: Conscious sedation with iv midazolam and fentanyl dosed according to age, weight and baseline conditions of the patients.
1602096|NCT02220517|Device|MR-guided in-bore prostate biopsy|Patients of arm A receive a targeted MR-guided in-bore prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken.
1602097|NCT02220517|Device|MRI/US fusion-guided prostate biopsy|Patients of arm B receive a targeted MRI/US fusion-guided prostate biopsy. From each prostate lesion defined in the diagnostic multiparametric MRI two targeted biopsy cores will be taken. Immediately after targeted biopsy patients undergo additional systematic TRUS-guided biopsy (12 biopsy cores)
1602098|NCT02220504|Other|Antipsychotic treatment discontinuation|Withdrawal of antipsychotic medication to stabilized patients.
1602099|NCT02220504|Other|Maintenance antipsychotic treatment|Maintenance antipsychotic medication to stabilized patients.
1602100|NCT02220491|Radiation|Single-fraction radiotherapy|Volumetric modulated arc therapy (VMAT) delivering 15 Gy in one fraction to brain metastases
1602101|NCT02220491|Radiation|Whole-brain radiotherapy|Whole brain radiotherapy delivering 20 Gy in five fractions to brain metastases
1602102|NCT02220478|Device|Posterior Lateral Approach Total Hip Arthroplasty|All patients enrolled in the study are indicated for a total hip replacement, and will receive this replacement from the surgeon via a Posterior Lateral surgical approach.
1602105|NCT02220452|Other|music listening during anesthesia|In patients allocated to the music listening group, audiotapes will be placed on patients' ears, playing soothing and relaxing music throughout anesthesia
1602106|NCT02220452|Other|absence of music listening during anesthesia|In patients allocated to absence of music listening group, audiotapes will be placed on the patients' ears, without however playing any music
1602107|NCT02220426|Drug|Xenon|Inhalation of hyperpolarized xenon gas
1602108|NCT02220400|Drug|Ketamine|
1602109|NCT02220387|Other|exposure to respirable silica dust|History of exposure to respirable silica dust due to job
1602110|NCT02220387|Other|exposure to polycyclic aromatic hydrocarbons exhaust|history of exposure to polycyclic aromatic hydrocarbons exhaust due to job
1602111|NCT02220374|Other|Supportive Finger Tape|Dorsally applied elasticated tape may or may not improve the kinetics of the PIPJ and therefore reduce pain as well as improve function
1602112|NCT02220361|Drug|placebo|received 20 ml intravenous physiological saline The infusion were completed in 30 minutes.
1602148|NCT02220062|Procedure|EUS-CPN|After initially identifying the celiac trunk on endoscopic ultrasound, each injection of 5~10cc ethanol would be performed as bilateral injections at the celiac trunk.
1602113|NCT02220361|Drug|low dose dexmedetomidine|received 0.5μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline The infusion were completed in 30 minutes.
1602114|NCT02220361|Drug|high dose dexmedetomidine|"received 1μgkg-1 intravenous dexmedetomidine (Jiang Su Heng Rui Medicine Co. Ltd, Jiangsu Province, China) diluted to 20ml with physiological saline.
The infusion was completed in 30 minutes"
1602115|NCT02220348|Drug|linaclotide|
1602116|NCT02220335|Procedure|Pulmonary arterial denervation|Contrast pulmonary artery （PA) angiography was performed to localize the pulmonary artery bifurcation level and calculate the PA diameter.Once the anatomy was deemed acceptable, the radiofrequency ablation catheter was introduced into the distal bifurcation area of the main PA.This was then maneuvered within the PA to allow energy delivery to ensure that the electrodes were tightly in contact with the endovascular surface. About two to three ablations at 1-15 W for 240 seconds each point were performed in the distal bifurcation area of the main PA.
1602117|NCT02220335|Drug|Standard treatment|Patients in the standard treatment group will take their baseline anti-heart failure medications at the original doses, without any changes except when medically required.The anti-heart failure drugs treatment is consistent in both arms.Patients in the standard treatment group will take one or combination of the following target drugs: endothelin receptor antagonist, 5'-PDE and prostacyclin. On the other hand, patients in the PADN group do not take any of the target drugs mentioned above.
1602118|NCT02220296|Drug|Insulin 338|Healthy subjects will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
1602119|NCT02220296|Drug|placebo|Healthy subjects will receive a single dose of placebo. Injected subcutaneously (under the skin).
1602120|NCT02220296|Drug|Insulin 338|Subjects with type 1 DM will receive a single dose of insulin 338 in ascending doses. Injected subcutaneously (under the skin).
1602121|NCT02220296|Drug|insulin glargine|Subjects with type 1 DM will receive 0.4 U/kg insulin glargine once daily for 4 days. Injected subcutaneously (under the skin).
1602122|NCT02220270|Device|ASD and PDA closure|
1602123|NCT02220244|Drug|MD1003 100mg capsule|
1602124|NCT02220231|Procedure|capnothorax|After patient positioning, the capnothorax will be created by insufflation of carbon dioxide in patients undergoing video-assisted thoracoscopic extended thymectomy.
1602125|NCT02220218|Drug|Canagliflozin + Metformin Immediate Release (IR) Fixed Dose Combination (FDC)|Canagliflozin and metformin IR FDC tablet 50 mg/500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
1602126|NCT02220218|Drug|Canagliflozin|Canagliflozin tablet 50 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
1602127|NCT02220218|Drug|Metformin IR|Metformin IR tablet 500 mg orally under fed or fasted conditions on Day 1 of any of the 4 treatment periods.
1602128|NCT02220205|Other|PelvicSim|
1602129|NCT02220205|Device|Manufacturer model|
1602130|NCT02220192|Procedure|Focal LEEP|Focal LEEP may or may not cause less damage to the cervix versus standard LEEP. This could potentially be an advantage by avoiding future complications during pregnancy.
1602131|NCT02220179|Behavioral|The Resilience Program|Se the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'
1602132|NCT02220166|Dietary Supplement|Triticum monococcum|
1602133|NCT02220153|Biological|UCB7665 Intravenous 1|"Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion"
1602134|NCT02220153|Biological|UCB7665 Intravenous 2|"Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion"
1602135|NCT02220153|Biological|UCB7665 Intravenous 3|"Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion"
1602136|NCT02220153|Biological|UCB7665 Intravenous 4|"Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion"
1602137|NCT02220153|Biological|UCB7665 Intravenous 5|"Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: intravenous infusion"
1602138|NCT02220153|Biological|UCB7665 Subcutaneous 1|"Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: subcutaneous infusion"
1602139|NCT02220153|Biological|UCB7665 Subcutaneous 2|"Active substance: UCB7665
Pharmaceutical form: solution
Concentration: 140 mg/mL
Route of Administration: subcutaneous infusion"
1602140|NCT02220153|Biological|Intravenous Placebo|"Active substance: Placebo
Pharmaceutical form: solution
Concentration: 0.9 % saline
Route of Administration: intravenous infusion"
1602141|NCT02220153|Biological|Subcutaneous Placebo|"Active substance: Placebo
Pharmaceutical form: solution
Concentration: 0.9 % saline
Route of Administration: subcutaneous infusion"
1602142|NCT02220140|Behavioral|The Resilience Program|See the CONSORT trial protocol at http://myresilience.org/ at the subsite 'about us'.
1602143|NCT02220127|Radiation|GKR with a single shot of the 8 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.
1602144|NCT02220127|Radiation|GKR with a single shot of the 4 mm collimator|Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
1602145|NCT02220114|Drug|Vigabatrin: Vigabatrin new ST formulation then Sabril®|"first treatment phase (V1/D1-V3/D84), in which patients already under Sabril® granules for oral solution and naive patients start the new ST formulation; patients already under Sabril® will start at the same dose and regimen as their usual Sabril®. Dose and regimen for naive patients will be chosen according to SPC.
second treatment phase (V3/D84-V4/D98) in which the patient is switched to Sabril® granules for oral solution (supplied by sponsor) for 15 days at the same dose as under the new ST formulation.
Dose and treatment regimen should be maintained as in first treatment phase.
- At V4/D98, patients who received Sabril® granules for oral solution (supplied by sponsor) continue with marketed Sabril® treatment (or switches to another AED, according to the natural evolution of the patient's condition and upon investigator decision)."
1602146|NCT02220088|Procedure|TACE|Retreatment with TACE: an embolization suspension consisting of mitomycin C, lobaplatin , epirubicin, iodized-oil (Lipiodol; Guerbet, Aulnay-sous-Bois, France), and gelatin-sponge particles.
1602147|NCT02220088|Other|non-TACE|Accept treatments other than TACE,such as sorafenib,radiotherapy,Best support conservative treatment and so on.
1602149|NCT02220062|Procedure|EUS-CGN|First, identify celiac ganglia. If the celiac ganglia are visualized under linear EUS, the injection of 2~3cc ethanol are applied directly into the each ganglia. If the ganglia are not identified by EUS, bilateral EUS-CPN would be performed
1602150|NCT02220049|Drug|Bortezomib|
1602151|NCT02220036|Dietary Supplement|Magnesium Oxide|Patients aged more than 18 years old with diabetic nephropathy having Fasting Blood Sugar more than 126 mg/dL and proteinuria 30-300 mg/dL (microalbuminuria) and Glomerular Filtration Rate more than 90 mL/min will be chosen. Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 12 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic, renal and inflammatory profiles will be measured at the beginning and end of the study as well as anthropometric measurements.
1602152|NCT02220023|Drug|INOmax Inhalation|
1602153|NCT02220010|Device|Pancreatic stent|The plastic stent is introduced in the pancreatic duct by a duodenoscope
1602154|NCT02219997|Device|Clear clip-on glasses|Clip-on glasses with no blue light filtering properties used as a placebo
1602155|NCT02219997|Device|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties similar to ACRYSOF® IOLs
1602156|NCT02219997|Device|ACRYSOF® IQ IOL|AcrySof IQ Aspheric Natural IOL Model SN60WF with UV and blue light filtering properties, previously implanted
1602157|NCT02219997|Device|Clear IOL|Clear IOL, previously implanted
1602158|NCT02219984|Drug|Anticoagulants|
1602159|NCT02219971|Drug|Kukoamine B Mesilate|Kukoamine B Mesilate or placebo single-dose and intravenous(IV) drip for 1 hour in healthy volunteers.
1602160|NCT02219945|Other|5 min exhaled breath sampling with soft nose clamp|study participants are requested to quietly sit and allow exhaled breath to be sampled through mouth piece breathing with nose clamp during 5 min while electronic data are collected in the device and later downloaded on a laptop pc
1602161|NCT02219932|Drug|fampridine|
1602162|NCT02219932|Drug|Placebo|Matched placebo
1602163|NCT02219919|Other|Surgical Group|The surgical group will receive a surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
1602164|NCT02219919|Other|Physical Therapy Group|The physical therapy group will receive 3 treatment sessions of manual therapy including desensitization maneuvers of the central nervous system of 30 minutes of duration, once per week.
1602165|NCT02219906|Drug|Resveratrol|1000mg tid
1602166|NCT02219906|Drug|Placebo|1000mg tid placebo
1602167|NCT02219893|Drug|MOC31PE Immunotoxin|Patients who meet inclusion criteria will be treated with a single intraperitoneal MOC31PE immunotoxin instillation for 6 hours on the first day after CRS and HIPEC
1602168|NCT02219880|Dietary Supplement|Kava (240mg of kavalactones per day)|Kava 60 milligrams per tablet = 240mg of kavalactones per day
1602169|NCT02219880|Dietary Supplement|Placebo|Inert tablets containing vegetable fibre matched for colour, size and consistency to active arm treatment.
1602170|NCT02219867|Drug|Ketamine|Drug (including placebo)
1602171|NCT02219854|Procedure|Laparoscopic gastrectomy|
1602172|NCT02219854|Procedure|Open gastrectomy|
1602174|NCT02219828|Drug|Anakinra|2mg/Kg daily sc up to 100mgday as maximum dose
1602175|NCT02219828|Drug|Placebo|Placebo
1602176|NCT02219815|Behavioral|Prehab Intervention|Pre-operative, structured exercise intervention.
1602177|NCT02219802|Procedure|Treatment according arm|
1602178|NCT02219789|Drug|Alisertib|Given PO
1602179|NCT02219789|Drug|Fulvestrant|Given IM
1602180|NCT02219789|Other|Laboratory Biomarker Analysis|Correlative studies
1602181|NCT02219776|Drug|Benzoyl Peroxide solution Plus Chlorhexidine Scrub|Subjects will be provided instructions on how to use and apply the chlorhexidine using a scrub brush and 1.5 oz bottle of 10% benzoyl peroxide emollient application
1602182|NCT02219776|Other|Standard of Care - Chlorhexidine Scrub only|Subjects will be given instructions on how to apply the Chlorhexidine using a scrub brush
1602183|NCT02219750|Drug|switch twice-daily insulin|"compare two different insuiln regimen in basal insuln base and premixed insulin.
NovoMix 30, drug class:biphasic insulins Lantus, drug class: long-acting insuiln Levemir, durg class: long-acting insulin NovoRapid, drug class: rapid-acting insulin"
1602184|NCT02219737|Drug|Carboplatin|Given IVPB
1602185|NCT02219737|Drug|Etoposide|Given IVPB
1602186|NCT02219737|Drug|Ibrutinib|Given PO
1602187|NCT02219737|Drug|Ifosfamide|Given IV
1602188|NCT02219737|Other|Laboratory Biomarker Analysis|Correlative studies
1602189|NCT02219737|Other|Pharmacological Study|Correlative studies
1602190|NCT02219737|Biological|Rituximab|Given IV
1602191|NCT02219724|Drug|MOXR0916|MOXR0916 will be administered as intravenous infusion on Day 1 of each 21-day cycle.
1602192|NCT02219711|Drug|MGCD516|MGCD516 capsules will be taken with water.
1602193|NCT02219698|Drug|Ibuprofen|
1602194|NCT02219698|Drug|Paracetamol|
1602195|NCT02219685|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
1602196|NCT02219685|Drug|Placebo|Tablet administered orally once daily
1602197|NCT02219672|Drug|Triplitode|"Drug: Triptolide Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
Other Name: Tripterygium Wilfordii Hook F (TwHF) Drug: cART Participants who will be enrolled in this Triplitode group would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir ."
1602198|NCT02219672|Drug|Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir|Participants who will be enrolled in this trial would be treated with Tenofovir plus lamivudine plus Lopinavir / ritonavir plus raltegravir.
1602226|NCT02219477|Drug|ombitasvir/paritaprevir/ritonavir|tablet; paritaprevir co-formulated with ritonavir and ombitasvir
1602227|NCT02219477|Drug|dasabuvir|tablet
1602228|NCT02219477|Drug|ribavirin|tablet
1602229|NCT02219464|Device|Nasopharyngeal catheter|
1602230|NCT02219464|Device|Nasal Cannula|
1602231|NCT02219464|Procedure|Oxygen Supplementation|Initially set at 3 liters/minute
1602199|NCT02219659|Drug|Sedation Protocol with Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning both infusions are stopped and when the patient is awake and met the SBT safety screen, 120-min CPAP trial is performed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
1602200|NCT02219659|Drug|Sedation Protocol Without Daily Interruption|Continuous infusion of fentanyl and midazolam is started and titrated to target pain and RASS score: Fentanyl started at 25 mcg/hr titrated by 25 mcg/hr every 30 minutes to goal pain score; Midazolam started at 1 mg/hr titrated by 1 mg/hr every hour to goal RASS score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when the patient's RASS score is 0 to -2 and the patient passes the SBT safety screen, 120-min CPAP trial is porformed. If the patient meets the CPAP passing criteria, arterial blood gas (ABG) is done and the patient is placed back to the previous ventilator setting. ABG result is notified to the physician for determination for extubation. If the patient does not pass the CPAP trial it is repeated next morning.
1602201|NCT02219659|Drug|Fentanyl Push First|Fentanyl 25 mcg IVP every 5 min up to 4 doses hourly PRN to target pain score for the study design duration (28 days) or for the duration of mechanical ventilation. Every morning when patient's RASS is 0 to -2 and passes the SBT safety screen, 120-min CPAP trial is performed. If patient meets CPAP passing criteria, the physician will be notified for determination of extubation. If patient does not pass, it is repeated next morning. If target RASS is not achieved with fentanyl IV push alone, study team is notified and fentanyl infusion at 50 mcg/hr titrated by 25 mcg/hr every 30 min to target pain score (max 6 hrs). If target RASS score is not achieved with the fentanyl IV, propofol infusion is started at 5 mcg/kg/hr titrated by 5 mcg/kg/hr every 15 min to target RASS score (max 6 hrs).
1602202|NCT02219646|Drug|Vardenafil|Vardenafil 10 mg twice daily for six months
1602203|NCT02219646|Drug|Placebo|Placebo two tablets daily for 6 months
1602204|NCT02219633|Drug|LEO 39652 cream|Applied for 21 days
1602205|NCT02219620|Behavioral|Music, Imagery, Movement|Implementation of music, art and imagery activation, and movement in group modality
1602206|NCT02219620|Behavioral|Social Control|social conversational group facilitated by care counselor
1602207|NCT02219594|Device|CT image for patient with suspected in-stent restenosis|"Gemstone CT or 320-detector row spiral CT was assigned randomly to patient who was suspected in-stent restenosis.About after 10 days,they would accept the check of OCT which wold be the gold standard of in-stent restenosis."
1602208|NCT02219581|Drug|Dexamethasone 10 mg|Two doses of dexamethasone 10 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
1602209|NCT02219581|Drug|Dexamethasone 20 mg|Two doses of dexamethasone 20 mg will be given intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
1602210|NCT02219581|Drug|Standard multimodal pain management regimen|"The standard multimodal postoperative pain management regimen typically used for total knee arthroplasty consists of the following:
Preoperative:
Decadron: 10 or 20mg IV x 1 2 doses, 8 hours apart (if randomized to study group)
Intraoperative:
Ropivacaine: Given intraoperatively. Capsule, subcutaneous tissue/skin. Administered in standard fashion. (300mg)
Toradol: 30mg q 6hr for 6 total doses. 1st dose given intraoperatively at incision. (15 mg if older patient or CrCl low)
Postoperative
Tylenol: 1000mg po q 8hr (scheduled)
Oxycodone: 5mg or 10mg q 3-4hr prn pain, If intolerant to Oxycodone: second agent line is Hydrocodone or Oral Dilaudid
IV Morphine (or Dilaudid): 1 or 2 mg q 2hr prn breakthrough pain
Morphine PCA: only for failure of the above
MS Contin: Use as backup prn pain"
1602211|NCT02219581|Drug|Placebo|Participants in the placebo arm will receive two doses of saline intravenously. The first dose will be given preoperatively within 3 hours of surgery and the second dose will be administered 8 hours after the first dose in the inpatient setting.
1602212|NCT02219568|Procedure|CT enterography|CT enterography is performed using 64-channel multi-detector row CT scanners (Siemens Sensation 64, Siemens Medical solution, Forchiem, Germany). Prior to the scan, 1500 cc of a neutral oral-enteric contrast material, polyethylene glycol (NIFLEC) is taken by the patient. During the scan, 2cc/kg of intravenous contrast (iohexol, Ominipaque Amersham GE-Health care, Princeton, NJ) is injected at the velocity 5 cc/sec.
1602213|NCT02219568|Device|video capsule endoscopy|Video capsule endoscopy is performed using PillCam SB (Given Imaging, Yokneam, Israel). Polyethylene glycol (NIFLEC) is used for bowel preparation.
1602214|NCT02219555|Drug|NaCl and lidocaine placebo/salt water|1ml of 0.9% NaCl and 2 ml of 1% lidocaine placebo/salt water injection at the time of enrollment into the study. If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection which would be the active drug, surgery or any other choice that they and their doctor agree to
1602215|NCT02219555|Drug|triamcinolone acetonide, lidocaine|a mixture of one ml of triamcinolone acetonide, 240 mg/ml, and 2 ml of 1% lidocaine, active medication injection. If patient had an injection but continues to have ongoing symptoms, they and their doctor will be free to choose any treatment for carpal tunnel syndrome, including either a second injection which would be the active drug, surgery or any other choice that they and their doctor agree to
1602216|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL saline
1602217|NCT02219542|Drug|transversus abdominis plane block|transversus abdominis plane block with 20 mL 0.25% ropivacaine
1602218|NCT02219529|Device|MCE|
1602219|NCT02219529|Device|Standard gastroscopy|
1602220|NCT02219516|Drug|RDEA3170|
1602221|NCT02219503|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
1602222|NCT02219503|Drug|Dasabuvir|Tablet
1602223|NCT02219490|Drug|ABT-450/r/ABT-267|tablet
1602224|NCT02219490|Drug|ABT-333|tablet
1602225|NCT02219490|Drug|Ribavirin (RBV)|tablet
1602468|NCT02217917|Drug|Placebo|Matched Placebo administered as single dose subcutaneously with rHuPH20.
1602232|NCT02219464|Procedure|Sedation|Midazolam 2mg IV, Fentanyl 100mcg IV, Propofol 100 mcg/kg/min. Additional doses of propofol at the discretion of the attending anesthesiologist.
1602233|NCT02219451|Other|exercise training|exercise training
1602234|NCT02219438|Drug|ropivacaine|
1602235|NCT02219425|Procedure|endometrial biopsy|
1602236|NCT02219412|Drug|ticagrelor|90 mg bid for 2 weeks
1602237|NCT02219412|Drug|Aspirin|100mg Qd for 2 weeks.
1602238|NCT02219399|Dietary Supplement|600 mg DHA|Pregnant women were given 600 mg DHA in the last trimester of pregnancy
1602239|NCT02219399|Dietary Supplement|300 mg DHA|Pregnant women were given 300 mg DHA in the last trimester of pregnancy and through the first 3 months of breastfeeding
1602240|NCT02219399|Dietary Supplement|Placebo|Pregnant women in the control group received placebo of either olive oil or high oleic acid sunflower oil during the study period
1602241|NCT02219386|Other|Group 1. Deep dry needling|Deep dry needling and stretch. The intervention included DDN of every active MTrP found in the trapezius muscle using a 4 cm x 0.32 mm acupuncture needle as described by Simons et al. (Simons et al., 1999). Once the needle was inserted into the MTrP previously marked by the blinded assessor, local twitch responses (LTRs) were obtained by using Hong's fast-in and fast-out technique, which involves rapid movements of the needle in and out of the MTrP. After four LTRs, the needle was withdrawn and the area was disinfected with alcohol again (Simons et al., 1999). Then, passive stretch was performed on the trapezius muscle.
1602242|NCT02219386|Other|group 2. Passive analitical stretch (performed in both groups)|
1602243|NCT02219373|Drug|Gabapentin|
1602244|NCT02219373|Drug|Oxcarbazepine|
1602245|NCT02219373|Other|Placebo|Patients taking placebo will have placebo dose escalated using similar frequency, periods of time, and volumes as those for the active drugs.
1602246|NCT02219347|Drug|DMARD cessation|Complete cessation of non-biologic DMARD therapy (single or combination of methotrexate, sulphasalazine and/or hydroxychloroquine)
1602247|NCT02219334|Device|NoseFrida|The NoseFrida has four components, the collection container, an interchangeable filter, flexible tubing and a mouth piece. The end of the collection devise is placed on the patient's nostril, a tight seal is made via the vacuum created from suctioning of the mouth piece and secretions are easily aspirated. This device disassembles for quick disinfecting and cleaning.
1602248|NCT02219321|Drug|Lidocaine infusion|Lidocaine intravenous 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg /kg /hour for 4 hours
1602249|NCT02219321|Drug|Saline infusion|A continuous intravenous infusion of saline at the same volume with lidocaine infusion for 4 hours
1602250|NCT02219308|Procedure|Paracervical Block (PCB)|"Drug: 1% Lidocaine Hydrochloride
Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix and 18 mL 1% buffered lidocaine solution evenly distributed between 4 o'clock and 8 o'clock positions of cervix with standard 22 gauge spinal needle.
IUD placement then proceeds"
1602251|NCT02219308|Procedure|No Paracervical Block (Sham PCB)|"Drug: 1% Lidocaine Hydrochloride
Injection of 2 mL 1% buffered lidocaine solution at anterior lip of cervix with standard 22 gauge spinal needle. Capped spinal needle is then held against the cervix at 4 o'clock and 8 o'clock positions of cervix, lightly so as not to cause blancing, indentation, or pain.
IUD placement then proceeds"
1602252|NCT02219295|Dietary Supplement|sweet block|oral application of the above mentioned substances in 300 ml tap water in 5 min. , collection of blood at 0,15,30, 60 ,120,180 minutes for measurement of incretins GIP(gastrointestinal polypeptide) and GLP-1 (glucagon like peptide 1), Protein hormones PYY(Peptide YY),CCK (cholecystokinin), Leptin and Insulin
1602253|NCT02219295|Dietary Supplement|bitter block|oral application of the above mentioned substances in 300 ml tap water, collection of blood samples at -15,0,15,30,60,120,180 min for Insulin, GIP,GLP-1, PYY and glucose
1602254|NCT02219295|Dietary Supplement|umami-block|oral application of umami substances as glutamate with and without IMP, collection of blood samples as above
1602255|NCT02219295|Other|gastroscopy|gastroscopy with and without oral application of saccharin, tissue samples from th upper duodenum by endoscopy for the detection of taste receptor cells in the upper bowel
1602256|NCT02219282|Other|Laryngeal Mask Unique insertion|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than three years experience.
1602257|NCT02219256|Drug|TAK-079|TAK-079 solution
1602258|NCT02219256|Drug|Placebo to TAK-079|Placebo to TAK-079 solution
1602259|NCT02219243|Behavioral|Online Interpretation Training Condition 1|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
1602260|NCT02219243|Behavioral|Online Interpretation Training Condition 2|The online computerized training is a web-based tool that modifies how children interpret ambiguous scenarios.
2009676|NCT03194555|Drug|Placebo Capsules|One capsule contains placebo for component A and one capsule contains placebo for component B taken together twice daily for 12 weeks.
1602264|NCT02219217|Drug|Dolutegravir, Elvitegravir and Cobicistat|
1602265|NCT02219204|Procedure|Acupuncture|
1602266|NCT02219204|Other|Herbal treatment|
1602267|NCT02219191|Drug|puerarin tablet 50 mg|
1602268|NCT02219191|Drug|Atorvastatin tablet 20 mg|Approval No.: H19990258
1602269|NCT02219178|Drug|lenalidomide|25mg days 1 - 14 of 21 day schedule
1602270|NCT02219178|Drug|Subcutaneous bortezomib|1.3mg/m2 days 1, 4, 8, 11 of 21 day schedule
1602271|NCT02219178|Drug|Dexamethasone|20mg on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 day schedule
1602272|NCT02219165|Drug|Intravenous human immunoglobulin|Single administration of IVIG 2 g/kg within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The bottles of IVIG used will contain 10 g of proteins in 100 ml of solution. Thus, to reach a concentration of 2 g/kg, will be administered 1 bottle per 5 kg of body weight (with a maximum of 14 bottles for 70 kg patients and over).
1602595|NCT02216825|Dietary Supplement|Standard vegetarian capsule, L. reuteri NCIMB 30242, escalated dose|
1602273|NCT02219165|Drug|Albumin|Single administration of albumin 4% within the 12 hours following PICU admission (or following the manifestation of the first signs of shock). The solution will be given at the same volume as IVIG (that is: 1 bottle / 5 kg of body weight).
1602274|NCT02219152|Drug|tranexamic acid|
1602275|NCT02219152|Drug|saline|
1602276|NCT02219139|Device|ESTA abutment Roxolid|Enhanced Soft Tissue Attachment surface on Roxolid or machined surface on Roxolid abutment placement.
1602277|NCT02219126|Other|Dietary intervention|
1602278|NCT02219113|Procedure|Arthroscopic surgery|
1602279|NCT02219113|Procedure|Liposuction|
1602280|NCT02219113|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
1602281|NCT02219113|Other|Intraarticular administration of autologous ADRC|
1602282|NCT02219100|Drug|Home administration of 200 mg mifepristone|Home administration of 200 mg mifepristone
1602285|NCT02219074|Device|Sebacia microparticle and laser treatment|
1602286|NCT02219074|Device|Vehicle and laser treatment|
1602289|NCT02219022|Other|Control group|
1602290|NCT02219022|Other|Experimental group|
1602291|NCT02219009|Device|MIND1 System|Subjects will receive aripiprazole tablets embedded with an IEM. They will discontinue their normally prescribed oral aripiprazole tablets and will take the aripiprazole + IEM tablets (eg, at the previously prescribed dose) during the 8-week treatment period for this study. Aripiprazole + IEM tablets must be taken on a once-daily dosing schedule.
1602292|NCT02218996|Other|Psychosocial treatment|Regular psychosocial treatment in clinical outpatient service.
1602293|NCT02218983|Device|Limited Transthoracic Echocardiogram (LTTE, SonoSite Ultrasound)|
1602294|NCT02218983|Other|Usual care|
1602295|NCT02218970|Behavioral|strength training|
1602296|NCT02218970|Behavioral|no training (control)|
1602297|NCT02218957|Procedure|Extended Pouch RYGB|
1602298|NCT02218957|Procedure|Standard RYGB|
1602299|NCT02218944|Behavioral|Response Inhibition Training|The primary purpose of this research is to examine the feasibility and efficacy of a smoking specific response inhibition training program in the context of a quit attempt. The task is based on a modified stop-signal task. The study utilizes a one-way nested design with three conditions.
1602300|NCT02218931|Behavioral|Targeted ESTEEM diet|"The key components of the diet are:
High intake of vegetables, nuts, non-refined grains, legumes and fruits;Moderate to high consumption of fish;Small to moderate intake of poultry and dairy products such as yoghurt and cheese;Low consumption of red meat and processed meat and avoidance of sugary drinks, fast food and high fat food;High fibre;Intake of nuts including walnuts and almonds that are rich sources of monounsaturated and polyunsaturated fatty acids (30 g/day);Olive oil to cook and dress salads as the main source of fat (0.5 l/week)
The intervention will include structured meal plans and grocery lists, recipes for healthy diet and appropriate choices at restaurants"
1602301|NCT02218931|Other|Non-randomised cohort|Non-randomised cohort of women with no metabolic risk factors will be followed up to delivery to collect outcome data
1602304|NCT02218905|Behavioral|Sit to stand test|Subjects will be asked to sit to stand in 40 inches chair for 60 seconds.
1602305|NCT02218879|Drug|Tecfidera|Oral Tecfidera 240 mg bid
1602306|NCT02218840|Other|Smoking topography|Evaluation of cigar smoking topography
1602307|NCT02218827|Drug|Loteprednol Etabonate (FML)|a steroid topical treatment used for moderate dry eye symptoms. this drug causes less increase in intra ocular pressure
1602308|NCT02218814|Procedure|Adductor Canal Block, Bupivacaine|"Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL (100 mg) of Bupivacaine is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration.
Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml of PF Normal Saline is deposited adjacent to the femoral artery at the level of inguinal crease."
1602309|NCT02218814|Procedure|Femoral Nerve Block, Bupivacaine|"Femoral Nerve Block: Under US guidance, using a twitch monitor and sterile technique, 30 ml (100 mg) of Bupivacaine is deposited adjacent to the femoral artery at the level of inguinal crease.
Adductor Canal Nerve Block: Under US guidance and sterile technique 30 mL of PF Normal Saline is deposited adjacent to the femoral artery and deep to the Sartorius muscle, using intermittent aspiration."
1602310|NCT02218801|Other|Evaluation of treatment for liver metastasis|
1602311|NCT02218775|Drug|LY2456302|Mood and Anxiety Disorders
1602312|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of powder comprising of a blend of fluticasone propionate (micronized)(100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One blister to be administered twice daily via DISKUS inhaler
1602313|NCT02218762|Drug|Placebo to Match DISKUS|A blister strip contained within the DISKUS inhaler. Each blister contains a small quantity of lactose and powder comprising of excipient(s). One blister to be administered twice daily via DISKUS inhaler
1602314|NCT02218762|Drug|Fluticasone Propionate/Salmeterol Xinafoate ROTACAPS|A capsule containing a small quantity of powder comprising of a blend of fluticasone propionate (micronized) (100 mcg), salmeterol xinafoate (micronized) (50 mcg) and excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
1602315|NCT02218762|Drug|Placebo to Match ROTACAPS|A capsule containing a small quantity of lactose and powder comprising of excipient(s). One capsule to be administered twice daily via ROTAHALER inhaler
1602316|NCT02218749|Other|Initially triaged to physiotherapist|
1602317|NCT02218749|Other|Initially triaged to physician|
1602318|NCT02218736|Drug|CERC-501|Oral dosing of 10 mg CERC-501 daily for 8 weeks
1602319|NCT02218736|Drug|placebo|oral dosing of 10 mg placebo daily for 8 weeks
1602596|NCT02216812|Drug|500 mg vitamin c, 1 pill per day for 6 weeks|
1602320|NCT02218723|Drug|FF UD-DPI|A blister containing a small quantity of powder comprising of a blend of FF (micronised) and excipient(s) will be administered using UD-DPI. It is available in following dosages: 80mcg/Blister (0.8% Blend); 100mcg/Blister (0.8% Blend); 140mcg/Blister (0.8% Blend); 100mcg/Blister (0.6% Blend)
1602321|NCT02218723|Drug|FF ELLIPTA DPI|A blister strip contained within the ELLIPTA device. Each blister contains a small quantity of powder comprising of a blend of FF and excipient(s) in dose 100mcg/Blister (0.8% Blend)
2009677|NCT03194412|Dietary Supplement|Diet /nutritional|"• Duration:
the first stage - 3 months: 12 weeks
second stage - 3 months: 12 weeks
Each patient collect a detailed menu of the last two days before making the description. Then the menu is analyzed by a nutrition consultant. The role of nutrition consultant is:
make a diet modification to include the products recommended in frailty
modifying eating habits
The diet modification is mainly focused on adequate supply:
vitamin D (according to Central Europe guidelines -2013 for seniors)
protein (according to European Society for Clinical Nutrition and Metabolism (ESPEN recommendations)"
1602325|NCT02218684|Drug|Telmisartan|
1602326|NCT02218684|Drug|Lacidipine|
1602327|NCT02218684|Drug|Placebo|
1602328|NCT02218671|Drug|WE 941 OD tablets|
1602329|NCT02218658|Drug|WE941 OD tablets|
1602330|NCT02218658|Drug|Brotizolam|
1602331|NCT02218645|Drug|WE 941 OD tablets|
1602332|NCT02218645|Drug|Brotizolam|
1602333|NCT02218632|Other|lactose-free diet|standard diet
1602334|NCT02218632|Dietary Supplement|Temporary oral galactose supplements|galactose supplements in the range of physiological galactose production
1602335|NCT02218619|Drug|Tauroursodeoxycholic Acid (TUDCA)|TUDCA at 1750 mg/day x 12 months
1602336|NCT02218619|Drug|Sugar Pill (placebo)|Placebo
1602337|NCT02218606|Drug|Abiraterone acetate 1000 mg po daily|
1602338|NCT02218606|Drug|Cabazitaxel 25 mg/m2 IV|
1602339|NCT02218606|Drug|prednisone 5 mg po BID|
1602340|NCT02218593|Device|WREX orthosis|Upper extremity exoskleton used to assist movement
1602341|NCT02218580|Other|Massage therapy|
1602342|NCT02218580|Other|Standard care|
1602343|NCT02218567|Behavioral|questionnaire qualilty of life|
1602344|NCT02218567|Behavioral|psychological interview|
1602345|NCT02218567|Behavioral|psychological tests|
1602346|NCT02218567|Other|Motor evaluation|
1602347|NCT02218567|Behavioral|Behavioral evaluation|
1602348|NCT02218567|Behavioral|cognitive tests|
1602349|NCT02218554|Genetic|BRONJ|collection of the blood sample from the subject for evaluation of the Micromedic BRONJ Risk Assessment in vitro Diagnostic Assay
1602350|NCT02218541|Device|abutment margin .5mm subgingival|
1602351|NCT02218541|Device|abutment margin 1.5mm subgingival|
1602352|NCT02218528|Dietary Supplement|Plant-based ingredient|
1602353|NCT02218528|Dietary Supplement|No Plant-based ingredient|
1602354|NCT02218515|Procedure|Open Flap Debridement|Open Flap Debridement (Control Group)
1602355|NCT02218515|Biological|EmdogainⓇ(Enamel Matrix Derivative)|Open Flap Debridement+Enamel Matrix Derivative
1602356|NCT02218515|Biological|EmdogainⓇEnamel Matrix Derivative+Autogenous Bone|Open Flap Debridement+EmdogainⓇ(Enamel Matrix Derivative)+Autogenous Bone
1602357|NCT02218502|Other|Ultrasound by general gynaecologist|All patients will undergo an ultrasound by a general gynaecologist at the moment of inclusion. Based on this ultrasound, the gynaecologist will use both the RMI and the simple rules to predict the chance of malignancy.
1602358|NCT02218502|Other|Ultrasound by an expert ultrasonographist|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a second ultrasound scan. This scan is performed by an expert in gynaecological ultrasound.
1602359|NCT02218502|Other|DW-MRI|Patients in which the simple rules yield an inconclusive result (about 20% of all patients) will undergo a diffusion weighted MRI.
1602360|NCT02218502|Other|Give blood sample|Patients in which the simple rules yield an inconclusive result (about 20% of the patients) will be asked for an extra blood sample. We will use these materials to perform translational research and validate new biomarkers in the diagnosis of ovarian cancer.
1602361|NCT02218489|Drug|KPI-121|KPI-121 drug product will be supplied in 0.25% strength as a suspension in opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arm will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
1602362|NCT02218489|Drug|Vehicle|The vehicle control has the same composition as KPI-121 0.25% ophthalmic suspension except it does not contain LE. The vehicle is essentially isotonic and is buffered to maintain pH 5.0 - 7.0. It is a sterile, aqueous solution supplied in the same white, low-density polyethylene plastic dropper bottle with the same white, controlled-drop polyethylene tip and white polypropylene closure as KPI-121 0.25% ophthalmic suspension.
1602363|NCT02218476|Drug|CoQ10|
1602364|NCT02218476|Drug|Placebo|
1602367|NCT02217358|Device|NBI endoscopy|"see in detail description of the study part of the protocol"
1602370|NCT02217332|Drug|dexpramipexole|Dexpramipexole capsule-shaped film-coated tablets at the dose strength of 150 mg administered orally as 1 tablet twice daily (300 mg/day)
1602371|NCT02217319|Drug|Sevoflurane|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min). After induction of anesthesia the propofol infusion is stopped and patients receive 1 MAC Sevoflurane over 30 min. Then the propofol infusion is restarted and Sevoflurane is washed out.
1602372|NCT02217319|Drug|TIVA|Anaesthesia is induced (1-2 mg/kg) and maintained (5-7 mg/kg/h) with propofol and remifentanil (1 µg/kg and 0,2-0,4 µg/kg/min).
1602373|NCT02217293|Device|Pulsed Radiofrequency|Pulsed radiofrequency (PRF) treatment, a relative novel pain intervention at recent decade, was found to be able to alleviate pain by delivering an electrical field and heat bursts at a temperature less than 42°C to neural tissue in the absence of neural injury. The ultrasound-guided PRF was performed before night splint in intervention group.
1602597|NCT02216812|Drug|1 placebo pill for 6 weeks|
1602374|NCT02217280|Drug|Injection with Gadolinium|Gadavist (gadobutrol) injection is a gadolinium-based contrast agent indicated for intravenous use in diagnostic magnetic resonance imaging (MRI) in adults and children (2 years of age and older) to detect and visualize areas with disrupted blood brain barrier (BBB) and/or abnormal vascularity of the central nervous system
1602375|NCT02217267|Drug|Lidocaine|Lidocaine 3 mg/kg dilute in Normal Saline to 50 ml intravenous infusion in 1 hour
1602376|NCT02217267|Drug|Placebo|
1602377|NCT02217254|Procedure|Atrial fibrillation catheter ablation using the Medtronic Arctic Front Ablation System|
1602378|NCT02217254|Device|Cryoballoon catheter ablation|
1602379|NCT02217241|Other|Handoff Workshop|
1602380|NCT02217228|Device|Sebacia microparticles and laser|
1602381|NCT02217228|Device|Vehicle suspension and laser|
1602382|NCT02217228|Device|Sebacia microparticles without laser|
1602383|NCT02218437|Drug|MSC+ATG|MSC+ATG:Starting dose was 0.5-1.0 × 106 cells /kg; And the maximum tolerated dose was 1 ×107 cells /kg after ATG application.
1602384|NCT02218424|Drug|Magnesium|
1602385|NCT02218424|Drug|Normal saline|
1602386|NCT02218411|Other|Exercise training|Exercises routine based on the Otago exercise programme
1602387|NCT02218398|Drug|Albuterol|
1602388|NCT02218385|Device|ForeCYTE Breast Aspirator|ForeCYTE Breast Aspirator used for bilateral collection of Nipple Aspirate Fluid (NAF) for cytologic testing
1602389|NCT02218372|Drug|Fidaxomicin|Oral suspension to be given to patients from Birth (only in Europe and Canada) to &lt; 6 years; oral tablets to be given to patients with ages ≥ 6 years to &lt; 18 years
1602390|NCT02218372|Drug|Vancomycin|Oral liquid to be given to patients from Birth (only in Europe and Canada) to &lt; 6 years; oral capsules to be given to patients with ages ≥ 6 years to &lt; 18 years
1602391|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the AFIS Inline System
1602392|NCT02218359|Drug|Aerosolized placebo|Placebo twice daily for Days 1 -5 to be administered by aerosol using the eFlow Inline System.
1602393|NCT02218359|Drug|Amikacin Fosfomycin Inhalation Solution|Open-label crossover for all patients Days 6-10
1602394|NCT02218346|Drug|AG221|AG221 in fed and fasted conditions
1602395|NCT02218333|Dietary Supplement|Milk|4 dl milk will be consumed daily with breakfast and supper for 12 weeks
1602396|NCT02218333|Dietary Supplement|Placebo|
2009678|NCT03194412|Behavioral|Physical activity|"Duration:
the first stage - 3 months: 12 weeks
second stage - 3 months: 12 weeks
Frequency: twice a week
Duration of each session: 60 minutes
Worksheets for the elderly with frailty syndrome have been developed:
resistance exercises and strength training, which aim to improve muscle strength in the limbs
exercises aimed at improving motor coordination, flexibility and speed
stretching exercises."
2009679|NCT03194412|Combination Product|Comprehensive therapy|"Combination of special diet for elderly (as in Group 1) and regular physical activity into everyday life of the elderly (as in Group 2)
Duration:
the first stage - 3 months- 12 weeks
the second stage - 3 months- 12 weeks Frequency of physical activity: twice a week Duration of each session: 60 minutes"
2009680|NCT03194412|Behavioral|Caregivers of elderly|"Group: formal and informal caregivers of elderly with frailty syndrome Materials and Tools: multimedia presentation about frailty prevention and treatment (nutrition, physical activity, dietary supplement diet).
Duration:
the first stage - 3 months: 12 weeks
the second stage - 3 months: 12 weeks
Frequency: 1 (at the beginning of stage 0, 1 and 2) Duration: 60 minutes"
1602400|NCT02218307|Drug|Mupirocin|
1602401|NCT02218307|Drug|Placebo|
1602402|NCT02218294|Drug|BCX4161|
1602403|NCT02218281|Behavioral|C2Q-Teen app|Commit to Quit (C2Q)-Teen app provides smoking cessation assistance incorporating mindfulness training.
1602404|NCT02218281|Behavioral|NCI's QuitSTART app|NCI's smoking cessation app
1602405|NCT02218281|Behavioral|Written smoking cessation materials only|Receipt of written smoking cessation materials
1602406|NCT02218268|Drug|Pre-meal bolus|Long acting insulin as scheduled per usual routine PLUS rapid/ short acting (bolus) prior to Boost
1602407|NCT02218268|Drug|No meal bolus|Long Acting insulin as scheduled per usual routine (given once daily)
1602408|NCT02218255|Device|Eeva™ results|
1602409|NCT02218242|Device|Intraoperative ultrasound|Intraoperative ultrasound
1602411|NCT02218216|Device|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
1602416|NCT02218190|Drug|Alvimopan|
1602417|NCT02218190|Drug|Placebo|
1602418|NCT02218177|Drug|Aflibercept|anti-VEGF treatment for wet age related macular degeneration
1602419|NCT02218177|Drug|Ranibizumab|anti-VEGF treatment for wet age related macular degeneration
1602420|NCT02218177|Procedure|Combination Photodynamic Therapy|Use of cold laser with an intravitreal injection of dexamethasone to treat wet age related macular degeneration
1602421|NCT02218164|Drug|Pegylated Interferon alpha-2b|Drug administration will occur on an outpatient basis at the infusion center at Moffitt Cancer Center. Dose will be weight-based. Starting treatment doses of 3 mcg/kg will be given subcutaneously (SC) injection in the thigh, abdominal wall, or upper arm every week for a total of 27 weeks as tolerated.
1602422|NCT02218164|Drug|Capecitabine|Drug administration will be on an outpatient basis. Capecitabine will be administered at an initial dose of 800 mg/m^2 by mouth twice daily on days 1-14 of a 21 day cycle with days 15-21 off. This cycle will be repeated every 21 days during the study for a maximum of 9 cycles as tolerated. Administration via feeding tube in patients unable to swallow is permitted.
1602423|NCT02218164|Drug|5-FU|If participants are not able to acquire oral capecitabine, then treating physicians will start participants on infusional 5-FU which can be delivered via standard of care. Participants will need to have a port placed for continuous infusion treatments. 5-FU pumps will be activated in the infusion center at Moffitt Cancer Center with a starting dose of 800 mg/m^2 days 1-4, with pump removal on day 5 at the infusion center. 5-FU pumps will be attached every 21 days (1 cycle) for a maximum of 9 cycles.
1602598|NCT02216799|Drug|Glargine Insulin|80% of the insulin doses administrated via sliding scale will be administered every night as insulin glargine
1603284|NCT02211664|Device|Passeo-18 Lux drug releasing balloon|
1602424|NCT02218151|Other|Patient-Centered Medical Home (PCMH)|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period at home. Advanced Practice Providers (APP) will travel to subjects' homes in the morning, where they will perform the same daily assessment as standard care. They will draw labs and bring them back to the hospital for processing. When results are available, a second home visit is made to deliver necessary interventions. Subjects will have internet access through cellular-networked iPads and have daily videoconferences with their physicians. Daily follow up at home will continue until discharge as per above criteria.
1602425|NCT02218151|Other|Standard Care|Subjects will receive their conditioning chemotherapy +/- radiation and stem cells in the hospital or day hospital, after which they will receive care during the neutropenic/recovery period inpatient or outpatient. Advanced practice providers (APPs) will perform histories and physical exams. Nurses will collect labs and inpatient rounds occur twice daily, or for outpatients receiving care through our outpatient clinics, a healthcare provider typically sees them daily for the first month following transplant or discharge from the day hospital.
1602426|NCT02218138|Behavioral|Learning 2 BREATHE|Mindfulness-based group program
1602427|NCT02218138|Behavioral|Colorado Blues|Colorado Blues, Cognitive-behavioral depression prevention group
1602428|NCT02218125|Biological|MVA Mosaic|0.5 mL (1x10E8 pfu) MVA Mosaic (comprised of MVA Mosaic 1 and MVA Mosaic 2 mixed in a 1:1 ratio before administration) will be administered by intramuscular (IM) injection.
1602429|NCT02218125|Biological|Placebo|0.5 mL Sodium Chloride Injection USP, 0.9%will be administered by intramuscular (IM) injection.
1602430|NCT02218112|Procedure|bariatric surgery (gastric bypass)|
1602431|NCT02218099|Drug|ASP8232|Oral
1602432|NCT02218099|Drug|Placebo|Oral
1602433|NCT02218086|Device|Slackline|Slackbase PRO CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
1602434|NCT02218086|Device|Wobbling Board|Wobbling Board CE: certificated by european law for medical devices (EG Richtlinie 93/42/EWG)
1602435|NCT02218086|Device|Pre-training|First investigation of the beginners with less than 1 hour experience with slacklining.
1602436|NCT02218086|Device|Fix visual anchor|Professionals have to gaze at a fixed visual anchor during the slacklining.
1602437|NCT02218086|Device|Moving visual anchor|Professionals have to gaze at a moving visual anchor during the slacklining.
1602438|NCT02218086|Device|Post-training|Second investigation of the beginners occurs after a training session of 9 times 30 minutes within a few weeks.
1602439|NCT02218073|Drug|JNJ-42756493 10 mg tablet|Participants will be administered with 10 milligram (mg) JNJ-42756493 tablet orally either on Day 1 of Period 1 or on Day 1 of Period 2.
1602440|NCT02218073|Drug|JNJ-42756493 10 mg Oral Solution|Participants will be administered with 10 mg JNJ-42756493 oral solution either on Day 1 of Period 1 or on Day 1 of Period 2.
1602441|NCT02218073|Drug|JNJ-61818549|Participants will receive 100 mcg of JNJ-61818549 as intravenous injection on Day 1 of Period 2 or Day 1 of Period 1.
1602442|NCT02218060|Procedure|Coronary CT angiography on SOMATOM Force|Coronary CT angiography using iodinated contrast; metoprolol and/or nitroglycerin may also be administered on a per-patient basis
1602443|NCT02218060|Procedure|Previous coronary CT angiography on 2nd generation CT scanner|Clinically indicated coronary CT angiography previously performed on a 2nd generation CT scanner
1602444|NCT02218047|Drug|Pegylated-Proline-interferon alpha-2b|Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit [Hct]<45%, platelets [PLTs]<400 x 109/L and leukocytes [WBCs]<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
1602445|NCT02218047|Drug|Best available therapy (BAT)|Best available therapy as selected by the investigator
1602446|NCT02218034|Drug|AGN-190168 Formulation 1|AGN-190168 Formulation 1 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
1602447|NCT02218034|Drug|AGN-190168 Formulation 2|AGN-190168 Formulation 2 applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
1602448|NCT02218034|Drug|tazarotene gel 0.1%|Tazarotene gel 0.1% applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
1602449|NCT02218034|Drug|tazarotene cream 0.1%|Tazarotene cream 0.1% cream applied topically to the face, neck, upper chest, upper back, and shoulders once daily for 29 days.
1602450|NCT02218021|Drug|Samidorphan|
1602451|NCT02218021|Drug|Placebo|
1602452|NCT02218021|Drug|Oxycodone|
1602453|NCT02218008|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
1602454|NCT02218008|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
1602455|NCT02217995|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|"MBCT teaches patients to become more aware of, and to relate differently to, their thoughts, feelings, and bodily sensations. Through MBCT, patients will learn skills that allow them to disengage from habitual (automatic) dysfunctional cognitive routines, such as obsessional thinking. As an example, patients are encouraged to relate to thoughts and feelings as passing events in the mind, rather than to identify with them or treat them as accurate representations of reality. The MBCT protocol for OCD patients is adapted from Segal et al.'s original MBCT manual for depression (Segal, Williams & Teasdale, 2002)."
1602456|NCT02217982|Drug|Simethicone|
1602457|NCT02217982|Drug|Loperamide|
1602458|NCT02217982|Other|Peanut Butter|
1602459|NCT02217969|Behavioral|Electronic alert to SLUScore increase|Treat hypotension to minimize further progression of the SLUScore
1602460|NCT02217956|Drug|Cisplatin|
1602461|NCT02217956|Drug|Bevacizumab|
1602462|NCT02217943|Procedure|Roux-en-Y gastric bypass|
1602463|NCT02217943|Procedure|Sleeve gastrectomy|
1602464|NCT02217930|Drug|WCK 2349|
1602465|NCT02217930|Drug|Placebo|
1602466|NCT02217930|Drug|Moxifloxacin|
1602467|NCT02217917|Drug|Rivipansel|Rivipansel administered as a single dose subcutaneously with rHuPH20 in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of rivipansel). The planned dose levels are 350 mg, 1210 mg, and 4200 mg (these are subject to change based on emerging data).
1602469|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 1400 mg loading and 700 mg maintenance for 12 doses (these are subject to change based on emerging data).
1602470|NCT02217917|Drug|Rivipansel|Rivipansel administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20. Planned doses are 2800 mg loading and 1400 mg maintenance for 12 doses (these are subject to change based on emerging data).
1602471|NCT02217917|Drug|Placebo|Matched Placebo administered q12h for 7 days (a total of 13 doses) subcutaneously with rHuPH20.
1602472|NCT02217904|Drug|1 mg MK-8591|Single oral dose of 1 mg MK-8591 administered following ≥8 hour fast
1602473|NCT02217904|Drug|2 mg MK-8591|Single oral dose of 2 mg MK-8591 administered following ≥8 hour fast
1602474|NCT02217904|Drug|10 mg MK-8591|Single oral dose of 10 mg MK-8591 administered following ≥8 hour fast
1602475|NCT02217904|Drug|30 mg MK-8591|Single oral dose of 30 mg MK-8591 administered following ≥8 hour fast
1602476|NCT02217904|Drug|0.5 mg MK-8591|Single oral dose of 0.5 mg MK-8591 administered following ≥8 hour fast
1602477|NCT02217904|Drug|0.25 mg MK-8591|Single oral dose of 0.25 mg MK-8591 administered following ≥8 hour fast
1602478|NCT02217891|Behavioral|Semi-structured interview|Pts will participate in a 45-60-minute, one-on-one, audio-recorded interview. They will be conducted over the telephone or in person at the MSK Counseling Center. They will be conducted in accordance with a semi-structured interview guide developed by our study team of experts in clinical genetics, health psychology, & qualitative methodology. Topics to be covered in the interview include: 1) perceived potential benefits & harms of tumor genomic profiling; 2) interest in & perceived benefits & harms of incidental findings arising from tumor genomic profiling; 3) anticipated process & needs for decision-making about learning incidental findings; 4) interest in learning specific kinds of incidental findings (including those related to treatable diseases, different cancers, non-treatable diseases, & those that only have meaning for family members); 5) preferences about sharing incidental findings with other people; & 6) implications of & concerns about incidental findings for family.
1602479|NCT02217878|Drug|Morphine|IV bolus injection
1602480|NCT02217878|Drug|Placebo|IV bolus injection
1602481|NCT02217878|Drug|Ticagrelor|180 mg loading dose
1602482|NCT02217865|Behavioral|Interviews - Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
1602483|NCT02217865|Behavioral|Questionnaire|Questionnaire completion asking general health and demographic questions.
1602484|NCT02217865|Behavioral|Focus Groups|Focus groups conducted with participants and caregivers. Up to 4 focus groups conducted with up to 30 participants each. Focus groups expected to take 30 to 60 minutes.
1602485|NCT02217865|Behavioral|Interviews - Caregivers of Colorectal Cancer Participants|Semi-structured interviews conducted exploring key issues relevant to colorectal cancer surveillance following curative resection. Interviews take between 30 minutes and 1 hour.
1602486|NCT02217852|Drug|Nitrendipine|doses used range from 10-20mg po bid. Total duration would be until completion or study or medication intolerance.
1602487|NCT02217852|Drug|Hydrochlorothiazide|doses used range from 12.5-25mg po qd. Total duration would be until completion or study or medication intolerance.
1602488|NCT02217852|Drug|Captopril,Hydrochlorothiazide|doses used range from 25-50mg po tid for captopril and 12.5-25mg po qd for hydrochlorothiazide. Total duration would be until completion or study or medication intolerance.
1602489|NCT02217852|Drug|Beijing hypotensive No.0|1 pile po qd or less. Total duration would be until completion or study or medication intolerance.
1602490|NCT02217839|Drug|DG3173|
1602491|NCT02217839|Drug|DG3173+Octreotide|
1602492|NCT02217839|Drug|Octreotide|
1602493|NCT02217839|Drug|DG3173 Placebo|
1602494|NCT02217839|Drug|DG3173 Placebo+Octreotide Placebo|
1602495|NCT02217839|Drug|Octreotide+DG3173 Placebo|
1602496|NCT02217826|Drug|DG3173|
1602497|NCT02217826|Drug|Saline|
1602498|NCT02217826|Drug|Octreotide|
1602499|NCT02217813|Drug|Tafamidis|20 mg of current commercial formulation
1602500|NCT02217813|Drug|Tafamidis|20 mg of new formulation
2009681|NCT03194126|Procedure|Misoprostol + 3 laminaria|Three laminaria placed 12 hours prior to administration of misoprostol
2009682|NCT03194126|Procedure|Mifepristone + Misoprostol|Standard maturation using 600mg mifepristone followed 36 hours later by 400mg misoprostol every 3 hours
2009683|NCT03192020|Procedure|Percutaneous needle fasciotomy|PNF is a treatment in which the cord causing the contracture is not excised, but only divided with a hypodermic needle. The division of the cord can be made under local anesthesia in the clinic and takes only a few minutes to perform. It can be performed whenever the cord is palpable. There are only puncture wounds left, and hence, the patient can start normal use of the hand the day after the procedure.
1602504|NCT02217787|Drug|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
1602505|NCT02217787|Drug|PF-06372865|7.5 mg as 3 x 2.5 mg tablets single dose
1602506|NCT02217774|Device|MGUIDE MORE|MGUIDE MORE System (MGS), consisting of MGUIDE MORE software, MGUIDE MORE surgical kit and MGUIDE MORE template, will be used for planning, drilling and inserting dental implants.
1602507|NCT02217748|Other|Survey questionnaire|
1602508|NCT02217735|Behavioral|Writing Intervention|Participants wrote for 20 minutes on three occasions about an emotional or traumatic topic (expressive writing intervention condition) or what they did the day before, while refraining from including emotional details.
1602509|NCT02217722|Other|Ulcerative Colitis Diet|we have postulated that a diet that increases butyrate through fiber exposure, reduces intestinal sulfur exposure, and increases vitamin D levels could be beneficial for patients with Ulcerative Colitis. To date, no study has explored this possibility.
1602871|NCT02214888|Drug|BIRB 796 BS, low dose|
2009684|NCT03192020|Drug|Collagenase Clostridium Histolyticum 2.9 MG/ML [Xiaflex]|CCH chemically dissolves type I collagen of which the cord is composed of. It is injected inside the cord in the outpatient clinic and the cord can be ruptured by gently force after a day or two.
1602510|NCT02217722|Drug|Antibiotic cocktail|We have postulating that antibiotic therapy can alter the microbiota clinically. Controlling the microbiota by antibiotics may allow for control of the disease without immune suppression
1602511|NCT02217709|Drug|phenelzine sulfate|Given by mouth
1602512|NCT02217709|Other|laboratory biomarker analysis|Correlative studies
1602513|NCT02217709|Other|questionnaire administration|Ancillary studies
1602514|NCT02217696|Other|Computerized reading training|
1602515|NCT02217683|Drug|Nitric Oxide|Nitric oxide at 80 part per million will be administrated by inhalation for approximately 1 hour during the blood transfusion
1602516|NCT02217670|Drug|Metformin 1000 mg granules|
1602517|NCT02217670|Drug|Metformin 1000 mg film-coated tablets|
1602518|NCT02217657|Device|Thermocool Smart Touch Catheter|Physician informed to contact force
1602519|NCT02217644|Drug|BI 653048 H3PO4 solution|
1602520|NCT02217644|Drug|BI 653048 H3PO4 low dose capsule|
1602521|NCT02217644|Drug|BI 653048 H3PO4 high dose capsule|
1602522|NCT02217644|Drug|Placebo|
1602523|NCT02217631|Drug|BI 653048 BS H3PO4|
1602524|NCT02217631|Drug|Prednisolone low dose|
1602525|NCT02217631|Drug|Prednisolone high dose|
1602526|NCT02217631|Drug|Placebo|
1602527|NCT02217618|Drug|LY2409021|Administered orally
1602528|NCT02217605|Dietary Supplement|Fructose|Oral Fructose Challenge (75 g fructose in 500 ml water) following overnight fast
2009685|NCT03192020|Procedure|Limited fasciectomy|In LF, the thickened part of the palmar fascia causing the contracture is excised through skin incision. LF is performed in general or regional anesthesia in operating room. LF has been the dominant technique of surgical treatment.
2009686|NCT03191669|Other|Auto-questionnaire|Single Auto-questionnaire administered during or after a consultation/hospitalization
1602533|NCT02217566|Drug|Abiraterone acetate|Participants will receive abiraterone acetate 1000 mg (4*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
1602534|NCT02217566|Drug|Prednisone|Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.
1602535|NCT02217566|Drug|Androgen deprivation therapy (ADT)|Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
1602536|NCT02217553|Drug|Cholecalciferol|The study participants will receive 180 soft gel cholecalciferol capsules, to be taken 2 capsules once a day for 90 days
1602537|NCT02217540|Other|Standard protocol|Control group intervention is the physiotherapy treatment standard protocol proposed by the Spanish Rheumatology Society for shoulder dysfunction
1602538|NCT02217540|Other|Mulligan Concept Mobilisation with Movement|The internal hand of the physiotherapist stabilises participants´ shoulder girdle and with the thenar eminence of the other hand, performs a posterior-lateral glide of the humeral head. Participants are asked to raise the affected arm in the point of pain onset while the physiotherapist sustains the gliding force to humeral head. The physiotherapist tries to maintain the glide at right angles to the plane of movement throughout the entire range while participants are requested to perform an active elevation. Participants are instructed that the mobilisation procedure, including shoulder movement, had to be pain free
1602539|NCT02217527|Drug|Active JNJ Drug|200 mg/day (100 mg b.i.d.) of Active JNJ Drug will be used for one week while attempting to briefly quit smoking on Mon-Fri of that week.
1602540|NCT02217527|Drug|Placebo pill|Placebo pill will be taken daily to assess ability to briefly quit smoking on Mon-Fri for one week.
1602541|NCT02217514|Drug|Midazolam|
1602542|NCT02217514|Drug|BI 44370 low dose|
1602543|NCT02217514|Drug|BI 44370 medium dose|
1602544|NCT02217514|Drug|BI 44370 high dose|
1602545|NCT02217501|Drug|Clopidogrel|Clopidogrel 75 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
1602546|NCT02217501|Drug|Acetylsalicylic acid (ASA)|Acetylsalicylic acid (ASA) 75-100 mg once daily for clinically indicated duration or for clinically indication duration + 12 months
1602547|NCT02217488|Drug|DG3173|
1602548|NCT02217488|Drug|Placebo|
1602549|NCT02217475|Drug|Cenicriviroc|CVC 150 mg, administered orally once daily and taken every morning with food
1602550|NCT02217475|Drug|Placebo|Placebo administered orally once daily and taken every morning with food
1602551|NCT02217449|Other|Prediction of histology|
1602552|NCT02217436|Device|iPad|iPad with age-appropriate applications, videos, and music
1602553|NCT02217436|Other|Standard Care|All study participants will receive standard care, which consists of procedural explanation and preparation by providers, verbal encouragement and comforting by providers and parents, and topical anesthetic (LET) followed by injectable lidocaine administration (whether one or both of these anesthetics will be used will be determined by the provider prior to randomization).
1602554|NCT02217423|Other|Chest physiotherapy chest wall expansion|chest physiotherapy The protocol consisted of breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion (decompression, Incentive Spirometry).
1602555|NCT02217423|Other|Chest physiotherapy airway clearance modality|The protocol will be consisted the breathing exercises during 30 minutes: passive and localized exercises, deep diaphragmatic breathing and exercises on the chest (vibration, compression) and active cough.
1602556|NCT02217410|Biological|CFZ533|
1602557|NCT02217410|Drug|Tacrolimus (Tac)|
1602558|NCT02217410|Drug|Mycophenolic acid (MPA)|
1602559|NCT02217410|Drug|Corticosteroids (CS)|
1602560|NCT02217410|Biological|anti-IL2 Induction|
1602561|NCT02217397|Device|OA, CPAP, combination therapy|
1602562|NCT02217371|Other|Neuropsychological tests|"The tests are :
Go/NoGo paradigm, Continuous Performance Test (CPT) II , Wisconsin Card Sorting Test (WCST), virtual CPT, Classic and virtual Stroop, PSG, MWT
These tests will be repeated during 32h each 4h (T0h, T4h, T8h, T12h, T16h, T20h, T24h, T28h et T32h)."
1602872|NCT02214888|Drug|BIRB 796 BS, high dose|
1602873|NCT02214888|Drug|Placebo|
1602563|NCT02217215|Device|CNDS Advanced Cervical Scan|"Subjects (approximately 500) will be initially enrolled from a general screening population in the first phase, and during the second phase from the colposcopy clinic population (approximately 300) based on their referral abnormal Pap cytology conducted within 120-days in order to achieve a statistically viable number of normal women, women with CIN1/2 and women with CIN3+, as described in Section 6.1, Cervical Cytology Enrollment Targets. After the CNDS test, a sample for Hybrid Capture 2 HPV testing and liquid cytology will be collected in addition to colposcopy and biopsy, if indicated."
1602564|NCT02217189|Dietary Supplement|zinc sulfate|The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).
1602565|NCT02217163|Drug|Carfilzomib, Cyclophosphamide, Dexamethasone|Carfilzomib is administered over 30 minutes as an infusion. For cycle 1 only, Carfilzomib is administered at 20mg/m2 IV on days 1 and 2, followed by escalation to 56mg/m2 on days 8,9,15 and 16 on a 28 day cycle. Patients who tolerate 56mg/m2 dose are kept at this dose for the subsequent cycles on Days 1,2,8,9,15,16 on a 28 day cycle. Dose and schedule modifications for intolerable side effects are detailed in the protocol. Additionally Cyclophosphamide is given a fixed dose of 500mg once per week orally, along with dexamethasone is given on the days of Carfilzomib administration, 30 minutes to 4 hours prior to Carfilzomib.
1602566|NCT02217124|Other|dried apples|120 calories
1602567|NCT02217124|Other|muffin|120 calories
1602568|NCT02217111|Behavioral|Adventures in Voice: Pediatric Voice Therapy|
1602569|NCT02217098|Procedure|GIC Restorations|Restorations using Glass Ionomer Cement
1602570|NCT02217098|Procedure|Carbomer Restorations|Restorations using Glass Carbomer
1602571|NCT02217098|Procedure|Compomer Restorations|Restorations using Compomer
1602572|NCT02217072|Behavioral|School intervention|A school-based intervention that builds on the promising Swedish programme SkolFam, but is adapted to a Danish school context. The two main components of the programme are a) comprehensive assessment of the child, involving testing of the child's cognitive and academic abilities and difficulties as well as an evaluation of the child's behaviour, school-related social relations and well-being, and b) a systematic and individually targeted intervention plan, made in collaboration between a psychologist, the teachers, and a special educational teacher at the school (e.g., the reading counsellor).
1602573|NCT02217072|Behavioral|Parents as Tutors|A home-based intervention, comprising a structured tutoring programme that allows foster parents to systematically support the foster child's school performance. Foster parents will attend an introductory tutor training seminar at which they will be introduced to relevant theory on learning and counselled on tutoring practice. The intervention itself is designed to provide approximately three hours per week of individual home-based tutoring for a period of 40 weeks.
1602574|NCT02217046|Procedure|device replacement(pocket capsule removal)|remove previously inserted cardiac device and posterior pocket capsule. the pocket that will receive the heart mechanism is sterilized with a hydroperoxide soaked gauze
1602575|NCT02217033|Other|'R' (Electro-kinetically altered beverage)|
1602576|NCT02217033|Other|Placebo (water)|
1602577|NCT02217020|Drug|FOLFOXIRI|irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
1602578|NCT02217007|Drug|SNC-102 sustained release tablet|SNC-102 is an 800 mg tablet. It will be administered twice daily (morning and evening) for a total of 8 weeks: the initial 4 weeks will be 1 tablet in the morning and 1 tablet in the evening; the next 4 weeks will be 2 tablets in the morning and 1 tablet in the evening.
1602579|NCT02216994|Drug|high dose lactulose|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
1602580|NCT02216994|Behavioral|conservative treatment|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
1602581|NCT02216994|Drug|paraffin oil|The patients with a score less than 5 are mostly indicative of HAD, and receive conservative therapies that included colonic irrigation, enema, high dose lactulose, and oral paraffin oil for at least 6 months. When there is no clinical improvement, patients are consented for surgical procedures to remove the dysganglionic bowel segments.
1602582|NCT02216981|Behavioral|Cognitive Behavioural Therapy (CBT)|
1602583|NCT02216968|Behavioral|Increase vegetable intake in pre-school children|"6-week Intervention: 120 AA and HA children will be shown the Puppet Shows and will be given a bag of ingredients to prepare the vegetable highlighted that week in the Puppet Show. The 6 week intervention includes a baseline assessment (1 week), followed by the intervention (4 weeks), and post assessment (1 week). The primary hypothesis to be tested is children who receive the PUPPET intervention with a parent/teacher component will demonstrate increase vegetable intake in pre-school children."
1602584|NCT02216942|Drug|Endodontic treatment using Vitapex|Endodontic treatment using Vitapex
1602585|NCT02216942|Drug|Endodontic treatment using Guedes Pinto|Endodontic treatment using Guedes Pinto paste
1602586|NCT02216916|Drug|HM781-36B|
1602587|NCT02216890|Drug|SGN-CD70A|Given intravenously every 3 weeks (or an alternate dosing schedule up to every 6 weeks)
1602588|NCT02216877|Drug|Mablet 360 mg|
1602589|NCT02216877|Drug|Placebo|
1602590|NCT02216864|Procedure|Multiple Subcision|At the start of the procedure, a straight vitrectomy knife will be inserted subdermally and will be slowly advanced parallel to the dermis. Rapid advancement and retraction of the needle under the scarred area in a lancing motion will be performed to abrade the underside of the dermis followed by side to side sweeping motions attempting to break any fibrous attachments to the deeper tissues.
1602591|NCT02216851|Device|Restylane Perlane|Intradermal injection
1602592|NCT02216838|Drug|botulinum toxin A|A total of 10U will be injected at 1cm increments by the blinded dermatologist into the respective randomized side.
1602593|NCT02216838|Other|Saline Control|A total of 0.5cc benzyl alcohol containing saline will be injected at 1cm increments by the blinded dermatologist into the respective randomized side
1602594|NCT02216825|Dietary Supplement|Delayed release capsule, L. reuteri NCIMB 30242, escalated dose|
1602599|NCT02216799|Drug|Regular insulin|80% of the Regular insulin administrated via sliding scale will be will be added to TPN bag to run over 24 hours
1602600|NCT02216786|Drug|AZD2014|Oral tablet
1602601|NCT02216786|Drug|Everolimus|Oral tablet
1602602|NCT02216786|Drug|Fulvestrant|Im injection
1602603|NCT02216773|Procedure|Radiofrequency assisted liver partition with portal vein ligation (RALPP)|
1602604|NCT02216773|Procedure|Portal vein embolization (PVE)|
1602605|NCT02216760|Device|Ripple Mapping guided VT ablation|RM will be used to guide identification of conduction channels and hence substrate guided ablation
1602606|NCT02216760|Device|Conventional VT ablation|Substrate guided ablation using conventional methods (pace-mapping, LAVA/late potential abolition, scar border zone ablation)
1602607|NCT02216747|Drug|prednisone 60 mg/meter square Body Surface Area|treatment with prednisone 60 mg /meter square Body Surface Area to compare to other arms
1602608|NCT02216747|Drug|prednisone 45 mg|treatment with 45 mg prednisone to compare with other arms
1602609|NCT02216747|Drug|prednisone 30 mg|treatment with 30 mg prednisone to compare with other arms.
1602610|NCT02216734|Behavioral|Mother support groups for HIV+ mothers|Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
1602611|NCT02216708|Other|Rapid dehydration|
1602612|NCT02216708|Other|Slow rehydration|
1602613|NCT02216669|Drug|DTP348|Patients will receive a continuous oral dose of DTP348 for 7 days per week for 7 weeks
1602614|NCT02216656|Drug|Placebo|Oral administration
1602615|NCT02216656|Drug|KHK7580 low dose|Oral administration
1602616|NCT02216656|Drug|KHK7580 middle dose|Oral administration
1602617|NCT02216656|Drug|KHK7580 high dose|Oral administration
1602618|NCT02216656|Drug|KRN1493|Oral administration
1602619|NCT02216643|Procedure|Thrombectomy|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever Solitaire and/or thromboaspiration with Penumbra System versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
1602620|NCT02216643|Device|Stentriever Solitaire or Penumbra System|Patients with acute ischemic stroke with anterior circulation large vessel occlusion will be randomized to receive mechanical thrombectomy with stent-retriever and/or thromboaspiration versus medical management alone versus medical management alone. A maximum of six attempts to retrieve the thrombus in a single vessel can be made . No additional treatment will be allowed either with IA tPA, other mechanical devices or angioplasty/stenting.
1602621|NCT02216630|Drug|Adipose Derived Stem Cell (ADSC) Therapy|Patients undergo a liposuction where 100 cc of fat are extracted. The ADSCs are then isolated and injected intravenously.
2009687|NCT03191396|Drug|Semaglutide|Dose gradually increased to 1.0 mg, given s.c. (under the skin), once-weekly for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs (tablets), if any
1602623|NCT02216604|Behavioral|Multimodal Exercise Intervention|During their inpatient hospitalization the participants perform 3-5x weekly guided training sessions about 15-30min. The intervention includes: game console-based training using Nintendo Wii® (endurance, strength endurance and balance), age-specific resistance training and sessions of body awareness. During the outpatient phases the participants perform a home-based exercise training 3-5x weekly using a training manual. In addition, the patients obtain a movement diary and a pedometer for documenting their activity level.
1602624|NCT02216591|Device|Active Cognitive Training (ACT)|
1602625|NCT02216591|Device|Control (CON)|
1602627|NCT02216565|Other|Hospitalization in specialized neuro-vascular unit|
1602628|NCT02216565|Drug|Alteplase if patient is eligible|Alteplase intravenous thrombolysis performed if patient is eligible (if not contraindicated)
1602629|NCT02216565|Other|Supportive care|Drugs, procedures and techniques aimed at preventing/managing complications or aggravation of the patient's neurological condition
1602630|NCT02216565|Procedure|Endovascular treatment|Recanalization treatment (thrombectomy / intraarterial thrombolysis)
1602631|NCT02216552|Dietary Supplement|Resveratrol|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
1602632|NCT02216552|Dietary Supplement|Placebo|All adolescents will receive standardized lifestyle counselling at enrolment designed and disseminated by a registered dietitian as well as a licensed physiotherapist who both have experience working with overweight adolescents. The lifestyle component will be goal-based and tailored to each participant. The overall content and messaging will be consistent for all participants with nutritional recommendations based on Canada Food Guide and physical activity counselling aligning with the Healthy Active Living Recommendations of the Canadian Pediatric Society and Health Canada's Physical Activity Guidelines.
1602633|NCT02216539|Behavioral|Self-hypnosis|Patients will be trained to self-hypnosis prior to surgery, in order to be able to use self-hypnosis as a pain-management tool after surgery
1602634|NCT02216539|Procedure|Lung transplantation|
1602635|NCT02216539|Other|Standard post-operative pain management|Post-operative pain management treatments as per usual protocols in the hospital
1602638|NCT02216513|Drug|desferrioxamine (DFO)|DFO (20mg/kg/hr) in normal saline for 4 hours for 5 consecutive days
1602639|NCT02216513|Drug|placebo|normal saline IV for 4 hours for 5 consecutive days
1603285|NCT02211664|Device|Pulsar-18 stent|
2009688|NCT03191396|Drug|Liraglutide|Dose gradually increased to 1.2 mg, given s.c. once-daily for 30 weeks. Participants will remain on their pre-study anti-diabetic drugs, if any
1602641|NCT02216487|Drug|HA-Irinotecan|HA-Irinotecan is administered as part of FOLFIRI/cetuximab treatment in place of irinotecan for treatment of mCRC.
1602642|NCT02216474|Other|Transcranial direct current stimulation|
1602643|NCT02216461|Drug|Low dose of BIBW 2948 BS for oral inhalation|
1602644|NCT02216461|Drug|Medium dose of BIBW 2948 BS for oral inhalation|
1602645|NCT02216461|Drug|High dose of BIBW 2948 BS for oral inhalation|
1602646|NCT02216461|Drug|Placebo|
1602647|NCT02216448|Other|Training knee simulator|Training in a lab on a virtual reality knee arthroscopy simulator
1602648|NCT02216448|Other|OR Training|Training on diagnostic knee arthroscopy in the OR
1602649|NCT02216422|Drug|Ombitasvir/Paritaprevir/Ritonavir|Tablet; paritaprevir co-formulated with ritonavir and ombitasvir
1602650|NCT02216422|Drug|Dasabuvir|Tablet
1602651|NCT02216422|Drug|Ribavirin (RBV)|Tablet
1602652|NCT02216409|Drug|Hu5F9-G4|
1602653|NCT02216383|Drug|Carbetocin|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Carbetocin, listed here, is one of the of the three study drugs.
1602654|NCT02216383|Drug|Syntocinon|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntocinon, listed here, is one of the of the three study drugs.
1602655|NCT02216383|Drug|Syntometrine|The intervention is the administration of one dose of study drug to the recruited patient at the time of delivery. Syntometrine, listed here, is one of the of the three study drugs.
1602656|NCT02216357|Drug|Ifetroban, Oral Capsule|
1602657|NCT02216357|Drug|Placebo, Oral Capsule|
1602658|NCT02216331|Drug|TMC207|"This is a two group, 2 period study design with both groups in the first period receiving TMC207 alone, followed by one group in the second period receiving TMC207 in the presence of dosing with rifapentine and the other group receiving TMC207 in the presence of dosing with rifampicin. All treatments details specified under Arms description."
1602659|NCT02216331|Drug|rifapentine|
1602660|NCT02216331|Drug|rifampicin|
1602661|NCT02216318|Other|blue light|
1602662|NCT02216305|Procedure|Hemorrhoidectomy|Open hemorrhoidectomy may include one to three anal cushions and made according to the Milligan-Morgan technique, with resection of the anal cushion and the external hemorrhoidal epidermal component using electrocautery and ligation of the hemorroidal base with absorbable suture
1602663|NCT02216305|Procedure|HAL-RAR|Hemorrhoidal artery ligation and rectoanal repair will be performed with the AMI minimally invasive surgery device HAL/RAR, and consist in the ligation of the terminal branches of the superior rectal artery with 2-0 absorbable polyglycolic acid suture after identifying the blood flow approximately 3 cm above the dentate line by using Doppler guidance. Subsequently, a running suture was added from the suture point to 5 mm above the dentate line to lift the prolapsing hemorroid. Other procedures will not be associated.
1602664|NCT02216292|Other|Control Group|Infants received preterm formula during their first days of life until breastmilk from their own mother was available
1602665|NCT02216292|Other|Preterm Single Donor Milk Group|Infants received preterm single donor milk during their first days of life until breastmilk from their own mother was available
1602666|NCT02216279|Drug|PulmoBind|PulmoBind is a peptide derived from human adrenomedullin (hAM1-52), labelled with 99mTc (imaging isotope used in clinical medicine).
1602667|NCT02216266|Drug|Physostigmine|
1602668|NCT02216266|Other|Sodium Chloride solution|
1602669|NCT02216253|Drug|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract|L-methionine, Hibiscus Sabdariffa and Boswellia Leaf Extract tablet twice a day 7 days before and after surgery
1602670|NCT02216253|Other|Placebo|Placebo tablet twice a day 7 days before and after surgery
1602671|NCT02216240|Other|Paramedic|
1602672|NCT02216240|Other|Standard care|
1602673|NCT02216227|Drug|Mupirocin|Patients with known positive MRSA or MSSA and patients who have unknown status will decolonize BID x 5 days
1602674|NCT02216227|Drug|Chlorhexidine gluconate|"Patients that are MRSA or MSSA positive or have unknown status will bathe in CHG daily x 5 days.
Patients that are MRSA or MSSA negative will bathe with CHG the night before and morning of surgery."
1602675|NCT02216227|Drug|Cefazolin|All patients will receive Cefazolin during surgery
1602676|NCT02216227|Drug|Vancomycin|Patients who are positive for MRSA, or have unknown MRSA status, will receive vancomycin along with cefazolin during surgery.
1602677|NCT02216214|Drug|Mirabegron|oral
1602678|NCT02216214|Drug|Placebo|oral
1602679|NCT02216188|Biological|AFFITOPE® PD01A|s.c. injection
1602680|NCT02216188|Other|Control|Untreated control group
1602681|NCT02216175|Other|SLIT to cow's milk|
1602682|NCT02216175|Other|OIT to cow's milk|
1602683|NCT02216162|Other|Arm A: adapted physical activity + enhanced geriatric follow-up|"Patients have 3-monthly geriatric follow-up with biological tests, anti-aromatase agents blood dosing and a clinical assessment (M3 to M9, M15 to M22 and M27 to M33). Musculoskeletal adverse events and quality of life level will be reported and analgesic treatment adapted. Patients will be proposed weekly Taï-Chi exercises to improve joint flexibility, muscular tonus and balance and reduce fall risk.
A broader geriatric assessment including functionality, gait analysis and nutrition will be performed each year (M12, M24 and M36)."
1602684|NCT02216162|Other|No intervention|Usual clinical follow-up
1602685|NCT02216149|Drug|S-1|S-1 25 mg/m2/day BID d1-14
1602686|NCT02216149|Drug|Capecitabine|capecitabine 2000 mg/m2/day divided in 2 daily doses d1-14
1602687|NCT02216123|Drug|Tafenoquine|Tafenoquine will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides. Each tablet will contain 150mg TQ.
1602688|NCT02216123|Drug|Tafenoquine Placebo|Placebo TQ tablets will be supplied as a dark pink, capsule-shaped, film-coated tablet that is plain on both sides, with common excipients of appropriate quality.
1602689|NCT02216123|Drug|Chloroquine|"One of two formulations of commercially available generic chloroquine may be utilized in this study:
tablets containing 500 mg chloroquine phosphate (equivalent to 300 mg chloroquine free base); or,
tablets containing 250 mg chloroquine phosphate (equivalent to 155 mg chloroquine free base)."
1602690|NCT02216123|Drug|Primaquine|Commercially available primaquine containing primaquine phosphate united states pharmacopeia (USP), 26.3 mg (equivalent to primaquine base 15 mg) will be utilized in this study. Primaquine, a pink film-coated tablet imprinted W on one side and P97 on the other side. The PQ tablets for this study have been over-encapsulated in a Swedish orange size B supro capsule.
1602691|NCT02216123|Drug|Primaquine Placebo|Placebo to match PQ will be supplied as Swedish orange size B supro capsules with common excipients of appropriate quality.
1602692|NCT02216110|Procedure|Surgery|Surgery for early gastric cancer includes distal gastrectomy, total gastrectomy, proximal gastrectomy, and wedge resection
1602693|NCT02216097|Drug|PF-04457845|4mg PF-04457845 tablet taken once daily for 7 days.
1602694|NCT02216097|Drug|Placebo|Matching placebo tablet taken once daily for 7 days.
2009689|NCT03190967|Drug|T-DM1|T-DM1 3.6 mg/kg IV every 21 days
1602696|NCT02216071|Drug|Ciprodex®|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
1602697|NCT02216071|Drug|EXL CDOS (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Sterile Otic Suspension|Treatment of acute otitis externa (AOE) when administered twice daily for 7 days
1602698|NCT02216058|Device|NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System|
1602699|NCT02216045|Drug|Peginterferon, Ribavirin, camel milk|"Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.
Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .
camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks."
1602700|NCT02216045|Drug|Peginterferon, Ribavirin|"Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.
Ribavirin (RBV) tablets (body-weight adjusted dose: < 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks."
1602701|NCT02216032|Other|TMW Curriculum|
1602702|NCT02216032|Other|Nutrition Curriculum|
1602703|NCT02216019|Other|Whole blood|preoparatoire whole blood and postoperative whole blood
1602704|NCT02216006|Procedure|Control group, conventional ventilatory settings|"Handling of the airway during induction and intubation is performed in a conventional manner.
Initial ventilatory settings are also done in a conventional manner. As soon as correct position of the endotracheal tube is confirmed, controlled ventilation is started with a tidal volume of 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25) and a respiratory frequency of 10. The fresh gas flow is set to 1 Liter per minute with an oxygen mixture of 40%, aiming for an inspired FiO2 of 30-35%.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
1602705|NCT02216006|Procedure|High fresh gas flow, high minute ventilation|"Handling of the airway during induction and intubation is performed in a conventional manner.
Immediately after confirming a successful intubation, the effect of preoxygenation is eliminated with a fresh gas flow of 10 L/min of air, delivered with volume controlled ventilation consisting of tidal volumes of approximately 15 ml/kg ideal body weight, a positive expiratory pressure of 10 cm H20 and a respiratory frequency of 10. As soon as the end tidal O2 reaches 25%, the ventilator settings are adjusted to normal values (same as in the control group), i.e. tidal volume 7 mL/kg ideal body weight, PEEP 6 or 8 cm H2O (8 if BMI >25). The mixture of oxygen in the fresh gas is increased to 40% and the fresh gas flow is set to 1 Liter per minute, aiming for an inspired FiO2 of 30-35%.
Unless the patient´s SpO2 falls below 90%, the FiO2 remains unchanged throughout the procedure."
1602706|NCT02215993|Drug|Prasugrel|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
1602707|NCT02215993|Drug|Ticagrelor|After 8 to 6 hours after the dose of 300mg and 600mg respectively. Patients will be randomized in a 1:1 ratio to receive ticagrelor the dose of 180mg and maintained dose of 90 mg twice a day for thirty days or prasugrel dose of 60mg and maintained for thirty days at a daily dose of 10mg.
1602708|NCT02215980|Drug|Lenalidomide|
1602709|NCT02215980|Drug|Dexamethasone|
2009690|NCT03190967|Drug|TMZ|Phase I: TMZ 30, 40 or 50 mg/m^2 daily; Phase II: TMZ at RP2D estimated in Phase I
2009691|NCT03190941|Drug|Cyclophosphamide|Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 mlD5W.
2009692|NCT03190941|Drug|Fludarabine|Days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1602713|NCT02215954|Drug|FE 999169|FE 999169 is a white crystalline powder for oral solution. Each sachet (16.1 g) contains sodium picosulfate hydrate 10 mg, magnesium oxide 3.5 g and anhydrous citric acid 12 g as well as orange flavour, potassium bicarbonate and sodium saccharin as excipients. FE 999916 is dissolved by mixing the contents of the sachet with approximately 150mL of cold water in a cup before administration.
1602714|NCT02215954|Drug|Niflec|Niflec is a white-yellowish powder for oral solution. Each plastic sachet (137.155 g) contains sodium chloride 2.93 g, potassium chloride 1.485 g, sodium bicarbonate 3.37 g and sodium sulfate anhydrous 11.37 g, as well as macrogol 4000, saccharin sodium hydrate, flavour as excipients. Niflec is dissolved in water to make approximately 2 L of solution before administration.
1602715|NCT02215941|Drug|TV-45070|TV-45070 8% ointment
1602716|NCT02215941|Drug|Placebo|Placebo
1602717|NCT02215928|Genetic|mutation analysis|Correlative studies
1602718|NCT02215928|Other|cytology specimen collection procedure|Correlative studies
1602719|NCT02215928|Other|laboratory biomarker analysis|Correlative studies
1602720|NCT02215915|Procedure|Angiography|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
1603015|NCT02213757|Drug|Premarin vaginal estrogen cream|
1603016|NCT02213757|Drug|Placebo vaginal cream|Inactive vaginal cream manufactured to mimic Premarin vaginal cream
1603017|NCT02213744|Drug|MM-302|
2009693|NCT03190941|Biological|anti-KRAS G12V mTCR|Day 0: Cells will be infused intravenously (IV) on the Patient Care Unit over 20 to 30 minutes.
1602721|NCT02215915|Procedure|IVUS|The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
1602722|NCT02215915|Procedure|DES implantation|
1602723|NCT02215902|Device|Affinity plasmapheresis|Insert investigational affinity plasma filter into hemodialysis circuit during routine hemodialysis treatments.
1602724|NCT02215889|Procedure|Liver transplantation|
1602725|NCT02215876|Drug|Doxorubicin|Doxorubicin 60mg/m2 administered intravenously over 5 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
1602726|NCT02215876|Drug|Cyclophosphamide|Cyclophosphamide 600mg/m2 administered intravenously over 60 minutes on day 1 of a 14 of 21 days cycle IV for 4 cycles
1602727|NCT02215876|Drug|Eribulin|Eribulin 1.4 mg/m2 administered intravenously over 2-5 minutes on days 1 and 8 of a 21 day cycle for 4 cycles
1602728|NCT02215863|Biological|Fluad and Prevenar13|
1602729|NCT02215863|Biological|Fluad|
1602730|NCT02215863|Biological|Prevenar13|
1602731|NCT02215850|Drug|SLC-0111|
1602732|NCT02215837|Drug|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
1602733|NCT02215837|Biological|Ag-D-CIK|8×10^9 autologous tumor lysate pulsed D-CIK cells for each infusion, IV (in the vein) for 3 cycles, each cycle received four infusions on day 14, 16, 30 and 32.
1602734|NCT02215824|Drug|BIWH 3|
1602735|NCT02215824|Drug|Placebo|
1602736|NCT02215811|Biological|Mesenchymal stromal cells|
1602737|NCT02215798|Drug|Cymbalta|
1602738|NCT02215785|Other|Kiwifruit|Throughout the five-week study period the patient had to continue their normal eating habits and exercise regime.
1602739|NCT02215772|Drug|BI 44370 BS|
1602740|NCT02215759|Drug|BI 44370 TA|
1602741|NCT02215759|Drug|Placebo|
1602742|NCT02215746|Drug|BI 44370 powder for oral solution|
1602743|NCT02215746|Drug|BI 44370 tablet|
1602744|NCT02215746|Other|high fat breakfast|
1602745|NCT02215733|Drug|ARB|other than telmisartan
1602746|NCT02215733|Drug|ACEI|
1602747|NCT02215733|Drug|Beta-blockers|
1602748|NCT02215733|Drug|Diuretics|
1602749|NCT02215733|Drug|Telmisartan|
1602750|NCT02215720|Drug|Cetuximab|
1602751|NCT02215720|Drug|Temsirolimus|
1602752|NCT02215707|Biological|PfSPZ Vaccine|Suspension of metabolically active, non-replicating (live), radiation-attenuated, purified, cryopreserved, aseptic Plasmodium falciparum (Pf) sporozoites (SPZ)
1602753|NCT02215694|Dietary Supplement|dual probiotics|2g of powder daily containing dual probiotics(Lactobacillus curvatus HY7601 and Lactobacillus plantarum KY1032)
1602754|NCT02215694|Dietary Supplement|placebo|2g of powder daily without probiotics
1602755|NCT02215681|Device|acupuncture|
1602757|NCT02215655|Behavioral|Motivational interviewing|Motivational interviewing counselling sessions will be administered to the subjects.
1602758|NCT02215629|Drug|VS-4718|
1602761|NCT02215603|Behavioral|Breaking prolonged sitting with physical activity|
1602762|NCT02215590|Device|Re-Step|"Research Group:
Each session begins with a warm-up exercise, muscle-stretching and strengthening exercises: duration 10 minutes.
Afterwards, walking exercises with Re-Step according to a program individually tailored and progressing with the training. Progress is shown by increased range of tilting of the shoe and speed of changes, according to the individual ability of each patient.
At the end of the session 5 min of cool down exercises
20 training sessions of 60 minutes, two/three a week."
1602763|NCT02215577|Procedure|In-situ split|The portal branches to the diseased side should be completely divided. The bile duct to the diseased side should not be divided. The parenchyma should be transected all the way through the transection plane and place a plastic sheet on the diseased transection surface.
1602764|NCT02215577|Procedure|Portal embolization or ligation|Portal vein embolization is performed according to the intervention used at the different sites.
1602765|NCT02215538|Drug|OROS methylphenidate|
1602766|NCT02215538|Drug|Placebo|Placebo medication appears identical to the active medication OROS methylphenidate
1602767|NCT02215525|Device|UVA|device uses UVA
1602768|NCT02215525|Dietary Supplement|Herbal|Herbal tablets, 1000 mg every 6 hours daily for 6 months
1602769|NCT02215512|Drug|RRx-001 + WBRT|Subjects will receive a combination of RRx-001 and whole brain radiotherapy.
1602770|NCT02215499|Drug|Placebo|
1602771|NCT02215499|Drug|Sodium Oxybate|
1602772|NCT02215499|Drug|JZP-386|
1602773|NCT02215486|Other|Head Massage Therapy|Intervention consists of administering head massage therapy according to the Chinese head massage protocol for approximately 10 minutes.
1602774|NCT02215486|Other|Simple relaxation (No Head Massage)|Consists of a simple relaxation in the same sitting position as the head massage therapy session.
1602775|NCT02215473|Drug|Chlorhexidine gluconate mouth rinse|Before local oral anesthesia and periodontal instrumentation individuals performed a single oral rinse (15mL of 0.12% chlorhexidine gluconate for 30 seconds). Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
1602776|NCT02215473|Procedure|Periodontal instrumentation|Individuals only received local oral anesthesia before periodontal instrumentation. Debridement procedures were carried out with manual Gracey and McCall curettes and Hirschfield files.
1602777|NCT02215460|Procedure|FMS full-mouth scaling|Participants received oral hygiene instructions and full-mouth scaling within 24 hours. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
1603018|NCT02213744|Drug|Gemcitabine|
1603019|NCT02213744|Drug|Capecitabine|
1603020|NCT02213744|Drug|Vinorelbine|
1602778|NCT02215460|Procedure|QS quadrant scaling|Participants received oral hygiene instructions and quadrant scaling in 4 weekly sections. Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
1602779|NCT02215460|Drug|FMS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
1602780|NCT02215460|Drug|FMS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 60-day use of placebo mouth rinse (15mL/30 seconds/ 2 times a day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
1602781|NCT02215460|Drug|FMS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
1602782|NCT02215460|Drug|FMS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling within 24 hours followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
1602783|NCT02215460|Drug|QS azithromycin tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of azithromycin tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
1602784|NCT02215460|Drug|QS placebo tablets|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 3-day use of placebo tablets (1 tablet/day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
1602785|NCT02215460|Drug|QS chlorhexidine rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% chlorhexidine mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
1602786|NCT02215460|Drug|QS placebo rinse|Participants received oral hygiene instructions and full-mouth scaling in 4 weekly sections followed by a 60-day use of 0.12% placebo mouth rinse (15mL/30 seconds/2 times a day). Debridement procedures were carried out Debridement procedures were carried out under local anesthesia with manual Gracey and McCall curettes and Hirschfield files.
1602787|NCT02215447|Drug|NAB paclitaxel|100 mg/m2 i.v. every week (d1,8,15) in three weekly cycle Number of Cycles: until progression or unacceptable toxicity develops.
1602788|NCT02215447|Drug|Carboplatin|
1602789|NCT02215434|Drug|Biolipid B2 (blanked/placebo)|the intervention will be the comparison effects of both emulsions
1602790|NCT02215434|Drug|Testosterone, Transdermal, Behavior|Transdermal 0.5% testosterone Biolipid/B2
1602791|NCT02215421|Behavioral|Mommio|"The objective is to build parent's skills in encouraging their child to eat vegetables. The player is asked to read a novella, Totally Frobisher (providing backstory to the game), and play a game called Mommio (a casual video game for parents of 3 to 5 year old children). The player calls Kiddio, the child character, to dinner, and offers a vegetable (V) (selected from among several). Kiddio refuses. The player is offered a selection of V parenting statements (from the scientific literature on food parenting) or manipulation of the environment (e.g. turning off the kitchen TV) to control the situation and encourage the child to eat the V. As problems arise (e.g. a permissive father saying he doesn't like vegetables), the player must select ways to cope. Players set a goal to do with their child at home what they learned in the game. Game episodes include food store shopping, eating in the car, at grandma's, and at a fast food store."
1602792|NCT02215408|Behavioral|CVRS Intervention|A clinical pharmacist working in the University of Iowa CVRS will follow each patient for 12 months, working on lifestyle modification and recommending medication changes to the patient's clinical pharmacist in the local clinic.
1602793|NCT02215395|Drug|NES/EE CVR|Concurrent administration of vaginal antimycotic medication (Miconazole Nitrate) on the pharmacokinetics of Nestorone (NES) and ethinyl estradiol (EE) delivered by a contraceptive vaginal ring (CVR)
1602794|NCT02215382|Drug|sugammadex|sugammadex 2 mg/kg
1602795|NCT02215382|Drug|neostigmine+atropine|neostigmine 0,05 mg/kg + atropine 0,025 mg/kg
1602796|NCT02215369|Device|VenaCure EVLT 400 µm fiber Procedure Kit|The study intervention will be conducted according to the DFU included with the VenaCure EVLT 400 µm fiber Procedure Kit.
1602797|NCT02215356|Drug|Icotinib with concurrent radiotherapy|Icotinib: 125 mg is administered orally three times per day.
1602798|NCT02215356|Drug|Chemoradiotherapy|Etoposide 50mg/m2, ivgtt, d1-d5; cisplatin 50mg/m2, ivgtt, d1 and d8, every 28 days for a cycle, a total of 2 cycles
1602799|NCT02215343|Dietary Supplement|Wheat bran extract|Patients will be provided with 15g of wheat bran extract (WBE) (Cargill R&D Centre Europe).
1602800|NCT02215343|Dietary Supplement|Fish oil|Patients will be provided with a fish oil supplement (capsules), containing 3-4g of N-3 fatty acids (Axellus A/S, Ishøj, Denmark).
1602801|NCT02215330|Drug|Eplerenone|
1602802|NCT02215330|Drug|Maltodextrin|
1602803|NCT02215304|Dietary Supplement|Bifidobacterium longum ssp infantis R0033|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.
During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
1602804|NCT02215304|Dietary Supplement|Lactobacillus helveticus R0052|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.
During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
1602805|NCT02215304|Dietary Supplement|Bifidobacterium bifidum R0071|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.
During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
1603021|NCT02213744|Drug|Trastuzumab|
1602806|NCT02215304|Dietary Supplement|Placebo|"12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.
During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3*10E9 colony forming units (CFU)"
1602807|NCT02215278|Dietary Supplement|10 x 55 g/ bean per arm|
1602808|NCT02215265|Drug|Cisplatin|Chemotherapy
1602809|NCT02215265|Radiation|Postoperative radiotherapy|Postoperative radiotherapy (PORT)
1602810|NCT02215252|Drug|PF-05089771 150 mg|PF-05089771 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
1602811|NCT02215252|Drug|Matched placebo for PF-05089771 150 mg and pregabalin 300 mg|Matched placebo for PF-05089771 150 mg twice daily and pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
1602812|NCT02215252|Drug|Pregabalin 300 mg|Pregabalin 150 mg twice daily oral dosing with capsules. Treatment period = 4 weeks.
1602813|NCT02215252|Drug|PF-05089771 150 mg + Pregabalin 300 mg|PF-05089771 150 mg twice daily oral capsules with pregabalin 150 mg twice daily oral capsules. Treatment period = 4 weeks.
1602814|NCT02215239|Behavioral|Workplace intervention|WHO Healthy Workplace Framework and Model. The intervention plan is to implement a cyclic or iterative process recommended by WHO. The process includes eight steps: (1) Mobilize; (2) Assemble; (3) Assess; (4) Prioritize; (5) Plan; (6) Do; (7) Evaluate; (8) Improve. We focus on different phases of exercise and prescribe individualized physical activity program.
1602815|NCT02215213|Drug|Vitamin D supplement|comparison of different dosages of vitamin D
1602816|NCT02215213|Drug|Vitamin D supplement|comparison of different dosages of vitamin D Supplement
1602817|NCT02215200|Drug|Anti-Thymocyte Globulin (ATG)|Thymoglobulin
1602818|NCT02215200|Drug|Granulocyte colony stimulating factor (GCSF)|Granulocyte colony stimulating factor (GCSF)
1602819|NCT02215200|Drug|Placebo (for ATG)|Normal saline administered by IV infusion to mimic ATG
1602820|NCT02215200|Drug|Placebo (for GCSF)|Placebo prepared to mimic 6mg subcutaneous injection of GCSF
1602821|NCT02215187|Behavioral|Problem-Solving Training (PST)|Training in problem-solving skills to be applied to military caregiver problems.
1602822|NCT02215187|Behavioral|Attention Control|Social contact control (health education/no skill training)
1602823|NCT02215174|Drug|Rosuvastatin|Rosuvastatin 20mg po x1
1602824|NCT02215161|Drug|Selinexor|
1602825|NCT02215148|Drug|Tolvaptan|
1602826|NCT02215135|Drug|Corifollitropin alfa|In GnRH antagonist protocol, ovarian stimulation with single dose of 100μg (BW≦60 kg) or 150μg (BW> 60 kg) corifollitropin alfa (Elonva, SC), followed 1 week later (stimulation day 8) by a daily dose of rFSH to the day of GnRH agonist triggering final oocyte maturation.
1602827|NCT02215122|Drug|MGR001|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
1602828|NCT02215122|Drug|Advair® Diskus®|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
1602829|NCT02215122|Drug|Seretide™ Accuhaler™|Fluticasone Propionate is an inhaled corticosteroid (ICS) Salmeterol is a long acting β2 agonist (LABA)
1602830|NCT02215096|Drug|GSK2636771|GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water
1602831|NCT02215096|Drug|Enzalutamide|Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
1602832|NCT02215083|Dietary Supplement|L-glutamine|10,000mg by mouth, twice daily for nine weeks (± 7 days) with one permitted dose escalation to a maximum of 10,000mg by mouth three times daily.
1602833|NCT02215070|Drug|Pasireotide + Chemo|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Chemotherapy (Busulfan) will be given 4 days before stem cell transplant.
1602834|NCT02215070|Drug|Pasireotide + Total Body Irradiation|Eligible subjects will receive pasireotide daily for 5 days before stem cell transplant, the day of the stem cell transplant, and daily for 8 days following the stem cell transplant. Total Body Irradiation (TBI) will be given 4 days before stem cell transplant.
1602835|NCT02215057|Drug|topical anesthesia|topical anesthetic drops and Group 2
1602836|NCT02215057|Drug|topical anesthesia plus intracameral lidocaine 1%|received topical anesthesia plus intracameral lidocaine 1%
1602837|NCT02215044|Drug|BI 2536, intravenous|
1602838|NCT02215044|Drug|Gemcitabine, intravenous|
1602839|NCT02215031|Drug|BI 44370|
1602840|NCT02215031|Drug|Placebo|
1602841|NCT02215018|Drug|BI 44370 TA solution|
1602842|NCT02215018|Drug|BI 44370 TA tablet|
1602843|NCT02215018|Drug|Placebo solution|
1602844|NCT02215018|Drug|Placebo tablet|
1602845|NCT02215005|Drug|Telmisartan|
1602846|NCT02215005|Drug|Ramipril|
1602847|NCT02214992|Drug|Telmisartan/Ramipril|Fixed dose combination tablet
1602848|NCT02214992|Drug|Telmisartan|
1602849|NCT02214992|Drug|Ramipril capsule|
1602850|NCT02214992|Drug|Ramipril tablet|
1602851|NCT02214979|Drug|Telmisartan/Ramipril|fixed dose combination tablet
1602852|NCT02214979|Drug|Telmisartan|
1602853|NCT02214979|Drug|Ramipril capsule|
1602854|NCT02214979|Drug|Ramipril tablet|
1602855|NCT02214966|Drug|Telmisartan/Ramipril, fixed dose combination tablet|
1602856|NCT02214966|Other|high fat, high caloric meal|
1602857|NCT02214953|Drug|BI 11634 ER formulation A|
1602858|NCT02214953|Drug|BI 11634 ER formulation B|
1602859|NCT02214953|Drug|BI 11634 ER formulation M|
1602860|NCT02214953|Drug|BI 11634 ER formulation C|
1602861|NCT02214953|Drug|BI 11634 IR tablet|
1602862|NCT02214940|Drug|BI 11634|
1602863|NCT02214940|Drug|Placebo|
1602864|NCT02214927|Drug|BI 11634 tablet|
1602865|NCT02214927|Drug|BI 11634 drinking solution|
1602866|NCT02214914|Drug|BI 11634 drinking solution|
1602867|NCT02214914|Drug|BI 11634 tablet|
1602868|NCT02214914|Drug|Placebo|
1602869|NCT02214901|Drug|BIBW 2948 BS for oral inhalation|
1602870|NCT02214901|Drug|Placebo|
1602874|NCT02214875|Other|CQI/BTS|Application of CQI/BTS interventions through employing rapid structured cycles of data collection, testing of solutions and review of changes will be implemented. At each site a Quality Improvement Team (QIT) will be established from among the facility staff. Local Government and State level QI teams will provide oversight function of the health facilities' QI initiatives. BTS as a collaborative learning approach will be conducted quarterly in each study state at a central location with participants from the intervention sites. The sessions will provide opportunity for teams to learn from each other and to adapt and implement changes using the Plan-Do-Study-Act (PDSA) model.
1602875|NCT02214875|Other|Control|Facilities in control will continue will routine unstructured, irregular continuous quality improvement. Break Through Collaborative will not be applied to the control facilities.
1602876|NCT02214862|Drug|[F18]-FDDNP|radiopharmaceutical tracer
1602877|NCT02214849|Behavioral|LATCH Intervention|
2009694|NCT03190941|Drug|Aldesleukin|Aldesleukin will be administered at a dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15-minute period beginning within 24 hrs of cell infusion and continuing for up to 3 days (maximum 9 doses).
1602879|NCT02214823|Device|FES-Cycling|
1602880|NCT02214823|Other|Standard Care|standard care physiotherapy including respiratory and rehabilitation with mobilisation activities such as sitting out of bed, marching on the spot, and mobility training.
1602881|NCT02214810|Drug|Bupivacaine/Exparel|The opaque envelope, which was selected by the treating physician, will accompany each of the study participants will be opened and the patient identified as belonging to either Group 1 or Group 2. It is important to note that randomization of the envelopes were computer-generated and placed by a co-investigator; the treating physician is completely unaware of the order of the opaque envelopes. Patients in Group 1 will receive a standardized medication regimen including non-liposomal bupivacaine by soft-tissue injection at the conclusion of their surgical procedure. Those in Group 2 will receive non-liposomal bupivacaine and ExparelTM by soft-tissue injection at the conclusion of their surgical procedure. Study participants will undergo injection in this manner until the conclusion of the study.
1602882|NCT02214797|Device|Etafilcon A, Lotrafilcon B , Senofilcon A|
1602883|NCT02214784|Device|Active Neurotech Vital|12 weeks treatment for 30 minutes per day, 5 days out of 7.
1602884|NCT02214784|Device|Modified Neurotech Vital Device|12 weeks treatment for 30 minutes per day for 5 days out of 7.
2009695|NCT03190915|Other|Laboratory Biomarker Analysis|Correlative studies
2009696|NCT03190915|Other|Pharmacological Study|Correlative studies
1602887|NCT02214758|Other|Nutrition and oral health interventions|On the basis of a blood test, Mini Nutritional Assessment, and nutritional anamnesis, the nutritionist developed a plan for individualised nutritional care and discussed with the participant and her/his nurse or family members. If the participants seemed unable to increase the energy and/or protein of their diet, daily complementary dietary drinks were recommended to them. After the dental hygienist interview and oral health examination, the participants in need were targeted for oral health intervention. The intervention included individualised instructions on either dental hygiene, denture hygiene, cleaning of the oral mucosa or for dry mouth. The participants were re-examined six months after the baseline interviews to evaluate the effectiveness of the interventions. Both the intervention and control groups had the same examinations as with the exception of the nutritional and oral health intervention.
1602888|NCT02214745|Other|Questionnaire|Questionnaire developed for this purpose by the investigators
2009697|NCT03190915|Drug|Trametinib|Given PO
1602890|NCT02214719|Behavioral|EASI-IDM use|EASI-IDM use is the intervention involving the use of the Edmonton Automated Sugar Intelligence system linked to the Intelligent Diabetes Website by people with type 1 diabetes to facilitate glucose record keeping, clinical monitoring and we will assess if this app helps lead to improved glucose control and more patient involvement with their diabetes management.
1602891|NCT02214706|Drug|Sirolimus|sirolimus (40 µl) will be applied under occlusion, using van der Bend patch-test chambers (size: 1cm2), and left in situ for 7 days.
1602892|NCT02214706|Other|Erbium yag laser|Er:Yag laser ablation of the stratum corneum
1602893|NCT02214706|Device|Pulsed Dye Laser|
1602894|NCT02214693|Drug|DA-1229|
1602895|NCT02214680|Drug|Combigan (Combination of Brimonidine and Timolol)|On the first exam the subject will receive Combigan (Combination of Brimonidine and Timolol) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops. On the second exam the subject will receive Timolol (0.5%) eye drop to the right eye and a Brimonidine drop to the left eye. The effect on pupil size before and 30 minutes, 60 minutes, 240 minutes, and 300 minutes after instillation of eyedrops.
1602896|NCT02214680|Drug|Timolol|0.5% eye drop
1602897|NCT02214667|Behavioral|Dual-diagnosis motivational interviewing (DDMI)|DDMI is an evidence-based adaptation to motivational interviewing. DDMI incorporates an integrated framework and accommodates cognitive impairments and disordered thinking associated with co-occurring substance use and mental disorders.
1602898|NCT02214667|Behavioral|Integrated group therapy (IGT)|IGT is an evidence-based practice for treating co-occurring disorders. IGT focuses on relapse prevention by reducing substance use and stabilizing psychiatric symptoms.
1602899|NCT02214667|Behavioral|Jail and community-based behavioral health services|Existing behavioral health service programs
1602900|NCT02214641|Behavioral|Resilient, Empowered, Active Living with Diabetes|Individualized lifestyle intervention incorporating the following topics: Diabetes knowledge; access to healthcare; communication with healthcare providers; incorporation of diabetes self-care tasks within daily habits and routines; social support; and emotional well-being. Participants receive a total of 10-16 hours of intervention by a licensed occupational therapist with training in diabetes education, motivational interviewing and the REAL Diabetes intervention protocol.
1603026|NCT02213705|Biological|INJECTION OF ALLOGENEIC MESENCHYMAL STEM CELLS|
1602901|NCT02214641|Behavioral|Information Control|Participants will receive a packet of informational materials about diabetes, and receive periodic follow-up phone calls to match for attention dose. The packet of materials will be delivered in an initial home visit. Follow-up phone calls will occur at approximately two week intervals to inquire whether participants have reviewed specific sections of the intervention materials, and clarify information included in the packet.
1602902|NCT02214628|Drug|Fovista® (anti-PDGF BB) plus anti-VEGF|
1602903|NCT02214615|Drug|Carbamazepine|"Day 1: Take 200 mg twice a day. Day 2: Take 200 mg twice a day. Day 3: Take 200 mg twice a day. Day 4: Take 200 mg twice a day. Day 5: Take 400 mg twice a day. Day 6: Take 400 mg twice a day. Day 7: Take 400 mg twice a day. Day 8: Take 400 mg twice a day. Day 9: Take 600 mg twice a day. Day 10: Take 600 mg twice a day. Day 11: Take 600 mg twice a day. Day 12: Take 600 mg twice a day. Day 13: Take 800 mg capsules twice a day. Day 14: Take 800 mg twice a day. Day 15: 800 mg twice a day. Day 16: Take 800 mg twice a day.
Taper Down (After Visit 4 and 7) If maximal dose of 800 mg/day has been achieved, tapering down will take 9 days Taper down for 600 mg/day will take 6 days, and for 400 mg/day will take 3 days."
1602904|NCT02214615|Drug|Placebo|
1602905|NCT02214602|Drug|Epirubicin|"Experimental: Study group(Epirubicin)
in the arm -study group(Epirubicin)- : patients will receive immediate intravesical instillation of 50 mg of epirubicin in 50 ml of saline 0.9 % after 30 min after compete transurethral resection of bladder tumor"
1602906|NCT02214589|Other|Oral glucose, facilitated tucking, NNS|
1602907|NCT02214589|Other|Oral glucose and NNS|
1602908|NCT02214589|Other|Facilitated tucking and NNS|
1602909|NCT02214563|Dietary Supplement|Cholecalciferol|Made for this trial by Molecular Physiological Chemistry Laboratory, Inc.
1602910|NCT02214563|Dietary Supplement|Olive oil|
1602911|NCT02214550|Drug|microgestin 1/20|"Cyclic OC Use - Participants will ingest pills containing active hormones for 21 days followed by 7 days of no pills, and then the cycle will repeat
Continuous OC use - Pills containing hormones will be taken every day for 1 year"
1602912|NCT02214537|Other|MACS|
1602913|NCT02214524|Device|Bair Hugger forced air warming system|Bair Hugger Model 775 temperature management unit-offers two airflow settings, hose-end temperature sensing, and precise temperature delivery
1602914|NCT02214511|Behavioral|emotional facial stimuli|Subjects watch passively dynamic facial emotions obtained by emotionnal faces photos morphing. Their rapid facial reactions are recorded by faciel EMG device as eye movement by occulometric device.
1602915|NCT02214511|Behavioral|Cyberball game|Ball tossing computer game to manipulate social inclusion status : rejection or inclusion. Social behavior, social pain and inflammatory modification will be assessed after the game.
1602916|NCT02214498|Drug|Enalapril/hydrochlorothiazide|The intervention implies that morning and evening administration of enalapril/hydrochlorothiazide will be compared
1602917|NCT02214498|Drug|Placebo|
1602918|NCT02214485|Behavioral|integrated care|Participants visit the study site with health education, social activities, warm up, stretch, and low intensity resistance exercise for about 1 hour per week. If any medical problems or functional decline suspected during the visit, the case manager refers participants to their primary care physicians for further managements.
1602919|NCT02214485|Behavioral|lower extremity strength training|Participants receive 2 sessions of 30-minute lower extremity strength straining using isotonic strength training machines each week. The intensity is set at 60-80% of 1 repetition maximum (RM). Evaluation of the exercise protocol are repeated every 2 weeks for individualized adjustments.
1602920|NCT02214472|Behavioral|Biofeedback|
1602921|NCT02214472|Drug|Placebo|
1602922|NCT02214459|Behavioral|DASH Mobile mhealth enhanced coaching|Phone calls with a health coach that utilize the tracking data collected by the app and devices.
1602923|NCT02214433|Drug|Placebo IV Solution|A sterile IV solution of 5% dextrose in water
1602924|NCT02214433|Drug|Debio 1450 IV Solution|A white to off-white powder (40 mg Debio 1450 per vial) to be reconstituted and formulated in a sterile IV solution of 5% dextrose in water
1602925|NCT02214433|Drug|Placebo Tablet or Capsule|Placebo tablet or capsule, matching Debio 1450 coated tablet or capsule
1602926|NCT02214433|Drug|Debio 1450 Tablet|Debio 1450 40 mg coated tablets
1602927|NCT02214433|Drug|Debio 1450 Capsule|Debio 1450 40 mg capsules
1602928|NCT02214433|Drug|Debio 1450 Oral Solution|Lyophilized Debio 1450 (40 mg per vial) reconstituted in 5% dextrose in water
1602929|NCT02214433|Drug|Pantoprazole|Pantoprazole 40 mg orally
1602930|NCT02214420|Drug|Simeprevir|
1602931|NCT02214420|Drug|Sofosbuvir|
1602932|NCT02214420|Drug|Ribavirin|
1602933|NCT02214407|Drug|Decitabine|"Decitabine (DAC) will be administered at 20 mg/m2 intravenously daily for 5 days every 28 days. Hydroxyurea may be added during the first 3 cycles if WBC counts > 30 G/L, and mandatory if WBC > 50 G/L. The daily dose will be adapted to maintain WBC below 15 to 20 G/L.
Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
1602934|NCT02214407|Drug|HYDROXYUREA|"Hydroxyurea (HY) 1g/d once daily, with dose adjustments (up to 4g/d) to maintain a WBC count between 5 and 10 G/L. Allopurinol, 300mg/d started at the time of inclusion will be administered to all patients.
Treatment will be continued until an event is reached. Events and thus study exit will be acknowledged only after agreement between the investigator and a Trial Committee."
1602935|NCT02214394|Other|High-performance liquid chromatography Analysis|Blood samples will be collected for HPLC analysis to compare with the breath samples.
1602936|NCT02214394|Device|SMART Device|Breath collection for GC-MS analysis to compare with Blood collection.
1602937|NCT02214381|Drug|Myocet|
1602938|NCT02214381|Drug|Cyclophosphamide|
1602939|NCT02214381|Drug|Paclitaxel|
1602940|NCT02214368|Other|Early application of NIV|"Device:BiPAP Vision.
NIV bundle group : Early application of NIV(BiPAP Vision) in 1 h after randomization."
1602941|NCT02214368|Device|Fiberoptic bronchoscopy|Device:fiberoptic bronchoscopy. NIV bundle group :When patients were inability to spontaneously clear airways from excessive secretions during NIV, fiberoptic bronchoscopy (FBO) was used for suction of secretions.
1603023|NCT02213718|Drug|Desflurane|desflurane (7%-8% end-tidal concentration)
1602942|NCT02214368|Drug|Propofol|"Drug:propofol.continuous perfusion of propofol (0.50-2.00 mg/kg/h).
NIV bundle group :When patients showed intolerance or inadequate patient cooperation during the NIV session, they were sedated (Ramsay scale 2-3) by a continuous perfusion of propofol (0.50-2.00 mg/kg/h).
In the conventional treatment group: No intervention."
1602943|NCT02214368|Other|Conventional application of NIV|Conventional treatment group:NIV(BiPAP Vision) was used, when patients failed the supplemental oxygen and met at least two of the following criteria:(1) severe respiratory distress with dyspnoea, respiratory rate>30breaths/min, and clinical signs suggestive of respiratory-muscle fatigue or increased respiratory effort (use of accessory respiratory muscles or paradoxical abdominal breathing, or intercostal indrawing), (2) respiratory acidosis (arterial pH of 7.35 or less with PaCO2 of 45 mm Hg or more) ;(3) arterial O2 saturation by pulse oximetry less than 90% or PaO2 less than 60 mm Hg at an FiO2> 0.5 or breathing at least 10 L/min oxygen.
1602944|NCT02214342|Other|Balance Training|"Experimental: Balance Training Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
1602945|NCT02214329|Device|Sensor-based exercise training|Body-worn sensors are mounted on different body segments to acquire joint kinematic data and provide real-time joint feedback during exercise training.
1602946|NCT02214329|Other|In-home balance training|The control group performs similar exercise as intervention without sensors and with no visual feedback from sensors.
1602947|NCT02214316|Other|Hypertonic Saline|
1602948|NCT02214290|Drug|Caffeine|A 200 mg caffeine tablet was given to subject to examine the drugs effect on arterial function.
1602949|NCT02214290|Drug|Placebo|A 750 gram placebo capsule (maltodextrin) was given to subjects to examine the effect of the drug on arterial function.
1602950|NCT02214290|Dietary Supplement|L-citrulline|L-citrulline was used to examine the effect of the supplement on arterial function.
1602953|NCT02214264|Behavioral|Loving-Kindness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided reflections and intentions related to feeling loving-kindness towards the self and others.
1602954|NCT02214264|Behavioral|Breath Awareness meditation training|Participants undergo training for approximately 12 minutes. Training involves guided awareness focused on sensations of breathing.
1602955|NCT02214264|Behavioral|Gratitude|Participants undergo training for approximately 12 minutes. Training involves reflections of gratitude for people, events, and things in one's life.
1602956|NCT02214264|Behavioral|Control|Participants will write and then think about the physical space in which they live (i.e., their home) for approximately 12 minutes.
1602957|NCT02214251|Device|PK-16CH EXG system|
1602958|NCT02214238|Device|PAP device|
1602959|NCT02214225|Biological|Quadrivalent Influenza Vaccine (QIV)|One 0.5 mL intramuscular dose into the deltoid muscle
1602960|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-1)|One 0.5 mL intramuscular dose into the deltoid muscle.
1602961|NCT02214225|Biological|Trivalent Influenza Vaccine (TIV-2)|One 0.5 mL intramuscular dose into the deltoid muscle.
1602962|NCT02214212|Device|Bright White Light (BWL)|The device emitting BWL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
1602963|NCT02214212|Device|Red Light (RL)|The device emitting RL will be placed 24 inches from the participant's face on a pre-measured table. The participant will spend 30 minutes with the eyes open in front of the device. This will occur each morning for 10 days.
1602964|NCT02214199|Other|Manipulative Therapy Techniques|
1602965|NCT02214199|Other|Home Exercises|
1602966|NCT02214186|Other|Restrictive Fluid Therapy|The intervention in this randomized clinical trial is fluid restriction during cesarean section. The restricted group will receive 250 mL of crystalloid during surgery.
1602967|NCT02214173|Dietary Supplement|rice bran arabinoxylan compound (RBAC)|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
1602968|NCT02214173|Dietary Supplement|Placebo|2 capsules with 6 to 8 ounces of water 3 times per day (6 tablets total per day) for 6 months.
1602969|NCT02214160|Drug|UX007|Subjects will begin or continue treatment with daily open-label UX007 while maintaining their other dietary restrictions.
1602970|NCT02214147|Drug|Alisertib|Alisertib will be supplied as enteric coated tablets.
1602971|NCT02214134|Genetic|Tumour markers testing|
1602972|NCT02214121|Drug|Ticagrelor Dose 1a + Dose 2a|Ticagrelor Dose 1a and ticagrelor Dose 2a single doses + 1 week ticagrelor repeated dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
1602973|NCT02214121|Drug|Ticagrelor Dose 1b + Dose 2b|Ticagrelor Dose 1b and ticagrelor Dose 2b single doses + 1 week ticagrelor repeted dosing followed by 4 weeks repeated dosing ticagrelor or placebo.
1602974|NCT02214108|Other|Nintendo Wii|Tennis, box and bowling on Nintendo Wii, 3 hours per week.
1602975|NCT02214095|Drug|glucosamine sulphate|group I (G1) patients received 500 mg glucosamine sulphate capsules (Glucosamine Compound) , three times daily for 3 months following initial cause related therapy. Group II patients were given placebo capsules( Lactose) for the same period following initial cause related therapy
1602976|NCT02214095|Drug|lactose capsules|
1602977|NCT02214082|Other|Same Day Discharge|This group will be discharged home, on the same day after their elective angioplasty
1602978|NCT02214069|Device|Record and transmit heart rhythm|The patient uses the AliveCor device to record and transmit heart rhythm two times a day. The patient, device software, and Electrophysiologist interpret the rhythm
1602979|NCT02214056|Other|Patient recruitment|Participating general practitioners (GPs) will inform and recruit participants from among regular patient consults. Using the provided web tools, GPs will organize a visit with the mobile team that fits the needs of the patient.
1603024|NCT02213718|Drug|propofol|propofol (TCI:3.5-4.0μg/min)
1603025|NCT02213718|Drug|sufentanil|TCI: 2-3 ng/ml during the duration of surgery, an expected average of 4 hours
1602980|NCT02214056|Procedure|Mobile team exam|"Each patient enrolled will receive a standardized assessment in one locality, made in about two hours, and comprising:
questionnaire responses, a complete physical exam, a 12-lead ECG, spirometry before and after administration of β2-agonists, an arterial Doppler ultrasound (carotid and abdominal), ankle-brachial index (systolic pressure at the toe).
At the end of two hours, each patient will evaluate their satisfaction using a survey of acceptability and leave with a full report to the attention of their general practitioner (copy sent to Physician if needed) detailing the results of the different examinations."
1602981|NCT02214030|Device|Assiut Femoral Compression Device|Assiut Femoral Compression Devices (AFCD) is a femoral compression system, The pressure dome is situated over the vessel puncture site in the groin and applies a mechanical pressure over the vessel puncture site to induce hemostasis.
1602984|NCT02214004|Drug|Trastuzumab|"- Eight times IV administration of trastuzumab per 3 weeks
Trastuzumab 8mg/kg on Day 1 of Cycle 1
Trastuzumab 6mg/kg from Day 1 of Cycle 2 to Day 1 of Cycle 8"
1602985|NCT02214004|Drug|Letrozole|- Daily letrozole 2.5 mg/day for 24 weeks
1602986|NCT02213991|Device|Intraoperative radiotherapy using Intrabeam®|"Operation day
Aftuer tumor lump is removed and negative tumor margins are achieved, applicator of Intrabeam® is located within tumor cavity.
Purse string suture pulles up tissues and wraps up the applicator.
Intraoperative radiotherapy using Intrabeam® (20Gy) is followed.
After IORT, applicator was out of the operative field, and usual wound closure will be done.
Postoperative period
Chemotherapy WBRT (46 Gy) for 4~5 weeks
Endocrine therapy or target therapy"
1602987|NCT02213965|Device|Peripheral IV catheter|Intravenous access according to Instructions For Use
1602988|NCT02213952|Drug|Platelet-Rich Plasma|For obtaining autologous PRP, will be drawn from 9-30 ml of blood of the patient in sterile tubes containing 4.5 ml of 3.8% sodium citrate. The tubes will be centrifuged for 8 min at 580 Gs to separate the different blood components according to density gradient. After centrifugation, we will aspire the PRP. We will add CaCl2 to the PRP (50l per ml of liquid plasma). While the plasma will get gelified, we will cure the ulcer with saline cleaning and mechanical removal. Then the ulcer will be covered with gelified PRP and a secondary dressing. This cure will be done each 7 days.
1602989|NCT02213952|Other|Usual treatment|Usual treatment: Patients in the control group will be treated according to Osakidetza recommendations of humid environment cure. The choice of material for the cure depends on the prior assessment of the wound and surrounding skin, appearance and amount of exudate and the presence or absence of signs of infection. These cures will be performed every 48-72 hours.
1602990|NCT02213926|Drug|ACP-196 (acalabrutinib)|
1602991|NCT02213913|Drug|lenalidomide|Given PO
1602992|NCT02213913|Drug|etoposide|Given IV
1602993|NCT02213913|Drug|prednisone|Given PO
1602994|NCT02213913|Drug|vincristine sulfate|Given IV
1602995|NCT02213913|Drug|doxorubicin hydrochloride|Given IV
1602996|NCT02213913|Drug|cyclophosphamide|Given IV
1602997|NCT02213913|Biological|rituximab|Given IV
1602998|NCT02213913|Other|quality-of-life assessment|Ancillary studies
1602999|NCT02213913|Other|laboratory biomarker analysis|Correlative studies
1603000|NCT02213900|Drug|Haloperidol|0.5mg IV Push immediately after surgery and Q8H following for a total of 4 days
1603001|NCT02213900|Drug|Placebo|
1603002|NCT02213887|Drug|Pantoprazole|40 mg PO QAM
1603003|NCT02213887|Drug|Pantoprazole|0 mg PO QAM
1603004|NCT02213874|Other|Questionnaire|A questionnaire will be administered during the early stages of prenatal care & again during the postpartum period. The initial questionnaire will assess trust in the health care system, locus of control, religiosity, health literacy & collect information about demographics, contraceptive & reproductive history, future pregnancy intentions, & baseline knowledge about contraception. The postpartum questionnaire will repeat questions about future pregnancy & contraception intentions, trust in the health care system, knowledge of contraception and collect new information about characteristics of antenatal contraceptive counseling received including whether a provider recommended a specific method of contraception, the amount of counseling received, & the type of counseling received.
1603005|NCT02213861|Drug|SHAPE|topical gel
1603006|NCT02213848|Drug|Calcium|Administration of calcium chloride 5 mg/kg along with neostigmine 25 mcg/kg + atropine 15 mcg/kg
1603007|NCT02213848|Drug|control|In the control group, all the procedures were the same with calcium group, except for the fact that calcium chloride is not administered
1603008|NCT02213835|Other|Specific Carbohydrate diet (SCD)|
1603009|NCT02213822|Other|Molecular Analysis of Cancer|The intervention performed in this study is the molecular analysis of cancer. Samples to be tested for genetic alterations will be collected during the course of a routine diagnostic procedure such as a surgery or tumor biopsy. Samples that have been stored from previous diagnostic procedures will be analyzed as well. This testing will be performed by the Department of Pathology at Rhode Island Hospital or an outside laboratory designated by Rhode Island Hospital. The extent of molecular testing will be different in each individual case. For example, in some cases, study of genetic alterations will start with whole genome or exome sequencing and will be confirmed by targeted Sanger resequencing, single nucleotide polymorphism, and transcriptome analysis. In other cases targeted multigene panel sequencing or targeted amplicon Sanger sequencing will be the initial and only step.
1603010|NCT02213809|Behavioral|Case method education in COPD|In case method a rich narrative describing of a real-life situation (teaching case) is presented, in which the learning group must make a decision or solve a problem. The teaching case provide information, but neither analysis nor conclusions. The analytical work of explaining the relationships among events in the case, identifying options, evaluating choices and predicting the effects of actions is the work done by students during the discussion.
1603011|NCT02213809|Behavioral|Traditional education in COPD|Traditional education in this study means that the teacher mainly speaks to the group. Although short cases may be used for illustration, the main focus is not that the group shall solve problems from a narrative case.
1603012|NCT02213796|Drug|Meropenem|
1603013|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 0.5 hr infusion every 6 hr at room temperature
1603014|NCT02213783|Drug|Imipenem|Each patient will receive 0.5 g of imipenem, 4 hr infusion every 6 hr of at room temperature
1603027|NCT02213679|Dietary Supplement|Guanidinoacetic acid|Dietary supplement
1603028|NCT02213679|Other|Placebo|Placebo
1603029|NCT02213666|Device|Intracardiac Imaging|Imaging of the RAA and LAA with ICE and assessment of thrombus.
1603030|NCT02213653|Drug|ARM A : IV iron + epoietin zeta|"Epoietin zeta at a dose of 450 IU / kg per week subcutaneously
Carboxymaltose ferric (Ferinject ®) at week 1; Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).
Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1."
1603031|NCT02213653|Drug|ARM B: IV iron + epoietin zeta sequence|"Epoietin zeta at a dose of 450 IU / kg per week subcutaneously started in week 7
carboxymaltose ferric (Ferinject ®) at week 1
Intravenous infusion not exceeding 1000 mg (administered once if weight> 50 kg, 500 mg twice otherwise, with an interval of one week between each administration).
Renewable with a minimum of 4 weeks depending on the iron status (if CST <20% and absence of serum ferritin> 800) in the same manner as week 1."
1603032|NCT02213653|Drug|ARM C : single epoietin zeta|Epoietin zeta at a dose of 450 IU / kg per week subcutaneously begun in week 1
1603033|NCT02213640|Device|transcranial direct current stimulation (tDCS)|Anodal tDCS over the primary motor cortex. Stimulation intensity of 1mA during 20 minutes (5 consecutive sessions during one week).
1603034|NCT02213640|Device|Control: placebo stimulation|electrode of sham tDCS over the primary motor cortex during 20 minutes (5 consecutive sessions during one week).
1603038|NCT02213614|Dietary Supplement|Lithium Water|Supply daily doses of Lithium water in form bottled mineral water
1603039|NCT02213614|Dietary Supplement|placebo: spring mineral water|Drink spring natural water a placebo 3 times a day
1603040|NCT02213614|Other|natural spring water|A group will drink natural spring water for 4 months
1603041|NCT02213601|Behavioral|Yoga|
1603042|NCT02213588|Dietary Supplement|AOX blend|Antioxidant supplement
1603043|NCT02213588|Dietary Supplement|Placebo|
1603044|NCT02213575|Drug|Minocycline|Subjects will receive the dose of Minocycline determined to best lower BP and will undergo baseline and week 12-24 follow-up MRI and PET scans for changes in the paraventricular nucleus.
1603045|NCT02213562|Dietary Supplement|200 mg of chrysanthemum flower oil|
1603046|NCT02213562|Dietary Supplement|300 mg of chrysanthemum flower oil|
1603047|NCT02213562|Dietary Supplement|400 mg of chrysanthemum flower oil|
1603048|NCT02213549|Dietary Supplement|Placebo|
1603049|NCT02213549|Dietary Supplement|Ume paste and ginger powder|
1603050|NCT02213536|Radiation|VMAT (Volumetric Modulated Arc Therapy)|Delivering a prescribed radiation dose to the whole brain using VMAT to reduce dose to hair follicles on scalp.
1603051|NCT02213523|Dietary Supplement|Plant concentrate A|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
1603052|NCT02213523|Dietary Supplement|Plant concentrate B|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
1603053|NCT02213523|Dietary Supplement|Plant concentrate C|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
1603054|NCT02213523|Dietary Supplement|Plant concentrate D|Screening for the optimal dosage by starting with with a low dose of 300 mg for one week then switch to 600 mg for one week.
1603055|NCT02213510|Device|Zip Surgical Skin Closure Device|The Zip Surgical Skin Closure device is a single use, sterile medical device that replaces sutures, staples, and glue for closure of the skin layer for surgical incisions or laceration repair. The device will applied by the surgeon at the end of the CIED procedure and be worn until the two week post-operative wound check.
1603056|NCT02213510|Device|Standard Suture Closure|The surgeon will perform standard suture closure for the skin layer following CIED procedure.
1603057|NCT02213497|Radiation|18F-FDG (Fluorodeoxyglucose) PET|
1603058|NCT02213497|Drug|Carboplatin|
1603059|NCT02213497|Drug|Paclitaxel|
1603060|NCT02213458|Behavioral|Navigated Care|"Navigated Care emphasizes continuous and personalized care and is based on 3 modules: the Caregiver Module that includes educational interventions and connects families with community resources, the Decision-Making Module that facilitates proactive medical, financial, and safety decisions, and the Medication Module that identifies inappropriate medication usage via pharmacist review. Innovative technology in the form of a dashboard functions as a patient care management system used by Care Team Navigators (CTNs)."
1603061|NCT02213432|Biological|Different timing of influenza vaccination|The timing of Influenza vaccination for cancer patients receiving chemotherapy will be differently assigned to day 1 or day 11.
1603062|NCT02213419|Drug|Endoscopic ultrasonography-guided double ethanol lavage|"A radial echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration and ethanol lavage.
The 80 percent volume of cyst fluid was aspirated, and the pure ethanol was injected into the collapsed cyst until the original shape was restored. After 3-5 minutes, the reaspiration of the injected ethanol was then performed. The pure ethanol was reinjected into the collapsed cyst, followed by reaspiration of maximal possible volume for 3-5 minutes."
1603063|NCT02213406|Dietary Supplement|yogurt|Subjects will receive yogurt with varying fat concentrations
1603064|NCT02213393|Dietary Supplement|Protein enriched products|The intervention group receives CwC protein enriched products. After discharge the intervention group receives CwC products delivered at home for 12 weeks.
1603065|NCT02213393|Dietary Supplement|Usual menu|The control group receives the usual menu, which is energy and protein rich in this elderly patient group. After discharge the control group receives regular products, no protein enrichment, at home for 12 weeks.
1603066|NCT02213380|Procedure|method of anesthesia|"Method of anesthesia includes: general anesthesia and regional anesthesia.
General anesthesia(general anesthesia combined with peripheral nerve blockade, general anesthesia combined with spinal/epidural anesthesia or single general anesthesia) will be used in group GA.
Regional anesthesia(epidural, spinal, combined spinal and epidural anesthesia or nerve block) will be used in group RA"
1603067|NCT02213367|Drug|Bilastine|20mg (8 weeks)
1603068|NCT02213367|Drug|Bilastine|40mg
1603069|NCT02213367|Drug|Bilastin|80mg
1603070|NCT02213354|Drug|MF59|Microfluoridized adjuvant 59 (MF59) is an oil-in-water emulsion. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
1603071|NCT02213354|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent inactivated split influenza virus vaccine made with HA antigen derived from the influenza A/Shanghai/2/2013 virus. Monovalent influenza A/H7N9 virus vaccine. Group 1-6 receive 3.75 mcg, 7.5 mcg and 15 mcg.
1603072|NCT02213341|Procedure|Skin prick allergen test|To test for hypersensitivity to milk, egg, or peanut
1603073|NCT02213341|Procedure|Blood draw|
1603074|NCT02213328|Drug|Truvada|Fixed-dose combination tablet containing 200 mg of FTC plus 300 mg of TDF, taken once daily by mouth.
1603075|NCT02213315|Drug|100mg Mavrilimumab|100mg Mavrilimumab
1603076|NCT02213315|Drug|150mg mavrilimumab|150mg mavrilmumab
1603077|NCT02213315|Other|Placebo|Placebo
1603078|NCT02213302|Drug|placebo administration|
1603079|NCT02213302|Drug|midazolam intravenous administration|
1603080|NCT02213289|Drug|Trastuzumab|HER2 Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line) + Trastuzumab
1603081|NCT02213289|Drug|TBD|MET group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ TBD
1603082|NCT02213289|Drug|ABT-806|EGFR Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ ABT-806
1603083|NCT02213289|Drug|TBD2|FGFR2 Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ TBD2
1603084|NCT02213289|Drug|Ramucirumab|VEGFR2 Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ Ramucirumab
1603085|NCT02213289|Drug|Nivolumab|MSI-H Group: FOLFOX (First Line) +FOLFIRI (Second Line) +FOLTAX (Third Line)+ Nivolumab
1603086|NCT02213276|Other|Oral Glucose Tolerance Test (OGTT)|At baseline participants are asked to drink a glucose solution consisting of 75 grams of glucose dissolved in 250 ml of water. Meanwhile and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from an intravenous access, in order to asses primary and secondary outcomes.
1603087|NCT02213276|Other|Intravenous Glucose Tolerance Test (IVGTT)|In this intervention, the participant needs to have two intravenous accesses. In one we infuse an adjustable 20% glucose solution, and try to mimic the glucose profile found in the oral glucose tolerance test. In order to do this, blood glucose is measured every 5 minutes. At baseline and 15 minutes, 30 minutes, 1 hour, 2 hours and 3 hours later, blood is collected from another intravenous access, in order to asses primary and secondary outcomes.
1603090|NCT02213250|Drug|BENEFIX|Single dose of 50 IU/kg of BeneFIX by intravenous infusion within 10 minutes.
1603091|NCT02213224|Drug|Perindopril|Perindopril is a kind of angiotensin converting enzyme inhibitors (ACEIs) which has been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
1603092|NCT02213224|Drug|Telmisartan|Telmisartan is a kind of angiotensin receptor blockers (ARBs) which has also been considered as the first-line drugs for the treatment of hypertension and has been proved safe during the widespread use.
1603093|NCT02213224|Drug|Amlodipine|Amlodipine is also a kind of widely used first-line drugs for the treatment of hypertension, and there is no evidence showing that it is effective for NAFLD.
1603094|NCT02213211|Drug|Artemether lumefantrine|
1603095|NCT02213198|Behavioral|Engagement focused care|Engagement focused care includes a group intake appointment called Access group with flexible scheduling allowing ease of rescheduling and access as soon as the same day, as well as Shared Decision Making coaching. For Shared Decision Making, a coach meets with the person prior to or following appointments with the prescriber to assist the person regarding what to ask, what to tell, to review options, and to foster choice.
1603096|NCT02213198|Behavioral|Standard Care|Standard treatment provided by a university based transitional care clinic, with individual intakes and follow-ups for medication/therapy scheduled as soon as possible from intake but at least 1 week away-no prioritization of cases
1603097|NCT02213185|Other|EMLA patches|EMLA patches 1.5 hrs before sterile water injections
1603098|NCT02213172|Dietary Supplement|Bifidobacterium longum R0175|
1603099|NCT02213172|Dietary Supplement|Lactobacillus paracasei HA-196|
1603100|NCT02213172|Other|Placebo|
1603101|NCT02213159|Drug|Dexmedetomidine|
1603102|NCT02213159|Drug|Morphine|
1603103|NCT02213146|Drug|BioChaperone human insulin|Single dose of 0.2 U/kg body weight injected subcutaneously
1603104|NCT02213146|Drug|Huminsulin® Normal|Single dose of 0.2 U/kg body weight injected subcutaneously
1603105|NCT02213146|Drug|Humalog®|Single dose of 0.2 U/kg body weight injected subcutaneously
1603106|NCT02213133|Drug|Selinexor (KPT-330)|Oral tablet or suspension at 60, 80, 100 or 120 mg per patient-specific body surface area category. Dosing will occur twice weekly.
1603107|NCT02213107|Drug|Enzalutamide and Dutasteride|Enzalutamide by mouth daily. Dutasteride by mouth daily.
1603108|NCT02213094|Drug|Nicotinamide|Nicotinamide daily for up to 14 days or to delivery, which occurs first
1603109|NCT02213081|Drug|Ulipristal|Patients will take 15mg every other day, or every 4 days per week.
1603110|NCT02213068|Drug|belatacept|Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
1603111|NCT02213068|Drug|Tacrolimus|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
1603112|NCT02213068|Drug|MPA|Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
1603113|NCT02213055|Drug|LICEMD|Parents/guardians of infested children will provide consent for their child's participation. Infested children whose parents agree to use the investigational product will be enrolled on the experimental arm of the study using the LiceMD product as treatment. Participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application.
1603152|NCT02212769|Drug|Losartan 50mg|Losartan 50mg once daily for 7 days
1603114|NCT02213055|Drug|Standard Head lice product|The most common treatments are pesticide-based, over-the-counter remedies of permethrin (1%), or pyrethrin-based products.After baseline scalp exam for lice count and preexisting signs of irritation, parents who agree to the comparison arm may purchase any other head lice treatment of their choice. All treatments are to be done at home by a parent or guardian. All participants will be examined for lice count and scalp irritation the day after the first application, and one and two weeks after the first application. Participants may also be examined by parents or the school nurse at any time if signs of irritation or re-infestation occur. If the child is still found to be infested during any examination, the school nurse will instruct the parent/guardian to retreat.
2009698|NCT03191461|Diagnostic Test|Adenosine stress test MRI|Participants will receive a contrasted adenosine stress CMR examination on a 1.5T Siemens Avanto scanner (Siemens Medical Solutions, Malvern, PA) dedicated to cardiovascular imaging. Adenosine stress was selected due to attenuated endothelium dependent and -independent vasodilation after doxorubicin receipt in humans to allow the investigators to understand the potential effect of perivascular fibrosis on perfusion reserve. Standardized CMR protocols will be performed to measure LV volumes (to assess wall motion abnormalities and identify any potential myocardial dysfunction), Native T1, ECV, and myocardial perfusion reserve in the short-axis plane
2009699|NCT03190395|Procedure|CPVI Group|CPVI Group:The ablation strategy of Circumferential pulmonary vein isolation (CPVI)will be operated on 60 patients with paroxysmal atrial fibrillation.
1603117|NCT02213029|Drug|Epelsiban|White to off white Oral tablets with unit dose strength of 5 mg or 25 mg for dose level of 25 mg, 150mg or >150mg
1603118|NCT02213029|Drug|Placebo|White to off white oral placebo tablets to match 5mg epelsiban
1603119|NCT02213029|Drug|Oxytocin|Oxytocin for IV infusion (at doses of 5, 10, and 20 milliunits), IV bolus (5 IU administered IV as a bolus over 15 seconds) and IM (5 IU administered IM).
1603120|NCT02213029|Drug|Ortho-Cylcen (21)® tablet|White, blue or green tablets for oral administration per product insert to synchronize the menstrual cycles with ovulation. Ortho Cyclen (21) ® is a registered trademark of Johnson & Johnson
1603121|NCT02213016|Device|Transcranial Magnetic Stimulation|
1603122|NCT02213016|Device|Sham Transcranial Magnetic Stimulation|
2009700|NCT03190395|Procedure|CPVI+LARA Group|CPVI+LARA Group: The ablation strategy of Circumferential pulmonary vein isolation combine with Left atrium roofline ablation(CPVI+LARA) will be operated on 60 patients with paroxysmal atrial fibrillation.
1603124|NCT02212990|Drug|Acetaminophen Arm|Blinded Therapy
1603125|NCT02212990|Drug|Placebo Arm|Blinded Therapy
1603126|NCT02212990|Drug|Ibuprofen Arm|Open Label Therapy
1603127|NCT02212977|Device|Octylcyanoacrylate|Skin incision closure with topic skin adhesive Octylcyanoacrylate
1603128|NCT02212977|Procedure|Suture|Skin incision closure with standard subcuticular technique using a running 4-0 Polysorb suture
1603129|NCT02212951|Drug|BIOD-531|
1603130|NCT02212951|Drug|Humalog Mix 75/25|
1603131|NCT02212951|Drug|Humulin R U-500|
1603132|NCT02212938|Drug|BI 14332 CL|
1603133|NCT02212938|Other|high fat breakfast|
1603134|NCT02212925|Drug|BI 14332 CL|
1603135|NCT02212925|Drug|Placebo|
2009701|NCT03189446|Radiation|Vaginal Cuff Brachytherapy|Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy
2009702|NCT03189446|Drug|Carboplatin|Carboplatin (AUC6) on day 1 for 3 cycles
1603138|NCT02212886|Drug|GA Depot 80 mg|Recruitment completed
1603139|NCT02212886|Drug|GA Depot 40 mg|Recruitment completed
1603140|NCT02212873|Other|MyBFF@school program|Students will be required to participate in all 3 components of MyBFF@school (SSG, nutrition and psychology sessions) for 16 weeks under the supervision of trained researchers, then for another 16 weeks supervised by their respective teachers-in-charge of physical education and/or co-curriculum activity. Each SSG session will be for an hour, thrice weekly while the nutrition or psychology session will be for 30-45 minutes once a week.
1603141|NCT02212860|Radiation|Stereotactic Body Radiation Then Surgery|Stereotactic image-guided neoadjuvant ablative radiation (single dose, 21 Gy) followed by lumpectomy for stage I and IIA early stage breast carcinoma
1603142|NCT02212847|Other|vestibular stimulation|
1603143|NCT02212821|Drug|Erythromycin|
1603144|NCT02212821|Drug|Placebo|physiological saline
1603145|NCT02212808|Other|Antimicrobial restriction|All prescriptions for targeted antibiotics will require phone approval by the trained PharmD during this arm. Prescribers will be instructed to contact the pharmacist via pager or phone call to discuss the patient details and the rationale for the desired antimicrobial. The pharmacist will then decide if the targeted antibiotic is approved or denied. If the pharmacist denies the use of the targeted antibiotic, the pharmacist will provide recommendations for alternative antibiotics for the specific clinical scenario. The pharmacist will document this interaction in the REDCap database.
1603146|NCT02212808|Other|Post-antimicrobial prescription review|All prescriptions for targeted antibiotics will be reviewed by the study pharmacist approximately 72 hours after initially written. The pharmacist will review and document the patient's current symptoms, pertinent clinical data, and the indication for the targeted antibiotic documented in the chart. Based on this review, the pharmacist will decide if the targeted antibiotic is necessary and/or if it needs to be modified. If a change is recommended, the pharmacist will then contact the prescriber to discuss the pharmacist's recommendations. The interaction will be documented in the REDCap database.
1603147|NCT02212795|Drug|Zabofloxacin 183mg|Zabofloxacin 183mg single dose
1603148|NCT02212795|Drug|Levofloxacin 250mg|Levofloxacin 250mg single dose
1603149|NCT02212795|Drug|Zabofloxacin 367mg|Zabofloxacin 367mg single dose
1603150|NCT02212782|Drug|Linagliptin 5mg|Linagliptin 5mg once daily for 7 days
1603151|NCT02212782|Drug|DW1029M 1200mg and Linagliptin 5mg|Linagliptin 5mg 1 tablet once daily and DW1029M 300mg 2 tablets b.i.d for 7 days
2009703|NCT03189446|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV over 1 hour on days 1,8 and 15 for 3 cycles
2009704|NCT03188822|Device|Bioabsorbable steroid releasing sinus implant|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable steroid releasing implant placed in the frontal sinus opening, which will remain in place for 14 days.
1603153|NCT02212769|Drug|DW1029M 1200mg and Losartan 50mg|Losartan 50mg 1 Tablet once daily and DW1029M 300mg 2 Tablets b.i.d. for 7days
1603154|NCT02212756|Drug|DW1029M 1200mg and Metformin 1000mg|Metformin 500mg 1 Tablet and DW1029M 300mg 2 Tablets b.i.d. for 7days
1603155|NCT02212756|Drug|Metformin 1000mg|Metformin 500mg b.i.d. for 7 days
1603156|NCT02212730|Drug|Pembrolizumab Pre-Resection|Up to 3 doses of 200 mg, administered by IV, every 3 weeks
1603157|NCT02212730|Procedure|Surgical Resection|Standard of care surgical resection of RCC tumor
1603158|NCT02212730|Drug|Pembrolizumab Post-Resection|Up to 17 doses of 200 mg, administered by IV, every 3 weeks
1603159|NCT02212717|Procedure|EUS-guided gallbladder drainage (EGBD)|The gallbladder would be identified by a linear echoendoscope (EUS) and a suitable puncture site in the stomach or the duodenum without intervening blood vessels would be located. The gallbladder would be punctured with a 19-gauge needle and a guidewire would be passed through the needle and looped in the gallbladder. The Hot AXIOS stent would then be inserted. A naso-gallbladder drain or a 5-7Fr double pigtail stents can be inserted into gallbladder if the effluent failed to clear after irrigation. This would be performed to improve drainage and avoid obstruction of the stent.
1603160|NCT02212717|Procedure|Percutaneous cholecystostomy (PC)|Trained interventional radiologists in the respective hospitals would perform the procedure under local anesthesia. A transhepatic route would be used in all patients to decrease bile leakage. An 8.5 Fr pigtail drainage catheter would be placed between the 8th or 9th intercostal space under sonographic and fluoroscopic guidance. The pigtail catheter would be drained to a bedside bag.
1603161|NCT02212704|Other|Vestibular stimulation by use of the turntable (static roll-tilt while the head is roll-tilted relative to the trunk)|
1603162|NCT02212704|Other|3D-video-head impulse testing|Evaluation of semicircular canal function. This intervention is part of the screening to determine suitability for this study
1603163|NCT02212704|Other|Vestibular-evoked myogenic potentials (VEMPs)|Evaluation of otolith function. This intervention is part of the screening to determine suitability for this study
1603164|NCT02212678|Drug|N-acetylcysteine capsule|N-acetylcysteine capsule
1603165|NCT02212665|Behavioral|High intense interval training|
1603166|NCT02212665|Behavioral|Increased daily activity detected by the pedometer|
1603167|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+HIIT|
1603168|NCT02212665|Behavioral|Increased daily activity detected by the pedometer+group intervention|
1603169|NCT02212652|Dietary Supplement|Vitamin D|10,000 IU of VitD3 daily (one gel daily)
1603170|NCT02212652|Other|Placebo|Gummy button placebo, which will appear very similar to the vitamin D supplement.
1603171|NCT02212652|Other|Standard of Care|Patients will receive the standard care provided to all patients undergoing bariatric surgery regardless of research study participation status.
1603172|NCT02212639|Drug|digoxin|All patients will receive Digoxin without interruption. Doses can be modified individually to reach a serum drug concentration of 0.6 to 1.2 ng/ml for patients <75 years and between 0.5-0.8 ng/ml in patients older than 75 years
1603173|NCT02212626|Device|Rotarex S|
1603174|NCT02212613|Drug|Brexpiprazole|Treatment (6 weeks) Up to 2 mg/day, once daily dose, tablets, orally
1603175|NCT02212600|Other|Observational|
1603176|NCT02212587|Drug|TOBI|New inhalation devices such as the podhaler can administer tobramycin inhalation powder TIP/TOBI and achieve very high sputum drug levels. TOBI will be administered using the Podhaler
1603177|NCT02212574|Drug|Lomustine|Chemotherapy Cycle A Lomustine (CCNU) is given by mouth on Day 1.
1603178|NCT02212574|Drug|Vincristine|Chemotherapy Cycle A Vincristine is given directly into a vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1, 8, and 15.
1603179|NCT02212574|Drug|Cisplatin|Chemotherapy Cycle A Cisplatin is given directly into a vein over 8 hours on Day 1.
1603180|NCT02212574|Drug|Cyclophosphamide|Chemotherapy Cycle B Cyclophosphamide is given into a vein over 1 hour on Days 1 and 2.
1603181|NCT02212574|Drug|Mesna|Chemotherapy Cycle B MESNA, a drug to protect the bladder from the effects of cyclophosphamide, will be given 15 minutes before each dose of cyclophosphamide and repeated at 3 and 6 hours.
1603182|NCT02212574|Drug|Vincristine|Chemotherapy Cycle B Vincristine is given directly into a vein directly into the vein (IV) over one minute or using a minibag over several minutes by some institutions on Days 1 and 8.
1603183|NCT02212561|Drug|Selinexor|Given orally on days 1,3,8,10,22 and 24 of each cycle
1603184|NCT02212561|Drug|Fludarabine|Will be given intravenously (IV) over 30 minutes daily on days 16 through 20. Fludarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
1603185|NCT02212561|Drug|Cytarabine|Will be given IV over 4 hours daily on days 16 through 20. Cytarabine may be given prior to day 16 if it is determined to be in the participant's best interest based on disease progression. Chemotherapy may be delayed by 1-3 days if clinically indicated.
1603186|NCT02212561|Drug|methotrexate/hydrocortisone/cytarabine|Intrathecal (IT) triples will be given prior to cycle 1: IT cytarabine, IT methotrexate, and IT methotrexate/hydrocortisone/cytarabine (MHA) are acceptable. Patients without evidence of central nervous system (CNS) leukemia will receive no further IT therapy during cycle 1. Patients with CNS disease will receive weekly ITMHA until the cerebrospinal fluid becomes free of leukemia (minimum of 4 doses).
1603187|NCT02212548|Device|PEG Hydrogel (SpaceOAR)|A single injection of PEG hydrogel (SpaceOAR) through the perineum under transrectal ultrasound guidance while under general anaesthetic.
1603188|NCT02212535|Drug|Plerixafor|0.24 mg / kg / day, by subcutaneous injection, 11h before the beginning of cytapheresis
1603189|NCT02212522|Other|Collect of environmental data on T1D patients before diagnosis|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
1603190|NCT02212522|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
1603191|NCT02212522|Other|Collect of clinical data on the disease and its evolution|Collect of clinical data on the disease and its evolution every 6 months after enrollment
1603192|NCT02212522|Other|Collect of environmental data on French controls (age-matched for T1D patients)|Questionnaires on large environment during mother's pregnancy and patient's childhood, health book copies, addresses' geolocation, quantification of viral exposures using Sentinel Network data
1603193|NCT02212522|Genetic|Collect of blood samples for DNA extraction and genetic characterization (GWAS)|Collect of blood samples for DNA extraction and genetic characterization (GWAS) on Illumina platform (Centre National de Genotype)
1603194|NCT02212483|Other|First home intervention with advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, audit and advices.
1603195|NCT02212483|Other|First home intervention without any advice|A first home intervention of a MIEC during the 4 weeks following inclusion, with sampling, home audit but without any advice.
1603196|NCT02212483|Other|Final home visit|"Final home visit at the end of the study after 12 months, with sampling and home audit.
For the intervention group, checking of the advice compliance. For the both comparative groups, delivery of advices."
1603197|NCT02212470|Device|Drug Eluting Balloon Angioplasty|Angioplasty with Drug eluting balloon after pre dilatation
1603198|NCT02212470|Device|Nitinol stenting|Nitinol stent deployment
1603199|NCT02212457|Biological|Bexsero™|Two doses administered intramuscularly into the deltoid area at Months 0 and 2 in rMenB_0_2 Group.
1603200|NCT02212457|Other|Saline Placebo|One dose administered intramusculary in the deltoid muscle at Month 1 in ABCWY_ 0_2 Group and rMenB_0_2 Group, Month 2 in ABCWY_0_6 Group and ABCWY_0_11 Group and Month 6 in ABCWY_0_1 Group.
1603201|NCT02212457|Biological|Havrix®|Two doses administered in the deltoid muscle at Month 2 and 12 in ABCWY_0_1 Group, Month 1 and 12 in Group ABCWY_0_6 Group and ABCWY_0_2_6 Group , Month 0 and 6 in ABCWY_0_11 Group and Month 6 and 12 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
1603202|NCT02212457|Biological|MenABCWY|Two to three doses administered in the deltoid muscle at Month 0 and 1 in ABCWY_0_1 Group, Month 0 and 6 in ABCWY_0_6 Group, Month 1 and 12 in ABCWY_0_11 Group, Month 0, 2 and 6 in ABCWY_0_2_6 Group, Month 0 and 2 in ABCWY_ 0_2 Group and rMenB_0_2 Group.
1603203|NCT02212444|Device|Dynamic elastomeric fabric orthoses (DEFO)|A patient customised dynamic elastomeric fabric orthoses (DEFO)
1603204|NCT02212444|Device|Off -the-shelf triplanar orthoses|
1603205|NCT02212431|Drug|Cysteamine|Dose will be increased weekly from 450mg od to 450mg bd, to 450mg tds to 450mg qds, will remain on highest dose for 2 weeks
1603206|NCT02212418|Other|Abdominal hypopressive technique|postural technique based on self-elongating, body axis anteriorization, shoulders extension, and maintenance of an expiratory apnea as long as possible
1603207|NCT02212405|Device|repetitive Transcranial Magnetic Stimulation|Each participant will participate in all three arms to receive sham, 1hz and 10hz rTMS as well as PET imaging.
1603208|NCT02212405|Other|repetitive Transcranial Magnetic Stimulation Sham|The sham coil is built in the same helmet of the active coil. The sham coil is has a circular shape and placed perpendicular to the scalp within the same helmet. This coil produces a similar sound and scalp sensation as the real coil.
1603209|NCT02212392|Drug|Meropenem|inj. MEROPENEM IV 1 gram twice daily at 12 hours interval for 7-10 days
1603210|NCT02212379|Drug|raltegravir and etravirine|"Raltegravir (RAL, ISENTRESS®) 400 mg tablets will be administered as one 400 mg oral tablet PO twice daily (800 mg per day) after a meal.
Etravirine (ETR, INTELENCE®) 200 mg tablets will be administered as one 200 mg oral tablet PO twice daily (400 mg per day) after a meal."
1603211|NCT02212366|Device|Active TDCS|Active Stimulation
1603212|NCT02212366|Device|Sham TDCS|Sham Stimulation
1603213|NCT02212353|Other|Observational study, not interventional|
1603214|NCT02212340|Drug|fresofol and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
1603215|NCT02212340|Drug|desflurane and remifentanil|Anesthesia is maintained with fresofol and remifentanil in TIVA group or with desflurane and remifentanil in Des group according to randomly allocated group.
1603216|NCT02212314|Behavioral|Response Inhibition Training|Computerized response inhibition training will be delivered via the Internet for 10 individual sessions.
1603217|NCT02212301|Device|senofilcon A|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
1603218|NCT02212301|Device|lotrafilcon B|Each study contact lens will be worn as daily wear modality for a period of 2 weeks each.
1603219|NCT02212288|Other|Blood sample|Blood samples are for metabolic and genetic and biological investigation
1603220|NCT02212288|Other|Urine sample|Urine sample for biological investigation
1603221|NCT02212275|Drug|Dextromethophan|A single age and weight appropriate dose of over the counter Delsym Cough Syrup containing only DXM as an active ingredient.
1603222|NCT02212249|Biological|soluble Ve cadherin|dosage of soluble VE cadherine in each arms
1603223|NCT02212236|Other|Psychological preparation|Ninety-minute, group-based psychological preparation delivered prior to haematopoietic stem cell transplantation aiming at alleviating psychological distress during the procedure by enhancing perceptions of the procedure and fostering more helpful coping.
1603224|NCT02212223|Dietary Supplement|Vitamin D3|
1603225|NCT02212210|Drug|Methylprednisolone|
1603226|NCT02212210|Drug|Normal saline|
1603227|NCT02212197|Drug|leuprolide acetate FluidCrystal® injection depot|
1603228|NCT02212197|Drug|leuprolide acetate|
1603229|NCT02212184|Other|Manual Diaphragm Release Technique|The therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. During inspiration, pulls the points of contact with both hands, in the direction of the head, accompanying the elevation movement of the ribs. During exhalation, deepens contact toward the inner costal, maintaining resistance. 2 sets x 10 breaths (1 min interval). Treatment will last two weeks (6 sessions) All patients will undertake four evaluations throughout treatment: Baseline Day 1 and post Day 1; Baseline Day 6 and post Day 6.
1603279|NCT02211729|Drug|suplhadoxine-pyrimethemine + amodiaquine + placebo azithromycin|suplhadoxine-pyrimethemine + amodiaquine + placebo azithromycin 4 rounds during malaria transmission season
1603280|NCT02211716|Device|BeGraft Peripheral Stent Graft System|
1603281|NCT02211690|Drug|dolutegravir 50 mg (one tablet daily)|
1603287|NCT02211625|Drug|Open-label TRV734 125 mg|125 mg
1603230|NCT02212184|Other|Manual Diaphragm release technique (sham)|Manual Diaphragm release technique (sham) In attempt to execute the sham protocol the therapist performs manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib. The therapist will hold only light touch in the landmarks, without exerting pressure or traction. The maneuver will be performed in two sets of ten deep breaths, with an one minute interval between them.
1603231|NCT02212171|Other|TRIAP|"The primary healthcare professionals organised in healthcare mini-teams, composed of 2 doctors, 2 nurses and 1 member of the administrative staff.
Administrative staff:
Following a flow chart, they will refer patients with mild self-limiting illnesses as well as consultations regarding chronic disorders in adults to the nurses. They will also perform administrative tasks such as the printing of prescriptions, sick leave reports and medical notes (justifying absence), etc.
Nursing staff:
They will carry out activities focused on health promotion, self-management and de-medicalisation during visits from patients with mild self-limiting illnesses as well as appointments for chronic diseases in adults.
GP:
They will develop the new portfolio of services: health promotion, joint review of patient medical records by doctors and nurses to improve the management of certain groups of patients, and organization of minor surgery services, etc."
1603232|NCT02212158|Behavioral|motivational interviewing group|Group therapy sessions will include 8 teen sessions that cover the following topics: acceptance of diabetes, family issues, division of diabetes management, communication and facilitating motivation and skill development to improve diabetes care. Motivational interviewing and cognitive behavioral techniques will be the therapeutic modalities used in sessions. Parents will be involved in 3 therapy sessions that cover topics regarding family functioning, division of responsibility and parenting strategies.
1603233|NCT02212132|Other|behavioral assessments|Neuropsychological evaluation, psychopathological assessment and fatigue
1603234|NCT02212119|Drug|Botulinum Toxin|
1603235|NCT02212119|Drug|Saline|
1603236|NCT02212106|Biological|bioCSL Trivalent Influenza Virus Vaccine (CSL TIV)|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
1603237|NCT02212106|Biological|Comparator Quadrivalent Influenza Virus Vaccine|Subjects will receive one or two study vaccinations depending on their influenza vaccine history. The vaccine will be administered by intramuscular injection.
1603238|NCT02212080|Drug|BAY1214784|Escalating doses of 5, 20, 60, 150, 300, 600, 1000 mg of BAY1214784; single dose administration; liquid dosage form
1603239|NCT02212080|Drug|Placebo|Dose 1, 2,3, 4, 5, 6 and 7 of respective placebos; single dose administration; liquid dosage form
1603240|NCT02212067|Drug|semaglutide|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
1603241|NCT02212067|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 12 weeks.
1603242|NCT02212054|Behavioral|conservative|anal dilatation; colonic lavage; oral probiotic
1603243|NCT02212054|Procedure|operative|one stage pull through radical colectomy
1603244|NCT02212041|Other|disposable electronic cigarettes|"Participants will receive e-cigs free of charge during 6-week. Each week for 6 weeks, participants will receive enough e-cigs to cover 150% of their usual weekly cigarette smoking rate. We will encourage participants to use the e-cigs whenever they would usually smoke a cigarette.
During a 4-week post-distribution period, we will assess e-cig and cigarette use and other measures when e-cigs are not being freely provided and participants must purchase them on their own. The Week 10 session at the end of this period includes assessment of total nicotine intake, nicotine dependence, subjective and reinforcing effects of e-cigs and cigarettes, attitudes toward e-cigs, motivation to quit and self-efficacy for smoking cessation. At the Week 24 follow-up session we will again collect these measures to determine if any changes observed during the intervention phases have been maintained."
1603245|NCT02212028|Drug|prasugrel|the effects of whole tablets versus crushed tablets will be compared
1603246|NCT02212015|Drug|Pazopanib + Paclitaxel|pazopanib in combination with paclitaxel in the treatment of patients with advanced or metastatic angiosarcoma.
1603247|NCT02212002|Drug|IAP|maternal IAP, consisting of intravenous ampicillin given every 4 hours until delivery (first dose 2 g, following doses 1 g each).
1603248|NCT02211989|Drug|BI 14332 CL|
1603249|NCT02211989|Drug|Placebo|
1603250|NCT02211976|Drug|Bisacodyl|
1603251|NCT02211976|Drug|Simeticone|
1603252|NCT02211963|Drug|BI 44847|
1603253|NCT02211963|Drug|Placebo|
1603254|NCT02211950|Drug|BI 44847|
1603255|NCT02211950|Drug|Acarbose|
1603256|NCT02211950|Other|Japanese diet|
1603257|NCT02211937|Drug|BI 44847 solution, low dose|
1603258|NCT02211937|Drug|BI 44847 suspension, high dose|
1603259|NCT02211937|Drug|BI 44847 tablet, low dose|
1603260|NCT02211937|Drug|BI 44847 tablet, high dose|
1603261|NCT02211937|Other|high fat breakfast|
1603262|NCT02211924|Drug|BI 44847|
1603263|NCT02211924|Drug|Placebo|
1603264|NCT02211911|Drug|Bisacodyl|
1603265|NCT02211911|Drug|Sodium picosulfate|
1603266|NCT02211898|Drug|BNS003|
1603267|NCT02211885|Drug|14C-BIRB 796 BS|14C-radiolabeled BIRB 796 BS
1603268|NCT02211872|Drug|BI 2536 BS, intravenous|
1603269|NCT02211859|Drug|BI 2536|
1603270|NCT02211846|Drug|Mirabegron|oral
1603271|NCT02211833|Drug|BI 2536|
1603272|NCT02211833|Drug|Pemetrexed|
1603273|NCT02211794|Other|data collection|
2009705|NCT03188822|Device|Bioabsorbable nasal dressing impregnated with steroid|After completion of indicated frontal sinus surgery, patients will have a bioabsorbable nasal dressing impregnated with steroid placed in the frontal sinus opening, which will remain in place for 14 days.
1603277|NCT02211742|Drug|Dapagliflozin|euglycemic hyperinsulinemic clamp tests and euglycemic oral glucose tolerance clamp tests after the short-term (i.e.: 3 days, equals 10mg / 24h) intake of dapagliflozin
1603278|NCT02211729|Drug|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin|Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin 4 rounds during malaria transmission season
1603282|NCT02211690|Drug|emtricitabine-tenofovir 300/200 mg (one tablet daily)|
1603283|NCT02211664|Device|Passeo-18 balloon|
1603288|NCT02211625|Drug|TRV734 blinded|blinded, multiple ascending dose
1603289|NCT02211625|Drug|Oxycodone IR 10 mg|
1603290|NCT02211625|Drug|Placebo|TRV734-matched and oxycodone placebo
1603291|NCT02211612|Dietary Supplement|PUFA-group|
1603292|NCT02211612|Dietary Supplement|SFA-group|
1603293|NCT02211599|Other|15% protein|Meal to provide 15%en from protein.
1603294|NCT02211599|Other|30% protein|Meal to provide 30%en from protein.
1603295|NCT02211599|Other|Sweetened beverage|Beverage sweetened with either sugar (sucrose) or sucralose (non-nutritive sweetener).
1603296|NCT02211586|Drug|Insulin Glargine or LY2605541|When initiating LY2605541, the patient will administer their basal insulin dose of LY2605541 in addition to a tapered dose of insulin glargine. On Day -2, the patient will administer the determined dose of LY2605541 plus 50% of the determined dose of insulin glargine. On Day -1, the patient will administer the determined dose of LY2605541 plus 25% of the determined dose of insulin glargine. On Day 1, the patient will administer the determined dose of LY2605541 only (no insulin glargine). Stable doses of LY2605541 will be administered for a minimum period of 4 weeks.
1603297|NCT02211573|Other|Exercise, Aerobic (Water based)|Patients of this group were submitted to an aerobic water based physical training
1603298|NCT02211560|Other|Phosphatidylserine|
1603299|NCT02211560|Other|Placebo|
1603300|NCT02211547|Device|Epic 10 Diode Laser by Biolase Inc.|
1603301|NCT02211547|Other|Placebo|Single blind lack of laser treatment (the laser will be positioned and operated as if applying the treatment, but the energy transfer will not take place).
2009706|NCT03188653|Other|CeraVe® Eczema Soothing Body Wash|One of the 7 arm locations will be selected to receive CeraVe® Eczema Soothing Body Wash
2009707|NCT03188653|Other|Cetaphil® RestoraDerm® Eczema Calming Body Wash|One of the 7 arm locations will be selected to receive Cetaphil® RestoraDerm® Eczema Calming Body Wash
1603304|NCT02211521|Biological|PRP|3ml of PRP
1603305|NCT02211521|Drug|Hyaluronic acid|3ml hyaluronic acid
1603306|NCT02211508|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
1603307|NCT02211495|Device|GEKO device|Placed on the lateral aspect of the knee, when activated it causes the leg to twitch
1603308|NCT02211495|Other|Best Medical Therapy|Seen in outpatient clinic for wound care and ongoing advice
1603309|NCT02211482|Drug|dolutegravir, lamivudine|single arm
1603310|NCT02211469|Drug|BMS-986104|
1603311|NCT02211469|Drug|Placebo|
1603312|NCT02211456|Procedure|Atrial Fibrillation/flutter (AF) or Ventricular Tachycardia (VT) ablation with multi-site pacing protocol|Pacing at several endocardial sites in isolation and individually will be performed, with response to this assessed by LV dp/dt max
1603313|NCT02211443|Biological|Recombinant full human Anti-EGFR Monoclonal Antibody|
1603314|NCT02211430|Behavioral|Cognitive-Behavioral Counseling (CBC)|Participants of CBC were educated about the effects of smoking on their personal health and their pregnancy during session 1 (45 minutes counseling), and were encouraged to explore their risk perceptions and emotions, for themselves and their unborn child. During session 2, the 15-minute counseling segment highlighted the cognitive and emotion barriers undermining the participant's motivation to quit and the self-regulatory techniques for resisting personal smoking triggers. Session 3 (45 minutes counseling) involved reviewing smoking status and smoking history over the course of the pregnancy, as well as the effects of smoking on both their health and the health of their infant. Booster session was held by phone for 15 min.
1603315|NCT02211430|Behavioral|Best Practice (BC) Control|"For ethical considerations, and consistent with practice guidelines for treating tobacco addiction (Fiore et al., 2000) which mandates that every pregnant smoker be offered smoking cessation treatment, the control group has been designed to be comparable to the current best practice guidelines for smoking cessation treatments. This condition, devised from a review of the current literature, will include one brief (5-15 minutes) prenatal individual session (session 1) consisting of smoking cessation education and advice, on-site brochure pick up (session 2), and a second brief postpartum individual session (session 3) followed by receipt of a newsletter (session 4)."
1603316|NCT02211417|Drug|DS107G|
1603317|NCT02211417|Drug|Placebo|
1603318|NCT02211391|Other|Casein Protein|The effect of casein protein consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
1603319|NCT02211391|Other|Non-caloric placebo|The effect of a non-caloric placebo consumed within 30 minutes of sleep on overnight lipolysis and next morning metabolism and appetite will be examined
1603320|NCT02211378|Other|Observer|Trainees are in the role of observers (not actively participating in simulation scenario) during first 2 simulation sessions, then placed in the role in the 'hotseat' actively participating during the third simulation session.
1603321|NCT02211378|Other|Hotseat|Trainees in the hotseat group are placed in the 'hotseat' to actively participate and manage the simulated medical crises in the simulation scenarios.
1603322|NCT02211352|Drug|Korean Red Ginseng Capsules|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
1603323|NCT02211352|Drug|Placebo|Korean Red Ginseng Capsules 2mg,daily, 8 week and than crossover to placebo capsules(2g), daily 8week
1603324|NCT02211339|Behavioral|Peer tutor training|Peer tutor training to meet the interaction needs of the group.
1603325|NCT02211339|Other|Usual care|Usual care
1603326|NCT02211326|Behavioral|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3 days of treatment will be determined by IWPC( International Warfarin Pharmacogenetics Consortium) algorithm (PG-1),a second dose adjustment will be made after 3 doses of warfarin using a dose revision algorithm (PG-2) that combined INR values,the dose will be adjusted depending on the measurements of INR values after 7 days.
1603422|NCT02210767|Other|Low ALA Diet|ALA replaced by oleic acid
1603423|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
2009708|NCT03188653|Other|Dove® Sensitive Skin Body Wash|One of the 7 arm locations will be selected to receive Dove® Sensitive Skin Body Wash
2009709|NCT03188653|Other|Eucerin® Skin Calming Body Wash|One of the 7 arm locations will be selected to receive Eucerin® Skin Calming Body Wash
2009710|NCT03188653|Other|Aveeno® Skin Relief Body Wash|One of the 7 arm locations will be selected to receive Aveeno® Skin Relief Body Wash
1603327|NCT02211326|Behavioral|Standard initiation dose for warfarin|Initial dosing of warfarin for the first 3 days of treatment will be determined by standard initiation dose. Following this initiation dose of warfarin,the dose will be adjusted depending on the measurements of INR values after 3 days.
1603328|NCT02211313|Device|Randomization to size 6 French soft vs. size 6 French hydrophobic ureteral stent.|Subjects will be randomized to one of two study arms according to ureteral stent size and degree of firmness (size 6Fr, soft vs. size 6Fr, hydrophobic) with allocation ratio of 1:1.
1603329|NCT02211300|Device|The OptiScanner|treatment of blood glucose per standard of care
1603330|NCT02211300|Device|YSI 2300 STAT Plus™|
2009711|NCT03188653|Other|MooGoo® Milk Wash|One of the 7 arm locations will be selected to receive MooGoo® Milk Wash
2009712|NCT03188653|Other|Free & Clear Liquid Cleanser|One of the 7 arm locations will be selected to receive Free & Clear Liquid Cleanser
1603333|NCT02211274|Other|Everyday Competence Assessment and Planning for Community Transitions|The Everyday Competence Assessment and Planning for Community Transitions (ECAP-CT) toolkit will allow CLC interdisciplinary team members to 1) assess the Veteran's everyday competence for safe and independent living; 2) develop personally meaningful rehabilitation goals that facilitate successful transition out of the CLC based on everyday competence; and 3) conduct structured treatment planning to support resident goals around transitioning back into the community. By considering everyday competence and goal-setting in this context, Veterans will have optimal P-E fit upon returning to the community, ensuring a successful transition.
1603334|NCT02211261|Biological|PF-06293620|subcutaneous, single dose 0.3 mg/kg
1603335|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
1603336|NCT02211261|Biological|PF-06293620|Subcutaneous, single dose 1.0 mg/kg
1603337|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
1603338|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 3 mg/kg
1603339|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
1603340|NCT02211261|Biological|PF-06293620|Subcutaneous single dose 6 mg/kg
1603341|NCT02211261|Biological|Placebo|Subcutaneous normal saline single dose
1603342|NCT02211261|Biological|PF-06293620|Intravenous infusion single dose 1 mg/kg
1603343|NCT02211261|Biological|Placebo|Intravenous infusion normal saline single dose
1603344|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 75 mg (Days 1, 29 and 57)
1603345|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
1603346|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 150 mg (Days 1, 29 and 57)
1603347|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
1603348|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose 250 mg (Days 1, 29 and 57)
1603349|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days 1, 29 and 57)
1603350|NCT02211261|Biological|PF-06293620|Subcutaneous injection multiple dose TBD mg (Days TBD)
1603351|NCT02211261|Biological|Placebo|Subcutaneous injection normal saline multiple dose (Days TBD)
1603352|NCT02211248|Other|Multidisciplinary assistance|Multidisciplinary group assistance was effected every two months by all professionals (physician, nurse, dietitian, physiotherapist and psychologist) and consisted in orientations and mechanisms to medication and non-pharmacological adherence (lifestyle changes).
1603353|NCT02211248|Other|Conventional treatment and follow up|Assistance was effected by physician and nurse and consisted about adapting to the drug
1603354|NCT02211222|Drug|Lenvatinib|Lenvatinib at starting doses of 24-mg, 20-mg, or 14-mg will be administered as a combination of 10-mg capsules and 4-mg capsules to be taken once a day (QD) (recommended to be taken the same time each day). Subjects will receive one of three starting doses of lenvatinib, 24-mg/day, 20-mg/day, or 14-mg/day. Dose reductions occur in succession based on the previous dose level (24, 20, 14, and 10 mg/day). Any dose reduction below 10 mg/day must be discussed with the sponsor. Once the dose has been reduced, it cannot be increased at a later date.
1603355|NCT02211209|Drug|volanesorsen|
1603356|NCT02211209|Drug|Placebo|
1603357|NCT02211196|Behavioral|smoking cessation intervention|Receive evidence-based tobacco cessation strategies
1603358|NCT02211196|Other|survey administration|Ancillary studies
1603359|NCT02211196|Other|questionnaire administration|Ancillary studies
1603360|NCT02211183|Procedure|Best Repair of torn Rotator Cuff|
1603361|NCT02211183|Device|InSpace™ system|
1603362|NCT02211170|Drug|BIBR 796 BS, low dose|
1603363|NCT02211170|Drug|BIBR 796 BS, high dose|
1603364|NCT02211170|Drug|Placebo|
1603365|NCT02211170|Drug|Lipopolysaccharide|Lipopolysaccharide (LPS) for endotoxin challenge
1603366|NCT02211157|Drug|BIBR 796 BS|
1603367|NCT02211157|Drug|Placebo|
1603368|NCT02211157|Other|high fat breakfast|
1603369|NCT02211144|Drug|BIBR 796 BS|
1603370|NCT02211144|Drug|Placebo|
1603371|NCT02211131|Drug|Talimogene Laherparepvec|Talimogene laherparepvec will be administered by intralesional injection into the injectable cutaneous, subcutaneous, and nodal tumors initially at a dose of 10^6 plaque forming units (PFU)/mL at day 1 of week 1 followed by a dose of 10^8 PFU/mL at day 1 (±3 days) of week 4, 6, 8, 10 and 12 or until all injectable tumors have disappeared, or intolerance of study treatment or in the opinion of the investigator, immediate surgical resection or any other treatment for melanoma is warranted, whichever occurs first.
1603372|NCT02211131|Procedure|Immediate surgical resection of melanoma lesion(s)|Surgical resection of melanoma tumor lesion(s) will be performed after randomization any time during weeks 1 to 6.
1603373|NCT02211118|Drug|Intranasal dexemdetomidine (IN-DEX)|
1603424|NCT02210754|Other|blu™ Classic Tobacco rechargeable (2.4% nicotine, glycerin/PG vehicle)|electronic cigarettes
1603425|NCT02210754|Other|blu™ Magnificent Menthol rechargeable (2.4% nicotine, glycerin vehicle)|electronic cigarettes
2009713|NCT03188029|Diagnostic Test|adrenocortical function|"Blood samples for cortisol dosage are performed and 24 hours after the sixth session. All blood samples are performed at 9 and collected in normal tube.
Blood samples for glycaemia, sodium, potassium and bicarbonates are performed at the same rate."
1603374|NCT02211092|Behavioral|Physical activity intervention|A 12 week individually tailored home-based physical activity program with goal-setting, a physical activity self-monitoring technique, and weekly telephone calls provided by the intervener for coaching and support.
1603375|NCT02211092|Other|Usual care|Access to usual community resources but no active lifestyle coaching.
1603376|NCT02211079|Drug|JNJ-54861911|JNJ-54861911, 50 mg (2*25 mg tablets) orally once daily from Day 2 to Day 9.
1603377|NCT02211079|Drug|Caffeine|Single oral dose of caffeine 100 mg (2*50 mg tablets), on Day 1, 2, and 9.
1603378|NCT02211079|Drug|Midazolam|Single oral dose of midazolam 2 mg (1 mL, 2 mg/mL solution), on Day 1, 2, and 9.
1603379|NCT02211079|Drug|Tolbutamide|Single oral dose of Tolbutamide 500 mg tablet, on Day 1, 2, and 9.
1603380|NCT02211066|Drug|Clopidogrel|
1603381|NCT02211066|Drug|Ticagrelor|
1603382|NCT02211053|Drug|Levothyroxine|20 mg IV bolus + 10 mg/h infusion
1603383|NCT02211053|Drug|placebo|
1603384|NCT02211040|Behavioral|My Plan|"The intervention consists of three sessions for each behaviour (ie., physical activity, fruit and vegetables intake) and is available on a website and tablets to deliver it in general practice.
Adults can start session one on a tablet in general practice or on their own computer at home, after receiving a flyer in general practice.
In this first session adults receive general information, monitor their behaviour and receive tailored feedback to increase awareness.
Adults are also guided to set goals and self-efficacy is increased by modeling and problem solving methods.
In the second and third session, adults can evaluate if they reached their goals, make coping plans and adapt their action plans."
1603385|NCT02211027|Biological|Semi-allogenic human fibroblast (MRC-5) transfected with DNA|"Each vaccination consists of up to 1 x 10e7 (not less than 7 x 10e6) DNA-transfected irradiated fibroblasts. Each vaccination will be administered intradermally using a 1 mL syringe and a 25 gauge needle.The first immunization will be administered at least 12 weeks after surgery or completion of adjuvant chemotherapy and/or radiotherapy.Three additional vaccines will be administered once a week for a total of four vaccines.
Patients will have vaccinations administered at 4 different sites as follows:
Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh. Approximately equal numbers of transfected fibroblasts will be administered at each site."
1603386|NCT02211014|Drug|acalabrutinib|
1603387|NCT02211001|Other|Pilates Group|The exercises were applied once a week during eight weeks.
1603388|NCT02211001|Other|Segmented Dynamic Exercises Group|The exercises were applied once a week during eight weeks. once a week for eight weeks.
1603389|NCT02211001|Other|Global Postural Reeducation|The exercises were applied once a week during eight weeks.
1603390|NCT02210988|Other|acupuncture|
1603391|NCT02210988|Device|acupuncture|experimental
1603392|NCT02210988|Device|Acupuncture|
1603393|NCT02210975|Device|LES-Stimulation Device|
1603394|NCT02210962|Dietary Supplement|essential fatty acids|Yellow capsules containing eicosapentaenoic acid, docosahexaenoic acid (active)
1603395|NCT02210962|Dietary Supplement|olive oil|Yellow capsules containing olive oil (placebo)
1603396|NCT02210949|Drug|Erythropoietin subcutaneously and Iron intravenously|Administration of Erythropoietin subcutaneously and administration of iron intravenously
1603397|NCT02210936|Other|Educational Intervention|"The design is primarily a pre-post, non-equivalent comparison group test of program effectiveness. If final sample size permits, we will examine program effects for each practice environment separately. For measures that require interview data there will be no comparison group data.
We will construct matched comparison groups of physicians for each environment for which only secondary data analysis will be conducted. The matched comparison group will be constructed using prescription data from the DoD's pharmacy data transaction system (MACH and DORN VAMC) and from SCRIPTS (community-based physicians and VA prescribers)."
1603398|NCT02210910|Device|InSpace™ system over repair|
1603399|NCT02210910|Procedure|Best Repair of torn Rotator Cuff|
1603400|NCT02210884|Dietary Supplement|Vitamin D|Weekly oral supplementation with 15,000 IU vitamin D
1603401|NCT02210871|Drug|semaglutide|All subjects will be treated with a single subcutane (s.c., under the skin) injection of 0.5 mg semaglutide.
1603402|NCT02210858|Other|Laboratory Biomarker Analysis|Correlative studies
1603403|NCT02210858|Drug|Tipifarnib|Given PO
1603404|NCT02210845|Behavioral|Supervised exercise|Supervised exercise intervention is training with professional trainers once a week. It will include aerobic exercise tailored to the individual participant.
1603405|NCT02210845|Behavioral|Financially incentivized weight Loss|Financially incentivized weight loss encourages participants to achieve a monthly goal weight reduction for a 50 dollars prize.
1603406|NCT02210845|Other|Standard Care at BCDiabetes|usual care dictated by GCP at BCDiabetes.ca
1603407|NCT02210832|Behavioral|Best practices|
1603408|NCT02210832|Behavioral|financial incentives|financial incentives provided contingent on biochemically confirmed smoking abstinence
1603409|NCT02210819|Drug|Rivaroxaban (Xarelto, BAY59-7939)|"Cohort participants are classified as rivaroxaban patient, if the patient receives initial rivaroxaban VTE treatment. Dosing according to daily clinical routine"
1603410|NCT02210819|Drug|Recommended VTE pharmacological treatments according to international guidelines|"Cohort participants are classified as Standard of care patients, if the patient receives recommended VTE pharmacological treatments according to international guidelines, e.g. unfractionated heparin, LMWH, fondaparinux, VKA, if these are also approved pharmacological treatments for VTE in the respective country. Dosing according to daily clinical routine."
1603411|NCT02210806|Drug|A006 DPI|Single dose 110 mcg, 1 inhalation
1603412|NCT02210806|Drug|A006 DPI|Single dose 220 mcg, 1 inhalation
1603413|NCT02210806|Other|Placebo DPI|Placebo, 1 inhalation
1603414|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 1 inhalation
1603415|NCT02210806|Drug|Proventil® MDI|Single dose 90 mcg, 2 inhalations
1603416|NCT02210793|Procedure|transepithelial PRK|
1603417|NCT02210793|Procedure|LASIK|
1603418|NCT02210780|Drug|Dupilumab|Administered via subcutaneous injection.
1603419|NCT02210780|Drug|placebo|An inactive substance containing no medicine administered via subcutaneous injection
1603420|NCT02210767|Other|Walnut Diet|2 oz. walnuts/day (2-3% of total calories from ALA)
1603421|NCT02210767|Other|Walnut Control Diet|2-3% ALA but no walnuts provided
1603426|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin vehicle)|electronic cigarettes
1603427|NCT02210754|Other|blu™ Classic Tobacco rechargeable (1.6% nicotine, glycerin/PG vehicle)|electronic cigarettes
1603428|NCT02210754|Other|Marlboro Cigarette|cigarettes
1603429|NCT02210728|Drug|methylphenidate or amphetamine product|Medication is titrated over a 4-week period with stepwise increments each week. Patients and significant others complete ADHD symptom scales at baseline and before each medication visit. Patients also complete side effects scales at baseline and before each medication visit. The gradual increase will continue until there is no further improvement in symptoms and in the Clinical Global Improvement Scale or side effects are such that further increases are not indicated. Once the optimal dose is reached, the subjects remain on this dose for the remainder of the study.
1603430|NCT02210728|Behavioral|Cognitive behavioral therapy|12 sessions of group cognitive behavioral therapy. Participants also receive individual coaching 3 times a week (twice over telephone and once in person). Coaching sessions are 15 minutes each in duration and are aimed at implementation, practice, and generalization of skills acquired in therapy.
1603431|NCT02210715|Drug|Isentress.|28 subjects will change from their normal cART treatment to Raltegravir, which will be given at the standard dose of 400 mg p.o. b.i.d. for 24 months.
1603432|NCT02210715|Other|Continue usual antiretroviral therapy|28 subjects will continue with their normal cART treatment, as prescribed by their treating physician.
1603433|NCT02210702|Drug|Ethinyl Estradiol 35mcg/Norethindrone 1mg|
1603434|NCT02210702|Drug|Ethinyl Estradiol 20mcg/Norethindrone 1mg|
1603435|NCT02210689|Drug|clindamycin phosphate vaginal cream 2%|
1603436|NCT02210676|Other|PROMIS Upper Extremity|
1603437|NCT02210676|Other|Likert Pain Scale|
1603438|NCT02210676|Other|Mallet Finger Extensor Lag Measurement|
1603439|NCT02210663|Drug|veliparib (ABT-888)|Subjects will be given veliparib twice daily on Days 1-28 every 28 days orally.
1603440|NCT02210650|Procedure|Ureteral stone removal|Ureteral stone removal by the surgical procedure called Ureteroscopy
1603441|NCT02210650|Procedure|Asymptomatic kidney stones and ureteral stone removed|Asymptomatic kidney stones and Ureteral stone removal by the surgical procedure called Ureteroscopy
1603442|NCT02210624|Biological|HYNR-CS inj.|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
1603443|NCT02210611|Procedure|Intrauterine Insemination 36 hours|Intrauterine insemination 36 hours after ovulation induction
1603444|NCT02210611|Procedure|Intrauterine Insemination 42 hours|Intrauterine insemination 42 hours after ovulation induction
1603445|NCT02210598|Device|inpatient Foley balloon induction|The catheter will be left in place and IV oxytocin will be started per LAC+USC protocol. The foley catheter will be removed after 12 hours if not spontaneously extruded.
1603446|NCT02210598|Device|outpatient Foley balloon induction|The catheter will be deflated and removed within 10 minutes of placement. The patient will then undergo a non-stress test (NST). If the patient has a reactive NST with no late or variable decelerations or uterine tachysystole, the patient will be discharged home with clear return precautions and instructions to return to the triage area in 24 hours.
1603447|NCT02210598|Drug|Oxytocin|"When a patient randomized to the outpatient Foley Balloon induction group returns to the hospital, a sterile vaginal exam will be done and Bishop score documented. The patient will then be admitted to L&D for inpatient continuation of induction with IV oxytocin per LAC+USC protocol.
Patients randomized to the inpatient Foley balloon induction group will have IV oxytocin initiated per LAC+USC protocol at the time of Foley balloon placement."
1603448|NCT02210585|Other|Rehabilitation|"12 weeks : 5 sessions per week (1 supervised session at home every month)
92 weeks : spontaneous training (supervised by phone every month)"
1603449|NCT02210572|Dietary Supplement|Bimuno Galacto-oligosaccharide 1.37 g/d|Prebiotic versus low-FODMAPs diet
1603450|NCT02210572|Dietary Supplement|Low- FODMAPs diet|
1603451|NCT02210559|Drug|FG-3019|FG-3019 is administered in TREATMENT ARM A ONLY on Days 1, 8 and 15 of Treatment Cycle 1 and on Day 1 and 15 of each subsequent treatment cycle via IV infusion. The dose level is 35 mg/kg.
1603452|NCT02210559|Drug|Gemcitabine|Gemcitabine is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. The dose level is 1000 mg/m2.
1603453|NCT02210559|Drug|Nab-paclitaxel|Nab-paclitaxel is administered on Days 1, 8 and 15 of each 28 day treatment cycle via IV infusion. The dose level is 125 mg/m2.
1603454|NCT02210546|Other|Magnetic Resonance Imaging (MRI)|
1603455|NCT02210546|Other|Mammography (Mx) + ultrasonography (US)|
1603456|NCT02210520|Device|pulsatile ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
1603457|NCT02210520|Device|continuous ultrasound|1 W/cm², 2 minutes in 6 points around the back spine, three times in the week, during 10 sessions per four weeks.
1603458|NCT02210520|Device|laser|1 W/cm², 2 minutes in 6 points around the back spine
1603459|NCT02210507|Other|Biofortified cassava gari|Cassava, bred to contain high amounts of vitamin A-forming carotenoids (primarily beta-carotene and its cis-derivatives).
1603460|NCT02210507|Other|White cassava gari|Non-biofortified (white) cassava and a retinyl palmitate reference dose.
1603461|NCT02210507|Other|White cassava gari + red palm oil|Non-biofortified (white) cassava gari containing red palm oil.
1603462|NCT02210494|Drug|Secretrol|
1603463|NCT02210468|Device|APIC-CF, 4 cc|
1603464|NCT02210468|Device|APIC-CF, 2 cc|
1603465|NCT02210468|Other|Placebo Comparator: Saline|Placebo Comparator: Saline
1603466|NCT02210455|Behavioral|Strongest Families FASD intervention|
1603467|NCT02210455|Other|Psychoeducation|
1603468|NCT02210442|Behavioral|educaguia intervention|Health professionals (residents) play with educational games in order to acquire knowledge and skill about management of clinical practice guidelines.
1603469|NCT02210442|Other|control group|Health professional will learn how to manage a clinical practice guidelines with standard clinical practice.
1603470|NCT02210429|Procedure|Elbow Fracture Fixation|
1603471|NCT02210416|Procedure|inguinal hernia surgery|
1603472|NCT02210403|Device|transcranial direct current stimulation (tDCS)|
1603473|NCT02210390|Behavioral|Psycho education|Psycho-education Sessions will be offered weekly basis
1603634|NCT02209207|Other|walking training|
1603474|NCT02210377|Other|Tianjiu|After randomization, patients in Tianjiu and placebo (non-Tianjiu) groups will receive 12 sessions of treatment over a 4-week treatment period.The format of the Tianjiu intervention will be the same as in the treatment group. Participants will be instructed to lie supine before their HD session, and then the bilateral KI1 and CV4
1603475|NCT02210377|Other|Placebo (non-Tianjiu)|The format of the placebo (clay) intervention will be the same as in the treatment group.
1603476|NCT02210364|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) 1 mg and 4 mg vials
1603477|NCT02210364|Drug|capecitabine|capecitabine 150 mg tablets
1603478|NCT02210351|Device|MRI test|
1603479|NCT02210338|Device|Karl Storz C-MAC|
1603480|NCT02210338|Device|Bonfils Intubation Fibrescope|
1603481|NCT02210325|Drug|solithromycin|
1603482|NCT02210325|Drug|ceftriaxone|
1603483|NCT02210325|Drug|azithromycin|
1603484|NCT02210299|Other|Exposure study|Sampling of blood, food, water, air and dust and delivery of dietary questionnaire
1603485|NCT02210286|Dietary Supplement|Magtein|
1603486|NCT02210273|Device|Solace Bladder Control Balloon|Subjects may undergo treatment every 12 months until study completion.
1603487|NCT02210273|Device|Solace Sham Treatment|Sham treatment that resembles treatment with the Solace Bladder Control Balloon
1603488|NCT02210260|Procedure|Spinal and infusion of local anaesthetic|"Spinal anaesthetic will be performed in the lateral position using a midline approach. L3/4 interspace will be identified using Tuffier's as the anatomical landmark. After confirmation of correct placement using a 25G Whitacre needle, 12.5 mg of hyperbaric Bupivacaine in a mixture with 500mcg Diamorphine will be injected intrathecally.
PLUS
Painbuster® catheters will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine."
1603489|NCT02210260|Procedure|Continuous infusion of local anaesthetic|A Painbuster® catheter will be placed by the surgeon at the end of the procedure in a location determined by the surgical approach. A bolus dose of 20ml 0.25% L-Bupivacaine will be injected down the catheters prior to the connection of the elastomeric pump which will also contain 270ml 0.25% L-Bupivacaine.
1603490|NCT02210260|Drug|Bupivacaine|
1603491|NCT02210260|Drug|Diamorphine|500mcg
1603492|NCT02210260|Device|A Painbuster® catheter|
1603493|NCT02210260|Device|25G Whitacre needle|
2009714|NCT03187223|Drug|Melphalan|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive melphalan at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day on days -2 and -1, with the ASCT at day 0.
1603495|NCT02210234|Dietary Supplement|50 grams of whole wheat bran cereal|This arm was randomized to eat 50 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
1603496|NCT02210234|Dietary Supplement|100 grams of whole wheat bran cereal|This arm was randomized to eat 100 grams of whole wheat cereal during the day for 3 weeks. At baseline and at week 3 a blood sample was taken to determine if there was any alteration to the proliferation of gamma-delta T-cells.
1603497|NCT02210208|Device|Mepitel Ag|
1603498|NCT02210195|Drug|aprepitant|125 mg daily for 8 weeks.
1603499|NCT02210195|Drug|Placebo|Placebo daily for 8 weeks.
1603500|NCT02210195|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
1603501|NCT02210182|Drug|Oral Pentamidine|Oral pentamidine given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
1603502|NCT02210182|Other|Placebo|Placebo given at 300 mg, 600 mg, 900 mg or 1200 mg QD x 3 consecutive days
1603503|NCT02210169|Drug|Continuous infusion of vancomycin|Continuous infusion of vancomycin will be given as a loading dose over 1 hour then as a continuous infusion over a 24-hours period.
1603504|NCT02210156|Dietary Supplement|Omniplus Supreme|Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
1603505|NCT02210156|Other|Placebo|A product with maltodextrins, flavors and colorants without vitamins, minerals and plant extracts. Two dietitians prepared the products (one preparer per product) by dissolving two envelopes of 20 ml of the product in 240 ml of water in a disposable cup, every day from Monday to Saturday during the intervention period (90 days of actual consumption). In order to maintain blinding, these dietitians then gave the prepared cups to two different supervisors who in turn gave the product to each participant for consumption (once-daily doses). The preparation and delivery of the product was carried out during two work shifts (morning and afternoon), depending on each participants work schedule. The supervisors recorded product administration and consumption for each participant on a control form.
1603506|NCT02210117|Drug|Nivolumab|"Arms A + B: 3 mg/kg by vein every 2 weeks for 6 weeks.
Arm C: 3 mg/kg by vein every 3 weeks for 6 weeks."
1603507|NCT02210117|Drug|Bevacizumab|Arm B: 10 mg/kg by vein every 2 weeks for 6 weeks.
1603508|NCT02210117|Drug|Ipilimumab|Arm C: 1 mg/kg by vein every 3 weeks for 6 weeks.
1603509|NCT02210104|Drug|Ipilimumab|Starting Dose of Ipilimumab: 1.0 mg /kg by vein on Days 1, 22, 43, and 64.
1603510|NCT02210104|Drug|Cyclophosphamide|300 mg/m2 administered intravenously 2 days prior to T cell infusion.
1603511|NCT02210104|Biological|CD4+ T cells|Antigen-specific CD4+ T cells administered at a dose of 10^10 cells/m^2 on Day 0.
1603515|NCT02210078|Biological|Cytotoxic T-Lymphocytes (CTL)|CTL dose infused will not be greater than 10e5 viable CD3+ T cells/kg. If patient has a partial response, stable disease or progressive disease, then eligible to receive one additional dose of CTL at a minimum of 2 weeks interval from the first CTL infusion.
1603516|NCT02210065|Biological|Cytomegalovirus (CMV)-Specific Cytotoxic T Cells (CTLs)|CTL product given as single infusion within 72 hours of CMV reactivation. CTL dose infused will be at a maximum dose of 10e5 viable CD3+ T cells/kg.
1603517|NCT02210052|Device|Radiofrequency cannula|Subjects with spinal hardware that are undergoing radiofrequency ablation procedures will have an additional radiofrequency cannula placed at the site of adjacent pedicle screws for temperature measurement only.
1603518|NCT02210039|Device|SECM Probe|Imaging of the esophagus using SECM probe and system.
2009715|NCT03187223|Drug|Bendamustine|High-dose chemotherapy regimen for conditioning treatment before autologous stem cell Transplantation. Patients will receive bendamustine at a total dose of 400mg/m2, divided in two doses of 200mg/m2/day on days -4 and -3. Melphalan is given at a total dose of 200mg/m2, divided in two doses of 100mg/m2/day, each on days -2 and -1, with the ASCT at day 0.
2009716|NCT03187197|Drug|Pradaxa®|Dabigatran etexilate
1603522|NCT02209987|Drug|GS-5745 SC|GS-5745 150 mg administered by SC injection formulated as a sterile, aqueous buffered solution in a single-use pre-filled syringe
1603523|NCT02209987|Drug|GS-5745 IV|GS-5745 150 mg administered by IV infusion formulated as a sterile, aqueous buffered solution in single-use glass vials
1603524|NCT02209974|Drug|Fluticasone|Administration of inhaled corticosteroids (fluticasone, 0.5 mg) each 12 hours to 8 of the 16 COPD patients versus placebo.
1603525|NCT02209974|Drug|Inhaled Placebo|
1603526|NCT02209948|Drug|Temozolomide|
1603527|NCT02209935|Other|Early Rehabilitation Protocol|
1603528|NCT02209935|Other|Usual care|
1603529|NCT02209922|Device|Transcranial direct current stimulation (tDCS)|Participants underwent tDCS(2mA) brain stimulation (20 minutes) and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
1603530|NCT02209922|Device|Sham|During sham stimulation, the current ramped up for 30 seconds, ramped back down for 30 seconds, and then remained off for the duration of the stimulation then and simultaneous balance training(20 minutes) for 5 consecutive days,for 1 week.
1603531|NCT02209909|Drug|aspirin continuation|Patients are randomized to continue aspirin before OPCAB surgery.
1603532|NCT02209909|Drug|aspirin discontinuation|Patients are randomized to discontinue aspirin more than 4 days before OPCAB surgery.
1603533|NCT02209896|Device|The Reprieve system|BlueWind Medical neurostimulator for the treatment of neuropathic pain
1603534|NCT02209870|Behavioral|E-checklist Group|The patient group after E-checklist system deployed
1603535|NCT02209844|Drug|BI 44847|
1603536|NCT02209844|Drug|Placebo|
1603537|NCT02209831|Device|BIBR 796 BS|single dose
1603538|NCT02209831|Drug|Pantoprazole|5 days
1603539|NCT02209818|Radiation|Laser Irradiation One dose|
1603540|NCT02209818|Radiation|Laser Irradiation Two doses|
1603541|NCT02209805|Drug|BIRB 796 BS, low dose|
1603542|NCT02209805|Drug|BIRB 796 BS, high dose|
1603543|NCT02209805|Drug|Placebo|
1603544|NCT02209792|Drug|Placebo|
1603545|NCT02209792|Drug|BIBR 796 BS, 5 mg|
1603546|NCT02209792|Drug|BIBR 796 BS, 20 mg|
1603547|NCT02209779|Drug|BIBR 796 BS|
1603548|NCT02209779|Drug|Placebo|
1603549|NCT02209766|Drug|D5884|1st cohort: Dose 1(2g) D5884(n=6) in Japanese 2nd cohort: Dose 2(4g) D5884(n=6) in Japanese 3rd cohort: Dose 2(4g) D5884(n=6) in Caucasian
1603550|NCT02209766|Drug|Placebo|"st cohort: Dose 1(2g) D5884(n=3) in Japanese
nd cohort: Dose 2(4g) D5884(n=3) in Japanese"
1603551|NCT02209753|Drug|BIRB 796 BS, low dose|
1603552|NCT02209753|Drug|BIRB 796 BS, medium dose 1|
1603553|NCT02209753|Drug|BIRB 796 BS, medium dose 2|
1603554|NCT02209753|Drug|BIRB 796 BS, high dose|
1603555|NCT02209753|Drug|Placebo|
1603556|NCT02209740|Other|Tenofovir switch|Patients switched tenofovir to different antiretroviral regimen according to physicians decision
1603557|NCT02209727|Drug|131I-Sibrotuzumab|50 mg Sibrotuzumab conjugated with 131I
1603558|NCT02209714|Drug|BIIF 1149 BS|
1603559|NCT02209714|Drug|Placebo|
1603560|NCT02209701|Drug|Porfiromycin|
1603561|NCT02209688|Drug|ESR 1150 CL|
1603562|NCT02209688|Drug|Placebo|
1603563|NCT02209675|Other|liver biopsy|C4d assessment by immunohistchemistry in liver biopsy
1603564|NCT02209662|Device|APIC-PRP|APIC-PRP
1603565|NCT02209662|Other|Placebo, Saline plus standard of care|Placebo, Saline plus standard of care
1603566|NCT02209649|Drug|Lacidipine and Telmisartan fixed dose combination (FDC) tablet|
1603567|NCT02209649|Drug|Lacidipine|
1603568|NCT02209649|Drug|Telmisartan|
1603569|NCT02209636|Drug|Lanthanum carbonate|Non-calcium containing phosphorus binder
1603570|NCT02209636|Drug|placebo|Table identical to lanthanum carbonate but with no active ingredient
1603571|NCT02209636|Drug|Ascorbic Acid|Intravenous administration during measurement of flow mediated dilation.
1603572|NCT02209636|Drug|Nitroglycerin|Drug that is administered under the tongue that relaxes blood vessels. To be administered during measurement of flow mediated dilation.
1603573|NCT02209636|Procedure|Flow-mediated dilation measurement|Measurement of the blood flow in the brachial artery, an artery in the upper arm, using ultrasound.
1603574|NCT02209636|Procedure|Aortic pulse-wave velocity|Measurement of the stiffness of the arteries using a transcutaneous tonometer, a small device placed over the skin over the carotid, brachial, radial and femoral arteries.
1603575|NCT02209636|Procedure|Endothelial cell collection|Collection of endothelial cells from vein in arm. A flexible wire is inserted through an IV into a forearm vein to collect endothelial cells for further study. This is performed at the baseline visit and and the final study visit.
1603576|NCT02209623|Biological|TDAP|
1603577|NCT02209610|Device|Electrical and Magnetic Nerve Stimulators|Stimulation of motor nerve and central nervous system
1603578|NCT02209610|Drug|Intrathecal Fentanyl|Mu-opioid receptor agonist
1603579|NCT02209597|Drug|Wellbutrin XL® 300mg|
1603580|NCT02209597|Drug|300mg bupropion XL 1|
1603581|NCT02209597|Drug|300mg bupropion XL 2|
1603582|NCT02209597|Drug|300mg bupropion XL 3|
1603583|NCT02209571|Other|Venous blood markers|Routine venous blood sampling
1603584|NCT02209558|Behavioral|Visual Sternal Precautions|"Visual depiction of SPs in addition to standard of care written precautions"
1603585|NCT02209545|Drug|Misoprostol|25 patients undergoing abdominal myomectomy operation will receive two tablets of misoprostol (400 mcg) buccally one hour before the operation.
1603586|NCT02209545|Drug|Placebo|25 patients undergoing abdominal myomectomy operation will receive two tablets of Vitamin B6 (100mg) buccally one hour before the operation.
1603587|NCT02209532|Device|PINPOINT|PINPOINT® Near Infrared Fluorescence Imaging to identify lymph nodes
2009717|NCT03186911|Behavioral|E-liquid sampling and preference assessment|Participants will sample two different e-liquids that vary in nicotine content, complete questionnaires about each one, and then choose between the two e-liquids in a preference assessment task.
1603590|NCT02209506|Drug|MLN3126|MLN3126 tablets
1603591|NCT02209506|Drug|MLN3126 Matched Placebo|MLN3126 placebo-matching tablets
1603592|NCT02209493|Behavioral|Food supplementation: nopales|Consumption of 2 cups/day of test food: nopales
1603593|NCT02209493|Behavioral|Food supplementation: cucumber|Consumption of 2 cups/day of test food: cucumber
1603594|NCT02209480|Behavioral|Alexander Technique|
1603595|NCT02209480|Device|Heat pad application|
1603596|NCT02209480|Behavioral|guided imagery|
1603597|NCT02209467|Other|Group balance training|Group balance training 60 minutes 2 times per week plus 3-5 home exercises 2 times/week. Exercises focus om core stability in sitting, standing and lying.
1603598|NCT02209454|Drug|Enantyum® oral solution|One dose of 25 mg DKP oral solution
1603599|NCT02209454|Drug|Keral® tablet|One dose of 25 mg DKP tablet
1603600|NCT02209441|Drug|Phase I Dose-finding Study of Sorafenib Study|
1603601|NCT02209428|Drug|Temozolomide|75 mg/m2/day for 21 days repeated every 4 weeks, 6 cycles.
1603602|NCT02209415|Behavioral|standard follow-up|Outpatient clinic visits
1603603|NCT02209415|Procedure|PET/CT and EUS|PET/CT and EUS
1603604|NCT02209402|Behavioral|Exercise Training|Home-based training programme consisting of daily 4x10 minutes physical exercise on a magnetically braked bicycle at a heart rate corresponding to 80-90% of the heart rate achieved at the anaerobic threshold.
1603605|NCT02209389|Device|MRI|For any sample that is identified with a positive OctavaPink result, a negative sample from the same center, as close in time as possible, and of the same age decade, will be identified and will be recalled for an MRI and any additional testing if requested by doctor's (according to MRI's results).
1603606|NCT02209376|Biological|CART-EGFRvIII T cells|
1603607|NCT02209363|Device|auto-adjusting positive airway pressure|nightly use for 6 months
1603608|NCT02209363|Other|Nasal dilator strips|nightly use for 6 months
1603609|NCT02209350|Procedure|Aorta-femoral bypass|"Access to the femoral artery is performed through a lateral incision from the inguinal ligament. Operations technique on the abdominal aorta.
Aorta-femoral bypass. Proximal anastomosis between the prosthesis and aorta is applied in the sort of end-to-side in the reconstruction by shunting.
After jaws prosthesis conduction on hip distal anastomosis is formed with twisting controlling. In a case of preserved antegrade blood flow the femoral artery anastomosis applied in the sort of end-to-side. If antegrade flow is absent, anastomosis is formed in the sort of end to end."
1603610|NCT02209350|Procedure|Recanalization and stenting of aorta-iliac segment|"Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized.
Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. Tomaximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter)."
1603611|NCT02209350|Drug|Therapy: aspirin and clopidogrel|prescribed long-term aspirin (100 mg daily) and clopidogrel for 3 months (75 mg daily).
1603612|NCT02209337|Device|SRS|
1603613|NCT02209324|Drug|ASP2151|
1603614|NCT02209311|Procedure|Oral mucosa biopsy|
1603615|NCT02209311|Procedure|Sinus lift with implantation of tissue engineered construction|
1603616|NCT02209311|Device|Dental implant|
1603618|NCT02209285|Behavioral|ACHRU - Community Partnership Program|Individuals in the ACHRU - CPP for Older Adults with Multiple Chronic Conditions group will receive a six-month community intervention consisting of three components: (1) intensive case management and community navigation; (2) a maximum of two in-home visits by the care coordinator, two in-home visits by a Registered Nurse, and three in-home visits by the Occupational therapist or Physiotherapist, and six visits by a Personal Support Worker over 6 months in addition to usual home care services; and (3) monthly interprofessional team case conferences to develop an evidence-based, patient-centred community reintegration plan.
1603619|NCT02209272|Drug|bacteriostatic saline|
1603620|NCT02209272|Drug|buffered lidocaine|
1603627|NCT02209246|Other|PROMIS CAT Pain Interference|
1603628|NCT02209246|Other|PROMIS CAT Pain Behavior|
1603629|NCT02209246|Other|PROMIS CAT Physical Function|
1603630|NCT02209246|Other|MISS-21|
1603631|NCT02209233|Other|Massage Therapy|
1603632|NCT02209220|Device|Positive airway pressure for the treatment of OSA|
1603633|NCT02209207|Device|Treadmill|
1603635|NCT02209194|Device|E-liac Stent Graft System|Implantation of the E-liac Stent Graft System in combination with a peripheral covered stent and in case of aortoiliac aneurysm in combination with a AAA Stent Graft
1603636|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
1603637|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
1603638|NCT02209181|Drug|JNJ-10450232 / Not yet marketed|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
1603639|NCT02209181|Drug|acetaminophen / Tylenol|Subjects who meet the randomization criteria at baseline within 4.5 hours after dental surgery will be assigned to one of four treatment groups stratified by pharmacokinetic blood sampling schedule and by baseline pain intensity level.
1603640|NCT02209155|Drug|R-verapamil 75 mg tablet|
1603641|NCT02209155|Drug|Placebo|
1603642|NCT02209142|Other|blood prelevement|blood sample will be done at the inclusion then at T 2 weeks, T8 weeks, T30weeks
1603643|NCT02209142|Other|psychometric data collection|
1603644|NCT02209116|Other|Qb Test|Given to all participants but the results will be open or blind depending on arm allocation
1603645|NCT02209103|Dietary Supplement|Lozenge containing citrus flavonoid|
1603646|NCT02209103|Dietary Supplement|Lozenge containing citrus flavonoid formulation|
1603647|NCT02209103|Dietary Supplement|Identical looking placebo|
1603650|NCT02209077|Device|OCT performed to collect data from the back of the eye|comparative retinal parameters with Spectralis OCT
1603651|NCT02209064|Device|Pericardial access|Access to the pericardium to enable further treatments.
1603652|NCT02209051|Other|AMNIOEXCEL|Application of AMNIOEXCEL every 1-2 weeks for a period of 6 weeks or until wound closure, whichever is sooner.
1603653|NCT02209051|Other|Standard of Care, Diabetic Foot Ulcers|Advanced wound care dressings and offloading applied daily for a period of 8 weeks or until wound closure
1603654|NCT02209038|Behavioral|Expanded AD Choice|
1603655|NCT02209038|Behavioral|Expanded Life-sustaining Therapy Choice|
1603656|NCT02209025|Dietary Supplement|Theobromine|Theobromine a compound for cocoa
1603657|NCT02209025|Dietary Supplement|Placebo drink|
1603658|NCT02209012|Drug|Aminolevulinic Acid (ALA)|Levulan PDT given in CP0108
1603659|NCT02209012|Drug|Topical Solution Vehicle|Vehicle PDT given in CP0108
1603660|NCT02209012|Device|BLU-U Blue Light Photodynamic Therapy Illuminator|PDT given in CP0108
1603661|NCT02208999|Device|Neurostimulator Precision|All patients included must have been implanted with the neurostimulator Precision
1603662|NCT02208986|Drug|Triptorelin|Triptorelin is given by s.c injection for ovulation triggering.
1603663|NCT02208973|Drug|PBF-680|5, 10, 20, 40 and 60 mg of PBF-680
1603664|NCT02208973|Drug|Placebo|placebo for the dose of 5, 10, 20 and 40 mg of PBF-680
1603665|NCT02208960|Device|Neonatal Kit|"Contents of the neonatal kit:
Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.
4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.
Sunflower oil emollient (50 mL)
ThermoSpot
Mylar infant sleeve
Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.
Handheld battery-operated scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Community Health Worker."
1603666|NCT02208960|Behavioral|Neonatal Stimulation|"A sub-set of children in the study will receive a neonatal stimulation program either on its own or in combination with the neonatal kit described above. The stimulation program will focus on teaching three key messages to enhance the caregivers' current caregiving practices, and each message is to be integrated into daily activities (e.g. during feeding, bathing, bedtime routines). By integrating the delivery of the interventions into the caregivers' daily routine, no additional time inconvenience will be added to their schedules. The key messages include:
Eye contact and talking to children
Responsive feeding and caregiving
Singing songs, including those with gentle touch"
1603667|NCT02208947|Behavioral|Consumer financial incentive|Immediate financial reward upon completing self-directed ACP (e.g., completing the web-based educational modules on PREPARE steps 1-4) and a small probability of a large reward for discussing the plans with their physician (e.g., PREPARE step 5, documented by the PHC ACP attestation form).
1603668|NCT02208947|Behavioral|PREPARE|"PREPARE for your care is 5-step on-line ACP process developed specifically for low-literacy Medi-Cal populations. PREPARE can be navigated as interactive, self-directed modules or played like a movie, at a time or a place of the subject's own choosing (e.g., home, work, public library)."
1603669|NCT02208934|Drug|PBF-999|5, 10, 20 and 40 mg of PBF-999
1603670|NCT02208934|Drug|Placebo|Placebo for all dosis of PBF-999
1603671|NCT02208908|Other|Evaluation of the oral conditionand proper care|An accurate assessment of the oral condition and proper care will be carried out on day 2 (J2) of hospitalization and repeated on the day of hospital discharge by the nurse detached service, regardless of caregivers.
1603672|NCT02208882|Drug|BMS-986120|
1603673|NCT02208882|Drug|Placebo|
1603674|NCT02208882|Drug|Midazolam|
1603675|NCT02208856|Drug|BIBR 796 BS|
1603676|NCT02208856|Drug|Placebo|
1603677|NCT02208856|Other|high fat standardized breakfast|
1603678|NCT02208843|Drug|Afatinib|Afatinib tablet once daily until progression
1603679|NCT02208830|Other|pulmonary rehabilitation|Pulmonary rehabilitation: 8 week, twice weekly exercise program with aerobic treadmill training and lower limb strength training.
1603761|NCT02208310|Drug|Cholecalciferol 400 IU|Cholecalciferol 400 IU po daily
1603762|NCT02208297|Drug|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
1603680|NCT02208830|Other|conventional program|The conventional program is conducted with duration of 8 week, twice weekly. The techniques used will be: expiration with the glottis open in lateral posture (Eltgol), autogenous drainage (AD) and shaker. Each technique will last for 30 minutes.
1603681|NCT02208804|Device|Holmium-166-poly (L-lactic acid) microspheres|
1603682|NCT02208791|Drug|Sirolimus|Sirolimus, 2mg once daily, will be added to the maintenance immunosuppression composed of tacrolimus, prednisone and mycophenolate. The prescription of tacrolimus will be tapered down to achieve a peripheral blood trough level between 3 e 5 ng/mL and micophenolate will be reduced to 540mg bid.
1603683|NCT02208791|Drug|No intervention|
1603684|NCT02208778|Drug|Duloxetine|54 participants will be allocated for duloxetine treatment
1603685|NCT02208778|Drug|Remifentanil|27 participants will be allocated to Remifentanil infusion
1603686|NCT02208778|Drug|Placebo (for Remifentanil)|Placebo comparator to Remifentanil treatment. 27 participants will be allocated to this arm
1603687|NCT02208778|Drug|Placebo (for Duloxetine)|Sugar pill manufactured to mimic Duloxetine 30mg. 27 participants will be allocated to this intervention
1603688|NCT02208765|Device|Stress Single Photon Emission Computed Tomography|
1603690|NCT02208739|Procedure|Nonsurgical periodontal therapy|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
1603691|NCT02208739|Procedure|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
1603692|NCT02208726|Other|Sucrose pillules|Unmedicated sucrose pillules
1603693|NCT02208726|Other|Homeopathic homaccord|Sucrose pillules medicated with Picricum acidum and Phosphoricum acidum in potencies of 6CH, 30CH and 200CH.
1603694|NCT02208713|Biological|Intramuscular injection|Intramuscular injection of stem cells in patients with FSHD.
1603695|NCT02208700|Other|Oxepa|Therapeutic nutrition with EPA, GLA< and antioxidants
1603696|NCT02208700|Other|Jevity 1.5|Complete balanced nutrition with a unique fiber blend
1603697|NCT02208687|Behavioral|Energetic|Physiotherapy and occupational therapy aimed at reconditioning and social participation.
1603698|NCT02208687|Other|Control group|Usual care
1603699|NCT02208674|Other|Protocolized, pharmacist-delivered CKD Action Plan|The CKD Action plan protocolizes the screening and treatment of primary risk factors for CKD progression and cardiovascular disease among individuals with stage G3A CKD
1603700|NCT02208635|Other|Biofortified Maize|Participant in this arm were fed zinc biofortified maize (~30 µg Zn/g).
1603701|NCT02208635|Other|Fortified Maize|Participants in this arm were fed zinc-oxide fortified maize (total level of ~60 µg Zn/g).
1603702|NCT02208635|Other|Control Maize|Participants in this arm were fed maize that was not fortified or biofortified (~15 µg Zn/g maize).
1603703|NCT02208622|Dietary Supplement|Study 1: Whey Supplement Day 1|Whey supplement was given on day 1, control diet on day 2
1603704|NCT02208622|Dietary Supplement|Study 1: Whey Supplement Day 2|Control diet was given day 1, whey supplement was given day 2
1603705|NCT02208622|Dietary Supplement|Study 2: Whey Supplement|Whey supplement was given as part of diet for both day 1 and 2 of study
1603706|NCT02208609|Other|Day 1: Maize Tortillas with 20% Amaranth|Subjects received Maize tortillas with 20% Amaranth added.
1603707|NCT02208609|Other|Day 2 Maize Tortillas without 20% Amaranth|Maize tortillas without Amaranth.
1603708|NCT02208596|Drug|pentazocine|Every patient enrolled in the study will be given 15 mg pentazocine before induction.
1603709|NCT02208596|Drug|propofol|
1603710|NCT02208596|Drug|Etomidate|
1603711|NCT02208583|Drug|Docetaxel & Prednisone|Docetaxel & Prednisone: Docetaxel 75mg/m2，d1;Prednisone 5mg，bid，d1-21
1603712|NCT02208583|Drug|DP & Targeted drugs|Docetaxel 75mg/m2，d1; Prednisone 5mg，bid，d1-21;Targeted drugs for PO. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
1603713|NCT02208583|Drug|cisplatin & Etoposide|cisplatin & Etoposide:cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3
1603714|NCT02208583|Drug|EP & Targeted drugs|cisplatin 25mg/m2，d1-3; Etoposide 100 mg/m2，d1-3; Targeted drugs for po. Participants with EGFR gene mutation will receive a drug called Gefitinib; Participants with BRAF gene mutations will receive a drug called Vemurafenib; Participants with AKT1 gene mutations will receive a drug called Celecoxib; Participants who have ERBB2 gene mutation will receive a drug called lapatinib; Participants with PDGFRA gene mutations will receive a drug called sunitinib; Participants with PIK3CA gene mutations will receive a drug called Everolimus
1603715|NCT02208570|Other|PPV>14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation exceed 14
1603716|NCT02208570|Drug|Volume loading|Hydroxyethyl starch solution 6ml/kg iv injection
1603717|NCT02208570|Other|PPV<14%|Patients whose preoperative pulse pressure variation during spontaneous ventilation does not exceed 14
1603718|NCT02208557|Procedure|Reinforcement with Absorbable Mesh|
1603719|NCT02208557|Radiation|Control CT|"At the end of the follow up (6 Months) a CT scan will be done. Radiologically the incisional hernia is defined as a solution of continuity of the linea alba seen on the abdominal CT scan with the patient at rest.
The radiologist is blinded to the patient's history and the technique used for midline fascial closure."
1603763|NCT02208297|Drug|Vehicle Gel (BID)|One drop of vehicle gel instilled into the study eye two times per day (BID) for 14 days
1603720|NCT02208557|Other|Clinical Follow Up|The presence of incisional hernia was evaluated by physical examination at scheduled clinical visits (3 and 6 months after surgery) Clinically, an incisional hernia is defined as the presence of a reducible bulge or protrusion at the laparotomy incision scar, palpable during the Valsalva maneuver.
1603721|NCT02208544|Procedure|Diagnostic Thyroid Surgery|Diagnostic Thyroid Surgery
1603722|NCT02208544|Device|Ultrasound of the head and neck|Confirmatory Neck Ultrasonography in FDG-PET/CT negative patient in the experimental arm
1603723|NCT02208544|Radiation|FDG-PET/CT|Head and Neck FDG-PET/CT
1603724|NCT02208531|Behavioral|Psychosocial Stimulation and Nutritional Care|Psychosocial Stimulation and Nutritional Care will be provided to malnourished children and their mothers every fortnight in the Community Clinics for one year.
1603725|NCT02208518|Procedure|endoscopy ultrasound elastography|During a endoscopy ultrasound (EUS) procedure, in patients with normal pancreas at EUS, elastography was performed using a software already included in Hitachi-Avius machine, pressing the button and obtaining colors and pressure curve given by the software
1603726|NCT02208518|Device|EUS-elastography|
1603729|NCT02208492|Drug|Levetiracetam|Levetiracetam is a second-generation antiepileptic drug that has been approved for the treatment of epilepsy in both children and adults. This anticonvulsant works by binding to the synaptic vesicle protein 2A resulting in a possible effect on neurotransmitter release from presynaptic vesicles, while the exact mechanism of action is still unclear. In both adults and children, levetiracetam treatment in has a proven efficacy in both localization-related and generalized epilepsies. In contrast to first generation, levetiracetam reports less side effects of somnolence or lethargy, but behavioral adverse events, such as changed mood state, aggression, and irritability are noted, but only a few studies have reported such effects in a systemic fashion.
1603730|NCT02208492|Drug|Carabamazepine|Carbamazepine, a first-generation antiepileptic medication, stabilizes the inactivated state of voltage-gated sodium channels, making fewer of these channels available to subsequently open, which leaves the affected cells less excitable and less seizure prone. It is approved for both focal seizures and generalized tonic-clonic or combined seizures for adults and children.
1603731|NCT02208479|Other|Non invasive ultrasound measurement of the diaphragm thickness during breathing|
1603732|NCT02208466|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo active low-frequency rTMS (1Hz continuous). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
1603733|NCT02208466|Drug|Fluoxetine|Subjects will receive active fluoxetine (20mg) and take orally consecutively for 90 days.
1603734|NCT02208466|Device|Sham repetitive transcranial magnetic stimulation (rTMS)|Subjects will undergo sham low-frequency rTMS (using sham coil). This session will last 20 minutes, just as the active session would, however, no magnetic pulses will be delivered.
1603735|NCT02208466|Drug|Placebo Fluoxetine|Subject will receive placebo fluoxetine (sugar pills) and will take orally consecutively for 90 days.
1603736|NCT02208453|Device|InSpace Implantation|InSpace device Implantation
1603737|NCT02208440|Procedure|Best Repair of torn Rotator Cuff|
1603738|NCT02208440|Device|InSpace™ system|
1603739|NCT02208427|Drug|Rifapentine and Isoniazid for 3 months|weekly oral Rifapentine 15 mg/kg plus Isoniazid 15 mg/kg for 12 doses
1603740|NCT02208427|Drug|Isoniazid for 9 months|daily oral Isoniazid 5 mg/kg for 9 months under supervision (conventional IPT)
1603741|NCT02208414|Procedure|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding crab and shrimp energy signature vial
1603742|NCT02208414|Procedure|NAET|NAET with acupressure and/or chiropractic procedures with the participant holding water vial
1603743|NCT02208401|Procedure|conventional cold snare polypectomy|conventional cold snare polypectomy
1603744|NCT02208401|Procedure|Cold snare polypectomy with suction|Cold snare polypectomy with suction
1603745|NCT02208388|Device|computed tomography perfusion guided treatment|
1603746|NCT02208388|Device|Fractional flow reserve guided treatment|
1603747|NCT02208375|Drug|Olaparib|"Dose Escalation Starting Dose of Olaparib: 100 mg by mouth twice a day, or 300 mg by mouth twice a day if in Group 3.
Dose Expansion Starting Dose of Olaparib: MTD from Dose Escalation Phase."
1603748|NCT02208375|Drug|AZD2014|"Dose Escalation Starting Dose of AZD2014: 25 mg by mouth twice a day for Olaparib + AZD2014 (continuous dosing) group, and 125 mg by mouth twice a day for Olaparib + AZD2014 (intermittent dosing) group.
Dose Expansion Starting Dose of AZD2014: MTD from Dose Escalation Phase."
1603749|NCT02208375|Drug|AZD5363|"Dose Escalation Starting Dose of AZD5363: 320 mg by mouth twice a day.
Dose Expansion Starting Dose of AZD5363: MTD from Dose Escalation Phase."
1603750|NCT02208362|Biological|IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing Autologous T lymphocytes|Given via intratumoral or intracavitary or intraventricular catheter
1603751|NCT02208362|Other|laboratory biomarker analysis|Correlative studies
1603752|NCT02208362|Other|quality-of-life assessment|Ancillary studies
1603753|NCT02208362|Procedure|Magnetic Resonance Imaging|Correlative studies
1603754|NCT02208362|Procedure|Magnetic Resonance Spectroscopic Imaging|Correlative studies
1603755|NCT02208362|Biological|IL13Rα2-specific, hinge-optimized, 41BB-costimulatory CAR/truncated CD19-expressing Autologous T lymphocytes|Given via intratumoral and intraventricular catheter
1603756|NCT02208349|Device|King Video Laryngoscope|We will outfit ½ of the ambulance crews with the King Video Laryngoscope (KVL) for 6 months while the other ½ of the ambulances will use traditional direct laryngoscopy (DL). After 6 months, the groups will switch devices. We will randomly assign those ambulances that first use the KVL. After one year (12 months) we will compare the outcomes between the two methods.
1603757|NCT02208349|Device|traditional direct laryngoscopy (DL)|
1603758|NCT02208336|Other|medical chart review|Ancillary studies
1603759|NCT02208323|Device|Bubble CPAP|Respiratory assistance
1603760|NCT02208310|Drug|Cholecalciferol 10,000 IU|Cholecalciferol 10,000 IU po daily
1603764|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
1603765|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
1603766|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
1603767|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
1603768|NCT02208284|Drug|PF-06427878|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
1603769|NCT02208284|Drug|Placebo|PF-06427878 or placebo will be administered once in each period as an extemporaneously prepared suspension.
1603770|NCT02208258|Device|Consure 120 Stool Management System|Novel device designed to manage fecal incontinence in hospitalized bedridden patients with liquid to semi-formed stool.
1603771|NCT02208245|Device|Ultrasound: Axillary block|Ultrasound guided axillary block
1603772|NCT02208245|Device|Ultrasound: Infraclavicular block|Ultrasound guided infraclvicular block
1603773|NCT02208245|Drug|Ropivacaine|20 ml of ropivacaine 0,5% in both groups ( axillary block and infraclavicular block)
1603774|NCT02208232|Procedure|cataract surgery|cataract surgery with implantation of intraocular lens
1603775|NCT02208219|Behavioral|Music-supported Therapy|A Music-supported Therapy training will be provided to participants in the hospital during 4 weeks (5 sessions per week, 30 min per session). In this treatment, two different musical instruments will be used: a MIDI-piano and an electronic drum set to train fine and gross movements of the affected hand, respectively. Exercises will follow a modular therapy regime with stepwise increase of complexity in the number of tones to perform, velocity, order of playing, and fingers used for playing. Each exercise will be first played by the experimenter and will be subsequently repeated by the patient.
1603776|NCT02208219|Behavioral|home-based Music-supported Therapy|A Music-supported Therapy training at home will be provided to participants during 4 weeks (5 sessions per week, 30 min per session). Patients will play a portable roll-up MIDI-piano at home connected to the Synthesia LLC software. This software displays visual stimuli across a virtual piano on the computer screen which are served as cues to press the correct piano keys. A modular regime with stepwise increase in difficulty will be set in the program. With the aim to reinforce the training and solve problems that could appear at home, once per week patients will carry out the MST session in the hospital with the therapist. During this visit, each patient will complement his/her training with the electronic drum set and in order to train gross movements.
1603777|NCT02208219|Behavioral|Conventional treatment|"This intervention comprises intensive training of the affected upper extremity during 4 weeks (5 sessions per week, 30 min per session). The conventional therapy program corresponds to standard therapies, prescribed by attending neurologists and adapted to the needs of every individual patient. Patients will receive intensive training on fine and gross movements of the affected upper extremity. A physical and occupational therapist will provide multiple exercises from the following options:
Passive mobilization: controlled manipulation of movements to release a joint.
Stretch and progressive resistance training.
Task-specific training: reaching and manipulation of different objects.
Intense physical training: repetition of sequence of movements."
1603778|NCT02208193|Behavioral|Cognitive and psycho-behavioral effects of an artistic dimension|
1603779|NCT02208180|Behavioral|Return of genomic results on cardiovascular disease risk|"Experimental group: Participants will receive genomic cardiovascular disease risk information.
Comparator: Participants will receive lifestyle cardiovascular disease risk information. Genomic risk information will be returned after the conclusion of the study."
1603780|NCT02208167|Biological|HXTC infusion|
1603784|NCT02208128|Drug|Sunitinib, Pazopanib, Bevacizumab, Everolimus...|Clinical standard
1603785|NCT02208115|Dietary Supplement|Meal composition - Low versus high GI.|
1603787|NCT02208089|Procedure|Transepithelial Photorefractive Keratectomy (TransPRK)|Aberrometry or topography guided transepithelial photorefractive keratectomy (TransPRK) using the Schwind Amaris 750s excimer laser (www.eye-tech-solutions.com), an 8mm treatment diameter, and a tissue saving algorithm targeting selected higher order aberrations only. TransPRK will be followed immediately by corneal collagen cross-linking (CXL).
1603788|NCT02208089|Procedure|Corneal Collagen Cross-Linking (CXL)|"Riboflavin soak: 10 minutes total soak time; application of 0.1% riboflavin preparation (VibeX Rapid - www.avedro.com) each 2 minutes with gentle balanced salt solution irrigation to remove excess riboflavin prior to UV light exposure.
UV light exposure: Total treatment time 8 minutes (370nm wavelength; 30mW/cm2 irradiance; 4 minutes total UV exposure time, pulsed 1.5 seconds on 1.5 seconds off; Avedro KXL I light source)"
1603789|NCT02208076|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
1603790|NCT02208063|Drug|Telavancin|
1603791|NCT02208063|Drug|Vancomycin|
1603792|NCT02208063|Drug|Daptomycin|
1603793|NCT02208063|Drug|Synthetic penicillin|
1603794|NCT02208063|Drug|Cefazolin|
1603795|NCT02208050|Drug|Fampridine|
1603796|NCT02208050|Drug|Placebo|
1603821|NCT02207920|Biological|Placebo for AIDSVAX B/E|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
1603822|NCT02207907|Drug|Sodium bicarbonate plus sodium fluoride|Experimental dentifrice containing sodium bicarbonate plus 1150 parts per million (ppm) fluoride as sodium fluoride
1603823|NCT02207907|Drug|Sodium fluoride|Toothpaste containing 1100 ppm fluoride as sodium fluoride
1603824|NCT02207881|Drug|VDO gel|VDO gel
1603825|NCT02207881|Drug|placebo|matching placebo gel
1603797|NCT02208037|Drug|Tacrolimus (ARM with Methotrexate)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day -3. The dose of tacrolimus may be rounded to the nearest 0.5 mg for oral formulations. Subsequent dosing will be based on blood levels. The dose should be adjusted accordingly to maintain a suggested level of 5-15 ng/mL. If patients are on medications which alter the metabolism of tacrolimus (e.g. azoles), the initial starting dose and subsequent doses should be altered as per institutional practices. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
1603798|NCT02208037|Drug|Tacrolimus (ARM with MMF and Cyclophosphamide)|Tacrolimus will be given orally at a dose of 0.05 mg/kg or intravenously at a dose of 0.03 mg/kg starting Day +5. Serum levels of tacrolimus will be measured at Day 7 and then should be checked weekly thereafter, and the dose adjusted accordingly to maintain a suggested level of 5-15 ng/mL. Tacrolimus taper can be initiated at a minimum of 90 days post HSCT if there is no evidence of active GVHD. The rate of tapering will be done according to institutional practices but patients should be off tacrolimus by Day 180 post HSCT if there is no evidence of active GVHD.
1603799|NCT02208037|Drug|Methotrexate (ARM with Maraviroc)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of maraviroc. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
1603800|NCT02208037|Drug|Methotrexate (ARM with Bortezomib)|Methotrexate will be administered, per institutional practices, at the doses of 15 mg/m2 IV bolus on Day +1, and 10 mg/m2 IV bolus on Days +3, +6 and +11 after hematopoietic stem cell infusion. The Day +1 dose of methotrexate will be given at least 24 hours after the hematopoietic stem cell infusion and at least 30 minutes after the first dose of bortezomib. Dose reduction of MTX due to worsening creatinine clearance after initiation of conditioning regimen, high serum levels or development of oral mucositis is allowed according to institutional practices.
1603801|NCT02208037|Drug|Maraviroc|Maraviroc will be dosed at 300 mg orally twice a day and will start on Day -3 prior to hematopoietic stem cell infusion, and continue until Day 30 post HSCT. If the patient requires a two-day stem cell infusion, maraviroc treatment will end 30 days after the first infusion day.
1603802|NCT02208037|Drug|Bortezomib|Bortezomib will be administered at the dose of 1.3 mg/m2 based upon actual body weight (ABW) as an approximately 3-5 second IV push on Days +1, +4, and +7 after hematopoietic stem cell infusion. There must be at least 72 hours between each dose of bortezomib. Subcutaneous administration of bortezomib is not allowed on this protocol.
1603803|NCT02208037|Drug|Mycophenolate mofetil|MMF will be given at a dose of 15 mg/kg three times a day (TID) based upon ABW with the maximum total daily dose not to exceed 3 grams (1g TID, IV or PO). MMF prophylaxis will start Day 5 and discontinue after the last dose on Day 35, or may be continued if active GVHD is present.
1603804|NCT02208037|Drug|Cyclophosphamide|"Hydration prior to cyclophosphamide may be given according to institutional standards.
Mesna will be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide or administered per institutional standards. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of Mesna is equal to 80% of the total daily dose of cyclophosphamide.
Cyclophosphamide [50 mg/kg ideal body weight (IBW); if ABW < IBW, use ABW] will be given on Day 3 post-transplant (between 60 and 72 hours after the start of the HSCT) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
1603805|NCT02208024|Radiation|Stereotactic Body Radiation Therapy|
1603806|NCT02207998|Drug|Homeopathic complex and physiotherapy|Homoeopathic complex (Arnica montana 6CH, Bryonia alba 6CH, Causticum 6CH, Kalmia latifolia 6CH, Rhus toxicodendron 6CH and Calcarea fluoride 6CH) will comprise of medicated lactose tablets.
1603807|NCT02207998|Drug|Placebo and physiotherapy|Unmedicated lactose tablets. Physiotherapy: lower back classic massage, lumber joint manipulation and the application of a hot pack
1603808|NCT02207985|Procedure|Allogeneic hematopoietic stem cell transplantation|
1603811|NCT02207959|Drug|Proflavine Hemisulphate salt|The stomach will be sprayed with 1-10 ml of 0.01% proflavine using a standard endoscopic spray-catheter.
1603812|NCT02207959|Procedure|White-light examination|standard white light examination
1603813|NCT02207959|Procedure|Imaging with High Resolution Microendoscope|HRME will be inserted through the biopsy channel of the endoscope, gently placed against the mucosa, and images of suspicious areas will be obtained.
1603814|NCT02207946|Drug|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
1603815|NCT02207946|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
1603816|NCT02207933|Procedure|AP shifting training|AP shifting training in addition to gait training 3 times a week for 6 weeks
1603817|NCT02207933|Procedure|Gait training|Gait training only for 3 times a week for 6 weeks.
1603818|NCT02207920|Biological|AIDSVAX B/E Vaccine|600 mcg/mL to be administered as 1 mL intramuscular (IM) injection
1603819|NCT02207920|Biological|DNA-HIV-PT123 Vaccine|4 mg/mL to be administered as 1 mL IM injection
1603820|NCT02207920|Biological|Placebo for DNA-HIV-PT123|Sodium chloride for injection USP, 0.9%; administered as 1 mL IM injection
1603826|NCT02207855|Drug|Chloroprocaine|
1603827|NCT02207829|Drug|Umeclidinium|Umeclidinium 62.5 mcg once daily in the morning via nDPI
1603828|NCT02207829|Drug|Umeclidinium matching placebo|Umeclidinium matching placebo once daily in the morning via nDPI
1603829|NCT02207829|Drug|Tiotropium|Tiotropium 18 mcg once daily in the morning via HANDIHALER inhaler
1603830|NCT02207829|Drug|Tiotropium matching placebo|Tiotropium matching placebo once daily in the morning via HANDIHALER inhaler
1603831|NCT02207816|Procedure|Blood sampling|Annual blood sampling (Year 1, Year 2 and Year 3) during the present study.
1603833|NCT02207790|Drug|E2609|
1603834|NCT02207790|Drug|Placebo|E2609 low-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy Japanese subjects, E2609 high-dose and placebo in healthy Japanese subjects, E2609 mid-dose and placebo in healthy White subjects
1603835|NCT02207777|Procedure|Roux-en-Y gastric bypass surgery|A surgical procedure to help subjects lose 16-18% of their body weight.
1603836|NCT02207777|Behavioral|Low-calorie diet|Subjects will meet with a dietitian over 4-6 months to lose 16-18% of their body weight.
1603837|NCT02207777|Procedure|BPD|Biliopancreatic Diversion with duodenal switch (BPD) is a surgical procedure to help subjects lose 16-18% of their body weight.
1603838|NCT02207777|Procedure|SG|Sleeve Gastrectomy (SG) is a surgical procedure to help subjects lose 16-18% of their body weight.
1603839|NCT02207777|Procedure|LAGB|Laparoscopic Adjustable Gastric Banding is a surgical procedure to help subjects lose 16-18% of their body weight.
1603840|NCT02207764|Behavioral|Reiki|Each study participant in the intervention group will receive one Reiki intervention by a registered nurse trained in Advanced Level Reiki through the Usui Shiki Ryoho method.
1603841|NCT02207738|Device|microneedling radiofrequency device|Microneedling radiofrequency device is composed of 49 insulated microneedle which emit radiofrequency from the needle tip. This radiofreqeuncy generates dermal heat which evokes biological effect.
1603842|NCT02207738|Device|bipolar radiofrequency|bipolar radiofrequency instrument gives out bipolar radiofrequency from the hand piece tip. This bipolar radiofrequency generates dermal heat which has a lot of bilogical effect.
1603843|NCT02207725|Biological|Andexanet|
1603844|NCT02207725|Other|Placebo|
1603845|NCT02207712|Device|Noctura 400 Eye Mask|The intervention is the wearing of the eye mask
1603846|NCT02207712|Drug|Ranibizumab|Standard ranibizumab treatment only
1603847|NCT02207699|Drug|Benzonatate 200 mg|2 benzonatate 100 mg perles and 6 placebo perles give by mouth once
1603848|NCT02207699|Drug|Benzonatate 800 mg|8 benzonatate 100 mg perles given by mouth once
1603849|NCT02207699|Drug|Moxifloxacin 400 mg|1 moxifloxacin 400 mg tablet given by mouth once
1603850|NCT02207699|Drug|Placebo|8 placebo perles given by mouth once
1603851|NCT02207673|Procedure|Tailoring of the resection based on biomarker in aEcoG during epilepsy surgery|
1603852|NCT02207660|Drug|Cisplatin,P-HDFL|The P-HDFL regimen was given as follows: In each 21-day cycle, patients received 24-hour infusions of cisplatin at 45 or 50 mg/m2 and 5-FU 2,600mg/m2 plus leucovorin 300 mg/m2 intravenous 24-hour infusion on Day 1. Normal saline hydration (≧1000 mL), dexamethasone, and antiemetics (ondansetron or granisetron) were given prophylactically before each dose of cisplatin.
1603853|NCT02207647|Other|no intervention|
1603854|NCT02207634|Biological|Evolocumab (AMG 145)|Evolocumab (AMG 145)
1603855|NCT02207634|Other|Placebo|Placebo
1603856|NCT02207634|Drug|Effective statin therapy|Effective statin therapy defined as greater than or equal to atorvastatin 20 mg or an equivalent statin
1603857|NCT02207621|Drug|Netarsudil (AR-13324) Ophthalmic Solution|1 drop daily (evening)
1603858|NCT02207621|Drug|Timolol maleate Ophthalmic Solution|2 drops daily
1603859|NCT02207608|Drug|Hyaluronic Acid|Add hyaluronic acid to BCG Treatment
1603860|NCT02207608|Drug|BCG (Immucist®)|Usual BCG treatment
1603861|NCT02207595|Drug|UCB5857|"Active Substance: UCB5857
Pharmaceutical Form: Capsule
Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg
Route of Administration: Oral Use"
1603862|NCT02207595|Other|Placebo|"Active Substance: Placebo
Pharmaceutical Form: Capsule
Concentrations: 5 mg, 10 mg, 20 mg, 30 mg, 50 mg, 100 mg
Route of Administration: Oral Use"
1603863|NCT02207582|Device|Verum Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds.
1603864|NCT02207582|Device|Placebo Prefrontal tRNS|2mA of tRNS (DC-Stimulator, NeuroConn GmbH, Germany) with a zero offset will be applied to the left and right dorsolateral prefrontal cortex. Treatment will consist of 15 days with 20 minutes stimulation per day. Voltage will be ramped at the begin and end of a stimulation for 10 seconds. Placebo stimulation will consist of just applying the ramps at the begin and end of the stimulation.
1603867|NCT02207543|Other|Medical telephone contact|Evaluations will be conducted by telephone 15 days after hospital discharge, 30 days and then every month until 6 months.
1603868|NCT02207530|Drug|MEDI4736|MEDI4736 monotherapy
1603869|NCT02207517|Procedure|Office-based vergence/accommodative therapy|The OBVAT program has been divided into 4 phases. Within each phase there are a number of categories such as gross convergence, vergence, and accommodation. The therapy procedures in each category have been arranged sequentially from easiest to most difficult
1603872|NCT02207491|Drug|Timolol maleate Ophthalmic Solution|1 drop twice daily
1603873|NCT02207491|Drug|Netarsudil (AR-13324) Ophthalmic Solution|1 drop daily
1603960|NCT02206789|Drug|Prednisolone acetate1%,|efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
1604214|NCT02205047|Procedure|gastrectomy|D2 gastrectomy
1603874|NCT02207478|Procedure|ENB|ENB is performed using an electromagnetic navigation system (LK-DW-NK-Z; Suzhou Lungcare Medical Technology Inc., China) with an internal locatable guide (LG; Lungcare) with diameter of 1.45 mm. Bronchoscopes with a working channel diameter of 2.0 mm are used (BF-260 and BF-P260F; Olympus, Japan). The LG is inserted into the GS(K-201; Olympus) beforehand, and the GS-covered LG is introduced via the working channel of the bronchoscope and navigated to the PPL finally. The LG and GS are confirmed to reach the lesion by radiograph fluoroscopy.
1603875|NCT02207478|Procedure|GS-TBLB-X-ray|A GS is introduced in the working channel of the bronchoscope alone. The GS is confirmed to reach the lesion by radiograph fluoroscopy, pathologic specimens are obtained under fluoroscopic guidance.
1603876|NCT02207465|Radiation|Radiotherapy|
1603877|NCT02207465|Drug|Gemcitabine 1000 mg|
1603878|NCT02207465|Drug|nab-paclitaxel 125 mg|
1603879|NCT02207452|Device|He-3 MRI|Hyperpolarised helium-3 Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
1603880|NCT02207452|Drug|Salbutamol|Salbutamol 5mg nebulised single dose
1603881|NCT02207452|Drug|Ipratropium|Ipratropium 500mcg nebulised single dose
1603882|NCT02207452|Device|MRI|Proton Magnetic Resonance Imaging (MRI) scan pre-bronchodilator and 1 hour post-bronchodilator (after 1 hour post-bronchodilator assessments/procedures completed).
1603883|NCT02207439|Drug|Nelfinavir (Viracept®) 1250 mg|
1603884|NCT02207426|Drug|Tobramycin|
1603885|NCT02207413|Biological|Influsplit Tetra™ vaccine produced by investigational process (IP)|Influsplit Tetra™ vaccine using a new manufacturing process administered intramuscularly (IM) in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
1603886|NCT02207413|Biological|Influsplit Tetra™ vaccine produced by licensed process (LP)|Influsplit Tetra™ vaccine using a licensed manufacturing process administered IM in the deltoid region of non-dominant arm (Dose 1) in Adults Group and in non-dominant deltoid or left anterolateral thigh (Dose 1) and dominant deltoid or right anterolateral (Dose 2 - unprimed subjects) in 6-35m and 3-17y Groups.
1603887|NCT02207400|Drug|Sodium bicarbonate and sodium fluoride|Experimental toothpaste containing sodium bicarbonate experimental dentifrice plus 1150 parts per million (ppm) fluoride as sodium fluoride
1603888|NCT02207400|Drug|Sodium fluoride|Comparator toothpaste containing 1100 ppm fluoride as sodium fluoride
1603889|NCT02207387|Drug|Azilect|Rasagiline is Parkinson's medication that can be taken alone early in the disease or with other medication and is hypothesized to produce synergistic effects with exercise.
1603890|NCT02207387|Behavioral|Exercise|Walking and other forms of exercise have been seen clinically and in numerous research studies to be effective against Parkinson's symptoms.
1603891|NCT02207387|Other|Music|
1603892|NCT02207374|Drug|semaglutide|Subject will receive either a dose of 0.5 or 1.0 mg of semaglutide once weekly (subcutaneous (s.c.) injection).Treatment duration 56 weeks.
1603893|NCT02207374|Drug|DPP-4 inhibitor|Subjects will receive one DPP-4 inhibitor in addition to pre-trial OAD monotherapy, if any, for 56 weeks.
1603894|NCT02207361|Drug|Paclitaxel, Carboplatin|Paclitaxel: 175mg/m2, IV, d1 Carboplatin: AUC 5, IV, d1 Every 21 days to 1 course of treatment.
1603895|NCT02207361|Drug|Paclitaxel, Epirubicin|Paclitaxel: 175mg/m2, IV, d1 Epirubicin: 60-80mg/m2, IV, d1 Every 21 days to 1 course of treatment.
1603896|NCT02207348|Drug|liraglutide|Each subject will receive two single doses of 0.6 mg liraglutide (one with each of the two pen-injectors)
1603897|NCT02207335|Drug|Gemcitabine，Capecitabine|Gemcitabine: 1250 mg/m2, ivgtt, 30mins, D1,8 Capecitabine: 1250 mg/m2, PO, Q12h, D1-14
1603898|NCT02207335|Drug|Gemcitabine, Carboplatin|Gemcitabine: 1250 mg/m2, ivgtt,30mins, D1,8 Carboplatin: AUC 2, ivgtt, 60mins, D1,8
1603899|NCT02207322|Other|transplant with early palliative care|the intervention include integrating early palliative care with standard transplant care to evaluate and treat patients' symptoms during stem cell transplantation
1603900|NCT02207309|Drug|Pazopanib|
1603901|NCT02207309|Drug|Placebo (for Pazopanib)|
1603902|NCT02207296|Device|Plethysmographic variability index|
1603903|NCT02207283|Drug|Tadalafil|
1603904|NCT02207283|Drug|Placebo|
1603905|NCT02207270|Procedure|Same day discharge|"Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
Patients randomized to ON will receive usual overnight care and will be discharged the following morning. Costs and outcomes will be identified in-hospital by study personnel. They will receive a follow up phone call from a study coordinator at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred."
1603906|NCT02207257|Drug|PER977|Reversal of edoxaban-induced anticoagulation
1603907|NCT02207257|Drug|Placebo|Reversal of edxoaban-induced anticoagulation
2009718|NCT03186794|Other|Treadmill exercise training|The target training heart rate range is 70-80% of heart rate reserve, computed as: 0.7 and 0.85 (peak heart rate minus resting heart rate) + resting heart rate. Subjects will exercise for 30 minutes per session, completing on average 3 sessions per week, over approximately 12 weeks. During the training session, heart rate, treadmill speed, treadmill inclination, perceived fatigability index and RPE will be recorded. In the event that subjects cannot sustain 30 minutes of continuous treadmill walking at the target intensity, an interval approach will be used in which walking at the target will be sustained at smaller training interval durations of no shorter than 5 minutes followed by an active rest interval that is no longer than 1.5 times the training interval until the subject achieves a total exercise time of 30 minutes, excluding the rest intervals. Each of these sessions will last about 60 minutes but slightly longer if an interval approached is used.
2009719|NCT03186781|Biological|VRC-FLUNPF081-00-VP (HA-F A/Sing)|VRC-FLUNPF081-00-VP (HA-FA/Sing) is an investigational ferritin vaccine.
2009720|NCT03186781|Biological|VRC-FLUDNA082-00-VP (DNA A/Sing)|VRC-FLUDNA082-00-VP (DNA A/Sing)is an investigational plasmid DNA vaccine.
2009721|NCT03187210|Drug|Brentuximab Vedotin|Brentuximab Vedotin at day -8 together with standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
2009722|NCT03187210|Drug|BeEAM Regimen|standard BeEAM chemotherapy at days -7 to -1 followed by ASCT on day 0
2009723|NCT03185546|Other|NNC Spectrum Cigarette|Participants are provided with normal nicotine content Spectrum Cigarette for 7 weeks
2009724|NCT03185546|Other|VLNC Spectrum Cigarette|Participants are provided with very low nicotine content Spectrum Cigarette for 7 weeks
2009725|NCT03185546|Other|Moderate nicotine level e-liquid|Participants are provided with moderate nicotine level e-liquid for 7 weeks
1603916|NCT02207218|Drug|turoctocog alfa|No treatment given. Patients will be treated with commercially available NovoEight®. Patients will be treated according to local clinical practice at the direction of the physician.
1603917|NCT02207205|Drug|Blood drawn from indwelling catheters versus direct venipuncture|Evaluation of the source of blood samples on whole blood clotting time
1603918|NCT02207192|Other|Postural change in lung volumes: sitting to Supine|"Pulmonary function and arterial blood gases were assessed both prior to and after weight loss as part of pre-operative and 12-month follow-up evaluations.
Pulmonary function tests were performed both in the sitting and then in the supine position."
1603919|NCT02207179|Device|LumaScan Image Guided Surgery|
1603920|NCT02207140|Dietary Supplement|HOWARU Restore|
1603921|NCT02207127|Procedure|MRI, DISE, and Surgery|
1603922|NCT02207114|Other|Biomarker Algorithm Intervention|The intervention will consist of using the biomarker identified as useful in Phase I to compile an algorithm along containing the patient's biomarker assay results and providing this as additional information for a clinical team consider using to assist in deciding to continue antibiotics. Biomarker algorithms may be different for adult versus pediatric patients, and across different types of ICUs.
1603923|NCT02207101|Dietary Supplement|E-OJ-01 (OXYJUN)|
1603924|NCT02207101|Dietary Supplement|Placebo|
2009726|NCT03185546|Other|Low/O nicotine level e-liquid|Participants are provided with very low or nicotine-free nicotine level e-liquid for 7 weeks
2009727|NCT03185546|Other|Cigarette flavors|Participants can choose e-liquid flavors from a selection of cigarette flavors
1603928|NCT02207075|Radiation|[C11]PK-1195 PET scan|PET scan with tracer [C11]PK-1195
1603929|NCT02207062|Drug|Ibrutinib|Given PO
1603930|NCT02207062|Other|Laboratory Biomarker Analysis|Correlative studies
1603931|NCT02207049|Behavioral|Snacking|Snacks will be provided to preschoolers, either as part of total caloric needs or above total caloric needs
1603932|NCT02207049|Behavioral|No Snacking|Caloric needs will be provided to preschoolers within three meals
1603933|NCT02207036|Behavioral|Facebook intervention|90 days of Facebook messaging, weekly Ask the Doctor sessions
1603934|NCT02207036|Behavioral|Smokefree.gov|referral to the NCI Smokefree.gov website
1603935|NCT02207023|Behavioral|Healthy Lifestyle Training Program|Study participants in the Healthy Lifestyle Training Program will each receive 7 lifestyle coaching telephone-sessions (30-60 minutes) with a trained lifestyle coach over a 6 month period. The lifestyle coaches will work on a 1:1 basis with each participant to encourage healthy lifestyles.
1603936|NCT02207010|Biological|AZD1775|All patients receive a single dose of the oral study drug prior to surgery for resection of GBM.
1603937|NCT02206984|Drug|Tamoxifen|
1603938|NCT02206984|Drug|Anastrozole|
1603939|NCT02206984|Drug|Fulvestrant|
1603940|NCT02206971|Other|urine analyses feedback|biomarker feedback report regarding the urine sample analyzed for the tobacco chemicals, cotinine, nicotine and NNAL
1603941|NCT02206958|Behavioral|Behavioral Urinary Incontinence Treatment|"12 week program with 3 components
Continence program administered by a registered nurse during 4 home visits. Participants do pelvic floor muscle exercises 5 days/week using a 13-minute instructional audio CD. Based on participant symptoms and preferences the following strategies are taught: bladder training, urge and suppression techniques, caffeine reduction, eliminating bladder irritants, medication adjustment, adequate fluid intake, constipation management, and reducing nocturia.
Physical activity program including moderate intensity walking (30 minutes, 5 days weekly) and twice weekly group strength training sessions using Therabands led by a trained exercise instructor.
Recommendations for improving toilet access (i.e., lighting, toileting and dressing devices, grab bars, raised toilet seats, clearing path to toilet)."
1603942|NCT02206945|Behavioral|neurofeedback|Subject provided with feedback of activity in target brain area in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
1603943|NCT02206945|Behavioral|control feedback|Subject provided with a control/placebo type of feedback in the form of a line graph. Cued to try to make the line go up at certain times and down at other times.
1603944|NCT02206932|Drug|Sofosbuvir + Simeprevir|
1603945|NCT02206906|Behavioral|Incentive intervention model|All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
1603946|NCT02206893|Behavioral|Self-monitoring via Smartphone|
1603947|NCT02206893|Behavioral|Peer support via Smartphone|
1603948|NCT02206893|Behavioral|Professional support via Smartphone|
1603949|NCT02206893|Behavioral|Self-monitoring via Web (Static)|
1603950|NCT02206867|Biological|LBAL|Anti-inflammatory agents
1603951|NCT02206867|Biological|Humira|Anti-inflammatory agents
1603952|NCT02206854|Drug|R-flurbiprofen|200 mg gelatine capsule once orally
1603953|NCT02206841|Procedure|Liver biopsy|Percutaneously liver biopsy will be performed for evaluate steatosis and fibrosis.
1603954|NCT02206841|Device|ARFI|Acoustic radiation force impulse (ARFI) imaging will be performed for evaluate fibrosis of liver.
1603955|NCT02206841|Device|SWE|Supersonic shear wave elastography (SWE) will be performed for evaluate fibrosis of liver.
1603956|NCT02206841|Device|Transient elastography (Fibroscan)|Transient elastography will be performed for evaluate fibrosis of liver.
1603957|NCT02206815|Drug|Ticagrelor+Warfarin|Ticagrelor 90mg/bid + Warfarin (maintain INR 2.0-2.5)
1603958|NCT02206815|Drug|Clopidogrel+Aspirin+Warfarin|Clopidogrel 75mg/day + Aspirin 100mg/day + Warfarin(maintain INR 2.0-2.5)
1603959|NCT02206802|Drug|5% minoxidil topical foam|5% minoxidil topical foam
1603961|NCT02206789|Drug|Prednisolone acetate1%, cyclosporine 2%|penetrating keratoplasty--efficacy of prednisolone acetate1%alone versus prednisolone acetate 1%and cyclosporine 2% in preventing graft rejection
1603962|NCT02206776|Drug|Intranasal Ketamine|A single dose of intranasal ketamine up to 50 mg
1603963|NCT02206776|Drug|Intranasal Midazolam|A single dose of intranasal Midazolam up to 4 mg
1603964|NCT02206763|Drug|MMB|Tablet(s) administered orally once or twice daily
1603965|NCT02206763|Drug|Erlotinib|Tablet(s) administered orally once daily.
1603966|NCT02206750|Other|Clean Air|Each subject will be exposed to clean air for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
1603967|NCT02206750|Other|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. Subjects will exercise on a bike or treadmill. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
1603968|NCT02206737|Device|No nicotine e-cigarette|
1603969|NCT02206737|Device|Low dose nicotine e-cigarette|
1603970|NCT02206737|Device|High dose nicotine e-cigarette|
1603971|NCT02206724|Radiation|STEREOTACTIC BODY RADIOTHERAPY to the prostate gland|
1603972|NCT02206711|Drug|BMS-955176|Single dose of drug on Day 1
1603973|NCT02206685|Drug|Methadone|The treatment group will receive 0.2 mg/kg methadone diluted to a 20 ml infusion over 10 minutes
1603974|NCT02206685|Drug|Normal Saline|the control group will receive a 20 ml normal saline placebo infusion over 10 minutes
1603975|NCT02206672|Other|Micro reinjection of autologus adipose tissue|
1603976|NCT02206659|Drug|Telmisartan|
1603977|NCT02206659|Drug|Placebo|
1603978|NCT02206646|Drug|Metalyse|
1603979|NCT02206633|Device|Hydration Monitor|Measurement of the ultrasound velocity with the Hydration Monitor for specific anatomic locations. Triplicate measurements will be made for each time-point. All subjects will also be measured for bioelectrical impedance analysis (BIA) and estimation of total body water using a leg-to-leg BIA machine.
1603980|NCT02206620|Drug|Donepezil|
1603981|NCT02206607|Drug|PF-04937319 IR MST|Immediate release material sparing tablet (IR MST) administered as 150 mg with morning meal and 100 mg with lunch
1603982|NCT02206607|Drug|PF-04937319 MR 1|Modified release formulation #1 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
1603983|NCT02206607|Drug|PF-04937319 MR 2|Modified release formulation #2 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
1603984|NCT02206607|Drug|PF-04937319 MR 3|Modified release formulation #3 administered with the morning meal at a dose predicted to yield exposure (AUC24) equivalent to 300 mg IR MST
1603985|NCT02206594|Procedure|Descemetorhexis|
1603986|NCT02206581|Device|Hydration Monitor|
1603987|NCT02206568|Drug|URAL|
1603988|NCT02206555|Drug|emtricitabine/tenofovir disoproxil fumarate|
1603989|NCT02206542|Device|Upper limb rehabilitation robot|Upper limb rehabilitation robot is to carry out passive shoulder joint movements including shoulder flexion, shoulder abduction, shoulder horizontal-abduction and shoulder rotation.
1603990|NCT02206542|Other|Physical therapy|
1603991|NCT02206542|Device|Electroacupuncture|
2009728|NCT03185546|Other|Cigarette and non-cigarette e-liquid flavors|Participants can choose e-liquid flavors from a selection of flavors that includes cigarette and non-cigarette choices
2009729|NCT03185143|Drug|ALLOD-2 Capsules|One capsule contains component A and one capsule contains component B taken together to treat a single Qualified Migraine attack.
1603994|NCT02206516|Device|Transcranial Direct Current Stimulation|
1603995|NCT02206503|Drug|Cyclophosphamide|This protocol is a phase II multicenter, open label study designed to determine whether the addition of Cyclophosphamide to Rd (CRd) treatment significantly increases response rates and prolonged the outcome (PFS, OS) in patients who experienced a biochemical relapse, without CRAB under Rd treatment. The treatment period includes: administration of the combination CRd for 9 cycles. In order to assess the efficacy and safety of treatment, patients will attend the study center visits at least every 2 weeks. The response will be assessed after each cycle. During the LTFU period, after development of confirmed PD, all patients are to be followed for survival every 1-3 months via telephone or office visit.
1603996|NCT02206503|Drug|Lenalidomide|
1603997|NCT02206503|Drug|Dexamethasone|
1603998|NCT02206490|Drug|naltrexone|Randomized controlled trial of naltrexone for Gulf War Illness.
1603999|NCT02206490|Drug|Dextromethorphan|Randomized controlled trial of dextromethorphan for Gulf War Illness
1604000|NCT02206477|Drug|Dimethyl Sulfoxide|
1604001|NCT02206477|Drug|Saline 0.9%|
1604002|NCT02206464|Biological|A/Shanghai/02/2013 (H7N9) MIV|Monovalent Influenza Subvirion Vaccine for H7N9 avian influenza (H7N9 MIV)
1604003|NCT02206464|Biological|VRC-FLUDNA071-00-VP|H7 DNA Vaccine
1604004|NCT02206438|Device|Insertion of C-LMA|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
1604005|NCT02206438|Device|Insertion of air-Q according|After induction of general anesthesia, C-LMA or Air-Q was inserted according to randomly allocated group.
1604006|NCT02206425|Drug|Melphalan|Melphalan will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
1604007|NCT02206425|Drug|Prednisone|Prednisone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
1604008|NCT02206425|Drug|Cyclophosphamide|Cyclophosphamide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
1604009|NCT02206425|Drug|Dexamethasone|Dexamethasone will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
1604010|NCT02206425|Dietary Supplement|Ascorbic acid|Vitamin C will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
1604165|NCT02205359|Device|aCRT ON|CRT device with AdaptivCRT enabled
1604011|NCT02206425|Drug|PLD|Pegylated liposomal doxorubicin will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
1604012|NCT02206425|Drug|Lenalidomide|Lenalidomide will be administered at the same schedule and dose intensity as those of the last PI-containing treatment the patient failed (it varies with each patient).
1604013|NCT02206386|Other|MHTraining-Net|See Arm Description for more details.
1604014|NCT02206386|Other|Enhanced Support|Nurses in agencies randomized to Enhanced Support have full access to the study protocol and to recorded training in the use of the protocol and depression screening posted by Brightree.
1604015|NCT02206360|Procedure|Endoscopic Ultrasound|
1604016|NCT02206360|Procedure|Magnetic Resonance Imaging (MRI)|
2009730|NCT03185143|Drug|Sumatriptan 100 mg Capsules|One capsule contains Sumatriptan 100 mg and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
1604018|NCT02206334|Radiation|Stereotactic Radiosurgery|Undergo SBRT
1604019|NCT02206321|Procedure|Navigation total knee arthroplasty|computer assisted navigation total knee arthroplasty without femur intramedullary involvement
1604020|NCT02206321|Procedure|Conventional total knee arthroplasty|conventional technique with femur intramedullary violation
1604021|NCT02206308|Biological|Chimeric anti-CD20 monoclonal antibody|
1604022|NCT02206295|Drug|selexipag|
1604023|NCT02206269|Device|Alair System|The Alair system is used for doing bronchial thermoplasty.
1604024|NCT02206256|Drug|Omega-3 fatty acid capsules|2 times a day 1 capsule for 4 weeks before gastric bypass surgery
1604025|NCT02206256|Behavioral|Low calorie diet|A low calorie diet of 600 kcal/day during 2 weeks, using Modifast or an adjusted normal diet.
1604026|NCT02206243|Drug|Embozene Microspheres|Intraarterial application
1604027|NCT02206230|Radiation|Hypofractionated radiation therapy|
1604028|NCT02206230|Radiation|Standard radiation therapy|
1604029|NCT02206217|Device|Multiple-Segment spectacle lens|A multifocal spectacle lens that corrects distance refraction and provides myopic defocus images simultaneously. The myopic defocus aims at slowing down myopia progression.
1604030|NCT02206204|Drug|selexipag|
1604031|NCT02206204|Drug|placebo for selexipag|
1604032|NCT02206204|Drug|moxifloxacin|
1604033|NCT02206204|Drug|moxifloxacin-matching placebo|
1604034|NCT02206178|Drug|N-acetylcysteine combination with acetaminophen|
1604035|NCT02206178|Drug|Placebo|
1604036|NCT02206165|Drug|Candesartan 8mg|Once a day, 8 weeks
1604037|NCT02206165|Drug|Candesartan 16mg|Once a day, 8 weeks
1604038|NCT02206165|Drug|Amlodipine 5mg|Once a day, 8 weeks
1604039|NCT02206165|Drug|Amlodipine 10mg|Once a day, 8 weeks
1604040|NCT02206152|Drug|N-acetyl cysteine|N-acetyl cysteine (or saline) IV infusion given as a 150 mg/kg loading dose over the first hour and then follow that with a 50 mg/kg maintenance dose infused over the next 4 hours during a controlled hyperinsulinemic hypoglycemic insulin clamp
1604041|NCT02206152|Drug|Placebo|
1604042|NCT02206126|Behavioral|Energy Restriction|The energy restriction group was instructed to follow an energy-restricted diet (-800 kcal/day).
1604043|NCT02206113|Behavioral|Standing workstation|
1604044|NCT02206100|Drug|PER977|reversal of edoxaban-induced anticoagulation
1604045|NCT02206100|Drug|Placebo|Reversal of edoxaban-induced anticoagulation
1604046|NCT02206087|Drug|PER977|Reversal of heparin-induced anticoagulation
1604047|NCT02206087|Drug|Placebo|Reversal of heparin-induced anticoagulation
1604048|NCT02206074|Dietary Supplement|Beetroot|
1604049|NCT02206061|Behavioral|School-Based Asthma Care for Teens (SB-ACT)|
1604050|NCT02206061|Behavioral|Directly Observed Therapy|
1604051|NCT02206061|Behavioral|Asthma Education|
1604052|NCT02206048|Drug|Proflavine|0.01% proflavine solution topically applied to cervix before high-resolution microendoscopy (HRME) imaging.
1604053|NCT02206048|Procedure|High-Resolution Microendoscopy (HRME) Imaging|in-vivo high-resolution microendoscopy (HRME) images of cervical adenocarcinoma in situ (AIS) performed immediately prior to conization.
2009731|NCT03185143|Drug|Placebo capsules|One capsule contains a sham for component A and one capsule contains a sham for component B taken together to treat a single Qualified Migraine attack.
2009732|NCT03185689|Behavioral|Effectiveness of an intensified DSME in T2D adult patients|
2009733|NCT03184090|Drug|Palbociclib|palbociclib in combination with endocrine therapy (investigator's choice)
1604057|NCT02206022|Drug|Remifentanil|Pain's evaluation for Remifentanil Group
1604058|NCT02206022|Drug|Placebo|CVC pain's evaluation after local anesthesia + placebo infusion
1604059|NCT02206009|Device|Collagen Membrane|First, the recipient site is prepared, and the collagen membrane hydrated. The collagen membrane is sutured firmly against the prepared vascular bed with a long-lasting suture material. The subject is requested to minimize the amount of manipulation to the area to maintain graft stability.
1604060|NCT02205996|Drug|Insulin (Humulin S)|Using insulin and glucose infusions (hyperinsulinaemic clamps), blood glucose levels were stabilised over 1 hour to reach 5 mmol/L and maintained at that level for 1 hour, then gradually reduced over 1 hour to 2.8 mmol/L and maintained at that level for 1 hour. Blood samples were collected at times 0 (baseline), 2 hours (euglycaemia), 4 hours (hypoglycaemia) and at 24 hours after the clamp studies.
1604061|NCT02205996|Device|Euglycaemic Hypoglycaemic Insulin clamp|
1604062|NCT02205983|Drug|Oral hydromorphone|We are administering oral hydromorphone to healthy volunteers to measure its effects on the performance of a verbal task.
1604063|NCT02205983|Drug|Buprenorphine|We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
2009734|NCT03184090|Drug|Endocrine therapy (non IMP)|Endocrine therapy (physician's choice based on prior administered agent including tamoxifen, exemestane, fulvestrant, anastrozole, or letrozole). Endocrine therapy must be different from previous treatment line.
2009735|NCT03182244|Drug|gilteritinib|oral
1604166|NCT02205359|Device|aCRT OFF|CRT device with AdaptivCRT disabled
1604167|NCT02205333|Biological|MEDI6469 Monotherapy|single intravenous (IV) administration of MEDI6469
1604066|NCT02205944|Other|Progressive Handgrip Exercise|"Group 1 (Normal Exercise Group): Daily, at home for 20 minutes using an adjustable handgrip trainer up to 8 weeks prior to a scheduled surgery for fistula creation. The exercise intensity is tailored using the Borg CR100 scale (Borg & Borg, 2001).
Group 2 (Restricted Blood Flow Exercise Group): Same as the exercise performed by Group 1 with controlled tourniquet."
1604067|NCT02205931|Other|Ketogenic diet|The ketogenic diet is a high fat diet designed to mimic the effects on the body of starvation. The premise is the main energy intake is fat, which is utilised in the body and produces ketones.
1604068|NCT02205931|Drug|Antiepileptic drug therapy|The control intervention will be drug therapy with the most appropriate further antiepileptic drug for a particular child, depending on their presenting seizures and syndrome and previous drugs used, and chosen by the expert clinician responsible for management of the patient's epilepsy.
1604069|NCT02205918|Other|Active TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive 1hz active TMS. Tics and urges will be monitored immediately before and after TMS."
1604070|NCT02205918|Other|Sham TMS|"There will be one, 30-minute TMS session. Participants randomly assigned to this group will receive inactive (sham) TMS. Tics and urges will be monitored immediately before and after TMS."
1604071|NCT02205905|Drug|14C PER977|Open-label, single dose
1604072|NCT02205892|Drug|Lupeol|Patients are supposed to apply 2% lupeol cream to one side of their face two times per day for 4 weeks. Application side is randomly determined.
1604073|NCT02205892|Drug|Placebo vehicle|Patients are supposed to apply their control vehicle cream two times per day to the other side of their face for 4 weeks. Application side is randomly determined.
1604074|NCT02205879|Drug|Pregabalin|
1604075|NCT02205879|Drug|Placebo|
1604076|NCT02205866|Other|Endometrial Receptivity Array analysis of endometrial biopsy|A biopsy of endometrium is peformed and Endometrial Receptivity Array analysis is carried out, as well as analysis of fat distribution and risk factors of Metabolic Syndrome.
1604077|NCT02205853|Other|The patient-directed (PD) strategy|The patient-directed strategy will be designed to embed the success of implementation of PCRPs by influencing the patients.
1604078|NCT02205853|Other|The multi-faceted (MF) strategy|The multi-faceted strategy will be designed to embed the success by not only influencing the patients, but also professionals and organizational aspects.
1604079|NCT02205840|Drug|SI-614|1 drop in each eye
1604080|NCT02205840|Drug|Vehicle|1 drop in each eye
1604081|NCT02205827|Other|Single-arm|collection of blood for assessment of whole blood clotting time
1604082|NCT02205814|Drug|Fasitibant- low dose|Single intra-articular injection of low dose of fasitibant
1604083|NCT02205814|Drug|Fasitibant- intermediate dose|Single intra-articular injection of intermediate dose of fasitibant
1604084|NCT02205814|Drug|Fasitibant- high dose|Single intra-articular injection of high dose of fasitibant
1604085|NCT02205814|Drug|Placebo comparator|Single intra-articular injection of placebo
1604086|NCT02205801|Procedure|Superficial Cervical Plexus Block|0.25% Marcaine is injected lateral to the sternocleidomastoid bilaterally (10mL on each side) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
1604087|NCT02205801|Procedure|Local Wound Infiltration|0.25% Marcaine is injected at the site of incision (20mL) after induction of anesthesia and prior to incision and scheduled thyroidectomy or parathyroidectomy.
1604088|NCT02205801|Drug|0.9% saline|
1604089|NCT02205801|Drug|Marcaine|
1604090|NCT02205775|Drug|Atorvastatin|80 + 40 mg pre PCI
1604091|NCT02205775|Drug|Rosuvastatin|40 + 40 mg before PCI
1604092|NCT02205775|Drug|Rosuvastatin|5 mg twice before PCI (+ 10 mg ezetimibe)
1604093|NCT02205775|Drug|Ezetimibe|10 mg twice before PCI (+ 5 mg rosuvastatin)
1604094|NCT02205775|Drug|placebo|twice before PCI
1604095|NCT02205762|Drug|Prednisone|Stratum I
1604096|NCT02205762|Drug|Vinblastine|Stratum I
1604097|NCT02205762|Drug|mercaptopurine|Stratum I
1604098|NCT02205762|Drug|INDOMETHACIN|Indomethacin fixed dose given daily orally in two divided doses with gastric protection for total treatment duration of 24 months.
1604099|NCT02205762|Drug|Methotrexate|fixed dose weekly orally for total treatment duration of 24 months.
1604100|NCT02205762|Drug|Cytosine Arabinoside|
1604101|NCT02205762|Drug|2-chlorodeoxyadenosine|
1604102|NCT02205762|Procedure|hematopoietic stem cell transplantation (RIC-HSCT)|
1604103|NCT02205762|Biological|Intravenous immunoglobulin|
1604104|NCT02205749|Behavioral|Study-specific consent model|• Review plain language brochure describing consent to a biobank based on the study-specific model of consent
1604105|NCT02205749|Behavioral|Broad consent model|• Review plain language brochure describing consent to a biobank based on the broad model of consent
1604106|NCT02205749|Behavioral|Notice consent model|• Review plain language brochure describing consent to a biobank based on the notice model of consent
2009736|NCT03182244|Drug|LoDAC (Low Dose Cytarabine)|subcutaneous (SC) or intravenous (IV) injection
1604110|NCT02205710|Other|Computerized cognitive training|
1604111|NCT02205710|Other|Computerized games|
1604112|NCT02205697|Behavioral|Implementation intention|The intervention consists of an implementation intention whereby subjects create a unique plan to increase their fruit and vegetable intake by planning the where, when, and what to increase their fruit and vegetable intake.
1604113|NCT02205684|Other|Computer game skills training|Playing Nintendo Wii Sports
1604114|NCT02205684|Other|Physical activity|Aerobic High Intensity Training (HIT)
1604115|NCT02205671|Behavioral|Building Better Caregivers Small-group Workshop|
1604116|NCT02205645|Device|FibroFix™ Meniscus scaffold|"The test article for this study is the FibroFix™ Meniscus scaffold supplied by Orthox Ltd. The FibroFix™ Meniscus scaffold has been developed for repair of defects of the meniscus.
The FibroFix™ Meniscus scaffold used in this study is a silk derived product developed to functionally replace the excised unstable meniscus following a meniscal tear."
1604117|NCT02205632|Device|MPS II|
1604211|NCT02205047|Drug|5-fluorouracil or Capecitabine|
1604118|NCT02205619|Device|Air Flow Master Piezon®, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with US devices ( Air Flow Master Piezon®, EMS SA, Nyon, Swiss) were performed with medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
1604119|NCT02205619|Device|Gracey curettes, American Eagle, Missoula, MT, USA|comparison of different instruments on root cementum Hand instruments (Gracey curettes 5/6, 11/12, 13/14 American Eagle, Missoula, MT, USA) were used for subgingival root instrumentation. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia.
1604120|NCT02205619|Device|Air-flow® Powder Perio, EMS SA, Nyon, Swiss|comparison of different instruments on root cementum: Instrumentations with air polishing (Air-flow® Powder Perio, EMS SA, Nyon, Swiss) were performed with a special nozzle and medium power settings and with the use of water cooling (as instructed by the manufacturer). One approximal root surface (distal and mesial) of each tooth was randomly subjected to debridement and the other approximal surface was used as control. All the measurements and instrumentations of teeth were performed by a single operator. The criteria for adequate treatment were smooth, hard root surfaces, with no remnants of calculus. The cleanliness and smoothness of the root surface were checked using a fine dental explorer. The instrumentations were done under local anesthesia
1604121|NCT02205606|Drug|HGP0816 5mg|P.O.
1604122|NCT02205606|Drug|HGP0816 10mg|P.O.
1604123|NCT02205606|Drug|HGP0816 20mg|P.O.
1604124|NCT02205606|Drug|HCP1306 5/10mg|P.O.
1604125|NCT02205606|Drug|HCP1306 10/10mg|P.O.
1604126|NCT02205606|Drug|HCP1306 20/10mg|P.O.
1604127|NCT02205593|Behavioral|Control|Regular follow-up and treatment WITHOUT behavioural intervention
1604128|NCT02205580|Drug|continuous intravenous sufentanil 0.02μg•kg－1•h－1 infusion|
1604129|NCT02205580|Drug|continuous intravenous sufentanil 0.03μg•kg－1•h－1 infusion|
1604130|NCT02205580|Drug|continuous intravenous sufentanil 0.04μg•kg－1•h－1 infusion|
1604131|NCT02205567|Dietary Supplement|Bergamot-derived product|Group 1: 500mg/day Group 2: 1000mg/day
1604132|NCT02205554|Drug|Omnitram|Nine 20 mg doses administered every 6 hours
1604133|NCT02205554|Drug|Tramadol|Nine 50 mg doses administered every 6 hours.
1604134|NCT02205554|Drug|Placebo|Nine doses administered every 6 hours.
2009737|NCT03182244|Drug|MEC (Mitoxantrone, Etoposide, Cytarabine)|intravenous
2009738|NCT03182244|Drug|FLAG (Granulocyte colony-stimulating factor (G-CSF), Fludarabine, Cytarabine)|intravenous
1604137|NCT02205528|Drug|Liraglutide|Liraglutide will be self-administered daily via SC injection according to manufacturer specifications.
1604138|NCT02205528|Drug|Metformin|Metformin hydrochloride immediate- or extended-release oral tablets will be supplied by the participant or investigational site as standard-of-care treatment beginning at least 8 weeks prior to randomization and throughout the 12-week treatment period. Metformin will also be continued during the 4-week follow-up. Dose selection will be based upon manufacturer specifications.
1604139|NCT02205528|Drug|Placebo|Matching placebo to NNC0090-2746 will be self-administered daily via SC injection.
1604140|NCT02205528|Drug|NNC0090-2746|NNC0090-2746 solution will be self-administered in daily doses of 1.8 mg via SC injection.
1604141|NCT02205515|Drug|Everolimus|Everolimus is a novel derivative of rapamycin.
1604142|NCT02205502|Drug|Lidocaine|Normal saline will be injected subcutaneously as a placebo for lidocaine in study group of children.
1604143|NCT02205502|Drug|Normal saline|
1604144|NCT02205489|Drug|Alemtuzumab GZ402673|Pharmaceutical form:concentration for solution Route of administration: intravenous infusion
1604145|NCT02205489|Drug|cetirizine|Pharmaceutical form:tablet Route of administration: oral
1604146|NCT02205489|Drug|ranitidine|Pharmaceutical form:tablet Route of administration: oral
1604147|NCT02205489|Drug|methylprednisolone|Pharmaceutical form:tablet Route of administration: oral
1604148|NCT02205489|Drug|methylprednisolone|Pharmaceutical form:solution Route of administration: intravenous
1604149|NCT02205489|Drug|aciclovir|Pharmaceutical form:tablet Route of administration: oral
1604150|NCT02205489|Drug|esomeprazole|Pharmaceutical form:tablet Route of administration: oral
1604151|NCT02205489|Drug|ibuprofen|Pharmaceutical form:tablet Route of administration: oral
1604152|NCT02205489|Drug|paracetamol|Pharmaceutical form:tablet Route of administration: oral
1604153|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 4 administration of PF-06473871.
1604154|NCT02205476|Drug|PF-06473871|Subjects who previously were randomized in B5301001 study will go under a second revision surgery followed by 3 administration of PF-06473871.
1604155|NCT02205463|Drug|KD019|
1604156|NCT02205450|Drug|Recombinant Somatropin|
1604157|NCT02205411|Device|HeartAssist 5® VAD System|The HeartAssist 5® VAD System is a small, implantable pump that is designed to increase blood flow for patients who have heart failure. The device is intended to support patients in the hospital or at home.
1604158|NCT02205411|Device|Control VAD|The HeartMate II® VAD or HVAD®
1604159|NCT02205398|Drug|INC280|
1604160|NCT02205398|Drug|cetuximab|
1604161|NCT02205385|Procedure|Targeted Muscle Reinnervation|
1604162|NCT02205385|Procedure|Traction Neurectomy|
1604163|NCT02205372|Drug|MT-3995|
1604164|NCT02205372|Drug|Placebo|
1604212|NCT02205047|Drug|Trastuzumab|
2009739|NCT03182686|Biological|Ampion|Ampion (<5 kilodalton (kDa) ultrafiltrate of 5% HSA)
2009740|NCT03182686|Other|Saline|0.9% sodium chloride
1604168|NCT02205333|Biological|MEDI6469 Plus Tremelimumab|MEDI6469 in combination with Tremelimumab
1604169|NCT02205333|Biological|MEDI6469 Plus Durvalumab|MEDI6469 in combination with Durvalumab
1604170|NCT02205333|Biological|MEDI6469 plus Rituximab|MEDI6469 in combination with Rituximab
1604171|NCT02205320|Biological|DRL_PG|
1604172|NCT02205320|Biological|Pegfilgrastim Form A|
1604173|NCT02205320|Biological|Pegfilgrastim Form B|
1604174|NCT02205307|Device|PINPOINT|
1604175|NCT02205307|Device|SPY Elite|
1604176|NCT02205294|Other|Osteopathic Treatment|The osteopathic treatment will be a gentle hands treatment using myofascial release techniques.
1604177|NCT02205281|Behavioral|Lifestyle Intervention|The intervention is a multi-component program designed to prevent excessive gestational weight gain in overweight and obese women and to promote weight loss in their non-pregnant overweight and obese partners through modifications of diet, exercise, and behavioral strategies during pregnancy.
1604178|NCT02205268|Procedure|Near infrared spectroscopy neurofeedback training|
1604179|NCT02205255|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
1604180|NCT02205255|Drug|Placebo|
1604181|NCT02205242|Drug|Azithromycin|From day 1 up to and including day 3: 500 mg azithromycin or placebo PO once a day From day 4 up to and including day 90: 250 mg azithromycin or placebo PO once every 2 days
1604182|NCT02205242|Device|Dynaport®|Registering physical activity during 7 days post discharge from hospital (0 months), 3 months and 9 months
1604183|NCT02205242|Drug|Placebo|
1604184|NCT02205229|Drug|Multi-ingredient, topical compounded medications|
1604185|NCT02205216|Device|Active tDCS|anode over the motor and premotor cortex with cathodes placed over both mastoids. TDCS will be applied for 20 minutes at 2 mA.
1604186|NCT02205216|Device|Sham tDCS|"anode and cathode placed 1 cm apart over the forehead and DC (1mA) applied for 1-2 min, short-circuited through the skin creating the same temporary tingling sensation without effects on the brain."
1604187|NCT02205216|Behavioral|Rehabilitation Therapy|"All patients will undergo a rehabilitation therapy intervention (2x a week for 4 weeks = 8 intervention sessions) with simultaneous sham or active tDCS. The trained physiotherapist will follow a standardized program with checklist. Each of the 8 training session will last approximately 45min. The rehabilitative interventions include:
cognitive training: attentional strategies (mental counting, mental obstacle)
transfer training: everyday activities
motor training (walking) with sensory cueing (visual, acoustic, cane, ball) The rehabilitation therapy is divided into two sessions both including a 5 minutes warm-up and the learning of cueing and movement strategies based on different modalities (cognitive, visual, tactile and auditory)."
2009741|NCT03182166|Drug|Golimumab (Optimization)|"Increase dose of golimumab.
For patients treated at 50 mg will be performed, dose will be intensified at 100 mg every four weeks.
For patients treated at 100 mg will be performed, dose will be intensified at 100 mg every two weeks while four weeks."
2009742|NCT03182166|Diagnostic Test|Rectosigmoidoscopy|Rectosigmoidoscopy will be realized for calculated Mayo score
1604190|NCT02205190|Drug|Fimasartan|
1604191|NCT02205190|Drug|Rosuvastatin|
1604192|NCT02205190|Drug|Fimasartan/Rosuvastatin combination|
1604193|NCT02205177|Device|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
1604194|NCT02205164|Drug|Palonosetron + Aprepitant|Aloxi 0.25mg Emend 125/80/80 mg
1604195|NCT02205164|Drug|Palonosetron|Aloxi 0.25mg
1604196|NCT02205151|Drug|Fimasartan|
1604197|NCT02205151|Drug|Amlodipine|
1604198|NCT02205151|Drug|Fimasartan/Amlodipine combination|
1604199|NCT02205138|Drug|ALLOB® cells with ceramic scaffold|Each patient will undergo a single administration of ALLOB®/ceramic scaffold mix into the lumbar interbody fusion site under anaesthesia
2009743|NCT03182166|Biological|Blood samples|Blood samples will be collected for analysis the concentration of golimumab and antibodies to golimumab (ADAb) in the blood
2009744|NCT03181776|Other|left lateral tilting in 15 degrees|The mother will be placed in left lateral tilted position (15 degrees) using a standard wedge
1604202|NCT02205099|Drug|SKL15508|
1604203|NCT02205099|Drug|Placebo|
1604204|NCT02205086|Other|Diagnosis|"Unaided: The testers will record a differential diagnosis consisting of a list of diseases and their ranking and a prioritized list of test orders, as well as the most appropriate referral for further evaluation and treatment of the patient.
Aided: Then testers will enter the case into diagnostic decision support software and after getting advice from the software, the testers will record the same information as in Unaided, but allowing for the possibility that responses could differ as a result of using the software."
1604205|NCT02205073|Drug|Placebo RD + AVP SD|Placebo (matching to study drug) repeat doses + intranasal AVP single dose
1604206|NCT02205073|Drug|Placebo RD + Placebo SD|Placebo (matching to study drug) repeat doses + intranasal Placebo (matching to intranasal AVP) single dose
1604207|NCT02205073|Drug|RG7314 RD + AVP SD|RG7314 repeat doses + intranasal AVP single dose
1604208|NCT02205060|Other|virtual reality exposure treatment|
1604209|NCT02205060|Other|cognitive and behavioral approaches therapy|
1604210|NCT02205047|Drug|Cisplatin|
2009745|NCT03181776|Other|left lateral tilting in 30 degrees|The mother will be placed in left lateral tilted position (30 degrees) using a standard wedge
2009746|NCT03181776|Other|supine position|The mother will be placed in standard supine position
2009747|NCT03181763|Drug|Placebo|Placebo given day after startle assessment
2009748|NCT03181763|Drug|MDMA|Participant will receive 100 mg MDMA one day after startle assessment
2009749|NCT03181763|Behavioral|Acoustic startle|Startle assessment
1604215|NCT02205034|Drug|oxytocin|Intranasal administration
1604216|NCT02205021|Other|No intervention|
1604217|NCT02205008|Procedure|surgery|Total or subtotal gastrectomy with D2
1604218|NCT02205008|Drug|adjuvant systemic chemotherapy|adjuvant systemic chemotherapy with S-1 (<1.25m2:40mg, 1.25-1.5m2:50mg, >1.5m2:60mg, bid)
1604219|NCT02205008|Drug|Early postoperative intraperitoneal chemothgerapy|"operation day: 0.9％ saline solution 1L plus mitomycin C 10 mg/m2
1 - 4 postoprative day: 0.9％ saline solution 1L plus 5-FU 700 mg/m2 plus sodium bicarbonate 50 mEq"
1604220|NCT02204995|Procedure|Trapeziectomy with LRTI|Trapeziectomy with Ligament Reconstruction and Tendon Interposition
1604221|NCT02204995|Procedure|Trapeziectomy|Trapeziectomy
1604222|NCT02204982|Drug|IPI-145 (duvelisib)|IPI-145 (25 mg BID) administered orally in 28-day continuous treatment cycles
1604223|NCT02204982|Drug|Placebo|Matching Placebo (25 mg BID) administered orally in 28-day continuous treatment cycles.
1604224|NCT02204982|Drug|Rituximab|IV infusion of rituximab (375 mg/m2) once weekly for 4 weeks during Cycle 1, then once on Day 1 of Cycles 4, 6, 8, and 10.
1604225|NCT02204969|Dietary Supplement|Lithia water|"Experimental: Lithia spring water Lithia water (active) for 4 weeks then placebo water for 4 weeks Intervention: Dietary Supplement: Lithia water
Placebo Comparator: Natural spring water Placebo water for 4 weeks then lithia water (active) for 4 weeks Intervention: Dietary Supplement: Natural spring water with negligible lithium levels"
1604226|NCT02204969|Device|Transcranial Magnetic stimulation|All participants will receive standard medical therapy for AD. In addition, patients recruited for the study will receive 16 sessions of TMS with the H2 coil over 8 weeks. The first group will receive excitatory stimulation of 10 Hz over the prefrontal and parietal cortex, the second group will receive inhibitory stimulation of 1 Hz over similar brain areas and control patients will receive the same amount of Sham sessions. Patient will receive 3 treatments per week in the first 3 weeks and then 1 treatment per week for additional 4 weeks.
1604227|NCT02204956|Behavioral|Extended Care|
1604228|NCT02204956|Behavioral|Brief Education|
1604229|NCT02204943|Other|Biomarker analysis|Pharmacodynamic study of Radium-223 in bone biopsy and circulating tumor cell samples
1604230|NCT02204943|Drug|Administration of radium-223|Subjects will receive radium-223 treatment for their disease as standard of care in this protocol. They will be receiving this treatment regardless of their participation in this protocol.
1604231|NCT02204930|Drug|PeproStat|A solution of PeproStat containing up to 9.25mg protein soaked immediately prior to use onto a Gelita-Spon® gelatin sponge.
2009750|NCT03182504|Drug|nacubactam|Participants will receive a single 2000 milligram (mg) intravenous (IV) infusion of nacubactam over 1.5 hours.
1604233|NCT02204904|Genetic|Allo-HSCT|Allogeneic Hematopoietic Stem Cell Transplantation
1604234|NCT02204891|Dietary Supplement|Probiotics in SIBO|Mixture of the four probiotics in one capsule. One capsule twice daily for 30 days
1604235|NCT02204891|Dietary Supplement|Probiotics|One capsule twice daily for 30 days
1604236|NCT02204878|Drug|Parecoxib Sodium|Dynastat 40mg was given before anesthesia. PCA will be attached right before closing abdomen. Concentration of sufentanil is 1ug/ml. PCA settings: 1) no background infusion; 2) bolus 2ml sufentanil each; 3) with the lockout time 5 min, 1 hour limit: 10ml. Dynastat 40mg Q12h will be given within 72 hours after surgery
1604237|NCT02204865|Device|Pacemaker/ICD|Implantation of an ICD or CRT device with ApneaScan function
1604238|NCT02204852|Drug|Iloprost+eptifibatide|
1604239|NCT02204852|Drug|Placebo|
1604240|NCT02204839|Drug|Basal insulin dose|
1604241|NCT02204826|Drug|Korean Red Ginseng (KRG)|"The KRG capsules were provided by Korean Ginseng Corporation (Daejeon, Korea). KRG powder was manufactured from roots of a 6-year-old red ginseng, Panax ginseng Meyer, harvested in Republic of Korea. KRG was made by steaming fresh ginseng at 90-100 ◦C for 3 h and then drying at 50-80 ◦C.
KRG powder prepared from grinded red ginseng (KRG capsule : 500mg/capsule). KRG was analyzed by high-performance liquid chromatography. KRG extract contained major ginsenoside-Rb1: 4.26mg/g, -Rb2: 1.62mg/g, -Rc: 1.80mg/g, -Rd: 0.29mg/g, -Re: 1.71mg/g, -Rf: 0.67mg/g, -Rg1: 2.61mg/g, -Rg2: 0.20mg/g, -Rg3: 0.13mg/g, and other minor ginsenosides. During the study period, three capsules were taken daily for 12 weeks."
1604242|NCT02204826|Procedure|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
1604243|NCT02204813|Drug|Placebo|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.
Starting at minus 15 minutes, an intravenous infusion of albumin alone (placebo) will be administered for 5.25 hours."
1604244|NCT02204813|Drug|Lo-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.
Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 4 pmoles/kg/min will be administered for 5.25 hours."
1604245|NCT02204813|Drug|Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.
Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 12 pmoles/kg/min will be administered for 5.25 hours."
1604246|NCT02204813|Drug|Extra Hi-Xenin|"A liquid mixed meal containing 1.5 grams of acetaminophen will be ingested in 7 equal portions from 0-30 minutes.
Starting at minus 15 minutes, an intravenous infusion of xenin-25 at a dose of 24 pmoles/kg/min will be administered for 5.25 hours."
1604247|NCT02204787|Device|transcranial direct current stimulation|
1604248|NCT02204761|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
1604249|NCT02204748|Device|DePuy Attune posterior stabilizing fixed bearing knee system|
1604250|NCT02204735|Behavioral|Eat majority of calories in the morning|
1604251|NCT02204735|Behavioral|Eat the majority of calories in the evening|
1604252|NCT02204722|Drug|600mg/day of Imatinib|
1604253|NCT02204722|Drug|400mg/day of Imatinib|
1604254|NCT02204709|Other|2N Trout|Diploid/2N trout source
1604255|NCT02204709|Other|3N Trout|Triploid/3N trout source
1604256|NCT02204709|Other|Tilapia|Tilapia/control fish source
1604257|NCT02204696|Procedure|Tonsillectomy|Study participants will be scheduled for tonsillectomy based on clinical indications, with the need for surgery determined prior to study enrollment and not based on study enrollment.
2009751|NCT03182504|Drug|meropenem|Participants will receive a single 2000 mg IV infusion of meropenem over 1.5 hours.
1604258|NCT02204683|Drug|Aflibercept|Intravitreal aflibercept
1604259|NCT02204670|Other|Acute release of irisin after a single exercise session.|We will determine the amount of Irisin secreted after a single bout of resistance exercise. Participants will be stratified into 3 groups based on the degree of Irisin release during this acute bout of resistance exercise. The metabolic adaptations to the 4 weeks of resistance training will be compared between youth stratified according to the amount of Irisin released during the acute bout of resistance exercise.
1604260|NCT02204657|Device|Continuous Glucose Monitoring System|Patients in the intervention group will receive Continuous Glucose Monitoring(CGMS) at weeks 28, 32 and 36 and have the CGMS reviewed at weeks 29, 33 and 37 and management adjusted based on the CGMS readings
1604261|NCT02204644|Drug|Flumatinib 600mg qd|
1604262|NCT02204644|Drug|Imatinib 400mg qd|
1604263|NCT02204631|Other|Head and Neck Educational Handbook|
1604266|NCT02204605|Behavioral|Video-based Consensus Opinion|
1604267|NCT02204579|Drug|NPSP795|
1604268|NCT02204566|Device|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
1604269|NCT02204553|Drug|Panobinostat|Treating patients with relapsed and/or refractory Multiple Myeloma
1604270|NCT02204540|Behavioral|Mock study intervention|Participants will swallow a pill and consume food in a mock research study, while their performance of the task is being monitored.
1604271|NCT02204527|Dietary Supplement|supplementation of 100.000 IU of vitamin D3|supplementation of vitamin D ( with 2 pills of Addera D3 (50.000IU each pill))
1604272|NCT02204527|Dietary Supplement|placebo pill|Placebo
1604273|NCT02204514|Procedure|Surgery for external snapping hip|
1604274|NCT02204501|Drug|Midazolam 5mg Syrup|"All twenty four subjects will receive 5 mg midazolam syrup at four different time points during the study for a total of four non-subsequent dosing days.
On Study Days 0 and 12, subjects will receive only 5 mg midazolam syrup dosed in the morning.
On Study Days 6 and 9, subjects will have 5 mg midazolam syrup co-administered with their assigned dose of vapendavir in the morning. Co-administration of midazolam will not occur at the time of the evening dose for Group B."
1604275|NCT02204501|Drug|Vapendavir 264 mg BID|Twelve subjects (6 male and 6 female) will receive 264 mg vapendavir (achieved with two 132 mg vapendavir capsules) BID daily as divided dose given in the morning and evening 12 hours apart for seven days.
1604276|NCT02204501|Drug|Vapendavir 528 mg QD|Twelve subjects (6 male and 6 female) will receive 528 mg vapendavir (achieved with four 132 mg vapendavir capsules) QD in the morning for seven days
1604277|NCT02204488|Procedure|Total Joint Arthroplasty|Total Joint Arthroplasty with device: Maïa® trapezio-metacarpal joint prosthesis, Groupe Lépine, Genay, France
1604278|NCT02204488|Procedure|Trapeziectomy|Trapeziectomy
1604279|NCT02204475|Drug|Grazoprevir/Elbasvir|Participants take a fixed-dose combination of grazoprevir 100 mg and elbasvir 50 mg once daily (QD) by mouth (PO).
1604280|NCT02204475|Drug|Boceprevir|Participants take Boceprevir (BOC) 800 mg three times daily (TID) PO.
1604281|NCT02204475|Drug|PegIntron|Participants take 1.5 mcg/kg PegIntron (P) once weekly (QW) via subcutaneous injection.
1604282|NCT02204475|Drug|Ribavarin|Participants take Ribavarin (R) 800-1400 mg (depending on body weight) twice daily (BID) PO.
1604283|NCT02204462|Drug|FBnTP|A PET imaging radiotracer
1604284|NCT02204449|Behavioral|Cardiac Rehabilitation Peer Mentorship|
1604285|NCT02204436|Other|Emulsion and gel|A fixed similar quantity of both emulsion and gel were applied consequentially on the hand twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage, until complete absorption, for 8 weeks.
1604286|NCT02204423|Procedure|Trans-Radial Percutaneous Coronary Intervention (TR-PCI)|
1604287|NCT02204410|Dietary Supplement|Omega-3 Fatty Acid|
1604288|NCT02204410|Drug|ADHD Medication|
1604289|NCT02204397|Drug|INGAP Peptide, Ustekinumab|
1604290|NCT02204384|Other|HFD Meal: High fiber from food|High amount of fiber from diet food sources (HFD; total fiber 9.7g; soluble fiber 5.4g)
1604291|NCT02204384|Dietary Supplement|HFS Meal: High fiber from supplement|High amount of soluble fiber from guar gum supplement (HFS; total fiber 9.1g; soluble fiber 5.4g) - sachet 5 g Fiber Mais, Nestlé Brasil, São Paulo, BR
1604292|NCT02204384|Other|UF Meal: usual amount of fiber|Usual amount of fiber (UF; total fiber 2.4g; soluble fiber 0.8g)
1604293|NCT02204371|Drug|Pazopanib|Pazopanib is available as 50 mg and 200 mg tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
1604294|NCT02204371|Drug|Placebo|Pazopanib matching placebo is available as tablets to be administered orally once daily in the morning at least one hour before or two hours after a meal for 12 weeks
1604295|NCT02204358|Procedure|autologous bone marrow stem cells|"Before considering whether patients meet the inclusion criteria, they are diagnosed with severe intrauterine adhesions uterus, endometrial dysplasia. And after that there will be history taking, physical examination, chromosome examination, B-ultrasound examination, hysteroscopy examination and so on.
If patients agree to participate, they will receive a bone marrow stem cells collection and separation of adhesions by hysteroscopy surgery. Postoperative observation period is about three months, including B-ultrasound examination once a month and hysteroscopy after 3 months. According to the endometrial conditions, the doctor will select an appropriate time for pregnancy and follow-up. The doctor may also require patients to do some unscheduled visits."
1604296|NCT02204345|Drug|Carboplatin|Carboplatin by intravenous infusion q3w for 4-6 cycles and thereafter as per investigator's discretion.
1604297|NCT02204345|Drug|Paclitaxel|Paclitaxel by intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
1604298|NCT02204345|Drug|RO5479599|RO5479599 will be administered as an intravenous infusion q3w until disease progression, death, unacceptable toxicity or withdrawal of consent.
1604299|NCT02204332|Drug|Cabazitaxel|
1604300|NCT02204332|Other|Best Supportive Care|
1604301|NCT02204319|Device|Cold laser|Erchonia Corporation variable frequency pulsed wave low level laser device employing three independent 7 milliWatt, 635 nanometer red light diodes mounted in a hand-held device and is a variable frequency pulsed wave device.
1604302|NCT02204306|Genetic|TSER|TS gene will be genotyped for each patients prior to chemotherapy. Patients will be assigned to different arms according to specific TSER genotype.
1604303|NCT02204293|Drug|Canakinumab|Canakinumab will be injected subcutaneously in a dose of 4mg/kg body weight up to a maximum of 300 mg every 4 weeks.
1604304|NCT02204293|Drug|Placebo|
1604307|NCT02204254|Device|Radiofrequence|Associated to arm radiofrequence
1604308|NCT02204254|Drug|Doxycycline|doxycycline 100 mg / day for 3 months with clinical evaluation, photos, and confocal SSSB V1 and V4 (M6). Tour V2 M1 for clinical evaluation of safety review, collection of adverse events and issuing end of treatment. Visit V3 M3 on adverse effects.
1604309|NCT02204241|Drug|Carfilzomib|
1604310|NCT02204241|Drug|Cyclophosphamide|
1604311|NCT02204241|Drug|Dexamethasone|
1604312|NCT02204228|Device|TITAN™ Reverse Shoulder System (TRS)|All patients will be operated on with the TITAN™ Reverse Shoulder System (TRS).
1604313|NCT02204215|Device|electric acupuncture|Electric acupuncture therapy was made on LI4, LI11, ST36, and ST41 on four limbs for each patient, 30 min for each time, twice per day. Starting from the beginning of mechanical ventilation, to the weaning of the mechanical ventilation.
1604314|NCT02204215|Other|conservative|General treatment, without electric acupuncture, include passive range-of-motion exercise，q2H turning，minimizing the use of sedation, etc.
1604315|NCT02204202|Drug|[18F]FDG|10 millicuries (mCi) of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
1604316|NCT02204202|Drug|[18F]ISO-1|8 mCi of [18F]ISO-1 will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
1604317|NCT02204189|Drug|TongFuSan|TongFuSan 1g
1604318|NCT02204176|Other|Exercise info|"Discussion:
benefits of exercise
types of exercise
exercise guidelines
components of an exercise session
how to reduce risk of injuries"
1604319|NCT02204176|Other|Implementation intentions|"Discussion of:
barriers to exercise and how to address/overcome barriers
how to create detailed exercise plans"
1604320|NCT02204176|Other|Industriousness|"Discussion of:
realistic monitoring of efforts related to exercise
reaching and pushing past thresholds for sustained effort for exercise"
1604321|NCT02204176|Device|pedometer|
1604322|NCT02204163|Drug|Eutropin|
1604323|NCT02204163|Drug|Genotropin|
1604324|NCT02204150|Device|OFDI Capsule|Imaging of the esophagus using the OFDI Capsule and system
1604325|NCT02204137|Other|Falls Risk Questionnaire|
1604326|NCT02204137|Other|Cancer and Aging Research Group Geriatric Assessment|
1604327|NCT02204137|Other|Falls Efficacy Scale-International (FES-1)|
1604328|NCT02204137|Other|Health Related Quality of Life using the Functional Assessment of Cancer Therapy - Gynecologic Oncology Group Neurotoxicity Scale (FACT GOG/NTX)|
1604329|NCT02204124|Device|Thunderbeat|Thunderbeat uses ultrasonic and high frequency bipolar energy simultaneously to seal and cut tissue compared to placebo comparator.
1604330|NCT02204124|Device|Standard of care scissors, ligatures, clips, and sutures|
1604331|NCT02204111|Other|Intervention|Individualized treatment proposals (e.g. pain therapy, physiotherapy, psychological contact) from expert consensus, based on Patient Reported Outcomes
1604332|NCT02204098|Biological|Mammaglobin-A DNA Vaccine|
1604333|NCT02204098|Drug|Anastrozole|"Anastrozole is in a class of drugs called nonsteroidal aromatase inhibitors and is considered endocrine therapy.
The treating physician will decide what type and dose of endocrine therapy the participant will receive."
1604334|NCT02204098|Drug|Letrozole|"Letrozole is in a class of drugs called nonsteroidal aromatase inhibitors and is considered endocrine therapy.
The treating physician will decide what type and dose of endocrine therapy the participant will receive."
1604335|NCT02204098|Drug|Tamoxifen|"Tamoxifen is in a class of drugs called selective estrogen receptor modulators and is considered endocrine therapy.
The treating physician will decide what type and dose of endocrine therapy the participant will receive."
1604336|NCT02204098|Drug|Exemestane|"Exemestane is in a class of drugs called aromatase inhibitors and is considered endocrine therapy.
The treating physician will decide what type and dose of endocrine therapy the participant will receive."
1604337|NCT02204098|Drug|Goserelin|"Letrozole is in a class of drugs called gonadotropin-releasing hormone (GnRH) agonists and is considered endocrine therapy. This drug is given to women who are pre-menopausal.
The treating physician will decide what type and dose of endocrine therapy the participant will receive."
1604338|NCT02204085|Drug|GO-203-2c|
1604339|NCT02204085|Drug|GO-203-2c + Decitabine|
1604343|NCT02204059|Drug|hMAb BIWA 4|
1604344|NCT02204046|Drug|BIWA 4|
1604345|NCT02204033|Drug|99mTc - labelled hMAb BIWA 4|
1604346|NCT02204033|Drug|186 Re - labelled hMAb BIWA 4|
1604347|NCT02204033|Drug|unlabelled hMAb BIWA 4 - low dose|
1604348|NCT02204033|Drug|unlabelled hMAb BIWA 4 - medium dose|
1604349|NCT02204033|Drug|unlabelled hMAb BIWA 4 - high dose|
1604350|NCT02204020|Drug|5-azacytidine (5-aza) maintenance therapy after transplant|The planned initial dose of 5-aza is 32mg/m2 (Level 0) administered either subcutaneously or intravenously for days 1 through 5 of a 28-day cycle, which will be initiated between day+30 and day+100 after HCT. Patients who tolerate this dose based on hematologic parameters and with no SAEs for two consecutive cycles will be eligible for a dose escalation to 50mg/m2 (Level +1). Patients who tolerate this dose based on the same criteria as above for two consecutive cycles will be eligible for a dose escalation to 75mg/m² (Level +2). Patients will continue at dose Level +2 for the remainder of the study provided there are no toxicities that require dose reduction. Patients requiring a dose reduction are not eligible for re-escalation.
1604351|NCT02204007|Device|3D imaging & surrogate bone model|3D imaging & surrogate bone model to assist with acetabular shell placement. Different that standard of care preoperative imaging
1604352|NCT02203994|Device|"Duolith® SD 1 T-Top (Storz Medical AG, Switzerland)"|2000 pulses per muscle, energy level: 0.030 mJ/mm2, frequency: 4 Hz
1604353|NCT02203968|Drug|Fibrinogen concentrate|Six grams of fibrinogen concentrate (RiaSTAP™) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
1604354|NCT02203968|Drug|Placebo Comparator|Placebo Comparator: Normal saline Placebo (normal saline) will be administered intravenously as a single 300ml rapid infusion (less than 3min) via level I automated pressure pump within one hour of hospital admission.
1604355|NCT02203955|Drug|Short-Chain Fructooligosaccharide|4 chews (8.0 g scFOS) orally for 12 months
1604356|NCT02203955|Drug|Maltodextrin|4 chews (maltodextrin) daily for 12 months
1604357|NCT02203942|Other|NAAT testing|comparison of NAAT testing for BV, VVC and trich to Amsel criteria, Nugent score, yeast culture and TV culture.
1604358|NCT02203916|Drug|Azilsartan medoxomil|Azilsartan medoxomil tablets
1604359|NCT02203916|Drug|Azilsartan medoxomil placebo|Azilsartan medoxomil placebo-matching tablets
1604361|NCT02203877|Dietary Supplement|Lactobacillus fermentum CECT5716|Intervention with a probiotic strain in form of a daily capsule containing 3x109cfu/capsule.
1604362|NCT02203877|Dietary Supplement|Maltodextrin|Intervention with a daily capsule containing maltodextrin as placebo
1604363|NCT02203864|Biological|BIBW2 component A|BIBW2 without IL-2 secreting cell line
1604364|NCT02203864|Biological|BIBW2 component B|BIBW2 with IL-2 secreting cell line
1604365|NCT02203851|Drug|ABBV-066|ABBV-066 administered by subcutaneous injection
1604366|NCT02203838|Drug|RBP-7000 - 120-mg dose|120-mg of RBP-7000 dose Patients subject to a one-time down-titration to 90-mg RBP-7000 for tolerability, at the investigator's discretion
1604367|NCT02203825|Biological|CM-CS1 T-cell infusion|Each patient will receive a single dose of CM-CS1 T-cells by intravenous infusion.
1604368|NCT02203812|Drug|Probiotic Arm|Each Inersan lozenge contains at least 1 billion colony forming unit of Lactobacillus brevis CD2
1604369|NCT02203812|Drug|Placebo Arm|Placebo lozenges contain all ingredients except the active constituent (probiotic, Lactobacillus brevis CD2)
1604370|NCT02203799|Biological|Peanut Oral Immunotherapy (POIT)|The peanut protein is ingested in the form of peanut flour. Peanut flour will be given in small pre-measured soufflé cups containing the amount of peanut flour that needs to be eaten for one dose. One dose will be taken per day. Dosage of the peanut flour will begin with 1.8 mg of peanut protein during the initial visit or the lowest tolerated dose on initial challenge and increased every 2 during the build-up phase until the maintenance dose of peanut protein (3900 mg) is reached.
1604371|NCT02203786|Drug|Haloperidol|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the haloperidol antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).
Dose 1: 3 visually identical capsules, each containing 1 mg haloperidol."
1604372|NCT02203786|Drug|Fluphenazine|"Dose/maximum dose = 3-mg; route = oral. Participants assigned to the fluphenazine antagonist group will receive 2 doses (@ 3 mg) on alternate sessions (with minimum of 2 weeks between individual doses).
Dose 1: 3 visually identical capsules, each containing 1 mg fluphenazine."
1604373|NCT02203786|Drug|Dexedrine|"Dose/maximum dose = 20-mg; route = oral. All participants will receive 2 doses (@ 20 mg) during Phase II - sessions 3, 4, with minimum 1 week between individual doses.
Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 3 and 4 (Phase II), the dose will consist of 2 visually identical capsules each containing 10 mg D-amphetamine."
1604374|NCT02203786|Drug|Placebo|"Dose 1: On alternate sessions (1 and 3 or 2 and 4, depending on counterbalancing) participants will receive 3 visually identical placebo (lactose) capsules.
Dose 2: when participants reach expected peak blood levels for dose 1, they will receive their second dose. On sessions 1 and 2 (Phase I), this will consist of 2 dummy capsules, visually identical to those administered for dose 1."
1604375|NCT02203786|Behavioral|Slot Machine|15 minute play of a commercial slot machine game in bar-simulated laboratory setting.
2009752|NCT03180034|Biological|Cervarix|Vaccine indicated in females 9 through 25 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer. In Costa Rica, in patients 9-15 years old, this vaccine is approved for two doses (0.5-mL each) intramuscular injection at 0, 6 months (second dose between 5 and 13 months after first dose). In patients 16 years old and older, it is approved for use in females 9 through 25 years of age. Approved for three doses (0.5-mL each) by intramuscular injection at 0, 1, and 6 months. Intervention will be one dose at 0 months or two doses at 0 and 6 months. One-dose intervention will be in 5000 girls ages 12-16 years, and two-dose intervention will be in 5000 girls ages 12-16 years.
1604380|NCT02203760|Drug|Pazopanib plus Gemcitabine|Pazopanib 800 mg orally once daily plus Gemcitabine 1000 mg/m2 i.v. over 30 min d 1 and d 8 q3w or
1604381|NCT02203760|Drug|Pazopanib|Pazopanib 800 mg orally once daily
1604382|NCT02203747|Other|Administration of patient self-assessment|
1604383|NCT02203734|Procedure|Moderate Pressure Massage|The massage therapy will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs. The effective moderate pressure (measured by a pressure meter) is 8 db or a slight indentation in the skin.
1604440|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine + Lopinavir/ritonavir|Truvada®/ Kaletra® 200/50 mg QD, d1-14
1604441|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine + ritonavir-boosted darunavir|Truvada®/Prezista® 800 mg/Norvir®100 mg Medication, QD, d1-14
1604442|NCT02203448|Device|Facet Wedge spinal system|
1604384|NCT02203734|Procedure|Light Pressure Massage|The light pressure massage group will receive light pressure massage in contrast to the treatment group who will receive moderate pressure massage. As with moderate pressure massage, each session will begin with the mother in a side-lying position, with pillows positioned behind her back and between her legs for support. The massage is given in the following sequence and repeated twice (10 minutes on each side for 20 minutes total) on the following areas: 1) Head and neck: 2) Back: 3) Arms: and 4) Legs.
1604385|NCT02203721|Device|TECNIS Symfony Extended Range of Vision IOL, Model ZXR00|
1604386|NCT02203721|Device|TECNIS Monofocal IOL, Model ZCB00|
1604387|NCT02203708|Other|Supportive Program for Mother with BPD (SuPMother-B).|"The development of the program is based on several principles: group process, groupware, mentalization, parental values, behavioral strategies and information on the child's needs, knowledge of the BPD and the strategies of get better. The program will last 10 sessions of group of about 2h.
Minimal intervention. All study participants receive an individual interview about 45 minutes with a psychiatrist for three objectives: information on the diagnosis of BPD, information on resources for health care and educational aids."
1604388|NCT02203695|Drug|Enzalutamide|Enzalutamide (MDV3100) 160 mg PO once daily for 6 months (2 months prior to SRT, 2 months during SRT and 2 months following SRT)
1604389|NCT02203695|Radiation|SRT|Salvage radiation therapy (3D-CRT (Three dimensional conformal radiation therapy)/IMRT) 66.6-70.2 Gy given 1.8 Gy M-F for 37 -39 fx
1604390|NCT02203682|Drug|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
1604391|NCT02203682|Drug|placebo|Tablet placebo for 12 weeks
1604392|NCT02203669|Other|Home therapy|Study subjects complete home therapy independently for four (4) weeks based on handouts of exercises adapted for post-operative breast reconstruction patients along with an instructional handout for stretching complied by a certified occupational therapist.
1604393|NCT02203669|Other|Structured In-Office Therapy|Study subjects will participate in Structured In-Office Therapy twice a week for four (4) weeks. Each visit will last approximately sixty (60) minutes. Subjects will receive therapy instruction by a certified occupational therapist on upper extremity stretching, relaxation, cardio rehabilitation, and strength training. These subjects will also receive exercise and stretching handouts to use at home between therapy visits.
1604394|NCT02203656|Drug|Placebo|placebo supplement
1604395|NCT02203656|Dietary Supplement|Nutritional Supplement|protein supplement
1604396|NCT02203656|Behavioral|In-home exercise|In-home exercise program
1604397|NCT02203656|Drug|Testosterone|Testosterone injection
1604398|NCT02203643|Drug|Carfilzomib|
1604399|NCT02203643|Drug|Cyclophosphamide|
1604400|NCT02203643|Drug|Lenalidomide|
1604401|NCT02203643|Drug|Dexamethasone|
1604402|NCT02203630|Drug|Phenylephrine|Phenylephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
1604403|NCT02203630|Drug|Norepinephrine|Norepinephrine, in intravenous formulation, will be administered as the primary vasopressor for the treatment of septic shock
1604404|NCT02203617|Behavioral|Educational Content/Pediatric Anticipatory Guidance|educational information from Bright Futures Guidelines for Health Supervision for birth to 18 months
1604405|NCT02203617|Behavioral|Book provision|Given free books prenatally and at 2, 4, 6, 9, 12, and 18 months postpartum
1604406|NCT02203604|Biological|aldesleukin|Given IV
1604407|NCT02203604|Biological|ipilimumab|Given IV
1604408|NCT02203604|Other|laboratory biomarker analysis|Correlative studies
1604409|NCT02203591|Drug|3M CHG/IPA Prep C|Apply topically.
1604410|NCT02203591|Drug|3M CHG/IPA Prep CH|Apply topically.
1604411|NCT02203591|Drug|ChloraPrep Clear|Apply topically.
1604412|NCT02203591|Drug|Normal Saline|Apply topically.
1604413|NCT02203578|Drug|romidepsin|Given IV
1604414|NCT02203578|Other|laboratory biomarker analysis|Correlative studies
1604415|NCT02203565|Drug|Dakin's solution|Applied topically
1604416|NCT02203565|Radiation|radiation therapy|Undergo radiation therapy
1604417|NCT02203565|Other|questionnaire administration|Ancillary studies
1604418|NCT02203565|Other|laboratory biomarker analysis|Optional correlative studies
1604419|NCT02203552|Drug|minocycline hydrochloride|100 mg bid given by mouth for 9 weeks
1604420|NCT02203552|Other|placebo|Placebo given by mouth for 9 weeks
1604421|NCT02203552|Other|laboratory biomarker analysis|Correlative blood levels for cortisol, high sensitivity c-reactive protein (hs-CRP) and inflammatory factors including but not limited to IL-6, TNF-α, IL-1β, and MCP-1 will also be obtained weekly on protocol.
1604422|NCT02203552|Other|Questionnaire administration|The CES-D and STAI will be administrated weekly.
1604423|NCT02203539|Other|exposure to normal light|exposure for 60 minutes in duration
1604424|NCT02203539|Other|exposure to bright light|exposure to bright light for 60 minutes of duration
1604425|NCT02203539|Other|exposure to blue-enriched light|exposure to blue-enriched light for 60 minutes of duration
2009753|NCT03180034|Biological|Gardasil 9|Vaccine indicated in females 9 through 26 years of age for the prevention of the following diseases: Cervical, vulvar, vaginal, and anal cancer caused by Human Papillomavirus (HPV) types 16, 18, 31, 33, 45, 52, and 58; and Genital warts (condyloma acuminata) caused by HPV types 6 and 11. In Costa Rica, in patients 9-15 years old, this vaccine is approved for two doses (0.5-mL each) intramuscular injection at 0, 6 months (second dose between 5 and 13 months after first dose). In patients 16 years old and older, it is approved for three doses (0.5- mL each) intramuscular injection at 0, 2 months, and 6 months. Intervention will be one dose at 0 months or two doses at 0 and 6 months. One-dose intervention will be in 5000 girls ages 12-16 years, and two-dose intervention will be in 5000 girls ages 12-16 years.
1604432|NCT02203500|Drug|Lacidipine|
1604433|NCT02203500|Drug|Telmisartan|
1604434|NCT02203487|Drug|BIIF 1149 BS - single rising dose|
1604435|NCT02203487|Drug|Placebo|
1604436|NCT02203474|Drug|Tiotropium HFA BAI 5 mcg|
1604437|NCT02203474|Drug|Tiotropium 18 mcg Capsule|
1604438|NCT02203474|Drug|Placebo|Placebo
1604439|NCT02203461|Drug|Tenofovir disaproxil fumarate/emtricitabine/elvitegravir/cobicistat|STRIBILD® QD, d1-14
1604612|NCT02202213|Drug|Lu AF11167|
1604443|NCT02203422|Drug|Cyclosporin A|given orally at a dose of 1.5-2.0mg/kg twice daily for 3 consecutive months, adjusted to maintain serum levels between 200-400 ng/ml and tapered by 50 mg/d per week if patients achieved a complete response.
1604444|NCT02203422|Drug|rhTPO|given subcutaneously at a dose of 300 Units/kg for 14 consecutive days, following with a flexible dosage depending on platelet count until the 29th day
1604445|NCT02203409|Procedure|Laparoscopic ALPPS|Laparoscopic Associating Liver Partition and Portal Vein Ligation for Two-stage Hepatectomy
1604446|NCT02203396|Drug|rabbit ATG, Cyclosporine, Levamisole|rATG is administered at a dose of 1.97 mg/kg/day for 9 days CSA is administered orally at a dose of 3 mg/kg qod Levamisole is administered orally at a dose of 2.5 mg/kg qod. The CSA and LMS is designed to alternately every other day.
1604447|NCT02203383|Device|CRT Implantation|Implantation of a biventricular pacemaker or defibrillator.
1604448|NCT02203370|Device|NIRS - Near-infrared spectroscopy|
1604449|NCT02203357|Biological|Hepatitis B vaccine|Hepatitis B vaccine, 60 μg/1ml recombinant hepatitis B vaccine,20 μg/1ml recombinant hepatitis B vaccine, Shenzhen Kangtai Biological Products Co, LTD.
2009754|NCT03180931|Device|Bioresorbable vascular scaffold|"No study specific procedures will be applied. Optical coherence tomography recordings at the time of very late scaffold thrombosis were obtained during clinical routine with one of the commercially available and approved optical coherence tomography consoles and catheters. The analysis will be conducted at the Core laboratory at Bern University Hospital, Bern, Switzerland using a systematic and validated approach.
Every participant will be coded by getting a number (pseudonym) in the local institutes. In the Core Laboratory, data will be further coded to ensure anonymity of the participants."
2009755|NCT03180177|Procedure|Hyperthermic Intraperitoneal Chemotherapy|HIPEC is performed as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer. The first HIPEC is conducted within 24h after laparoscopic exploration or Interval debulking surgery: Paclitaxel 175 mg/m^2, 43°C, 90min. The second HIPEC is performed after 48 hours of the first HIPEC. The third HIPEC regimens are cisplatin 75 mg/m^2, 43°C, 90min.
2009756|NCT03180177|Procedure|Interval debulking surgery|Cytoreductive surgery (CRS) is performed after neoadjuvant chemotherapy.
1604456|NCT02203305|Device|Cochlear Implant|cochlear implantation used a treatment for single-sided deafness and/or asymmetric hearing loss
1604457|NCT02203305|Other|Control Group|Subjects in the control group will have had listening experience with a bone-conduction device, which is an approved treatment for SSD.
1604458|NCT02203292|Behavioral|Liberal transfusion strategy|Patients will have red blood cells transfused only if Hb < 9.0 g/dL
1604459|NCT02203292|Behavioral|Restrictive transfusion strategy|Patients will have red blood cells transfused only if Hb < 7.0 g/dL
1604460|NCT02203279|Other|Rebase II Fast|It is going to be used a direct relining material
1604461|NCT02203279|Other|Flexacryl|This is going to be used as a second direct relining material
1604462|NCT02203279|Other|Vertex|This is going to be used as an indirect relining material
1604463|NCT02203266|Device|Feedback|Feedback on the patient's own inhaler use, with personalized information on the patients technique and timing of use of the diskus inhaler as recorded on the INCA device will be provided to patients in the feedback group after 1,2 and 6 months.
1604464|NCT02203266|Behavioral|Education|Feedback on the patient's own inhaler technique as observed by pharmacist and education to support best use will be provided to patients in the demonstration group after 1,2 and 6 months.
1604465|NCT02203253|Drug|Thalidomide|100 mg by mouth twice a day on days 1-5 after chemotherapy, cycle 1
1604466|NCT02203253|Drug|Placebo for thalidomide|Placebo tablet manufactured to mimic Thalidomide 25 mg tablet 100 mg by mouth twice a day on days 1-5 after chemotherapy , cycle 1
1604467|NCT02203253|Drug|Palonosetron and Dexamethasone|Palonosetron 0.25 mg intravenously on day 1; Dexamethasone 12 mg by mouth or intravenously before chemotherapy on day 1 and 8 mg on days 2-4; cycle 1.
1604468|NCT02203240|Other|Cocoa|
1604469|NCT02203227|Dietary Supplement|Placebo|
1604470|NCT02203227|Dietary Supplement|BioTurmin (Curcuma longa rhizomes extract)|
1604471|NCT02203227|Dietary Supplement|BioTurmin-WD (Water dispersible curcuminoids)|
1604472|NCT02203227|Dietary Supplement|MaQxan|
1604473|NCT02203214|Device|Ligamys|All patients are treated with Ligamys within 21 days after injury. The Ligamys implant has to be used in accordance with the instructions for use.
1604474|NCT02203188|Procedure|Lid debridgement scaling|
1604475|NCT02203175|Drug|saline|Before the anesthesia induction, 5 ml isotonic saline
1604476|NCT02203175|Drug|fentanyl|before the anesthesia induction 50 mcgr fentanyl
1604477|NCT02203175|Drug|propofol|during anesthesia 50 mg proposal with 50 mcgr fentanyl
1604478|NCT02203162|Device|electronic cigarette exposure|30 puffs of a disposable electronic cigarette, 30 seconds apart.
1604479|NCT02203149|Drug|Grazoprevir|One or two 50 mg tablets (depending on randomization) taken orally once daily for 12 weeks.
1604480|NCT02203149|Drug|Elbasvir|One 50 mg tablet taken orally once daily for 12 weeks.
1604481|NCT02203149|Drug|Placebo to Grazoprevir|One tablet of placebo matched to grazoprevir, taken orally once daily for 12 weeks.
1604482|NCT02203149|Drug|Placebo to Elbasvir|One tablet of placebo matched to elbasvir, taken orally once daily for 12 weeks.
1604483|NCT02203136|Procedure|Tissue Biopsy|During bladder cancer surgery, tissue specimen taken for molecular profiling.
1604484|NCT02203136|Procedure|Magnetic Resonance Imaging (MRI)|3 Tesla pelvic magnetic resonance imaging (MRI) performed four weeks after bladder cancer surgery.
1604485|NCT02203123|Device|Ultrasound|
1604486|NCT02203123|Drug|normal saline|
1604487|NCT02203097|Procedure|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
1604488|NCT02203097|Drug|Propofol|Propofol is administered to all patients via target-controlled infusion (TCI) to reach 4 mcg/ml constant plasma concentration according to the Schneider model during the course of the narcosis.
1604778|NCT02200991|Drug|LIXISENATIDE AVE0010|Pharmaceutical form:solution Route of administration: subcutaneous
1604784|NCT02200978|Drug|mitoxantrone|Given IV
1604489|NCT02203084|Other|Social Determinants Questionnaire|The questionnaire contains a general background information section common to all medical conditions. It then contains separate sections with medical condition specific questions.
1604490|NCT02203058|Other|Pursed-lips breathing|Expiration with pursed-lips during functional capacity tests.
1604491|NCT02203058|Other|No pursed-lips breathing|To avoid pursed-lips breathing, subjects use a a mouthpiece (2cm diameter X 2cm length) such as the one used in pulmonary functional tests.
1604492|NCT02203045|Other|Total Knee Arthroplasty|
1604493|NCT02203032|Drug|Ustekinumab|45 mg or 90 mg given by subcutaneous injection at Weeks 0 and 4 for all participants. Participants with an IGA score of 0 or 1 at Week 16 will also receive ustekinumab every 12 weeks (q12w) from Week 16 to Week 40.
1604494|NCT02203032|Drug|Guselkumab|100 mg given by subcutaneous injection at Weeks 16 and 20 and every 8 weeks (q8w) thereafter through Week 44.
1604495|NCT02203032|Drug|Placebo for ustekinumab|Subcutaneous injection at Weeks 16, 28, and 40 to maintain the blind for participants randomized to treatment with guselkumab.
1604496|NCT02203032|Drug|Placebo for guselkumab|Subcutaneous injection at Weeks 16 and 20 and q8w thereafter through Week 44 to maintain the blind for participants randomized to treatment with ustekinumab.
2009757|NCT03180177|Drug|neoadjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.
Systemic chemotherapy regimens after laparoscopic exploration are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group."
2009758|NCT03180177|Drug|adjuvant chemotherapy|"Systemic chemotherapy regimens after HIPEC treatment are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 2 cycles in experimental group.
Systemic chemotherapy regimens after IDS are paclitaxel 175 mg/m^2 IV>3 hour+ carboplatin AUC = 5-6 IV>1 hour, every 3 weeks for 3 cycles in control group."
2009759|NCT03181451|Drug|Ferric Maltol|To assess the pharmacokinetics and iron uptake of Ferric Maltol through measurement of serum iron, transferrin saturation (TSAT) and plasma concentrations of maltol and maltol glucuronide.
1604500|NCT02203006|Biological|OVIHD|7 ml of blood will be taken during a follow-up consultation and kept in a biological collection. Clinical data will be collected in a database.
1604501|NCT02202993|Drug|Mibefradil with Radiation|"Patients will receive mibefradil dihydrochloride, which will be dose escalated from 150mg/day until the maximum tolerated dose (MTD) is determined, or until a dose of 350 mg/day is reached using a standard 3 + 3 design. Mibefradil dihydrochloride will be dosed orally in 4 divided doses per day for 17 consecutive days to the MTD.
This will be given concurrently with hypofractionated radiation therapy."
2009760|NCT03181126|Drug|Venetoclax|tablet
2009761|NCT03181126|Drug|Navitoclax|tablet
1604506|NCT02202967|Drug|Misoprostol|Misoprostol oral tablets/ capsules contain 200 mcg of Misoprostol, a synthetic prostaglandin E1 analog
1604507|NCT02202967|Drug|Placebo|Placebo contains lactose granules
1604508|NCT02202954|Other|Guided Self-rehabilitation Contract|"In Guided Self-rehabilitation Contracts, the therapist acts as a coach, in the sports' sense, providing double guidance: technical, selecting and teaching the required exercises to the patient using infrequent thorough visits, for example every month; Psychological, binding with the patient on the contract.
The patient agrees to perform the prescribed daily stretch postures and rapid alternating movements over the long term and to document this work in a written diary."
1604509|NCT02202941|Other|Procalcitonin guided treatment|Patients who will be randomized to arm will receive antibiotics therapy based on procalcitonin measurement on day 1, 3, 5, 7, 9, 11 and 13.
1604510|NCT02202941|Other|Conventional treatment|Patients who will be randomized to this arm will receive antibiotic therapy based on conventional practice.
1604511|NCT02202928|Biological|DC-CIK|8×10^9 autologous tumor lysate pulsed DC-CIK cells for each infusion, IV (in the vein) for four cycles, each cycle received four infusions with a 1 day interval.
1604512|NCT02202928|Radiation|Radiotherapy|45~50 Gy in 25-28 fractions.
1604513|NCT02202928|Drug|Chemotherapy|Oxaliplatin 85mg/m2 IV over 2 hours, day 1; Leucovorin 400mg/m2 IV over 2 hours, day 1; 5-FU 400mg/m2 IV bolus on day 1, then 1200mg/m2/day for 2 days IV continuous infusion; Repeat every 2 weeks.
1604514|NCT02202915|Behavioral|Behavioral Checklist|
1604515|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before and 6 month after treatment
1604516|NCT02202902|Other|1H magnetic resonance spectroscopy and CMRI|Metabolic status of the patients evaluated by an OGTT (measuring plasma glucose, insulin and plasma nonesterified fatty acids concentrations) and myocardial Imaging and spectroscopy will be performed before treatment
1604517|NCT02202889|Behavioral|Adequate Calcium Today|A school-randomized behavioral intervention study called the Adequate Calcium Today (ACT) project was conducted in sixth grade classrooms located in six states (Arizona, California, Hawaii, Indiana, Nevada, and Ohio).
1604518|NCT02202876|Drug|Oral Glucose Tolerance Test|1.75 gm/kg to a maximum of 75 gm of an oral glucose solution
1604519|NCT02202876|Other|High Glycemic Index Meal|"isocaloric breakfasts - set the high glycemic index to 80
The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
1604520|NCT02202876|Other|Low Glycemic Index Meal|"isocaloric breakfasts - set the low glycemic index to 30
The nutrient composition of each meal will be 10 kcal per kg, 50% kcal from carbohydrates, 20% kcal from protein, and 30% kcal from fat"
1604521|NCT02202863|Dietary Supplement|Red wine grape pomace flour (WGPF)|Pomace, a byproduct from wine production, was obtained from red wine grapes, Cabernet Sauvignon, vintage 2011, Maipo Valley, Chile, after alcoholic fermentation. The wine grape pomace was dried and grounded to obtain the flour. Intervention group ate 20 g per day of this flour, which contained 10 g of dietary fiber and an antioxidant capacity of 7,258 ORAC units.
1604522|NCT02202850|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
1604523|NCT02202850|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
1604524|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
1604525|NCT02202837|Drug|etanercept|etanercept 1 x 50 mg/week or 2 x 25mg/week
1604779|NCT02200991|Drug|Sitagliptin|Pharmaceutical form:tablet Route of administration: oral
1604526|NCT02202824|Other|Survey questionnaire|Each of the scale versions elicits personal attitudes toward intimate partner violence and perceived norms about intimate partner violence, in a different fashion
1604527|NCT02202811|Behavioral|Forced Desynchrony|all sleep opportunities and other activities will be scheduled by the experimenter so that by the end of the study these activities are spread evenly across all phases of the internal body clock.
1604528|NCT02202798|Device|Syringe device|
1604529|NCT02202785|Drug|MLN0264|MLN0264 IV infusion
1604530|NCT02202772|Drug|Cabazitaxel|Intravesical instillation of the Cabazitaxel for 2 hours
1604531|NCT02202772|Drug|Gemcitabine|Intravesical instillation of Gemcitabine for 2 hours
1604532|NCT02202772|Drug|Cisplatin|Intravesical installation of Cisplatin for 2hours
1604533|NCT02202759|Drug|MLN0264|MLN0264 IV infusion
1604534|NCT02202746|Drug|Lucitanib|Lucitanib is a potent, orally available selective inhibitor of the tyrosine kinase activity of fibroblast growth factor receptors (FGFR1-3), vascular endothelial growth factor receptors (VEGFR1-3), and platelet-derived growth factor receptors alpha and beta (PDGFR alpha and beta)
1604535|NCT02202733|Other|Cooking|The aim is to test the feasibility of a skill-based cooking intervention to reduce the consumption of foods prepared away from home for the evening meal (e.g., pre-prepared frozen foods, restaurant foods, fast food, take-out), energy intake from evening meals, and parent/child weight status.
1604536|NCT02202720|Drug|Sevoflurane|Short term sedation with sevoflurane in ICU
1604537|NCT02202707|Drug|Gabapentin|Study medication, gabapentin, will be distributed to all study participants and participants will be instructed as to how to take and titrate the medication dose. Participants will take gabapentin daily for up to six weeks.
1604538|NCT02202694|Behavioral|Culturally Adapted Cognitive behavior therapy|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
1604539|NCT02202681|Device|OFDI Capsule|Imaging of the duodenum with the OFDI capsule and system
1604540|NCT02202668|Device|TRS|"TRS measurements of subcutaneous deep wound soft tissue and underlying bone will be collected at the same standard locations that are used to measure wound dimensions. The probe will never be in contact with the wound, but we will sterilize the probe head in advance in order to ease potential concerns regarding equipment sterility. A single point TRS measurement can be obtained in less than 60 seconds. At a minimum we will collect measurements at the geometric center of the wound as well as at the 6 and 12 and 3 and 9 ulcer coordinates. These coordinates are commonly used to estimate ulcer dimensions. It is anticipated that the PhAT probe will be used with a beam diameter of 7.5 mm. It is possible that the incident laser beam diameter will need to be adjusted (7.5 mm to 6.0 mm) to accommodate smaller wounds. If incident laser beam diameter adjustment is necessary we will also adjust the laser intensity to maintain the maximum permissible exposure of 0.3 W/cm2 per ANSI guidelines."
1604541|NCT02202642|Procedure|collagenase|Cultured limbal stem cells transplantation
1604542|NCT02202629|Other|Beverage containing plant based extracts|Intervention involves single exposure, oral consumption of test article following baseline measurements
1604543|NCT02202616|Drug|Glycopyrronium /Indacaterol maleate|Glycopyrronium 50mcg/Indacaterol maleate 110mcg once daily by a breezhaler device
1604544|NCT02202603|Drug|Teriparatide|single oral tablet
1604545|NCT02202603|Drug|Teriparatide|subcutaneous standard injection
1604546|NCT02202603|Drug|placebo|Oral placebo
1604547|NCT02202590|Device|SECM Capsule|Imaging of the esophagus using the SECM capsule and system
1604548|NCT02202577|Drug|Chlorhexidine - Isopropyl alcohol|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
1604549|NCT02202577|Drug|Povidone-Iodine Scrub and Paint|Applied to skin pre-operatively for surgical site anti-sepsis; regulated as a drug by FDA
1604550|NCT02202564|Procedure|LT|Orthotopic LT
1604551|NCT02202564|Drug|ADV-TK|
1604552|NCT02202564|Drug|ganciclovir|
2009762|NCT03181126|Drug|Chemotherapy|peg-asparaginase (intravenous) + vincristine (intravenous) + dexamethasone (oral)
1604554|NCT02202538|Device|Indego|Indego
1604555|NCT02202525|Drug|Micardis®|
1604556|NCT02202525|Drug|Other hypertensives|
1604557|NCT02202512|Drug|Placebo|tablets
1604558|NCT02202512|Drug|Cimetidine|
1604559|NCT02202512|Drug|Placebo|tablets
1604560|NCT02202512|Drug|Placebo|tablets
1604561|NCT02202512|Drug|BI 1060469 high dose|tablets
1604562|NCT02202512|Drug|BI 1060469 low dose|tablets
1604563|NCT02202512|Drug|Naproxen|
1604564|NCT02202512|Drug|BI 1021958|tablets
2009763|NCT03179085|Behavioral|Home-Based Kidney Care|All subjects randomized to the HBKC arm will be visited by a community health representative in their home at least every two weeks for the duration of the 12 month intervention. Each visit will last 30 minutes to one hour and cover materials like, (1) Kidney 101, (2) weight management, (3) exercise, (4) healthy eating, (5) medication management, (6) coping with stress, (7) risk factor management (i.e.- blood pressure, hyperlipidemia), (8) alcohol and substance abuse, (9) smoking cessation, and related health concerns.
2009764|NCT03178123|Biological|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
2009765|NCT03178123|Biological|high-dose recombinant interferon a-2B|15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 15*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks.
1604568|NCT02202486|Other|Brain MRI|Brain MRI with gadolinium contrast
1604569|NCT02202473|Drug|Lamivudine|
1604570|NCT02202473|Drug|Lamivudine+Oxymatrine Capsules|
1604571|NCT02202447|Drug|EC1169|"PART A: EC1169 - Dose dependent on cohort, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.
PART B: EC1169 cohort 1 - taxane naive - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule.
PART B: EC1169 cohort 2 - taxane exposed - Recommended Phase 2 dose, IV (in the vein) on days 1 and 8 of each 21 day cycle for the QW schedule."
2009766|NCT03178071|Drug|Lorlatinib (PF-06463922)|oral tablets, administered daily, continuously
1604572|NCT02202447|Other|EC0652|PART A AND B: EC0652 is in development as a radioimaging agent for PSMA-expressing tumors. All patients receive a baseline 99mTc-EC0652 SPECT/CT scan for PSMA expression prior to Cycle 1 Day 1.
2009767|NCT03177603|Drug|GSK2586881|GSK2586881 is a clear colorless liquid for IV infusion over 3- 5 minutes and will be administered a maximum dose of 1.2 mg/kg.
2009768|NCT03177460|Drug|Daratumumab|16 mg/kg given by vein 1 time each week for 4 weeks before prostatectomy.
2009769|NCT03177460|Procedure|Prostatectomy|Radical prostatectomy dissection performed on or after Week 6.
2009770|NCT03176784|Drug|Varenicline|0.5mg and 1.0 mg pills used. See arms for specific durations.
2009771|NCT03176784|Drug|Nicotine patch|14 mg and 7 mg nicotine patches used. See arms for specific durations.
2009772|NCT03176784|Other|Placebo Patch|Placebo patches matched in appearance to the Active 14 mg and 7 mg nicotine patches used in the Nicotine patch intervention. See arms for specific durations.
1604579|NCT02202395|Drug|LTS 0.25mg|use LTS 0.25mg/d
1604580|NCT02202395|Drug|LTS 0.5mg|use LTS 0.5mg/d
1604581|NCT02202395|Drug|LTS 1.0mg|use LTS 1.0mg/d
1604582|NCT02202395|Drug|Placebo|use placebo once daily
1604583|NCT02202382|Drug|Korean Red Ginseng, Varicocelectomy|
1604584|NCT02202382|Drug|Placebo|Placebo were provided by Korean Ginseng Corporation (Daejeon, Korea). The placebo capsules were identical in shape, color, and taste.
1604585|NCT02202382|Procedure|Varicocelectomy|Surgical microscope-assisted varicocelectomy using the subinguinal approach was conducted by a single surgeon.
1604586|NCT02202369|Other|Multimodal Analgesia Treatment|Subjects are given medications preop (Pregabalin, Oxycodone, Acetaminophen, Transdermal Scopolamine, Cyclobenzaprine), intraop (Propofol induction, Sevoflorane maintenance, Dexamethasone, Fentanyl, Ketamine, Marcaine, Zofran) and postop(Acetaminophen, Pregabalin, Tramadol, Cyclobenzaprine) that implement a multi-modal approach to managing pain.
1604587|NCT02202369|Other|Standard of Care Pain Management Protocol|Subjects will be treated with patient controlled (standard of care) narcotic analgesia for pain management. (Marcaine, Dexamethasone, Zofran, Morphine, Acetaminophen, Cyclobenzaprine)
2009773|NCT03176784|Other|Placebo Pill|Placebo pills matched in appearance to the Active Varenicline pills in the Varenicline intervention. See arms for specific durations.
2009774|NCT03176511|Behavioral|A Matter of Balance plus Dual-Task Balance Challenge Group|Participants will receive the standard MOB classes, along with a 15-min DTBC each class, i.e., right and left foot ankle-reaching to three differently colored markers. Three colored dots are placed on the ground in an arc, using different colored stick-on dots. A chair can be placed in front of the color pattern, as needed for safety.
1604590|NCT02202343|Behavioral|school based health and nutrition education|
1604591|NCT02202330|Other|Video Arm|"5 minute videos, on various stroke related topics/ themes delivered in one session before discharge from the hospital (list topics on which videos have to made)
Discussion and questions and answers after viewing video to ensure that core message has been understood and there are no lacunae in understanding the message of video.
Phone card - a memory chip installed in the cell phones of intervention team that ensures that the videos can be replayed at home to refresh memory of some details that may not have been captured in the mandatory viewing sessions."
1604593|NCT02202304|Drug|Chlorhexidine/Thymol varnish|This will be applied on abutment teeth on partial denture wearers every 3 months during a period of 2 years.
1604594|NCT02202291|Genetic|Demonstration of genetic mutations causing Raynaud's phenomenon|"Such an approach allows to highlight chromosomal regions shared only by individuals within a family and thus highlight the genetic mutations causing the Raynaud phenomenon . The ultimate goal is to identify new pathways involved in vasospasm.
Patients with primary Raynaud phenomenon will be identified during a consultation of vascular medicine and internal medicine in one of the centers participating to the study. Those patients with a primary PR will be considered as Index cases.
The investigators will conduct genealogical trees of index cases to identify families, whose number of healthy individuals and those with relevant PR makes sense for a family genetic study, i.e. a genetically informative family."
1604595|NCT02202265|Dietary Supplement|Olive oil|30ml a day of olive oil
1604596|NCT02202265|Dietary Supplement|Nuts|30g a day of nuts
1604597|NCT02202265|Dietary Supplement|Control diet|Diet based on standard guidelines
1604598|NCT02202252|Procedure|Insertion of a single drain|A negative pressure drain will be inserted below the lower flap directing to the axilla.
1604599|NCT02202252|Procedure|Insertion of double drains|Two drains will be inserted into the axilla and below the lower flap in the double drains group.
1604600|NCT02202252|Procedure|Ultrasonography after removal of the drains|One day after removal of the drains seroma under the flaps and in the axilla will be examined by ultrasonography.
1604601|NCT02202239|Drug|midazolam|Before induction, midazolam 0.05mg/kg will be injected intravenously.
1604602|NCT02202239|Drug|Penehyclidine Hydrochloride Injection|Penehyclidine Hydrochloride 0.01mg/kg will be injected intravenously after midazolam is injected.
1604603|NCT02202239|Drug|Etomidate|Induction dose: 0.3 mg/kg. Maintenance dose: 10 μg•kg-1•min-1.
1604604|NCT02202239|Drug|Propofol|Induction dose: 2.0 mg/kg. Maintenance dose: 4 to 6 mg/kg/h.
1604605|NCT02202239|Drug|Fentanyl|During induction, after injection of etomidate, fentanyl 3 μg/kg will be given intravenously.
1604606|NCT02202239|Drug|Cisatracurium Besilate|"Cisatracurium Besilate 0.14 mg/kg will be used after fentanyl is injected for induction.
During maintenance, intermittent bolus of cisatracurium will be used for maintain muscle relaxation."
1604607|NCT02202239|Drug|Remifentanil|Remifentanil will be injected continuously during maintenance of anesthesia.
1604608|NCT02202239|Drug|Sevoflurane|Sevoflurane of 1% to 2% will be administered via inhalation to keep bispectral index（BIS) between 50 to 55.
1604609|NCT02202226|Drug|Lu AF35700|
1604610|NCT02202226|Drug|Placebo|
1604611|NCT02202213|Drug|Placebo|
2009775|NCT03176511|Behavioral|A Matter of Balance Group|Participants will receive the standard MOB class, taught by a certified MOB, using course materials developed by MaineHealth's Partnering for Healthy Aging (http://www.mainehealth.org/pfha).
2009776|NCT03175172|Biological|CRS-207|Intravenous infusion
1604613|NCT02202200|Drug|PD- 0332991|"PD-0332991 Inhibitor of cyclin-dependant kinase (CDK) 8 schedules will be evaluated PD-0332991 PO QD either at 25 mg, 50 mg, 75 mg, 100 mg, 125 mg, 150 mg, 175 mg and 200 mg
All patients will receive vemurafenib as background therapy ,bid at 720mg bid for the first group (during the first 2 cycle then 960 mg bid if good tolerance) and 960mg bid for all other patients"
1604614|NCT02202187|Drug|GSK2140944|Investigational Study Drug
1604615|NCT02202187|Other|Placebo|Placebo
1604616|NCT02202174|Device|Supraglottic Airway Device|
2009777|NCT03175172|Biological|Pembrolizumab|intravenous infusion
2009778|NCT03174925|Procedure|Shear Wave Elastography|Undergo elastography
2009779|NCT03175666|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
2009780|NCT03175666|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
1604621|NCT02202135|Drug|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
1604622|NCT02202135|Drug|Vancomycin|IV vancomycin 15mg/kg every 12 hours
1604623|NCT02202135|Drug|Aztreonam|IV aztreonam 1 g every 8 hours
1604624|NCT02202122|Other|OSA Scoring|Comparison of the preoperative OSA scoring (STOP-BANG, DES-OSA, P-SAP and OSA50) with the postoperative mortality at one month.
1604625|NCT02202109|Behavioral|CHW and Self-sampling for Cervical Cancer|Behavioral: CHW and Self-sampling for Cervical Cancer The intervention strategies will involve one home visit: 1) provide brief health education on cervical cancer screening, 2) provide and collect self-sampler test. We envision visits lasting no more than 60 minutes.
1604626|NCT02202109|Behavioral|Mailed Self Sampler|Mailed Self Sampler. Women randomized to this intervention arm will receive a self-sampling kit via mail. This kit will include: 1) the self-sampler; 2) the vial for collecting and storing the specimen; 3) a pre-addressed, stamped envelope for returning the vial; 4) a brief introductory letter/postcard which includes a picture of the CHE and the CHW and serves to re-orient the participant to the focus of the study; 5) instructional guide that visually depicts the steps for self-sampling;
1604627|NCT02202096|Other|Patient education: One-on-one visit|The navigator or surgeon will have a one-on-one visit with he patient to answer any questions.
1604628|NCT02202096|Other|Discharge planning: Assessment of barriers to discharge|Case management will be consulted on the day of surgery. The navigator will perform an assessment of barriers to discharge based on one-on-one interviews with the patient.
1604629|NCT02202096|Other|Medication reconciliation: Patient medication review|The navigator will review the patient's medications with him/her prior to discharge.
1604630|NCT02202096|Other|Appointment before discharge: Additional measure to ensure awareness of next clinic visit|Additional measures to ensure that patients are aware of the date, time, and place of their clinic visit(s) may include a phone calls or text messages to patients and their caregivers by the navigator, surgeon or clinic nurse.
1604631|NCT02202096|Other|Transition coach|The navigator will assist with coordination of care and tracking follow-up appointments and tests.
1604632|NCT02202096|Other|Patient-centered discharge instructions: Enhanced|Enhanced, language-specific, discharge instructions will be developed and provided to all patients verbally and in a written format designed for patients with limited literacy skills.
1604633|NCT02202096|Other|Provider continuity: Specific surgeons responsible for coordinating care with medical/radiation oncology|"Drs. Stefanos Millas (colorectal surgery) and Curtis Wray (surgical oncology) will be responsible for coordinating care with medical and radiation oncology as well as consulting when patients are readmitted to the hospital (if not admitted to the surgical service). Changes will be made to the clinic scheduling process for colorectal cancer surgery patients to minimize wait times, to allow them to be seen on a walk-in basis, and to prioritize visits for patients with urgent problems as identified by follow-up calls or inquiries to the Ask My Nurse hotline."
1604634|NCT02202096|Other|Timely follow-up: Barriers to clinic follow-up visits will be discussed|Patients will be queried about financial barriers to clinic follow-up such as lack of money for parking and/or lack of transportation; parking vouchers and taxi/bus vouchers may be provided.
1604635|NCT02202096|Other|Timely PCP communication|The operating surgeon will phone the PCP prior to and upon discharge to discuss concerns and follow-up care plans. Communication via the electronic medical record (EPIC) will also be sent. If the patient does not have a PCP, a referral will be made prior at the initial clinic visit and one provided.
1604636|NCT02202096|Other|Follow-up telephone call|Patients will be contacted by phone by the navigator or surgeon on post-discharge day 1 to identify and address any concerns. If there are concerns, calls may be made on subsequent post-operative days.
1604637|NCT02202096|Other|Patient hotline: 24 hour follow-up following call to Ask My Nurse number|Follow-up will occur within 24 hours of calling the Ask My Nurse number. Patients with emergent problems will be seen immediately by the surgical oncology team if available or the on call surgery team. Patients with non-urgent matters will be called by a member of the surgical oncology team. Arrangements will be made to see the patient in clinic or the ER within the next 8-16 hours depending upon severity and time of day.
1604638|NCT02202083|Other|Cook Balloon|"There are two groups. Acoording to the bishop score, one group uses the oxytocin , and the other uses the cook balloon.
This group is term gestaion,with bishop score less than 6."
1604639|NCT02202070|Drug|onabotulinumtoxinA|
1604640|NCT02202057|Other|Respiratory resistive load on inhalation|"The participant will be seated in a chair, and will be instructed to relax and breathe through a facemask. Five respiratory resistive loads (5-40 cmH2O resistive pressure) will be applied between 3-5 times during inhalation. Following each loaded breath, participants will rate the perceived difficulty of breathing in."
1604726|NCT02201381|Drug|Metabolic treatment|While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention
1604780|NCT02200991|Drug|Insulin glargine HOE901|Pharmaceutical form:solution Route of administration: subcutaneous
1604781|NCT02200978|Drug|ATO|Given IV
2009781|NCT03175666|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
2009782|NCT03175666|Drug|cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
2009783|NCT03175666|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
2009784|NCT03175666|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
1604641|NCT02202057|Other|Fluoroscopic swallowing evaluation|Participants with PD only will receive a swallowing evaluation as part of their routine clinical care. Generally, the standard clinical evaluation protocol consists of multiple swallows of thin liquid barium, pudding-thick barium, and a cracker or cookie coated with barium. Results are reviewed by the treatment speech-language pathologist, and for the purposes of this study, the researchers will review the most recently recorded swallow study and identify the worst observed penetration-aspiration (PA) score.
1604642|NCT02202044|Device|Intravesical BCG and EMDA/MMC|Patients are assigned one course of treatment per week for 6 weeks with sequential 'Intravesical instillation of sequential Bacillus Calmette-Guérin (BCG) and Electromotive Drug Administration /Mitomycin-C
1604643|NCT02202031|Behavioral|Paced Respiration|
1604644|NCT02202031|Behavioral|Music Therapy|
1604645|NCT02202018|Other|Active KT intervention|"Provider & patient-directed infographics educating patients about home dialysis will be displayed in prominent clinic wall space
Educational white board presentations promoting home dialysis
Each clinic will receive reports outlining their current use of home dialysis in incident ESRD patients compared with provincial & national averages
A Canadian version of the MATCH D tool will be provided to clinic staff, to help evaluate patient appropriateness for home dialysis.
Each clinic will receive an in-person visit from one of the study investigators/collaborators detailing the benefits of home dialysis, and the educational tools being offered to support care within their clinic."
1604646|NCT02202005|Drug|Nevirapine|Nevirapine 400mg PR tablet
1604647|NCT02202005|Drug|Viramune®|Viramune® 400 mg Retardtabletten
1604648|NCT02201992|Drug|Crizotinib|Given PO
1604649|NCT02201992|Other|Laboratory Biomarker Analysis|Correlative studies
1604650|NCT02201992|Other|Placebo|Given PO
1604651|NCT02201979|Procedure|Vertical breast lift with implants|
1604652|NCT02201953|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
1604653|NCT02201953|Drug|SOF|400 mg tablet administered orally once daily
1604654|NCT02201953|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1604655|NCT02201940|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
1604656|NCT02201940|Drug|Placebo|Tablet administered orally once daily
1604657|NCT02201927|Device|galvanic vestibular stimulation|
1604658|NCT02201914|Drug|Clomiphene citrate|patients receive clomiphene citrate 100 mg daily starting on day 2 for 5 days and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 5; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection
1604659|NCT02201914|Drug|Daily FSH and LH plus Cetrorelix|Women receive an initial daily dose of 450 IU recombinant FSH and 225 IU recombinant LH starting on day 3; Cetrorelix 0,25 mg was administered daily when one or more follicle reached 13-14 mm in diameter until the hCG injection.
1604660|NCT02201914|Drug|Triptorelin plus daily FSH anh LH|women receive short-acting Triptorelin 0,05 mg daily starting on day 1 until the hCG injection and 450 IU recombinant FSH and 225 IU recombinant LH daily starting on day 2.
1604661|NCT02201901|Drug|SOF/VEL|400/100 mg tablets administered orally once daily
1604662|NCT02201901|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1604663|NCT02201888|Behavioral|Computer-assisted cognitive training|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
1604664|NCT02201888|Other|Computerized active condition|Treatment lasted six months. The CRT and CC conditions consisted of biweekly sessions of 45 minutes. Patients in both conditions trained in groups of up to 8, supervised by a single person. The CRT and CC groups were scheduled at different times. The same personnel supervised both treatment conditions. All supervisors were trained by the coordinator of the study in the technical management of the two conditions.
1604665|NCT02201888|Other|Treatment as usual (TAU)|TAU: Patients in this condition participated in their (individually variable) daily rehabilitative activities. Patients allocated to the other two conditions also participated in these activities.
1604666|NCT02201849|Drug|Study Drug|
1604667|NCT02201849|Drug|Active Control|
1604668|NCT02201849|Drug|Placebo|
1604669|NCT02201836|Other|One time music therapy|
1604670|NCT02201836|Other|Group music therapy|
1604671|NCT02201823|Drug|ABTL0812|ABTL0812. Five cohorts and one extension phase.
1604672|NCT02201810|Behavioral|Rate reduction intervention|
1604673|NCT02201810|Behavioral|Recycling Group|
1604674|NCT02201810|Behavioral|Choice Group|
1604675|NCT02201810|Behavioral|Proactive QL|
1604676|NCT02201797|Other|DCE MRI|
1604677|NCT02201784|Drug|Levobupivacaine|Comparison of Equipotent doses
1604678|NCT02201784|Drug|Ropivacaine|Comparison of equipotent doses
1604679|NCT02201771|Drug|Aspirin|
1604680|NCT02201771|Drug|Ticagrelor|
1604681|NCT02201758|Dietary Supplement|Flaxseed lignan-enriched complex (FLC)|Subjects will undergo treatment with FLC for an 8-week period; participants will take 300 mg flaxseed lignan-enriched complex (FLC) taken orally twice daily
1604682|NCT02201758|Other|Placebo|Placebo will consist of unflavored whey protein (manufactured by Natural Factors®)
1604683|NCT02201732|Procedure|Hysteroscopy|Performed under general or local anesthesia, antibioprophylaxis in accordance to center practices may be administered. Cervical dilatation, will be made in order to introduce the hysteroscope. Operative hysteroscope used will include a handle. The distension of the uterine cavity will be performed with physiological saline or glycocoll, depending on the polarity of the high frequency generator necessary for resection system (monopolar or bipolar), with a pressure of maximum irrigation of 110 mm Hg.
1604727|NCT02201368|Drug|Triheptanoin (SpezialölÒ 107®)|"Randomization: Treatment with Triheptanoin for 6 months
Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months
Crossover: Treatment with MCT(Medium-Chain Triglycerides)for 6 months"
1604782|NCT02200978|Drug|RIF|Given orally
1604684|NCT02201732|Procedure|Curettage|Performed under general or local anesthesia, the used material may be rigid or flexible vacurette. In the same way, the prophylactic antibiotic, the diameter of the used vacurette, the importance of cervical dilation necessary and a possible peroperative ultrasound guidance will be left at the discretion of the operator and habits of the center. A check of the uterine vacuity by foam curette will be conducted at the end of curettage.
1604685|NCT02201706|Procedure|Multi-electrocoagulation retinectomy|"a modified surgery named multi-electrocoagulation retinectomy to re-attach the retina.
All the single surgical technique and devices involved in this modified surgery are used commonly in clinic.
Base on this, the investigator changes the traditional sequence of these single surgical techniques, and combine them into a new surgical process."
1604686|NCT02201693|Dietary Supplement|MODULEN IBD|2 week ON / 6 weeks OFF treatment every 8 weeks covering at least 100% of daily caloric requirement (approx. 2-2.5L/day).
1604687|NCT02201693|Dietary Supplement|MODULEN IBD|25% of daily caloric requirements, approx. 500mL/day
1604688|NCT02201667|Drug|Ticagrelor|180-mg loading dose followed by 90mg twice daily for 30 days
1604689|NCT02201667|Drug|clopidogrel|300-mg loading dose followed by 75mg once daily for 30 days.
1604690|NCT02201667|Drug|Aspirin|300mg loading dose aspirin and followed by 100mg once daily
1604691|NCT02201667|Procedure|PCI|PCI is performed according to indication for early PCI according to 2012 Chinese NSTE-ACS guideline recommendation
1604692|NCT02201654|Other|EBUS without stylet|the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
1604693|NCT02201641|Radiation|Cone Beam computed tomography (Morita Accuitomo)|CBCT scans are taken to assess the efficacy of this method in detecting the presence of early peri-radicular lesions.
1604694|NCT02201641|Radiation|Periapical radiographs|Periapical radiographs are taken as a control to detect the presence of early peri-radicular lesions.
1604695|NCT02201641|Device|calcium silicate cement (Biodentine™)|calcium silicate cement (Biodentine™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulps.
1604696|NCT02201641|Device|glass ionomer cement ( Fuji IX™)|glass ionomer cement ( Fuji IX™) used for indirect pulp capping of teeth with deep carious lesions and inflammed pulp.
1604697|NCT02201628|Device|Nasopharyngeal and oesophageal temperature probes|
1604698|NCT02201615|Other|Perineal massage in childbirth|
1604699|NCT02201602|Drug|Gliclazide|
1604700|NCT02201602|Drug|Glibenclamide|
1604701|NCT02201589|Device|Endovascular repair with Valiant PS-IDE Stent Graft|Endovascular stent graft repair of lesions in the ascending thoracic aorta using the Medtronic Valiant PS-IDE (Physician Sponsored-Investigational Device Exemption) Stent Graft System with the Captivia Delivery System
1604702|NCT02201576|Drug|Bortezomib|"Five plasma exchanges +0.1 g/kg of intravenous globulins at the end of each course
two cycles of bortezomib (1.3 mg/m2 IV at day-1, day-4, day-8, day-11) + oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11)
four courses of polyclonal intravenous globulins every three weeks (2g/kg, the first two courses are performed simultaneously with the two bortezomib cycles)"
1604703|NCT02201576|Drug|Plasma exchanges and intravenous immunoglobulins|"Five plasma exchanges +0.1 g/kg of intravenous globulins at the end of each course
four courses of polyclonal intravenous immunoglobulins every three weeks (2g/kg)
oral dexamethasone (20 mg po at day-1, day-4, day-8, day-11 of the two first intravenous immunoglobulins courses)"
1604704|NCT02201563|Drug|Minocycline|Oral minocycline (100mg twice a day) for 3 months
1604705|NCT02201537|Device|renal echography|"Renal biopsy will be performed at 3 and 12 months.
The functional imaging examinations will be held as follows:
Step 1: the conventional Doppler ultrasound Step 2: ultrasound elastography Step 3: CEUS"
1604706|NCT02201524|Drug|PF-04965842|Subjects will receive 200 mg PF 04965842 twice daily for 4 weeks
1604707|NCT02201524|Drug|PF-04965842|Subjects will receive 400 mg PF 04965842 daily for 4 weeks
1604708|NCT02201524|Drug|PF-04965842|Subjects will receive 200 mg PF 04965842 daily for 4 weeks
1604709|NCT02201524|Other|Placebo|Subjects will receive placebo for 4 weeks
1604710|NCT02201511|Drug|3 mg PF-06412562 MR tablets_Fasted|A single modified release tablet with 3 mg PF-06412562 administered after an overnight fast
1604711|NCT02201511|Drug|2 x 15 mg PF-06412562 MR tablets_Fasted|Two 15 mg PF-06412562 modified release tablets administered after an overnight fast
1604712|NCT02201511|Drug|2 x 15 mg PF-06412562 MR tablets_Fed|Two 15 mg PF-06412562 modified release tablets administered after a high fat breakfast
1604713|NCT02201511|Drug|10 mg PF-06412562 IR tablets|a single immediate release tablet of 10 mg PF-06412562 after an overnight fast
1604714|NCT02201498|Procedure|Pulpotomies with Formocresol/OZE and Biodentine|
1604715|NCT02201485|Device|Stent|
1604716|NCT02201485|Device|Balloon|
1604717|NCT02201472|Device|MRI with MRE|Magnetic Resonance Imaging with Magnetic Resonance Elastography using the GE MR Touch device
1604718|NCT02201459|Drug|Nilotinib (Tasigna ®), capsules of 150 mg|Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months
1604719|NCT02201459|Drug|Nilotinib (Tasigna ®) and Pegylated interferon alfa 2a (Pegasys®)|"Nilotinib 2 capsules of 150 mg orally twice daily at 12 hours difference, fasting (minimum 1 hour before or 2 hours after a meal) for at least 36 months and
Pegylated interferon alfa 2a subcutaneously once a week (auto-injection syringes of 135 and 90 micrograms) at 30 micrograms/week the first month alone (= priming procedure), then at 30 micrograms/2weeks the first month of combination to nilotinib and then at 45 micrograms/week thereafter until month 24 after nilotinib initiation."
1604720|NCT02201420|Drug|Tc 99m tilmanocept|
1604721|NCT02201407|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a treatment according to standard of care, current summary of product characteristics and in line with the local labeling.
2009785|NCT03175666|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
2009786|NCT03175666|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
2009787|NCT03175666|Drug|Lovaza|omega-3-acid ethyl esters)
2009788|NCT03175666|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
1604728|NCT02201368|Dietary Supplement|MCT (Medium-Chain Triglycerides)|"Randomization: Treatment with MCT(Medium-Chain Triglycerides)for 6 months
Washout Period: Treatment with MCT(Medium-Chain Triglycerides)for 2 months
Crossover: Treatment with Triheptanoin for 6 months"
1604729|NCT02201355|Radiation|Intensity Modulated Radiotherapy|Patients treated five fractions per week with radiotherapy dose per fraction and cisplatin dose increased according to the treatment table
1604730|NCT02201342|Drug|Udenafil|Drug
2009789|NCT03175666|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
2009790|NCT03175666|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-CEA (carcinoembryonic antigen)
1604733|NCT02201316|Drug|Reference mosapride citrate (GASMOTIN)|Reference mosapride citrate (GASMOTIN) 5mg will be supplied as caplet shaped tablet embossed with P218 and film-coated; administer orally with approximately 240 mL of water.
1604734|NCT02201316|Drug|GR107719B (Formulation 1)|GR107719B (Formulation 1) 5 mg will be supplied as L-HPC disintegrant caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
1604735|NCT02201316|Drug|GR107719B (Formulation 2)|GR107719B (Formulation 2) 5 mg will be supplied as caplet shaped tablet, embossed and film-coated; administer orally with approximately 240 mL of water.
1604736|NCT02201303|Drug|Danirixin|Powdered form for in-vitro administration to blood sample
1604737|NCT02201303|Other|CXCL1|Escalating concentrations of CXCL1 will be added to whole blood in vitro. A CXCL1/CD11b upregulation concentration response curve will determine the concentration to be used in Part 2.
1604738|NCT02201290|Drug|Eltrombopag Tablets|Eltrombopag tablets will be white, round film coated tablets containing eltrombopag olamine equivalent to 12.5 mg, 25 mg, 50 mg and 75 mg of eltrombopag. The 12.5 mg tablet will be smaller than the 25 mg, 50 mg and 75 mg tablets. Subjects will receive maximum dose of 75 mg once daily (QD).
1604739|NCT02201290|Drug|Eltrombopag PfOS|Eltrombopag PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain eltrombopag olamine equivalent to 20 mg of eltrombopag per gram of powder. Subjects will receive maximum dose of 75 mg once daily (QD)
1604740|NCT02201277|Device|Option IVC Filter|Option brand IVC Filter will be placed in patients randomized to Option Arm.
1604741|NCT02201277|Device|Denali IVC Filter|Denali brand IVC Filter will be placed in patients randomized to Denali Arm.
1604742|NCT02201251|Drug|Topiramate|Topiramate weight based dosing for participants 2 to < 10 years of age not to exceed 350 mg/day, as tolerated; 400 mg/day in participants 10-15 years of age. brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm.
1604743|NCT02201251|Drug|Levetiracetam|Levetiracetam weight based dosing for all participants 2-15 years of age, not to exceed 60 mg/kg/day, as tolerated. The maximum recommended daily dosage is 3,000 mg.
1604744|NCT02201238|Drug|Diclofenac sodium|Diclofenac sodium
1604745|NCT02201238|Drug|Menthol|Menthol
1604746|NCT02201225|Dietary Supplement|Nutritional supplement with micronutrient|Nutritional supplement powder with micronutrients packed as 27 g individual sachet, administered orally as a single serve
1604747|NCT02201225|Dietary Supplement|Nutritional supplement without micronutrient|Nutritional supplement powder without micronutrients packed as 27 g individual sachet, administered orally as a single serve
1604748|NCT02201212|Drug|Everolimus|
1604749|NCT02201199|Drug|insulin glargine U200 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1604750|NCT02201199|Drug|insulin glargine U500 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1604751|NCT02201199|Drug|insulin glargine U100 HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1604752|NCT02201186|Other|Manuka honey enema|Study patients diagnosed with acute pouchitis will perform manuka honey enemas twice a day for 30 days.
1604753|NCT02201173|Behavioral|Locomotor Training|Progressive retraining in functional skills including balance, transfers, activities of daily living and ambulation. Compliance to eliminate or minimize lower limb orthotics is also expected to optimize sensory input to the spinal cord and promote optimal recovery. Intensive therapy occurs in all three environments 5 times/ week for 90 minutes
1604754|NCT02201160|Dietary Supplement|omega 3|Two groups from our cohort will be supplemented either with omega-3 PUFA or placebo during 3 months. Each subject will take 4 capsules/d. after 3 months, the subjects under omega-3 will continue for another 3 months and the group under placebo will take omega-3 PUFA during another 3 months.
1604755|NCT02201147|Procedure|Cold biopsy polypectomy|removal of eligible polyps using cold biopsy technique until no polyp was visible by narrow-band imaging endoscopy
1604756|NCT02201147|Procedure|Cold snare polypectomy|removal of eligible polyps using cold snare polypectomy technique
1604757|NCT02201147|Device|Cold snare polypectomy|mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
1604758|NCT02201147|Device|Cold biopsy polypectomy|standard- capacity forceps with narrow band imaging endoscopy
1604759|NCT02201134|Drug|sevoflurane|
1604760|NCT02201121|Other|Influences of phenylephrine, dopamine and ephedrine on stroke volume variation and pulse pressure variation|This research mainly study the effect of clinical commonly used vasoconstrictor drugs on blood pressure of pressure
2009791|NCT03175666|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
2009792|NCT03175666|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 (MUC1)
1604763|NCT02201095|Device|Forced air warming|
1604764|NCT02201095|Device|Conduction warming mattress|
1604765|NCT02201082|Procedure|Airway clearance technique|
1604766|NCT02201082|Drug|Amikacin nebulization|
1604767|NCT02201069|Behavioral|health coaching|
1604768|NCT02201056|Drug|TAK-935|TAK-935 oral solution
1604769|NCT02201056|Drug|Placebo|TAK-935 placebo-matching oral solution
1604770|NCT02201043|Drug|Thalidomide 150mg|
1604771|NCT02201043|Drug|Thalidomide 100mg|
1604772|NCT02201043|Drug|Placebo|
1604773|NCT02201030|Biological|NBP606|A single intramuscular injection into the thigh
1604774|NCT02201030|Biological|Prevnar13|A single intramuscular injection into the thigh
2009793|NCT03175666|Biological|GI-4000|RAS yeast vaccine
1604783|NCT02200978|Drug|ATRA|Given orally
1604788|NCT02200978|Other|intrathecal injection|Ara-C and dexamethasone
1604789|NCT02200965|Other|My Diabetes, My Information, My Plan Document|A structured, understandable, well designed, user friendly, user developed and approved letter has been developed and undergone user acceptability testing for this purpose. It succinctly contains all information mapping to core diabetes care processes, is simple and easy to digest and effective in encouraging self-understanding and prompting self-care and empowering informative engagement with services and care providers. The satisfaction of users with the communicating letter both in a developmental pilot phase has been assessed by user group feedback and patient questionnaire.
1604790|NCT02200952|Drug|recombinant LH|recombinant LH twice/day for 10 days from pick up
1604791|NCT02200939|Device|Bioinductive implant|
1604792|NCT02200939|Device|Surgical repair|Surgical repair with commercially-available sutures/suture anchors.
1604793|NCT02200926|Other|Loaded breathing training|7 days/weeks, for 8 weeks
1604794|NCT02200926|Other|Unloaded breathing training|7 days/week, for 8 weeks
1604795|NCT02200926|Other|Placebo|7 days/week, for 8 weeks
1604796|NCT02200913|Other|core stabilization exercise|core stabilization exercise, 2 times/week, 10 weeks
1604797|NCT02200913|Other|general trunk strengthening exercise|general trunk strengthening exercise, 2 times/week, 10 weeks
1604798|NCT02200900|Other|Pharyngeal pressure|Babies will have pharyngeal pressures measured during the CPAP and HFNC respiratory support.
1604799|NCT02200900|Other|Transcutaneous carbon dioxide|Babies will have transcutaneous carbon dioxide measured during CPAP and HFNC respiratory support.
1604800|NCT02200900|Other|Pharyngeal gas concentrations|Measurement of pharyngeal oxygen and carbon dioxide concentration will be done during CPAP and HFNC respiratory support.
1604801|NCT02200900|Other|Tidal volume|Tidal breathing indices including tidal volume and FRC base line changes will be recorded during CPAP and HFNC respiratory support.
1604802|NCT02200848|Drug|Lenalidomide, Ibrutinib, Rituximab|Dose level -2 Ibrutinib 280 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level -1 Ibrutinib 420 mg; Lenalidomide 2.5 mg; Rituximab 375 mg/m2 Level 1 Ibrutinib 420 mg; Lenalidomide 5 mg; Rituximab 375 mg/m2 Level 2 Ibrutinib 420 mg; Lenalidomide 10 mg; Rituximab 375 mg/m2 Level 3 Ibrutinib 420 mg; Lenalidomide 15 mg; Rituximab 375 mg/m2
1604803|NCT02200822|Drug|beta blockers|
1604804|NCT02200822|Drug|RAAS blockers|RAAS blockers (combination of ACE-I/ARB and a mineralocorticoid receptor antagonist)
1604805|NCT02200809|Device|MR-guided focal laser ablation|
1604806|NCT02200796|Other|Control Meal|High carbohydrate meal
1604807|NCT02200796|Other|Low Protein Meal|Omelet with 15 g of protein
1604808|NCT02200796|Other|Moderate Protein Meal|Omelet with 30 g of protein
1604809|NCT02200796|Other|High Protein Meal|Omelet with 45 g of protein
1604810|NCT02200783|Device|TripTable|Details of the device previously described, designed to medical operator radioprotection. No changes in radial technique beyond the use of the supportive device will be performed.
1604811|NCT02200783|Device|Radial|Standard radial artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary.
1604812|NCT02200783|Device|Femoral|Standard femoral artery catheterization procedure, performed for the purpose of coronary angiography and ad hoc angioplasty if necessary. The supporting device will be the patient's own body, placing the material above the legs.
1604813|NCT02200770|Biological|MEDI-551|
1604814|NCT02200770|Other|Placebo|Matching placebo
1604815|NCT02200757|Drug|Aldoxorubicin|230 mg/m2 (170 mg/m2 doxorubicin equivalent) intravenously on Day 1 of each 21-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs.
1604816|NCT02200757|Drug|Topotecan|1.5 mg/m2/day intravenously for 5 consecutive days on Day 1 of each 21-day cycle OR 4 mg/m2 intravenously on Days 1, 8 and 15 of each 28-day cycle. Number of cycles: until tumor progression or unacceptable toxicity occurs
1604817|NCT02200731|Behavioral|FAMOS: psychosocial family intervention|The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
1604818|NCT02200718|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA BV5S2, BV6S5 BV13S1
1604819|NCT02200718|Biological|IFA Incomplete Freund's Adjuvant|IFA Incomplete Freund's Adjuvant is a vaccine adjuvant composed of a light mineral oil and a surfactant system designed to make a water-in-oil emulsion
1604820|NCT02200705|Device|Ice-Sense3TM|
1604821|NCT02200653|Drug|High dose of MICARDIS®, once daily|
1604822|NCT02200653|Drug|Low dose of MICARDIS®, once daily|
1604823|NCT02200653|Drug|Low dose of COZAAR® / LORZAAR®, once daily|
1604824|NCT02200653|Drug|High dose of COZAAR® / LORZAAR®, once daily|
1604825|NCT02200653|Drug|Placebo|
1604826|NCT02200640|Drug|High dose of Micardis®, once daily|
1604827|NCT02200640|Drug|Low dose of Micardis®, once daily|
1604828|NCT02200640|Drug|Low dose of COZAAR®, once daily|
1604829|NCT02200640|Drug|High dose of COZAAR®, once daily|
1604830|NCT02200640|Drug|Placebo|
2009794|NCT03175666|Biological|GI-6207|CEA yeast vaccine
2009795|NCT03175666|Biological|GI-6301|Brachyury yeast vaccine
1604833|NCT02200601|Device|Seipher Wellness|
1604834|NCT02200575|Drug|Telmisartan|
1604835|NCT02200562|Drug|ipilimumab and dabrafenib|
1604836|NCT02200549|Device|Control group|Neither cycle training nor inspiratory muscle training.
1604837|NCT02200549|Device|calibrated cycle ergometer|The most common device to proform cycle training is calibrated cycle ergometer.
1604838|NCT02200549|Device|calibrated cycle ergometer and threshold loading device|Combined cycle training and inspiratory muscle training.The threshold loading device is composed of a mouth -piece attached to a small plastic cylinder that contains a spring-loaded poppet value. The valve opens to permit inspiratory flow only once the person has generated adequate negative intrathoracic pressure to condense the spring.
1604839|NCT02200536|Other|Infant oral health promotion package|Infant oral health promotion package includes an infant oral health pamphlet, a baby toothbrush, fluoride toothpaste (1000 ppm) and a trainer cup.
1604840|NCT02200536|Other|Infant oral health pamphlet|Infant oral health pamphlet
1604841|NCT02200523|Device|SARA electrode|
1604842|NCT02200523|Device|Gold cup|
1604843|NCT02200510|Behavioral|Self-management intervention for Adolescents with SCD|Chronic Disease Self-Management Program
1604844|NCT02200510|Behavioral|Patient Portal Intervention for Adolescents with SCD|MyChart for SCD intervention
1604845|NCT02200484|Behavioral|Combined parent training and obesity prevention program|
1604846|NCT02200484|Behavioral|Wellness program (active contact control)|
1604847|NCT02200471|Device|VeinViewer|
1604848|NCT02200458|Device|VeinViewer|Updated software on the VeinViewer device will be used to project an image of the vasculature on the skin.
1604849|NCT02200445|Drug|Interleukin-2 (aldesleukin).|"Description of intervention is covered in Arm, above."
1604850|NCT02200432|Other|PERSPeCT Recommender System|"PERSPeCT will use data to predict messages that would be most influential to the participant in health behavioral change.
Patient Experience Recommender System for Persuasive Communication Tailoring. PERSPeCT is an adaptive computer system that will assess a patient's individual perspective, understand the patient's preferences for health messages, and provide personalized, persuasive health communication relevant to the individual patient."
1604851|NCT02200419|Other|POC-based transfusion algorithm|A transfusion algorithm based on point-of-care coagulation testing.
1604852|NCT02200406|Drug|Desvenlafaxine|All subjects will receive 50 mg of the medication during week 1 and 2, then 50-100 mg (based on the psychiatrist judgment) for the following 6 weeks. Subjects who experience significant adverse reactions with the 100mg dose during weeks 2 to 4 could return to the lower dose of 50 mg if judged clinically appropriate by the study psychiatrist.
1604853|NCT02200393|Device|Abdominal FES|"Stimulation intensity was adjusted on a channel by channel basis until a strong visible contraction of the abdominal muscles is observed. During the session, manual adjustment of both the stimulation intensity (to compensate for fatigue) and the duty cycle is possible.
Four pairs of surface electrodes were placed on the participant's abdomen. One pair will be placed on both the right and left side of the rectus abdominis around the naval. One pair of electrodes will also be placed on both the right and left side of the external oblique muscles with one electrode being placed just below the participant's bottom rib and the other below this with a separation of around 3cm."
1604854|NCT02200380|Drug|CDX-301|Related donors will receive CDX-301 for 5 days or 7 days.
1604855|NCT02200380|Drug|CDX-301 and plerixafor|Related donors will receive CDX-301 for 5 or 7 days plus plerixafor.
1604856|NCT02200367|Behavioral|e-mental health collaborative programme|
1604857|NCT02200367|Other|Usual Care|
1604858|NCT02200354|Drug|pemetrexed with bevacizumab|
1604859|NCT02200341|Behavioral|MBCT|
1604860|NCT02200341|Behavioral|PRT-PsyEd|
1604861|NCT02200328|Drug|Metronidazole|Metronidazole tablets 500mg orally or IV , 3 times a day for a maximum of 14 days
1604862|NCT02200328|Drug|Placebo|Placebo(Corn starch pill) orally 3 times a day for a maximum of 14 days
1604863|NCT02200315|Other|No Antimicrobial prophylaxis|Antimicrobial prophylaxis are not administered during an operation
1604864|NCT02200276|Biological|Influenza|
1604865|NCT02200263|Dietary Supplement|Lutein plus Zeaxanthin|dose: two softgels once a day with a meal
1604866|NCT02200263|Dietary Supplement|Placebo|two softgels once-daily with a meal
1604867|NCT02200237|Biological|EV71 with adjuvant aluminium phosphate|Two arms, EV71 with aluminium phosphate
1604868|NCT02200237|Biological|Placebo|Phosphate Buffer Saline with adjuvant aluminium phosphate
1604869|NCT02200224|Other|Rapid Testing|
1604870|NCT02200211|Device|iPad®|Binocular therapy on iPad®
1604871|NCT02200211|Other|Patching 2 hours per day, 7 days per week|
1604872|NCT02200198|Other|Expiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold with Positive Expiratory Pressure with a load of 30% of maximal expiratory pressure assessed by digital peak respiratory pressure monitor
1604873|NCT02200198|Other|Inspiratory muscle training|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold for Inspiratory Muscle Training with a load of 30% of maximal inspiratory pressure assessed by digital peak respiratory pressure monitor
1604874|NCT02200198|Other|Sham group|Patient performs training for 30 minutes per day, during 7 consecutive days, using a Threshold without load
1604875|NCT02200185|Drug|IV titrated morphine|"Intravenous morphine : 2 mg every 5 minutes by IV root and nebulized placebo:
SS nebulised : 5 ml SS nebulised over 10 minutes and repeated 3 times"
1604876|NCT02200185|Drug|Low dose nebulised morphine|10 mg morphine in 4 ml Serum Saline(SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
1604877|NCT02200185|Drug|High dose nebulised morphine|20 mg morphine in 3 ml serum saline (SS) nebulised over 10 minutes and repeated 3 times, and SS IV placebo : 2 ml by IV root every 5 minutes
1604878|NCT02200172|Other|Melatonin|Sublingual 3mg non-animal synthetic source melatonin daily at 21.00 hours (±1 hour).
1604879|NCT02200172|Other|Placebo|
1604880|NCT02200159|Drug|Sedation with dexmedetomidine|
1604881|NCT02200146|Drug|Prednisone|Prednisone per os 0,5 mg/kg/die once/day for 3 months. After 3 months, between responders, prednisone was slowly tapered (5 mg/week maintaining the new reduced dose for one week) to 0,2 mg/kg/die for further 6 months.
1604882|NCT02200146|Drug|Hydroxychloroquine + Prednisone|Hydroxychloroquine per os 200 mg/die (or adjusted for body weight if less than 61 kg), twice/day + prednisone 0,15 mg/kg per os daily, once/day for 3 months, than for further 6 months between responders.
1604883|NCT02200133|Other|Individualized Survivorship Care Plan (SCP)|The individualized SCP incorporates patient specific treatment exposures and provides a framework for long term followup based on those exposures and subsequent risks for late complications.
1604884|NCT02200107|Behavioral|self management education|
1604885|NCT02200094|Drug|Low dose of Telmisartan, once daily|
1604886|NCT02200094|Drug|High dose of Telmisartan, once daily|
1604887|NCT02200081|Drug|MGN1703|
1604888|NCT02200081|Other|Standard of care|Usual Standard of Care according to local investigators practise, e.g. Treatment break continous treatment and other
1604889|NCT02200068|Other|SANOIA Website|
1604890|NCT02200055|Device|Bodystat Quadscan 4000|"Each patient involved in the study will be evaluated with a bioimpedance monitor to assess total body water, estimated body water, and intravascular body water volume preoperatively, postoperatively, and daily during the postoperative recovery period.
Bioimpedance Assessment"
1604891|NCT02200042|Drug|Cisplatin|Given IV
1604892|NCT02200042|Drug|Gemcitabine Hydrochloride|Given IV
1604893|NCT02200042|Radiation|Image Guided Radiation Therapy|Undergo image-guided radiation therapy
1604894|NCT02200042|Other|Laboratory Biomarker Analysis|Correlative studies
1604895|NCT02200029|Drug|Ademetionine IV+tablet|IV ademetionine (500 mg/vial) for 2 weeks followed by oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 6 weeks
1604896|NCT02200029|Drug|Ademetionine tablet|oral ademetionine (500 mg/tablet, 2 in the morning and 1 before dinner) for 8 weeks
1604897|NCT02200016|Procedure|Ultrasound guided short axis (SAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the short axis of the sciatic nerve behind the knee.
1604898|NCT02200016|Procedure|Ultrasound guided long axis (LAX) placement of sciatic nerve catheters|Sonosite EDGE ultrasound scanner guided insertion of a B Braun Contiplex S catheter along the long axis of the sciatic nerve behind the knee.
1604899|NCT02200016|Device|B Braun Contiplex S catheter|
1604900|NCT02200003|Behavioral|attention bias modification for anxiety|
1604901|NCT02199977|Other|Free Malaria Rapid Diagnostic Test|Malaria RDT is offered free if patients choose to be tested
1604902|NCT02199977|Other|Conditional ACT voucher|"Participants will be eligible to receive a drug subsidy for a set amount (in the form of a voucher) conditional on a positive malaria test. When a conditional subsidy is offered, it is valid for use on a Green Leaf approved malaria drug."
1604903|NCT02199977|Other|Malaria Rapid Diagnostic test for a charge|Participants can receive a malaria RDT for a set amount (i.e., not for free).
2009796|NCT03175666|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion (haNK™ for Infusion)
2009797|NCT03174665|Other|No intervention|
1604906|NCT02199951|Drug|Dihydroartemisinin and piperaquine|Antimalarial
1604907|NCT02199938|Other|Identification and characterization of molecular markers in musculoskeletal tumors|
1604908|NCT02199925|Drug|Gammaplex 5%|
1604909|NCT02199912|Procedure|Biopsy of adipose and muscular tissue|
1604910|NCT02199912|Other|Blood sampling|
1604911|NCT02199912|Other|Calorimetry|
1604912|NCT02199912|Other|Impedance measure|Evaluation of physical composition (non-invasive method)
1604913|NCT02199912|Other|Evaluation of nutritional status|"Nutritional status will be assessed by using the Mini Nutritional Assessment (MNA) questionnaire and a scale that evaluates anorexia"
1604914|NCT02199912|Other|Evaluation of physical performance|"This will be assessed by using a tiredness scale named Echelle Visuelle Analogique (EVA) in french"
1604915|NCT02199912|Other|Evaluation of muscular strength|Muscular strength will be assessed thanks to the Handgrip Strength Test and the Short Physical Performance Battery (SPPB)
1604916|NCT02199912|Other|Evaluation of emotional status|The emotional status wil be assessed thanks to the Yesavage Geriatric Depression Scale (GDS)
1604917|NCT02199912|Other|Evaluation of functional status|The functional status will be assessed by using the Activity of Daily Life (ADL) questionnaire and the Instrumental Activities of Daily Living (IADL) Questionnaire
1604918|NCT02199899|Drug|BIIF 1149 BS - single rising doses|
1604919|NCT02199899|Drug|Placebo|
1604920|NCT02199886|Drug|BIBH 1|labeled with eight to ten millicurie of 131I
1604921|NCT02199873|Drug|BIIX 1 XX - single rising dose|
1604922|NCT02199873|Drug|Placebo|
1604923|NCT02199860|Drug|SD I|
1604924|NCT02199860|Drug|SD II|
1604925|NCT02199860|Drug|Placebo|
1604926|NCT02199847|Drug|Pharmaton® Caplets|
1604927|NCT02199847|Drug|Placebo|
1604928|NCT02199834|Behavioral|Peer support|15 patients who have good glycemic control and self-care will be trained as peer supporters to deliver peer support under supervision by a program manager. Peer supporters will call their peers at least 12 times a year to provide both informational and emotional support.
1604929|NCT02199834|Behavioral|Personalized feedback report|Patients will receive a personalized feedback report displaying trends of metabolic control of A1c, BP, LDL-C, and body weight, with automated decision support based on their own attained values every 4 months through mails.
1604930|NCT02199821|Dietary Supplement|Formula with soybean oil, medium-chain triglycerides|
1604931|NCT02199821|Dietary Supplement|Soybean oil formula commonly used in the hospital|
2009798|NCT03173963|Drug|Empagliflozin|10 mg tablet of empagliflozin daily in addition to best clinical practice for management of diabetes.
2009799|NCT03173963|Other|Placebo|1placebo tablet per day
1604934|NCT02199782|Other|Welsh language Cognitive Assessment|This intervention may intervene by displaying a more realisitic reflection of the patient's cognitive ability by assessing the patient in their first language
1604935|NCT02199769|Other|Clinical Decision Support|Investigators will develop and implement an automated Diabetes Detection Tool (DDT) that does data mining on EMR lab data to systematically identify all primary care patients with elevated RPGs who are at high risk of diabetes and in need of further diabetes testing/screening.
1604936|NCT02199743|Drug|Lurasidone|Compare to haloperidol and perphenazine
1604937|NCT02199743|Drug|Haloperidol|Compare to lurasidone
1604938|NCT02199743|Drug|Perphenazine|Compare to lurasidone
1604939|NCT02199717|Device|Accelerometer|
1604940|NCT02199704|Other|Self Directed Positive Parenting Program|"Individuals with psychosis who are parents will receive a copy of the Every Parent's Self Help Workbook (Markie-Dadds, Sanders & Turner, 1999) and up to ten sessions of support. This is a case series study."
1604941|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
1604942|NCT02199691|Biological|Meningococcal (Groups A, C, Y and W135) Oligosaccharide Diphtheria CRM197Conjugate Vaccine|0.5 mL, IM
1604943|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
1605425|NCT02195921|Drug|only antiemetic drug|
1604944|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
1604945|NCT02199691|Biological|Meningococcal Polysaccharide (Serogroups A, C, Y, and W135) Tetanus Toxoid Conjugate Vaccine|0.5 mL, Intramuscular (IM)
1604946|NCT02199691|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, IM
1604947|NCT02199691|Biological|GARDASIL®: Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine, Recombinant|0.5 mL, IM
1604948|NCT02199678|Drug|Placebo|placebo
1604949|NCT02199678|Drug|ketamine 25 mg|ketamine
1604950|NCT02199678|Drug|ketamine 35 mg|ketamine
1604951|NCT02199678|Drug|ketamine 50 mg|ketamine
1604952|NCT02199665|Drug|selinexor|Given PO
1604953|NCT02199665|Drug|carfilzomib|Given IV
1604954|NCT02199665|Drug|dexamethasone|Given PO or IV
1604955|NCT02199665|Other|laboratory biomarker analysis|Correlative studies
1604956|NCT02199665|Other|pharmacological study|Correlative studies
1604957|NCT02199665|Other|questionnaire administration|Ancillary studies
1604958|NCT02199652|Drug|Prazosin|
1604959|NCT02199652|Drug|Placebo|
1604960|NCT02199626|Device|Second generation of colon capsule endoscopy (GIVEN IMAGING)|
1604961|NCT02199613|Drug|Treatment simplification|Eligible, consenting subjects will start open-label darunavir 800mg plus the co-formulated tenofovir DF/FTC/cobicistat/elvitegravir (Stribild) tablet once daily with food, following the study procedures at the baseline visit. They will be assessed at weeks 2, 12, 24, 36, and 48 after starting the new regimen.
1604962|NCT02199600|Device|GMK Sphere Knee Replacement|
1604963|NCT02199587|Behavioral|Presence of medical clown during endocrine test|
1604964|NCT02199574|Drug|EXPAREL|133 mg EXPAREL in 10 mL.
1604965|NCT02199561|Biological|Fecal Microbiota Transplant|Fecal transplant processed from routinely screened universal donor
1604966|NCT02199548|Other|Interview|This study involves teen participants taking part in one private interview with the study team. Interviews last less than one hour and are scheduled at the participant's convenience. Interviews will be audio/digital recorded. Participants may answer any or all of the questions.
1604967|NCT02199522|Procedure|titration induction to propofol|propofol intravenously by Fresenius pump at the speed of 1 mg•kg-1•min-1, and OAA/S scale of the patients was titrated to 1
1604968|NCT02199509|Drug|Levetiracetam|Anticonvulsant
1604970|NCT02199457|Device|SVSS and reference devices|Blood pressure will be measured with standard mercury manometer
1604971|NCT02199457|Device|SVSS and reference devices|Body temperature taken with infrared thermometer
1604972|NCT02199457|Device|SVSS and reference devices|Pulse rate and Sp02 measured with a reference pulse oximter. The pulse oximeter is just clipped to the end of the finger.
1604973|NCT02199457|Device|SVSS and reference devices|Measurement of respiration rate
1604974|NCT02199444|Drug|Sevelamer|The dose of Sev was 2400 mg (800 mg three times a day) in all patients.
1604975|NCT02199444|Drug|Placebo|
1604976|NCT02199431|Drug|Lu AF11167|
1604977|NCT02199431|Drug|Itraconazole|
1604978|NCT02199418|Drug|Paclitaxel|
1604979|NCT02199418|Drug|Cisplatin|
1604980|NCT02199405|Other|Massage of chiropractic and adjusting cervical curvature|Massage of chiropractic and adjusting cervical curvature, 10 minutes, three times one week for 4 weeks
1604981|NCT02199405|Other|Sishi Daoyin|Sishi Daoyin, practicing during 9-11am, once a day for 4 weeks
1604982|NCT02199405|Other|conventional massage|Conventional massage , 15 minutes, three times one week for 4 weeks
1604983|NCT02199405|Other|Cervical traction|
1604984|NCT02199392|Drug|Lenvatinib|subjects will take a single oral dose of 24 mg lenvatinib on three separate occasions (Period 1, Day 1; Period 2, Day 15; and Period 3, Day 43). In Period 2, Day 15, subjects will also take a single oral dose of 600 mg po rifampin. In Period 3, subjects will receive 600 mg rifampin po daily for 21 days (Period 3, Days 29 to 49). On Day 43 of Period 3, subjects will take 24 mg lenvatinib in addition to the rifampin.
1604985|NCT02199379|Drug|Lenvatinib|Lenvatinib will be taken as a single dose of 24 mg consisting of 2 x 10 mg and 1 x 4 mg capsules. Treatment will be administered orally with 240 mL of water following a 10-hour overnight fast.
1604986|NCT02199366|Procedure|Cardiac magnetic resonance (cardiac MRI)|Participants will have a cardiac MRI at baseline and within 1 year after completion of radiation therapy.
1604987|NCT02199353|Other|Stimulation of Activities Daily Living|"Experimental group: SADL programme which is a new treatment approach created by the authors of this study for the training of ADL through cognitive intervention. The programme is based on the reestablishment of the cognitive functions implied in the performance of basic activities of daily living.
The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
1604988|NCT02199353|Other|Conventional ADLOccupational Therapy|"Control group treatment: conventional occupational therapy intervention for the management of ADL deficits. The compensation approach was used and environment modifications and simplification of activities were applied as the intervention method.
The treatment was carried out twice a week (Tuesday and Thursday) for 45 minutes during 5 weeks."
1604989|NCT02199340|Other|iStep exercise test|newly developed submaximal exercise test
1604990|NCT02199340|Other|CPET exercise test|maximal gold standard exercise test
1604991|NCT02199327|Drug|Mitomycin C|Patients treated with mitomycin will be handled by cycles until resolution of the lesion, which according to previous studies is expected between 3 and 6 cycles (between half months and 3 months).
1604992|NCT02199327|Drug|Interferon Alfa-2b|Patients managed with interferon will be treated for a period ranging from one month to 12 months according to clinical resolution of the lesion. Both groups will be evaluated by at least one year after the resolution of the lesion to determine the presence of recurrences
1604993|NCT02199314|Procedure|Intraoperative Neurophysiologic Monitoring|transcranial motor evoked potentials are collected prior to the administration of desflurane (under intravenous anesthesia) and again after desflurane is added for at least 5 minutes and is at 3%.
1604994|NCT02199314|Drug|Desflurane|
1604995|NCT02199301|Procedure|Transplantation Conditioning for BMT|Transplantation Conditioning for BMT (POD#-7~-1) POD#-7: Rituximab (Mabthera, Roche Pharma Aktiengesellschaft (AG) Swiss) 375/m2 iv infusion POD#-6~-3: Fludarabine (Fludara Inj., Bayer AG, Germany) 30mg/m2/day iv infusion POD#-5~-4: Cyclophosphamide (Endoxan Inj., Baxter Oncology Gesellschaft mit beschränkter Haftung (GmbH), Germany) 30mg/kg/day iv infusion POD#-2: (Rituximab 375/m2 iv infusion) POD#-1: Thymic irradiation (Dose, 700cGy)
1604996|NCT02199262|Other|music intervention|reminder+ 20 minutes in the morning and 20 minutes in the afternoon of music listening(classical or soft background music), delivered by compact disc players with headphones with disposable ear pads.
1604997|NCT02199262|Other|reflexology|reminder + 20 minutes per day feet reflexology massage provided by certified specialist in reflexology massages
1604998|NCT02199262|Other|reminder|Implementation of a reminder of guidelines of agitation diagnosis and management
1604999|NCT02199249|Device|Open reduction Tightrope fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of a single Tightrope (Arthrex-Knotless) device. Open Reduction Tightrope fixation (OT)
1605000|NCT02199249|Device|open reduction screw fixation|Device: Following fixation of Weber C fibular fracture according to AO standards, the syndesmosis will be stabilized by open reduction followed by use of two or more syndesmosis screws. Open Reduction screw fixation (OS)
1605001|NCT02199236|Radiation|endorectal brachytherapy|Patients will receive 3 fractions of endorectal brachytherapy, each spaced apart by 7 days (+/- 1 day). The three dose tiers will be 1500cGy (500cGy per fraction), 1800cGy (600cGy per fraction), and 2100cGy (700cGy per fraction).
1605002|NCT02199236|Drug|concurrent capecitabine or 5-FU|"Patients will receive 500 mg and 150 mg oral tablets of capecitabine for the prescribed dose of 825 mg/m2 BID, morning and evening (total daily dose of 1650 mg/m2 ). Dosages will be rounded to the nearest 150 mg or 500 mg. Tablets should be swallowed with water within 30 minutes after a meal. Capecitabine will be started on the Monday of the first week of brachytherapy (day 1) and taken on weekdays (Monday through Friday) during weeks of brachytherapy only.
Administration of 5-FU should be only by the intravenous route taking care to avoid extravasation. Patients will receive 225 mg/m2/day, as a continuous venous infusion by a portable pump for the 3 weeks of treatment. The infusional 5-FU will be exchanged every 7 days."
1605003|NCT02199236|Behavioral|Questionnaires|Patients should complete the 2 quality of life questionnaires during their follow-up appointments. If they are unable to be seen in follow-up, they may complete the questionnaires at home and email or mail them back to the investigator. Should there be any incomplete or ambiguous answers, a follow-up phone call will be made by a member of the research team for clarification. Additionally, if the questionnaires have not been returned within 3 weeks after the time when they are due, a member of the research team will call the patient, and the questions will be completed over the phone.
1605004|NCT02199223|Drug|regorafenib + panitumumab|
1605005|NCT02199210|Other|Prompting forethought|Participants will be asked questions which elicit specific forethought elements related to the given clinical situation. These are elements that relate to strategic planning, goal setting, goal orientation, imagery, outcome expectation. These context specific questions will be determined in the Pilot study and validated in Study I.
1605006|NCT02199197|Drug|Radium Ra 223 dichloride with Enzalutamide|
1605007|NCT02199197|Drug|Enzalutamide|
1605008|NCT02199184|Drug|Ofatumumab|300 mg by vein on day 1 (before infusions) and 2,000 mg on days 2 and 11 during Cycle 1 only. Starting with Cycle 2, participants receive Ofatumumab 2,000 mg by vein on days 1 and 8 of Cycles 2 and 4, and day 1 and 11 of Cycle 3 for a total of 8 injections of ofatumumab. Cycles are 21 - 28 days.
1605009|NCT02199184|Drug|Etoposide|50 mg/m2/day by vein days 1- 4 of a 21 - 28 day cycle.
1605010|NCT02199184|Drug|Doxorubicin|10 mg/m2/day by vein days 1 - 4 of a 21 - 28 day cycle.
1605011|NCT02199184|Drug|Vincristine|0.5 mg by vein days 1 - 4 of a 21 - 28 day cycle.
1605012|NCT02199184|Drug|Cyclophosphamide|750 mg/m2 by vein on day 5 of a 21 - 28 day cycle.
1605013|NCT02199184|Drug|Prednisone|60 mg by mouth twice a day on days 1 - 5 of a 21 - 28 day cycle.
1605014|NCT02199184|Drug|Rituximab|375 mg/m2 by vein on days 1 and 11 of Cycle 1 and 3 and days 2 and 8 of Cycle 2 and 4 of a 21 - 28 day cycle. Rituximab replaces ofatumumab if insurance does not approve ofatumumab.
1605015|NCT02199184|Drug|Pegfilgrastim|6 mg within 72 hours after completion of chemotherapy.
1605016|NCT02199184|Drug|G-CSF|10 µg/kg/day until neutrophil recovery 1 x 109/L or higher, can be substituted or can be added to Pegfilgrastim if neutrophils have not recovered to 1 x 109/L by day 21.
1605017|NCT02199184|Behavioral|Phone Calls|Participant receives phone calls from study staff every 3 months for 1 year after receiving the study drugs. These calls should last about 5 minutes each time.
1605018|NCT02199171|Drug|carboplatin|Given via HIPEC
1605019|NCT02199158|Procedure|Argon Laser Peripheral Iridoplasty|ALPI was applied with a VISULAS diode laser of 532 nm (Carl Zeiss Meditec, Dublin, CA) by the same ophthalmologist (JML). Twenty to 40 spots of 400 mW power with 500 microns of size and duration of 500 ms were applied. Power was modified arbitrarily until an effective iris contraction was obtained. It was considered an effective contraction as that which causes a concentric movement around the laser spot, with minimal iris pigmentation and immediate angle opening observed through the lens mirrors using a Goldmann lens. Power was lowered if there was any bursting sound perceived, pigment dispersion, air bubbles or considerable pain.
1605020|NCT02199145|Procedure|Blood and urine analysis|creatinine, albumin, blood electrolytes, proteinuria / creatinine in sample 1 assay Ac anti-PLA2R1 on 3 ELISA (human, rabbit and mouse)
1605021|NCT02199119|Behavioral|Exercise|30 min of moderate exercise on a treadmill
1605022|NCT02199119|Behavioral|TV viewing|watching TV (animated children's programming) for 30 min
1605023|NCT02199119|Behavioral|Sitting quietly|Sitting quietly for 30 min
1605024|NCT02199106|Device|Left temporal verum cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session)
Arms: Left temporal verum cTBS"
1605058|NCT02198872|Other|Exercise, Aerobic (Water based)|Patients of this group will be submitted to an aerobic water based physical training
1605426|NCT02195908|Other|single point Neiguan(PC6) plus antiemetic drug|
1605025|NCT02199106|Device|Left temporal placebo cTBS|"Continuous theta burst stimulation (MC-B70, MagPro,MagOption, Medtronic, Germany): 400 triplets of stimuli (triplets with 50Hz) at an frequency of 5Hz (in sum 1200 stimuli) with a break after 200 bursts over the left Heschl's gyrus targeted with anatomical neuronavigation (Localite, Germany); 30% maximum stimulator output (each session); coil tilted by 45° over both wings
Arms: Left temporal placebo cTBS"
1605026|NCT02199093|Other|Functional Rehabilitation of apraxia|"The intervention will cover every type of approaches related with upper limb apraxia.
We will use different kinds of tools to activate cerebral networks implied on apraxia, for facilitating the cerebral neuroplasticity in the recovering of the patient.
On the other hand, when the function can not be improved, we will provide skills and strategies for enhance the environment adaptation and increasing the autonomy and independence."
1605027|NCT02199093|Other|Traditional health educative protocol|The traditional health educative protocol consist in an educational workshop for patients and caregivers where they are taught the implications of apraxia in their daily live, kind of errors of apraxia for gaining consciousness of the syndrome, and some strategies to facilitate the adaptation of the patient in her house.
1605028|NCT02199080|Other|D-dimer assay before ablation of atrial fibrillation|Blood sample collection for D-dimers measurement
1605029|NCT02199054|Other|wheat-safflower oil pretzels|Each serving (6 pieces) of the wheat-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, safflower oil, sugar, yeast, salt, and ascorbic acid.
1605030|NCT02199054|Other|soy-safflower oil pretzels|Each serving (6 pieces) of the soy-safflower oil pretzel contains 6 grams of safflower oil. Ingredients in the pretzel are high gluten wheat flour, soy flour, soymilk, safflower oil, sugar, yeast, salt, and ascorbic acid.
1605031|NCT02199054|Other|control wheat pretzels|Each serving (6 pieces) of the control wheat pretzel contains 6 grams of vegetable shortening. Ingredients in the pretzel are high gluten wheat flour, vegetable shortening, sugar, yeast, salt, and ascorbic acid.
2009800|NCT03173105|Device|active tDCS|TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution. For stimulation of the motor motor, somatosensory, and visual cortices with a current of 2mA for 20 minutes. The cathode will be positioned in the medial supraorbital region.
2009801|NCT03173105|Device|sham tDCS|Sham TDCS will be administered using with two sponge (non-metallic) surface electrodes (5 x 7 cm2) moistened with saline solution The stimulator will only be switched on for the first 30 seconds, giving the participant the initial sensation of tDCS, but no active stimulation throughout the remainder of the session the proprioceptive exercise session
2009802|NCT03173105|Other|Dynamic proprioceptive exercises|The dynamic proprioceptive exercises will be conducted as follows: 1) walking slowly then more quickly on a trampoline; 2) walking backward with one foot behind the other; 3) walking forward on a beam; 4) going up and down a flight of stairs; and 5) sitting on a Swiss exercise ball (65 cm) and performing laterolateral, anteroposterior, circling movements and bouncing. Activities will be performed in three one-minute sets.
2009803|NCT03173105|Other|static proprioceptive exercises|The static exercises will be conducted as follows: 1) standing on toes with feet apart; and 2) with feet together; 3) standing on only right leg without support; and 4) on only left leg without support; and 5) standing with heel of right (or left) foot touching toes of left (or right) foot with feet in a straight line over on an unstable surface (wobble board) performed in six sets of 30 seconds each, with a one-minute rest interval between sets
2009804|NCT03172884|Drug|Copanlisib BAY80-6946|12mg single dose, intravenous on Day 0
2009805|NCT03172702|Drug|Zirconium Cyclosilicate|Correction Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) from 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) (or 2.5 g QD) based on i-STAT potassium measurements up to 12 months.
2009806|NCT03171064|Behavioral|Resistance and Endurance Exercise|Machine-based, 2x/week endurance and resistance training for 12 weeks
2009807|NCT03170375|Behavioral|Performance of WHEELS-I in promoting DASH/SRD adoption|Participants will receive the WHEELS-I electronically-delivered tailored messaging intervention in addition to motivational interviewing-based counseling.
1605045|NCT02199015|Device|Lateral spinal cord surgical implant of electrodes|"The procedure is based on the classic approaches to posterior cervical region for herniated discs, actually not longer employed for that aim A unilateral hemilaminectomy will be performed at C3-C4 level, starting from 4th cervical spinous process.
A multicontact electrode will be placed on the lateral surface of the spinal cord that will be subcutaneusly connected to an implanted pulse generator (IPG)."
1605046|NCT02199002|Device|multi-pH-impedance manometry catheter|a special catheter will be placed in the esophagus of all study groups. Measurment of pH, impedance and pressure will be performed.
1605047|NCT02198989|Behavioral|peer support and yoga music therapy|Patients in the intervention group will receive peer support and yoga music therapy before bed.
1605048|NCT02198963|Drug|Hypochlorous acid solution 106 mg/L|test product
1605049|NCT02198963|Drug|0.1% (w/v) Sodium Lauryl Sulfate|positive control
1605050|NCT02198963|Drug|0.9% Physiological Saline, USP|negative control
1605051|NCT02198937|Other|Blood sample|
1605052|NCT02198924|Drug|Parecoxib and Celecoxib|Patients in the study group are supplied sequential treatment with Parecoxib 40 mg intravenously (IV) twice daily (Q12h) for the first 3 days post-surgery followed by Celecoxib 200mg orally twice daily (Q12h) up to 6 weeks post-surgery.
1605053|NCT02198924|Drug|placebo|control patients are supplied with the corresponding placebo with the same instructions.
1605054|NCT02198911|Other|NO GUM|For the NO GUM condition, participants will not chew gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
1605055|NCT02198911|Other|MCC (Mint Chocolate Chip gum)|For the MCC gum condition, participants will chew MCC gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
1605056|NCT02198911|Other|C (Cinnamon gum)|For the C gum condition, participants will chew Cinnamon gum before engaging in a computer task that will allow participants to earn points for MCC ice cream that they can consume.
1605057|NCT02198898|Device|GUARDIX-SG|
1605059|NCT02198872|Other|Land Group|Patients of this group perform physical training on bicycle.
1605060|NCT02198859|Drug|Lithium Carbonate|
1605061|NCT02198846|Device|insulin pump|stop any antihyperglycemic medication and convert to insulin pump
1605062|NCT02198846|Drug|conventional treatment|intensification of conventional treatment by adding oral antihyperglycemic agents or subcutaneous insulin (once / twice/ multiple injection)
1605063|NCT02198833|Biological|Urine Culture|Obtain urine culture every third day
1605064|NCT02198833|Device|Foley Catheter Tip Culture|Catheter Tip Roll Plate Culture
1605065|NCT02198833|Device|Scanning Electron Microscopy|Houston Site Only
1605066|NCT02198833|Procedure|Device Specific Adverse Event Assessment|Assessment will be made of catheter patency and/or trauma related to catheter placement
1605067|NCT02198833|Procedure|Foley Catheter Insertion|Insert Foley catheter for 15 day duration
1605068|NCT02198820|Drug|General Anesthesia|General anesthesia with proposal, rocuronium and sufentanil
1605069|NCT02198820|Drug|Loco Regional Anesthesia|Loco Regional Anesthesia with marcaine
1605070|NCT02198807|Drug|Fosmidomycin-Piperaquine|
1605071|NCT02198794|Drug|SD-809|SD-809 tablets dose titrated for 6 weeks until optimal dose is reached. The dose is maintained for the duration of the study.
1605072|NCT02198755|Device|Hitachi-Aloka Noblus ultrasound scanner|High resolution ultrasound with the Hitachi-Aloka Noblus Scanner and a 8-15mHz transducer
1605073|NCT02198755|Device|Magnetic Resonance Imaging (MRI)|MRI with or without contrast
1605074|NCT02198742|Device|Miller blade|To participate in the study the subjects must have >500 intubations with the miller blade.
1605075|NCT02198742|Device|Truview PCD|Subjects were given a quick guide of the Truview PCD supplied by the manufacturer with step by step instructions for use. They were also given time to practice with the device on a normal model until they felt comfortable.
1605076|NCT02198742|Device|Glidescope Cobolt|Subjects were required to watch a instructional video provided by the manufacturer. Subjects were then allowed to practice on a normal model until they felt comfortable before beginning the study. There is no placebo group, and each subject wil be his or her own control.
1605077|NCT02198729|Procedure|Endoscopic Submucosal Dissection|
1605078|NCT02198729|Procedure|Endoscopic Mucosal Resection|
1605079|NCT02198716|Procedure|Percutaneous Coronary Intervention using drug eluting stents|Percutaneous Coronary Intervention using drug eluting stents
1605080|NCT02198716|Procedure|Percutaneous Coronary Intervention using bare metal stents|Percutaneous Coronary Intervention using bare metal stents
1605081|NCT02198703|Dietary Supplement|Probiotics bacterial strains|
1605082|NCT02198690|Other|Mammography decision aid|
1605083|NCT02198690|Other|Home safety pamphlet|
1605084|NCT02198677|Procedure|Anterior to posterior pressures|Anterior to posterior pressures
1605085|NCT02198677|Procedure|Lateral glide|Lateral glide
1605086|NCT02198664|Biological|Peanut protein capsule|characterized peanut allergen provided in break apart capsules for oral immunotherapy
1990801|NCT01795586|Drug|Eribulin|"Eribulin will be administered on days 1 and 8 slow IV push over 2 to 5 minutes. Premedications will be given per institutional guidelines.
Level 1: 0.9 mg/m^2; Level 2: 1.1 mg/m^2; Level 3: 1.4 mg/m^2"
1605089|NCT02198638|Biological|A nasal swab|A nasal swab was performed by a research assistant and influenza virus infection was confirmed by enzyme-linked immunosorbent assay and reverse transcription-polymerase chain reaction on viral cultures
1605090|NCT02198625|Other|Moderate FiO2 and Protective Lung Ventilation Using|
1605091|NCT02198612|Other|Manual puncture point compression|Manual puncture point compression following a diagnostic or therapeutic procedure by endovascular technique involving retrograde femoral puncture point with 5F guide catheter
1605092|NCT02198599|Procedure|Mobility-enhancing-nursing intervention|Patients' mattresses are placed on the floor, which enables the patients to explore their environment safely without the risk of falling. Additionally, the patients' environment is arranged in accordance with a nursing assessment pertaining to the patients' impairment and abilities, their goals in terms of improved mobility, and the mobility they would require in order to live at home as independently as possible. Initially, most patients favour a specific side to get up. The goal of the intervention is to teach the patients to get up step by step and to move independently over both sides.
1605093|NCT02198560|Device|RS-3000 Lite|
1605094|NCT02198547|Drug|Magnesium Sulfate|Mg used with ropivacaine for sciatic nerve blick
1605095|NCT02198547|Drug|Ropivacaine|Ropivacaine 7,5 mg/ml used for sciatic nerve block
1605096|NCT02198534|Device|Methodology of visual acuity assessment|
1605099|NCT02198495|Drug|Supplementation of ferric carboxymaltose|
1605100|NCT02198495|Drug|Supplementation of iron sucrose|
1605101|NCT02198482|Drug|Volasertib|
1605102|NCT02198482|Drug|Cytarabine|
1605103|NCT02198482|Drug|Daunorubicin|
1605104|NCT02198482|Drug|Mitoxantrone|
1605105|NCT02198469|Drug|Er:YAG AFL-PDT|Er:YAG AFL was performed with 350 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
1605106|NCT02198469|Drug|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
1605107|NCT02198443|Drug|Tenofovir + emtricitabine (Truvada),+lopinavir/ritonavir (Kaletra)|(TRUVADA) film-coated 200/245 mg tablet / day tablets (Kaletra) film-coated 200/50 mg tablets twice / day tablets
1605108|NCT02198443|Drug|elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil|Film-coated tablets of 150 mg of elvitegravir, cobicistat 150 mg, 200 mg of emtricitabine and 245 mg of tenofovir disoproxil. One tablet once / day.
1605109|NCT02198417|Drug|Metformin ER|Treatment with metformin ER for 12 weeks
1605427|NCT02195908|Other|single point Zhongwan(CV12) plus antiemetic drug|
1605110|NCT02198404|Drug|sedation with propofol|induction with propofol at 20mg/kg/h. Then, when the patient is sleeping, dosage is decreased to 6 mg/kg/h
2009808|NCT03170375|Behavioral|Effects of a 2-week DASH/SRD intervention vs. control diet on HFpEF functional cardiovascular risk factors|Participants will be randomized to the sequence DASH/SRD-control diet or control diet-DASH/SRD, and consume the diets for 14 days each.
2009809|NCT03169179|Behavioral|Fitbit and Bupa Boost app|Fitbit Charge 2™ wearable physical activity monitor and Bupa Boost health and wellbeing smartphone app. 12 weeks initial use (individual goal-setting in weeks 1-6 then social features of the app in weeks 7-12) followed by a further five months of optional use (as desired by the participant).
1605113|NCT02198352|Drug|BIBN 4096 BS - in single rising doses|
1605114|NCT02198352|Drug|Placebo|
1605115|NCT02198339|Drug|BIBN 4096 BS|
1605116|NCT02198339|Drug|Placebo|
1605117|NCT02198326|Drug|BIBN 4096 BS- in single rising doses|
1605118|NCT02198326|Drug|Placebo|
1605119|NCT02198313|Drug|BIIX 1 XX - D1|
1605120|NCT02198313|Drug|BIIX 1 XX - D2|
1605121|NCT02198313|Drug|BIIX 1 XX - D3|
1605122|NCT02198313|Drug|Placebo|
1605123|NCT02198300|Procedure|Coronary angioplasty with stent implantation|
1605124|NCT02198300|Drug|Dual antipletlet therapy (DAPT)|DAPT given to each patient before stent implantation
1605125|NCT02198287|Drug|BIIX 1 XX inhalation solution|single doses of 800, 1000, 1200, 1400, 1600, 1800, or 2000 mcg
1605126|NCT02198287|Drug|Placebo|
1605127|NCT02198274|Drug|BIBH 1|100 mg/week
1605128|NCT02198261|Drug|5% minoxidil topical foam|5% minoxidil topical foam
1605129|NCT02198248|Drug|Rituximab|Patients will be administered rituximab (375mg/m2/w x4 infusions) for reducing glucocorticoid dose in remission induction phase.
1605130|NCT02198248|Drug|Glucocorticoids|"Low-dose group commenced 0.5mg/kg/day, then taper and stop within 6 months following pre-defined schedule.
High-dose group commenced 1.0mg/kg/day, then taper to 10mg/day within 6 months following pre-defined schedule."
1605131|NCT02198235|Drug|Dexamethasone|
1605132|NCT02198235|Drug|Buprenorphine|
1605133|NCT02198209|Drug|Liraglutide|"acute study: one injection of 0.6 mg s.c. before IVGTT
chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c)."
1605134|NCT02198196|Behavioral|Weight Talk-Mindfulness|
1605135|NCT02198183|Device|Casmed Fore-Sight Elite|
1605136|NCT02198183|Device|Non-invasive Cardiac Output Monitor (NICOM)|
1605137|NCT02198170|Drug|ketoconazole-placebo|Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period. Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period.
1605138|NCT02198170|Drug|placebo-ketoconazole|Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
1605139|NCT02198157|Other|urinary catheterization|nullipara women with epidural anaesthesia who pose urination difficulty will be randomize to receive intermittent or continuous urinary catheterization.
1605140|NCT02198144|Other|barbershop-based BP measurement|BP Measurements and blood pressure reducing medication
1605141|NCT02198131|Procedure|laser therapy|Undergo pulsed dye laser
1605142|NCT02198131|Other|questionnaire administration|Ancillary studies
1605143|NCT02198118|Other|Domiciliary exercises for the upper limbs|Study group (SG) instructed to perform domiciliary exercises for the upper limbs.
1605144|NCT02198105|Device|Cutting-Balloon-PTA (VascuTrak) and Drug Coated Ballon PTA|"Interventional procedure:
PTA with Cutting-Balloon (60-120 seconds).
PTA with DC-Balloon (60 seconds).
Technical success is defined as
no recoil >30%
no dissection >Type B
no stenting >30% of lesion length."
1605145|NCT02198092|Other|Epi proColon Testing|"Plasma specimens will be collected and processed according to the Instructions for Use of the Epi proColon investigational device.
For circulating colonic epithelial cell analysis, at least one ml whole blood will be required for analysis. Samples will be analyzed for circulating epithelial cells using the geometrically enhanced immunocapture device (GEDI; Gleghorn et al., 2009). Circulating epithelial cells will be captured using EpCAM antibodies and quantified by immunofluorescence microscopy as defined as cells that are DAPI+, CK+, CD45-. Captured cells will be fixed and stored at -20˚C."
1605146|NCT02198079|Biological|Sputum|
1605147|NCT02198066|Other|Dry Sterile Dressing|Described in Arm Description.
1605148|NCT02198066|Other|Metallic Silver Dressing|Described in Arm Description.
1605149|NCT02198066|Other|Ionic Silver Dressing|Described in Arm Description.
1605150|NCT02198040|Other|Manual Therapy|"5 minutes. Termotherapy shalow to 50 cm away from the elbow, using a bulb of 250w.
15 minutes. Joint traction of elbow, in submaximal mobility amplitude with distal fixation of humerus and proximal fixation of radius and ulna in neutral position of forearm. Joint traction in I-II degree of flexion and extension submaximal of elbow.
15 minutes. Passive muscle stretching (within the limits of mobility).
15 minutes. Proprioceptive neuromuscular facilitation (PNF) of upper limb, from the abduction, flexion and external rotation of shoulder.
10 minutes. Local cryotherapy with ice bag and protection between it and the skin"
1605151|NCT02198040|Other|Educational group|"Theory: Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of elbow; Anatomy of elbow musculature. Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations and treatment; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.
Practice: exercises in favor of gravity; isometric and isotonic exercises of elbow; active exercises for mobility and pain management; elbow proprioception exercises; and swimming technique."
1605152|NCT02198027|Drug|Bupivacaine|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of 0.25 % Bupivacaine into renal capsule to skin.
1605153|NCT02198027|Other|Normal saline infiltration|23 G spinal needle will be introduced along the nephrostomy tube for peri-tubal infiltration of 10 ml of normal saline into renal capsule to skin
1605239|NCT02197260|Drug|3/d 500 mg metronidazole plus 375 mg amoxicillin for 7 days|Systemic antibiotics after sub gingival mechanical debridement
2009810|NCT03169764|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
2009811|NCT03169764|Biological|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
1605156|NCT02198001|Drug|tooth extraction with antibiotics (amoxicillin- clavulanate, clindamycine)|"BPs per os< 3ans: amoxicillin- clavulanate J-1 à J+10
BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):
amoxicillin- clavulanate J-3 à J+10
In case of allergy:
BPs per os: clindamycine J-1 à J+10
BPs IV ou per os> 3ans ou per os + comordibities (diabetes, immunosuppression, tobacco):
clindamycine J-3 à J+10"
1605157|NCT02198001|Procedure|atraumatic extraction|Atraumatic tooth extraction, alveolar bone reduction, hermetic mucosal closure
2009812|NCT03169764|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
2009813|NCT03169764|Biological|Cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
1605160|NCT02197975|Drug|PT010 Dose 1|PT010 Dose 1; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
1605161|NCT02197975|Drug|PT010 Dose 2|PT010 Dose 2; Budesonide, Glycopyrrolate, and Formoterol Fumarate (BGF) Inhalation Aerosol. Administered as 2 inhalations.
1605162|NCT02197975|Drug|Placebo MDI|Placebo MDI. Administered as 2 inhalations
1605163|NCT02197962|Device|Extracorporeal Radial shockwaves|Patients will receive 2,000 impulses of extracorporeal radial shockwaves or per week, with pressure of 2.5bar to 4.0bar, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
1605164|NCT02197962|Device|Placebo Radial Shockwaves|Patients will receive 2,000 impulses of placebo extracorporeal radial shockwaves per week, without any pressure, therefore no energy will be applied, at the frequency of 8Hz. The impulses will be applied at the most painful site of the knee joint interface on manual palpation, for three consecutive weeks.
1605165|NCT02197923|Procedure|Myometrial biopsy|transvaginal ultrasound guided biopsy of the myometria
1605166|NCT02197923|Procedure|endometrial biopsy|transcervical endometrial biopsy
2009814|NCT03169764|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
2009815|NCT03169764|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
1605169|NCT02197897|Drug|Tamoxifen Citrate|Single-center, two-stage phase-II clinical trial (Simon design)
1605170|NCT02197884|Drug|JNJ-54861911, 25 mg|JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9.
1605171|NCT02197884|Drug|Itraconazole 200 mg|Itraconazole 200 mg (2*100 mg capsule) orally once daily from Day 5 to Day 12.
1605172|NCT02197884|Drug|Clarithromycin 500 mg|Clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
1605173|NCT02197871|Dietary Supplement|enteral nutrition emulsion|The patient should drink the oral nutritional supplements according to the estimated energy intake and make a record everyday.The patients will be followed up regularly.
1605174|NCT02197845|Behavioral|Patient Navigator|A specially trained (SCD knowledgable) Patient Navigator will act as a liaison who assists participants in increasing adherence to HU through disease education, addressing barriers to care and improving adherence to HU. PN utilize various techniques geared toward the individual patients needs. Interventions utilized by a PN include improving disease management skills, educational materials about disease, HU adherence, motivational interviewing, care coordination and social support.
1605175|NCT02197845|Behavioral|Recruitment into Specialty Care|A specially trained (SCD knowledgeable) Patient Navigator will act as a liaison to participants in increasing adherence to Hydroxyurea. Interventions utilized by a PN include teaching disease management skills, addressing barriers to care, disease education, HU management, motivational interviewing, care coordination and social support.
1605176|NCT02197832|Procedure|Endometrial biopsy|The procedure was performed in a standard approach using a Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France). The pipelle catheter was introduced through the cervix up to the uterine fundus. The piston was drawn back to the end of the sheath to create a negative pressure. The sheath was rotated and moved back and forth between the fundus and internal os for at least 3-4 times before it was gently withdrawn.
1605177|NCT02197832|Procedure|control procedure|Using pipelle catheter without entering the uterine cavity.
1605178|NCT02197832|Device|Pipelle catheter (Pipelle de Cornier, Laboratoire C.C.D., France)|
1605179|NCT02197819|Device|Sling|
1605180|NCT02197819|Device|External Rotation Brace|
1605181|NCT02197806|Drug|AGN-199201|1 to 2 drops of AGN-199201 ophthalmic solution in the eye(s) as per protocol.
1605182|NCT02197806|Drug|AGN-190584|1 to 2 drops of AGN-190584 ophthalmic solution in the eye(s) as per protocol.
1605183|NCT02197806|Drug|AGN-199201 Vehicle|1 to 2 drops of AGN-199201 vehicle in the eye(s) as per protocol.
1605184|NCT02197793|Behavioral|Community Mobilization Program|
2009816|NCT03169764|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
2009817|NCT03169764|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
2009818|NCT03169764|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
2009819|NCT03169764|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
2009820|NCT03169764|Biological|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
2009821|NCT03169764|Drug|Lovaza|Omega-3-acid ethyl esters
2009822|NCT03169764|Radiation|Stereotactic Body Radiation Therapy|(SRBT)
2009823|NCT03169764|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL 15N72D:IL-15RαSu/IgG1 Fc complex]
2009824|NCT03169764|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen (CEA) vaccine
2009825|NCT03169764|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 (HER2) vaccine
2009826|NCT03169764|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
2009827|NCT03169764|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 (MUC1) vaccine
2009828|NCT03169764|Biological|GI-4000|Ras yeast vaccine
2009829|NCT03169764|Biological|GI-6207|CEA yeast vaccine
2009830|NCT03169764|Biological|GI-6301|Brachyury yeast vaccine
1605186|NCT02197754|Other|Controlled diet|"Volunteers will be provided a controlled diet during the entirety of the 10 week treatment period. Meals will be prepared using traditional American foods.
The controlled diet will include polyphenol-rich foods, including apples, berries, and green tea. A blend of multiple polyphenol-rich foods was chosen to investigate whole foods, multiple commodities, and multiple bioactives."
1605187|NCT02197741|Drug|opiate with bolus|
1605188|NCT02197728|Device|Use of the Colpo-Probe™ Vaginal Fornix Delineator or Hohl manipulator® during total laparoscopic hysterectomy|
2009831|NCT03169764|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
2009832|NCT03169738|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
2009833|NCT03169738|Biological|Bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) immunoglobulin (Ig) G1 monoclonal antibody
1605192|NCT02197702|Dietary Supplement|vitamin D|Two doses of cholecalciferol 100,000 unit (2 mL) given 3.5 months apart, once in the fall, once in the winter
1605193|NCT02197702|Dietary Supplement|placebo|Two doses of identical placebo (2 mL) given 3.5 months part, once in the fall, once in the winter
1605194|NCT02197689|Device|Personalized Medication Management Platform for SMS Reminder|The Personalized Medication Management Platform was developed by investigators that integrated with Hospital Information System (HIS) to collect the prescription information of patients and automatically send SMS to remind
1605195|NCT02197676|Drug|SGI-110 administration|"SGI-110 will be administered SC at 60 mg/m²/day x5 consecutive days for each cycle. Cycle duration is 28 days. Patients with Complete Remission (CR), Partial Remission (PR), marrow CR or Hematological Improvement (HI) after 6 Cycles of therapy (IWG 2006 criteria) may continue treatment until progression.
A dose reduction to 45 and even 30 mg/m²/day will be made in case of haematological toxicity. Patients with no response (NR) to treatment will be withdrawn from the protocol after the last treatment Cycle."
1605196|NCT02197663|Procedure|acupuncture(44mm in length and 32-gauge)|"The whole course of the acupuncture contains 24times(about 3 months). The acupoints are fixed and located over head and limbs.
The whole course of the sham acupuncture contains 24times(about 3 months). The acupoints are fixed and 1cm away from meridian and no acupoints over head were chosen."
1605197|NCT02197650|Drug|suspension of erythrocytes encapsulating L-asparaginase|Erythrocytes encapsulating L-asparaginase
1605198|NCT02197637|Drug|ORAL VINORELBINE|Orally vinorelbine 60 mg/m2 D1, 8 and 15 Cycle of 28 days For a maximum of 12 cycles The dose of vinorelbine should be increased to 80 mg/m2 from the 2nd cycle If on D8 and D15, the administration conditions are not met, the administration is canceled and not delayed.
1605199|NCT02197598|Drug|nalmefene|
1605200|NCT02197585|Procedure|Inguinal mesh hernioplasty|
1605201|NCT02197572|Drug|MLN0128|MLN0128 capsules
1605202|NCT02197559|Procedure|DES group|all the participants in this group will be performed with drug -eluting stents
1605203|NCT02197559|Procedure|BMS group|all the participants in this group will be performed with bare-metal stents
1605204|NCT02197546|Other|Acupuncture & acupressure|Bilateral acupuncture with indwelling fixed needles 1.5 mm length with subsequent acupressure by the parents
1605205|NCT02197533|Other|Written List|Written list of seven management strategies for OAB to be produced during verbal discussion about management.
1605206|NCT02197520|Drug|Insulin Peglispro|Administered subcutaneously
1605207|NCT02197520|Drug|Insulin Glargine|Administered subcutaneously
1605208|NCT02197520|Drug|Insulin Lispro|Administered subcutaneously
1605209|NCT02197507|Device|Digitized sensor|Measure of grip strength of the dominant hand
1605210|NCT02197494|Drug|Valsartan|320mg tablets
2009834|NCT03169738|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
2009835|NCT03169738|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
1605213|NCT02197455|Drug|Tofacitinib Administration|5 mg of Tofacitinib will be taken by mouth twice daily for 3 months.
1605214|NCT02197442|Drug|Valsartan|
1605215|NCT02197429|Other|Acupuncture|
2009836|NCT03169738|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
1605217|NCT02197403|Drug|Dexmedetomidine|200mcg in 50mL of normal saline 0.75mcg/Kg bolus injection in 10 minutes 0.1~1.0mcg/Kg infusion
1605218|NCT02197403|Drug|Propofol|25~75mcg/kg/min continuous infusion
1605219|NCT02197390|Behavioral|Family wellness workshops|Nine family wellness workshops and eight family physical activity sessions facilitated by community health workers.
1605220|NCT02197390|Behavioral|Obesity chronic care model|
1605221|NCT02197390|Behavioral|Physical activity, healthy eating, water drinking, healthy sleep promotion|
1605222|NCT02197390|Behavioral|Environment, policy, systems changes in clinic setting only|
1605223|NCT02197390|Behavioral|No intervention|No intervention.
1605224|NCT02197390|Behavioral|Environment, policy, and systems changes in schools, early child care education & recreation|
2009837|NCT03169738|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
1605227|NCT02197351|Procedure|White light biopsy|Endoscopy with biopsies guided by high definition white light
1605228|NCT02197351|Procedure|Protocolled|Upper Endoscopy with Protocolled Biopsy (i.e. biopsy by predetermined guideline not influenced by white light or narrow band imaging findings)
1605229|NCT02197351|Procedure|Narrow Band Imaging Guided Biopsy|Upper Endoscopy with biopsy guided by narrow and imaging
1605230|NCT02197338|Other|Bile Duct Cannulation|Initial bile duct cannulation (first 8 attempts) will be made in each subject using one of the four cannulation strategies described in the 4 arms. The arm for each subject will be assigned by randomziation.
1605231|NCT02197325|Device|PICSO|Pressure controlled Intermittent Coronary Pressure Occlusion
1605232|NCT02197312|Device|NobelProcera Bridge Shaded Zirconia|
1605233|NCT02197299|Dietary Supplement|L-carnitine|
1605234|NCT02197299|Dietary Supplement|Placebo|
1605235|NCT02197286|Drug|Cholecalciferol|One capsule containing 4,000 IU of Cholecalciferol, per day
1605236|NCT02197286|Drug|Placebo|Daily dose of a single gelatin placebo capsule.
1605237|NCT02197273|Drug|Liposomal bupivacaine|
1605238|NCT02197273|Drug|Standard of care analgesia|
2009838|NCT03169738|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
2009839|NCT03169738|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5- formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
1605245|NCT02197234|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
1605246|NCT02197234|Drug|Simvastatin|Simvastatin (CYP substrate) 40mg taken once daily on Days 1 and 31 (Part A)
1605247|NCT02197234|Drug|AZD9291 tablet dosing|AZD9291 80mg tablet taken from Days 3 to 32. (Part B) AZD9291 80mg tablet taken daily for 12 months.
1605248|NCT02197234|Procedure|Pharmacokinetic sampling - simvastatin|Blood sampling to measure simvastatin levels
1605249|NCT02197234|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
1605250|NCT02197221|Drug|Bortezomib-Melphalan|Bortezomib will be administered on days: -6, -3, +1, +4. Melphalan will be administered on day -2. The PBSC will be injected on day 0.
1605251|NCT02197221|Drug|Melphalan|Melphalan will be administered on day -2. The PBSC will be injected on day 0.
1605252|NCT02197208|Procedure|Daily monitoring of LH and E2|ultrasound scanning would be carried out from 18 days before the expected period to confirm follicular growth, followed by daily blood monitoring of serum E2 and LH levels when the dominant follicle reaches 13-14mm in diameter. Ultrasound scanning can be arranged accordingly if the leading follicle remains less than 10mm in diameter. 5 ml of blood would be taken daily. LH surge is defined as the LH level being double of the average of the previous three days and higher than 20 IU/L. Ultrasound examination will be performed on the next day after the LH surge to measure the endometrial thickness. The transfer will be scheduled three or four days after the LH surge (for cleavage stage embryos) or six days after LH surge (for blastocyst transfer).
1605253|NCT02197208|Procedure|hCG induced natural cycle|ultrasound monitoring would be started from 18 days before the expected period to monitor follicular growth, followed by USG every 2-3 days. hCG, 5,000-10,000 IU will be given when the leading follicle is >/= 17 mm and the endometrium measures >/=8 mm. Serum E2, LH and progesterone levels will be measured on the day of hCG. Embryo transfer would be scheduled on the fourth or fifth days after hCG injection (for cleavage stage embryos) or seventh days (for blastocyst transfer).
1605254|NCT02197208|Device|ultrasound|
1605255|NCT02197195|Dietary Supplement|Chocolate Milk|
1605256|NCT02197195|Dietary Supplement|Fruit Drink|
1605257|NCT02197195|Behavioral|Exercise|
1605258|NCT02197182|Drug|LUXSOL copper containing cream|Active comparator arm
1605259|NCT02197182|Drug|Metronidazole gel|Active comparator for treatment of bacterial vaginosis
1605260|NCT02197169|Drug|Single intratumoral injection of DNX-2401|"In the randomized group, following brain tumor biopsy and histological confirmation of recurrent glioblastoma/gliosarcoma, a single injection of DNX-2401 was administered directly into the brain tumor with or without subsequent interferon gamma (IFN-γ)
No additional subjects will be randomized. A single intratumoral dose of DNX-2401 will be delivered by cannula."
1605261|NCT02197169|Drug|Interferon-gamma|In the randomized group, a single injection of DNX-2401 was followed by interferon gamma (IFN-γ). No additional subjects will be randomized or receive IFN-γ following DNX-2401
1605262|NCT02197156|Drug|10 mg HC-ER|Single dose
1605263|NCT02197156|Drug|20 mg HC-ER|Single dose
1605264|NCT02197156|Drug|30 mg HC-ER|Single dose
1605265|NCT02197156|Drug|40 mg HC-ER|Single dose
1605266|NCT02197156|Drug|10 mg HC / 325 mg APAP|Single dose
1605267|NCT02197156|Drug|Matching Placebo|Single dose
1605268|NCT02197143|Drug|esomeprazole|40 mg esomeprazole in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
1605269|NCT02197143|Drug|Ranitidine|50mg Ranitidine in 150 ml normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
1605270|NCT02197143|Drug|hydrotalcid|150 ml only normal saline given as a slow intravenous infusion over 15 minutes and p.o. 10ml Hydrotalcid
2009840|NCT03169738|Drug|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11- en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
2009841|NCT03169738|Biological|nivolumab|Human anti-PD-1 IgG4 kappa monoclonal antibody
2009842|NCT03169738|Drug|Lovaza|Omega-3-acid ethyl esters
1605274|NCT02197117|Device|Remote ischemic conditioning|
1605275|NCT02197117|Device|Control|
1605276|NCT02197104|Drug|citocoline|
1605277|NCT02197091|Other|questionnaire administration|Ancillary studies
1605278|NCT02197091|Other|medical chart review|Ancillary studies
1605279|NCT02197065|Drug|Atorvastatin|Atorvastatin or placebo will be started at least 4 hours prior to surgery, and continued nightly until postoperative day 45
1605280|NCT02197065|Drug|Placebo|
1605281|NCT02197039|Drug|esomeprazole or pantoprazole|Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis is achieved spontaneously or by gastroscopy. Patients then receive a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Because of concern for patient safety with certain drug-drug interactions, patients who take clopidogrel receive intravenous pantoprazole (Pantoloc®, Takeda, Singen, Germany), including an 80 mg loading dose and a 3-day continuous high-dose (8 mg/h) of infusion.
1605282|NCT02197039|Procedure|Endoscopic hemostasis|At the index gastroscopy, bleeding ulcers are checked. If the adherent clot is found over the ulcer base, it will be vigorously washed away with water jet. All of the stigmata of recent hemorrhage (SRH) are treated by one or a combination of endoscopic therapies including local injection of diluted epinephrine 1:10000, bipolar heated probe at 20 J per goal consecutively until achievement of coaptive coagulation, argon plasma coagulation, band ligation, or hemoclip therapy. The success of endoscopic hemostasis is defined as cessation of bleeding together with achievement of cavitation at the vessel after application of the heater probe.
1605283|NCT02197026|Drug|Hylan G-F 20|
1605284|NCT02197026|Drug|Standard treatment|Standard drug treatment at the discretion of the investigator
2009843|NCT03169738|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
2009844|NCT03169738|Radiation|Stereotactic Body Radiation Therapy|(SRBT)
2009845|NCT03169738|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex [also known as IL15N72D:IL-15RαSu/IgG1 Fc complex]
2009846|NCT03169738|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
1605288|NCT02196987|Other|Urination during urethral catheterisation|Requesting the patient to urinate while inserting urethral catheter
1605289|NCT02196987|Other|Urethral catheterisation, without further guidance|Lying, inserting urethral catheter, without further guidance from health care professional
1605290|NCT02196974|Procedure|cryobiopsy|
1605291|NCT02196961|Drug|Ipilimumab|adjuvant treatment of completely resected Merkel cell carcinoma
1605292|NCT02196961|Drug|Nivolumab|adjuvant treatment of completely resected Merkel cell carcinoma
1605293|NCT02196948|Other|Electrolysis Percutaneous Therapeutic (EPTE)|
1605294|NCT02196948|Other|Eccentric exercise|
1605295|NCT02196935|Other|clinical course|Detailed presentation including labs, demographics, imaging of those who undergo ERCP/EUS with be prospectively recorded. Details of procedure including sedation strategy and success will be collected. Results of procedure including final pathology results with be recorded.
2009847|NCT03169738|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
2009848|NCT03169738|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
2009849|NCT03169738|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
2009850|NCT03169738|Biological|GI-4000|Ras yeast vaccine
2009851|NCT03169738|Biological|GI-6207|CEA yeast vaccine
1605301|NCT02196896|Other|deprexis®|Online self-help program in addition to inpatient psychosomatic treatment for 90 days.
1605302|NCT02196896|Other|Information|The patients receive online information about depression once a week for 90 days.
1605303|NCT02196883|Procedure|Transforaminal Epidural Steroid Injection|
1605304|NCT02196857|Drug|Azacytidine|75 mg/m2 administered subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 for a 28 day cycle.
1605305|NCT02196857|Drug|Sorafenib|400 mg by mouth twice daily about 12 hours apart, every day for a 28 day cycle.
1605306|NCT02196844|Behavioral|Hatha Yoga|5-6 weeks of a couple-based yoga program, three sessions per week (up to 15 sessions) during radiation treatment.
1605307|NCT02196844|Behavioral|Questionnaires|10 questionnaires completed before first radiation treatment, each week during radiation, 5 questionnaires halfway through radiation treatment schedule. at radiation treatment completion, and again 3 months later.
1605308|NCT02196844|Other|Walk Test|6-minute walk test performed at baseline, at the end of radiation therapy, and 3 months after radiation therapy.
1605309|NCT02196831|Drug|tesamorelin|
1605310|NCT02196831|Drug|Placebo|inactive substance that looks like tesamorelin
1605311|NCT02196818|Device|Mpact Acetabular Shell|Total Hip Replacement
1605312|NCT02196805|Drug|Group A: imported Probucol ( Lorelco)|Group A: take imported Probucol( Lorelco) (250mg/tablet), Qd, P.O.
1605313|NCT02196805|Drug|Group B: Marketed Probucol ( Chang Tai)|Group B: take Marketed Probucol(Chang Tai)(250mg/tablet), Qd, P.O.
1605314|NCT02196792|Device|E-Poly liner|E-Poly liner with a titanium cup
1605315|NCT02196792|Device|ArComXL liner|ArComXL liner with a titanium cup
1605316|NCT02196792|Device|32 mm femoral head|Stem with a 32 mm CoCr femoral head
1605317|NCT02196792|Device|36 mm femoral head|Stem with a 36 mm CoCr femoral head
1605318|NCT02196766|Other|Bioclean First Care EX / comfilcon A|Subjects dispensed Bioclean First Care EX / comfilcon A combination then crossed over to the alternate combination.
1605319|NCT02196766|Other|Aosept Clearcare / comfilcon A|Subjects dispensed Aosept Clearcare / comfilcon A combination then crossed over to the alternate combination.
1605320|NCT02196753|Other|PET CT|"All patients are examined by a physicians before PET CT and if there are no contraindications they are given isotope intravenously. Then they stay in a warm waiting room. The dose of 18-FDG depends on patient`s weight and varies from 270 to 420 MBq. Isotope uptake time is about 45-180 minutes. After that time the patient is asked to empty his or her bladder and go to the examination room. First CT scan lasting 2 min is performed followed by the PET scan lasting about 20 min. Usually area from mid tigh to eye level is scanned.
In PET we use iterative reconstruction method (number of subsets 28, number of iterations 2), time of acquisition in one position of a table - 2 minutes. The following parameters will be analyzed: standardized uptake value (SUV) in the CIED area (pocket, leads), SUV of vascular background - pulmonary trunk, SUV of a liver, SUV max. in other potential changed areas, volume with increased SUV> 40% of the background."
1605321|NCT02196740|Drug|Metronidazole-Ciprofloxacin gatifloxacin-Clindamycin paste|Pulp removal,Root canal irrigation and disinfection,
1605322|NCT02196740|Drug|creosote|Pulp removal,Root canal irrigation and disinfection
1605323|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 1|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 1; PT003 administered as 2 inhalations twice-daily (BID)
1605324|NCT02196714|Drug|Glycopyrronium and Formoterol Fumarate (GFF) Dose 2|Glycopyrronium and Formoterol Fumarate metered-dose inhaler MDI (GFF MDI), Dose 2; PT003 administered as 2 inhalations twice-daily (BID)
1605325|NCT02196714|Drug|Glycopyrronium (GP) Dose 1|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 1; PT001 administered as 2 inhalations twice-daily (BID)
1605326|NCT02196714|Drug|Glycopyrronium (GP) Dose 2|Glycopyrronium metered-dose inhaler MDI (GP MDI), Dose 2; PT001 administered as 2 inhalations twice-daily (BID)
1605327|NCT02196701|Drug|Adalimumab|
1605328|NCT02196701|Drug|Methotrexate|
1605329|NCT02196688|Drug|fruquintinib|fruquintinib is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
1605330|NCT02196688|Drug|placebo|Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
1605331|NCT02196675|Device|Endocutter|The study utilized Echelon FlexTM Powered ENDOPATH® Stapler (Ethicon, Cincinnati, USA) along with compatible cartridges: Gray (closed staple height, 0.75mm), White (1.0mm), Blue (1.5mm), Gold (1.8mm), Green (2.0mm), and Black (2.3mm).
1605332|NCT02196662|Drug|IBD98-M:|single adiministration
1605333|NCT02196662|Drug|IBD98-M without HA|single adiministration
1605334|NCT02196662|Drug|Delzicol|single adiministration
1605335|NCT02196649|Device|Endoscopic Clip|
2009852|NCT03169738|Biological|GI-6301|Brachyury yeast vaccine
2009853|NCT03169738|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
1605336|NCT02196636|Drug|Placebo|Matching placebo, administered orally with approximately 240 mL of buffer
1605337|NCT02196636|Drug|RO6806127|Administered orally with approximately 240 mL of buffer
1605338|NCT02196623|Other|Hypoxic exercise|Supervised, progressive aerobic exercise program for 8 weeks under hypoxic conditions
1605339|NCT02196623|Other|Normoxic Exercise|Supervised, progressive aerobic exercise program for 8 weeks under normoxic conditions
1605340|NCT02196610|Other|Applanation tonometry|Two consecutive sets of carotid-femoral Pulse Wave Velocity (PWV) measurements by Applanation tonometry with a time-interval of 1 week will be obtained (1 week ± 2 days). Two research assistants will each perform a carotid-femoral-PWV measurement at each time point with the testing order randomized.
1605341|NCT02196571|Other|Structured Exercise|
1605342|NCT02196558|Drug|E6011|
1605343|NCT02196545|Behavioral|Exercise|
1605344|NCT02196532|Device|Device: Optical coherence tomography|
1605345|NCT02196519|Device|Sylys Surgical Sealant|
2009854|NCT03169556|Device|Video-laryngoscope guided lightwand|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. For intubation, video-laryngoscope is inserted into the oral cavity ntil the epiglottis tip was visible without lifting the epiglottic vallecula. Then, the endotracheal tube with lightwand is inserted toward the midline under the epiglottis and the intubation is performed looking the transilluminated light of lightwand.
2009855|NCT03169556|Device|lightwand alone|After anesthetic induction,the difficult airway is simulated by wearing a semi-hard neck collar. Then, the endotracheal tube with lightwand is inserted and the intubation is performed with conventional method (blind technique by confirming transillumination).
1605348|NCT02196493|Drug|Azithromycin|250mg azithromycin three times per week for 12 weeks
1605349|NCT02196480|Biological|anti-TNF|Anti-tumor necrosis factor therapy
1605350|NCT02196467|Biological|Myoblast transplantation|30 million myoblasts will be transplanted per centimeter cube in the Extensor carpi radialis of one of the patient's forearm, resuspended in saline (a total of 0.5 ml of suspension per centimetre cube of muscle).
1605351|NCT02196467|Procedure|Saline injection|A saline solution (the same used to resuspend de myoblasts in the first intervention) will be injected similarly in the Extensor carpi radialis of the contralateral patient's forearm (a total of 0.5 ml of saline per centimetre cube of muscle).
1605352|NCT02196454|Other|Educational Video with Male or Female Narrator|Participants will watch an educational video about the quadrivalent HPV vaccine (Gardasil) narrated by either a male or female.
1605353|NCT02196441|Drug|2% tetracaine local anaesthetic drops|topical anaesthetic drops
1605354|NCT02196441|Drug|0.5% bupivacaine|was performed using two sponges (2x3mm) soaked with 0.5% bupivacaine, applied deep in the conjunctival fornices after anaesthetising the conjunctiva with tetracaine local anaesthetic drops. The sponges were removed after 15 minutes. The anaesthetic effect was tested by grasping the limbus with Castroviejo 0.12 tissue forceps.
1605355|NCT02196428|Other|Telemonitoring and Teleconsultation|The interventions of this study are supported by a so-called Ambient Assisted Living Wizard (AAL Wizard). This is an IHE-compliant documentation and communication platform with an integrated electronic health record, which enables the study participants (elderly) to manage and store their relevant health data. It includes personal master data and the documentation of telemonitoring data. Additionally, the AAL-Wizard provides the communication modules such as telephone -, video- and time- and online consultation. The tele doctor assess the data (eg, vital signs and content of the medical teleconsultation) and collaborates in this way with the older person, family physicians and other health care providers based on an innovative and flexible telemedical home care service.
2009856|NCT03169790|Biological|avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
1605357|NCT02196389|Device|Nasal dilator Nasanita|Nasal Dilator
1605358|NCT02196389|Device|Nasal dilator Nozovent|
1605359|NCT02196389|Device|Nasal dilator Breath Right|
1605360|NCT02196389|Device|Nasal dilator Airmax|
1605361|NCT02196376|Other|History|the physician / PI will conduct a history that may include: demographics Framingham risk factors metabolic diseases inflammatory diseases autoimmune disorders review of medications date of last menstrual period (females) family history of autonomic disorders Onset of postural orthostatic tachycardia syndrome
1605362|NCT02196376|Other|Physical|"the physical exam will include: height weight orthostatic vitals (heart rate and blood pressure), supine and standing for up to 10 minutes.
Beighton Criteria for Join Hypermobility Syndrome Dependent acrocyanosis"
1605363|NCT02196376|Other|blood draw|"blood will be drawn for: antibodies regulating cardiovascular function inflammatory markers
no more than 15 ml (1 TBSP) will be drawn."
1605364|NCT02196376|Behavioral|Questionnaires|"The questionnaires will be completed directly online (web-based interface) using a personalized link that will be provided to the subjects after they give their informed consent. These will be created in a REDCap-Survey environment, with the data collected and stored on a password-protected, HIPAA-compliant, secure computer server.
The following questionnaires will be conducted:
RAND-36 Health Thermometer Chalder Fatigue Scale Daily diary of Fatigue Symptoms - Fibromyalgia Pain Detect Questionnaire Orthostatic Grading Scale COMPASS-31"
1605368|NCT02196324|Drug|serlopitant|NK1 receptor antagonist
1605369|NCT02196324|Drug|Placebo|Placebo
1605370|NCT02196298|Device|Lokomat|16 sessions in total, 30 minutes each plus set-up time followed by 5 minutes of overground walking. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
1605371|NCT02196298|Other|Physiotherapy|16 sessions, 35 minutes. Provided by study PT twice weekly for a period of 8 weeks to maximum of 10 weeks.
1605372|NCT02196285|Biological|Double viral (MR) vaccine|Measles and Rubella vaccine, as single arm
1605373|NCT02196272|Behavioral|Nurse-led reminder program through email|"Both groups will receive an educational program and usual care. The educational program will consist of:
- 1-hour session, during which the NCM give advices and enphasize the importance of the correct procedure of glycemic control, report non-pharmacological strategies for a healty lifestyle and instruction on how to fill a self assessment form."
1605374|NCT02196259|Drug|Anesthetics, Dissociative|The subject will receive intravenous anesthesia at a dose of 0.5mg/kg delivered over 40 minutes in a constant infusion or bolus plus infusion method to maintain steady state (10 minutes initial induction, 30 minutes steady-state, for 40 minutes total)
1605375|NCT02196207|Drug|Long-acting recombinant factor VIII Fc fusion protein|Eloctate (50 IU/kg weekly) will be administered prophylactically in previously untreated children with severe hemophilia A before the first bleed.
1605376|NCT02196194|Drug|Tiotropium|
2009857|NCT03169790|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
2009858|NCT03169790|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
2009859|NCT03169790|Drug|cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
1605380|NCT02196168|Drug|Cisplatin|Given IV
1605381|NCT02196168|Other|Laboratory Biomarker Analysis|Correlative studies
1605382|NCT02196168|Other|Pharmacological Study|Correlative studies
1605383|NCT02196168|Other|Placebo|Given PO
1605384|NCT02196168|Drug|WEE1 Inhibitor AZD1775|Given PO
1605385|NCT02196155|Drug|Botulinum toxin A|"Researchers discovered in the 1950s that injecting overactive muscles with minute quantities of botulinum toxin type-A would result in decreased muscle activity. Botulinum toxin type-A has this effect because it prevents the vesicle where the acetylcholine is stored from binding to the membrane where the neurotransmitter can be released. Botulinum toxin type-A thus blocks the release of acetylcholine by the neuron. This will effectively weaken the muscle for a period of three to four months.
In addition to its cosmetic applications, Botox is currently used in the treatment of spasms and dystonias, by weakening involved muscles, for the 60-70 day effective period of the drug. The main conditions treated with botulinum toxin are: Cervical dystonia (spasmodic torticollis) (a neuromuscular disorder involving the head and neck), Blepharospasm (excessive blinking) etc.."
1605386|NCT02196155|Drug|cortisone|
1605387|NCT02196155|Drug|Saline|
1605388|NCT02196142|Drug|Cortisol 20mg|Drug: Cortisol 20mg
1605389|NCT02196142|Drug|Placebo Mannitol|Drug: Placebo Mannitol
1605390|NCT02196129|Drug|Sinbaro-3|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
1605391|NCT02196129|Drug|Hwangryun|1cc administered to site of pain(ashi acupoints), once and once only before any other intervention/if pain in both low back and extermities, the site of most pain
1605392|NCT02196116|Other|PET|PET Scan with [18F]-Flutemetamol
1605393|NCT02196116|Other|MRI|
1605394|NCT02196116|Other|neuropsychological tests|
1605395|NCT02196103|Device|Double balloon cervical catheter|
1605396|NCT02196090|Behavioral|Exposure and Response Prevention|A procedure where patients with OCD test out their fears without responding by compulsive act.
1605397|NCT02196090|Device|Cold face gel mask|Temporary application of cold eye mask on the face is commonly used for relaxation purpose.
1605398|NCT02196077|Drug|BFF MDI 320/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 320/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
1605399|NCT02196077|Drug|BFF MDI 160/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 160/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
1605400|NCT02196077|Drug|BFF MDI 80/9.6 μg|Budesonide and formoterol fumarate metered dose inhaler (BFF MDI) 80/9.6 μg; PT009 administered as 2 inhalations, twice daily (BID)
1605401|NCT02196077|Drug|BD MDI 320 μg|Budesonide metered dose inhaler (BD MDI) 320 μg; PT008 administered as 2 inhalations, twice daily (BID)
1605402|NCT02196077|Drug|FF MDI 9.6 μg|Formoterol fumarate metered dose inhaler (FF MDI) 9.6 μg; PT005 administered as 2 inhalations, twice daily (BID)
1605404|NCT02196038|Behavioral|multi-domain rehabilitation intervention|Individual, tailored, progressive physical function rehabilitation intervention
1605405|NCT02196038|Behavioral|Attention Control|Usual care with bi-weekly contact from study staff
1605406|NCT02196025|Device|Transcranial magnetic stimulation|Patients will receive sequential bilateral bifrontal low frequency TMS stimulation daily on weekdays for three weeks. In addition, a Pittsburgh Sleep Quality Index (PSQI), Insomnia severity rating index, Montgomery Asberg Depression Rating Scale, and a sleep diary will be kept.
1605407|NCT02196012|Behavioral|Intervention group|
1605408|NCT02196012|Behavioral|attention control condition|
1605409|NCT02195999|Other|Magnetic Resonance Imaging (MRI)|It is a non-invasive method to determine ventricular size, volumes, mass, and ejection fraction.
1605410|NCT02195999|Other|Pulmonary Function Testing (PFT)|It is non-invasive breathing tests that characterize respiratory muscle function, as well as lung compliance and physiology.
1605411|NCT02195999|Other|Metabolic Exercise Testing using stationary bicycle|Metabolic exercise testing, including assessment of exercise capacity and MVO2, evaluates global cardiopulmonary functional status. This is performed with the use of a stationary bicycle.
1605412|NCT02195999|Other|Echocardiogram|The echocardiogram performed with the multiple-echo Dixon method helps to assess participants cross-sectionally and longitudinally for variations and changes in myocardial structure.
1605413|NCT02195986|Drug|Estradiol Vaginal Cream, 0.01%|Estradiol Vaginal Cream, 0.01% (1 x 2g for 7 days)
1605414|NCT02195986|Drug|Estrace® 0.01% cream|Estrace® 0.01% vaginal cream ( 1 x 2g for 7 days)
1605415|NCT02195986|Drug|Placebo Vaginal Cream|Placebo Vaginal Cream ( 1 x 2 g for 7 days)
1605416|NCT02195973|Drug|LDE225|After six cycles of weekly paclitaxel and LDE225, patients with a clinically beneficial response may be continued on weekly paclitaxel alone until disease progression.
1605417|NCT02195960|Dietary Supplement|Placebo|intake corn extract poor in anthocyanins: three daily stick packs containing water-soluble extract from corn cobs poor in anthocyanins
1605418|NCT02195960|Dietary Supplement|intake anthocyanin-rich corn extract|intake anthocyanin-rich corn extract: three daily stick packs containing water-soluble extract from high-anthocyanin rich corn cobs
1605419|NCT02195947|Drug|Growth Hormone|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
1605420|NCT02195934|Other|Standard (blonde) orange juice|Consumption of 500ml standard (blonde) orange juice daily for 28 days
1605421|NCT02195934|Other|Blood orange juice|Consumption of 500ml blood orange juice daily for 28 days
1605422|NCT02195921|Other|single point Neiguan(CV12) plus antiemetic drug|
1605423|NCT02195921|Other|single point Zusanli(ST36) plus antiemetic drug|
1605424|NCT02195921|Other|matching points Zusanli(ST36)and Neiguan(CV12) plus antiemetic drug|
1605428|NCT02195908|Other|matching points Neiguan(PC6) and Zhongwan(CV12) plus antiemetic drug|
1605429|NCT02195908|Drug|only antiemetic drug|
1605430|NCT02195895|Drug|Alendronate|Weekly oral alendronate 70 mg for 12 months
1605431|NCT02195895|Dietary Supplement|Calcium|1000 mg Calcium PO QD
1605432|NCT02195895|Dietary Supplement|Vitamin D|1000 IU PO QD
1605433|NCT02195882|Procedure|Exercise program of the scapular muscle stabilizers|
1605434|NCT02195869|Drug|Ibrutinib|
1605435|NCT02195856|Dietary Supplement|Beetroot juice|140mL concentrated Beetroot juice or placebo juice
1605436|NCT02195856|Dietary Supplement|Placebo|
1605437|NCT02195843|Other|Electrical optimization by RVLV Conduction Time with VectSelect|"VectSelect Quartet multivector testing is a programmer-based feature that provides centralized vector testing and programming with the flexibility to select the appropriate pacing vector to meet individual patient needs.
The Right ventricle - Left Ventricle (RV-LV) conduction time measurement will automatically identify the RV-LV conduction time for each LV electrode ."
1605438|NCT02195843|Other|Anatomical optimization of device and leads|Patients will be implanted with left ventricular leads which will be positioned most basal, most apical or midway in the left ventricle. This follows the physician's routine clinical practice and judgement.
1605439|NCT02195843|Device|Implanted device and lead (Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system)|All participants will be implanted with a St Jude Medical (SJM) Cardiac Resynchronization Therapy Defibrillator (CRT-D) device and SJM Quadripolar lead system. Patients who fulfill the criteria for CRT D implant, will be invited to participate in this clinical investigation. Patients implanted with chronic leads requiring device upgrade to CRT-D can also be enrolled in the study, provided they are receiving a CRT-D device for the first time.
1605440|NCT02195830|Other|Ultrasound of the inferior vena cava|B mode ultrasound of the inferior vena cava Measurements taken 2cm from the hepatic vein IVC junction or 3cm from the right atrium IVC junction
1605441|NCT02195817|Drug|Selincro® 18 mg with continuous psychosocial support: Cohort A|
1605442|NCT02195817|Other|Initial psychosocial support: Cohort B|
1605443|NCT02195804|Drug|Ranitidine hydrochloride ODT|Ranitidine hydrochloride ODT#1 150 mg (Vanilla-Mint)
1605444|NCT02195804|Drug|Ranitidine hydrochloride ODT RM|Ranitidine hydrochloride ODT Reduced Mannitol (RM) 150 mg Vanilla-Mint (ODT#2)
1605445|NCT02195804|Drug|Ranitidine hydrochloride|
1605446|NCT02195791|Drug|Pioglitazone|Pioglitazone 30mg/tab (oral) 1 tab once daily for 7 days
1605447|NCT02195791|Drug|Placebo|Placebo (oral) 1 tab once daily for 7 days
1605448|NCT02195765|Drug|enamel matrix derivative|Open flap debridement associated with enamel matrix derivative
1605449|NCT02195765|Procedure|Open flap debridement|Open flap debridement
1605450|NCT02195752|Other|Compounded Pain Cream|All patients will have been prescribed a topical pain cream prepared by a qualified compounding pharmacy
1605451|NCT02195726|Procedure|Remote ischemic preconditioning|four times 5-minute inflations of a blood pressure cuff to 200 mmHg around the upper non dominant arm (or if systolic pressure is more than 150 mmHg, inflation will reach 50 mmHg up per than baseline), followed by 5-minute intervals of reperfusion.
1605452|NCT02195726|Procedure|Sham remote ischemic preconditioning|In the control group sham preconditioning will be performed with inflation of 10 mmHg more than baseline.
1605453|NCT02195713|Device|Accuryn|Accuryn is a novel electronic urine output monitor
1605454|NCT02195700|Drug|SD-809|SD-809 tablets taken twice daily for 12 weeks, includes a dose titration period and maintenance period.
1605455|NCT02195700|Drug|Placebo|Placebo tablets taken twice daily for 12 weeks.
1605456|NCT02195687|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) injected into bilateral crow's feet line areas.
1605457|NCT02195687|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral Crow's Feet Line areas.
1605458|NCT02195661|Dietary Supplement|Melatonin|
1605459|NCT02195661|Drug|Chloral Hydrate|
1605460|NCT02195648|Other|Experimental: Treatment of sub-occipital muscle inhibition|"Experimental: Sub-occipital muscle inhibition
The intervention will last for 4 weeks with 2 days of treatment at week.
Each of the interventions will consist in application of sub-occipital muscle inhibition technique associated with interferential electrotherapy."
1605461|NCT02195635|Drug|Telotristat etiprate|500 mg telotristat etiprate
1605462|NCT02195635|Drug|Octreotide acetate|200 µg octreotide acetate three times daily
1605463|NCT02195622|Device|Lumenis VersaCut Morcellator|
1605464|NCT02195622|Device|Wolf Piranha Morcellator|
1605465|NCT02195609|Dietary Supplement|Omega-3|600 mg oral twice a day
1605466|NCT02195609|Dietary Supplement|Soy Isoflavones|54.4 mg oral twice a day
1605467|NCT02195596|Other|High intensity aerobic exercise+strength|"The program consist in a Continuous High aerobic exercise and moderate intensity intervals (ShoshanaB et al, 2012) combined with muscular strength exercises and joint mobility. Patients come three times a week for six months to the primary health center and will be supervised by an expert nurse."
1605468|NCT02195596|Other|Low intensity aerobic exercise+strength|Low intensity aerobic exercise+strength program is similar to the other intervention but differs in the intensity of the exercise as it works with intensities below 40% of heart rate reserve.
1605469|NCT02195583|Drug|Sodium fluoride (1426 ppm)|Non-zinc, 1426ppm fluoride as sodium fluoride in a silica gel base
1605470|NCT02195583|Drug|Sodium fluoride (1150 ppm)|Non-zinc, 1150ppm fluoride as sodium fluoride in a silica gel base
1605471|NCT02195583|Drug|Sodium fluoride (250 ppm)|Non-zinc, 250ppm fluoride as sodium fluoride in a silica gel base
1605472|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base A|Zinc base A, 1426ppm fluoride as sodium fluoride in a silica gel base
1605473|NCT02195583|Drug|Sodium fluoride (1426 ppm) + zinc base B|Zinc base B, 1426ppm fluoride as sodium fluoride in a silica gel base
1605474|NCT02195583|Drug|Fluoride (0 ppm)|Non-zinc, 0ppm fluoride in a silica gel base
1605516|NCT02195219|Procedure|open reduction internal fixation|MINAR device allows for reduction of the acromioclavicular joint and the reconstruction of coracoclavicular ligaments with a suture cerclage system. Three weeks after surgery a rehabilitation program will be carried out.
2009860|NCT03169790|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
1605475|NCT02195570|Other|Quit Smoking Now (QSN)|"The Quit Smoking Now (QSN) program, offered by the Florida Area Health Education Center, was developed based on principles of the Centers for Disease Control and Prevention's Best Practices for Comprehensive Tobacco Control, and the U.S. Department of Health and Human Services' Treating Tobacco Use and Dependence Clinical Guidelines with an emphasis on reaching medically-underserved populations. The QSN curriculum will be delivered in 6 one-hour sessions . Pregnancy-specific session goals and content cover the effects of smoking on the developing fetus, secondhand smoke exposure, the importance of social support, and postpartum relapse."
1605476|NCT02195570|Behavioral|Prize-based Contingency Management (CM)|Women will earn chances to win prizes for biochemically verified abstinence from tobacco.
1605477|NCT02195557|Drug|Synvisc®|
1605478|NCT02195544|Drug|Synvisc®|
1605479|NCT02195531|Behavioral|Education and feedback|The education leaflets are information concerning OSA and CPAP treatment. The feedback reports are CPAP usage patterns.
2009861|NCT03169790|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
1605481|NCT02195492|Drug|Synvisc®|
2009862|NCT03169790|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
2009863|NCT03169790|Drug|Lovaza|Omega-3-acid ethyl esters
2009864|NCT03169790|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
2009865|NCT03169790|Drug|rituximab|Chimeric murine/human anti-CD20 monoclonal IgG1 kappa antibody
2009866|NCT03169790|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
1605487|NCT02195466|Drug|Tipranavir (TPV)|500 mg bid on days 7-14
1605488|NCT02195466|Drug|Ritonavir (RTV)|200 mg bid on days 7-14
1605489|NCT02195466|Drug|Fluconazole (FCZ)|200 mg loading dose on day 1, followed by 100 mg qd until day 13
1605490|NCT02195453|Drug|Yangzhengxiaoji Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m² IV drip on D1 and D8,21 days for a cycle.
Cisplatin 75mg/m² IV drip for one day or two-three days total injection,21 days for a cycle.
Yangzhengxiaoji Capsule four granules t.i.d po."
1605491|NCT02195453|Drug|Placebo Capsule|"Gemcitabine 1000mg/m² or Pemetrexed 500mg/m²IV drip on D1 and D8,21 days for a cycle.
Cisplatin 75mg/m² IV drip for one day or two-three days total injection, 21 days for a cycle.
Placebo Capsule four granules t.i.d po."
1605492|NCT02195440|Drug|PRI-724|10 - 160 mg/m2, 7 days CIV (in the vein) with 7 days rest per one cycle. Number of Cycles: 6.
1605493|NCT02195414|Device|NeoVas BCS|The NeoVas First-in-Man study is a prospective, two centers, single arm trial, which will enroll a total of 30 patients. The hypothesis of this study is to evaluate clinical feasibility, safety, and efficacy of NeoVas sirolimus-eluting bioresorbable coronary scaffold in the treatment of patients with de novo coronary lesion. The primary endpoint is a composite endpoint of cardiac death, target vessel related myocardial infarction, and ischemia driven target lesion revascularization (TLF) at 1 month follow up. At 6 months, 1, 2, 3, 4 and 5 years follow-up, clinical endpoints include TLF (its individual components), Patient-oriented cardiac event (all cause death, all MI, and all revascularization) target vessel revascularization, scaffold thrombosis.
1605494|NCT02195401|Other|Cleanroom|Cleanroom with air the quality of the pre-industrial age
1605495|NCT02195388|Other|comprehensive cardiac rehabilitation|Standard program of comprehensive cardiac rehabilitation CR with physical activity, behavioral intervention, risk factor modification and intervention.
1605496|NCT02195375|Drug|Flutiform 500/20 µg BID|
1605497|NCT02195375|Drug|Flutiform 250/10 µg BID|
1605498|NCT02195375|Drug|Seretide Accuhaler 50/500 µg BID|
1605499|NCT02195349|Biological|GSK2831781|GSK2831781 (100 milligram (mg)/mL) and its dilutions (Diluent - 0.9 percent saline solution containing 0.015 percent Polysorbate 80) as clear or opalescent, colourless, yellow to brown liquid solution administered by IV over approximately 2 hours.
1605500|NCT02195349|Biological|Placebo|Commercial saline solution administered by IV over approximately 2 hours
1605501|NCT02195336|Device|dMRT|Baseline, day 8, day 28, day 92, progression/relapse.
1605502|NCT02195336|Drug|Bevacizumab|7.5mg/kg every 3 weeks for 3 cycles. Thereafter every 3 weeks until progression/relapse or unacceptable toxicity.
1605503|NCT02195336|Drug|paclitaxel and carboplatin|Standard of care NSCLC first-line chemotherapy Every 3 weeks for 3 cycles. Doublets containing paclitaxel and carboplatin are preferred
1605504|NCT02195323|Biological|Intravenous injection|Intravenous injection of bone marrow derived MSC in patients with CKD.
1605505|NCT02195310|Device|Prevena™ Incision Management System|Prevena™ Incision Management System is used after sternotomy on the closed incision
1605506|NCT02195310|Device|Conventional sterile wound dressings|Conventional sterile wound dressings are placed after sternotomy on the closed incision
1605507|NCT02195297|Other|ANTICELLULITE GMG GIULIANI Cream and SOMATOLINE Cream|Products application: mono-laterally, once a day at evening (4 doses from each dispenser for the first 2 day-treatment and 2 doses for the following days)
2009867|NCT03169790|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
2009868|NCT03169790|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1[MUC1]
2009869|NCT03169790|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
2009870|NCT03168711|Drug|Inosine|Subjects on inosine will receive 1-6 capsules a day of 500 mg inosine titrated to target urate levels of 7 - 8 mg/dL.
1605512|NCT02195271|Device|Transcranial Direct Current Stimulation (tDCS)|
1605513|NCT02195271|Drug|Melatonin|
1605514|NCT02195245|Device|memsorb|
1605515|NCT02195232|Drug|Isoquercetin|
1605658|NCT02194179|Drug|NVP XR 400 mg (KCR 25%)|
2009871|NCT03168711|Drug|Placebo|Subjects on placebo will receive 1-6 capsules a day of 500 mg placebo (sugar pill) titrated to target urate levels of 7 - 8 mg/dL.
2009872|NCT03168308|Drug|Sugammadex|Sugammadex 2 mg/kg
2009873|NCT03168308|Drug|Neostigmine w/ Glycopyrrolate|Neostigmine 50 mcg/kg, maximum 5 mg Glycopyrrolate, 8 mcg/kg, maximum 1 mg
2009874|NCT03168243|Dietary Supplement|High Energy High Protein Tube Feed|Following a 3 day baseline period all patients will receive the high energy, high protein tube feed for a period of 4 weeks (28 days).
1605517|NCT02195219|Other|sling rest and early functional recovery|Immobilization with a sling for three weeks and, from this time, the same rehabilitation program will be performed.
1605518|NCT02195193|Other|Integrated care model for ACS and depression|an integrated care model for ACS and depression delivered by a collaborative team composed of cardiologists/internists and nurses in the same rural county hospital. The collaborative team will be able to provide medical services for the diagnosis and treatment at acute phase of ACS during hospitalization, ACS secondary prevention therapies at and after discharge, and screening and treatment of depression depressive symptom during hospitalization and after discharge. The core of the interventions includes: depressidepressive symptomon screening and classification, individual counseling and medical treatment of depression, group counseling and health education, and follow-up for ACS and depression treatments compliance, IT- system- assisting theassisted management and necessary referral.
1605519|NCT02195180|Drug|ERY001|
1605520|NCT02195180|Drug|Gemcitabine|
1605521|NCT02195180|Drug|5-fluoro-uracil/oxaliplatin/leucovorin (folfox)|oxaliplatin 85 mg/m2 levo-leucovorin 200 mg/m2 5-FU 400 mg/m2
1605522|NCT02195167|Drug|Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily|"Dasotraline 1 mg, 2 mg, 4 mg, 8 mg, 12 mg, 16 mg, 20 mg, 24 mg, 28 mg, 32 mg once daily. The planned dose for the first cohort is 1mg. There will be no more than a 2-fold increase in dose increase in dose between consecutive dose cohorts up to 8 mg, and dose cohorts beyond the 8 mg level will increment no more than 4mg. The maximum dose will not exceed 32mg. The language should precede the text that is currently there"
1605523|NCT02195154|Drug|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging. The compound is labeled with fluorine 18F that decays by positron (β+) emission and has a half life of 109.7 min. The principal photons useful for diagnostic imaging are the 511 keV gamma photons, resulting from the interaction of the emitted positron with an electron.
The proposed dose for this study is based on the phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
1605524|NCT02195141|Radiation|conventional fraction|capecitabine 825mg/m2 p.o. twice daily Radiotherapy 50Gy/25f
1605525|NCT02195141|Radiation|SIB|Concomitant chemoradiotherapy Radiotherapy with boost Radiotherapy (25 x 2 Gy), with a simultaneous integrated boost up to 56 Gy on the primary tumor capecitabine 825mg/m2 p.o. twice daily
1605526|NCT02195115|Procedure|Laparoscopic Cholecystectomy|
1605527|NCT02195115|Drug|amitriptyline|
1605528|NCT02195115|Other|low-fat and low cholesterol diet|
1605529|NCT02195102|Device|Transcatheter aortic valve Replacement|
1605530|NCT02195089|Drug|BLS_ILS_E710c 500mg|- 2 capsules per day for 20 days (week 1,2,4 & 8)
1605531|NCT02195089|Drug|BLS_ILB_710c 1000mg|- 4 capsules per day for 20 days (week 1,2,4 & 8)
1605532|NCT02195089|Drug|BLS_ILS_E710c 1500mg|- 6 capsules per day for 8 weeks (week 1,2,4 & 8)
1605533|NCT02195076|Other|non-invasive detection of cancer odor|The odor VOCs of the specimens will be subjected to our system for detection by the biosensors. If the sample is cancerous the biosensors will report it (YES signal). If the sample s not cancerous, the biosensors will not report it (NO signal).
1605534|NCT02195024|Procedure|cardiac MRI group|• All subjects of the MRI group will undergo a predefined series of magnetic resonance heart scans ≥ six (6) weeks after device exchange
1605535|NCT02195011|Device|SIR-Spheres|Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
1605536|NCT02195011|Drug|Regorafenib|All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
1605537|NCT02194998|Drug|Paritaprevir/ritonavir/ombitasvir (PTV/r/OBT)|PTV/r/OBT: 150/100/25 mg (two 75/50/12.5 mg fixed-dose combination tablets) orally once a day
1605538|NCT02194998|Drug|Dasabuvir (DSV)|DSV: 250 mg orally twice a day
1605539|NCT02194998|Drug|Ribavirin (RBV)|RBV: 1,000 or 1,200 mg (weight-based) dosed in two divided doses orally twice a day (participants with HCV genotype 1a only; participants with HCV genotype 1b will not receive RBV)
1605540|NCT02194985|Drug|migalastat HCl 150 mg|Capsule provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken or a punch-out reminder is used on the days between migalastat HCl.
1605541|NCT02194972|Drug|Pectin|pectin （Andeli Ltd. Yantai, China）, 24g/d for 4weeks
1605542|NCT02194959|Behavioral|Peer PN|Navigation by Peer Patient Navigators
1605543|NCT02194959|Behavioral|Pro PN|Navigation by Standard Hospital Navigators
1605544|NCT02194946|Drug|CM therapies|The choice of CM patterns will be at the treating physician's discretion. The dosing regimen of Chinese herbs and Chinese patent medicine will be as per the 2010 Chinese pharmacopoeia.The oral Chinese herbal formula will be composed of 18 herbs:Radix Astragali, Radix Codonopsis, Rhizoma Atractylodis Macrocephalae, Rhizoma diosscoreae, Poria, Semen Cuscutae, Radix Morindae Officinalis, Herba Epimedii, Herba Cistanches, Fructus Ligustri Lucidi, Rhizoma Polygonati, Fructus Amomi, Herba Agastaches, Rhizoma Coptidis, Radix et Rhizoma Rhei, Semen Coicis, Radix Salviae Miltiorrhizae, and stir-baked Semen Persicae. The Chinese herbal formula via Colonic administration will be composed of 3 herbs: Radix et Rhizoma Rhei, Calcined Concha Osterae, Herba Taraxaci.
1605545|NCT02194946|Drug|CKD-related management|Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
2009875|NCT03168204|Behavioral|Tailored care and support|Offering tailored care and support whereby the competences, strengths and resources of the older person are taken into account.The intervention will be an enhancement of usual care and will depend on the availability of the municipality, and could be formal (i.e., home care) or informal (e.g. activities of an older adult's association).
1605547|NCT02194920|Procedure|Thyroidectomy and parathyroid reimplantation in forearm subcutaneous tissue|
1605549|NCT02194894|Drug|Acetaminophen|acetaminophen will be given for patient for both arms for 14 days
1605550|NCT02194881|Drug|CF patients with a G551D mutation and treated with Ivacaftor|
1605659|NCT02194179|Drug|NVP XR 400 mg (KCR 20%)|
1605660|NCT02194179|Drug|NVP XR 300 mg (KCR 25%)|
1605661|NCT02194179|Drug|NVP XR 300 mg (KCR 20%)|
1605551|NCT02194868|Biological|Recipients|"Adult recipient:
collected 20 ml pre-transplant
collected 30 ml for adults on day 20 post-transplant at engraftment for cell phenotype,
collected 30 ml on days 30, 60, 90, 180, 360 days post-HSCT for cell phenotyping at all time points, functional INKT at day 60 or 90 depending on the number of cells collected and anti-viral ELISPOT studies on days 180 and 360
Children recipients
collected residual blood pre-transplant
collected residual blood on day 20 post-transplant at engraftment for cell phenotype,
collected residual blood on days 20, 30, 90, 180 and 360 post-HSCT"
1605552|NCT02194868|Biological|Donors|"Adult donors :
collected 20 ml of blood, (if possible before GCSF administration)
collected 1 ml of the stem cell graft for adult recipient or 2 ml of bone marrow for children recipients These samples will be collected at the same time of those needed for transplant.
Children donors samples
collected residual blood
2ml of bone marrow (bottom of tube)"
1605553|NCT02194855|Drug|rocuronium|Rocuronium 0.6 mg.kg-1 was administered within 5 s as an intravenous bolus
1605554|NCT02194855|Drug|cisatracurium|cisatracurium 0.15mg.kg-1 was administered within 5 s as an intravenous bolus
1605555|NCT02194842|Drug|Ra223|
1605556|NCT02194842|Drug|Enzalutamide|
1605557|NCT02194829|Drug|Gemcitabine Hydrochloride|Given IV
1605558|NCT02194829|Other|Laboratory Biomarker Analysis|Correlative studies
1605559|NCT02194829|Drug|Nab-paclitaxel|Given IV
1605560|NCT02194829|Other|Pharmacological Study|Correlative studies
1605561|NCT02194829|Other|Placebo|Given PO
1605562|NCT02194829|Drug|WEE1 Inhibitor AZD1775|Given PO
1605563|NCT02194790|Behavioral|Community-based Integrated CKD Care|Patients received, in addition to the standard care, educational activities provided by nutritionist, pharmacist and physiotherapist, and quarterly home visits. Our home visits team consisted of nurse, health care officers and village health volunteers
1605564|NCT02194777|Drug|BIBN 4096 BS - in single rising doses|
1605565|NCT02194777|Drug|Placebo|
1605566|NCT02194764|Drug|Naltrexone and 2-butanol|50mg of Naltrexone and 40 or 80 mg of 2-butanol (depending on Stability Formulation in the first part of the study)
1605567|NCT02194764|Drug|2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form)|a capsule-in-capsule (CIC) design, will be prepared in the pharmacy by incorporating 40 or 80 mg (determined from the first part of the study) of 2-butanol which is encapsulated (size 3 capsule) plus 50 mg of naltrexone (HCl form) in a size 0 double blind hard gel capsule.
1605568|NCT02194751|Biological|Oncoquest-L vaccine|Patients will receive a total of 5 single administrations of Oncoquest-L; the first 2 doses administered will be separated by a 2-week interval and the remaining 3 doses will be administered each at 1-month intervals. With each dose of Oncoquest-L vaccine, the vaccine will be administered subcutaneously at 2 different sites in the upper arms or upper legs, with alternation of the injection sites with each administration. For each vaccination, a total of 1.0 mL of vaccine will be administered, divided into 2 subcutaneous injections of 0.5 mL each at 2 different injection sites.
1605571|NCT02194712|Other|Urine CAA detection|In addition to routine diagnostics, serum and urine samples are stored for retrospective UCP-CAA antigen determination.
2009876|NCT03169777|Biological|avelumab|Fully human anti-programmed death-ligand 1 (PD-L1) immunoglobulin (Ig)G1 lambda monoclonal antibody
2009877|NCT03169777|Biological|bevacizumab|Recombinant human anti-vascular endothelial growth factor (VEGF) IgG1 monoclonal antibody
1605574|NCT02194686|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
1605575|NCT02194686|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
1605576|NCT02194673|Other|Trans free palm margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
1605577|NCT02194673|Other|Interesterified Palm based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
1605578|NCT02194673|Other|IE Soybean oil-based margarine|A randomised, double-blind crossover (3 × 3 arms) orthogonal Latin-square design was used and conducted on 10 males and 10 females adults.
1605579|NCT02194634|Drug|Conbercept|Intravitreal injection of 0.5 mg Conbercept at first month, then repeated as needed.
1605580|NCT02194634|Other|Sham injection|Sham intravitreal injection at first month, then repeated as needed.
1605581|NCT02194634|Procedure|Laser|Laser treatment at first month, then repeated as needed.
1605582|NCT02194634|Other|Sham laser|Sham laser at first month, then repeated as needed.
1605583|NCT02194621|Drug|Total Flavor option 1|Total toothpaste containing triclosan/copolymer/sodium fluoride with new OM complex 1 ingredient -Total Flavor Option 1
1605584|NCT02194621|Drug|Total Flavor option 2|Total toothpaste containing triclosan/copolymer/sodium fluoride and new OM complex 2 ingredient. Total Flavor option 2
1605585|NCT02194621|Drug|Placebo toothpaste: Crest Cavity Protection toothpaste|Placebo toothpaste: Crest Cavity Protection toothpaste w/sodium fluoride (currently marketed)
1605586|NCT02194608|Device|Home telehealth system|Participants will receive a weighing machine, glucometer, and a sphygmomanometer connected through a Bluetooth system from their home to the Telehealth center via a HUB.
1605587|NCT02194595|Drug|Basal insulin and exenatide|
1605588|NCT02194595|Drug|Basal insulin only|
1605589|NCT02194595|Drug|Basal insulin and bolus insulin|
1605590|NCT02194569|Drug|Citrate|
1605591|NCT02194556|Drug|Sequential and maintenance icotinib|Patients are administered with sequential and maintenance icotinib plus chemotherapy. Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1, sequential icotinib 125 mg is administered orally three times per day at d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib until disease progression or intolerable toxicity.
1605592|NCT02194556|Drug|Maintenance icotinib|Gemcitabine 1000mg/m2 iv d1 and d8, cisplatin 75mg/m2 iv d1. After receiving a maximum of 4-cycle treatment, non-progressive patients continue to receive maintenance icotinib (125 mg three times per day) until disease progression or intolerable toxicity.
1605662|NCT02194179|Other|high-fat breakfast|
1605663|NCT02194179|Drug|NVP IR 200 mg (Viramune®)|
2009878|NCT03169777|Drug|capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
2009879|NCT03169777|Biological|cetuximab|Recombinant human/mouse chimeric anti-epidermal growth factor receptor (EGFR) IgG1 monoclonal antibody
1605593|NCT02194517|Device|ELKa|ELKa should be used for every meal preparation. After choosing the name of particular product from the list, the program will give precise information about the amount of CHO and FP exchanges in serving. No standard calculation of exchanges need to be performed.
1605594|NCT02194504|Other|Dietary advice, Western|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with Western type nutrient composition (SFA, carbohydrates, sugars, fruit juice, meat, dairy)
1605595|NCT02194504|Other|Dietary advice, Targeted|Dietary advice, guided by professional dieticians. Caloric restricted (-30en%) diet with nutrient composition aiming at an improvement in organ health and a reduction in liver fat (PUFA, fish, soy protein, whole grain)
1605596|NCT02194491|Other|[11C]AS2471907|intravenous radiotracer
1605597|NCT02194491|Radiation|Positron Emission Tomography (PET)|Imaging scanning procedure
1605598|NCT02194491|Drug|ASP3662|oral
1605599|NCT02194478|Behavioral|Meditation|30 minute, 8 week meditation
1605600|NCT02194465|Drug|LY2623091|Administered orally
1605601|NCT02194465|Drug|Tadalafil|Administered orally
1605602|NCT02194465|Drug|Spironolactone|Administered orally
1605603|NCT02194465|Drug|Placebo|Administered orally
1605604|NCT02194452|Radiation|gallium Ga 68-edotreotide|Undergo gallium Ga 68-edotreotide PET/CT
1605605|NCT02194452|Procedure|positron emission tomography|Undergo gallium Ga 68-edotreotide PET/CT
1605606|NCT02194452|Procedure|computed tomography|Undergo gallium Ga 68-edotreotide PET/CT
1605607|NCT02194452|Other|laboratory biomarker analysis|Correlative studies
2009880|NCT03169777|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
1605609|NCT02194413|Procedure|therapeutic touch|receiving healing touch
1605610|NCT02194413|Other|quality-of-life assessment|Ancillary studies
1605611|NCT02194413|Other|questionnaire administration|Ancillary studies
1605612|NCT02194400|Biological|RSLV-132|0.3 - 10.0 mg/kg RSLV-132 weekly for 4 weeks
1605613|NCT02194387|Behavioral|Telephone Coaching|Participant has 30-45 minute telephone calls 1 time each week with a telephone coach trained in motivational interviewing.
1605614|NCT02194387|Behavioral|Text Messaging|Participant receives 7-12 messages/week, 1-3 messages/day during the 16 week intervention period.
1605615|NCT02194387|Behavioral|Resistance Training|Participant given set of resistance exercise bands, a list of exercises and instructional videos on how to do each exercise. Participant logs resistance exercises on a weekly activity log.
1605616|NCT02194387|Behavioral|Daily Self-Monitoring|Participant enters additional information about their diet and activity every day through the FitBit website.
1605617|NCT02194387|Behavioral|4 - 7 Days a Week Self-Monitoring|Participant enters additional information about their diet and activity 4-7 days per week through the FitBit website.
1605618|NCT02194387|Behavioral|Questionnaires|Questionnaire completion at baseline, 8 weeks and 16 weeks.
1605619|NCT02194387|Behavioral|Email Coaching|Participant called during first week to discuss the interventions. This call will last about 10-15 minutes. Participant then receives 1 email each week in Weeks 1-16 in which the coach provides feedback about participant's goals and asks 1-2 questions similar to what telephone coach would ask.
1605620|NCT02194374|Procedure|ROR1R-CAR-T Cell Infusion|"Dose Escalation Cohort starting dose level of ROR1R-CAR-T cells/kg: 105 cell/kg infused via central venous catheter or by vein on Day 1.
Dose Expansion Cohort starting dose level of ROR1R-CAR-T cells/kg: MTD from Dose Escalation Cohort."
1605621|NCT02194374|Drug|Fludarabine|"FCR Regimen: 25 mg/m2 by vein on Days -5, -4, and -3.
FBR Regimen: 20 mg/m2 by vein Days -5, -4, and -3."
1605622|NCT02194374|Drug|Cyclophosphamide|FCR Regimen : 250 mg/m2 by vein on Days -5, -4, and -3.
1605623|NCT02194374|Drug|Rituximab|"FCR and FBR Regimen: 375-500 mg/m2 by vein on Day -5.
BR Regimen: 375-500 mg/m2 by vein on Day -4."
1605624|NCT02194374|Drug|Bendamustine|"BR Regimen: 70-90 mg/m2 by vein on Days -4 and -3.
FBR Regimen: 30-50 mg/m2 by vein on Days -5 to -3."
1605625|NCT02194361|Drug|Anthocyan capsules|Bilberry extract capsules, 160 mg (25% anthocyanosides)
1605626|NCT02194361|Drug|Placebo|
1605627|NCT02194348|Drug|BIBN 4096 BS - in single rising doses|
1605628|NCT02194348|Drug|Placebo|
1605629|NCT02194335|Drug|BIBN 4096 BS - in single rising doses|
1605630|NCT02194335|Drug|Placebo|
1605631|NCT02194322|Drug|BIBN 4096 BS - in single rising doses|
1605632|NCT02194322|Drug|Placebo|
1605633|NCT02194309|Drug|Telmisartan low|
1605634|NCT02194309|Drug|Telmisartan high|
1605635|NCT02194309|Drug|amlodipine|
1605636|NCT02194296|Drug|Ambroxol hydrochloride - lozenge|
1605637|NCT02194296|Drug|Ambroxol hydrochloride - syrup|
1605638|NCT02194283|Drug|Ambroxol - in single rising doses|
1605639|NCT02194283|Drug|Placebo|
1605640|NCT02194270|Drug|Ambroxol hydrochloride - soft pastille|
1605641|NCT02194270|Drug|Ambroxol hydrochloride - syrup - low dose|
1605642|NCT02194270|Drug|Ambroxol hydrochloride - syrup - high dose|
1605643|NCT02194257|Drug|[14C]-cyclohexane ambroxol oral solution|
1605644|NCT02194257|Drug|[14C]-benzyl ambroxol oral solution|
1605645|NCT02194257|Drug|Ambroxol lozenge|
1605646|NCT02194244|Drug|RG1662 granules|Single dose, oral administration of RG1662 immediate release granules
1605647|NCT02194244|Drug|RG1662 tablet|Single dose, oral administration of film-coated RG1662 immediate release tablet
1605648|NCT02194231|Drug|Trabectedin|Patients will receive 1.1 mg/m2 intravenous trabectedin infusion in 5% glucose via central venous catheter over 3 hours every 21 days. Trabectedin infusion will be preceded by 20 mg of intravenous dexamethasone
1605649|NCT02194218|Drug|Nevirapine, low dose|50 mg
1605650|NCT02194218|Drug|Nevirapine, high dose|100 mg
1605651|NCT02194205|Drug|COMBIVENT HFA|
1605652|NCT02194205|Drug|Placebo HFA|
1605653|NCT02194205|Drug|COMBIVENT CFC|
1605654|NCT02194205|Drug|Placebo CFC|
1605655|NCT02194192|Drug|Placebo|Normal saline 10 ml
1605656|NCT02194192|Drug|Ondansetron|Ondasetron 8 mg IV after spinal anesthesia
1605657|NCT02194192|Drug|Ephedrine|Ephedrine 10 mg IV after spinal anesthesia
2009881|NCT03169777|Drug|5-Fluorouracil (5-FU)|5-fluoro-2,4 (1H,3H)-pyrimidinedione
1605667|NCT02194153|Drug|Metalyse weight-adjusted|
1605668|NCT02194140|Other|oral iodinated contrast material|diluted in water
1605669|NCT02194127|Drug|Anthocyan capsules|
1605670|NCT02194127|Drug|Placebo|
1605671|NCT02194114|Other|Protein Diet|Protein diets fed for 17-19 days to each patient in random order: 0.6 g protein/kg/day, 0.8 g protein/kg/day, 1.0 g protein/kg/day, 1.15 g protein/kg/day, 1.3 g protein/kg/day.
1605672|NCT02194101|Procedure|Supernormal oxygen delivery goal therapy|A 10% increase in stroke volume (SV) after fluid challenge (5 ml/kg) with Ringer's lactate solution will be deemed positive. Oxygen delivery will be check when fluid challenge becomes negative. If oxygen delivery index (DO2I) can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 10 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 100 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL.
1605673|NCT02194088|Drug|Diclofenac and Atropine combination drug|Diclofenac will be associated with a small dose of atropine 1.2mg
1605674|NCT02194088|Drug|Placebo|For each capsule of active medication, a capsule of placebo will be provided, identical looking.
1605675|NCT02194075|Drug|Fluvoxamine+Methylphenidate hydrochloride|
1605676|NCT02194075|Drug|Fluvoxamine+sugar pill|
1605677|NCT02194062|Drug|fluticasone nasal spray|use 2-50 mcg sprays to each nostril two times per day
1605678|NCT02194062|Drug|Budesonide head upright|(0.5 mg/2mL) to instill into each nostril in the upright position two times per day
1605679|NCT02194062|Drug|Budesonide head forward|(0.5 mg/2mL) to instill into each nostril in the head forward position two times per day
1605680|NCT02194049|Drug|BKM120|Given PO
1605681|NCT02194049|Drug|cisplatin|Given IV
1605682|NCT02194049|Drug|etoposide|Given IV
1605683|NCT02194036|Behavioral|Learning Oriented Physiotherapy|Clinical practice based on a new understanding of the neurobiological basis for the interaction between body and mind, the foundation of learning and what is needed to bring about change of behavior.
1605684|NCT02194036|Behavioral|Widely Recognized Psychiatric Treatment|Standard recognized psychiatric treatment tailored to individual needs.
1605685|NCT02194023|Drug|Placebo: PCB|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
1605686|NCT02194023|Drug|0.12%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
1605687|NCT02194023|Drug|0.03%NF|Participants were asked to rinse every 12 hours, with 15 ml for 30 seconds, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
1605688|NCT02194023|Drug|PAT|Patients were asked to rinse every 12 hours, and after spitting to refrain from rinsing their mouths with water and from eating or drinking for at least 60 minutes.
1605689|NCT02193997|Other|Fiber|
1605690|NCT02193997|Other|Fiber|
1605691|NCT02193997|Other|Placebo|
1990802|NCT01795586|Drug|Carboplatin|Carboplatin will be administered intravenously on day 1 and day 8 of each cycle, immediately following eribulin infusion at a dose of area-under-the-curve (AUC) 2 over 30 minutes in 250 ML of 0.9 % normal saline. Carboplatin dose will be calculated using the Calvert formula using AUC of 2 as follows: Carboplatin dose (mg) = 2 X (GFR + 25).
1605696|NCT02193958|Drug|FF-10501-01|FF-10501-01 will be administered orally on Days 1-14 of a 28-day cycle. The dose-escalation will proceed until Maximum Tolerated Dose (MTD) is reached. The treatment will continue until disease progression, intolerable toxicity or investigation/subject decision.
1605697|NCT02193932|Other|EEG Triggered fMRI using Micro Maglink|
1605698|NCT02193906|Other|Cognitive training|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients who have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb® during 3 months. Patients who don't have computer with internet access at home will perform a minimum of 3 sessions per week of Cogweb Monthly Notebooks® during 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
1605699|NCT02193906|Other|Placebo task|Every patient will have 3 neuropsychological evaluations (with the same battery): baseline, after a 3-month period of training and 6 months after the conclusion of the training. Patients will have to complete a placebo task (send an email with a copy of a journal/magazine heading) a minimum of 3 times a week, for 3 months. Every patient included will have an outpatient appointment in the end of the first and second months of training.
1605700|NCT02193893|Other|Biological: Cell-based therapeutics|Human autologous bone marrow-derived stem/progenitor cell transplantation in ALS patients.
1605701|NCT02193893|Other|Symptomatic treatment of ALS|Symptomatic neurological treatment of ALS
1605702|NCT02193880|Device|Alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.|Post-transplant alpha-beta depleted T-cell infusion after post-transplant cyclophosphamide.
1605703|NCT02193867|Drug|sebelipase alfa|Sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL). The investigational medicinal product is an enzyme replacement therapy intended for treatment of patients with Lysosomal Acid Lipase Deficiency. Dosing will occur once weekly for up to three years.
1605704|NCT02193854|Device|Mobile Phone|Investigators used Sana system, that is a mobile phone-based, open source software platform for telemedicine services. The Android-based system supports multimedia, location-based data, and text. In the village health clinic, a healthcare worker will interact with a patient and collects data through a step-by-step clinical questionnaire on a smart mobile phone. As patients' data is uploaded to an open source electronic medical record system (OpenMRS) with a diagnosis-specific information and images. The consultant can access the clinical information about the patient and make appropriate diagnoses and treatment recommendations from the secondary hospital.
1605705|NCT02193841|Procedure|Curettage with puncture (C & P)|A curette will be inserted to scrape the contents of the cyst (curettage) and a hole in the cyst wall will be made (puncture) near the bone marrow cavity
1605706|NCT02193841|Device|Curette|A small surgical instrument with a rounded edge designed for scraping
1605707|NCT02193841|Device|Vitoss morsels|A bone substitute intended for use as a filler for voids or gaps in bones
1605708|NCT02193828|Biological|Collagenase clostridium histolyticum|Single injection into nodule
1605709|NCT02193828|Biological|Placebo|Single injection into nodule
1605710|NCT02193815|Drug|PF06263276|4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
1605711|NCT02193815|Other|Vehicle|Active ingredient-free vehicle to 4% solution
1605712|NCT02193815|Drug|2%Tofacitinib Ointment|Daily Dosage: approximately 4 mg tofacitinib
1605713|NCT02193815|Other|Vehicle|Active ingredient-free vehicle to 2% Ointment
1605714|NCT02193815|Drug|Daivonex|Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
1605715|NCT02193815|Drug|Daivonex Ointment|Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
1605716|NCT02193802|Device|PillCam® SB3 capsules|"Patient preparation for PillCam® SB3 capsule procedure:
Patients will drink only clear liquids beginning 12 noon the day prior to the procedure,12 hour fast prior to the procedure and 1 L of PEG on the morning two hours before the capsule ingestion.
Patients can drink clear liquids 2 hours and eat 4 hours post ingestion. Eight hours post ingestion the data recorder should be removed. Patients will confirm excretion of the capsule or as required by the investigator."
1605717|NCT02193789|Procedure|deployment of through the scope covered metallic stent at the stricture site|Deployment of Covered Self-expandable Metallic Stents Insertion fixing with Clips and Suture Material at the stricture site
1605718|NCT02193789|Device|Covered Self-expandable Metallic Stents|
1605719|NCT02193776|Drug|Pa-824|oral
1605720|NCT02193776|Drug|bedaquiline|oral
1605721|NCT02193776|Drug|moxifloxacin|oral
1605722|NCT02193776|Drug|pyrazinamide|oral
1605723|NCT02193776|Drug|isoniazid, rifampicin, pyrazinamide and ethambutol combination tablet|oral
1605724|NCT02193763|Procedure|Ultrasound assisted lumbar puncture|An investigator will perform beside ultrasound on the spinal area using a bedside ultrasound device. Attempts will be made to visualize the spinous processes and vertebral bodies in the general lumbarsacral area, as well as the presence of CSF in the thecal space below the conus medullaris, and identify the optimal location to perform the LP. This will be marked with a skin marker (If no CSF or abnormal anatomy is visualized, the LP will be advised to be postponed or cancelled). The treating physician will then proceed with the LP guided by the skin markings.
1605725|NCT02193750|Dietary Supplement|Placebo|1 placebo muesli bar and 1 serving placebo muesli per day (0.55 g total fructans/GOS)
1605726|NCT02193750|Dietary Supplement|Moderate Oligosaccharide Group|1 placebo muesli bar and 1 serving intervention muesli per day (3.25 g total fructans/GOS)
1605727|NCT02193750|Dietary Supplement|High Oligosaccharide Group|1 placebo muesli bar and 1 serving placebo muesli per day (5.43 g total fructans/GOS)
1605728|NCT02193737|Procedure|Early oral fluid recovery.|
1605729|NCT02193737|Procedure|Delayed oral fluid recovery.|
1605730|NCT02193724|Other|Skin Biopsy|A very small skin sample will be taken from the participant's arm. This will only be performed while the patient is under sedation for clinical purposes (e.g. exam under anesthesia, MRI, or other procedure requiring sedation).
1605731|NCT02193724|Other|Blood Draw|About 1 teaspoon of blood will be drawn from the participant's arm or from a central line catheter if present. Blood collection will be done at the same time the participant has blood drawn for routine clinical care.
1605732|NCT02193711|Other|Topical Arthritis Cream|
1605733|NCT02193698|Drug|Lenalidomide+Dexamethasone|Lenalidomide 25mg/day (day 1-21) Dexamethasone 20mg/day (day 2. 9, 16, 23)
1605734|NCT02193672|Drug|[18F] Fluciclatide|[18F] Fluciclatide given by vein before PET/CT scan.
1605735|NCT02193672|Procedure|PET/CT Scan|PET/CT scan performed at treatment baseline visit, and about 1 week before first cycle of chemotherapy. Then, a PET/CT scan performed at end of first cycle of chemotherapy.
1605736|NCT02193672|Behavioral|Phone Calls|Phone call to participants by study staff about 24 hours after each PET/CT is performed.
1605737|NCT02193659|Dietary Supplement|Cereals|The participants were randomly single blind controlled trial distributed into three groups: (1, n =38), (2, n =38), (3, n =37). For 30 days, participants in group 1 took cereals with omega-3 in the breakfast with diet, group 2 took cereals and diet, and group 3 only received the diet.
1605738|NCT02193633|Drug|AZD2014 3 on/4 off & weekly paclitaxel|AZD2014 3 days on, 4 days off + weekly paclitaxel
1605739|NCT02193633|Drug|AZD2014 2 on/5 off & weekly paclitaxel|AZD2014 2 days on, 5 Days off + weekly paclitaxel
1605740|NCT02193620|Drug|PHN131 soft capsule with Nalbuphine HCl 60 mg/cap|Multiple dose of oral PHN131 soft capsule with Nalbuphine HCl 60 mg/cap, initial dose : 120 mg ( 2 capsules), then 60 mg (1 capsule); t.i.d.
1605741|NCT02193620|Drug|Placebo soft capsules|Multiple dose of oral Placebo soft capsules, initial dose: 2 capsules, then 1 capsule; t.i.d.
1605742|NCT02193620|Drug|Dicofenac|All subjects will receive diclofenac by IM injection for analgesia as rescue pain control.
1605743|NCT02193607|Procedure|TVT-O|Artificial mesh belt is placed in the middle urethra to provide support to remain no leak
1605744|NCT02193607|Procedure|Improved reconstruction pelvic surgery|Repair of severe pelvic organ prolapse with mesh.
1605745|NCT02193594|Radiation|Preoperative concurrent chemoradiotherapy|The patients will receive radiotherapy in the total amount of 50Gy(25 fractions) preoperatively,concurrently combined with chemotherapy,which consist of oxaliplatin 40mg/m2 administrated on days 1,8,15,22,29 and S-1® 30mg/m2 twice per day on days 1 to 5 per week.
1605746|NCT02193594|Procedure|Radical D2 total gastrectomy|Within 5-6 weeks after the completion of neoadjuvant therapy,the patients in CCRT group will receive the radical total gastrectomy with D2 lymphadenectomy,and patients in the CT group will receive the surgery right after randomization.
1605747|NCT02193594|Drug|Adjuvant chemotherapy|Within 2 months after surgery,the patients will receive chemotherapy for 6 to 8 cycles ,consist of oxaliplatin 130mg/m2 administrated on day1 and S-1® 40-60mg twice per day on days 1 to 14 per 3 weeks.The S-1® dosage depends on the patient BSA(BSA＜1.25m2 40mg,1.25 m2≤BSA≤1.5 m2 50mg ,BSA＞1.5 m2 60mg). Patients in the CCRT group will receive 6 cycles of chemotherapy and patients in the CT group will receive 8 cycles of chemotherapy.
1605748|NCT02193581|Device|MDS|Patients with a suspicious lesion, referred for a biopsy is tested using MDS.
1605749|NCT02193568|Procedure|Arm I (light sedation)|If patients experience excessive preoperative anxiety they will receive light sedation of midazolam 1 mg IV.In our standard practice, it is very rare that patients receive anxiolytic premedication for craniotomies, so it is unlikely that many will require midazolam. Two IVs will be placed, one for infusion of meds and one for possible resuscitation.
1605750|NCT02193568|Procedure|Arm II (intubated general anesthesia)|Receive intubated general anesthesia
1605751|NCT02193568|Procedure|Arm II (intubated general anesthesia)|Undergo craniotomy
1605752|NCT02193568|Other|Arm II (intubated general anesthesia)|Ancillary studies
1605753|NCT02193568|Procedure|Arm I (light sedation)|Undergo craniotomy
1605754|NCT02193568|Other|Arm I (light sedation)|Ancillary studies
1605755|NCT02193555|Device|Etafilcon A, Senofilcon A|1 pair of either test or control lenses will be fitted on the subject for up to 1 hour of lens wear per visit (total of 2 fitting visits).
1605756|NCT02193503|Other|Treatment|Treatment is the implantation of loaded capsules + injection of irradiated autologous tumor cells
1605757|NCT02193490|Drug|DNase|DNase 0.1% eye drops four times a day for 8 weeks
1605758|NCT02193490|Drug|Vehicle|Drug vehicle eye drops four times a day for 8 weeks
1605759|NCT02193477|Device|TEAS|Electric stimulation was given through electrode attached to specific acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
1605760|NCT02193477|Device|Sham TEAS|Electric stimulation was given through electrode attached to non-acupoints for 30mins before general anesthesia induction,1th day and 2nd day after surgery.
1605761|NCT02193451|Procedure|Urodynamics|Diagnostic test for urinary storage and voiding function
1605762|NCT02193451|Procedure|Usual care|
1605763|NCT02193438|Other|Spices intake|Each subject had to ingest a single dose of each of the spices and placebo. Recording of outcomes was realized throughout the 90 minutes following ingestion.
1605764|NCT02193438|Other|Placebo|Tomato juice intake
2009882|NCT03169777|Drug|fulvestrant|7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
2009883|NCT03169777|Drug|leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
1605767|NCT02193412|Procedure|noxious stimulus|standardized noxious stimulus with tetanic stimulation
1605768|NCT02193412|Procedure|change in operating table slope: head-down tilt position|-30°
1605769|NCT02193412|Procedure|change in operating table slope: head-up tilt position|+30°
1605770|NCT02193399|Other|Physiotherapy in patients with stem cell transplantation|"The exercises are repeated in both upper limbs and both lower limbs. All exercises are performed with specific respiratory exercises simultaneously the movement that takes place each year form.
The exercises are carried out by the physiotherapist applying in a passive way (ascending or descending) progressive strength and degree of difficulty and variables depending on the clinical condition of the patient."
1605771|NCT02193386|Other|No intervention, no follow-up, only registration|Usual Care
1605772|NCT02193386|Other|Intervention period|Predefined intervention program
2009884|NCT03169777|Drug|nab paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
1605775|NCT02193360|Drug|FFP104|Cohorts receiving multiple weekly or biweekly i.v. doses of FFP104. FFP104 dose levels: 1.0, 2.5 and 5.0 mg/kg. Subjects will be treated for 12 weeks and then followed for safety and efficacy assessments for an additional 12 weeks.
1605776|NCT02193347|Biological|PEPIDH1M vaccine|PEPIDH1M vaccine is made up of 500 µg of 25 amino acid peptide administered with 150 µg of GM-CSF mixed 1:1 with Montanide ISA 51 administered intradermally. The peptide vaccine is administered in the groin area approximately 10 cm below the inguinal ligament.
1605777|NCT02193347|Biological|Tetanus-Diphtheria Toxoid (Td)|After consent has been signed, all subjects will undergo standard of care vaccination with 0.5 mL of Td (tetanus and diphtheria toxoids adsorbed) intramuscularly (I.M.) into the deltoid muscle to ensure adequate immunity to the tetanus antigen. Within 48 hours of leukapheresis, subjects will receive a vaccine site pre-conditioning as a single dose of Td toxoid (1 flocculation unit, Lf, in a total volume of 0.4 mLs saline) administered intradermally to the right side of the groin twelve hours to one day prior to receiving the first PEPIDH1M vaccine.
1605778|NCT02193347|Drug|Temozolomide|Subjects are treated with temozolomide (TMZ) at a targeted dose of 50-100mg/m2/d for 21 days every 28 days for up to 12 cycles. Subjects that have transitioned to a higher grade brain tumor at time of surgery will receive TMZ and radiation therapy per standard of care before starting TMZ cycles.
1605779|NCT02193334|Drug|KP-100IT|
1605780|NCT02193334|Drug|Placebo|
1605781|NCT02193321|Biological|Amniotic Membrane Patch|
1605782|NCT02193308|Drug|Telmisartan/Amlodipine FDC|
1605783|NCT02193308|Drug|Telmisartan|
1605784|NCT02193308|Drug|Amlodipine|
1990810|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/8 mg, orally once daily
1605790|NCT02193269|Drug|Sugar pill|you will receive 0.0 mg as a single daily dose for 4 days
1605791|NCT02193269|Drug|Minocycline|you will receive 200 mg as a single daily dose for 4 days
1605792|NCT02193256|Drug|Varenicline|Titrated over 1 week to a maximum dose of 2mg/day
1605793|NCT02193256|Drug|Prazosin|Titrated over 3 weeks to a maximum dose of 8mg/day
1605794|NCT02193256|Drug|Placebo|
1605795|NCT02193217|Drug|MT-1303-Low|
1605796|NCT02193217|Drug|MT-1303-High|
1605797|NCT02193217|Drug|Fingolimod|
1605798|NCT02193217|Drug|Placebo|
1605838|NCT02192892|Dietary Supplement|CSB + α-amylase|CSB + α-amylase: porridge from Corn Soy Blend with α-amylase
1605839|NCT02192892|Dietary Supplement|RSB + α-amylase|RSB + α-amylase: Porridge from Rice Soy Blend with α-amylase
1605840|NCT02192892|Dietary Supplement|WSB + α-amylase|WSB + α-amylase: Porridge from Wheat Soy Blend with α-amylase
1606032|NCT02191527|Device|SD Bioline® (Standard Diagnostics Inc., South-Korea) for qualitative analysis of syphilis|
1990811|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 30/16 mg, orally once daily
1605799|NCT02193204|Behavioral|Personal Stress Imagery|"The stress imagery script will be based on participants' description of a recent personal event experienced as most stressful, and determined as such by rating it above 8 on a 10-point stress scale. These may include breakup with a significant other or job-related stress. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions."
1605800|NCT02193204|Behavioral|Neutral Imagery|The neutral script will be developed from a personal non-alcohol-related relaxing situation. A 5-minute 'script' of each scenario will be written using Scene Construction Questionnaires where physiological, bodily sensations regarding the event will be obtained. Scripts will then be recorded onto audiotape for guided imagery in the laboratory sessions.
1605801|NCT02193191|Drug|Plerixafor|
1605802|NCT02193178|Device|comfilcon A Toric|Contact lenses
1605803|NCT02193165|Drug|triclosan/fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Total toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using a Total 360 toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of mouthwash for 30 seconds.
1605804|NCT02193165|Drug|stannous fluoride toothpaste + cetylpyridinium chloride Mouthwash|Brush whole mouth with Crest Pro-Health toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Pro-Health toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health Multi-Protection mouthwash for 30 seconds.
1605805|NCT02193165|Drug|fluoride toothpaste + fluoride Mouthwash|Brush whole mouth with Crest Cavity Protection toothpaste for 1 minute, 2 times/day for 6 weeks (study duration) using an Oral B Indicator toothbrush. Immediately after each toothbrushing, rinse whole mouth with 20 ml of Crest Pro-Health For Me Breezy Mint mouthwash for 30 seconds.
1605806|NCT02193152|Drug|Pazopanib|
1605807|NCT02193139|Drug|WL8713, 6 mg|
1605808|NCT02193139|Drug|WL8713, 12 mg|
1605809|NCT02193139|Drug|WL8713, 18 mg|
1605810|NCT02193139|Drug|WL8713, 24 mg|
1605811|NCT02193139|Drug|Placebo|
1605812|NCT02193126|Other|Trauma Affect Regulation: Guide for Education and Therapy (TARGET)|The intervention is called the Trauma Affect Regulation: Guide for Education and Therapy (TARGET). TARGET is a manualized, psycho-educational intervention delivered in 10 - 12 sessions. TARGET is designed to address complex trauma and difficulties with emotional regulation and relational engagement that occur across a wide range of trauma-related difficulties, including trauma-related and behavioral symptoms. The full TARGET model consists of learning 7 essential core skills. These skills are called the FREEDOM steps: Focus, Recognize triggers, Emotion self-check, Evaluate thoughts, Define goals, Options, and Make a contribution.
1605813|NCT02193113|Drug|KVD001 Injection|A novel plasma kallikrein inhibitor
1605814|NCT02193087|Drug|TDV Liquid Formulation 1|TDV Liquid Formulation 1 for subcutaneous injection
1605815|NCT02193087|Drug|TDV Liquid Formulation 2|TDV Liquid Formulation 2 for subcutaneous injection
1605816|NCT02193087|Drug|TDV IDT Lyophilized|TDV Lyophilized Formulation for subcutaneous injection
1605817|NCT02193087|Drug|Placebo|TDV liquid formulation placebo-matching solution for subcutaneous injection
1605818|NCT02193074|Drug|nusinersen|Administered by intrathecal (IT) injection as specified in the treatment arm.
1605819|NCT02193074|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
1605820|NCT02193061|Biological|Rotarix|
1605821|NCT02193061|Biological|RotaTeq|
2009885|NCT03169777|Biological|nivolumab|Human anti-programmed cell death protein 1 (PD-1) IgG4 kappa monoclonal antibody
1605823|NCT02193035|Other|Microparticle levels|Microparticle levels will be evaluated with flow cytometry and nanoparticle tracking analysis
1605824|NCT02193022|Drug|Miltefosine|
1605825|NCT02193009|Behavioral|SipSmarter|6-month behavioral trial
1605826|NCT02193009|Behavioral|MoveMore|6 month behavioral trial
1605827|NCT02192996|Dietary Supplement|Probiotic|blood and fecal samples were collected from five VLBW preterms which were supplemented with a probiotic mixture of Bifidobacterium breve / Lactobacillus salivarius isolated from human milk
1605828|NCT02192970|Drug|Bevacizumab|
1605829|NCT02192957|Device|Lifepak 20E Defibrillator, Licence No: 61944|"Intervention will be carried out using Health Canada approved devices for electrical cardioversion, following the steps pre-specified in the Ottawa AF Protocol.
Ottawa AF Cardioversion"
1605830|NCT02192944|Drug|Chloroquine|Chloroquine base 600 mg single dose. To monitor ECG 12 lead at 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
1605831|NCT02192944|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine 120/960 mg single dose To monitor ECG 12 lead at: 0 (pre-dose), 1, 2, 4, 8, 12 and 24 hours after dosing.
1605832|NCT02192931|Drug|Creatine monohydrate|
1605833|NCT02192918|Behavioral|Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants in the airbrush condition will receive 4 airbrush tan sessions, once every two weeks, over the course of 2 months.
1605834|NCT02192918|Behavioral|Airbrush Plus|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will complete 4 airbrush tan sessions, once every two weeks, over the course of 2 months. Additionally, they may choose 8 sessions, 1 per week, of the following activities at no cost: massage, pedicure, yoga class, or dance class.
1605835|NCT02192918|Behavioral|Delayed Airbrush|The American Academy of Dermatology Sun Smart pamphlet will be given at the baseline session. It has brief tips for reducing skin cancer risk, but does not mention sunless tanning or relaxation activities. Participants will receive access to one of each of the following after the 6-month assessment at no cost: airbrush tan, massage, pedicure, yoga class, and dance class
2009886|NCT03169777|Drug|Lovaza|Omega-3-acid ethyl esters
1605837|NCT02192892|Dietary Supplement|CSB drum dried + α-amylase|CSB drum dried + α-amylase: Porridge from drum dried Corn Soy Blend with α-amylase
1606126|NCT02190695|Drug|Decitabine|20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
2009887|NCT03169777|Drug|oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
1605841|NCT02192892|Dietary Supplement|CSB PLUS drum dried + α-amylase|CSB PLUS drum dried + α-amylase: Porridge from drum dried Corn Soy Blend PLUS with α-amylase
1605842|NCT02192892|Dietary Supplement|CSB PLUS + α-amylase|CSB PLUS + α-amylase: Porridge from Corn Soy Blend PLUS with α-amylase
1605843|NCT02192892|Dietary Supplement|RSB PLUS + α-amylase|RSB PLUS + α-amylase: Porridge from Rice Soy Blend PLUS with α-amylase
1605844|NCT02192892|Dietary Supplement|WSB PLUS + α-amylase|WSB PLUS + α-amylase: Porridge from Wheat Soy Blend PLUS with α-amylase
1605845|NCT02192892|Dietary Supplement|Commercial porridge flour|Porridge from commercial porridge flour
1605846|NCT02192892|Dietary Supplement|Commercial porridge bar|Porridge from commercial porridge bar
1605847|NCT02192892|Dietary Supplement|Commercial MSB + α-amylase|Commercial MSB + α-amylase: Commercial porridge from Mais Soy Blend with α-amylase
1605848|NCT02192879|Device|thoracic epidural|Thoracic Epidural catheters will be placed between T8-12 interspaces preoperatively. Epidural hydromorphone (200-600mcg) will be given preoperatively. TEA will be dosed intraoperatively with a continuous infusion of 0.25% bupivacaine at 3-6ml per hour. At the end of surgery, infusion will be changed to 0.125% bupivacaine + 10mcg/ml hydromorphone at 4-6ml/hour. In PACU, a PCEA button will given to the patient for bolus dosing of 1-2ml and a lockout of 30 minutes. Changes to the epidural infusion solution, rate, and PCEA bolus dosing will be made clinically as required by the Acute Pain Service (APS).
1605849|NCT02192879|Device|continuous paravertebral catheter|Bilateral PVB catheters will be placed between the T8-12 interspaces preoperatively. 10ml of 0.5% ropivacaine will be injected into the paravertebral space, then catheter placed. The same procedure will be used for the placement of the PVB catheter on the opposite side. The catheter may be bolused with 5ml 0.5% ropivacaine hourly intraoperatively if needed. In PACU, PVB catheters will be infused continuously with 0.2% ropivacaine at 8-12ml/hr. Subjects will also be given a hydromorphone PCA button to deliver additional IV opioid medication to the patient as needed.
1605850|NCT02192879|Drug|Patient-Controlled Analgesia|Intravenous hydromorphone PCA will be initiated postoperatively with dosing prescriptions made by the primary surgical team.
1605851|NCT02192853|Drug|sitagliptin|"In randomized order:
Day 1: tablet of 25 mg of sitagliptin + i.v. GLP-1 infusion Day 2: tablet of 100 mg of sitagliptin + i.v. GLP-1 infusion Day 3: tablet of 200 mg of sitagliptin + i.v. GLP-1 infusion"
1605852|NCT02192853|Drug|Placebo|Day 4: placebo tablet
1605853|NCT02192840|Procedure|Coronary angioplasty with stent implantation|Coronary angioplasty in bifurcation lesion with drug-eluting stent implantation: BiOSS or regular DES (rDES)
1605854|NCT02192827|Drug|Dexamethasone Sodium Phosphate Injection|
1605855|NCT02192814|Drug|Lacosamide (200 mg/20 mL)|"Active Substance: Lacosamide
Pharmaceutical form: Solution for intravenous (iv) infusion
Concentration: adapted on concentration of oral dose in EP0009
Route of Administration: Drip infusion"
1605856|NCT02192788|Radiation|Stereotactic Body Radiation Therapy for Oligometastases|
1605857|NCT02192775|Drug|MV-NIS|one dose in conjunction with a 4 day course intravenously
1605858|NCT02192762|Behavioral|Withdrawal regulation training|Withdrawal coping skills
1605859|NCT02192762|Behavioral|Relaxation training|Relaxation skills instruction
2009888|NCT03169777|Radiation|Stereotactic Body Radiation Therapy|(SBRT)
1605861|NCT02192736|Biological|Trophic factors from umbilical cord mesenchymal stem cells|
1605862|NCT02192723|Drug|Typical antipsychotic|Haloperidol (6~20mg/day) and perphenazine (16~64mg/day), twice per day, 8 weeks
1605863|NCT02192723|Drug|Risperidone|2~6mg/day, twice per day, 8 weeks
1605864|NCT02192723|Drug|Olanzapine|Olanzapine, 400~750mg/day, twice per day, 8 weeks
1605865|NCT02192723|Drug|Quetiapine|Quetiapine, 400～750mg/day, twice per day, 8 weeks
1605866|NCT02192723|Device|Aripiprazole|Aripiprazole, 10～30mg/day, twice per day, 8 weeks
1605867|NCT02192723|Drug|Ziprasidone|Ziprasidone 80~160mg/day, twice per day, 8 weeks
1605868|NCT02192710|Procedure|electronic tab|classic use of an electronic tab with age specific games
1605869|NCT02192710|Drug|Midazolam oral intake|
1605870|NCT02192697|Drug|ASP8273|Oral administration
1605871|NCT02192684|Drug|Pioglitazone|45 mg daily Insulin sensitizing
1605872|NCT02192684|Drug|placebo|Compare with pioglitazone
1605873|NCT02192671|Procedure|Hepatic Resection|Indications for HR are the presence of appropriate residual liver volume determined by volumetric computed tomography.
1605874|NCT02192671|Procedure|Radiofrequency Ablation|
1605875|NCT02192645|Drug|Sanfujiu|
1605876|NCT02192645|Drug|Placebo|The placebo ointment is composed of flour, buckwheat flour, food colorants and water, resulting in an ointment similar in appearance to the Sanfujiu ointment.
1605877|NCT02192632|Drug|Epiduo once daily with detailed instruction for how to apply it|
1605878|NCT02192632|Drug|Epiduo- once daily, simple instruction for application|
1605879|NCT02192632|Drug|BPO once daily|
1605880|NCT02192619|Other|observational|
1605881|NCT02192606|Device|Storz 3D Laparoscopy System|The Storz 3D Laparoscopy System is a new device that allows for laparoscopic surgeons to utilize 3D imaging during surgery with a fraction of the cost of the da Vinci Surgical System, a three-dimensional visual system.
1605882|NCT02192606|Device|2D Laparoscopy|The standard 2D Laparoscopy System to be used at time of the total laparoscopic hysterectomy.
1605883|NCT02192593|Behavioral|Computer CBT|
1605884|NCT02192580|Drug|Omega-3|Children less than 18 kg:26 mg/kg EPA and 11 mg/kg DHA Children 18-24 kg:504 mg EPA and 216 mg DHA Children 25-32 kg:672 mg EPA and 288 mg DHA Children 33-41 kg:840 mg EPA and 360 mg DHA Children 5-15 years:1000 mg EPA and 878 mg DHA omega-3 in divided 3 times/day in addition to standard regimens
1605885|NCT02192567|Drug|DS-5573a|"Step 1 of this study will use a starting intravenous (IV) dose of 0.1 mg/kg. Eight dose levels are planned, level 1: 0.1 mg/kg, level 1.5: 0.1 mg/kg, 0.3 mg/kg, level 2: 0.3 mg/kg, level 3: 1 mg/kg, level 4: 3 mg/kg, level 5: 10 mg/kg, level 6: 20 mg/kg, level 7: 30 mg/kg.
Step 2: 30 subjects will use the dose determined in Step 1."
1605943|NCT02192294|Drug|Intravenous infusion of bosutinib|a single dose of 120 mg of bosutinib intravenous infusion (1 hour)
2009889|NCT03169777|Biological|ALT-803|recombinant human super agonist interleukin-15 (IL-15) complex
1605888|NCT02192515|Drug|APD356 10 mg|One tablet of APD356 10 mg will be orally administered in fasted state.
1605889|NCT02192515|Drug|APD356 XR-20 mg|One tablet of APD356 XR-20 mg will be orally administered in fasted state.
1605890|NCT02192515|Drug|APD356 10 mg matching Placebo|One tablet of APD356 10 mg matching placebo will be orally administered in fasted state.
1605891|NCT02192515|Drug|APD356 XR-20 mg matching Placebo|One tablet of APD356 XR matching placebo will be orally administered in fasted state.
1605892|NCT02192515|Drug|APD356 20 mg|Two tablets of APD356 10 mg will be orally administered in fasted state.
1605893|NCT02192515|Drug|APD356 20 mg matching Placebo|Two tablets of APD356 10 mg matching placebo will be orally administered in fasted state.
1605894|NCT02192515|Drug|APD356 XR-20 mg (orange tablet)|One tablet of APD356 XR-20 mg orange tablet will be orally administered in fasted state.
1605895|NCT02192515|Drug|APD356 XR-20mg (orange tablet, fed state)|One tablet of APD356 XR-20 mg orange tablet will be orally administered 30 minutes after the start of a meal.
1605896|NCT02192502|Drug|human albumin 5%|
1605897|NCT02192502|Drug|HES 130/0.4 (Voluven)|
1605898|NCT02192489|Drug|CC-220 0.3 mg Daily|
1605899|NCT02192489|Drug|CC-220 0.6mg Daily|
1605900|NCT02192489|Drug|Placebo|
1605901|NCT02192476|Other|conventional neuro rehabilitation programme|All the conventional group subjects were received standardized conventional neuro rehabilitation programme. The conventional neuro rehabilitation treatment includes, active, and passive range of motion exercise, bilateral activation of pectoralis major, activation of latissimus dorsa, activation of the retractors, weight bearing exercise of upper extremity, activation of supraspinatus, reaching activities, grasping, holding and release, and activity of daily living (ADL) activities. Every participant was received conventional neuro rehabilitation for 45 minutes and 5 days a week.
1605902|NCT02192476|Other|California tri-pull taping (CTPT)|Two types of tape was used, a self-adhesive 1.5ʺ cotton undercover tape and a 1ʺ rigid strapping tape. Participants placed their affected arm on a supporting surface to better approximate the humeral head back into the glenoid fossa. The three pieces of rigid tape were applied to the patient's shoulder on top of the already applied self-adhesive cotton tape.
1605903|NCT02192463|Drug|NVP ER 300 mg (KCR 20%) Medium Release|
1605904|NCT02192463|Drug|NVP ER 300 mg (KCR 25%) Medium Release|
1605905|NCT02192463|Drug|NVP ER 300 mg (KCR 30%) Slow Release|
1605906|NCT02192463|Drug|NVP ER 400 mg (KCR 25%) Medium Release|
1605907|NCT02192463|Drug|NVP ER 300 mg (KCR 40%) Slow Release|
1605908|NCT02192463|Drug|NVP ER 300 mg (ECR 20%) Fast Release|
1605909|NCT02192463|Drug|NVP ER 400 mg (KCR 20%) Medium Release|
1605910|NCT02192463|Drug|NVP ER 400 mg (KCR 30%) Slow Release|
1605911|NCT02192463|Drug|NVP ER 400 mg (KCR 40%) Slow Release|
1605912|NCT02192463|Drug|NVP ER 400 mg (ECR 20%) Fast Release|
1605913|NCT02192463|Drug|Nevirapine immediate release (IR) 200 mg|
1605914|NCT02192450|Drug|Insulin aspart/glargine|
1605915|NCT02192450|Drug|Insulin aspart/degludec|
1605916|NCT02192437|Other|Sulfur amino acid restricted diet|Methionine restricted diet: 70% or 90% restriction Methionine and cysteine restricted diet: 50% or 65% restriction
2009890|NCT03169777|Biological|ETBX-011|adenovirus serotype-5 [Ad5] [E1-, E2b-]-carcinoembryonic antigen [CEA] vaccine
2009891|NCT03169777|Biological|ETBX-021|Ad5 [E1-, E2b-]-human epidermal growth factor receptor 2 [HER2] vaccine
1605919|NCT02192411|Drug|Lidocaine|1/4 dose lidocaine
1605920|NCT02192398|Drug|Guanfacine|"Subjects will be randomized into 1 of the following 3 treatment groups:
guanfacine (2mg)
guanfacine (1mg)
placebo
To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
1605921|NCT02192398|Drug|Placebo|"Subjects will be randomized into 1 of the following 3 treatment groups:
guanfacine (2mg)
guanfacine (1mg)
placebo To compare pain threshold, pain tolerance, and wind up, as measured by QST, throughout 4 weeks of drug treatment (guanfacine or placebo)."
1605922|NCT02192359|Biological|carboxylesterase-expressing allogeneic neural stem cells|Given intracranially
1605923|NCT02192359|Drug|irinotecan hydrochloride|Given IV
1605924|NCT02192359|Other|laboratory biomarker analysis|Correlative studies
1605925|NCT02192359|Other|pharmacological study|Correlative studies
1605926|NCT02192346|Drug|2.4 mg/kg α-TEA|Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.
1605927|NCT02192346|Drug|4.8 mg/kg α-TEA|Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.
1605928|NCT02192346|Drug|8.0 mg/kg α-TEA|Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.
1605929|NCT02192346|Drug|9.6 mg/kg α-TEA|Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.
1605930|NCT02192346|Drug|12 mg/kg α-TEA|Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.
1605931|NCT02192346|Drug|16.8 mg/kg α-TEA|Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.
1605932|NCT02192346|Drug|19.2 mg/kg α-TEA|Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.
1605933|NCT02192346|Drug|22.3 mg/kg α-TEA|Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.
1605934|NCT02192346|Drug|26.8 mg/kg α-TEA|Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.
2009892|NCT03169777|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury vaccine
2009893|NCT03169777|Biological|ETBX-061|Ad5 [E1-, E2b-]-mucin 1 [MUC1] vaccine
2009894|NCT03169777|Biological|GI-4000|RAS yeast vaccine
2009895|NCT03169777|Biological|GI-6207|CEA yeast vaccine
1605939|NCT02192320|Drug|Atorvastatin|20 mg (every evening orally) for 5 weeks
1605940|NCT02192320|Drug|Atorvastatin and Dexamethasone|"Atorvastatin: 20 mg (every evening orally) for 5 weeks;
Dexamethasone:0.75mg Tid (1st-2nd week), 0.75mg Bid (3th week), 0.75mg Qd (4th week), 0.375mg Qd (5th week)"
1605941|NCT02192307|Device|Potassium oxalate|
1605942|NCT02192294|Drug|Oral Bosutinib|a single dose of 500 mg oral bosutinib
2009896|NCT03169777|Biological|GI-6301|Brachyury yeast vaccine
1605944|NCT02192281|Other|Playworks|The Playworks program places full-time coaches in low-income schools to provide opportunities for organized play during recess and throughout the school day.
1605945|NCT02192268|Other|PEP|
1605946|NCT02192268|Other|HFOO|
1605947|NCT02192268|Other|Assisted Coughing|
1605948|NCT02192255|Behavioral|Intervention Phone Call|The intervention arm consisted of one protocol-structured telephone call from an interventionist who was a nurse health manager (1 site), diabetes educator or diabetes educator trainee (1 site), or pharmacist (2 sites). Interventionists followed the same structured telephone interview protocol to ascertain whether the subject had started taking the new prescription. Those taking the new medication as prescribed received positive reinforcement. Those who either had not filled the prescription or were not taking the medication as directed, were asked about reasons for nonadherence and assisted in identifying and resolving barriers. The median call lasted < than 5 minutes, and up to 3 call attempts were made. Most intervention calls occurred within 2 to 6 weeks after the prescription date.
1605949|NCT02192242|Other|acute ischemic pain|acute ischemic pain was induced by treadmill exercise
1605950|NCT02192229|Drug|50.000 IU vitamin D3 (Biodal 50,000 IU)|
1605951|NCT02192229|Drug|Placebo (to mimic Biodal 50,000 IU)|Placebo Tablet will be manufactured in a pharmaceutical factory to be identical to vitamin D3 Tablet in color, shape, size, and packaging
1605952|NCT02192216|Behavioral|Exercise|
1605953|NCT02192203|Drug|Diclofenac + Menthol Gel|1% diclofenac, 3% menthol
1605954|NCT02192203|Drug|Diclofenac Only Gel|1% diclofenac, 0.09% menthol
1605955|NCT02192203|Drug|Menthol Only Gel|3% menthol
1605956|NCT02192203|Drug|Placebo Only Gel|0.09% menthol
1605957|NCT02192190|Drug|LY2951742|Administered SC
1605958|NCT02192190|Other|Placebo - Oral|Administered orally
1605959|NCT02192190|Other|Placebo - SC|Administered SC
1605960|NCT02192190|Drug|Celecoxib|Administered orally
1605961|NCT02192164|Behavioral|smoking questionnaire|patients fill in a smoking questionnaire about their smoking habits
1605962|NCT02192138|Procedure|Therapeutic thoracentesis|Therapeutic thoracentesis with pleural fluid withdrawal
1605963|NCT02192138|Device|Pleural catheter|
1605964|NCT02192138|Device|Pleural manometer|
1605965|NCT02192125|Device|REWIRE-System|"The REWIRE rehabilitation platform consists of three hierarchical components:
patient station (PS), which is installed in the home environment of the patient:
Includes:
Laptop with software - Game Tymoplate® - balanceboard Kinect® - 3D tracking
Hospital Station (HS), which allows an exchange of information with more patient station and is served by the therapists in the hospital;
Includes:
Laptop MySQL- database
station networking (NS), which allows a combination of a several of HS. database"
1605966|NCT02192099|Drug|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm. Can be adjusted to 5 mg/kg weekly or biweekly.
1605967|NCT02192086|Other|goal directed fluid therapy|"The treatment group will initially be given a 1L bolus after induction over 20 minutes (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) followed by maintenance infusion at a rate of 5mL/kg/hr until the graft kidney is removed from ice. After removing the organ from ice, the kidney recipient will be administered supplemental crystalloid until PVI is 10 or lower. Plasmalyte will be warmed in accordance to the departmental hypothermia protocol. A PVI of 12 or lower will be maintained until emergence of anesthesia, at which time the PVI monitor will be removed and all patients will be managed by existing standards (pain control, fluid replacement, hemodynamic goals, etc).
a.At the time the treatment group begins receiving goal directed fluid therapy the anesthesia team is to wean any vasopressors aggressively with the goal of terminating infusion as quickly as is safe."
1605968|NCT02192086|Other|Control Group|"Control patients will be given a constant infusion of crystalloid (first liter may be Lactated Ringers solution or Plasmalyte, subsequent fluid will be Plasmalyte) at a rate determined by the following: 70mL/kg for the duration of the surgery, 1L bolus after induction (over 20-30 minutes) followed by the remainder as a constant infusion determined by (70mL/kg * wt - 1000mL) / 160 minutes (using the local average of approximately 180 minutes of operative time).
a.A Masimo PVI monitor will be placed on the patient on an extremity not affected by an AV fistula and recorded for evaluation, but no fluid administration decisions will be made based on it (providers will not have access to its values)."
2009897|NCT03169777|Biological|haNK|NK-92 [CD16.158V, ER IL-2], Suspension for Intravenous [IV] Infusion
1605971|NCT02192060|Other|Test - Using of a suspension containing Triclosan|The participants should have used only the suspension containing Triclosan during 5 days and have stopped with their biofilm control homemade procedures.
1605972|NCT02192060|Other|Control - Using of a suspension without Triclosan|The participants should have used only the Placebo suspension during 5 days and have stopped with their biofilm control homemade procedures.
1605973|NCT02192047|Other|Palm Olein|8 weeks
1605974|NCT02192047|Other|IE Palm olein|8 weeks
1605975|NCT02192047|Other|IE soybean oil-based|8 weeks
1605976|NCT02192034|Behavioral|Navigation|
1605977|NCT02192021|Drug|Micro needle array-Doxorubicin (MNA-D)|MNA-D patches will be applied to 3-4 CTCL skin patches or plaques at each weekly visit (4/cycle). The initial safety, dose-finding phase will include one cycle of applications and the second phase will include weekly applications (4/cycle) for up to 6-8 cycles.
1605978|NCT02192008|Biological|Salmonella Typhi|
1605979|NCT02192008|Biological|Salmonella Paratyphi|
1605980|NCT02191995|Behavioral|yoga|
1605981|NCT02191982|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
1605982|NCT02191969|Behavioral|Walk With Ease|A self-directed walking intervention developed by the Arthritis Foundation. The intervention is a workbook that coaches participants through walking regularly at a safe, comfortable pace with the ultimate goal of walking at least 30 minutes a day five days a week.
1605983|NCT02191956|Behavioral|Behavioral Parent Training|Weekly clinic session, mid-week call, home practice
1606030|NCT02191527|Device|PIMA® for quantitative analysis of CD4-count|
1606031|NCT02191527|Device|Hemocue® (HemoCue AB, Angelhom, Sweden) for quantitative analysis of hemoglobin|
1605984|NCT02191943|Device|Duraphat|The subjects in the control group will be the subject of personalized oral hygiene instructions on the basis of obtained indices, and will also receive a professional prophylaxis. Following this, the surfaces of the teeth in the control group involved in the trial will be treated with a fluoride varnish (Duraphat®) that will be applied with a brush to all surfaces of the teeth, working the varnish approximally with the brush. This treatment will be repeated in the comparative group at each follow-up appointment.
1605985|NCT02191943|Device|Icon approximal caries infiltration kit|Carious lesions in the teeth in the test group shall be treated with the infiltrant ICON® according to the manufacturer's instructions. Step by step instructions for application are as follows:
1605986|NCT02191930|Drug|B-CAP|
1605987|NCT02191930|Drug|Brentuximab Vedotin|
1990812|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/16 mg, orally once daily
1605989|NCT02191904|Other|Macintosh type, Truview EVO2® type and Airtraq® type laryngoscopes|
2009898|NCT03167697|Dietary Supplement|Synergy|Small serving (x1 33 g serving daily) of the new phenylalanine-free protein substitute made up with 100mL of water daily (28 days).
1605992|NCT02191878|Drug|TKM-080301|TKM-080301 intravenous infusion
1605993|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
1605994|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
1605995|NCT02191865|Drug|Nintedanib|Soft gelatine capsule
1605996|NCT02191852|Drug|Seresis®|
1605997|NCT02191839|Drug|Alpha 1-Antitrypsin|
1605998|NCT02191826|Drug|SOM0226|Oral
1605999|NCT02191813|Drug|Seresis®|
1606000|NCT02191813|Drug|Placebo|
1606001|NCT02191787|Drug|Seresis®|
1606002|NCT02191787|Drug|Placebo|
1606003|NCT02191774|Procedure|Medical abortion at home|Medical abortion using Mifepristone at the clinic followed by Cytotec at home
1606004|NCT02191761|Drug|SM04755|Escalating Doses
1606005|NCT02191748|Procedure|Needling|Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.
1606006|NCT02191748|Drug|Triamcinolone|During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
1606007|NCT02191735|Device|RAMP 200|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® 200 is Response Biomedical's second generation reader. The RAMP® 200 is designed to process more tests with a smaller footprint.
1606008|NCT02191735|Device|RAMP Reader|The RAMP® Reader is a general use fluorometer that analyzes results produced by immunoassays that use a fluorophore having an excitation wavelength at 560 nm and an emission wavelength of 610 nm. The RAMP® Reader is Response Biomedical's first generation reader instrument. Designed for use at near-patient/bedside or locations such as: laboratories, hospitals, on-site Emergency Response and Emergency Rooms.
1606009|NCT02191722|Behavioral|reading comics booklet|
1606010|NCT02191709|Drug|Dextromethorphan syrup|
1606011|NCT02191709|Drug|Dextromethorphan soft pastilles|
1606012|NCT02191696|Device|IMED-4 recording|
1606013|NCT02191670|Drug|METALYSE®|weight-adjusted dosage as single bolus over 5 to 10 seconds
1606014|NCT02191657|Drug|Deferiprone|Oral iron chelator
1606015|NCT02191644|Dietary Supplement|Dietary intervention-refined rice|Subjects in the control group maintained the usual refined-rice diet.
1606016|NCT02191644|Dietary Supplement|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group replaced refined rice with a mix of 1/3 legumes, 1/3 barley, and 1/3 wild rice three times per day, and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
1606017|NCT02191631|Behavioral|Internet-delivered Cognitive Behavior Therapy|The treatment consists of standard cognitive behavior therapy for obsessive-compulsive disorder and is delivered via an internet plattform and regular therapist contact several times per week via email and telephone. The treatment is 12 weeks.
1606018|NCT02191618|Device|WEB|The WEB is an intra-aneurysmal device intended for use in endovascular embolization of intracranial aneurysms.
1606019|NCT02191605|Behavioral|eSBIRT|A single 20 minute interactive computer-delivered intervention designed to promote motivation to change prenatal marijuana use, without presuming the participant to be currently using marijuana while pregnant.
1606020|NCT02191605|Behavioral|Tailored texting|Group text messaging software from Trumpia, Inc. will be used to create the tailored text messages that will be sent to participants assigned to this intervention. Text messages will sent after the initial study participation visit until childbirth or participant opts out of receiving them.
1990813|NCT01788358|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), tablet, 60/32 mg, orally once daily
1606023|NCT02191566|Drug|S-1 (452500ACH)|S-1 80 mg/m²/day from day 1 to day 14, every 21 days, for 12 months
1606024|NCT02191566|Drug|OXALIPLATIN (205803BIJ)|Oxaliplatin 130 mg/m² for day 1, every 21 days, for 6 months
1606025|NCT02191553|Behavioral|Control group relaxation techniques|Jacobson's progressive muscular relaxation, emotional imagining and Schultz's autogenic training.
1606026|NCT02191553|Behavioral|Loving-kindness meditation|Following Kristin Neff protocol
1606027|NCT02191553|Behavioral|Body scan|Body scan: Attention being directed with detailed awareness to every part of the body for a sustained period of time.
1606028|NCT02191553|Behavioral|Sitting practice|In the sitting exercise, participants are guided to pay attention to a certain range of still points, starting with attention to breathing. In this exercise attention is fully concentrated on a single object: the sensation attached to breathing. If the mind wanders or is distracted by an external stimulus, attention is gently returned to sensations derived from breathing.
1606029|NCT02191540|Drug|Abnoba Viscum F 20mg|intravesical instillation of five amples of AbnobaViscum® F20mg and 0.9% normal saline into the pleural space
1990815|NCT01786577|Other|Magnetic Resonance Imaging|Both groups will undergo two MRIs at baseline and within 48 hours after surgery/non-surgery.
1606033|NCT02191501|Procedure|Pyloric restriction|"The Apollo Overstitch Suturing Device is FDA approved for suturing in the gastrointestinal tract.
However, the suturing device has never been used for suturing the pylorus in humans before. This procedure is not standard medical care. The safety and effectiveness of this procedure are being tested."
1606034|NCT02191488|Drug|5-aminolevulinic acid|
1606035|NCT02191475|Drug|glycopeptide plus carbapenem|The control group antibiotic selection according to the classical scheme use of glycopeptide plus carbapenem antibiotic (or oxazolidinone antibiotics), with or without antifungal therapy
1606036|NCT02191475|Drug|Haizheng Li Xing ® plus tazocin ®|Tigecycline (Haizheng Li Xing ®) combined with piperacillin/tazobactam (tazocin ®), with or without antifungal therapy
1606037|NCT02191462|Dietary Supplement|Niagen 100mg|
1606038|NCT02191462|Dietary Supplement|Niagen 300mg|
1606039|NCT02191462|Dietary Supplement|Niagen 1000mg|
1606040|NCT02191423|Drug|Oxytocin|administered pre-fMRI assessment
1606041|NCT02191423|Drug|placebo|administered pre-fMRI assessment
1606042|NCT02191423|Behavioral|Dyadic psychotherapy|
1606043|NCT02191410|Procedure|High Frequency Positive Pressure Ventilation|TV 2 mL kg-1 PBW, I:E ratio > 0.3, RR 60 breaths min-1 and a FGF of < 2 L min-1, using a second identical ventilator with low compliant internal circuit
1606044|NCT02191410|Procedure|Continuous Positive Airway Pressure|CPAP of 2 cm H2O
2009899|NCT03167697|Other|Routine|Patients will continue their usual dietary and/or protein substitute regimen (28 days).
2009900|NCT03167437|Drug|Vorinostat|100mg PO BID for 12 weeks
2009901|NCT03167723|Device|Chest tube placement|Placing tube thoracostomy for hemothorax or hemopneumothorax utilizing maximal barrier precautions.
2009902|NCT03167164|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
1606049|NCT02191384|Drug|Orcinoside|oral, twice per day
1606050|NCT02191371|Drug|propofol|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
1606051|NCT02191371|Drug|desflurane|Patients are randomized to receive intravenous anesthetic (propofol) or inhalational anesthetic (desflurane) as a maintenance anesthetic.
1606052|NCT02191345|Behavioral|Guided Imagery|Guided imagery is a stress management technique that uses verbal suggestion and descriptive language to guide the listener into imagining sensations and visualizing images in the mind in order to bring about a desired physical response, such as reduction in anxiety, stress, or pain. The guided imagery tracks chosen for the study were chosen because their goal is relaxation and stress relief, and their length is under 15 minutes.
1606053|NCT02191332|Drug|Viramune|
1606054|NCT02191319|Drug|Viramune®|
1606055|NCT02191293|Drug|Viramune® tablets|
1606056|NCT02191280|Drug|Antistax®, low dose|
1606057|NCT02191280|Drug|Antistax®, high dose|
1606058|NCT02191280|Drug|Placebo|
1606059|NCT02191267|Radiation|[F18]-T807|[F18]-T807 PET Scan to measure tau deposition in the brain.
1606060|NCT02191267|Radiation|[F18]-Florbetapir|[F18]-Florbetapir PET scan to measure Beta-amyloid deposition in the brain.
1606061|NCT02191267|Device|MRI/MRS|Two scans (structural, diffusion tensor imaging, and susceptibility weighted imaging scanned as part of one MR protocol, and a one-dimensional and two-dimensional spectroscopy examination as part of the other MR protocol.
1606062|NCT02191267|Genetic|Genetic Analysis for Genetic Risk Score for Tau.|DNA will be extracted from previously acquired and de-identified frozen blood specimens using a standard protocol (Gentra Puregene Kit, Qiagen 158422). Genotyping will be performed using the iPLEX Sequenom MassARRAY platform and samples will be genotyped for single nucleotide polymorphisms (SNPs) associated with the deposition of neurofibrillary tangles.
1606063|NCT02191254|Drug|Antistax®|
1606064|NCT02191254|Drug|Placebo|
1606065|NCT02191241|Drug|Red Vine Leaf Extract|
1606066|NCT02191228|Drug|Linagliptin - single dose|
1606067|NCT02191228|Drug|Linagliptin - Multiple dose|
1606068|NCT02191215|Drug|Nevirapine (Viramune®)|
1606069|NCT02191202|Drug|Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)|
1606070|NCT02191189|Drug|Nevirapine suspension, into Enterion™ capsule|
1606071|NCT02191189|Drug|Nevirapine suspension|
1606072|NCT02191176|Drug|Dextromethorphan syrup - low dose|
1606073|NCT02191176|Drug|Dextromethorphan syrup - high dose|
1606074|NCT02191176|Drug|Placebo|
1606075|NCT02191163|Drug|Antistax®|
1606076|NCT02191163|Drug|Placebo|
2009903|NCT03167164|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
1606078|NCT02191124|Drug|Paroxetine|Patients in both groups (MBC or ST) receive open-label paroxetine (20-60mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China.
1606079|NCT02191124|Drug|Mirtazapine|Patients in both groups (MBC or ST) receive open-label mirtazapine (15-45mg/day) within the therapeutic dose range recommended by the Guidelines for the Prevention and Treatment of Major Depression in China
2009904|NCT03167164|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
1606081|NCT02191098|Drug|ALT-803|Interleukin 15 (IL-15) is a common γ-chain cytokine that is related to interleukin-2 (IL-2) and is a critical factor for the development, proliferation, and activation of effector natural killer (NK) and CD8+ memory T cells
1606127|NCT02190695|Drug|Carboplatin|AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
1606128|NCT02190695|Drug|Arsenic trioxide|0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
1606129|NCT02190669|Other|exercise|Sprinting, walking on a treadmill, and stationary bicycle riding
1606130|NCT02190643|Behavioral|Cessation counseling with adherence focus|
1606131|NCT02190643|Behavioral|Cessation counseling without adherence focus|
1606172|NCT02190162|Drug|Tantum Verde® mouthwash|
2009905|NCT03167164|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
2009906|NCT03167164|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
2009907|NCT03167164|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
2009908|NCT03167164|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
1606082|NCT02191085|Procedure|Fast Track|"In the Fast Track arm, an ACP will perform the initial assessment and will determine the management plan with the patient. To ensure patient safety, the management plan will be discussed with a sleep respirologist, who will be designated as the patient's primary sleep physician. This sleep physician will be available at the FMC Sleep Centre during the Fast Track clinic to assist with the assessment of patients who appear unwell. As in the Standard Management arm, follow-up visits to review test results, discuss and initiate treatment, or to assess treatment response may occur with the ACP who performed the initial assessment or may be delegated to any other ACP."
1606083|NCT02191072|Drug|omalizumab|a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE)
1606084|NCT02191059|Drug|Icotinib|
1606085|NCT02191059|Drug|Docetaxel|
1606086|NCT02191046|Device|squeezable bottle|nasal irrigation twice daily for 2 weeks period
1606087|NCT02191046|Device|syringe 20 ml|nasal irrigation twice daily for 2 weeks
1606088|NCT02191033|Behavioral|Smoking counseling|
1606089|NCT02191033|Behavioral|Text messaging|
1606090|NCT02191033|Drug|Nicotine patch|
1606091|NCT02191020|Drug|Total glucosides of paeony & Acitretin Capsules|
1606092|NCT02191020|Drug|Acitretin Capsules|
1606093|NCT02191007|Drug|Calcipotriol Betamethasone ointment and Calcipotriol ointment|
1606094|NCT02191007|Drug|Calcipotriol Betamethasone ointment|
1606095|NCT02191007|Drug|Calcipotriol Betamethasone ointment and Urea Cream|
1606096|NCT02190994|Drug|Hydrocortisone|used intravenously
1606097|NCT02190994|Drug|Prednisone|used as tablet form
1606098|NCT02190981|Device|Ultrasound for Small Bowel Obstruction|Point-of-care ultrasound to evaluate emergency department patients for suspected small bowel obstruction
1606099|NCT02190968|Behavioral|Usual Depression Care|Usual Depression Care will be based on the Kaiser Permanente Adult Depression National Guidelines - an adaptation of STAR*D (Rush et al., 2006) for antidepressant management and the IMPACT (Unitzer et al., 2002; 2008) model for therapy.
1606100|NCT02190968|Behavioral|Mindful Mood Balance|Mindful Mood Balance is an individually tailored, web-based version of Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2002) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participated in 8 internet sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
2009909|NCT03167164|Drug|nab-Paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
2009910|NCT03167164|Drug|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
1606105|NCT02190851|Device|TENS|"Two electrodes are attached around the internal malleolus and connected to the TENS unit.
The sessions last 20 minutes daily (frequency 10Hz, duration 200µs), at maximum intensity of painless stimulation, every day at the same time, on the right side for 3 months."
1606106|NCT02190851|Device|Control|The device will have been previously set to deliver a stimulation below the effective threshold. In all cases, the device displays 20mA. Stimulation sessions are 20 minutes daily, every day at the same time, on the right side for 3 months.
1606107|NCT02190838|Drug|Metformin|per os 850 mg BID
1606108|NCT02190838|Drug|Melatonin|per os 3 mg daily
1606109|NCT02190838|Drug|Dacarbazine|IV 1 hour 1000 mg/m^2 once in 28 days
1606110|NCT02190825|Device|NeuGuide device|The NeuGuideTM device is indicated for anchoring sutures to ligaments of the pelvic floor
1606111|NCT02190812|Device|Forearm supporter|The forearm supporter be use in tennis elbow.
1606112|NCT02190812|Device|Grip ball|
1606113|NCT02190799|Biological|Convalescent plasma|Convalescent plasma from patients who recently recovered from MERS-CoV, HCWs who had potential exposure and subjects who are willing to donate plasma and have their blood tested for anti MERS-CoV serology and RT-PCR after obtaining their consent
1606114|NCT02190786|Drug|KUX-1151|
1606115|NCT02190760|Drug|Dexamethasone|
1606116|NCT02190760|Drug|Bupivacaine|
2009911|NCT03167164|Radiation|Stereotactic Body Radiation Therapy|radiation
2009912|NCT03167164|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
1606119|NCT02190734|Other|Sitting in wheel chair|Placebo/control intervention- No treatment, sitting in a wheelchair for 30 minutes
1606120|NCT02190734|Other|Gait training on treadmill|Walking on a treadmill with or without body weight support during 30 minute treatment
1606121|NCT02190734|Other|Gait training overground|Walking overground with or without body weight support during 30 minute treatment
1606122|NCT02190721|Drug|tbo-filgrastim|5 μg/kg
1606123|NCT02190708|Drug|PQ912|from day2 up to day6 twice daily oral dose of PQ912
1606124|NCT02190708|Drug|Midazolam|single oral dose on day1 and day 6
1606125|NCT02190708|Drug|Omeprazole|single oral dose on day1 and day6
1606170|NCT02190188|Device|Wedge Insole 5mm|
2009913|NCT03167164|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
2009914|NCT03167164|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
2009915|NCT03167164|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
2009916|NCT03167164|Biological|haNK|NK-92 [CD16.158V, ER IL-2] (high-affinity activated Natural Killer cells)
2009917|NCT03166930|Behavioral|Spasticity Take Control|Participants will attend two 2-hour classes, one week apart, consisting of a stretching program developed by the principal investigator for spasticity management.
2009918|NCT03166930|Behavioral|Usual care|"Participants will attend two 2-hour classes, one week apart, consisting of exercises as outlined in the National MS Society brochure, Stretching for People with MS: An Illustrated Manual."
2009919|NCT03166735|Drug|BI 1467335|once daily
2009920|NCT03166735|Drug|Placebo|once daily
2009921|NCT03167177|Biological|Avelumab|Fully human anti-PD-L1 IgG1 lambda monoclonal antibody
2009922|NCT03167177|Biological|Bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal antibody
1606132|NCT02190630|Device|Modified Clark Twin Block|The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
1606133|NCT02190617|Behavioral|Enhanced Clinic+ Unified Plan + CHW|"Unified asthma management plan and asthma support team coordination: A support team will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan.
Home visit intervention: Community health workers will provide in-home tailored asthma support and conduct follow-up to support patient actions to improve asthma control based on unified asthma management plan.
Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
1606134|NCT02190617|Behavioral|Enhanced Clinic+ Unified Management Plan|"Unified asthma management plan and asthma support team coordination: A support team (clinicians, CHWs and plan care managers) will partner with each patient to develop a single asthma management plan. An EMR will provide a web-based platform for sharing the unified asthma management plan and enhancing communications among care team.
Enhanced clinic intervention: Intervention clinics will implement a multicomponent intervention that will include decision support, audit and feedback, provider and staff education, asthma champions, team-based care, and spirometry, all supported by EMR enhancements and clinic systems redesign."
1606135|NCT02190617|Behavioral|CHW Home Visit Only|-Home visit intervention: Community health workers will provide in-home tailored asthma support: assess asthma self-management knowledge and skills, conduct a home environmental assessment focused on asthma triggers, and conduct follow-up visits to support patient actions to improve asthma control based on unified asthma management plan.
1606136|NCT02190604|Drug|Placebo|Capsule- oral dose
1606137|NCT02190604|Drug|QBW251|Capsule - oral dose
1606138|NCT02190591|Device|Peanut Labor Ball|Peanut Labor Ball
1606139|NCT02190578|Device|Reveal G4|All subjects tested with the investigational device, Reveal G4, plus with an algorithm of approved assays for HIV.
1606140|NCT02190565|Dietary Supplement|Food supplement|Randomized double-blind, placebo-controlled
1606141|NCT02190552|Device|EmboTrap® Revascularization Device|
1606142|NCT02190539|Other|Homeopathic treatment|Remedies are sold over the counter without a physician prescription (approved by the Israeli Ministry of Health). No toxicity or side effects are expected to be observed, potencies (dilutions) of substances beyond 7C (7 dilutions, each 1:100) do not contain a sufficient number of molecules of the original material to be pharmacologically active. Since the remedies being used in this trial are diluted at 30c and 200c, levels that are way beyond Avogrado's number, so no original material is expected to be found. This fact was verified utilizing high pressure liquid chromatography (HPLC) method. Due to those facts, most scientists do not accept that these remedies have any biological effects and consign any positive response to the placebo effect.
1606143|NCT02190526|Drug|Mesalazine(asacol 800 mg)|
1606144|NCT02190526|Drug|Amitriptyline|
1606145|NCT02190526|Drug|placebo like asacol|
1606146|NCT02190526|Drug|placebo like amitriptyline|
1606147|NCT02190500|Other|Mobile Stroke Unit Management|Mobile Stroke Unit is a standard 12' Houston Fire Department ambulance equipped with point of care lab, CT scanner and staffed by a Vascular Neurologist, Registered Nurse with acute stroke and research experience, CT Technician and a Registered EMT-P. The MSU is dispatched in coordination with Houston, Bellaire and West University fire department/emergency medical services.
1606148|NCT02190474|Behavioral|Mindfulness Group|Participants will attend weekly 1-2-hour group sessions (of 6-8 persons) led by a trained expert based on the working MBSR protocol. The weekly sessions will be scheduled in a time mutually convenient for participants and their parent/guardian that will accompany them to each group session. The MBSR group sessions will take place at the Yale School of Medicine.
1606149|NCT02190461|Procedure|Early Respiratory Rehabilitation Program|
1606150|NCT02190461|Procedure|Conventional Respiratory Rehabilitation Program|
1606151|NCT02190448|Dietary Supplement|study herbal tea|3-5 cups, 8oz tea daily for 4 weeks
1606152|NCT02190448|Dietary Supplement|herbal placebo tea|3-5 cups, 8oz each daily for 4 weeks
1606153|NCT02190435|Device|Stryker ADAPT computer-assisted navigation|Adaptive Positioning Technology for Gamma 3
1606154|NCT02190435|Device|Conventional technique|Conventional Technique
1606155|NCT02190409|Device|Dental implant|This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 4 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach
1606156|NCT02190383|Behavioral|Habit Reversal Training|awareness training, competing response training
1606157|NCT02190370|Behavioral|Resources activation|
1606158|NCT02190357|Drug|Rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
1606159|NCT02190344|Device|8-channel paddle coil|MRI Coil
1606160|NCT02190331|Other|Interventional program postural correction training|The postural correction training program was applied in the last 15-20 minutes of each PE class, twice a week, with the supervision and help of the PE teacher.
1606161|NCT02190331|Other|Control Group physical education classes|Only performed the physical education classes
1606162|NCT02190318|Drug|Losartan|
1606163|NCT02190318|Drug|spirolactone|
1606164|NCT02190318|Other|blank control|
1606165|NCT02190305|Device|Multiplo HBc/HIV/HCV and Reveal HBsAg|All subjects tested with both investigational devices, plus with algorithms of approved assays for HIV and hepatitis B and C.
2009923|NCT03167177|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
1606167|NCT02190227|Device|Tumor RDA biopsy|Tumor RDA score measured from an FNA biopsy after cycle 1-2-3 of neoadjuvant chemotherapy and after first cycle of second chemotherapy agent if palpable tumour present.
1606168|NCT02190201|Device|videolaryngoscope|a kind of videolaryngoscopes, which are widely used in difficult airways.
1606169|NCT02190201|Device|Direct laryngoscope|A kind of traditional laryngoscopes
2009924|NCT03167177|Drug|Cisplatin|(SP-4-2)-diamminedichloroplatinum(II)
1606173|NCT02190162|Other|Placebo mouthwash|Mouthwash with placebo solution
2009925|NCT03167177|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
1606176|NCT02190136|Other|Protein whole foods|Protein-rich whole foods consumed at 20-30 grams of protein at each of 4-6 meals per day
1606177|NCT02190136|Other|Protein Resistance Exercise Training|Protein rich whole foods diet and resistance training 3 times per week for 11 weeks
1606178|NCT02190136|Other|Protein Stretching/Yoga Training|Protein-rich whole foods diet of 20-30 grams of protein at each of 4-6 meals per day with stretching/yoga training 3 times per week for 11 weeks
1606179|NCT02190123|Drug|ACS patients treated with OAP|Patients with ACS who have been initiated and treated with ticagrelor and other oral antiplatelets.
1606180|NCT02190097|Other|Paleolithic diet|see procedures section for more details
1606181|NCT02190097|Other|American Diabetes Association diet|see procedures section
1606182|NCT02190084|Device|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 20 treatment sessions are given over a four week period.
1606183|NCT02190058|Drug|DS-1971a|suspension
1606184|NCT02190058|Drug|placebo|placebo matching DS-1971a
1606185|NCT02190045|Other|Wii-Fit exercises|Wii-Fit exercises will be administered for 45 minutes 3 days of the week for 8 weeks
1606186|NCT02190045|Other|Cognitive remediation exercises|Cognitive Remediation exercises will be administered for 45 minutes 3 days of the week for 8 weeks
1606187|NCT02190032|Device|Mallinckrodt endotracheal tube with a modified angle|At sniffing position, the distal tip of a double-lumen tube is located at the patient's cricoid cartilage level and then the tube is bent at the intersection point of oral axis and the pharyngolaryngeal axis with an angle between the two axes.
1606188|NCT02190032|Device|Mallinckrodt endobronchial tube with a conventional angle|Inserting a manufacturer-provided conventional-angled tube
1606189|NCT02190019|Device|Neurostar repetitive transcranial magnetic stimulator|The active procedure will stimulate at 120% motor threshold for 4 seconds at a frequency of 10 Hz, with an inter-train interval of 26 seconds for a total of 3,000 pulses. 10 treatment sessions are given over a two week period.
1606190|NCT02189980|Other|Aromatherapy blend|A blend of 45% ginger, 25% peppermint, 5% spearmint, and 25% cardamom essential oils
1606191|NCT02189980|Other|Duration of effectiveness of the essential oil blend|Evidence of effectiveness of tested aromatherapy blend in reducing symptoms of post-operative nausea as measured by patient self-report using Likert-type scale measure immediately to one-day post-operative.
1606192|NCT02189980|Other|Participant comfort using the nasal clip delivery system|Comfort of participants using nasal clip delivery system for aromatherapy will be measured by self-report using Likert-type scale immediately to one-day post-operative.
1606193|NCT02189967|Radiation|conventional fractionation|In this treatment arm patients will receive radiotherapy with the currently used conventional fractionation schedule i.e. 5 fractions per week, 2 Gy single dose.
1606194|NCT02189967|Radiation|accelerated fraction|In this treatment arm patients will receive radiotherapy with an accelerated fractionation schedule i.e. 7 fractions per week, 2 Gy single dose.
1606195|NCT02189954|Procedure|The placement according to the manufacturer's instructions|Before insertion the laryngeal mask used in daily routine (Laryngeal Mask Unique®(LMU)) was lubricated with a water-based gel and the cuff was completely deflated. After induction when BIS values were between 40 and 60 and sufficient chin relaxation was obtained for patients weighing less than 50 kg no. 3 LMU, for those between 50-90 kg no. 4 and for patients above 90 kg no. 5 LMU was inserted by an anesthetist with more than five years experience
1606196|NCT02189954|Procedure|Cuff inner pressure was held below 44 mmHg|cuff pressure limitation (Group Pressure Limiting (PL), n=45) cuff inner pressure was held below 60 cmH2O (44 mmHg)
1606197|NCT02189941|Drug|Deferiprone sustained-release|Deferiprone sustained-release tablets
1606198|NCT02189941|Drug|Deferiprone immediate-release|Deferiprone immediate-release tablets
1606199|NCT02189928|Device|Lower limb tourniquet|"Lower limb tourniquet will be put on half thigh. The protocol will include 4 cycles of inflation cuff 110 mm Hg above systolic blood pressure followed by 4 cycles of deflation in between.
The total duration of per-CID protocol will be 40 minutes (4 phases of 5 minutes inflations' of and 4 phases of 5 minutes deflations')."
1606200|NCT02189928|Other|Usual care|
1606201|NCT02189915|Drug|Creatine monohydrate|
1606202|NCT02189902|Dietary Supplement|4000 IU/d D3 over 12 weeks|
1606203|NCT02189902|Dietary Supplement|7000 IU/d D3 over 12 weeks|
1606204|NCT02189889|Drug|EPO|The treatment group will receive up to three doses of EPO 300U/kg. The first dose of study medication will be administered up to 28 days before the day of surgery and the second will be administered 1-7 days before the day of surgery. These first two doses will be given at least 7 days apart. A third dose may be administered two days following surgery. All 3 doses will be administered per surveillance strategy guidelines.
1606205|NCT02189889|Drug|Feraheme|Supplementation with Feraheme, 510mg delivered as an IV infusion, will be given following the first two preoperative doses of EPO.
1606206|NCT02189876|Behavioral|Standard of Care|All participants will be provided a STD/HIV pre-test counseling session. This session will be provided by either certified project staff or clinical staff at a Los Angeles clinic that conduct State of CA Fam Pact services for patients who are of child bearing age, including our current study partner St. John's Well Child and Family Center and our former study partner, JWCH (John Wesley Community Health) Institute-Wesley Health Center Clinics. Following the counseling session, the participant will be asked to provide a sample of urine to test for Chlamydia and Gonorrhea.
1606207|NCT02189876|Behavioral|FemAALES|Women will attend 9 small group sessions over 4 weeks. Three of these sessions will focus specifically on participants learning to use a computer, set up an email account, communicate with the team and the group using the Internet, and developing a prevention message for display on project website and social media accounts. The other 6 sessions will include discussions on the following topics: being a Black woman in American, Black history, assessing personal health, changing current behaviors, HIV/AIDS information, and education, self-empowerment, communication skills, reasons to change, and goal setting.
1606208|NCT02189863|Device|Lotrafilcon B MF|Multifocal contact lenses worn in both eyes
1606209|NCT02189863|Device|Lotrafilcon B MV|Spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near
1606210|NCT02189863|Device|Lotrafilcon B SVD|Spherical contact lenses worn with both eyes corrected for distance
1606211|NCT02189863|Device|Comfilcon A MF|Multifocal contact lenses worn in both eyes
1606212|NCT02189863|Device|Habitual contact lenses|Contact lenses worn in both eyes per subject's habitual prescription
1606213|NCT02189850|Drug|BLI800 - Dose 1|BLI800 oral solution
1606214|NCT02189850|Drug|BLI800 - Dose 2|BLI800 oral solution
1990816|NCT01786577|Behavioral|Cognitive assessment testing|Both groups will undergo in-person baseline assessment of cognitive functioning as well as assessments at three weeks, three months and one year.
2009926|NCT03167177|Drug|5-fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
1606219|NCT02189824|Biological|Partially HLA-matched unrelated donor cells|
1606220|NCT02189811|Biological|IPV|IPV at birth, 6, 10, 14 weeks of age and tOPV at 18 and 22 weeks of age
1606221|NCT02189811|Biological|bOPV|bOPV at birth, 6, 10, 14 weeks and tOPV at 18 and 22 weeks of age
1606222|NCT02189811|Biological|bOPV and IPV|bOPV till week 10, bOPV+IPV at 14 and tOPV at 18 and 22 weeks of age
1606223|NCT02189811|Biological|bOPV and IPV and IPV2|bOPV till week 10, bOPV+IPV at 14, tOPV+IPV2 at 18 and tOPV at 22 weeks of age
1606224|NCT02189811|Biological|tOPV|tOPV till 22 weeks of age
1606225|NCT02189798|Device|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode|HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be implanted in adults with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss).
1606226|NCT02189798|Device|EAS sound processor|Patients with partial deafness (considerable low frequency acoustic hearing profiles with severe-to-profound high frequency sensorineural hearing loss) implanted with HiRes 90K™ Advantage implant with HiFocus™ Mid-Scala electrode will be fitted with the EAS sound processor.
1606227|NCT02189772|Drug|Metadoxine extended release|MG01CI
1606228|NCT02189772|Drug|Placebo|Inactive drug
1606229|NCT02189759|Other|Continuous Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
1606230|NCT02189759|Other|Standard Kangaroo Mother Care to one hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
1606231|NCT02189759|Other|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
1606232|NCT02189759|Other|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
1606233|NCT02189746|Other|Continuous Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible until 1 hour of birth. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
1606234|NCT02189746|Other|Standard Kangaroo Mother Care to 1 hour after birth|Infants will receive the standard WHO thermoregulation care of Kangaroo Mother Care for as much as possible until 1 hour of birth, without additional encouragement per study personnel. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. All infants will be resuscitated as usual per Neonatal Resuscitation Program guidelines and hospital standard practices. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will receive standard care which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age.
1606401|NCT02188563|Behavioral|Enhanced usual care|
1606235|NCT02189746|Other|Continuous Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care with encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from one hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), the infant will be removed from KMC and routine bundling practices will be used. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
1606236|NCT02189746|Other|Standard Kangaroo Mother Care to discharge|Infants will receive the standard WHO thermoregulation care without additional encouragement from study personnel to keep infant in Kangaroo Mother Care for as much as possible from 1 hour after birth to discharge. In KMC, the naked newborn infant with cap and diaper will be placed prone on mom's bare chest with blanket covering the infant's back. The nursing staff will supervise mother-infant when mother is sleeping with infant in KMC. If infant becomes hyperthermic (>38 degrees Celsius), standard treatment will be given which may include removal from KMC and use of routine bundling practices. The infant's temperature will be taken via axillae with a digital thermometer at one hour of age and again at discharge or 24 hours whichever occurs first.
1606237|NCT02189733|Biological|Caplacizumab|Comparison of reconstituted lyophilised formulation versus liquid formulation of caplacizumab
1606238|NCT02189720|Drug|Amifampridine Phosphate|"Dosage form: tablets containing the equivalent of 10 mg amifampridine base per tablet.
Amifampridine Phosphate is taken with food and each patient is given an individualized dose based on Investigator assessment of optimal neuromuscular benefit. Doses range from 30 mg to 80 mg, divided into doses taken 3 to 4 times per day, with a maximum single dose of 20 mg."
1606239|NCT02189707|Dietary Supplement|Probiotic Bifidobacterium 1x1010 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks.
1606240|NCT02189707|Dietary Supplement|Probiotic Bifidobacterium 1x109 cfu|Participants who pass the initial screening will enter a 2-week placebo-only run-in period. Participants who successfully complete the run-in period will be randomized to daily supplementation with B. lactis HN019 (1 x 1010 cfu), B. lactis HN019 (1 x 109 cfu), or placebo for 4 weeks. One capsule of study product, mixed with provided yogurt, will be consumed once a day.
1606241|NCT02189707|Other|Placebo powder in capsules|Participants will consume placebo capsules only during the 2-week run-in period. After randomization, participants will be administered their assigned study product and will continue on the product for 4 weeks.
1606242|NCT02189694|Device|Single-hormone closed-loop strategy|Variable subcutaneous insulin infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
1606243|NCT02189694|Device|Dual-hormone closed-loop strategy|Variable subcutaneous insulin and glucagon infusion rates will be used to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) and Glucagon (Eli Lilly and Company) will be used.
1606244|NCT02189694|Device|Insulin pump therapy|Subjects will use conventional pump therapy to regulate glucose levels. Insulin Aspart (Novorapid, Novo Nordisk) will be used.
1606245|NCT02189681|Procedure|Conventional landmark guided midline spinal anaesthesia|Spinal anaesthesia was administered based on conventional landmark based midline approach.
1606246|NCT02189681|Procedure|pre-procedure ultrasound guided L5S1 paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The L5 S1 interspinous space with best image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained. At this selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.Spinal anaesthesia is then administered based on these landmarks.
1606247|NCT02189681|Device|spinal anaesthesia|Spinal anaesthesia is administered with appropriate spinal needle
1606248|NCT02189668|Drug|Antibiotics only (Zosyn then Augmentin)|Intravenous and oral antibiotics without surgery Piperacillin/Tazobactam and then Augmentin Cipro/Flagyl if Penicillin allergic
1606249|NCT02189655|Procedure|bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid|Hyperbaric bupivacaine 0.5% 2.5 mL diluting with cerebrospinal fluid was administered intrathecally in 30 seconds
1606250|NCT02189629|Drug|CD5789|
1606251|NCT02189616|Behavioral|SMS reminder|send weekly mobile phone short message reminders to the intervention group
1606252|NCT02189616|Other|SMS consultation|told patients to consult qualified asthma nurses by SMS when they need
1606253|NCT02189616|Other|regular care|patients are asked to fill in their paper asthma diary daily for 3 months
1606254|NCT02189603|Biological|Recombinant (E. Coli) Hepatitis E Vaccine|
1606255|NCT02189590|Device|i-gel|Patients randomized to this intervention will have the i-gel placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
1606256|NCT02189590|Device|air-Q|Patients randomized to this intervention will have the air-Q placed following induction of general anesthesia. Subsequent tracheal intubation will be performed using the device as a conduit for fiberoptic-guided intubation. Following successful tracheal intubation, the device will be removed.
1606257|NCT02189577|Drug|CHF 5259|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
1606258|NCT02189577|Drug|Placebo|Comparison of CHF 5259 versus placebo over a treatment period. Allocation of 1 of the 2 possible treatments performed in sequence during a cross over design.
1606259|NCT02189564|Behavioral|Feedback about good performance|
1606260|NCT02189564|Behavioral|Feedback about good performance + money|
1606261|NCT02189564|Behavioral|Feedback about average performance|
1606262|NCT02189551|Behavioral|Gait training with Lokomat Pro|
1606263|NCT02189551|Behavioral|Gait training with Lokomat Pro FreeD|
1606264|NCT02189538|Dietary Supplement|ω-3 PUFA|The patients are fed as long as the clinically required with the randomly attributed enteral solution.
1606265|NCT02189538|Dietary Supplement|Low fat enteral diet|The patients are fed as long as the clinically required with the randomly attributed enteral solution
1606266|NCT02189512|Other|blood sampling|cases - blood sampling controles - blood sampling
1606267|NCT02189499|Device|AmM FORTITUDE Bioresorbable Drug-Eluting Coronary Scaffold|Placement of the investigational device into the diseased coronary artery to eliminate the vascular stenosis.
1606268|NCT02189473|Radiation|radiotherapy|external beam radiotherapy (5 x 4 Gy versus 10 x 3 Gy)
1606269|NCT02189447|Procedure|Simultaneous Photorefractive Keratectomy and Collagen Cross-linking in patients with keratoconus|Photorefractive Keratectomy followed by Collagen Cross-linking in patients with keratoconus in the same surgical setting
1606270|NCT02189434|Other|Serum procalcitonin lab draws|"Blood will be collected in a 4mL capacity, green top lithium heparin tube. Samples can be drawn from a port with other labs. The samples will be centrifuged and then the plasma/serum will be removed and placed into a screw-capped round bottom plastic vial. Samples will be stored at -20○C until processing. Serum samples will be batch processed for each participant at the conclusion of their study period.
These draws will be conducted for the sole purpose of this study, and whenever possible, they will be performed at the same time as routine blood draws conducted for medical monitoring to reduce the burden to the patients."
1606271|NCT02189421|Device|ultra-slim upper endoscope|Direct peroral cholangioscopy by using an ultra-slim upper endoscope without assisting accessories
1606272|NCT02189408|Biological|Platelet rich plasma|
1606273|NCT02189395|Drug|NPH and regular insulin|
1606274|NCT02189395|Drug|glargine and humalog|
1606275|NCT02189382|Device|Potassium Oxalate|
1606276|NCT02189382|Other|Water|
1606277|NCT02189369|Other|Day 3 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 3 embryo transfer
1606278|NCT02189369|Other|Day 5 embryo transfer|Extraction of endometrial fluid, analysis of prostaglandine and Day 5 embryo transfer
1606279|NCT02189356|Behavioral|exercise programme|The study was a prospective randomized trial with a control group (standard care group) and an intervention group, using a repeated measures design. Forty-eight pregnant participants with pregnancy-related LBPP were included in the control group and 48 pregnant participants with pregnancy-related LBPP were included in the intervention (exercise) group
1606280|NCT02189356|Behavioral|standard care|standard pregnancy follow up
1606281|NCT02189343|Drug|ACY-1215 in combination with pomalidomide and dexamethasone|Escalating dose Cohorts to determine a potential Maximum Tolerated Dose to recommend for a dosing schedule.
1606282|NCT02189330|Drug|Tafamidis|20 mg of current commercial formulation.
1606283|NCT02189330|Drug|Tafamidis|12.2 mgA free acid tablet.
1606284|NCT02189330|Drug|Tafamidis|20 mg new soft gelatin capsule.
1606285|NCT02189330|Drug|Tafamidis|4 capsules of 20 mg tafamidis of current commercial formulation.
1606286|NCT02189330|Drug|Tafamidis|4 capsules of 12.2 mg tafamidis of free acid tablet..
1606287|NCT02189317|Drug|Exparel|For the treatment group a total of 40 cc consisting of 20 cc of 1.3% Exparel® and 20 cc of 0.5 % marcaine will be administered to the ACL harvest site, into the periosteum surrounding the distal tibial tunnel site, and in the proximity of the skin incisions. No infiltration of Exparel will be provided intra-articularly.
1606288|NCT02189304|Drug|PT010|PT010; Budesonide, Glycopyrrolate, and Formoterol Fumarate Inhalation Aerosol. Administered as 2 inhalations
1606289|NCT02189304|Drug|PT009|PT009 administered as 2 inhalations
1606290|NCT02189304|Drug|Symbicort Turbohaler|Symbicort Turbohaler taken as 2 inhalations
1606291|NCT02189291|Procedure|Immediate catheter removal|The indwelling catheter will be removed prior to exiting the operating room.
1606292|NCT02189291|Procedure|Post op day 1 catheter removal|For patients assigned to catheter removal on post operative day one, which is the standard of care at this point.
1606293|NCT02189278|Behavioral|Psychosocial Intervention|Telephone-based psychosocial intervention involving six telephone encounters. Each encounter focuses on teaching skills for improving adherence and overcoming barriers to obtaining recommended surveillance.
1606294|NCT02189265|Other|Smoke-free legislation|The intervention under study is the ban on smoking in workplaces, and in bars and restaurants implemented in the Netherlands on January 1st, 2004 and July 1st, 2008, respectively.
1606295|NCT02189252|Drug|Epanova|
1606296|NCT02189252|Drug|Lovaza|
1606297|NCT02189239|Drug|Zeller Entspannung film coated tablet|
1606298|NCT02189239|Drug|Placebo|
1606299|NCT02189239|Other|No Treatment|
1606300|NCT02189226|Device|Endoscopic submucosal dissection (ESD) with or without probe-based confocal laser endomicroscopy (pCLE)|Before ESD, the lesion will be observed either by pCLE or by CE to determine proximal and distal margin of the lesion. In the pCLE group, after injection of intravenous fluorescein, the lesion will be observed using a flexible confocal miniprobe. In the CE group, the lesion will be observed conventionally under white light after spraying indigocarmine directly via the forceps channel. Marking dots will be placed on both margins using needle knife. Then several dots will be marked on the surrounding normal mucosa 5 mm from the tumor with Argon plasma coagulation. After injection of saline solution with epinephrine into the submucosa, an initial cut will be made with needle knife outside the line of surrounding marks. An insulation-tipped (IT) knife will be inserted into initial cut, and electrosurgical current will be applied to complete the incision around the tumor. After the circumferential cut, the submucosa will be dissected with the IT knife.
1606301|NCT02189213|Drug|Sertraline|Sertraline will be administered to treat anxiety disorders in children and adolescents.
1606302|NCT02189213|Drug|Fluoxetine|Fluoxetine will be administered to treat anxiety disorders in children and adolescents.
1606303|NCT02189213|Drug|Escitalopram|Lexapro will be administered to treat anxiety disorders in children and adolescents.
1606304|NCT02189200|Dietary Supplement|oat bran - 40g|oat bran - 40g per day
1606305|NCT02189200|Dietary Supplement|refined rice flour- 40g|refined rice flour - 40g per day
1606306|NCT02189187|Behavioral|Mindfulness|
1606307|NCT02189187|Behavioral|Psychoeducation|
1606308|NCT02189174|Drug|CLR457|
1606449|NCT02188212|Device|NobelProcera Crown Shaded Zirconia|
1606309|NCT02189161|Device|Radiofrequency Ablation (Barrx™)|Anal canal RFA is performed to the full anal canal, 3 cm above the dentate line to the anocutaneous line proximal to the verge. The procedure entails Barrx60 ablation device, introducing the device into the anus through the anoscope, placing the electrode surface in contact with the target tissue and delivering 3 bursts of energy in rapid succession at an energy density setting of 12 J/cm2.
1606310|NCT02189135|Device|Telemedicine|The glucometer acts by automatically uploading any glucose readings to an online portal. A summary of the patient's glycaemic and metabolic control, self-management skills as well as compliance to other key measures such as eye examination, screening for microvascular complications would also be provided if available. All patients in this intervention arm would be given a system-driven guidance on when to test their blood glucose based on their disease status, medication regimen, and time of poorest control so that the most useful, patient specific blood profile can be created and used for future self-management coaching for patient
1606311|NCT02189122|Drug|Bradykinin|Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
1606312|NCT02189122|Drug|Aspirin 81 mg|Subjects will take Aspirin 81 mg per day for five days.
1606313|NCT02189122|Drug|Aspirin 162 mg|Subjects will take aspirin 162 mg per day for 5 days.
1606314|NCT02189122|Drug|NHP544-C 81 mg|Subjects will take NHP544C 81 mg per day for five days.
1606315|NCT02189122|Drug|NHP544C 162 mg|Subjects will take NHP544C 162 mg once a day for five days.
1606316|NCT02189122|Drug|Placebo|Subjects will take matching placebo for five days.
1606317|NCT02189109|Drug|NVX-108|0.2% emulsion administered i.v.
1606318|NCT02189096|Other|NEWS and Sepsis Screening|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). The NEWS will be available to the paramedic crew.
1606319|NCT02189096|Other|Point of care lactate measurement|Each Paramedic crew will continue to routinely document patient observations in an electronic Patient Report Form (ePRF) on every patient encounter. These physiological parameters will be used to calculate NEWS and screen for Sepsis (2 or more modified SIRS criteria and suspicion of infection). If NEWS is greater than or equal to 4 or the patient screens positive for Sepsis, then a Lactate will be measured on the CG4+ i-STAT cartridge.
1606320|NCT02189083|Drug|TSD|"TSD is composed of 15 individual Chinese medicines: Astragalus Membranaceus, Semen Coicis, Poria, Curcuma longa L, and Fritillaria Thunbergii Miq, Cassia twig, Pollen typhae, Resina draconis, Lithospermum erythrorhizon, Halloysitum Rubrum, Rhizoma Corydalis processed with vinegar, Hirudo, Calcined corrugated sub , Oyster Shell and Laminaria Japonica Aresch.
High dose (127g) or Low dose (69g) TSD decoction boiled as 200ml per bag; 2 bags per day, 6 days per week; Orally in-take one bag of TSD decoction in morning and another in evening after meal; The whole treatment lasts for 16 weeks."
1606321|NCT02189057|Other|AssureRx GeneSight genotyping results|
1606322|NCT02189057|Other|Treatment as usual|
1606323|NCT02189044|Other|Pilates Exercise|"The training through the Pilates exercises were performed in eleven weeks. Each class consisted of five exercises lasting 40 minutes each lesson.
During the first four weeks exercises performed were: Cat, Coffee Table, Single legcircle, pelvic movements, contraction of the glutes and closure was performed with posterior chain elongation range.
In the next four weeks began a new series of exercises, which are: Bridge, Side Table, Bridge hip roll with legextension, Abdominal - halfhollup, obliques, and ultimately Stretching - Series of William's.
In the last four weeks of training proposed a new series of exercises involving: Beaststroke, Support heel Bridge - hip roll with leg extension, and Hundred Squats with bat on the wall."
1606324|NCT02189031|Device|Tactor array|
1606325|NCT02189031|Device|Bypass Tactor|
1606326|NCT02189018|Other|Active Exercise|Active exercise on a treadmill
1606327|NCT02189018|Other|Neuromuscular electrical stimulation|Neuromuscular electrical stimulation
1606328|NCT02189018|Other|Weight loss and active exercise|Weight loss and active exercise on a treadmill
1606329|NCT02189018|Other|Ad lib activity at home|Ad lib activity at home
1606330|NCT02189005|Dietary Supplement|Study dietary supplement (PreCrea 600 mg capsules)|Study dietary supplement (PreCrea 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with life style modification.
1606331|NCT02189005|Dietary Supplement|Placebo|
1606332|NCT02188966|Device|Geographic Information System|"GIS data is delivered by SimaTech Enterprise System communicating via the mobile network and TETRA (in Denmark called SINE). It is developed as a Java Enterprise application and is executed on a JBOSS application platform"
1606333|NCT02188953|Drug|ACCS100|ACCS100 is made from Hydrated Sodium Calcium Aluminosilicate, which is a substance generally recognized as safe by the U.S. FDA.
1606334|NCT02188953|Drug|Calcium carbonate placebo|
1606335|NCT02188940|Behavioral|Dietary|The dietary therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a dietitian. Patients will be advised to follow restricted-calorie diet based on the hypocaloric dietary guidance, multiplying the patient's weight by 20 to 25 calories. The Nutwin ® program will be used to structure the patient's diets, based on 24 hours food record and calories tables. Throughout the program, issues related to food control, the benefits of following a balanced diet and the changing food habits will be discussed.
1606336|NCT02188940|Behavioral|Education Program|The education program will consist of 4 classes lasting 6 hours at the beginning of the interventions, in which issues related to asthma and physical activity will be discussed. Presentations and group discussions will be carried out, including information about asthma pathophysiology, medication and peakflowmeter skills, self-monitoring techniques, environmental control, benefits and current recommendations of physical activity.
1606337|NCT02188940|Behavioral|Behavioral Therapy|The Behavioral therapy will be performed every 15 days, totaling 6 sessions of 60 minutes each by a psychologist. Sessions of group dynamics will be performed to increase the patient adherence in a weight loss program using behavior modification techniques, such as self-management, motivational strategies, positive reinforcement and relapse prevention. Relaxation techniques, experiences and patient's report will also be used.
1606398|NCT02188576|Drug|high dose TXA|Subjects will be randomized to either high dose TXA or low dose TXA to be given as an infusion in a blinded fashion during the surgery.
1606338|NCT02188940|Other|Exercise Training|The aerobic training will be performed on a treadmill and a bike (or an elliptical), twice a week, totaling 24 sessions of 60 minutes each. The initial intensity will be 50% to 60% of VO2 max reaching a maximal 75% of VO2 max and the progression will take place according to the level of effort (Borg) in the last two sessions. Patients will be advised to walk outside at least twice a week for 30 minutes and write down their activity in a diary. Furthermore, they will be given an accelerometer in week 6 to record their daily steps. The resistance training will consist of exercises for the upper and lower limbs. Initially, the patients will perform 2 sets of 10 repetitions with load of 50% to 70% of 1-RM and the progression will take place in the number of repetition, and then in the load.
1606339|NCT02188940|Other|Stretching and Breathing exercise|"Breathing exercise will consist of 3 exercises adapted from yoga's breathing technique (kapalabhati, uddhiyana and agnisara) twice a week, totaling 24 sessions of 30 minutes each. Every exercise will be performed in sets of 3 (2 minutes each) with 60 seconds of rest between them. The stretching will consist of stretching exercises for the major muscle groups in 3 sets of 10 seconds each. The program will be performed twice a week, totaling 24 sessions of 30 minutes each.
*Both breathing and stretching exercises will be performed as placebo to ensure the same duration of treatment between the two groups."
1606340|NCT02188927|Other|Implementation of ANL|Advance Notification Letter will be send two weeks before Standard Invitation for screening colonoscopy
1606341|NCT02188927|Behavioral|No included ANL|Sending Standard Invitation only six weeks before planned screening colonoscopy
1606342|NCT02188914|Radiation|Positron emission tomography scan|
1606343|NCT02188914|Other|Magnetic resonance imaging|
1606344|NCT02188901|Other|Sonazoid-enhanced ultrasonography|Sonazoid (perflubutane) [GE healthcare]
1606345|NCT02188888|Drug|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm
1606348|NCT02188849|Other|Resistance exercise training|All participants will be subjected to resistance training of upper and lower limbs, using elastic bands and tubing and free weights. Training will be calibrated at 60% of one repetition maximum for each muscle group with three sets of 15 repetitions with one minute rest between each set. All exercises will be additionally calibrated to be of moderate intensity according to the Borg scale. The exercise load will be adapted according to the progression of each participant.
1606349|NCT02188849|Drug|Creatine|Creatine powder 5 g day
1606350|NCT02188836|Device|Electromagnetic stimulation|Electromagnetic stimulation with a new device produced by the investigators for this study.
1606351|NCT02188836|Device|Sham stimulation|This is a device that look exactly the same to the electrostimulation device, but that does not generate the electromagnetic field. It is a placebo device.
1606352|NCT02188823|Behavioral|Low carbohydrate diet|
1606353|NCT02188810|Biological|PAL|Single dose administered intramuscularly.
1606354|NCT02188810|Biological|TIV|Single dose administered intramuscularly .
1606355|NCT02188797|Behavioral|Group MI risk reduction program|
1606356|NCT02188784|Drug|Polysaccharide Iron Complex 150 mg|Oral Iron
1606357|NCT02188784|Drug|Placebo (for Polysaccharide Iron Complex)|Sugar capsule designed to mimic Polysaccharide Iron Complex.
1606358|NCT02188771|Device|intra-articular administration of RegenoGel-SP or hyaluronic acid (HA)|Intra-articular Injection: single injection of RegenoGel SP or 3 injections of HA
1606359|NCT02188758|Other|Adults - CFPE Treatment|Hospitalization for comprehensive treatment of CF pulmonary exacerbation, including intravenous (IV) antibiotics, nutritional assessment and support, airway clearance of mucus, use of inhaled mucolytic agents and bronchodilators, glycemic control with insulin, and psychosocial support.
1606360|NCT02188745|Drug|17B-estradiol|Anti-estrogen
1606361|NCT02188745|Drug|Letrozole|Aromatase inhibitors work by blocking estrogen receptors; they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
1606362|NCT02188745|Drug|Anastrozole|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
1606363|NCT02188745|Drug|Exemestane|Aromatase inhibitors work differently from tamoxifen and raloxifene. Instead of blocking the estrogen receptors, they stop a key enzyme (called aromatase) from changing other hormones into estrogen. This lowers estrogen levels in the body, taking away the fuel that estrogen receptor-positive breast cancers need to grow.
1606364|NCT02188732|Behavioral|CBHH+AT|"Community Based Health Home + Automated Telehealth (CBHH+AT):
Community-Based Health Home (CBHH) PLUS Automated Telehealth: a wireless telehealth device programmed with psychiatric content corresponding to the primary psychiatric diagnosis, and medical content tailored to the primary medical diagnosis. Daily interactive sessions last 5-10 min. Branching logic tailors questions or feedback to the user's responses (e.g., if a participant endorses medication nonadherence, a question appears asking why medications were not taken). The device automatically provides specific instructions to participants demonstrating signs of high risk."
1606365|NCT02188732|Behavioral|CBHH+SMT|Illness Management and Recovery (IMR) for psychiatric illness combines (1) psychoeducation, which improves knowledge about mental illness management, (2) behavioral tailoring, which improves medication adherence, (3) relapse prevention training, which decreases relapses and rehospitalizations, and (4) coping skills training, which reduces distress related to symptoms. Illness Management and Recovery (I-IMR) by adding chronic medical illness self-management to psychiatric illness self-management. For each psychiatric self-management skill module, there is a corresponding medical illness self-management training component using established methods in self-management of common chronic health conditions (e.g., diabetes, hypertension, congestive heart failure, chronic obstructive pulmonary disease, etc.).
1606399|NCT02188576|Drug|Low dose TXA|Subjects will be randomized to either high dose TXA or low dose TXA to be given as an infusion in a blinded fashion during the surgery.
1606400|NCT02188563|Other|Comprehensive smoking cessation intervention|
1606366|NCT02188732|Behavioral|CBHH|Community-based Health Home (CBHH): Each team has a staff-to-participant ratio of approximately 1:12, with each team serving approximately 120 participants with SMI using person-centered planning and recovery-oriented, flexible service models. Each team provides mobile outreach and includes a team leader; a peer counselor; a psychiatric nurse coordinator; a clinical care coordinator; specialists in substance abuse (dual diagnosis), community integration, rehabilitation, employment, and housing; and a medical nurse practitioner (MNP) and a health outreach worker (HOW).
2009927|NCT03167177|Drug|Leucovorin|Calcium N-[p-[[[(6RS)-2-amino-5-formyl-5,6,7,8-tetrahydro-4-hydroxy-6- pteridinyl]methyl]amino]benzoyl]-L-glutamate (1:1)
2009928|NCT03167177|Drug|nab-paclitaxel|5β,20-Epoxy-1,2α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
2009929|NCT03167177|Biological|Nivolumab|Recombinant human anti-PD-1 IgG4 monoclonal antibody
2009930|NCT03167177|Drug|omega-3-acid ethyl esters|Omega-3-acid ethyl esters
2009931|NCT03167177|Radiation|Stereotactic Body Radiation Therapy|radiation
2009932|NCT03167177|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
2009933|NCT03167177|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
2009934|NCT03167177|Biological|ETBX-051|Ad5 [E1-, E2b-]-Brachyury
2009935|NCT03167177|Biological|ETBX-061|Ad5 [E1-, E2b-]-MUC1
2009936|NCT03167177|Biological|GI-6207|Heat-killed S. cerevisiae yeast expressing CEA
2009937|NCT03167177|Biological|GI-6301|Heat-killed S. cerevisiae yeast expressing the human Brachyury (hBrachyury) oncoprotein
2009938|NCT03167177|Biological|haNK|NK-92 [CD16.158V, ER IL-2] (high-affinity activated Natural Killer cells)
2009939|NCT03165240|Drug|BI 690517|Film-coated tablet
1606380|NCT02188706|Drug|Decitabine|20 mg/m2 by vein daily over 1 hour on Days 1-5 of each 28 day cycle.
1606381|NCT02188706|Drug|Carboplatin|AUC 5 by vein over 1 hour on Day 8 of each 28 day cycle.
1606382|NCT02188706|Drug|Arsenic Trioxide|0.15 mg/kg by vein over 1 hour on Days 1-5 of each 28 day cycle.
1606383|NCT02188680|Other|Low FODMAPS diet|FODMPAS low diet in patients with IBS and positive breath test for fructose FODMAPS low diet in patients with IBS and negative breath test for fructose
1606384|NCT02188667|Other|Providers of Novel Care|Providers in the treatment group will be asked (1) to complete a series of six online education modules in pain care, (2) will be given access to new patient reported outcomes questionnaire data collected from patients within the electronic health record, (3) asked to review this data and related care recommendations during the patient visit, and (4) asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
1606385|NCT02188667|Other|Providers of Usual Care|Providers in the control group will provide care as usual to patients and will be asked to complete baseline and monthly online surveys related to experiences and satisfaction with providing care to patients with chronic noncancer pain.
1606386|NCT02188654|Drug|Metformin|500mg/day retarded formulation of metformin
1606387|NCT02188654|Drug|Placebo|500 mg/day of placebo tablets
1606388|NCT02188641|Other|Diet|
1606389|NCT02188641|Other|Exercise|
1606390|NCT02188641|Other|Diet and Exercise|
1606391|NCT02188641|Other|Healthy Lifestyle (Control) Group|
1606392|NCT02188628|Device|H-Man|H-man is a portable end-effector planar upper limb robot.
1606393|NCT02188628|Other|Additional Conventional Therapy|Repetitive goals based arm therapy
1606394|NCT02188615|Procedure|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE|Neo-adjuvant Chemoradiotherapy followed by Mckeown MIE
1606395|NCT02188615|Drug|Cisplatin|only Radical Chemoradiotherapy
1606396|NCT02188615|Device|Mckeown MIE|only Mckeown MIE using thoracoscopy and laparoscopy
1606397|NCT02188589|Device|Nasal implant|Treatment group may receive bilateral nasal implants (maximum of 4, 2 per side)
2009940|NCT03165240|Drug|Eplerenone|Film-coated tablet
2009941|NCT03165240|Drug|Placebo|Film-coated tablet
2009942|NCT03165227|Drug|BI 685509|Taken orally
2009943|NCT03165227|Drug|Placebo|Taken orally
2009944|NCT03164564|Drug|Oral CAB|CAB 30 mg tablet
2009945|NCT03164564|Drug|Oral TDF/FTC|TDF/FTC 300 mg/200 mg fixed dose combination tablet
2009946|NCT03164564|Drug|Placebo for oral CAB|Placebo tablets
2009947|NCT03164564|Drug|Placebo for oral TDF/FTC|Placebo tablets
2009948|NCT03164564|Drug|CAB LA|600 mg administered as one 3 mL (600 mg) intramuscular injection in the gluteal muscle
2009949|NCT03164564|Drug|Placebo for CAB LA|Administered as one 3 mL intramuscular injection in the gluteal muscle
2009950|NCT03163485|Device|Dialytrode|Multimodal neuromonitoring by intracerebral depth EEG recording combined with microdialysis for the sampling of cerebrospinal fluid during EEG recording
2009951|NCT03163485|Device|Standard treatment|Monitoring of intracranial pressure by EVD and/or multimodal neuromonitoring by microdialysis for sampling of cerebrospinal fluid
2009952|NCT03162458|Drug|Anaferon for children (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
2009953|NCT03162458|Drug|Placebo (liquid dosage form)|10 drops per dose. Day 1: 10 drops every 30 minutes for the first 2 hours, followed by three more doses regularly spaced during the rest of the day. Day 2 to 5: 10 drops three times daily.
2009954|NCT03162055|Drug|Glycopyrronium/Formoterol Fumarate|Metered dose inhaler (MDI), contains glycopyrronium/formoterol fumarate fixed-dose combination 7.2/4.8 μg per actuation
2009955|NCT03162055|Drug|umeclidinium/vilanterol|Dry powder inhaler (DPI), Each metered dose contains umeclidinium/vilanterol 62.5/ 25μg fixed-dose combination per inhalation
2009956|NCT03162900|Drug|Glasdegib Therapeutic Exposure|Subjects Receive a single 150 mg dose of Glasdegib followed by ECG and PK assessments.
2009957|NCT03162900|Drug|Glasdegib Supra-therapeutic Exposure|Subjects receive a single 300 mg dose of glasdegib followed by ECG and PK assessments.
2009958|NCT03162900|Drug|Positive Control (Moxifloxacin)|Subjects will receive a single 400 mg dose of moxifloxacin followed by ECG and PK assessments.
2009959|NCT03162900|Other|Placebo Control|Subjects will receive placebo dose followed by ECG and PK assessments.
1606402|NCT02188550|Drug|everolimus and letrozole|"This is a single arm, non-randomized, open-label study with a combination of everolimus and letrozole once a day dosing . Each cycle would be 28days and patients would be scanned after every 3 cycles for response, until disease progression is documented
The duration of the study will be until disease progression
Everolimus and Letrozole will be administered as noted below;
6.1.1 Dosing regimen
Dosage : Everolimus Dose: 10 Unit: mg Frequency: daily Route of administration: Orally Dosage : Letrozole Dose: 2.5 Unit: mg Frequency: daily Route of administration: Orally"
1606403|NCT02188537|Drug|Nelfinavir|Nelfinavir 2x 2500 mg p.o. days 1 - 14
1606404|NCT02188537|Drug|bortezomib|Bortezomib 1.3 mg/m2 i.v. or s.c. days 1, 4, 8, 11
1606405|NCT02188537|Drug|Dexamethasone|Dexamethasone 20 mg p.o. days 1-2, 4-5, 8-9, 11-12
1606406|NCT02188524|Other|Exercise|Tai Chi and Compensatory Stepping
1606407|NCT02188511|Other|Group A|90 minutes prior to the bronchoscopy on day 8, the subject will be asked to inhale 10 puffs of a Blu brand e-cigarette (for the nicotine-containing e-cigarette, this is approximately equivalent to < 1 cigarette). At 30 minutes prior to the bronchoscopy procedure if the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette.
1606408|NCT02188511|Other|Group B|On days 7 and 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
1606409|NCT02188511|Other|Group C|On days 6 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
1606410|NCT02188511|Other|Group D|On days 5 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
1606411|NCT02188511|Other|Group E|"On days 4 through 8, subjects will be asked to inhale 10 puffs of a Blu brand e-cigarette (90 minutes prior to bronchoscopy on day 8). If the subject has no adverse effect to the e-cigarette he/she will again be asked to inhale 10 puffs of the Blu e-cigarette an hour later (30 minutes prior to bronchoscopy on day 8).
Exposure to e-cigarettes will be limited to the nicotine equivalent of 1/2 pack of cigarettes to mitigate the risk of addiction to nicotine."
1606412|NCT02188498|Procedure|Polysomnography|Polysomnography, also called a sleep study, is a test used to diagnose sleep disorders. Polysomnography records your brain waves, the oxygen level in your blood, heart rate and breathing, as well as eye and leg movements during the study.
1606413|NCT02188485|Behavioral|ENGAGE|Up to 10 sessions delivered in the home.
1606414|NCT02188472|Drug|Penicillin V|Penicillin V: 2 x 330mg tablets should be taken twice daily
1606415|NCT02188472|Drug|Trimethoprim|Trimopan: 2 x 100mg tablets should be taken twice daily
1606416|NCT02188472|Drug|Placebo|Placebo: 2 tablets should be taken twice daily
1606417|NCT02188459|Drug|Bupropion|A total of 360 participants will be randomly assigned to one of two treatment conditions: Bupropion 300 mg/day (n = 180) or placebo (n = 180). We will use small-block randomization by site (Penn). A PHQ-9 score of 10 or greater will be used to identify major depression and stratify the randomization on it. Study site (Penn) will be the second of the two stratification variables.
1606418|NCT02188446|Behavioral|Educational programme for smoking and alcohol cessation|5 meetings within 6 weeks containing education and pharmacologic support
1606419|NCT02188433|Behavioral|Quit immediately (QI) / cut down to quit (CDTQ)|Use quit immediately (QI) or cut down to quit (CDTQ) interventions to achieve smoking abstinence
1990823|NCT01779739|Procedure|Perineorrhaphy|Procedure to build up the vaginal opening
1990824|NCT01776723|Drug|Ruxolitinib|In Phase I, participants will be allocated to twice a day (BID) doses of 10 mg/d up to 40mg/d. The starting dose will be 10 mg/d (5mg BID). Each cohort will include up to 6 subjects. Once MTD is reached, 10 additional participants will be treated during the first stage of Phase II (stage 1) at the MTD.
1606423|NCT02188394|Drug|Anesthetic blockades with bupivacaine|
1606424|NCT02188394|Drug|Isotonic saline injection|
1606425|NCT02188381|Other|Stool Sample and Blood Sample|All subjects will provide a stool sample and a blood sample at baseline. Subjects in NCT02133872 will provide a second stool sample and blood sample at their 3 month visit.
1606426|NCT02188368|Drug|POM|
1606427|NCT02188368|Drug|Steroids|
1606428|NCT02188368|Drug|PLD|
1606429|NCT02188368|Drug|CFZ|
1606430|NCT02188368|Drug|BTZ|
1606431|NCT02188368|Drug|CLA|
1606432|NCT02188368|Drug|Other drugs|
1606433|NCT02188342|Behavioral|HIT|12 HIT exercise sessions in 31 days on a stationary cycle ergometer
1606434|NCT02188316|Device|Jumbo forceps|comparison of different polypectomy devices
1606435|NCT02188316|Device|Hot biopsy forceps|comparison of different polypectomy devices
1606436|NCT02188303|Drug|LY2944876|Administered SC
1606437|NCT02188303|Drug|Placebo|Administered SC
1606438|NCT02188277|Drug|Xeomin|"Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius."
1606439|NCT02188277|Drug|Botox®|Administration route is intramuscular injection into medial (two points) and lateral heads (two points) of gastrocnemius.
1606444|NCT02188251|Dietary Supplement|Activamp|
1606445|NCT02188251|Other|Placebo|
1606446|NCT02188238|Other|Saliva Sample Collection|Saliva samples will be collected from healthy volunteers recruited locally. Stimulated whole mouth saliva is collected through stimulation by inert gum, and collecting the saliva by gently spitting into a sterile tube.
1606447|NCT02188225|Procedure|acupuncture|12 sessions acupuncture during 12 weeks (3 sessions weekly), each session lasting 20 minutes
1606448|NCT02188225|Drug|fluoxetine|10 mg/ daily
2009960|NCT03160287|Behavioral|Motivaltional interviews and infrequent motivational text messages|A self-management intervention will integrate use of mobile technology to prompt older adults to be physically active, provides ongoing monitoring of the amount of their physical activity and includes self-efficacy enhancements is a novel non-pharmacological intervention both for prevention and treatment of sleep deficiency in persons with OA
1606452|NCT02188173|Drug|dexamethasone 700 ㎍ intravitreal implant|Patients who receive dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Diabetic Macular Edema. All decisions regarding treatment are made at the sole discretion of the treating physician in accordance with their usual practices.
1606453|NCT02188160|Drug|KPI-121|KPI-121 drug product will be supplied as 0.25% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate.
1606454|NCT02188160|Drug|Placebo|Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
1606455|NCT02188147|Device|Short Term Wearable Defibrillator|Short-term Wearable Defibrillator (SWD 1000)
1606456|NCT02188121|Drug|Simvastatin|HMG CoA reductase inhibitor
1606457|NCT02188121|Drug|Losartan|Angiotensin II receptor antagonist
1606458|NCT02188108|Other|Wisconsin Stone-QOL survey|Patients will complete a health-related quality of life survey at multiple time points at enrollment and at multiple time points thereafter.
1606459|NCT02188082|Drug|IvabRadine hemisulfate Sustained-release Tablets|
1606460|NCT02188082|Drug|placebo|
1606461|NCT02188043|Behavioral|Relay Model|"The Clinical staff hand out and collect lifestyle - questionnaires to admitted patients, and screen by 10 alcohol questions (AUDIT) , and report score to outpatient Alcohol Clinic.
Based on the questionnaire that the patient filled out, the Alcohol therapist perform a brief Motivational Intervention on patients with an AUDIT score of 8+, focusing the patients alcohol consumption habits and offer an appointment to patients with an AUDIT score of 16+."
1606462|NCT02188030|Other|Group Exercise Program|The participants allocated into the GET Group will receive a general exercise training realized in group of workers. Each training session started with a five minute swarm-up by slowly moving the neck, upper back, shoulder, arms and hands through pain-free range of motion; followed by 30 minutes of stretching and strengthening exercises for neck, upper back, shoulder, arms and hands, performed in the standing posture, sitting or lying. For resistance exercise, will be adopted 3 sets of 10 repetitions with a load of 80% of 1 repetitions maximum. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises.
1606463|NCT02188030|Other|Individual Exercise Program|"The participants allocated into the IET Group will receive a individual and specific strength training with seven different exercises, based in training programme describe by Andersen et al.3 and Sundstrup et al4.
During the intervention period, the training intensity were progressively increased according to the principle of periodization and progressive overload5. Dumbbells and elastic bands and will be used as accessories to perform the resistance exercises. Experienced instructors supervised every other training session."
2009961|NCT03160105|Drug|Switch to DTG + FTC|Switch from standard cART to DTG + FTC dual maintenance therapy.
1606465|NCT02187991|Drug|Paclitaxel|either 60 mg/m2 intravenously (IV) on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel plus Alisertib arm) or 90 mg/m2 IV on days 1, 8 and 15 of a 28-day cycle (on Paclitaxel Alone arm)
1606466|NCT02187991|Drug|Alisertib|40 mg BID (twice a day) on days 1-3, 8-10, and 15-17 of a 28-day cycle
1606467|NCT02187978|Other|Early total enteral feeding (ETEF)|In ETEF Group total required volume of fluid will be administered as oral feeds and no intravenous fluid will be given. Feeds will be started at 80 mL/kg and increased till 150ml/kg is attained.
1606468|NCT02187978|Other|Conventional enteral feeding (CEF)|CEF Group will receive some feed and some Intravenous fluids. Feeds will be slowly increased from 20 mL/kg on day 1 till full feeds 150ml/kg is attained on day 6 of life.
1606469|NCT02187952|Behavioral|Behavioral feeding intervention|Behavioral feeding intervention will include escape extinction.
1606470|NCT02187939|Other|Summer science wellness program emphasizing health education pertaining to nutrition, physical activity, and healthy lifestyle.|The enhanced virtual world education (GROOVE+) will be compared to conventional approach (GROOVE). Each program is Monday-Friday, 9:30-3:30, for 3 weeks in the summer.
2009962|NCT03160105|Other|Patient-centered monitoring|Immunological and safety blood examinations performed only once per year at least one options (decentralised venipuncture and blood tests, delivery of ARV drugs by mail and interview by phone or skype call) for weeks 6, 12 and 36
1606472|NCT02187900|Drug|Multi-glycoside of Tripterygium Wilfordii HOOK. f. (TWH)|The dosage of 40 mg of Multi-glycoside of Tripterygium Wilfordii HOOK. f. was divided into 2 equal doses at 12-hour intervals for 6 months.
1606473|NCT02187900|Drug|Mycophenolate mofetil (MMF)|Mycophenolate mofetil 1.5mg/day for the treatment of IgAN for 6 months
1606474|NCT02187887|Behavioral|Personalized normative feedback|Participants receive behavioral norms feedback based on their response to items in a baseline survey. Personal responses are presented along with perceptions of other same gender veterans and actual drinking norms of same gender veterans.
1606475|NCT02187874|Procedure|delayed umbilical cord occlusion|
1606476|NCT02187874|Procedure|early umbilical cord occlusion|
1606477|NCT02187874|Drug|Oxytocin|
2009963|NCT03160898|Drug|CK-2127107|Oral
2009964|NCT03160898|Drug|Placebo|Oral
2009965|NCT03159455|Drug|BI 1467335|Duration - 28 days
1606481|NCT02187848|Drug|SAR408701|Pharmaceutical form: concentrate for solution for infusion Route of administration: intravenous
1606482|NCT02187822|Drug|TPI 287|TPI 287 is an infusion given through veins. Dose escalation will begin at 14 mg/m^2/dose. Dose expansion will begin at the maximum tolerated dose (MTD).
1606483|NCT02187822|Procedure|Fractionated Stereotactic Radiotherapy (FSRT)|The prescription dose will be 25 gray (Gy) in 5 daily fractions delivered to the planning target volume (PTV).
1606484|NCT02187809|Drug|Clobazam|
2009966|NCT03159455|Drug|Placebo|Duration - 28 days
1606486|NCT02187770|Device|IMED-4|Non invasive recording electrode used to assess lung fluid
2009967|NCT03158610|Drug|Capecitabine|Oral fluorouracil
2009968|NCT03158389|Drug|APG101|weekly i.v.
2009969|NCT03158389|Drug|Alectinib|twice daily
1606487|NCT02187757|Dietary Supplement|Study Dietary Supplement (Prelipid 500 mg capsules)|Study Dietary Supplement (PreLipid 600 mg capsules) will be given to subjects twice daily 30 mins before food for 90 days along with lifestyle modification.
1606488|NCT02187757|Dietary Supplement|Placebo|
1606489|NCT02187744|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum of 6 cycles.
1606490|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
1606491|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
1606492|NCT02187744|Biological|Trastuzumab-EU|Concentrate for solution for infusion, sterile vial 150 mg, Day 1 Cycle 1 will be a loading dose of 8 mg/kg infused over 90 minutes. Subsequent infusions will follow every 3 weeks (i.e., cycled every 21 days) with a dose of 6 mg/kg administered over 30 to 90 minutes depending on tolerability, maximum 6 cycles.
1606493|NCT02187744|Drug|Taxotere®|Injection concentrate single-dose vials containing 20 mg (0.5 mL) or 80 mg (2 mL), each mL contains 40 mg docetaxel (anhydrous) and 1040 mg polysorbate 80, The starting dose of Taxotere® (docetaxel) will be 75 mg/m2 administered intravenously over 60 minutes every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
1606494|NCT02187744|Drug|Paraplatin®|Lyophilized powder, single-dose vials containing 50 mg, 150 mg, and 450 mg of Carboplatin for administration by intravenous infusion (each vial contains equal parts by weight of Carboplatin and mannitol), starting dose 6 AUC, over 15 minutes or longer every three weeks on Day 1 of each cycle (i.e., every 21 days), maximum 6 cycles.
1606495|NCT02187718|Procedure|Sentinel Node Procedure under Local Anaesthesia|
1606496|NCT02187718|Procedure|Sentinel Node Procedure under General Anaesthesia|
1606497|NCT02187705|Drug|Telmisartan tablets|All patients were treated with different doses of telmisartan for 14 days
1606498|NCT02187692|Behavioral|MCT|The meta-cognitive training (the MCT) consists of eight structurized psychological therapy modules that provides basic knowledge about cognitive biases that are associated with schizophrenia and it provides the sklills how to overcome negative consequences of the biases. The MCT includes: Module 1 manages self-serving bias (i.e. external-personal attribution for failure, internal attribution for positive events); Module 2 and 7 target the jumping to conclusion; Module 3 and 7 concern beliefs flexibility and bias against disconfirmatory evidence; Module 4 and 6 target deficits in theory of mind; Module 5 is devote to ameliorate the cognitive over-confidence in false memories; Module 8 deals with depressive thinking style.
1606499|NCT02187679|Drug|Abobotulinum toxin A|
1606500|NCT02187640|Behavioral|Self-administered acupressure|Self-administered acupressure: In order to ensure the compliance of treatment, they would apply this intervention according to the acupressure group protocol once per day in groups with one trained research nurse's instructions and supervision .
1606501|NCT02187640|Behavioral|Sham control group|Sham intervention: Patients received similar aupressure intervention on the non-acupoints.
1606502|NCT02187627|Drug|[11C]RO6924963|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [11C]RO6924963 injected will be </=10 micrograms (mcg), injection volume </=20 milliliters (mL). Target injected activity for [11C]RO6924963 will be 370-740 megabecquerel (MBq) [10-20 millicurie (mCi)].
1606503|NCT02187627|Drug|[11C]RO6931643|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [11C]RO6931643 injected will be </=10 mcg, injection volume </=20 mL. Target injected activity for [11C]RO6931643 will be 370-740 MBq (10-20 mCi).
1606504|NCT02187627|Drug|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single intravenous injection. The mass dose of [18F]RO6958948 injected will be </=10 mcg, injection volume </=20 mL. Target injected activity for [18F]RO6958948 will be 185-370 MBq (5-10 mCi). The final activity of [18F] RO6958948 will be adjusted up to 10 mCi per scan to allow sufficient counts by end of 200 minutes post radiotracer injection.
1606505|NCT02187614|Drug|Diclofenac|
1606506|NCT02187614|Drug|Morphine|
1606507|NCT02187614|Drug|Paracetamol|
1606508|NCT02187614|Drug|Placebos|
1606509|NCT02187601|Device|MPBA System|MPBA is the new generation Multi Purpose Breath Analyzer
1606510|NCT02187601|Device|BreathID|BreathID is the name of the original Exalenz breath analyzer system
1606511|NCT02187588|Drug|Eschscholtzia Californica - low dose|
1606512|NCT02187588|Drug|Eschscholtzia Californica - high dose|
1606513|NCT02187588|Drug|Ibuprofen|
1606514|NCT02187588|Drug|Eschscholtzia Californica - low dose Placebo|
1606515|NCT02187588|Drug|Eschscholtzia Californica - high dose Placebo|
1606516|NCT02187588|Drug|Ibuprofen Placebo|
1606517|NCT02187575|Drug|UHAC 62 XX tablet|
1606518|NCT02187575|Drug|UHAC 62 XX capsule|
1606519|NCT02187562|Drug|Meloxicam|
1606520|NCT02187562|Drug|Aspirin|
1606521|NCT02187549|Device|HYMOVIS|Intra-articular injection
1606522|NCT02187549|Device|Placebo|Intra-Articular Injection
1606523|NCT02187536|Drug|Telmisartan|
1606524|NCT02187536|Drug|Simvastatin|
1606525|NCT02187536|Drug|Telmisartan placebo|
1606526|NCT02187523|Drug|Hydrochlorothiazide|
1606527|NCT02187523|Drug|Telmisartan|
1606528|NCT02187523|Drug|Telmisartan/HCTZ FDC|
1606529|NCT02187510|Procedure|Umbilical cord milking|Once the preterm is born keep the baby from the mother's thighs. The obstetrician cord milking three times (2seconds/milking) taking the cord from the base 20cm respect towards the baby. Then clamp de cord.
1606580|NCT02187133|Drug|Bendamustine|IV; mg/m2; Days 1, 2
1606581|NCT02187133|Drug|Rituximab|IV; mg/m2; Day 9 Cycle 1, Day 1 subsequent cycles
1607260|NCT02182544|Drug|Ketotifen fumarate dry syrup|
1606530|NCT02187510|Procedure|Delayed cord clamping|Once the preterm is born the neonatologist keep the baby beside the mother at level of the operating table during 30 seconds without cord clamping. The baby is covered with a polythene bag and put a cap on his head. Then the obstetritian clamp the cord.
1606531|NCT02187497|Drug|Low dose of BIBR 277|
1606532|NCT02187497|Drug|Medium dose of BIBR 277|
1606533|NCT02187497|Drug|High dose of BIBR 277|
1606534|NCT02187484|Drug|BIBR 277|
1606535|NCT02187471|Drug|DS-5565 15mg tablet|
1606536|NCT02187471|Drug|150mg pregabalin capsule|
1606537|NCT02187471|Drug|placebo tablet|matching DS-5565 tablet
1606538|NCT02187471|Drug|placebo capsule|matching pregabalin capsule
1606539|NCT02187471|Drug|75mg pregabalin capsule|
1606540|NCT02187445|Drug|Budesonide inhalation suspension|To determine the acceptability of budesonide inhalation suspension (BIS) 0.5 QD for 6 months for children with SCD that develop ACS between 1 and 4 years of age (n=10).
1606541|NCT02187419|Other|Hypnosis|"Hypnosis is a promising, but under-studied non-pharmacological treatment option for poor sleep during the menopausal transition. Hypnosis is a mind-body therapy that may be defined as a deeply relaxed state involving mental imagery and suggestion. The hypnotic state has been described variously as being an altered state of consciousness, focused attention, imaginative involvement, and role assumption.
However, it is generally agreed that hypnosis is a state or condition, which occurs when appropriate suggestions elicit distortions of perception, memory, or mood. Research has shown that most people are hypnotizable. Hypnosis intervention for managing chronic symptoms usually involves a hypnotic induction, instruction in self-hypnosis and practice using audio recordings."
1606542|NCT02187406|Procedure|Modified ankle athletic taping|
1606543|NCT02187406|Procedure|Traditional ankle athletic taping|
1606544|NCT02187367|Biological|EGF Vaccine|1.2mL of conjugate-adjuvant mix injection at four sites during the Post First-Line Chemotherapy. Reduced dose of injection at two sites during the Pre-Progression Phase.
1606545|NCT02187354|Drug|Blinatumomab|A single cycle of blinatumomab (CIVI) treatment is 6wks, 4wks of treatment followed by a 2wk treatment-free interval. Up to 5 cycles will be administered per subject. In the first cycle, for patients with an M3 bone marrow, the initial dose will be 5μg/m2/day for the first 7days, escalated to 15μg/m2/day on D8-D29. For all subsequent cycles 15μg/m2/day will be the dose for all 4wks of continuous treatment. In case of M2 bone marrow or M1 bone marrow with an MRD relapse at screening, the initial dose will start at 15μg/m2/day for the first 7days of treatment & no dose step at D8. For all subsequent cycles the dose will remain 15μg/m2/day. A dose of 9μg/day for the initial dose (if applicable) & 28μg/day for the escalated dose after dose step should not be exceeded.
1606546|NCT02187341|Dietary Supplement|5-HTP|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
1606547|NCT02187341|Dietary Supplement|Placebo|Volunteers participate in two visits at least 5 days apart . The day of their visit they ingest (2 hours before reporting to the laboratory) either a capsule containing 200 mg of 5-HTP or a capsule containing placebo (sugar pill). The order of the visits is randomized
1606548|NCT02187328|Other|Grapefruit juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
1606549|NCT02187328|Other|Apple juice|Volunteers participate in two visits at least 5 days apart. The day of their visit they ingest 12.5 oz of grapefruit juice or Apple juice ingested in the morning and 12.5 oz of grapefruit juice ingested in the afternoon, 3h before reporting to the laboratory. The order of the visits is randomized, one visit volunteers ingest apple juice only, the other visit grapefruit juice only
1606550|NCT02187315|Device|Chrono-chemotherapy pump:Melodie|
1606551|NCT02187315|Device|Routine intravenous drip|
1606552|NCT02187315|Drug|induction chemotherapy|
1606553|NCT02187315|Drug|cisplatin chrono-chemotherapy|
1606554|NCT02187315|Radiation|intensity-modulated radiation therapy|
1606555|NCT02187315|Drug|cisplatin routine-chemotherapy|
1606556|NCT02187302|Drug|CRLX101|
1606557|NCT02187302|Drug|Bevacizumab|
1606558|NCT02187302|Drug|Standard of Care (Investigator Choice)|
1606559|NCT02187289|Device|Night-time compression bandages|Daytime compression sleeve plus night-time compression by self-administered or assisted multi-layered compression bandages.
1606560|NCT02187289|Device|Compression Sleeve, daytime wear|
1606561|NCT02187289|Device|Night-time Compression custom-made garment|Standard Care plus night-time compression by a custom-made night time compression system garment.
1606562|NCT02187276|Drug|cholinesterase inhibitors|The first group received donepezil (5 or 10 mg) the second group received galantamine (16 or 24 mg) The third group received rivastigmine (3 or 4,5 or 6 mg BID) according to the treating physician.
1606563|NCT02187250|Drug|metformin|
1606564|NCT02187250|Drug|liraglutide|
1606565|NCT02187250|Drug|roflumilast|
2009970|NCT03158389|Drug|Idasanutlin|on 5 days of a 28 days cycle
1606567|NCT02187224|Drug|Progesterone|
1606568|NCT02187224|Drug|Placebo (for Progesterone)|
1606569|NCT02187211|Drug|Minocycline|
1606570|NCT02187211|Drug|Placebo (for Minocycline)|
2009971|NCT03158389|Drug|Atezolizumab|i.v. every 3 weeks
1606572|NCT02187185|Device|Sonicare/Elite-Flexcare Toothbrush|Philips Oral Healthcare product - battery powered menchanic toothbrush with nylon bristles
1606573|NCT02187185|Device|Manual Toothbrush|traditional (non-mechanical) toothbrush with nylon bristles and plastic handle
1606574|NCT02187172|Drug|Ustekinumab|
1606575|NCT02187172|Drug|Placebo|
2009972|NCT03158389|Drug|Vismodegib|daily orally
2009973|NCT03158389|Drug|Temsirolimus|weekly i.v.
2009974|NCT03158389|Drug|Palbociclib|orally on 21 days of a 28 days cycle
1606579|NCT02187133|Drug|Carfilzomib|IV; mg/m2; Days 2, 9, 16
2009975|NCT03159195|Drug|Palbociclib|CDK 4/6 inhibitor for advanced/ metastatic breast cancer
1606582|NCT02187120|Drug|Tranexamic Acid|Tranexamic acid is a synthetic lysine derivative that inhibits fibrinolysis by blocking the lysine binding sites on plasminogen therefore inhibiting the conversion of plasminogen to plasmin. Intravenous injection of 1g Tranexamic Acid will be administered in the pre-hospital setting followed by 1g Tranexamic Acid infused intravenously over 8 hours initiated in the hospital emergency department.
1606583|NCT02187120|Drug|Placebo|
1606584|NCT02187107|Drug|TMC114|300 mg tablets of TMC114 ethanolate with microcrystalline cellulose, colloidal silicon dioxide, crospovidone, magnesium stearate, and Opadry® Orange
1606585|NCT02187107|Drug|rtv|100 mg tablet of Norvir®
1606586|NCT02187094|Drug|TC-6499|
1606587|NCT02187094|Drug|Placebo|
1606588|NCT02187081|Procedure|radiofrequency ablation plus Sorafenib|To treat HCC with the combination of radiofrequency ablation and sorafenib
1606589|NCT02187081|Procedure|Radiofrequency ablation|To treat HCC with radiofrequency ablation alone.
1606590|NCT02187068|Drug|Dexmedetomidine|Dexmedetomidine administered intravenously
1606591|NCT02187055|Drug|Tofacitinib with methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
1606592|NCT02187055|Drug|Tofacitinib without methotrexate|Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
1606593|NCT02187055|Biological|Adalimumab with methotrexate|Placebo for tofacitinib twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Adalimumab 40 mg every other week, subcutaneous for 12 months
1606594|NCT02187042|Other|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
1606595|NCT02187042|Other|call center|Nurses from a call center will call the patients at regular time to help patients in the management of their cancer, with some dietetic advices, medical advices etc.
1606596|NCT02187042|Other|Best supportive care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
1606597|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 1) tablet for 14 days
1606598|NCT02187029|Other|Placebo|Daily dosing (tablet) for 14 days
1606599|NCT02187029|Drug|PF-06743649|Daily dosing (dose level 2) tablet(s) for 14 days
1606600|NCT02187029|Other|Placebo|Daily dosing (tablets) for 14 days
1606601|NCT02187016|Device|AirFloss + BreathRx|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
1606602|NCT02187016|Device|AirFloss + Listerine|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning plus Rinse used once daily.
1606603|NCT02187016|Device|Dental Floss|Manual Toothbrush used twice daily, 1 minute. Interproximal cleaning used once daily.
1606604|NCT02187016|Device|Manual Toothbrush|Manual Toothbrush used twice daily, 1 minute.
2009976|NCT03156738|Drug|MT-2990|Subjects will receive a single IV dose of MT-2990
2009977|NCT03156738|Drug|Placebo|Subjects will receive a single IV dose of placebo
1606607|NCT02186990|Drug|propofol|2,5 mg/kg
1606608|NCT02186990|Drug|etomidate|0,3 mg/kg
1606609|NCT02186990|Drug|etomidate-propofol|0,15 mg/kg etomidate + 1,25 mg/kg propofol
1606610|NCT02186977|Device|VAX-ID|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
1606611|NCT02186977|Drug|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)|1.0 cc HBVAXPRO 10mcgr/ml (Sanofi Pasteur MSD)
1606612|NCT02186977|Drug|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD)|0.1cc HBVAXPRO 40mcgr/ml (Sanofi Pasteur MSD) with each injection
1606613|NCT02186964|Procedure|tension free primary closure|tension free primary closure of the defects created by excision of the pilonidal sinus
1606614|NCT02186964|Procedure|karydakis|the defect after excision of the pilonidal sinus is closed by Karydakis procedure
1606615|NCT02186964|Procedure|Limberg flap|defect after excision of the pilonidal sinus is closed by Limberg flap procedure
1606616|NCT02186951|Drug|Amoxicillin - clavulanic acid|Amoxicillin-clavulanic acid 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
1606617|NCT02186951|Drug|Placebo|Placebo 1g, three times a day during 2 days, started within one hour after randomization and before the beginning of hypothermia.
2009978|NCT03156608|Device|Novii ECG/EKG System|External fetal heart rate monitoring
1606619|NCT02186912|Device|Nobel Active, Nobel Procera IBO|
1606620|NCT02186899|Other|Ultrasound Guided Femoral Sciatic Obturator nerve blocks|
1606621|NCT02186899|Other|General Anesthesia femoral bolus|
1606622|NCT02186899|Other|General anesthesia femoral continuous|
1606623|NCT02186886|Drug|Golimumab|Physiological Intermolecular Modification Spectroscopy
2009979|NCT03156608|Device|External fetal heart rate monitoring|External fetal heart rate monitoring
2009980|NCT03157791|Drug|Simethicone 180Mg Cap|Simethicone Group A will take a total of 360mg prior to colonoscopy of Simethicone 180Mg Cap.
1606626|NCT02186860|Biological|Third generation CAR-T cells|Given IV
1606627|NCT02186847|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo radiation therapy
1606628|NCT02186847|Drug|Carboplatin|Given IV
1606629|NCT02186847|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiation therapy
1606630|NCT02186847|Other|Laboratory Biomarker Analysis|Correlative studies
1606631|NCT02186847|Drug|Metformin Hydrochloride|Given PO
1606632|NCT02186847|Drug|Paclitaxel|Given IV
1606633|NCT02186847|Radiation|Volume Modulated Arc Therapy|Undergo radiation therapy
1606716|NCT02186132|Drug|Atropine 1.2 mg|Atropine 1.2 mg intravenous
1606717|NCT02186119|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
2009981|NCT03155620|Procedure|Biopsy|Undergo biopsy
2009982|NCT03155620|Procedure|Biospecimen Collection|Undergo collection of blood
2009983|NCT03155620|Drug|Ensartinib|Given PO
2009984|NCT03155620|Drug|Erdafitinib|Given PO
2009985|NCT03155620|Other|Laboratory Biomarker Analysis|Undergo molecular analysis
1606634|NCT02186834|Drug|Selinexor|After the initial screening visit and registration in the study, participants will receive Selinexor orally at a dose of 80 mg for 2 weeks. After 2 weeks of dosing with selinexor and dexamethasone, patients will receive weekly selinexor at a starting dose of 40 mg/m² in combination with pegylated liposomal doxorubicin at a starting dose of 20 mg/m², and dexamethasone at 40 mg orally weekly.
1606635|NCT02186834|Drug|Liposomal doxorubicin|During the induction phase, participants will receive liposomal doxorubicin (Lipodox) at a starting dose of 20 mg/m² on Day 1 of the cycle.
1606636|NCT02186834|Drug|Dexamethasone|Participants will be instructed to take Dexamethasone 40 mg (10 tablets) orally once weekly with meals (ideally with breakfast to minimize insomnia). Participants older than 75 years and patients previously intolerant to 40 mg dosage will be allowed to receive 20 mg (5 tablets) once a week.
1606637|NCT02186821|Drug|Ceritinib (LDK378)|Ceritinib will be dosed on a flat scale of 750 mg (e.g., 5 x 150 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
1606638|NCT02186808|Device|Procera® Bridge Zirconia|Patients planned for treatment with a tooth-supported 3 to 4-unit bridge in any position of the maxilla or the mandible.
1606639|NCT02186782|Drug|Clomiphene citrate and Estradiol|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and estradiol (2 mg/day for 5 consecutive days from day 2 of cycle)
1606640|NCT02186782|Drug|Clomiphene citrate and Placebo|Women will receive clomiphene citrate (100 mg/day for 5 consecutive days from day 2 of cycle) and placebo (for 5 consecutive days from day 2 of cycle)
1606641|NCT02186769|Drug|Risperdal® Consta®|
1606642|NCT02186769|Drug|LY03004|
1606643|NCT02186756|Other|EMG-Biofeedback and Usual care|Please refer to arm description
2009986|NCT03155620|Drug|Larotrectinib|Given PO or via nasogastric- or gastric-tube
1606645|NCT02186730|Behavioral|Stressbusters|cCBT
1606646|NCT02186730|Behavioral|Websites|Self help websites
1606647|NCT02186717|Dietary Supplement|Chewing gum|Patients will be asked to chew gum three times a day for 30 minutes each time
1606648|NCT02186704|Device|ICD with DX system|Implantable cardioverter defibrillator (ICD) system implantation with single lead with ventricular sensing and pacing and defibrillation combined with dedicated atrial sensing dipole.
1606649|NCT02186691|Other|MRI|
1606650|NCT02186678|Other|PET-CT|
1606651|NCT02186665|Drug|calcitriol ointment|
1606652|NCT02186665|Drug|placebo comparator|
1606653|NCT02186652|Drug|Pantoprazole|
1606654|NCT02186626|Biological|WN/DEN4Δ30 Vaccine|WN/DEN4Δ30 vaccine is a live attenuated, recombinant, chimeric virus. Dose: 10^4 plaque-forming units (PFUs); delivered by subcutaneous injection in the deltoid region of the upper arm.
1606655|NCT02186626|Biological|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm.
1606656|NCT02186613|Behavioral|Telephone support|Telephone support intervention to improve breastfeeding rates. The intervention will consist in weekly calls during the first two months and every two weeks between the second and the sixth month. The intervention will be done by pediatric nurses and we have developed a protocol of important issues to deal depending on the age of the baby.
1606657|NCT02186600|Drug|Calcium carbonate|Used as daily supplement to ensure subject obtains 1200 mg of calcium per day (diet + supplement)
1606658|NCT02186600|Drug|Vitamin D3|Subjects will receive Vitamin D3 supplements to ensure serum level of Vitamin D is at least 30 ng/ml.
1606659|NCT02186600|Drug|Risedronate|Risedronate 35 mg orally will be ingested weekly by subjects in Risedronate group.
1606660|NCT02186600|Behavioral|Bone-loading exercises|Subjects will participate in bone loading exercises (weight-bearing and resistance) three times weekly at community YMCAs.
1606661|NCT02186587|Device|ConforMIS custom total knee|Total knee arthroplasty using ConforMIS custom total knee system with follow-up at 6 months
1606663|NCT02186561|Device|Pipeline™ Embolization Device/ Pipeline™Flex Embolization Device|
1606664|NCT02186548|Procedure|Closed surgical technique|"Surgically uncovering of the impacted canine with a mucoperiosteal flap dissected off the bone
The bone covering the canine is being removed
Attachment with a chain is bonded to the exposed tooth
The palatal flap is repositioned and sutured back with the chain above the mucosa. Shortly after the surgery
The canine is orthodontically moved beneath the palatal mucosa"
1606665|NCT02186548|Procedure|Open surgical technique|"Surgically uncovering of the impacted canine, removing a window of tissue from around the tooth
Pack/filling material is applied on the tooth
Spontaneous eruption of the palatally impacted canine is allowed expected
The canine is orthodontically moved above the mucosa"
1606666|NCT02186535|Dietary Supplement|Vitamin D and Calcium|
2009987|NCT03155620|Procedure|Mutation Carrier Screening|Undergo tumor tissue mutation screening
2009988|NCT03155620|Drug|Olaparib|Given PO
2009989|NCT03155620|Other|Pharmacological Study|Correlative studies
2009990|NCT03155620|Drug|PI3K/mTOR Inhibitor LY3023414|Given PO
1606671|NCT02186496|Drug|CKD-330 8/5mg|
1606672|NCT02186496|Drug|Candesartan 8mg and Amlodipine 5mg|
1606673|NCT02186483|Drug|Metformin|Metformin,1000mg, once daily
1606674|NCT02186483|Drug|Rosuvastatin|Rosuvastatin, 20 mg, once daily
1606675|NCT02186483|Drug|Metformin and Rosuvastatin|Metformin, 1000mg, once daily Rosuvastatin, 20mg, once daily
1606676|NCT02186470|Radiation|accelerated partial breast irradiation|Undergo image-guided intensity-modulated APBI
1606677|NCT02186470|Radiation|intensity-modulated radiation therapy|Undergo image-guided intensity-modulated APBI
1606678|NCT02186470|Radiation|image-guided radiation therapy|Undergo image-guided intensity-modulated APBI
1606679|NCT02186470|Procedure|therapeutic conventional surgery|Lumpectomy
1606680|NCT02186457|Drug|Polymyxin B in Normal Saline|Antibiotic irrigation via peritoneal lavage
1606681|NCT02186457|Other|Placebo: Normal Saline|Placebo irrigation via peritoneal lavage
1607261|NCT02182544|Drug|Ketotifen fumarate dry syrup placebo|
2009991|NCT03155620|Drug|Selumetinib Sulfate|Given PO
2009992|NCT03155620|Drug|Tazemetostat|Given PO
2009993|NCT03155620|Drug|Vemurafenib|Given PO
1606682|NCT02186444|Other|Personalized Health Information Navigator (PHIN)|"The application (or app) titled Personalized Health Information Navigator (PHIN) is an interactive psycho-educational intervention that will be delivered via mobile tablet technology. The PHIN provides patient-centered education. At the first meeting, the community navigator will provide a visual demonstration of PHIN on the Apple iPad. The community navigator will leave the iPad with the participant for 6-weeks and will stress the importance of using the PHIN app to address any educational or psychosocial needs."
1606683|NCT02186444|Other|NCI Information Booklets (IB)|"Participants will receive a packet of information booklets (What You Need to Know About Prostate Cancer; Taking Time: Support for People with Cancer; and Facing Forward, Life After Cancer Treatment) that address prostate cancer treatment options, the late and long term effects, follow-up care, and sources of support. At the first meeting, the community navigator will provide a review of the print materials and stress the importance of reading the booklets carefully to help prepare for the discussion with your healthcare provider. The community navigator will leave the print materials with the participant for 6-weeks."
1606684|NCT02186431|Device|senofilcon A|
1606685|NCT02186418|Genetic|Gene transfer|Gene transfer using a gamma-globin lentivirus vector
1606686|NCT02186405|Drug|LEVOTHYROXINE|administration of levothyroxine
1606687|NCT02186392|Device|Circadian Light luminaries|The light is programmed to have the desired light intensity (lux), color temperature (Kelvin) and wavelength (nm) according to the knowledge about the phase-response curve.
1606688|NCT02186379|Behavioral|RePace Intervention|The Re-Pace intervention will provide children and parents/caregivers training in strategies to promote slower eating pace and greater awareness of satiety levels. These skill building strategies can be classified as follows: 1) learning to slow eating rate, 2) awareness-raising activities; 3) role play activities; 4) self-monitoring training; 5) goal setting challenges; and 6) parent training. A core strategy for achieving slower eating pace and improved satiety will be to increase fruit and vegetable intake to meet United States Department of Agriculture (USDA) guidelines (www.myplate.gov). There are 5 intervention visits lasting about 1 to 1.25 hours each. See Section 4.3.1 for more details of the Re-Pace intervention.
1606689|NCT02186379|Behavioral|Usual Care Control|"Following the second test meal session, parents and children will receive a brief (25 minute) instruction on healthy eating using materials from www.ChooseMyPlate.gov site, including What's on Your Plate and My Plate for Kids mini-posters."
1606690|NCT02186366|Other|Abdominal Massage Therapy|Abdominal Massage Therapy , 30 minutes, three times one week for 6 weeks. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
1606691|NCT02186366|Drug|Buspirone|Buspirone by mouth 5mg three times per day for 6week. If the subjects have recovered in the treatment of 6 weeks, we can end treatment early.
1606692|NCT02186353|Behavioral|Partial feeding study|Provision of all grain foods where only the processing of kernels used to produce the grain foods will differ among test diets. Each participant will be assigned to complete the three 4-week test diets in random sequence.
1606693|NCT02186340|Procedure|Inspiratory muscle training|
1606694|NCT02186327|Behavioral|Integrative Health Coaching|Coaching sessions will guide subjects in establishing and maintaining behavior change goals related to their health and overall well-being.
1606695|NCT02186314|Device|Pacemaker Biotronik: apical stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in apical stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( bifocal stimulation) and patients will be kept in the new pacing mode for two months when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
1606696|NCT02186314|Device|Pacemaker Biotronik: bifocal stimulation|Patients with pacemaker (Biotronik): an electrode will be implanted in the apical position of the right ventricle and an electrode implanted in the septal position of the right ventricle.The patients will remained in bifocal stimulation for two months, after that they will be subjected to evaluation. At the end of the evaluation, patients will undergo cross-over groups( apical stimulation) and patients will be kept in the new pacing mode for two months, when they will be submitted to clinical, laboratory evaluation and assessment of pacemaker
1606697|NCT02186301|Drug|Rociletinib Mono-Therapy|Rociletinib will be administered twice daily
1606698|NCT02186301|Drug|Erlotinib Mono-Therapy|Erlotinib will be administered once a day
1606699|NCT02186288|Other|High-flow nasal cannula oxygen|
2009994|NCT03154255|Behavioral|Mediterranean-Style Diet Educational Training|"The intervention consists in a standard diet according to routine clinical practice + a 30 minutes Mediterranean-Style Diet educational training with explanation of Mediterranean pyramid + gamification to Mediterranean diet inside the Hospital and at home throughout The Mediterranean Goose."
2009995|NCT03154177|Behavioral|Group ANC/PNC|The primary intervention is group antenatal and postnatal care wherein women receive their care in a group with other women with similar due dates. After an initial individual visit all care is given in groups although the majority of the time is dedicated to facilitated discussion and women can come for additional acute care if needed. Group antenatal care will be three group visits between 20 and 40 weeks gestation and group postnatal care will be one group visit and approximately 6 weeks post delivery.
1606702|NCT02186249|Drug|Nivolumab|
1606703|NCT02186249|Drug|Ipilimumab|
1606704|NCT02186223|Device|The Angel® Catheter|The Angel® Catheter is a temporary device that combines the functions of an inferior vena cava (IVC) filter and a 3-lumen central venous catheter (CVC). The device can be placed at the bedside into the inferior vena cava via the femoral vein for the prevention of Pulmonary Embolism (PE) and for access to the central venous system. The device is intended for short-term (less than 30 days) vascular access via the femoral vein.
1606706|NCT02186197|Other|Critical Care Ultrasound|A critical care ultrasound exam will be performed on all patients included in this study
1606707|NCT02186184|Device|Orthokeratology|
1606708|NCT02186184|Device|Spectacle|
1606711|NCT02186158|Drug|Vitamin C|
1606712|NCT02186158|Drug|Placebo|
1606713|NCT02186145|Drug|Association of metronidazole; nystatin and dexamethasone|
1606714|NCT02186145|Drug|Flagyl|Vaginal cream of metronidazole and nystatin
1606715|NCT02186132|Drug|Atropine 0.6 mg|Atropine 0.6 mg intravenous
1606718|NCT02186119|Drug|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 24.
1606719|NCT02186119|Other|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
1606720|NCT02186106|Drug|Cholecalciferol|
1606721|NCT02186080|Drug|Gemigliptin|
1606722|NCT02186080|Drug|Placebo|
1606723|NCT02186067|Other|Referral System|"Primary Level:
Refer patients to secondary care centre if Patients has complicated hypertension (Patients with target organ damage, CVD, CKD or more the 3 drugs)
Secondary Level:
Community health center at Aga Khan University will serve as the secondary care center.
Family physician will manage patients with CVD, CKD or more than 3 drugs.
Tertiary care:
Cardiologist at the Aga Khan University will manage secondary, resistant and difficult to treat hypertension.
Behavioral: Other Interventions CME session by Cardiologist/Consultant Family Physician : At start , and at two months Community screening by Family physicians at the primary care center (open house) once in three months Patient group education session. Once in three months"
1606724|NCT02186054|Device|MRI examinations|Consented patients will be required to stay in the MRI scanner to complete the 2 additional sequences once their standard exam is completed.
1606725|NCT02186041|Device|Sacral Nerve Modulation|
1606726|NCT02186028|Drug|Vitamin D|Vit D 400 IU vs. Vit D 200 IU
1606727|NCT02186015|Drug|Cholecalciferol|Enrolled women will receive 50,000 IU weekly supplementation of cholecalciferol for 8 weeks.
1606728|NCT02186002|Drug|ACT-451840 10 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
1606729|NCT02186002|Drug|ACT-451840 50 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
1606730|NCT02186002|Drug|ACT-451840 200 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
1606731|NCT02186002|Drug|ACT-451840 500 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
1606732|NCT02186002|Drug|ACT-451840 1000 mg|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
1606733|NCT02186002|Drug|ACT-451840 (Dose to be determined)|ACT-451840 was provided as dry powder, which was reconstituted as a suspension with 25 mL of tap water
1606734|NCT02186002|Drug|Placebo|
1606735|NCT02185989|Other|Early electrical stimulation and early leg bicycling added to early standard rehabilitation|
1606736|NCT02185976|Other|cartoon|5 different cartoons which will be recorded on a tablet PC.
1606737|NCT02185963|Drug|Rosuvastatin|Rosuvastatin 20mg once a daily for 12 weeks
1606738|NCT02185950|Device|ultrasound|
1606739|NCT02185950|Device|paraffin|
1606740|NCT02185950|Device|endermotherapy|
1606741|NCT02185937|Dietary Supplement|cola|imatinib intake with coca-cola
1606742|NCT02185924|Drug|Parecoxib|
1606743|NCT02185924|Drug|CONTINUOUS FEMORAL BLOCK WITH ROPIVACAINE 0,2%|
1606744|NCT02185924|Drug|N/S 0.9%|
1606745|NCT02185898|Other|Leading U.S. non-menthol cigarette|Tobacco-burning non-menthol cigarette
1606746|NCT02185898|Other|Leading U.S. menthol cigarette|Tobacco-burning menthol cigarette
1606747|NCT02185898|Other|Electronic cigarette #1|Electronic cigarette
1606748|NCT02185898|Other|Electronic cigarette #2|Electronic cigarette
1606749|NCT02185898|Other|Electronic cigarette #3|Electronic cigarette
1606750|NCT02185898|Other|U.S. Market-sample electronic cigarettes|Marketed electronic cigarettes
1606751|NCT02185885|Procedure|Increased bloodpressure during CPB.|
1606752|NCT02185872|Other|High-Intensity Functional Training|Participants were instructed to work as hard as they could while maintaining safe technique and proper form to achieve as many reps or rounds as possible in the prescribed time frame. As HIFT participants became accustomed to specific movements, less time was dedicated to practicing movements and technique.
1606753|NCT02185872|Other|Aerobic and Resistance Training|The protocol was based upon current guidelines of 150 minutes moderate-intensity aerobic activity and 2 days of muscle strengthening per week.
1606754|NCT02185859|Drug|Lidocaine|The lidocaine group (Group L)- 1% lidocaine 40 mL is prepared in a 50 mL syringe; A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. (Group L subjects are administered lidocaine 2 mg/kg for 15 minutes immediately after the anesthesia induction, and then lidocaine 2 mg/kg/h is continuously injected. The dose of lidocaine and magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.)
1606755|NCT02185859|Drug|Magnesium Sulfate|the magnesium group (Group M)- MgSO4 4g 40 mL is prepared in a 50 mL syringe.) A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room. The dose of magnesium in this study has been shown in previous studies to be safe and to have an analgesic effect.
1606756|NCT02185859|Drug|Saline|the control group (Group C) - 0.9% normal saline 40 mL is prepared in a 50 cc syringe. A bolus dose of the studied drugs are administered for 15 minutes immediately after a subject is brought into the operating room, and the vital signs are checked (from the beginning of anesthesia induction). Subsequently, an intravenous injection of the maintenance dose is continuously performed and later stopped just before transferring the subject to a recovery room.Group C subjects are administered the same dose of normal saline.
1606757|NCT02185846|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
1606758|NCT02185846|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
1606759|NCT02185833|Drug|DIRITHROMYCIN 500 MG ENTERIC COATED TABLET|
1606760|NCT02185833|Drug|DYNABAC 250 MG ENTERIC COATED TABLET|
1606761|NCT02185820|Drug|Carfilzomib|
1606762|NCT02185820|Drug|Pomalidomide|
1606763|NCT02185820|Drug|Dexamethasone|
1606764|NCT02185807|Procedure|video-assisted group|The video assistance patients watch a video in Cantonese or Mandarin explaining the surgery procedure and its risks, benefits and alternatives before discussion with their physicians.
1606765|NCT02185807|Procedure|control group|The control patients receive verbal information and discussion from their physicians.
1606766|NCT02185794|Drug|GS-9857|GS-9857 tablets administered orally once daily
1606767|NCT02185794|Drug|Placebo to match GS-9857|Placebo to match GS-9857 tablets administered orally once daily
1606768|NCT02185794|Drug|SOF/GS-5816|Sofosbuvir (SOF) 400 mg/GS-5816 100 mg FDC tablet administered orally once daily
1606769|NCT02185781|Other|Autologous NK cells infusions|"Each patient will receive repeated intravenous (IV) infusions of escalating doses of expanded autologous NK cells.
The initial dose will be 1 x 106/kg of recipient body weight (BW), followed by half log increments of the dose level for each infusion, to a maximum of 1 x 108/kg of recipient BW or until they experience any toxicity, for a maximum of 5 infusions. The minimum interval between each infusion will be 28 days. No conditioning therapies will be administered before the infusion of the expanded NK cells. Patients may receive TKI maintenance."
1606770|NCT02185768|Drug|idarubicin|
1606771|NCT02185768|Device|Dc- Beads 300-500µm|
1606772|NCT02185755|Other|Internet-Based Glucose Monitoring System|
1606773|NCT02185755|Drug|Normal Medication Positive Control|
1606774|NCT02185742|Behavioral|Strength Based Case Management|
1606775|NCT02185729|Drug|Intralipid|Infusion of Intralipid (soybean-derived fat)
1606776|NCT02185729|Drug|ClinOleic|Infusion of ClinOleic (olive oil-based)
1606777|NCT02185729|Drug|Dextrose|Infusion of dextrose (sugar) without fat
1606778|NCT02185729|Other|Saline (control)|Infusion of 0.9% normal saline
1606779|NCT02185716|Drug|Levobupivacaine 0.25 %|
1606780|NCT02185716|Drug|Levobupivacaine 0.5%|
1606781|NCT02185703|Device|Chordate System S020 in treatment mode|
1606782|NCT02185703|Device|Chordate System S020 in placebo mode|
1606783|NCT02185690|Drug|Binimetinib|"Continuous MEK162 with dose escalation until the Recommended Phase 2 dose (RP2D) one dose level below the Maximum administered dose (MAD) or progression of disease.
MEK162 tablets 15 mg strength will be taken orally on a BID dose schedule."
1606784|NCT02185690|Drug|Pemetrexed|4-6 cycles given intravenously in combination with carboplatin as per standard therapy.
1606785|NCT02185690|Drug|Carboplatin|4-6 cycles of intravenous Carboplatin in combination with Pemetrexed as per standard therapy.
1606786|NCT02185677|Other|Clinical evaluation|
1606787|NCT02185677|Other|neuropsychological battery test|
1606788|NCT02185677|Other|MRI|
1606789|NCT02185677|Other|Actigraphy|Actigraphy recording will be performed during 7 days after inclusion.
1606790|NCT02185664|Procedure|landmark technique|The apex of the imaginary triangle formed between the two heads of sternocleidomastoid and clavicle was used as the point of needle entry, just lateral to the pulsation of the internal carotid artery and directed towards the ipsilateral nipple at an angle of 45 degrees.
1606791|NCT02185664|Device|Static Ultrasound technique|Static ultrasound guided internal jugular vein cannulation was performed by using the transthoracic echocardiography probe supplied with the transesophageal echocardiography machine in the cardiothoracic surgery operation theatre. The internal jugular vein was located and marked using this method prior to puncture.
1606792|NCT02185651|Drug|Zavesca® Prescription|"Following baseline evaluation, Zavesca® prescription is given.
Week 2, 4, and 6 ERT infusion with pre-medication are completed at local/home infusion center. Travel to site for week 7 study visit includes physical exam, blood collection and punch muscle biopsy. Health survey is completed."
1606793|NCT02185638|Other|Appetite suppressant properties of YGD and A20-50|3-arm crossover study for investigation of the effect of herbal supplements A20-50 compared to YGD blend and placebo on subjective appetite sensations, glucose, insulin, ghrelin, GLP-1, CCK and ad libitum energy intake
1606794|NCT02185625|Device|Safe Delivery smartphone application|The intervention is the use of a smartphone application called Safe Delivery, designed by University of Copenhagen, Denmark and Maternity Foundation Denmark. The application contains animated videos aimed to train midwives in the prevention and management of postpartum hemorrhage and the treatment of neonatal resuscitation. The instructions in the videos are based on WHO recommendations, and the application is designed to be an on-going tool for midwives, so that they can drill themselves in the emergencies of postpartum hemorrhage and neonatal resuscitation.
1606795|NCT02185612|Behavioral|Savings program|The intervention is a web-based centralized savings account, which is a secure online account without fees. The account offers eligible savers nominal financial rewards for each deposit they make, as a financial incentive for savings.
2009996|NCT03154177|Procedure|Ultrasound+Pregnancy Testing|"Half of all study sites will receive early pregnancy testing, conducted by community health workers at community level and ultrasound for gestational age dating and early screening at the health center.
The primary analysis will not assess the effectiveness of this intervention."
1606797|NCT02185586|Procedure|laparoscopic cholecystectomy|
1606798|NCT02185573|Procedure|Bulk fill|This is one of the composite restoration application techniques
1606799|NCT02185573|Procedure|SonicFill|This is the recent intervention under evaluation
1606801|NCT02185547|Drug|Zoloft|Sertraline treatment 25 mg
1606802|NCT02185547|Behavioral|ICBT|Internet behavioral cognitive therapy only
1606803|NCT02185534|Drug|Clopidogrel|European clopidogrel tablets, 75 mg (test) versus Japanese clopidogrel tablets, 75 mg (reference); European clopidogrel tablets, 75 mg (test) versus US clopidogrel tablets, 75 mg (reference)
1606805|NCT02185495|Behavioral|Observer nodule detection|Radiologists will detect the nodules.
1606806|NCT02185495|Device|Computer-aided nodule detection|Computed-aided detection (CAD) software will be used to detect the nodules.
1606807|NCT02185482|Behavioral|Physician Supported Care|
1606808|NCT02185482|Other|Usual care|
1606839|NCT02185222|Drug|Cholecalciferol 100 000 UI|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
1606809|NCT02185469|Procedure|Pneumatic retinopexy|First, a 5/8-in 25-gauge needle will be used to perform an anterior chamber paracentesis, aiming to withdraw a minimum of 0.3 ml of aqueous fluid form the anterior chamber. Then, sulfur hexafluoride (SF6) will be injected in the vitreous cavity. The total volume of gas injected will exceed by 0.3 ml the amount of fluid withdrawn by the anterior chamber paracentesis (ex: 0.6 ml of SF6 would be injected after having withdrawn 0.3 ml). The laser retinopexy will be performed 48 hours later with laser.
1606810|NCT02185469|Procedure|vitrectomy|Under certain circumstances, pneumatic retinopexy can't be considered as a primary treatment for rhegmatogenous retinal detachment. In these cases, the patient will be booked for urgent 25 G vitrectomy with intraoperative laser retinopexy and gas injection to treat retinal detachment
1606811|NCT02185469|Drug|sulfur hexafluoride (SF6)|
1606812|NCT02185469|Device|5/8-in 25-gauge needle|
1606813|NCT02185469|Device|laser|intraoperative laser retinopexy
1606814|NCT02185456|Drug|750 mg metronidazole/ 200 mg miconazole vaginal suppository|The higher dose 750 mg metronidazole/ 200 mg miconazole vaginal suppository will be given to patients who were refractory to the standard of care therapy, oral metronidazole 500 mg twice a day for 7 days, and to asymptomatic patients in a randomized arm, who show poor responses based on the qPCR test result.
1606815|NCT02185456|Drug|Standard of care|oral metronidazole 500 mg twice a day for 7 days
1606816|NCT02185443|Radiation|SBRT|"60Gy in 3 fractions (20Gy/fraction) over 14 days
60Gy in 5 fractions (12Gy/fraction) over 18 days if organ at risk constraints cannot be met with fractionation above"
1606817|NCT02185430|Drug|saline infusion|saline infusion, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
1606818|NCT02185430|Drug|dexmedetomidine infusion|dexmedetomidine, bolus of 1.0 μg kg-1 over 10 min followed by a continuous infusion at 0.5 μg kg-1 h-1 infusion during one-lung ventilation, intravenous
1606819|NCT02185417|Drug|Hydrochlorothiazide (HCTZ)|Thiazide-type diuretic. Daily dose of 50 or 25 mg for duration of the study.
1606820|NCT02185417|Drug|Chlorthalidone|Thiazide-type diuretic. Daily dose of 25 or 12.5 mg for duration of the study.
1606821|NCT02185404|Device|wearing the GEMS|The GEMS mimics the actions of the split-belt treadmill, but can be used during over-ground walking and in one's own home, thus enabling long-term training. This GEMS does not require any external power and is completely passive; all necessary forces are redirected from the natural forces present during walking since it utilizes the wearer's weight to generate its movements. While the movements of the GEMS are similar to the split belt treadmill, and the GEMS generates a similar aftereffect, the efficacy of this shoe in modifying the gait of an individual with stroke is not yet verified. This research aims to test the GEMS on individuals with stroke to determine if the related effects that show up on healthy subjects can benefit individuals with stroke.
1606822|NCT02185391|Procedure|Audience Response System|patients use during oral presentations an audience response system
1606823|NCT02185391|Behavioral|Telephone interview|patients receive motivational telephone interviews after their residence in rehabilitation clinics
1606824|NCT02185378|Procedure|I:E ratio 1:2|We plan to evaluate the improvement on respiratory function with different ventilation I:E ratios (1:2 vs. 1:1) during the one-lung ventilation in an obese patients.
1606825|NCT02185378|Procedure|I:E ratio 1:1|The purpose of our study is to compare the effects of minimal prolonged 1:1 IE ratioventilation on respiratory mechanics and oxygenation with conventional 1:2 IE ratio ventilation during OLV in obese patients.
1606826|NCT02185365|Other|Gadolinium|Gadolinium is a contrast agent used to visualize cartilage during an MRI.
1606827|NCT02185352|Drug|BEEP regimen|Bevacizumab 15mg/kg IVF on D1, Etoposide 70 mg/m2 IVF QD, D2-4, Cisplatin 70 mg/m2 IVF on D2, repeat every 3 weeks, for 3 cycles
1606828|NCT02185339|Drug|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep post-tetanic count between 1 to 2.
1606829|NCT02185339|Drug|Rocuronium|Intravenous infusion rate of rocuronium will be titrated to keep train-of-four count between 1 to 2.
1606830|NCT02185326|Drug|Growth hormone (Norditropin, Novo nordisk)|Growth hormone (Norditropin, Novo nordisk) was administrated on day 6 of HMG stimulation daily in a dose of 2.5 mg S.C. till the day of hCG administration.
1606831|NCT02185313|Other|visual stimulus to follow|
1606832|NCT02185300|Drug|Dolutegravir Pediatric Granules|Dolutegravir pediatric granules are supplied as 40 grams bulk bottles containing 0.4% weight by weight of dolutegravir to be reconstituted with 73 mL of purified water to yield a dolutegravir concentration of 1.6 milligram / millilitre. 12.5 mL of reconstituted granules contain 20 mg DTG
1606833|NCT02185300|Drug|Dolutegravir Dispersible Tablet|Dolutegravir is available as 5mg dispersible tablets and can be administered as 4 tablets dispersed in 12.5 mL LMC water and consumed immediately or 4 tablets dispersed in 12.5 mL CONTREX mineral water and consumed immediately or 4 tablets dispersed in 12.5 mL LMC water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed or 4 tablets dispersed in 12.5 mL CONTREX mineral water, allow to stand at room temperature for 30 mins, re-suspend mixture and consumed
1606834|NCT02185261|Drug|Interferon Alfa-2b|Patients who were deemed MRD-positive after day 60 post-transplantation receive interferon α-2b (subcutaneously at dosages of 3 million units 2-3 times per week) . Interferon treatment continues for 6 months in the absence of disease progression or unacceptable toxicity.
1606835|NCT02185248|Behavioral|Wellness Action Plan|The plan included a color-coded BMI chart to help parents understand their child's weight category as well as a brief action planning worksheet to help families create personalized plans around healthy diet and activity changes.
1606836|NCT02185235|Device|Electrical Stimulation|"The Chartered Society of Physiotherapy recommends the following standard for electrical devices.
Frequency: 35 Hertz. Pulse width: 250µs (0.25ms). Current type: bi-phasic rectangular. Intensity: maximum tolerated. Duty-cycle: 5 seconds on/10 seconds off. Very weak muscles: 5 seconds on/15 seconds off.
Treatment time: 5 minutes initially, gradually increasing to 20 minutes."
1606837|NCT02185235|Device|Biofeedback|Biofeedback is a treatment technique in which people are trained to improve their health by using signals from their own bodies
1606838|NCT02185235|Other|Pelvic Floor Training|"First, as you are sitting or lying down, try to contract the muscles you would use to stop urinating To contract the pelvic muscles, squeeze for 3 seconds and then relax for 3 seconds.
Repeat this exercise to 20 minutes each session."
1606969|NCT02184338|Drug|Placebo|PEG 400
1606840|NCT02185222|Drug|Placebo|Study of superiority between Cholecalciferol high dose 100 000 UI versus placebo : one bulb per month during two years
1606841|NCT02185209|Drug|Placebo|Place capsule to mimic antibiotics
1606842|NCT02185209|Drug|Amoxicillin Sandoz|Tablet 500 mg amoxicillin Sandoz three times a day
1606843|NCT02185209|Drug|Metronidazole Sanofi|400 mg metronidazole Sanofi administered three times a day (TID)
1606844|NCT02185209|Drug|Phenoxymethylpenicillin Meda|1600 mg phenoxymethylpenicillin Meda, three time a day (TID)
1606845|NCT02185196|Drug|Vitamin D3|20,000 IU vitamin D3 in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
1606846|NCT02185196|Drug|Placebo|20,000 IU Miglyol-oil in children <6 months, 50,000 IU in children 6-12 months and 1,00,000 IU in children 13-59 months of age on first day and thereafter 10,000 IU for next 4 days
1606847|NCT02185183|Drug|Alequel|Alequel
1606848|NCT02185170|Procedure|Trans-urethral resection|All subjects of the study are going to have a trans-urethral resection of prostate.
1606849|NCT02185170|Device|Use of the FEMTO-ST institute medical device|The FEMTO-ST institute medical device is use to detect prostatic and malignant tissue.
1606850|NCT02185170|Device|Use of the Light-CT scanner|The Light-CT Scanner is use in the tissue structural observation
1606851|NCT02185157|Other|dual -task exercises|physical exercises sections with gait and a second task like talk answering some questions or making some exercise with the arms.
1606852|NCT02185157|Other|Aerobic training|The same doses of aerobic training, i.e., 50 minutes, was delivered in groups of five participants. Each session will include 10 minutes of warm-up, 30 minutes of aerobic training on an ergometric bicycle at 60 to 80% of the participants' maximum heart rates,and 10 minutes of cool-down exercises.
1606853|NCT02185144|Behavioral|PATH For Triples|In addition to providing weekly home-health nursing focused psycho-education aimed at insuring adherence to drug treatment regimen, the nurse health navigator model provided in PFT combines continuous and integrated care across mental health, substance abuse, and infectious disease provides. The nurses will accompany the patient to appointments, or make collateral contacts with other care providers. Often the nurses serve as intermediaries and ensure accurate and timely information exchange. Their specialized training also allows them to monitor side effects of medications and advocate for the patients with their various specialty providers. A treatment cascade approach is utilized when the patient is non-adherent to treatment allowing for increased patient monitoring.
1606854|NCT02185144|Behavioral|Treatment as Usual|Control subjects receive enhanced TAU care which will consist of the opportunity to complete the full complement of baseline instruments that will then be shared with their outpatient mental health case manager to facilitate linkage with needed MH, SA, and ID care
1606855|NCT02185131|Drug|Mirtazapine|Gelatin capsules mirtazapine 15 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a dose of 2 capsules barring side effects, at Week 2.
1606856|NCT02185131|Drug|Placebo|Gelatin capsules Placebo capsules, identical to mirtazapine capsules, 1 capsule every a.m. Medication will be increased by one capsule to 2 capsules at Week 2, barring any side effects.
1606857|NCT02185118|Drug|oxygen|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.
Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
1606858|NCT02185118|Drug|Sevoflurane|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.
Treatment of 100% oxygen or subanesthetic sevoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
1606859|NCT02185118|Drug|Isoflurane|"Clinical in-vitro sepsis was induced in peripheral blood monocytes of non-septic patients by lipopolysaccharide or plasma from septic patients.
Treatment of 100% oxygen or subanesthetic isoflurane in 60% oxygen was performed on human peripheral blood mononuclear cells (PBMCs) stimulated by lipopolysaccharide or plasma from septic patients."
1606860|NCT02185105|Device|comfilcon A MTO|Randomized to a test lens in one eye and control lens in the other as a matched pair.
1606861|NCT02185105|Device|comfilcon A|Randomized to a test lens in one eye and control lens in the other as a matched pair.
1606862|NCT02185092|Dietary Supplement|Lactobacillus GG|probiotic supplement
1606863|NCT02185092|Other|Sugar pill|placebo
1606864|NCT02185079|Behavioral|Training to proficiency|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm as well.Trainees in this arm in addition will be trained to proficience based on the metrics developed for labor epidural catheter placement in a epidural simulator.
1606865|NCT02185079|Behavioral|Conventional training|Conventional training for epidural catheter placement as per department protocols will be given to the trainees in this arm. Access to epidural simulator for 2 days will be given.
1606866|NCT02185066|Drug|Atorvastatin 20mg and Metformin XR 500mg (Reference)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.
Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
1606867|NCT02185066|Drug|CJ-30056 20/500mg (Test)|"Group 1 receives Atorvastatin 20mg and Metformin XR 500mg first, then CJ-30056 second, with at 7-day wash-out period in between.
Group 2 receives CJ-30056 first, then Atorvastatin 20mg and Metformin XR 500mg second, with 7-day wash-out period in between."
1606868|NCT02185053|Drug|CPC-201|
1606869|NCT02185040|Drug|CC-220|0.3 mg oral capsules once every other day with or without food
1606870|NCT02185040|Drug|CC-220|Subjects will receive 0.3 mg oral capsules every day with or without food
1606871|NCT02185040|Drug|CC-220|CC-220 oral capsules 0.6 mg and 0.3 mg on alternating days with or without food
1606872|NCT02185040|Drug|CC-220|CC-220 oral capsule 0.6 mg QD with or without food
1606873|NCT02185040|Drug|Placebo|Matching oral placebo daily
1606874|NCT02185027|Other|complications and compliance with GIHP recommendations|Description of complications, compliance, major bleeding events, treatments, reversal strategies.
1606970|NCT02184325|Drug|Kiddi® Pharmaton Fizz, effervescent tablets|
1606876|NCT02185001|Procedure|Direct Medial Patellofemoral Ligament (MPFL) Repair|The MPFL will be repaired directly at the site of the traumatic injury.
1606877|NCT02185001|Procedure|Physical therapy|Patellar immobilization, stabilization, and strengthening under the direction and guidance of the physician and physical therapist.
1606878|NCT02184988|Biological|Botulinum purified neurotoxin, Type A|The subject is to be injected intra-muscularly into a total of five sites: the mid-line of the procures muscle, the inferomedial aspect of each corrugator muscle and the superior middle aspect of each corrugator, at least 1 cm above the bony orbital rim. Each site is injected with 0.1 ml (4U), for a total of 20 U and 0.5 ml.
1606879|NCT02184975|Procedure|Cold Knife Conization with stitches|In the research arm patients who underwent cold-knife conization of the cervix underwent hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. These sutures were held prior to the onset of cold conization of the cervix.
1606880|NCT02184975|Procedure|Cold knife Conization without stitches|In the research arm patients who underwent cold-knife conization of the cervix have not undergone hemostatic sutures laterally to the cervix, at localization of 3 and 9 hours with 2-0 vicryl thread. After patient anesthesia and routine antisepsis was performed, cold knife conization of the cervix was performed.
1606881|NCT02184949|Procedure|Percutaneous Coronary Intervention|
1606882|NCT02184949|Procedure|Primary Percutaneous Coronary Intervention|
1606884|NCT02184923|Other|presentation of visual vertical|
1606885|NCT02184910|Drug|pepsinogen and gastrin|
1606886|NCT02184897|Drug|lenograstim 10 microgram/kg/day|
1606887|NCT02184884|Device|MACE after OPCAB|
1606888|NCT02184884|Device|without MACE after OPCAB|
1606889|NCT02184871|Other|exposure to different risk factors and molecular assessment|
1606890|NCT02184858|Drug|lisinopril, ACE-inhibitor|Lisinopril 0.1mg/kg/d, titration with + 0.1mg/kg/d. Max; daily dose: 0.4mg/kg. CAVE: dose reduction in case of renal impairment
1606891|NCT02184845|Device|Implant NobelActive 3.0|
1606892|NCT02184832|Drug|Metformin|2 doses of 500 mg metformin given approximately 12 hrs apart
1606893|NCT02184832|Other|Low tryptophan diet|
1606894|NCT02184832|Other|High tryptophan diet|
1606895|NCT02184819|Drug|levosimendan|24 hour continuous infusion at the rate of 0,1 µg/kg/min
1606896|NCT02184819|Drug|Placebo|24 hour infusion at a rate of 0,1 µg/kg/min assuming that it contains study drug
1606897|NCT02184806|Procedure|orthotopic graft|(1) laparoscopy (2) ovarian fragments can be put back inside the pelvic cavity close to the natural location of the ovaries or
1606898|NCT02184806|Procedure|heterotopic graft|"put under the skin
the ovarian fragments can be put under the skin of the abdomen"
1606899|NCT02184793|Device|EMD (Inclinomax)|EMD (electronic monitoring device) : recording the head of bed inclination degree with digital display and alarm on
1606900|NCT02184767|Drug|ADASUVE®|ADASUVE® 2.5, 5, or 10 mg
1606901|NCT02184754|Procedure|Magnetic endoscope imaging (MEI)|
1606902|NCT02184741|Drug|GB-0998|Subjects recieved GB-0998 at a dose of 400mg/kg/day for five days until the 6th gestational week.
1606903|NCT02184741|Drug|Placebo|Subjects recieved saline of the same volume as GB-0998 for five days until the 6th gestational week.
1606904|NCT02184728|Device|End-tidal CO2(portable capnometer)|End-tidal CO2(portable capnometer: EMMATM, Side stream capnometry module:Datex-Ohmeda S5 Anesthesia Monitor )levels were recorded at the time of arterial blood gas sampling.
1606905|NCT02184715|Other|virtual reality system|The participants were randomly assigned to either Group A or Group B. Group A received rehabilitation treatment and additional virtual reality system for 1 month, followed by rehabilitation treatment for 1 month; by contrast, the participants in Group B received rehabilitation treatment for 1 month, followed by rehabilitation treatment and additional virtual reality system for 1 month.
1606906|NCT02184689|Drug|fexinidazole|
1606907|NCT02184676|Biological|Analysis of early immune modifications|"blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)
cord blood sampling
stool sampling in mothers and newborns at birth (day 7)
blood and stool sampling in children at the age of 8, 18, 30 and 42 months"
1606908|NCT02184676|Other|Collection of clinical and socio-demographic data|"Questionnaire filled in by clinicians at enrollment and at birth
Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42"
1606909|NCT02184663|Other|without APA program|Control Arm : chemotherapy alone
1606910|NCT02184663|Other|APA program|Experimental Arm : chemotherapy + APA program during 16 weeks (aerobic and muscular strength exercises)
1606911|NCT02184650|Other|Premature infants with a GA < 32 weeks|At 3 years of age: ASQ (filled in by parents)
1606912|NCT02184637|Drug|Tafenoquine|A dark pink, capsule-shaped, film-coated tablet containing 150mg tafenoquine. To be administered orally
1606913|NCT02184637|Drug|Dihydroartemisinin + Piperaquine tetraphosphate|"White, oblong, biconvex, film-coated tablet with a break-line and marked on one side with two σ letters containing 320 mg piperaquine tetraphosphate (as the tetrahydrate; PQP) and 40 mg dihydroartemisinin (DHA). To be administered orally"
1606914|NCT02184637|Drug|Artemether + Lumefantrine|"Light yellow, round tablet with NC debossed on one side and CG on the other, containing 20 mg artemether and 120 mg lumefantrine. To be administered orally"
1606915|NCT02184624|Device|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate.
1606916|NCT02184624|Device|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
1606917|NCT02184624|Device|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane).
1606918|NCT02184624|Device|TURBUHALER|Placebo inhaler containing lactose monohydrate.
1606919|NCT02184624|Device|HANDIHALER|Placebo inhaler containing lactose monohydrate in a capsule.
1606920|NCT02184624|Device|BREEZEHALER|Placebo inhaler containing lactose monohydrate in a capsule.
1606971|NCT02184325|Drug|Kiddi® Pharmaton Fizz, effervescent tablets: marketed formula|
2009997|NCT03154541|Drug|Synrinse|"Non-CF Cohort The first 10 non-CF subjects will be instructed to once daily irrigate both nasal passages with SynRinse (supplied) delivered via nasal irrigation using the NeilMed® Sinus Rinse™ system for 1 week. The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.
The second set of 10 non-CF subjects (if the study continues to this point) will be instructed to irrigate both nasal passages twice daily (rather than once daily) for one week with SynRinse (supplied). The subjects will be asked to refrain from performing any sinus irrigations during the test treatment period with any product including saline.
CF Cohort The first 5 subjects in the CF cohort will irrigate with with SynRinse delivered via nasal irrigation using the NeilMed Sinus Rinse system for 1 week. The second set of 5 subjects with CF will irrigate both nasal passages twice daily for one week with SynRinse."
2009998|NCT03152032|Behavioral|In-House Vocational Training Programs|At the beginning of the IHVT programs, the job placement for each participant was determined jointly by the participant's interest, the demands of local job markets and the team evaluation. The programs covered 6 to 10 months in length, 5 days a week and 4 to 6 hours a day. The programs contained three sessions: (a) the work-related behavior training session, such as proper appearance, communication and self assertion, and workplace social skills, (b) the on-the-job skill training session where participants gained job-specific training and interventions from job coaches and occupational therapists, and (c) the life balance counseling session including individual and group counseling that aimed to enhance the participants' ability to tackle potential hardships and barriers to work.
1606923|NCT02184598|Behavioral|Cognitive training|12 weeks of cognitive training; 4 sessions/week; duration 30 min
1606924|NCT02184598|Behavioral|Placebo cognitive training|In the control group, we will use a placebo training that will consist of the same exposure time of the active training but not related to any element of cognitive training. To this end, we will set up an online platform with quiz and educational videos - being the most related to school content - without any component of executive function or working memory.
2009999|NCT03151304|Drug|Pracinostat|45 mg capsule
2010000|NCT03151304|Drug|Azacitidine|SC or IV injection
2010001|NCT03151304|Drug|Placebos|oral capsules
1606933|NCT02184559|Drug|Ropivacaine|comparaison of two methods of administration for analgesia using the same drugs in the same indication after Caesarean section
1606934|NCT02184559|Device|The infiltration continues catheter|
1606935|NCT02184533|Drug|sodium selenite|Given PO
1606936|NCT02184533|Radiation|radiation therapy|Undergo radiation therapy
1606937|NCT02184533|Other|laboratory biomarker analysis|Correlative studies
1606938|NCT02184533|Other|pharmacological study|Correlative studies
1606939|NCT02184533|Other|questionnaire administration|Ancillary studies
1606940|NCT02184520|Device|TRANSITION|
1606941|NCT02184520|Device|REVERE|
1606942|NCT02184507|Dietary Supplement|Supplement pre CABG|One sachet of the supplement was consumed daily for 7 days before surgery.
1606943|NCT02184507|Dietary Supplement|Supplement post CABG|One sachet of the supplement was consumed daily for 30 days after surgery
1606944|NCT02184507|Dietary Supplement|Supplement pre and post CABG|One sachet of the supplement was consumed daily for 7 days before surgery and 30 days after CABG
1606945|NCT02184507|Drug|Placebo|One sachet of placebo was consumed daily for 7 days before surgery and 30 days after CABG
1606946|NCT02184494|Device|pro5 AIRdaptive Power Plate (Badhoevedorp, The Netherlands)|"Subjects will be exposed to vertical vibration with a frequency and peak-to-peak displacement of 30 Hz and 1 mm, respectively, which provides a peak-to-peak acceleration of about 4.16 G.
Whole Body Vibration"
1606947|NCT02184481|Behavioral|Working memory training|
1606948|NCT02184481|Behavioral|Placebo training|
1606949|NCT02184468|Other|Simultaneously dispatch of firefighters and/or police in case of OHCA|In case of OHCA, firefighters and/or police trained in CPR and equipped with AEDs will be dispatched in parallel with EMS in nine counties in Sweden.
1606950|NCT02184455|Biological|DermGEN|DermGEN is a product created by a patented process that decellularizes and sterilizes donated human tissue.
1606951|NCT02184442|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Inoperable and high risk operable patients requiring the transcatheter aortic heart valve replacement
1606952|NCT02184429|Drug|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 0.2 mg 0.4 mg, 0.75 mg, 1.50 mg and placebo
1606953|NCT02184429|Drug|PF-06669571|Single ascending doses of PF-06669571 as extemporaneously prepared solution/suspension, once week in a cross over study: 3 mg 6 mg, 10 mg, 3 mg (fed) and placebo
1606954|NCT02184429|Drug|PF-06669571|Oral dosing of 0.15 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
1606955|NCT02184429|Drug|PF-06669571|Oral dosing of 0.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days
1606956|NCT02184429|Drug|PF-06669571|Oral dosing of 1.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
1606957|NCT02184429|Drug|PF-06669571|Oral dosing of 4.5 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule formulation for 14 days. This dose may be reached by a titration scheme
1606958|NCT02184429|Drug|PF-06669571|Oral dosing of 9.0 mg PF-06669571 as extemporaneously prepared solution/suspension or powder in capsule for 14 days. This dose may be reached by a titration scheme
1606960|NCT02184390|Other|On LIne Parent Training Tutorial|Interactive on line tutorial for parenting skills for autism
1606961|NCT02184364|Drug|Low dose of Klimadynon®|
1606962|NCT02184364|Drug|Medium dose of Klimadynon®|
1606963|NCT02184364|Drug|High dose of Klimadynon®|
1606964|NCT02184364|Drug|Oestrofeminal®|
1606965|NCT02184364|Drug|Placebo|
1606966|NCT02184351|Drug|Roxanes's clotrimazole troches|
1606967|NCT02184351|Drug|Mycelex® troches|
1606968|NCT02184338|Drug|BIBR 1017 BS powder|
1606972|NCT02184325|Drug|Comparator product|active substances: Vitamin A, Vitamin B1, Vitamin B2, Vitamin B5, Vitamin B6, Vitamin B12, Vitamin C, Vitamin D, Vitamin E, Manganese, Copper, Calcium, Magnesium, Phosphorous, Iron, Zinc, Sodium, Molybden
1606973|NCT02184312|Drug|Nevirapine XR low dose|
1606974|NCT02184312|Drug|Nevirapine XR medium dose|
1606975|NCT02184312|Drug|Nevirapine XR high dose|
1606976|NCT02184312|Drug|Nevirapine (VIRAMUNE®)|
1606977|NCT02184299|Drug|Nevirapine|
1606978|NCT02184299|Drug|Prednisone|
1606979|NCT02184286|Drug|Nevirapine|200 mg q.d. days 1-14 followed by 200 mg b.i.d. days 15-28
1606980|NCT02184286|Drug|Saquinavir-sgc|1600 mg b.i.d. from pre trial to day 28
1606981|NCT02184273|Drug|Magnesium metamizol|
1606982|NCT02184273|Drug|Placebo|
1606983|NCT02184260|Drug|Metamizole|
1606984|NCT02184260|Drug|Placebo|
1606985|NCT02184247|Drug|anhydrous theophylline, 350 mg|
1606986|NCT02184247|Drug|anhydrous theophylline, 300 mg|
1606987|NCT02184234|Drug|Antistax film coated tablets|
1606988|NCT02184221|Device|High frequency stimulation|The parameter of DMS: alpha frequency
1606989|NCT02184221|Device|Low frequency stimulation|The parameter of DMS: 0.5Hz
1606990|NCT02184195|Drug|Olaparib|Tablet -100mg
1606991|NCT02184195|Drug|Olaparib|Tablet-150mg
1606992|NCT02184195|Drug|Placebo|Match Olaparib 100mg placebo
1606993|NCT02184195|Drug|Placebo|Match Olaparib 150mg placebo
1606994|NCT02184182|Procedure|VLS ablation/portal ligation/hepatectomy|"Step1:
exploratory laparoscopy to exclude extrahepatic disease
right portal vein ligation if surgically feasible
RF/MW ablation on the future line of transection (of segment 4 close to left lateral lobe)
radiological portal embolization within 48h form the laparoscopic procedure if the right portal vein ligation is not feasible
CT volumetric scan to evaluate the left lateral lobe hypertrophy after 9±2 from Step 1
Step 2: only if FRL/body weight > 0.5
- laparoscopic/laparotomic right trisectionectomy"
1606995|NCT02184169|Device|General Electric Healthcare E-COVX Gas Monitoring Module for VO2 Measurments|Breath to breath VO2 measurements
1606996|NCT02184169|Device|Edwards Continuous SVO2 Catheter and Monitoring System - 4.5 fr|Edwards continuous SVO2 measurement system
1606997|NCT02184156|Biological|Ampion <5 kDa ultrafiltrate of 5% human serum albumin|4 mL intra-articular injection of Ampion
1606998|NCT02184143|Behavioral|CBPT|Changing Behavior through Physical Therapy (CBPT) is a cognitive-behavioral based self-management program.
1606999|NCT02184143|Other|Education|Patient education
1607000|NCT02184130|Other|transcranial magnetic stimulation and motion stimuli|
1607001|NCT02184117|Drug|Adenosine|Intracoronary or intravenous adenosine to induce hyperemia for reference FFR
1607002|NCT02184117|Drug|Contrast Media|"Intracoronary injection of contrast medium to induce hyperemia for contrast FFR"
1607003|NCT02184117|Drug|Resting conditions|Baseline measurement of aortic and coronary pressures
1607005|NCT02184091|Drug|Nevirapine|
1607006|NCT02184078|Drug|Nevirapine|
1607007|NCT02184078|Drug|Rifabutin|
1607008|NCT02184065|Drug|Meloxicam|
1607009|NCT02184052|Drug|Meloxicam|7.5 mg or 15 mg
1607010|NCT02184026|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing, child-friendly exposure to the trauma-nightmare, and rescription.
1607011|NCT02184013|Procedure|Catheter ablation|Catheter ablation (in addition ot PVI) guided by ECGI mapping, and atrial fibrosis mapping (DE-MRI).
1607012|NCT02183987|Other|Active Knowledge Translation Intervention|"Access to CSN guidelines, & provider- & patient-directed infographics recommending an intent-to-defer dialysis initiation strategy will be displayed in prominent clinic wall space & disseminated to patients.
Educational whiteboard video will be made available as a resource for clinic staff & patients.
Each clinic will receive reports from the Canadian Organ Replacement Register (CORR) outlining the proportion of patients followed by a Nephrologist (>3 months) starting dialysis early (eGFR >10.5 ml/min), for all incident dialysis patients from the clinic, with provincial & national average comparisons. These reports, & the CSN guideline on timing of dialysis initiation recommendation, will be delivered to the medical lead for each CKD clinic.
Each clinic will receive an in-person visit from one of the study investigators/collaborators highlighting the clinical practice guidelines & evidence supporting an intent-to-defer strategy, & will receive follow-up."
1607013|NCT02183974|Procedure|Peptest|
1607014|NCT02183961|Other|Restech|
1607015|NCT02183961|Other|Peptest|
1607016|NCT02183961|Other|Detection of pepsin in adenoid specimen|
1607017|NCT02183948|Drug|Oxytocin|
1607018|NCT02183948|Drug|Placebo|
1607019|NCT02183935|Device|Duodena-jejunal liner|
1607020|NCT02183922|Dietary Supplement|microencapsulated conjugated linoleic acid|The microencapsulated conjugated linoleic acid received light fruit jam with microencapsulated conjugated linoleic acid (3 g/day) during 12 weeks.
1607021|NCT02183922|Dietary Supplement|microencapsulated fish oil|The microencapsulated fish oil group received light fruit jam with microencapsulated fish oil (3 g/day) during 12 weeks.
1607022|NCT02183922|Dietary Supplement|light fruit jam|The placebo group received light fruit jam (15 g/day) during 12 weeks.
1607023|NCT02183909|Other|Testing and linkage to care for Y/MSM|Implementation of strategies to enhance testing and linkage to care of Y/MSM, including social network testing and a youth outreach corps working with existing and new community partner agencies.
1607024|NCT02183909|Behavioral|Engagement and retention for HIV-positive Y/MSM in care|Optimizing current HIV care and treatment services at DYC by implementing a patient peer mentoring component, a linkage and retention specialist, and psychosocial support for program staff.
1607025|NCT02183909|Other|Engagement and retention for HIV-negative Y/MSM in sexual health services|Offering a highly effective combination HIV prevention strategy, including PrEP; warm-hand offs for high-risk negatives, nPEP; risk reduction counseling; frequent HIV and STI testing, including testing a highly sensitive method of detecting early HIV infection; and youth-focused programming.
1607026|NCT02183909|Drug|Stribild PEP Substudy|A substudy of 28 days of once-daily Stribild® initiated within 72 hours of a high risk sexual exposure for HIV post-exposure prophylaxis (PEP).
1607027|NCT02183896|Biological|Platelet-rich plasma (PRP)|
1607028|NCT02183896|Drug|Saline|
1607029|NCT02183883|Drug|Afatinib|"40mg, 30mg, 20mg, OD, taken until progression, unacceptable toxicity, intercurrent illness, patient/clinician decision.
EGFR positive mutation patients only: dose escalation to a maximum of 50 mg/day may be considered in patients who tolerate a 40 mg/day dose (i.e. absence of diarrhoea, skin rash, stomatitis, and other adverse reactions with CTCAE Grade > 1) in the first 3 weeks. The dose should not be escalated in any patients with a prior dose reduction. The maximum daily dose for EGFR mutation positive patients is 50 mg."
1607030|NCT02183870|Drug|Crizotinib|250mg crizotinib bid until end of treatment
1607031|NCT02183857|Device|Ultrasound|
1607032|NCT02183857|Other|Landmark|
1607033|NCT02183844|Behavioral|Psychosocial Weight Intervention|Weekly group intervention for diet and exercise, designed specifically for individuals with serious mental illness and the cognitive deficits that accompany those illnesses
1607034|NCT02183831|Device|Insertion of the capsular tension ring|
1607035|NCT02183805|Drug|Abraxane,Cyclophosphamide,Carboplatin|High dose chemotherapy: Abraxane, Cyclophosphamide, Carboplatin
1607036|NCT02183792|Drug|Tolvaptan|
1607037|NCT02183792|Drug|Furosemide|
1607038|NCT02183779|Procedure|post-occlusive hyperemia|
1607039|NCT02183779|Procedure|cooling box|
1607040|NCT02183779|Drug|L-NMMA and Fluconazole dermic injection|
1607041|NCT02183766|Dietary Supplement|Galactooligosaccharide prebiotic|6 mL once a day
1607042|NCT02183766|Drug|Maltodextrin|6 mL once a day
1607043|NCT02183753|Other|wood smoke|
1607044|NCT02183753|Other|clean air|
1607045|NCT02183740|Behavioral|Multifaceted educational program|
1607046|NCT02183727|Device|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
1607047|NCT02183727|Procedure|Hamstring Autograft|The gold-standard treatment for ACL reconstruction is autograft tissue. Autograft is a piece of tendon harvested from another part of the patient's body, such as the hamstring or kneecap. In this study, the hamstring tendon from the back of the thigh of the injured (target) leg will be harvested and surgically transferred to replace the torn ACL. The attachment of the autologous tendon in the femoral and tibial bone tunnels will utilize techniques that are similar to those for the L-C Ligament. Over time the replacement tendon resorbs and a new ACL is regenerated.
1607048|NCT02183714|Drug|Songha Night ®|
1607049|NCT02183714|Drug|Placebo|
1607050|NCT02183701|Drug|Telmisartan|
1607051|NCT02183701|Drug|Losartan + Hydrochlorothiazide|
1607052|NCT02183701|Drug|Placebo|
1607053|NCT02183688|Drug|Low dose ASA|
1607054|NCT02183688|Drug|High dose ASA|
1607055|NCT02183688|Drug|Low dose paracetamol|
1607056|NCT02183688|Drug|High dose paracetamol|
1607057|NCT02183688|Drug|Caffeine|
1607058|NCT02183688|Drug|Placebo|
1607059|NCT02183675|Drug|Telmisartan/Amlodipine|Telmisartan/Amlodipine fixed-dose combination
1607060|NCT02183675|Drug|Telmisartan/Amlodipine/HCTZ|Telmisartan/Amlodipine/HCTZ fixed-dose combination
1607061|NCT02183675|Drug|Telmisartan/HCTZ|Telmisartan/HCTZ fixed-dose combination
1607062|NCT02183662|Drug|BI 224436|
1607063|NCT02183662|Drug|Placebo to BI 224436|
1607064|NCT02183649|Drug|pentoxyverine citrate|
1607065|NCT02183649|Drug|Placebo|
1607066|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C5|film coated tablet (5 mg/45 mg)
1607067|NCT02183636|Drug|Linagliptin/pioglitazone, FDC formulation C8|film coated tablet (5 mg/45 mg)
1607068|NCT02183636|Drug|Linagliptin tablet|5 mg
1607069|NCT02183636|Drug|pioglitazone tablet (Actos®)|45 mg
1607070|NCT02183623|Drug|Simvastatin|
1607071|NCT02183623|Drug|10 mg BI 1356 BS|
1607072|NCT02183610|Drug|[14C] BI 1356 as oral (p.o.) solution|
1607073|NCT02183610|Drug|[14C] BI 1356 solution for i.v. infusion|
1607074|NCT02183584|Drug|Rifampicin|
1607075|NCT02183584|Drug|Linagliptin|
1607076|NCT02183571|Drug|Merck Glucophage® high dose|Part I: Treatment A
1607077|NCT02183571|Drug|BMS Glucophage® high dose|Part I: Treatment B
1607078|NCT02183571|Drug|Merck Glucophage® low dose|Part II: Treatment C
1607079|NCT02183571|Drug|BMS Glucophage® low dose|Part II: Treatment D
1607080|NCT02183558|Other|OGTT by randomization|
1607081|NCT02183558|Other|OGTT by indication|
1607082|NCT02183545|Drug|BI 1060469|single rising doses given as tablet
1607083|NCT02183545|Drug|Placebo|given as tablet (matching placebo of BI 1060469)
1607084|NCT02183532|Drug|BI 1356 BS|single dose
1607085|NCT02183532|Drug|BI 1356 BS|multiple doses
1607086|NCT02183519|Drug|Capsaicin|For reflex cough testing, all participants will receive various concentrations of nebulized capsaicin. Delivery of multiple concentrations and doses of capsaicin allows for accurate assessment of both the strength (airflow measures) of reflex, as well as cough sensitivity.
1607087|NCT02183519|Other|Voluntary cough test|Participants will be fitted with a facemask covering their mouth and nose, and instructed to cough into the facemask.
1607088|NCT02183506|Drug|Metformin|
1607089|NCT02183506|Drug|BI 1356 BS|
1607090|NCT02183493|Drug|BI 1356|
1607091|NCT02183480|Drug|Linagliptin, low dose|
1607092|NCT02183480|Drug|Linagliptin, medium dose|
1607093|NCT02183480|Drug|Linagliptin, high dose|
1607094|NCT02183467|Drug|BI 1356, low dose|
1607095|NCT02183467|Drug|BI 1356, high dose|
1607096|NCT02183467|Drug|Placebo|
1607098|NCT02183454|Device|OrbusNeich COMBO stent|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
1607099|NCT02183441|Drug|BI 1356|
1607100|NCT02183441|Drug|Ritonavir|
1607101|NCT02183428|Drug|BI 1356|
1607102|NCT02183428|Drug|Glyburide|
1607103|NCT02183428|Drug|BI 1356 + Glyburide|
1607104|NCT02183415|Drug|BI 1356 BS, low dose|
1607105|NCT02183415|Drug|BI 1356 BS, medium dose|
1607106|NCT02183415|Drug|BI 1356 BS, high dose|
1607107|NCT02183415|Drug|Placebo|
1607108|NCT02183402|Drug|Digoxin|
1607109|NCT02183402|Drug|BI 1356|
1607110|NCT02183389|Drug|Warfarin|
1607111|NCT02183389|Drug|BI 1356|
1607112|NCT02183376|Drug|BI 1356|
1607113|NCT02183363|Drug|BI 1356 - Tablet TFII|
1607114|NCT02183363|Drug|BI 1356 - Tablet iFF|
1607115|NCT02183363|Drug|BI 1356 - Tablet TFIIb|
1607116|NCT02183350|Drug|BI 1356 BS - single rising dose|
1607117|NCT02183350|Drug|Placebo|
1607118|NCT02183337|Drug|BI 1356|
1607119|NCT02183337|Drug|BI 1356 + Pioglitazone|
1607120|NCT02183337|Drug|Pioglitazone|
1607121|NCT02183324|Drug|Low dose of BI 1356 BS|
1607122|NCT02183324|Drug|Medium dose of BI 1356 BS|
1607123|NCT02183324|Drug|High dose of BI 1356 BS|
1607124|NCT02183324|Drug|Placebo|
1607125|NCT02183311|Drug|BI 1356 BS - single rising dose|
1607126|NCT02183311|Drug|BI 1356 BS - multiple rising dose|
1607127|NCT02183311|Drug|Placebo|
1607128|NCT02183298|Drug|BI 1356 BS - intravenous|
1607129|NCT02183298|Drug|BI 1356 BS - Tablet|
1607130|NCT02183298|Drug|Placebo|
1607131|NCT02183285|Dietary Supplement|Pharmaton PHL 00747 soft gelatine capsules|
1607132|NCT02183285|Dietary Supplement|Pharmaton PHL 00747 film-coated tablets|
1607133|NCT02183285|Dietary Supplement|Placebo film-coated tablets (fct)|
1607134|NCT02183285|Dietary Supplement|Placebo soft gelatine capsules|
1607135|NCT02183272|Drug|Intranasal Ketamine|Ketamine in liquid form to be distributed nasally by a board-certified physician while the subject is already in the hospital for suicidal ideation.
1607136|NCT02183272|Drug|Intranasal Saline Placebo|Intranasal Saline to be distributed by a board-certified physician while the patient is already hospitalized for suicidal ideation.
1607137|NCT02183259|Drug|ESR 1150 CL, Capsule, oral|
1607138|NCT02183259|Drug|ESR 1150 CL, solution, intravenous|
1607139|NCT02183246|Drug|Porfiromycin|
1607140|NCT02183246|Drug|Placebo|
1607141|NCT02183246|Radiation|Radiotherapy|
1607142|NCT02183233|Drug|Eschscholtzia Californica|
1607143|NCT02183233|Drug|Eschscholtzia Californica Placebo|
1607144|NCT02183220|Drug|Metamizol|
1607145|NCT02183220|Drug|Acetylsalicylic acid (ASA)|
1607146|NCT02183220|Drug|Metamizol placebo|
1607147|NCT02183220|Drug|ASA placebo|
1607148|NCT02183207|Procedure|Percutaneous Endoscopic Gastrostomy|Percutaneous Endoscopic Gastrostomy by introducer method via visualization through E.G. ScanTM
1607149|NCT02183194|Device|Lutonix Paclitaxel Drug Coated Balloon|
1607150|NCT02183181|Drug|Meloxicam capsule|
1607151|NCT02183181|Drug|Meloxicam tablet|
1607152|NCT02183168|Drug|Meloxicam suppository|
1607153|NCT02183168|Drug|Meloxicam tablet|
1607154|NCT02183168|Drug|Indomethacin|
1607155|NCT02183155|Drug|Meloxicam - low|
1607156|NCT02183155|Drug|Meloxicam - medium|
1607157|NCT02183155|Drug|Meloxicam - high|
1607158|NCT02183155|Drug|Placebo|
1607159|NCT02183155|Drug|Extended-release indomethacin|
1607160|NCT02183142|Drug|Mobic, China, 7.5 mg|
1607161|NCT02183142|Drug|Mobic, Germany, 7.5 mg|
1607162|NCT02183129|Drug|Diclofenac|
1607163|NCT02183129|Drug|Meloxicam|
1607164|NCT02183116|Drug|Meloxicam|
1607165|NCT02183103|Drug|meloxicam rapid release tablet, 12mg, UH AC62MU|
1607166|NCT02183090|Drug|Meloxicam ampoule|
1607167|NCT02183090|Drug|Meloxicam tablet|
1607168|NCT02183077|Drug|Meloxicam gel|
1607169|NCT02183077|Drug|Meloxicam tablet|
1607170|NCT02183064|Drug|Meloxicam|
1607171|NCT02183064|Drug|NSAID|
1607172|NCT02183051|Drug|Meloxicam 7.5 mg|
1607173|NCT02183051|Drug|Meloxicam 3.75 mg|
1607174|NCT02183051|Drug|Meloxicam 1.875 mg|
1607175|NCT02183051|Drug|Ibuprofen 200 mg|
1607176|NCT02183051|Drug|Placebo|
1607177|NCT02183051|Drug|Meloxicam 15 mg|
1607178|NCT02183051|Drug|Ibuprofen 400 mg|
1607179|NCT02183038|Drug|Meloxicam low|
1607180|NCT02183038|Drug|Meloxicam high|
1607181|NCT02183038|Drug|Naproxen sodium|
1607182|NCT02183038|Drug|Meloxicam placebo low|
1607183|NCT02183038|Drug|Meloxicam placebo high|
1607184|NCT02183038|Drug|Naproxen sodium placebo|
1607185|NCT02183025|Drug|Meloxicam 7.5 mg|
1607186|NCT02183025|Drug|Meloxicam 15 mg|
1607187|NCT02183025|Drug|Mefenamic acid 500 mg|
1607188|NCT02183025|Drug|Placebo matching 7.5 mg meloxicam|
1607189|NCT02183025|Drug|Placebo matching 15 mg meloxicam|
1607190|NCT02183025|Drug|Placebo matching 500 mg mefenamic acid|
1607191|NCT02183012|Drug|Ibuprofen extrudate|
1607192|NCT02183012|Drug|Ibuprofen lysinate|
1607193|NCT02183012|Drug|Ibuprofen|
2010002|NCT03151161|Drug|Icotinib,Pemetrexed,Carboplatin|Pemetrexed (500mg/m2) + Carboplatin (AUC=5), every 3 weeks, maximum 4 cycles; icotinib 125mg, three times a day, d2-15 in each cycle, and icotinib 125mg,three times a day, since the last cycle until disease progression
1607262|NCT02182544|Drug|WAL 801 CL dry syrup placebo|
1607263|NCT02182531|Drug|Epinastine|
2010003|NCT03151161|Drug|Icotinib|Single drug: Icotinib 125mg, three times a day, continuous until disease progression.
2010004|NCT03152084|Drug|Dapagliflozin|The study consists of a 2-week, open label, dapagliflozin (10mg) treatment period.
2010005|NCT03148795|Drug|Talazoparib|1 mg daily
1607197|NCT02182986|Procedure|transplant|All subjects enrolled in this study are candidates for/recipients of solid organ transplants as a therapeutic for end stage diseases (e.g., heart, liver, heart with liver, kidney, small intestine, or liver with small intestine transplants).
1607198|NCT02182986|Drug|Immunosuppressive Drugs|Immunosuppressive drugs prescribed as standard of care to prevent rejection of the allograft.
1607199|NCT02182973|Dietary Supplement|donor human milk|"Infants with NAS requiring pharmacologic management will be fed donor human milk instead of formula for 2 weeks.
GI-subscores from the Finnegan NAS Scoring system will be computed."
1607200|NCT02182960|Drug|Ibuprofen syrup|
1607201|NCT02182960|Drug|Brufen syrup|
1607202|NCT02182947|Device|Capsule endoscopy|Pediatric patients with indeterminate colitis (IC) or Crohn's disease (CD) who are scheduled to undergo routine small bowel screening or surveillance using MRE. Subjects will swallow a patency capsule (PC) to study bowel patency.Those patients, who pass an intact PC, usually within 40 hours, will ingest the wireless capsule endoscopy (WCE). The WCE will be performed within 1 week of completion of MRE.
1607203|NCT02182934|Drug|Ginsana|
1607204|NCT02182934|Drug|Placebo|
1607205|NCT02182908|Other|PET-Scan|PET-Scan
1607206|NCT02182895|Drug|Saxagliptin|2.5-5 mg daily
1607207|NCT02182882|Drug|GINSANA|
1607208|NCT02182882|Drug|Placebo|
1607209|NCT02182869|Drug|Combivent® HFA inhalation aerosol|
1607210|NCT02182869|Drug|Combivent® CFC inhalation aerosol|
1607211|NCT02182856|Drug|Ipratropium bromide 500 µg/salbutamol sulphate 3 mg|
1607212|NCT02182856|Drug|Ipratropium 500 µg|
1607213|NCT02182856|Drug|Salbutamol sulphate 3 mg|
1607214|NCT02182856|Drug|Salbutamol sulphate 6 mg|
1607215|NCT02182843|Biological|Cellentra VCBM|Cellentra™ VCBM is an allogenic bone graft containing naturally occurring viable donor cells intended for homologous use in the repair, replacement, reconstruction or supplementation of the recipient's tissue in musculoskeletal defects.
1607216|NCT02182830|Drug|Empagliflizon low dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
1607217|NCT02182830|Drug|placebo|starting dose 10mg; forced titration after 4 weeks 25mg dose
1607218|NCT02182830|Drug|Empagliflizon high dose|starting dose 10mg; forced titration after 4 weeks 25mg dose
1607219|NCT02182804|Device|Olympus|narrow band imaging with magnification
1607220|NCT02182804|Device|Cellvizio|probe-based confocal laser endomicroscopy
1607221|NCT02182791|Drug|Nevirapine|
1607222|NCT02182791|Drug|EE/NET|
2010006|NCT03147066|Drug|Dezocine|Dezocine (0.1 mg/kg）will be infused during surgery
2010007|NCT03147066|Drug|Flurbiprofen Axetil|Flurbiprofen Axetil (1 mg/kg）will be infused during surgery
1607225|NCT02182765|Drug|Nevirapine|
1607226|NCT02182765|Drug|Amprenavir|
1607227|NCT02182765|Drug|Abacavir|
1607228|NCT02182752|Drug|Ropivacaine - Tramadol|Interscalene block using ropivacaine plus tramadol
1607229|NCT02182752|Drug|Ropivacaine|Interscalene block using ropivacaine
1607230|NCT02182739|Drug|Meloxicam|tablets or injectable solution
1607231|NCT02182726|Drug|MOBEC|
1607232|NCT02182713|Drug|Salbutamol sulfate/Ipratropium bromide|Salbutamol sulfate 120 mcg + Ipratropium bromide 20 mcg per puff
1607233|NCT02182713|Drug|Salbutamol|Salbutamol 100 mcg per puff
1607234|NCT02182700|Drug|salbutamol sulfate + ipratropium bromide|120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)
1607235|NCT02182687|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be delivered in five total fractions, with at a minimum of one day between any two treatments. The entire treatment must be delivered within 15 total days.
1607236|NCT02182687|Procedure|Trans-Arterial Chemoembolization (TACE)|First day will be administered and a second TACE will be administered after 4 weeks and subsequently if imaging is showing disease progression. Following each TACE procedure all patients will remain in hospital for observation.
1607237|NCT02182687|Drug|Doxorubin|This procedure will be completed with 2 vials of drug eluting beads each loaded with 50 mg of Doxorubin.
1607238|NCT02182674|Drug|Placebo Combivent HFA|
1607239|NCT02182674|Drug|Combivent HFA|
1607240|NCT02182674|Drug|Combivent (CFC)|
1607241|NCT02182674|Drug|Placebo Combivent (CFC)|
1607242|NCT02182661|Drug|Ba253BINEB|
1607243|NCT02182648|Drug|etomidate|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.
infusion of etomidate at 2 minutes before anesthesia induction"
1607244|NCT02182648|Drug|propofol|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.
infusion of propofol at 2 minutes before anesthesia induction"
1607245|NCT02182648|Drug|sevoflurane|"intravenous injection midazolam 0.08 mg/kg, fentanyl 0.002 mg/kg, cisatracurium 0.15 mg/kg for induction of anesthesia.
inhale sevoflurane for anesthesia induction and maintenance"
1607246|NCT02182635|Drug|Ba253BINEB|
1607247|NCT02182622|Drug|Docetaxel|
1607248|NCT02182622|Drug|Prednisone|
1607249|NCT02182622|Drug|LDE225|
1607250|NCT02182609|Drug|Kit for the Preparation of 99mTc-rhAnnexin V-128|Kit for the Preparation of Tc-99m Recombinant Human Annexin V-128 for Injection
1607251|NCT02182596|Drug|Mylotarg|Dose level study
1607252|NCT02182583|Drug|Ba253MDI|
1607253|NCT02182583|Drug|Ba253BINEB|
1607254|NCT02182570|Drug|WAL 801 CL dry syrup|
1607255|NCT02182557|Drug|WAL 801 CL Dry Syrup|
1607256|NCT02182557|Drug|Ketotifen Fumarate Dry Syrup|
1607257|NCT02182557|Drug|WAL 801 CL Dry Syrup placebo|
1607258|NCT02182557|Drug|Ketotifen Fumarate Dry Syrup placebo|
1607259|NCT02182544|Drug|WAL801CL dry syrup|
1607264|NCT02182531|Drug|Pseudoephedrine|
2010008|NCT03146065|Biological|PF-06730512|Comparison of different dosages of PF-06730512 to Placebo
2010009|NCT03146065|Drug|Placebo|Comparison of Placebo to different doses of PF-06730512
1607265|NCT02182531|Drug|Epinastine + Pseudoephedrine combination|
1607266|NCT02182518|Drug|Epinastine|
1607267|NCT02182518|Drug|Pseudoephedrine|
1607268|NCT02182518|Drug|Placebo|Placebo during run-in period
1607269|NCT02182505|Drug|Berodual® Respimat®, low dose|
1607270|NCT02182505|Drug|Berodual® Respimat®, high dose|
1607271|NCT02182505|Drug|Berodual® MDI|
2010010|NCT03145376|Diagnostic Test|geriatric assessment|"Clinical evaluation and geriatric assessment with:
CIRS: CIRS (Cumulative Illness Rating Scale)
ADL (Activities of Daily Living);
IADL (InstrumentalActivities of Daily Living);
Mini Nutritional Assessment;
Evaluation of quality of life (Short Form 36, SF-36).
Making a traditional 12-lead ECG.
A single lead electrocardiographic registration (DI, D II and D III) of 5 minutes baseline and 5 minutes with controlled breathing (15 breaths / min), using the Spectralink 2011 program, which allows us to identify and calculate the variables object of study;
transthoracic echocardiogram."
1607274|NCT02182479|Drug|Berodual® via Respimat®, high dose|
1607275|NCT02182479|Drug|Berodual® via Respimat®, low dose|
1607276|NCT02182479|Drug|Berodual® via MDI, high dose|
1607277|NCT02182479|Drug|Placebo Respimat®|
1607278|NCT02182479|Drug|Placebo MDI|
1607279|NCT02182466|Device|Colon capsule endoscopy|
1607280|NCT02182453|Drug|BI 10773 - single rising dose|
1607281|NCT02182453|Drug|Placebo|
1607282|NCT02182440|Biological|recAP|One hour infusions once daily for three days
1607283|NCT02182440|Other|Placebo|1 hour IV infusion once daily for 3 days
1607284|NCT02182414|Drug|BI 207127 NA (TF-I)|200 mg tablet
1607285|NCT02182414|Drug|BI 207127 NA (TF-II)|400 mg tablet
1607286|NCT02182414|Drug|BI 207127 NA delayed release|400 mg tablet
1607287|NCT02182414|Drug|BI 207127 NA extended release (10% HPMC)|400 mg tablet
1607288|NCT02182414|Drug|BI 207127 NA extended release (15% PEO)|400 mg tablet
1607289|NCT02182414|Drug|BI 207127 NA extended release (20% HPMC)|400 mg tablet
1607290|NCT02182401|Drug|BI 207127 NA|Days 3-8 and days 25-30
1607291|NCT02182401|Drug|BI 201335 NA|Days 15-30
1607292|NCT02182401|Drug|Midazolam|Days 1, 7, 23 and 29
1607293|NCT02182401|Drug|Tolbutamide|Days 1, 7, 23 and 29
1607294|NCT02182388|Drug|Placebo|
1607295|NCT02182388|Drug|BI 207127 NA powder for solution|
1607296|NCT02182388|Drug|BI 207127 NA tablet|
1607297|NCT02182375|Drug|BI 201335 NA|
1607298|NCT02182375|Drug|Raltegravir|
1607299|NCT02182362|Drug|BI 201335 NA|
1607300|NCT02182362|Drug|Placebo|
1607301|NCT02182349|Drug|BI 201335 NA soft gelatin capsule|
1607302|NCT02182349|Drug|[14C]-BI 201335 NA radiolabelled drug|
1607303|NCT02182336|Drug|BI 201335 NA|"480 mg BI 201335 NA in the morning, 240 mg BI 201335 NA in the evening of day 10
240 mg BI 201335 NA bid from day 11 to 23"
1607304|NCT02182336|Drug|Caffeine|days 1, 10 and 19
1607305|NCT02182336|Drug|Warfarin sodium|days 1, 10 and 19
1607306|NCT02182336|Drug|Vitamin K|days 1, 10 and 19
1607307|NCT02182336|Drug|Omeprazole|days 1, 10 and 19
1607308|NCT02182336|Drug|Dextromethorphan hydrobromide|days 1, 10 and 19
1607309|NCT02182336|Drug|Midazolam HCl solution|Days 3 and 21
1607310|NCT02182336|Drug|Midazolam HCl oral syrup|days 1, 10 and 19
1607311|NCT02182336|Drug|Digoxin|Days 2 and 20
1607312|NCT02182323|Drug|BI 201335 NA|
1607313|NCT02182323|Drug|Placebo solution|
1607314|NCT02182310|Drug|BI 201335 low dose|
1607315|NCT02182310|Drug|BI 201335 placebo|
1607316|NCT02182310|Drug|Moxifloxacin|
1607317|NCT02182310|Drug|BI 201335 high dose|
1607318|NCT02182297|Drug|BI 201335 NA in single rising doses|
1607319|NCT02182297|Drug|Placebo|
1607320|NCT02182284|Drug|low dose BI 201335 NA soft gelatine capsule (SGC)|
1607321|NCT02182284|Drug|high dose BI 201335 NA soft gelatine capsule (SGC)|
1607322|NCT02182284|Drug|low dose BI 201335 NA powder in bottle (PIB)|
1607323|NCT02182284|Drug|high dose BI 201335 NA powder in bottle (PIB)|
1607324|NCT02182271|Drug|BI 201335 ZW - single rising dose|
1607325|NCT02182271|Drug|Placebo|
1607326|NCT02182258|Drug|BIBF 1120 soft gelatine capsule|
1607327|NCT02182258|Drug|BIBF 1120 intravenous solution|
1607328|NCT02182258|Drug|Placebo ampoule|
1607329|NCT02182245|Drug|BIBF 1120|
1607330|NCT02182245|Drug|Paclitaxel|
1607331|NCT02182245|Drug|Carboplatin|
1607332|NCT02182232|Drug|BIBF 1120|
1607333|NCT02182232|Drug|Paclitaxel|
1607334|NCT02182232|Drug|Carboplatin|
1607335|NCT02182219|Drug|BIBF 1120|
1607336|NCT02182206|Drug|BIBF 1120|
1607337|NCT02182193|Drug|BIBF 1120 capsules charge 1|
1607338|NCT02182193|Drug|BIBF 1120 capsules charge 2|
1607339|NCT02182193|Drug|BIBF 1120 drinking solution|
1607340|NCT02182167|Drug|IV N-acetylcysteine (NAC)|
1607341|NCT02182167|Drug|Water|
1607342|NCT02182154|Drug|BIBF 1120 ES|
1607343|NCT02182141|Drug|BIBF 1120 ES|
1607344|NCT02182128|Drug|BIBF 1120|
1607347|NCT02182102|Drug|BIBF 1120|
1607348|NCT02182102|Drug|Pemetrexed|
1607349|NCT02182076|Drug|BIBF 1120|150 mg of BIBF 1120 ES soft gelatine capsules
1607350|NCT02182063|Drug|BIBF 1120 low dose|
1607351|NCT02182063|Drug|BIBF 1120 high dose|
1607352|NCT02182050|Drug|BIBF 1120 ES low dose|
1607353|NCT02182050|Drug|BIBF 1120 ES high dose|
1607354|NCT02182050|Drug|Placebo to BIBF 1120 ES|
1607355|NCT02182037|Drug|Single rising doses of BIBT 1011 BS|
1607356|NCT02182037|Drug|BIBT 1011 BS placebo|
1607357|NCT02182024|Drug|Dabigatran etexilate high dose|
1607358|NCT02182024|Drug|Dabigatran etexilate low dose|
1607359|NCT02182011|Drug|Tenecteplase|
1607360|NCT02182011|Drug|Alteplase|
1607361|NCT02182011|Drug|Streptokinase|
1607362|NCT02181998|Drug|Full dose tenecteplase|
1607363|NCT02181998|Drug|Unfractioned heparin|
1607364|NCT02181998|Drug|Enoxaparin|
1607365|NCT02181985|Drug|Full dose TNK-tPA|
1607366|NCT02181985|Drug|Half dose TNK-tPA|
1607367|NCT02181985|Drug|Heparin|
1607368|NCT02181985|Drug|Enoxaparin|
1607369|NCT02181985|Drug|Abciximab|
1607370|NCT02181972|Drug|Gingko biloba|
1607371|NCT02181972|Drug|Placebo|
1607372|NCT02181959|Drug|Pharmaton® with DMAE|
1607373|NCT02181959|Drug|Pharmaton® without DMAE|
1607374|NCT02181959|Drug|Placebo|
1607375|NCT02181946|Drug|Fluconazole|
1607376|NCT02181946|Drug|Nevirapine|
1607377|NCT02181933|Drug|Nevirapine|
1607378|NCT02181933|Drug|Zidovudine (ZDV)|
1607379|NCT02181933|Drug|Lamivudine (3TC)|
1607380|NCT02181920|Drug|Metamizole|
1607381|NCT02181920|Drug|Diclofenac|
1607382|NCT02181920|Drug|Diclofenac placebo|
1607383|NCT02181920|Drug|Metamizole placebo|
1607384|NCT02181907|Drug|UH-AC 62 XX tablet|
1607385|NCT02181907|Drug|UH-AC 62 XX capsule|
1607386|NCT02181881|Behavioral|DuoPACT|Intervention sessions are administered weekly by a counselor.
1607387|NCT02181881|Behavioral|Life Steps|Intervention sessions are administered weekly by a counselor.
1607388|NCT02181868|Other|Biodegradable and titanium fixation used in mandibular fractures.|
1607389|NCT02181855|Procedure|Full-thickness gastroplication (GERD-X)|Endoscopic full-thickness gastroplication wit the GERD-X device
2010011|NCT03145181|Drug|JNJ-64007957|Participants will receive IV infusion of JNJ-64007957.
1607391|NCT02181829|Radiation|Whole Lung IMRT|External beam radiation therapy will be administered on an outpatient basis, once daily (except weekends and holidays) for approximately two weeks. Patients will undergo a simulation prior to initiation of radiation. Once an IMRT plan is generated which meets all dose constraints specified patients will be treated with 6MV photons for 10 treatments.
1607392|NCT02181816|Drug|Azilsartan/amlodipine|Azilsartan/amlodipine combination tablets LD & HD
1607393|NCT02181803|Drug|MK-8189|MK-8189, oral, 2 mg and/or 10 mg tablets, taken QD for a daily dose of 2 mg, 4 mg, 8 mg, 10 mg, 14 mg, 16 mg, 20 mg, or 40 mg
1607394|NCT02181803|Drug|Placebo|Placebo matching oral 2 mg and/or 10 mg MK-8189 tablets, taken QD
1607395|NCT02181803|Drug|Base Monotherapy|For Part 2 only: participants need to be on monotherapy with an atypical antipsychotic medication (eg, Olanzapine, Quetiapine, Paliperidone, Asenapine, Iloperidone, Aripirprazole, Lurasidone, Risperidone [not to exceed daily dose of 6 mg], or Ziprasidone.) The participant should be on a stable and well tolerated treatment regimen for at least 2 months prior to screening. NOTE: Clozapine is not allowed.
1607396|NCT02181790|Device|Excimer laser|twice weekly treatments with the excimer laser for a total of 8 weeks.
1607397|NCT02181790|Drug|Acitretin|17.5mg/d
1607398|NCT02181777|Behavioral|GRASP|GRoup trAining for Social skills in Psychosis
1607399|NCT02181777|Behavioral|Standard care|Treatment as usual
1607400|NCT02181764|Drug|KRN23|Single SC administration on day 1: 0.3, 0.6 and 1.0 mg/kg
1607401|NCT02181751|Other|Trauma Focused Cognitive Behavioural Therapy Group|Throughout the length of a year children will participate in trauma focused cognitive behavioural group therapy (TF-CBT) with 7 other children in his/her cohort. The group will take place either on site at the Be Brave Ranch, or via skype in their own homes with their parent or caregiver present. In total children will receive over 200 hours of TF-CBT group therapy.
2010012|NCT03146143|Procedure|ultrafiltration|ultrafiltration after cardiopulmonary bypass
2010013|NCT03143452|Drug|lidocaine gel|2% lidocaine gel in 1 ml syringe, applied to the eye 5 minutes before phacoemulsification
1607406|NCT02181725|Behavioral|Multimodal Rehabilitation Program|The Multimodal Rehabilitation Program is a Graded exposure based treatment. It consists of a Graded Exposure Module (GE), a Combination Module (HMGE) and a Parent Module (PM).
1607407|NCT02181725|Behavioral|Care as Usual|Care as usual is the care currently provided to adolescents with musculoskeletal chronic pain and is based on the principles of Graded Activity.
1607408|NCT02181712|Biological|Mesenchymal stem cell|
1607409|NCT02181699|Drug|KHK2823|single agent KHK2823
1607410|NCT02181673|Drug|Placebo|Participants will receive intravenous infusions of placebo at Weeks 0, 4, 12 and 20 in treatment Group 1 and intravenous infusions of placebo at Week 24 to maintain the blind in treatment Group 2.
1607411|NCT02181673|Drug|Golimumab|Participants will receive intravenous infusions of golimumab 2mg/kg at Weeks 0, 4 and thereafter every 8 weeks up to Week 52 in treatment Group 2 and intravenous infusions of golimumab (2mg/kg) at Weeks 24, 28 and thereafter every 8 weeks up to Week 52 in treatment Group 1.
1607412|NCT02181660|Drug|ASP2215|oral
1607413|NCT02181647|Behavioral|Safe Touches: Personal Safety Training for Children|The intervention includes a 50-minute interactive training and an age-appropriate activity book on personal body safety to take home and complete with caregivers. Using culturally appropriate puppets, workshop facilitators use role-play to model scenarios to help children: a) recognize safe and not-safe touches, b) understand body safety, c) practice assertiveness skills, and d) help children identify whom they can go to for help.
1607414|NCT02181634|Drug|Nab-Paclitaxel and Gemcitabine|Nab-Paclitaxel will be administered first, at a dose of 125 mg/m² IV over a period of 30 minutes; gemcitabine will be administered second, at a dose of 1000 mg/m² over a period of 30 minutes.
1607415|NCT02181621|Device|Iodosorb|Cadexomer iodine gel
1607416|NCT02181621|Device|Solosite gel|Hydrogel
1607418|NCT02181582|Drug|Emapunil|Single peroral administration
1607419|NCT02181582|Device|PET|Positron emission tomography, which creates images by detecting radioactivity.
1607420|NCT02181556|Drug|FOLFIR + Aflibercept|injection of FOLFIRI and Aflibercept every 14 days until progression of disease
1607421|NCT02181543|Drug|Clonidine|1μg/Kg, IV (in the vein) intraoperative. Number of Cycles: single dose.
1607422|NCT02181530|Other|No Intervention|No treatment (intervention) is being administered as part of this study.
1607423|NCT02181517|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
1607568|NCT02180503|Drug|BI 1356 BS PIB - high dose|
1607569|NCT02180503|Drug|BI 1356 BS tablet - high dose|
1607424|NCT02181517|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
1607425|NCT02181517|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
1607426|NCT02181504|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at day 1, weeks 4 and 8.
1607427|NCT02181504|Drug|ranibizumab|Ranibizumab (Lucentis®) 0.5 mg administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 16.
1607428|NCT02181504|Other|sham procedure|Sham procedure to the study eye at weeks 12 and 16.
1607429|NCT02181491|Other|[11C]-P943|
1607430|NCT02181478|Drug|cyclophosphamide|All patients will receive a single IV dose of 50 mg/kg of cyclophosphamide on day -6
1607431|NCT02181478|Drug|fludarabine phosphate|Given by IV during prep at 40mg/m2 for 5 days
1607432|NCT02181478|Radiation|total-body irradiation|Undergo single fraction of reduced intensity conditioning (RIC) regimen of 200 cGy TBI without shielding on day -1
1607433|NCT02181478|Drug|cyclosporine|Initiated in patients on the day -5. Cyclosporine will be administered orally or intravenously at 2 mg/kg/dose every 12 hours for 2-hour period. Cyclosporine will continue until day +100
1607434|NCT02181478|Drug|mycophenolate mofetil|Given at 1g intravenously or orally twice daily from day -5 to +100, or as clinically indicated.
1607435|NCT02181478|Procedure|umbilical cord blood transplantation|Following RIC, on day T+0, dimethylsulphoxide will be removed from the cord blood cells and given as transplant.
1607436|NCT02181478|Procedure|mesenchymal stem cell transplantation|The total dosage of hMSC will be 2x10^6cells/kg (+/-20%).
1607437|NCT02181465|Biological|G17DT|
1607438|NCT02181439|Device|(LLLT Low Level Laser Therapy) SiroLaser advance|Irradiation scanning distance of the mucosa over an area ranging from the mesial surface of the maxillary canine to the distal surface of the maxillary first molar in the sagittal direction, and the CEJ to the bottom of the vestibule in the vertical direction.
1607439|NCT02181426|Drug|Ketorolac Dose|Subjects will be assigned an enrollment number. Enrollment numbers will be assigned consecutively in the order of study enrollment. Based on the enrollment number, subjects will be randomized by a pre-determined computer randomization list created by a statistician to receive a ketorolac dose (0, 7.5, 15, 30 mg).
1607440|NCT02181413|Drug|Ixazomib Citrate|Ixazomib citrate capsules
1607441|NCT02181413|Drug|Placebo|Ixazomib citrate placebo-matching capsules
1607442|NCT02181400|Device|Ellex Integre NIR laser|"Each NIR light treatment will consist of a 90 second exposure of the macula of the study eye to the Ellex Integre NIR laser with the patient fixating on the central aiming beam. The laser light beam is 4.5mm in diameter with a central masked area of 1.0 mm diameter containing the central fixation target. In this way the central macula will be spared in the event of an adverse effect of the laser, which we do not anticipate.
The patient will be seated at the slit lamp laser delivery system and after the eye has been dilated and anesthetised with topical eye drops a standard fundus contact lens will be placed on the eye through which the post area pole will be visualised while the treatment is delivered. There will be 12 treatments administered over a 5 week period."
1607443|NCT02181387|Drug|Acetaminophen|administered every 6 hours by mouth up to 4 doses
1607444|NCT02181387|Drug|Placebo|
1607445|NCT02181361|Drug|aspirin plus hirudin|hirudin two tables, three times a day and aspirin 100mg, once daily.
1607446|NCT02181361|Drug|Warfarin|An initial dose of Warfarin is 1.5mg,once daily. 3 days later,we check the international normalized ratio(INR) values and adjust the warfarin dose make INR between 2-3 steady.Then, we maintain this warfarin dose.
1607447|NCT02181348|Drug|Vitamin E|dl-alpha tocopheryl acetate 400 mg once daily for 3 months
1607448|NCT02181348|Drug|placebo (edible oil)|
1607449|NCT02181335|Drug|Respimat® Budesonide low dose|
1607450|NCT02181335|Drug|Respimat® Budesonide high dose|
1607451|NCT02181335|Drug|Turbohaler® Budesonide|
1607452|NCT02181335|Drug|Placebo|
1607453|NCT02181322|Drug|Meloxicam - low dose|
1607454|NCT02181322|Drug|Meloxicam - medium dose|
1607455|NCT02181322|Drug|Meloxicam - high dose|
1607456|NCT02181309|Drug|Meloxicam, low dose|
1607457|NCT02181309|Drug|Meloxicam, medium dose|
1607458|NCT02181309|Drug|Meloxicam, high dose|
1607460|NCT02181283|Behavioral|W+W|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.
Web booster sessions: Web boosters will be completed at 1, 2 and 3 months post-BI. Content is tailored to the individual based on answers to baseline questions and responses during Web-based BI. Web-based Booster will: 1) briefly ascertain current AOS use, 2) changes in AOS since completing Web BI, 3) progress toward goals, and 4) plans and encouragement for next steps."
1607461|NCT02181283|Behavioral|W+P|"Web-delivered brief intervention: Participants receive a 30-40 minute Web-based intervention which includes a tailored review of participants' goals/values, feedback regarding their present alcohol/prescribed opioid/sedative use patterns and consequences, developing a discrepancy between their alcohol or prescribed drug use, ability to meet goals and values through a decisional balance exercise, and formulation of a tailored change plan.
Peer booster sessions: The peer supporter will work with participants at 1, 2, and 3 months post-Web-based BI. Peer supports will address Service Members' own goals and will provide emotional and informational support."
1607462|NCT02181270|Other|high intensity exercise|Subjects will perform 5-10 minute warm-up (50% VO2peak). Subjects will then exercise at an exercise intensity that corresponds to 90% HRmax, for 4 minutes. This will be followed by 3 min of exercise at 55% HRmax. Four of these exercise intervals/recovery periods will be completed. The total exercise commitment will be ~45 minutes
1607463|NCT02181270|Other|continuous moderate exercise|Subjects will perform a 5-10 minute warm-up at 50% VO2peak. Thereafter, the intensity of exercise will be increased to 70% VO2peak by increasing the speed and incline of the treadmill. Subjects will exercise at this intensity for 60 minutes.
1607570|NCT02180503|Drug|BI 1356 BS tablet - high dose with food|
1607571|NCT02180490|Drug|UHAC 62 XX tablet|
1607464|NCT02181257|Drug|Methoxsalen|Procedure ECP Treatments will be performed using Therakos UVAR XTS system or the Therakos CELLEX system
1607465|NCT02181244|Other|Egg, one a day, for breakfast|One egg per day as breakfast for 5 weeks followed by a 3 week washout period and 5 additional weeks on oatmeal. This is a randomized crossover design. Half of subjects started with the eggs and the other half with oatmeal. Blood lipids, glucose and inflammatory measurements will be finished 24. weeks after completion of the study. Data will be reported 1 year after the completion of the study.
1607466|NCT02181244|Other|Oatmeal, one cup a day|Subjects will be fed oatmeal for a period of 5 weeks. After 3 weeks they will be switched to the alternate diet. This is a randomized control trail in which plasma glucose, plasma lipids and inflammatory markers will be measured. All these measurements will be finished 24 weeks after completion of the study. Data will be reported after 1 year of the completion of the study.
2010014|NCT03143452|Drug|tetracaine eye drop|0.5% tetracaine eye drop was given 5 minutes before phacoemulsification
2010015|NCT03142646|Biological|IM19 CAR-T|All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.
2010016|NCT03142334|Biological|Pembrolizumab|IV infusion
1607470|NCT02181218|Drug|Romidepsin|
1607471|NCT02181218|Drug|Gemcitabine|
1607472|NCT02181218|Drug|Oxaliplatin|
1607473|NCT02181218|Drug|Dexamethasone|
1607474|NCT02181218|Drug|Pegfilgrastim|
1607475|NCT02181205|Drug|bupivacaine|
1607476|NCT02181205|Drug|placebo|
1607477|NCT02181192|Device|PET/CT|PET/CT
1607478|NCT02181192|Radiation|Instant Radiotherapy according to guidelines|Instant Radiotherapy according to guidelines
1607479|NCT02181192|Radiation|Radiotherapy after achievement of PSA marginal value|Radiotherapy after achievement of PSA marginal value
2010017|NCT03142334|Drug|Placebo (saline solution)|IV infusion
1607481|NCT02181166|Other|Kinesiotherapy|
1607482|NCT02181166|Other|Isquemic compression|
1607483|NCT02181166|Other|High voltage electrical stimulation|
1607484|NCT02181153|Other|sample blood and fecal collection|Blood and fecal samples will be collected at the day of enrolment
1607485|NCT02181140|Device|EUS guided FNA and fine needle punction|punction of a suspect area by a EUS guided fine needle as well as pro core fine needle to evacuate histology and smear biologics
1607486|NCT02181127|Device|Glucagon-only Bionic Pancreas|A computer algorithm will automatically deliver glucagon based on the signal from a minimally invasive continuous glucose monitor.
1607487|NCT02181114|Behavioral|Expert System Coaching|Patients will receive coaching and feedback over the phone and stag-appropriate educational materials (i.e. paphlets, brochures, personalized feedback report) based on their answers to the survey questions and where they are in their kidney transplant evaluation process.
1607488|NCT02181101|Drug|FEC-DocGemzar adjuvant chemotherapy|
1607489|NCT02181101|Drug|FEC-Doc adjuvant chemotherapy|
1607490|NCT02181101|Drug|Zoledronic acid i.v. 2 years|
1607491|NCT02181101|Drug|Zoledronic acid i.v. 5 years|
1607492|NCT02181088|Biological|ChAd63 RH5 low dose|ChAd63 RH5 at 5 x 10^9 vp
1607493|NCT02181088|Biological|ChAd63 RH5 full dose|ChAd63 RH5 at 5 x 10^10 vp
1607494|NCT02181088|Biological|MVA RH5 low dose|MVA RH5 at 1 x 10^8 pfu
1607495|NCT02181088|Biological|MVA RH5 full dose|MVA RH5 at 2 x 10^8 pfu
1607496|NCT02181075|Drug|lyso-thermosensitive liposomal (LTSL) doxorubicin|ThermoDox® infusion at a dose of 50mg/m2 whilst under general anaesthetic during intervention (Day 1)
2010018|NCT03140176|Drug|Sunitinib|Sunitinib is an FDA approved targeted therapy for use as first line therapy for patients with metastatic renal cell carcinoma.
1607498|NCT02181036|Other|family work shop|2-3 hours per session, one session per week, a total of 6 weeks of family work shop
1607499|NCT02181023|Drug|Aclidinium Bromide|Aclidinium Bromide 322 mcg inhalation powder via Genuair inhaler (Eklira) Product by Almirall, S.A. Ronda General Mitre, 151. ES-08022 Barcelona, Spain
1607500|NCT02181023|Drug|Glycopyrronium Bromide|Glycopyrronium Bromide 44 mcg dry powder (capsules) inhaled via Breezehaler inhaler, Seebri - product by Novartis Europharm Limited - Wimblehurst Road, Horsham, West Sussex, RH12 5AB; United Kingdom
1607501|NCT02181010|Behavioral|Intervention|Intervention components will occur at the policy level (working within Baltimore City policy makers to sustain intervention components, and develop virtual simulations of the Baltimore food environment); food wholesaler level (working with wholesalers to stock healthier food items and provide pricing incentives to storeowners on healthier foods); small food retail outlet level (working with corner store and carry-out owners to stock, promote, and sell healthier foods and beverages); neighborhood level (working with Baltimore college students to deliver nutrition intervention sessions to younger youth in recreation centers in intervention neighborhoods); household level (providing a text messaging and social media program that provides parents and caregivers tips for healthier eating in their respective neighborhoods).
1607502|NCT02180997|Drug|Tamsulosin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily
1607503|NCT02180997|Drug|Solifenacin|Tamsulosin and solifenacin: Solifenacin 10 mg, once daily
1607504|NCT02180997|Drug|Tamsulosin and solifenacin|Tamsulosin and solifenacin: Tamsulosin 0.4mg, once daily, Solifenacin 10 mg, once daily
1607572|NCT02180490|Drug|UHAC 62 XX capsule|
2010019|NCT03140670|Drug|RUCAPARIB|Rucaparib is a PARP inhibitor used as an anti-cancer agent. Rucaparib is a first-in-class pharmaceutical drug targeting the DNA repair enzyme poly-ADP ribose polymerase-1.
2010020|NCT03139916|Drug|Temozolomide|Temozolomide causes cell death and shrinks and kills the cancer cells
2010021|NCT03139916|Drug|Bavituximab|Bavituximab may activate (cause) the immune system to attack the cancer cells
2010022|NCT03139916|Radiation|Radiation|Radiation causes cell death and shrinks and kills the cancer cells.
2010023|NCT03140215|Device|laryngeal mask insertion (Baska)|
2010024|NCT03140215|Device|laryngeal mask insertion (I-gel )|
2010025|NCT03138538|Drug|M8891|Subjects will receive M8891 orally once daily or twice daily at escalated dose levels for consecutive 21-day cycles of continuous treatment until disease progression, unacceptable toxicity, withdrawal of consent, or any criterion for withdrawal from the study.
1607505|NCT02180984|Device|TMS|Transcranial Magnetic Stimulation has developed into a powerful tool that utilizes magnetic fluxes to non-invasively stimulate the human cortex. The technique involves placement of a small coil over the scalp; passing a rapidly alternating current through the coil wire, which produces a magnetic field that passes unimpeded through the scalp and bone, resulting in electrical stimulation of the cortex.
1607506|NCT02180971|Procedure|Positive CAG with EG test|A positive finding for coronary angiography with an ergonovine provocation test is defined as transient, total, or sub-total occlusion (>90% stenosis) with signs/symptoms of myocardial ischemia (chest pain and ischemic ECG change).
1607507|NCT02180971|Procedure|Negative CAG with EG test|Negative test: less than 70% luminal narrowing, without chest pain or ST-segment changes after ergonovine coronary injection
1607508|NCT02180932|Biological|periodontal pocket samples|
1607509|NCT02180919|Device|CE marked Philips Motiva system|Telemonitoring will be carried out in the patient's home using the CE marked Philips Motiva system which comprises weight scales, blood pressure and heart rate monitoring, finger pulse oximeter and provides question/answer prompts all of which is linked to the patient's television screen and can be tuned into just as like a TV channel. Measurements of blood pressure, heart rate and weight will be obtained from the heart failure patients daily. In the respiratory patients heart rate and oximetry will be measured daily, and blood pressure and weight once a week.
1607510|NCT02180893|Other|Paravertebral Block|Paravertebral nerve block injection
1607511|NCT02180893|Other|Placebo Comparator|"No block
Patients who did not receive PVB"
1607512|NCT02180880|Drug|Pregabalin and Oxcarbazepine|"Subjects will take pregabalin for the duration of 2 weeks. The dosage will be increased from 75 mg twice to 150 mg twice a day.
Subjects will stop pregabalin for 1 week and take oxcarbazepine 150mg twice."
2010026|NCT03138369|Device|Vestibular nerve stimulator|Battery powered headset that can be recharged when not being used.
2010027|NCT03138369|Device|Control|Identical in external appearance to the vestibular nerve stimulation device, this device is also powered by a battery and needs to be periodically recharge when not being used. However it discharges into an internal resistor and does not stimulate the vestibular nerve.
2010028|NCT03137433|Dietary Supplement|Meal-replacement Therapy|We seek to examine the effect of meal-replacement therapy on weight loss outcomes in teens with severe obesity.
2010029|NCT03137381|Drug|CTP-543|tablets
2010030|NCT03137381|Drug|Placebo|tablets
2010031|NCT03137134|Drug|Crizotinib|Crizotinib in a coated microsphere formulation
2010032|NCT03137134|Drug|Esomeprazole|Proton pump inhibitor, esomeprazole
1607520|NCT02180854|Other|Control group|
1607521|NCT02180854|Other|Increased monitoring frequency|
1607522|NCT02180841|Dietary Supplement|Soy Protein Powder (25g/d)|Participants will consume 25g soy protein powder daily for a 6 week treatment period.
1607523|NCT02180841|Dietary Supplement|Placebo|Participants will consume a placebo control powder containing 0g soy protein powder daily for a 6 week treatment period.
1607524|NCT02180841|Dietary Supplement|Soy Protein Powder (50g/d)|Participants will consume 50g soy protein powder daily for a 6 week treatment period.
1607525|NCT02180828|Drug|Clotrimazole vaginal tablet|2 doses of 500 mg Clotrimazole administered intravaginally (at day1 and day4)
1607526|NCT02180828|Drug|Fluconazole|2 doses of 150 mg oral Fluconazole (at day1 and day4)
1607527|NCT02180815|Device|ReVENT Sleep Apnea System|
1607528|NCT02180802|Behavioral|motivational interviewing|
1607529|NCT02180802|Behavioral|motivational interviewing with parental involvement|
1607530|NCT02180802|Behavioral|Control group|
1607531|NCT02180789|Drug|Tamsulosin OCAS|oral
1607532|NCT02180776|Other|Summit 456 TLSO|Thoracolumbarsacral orthosis
1607533|NCT02180763|Biological|Gammanorm|Sub-Q IgG
1607534|NCT02180750|Other|Memory Work Therapy|
1607535|NCT02180750|Other|Standard care|Pediatric clinic, ART
1607536|NCT02180737|Drug|Dexmeditomedine|
1607537|NCT02180724|Drug|Acalabrutinib|
1607538|NCT02180711|Drug|acalabrutinib|
1607539|NCT02180711|Drug|rituximab (IV)|
1607540|NCT02180698|Other|Laboratory Biomarker Analysis|Correlative studies
1607541|NCT02180698|Radiation|Radiation Therapy|Undergo radiation therapy
1607542|NCT02180698|Drug|TLR4 Agonist GLA-SE|Given intratumorally
1607543|NCT02180685|Other|Anchor fixation|
1607550|NCT02180646|Other|High protein breakfast|a high protein breakfast - 500 kcal (35% protein, 45% CHO, 20% fat)
1607551|NCT02180646|Other|High carb breakfast|a high carbohydrate breakfast - 500 kcal (15% protein, 65% CHO, 20% fat)
1607552|NCT02180633|Other|Optical Coherence Tomography Scan|As an observational study, the only interventive action taken is the acquisition of a non-invasive volumetric image of the retina via optical coherence tomography (OCT).
1607553|NCT02180620|Other|No exercise|During the no exercise trial (NoEX), the participants will remain sedentary during testing.
1607554|NCT02180620|Other|Meal then exercise|During the post-meal exercise trial (M→EX), 45 min of resistance training will be performed
1607555|NCT02180620|Other|exercise then meal|During the exercise prior to the meal trial (EX→M), 45 min of resistance training will be performed
1607556|NCT02180581|Dietary Supplement|Probiotic (2 * 10^9 cfu/day)|Combination of two probiotics (2 * 10^9 cfu/day) or probiotics for 6 months
1607557|NCT02180581|Dietary Supplement|Placebo|Placebo for 6 months
1607558|NCT02180568|Procedure|Lipiodol|Lipiodol-guided lung localization technique
1607559|NCT02180568|Procedure|Hookwire|Hookwire-guided lung localization technique
1607560|NCT02180568|Drug|Lipiodol|
1607561|NCT02180555|Other|Oral glucose tolerance test|
1607562|NCT02180529|Drug|Methylphenidate|On the intervention days (days 2-4) participants will undergo cognitive assessment at 9:00 in the morning, followed by the administration (at 10:30) of different doses of Ritalin (10, 20 and 30mg) every day of intervention.
1607563|NCT02180529|Drug|Placebo|
1607564|NCT02180516|Drug|Meloxicam|
1607565|NCT02180516|Drug|Other Non Steroidal Anti-Inflammatory Drugs (NSAIDs) except etodolac|
1607566|NCT02180503|Drug|BI 1356 BS PIB - low dose|
1607567|NCT02180503|Drug|BI 1356 BS tablet - low dose|
1607573|NCT02180477|Drug|UHAC 62 XX - TF1 tablet|
1607574|NCT02180477|Drug|UHAC 62 XX - TF2 tablet|
1607575|NCT02180477|Drug|UHAC 62 XX - capsules|
1607576|NCT02180464|Drug|LAS41004|
1607577|NCT02180464|Drug|control|
1607578|NCT02180438|Drug|Stribild (Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF) 1 tablet daily X 48 weeks|
1607579|NCT02180425|Drug|Tretinoin or Adapalene|Subjects will apply a pea sized amount of topical retinoid cream once daily at night for 30 days. Subjects will return for a follow-up visit.
1607580|NCT02180425|Drug|Isotretinoin|Subjects will take one pill once daily for 5 months. Subjects will return after 1 month and after 4-5 months of treatment for skin lipid profiling.
1607581|NCT02180412|Biological|Panhematin|Glucose loading
1607582|NCT02180412|Other|Glucose|Glucose is administered to both groups as routine care.
1607583|NCT02180386|Behavioral|Patients will play a video game with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.|videogame can be considered as a method of distraction.
1607584|NCT02180360|Other|Capoeira training group|"Capoeira training: The experimental Capoeira training protocol, based in the modern styles of Capoeira was applied by an instructor with 17 years of experience in teaching Capoeira, followed the directions of the Basic Programmed Lesson, created by Geraldo Pereira d'Santana (Master Santana) in a Capoeira group called IUNA from the city of São Paulo, Brazil.
In order to perform the Basic Programmed Lesson program, the activities were divided in four stages, being composed of the main movement that characterizes Capoeira (the ginga) and by other movements such as: dodging, unbalancing, traumatizing and acrobatic.
An important thing to highlight in the experimental protocol is that the training performed in the present study used only specific movements of Capoeira, without applying any other traditional stretching exercises. Therefore, it is possible to infer that the results obtained are due to the experimental protocol."
1607585|NCT02180347|Device|Contact lenses|
1607586|NCT02180334|Drug|Mosapride citrate|On the day of MMTT, 1 tablet (5 mg) of mosapride will be administered orally to participants of 'mosapride' arm. After 1 hour, MMTT will be performed.
1607587|NCT02180334|Drug|Linagliptin|During run-in period, 1 tablet (5mg) per day will provided for 7 days. On the day of MMTT, 1 tablet (5 mg) of linagliptin will be administered orally to participants of both arms. After 1 hour, MMTT will be performed.
1607588|NCT02180334|Drug|Acetaminophen (paracetamol)|On the day of MMTT, 3 tablets (1500 mg) of acetaminophen (paracetamol) will be administered orally to participants of both arms at the start of MMTT with manufactured mixed meal (0 min).
1607589|NCT02180321|Drug|Tranexamic Acid|10mg/kg of tranexamic acid loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
1607590|NCT02180321|Drug|normal saline|10mg/kg of normal saline loading infusion for 15 min from beginning of the surgery, then continuous infusion throughout the surgery for 5mg/kg/hr
1607591|NCT02180308|Device|PET/MRI|Simultaneous PET/MRI (3T system)
1607592|NCT02180295|Biological|V212 Lot 1|Inactivated Varicella Zoster Virus vaccine
1607593|NCT02180295|Biological|V212 Lot 2|Inactivated Varicella Zoster Virus vaccine
1607594|NCT02180295|Biological|V212 Lot 3|Inactivated Varicella Zoster Virus vaccine
1607595|NCT02180282|Device|M22-IPL|"The M22 is an advanced computer-controlled light emission system that incorporates several different light modules.
The IPL hand piece operates at a spectrum of 400-1200nm with 7 different filters that can be easily inserted to the hand piece to treat different conditions. The IPL hand piece also includes 2 different sapphire cooled light guides of 8x15mm and 15x35mm. The cut-off filter that will be used for this evaluation is the Acne Filter that cuts off all light with the wavelength of 400-600 and 800-1200nm."
1607596|NCT02180269|Drug|JNJ-54861911 (25 mg)|Single oral dose of JNJ-54861911, 25 mg on Day 1.
1607597|NCT02180269|Drug|JNJ-54861911 (50 mg)|Single oral dose of JNJ-54861911, 50 mg on Day 1.
1607598|NCT02180269|Drug|JNJ-54861911 (100 mg)|Single oral dose of JNJ-54861911, 100 mg on Day 1.
1607599|NCT02180269|Drug|Placebo|Single oral dose of placebo matched to JNJ-54861911 on Day 1.
1607600|NCT02180256|Procedure|Endometrial Scratching|The intentional damage to the endometrium performed with the objective of improving the reproductive outcomes of women desiring pregnancy.
2010033|NCT03136406|Drug|Cyclophosphamide|2-[bis(2-chloroethyl)amino]tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
2010034|NCT03136406|Drug|Oxaliplatin|cis-[(1 R,2 R)-1,2-cyclohexanediamine-N,N'] [oxalato(2-)- O,O'] platinum
1607603|NCT02180230|Device|Shorty implants|Dental implant insertion to maxilla or mandible
2010035|NCT03136406|Drug|Capecitabine|5'-deoxy-5-fluoro-N-[(pentyloxy) carbonyl]-cytidine
1607605|NCT02180204|Drug|Tenecteplase|Tenecteplase 0.25 mg/kg IV - Maximum 25 mg
1607606|NCT02180204|Drug|Alteplase|Alteplase 0.9 mg/kg IV - Maximum: 90 mg
1607607|NCT02180191|Other|Comparison of the gut microbiota composition|
1607608|NCT02180178|Other|observational only- no intervention|
1607609|NCT02180165|Drug|Posaconazole|300 mg posaconazole twice on Day 1, either by oral tablet or IV solution; followed by 300 mg once daily for up to 84 days
1607610|NCT02180165|Drug|Voriconazole|300 mg voriconazole oral tablet (or 6 mg/kg IV solution) twice on Day 1, followed by 200 mg oral tablet (or 4 mg/kg IV solution) twice daily for up to 84 days
1607611|NCT02180152|Behavioral|Postprandial walks|Obese pregnant women will be target to carry out walks lasting 10' after the main meals (breakfast, lunch and dinner), Monday to Friday, during 8 weeks. Adherence to the program will be determined by daily readings of pedometers previously provided to pregnant women; minimum of 1500 steps per day from Monday to Friday.
1607612|NCT02180139|Device|transcranial direct current stimulation|tDCS using a constant current of 2 mA via two 35 cm2 saline soaked sponge electrodes. Treatment is 1x/day for 4 days.
1607613|NCT02180126|Other|Follow-up|Follow-up of of patients with borderline positive ANCA test results
1607614|NCT02180113|Device|Fibroscan® examination|Each patient undergo 1 LSM and at least 1 SSM (2 in more if the patient accept to participate at the ancillary study (intra and inter operator reproducibility of SSM).
1607615|NCT02180100|Drug|Terconazole Vaginal Suppository|Terconazole Vaginal Suppository inserted intravaginally once daily before bedtime for 6 consecutive days
1607616|NCT02180100|Drug|Fluconazole|orally Fluconazole 150 mg (Pfizer Pharmaceuticals) at day 1 and day 4.
1607618|NCT02180061|Biological|Pembrolizumab|IV infusion
1607619|NCT02180048|Dietary Supplement|400 mg of caffeine/day (Two 200mg pills/day)|One phase of treatment will have participants consume two 200 mg-caffeine pills day (total of 400 mg of caffeine/ d) for 7 days.
1607620|NCT02180048|Dietary Supplement|200 mg of caffeine/day (One 200mg pill and one placebo pill)|This arm will receive one 200 mg caffeine pill and one sugar pill (placebo pill)
1607621|NCT02180048|Dietary Supplement|Two placebo pills/day|This arm will have participants consume two placebo pills each day.
2010036|NCT03136406|Drug|5-Fluorouracil|5-fluoro-2,4 (1H,3H)-pyrimidinedione
2010037|NCT03136406|Drug|Leucovorin|L-Glutamic acid, N-[4-[[(2-amino-5-formyl-1,4,5,6,7,8-hexahydro-4-oxo-6-pteridinyl)methyl]amino]benzoyl]-, calcium salt
2010038|NCT03136406|Drug|nab-paclitaxel|Benzenepropanoic acid, β-(benzoylamino)-α-hydroxy-(2aR, 4S, 4aS, 6R, 9S, 11S, 12S, 12aR, 12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a, 3, 4, 4a, 5, 6, 9, 10, 11, 12, 12a, 12b-dodecahydro-4,11-dihydroxy-4a, 8, 13, 13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-y1ester,(αR,βS)-(9CI) bound to albumin
1607625|NCT02180022|Drug|Placebo|After randomization, placebo was treated for 12 weeks
1607626|NCT02180022|Drug|Onion peel extract|After randomization, onion peel extract was treated for 12 weeks
1607627|NCT02179996|Biological|Three vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections at two, three, four months after birth
1607628|NCT02179996|Biological|Two vaccine injections DTP-pertussis-Hib|DTP-pertussis-Hib injections are administered at two and four months after birth
1607629|NCT02179983|Procedure|Pulmonary rehabilitation|6 weeks of supervised exercise and education (pulmonary rehabilitation)
1607630|NCT02179983|Procedure|Pulmonary rehabilitation|6 weeks of exercise and patient education following exacerbation (pulmonary rehabilitation)
1607631|NCT02179970|Drug|Plerixafor|A continuous 7 day intravenous infusion, starting at a dose of 20 ug/kg/hr, and subsequent dose levels of 40, 80 and 120 ug/kg/hr.
1607632|NCT02179931|Drug|Flupentixol/melitracen film-coated tablet|
1607633|NCT02179931|Drug|Flupentixol/melitracen coated tablet (Deanxit®)|
1607634|NCT02179918|Drug|PF-05082566|Starting dose of 0.45 mg/kg q3wks IV, dose escalation
1607635|NCT02179918|Drug|MK-3475|2 mg/kg q3wks, IV
2010039|NCT03136406|Biological|bevacizumab|Recombinant human anti-VEGF IgG1 monoclonal
2010040|NCT03136406|Biological|avelumab|Recombinant human anti-PD-L1 IgG1 monoclonal antibody
2010041|NCT03136406|Biological|ALT-803|Recombinant human super agonist interleukin-15 (IL-15) complex
2010042|NCT03136406|Biological|aNK for Infusion|NK-92 cells
1607640|NCT02179879|Other|Video validation|Video taping of anaesthetist (experts and novices) perfoming labor epidural.
1607641|NCT02179866|Drug|RO5285119|Single oral dose of RO5285119 with approximately 2.1 MBq (56.6 uCi) [14C]-radiolabeled RO5285119 administered as a drinking solution under fasted conditions on Day -1
2010043|NCT03136406|Biological|ETBX-011|Ad5 [E1-, E2b-]-CEA
1607643|NCT02179840|Procedure|Mechanical ventilation adjustment|Mechanical ventilation adjustment and study procedure: This is a validation study of the CHS method in assessing cerebral microvascular hemodynamic changes. Cyclical physiological events such as respiration are essential in CHS methodology. The previous study shows that the robust measurement of the CHS method occurs at a respiratory rate of about 4-10 breaths per minute. Therefore, we propose the following respiration adjustment in this study with the consideration that CO2 is a powerful regulator of cerebral blood flow. Blood gas analysis will be performed during the 1st and 2nd rounds of ventilation adjustment.
1607644|NCT02179814|Drug|AMPT/ Demser|alpha-methyl-paratyrosine (AMPT, trade name: Demser) body-weight adjusted dosage (40 mg/kg body weight, maximum 4000mg) at 4 medication intake time points over 24 hours
1607645|NCT02179814|Drug|Diphenhydramine|Diphenhydramine (25mg) at the first medication intake time point
1607646|NCT02179814|Drug|Placebo|Placebo at the second, third and fourth medication intake time point
1607647|NCT02179788|Behavioral|Standard care|Mothers will be instructed to thoroughly empty their breasts at least 8 times per 24 hours by breastfeeding, followed by breast expression with a combination of hand -expression and the use of a hospital-grade electric breast pump (provided by study).
1607648|NCT02179788|Drug|Metformin|"The metformin arm will be consuming Glucophage XR (metformin hydrochloride extended release, 750 or 500 mg, encapsulated in #00 opaque capsules for 4 weeks according to the following schedule:
Days 1-7, take one 750 mg capsule with evening meal (750 mg/day)
Days 8-14, take three 500 mg capsule with evening meal (1500 mg/day)
Days 14-28 (or through completion of post-intervention data collection), take four 500 mg capsules with evening meal (2000 mg/day)
Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator.
The trial duration is 28 days (with a +/- 3 day cushion)"
1607649|NCT02179788|Drug|Placebo|"The placebo arm will be consuming methylcellulose USP Powder encapsulated in #00 opaque capsules (supplied by PCCA, Houston TX) for 4 weeks according to the following schedule:
Days 1-7, take 1 capsule with evening meal
Days 8-14, take 3 capsules with evening meal
Days 14-28 (or through completion of post-intervention data collection), take four capsules with evening meal
Actual increase in dose may occur more slowly if standard titration schedule is not well tolerated. Adjustments to schedule will be made in consultation with the adult medicine study co-investigator."
1607650|NCT02179775|Drug|propranolol|
1607651|NCT02179775|Drug|Quince's oxymel|
1607652|NCT02179775|Drug|placebo|
1607653|NCT02179762|Behavioral|moderate exercise intervention|Perform moderate exercise therapy
1607654|NCT02179762|Behavioral|vigorous exercise intervention - standard|Perform HIIT exercise therapy on a standard stationary bike
2010044|NCT03136406|Biological|GI-4000|Vaccine derived from recombinant Saccharomyces cerevisiae yeast expressing mutant Ras proteins
2010045|NCT03135899|Drug|BI 443651|Three doses, each 12 hours apart
2010046|NCT03135899|Drug|Placebo|Three doses, each 12 hours apart
2010047|NCT03135028|Drug|Entospletinib|400 mg tablet (s) orally twice daily
2010048|NCT03135028|Drug|Daunorubicin|60 mg/m^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle
1607655|NCT02179762|Other|questionnaire administration|Ancillary studies: Functional Assessment of Cancer Therapy-General (FACT-G), Godin Leisure-Time Exercise questionnaire, 24-hour diet recalls, USDA 5 Step Multiple Pass Method, Memorial Anxiety Scale for Prostate Cancer, Pittsburgh Sleep Quality Index (PSQI)
1607656|NCT02179762|Other|laboratory biomarker analysis|Correlative studies
1607657|NCT02179762|Behavioral|vigorous exercise intervention - cybercycling|perform HIIT exercise on cybercycles aided by electronic racing and other games
1607658|NCT02179762|Behavioral|Exercise Logs|The exercise physiologists will keep exercise logs and tracking sheets that log the date, start and stop time (duration) of exercise sessions as well as time in the THR and RPE for each exercise session.
1607659|NCT02179762|Behavioral|Adherence|We will assess barriers to adhering to the exercise protocol by asking an open-ended question to solicit barriers. If the patient calls to cancel an exercise session, he will be called and probed for reasons
1607660|NCT02179762|Behavioral|Exercise and body composition test|Height will be measured to the nearest 0.1 cm and weight will be measured to the nearest 0.1 kg. Waist and hip circumference will be measured to the nearest 1/8 inch. Whole body dual-energy X-ray absorptiometry scans will be conducted at baseline and end of treatment to quantify total body fat.
1607661|NCT02179749|Drug|Mifepristone 1200 mg daily|Mifepristone, 300 mg tablets, Four tablets daily/am for 1-week duration.
1607662|NCT02179749|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 8 week duration.
1607663|NCT02179749|Drug|Mifepristone 600 mg daily|Mifepristone, 300 mg tablets, Two tablets daily/am plus two placebo tablets daily/am for 1-week duration.
1607664|NCT02179749|Drug|Placebo|Placebo tablets, Four tablets daily/am for 1-week duration.
1607665|NCT02179736|Device|Restylane|
1607666|NCT02179723|Device|Leukosan Adhesive|Leukosan adhesive applied to one wound
1607667|NCT02179723|Device|Transcutaneous suture|Transcutaneous suture applied to one wound
1607668|NCT02179710|Behavioral|Adherence dashboard motivational interviewing|These data will be aggregated and displayed graphically in weekly intervals. Adherence will be displayed as percentage and timing percentage within a set criterion of prescribed inter-dose interval. Drug holidays, operationally defined as missing two or more consecutive doses will be displayed along with average length. Patient self-reported adherence information, collected via handheld (i.e, smart phone, tablet, laptop) application will be displayed as percentage and timing percentage on the dashboard. Review of dashboard weekly with investigator for motivational interviewing
1607669|NCT02179697|Other|Patient's Choice|Patient chooses between surgery plus bracing or bracing alone. The patient will be followed according to the same schedule as Group 1.
1607670|NCT02179697|Procedure|Surgery + Bracing vs. Bracing Alone|Surgery + Bracing vs. Bracing Alone
1607671|NCT02179684|Procedure|Baby-sitter surgery N. fascialis|
1607672|NCT02179684|Other|Conventional treatment and follow-up|Patient´s with Bells´palasy are treated with conventional treatment and follow-up
2010049|NCT03135028|Drug|Cytarabine|"100 mg/m^2 intravenous (IV) administration twice daily on Days 1 to 7 of each 28-day induction cycle
3g/m^2 IV administration twice daily on days 1, 3 and 5 (<=60 years of age) or 1g/m^2 IV administration once daily on days 1-5 (>60 years of age) of each 28-day post-remission cycle (Hi-DAC)"
2010050|NCT03134911|Drug|DOAC or VKA|6 months - 2 years
2010051|NCT03134911|Drug|VKA|6 months - 2 years
2010052|NCT03134560|Device|Vein Display Instrument|
1607677|NCT02179658|Drug|OPT-80|oral
1607678|NCT02179658|Drug|vancomycin|oral
1607679|NCT02179645|Drug|GRC 27864|
1607680|NCT02179645|Drug|Celecoxib|
1607681|NCT02179645|Drug|Placebo|
1607682|NCT02179632|Behavioral|Exposure to disclosure website|Participants are exposed to a physician payment disclosure website.
1607683|NCT02179619|Device|Dermalax(Deep)|Dermalax(Deep) injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
1607684|NCT02179619|Device|Restylane|Restylane Injection into one nasolabial fold (NLF) of one side of the face (blinded, split-face study design) in the Initial Treatment period
1607685|NCT02179606|Device|Dermalax Implant Plus|Dermalax implant plus injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
1607686|NCT02179606|Device|Restylane Sub-Q|Restylane Sub-Q injection into one nasolabial fold(NFL) of one side of the face(blinded, split-face study design) in the initial treatment period.
1607687|NCT02179593|Other|2-Segment SARPE|Le Fort I osteotomy with oppening of the median palatal suture and SARPE.
1607688|NCT02179593|Other|3-Segment SARPE|Le Fort I osteotomy with two parallel osteotomies symetrically positioned with reference to the median palatal suture and SARPE.
1607689|NCT02179580|Drug|Xiang-Sha-Liu-Jun-Zi-Tang|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. We use the Chinese herb for the treat of IBS patient
1607690|NCT02179580|Drug|Placebo|Xiang-Sha-Liu-Jun-Zi-Tang at a rate of 3.0 g three times per day for 28 days. Placebo drug is 1/10 dose of experiment drug .
1607691|NCT02179567|Drug|Docetaxel|Docetaxel: 60mg/m2 i.v on day 1. Cycle repeated ever 3 weeks
1607692|NCT02179567|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg, iv on day 1. Cycle repeated every 3 weeks
1607693|NCT02179541|Other|RGB|When a circular area of 30 surrounding pixels are placed exactly upon the above-mentioned standardized points, the Adobe Photoshop Elements 7.0 program automatically measures the numerical values of the RGB color components in that area. The RGB values of the same points on the tympanic membrane images of the two groups were obtained and compared. Diagnostic significance of objectively assessed color changes at the tympanic membrane in OME patients was evaluated.
1607694|NCT02179528|Drug|Etoposide|
1607696|NCT02179502|Drug|GLPG1690 single ascending doses|Single dose, oral suspension or solid formulation, starting dose of 20mg escalating up to 1500mg
1607697|NCT02179502|Drug|Placebo single ascending doses|Single dose, oral suspension or solid formulation matching placebo
1607698|NCT02179502|Drug|GLPG1690, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension, anticipated doses: 300mg to 1000mg
1607699|NCT02179502|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
1607847|NCT02178306|Drug|Placebo|Run-in phase
1607700|NCT02179489|Procedure|Surgery and Hyperthermic Intraperitoneal Chemotherapy with MMC|HIPEC with MMC: Mitomycin C (MMC) (30 mg/m2 of body surface area). Closed technique, as preferred. Duration: 60 minutes. Mean Intra-abdominal Temperature: 43°C.
1607701|NCT02179476|Device|Glyder|The Glyder Facet Restoration Device is intended for minimally invasive bilateral implantation in one or two lumbar facet levels
1607702|NCT02179424|Behavioral|Workshop|Intensive psychological intervention included motivation of quitting enhancement, stress management and smoking triggers, craving and relapse are used to provide smoking cessation intervention
1607703|NCT02179424|Behavioral|Face-to-face counseling|Use motivational interview strategies through face-to-face counseling to provide smoking cessation intervention
1607704|NCT02179424|Behavioral|Phone counseling|Use motivational interview strategies through phone counseling to provide smoking cessation intervention.
1607705|NCT02179424|Behavioral|Health talk|Health talk provided information about hazards of tobacco (active smoking, second- and third-hand smoke), benefits of quitting smoking and methods to quit smoking.
1607706|NCT02179424|Behavioral|Booklet|A 26-page booklet included information about smoking and diseases, benefits of quitting smoking, methods to quit smoking, how to handle withdrawal symptoms, stress management, declaration of quitting smoking, decisional balance of smoking or quitting.
1607707|NCT02179424|Behavioral|SMS|Fifteen SMS were sent to subjects included welcome messages, risk of smoking, correction of myths about smoking or quitting, quitting tips, benefits of quitting, encouragement of quitting
1607708|NCT02179411|Other|tilt test|
1607709|NCT02179398|Biological|Allocation to the Lab-score group|
1607710|NCT02179398|Biological|Allocation to the control group|
1607711|NCT02179385|Behavioral|Health Coaching|
1607712|NCT02179372|Dietary Supplement|Eicosapentaenoic acid|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value >150 μg/g will recive 2 g/day of Eicosapentaenoic acid for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured. The effect of Eicosapentaenoic acid on fecal calprotectin level will be monitored. Clinical relapses will be considered during the study.
1607713|NCT02179372|Dietary Supplement|Medium chain fatty acid (placebo)|30 subject with Crohn's Disease and/or Ulcerative Colitis in clinical remission but with fecal calprotectin value >150 μg/g will recive 2 g/day of medium chain fatty acids for 6 months treatment. At 3 months and 6 months, fecal calprotectin and clinical activity (CDAI for Crohn's Disease and SCCAI for Ulcerative Colitis) will be measured.
1607714|NCT02179359|Drug|Reduced Toxicity Ablative Regimen|"Anti-thymocyte Globulin (ATG)
Fludarabine
Busulfan
Stem Cell Infusion Day 0"
1607715|NCT02179359|Drug|Reduced Intensity Preparative Regimen|"Alemtuzumab
Cyclophosphamide
Fludarabine
Total Body Irradiation (TBI)
Stem Cell Infusion Day 0"
1607716|NCT02179359|Drug|Myeloablative Preparative Regimen|"Alemtuzumab
Cyclophosphamide
Busulfan
Stem Cell Infusion Day 0"
1607717|NCT02179333|Other|Ataxia rating scale|Administer new rating scale for ataxia. This will be administered by two different raters on two separate occassions, 4 to 6 weeks apart.
1607718|NCT02179320|Procedure|Dry needling|Dry needling of the painful muscles, with an acupuncture needle 0,25 x 40mm
1607719|NCT02179320|Device|acupuncture needle 0,25 x 40mm|
1607720|NCT02179307|Behavioral|12-week progressive strength training protocol|Every study participant will complete 12 weeks of progressive strength training with one leg performing 1-set per exercise per session and the contralateral leg performing 3-sets per exercise per session. Allocation of dominant/non-dominant leg to either 1- or 3-set protocol will be done in a stratified, randomized fashion (stratified with regard to sex and baseline strength).
1607721|NCT02179294|Drug|Pethidine|100mg by intramuscular injection, up to 4 hourly in frequency (up to a maximum of 4 doses). The maximum dose being 400mg in 24 hours.
1607722|NCT02179294|Drug|Remifentanil|"Dedicated intravenous cannula for remifentanil administration PCA protocol
PCA bolus remifentanil 40 μg
Lockout interval 2 minutes
In the event of excess sedation being recorded by regular observation of respiratory function, the regimen will be altered by reduction of the remifentanil bolus dose to 30 μg with a lock-out interval of 2 minutes."
1607723|NCT02179281|Device|Medtronic MiniMed™ 640G system|The MiniMed™ 640G system is indicated for the continuous delivery of insulin, for continuous or periodic monitoring of glucose levels in the fluid under the skin, with a feature for a prediction of low or high glucose episodes.
1607724|NCT02179268|Drug|sertraline|50mg, 50-150mg/d,qd for one year
1607725|NCT02179268|Drug|citalopram|20mg, 20-40mg/d,qd,for one year
1607726|NCT02179268|Drug|venlafaxine|venlafaxine,25mg, 75-100mg/d, bid, for one year
1607727|NCT02179268|Drug|reboxetine|reboxetine,4mg, 4-8mg/d,qd for one year
1607728|NCT02179268|Behavioral|control|50min, every week for three months, every month, for nine months
1607729|NCT02179255|Drug|Human Growth Hormone|1.9 mg (5.7 units) daily injection of Recombinant Human Growth Hormone (HGH) for at least 6 weeks (42 days) continuing into the approximately 14 days of ovulation induction phase of the trial.
1607730|NCT02179255|Drug|Follicle Stimulating Hormone|FSH 450 to 600 units per day administered SQ daily dose adjusted based on the patients response starting on day 2 of the 28 day menstrual cycle and continued until Ovulation trigger
1607731|NCT02179242|Other|Cardiac rehab|
1607732|NCT02179229|Dietary Supplement|CONTROL|Placebo will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
1607733|NCT02179229|Dietary Supplement|SYNBIOTIC|Probinul Neutro® will be taken at home for four weeks as 5 g powder packets to be dissolved in water three times a day far from meals.
1607734|NCT02179216|Other|Hydration|Hydratation the first day in the arm 1 Hydration the second day in the arm 2
1607735|NCT02179216|Other|Venous contention|Venous contention the second day in the arm 1 Venous contention the first day in the arm 2
1607736|NCT02179190|Device|BARREL VRD|BARREL VRD placement adjunctive to coiling treatment.
1607737|NCT02179177|Drug|Apixaban|Drug is taken by mouth twice a day for 6 months
1607738|NCT02179177|Drug|Placebo|
1607739|NCT02179151|Drug|ZGN-440 for Injectable Suspension|Subjects will receive ZGN-440 twice weekly subcutaneous injections for up to 28 weeks.
1607846|NCT02178306|Drug|Telmisartan high dose|patients switch to high dose if mean SBP >= 85 mmHg after 4 weeks of treatment
1607740|NCT02179151|Drug|ZGN-440 Placebo for Injectable Suspension|Subjects will receive placebo twice weekly subcutaneous injections for up to 28 weeks.
1607741|NCT02179138|Drug|TFV 1% gel|
1607742|NCT02179125|Device|RePneu Lung Volume Reduction Coil System|Bronchoscopic lung volume reduction treatment with Coils.
1607743|NCT02179112|Procedure|Emergency Abdominal Surgery|Emergency intra-peritoneal surgery (only exclusion: Caesarian section).
1607744|NCT02179099|Device|BTX mixed with TC-3 Gel|Patients will be treated with a single intravesical instillation of 40 ml TC-3 gel mixed with 300U BTX
1607745|NCT02179086|Radiation|3-dimensional conformal radiation therapy|Undergo standard-dose 3D-CRT
1607746|NCT02179086|Radiation|intensity-modulated radiation therapy|Undergo standard-dose IMRT
1607747|NCT02179086|Radiation|photon beam radiation therapy|Undergo dose-escalated and -intensified photon IMRT
1607748|NCT02179086|Radiation|intensity-modulated radiation therapy|Undergo dose-escalated and -intensified photon IMRT
1607749|NCT02179086|Radiation|proton beam radiation therapy|Undergo dose-escalated and -intensified proton beam radiation therapy
1607750|NCT02179086|Drug|temozolomide|Given PO
1607751|NCT02179086|Other|laboratory biomarker analysis|Correlative studies
1607752|NCT02179047|Procedure|coronary angiography|percutaneous coronary intervention. coronary angiography.
1607753|NCT02179034|Drug|Nicotine|Participants will receive no nicotine, low dose nicotine (6 mg/ml) or high dose nicotine (12 mg/ml)
1607754|NCT02179034|Other|Low Dose Menthol|A low dose of menthol will be added to the tobacco flavor.
1607755|NCT02179034|Other|High Dose Menthol|A high dose of menthol will be added to the tobacco flavor.
1607756|NCT02179008|Drug|DE-117 Low Dose ophthalmic solution|Low Dose DE-117 ophthalmic solution
1607757|NCT02179008|Drug|DE-117 Low/Middle Dose ophthalmic solution|Low/Middle Dose DE-117
1607758|NCT02179008|Drug|DE-117 Middle Dose ophthalmic solution|Middle Dose DE-117
1607759|NCT02179008|Drug|DE-117 Middle/High Dose ophthalmic solution|Middle/High Dose DE-117
1607760|NCT02179008|Drug|DE-117 High Dose ophthalmic solution|High Dose DE-117
1607761|NCT02179008|Drug|latanoprost ophthalmic solution 0.005%|0.005% latanoprost
1607762|NCT02178995|Drug|Methylphenidate|"Participants with epilepsy will first receive blinded, single-dose capsules which contain either:
Placebo 20mg of methylphenidate or 10mg of methylphenidate.
At each visit, they will receive one capsule and then complete the neurocognitive batteries and neuropsychiatric questionnaires. There will be no medication administered between visits during this time. Following the final randomized visit, interested participants will be prescribed 10mg of methylphenidate twice daily, to be increased to 20mg of methylphenidate twice daily. After four weeks, their scores on the batteries and questionnaires will again be assessed."
1607763|NCT02178956|Drug|BBI608|BBI608 480 mg orally two times daily (960 mg total daily dose)
1607764|NCT02178956|Drug|Paclitaxel|Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle
1607765|NCT02178956|Other|Placebo|Orally two times daily
1607766|NCT02178930|Other|Integrated self management support|The intervention comprises a consultation engagement, at home exploration, phone and web-based health coaching.
1607767|NCT02178917|Other|Neurofeedback therapy|
1607768|NCT02178917|Other|No neurofeedback therapy|
1607769|NCT02178904|Procedure|CT and stress test|Coronary computed tomographic angiography (CCTA) plus computed tomography stress myocardial perfusion imaging (CTP)
2010053|NCT03135548|Drug|BI 655130 (low dose)|12 weeks treatment
1607771|NCT02178878|Genetic|Progress, Pain|Progress, Pain
1607772|NCT02178852|Device|TRIGEMINAL NERVE STIMULATION (TNS)|TNS stimulation over V1 branches of V cranial nerve. Single session for 30 minutes. The patient will undergo a specific cue-induced cigarette craving model during the final 3 minutes of stimulation. Craving scores will be rated before and after stimulation
1607773|NCT02178839|Dietary Supplement|β- glucan|8.5 g/d of Oat Supplement Containing 3g β- glucan
1607774|NCT02178839|Dietary Supplement|Maltodextrin|8.5 g/d Maltodextrin
1607775|NCT02178826|Device|Rapid Maxillary Expansion|The Rapid Maxillary Expander will over 10-14 days create a palatal expansion of about 5mm.
1607776|NCT02178826|Device|Placebo Appliance|The Placebo Appliance looks exactly like the Rapid maxillary Expander but the expansion screw does not work. When the expansion screw is activated it does not create a palatal expansion.
1607777|NCT02178813|Drug|Administration of minocycline|"Administration of minocycline with the following schedule:
Day prior to procedure: 800mg p.o., 700mg p.o.
Day of procedure: 600mg i.v., 500mg p.o.
Day after procedure: 400mg p.o., 400mg p.o."
1607778|NCT02178800|Drug|GSK1265744 Tablets|30-mg tablets, taken orally
1607779|NCT02178800|Drug|Injectable GSK1265744|"Cohort 1: 800-mg injection, administered as two 400-mg intramuscular (IM) gluteal injections
Cohort 2: 600-mg injection, administered as one IM gluteal injection"
1607780|NCT02178800|Drug|Placebo for GSK1265744 Tablets|Taken orally
1607781|NCT02178800|Drug|Injectable Placebo for GSK1265744|"Cohort 1: Sodium Chloride for Injection USP, 0.9%; administered as two 400-mg IM gluteal injections
Cohort 2: Sodium Chloride for Injection USP, 0.9%; administered as one 600-mg IM gluteal injection"
1607782|NCT02178761|Device|drug-eluting balloon|angioplasty completed with drug-eluting balloons
1607783|NCT02178761|Device|biodegradable vascular scaffold stent|Stenting with biodegradable vascular scaffold stents
1607784|NCT02178761|Device|Apex™ PTCA Dilatation Catheter|plain old balloon angioplasty alone
1607785|NCT02178761|Device|Stent System|stenting with either bare-metal stents or drug-eluting stents
1607786|NCT02178748|Biological|MVA85A|Single dose of 1x10^8pfu MVA85A intramuscular vaccination
1607787|NCT02178735|Procedure|Anterior vaginal tailored mesh surgery|Anterior vaginal tailored mesh surgery for repair of cystocele with or without stress urinary incontinence
1607788|NCT02178735|Procedure|Posterior vaginal tailored mesh surgery|Posterior vaginal tailored mesh surgery for repair of enterocele, rectocele, vaginal vault prolapse or uterine prolapse
1607844|NCT02178319|Procedure|laparoscopic surgical procedure|laparoscopic esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
1607791|NCT02178709|Drug|FOLFIRINOX|"FOLFIRINOX consists of the following combination of drugs:
Oxaliplatin, 85 mg/m2, IV over 2 hours prior to irinotecan, administered on days 1 and 15 of each 28 day cycle
Leucovorin, 400 mg/m2, IV over 2 hours with irinotecan, administered on days 1 and 15 of each 28 day cycle
Irinotecan, 180 mg/m2, IV over 90 minutes with leucovorin, administered on days 1 and 15 of each 28 day cycle 4.5 FU, 400 mg/m2, IV bolus over 2 minutes after irinotecan, administered on days 1 and 15 of each 28 day cycle.
5.5FU, 2400 mg/m2, IV infusion over 46 hours after 5FU bolus injection, administered on days 1 and 15 of each 28 day cycle."
2010054|NCT03135548|Drug|Placebo|12 weeks treatment
2010055|NCT03135548|Drug|BI 655130 (high dose)|12 weeks treatment
2010056|NCT03133741|Other|GIP-A|GIP-A (GIP receptor antagonist)
1607795|NCT02178683|Drug|Tacrolimus and MMF.|First dose of Tacrolimus is given day -4, this continues through day +365. First dose of MMF is given within 4 hours of stem cell infusion, this continues through day +365.
1607796|NCT02178670|Biological|CSC-DC|
1607797|NCT02178657|Drug|Autologous bone marrow mononuclear cell intra-arterial injection|
1607798|NCT02178644|Drug|Chemo with concomitant Capecitabine and KD018|Patients will receive a course of chemo-radiation with concomitant Capecitabine and KD018, and to compare this to the toxicity seen in patients treated with Capecitabine and radiation therapy alone, in patients with T3-T4 and N0-N2, M0 rectal cancer.
1607799|NCT02178631|Behavioral|Deprexis|Online self-help
1607800|NCT02178631|Other|CAU|Care as usual
1607801|NCT02178618|Device|Deployment of Partially covered biliary self expandable metal stent|
1607802|NCT02178618|Device|Deployment of uncovered biliary self expandable metal stent|
1607803|NCT02178605|Procedure|Cervical arthrodesis with rhBMP-2|Cervical arthrodesis with rhBMP-2
1607804|NCT02178592|Drug|DTG 50 mg|DTG is available as 50 mg film-coated tablet. DTG may be administered with or without food
1607805|NCT02178592|Drug|EFV 600 mg|EFV is supplied as film-coated capsule-shaped oral tablet containing 600 mg of EFV and must be administered without food
1607806|NCT02178566|Drug|Inhaled Treprostinil|A dose of inhaled treprostinil or placebo will be administered to all study participants prior to each of their Pulmonary Rehab sessions. Three puffs of inhaled treprostinil dose will be administered each time to all patients .
1607807|NCT02178553|Drug|Epidural|
1607808|NCT02178553|Drug|Intercostal Bupivicaine (Exparel)|
1607809|NCT02178540|Drug|Placebo|one dose (4 capsules) of placebo
1607810|NCT02178540|Device|Tobi Podhaler|The capsule containing the study medication has to be released from the blister card, be inserted into the Podhaler device, actuated and the study drug be inhaled according to instructions for use
1607811|NCT02178527|Other|Foot and ankle exercises, foot orthoses, footwear provision|Participants in the intervention group will receive orthoses and footwear as part of the study. The research team will train care home staff in the provision of foot and ankle exercises. The exercise protocol states that exercises will be carried out 3 times per week for 12 weeks.
1607812|NCT02178527|Other|Usual Care|Usual general podiatry care provded by UK National Health Service
1607813|NCT02178514|Other|Formula fed with BabyNes Nutrition System|
1607814|NCT02178501|Dietary Supplement|Omega-3 PUFA|comparison of omega-3 PUFA supplementation 2000 mg once daily (1000 mg EPA and 1000 mg DHA) versus placebo
1607815|NCT02178488|Drug|Cholecalciferol|Cholecalciferol 4000 IU/day for 12 months
1607816|NCT02178488|Other|Placebo|Placebo (mimic of cholecalciferol) in the same amount and same time frame as Cholecalciferol for 12 months
2010057|NCT03133741|Other|GLP-1 receptor antagonist Exendin[9-39]|Exendin[9-39]
2010058|NCT03133741|Other|Placebo|Saline (9mg/mL)
2010059|NCT03133741|Other|GIP-A + Exendin[9-39]|GIP receptor antagonist + GLP-1 receptor antagonist
1607820|NCT02178436|Drug|gemcitabine hydrochloride|Given IV
1607821|NCT02178436|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1607822|NCT02178436|Drug|selinexor|Given PO
1607823|NCT02178436|Other|pharmacological study|Correlative studies
1607824|NCT02178436|Other|laboratory biomarker analysis|Correlative studies
1607825|NCT02178423|Procedure|Ultrasound for diagnosis of CVC position in children|Using the ultrasound for diagnosis of the correct position of a central venous catheter in children immediate after the puncture.
1607826|NCT02178410|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
1607827|NCT02178410|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
1607828|NCT02178410|Dietary Supplement|Fish oil placebo|Fish oil placebo
1607829|NCT02178410|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
1607830|NCT02178397|Drug|ERLOTINIB WITH CHEMOTHERAPY|
1607831|NCT02178397|Drug|CHEMOTHERAPY ONLY|
1607832|NCT02178384|Procedure|Altered cast technique|This techniques deals with the procedures that are employed when constructing the removable partial denture on working casts.
1607833|NCT02178384|Device|Precision Attachments|These are minor attachments used to split the loading forces during appliance wear
1607834|NCT02178384|Procedure|Resilient layer|This is a layer beneath the appliance which helps in reducing the transmission of loading forces to the underlying soft tissues
1607835|NCT02178371|Procedure|mCIMT|
1607836|NCT02178358|Drug|LY2157299|Administered orally
1607837|NCT02178358|Drug|Sorafenib|Administered orally
1607838|NCT02178358|Drug|Placebo|Administered orally
1607839|NCT02178345|Procedure|diffusion weighted (DW) MRI|
1607840|NCT02178345|Procedure|dynamic contrast agent (DCE) MRI|
1607841|NCT02178332|Other|Yhteispeli, whole school programme|
1607842|NCT02178332|Other|Two theoretical lectures|
1607843|NCT02178319|Procedure|open surgical procedure|open esophagogastric devascularization and splenectomy will perform as surgical procedure in the patients
1607845|NCT02178306|Drug|Telmisartan low dose|
1607848|NCT02178293|Drug|Benzidamine hydrochloride|
1607849|NCT02178293|Drug|Ketoprofen lysine salt|
1607850|NCT02178280|Other|liver transplantation combined with neoadjuvant therapy|liver transplantation combined with neoadjuvant radiochemotherapy
1607851|NCT02178267|Dietary Supplement|Lactobacillus reuteri (biogai AB, Sweden)|Lactobacillus reuteri (biogai AB, Sweden) was given to probiotic group, same way to all newborn newborn preterm infants, directly oral feeding and without any along with a mixture, admission following the in nicu, as a daily dose 1x108 cfu / day (1x5 drops / day) during hospitalization
1607852|NCT02178254|Drug|Fosfomycin tromethamine|A phosphonic acid derivative is the mono-acid salt of Fosfomycin with Tromethamine. Sequence 1-3 receive 3 grams oral sachet
1607853|NCT02178254|Drug|Fosfomycin disodium|ZTI-01 is a phosphonic acid derivative formulated as a disodium salt intravenous formulation. ZTI-01 acts by inhibiting peptidoglycan assembly, thereby disrupting cell wall synthesis. Sequence 1-3 receive 1 gram and 8 grams of Intravenous ZTI-01 for 1-hour infusion
1607854|NCT02178241|Drug|Eribulin Mesylate|Given IV
1607855|NCT02178241|Drug|Gemcitabine Hydrochloride|Given IV
1607856|NCT02178215|Other|Placebo shower gel|Wash forearm with placebo shower gel for 10 seconds, twice a day, 2 weeks
1607857|NCT02178215|Other|Holly Mangrove Shower Gel|Wash forearm with Holly Mangrove shower gel containing Acanthus ebracteatus Vahl for 10 seconds, twice a day, 2 weeks
1607858|NCT02178202|Behavioral|McKenzie exercise|First to sixth McKenzie exercises were performed for 5 times/week and 10 treatment sessions totally.
1607859|NCT02178202|Device|Harmonic technique|Lower limb suspension exercise was performed for 5 times/week and 10 treatment sessions totally
1607860|NCT02178189|Other|High Calorie Infant formula|Infants were randomized to be fed high calorie formula from 72 hours of life until age 21 days.
1607861|NCT02178189|Other|Standard Calorie Infant Formula|Infants were randomized to be fed standard calorie formula from 72 hours of life until age 21 days.
1607862|NCT02178176|Behavioral|Education, encouragement, card sort|"Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
We will recognize patients' social and cultural context by addressing health-related priorities identified by the patient. The goal will be to identify those priorities which are likely to influence engagement in care and adherence to treatment. We will assess both biomedical (physical symptoms, diet and exercise) and nonbiomedical (financial, social and emotional) needs patients with Type 2 diabetes mellitus and depressive symptoms may wish to discuss in the context of their health. After the patients complete the card sort, interventionists will engage the patient in the 4-step problem solving process."
1607863|NCT02178176|Behavioral|Education, encouragement|Patients will identify factors involved in nonadherence. For each factor influencing adherence, the interventionist will engage the patient in a 4-step problem solving process.
1607864|NCT02178163|Other|cytology specimen collection procedure|Correlative studies
1607865|NCT02178163|Other|laboratory biomarker analysis|Correlative studies
1607866|NCT02178150|Dietary Supplement|Magnesium Oxide|This is a double-blind randomized clinical trial which will be started at June 2014 and end on June 2015 in Isfahan city. Serum insulin level is considered as a key variable and the sample size was calculated to be 70 persons (35 persons for control group and 35 persons for patient group). Patient group will receive magnesium supplement (250 milligram) and the other group will receive placebo which is similar to the magnesium tablets in color, odor and appearance both for 8 weeks. All subjects will complete 4 physical activity and 4 dietary records. Outcome measurements including metabolic and inflammatory profiles,sex hormone levels will be measured at the beginning and end of the study as well as anthropometric measurements.
1607867|NCT02178150|Dietary Supplement|Placebo|
1607868|NCT02178137|Drug|Diacerien|
1607869|NCT02178137|Drug|Glucosamine/Chondroitin|
1607870|NCT02178137|Drug|Placebo|
1607871|NCT02178124|Drug|Donepezil|
1607872|NCT02178124|Drug|placebo|
1607873|NCT02178111|Other|Never perform episiotomy|In this group birth attendants will be sought to avoid at all cost episiotomy. The intention is to never perform episiotomy in this group.
1607874|NCT02178111|Procedure|episiotomy|
1607875|NCT02178098|Drug|ETC-1002|ETC-1002 capsules taken once daily
1607876|NCT02178098|Drug|Placebo|Placebo capsules taken once daily
1607877|NCT02178085|Other|Flow imaging|Participants will undergo morphological and then flow MRI. Flow MR images will be processed adequately to obtain quantitative values of arterial and venous flow as well as CSF flow.
1607878|NCT02178072|Drug|5-Azacitadine|
1607879|NCT02178059|Drug|terbutaline sulphate delivered dose|0.4 mg terbutaline sulphate (delivered dose) per inhalation
1607880|NCT02178059|Drug|terbutaline sulphate metered dose|0.5 mg terbutaline sulphate (metered dose) per inhalation
1607881|NCT02178046|Device|optical measurements|Laser Speckle Imaging, Optical Coherence Tomography and Multiphoton Microscopy
1607882|NCT02178033|Drug|Split dose low-volume PEG solution|"All participants will receive low-volume (2L) PEG plus ascorbic acid solution (MOVIPREP®, Norgine, Harefield, United Kingdom); in the control arm the whole colonoscopy preparation is administered the day before colonoscopy; in the  active comparator  arm one liter of the bowel preparation is administered on the evening before the colonoscopy and the remaining liter on the day of the procedure."
1607883|NCT02178020|Device|knee arthroplasty, standard polyethylene|total knee replacement follow-up; clinical and radiographic; revision rate
1607884|NCT02178020|Device|knee arthroplasty, XLP polyethylene|total knee arthroplasty with highly crosslinked polyethylene tibial liner
1607885|NCT02177994|Drug|ceftriaxone 1gm for intravenous infusion|Patients undergoing elective cesarean section with Gestational age 37 weeks or more. comparing the effect of administration of 1 gm ceftriaxone in elective cesarean section 30-60 min before skin incision versus after cord clamping.on post-cesarean section infection(wound infection as a primary outcome)
1607886|NCT02177981|Procedure|Remote ischemic preconditioning|A blood pressure cuff will be placed on the left arm and three cycles of 5 min ischemia followed by 5 min reperfusion will be applied.
1607887|NCT02177981|Procedure|Control|The cuff will be placed around the arm but not inflated.
1607888|NCT02177968|Other|descriptive analysis of characteristics|comparison between elderly fallers and non-fallers
1608257|NCT02175342|Drug|Tiotropium 5 mcg/puff|
1607889|NCT02177955|Drug|7.5 mg Midazolam|7.5 mg midazolam 45 minutes before surgery
1607890|NCT02177955|Drug|10 mg diazepam|10 mg midazolam 45 minutes before surgery
1607893|NCT02177929|Other|adapted canoeing, hadbike and conventional physiotherapy|"The subjects adapted canoeing group will practice on the kayak and rowing exercises associating with ball.
The individuals in the group will handbike workouts outdoors and surpassing cirucuitos mounted with cones.
Individuals in the conventional physiotherapy group will make stretching and strengthening exercises."
1607894|NCT02177916|Other|Education|
1607895|NCT02177903|Device|Bair Paws Patient Adjustable Warming System|Bair Paws system uses forced-air warming. This system will be used for patients randomized to active pre-warming.
1607896|NCT02177890|Device|Transcutaneous vagal nerve stimulation|
1607897|NCT02177890|Device|Sham vagal nerve stimulation|
1607898|NCT02177864|Dietary Supplement|Fiber|
1607899|NCT02177864|Other|Placebo (low fiber bar)|
1607900|NCT02177851|Dietary Supplement|Single oral iron dose of 120 mg per day for 3 consecutive days|
1607901|NCT02177851|Dietary Supplement|Two oral iron doses of 60 mg per day (morning + afternoon) for 3 consecutive days|
1607902|NCT02177838|Biological|cetuximab|Given IV
1607903|NCT02177838|Drug|cisplatin|Given IV
1607904|NCT02177838|Radiation|external beam radiation therapy|Undergo EBRT
1607905|NCT02177838|Other|laboratory biomarker analysis|Correlative studies
1607906|NCT02177825|Drug|Imatinib Mesylate|oral administration
1607908|NCT02177786|Drug|Selonsertib|Tablets administered orally once daily
1607909|NCT02177786|Drug|Placebo to match selonsertib|Tablets administered orally once daily
1607910|NCT02177773|Drug|DOTA-TOC PET/CT|Single Gallium-68 DOTA-TOC PET/CT in patients with somatostatin receptor positive malignancies.
1607911|NCT02177760|Drug|Sirolimus|
1607912|NCT02177747|Other|Ophthalmoscopy conducted using a smartphone equipped with a compact addon|
1607913|NCT02177747|Device|Smartphone|
1607914|NCT02177734|Biological|Investigational H7N9 vaccine GSK3277510A|One dose of GSK3277510A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277510A H7N9 vaccine administered IM in the deltoid region of dominant arm at Day 21
1607915|NCT02177734|Biological|Investigational H7N9 vaccine GSK3277509A|One dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of GSK3277509A H7N9 vaccine administered IM at the deltoid region of dominant arm at Day 21
1607916|NCT02177734|Biological|Placebo|One dose of placebo administered IM at the deltoid region of non-dominant arm at Day 0 and the second dose of placebo administered IM at the deltoid region of dominant arm at Day 21
1607917|NCT02177721|Biological|Collection of samples|"Whenever possible serum samples will be collected from all subjects to determine serum raxibacumab concentrations pre-infusion, and at specific timepoints post-infusion. In the event cerebrospinal fluid (CSF), pleural, ascites, or bronchoalveolar lavage (BAL) fluid are collected for ad hoc clinical laboratory testing, any remaining excess sample will be provided to GSK for determination of raxibacumab concentrations.
Any available serum remaining from ad hoc clinical laboratory specimen collections prior to raxibacumab administration will be provided to GSK for measurement of serum PA concentrations. In addition, remaining post raxibacumab dose serum specimens may also be analyzed for TNA or ADA. If serum, pleural fluid, ascitic fluid, CSF, and BAL sample volume remains following analyses by GSK, the remaining sample may be sent to CDC for investigational analyses. Any such analyses performed by CDC will be reported separately, by the CDC."
1607918|NCT02177695|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2, IV (in the vein) on Days 1 and 8 of each 21 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
1607919|NCT02177695|Drug|Cisplatin|"Cisplatin, 70 mg/m2, IV (in the vein) on Day 1 of each 21 day cycle (or Day 1 or 2 of each 14 day cycle).
Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops."
1607920|NCT02177695|Drug|Methotrexate|Methotrexate, 30 mg/m2, IV (in the vein) on Days 1 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
1607921|NCT02177695|Drug|Vinblastine|Vinblastine, 3 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
1607922|NCT02177695|Drug|Doxorubicin|Doxorubicin, 30 mg/m2, IV (in the vein) on Days 1 or 2 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
1607923|NCT02177695|Drug|Filgrastim|Filgrastim, 5 mcg/kg, SubQ/IV (in the vein) on Days 3-7 of each 14 day cycle. Number of Cycles: 4 cycles or until progression or unacceptable toxicity develops.
1607924|NCT02177682|Drug|Afuresertib|Size 4 and Size 1 opaque white capsules containing 25 mg and 100 mg of afuresertib, respectively, to be administered orally.
1607925|NCT02177669|Other|quick Contrast Sensitivity Function test|
1607926|NCT02177656|Behavioral|Motivational Interviewing tailored intervention|MI is grounded in client-centered counseling, cognitive-behavioral therapy, and social cognitive therapy. MI integrates the concepts of relationship building from humanistic therapy with active strategies oriented towards stages of change.The main characteristics of motivational interviewing are: expressing empathy, developing discrepancy, rolling with resistance, and supporting self-efficacy. The interviewer maintains a nonjudgmental approach and allows the patient to determine the need for behavioral change, rather than offering unsolicited advice on the need for change. The interviewer only explores ways to implement change once the patient expresses the desire and confidence to change. The goal of MI is to help individuals work through inherent ambivalence present in problematic or unhealthy behaviors and to help them verbally express reasons for or against change using a nonjudgmental, empathetic and encouraging tone.
1607927|NCT02177643|Drug|Diacerein|Diacerein oral capsules
1607928|NCT02177643|Drug|Placebo|Placebo oral capsules
1608258|NCT02175342|Drug|Placebo solution|
1607930|NCT02177617|Drug|Botox injection|Participants will receive a tailored dose of Botox to address their Cervical Dystonia symptoms
1607931|NCT02177617|Behavioral|Physical Therapy|Participants will undergo physical therapy sessions with a physical therapist trained in movement disorders. Participants will be instructed to continue these exercises five times per week, and will be called weekly by the investigator to check progress.
1607932|NCT02177617|Procedure|Transcranial magnetic stimulation (TMS)|For these tests, participants will sit in a chair that looks like one found at the dentist's office. A nerve stimulator will be placed on the wrist of the right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of the head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of the head.
1607933|NCT02177604|Other|Wingate HIT|"3 sessions of Wingate based High-Intensity Interval Training (4 x 30 second all out sprints on a cycle ergometer interspersed by 3.5 minutes recovery)"
1607934|NCT02177604|Other|Modified HIT|3 sessions of Modified High-Intensity Interval Training (8 x 60 second sprints at approximately 90-95% VO2 peak on a cycle ergometer interspersed by 60 seconds recovery)
1607935|NCT02177604|Other|High-fat overfeeding|7 days of high-fat overfeeding (50% excess calories)
1607936|NCT02177578|Drug|Temozolomide|Patients will be scheduled to receive continuous daily temozolomide (75 mg per square meter of body surface area per day, 7 days per week from the first to the last day of radiation therapy), followed by 6 cycles of adjuvant temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle).
1607937|NCT02177578|Radiation|Subventricular Zone radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:
Initial treatment plan:
Will be prescribed to 46 Gy in 2 Gy fractions
Cone down treatment plan:
Will be prescribed to 14 Gy in 2 Gy fractions"
1607938|NCT02177578|Radiation|Neural Progenitor Cell Sparing radiation|"Patients will receive 60 Gy in 30 fractions, 5 days per week using IMRT. The target delineation and treatment volumes will be as follows:
Initial treatment plan:
Will be prescribed to 46 Gy in 2 Gy fractions
Cone down treatment plan:
Will be prescribed to 14 Gy in 2 Gy fractions"
1607939|NCT02177565|Biological|carrier plus in vitro expanded autologous BMSCs|The non-unions of fractures were stabilized with internal or external fixation devices. The non-union site was clearly exposed and decorticated to introduce sub-periosteal bone graft. Depending on the surgical approach, the site was partitioned in either medial/lateral or anterior/posterior sides. The contents of each universal container were mixed individually with a carrier by the surgeon, who was blinded to the contents of the container
1607940|NCT02177552|Drug|Carboplatin|
1607941|NCT02177552|Drug|Docetaxel|
1607942|NCT02177552|Drug|Capecitabine|
1607943|NCT02177552|Drug|Epirubicin|
1607944|NCT02177552|Drug|Oxaliplatin|
1607947|NCT02177526|Device|Imaging|15 patients with malignant comedo-type necrosis and calcifications detected with histo-pathology from guided biopsies will be enrolled after obtaining informed consent. 15 patients with biopsy proven Gleason pattern 5 tumor and without comedo-type necrosis associated calcification will serve as a comparison group after providing informed consent for a total of 30 patients.
1607948|NCT02177513|Drug|Placebo + Placebo|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
1607949|NCT02177513|Drug|Oral Cannabis + Placebo|Participants will consume a brownie containing the equivalent of one active (6.9% THC) cannabis cigarette followed by either smoking or inhaling (after vaporization) the equivalent of one placebo (0.001% THC) cigarette.
1607950|NCT02177513|Drug|Placebo + Inhaled Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette
1607951|NCT02177513|Drug|Placebo + Smoked Cannabis|Participants will consume a brownie containing the equivalent of one placebo (0.001% THC) cigarette followed by smoking the equivalent of one active (6.9% THC) cigarette.
1607952|NCT02177513|Drug|6.9% cannabis oral|Participants will consume a brownie containing the equivalent of one active (6.91% THC) cannabis cigarette.
1607953|NCT02177500|Drug|Telmisartan + hydrochlorothiazide|
1607954|NCT02177500|Drug|Telmisartan|
1607955|NCT02177500|Drug|Placebo|
1607956|NCT02177487|Drug|Telmisartan/hydrochlorothiazide|
1607957|NCT02177474|Behavioral|Telephone based peer support|
1607958|NCT02177461|Drug|Telmisartan|
1607959|NCT02177461|Drug|Enalapril|
1607960|NCT02177461|Drug|Clonidine|
1607961|NCT02177448|Drug|BIBR277 low dose|
1607962|NCT02177448|Drug|BIBR277 medium dose|
1607963|NCT02177448|Drug|BIBR277 high dose|
1607964|NCT02177448|Drug|Enalapril low dose|
1607965|NCT02177448|Drug|Enalapril medium dose|
1607966|NCT02177448|Drug|Enalapril high dose|
1607967|NCT02177448|Drug|Placebo matching BIBR277|
1607968|NCT02177448|Drug|Placebo matching enalapril|
1607969|NCT02177435|Drug|Telmisartan|
1607970|NCT02177435|Drug|Telmisartan/Hydrochlorothiazide|
1607971|NCT02177435|Drug|Placebo|
1607972|NCT02177422|Drug|Telmisartan|telmisartan 80 mg once daily
1607973|NCT02177422|Drug|Hydrochlorothiazide|12.5 mg or 25 mg Hydrochlorothiazide in addition to telmisartan in case that the goal response (mean sitting diastolic blood pressure < 90 mmHg) is not met after at least 4 weeks of treatment with telmisartan
1607974|NCT02177409|Drug|Telmisartan|
1607975|NCT02177409|Device|Amlodipine|
1607976|NCT02177409|Drug|Placebo|
1607977|NCT02177396|Drug|Telmisartan|
1607978|NCT02177396|Drug|Valsartan|
1607979|NCT02177396|Drug|Placebo|
1608032|NCT02177058|Other|Quarterly surveys/data reporting|The nursing homes are asked to complete quarterly surveys between APR 2013 to MAR 2014
1608033|NCT02177045|Drug|Sonovue, Bracco|Intravenous injection
1607980|NCT02177383|Dietary Supplement|Docosahexaenoic acid diet supplementation|"Nine soccer players (19 and 22 years old) took 1 liter/day of one experimental beverage (containing 0.2% olive oil + 0.6% DHA-S Martek). Follow-up 8 weeks. At week 8 an acute exercise season was programed.
One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
1607981|NCT02177383|Dietary Supplement|Placebo supplementation|"Six professionals soccer players (19 and 22 years old) took 1 liter/day of placebo beverage (containing 0.8% olive oil). Follow-up 8 weeks. At week 8 an acute exercise season was programed.
One blood sample was taken in resting conditions at beginning of the nutritional intervention (week 0, baseline). Another two blood samples were taken at the end of the nutritional intervention, in resting (week 8, pre-exercise) and post-exercise conditions (week 8, post-exercise). Biochemical measures, oxidative damage markers on lipids, proteins and DNA, antioxidant capabilities (enzyme activities and quantity of enzyme protein and gene expression) and inflammatory markers were measured in serum, plasma, erythrocytes, neutrophils and peripheral blood mononuclear cells."
1607982|NCT02177370|Drug|Fenoterol MDI|
1607983|NCT02177370|Drug|DSCG MDI|
1607984|NCT02177357|Drug|Pramipexole|
1607985|NCT02177357|Drug|Placebo|
1607986|NCT02177344|Drug|Low dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
1607987|NCT02177344|Drug|High dose of Ipratropium bromide|One puff, 4 times daily by oral inhalation
1607988|NCT02177344|Drug|Atrovent|Two puffs, 4 times daily by oral inhalation
1607989|NCT02177344|Drug|Placebo|
1607990|NCT02177331|Drug|Lacidipine|
1607991|NCT02177318|Drug|Spiriva (tiotropium bromide) inhalation capsules|Survey of patients with COPD using Spiriva (tiotropium bromide) inhalation capsules
1607992|NCT02177305|Drug|0.02 mcg tiotropium solution|
1607993|NCT02177305|Drug|0.04 mcg tiotropium solution|
1607994|NCT02177305|Drug|0.08 mcg tiotropium solution|
1607995|NCT02177305|Drug|0.16 mcg tiotropium solution|
1607996|NCT02177305|Drug|0.28 mcg tiotropium solution|
1607997|NCT02177305|Drug|0.40 mcg tiotropium solution|
1607998|NCT02177305|Drug|Placebo solution|
1608000|NCT02177279|Other|Visit A high wheat bran|
1608001|NCT02177279|Other|Visit B normal wheat bran|
1608002|NCT02177279|Other|Follow up normal (8days) and high (1day) bran consumption|
1608003|NCT02177266|Drug|Colchicine|Colchicine 0.6mg bid will be given to study participants randomized to the study drug arm beginning at 48-72 hours prior to the planned cardiac surgery and then continued for a total of 30 days.
1608004|NCT02177266|Drug|Placebo|The placebo will match the study drug.
1608005|NCT02177253|Drug|Ipratropium bromide / Salbutamol|
1608006|NCT02177253|Drug|Placebo Inhalation solution|
1608007|NCT02177253|Drug|Ipratropium bromide|
1608008|NCT02177253|Drug|COMBIVENT Inhalation Aerosol|
1608009|NCT02177253|Drug|Placebo Inhalation Aerosol|
1608010|NCT02177240|Device|GlideScope® intubation with Flex-it® stylet|GlideScope® intubation with Flex-it® stylet of a simulated difficult airway
1608011|NCT02177240|Device|GlideScope® intubation with GRS® stylet|GlideScope® intubation with GRS® stylet of a simulated difficult airway
1608012|NCT02177227|Device|Attune TruMatch (TM) Patient-Specific Instrumentation|Patients to receive total knee replacement with TruMatch Patient-Specific Instrumentation
1608013|NCT02177214|Procedure|MRI scan|Visualization of the mesh surface observed with MRI scan at 3 weeks and 13 months after ventral hernia repair with a visible IPOM prosthesis (Dynamesh®)
1608014|NCT02177201|Other|Group 1|Intravenous access was established and 10 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
1608015|NCT02177201|Other|Group 2|Intravenous access was established and 20 ml/kg/h 0.9% saline solution was delivered following the induction of anesthesia and until the end of the operation.
1608016|NCT02177188|Device|LBNP Lower Bodi Negative Pressure Chamber|
1608017|NCT02177175|Drug|Carvedilol|
1608018|NCT02177175|Other|placebo|
1608019|NCT02177162|Other|Education to physiotherapists|
1608020|NCT02177149|Device|Standard of Care|Patients in the standard of care arm will have their DBS programmed per standard of care which is testing multiple settings and looking for symptom relief through a trial and error process.
1608021|NCT02177149|Device|DBS using Clinical Support System.|The DBS RN (Registered Nurse) will use ImageVis3D Mobile app on the iPad to program the DBS system, this software does not interact with imaging systems. The study team uses identified images provided by the Froedtert PACS system, de identifies them, adds a study code. The images are loaded into the software system and used to identify the leads locations. The Patients will be assessed for 6 months starting with the initial DBS programming session. Importantly, the investigators do not anticipate that the clinical decision support tool will provide the final DBS settings, nor do the investigators anticipate that the approach will obviate the need for motor exams. The clinical decision support system will help nurses choose good initial settings and then explore around those initial settings.
1608022|NCT02177136|Drug|OCA|
1608023|NCT02177136|Drug|Placebo|
1608024|NCT02177123|Device|InnFocus MicroShunt implantation|Implantation will include the use of Mitomycin C applied with sponges.
1608025|NCT02177097|Biological|Blood samples|4 x 10 ml blood samples.
1608026|NCT02177084|Device|PTNS|
1608027|NCT02177071|Drug|INFLIXIMAB|
1608028|NCT02177071|Drug|AZATHIOPRINE|
1608029|NCT02177071|Drug|MERCAPTOPURINE|
1608030|NCT02177071|Drug|Methotrexate|
1608031|NCT02177058|Other|INTERACT Quality improvement program|INTERACT training and implementation between APR 2013 and MAR 2014
1608034|NCT02177032|Biological|Rabies vaccine|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8)."
1608035|NCT02177032|Biological|Rabies vaccines + Rabies immunoglobulins|"12 doses of the PCEC rabies vaccine, administered ID (0.1mL for each injection) to adults only, according to the 4-sites, 1-week regimen (i.e. 4 doses of vaccine; in both deltoids and anterolateral thigh areas, administered on days 1, 4, and 8). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
1608036|NCT02177032|Biological|Rabies vaccine|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29)."
1608037|NCT02177032|Biological|Rabies vaccines + Rabies immunoglobulins|"8 doses of the PCEC rabies vaccine, administered ID (0.1ml for each injection) to adults only, according to the 2-sites, TRC, updated Thai Red Cross regimen (i.e. 2 doses of vaccine; in both deltoids, administered on days 1, 4, 8, and 29). HRIG will be administered on day 1 (before the first dose of the vaccine) in a dose of 20 IU/kg body weight intramuscularly into the gluteal muscle."
1608038|NCT02177019|Other|Personalized health plan|
1608039|NCT02177006|Behavioral|Sun Protection Program|"The intervention includes two phases:
Phase 1: From June to August 2014, a voucher to obtain a swim shirt for sun protection provided by the Pediatric Sun Protection Foundation will be affixed to the anticipatory guidance sheet provided by the practice to caregivers of children 2-6 years of age.
Phase 2: Analysis of online redemption of vouchers in comparison with the self-reported surveys"
1608040|NCT02176980|Behavioral|Brief alcohol counseling|Medical provider gives feedback on how the patient's alcohol use may affect their current and future health, noting that it is the patient's responsibility to change behavior; giving advice to stop drinking based on medical concern; giving a menu of options for cutting down on drinking; expressing empathy; and reinforcing the patient's self-efficacy to change.
1608041|NCT02176980|Behavioral|Group and Individual Therapy Sessions|Session content integrates HCV and alcohol issues in treatment, liver health, and personal realms. Sessions include psychoeducational content on how alcohol affects the liver among people with HCV; HCV stigma; family issues around drinking and the HCV diagnosis; nutrition; life goals and positive affect; and alcohol reduction strategies.
1608042|NCT02176967|Other|Clinical Observation|Undergo clinical observation
1608043|NCT02176967|Drug|Carboplatin|Given IV
1608044|NCT02176967|Drug|Etoposide|Given IV
1608045|NCT02176967|Drug|Cyclophosphamide|Given IV
1608046|NCT02176967|Drug|Doxorubicin Hydrochloride|Given IV
1608047|NCT02176967|Other|Laboratory Biomarker Analysis|Correlative studies
1608048|NCT02176967|Other|Pharmacological Study|Optional correlative studies
1608049|NCT02176954|Device|Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
1608050|NCT02176954|Device|Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
1608051|NCT02176954|Device|Comparator|"Two comparators will be used: Moderma Flex (Hollister) or Confidence Natural drainable (Salts).These product are commercially available.
Subjects will be randomized into one of twelwe arms. Data will be analyzed by pooling the two comparators, Moderma Flex and Confidence Natural, Drainable, why six arms are displayed."
1608052|NCT02176928|Device|AutoPAP|"PAP will be delivered by an auto-titrating device (IntelliPAP AutoAdjust®). These devices automatically set the level of delivered pressure to ensure upper airway patency, to treat detected apneas and hypopneas.
AutoPAP treatment 7 nights a week for four months (16 weeks)."
1608053|NCT02176928|Device|Sham PAP|"Sham PAP treatment will be delivered by an auto-PAP device (IntelliPAP AutoAdjust®) that is set to a fixed low pressure of 3 cmH20 without an ability to titrate according to detected respiratory events. The pressure is too low to eliminate respiratory events and serves as sham or sub-therapeutic PAP.
Sham PAP treatment 7 nights a week for four months (16 weeks)./"
1608054|NCT02176915|Behavioral|Group program|
1608055|NCT02176915|Behavioral|Print Materials|
1608056|NCT02176902|Behavioral|behavioral dietary intervention|Receive dietary counseling
1608057|NCT02176902|Behavioral|behavioral dietary intervention|Receive guidelines for low-fat diet
1608058|NCT02176902|Dietary Supplement|omega-3 fatty acid|Given PO
1608059|NCT02176902|Other|laboratory biomarker analysis|Correlative studies
1608060|NCT02176889|Dietary Supplement|Lactospore|Bacillus coagulans MTCC 5856
1608061|NCT02176889|Other|Placebo|
1608062|NCT02176876|Drug|GS-5745|GS-5745 400 mg administered intravenously
1608063|NCT02176876|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
1608064|NCT02176863|Biological|Flebogamma 5% DIF|Human plasma-derived immunoglobulin
1608065|NCT02176863|Other|Placebo|Normal saline solution
1608066|NCT02176850|Drug|Micardis®|
1608068|NCT02176824|Behavioral|Total Sleep deprivation, Sleep Phase Advance, and Bright Light Therapy|Sleep deprivation, Sleep phase advance, and Bright light therapy
1608069|NCT02176824|Behavioral|Partial Sleep deprivation, Sleep Phase Delay, and Low amber light.|
1608070|NCT02176824|Other|Treatment as usual|
1608071|NCT02176785|Device|transcranial Direct Current Stimulation (tDCS)|tDCS will be delivered using a Chattanooga Ionto™ Iontophoresis System - Phoresor.
1608072|NCT02176772|Other|Stable iron isotopes, non-drug intervention|
1608073|NCT02176759|Other|Administration of rice fortified with regular FePP|
1608074|NCT02176759|Other|Administration of rice fortified with regular FePP with citrate added during extrusion|
1608075|NCT02176759|Other|Administration of rice fortified with regular FePP and citrate added at consumption|
1608076|NCT02176759|Other|Administration of rice fortified with ferrous sulphate|
1608077|NCT02176746|Biological|cancer stem cell vaccine|
1608078|NCT02176733|Drug|cyclosporine|
1608259|NCT02175342|Drug|Tiotropium-18 lactose powder|
1608079|NCT02176720|Drug|FDOPA PET|[18F]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
1608080|NCT02176694|Behavioral|Text Messaging|Website that allows adolescents to create, schedule and send one-time or recurring text messages that will serve as a reminder to take asthma medication or follow up with another health-related matter.
1608081|NCT02176681|Drug|Vildagliptin (Galvus)|Use Vildagliptin (50 mg/day) added to insulin during 3 months
1608082|NCT02176681|Drug|Insulin|Insulin
1608083|NCT02176668|Drug|YH4808 NF 100|The number of times : multiple-dose Rout : oral administration
1608084|NCT02176668|Drug|YH4808 OF 200|The number of times : multiple-dose Rout : oral administration
1608085|NCT02176668|Drug|YH4808 NF 200|The number of times : multiple-dose Rout : oral administration
1608086|NCT02176668|Drug|YH4808 NF 400|The number of times : multiple-dose Rout : oral administration
1608087|NCT02176655|Drug|VVD-101|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
1608088|NCT02176655|Drug|Placebo|All subjects will treat 6 headaches with either VVD-101 or placebo in a randomized order.
1608089|NCT02176642|Drug|Oxybutynin extended release|5mg tablet taken by mouth daily for 6 weeks
1608090|NCT02176642|Device|Posterior Tibial Nerve Stimulation|In office therapy administered for 30 minutes once every week for a total of 6 weeks
1608091|NCT02176642|Drug|Placebo|Tablet taken by mouth daily for 6 weeks
1608092|NCT02176629|Other|Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)|
1608093|NCT02176629|Other|Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)|
1608094|NCT02176616|Procedure|linear ablation|The group of positive control is the operation to add in conventional liner ablation to conventional pulmonary vein isolation with in patients based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
1608095|NCT02176616|Procedure|pulmonary vein isolation|The group of negative is the operation to patients with only pulmonary vein isolation based on patients who were changed to paroxysmal atrial fibrillation from persistent atrial fibrillation
1608096|NCT02176590|Behavioral|Power PATH|PATHS: Teacher-led classroom curriculum promoting a positive classroom environment and teaching social-emotional skills
1608097|NCT02176590|Other|Head Start as usual|Standard Head Start programming (including classroom instruction, meals, and family services)
1608098|NCT02176577|Drug|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
1608099|NCT02176564|Drug|inhaled bronchodilator|
1608100|NCT02176551|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days.
1608101|NCT02176551|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
1608102|NCT02176538|Drug|Product 0405|Product 0405 will be administered topically twice daily for 28 days
1608103|NCT02176538|Drug|Placebo for Product 0405|Placebo for Product 0405 will be administered topically twice daily for 28 days.
1608104|NCT02176525|Drug|BI 207127 NA|
1608105|NCT02176525|Drug|Placebo|
1608106|NCT02176512|Drug|BIBR 277 SE and HCTZ|Treatment A - fixed dose combination
1608107|NCT02176512|Drug|BIBR 277 SE|Treatment B - Monocomponent
1608108|NCT02176512|Drug|HCTZ|Treatment B -Monocomponent
1608109|NCT02176499|Drug|Telmisartan, low dose|
1608110|NCT02176499|Drug|Telmisartan, high dose|
1608111|NCT02176499|Drug|Placebo|
1608112|NCT02176486|Drug|Ixazomib|Ixazomib capsules
1608113|NCT02176486|Drug|Placebo|Ixazomib placebo-matching capsules
1608114|NCT02176473|Behavioral|Computerized Cognitive Behavioral Therapy|"The c-CBT software focuses on the same principles of traditional CBT, namely, identifying, labeling, and modifying automatic thoughts; the link between thought and action; identifying and modifying schemas; and identifying and correcting cognitive errors.9 C-CBT is delivered in 9 online lessons, each designed to take 30-45 minutes to complete. The software provides modeling of CBT principles (in the form of short videos), enables an interactive forum by giving users feedback based on responses to questions, and encourages participants to employ the skills learned in CBT to their situations. A 9-minute video demonstrating the functionality of Good Days Ahead can be found at: http://www.empower-interactive.com/solutions/good-days-ahead/."
1608115|NCT02176460|Drug|Colchicine|0.5mg twice daily for 16 weeks
1608116|NCT02176460|Drug|Placebo|1 tablet twice daily
1608117|NCT02176434|Procedure|Kidney and hematopoietic stem cell transplantation|Kidney transplantation (day 0) Induction therapy (s. above) Hematopoietic stem cell transplantation (s. above)
1608118|NCT02176434|Biological|hematopoietic stem cell|
1608119|NCT02176421|Device|VOLBELLA® with lidocaine|VOLBELLA® with lidocaine administered to correct skin depression during initial treatment and optional top-up treatment 14 days later.
1608120|NCT02176408|Behavioral|Behavioral Activation|Behavioral Activation Therapy (BA). All participants will receive a standard behavioral activation treatment based on the manualized treatment described by Lejuez et al., 2011. Treatment will be delivered in 60-minute weekly sessions over a 6-week period followed by 3 biweekly booster sessions. Behavioral activation includes scheduling activities the patient will enjoy and find important with the purpose of improving mood.
1608121|NCT02176408|Behavioral|Exercise Intervention|Exercise Intervention (EX). The exercise intervention will immediately follow each of the first six weekly BA sessions. Each EX session will comprise 30 minutes of either providing rationale for the program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 40 minutes of aerobic exercise at 60-75% of maximum heart rate on three days each week, with 5 minute stretching warm up and cool down. We will help all participants initiate and plan their at-home program of exercise.
1608122|NCT02176408|Behavioral|Stretching Intervention|Stretching Intervention (STR). The stretching intervention will also follow each of the first six weekly BA sessions. These sessions will comprise 30 minutes of providing rationale for the stretching program or reviewing the previous week's progress. As part of the intervention, participants will be asked to perform 50 minutes of stretching on three days each week. Participants in this condition will be provided with a 50-minute DVD of stretching exercises and will work with the therapist to plan their at-home stretching exercises.
1608164|NCT02176122|Drug|Meropenem|Meropenem is a carbapenem anti-bacterial used for the treatment of serious infections in patients.
1608123|NCT02176395|Drug|Danhong injection|40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
1608124|NCT02176395|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
1608125|NCT02176395|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
1608126|NCT02176382|Drug|denosumab|denosumab subcutaneous injection
1608127|NCT02176382|Drug|teriparatide|teriparatide daily subcutaneous injection
1608128|NCT02176382|Drug|Zoledronic acid|zoledronic acid infusion
1608129|NCT02176369|Drug|Vinorelbine|Capsule soft (20/30 mg) - 50 mg three times a week (monday, wednesday and friday) for a three weeks cycle (then recycled the next week at the same doses)Treatment will be continued until progression, unacceptable toxicity or death.
1608130|NCT02176356|Biological|onabotulinumtoxinA|onabotulinumtoxinA (BOTOX® Cosmetic) 20U total dose per treatment to glabellar areas and/or 24U total dose per treatment to crow's feet line areas.
1608131|NCT02176356|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LATISSE®) 1 drop applied to the upper eyelid at the base of eyelashes once daily in the evening for 17 weeks.
1608132|NCT02176356|Device|JUVÉDERM® ULTRA XC|JUVÉDERM® ULTRA XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
1608133|NCT02176356|Device|JUVÉDERM® ULTRA PLUS XC|JUVÉDERM® ULTRA PLUS XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
1608134|NCT02176356|Device|JUVÉDERM® VOLUMA® XC|JUVÉDERM® VOLUMA® XC, a hyaluronic acid gel implant (dermal filler), volume injected determined by the investigator.
1608135|NCT02176343|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
1608136|NCT02176330|Other|ePAQ-PF followed by a telephone consultation.|All women randomised to this arm of the study were entered onto the hospital electronic patient record system under the ePAQ clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. The research nurse (HJW) then arranged their telephone consultation. Women in this group who felt unable to complete the questionnaire online would use this telephone call with the research nurse to make arrangements to attend and complete the questionnaire at the hospital.
1608137|NCT02176330|Other|ePAQ-PF followed by a face to face consultation|All women randomised to this arm of the study were posted an appointment to attend the urogynaecology clinic. They were were posted an information letter and an epaq-online voucher inviting them to complete the questionnaire on-line. The clinician used these results along with the patient's own casenotes and original referral letter to support the subsequent consultation. Women then attended for their face to face clinic consultation as normal. Women in this group who felt unable to complete the questionnaire online were given the opportunity to complete the questionnaire at the hospital when they attended for their consultation.
1608138|NCT02176317|Biological|Autologous Umbilical Cord Blood|All participants will receive autologous umbilical cord blood cells with a pre-cryopreservation cell dose of 1-5 x 10^7 Total Nucleated Cells (TNC)/kilogram of subject body weight. The cells will be administered as a single intravenous (into the vein) infusion over 2 to 25 minutes
1608139|NCT02176304|Drug|Depomedrol|Depomedrol 40 mg/ml, 1 ml injected to knee on day one of intervention.
1608140|NCT02176304|Drug|Lidocaine|Lidocaine 2% soln, 4 ml injected to knee on day 1 of intervention
1608143|NCT02176278|Other|Telephone Reminder|Nurse will provide telephone contact to patients every 3 month to remind them to adhere to treatment, provide support and empower them to discuss with their doctors about their treatment needs and any concerns
1608144|NCT02176278|Other|Doctor-Nurse Follow Up|Patient will be followed by a doctor-nurse team at least 3 monthly to achieve multiple targets recommended as A1c<7%, BP<130/80 mmHg, LDL-C<1.8 mmol/l, triglyceride<1.7 mmol/l and persistence with RAS inhibitors taking into consideration safety and tolerability (e.g. hypoglycemia, hypotension, changes in electrolytes). Patient report will be given after follow up.
1608145|NCT02176278|Other|Personalized Risk Report for Patient Empowerment|Patients will be given with personalized risk reports after baseline and 12-month repeat comprehensive assessments.
1608146|NCT02176265|Device|Qvanteq bioactive coronary stent|PCI
1608147|NCT02176252|Drug|AZD1722|
1608148|NCT02176252|Drug|Placebo|
1608150|NCT02176213|Drug|Pomalidomide|4 mg PO x 21 days
1608151|NCT02176213|Drug|Cyclophosphamide|low dose cyclophosphamide 50 mg PO BID x 21 days
1608152|NCT02176213|Drug|Dexamethasone|dexamethasone 40 mg PO weekly (or 20 mg if ≥ 75 years old).
1608153|NCT02176200|Drug|Berodual® Respimat®, low inspiratory flow rate|
1608154|NCT02176200|Drug|Berodual® Respimat®, medium inspiratory flow rate|
1608155|NCT02176200|Drug|Berodual® Respimat®, high inspiratory flow rate|
1608156|NCT02176200|Drug|Berodual® HFA-MDI, low inspiratory flow rate|
1608157|NCT02176200|Drug|Berodual® HFA-MDI, medium inspiratory flow rate|
1608158|NCT02176200|Drug|Berodual® HFA-MDI, high inspiratory flow rate|
1608159|NCT02176187|Drug|Berodual® Respimat® inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
1608160|NCT02176187|Drug|Berodual® metered dose inhaler|fenoterol hydrobromide 50μg + ipratropium bromide 20μg
1608161|NCT02176161|Drug|Metformin Hydrochloride Extended Release 750mg|Metformin Hydrochloride Extended Release 750mg twice per day for 9 months.
1608162|NCT02176148|Drug|fluocinonide 0.05% cream|
1608163|NCT02176135|Drug|Auranofin|3 mg tablets
1608253|NCT02175355|Drug|Placebo|
1608165|NCT02176122|Drug|Piperacillin-tazobactam combination product|Piperacillin-tazobactam is used for the treatment of patients with systemic and/or local bacterial infections.
1608166|NCT02176096|Dietary Supplement|Glycosade|
1608167|NCT02176083|Behavioral|Text message management prompts|
1608168|NCT02176057|Drug|Azithromycin|
1608169|NCT02176044|Drug|Sodium Nitroprusside infusion|
1608170|NCT02176044|Other|Placebo|
1608171|NCT02176031|Drug|Natalizumab|
1608172|NCT02176031|Drug|Methylprednisolone|
1608173|NCT02176018|Drug|Dextromethorphan and quinidine|
1608174|NCT02176018|Drug|Placebo|
1608175|NCT02176005|Device|DAV132|DAV132 is associated to moxifloxacin or it is evaluated alone
1608176|NCT02176005|Drug|Moxifloxacin|Moxifloxacin is used alone or associated to DAV132
1608177|NCT02176005|Other|Negative Control|Moxifloxacin is used alone
1608178|NCT02175979|Dietary Supplement|enriched enteral nutrition|enriched enteral tube feeding perioperative
1608179|NCT02175979|Dietary Supplement|standard|standard of care
1608180|NCT02175966|Drug|DCV/ASV/BMS-791325|
1608181|NCT02175966|Drug|Ribavirin|
1608182|NCT02175966|Drug|Sofosbuvir|
1608183|NCT02175966|Drug|Peginterferon α-2a|
1608184|NCT02175953|Behavioral|Psychotherapy|The program is designed for 10 participants and consists of two modules of caregiver education followed by ten psychotherapeutic group modules. The major overarching topics will be (i) caregiver´s emotional and physical limits, (ii) conscious and unconscious feelings and emotions towards the people with dementia and (iii) activation of caregivers´ social resources. Duration of each module is planned to be 90 minutes including a relaxation exercise at the end of each module.
1608190|NCT02175914|Drug|Erythromycin|Oral Treatment with Erythromycin 500mg, twice daily, for 12 weeks
1608191|NCT02175901|Drug|Lansoprazole|antisecretory drug of each quadruple therapy
1608192|NCT02175901|Drug|Bismuth Potassium Citrate|one component of each quadruple therapy
1608193|NCT02175901|Drug|Amoxicillin|antibiotic of each quadruple therapy
1608194|NCT02175901|Drug|Metronidazole|antibiotic of the amoxicillin/metronidazole-based quadruple therapy
1608195|NCT02175901|Drug|Clarithromycin|antibiotic of the amoxicillin/clarithromycin-based quadruple therapy
1608196|NCT02175888|Dietary Supplement|Daily administration of 60 mg iron in form of ferrous sulphate capsules for 14 consecutive days|
1608197|NCT02175888|Dietary Supplement|Administrations of 60 mg iron in form of ferrous sulphate capsules on every second day for 28 days|
1608198|NCT02175797|Device|MRI|at least 6 weeks after the implantation of the pacemaker a MRI exam is performed
1608199|NCT02175784|Drug|ipragliflozin|oral
1608200|NCT02175784|Drug|placebo|oral
1608201|NCT02175771|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient.
During the treatment period, participants were randomized to either 100 mcg or 200 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 400 mcg. Study drug was administered in the morning and in the evening."
1608202|NCT02175771|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient.
During the treatment period, participants were randomized to either Fp/Sx MDPI 100/12.5 mcg or Fp/Sx MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg Fp/Sx. Study drug was administered in the morning and in the evening."
1608203|NCT02175771|Drug|FLOVENT HFA|"FLOVENT HFA is a hydrofluoroalkane (HFA) inhaler containing fluticasone propionate.
During the treatment period, participants were randomized to either 110 mcg or 220 mcg of FLOVENT two puffs, twice a day for a total daily dose of 440 mcg or 880 mcg. Study drug was administered in the morning and in the evening."
1608204|NCT02175771|Drug|ADVAIR DISKUS|"ADVAIR DISKUS contains a dry powder formulation of fluticasone propionate (Fp) and salmeterol xinafoate (Sx) in a lactose excipient.
During the treatment period, participants were randomized to Fp 250 mcg/Sx 50 mcg or Fp 500 mcg/Sx 50 mcg one inhalation, twice a day for a total daily dose of 500/100 mcg or 1000/100 mcg. Study drug was administered in the morning and in the evening."
1608205|NCT02175771|Drug|albuterol/salbutamol HFA|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
1608206|NCT02175758|Drug|SOF (oral tablets)|SOF tablets administered orally once daily
1608207|NCT02175758|Drug|RBV|RBV administered as capsules or oral solution
1608208|NCT02175758|Drug|SOF (oral granules)|SOF oral granule capsules administered orally once daily
1608209|NCT02175745|Drug|18F-fluoro-dihydroxyphenylalanine|Administered intravenously (IV)
1608210|NCT02175745|Procedure|Positron emission tomography (PET)|Component of an 18F-FDOPA PET/CT or PET/MRI scan
1608211|NCT02175745|Procedure|Computed tomography (CT)|Component of an 18F-FDOPA PET/CT
1608212|NCT02175745|Procedure|Magnetic resonance imaging|Component of an 18F-FDOPA PET/MRI
1608213|NCT02175732|Behavioral|'KnowIt'|"Participants in the 'KnowIt' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will focus on recent advances in diabetes care and self-management.
During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
1608254|NCT02175342|Drug|Tiotropium 0.625 mcg/puff|
1608255|NCT02175342|Drug|Tiotropium 1.25 mcg/puff|
1608256|NCT02175342|Drug|Tiotropium 2.5 mcg/puff|
1608214|NCT02175732|Behavioral|'OnTrack'|"Participants in the 'OnTrack' group will participate in a single, day-long group workshop led by a trained facilitator. Content covered during the program will utilize an emotion-based adaptation of Problem Solving Therapy to target and reduce diabetes distress.
During the three months following the initial workshop, participants will receive four telephone calls with their group facilitator to address any questions and challenges. One week after each phone call participants will take part in a 60 minute web meetings with their facilitator and other group members to review program content and discuss any challenges. Finally, participants will receive two further phone calls from their facilitator during months four to nine."
1608215|NCT02175706|Device|Resolute Integrity®|Biolinx-zotarolimus coating on a chobalt-cromium alloy stent platform that has a novel sinusoidal design.
1608216|NCT02175706|Device|Promus Element®|fluoropolymer-everolimus coating on a novel stent platform made from a platinum-chromium alloy
1608217|NCT02175680|Drug|PRO 140 350mg weekly SQ injection.|CCR5 Antagonist
1608218|NCT02175667|Procedure|Global Postural Reeducation|Experimental group is treated in a 45 minutes GPR session, with three postures: the first was for the anterior muscular chain with the patient lying supine on a couch with arms at 45 degrees, hips open, and feet in opposition on top of the table. This posture is maintained 25-30 minutes. The second GPR posture, to stretch the posterior muscle chain, the participant is positioned with legs elevated, for 12-15 minutes. Third position is with the participant standing and 2-5 minutes to integrate the postural corrections. During all the time, the physiotherapist use manual therapy for stretch the muscles under the official rules of GPR techniques. Group control do not receive any technique.
1608219|NCT02175654|Drug|Regorafenib|
1608220|NCT02175641|Behavioral|Peer-Led Group Lifestyle Balance|The intervention follows the Group Lifestyle Balance curriculum derived from the Diabetes Prevention Program and The intervention will be delivered by trained peer-specialists employed at the supportive housing agencies and supervised by the study team. Peer GLB is a 12-month group intervention that focuses helping people lose weight by improving people's diet and increasing their physical activity and consists of weekly core group sessions (3 mo.), bi-monthly transitional group sessions (3 mo.), and maintenance monthly sessions (6 mo.).
1608221|NCT02175641|Behavioral|Usual Care Services|The usual care condition encompasses the regular services offered at supportive housing agencies to help clients with their physical health and wellness.
1608222|NCT02175628|Device|Acoustic Angiography|"Acoustic angiography imaging involves a research high frequency ultrasound scanner (VisualSonics Vevo 770) and a prototype transducer as well as conventional b-mode ultrasound to guide the location of the imaging. The conventional ultrasound will be conducted just prior to the acoustic angiography for localization. The imaging also requires administration of Definity ultrasound contrast agent.
Acoustic angiography imaging will be performed by trained medical personnel using mild compression to eliminate motion. Total imaging time is estimated to be less than 15 minutes. All image data will be de-identified and transferred for off-line analysis based on a study ID. The research images will NOT be interpreted or analyzed for clinical decisions related to the patient."
1608223|NCT02175602|Drug|Escitalopram|10 milligrams administered each morning
1608224|NCT02175602|Drug|Sertraline|50 milligrams administered each morning
1608225|NCT02175602|Drug|DCV 3DAA FDC|Fixed dose combination (daclatasvir [DCV] 30 milligrams, asunaprevir [ASV] 200 milligrams, and BMS-791325 75 milligrams) one tablet administered twice daily
1608226|NCT02175602|Drug|BMS-791325|75 milligrams single-agent film coated oral tablet administered twice daily
1608227|NCT02175589|Other|Colchicine Cessation|Colchicine Cessation
1608228|NCT02175576|Device|Vanguard XP Bicruciate Knee System|The Vanguard XP is a bicruciate retaining total knee design and is constrained by natural soft tissue.
1608229|NCT02175576|Device|Vanguard CR Knee System|The Vanguard CR system requires the ACL to be sacrificed and is constrained by soft tissue and device design.
1608230|NCT02175563|Device|Audiovisual feedback from smartphone based app|
1608231|NCT02175550|Device|NR CC|
1608232|NCT02175537|Behavioral|Microclinic Social Induction Diabetes and Obesity Program|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support.
1608233|NCT02175511|Device|Cloud-based home BP monitoring|"a sphygmomanometer-style BP measurement device (Microlife®, WatchBP Home) that stored and transmitted data to a secure cloud BP system directly via a General Packet Radio Service (GPRS) gateway through cell phone network."
1608234|NCT02175498|Drug|Homoeopathic medicines|4 pills once a week of the indicated Similimum
1608235|NCT02175485|Drug|Fexofenadine HCl 30 mg+Pseudophedrine HCl 60 mg|Pharmaceutical form:tablet Route of administration: oral
1608236|NCT02175472|Device|Spectramax light therapy device|Spectramax light therapy device emits a specific combination of bandwidths and intensities of light.
1608237|NCT02175472|Device|Control light device|The control light device is identical in appearance to the Spectramax light therapy device, except that when turned on, emits a different combination of bandwidths and intensity, not believed to produce a therapeutic response.
1608238|NCT02175446|Drug|Bevacizumab and eribulin|"In this study, Bevacizumab and Eribulin are considered to be the investigational study drugs. Bevacizumab is provided as 25 mg/ml concentrate for infusion. Vials contain 100 mg of Bevacizumab in 4 ml and/or 400 mg in 16 ml. Eribulin is provided as vials containing 1 mg/2 mL Eribulin as a 500 µg/mL solution in ethanol/water"
1608239|NCT02175433|Drug|AGS67E|intravenous (IV) infusion
1608240|NCT02175420|Biological|BCG|
1608241|NCT02175420|Biological|TFV|
1608242|NCT02175407|Drug|ASP1707|oral
1608243|NCT02175407|Drug|itraconazole|oral
1608244|NCT02175394|Drug|Microgynon®|
1608245|NCT02175394|Drug|BI 1356|
1608246|NCT02175381|Drug|Carboplatin|Carboplatin: 2.5 AUC i.v on day 1. Cycle repeated ever 2 weeks
1608247|NCT02175381|Drug|Gemcitabine|Gemcitabine: 1100 mg/m2, iv on day 1. Cycle repeated every 2 weeks
1608248|NCT02175368|Device|Adhese One F Upgrade|
1608249|NCT02175355|Drug|Low dose of Micardis®|
1608250|NCT02175355|Drug|Medium dose of Micardis®|
1608251|NCT02175355|Drug|High dose of Micardis®|
1608252|NCT02175355|Drug|Hydrochlorothiazide|
1608260|NCT02175342|Drug|Placebo lactose powder|
1608261|NCT02175342|Drug|Tiotropium 10 mcg/puff|
1608262|NCT02175342|Device|Respimat|
1608263|NCT02175342|Device|Handihaler|
1608264|NCT02175329|Device|CAD/CAM Veneering|CAD/CAM fabricated zirconia bridge framework is veneered with CAD/CAM fabricated lithium disilicate ceramic veneer
1608265|NCT02175329|Device|Manually layered veneering|
1608266|NCT02175316|Device|Enhanced External Counterpulsation|Enhanced External Counterpulsation
1608267|NCT02175303|Biological|Decidual stromal cell therapy|Decidual stromal cells from placenta will be infused intravenously at approximately 1x10^6 cells/kg at one or more occasions at weekly intervals.
1608268|NCT02175277|Drug|Darbepoetin Alfa|Darbepoetin Alfa will be given at 500 μg three-times per week/two-times per week. The first dose and dosing frequency on day 1 / week 1 should carry forward from the last dose and frequency from the parent study (darbepoetin alfa MDS 20090160 study) administered at week 70 / 71. The day 1 / week 1 visit should align within +10 days of the End of Active Treatment Period (EOATP) visit at week 72 / 73 from the darbepoetin alfa MDS 20090160 study. The investigator may choose to increase the dose of darbepoetin alfa with the maximum dose permitted of 500 μg two-times per week. Dose increases should follow a step-wise approach, (eg, 300 μg to 500 μg; 200 μg to 300 μg) with at least 8 weeks at a given dose before the dose may be increased.
1608269|NCT02175264|Genetic|Blood sample|
2010060|NCT03134092|Other|Narrative Enhanced Risk Tool (NERT)|Participants assigned to this arm will receive the PRT described above but will also be instructed to watch one or more narrative videos. This video intervention will include a brief narrative video of a patients cautionary tale around prolonged opioid uses. Narrative videos are developed from actual patient stories - put into a in a structured format of ~ 2-minute length and recorded using actors. The video will also mention the risks of keeping unused opioids at home, including the risk of diversion.
1608273|NCT02175238|Drug|BI 691751 fasted|single dose BI 691751 in fasted state
1608274|NCT02175238|Drug|BI 691751 after high fat breakfast|single dose BI 691751 after a standardised high fat breakfast
1608275|NCT02175225|Drug|Deferoxamine Mesylate|
1608276|NCT02175225|Drug|Placebo (for Deferoxamine Mesylate)|
1608277|NCT02175212|Drug|Short term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months"
1608278|NCT02175212|Drug|Long term androgen deprivation|"Gosereline 3.6 mg 1 month plus 10.8 mg subcutaneously 3 months (total 4 months)
Bicalutamide 50 mg tablet every day for 2 months
Gosereline 10.8 mg by subcutaneous injection every 3 moths for 2 years at the end of the radiotherapy"
1608279|NCT02175212|Radiation|Short term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
1608280|NCT02175212|Radiation|Long term androgen deprivation|Minimum dose of 76 Gy (range 76-82 Gy)
1608281|NCT02175199|Device|Lotrafilcon B contact lenses with color printing|
1608282|NCT02175199|Device|Phemfilcon A contact lenses with color printing|
1608283|NCT02175186|Drug|ALBIS|
1608284|NCT02175186|Drug|Placebo|
1608285|NCT02175173|Drug|Rufinamide|Administration of Inoveron 100mg or 200mg Tablets
1608286|NCT02175160|Other|Braking and functionality|
1608287|NCT02175134|Other|Blood and Ascites ELISPOT|
1608288|NCT02175121|Drug|Placebo|Tablet, once daily for 28 days
1608289|NCT02175121|Drug|PF-06291874|Tablet, 15 mg, once daily for 28 days
1608290|NCT02175121|Drug|PF-06291874|Tablet, 35 mg, once daily for 28 days
1608291|NCT02175121|Drug|PF-06291874|Tablet, 75 mg, once daily for 28 days
1608292|NCT02175121|Drug|PF-06291874|Tablet, 150 mg, once daily for 28 days
1608293|NCT02175095|Drug|Regorafenib|After checking the eligibility for the study entry, patients will be scheduled to perform [18F]FLT-PET scans before and on 21st day from the administration of regorafenib. Regorafenib will be administered 160 mg/day given orally on day 1 to days 21 following 7 days break, which consists of 4 weeks as 1 cycle. Treatment will be repeated every 4 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal. Standard anatomical response evaluation will be performed every 8 weeks (without regard to the cycles or schedules of chemotherapy).
1608294|NCT02175082|Other|Cycling at Forced rate|
1608295|NCT02175082|Other|Cycling at self-selected rate|
1608296|NCT02175069|Procedure|Interscalene Nerve Block|ultrasound guided interscalene plexus block (UISB) immediately before magnetic resonance imaging of the neck.
1608297|NCT02175069|Drug|Ropivacaine 0.75%, 20ml|20 ml of ropivacaine 0.75%
1608298|NCT02175069|Drug|Gadopentetate-Dimeglumine 0.0125 mmol|0.0125 mmol of gadopentetate-dimeglumine
1608299|NCT02175069|Drug|Gadopentetate-Dimeglumine 0.05 mmol|0.05 mmol of gadopentetate-dimeglumine
1608300|NCT02175069|Drug|Ropivacaine 0.75%, 5ml|5 ml of ropivacaine 0.75%
1608301|NCT02175069|Procedure|Shoulder Surgery|As per individual requirement (patient-dependent)
1608302|NCT02175056|Biological|HL2351|Dose-escalation For 5 level dose groups A ~ E(each 1, 2, 4, 8, 12mg/kg), 10 subjects (8 for the study drug and 2 for placebo) are randomized to each dose group, and the study drug or placebo is subcutaneously administered for the relevant dose group.
1608303|NCT02175056|Biological|Kineret(Anakinra)|Active comparator(group F) is implemented in parallel with dose groups A~E in an open-label manner and 8 subjects subcutaneously administer Kineret® 100 mg.
1608304|NCT02175043|Procedure|atrial electrogram and liner ablation|"The group of positive control is the operation to add in CFAE to conventional liner ablation in persistent atrial fibrillation patients
The group of negative is the operation to only doing conventional liner ablation with persistent atrial fibrillation"
1608305|NCT02175030|Drug|Copper IUD|Randomization to copper/Paragard IUD for emergency contraception
1608306|NCT02175030|Drug|Levonorgestrel IUD|Randomization to Levonorgestrel/Mirena IUD for emergency contraception
1608307|NCT02175017|Drug|ONO-4538|
1608309|NCT02174991|Drug|Rho-Kinase Inhibitor (AR-12286)|
1608312|NCT02174965|Device|MiniHip (Corin U.K.)|MiniHip (Corin U.K.) femoral component
1608313|NCT02174965|Device|Metafix (Corin, U.K)|Metafix (Corin, U.K) conventional cementless stem
1608314|NCT02174952|Behavioral|Self-help version of the New Forest Parenting Programme|
1608315|NCT02174939|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
1608316|NCT02174939|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
1608317|NCT02174926|Procedure|Elective laparoscopic sigmoid resection|
1608318|NCT02174926|Dietary Supplement|Conservative treatment|Written lifestyle guidance and fiber supplements
2010061|NCT03134092|Other|probabilistic risk communication tool (PRT)|The probabilistic risk communication tool (PRT) is a visual tool that communicates risk using the previously validated Opioid Risk Tool (ORT). The ORT is designed to assess risk of opioid dependency for patients for whom an opioid pain relief prescription is being considered in outpatient settings. Patients in this arm will be given an iPad which will prompt them to take a short survey that automatically communicates their risk score. After which the iPad will show them a color coded visual thermometer that informs them of their risk of having issues related to opioids (PRT image attached to the protocol).
1608320|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.25 mg/kg primaquine|
1608321|NCT02174900|Drug|Artemether-Lumefantrine (AL) combination|
1608322|NCT02174900|Drug|Artemether-Lumefantrine (AL) + 0.4 mg/kg primaquine|
1608323|NCT02174887|Drug|Nab-paclitaxel + Gemcitabine|"Gemcitabine 1 g/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days in combination with Nab-paclitaxel 125 mg/m² IV infusion over 30 minutes at D1-D8-D15 every 28 days
The patients will receive 2 cycles of treatment every 28 days:"
1608324|NCT02174861|Drug|AMG 334|All subjects will receive AMG 334 periodically for 13 months followed by a safety follow up visit .The subjects who complete the 12-week double-blind treatment phase of the AMG 334 20120295 parent study and meet all AMG 334 20130255 eligibility criteria will be enrolled into this study. Enrollment should occur within 14 days after the week 12 visit of the parent study.
1608325|NCT02174848|Drug|Deferiprone oral solution|Oral iron chelator
1608326|NCT02174848|Drug|Deferiprone|Deferiprone oral solution up to 15 mg per kilogram of body weight, twice a day
1608327|NCT02174835|Drug|AVP-786|
1608328|NCT02174835|Drug|AVP-923|
1608329|NCT02174822|Drug|AVP-786|
1608330|NCT02174822|Drug|Paroxetine|
1608331|NCT02174822|Drug|Duloxetine|
1608332|NCT02174809|Behavioral|Use of 5As to discuss gestational weight gain|
1608333|NCT02174809|Behavioral|Usual care|
1608334|NCT02174796|Procedure|surgical treatment|patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
1608335|NCT02174796|Procedure|orthopedic treatment|orthopedic treatment by vacuum bell.
1608336|NCT02174783|Other|Control group|Patient will be provided with basic nutrition educational materials that outline principles of a healthy diet, including: moderation, portion control, increased intakes of fruits, vegetables and whole grains and reduced intakes of saturated fat, salt and sugar. Brief education will be provided by the hepatologist without dietitian referral.
1608337|NCT02174783|Other|Mediterranean diet|Patient will receive verbal diet instruction from the dietitian or from the hepatologist who has received instruction from the dietitian on following the Mediterranean diet.
1608338|NCT02174783|Other|Protein-Sparing Modified Fast (PSMF)|"Patient will be referred to the dietitian for an appointment to discuss the PSMF plan.
Protein needs of 1.5 grams/kilogram will be calculated based on patient's actual body weight.
Patient will receive verbal instruction from the dietitian, as well as printed materials for reference at home. Dietitian will provide a list of allowed and prohibited foods as per Cleveland Clinic's PSMF diet standards."
1608339|NCT02174770|Other|Blood Flow Restriction (BFR) Training|This is a modality of physical therapy where during low-load resistance activity, the venous return of blood from an extremity is limited only during the duration of the exercise. This can be accomplished through multiple means. For the purposes of our study, we will use an inflatable tourniquet.
1608340|NCT02174770|Other|Standard ACSM-guided strength training|This is the standard protocol to be used for post-operative and other physical therapy patients for rehabilitation. It includes the use of American College of Sports Medicine-guidelines for how much weight to use during the strength training portion of the rehabilitation.
1608341|NCT02174757|Drug|Inersan|Probiotic
1608342|NCT02174757|Drug|Doxycycline|Antibiotic
1608343|NCT02174744|Other|numeric pain rating scale|
2010062|NCT03134235|Other|Dietary Intervention|Subjects consumed a raw, vegan diet for 4-weeks with an emphasis on raw fruit and vegetable consumption.
1608346|NCT02174718|Dietary Supplement|Transdermal D Patch|
1608347|NCT02174718|Dietary Supplement|Oral vitamin D3|
1608348|NCT02174718|Dietary Supplement|Placebo patch|
1608349|NCT02174718|Dietary Supplement|Oral placebo|
1608350|NCT02174705|Drug|Sucrose|Sucrose 24% orally prior to vaccine injections
1608351|NCT02174705|Drug|Rotavirus|Rotavirus vaccine orally prior to vaccine injections
1608352|NCT02174692|Other|Exercise|"One leg eccentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum Contralateral leg concentric exercise: 7 sets of 10 repetitions at 80% 1 repetition maximum
2 mins rest between sets"
1608353|NCT02174679|Drug|68Ga DOTATATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTATATE PET/CT.
1608354|NCT02174666|Dietary Supplement|Red clover extract|Aglycone isoflavones 80mg/d
1608355|NCT02174666|Dietary Supplement|Supplementation (placebo)|
1608356|NCT02174653|Drug|EPs® 7630|20 mg EPs® 7630 film-coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
1608357|NCT02174653|Drug|Placebo|Control: Placebo film coated tablets during 4 months Orally intake three times a day (in the morning, midday and evening)
1608358|NCT02174640|Dietary Supplement|Coffee|Coffee Beverage
1608359|NCT02174640|Dietary Supplement|Water|Water
1608362|NCT02174614|Behavioral|Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time.
1608407|NCT02174250|Drug|Istradefylline 40 mg|On Day 1, istradefylline 1 × 40-mg tablet administered alone
1608550|NCT02173145|Drug|azithromycin|Azithromycin is a macrolide antibiotic. 500mg Azithromycin will be given p.o. 3 times a week for 3 months. Azithromycin will be compared to placebo.
1608363|NCT02174614|Behavioral|TAU plus Rapid Abstinence Initiation (RAI)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment followed by 8 weeks of CBT4CBT computerized therapy.
1608364|NCT02174614|Behavioral|TAU plus RAI plus Cognitive Control Training (CCT)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions three times per week lasting three hours each time PLUS the chance to earn money for urine specimens that are negative for cocaine during the first 4 weeks of treatment PLUS sessions of computerized cognitive control training (CCT) 3 times per week for the first 4 weeks followed by 8 weeks of CBT4CBT computerized therapy.
1608365|NCT02174588|Drug|Midazolam + propofol|Midazolam and propofol are used for sedation drug. Balanced propofol sedation (BPS) refers to the administration of an opiate, a benzodiazepine, and propofol.
1608366|NCT02174588|Drug|propofol|propofol are used for sedation drug
1608367|NCT02174575|Drug|Sevoflurane|Sevoflurane is administered during anesthesia in Sevoflurane group.
1608368|NCT02174575|Drug|Desflurane|Desflurane is administered during anesthesia in Desflurane group.
2010063|NCT03132792|Genetic|Autologous genetically modified AFPᶜ³³²T cells|Infusion of autologous genetically modified AFPᶜ³³²T cells on Day 1.
2010064|NCT03132675|Biological|pIL-12|Intratumoral pIL-12 delivered by electroporation every 6 weeks
1608371|NCT02174549|Drug|Tirapazamine|Intravenous administration for the first two cohorts and then Intra-arterial injection into the tumor feeding artery for subsequent cohorts
1608372|NCT02174549|Procedure|Transarterial embolization (TAE)|A standard of care for hepatocellular carcinoma.
1608373|NCT02174536|Biological|Decidual stromal cells|Decidual stromal cells (approximately 1x10^6 cells/kg) will be infused intravenously.
1608374|NCT02174536|Biological|Placebo|
1608375|NCT02174523|Drug|40mg lurasidone|
1608376|NCT02174523|Drug|40mg lurasidone placebo|
1608377|NCT02174510|Drug|20mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
1608378|NCT02174510|Drug|40mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
1608379|NCT02174510|Drug|80mg lurasidone|single oral lurasidone or placebo in 30 minutes after beginning of the over 350 kcal breakfast on day 1.
1608380|NCT02174510|Drug|placebo|
1608381|NCT02174458|Procedure|Body Contouring Surgery|Patients after bariatric surgery (BS) and patients with no history of BS but after natural weight loss and some degree of skin laxity who underwent Body contouring will be included after written informed consent is obtained.
1608382|NCT02174445|Drug|Imatinib|Imatinib, 400 to 800 mg p.o., daily
1608383|NCT02174445|Drug|Nilotinib|300mg p.o., twice-daily
1608384|NCT02174432|Drug|nalbuphine HCl ER 90 mg BID|nalbuphine HCl ER 90 mg BID for up to 50 weeks
1608385|NCT02174432|Drug|nalbuphine HCl ER 120 mg BID|nalbuphine HCl ER 120 mg BID for up to 50 weeks
1608386|NCT02174432|Drug|nalbuphine HCl ER 180 mg BID|nalbuphine HCl ER 180 mg BID for up to 50 weeks
1608387|NCT02174419|Drug|nalbuphine HCl ER tablets 90 mg BID|nalbuphine HCl ER tablets 90 mg BID administered for 8 weeks
1608388|NCT02174419|Drug|nalbuphine HCl ER tablets 180 mg BID|nalbuphine HCl ER tablets 180 mg BID administered for 8 weeks
1608389|NCT02174419|Drug|Placebo tablets BID|Placebo tablets BID administered for 10 weeks
1608390|NCT02174406|Procedure|breast ultrasound|
1608391|NCT02174406|Procedure|DBT (Full field digital mammography + tomosynthesis)|
1608392|NCT02174393|Drug|Universal Peel|Universal Peel: is a chemical peel consisting of a mild acid solution. (5 min Peel and 5 min Retinol)
1608393|NCT02174393|Procedure|Microneedling|"Microneedling: is a device for all skin types that creates micro injuries in the dermis (layer of the skin underneath the outermost layer) in an attempt to trigger new collagen (natural component of skin tissue) production for smoother, firmer and younger-looking skin.
For this protocol, the needle depth will be increased over the 3 sessions:
Forehead: 0.75 mm, 0.85 mm, 1.0 mm. Cheeks/Chin: 1.0 mm, 1.5 mm, 2.0 mm.
Each Session: Microneedling procedure on Day 1, followed by skin care regimen"
1608394|NCT02174393|Drug|Post-Microneedling Skin Care|"On Day 1 (after Microneedling procedure):
Gentle Antioxidant Soothing Cleanser daily
Soothing Recovery Ointment and Sheer Physical Sunscreen
On Day 2-7:
AM: Physical sheer sunscreen and recovery ointment
PM: Retinol/Vitamin C in the evening and soothing recovery ointment
On Day 7:
AM: BD Hydrating Day/Night Cream
PM: Retinol and Vitamin C and the BD Hydrating Day/Night Cream (if necessary)"
1608395|NCT02174393|Drug|Post-Universal Peel Skin Care|"Gentle Antioxidant Soothing Cleanser daily
Physical Sunscreen daily
Soothing recovery ointment fortified with silver only when peeling occurs
After completely peeling, vitamin c product in the morning and the retinol in the evening"
1608396|NCT02174380|Other|Active Household Contact Evaluation|Active evaluation of TB household contacts will be introducted as a new intervention in the district. The intervention will be undertaken by routine public health staff under routine conditions, however the assignment, training, monitoring and supervision of this intervention will occur in a stepped wedge roll out.
1608397|NCT02174367|Device|Transient elastography|a noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis
1608398|NCT02174328|Drug|Acetylsalicylic acid|Acetylsalicylic acid once a day until 36 week
1608399|NCT02174328|Drug|Placebo|Placebo once a day until 36 week
1608400|NCT02174315|Behavioral|Contingency Management|
1608401|NCT02174289|Device|Targeted left ventricular endocardial lead placement|The left ventricular endocardial lead will be passed through the intra-atrial septum
1608402|NCT02174276|Drug|TDF|300 mg tablets administered orally once daily.
1608403|NCT02174276|Biological|GS-4774|Administered as a subcutaneous injection every four weeks for a total of 6 doses
1608404|NCT02174263|Biological|tocilizumab|Given IV
1608405|NCT02174263|Other|laboratory biomarker analysis|Correlative studies
1608406|NCT02174263|Other|quality-of-life assessment|Ancillary studies
1608672|NCT02172300|Drug|Tiotropium inhalation capsules|
2010065|NCT03132675|Biological|Pembrolizumab|intravenous 3 weekly treatments
2010066|NCT03132675|Device|Immunopulse|device that provides electroporation
1608408|NCT02174250|Drug|Rifampin 300mg BID + istradefylline 40mg Day 8 only|On Days 1 - 20, rifampin 300mg BID; On Day 8, istradefylline 40 mg administered first with rifampin about 2 hours after istradefylline administration
1608409|NCT02174237|Drug|LNP1892|Tablets of two strengths (5 and 25 mg)
1608410|NCT02174237|Drug|Placebo|Matching placebo
1608411|NCT02174224|Behavioral|Brief Intervention|Goals of the bedside intervention will be to help the patient understand their risky behaviors that resulted in the injury and to assess and deescalate any threat of retaliatory violence by the patient. The outreach worker will: (1) develop a rapport with the patient by introducing themselves and describing their (outreach worker's) background and reason for the bedside visit; (2) assess the emotional response to the current injury; (3) ensure the patient and/or family understand the nature of the injury and ED course; (4) address any immediate concerns of the patient; and (5) develop a plan for staying safe following discharge.
1608412|NCT02174224|Behavioral|Case Management|Case management based on needs-assessment. Resource connection and mentoring.
1608413|NCT02174224|Behavioral|Standard Medical Care|This will include physician discretion for medical treatment and potentially a social worker visit as the physician sees fit for the patient. This will also include a list of resources that are typically needed and used for violently injured youth.
1608414|NCT02174211|Drug|Ranibizumab|
1608415|NCT02174198|Device|BioOss Collagen at the time of implant placement|Experimental: placement of BioOss Collagen No intervention: no BioOss Collagen
1608416|NCT02174185|Behavioral|validated health-related quality of life questionnaires|All eligible patients who agree to participate will be asked to fulfill three different validated health-related quality of life questionnaires (EORTC-QLQ-C30/BLM, FACT-BL and BCI) prior to surgery and at 3, 6, 12, 18 months postoperatively.
1608417|NCT02174172|Drug|Atezolizumab|Participant will receive atezolizumab 600 milligrams (mg) or 1200 mg by IV infusion q3w.
1608418|NCT02174172|Drug|Bevacizumab|Participant will receive Bevacizumab 15 milligrams per kilograms (mg/kg) IV infusion q3w.
1608419|NCT02174172|Drug|Interferon alfa-2b|Participants will receive Interferon alfa-2b 3, 5, or 10 million international units subcutaneously every other day for up to 3 doses per week.
1608420|NCT02174172|Drug|Ipilimumab|Participants will receive Ipilimumab 1, or 3 mg/kg IV, single dose, or multiple-dose regimen q3w for up to 4 cycles.
1608421|NCT02174172|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams will be administered as pre-treatment on 2 consecutive days (Day -13 and Day -12) prior to treatment start with atezolizumab on Cycle 1, Day 1 (cycle length=21 days). An additional two doses of obinutuzumab will be administered on Days 85 and 86 of study treatment (Cycle 5, Day 1 and Cycle 5, Day 2).
1608422|NCT02174172|Drug|PEG-interferon alfa-2a|Participant will receive PEG-interferon alfa-2a 180 micrograms subcutaneous injection q3w for a total of 6 cycles.
1608423|NCT02174159|Drug|MK-8507|MK-8507 administered as a single oral dose
1608424|NCT02174146|Procedure|non-surgical periodontal therapy|supra and subgingival debridement
1608425|NCT02174120|Drug|propofol|
1608426|NCT02174120|Drug|etomidate|
1608427|NCT02174107|Radiation|External radiotherapy|The radiation technique used for each patient will be based on local clinical practices and on number of vertebae to treat between 1*8 Gy; 5*4 Gy and 10*3 Gy
1608428|NCT02174107|Procedure|Percutaneous vertebroplasty|
1608429|NCT02174094|Drug|Clobazam|
1608430|NCT02174094|Drug|Placebo|
1608431|NCT02174068|Drug|paracetamol 1000 mg per os, nefopam 60mg per os, paracetamol 1000 mg + nefopam 60 mg per os|
1608432|NCT02174055|Behavioral|Patient Interviews|
1608433|NCT02174055|Behavioral|newly developed questionnaire|
1608434|NCT02174042|Drug|Tangning Tongluo Capsule|Taken drugs 3 times a day, with each time 3 grains
1608435|NCT02174029|Procedure|Ventilation- mandatory|Patient days during which only a mandatory ventilation mode was used and prior to this no voluntary mode was used.
1608436|NCT02174029|Procedure|Ventilation- voluntary mode only|Patient days on a voluntary mode with no preceding days with a majority of time spend on a mandatory mode
1608437|NCT02174029|Procedure|Voluntary with preceding mandatory|Patient days on a voluntary vent mode with at least one day prior during which the majority of the vent mode was mandatory.
1608438|NCT02174016|Dietary Supplement|Ketogenic diet|
1608439|NCT02174003|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
1608440|NCT02173990|Drug|Aflibercept-FOLFIRI|"Aflibercept : 4 mg/kg, IV over 1 h on Day 1
FOLFIRI :
Irinotecan 180 mg/m² IV infusion in 500 mL D5W (5% Dextrose in Water solution) over 90 minutes and dl leucovorin* 400 mg/m² IV infusion over 2 hours, at the same time, in bags using a Y-line, followed by :
5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by :
5-FU 2400 mg/m² continuous IV infusion in 500 mL over 46-hours.
*400 mg/m² of leucovorin expressed in dl racemic. When the l-isomer form is used the dose should be divided by 2, i.e. 200 mg/m²"
1608441|NCT02173977|Other|ARM A- Agonist/Antagonist protocol|In vitro fertilization (IVF/ICSI)
1608442|NCT02173977|Other|ARM B- Antagonist protocol|In vitro fertilization (IVF/ICSI)
1608443|NCT02173964|Drug|pinaverium bromide|pinverin 50 mg per oral single dose versus simple water ingestion
1608444|NCT02173964|Drug|water|same amount of water for pinverin administration
1608445|NCT02173951|Drug|Deferiprone|"in arm 1 ( active comparator) will receive a starting dose of Deferiprone (DFP) 50mg⁄ kg ⁄ d, administered orally 3 times daily. Routine dose adjustments will be made according to serum ferritin trends and safety.
Patients reaching serum ferritin ≥1000 will be subjected to dose escalation of DFP to 75 mg/kg/d.
Patients in Placebo Comparator arm when reaching end point elevation of SF to around 1000 ng/ml or more or Tsat > 90 % and or LPI > 0.6 will start deferiprone 75 mg/kg/d"
1608446|NCT02173938|Other|Tobacco Dependence Treatment|face to face, outpatient tobacco dependence treatment based on the Public Health Service guidelines for treating tobacco use and dependence
1608447|NCT02173912|Drug|Candesartan cilexetil 16 mg and Amlodipine besylate 10mg (Reference)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.
Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
1608448|NCT02173912|Drug|CJ-30059 (Test)|"Sequence 1 receives Candesartan cilexetil 16 mg and Amlodipine besylate 10mg first, then CJ-30059 second, with at least 14-day wash-out period in between.
Sequence 2 receives CJ-30059 first, then Candesartan cilexetil 16 mg and Amlodipine besylate 10mg second, with at least 14-day wash-out period in between."
2010067|NCT03134144|Behavioral|"Exoskeleton Chairless Chair"|One solution to reduce the exposure of employees to associated risks for developing work-related musculoskeletal disorders is to use exoskeletons. Using such a device in dynamic environments has the advantage over, e.g., robotics because it does not need any programming or teaching of robots. Moreover, exoskeletons are worn at the body and do not have to overcome spatial issues. In a recent review, 26 different exoskeletons have been described of which only two were designed to support the lower body during heavy work (de Looze et al. 2015). For lower intensive work tasks, like assembly tasks in the automobile industry, no study has focused on using exoskeletons to relieve employees while performing the work standing.
1608452|NCT02173886|Drug|Bupropion SR and XL|
1608453|NCT02173873|Drug|ziv-aflibercept drug|intravitreal injection of ziv-ablicerpt in one eye of each patient with retinal disease and poor vision
1608454|NCT02173860|Procedure|FFR-guided surgical revascularization|
1608455|NCT02173860|Procedure|Angio-guided surgical revascularization|
1608456|NCT02173847|Procedure|Penetrating keratoplasty|Femtosecond laser sculptured anvil graft. Laser welding of the flap in its final position. 12 months follow up study
1608457|NCT02173847|Device|Femtosecond laser|A commercial femtosecond laser to cut a particular shaped graft
1608458|NCT02173847|Device|Diode laser|Low power, near infrared diode laser for welding the surgical wound
1608459|NCT02173834|Other|18F- fluorodeoxyglucose-positron emission tomography Computed Tomography scan and 123I-metaiodobenzylguanidine-single-photon emission computed tomography scan|
1608460|NCT02173821|Procedure|Blood sampling|Blood sample will be collected at a single visit
1608461|NCT02173808|Biological|levonorgestrel butanoate|
1608462|NCT02173795|Drug|Berodual® Respimat®|
1608463|NCT02173795|Drug|Berodual® MA HFA|
1608464|NCT02173782|Drug|Berodual® Respimat ® high dose|
1608465|NCT02173782|Drug|Berodual® Respimat ® low dose|
1608466|NCT02173782|Drug|Berodual® MDI|
1608467|NCT02173782|Drug|Placebo|
1608468|NCT02173769|Drug|Spiriva® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
1608469|NCT02173769|Drug|Striverdi® Respimat®|Spiriva® Respimat® plus Striverdi® Respimat® or Spiriva® 18 Microgramm plus Striverdi® Respimat®
1608470|NCT02173756|Drug|morphine gel|1 mg / ml ofmorphine hydrochloride, presented in a 5 mL sterile syringe (single dose), raspberry aroma, 30% glucose
1608471|NCT02173756|Drug|placebo gel|Sterile placebo gel with raspberry aroma, 30% glucose presented in 5 mL syringe (single dose) of the same appearance and the same packaging as morphine gel to maintain the blind
1608472|NCT02173743|Other|PRP|platelet enriched autologous blood plasma
1608473|NCT02173743|Other|Control|Regular barbotage/care as usual
1608474|NCT02173730|Drug|BIBR 1048 MS|BIBR 1048 MS capsule 150 mg
1608475|NCT02173730|Drug|Pantoprazole|Pantoprazole tablet 40 mg
1608476|NCT02173717|Drug|Dabigatran etexilate|150 mg Dabigatran etexilate
1608477|NCT02173717|Drug|Rifampicin|600 mg Rifampicin
1608480|NCT02173691|Drug|Tiotropium inhalation powder capsules|
1608481|NCT02173691|Drug|Salmeterol inhalation aerosol|
1608482|NCT02173691|Drug|Placebo inhalation aerosol|
1608483|NCT02173691|Drug|Placebo inhalation powder capsules|
1608484|NCT02173678|Drug|COMBIVENT® HFA-MDI|
1608485|NCT02173678|Drug|COMBIVENT® CFC-MDI|
1608486|NCT02173678|Drug|Placebo HFA-MDI|
1608487|NCT02173665|Drug|BI 1356 BS - Powder in bottle (PIB)|
1608488|NCT02173665|Drug|BI 1356 BS - Tablet|
1608489|NCT02173665|Drug|Placebo|
1608490|NCT02173652|Drug|BI 1356, high dose|
1608491|NCT02173652|Drug|BI 1356, low dose|
1608492|NCT02173639|Drug|BI 1356/metformin|fixed dose combination tablet
1608493|NCT02173639|Drug|BI 1356|
1608494|NCT02173639|Drug|Metformin|
1608495|NCT02173626|Behavioral|Mindfulness Training|Participants enrolled on a first-come, first-serve basis, engaging in three 90-minute in person trainings, weekly online video-module trainings, and weekly teleconference coaching calls. Video-module trainings were available at all times, to be accessed at the participants' convenience. Journals and a guided meditation audio library were also provided.
1608496|NCT02173613|Other|procalcitonine|"The recommendations will be based on the level of PCT: 4 levels of advice will be given:
It is highly recommended to stop antibiotics if PCT <0.1ng/ml, and the recommended stop if 0.1ng/ml <PCT <0.25 ng / ml.
It is recommended to continue treatment if 0.25 ng / ml <PCT ng / ml.
Finally, if the initial PCT greater than 10 ng / ml, a stop will be advised in case of reduction to less than 10% of baseline level."
1608497|NCT02173600|Behavioral|Group-level Intensive dietary Counselling|
1608498|NCT02173600|Behavioral|Individual-level Intensive Dietary Counselling|
1608499|NCT02173587|Dietary Supplement|Mussel oil capsules|Each mussel oil capsule contained 200mg thick shell mussel lipid extract and 200mg corn oil.Each patient in this group received daily four mussel oil capsules (containing 800mg mussel oil and 800mg corn oil) for first two months and two mussel oil capsules per day thereafter
1608500|NCT02173587|Dietary Supplement|Corn oil capsules|Each corn oil capsule contained 400mg corn oil.Each patient in this group received daily four corn oil capsules (1600mg corn oil) for first two months and two corn oil capsules per day thereafter
1608501|NCT02173574|Drug|DEB025|
1608502|NCT02173574|Drug|EDP239|
1608547|NCT02173184|Biological|Placebo|1 IM injection of Placebo per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
1608503|NCT02173561|Behavioral|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only version (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT-C is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted in groups of 8-12 participants. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
1608504|NCT02173561|Behavioral|Individual Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy-Cognitive Only (CPT-C) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Individual sessions will be conducted twice weekly for six weeks; each session is 60 minutes.
1608505|NCT02173548|Drug|Anakinra|
1608506|NCT02173548|Drug|Placebo|
1608507|NCT02173535|Device|etafilcon test contact lens Variant AP|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
1608508|NCT02173535|Device|etafilcon test contact lens Variant JG|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
1608509|NCT02173535|Device|etafilcon test contact lens Variant CS|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
1608510|NCT02173535|Device|etafilcon test contact lens Variant VC|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
1608511|NCT02173535|Device|etafilcon test contact lens Variant LA|Subject will complete a questionnaire regarding cosmetic effect of the lens post insertion, then remove the lens.
1608512|NCT02173522|Device|Prostate artery embolization (PAE)|Embolization of the arteries carrying blood to the prostate. All PAE procedures will be conducted with Embosphere Microspheres.
1608513|NCT02173509|Other|Multidisciplinary and multifaceted educational intervention.|Outreach visits (40 minutes) which included a PowerPoint presentation and impress materials: poster; flyers; participation certificate and articles mentioned in the presentation. This outreach visit aimed to change the knowledge-attitudes previously identified in a previous study as being associated with poor prescribing of antibiotics in the case of physicians and propensity to dispense antibiotics without medical prescription in the case of pharmacists.
1608514|NCT02173496|Other|Colour Contrast Sensitivity|Reading of numbers or letters from a monitor
1608515|NCT02173483|Procedure|Quadriceps graft|
1608517|NCT02173457|Drug|Chiglitazar|Take orally
1608518|NCT02173457|Drug|Sitagliptin|Take orally
1608519|NCT02173444|Other|Blood test|
1608520|NCT02173418|Drug|Phrenic nerve block with Ropivacaine|
1608521|NCT02173418|Drug|Phrenic nerve block with saline|
1608522|NCT02173405|Drug|OnabotulinumtoxinA|comparison of OnabotulinumtoxinA with placebo
1608523|NCT02173405|Drug|Placebo|comparison of placebo with investigational drug OnabotulinumtoxinA
1608524|NCT02173392|Drug|Brodalumab|Brodalumab is a large molecule for the treatment of inflammatory diseases
1608525|NCT02173379|Device|Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
Once Absorb GT1™ BVS System is commercially available, it can also be used in the ABSORB IV trial. Scaffold diameters: 2.5, 3.0 and 3.5 mm of and scaffold lengths: 8, 12, 18, 23, and 28 mm.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
1608526|NCT02173379|Device|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm. The 3.25 mm is only available for XIENCE Xpedition
Stent lengths: 8, 12, 15, 18, 23, and 28 mm
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
1608527|NCT02173366|Behavioral|Change Club Intervention|
1608528|NCT02173353|Device|Ultrasound|Ultrasound to be done just before standard radiation therapy treatment
1608529|NCT02173327|Device|Continuously helm CPAP|6 hours
1608530|NCT02173327|Device|Intermittent Mask CPAP|10min every 2 hour for 18 hours
1608531|NCT02173314|Other|SAFE FC|SAFE - FC, a combination of SAFE (developed by ACTION for Child Protection) and Family Connections (developed by Ruth H. Young Center for Families and Children, University of Maryland School of Social Work) for Populations 1 and 2.
1608532|NCT02173314|Other|Family Search and Engagement (FSE)|Intense search practices to identify possible permanency resources
1608533|NCT02173301|Drug|XP23829 400 mg QD|XP23829 400 mg QD
1608534|NCT02173301|Drug|XP 23829 800 mg QD|XP23829 800 mg QD
1608535|NCT02173301|Drug|XP23829 400 mg BID|XP23829 400 mg BID
1608536|NCT02173301|Drug|Placebo|Placebo
1608537|NCT02173288|Drug|Standard medical therapy|
1608538|NCT02173288|Drug|Tolvaptan|
1608539|NCT02173288|Drug|Midodrine|
1608540|NCT02173262|Drug|G-CSF|
1608541|NCT02173262|Drug|Ciprofloxacin|
1608542|NCT02173249|Drug|AC 170 0.24%|1 drop in each eye 2 times daily for 1 week
1608543|NCT02173236|Other|platform-switched implants|
1608544|NCT02173236|Other|platform-matched implant|
1608545|NCT02173223|Drug|Rho-Kinase Inhibitor|
1608546|NCT02173184|Biological|Gynevac|1 IM injection of Gynevac per week, for 4 weeks (five injections in total). Vaccination can take place in no less than 7 days intervals (+3 days).
1608549|NCT02173158|Drug|lomitapide|
1608551|NCT02173145|Drug|placebo|Placebo will be given 3 times a wek over a period of 3 months.
1608552|NCT02173132|Drug|Acetyl-L-carnitine|
1608553|NCT02173132|Other|Placebo|
1608554|NCT02173119|Other|MRI post-TACE|Perform lipiodol delivery measurements with MRI post-TACE.
1608555|NCT02173106|Drug|steroid & Cyclosporin|oral methylprednisolone 0.4mg/kg/d and Cyclosporin for 6 months
1608556|NCT02173093|Biological|IL-2|Given SC
1608557|NCT02173093|Biological|GD2Bi-aATC|Given IV
1608558|NCT02173093|Biological|GM-CSF|Given SC
1608559|NCT02173093|Other|laboratory evaluations of immune responses|Correlative studies
1608560|NCT02173080|Other|PLD-Q|polycystic liver disease questionnaire
1608561|NCT02173054|Other|Adapalene gel with Eucerin|Eucerin: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
1608562|NCT02173054|Other|Adapalene gel|Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
1608563|NCT02173054|Other|Adapalene gel with placebo moisturizer|Placebo: 2 fingertip unit to cover all over the face twice a day. Adapalene gel: 2 fingertip unit to cover all over the face before going to bed
1608564|NCT02173041|Other|Prevention Awareness Groups (PAG)|
1608565|NCT02173041|Other|Standard Care|
1608566|NCT02173015|Other|Compensatory step training|The training consists of a progression of anterior or posterior treadmill belt movements applied as the subject is standing or walking. This training specifically focuses on aspects important to trip and slip recovery. Subjects will participate in up to 6 sessions in 7 to 30 days. The training intensity (magnitude of disturbance delivered) is progressive and dependent on subject performance. Subjects will be instructed to respond with single or multiple steps in order to prevent a fall. All subjects will be outfitted with a safety harness to prevent injury. Up to 72 disturbances will be delivered each session.
1608567|NCT02173002|Other|myIBDcoach|
1608568|NCT02173002|Other|Standard care|
1608569|NCT02172976|Drug|Gemcitabine|
1608570|NCT02172976|Drug|Oxaliplatin|
1608571|NCT02172976|Drug|5-Fluorouracil|
1608572|NCT02172976|Drug|Irinotecan|
1608573|NCT02172976|Drug|Natriumfolinate|
1608574|NCT02172963|Biological|Decidual Stromal Cell therapy|Intravenous injection with placenta derived Decidual Stromal Cells. 1-2x10^6 cells/kg.
2010068|NCT03128411|Drug|Bosutinib|All patinets will receive bosutinib at a starting dose of 400 mg QD.
1608576|NCT02172937|Biological|Decidual Stromal Cells thawed in plasma|
1608577|NCT02172937|Biological|Decidual Stromal Cells thawed in human albumin|
1608578|NCT02172924|Biological|Early Decidual stromal cell therapy|Intervention given within 7 days after corticosteroids.
1608579|NCT02172924|Biological|Late Decidual stromal cell therapy|Intervention given after 7 days after corticosteroids.
1608580|NCT02172911|Biological|1.1 mL of INO-3112 delivered via IM EP|Eligible subjects who consent to participate in the study will receive a 1.1 mL IM injection of INO-3112 in the deltoid followed immediately by EP with CELLECTRA®-5P.
1608581|NCT02172885|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cell Infusions
1608582|NCT02172872|Drug|standard combination chemotherapy|"Cycle 1
daunorubicin (60 mg/m²) infusion (15-30 min) for 3 days
cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.
Cycle 2
daunorubicin (45 mg/m²) infusion (15-30 min) for 3 days
cytarabine (200 mg/m²) continuous infusion (24 hrs) for 7 days.
Cycle 3 (mini-ICE)
idarubicin (8 mg/m²) infusion (15-30 min) for 3 days
cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days
etoposide (100 mg/m²) infusion (1 hr) for 3 days
Cycle 4 (mini-ICE) (optional)
idarubicin (8 mg/m²) infusion (15-30 min) for 3 days
cytarabine (100 mg/m²) continuous infusion (24 hrs) for 5 days
etoposide (100 mg/m²) infusion (1 hr) for 3 days"
1608583|NCT02172872|Drug|decitabine|"Cycle 1: decitabine (20 mg/m²) infusion (1 hr) for 10 days
Cycle 2
if bone marrow (BM) blasts < 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days
if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days
Cycle 3
if BM blasts < 5%: decitabine (20 mg/m²) infusion (1 hr) for 5 days
if BM blasts >= 5%: decitabine (20 mg/m²) infusion (1 hr) for 10 days
Cycle 4-6: decitabine (20 mg/m²) infusion (1 hr) for 5 days
Continuation therapy from Cycle 7 and until 'progression or toxicity': decitabine (20 mg/m²) infusion (1 hr) for 5 days or 3 days
Note: All patients considered eligible for transplant should be consolidated with alloHCT once donor is available."
1608584|NCT02172859|Dietary Supplement|lumiVida™|
1608585|NCT02172859|Dietary Supplement|Placebo|
1608586|NCT02172846|Radiation|Proton beam radiation therapy (PBT)|
1608587|NCT02172846|Drug|Paclitaxel|
1608588|NCT02172846|Drug|Carboplatin|
1608589|NCT02172820|Behavioral|Financial incentives|Patients in the experimental group will receive financial incentives for completing exercise sessions.
1608590|NCT02172807|Drug|Tiotropium low|Tiotropium 18 µg inhalation capsule
1608591|NCT02172807|Drug|Tiotropium high|Tiotropium 36 µg inhalation capsule
1608592|NCT02172807|Drug|Placebo MDI|Placebo metered dose inhaler (MDI)
1608593|NCT02172807|Drug|Placebo inhalation capsule|
1608594|NCT02172807|Drug|Oxitropium|Oxitropium MDI (100 µg/puff)
1608595|NCT02172794|Drug|Tiotropium|
1608596|NCT02172794|Drug|Placebo to tiotropium|
1608597|NCT02172794|Drug|Salmeterol|
1608598|NCT02172794|Drug|Placebo to salmeterol|
1608599|NCT02172781|Drug|Ipratropium - unit dose vial|
1608600|NCT02172781|Drug|Tiotropium - inhalation capsule|
1608601|NCT02172781|Drug|Placebo matching tiotropium|
1608602|NCT02172781|Drug|Placebo matching ipratropium|
1608603|NCT02172768|Other|alternate dosing|treatment for 8 days with intravenous micafungin twice weekly
1608604|NCT02172768|Other|daily dosing|micafungin daily for 8 days
1608605|NCT02172768|Drug|micafungin|
1608606|NCT02172755|Drug|BIA 2-093|During the whole study, subjects were to receive a single 600 mg dose of BIA 2-093 (Phase A) followed by 600 mg BIA 2-093 once daily for 8 days in Phase B. Phase B was to begun 96 hours post-Phase A dose.
1608607|NCT02172742|Drug|BIA 2-093|BIA 2-093 1200 mg once-daily
1608608|NCT02172742|Drug|Placebo|matching placebo
1608609|NCT02172742|Drug|Digoxin|Digoxin (days 1 and 2: loading dose of 0.5 mg/day; days 3 to 8: 0.25 mg/day).
1608673|NCT02172300|Drug|Placebo inhalation capsules|
1608610|NCT02172729|Drug|Adductor canal block with 20 ml lidocaine, single bolus|Duration of an adductor canal block with 20 ml lidocaine, single bolus, administered as 5 or 15 mg/ml
1608611|NCT02172716|Procedure|Nonsurgical periodontal treatment|"All patients with GCP will receive full-mouth scaling and root planning under local analgesia in one session. Hopeless teeth will be treated similarly and extracted after de 30 days visit. Oral hygiene instructions will be given as needed.
Supragingival scaling Periodontally healthy subjects will receive supra-gingival scaling and polishing in one appointment as needed. Oral hygiene instructions will be given as needed."
1608612|NCT02172703|Device|Non-invasive ICP measurement device|"The non-invasive ICP measurement device used in this study has been developed in the Telematic Science Laboratory at the Kaunas University of Technology, Lithuania.
The non-invasive method is based on two-depth TCD technique for simultaneously measuring flow velocities in the intracranial and extracranial segments of the ophthalmic artery (OA)."
1608613|NCT02172690|Procedure|Laparoscopic Staging|Laparoscopic Staging
1608614|NCT02172677|Behavioral|Episodic memory task|
1608615|NCT02172677|Device|fMRI|
1608616|NCT02172664|Procedure|Self etch enamel etching|The adhesive will be applied according to manufacturer's instructions. If the lesion is greater than 2 mm in any dimension, incremental placement of Tetric EvoCeram composite (Ivoclar Vivadent) will occur with the first increment being placed against enamel.
1608617|NCT02172664|Procedure|selective etch protocol|Total Etch (37% phosphoric acid; Ivoclar) will be placed on the enamel margin with no intentional placement on the dentin within the lesion. The adhesive will then be applied as instructed by the manufacturer. Tetric EvoCeram composite will be placed, light-cured, finished, and polished in the same manner as for the self-etch group.
1608618|NCT02172664|Device|Adhese Universal|the universal adhesive, Adhese Universal , will be applied to the selected tooth following manufacturer instructions
1608619|NCT02172651|Drug|Vitamin D3|
1608620|NCT02172638|Procedure|Fast-Track Protocol|
1608621|NCT02172638|Procedure|Usual management|
1608622|NCT02172625|Dietary Supplement|Protandim Dietary Supplement|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of Protandim for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
1608623|NCT02172625|Other|Placebo Group|This was a randomized, block design, controlling for 5-km performance and sex. Subjects were given 675 mg per day (1 pill per day) of corn starch for 90 days. Subjects ran a 5-km time trial before and after the supplementation period. Blood samples were taken pre and post supplementation.
1608624|NCT02172612|Other|Arm 1 Education Session|Those included in the intervention group will undergo an educational session with the study pharmacist and one of the licensed prescribers from Sanders-Brown to discuss recommended changes in their treatment plan. If changes in medications are indicated by the pharmacist-prescriber team, and accepted by the patient, new prescriptions will be provided and a letter will be sent to the primary care physicians detailing the changes made and the rationale behind such changes.
1608625|NCT02172599|Behavioral|Sit-stand workstation provision|The research compares the effects of a sit-stand workstation only and a multi-component sit-stand workstation intervention including individual and organisation-level approaches, with usual office-based working practice (no sit-stand workstation) over 12 months.
1608626|NCT02172586|Drug|Telmisartan|
1608627|NCT02172586|Drug|Losartan|
1608628|NCT02172586|Drug|Hydrochlorothiazide|
1608629|NCT02172573|Drug|Pramipexole|
1608630|NCT02172573|Drug|Bromocriptine|
1608631|NCT02172573|Drug|Placebo pramipexole|
1608632|NCT02172573|Drug|Placebo bromocriptine|
1608633|NCT02172560|Drug|Tiotropium|
1608634|NCT02172547|Drug|Spiriva|
1608635|NCT02172534|Drug|Tiotropium bromide low|
1608636|NCT02172534|Drug|Tiotropium bromide medium|
1608637|NCT02172534|Drug|Tiotropium bromide high|
1608638|NCT02172534|Drug|Placebo|
1608639|NCT02172521|Drug|Tiotropium bromide|Tiotropium bromide18 micrograms by oral inhalation (1 x daily) with the HandiHaler®
1608640|NCT02172508|Drug|Tiotropium Inhalation Capsule|
1608641|NCT02172508|Drug|Placebo Lactose Capsule|
1608642|NCT02172495|Drug|Tiotropium bromide|Tiotropium bromide 18 micrograms
1608643|NCT02172482|Drug|Tiotropium bromide|Tiotropium bromide18 micrograms (capsule with powder for inhalation)
1608644|NCT02172469|Drug|Tiotropium inhalation powder capsule|
1608645|NCT02172469|Drug|Placebo Metered Dose Inhaler|
1608646|NCT02172469|Drug|Ipratropium Bromide Metered Dose Inhaler|
1608647|NCT02172469|Drug|Placebo inhalation powder capsule|
1608648|NCT02172456|Drug|99mTc-radiolabelled tiotropium|
1608649|NCT02172456|Drug|non-radiolabelled tiotropium|
1608650|NCT02172443|Drug|tiotropium inhalation powder capsules|
1608651|NCT02172443|Drug|Atrovent|
1608652|NCT02172443|Drug|placebo to Atrovent|
1608653|NCT02172443|Drug|placebo to tiotropium inhalation capsules|
1608654|NCT02172430|Drug|Tiotropium powder inhalation capsules|Powder inhalation via the HandiHaler® once daily
1608655|NCT02172430|Drug|Tersigan®|2 puffs of oxitropium three times daily via MDI
1608656|NCT02172417|Drug|Cimetidine + Tiotropium|
1608657|NCT02172417|Drug|Ranitidine + Tiotropium|
1608658|NCT02172417|Drug|Tiotropium|
1608659|NCT02172404|Device|Placebo capsule administered via the HandiHaler®|
1608660|NCT02172404|Device|Ipratropium metered dose inhaler (MDI)|
1608661|NCT02172391|Drug|Tiotropium inhalation powder capsules|
1608662|NCT02172391|Drug|Placebo inhalation powder capsules|
1608663|NCT02172378|Drug|Tiotropium inhalation capsules|
1608664|NCT02172378|Drug|Placebo inhalation capsules|
1608665|NCT02172352|Drug|Ba 679 BR low dose|
1608666|NCT02172352|Drug|Ba 679 BR middle dose|
1608667|NCT02172352|Drug|Ba 679 BR high dose|
1608668|NCT02172352|Drug|Placebo inhalation powder|
1608669|NCT02172339|Drug|Tiotropium, solution ampoules|
1608670|NCT02172326|Drug|Tiotropium inhalation capsules for oral inhalation|Powder inhalation via HandiHaler®
1608671|NCT02172313|Drug|semaglutide|For oral administration.
1608674|NCT02172287|Drug|Tiotropium (Ba679 BR)|One capsule once daily by oral inhalation
1608675|NCT02172287|Drug|Salmeterol|Inhalation aerosol twice daily
1608676|NCT02172287|Drug|Placebo (for Tiotropium )|Placebo for Tiotropium delivered by inhalation capsule
1608677|NCT02172287|Drug|Placebo (for Salmeterol)|Placebo for Salmeterol delivered by inhalation aerosol
1608678|NCT02172274|Drug|[14C]-BI 10773 - oral solution|
1608679|NCT02172261|Drug|BI 10773|
1608680|NCT02172261|Drug|Glimepiride|
1608681|NCT02172248|Drug|BI 10773|
1608682|NCT02172248|Drug|Metformin|
1608683|NCT02172235|Drug|Pioglitazone|
1608684|NCT02172235|Drug|Pioglitazone - low dose|
1608685|NCT02172235|Drug|BI 10773 - low dose|
1608686|NCT02172235|Drug|BI 10773 - medium dose|
1608687|NCT02172235|Drug|BI 10773 - high dose|
1608688|NCT02172222|Drug|BI 10773|
1608689|NCT02172222|Drug|Linagliptin|
1608690|NCT02172209|Drug|BI 10773|
1608691|NCT02172196|Drug|BI 10773|
1608692|NCT02172196|Drug|Sitagliptin|
1608693|NCT02172183|Drug|Psychopharmacological treatment|methylphenidate or atomoxetine
1608694|NCT02172183|Behavioral|CBT group|
1608695|NCT02172170|Drug|BI 10773 single rising dose|
1608696|NCT02172170|Drug|Placebo|
1608697|NCT02172157|Drug|BI 1744 CL i.v.|
1608698|NCT02172157|Drug|BI 1744 CL oral|
1608699|NCT02172144|Drug|BI 1744 CL solution for inhalation|
1608700|NCT02172144|Drug|Placebo matching BI 1744 CL|
1608701|NCT02172144|Drug|Moxifloxacin (Avalox®)|
1608702|NCT02172131|Drug|BI 1744 CL|
1608703|NCT02172131|Drug|Placebo|
1608704|NCT02172118|Drug|BI 1774 CL|
1608705|NCT02172105|Drug|BI 1744 CL|
1608706|NCT02172105|Drug|Placebo|
1608707|NCT02172092|Drug|SodiumChloride|Infusion of SodiumChloride, blood samples to calculate extracellular volume.
1608708|NCT02172079|Other|Real mobilization-with-movement (MWM)|
1608709|NCT02172079|Other|Sham mobilization-with-movement (MWM)|
1608710|NCT02172066|Behavioral|Narrative Exposure Therapy (NET)|
1608711|NCT02172053|Other|Compensatory Workplace Exercise (CWE) - Comparative Group|The comparative group will receive warming up and stretching and light resisted exercise with elastic bands. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up for 5 minutes and 15 minutes of the specific training . The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
1608712|NCT02172053|Other|Individual Resistance Exercise (IRE) - Intervention Group|Intervention group will receive warming up and stretching, and a specific resistance training with increase progress load. The exercise will realize three times per week, 20 minutes for day in total 60 minutes per week. With warming up and stretching for 5 minutes and 15 minutes of the specific training. The exercise will realize in 3 series with 10 repetitions and rest 30 seconds between series.
1608713|NCT02172040|Drug|Over-encapsulated 10 mg amlodipine besylate tablet|Over-encapsulated 10 mg amlodipine besylate tablet once a day for two weeks
1608714|NCT02172040|Drug|Matched placebo capsule for over-encapsulated celecoxib capsule|Matched placebo capsule for over-encapsulated celecoxib capsule once a day for two weeks
1608715|NCT02172040|Drug|Over-encapsulated 200 mg celecoxib capsule|Over-encapsulated 200 mg celecoxib capsule once a day for two weeks
1608716|NCT02172040|Drug|Matched placebo tablet for over-encapsulated amlodipine besylate tablet|Matched placebo tablet for over-encapsulated amlodipine besylate tablet once a day for two weeks
1608717|NCT02172027|Device|Immunomagnetic Detection|Analysis of pleural effusion through immunomagnetic detection device.
1608718|NCT02172014|Drug|midazolam and fentanyl citrate infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
1608719|NCT02172014|Drug|midazolam and normal saline infusion|comparing the sedative effect of combination of midazolam and fentanyl citrate versus combination of midazolam and normal saline for 48 hours during ventilator care
1608720|NCT02172001|Drug|Iron isomaltoside 1000|
1608721|NCT02172001|Drug|Natrium Chloride 0,9%|100 ml or 5 ml
1608722|NCT02171988|Drug|Propranolol|Start propranolol 10mg bid, and then dose up to 20mg bid after one month if tolerable
1608723|NCT02171988|Drug|Bisoprolol|Start bisoprolol 2.5mg qd P.O, and then dose up to 5mg qd. if tolerable
1608724|NCT02171988|Drug|Propranolol+pyridostigmine|Start propranolol+pyridostigmine 10mg bid +30mg bid, and then dose up to 20mg bid+30mg bid. if tolerable.
1608725|NCT02171988|Drug|Bisoprolol+pyridostgmine|Start bisoprolol+pyridostgmine 2.5mg qd+30mg bid, and then, dose up to 5mg qd+30mg bid. if tolerable
1608726|NCT02171975|Procedure|pre-procedure ultrasound guided paramedian spinal|In group P, a portable ultrasound unit was used for initial pre-procedural marking. The interspinous space at which the clearest image of the anterior complex (ligamentum flavum dura complex- LFD) and posterior complex (posterior longitudinal ligament- PLL) was obtained, was selected. At the selected interspace, and with the probe positioned to obtain the clearest ultrasound image, a skin marker was used to mark the midpoint of the long border of the probe and the midpoints of the short borders of the probe . At the same horizontal level as the midpoint of the long border of the probe, the midpoint of the line drawn between the two short border midpoints of the probe was used as paramedian insertion point for the spinal needle.
1608727|NCT02171975|Procedure|Conventional landmark guided midline spinal anaesthetic|Spinal anaesthesia was administered based on conventional landmark based midline approach.
1608728|NCT02171962|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Zilver® PTX® Drug-Eluting Peripheral Stent for treatment of lesions of the above-the-knee femoropopliteal artery
1608729|NCT02171949|Biological|Infusion of bone marrow mononuclear cells.|Patients on this group will receive therapy with mononuclear cells. The cells will be diluted on saline and then injected on the hepatic artery through femoral artery puncture.
1608730|NCT02171936|Other|Questionnaire EPICES (Evaluation of the Precariousness and the Disparities of Health for the Centers of Examination of Health).|
1608731|NCT02171910|Drug|Doxapram|
1608732|NCT02171910|Drug|Placebo|An injection and infusion of normal saline (NaCl 0.9%) as a placebo comparator to doxapram
1608733|NCT02171897|Procedure|Osteosynthesis|
1608734|NCT02171897|Procedure|Total hip replacement|
1608735|NCT02171884|Other|Sample of cord blood|
1608736|NCT02171884|Other|Sample of placenta|
1608737|NCT02171871|Other|exposed to a smoking environment|Then the subjects will be exposed to a smoking environment for 20 minutes, under a continuous measurement of emitted particles using the SIDEPAK AM510 in Pm level 2,5=250, in a closed space of 20 m3. The passive smoking environment will be achieved via a smoking machine. Afterwards, the subject will again undergo IOS in four positions (standing, sitting, right and left lateral decubitus) and nitrogen washout test in two positions (sitting and decubitus). Thanks to the above mentioned techniques, changes in measured parameters will be evaluated.
1608738|NCT02171845|Other|surgical biopsies|
1608739|NCT02171832|Drug|BI 1744 CL, low dose|
1608740|NCT02171832|Drug|BI 1744 CL, high dose|
1608741|NCT02171819|Biological|IVACFLU-A/H5N1, 7.5 mcg|"IVACFLU-A/H5N1 is formulated to contain 7.5 mcg or 15 mcg hemagglutinin (HA) and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose, and filled in single dose vials. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 0.02%) and sucrose (not more than 2.0%).
IVACFLU-A/H5N1 is a sterile, slightly opalescent suspension after shaking well. Antibiotics are not used in the manufacture of IVACFLU-A/H5N1. IVACFLU-A/H5N1 does not contain latex."
1608742|NCT02171819|Biological|IVACFLU-A/H5N1, 15 mcg|"IVACFLU-A/H5N1 is formulated to contain 7.5 mcg or 15 mcg hemagglutinin (HA) and 0.6 mg of aluminum hydroxide adjuvant per 0.5 mL dose, and filled in single dose vials. Each 0.5 mL dose may contain residual amounts of formaldehyde (not more than 0.02%) and sucrose (not more than 2.0%).
IVACFLU-A/H5N1 is a sterile, slightly opalescent suspension after shaking well. Antibiotics are not used in the manufacture of IVACFLU-A/H5N1. IVACFLU-A/H5N1 does not contain latex."
1608743|NCT02171819|Biological|Placebo Comparator|Placebo (PBS) will be manufactured by IVAC. PBS, pH 7.2, will also be in 0.5 mL single-dose vials. Every vial contain : Nacl 4.500mg;Na2HPO4.2H2O: 0.685 mg; NaH2PO4.2H2O:0.186 mg and Water For Injection (qs):0.5 mL
1608744|NCT02171806|Drug|BI 1744 CL|
1608745|NCT02171806|Drug|Placebo|
1608746|NCT02171793|Drug|BI 1744 CL|
1608747|NCT02171793|Drug|Placebo|
1608748|NCT02171780|Drug|BI 1744 CL|
1608749|NCT02171780|Drug|Placebo|
1608750|NCT02171767|Drug|BIBW 2992 MA2 - single rising dose|
1608751|NCT02171754|Drug|BIBW 2992|
1608752|NCT02171754|Drug|Ritonavir|
1608753|NCT02171741|Drug|BIBW 2992|continuous daily dosing for 20 or 13 days
1608754|NCT02171741|Drug|Docetaxel|single infusion on day 1
1608755|NCT02171728|Drug|BIBW 2992|
1608756|NCT02171715|Drug|BIBW 2992 MA2|film-coated immediate release tablet - final formulation
1608757|NCT02171715|Drug|BIBW 2992 MA2|film-coated immediate release tablet - trial formulation II
1608758|NCT02171715|Drug|BIBW 2992 MA2|powder for oral solution
1608759|NCT02171702|Drug|BIBW 2992|
1608760|NCT02171689|Drug|[14C]- BIBW 2992 MA2|
1608761|NCT02171676|Drug|Docetaxel|
1608762|NCT02171676|Drug|BIBW 2992|
1608763|NCT02171663|Drug|BIBW 2992|
1608764|NCT02171650|Drug|BIBW 2992|
1608765|NCT02171637|Drug|BIBW 2992|escalating doses
1608766|NCT02171624|Drug|dabigatran etexilate|
1608767|NCT02171624|Drug|quinidine|
1608768|NCT02171611|Drug|Dabigatran etexilate pellets|
1608769|NCT02171611|Drug|Dabigatran etexilate powder|
1608770|NCT02171611|Drug|Dabigatran etexilate capsule|
1608771|NCT02171598|Drug|Clopidogrel|
1608772|NCT02171598|Drug|Dabigatran high dose|
1608773|NCT02171598|Drug|Dabigatran low dose|
1608774|NCT02171585|Drug|Dabigatran etexilate|
1608775|NCT02171585|Drug|Clarithromycin|
1608776|NCT02171572|Drug|Dabigatran etexilate low|
1608777|NCT02171572|Drug|Dabigatran etexilate high|
1608778|NCT02171559|Drug|Enoxaparin prefilled syringes|
1608779|NCT02171559|Drug|Dabigatran etexilate capsules|
1608780|NCT02171546|Drug|Dabigatran etexilate capsules|
1608781|NCT02171546|Drug|Quinidine sulfate tablets|
1608782|NCT02171546|Drug|Fexofenadine tablets|
1608783|NCT02171533|Drug|dabigatran|
1608784|NCT02171533|Drug|Verapamil|
1608785|NCT02171533|Drug|Verapamil ER|
1608786|NCT02171520|Drug|Dabigatran etexilate generation I|
1608787|NCT02171520|Drug|Dabigatran etexilate generation II|
1608788|NCT02171507|Drug|Dabigatran etexilate|
1608789|NCT02171507|Drug|Diclofenac|
1608790|NCT02171494|Drug|IVAX Warfarin|
1608791|NCT02171494|Drug|BMS Coumadin|
1608792|NCT02171481|Drug|Dabigatran etexilate polymorph II|
1608793|NCT02171481|Drug|Dabigatran etexilate polymorph I|
1608794|NCT02171468|Drug|Dabigatran high dose|
1608795|NCT02171468|Drug|Dabigatran low dose|
1608796|NCT02171455|Drug|Dabigatran etexilate low dose|
1608797|NCT02171455|Drug|Dabigatran etexilate medium dose|
1608798|NCT02171455|Drug|Dabigatran etexilate high dose|
1608799|NCT02171455|Drug|Placebo|
1608800|NCT02171442|Drug|BIBR 953 ZW Intravenously|5 mg, 2.8 MBq (76 µCi)
1608801|NCT02171442|Drug|BIBR 1048 Oral Solution|200 mg free base, 2.8 MBq (76 µCi)
1608802|NCT02171429|Drug|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
1608803|NCT02171429|Other|Adalimumab Placebo|Placebo matched to adalimumab will be administered SC at Weeks 0, 2, 4, 6 and 8.
1608804|NCT02171429|Drug|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W).
1608805|NCT02171429|Other|Etrolizumab Placebo|Placebo matched to etrolizumab will be administered SC Q4W.
1608806|NCT02171416|Drug|Rilonacept|
1608807|NCT02171416|Drug|Placebo|
1608808|NCT02171390|Drug|Testosterone 250mg injection|The testosterone 250mg ester intramuscular injections performed in three weeks
1608809|NCT02171390|Drug|Testosteron 50 mg transdermal gel|50mg testosterone gel implemented on every night
1608868|NCT02170987|Drug|Placebo|
1608869|NCT02170974|Drug|BIBR 1048 MS polymorph II|
1608810|NCT02171377|Device|group 2 : quadricipital electrical stimulation|bilateral quadricipital electrical stimulation 5 sessions a week, (6 - 8 weeks)
1608811|NCT02171377|Other|pulmonary rehabilitation|exercise training, 3 to 5 times per week, 8 weeks
1608812|NCT02171377|Device|muscular electrical stimulation|Bilateral quadricipital electrical stimulation 30 min, 5 times per week, 8 weeks,in addition to pulmonary rehabilitation
1608813|NCT02171377|Other|pulmonary rehabilitation|exercise training, 45 min, 3 to 5 times per week, 8 weeks
1608814|NCT02171364|Procedure|Virtual ablation in based 3D CT of patient who diagnosed AF|
1608815|NCT02171364|Procedure|conventional ablation based on physician's personal experience|
1608816|NCT02171351|Device|effect of neuromuscular electrostimulation (NMES)|Each subject (type 2 diabetes and control) will be assessed with microneurography during a single session of neuromuscular electrostimulation (NMES).
1608817|NCT02171351|Device|effect of neuro electrostimulation (NES)|Each subject (type 2 diabetes and control) will be assessed with microneurography during a single session of neuro electrostimulation (NES)
1608818|NCT02171351|Other|effect of voluntary contractions (VC)|Each subject (type 2 diabetes and control) will be assessed with microneurography during a single session of voluntary contractions (VC)
1608819|NCT02171338|Other|PCT-level|PCT-level is available to the treating doctor.
1608820|NCT02171338|Behavioral|Antibiotic treatment based on PCT-level|"PCT-level is available to the treating doctor and the decision whether or not to treat with antibiotic is based on the level of PCT.
The type of antibiotic chosen to treat is based on the existing antibiotic treatment guidelines of Holbaek Hospital and includes the antibiotics listed above."
1608821|NCT02171325|Drug|irinotecan|60 mg/m2、65mg/m2、70mg/m2、75mg/m2、80mg/m2、85mg/m2、90mg/m2、95mg/m2、100mg/m2
1608822|NCT02171312|Device|iDETECT Assessment|The iDETECT device is an open platform for an evaluation of cognitive, balance, and oculomotor performance after mild traumatic brain injury (mTBI). It is a rugged, portable, neurocognitive assessment tool designed specifically for use in field and triage settings for the rapid evaluation of functional neurologic impairment after potential concussive injury. The apparatus includes an enhanced heads-up display visor with integration motion detection technology, noise-reducing headphones optimized with pink noise, and a handheld display for test battery administration, subject response inputs, and user data output. iDETECT will be used to assess multimodal neurologic function in participants.
1608823|NCT02171312|Behavioral|Routine Balance and Vestibular Testing|A clinician will assess balance and vision by standard of care routine tests for neurologic function.
1608824|NCT02171299|Procedure|Wound infiltration with local anaesthetic|
1608825|NCT02171299|Drug|Ropivacaine|
1608826|NCT02171273|Behavioral|Circadian Disruption|Following a baseline of adequate time in bed, study participants will spend 3 weeks on a daily jet-lag schedule (where each day is longer than 24 hours).
1608827|NCT02171273|Behavioral|Sleep Restriction|Following a baseline of adequate time in bed, study participants will have a shortened opportunity for sleep during each 24-hour day (for three weeks).
1608828|NCT02171273|Behavioral|Control|Following a baseline of adequate time in bed, study participants will continue to have adequate time in bed and opportunity for sleep during each 24-hour day, for 3 weeks.
1608829|NCT02171260|Drug|Eribulin Mesilate|Eribulin mesylate will be administered intravenously on Days 1 and 8 of each 21-day cycle.
1608830|NCT02171247|Drug|Isovue 370|Isovue 370 is a contrast agent with increased iodine concentration.
1608831|NCT02171247|Drug|Visipaque 320|Visipaque 320 is standard protocol.
1608832|NCT02171234|Drug|Placebo|
1608833|NCT02171234|Drug|BIA 2-093|
1608834|NCT02171221|Drug|Oral DFP-11207|
1608835|NCT02171208|Drug|dimethyl fumarate - Reference form|single dose 240 mg
1608836|NCT02171208|Drug|dimethyl fumarate - Test form|single dose 240 mg
1608837|NCT02171195|Drug|BIA 2-093|BIA 2-093 20mg, 50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 900 mg, 1200 mg
1608838|NCT02171195|Drug|Placebo|Identical placebo administered as oral tablets with 200 ml potable water.
1608839|NCT02171182|Drug|Qutenza|capsaicin patch
1608840|NCT02171156|Drug|nintedanib|soft gelatin capsule
1608841|NCT02171143|Drug|ASP2409|intravenous (IV)
1608842|NCT02171143|Drug|Placebo|intravenous (IV)
1608843|NCT02171130|Drug|3 mg glucagon powder|3 mg glucagon powder
1608844|NCT02171117|Procedure|microtransplantation|infusion of granulocyte colony stimulating factor (G-CSF) mobilized HLA-mismatched peripheral blood stem cells (GPBSC)
1608845|NCT02171117|Biological|HLA-mismatched donor peripheral stem cell infusion|
2010069|NCT03128307|Device|Zyppah Anti-snoring Appliance|Use of an OTC mouth guard at night to prevent snoring
2010070|NCT03127722|Procedure|Blood draw|Decision for either treatment will be based upon clinical practice and physician/patient counseling. In addition of routine care practice, blood draws will be performed at baseline and 12 months on subjects undergoing either an ESSURE procedure or a laparoscopic tubal sterilization
2010071|NCT03127722|Device|ESSURE (BAY1454032)|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol
2010072|NCT03127722|Procedure|Laparoscopic tubal sterilization|Decision for either treatment will be based upon clinical practice and physician/patient counseling, and will not be specified in the study protocol
2010073|NCT03126214|Drug|Anticoagulants|Anticoagulant therapy will be initiated/titrated in patients with atrial fibrillation in accordance with the Canadian Cardiovascular Society Guidelines for Atrial Fibrillation.
1608854|NCT02171065|Device|sham|
1608855|NCT02171065|Device|ABSORB BVS|
1608856|NCT02171052|Drug|Dabigatran etexilate|
1608857|NCT02171052|Drug|Digoxin|
1608858|NCT02171039|Drug|Dabigatran|
1608859|NCT02171039|Drug|Atorvastatin|
1608860|NCT02171026|Drug|Dabigatran etexilate|
1608861|NCT02171026|Drug|Amiodarone|
1608862|NCT02171013|Drug|Dabigatran polymorph I (≈ 83%) and polymorph II (≈17%)|
1608863|NCT02171013|Drug|Dabigatran polymorph I|
1608864|NCT02171000|Drug|BIBR 1048 MS|150 mg capsules, b.i.d, 7 days
1608865|NCT02170987|Drug|Dabigatran etexilate low|
1608866|NCT02170987|Drug|Dabigatran etexilate high|
1608867|NCT02170987|Drug|Moxifloxacin|
1608870|NCT02170974|Drug|BIBR 1048 MS polymorph I|
1608871|NCT02170948|Drug|Dexmedetomidine|An anesthetic concoction of 2% Lidocaine, 1% Ropivacaine, and Dexmedetomidine diluted solution will be provided via a series of anesthetic injections related to the ankle block procedure
1608872|NCT02170935|Drug|BIBR 1048 capsule|
1608873|NCT02170922|Drug|BIBR 1048 MS tablet|
1608874|NCT02170922|Drug|BIBR 1048 MS solution|
1608875|NCT02170909|Drug|BIBR 1048 MS low dose|
1608876|NCT02170909|Drug|BIBR 1048 MS medium dose|
1608877|NCT02170909|Drug|BIBR 1048 MS high dose|
1608878|NCT02170896|Drug|BIBR 1048 MS Capsule A|
1608879|NCT02170896|Drug|BIBR 1048 MS Capsule B|
1608880|NCT02170896|Drug|BIBR 1048 MS Capsule C|
1608881|NCT02170896|Drug|BIBR 1048 MS Capsule D|
1608882|NCT02170896|Drug|BIBR 1048 MS tartaric acid solution|
1608883|NCT02170896|Drug|Pantoprazole|
1608884|NCT02170883|Other|Interactive SMS|
1608885|NCT02170883|Other|Usual care|
1608886|NCT02170870|Drug|Exendin 9-39|Exendin 9-39 will be administered intravenously (1,200 pmol/kg bolus followed by infusion at 300 pmol/kg/min).
1608887|NCT02170870|Drug|Microlipid|Lipid infusion {66.7 mL Microlipid (0.5 gm/mL diluted in water to 222 ml).
1608888|NCT02170870|Drug|Placebo|Normal saline infusion will be prepared to match the appearance of Exendin 9-39
1608889|NCT02170857|Drug|Hyaluronic Acid|This material will be used in conjunction with the ordinary surgical procedure
1608890|NCT02170844|Drug|BIBR 1048 MS|
1608891|NCT02170844|Drug|Placebo of BIBR 1048 MS|
1608892|NCT02170831|Drug|BIBR 1048 MS low|
1608893|NCT02170831|Drug|BIBR 1048 MS medium 1|
1608894|NCT02170831|Drug|BIBR 1048 MS medium 2|
1608895|NCT02170831|Drug|BIBR 1048 MS high|
1608896|NCT02170831|Drug|BIBR 1048 MS placebo|
1608897|NCT02170818|Other|Educational Workshop on Speaking-Up|Educational workshop including lecture, discussion, role-play Concepts include: 2-challenge rule, pairing advocacy and inquiry
1608898|NCT02170818|Other|Unrelated Education (CPR)|Unrelated Education (CPR workshop) including: lecture, discussion Topics covered: Cardiac Life Support algorithms, CPR, Medications
1608899|NCT02170805|Drug|BIBR 1048 MS capsule formulation A|BIBR 1048 MS, formulation A 50 mg
1608900|NCT02170805|Drug|BIBR 1048 MS capsule formulation B|BIBR 1048 MS, formulation B 50 mg
1608901|NCT02170805|Drug|BIBR 1048 MS powder plus solution|BIBR 1048 MS, powder plus solution 50 mg
1608902|NCT02170805|Drug|Pantoprazole|Pantoprazole 40 mg
1608903|NCT02170792|Drug|BIBR 1048 MS|Low, medium or high dose
1608904|NCT02170792|Drug|Ranitidine|150mg
1608905|NCT02170779|Behavioral|Spasticity: Take Control|4 visits: baseline, view and discuss DVDs, practice stretching, outcome measures
1608906|NCT02170779|Other|Usual care|2 visits: baseline followed by usual care of brochure for stretching then outcome measures
1608907|NCT02170766|Drug|BIBR 1048 low1|
1608908|NCT02170766|Drug|BIBR 1048 low2|
1608909|NCT02170766|Drug|BIBR 1048 medium|
1608910|NCT02170766|Drug|BIBR 1048 high|
1608911|NCT02170766|Drug|Pantoprazole|
1608912|NCT02170753|Procedure|Regional manual therapy|The experimental group will receive regional thoracic, pelvic, and hip manual therapy and a standard physical therapy approach including motor control exercise and local lumbar spine manual therapy.
1608913|NCT02170753|Procedure|Standard physical therapy|The control group will receive standard physical therapy including motor control exercise and local lumbar spine manual therapy.
1608914|NCT02170740|Drug|BIBR 1048 MS - low dose|
1608915|NCT02170740|Drug|BIBR 1048 MS - high dose|
1608916|NCT02170740|Drug|BIBR 1048 MS + Pantoprazole|
1608917|NCT02170727|Drug|DCV/ASV/BMS-791325|
1608918|NCT02170714|Other|Clinical and laboratory assessment|Clinical assessment through PUCAI and laboratory data (Erythrocyte Sedimentation Rate, C-Reactive Protein, hemoglobin, albumin, hematocrit, ferritin) were recorded at admission and at day 3 and 5. All patients were treated according to the 2011 ECCO-ESPGHAN guidelines for ASC: all patients received intravenous (iv) corticosteroids (methylprednisolone 1.5-2 mg/Kg/day) for 5 days. Patients not responding to corticosteroids (i.e. PUCAI>65 at day 5) started Infliximab (IFX, 5 mg/Kg 0,2,6 then every 8 weeks) as second-line therapy. All therapies were decided at the discretion of the referral gastroenterologist and recorded on standardized case report forms
1608919|NCT02170701|Drug|BIBR 1048|Ascending doses (in mg) given twice daily
1608920|NCT02170688|Drug|Isovue 370|All contrast media doses administered for this study are within the FDA approved dose range in the package insert.
1608921|NCT02170688|Other|Weight calculation|
1608922|NCT02170675|Drug|Dabigatran etexilate|
1608923|NCT02170675|Drug|Ketoconazole|
1608924|NCT02170662|Drug|Bimatoprost|Bimatoprost 0.03% ophthalmic solution as purchased from the manufacturer will be the active drug.
1608925|NCT02170662|Drug|Placebo|
1608926|NCT02170649|Drug|BIA 2-093|
1608927|NCT02170636|Drug|BIBR 1048 MS Capsule E|50 mg BIBR 1048 MS
1608928|NCT02170636|Drug|BIBR 1048 MS Capsule F|50 mg BIBR 1048 MS
1608929|NCT02170636|Drug|BIBR 1048 MS Capsule G|50 mg BIBR 1048 MS
1608930|NCT02170636|Drug|BIBR 1048 MS Tablet H|50 mg BIBR 1048 MS
1608931|NCT02170636|Drug|BIBR 1048 MS Drinking solution|50 mg BIBR 1048 MS tartaric acid solution
1608932|NCT02170636|Drug|Pantoprazole|40 mg Pantoprazole
1608933|NCT02170623|Drug|BIBR 1048 MS Capsule I|25 mg BIBR 1048 MS
1608934|NCT02170623|Drug|BIBR 1048 MS Capsule K|50 mg BIBR 1048 MS
1608935|NCT02170623|Drug|Pantoprazole|40 mg pantoprazole
1608936|NCT02170623|Drug|BIBR 1048 MS drinking solution|50 mg BIBR 1048 MS powder plus solution
1608937|NCT02170610|Drug|BIBR 1048 MS|
1608938|NCT02170610|Drug|Pantoprazole|
1608939|NCT02170597|Drug|BIBR 1048 MS HPMC capsule|
1608940|NCT02170597|Drug|BIBR 1048 MS gelatine capsule|
1608941|NCT02170584|Drug|BIBR 953 ZW IV|
1608942|NCT02170584|Drug|BIBR 1048 MS tablet|
1608943|NCT02170584|Drug|BIBR 1048 MS oral solution|
1608944|NCT02170584|Drug|BIBR 953 ZW IV Placebo|
1608945|NCT02170571|Drug|Dabigatran etexilate|
1608946|NCT02170558|Device|TM- Ardis implant and Metal Reduction CT software|TM- Ardis implant and Metal Reduction CT software
1608947|NCT02170545|Other|Dual Energy Computed Tomography|A Dual Energy Computed Tomography scan will be performed on both upper arms.
1608948|NCT02170532|Drug|levalbuterol|0.5 ml. levalbuterol
1608949|NCT02170532|Drug|saline|0.5ml saline
1608950|NCT02170532|Other|levalbuterol MDI|
1608951|NCT02170532|Device|breath actuated nebulizer|
1608952|NCT02170532|Device|aerochamber max|
1608953|NCT02170532|Drug|ipratroprium|
1608954|NCT02170519|Drug|Inhaled Iloprost|A 20 mcg dose of Iloprost will be given initially.
1608955|NCT02170506|Device|Urostim 2 stimulation|Sensory transcutaneous electrical stimulation will be started for a period of 20 minutes. It is applied by means of two surface electrodes placed under chin stimulation of both sides of the center line of the preceding side. Sensory transcutaneous electrical stimulation will inhibit the cerebral control of swallowing.
1608956|NCT02170467|Other|assessment of the intestinal permeability|
1608957|NCT02170454|Procedure|magnetic stimulation|rTMS on pharyngeal cortical area in healthy subjects or sham rTMS on pharyngeal cortical area in healthy subjects
1608958|NCT02170415|Drug|Protective analgesia|"Participants in the intervention arm of the study (if no contraindications exist) will be administered one pre-procedure dose of 150mg of oral pregabalin.
For a total of five days post-procedure the participants in the intervention limb of the study will take oral pregablin twice daily at a dose of 75mg twice a day."
1608959|NCT02170415|Other|Pain education|Participant will receive a pain education leaflet
1608960|NCT02170415|Behavioral|Psychological support|Participants demonstrating psychological morbidity will be offered psychological support prior to surgery
1608961|NCT02170415|Procedure|Paravertebral block/local anaesthetic infiltration|Patients on the intervention limb will be encouraged to have a paravertebral block if not contraindicated
1608962|NCT02170415|Other|Daily visits from pain team whilst in hospital|
2010074|NCT03123874|Device|Sterile pump|Medela symphony breast pump (model number 0240108) and sterile collection kits (model number 6007092).
1608964|NCT02170389|Other|Laboratory Biomarker Analysis|Correlative studies
1608965|NCT02170389|Procedure|Nephrectomy|Undergo partial or radical nephrectomy
1608966|NCT02170389|Biological|Renal Cell Carcinoma/CD40L RNA-Transfected Autologous Dendritic Cell Vaccine AGS-003|Given ID
1608967|NCT02170376|Drug|BIA 9-1067|BIA 9-1067 25 mg and 50 mg
1608968|NCT02170376|Drug|Entacapone|Entacapone (ENT), over-encapsulated tablet 200 mg
1608969|NCT02170376|Drug|Placebo|PLC, placebo
1608970|NCT02170376|Drug|Levodopa/carbidopa|Levodopa/carbidopa, tablet 100/25 mg
2010075|NCT03123874|Device|Mom's own pump|Mom's own pump and mom's own collection kit.
2010076|NCT03123874|Other|Home storage|One ounce of human milk will be collected from each pumping session and stored at home for 0, 2, 4, and 30 days after pumping.
2010077|NCT03122912|Dietary Supplement|Fish Oil|Capsules contain omega-3 fatty acids (fish oil). Dosage of 3180 mg of omega-3 fatty acids will be taken orally daily up to 16 weeks.
1608975|NCT02170337|Drug|AMG 282|AMG 282 is for the treatment of subjects with chronic rhinosinusitis with nasal polyps
1608976|NCT02170337|Drug|Placebo|Contains no active drug
1608977|NCT02170324|Drug|Exenatide|
1608978|NCT02170324|Drug|Placebo|
1608979|NCT02170311|Drug|Z-213|
1608980|NCT02170298|Drug|Lisdexamfetamine|Participants will be given either the study drug or placebo in tablet form. All participants will start with a 20 mg dose and will be titrated up to a 70 mg daily dose over 9 weeks. Participants between 12-18 years of age will be titrated in 10 mg increments and participants between 18-25 years of age in 10-20 mg increments.
1608981|NCT02170285|Device|Interventional TDCS|The primary intervention will be cathodal (inhibitory) tDCS over non-lesioned M1. This will be targeted using TMS baseline mapping data and neuronavigation (Brainsight2, Rogue Research, Montreal) individualized to the subjects MRI. Soft, replaceable 25cm2 electrodes will be placed over clean, dry scalp with the cathode over marked M1 and the reference electrode over contralateral forehead/orbit consistent with standard protocols. The current-controlled DC stimulator (neuroConn GmbH, Ilmenau, GE) will be turned up slowly over 30 seconds to the treatment current of 1.0 mA. TDCS will be administered each day during the first 20 minutes of the 90 minute therapy session. Child, family, and both treating and measuring occupational therapists are blinded to treatment allocation.
1608982|NCT02170285|Device|Sham TDCS|Sham subjects will undergo exactly the same tDCS protocol as outlined above. This includes the initial stimulation sequence, generating the initial transient scalp sensations identical to the treatment group. The stimulator will be programmed by the technologist to automatically ramp down to off over 30 seconds after 120 seconds of stimulation.
1608983|NCT02170272|Behavioral|Home-based Lymphedema Care Program|Undergo HBLCP
1608984|NCT02170259|Other|The suboccipital technique|"The suboccipital technique (ST) aims to release the spasm of the muscles affected in tension-type headaches and in general of suboccipital soft tissues, as they are responsible for the mobility dysfunction of the occiput-atlas-axis joint; this releases the facial restriction of this region. Patients lied on the stretcher, in supine position, with their occiput resting against the physiotherapist's hands. Fingertips slide until contacting the posterior arch of atlas so that it hangs from the fingers. A deep and progressive pressure is applied, perpendicularly to muscle fibers, until the therapist perceives that muscle tone decreases. Approximate duration of ST is 10 minutes and it is performed with patients' eyes closed because of the connection between craniocervical muscle tone and eye movements"
1608985|NCT02170259|Other|The articulatory technique|The articulatory technique (AT) was administered to correct and restore the mobility of joints between occiput, atlas and axis - correcting a global joint dysfunction. This technique was performed in supine position, in the same manner as the preceding technique, bilaterally and in two phases. First, a gentle head decompression is applied, followed by small circumduction searching for the joint barrier in rotation through selective tension. Second, the manipulation is performed by a cranial rotation towards the same side as the circumduction and around a vertical axis passing through the axis, without cervical flexion or extension and very little bending
1609240|NCT02168530|Drug|placebo|matching placebo administered daily orally
1608986|NCT02170259|Other|Combined treatment|Combined treatment (ST and AT). Combination treatment consisted of the application of the two preceding treatments in the same sequence: first, treatment with ST and then AT, thereafter maintaining the resting position for five minutes
1608987|NCT02170246|Drug|Telmisartan|
1608988|NCT02170220|Drug|Vortioxetine|Vortioxetine tablets
1608989|NCT02170207|Drug|Lansoprazole|Lansoprazole 30 mg injection
1608990|NCT02170194|Behavioral|Resilience Enhancement Training via Smart Phone|
1608991|NCT02170194|Behavioral|Daily Text Messages|
1608992|NCT02170181|Radiation|SBRT|SBRT to Oligometastases
1608993|NCT02170168|Other|integrated palliative care program|a standardised care pathway, an educational programme and information to general public, patients and their carers
1608994|NCT02170142|Device|MRI|non-invasive MRI techniques (DTI) and (ASL) will be used to assess normal brain development. DTI is capable of invasively delineating macroscopic anatomic components with high contrast and revealing structures at the microscopic level. ASL is capable of measuring cerebral blood flow and cerebral metabolic rate of oxygen.
1608995|NCT02170129|Device|50% AAB plus 50% autologous bone|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).
A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later.
Both groups received tapered implants with an anodised surface."
1608996|NCT02170129|Device|100% AAB|"All patients were evaluated clinically and their medical histories were recorded. Preliminary screening, including the acquisition of intraoral and panoramic radiographs, was performed to evaluate potential patients' eligibility. Patients who met the selection criteria received oral hygiene instructions and debridement, if required, after which bone volumes were analysed using cone-beam computed tomography (CBCT; Imaging Sciences International, Hatfield, PA, USA).
A staged approach was carried out at all sites. Thus, sinus lift grafting procedures were followed by implant placement 7-8 months later. Both groups received tapered implants with an anodised surface."
1608997|NCT02170116|Drug|BIBR 1048 MS dose 1|
1608998|NCT02170116|Drug|BIBR 1048 MS dose 2|
1608999|NCT02170116|Drug|BIBR 1048 MS dose 3|
1609000|NCT02170116|Drug|BIBR 1048 MS dose 4|
1609001|NCT02170116|Drug|BIBR 1048 MS dose 5|
1609002|NCT02170116|Drug|Placebo to BIBR 1048 MS|
1609003|NCT02170103|Procedure|percutaneous intervention (PCI)|
1609004|NCT02170103|Drug|Microbubbles|The agents will be divided into two separate doses (two vials per study), and mixed with approximately 29 milliliters of saline (approximately a 2.0-4.0% infusion). The first dilution will be administered pre PCI therapy, and the second dilution infused immediately post PCI. Since Optison is less stable in saline, an alternative approach will be to give the Optison as intermittent 0.1 milliliter boluses followed by 3-5 saline flushes over 10 seconds. The entire duration of each treatment before PCI will be up to 30 minutes depending on time constraints in getting to the catheterization laboratory, while the duration of treatment immediately after PCI will be 30 minutes.
1609005|NCT02170103|Procedure|Ultrasound|Intermittent high MI (Mechanical Index) impulses (0.8-1.4 MI; Frequency 1.0-1.7 MHz;pulse duration 4-44 microseconds) will be administered over the microvasculature where there are wall motion abnormalities and a perfusion defect using an imaging plane that best aligns itself with the risk area
2010078|NCT03122912|Dietary Supplement|Soybean Oil|Dosage will be 3000 mg of soybean oil taken orally daily for up to 16 weeks.
1609009|NCT02170077|Drug|BIA 2-093|BIA 2-093 (tablets) administered at increasing daily doses of 400 mg, 800 mg and 1200 mg once-daily or twice-daily, oral route
1609010|NCT02170077|Drug|Placebo|Placebo tablets administered orally
1609011|NCT02170064|Drug|BIA 2-093 (Eslicarbazepine acetate)|Eslicarbazepine acetate administered at increasing daily doses of 5 mg/kg, 15 mg/kg, and 30 mg/kg (or 1800 mg, whichever less); once-daily; oral route
1609014|NCT02170038|Drug|Microgynon|Subjects will receive 21 daily oral doses of Microgynon tablets containing 0.15 mg levonorgestrel und 0.03 mg ethinylestradiol.
1609015|NCT02170038|Drug|Noristerat(BAY86-6308)|Subjects will receive one intramuscular dose of Noristerat (oily solution for intramuscular injection) containing 200 mg norethisterone enantate.
1609016|NCT02170025|Drug|Riociguat (Adempas, BAY63-2521)|Pat 1: The patients will receive 0.5 mg three times a day for the initial 14 days and a 1 mg for the second 14 days.
1609017|NCT02170025|Drug|Placebo|Part 1: Placebo tablet, three times a day for duration of 28 days
1609018|NCT02170025|Drug|Riociguat (Adempas, BAY63-2521)|Part 2: Patients not on Orkambi therapy will receive 0.25 mg BAY63-2521 tid for 14 days, increasing to 0.5 mg, 1 mg and 2 mg for 14 days each.
1609019|NCT02170025|Drug|Riociguat (Adempas, BAY63-2521)|Part 2: Patients receiving Orkambi therapy for at least 3 months as their standard of care will receive 0.25 mg BAY63-2521 tid for 14 days, increasing to 0.5 mg, 1 mg and 2 mg for 14 days each.
1609020|NCT02170012|Drug|PF-06743649|20 mg tablet once daily dosing for 14 days
1609021|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
1609022|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
1609023|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
1609024|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
1609025|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
1609026|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
1609027|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
1609028|NCT02170012|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
1609029|NCT02170012|Drug|Placebo|Placebo tablet once daily dosing for 14 days
1609074|NCT02169765|Other|Radiofrequency ablation|Radiofrequency ablation is performed in less than one week after clinical diagnosis.
1609030|NCT02169999|Other|Personalized Diabetes Care Website|Subjects enrolled in the intervention view the Personalized Diabetes Care website and enter their self-reported medical history and personal preferences into the website. A model runs and creates a 2 page print out with risk estimates for the subject to review with their physician.
1609031|NCT02169986|Behavioral|electronic reminders|
1609032|NCT02169973|Drug|JNJ-42165279|Participants will receive oral suspension of JNJ-42165279 in Part B as single dose on Day 1 (100 mg) and on Day 8 (up to 250 mg); in Part C as once daily dose (up to 100 mg) from Day 1 to Day 7.
1609033|NCT02169973|Drug|11C-MK-3168|Participants will receive 11C-MK-3168 in the target range of 185 to 370 megabecquerel (MBq) intravenously (into a vein) before every positron emission tomography scan in Parts A, B, and C.
1609034|NCT02169960|Behavioral|Smart, Positive, Active, Realistic X-factor thoughts (SPARX)|Cognitive Behavioral Therapy based online intervention for depression
1609035|NCT02169960|Behavioral|Breaking Free|Online based intervention for Drug and Alcohol Use
1609036|NCT02169960|Behavioral|This Way Up|Cognitive Behavioral Therapy online intervention for Depression and Anxiety
1609037|NCT02169960|Behavioral|Resiliency Training|Op Volle Kracht (OVK)
1609038|NCT02169947|Behavioral|Weight loss core|The weight loss core is a culturally adapted version of the Diabetes Prevention Program core 16 week session program.
1609039|NCT02169947|Behavioral|Weight loss core plus maintenance|The intervention is a culturally adapted version of the Diabetes Prevention Program core 16 sessions plus 12 maintenance sessions.
1609040|NCT02169934|Drug|Radiolabeled TRV130|A single 2 mg IV dose administered as a 10 mL manual IV push over 2 minutes
1609041|NCT02169921|Device|Atherectomy Catheter|"Atherectomy Catheter, TurboHawk, is used for Angioplasty. Spider FX can concomitantly be used with TurboHawk.
TurboHawkTM LS-C, TurboHawk LX-C, TurboHawk SS-CL and TurboHawk SX-C are paticipated in this arm."
1609042|NCT02169908|Device|Thermotest|
1609043|NCT02169908|Device|von Frey hairs|
1609044|NCT02169895|Drug|BIA 9-1067|
1609045|NCT02169895|Drug|Placebo|
1609046|NCT02169895|Drug|Prolopa®|levodopa/benserazide 100/25 mg
1609047|NCT02169882|Drug|Placebo|"Patients receiving 450 mg rifampicin will receive additional 2 placebo tablets, while those who receive 900 mg rifampicin will receive 1 placebo tablet.
Patients receiving 1350 mg rifampicin will not receive any placebo tablet.
With this arrangement, every subject will receive 3 tablets of study drugs."
1609048|NCT02169882|Drug|Rifampicin|"Patients in experimental arms will receive either 1 or 2 additional tablets of rifampicin.
Placebo tablets will be added accordingly, so that every study subject will receive 3 tablets of rifampicin plus placebo as described in the Arms section."
1609049|NCT02169882|Drug|Other TB drugs|"Along with study drug and placebo, patients will receive other oral TB drugs (INH, Ethambutol, and Pyrazinamide) and pyridoxin, in accordance to National TB Program guidelines for 6 months.
Unconscious subjects will receive oral drugs via nasogastric tubes (NGT)"
1609050|NCT02169882|Drug|Adjuvant dexamethasone|Patients will receive dexamethasone in decreasing dose (in 6-8 weeks, according to TBM severity grade on admission)
2010079|NCT03122730|Combination Product|VentaProst|Part I - an equivalent dose of VentaProst compared to conventionally-administered aerosolized epoprostenol with subsequent dose titration to achieve a clinically significant hemodynamic response Part II - Dose titration to achieve a clinically significant hemodynamic response.
2010080|NCT03122717|Drug|Gerfitinib|gefitinib is a EGFR inhibitors
1609053|NCT02169856|Behavioral|EFTs (emotional freedom techniques)|The Emotional Freedom Techniques (EFTs) which has been pioneered by Gary Craig is a form of alternate medicine which works by tapping on body energy meridian points. Unlike drugs the EFTs has no side effects too
1609054|NCT02169856|Drug|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
1609055|NCT02169856|Drug|Inj. Midazolam 0.7mg/kg|Inj . Midazolam 0.7 mg/kg given as premedication 45 min before surgery.
1609056|NCT02169856|Drug|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
1609057|NCT02169856|Drug|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia
1609058|NCT02169856|Drug|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
1609059|NCT02169856|Drug|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
1609060|NCT02169856|Drug|Drug: Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period
1609061|NCT02169856|Drug|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
1609062|NCT02169843|Drug|Sevoflurane|inhale Sevoflurane
1609063|NCT02169843|Drug|Dexmedetomidine|intravenous pumping Dexmedetomidine 0.2µg/kg/h
1609064|NCT02169843|Drug|Placebo(for Dexmedetomidine)|normal saline mimic Dexmedetomidine, intravenous pumping 0.05ml/kg/h
2010081|NCT03122717|Drug|Osimertinib|An orally available, irreversible, third-generation, mutant-selective epidermal growth factor receptor (EGFR) inhibitor
2010082|NCT03123120|Drug|BI 655130|12 weeks treatment
1609067|NCT02169817|Drug|Bacillus clausii|Pharmaceutical form:aqueous suspension Route of administration: oral
1609068|NCT02169817|Drug|Oral Rehydration Therapy|Pharmaceutical form:vials/sachets for solution Route of administration: oral
1609069|NCT02169804|Drug|Androxal 25 mg|
1609070|NCT02169791|Drug|MLN9708|MLN9708 will be given weekly x 3 weeks every 28 day cycles, for up to 12 cycles starting at D+5 post-transplant.
1609071|NCT02169778|Behavioral|Intermittent energy restricted diet|
1609072|NCT02169778|Behavioral|Continuous energy restricted diet|
1609073|NCT02169765|Other|Hepatic resection|Adequate remnant liver volume was 30% for HCC patients without cirrhosis, and >50% for HCC patients with chronic hepatitis, cirrhosis, or severe fatty liver.
1609241|NCT02168530|Drug|vismodegib|vismodegib 150 mg administered daily orally
2010083|NCT03123120|Drug|Placebo|12 weeks treatment
2010084|NCT03122288|Behavioral|Individualized Cognitive Training|These are specific computerized exercises that are designed to improve performance in particular cognitive domains (e.g., attention, speed of processing, verbal learning/memory).
1609075|NCT02169752|Drug|Ambrisentan|"Subjects will be randomized 1:1 ratio according to computer generated random numbers to receive either placebo or ambrisentan 5mg daily for one month followed by 10 mg daily for the 5 months in a double-blinded manner."
1609077|NCT02169726|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy Imaging measure blood flow,oxygen, temperature in back muscle when they are treated with therapeutic ultrasound and can improve the treatment
1609078|NCT02169713|Drug|Mirabegron|Oral
1609079|NCT02169713|Drug|Solifenacin succinate|Oral
1609080|NCT02169713|Drug|Tamsulosin HCl|Oral
1609081|NCT02169713|Drug|Placebo|Oral
1609082|NCT02169700|Procedure|Ischemic compression. Dry Needling|Ischemic compression was carried out after dry needling. Dry needling was performed with a solid filament needle. Subjects were asked to lie in a prone position. The MTrP was held firmly in a pincer grasp. Before inserting the needle, the patient was advised about the possible sharp pain and muscle twitching. The needle was inserted perpendicular to the skin. Then, the muscle fibers were repeatedly perforated by rapidly inserting and partially withdrawing the needles from the MTrP until two local twitch responses were elicited from the muscle. On removal of the needle, the area was compressed firmly with a cotton bud for two minutes. Immediately after the needling, subjects were randomly assigned to one of three groups (IC, sham and control).
1609083|NCT02169687|Device|HIFU|High Intensity focalized Ultrasounds
1609084|NCT02169661|Other|Burger and Beetroot Study|50% fat, 10% beetroot extract
1609085|NCT02169648|Drug|ranibizumab|intravitreal injection of 0.50 mg (0.05ml) ranibizumab monthly as needed.
1609086|NCT02169635|Procedure|macular buckle|macular buckle with a three-armed silicone capsule
1609087|NCT02169609|Drug|Dinutuximab. Immunotherapy|"Patients will receive 5 courses of Dinutuximab + GM-CSF + IL2 at intervals of 28 days for all courses. In addition, all patients will receive isotretinoin (13-cis-retinoic acid, or RA) at 160 mg/m2/dose twice a day for 14 days every 28 days, for 6 courses.
Patients come off study if progressive disease develops at any time after cycle 1 or life-threatening grade 4 toxicity occurs clearly attributable to Immunotherapy."
1609088|NCT02169596|Other|Blood Test|Blood tests taken for flow cytometry
1609089|NCT02169596|Other|EndoPAT - endothelial assessment|
1609090|NCT02169583|Drug|GSK1325756 Solution|Solution containing 2 mg/mL GSK1325756 in sterile water for injection, to be administered intravenously.
1609091|NCT02169583|Drug|GSK1325756 Solution Matching Placebo|Solution containing sterile water for injection matching GSK1325756 solution, to be administered intravenously.
1609092|NCT02169583|Drug|GSK1325756 Tablet|A white film coated tablet containing 50 mg GSK1325756 to be administered orally.
1609093|NCT02169583|Drug|GSK1325756 Tablet Matching Placebo|A white film coated tablet matching GSK1325756 tablet, to be administered orally.
1609094|NCT02169570|Dietary Supplement|Vitamin D|
1609095|NCT02169570|Dietary Supplement|Calcium|
1609096|NCT02169570|Dietary Supplement|Placebo Vit D|
1609097|NCT02169570|Dietary Supplement|Placebo Calcium|
1609098|NCT02169557|Drug|Fexinidazole|
1609099|NCT02169544|Drug|Abatacept|
1609100|NCT02169531|Drug|ex vivo Activated Immune Cells|The patients who take medication before the enrollment will be required to reduce at least half the amount of the medication before the treatment. The reduction of the medication will continue during and after the therapy until the levels of plasma hemoglobin A1c (HbA1c) increase to equal or above the levels of the baseline measured before the treatment.
1609101|NCT02169505|Drug|Brentuximab Vedotin|Starting dose: 1.2 mg/kg by vein on Day 1 for the first 2, 21 day cycles. Dose increased to 1.8 mg/kg by vein after the second cycle for all subsequent cycles.
1609102|NCT02169479|Drug|BIA 9-1067|OPC, Opicapone
1609103|NCT02169479|Drug|Placebo|PLC, Placebo
1609104|NCT02169479|Drug|Sinemet® 100/25|Immediate-release levodopa/carbidopa 100/25 mg
1609105|NCT02169466|Drug|BIA 9-1067|OPC, Opicapone
1609106|NCT02169466|Drug|Placebo|PLC, Placebo
1609107|NCT02169466|Drug|Madopar® HBS|controlled-release levodopa 100 mg/benserazide 25 mg
1609108|NCT02169453|Drug|BIA 9-1067|OPC, Opicapone
1609109|NCT02169453|Drug|Placebo|PLC, Placebo
1609110|NCT02169453|Drug|Sinemet® CR 100/25|Controlled-release levodopa/carbidopa 100/25 mg
1609111|NCT02169440|Drug|BIA 9-1067|BIA 9-1067 25 mg
1609112|NCT02169440|Drug|Warfarin|Warfarin 25 mg
1609113|NCT02169427|Drug|OPC|The drug substance of 100 mg OPC was administered as 1 capsule.
1609114|NCT02169414|Drug|BIA 9-1067 5 mg|OPC, Opicapone
1609115|NCT02169414|Drug|BIA 9-1067 25 mg|OPC, Opicapone
1609116|NCT02169414|Drug|levodopa/carbidopa 100/25|immediate (standard) release levodopa/carbidopa 100/25
1609117|NCT02169414|Drug|Placebo|PLC, Placebo
1609118|NCT02169414|Drug|levodopa/benserazide 100/25 mg|immediate (standard) release levodopa/benserazide
1609119|NCT02169401|Device|Implantation with the commercially available Axium Neurostimulator|
1609120|NCT02169388|Drug|Probiotic|Microbial composition using probiotic
1609121|NCT02169388|Drug|placebo（for probiotic）|microbiota modulation using placebo
1609122|NCT02169375|Other|Brain computer Interface Mu (SMR) rhythm|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 10 sessions.
1609123|NCT02169362|Device|Autologous Platelet Rich Plasma (PRP) Gel (Magellan® Bio-Bandage™)|Application of up to 18 mL of autologous PRP gel (Magellan® Bio-Bandage™) to the surface of an acute deep partial thickness burn wound no greater than 72 cm squared within 72 hours of the initial injury. Intervention is in addition to standard of care treatment. The PRP Bio-Bandage™ is prepared using the Magellan® System and is FDA cleared via BK030040 and BK040068.
1609124|NCT02169349|Other|laboratory biomarker analysis|
1609125|NCT02169349|Other|Next Generation Sequencing|
1609126|NCT02169349|Genetic|DNA Analysis|
1609127|NCT02169336|Drug|Intranasal Dexmedetomidine|
1609128|NCT02169336|Other|Intranasal Placebo|
1609129|NCT02169323|Other|Step-down|Step-down of the inhaled corticosteroid (ICS) dose until discontinuation for 6 months
1609130|NCT02169297|Procedure|Ultrasound-guided Sub-Paraspinal Block|Treatment group received bilateral ultrasound-guided placement of multi-perforated soaker catheter at sub-paraspinal location. Catheter position was considered adequate when live ultrasound imaging confirmed placement directly over the rib surface and lateral to the transverse process at the T2-T10 level. An infusion of ropivacaine 0.2% was started via the On-Q infusion system at a rate of 0.25 mg/kg/hour per catheter (maximum of 8 ml/hr catheter [maximum pump infusion rate]). The local anesthetic infusion was stopped on post-operative day number 3 and the catheters removed.
1609131|NCT02169297|Procedure|PCA only|Patients received intravenous PCA post-operatively
1609132|NCT02169284|Drug|Erlotinib Hydrochloride|Given PO
1609133|NCT02169284|Other|Laboratory Biomarker Analysis|Correlative studies
1609134|NCT02169284|Other|Pharmacological Study|Correlative studies
1609135|NCT02169284|Other|Placebo|Given PO
1609136|NCT02169284|Other|Quality-of-Life Assessment|Ancillary studies
1609137|NCT02169284|Procedure|Therapeutic Conventional Surgery|Undergo TURBT or cystectomy
1609141|NCT02169258|Procedure|Systemic Strategy|Significant CAD needing further revascularization is defined as patients who have luminal stenosis > 70% of the major epicardial vessels and bypass graft vessel or their major branches (> 50% for left main trunk or in-stent restenotic lesion) with reference vessel larger than 2.5 mm in diameter and moderate area of vulnerable myocardium for ischemia. Intermediate stenotic lesions should be determined if they are hemodynamic significant by fractional flow reserve (FFR) (<=0.8). The choice of revascularization procedure, either percutaneous coronary intervention or coronary artery bypass surgery, depends on operator's or cardiovascular team's suggestion and patient's decision.
1609142|NCT02169245|Other|Dietary control of protein and fiber intake at breakfast|Participants will be provided breakfast meals for 4, 2 week long interventions. The intervention arms are 1) average protein and fiber, 2) average protein and high fiber, 3) high protein and average fiber, and 4) high protein and fiber.
1609143|NCT02169232|Device|Videolaryngoscope|
1609144|NCT02169232|Device|Fiberoptic|
1609145|NCT02169219|Drug|Glucocorticoids|"Patients will begin prednisone therapy at a dose selected by the investigator or the treating physician with oral prednisone 60mg or 1mg/kg (if weight less than 60kg) or intravenous methylprednisolone, up to 1g/day for three days.
Prednisone will be tapered over 8 weeks as follows:
60mg for 2 weeks
40mg for 2 weeks
30mg for 1 week
20mg for 1 week
10mg for 1 week
5mg for 1 week"
1609146|NCT02169219|Drug|Rituximab|Rituximab will be administered in four weekly doses at 375mg/m2
1609147|NCT02169206|Radiation|Bilateral shoulder anteroposterior radiography|"Patient standing with the tube in front and 105 cm far from the shoulder radiating perpendicular to the cassette in the back, both arms hanging aside the trunk in 0 degrees of arm abduction, 0 degrees of rotation and 0 degrees of extension with the thumb facing forward to obtain true bilateral shoulder anteroposterior view. Voltage and exposure time differs regarding each person's body mass.
In the same position, the patient only elevates the arm up to 90 degrees of abduction."
1609148|NCT02169193|Radiation|99mTc-Rhenium Sulfide Nanocolloid|12 MBq of NanoCis added to 500 ml of enteral feeding
1609149|NCT02169180|Drug|Ibrutinib|Participants will receive ibrutinib capsules 560 milligram (mg) orally, once daily on a 28-day cycle up to 7 cycles or until disease progression (or relapse if the participant achieved a complete response [CR]), unacceptable toxicity, or end of treatment, whichever occurs first.
1609150|NCT02169167|Device|Resin salve treatment|Resin is collected in the municipality of Kolari, Finland, from the trunks of full-grown Norway spruce (Picea acies) trees. Bark and other impurities are removed mechanically. The resin is then liquefied and purified by filtering. Resin salve is composed of a 10% (w/w) mixture of purified spruce resin in a standardized salve base. None of the components of the salve base have antibacterial properties. Resin salve is produced from the pure resin to the final product in accordance with the Good Manufacturing Standards (GMP) and it holds the European CE mark (Abilar 10% Resin Salve, Repolar Ltd., Espoo, Finland, CE 0537).
1609151|NCT02169167|Device|Octenidine treatment|Octenidine dihydrochloride is a cationic surfactant and bis-(dihydropyridinyl)-decane derivative, used in concentrations of 0.1-2.0%. It is similar in its action to the quaternary ammonium compounds, but is of somewhat broader spectrum of activity. Octenidine is currently increasingly used in continental Europe as a substitute for quats or chlorhexidine (with respect to its slow action and concerns about the carcinogenic impurity 4-chloroaniline) in water- or alcohol-based skin, mucosa and wound antiseptics. In aqueous formulations, it is often potentiated with addition of 2-phenoxyethanol.
1609152|NCT02169154|Drug|1% Diclofenac Sodium|1% diclofenac sodium
1609153|NCT02169154|Drug|3% Menthol|3% Menthol
1609154|NCT02169154|Drug|0.09% Menthol|0.09% Menthol
1609155|NCT02169154|Drug|0.2% Sodium Lauryl Sulfate|0.2% Sodium Lauryl Sulfate
1609156|NCT02169154|Drug|0.9% Saline|0.9% Saline
1609157|NCT02169141|Other|Pharmacokinetics|multiple blood samples are obtained by means of an indwelling intravenous catheter for calculating PK parameters
1609158|NCT02169115|Drug|Omalizumab|150mg, s.c., every 4 weeks
1609159|NCT02169115|Drug|Omalizumab|300mg, s.c., every 4 weeks
1609160|NCT02169115|Drug|Placebo|Placebo, s.c., every 4 weeks
1609161|NCT02169102|Other|No additional Intervention (control)|No additional intervention previously to the urgency endodontic treatment (Control)
1609162|NCT02169102|Radiation|Sham Laser Irradiation|Fifteen minutes previously the urgency endodontic treatment, sham laser irradiation was performed in the tooth with irreversible inflammation in pulp.
1609163|NCT02169102|Radiation|Laser 1 (at 0,16 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 0,16 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
1609164|NCT02169102|Radiation|Laser 2 (1,6 Joules/point of irradiation)|Fifteen minutes previously the urgency endodontic treatment, laser irradiation will be performed in the tooth with irreversible inflammation in pulp at 1,6 Joules/point at 2 points (perpendicularly to tooth crown and in periapex region)
1609457|NCT02166853|Drug|sevoflurane|Sedation with inhaled sevoflurane
1609165|NCT02169089|Drug|Spironolactone|Patients will be given Spironolactone 12.5 mg on week 0 (visit 2). Patients will be escalated to 25 mg daily Spironolactone or maximal tolerated dose over a 4-week period. Patients will continue treatment for an additional 48 weeks.
1609166|NCT02169089|Drug|Placebo|Placebo
1609167|NCT02169076|Device|Cardiac Resynchronization Therapy|The cardiac resynchronization therapy of the ICD/Pacemaker device of the patients enrolled in the study will be programed under a standardized protocol and enabled or disabled in a crossover fashion during the study.
1609168|NCT02169063|Radiation|carbon-11 acetate|Given IV
1609169|NCT02169063|Radiation|fluorine F 18 sodium fluoride|Given IV
1609170|NCT02169063|Procedure|positron emission tomography|Undergo 11C-acetate and 18F-fluoride PET
1609171|NCT02169063|Other|laboratory biomarker analysis|Correlative studies
1609172|NCT02169037|Procedure|FIRM Ablation|Substrate ablation for AF, via ablation of rotors and focal sources alone.
1609173|NCT02169037|Procedure|Conventional AF ablation with PVI|Trigger Based Ablation for AF, using Pulmonary Vein Isolation alone.
1609174|NCT02169024|Behavioral|Expect With Me group prenatal care|Expect With Me group prenatal care was designed based on: principles of group care; evidence from RCTs demonstrating improved birth outcomes; ACOG clinical guidelines; and research on patient and provider engagement through technology. Designed with national dissemination as a primary consideration, Expect With Me incorporates best evidence-based aspects of existing models of group care, with a novel IT platform to improve patient engagement and support, enhance health behaviors and decision making, connect providers and patients, and improve health service delivery. Expect With Me provides care to groups of 8-12 women of the same gestational age, implemented after initial individual assessment through delivery. Group visits are 90-120 minutes each, and follow a structured curriculum that incorporates standard content of prenatal care, and emphasizes critical health issues relevant to pregnancy, such as nutrition, physical activity, stress/mental health and sexual health.
1609175|NCT02169011|Procedure|Latissimus Dorsi Flap Reconstruction|Delayed, unilateral breast reconstruction with the LD-flap. The reconstruction will be performed in a standard fashion as specified in the protocol. Implants should be used when required to gain sufficient volume of the breast.
1609176|NCT02169011|Procedure|TAP Flap Reconstruction|Delayed, unilateral breast reconstruction with the TAP-flap. The reconstruction will be performed as specified in the protocol and when implants are required to gain sufficient volume they should be combined with an acellular dermal matrix.
1609177|NCT02168998|Behavioral|Clown|Comparison of routine venipuncture with a distraction technique by a medical clown
1609178|NCT02168985|Behavioral|TFH program|The Faithful House (TFH), is a three-day faith-based skills-building curriculum. The curriculum aims to increase household resilience by strengthening families and couples' relationships through enhanced couple communication
1609179|NCT02168972|Device|Global mapping and ablation device|During the procedure the Globe catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the LA will be followed by pulmonary vein isolation (PVI) by RF ablation. Additional lesions will be created as deemed appropriate by the investigator.
1609180|NCT02168959|Drug|bupivacaine|This drug is standard of care. The point of the study is to see if this method will yield better pain scores and improved patient satisfaction vs. non-nerve block. Simply: prospective observation of two standard methods.
1609181|NCT02168946|Drug|Carbavance|Carbavance for IV injection, administered as a 2 g/2 g dose
1609182|NCT02168946|Drug|Best Available Therapy|
2010085|NCT03122288|Other|No-Contact Control|This is simply a no-contact control group. Participants in this group will receive no additional contact with the study beyond the baseline and posttest assessments.
2010086|NCT03118050|Behavioral|Resistance exercise training|Supervised resistance exercise training, 3 times a week for 3 months
2010087|NCT03118050|Behavioral|Bed rest|Bed rest for 5 days, followed by standard rehabilitation for 2 days
1609189|NCT02168907|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
1609190|NCT02168907|Drug|bendamustine hydrochloride|Given IV
1609191|NCT02168907|Biological|rituximab|Given IV
1609192|NCT02168907|Other|laboratory biomarker analysis|Correlative studies
1609193|NCT02168894|Procedure|Acupuncture|"Group 1: Acupuncture sessions with electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, take a 2 week break. After that, participant randomly assigned to receive 12 sessions of acupuncture with electrical stimulation as before or not have anymore sessions in this study.
Group 2: Acupuncture sessions without electrical stimulation 3 times a week for 4 weeks, for a total of 12 sessions. Then, will take a 2 week break. After that, participant randomly assigned to receive 12 extra sessions of acupuncture without electrical stimulation or not have anymore sessions in this study.
Group 3: Acupuncture sessions 3 times per week over 4 weeks for a total of 12 sessions. Participant may or may not have electrical stimulation at these sessions. These sessions will begin 14 weeks after enrollment."
1609194|NCT02168894|Procedure|Nerve Function Tests|Nerve function tests consisting of hand tasks and balance evaluation performed at visit before acupuncture, and at end of study visit.
1609195|NCT02168894|Behavioral|Questionnaires|Questionnaire completion at baseline, visit before acupuncture, after 6th and 12th acupuncture session, and at end of study visit.
1609196|NCT02168881|Drug|Misoprostol|
1609197|NCT02168881|Drug|Dinoprostone|
1609198|NCT02168855|Drug|active nicotine gum|2 mg, standard over-the-counter nicotine replacement therapy gum
1609199|NCT02168855|Behavioral|Standard behavioral therapy|Standard behavioral therapy for smoking cessation
1609200|NCT02168842|Drug|Isradipine|Oral capsules Isradipine IR, up to 10 mg, taken twice daily
1609201|NCT02168842|Drug|Placebo (for Isradipine)|Sugar Pill manufactured to look like Isradipine but has no active ingredients
1609202|NCT02168829|Drug|Rivaroxaban|
1609203|NCT02168829|Drug|Acetylsalicylic acid|
1609234|NCT02168569|Drug|Coarsucam™ (Amodiaquine-artesunate combination)|AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children <9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children >18-35kg.
1609235|NCT02168556|Behavioral|Music|Subject listens to music that is 60bpm while undergoing urodynamic testing.
1990830|NCT01775865|Drug|Salsalate|
1609204|NCT02168816|Drug|piperacillin/tazobactam, cefepime, metronidazole, aztreonam,vancomycin, daptomycin, linezolid ,meropenem|Individuals are not assigned to specific medications. Rather, individuals are only assigned to a route of therapy. Individuals assigned to intravenous therapy will receive an intravenous therapy as determined by their primary healthcare provider. This therapy is usually one of the following intravenous medications: (i) piperacillin/tazobactam (Zosyn), (ii) cefepime, (iii) metronidazole, (iv) aztreonam, (v) vancomycin, (vi) daptomycin, (vii) linezolid (Zyvox), and/or (viii) meropenem.
1609205|NCT02168816|Drug|sulfamethoxazole/trimethoprim , clindamycin ,linezolid, moxifloxacin ,ciprofloxacin ,metronidazole|Individuals are not assigned to specific medications. Rather, individuals are only assigned to a route of therapy. Individuals assigned to oral therapy will receive an oral therapy as determined by their primary healthcare provider. Individuals assigned to oral therapy will usually receive at least one of the following medications: (i) sulfamethoxazole/trimethoprim (SMX-TMP), (ii) clindamycin (Clindesse), (iii) linezolid (Zyvox), (iv) moxifloxacin (Avelox), (v) ciprofloxacin (Cetraxal), and/or (vi) metronidazole (Flagyl)
1609206|NCT02168803|Drug|Evacetrapib|Administered orally
1609207|NCT02168790|Device|Amniotic membrane ring|The amniotic membrane ring system (AmnioClip) is device for sutureless application of amniotic membrane to oculare surfaces. Amniotic membrane is mounted between the two rings with a specially designed, accessory mounting device.
2010088|NCT03118050|Behavioral|Intensive physical therapy|Intensive weight bearing PT, daily, during bed rest
2010089|NCT03118466|Drug|Etoposide|A Drug that interfere with the action of topoisomerase enzymes (topoisomerase I and II). Topoisomerase enzymes control the manipulation of the structure of DNA necessary for replication.
1609210|NCT02168764|Device|ATI Neurostimulation System|All subjects will be implanted with the ATI Neurostimulator which, along with the ATI Remote Controller, provides electrical stimulation.
1609211|NCT02168751|Drug|propofol|
1609212|NCT02168751|Drug|Sevoflurane|
1609213|NCT02168738|Drug|13-C labeled AceDoPC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.
The dose contains 50 mg 13C-DHA. The wash-out period is four months"
1609214|NCT02168738|Drug|13-C labeled TG-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.
The dose contains 50 mg 13C-DHA. The wash-out period is four months"
1609215|NCT02168738|Drug|13-C labeled PC-DHA|"Each subject will receive a single dose of either lipid sequentially (according to randomization) a triglyceride (TG-DHA), a phospholipid (PC-DHA) or acetylated lysophosphatidylcholine (AceDoPC) labeled with 13C.
The dose contains 50 mg 13C-DHA. The wash-out period is four months"
1609216|NCT02168725|Drug|briciclib|
1609217|NCT02168712|Other|Moderate continuous exercise training|
1609218|NCT02168712|Other|Interval exercise training|
1609219|NCT02168699|Other|Ultrasound examination of the axilla|
1609220|NCT02168686|Genetic|ADVM-043|Gene transfer vector administration
1609221|NCT02168660|Drug|Vitamin D3|Vitamin D3, liquid formulation, 5000 IU/mL.
1609222|NCT02168647|Behavioral|Behavioral Lifestyle counseling|Participants in the intervention group will take part in one-on-one visits with a registered dietitian nutritionist (RDN) from no later than week 14 to child birth at the OBGYN clinic where the participant receives her routine prenatal care or the Nutrition Wellness Research Center in the Iowa State Research Park. These visits will be coordinated with her routine prenatal appointment; therefore a minimum of 6 face-to-face meetings will occur. The counseling sessions will focus on appropriate weight gain during pregnancy through the use of an individualized meal plan, physical activity goals, and behavioral modification. Weight gain will be plotted on an IOM weight gain chart and discussed with study RDN.
1609223|NCT02168647|Other|Control|Participants in the control arm will receive no form of lifestyle intervention. Women will be provided with usual care by their physician. Participants in the control arm will have their weight gain plotted on an IOM growth chart and sent electronically by research staff after each routine prenatal appointment. No other feedback on weight gain or behavior modification will be provided by the study RDN.
1609224|NCT02168634|Drug|Botulinum Toxins|5U botulinum toxin in 1c.c. normal saline, local injection
1609225|NCT02168634|Drug|Placebo|1cc normal saline, local injection
1609226|NCT02168621|Procedure|Full-mouth ultrasonic debridement|Motivation and instruction in proper oral hygiene. Before initiation of the subgingival debridement the patient must show sufficient self-performed infection control (full-mouth plaque score <30%). One session of full-mouth ultrasonic pocket/root debridement using a piezoceramic ultrasonic instrument.
1609227|NCT02168621|Procedure|Section-wise scaling and root planing|Conventional treatment approach comprising motivation, oral hygiene instructions and section-wise scaling and root planing at required number of consecutive appointments with 1-2 week interval.
1609228|NCT02168608|Other|Remote ischemia precondition|Three cycles of 5-min ischemia/5-min reperfusion induced by a blood pressure cuff placed on the right upper arm served as RIPC stimulus.
1609229|NCT02168608|Other|None remote ischemia precondition|Placed an uninflated cuff on the right upper arm for 30 min.
1609230|NCT02168595|Drug|GMI-1271|GMI-1271 is a potent, rationally designed glycomimetic E-selectin antagonist
1609231|NCT02168595|Drug|Placebo|
1609232|NCT02168582|Behavioral|physiotherapy as usual in primary care|
1609233|NCT02168569|Drug|Coartem™ (Artemether-lumefantrine combination)|AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to <15kg, two tablets per dose for those 15 to <25kg, and three tablets per dose for those 25 to <35kg.
1609236|NCT02168556|Behavioral|Video|Subject watches an informational video prior to undergoing urodynamic testing.
1609237|NCT02168556|Other|Standard of care|Standard of care
2010090|NCT03118466|Drug|Cytarabine|Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA.
2010091|NCT03118466|Drug|Lenalidomide|It may act by inhibiting the growth of new blood vessels (angiogenesis) in tumors, enhancing the status of the immune system, or decreasing cytokine and growth factor production
2010092|NCT03118466|Drug|Mitoxantrone|It interfere with cell reproduction
1609242|NCT02168491|Drug|Lixisenatide|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
1609243|NCT02168491|Drug|Insulin glargine|Patients will be switched to basal insulin glargine (Lantus, once daily in the morning) and GLP-1 receptor agonist Lixisenatide (Lyxumia, once daily in the morning before breakfast; days 1-14 10 µg thereafter 20 µg). The (mean) daily dose of premixed insulin will be calculated based on the records of the run in period. The initial dose of insulin glargine will be adjusted at about 60% of the daily insulin dose of premixed insulin. This is based on the observed reduction of required insulin dose described in recent literature upon initiation with a GLP-1 agonist.
1609244|NCT02168478|Drug|Neo-Synalar Cream|Approximately 0.2 g of test material is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
1609245|NCT02168478|Other|Sodium Lauryl Sulfate Aqueous Solution (0.40%)|Approximately 0.2 ml of the positive , 0.40% aqueous solution of sodium lauryl sulfate is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
1609246|NCT02168478|Other|Saline|Saline is applied to the absorbent pad portion of a semi-occlusive dressing and applied as received to the upper back between the scapulae. The patches are applied to a designated treatment site and allowed to remain in direct skin contact for a period of 48 hours.
1609247|NCT02168465|Behavioral|teaching self-management of an intermittent catheter|Specifically, we will teach awareness, self-monitoring and self-management strategies to CIC uses with SCI in an online format. Nurse telephone consultation for teaching self-management will be combined with peer leaders for online forums.
1609248|NCT02168452|Procedure|sentinel lymph node biopsy(SLNB)|"incision will be made over the skin site that had fluorescence lymphatic flow which visualized using fluorescence imaging camera and gamma probe.
double check after removal of the sentinel lymph node
sending frozen biopsy"
1609249|NCT02168439|Drug|Dexmedetomidine|
1609250|NCT02168439|Drug|Midazolam|
1609251|NCT02168426|Procedure|Guardix|Applying 6g of guardix during abdominal surgery
1609252|NCT02168426|Procedure|Seprafilm|Applying 1 sheet of seprafilm during abdominal surgery
2010093|NCT03117270|Drug|filgotinib|one filgotinib oral tablet q.d.
1609254|NCT02168387|Device|continuous high frequency oscillator (CHFO)|
1609255|NCT02168387|Drug|Acetylcysteine|
1609256|NCT02168387|Drug|dornase alfa|
1609257|NCT02168374|Other|Indirect pulp treatment|Carious dentine was sampled from the mesial portion of the cavity floor and the pulpal wall was entirely covered with one of the randomly selected materials: GIC containing 4.5% DOX; GIC containing 1.25% CHX or GIC as a control group. The antimicrobial concentrations were chosen based in the previous in vitro results obtained in this study. The cavities were then temporarily restored using a conventional GIC. Within 3 months after the initial treatment,the materials were carefully and completely removed, a new dentine sample was collected, and the teeth were then restored with a light-cured composite resin using a bonding system, after a new placement of the initial liner material.
1609258|NCT02168361|Drug|Pegylated Interferon alfa-2b|1.5 ugm/kg/week subcutaneously injected along with ribavirin and sofosbuvir for 12 weeks total
1609259|NCT02168361|Drug|Simeprevir|150 mg daily orally along with pegylated interferon and sofosbuvir for a total of 12 weeks
1609260|NCT02168361|Drug|Ribavirin|1000-1200 mg daily divided twice daily for 12 weeks in combination with pegylated interferon and sofosbuvir
1609261|NCT02168361|Drug|Sofosbuvir|12 weeks of combination sofosbuvir and simeprevir
1609262|NCT02168348|Other|biological examination at consultations at 3 and 6 months|
1609263|NCT02168335|Other|OrasaltsTM|OrasaltsTM mouthwash is composed of 119.5g of natural sea salt, Arnica montana 30C, Echinacea angustifolia 30C, Staphysagria 30C, Phosphorus 30C, Hepar sulphuris 30C, 0.27g cinnamon and 0.27g of liquorice
1609264|NCT02168335|Other|Sea salt|Unmedicated sea salt
1609265|NCT02168322|Device|collagen membrane|bovine collagen membrane used for selective tissue regeneration
1609266|NCT02168322|Device|collagen membrane|collagen bovine occlusive membrane for selective tissue regneration
2010094|NCT03117270|Drug|Placebo Oral Tablet|one placebo oral tablet q.d.
2010095|NCT03116971|Drug|M3814|Phase Ib: Subjects will receive M3814 orally once daily, at the assigned dose level in combination with etoposide (intravenously) and cisplatin for 6 cycles with each cycle lasting 3 weeks (21 days).
1609269|NCT02168296|Dietary Supplement|Plant-based ingredient added to starchy meal|
1609270|NCT02168296|Dietary Supplement|Plant-based ingredient added to liquid|
1609271|NCT02168296|Dietary Supplement|No Plant-based ingredient|
1609272|NCT02168283|Combination Product|treatment arm|Hypertonic peritoneal dialysis cycles
1609273|NCT02168283|Behavioral|Control arm|Dietary counseling
1609274|NCT02168270|Dietary Supplement|ascorbic acid|Given IV
1609275|NCT02168270|Drug|temozolomide|Given PO
1609276|NCT02168270|Other|quality-of-life assessment|Ancillary studies
1609277|NCT02168270|Other|laboratory biomarker analysis|Correlative studies
1609278|NCT02168257|Device|RAM Cannula|
1609279|NCT02168257|Device|Binasal Prong CPAP|
1609280|NCT02168244|Other|Heating Pack|Application of heat to skin for 2-3 minutes prior to injection of biologic drug
2010096|NCT03116971|Drug|M3814 matching placebo|Phase II: Subjects receive M3814 matching placebo in combination with cisplatin and etoposide for 6 cycles with each cycle lasting 3 weeks (21 days).
2010097|NCT03116971|Drug|Cisplatin|Phase Ib: Cisplatin 75 milligram per square meter (mg/m^2) will be administered over a 60-minute intravenous infusion on Day 1.
2010098|NCT03116971|Drug|Etoposide|Phase Ib: Etoposide 100 mg/m^2 over a 60 minute IV infusion on Days 1-3 will be administered for 6 cycles with each cycle lasting 3 weeks (21 days).
1609281|NCT02168244|Other|Ice pack|Application of cold to skin for 2-3 minutes prior to injection of biologic drug
1609282|NCT02168231|Procedure|Complex abdominal wall repair Strattice|Not applicable (cross-sectional data from a cohort selected after initial complex abdominal wall surgery with Strattice)
1609283|NCT02168218|Other|7-day overfeeding|7-day overfeeding with an excess sucrose intake corresponding to 40% total energy requirements
1609284|NCT02168205|Drug|Pomalidomide|Capsules
1609285|NCT02168205|Other|Caffeine|Capsules
1609286|NCT02168205|Other|Tobacco|Cigarettes
1609287|NCT02168192|Behavioral|Simulation-Debrief|Subjects underwent a formal debrief, reviewing the BBN skills exhibited in their prior simulation of an obstetrical communication skills scenario.
1609288|NCT02168192|Behavioral|Traditional lecture|Control group underwent lecture for approximately 10 minutes reviewing BBN skills.
1609289|NCT02168179|Procedure|dermatologic complications management/prevention|Apply KeraStat Skin Therapy topically
1609290|NCT02168179|Other|questionnaire administration|Ancillary studies
1609291|NCT02168166|Behavioral|Executive Function Training|
1609292|NCT02168166|Behavioral|Placebo|Placebo version of executive function training
1609293|NCT02168153|Other|Chiropractic Manipulative Therapy|Participants will receive chiropractic spinal manipulative therapy consisting of High velocity low amplitude (HVLA) spinal manipulative procedures. These procedures are typically associated with a quick manual thrust and a cavitation sound. For the cervical spine, a procedure called a cervical index pillar push, thoracic manipulation will occur with unilateral or bimanual contacts in the prone or supine positions and lumbar/pelvis manipulation will be performed with a procedure referred to as side-lying or side-posture.
1609294|NCT02168153|Other|Wait-list|Participants randomized to the wait-list control group will complete questionnaires and perform the same study procedures as those randomized to the chiropractic manipulative therapy arm. After completing the required 2-week waiting period, those who wish to receive chiropractic manipulative therapy will be eligible to schedule treatment visits.
1609295|NCT02168140|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
1609296|NCT02168140|Drug|bendamustine hydrochloride|Given IV
1609297|NCT02168127|Drug|Drug: PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
1609298|NCT02168127|Drug|PRC-063|Methylphenidate Hydrochloride Extended-Release Capsules
1609299|NCT02168114|Other|Exercising|This arm will only include subjects that have a confirmed diagnosis of Duchenne Muscular Dystrophy. Subjects in this arm will not undergo any exercising, and will only be imaged by Optical and Magnetic Resonance Imaging and Spectroscopy techniques at a single time point.
1609300|NCT02168114|Procedure|Optical and Magnetic Resonance Imaging and Spectroscopy|This arm will contain subjects that are not affected by Duchenne Muscular Dystrophy. These subjects will undergo concentric exercising of one forearm, and eccentric exercising of the contralateral forearm. Two days following the exercising, subjects will undergo Optical Imaging and Magnetic Resonance Imaging and Spectroscopy.
1609301|NCT02168101|Drug|MLN9708|"Dose-Escalation Phase: MLN9708 will be administered orally (PO) as monotherapy.
Cohort 1: 2.3mg single weekly dose
Cohort 2: 3mg single weekly dose
Cohort 3: 4mg single weekly dose
Expansion Phase: An additional 20 patients will receive MLN9708 at the MTD"
1609302|NCT02168075|Drug|0.25g/kgof 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.25g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
1609303|NCT02168075|Drug|0.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 0.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
1609304|NCT02168075|Drug|1.0g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull, 1.0g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
1609305|NCT02168075|Drug|1.5g/kg of 20% mannitol|When the neurosurgeon starts the drilling of skull,1.5g/kg of 20% mannitol administered through the IV catheter with fulldrip. Neurosurgeon evaluate the degree of brain relaxation after dura opening in 4 point scale ( 1=bulging brain, 2=firm brain, 3-satisfactorily relaxed, 4=perfectly relaxed).
1609306|NCT02168062|Drug|Luteinizing hormone releasing hormone agonists|
1609307|NCT02168049|Device|Integrated CardioRespiratory System|Participants will be asked to wear a non-invasive band on their upper abdomen while laying down. This band includes acoustic sensors. A remote monitoring device will continuously monitor and record heart rate and lung volumes and function.
1609308|NCT02168049|Device|Transthoracic Echocardiography (TTE)|Participants will undergo a TTE examination. During the TTE, a technician obtains views of the heart by moving a small instrument called a transducer to different locations on the chest or abdominal wall.
1609309|NCT02168049|Device|Electrocardiography|Participants will also have ECG monitoring as part of the TTE exam, which records the electrical activity of the heart using electrodes placed on the body.
1609310|NCT02168023|Device|DACC impregnated dressing|DACC impregnated dressing Sorbact Surgical Dressing ® (ABIGO Medical AB, Sweden) placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
1609311|NCT02168023|Device|Standard surgical dressing|Standard surgical dressing placed over post-caesarean wound after skin closure, the dressing will be removed after the first 48 hours postoperatively
1609312|NCT02168010|Drug|Analgecine|Analgesic drug under test
1609313|NCT02168010|Drug|Neurotropin|Analgesic drug as positive control
1609314|NCT02168010|Drug|Placebo|Blank tablet as placebo.
1609315|NCT02167971|Other|Active Coil|The patients will undergo 10 sessions (2,000 pulses each, lasting 20 minutes) of repetitive transcranial magnetic stimulation over the left dorsolateral prefrontal cortex with the following parameters: 10Hz, 50 trains (40 pulses on each train), biphasic wave, 25 seconds between the trains.
1609316|NCT02167971|Other|Sham|The patients assigned to this group will undergo 10 sessions of rTMS but with an inactive coil, which will not generate electromagnetic pulses.
1609458|NCT02166853|Drug|midazolam|Sedation with intravenous midazolam
1609317|NCT02167958|Drug|Fludarabine|"Fludarabine 30 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2. Fludarabine will be dosed according to the recipient's Adjusted Ideal Body Weight (AIBW) unless AIBW is less than Ideal Body Weight (IBW).
For decreased creatinine clearance (< 61 mL/min) determined by the Cockcroft Formula:
Cockcroft-Gault CrCl = (140-age) * (Wt in kg) * (0.85 if female) / (72 * Cr)
Fludarabine dosage should be reduced per standard of care."
1609318|NCT02167958|Drug|Cyclophosphamide|"Pre-transplant
Cy 14.5 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -6 and -5. Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW
Post-transplant
Hydration prior to cyclophosphamide may be given according to Standard Practice Guidelines.
Cyclophosphamide [50mg/kg] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cy will be dosed according to the recipient's actual body weight unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the adjusted IBW. Cyclophosphamide will be given as an IV infusion over 1-2 hours."
1609319|NCT02167958|Drug|Mesna|"Pre-transplant
Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide.
Post-transplant
Mesna should be given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post-cyclophosphamide. Mesna dose will be based on the cyclophosphamide dose being given. The total daily dose of mesna is equal to 100% of the total daily dose of cyclophosphamide."
1609320|NCT02167958|Radiation|Total Body Irradiation|200 cGy will be administered in a single fraction on Day -1 via linear accelerator.
1609321|NCT02167958|Other|Hematopoietic stem cell infusion|Donors who consent to PBSC donation will receive 5 daily doses of G-CSF, 10 μg/kg/day by subcutaneous injection commencing on day -5. PBSC's will be collected in the afternoon of day -1, stored at 4C overnight, and infused as soon as possible on day 0. If the collection on day -1 contains less than 5.0 X 106 CD34+ cells per kg recipient weight, a second collection will be performed the following morning and infused on day 0. Quantitation of CD34 and CD3 cells will be performed by the Cellular Therapy Lab. For all patients, the target number of CD34 cells to be infused should be 5-6 X 106 cells per kg recipient weight. PBSC in excess of 6.0 x 106 CD34 cells/kg recipient weight may be cryopreserved.
1609322|NCT02167958|Drug|Tacrolimus|Tacrolimus will be given at a dose of .03 mg/kg IV over 24 hours. Tacrolimus will be changed to a PO dosing schedule once a therapeutic level is achieved and the patient is tolerating PO. Whole bloodblood levels of tacrolimus will be measured around Day 7 and then should be checked at least weekly thereafter and the dose adjusted accordingly to maintain a level of 5-10 ng/mL. Tacrolimus will be discontinued after the last dose around Day 180, or may be continued if active GVHD is present. Cyclosporine (target concentration 200-400 ng/ml) may be substituted for tacrolimus if the patient is intolerant of tacrolimus.
1609323|NCT02167958|Drug|Mycophenolate|Either the sodium salt of mycophenolate or mycophenolate mofetil (MMF) may be used as prophylaxis of GvHD and will be dosed by actual bodyweight. Only MMF is available as IV formulation. Sodium mycophenolate will be given at a dose of 10mg/kg PO TID rounded to the nearest number of 180mg tablets. MMF will be given at a dose of 15 mg/kg PO TID. The maximum total daily dose should not exceed 2160 mg (sodium salt) or 3 grams (mofetil). Mycophenolate prophylaxis will be discontinued after the last dose on Day 35, or may be continued if active GVHD is present.
1609324|NCT02167958|Drug|G-CSF|G-CSF will be given beginning on Day 5 at a dose of 5 mcg/kg/day (rounding to the nearest vial dose is allowed), until the absolute neutrophil count (ANC) is > 1,000/mm3 for three consecutive days.
1609328|NCT02167932|Behavioral|Walk With Ease|Walk With Ease is the Arthritis Foundation's evidence-based walking intervention to help with fatigue and pain. The intervention is a self-directed program that helps guide participants in a safe and comfortable paced walking program with an ultimate goal of walking for 30 minutes a day, five days a week.
1609329|NCT02167919|Device|Microspheres|Prostatic artery embolization (PAE) is a new procedure that decreases the size of the prostate by blocking its arterial blood flow. Through a tiny puncture in the upper thigh or forearm a catheter is directed to the prostatic artery using fluoroscopic guidance. Once in place, sub-millimeter particles are injected that obstruct the prostatic arteries resulting in gland ischemia, and ultimately, reduction in size. The technique has only been recently developed in Portugal and Brazil and has similarities to Uterine Artery Embolization used to treat uterine fibroids.
1609330|NCT02167906|Other|arterial stiffness measurement|
1609331|NCT02167893|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg injection kit
1609332|NCT02167867|Device|Lay End Users|Lay End Users administer 40 minutes of treatment with the ZERONA Z6 to the waist, hips and thighs (20 minutes to the front side and 20 minutes to the back side) of a Treatment Subject, 6 times evenly spaced across two consecutive weeks.
1609333|NCT02167867|Device|Treatment Subject Group|Treatment subject received 6 40-minute evenly spaced treatments to the hips, waist and thighs (20 minutes to the front side and 20 minutes to the back side) with the ZERONA Z6 over 2 consecutive weeks. The ZERONA Z6 contains 6 17.25 milliWatts (mW) 635 nanometers (nm) light-emitting diodes.
1609334|NCT02167854|Drug|BYL719|
1609335|NCT02167854|Drug|LJM716|
1609336|NCT02167854|Drug|TRASTUZUMAB|
1609337|NCT02167841|Behavioral|Knee-Chest Position|
1609338|NCT02167828|Behavioral|Social Support|
1609339|NCT02167815|Device|Mepilex XT|Experimental arm
1609340|NCT02167815|Other|standard care|
1609341|NCT02167789|Device|Paradym CRT 8770|
1609377|NCT02167542|Device|Noninvasive Positive Pressure Ventilation|Patients assigned to NPPV were connected to the ventilator through a face mask (VBM Endoscopy Mask) that was secured to the patient's face by the investigator. Only one type of mechanical ventilator will be used (Vision, Philips Respironics). Ventilator parameters and supplemental oxygen will be titrated by the investigator to achieve SpO2>92%. Ventilatory support via face mask will be maintained with the same pressures for at least 30min after FOB, and then will be replaced by the FIO2 mask's if needed.
1609416|NCT02167178|Other|Administration of 0.9% NaCl solution|Volunteers administered 0.9% NaCl solution in 250ml boluses
1609342|NCT02167776|Behavioral|Church-based teaching|In villages that are randomized to receive the intervention, Christian church leaders of both genders and all denominations will be invited to attend an educational seminar about male circumcision. This seminar will last for one day in each intervention village, and will use a curriculum that the investigators' team developed in 2012 based on prior focus group work. Seminars will be conducted in Kiswahili (the national language) and co-taught by a Tanzanian pastor and a Tanzanian clinician who works with the male circumcision outreach campaign. Church leaders will be taught medical, historical, religious, tribal, and social aspects of male circumcision and given tools to lead their congregations in the understanding and practice of male circumcision.
1609343|NCT02167763|Device|VeraCept Intrauterine Copper Contraceptive|
1609344|NCT02167763|Device|TCu380 IUD|
1609345|NCT02167750|Other|Cherry Flavored Beverage|Intervention involves consuming one beverage at the beginning of each visit of the crossover sequence.
1609346|NCT02167737|Behavioral|Bedside Decision Aid|"This group will have an initial FES and VES screening completed in the ED, the TUG test and Chair 30-Second Stand test, and the participant's risk of falling evaluated using our Bedside Decision worksheets. A study team member explains what subjects can do to decrease their risk of falling and discuss what mobility goals are the most important to them.
Participants will receive a follow-up telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
1609347|NCT02167737|Behavioral|Control Arm|"This group will also have an initial FES and VES screening completed in the ED and the same two mobility tests (TUG and Chair 30-Second Stand). Study staff will advise subjects on how to take action to prevent falls and give them a brochure, What YOU Can Do to Prevent Falls, from the CDC's STEADI Tool Kit for Health Care Providers.
Participants will receive a telephone call approximately six weeks after their discharge from the ED to collect self-reported data about goal completion, and then at four additional times--three, six, nine and 12 months--over the course of a year to collect self-reported data such as fall history."
1609348|NCT02167724|Other|Bucco-dental examination|
1609349|NCT02167724|Other|Blood sample|
1609350|NCT02167724|Other|Clinical and social questionnaire|
2010099|NCT03116971|Drug|M3814|Phase II: Subjects will receive M3814 at the Recommended Phase II dose (RP2D) identified in the Phase Ib part of the study in combination with cisplatin and etoposide for 6 cycles with each cycle lasting 3 weeks (21 days).
1609352|NCT02167698|Device|Airway Pressure Release Ventilation (APRV)|This is a newer mode of ventilation that has been hypothesized to be equivalent or even superior to the conventional low-tidal volume mode of ventilation
1609353|NCT02167698|Other|Low-tidal volume ventilation|This mode of ventilation is the standard of care worldwide for ventilating children with ARDS.
1609354|NCT02167698|Drug|Methylprednisolone|Children with primary ARDS presenting within the first 14 days would receive IV low dose Methylprednisolone infusion.
1609355|NCT02167698|Other|Restrictive fluid therapy|Fluid & hemodynamics would be titrated as per pre-designed decision-making protocols
1609356|NCT02167698|Drug|sedo-analgesia titration|
1609357|NCT02167698|Other|Protocolized early enteral nutrition|Early enteral nutrition and attempt to meet calorie-protein goals
1609358|NCT02167698|Other|Protocolized supportive care|Eye care, chlorhexidine mouth wash Q6 hourly, Strict aseptic precautions prior to any procedures, Skin care & bed sore prevention, Adequate pulmonary toileting and chest physiotherapy, frequent position changes, limb physiotherapy, family-centered care
1609359|NCT02167698|Other|Biomarker Assay|Biomarker Assay for patients in both arms
1609360|NCT02167685|Drug|CMX001|
1609361|NCT02167659|Device|23-32 mmHg compression sleeve with gauntlet|A compression intervention consisting of a sleeve and gauntlet with 23-32mm of tension worn for four weeks that is initiated based on a BIS L-Dex change that is ≥6.5 units higher than pre-surgical baseline measure, or a tape measurement guided volume change in the affected arm that is between ≥5% and <10% above pre-surgical baseline.
1609362|NCT02167646|Procedure|Flap including bilateral nerve branches|Two nerve branches are attached with the flap for sensory coverage
1609363|NCT02167633|Procedure|Decompression surgery|Patients will undergo posterior decompression/laminectomy on relevant spinal levels depending on neurological symptoms. If there is a need of spinal stabilization after decompression, patients will undergo posterior instrumentation with pedicle screws and titanium rods. Instrumentation will be done two or three levels above and below each level with metastatic affection.
1609364|NCT02167633|Radiation|Radiosurgery|Patients treated with radiosurgery/SBRT will receive a prescribed dose of 16 Gy in 1 fraction to cover as large a fraction as possible the defined target volume
1609365|NCT02167633|Radiation|Fractionated Radiotherapy|"Patients allocated to surgery will receive postoperative radiotherapy commencing between 10 to 21 days after decompressive surgery. Target should include the entire vertebral body and the vertebral arch at the operated level of the vertebral column.
Patients receiving postoperative radiotherapy will receive 30 Gy in 10 fractions with 3 Gy pr. fraction. The prescribed dose should cover at least 90 % of the defined target volume."
1609366|NCT02167633|Drug|Glucocorticoids|All patients referred with clinical suspicion of metastatic spinal cord compression will receive high dose glucocorticoids. Dose adjusted to risc of side effects.
1609367|NCT02167633|Drug|Pantoprazole|All patients receiving high dose glucocorticoids will also be prescribed with pantoprazole 40/daily to prevent gastric ulcers
1609368|NCT02167620|Drug|Metformin|Metformin will be dispensed on a biweekly basis, and pill counts conducted at each visit.
1609369|NCT02167620|Drug|Placebo|Placebo will be dispensed on a biweekly basis, and pill counts conducted at each visit.
1609370|NCT02167607|Dietary Supplement|Active Comparator|Purple Potato
1609371|NCT02167607|Dietary Supplement|Placebo Comparator|Placebo Comparator
1609372|NCT02167594|Drug|18F-AV-1451|
1609373|NCT02167594|Drug|florbetapir F18|
1609374|NCT02167568|Genetic|Genetic|
1609375|NCT02167555|Dietary Supplement|Active Comparator|Wild Blueberry Beverage
1609376|NCT02167555|Dietary Supplement|Placebo Comparator|Placebo Beverage
1609415|NCT02167191|Behavioral|HIT|12 sessions of HIT exercise in 31 days on a stationary cycle ergometer
1609378|NCT02167542|Device|CPAP valve (Boussignac)|"Patients assigned to CPAP Boussignac valve are connected to this device through a face mask that is secured to the patient's face with elastic straps. This kind of CPAP allows the delivery of pressure by constant-flow oxygen insufflation. Four funnel-shaped microchannels are included in the wall of this device and connected to an external opening connected to the oxygen source. These microchannels generate high-velocity microjets, which in turn generate the pressure resulting from the air entrainment mechanism thus created.
Oxygen flow will be titrated by the investigator to ensure SpO2>92%."
1609379|NCT02167516|Drug|glucosamine sulfate|glucosamine sulfate capsule: One each time, 3 times a day, Oral,for 4 weeks placebo(for Xinfeng capsule): Three each time, 3 times a day, Oral,for 4 weeks
1609380|NCT02167516|Drug|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 4 weeks placebo(for glucosamine sulfate capsule): One each time, 3 times a day, Oral,for 4 weeks
1609381|NCT02167490|Procedure|Arm 1: sentinel node biopsy|Sentinel node biopsy policy
1609382|NCT02167477|Device|Macintosh laryngoscopy|Tracheal intubation
1609383|NCT02167477|Device|Storz C-MAC, standard blade|Tracheal intubation
1609384|NCT02167477|Device|Storz C-MAC, D-BLADE|Tracheal intubation
1609385|NCT02167464|Drug|Renin treatment-guided Therapeutics|Patients are treated based upon their renin levels according to an approved algorithm.
1609386|NCT02167464|Other|Referral Hypertension specialist|Patients are referred to a hypertension specialist.
1609387|NCT02167464|Drug|Aldosterone Antagonist|Spironolactone 12.5 - 25mg daily
1609388|NCT02167451|Drug|Maraviroc|
1609389|NCT02167438|Device|Hem-Avert Perianal Stabilizer|
1609390|NCT02167425|Other|IMAT|The IMAT intervention will combine three main strategies: point-of-care (POC) CD4 screening, provider training and mentoring, and an alerts and reminder dashboard. The POC CD4 platform will provide real-time clinical staging, enabling providers within the methadone clinic to screen HIV-infected patients for ART eligibility. Coupled with this technology, appropriate training and mentoring will predispose providers to effectively link patients to ART and integration of an alert and reminder dashboard will reinforce behavior change and strengthen processes.
1609391|NCT02167412|Device|Abdominal and lower extremity compression|POTS patients will have a repeat HUT test while wearing the Zoex compression suit.
1609392|NCT02167386|Behavioral|Enhanced PrEP Adherence|
1609393|NCT02167386|Behavioral|Standard PrEP Adherence|
1609394|NCT02167373|Other|Cogito Companion Intervention|
1609395|NCT02167373|Device|mobile phone application|
1609396|NCT02167360|Drug|CTL019|A dose of CTL019 transduced cells will consist of a single infusion of 2 to 10 x 108 CTL019 transduced cells.
1609397|NCT02167347|Behavioral|Family intervention|This 10 session Multi-modal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component
1609398|NCT02167334|Device|positive pressure ventilation|Positive Pressure Ventilation with a 4 cmH2O inhale pressure, a positive end-expiratory pressure of 4 cm H2O, a trigger 2, an inspiratory slope of 0, an inhaled oxygen fraction of 100% administered at a 10 L / min flow.
1609399|NCT02167334|Procedure|Oxygenation with simple breathing mask|Spontaneously breathing preoxygenation with adapted face mask, to restrict leakage, at 10L/min oxygen, with inhaled fraction of 100% and a 2 L balloon volume.
1609400|NCT02167321|Drug|Arm A : standard neoadjuvant chemoradiotherapy group|radiation : 45Gy±5.4Gy/28Fx/5.5weeks concurrent chemoradiotherapy : 5-FU (400 mg/m2, IV bolus on D1-3, D29-31), leucovorin (20 mg/m2, IV bolus on D1-3, D29-31), preoperative capecitabine : 825 mg/m² p.o. twice daily during XRT, postoperative FL : 5-FU (400 mg/m2, IV bolus)+leucovorin (20m g/m2, IV bolus) on days 1-5 of each 28 day postoperative capecitabine : 1250 mg/m² p.o. twice daily on days 1-14 of each 21 day cycle FOLFOX : oxaliplatin 85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, leucovorin 200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle, 5-FU 400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle
1609401|NCT02167321|Drug|Arm B : adjuvant FOLFOX group|FOLFOX : oxaliplatin (85 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), leucovorin (200 mg/m2, IV over 2 hours on day 1 of each 14 day cycle), 5-FU (400 mg/m2, IV bolus on day 1 followed by 1200mg/m2 IV over 24 hours on days 1 and 2 of each 14 day cycle) postoperative irradiation(if needed) : 54Gy/30Fx/6weeks
1609402|NCT02167308|Device|Laser acupuncture|a GaAlAs semiconductor diode Laser Phototherapy Device with a wavelength of 808nm. Maximum power output is 150 milliwatt in continuous wave mode.
1609403|NCT02167269|Device|Baby EAR|A modification of the Enclosed Afferent Reservoir anesthesia circuit (EAR) for pediatric use by adding a KKU one-way valve in the expiratory limb
1609404|NCT02167256|Drug|AZD0530 100mg daily|All patients in experimental group (50%) will be started on 100mg AZD0530 daily
1609405|NCT02167256|Drug|AZD0530 125mg daily|Patients with plasma drug level <100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
1609406|NCT02167256|Drug|Placebo|50% of patients will receive placebo treatment for the duration of the study.
1609407|NCT02167243|Behavioral|Reinforcement for BG testing|Subjects will receive reinforcement for BG tests. The intervention will reinforce subjects for conducting Self Monitoring of Blood Glucose (SMBG), with escalating reinforcers provided when subjects achieved sustained periods of testing at least 4 times/day at appropriate intervals.
1609408|NCT02167243|Other|Standard of care|Subjects receive standard of care
1609409|NCT02167230|Procedure|Jailed-balloon technique|A monorail balloon is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to nominal pressure, the balloon in SB is inflated to 3 atm generally but to higher pressure to perform angioplasty if the blood flow in SB is compromised. The balloon in SB is then removed while the wire in SB is left in place. The MB stent balloon is inflated again for stent apposition. The SB wire is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the stent balloon is inflated again.
1609410|NCT02167230|Procedure|Jailed-wire technique|A percutaneous transluminal coronary angioplasty(PTCA) wire is placed in the side branch(SB) before the stent in main branch(MB) is deployed. After MB stent is deployed to some pressure to achieve full apposition, the wire in SB is left in place to facilitate rewiring if the blood flow in SB is compromised. Otherwise the SB wire is removed after the MB stent is deployed.
1609411|NCT02167217|Drug|Prednisolone|Prednisolone (5mg per kg )will be taken on two consecutive days, Friday and Saturday mornings each week with breakfast
1609417|NCT02167178|Other|Measurement of stroke volume|The measurement of stroke volume will be performed using an Oesophageal Doppler Monitor.
1609418|NCT02167178|Other|Measurement of microvascular blood flow|Microvascular blood flow will be measured using a contrast enhanced ultrasound scan.
1609419|NCT02167178|Other|Administration of gelofusine|Volunteers administered gelofusine in 250ml boluses
1609420|NCT02167165|Drug|Digoxin|Patients consulting the ED for Acute onset AF received 0.5 mg digoxin by oral root
1609421|NCT02167152|Device|Blood Pressure Cuff|Ischemic preconditioning will be accomplished through 4 cycles of alternating 5-minute inflation and 5-minute deflation of an upper-arm blood pressure cuff to the patient's systolic blood pressure plus 50% to induce ischemia and reperfusion.
1609422|NCT02167139|Drug|Humira (adalimumab)|
1609423|NCT02167139|Drug|SB5 (proposed biosimilar to adalimumab)|
1609424|NCT02167126|Device|Kinesio Taping|"using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, passing around the patella and finishing on the tibial tuberosity."
1609425|NCT02167126|Device|Placebo Tape|"Micropore tape was applied using the V technique, the knee was positioned at 45º of flexion, the origin of both tapes was located 10 cm below the anterior-superior iliac spine with one tape going laterally and one medially to the rectus femoris muscle belly, but because it is not elastic, the knee joint was not crossed and the end points were the medial and lateral aspects of the patella."
1609426|NCT02167087|Procedure|Sentinel node mapping|Through transabdominal access via laparoscopic ports indocyanine green solution is injected around the tumor (25 mg indocyanine green dissolved in 9 ml sterile water and 1 ml 20% human albumin). This is done by the construction of two small boluses of 0.5 mL each into the colonic wall just orally and anally to the tumor margin, but not within the tumor itself. When the bolus is injected the fluorescence is controlled and after 20 minutes the surgeon looks for sentinel nodes in a standardized manner.
1609427|NCT02167074|Device|25G FNA needle|
1609428|NCT02167074|Device|20G ProCore FNB needle|
1609429|NCT02167061|Drug|DA-1229_01|complex single administration
1609430|NCT02167061|Drug|E+M|co-administration of 2 drugs
1609431|NCT02167061|Drug|DA-1229_01 fast|
1609432|NCT02167061|Drug|DA-1229_01 fed|
1609433|NCT02167048|Drug|Psychostimulants|"Participants will be tested twice 2 weeks apart. All will continue on their normal Psychostimulant dose up until 3 days before the testing day. 3 days before their 1st testing session, half the participants will start on either their current-dose of Psychostimulant or half their current dose depending on the arm they were randomized to (we provide those pills).
To control for different pharmacokinetics of the Psychostimulant medications, a given participant will be tested at roughly the peak time for his/her specific version of Psychostimulant and at the same time of day for his/her two testing sessions."
1609434|NCT02167035|Drug|Combigan BID|
1609435|NCT02167035|Drug|Simbrinza TID|
1609436|NCT02167022|Other|Physical and occupational therapy|The type of physiotherapy to be administered is Perception-Action (P-A). The P-A (motor) intervention is a child-driven approach without the need for special equipment and considers the child and environment as a single unit.Treatment is a coupling of the child with the environment. The environment is changed to enable, enhance or stimulate movement. The action is initiated by the child with the therapist augmenting the child's environment using touch (tactile information) or light support (cushions, bolsters, and gentle touch or pressure) to assist and/or alter the child's active movement. Toys are used and positioned in different places to encourage movement of upper and lower extremities and the trunk; reaching, turning, sitting balance, crawling, walking.
1609437|NCT02167009|Device|Embosphere Microspheres|
1609438|NCT02166996|Procedure|Suture removal time 7 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 7 days.
1609439|NCT02166996|Procedure|Suture removal time14 days|To compare cosmetic outcome of surgical defects of head and neck, repaired with non-resorbable monofilament nylon sutures from the aspect of suture removal time 14 days
1609440|NCT02166983|Other|computer-assisted cognitive training|Complete Lumosity cognitive exercises
1609441|NCT02166983|Other|cognitive intervention|Complete Active Journaling cognitive exercises
1609442|NCT02166983|Procedure|mind-body intervention procedure|Complete relaxation exercises
1609443|NCT02166983|Other|memory intervention|Complete compensatory strategies
1609444|NCT02166983|Other|questionnaire administration|Ancillary studies
1609445|NCT02166970|Device|Metallic stent deployment in hilar obstruction|Single stent insertion: metal stent deployment to right or left intrahepatic duct Multiple stenting: Stent-in-stent or side-by-side deployment
1609446|NCT02166957|Procedure|Recanalization|"All patients received clear and detailed information about the different steps, the benefits and the risks of the procedure they would undergo, and gave an informed consent.
The rendez-vous technique shared some common characteristics whatever the etiology and the length of esophageal disruption. First, prior to start the specific endoscopic management, all the patients needed to have undergone a surgical gastrostomy one month earlier in order to allow the retrograde access. This one-month delay was necessary to get it completely healed before using it for the procedure.
The principle of the combined anterograde retrograde approach is to get an endoscopic access to both the proximal and distal side of the obstruction in the purpose to achieve better and safer recanalization, which could be carried out with either transillumination or using a needle under x-rays guidance."
1609447|NCT02166944|Drug|tamoxifen 40 mg daily for one year|both arms with riluzole daily
1609448|NCT02166931|Dietary Supplement|Chicken Essence|BRAND'S® Chicken Essence of 70cc daily for 2 weeks Placebo 70 cc daily for 2 weeks
1609449|NCT02166905|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given via intracutaneous injection
1609450|NCT02166905|Drug|Epacadostat|Given PO
1609451|NCT02166905|Other|Laboratory Biomarker Analysis|Correlative studies
1609452|NCT02166905|Other|Pharmacological Study|Correlative studies
1609453|NCT02166905|Drug|Poly ICLC|Given SC
1609454|NCT02166892|Other|Specially designed plates|
1609455|NCT02166879|Behavioral|Questionnaire|Participants complete anesthesia questionnaire before elective surgical procedure.
1609456|NCT02166866|Other|Quality of Life Questionairre and Education|
1609459|NCT02166840|Procedure|Plastic stent (7-10Fr)|
1609460|NCT02166840|Procedure|Self Expanding Metal Stent|
1609461|NCT02166827|Device|NeuroAD|Synchronized TMS and cognitive stimulation to 6 brain areas.
1609462|NCT02166827|Device|Sham TMS+Cog|Sham Device, has the same appearance and sound as the real device, combined with sham cognitive exercises.
1609463|NCT02166814|Drug|Fimasartan and Rosuvastatin|
1609464|NCT02166814|Drug|Fimasartan|
1609465|NCT02166814|Drug|Rosuvastatin|
1609466|NCT02166801|Behavioral|Early intervention for infants|Three foci are included in the intervention: Communication, Hand function and Mobility/gross motor function. The Hand & Cognition and Mobility steps will be conducted during two time-periods. Communication will have a separate one-time intervention at the start of the study (prior to step I) in addition to one intervention period during step III (figure 1). General principles for the small step program: Training will be conducted in the children's home by the parents on a daily basis. The families will get instructions and supervision in their home every week by the therapist responsible for each specific step of the intervention. For each focus there will be different steps using an adaptive logarithm for training, i.e., adapted to the functional level of the child aiming at the next small developmental step. The family will be actively involved in identifying new foci for practice.
1609467|NCT02166801|Behavioral|usual care|Children displaying delayed development and at risk of developing cerebral palsy are continuously followed-up at the children's hospital. There are no strict rules for the frequency of appointments within the usual care program but the families typically meet a physiotherapist every third week during the first 2-3 months, thereafter about once a month. The frequency depends on the family's needs and wishes. If there is a continuous need for therapeutic intervention and need of contact with different professions, the families will be referred to the Habilitation Services when the child is between 8-12 months. The control group will follow this customary procedure in the hospital. The only difference will be the assessment procedure, the sessions with the speech pathologist and that they will get feedback of the children's progress after each examination.
1609468|NCT02166788|Procedure|Inguinal Lymphadenectomy|
1609469|NCT02166788|Procedure|Ilio-inguinal Lymphadenectomy|
1609470|NCT02166762|Procedure|QLV interval measurement|Measurements of the QLV interval is defined from the onset of the QRS width of the surface ECG to the first large positive or negative peak of the LV EGM during a cardiac cycle. Recorded EGM's will be measured at three distinct points (basal, mid, and distal) within each target vessel.
1609471|NCT02166749|Procedure|Subtotal abdominal hysterectomy|Comparison of women undergoing subtotal abdominal hysterectomy (n=107) and women with total abdominal hysterectomy (n=105) a mean of 33 years ago.
1609472|NCT02166736|Device|iFR|Treatment guided by Instantaneous wave-free ratio (iFR®)
1609473|NCT02166736|Device|FFR|Intervention guided by Fractional Flow Reserve
1609474|NCT02166723|Device|Cryoballoon Ablation|. The goal was to isolate all 4 veins with application of cryoballoon on the ostium of the vein. A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. . In each patient the left atrium was debulked by applying cryoballoon
1609475|NCT02166723|Device|cryoballoon ablation|A 28 mm balloon was used with centrifugal cooling system. The maximum temperature reached was between -45 C and -60 C to optimize irreversible isolation without causing extracardiac complications. A circular catheter (Achieve) was used to map electrograms in conjunction with the NavX ENSITE 3000, St Judes . Intracardiac ultrasound was used to measure the pulmonary vein diameter, check for intraoperative complications, determine complete occlusion of the vein by the balloon and guide transeptal puncture. In each patient the left atrium was debulked by applying cryoballoon to the left and right sides of the left atrial roof and cryoablation of the left lateral ridge from within the left atrial appendage.
1609476|NCT02166710|Device|Adductor canal femoral nerve block|A 18 Gauge Tuohy needle will be inserted and its position will be confirmed using ultrasound guidance. Once the adequacy of the position is confirmed, the anesthesiologist will administer 15 mL of bupivacaine 0.25% with epinephrine in divided doses and examine the quality of its spread. A 20 Gauge polyamide catheter will be inserted at 2 cm in the space. The needle will then be withdrawn and the catheter will be fixed in place. Three mL of the same mixture of local anesthetics will be administered through the catheter and the anesthesiologist will observe the quality of its distribution. Bupivacaine 0.125% will be administered through the catheter using an infusion pump for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
1609477|NCT02166710|Device|Simulated nerve blockade|The insertion of the Tuohy needle and the injection of 15 mL of bupivacaine 0.25% with epinephrine will be simulated. The insertion of the polyamide catheter, the withdrawal of the needle and the injection of local anesthetics through the catheter will also be simulated. The infusion of bupivacaine 0.125% will also be simulated for 48 hours. Knee extensor muscle strength, pain and side-effects will be assessed at different time-points.
1609478|NCT02166697|Drug|candesartan cilexetil|candesartan cilexetil tablets
1609479|NCT02166684|Device|Do-it-yourself devices|"Medisana Vifit is worn every day all-day by each subject
Subjects use Medisana MTX Blood pressure monitor twice per week for 13 weeks to measure their blood pressure.
Blood cholesterol is measured by subjects using the Mission Cholesterol 3-1 meter once at baseline and once after 13 weeks
Subjects use Medisana BS 440 BT scale daily
In three weeks (week 1, week 7 and week 13) subjects self-record food intake at three days (two week days and on weekend day) using the FatSecret app.
Subjects self-measure fasting blood glucose twice per week for 13 weeks.
Subjects perform a do-it-yourself Oral Glucose Tolerance Test in week 1 and week 13. Subjects use the Medisana MediTouch 2 for assessing blood glucose levels at t=0, t=30, t=60, t=90 and t=120."
1609480|NCT02166671|Biological|HBV booster vaccination 1dose|
1609481|NCT02166658|Drug|Cabazitaxel|Cabazitaxel 25 mg/m2 i.v. infusion (infusion time about 1h) on D1 of each 21-day cycle. Continuation of treatment until progression of brain metastases or unacceptable toxicity.
1609527|NCT02166333|Dietary Supplement|2000 IU/d cholecalciferol|
1609528|NCT02166333|Dietary Supplement|4000 IU/d cholecalciferol|
1609529|NCT02166320|Device|Partially covered SEMS|
1609482|NCT02166645|Other|Prone position|Participants of intervention group will be placed in prone position immediately after extubation and positioned over a roll to raise the chest and facilitate diaphragmatic dynamic, with lateralized head and aligned with the trunk, upper and lower limbs flexed and hands near the face, facilitating hand-mouth access.
1609483|NCT02166645|Other|Supine position|Participants of control group remain in supine position after extubation and positioned with the head in the midline, with the upper side of the thorax and brought forward and rolls down the legs to promote slight flexion (30-40º) in the hips and knees.
1609484|NCT02166632|Procedure|Intracapsular Injection|"The amount of bupivacaine liposome (ExparelTM) will be injected directly into the joint capsule (intracapsular injection), effectively bathing the joint in the medication."
1609485|NCT02166632|Procedure|Periarticular Injection|The amount of bupivacaine liposome (ExparelTM) will be injected periarticulary, via 9 standard periarticular tissue sites around the joint
2010100|NCT03116971|Drug|Cisplatin|Phase II: Cisplatin 75 milligram per square meter (mg/m^2) will be administered over a 60-minute intravenous infusion on Day 1
1609487|NCT02166606|Device|ImageReady MR Conditional Pacing System Implant|Implant according to standard-of-care. No study-specific interventions in that registry.
1609488|NCT02166593|Drug|Pravastatin40mg/Fenofibrate160mg|Pravafenix(Pravastatin40mg/Fenofibrate160mg)
1609489|NCT02166593|Drug|Atorvastatin Sodium 10mg|Lipitor 10mg(Atorvastatin Sodium)
1609490|NCT02166567|Procedure|Staining of spermatozoa with the YoPro dye and sorting of the stained spermatozoa with FACS|
1609491|NCT02166567|Procedure|Swim-up|Semen processing will be carried out with the conventional swim-up method.
1609492|NCT02166554|Other|Saline|On the day of initial surgery
1609493|NCT02166554|Device|Cross-linked Hyaluronan Hydrogel|On the day of the initial surgery
1609494|NCT02166541|Procedure|BCSK|"The BCSK is a specific technique of polysegmental spinal manipulation developed by Professor Kozyavkin based on applying quick short impulse aimed on moving intervertebral joints outside restrictive barrier."
1609495|NCT02166541|Procedure|Traditional spinal manipulation|Spinal manipulation by traditional technique is a mild mobilization without impulse, based on applying gentle repetitive force without crossing restrictive barrier.
1609496|NCT02166541|Procedure|INRS|"The INRS is a treatment program developed at the International Clinic of Rehabilitation where the spinal manipulation is one of several components. There may be some variation in treatment depending on the clinical situation. All children receive the main treatment components which are massage, physical therapy, warm wax and paraffin applications and low electro stimulation with a special portable device as a part of treatment called Reflexotherapy."
1609497|NCT02166489|Biological|Intravenous injection autologous mesenchymal stem cells|Intravenous injection of mesenchymal stem cell in patients with PKD
2010101|NCT03116971|Drug|Etoposide|Phase II: Etoposide 100 mg/m^2 over a 60 minute IV infusion on Days 1-3 will be administered for 6 cycles with each cycle lasting 3 weeks (21 days).
2010102|NCT03116217|Procedure|Fetuses with suspected Posterior Urethral Valves|Fetal urine, post-natal urine, post-natal serum and, possibly, amniotic liquid analysis.
2010103|NCT03116659|Drug|Doxycycline|Doxycycline 100 mg PO BID x 14 days
2010104|NCT03116659|Drug|Imiquimod|up to 2 packs 3/ week x 28 days
2010105|NCT03114501|Behavioral|Yoga|Participants receive yoga sessions up to 5 days per week, based on the patient's schedule, over the course of patients' Radiation Therapy (up to 15 sessions, 45-60 min. each). Yoga sessions audio and video recorded.
2010106|NCT03114501|Behavioral|Yoga Questionnaire|Questionnaire completed during each week of radiation therapy about participant's feelings about the yoga sessions.
2010107|NCT03114501|Behavioral|Symptom Questionnaires|Symptom questionnaires completed before first radiation treatment, during week 3 of radiation therapy, and again after completion of treatment schedule (usually 6 weeks later).
2010108|NCT03113188|Drug|CBP501|CBP501, CDDP plus Nivolumab
2010109|NCT03112187|Drug|Iron Supplement|Ferfer® is a multi-ingredient supplement containing micro-encapsulated iron pyrophosphate (to form liposomes), vitamin C and vitamin B12 which are valuable for the control of nutritional deficiencies or increased organic needs of iron.
2010110|NCT03113500|Drug|Brentuximab Vedotin|Given IV
2010111|NCT03113500|Drug|Cyclophosphamide|Given IV
2010112|NCT03113500|Drug|Doxorubicin|Given IV
2010113|NCT03113500|Drug|Etoposide|Given IV
2010114|NCT03113500|Other|Laboratory Biomarker Analysis|Correlative studies
1609513|NCT02166450|Drug|Nystatin|100 000 IU every 6 h as a suspension
1609516|NCT02166411|Procedure|myomectomy using barbed sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . The myometrial edges will be reapproximated in one or two layers (according to the depth of the uterine wound) by using a 24-cm × 24-cm 0 polydioxanone double-armed suture on a 26-mm half-circle reverse cutting needle( STRATAFIX™ Spiral PDO Knotless Tissue Control Device, Ethicon Inc , Somerville, NJ, USA ).
1609517|NCT02166411|Procedure|myomectomy using conventional sutures|A transverse incision will be made over the myoma using unipolar hook and a cleavage plane between the myoma and uterus will be developed by sharp dissection. After the identification of the cleavage plane, the fibroid will be enucleated by means of adequate traction with a strong grasper and countertraction maneuvers with another grasping forceps . Bipolar forceps will be used to coagulate bleeding points . Myometrial edges will be re-approximated using 1-0 polyglactin 910 suture(VICRYL™.; Ethicon Inc, Sommerville, NJ)
1609518|NCT02166398|Drug|UI15AML055MT|tab, PO
1609519|NCT02166398|Drug|Amosartan 5/50|tab, PO
1609520|NCT02166372|Other|Observation of natural course of Diabetes Mellitus Type 2|
1609521|NCT02166359|Drug|Extraneal (Icodextrin)|
1609522|NCT02166359|Drug|Glucose solution|
1609523|NCT02166346|Drug|Dalfampridine|Dalfampridine 10 mg twice daily for 8 weeks
1609524|NCT02166346|Drug|Placebo|Placebo pill 1 tablet twice daily for 8 weeks
1609525|NCT02166333|Dietary Supplement|200 IU/d cholecalciferol|
1609526|NCT02166333|Dietary Supplement|1000 IU/d cholecalciferol|
1990831|NCT01775865|Drug|Placebo (for salsalate)|
1609530|NCT02166320|Device|Fully covered SEMS|
1609531|NCT02166294|Other|NEOX® CORD 1K|Amniotic Membrane Tissue is fetal membrane tissue that comprises the innermost layer of the human placenta, and the outermost lining of the umbilical cord. In addition to amniotic membrane, the umbilical cord also contains Wharton's jelly, a rich source of proteoglycans and growth factors. These tissues share the same cell origin as the fetus and serve to protect the fetus during development. This product does not contain live cells.
1609532|NCT02166294|Procedure|Standard of Care (Pressure Bandage)|Standard of Care wound, pressure dressing applied as needed at each visit.
1609533|NCT02166268|Drug|AVANZ Phleum pratense 15,000 SQ+|
1609534|NCT02166268|Drug|Placebo|
1609535|NCT02166255|Biological|siRNA-transfected peripheral blood mononuclear cells APN401|Given IV
1609536|NCT02166255|Other|laboratory biomarker analysis|Correlative studies
1609537|NCT02166242|Drug|ethaselen|ethaselen is a specific thioredoxin reductase inhibitor, which has finished phase 1a study in China, phase 1 study of ethaselen showed that 600 mg ethaselen bid could be well tolerated
1609538|NCT02166229|Drug|Divalproex sodium|
1609539|NCT02166190|Procedure|Radiofrequency Ablation using EndoHPB Probe|Radiofrequency Ablation using EndoHPB Probe
1609540|NCT02166190|Procedure|Stenting only|Stenting only
1609541|NCT02166177|Drug|Autologous regulatory T cell product|Autologous regulatory T cell therapy infused intravenously (2 dose groups: low dose and high dose). The patients also receive rabbit Antithymocyte Globulin (rATG), tacrolimus, and sirolimus.
1609542|NCT02166164|Other|Brief thermal sensitization|A small area of the skin of the study participants are heated to 45 degree celsius for 3 minutes, followed by evaluation of secondary hyperalgesia.
1609543|NCT02166164|Other|Long thermal stimulation|A small area of the skin of the study participants are heated to 45 degrees celsius for 1 minute. During the 1 minute period, the study participant will continually report pain on an electronic visual analog scale.
1609544|NCT02166164|Other|Heat-pain-detection threshold|"The threshold for heat pain are evaluated by heating a small area of the study participants skin. When the study participant feels pain, the temperature (degrees celsius) is registered.
4 threshold measurements per session. Heat pain threshold is defined as the average temperature of the 4 measurements."
1609545|NCT02166151|Drug|Omalizimab|Omalizimab 150 mg S.C. once a month for consecutive 3 months
1609546|NCT02166138|Procedure|Non-Abilative Laser treatment|Patients in this group will be given the laser treatment with the non-abilative 1540 nm wavelength. Patients will be blinded to this procedure as they will be wearing protective eye wear and noise canceling headphones. These patients will undergo the treatment 3 times, one at day of discharge, second at the 4 week follow up visit, and third at the 8 week follow up visit. After the 8 week follow up visit, patients will be asked to come in for the 3 month follow up visit and 1 year follow up visit for an evaluation. At each visit, the patient's scar will be photograph for evaluation. Each patient will also be asked to fill out the POSAS, and KOOS at each follow up visits.
1609547|NCT02166125|Procedure|Endosuturing|Endoscopic suturing
1609548|NCT02166112|Procedure|Permacol mesh placement|All patients were treated for a complex abdominal wall hernia by implantation of Permacol mesh. This intervention took place before patients were included in the cohort.
1609549|NCT02166099|Procedure|Choledochoscopy using Digital Spyglass|Choledochoscopy using Digital Spyglass during Endoscopy
1609550|NCT02166086|Procedure|Endoscopy|Endoscopy involving advanced imaging techniques
1609551|NCT02166060|Drug|Ivabradine|Ivabradine 5 mg twice a day or 7,5 mg twice a day
1609552|NCT02166047|Drug|GS-9620|GS-9620 tablets administered orally every 7 days
1609553|NCT02166047|Drug|Placebo to match GS-9620|Placebo to match GS-9620 tablets administered orally every 7 days
1609554|NCT02166034|Behavioral|garden intervention|The intervention includes raised bed garden kits for participating classes as well as access to garden-based curriculum.
1609555|NCT02166021|Biological|Mesenchymal stem cells|
1609556|NCT02166008|Drug|Repamipide|
1609557|NCT02166008|Drug|Placebo|
1609558|NCT02165995|Procedure|Motor Mapping|Motor mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Pads to monitor movements placed on face, arms and legs. A coil that is used to deliver stimulation will be placed on head. During stimulation, participant be asked to move certain muscles and will be monitored for motor responses over the course of 20 to 30 minutes.
1609559|NCT02165995|Procedure|Speech Mapping|Speech mapping performed using nTMS system before surgery, then again at 1, 3, 6, and 12 months following surgery. Participant shown 95 black-and-white drawings of common objects and asked to name them. During stimulation, participant asked to name the objects again and will be monitored for changes in speech or delays. This should take about 1½-2 hours to complete.
1609560|NCT02165969|Procedure|endoscopic endonasal surgery with UPSIT|
1609561|NCT02165956|Dietary Supplement|New Infant Cereal|New Infant Cereal
1609562|NCT02165956|Dietary Supplement|Standard Infant Cereal|Standard Infant Cereal
1609563|NCT02165943|Device|Vitoss|Vitoss is a synthetic calcium-based bone void filler made of beta-tricalcium phosphate.
1609564|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with water, under fasting conditions
1609565|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before,and 12 hours after study drug administration).
1609566|NCT02165930|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, administered with 40% ethanol, under fasting conditions
1609567|NCT02165930|Drug|Naltrexone|Single dose of 40 mg PF-00345439 under naltrexone block (50 mg of naltrexone administered by mouth 12 hours before, 30 minutes before, and 12 hours after study drug administration).
1609568|NCT02165917|Procedure|Excision plus hyaluronic acid gel|Excision of endometriosis foci by laparoscopic standard methods followed by an application of 10 cc Hyaluronic acid gel, in order to prevent postsurgical adhesions.
1609569|NCT02165917|Procedure|Excision only|Excision of endometriosis foci by laparoscopic standard methods only.
1609570|NCT02165904|Biological|Adult Autologous Mesenchymal Bone Marrow Cell|Diagnosed patients with incomplete spinal cord injury and chronically established SCI will be treated with Adult Autologous Mesenchymal Bone Marrow Cells.
1609831|NCT02163746|Procedure|CO2 (carbon dioxide) laser|
1609571|NCT02165891|Drug|insertion of a chest drain with urokinase instillation|Other interventions except drainage procedure are the same in both arms
1609572|NCT02165891|Procedure|primary video-assisted thorascopic surgery|
1609573|NCT02165865|Procedure|upper extremity/ hand transplantation|hand transplant on unilateral dominant hand or bilateral upper extremity amputees
1609574|NCT02165852|Procedure|Papillectomy without injection|Conventional endoscopic mucosal resection of ampulla of Vater using a snare with electrocurrent.
1609575|NCT02165852|Procedure|Papillectomy with injection|Conventional endoscopic mucosal resection of ampulla of Vater without submucosal saline or diluted epinephrine injection.
1609576|NCT02165839|Behavioral|Brief Behavioral Therapy for Insomnia (BBT-I)|
1609577|NCT02165839|Behavioral|Healthy Eating Education Learning (HEAL)|
1609578|NCT02165826|Drug|Roflumilast|Roflumilast tablets
1609579|NCT02165826|Drug|Roflumilast Placebo|Roflumilast placebo-matching tablets
1609580|NCT02165826|Drug|Standard of Care COPD Treatment|The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
2010115|NCT03113500|Drug|Prednisone|Given PO
2010116|NCT03113266|Biological|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
1609583|NCT02165800|Procedure|L-PANP-TME|
1609584|NCT02165800|Procedure|O-PANP-TME|
1609585|NCT02165774|Device|Turning OFF the neuromodulator|Turning OFF the neuromodulator in 50% of the patients in a randomized way by an investigator not involved in the assessment of the clinical outcome during the regular outpatient visit 2 months after neuromodulator implantation. It then follows a 2 months double-blind phase. Thereafter, i.e. during the regular outpatient visit 4 months after neuromodulator implantation, the unblinding takes place and in patients with sacral neuromodulation OFF, the neuromodulator is switched ON.
1609586|NCT02165774|Device|Turning ON the neuromodulator|
1609587|NCT02165761|Device|GORE® Hybrid Vascular Graft|
1609588|NCT02165761|Device|Non-heparin bonded synthetic graft|
2010117|NCT03111108|Drug|MK-5172A (EBR/GZR FDC [50 mg/100 mg])|One FDC tablet orally once daily for 8 or 12 weeks depending upon randomization.
2010118|NCT03111017|Other|Exercise Training|HFpEF patients randomized to either 16 weeks of exercise training or attention control group.
2010119|NCT03110380|Drug|B/F/TAF|50/200/25 mg FDC tablet(s) administered orally once daily
1609592|NCT02165709|Procedure|Salpingectomy|
1609593|NCT02165709|Procedure|Traditional sterilization|
1609594|NCT02165696|Other|Multimodal treatment: compression bandaging and manual lymph drainage.|30 minutes and one hour maximum time of manual lymphatic drainage and compression bandaging with multilayer inelastic bandages with low extensibility. It is possible to apply bandages two or three times per week. Also, an elastic bandage is also held in hand fingers with slight compression and other protective bandage is used in skin. The treatment will be carried out for six weeks five days a week
1609595|NCT02165696|Other|Manual lymph drainage|30 minutes and one hour maximum time of manual lymphatic drainage. The treatment will be carried out for six weeks five days a week.
1609596|NCT02165670|Device|Coronary stenting with CE-marked stent|
1609597|NCT02165657|Device|Excimer laser treatment|Excimer laser irradiation twice a week for up to 20 treatments.
1609598|NCT02165644|Drug|Acetazolamide|"Acetazolamide 250 mg QID oral for 4 days along with standard of care which includes Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days.
If the drug can't be given orally, then feeding tube (NG Tube or DHT) will be used for drug administration."
1609599|NCT02165644|Drug|Nimodipine|Nimodipine 60 mg orally every 4 hours, with therapy starting within 96 hours of the event and continued for 21 days
1609600|NCT02165618|Other|Medication review, based on but not limited to the RASP list|"Systematic approach:
Medication reconciliation
Applying the RASP list
Expert review (not based on the RASP list)
Multidisciplinary discussion"
1609601|NCT02165605|Drug|HylaCare|cream
1609602|NCT02165605|Drug|Placebo|placebo
1609603|NCT02165579|Other|1 cohort, standard care, observational|
1609604|NCT02165566|Drug|Regular-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
1609605|NCT02165566|Drug|Lispro-insulin|patients are assigned in a random sequence to receive Regular-insulin or lispro-insulin infusion
1609606|NCT02165553|Dietary Supplement|Hibiscus sabdariffa calyces extract as a cold drink|
1609607|NCT02165540|Other|Doula|A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
1609608|NCT02165527|Procedure|Lunar iXDA scan|Subject will receive a total body scan taken by the Lunar iXDA. This scan will take approximately 8 minutes to complete. Following the scan, the computer of the Lunar iXDA will calculate the bone length.
1609609|NCT02165514|Procedure|Lunar iDXA x-ray scan|Subjects will lay either on their back or side depending whether subject has kyphosis or scoliosis. After the DEXA scan the computer will calculate the Cobb angle. The calculation of Cobb angle from the DEXA scan will be compared to the conventional spine x-ray.
1609610|NCT02165475|Behavioral|Biofeedback|
1609611|NCT02165475|Drug|Loperamide|
1609612|NCT02165475|Drug|Stool bulking agent (stericulia or isphagula husk)|
1609613|NCT02165475|Other|Combination of biofeedback and medical treatment|
1609614|NCT02165462|Other|Patients with haemophilia|Assessment of bilateral deficit phenomenon during dynamic plantar flexion task with a force platform (Kistler 9286 BA model, Kistler Instruments, Amherst, NY, USA)
1609648|NCT02165215|Drug|Etrolizumab|Participants will receive 105 mg etrolizumab SC injection Q4W.
2010120|NCT03110380|Drug|F/TAF|200/25 mg FDC tablet(s) administered orally once daily
2010121|NCT03110380|Drug|DTG|50 mg tablet(s) administered orally once daily
2010122|NCT03110380|Drug|DTG Placebo|Tablet(s) administered orally once daily
1609615|NCT02165449|Drug|Ketamine|Approved FDA indications for ketamine include use as an adjunct in the induction and maintenance of general anesthesia and for procedural sedation. For general anesthesia, ketamine is given at dosages ranging from 1-2mg/kg and given either as bolus injection or run continuously (0.1 to 0.3mg/kg/min) in conjunction with another anesthetic or sedation agent. In this study, ketamine at a subanesthetic dose of 0.5mg/kg will be diluted in 60cc of normal saline and administered via a slow IV infusion over 40 minutes at each treatment session in patients while undergoing hemodynamic monitoring. When used in this manner, ketamine infusion does not induce general anesthesia or states of unconsciousness, and patients remain fully awake, responsive to commands, and do not lose respiratory drive.
1609616|NCT02165436|Other|Chewing gum|Subjective assessment - subjective assessment of abdominal pain and nausea.
1609617|NCT02165436|Other|Control|No intervention will be assessed for this group.
1609618|NCT02165423|Behavioral|myFAMI iPad application|
1609619|NCT02165410|Procedure|ASL-MRI|ASL MRI is a non-invasive technique without injection to measure rCBF at rest marking the intravascular water molecules and use it as an endogenous tracer. Premedication, if required, will concern autistic and mentally retarded subjects only.
1609620|NCT02165410|Procedure|Diffusion tensor imaging (diffusion MRI)|Diffusion MRI enables the mapping of the diffusion process of water molecules, which allows visualizing anatomical connections between different parts of the brain, noninvasively and on an individual basis. The sequence is acquired following clinical MRI sequences, while the child is still inside the MRI machine, with no further intervention applied.
1609621|NCT02165410|Procedure|Eye-tracking|Eye tracking is a non-invasive method that allows objectifying gaze parameters during presentation of stimuli on a computer screen. Children will be presented with a series of social and no social stimuli and are required to watch it, with no further intervention applied.
1609622|NCT02165410|Procedure|Cognitive profile|Children will be asked to perform certain tasks, adapted for their age.
1609623|NCT02165397|Drug|Ibrutinib|Subjects will receive 420 mg of Ibrutinib orally. Other Name: PCI-32765
1609624|NCT02165397|Drug|Placebo|Subjects will receive placebo capsules orally.
1609625|NCT02165397|Drug|Rituximab|Drug: rituximab Subjects will receive rituximab 375mg/m2 intravenously Other Name: Rituxan
1609626|NCT02165384|Device|Ear tube placement with the Hummingbird TTS|Using the Hummingbird TTS to make a myringotomy and deliver a tympanostomy tube across the tympanic membrane with one pass.
1609627|NCT02165371|Behavioral|Sinovuyo Caring Families Programme|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.
Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.
The program is manualized in isiXhosa."
1609628|NCT02165345|Drug|Tocilizumab|162 mg tocilizumab will be administered by SC injection at the following intervals: pJIA participants less than (<) 30 kilograms (kg): every 3 weeks; pJIA participants greater than or equal to (>=) 30 kg: every 2 weeks; sJIA participants <30 kg: every 2 weeks; sJIA participants >/= 30 kg: once weekly
1609629|NCT02165332|Drug|Part 1: SAD RO7033877|Single dose
1609630|NCT02165332|Drug|Part 1: SAD placebo|Single dose
1609631|NCT02165332|Drug|Part 2: Treatment A, RO7033877|Single dose RO7033877 and moxifloxacin placebo
1609632|NCT02165332|Drug|Part 2: Treatment B, RO7033877|Single dose RO7033877 and moxifloxacin placebo
1609633|NCT02165332|Drug|Part 2: Treatment C, moxifloxacin|Single dose moxifloxacin and RO7033877 placebo
1609634|NCT02165332|Drug|Part 2: Treatment D, RO7033877 and moxifloxacin placebo|Single dose moxifloxacin placebo and RO7033877 placebo
1609635|NCT02165319|Device|Barrel|Barrel-shaped endotracheal tube will be used during general anesthesia.
1609636|NCT02165319|Device|Tapered|Tapered-shaped tube will be used during general anesthesia.
1609637|NCT02165306|Behavioral|Motivational Interviewing (MI)|"A multifaceted intervention program was used to improve adherence and clinical outcomes in epileptic patients. However, this study mainly focused on behavioral treatment in the patients.
Patient's intervention A three-week session will perform to improve medication adherence in patients in the intervention group. Face to face introductory motivational interviews (MI) will conduct to resolve patient ambivalence about change.
Besides providingthe intervention for the patients, the health care team and the patient's family member will receive a brief intervention.All GPs and nurses as well as patients' family members participate in a single session MI with the same procedure"
1609638|NCT02165306|Behavioral|Routine counseling|All participants of the study in both group receive the Standard Care. Usually, patients in clinics receive a one-time session of brief advice to use medications regularly lasting approximately 5 minutes and deliver by nurse or physician. Some issues rise in this short session including coexisting diseases, the history of drug use, current disease and advice about the health risks of irregular medication use.
1609639|NCT02165293|Drug|RO7033877 + Bronchoscopy|Days 1, 2, and 3: 2.5 mg/kg RO7033877 infused IV over 2 hours, every 8 hours for a total of 7 doses; BAL procedure on Day 3.
1609640|NCT02165280|Behavioral|Guided IMagery (GIM)|It's a program of directed thoughts and suggestions that guide your imagination to a relaxed and focused state.
1609641|NCT02165267|Biological|VRC01|Administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP) or administered SC by needle and syringe injection.
1609642|NCT02165267|Biological|SC placebo for VRC01|Sterile, buffered aqueous solution of 25 mM Sodium Citrate, 50 mM Sodium Chloride, 150 mM L-Arginine Hydrochloride, 10% Dextran 40, and 0.005% Polysorbate 80 at pH 5.8 administered SC by needle and syringe injection
1609643|NCT02165267|Biological|IV placebo for VRC01|Sodium Chloride for Injection 0.9%, USP administered IV in 100 mL of normal saline (Sodium Chloride for Injection 0.9%, USP)
1609644|NCT02165254|Behavioral|PLUS|1 hour tai chi session 3 times a week (weeks 1-12), to twice a week (week 13-16), and every other week (week 17-26) for a total of 24 weeks
1609645|NCT02165254|Behavioral|LITE|1 hour tai chi session 3 times a week (weeks 1-12)
1609646|NCT02165228|Behavioral|Mindfulness-based stress reduction|Stress reduction class and behavioral intervention
1609647|NCT02165228|Behavioral|Nutrition Enhancement|Nutrition education class and behavioral intervention
1609707|NCT02164812|Drug|Placebo|
1609649|NCT02165215|Drug|Placebo|Participants will receive etrolizumab matching placebo Q4W.
1609650|NCT02165202|Drug|Rilpivirine|Rilpivirine (TMC278), a non-nucleoside reverse transcriptase inhibitor (NNRTI) is a substituted diaryl-pyrimidine (DAPY) derivative with potent antiviral activity against HIV. It is approved by the US FDA for once daily oral administration and is effective as part of treatment for ARV-na'ive HIV-infected patients as rilpivirine 25 mg capsules. It is also co-formulated with TDF and FTC for use as a once- daily single fixed-dose combination (Complera™).
1609651|NCT02165202|Drug|Placebo|Participants randomized to the placebo arm will receive oral placebo capsules prior to injection of saline solution (0.9%NaCI). Participants will be observed while taking the study product by site staff on approximately six occasions during the first two weeks of the oral run-in at Week 0 (Enrollment), at Week 2 (Oral Run-in Safety Visit), and on four separate DOT visits between Weeks 0 and 2. Cervicovaginal and rectal fluid will be collected for PK studies at a single follow-up visit.
1609652|NCT02165189|Drug|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 12 weeks.
1609653|NCT02165189|Drug|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 12 weeks.
1609654|NCT02165189|Drug|Ribavirin|Participants will be administered ribavirin 2 x 200 mg tablets (for participants weighing less than 75 kilogram ([kg]) or 3 x 200 mg tablets (for participants weighing more than 75 kg) orally once daily up to 12 weeks.
1609655|NCT02165189|Drug|Simeprevir|Participants will be administered simeprevir capsule 150 mg orally once daily up to 24 weeks.
1609656|NCT02165189|Drug|Sofosbuvir|Participants will be administered sofosbuvir 400 mg tablet orally once daily up to 24 weeks.
1609657|NCT02165176|Drug|Oral cannabis|
1609658|NCT02165163|Other|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
1609659|NCT02165150|Other|Wheelchair-bound Senior Elastic Band exercise program|three times per week, 40 minutes per practice
1609660|NCT02165124|Device|Artificial Embolization Device|Embosphere Microspheres
1609661|NCT02165111|Drug|Onabotulinumtoxin A|
1609662|NCT02165111|Drug|sterile saline solution|
1609663|NCT02165098|Drug|Cariprazine prolonged release tablet A|Cariprazine prolonged release tablet A - fasted
1609664|NCT02165098|Drug|Cariprazine prolonged release tablet B|Cariprazine prolonged release tablet B - fasted
1609665|NCT02165098|Drug|Cariprazine capsule|Cariprazine capsule - fasted
1609666|NCT02165098|Drug|Cariprazine PR tablet A|Cariprazine Prolonged Release tablet A - fed
1609667|NCT02165098|Drug|Cariprazine PR tablet B|Cariprazine Prolonged Release tablet B - fed
1609668|NCT02165046|Drug|Budesonide|
1609669|NCT02165046|Drug|Procaterol|
1609670|NCT02165033|Drug|Budesonide/Procaterol 180/10 X 4 puffs|Budesonide/Procaterol 180/10mcg, 4 puffs, Repeated dose
1609671|NCT02165020|Device|Hyaluronic acid (Macrolane VRF 30®, Q-MED)|"One injection of 3 to 10 cc of hyaluronic acid (Macrolane VRF 30®, Q-MED) introduced in the perirectal fat between the rectum and the prostate in connection with an ultrasound.
The injection is performed under local anesthesia (with Lidocaine) and ultrasound guidance, using a 16 gauge needle."
2010123|NCT03110380|Drug|F/TAF Placebo|Tablet(s) administered orally once daily
1609673|NCT02164981|Drug|sodium nitroprusside|intravenous
1609674|NCT02164981|Other|Placebo|Placebo
1609675|NCT02164955|Drug|IMNOVID|IMNOVID (pomalidomide) as prescribed in routine clinical practice
2010124|NCT03110380|Drug|B/F/TAF Placebo|Tablet(s) administered orally once daily
2010125|NCT03110367|Behavioral|Pain Reframing Intervention|Parents and youth in the intervention group will receive instructions about adaptive ways of reminiscing about the in-hospital and post-surgery periods. The intervention will draw from existing narrative-based interventions that have taught parents to reminisce with their children about past negative events in more elaborative and emotion-rich ways (e.g., using more open-ended questions, to follow in on children's answers by providing new details about the event, to talk more about emotions, and to praise children's answers).
2010126|NCT03110367|Behavioral|Attention Control Group|Parents and youth in the attention control group will watch a neutral 20-minute video that is not related to surgery (Planet Earth). Importantly, they will not talk about pain or the past surgery experience.
2010127|NCT03110133|Drug|Full Spectrum Microbiota|Orally administered donor derived microbiota
2010128|NCT03110133|Drug|Placebo|Placebo for CP101
2010129|NCT03109301|Drug|Selumetinib (AZD6244 hyd sulfate)|Selumetinib will be administered at a starting dose of 50 mg/dose orally in patients 18 years or older and 25 mg/m^2/dose in children <18 years of age; drug will be given twice daily continuously in the absence of toxicity or disease progression, using 28-day cycles.
2010130|NCT03109769|Behavioral|Mobile phone application|
2010131|NCT03109769|Behavioral|Verbal oral hygiene instructions|
1609691|NCT02164903|Other|QoL Survey Booklet|
1609692|NCT02164890|Other|micafungin|This is a pharmacokinetic study where a total number of 14 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected.
1609693|NCT02164877|Drug|pectin|Patients allocated to experiment group will receive 15g pectin each day
1609694|NCT02164864|Drug|Dabigatran Etexilate 110mg|Active treatment
1609695|NCT02164864|Drug|Warfarin 3mg|Active comparator
1609696|NCT02164864|Drug|Aspirin|Active comparator
1609697|NCT02164864|Drug|Dabigatran Etexilate 150mg|Active treatment
1609698|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active comparator
1609699|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active comparator
1609700|NCT02164864|Drug|Warfarin 5mg|Active comparator
1609701|NCT02164864|Drug|Clopidogrel or Ticagrelor|Active comparator
1609702|NCT02164864|Drug|Warfarin 1mg|Active comparator
1609703|NCT02164838|Drug|Axitinib|
1609704|NCT02164825|Drug|Ropivacaine perineural injection|Ultrasound guided single-shot femoral nerve block
1609705|NCT02164825|Drug|morphine and ropivacaine|Continuous epidural analgesic perfusion Epidural perfusion with morphine and ropivacaine.
1609706|NCT02164812|Drug|Moxifloxacin|
1609709|NCT02164773|Drug|Magnesium Sulfate|use of 50mg magnesium sulfate in caudal analgesia added to 1ml/kg of 0.25% of bupivacaine in children undergoing lower abdominal surgery for prevention of postoperative emergence agitation.
1609710|NCT02164773|Drug|0.9%normal saline|use of 1ml of 0.9%normal saline added to 1ml/kg of 0.25% of bupivacaine in the caudal block as placebo to compare with active comparator.
1609711|NCT02164760|Device|Novomaix dermal substitute in combination with STSG|Novomaix dermal substitute in combination with STSG
1609712|NCT02164747|Device|Residents of nursing homes with telemedicine after implementation of telemedicine|
1609713|NCT02164734|Device|Endotracheal intubation|
1609714|NCT02164734|Device|Laryngeal mask airway|
1609715|NCT02164734|Drug|remifentanil|additional premedication in the endotracheal intubation/INSURE arm
1609716|NCT02164721|Device|Three-lead CRT-D (Defibrillator)|The three-lead CRT-D (Defibrillator) will consist of a pulse generator, a right atrial lead, a right ventricular lead and a left ventricular lead.
1609717|NCT02164708|Behavioral|Mindfulness Meditation|"The program progressively trained students in mindfulness of breathing, a form of meditation frequently employed secularly. The tutorials were held on campus five times weekly, led by a faculty member and a graduate student who were trained, experienced MM practitioners. The tutorials were one hour in duration and typically involved 40-45 minutes of guided MM followed by a question-answer period that addressed recent research findings. Program participation required attendance at one tutorial per week, and participants were encouraged to maintain autonomous MM practice."
1609718|NCT02164695|Procedure|Remote ischemic perconditioning (RIPC)|All patients will be prepared with an upper-arm blood pressure cuff before arterial puncture (contralateral in case of radial access). In patients allocated into PPCI plus RIPC group, the protocol will be started immediately after cuff preparation. Upper-arm will be exposed to 4 cycles of ischemia/reperfusion, each obtained by 5 min cuff inflation at 200mmHg, followed by 5 min complete deflation.
1609719|NCT02164682|Procedure|IV PCA group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen
1609720|NCT02164682|Procedure|IV PCA+ caudal block group|The IV PCA is performed by injecting fentanyl 15 mcg/kg with the following regimen + caudal block was 0.15% ropivacaine 1.2 cc/kg; a total volume of 100 cc, basal 2 cc, bolus 0.5 cc, and lockout time 15 minutes.)
1609721|NCT02164656|Behavioral|mindfulness for smokers|
1609722|NCT02164643|Drug|Flutemetamol (18F)|
1609723|NCT02164643|Drug|Florbetapir (18F)|
1609724|NCT02164630|Behavioral|Hope Therapy|Hope therapy is designed to address key components of hope theory through augmentation of hopeful thinking and enhancement of goal-directed activities. Training focuses on effective goal setting, mobilization of internal resources to reach goals, identification of resilience factors to formulate hopeful thinking, and enhancing maintenance of future goal development.
1609725|NCT02164630|Other|Pain Education|Pain Education is aimed to increase understanding of TMD symptomatology and etiology, as well as provide general education on pain, lifestyle management, and effective pain communication methods.
1609726|NCT02164617|Other|Wheelchair-bound Senior Elastic Band exercise program (WSEB)|Wheelchair-bound Senior Elastic Band exercise program (WSEB) three times per week, 40 minutes per practice
1609727|NCT02164604|Drug|intravitreal injection of 0.03ml ranibizumab|
1609728|NCT02164578|Drug|Rivaroxaban|
1609729|NCT02164578|Drug|Aspirin|
1609730|NCT02164565|Drug|Tranexamic Acid (TXA) treatment|Tranexamic Acid (TXA) treatment
1609731|NCT02164565|Drug|control grup: without Tranexamic Acid (TXA) treatment.|control grup: without Tranexamic Acid (TXA) treatment.
1609732|NCT02164552|Dietary Supplement|Vitamin D3 pills|Dietary supplement
1609733|NCT02164552|Other|Placebo pills|Placebo pills similar in appearance and shape but without vitamin D
2010132|NCT03108495|Biological|LN-145|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes.
2010133|NCT03106779|Drug|ABL001|40 mg tablets will be taken orally twice a day (BID)
2010134|NCT03106779|Drug|Bosutinib|500 mg tablets will be taken orally once daily (QD)
1609737|NCT02164526|Other|Routine therapy|Routine therapy
2010135|NCT03105193|Drug|IV Saline bolus and infusion|Intravenous bolus of normal saline at induction 3 day postoperative infusion of normal saline administered by ambit pump
2010136|NCT03105193|Drug|IP Saline bolus and infusion|Intraperitoneal bolus of normal saline down first port site. 3 day post operative intraperitoneal infusion of normal saline via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
2010137|NCT03105193|Drug|IV lignocaine bolus and infusion|Intravenous lignocaine bolus at induction. 3 day postoperative IV infusion of lignocaine administered by ambit pump
1609741|NCT02164500|Drug|Ruxolitinib|
1609742|NCT02164474|Behavioral|High-Intensity Interval Training|Specifically, individuals randomized to HIIT will begin the intervention with four intervals lasting 1-minute each at ~85-90% peak oxygen uptake [VO2peak] and increasing to 10 X 1-min intervals by day 10 of the intervention. Individuals randomized to moderate-intensity exercise condition will begin the intervention with 20 minutes of continuous activity at ~55-60% V02peak and gradually increase the duration to 50 minutes by day 10 of the intervention.
1609743|NCT02164461|Biological|ADXS11-001|
1609744|NCT02164448|Drug|the dexmedetomidine group|the dexmedetomidine group: dexmedetomidine infusion from induction of anesthesia to end of surgery
1609745|NCT02164448|Drug|the control group|saline infusion from induction of anesthesia to end of surgery
1609746|NCT02164435|Procedure|Renal Denervation (EnligHTN™) Renal artery ablation with the EnligHTN™ Renal Denervation System.|
1609747|NCT02164422|Drug|Guanfacine 3mg/day|3 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
1609832|NCT02163746|Procedure|Surgical Deroofing|
2010138|NCT03105193|Drug|IP Lignocaine bolus and infusion|Intraperitoneal bolus of lignocaine down first port site. 3 day post operative intraperitoneal infusion of lignocaine via an intraperitoneal line inserted by the surgeon. Infusion will be administered by ambit pump.
2010139|NCT03105089|Procedure|ischemic preconditioning|) ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
1609748|NCT02164422|Drug|Guanfacine 1.5mg/day|1.5 mg/day Guanfacine with 3-week lead-in period. Maintained at steady state throughout lab sessions. After lab sessions, given taper supply of medication. Follow up 2 weeks after completion of taper.
1609749|NCT02164422|Drug|Placebo|
1609750|NCT02164409|Procedure|Endoscopy tissue collection|The investigational part of this study is the requirement for an additional biopsy from a site that is already being biopsied at the time of a routine endoscopy. Any patients who develop bleeding following their routine clinical biopsies will not undergo any additional research biopsies.
1609751|NCT02164396|Device|Spectacle Lens|Spectacle Lens Only
1609752|NCT02164396|Device|Habitual Soft Contact Lens|subject's own contact lens
1609753|NCT02164396|Device|Test Lens|senofilcon A or narafilcon A
1609754|NCT02164383|Drug|Nicotine patch|4-week starter kit of nicotine patch
1609755|NCT02164383|Behavioral|Cessation Counseling|5 brief counseling sessions
1609756|NCT02164383|Device|Mobile Games|
1609757|NCT02164357|Procedure|EVT (endovascular treatment )|
1609758|NCT02164357|Procedure|IVT (intravenous thrombolytic therapy)|
1609759|NCT02164344|Dietary Supplement|probiotics|probiotics (Streptococcus salivarius ssp. termophilus, Bifidobacterium breve, Bifidobacterium infantis, Bifidobacterium longum, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus casei, Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus faecium)
1609760|NCT02164331|Behavioral|JNC guideline training|Providers will receive a series of trainings on what the JNC guidelines for treating uncontrolled hypertensives are and strategies for meeting those guidelines.
2010140|NCT03104842|Drug|Isatuximab|Antibody Intravenous
2010141|NCT03104842|Drug|Carfilzomib|Intravenous
1609763|NCT02164305|Other|Strengthening group|Open-chain exercise for rotator cuff and scapular muscles
1609764|NCT02164305|Other|Neuromuscular group|Closed-chain exercise for shoulder muscles
1609765|NCT02164305|Other|Control|No exercise training
1609766|NCT02164292|Procedure|ALPPS|Associating Liver Partition and Portal vein ligation for Staged hepatectomy
1609767|NCT02164279|Other|Urinary sample collection|urinary sample collection will be done at the inclusion visit for the assessment of the microalbuminuria ( < or > than 100mg/L)
1609768|NCT02164266|Drug|Placebo|Matching placebo daily oral administration
1609769|NCT02164266|Drug|RO6799477|Daily oral administration of RO6799477
1609770|NCT02164253|Drug|Deferiprone|30 mg/kg per day, oral use
1609771|NCT02164240|Drug|Sunitinib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
1609772|NCT02164240|Drug|Regorafenib|Intervention Description: 3 days of once daily sunitinib alternating with 4 days of once daily regorafenib throughout each 28 day cycle. The starting dose level (level 1) is sunitinib 37.5 mg/d and regorafenib 120 mg/d, and doses will be escalated in subsequent cohorts following a classical 3+3 design up to sunitinib 50 mg/d and regorafenib 160 mg/d or until maximum tolerable dosage (MTD) and recommended phase II dose (RP2D) is determined. Number of Cycles: until progression or unacceptable toxicity develops.
1609773|NCT02164227|Other|Respiratory pattern|
1609774|NCT02164214|Drug|etanercept Treatment|
1609775|NCT02164188|Behavioral|Flourishing protocol|This intervention is based on relaxation, well-being promotion, meditation practices, positive psychology principles. The format is 1hour and half meetings during 8 weeks, and daily practices. MP3 audios are presented for daily practices.
1609776|NCT02164175|Device|HeRO Graft implant for dialysis access|End Stage Renal Disease patients who receive HeRO Graft implant for dialysis access
1609777|NCT02164162|Device|Lokomat (Hocoma, Zurich, Switzerland)|Patients allocated to the Experimental group performed a Robotic Assistested Gait Training by means of the Lokomat. The Lokomat is robotic device set up as an exoskeleton on the lower limbs of the patient. The system uses a dynamic body weight-support system to support he participant above a motorized treadmill synchronized with the Lokomat.
1609778|NCT02164162|Other|Conventional physical treatment|Patients allocated to the Control Group performed a general exercise program and a conventional gait training. The general exercise program consisted in cardiovascular warm-up exercises, muscle stretching exercises, active-assisted or active isometric and isotonic exercises for the main muscles of the trunk and limbs, relaxation exercises, coordination and dual task activities and balance exercises. The conventional gait therapy was based on the proprioceptive neuromuscular facilitation (PNF) concept (lasting 30 minutes), with rhythmic initiation, slow reversal, and agonistic reversal exercises applied to the pelvic region, each 10 minutes long. The same trained therapist treated all the patients in this group and standardized the duration of each part of the treatment.
1609779|NCT02164149|Other|Patients with primary colon cancer|CT scan two days after surgery
1609780|NCT02164136|Procedure|L-PANP-TME|
1609781|NCT02164136|Procedure|O-PANP-TME|
1609782|NCT02164123|Other|Spinal mobilization|Experimental group
1609783|NCT02164123|Other|Spinal Mobilization II|Active comparator group
1609784|NCT02164123|Other|Placebo|Placebo group
1609785|NCT02164110|Biological|Euvichol|"Number of doses and intervals: two doses/Weeks 0 and 2
Method of administration: oral administration
Dose of drug to be administered: 1.5 mL/dose"
1609786|NCT02164110|Biological|Shanchol|"Number of doses and intervals: two doses/Weeks 0 and 2
Method of administration: oral administration
Dose of drug to be administered: 1.5 mL/dose"
1609787|NCT02164097|Drug|ODSH|
1609788|NCT02164084|Drug|SB204|SB204 Gel with hydrogel
1609789|NCT02164084|Drug|Vehicle Gel|Vehicle Gel with hydrogel
1609790|NCT02164071|Other|Geriatric Assessment of Health Status Scale administration|Scale will be administered to all patients (3 cohorts) at baseline and then after 5 and not more than 15 days
1609791|NCT02164058|Device|TandemHeart System|
1609792|NCT02164058|Procedure|Percutaneous coronary intervention|
1609793|NCT02164045|Drug|BMS-663068|BMS-663068
1609833|NCT02163733|Drug|AZD9291 tablets|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
2010142|NCT03104842|Drug|Lenalidomide|Capsel
2010143|NCT03104842|Drug|Dexamethasone|Capsel
2010144|NCT03104998|Drug|Coenzyme Q10|200 mg of CoQ10 or placebo daily by mouth from day 1 till 26 weeks. CoQ10 treatment is safe, even at the highest doses cited in the literature. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. However, gastrointestinal effects such as abdominal discomfort, nausea, vomiting, diarrhea, and anorexia have occurred. Allergic rash and headache have also been reported
2010145|NCT03101670|Drug|filgotinib|one filgotinib oral tablet q.d.
2010146|NCT03101670|Drug|Placebo Oral Tablet|one placebo oral tablet q.d.
2010147|NCT03102125|Drug|Regadenoson|For use in stress myocardial perfusion imaging.
1609800|NCT02164006|Drug|TGR-1202 + brentuximab vedotin|TGR-1202 an oral daily dose with an IV infusion of brentuximab vedotin
1609801|NCT02163993|Drug|LY2951742|Administered SQ
1609802|NCT02163993|Drug|Placebo|Administered SQ
1609803|NCT02163980|Drug|Caudal ropivacaine + normal saline|
1609804|NCT02163980|Drug|Caudal ropivacaine + dexmedetomidine|
1609805|NCT02163967|Device|Cranial Electrical Stimulation Fisher-Wallace Stimulator (Model FW100)|low voltage alternating current transcranial electrical stimulation
1609806|NCT02163954|Drug|Ticagrelor|After randomization, an initial loading dose of ticagrelor (180 mg) was given and maintenance doses (ticagrelor 90 mg twice daily) was treated for 14 days.
1609807|NCT02163954|Drug|Clopidogrel|After randomization, an initial loading dose of clopidogrel (300 mg) was given and maintenance doses (clopidogrel 75 mg once daily) was treated for 14 days.
1609808|NCT02163941|Behavioral|Compassion Training|
1609809|NCT02163928|Other|Food-based intervention; increased fruits and vegetables|4-6 cups of fruits and vegetables daily for 8-weeks
1609810|NCT02163915|Drug|TAK-137|TAK-137 tablets
1609811|NCT02163915|Drug|TAK-137 Placebo|TAK-137 placebo-matching tablets
1609812|NCT02163902|Drug|ATX-101|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
1609813|NCT02163902|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements, recording of adverse events
1609814|NCT02163876|Drug|HuCNS-SC cells|surgery arm
1609815|NCT02163863|Device|Femoropopliteal stenting|
1609816|NCT02163850|Device|Direct Flow Medical|Direct Flow Medical Transcatheter Aortic Valve Replacement System (TAVR)
1609817|NCT02163850|Device|Commercially Available|Medtronic CoreValve Transcatheter Aortic Valve Replacement System (TAVR) or Edwards SAPIEN Transcatheter Aortic Valve Replacement System (TAVR)
2010148|NCT03099096|Drug|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within an autoinjector.
1609819|NCT02163824|Drug|KPI-121|KPI-121 drug product will be supplied in two strengths: 0.25% and 1.0% as a suspension in identically packaged opaque dropper bottles. KPI-121 drug product is a sterile, aqueous, submicron suspension of loteprednol etabonate. Subjects randomized to placebo control arms will receive the same bottles containing all components at the concentrations used in the KPI-121 drug product with the exception of the active component, loteprednol etabonate.
1609820|NCT02163824|Drug|Vehicle of KPI-121 Ophthalmic Suspension|Vehicle of KPI-121 0.25% Ophthalmic Suspension will be dosed QID (Placebo A), Vehicle of KPI-121 1.0 % Ophthalmic Suspension will be dosed BID (Placebo B).
1609821|NCT02163811|Behavioral|VETPALS|"VETPALS is an adaption of an empirically supported self-management program, PALS (Promoting Amputee Life Skills). The PALS program demonstrated improved physical and psychosocial functioning when delivered in community-based support groups for amputees, but this program has not been adapted for the needs of Veterans and implemented in the VA healthcare system.
VETPALS is a five session course for people with life changes after amputation. The five sessions are held weekly, and are facilitated by a VA clinician in conjunction with a peer facilitator (Veteran with limb loss). Veterans receive all usual care."
1609822|NCT02163811|Behavioral|Individual Education Support Program|VETPALS facilitator provide post-amputation education materials from the Amputee Coalition, including First Step - A Guide for Adapting to Limb Loss and Side Step - A Guide to Preventing and Managing Diabetes and Its Complications. Veterans receive all usual care.
1609823|NCT02163798|Behavioral|12-week instructor-led Tai Chi training program|A 12-week (45 min per day, 5 days per week) instructor-led Tai Chi training program was conducted in the Tai Chi group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of Tai Chi exercise, and 5-min cool down stretching. The modified 32 Yang-style Tai Chi Chuan was used, because it could be learned within a relatively short time, and has been widely promoted in HK community. An exercise log was used to record the actual implementation of the training (instructor-led & self-practice).
1609824|NCT02163798|Behavioral|12-week instructor-led brisk walking training program|A 12-week (45 min per day, 5 days per week) instructor-led brisk walking training program was conducted in the walking group. Of the 5 days of exercise, 3 days were led by qualified instructors, and 2 other days for self-practice. Each session consisted of a 10-min standard warm-up, 30-min of walking exercise, and 5-min cool down stretching. An exercise log was used to record the actual implementation of the training (instructor-led & self-practice).
1609825|NCT02163785|Procedure|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer|Abdominoperineal extra-elevators rectal resection for low lying rectal cancer involving anal sphincter complex
1609826|NCT02163772|Procedure|Intracordal hyaluronate injection|
1609827|NCT02163759|Drug|Adalimumab|Adalimumab 160 milligrams (mg) will be administered subcutaneously (SC) at Week 0; 80 mg SC at Week 2; 40 mg SC at Weeks 4, 6 and 8.
1609828|NCT02163759|Other|Adalimumab Placebo|Placebo matched to adalimumab will be administered SC at Weeks 0, 2, 4, 6 and 8.
1609829|NCT02163759|Drug|Etrolizumab|Etrolizumab 105 mg will be administered SC every 4 weeks (Q4W).
1609830|NCT02163759|Other|Etrolizumab Placebo|Placebo matched to etrolizumab will be administered SC Q4W.
2010149|NCT03098459|Other|Non-interventional observational prospective cohort study|Non-interventional observational prospective cohort study
1609834|NCT02163733|Procedure|Pharmacokinetic sampling - AZD9291|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
1609835|NCT02163733|Other|Dietary Fasted|Fasted from 10 hours prior to dosing with 80mg AZD9291 tablet and 4 hours after dosing
1609836|NCT02163733|Other|Dietary High Fat|Allocated breakfast prior to dosing with 80mg AZD9291 tablet
1609837|NCT02163733|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples taken pre and post dosing of AZD9291 following either a period of fasting or consumption of a meal.
1609838|NCT02163720|Drug|Yondelis®-Caelyx®|Observation of Yondelis®-Caelyx® administration
1609839|NCT02163707|Drug|Psilocybin|Dose 1: 0.3 mg/kg (approximately 20mg/70kg) Dose 2: 0.45 mg/kg (approximately 30 mg/70 kg) Dose 3: 0.6 mg/kg (approximately 40 mg/70 kg)
1609840|NCT02163694|Drug|Veliparib|Veliparib on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
1609841|NCT02163694|Drug|Carboplatin|Day 1 of 21-day cycle
1609842|NCT02163694|Drug|Paclitaxel|Day 1 of 21-day cycle
1609843|NCT02163694|Other|Placebo|Placebo on Day -2 through 5 of a 21-day cycle. In addition, carboplatin and paclitaxel will be administered on Day 1 of a 21-day cycle.
2010150|NCT03097692|Procedure|ischemic preconditioning|ischemic preconditioning will be done after induction and before cardiopulmonary bypass by inflation the cuff of blood pressure above 200mmhg in the lower limb every 5 min for 3cycles
1609845|NCT02163668|Other|Yoga Group|8 months of Yoga training
1609846|NCT02163655|Drug|FUROSEMIDE|Furosemide, 20mg pills, will be administered every 24 houras, for a maximum of five days
1609847|NCT02163655|Drug|Placebo|Placebo pills, identical to the intervention (furosemide pills), will be administered every 24 hour for a maximum of five days
1609848|NCT02163642|Device|Cyranose® 320|Detection of patterns of specific Volatile Organic Compounds in exhaled air
1609849|NCT02163629|Behavioral|Stress management|
1609850|NCT02163616|Drug|Misoprostol|800 mcg of sublingual misoprostol
1609851|NCT02163603|Procedure|Pelvic osteotomy|
1609852|NCT02163590|Other|2Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
1609853|NCT02163590|Other|0,5Hz mobilisation|This intervention will be applied for 3 sets of 1 minute, with 1 minute rest period in between each set.
1609854|NCT02163590|Other|Placebo|Intervention that mimics the experimental procedures
2010151|NCT03097484|Drug|lavender and chamomile essential oils|Our patches are obtained from BioEsse Technologies™. Each patch contains a 50:50 mixture of Lavender and Chamomile essential oils in a 55 microliter standard dose patch. The patches release the aromatherapy over a 2-8 hours period and the diffusion rate of each patch is identical. The back of the patch is layered with a hypoallergenic medical grade adhesive, similar to the material found on ECG leads.
1609856|NCT02163564|Behavioral|Cognitive Behavioral Therapy for Insomnia|A non-pharmacological therapy for insomnia based on behavior and cognitive therapy approaches
2010152|NCT03098160|Drug|Evofosfamide|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
1609859|NCT02163525|Procedure|Global Fibroid Ablation (GFA)|GFA is radiofrequency ablation of fibroids. This is a laparoscopic procedure whereby a radiofrequency probe is inserted into the fibroid under laparoscopic and ultrasound guidance. Each fibroid is heated to temperatures averaging 95 deg C. The fibroid undergoes coagulative necrosis and shrinks and/or disappears.
1609860|NCT02163525|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which an incision is made into the uterus and the fibroids are surgically removed from the uterus. The uterine incision is closed with sutures. This procedure can be performed through an abdominal incision or via laparoscopy.
1609861|NCT02163525|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids. An embolic material is injected into the uterine artery(ies) to block blood flow to one or more fibroids. This procedure is performed by an interventional radiologist.
1609862|NCT02163499|Drug|Sodium Zirconium Cyclosilicate|Acute Phase Dosing: Sodium Zirconium Cyclosilicate 10 g three times daily (TID) for 24 to 72 Extended Dosing: Sodium Zirconium Cyclosilicate 5 g once daily (QD). Sodium Zirconium Cyclosilicate dose increased or decreased in increments/decrements of 5 g QD up to a maximum of 15 g QD or a minimum of 5 g every other day (QOD) based on i-STAT potassium measurements up to 12 months.
1609865|NCT02163473|Procedure|Septic patients|The investigators will draw two sets of blood samples. One at baseline, 10 mL, and another, 24 hours later, 10 mL, for a total of 20 mL.
1609866|NCT02163473|Procedure|Healthy Control|The investigators will draw 10 mL, once, during baseline for a total of 10 mL among the healthy control group.
1609867|NCT02163460|Procedure|Drain|In group 1, a 4.8 mm diameter continuous closed-suction tubular drain (Medsharp Ind.Com.Prod.Hosp.Ltda - reg. MS (Ministério da Saúde [Health Ministry registry]): 80267170001) was placed between the aponeurosis and the subcutaneous tissue caudally to the incision.
1609868|NCT02163460|Procedure|Progressive Tension Sutures|Drains were not used in group 2, but separate absorbable polyglactin 920 2/0 sutures were placed from the subcutaneous mesh to the aponeurosis every 2 cm by means of the progressive tension suture (or Quilting Sutures) technique, as described by Pollock et al
1609869|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
1609870|NCT02163447|Drug|3 dose dihydroartemisinin-piperaquine (DP) for adult women during pregnancy|
1609871|NCT02163447|Drug|3 dose sulfadoxine-pyrimethamine (SP) for adult women during pregnancy|
1609872|NCT02163447|Drug|Monthly dihydroartemisinin-piperaquine (DP) for infants|
1609873|NCT02163447|Drug|3-monthly dihydroartemisinin-piperaquine (DP) for infants|
1609874|NCT02163434|Drug|Gabapentin|
1609875|NCT02163434|Drug|Metoclopramide|
1609876|NCT02163421|Drug|Vedolizumab SC|Vedolizumab injection, for subcutaneous use (vedolizumab SC)
1609877|NCT02163421|Drug|Vedolizumab IV|Vedolizumab injection, for intravenous use (vedolizumab IV)
1610265|NCT02160496|Behavioral|Weight loss interventional study with 27% protein-diet|
1610266|NCT02160496|Behavioral|Weight loss interventional study with 35% protein-diet|
1609878|NCT02163408|Other|MRI with/without contrast|Bilateral carotid plaque imaging at 3.0T. Conventional MRI scans with T1-, T2-weightings and scans using the developed techniques. MR contrast may be used in conventional protocol when it is needed to evaluate the performance of the developed techniques
1609879|NCT02163395|Device|FullCeram implant|FullCeram implantation
1609880|NCT02163382|Device|Neurovent Monitor XIII|Nasogastric tiube installation to monitor EAdi
1609881|NCT02163382|Device|Neurovent Monitor XIII|RIP jacket installation
1609882|NCT02163382|Device|Neurovent Monitor XIII|Ventilator change (if a different ventilator was used prior to the study).
1609883|NCT02163382|Device|Neurovent Monitor XIII|Determination of NAVA parametersVentilator
1609884|NCT02163382|Device|Neurovent Monitor XIII|Second period with conventional NIV settings
1609885|NCT02163369|Drug|Peppermint and Lavender Essential Oils|
1609886|NCT02163356|Drug|Fenretinide/LXS Oral Powder|Oral Powder
1609887|NCT02163356|Drug|Ketoconazole|Oral Tablet
1609888|NCT02163356|Drug|Vincristine|IV
1609889|NCT02163330|Drug|Acetazolamide|
1609890|NCT02163330|Drug|sugar pill|
1609891|NCT02163317|Radiation|stereotactic radiosurgery|Undergo MRI-guided focal SRS
1609892|NCT02163317|Device|magnetic resonance imaging|Undergo staging MRI with contrast
1609893|NCT02163317|Other|quality-of-life assessment|Quality of life scores will be summarized graphically and repeated measures of variance will be conducted to test for changes in scores over time
1609894|NCT02163317|Procedure|Serum Prostate Antigen Test|Test of the PSA protein in blood. The test will be run every three months for up to two years during the study.
1609895|NCT02163317|Procedure|Digital Rectal Exam|Exam of rectal health. Performed every three months for up to two years throughout the study.
1609896|NCT02163317|Behavioral|Expanded Prostate Cancer Index Composite|This survey measures a patient's function and bother after prostate cancer treatment. It will be analyzed using ANOVA using data collected every 6 months for up to 2 years of the study.
1609897|NCT02163304|Other|Sucrose|
1609898|NCT02163304|Other|Artificial Sweetner|
1609899|NCT02163304|Other|Tasteless Solution|
1609900|NCT02163291|Drug|paclitaxel liposome|S-1 40 mg/m2 bid d1-14 po and paclitaxel liposome 175mg/m2 d1 intravenously infusion for 3 hours, every 3 weeks. After 2 cycles' treatment, if clinical response is complete response（CR）,partial regression（PR） or stable disease（SD）, another 2 cycles is administered and operation is performed after the total 4 cycles. If response is progressive disease（PD）, chemotherapy is stopped and operation is performed.
1609901|NCT02163278|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
1609902|NCT02163278|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
1609903|NCT02163265|Procedure|Surgery|Patients suffering from Pectus excavatum Pectus carinatum will be treated surgically according to normal procedures
1609904|NCT02163252|Behavioral|Standard|
1609905|NCT02163252|Behavioral|Early Intervention|
1609906|NCT02163239|Device|Cannula and Blunt Obturator|The FloShield 10mm Endoscopic Cannula and Blunt Obturator will be used to maintain access to the peritoneal cavity during robot-assisted single site laparoscopic surgery
2010153|NCT03098160|Drug|Ipilimumab|Evofosfamide given on day one and in combination with Ipilimumab on day 8 of the first two cycles, Ipilimumab given alone on day 8 of last two cycles for a total of four 21 day dosing cycles.
2010154|NCT03096327|Drug|Montelukast|Montelukast sodium is a selective blocker of the CysLT1 receptor. For treatment of chronic asthma, montelukast is administered once daily to adults as a 10-mg film-coated tablet, to children aged 6-14 years as a 5-mg chewable tablet, and to children aged 2-5 years as a 4-mg chewable tablet form.
2010155|NCT03096327|Drug|Placebo|Patients in placebo group will receive identical looking drug (placebo) produced by same manufactured
2010156|NCT03095547|Drug|cyclosporine A|Pharmacokinetic assessment Area Under the plasma concentration: time Curve (AUC) 0-t
2010157|NCT03095547|Drug|Posaconazole|Pharmacokinetic assessment AUC 0-tau
2010158|NCT03095547|Drug|Pantoprazole|Pharmacokinetic assessment AUC 0-tau
2010159|NCT03095547|Drug|F901318|Pharmacokinetic assessment AUC 0-tau
2010160|NCT03095547|Drug|Tacrolimus|Pharmacokinetic assessment AUC 0-t
2010161|NCT03094507|Drug|Tivicay|50 mg once daily
1609916|NCT02163174|Drug|Pentoxifylline (PTX)|Patients were randomly assigned to receive intravenous Pentoxifylline 5 mg/kg/hr for 6 hours on 6 successive days in addition to antibiotics
1609917|NCT02163174|Drug|Placebo|Patients were randomly assigned to receive intravenous normal saline 5 mg/kg/hr for 6 hours on 6 successive days as a placebo in addition to antibiotics.
1609918|NCT02163161|Drug|PF-04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fasted conditions
1609919|NCT02163161|Drug|PF-04965842|Subjects will receive 400 mg PF 04965842 oral suspension under fasted conditions
1609920|NCT02163161|Drug|PF- 04965842|Subjects will receive 4 x 100 mg PF 04965842 tablet under fed conditions
1609921|NCT02163148|Behavioral|Massed speech exposure session|One session consisting of 4 speech exposures, each 5 minutes long.
1609922|NCT02163122|Procedure|Nasal Allergen Challenge|Cat allergen (FelD1) applied directly to the nasal tissues
1609923|NCT02163122|Other|Environmental Exposure Chamber|The mobile EEC (mEEC) is a movable facility, designed with clean-room technology, used to expose subjects to aeroallergens (in this trial, the allergen FelD1 from cats) at controlled, consistent airborne levels, similar to that experienced in subjects' daily lives.
1609924|NCT02163122|Biological|Cat allergen (FelD1)|
1609925|NCT02163083|Procedure|ICG|Improvement of detection of positive lymphnodes
1609926|NCT02163070|Dietary Supplement|whey drink,|consumption of 220 milliliters of whey drink three times a week,
1609927|NCT02163070|Dietary Supplement|whey drink fortified with vitaminE|consumption of 220 milliliters of whey drink fortified with 400 milligrams of vitamin E three times a week,
1609928|NCT02163070|Dietary Supplement|vitamin E|consumption of 400 milligrams of vitamin E three times a week,
1609964|NCT02162810|Drug|Prednisolone|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
1609929|NCT02163057|Biological|1.1 mL of INO-3112 (VGX-3100 + INO-9012) delivered IM via EP with CELLECTRA-5P device|Eligible subjects who consent to participate in the study will receive a 1.1 mL IM injection of INO-3112 (VGX-3100 and INO-9012) via IM+EP with CELLECTRA®-5P. All subjects will receive a total of 4 doses of immunotherapy
1609930|NCT02163031|Device|devices used in the coronary angiography|devices used in coronary angiography by left or right radial route
1609931|NCT02163018|Drug|HAL-MPE1|Subcutaneous administration of increasing doses of HAL-MPE1
1609932|NCT02163018|Drug|Placebo|Subcutaneous administration of increasing doses of placebo
1609933|NCT02163005|Drug|Gadolinium|-agent will be administered intravenously and a CT scan will be performed to evaluate contrast enhancement characteristics of the agent to assess its feasibility as an alternative to Iodine based contrast agents.
1609934|NCT02162992|Other|No intervention|Observational
2010162|NCT03094507|Drug|Rezolsta|darunavir 800 mg/cobicistat 150 mg once daily
1609937|NCT02162966|Drug|High Dose Colistin|High Dose Colistin
1609938|NCT02162966|Drug|Standard Dose Colistin|Standard Dose Colistin
1609939|NCT02162940|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
1609940|NCT02162940|Other|The SF 36 test|The SF 36 test (SHORT FORM 36) was used to evaluate quality of life.
1609941|NCT02162927|Dietary Supplement|Dietary Nitrate|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
1609942|NCT02162927|Dietary Supplement|Potassium Chloride (placebo)|This pill must be taken on an empty stomach (2-3 hours after eating) and must be taken about 2-3 hours before exercise.
1609943|NCT02162914|Drug|Regorafenib/active|Subjects randomized to be treated with Regorafenib/active will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
1609944|NCT02162914|Drug|Regorafenib/placebo|Subjects randomized to be treated with Regorafenib/placebo will receive once a day 160 mg po (four tablets of 40 mg) for 3 weeks of every 4 weeks cycle (3 weeks on and 1 week off) Duration of one cycle is 28 days
1609945|NCT02162901|Behavioral|Choice-Class with IVR Calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone call over a period of 12 months.
1609946|NCT02162901|Behavioral|Random-Class with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
1609947|NCT02162901|Behavioral|Random-Class only|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After attending one 2-hour class to be introduced to the program and set goals, these lessons are delivered to the participant through a printed workbook.
1609948|NCT02162901|Behavioral|Choice-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
1609949|NCT02162901|Behavioral|Random-DVD with IVR calls|The intervention for this arm consists of an educational program which is an adaptation of the 16 lessons from the original Diabetes Prevention Program, both Core and After-Core sessions. After watching a DVD at home to be introduced to the program and set goals, these lessons are delivered to the participant through 22 Interactive Voice Response telephone calls over a period of 12 months.
1609950|NCT02162888|Drug|Test Product (Bendamustine)|
1609951|NCT02162875|Drug|Praziquantel|Six different treatment strategies with praziquantel
1609952|NCT02162862|Behavioral|Behavioral Counseling|
1609953|NCT02162862|Drug|bupropion-SR|
1609954|NCT02162849|Drug|Varenicline|Varenicline Dosing: 0.5 mg/day by mouth for Days 1-3; 0.5 mg twice a day for Days 4-7, and 1 mg twice a day thereafter.
1609955|NCT02162849|Drug|Nicotine Patch|Starting on Day 8, and then every day after that, participant applies 1, 21 mg nicotine patch for 11 weeks.
1609956|NCT02162849|Drug|Placebo Patch|Starting on Day 8, and then every day after that, participant applies 1 placebo patch each day for 11 weeks.
1609957|NCT02162849|Drug|Placebo Tablet|Participant takes placebo tablet 1-10 days after Visit 1. On Days 1-3, participant takes 1 dose of the placebo each morning. Starting on Day 4, and then every day after that, participant takes 1 dose in the morning and 1 dose in the evening.
1609958|NCT02162849|Behavioral|Questionnaires|Questionnaire completion 1 to 10 days before first study drug/placebo dose and on Days 8, 17, 24, 31, 38, 52, and 73. Questionnaires should take about 30-45 minutes total to complete. On Days 17, 24, 38, and 73, done over the phone.
1609959|NCT02162849|Behavioral|Counseling Sessions|Counseling sessions performed on Days 8, 17, 24, 31, 38, 52, and 73. On Days 17, 24, 38, and 73, done over the phone. These sessions take about 15 minutes each time.
1609960|NCT02162849|Other|Lab Session|Participant asked to watch slides. During the lab session, brain electrical activity checked with an electroencephalogram (EEG). Participant completes computer tasks, including questionnaires, that will measure emotions and attention level. These tasks should take about 90 minutes to complete. The lab session may last up to 2 hours.
1609961|NCT02162849|Other|Saliva Test|Saliva tested to check cotinine level at baseline, on Days 8 and 17, end of treatment visit, and at 3 months and 6 months after quitting smoking.
1609962|NCT02162836|Drug|JNJ-56021927|Participants will receive 8 capsules of JNJ-56021927, 240 milligram (mg) as single oral dose on Day 1. After participants will receive daily JNJ-56021927, 240 mg on Day 1 of Cycle 1 until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever comes first.
1609963|NCT02162823|Procedure|Pancreatic Surgery|Surgical removal of the pancreatic tumour (cancer) in the intervention group
1609965|NCT02162810|Drug|placebo-controlled|In order to analyze the data, we will establish a chart which will show the degree of cosmetic appearance, incidences and degree of complications. This we be assessed on a mild to severe scale.
1609966|NCT02162797|Dietary Supplement|Zinc supplementation|Intervention group A: Patients who will orally receive zinc for 3 months.
1609967|NCT02162797|Dietary Supplement|Placebo supplementation|Intervention Group B: Patients who will orally receive a placebo for 3 months.
1609968|NCT02162784|Drug|Budesonide/Procaterol, 180/10mcg X1|one puff
1609969|NCT02162784|Drug|Budesonide/procaterol 180/10 mcg X 2|2 puffs
1609970|NCT02162784|Drug|Albuterol HFA MDI 100mcg X2|HFA MDI, 100mcg, 2 puffs
1609971|NCT02162771|Biological|Rituximab|
1609972|NCT02162771|Biological|CT-P10|
1609973|NCT02162771|Drug|Cyclophosphamide|
1609974|NCT02162771|Drug|Vincristine|
1609975|NCT02162771|Drug|Prednisone|
1609976|NCT02162758|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules
1609977|NCT02162758|Drug|Dexlansoprazole Placebo|Dexlansoprazole placebo-matching capsules
1609978|NCT02162745|Drug|Isotonic solution (NaCl 0.9%)|
1609979|NCT02162745|Drug|Hypertonic solution (NaCl 3%)|
1609980|NCT02162732|Device|Guided Therapy|A total of 200 neuroblastoma, brain tumor, and rare tumor patients will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
1609981|NCT02162719|Drug|Ipatasertib|Participants will receive ipatasertib orally 400 milligrams (mg) daily on Days 1-21 of each 28-day cycle.
1609982|NCT02162719|Drug|Paclitaxel|Participants will receive paclitaxel 80 milligrams per square meter (mg/m^2) intravenously (IV) on Days 1, 8, and 15 of each cycle.
1609983|NCT02162719|Drug|Placebo|Participants will receive oral placebo matched to ipatasertib, daily on Days 1-21 of each 28-day cycle.
2010163|NCT03093987|Other|Critical care ultrasound|Circulateory will be managed according to the result of critical ultrasound joint clearance of lactic acid in patients with shock
2010164|NCT03093714|Drug|FDL169|CFTR corrector
1609986|NCT02162680|Drug|1% lidocaine|
1609987|NCT02162680|Drug|bacteriostatic normal saline (BNS)|
1609989|NCT02162654|Procedure|Remote ischemic preconditioning|The blood pressure cuff is inflated to 200 mmHg for 3 x 5 minutes with 5 minutes of reperfusion by complete cuff deflation each.
1609990|NCT02162654|Procedure|Sham preconditioning|The blood pressure cuff is inflated to 10 mmHg for 3 x 5 minutes with 5 minutes of complete cuff deflation each.
1609991|NCT02162641|Procedure|Sentinel lymph node biopsy|
1609992|NCT02162628|Device|Exair Prolapse Repair System|
1609993|NCT02162628|Procedure|Total Native Tissue Repair|
1609994|NCT02162615|Device|Restorelle Direct Fix A|
1609995|NCT02162615|Device|Restorelle Direct Fix P|
1609996|NCT02162615|Procedure|Native Tissue Repair Anterior|
1609997|NCT02162615|Procedure|Native Tissue Repair Posterior|
1609998|NCT02162589|Procedure|POEM|Per oral endoscopic myotomy
2010165|NCT03093714|Drug|Placebo|Placebo for FDL169
2010166|NCT03092557|Other|Determination of local pleural strain|For each tidal volume, the local pleural strain will be determined over three consecutive respiratory cycles at four predetermined sites using lung ultrasonography.
2010167|NCT03092973|Diagnostic Test|Ultrasound|
2010168|NCT03091257|Drug|Dabrafenib|Administered Orally BID
1610003|NCT02162550|Drug|Bydureon|once weekly injection
1610004|NCT02162550|Drug|placebo|once weekly injection
1610005|NCT02162537|Drug|Cisplatin|Cisplatin 75 mg/m2 IV (with adequate hydration) on D1 every 3 weeks.
1610006|NCT02162537|Drug|Pemetrexed|500mg/m² IV(10 min. infusion, preceded by the usual folic acid, vitamin B12 and corticosteroid premedication)on D1 every 3 weeks
1610007|NCT02162537|Drug|Bevacizumab|7.5 mg/kg on D1 every 3 weeks. In case of eligibility for Bevacizumab, the latter will not be started until C2.
1610143|NCT02161549|Device|Motus Gl CleanUp System|
2010169|NCT03091257|Drug|Trametinib|Administered Orally once daily
2010170|NCT03092024|Other|SPIN-HAND program|The internet-based SPIN-HAND program consists of 4 modules (1) Thumb Flexibility and Strength (3 exercises); (2) Finger Bending (3 exercises); (3) Finger Extension (3 exercises); and (4) Wrist Flexibility and Strength (2 exercises). The program includes sections on developing a personalized program, goal-setting strategies and examples, progress tracking, sharing goals and progress with friends and family, and patient stories of experiences with hand disability and hand exercises. Instructional videos demonstrate and explain how to perform each exercise properly with pictures to illustrate common mistakes. Separate versions of each exercise are available for patients with mild/moderate and more severe hand involvement.
2010171|NCT03089502|Other|Exercise Rehabilitation|The intervention will consist of a walking or biking program performed at an intensity of 60-80% of VO2peak, progressing to a minimum of 150 minutes/week. Each session will include a warm up and cool down. One weekly exercise session will be supervised and participants will be expected to complete four additional aerobic training sessions at home or in the community each week. Resistance training will be introduced during the 4th week of the program and will consist of 10 exercises targeting all major muscle groups. One weekly resistance training session will be supervised following the aerobic training, and participants will be expected to complete one to two additional sessions at home or in the community each week. Weekly education sessions will follow the supervised exercise session.
2010172|NCT03086174|Biological|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
1610008|NCT02162537|Radiation|Cerebral Radiotherapy|Cerebral radiotherapy (encephalon in toto, 30 gy 10 sessions and 12 days) immediately after randomization before D1.If the number of brain metastases is less than or equal to 5 and less than or equal to 5 cm size, cerebral stereotactic radiotherapy condition may be proposed. The recommended interval between randomisation and D1 will be approximately 4 weeks.
1610009|NCT02162524|Behavioral|Aerobic Exercise|The exercise groups will be closely monitored during exercise sessions for six months in our exercise-training laboratory. The intensity will be 65% VO2peak and all exercise will occur on a treadmill. One exercise group will obtain 8 KKW (kcal/kg/week) over 3-4 sessions per week, which will result in each session lasting approximately 30 minutes. The other exercise group will obtain 20 KKW, performing 4-5 sessions per week for approximately 50-70 minutes per session. These groups are combined for this ancillary study.
1610010|NCT02162511|Device|CliniMACS CD34+ cell enrichment and T-cell depletion|
1610011|NCT02162498|Behavioral|Feeding buddies|"The Window of Opportunity program is implementing feeding buddies within their comprehensive programming. Their feeding buddies intervention targets all mothers at ANC for promoting health behaviors, especially exclusive breastfeeding.
The NIH study is an implementation science award to evaluate the feeding buddies intervention, specifically among HIV positive recipients and evaluating the outcome of adherence to PMTCT recommendations."
1610012|NCT02162485|Drug|Salmeterol/fluticasone Easyhaler|
1610013|NCT02162485|Drug|Salmeterol/fluticasone Easyhaler with charcoal|
1610014|NCT02162485|Drug|Seretide Diskus|
1610015|NCT02162485|Drug|Seretide Diskus with charcoal|
1610016|NCT02162446|Drug|68Ga-OPS202|
1610017|NCT02162433|Drug|Normal Saline|to arms 2,4. Serves as the placebo.
1610018|NCT02162433|Drug|Dexmedetomidine|to arms 1,3
1610019|NCT02162420|Drug|Alemtuzumab|Alemtuzumab 0.2 mg/kg IV over 2 hours on days -10 to -6 from transplant.
1610020|NCT02162420|Drug|Fludarabine|Fludarabine 40 mg/m2 IV over 1 hour on days -6 to -2 from transplant.
1610021|NCT02162420|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -7 from transplant.
1610022|NCT02162420|Radiation|Total Body Irradiation|TBI 200 cGy as a single fraction on day -1 from transplant.
1610023|NCT02162420|Biological|Stem Cell Transplant|Stem cell transplant on day 0.
1610024|NCT02162420|Drug|Anti-thymocyte globulin|ATG (Thymoglobulin - Rabbit ) 3 mg/kg IV on days -5 to -3 from stem cell transplant.
1610025|NCT02162407|Drug|insulin detemir|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
1610026|NCT02162407|Drug|human soluble insulin|Given as intravenous infusion (i.v.) over a period of 8 hours during euglycaemic clamp
1610027|NCT02162394|Device|Observational ambulatory ECG monitoring|
1610028|NCT02162381|Drug|methylphenidate|a single dose of methylphenidate 10 mg to be taken orally in the morning
1610029|NCT02162381|Other|guidance|subjects will be given an explanation and advice about how to perform well in visual field testing
1610030|NCT02162355|Drug|GLPG0634 50 mg|2 tablets of 25 mg GLPG0634 once daily for 10 days
1610031|NCT02162355|Drug|GLPG0634 100 mg|1 tablet of 100 mg GLPG0634 once daily for 10 days
1610032|NCT02162355|Drug|GLPG0634 200 mg|2 tablets of 100 mg GLPG0634 once daily for 10 days
1610033|NCT02162355|Drug|Placebo|1 or 2 matching placebo tablets once daily for 10 days
1610034|NCT02162342|Other|Rehabilitative treatment|Surgical intervention, orthotics or injections of muscle/nerve medications as prescribed by the treating physician and unrelated to the study.
1610035|NCT02162329|Behavioral|Questionnaires|"Participants fill out several questionnaires asking questions about memory and concentration, mood, fatigue, how they have been feeling, and general quality of life. The questionnaires should take about 30 minutes to complete.
Meditation Group and Wait-List Group also complete questionnaires at follow up visit."
1610036|NCT02162329|Procedure|Electroencephalography (EEG)|"Meditation Group and Wait-List Group: Electroencephalography (EEG) performed at baseline and at follow up visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions.
Healthy Control Group: Electroencephalography (EEG) performed at study visit. During EEG, 3 tests to check attention, short-term memory, and levels of emotions."
1610037|NCT02162329|Procedure|Magnetic Resonance Imaging (fMRI|"Healthy Control Group: Magnetic resonance imaging (fMRI) scan performed.
Meditation Group and Wait-List Group: Magnetic resonance imaging (fMRI) scan of brain performed at baseline and at follow up visit."
1610038|NCT02162329|Behavioral|Meditation Classes|Participants take part in up to 16 meditation classes for a total of 8 weeks. All sessions videotaped.
1610039|NCT02162316|Drug|Motilitone®|
1610040|NCT02162316|Drug|A-Cilin®, Clari® and Pantoline®|
1610041|NCT02162303|Drug|Colchicine|0.6 mg a day of active treatment or placebo for 24 weeks
1610042|NCT02162303|Drug|Placebo|Sugar,given once daily, over 6 months.To mimic active treatment
1610043|NCT02162290|Other|Interval exercise training|Exercise bouts in low and high intensities
1610044|NCT02162290|Other|Continuous exercise training|
2010173|NCT03085797|Drug|Mepolizumab|Mepolizumab injection 100 mg/millilitre (mL) is a clear to opalescent, colorless to pale yellow to pale brown sterile solution for SC injection in a single-use, safety syringe.
1610046|NCT02162264|Drug|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
1610047|NCT02162251|Drug|Donepezil Hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
1610048|NCT02162238|Device|LSF-filtering device|Device: LSF-filtering device LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (<0.5 Nephelometric Turbidity units turbidity reduction), bacteria (>Log 6 reduction), viruses (>Log 4 reduction) and cysts (>Log 3 reduction). Zinc enrichment is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, >100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
1610049|NCT02162225|Drug|beet juice (Unbeetable)|"Volunteers will drink a single 8 ounce bottle of beet juice (Unbeetable) per day for 28 days.
On days 1,14, and 28, the juice will be drunk just prior to having blood drawn. Blood will also be drawn 1.5 hours after drinking the juice on days 1,14, and 28."
1610050|NCT02162212|Other|Optimized Shoulder Movement Program|"A trained physical therapist will see the participant for a max of 6 visits over the 3 month intervention; for baseline instruction, and at 2, 4, 6, and 8 weeks to progress and check subject adherence before a final check-out and testing visit at 3 months. Participants will perform 3 assigned stretching motions a min of 2 sets of 10 reps each and will be instructed in active shoulder movements with a dose based on the subject's measured activity count at baseline and with enough duration to increase it by 10%. Exercise: 10-15 minutes 2x/day for 3 month duration. Participants will log their activity."
1610051|NCT02162212|Other|ADA Guideline Instructed|The ADA guideline instructions are to include: blood sugar control (goal is A1c < 7.0%), physical activity (150 minutes/week of moderate intensity aerobic activity), foot care (examine feet daily, monofilament testing), and blood pressure control (goal is <130/80). Participants will receive a logbook to record daily outcomes. The goal of this intervention is to control for personal interactions with investigators and provide useful information for disease management but not provide intervention that likely would improve shoulder joint motion. The control group will be given instruction in the exercise program at the end of the 1 year study period.
1610052|NCT02162199|Drug|Debio 1450|Single sentinel dosing of 40 mg per unit capsules is planned to escalate from 80 mg to 160, 320, 480, 640 and 800 mg, per respective dosing group. Doses may be modified based on review of available safety and pharmacokinetic (PK) data.
1610053|NCT02162199|Drug|Placebo|Matching single sentinel dosing of placebo capsules is planned to escalate from 2 capsules to 4, 8, 12, 16 and 20 capsules, per respective dosing group. The number of capsules will match those delivering Debio 1450 for the group, as those doses may be modified based on review of available safety and pharmacokinetic (PK) data.
1610054|NCT02162173|Procedure|Endoscopy|Endoscopist performed white light endoscopy for polyp detection, then switch to dual focus NBI for characterization. Then probe-based confocal laser endomicroscopy was applied for characterization by another endoscopist independently and finally biopsy.
1610055|NCT02162160|Device|probiotic creme|Probiotic creme applied
1610056|NCT02162160|Drug|Placebo|Creme without probiotics applied in same manner
1610057|NCT02162134|Other|sugar free chewing gum|Sugar free chewing gum (orbit) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
1610058|NCT02162134|Other|sugared chewing gum|Sugared chewing gum (singsong bubble gum) was given to patients. They were asked to chew it 4 hours after surgery and continue to chew it 8 hourly for 20 to 25 min each time until oral feeding was started.
1610059|NCT02162134|Drug|Tab. Midazolam 7.5 mg|Tab. Midazolam 7.5 mg will be given to all patients at night before surgery.
1610060|NCT02162134|Drug|Inj. Midazolam 0.7mg/kg 45 min before surgery|Inj . Midazolam 0.7 mg/kg given as premedication.
1610061|NCT02162134|Drug|Inj. Propofol 2.5mg/kg|It was given to induce anesthesia after 3 min of pre oxygenation.
1610062|NCT02162134|Drug|Inj. Atracurium 0.5 mg/kg|It was given to induce muscle relaxation during anesthesia.
1610063|NCT02162134|Drug|Sevoflurane 2.5 vol %|It was given to maintain anesthesia during surgery alongwith oxygen in air mixture
1610064|NCT02162134|Drug|Inj. Cefuroxime 1.5 g IV|It was given as prophylactic antibiotic. 2 doses given. 1st 30-60 min before surgery. 2nd 6 hours after surgery
1610065|NCT02162134|Drug|Inj. Ketorolac 30 mg IV|3 doses for analgesia. 1st immediate postoperative, 2nd at 8 hours postoperative and 3 rd at 16 hours postoperative period.
1610066|NCT02162134|Drug|Inj. Zantac 50mg IV|2 doses. 1st at immediate postoperative and 2nd 12 hours after surgery
1610067|NCT02162121|Procedure|Continuous lumbar plexus: stimulating catheter|"Perinervous stimulating catheter (Stimulong, Pajunk, Germany) will be insert in lumbar plexus through tuohy needle (18G, 100mm length). 15ml mepivacaine 1% are injected before the complete resolution of the spinal anesthesia."
1610068|NCT02162121|Procedure|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 15mg will be injected.
1610069|NCT02162121|Procedure|Local anesthetic infusion|Continuous infusion (Mini Rythmic Evolution, Micrel) of ropivacaine 0,2% at 3ml/h, bolus 3 ml, lockout time 15 min, 12 ml/h maximum dose through perinervous catheter until 3rd postoperative day
1610070|NCT02162121|Procedure|Intravenous analgesia|Ketorolac 30mg 3 times a day
1610071|NCT02162121|Procedure|Opioids rescue analgesia|Buprenorphine 0,2mg twice a day if VAS>4
1610072|NCT02162121|Drug|Mepivacaine 1%|
1610073|NCT02162121|Drug|Levobupivacaine 0,5%|
1610074|NCT02162121|Drug|Ropivacaine 0,2%|
1610075|NCT02162121|Drug|Ketorolac 30mg|
1610076|NCT02162121|Drug|Buprenorphine 0,2mg|
1610077|NCT02162121|Device|Stimulong, Pajunk, Germany.|
1610078|NCT02162121|Procedure|Continuous lumbar plexus: non-stimulating catheter|
1610079|NCT02162082|Device|stent or scaffold|implantation of a CE certified drug-eluting stent, bare-metal stent or scaffold
1610080|NCT02162069|Device|CE certified transcatheter ( aortic valve replacement)|Patients receive a transcatheter aortic valve replacement with CE certified transcatheter aortic valves.
1610081|NCT02162056|Device|use of bioresorbable vascular scaffolds|Implantation of bioresorbable vascular scaffolds for coronary artery disease.
1610082|NCT02162030|Behavioral|Acceptance and Commitment Therapy|Half of the participants will receive an eight-session ACT intervention whereby each component of the psychological flexibility model will be covered. Half of the participants will receive an eight-session act intervention whereby each component except self as context will be covered.
1610083|NCT02162017|Other|The lying flat (0°) head position for 24 hours|The patients should have strict bed rest for the first 24 hours after admission to hospital. They can be nursed in the side-lying position and feeding should be avoided or only given in the ≥30° position to reduce the risk of aspiration, and after a standard swallowing screening. Patients should have no more than 3 breaks of 30 minutes in a 30°head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
1610145|NCT02161510|Drug|MK-2248|MK-2248 in once-daily oral doses of 200-≤800 mg for 7 days
1610417|NCT02159378|Other|Fructosamines|
1610084|NCT02162017|Other|The sitting-up (≥30°) head position for 24 hours|For sites that have been randomised to this position, the usual nursing care will be to have patients positioned to sitting-up with the head elevated at 30° or more by raising the head of the bed or use of extra pillows, whatever is the most appropriate, immediately upon presentation to the ED and to remain in that position for 24 hours. Patients should have no more than 3 breaks of 30 minutes in a lying flat head position in the first 24 hours, and none of the breaks are to be grouped together (i.e. no back-to back breaks are permitted).
1610085|NCT02162004|Procedure|Continuous Correction|
1610086|NCT02161991|Drug|Aprepitant|aprepitant should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
1610087|NCT02161991|Drug|placebo|placebo should be give when patients receive platinum based chemotherapy, 125mg for day1, 80mg for day2 and day3.
1610088|NCT02161965|Drug|Rivaroxaban|20mg or 15mg
1610089|NCT02161965|Drug|Fluindione|
1610090|NCT02161965|Drug|Warfarin|
1610091|NCT02161952|Drug|Pirfenidone|Pirfenidone was supplied orally in 400 mg gel capsules three times daily (every 8 hours) for a full dosage of 1200 mg daily during 24 months.
1610092|NCT02161952|Drug|Matched equivalent placebo|
1610093|NCT02161939|Drug|Daclatasvir (BMS-790052)|
1610094|NCT02161939|Drug|Sofosbuvir|
1610095|NCT02161926|Other|dietary restrictions|Dietary restrictions during 8 weeks
1610096|NCT02161913|Behavioral|Multi-Family Group Treatment|
1610097|NCT02161913|Behavioral|SCI Education Control Group|
1610098|NCT02161900|Other|Yogic and routine exercises|All newly diagnosed cases with stage I-III of breast cancer who present to Tata Memorial Hospital will be randomly assigned to perform either a set of 'Yogic and Routine Exercises (referred to as exercise I) or Routine Exercises'(referred to as exercise II) . Patients will begin the exercises within a week of starting treatment.
1610099|NCT02161874|Device|T3 with DCD tapered Prevail implant|T3 with DCD implant with Certain (internal) connection and platform-switch design
1610100|NCT02161874|Device|Nanotite Certain tapered implant|Nanotite (DCD) implant with Certain (internal) connection and non- platform-switch design
1610101|NCT02161861|Other|cFFE increase the fusiogenic capacities of a gamete|
1610102|NCT02161848|Other|Magnetic Resonance Imaging|MRI of eye muscles, lower bag muscles, thigh muscles and calf muscles.
1610103|NCT02161835|Other|Training|30 minutes of home based pulse watch regulated cycle-ergometer exercise, three times a week at 75% of maximal oxygen consumption.
1610104|NCT02161822|Drug|simvastatin|simvastatin 80mg qd for 5weeks
1610105|NCT02161809|Behavioral|Healthy Eating and Physical Activity|The Healthy Eating and Physical Activity (HEPA) intervention aims to increase the quality of foods and beverages and physical activity opportunities in summer day camps. Through staff-level training, physical activity opportunities are modified to provide children with a substantial amount of meaningful physical activity. Through working with foods service providers, changes to the types of foods and beverages served will be made.
1610106|NCT02161796|Drug|FG-4592|Oral
1610107|NCT02161796|Drug|Placebo|Oral
2010174|NCT03085797|Drug|Placebo|Placebo is a clear to opalescent, colorless sterile solution for SC injection in a single-use, safety syringe.
2010175|NCT03085797|Drug|Mometasone furoate|All participants will receive mometasone furoate usually 400 micrograms (mcg), 2 actuations (50 mcg/actuation) in each nostril twice daily. Intolerant participants will use 200g (2 actuations [50 g/actuation] in each nostril once daily).
2010176|NCT03084523|Drug|Ferumoxytol Injectable Product|Patients will be administered a single dose of ferumoxytol as an MRI contrast
1610112|NCT02161770|Drug|AZD9291 tablet dosing|Part A - single 80mg oral dose AZD9291 (administered as 1 80mg tablet). Part B - 80mg oral dose AZD9291 od.
1610113|NCT02161770|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291 pharmacokinetic parameters.
1610114|NCT02161770|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure the pharmacokinetic parameters of AZ5104 and AZ7550.
1610115|NCT02161757|Biological|Tralokinumab|Subcutaneous injection
1610116|NCT02161757|Other|Placebo|Subcutaneous injection
1610117|NCT02161744|Procedure|Lipoaspiration and intravenous injection of SVF cells in saline solution|100- 240 cc of lipoaspirate will be extracted from the patient. The stromal vascular fraction (SVF) will be isolated with minimal manipulation. The cell pellet will be reconstituted in saline solution and administered intravenously to the patient.
1610118|NCT02161731|Drug|Evacetrapib|Oral administration
1610119|NCT02161731|Drug|Warfarin|Oral administration
1610120|NCT02161718|Drug|Samidorphan + olanzapine (ALKS 3831)|Oral tablet, taken once daily
1610121|NCT02161718|Drug|Placebo + olanzapine|Oral tablet, taken once daily
1610122|NCT02161705|Drug|Ropivacaine|0.5% ropivacaine (up to 0.8 mL/kg, equivalent to 4mg/kg) administered in paravertebral block
1610123|NCT02161705|Drug|Saline|Up to 0.8 mL/kg of normal saline administered
1610124|NCT02161692|Drug|Cyclophosphamide|
1610125|NCT02161692|Drug|Etoposide|
1610126|NCT02161692|Drug|Cisplatin|
1610127|NCT02161692|Drug|Bleomycin|
1610128|NCT02161692|Drug|Carboplatin|High dose carboplatin
1610129|NCT02161679|Drug|IMMU-132 infusion is administered to participants in one arm for the study|
1610130|NCT02161679|Drug|IMMU-132 plus Carboplatin infusion|
1610131|NCT02161653|Drug|Prednisone plus Metadoxine|
1610132|NCT02161653|Drug|Pentoxifylline plus Metadoxine|
1610133|NCT02161627|Device|Saluda Medical External Trial System|
1610134|NCT02161627|Device|Saluda Medical External Trial System|
1610135|NCT02161614|Drug|Estradiol valerate|
1610136|NCT02161614|Drug|Placebo|
1610137|NCT02161601|Procedure|Cricoid Pressure|Correct Cricoid pressure applied against the cricoid cartilage, Incorrect Cricoid pressure applied against the thyroid cartilage and trachea
1610138|NCT02161588|Drug|semaglutide|Once-daily oral administration as tablets. The dose level of oral semaglutide used in the 'Dose escalation period', 'Treatment period 1', 'Treatment period 2' and 'Treatment period 3' will be 5, 10, 20 and 40 mg per day, respectively.
1610139|NCT02161588|Drug|placebo|Once-daily oral administration as tablets.
1610140|NCT02161575|Drug|Ranibizumab|
1610418|NCT02159365|Drug|Elotuzumab|
1610146|NCT02161484|Procedure|Continuous Lumbar Plexus Block|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm. In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
1610147|NCT02161484|Procedure|Parasacral Nerve Block|A single shot parasacral (sciatic) nerve block will then be place under the ultrasound guidance. Ropivacaine 0.2% 9 ml will be injected.
1610148|NCT02161484|Drug|Ropivacine 0.2%|Lumbar plexus nerve block placement and activation: After subcutaneous infiltration of local anesthetic, 20 mL of Ropivacaine 0.2% will be injected; the catheter will be introduced for 5 cm past the needle tip and secured with steri strips and tegaderm.
1610149|NCT02161484|Drug|Bupivacaine 0.0625%|In PACU, the catheter will be connected to a pump of 0.0625% bupivacaine at 5 - 10 mL per hour at the discretion of the Acute Interventional Perioperative Pain Service (AIPPS). Additional 5mL boluses of 0.0625% bupivacaine will be given on demand once per hour prn.
2010177|NCT03083054|Biological|Autologous dendritic cells electroporated with WT1 mRNA|Production and application of autologous dendritic cells vaccines, 4 doses, biweekly
2010178|NCT03081481|Drug|PRX302|Single prostate cancer lesion injected with PRX302
2010179|NCT03080883|Drug|Apixaban|Given PO
2010180|NCT03078270|Drug|botulinum toxin A|Single treatment visit for 5 injections of botulinum toxin A, 40 units (for females) and 50 units (for males)/
1610154|NCT02161432|Drug|BI 187004|single dose BI 187004 given as tablet in fed state
1610155|NCT02161432|Drug|BI 187004|single dose BI 187004 given as tablet in fasted state
1610156|NCT02161432|Drug|BI 187004|single dose BI 187004 given as oral solution
1610157|NCT02161419|Drug|Roniciclib (BAY1000394)|Patients will receive roniciclib treatment as a 3 days on / 4 days schedule off with two 2.5 mg tablets twice daily for a total dose of 10.0 mg/day during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study.
1610158|NCT02161419|Drug|Placebo|Patients will receive placebo treatment as a 3 days on / 4 days schedule off with two tablets twice daily during 6 cycles (21 days each) of chemotherapy with Carboplatin/etoposide or Cisplatin/etoposide and continue thereafter as monotherapy until tumor progression, unacceptable toxicity, death, consent withdrawal, or withdrawal from the study
1610159|NCT02161406|Drug|Abatacept|Subjects will be treated with injections of 125 mg of abatacept or placebo weekly for 52 weeks
1610160|NCT02161406|Drug|Placebo|125 mg of Placebo
1610161|NCT02161393|Behavioral|Physical Activity Intervention|The 12 week home-based pedometer-driven walking programme will consist of weekly physical activity consultations. Pedometers will be used to set weekly step goals and motivate patients. Patients will wear the pedometer for 7 days and will record their daily steps in a step diary. At the next appointment the step target for the subsequent week will be agreed between the physiotherapist/researcher and participant. Each week thereafter the physiotherapist/researcher and patient will discuss their progress, document their mean daily step count for the previous week, and agree to a new daily step target for the subsequent week. The walking programme will be tailored to the individual and progressed on a weekly basis.
1610162|NCT02161393|Behavioral|Pulmonary Rehabilitation Programme|This will be a 6-week supervised outpatient programme. The exercise component will last for one hour and be delivered twice weekly. It will consist of cardiovascular exercises and lower and upper body strengthening exercises. Education sessions will be delivered once weekly. Each patient will be provided with a home exercise programme to complete unsupervised once weekly.
1610163|NCT02161380|Drug|injection of scAAV2-P1ND4v2 5.00x10e9 vg (Low),|injection of Total Volume of each intravitreal injection is 200 µL
1610164|NCT02161380|Drug|injection of scAAV2-P1ND4v2 2.46X10e10 vg (Med)|injection of Total Volume of each intravitreal injection is 200 µL
1610165|NCT02161380|Drug|injection of scAAV2-P1ND4v2 1.0X10e11vg (High)|injection of Total Volume of each intravitreal injection is 200 µL
1610166|NCT02161367|Drug|Simethicone|"Pharmacological category: antiflatulent
160mg Simethicone orally, 4 times a day for the first five postoperative days"
1610167|NCT02161367|Drug|Oral Suspending Vehicle|"ORA-Plus is an aqueous-based vehicle.
Identical to the test drug formulation except for being pharmacologically inert. 160mg Ora-Plus orally, 4 times a day for the first five postoperative days"
1610168|NCT02161354|Drug|NTC-510 capsules|Subjects will be randomized to one of 3 groups and NTC-510 will be given as a single oral dose of 2.0 mg, a split dose of 2.0 mg followed by 2.0 mg an hour later, or 6.0 mg for acute pain relief (PR) following third molar extraction.
1610169|NCT02161354|Drug|Placebo Capsules|Subjects will be randomized to one of 3 groups and placebo capsules will be given as a single oral dose of for acute dental pain following third molar extraction.
1610170|NCT02161354|Drug|NTC-510A Capsules|Subjects will be randomized to one of 3 groups where NTC-510A or placebo will be given as a single oral dose of 2.0, 4.0, or 6 mg for acute pain relief (PR) following third molar extraction
1610171|NCT02161328|Other|EIT belt|
1610172|NCT02161302|Device|transcranial direct current stimulation (tDCS)|The stimulation will be administered with a pair of surface electrodes, sponge coated, soaked in saline. A battery-powered constant current stimulator will be used for this purpose (tDCS device Soterix 1X1). The stimulation is performed by placing the anodal electrode in the primary motor cortex (M1) and the cathodal one in the contralateral supraorbital area and it will use a 2 mA current.
1610263|NCT02160509|Device|IPhone based realtime remote ultrasound interpretation|
1610264|NCT02160496|Behavioral|Weight loss interventional study with 20% protein-diet|
2010181|NCT03078270|Other|Placebo|single treatment visit for 5 injections of normal saline
2010182|NCT03077776|Procedure|Biopsy|Biopsy of primary tumour to be performed prior to initiation of neoadjuvant chemotherapy
2010183|NCT03077776|Procedure|Biopsy (optional)|[Optional] biopsy of primary tumour to be performed after 4 weeks of neoadjuvant chemotherapy
2010184|NCT03077776|Procedure|Biopsy (metastatic)|Biopsy of metastatic site to be performed at the time of relapse
2010185|NCT03077750|Drug|VBP-245 Topical Gel|Topical application BID
1610173|NCT02161302|Device|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 20 minutes that the session lasts.
1610174|NCT02161276|Drug|TNTL capsule|Patients were asked to taken drugs 3 times a day, with each time 3 grains
1610175|NCT02161276|Drug|Placebo|Patients were asked to taken drugs 3 times a day, with each time 3 grains
1610176|NCT02161263|Other|Patient Quality of Life andVision after LASIK Surgery|Patient questionnaire
2010186|NCT03077750|Drug|Vehicle|Vehicle Control With No Active Pharmaceutical Ingredients
2010187|NCT03077607|Drug|Talazoparib|Arm A: 0.5 mg oral dose Arm B: 1 mg oral dose
1610179|NCT02161237|Drug|Advagraf®|oral
1610180|NCT02161224|Drug|FG-4592|Oral
1610181|NCT02161211|Behavioral|De-coupling|Six sessions of CBT for anxiety-alcohol de-coupling
1610182|NCT02161211|Behavioral|Anxiety Reduction|Six sessions of CBT for anxiety reduction.
1610183|NCT02161211|Behavioral|Combined|Three sessions devoted to anxiety reduction and to anxiety-alcohol de-coupling each.
1610184|NCT02161198|Dietary Supplement|Y-75|Y-75 (1 g) and starch (1 g) as a diluting agent and were packed to contain 2 g/package
1610185|NCT02161198|Dietary Supplement|Placebo|Caramel syrup (0.03 g) and starch (1.97 g) were packed identically to the active treatment
1610186|NCT02161185|Drug|USL261|5 mg, intranasal dose for seizure cluster, may repeat as indicated by protocol
1610187|NCT02161159|Biological|botulinum toxin Type A|botulinum toxin Type A administered in accordance with physician standard practice.
1610188|NCT02161146|Drug|AGN-229666|One drop of AGN-229666 in the eye on Days 1 and 15.
1610189|NCT02161146|Drug|Vehicle to AGN-229666|One drop of Vehicle to AGN-229666 in the eye on Days 1 and 15.
1610190|NCT02161146|Drug|Olopatadine|One drop of olopatadine in the eye on Days 1 and 15.
2010188|NCT03077607|Drug|Itraconazole|100 mg oral dose
2010189|NCT03077607|Drug|Rifampin|600 mg oral dose
2010190|NCT03077698|Drug|Sodium Cridanimod|The study will investigate the efficacy of Sodium Cridanimod in conjunction with progestin therapy in a population of subjects with endometrial cancer, who have failed progestin monotherapy or who have been identified as PrR negative.
2010191|NCT03077698|Drug|progestin therapy|The study will investigator the use of progestin therapy in conjunction with Sodium Cridanimod
1610195|NCT02161107|Biological|Grass-SPIRE|Intradermal injection
1610196|NCT02161107|Biological|Placebo|Intradermal injection
1610197|NCT02161094|Behavioral|Give incentives to physicians based on their patient's HbA1c improvement|
1610198|NCT02161094|Behavioral|Give incentives to patients based on their own HbA1c improvement|
1610199|NCT02161081|Procedure|Myocardial CT perfusion|Adenosine-stress dynamic myocardial CT perfusion using 128-slice dual-source CT
2010192|NCT03076905|Drug|F901318|Evaluation of AUC0-t
1610201|NCT02161029|Device|Flexible drill biopsy instrument|Biopsies taken with the new drill biopsy instrument for flexible endoscopy
1610202|NCT02161029|Device|conventional biopsy instrument|Biopsies taken with conventional biopsy forceps for flexible endoscopic instruments
1610203|NCT02161016|Device|map3|Patients will receive map3® Cellular Allogeneic Bone Graft containing donor matched stem cells.
1610204|NCT02161003|Procedure|Stem Cells Injection Technique|Injection of MSCs for the treatment of anal sphincter insufficiency is a potential alternative therapy for imperforate anus patients who have undergone primary PSARP with post-operative FI. In this study a single dose of 1.2 ml MSC will be divided into 12 part of 0.1ml of MSC, doses will be injected into the anal sphincter all around in 12 injection sites according to the clock meridian under general anesthesia without giving muscle relaxant.
1610205|NCT02161003|Procedure|Stem Cell Isolation|From the upper posterior iliac crest 10 ml bone marrow sample will be extracted from patients using a heparinized syringe, under general anesthesia, in a suitable clean operation room.
1610206|NCT02160990|Drug|Exenatide|5 mcg exenatide subcutaneously twice daily for 30 days
1610207|NCT02160990|Drug|Placebo|placebo subcutaneously twice daily for 30 days
1610208|NCT02160977|Procedure|total knee arthroplasty|
1610209|NCT02160951|Drug|LGH447|LGH447, QD
1610210|NCT02160938|Other|3-year follow-up|"When the infants reach 24 months of age, the Study Follow-up Specialist will send all participants an age- appropriate Ages and Stages Questionnaire (ASQ) for completion.
At the age of 3, the following exams will be performed and are described below:
The Vineland-II Adaptive Behavior Scale (VABS)
Wechsler Preschool and Primary Scale of Intelligence IV (WPPSI-IV), or Wechsler Intelligence Scale for Children - Fifth Edition (WISC-V, for siblings older than 7 years 7 months, when necessary)
Children will also be photographed (for review by the study dysmorphologist)"
1610211|NCT02160925|Other|Preoperative 99mTc-Sestamibi SPECT/CT|
1610212|NCT02160899|Drug|ISIS-APO(a)Rx|
1610213|NCT02160899|Drug|Placebo|
1610214|NCT02160886|Behavioral|child-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.
The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.
The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks.
The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
2010193|NCT03075215|Device|Device Programming of the Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D)|The optimization during the standard of care visits in the first 12 months following implantation
2010194|NCT03073876|Drug|Donepezil Hydrochloride|5mg of Donepezil Hydrochloride by mouth
2010195|NCT03073876|Drug|Placebo|prepared placebo looking exactly the same as drug. Participants took placebo by mouth for approximately 6 weeks, and after unblinding, they took donepezil hydrochloride for 6 months.
2010196|NCT03072927|Device|MILD|MILD is performed under fluoroscopic image guidance through an ipsilateral interlaminar dorsal approach to the spine. Following epidurography, partial decompression is performed through the removal of tissue and bone at the symptomatic level confirmed with correlated MRI and clinical findings.
1610215|NCT02160886|Behavioral|parent-goal|"The 8-week goal-directed intervention include completing a daily home program and a weekly follow-up session with the child's occupational therapist.
The parents are responsible for the day to day practice and are encouraged to let the children practice daily in their natural environment.
The home-programs focus on enhancing the agreed upon goal specific task performance. They include structured practice of tasks and adaptations and modifications of the environment and the tasks. .
The weekly sessions with the occupational therapist are meant to sustain motivation, follow-up on progress, adjust the home program for the coming week and support parents in how to carry out the daily interventions."
1610216|NCT02160873|Other|chocolate milk|12 oz, 7-8 hours prior to exercise trial (night before)
1610217|NCT02160873|Other|flavor-matched placebo|12 oz, non-caloric flavor-matched placebo
2010197|NCT03070041|Other|Baby-friendly Hospital Initiative|The intervention is Baby-friendly Hospital Initiative as described by WHO and UNICEF. The ten steps to successful breastfeeding will be implemented in the hospital.
1610219|NCT02160834|Behavioral|B-MOBILE Smartphone-Based Intervention (3-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 30 continuous sedentary minutes to walk for at least 3 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
1610220|NCT02160834|Behavioral|B-MOBILE Smartphone-Based Intervention (6-min break)|"Participants will receive a smartphone with B-MOBILE app that automatically monitors their sedentary time and prompts them after every 60 continuous sedentary minutes to walk for at least 6 minutes. Participants who meet this goal will receive reinforcing feedback in real time."
1610221|NCT02160821|Procedure|Caudal Epidural|Ultrasound Guided Caudal Block
1610222|NCT02160821|Procedure|Transversus Abdominis Plane Block|Ultrasound Guided Transversus Abdominis Plane Block
1610223|NCT02160808|Drug|Secretin|Drug to stimulate pancreatic secretion
1610224|NCT02160808|Drug|Placebo|
1610225|NCT02160782|Drug|LUM001|LUM001 administered orally once each day
1610226|NCT02160782|Drug|Placebo|Placebo administered orally once each day during randomized withdrawal period
1610227|NCT02160756|Drug|JNJ-56021927 Softgel Capsule|Single oral dose of JNJ-56021927 240 mg softgel capsule on Day 1.
1610228|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 1|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 1 on Day 1.
1610229|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 2|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 2 on Day 1.
1610230|NCT02160756|Drug|JNJ-56021927 Tablet Formulation 3|Single oral dose of JNJ-56021927 240 mg Tablet Formulation 3 on Day 1.
1610231|NCT02160743|Dietary Supplement|CJ-30056 20/500mg (atorvastatin/metformin XR 20/500mg)|
1610232|NCT02160730|Drug|R-roscovitine|See Arm Description
1610233|NCT02160704|Drug|Enclomiphene citrate|25 mg daily for 16 weeks
1610234|NCT02160704|Other|Placebo|placebo daily for 16 weeks
1610235|NCT02160691|Device|Anxiety Meter|This is a new device developed to measure changes in heart rate and translate these into a visual display of arousal level in children with autism spectrum disorder.
1610236|NCT02160678|Drug|Vehicle|Cream Vehicle (placebo) (G & W Laboratories, Inc.)- vehicle
1610237|NCT02160678|Drug|Tazarotene Cream, 0.1 %|Tazarotene Cream, 0.1 % (G & W Laboratories, Inc.) - test product
1610238|NCT02160678|Drug|Tazorac Cream, 0.1%|Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
1610239|NCT02160665|Drug|Tazarotene Cream, 0.05%|Tazarotene Cream, 0.05% (G & W Laboratories, Inc.)
1610240|NCT02160665|Drug|Vehicle|Vehicle of Test product (G & W Laboratories, Inc.)
1610241|NCT02160665|Drug|Reference: Tazorac Cream, 0.05%|Reference: Tazorac (tazarotene) Cream, 0.05% (Allergan, Inc.)
2010198|NCT03069976|Drug|Metronidazole|Flagyl x 14 days.
1610243|NCT02160639|Other|diabetes self management support|diabetes self management support is telephonic and provided by health investigators
1610244|NCT02160626|Drug|A-101 Vehicle|Placebo control
1610245|NCT02160626|Drug|A-101 (40) Topical Solution|A-101 (40) Topical Solution - high dose
1610246|NCT02160626|Drug|A-101 (32.5) Topical Solution|A-101 (32.5) Topical Solution - low dose
1610247|NCT02160613|Procedure|Open flap debridement|an access flap
1610248|NCT02160600|Other|Standard multiphase CT|
1610249|NCT02160600|Other|split bolus Dual energy CT|
1610250|NCT02160587|Drug|Chloraprep|ChloraPrep will be compared to ZuraPrep with regard to skin sensitization and irritation.
1610251|NCT02160587|Drug|0.9% Physiological Saline|0.9% Physiological Saline will be compared to ZuraPrep with regard to skin sensitization and irritation.
1610252|NCT02160587|Other|ZuraPrep without IPA|ZuraPrep without IPA will be compared to ZuraPrep with regard to skin sensitization and irritation
1610253|NCT02160574|Drug|ChloraPrep|The degree of skin irritation caused by ChloraPrep will be graded and compared to ZuraPrep and ZuraPrep without IPA.
1610254|NCT02160574|Drug|0.1% Sodium Lauryl Sulfate|The degree of skin irritation caused by 0.1% Sodium Lauryl Sulfate will be graded and compared to ZuraPrep and ZuraPrep without IPA.
1610255|NCT02160574|Drug|0.9% Physiological Saline|The degree of skin irritation caused by 0.9% Physiological Saline will be graded and compared to ZuraPrep and ZuraPrep without IPA.
1610256|NCT02160574|Other|ZuraPrep without IPA|Results from exposure to ZuraPrep will be compared statistically those from exposure to ZuraPrep without IPA
1610257|NCT02160561|Other|Intervention Arm|Placing patients who are in critical illness with acute respiratory failure and are mechanically ventilated in an upright reverse trendelenburg position
1610258|NCT02160548|Drug|Standard care|Standard management for OP poisoning
1610259|NCT02160548|Drug|Standard care+ 2.5 mg Salbutamol|Ventolin respiratory solution 2.5 mg
1610260|NCT02160548|Drug|Standard care+ 5 mg Salbutamol|Ventolin respiratory solution 5 mg
2010199|NCT03068624|Biological|CD 8+ T Cells|"Dose Escalation Run-In: The first cohort of patients receive a single infusion of 3.3 x 10^9 cells/m2 on Day 0 and observed for any signs of toxicity.
Dose Expansion Cohort: Maximum tolerated dose of CD 8+ T Cells from Dose Escalation Run-In given on Day 0."
1610262|NCT02160522|Device|Cuffed ETT|Measurement of the cuff pressure on an endotracheal tube and lower pressure to a safe range if it is elevated.
1610419|NCT02159365|Drug|Lenalidomide|
1610267|NCT02160483|Other|Functional magnetic resonance imaging|3 Tesla magnetic resonance imaging
1610268|NCT02160470|Behavioral|Exposure Therapy with Retrieval|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a fear retrieval trial, which is a brief exposure to the feared stimulus (snake or spider). Based on recent basic science research, the fear retrieval trial is expected to enhance the efficacy of exposure therapy.
1610269|NCT02160470|Behavioral|Exposure Therapy with Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. As a component of therapy, participants will receive compound extinction, which consists of exposure to two feared stimuli simultaneously (two spiders or two snakes). Based on recent basic science research, compound extinction is expected to enhance the efficacy of exposure therapy.
1610270|NCT02160470|Behavioral|Exposure Therapy with Retrieval and Compound Extinction|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes. Thirty minutes prior to exposure therapy, participants will receive a brief fear retrieval trial. As a component of therapy, participants will also receive compound extinction.
1610271|NCT02160470|Behavioral|Therapist-guided Exposure Therapy|Participants will receive one-session exposure therapy (up to 92 minutes) for fear of spiders or fear of snakes.
1610272|NCT02160457|Other|Intervention with IGA|"Individually tailored interdisciplinary intervention based on measures performed as part of the Cerebral Palsy follow-Up Program and other clinical examinations AND instrumented gait analysis
The instrumented gait analysis consists of four steps:
Instrumented gait analysis (data collection with a 8-camera Vicon T40 system (Vicon, Oxford, UK) and 2 force plates (AMTI, OR6-7-1000)
Impairment-Focused Interpretation
Recommendation for interdisciplinary interventions
Dissemination of recommendations
The two modalities differs in the use of IGA, but the study is not indented to document the effect of IGA alone, but to document the difference in the effects of the interdisciplinary interventions, when IGA is implemented to the experimental group."
1610273|NCT02160444|Behavioral|CBT plus Parent as CBT Coach Training|Standard CBT for treatment of anxiety disorders in youth is completed by the children while their primary caregiver receives training in the same cognitive behavioral skills, how to recognize when he or she is accommodating his or her child's anxiety, and how to create and implement exposure activities.
1610274|NCT02160431|Behavioral|CBT for pediatric OCD|Participants complete standard CBT for OCD as delivered in the POTS study .
1610275|NCT02160418|Behavioral|Financial Incentives|
1610276|NCT02160418|Behavioral|Cognitive Incentives|
1610277|NCT02160418|Behavioral|Financial and Cognitive Incentives|
1610278|NCT02160405|Dietary Supplement|native potato|
1610279|NCT02160392|Procedure|Endometrial biopsy|Endometrial biopsy (EMB) specimens were collected via a 3 mm diameter plastic pipelle that was inserted into the uterus following EML. A sample of tissue was obtained by retracting the pipelle's plunger leading to negative suction and rotating the cannula for approximately 15 seconds.
1610280|NCT02160379|Other|standard test meal|
1610281|NCT02160366|Other|Biomarker Research|Research studies on new biomarkers conducted on previously banked blood and/or tumor tissue. Samples collected may include blood, fresh tumor tissue, urine, saliva, bone marrow, pleural fluid, ascites, skin or hair follicle.
1610282|NCT02160353|Drug|Abiraterone acetate, Prednisolone|
1610283|NCT02160314|Device|pessary|disposable, single-use pessary
1610284|NCT02160314|Device|Absorbent pad|
1610285|NCT02160301|Drug|Gabapentin|PO
1610286|NCT02160301|Drug|Acetaminophen|PO
1610287|NCT02160301|Drug|Acetaminophen|IV
1610288|NCT02160301|Drug|Celecoxib|PO
1610289|NCT02160301|Drug|Dexamethasone|IV
1610290|NCT02160301|Drug|Oxycodone|PO
2010200|NCT03068624|Drug|Cyclophosphamide|300 mg/m2 by vein 48 to 72 hours prior (Day -3 to Day -2) to T cell infusion as an outpatient procedure.
1610293|NCT02160275|Device|Artificial Pancreas (Inreda Diabetic BV)|Bi-hormonal reactive closed loop system without mealtime announcement, miniaturized prototype
1610294|NCT02160275|Device|Insulin pump therapy|Patients' own insulin pump with fast-acting insulin analog
1610295|NCT02160262|Drug|Dasotraline|Dasotraline 4 mg, 6 mg, 8 mg, flexibly dosed, once daily
1610296|NCT02160249|Behavioral|Community-based rehabilitation|
1610297|NCT02160249|Other|Facility based care|
1610298|NCT02160236|Drug|dexketoprofen trometamol|before end of the surgery via intravenous administration 50 mg dexketoprofen trometamol in 0.9 % NaCl 100 cc
1610299|NCT02160236|Drug|tenoxicam|before the end of the surgery via administration intravenous 20 mg tenoxicam in 0.9% NaCl in 100 cc
1610300|NCT02160236|Drug|serum physiologic|before end of the surgery via administration intravenous 0.9 % NaCl 100 cc
1610301|NCT02160223|Drug|Sugammadex|Group S patients will receive 2 mg kg -1 sugammadex at he end of surgery
1610302|NCT02160223|Drug|Neostigmine|Patient in Gropu N will receive 50 µg kg-1 neostigmin and 05 mg atropin at the end of surgery
1610303|NCT02160210|Device|Ultrafine Endoscope|Ultrafine endoscope reaching to the cecum within 15mins is thought to be successful.Water colonoscopy with standard colonoscope will be performed in unsuccessful subjects subsequently.
1610304|NCT02160197|Device|Aircast XP Walker boot|Ankle boot allowing weight bearing as tolerated
1610305|NCT02160197|Device|Plaster Immobilisation|Plaster immobilisation with no weight bearing allowed.
1610306|NCT02160184|Device|Artificial pancreas system consisting of a predictive rule-based algorithm integrated on the Medtronic Portable Glucose Control System (PGCS)|
1610307|NCT02160171|Device|Algorithm for Neonatal Seizure Recognition|Software system for neonatal seizure detection recognition
1610308|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
1610309|NCT02160158|Drug|Fesoterodine SR3 (fasted)|Fesoterodine SR3 4 mg (single dose)
1610310|NCT02160158|Drug|Fesoterodine SR3 (fed)|Fesoterodine SR3 4 mg (single dose) with high-fat meal
1610311|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
1610312|NCT02160158|Drug|Fesoterodine SR3 (sprinkle)|Fesoterodine SR3 4 mg (single dose) beads sprinkled on applesauce
1610313|NCT02160158|Drug|Fesoterodine ER (fasted)|Commercial Fesoterodine ER 4 mg (single dose)
1610314|NCT02160158|Drug|Fesoterodine SR4 (fasted)|Fesoterodine SR4 4 mg (single dose)
1610315|NCT02160158|Drug|Fesoterodine SR4 (fed)|Fesoterodine SR4 4 mg (single dose) with high-fat/high calorie meal
1610316|NCT02160158|Drug|Fesoterodine ER (fed)|Commercial Fesoterodine ER 4 mg (single dose) with high-fat meal
1610317|NCT02160158|Drug|Fesoterodine SR4 (sprinkle)|Fesoterodine SR4 4 mg (single dose) beads sprinkled on applesauce
2010201|NCT03068624|Drug|Interleukin-2|IL-2 initiated within 6 hours of T cell infusion at 250,000 U/m2 subcutaneously twice daily for 14 days.
2010202|NCT03068624|Drug|Ipilimumab|3 mg/kg by vein over approximately 90 minutes initiated approximately 24 hours after the T cell infusion, and every 3 weeks thereafter for a total of 4 doses.
1610320|NCT02160132|Drug|Methylprednisolone(intravenously in the 1st-2nd-3rd month )|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-2nd-3rd month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
1610321|NCT02160132|Drug|Methylprednisolone(intravenously in the 1st-3rd-5th month)|Methylprednisolone 0.5g/d intravenously for 3 consecutive days in the 1st-3rd-5th month ,and oral methylprednisolone 0.4mg/kg/d on consecutive days for 6 months.
1610322|NCT02160119|Other|MRI-based techniques|fMRI, DTI
1610323|NCT02160119|Other|EEG|ERP
1610324|NCT02160106|Drug|TEW-7197|Single daily doses by oral administration on Days 1, 2, 3, 4, 5, Days 8, 9, 10, 11, 12, Days 15, 16, 17, 18, 19 and Days 22, 23, 24, 25, 26 of each 28 day cycle. Starting dose is 30 mg, with escalation to 60 mg, and subsequent dose escalation using a modified Fibonacci algorithm.
1610325|NCT02160080|Drug|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin|Boceprevir 800mg/TID+Pegylated interferon alfa+Ribavirin
1610326|NCT02160067|Drug|Second generation BTDS patch|
1610327|NCT02160067|Drug|First generation BuTrans patch|
1610328|NCT02160054|Drug|Graceptor®|oral
1610329|NCT02160041|Drug|BGJ398|BGJ398 will be dosed on a flat scale of 125 mg (e.g., 1 x 100 mg and 1 x 25 mg capsules) once daily for the first 21 days of the 28-day cycle (3 weeks on, 1 week off in a cycle). A complete treatment cycle is defined as 28 days.
1610330|NCT02160028|Other|anesthetics and extended information before dental treatment|The extended information is a comprehensive explanation about what to expect of the treatment and the anesthetic method, phrased in positive words and opening up for questions after information is given.
1610331|NCT02160028|Other|anesthetics and standard information before dental treatment|The standard information is short and concise, telling in neutral words what to expect.
1610336|NCT02160002|Procedure|Weaning from an incubator at a lower weight (1600 grams)|Infants will be weaned from an incubator at a lower weight (1600 grams)
1610337|NCT02160002|Procedure|Weaning from an incubator at a higher weight (1800 grams)|Infants will be weaned from an incubator at a higher weight (1800 grams)
1610338|NCT02159989|Other|Laboratory Biomarker Analysis|Correlative studies
1610339|NCT02159989|Drug|Sapanisertib|Given PO
1610340|NCT02159989|Biological|Ziv-Aflibercept|Given IV
2010203|NCT03067571|Drug|Daratumumab|16 mg/kg by vein for the first 2 Cycles (one time per week for 8 weeks) of treatment, followed by every 2 weeks for 4 cycles (or 16 weeks) and then every 4 weeks until progression or up to 1 year whichever comes earlier. All cycles are 4 weeks (28 days).
2010204|NCT03061734|Drug|ALLOD-2|ALLOD-2: Component A (regular dose) plus Component B
1610347|NCT02159963|Other|Supervised training|8 weeks high intensity interval training, 3 times a week, one is supervised, two are home based unsupervised.
1610348|NCT02159963|Other|Unsupervised training|8 weeks home based high-intensity-interval cycle-training 3 times a week.
1610349|NCT02159963|Other|Optional training|8 weeks of optional home based, unsupervised training.
1610350|NCT02159963|Other|Control|8 weeks of control period. Participants are doing daily living.
1610351|NCT02159950|Other|Laboratory Biomarker Analysis|Correlative studies
1610352|NCT02159950|Biological|Sipuleucel-T|Given IV
1610353|NCT02159950|Drug|Tasquinimod|Given PO
1610354|NCT02159937|Other|Blood sampling by vena punction.|In vitro tests will be performed after blood sample collection from metastatic cancer patients
1610355|NCT02159911|Drug|Misoprostol administered orally one hour before surgery|"Closed and numbered envelopes, containing a capsule with either 200mcg or 400mcg of misoprostol were randomly distributed to the patients. Each envelope was coded randomly and only the pharmaceutical department of the hospital knew the content of these envelopes and kept a list of their codes.
The misoprostol was administered by the floor nurse, per-os to the patient one hour before hysteroscopy with a small amount of water. The number on the envelope was noted by the nurse on the document relative to the patient. Hence, the patient, the physician performing the biopsy, the nurse and the research associate did not know the exact dose of misoprostol that was ingested by the patient."
1610356|NCT02159898|Device|EndoMAXX EVT|
1610357|NCT02159898|Device|EndoMAXX|
1610358|NCT02159885|Other|Telemonitoring|
1610359|NCT02159872|Drug|Omacetaxine|1.25 mg/m2 subcutaneously every 12 hours on Days 1-3 of every 28-day study cycle.
1610360|NCT02159859|Drug|Ertapenem|Subjects are hemodialysis patients who are admitted to Oakwood Hospital - Dearborn
1610361|NCT02159833|Other|Intranasal challenge with active substance (food protein)|
1610362|NCT02159833|Other|Intranasal challenge with placebo|
1610363|NCT02159820|Drug|Decitabine (DTC Arm)|Patients in DTC arm will receive lower-dose decitabine (7 mg/m2) administered intravenously within 1 hour for a consecutive 5 days, followed by TC regimen on day 6.
1610364|NCT02159820|Drug|Paclitaxel and Carboplatin (TC Arm)|The TC arm consisted of paclitaxel 150 mg/m2 administered intravenously (IV) over 3 hours followed by carboplatin (area under the curve [AUC] 5) administered by IV over 30 to 60 minutes both on day 1 of a 3-week schedule. Dose reductions were allowed depending on hematologic or nonhematologic toxicity, as follows: carboplatin AUC4; paclitaxel 135 mg/m2. Patients who achieved partial remission after six cycles could receive additional cycles on their physicians' discretion.
1610420|NCT02159365|Drug|Dexamethasone|
1610421|NCT02159352|Drug|Daclatasvir|
1610422|NCT02159352|Drug|Darunavir|
1610365|NCT02159807|Drug|Bupivacaine|These groups relate to the dose of bupivacaine that will be administered intrathecally during placement of the spinal anesthetic. Syringes will be prepared in advance by pharmacy containing one of the three doses of bupivacaine being identified only by a syringe number. Twenty micrograms of fentanyl is routinely administered in combination with bupivacaine in the spinal
1610366|NCT02159794|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
1610367|NCT02159781|Procedure|periodontal treatment - scaling and root planning|
1610368|NCT02159768|Device|Airtraq visualization|Larynx visualization with Airtraq and attached handphone
2010205|NCT03061734|Drug|ALLOD-2H|ALLOD-2H: Component A (high dose) plus Component B
2010206|NCT03061734|Drug|Component A (regular dose)|Component A (regular dose) of ALLOD-2
2010207|NCT03061734|Drug|Component B|Component B of ALLOD-2
2010208|NCT03061734|Drug|Placebo|Placebo for Component A plus Placebo for Component B
1610373|NCT02159742|Other|Data Collection|
1610374|NCT02159729|Drug|Placebo|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
1610375|NCT02159729|Drug|ATX-101 (1 mg/cm2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
1610376|NCT02159729|Drug|ATX-101 (2 mg/cm2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
1610377|NCT02159729|Drug|ATX-101 (4 mg/cm2)|Clinical evaluation, patient reported outcome questionnaires, photographs, caliper measurements and recording adverse events
1610378|NCT02159716|Biological|CART-meso|CART-meso are autologous T cells lentivirally transduced with chimeric anti-mesothelin immunoreceptor SS1 fused to the 4-1BB and CD3ζ signaling domains.
1610379|NCT02159703|Procedure|TORS|
1610380|NCT02159703|Radiation|Adjuvant Radiation Therapy|
1610381|NCT02159690|Drug|Enzalutamide|160mg
1610382|NCT02159690|Drug|Abiraterone acetate|1000mg
1610383|NCT02159690|Drug|Prednisone|5mg twice daily (to blunt mineralocorticoid side effects from abiraterone)
1610384|NCT02159690|Drug|Dutasteride|0.5mg
1610385|NCT02159690|Drug|Degarelix|240mg SC loading dose on day 1, then three 80mg SC injections every 4 weeks thereafter
1610386|NCT02159677|Device|EIM Measurements|
1610387|NCT02159664|Other|didgeridoo practice|instrument lessons, 1X/w and daily practice, 20 min /d
1610388|NCT02159651|Drug|tacrolimus|oral
1610389|NCT02159638|Device|Guardian Enlite sensor|Sensor insertion
1610390|NCT02159638|Device|Dexcom G4 platinum sensor|Sensor insertion
1610391|NCT02159625|Device|Abdominal Compression Elastic Support|The ACES will be used for HD patients who have had IDH episodes in the last month. For these patients, the ACES will impose a compression pressure of 15 mmHg to compress the abdominal section over the last three hours of the HD treatment. This action can increase venous return and hence cardiac output to improve the cardiovascular function of the patient. In this way, the IDH episode may be prevented or reduced in severity. This use is much less cumbersome over the use of IAB in dealing with PDOH. We perform this trial study to show the use ACES is more effective than the Trendelenburg maneuver or the infusion of isotonic saline, for example.
1610392|NCT02159612|Other|MRI|MRI scan of muscles in the back and legs. Including T1, DIXON and STIR images.
1610393|NCT02159599|Drug|Darunavir/Ritonavir|Darunavir/ritonavir (800/100 mg): QD (quaque die )
1610394|NCT02159599|Drug|Lamivudine|Lamivudine (300mg) : QD
1610395|NCT02159599|Drug|Emtricitabine/tenofovir or abacavir/lamivudine|Emtricitabine/tenofovir (300/200 mg) or abacavir/lamivudine (600/300 mg): QD
1610396|NCT02159573|Biological|natalizumab|Administered as per routine clinical practice
1610397|NCT02159573|Drug|dimethyl fumarate|Administered as per routine clinical practice
1610398|NCT02159560|Device|Epidural catheter|The intervention is the use of an end-holed epidural catheter or three-holed side port epidural catheter
1610399|NCT02159547|Drug|Dexketoprofen|50 mg intravenous arveles in 50 ml saline in 5 minutes
1610400|NCT02159547|Other|Normal Saline|50 ml normal saline
1610401|NCT02159534|Other|Primebrain|Primebrain stimulation programme aims to facilitate the infant's self-organization of postural competences by proposing varied sensorimotor experiences in a context supporting parent-child interaction.
1610402|NCT02159521|Device|EkoSonic Endovascular System|ultrasound catheter directed thrombolysis
1610403|NCT02159508|Behavioral|Nutritional counselling|In both study arms, daily estimated energy requirements were calculated from the basal energy requirements according to WHO multiplied by a 1.5 activity factor and protein requirement (g/day) was calculated multiplying ideal body weight (defined as BMI 22) by 1.2 to 1.5.
1610404|NCT02159495|Drug|cyclophosphamide|Given IV
1610405|NCT02159495|Biological|Autologous CD123CAR-CD28-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
1610406|NCT02159495|Other|laboratory biomarker analysis|Correlative studies
1610407|NCT02159495|Biological|Allogeneic CD123CAR-CD28-CD3zeta-EGFRt-expressing T-lymphocytes|Given IV
1610408|NCT02159495|Drug|Fludarabine Phosphate|Given IV
1610409|NCT02159482|Drug|Interferon Alfa-2a|
1610410|NCT02159469|Drug|Testosterone enanthate auto-injector|Dose Adjustment 100 mg / 75 mg / 50 mg
1610411|NCT02159456|Other|Continuous enteral feeding via infusion pump|
1610412|NCT02159456|Other|Intermittent enteral feeding via gravity-based infusion|
1610413|NCT02159430|Other|Clinical and psychopathological assessment of HAE patients|
1610414|NCT02159417|Other|Therapeutic Education|"Realization of a consultation of educational diagnosis, followed by the participation for every patient to 4 educational collective workshops therapeutic:
Knowledge of the disease
Food
Physical Activity and care of feet
The therapeutics"
1610416|NCT02159391|Behavioral|Brief Motivational Interview|The Brief Motivational Interview implies an empathic interviewing style which (i) recognizes, examines and tries to resolve the patient´s ambivalence to facilitate behavioral change, (ii) promotes self-efficacy, (iii) allows flexibility in strategies, including short-term aims to reduce consumption and decrease damage linked to this consumption (like road accidents), (iv) works to reduce the patient's resistances, and (v) provides individualized feedback, if deemed appropriate, to promote recognition of the problem and cognitive restructuring.
1610424|NCT02159352|Drug|Lopinavir/Ritonavir|
1610425|NCT02159326|Drug|Microgynon|single oral tablet dose of Microgynon (0.03 mg EE and 0.15 mg LNG, fasted)
1610426|NCT02159326|Drug|Riociguat (Adempas,BAY63-2521)|multiple oral tablet doses of 2.5 mg riociguat TID over 12 days and, on the seventh day of this treatment
1610427|NCT02159313|Drug|Riociguat(Adempas,BAY63-2521)|Single dose of a whole 2.5 mg riociguat tablet
1610428|NCT02159300|Behavioral|experience brain activity recording|Intervention: experience brain activity recording
2010209|NCT03058679|Other|Diet|food for the diet will be provided to the participants for 6 weeks
2010210|NCT03062618|Drug|PRCL-02|Oral tablet(s) administered with water
1610431|NCT02159261|Drug|BAY98-7071_EE20/DRSP/L-5-MTHF|Patients treated by Physicians under approved local prescriptions
1610432|NCT02159248|Drug|Tolfenamic acid + gemcitabine + radiation|"Cohort 1: 200mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).
Cohort 2: 400mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).
Cohort 3: 600mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day).
Cohort 4: 800mg of oral tolfenamic acid, three times per day for 6 1/2 weeks, in combination with weekly intravenous gemcitabine at 400mg/m2 for 5 doses and external beam radiation for 5 1/2 weeks (28 doses at 1.8 Gy/Fx/day)."
2010211|NCT03062618|Drug|Placebo Oral Tablet|Administered with water
1610434|NCT02159196|Drug|acetylcysteine and salbutamol|routine nebulisation of a 3 mL-solution of acetylcysteine (fluimucil 100mg/ml) and a 2.5 mL solution containing salbutamol (ventolin 2.5 Nebules 2.5mg/2.5 ml) four times daily
1610435|NCT02159196|Drug|acetylcysteine|nebulisation of acetylcysteine on strict clinical indications only', i.e. in case of occurrence of persistent thick and tenacious sputum
1610436|NCT02159196|Drug|salbutamol|nebulisation of salbutamol on strict clinical indications only', i.e. in case of occurrence of bronchospasm
1610437|NCT02159183|Device|Standard Plus ESTA STL Roxolid implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.
1610438|NCT02159183|Device|Standard Plus STL implant|The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.
1610439|NCT02159170|Biological|NGF injection|single injection of NGF into the volar forearm / single injection of NaCl into the volar forearm
1610440|NCT02159157|Behavioral|Exercise prescription|A physical therapist will design an exercise plan for each participant on the intervention arm. The participants randomized to the intervention arm will also receive phone calls to assist with tracking the study participant's exercise and motivating the study participant to adhere to the exercise prescription.
1610441|NCT02159144|Other|cold stress|
1610442|NCT02159131|Drug|Ethinyl Estadiol|EE is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
1610443|NCT02159131|Drug|Levonorgestrel|LNG is available as a combination of EE 0.03 mg and LNG 0.15mg, a monophasic oral contraceptive tablet to be taken along with 240 mL water
1610444|NCT02159131|Drug|GSK1265744|GSK1265744 is available as 30 mg tablet to be taken along with 240 mL water
1610445|NCT02159118|Device|Manual bone marrow aspiration and biopsy device|Use of the manual bone marrow aspiration and biopsy device to collect bone marrow aspiration and bone marrow biopsy specimens.
1610446|NCT02159118|Device|Powered bone marrow aspiration and biopsy device|Use of the powered bone marrow aspiration and biopsy device to collect bone marrow aspiration specimens and bone marrow biopsy specimens.
1610447|NCT02159105|Device|FAST scan and non-invasive hemoglobin measurement|"A FAST scan, or abdominal ultrasound will be performed within one hour of cesarean delivery to establish normal levels of postoperative intraabdominal fluid.
Women will also have their hemoglobin measured via a non-invasive method, the Masimo Pronto 7, at 3 time points: immediately prior to surgery (within 2 hours), immediately after surgery (within 1 hour), and the morning following surgery (within 24 hours)."
1610448|NCT02159092|Behavioral|Contingency Management|Monetary incentive for the CM groups is contingent on a saliva cotinine reading that indicates smoking abstinence. Participants were assessed 10 times (Mondays/Thursdays) for abstinence from smoking waterpipe verified by saliva cotinine. The maximum monetary incentives this group can receive is $192.50. The CM groups followed an escalating schedule where: 1) the dollar amount of the incentive increases by $.50 as long as the participant is abstinent at each visit;; and 2) resets to the starting incentive ($14) if the participant was non-compliant at the previous visit, but is compliant at the current visit. Also, Participants were given $10 bonus for every three consecutive compliant visits.
1610449|NCT02159079|Other|Conservative Fluid Management Strategy|For patients in the conservative fluid management arm, beginning 12 hours after admission to study ICU and ending at the first of ICU discharge, death, return to home inspired oxygen, or study day 14, fluid management will be controlled by a study protocol. Patients in shock will receive fluid boluses only as specified by the protocol for oliguria and rapidly increasing vasopressor requirement. Patients not in shock will receive fluid boluses only as specified by the protocol for oliguria. Output will exceed input each day using a diuretic drip if required. Study protocol will be held only for pre-specified Safety Endpoints of persistent oliguria, decompensating shock, diuretic side effect, and intervening acute event.
1610450|NCT02159066|Drug|LGX818|Combination of LGX818 and MEK162 (Part I)
1610451|NCT02159066|Drug|MEK162|Combination of LGX818 and MEK162 (Part I)
1610452|NCT02159066|Drug|LEE011|Combination of LGX818 + MEK162 + LEE011 (Part II)
1610453|NCT02159066|Drug|BGJ398|Combination of LGX818 + MEK162 + BGJ398 (Part II)
1610454|NCT02159066|Drug|BKM120|Combination of LGX818 + MEK162 + BKM120 (Part II)
1610455|NCT02159066|Drug|INC280|Combination of LGX818 + MEK162 + INC280 (Part II)
1610456|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
1611197|NCT02152995|Radiation|Iodine I 124|Undergo iodine I-124 PET/CT
1610457|NCT02159053|Biological|Secukinumab|Eligible subjects are randomized to each of the three treatment arms in 1:1:1 ratio
1610458|NCT02159053|Biological|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
1610459|NCT02159040|Drug|Azacitidine|SC or IV AZA at 75mg/m2 7 days/28 day cycle
1610460|NCT02159040|Drug|Azacitidine plus Deferasirox|SC or IV AZA at 75mg/m2 7 days/28 day cycle DFX 10mg/kg/day
1610461|NCT02159027|Drug|Maraviroc|Maraviroc administered twice daily, dosage based on concomitant medication being taken.
1610462|NCT02159027|Drug|Placebo|Maraviroc placebo administered twice daily, dosage based on concomitant medication being taken.
1610463|NCT02159014|Behavioral|Facilitated group-based aerobic dance|Physical activity facilitated by instructor
1610464|NCT02159014|Behavioral|Online, video prompted, individual aerobic dance|Supported online activity intervention
1610465|NCT02159014|Behavioral|Facilitated group-based nutritional intervention|Education, skill training, access and use of NHS Change4Life Eat Well web resource
1610466|NCT02159014|Behavioral|Self-paced online aerobic dance activity|Self paced physical activity
1610467|NCT02159014|Behavioral|Individual self-paced nutritional intervention|Individual use of online nutritional advice resources.
1610468|NCT02159001|Device|electroconvulsive therapy|10-course, three times a week bilateral frontotemporal ECT
1610469|NCT02158988|Procedure|HIPEC|"HIPEC:
Mitomycin C: 15 mg/m2 (max. 30 mg/ m2, max. 5 L Perfusion). Cisplatin: 75 mg/m2/L (max. 150 mg/m2, max. 5 L Perfusion). 4-12 weeks after cytoreductive surgery 3 cycles postoperative chemotherapy will be applied."
2010212|NCT03058042|Other|Exercises of the pelvic floor muscle at home|Patients will perform pelvic floor exercises at home.
1610471|NCT02158962|Behavioral|Behavioral - Education|"Behavioral - Education
3 educational sessions aimed at reducing risks partner violence, and sexual transmitted infections"
1610472|NCT02158949|Behavioral|mROAD|
2010213|NCT03058042|Other|Exercises of the pelvic floor muscle in the outpatient|Patients will perform pelvic floor exercises in the outpatient.
2010214|NCT03056339|Drug|Fludarabine|30 mg/m2 by vein on Days -5 to -3.
2010215|NCT03056339|Drug|Cyclophosphamide|300 mg/m2 by vein on Days -5 to -3.
1610476|NCT02158923|Procedure|Alveolar recruitment maneuver|To start Alveolar Recruitment Maneuver (ARM), change ventilatory pressure-controlled mode (PCV) with 15 cmH2O pressure control ventilation. A respiratory rate (RR) of 15 rpm, inspiration: expiration ratio of 1:1, FiO2 of 0.8 and PEEP of 10 cmH2O. PEEP level will increase 5 on 5 cmH2O every 10 respiratory cycles, increasing to 15 cycles in the last level of PEEP (25 cmH2O), getting an opening pressure at 40 cmH2O airway (duration of the maneuver: 160 sec.)
1610477|NCT02158923|Procedure|Calculation of optimal PEEP|Change ventilation mode to volume controlled ventilation (VCV) with a VT of 8 ml / kg, RR 15 rpm and adjust a PEEP of 20 cmH2O. Descend PEEP level 2 by 2 cmH2O every 30 seconds until obtain the best respiratory system compliance (Crs) PEEP. Once you know the optimal level of PEEP (best Crs PEEP), will be conducted again alveolar recruitment maneuver and adjust the best Crs level of PEEP + 2 cmH2O .
1610478|NCT02158923|Procedure|Postoperative CPAP|Postoperatively, non-invasive mechanical ventilation with a CPAP of 5 cmH2O (or 10 cmH2O if BMI> 30) with a FiO2 of 0.5 will be applied.
1610479|NCT02158910|Drug|Aricept|5 mg Aricept increasing dose to 10 mg Aricept, or 10 mg Aricept increasing dose to 23 mg Aricept
1610480|NCT02158897|Other|Prolon diet|3 cycles of a 5-day Prolon diet very month
1610481|NCT02158884|Device|IDEO brace|All participants will receive the IDEO brace.
1610482|NCT02158871|Behavioral|Beyond Silence|Pilot data from initial phases of the project and best practice principles in contact based education and adult learning theory informed curriculum design. The six in-person sessions use workplace-based vignettes to prompt reflection and discussion, build mental health literacy, reduce stigma, and promote communication and coping skill development. The virtual sessions use a secure online discussion board for participants to explore relevant online resources. All sessions will be co-led by trained peer educators; employees who have personally experienced mental ill health and recovery and are viewed as credible leaders within the organization. They will be recruited and trained to effectively teach the content, share personal experiences, and facilitate discussion.
1610483|NCT02158871|Behavioral|Mental Health First Aid (MHFA)|MHFA is a standardized, twelve-hour educational program designed to teach participants how to recognize the early warning signs of mental illness, how to provide initial help to someone in a mental health crisis, and how to support people who are developing mental health problems. It is an evidence-based approach that originated in Australia, but is being implemented across Canada, under the leadership of the Mental Health Commission of Canada. Leadership of the MHFA will be provided by an employee in each organization who has been trained through the 5-day national MHFA instructor training program. The instructor does not share any personal experiences regarding mental health issues.
1610484|NCT02158858|Drug|CPI-0610|
1610485|NCT02158845|Drug|LNG-IUS: levonorgestrel intrauterine system|LNG-IUS (levonorgestrel intrauterine system) is inserted until the fifth day of the cycle. It releases 20 mcg/day of LNG
1610486|NCT02158845|Drug|GnRHa: leuprolide|3.75 mg leuprolide injected intramuscularly on a monthly basis
1610487|NCT02158832|Device|Acupuncture + Electrical Stimulation|"2 acupuncture needles are inserted into the upper back. 10Hz, 0.5ms biphasic square wave electrical pulses are applied to needles x20 mins. Current >sensation threshold & maintained at a level that is comfortable/painless & does not elicit skeletal muscle contractions (~5mA, <10mA).
Needle locations are in the vicinity of nerves that supply the affected upper limb:
EX-B1': Affected hemisphere, 1.5cm lateral to C5 spinous process. Insertion angle: shallow, 'inferior-lateral', ~15⁰ perpendicular to the skin, ~15⁰ lateral to the midline. Depth: ~1.5 cm (secure anchorage).
EX-HN15': Affected hemisphere, 1.5cm lateral to the C7 spinous process. Insertion angle: shallow, 'inferior-medial' ~15⁰ perpendicular to the skin, ~15⁰ medial. Depth: ~1.5 cm (secure anchorage)."
1610488|NCT02158819|Device|Total knee arthroplasty with Visionaire|Patient Specific Instrumentation
1610489|NCT02158806|Drug|Aspirin|150 mg aspirin in capsule form once daily for up to 24 weeks
1610490|NCT02158806|Drug|Placebo|Matching placebo capsule containing inert bulking agent
1610491|NCT02158793|Procedure|Craniomaxillofacial allotransplantation|Transplantation of donor face
1610492|NCT02158780|Procedure|Scrotal Orchidopexy|Single incision
1610493|NCT02158780|Procedure|Inguinal Orchidopexy|Double Incision (Standard)
1610494|NCT02158767|Biological|Allogenic T cell-depleted hematopoietic stem cell transplantation|Undergo CD34+ enriched T-cell depleted allogeneic peripheral blood stem cell transplant. T-cells will be removed using the experimental CliniMACS(r) Reagent System used in vitro to select and enrich CD34+ cells
2010216|NCT03056339|Drug|Mesna|300 mg/m2 by vein on Days -5 to -3 before and after the cyclophosphamide dose.
1610496|NCT02158741|Behavioral|Home Visits and Lifestyle Education Support|
1610497|NCT02158715|Device|Site of smartphone on chest compressor' arm|
1610498|NCT02158702|Drug|Pomalidomide and Dexamethasone|Pomalidomide will be given at 4mg once daily for 21 days in a 28-day cycle. Dexamethasone will be given at a dose of 40mg orally once a week for 4 weeks (D1,8,15,22).
1610499|NCT02158689|Drug|Letrozole|
1610500|NCT02158689|Drug|human menopausal gonadotropin (hMG)|
1610501|NCT02158676|Dietary Supplement|Prebiotic|Fructooligosaccharides
1610502|NCT02158676|Dietary Supplement|Synbiotic|Fructooligosaccharides + Lactobacillus paracasei LPC-37 + Lactobacillus rhamnosus HN001 + Lactobacillus acidophilus NCFM + Bifidobacterium lactis HN019
1610503|NCT02158676|Other|Placebo|Maltodextrin
1610504|NCT02158663|Device|Repetitive Transcranial Magnetic Stimulation|TMS Device
1610505|NCT02158650|Behavioral|Video-Based Informed Consent|
1610506|NCT02158624|Drug|Intravitreal Lucentis 0.5mg|
1610507|NCT02158611|Other|Lifestyle counseling|
1610508|NCT02158598|Drug|Vitamin D chewable tablet supplementation|
1610509|NCT02158598|Drug|Vitamin D pill supplementation|
1610510|NCT02158585|Drug|Lamotrigine|Lamotrigine will be taken orally on a daily basis for the duration of 20 weeks, consisting of a six-week titration, 12-week study period, and two-week taper. Possible doses for patients are 25mg twice a day, 50mg twice a day, 100 mg twice a day and 150mg twice a day during titration; 150mg twice a day or 100mg twice a day for the 12-week study period; 150mg once a day or 100mg once a day for Week 1 of the taper; and 75mg once a day, or 50mg once a day for Week 2 of the taper. Each increase in dose will be maintained for two weeks before deciding to further increase or decrease based on tolerability. Patients who discontinue at any point of the study will have a two-week taper consisting of the current dose once a day for one week followed by half the dose once a day for another week.
1610511|NCT02158585|Drug|Placebo|The placebo will match the lamotrigine dosage, frequency and duration.
1610512|NCT02158572|Drug|AG200-15|Transdermal contraceptive delivery system
1610513|NCT02158559|Drug|Danhong Injection|Danhong injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
1610514|NCT02158559|Drug|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 7 days;
1610515|NCT02158546|Drug|ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
1610516|NCT02158546|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
1610517|NCT02158533|Drug|High Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
1610518|NCT02158533|Drug|Low Dose ALKS 5461|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
1610519|NCT02158533|Drug|Placebo|Sublingual tablet, taken once daily (in addition to open-label treatment with a commercially available antidepressant)
2010217|NCT03056339|Biological|iC9/CAR.19/IL15-Transduced CB-NK Cells|"Infusion of iC9/CAR.19/IL15-transduced CB-NK cells on Day 0 by vein.
Starting dose: 10E5"
2010218|NCT03056339|Drug|AP1903|If participant has graft-versus-host disease (GvHD) or cytokine release syndrome after the NK cell infusion, they will receive AP1903 0.4 mg/kg administered as an intravenous infusion.
2010219|NCT03055013|Procedure|Conventional Surgery|Undergo nephrectomy
2010220|NCT03055013|Other|Laboratory Biomarker Analysis|Correlative studies
1610525|NCT02158507|Drug|Combination of Veliparib + Lapatinib|Treatment cannot be in administered conjunction with other chemotherapy, targeted therapy, radiation therapy, or other investigational drugs.
1610526|NCT02158494|Device|Balance and Gait Training using neurostimulation modulation.|CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
1610527|NCT02158481|Dietary Supplement|A capsule containing both polyphenols and carotenoids|
1610528|NCT02158481|Dietary Supplement|Placebo intervention|Placebo intervention
1610529|NCT02158468|Device|Combined intrahospital pre- and postconditioning|After admission to hospital 3 cycles of preconditioning with 5-min inflation and 5-min deflation of a blood-pressure cuff. After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
1610530|NCT02158468|Device|Postconditioning|After primary PCI/stenting 4 cycles of postconditioning (30s ischemia and 30s reperfusion)
1610531|NCT02158455|Procedure|NT SVG grafts|
1610532|NCT02158442|Procedure|Percutaneous Isolated Limb Perfusion (PILP) delivery|The Percutaneous Isolated Limb Perfusion (PILP) delivery intervention procedure enables the use of existing antibiotic therapies in a more targeted and aggressive fashion; it addresses limitations associated with the use of conventional antibiotic drug delivery. As part of the procedure, the circulation of the limb is isolated separately from the general circulatory system enabling the delivery of antibiotic at high therapeutic doses that are not achievable when standard doses are administered intravenously.
1610533|NCT02158442|Drug|Timentin|The Control Group will receive standard dosings of intravenous Timentin plus other standard care.
1610534|NCT02158429|Other|2 dimensional vs. 3 dimensional ultrasound|At the end of a regularly scheduled ultrasound measuring fetal growth an additional 5-10 minute ultrasound will be performed, either in 2-dimensional or 3-dimensional mode
1610535|NCT02158403|Other|Clinical Management Recommendations for reducing pump thrombosis|Clinical Management Recommendations for reducing pump thrombosis
1610536|NCT02158390|Behavioral|Jasper-EMT with words and AAC|"Jasper-EMT with words and AAC
A therapist plus parent implemented social communication intervention which include use of the iPad for a mode of communication. A total of 6 hour long workshops with the parent and 42 hour long intervention sessions with the child occur; half include the parent as therapist and occur in the home. The treatment lasts approximately 4 months."
1610537|NCT02158377|Device|Trabecular metal dental implants (TM)|Patients receive TM dental implants in this arm. The early stability is measured and compared to the stability of the TSV implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
1610538|NCT02158377|Device|Tapered screw-vent implants (TSV)|Patients receive TSV dental implants in this arm. The early stability is measured and compared to the stability of the TM implants. The implants are loaded and provisionalized early at 3 or 6 weeks if stability permits.
2010221|NCT03055013|Biological|Nivolumab|Given IV
1610540|NCT02158351|Procedure|liver and white adipose tissue biopsies|
1610541|NCT02158338|Other|Asthma|mothers who have children that have been diagnosed with respiratory issues
1610542|NCT02158338|Other|Non-asthma|mothers who have children that do not have a diagnosis of respiratory problems
1610543|NCT02158325|Procedure|anterior capsulorhexis sizes|Pediatric cataract surgery performed with different anterior capsulorhexis sizes (3.0~3.9, 4.0~5.0, 5.1~6.0 mm in diameter)
1610544|NCT02158312|Device|Magstim Eldith DC-stimulator(Magstim Co., Whitland, UK)|2 mA for 20 minutes transcranial direct current stimulation
1610545|NCT02158299|Drug|Avitene|
1610546|NCT02158299|Drug|Sapylin|
1610547|NCT02158299|Behavioral|axillary drainage|
1610548|NCT02158299|Other|reexamine|
1610549|NCT02158286|Other|Measuring emptying rate from the gastric tube|
1610550|NCT02158273|Drug|Sugar Pill|145 mg/day, oral pill, 9 days
1610551|NCT02158273|Drug|TRICOR (fenofibrate)|145 mg/day, oral pill, 9 days
1610552|NCT02158260|Behavioral|Position changing|
1610553|NCT02158234|Drug|Cisplatin|Cisplatin 15 mg/m^2 prior to each fraction
1610554|NCT02158234|Radiation|Stereotactic Body Radiation Therapy (SBRT)|All participants will be treated every other day (excluding Saturday/Sunday). Starting Dose: 6 Gy/ Fraction 5/ Total 30 Gy.
1610555|NCT02158221|Drug|PACAP|Pituitary adenylate cyclase-activating polypeptide (PACAP)
1610556|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube at the diagnosis and after 3 months of treatment|
1610557|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes at the diagnosis and after 3 months of treatment|
1610558|NCT02158208|Other|Blood sample drawn into a 5 mL dry tube|
1610559|NCT02158208|Other|16 blood samples drawn into 6 mL heparinized tubes|
1610560|NCT02158195|Biological|blood samples|
1610561|NCT02158182|Drug|Lactulose|30 ml by mouth three times daily until melena resolved, then adjusted to dose-response to obtain two to three soft stools. Duration of therapy: 7 days
1610562|NCT02158182|Drug|L-ornithine L-aspartate|10 grams by intravenous way for 24 hours. Duration of therapy: 7 days
1610563|NCT02158182|Drug|Rifaximin|2 tablets (400mg) three times daily. Duration of therapy: 7 days
1610564|NCT02158182|Drug|Placebo|"Placebo (for lactulose) 30ml of dextrose solution by mouth three times daily, for 7 days.
Placebo (for L-ornithine L-aspartate) saline solution 500ml by intravenous way for 24 hours, for 7 days.
Placebo (for rifaximin) 2 dextrose tablets three times daily for 7 days."
1610565|NCT02158156|Behavioral|Exercise|Ten weeks of home-training on a cycle ergometer 3 times a week for 30 minutes.
1610566|NCT02158143|Dietary Supplement|vitamin D3|
1610567|NCT02158117|Drug|nasal naloxone|one puff in one nostril with the subject is lying down
1610568|NCT02158104|Procedure|Deep dry needling|
1610569|NCT02158091|Drug|IPI-145|oral PI3K delta/gamma inhibitor
1610570|NCT02158091|Drug|Fludarabine|intravenous chemotherapy
1610571|NCT02158091|Drug|Cyclophosphamide|intravenous chemotherapy
1610572|NCT02158091|Drug|Rituximab|intravenous immunotherapy
1610573|NCT02158078|Device|PaQ® Insulin Delivery Device|PaQ is a 3 day insulin delivery device. Utilizes U 100 rapid-acting insulin. Provides basal insulin at preset basal doses and bolus insulin (in 2 unit increments) with a push of a button.
1610574|NCT02158065|Other|Coaching program|The coaching program consists of a (1) Step counter used as a coaching activity monitor to collect number of steps walked by the patients and (2) the Linkcare System, a mobile phone or tablet PC placed in the patient's home to collect data from the step counter. The system will set a daily activity goal for the patient based on achieved activity levels which will be measured by the step counter. Patients will also receive feedback, motivational and educational messages and direct calls from the coaching team at each institution.
1610575|NCT02158052|Drug|Tacrolimus|Tacrolimus starting on Day -1
1610576|NCT02158052|Drug|Anti-thymocyte globulin|20 mg/kg IV on Days -3, -1, +1, +3
1610577|NCT02158052|Procedure|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques.
1610578|NCT02158052|Drug|Bone marrow transplant from a related donor|Donor bone marrow (> 2 x 10e8 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed.
1610579|NCT02158052|Radiation|Total body irradiation 400 centigray (200 cGy X 2)|on day -1
1610580|NCT02158039|Drug|Ethanol|EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
1610581|NCT02158039|Drug|Lidocaine|The final solution contained 1% lidocaine except in subjects allergic to local anesthetics.
1610582|NCT02158013|Other|Levorag Emulgel|
1610583|NCT02158013|Drug|Diltiazem|
1610584|NCT02158000|Other|group A|one tab every 8 hs Diosmin ( 500mg) beginning from the day of ovum retrieval in addition to aspiration of the fluid by an IUI catheter
1610585|NCT02157987|Drug|bevacuzimab spray|
1610586|NCT02157974|Drug|Byetta 5Mcg Pen Injection|
1610587|NCT02157948|Drug|Denosumab (CP2)|Denosumab produced by a process referred to as CP2, administered subcutaneously from a prefilled syringe.
1610588|NCT02157948|Drug|Denosumab (CP4)|Denosumab produced by a process referred to as CP4, administered subcutaneously from a prefilled syringe.
1610589|NCT02157935|Drug|Symbicort|Budesonide/formoterol pMDI, 160/4.5 μg x 2 actuations BID, for oral inhalation, 120 doses
1610590|NCT02157935|Drug|Formoterol turbohaler|Formoterol Turbuhaler 4.5 μg x 2 actuations BID, for oral inhalation, 60 doses
2010222|NCT03055013|Other|Patient Observation|Undergo observation
2010223|NCT03055013|Other|Pharmacological Study|Correlative studies
1610591|NCT02157935|Other|Placebo for Symbicort pMDI|pMDI, aerosol for oral inhalation, placebo, 120 doses
1610592|NCT02157935|Other|Placebo for Formoterol Turbohaler|PLacebo powder for oral inhalation, 60 doses
1610593|NCT02157922|Drug|alginate oligosaccharide|Inhalation
1610594|NCT02157909|Device|Lotrafilcon B sphere modified design contact lenses|
1610595|NCT02157909|Device|Lotrafilcon B sphere contact lenses|
1610596|NCT02157883|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with AZD9291+/- itraconazole
1610597|NCT02157883|Drug|AZD9291|AZD9291 tablets: Part A 80mg od, days 1 and 10 only. Part B 80mg od for 12 months.
1610598|NCT02157883|Drug|Itraconazole|Itraconazole tablets: 2x100mg bd, Part A days 6 to 19 only
1610599|NCT02157870|Biological|Intraperitoneal tgDCC-E1A|Starting Dose Level: 1.8 mg DNA/m^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
1610600|NCT02157870|Drug|Paclitaxel|80 mg/m^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
1610601|NCT02157831|Biological|CP-870,893|
1610602|NCT02157818|Drug|midazolam|
1610603|NCT02157818|Drug|Dexmedetomidine|
1610604|NCT02157805|Other|beef meat|"Meat cooking conditions
st condition : beef meat cooked during 5 minutes at 55°C
nd condition : beef meat cooked during 30 minutes à 90°C"
1610605|NCT02157792|Drug|VX-970|
1610606|NCT02157792|Drug|Gemcitabine|
1610607|NCT02157792|Drug|Cisplatin|
1610608|NCT02157792|Drug|Etoposide|
1610609|NCT02157792|Drug|Carboplatin|
1610610|NCT02157779|Behavioral|Cognitive Behavioral Intervention|Includes individual therapy sessions using cognitive and behavioral strategies addressing problems with anger intensity / frequency / management
1610611|NCT02157779|Behavioral|Supportive Intervention|Includes individual therapy sessions using supportive and problem-solving strategies.
1610612|NCT02157766|Behavioral|Intensive Meditation Practice|Long term meditators complete three days of of mindfulness or compassion/loving kindness meditation at T2 and T3 (one meditation type per visit).
1610613|NCT02157766|Behavioral|Mindfulness Based Stress Reduction|8 week class designed to enhance well-being through training in mindfulness.
1610614|NCT02157766|Behavioral|Health Enhancement Program|8 week class designed to enhance well-being through training in physical activity, functional movement, music therapy and nutrition.
1610615|NCT02157740|Device|Residents of nursing homes with telemedicine after implementation of telemedicine|
1610616|NCT02157727|Device|Infants hospitalized in health facilities performing Tele-expertise|
1610617|NCT02157714|Drug|PRX002|
1610618|NCT02157714|Other|Placebo|
1610619|NCT02157701|Dietary Supplement|Polyherbal capsule|
1610620|NCT02157701|Dietary Supplement|Placebo capsule|
1610621|NCT02157688|Other|no intervention : case control study|
1610622|NCT02157675|Dietary Supplement|Polyherbal capsule|
1610623|NCT02157675|Dietary Supplement|Placebo capsule|
1610624|NCT02157649|Drug|IR Tablet under Fasted conditions|Administration of IR Tablets combination of Codeine Phosphate/Guaifenesin 20mg/400mg every 4 hours for 12 hours total.
1610625|NCT02157649|Drug|ER Tablet under Fed Conditions|Administration of two ER Tablet combination of Codeine Phosphate/Guaifenesin 30mg/600mg
1610626|NCT02157649|Drug|ER Tablet under Fasted Conditions|Administration of two Codeine Phosphate/Guaifenesin 30mg/600mg ER Tablets under fasted conditions.
1610627|NCT02157636|Drug|CPI-0610|
1610628|NCT02157623|Drug|Levulan|Levulan application followed by Red or Blue light PDT on randomized treatment fields
1610629|NCT02157623|Other|Red Light Photodynamic Therapy|Aktilite™ (red lamp) after Levulan application on randomized treatment field
1610630|NCT02157623|Other|Blue Light Photodynamic Therapy|Blu-U® (blue lamp) after Levulan application on randomized treatment field
1610631|NCT02157610|Behavioral|Self-Help Materials|Participants receive free self-help materials mailed at baseline, 6, and 12 months. and a referral to the Oklahoma Quitline.
1610632|NCT02157610|Drug|Nicotine Patch|Participants receive a 6-week supply of nicotine patch. Nicotine patch regime based on participant's self-reported smoking rate. Participants who smoke >10 cigarettes/day receive 4 weeks of 21 mg, 1 week of 14 mg, and 1 week of 7 mg patches. Those who smoke 5-10 cigarettes/day receive 4 weeks of 14 mg and 2 weeks of 7 mg patches. Participants who smoke < 5 cigarettes/day given 6 weeks of 7 mg patches.
1610633|NCT02157610|Behavioral|REDCap|REDCap will be used to collect all questionnaires data over the phone. Questionnaires done at baseline to randomize, then at 3, 6, 12, and 18 months.
1610634|NCT02157610|Procedure|Saliva Test|Saliva test performed at 3, 6, 12, and 18 months.
1610635|NCT02157610|Behavioral|Telephone Counseling Sessions|6 telephone counseling sessions performed over 12 months. Sessions performed at baseline, 3, 6, 12, and 18 months. Sessions digitally recorded.
1610636|NCT02157597|Other|NIRS based management|"Check NIRS, mechanics, muscle relaxation, hemodynamics, ventilation, hematocrit, surgical repair
Deepen anesthesia with volatile or intravenous agent.
Consider Extra-Corporeal Membrane Oxygenation (ECMO)."
1610637|NCT02157597|Other|Control|During the Control Arm, the medical team completes all tasks as clinically necessary and in the best medical interest of the patient, without any input from the study procedures
1610638|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fed conditions /high-fat / high caloric meal)
1610639|NCT02157584|Drug|Telotristat etiprate|2 × 250 mg (as free base) telotristat etiprate tablets (fasted conditions)
1610640|NCT02157571|Drug|Prulifloxacin|600 mg/tablet, oral administration of a single tablet.
1610641|NCT02157571|Drug|Levofloxacin|500 mg/tablet, oral administration of a tablet daily.
1610642|NCT02157571|Drug|Levofloxacin Placebo|Placebo of levofloxacin hydrochloride tablet, without active components.
1610643|NCT02157571|Drug|Prulifloxacin placebo|Placebo of prulifloxacin film-coated tablet without active components.
1610644|NCT02157558|Drug|Fexofenadine|All subjects will receive 180 mg fexofenadine
1610645|NCT02157558|Drug|Telotristat etiprate|All subjects will receive 500 mg (2 X 250 mg tablets) telotristat etiprate tablets three times daily
1610646|NCT02157532|Procedure|mechanical thrombectomy|Mechanical thrombectomy using any already approved stent-retriever device
1610647|NCT02157532|Drug|Best standard treatment|Intravenous r-tPA infusion or any other medical management option
2010224|NCT03055013|Other|Quality-of-Life Assessment|Ancillary studies
1610649|NCT02157506|Drug|CXL-1427|
1610650|NCT02157506|Drug|Placebo|
1610651|NCT02157493|Behavioral|Arrowhead Business Group Curriculum|Arrowhead Business Group (ABG) is a culturally tailored entrepreneurship/life-skills intervention, which features instruction from American Indian paraprofessionals in an effort to decrease drug use, depressive symptoms, hopelessness and other high-risk behaviors among youth while improving their school performance and college/career aspirations.
1610652|NCT02157493|Behavioral|Recreational League Control Condition|The control condition will consist of a recreational sports league that will be led by local American Indian study staff who are experienced with Johns Hopkins camps and community-based Apache sports programs. Activities will be conducted on 3 Saturdays during the academic year to mixed gender groups of approximately 50 participants.
1610653|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 3 days per week .|outpatient biquadricipital electrostimulation 3 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
1610654|NCT02157480|Device|electrostimulation (with Compex® Compex2* (DJO, Vista, CA, USA)) 5 days per week|outpatient biquadricipital electrostimulation 5 days per week with an electrostimulator Compex2* (DJO, Vista, CA, USA)
1610655|NCT02157467|Drug|BMS-955176|
1610656|NCT02157467|Drug|Ortho Cyclen|
1610657|NCT02157454|Other|Website access|Access to the colorectal cancer module of the website www.krankheitserfahrungen.de which provides free, reliable information about health issues by sharing people's real-life experiences
1610658|NCT02157441|Procedure|lower uterine compression sutures|intervention is lower uterine compression sutures (involved bilateral uterine artery ligation and compression of the lower uterine segment at the same time with one circular stitch) as a conservative treatment for the treatment of postpartum hemorrhage in women with placenta previa complete centralis.
1610659|NCT02157428|Drug|Flumazenil|
1610660|NCT02157428|Drug|saline|
1610661|NCT02157415|Device|Uro-Tainer Polihexanide 0.02%|Catheters will be rinsed by gravity feed with 100ml solution of UT-P 0.02% once a day for a maximum of 5 instillations.
1610662|NCT02157402|Behavioral|Social marketing activities and pop-up events to promote healthy lifestyles|
1610663|NCT02157389|Other|Administration of a pharmacological placebo|
1610664|NCT02157376|Drug|Esomeprazole|iv esomeprazole 30 min intermittent infusions given for maximum 14 days
1610665|NCT02157376|Drug|Cimetidine|iv cimetidine 30 min bolus infusion followed by iv cimetidine continuous infusion given for maximum 14 days
2010225|NCT03053440|Drug|BGB-3111|160mg PO BID until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
2010226|NCT03053440|Drug|Ibrutinib|420mg PO QD until progressive disease, unacceptable toxicity, death, withdrawal of consent, or study termination by sponsor
1610668|NCT02157350|Procedure|Panretinal laser photocoagulation|Panretinal photocoagulation. Laser energy is given to the retina in two sittings, carefully avoiding the macular. The energy are placed 2 to 3 disc diameters away from the macula and the disc outside the arcades and extended peripherally upto the equator and beyond.
1610669|NCT02157337|Drug|Atorvastatin|80 mg (PO) once daily for 6 days
1610670|NCT02157337|Drug|placebo|80 mg (PO) once daily for 6 days
1610671|NCT02157324|Drug|acalabrutinib|
1610672|NCT02157324|Drug|ACP-319|
1610673|NCT02157311|Drug|Four consecutive days on treatment and 3 days off|All patients will take a combination of three of these treatment with a weekly strategy of 4 consecutive days on treatment followed by 3 days off treatment
1610674|NCT02157298|Drug|Dapagliflozin 5 mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
1610675|NCT02157298|Drug|Placebo tablet|Placebo tablet. Oral dose
1610676|NCT02157285|Behavioral|Peer Mentor Counseling|Peer mentoring will entail the peer mentor describing her positive experience with her LARC method. The participant will then have a chance to ask any experience related questions to the mentor. Any clinical inquiries or questions the mentor does not feel comfortable answering, she will defer to the contraceptive counselor/ physician who will be subsequently providing the routine counseling. The entire peer mentor encounter should not last more than 10 minutes.
1610677|NCT02157272|Drug|Experimental: Rivaroxaban|The investigated drug is Rivaroxaban 20mg, a film coated tablet, which is a highly selective direct factor Xa inhibitor. It should be administered orally, every day at any time (always the same), with food. The treatment should be performed for all the treatment period.
1610678|NCT02157246|Other|Pimonidazole|
1610679|NCT02157246|Other|F-MISO PET|
1610680|NCT02157246|Other|pCT|
1610681|NCT02157246|Other|Functional MRI|
1610682|NCT02157246|Procedure|Biopsy|
1610683|NCT02157246|Procedure|Blood sample|
1610684|NCT02157233|Behavioral|Rest|
1610685|NCT02157233|Behavioral|Exercise|
1610686|NCT02157220|Device|Fixed bearing prosthesis|
1610687|NCT02157220|Device|Mobile bearing prosthesis|
1610688|NCT02157207|Dietary Supplement|Antioxidant|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
1610689|NCT02157207|Other|Placebo|Comparison of antioxidant supplementation with a placebo. Effects of race and age and race in repsonse to the supplementation will be evaluated.
1610690|NCT02157181|Drug|2CdA +/- Rituximab|Cladribine 0.14 mg/kg daily subcutaneous bolus injection Rituximab 375 mg/m² infusion
1610730|NCT02156752|Behavioral|SR|Treatment is based on Self-Regulation theory.
1610731|NCT02156752|Behavioral|WLO|Treatment is based on cooking tips and demonstrations.
1610732|NCT02156739|Drug|Gadoxetate|Participants undergoing a follow-up MR with initial administration of Gadoxetate 0.025mmol/kg by vein over about 1 minute.
1610733|NCT02156739|Drug|Gadopentetate Dimeglumine|Participants undergoing a follow-up MRI receive Gadopentetate Dimeglumine 0.1mmol//kg by vein over about 1 minute, 20 minutes after receiving Gadoxetate.
2010227|NCT03053063|Drug|SEL|Tablets administered orally once daily
2010228|NCT03053063|Drug|Placebo|Tablets administered orally once daily
2010229|NCT03052725|Drug|reslizumab|110-mg
2010230|NCT03052608|Drug|Lorlatinib|ALK-positive NSCL treatment
2010231|NCT03052608|Drug|Crizotinib|ALK-positive NSCL treatment
1610692|NCT02157155|Biological|LPS|LPS is endotoxin from gram negative bacteria. It is used scientifically to mimic infection lasting 4-8 hours.
1610693|NCT02157142|Device|HLT Transcatheter Aortic Valve System|Transcatheter aortic valve replacement with an HLT Transcatheter Aortic Valve System
1610694|NCT02157129|Device|LipoAerosol© inhalation|LipoAerosol© inhalation, 5x/d for 30min
1610695|NCT02157129|Other|Physiologic saline inhalation|Physiologic saline inhalation, 5x/d for 30min
1610696|NCT02157116|Drug|cisplatin|
1610697|NCT02157116|Drug|Docetaxel|
1610698|NCT02157116|Drug|Pegfilgrastim|
1610699|NCT02157103|Drug|Bevacizumab 25 mg in 1 ml subcutaneously daily|Bevacizumab delivered by subcutaneous injection instead of intravenous infusion.
1610700|NCT02157090|Other|Herpes Patch SOS (Hansaplast®)|
1610701|NCT02157090|Other|Herpes vesicle patch of Compeed®|
1610702|NCT02157077|Drug|Aflibercept|Intravitreal Injection
1610703|NCT02157051|Biological|CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine|Given ID
1610704|NCT02157051|Other|Laboratory Biomarker Analysis|Correlative studies
2010232|NCT03052517|Drug|QAW039 Dose 1|QAW039 Dose 1 once daily
2010233|NCT03052517|Drug|QAW039 Dose 2|QAW039 Dose 2 once daily
1610707|NCT02157025|Device|Cartoon video fixation target and cartoon character voice audio instructions during Humphrey perimetry|
1610708|NCT02157025|Other|Usual Care procedures during Humphrey perimetry for children|
2010234|NCT03052517|Drug|Placebo|Placebo once daily
2010235|NCT03051659|Drug|Eribulin Mesylate|Eribulin mesylate is developed from a natural substance found in a sea sponge. Eribulin mesylate works by preventing cancer cells from multiplying
1610711|NCT02156973|Other|Video information|A six minute information film to address the common themes raised by patients. This will clearly show the scanner, discuss the use of beta-blockers and radiation, and explain the likely side effects of x-ray dye (which can be alarming if patients are not expecting them). In this way we hope patients will be better prepared for the scan.
2010236|NCT03051659|Drug|Pembrolizumab|Pembrolizumab binds to PD-1, an inhibitory signaling receptor expressed on the surface of activated T cells, and blocks the binding to and activation of PD-1 by its ligands, which results in the activation of T-cell-mediated immune responses against tumor cells.
2010237|NCT03053050|Drug|SEL|Tablets administered orally once daily
2010238|NCT03053050|Drug|Placebo|Tablets administered orally once daily
1610715|NCT02156947|Procedure|Laparoscopic cholecystectomy|The technique used for LC was the conventional four-trocar approach (10-mm optic at the umbilicus, 10-mm trocar in the epigastrium and two 5-mm trocars in the right upper abdomen).
1610716|NCT02156934|Biological|paraurethral injection|Paraurethral injection of muscle derived stem cell in patients with stress urine incontinency.
1610717|NCT02156921|Other|App-based training|
2010239|NCT03050502|Device|Chest tube drain|This group will have an intra-pleural catheter placed with the intent of draining all intra-pleural blood (HTX). The size and nature of the catheter, manner of placement, and timing of removal will be at the discretion of the attending clinician.
2010240|NCT03050502|Other|Expectant management|This group will not have an intra-pleural catheter placed on the basis of the HTX, but will undergo standard observation/conservative management by the trauma service. Intra-pleural catheters may be placed after enrollment at the attending clinician's discretion.
1610721|NCT02156869|Other|Decision aid|Intervention was use of a decision aid. Decision aid contained information about: 1) the epidemiology of prostate cancer; 2) what is a PSA test and advantages and limits of screening for prostate cancer using it (including risk of overtreatment and risk of becoming impotent and/or incontinent) and; 3) the position on screening for prostate cancer of major scientific societies in France at the time of the study. The second page contained a visual representation of the benefits of PSA screening for prostate cancer versus usual care based on the results of the European Randomized study of Screening for Prostate Cancer trial (ERSPC) The decision aid was pretested with 20 patients to ensure clarity and wording. It was revised accordingly to comments.
1610722|NCT02156843|Drug|Pyridorin|300 mg BID (twice daily, every 12 hours), oral capsule taken until end stage renal disease or death occurs, or the study is terminated by the sponsor.
1610723|NCT02156843|Drug|Placebo|Placebo excipients without the active drug, oral capsule taken BID (twice daily, every 12 hours), until end stage renal disease or death occurs, or the study is terminated by the sponsor.
1610724|NCT02156817|Other|Amplitude integrated electroencephalogram, Cardiorespiratory signal acquisition|
2010241|NCT03051490|Drug|Liprotamase|oral, soluble, non-enterically coated, non-porcine, pancreatic enzyme replacement
1610726|NCT02156791|Biological|gpASIT+TM|
2010242|NCT03051490|Drug|porcine PERT|oral, enterically-coated, pig-derived, pancreatic enzyme replacement
2010243|NCT03048968|Procedure|Gait, sit-to-stand movement and stair climbing|Spatio temporal characteristics, muscle activation and foot pressure distribution are measured by motion capture system, surface electromyography (sEMG) and F-Scan Mobile system during 10m walking test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test.Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during stair climbing.
1610729|NCT02156752|Behavioral|ACT|Treatment is based on Acceptance and Commitment Therapy
2010244|NCT03048968|Procedure|Sit-to-stand movement and treadmill gait|Muscle activation and foot pressure distribution are measured by surface electromyography (sEMG) and F-Scan Mobile system during five times sit-to-stand test. Brain activity is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
2010245|NCT03048968|Device|gait enhancing mechatronic system (GEMS)|"Gait, sit-to-stand movement and stair climbing with GEMS and without GEMS in elderly adults.
Sit-to-stand movement and treadmill gait with GEMS and without GEMS in stroke patients."
2010246|NCT03048968|Device|treadmill|In stroke patients, brain activity is measured by functional Near-Infrared-Spectroscopy (fNIRS) (NIRScout, NIRx, Germany) during treadmill gait.
1610734|NCT02156726|Drug|low-dose FCR|FCR with attenuated dose of fludarabine and cyclophosphamide
1610735|NCT02156713|Behavioral|CIMT Camp|
1610736|NCT02156700|Procedure|Shear wave elastography|Measurement of tumor stiffness by Shear wave elastography - SWE™
1610737|NCT02156687|Device|Y mesh|Y mesh
1610738|NCT02156687|Device|Dual flat mesh|Dual flat mesh
1610739|NCT02156674|Drug|Naglazyme®|1 mg per kg of body weight administered once weekly as an intravenous infusion
1610740|NCT02156661|Drug|Oxytocin|
1610741|NCT02156648|Other|Feasibility study|All participants will have blood draws for biomarkers during the course of the study at visit 1, 2, 3, 4, 5, 6, 7 and 8. they will also have the speckle tracking echocardiogram at visit 1, 4, 5, 6, 7 and 8. For women 45 an over a cardiac PET scan will be performed at visit 1 and 5.
1610742|NCT02156635|Device|Transcranial direct current stimulation|
1610743|NCT02156635|Behavioral|Constraint-Induced Movement Therapy|
1610744|NCT02156635|Other|Placebo|
1610745|NCT02156609|Device|Percutaneous ventricular support with the HeartMate PHP|The HeartMate PHP device will be inserted percutaneously prior to the start of high risk coronary interventions (complex disease, reduced ejection fraction, etc.) to provide hemodynamic support,
1610746|NCT02156596|Drug|IV NSAI|100 mg of ketoprofen in 50 ml volume given in 30 minutes by IV root
1610747|NCT02156596|Drug|NM|3 nebulisations of 5 mg morphine chlorhydrate each given over 30 minutes (10 minutes per nebulisation)
1610748|NCT02156596|Drug|IV Serum Saline|50 ml of SS is given by IV root over 30 minutes
1610749|NCT02156596|Drug|Nebulised Serum Saline|3 nebulisations of 5ml SS each are given over 30 minutes
1610750|NCT02156570|Drug|Sofosbuvir and ribavirin|Sofosbuvir 400mg daily plus weight-based dosing ribavirin (1000mg <75kg, 1200mg >/= 75 kg) Treatment will be for 6 weeks in all participants.
1610751|NCT02156557|Biological|Colon KCC Heptapeptide|"Your colonoscopy will happen as it would normally, including the medications, the colonoscope, and any clinically indicated biopsies or polypectomies.
The fluorescent peptide will be sprayed on to the walls of your colon around the areas that might have a polyp, areas of IBD, or another area of interest. Your doctor will select one area to apply the peptide in your colon. The peptide comes in a single-use sealed vial from the investigational pharmacy. Sterile saline (salt-water) is added to the vial. The powder is mixed well and pulled into a syringe. The peptide is then injected into a special, single-use sprayer, like a garden hose, that fits down the endoscope channel. The peptide will be sprayed in your colon. This is part of the study.
The endoscopist will take pictures of the area before and after the peptide spraying. They will use the camera that is part of the colonoscope.
We will obtain copies of your endoscopy report and any pathology reports."
1610752|NCT02156544|Drug|CKD-519|
1610753|NCT02156544|Drug|placebo|
1610754|NCT02156531|Behavioral|Self-Administered, Active Cognitive Bias Modification (CBM)|Cognitive Bias Modification (CBM) is a novel treatment delivered via a downloadable computer program. CBM retrains individuals' attention away from negative/threatening stimuli and toward more balanced attention toward neutral stimuli.
1610755|NCT02156531|Behavioral|Self-Administered, minimally effective attention-control version of the CBM program|Identical to the active CBM program except that during the presentation of the trails where a disgusted face is present, the probe will appear with equal frequency (50-50) in the position of disgusted or neutral face. This, the balanced (random) presentation of the probe in this condition is not designed to explicitly train attention away from threat and toward neutral stimuli, in contrast to the active version of CBM.
1610756|NCT02156518|Procedure|Vocal Function Exercises|Vocal Function Exercises
1610757|NCT02156518|Procedure|Vocal Hygiene|Vocal Hygiene
1610758|NCT02156505|Procedure|placement of double bare stent|
1610759|NCT02156505|Device|DoubleBare stent|
1610760|NCT02156492|Drug|Evacetrapib|Administered orally.
1610761|NCT02156492|Drug|Simvastatin|Administered orally.
1610762|NCT02156492|Drug|Atorvastatin|Administered orally.
1610763|NCT02156466|Drug|MSB0010841|MSB0010841(Anti- IL-17A/F Nanobody) will be administered at a dose of 30 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
1610764|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 60 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
1610765|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 120 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
1610766|NCT02156466|Drug|MSB0010841|MSB0010841 will be administered at a dose of 240 mg as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
1610767|NCT02156466|Drug|Placebo|Placebo matched to MSB0010841 will be administered as SC injection every other week (Day 1, Day 15 and Day 29) for a total duration of 6 weeks.
1610768|NCT02156453|Procedure|Total knee arthroplasty|All patients will undergo total knee replacement using midvastus approach by single surgeon.
1610769|NCT02156440|Dietary Supplement|SierraSil Joint Formula 14|667 mg SierraSil® hydrothermal mineral complex
1610770|NCT02156440|Dietary Supplement|Placebo|
1610771|NCT02156427|Device|VITICELL|
1610772|NCT02156427|Device|PLACEBO|
1610773|NCT02156414|Procedure|Radical Prostatectomy|Radical Prostatectomy
1610774|NCT02156414|Procedure|Extended Lymphadenectomy|Extended Lymphadenectomy
1610775|NCT02156388|Biological|GW003|freeze-dried powder；single SC injection
1610776|NCT02156375|Drug|Ustekinumab|Participants will receive a single 6 milligram per kilogram (mg/kg) intravenous infusion of 90 milligram per milliliter (mg/mL) liquid in vial (LIV) formulation, diluted in saline, on Day 1.
1610777|NCT02156375|Drug|Ustekinumab|Participants will receive a single 6 mg/kg intravenous infusion of 5 mg/mL LIV formulation, diluted in saline, on Day 1.
1610778|NCT02156362|Other|follow up visit|At least 1 follow up visit per year will be done and an additional visit if needed.
1610779|NCT02156349|Device|Accu-Chek Smart Pix Software|Software with adherence evaluation software used according to Integrated Personalized Diabetes Management (PDM)
1610780|NCT02156349|Device|Accu-Chek Smart Pix readout Device|Smartpix device for data upload out of blood glucose meter devices
1610781|NCT02156336|Drug|Ranolazine|Oral administration, BID; for a maximum of 51 days.
1611198|NCT02152995|Radiation|Iodine I-131|Given PO
1610782|NCT02156336|Drug|Placebo|Oral administration, BID; for a maximum of 51 days.
1610783|NCT02156323|Drug|CMS|Multiple doses of CMS over 2.5 days
1610784|NCT02156323|Drug|RO7033877|Multiple doses of RO7033877 over 2.5 days
1610785|NCT02156323|Drug|RO7033877 + CMS|Multiple doses of RO7033877 and CMS over 2.5 days
1610786|NCT02156284|Behavioral|Empathic behaviour by nurses|"Control group: patients without specific empathic behaviour
Intervention group: patients who received the empathic behaviour was performed by a trained nurse."
1610787|NCT02156271|Drug|ramelteon|
1610788|NCT02156271|Drug|placebo|
1610789|NCT02156258|Device|FFDM Mammography|Standard mammography image collection
1610790|NCT02156258|Device|DBT Mammography|Collection of breast images using DBT mammography
1610791|NCT02156245|Other|conventional rehabilitation program (including concentric cycle ergometer)|
1610792|NCT02156245|Other|cycling included into a conventional rehabilitation program|
1610793|NCT02156232|Procedure|TIPS|TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. TIPS revision was planned if any evidence of shunt dysfunction was seen.
1610794|NCT02156232|Procedure|embolization|Embolization of SPSS was conducted via the same jugular vein before TIPS implantation. The major procedures included (a)angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b)embolization of SPSS with coils of varying diameters, which resulted in the SPSS disappearing at postembolization angiography.
1610795|NCT02156219|Other|Separation of women and men in the metro of Mexico City|"The measure of separation between men and women exists in all modes of public transport in Mexico City (metro, metro-bus, trolley, bus and light rail), although it is not 100% implemented on all lines and in all hours. These differences in implementation schedule can be a way to identify a treatment group and a control group, and the fact that it has not been implanted in all lines/paths will allow to have a baseline.
The implementation of the measure of separation of men and women on the subway consists of three operational tasks:
Control: Surveillance that men do not use cars corresponding to women.
Dosage: Regulation of entry women.
Assignment: Of the women, to the part of the platform where the first wagons stop."
1610796|NCT02156206|Behavioral|123 women emergency phone line in Medellin, Colombia|"123 is the emergency number in Colombia. The 123- woman line consists of supplementary emergency services to meet the demands of urgency in relation to cases of VAW. This service is implemented by the mayor of Medellin, in collaboration with the national police who is the institution in charge of managing the 123 line.
When the police attends an emergency on VCM, the call is derived to the 123- woman line. There, a team consisting of a psychologist and a lawyer serves women in crisis, as emergency services provided by the police are developed in parallel. The team verifies that the rights of women are respected and that women are oriented to the relevant services. The 123- woman line operates from 7:00 am to 7:00 pm, Monday through Friday."
1610797|NCT02156193|Procedure|Prophylactic clip|Prophylactic clipping
1610798|NCT02156193|Procedure|No prophylactic management|No prophylaxis
1610799|NCT02156167|Device|CP810 and Codacs™ system test|Nucleus® CP810 Sound Processor for the Codacs™ system (CE marked) and Codacs™ Test System (CE marked)
1610800|NCT02156154|Drug|Intravenous Acetaminophen|
1610801|NCT02156141|Other|Supervised high intensity training|8 weeks of supervised training
1610802|NCT02156141|Other|Optional training|8 weeks of optional training on cycle ergometer. No program needs to be followed. Participant decides whether they want to keep training or not.
1610803|NCT02156141|Other|Control period|8 weeks with no training.
1610804|NCT02156141|Other|Unsupervised High intensity training|8 weeks of unsupervised high intensity training.
1610805|NCT02156128|Behavioral|Cogmed working memory training|
1610806|NCT02156128|Behavioral|Control group|
2010247|NCT03046069|Other|Telephone interviews|Qualitative concept elicitation telephone interviews will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
1610808|NCT02156076|Drug|BMS-919373|
1610809|NCT02156076|Drug|Placebo (Matching with BMS-919373)|
1610810|NCT02156063|Drug|NT100|
1610811|NCT02156063|Drug|Placebo|
1610812|NCT02156050|Device|two sessions of 4 hours Phototherapy treatment|two sessions of 4 hours Phototherapy treatment
2010248|NCT03046069|Other|In-person focus groups|Qualitative concept elicitation in-person focus groups will be conducted in subjects with COPD to explore treatment effectiveness, symptoms, quality of life, and features of treatment that are considered to be most important to them when making treatment choices.
1610815|NCT02156024|Drug|Gastrodia and Uncaria Drink|Gastrodia and Uncaria Drink, 1 dose at a time, twice a day, duration: 4 weeks
1610816|NCT02155985|Drug|Aspirin|Aspirin is a nonsteroidal antiinflammatory drug (NSAID) effective in treating fever, pain, and inflammation in the body.
1610817|NCT02155985|Drug|Placebo|Placebo for aspirin
1610818|NCT02155972|Dietary Supplement|Bifidobacterium infantis|Probiotic supplement
1610819|NCT02155972|Other|Placebo|Placebo capsules
1610820|NCT02155959|Device|toric intraocular lens|toric intraocular lens
1610821|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
1610822|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
1610823|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Active brain stimulation
1610824|NCT02155946|Device|Transcranial direct current stimulation (tDCS) Soterix Medical Inc. tDCS unit|Sham (placebo)
1610825|NCT02155933|Other|Blood sampling|Blood sampling for later hormone measurements
1610826|NCT02155920|Drug|Everolimus|The recommended dose of Everolimus is 4.5 mg/m2/dose, once daily for up to 2 years, until disease progression or unacceptable toxicity occurs.
1610860|NCT02155673|Drug|GCS-100|1.5 mg/m2 or 30 mg/m2 GCS-100. GCS-100 will be administered as IV infusions once weekly for 8 weeks with a 1 week and 4 week follow-up period and then at least every 30 days for up to a total of 1 year.
1611199|NCT02152995|Other|Laboratory Biomarker Analysis|Correlative studies
1610827|NCT02155894|Behavioral|Disease control, Telemedicine, doctor|"Control of disease activity by a telemedicine consultation carried out by a doctor.
The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.
Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.
During telephone consultation, updated clinical test results will be available through the electronic medical system."
1610828|NCT02155894|Behavioral|Disease control, Telemedicine, nurse|"Control of disease activity by a telemedicine consultation carried out by a nurse.
The telemedicine consultation will be based on a telephone consultation, following a predefined consultation checklist.
Patients who have expressed a desire to complete questionnaires in webform, will receive a letter a week before the consultation to remind them that they must assess their disease activity through the software interphase, within the next couple of days. Patients, who have expressed a wish to fill in questionnaires in paperform, will receive the questionnaire a week before the consultation.
During telephone consultation, updated clinical test results will be available through the electronic medical system."
1610829|NCT02155881|Drug|Ciclesonide|Ciclesonide nasal spray 50 mcg/actuation
1610830|NCT02155881|Drug|Ciclesonide Placebo|Ciclesonide placebo-matching nasal spray
1610831|NCT02155868|Other|Correction rSO2 desaturation.|"Predefined protocol of interventions for correcting rSO2 desaturation (< 60%) during cardiac surgery and the first six hours after it.
In case of rSO2 decrease less than 60% correct:
head position; position of aortic,venous cannulae and central venous catheters; partial pressure of carbon dioxide in arterial blood < 35 mmHg; mean arterial pressure < 60 mmHg; central venous pressure > 10 mmHg; cardiac index < 2.0 l/min/m2; mixed venous oxygen saturation < 60%; hemoglobin < 65 g/L during cardiopulmonary bypass or hemoglobin < 90 g/L after cardiopulmonary bypass; decrease cerebral O2 consumption."
1610832|NCT02155868|Other|Standard treatment|Standard treatment
2010249|NCT03046069|Other|DCE surveys- cognitive interviews|Draft version of the DCE surveys will be tested with subjects in cognitive interviews to explore the saliency of the attribute choices and assess whether the attributes are understandable, meaningful and comprehensive.
2010250|NCT03046069|Other|Modified DCE|The modified DCEs will be piloted with subjects with COPD in each country to refine the underlying design and ensure that information is collected in an efficient way to enable the statistical analysis to be as precise as possible.
1610835|NCT02155842|Behavioral|High intensity endurance exercise|
1610836|NCT02155842|Behavioral|Moderate continuous endurance exercise|
1610837|NCT02155829|Drug|Riluzole|
1610838|NCT02155829|Drug|Placebo (for Riluzole)|
1610839|NCT02155816|Dietary Supplement|Omega 7 + 3|Ingestion of omega 7 + 3 daily for 8 weeks.
1610840|NCT02155816|Dietary Supplement|Omega 3|Omega 3 daily for 8 weeks.
1610841|NCT02155816|Dietary Supplement|Placebo|Medium chain triglycerides
1610842|NCT02155803|Drug|ACTHAR Gel (adrenocorticotropic hormone)|ACTHAR GEL (adrenocorticotropic hormone) 80 units subcutaneously twice weekly for 12 weeks
1610843|NCT02155790|Device|The Peregrine System Infusion Catheter|The ASI catheter is inserted bilaterally into the renal arteries and a specified amount of a neurolytic agent is inserted into the vessel walls.
1610844|NCT02155777|Drug|OrthoNovum 1/35|
1610845|NCT02155764|Device|Octacalcium phosphate|Bone augmentation, after tooth extraction, with Octacalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
1610846|NCT02155764|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide
1610847|NCT02155764|Device|Tricalcium phosphate|Bone augmentation, after tooth extraction, with Tricalcium Phosphate (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
1610848|NCT02155751|Behavioral|Nutrition Lifestyle Intervention Program (NLIP)|The dietary program will mimic the gestational diabetic meal plan: a) individualize total energy intake with a minimum of 2000 kcal/day (8360 kJ/day), taking into account the usual energy intake as indicated by each dietary assessment (including 3-day food intake records) with a restriction of not more than 33% total energy intake; b) adjust if necessary the total carbohydrate intake to 40-50% of total energy intake, distributing carbohydrate intake throughout the day with three balanced meals, and three snacks per day emphasizing complex carbohydrates and low glycemic index foods; c) adjust the total fat intake to 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), with the remaining 30% dedicated to protein intake; and d) meet all micronutrient and fluid needs recommended during pregnancy.
1610849|NCT02155751|Behavioral|Exercise Lifestyle Intervention Program (ELIP)|The exercise program includes a walking program in which pregnant women walk for 25 minutes, 3 to 4 times per week, adding 2 minutes each week, until 40 minutes is reached and then maintained until delivery. Each woman will be given a pedometer and log sheet to keep track of daily steps and to initiate self-monitoring behaviour.
1610850|NCT02155738|Drug|IV Acetaminophen|
1610851|NCT02155738|Drug|IV normal saline|
1610852|NCT02155725|Drug|Human Fibrinogen concentrate|Injection as soon as possible and within 30 min following the start of prostaglandin infusion
1610853|NCT02155725|Drug|Placebo|As soon as possible and within 30 min following the start of prostaglandin infusion
1610854|NCT02155712|Device|Triathlon Tritanium Knee|Cementless
1610855|NCT02155712|Device|Triathlon Knee|Cemented
1610856|NCT02155699|Behavioral|Exercise 1|65% of VO2max and 2 sessions per week
1610857|NCT02155699|Behavioral|Exercise 2|85% intensity and 3 sessions per peek
1610858|NCT02155686|Device|Biosensors|Device: Biometric sensors; Home automation; telecare
1610859|NCT02155686|Device|Home automation|
1610861|NCT02155660|Drug|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
2010251|NCT03046069|Other|Online DCE survey|An online DCE survey questionnaire will be given to the subjects to identify subject preferences, priorities and treatment goals.
2010252|NCT03045133|Drug|Methadone|Immediately after the induction of anesthesia, patients will receive intravenously methadone 0.1 mg/kg
1610862|NCT02155660|Drug|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
1610863|NCT02155660|Drug|Benralizumab Arm C|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
1610864|NCT02155660|Drug|Placebo|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
2010253|NCT03045133|Drug|Morphine|Immediately after the induction of anesthesia, patients will receive intravenously morphine 0.1 mg/kg
1610866|NCT02155634|Drug|Lenalidomide|Treatment with lenalidomide capsules 10 mg, 5mg daily or 5mg every other day given on days 1-21 of each 28 day cycle.
1610867|NCT02155621|Genetic|Genome sequencing|Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis
1610868|NCT02155608|Device|Active TNS|Participants will receive active trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks.
1610869|NCT02155608|Device|Sham TNS|Participants will receive sham trigeminal nerve stimulation (TNS) administered by the Monarch eTNS System nightly during sleep for 4 weeks.
1610870|NCT02155595|Other|500 without BP treatment|lab tests, X-ray, bone scan or MRI, as needed
1610871|NCT02155595|Other|500 with BP treatment|lab tests, X-ray, bone scan or MRI, as needed (90 of these individuals can opt for iliac crest bone biopsy)
1610872|NCT02155582|Drug|Copanlisib (BAY80-6946)|0.8 mg/kg body weight and 0.4 mg/kg (not to exceed 65 mg) for the non-diabetic patients;45 mg and 60 mg for the diabetic patients; Intravenous (IV) infusion over 1 hour. Dosing of copanlisib will be on Days 1, 8, and 15 of each 28 day treatment cycle.
1610873|NCT02155569|Procedure|Extraperitoneal Cesarean|Pfannenstiel incision, paravesical approach to lower uterine segment extraperitoneally and Kerr incision for uterine entry
1610874|NCT02155569|Procedure|Transperitoneal Cesarean|Pfannenstiel-Kerr technique for laparatomy and uterine entry
1610875|NCT02155543|Drug|AGN-223575 Formulation A|One drop of AGN-223575 Formulation A administered in the study eye(s) per protocol.
1610876|NCT02155543|Drug|AGN-223575 Formulation B|One drop of AGN-223575 Formulation B in both eyes on day 1, followed by one drop of AGN-223575 Formulation B twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation B in both eyes on day 15.
1610877|NCT02155543|Drug|AGN-223575 Formulation C|One drop of AGN-223575 Formulation C in both eyes on day 1, followed by one drop of AGN-223575 Formulation C twice daily in both eyes for 13 days, and a single drop of AGN-223575 Formulation C in both eyes on day 15.
1610878|NCT02155543|Drug|AGN-223575 Vehicle|One drop of AGN-223575 vehicle administered in the study eye(s) per protocol.
1610879|NCT02155530|Drug|Atorvastatin 40mg|homogenous neointimal pattern at baseline OCT and randomized to atorvastatin 40 mg group
1610880|NCT02155530|Drug|pravastatin 20 mg|Intervention description : homogenous neointimal pattern at baseline OCT and randomized to pravastatin 20 mg group
1610881|NCT02155517|Drug|Evaluation of propofol effect|"The study will make in two stages:
STAGE I: All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI device, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes."
1610882|NCT02155517|Drug|Evaluation of propofol effect|STAGE II: 72 hours after stage I . All volunteers will receive propofol infusion with the first model randomly chosen (Schnider or Cortinez) using TCI devices, and the initial effect-site target concentration of propofol will be 3 ug/ml for 20 minutes.
1610883|NCT02155504|Drug|ASP3700|oral
1610884|NCT02155504|Drug|itraconazole|oral
1610885|NCT02155504|Drug|Placebo|oral
1610886|NCT02155478|Device|ISERT 250 (HOYA, Japan): a standard IOL|
1610887|NCT02155478|Device|AMO ZCB00 IOL (Abbott Medical Optics, United States): a standard IOL|
1610890|NCT02155452|Procedure|ALA Test group|"Prior to surgery all patients would receive freshly prepared solution of 5-ALA, 20 mg/kg bodyweight dissolved in 100 ml of potable water orally approximately 4 hours (range 4-6 hrs) before the commencement of anesthesia induction for surgery.
The surgery would then be performed with the help of navigation. After craniotomy, the navigation software would be used to identify the selected target areas based on the preoperative images (MR as well as PET when available) and directed image-guided biopsies from these representative areas will be collected for histological evaluation"
1610891|NCT02155439|Drug|5-fluorouracil|antimitotic drug
1610892|NCT02155439|Drug|Triamcinolone|
1610893|NCT02155400|Device|Bair Hugger|Forced Air Warming Blanket placed over the body of the patient during surgery
1610894|NCT02155400|Device|Prototype / Experimental device|Contact heating device provides heat to the sole of the foot and popliteal fossa while providing intermittent compression to the lower leg.
1610895|NCT02155374|Drug|Sliding scale insulin|
1610896|NCT02155374|Drug|Intermediate acting insulin|
1610897|NCT02155374|Behavioral|Dietary advice|Dietary advice to avoid food products with high glycemic index / high glucose load
1610898|NCT02155374|Drug|Glucose lowering medication|Regular glucose lowering medication as prescribed by the patient's own physician before study entry
1610899|NCT02155374|Drug|Chemotherapy|Chemotherapy (containing glucocorticoids) as prescribed by the patient's own physician
1610900|NCT02155361|Drug|Topical Citrullus colocynthis fruit oil (1%)|
1610901|NCT02155361|Drug|Topical vehicle oil|
1610902|NCT02155348|Procedure|Bilateral cataract surgery with implantation of multifocal IOLs|Lentis LS-313, multifocal, target refraction of the distance-dominant eye: 0.00D, target refraction of the other eye: -0.50D
1610903|NCT02155348|Procedure|Bilateral cataract surgery with monovision|Lentis L-313, monofocal, target refraction of the distance-dominant eye: 0.00D to -0.25D, target refraction of the other eye: -1.50D
1610904|NCT02155348|Device|Lentis LS-313|
1610905|NCT02155335|Drug|Prefilled Syringe delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using prefilled syringe
1610906|NCT02155335|Drug|Smartject Device delivery of Golimumab|Golimumab 50 mg solution for subcutaneous injection using Smartject Device.
1611200|NCT02152995|Other|Pharmacological Study|Correlative studies
1610907|NCT02155322|Biological|Pegylated Interferon Alfa-2b|6 μg/kg, weekly dosing, subcutaneous administration, Induction Phase - first 8 weeks
1610908|NCT02155322|Biological|Pegylated Interferon Alfa-2b|3 μg/kg SC once weekly for a 42-week maintenance phase (for a total treatment of up to approximately 1 year)
1610909|NCT02155309|Drug|Scopolamine|
1610910|NCT02155309|Drug|Placebo|
1610911|NCT02155296|Behavioral|Restorative Practices Intervention|"RPI has the 3 core components of an optimal comprehensive positive youth development intervention:
(1) sustained relationships with adults—RPI creates positive and sustained adult-youth relationships through teacher-student dialogue that occurs in circles; (2) skills building—RPI uses teachers and other school staff to coach students on 7 of the 11 essential practices; and (3) application of skills building—As students develop proficiency in the 7 essential practices they are coached to perform, school staff transfer responsibility for running the circles over to students. Restorative conferences for serious and or chronic behavior problems are the only circles that teachers continue to facilitate. Quasi-experimental studies have shown that schools implementing RPI have reductions in disciplinary referrals and school suspension."
1610912|NCT02155283|Device|Continuous Passive Motion|Daily self-treatments at home for 3 weeks, with up to three 10-minute treatment sessions per day
1610913|NCT02155270|Procedure|Corneal precut 600µm|
1610914|NCT02155270|Procedure|Corneal stabincision|
1610915|NCT02155257|Drug|Modafinil|
1610916|NCT02155257|Drug|Gabapentin|
1610917|NCT02155257|Drug|Placebo|
2010254|NCT03042572|Drug|Allogeneic Mesenchymal Stromal Cell|Intramuscular allogeneic BM-MSC injection: MSCs will be extracted from BM of healthy volunteers, expanded with human platelet lysate, and stored. Patients will receive intramuscular allogeneic BM-MSC injections at 30 sites in the lower leg of the ischemic limb. Blinded syringes are provided and cell suspensions will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL containing 5*10^6 MSC per site; total 150*10^6 BM-MSCs) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
1610921|NCT02155205|Drug|Telotristat etiprate|1500 mg telotristat etiprate (six 250 mg tablets)
1610922|NCT02155205|Drug|Placebo|Matching placebo
1610923|NCT02155205|Drug|Moxifloxacin|400 mg moxifloxacin (one 400 mg tablet)
1610924|NCT02155192|Drug|No Intervention|
1610925|NCT02155166|Drug|Intracervical anesthesia with lidocaine 2%|5 min before LNG-IUS placemen
1610926|NCT02155166|Drug|ibuprofen 400 mg|1 hour prior to the LNG-IUS insertion
1610927|NCT02155153|Other|Sugar Free Chewing Gum|'Extra' sugar free gum will be used as an intervention. Patients will be required to chew a gum for 30 min at intervals of 6 hours for first 48 hours post operatively or until they pass flatus.
1610928|NCT02155140|Dietary Supplement|Jejunal feeding|A feeding jejunostomy tube is inserted at the time of surgery to provide enteral nutritional support.
1610929|NCT02155127|Behavioral|walking|
1610930|NCT02155101|Drug|Darunavir|Darunavir (PREZISTA) is a film coated, oval shaped, light orange 19.1mm tablet, debossed with 400 mg on one side and TMC on the other side.
1610931|NCT02155101|Drug|ART with 2 NRTIs plus LPV/r (or ATV/r)|Patients on second line antiretroviral therapy take 2 NRTIs and either protease inhibitor lopinavir/ritonavir or atazanavir/ritonavir.
1610935|NCT02155062|Other|Whole grain rye|
1610936|NCT02155062|Other|Whole grain wheat|
1610937|NCT02155062|Other|Refined cereal|
1610938|NCT02155049|Drug|bimatoprost 0.03%|The patients will receive a single daily drop of bimatoprost for six months.
1610939|NCT02155036|Other|Exercise|The intervention will include 2 sessions of gym-based exercise per week, both of which will be supervised for 3 months, supervision will then decrease to once-weekly until 6 months, and then be through phone support for the remaining 6 months. Warm up and cool down of minimum of five minutes on stationary exercise cycle, rate of perceived exertion (RPE) ~11, followed by gentle stretching. Progressive resistance training (PRT) will use eight PRT machines training large muscle groups (e.g. bench press, latissimus pulldown, bicep curl, triceps pull down, leg press, knee extension, hamstring curl, calf raises). Intensity will be 80% of one repetition maximum (1RM), building up to 3 sets of 8 repetitions. 1RM will be re-assessed monthly, and program adjusted accordingly.
1610940|NCT02155023|Drug|Insulin dosing|
1610941|NCT02155023|Device|Glucose sensors IR-Glucose Reader (Joanneum Research, Austria), IR-CGM (IMM, Germany)|
1610942|NCT02155010|Drug|Dexmedetomidine|Dexmedetomidine infusion before intrathecal injection of heavy bupivacaine
1610943|NCT02155010|Drug|Dexmedetomidine with heavy bupivacaine|Dexmedetomidine infusion after IT of heavy bupivacaine
1610944|NCT02154984|Behavioral|behavioral dietary intervention|Follow tRD
1610945|NCT02154984|Behavioral|telephone-based intervention|Receive coaching calls
1610946|NCT02154984|Other|laboratory biomarker analysis|Correlative studies
1610947|NCT02154932|Drug|2 doses 400 microgram misoprostol|2 doses 400 microgram misoprostol, 3 and 1 hours
1610948|NCT02154932|Drug|single dose misoprostol|1 dose, 1 hours, prior surgery
1610949|NCT02154919|Procedure|Percutaneous coronary intervention|
1610950|NCT02154906|Device|DFDBA|
1610951|NCT02154906|Device|autologous platelet rich fibrin|
1610952|NCT02154893|Device|Ultrasound plus Laser and therapeutic exercise|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The resistance training was performed.The treatments are done once a week, for 3 months.
1610953|NCT02154893|Device|Ultrasound plus Laser|Ultrasound with frequency 1 Mhz and infrared laser with output power at 100 mW. The treatments are done once a week, for 3 months.
1610954|NCT02154893|Device|Utrasound plus Laser Placebo|The device with Ultrasound and infrared laser without emitting electromagnetic or mechanical waves was applied (null dose).
1610955|NCT02154880|Procedure|PFT|Lung function endpoints of FVC, FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder on a NDD EasyOne Pro system before and after bronchodilator administration.
1610956|NCT02154880|Procedure|lab work|The blood will be processed for serum, plasma, and PBMCS, and a portion stored to be used for future use. A hemoglobin and Carboxyhemoglobin will be done in order to calculate the DLCO.
1610957|NCT02154880|Procedure|6MWT|The six-minute walk tests are performed in a 100-foot segment of straight hallway marked at 1-foot intervals.
1610958|NCT02154880|Other|questionnaires|TEAL, MMRC and ST. George's Questionnaire will be administered. They are paper questionnaires that inquire about respiratory symptoms, quality of life, smoking history and other health issues
1610959|NCT02154867|Biological|Fecal transplantation|Preparation of flesh feces by blending in 0.9 % saline and crude filtering. The solution is applied in proximal colon of IBS patient by colonoscopy after standard bowel preparation.
1610960|NCT02154867|Other|Placebo fecal transplant|Fecal transplantation with own feces
1610961|NCT02154854|Drug|Tacrolimus targeted half-dose|
1610962|NCT02154854|Drug|Tacrolimus targeted plain dose|
1610963|NCT02154841|Behavioral|Questionnaire, taste test, visual food test|
1610964|NCT02154828|Behavioral|Integrative practices|
1610965|NCT02154815|Other|Questionnaires : Patient-Reported Outcomes|Patient-Reported Outcomes completion every six months prior to surgery, at hospital discharge, and at 3, 6,12, and 24 months
1610966|NCT02154802|Behavioral|video: community member|
1610967|NCT02154802|Behavioral|video: physician|
1610968|NCT02154802|Behavioral|video: choice of video|
1610969|NCT02154789|Drug|polidocanol|
1610970|NCT02154789|Procedure|infra-red coagulation|
1610971|NCT02154789|Procedure|cryotherapy|
1610972|NCT02154776|Drug|LEE011|3 weeks on and 1 week off
1610973|NCT02154776|Drug|Buparlisib|daily
1610974|NCT02154776|Drug|Letrozole|2.5 mg daily;
1610976|NCT02154750|Device|Long, fixed AV delay|Pacemaker will be set to a long, fixed AV delay to minimize ventricular pacing
1610977|NCT02154750|Device|Short, optimized AV delay|Pacemaker will be set to the AV delay that produces the greatest cardiac output in echocardiography for each patient enrolled.
1610978|NCT02154737|Drug|Gemcitabine|Gemcitabine will be administered intravenously at 1000 mg/m2 on Days 1, 8, and 15 of a 28-day cycle.
1610979|NCT02154737|Drug|Erlotinib|Erlotinib will be administered orally on Days 2-4 and Days 16-18 of a 28-day cycle in serial cohorts with doses of 750mg, 1000mg, 1250mg, 1500mg, 1750mg, and 2000mg.
1610980|NCT02154724|Device|aDBS|The aDBS is applied for 2 hours for two days with two different modalities (aDBS and DBS) in random order.
1610981|NCT02154724|Device|DBS|The aDBS s applied for two hous in DBS modality.
1610982|NCT02154698|Other|22-gauge Standard Needle|Acquisition of lymph nodes samples using the 22-gauge Standard Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
1610983|NCT02154698|Other|22-gauge ProCore Needle|Acquisition of lymph nodes samples using the 22-gauge ProCore Needle, following subject-sedation and the introduction of an EBUS scope into the airway.
1610984|NCT02154685|Behavioral|Retrieval-Extinction|A relatively brief exposure to cues prior to conducting more protracted cue exposure. This is referred to as retrieval-extinction training.
1610985|NCT02154685|Behavioral|Non-Retrieval Extinction|Neutral cue exposure.
1610986|NCT02154659|Device|24hr pH monitoring|
1610987|NCT02154646|Drug|LY2157299|Administered orally
1610988|NCT02154646|Drug|Gemcitabine|Administered IV
1610989|NCT02154633|Behavioral|Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
1610990|NCT02154633|Behavioral|Delayed Family Gene Toolkit|Psychosocial educational presentations over the Internet (Webinars) Two Webinars lasting 1 hour each One follow-up phone call lasting 20 minutes Webinars and phone calls are delivered to one mutation carrier and one non-tested relative Genetic counselors and nurses with master's degree and experienced in oncology deliver the content of the intervention
1610991|NCT02154620|Procedure|Volar plate|An anatomically countoured volar plate is implanted through a Henry's incision.
1610992|NCT02154620|Device|Synthes TCP volar plate|
1610993|NCT02154607|Device|CO2-Laser Treatment|
1610994|NCT02154594|Drug|Acacia catechu|
1610995|NCT02154594|Drug|Chlorhexidine gluconate|
1610996|NCT02154594|Other|Distilled water|
1610997|NCT02154581|Device|SLActive implant|
1610999|NCT02154555|Procedure|debridement|post-operative debridement at 1 week follow-up visit
1611000|NCT02154542|Device|Neurovent Monitor XIII|
1611001|NCT02154529|Drug|Tesevatinib in combination with Trastuzumab|
1611002|NCT02154516|Device|ODH Hip System|
1611003|NCT02154503|Device|topical 5% Minoxidil (Microneedling)|
1611004|NCT02154490|Drug|Docetaxel|Given IV
1611005|NCT02154490|Biological|Durvalumab|Given IV
1611006|NCT02154490|Drug|Erlotinib Hydrochloride|Given PO
1611007|NCT02154490|Drug|FGFR Inhibitor AZD4547|Given PO
1611008|NCT02154490|Biological|Ipilimumab|Given IV
1611009|NCT02154490|Other|Laboratory Biomarker Analysis|Correlative studies
1611010|NCT02154490|Biological|Nivolumab|Given IV
1611011|NCT02154490|Drug|Palbociclib|Given PO
1611012|NCT02154490|Biological|Rilotumumab|Given IV
1611013|NCT02154490|Drug|Taselisib|Given PO
1611016|NCT02154464|Drug|Paracetamol|
1611017|NCT02154464|Drug|Placebo|
1611018|NCT02154451|Device|Infrared Imaging Device- ALIAS|Infrared Camera
1611019|NCT02154438|Drug|Ketamine|ketamine 0.5mg/kg loading followed by 0.5mg/kg/h infusion during operation
1611059|NCT02154100|Dietary Supplement|Placebo|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
1611020|NCT02154425|Procedure|Breast milk sampling|Pharmacokinetic (PK) samples will be taken from breast milk of lactating mothers on an established dosing regimen of CZP on Day 0 of the Sampling Period, just prior to next scheduled dose of CZP, and on Days 2, 4, 6, 8, 10, 12, and 14 (pre-dose for mothers on CZP Q2W), relative to CZP administration on Day 0. In addition, in mothers on a CZP Q4W dosing regimen, the concentration of CZP in breast milk will also be evaluated on or about Day 28 (i.e., prior to and on the same day of the next scheduled administration of CZP).
1611021|NCT02154425|Biological|Certolizumab Pegol|Mothers who decided to continue on, or to start treatment with, Certolizumab Pegol (CZP) for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
1611022|NCT02154412|Other|Respiratory Muscle Training|Assembled together using a T-shaped connector, a threshold Positive Expiratory Pressure Device (Respironics, Inc.) & an Inspiratory Muscle Trainer (IMT, Respironics Inc.) with mouthpiece will be used. During inhalation, the subjects will initiate each breath from residual volume (RV) and to sustain the effort until their lungs feel full. During exhalation, the subjects will breathe from total lung capacity and sustain their effort until their lungs feel empty. Participants will be asked to train 45 minutes per day, 5 days per week, for 4 weeks. The training will be initiated with a load equal to 20% of their individual PImax and PEmax with progressive increases as tolerated up to 40% of their baseline PImax or PEmax.
1611023|NCT02154399|Drug|EF5|Given IV
1611024|NCT02154399|Other|Laboratory Biomarker Analysis|Correlative studies
1611025|NCT02154399|Procedure|Therapeutic Conventional Surgery|Undergo surgery/thoracotomy
1611026|NCT02154399|Other|Tissue Oxygen Measurement|Undergo tumor hypoxia measurement
1611027|NCT02154386|Device|Ridge preservation using DFDBA|tooth extraction followed by ridge preservation grafting using DFDBA
1611028|NCT02154360|Drug|Aprepitant|Subjects will add 375 mg daily dosing of aprepitant (Emend®) to their current antiretroviral therapy for 28 days
1611029|NCT02154347|Drug|KAD-1229|
1611030|NCT02154347|Drug|Placebo|
1611031|NCT02154347|Drug|Insulin|
1611032|NCT02154334|Drug|Esketamine|Participants will self-administer one Intranasal spray of 14 mg esketamine solution in each nostril on Day 1 at time 0 and 5 minutes (total esketamine dose will be 56 mg) in Period 1 and Period 2.
1611033|NCT02154334|Drug|Mometasone|Healthy participants will self-administer 2 intranasal sprays of 50 mcg mometasone suspension in each nostril for a total dose of 200 mcg on days 1 to 15 and 2 intranasal sprays of 50 mcg mometasone suspension in each nostril prior to 1 intranasal spray of esketamine solution 14 mg in each nostril at Time 0 and 5 minutes for a total dose of 56 mg on Day 16 in Period 2.
1611034|NCT02154334|Drug|Oxymetazoline|Nasal rhinitis participants will self-administer 2 intranasal sprays of Oxymetazoline 0.05% w/v solution in each nostril at time -1 hour before administration of 1 Intranasal spray of 14 mg esketamine solution in each nostril at time 0 and 5 minutes, for a total dose of 56 mg in Period 1or Period 2.
1611035|NCT02154321|Device|Electroencephalogram (EEG)|The electroencephalogram assesses brain electrical activity through surface recording disks (electrodes) which are placed near the participants' head using a custom designed Lycra cap. The electrodes transmit the signals which are then amplified and stored on a computer. The procedure is entirely non-invasive. Once an accurate signal is assured, the signal derived from the electrode cap is then amplified, transmitted to a computer, and stored for later analysis. Each participant will undergo the electroencephalogram (EEG) procedure only once for the duration of 30-45 minutes.
1611036|NCT02154308|Biological|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL|IL-YANG FLU Vaccine Prefilled Syringe INJ 0.5mL by intramuscular injection
1611037|NCT02154295|Device|Infraredx Test Catheter|
1611038|NCT02154282|Behavioral|ipod games|Patients will be given ipod games for 4 weeks and tested in related and unrelated cognitive measures
1611039|NCT02154269|Drug|Treatment with G-CSF (Granulocyte colony stimulating factor)|Subjects will be randomly assigned to receive treatment with G-CSF (10mg/kg/day) for five days, during 4 cicles.
1611040|NCT02154269|Drug|Placebo saline|Subjects will be randomly assigned to receive treatment saline for five days, during 4 cicles.
1611041|NCT02154256|Behavioral|Increasing incentives|Offer incentives that increase over time.
1611042|NCT02154256|Behavioral|Decreasing incentives|offer incentives that decrease over time
1611043|NCT02154256|Behavioral|stable incentives|offer incentives that are stable over time, but higher than usual care
1611044|NCT02154243|Drug|Midodrine|10 mg, p.o., once, on day of surgery after first physical therapy session
1611045|NCT02154243|Other|Intravenous fluid bolus|15 cc/kg, once, on day of surgery after first physical therapy session
1611046|NCT02154230|Dietary Supplement|"Acqua Santa di Chianciano® (sulphate-bicarbonate-calcium water)"|"During the first 4 weeks the SW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of Acqua Santa di Chianciano® at room temperature."
1611047|NCT02154230|Dietary Supplement|Tap water|During the first 4 weeks the TW-D patients will be asked to drink every morning, before breakfast, within 30 minutes, 500 mL of tap water at room temperature.
1611048|NCT02154217|Drug|Bimatoprost|
1611049|NCT02154217|Drug|Latanoprost/Timolol|
1611050|NCT02154191|Procedure|Surgical Intervention|The clinical intervention in this study is the routine surgical procedures taken for patients requiring surgery for degenerative lumbar spinal stenosis.
1611051|NCT02154178|Other|Biomarker group|use of invasive fungal disease biomarkers (β-1,3-glucan, mannan/anti-mannan antibodies)
1611052|NCT02154165|Other|Phototherapy|The infants were randomized to phototherapy with either blue og turquoise light
1611054|NCT02154139|Drug|Leuprorelin acetate|Leuprorelin acetate SR 11.25 mg for injection
1611055|NCT02154126|Device|Continuous Glucose Monitoring Device (Senseonics)|
1611056|NCT02154113|Device|Ultrashape|All subjects receive 3 successive Ultrashape treatments every two weeks in the anterior abdomen.
1611057|NCT02154113|Device|Velashape II|All subjects receive 3 successive Velashape treatments every two weeks in the anterior abdomen.
1611058|NCT02154100|Dietary Supplement|Tart Cherry|12 weeks of tart cherry juice taken in two doses of 240 ml per day.
1611155|NCT02153359|Device|High Efficiency Particulate Air Cleaner|
1611060|NCT02154087|Biological|HP802-247|260 µL (130 µL, one spray, of each component) containing 0.5 x 10.6 cells per mL, alternating weekly with Vehicle
1611061|NCT02154074|Drug|general anesthesia induction|general anesthesia induction: midazolam 0.1mg/Kg, sufentanil 1ug/Kg, cisatracurium 0.15mg/Kg, and then immediatly administrate etomidate 0.2 mg/Kg
1611062|NCT02154074|Drug|Isoflurane|inhale Isoflurane 1.5MAC
1611063|NCT02154074|Drug|Dexmedetomidine|anesthesia induction period: intravenous pumping Dexmedetomidine 4ug/Kg/h; after 10 minutes,turn to 0.4ug/Kg/h.
1611064|NCT02154074|Drug|normal saline|the same volume of saline + Isoflurane during operation
1611065|NCT02154061|Drug|Arm 1 and Arm 2: Inactivated Flu Vaccine|This is an FDA approved and tested Flu Vaccine.
1611066|NCT02154061|Drug|Metronidazole|This is a standard antibiotic
1611067|NCT02154061|Drug|Neomycin|This is a standard antibiotic.
1611068|NCT02154061|Drug|Vancomycin|This is a standard antibiotic.
1611069|NCT02154048|Drug|Ropivacaine|
1611070|NCT02154048|Drug|Dexamethasone|
1611071|NCT02154048|Other|Placebo|
2010255|NCT03042572|Other|Placebo|Intramuscular placebo injections. Patients will receive intramuscular placebo injections at 30 prespecified sites in the lower leg of the ischemic limb. Blinded syringes are provided and will be injected intramuscularly by an experienced operator into multiple sites (30 sites, 1-1.5cm in depth, volume of 1.0mL placebo per site) in the ischemic lower extremity. Injections will be performed under IV analgesia (fentanyl) and sedation (midazolam) if necessary.
2010256|NCT03040999|Biological|Pembrolizumab|Administered as an intravenous (IV) infusion every 3 weeks (Q3W)
2010257|NCT03040999|Drug|Placebo|Normal saline solution administered as an IV infusion Q3W
2010258|NCT03040999|Drug|Cisplatin|100 mg/m^2 administered as an IV infusion Q3W
2010259|NCT03040999|Radiation|Accelerated Fractionation (AFX) Radiotherapy|70 Gray (Gy) given in 35 fractions over 6 weeks
2010260|NCT03040999|Radiation|Standard Fractionation (SFX) Radiotherapy|70 Gy given in 35 fractions over 7 weeks
2010261|NCT03040726|Drug|Netupitant / Palonosetron|"Netupitant/Palonosetron (NEPA) by mouth on Day 6 and on Day 11 of the double-blind treatment period, and on Day 16 and on Day 21 of the open-label extension phase.
NEPA is a fixed dosed capsule consisting of 300 mg netupitant and 0.5 mg palonosetron."
2010262|NCT03040726|Other|Placebo|Participants take placebo orally on Day 6 and on Day 11 of the double-blind treatment period, and on Day 16 and on Day 21 of the open-label extension phase.
1611083|NCT02153892|Device|GDS Accucinch System|Percutaneous Coronary Intervention
1611084|NCT02153879|Drug|Fenofibrate|fenofibrate 145/day for 12 weeks
1611085|NCT02153879|Drug|Niacin plus laropiprant|Niacin 2 g/day plus Laropiprant for 12 weeks
1611086|NCT02153866|Biological|rotavirus vaccine|3ml/dose, oral
1611087|NCT02153866|Biological|measles-rubella vaccine|0.5ml per dose, subcutaneous injection
1611088|NCT02153866|Biological|measles-mumps-rubella vaccine|0.5ml per dose, subcutaneous injection
1611089|NCT02153840|Drug|PSORI-CM01（YXBCM01） granule|
1611090|NCT02153840|Drug|placebo|
1611091|NCT02153827|Other|Eccentric Shoulder External Rotator Training|Eccentric training exercise for the external rotators, 3 sets of 15 daily.
1611092|NCT02153827|Other|General Shoulder exercise|general exercise consisting of active shoulder movements
1611093|NCT02153814|Procedure|Endometrial Scratch|After cleansing the cervix with Betadine, the procedure will be performed using a 3mm endometrial sampling curette, with three passes made of the endometrium along the length of the fundus. Patients will be given the option to take ibuprofen 600mg one hour prior to the scheduled procedure. The first endometrial scratch procedure or sham procedure will be performed up to two weeks prior to expected menses, and the second endometrial scratch or sham procedure will be performed cycle day 5-11 of the stimulation cycle.
1611094|NCT02153814|Procedure|Sham procedure|For the sham procedure, after cleansing the cervix with betadine, the endometrial sampling curette will be placed 2-3cm into the cervix without entering the uterine cavity
1611095|NCT02153801|Procedure|During the surgical procedure of Laparoscopic Low Anterior Resection with Total mesorectal Excision .|"For High Ligation The opening of the peritoneum proceeds cephalad towards the duodenojejunal angle of Treitz, and the mesenteric root is incised 1 cm below the inferior margin of the pancreas. The aortomesenteric window is opened wide and the inferior mesenteric vessels are exposed. The inferior mesenteric artery (IMA) is ligated and divided at 2 cm from its origin. The inferior mesenteric vein is ligated and divided below the pancreatic margin.
For Low Ligation The opening of peritoneum proceeds upward and then laterally towards the sigmoid colon. Left colic artery is identified and preserved while low ligation of the inferior mesenteric artery (superior hemorrhoidal artery) is performed. Lymphadenectomy is carried on medially along the inferior mesenteric artery until 2 cm from the aorta.
For both groups dissection is then carried on windowing Toldt and Gerota fascias till the parietocolic gutter."
1611096|NCT02153788|Drug|Temazepam|Temazepam 15 mg orally at bedtime
1611097|NCT02153788|Drug|Placebo|
1611098|NCT02153775|Behavioral|Progressive Muscle Relaxation|Comparison of progressive muscle relaxation and no intervention (e.g., reading newspaper of the day) for the same amount of time.
1611099|NCT02153762|Drug|Locoid Lipocream|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
1611100|NCT02153762|Drug|Hylatopic Plus|Patients were randomized to apply Locoid Lipocream followed by Hylatopic Plus lotion on either the right or left side target lesion with the reverse order on the other side.
1611101|NCT02153749|Behavioral|Cognitive Regulation of Craving|"Regulation strategy practice: Participants will be trained to use a CBT-based cognitive regulation strategy. They will be asked to think of their individualized negative consequences for and thing of them when they see the instruction LATER during the task. Participants will practice using this strategy for multiple cigarette stimuli. High-Risk Situation Practice: Participants will identify 10 situations in which they usually smoke, or are likely to smoke in the next 48 hours. For each situation, they will be asked to practice using the strategy and to plan to use this strategy to regulate craving in daily life."
1611156|NCT02153359|Device|Sham air cleaner|
1611201|NCT02152995|Procedure|Positron Emission Tomography|Undergo iodine I-124 PET/CT
1611202|NCT02152995|Drug|Trametinib|Given PO
1611102|NCT02153749|Behavioral|Mindfulness-Based Regulation of Craving|"Each training session in this condition will be identical to the CBT-based training session described, with the exception of the strategy being trained. Specifically, participants will be trained in using the MBT-based strategy (notice craving and accept the feeling without judgment or reaction). To do so, they will be asked to generate their own non- reactive responses to craving (e.g., I can just sit here and notice this. I can ask myself, 'can I be ok with this feeling?') Participants will then be instructed to think of those accepting and non-reactive responses when they see the instruction ACCEPT during the task. All other components will be identical."
1611103|NCT02153736|Behavioral|SPEEDI Intervention|Behavioral intervention provided through a collaboration between the mother of enrolled subjects and a physical therapist. Intervention starts in the Neonatal Intensive Care Unit and continues after discharge. SPEEDI includes both parent education and developmental activities.
2010263|NCT03040726|Behavioral|Symptom Questionnaires|Symptom questionnaires completed at baseline and at Day 15. These questionnaires should take about 20 minutes to complete.
1611105|NCT02153710|Behavioral|Semantic Feature Analysis therapy|Control therapy; current standard of care therapy
1611106|NCT02153697|Device|Q-switched SINON Ruby Laser|Solar lentigines on the right back of the hand side are treated with the Q-switched SINON Ruby Laser at Baseline and if required at day 28.
1611107|NCT02153697|Drug|Pigmanorm Cream|Solar lentigines on the left back of the hand side are treated once a day during 7 weeks with Pigmanorm cream, a bleaching cream containing hydrochinon.
1611108|NCT02153671|Biological|Orniflu inactivated influenza vaccine|
1611109|NCT02153658|Procedure|Subjects cleaned the foreskin with soapy water using a syringe once a day.|
1611110|NCT02153658|Procedure|Subjects cleaned the foreskin with diluted chlorhexidine (1%) using a syringe once a day.|
1611111|NCT02153645|Drug|Amantadine ER Tablets|
1611112|NCT02153645|Drug|Placebo Tablets for Amantadine ER Tablets|
1611113|NCT02153632|Drug|Amantadine HCl ER (ALLAY-LID II)|
1611114|NCT02153632|Drug|Placebo|
2010264|NCT03040726|Behavioral|Patient Diary|Participants keep a patient diary to keep track of nausea, vomiting, and doses 1 time a day on Days 1-15. Participants should complete it at the end of each day before you go to sleep.
2010265|NCT03039452|Behavioral|High intensity interval training|Each training session will consist of a 3-5 minute warm-up, followed by 10 repetitions of 1-minute bouts at individualized training intensity with 1-minute rest periods.
1611118|NCT02153606|Drug|Glycerin Suppository|The treatment intervention will be a 250 mg glycerin suppository placed in the rectum once daily starting 48-72 hours after birth.
1611119|NCT02153606|Other|Sham Suppository|Sham suppositories will be created by placing a 250 mg glycerin suppository in the diaper once daily starting 48-72 hours after birth. This intervention works as a non-invasive placebo to maintain blinding.
1611120|NCT02153593|Drug|Tranexamic Acid|1g intra-articular before closing the wound surgery
1611121|NCT02153593|Drug|Fibrin glue|5mL intra-articular before closing the wound surgery
1611122|NCT02153593|Procedure|Electrocauterization|Coagulation blood from vessels by means of a electrocautery
1611123|NCT02153580|Drug|cyclophosphamide|Given IV
1611124|NCT02153580|Biological|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
1611125|NCT02153580|Other|laboratory biomarker analysis|Correlative studies
1611126|NCT02153580|Drug|Bendamustine Hydrochloride|Given IV
1611127|NCT02153580|Drug|Etoposide|Given IV
1611128|NCT02153580|Drug|Fludarabine Phosphate|Given IV
1611129|NCT02153567|Drug|Escitalopram|Escitalopram 5mg daily will be given for the first 2 weeks and then Escitalopram 10mg daily will be given for the next 8 weeks.
1611130|NCT02153567|Other|Placebo|Placebo will be given for the next 10 weeks.
1611131|NCT02153554|Behavioral|Training civil servants on attention to violence against women|The Secretary of Women of Medellin, through the ICONTEC, intends to conduct training to officials of the 22 family commissioners in Medellin. The objective of these trainings is to standardize procedures in order that women do not feel re-victimized and can forward complaints.
1611132|NCT02153541|Drug|Antipyrine-benzocaine otic solution|Participants receiving antipyrine-benzocaine otic solution are expected to decrease usage of rescue inhalers.
1611133|NCT02153541|Other|Mineral oil|50% of participants will receive the mineral oil. These participants will be randomly selected and unaware that they are receiving the placebo and are expected to have no change in usage of rescue inhalers.
1611134|NCT02153528|Drug|double rimfampicin|Compared to standard regimen dosing of rifampicin is doubled, while standard dose isoniazid, pyrazinamide and ethambutol are maintained
1611135|NCT02153528|Drug|Standard TB treatment|Standard regimen for TB treatment according to guidelines of the International Union against Tuberculosis and Lung Disease
1611136|NCT02153515|Other|Your own ( autologous) finger prick of blood produced with a diabetic lancet|
1611137|NCT02153502|Drug|AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination)|AVP-786 capsules administered twice a day over a 10-week period
1611138|NCT02153502|Drug|Placebo|Placebo capsules administered twice a day over a 10-week period
1611139|NCT02153489|Drug|Aclidinium bromide|
1611140|NCT02153489|Drug|Placebo|
1611141|NCT02153476|Drug|2.0mg of ALG-1001|
1611142|NCT02153476|Drug|Balanced Salt Solution|
1611143|NCT02153463|Behavioral|Physical Activity Counselling|Physical Activity Counselling weekly for 8 weeks
1611144|NCT02153450|Drug|metformin hydrochloride|Given PO
1611145|NCT02153450|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
1611146|NCT02153437|Drug|BMS-919373|
1611147|NCT02153437|Drug|Sotalol|
1611148|NCT02153437|Drug|Placebo for BMS-919373|
1611149|NCT02153424|Drug|Apixaban|
1611150|NCT02153398|Drug|D961H sachet 10 mg|
1611151|NCT02153398|Drug|D961H capsule 10mg|
1611152|NCT02153398|Drug|D961H capsule 20 mg|
1611153|NCT02153385|Other|Yoga|Yoga program was 60 min per session, twice per week for 8 weeks. Led by an experienced yoga instructor.
1611154|NCT02153372|Other|BMC2012|
1611157|NCT02153346|Other|Valuation of lost productivity questionnaire|A new, composite questionnaire that can be used to assess the impact of health conditions on lost productivity in monetary units. It measures absenteeism, presenteeism, and non work activities.
1611158|NCT02153346|Other|Work productivity and activity impairment questionnaire|A six item questionnaire used as a patient-reported quantitative assessment of the amount of absenteeism, presenteeism, and daily activity impairment attributable to a specific health problem.
1611159|NCT02153333|Procedure|Serum sample|Serum samples collected at pre-vaccination and at 1-2 months post Dose 2 in the previously conducted clinical trials will be assessed for anti-PCV-1 antibodies in this study. Additionally, pre-vaccination sera samples from any infants testing positive for PCV-1 antibodies at the post-vaccination time point will also be evaluated.
1611160|NCT02153320|Procedure|Blood Sampling|Single blood sample taken from subjects who had participated in the study 287615 (NCT00508833).
1611161|NCT02153307|Device|Implantable loop recorders system Reveal ICM LINQ®,|
1611162|NCT02153294|Procedure|low tidal volume|Patients are randomized and ventilated with a low tidal volume (4-6 ml/kg PBW)
1611163|NCT02153294|Procedure|high tidal volume|Patients are randomized and ventilated with a high tidal volume (8-10 ml/kg PBW)
1611164|NCT02153281|Other|phenelzine treatment|Subjects will have a PET and MRI scan before and after treatment with phenelzine.
1611165|NCT02153268|Procedure|Single Arm - Liposuction procedure and BonoFill transplantation will be done for all subjects on study|"Liposuction - will be performed on Visit 2, BonoFill will be based on subject's autologous Human Adipose Tissue Derived Cells (HATDCs).
BonoFill Transplantation will be performed on Visit 6. BonoFill will be administrated to the subject in a single session at one tested cell dose."
1611166|NCT02153229|Radiation|Photodynamic Therapy|
1611167|NCT02153229|Procedure|Radical Pleurectomy|
1611168|NCT02153229|Radiation|Chemotherapy|
1611169|NCT02153229|Drug|Photofrin 2.0 mg/kg|If randomized to the RP with PDT arm, subject will receive Photofrin 2.0 mg/kg as an intravenous infusion 24 hours (range 18-30 hours) prior to intra-operative light delivery (PDT) during radical pleurectectomy
1611170|NCT02153203|Behavioral|Prevent-Teach-Reinforce Model|Implementation of the model once to twice per week over a period of 8 weeks
1611171|NCT02153203|Other|Individual Parent Training Session|One 2- to 3-hour individual parent training session on the assessment and treatment of problem behavior
1611172|NCT02153190|Device|HYBRID|During the HYBRID Period, the patient will use the AP model when at home, from dinner to wake-up time whereas the patient will self manage glucose control with insulin pump and CGM for the rest of the day.
1611173|NCT02153190|Device|OPEN|During the control period called OPEN Period, patient self management of diabetes by insulin pump and CGM will be done at all times.
1611174|NCT02153177|Procedure|Rotator cuff repair|Arthroscopic procedure
1611175|NCT02153177|Drug|Ibuprofen, Hydrocodone/Acetaminophen, Omeprazole|In addition to pain medication after the procedure patients will receive Ibuprofen and Omeprazole. Omeprazole is given to minimize the gastrointestinal side effects of Ibuprofen.
1611176|NCT02153177|Drug|Hydrocodone/Acetaminophen|Hydrocodone/Acetaminophen is given for pain control after the surgery.
1611177|NCT02153151|Other|Cytology specimen|Correlative studies
1611178|NCT02153151|Other|Laboratory biomarker analysis|Correlative studies
1611179|NCT02153138|Device|Endo-pat 2000|"The endo peripheral arterial tonometry (PAT) provides an index of endothelial function in two forms:
The reactive hyperemia index (RHI) is the post-to-preocclusion PAT signal ratio in the occluded side, normalized to the control side and further corrected for baseline vascular tone.
The logarithm RHI (LnRHI) is s similar index as RHI after natural log transformation with a matched cutoff. LnRHI provides better double-sided distribution than RHI and one that is closer to normal distribution"
1611180|NCT02153138|Device|carotid intima media thickness Ultrasound|cIMT is the distance between the intimal-luminal interface and the medial-adventitial interface. It will be studied by B-mode ultrasonography of the extracranial carotid arteries. A duplex system with a 7-10 megahertz (MHz) linear array multi-frequency transducer will be used.
1611181|NCT02153138|Device|Dexa- Bone densitometer & Bone ultrasonometer System|A means of measuring bone mineral density and body composition by a dual energy X-ray absorptiometry (DEXA) machine
1611182|NCT02153125|Drug|Eplerenone|
1611183|NCT02153112|Biological|GI.1/GII.4 (15/15)|Norovirus GI.1/GII.4 (15 μg/15 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
1611184|NCT02153112|Biological|GI.1/GII.4 (15/50)|Norovirus GI.1/GII.4 (15 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
1611185|NCT02153112|Biological|GI.1/GII.4 (50/50)|Norovirus GI.1/GII.4 (50 μg/50 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
1611186|NCT02153112|Biological|GI.1/GII.4 (50/150)|Norovirus GI.1/GII.4 (50 μg/150 μg) bivalent VLP vaccine combined with 500 μg aluminum hydroxide for IM injection
1611187|NCT02153112|Drug|Placebo|Placebo saline solution
1611188|NCT02153099|Drug|TAK-058 (ENV8058)|TAK-058 (ENV8058) oral solution
1611189|NCT02153099|Drug|Placebo|TAK-058 (ENV8058) placebo-matching oral solution
1611190|NCT02153086|Drug|Ramelteon|Ramelteon tablets 8 mg
1611191|NCT02153073|Drug|Omega-3 fatty acid ethyl esters|Omega-3 fatty acid ethyl esters granular capsules
1611192|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days
1611193|NCT02153060|Drug|Dexamethasone|Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days
1611194|NCT02153047|Behavioral|Spirometry|Will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured 20-minutes visit with details of the spirometry data (values of respiratory capacity and volumes referring on the theoretical)
1611195|NCT02153021|Radiation|Phototherapy|"phototherapy: all patientes will received application of phototherapy after exercise session. The phototherapy will be applicated in abdominal and dorsal circumference/ quadriceps and biceps femoral.
Type Ga-Al-As Wavelength 808nm Frenquency Continue wave Optical output 100mW Spot diameter 0.6mm Power density 60W/cm2 Energy per minute 6J/point Number of Points 64points Total energy delivered 48J"
1611196|NCT02152995|Procedure|Computed Tomography|Undergo iodine I-124 PET/CT
2010266|NCT03039894|Other|Gradebook Game|Students in the intervention group will spend time meeting as teams to review their scorecards, and do team-building activities, all of which will occur during non-content periods at school (Advisory and Enrichment).
2010267|NCT03037411|Device|Peripheral stenting|stent implantation during the index procedure
2010268|NCT03038009|Drug|Pantoprazole|Pantoprazole (40mg qd) will be concomitant used with DAPT
1611208|NCT02152969|Drug|Telmisartan|
1611209|NCT02152969|Drug|Amlodipine|
1611210|NCT02152969|Drug|Chlorthalidone|
1611211|NCT02152956|Drug|MGD006|MGD006 is a CD123 x CD3 bi-specific antibody-based molecular construct referred to as a Dual Affinity Re-Targeting (DART®) molecule. MGD006 will be administered as a single agent.
1611212|NCT02152943|Drug|Everolimus|"Escalation Group Starting Dose of Everolimus: 5 mg by mouth daily.
Expansion Group Starting Dose of Everolimus: Maximum tolerated dose from Escalation Group."
1611213|NCT02152943|Drug|Trastuzumab|"Escalation Group Starting Dose of Trastuzumab: 4 mg/Kg loading dose by vein every 3 weeks, then 2 mg/Kg maintenance dose by vein every 3 weeks.
Expansion Group Starting Dose of Trastuzumab: Maximum tolerated dose from Escalation Group."
1611214|NCT02152943|Drug|Letrozole|Escalation Group and Expansion Group Letrozole Dose: 2.5 mg by mouth daily.
1611215|NCT02152930|Drug|Omega-3 fatty acids|1000 mg of omega-3 fatty acid ethylesters, 2 times daily, for 4 weeks, followed by 12 weeks of supervised exercise therapy in combination with 2 times daily omega-3 fatty acid supplementation.
1611216|NCT02152917|Drug|Tranexamic acid|
1611217|NCT02152917|Drug|Floseal®|
1611218|NCT02152891|Behavioral|CHAP-EMS/CP@clinic|Community Paramedicine program to assess cardiovascular, diabetes, and fall risk; discuss lifestyle changes and goals; and refer to appropriate resources.
1611219|NCT02152878|Device|Sham stimulation|For sham tDCS, the device will be turned off after 30 seconds of stimulation.
1611220|NCT02152878|Device|Active stimulation|"For active tDCS, we will place the anode and the cathode over the left and right dorsolateral prefrontal cortex areas, respectively (corresponding to F3 and F4 according to the EEG 10-20 system). We will use 5x5 cm electrodes and a 2mA current for 30 minutes per day. This montage is known as bifrontal setup and has been previously used in major depression trials"
1611221|NCT02152865|Drug|Lupeol|Patients are supposed to apply lupeol cream to one side of their face two times per day for 8 weeks.
1611222|NCT02152865|Drug|Control vehicle|Patients are supposed to apply their control vehicle to the other side of their face for 8 weeks
1611223|NCT02152852|Behavioral|Community Health Worker Intervention|For the intervention group, a trained Community Health Worker (CHW) will provide education, support and service coordination through in-home visits. The CHW will first make an in-home assessment visit. At the assessment visit, the participant has the opportunity to ask questions and sign written consent. During this visit, the CHW assesses the participant's history with diabetes, medication adherence, self-management activities, healthcare utilization and will administer a finger stick blood test for HbA1c and a full lipid panel. After enrollment, the participant receives up to five follow-up educational visits 0.5, 1.5, 3.5, 7 and 10 months later. In addition to scheduled visits, the CHWs work with their participants on an as-needed basis via telephone, or additional home visits.
1611224|NCT02152839|Behavioral|Resistance Exercise|6 Weeks progressive unilateral resistance exercise, 3 times per week, 70% 1-RM, 6 x 8 Repetitions. 2 minutes rest between sets
1611225|NCT02152826|Device|Potassium oxalate|Professional application
1611226|NCT02152813|Behavioral|TENS and Task-orientated training|All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
1611227|NCT02152800|Drug|valacyclovir hydrocholoride|
1611228|NCT02152787|Drug|Injection of propofol 1.0mg/kg|
1611229|NCT02152787|Drug|propofol 0.5mg/kg|
1611230|NCT02152787|Drug|normal saline|
1611231|NCT02152774|Drug|Rho-Kinase Inhibitor|
1611232|NCT02152761|Drug|bimagrumab|Bimagrumab will be administered as intravenous infusion starting on Day 1 until week 20.
1611233|NCT02152761|Other|placebo|Matching placebo will be administered as intravenous infusion starting on Day 1 until week 20.
1611234|NCT02152748|Genetic|analyze systematically morphological and molecular changes associated with glioblastoma progression and therapy-resistance|
1611235|NCT02152735|Procedure|Cleaning the uterine cavity|These participants will have their uterine cavities cleaned with a dry laparotomy sponge after delivery of the placenta. Per standard protocol, the uterus will be explored with one hand holding a sponge to remove any remaining membranes or placental tissue, while the other hand is placed on the fundus to stabilize the uterus
1611236|NCT02152709|Biological|3 dose of 10µg/0.5ml hepatitis B vaccine|3 dose of 10µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
1611237|NCT02152709|Biological|3 dose of 5µg/0.5ml hepatitis B vaccine|3 dose of 5µg/0.5ml hepatitis B vaccine made by recombinant deoxyribonudeic acid techniques in saccharomyces cereviside were administered intramuscular injection at 0, 1, 6 momth interval.
1611238|NCT02152696|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
1611239|NCT02152696|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
1611240|NCT02152696|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring
1611241|NCT02152683|Device|Renova|Low- Intensity Shockwave
1611242|NCT02152670|Drug|Methylphenidate|
1611243|NCT02152670|Drug|Alpha Methyl Para Tyrosine (AMPT)|
1611244|NCT02152670|Other|[11C]PHNO|
1611245|NCT02152670|Other|[11C]raclopride|
1611246|NCT02152657|Other|Mesenchymal stem cell transplantation|Mesenchymal stem cell transplantation through percutaneous injection.
1611376|NCT02151617|Drug|PF-06743649|40 mg tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
1611249|NCT02152618|Other|Parent Management Training - Oregon Model (PMTO)|Evidence-based, behavioral parent management training model, Parent Management Training - Oregon Model (PMTO) tailored to address permanency barriers of parents of children with SED.
1611250|NCT02152605|Drug|UMEC/VI|Dry white powder delivered via DPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg
1611251|NCT02152605|Drug|Placebo|Dry white powder delivered via DPI (2 strips with 30 blisters each, both containing lactose with magnesium stearate), administered as one inhalation of placebo
1611252|NCT02152592|Drug|PCM/Oxy1|Controlled Release oxycodone 10 mg orally twice a day for 24 hours
1611253|NCT02152592|Drug|PCM/Oxy2|CR oxycodone 10 mg orally twice a day for 48 hours
1611254|NCT02152579|Drug|Isosorbide-5-mononitrate|Patients will receive 20mg monocordil tablets (Baldacci Laboratories).
1611255|NCT02152566|Device|Nasal High flow therapy device|Nasal high flow therapy via nasal cannula.
1611256|NCT02152553|Drug|Hydrocortisone|
1611257|NCT02152553|Drug|Placebo|
1611258|NCT02152540|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
1611259|NCT02152540|Device|Sham rTMS|Placebo Device that simulates active rTMS treatment
1611260|NCT02152514|Drug|Intrathecal Morphine/Sufentanil|
1611261|NCT02152514|Device|PCA|
1611262|NCT02152501|Other|Exercise Energy Expenditure 300 kcal/day|
1611263|NCT02152501|Other|Exercise Energy Expenditure 600 kcal/day|
1611264|NCT02152475|Drug|mouthwash with curcumin|Mouthwash with 20 ml of curcumin solution for 5 minutes
1611265|NCT02152475|Device|blue LED illumination|Oral cavity was illuminated with blue light for 5 minutes
1611266|NCT02152462|Other|Exergaming|The participants in the Wii Fit exergaming group will be encouraged to meet and then maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. Goals per individual will be based on their baseline data. Exercise duration will increase gradually from 75 min/wk at week 1 to 150 min/wk by week 4. Thereafter, women will maintain >150 min/wk of moderate-intensity physical activity. The training will consist of 3 days/wk of supervised physical activity using Nintendo Wii Fit active videogames.
1611267|NCT02152449|Dietary Supplement|Oral nutritional supplementation|
1611268|NCT02152436|Other|Simulation - based curriculum|Operating room medical and non-medical members will be asked to carry out a simulation session preceded by an educational maze with videos. Outcomes will be compared and correlated after and before this curriculum
1611269|NCT02152423|Drug|LOVENOX|
1611270|NCT02152423|Drug|ENOXAMED|
1611271|NCT02152410|Device|acupuncture|Acupuncture will be applied according to the standards for reporting interventions in clinical trials of acupuncture (STRICTA)
1611272|NCT02152410|Drug|Morphine|bolus of 5 mg of morphine (5 cc) and 2 mg (2cc) every 10 minutes if no improvement of VAS (VAS> 30).
1611273|NCT02152397|Behavioral|Therapist-led brief intervention (TBI)|
1611274|NCT02152384|Drug|Insulin Peglispro|Administered SC
1611275|NCT02152384|Drug|Insulin Lispro|Administered SC
1611276|NCT02152384|Drug|Insulin Glargine|Administered SC
1611277|NCT02152371|Drug|Dulaglutide|Administered SQ
1611278|NCT02152371|Drug|Placebo|Administered SQ
1611279|NCT02152371|Drug|Insulin Glargine|Administered SQ
1611280|NCT02152371|Drug|Metformin|Administered orally
1611281|NCT02152358|Drug|Aciclovir|Intravenous 15 mg/kg/d during 14 days
1611282|NCT02152358|Drug|Ganciclovir|intravenous 10 mg/kg/d for 14 days
1611283|NCT02152358|Drug|Placebo|
1611284|NCT02152345|Drug|Belatacept|"Belatacept 10 mg/kg will be administered in the operating room approximately 1 hour prior to kidney allograft reperfusion (Day 0). It will then be administered at 10 mg/kg on the following post-transplantation days: Day 5, 14, 30, 56, and 84.
Belatacept 5 mg/kg will be administered every four weeks thereafter until end of study."
1611285|NCT02152345|Drug|Tacrolimus|"Tacrolimus 0.05 mg/kg by mouth every 12 hours will be on Day 0 after transplantation. It will then be administered at 8-12 ng/mL on the following post-transplantation days: Day 3-90; at 8-10 ng/mL Day 91-180.
Tacrolimus 6 - 8 ng/mL will be administered daily thereafter until end of study.
(standard of care)"
1611286|NCT02152345|Drug|Mycophenolate|"An immunosuppressive agent used with other medicines to lower the body's natural immunity in patients who receive kidney transplants.
720 mg by mouth every 12 hours (Day 0)(1080 mg AA).
(standard of care)"
1611287|NCT02152345|Drug|rATG|"1.5 mg/kg IV daily on Day 0-3.
(standard of care)"
1611288|NCT02152345|Drug|Methylprednisolone|"500 mg (Day 0), 250mg (Day 1), 125mg (Day 2), 75 mg (Day 3) IV administered from Day 0-3.
(standard of care)"
1611289|NCT02152345|Procedure|Renal transplant|Standard organ transplant of a kidney into a patient with end-stage renal disease.
1611290|NCT02152332|Drug|JNJ-54861911-Therapeutic Dose|JNJ-54861911 50 mg once daily for 7 days in all treatment sequence.
1611291|NCT02152332|Drug|JNJ-54861911 - Supratherapeutic Dose|JNJ-54861911 150 mg once daily for 7 days in all treatment sequence.
1611292|NCT02152332|Drug|JNJ-54861911-Matched Placebo|JNJ-54861911-matched placebo once daily for 7 days in all treatment sequence.
1611293|NCT02152332|Drug|Moxifloxacin|Moxifloxacin 400 mg on Day 7 in all treatment sequence.
1611294|NCT02152332|Drug|Moxifloxacin Matched Placebo|Moxifloxacin matched placebo, 400 mg on Day 7 in all treatment sequence.
1611295|NCT02152319|Device|KHV reporting|Clinicians will view the KHV motor symptom severity reports and use KHV to videoconference with subjects to titrate medications.
1611296|NCT02152319|Procedure|Standard care|Subjects will receive the same disease management as if they were not participating in this study.
1611297|NCT02152306|Drug|Fimasartan and Amlodipine|
1611298|NCT02152306|Drug|Fimasartan|
1611299|NCT02152280|Drug|Danhong Injection|Danhong Injection 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days.
1611300|NCT02152280|Drug|Normal Saline|0.9% sodium chloride solution 40 ml add 250 ml of 0.9% sodium chloride solution, injection intravenous drip, 1 time a day, for 10 days;
1611377|NCT02151617|Drug|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
1611378|NCT02151617|Drug|PF-06743649|To be decided dose, tablet once daily dosing for 14 days
1611301|NCT02152267|Device|tDCS|The transcranial direct current stimulation allows the neuronal membranes to neuromodulate and it can enhance or inhibit the potential actions on the cortex. Studies with animals has shown that anodal stimulation modulate the membrane in the way to depolarize which results in a long term potential in the stimulated area
1611302|NCT02152254|Drug|Targeted Therapy Based on Molecular Profiling|Patients randomized to receive targeted therapy will participate in clinical trials, and will be treated at the expansion phase of Phase I clinical trials or in Phase II clinical trials. If a clinical trial is not available and a commercially available targeted therapy exists (FDA-approved for another indication), patients may receive the FDA-approved drug.
1611303|NCT02152254|Drug|Standard-of-Care Therapy|Standard-of-care treatment regimen will be left to the discretion of the treating physician.
1611304|NCT02152228|Drug|EnteraBio's Oral Parathyroid Hormone (1-34)|Oral administration
1611305|NCT02152215|Procedure|Acellular dermal matrix membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive an intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft covered by an acellular dermal matrix, composed of human connective tissue matrix.
1611306|NCT02152215|Procedure|Polylactic acid membrane|The surgical procedure will consist of a full-thickness papilla preservation flap performed on the buccal and a full thickness flap on the palatal to expose the alveolar ridge and the tooth to be extracted. The group will receive intrasocket cancellous particulate allograft plus a facial overlay graft using a bovine xenograft, covered by a bioabsorbable membrane made of polylactic acid and a citric acid ester
1611307|NCT02152202|Other|Semi-upright position|In this group patients' bed will be set into 45 degree angle during sleep in the night time.
1611308|NCT02152202|Other|Supine position|Control: Supine position during nocturnal sleep for at least two postoperative nights.
1611309|NCT02152189|Other|Screening for Fabry disease|
1611310|NCT02152176|Device|Titration of morphine by Patient Controlled Analgesy|PCA is never used for titration but only for relay of titration. Self-controlled analgesia by PCA is our intervention.
1611311|NCT02152163|Drug|IV Ibuprofen|
1611312|NCT02152163|Drug|placebo|
1611313|NCT02152150|Other|Iron bio-fortified pearl millet|Pearl millet variety ICTP8203-Fe (82 mg/kg iron content) prepared as a traditional flatbread (bhakri)
1611314|NCT02152150|Other|Control pearl millet|Conventional pearl millet: variety DG9444 (22 mg/kg iron content) and JKBH778 (52 mg/kg iron content), prepared as a traditional flatbread (bhakri)
1611315|NCT02152137|Drug|efatutazone|Given PO
1611316|NCT02152137|Drug|paclitaxel|Given IV
1611317|NCT02152111|Dietary Supplement|Coconut flour|Patients 9 months following treatment, starting at 3 months with diet hipoenergetica 3 months washout and sixth month diet hiponergetic more coconut flour.
1611318|NCT02152111|Behavioral|Diet|Patients were instructed to follow the dietary treatment for 6 months.
1611319|NCT02152098|Procedure|Acute Early onset of rehabilitation|Early onset of rehabilitation
1611320|NCT02152098|Procedure|Acute Delayed onset of rehabilitation|Delayed onset of rehabilitation
1611321|NCT02152098|Procedure|Chronic Exercise|Exercise
1611322|NCT02152098|Procedure|Chronic Control|Control
1611323|NCT02152085|Device|Narrow pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises narrow (0.4 ms) stimulus pulses.
1611324|NCT02152085|Device|Wide pulse|Participants will be randomly assigned to one of two study arms to receive a 6 week treatment of electrical stimulation that comprises wide (1 ms) stimulus pulses.
1611325|NCT02152072|Other|Using Simulation-Based Training to Incorporate Lung Ultrasound into Physical Examination|
1611326|NCT02152059|Drug|BIBF1120|BIBF1120 is a VEGFR, FGFR and PDGFR inhibitor
1611327|NCT02152046|Procedure|ROP exam with spring loaded retractor|
1611328|NCT02152046|Procedure|ROP exam with screw retractor|
1611329|NCT02152033|Behavioral|Home-based Continuing Care|All sessions will occur over the phone or Cisco WebEx meetings. Parents will participate in 5 individual sessions and 1 joint session with their child (45-50 min. each). Young Adults (YAs) will participate in 1-3 individual meetings (30- 45 min. each) and 1 joint session (45-50 min.). In addition, YAs will be contacted weekly for the first 8 weeks of HCC, then every other week for the remaining 24 weeks (20 calls total). He or she will be asked questions addressing risk and protective factors for relapse. Finally, parents will be trained to collect and test their child's urine sample and deliver incentives to the YA contingent upon biologically-verified abstinence and verified engagement in continuing service plan activities. Urine samples will be collected regularly over a 32 week period.
1611330|NCT02152033|Behavioral|Services as Usual|Young Adults (YAs) will be told to follow the continuing service plan recommended by the residential treatment program. Parents will be told to support this and be sent information on continuing care developed by the Treatment Research Institute and the Partnership @ Drugfree.org (http://continuingcare.drugfree.org). We will provide no supplemental services during the study. We will train parents; however, on how to collect urine samples for research purposes only. They will not be trained on how to test the urine sample, only how to collect it and mail the sample to our staff for testing. We will offer separate 4 hour-workshops to parents and YAs after they have completed participation as an added study participation incentive for this group.
1611331|NCT02152020|Behavioral|Survey|
1611332|NCT02152007|Drug|1% sirolimus cream (TD201 1%)|1% sirolimus cream (TD201 1%)
1611333|NCT02151994|Drug|BIA 5-1058|oral administration
1611334|NCT02151994|Drug|Placebo|oral administration
1611335|NCT02151981|Drug|Chemotherapy|Randomization to either AZD9291 or platinum-based doublet-chemotherapy on Day 1 of every 21d cycle in a 2:1 (AZD9291:platinum-based doublet-chemotherapy) ratio
1611369|NCT02151669|Behavioral|Mediterranean Diet|Nutritional intervention conducted by a dietitian who designs a nutrition program to enhance the traditional Mediterranean diet pattern using new technology as an educational tool in primary care: DIET blog. Participants will be referred to a single annual visit and one group session per year for two years.
1611370|NCT02151656|Drug|F17464|
1611371|NCT02151656|Drug|Placebo|
1611336|NCT02151981|Drug|Cross-over to AZD9291|"Once subjects on the platinum-based doublet chemotherapy arm are determined to have objective radiological progression according to RECIST 1.1 by the investigator and confirmed by independent central imaging review, they will be given the opportunity to begin treatment with AZD9291 80mg, once daily. These subjects may continue treatment with AZD9291 even after disease progression, as long as they are continuing to show clinical benefit, as judged by the investigator.
Subjects who stop platinum-based doublet chemotherapy for reasons other than objective disease progression according to RECIST 1.1 will not be eligible to cross-over to AZD9291."
1611337|NCT02151968|Procedure|Local Anaesthetic Injection|Local anaesthetic is injected into the eye.
1611338|NCT02151968|Procedure|Ultrasound-Guidance|"Device: Ultrasound Machine
Peribulbar block local anaesthetic is injected into the eye with ultrasound guidance."
1611339|NCT02151955|Behavioral|Individual|10 to 15 Individual parent child therapeutic intervention focusing on the quality of the parent child relationships using attachment theory and parent infant psychotherapy
1611340|NCT02151929|Device|Bioresorbable vascular scaffold|stenting of an acute thrombotic lesion in patient within STEMI
1611341|NCT02151929|Device|Everolimus eluting stent|stenting of an acute thrombotic lesion in patient within STEMI
1611342|NCT02151916|Other|Dental care, AG, MI & fluoride varnish|Dental care during pregnancy, or soon thereafter, will comprise of a screening oral examination, extractions, restorations, scaling and prophylaxis, if needed, and will take as many dental visits as required to achieve a non-diseased mouth. Fluoride varnish application to the teeth of children in the immediate intervention group will occur when children are aged 6 to 10 months (time of tooth eruption), 12 and 18 months, as well as at 24 months. Oral health anticipatory guidance and motivational interviewing for the caregivers/mothers in the immediate intervention group will occur during pregnancy and when the children are aged 6-10 months (time of tooth eruption), 12 and 18 months.
1611343|NCT02151916|Other|Delayed intervention|Delayed intervention controlled design; all participants ultimately receive the benefits of the interventions. The intervention group receives the interventions when the mother is pregnant until the child is two years old. The delayed intervention group receives the interventions when the child is two years old until the child is three years old.
1611344|NCT02151903|Drug|DI-Leu16-IL2|DI-Leu16-IL2
1611345|NCT02151890|Biological|Stem Cell|Out of 112 high risk patients for POF diagnosis was established in 10 cases. Endometrial fractional biopsy was taken, stained with H&E stain and by Immunohistochemical (IH) staining by stem cell marker OCT4. IH expression of stem cell was evaluated before and after transplantation according to Edessy Stem Cell Scoring (ESS). After laparoscopic injection of stem cell sample in the ovaries, participants were followed up monthly for a period of one year by hormonal (FSH, LH and E2), clinical (resuming menstruation and pregnancy), US (folliculometry), histopathological (HP), and IH expression of stem cell (stem cell positivity and scoring according to ESS).
1611346|NCT02151877|Drug|Inhaled Nitric Oxide|delivering inhaled Nitric Oxide into the cardiopulmonary bypass circuit during neonatal cardiac surgery
1611347|NCT02151877|Drug|placebo|inhaled Nitric Oxide not delivered to the cardiopulmonary bypass circuit during neonatal cardiac surgery
1611348|NCT02151864|Drug|LDE225|LDE225 will be administered orally, on a continuous once daily dosing schedule at a dose determined by the cohort the patient is enrolled in until progression or unacceptable toxicity develops
2010269|NCT03036488|Biological|Pembrolizumab|On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion.
2010270|NCT03036488|Drug|Carboplatin|On Day 1 of Cycles 1-4 of the neoadjuvant phase of the study OR on Days 1, 8, 15 of Cycles 1-4 of the neoadjuvant phase of the study; IV infusion.
2010271|NCT03036488|Drug|Paclitaxel|On Days 1, 8 and 15 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion.
1611352|NCT02151825|Dietary Supplement|Synbiotic|3 capsules per day containing 4 billion CFU of Bifidobacterium lactis BB-12, Lactobacillus acidophilus LA-5, Lactobacillus casei 431 and Saccharomyces boulardii in combination with prebiotics Inulin (1 g) and Galactooligosaccharides (100 mg)
1611353|NCT02151825|Other|Placebo|3 capsules of Maltodextrin per day
1611354|NCT02151812|Device|Agent Paclitaxel-coated balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
1611355|NCT02151812|Device|SeQuent® Please Paclitaxel-coated Balloon|After successful pre-dilatation, the index lesion is dilated with a single drug-coated balloon that completely covers the restenotic lesion.
1611356|NCT02151799|Procedure|Abdominoplasty and liposuction|
1611357|NCT02151786|Drug|Lansoprazole|Lansoprazole intravenous 30 mg
1611358|NCT02151773|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
1611359|NCT02151760|Drug|18F-DCFPyL|
1611360|NCT02151734|Drug|KALOMIN™ Tab.|
1611361|NCT02151734|Drug|Umckamin syrup|
1611362|NCT02151721|Drug|Vorinostat, gefitinib|Vorinostat 200, 300, or 400 mg orally once daily on days 1-7 with washout on days 8-14 plus gefitinib 250 mg orally once daily on days 1-14
1611363|NCT02151708|Drug|Placebo|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
1611364|NCT02151708|Drug|motilitone|Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.
2010272|NCT03036488|Drug|Doxorubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
2010273|NCT03036488|Drug|Epirubicin|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection.
1611367|NCT02151682|Drug|Tapentadol prolonged release|Participants aged from 6 years to less than 18 years with body weight less than 22.5 kg (but more than 17.5 kg) will start on 25 mg of tapentadol orally (by mouth) twice daily during the first 24 hours and then if necessary gradually stepwise increase the dose.
1611368|NCT02151682|Drug|Morphine prolonged release|Participants aged from 6 years to less than 18 years with body weight less than 22.5 kg (but more than 17.5 kg) will start on 10 mg of morphine orally twice daily during the first 24 hours and then and then if necessary gradually stepwise increase the dose.
1611374|NCT02151630|Drug|Pyruvic acid|
1611375|NCT02151630|Drug|Salicylic Acid|
1611379|NCT02151617|Drug|Placebo|Placebo tablet once daily dosing for 14 days
1611380|NCT02151617|Drug|PF-06743649|To be decided dose, tablet, one time once with a meal and once without a meal, followed by once daily dosing for 14 days
1611381|NCT02151617|Drug|Placebo|Placebo tablet one time once with a meal and once without a meal, followed by once daily dosing for 14 days
1611382|NCT02151617|Drug|PF-06743649|To be decided dose, tablet, one time without a meal, followed by once daily dosing for 14 days
1611383|NCT02151617|Drug|Placebo|Placebo tablet one time once without a meal, followed by once daily dosing for 14 days
1611384|NCT02151617|Drug|PF-06743649|Tablet, to be decided dose, once daily, 14 days
1611385|NCT02151617|Drug|Placebo|Tablet, once daily, 14 days
1611386|NCT02151604|Other|Inhalation of hyperpolarized xenon gas|The xenon gas is inhaled immediately before acquisition of an MR image to enable the lung structure to be seen.
1611387|NCT02151591|Drug|Varenicline|"12-weeks of treatment. Dose will be titrated as follows:
Days 1-3: 1 0.5mg tablet once per day Days 4-7: 1 0.5mg tablet twice per day Day 8 - Week 11: 1 1mg tablet twice per day"
1611388|NCT02151578|Other|home/community case management|
1611389|NCT02151565|Device|HTEMS|
1611390|NCT02151565|Device|TENS|
1611391|NCT02151552|Drug|Endotoxin (E. coli O:113, Reference Endotoxin)|The endotoxin will be reconstituted with sterile water to a final concentration of 2,000 endotoxin units/ml. The dose of 4 ng/kg will be prepared to a final volume of 2 ml and will be administered using a 5F balloon-tipped monitoring catheter inserted via a fiberoptic bronchoscope into the lateral segment of the right middle lobe of the lung on the morning of Day 2.
1611392|NCT02151552|Drug|[18F](+/-)NOS|7 mCi of [18F](+/-)NOS will be injected intravenously at the start of a 60-minute dynamic PET scan acquisition
1611393|NCT02151539|Other|medical chart review|Ancillary studies
1611394|NCT02151539|Other|quality-of-life assessment|Ancillary studies
1611395|NCT02151526|Genetic|LentiGlobin BB305 Drug Product|"autologous CD34+ hematopoietic stem cells (HSCs) transduced with the LentiGlobin BB305 lentiviral vector encoding the human beta-A-T87Q globin gene
Subjects with beta-thalassemia major will undergo HSC procurement by bone marrow harvest or apheresis after mobilization with filgrastim, a granulocyte-colony stimulating factor (G-CSF), alone or in combination with plerixafor, as decided by the clinical transplant team.
Stem cell mobilization by is contraindicated in sickle cell disease (SCD), as it could induce a sickle cell crisis; thus, procurement of HSCs for subjects with severe SCD will be conducted by bone marrow harvest."
1611396|NCT02151513|Device|Intrathecal Pump Placement|
1611397|NCT02151500|Behavioral|Stress and Health Interview|A stress and health interview which aims to help patients: a) disclose their stressful experiences and emotional conflicts, which might be contributing to their symptoms; b) learn about associations between their stress and physical symptoms; and c) learn about the potential value of experiencing and expressing their emotions related to these stressful situations.
1611398|NCT02151487|Drug|Ropivacaine|Ropivacaine alone
1611399|NCT02151487|Drug|Ropivacaine, dexamethasone|Ropivacaine combination with dexamethasone
1611400|NCT02151487|Drug|Ropivacaine, dexamethasone, clonidine|Ropivacaine combination with dexamethasone and clonidine
1611401|NCT02151487|Drug|Ropivacaine, clonidine|Ropivacaine together with clonidine
1611402|NCT02151474|Drug|INCB047986|
1611403|NCT02151474|Drug|Placebo|
2010274|NCT03036488|Drug|Cyclophosphamide|On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion.
2010275|NCT03036488|Drug|Placebo|normal saline solution: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; IV infusion
2010276|NCT03033576|Biological|Ipilimumab|Given IV
2010277|NCT03033576|Other|Laboratory Biomarker Analysis|Correlative studies
1611408|NCT02151448|Biological|DC vaccine|Administered on Monday of each cycle: 1 intranodal ultrasound-guided injection (target dose of 3 x 10e6 cells in 0.5 mL) + 1 intradermal injection (target dose of 3 x 10e6 cells in 0.5 mL)
1611409|NCT02151448|Drug|Celecoxib|Administered at 200 mg, once a day orally, starting the day of the first DC vaccine through week 4/cycle 2. Participants will not take celecoxib while receiving standard of care chemotherapy as instructed by their local oncologist. Celecoxib will continue starting week 20/cycle 3 and continue until the Friday of the last day of the CKM administration, cycle 4. Administered at 400 mg, 200 mg twice a day orally, on days participants receive vaccine and CKM.
1611410|NCT02151448|Drug|Interferon Alfa-2b|Intravenous infusion over 20 minutes: doses tested in Phase 1 portion (5, 10, or 20 MU/m2) will determine the Phase 2 dose. Administered on the Tuesday of each CKM cycle.
1611411|NCT02151448|Biological|rintatolimod|Intravenous infusion of 200 mg on Wednesday and Friday only of the CKM regimen. The protocol allows for de-escalation to 100 mg if attributable adverse effects are observed.
1611412|NCT02151422|Behavioral|Breathing exercise|Patients will be thought 3 different exercises included yoga pranayama, diaphragmatic breathing and pursed lip breathing. Patients will be asked to repeat these exercises at least twice daily for a one month period. Also patients will be thought 4 different exercises which they could use in the event of an asthma exacerbation. Teaching will be supplemented by a breathing exercise brochure and patients will be asked to demonstrate proper technique at initial visit and at the return visit.
1611413|NCT02151409|Drug|NNC 0151-0000-0000|A single dose (SD), administrated i.v. (intravenous) at 8 dose levels.
1611414|NCT02151409|Drug|NNC 0151-0000-0000|A single dose (SD), administrated s.c. (subcutaneously) at 7 dose levels
1611415|NCT02151409|Drug|placebo|A single dose (SD), administrated i.v. (intravenous) or s.c. (subcutaneously).
1611416|NCT02151396|Behavioral|Working memory training|
1611417|NCT02151396|Device|Functional magnetic resonance imaging (fMRI)|
2010278|NCT03033576|Biological|Nivolumab|Given IV
1611419|NCT02151357|Drug|DCBCI0901|DCBCI0901 7.5mg/m2 iv infusion for day 1 to day 5 and day 15 to day 20
1611420|NCT02151344|Biological|H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10^7.0 fluorescent focus units (FFU) of the vaccine; the vaccine will be administered with a nose spray device.
1611421|NCT02151344|Biological|Inactivated subvirion H7N9 vaccine|Participants will receive a dose of 30 mcg of the vaccine; the vaccine will be administered as an injection.
1611843|NCT02148107|Drug|BI 691751|BI 691751 Dose 4
1611422|NCT02151331|Behavioral|External Facilitation|Non-responding sites randomized to receive external facilitation
1611423|NCT02151331|Behavioral|External + Internal Facilitation|Non-responding sites randomized to receive both internal and external facilitation
1611424|NCT02151305|Drug|Propofol, remifentanil|
1611425|NCT02151305|Drug|Sevoflurane|
1611426|NCT02151279|Other|Chitosan as wine fining agent|The possibility of allergic reactions attributed to traces of chitosan used as a fining agent in wine has not been ruled out, particularly in shrimp allergic patients to whom small traces of the potential allergen may be enough to trigger anaphylactic reactions.
1611427|NCT02151279|Other|Control|
1611428|NCT02151266|Behavioral|Exercise and Cognitive retraining|Walking 5 times per week at moderate intensity; cognitive retraining one-hour 2 times per week.
1611429|NCT02151266|Behavioral|Exercise Only|
1611430|NCT02151266|Behavioral|Stretching and Flexibility|
1611431|NCT02151253|Drug|Armodafinil|Armodafinil 50 - 250 mg pills Subjects took armodafinil once daily, before 8 am. Armodafinil was initiated at a dose of 50 mg (1 tablet) and titrated to 150 mg after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 250 mg or reduced back to 50 mg based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
1611432|NCT02151253|Drug|Placebo|Subject given placebo tablets to match Armodafinil pills. Subjects took placebo once daily, before 8 am. Placebo was initiated as 1 tablet and titrated to 3 tablets after 1 week on the basis of the investigator's and patient's perception of efficacy and side-effects. After two weeks the medication could be increased to 5 tablets or reduced back to 1 tablet based on the investigator's and patient's perception of efficacy/side-effects. No increases in dosage were allowed after week 2. The dosage was decreased at a week 3 phone call if indicated on the basis of side-effects.
1611433|NCT02151240|Drug|Foscarnet Sodium|
1611434|NCT02151240|Drug|Acyclovir|
1611435|NCT02151214|Other|Parenteral nutrition|Administration of standard intravenous nutritional products. The products are commonly used in the department where the research is conducted
1611436|NCT02151201|Behavioral|Influenza vaccination video education|Influenza vaccination video education
1611437|NCT02151201|Behavioral|Hand washing video education|Hand washing video education
1611438|NCT02151188|Dietary Supplement|Bread, Soy milk and cow milk|The study will examine the metabolic effects of two liquid proteins (soy milk and cow milk) with carbohydrate (bread) meals.
1611439|NCT02151188|Device|real-time ultrasonography (GE LOGIQ P5 ultrasound in CNRC)|
1611440|NCT02151175|Device|LIFUP|
1611441|NCT02151162|Behavioral|Mindfulness-based stress management program|Mindfulness-based stress management program will be conducted by senior nurses in four individual sessions within these three months. Senior nurses have taken a 7-hour workshop including lectures and role-playing sessions. The detailed manual and videos including lectures will be provided to the senior nurses.
1611442|NCT02151162|Dietary Supplement|Omega-3 fatty acids pills|Omega-3 fatty acids pills will include 1200 mg of eicosapentaenoic acid and 600 mg of docosahexaenoic acid per day.
1611443|NCT02151162|Behavioral|Psychoeducation leaflet|Psychoeducation leaflet will include information about screening of stress, sleep hygiene, relaxation, and a list of consultants about mental health.
1611444|NCT02151162|Dietary Supplement|Placebo pills|Placebo pills will include rapeseed oil, soybean oil, olive oil and fish oil.
1611445|NCT02151149|Drug|nab-paclitaxel|
1611446|NCT02151149|Drug|Carboplatin|
1611447|NCT02151136|Drug|TootSweet (24% sucrose)|
1611448|NCT02151136|Drug|Sterile water|
1611449|NCT02151136|Other|Standard care|The current standard of care at the study site is use of topical anesthetic (Ametop or EMLA), upright holding of toddler by parent/caregiver during procedure, use of age appropriate nurse directed distraction, and sucking on a pacifier (if normally used by child)
1611452|NCT02151084|Drug|Selumetinib|
1611453|NCT02151084|Drug|Cisplatin|
1611454|NCT02151084|Drug|Gemcitabine|
1611455|NCT02151071|Device|EnLight|The Lightpoint EnLight beta particle detector is an investigational non CE-marked medical device
1611456|NCT02151071|Device|LightPath|The LightPath Imaging System is an investigational non CE-marked in vitro diagnostic device
1611457|NCT02151058|Drug|Colgate® Regular Cavity Protection|Brushing twice daily with an ADA - Accepted fluoride - containing dentifrice (Colgate Cavity Protection)
1611458|NCT02151058|Drug|Experimental Mouth Rinse|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 10 mL for 60 seconds with the investigational product.
1611459|NCT02151058|Other|Crest® 3D White Multi-Care Whitening Rinse, Glamorous White, Fresh Mint|Brushing twice daily with an ADA - Accepted containing toothpaste, followed by rinsing with 15 mL for 60 seconds with the active comparator.
1611460|NCT02151045|Procedure|Non target epidural infiltration done at L3-L4 stage|For patients included in control arm, a non target posterior epidural space infiltration of corticoids will be done at L3-L4 stage on scan control
1611461|NCT02151045|Procedure|Epidural infiltration on contact of disco radicular conflict|For patients included in experimental arm, an epidural infiltration of corticoids will be done in lateral on contact of disco radicular conflict on scan control.
1611462|NCT02151032|Behavioral|Booklet|Participants read a booklet about colorectal cancer screening tests.
1611463|NCT02151032|Behavioral|Audio CD|Participants listen to an audio CD that will narrate the colorectal cancer screening tests booklet.
1611464|NCT02151032|Behavioral|Video with Non-Moving Images|Participants watch a video with non-moving images about colorectal cancer screening tests on an iPad.
1611465|NCT02151032|Behavioral|Video with Animated Images|Participants watch a video with animated images about colorectal cancer screening tests on an iPad.
1611466|NCT02151032|Behavioral|Questionnaires|Questionnaire completion before and after viewing the program.
1611467|NCT02151019|Radiation|IMRT|IMRT will be given to some patients to enable comparison of the acute grade 2 GI toxicities compared to those patients receiving their radiotherapy by 3-DCRT
1611468|NCT02151006|Drug|DHEA|
1611469|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Zidovudine|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + ZDV (Zidovudine 300 mg) 1 tb BID (mornings and evenings orally)
1611470|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Lopinavir/ritonavir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + Lop/r (Lopinavir/ritonavir lopinavir 200/50 mg) 2 tbs BID (mornings and evenings orally)
1611471|NCT02150993|Drug|Tenofovir + Emtricitabine or Lamivudine + Raltegravir|TDF +FTC or 3TC (Tenofovir disoproxil fumarate 245 mg and emtricitabine 200 mg or lamivudine 300mg) QD (evenings orally with meals) + RAL (Raltegravir 400 mg) 1 tb BID (mornings and evenings orally)
1611472|NCT02150967|Drug|BGJ398|Capsule for oral use
1611473|NCT02150954|Drug|pitocin|
1611474|NCT02150941|Device|BioVac Direct Suction Device|The BioVac Direct Suction Device (US Endoscopy) is an endoscopic device that enhances the suction power of the gastroscope.
1611475|NCT02150941|Device|Standard Endoscopy Suction|Standard Endoscopy Suction refers to the suction provided on the gastroscope (Olympus EVIS EXERA III).
1611476|NCT02150928|Drug|Erwinaze® (Asparaginase Erwinia Chrysanthemi)/Erwinase® (Crisantaspase)|"Enrolled patients will receive asparaginase Erwinia chrysanthemi 25,000 IU/m2 administered intramuscularly (IM) on a Monday/Wednesday/Friday schedule (all dosing regimens will start on a Monday)
All patients will receive at least 1 course (2 weeks) of treatment with asparaginase Erwinia chrysanthemi (1 course=6 doses), and a maximum number of courses needed to complete their remaining asparaginase therapy (up to 15 courses)
Eligible patients may not begin treatment with asparaginase Erwinia chrysanthemi until their serum asparaginase activity level is below the assay detectable limit"
1611477|NCT02150915|Other|Acupuncture therapy (leopard spot needling technique)|Comparison of the effects of a new or extraordinary acupoint versus a classical acupoint
1611478|NCT02150902|Procedure|Wide area circumferential catheter ablation|All subjects in the control arm of the trial will undergo wide area circumferential catheter ablation (WACA; lesions delivered 1-2 cm away from the pulmonary vein ostium) around all four pulmonary veins to the endpoint of electrical isolation (demonstrated by entry and exit block using differential pacing). Catheter ablation will be performed using contact force (CF) and electroanatomical mapping system guidance (average CF >10g, FTI > 500 g-sec and minimum ablation duration >10 sec). Dormant pulmonary vein conduction will be tested using adenosine, after completion of the lesion set, and additional lesions will be delivered to eliminate dormant PV conduction.
1611479|NCT02150902|Procedure|Augmented- wide area circumferential ablation procedure|Subjects in this group will have WACA performed as described for WACA. Following completion of the WACA procedure a second set of circumferential ablation lesions will be delivered around the first set of ablation lesions. The ablation catheter tip will be positioned at each of the ablation lesions along the first WACA line and then moved away (from the PV ostia) until healthy, non ablated tissue is recorded from the catheter tip. Energy will be delivered using CF and FTI data as described previously. Once the first WACA ablation line has been completely duplicated the procedure will be deemed complete. In case PV isolation is not achieved after the first WACA lesion set repeat electrophysiologic testing will be performed to determine whether the augmented-WACA procedure was successful in achieving PV isolation.
1611480|NCT02150889|Behavioral|Running Program|16 week supervised running program
1611481|NCT02150889|Behavioral|Yoga Program|once weekly supervised yoga
1611482|NCT02150863|Device|Ultrapulse Carbon Dioxide Laser|
1611483|NCT02150863|Device|Cellutome epidermal harvesting system|
1611484|NCT02150837|Other|5 & 2 & 2 Plan|Medifast has developed the 5 & 2 & 2 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 5 & 2 & 2 Plan consists of 5 Medifast meal replacements, 2 Lean & Green meals, and 2 healthy snacks and provides 1,200-1,400 kcal, >72g protein, >100g of carbohydrate, and <30% of calories from fat. The Lean & Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack(s) included in this plans consists of a consumer selected serving of grain/starch, dairy, or fruit.
1611485|NCT02150837|Other|4 & 2 & 1 Plan|Medifast has developed the 4 & 2 & 1 Plan as a higher calorie and higher carbohydrate alternative. This plan may be selected for very obese (BMI ≥ 40kg/m2) or older (>65 years) individuals, or for medical (e.g., diabetes) or behavioral reasons (individuals engages in high levels of physical activity). The 4 & 2 & 1 Plan consists of 4 Medifast meal replacements, 2 Lean & Green meals, and 1 healthy snack, providing 1,000-1,200 kcal, >72g protein, >100g carbohydrate, and <30% of calories from fat. The Lean & Green meal is consumer selected and consists of 5-7 ounces of a lean protein, 1 ½ - 3 cups of non-starchy vegetables, and up to 2 healthy fat servings. The healthy snack included in this plans consist of a consumer selected serving of grain/starch, dairy, or fruit.
1611486|NCT02150824|Drug|Placebo|BI 187004 high dose matching placebo once daily
1611487|NCT02150824|Drug|Placebo|BI 187004 medium dose matching placebo once daily
1611488|NCT02150824|Drug|Placebo|BI 187004 high dose matching placebo once daily add on to background metformin
1611489|NCT02150824|Drug|BI 187004|BI 187004 high dose once daily add on to background metformin
1611490|NCT02150824|Drug|Placebo|BI 187004 low dose matching placebo once daily
1611491|NCT02150824|Drug|BI 187004|BI 187004 medium dose once daily
1611492|NCT02150824|Drug|BI 187004|BI 187004 low dose once daily
1611493|NCT02150824|Drug|BI 187004|BI 187004 high dose once daily
1611494|NCT02150798|Other|High fat and low carbohydrate diet|high fat and low carbohydrate diet. At baseline and at 2 month of following, the variables that were evaluated,
1611495|NCT02150798|Other|Control diet|Control diet. At baseline and at 2 month of following, the variables that were evaluated,
1611496|NCT02150785|Drug|Streptokinase|
1611497|NCT02150772|Procedure|Shear Wave Elastography (SWE)|
1611498|NCT02150759|Drug|Dexmedetomidine|dexmedetomidine infusion during spinal anesthesia
1611499|NCT02150759|Drug|Fentanyl|add dexmedetomidine during position change
1611500|NCT02150759|Drug|Ketamine|add dexmedetomidine during position change
1611584|NCT02150096|Other|pulsed ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
1611501|NCT02150746|Procedure|Peripheral/Central Venous Blood Draw|Baseline sample of whole blood to be assessed for circulating tumor cells. Samples will be acquired via venipuncture unless a pre-existing central venous catheter is in place in which case the sample will be drawn from this.
1611502|NCT02150746|Procedure|Peritoneal Wash|Prior to the start of the surgical resection, irrigation of the abdominal cavity will be performed and collected to determine baseline pancreatic cancer cells that may be present in the abdominal cavity.
1611503|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 360 mg twice daily in the extension phase.
1611504|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg twice daily in the extension phase
1611505|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once daily in the extension phase
1611506|NCT02150733|Drug|Tivantinib|Single oral administration of Tivantinib 120 mg on Day 1 followed by Tivantinib 120 mg once every other day in the extension phase
1611507|NCT02150720|Drug|Tranexamic Acid|1g intra-articular before closing the wound surgery
1611508|NCT02150720|Drug|Fibrin glue|5mL intra-articular before closing the wound surgery
1611509|NCT02150720|Procedure|Electrocauterization|Coagulation blood from vessels by means of a electrocautery.
1611510|NCT02150707|Drug|Dipeptidyl-Peptidase IV Inhibitors|Dipeptidyl-Peptidase IV Inhibitors to treat hyperglycaemia
1611511|NCT02150707|Drug|Glucagon-Like Peptide 1|Glucagon-Like Peptide 1 to treat hyperglycaemia
1611512|NCT02150694|Procedure|Forearm venous occlusion plethysmography|Forearm venous occlusion plethysmography to study to measure forearm blood flow during intra-arterial infusion of the apelin peptides.
1611513|NCT02150694|Procedure|Aellig hand vein technique|Hand vein measurements will be used to assess the response to apelin peptides and apelin receptor blocker in the human hand vein vascular bed.
1611514|NCT02150694|Other|Apelin agonist infusion|Escalating doses of apelin (1/10/100nmol/min) will be administered.
1611515|NCT02150694|Other|Apelin receptor antagonist infusion|Dose finding study (range 1-300nmol/min) and co-infusion study with apelin peptides
1611516|NCT02150681|Behavioral|Mindfulness-based cognitive therapy|This is an 8-week treatment for women with mood disorders. The focus of sessions 1 through 4 is to establish a foundation of mindfulness practice and bringing nonjudgmental awareness to the present moment, beginning with concrete targets of attention and moves to more emotionally challenging and abstract targets (e.g., depression-specific thoughts). Participants are guided to become aware of the automatic patterns of their minds and in such moments to return attention to thoughts, feelings and body sensations. Participants engage experientially with the ways in which thoughts and emotions become engaged with rumination. In sessions 5 through 8, participants learn to extend their basic mindfulness skills to become aware of relapse risk signs and develop prevention plans.
1611517|NCT02150668|Behavioral|Homework, Organization, and Planning Skills (HOPS) Intervention|
1611518|NCT02150668|Behavioral|Homework Support Intervention (HSI)|
1611519|NCT02150655|Biological|Lactobacillus GR-1 and Lactobacillus RC-14 oral capsules|
1611520|NCT02150655|Biological|Placebo|
1611521|NCT02150616|Behavioral|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
1611522|NCT02150616|Behavioral|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
1611523|NCT02150616|Drug|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
1611524|NCT02150616|Drug|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
1611525|NCT02150590|Drug|Oxygen|Nocturnal nasal oxygen during stay at 2048 m
1611526|NCT02150590|Drug|sham oxygen (room air)|
1611527|NCT02150577|Behavioral|Evidence Based Quality Improvement|Facilitation of the identification, adoption, adaption and implementation of evidence based practices.
1611528|NCT02150564|Device|Sonowand|Initially a 2D acquisition will be performed and ultrasound parameters adjusted to obtain the best image resolution. Then anatomical landmarks will be identified if possible and the lesioncharacterized. Once the lesion is identified a rapid 3D-US acquisition will be performed. Tumor resection will proceed guided by the 3D US images using a trackable pointer to navigate. Repeat 3D US images will be obtained as many times as required during the surgery to update the information as tumor debulking proceeds. A final US will be obtained at the end of the procedure and after dural closure
1611529|NCT02150564|Procedure|Navigation|Routine microneurosurgical procedures would be adopted in all cases.Sonowand system will be used for navigation control arm as well as sononavigation experimental arm. Image registration (on the previously imported DICOM images) will be done on the system and after positioning, patient-toimage registration will be completed. The Registration accuracy will be documented.
1611530|NCT02150551|Biological|Allogeneic bone marrow-derived mesenchymal stromal cells|A fixed dose will be studied: 1 x 106 cells/kg administered intravenously (IV) weekly for 8 consecutive weeks. Toxicity will be monitored, using the department specific Standard Operating Procedure (SOP).
1611531|NCT02150538|Device|Cardiac resynchronization therapy pacemaker|biventricular stimulation with cardiac resynchronization therapy pacemaker (crt-p)
1611532|NCT02150538|Device|Dual chamber pacemaker|right ventricular stimulation with dual chamber pacemaker
1611533|NCT02150525|Dietary Supplement|omega-3 fatty acid|Given PO (by mouth) daily
1611534|NCT02150525|Other|placebo|Given PO(by mouth)daily
1611535|NCT02150525|Behavioral|Questionnaire administration|Measures of self-reported outcomes: Self-reported symptoms will be documented with the Urogenital Atrophy Questionnaire (UAQ), Menopausal Rating Scale (MRS), Female Sexual Function Index (FSFI), Center for Epidemiological Studies Short Depression Scale (CES-D 10), and Brief Pain Inventory (BPI).
1611585|NCT02150096|Other|low level laser therapy group|the group will be treated with 3 J 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
1611586|NCT02150083|Procedure|OR retrograde fill|
1611587|NCT02150070|Drug|ASP2408|Intravenous (IV) infusion and subcutaneous (SC) injection
1611588|NCT02150070|Drug|Placebo|Intravenous (IV) infusion and Subcutaneous (SC) injection
1611711|NCT02149173|Procedure|Positron Emission Tomography|Undergo F-18 FES PET/CT
1611536|NCT02150512|Device|Transpulmonary Thermodilution|Initial trigger for fluid loading when circulatory insufficiency is present will be SVV. If SVV ≤10% in patients on controlled mechanical ventilation with tidal volumes of ≥8 ml/kg, fluid loading will not be performed. If SVV >10% or spontaneous breathing efforts are present, a fluid challenge should be performed. Also if patients are on controlled mechanical ventilation with tidal volumes of ≤7 ml/kg, a fluid challenge should be performed. If fluid responsiveness is present and SVV decreases to ≤10%, further fluid loading should be stopped. If SVV is still >10%, the increase in EVLW will decide whether to continue fluid loading or not; if EVLW is ≥12 mL/kg PBW and EVLW increases upon fluid loading, further fluid loading should be stopped.
1611537|NCT02150512|Device|Surviving Sepsis Guidelines (SSG)|Initial trigger for fluid loading when circulatory insufficiency is present will be the CVP (target ≥12 mmHg). If circulatory insufficiency is absent, fluid loading will not be initiated or stopped independently of the actual CVP level.
1611538|NCT02150499|Drug|levalbuterol tartrate HFA inhalation aerosol|
1611539|NCT02150499|Drug|placebo|
1611542|NCT02150460|Procedure|One-site peribulbar injection|injection into the inferior medial orbital compartment
1611543|NCT02150460|Procedure|Two- site peribulbar injection|Two injections into the infero-temporal and supero-nasal orbital compartments
1611544|NCT02150447|Drug|Proton pump inhibitor|Lansoprazole 30 mg, daily
1611545|NCT02150447|Drug|Placebo|Placebo, daily
1611546|NCT02150434|Device|Automated oxygen titration|Automated oxygen titration every second to maintain stable SpO2 at a predefined value (94% in the present study)
1611547|NCT02150434|Drug|Compressed air|compressed air delivered at a fixed flow of 2 L/min
1611548|NCT02150434|Drug|Oxygen constant flow|oxygen delivered at a fixed flow of 2L/min
1611549|NCT02150408|Other|PET-CT|
1611550|NCT02150395|Other|music therapy|
1611551|NCT02150356|Other|Aleurone|Diet based in aleurone-enriched products for a period of 8 weeks.
1611552|NCT02150356|Other|Control|Diet based on refined cereal products for a period of 8 weeks.
1611553|NCT02150343|Drug|HDM-SPIRE|1 dose every 4 weeks
1611554|NCT02150343|Drug|Placebo|1 dose every 4 weeks
1611556|NCT02150317|Procedure|TACE+Sorafenib|TACE followed by Sorafenib
1611557|NCT02150317|Procedure|TACE|TACE alone
1611558|NCT02150291|Dietary Supplement|Folic acid|
1611559|NCT02150291|Drug|Neurobion|
1611560|NCT02150291|Drug|placebo|
1611561|NCT02150278|Behavioral|Brief intervention|The brief intervention consist of one face to face minimal advice to reduce drinking-driving behavior and it was personalized according to the state of change of the patient (based on the Prochaska and DiClemente model). An additional informative pamphlet is offered to the participant. The intervention was done by the general practitioner or nurse that regularly attends the patient.
1611562|NCT02150265|Behavioral|SMART manual cognitive behavioral therapy|
1611563|NCT02150252|Drug|Bu-Yang-Huan-Wu Tang|control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
1611564|NCT02150239|Procedure|operation|
1611565|NCT02150226|Device|Lava plus (3M) crowns and bridges|Zirconia monolithic dental crowns and bridges evaluation
1611566|NCT02150213|Procedure|MRI, CT or ultrasound was permitted if MRI was contraindicated|MRI/CT/ultrasound of abdomen
1611567|NCT02150213|Procedure|Dexamethasone Supression Test|Low dose of dexamethasone is administered in the evening; the next morning, a blood sample is collected to measure cortisol
1611568|NCT02150213|Procedure|Sonogram|Sonogram of the uterus (females only)
1611569|NCT02150213|Procedure|Biopsy|Uterine endometrial biopsy (females only)
1611570|NCT02150213|Drug|BGG492|No study-drug was administered in this study
1611571|NCT02150200|Other|shorter hospitalization stay|
1611572|NCT02150200|Other|questionnaires|
1611573|NCT02150187|Dietary Supplement|HCap Formula|Pill should be taken every other day during the treatment phase.
1611574|NCT02150187|Dietary Supplement|Placebo|Similar pills without active ingredients
1611575|NCT02150174|Behavioral|Retrieval practice effect using word pairs and cued recall tests with feedback|"In the first phase (encoding), people study a list of 48 word pairs non semantically associated.
Then (initial test), they recall half of word pairs or restudy the other half.
In the second phase (final test) which takes place 2 days later, they recall all the 48 the word pairs."
1611576|NCT02150161|Drug|Lidocaine/ ketamine|
1611577|NCT02150161|Drug|Fentanyl|
1611578|NCT02150148|Behavioral|Experimental: Mentored Gardening Intervention|receives raised bed or earthboxes and gardening supplies and instruction on vegetable gardening
1611579|NCT02150135|Other|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
1611580|NCT02150122|Dietary Supplement|Vitamin D3|
1611581|NCT02150109|Device|Subjects WITH/WITHOUT Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH and WITHOUT diabetes use Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
1611582|NCT02150109|Device|Subjects WITH Diabetes Use Karajishi Contour BGMS|Untrained subjects WITH diabetes use the Karajishi Contour BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick blood (and study staff tested subject fingerstick blood) using the Karajishi Contour BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
1611583|NCT02150096|Other|continuous ultrasound group|the group will be treated with 1,5 W/cm² 6 minutes in each side of the lumbar spine in 6 points around the lumbar spine
1611798|NCT02148406|Other|questionnaire administration|Ancillary studies
1611589|NCT02150057|Device|Fusion OA Knee Brace|This group is assigned to wear an unloading brace and report pain and quality of life by completion of a pain diary and related questionnaires.
1611590|NCT02150044|Device|Acclarent Tympanostomy Tube Delivery System (TTDS).|tympanostomy tube delivery system
1611591|NCT02150031|Drug|0.2% Chlorhexidine|mouthwash with 10 ml for 1 minute
1611592|NCT02150031|Drug|1% Chlorhexidine|subgingival irrigation
1611593|NCT02150031|Drug|1% Chlorhexidine|supragingival irrigation
1611594|NCT02150031|Procedure|Blood extraction|Blood extraction using an intravenous access at baseline, 30 seconds after antiseptic aplication, 30 seconds and 15 minutes after tooth extraction.
1611595|NCT02150031|Drug|Lidocaine plus adrenaline|local anaesthesia using lidocaine plus adrenaline (1:100,000) no more than 2 cartridges.
1611596|NCT02150031|Procedure|Tooth extraction|dental extraction
1611597|NCT02150018|Other|non invasive ventilation|
1611598|NCT02150005|Procedure|Periodontal treatment|
1611599|NCT02149992|Dietary Supplement|myo-inositol|myo-inositol, oral, 2g, twice a day for 5 days total
1611600|NCT02149992|Device|Continuous glucose monitoring surveillance|monitoring device will be placed by experienced research members to the patient on Day 1 and she will continue to wear until Day 7. This device monitors overall glycemia every 5 minutes and records the information, which can be downloaded after discontinued.
1611601|NCT02149992|Device|Glucose monitoring|patients will use the glucose meter, test strips, and lancets to determine her capillary glucose levels 4 times per day (fasting, and 1 hour post-prandial levels)
1611602|NCT02149979|Device|Temperature Controlled Laser Soldering|This study had a prospective within-subject design. Patients allocated to laparoscopic cholecystectomy procedure were enrolled. After the completion of the laparoscopic cholecystectomy surgical procedure, 4 trocar port sites were randomly either sutured or laser soldered by employing the temperature-controlled laser soldering system.
1611603|NCT02149966|Drug|AG-348|A range of doses of AG-348 will be tested based on the assessment of safety and tolerability. AG-348 will be administered by mouth (orally) each day for a period of 14 days.
1611604|NCT02149966|Drug|Placebo|Placebo will be administered by mouth (orally) each day for a period of 14 days.
2010279|NCT03034915|Drug|UMEC/VI 62.5/25 mcg via ELLIPTA|ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; the first strip contains umeclidinium bromide (62.5 mcg per blister) blended with lactose monohydrate and magnesium stearate and second strip contains vilanterol trifenatae (25 mcg per blister) blended with lactose monohydrate and magnesium stearate.
1611606|NCT02149940|Other|heart-failure related pharmaceutical intervention|
1611607|NCT02149927|Drug|Sevoflurane|
1611608|NCT02149914|Device|Ryodoraku|Ryodoraku to assess the energy of meridian system for each patient before and after taking the medication
1611609|NCT02149914|Device|ANSWatch|ANSWatch to assess the autonomic nervous system for each patient before and after taking the medication
1611610|NCT02149914|Device|UGI endoscopy|UGI endoscopy to assess the grade of reflux esophagitis for each patient before and after taking the medication
1611611|NCT02149914|Other|GerdQ|GerdQ to assess the severity of GERD for each patient before and after taking the medication
1611612|NCT02149914|Drug|PPI|
1611613|NCT02149901|Drug|Pseudoephedrine + 480 ml water|30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water
1611614|NCT02149901|Drug|Pseudoephedrine + 50 ml water|Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water
1611615|NCT02149901|Other|Placebo + 480 ml water (optional)|placebo PO with a pressor (480 ml) dose of drinking water
1611616|NCT02149901|Other|Placebo + 50 ml water (optional)|placebo PO with a non-pressor (50 ml) dose of drinking water
1611617|NCT02149888|Drug|Tenofovir/emtricitabine|Once daily Tenofovir/emtricitabine (Truvada®)
1611618|NCT02149875|Drug|Dl-3-n-butylphthalide|Intravenous infusion of 100 ml dl-3-n-butylphthalide and sodium chloride injection for 10 days, twice daily.
1611619|NCT02149875|Drug|Cerebrolysin|Intravenous infusion of 30 ml Cerebrolysin per day in 100 ml normal saline for 10 days.
1611620|NCT02149875|Drug|Placebo|100 ml saline intravenous infusion once daily for 10 days.
1611621|NCT02149862|Other|Urine infrared analysis|Collected urine sample will be stored at -80°C for further infrared analysis. Spectra will be analyzed by visual inspection, and statistical method such as Principal Components Analysis and logistic regressions methods.
1611622|NCT02149849|Procedure|Modified lateral positioning.|Right before surgery, the patient are posistioned in lateral position with arm elevated (not more than 90 degree from torso). In the intervention, the arm will be lowered and placed in towards the torso for patients enrolled in the experimantal arm.
1611623|NCT02149836|Drug|ezogabine|"Treatment Week 1: 100mg of Ezogabine by mouth three times per day (total daily dose = 300mg) Treatment Week 2: dose will be increased to 150 mg Ezogabine by mouth three times per day (total daily dose = 450mg).
Treatment Week 3: dose will be increased to 200mg of Ezogabine by mouth three times per day (total daily dose = 600mg).
Treatment Week 4: dose will be increased to 250mg of Ezogabine by mouth three times per day (total daily dose = 750mg).
Treatment Week 5: dose will be increased to 300mg of Ezogabine by mouth three times per (total daily dose = 900mg).
Participants will continue to take 900mg of Ezogabine per day and return weekly to the clinic for the remainder of the study.
Following this primary outcome visit, participants will be instructed to taper the study medication over the following 3 weeks based on FDA recommended guidelines as follows:
250 mg po TID daily x 1 week, then 200 mg po daily x 1 week, then 100 mg po daily x 1 week, then discontinue"
1611627|NCT02149810|Behavioral|Automatic Self Transcending Meditation|as above
1611628|NCT02149797|Procedure|Four port laparoscopic cholecystectomy|Classical four port laparoscopic cholecystectomy
1611673|NCT02149407|Drug|Glycerin|"Glycerin group GG will receive the 0.5 suppository (700 mg) twice daily for 48 hours. We will use the rounded part and discard the other part then will hold baby's buttocks for 2 minutes to ensure its delivery."
1611674|NCT02149407|Procedure|Rectal stimulation|"Rectal stimulation SG by soft cotton swab inserted to around 3 cm. The stick will press against the rectal wall in all direction for 2 minutes twice daily for 48 hours. Ky gel will be used to lubricate the stick and minimize direct friction to rectal wall."
1611844|NCT02148107|Drug|BI 691751|BI 691751 Dose 5
1611629|NCT02149797|Procedure|SILC-Pick'n roll-Beginning (group I)|"SILC-PR was performed by the intraumbilical single port technique. A 10-mm, 30º scope was used. The surgeon was elevated gallbladder fundus with left hand using grasper in whole operation. If required, infindibulum was freed with monopolar hook. A 2.0 straight needle was inserted through the right of the falciform ligament, grasped with a laparoscopic needleholder using by surgeon's right hand, and passed through the Hartmann's pouch at the lowest point. To allow free manipulation, the passing suture with needle was turned around the suture to form a half-knot. The needle was passed back out from the right of the midclavicular line. An assistant was grasped two ends of the suture and with the help of right or left hand dominant pulling tension, critical view of safety was provided"
1611630|NCT02149797|Procedure|SILC-Pick'n roll-Experienced (group II)|Similar technique of SILC-Pick'n roll-Beginning (group I) was used
1611631|NCT02149784|Procedure|Surgical resection of primary tumor|Surgical resection of primary tumor of mCRC patients who were respond to first line chemotherapy`
1611632|NCT02149771|Procedure|chemoembolization|Conventional chemoembolisation by administering Doxorubicin and Oxaliplatin mix with 5-20 mL iodised oil.Gelatine sponge was used to embolise the feeding artery of the tumour.Repeat if patients with viable lesions demonstrated by CT or MRI.
1611633|NCT02149771|Device|endovascular stents implantation|Bare stents implant within portal vein.
1611634|NCT02149771|Procedure|iodine-125 seed strand implantation|Iodine-125 seed strand implant within portal vein.
1611635|NCT02149758|Drug|Etoricoxib|
1611636|NCT02149745|Procedure|Calling the patient's name|calling the patient's name during anesthesia reversal
1611637|NCT02149745|Procedure|Not calling the patient's name|giving verbal stimulus other than the patient's name during anesthesia reversal
1611638|NCT02149732|Biological|cultivated oral mucosal epithelial sheet transplantation|Autologous cultivated oral mucosal epithelial cell sheet transplantation using oral mucosal adult stem cells in the patients with intractable corneal limbal deficiency
1611639|NCT02149719|Other|Desensitisation using boiled peanut|
1611640|NCT02149719|Other|Desensitisation using boiled peanut (deferred start)|
1611641|NCT02149706|Biological|NeuroVax|NeuroVax consists of a Trivalent TCR Peptide Formulation in IFA
1611642|NCT02149706|Biological|IFA Incomplete Freund's Adjuvant|IFA Placebo Incomplete Freund's Adjuvant
1611643|NCT02149693|Other|high-fidelity simulation and teamwork training|
1611644|NCT02149693|Other|traditional resuscitation training|
1611645|NCT02149667|Device|total hip arthroplasty implant|
1611647|NCT02149641|Radiation|Intensity modulated radiotherapy with chemotherapy|
1611648|NCT02149628|Drug|propofol|
1611649|NCT02149628|Drug|Desflurane|
1611650|NCT02149615|Other|Retinal nerve fibre layer measurement|Measurement of retinal nerve fibre layer thickness using optic coherence tomography.
1611651|NCT02149602|Radiation|Intensity modulated radiotherapy|Bilateral superficial lobe parotid sparing intensity modulated radiotherapy
1611652|NCT02149589|Procedure|Mechanical ventilation|
1611653|NCT02149576|Procedure|Low Dose Computed Tomography Imaging|
1611654|NCT02149576|Procedure|Chest Radiograph Imaging|
1611655|NCT02149563|Device|oxygen-enriched air -Normobaric hyperoxia treatment for depression|Forty percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours a day, throughout the night.
1611656|NCT02149550|Other|NF135 n=5|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
1611657|NCT02149550|Other|NF135 n=2|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
1611658|NCT02149550|Other|NF135 n=1|Subjects will be infected with the NF135.C10 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
1611659|NCT02149550|Other|NF166 n=5|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
1611660|NCT02149550|Other|NF166 n=2|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bites of 2 infected Anopheline mosquitoes.
1611661|NCT02149550|Other|NF166 n=1|Subjects will be infected with the NF166.C8 strain of Plasmodium falciparum through the bite of 1 infected Anopheline mosquito.
1611662|NCT02149537|Drug|hydroxyurea|
1611663|NCT02149524|Drug|Herceptin (trastuzuamb)|Intravenous administration
1611664|NCT02149524|Drug|SB3 (proposed trastuzumab biosimilar)|Intravenous administration
2010280|NCT03034915|Drug|UMEC 62.5 mcg via ELLIPTA|The ELLIPTA inhaler will contain one blister strip, which will have 30 blisters of umeclidinium bromide (62.5 mcg).
2010281|NCT03034915|Drug|Salmeterol 50 mcg via DISKUS|The DISKUS inhaler will contain one blister strip, which will have 60 blisters of salmeterol xinafoate (50 mcg). The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
1611668|NCT02149446|Device|Surgisis (C-SLRA-ECH60) made by COOK Medical|Surgisis is extracellular matrix collagen made of the submucosal layer of pigs intestines. Surgisis is gradually remodeled, leaving behind organized tissue
1611669|NCT02149433|Drug|Prednisone|The steroid regime will be oral prednisone at 2 mg/kg for 7 days, then 1 mg/kg for 7 days, then 0.5mg/kg for 7 days for a total of 21 days.
1611670|NCT02149433|Drug|Placebo|
1611671|NCT02149420|Drug|VAY736|
1611672|NCT02149420|Drug|Placebo|
1611709|NCT02149173|Drug|Fludeoxyglucose F-18|Undergo FDG PET/CT
1611710|NCT02149173|Other|Laboratory Biomarker Analysis|Correlative studies
1611675|NCT02149407|Other|Control|"Control group CG will receive routine NICU medical care without any specific intervention for the infant. The research nurse will do shame placebo twice daily by opening his diaper to blind the team for 2 minutes."
1611676|NCT02149394|Other|Ice popsicle|"Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The experimental group received an ice popsicle made of 10 mL mineral water.
The ice popsicles were made according to the predetermined volumes and packed in the freezer of the anesthetic recovery room at the institution researched. The block of ice were supported by a stick, allowing the patients to control the intensity of cold conferred by the ice for their comfort."
1611677|NCT02149394|Other|Water at room temperature|Patients were assessed according to the following criteria before each intervention: level of awareness; airway protection capacity; and absence of nausea and vomiting, according to the Safety Protocol for Thirst Management. The usual activities adopted by the nursing staff of the anesthetic recovery room were maintained for the control group that received 10 mL mineral water at room temperature in a syringe.
1611678|NCT02149381|Behavioral|CBASP|Cognitive behavioral group intervention for individuals suffering from chronic depression
1611679|NCT02149381|Behavioral|Befriending|Social support intervention, sessions once per week
1611680|NCT02149381|Other|Treatment as usual|Conventional psychiatric outpatient treatment (individual counseling)
1611681|NCT02149355|Other|teeth molding|teeth molding in patients suffering from congenital fourth nerve palsy
1611682|NCT02149342|Drug|Hexylaminolaevulinate cream|0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
1611683|NCT02149342|Drug|Methylaminolaevulinate cream|MAL 16% is used as photosensitizer for daylight-PDT
1611684|NCT02149329|Drug|Discontinuation of imipenem-cilastatin or meropenem|Discontinuation of imipenem-cilastatin or meropenem after 3x24 hours irrespective of presence of fever.
1611685|NCT02149316|Procedure|RIPC+RIPostC|Four 5 min cycles of upper limb ischemia and reperfusion by a cuff inflated to 200 mmHg, twice (after anesthesia induction and before surgery started, at 20min after aortic declamping)
1611686|NCT02149316|Procedure|control|a deflated cuff placed on the right upper arm
1611687|NCT02149303|Drug|Dabigatran 75 mg|PO BID
1611688|NCT02149303|Drug|Dabigatran 150 mg|PO BID
1611689|NCT02149290|Device|Trends-equipped LifeVest 4000|LifeVest 4000 monitors patients for VT/VF, notifies the patient if VT/VF occurs, and instructs them to press response buttons. In unresponsive patients, LifeVest delivers defibrillation therapy. Trends modifications for heart failure monitoring include: body position data collection; activity data collection; ability to perform a health survey; ability to guide patients through a walk test
1611690|NCT02149277|Drug|Filgrastim|The fertility specialist will inject the study medication or its placebo on the 6th day of gonadotrophin stimulation for IVF subjects. For the subjects undergoing embryo transfer, the injection will be done once the endometrial lining measure more than 8mm.
1611692|NCT02149251|Genetic|Pre-genetic diagnosis|
1611693|NCT02149238|Dietary Supplement|flavanol|
1611694|NCT02149238|Dietary Supplement|methylxanthine|
1611695|NCT02149238|Dietary Supplement|flavanol + methylxanthine|
1611696|NCT02149225|Drug|APVAC1 vaccine plus Poly-ICLC and GM-CSF|"APVAC1 vaccines (i.d.) will be individually assembled for each patient and can be applied to the patient approx. 3 months after enrollment. APVAC1 drug products are composed of 5 to 10 peptides from the GAPVAC warehouse. The APVAC1 vaccine will be applied concurrent to maintenance TMZ cycles after completion of chemoradiation therapy (CRT). Beginning on day 15 of the first maintenance TMZ cycle, patients will receive 11 vaccinations with APVAC1 drug products during 22 weeks. 578 μg per peptide per vial are used.
Poly ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2*) to avoid dose accumulation on consecutive days.
The 2. immunomodulator GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
1611697|NCT02149225|Drug|APVAC2 vaccine plus Poly-ICLC and GM-CSF|"APVAC2 vaccines (i.d.) will be ready for use ca. 6 months after enrollment, as these peptides have to be newly synthesized for each patient following identification of the mutanome and corresponding mutated peptides in the HLA ligandome. APVAC2 drug products are composed of 1 or 2 peptides de novo synthesized for an individual patient. Patients will be repeatedly vaccinated with APVAC2 drug products beginning on day 15 of the 4. maintenance TMZ cycle. Patients will receive 8 vaccinations within 10 weeks. 578 μg per peptide per vial are used.
Poly-ICLC (1.5 mg s.c.) will be used as immunomodulator with all vaccinations except the second applications of APVAC1 (Day 2) and APVAC2 vaccines (Day 2*) to avoid dose accumulation on consecutive days.
GM-CSF (75 μg) will be applied i.d. with the first six vaccinations with both vaccines, APVAC1 and APVAC2. A total of 12 GM-CSF doses will be applied. GM-CSF will be applied to the APVAC vaccination site 10-30 min before injection of the APVACs."
1611698|NCT02149212|Drug|Phlebotonic|Aminaftone -- 75 mg BID
1611699|NCT02149212|Device|Stent|Iliac Vein Stenting
1611700|NCT02149212|Procedure|Limb elastic compression support|CEAP 3-5 > 20-30 mmHg compression stockings CEAP 6 > elastic bandages
1611701|NCT02149212|Procedure|Unna boot dressing|CEAP 6 > Unna boot dressing
1611702|NCT02149199|Drug|budesonide/formoterol 'as needed' + budesonide placebo bid|Symbicort (budesonide/ formoterol) 160/4.5 μg powder for inhalation 'as needed' plus Pulmicort placebo 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
1611703|NCT02149199|Drug|terbutaline 'as needed' + placebo budesonide bid|Terbutaline 0.4 mg powder for inhalation 'as needed' plus placebo Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening), 52-week treatment
1611704|NCT02149199|Drug|budesonide bid + terbutaline 'as needed'|Pulmicort (budesonide) 200 μg powder for inhalation, 1 inhalation twice daily (morning and evening) plus terbutaline 0.4 mg powder for inhalation 'as needed', 52-week treatment
1611705|NCT02149186|Device|iCTuS-L|
1611706|NCT02149173|Procedure|Computed Tomography|Undergo F-18 FES PET/CT
1611707|NCT02149173|Procedure|Computed Tomography|Undergo FDG PET/CT
1611708|NCT02149173|Drug|F-18 16 Alpha-Fluoroestradiol|Undergo F-18 FES PET/CT
1611712|NCT02149173|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
1611713|NCT02149160|Drug|FRM-0334|
1611714|NCT02149160|Drug|Placebo|
1611715|NCT02149134|Dietary Supplement|TeHF2013-01|
1611716|NCT02149121|Biological|CT-P10|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
1611717|NCT02149121|Drug|Rituxan|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
1611718|NCT02149121|Drug|MabThera|1000mg by intravenous infusion. 2 infusions with a 2-week interval between the first and second infusion
1611719|NCT02149108|Drug|Nintedanib (BIBF 1120)|
1611720|NCT02149108|Drug|Placebo|
1611721|NCT02149108|Drug|BSC|
1611722|NCT02149108|Drug|BSC|
1611723|NCT02149095|Drug|TransCon PEG treprostinil|
1611724|NCT02149082|Device|Infrascanner Model 2000|The Infrascanner Model 2000 device is a small, portable handheld device that uses near infrared (NIR) technology to screen patients for intracranial bleeding.
1611725|NCT02149056|Behavioral|observation|
1611726|NCT02149056|Other|Impaired Glucose Tolerance|Impaired Glucose Tolerance
1611729|NCT02149030|Other|Cytological screening in A1 and A3|Cytological screening.
1611730|NCT02149017|Radiation|SNUBH-NM-333(18F)|5-10 mCi
1611731|NCT02148978|Drug|Saxagliptin|The participants in this study will undergo an OGTT at recruitment and then will start treatment with the DPP IV inhibitor- Saxagliptin at a dose between 2.5- 5mg a day. After 6 weeks of treatment the participants will return to perform a second OGTT.
1611732|NCT02148965|Behavioral|Physical Exercise / Physical Activity|Lifestyle intervention Exercise intervention, three weekly sessions. Each session will last around 60 minutes and will include aerobic exercises (treadmill or stationary cycling) and strength training (with focus on major muscle groups and pregnancy-specific exercises to help alleviate low back pain and work abdominal and pelvic floor muscles to prevent urinary incontinence).
1611733|NCT02148952|Behavioral|WHO Safe Childbirth Checklist Program|The IHF group will receive the WHO Safe Childbirth Checklist Program designed to maximize likelihood of effective and sustained uptake of the program by birth attendants in the designated facilities. The program includes three key implementation steps that involve: engagement of leadership and clinicians at the state, district, and local levels, a formal launch to introduce the Checklist, and support through peer coaching and data feedback. The intervention facilities will also receive a standardized maternity register to ensure appropriate data collection.
1611734|NCT02148913|Drug|Cohort 1: Carfilzomib 15 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 15 mg/m2 on day -2, -1, + 5 and +6
1611735|NCT02148913|Drug|Cohort 2: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 100 mg/m2 on day -2 and day -1 Carfilzomib 20 mg/m2 on day -2, -1, + 5 and +6
1611736|NCT02148913|Drug|Cohort 2b: Carfilzomib 20 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 20 mg/m2 on day -2, -1 and + 5
1611737|NCT02148913|Drug|Cohort 3b: Carfilzomib 27 mg/m2|Carfilzomib 20 mg/m2 on days -29, -28, -22, -21, -15, and -14 Bendamustine 120 mg/m2 on day -2 and 100 mg/m2 day -1 Melphalan 140 mg/m2 on day -1 Carfilzomib 27 mg/m2 on day -2, -1 and + 5
1611738|NCT02148874|Biological|influenza virus vaccination|comparison of immune responses to the flu vaccine in obese and non-obese populations
1611739|NCT02148861|Drug|insulin 287|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
1611740|NCT02148861|Drug|insulin degludec|Administered once-daily subcutaneously (s.c., under the skin) for 35 days
1611741|NCT02148861|Drug|placebo|Administered subcutaneously (s.c., under the skin) once-daily for 35 days
1611742|NCT02148861|Drug|placebo|Administered once-weekly subcutaneously (s.c., under the skin) for 35 days
2010282|NCT03034915|Drug|Placebo via ELLIPTA|Lactose dry powder will be administered using ELLIPTA for both treatment periods. ELLIPTA DPI inhaler will contain two individual blister strips with 30 blisters per strip; containing lactose dry powder.
2010283|NCT03034915|Drug|Placebo via DISKUS|Lactose dry powder will be administered using DISKUS for both treatment periods. The DISKUS inhaler will contain one blister strip, which will have 60 blisters of lactose dry powder. The DISKUS will provide a total of 60 doses (60 blisters) and will deliver, when actuated, the contents of a single blister strip.
2010284|NCT03031795|Drug|Ketorolac|Oral Tablet
1611746|NCT02148809|Radiation|1mL of I-131 Human Serum Albumin is injected prior to the measurements|
1611747|NCT02148796|Drug|Broncho-Vaxom|Active Ingredient: Lyophilised bacterial extract; Chemical Name: OM-85 BV; Strength: 3.5 mg; Excipients: bacterial extract, propyl gallate, sodium glutamate, mannitol, pregelatinised starch, magnesium stearate; Appearance: Blue and white capsule; Dosage Form: 3.5 mg capsule; Manufacturer: OM Pharma SA, Switzerland; Storage: Store in the original package
1611748|NCT02148796|Other|Placebo|A placebo capsule will be used that will be indistinguishable from the active study drug.
1611749|NCT02148783|Drug|methylphenidate|This is an open-labeled 4 week methylphenidate administration, 30 mg twice daily by mouth. Placebo and methylphenidate will also be administered as a single dose before one of the two PET and TMS sessions, in a single blinded manner (the participant will not know whether active drug or placebo was administered). PET imaging with [11C]-raclopride, a D2/D3 receptor ligand will be performed after administration of placebo or oral methylphenidate to measure endogenous DA release in TBI patients. Structural MRI will be performed before methylphenidate administration. TMS after placebo or methylphenidate will be performed to measure intracortical inhibition and dopaminergic activity.
1611750|NCT02148783|Drug|Placebo|
1611799|NCT02148406|Other|fatigue and depressive symptom assessment and management|Ancillary studies
1611800|NCT02148406|Other|psychological stress assessment|Ancillary studies
1611801|NCT02148406|Other|laboratory biomarker analysis|Correlative studies
1611802|NCT02148406|Other|Attention Control|
1611845|NCT02148107|Drug|BI 691751|BI 691751 Dose 6
1611846|NCT02148107|Drug|Placebo|Placebo
1611891|NCT02147821|Procedure|No Pleural Chest Tube|
2010285|NCT03031795|Drug|Placebos|
2010286|NCT03029611|Drug|Carboplatin|Given IV
1611751|NCT02148770|Device|Neurofeedback|Networks involved in eating behaviour can be modified by neurofeedback training. We will perform a neurofeedback task using the technology of fMRI-based Brain Computer Interface (BCI). BCI approaches based on real-time fMRI (rtfMRI) allow voluntary regulation of brain regions. For the rtfMRI, a well-established setup will be used which translates the blood oxygen level dependent (BOLD) signal of a specific brain region of interest into a visual signal (e.g. moving bar) in real time using brain voyager® and matlab. The study will include 1 training-sessions In the up-regulation condition subjects will learn to up regulate their dlPFC. In the sham-condition subjects are get the same instructions, however they will receive sham feedback.
1611752|NCT02148757|Procedure|Doppler Ultrasound|
1611753|NCT02148744|Biological|XmAb7195|Part 1 and 2: Single IV infusion of XmAb7195 or placebo Part 3: Two-dose sequential IV infusion of XmAb7195 or placebo on Day 1 and Day 8
1611754|NCT02148744|Biological|Placebo|
1611755|NCT02148731|Other|Frailty markers|Brief screening assessment, CGA and frailty markers will be evaluate at inclusion. CGA and frailty markers will be evaluated at 3, 6, 12 and 18 months after the beginning of chemotherapy. Criteria for toxicity and adverse outcomes will be recorded at each cycle or visits
1611756|NCT02148718|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
1611757|NCT02148705|Drug|NexoBrid|
1611758|NCT02148705|Procedure|Standard of Care (SOC)|
1611759|NCT02148705|Drug|Gel Vehicle|
1611760|NCT02148692|Procedure|Higher PEEP|
1611761|NCT02148692|Procedure|Lower PEEP|
1611762|NCT02148679|Other|DASH/SRD|Study food for this investigation will be designed and prepared by PurFoods, LLC (Des Moines, IA) dietitians under the direction of Dr. Sam Beattie, Ph. D., and in consultation with research dietitians at the University of Michigan and Columbia University. Study patients randomized to food delivery will select from an available menu of meal options that adhere to nutritional targets as above. Study food will be pre-packaged for storage with preparation (typically microwave heating) to be completed at home by the subject, and will be delivered every 1 to 2 weeks under the direction of PurFoods.
1611763|NCT02148679|Other|Usual care|Standardized advice to restrict dietary sodium intake to < 2000 mg/day
1611764|NCT02148653|Other|Multifunctional diet (MFD)|A mixed diet containing multiple functional foods/concepts with the ability to modulate blood lipid levels, glycemia, insulinemia and prothrombotic status.
1611765|NCT02148653|Other|Control diet|A nutritionally well formulated diet that excludes the functional food items present in the MFD.
1611766|NCT02148640|Drug|Innovator infliximab|
1611767|NCT02148640|Drug|Biosimilar infliximab|
1611768|NCT02148627|Drug|LY3041658 (SC)|Administered SC
1611769|NCT02148627|Drug|LY3041658 (IV)|Administered as slow IV infusion
1611770|NCT02148627|Drug|Placebo|Administered as slow IV infusion
1611771|NCT02148614|Drug|Placebo|Phase 1. Two tablets in a single preprandial dose Phase 2. Two tablets daily for 60 days
1611772|NCT02148614|Drug|Libramed|Phase 1. Two tablets in a single postprandial dose Phase 2. Two tablets daily for 60 days
1611773|NCT02148601|Other|Fecal Microbiota Transplantation|
1611774|NCT02148601|Drug|Standard Antibiotic Therapy|
1611775|NCT02148601|Drug|Vancomycin (before randomization)|Vancomycin will be administered in all patients for 5 days before randomization. Then, patients will be randomized in FMT Group or Standard Antibiotic therapy Group. Patients in the FMT Group will stop vancomycin 24 hours before the fecal microbiota transplantation. Patients in the Standard Antibiotic Therapy Group will continue vancomycin.
1611776|NCT02148588|Drug|Ultrasound-guided peripheral nerve block with 2% lidocaine|"Patients will have a peripheral nerve blockade with a local anesthetic (lidocaine)
Assessment of spontaneous and evoked pain responses
Completion of NPSI questionnaire
Mapping of the affected limb"
1611777|NCT02148575|Behavioral|Self-Management Group|
1611778|NCT02148575|Behavioral|Symptom Management Group|
1611779|NCT02148549|Drug|FIRINOX|FIRINOX regimen by eliminating LV and bolus 5-FU, and irinotecan reduced to 150mg/m2 of 180mg/m2 from FOLFIRINOX regimen.
1611780|NCT02148536|Procedure|Transjugular intrahepatic portosystemic shunt|
1611781|NCT02148523|Behavioral|Comparison to peers|
1611782|NCT02148523|Behavioral|Adherence feedback|
1611783|NCT02148523|Device|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
1611784|NCT02148510|Device|Monobloc|Construction fitted to upper and lower jaw
1611785|NCT02148510|Device|Bibloc|Biblock construction
1611786|NCT02148497|Procedure|Multi-colored Placido disk imaging|The multi-colored Placido disk instrument records the tear surface using video imaging.
1611787|NCT02148484|Behavioral|Prolonged Exposure for Adolescents|
1611788|NCT02148484|Behavioral|Client Centered Therapy|
1611789|NCT02148458|Other|Mediterranean diet|Mediterranean diet for 8 weeks, followed by 8 weeks of Mediterranean diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week)
1611790|NCT02148458|Other|Control group|control group eating their usual Western diet for 8 weeks, followed by 8 weeks of usual diet with intermittent fasting (i.e. 2 non-consecutive days of fasting per week).
1611791|NCT02148445|Other|Standard Smoking Cessation|Participants in the standard smoking cessation (SC) arm will receive a standard approach to smoking cessation, including smoking cessation counseling supplemented with 10 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) if they are willing to make a quit attempt.
1611792|NCT02148445|Other|Extended Nicotine Replacement Therapy|Participants in the guided maintenance therapy (GMT) arm will receive counseling focused on medication adherence and smoking reduction plus up to 52 weeks of combination nicotine replacement therapy (NRT) (nicotine patch plus choice of gum or lozenge) regardless of their interest in quitting.
1611793|NCT02148445|Drug|Nicotine replacement therapy|
1611794|NCT02148432|Drug|dexmedetomidine infusion rate, 0.5 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 0.5 mcg/kg/hr
1611795|NCT02148432|Drug|dexmedetomidine infusion rate, 1.0 mcg/kg/hr|continuous infusion of dexmedetomidine at rate of 1.0 mcg/kg/hr
1611796|NCT02148419|Other|no intervention|
1611797|NCT02148406|Behavioral|Yoga Skills Training (YST)|Undergo YST
1611803|NCT02148393|Procedure|Vitrification with subsequent-cycle embryo thawing/transfer|"The vitrification process will be performed under the same conditions of all other vitrification procedures usually performed in our centre. In summary, vitrification will be accomplished using closed high security straws (CryoBioSystem®) in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®).
In the meantime, patients will wait for a subsequent cycle before starting exogenous hormone therapy for endometrial preparation."
1611804|NCT02148393|Procedure|Intensified luteal phase support for fresh embryo transfer|A single administration of 1500 IU of exogenous hCG (Pregnyl®) 1 hour after oocyte retrieval followed by daily vaginally-administered progesterone 200 mg tid (Utrogestan®) and oestradiol valerate 2 mg bid (Progynova®).
1611805|NCT02148393|Drug|Pregnyl®|1500 IU
1611806|NCT02148393|Drug|Utrogestan®|200 mg tid
1611807|NCT02148393|Drug|Progynova®|2 mg bid
1611808|NCT02148393|Device|CryoBioSystem®|CryoBioSystem® in combination with dimethylsulfoxide, ethylene glycol and sucrose as cryoprotectants (Irvine ScientificR Freeze Kit®) closed in high security straws
1611809|NCT02148380|Drug|pemetrexed plus carboplatin|
1611810|NCT02148380|Drug|gefitinib|
1611811|NCT02148367|Drug|Erythropoietin|"This is a double blind randomized study. Randomization and blinding will be done by the NIH Pharmacy. Participants and study staff will be blinded as to group assignment.Participants randomized into the placebo group will receive placebo once weekly for 4 weeks. In total, 10 participants will be randomized in this group.
Participants randomized into the experimental group will receive active drug. In total, 20 participants will be randomized in this group. A clinic nurse or physician will administer the study drug, EPO or placebo, to the study participants at the Clinical Center. The study drug is administered by injection under the skin in the arm, leg, or buttock."
1611812|NCT02148354|Behavioral|Smiling is Fun|"Smiling is Fun is an internet-delivered self-help program for emotional disorders, which will allow the individual to learn and practice adaptive ways to cope with depression and daily problems. The program includes eight modules: Motivation for change, Understanding emotional problems; Learning to move on; Learning to enjoy; Learning to live; Living and learning and From now on, what else…?. Furthermore the program uses three transversal tools: 1) Activity report for self-monitoring, whose aim is to provide feedback to the user and help him see that his mood is related to the activities performed, 2) The calendar, and 3) How am I? offers a set of graphs and feedbacks to chart the user's progress."
1611813|NCT02148341|Other|Community of Practice Facilitation|
1611814|NCT02148341|Other|Usual Care|
1611815|NCT02148328|Biological|Trivalent virosomal influenza vaccine|Trivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
1611816|NCT02148328|Biological|Commercial vaccine 1|Trivalent commercial virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
1611817|NCT02148328|Biological|Quadrivalent virosomal influenza vaccine|Quadrivalent virosomal influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
1611818|NCT02148328|Biological|Commercial vaccine 2|Quadrivalent commercial influenza vaccine will be administered intramuscularly on Day 1 in healthy participants.
1611819|NCT02148315|Behavioral|garden|
1611820|NCT02148302|Device|Harvesting Device (CelluTome©)|Subjects who continue to meet eligibility criteria will be randomized to one of two groups: (1) Up to 3 applications of Epidermal grafting harvested utilizing the CelluTome® system at day zero, week 4 and week 8, visits plus standard of care (multi-layer compression) (2) Multilayer compression alone.
1611821|NCT02148289|Dietary Supplement|Nitrate rich beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
1611822|NCT02148289|Dietary Supplement|Nitrate free beverage|Following randomisation on day 1, subjects will consume either the nitrate or nitrate-free beverage and then the crossover beverage on day 8.
1611823|NCT02148263|Device|senofilcon A|
1611824|NCT02148250|Drug|U-500 insulin|Subjects are randomized to receive 100 or 200 syringe units of U-500 insulin. Subjects will receive opposite treatment after 4-8 weeks.
1611825|NCT02148237|Behavioral|Contingency Management|Participants in this condition will receive usual WIC care in addition to Contingency Management (CM). BF will be determined by direct observation.
1611826|NCT02148211|Other|Data collection|Initial and follow-up data will be collected using questionnaires.
1611827|NCT02148198|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
1611828|NCT02148198|Dietary Supplement|Placebo|A combination of sweetener + aroma, which was equal to the combination used in the intervention period was given as placebo comparator.
1611829|NCT02148185|Drug|MT-1303|
1611830|NCT02148172|Procedure|Standard Plyometric Training|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises.
1611831|NCT02148172|Procedure|Plyometric Training with BWS|Participants will undergo individualized practice exercises of jumping, hopping, and cutting tasks consistent with standard published exercises while their body weight is supported via adjustable harness.
1611832|NCT02148159|Device|Cachexia Acupuncture-A (Peace Classic Needles® )|Acupuncture-A group will receive acupuncture in a pre-determined set of the acupuncture points.
1611833|NCT02148159|Device|General Acupuncture-B (Peace Classic Needles®)|Acupuncture-B group will receive acupuncture in a pre-determined set of the acupuncture points.
1611834|NCT02148146|Drug|Omegaven|Fish oil emulsion given 1g/kg/day as infusion
1611835|NCT02148133|Drug|Eltrombopag 12.5 mg|White, round, film-coated tablets containing 12.5 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
1611836|NCT02148133|Drug|Eltrombopag 25 mg|White, round, film-coated tablets containing 25 mg of eltrombopag free acid (SB-497115-GR, eltrombopag) in each tablet
1611837|NCT02148120|Drug|Beclometasone Dipropionate 100 µg + Formoterol Fumarate 6 µg|
1611838|NCT02148120|Drug|Beclometasone Dipropionate 200 µg + Formoterol Fumarate 6 µg|
1611839|NCT02148120|Drug|Placebo|
1611840|NCT02148107|Drug|BI 691751|BI 691751 Dose 1
1611841|NCT02148107|Drug|BI 691751|BI 691751 Dose 2
1611842|NCT02148107|Drug|BI 691751|BI 691751 Dose 3
1611847|NCT02148094|Drug|Truvada|The demonstration project will use a prospective cohort design, enrolling individuals and following them up at multiple intervals over the course of 16 months. Study participants will be asked to take one tablet of Truvada daily, as HIV Pre-Exposure Prophylaxis, over this period. They will be asked to attend 7 regular visits at the project sites over the course of the project. In between visits, they will receive peer educator home visits every other day, as part of regular DMSC (Kolkata) and Ashodaya (Mysore/Mandya) outreach prevention activities. We plan to enroll 2000 female sex workers equally split between the two sites.
1611848|NCT02148068|Procedure|Bariatric Surgery|Patients enrolled will undergo either a laparoscopic Roux-en-y Gastric Bypass or laparoscopic Sleeve Gastrectomy. The determination of which operation performed will be made independent of patients' enrollment in the study.
1611849|NCT02148055|Other|Comparaison between MR and autopsy in the macroscopic evaluation of intra uterine death.|
1611850|NCT02148029|Other|Exercise|Upper and Lower extremity exercise
1611851|NCT02148029|Other|Control|Standard care: anticoagulation, compression & ad-lib ambulation
1611852|NCT02148016|Procedure|LSCs and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following removal of scar tissue due to chemical injury or pterygium. The contact lens will then be covered with amniotic membrane to secure it in place.
The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
1611853|NCT02148016|Procedure|Amniotic membrane only (Traditional Technique)|Amniotic membrane alone will be used to cover the corneal surface, after removal of scar tissue from a chemical injury or pterygium.
1611854|NCT02148016|Procedure|PRK, LSCs, and amniotic membrane (Modified Technique)|"Limbal stem cells (LSCs) from the contralateral eye will be harvested and expanded in feeder-free, chemically defined media for one week on a collagen-coated contact lens. The LSCs on contact lens will be transplanted onto a corneal surface in vivo, following photo-refractive keratectomy (PRK). The contact lens will then be covered with amniotic membrane to secure it in place.
The eye will be treated with antibiotics (levofloxacin) and steroids (betamethasone), and then patched."
1611855|NCT02148016|Procedure|PRK only (Traditional Technique)|PRK alone will be performed.
1611856|NCT02148016|Drug|Levofloxacin|
1611857|NCT02148016|Drug|Betamethasone|
1611858|NCT02148016|Drug|Limbal stem cells (LSCs)|
1611859|NCT02148003|Procedure|RFA at 90 degrees Celsius|Ablation at 90 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 90 degrees Celsius
1611860|NCT02148003|Procedure|RFA at 80 degrees Celsius|Ablation at 80 degrees Celsius is defined as radiofrequency ablation of the lumbar facets nerve supply will be performed at 80 degrees Celsius
1611861|NCT02148003|Device|C-arm guided 20-gauge radiofrequency needle|Needles will be adjusted to optimize sensory and motor stimulation.
1611862|NCT02147990|Drug|Rociletinib|Rociletinib will be administered to patients orally
1611863|NCT02147977|Dietary Supplement|dietary supplement: n-3 PUFA|
1611864|NCT02147977|Dietary Supplement|olive oil|
2010287|NCT03029611|Procedure|Gynecological Surgical Procedure|Undergo cytoreductive surgery
2010288|NCT03029611|Other|Laboratory Biomarker Analysis|Correlative studies
2010289|NCT03029611|Drug|Paclitaxel|Given IV
2010290|NCT03029611|Biological|pUMVC3-hIGFBP-2 Multi-Epitope Plasmid DNA Vaccine|Given ID
2010291|NCT03029416|Radiation|Stereotactic Body Radiation Therapy|Stereotactic Body Radiation Therapy using different fractionation schedules
2010292|NCT03027154|Biological|ESAT6-CFP10 in left arm and TB-PPD in right arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
2010293|NCT03027154|Biological|ESAT6-CFP10 in right arm and TB-PPD in left arm|All subjects including TB subjects in 5-18 years old、non-TB subjects in 5-18 years old、TB subjects under 5 years old and non-TB subjects under 5 years old inject ESAT6-CFP10 in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
1611872|NCT02147951|Drug|Talimogene Laherparepvec|Up to 4ml of talimogene laherparepvec per cycle visit
1611873|NCT02147938|Drug|Tacrolimus|oral
1611877|NCT02147912|Other|Aerobic Exercise|Aerobic exercise intervention consists of lower (treadmill and cyclette) and upper arts (arm ergometer Davenbike®) training, as well as calisthenic exercises with increasing intensity from a minimum of 80% to a maximum workload for lower arts in a minimum time.
1611878|NCT02147899|Drug|SYM-1219|
1611879|NCT02147899|Drug|Placebo|
1611880|NCT02147886|Drug|Cabaletta for IV infusion once weekly during 24 weeks|Cabaletta for IV infusion once weekly
1611881|NCT02147886|Drug|Cabaletta for IV infusion once weekly during 24 weeks|
1611882|NCT02147873|Drug|birinapant|
1611883|NCT02147873|Drug|Azacitidine|
1611884|NCT02147873|Drug|Placebo|
1611885|NCT02147860|Device|Diabetes Assistant (DiAs) with USS Virginia|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
1611886|NCT02147860|Other|Sensor Augmented Pump Therapy|Subjects randomized to this placebo group will wear a continuous glucose monitoring system (CGM) to measure sensor glucose and a physiological monitor to measure heart rate and 3-axis accelerometer for 24-72 hours.
1611887|NCT02147847|Behavioral|Video game based training 1|32 one-hour, home-based training sessions over 8 weeks
1611888|NCT02147847|Behavioral|Video game based training 2|32 one-hour, home-based training sessions over 8 weeks
1611889|NCT02147834|Drug|Ranolazine|"Ranolazine 500mg tablet
500mg tablet two times per day for 7 days then,
500mg tablet (1000mg) two times per day for 15 weeks"
1611890|NCT02147834|Drug|Sugar pill|"sugar pill manufactured to mimic ranolazine 500mg tablet
500mg tablet two times per day for 7 days then,
500mg tablet (1000mg) two times per day for 15 weeks"
1611892|NCT02147808|Drug|Telotristat etiprate|All subjects will receive two 250 mg telotristat etiprate tablets three times daily.
1611893|NCT02147808|Drug|Midazolam|All subjects will receive 3 mg (1.5 mL oral syrup [2mg/mL]).
1611894|NCT02147769|Device|NIRS monitoring|All enrolled infants will undergo NIRS monitoring of cerebral oxygenation in addition to monitoring of continuous arterial blood pressure.
1611895|NCT02147756|Device|CO2RE|"Subjects will be randomly assigned to three different time-points of laser treatment: immediately, 1 week or 4 weeks prior the scheduled abdominoplasty. Subjects will be required to attend between 2 to 3 visits depending on the interval between the treatment and the abdominoplasty procedure. One side of the abdomen will be treated using the CO2RE device and the other side with the RePair device. The investigator will also leave an untreated area (control).
Punch biopsies will be obtained before or during the abdominoplasty procedure from the two treated areas (CO2RE and RePair) and one control (un-treated) areas (on the abdominoplasty area) for histological evaluation."
1611896|NCT02147756|Device|Repair|
1611897|NCT02147743|Behavioral|CCP+MDFT|Multidimensional Family Therapy (MDFT; Liddle, 2002) is one of a new generation of multi-systems oriented family-based intervention for adolescent substance abuse and delinquency. It has demonstrated considerable success with juvenile justice youth at various stages of their involvement in the justice system. The model has demonstrated efficacy in reducing substance use and delinquency, increasing the prosocial behaviors (e.g., family functioning, school outcomes) of substance abusing and court involved adolescents.
1611898|NCT02147743|Behavioral|CCP+SAU|Services As Usual community partners will provide individualized mental health counseling and psychiatric services, psychoeducational groups and substance abuse counseling.
1611899|NCT02147730|Procedure|regional anesthesia|all patients receiving a regional anesthesia/analgesia technique
1611900|NCT02147730|Procedure|non-regional anesthesia|all patients receiving other-than-regional anesthesia techniques
1611901|NCT02147717|Device|Laser stimulation|"Infants will be divided in 2 groups:
Placebo group: Placebo (fake laser stimulation) plus opioid treatment before ETS
Experimental group: Laser stimulation plus opioid treatment before ETS. Low level laser acupuncture, 670 nm, 10Hz, 0,3 J per acupoint, 6 points per neonate (Zu san li, He Gu, Nei Guan) marquage CE, premio 30 laser duo de Sedatelec. Overall 3 minutes of treatment.
This sequence will be repeated 4 times during the study (1 hour before surgery and every 12 hours after surgery)"
1611902|NCT02147717|Device|Fake laser stimulation|newborns have the same preparation procedure as the intervention to put them under the same conditions group. The laser pen is turned off, off-voltage
1611903|NCT02147704|Dietary Supplement|High-sodium diet|"One of high- or low sodium intake for 7 days during each period
High sodium intake: 50 mmol/day by diet + 250 mmol/day by salt tablets"
1611904|NCT02147704|Dietary Supplement|low-sodium diet|"One of high- or low sodium intake for 7 days during each period
Low sodium intake : 50 mmol/day by diet"
1611905|NCT02147691|Drug|Azelaic acid 15%|Applied to the face each AM and PM
1611906|NCT02147691|Drug|Brimonidine 0.33%|Applied to the face each AM 30 minutes after the application of Azelaic acid 15%
1611907|NCT02147678|Drug|Etomidate|
1611908|NCT02147678|Drug|Propofol|
1611909|NCT02147678|Drug|Remifentanil|During anesthesia maintenance, all patients will be given remifentanil at the speed of 0.2~0.4 μg/kg/min.
1611910|NCT02147678|Drug|Anesthesia induction|For all patients, the induction protocol is midazolam 0.1 mg/kg, sufentanil 0.3 μg/kg, cisatracurium 0.15 mg/kg.
1611911|NCT02147665|Other|Hookah smoking|Subjects will smoke waterpipe in a controlled research environment.
1611912|NCT02147652|Other|Personalized music|
1611913|NCT02147639|Dietary Supplement|Sodium Nitrate|
1611914|NCT02147639|Dietary Supplement|Sodium Nitrate - double dose|
1611915|NCT02147639|Dietary Supplement|Placebo|
1611916|NCT02147639|Procedure|Increased exercise intensity|
1611917|NCT02147626|Behavioral|Web-based educational and motivational modules|
1611918|NCT02147626|Behavioral|Information and Screening Group|
2010294|NCT03026790|Other|Medication management|Individualized management of medications for pain
2010295|NCT03026790|Other|Non-pharmacological pain management|Individualized management of non-medication pain treatment approaches
2010296|NCT03026790|Drug|Buprenorphine-Naloxone|Option of using buprenorphine-naloxone to assist with opioid dose reduction or discontinuation
2010297|NCT03026114|Other|No intervention is planned in our study.|No intervention is planned in our study.
2010298|NCT03027128|Biological|haNK™ for Infusion|haNK™ for Infusion is a human, allogeneic, NK cell line that has been engineered to produce endogenous, intracellularly retained IL-2 and to express CD16, the high-affinity (158V) Fc gamma receptor (FcγRIIIa/CD16a).
1611924|NCT02147561|Biological|botulinum toxin Type A|Botulinum toxin Type A injected across specific head and neck muscles on Day 0.
1611925|NCT02147548|Drug|etifoxine|
1611926|NCT02147548|Drug|lorazepam|
1611927|NCT02147548|Drug|Placebo|
1611928|NCT02147535|Drug|Methylphenidate|10 mg as a single dose followed by one blood sample 3 hours post-dose
1611929|NCT02147522|Behavioral|Self-care management|AHH behavioral intervention is provided by promotoras
1611930|NCT02147509|Drug|0.02% Fm, SH|Sjogren's Syndrome patients with severe dry eye
1611931|NCT02147509|Drug|0.02% Fm, SH, 0.05% CsA|Sjogren's Syndrome patients with severe dry eye
1611932|NCT02147509|Other|0.02% Fm, SH, tBCL|Sjogren's Syndrome patients with severe dry eye
1611933|NCT02147509|Drug|0.02% Fm, SH, AS|Sjogren's Syndrome patients with severe dry eye
1611934|NCT02147496|Other|Dietary Intervention|
1611935|NCT02147483|Behavioral|Mindfulness Based Relapse Prevention|Mindfulness based relapse prevention therapy provided over eight sessions in person to prevent alcohol relapse.
1611936|NCT02147483|Behavioral|Treatment as usual|Treatment usually provided by clinician
2010299|NCT03024645|Behavioral|Be A Mom|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential.
1611937|NCT02147470|Drug|Definity ultrasound contrast agent|All subjects will undergo CEUS of the kidney at baseline to measure renal blood flow. This procedure will be repeated after volume expansion and if indicated, once again after treatment with albumin, midodrine and octreotide.
1611938|NCT02147431|Drug|semaglutide|"2 periods of 12 weeks of once weekly dosing with multiple doses of semaglutide, for subcutaneous (s.c., under the skin) injection, escalated up to 1.0 mg semaglutide.
Each treatment period will be followed by a hypoglycaemic clamp"
1611939|NCT02147431|Drug|placebo|"2 periods of 12 weeks of once weekly dosing, subcutaneous (s.c., under the skin) injection.
Each treatment period will be followed by a hypoglycaemic clamp."
1611940|NCT02147392|Drug|[11C]ER-176|
1611941|NCT02147379|Drug|Lurasidone|
1611942|NCT02147366|Behavioral|Music & lifestyle changes|Music intervention involved listening to raga bhimpalas played on bansuri/flute (an Indian instrument) for 15 minutes daily for 3 months.
1611943|NCT02147366|Behavioral|Lifestyle|Lifestyle intervention was based on Joint national committee VII guidelines for hypertension
1611946|NCT02147301|Device|LC Bead|"Doxorubicin Eluting Bead Transarterial Chemoembolization (DEB-TACE):
Doxorubicin-loaded LC Beads® are administered via a co-axially placed commercially available hepatic artery catheter into hepatic arteries targeted for treatment. Procedure is performed under direct fluoroscopic visualization until stasis of arterial flow is achieved or until a total of 4 ml of microspheres have been administered, whichever occurs first."
1611947|NCT02147288|Device|Renasys*GO Negative Pressure Wound Therapy System|Continuous, mechanical negative pressure wound therapy applied to drain in the immediate post-operative period (vs standard, closed-suction JP drains).
1611948|NCT02147262|Drug|doxycycline orally, 100 mg, bid, 14 days|
1611949|NCT02147262|Drug|doxycycline orally, 100 mg, bid, 28 days|
1611950|NCT02147249|Drug|antibiotic treatment|Patient will be treated with: doxycycline orally, 100 mg, bid, 14 days or cefuroxime axetil orally, 500 mg, bid, 14 days or amoxicillin orally, 500 mg, tid, 14 days
1611951|NCT02147236|Behavioral|Social Skills Training|
1611952|NCT02147223|Dietary Supplement|Flavanol rich intervention|Flavanol intervention products (250 mg, 500 mg and 750 mg flavanols)
1611953|NCT02147223|Dietary Supplement|Flavanol free intervention|Calorically, micro- and macronutrient matched control product free of flavanols
1611954|NCT02147210|Other|biological analysis|
1611955|NCT02147197|Drug|Ulipristal acetate 5 mg|
1611956|NCT02147197|Drug|Ulipristal acetate 10 mg|
1611957|NCT02147197|Drug|Placebo|
1611958|NCT02147171|Dietary Supplement|VisionAce|
1611959|NCT02147171|Dietary Supplement|Placebo|
1611960|NCT02147158|Drug|Ulipristal acetate (UPA) 5 mg|
1611961|NCT02147158|Drug|Ulipristal acetate (UPA) 10 mg|
1611962|NCT02147158|Drug|Placebo|
1611963|NCT02147132|Drug|Nicotine Nasal Spray|7 days. 1 mg/dose, up to 40x/day.
1611964|NCT02147132|Drug|Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily.
1611965|NCT02147132|Drug|Placebo Nasal Spray|7 days. 1 mg/dose, up to 40x/day.1 mg/dose, up to 40x/day. This will appear similar to the Nicotine Nasal Spray, but will be a placebo.
1611966|NCT02147132|Drug|Placebo Varenicline|14 days. Days 1-3: 0.5 mg once daily; Days 4-7: 0.5 mg twice daily; Days 8-14: 1 mg twice daily. This will appear identical to the drug Varenicline, but will be a placebo.
1611967|NCT02147119|Procedure|Coronary angiography|
1611968|NCT02147106|Other|Videoconsultation|
1611969|NCT02147093|Device|Test (multi-focal)|contact lens was to be worn a daily wear.
1611970|NCT02147093|Device|Control (Sphere)|contact lens was to be worn a daily wear with spectacles
1611971|NCT02147080|Behavioral|UV4me|Tailored website includes: personalized responses to quizzes, information on skin type and burn risk, UV damage photo of similar individual, avatar activity, age progression images, personal risk calculator, SPF (sun protection factor) calculator
1611972|NCT02147080|Behavioral|Skin Cancer Foundation website|Current best practice website for skin cancer and prevention. Includes information, images, news, and opportunities for advocacy.
1611973|NCT02147067|Drug|Ranolazine|Ranolazine 1,000 mg twice daily
1611974|NCT02147067|Drug|Placebo|Placebo
1611975|NCT02147054|Drug|Rocuronium|
1611976|NCT02147054|Drug|Sugammadex|Effect of Rocuronium will be reversed at the appropriate time using Sugammadex 16mg/kg as a single dose which may be repeated once.
1611977|NCT02147041|Drug|EGCG(Epigallocatechin Gallate)|500mg, three times a day, duration:12 weeks
1611978|NCT02147041|Drug|Placebo|
1611979|NCT02147028|Radiation|Hippocampal sparing whole brain radiotherapy|30 Gy in 10 fractions hippocampal sparing whole brain radiotherapy will be administered by Helical Tomotherapy, IMRT, or VMAT
1611980|NCT02147028|Radiation|Conventional whole brain radiotherapy|30 Gy in 10 fractions conventional whole brain radiotherapy will be administered
1611981|NCT02147015|Drug|Glucocorticoids|
1611982|NCT02147015|Drug|Antibiotics|
1611983|NCT02147015|Drug|Inhaled corticosteroid (ICS)|
1611984|NCT02147015|Drug|Long-Acting Muscarinic Antagonists(LAMA)|
1611985|NCT02147015|Drug|Short-acting beta2-agonist (SABA)|
1611986|NCT02147015|Other|Physical treatments|
1611987|NCT02147015|Drug|long-acting beta2-agonist (LABA)|
1611988|NCT02147002|Dietary Supplement|Gold omega 3|At the beginning and at the end of the observation period, besides the clinical test, some other tests will be carried out: echocardiography, pulse wave velocity (PWV), ambulatory blood pressure monitoring (ABPM). Blood will be collected for laboratory tests such as: lipid profile, uric acid, CRP, BUN, creatinine, morphology, Ca, P, Ca x P, ionogram, xanthine oxidase, MPC1,Omega-3 acids, resolvin and protectins - the metabolites of Omega-3 acids, creatinine excretion, MPC1 excretion and excretion of uric acid.The patients will be treated with Omega-3 acids as a Gold Omega 3 preparation (2x1 capsule where 1 capsule = 1000 mg) for 6 months.
1611989|NCT02146989|Other|reproducibility of upper extremity strength measurements|inter-rater reliability and test-retest reliability
1611990|NCT02146976|Drug|propofol|introvenious infusion of propofol
1611991|NCT02146976|Drug|sevoflurane|sevoflurane (1.0-1.3 Minimum Alveolar Concentration)
1611992|NCT02146937|Drug|Bicalutamide plus Finasteride- Combination therapy|3-month (90-day) course of bicalutamide 50 mg by mouth daily and finasteride 5 mg by mouth daily
1611996|NCT02146911|Drug|Bupropion|
1611997|NCT02146911|Drug|Varenicline|
1611998|NCT02146911|Behavioral|Weekly Motivational Emails|The e-mails will include tips on several things other than the medications that participants can do to help them quit smoking. The contents of the emails will vary from week to week. The e-mails will provide tips on ways to create an atmosphere that promotes quitting and staying abstinence. They will also include recommendations on how to address issues with withdrawal symptoms and cravings. In addition, they will provide positive motivational messages by stating facts on benefits of quitting smoking.
1611999|NCT02146898|Other|Position|
1612000|NCT02146885|Other|Weight Control|Weight Control
1612001|NCT02146846|Drug|Imatinib|Patients with chronic myeloid leukemia who receive Imatinib as treatment
1612002|NCT02146833|Drug|Selinexor|Comparison of different dosages and dosing schedules of drug.
1612003|NCT02146820|Device|GentleMax system|Picosecond Laser System for the Treatment of Pigmented Lesions
1612004|NCT02146807|Device|Picosecond Laser system|Picosecond Laser System for the Treatment of Unwanted Tattoos
1612005|NCT02146794|Device|Renal denervation|Renal denervation
1612006|NCT02146781|Biological|CryJ2-DNA-LAMP plasmid vaccine by intradermal injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.
Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intradermal injection using the Biojector 2000 devibe."
1612007|NCT02146781|Other|Saline Control|The subjects in Cohort 1 will receive four doses of saline control 14 days apart, beginning Day 0. Each dose will be delivered as four separate injections of 0.200 mL volumes administered Intradermally (ID) using the needless Biojector 2000 device in separate skin sites. The use of the four 0.200 mL volumes is necessitated in order to compare the skin test sites to the number of sites in Cohorts 2 (4 sites per dose) and Cohort 3 (2 sites per dose). The multiple intradermal administration sites per dose are because of the dilute vaccine material (2.7 mg/mL).
1612008|NCT02146742|Drug|ASP1707|oral
1612009|NCT02146742|Drug|Placebo|oral
1612010|NCT02146729|Procedure|Percutaneous Pedicle Screw Fixation|Percutaneous Pedicle Screw Fixation
1612011|NCT02146729|Procedure|Open Treatment|Midline posterior incision with instrumentation.
1612012|NCT02146716|Other|Energetic Resonance by Cutaneous Stimulation|Energetic Resonance by Cutaneous Stimulation (RESC) is a non-invasive method based on energetic Chinese medicine principles and digital contact. RESC is characterized by echo phenomena between two stimulation points.
1612013|NCT02146703|Drug|Gemcitabine, and S-1|"Treatment will be delivered as a 3-week cycle.
Gemcitabine 1000 mg/m2 iv on day 1, 8
S-1 60 mg/day po on day 1-14"
1612014|NCT02146690|Other|osteopathic manipulative treatment|
1612015|NCT02146690|Other|sham therapy|
1612016|NCT02146690|Other|usual care|
1612017|NCT02146677|Other|Osteopathic manipulative treatment|
1612018|NCT02146677|Other|Sham therapy|
1612019|NCT02146677|Other|Usual care|
1612020|NCT02146664|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
1612021|NCT02146664|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy which consists of: aspirin enteric-coated tablet 1 x 160 mg (two tablets @ 80 mg) and clopidogrel film-coated tablet 1 x 75 mg daily for eight weeks. Standard therapy alone will still be given afterwards, for another sixteen weeks
1612022|NCT02146651|Drug|BioChaperone insulin lispro 0.2U/Kg|Single dose of 0.2U/Kg body weight injected subcutaneously
1612023|NCT02146651|Drug|BioChaperone insulin lispro 0.1U/Kg|Single dose of 0.1U/Kg body weight injected subcutaneously
1612024|NCT02146651|Drug|BioChaperone insulin lispro 0.4U/Kg|Single dose of 0.4U/Kg body weight injected subcutaneously
1612025|NCT02146651|Drug|Humalog®|Single dose of 0.2U/Kg body weight injected subcutaneously
1612026|NCT02146638|Drug|Morphine|
1612027|NCT02146638|Drug|Fentanyl|
1612028|NCT02146625|Drug|CJ-40002|
1612029|NCT02146612|Other|Amino Acid Supplement Group|Group receiving nutritional supplement
1612030|NCT02146599|Other|Administration of patient self-assessment|
1612031|NCT02146573|Behavioral|Continuity Care Intensivist Communication Training|Physicians enrolled in the intervention arm will complete a two to three part communication training. Survey measures of communication competency and burnout will be administered at baseline, after training, and at the end of the study. After the communication training, physicians will undergo an OSCE assessment with a simulated patient to evaluate communication skills. At the end of the study, CCI providers will receive surveys that assess the experience and challenges of the role, repeat surveys assessing competency with communication and frequency of engaging families in goals of care conversations, in addition to a follow-up focus group that will assess their experience with the intervention, the time required and the potential tradeoffs in other duties required by them to participate as a CCI.
1612070|NCT02146339|Other|Cheese n°3- cheese n°2 - cheese n°1|"Each subject will receive a single dose of cheese n°3, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
1612107|NCT02146053|Dietary Supplement|ferrous sulfate|ferrous sulphate (200 mg capsules containing 65 mg of iron) to be taken at mealtimes twice daily for 7 days during the treatment period.
1612032|NCT02146573|Behavioral|Continuity Care Intensivist (CCI) Provider Program|"After undergoing CCI training, CCI providers will fulfill a standardized role with parent-patient dyads:
CCI will meet with families on a regular basis and at change of physician of record throughout their entire PICU hospitalization.
Help patients/families navigate decisions in concert with preferences and beliefs
Help patients/families and other care providers look at bigger picture; trajectory of illness, goals, and hopes for the patient.
Serve as point person for active intensivists on service and other specialists
Help resolve conflict when multiple providers have different opinions on course of action"
1612033|NCT02146547|Drug|Aripiprazole|Administration in once-a-day schedule without regard to meals.
1612034|NCT02146547|Drug|Aripiprazole depot|Abilify Maintena is an intramuscular (IM) depot formulation of oral aripiprazole. It provides the efficacy and safety profile of oral aripiprazole in a once-monthly injection.
1612035|NCT02146547|Drug|Paliperidone|Administration once a day orally standardised in relation to food intake.
1612036|NCT02146547|Drug|Paliperidone palmitate|In selected patients with schizophrenia and previous responsiveness to oral paliperidone or risperidone, Xeplion may be used without prior stabilization with oral treatment if psychotic symptoms are mild to moderate and a long-acting injectable is needed.
1612037|NCT02146534|Drug|extended release fampridine|pts will receive Fampyra 10 mg BID PO for the duration of the study
1612038|NCT02146534|Drug|Placebo|placebo will be taken PO BID
1612039|NCT02146508|Procedure|Endoscopic Mucosal Resection (EMR)|Endoscopic removal of regions of ESD.
1612040|NCT02146508|Device|Radiofrequency ablation|Endoscopic radiofrequency ablation of regions of ESD
1612041|NCT02146495|Device|EEG-NF|
1612042|NCT02146482|Other|Sit-stand computer workstation|A sit-stand computer workstation allows one to sit or stand throughout the day while maintaining continued use of one's computer.
1612043|NCT02146469|Biological|2 doses with an 3 months interval|varicella vaccination
1612044|NCT02146469|Biological|A second dose with an 1 year interval|varicella vaccine
1612045|NCT02146469|Biological|A second dose with an 3 year interval|varicella vaccine
1612046|NCT02146469|Biological|A second dose with an 5 year interval|varicella vaccine
1612047|NCT02146469|Biological|1 dose Varicella vaccine and 1 dose MMR given at the same time|varicella vaccine and MMR
1612048|NCT02146469|Biological|1 dose MMR|MMR
1612049|NCT02146456|Drug|Tranexamic Acid|
1612050|NCT02146443|Other|Stretched arm test|Measurement of static arm strength. Test subject is asked to hold a 2.5 kg weight in their dominant arm fully extended at 90-degree flexion and 15-degree abduction as long as possible without moving.
1612051|NCT02146443|Other|Stress|During completion of the star shaped manual dexterity test, the test subject is asked to identify cards from a regular deck of playing card by naming the suit and rank of the card. They will be asked to identify one random card during each of the 10 rounds in the completion of the test
1612052|NCT02146443|Device|Star shaped manual dexterity test|On a piece of wood, a piece of metal (dimensions 22 cm x 22 cm) is mounted. In the center of the metal plate, is a star shaped track. The star has 6 points and the track is 9 mm wide. It measures 15,3 cm from the tips of opposing arms of the star. With a surgical scissor in his dominant hand, the test subject is instructed to follow the star shaped track ten times, five times clockwise and five times counter clockwise. Contact with the border of the track is counted as an error. A computer software program automatically registers completion time and number of errors. The test is conducted in an undisturbed environment.
1612056|NCT02146417|Procedure|Low pressure pneumoperitoneum|
1612057|NCT02146417|Procedure|Normal pressure pneumoperitoneum (12 mmHg)|
1612058|NCT02146417|Procedure|Deep neuromuscular block|
1612059|NCT02146404|Other|hypoglycemia|Blood glucose levels will be kept at ~3.0 mmol/l
1612060|NCT02146404|Other|euglycemia|Blood glucose levels will be kept at ~5.0 mmol/l
1612061|NCT02146391|Drug|Androxal 25 mg Capsules|
1612063|NCT02146365|Procedure|nasopharyngeal swab|
1612064|NCT02146352|Device|AXIOS Stent with Electrocautery Enhanced Delivery System|Endoscopy with ultrasonography to implant AXIOS stent using electrocautery enhanced delivery system to allow drainage of pancreatic pseudocyst. Removal of AXIOS stent after 30 or 60 days.
1612065|NCT02146339|Other|Cheese n°1- cheese n°2 - cheese n°3|"Each subject will receive a single dose of cheese n°1, then cheese n°2 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
1612066|NCT02146339|Other|Cheese n°1- cheese n°3 - cheese n°2|"Each subject will receive a single dose of cheese n°1, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
1612067|NCT02146339|Other|cheese n°2 - cheese n°1- cheese n°3|"Each subject will receive a single dose of cheese n°2, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°3 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
1612068|NCT02146339|Other|Cheese n°2- cheese n°3 - cheese n°1|"Each subject will receive a single dose of cheese n°2, then cheese n°3 after a wash-out period of 4 weeks, then cheese n°1 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
1612069|NCT02146339|Other|Cheese n°3 - cheese n°1- cheese n°2|"Each subject will receive a single dose of cheese n°3, then cheese n°1 after a wash-out period of 4 weeks, then cheese n°2 after a wash-out period of 4 weeks.
Cheese n°1 = unfortified cheese product Cheese n°2 = 3 g milk polar lipid fortified cheese product Cheese n°3 = 5 g milk polar lipid fortified cheese product"
1612106|NCT02146066|Biological|DCVax-L|Autologous Dendritic Cells Pulsed with Tumor Lysate Antigen
1612071|NCT02146326|Behavioral|Motivational Interviewing (MI)|MI is a common counseling technique. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to MI. Each session occurred approximately one month apart.
1612072|NCT02146326|Behavioral|Burnout Reduction: Enhanced Awareness, Tools, Handouts, and Education (BREATHE)|BREATHE is a program developed to attempt to improve or prevent the symptoms of burnout. It was offered as an 8-9 hour workshop across 3 sessions to mental health agency staff who were randomly assigned to BREATHE. Each session occurred approximately one month apart.
1612074|NCT02146300|Biological|1. session birch pollen nasal exposure 2. session xylometazoline nasal exposure|Aquagen SQ 10 000 SQ/ml nasal exposure Xylometazoline 1 mg/ml nasal exposure
1612075|NCT02146287|Other|Cycled Light|"Cycled light was provided in an 11-hour-on, 11-hour-off pattern. Daylight (240-700 lux) was provided with the incubator cover folded on top of the incubator allowing light in from four sides, or with the bassinet cover off during day hours (0730-1830). With the daylight range of 240-700 lux and limited access to natural light, excessive daylight was prevented.
Continuous near darkness was provided as (5-30 lux) throughout the day except from 0630-0730 and 1830-1930, when lighting levels varied based on nursing care needs at the change of shift. Near-darkness (5-30 lux) was provided by using incubator (totally covered or with the front flap back) and bassinet covers, and dimming individual bedside light during the day (0730-1830) and night hours (1930-0630)."
1612076|NCT02146261|Drug|E6011|Subcutaneous administration of E6011 (at doses of 50, 100, 200 and 400 mg)
1612077|NCT02146261|Drug|Placebo|Subcutaneous administration of placebo
1612078|NCT02146248|Drug|combined oral contraceptive|combined oral contraceptive pill will be dosed continuously for 30 days without cycle interruption
1612079|NCT02146248|Drug|DepoProvera|injectable hormonal contraceptive
1612080|NCT02146235|Behavioral|Psycho-Music Therapy|
1612081|NCT02146222|Drug|VEGFR/PDGFR dual kinase inhibitor X-82|Given PO
1612082|NCT02146222|Drug|docetaxel|Given IV
1612083|NCT02146222|Other|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
1612084|NCT02146222|Procedure|positron emission tomography/computed tomography|Undergo FLT PET/CT
1612085|NCT02146222|Other|pharmacological study|Correlative studies
1612086|NCT02146222|Other|laboratory biomarker analysis|Correlative studies
1612087|NCT02146209|Drug|Metronidazole benzoate|Single oral dose of 400 mg
1612088|NCT02146209|Drug|Flagyl 125 mg/5 ml oral suspension|Single oral dose of 500 mg (20 ml suspension)
1612089|NCT02146209|Drug|Flagyl 400 mg Tablets|Single oral dose of 400 mg
1612090|NCT02146196|Device|4 weeks robotic assisted training with the Lokomat®|During a prespecified time period (4weeks) a three times weekly robotic assisted gait training during 30-45 minutes. Strength training, interval training and endurance training are possible.
1612091|NCT02146196|Device|One week robotic assisted gait training with the Lokomat®|During a prespecified time period (1week) a three times weekly robotic assisted gait training during 10-40 minutes. Strength training, interval training and endurance training are possible
1612092|NCT02146183|Dietary Supplement|Carbohydrate steviol glycosides|To investigate if intake of stevioside in addition to a carbohydrate-containing composition after work related depletion of muscle glycogen will increase the rate of glycogen re-synthesis as compared with intake of the carbohydrate-containing composition alone.
1612093|NCT02146183|Dietary Supplement|Placebo Corn Starch|500 mg/day
1612094|NCT02146157|Dietary Supplement|herb and mineral combination product|herb and mineral product containing cinnamon, turmeric and holy basil
1612095|NCT02146157|Dietary Supplement|Placebo|Placebo of herb and mineral product containing cinnamon, turmeric and holy basil
1612096|NCT02146144|Procedure|ILM Peeling|"common surgical procedure:
For phakic eyes with cataract • phacoemulsification and implantation of a posterior chamber intraocular lens
For all patients:
Central and peripheral 25 Gauge vitrectomy
dissection of the epimacular membrane
injection of Membraneblue-Dual® according to protocol, wait of 1 minute with the infusion line closed, and then suction of surplus and washing of the vitreous cavity
Intraoperative picture to see the possible spontaneous ILM peeling
If no spontaneous ILM peeling, the patient will be randomized at the operating block
Specific surgical procedure:
• • Randomization into two groups:
Arm 1: no peeling, where the ILM peeling will not be made
Arm 2: active peeling, where the ILM peeling will be made"
1612097|NCT02146131|Device|Standard FB with fluoroscopy|Technique used, to go through the patient's airway, locate and obtain samples from pulmonary lesions
1612098|NCT02146131|Device|R-EBUS with ultrathin bronchoscope|Technique used to go through the patient's airway and using radial ultrasound, locate and obtain samples from pulmonary lesions
1612099|NCT02146118|Drug|Erlotinib|Erlotinib 150 mg/day q 4 weeks
1612100|NCT02146118|Dietary Supplement|Silybin-phytosome|Silybin-phytosome 1g bid/day q 4 weeks
1612101|NCT02146105|Other|Yoga For Knee Osteoarthritis|Yoga program specifically for women with knee osteoarthritis.
1612102|NCT02146092|Procedure|Incentive spirometry|
1612103|NCT02146092|Other|Physiotherapy|Standard of care exercise training and supervision
1612104|NCT02146079|Drug|semaglutide|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule
1612105|NCT02146079|Drug|placebo|Subjects will be randomised to receive either semaglutide 0.5 mg, semaglutide 0.5 mg placebo, semaglutide 1.0 mg or semaglutide 1.0 mg placebo within each group. Treatment with active drug or placebo blinded within each dose level. After randomisation, the subjects will follow a fixed dose escalation. The maintenance dose of 0.5 mg will be reached after 4 weeks of 0.25 mg. The maintenance dose of 1.0 mg will be reached after 8 weeks (4 weeks) of 0.25 mg and 4 weeks of 0.5 mg). Once-weekly subcutaneous (s.c., under the skin) administration. Trial duration per subject is 18 to 21 weeks depending on the individual subject's schedule.
1612108|NCT02146053|Dietary Supplement|Placebo|placebo capsules: methyl cellulose
1612109|NCT02146027|Dietary Supplement|Fermented Milk Drink Yakult 40|Lactobacillus casei Shirota, with 40 billion bacteria per 80 g (concentration of 5 x 10^8 CFU/g). Intervention will be used for 12 weeks.
1612110|NCT02146027|Dietary Supplement|Fermented Milk Drink Yakult 40|Ingredients: Skimmed milk and/or Reconstituted Skimmed Milk, Sugar, Glucose, Live Lactic Bacteria (Lactobacillus casei Shirota) 40 billions per 80 g - concentration of 5 x 108 CFU/g), Flavour. Gluten Free.
1612111|NCT02146014|Other|Placebo|"Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
In the placebo group the current will be off."
1612112|NCT02146014|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation (tDCS) is a procedure that uses a small battery-driven unit to deliver weak electrical currents (1-2 mA) through the intact scalp. The procedure is painless and is thought to modulate the excitability of the underlying cerebral tissue for hours or days after sessions.
1612113|NCT02146001|Other|Reducing sedentary behavior group|This intervention will use individual counseling and the the BodyMedia armband to self-monitor sedentary behavior. The goal will be to decrease time spent in sedentary behavior by 60 minutes each day.
1612114|NCT02146001|Other|Moderate-to-vigorous activity group|This group will be administered an individual, behavioral intervention using the BodyMedia armband to self-monitor physical activity. The prescription will be 150 minutes of moderate exercise (e.g. brisk walking) each week.
1612115|NCT02145988|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
1612116|NCT02145988|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy: aspirin at the dose of 80 mg, once daily, every day for twelve weeks of study period
1612117|NCT02145975|Drug|Fentanyl|The nurse will administer 1 ug per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 100 ug of fentanyl which is diluted in 10 mL of normal saline leaving a 10μg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
1612118|NCT02145975|Drug|Morphine|The nurse will administer 0,1 mg per kg during 5 seconds when the patient complain of pain (visual analog scale, VAS, ≥7). Immediately with the onset of drug administration a timer started; every 5 minutes the researcher assess the EVA and the drug will be administered if VAS > 3, until the patient manifests as a lower pain VAS ≤ 3 (mild). The nurse in charge in the PACU will manage the drug and will take 10 mg of morphine which is diluted in 10 mL of normal saline leaving a 1 mg per ml concentration, are not labeled and for the physical and chemical characteristics of both drugs (colorless) risks of unblinded is minimized.
1612119|NCT02145962|Device|Forearm tissue exposure with ELF-MF|The treatment was delivered 2 hours/day, 2 times/week and consisted of sinusoidal oscillating magnetic fields of 120 Hz using a solenoid, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the forearm device is approximately 30 ml/min or 3.6 lt/session.
1612120|NCT02145962|Device|Thorax tissue exposure with ELF-MF|The treatment was delivered 25 minutes/day, 2 times/week and consisted of 120 Hz using a quasi-Helmholtz coil configuration, with nominal field amplitude of approximately 0.6-0.8 mT (6-8 Gauss) RMS at the center of the stimulation system. The amount of blood exposed to the therapeutic ELF-MF using the thorax device should be approximately 6,500 ml/min or 162.5 lt/session, which is approximately 45 times more blood volume stimulation per unit of time compared with the Forearm exposure system.
1612123|NCT02145936|Other|diet|Participants are fed diets enriched in oleic acid, palmitic acid or stearic acid.
1612124|NCT02145923|Procedure|Peripheral blood stem cell mobilisation and collection|
1612125|NCT02145923|Drug|High-dose chemotherapy|High-dose chemotherapy will be performed according to protocols ICE and BEAM (standard scheme)
1612126|NCT02145923|Drug|Bone marrow derived allogeneic MMSCs infusion|
1612127|NCT02145923|Procedure|Autologous peripheral blood stem cells infusion|
1612128|NCT02145910|Drug|Vemurafenib|Given PO
1612129|NCT02145910|Radiation|Whole-brain radiation therapy (WBRT)|Undergo WBRT
1612130|NCT02145910|Radiation|Radiosurgery (SRS)|Undergo SRS
1612131|NCT02145897|Biological|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) SVF divided in two fraction and infused intravenously and intramuscularly
1612132|NCT02145897|Biological|Autologous Adipose Derieved MSCs|Study arm B subjects will receive one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously and one dose of 1 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intramuscularly
1612133|NCT02145897|Other|Control|
1612134|NCT02145884|Drug|timolol maleate 0.5% gel|Apply timolol gel 1-2 drops twice a day to lesion
1612135|NCT02145871|Other|standard fluid management|
1612136|NCT02145871|Other|fluid management guided by the EV1000|
1612137|NCT02145858|Device|Blood drainage post cardiac surgery using PleuraFlow System|
1612138|NCT02145845|Device|Injectable SIS|Injectable SIS
1612139|NCT02145832|Drug|Fluconazole|
1612140|NCT02145832|Drug|Micafungin|
1612141|NCT02145819|Drug|hCG|
1612225|NCT02145156|Behavioral|Survey-only|Those in the usual care arm will be provided with a paper version of the Post Intervention Survey. This will be provided to participants after their clinic visit is completed.
1612226|NCT02145143|Drug|Vemurafenib|
1612142|NCT02145793|Behavioral|ADHD Group Curriculum|Study specific ADHD Group curriculum was designed and implemented for the study. Parent curriculum included the following topics: What is ADHD, medications, educational advocacy, how to prevent behavioral issues and how to defuse common behavioral challenges and manage stress. Child curriculum included the following topics: what is ADHD, social skills and friendships, handling school and organization skills, understanding feelings and managing negative emotions
1612143|NCT02145780|Dietary Supplement|2g of grape polyphenol extract|Men will have to consume daily 2g of grape polyphenol extract during the 31 days of overfeeding.
1612144|NCT02145780|Dietary Supplement|Dietary Supplement: 2g of placebo (lactose)|Men will have to consume daily 2g of placebo during the 31 days of overfeeding.
1612145|NCT02145767|Drug|Progesterone|
1612146|NCT02145767|Drug|Placebo|
1612147|NCT02145754|Other|MKP media|one half of skin specimen was put in MKP media
1612148|NCT02145754|Other|BSK-H media|one half of skin specimen was put in BSK-H media
1612149|NCT02145741|Drug|BI 836845, low dose, every week (qw)|Patient to receive low dose of BI 836845 IV
1612150|NCT02145741|Drug|BI 836845, middle dose, qw|Patient to receive middle dose of BI 836845 IV
1612151|NCT02145741|Drug|BI 836845, high dose, qw|Patient to receive high dose of BI 836845 IV
1612152|NCT02145728|Behavioral|Individual Cognitive Functional Therapy|Cognitive functional therapy (CFT) is a novel, patient centred behavioural intervention which addresses multiple dimensions in non-specific chronic low back pain (NSCLBP). It combines a functional behavioural approach of normalising provocative postures and movements while discouraging pain behaviours, with cognitive restructuring of the NSCLBP problem.
1612153|NCT02145728|Behavioral|Group Exercise Classes|Each class involves a combination of education, exercise and relaxation/mindfulness. The education topics include pain and the nervous system, posture and ergonomics, exercise and relaxation and sleep. The exercise component includes 10 stations of a combination of aerobic, strength and flexibility exercises. These will be walking/jogging on the spot, mini-squats, sit to stands, wall push ups, bridging, step-ups and a combination of leg and low back stretches. The relaxation/mindfulness component will take place at the end of each class and will involve breathing and relaxation of the body.
1612154|NCT02145715|Drug|Velcade|
1612155|NCT02145715|Drug|Thalidomide|
1612156|NCT02145715|Drug|Dexamethasone|
1612157|NCT02145715|Drug|Panobinostat|
1612158|NCT02145702|Other|Aerobic Exercise|Each exercise session will be conducted at the KUMC Exercise and Cardiovascular Health (REACH) Laboratory. Exercise sessions will include a warm-up period, exercise period and a cool down period. Exercise intervention individualized based on health of participant. Subject will be asked to completed two exercise sessions per week for 12 weeks.
1612159|NCT02145702|Procedure|Standard Care Dialysis|12 weeks of standard of care.
1612160|NCT02145689|Biological|onabotulinumtoxinA|Up to 4 treatments of onabotulinumtoxinA injected into muscles of the study limb on fulfillment of the retreatment criteria.
1612161|NCT02145676|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into predefined muscles of the study limb on Day 1.
1612162|NCT02145676|Drug|placebo (normal saline)|Placebo (normal saline) injected into predefined muscles of the study limb on Day 1.
1612163|NCT02145650|Other|No Intervention|There is no intervention administered in this study.
1612164|NCT02145637|Drug|Afatinib plus Ruxolitinib combination therapy|
1612165|NCT02145624|Drug|Repevax|vaccine
1612166|NCT02145624|Drug|Boostrix-IPV|vaccine
1612167|NCT02145611|Drug|Glibenclamide|Glibenclamide
1612168|NCT02145611|Drug|Vildagliptin|Vildagliptin
1612169|NCT02145598|Drug|Lenalidomide|after 6 cycles VMP Patients will receive Lenalidomide given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
1612170|NCT02145598|Drug|Placebo|after 6 cycles VMP Patients will receive Placebo given as two capsules 5 mg capsules p.o. daily until progressive disease (PD)
1612171|NCT02145585|Device|Test of pharmacologic anesthesia robot (labVIEW® software)|
1612172|NCT02145559|Drug|Metformin XR|
1612173|NCT02145559|Drug|Delayed Metformin|
1612174|NCT02145559|Drug|Sirolimus|
1612175|NCT02145546|Drug|Amiodarone|Amiodarone: 200mg three times a day for two weeks, then change to 200mg per day for the rest of the study.
1612176|NCT02145546|Drug|Propafenone|150mg per 8 hours, 3 times per day
1612177|NCT02145546|Drug|Sotalol|80mg twice per day.
1612178|NCT02145520|Drug|Magnesium Sulfate|The use of magnesium sulfate intravenous in patient with bronchiolitis in pediatric emergency; follow Broncholitis severity score and length of stay
1612179|NCT02145520|Other|placebo|use of placebo with standard therapy
1612181|NCT02145494|Radiation|Radiotherapy|Stereotactic body radiotherapy (SBRT) to the whole prostate (36.25 Gy in 5 fractions) with a focal boost (47.5 Gy in 5 fractions) to the MRI-defined dominant tumour nodule.
1612182|NCT02145481|Behavioral|Decision Aid|Decision aid describing treatment choices for patients with coronary artery disease.
1612183|NCT02145481|Behavioral|CAD Education|Education for patients with coronary artery disease
1612184|NCT02145468|Drug|Losmapimod 7.5 mg twice daily|Subjects will receive Losmapimod 7.5 mg as film-coated, round, plain faced tablets.
1612185|NCT02145468|Drug|Placebo twice daily|Subjects will receive placebo as film-coated, round, plain faced tablets.
1612186|NCT02145468|Drug|Standard therapy|Subjects will receive standard therapy consistent with the appropriate guidelines from professional societies. The standard therapy includes nitrates, morphine sulfate, beta adrenergic blockers, renin-angiotensin aldosterone inhibitors, other anti-ischemic therapies, and analgesic therapy.
1612187|NCT02145455|Device|Unity Total Knee Replacement System|
1612188|NCT02145455|Device|Unity Total Knee Replacement System|
1612189|NCT02145442|Dietary Supplement|Obex|Obex® will be administered two sachets daily dissolved in a glass of water, 30 minutes before lunch and dinner during three months. Participants will be not trained about changes of lifestyle on their diets, or physical activity.
1612227|NCT02145143|Device|serial 124I PET/CT|
1612228|NCT02145143|Drug|thyrotropin alpha|
1612580|NCT02142621|Other|transpyloric feeding|
1612581|NCT02142621|Other|gastric feeding|
1612190|NCT02145429|Behavioral|Problem Solving therapy and Brief Behavioral Treatment of Insomnia|"Problem Solving therapy teaches problem solving skills that participants can use in their everyday life. A problem is identified, various solutions identified and explored with the underlying focus to learn behavioral and self management strategies.Social casework and management of chronic disease is also included as per the participant's need.
Brief Behavioral Treatment of Insomnia focuses on improving sleep by promoting sleep hygiene such as time spent in bed and decreasing night time stimuli. The therapy has been suitably modified to suit the needs of the participants to be recruited in the Low and Middle income countries keeping in mind the low level of literacy and the local social and health care services."
1612191|NCT02145403|Drug|Carfilzomib|"Carfilzomib will be administered starting at dose level 1 (20 mg/m2 IV) on day +1, +2, +6 and +7.
Dose escalation will be performed on the day +6 and day +7 doses only in each dose level. Day +1 and day+2 doses will be fixed at 20 mg/m2 IV in all dose levels."
1612192|NCT02145403|Drug|Tacrolimus|Tacrolimus will be administered at 0.03 mg/kg continuous infusion over 24 hours, starting on day -3 as standard graft-versus-host disease prophylaxis.
2010300|NCT03024645|Behavioral|Be A Mom_with_partner|The Be a Mom program is a web-based self-guided cognitive-behavioral intervention to prevent postpartum depression, targeting postpartum women. It consists of 5 weekly modules, each module targeting a specific thematic content, and providing women with both information and specific therapeutic strategies (with a strong focus on cognitive-behavioral techniques) to address each thematic content. Modules are sequential. In this case, the intervention will be assisted by both members of the couple.
2010301|NCT03024645|Other|Treatment as usually (TAU)|performed in primary care settings
2010302|NCT03021538|Device|Extracorporeal Membrane Oxygenation|ECMO is used during lung transplant procedure
2010303|NCT03021538|Device|Cardiopulmonary Bypass|CPB is used during lung transplant procedure
1612197|NCT02145377|Biological|PXVX0200 10E8|Oral dose of PXVX0200 10E8
1612198|NCT02145377|Biological|PXVX0200 10E9|Oral dose of PXVX0200 10E9
1612199|NCT02145377|Biological|Placebo|Oral dose of sodium bicarbonate buffer
1612200|NCT02145377|Biological|Shanchol|Licensed comparator
1612201|NCT02145364|Device|Ultherapy® treatment|Microfocused ultrasound treatment
1612202|NCT02145351|Device|Rate adaptive atrial pacing using a dual-chamber pacemaker|The Advisa DR model A2DR01 is a permanent, dual-chamber cardiac pacemaker with the ability to continuously monitor and record patient activity, and respond to activity by pacing faster and increasing the heart rate (rate adaptive atrial pacing). It will be programmed in AAIR mode to pace the right atrium. The leads will be placed in the right atrium and right ventricle using CapSureFix model 5086.
1612203|NCT02145351|Device|Pacemaker system will be implanted but set to Pacing Off.|The identical pacing system will be implanted, but will be set to Pacing Off.
1612204|NCT02145338|Drug|Nitrofurantoin or Trimethoprim or Cefalexin|Antibiotic prophylaxis
1612205|NCT02145338|Other|No prophylaxis|Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.
1612206|NCT02145325|Drug|Expanded Tregs|
1612207|NCT02145312|Drug|BYL719|BYL719 is an oral class I α-specific PI3K inhibitor belonging to the 2-aminothiazole class of compounds.
1612208|NCT02145299|Device|TruePath CTO Device|"The TruePath CTO Device is composed of a 0.018 guidewire and a motor housing with a connector cable along with a sterile, disposable battery-powered Control Unit for manipulation of the device during operation. The TruePath CTO Device is indicated to facilitate the intra-luminal placement of conventional guidewires beyond peripheral artery chronic total occlusions."
1612209|NCT02145299|Device|CROSSER CTO Device|
1612210|NCT02145286|Radiation|Stereotactic Body Radiation Therapy|SBRT is a high dose and highly conformal radiation dose treatment with the goal of rapid tumor killing and/or ablation of tumors
1612211|NCT02145273|Behavioral|Interpersonal Psychotherapy for Depression -Group|
1612212|NCT02145260|Drug|Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate)|A lower dialysate sodium will bes used in the active comparator arm (138 mmol/L)
1612213|NCT02145260|Drug|Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)|A higher dialysate sodium will be used in the experimental arm (142 mmol/L)
1612214|NCT02145247|Drug|hCG|"3. On study day one, recombinant-hCG (r-hCG) will be administered intravenously at a dose of 25 micrograms.
4. Blood samples will be obtained at T = -0.5, 0, and +24 hours."
1612215|NCT02145234|Drug|BMS-986089|
1612216|NCT02145234|Drug|Placebo matching with BMS-986089|
1612217|NCT02145221|Other|Music Therapy|
1612218|NCT02145208|Device|TIND System|An implant
1612219|NCT02145195|Dietary Supplement|Vitamin D3 (cholecalciferol)|
1612220|NCT02145182|Drug|Eculizumab|Eculizumab will be administered by intravenous (IV) infusion over 25-45 minutes for two doses (on day of transplant then 18-24 hours later).
1612221|NCT02145182|Drug|Placebo|Placebo will be administered by intravenous (IV) infusion over 25-45 minutes for two doses (on day of transplant then 18-24 hours later).
1612222|NCT02145169|Drug|Inhaled Nitrous Oxide|Patients undergoing procedural sedation with Ketamine will receive inhaled Nitrous Oxide
1612223|NCT02145156|Behavioral|Tailored educational materials|The tailored intervention will use participants' baseline survey responses to generate tailored educational messages about the HPV vaccine. These educational messages will reflect the top concerns indicated by the participant about the HPV vaccine. Additional tailoring will occur in the form of images matched to self-reported race and age, and using participants' first name in the information presented.
1612224|NCT02145156|Behavioral|Untailored educational materials|"The untailored intervention will present educational information on the iPad that is not responsive to participants' baseline questionnaire answers and instead is derived directly from the HPV Vaccine Information Sheet that has been created by the Centers for Disease Control and Prevention."
2010304|NCT03021941|Drug|Elelyso 60 units/kg|All patients receive Elelyso 60 units/kg.
2010305|NCT03022513|Other|Gluten free diet|The investigators will evaluate the prevalence of fibromyalgia-like joint/muscle pain and the possible ultrasonographical alterations (i.e. synovitis) of hands and feet joints in NCWS patient at baseline (i.e. at the moment of diagnosis) and after a gluten free diet period of almost 6 months.
1612229|NCT02145130|Biological|denovoDerm|Transplantation of an autologous tissue-engineered dermal substitute, covered with autologous split-thickness skin
1612230|NCT02145130|Biological|denovoSkin|Transplantation of autologous tissue-engineered dermo-epidermal skin substitute, no additional coverage needed
1612231|NCT02145117|Behavioral|MBSR|Behavioral
1612232|NCT02145104|Drug|valsartan 160mg, cilnidipine 10mg, cilinidipine 5mg|
1612233|NCT02145091|Drug|Moderately-high dose of psilocybin|Oral dose of a moderately-high dose of psilocybin.
1612234|NCT02145091|Drug|Moderately-low dose of psilocybin|Oral dose of a moderately-low dose of psilocybin.
1612235|NCT02145091|Drug|Very-low dose of psilocybin|Oral dose of a very-low dose of psilocybin.
1612236|NCT02145091|Drug|Placebo|An oral placebo (lactose pill).
1612237|NCT02145078|Drug|docetaxel|Given IV
1612238|NCT02145078|Drug|pemetrexed disodium|Given IV
1612239|NCT02145078|Drug|gemcitabine hydrochloride|Given IV
1612240|NCT02145078|Other|laboratory biomarker analysis|Correlative studies
1612241|NCT02145065|Drug|Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland)|
1612242|NCT02145065|Device|Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)|
1612243|NCT02145052|Other|Continuous suture|A continuous suture is considered standard of care.
1612244|NCT02145052|Other|Interrupted suture|Interrupted sutures are considered standard of care.
1612245|NCT02145039|Drug|Fludarabine|Fludarabine 30 mg/m2 IV over 30-60 minutes on days -6 through -2 before transplant.
1612246|NCT02145039|Drug|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours on days -6 and -5 before transplant and Cyclophosphamide 50 mg/kg IV on days 3 and 4 post-transplant.
1612247|NCT02145039|Radiation|Total Body Irradiation|TBI 200cGy on day -1 before transplant.
1612248|NCT02145039|Biological|Haploidentical stem cell transplant|Non-T-cell depleted bone marrow infusion
1612250|NCT02145013|Procedure|Liver resection|Hepatectomy by either open, laparoscopic or robotic procedures
1612251|NCT02145000|Biological|Rotavirus vaccine (BRV-PV)|Three doses of BRV-PV containing ≥ Log10 5.6 FFU/Dose of each serotype G1, G2, G3, G4 and G9, or placebo, will be administered at 4 week intervals between doses (with a window of -1 to +4 weeks). The first administration will occur at 6-8 weeks of age.
1612252|NCT02145000|Biological|Placebo|
1612253|NCT02144987|Biological|Bone Marrow CD133+ Stem Cell Transplantation|"Bone Marrow Stem Cell (BMSC) mobilization peripheral blood induced by granulocyte-CSF (G-CSF) 5 mcg/kg sc every 12 hours for 4 days.
BMSC recollection with apheresis procedure and positive selection of the CD133+ cells.
The selection procedure will be performed for a maximum of 3 hours or until at least 50 million cells are collected.
CD133+ cells transplantation into the uterine spiral arterioles by intra-arterial catheterization
Subsequently Hormonal Replacement Therapy (HRT) will be given to the patients
Hysteroscopy will be performed 2-3 months after stem cell transplantation
Embryo transfer will be performed 3-6 months after stem cell transplantation with HRT endometrial preparation"
1612254|NCT02144948|Drug|e.-coli-nissle|1 ml qd for 24 weeks
1612255|NCT02144922|Drug|Pitavastatin|statin
1612256|NCT02144922|Other|Control|Life style modification alone
1612257|NCT02144909|Behavioral|Partners in Care with Semi-Structured Support Group|
1612258|NCT02144896|Other|Ankle splinting|Ankle dorsiflexion splinting will be performed 30 minutes per day, 5 days per week for 4 weeks.
1612259|NCT02144883|Behavioral|Telephone counseling|Subjects randomized into the telephone counseling condition received one comprehensive pre-quit call lasting about 45 minutes; five follow-up calls during the pregnancy, scheduled according to the risk of relapse after the quit attempt (1, 3, 7, 14, and 30 days after the quit date) one 30-minute pre-birth call scheduled after 36 weeks gestation and two additional follow-up sessions scheduled for 14 and 28 days after the baby's birth. The counseling used a proactive calling procedure in that counselors made all the calls based on agreed-upon dates with the clients. This proactive approach aimed to foster a positive counseling relationship, provide accountability, and create opportunities to address wavering motivation, reduce attrition, and minimize relapse.
1612260|NCT02144883|Behavioral|Self-help materials|All subjects received a self-help quit kit for pregnant smokers and fact sheets on second-hand smoke and additional tips for quitting while pregnant. Subjects in the counseling intervention group received five additional mailings. These mailings were designed to remind them of their commitment to quitting and of the presence of counseling support if they needed help. Mailings included a pamphlet on pregnancy facts, a refrigerator magnet with the quitline number, and a social support planning worksheet that were sent at 4.5 months, 6 months, and 7.5 months gestation, respectively. They also received a congratulatory card soon after the birth and a brochure with tips for parenting newborns that was sent at one month postpartum.
1612261|NCT02144870|Behavioral|Habit Reversal Training|awareness training, competing response training
1612262|NCT02144870|Behavioral|Resources activation|
1612263|NCT02144857|Drug|etanercept|50 mg
1612264|NCT02144857|Drug|ustekinumab|45 mg
1612265|NCT02144857|Drug|cyclosporine|Cyclosporine 2.5-3 mg/kgr
1612266|NCT02144844|Behavioral|Insight-Plus Cognitive Behavioral Intervention|Insight-Plus is a 6-session, manualized, cognitive behavioral intervention (CBI) culturally tailored for a diverse group of rural low-income women at low and high risk for antepartum depression.
1612267|NCT02144831|Drug|anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)|comparisson of what is the efficacy and safety of 10 days to 30 day treatment of aspirin (ASA)+Clopidogrel
1612268|NCT02144818|Drug|Ovitrel|Triggering of ovulation with Ovitrel
1612269|NCT02144818|Drug|Decapeptyl|Triggering with GnRH agonist
1612270|NCT02144805|Procedure|Suturing in a single layer|The procedure define the use of one single suture for closure of the uterine incision following cesarean section.
1612271|NCT02144805|Procedure|Suturing in two layer|The procedure define the use of two sutures for closing the uterine incision following cesarean section
1612272|NCT02144792|Drug|[11C] -verapamil PET|While P-gp inhibitor (Cyclosporin A, 2.5mg/kg/hr during 2hours, intravenous) is infused, PET scans were done using [11C] -verapamil, a substrate of P-gp.
1612416|NCT02143778|Device|Methacetin Breath Test|13C labelled methacetin solution for breath test monitoring
1612273|NCT02144779|Behavioral|Assigned to palliative care team|Communication and Support through the palliative care team assigned to intervention participants.
1612274|NCT02144779|Behavioral|Usual Care|usual hospital care, not assigned to palliative care team
1612275|NCT02144766|Drug|ropivacaine|caudal block with 1 ml/kg of ropivacaine 0.2%
1612276|NCT02144766|Drug|saline|caudal block with 1 ml/kg of saline
1612277|NCT02144753|Dietary Supplement|NTX-1|Investigational NTX-1 fiber to be taken as three (6g each) packets of the fiber per day, one 8g packet in the morning (one hour before eating breakfast) and the other two 8g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
1612278|NCT02144753|Drug|psyllium (15 g)|Psyllium (an over-the-counter fiber) to be taken as three (5g each) packets of the fiber per day, one 5g packet in the morning (one hour before eating breakfast) and the other two 5g packets in the afternoon and evening.Fasting required for the morning dose and recommended with afternoon and evening dose.
1612279|NCT02144740|Dietary Supplement|NWT-03, an egg-white protein hydrolysate|For placebo comparator, a combination of sweetener + aroma, which was equal to the combination used in the intervention period, was given
1612280|NCT02144740|Dietary Supplement|Placebo|A combination of sweetener + aroma , which was equal to the combination used in the intervention period, was given.
1612281|NCT02144727|Procedure|D2 distal subtotal gastrectomy|D2 includes Nos.1.3,4sb,4d,5,6,7,8a,9,11p,and 12a nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy.
1612282|NCT02144727|Procedure|D1+ distal subtotal gastrectomy|D1+ includes Nos.1,3,4sb,4d,5,6,7,8a,and 9 nodes in Japanese classification. Systemic en bloc lymph node dissection is mandatory. Resection margin should be negative for malignancy with intraoperative frozen biopsy
1612283|NCT02144714|Biological|SB5|
1612284|NCT02144714|Biological|EU sourced Humira®|
1612285|NCT02144714|Biological|US sourced Humira®|
2010306|NCT03022240|Drug|Propofol|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
2010307|NCT03022240|Drug|Sevoflurane|The child will be randomized via a block design to receive either a volatile anesthetic (induction: sevoflurane), or total intravenous anesthetic technique (induction: propofol)
1612288|NCT02144688|Drug|Change in antiretrovirals|Change in ARVs to improve cognition: Personalized change in antiretrovirals will be based on CSF analysis
2010308|NCT03022240|Drug|Ametop|Each patient will receive Ametop local anesthetic to the dorsum of both hands 30-45 minutes prior to induction.
2010309|NCT03022240|Drug|Ondansetron|Each patient will receive the antiemetic ondansetron 0.1mg/kg IV.
1612293|NCT02144662|Drug|Ranibizumab|0.5mg ranibizumab intravitreal injection
1612294|NCT02144649|Dietary Supplement|dietary intervention (tangerine tomato juice)|Group II will consume two 5.5 oz. cans of tangerine tomato juice every day until their scheduled surgery. (approximately 4 weeks).
1612295|NCT02144649|Dietary Supplement|dietary intervention (red tomato juice)|Group III will consume two 5.5 oz. cans of red tomato juice every day until their scheduled surgery (approximately 4 weeks).red tomato juice
1612296|NCT02144649|Other|questionnaire administration|Men enrolled in the study will be asked to complete a 3-Day Food Record and a series of additional questionnaires (urologic symptom and quality of life questionnaire) at home.
1612297|NCT02144649|Other|Correlative studies|Blood and urine samples at enrollment and blood, urine, and prostate tissue at the time of surgery to determine compliance with the intervention product and tomato phytochemical biodistribution. Additionally, we will correlate each type of tomato juice with lycopene presence in plasma, urine, and tissue provided by subjects on the day of surgery.
1612298|NCT02144636|Dietary Supplement|herbalife protein shake|
1612299|NCT02144623|Drug|Valproate|
1612300|NCT02144610|Biological|HGF Plasmid (AMG0001)|IM
1612301|NCT02144610|Biological|Matching Placebo|IM
1612302|NCT02144597|Dietary Supplement|Liquid formula low-calorie diet (LCD)|The liquid formula low-calorie diet (LCD) will provide 800kcal/day from powdered milkshakes and soups. The diet will be provided by Cambridge Weight Plan.
1612303|NCT02144597|Dietary Supplement|Control diet|The control diet will be a conventional food diet aiming to provide 800 to 1000 kcal/day. It will be prescribed by the dietitian at the Imperial Weight Centre.
1612304|NCT02144584|Drug|Memantine XR|The active drug will be encapsulated by the University of Utah Research Pharmacy to maintain blinding.
1612305|NCT02144584|Drug|Placebo (for memantine)|Placebo to be capsuled to look identical to active drug (memantine)
1612306|NCT02144571|Behavioral|Lifestyle|Participants are consented and randomized into the intervention group or delayed intervention group(intervention offered one year later). Participants in intervention group attend 12 weekly sessions and 9 monthly sessions. All participants attend 3 clinics in which we collect data, measurements and blood samples. These clinics occur at baseline, 12 weeks and one year.
1612307|NCT02144558|Other|penile vibratory stimulation (PVS) or masturbation|penile vibratory stimulation (PVS) or masturbation
1612308|NCT02144545|Procedure|Bougie Size 33 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
1612309|NCT02144545|Procedure|Bougie Size 42 Fr|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
1612310|NCT02144545|Procedure|Distance pylorus 2 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
1612311|NCT02144545|Procedure|Distance pylorus 5 cm|Comparison of the bougie size and distance from the pylorus for the sleeve gastrectomy
1612312|NCT02144532|Device|short-sleeved vest CICATREX SED®)|Each patient wears a compression custom-made garment (short-sleeved vest CICATREX SED®) according to the medical prescription during the first 4 weeks (BEFORE phase). Then each patient should not wear the compression garment for the next 4 weeks (AFTER phase).
1612316|NCT02144493|Other|The existence of periampullary diverticulum|Periampullary diverticulum has been postulated as risk factor of recurrent CBD stone.
1612317|NCT02144493|Other|CBD angle|Narrow CBD angle has been postulated as risk factor for the development of recurrent CBD stone
1612417|NCT02143765|Drug|Mitiglinide|three times a day, orally, for 12 weeks
1612318|NCT02144480|Behavioral|Intensive training|The IT group will receive physiotherapy twice daily with longer duration and higher intensity
1612319|NCT02144480|Behavioral|traditional training|usual care: conventional rehabilitation
1612320|NCT02144454|Dietary Supplement|Saturated fat|
1612321|NCT02144454|Dietary Supplement|Monounsaturated fat|
1612322|NCT02144454|Dietary Supplement|n-6 polyunsaturated fat|
1612323|NCT02144441|Drug|glargine and aspart|Inpatient will administer hospital-dispensed basal-bolus insulin (glargine and aspart) according to a regimen developed in collaboration with the diabetes consult service.
1612324|NCT02144415|Drug|EB-1020 400 mg|4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
1612325|NCT02144415|Drug|EB-1020 800 mg|8 x EB-1020 100-mg capsules
1612326|NCT02144415|Drug|lisdexamfetamine 150 mg|3 x capsules, each containing 1 lisdexamfetamine 50-mg capsule, and 5 x matching placebo capsules
1612327|NCT02144415|Drug|d-amphetamine 40 mg|4 x capsules, each containing 2 d-amphetamine 5-mg tablets, and 4 x matching placebo capsules
1612328|NCT02144415|Drug|Placebo|8 x matching placebo capsules
1612329|NCT02144402|Other|infant formula with DHASCO|
1612330|NCT02144402|Other|infant formula with DHASCO-B|
1612331|NCT02144389|Drug|Praziquantel (PZQ)|"40 mg/kg, a single dose, administered orally
1 g of corn/soybean oil (50%/50%), administered orally"
1612332|NCT02144389|Dietary Supplement|Arachidonic acid (ARA)|ARA (40% of total fatty acid)
1612333|NCT02144389|Dietary Supplement|PZQ+ARA|A single dose of PZQ administered seven days in advance of initial treatment with ARA.
1612334|NCT02144376|Dietary Supplement|Ispaghula|
1612335|NCT02144376|Dietary Supplement|Maltodextrin|
1612336|NCT02144350|Procedure|Hyperbaric oxygen|patients will be placed in a monoplane chamber and pressurized to 2.4 atmospheres with 100% oxygen for 90 minutes per session.
1612337|NCT02144350|Procedure|Sham Hyperbaric Air|Patients will undergo a brief compression to 1.34 atmospheres with room air and then they will be brought back to 1.1 atmospheres to complete a 90 minute session.
1612338|NCT02144337|Behavioral|Steps To Active Kids (STAK) programme|Intervention described in Arm/Group Description.
1612339|NCT02144324|Device|Tandem Appliance|We are going to use a modified version of the Tandem Appliance
1612340|NCT02144311|Procedure|PET/CT Scan|
1612341|NCT02144311|Procedure|MRI|
2010310|NCT03019939|Drug|Isavuconazole|Dosing is identical for oral and intravenous administration of Isavuconazonium Sulfate. Isavuconazonium sulfate administered at a dose of 372 mg (i.e., 2 capsules, or 200 mg of Isavuconazole) orally every 8 hours for 6 doses (48 hours), and 372 mg (i.e., 2 capsules, or 200 mg of Isavuconazole) orally once daily thereafter. Maintenance doses should be started 12 to 24 hours after the last loading dose.
2010311|NCT03020628|Biological|NBP607-QIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular [* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart]
1612346|NCT02144272|Drug|LY3114062 SC|LY3114062 administered SC.
1612347|NCT02144272|Drug|Placebo|Placebo administered SC.
1612348|NCT02144272|Drug|LY3114062 IV|LY3114062 administered IV.
1612349|NCT02144259|Drug|DMPA immediately postpartum|DMPA is an intramuscular injection of 150mg of depot medroxyprogesterone acetate.
1612350|NCT02144259|Drug|Implanon immediately postpartum|Implanon ® is a subdermal implant that contains 68mg of etonogestrel.
1612351|NCT02144246|Other|Non-hormonal period|
1612352|NCT02144246|Drug|Ortho-cyclen, Ethinyl estradiol/norgestimate, 0.035 mg/0.250 mg|
1612353|NCT02144233|Procedure|Occlusal adjustment|"The first step consists of the elimination of premature tooth contacts during retruded jaw closure.
The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)"
1612354|NCT02144233|Procedure|Placebo occlusal adjustment|Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
1612355|NCT02144220|Other|Virtual care visit|Video-conferencing visit with a Parkinson disease specialist
1612356|NCT02144207|Device|Glidescope|
1612357|NCT02144194|Drug|Vinorelbine-Docetaxel|Vinorelbine I.V: 20mg/m2 D1 Docetaxel: 60mg/m2 D1 Vinorelbine Oral: 60mg/m2 D8 Every 3 weeks x 6 cycles
1612358|NCT02144194|Drug|Vinorelbine|Oral Vinorelbine 60mg/m2 or 80mg/m2 D1, D8 every 3 weeks until disease progression, unacceptable toxicities or patient refusal to continue (dose schedule is at investigator's discretion)
1612359|NCT02144181|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1612360|NCT02144168|Dietary Supplement|Prebiotics-free enteral formula|Patient will be given Osmolite 1 cal for 2 weeks after baseline stool sample obtained
1612361|NCT02144168|Dietary Supplement|Prebiotics containing enteral formula|Patient will be given Ensure Fos for 2 weeks after baseline stool sample obtained
1612362|NCT02144155|Drug|Oxytocin: 24IU - 168 IU|Oxytocin: 24IU - 168 IU
1612363|NCT02144155|Drug|Placebo|placebo drug
1612364|NCT02144142|Biological|Moisturizer with each subject's own antimicrobial bacteria|
1612368|NCT02144116|Other|Dance-movement therapy|The dance-movement was practised in groups. Dance-movement therapy derived from dance education. The goals of dance-movement therapy included assessing patient needs, communicating emotions, improving self-control, organizing thoughts and actions, developing interpersonal skills, integrating physical and emotional selves, promoting body awareness, and supporting healing.
1612369|NCT02144116|Other|Control group|Standardized educational information in the form of a leaflet about balance disorders and quality of life in fibromyalgia.
1612370|NCT02144103|Other|Subtenon administration of autologous ADRC|
1612371|NCT02144103|Procedure|Liposuction|
1612372|NCT02144103|Device|ADRC isolation|ADRC isolation performed using Celution 800/CRS System (Cytori Therapeutics Inc) according to manufacturer's protocol
1612373|NCT02144090|Device|Fractional flow reserve measurement|Fractional flow reserve measurement
1612418|NCT02143765|Drug|Acarbose|three times a day, orally, for 12 weeks
1612582|NCT02142608|Drug|BR55|
2010312|NCT03020628|Biological|NBP607-TIV|For subjects 6 months to 35 months of age, Single dose administration, Intra-muscular [* 2 doses for subjects without influenza vaccination history, administered at least 4 weeks apart]
1612376|NCT02144064|Drug|Heparin|Group A (n = 100) are put on Inj. UFH (Cal-heparin) 5000 U subcutaneous twice daily plusAspirin 81 mg/day (Juspirin) with the ﬁrst positive pregnancy test, Inj. UFH is given either into anterior abdominal wall or anterior aspect of thigh subcutaneously
1612377|NCT02144051|Drug|AZD5312|AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
1612378|NCT02144038|Drug|LGH447|pan-PIM inhibitor
1612379|NCT02144038|Drug|BYL719|PI3K-alpha inhibitor
1612380|NCT02144025|Drug|Cyclosporine|Use of topical cyclosporine (one drop of cyclosporine in each eye, twice a day for 12 months)
1612381|NCT02144012|Drug|Trastuzumab|For the first three-week cycle, trastuzumab was administered IV at 8 mg/kg. For subsequent cycles, trastuzumab was administered IV at 6 mg/kg Q3W.
1612382|NCT02144012|Drug|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams/kilogram (mg/kg) was administered intravenously (IV) over 30-90 minutes Q3W.
1612383|NCT02144012|Drug|Docetaxel|Docetaxel was administered IV at either 75 milligrams/square meter (mg/m^2) or 100 mg/m^2 Q3W.
1612384|NCT02143973|Drug|nalbuphine HCl ER 60mg BID|nalbuphine HCl ER 60mg BID for up to 24 weeks
1612385|NCT02143973|Drug|nalbuphine HCl ER 90mg BID|nalbuphine HCl ER 90mg BID for up to 24 weeks
1612386|NCT02143973|Drug|nalbuphine HCl ER 120mg BID|nalbuphine HCl ER 120mg BID for up to 24 weeks
1612387|NCT02143960|Device|VelaShape III|Subjects will receive one treatment to their entire waist / love‐handle/ flanks area in a split‐waist fashion, so that one side is treated with one device and the other side is treated with the other device. The treatment session will include: one side (right or left) treated with the VelaShape III device and the other side (left or right, respectively) with the CoolSculpt device. The subject will be randomized to one of 2 treatment groups, one will receive treatment to the left side with the VelaShape II and the right side will receive treatment with the CoolSculpt. The other group will receive treatment to right side with the VelaShape II and the left side will receive treatment with the CoolSculpt.
1612388|NCT02143960|Device|CoolSculpt|Noninvasive Cryolipolysis
1612389|NCT02143947|Device|Maximal Arch Subtalar Stabilization|Custom made semi-rigid thermoplastic heel cup extending to the base of the metatarsals with a full foot length 3.0mm thick EVA and ultra-suede top cover
1612390|NCT02143947|Device|Full Contact Orthosis|"The Full Contact orthosis is constructed from a 5/32 blue polypropylene with posting material comprised of white polypropylene."
1612391|NCT02143934|Drug|Primaquine|
1612392|NCT02143934|Drug|Placebo|Sugar pills, appearance identical to Primaquine tablets
1612393|NCT02143934|Drug|Chloroquine|
1612394|NCT02143934|Drug|Artemether Lumefantrine|
1612395|NCT02143921|Behavioral|Training intervention|Intervention group service providers received intervention training
1612396|NCT02143908|Dietary Supplement|lysine supplementation|
1612397|NCT02143908|Dietary Supplement|Placebo|
1612398|NCT02143895|Drug|etifoxine|
1612399|NCT02143895|Drug|Lorazepam|
1612400|NCT02143895|Drug|Placebo|
1612401|NCT02143882|Drug|Fluenz|Live attenuated influenza vaccine
1612402|NCT02143869|Device|Bioelectrical Impedance Analysis|Measurements of body composition including fat mass, lean body mass, muscular mass, mineral mass, total body water, intra and extracellular water.
1612403|NCT02143856|Drug|100 mg GLPG1205|A single dose of 100 mg GLPG1205 administered as two capsules of 50 mg
1612404|NCT02143843|Drug|Bimatoprost Ocular Ring|Bimatoprost Ocular Ring used continuously for 7 months, then replaced with a new Bimatoprost Ocular Ring and used continuously for another 6 months.
1612405|NCT02143830|Drug|Busulfan|"A standard dose of busulfan, associated with excellent outcomes in our previous trial will be used for young patients with marrow aplasia (arm A).
A higher dose of busulfan will be used in younger patients with MDS and AML (arm B) to maximize disease control.
A lower dose of busulfan will be used in older patients (arm C) to minimize toxicity."
1612406|NCT02143830|Drug|Cyclophosphamide|Arms A, B and C - Cytoxan will be given as a 1-2 hour infusion for 4 days. The dose will be adjusted according to patients ideal body weight for obese patients.
1612407|NCT02143830|Drug|Fludarabine|Arms A, B and C - Fludarabine will be given IV over 30 minutes daily for 4 days. The dose will be adjusted according to renal function according to Institutional guidelines.
1612408|NCT02143830|Drug|rabbit ATG|Arms A, B and C - 4 doses will be given prior to transplant to promote engraftment.
1612409|NCT02143830|Drug|G-CSF|All patients will also receive G-CSF post-transplant to foster engraftment.
1612410|NCT02143830|Biological|Peripheral blood stem cell|The source of stem cells for all patients will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 4-6 days. T-cell depletion will be uniformly performed by positive CD34 selection with the use of the Miltenyi system (CliniMACS device).
1612411|NCT02143817|Dietary Supplement|L-citrulline supplementation|
1612412|NCT02143817|Other|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 8 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
1612413|NCT02143804|Biological|oncolytic adenovirus expressing GMCSF|Treatment once weekly by intravesical route. Use of DDM to first remove the GAG layer of the bladder and to improve virus transduction. Installation of 100 ml. of CG0070 at 10e12 viral particles for 45 minutes inside bladder.
1612414|NCT02143791|Procedure|Burst stimulation|
1612415|NCT02143791|Device|Prodigy system|
1612419|NCT02143752|Behavioral|Mindfulness|Group behavioral intervention using mindfulness to help smokers quit smoking
1612420|NCT02143752|Behavioral|Quit Line|see arm
1612421|NCT02143726|Drug|sorafenib|Given PO
1612422|NCT02143726|Drug|everolimus|Given PO
1612423|NCT02143713|Drug|Elagolix|Two different doses with matching placebo (to maintain blind) daily in two different arms over a 6-Month Treatment Period
2010313|NCT03018249|Drug|Entinostat|Given PO
1612425|NCT02143687|Behavioral|Moderate altitude sojourn|Participants will travel from Zurich (490 m) to St. Moritz Salastrains (2048 m) and stay there for 2 days
1612426|NCT02143687|Behavioral|Low altitude sojourn|Low altitude baseline evaluations will be performed during a stay at Zurich (490)
1612427|NCT02143687|Drug|Oxygen|Oxygen administration via a nasal cannula at a rate of 3 L/min during nights spent at 2048 m
1612428|NCT02143687|Drug|Sham oxygen (room air)|Sham oxygen (room air) administration via a nasal cannula at a rate of 3 L/min during nights at 490 m and 2048 m
1612429|NCT02143674|Other|Muscle stretching and Strength Training|"Each step of stretching on specific muscles was repeated three times by keeping the posture for 30 seconds, (Arnold and Kokkonen, 2007; Toraman A, Yildirim. 2010; Dai, Ware, Giuliani, 2012; Duque et al., 2013; Granacher et al., 2013). The Pectoral, Quadriceps, Paraspinal, Abdominal and Ischial tibial and sural triceps muscles were elongated.
Strength Training Muscle strengthening was performed using weights and dumbbells. The training load individually determined through the test of strength with 10 repetitions maximum. The load was reevaluated four weeks of training. The Abdominal, Paraspinal, Quadriceps and Posterior thigh muscles (hamstrings) were submitted to the intervention protocol."
1612430|NCT02143674|Other|Educated about physical exercises|
1612431|NCT02143648|Drug|nalbuphine HCl ER tablets 60 mg BID|nalbuphine HCl ER tablets 60 mg BID administered for 6 weeks
1612432|NCT02143648|Drug|nalbuphine HCl ER tablets 120mg BID|nalbuphine HCl ER tablets 120mg BID administered for 6 weeks
1612433|NCT02143648|Drug|Placebo tablets BID|Placebo tablets BID administered for 8 weeks
1612434|NCT02143635|Drug|HDM201|
1612435|NCT02143635|Drug|ancillary treatment|
1612436|NCT02143622|Biological|LJM716|antibody
1612437|NCT02143622|Biological|cetuximab|antibody
1612438|NCT02143609|Drug|oxygen|Nocturnal nasal oxygen during stay at 2048 m
1612439|NCT02143609|Drug|sham oxygen (room air)|Sham oxygen (room air) via nasal cannula, 3 L/min, at 2048 m
1612440|NCT02143596|Other|normal saline|the infusion rate of normal saline is determinated by clinicians according to Bun/Cr ratio followed
1612441|NCT02143570|Drug|Darifenacin|Darifenacin will be prescribed in a starting dose of 7.5mg, once daily. This dose may be increased to 15mg a day in cases with refractory symptoms.
1612442|NCT02143570|Procedure|Physiotherapy|All patients will received a tailored pelvic floor exercise programme as part of the standard of care of overactive bladder at the study centre. This intervention will be mainly comprised of biofeedback stimulation techniques.
1612443|NCT02143557|Other|Fat-Modified Breast Milk|
1612444|NCT02143557|Other|MCT formula|
1612445|NCT02143544|Device|Intra-aortic balloon pump.|Preoperative placement of the intra-aortic balloon pump.
1612446|NCT02143531|Drug|4 mg of Ondansetron IV|
1612447|NCT02143531|Drug|1mg of Haloperidol IV|
1612448|NCT02143518|Biological|Na-GST-1/Alhydrogel®|The Na-GST-1 candidate vaccine contains the recombinant Na-GST-1 protein expressed by Pichia pastoris. Purified Na-GST-1 was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10% glucose and 10 mM imidazole. The final concentration of Na-GST-1 in the drug product is 0.1 mg/ml whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-GST-1 will be delivered by injecting different volumes of the 0.1 mg/ml Na-GST-1 preparation.
1612449|NCT02143518|Biological|CpG 10104|Unmethylated cytosine-guanine dinucleotides (CpGs) are found in bacterial DNA in the expected frequency predicted by random usage, whereas their occurrence is suppressed 4-fold in vertebrate DNA. In vertebrate DNA CpG motifs are also usually methylated. Bacterial CpG-DNA motifs are recognized by the human innate immune system via Toll-like Receptor-9 (TLR-9), a pathogen-associated molecular pattern (PAMP) receptor that is expressed, in particular, by antigen-presenting dendritic cells. Interactions between CpG-DNA and TLR9 rapidly activate antigen-presenting dendritic cells to upregulate co-stimulatory molecules and to produce Th1-polarizing cytokines such as interleukin-12 and interferon gamma. CpG 10104 is a short synthetic oligodeoxynucleotide of the following sequence: 5'-TCG TCG TTT CGT CGT TTT GTC GTT-3'.
1612450|NCT02143505|Drug|Ca plus vit D|elemental calcium 1200mg/d plus vitamin D3 250 IU/d daily supplements
1612451|NCT02143479|Drug|Tacrolimus|oral
1612452|NCT02143466|Drug|Part A - AZD9291 in combination with AZD6094|Part A - AZD9291 and AZD6094 administered in different doses to investigate the safety and tolerability of this combination and define the combination dose for further clinical evaluation in Part B.
1612453|NCT02143466|Drug|Part A - AZD9291 in combination with continuous selumetinib (Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in Asian subjects and to define the combination dose for further clinical evaluation in Part B.
1612454|NCT02143466|Drug|Part A - AZD9291 in combination with continuous selumetinib (non-Asian subjects)|Part A - AZD9291 and selumetinib (continuous treatment) administered in different doses to investigate the safety and tolerability of this combination in non-Asian subjects and to define the combination dose for further clinical evaluation in Part B.
1612455|NCT02143466|Drug|Part A - AZD9291 in combination with intermittent selumetinib|Part A - AZD9291 and selumetinib (intermittent treatment) administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.
1612456|NCT02143466|Drug|Part A - AZD9291 in combination with MEDI4736|"Part A - AZD9291 and MEDI4736 administered in different doses to investigate the safety and tolerability of this combination and to define the combination dose for further clinical evaluation in Part B.
Note: combination terminated and no longer being evaluated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis)."
1612492|NCT02143245|Other|percutaneous synovial biopsy|
1612524|NCT02142985|Drug|Plasmagel|vascular filling with 500 ml of colloid solution (plasmagel) over 30 minutes
2010314|NCT03018249|Procedure|Hysterectomy|Undergo hysterectomy
1612457|NCT02143466|Drug|Part B - AZD9291 in combination with AZD6094|Part B - AZD9291 and AZD6094 administered in the dose identified in Part A (AZD9291 80mg OD + AZD6094 600mg OD) to further investigate the safety and tolerability of this combination.
1612458|NCT02143466|Drug|Part B - AZD9291 in combination with selumetinib|Part B - AZD9291 and selumetinib administered in the dose identified in Part A (AZD9291 80mg OD + selumetinib 75 mg BD intermittent [4 days on/3 days off]) to further investigate the safety and tolerability of this combination.
1612459|NCT02143466|Drug|Part B - AZD9291 in combination with MEDI4736|"Part A - AZD9291 and MEDI4736 administered in the dose identified in Part A to further investigate the safety and tolerability of this combination.
Note: combination terminated and no longer being evaluated due to an increased incidence of ILD-like events (interstitial lung disease/pneumonitis)."
1612460|NCT02143466|Drug|Part C - AZD6094 monotherapy (Japan only)|Part C - AZD6094 monotherapy to assess the safety, tolerability and pharmacokinetics of the monotherapy of AZD6094 in Japanese patients with advanced NSCLC with the purpose of conducting further dose expansion (Part B) in Japan.
1612461|NCT02143453|Other|Endurance training|30 to 60-minute continuous exercise at 80% of the peak heart rate
1612462|NCT02143453|Other|High intensity interval training|3 to 6 sets of 60-second sprints at 100% of the peak velocity interspersed by a 3-min active recovery period.
1612463|NCT02143440|Behavioral|The initial assessment of daily insulin dose.|
1612464|NCT02143427|Behavioral|Social Skills Training|"Behavioral: computer-based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 6 sessions with relatives of the child in most cases with the parents.
Arms: Social Skills Training"
1612465|NCT02143427|Behavioral|Treatment Program with techniques to activate resources|"Behavioral: Treatment Program with techniques to activate resources 16 sessions with the child aiming at the reduction of peer related aggressive behavior via activate resources. Additionally up to 2 sessions with relatives of the child in most cases with the parents and subsequent computer based Treatment Program for Children with Aggressive Behavior 16 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training.
Arms: Treatment Program with techniques to activate resources of the child and subsequent Social Skills Training"
1612473|NCT02143401|Other|Laboratory Biomarker Analysis|Correlative studies
1612474|NCT02143401|Biological|Navitoclax|Given PO
1612475|NCT02143401|Other|Pharmacological Study|Correlative studies
1612476|NCT02143401|Drug|Sorafenib Tosylate|Given PO
1612477|NCT02143388|Drug|IMRT combine with cisplatin concurrent chemotherapy|Patients in the control arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT.
1612478|NCT02143388|Drug|IMRT combine with cisplatin concurrent chemotherapy plus capecitabine adjuvant chemotherapy|Patients in the experimental arm received radical radiotherapy with IMRT, and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during RT,followed by adjuvant chemotherapy with oral capecitabine(1000mg/m2/ twice a day for 14 days)every three weeks for eight cycles.
1612479|NCT02143375|Device|810 Diode Laser|The 810-nm diode laser has energy and wavelength characteristics that specially target the soft tissues. It has an affinity for hemoglobin and melanin, so it is an excellent soft tissue laser and is applicated for cutting and coagulating gingival tissue.Today,sparse studies have been published assessing physiologic gingival pigmentation using diode laser,therefore the aim of this study was to evaluate the effect of diode laser on the treatment of gingival pigmentation in adult patients.
1612480|NCT02143362|Drug|Anesthesia induction,propofol, remifentanil ,cisatracurium|"Target Controlled Infusion propofol and remifentanil to targeted plasma concentrations are 4 μg/ ml and 4 ng/ml respectively.
Intermittent injection cisatracurium (0.15mg/kg).
A laryngeal mask airway will be placed when bispectral electroencephalogram index is reduced to 60."
1612481|NCT02143362|Drug|Anesthesia maintenance , propofol,remifentanil,cisatracurium|"Closed-loop target controlled infusion of propofol ,Bispectral electroencephalogram index feedback value will be set at 50.
Target Controlled Infusion remifentanil , targeted plasma concentrations are 3~6ng/ml ,maintain heart rate to 60~100 beats per minute and mean blood pressure to 70~105 mmHg.
Intermittent injection cisatracurium (0.05mg/kg)."
1612482|NCT02143362|Procedure|Awaken test|"Stopped Closed-loop target controlled infusion of cisatracurium and propofol 30 minutes before awaken test.
In dexmedetomidine group,dexmedetomidine infusion rate will be reduced to 0.1 μg•kg-1•h-1. In control group ,normal saline infusion will be given with the same infusion rate as dexmedetomidine group .
Call patients' name and require them to move both feet every 30 seconds after patients recovered normal respiration.
Patients will be considered to be awake when recover normal respiration and make responsive to verbal commands correctly .
Patients will receive initial anesthesia after finish awaken test."
1612483|NCT02143349|Dietary Supplement|Coleus forskohlii extract|Ingestion of 250 mg Coleus forskohlii extract capsule twice a day for 12 weeks
1612484|NCT02143349|Other|Placebo|Ingestion of 250 mg placebo capsule twice a day for 12 weeks
1612485|NCT02143336|Procedure|subcuticular suture|
1612486|NCT02143336|Procedure|Skin staples|
1612487|NCT02143323|Drug|Augmentin tablet|
1612488|NCT02143310|Device|EVP|
1612489|NCT02143284|Device|Endoscopy exploratory single arm (EndoChoice FUSE(TM) System)|The investigational device will be applied in otherwise standard procedures (upper and lower Gastrointestinal tract endoscopy)
1612490|NCT02143271|Drug|KHK7580|Oral administration
1612491|NCT02143258|Procedure|Stenting of the venous sinus|Patients with medically refractory idiopathic intracranial hypertension who meet the eligibility criteria will be offered stenting of their venous sinus in effort to reduce their intracranial pressure and improve their visual capabilities.
1612493|NCT02143232|Device|remote patient monitoring (Telus RPM)|All joint replacement patients in the study will use the same type of remote patient monitor for 4 days post operation at home.
1612494|NCT02143219|Drug|Oxaliplatine|Oxaliplatine : 85mg/m², 2-hours IV infusion (D1), then,
1612495|NCT02143219|Drug|Folinic acid|Folinic acid (FA): 400 mg/m² , 2-hour IV infusion (D1),
1612496|NCT02143219|Drug|Irinotecan|"Irinotecan (at the dosage determined by the UGT1A1 status), 90 min IV infusion starting 30 min after the FA starts
Homozygous 6/6 or 6/7: irinotecan will start at 150 mg/m², then will be increased according to clinical/biological tolerance by 10% steps, at each cycle, up to 180 mg/m² at max.
Homozygous 7/7: irinotecan will start at 130 mg/m² in the first cycle then be increased up to a max of 150 mg/m², by 10% steps, according to tolerance."
1612497|NCT02143219|Drug|5-FU|"5-FU (according to the DPD pharmacogenetic status), continuous IV infusion of 46 hours, starting at the end of FA infusion:
If no DPD deficiency, 5-FU start at 1600 mg/m² and can be modulated according to clinical/biological tolerance after each course, i.e., 1800 mg/m² the 2nd course and 2000 mg/m² the 3rd one
If partial DPD deficiency: 5-FU start at 1200 mg/m² and can be increased up to 1800, then 2000 if the clinical/biological tolerance are good at the 2nd and 3rd course."
1612498|NCT02143193|Behavioral|Skin-to-Skin Contact|
1612499|NCT02143167|Drug|SR-fampridine|"One arm receives SR-fampridine 10 mg BID for 24 weeks followed by four weeks of inactive placebo BID.
The other arm receives placebo BID for 24 weeks followed by four weeks of SR-fampridine 10 mg BID for four weeks."
1612500|NCT02143167|Drug|Placebo|
1612501|NCT02143141|Drug|duramorph|duramorph 150 mcg given with spinal anesthetic, then receipt of placebo capsules postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
1612502|NCT02143141|Drug|placebo|placebo in an equal volume to that of duramorph 150 mcg given with spinal anesthetic, then receipt of oral acetaminophen 1000mg during first 24 hours postoperatively. evaluation postoperative day 1 for measurement of itching, nausea, vomiting, pain and itching.
1612503|NCT02143115|Procedure|Optical colonoscopy|Examination of the colon with a colonoscope
1612504|NCT02143115|Radiation|CT-Colonography|A computerized X-ray that may find out if there are polyps or cancers and also pictures the contents of the abdomen and pelvis
1612505|NCT02143089|Device|Foley's Catheter|Urinary tract infection inpatient catheterized versus non catheterized
1612506|NCT02143076|Behavioral|Demographic Questionnaire|At study enrollment, participants will complete a questionnaire to collect demographic information about the participant's family background, education and living situation.
1612507|NCT02143076|Behavioral|Medical Adherence Measure Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire describing all medications prescribed for them, when they take their medications, how much medication they take each time, how many times during the week they missed taking or were late taking each medication, reasons why they missed or were late, and how they manage their medications.
In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
1612508|NCT02143076|Behavioral|Acceptability Questionnaire|"At the two-month follow-up visit, participants will be asked to complete a questionnaire about their perceptions of using the Wise electronic medication container.
In the case that a participant's clinic schedule is delayed greater than two months from the time of consent (e.g., missed appointment, change in clinic appointment frequency), procedures scheduled for the anticipated 2-month visit will take place at the participant's next clinic appointment."
1612509|NCT02143063|Behavioral|prize contingency management on a traditional twice weekly schedule for cocaine abstinence|
1612510|NCT02143063|Behavioral|prize contingency management on a variable interval schedule for cocaine abstinence|
1612511|NCT02143063|Behavioral|standard care|
1612512|NCT02143050|Drug|Dabrafenib|
1612513|NCT02143050|Drug|Trametinib|
1612514|NCT02143050|Drug|Metformin|
1612515|NCT02143037|Behavioral|prize contingency management for attending treatment|
1612516|NCT02143037|Behavioral|usual care|
1612517|NCT02143037|Device|The Secure Continuous Remote Alcohol Monitor (SCRAMx®)|
1612518|NCT02143024|Behavioral|Family-based depression intervention|The primary focus of our approach is on effectively engaging family members of depressed older men in the care of the patient. The interventionist (social worker) will 1) work jointly with a family member and older men to strengthen depression self-management and participation during primary care visits and 2) conduct a brief training module for primary care provider skills to strengthen their skills in working with family members.
1612519|NCT02143024|Behavioral|Usual care plus educational materials|Control subjects will receive usual care in the clinic augmented by psychoeducation. Family members will be given standard psychoeducational materials on depression.
1612520|NCT02143011|Other|orange juice|intervention assigned: 2-week consumption of naturally-sweetened orange juice providing 25% of energy requirement
1612521|NCT02143011|Other|sucrose|intervention assigned: 2-week consumption of sucrose-sweetened beverage providing 25% of energy requirement
1612522|NCT02142998|Other|24 pH monitoring|The study is performed with the patient fasting for a minimum of 6 hours. A single channel or dual channel (15 cm spacing) pH probe is inserted trans nasally. The pH sensor, or distal pH sensor in the case of 2 channel testing, is positioned 5 cm above the proximal margin of the LES, as determined by esophageal manometric testing. pH-Z ambulatory monitor (Given Imaging Digitrapper) is used for data acquisition and the data analyzed with pH Analysis Program (Given Imaging AccuView). The number of reflux events, defined as a drop in esophageal pH readings below 4.0, is recorded and the percentage of time with esophageal acid exposure is analyzed using defined protocols and accepted normal values.
1612523|NCT02142998|Other|Esophageal Manometry:|A high resolution esophageal manometry catheter is used for testing and inserted Trans nasally. The patient is given 10 liquid swallows (5mL of water), at intervals of approximately 30 seconds. The catheter (Sierra Scientific/Given Imaging) has 36 sensors, each one averaging pressures from 12 circumferential positions. This gives a total of 432 data points. The sensors are placed 1 cm apart, spanning a length of 35 cm. The catheter simultaneously records pressure readings from the esophagus, sphincter regions (UES and LES), pharynx and stomach without the need for a station pull-through technique. Results are reported according to defined protocols and accepted normal values.
1612525|NCT02142959|Drug|Omaveloxolone Lotion 0.5%|Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
1612526|NCT02142959|Drug|Omaveloxolone Lotion 3%|Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
1612527|NCT02142959|Drug|Lotion vehicle/Placebo|Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
1612528|NCT02142959|Radiation|3D conformal radiation therapy|45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
1612529|NCT02142933|Other|vagino-perineal swab|
1612530|NCT02142920|Drug|PF-05212384|Single 89 mg Dose via 30 minute IV infusion
1612531|NCT02142894|Device|CST001|
1612532|NCT02142881|Other|Antihypertensive medication intensification|Antihypertensive medications will be adjusted by study staff based on ambulatory and clinic BP results at baseline and 2 months with a target 24hr systolic blood pressure of <130 mmHg.
1612533|NCT02142881|Other|Usual care|Antihypertensive medications will be adjusted by the participants' providers (usual care).
1612534|NCT02142868|Drug|Palbociclib|Palbociclib will be administered orally once a day at 125 mg/day for 21 days followed by 7 days off treatment for each 28-day cycle (Schedule 3/1)
1612535|NCT02142868|Drug|Letrozole|Letrozole will be administered orally at 2.5 mg once daily as continuous daily dosing schedule according to product labeling and in compliance with its local prescribing information.
1612538|NCT02142842|Biological|Autologous adipose tissue stromal vascular fraction and platelet rich plasma|
2010315|NCT03018249|Other|Laboratory Biomarker Analysis|Correlative studies
2010316|NCT03018249|Drug|Medroxyprogesterone Acetate|Given IM
1612541|NCT02142816|Device|Doppler|Fluid therapy guided by doppler
1612542|NCT02142816|Other|PVI`|Fluid therapy guided by PVI
1612543|NCT02142803|Biological|Bevacizumab|Given IV
1612544|NCT02142803|Other|Laboratory Biomarker Analysis|Correlative studies
1612545|NCT02142803|Other|Pharmacological Study|Correlative studies
1612546|NCT02142803|Drug|Sapanisertib|Given PO
1612547|NCT02142790|Drug|paclitaxel liposome injection|
1612548|NCT02142777|Drug|S -Equol|We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
1612549|NCT02142777|Drug|Placebo|The placebo has no active ingredients but is made to look like the study drug.
1612550|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, twice, the day they sign their agreement and six months after in case of positive myelin pentamer test (at inclusion and 6 months after the inclusion).
1612551|NCT02142764|Biological|Blood samples|The blood will be sampled in order to be tested in Immunology, once, the day they sign their agreement (at the inclusion)
1612552|NCT02142751|Drug|Fosfomycin sodium intravenous|4g every 6 hours iv (60 min infusion)
1612553|NCT02142751|Drug|Meropenem intravenous|1g every 8 hours (15-30 min infusion) It depends on strain sensitivity: Strain with resistance to cephalosporins
1612554|NCT02142751|Drug|Ceftriaxone intravenous|1g every 24 hours iv (2-4 min infusion) It depends on strain sensitivity: Strain with resistance to quinolone but sensitivity to cephalosporins
1612555|NCT02142738|Drug|Pembrolizumab|Pembrolizumab IV solution
1612556|NCT02142738|Drug|Paclitaxel|Paclitaxel IV solution
1612557|NCT02142738|Drug|Carboplatin|Carboplatin IV solution
1612558|NCT02142738|Drug|Pemetrexed|Pemetrexed IV solution
1612559|NCT02142738|Drug|Cisplatin|Cisplatin IV solution
1612560|NCT02142738|Drug|Gemcitabine|Gemcitabine IV solution
1612561|NCT02142725|Drug|LT-02|four times per day
1612562|NCT02142725|Drug|LT-02|two times per day
1612563|NCT02142725|Drug|Placebo|four times per day
1612564|NCT02142712|Drug|Diphenhydramine|Diphenhydramine 12.5 mg BID intravenous or 25 mg BID oral for 4 days along with current standard of care.
1612565|NCT02142712|Drug|Pantoprazole|Pantoprazole intravenous 40mg q daily as part of standard of care for stress ulcer prophylaxis along with current standard of care.
1612566|NCT02142712|Drug|Famotidine|Famotidine 40 mg intravenous BID (maximum dose of 80 mg/day) for 4 days as part of standard of care for stress ulcer prophylaxis along with current standard of care.
1612567|NCT02142712|Drug|Dextromethorphan|Dextromethorphan 60 mg QID orally (maximum dose of 240 mg/day) for 2 days (total of 4 doses) along with current standard of care. If the drug can't be given orally, then feeding tube (G-tube, NG Tube or DHT) will be used for drug administration.
1612568|NCT02142699|Drug|Heme arginate|
1612569|NCT02142686|Device|Filling pressure 80|After the hysteroscope is introduced into the uterine cavity, the filling pressure will remain at 80mm Hg.
1612570|NCT02142686|Device|Filling pressure 50|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 50mm Hg.
1612571|NCT02142686|Device|Filling pressure 30|After the hysteroscope is introduced into the uterine cavity, the filling pressure will be reduced to 30mm
1612572|NCT02142673|Device|Filling pressure 80|The hysteroscope filling pressure will be 80mm Hg
1612573|NCT02142673|Device|Filling pressure 60|The hysteroscope filling pressure will be reduced to 50mm Hg
1612574|NCT02142673|Device|Filling pressure 40|The hysteroscope filling pressure will be 40mm Hg
1612575|NCT02142660|Procedure|ablation of gastric|Applied to the operating zone during an ablation of gastric died ring at obese patients programmed for the second bariatric surgery to type of bypass gastric or of gastrectomie in wing
1612576|NCT02142647|Behavioral|a high-protein complementary diet with meat|infants will consume a high-protein complementary diet with protein mainly from meat
1612577|NCT02142647|Behavioral|a high-protein complementary diet with dairy|infants will consume a high-protein complementary diet with protein mainly from dairy
1612578|NCT02142634|Drug|Budesonide granules 9 mg|per day
1612579|NCT02142634|Drug|Placebo granules|per day
2010317|NCT03017716|Other|Gluten free diet|The investigators will evaluate the effect of a gluten free diet (GFD) in IBP patients, randomly assigned to receive standard therapy for IBP or standard therapy for IBP plus GFD, for a period of at least one year.
2010318|NCT03015207|Drug|NNC0194-0499|
1612583|NCT02142595|Drug|dexmedetomidine|The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
1612584|NCT02142595|Drug|Midazolam|The sedative solution administered intravenously started at rate of kg (weight of patient)*0.6 ml/h over a 10-min period and then at rate of kg (weight of patient)*0.15 ml/h through syringe pump to the end of surgery
1612585|NCT02142582|Dietary Supplement|WHO ORS|Participants will be randomized into one of the two groups. They will be provided with one of the two ORS solutions. Then, they will be followed for 6 months.
1612586|NCT02142582|Dietary Supplement|Commercial ORS|Participants will be instructed to dilute contents of the provided ORS to a 1 liter bottle and sip all day.
1612587|NCT02142569|Drug|Sugar Pill|Sugar Pills/Placebo 4 capsules/day for 12 weeks.
1612588|NCT02142569|Drug|Chinese Red Yeast Rice (CRYR)|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + placebo (2 capsules) for 12 weeks.
1612589|NCT02142569|Drug|CRYR + TRF|CRYR 1200mg/day, including 6 mg mevinolin as Monacolin K (2 capsules) + TRF 300mg/day including 60 mg tocotrienols (2 capsules) per day for 12 weeks.
1612590|NCT02142569|Device|Tocotrienol-enriched Fraction of Palm Oil (TRF)|TRF 300mg/day, including 60 mg tocotrienols (2 capsules) + placebo (2 capsules) per day for 12 weeks.
1612591|NCT02142556|Drug|Administration of quetiapine XR|The treatment was initiated with a 7-day cross-titration period. Previous antipsychotic medication was maintained at the original dose from day 1 to day 3; then reduced to 50% of the original dose from day 4 to day 7 and discontinued on day 8. Meanwhile, the patients started quetiapine XR with daily dose at 300 mg on day 1, 600 mg on day 2 and up to 800 mg after day 2. From day 8 until the end of the study, the dose of quetiapine XR was adjusted within 400-800 mg per day, depending on the clinical response and tolerability of the patients.
1612592|NCT02142543|Drug|2-DeNT powder|powder included dexamethasone, diphenhydramine, tetracycline, metronidazole, nystatin, zinc oxide, and karaya gum
1612593|NCT02142543|Drug|Placebo Comparator|
1612594|NCT02142530|Drug|Carfilzomib|
1612595|NCT02142530|Drug|Belinostat|
1612596|NCT02142517|Procedure|Duct to mucosa PJ group|Duct to mucosa PJ was performed by a two layer end to side PJ. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic duct diameter. The inner layer duct to mucosa was performed in eight to twelve stitches with 5/0 prolene. A pancreatic duct stent was inserted during anastomosis to allow easy and accurate suture placement, ensure adequate pancreatic duct exposure, and protect the opposite wall from being inadvertently held by needles then it was removed at the end of anastomosis.
1612597|NCT02142517|Procedure|Invagination PJ group|Invagination PJ was performed as an end to side. The pancreatic capsule and jejunal serosa were anastomosed by interrupted silk suture 3/0 to form the outer layer in both the anterior and posterior wall of the anastomosis. Jejunostomy was done matched to the pancreatic stump diameter. The inner layer was performed with 5/0 prolene between pancreatic parenchyma and mucosa. The duct was taken posteriorly and anteriorly to jejunal mucosa. A pancreatic duct stent was inserted during anastomosis and removed at the end of taking the stitches. Reconstruction was completed by end to side hepaticojejunostomy (retrocolic) and gastrojejunostomy (GJ) (antecolic) end to side manually.
1612598|NCT02142504|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine adjuvanted with or without MPL and/or aluminum hydroxide IM injection
1612599|NCT02142504|Drug|Placebo (Saline)|Placebo-matching norovirus bivalent VLP vaccine
1612600|NCT02142478|Behavioral|Adapted Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week. In February 2012, Centre A introduced some changes to the EFH scheme as follows:
Pre-scheme meeting with a health trainer to help the patient decide if EFH is for them.
Participants offered specially tailored group classes (exclusive to EFH participants, e.g. low-impact circuits, Zumba) as well as access to the main gym.
Opportunities to attend daily.
Although subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members) is also available, this option is not openly advertised on the adapted scheme."
1612601|NCT02142478|Behavioral|Standard Exercise for Health (EFH) scheme|"12-week subsidised exercise programme at local authority-run leisure centres. Each participant receives a programme of activities tailored to their needs, based on a standard recommendation of two exercise sessions per week.
The scheme includes exclusive EFH gym sessions (i.e. includes EFH participants only) on two to three days of the week, plus subsidised access to mainstream group classes and swim sessions (i.e. includes all leisure centre members)."
1612602|NCT02141698|Drug|TAK-438|TAK-438 tablets
1612603|NCT02141698|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
1612604|NCT02141698|Drug|Esomeprazole|Esomeprazole tablets
1612605|NCT02142452|Behavioral|behavioral intervention|Behavioral intervention will include a group class for women in their 3rd trimester followed by a mobile texting program to support behavior change postpartum.
1612606|NCT02142452|Other|Usual Prenatal Care|
1612607|NCT02142439|Behavioral|Strength training|Three times per week with strength training
1612608|NCT02142400|Drug|DS-1093|DS-1093 in capsules with 2.5mg or 25mg per capsule
1612609|NCT02142400|Drug|placebo|matching placebo capsules to DS-1093 capsules
2010319|NCT03015207|Drug|Placebo|
1612611|NCT02142361|Device|enfilcon A|Silicone hydrogel toric lenses.
1612612|NCT02142335|Drug|Rituxan|The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 & 3 (days 1 & 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
1612613|NCT02142322|Drug|MODIFIED FOLFOX6|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
1612614|NCT02142309|Drug|Glimepiride|Weekly adjustment based on self-monitoring of blood glucose level to a maximum of 4 mg daily
1613008|NCT02139111|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
1612615|NCT02142309|Drug|Vildagliptin|Reduce to 50 mg if estimated glomerular filtration rate (eGFR) <45 mL/min
1612616|NCT02142309|Drug|Pioglitazone|Start with 15 mg/day and advance to 30 mg/day
1612617|NCT02142309|Drug|Canagliflozin|Start with 200 mg/day and advance to 300 mg/day on the basis of fasting glucose monitoring
1612618|NCT02142296|Drug|Eylea|monthly injections for 3 months and then every other month to 1 year. volume administered is 0.05ml
1612619|NCT02142283|Device|Trevo Thrombectomy Procedure|stent retriever; intended to restore blood flow in the neurovasculature by removing thrombus (clot)
1612620|NCT02142283|Other|Medical Management|Standard of Care not including mechanical thrombectomy, no intra arterial treatment, may include aspirin, therapy etc
1612621|NCT02142257|Procedure|Gastric Bypass|Gastric Bypass surgery reduces the size of the stomach by use of staples. The smaller gastric pouch is then connected to the intestine bypassing a portion of the small intestine.
1612622|NCT02142257|Device|AspireAssist Aspiration Therapy|AspireAssist employs an endoscopically placed A-Tube (similar to a gastrostomy tube) and a Companion system which facilitates portion control by aspiration of stomach contents 20 minutes after each meal combined with behavioral Therapy.
1612623|NCT02142244|Procedure|Near infra red sentinel node biopsy|Explicated in the protocol arm
1612624|NCT02142244|Drug|Indocyanine green|Explicated in the protocol arm
1612625|NCT02142244|Device|Intraoperative Near-Infrared Imaging System|Explicated in the protocol arm
1612626|NCT02142231|Device|Acupuncture|Sterile Acupuncture Needles (Seirin (R) 0.15x0.2) will be used, Needles are inserted for approx. 0.5-1 cm until deqi response is elicited
1612627|NCT02142231|Device|Laser Acupuncture|Therefore a laser irradiation is faked, approaching a nonfunctioning laser pen, which has been deactivated by the manufacturer (3B Scientific GmbH, Hamburg, Germany). Only red light is emitted. To further emphasize the imaginary power of this sham procedure, visual and acoustic signals accompany the red light emission. Patients are treated at the same acupuncture points as in the acupuncture group for one minute without skin contact. The resting time after treatment is 18 minutes.
1612628|NCT02142218|Drug|Nivolumab|
1612629|NCT02142205|Biological|BG00002|IV Infusion
1612630|NCT02142192|Drug|natalizumab|Administered as specified in the treatment arm
1612631|NCT02142179|Behavioral|Knowledge about Asthma and Respiratory Education (KARE)|KARE - Knowledge about Asthma and Respiratory Education is an educational curriculum intervention organized with school staff to be applied to the intervention group. This intervention will consist of theoretical - practical weekly workshops with a targeted content for asthma and involves aspects related to anatomy and physiology of the respiratory tract, conceptualization of asthma, prevention, treatment, maintenance and retrieval; recognition and actions in periods of exacerbations and use the action plan. These workshops are suitable for the course plan of disciplines sciences, biology, chemistry, physics, history, geography, portuguese and mathematics. Those are characterized as a mandatory curriculum component and they should be developed for all students.
1612632|NCT02142166|Procedure|Biomarker in serum, liquor, micro-dialysate|Daily (21 days) analysis of biomarker in serum, in liquor and in micro-dialysate
1612633|NCT02142166|Procedure|Biomarker in serum and in liquor|Single analysis of biomarker in serum and liquor
1612634|NCT02142153|Drug|F901318|"Comparison of adverse events, clinically significant safety laboratory abnormalities and ECG abnormalities.
Pharmacokinetic profile"
1612635|NCT02142153|Drug|Placebo|Comparison of adverse events and clinically sign significant safety lab and ECG abnormalities
1612636|NCT02142140|Behavioral|Academic and Organization skills|This program aims at teaching children organization, time management and stress management skills. They are also taught academic strategies in reading, writing, and math. The program consists of six, 90 minute sessions.
1612637|NCT02142140|Behavioral|Parent Training|The Parent Training Program: The parent training program is designed to increase parental understanding of ADHD; establish attentive, positive interactions, and solve problems collaboratively. Eight weekly group sessions lasting about 2 hours each will be conducted by trained psychologists, social workers, or clinical nurses. Homework assignments and detailed summary sheets will be used to promote technique acquisition and generalization.
1612638|NCT02142140|Behavioral|Social Skills Training|Social Skills and Anger Management Training: The social skills training program is based on understanding yourself and others, and being able to understand things from the other's perspective. The program uses direct instruction, modelling, behavioural rehearsal, feedback, and social reinforcement. The following are covered: joining in, understanding emotions, dealing with anger, using self-control, responding to teasing / bullying, and staying out of fights.
1612639|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed at regular once per three month visits for medication monitoring. In this group the child can be referred for a medication reevaluation and adjustment as many times as is needed.
1612640|NCT02142140|Drug|Long-acting stimulant|The medication prescribed is usually a long-acting stimulant that is carefully titrated to the child's optimal dose (normally that dose above which further improvement is not seen and side effects are manageable). Once optimal dose is reached, children are followed by their pediatrician, with a frequency at his/her discretion.
1612641|NCT02142127|Drug|14C-labelled GFT505 120 mg|
1612642|NCT02142114|Device|Eye injection by 30 or 32 gauge needle|Consented patients receiving monthly bi-lateral injections of the same dose of ranibizumab will have one eye injected with a 30 gauge needle and the other eye injected with a 32 gauge needle. Bi-lateral injections may be performed on the same day or with one week of each other, depending on the subject preference and their normal injection regimen. On the first visit following enrollment in the study, the eye to receive the injection from the 30 or 32 gauge needle will be determined randomly. The other eye will be injected with the other needle size. When the patient returns for their next set of bi-lateral injections, the eyes receiving the 30 and 32 gauge needle injection will switch.
1612643|NCT02142088|Device|GlySure Intravascular Continuous glucose monitoring sensor|Comparator device is an iSTAT device from Abbott Diagnostics
1612644|NCT02142075|Drug|Daptomycin|
1613009|NCT02139111|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
1612647|NCT02142036|Drug|EMA-approved ATI based targeted therapy|All drugs that may be used in the study are approved by EMA for treatment of disseminated cancer in the palliative setting, but not for the particular tumor type in question.
1612648|NCT02142010|Drug|paclitaxel liposome injection plus cisplatin|Paclitaxel liposome injection 80 mg/m2, given on days 1, 8,15 and 22 of a 28-day cycle. Cisplatin 25 mg/m2, given on days 1, 8 and 15 of a 28-day cycle, for 4 cycles(4 months)
1612649|NCT02141997|Biological|adalimumab|adalimumab administered as subcutaneous injection every other week (EOW)
1612650|NCT02141997|Biological|ABT-122|ABT-122 administered as subcutaneous injection every other week (EOW)
1612651|NCT02141958|Drug|Fenretinide|Fenretinide oral capsules of 100mg, each selected dose being administered once daily for 21 days (treatment cycle). Up to three total daily dose levels will be assessed in the study, as follows: 100mg of Fenretinide (one capsule) for the first treatment cycle, 200mg of Fenretinide (two capsules) in the second treatment cycle, and 300mg or 400mg of Fenretinide (3 or 4 capsules) will be selected for the third treatment cycle, based on safety and PK data collected.
1612652|NCT02141958|Drug|Placebo|A matching placebo will be used to keep the study double-blind.
1612653|NCT02141932|Procedure|Bed-side pocket size ultrasound imaging|
1612654|NCT02141932|Device|GE Ultrasound Vscan|
1612655|NCT02141919|Radiation|Stereotactic Ablative Radiation Therapy|Stereotactic Ablative Body Radiation Therapy (SABR): 3 fractions of 12Gy, or 4 fractions of 10Gy or 5 fractions of 8 Gy
1612656|NCT02141906|Device|Oncozene-DEB-TACE|ONCOZENE microspheres are the newly available microspheres for DEB-TACE. It appears (based on the preliminary bench tests) that these microspheres may allow more efficient drug loading, and slow elution and equivalent vascular occlusion(12). In this pilot study, we aim to assess the safety of these microspheres when used for chemoembolization of unresectable hepatocellular carcinoma.
1612657|NCT02141893|Behavioral|CALMA plus|Participants received a family education intervention (previously tested) known as CALMA plus physician education and organizational change of the clinics were addressed with a culturally tailored program developed by adapting content from several evidence-based provider training programs
1612658|NCT02141893|Behavioral|CALMA|Family Education Intervention on management of pediatric asthma
1612659|NCT02141854|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.
During the treatment period, participants were randomized to either fluticasone propionate/salmeterol MDPI 200/12.5 mcg or fluticasone propionate/salmeterol MDPI 100/12.5 mcg twice a day for a total daily dose of 200/25 mcg or 400/25 mcg.
Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
1612660|NCT02141854|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.
During the treatment period, participants were randomized to either 200 mcg or 100 mcg of Fp one inhalation twice a day for a total daily dose of 400 mcg or 200 mcg.
Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
1612661|NCT02141854|Drug|Placebo MDPI|The placebo multidose dry powder inhaler (MDPI) was identical to the devices used to deliver active drug, and indistinguishable from the active treatments. Patients took one inhalation twice a day (approximately 12 hours apart). Patients were instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
1612662|NCT02141854|Drug|Albuterol/salmeterol HFA MDI|Albuterol/salmeterol hydrofluoroalkane (HFA) metered dose inhaler (MDI) was supplied to participants throughout the study to be used as needed as a rescue medication.
1612663|NCT02141828|Drug|EPZ-5676|28-day continuous IV infusion of each 28-day cycle, given until disease progression or unacceptable toxicity develops.
1612664|NCT02141815|Dietary Supplement|Arabinoxylan-oligosaccharides|
1612665|NCT02141815|Dietary Supplement|Maltodextrine|
1612666|NCT02141802|Behavioral|Doubling standing time|Doubling standing time using child's previously prescribed standing frame with a progression of 10% increase in time/month up to 2 hrs/day maximum
1612667|NCT02141802|Behavioral|control|Continue with usual standing time with a progression of 10% increase in time/month up to 1 hr/day maximum
1612668|NCT02141789|Behavioral|Outpatient Cognitive Behavioral Psychotherapy|Integrated CBT intervention for alcohol dependence and comorbid psychiatric disorder (we include only patients with comorbid mood or anxiety disorders).
1612669|NCT02141789|Behavioral|Outpatient Cognitive Behavioral Psychotherapy|The intervention is a well established form of psychotherapy that has infrequently been used in the German system with this group of patients in contrast to many other countries where it is the standard approach, e.g. the US.
1612670|NCT02141776|Device|Transcranial direct current stimulation (t-DCS)|The subjects randomized to this group will receive anodal t-DCS stimulation daily for four weeks. The stimulation parameters: current 2 mA continuously for 30 minutes.
1612671|NCT02141776|Other|Sham Controlled Arm|The subjects randomized to this group will not receive stimulation daily for four weeks.
1612672|NCT02141763|Drug|UCB4940 40 mg|"Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous"
1612673|NCT02141763|Drug|UCB4940 80 mg|"Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous"
1612674|NCT02141763|Drug|UCB4940 160 mg|"Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous"
1612675|NCT02141763|Drug|UCB4940 240 mg|"Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous"
1612773|NCT02140970|Drug|Placebo|Similar-tasting and appearing liquid placebo of equal volume to be given once orally at least 15 minutes prior to ureteral stent removal
1613257|NCT02137239|Drug|Corticosteroids|
1612676|NCT02141763|Drug|UCB4940 320 mg|"Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous"
1612677|NCT02141763|Drug|UCB4940 560 mg|"Active Substance: UCB4940
Pharmaceutical Form: solution
Concentration: vials at 80 mg/mL will be diluted with 0.9 % sodium chloride to a final concentration calculated to achieve the correct dose
Route of Administration: intravenous"
1612678|NCT02141763|Other|Placebo|"Pharmaceutical Form: solution
Concentration: 0.9 % sodium chloride
Route of Administration: intravenous"
1612679|NCT02141737|Drug|Lidocaine Hydrochloride Injection|Lidocaine injection should be give before the injection of etomidate. In groups L1 and L2, 20 mg and 30 mg lidocaine injection will be diluted to 2ml separately.
1612680|NCT02141737|Drug|Etomidate Fat Emulsion Injection|1 minute after the injection of lidocaine, 0.3 mg/kg etomidate will be given in 30 to 60 s.
1612681|NCT02141737|Drug|normal saline|2 ml normal saline will be given 1 minute before the injection of etomidate in patients in group C, and in group L1 and L2, normal saline is used to dilute lidocaine injection to 2 ml.
1612682|NCT02141737|Drug|Midazolam Injection|0.02 mg/kg midazolam will be given to the patients in all groups 90 s after the injection of etomidate.
1612683|NCT02141737|Drug|Fentanyl Citrate Injection|3 μg/kg fentanyl will be given to patients in all groups after the injection of midazolam.
1612684|NCT02141737|Drug|Rocuronium Injection|0.6 mg/kg rocuronium will be given to patients in all groups after the injection of fentanyl.
1612685|NCT02141724|Other|Positioning consultation|Assessment of pain,bedsores and postural troubles
1612686|NCT02141711|Drug|TAK-438|TAK-438 tablets
1612687|NCT02141711|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
1612688|NCT02141672|Drug|Voclosporin High Dose|
1612689|NCT02141672|Drug|Voclosporin Low Dose|
1612690|NCT02141672|Drug|Placebo|
1612691|NCT02141659|Drug|TAK-385|Drug (including placebo)
1612692|NCT02141646|Behavioral|Motivational Interviewing|The main goals of motivational interviewing are to engage clients, elicit change talk, and evoke motivation to make positive changes from the client.
1612693|NCT02141646|Behavioral|Behavioral Skills Training|Behavioral Skills Training (BST) is a training package that utilizes instructions, modeling, rehearsal, and feedback in order to teach a new skill.
1612694|NCT02141633|Procedure|echocardiogram plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
1612695|NCT02141633|Procedure|airway blood flow plus albuterol|participants will performed echocardiogram before and 15 minutes after inhaled albuterol
1612696|NCT02141633|Drug|Fluticasone propionate|participant will be received a 4-week course of inhaled fluticasone (220 μg fluticasone twice a day administered as a MDI using a spacer)
1612697|NCT02141633|Drug|placebo|participant will be received a 4-week course of identically appearing placebo (2 puffs twice a day via spacer).
1612698|NCT02141620|Drug|Cocaine|The pharmacodynamic effects of cocaine will be determined during maintenance on placebo and n-acetylcysteine.
1612699|NCT02141620|Drug|n-Acetylcysteine|
1612700|NCT02141620|Drug|Placebo|
1612701|NCT02141581|Biological|Fluzone® (IM)|This vaccine is given intramuscularly (IM)
1612702|NCT02141581|Biological|Fluzone® Intradermal (ID)|This vaccine is given intradermally (ID)
1612703|NCT02141581|Biological|2011-2012 FluMist®|This vaccine is given intranasally
1612704|NCT02141568|Other|Medical and psychological treatment|"Medical and psychological treatment by the staff of the functional neurology clinic at Soroka UMC. This treatment will include an initial visit to the staff neurologist and further multidisciplinary treatment as per his decision (the team includes a psychologist and a physical therapist)."
1612705|NCT02141568|Other|Routine medical care|Treatment by an internal medicine physician on staff at Soroka UMC. Treatment will include an initial visit to the physician and further treatment as per his decision.
1612706|NCT02141555|Drug|Vaginal Misoprostol|Misoprostol inserted into vagina
1612707|NCT02141555|Drug|Buccal Misoprostol|Misoprostol placed between the gum and cheek and allowed to dissolve for 30 minutes with the remnants swallowed after this time.
1612708|NCT02141542|Drug|Tremelimumab|
1612709|NCT02141542|Drug|MEDI3617|
1612710|NCT02141529|Procedure|Unipolar pulsed radiofrequency thermocoagulation|Unipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
1612711|NCT02141529|Procedure|Bipolar pulsed radiofrequency thermocoagulation|Bipolar pulsed radiofrequency thermocoagulation, intraarticular administration into the knee joint
1612712|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
1612713|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
1612714|NCT02141516|Biological|rMenB+OMV|2 doses of vaccine 2 months apart
2010320|NCT03014414|Behavioral|Fun First|Learn key enjoyable maintenance skills before losing weight
1612716|NCT02141477|Drug|Omacetaxine|Phase I and Phase II Omacetaxine Dose: 1.25 mg/m2 subcutaneously every 12 hours on Days 1 - 3 of a 28 day cycle.
1612717|NCT02141477|Drug|Decitabine|"Phase I Starting Decitabine Dose: 20 mg/m2 by vein on Days 1 - 5 of a 28 day cycle.
Phase II Starting Decitabine Dose: Maximum tolerated dose from Phase I."
1612718|NCT02141451|Drug|Rituximab|Rituximab 375 mg/m2 IV after day +28 re-staging and again 1 and 7 weeks later
1612719|NCT02141451|Drug|INCB7839|INCB7839 at assigned dose twice daily for 90 days - begin the morning of the 2nd dose of rituximab
2010321|NCT03014414|Behavioral|Weight Watchers|Focus on losing weight first via convenient meetings and personalized online tools
1612721|NCT02141425|Drug|ASP015K|oral
1612722|NCT02141425|Drug|Placebo|oral
1612723|NCT02141412|Drug|dexmedetomidine 0.25 µg/kg IV|
1612724|NCT02141412|Drug|dexmedetomidine 0.5 µg/kg IV|
1612725|NCT02141412|Drug|dexmedetomidine 1 µg/kg IV|
1612726|NCT02141399|Drug|ALKS 5461|Sublingual tablet, taken daily
2010322|NCT03014479|Drug|Trelagliptin|Trelagliptin 100 mg or 50 mg
1612728|NCT02141373|Device|Glubran 2|
1612825|NCT02140489|Drug|amosartan and rosuvastatin|
2010323|NCT03014479|Drug|Daily DPP-4 inhibitor|Alogliptin, anagliptin, linagliptin, saxagliptin, sitagliptin, teneligliptin or vildagliptin
1612729|NCT02141360|Device|MRI Diagnostic|Commercially available MRI scanner using investigational or standard of care MR coils and a series of investigational Application Packs containing a predetermined set of MRI pulse sequences
1612730|NCT02141347|Drug|Tremelimumab|Tremelimumab administered intravenously
1612731|NCT02141347|Drug|MEDI4736|MEDI4736 administered intravenously.
1612732|NCT02141321|Drug|Misoprostol|
1612733|NCT02141321|Drug|Placebo|
1612734|NCT02141295|Drug|5-FU|5-FU will be administered according to dose and schedule described in respective arm.
1612735|NCT02141295|Drug|Bevacizumab|Bevacizumab will be administered according to dose and schedule described in respective arm.
1612736|NCT02141295|Drug|Folinic acid|Folinic acid will be administered according to dose and schedule described in respective arm.
1612737|NCT02141295|Drug|Oxaliplatin|Oxaliplatin will be administered according to dose and schedule described in respective arm.
1612738|NCT02141295|Drug|Vanucizumab|Vanucizumab will be administered according to dose and schedule described in respective arm.
2010324|NCT03013296|Other|GIP-A|GIP-A
1612740|NCT02141256|Dietary Supplement|Protein enriched products|Newly developed products with extra protein. Specially developed for elderly.
1612741|NCT02141243|Procedure|Lingual Frenotomy|For newborns receiving the ankyloglossia frenotomy, the tongue will be elevated and the frenulum exposed with a grooved director or 2 cotton tipped applicators. The frenulum tissue will then be incised with a straight scissor. If thick, it will be crushed with a straight clamp to provide anesthesia and decrease bleeding, and the exposed and previously clamped tongue frenulum will be incised with a straight scissor.
1612742|NCT02141243|Procedure|Labial Frenotomy|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
1612743|NCT02141243|Procedure|Sham Procedure|For newborns receiving the maxillary labial frenotomy, 0.1 ml of 1% lidocaine will be injected into the area. The upper lip will be lifted and the frenum stretched. Then an iLaseTM 940 ± 15 nm laser will be used to release its attachment to the level of the periosteum.
1612744|NCT02141230|Drug|Alli® 60 mg|Participants purchasing Alli®
1612745|NCT02141217|Drug|Amoxicillin/clavulanate|Amoxicillin/clavulanate 1 g bd for at least 5 days or maximum 7 days depending upon the treatment response.
1612746|NCT02141217|Drug|Clindamycin|Clindamycin 150 mg qid for at least 5 days or maximum 7 days depending upon the treatment response.
2010325|NCT03013296|Other|Placebo|Placebo
2010326|NCT03013296|Other|GLP-1 receptor antagonist Exendin[9-39]|Exendin[9-39]
1612749|NCT02141191|Drug|inhaled hypertonic saline (7%)|Inhaled hypertonic saline delivered by nasal cannula using the Parion transnasal Pulmonary Aerosol Delivery (tPAD) device
1612750|NCT02141178|Drug|Bupivacaine|
1612751|NCT02141178|Drug|Exparel|
1612752|NCT02141165|Device|Diagnosis, autoCPAP, follow up.|comparison between the efficacy of two protocol
1612753|NCT02141139|Drug|NSAIDS (ketorolac and ibuprofen)|
1612754|NCT02141126|Other|Resistance training|Usual physiotherapy care and twice weekly tailored and progressive resistance lower limb exercises Circuit-type format, sessions will last 35 minutes and will include a warm-up and cool-down period. Exercises tailored to each patient and will use ankle weights as the resistance, using 65-75% of their 1-Repetition Maximum. Intervention will last for 6 weeks.
1612755|NCT02141126|Other|Usual care|Standard inpatient 'usual care' physiotherapy
2010327|NCT03013296|Other|GIP-A + Exendin[9-39]|GIP-A + Exendin[9-39]
2010328|NCT03010995|Drug|Prazosin|Prazosin will used to study the mechanism involved in nicotine induced acute cardiovascular changes
1612758|NCT02141100|Drug|6-thioguanine|"All eligible patients will be supplemented with 6-thioguanine in addition to the standard therapy with 6-mercaptopurine and methotrexate.
In case of significant myelo-/hepatotoxicity all therapy will be paused. If patients develop VOD they will be excluded from further 6TG therapy."
1612759|NCT02141087|Drug|Pirfenidone|
2010329|NCT03008135|Other|Elderly Mobility Scale|The Elderly Mobility Scale was devised to assess the mobility of fragile elderly people, and contains seven items considered as essential for performing the basic activities of the daily routine: Lying down to sitting, sitting to lying down, sitting to standing, standing, Gait/ work on body posture, timed walk (6 meters) and work on Functional Reach/movements?
1612761|NCT02141061|Drug|Telapristone Acetate, Proellex 12 mg Formulation A|
1612762|NCT02141061|Drug|Telapristone Acetate, Proellex 12 mg Formulation B|
1612763|NCT02141048|Behavioral|Positive Parenting Skills Training|This parenting programme is delivered by facilitators from the Parent Centre. It is intended for any caregivers of children between the ages of 6-12 years. It consists of seven weekly 3-hour sessions, and is group-based. Once the group size reaches 20 or more people sessions are co-facilitated. The first session provides an overview of the programme. The remaining sessions consider topics including: factors that affect child behaviour, understanding children's feelings, building children's self-esteem, assertive parenting, gaining child-co-operation, effective discipline, and problem solving. The programme is knowledge-based and encourages the development of various parenting skills through the inclusion of experiential activities (e.g., role-plays and homework practice).
2010330|NCT03008135|Other|Frailty scale|"6 questions are asked to the person about his or her living conditions to determine the level of frailty. The scale is produced by the board High Health Authority"
1612766|NCT02141022|Other|plasticity-based computerized cognitive remediation program|
1612767|NCT02141022|Drug|Gileyna|
1612768|NCT02141009|Biological|Prevnar 13|
1612769|NCT02140996|Drug|Ad-sig-hMUC-1/ecdCD40L vector vaccine|
1612770|NCT02140983|Drug|Liraglutide|90 days of liraglutide up to 1.8mg/day.
1612771|NCT02140983|Drug|Placebo|Placebo medication
1612772|NCT02140970|Drug|Ibuprofen|10 mg/kg orally up to a maximum of 400 mg given once at least 15 minutes prior to ureteral stent removal
1612873|NCT02140125|Drug|Placebo|subcutaneous administration
1612774|NCT02140957|Behavioral|Educational Intervention|Parents of children in both intervention and control groups received standardized counseling on healthy nutrition based on Canadian Paediatric Society guidelines. In addition, during the same 9-month doctors visit, parents of infants allocated to the intervention group were given a sip cup (Avent Magic CupTM) and shown how to use it. A trained research assistant told intervention group parents the risks of continued bottle use. They were also instructed to limit daily milk consumption to 16 ounces. Parents were also counseled to discontinue bottle use in the next 1 week using a step-wise protocol described on a handout to be placed on their refrigerator. Parents of infants allocated to the control group did not receive this information.
1612775|NCT02140931|Procedure|Injections|Intra-muscular injections
1612776|NCT02140918|Drug|Fludrocortisone 100 μg|Fludrocortisone 100 μg/day
1612777|NCT02140918|Drug|Fludrocortisone 200 μg|Fludrocortisone 200 μg/day
1612778|NCT02140918|Drug|Fludrocortisone 400 μg|Fludrocortisone 400 μg/day
1612779|NCT02140918|Drug|Placebo|
1612780|NCT02140892|Procedure|respiratory physical therapy manual technique- Autogenic Drainage|
1612781|NCT02140892|Device|respiratory physical therapy technique- IPV|
1612782|NCT02140879|Dietary Supplement|Capsule 1 or Capsule 2|Capsules will be consumed on a daily basis during pregnancy. One group, the placebo group of the study, will take capsules (2/day) containing oil '1 ' which is a mixture of corn and soy oils . The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets.
1612783|NCT02140879|Dietary Supplement|Capsule 2|Two capsules will be consumed on a daily basis during pregnancy. The other group, the supplement group, will take capsules containing oil '2' which is an algal oil. Both oils are found in our diets. One group, the placebo group of the study, will take capsules containing oil '1 ' which is a mixture of corn and soy oils .
1612784|NCT02140866|Other|Hand Exercise|
1612785|NCT02140866|Other|Compensatory Intervention Program (CIP)|
1612786|NCT02140840|Drug|Trametinib|2 mg of Trametinib daily by mouth in 28 day cycles
1612787|NCT02140827|Other|IMP interactive education|The detail and FAQ (Frequently Asked Questions) of bowel preparation instructions is delivered by Wechat.
1612788|NCT02140814|Dietary Supplement|Niacinamide|
1612789|NCT02140801|Drug|Ticagrelor|Plain, round, yellow, filmcoated tablet, 90 mg
1612790|NCT02140801|Drug|Clopidogrel|Orange brown capsule, containing one 75 mg clopidogrel tablet (cut into 2 halves)
1612791|NCT02140788|Drug|Metformin|
1612792|NCT02140788|Drug|Fish Oil|
1612793|NCT02140775|Behavioral|Behavioral Activation Counseling|Behavioral Activation counseling is a manualized intervention adapted from a behavioral activation treatment for depression (BAT-D) and provides a basic foundation for behavior change. The individual sessions last one hour and are scheduled every two weeks. The counseling offers a brief, structured approach to identifying and scheduling activities in life areas to reduce avoidant behavior and increase activity level with the goal of achieving employment or enroll in training.
1612796|NCT02140749|Dietary Supplement|sc-FOS 2g/day|Chewing tablets containing Short-chain fructooligosaccharides 2g/day
1612797|NCT02140749|Dietary Supplement|sc-FOS 4g/day|Chewing tablets containing short-chain Fructooligosaccharides 4g/day
1612798|NCT02140749|Dietary Supplement|sc-FOS 8g/day|Chewing tablets containing short-chain Fructooligosaccharides 8g/day
1612799|NCT02140749|Dietary Supplement|Placebo|Chewing tablets without short-chain Fructooligosaccharides
1612800|NCT02140736|Drug|Epoetin biosimilar|
1612801|NCT02140723|Radiation|preoperative short course radiation|
1612802|NCT02140710|Procedure|Osteopathic treatment|visceral osteopathic treatment algorithm: Global listening and local listening on the abdomen Release lower ribs and thoracic diaphragm Pylorusrelaxation Release of the Duodenum and the C-Loop Small intestine diagnosis- Lifting the gut and bringing it to a stillpoint Root of mesentery diagnosis (and manipulation) Mobilisation of the ileocoecalic valve Mobilisation of colon ascendens, transversum, descendens Root of sigmoid diagnosis and manipulation
1612803|NCT02140697|Dietary Supplement|Hippophae rhamnoides L. Leaf Extract (3g/day)|Hippophae rhamnoides L. Leaf extract (3g/day), parallel design
1612804|NCT02140697|Dietary Supplement|Placebo (3g/day)|Placebo (3g/day), parallel design
1612805|NCT02140684|Device|eNO monitoring|Patient undergoing review with eNO monitored using either NIOX MINO® and NIOX Flex®
1612806|NCT02140658|Behavioral|multiple health education interventions|
1612807|NCT02140658|Behavioral|conventional health education|
1612808|NCT02140645|Drug|linagliptin|non-randomized
1612809|NCT02140632|Procedure|Local methylprednisolone acetate and lidnocaine injection|
1612810|NCT02140632|Device|wrist splinting|
1612811|NCT02140619|Behavioral|multiple health education interventions|
1612812|NCT02140606|Drug|Cafusertib Hydrochloride|Drug: Cafusertib Hydrochloride (d1 and 15) Cafusertib (d1 and 15 - one hour iv.v) Drug: Cytarabine Cytarabine 2 x 20 mg/d s.c. d1-15.
1612813|NCT02140593|Drug|Group STANDARD: Rocuronium 0.6 mg/kg followed by bolus rocuronium according to standard treatment combined with saline infusion (placebo).|
1612814|NCT02140593|Drug|Group DEEP: Rocuronium 0.6 mg/kg followed by rocuronium infusion with target level PTC 0-1 combined with bolus saline (placebo) mimicking standard treatment.|
1612815|NCT02140580|Device|Minimally invasive surfactant therapy|Active Comparator
1612816|NCT02140580|Other|Continuation on CPAP|Sham Comparator
1612817|NCT02140554|Genetic|LentiGlobin BB305 Drug Product|LentiGlobin BB305 Drug Product is administered by IV infusion following myeloablative conditioning with busulfan.
1612818|NCT02140554|Biological|Plerixafor|Plerixafor is administered by subcutaneous injection prior to apheresis.
1612819|NCT02140528|Biological|Mesenchymal stem cell injection|Injection of adipose derived mesenchymal stem cell in the site of tibia fracture .
1612820|NCT02140528|Biological|Placebo|
1612821|NCT02140515|Drug|Lutropin alfa|Administration of Gonal-F or recombinant Follicle Stimulating Hormone (rFSH)
1612822|NCT02140515|Drug|Follitropin alfa and Lutropin alfa|Administration of (rFSH) and (rLH)
1612823|NCT02140489|Drug|amosartan|
1612824|NCT02140489|Drug|rosuvastatin|
1612828|NCT02140450|Drug|Timolol|2 drops of timolol, 10 minutes apart, 1-2 hours before intravitreal injection
1612829|NCT02140450|Drug|Brimonidine|Brimonidine eyedrop, 2 drops 5 minutes apart, 1-2 hours before intravitreal injection
1612830|NCT02140450|Drug|Acetazolamide|Acetazolamide tablet, 2 tabs, 2 hours before intravitreal injection
1612831|NCT02140450|Drug|Mannitol|Intravenous mannitol, 1.5 gram/kg, 1 hour before intravitreal injection
1612832|NCT02140450|Drug|Placebo|Artificial tears, 2 drops, 1-2 hours before intravitreal injection
1612833|NCT02140437|Drug|Fulvestrant|Adding fulvestrant to the standard endocrine therapy, anastrozole
1612834|NCT02140437|Drug|Anastrozole|standard endocrine therapy
1612835|NCT02140411|Drug|Ranibizumab Intravitreal injections|Ranibizumab intravitreal injections 3 months 1 per month and after PRN treatment.
1612836|NCT02140398|Procedure|Endometrial Currettage|Only Laparoscopic ovarian drilling without endometrial currettage will be performed
1612837|NCT02140385|Procedure|Abdominoplasty-Scarpa's fascia preservation|Thicker abdominal flaps will be preserved during the surgery.
1612838|NCT02140385|Procedure|Abdominoplasty-Scarpa's fascia ablation|Thinner abdominal flaps will be preserved during surgery.
1612839|NCT02140385|Device|Lymphoscintigraphy|Post-operative lymphatic imaging will be conducted using a common radiographic medium
1612840|NCT02140385|Device|3D Imaging|Post-operative 3-dimensional photography will take place at a regularly scheduled clinic appointment.
1612841|NCT02140385|Device|Abdominal ultrasound|Post-operative abdominal ultrasound will be used to determine the presence of fluid collections (seromas).
1612842|NCT02140372|Drug|Colchicine|Colchicine 1.2 mg followed by 0.6 mg one hour later
1612843|NCT02140359|Behavioral|Motivational Network Interview|Residents of a housing first permanent supporting housing program will be randomly assigned to this arm after screening and baseline assessments. They will meet roughly every two weeks with a case manager and answer questions about their social network, will be shown visual feedback about their networks, and will participate in a motivational interview conducted by the case managers. The questions and visualizations will be facilitated by an electronic tool for presenting screens with questions, capturing responses, processing and visualizing social network data.
1612844|NCT02140346|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
1612845|NCT02140346|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
1612846|NCT02140333|Drug|Erlotinib|100mg vs. 150mg
1612847|NCT02140320|Drug|RV1729 single dose|Safety and tolerability of single dose
1612848|NCT02140320|Drug|RV1729 matching placebo single dose|Safety and tolerability of single dose
1612849|NCT02140320|Drug|RV1729 14 day repeat dose|Safety and tolerability of repeat doses
1612850|NCT02140320|Drug|RV1729 matching placebo 14 day repeat dose|Safety and tolerability of repeat doses
1612851|NCT02140320|Drug|RV1729 28 day repeat dose|Safety and tolerability of repeat doses
1612852|NCT02140320|Drug|RV1729 matching placebo 28 day repeat dose|Safety and tolerability of repeat doses
1612853|NCT02140307|Behavioral|Relaxation Response-based Mental Health Promotion (RR-MHP)|"The Open and Calm intervention is based on a standardized 9-week program. Week 1 uses a simple mantra-based meditation. Week 2 and 5 uses focus on the body. Week 3 and 6 uses focus on thoughts and emotions. Week 4 and 7 uses focus on social relationships. Weeks 8 and 9 were entitled The focus you feel like, where participants chose their own focus (e.g. two weeks of bodily focus if that was most relevant for a person, while another might chose 1 week focusing on emotions and another focusing on a social relationship)."
1612854|NCT02140294|Dietary Supplement|Polymeric nutritional supplements|
1612855|NCT02140294|Dietary Supplement|Standard Nutrional Treatment|
1612856|NCT02140281|Drug|Treatment A (cefadroxil alone)|A single 500 mg oral dose of cefadroxil will be given on the morning of Day 1
1612857|NCT02140281|Drug|Treatment B - AZD1722 followed by cefadroxil|15mg oral dose of AZD1722 will be given twice daily from Day 1 to Day 4 followed on the morning of Day 5 by a single dose of 15 mg AZD1722 taken together with a single 500mg dose of cefadroxil
1612858|NCT02140268|Drug|Midazolam|Volunteers will receive a single dose of Midazolam 7.5 mg on Day 1
1612859|NCT02140268|Drug|AZD1722|Volunteers will receive twice daily, oral doses of AZD1722 15 mg on Days 2-14
1612860|NCT02140268|Drug|AZD1722 and Midazolam|On Day 15 volunteers will receive AZD1722 15 mg and Midazolam 7.5 mg at the same time in the morning. In the evening on Day 15 AZD1722 15 mg will be administered alone.
1612861|NCT02140255|Drug|Intensive ART regimen|"Nucleoside reverse transcriptase inhibitor (1) chosen by clinician
Nucleoside reverse transcriptase inhibitor (2) chosen by clinician
Nevirapine
Lopinavir boosted with ritonavir"
1612862|NCT02140242|Drug|study part 1 - dose daunorubicin|standard induction dose of daunorubicin 60 mg/m2 on days 3-5
1612863|NCT02140242|Procedure|induction cycles|single induction cycle versus double induction cycles (only patients with good response after first induction) Allocation is randomized for cytogenetic risk.
1612864|NCT02140229|Device|US power doppler|Clinical evaluation according to DAS28 and US every 3 months. US examination is realized in B and Doppler power mode for each studied joint: Ankles, shoulders, elbows, wrists, MCP 1 to 5, PIP 1 to 5, knees and MTP 1 to 5.
1612865|NCT02140229|Other|Usual care|Clinical evaluation and follow-up according to the practice of the referring rheumatologist every 3 months
1612866|NCT02140229|Other|ACR/EULAR criteria|Evaluation based on clinical evaluation according to DAS28 and ACR/EULAR remission criteria every 3 months.
1612867|NCT02140203|Other|Yoga Training|one-year experimental training (three times per week and one hour per session)
1612868|NCT02140164|Drug|Minocycline|Oral dose of 100 mg (or appropriate weight-adjusted pediatric dose) of minocycline twice daily for 12 months.
1612869|NCT02140151|Drug|Ranibizumab 0.5mg|
1612870|NCT02140138|Biological|CV9104|
1612871|NCT02140138|Device|needle free injection device (Tropis®)|
1612872|NCT02140125|Drug|ASP2408|subcutaneous administration
1612876|NCT02140099|Behavioral|Healthy Relationships Plus Program (HRPP)|The Healthy Relationships Plus Program (HRPP) is an out-of-school time program that is facilitated by a teacher or other youth leader. HRPP sessions use interactive teaching strategies to discuss healthy relationships, dating violence, personal values/boundaries, communication skills, emotional health and well-being, and helping friends.
1612877|NCT02140099|Behavioral|Control Condition (Classroom Activities)|
1612878|NCT02140086|Behavioral|Buteyko based Remedial Breathing Therapy|Buteyko based remedial Breathing Therapy after Dr. Buteyko
1612879|NCT02140073|Drug|omeprazole+domperidone SR|omeprazole 20mg+domperidone SR 30mg, 2 capsules in the morning
1612880|NCT02140073|Drug|omeprazole|40mg in the morning
1612881|NCT02140060|Drug|Dose Level A / Brinzolamide 1% ophthalmic suspension|Fixed combination
1612882|NCT02140060|Drug|Dose Level B / Brinzolamide 1% ophthalmic suspension|Fixed combination
1612883|NCT02140060|Drug|Dose Level C / Brinzolamide 1% ophthalmic suspension|Fixed combination
1612884|NCT02140060|Drug|Brinzolamide 1% ophthalmic suspension AZOPT®|
1612885|NCT02140060|Drug|Travoprost 0.004% ophthalmic solution TRAVATAN Z®|
1612886|NCT02140060|Drug|Travoprost solution vehicle|Inactive ingredients used for masking purposes
1612887|NCT02140060|Drug|Brinzolamide suspension vehicle|Inactive ingredients used for masking purposes
1612888|NCT02140047|Biological|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-Low + DPT-IPV|0.25mL, subcutaneous injection
1612889|NCT02140047|Biological|Haemophilus b conjugate vaccine diphteria CRM197 protein conjugate)-High + DPT-IPV|0.5mL, subcutaneous injection
1612890|NCT02140047|Biological|Haemophilus influenza type b conjugate vaccine + DPT-IPV|0.5mL, subcutaneous injection
1612891|NCT02140034|Procedure|Extensive Peritoneal Lavage|
1612892|NCT02140021|Procedure|Anal Pap Test|During scheduled colposcopy or surgery, an anal pap test performed.
1612893|NCT02140021|Procedure|Anoscopy|During scheduled colposcopy or surgery, an anoscopy performed.
1612894|NCT02140008|Device|Insertion of I-gel|After induction of general anesthesia, I-gel will be inserted according to randomly allocated group.
1612895|NCT02140008|Device|Insertion of air-Q|After induction of general anesthesia, air-Q was inserted according to randomly allocated group.
1612896|NCT02139995|Behavioral|RBC transfusion based on different protocols|transfusion trigger for experimental group is the WCTS-CP；for active comparator is the physician's experience
1612897|NCT02139982|Procedure|specific nerve block|specific nerve blocks of the musculocutaneous, radial, ulnar, or median nerves at axillary region
1612898|NCT02139982|Drug|ropivacaine|Different concentration of ropivacaine
1997045|NCT02264860|Dietary Supplement|Zinc and SAMe|The subjects will have the supplements dispensed at visit 2. They will be contacted weekly for the next three weeks to ensure that they are tolerating the supplements without significant side-effects. If these side-effects are significant then the dose of zinc will be decreased for all subjects to 15 mg of elemental zinc/day; if symptoms persist the SAMe dose will then be decreased by 25% (to 1200 mg/day) and then by 50% (to 800 mg/day) if necessary until the supplements are tolerated. 12 mg of zinc and 800 mg of SAMe is the lowest dose possible.
1612900|NCT02139956|Device|ultrasonography|open
1612901|NCT02139943|Drug|Canagliflozin 100 mg|Canagliflozin capsule of 100 mg dose will be taken orally, before the first meal of the day.
1612902|NCT02139943|Drug|Canagliflozin 300 mg|Canagliflozin capsule of 300 mg dose will be taken orally, before the first meal of the day.
1612903|NCT02139943|Drug|Placebo|Matching placebo capsule will be taken orally, before the first meal of the day.
1612907|NCT02139917|Behavioral|Transitional community based palliative care|"transitional palliative care include:-
telephone follow up for early identification of signs and symptoms
relief of signs and symptoms encountered
home visit with spiritual support"
1612908|NCT02139904|Drug|Vinorelbine|Vinorelbine was first licensed in the UK for Non-Small Cell Lung Cancer (NSCLC) and advanced breast cancer in 1997. Vinorelbine (Navelbine®) is a semi-synthetic, third generation, vinca alkaloid. The cytotoxic effect of vinorelbine is through the disruption of mitotic spindle formation, blocking mitosis at the G2-M stage resulting in cell death.
1612909|NCT02139904|Other|Active Symptom Control|
1612910|NCT02139891|Device|Cardiac Resynchronization Therapy with MultiPoint Pacing|
1612911|NCT02139878|Other|Wild blueberry juice|
1612912|NCT02139878|Other|Placebo wild blueberry juice|
1612913|NCT02139865|Behavioral|30% 1RM|Participant exercises using a protocol tailored at 30% of their 1RM
1612914|NCT02139865|Behavioral|80% 1RM|Participant exercises using a protocol tailored at 80% of their 1RM
1612915|NCT02139852|Dietary Supplement|Capsaicin|
1612916|NCT02139839|Other|Lactobacillus capsules|L. rhamnosus GR-1 and L. reuteri RC-14 capsules manufactured by Chr. Hansen
1612917|NCT02139839|Drug|Placebo gelatin pill|Placebo Comparator capsules, identical in appearance to the active product; 98% Gelatin with no L. rhamnosus GR-1 and L. reuteri RC- 14.
1612918|NCT02139826|Drug|IX-01|
1612919|NCT02139813|Procedure|Laparoscopic Mini-gastric bypass|"The laparoscopic Omega Loop Bypass will consist of:
a long gastric tube, stapled approximately 1.5 cm from the left of the lesser curvature of the antrum to the angle of His
a narrow gastric tube will be calibrated to be approximately 1.5 cm wide
an Omega loop of 200 cm
a unique gastro-jejunal anatomosis of 200cm from the ligament of Treitz, using a linear stapler"
1612920|NCT02139813|Procedure|Procedure of reference in bariatric surgery|"The laparoscopic Roux-en-Y Gastric Bypass will consist of:
a small gastric pouch (about 30cc)
an antecolic alimentary limb
a gastro-jejunal anastomosis using a linear stapler
a 150cm long alimentary limb
a 50cm biliary limb
a latero-lateral jejuno-jejunal anastomosis
closure of the mesenteric defects"
1612921|NCT02139800|Procedure|Sustained Inflation|The first sustained inflation will use inflation pressure of 20 cm H20 for 15 seconds
1612922|NCT02139800|Procedure|Standard of Care|Newborn Resuscitation Program (NRP) Guidelines using a standard PEEP/CPAP of 5-7 cm H2O as compared to the Sustained Inflation intervention
1612923|NCT02139787|Other|Radio Story|
1612924|NCT02139787|Other|Control -listened to a brochure|
1612925|NCT02139774|Behavioral|Walk with Ease|A six week walking program by the Arthritis Foundation
1613007|NCT02139111|Drug|Placebo|Oral placebo capsule
1613258|NCT02137239|Drug|Everolimus(EVL)|
1612926|NCT02139761|Drug|l-tetrahydropalmatine (l-THP)|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
1612927|NCT02139761|Drug|Placebo|Subjects will be dosed 30 mg BID (2 capsules total a day, total of 60mg/day), matching placebo or l-THP) (total 60 mg daily). The half-life of l-THP is about 10 hours, so subjects will reach steady state in about 2-3 days. The l-THP will be prepared at the University of Maryland School of Pharmacy to Chemistry under Good Manufacturing Practice (GMP) and standards. The identical placebo and active capsules will be manufactured and sent to the Maryland Psychiatric Research Center Pharmacy, where they will be stored, randomized and dispensed. Medication will be transported by the study staff to the participant once dispensing occurs.
1612928|NCT02139748|Procedure|Dental Implant & ADM|A dental implant will be placed and the buccal soft tissue will be grafted using an acellular dermal matrix allograft.
1612929|NCT02139748|Procedure|Dental Implant & ADM & bone xenograft|A dental implant will be placed along with a buccal acellular dermal matrix allograft which will cover a bone xenograft.
1612930|NCT02139735|Other|Ultrasound|3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles bilaterally
1612931|NCT02139735|Other|Ultrasound associated with stretching|"3 MHz ultrasound in continuous mode with an intensity of 1.0 W / cm ² was applied for 3 minutes in the TMJ and masseter muscles, bilaterally.
Active stretching of the masseter muscles with mouth opening and closed lips"
1612932|NCT02139735|Other|Placebo|Turned off ultrasound application on area of TMJ and masseter muscle, bilaterally.
1612934|NCT02139709|Dietary Supplement|Ganglioside|
1612935|NCT02139709|Dietary Supplement|Placebo|
1612936|NCT02139683|Device|HIFU treatment|HIFU treatment in patients with fibroadenoma
1612937|NCT02139657|Biological|RIG-C|
1612938|NCT02139644|Drug|FS MDPI|"FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) and salmeterol xinafoate (Sx) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.
During the treatment period, participants were randomized to either 100/12.5 mcg Fp/Sx or 50/12.5 mcg Fp/Sx in the morning and evening for a total daily dose of 200/25 mcg or 100/25 mcg Fp/Sx.
Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
1612939|NCT02139644|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.
During the treatment period, participants were randomized to either 100 mcg or 50 mcg of Fp one inhalation twice a day for a total daily dose of 200 mcg or 100 mcg.
Participants were instructed to rinse their mouth and expectorate (not swallow) after study drug administration."
1612940|NCT02139644|Drug|Placebo MDPI|Placebo administered via a multidose dry powder inhaler (MDPI) one puff in the morning and one puff in the evening for 12 weeks.
1612941|NCT02139644|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
1612942|NCT02139644|Drug|Beclomethasone dipropionate|QVAR (beclomethasone dipropionate) 40 mcg inhalation aerosol is a pressurized MDI that contains a Food and Drug Administration (FDA)-approved formulation of beclomethasone dipropionate. Patients took 1 puff twice a day from open-label QVAR 40 mcg hydrofluoroalkane (specifically, HFA-134a) metered-dose inhaler (MDI) for the duration of the Run-in Period (14-21 days) and prior to randomization. A clinically equivalent dose of inhaled corticosteroid (ICS) was substituted in countries where QVAR 40 mcg was not available.
1612943|NCT02139631|Other|Noninvasive ventilation|Assess the hemodynamic repercussions of the positive end expiratory pressure applied noninvasively
1612944|NCT02139618|Drug|Methyl Aminolevulinate (MAL)|
1612945|NCT02139618|Drug|Placebo|
1612946|NCT02139605|Procedure|D3 Lymphadenectomy|D3 Lymphadenectomy involves surgical removal of lymph nodes from echelon or compartments 1 to 3 in gastric cancer patients
1612947|NCT02139592|Drug|Brentuximab vedotin (recombinant)|Brentuximab vedotin (recombinant) for IV infusion
1612948|NCT02139579|Drug|Bevacizumab|7.5 mg/kg every 3 weeks
1612949|NCT02139566|Behavioral|Video consent (high-tech)|Consent provided by an animated video with captions
1612950|NCT02139566|Behavioral|Video consent (low-tech)|This consent is a video production of the informed consent information, taped using a staff member with basic video equipment.
1612951|NCT02139566|Behavioral|FAQ format consent|"This consent modality will present the basic information from the informed consent in an interactive, frequently asked questions format. Upon clicking each question, the participant will be shown a short text response to that question."
1612952|NCT02139566|Behavioral|Standard consent|The standard consent form will present the full informed consent document in a scrolling text window within the browser window. Participants will be asked to review the document online.
1612953|NCT02139566|Behavioral|PDF informed consent document|A PDF of the full consent document will be available for download, through hyperlink on the consent page. This is provided for video (low-tech), video (high-tech), FAQ format, and standard informed consent.
1612954|NCT02139553|Procedure|Rhythmic rehabilitation|Stroke patients have 12 rehabilitation sessions on a planar rehabilitation robot, Reaplan, focussed on rhythmic arm movements.
1612955|NCT02139540|Drug|Nitrous Oxide|"Patients will receive either up to 50% nitrous oxide/50% oxygen for 1 hour or placebo (50% nitrogen [inert]/50% oxygen) in two separate sessions. Both sessions will be 1 week apart."
1612956|NCT02139540|Drug|Placebo|50% nitrogen [inert]/50% oxygen - otherwise completely identical administration and setup
1612957|NCT02139527|Device|Total Disc Replacement|
1612958|NCT02139514|Behavioral|Virtual Reality Social Cognition Training|Social skills training via virtual reality with trained therapist.
1612959|NCT02139501|Drug|Recombinant Human Thrombopoietin (rhTPO)|rhTPO was given intravenously at a dose of300Units/kg ,daily for 14 consecutive days;at a dose of 300Units/kg ,one times every other day for 7 times; or at a dose of 300Units/kg ,daily for 7 consecutive days
1612960|NCT02139488|Other|Fiducial markers|
1612961|NCT02139488|Other|Fiducial markers, Pet and MRI|Insertion of Fiducial markers in esophageal wall.
1612962|NCT02139475|Procedure|Colonoscopy|
1612963|NCT02139462|Other|Standard FBT training|Therapists will receive standard training in Family Based Treatment (FBT)
1612964|NCT02139462|Other|Novel FBT training|Therapists will receive a novel training in Family Based Treatment (FBT)
1612965|NCT02139449|Procedure|ICD/CRT|cardiac resynchronized therapy (CRT), implantable cardioverter defibrillator (ICD) implantation
1612966|NCT02139436|Other|FES-row-training|
1612967|NCT02139436|Other|Arms-only-row training|
1612968|NCT02139423|Other|CMV PCR|
1612969|NCT02139410|Procedure|IGF-1 serum value|Evaluation of IGF-1 serum value at baseline, 24 and 48 months
1612970|NCT02139397|Drug|DFMO|
1612971|NCT02139397|Drug|Bortezomib|
1612972|NCT02139371|Other|Injection of 64Cu-DOTA-AE105|One injection of 64Cu-DOTA-AE105 (app. 200 Mbq) followed by Positron Emission Tomography Scan 1, 3 and 24 hours post injection
1612973|NCT02139358|Drug|Gemcitabine|The Phase I trial will start at the recommended phase II dose (RP2D) for gemcitabine but will have a de-escalation dose levels in the event that an unacceptable toxicity requires dose reduction. Dose level 0 = gemcitabine (1200mg/m2) IV D1,8 q21 days; Dose level -1 = gemcitabine (1000 mg/m^2) IV D1,8 q21 days; Dose level -2 = gemcitabine (850 mg/m^2) IV D1,8 q21 days. The RP2D will be the dose level where 0-1 dose limiting toxicities (DLTs) in six patients occur.
1612974|NCT02139358|Drug|Trastuzumab|Trastuzumab will be given using an 8 mg/kg loading dose on cycle one, day one (C1D1), followed by 6 mg/kg IV on subsequent cycles every (q) 21 days.
1612975|NCT02139358|Drug|Pertuzumab|Pertuzumab will be given using an 840 mg IV loading dose on C1D1, followed by 420 mg IV on subsequent cycles q21 days.
1612976|NCT02139345|Device|TC-A PS Total Knee Replacement System|Subject will be implanted with the TC-A PS Total Knee Replacement System
1612977|NCT02139345|Device|TC-PLUS Solution PS Total Knee Replacement System|Subject will be implanted with the TC-PLUS Solution PS Total Knee Replacement System
1612978|NCT02139332|Behavioral|PFR Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session begins with a brief discussion and education on the target topic for that week . Then 20 minutes is spent on video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior (alternating weeks). Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
1612979|NCT02139332|Behavioral|Resource & Referral Group|The Resource & Referral program consists of 1) an initial needs assessment to determine if the enrolled family has any unmet needs (housing, financial, health, mental health, etc…), 2) a tailored resource and referral packet will be mailed to the participant with the most important referrals marked, 3) a follow-up call will be made two weeks after mailing the packet to verify that the participant has received it, and 4) a second follow-up call will be made three months after the initial session, to assess types of services actually received, barriers to receiving services, and reassessing resources needed and providing additional referrals if needed.
1612980|NCT02139319|Drug|Botulinum toxin|
1612981|NCT02139319|Drug|Placebo|
1612982|NCT02139306|Drug|Ataluren (PTC124®)|
1612983|NCT02139306|Drug|Placebo|
1612984|NCT02139293|Device|PrimeStim|Intermittent auricular vagus nerve stimulation at different ear points
1612985|NCT02139280|Drug|Cyclophosphamide|Mechanism of action: Cyclophosphamide is a pro drug that requires activation. Following hepatic and cellular activation, phosphoramide mustard and acrolein are formed. Phosphoramide mustard is the alkylating agent that demonstrates cytotoxic effects. Acrolein binds to proteins but does not contribute to the anti-tumor effects.
1612986|NCT02139267|Biological|GX-188E|DNA vaccine administered via IM route using TDS-IM electroporation device
1612987|NCT02139241|Drug|Ramosetron|0.3 mg IV as bolus before induction of general anesthesia
1612988|NCT02139241|Drug|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
1612989|NCT02139228|Biological|Hib-CRM197|No vaccine administered in V37_07E2 study
1612990|NCT02139228|Biological|Hib-TT|No vaccine administered in V37_07E2 study
1612991|NCT02139202|Behavioral|Social Influence|
1612992|NCT02139202|Behavioral|Electronic Pill Bottles|
1612993|NCT02139202|Behavioral|Financial Incentives|
1612994|NCT02139189|Device|P-ECM Implant|P-ECM Implant into damaged ischemic and/or infarcted myocardium
1612995|NCT02139176|Behavioral|contract referral|A female partner signs a contract saying it is permissible for a community worker to trace a male sex partner in the community.
1612996|NCT02139176|Behavioral|patient referral|A patient agrees to recruit their partner using the invitation.
1612997|NCT02139163|Other|Cohort Study|
1612998|NCT02139150|Radiation|[18F] FLT|
1612999|NCT02139150|Device|PET/CT scans|
1613000|NCT02139137|Other|Computerized Cognitive Training - active|Cognitive training using working memory span task
1613001|NCT02139137|Other|Computerized cognitive training - sham|Sham training condition
1997046|NCT02263560|Behavioral|Kinematic measurements|
1613010|NCT02139111|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
1613011|NCT02139111|Drug|PRC-063 85 mg|Oral 85 mg capsule - active
1613012|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 8 out of 17 nights
1613013|NCT02139098|Drug|Zolpidem|5 mg capsule zolpidem before going to bed on 8 out of 17 nights
1613014|NCT02139098|Drug|Amitriptyline|50 mg capsule amitriptyline before going to bed on 13 out of 17 nights
1613015|NCT02139098|Drug|Placebo|Placebo
1613016|NCT02139085|Device|GSV Electrocoagulation|The energy source will be the Electrosurgical Generator (FX-Valley Lab; USA) and the GSV thermo ablation will be performed with 60 Watts per 10 seconds. The catheter and electrocoagulation device head will be pulled back in increments of 2 cm also to overlap the treatment sites.
1613017|NCT02139085|Device|GSV Radiofrequency|The second generation RF device (Closure FAST; Covidien, USA) will be used. The treatment component of the device is 7 cm in length and works with a segmental pullback protocol. Once the catheter is in position, activation of the generator delivers 20- seconds cycles of energy to the catheter tip, which heats the vein wall to 120 o C.
1613018|NCT02139072|Device|CoaguChek XS|CoaguChek XS will be used to measure INR in patients with APL
1613019|NCT02139072|Procedure|Standard Lab Draw|Patients on warfarin for any indication other than APL will measure INR by venous lab draw
1613020|NCT02139059|Procedure|initial urinary drainage|initial urinary drainage is done using nephrostomy or double J stent to stabilize renal functions. this is followed several days later by definitive ureteroscopy.
1613021|NCT02139059|Procedure|direct ureteroscopy|direct ureteroscopy is done without initial urinary drainage and before return to normal chemistry. this is followed follow-up of renal functions for several days before treatment of the contralateral side.
1613022|NCT02139046|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
1613023|NCT02139046|Drug|Febuxostat XR|Febuxostat XR over-encapsulated capsules
1613024|NCT02139046|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
1613025|NCT02139046|Drug|Colchicine|Colchicine tablets
1613026|NCT02139046|Drug|Naproxen|Naproxen tablets
1613027|NCT02139046|Drug|Lansoprazole|Lansoprazole capsules
1613028|NCT02139033|Drug|Retaine™|
1613029|NCT02139020|Other|Plasma samples|Plasma samples at baseline (and one whole blood sample) and at every radiological evaluations
1613030|NCT02139007|Drug|Alendronate|
1613031|NCT02138994|Device|Next Science Wound Gel|
1613032|NCT02138994|Drug|Triple Antibiotic Ointment Neosporin|"Subjects randomized to Neosporin will be required to complete 1 month of treatment comprising a screening/baseline, 2-week and 1-month visits. After 1 month the following may occur based on wound progression and/or the investigator's clinical judgment:
Subject may continue the application of Neosporin until wound closure or
Subject may cross over to the treatment group for 3 months"
1613033|NCT02138981|Procedure|Chemoembolization and Response-Dependent Resection|patients underwent transarterial chemoembolization (TACE) as initial treatments, and only patients who showed good response were subjected to surgical resection.
1613034|NCT02138981|Procedure|Immediate Resection|patients received immediate surgical resection.
1613035|NCT02138968|Other|Multidisciplinary intervention|Multidimensional intervention based on: good control of baseline diseases, review of medication adequacy, exercise program, nutritional assessment and control, social assessment and control.
1613036|NCT02138955|Drug|Liposomeal curcumin|
1613037|NCT02138942|Device|Learning Intravenous Resuscitator (LIR) system|The usual patient pathways and recommendations concerning vascular filling remain strictly unchanged in this study. The only thing that differs from usual care is the use of the LIR system to automatically optimize fluid resuscitation during general anesthesia, with continuous supervision by the anesthesiologist present during the entire period of use of the device.
1613038|NCT02138929|Drug|Everolimus|Induction and Dose Expansion Phase: 10 mg by mouth daily in a 28 day cycle.
1613039|NCT02138929|Drug|LDE 225|"Induction Phase Starting Dose: 400 mg by mouth daily in a 28 day cycle.
Expansion Phase Starting Dose: Maximum tolerated dose from Induction Phase."
1613040|NCT02138916|Drug|Benralizumab Arm A|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
1613041|NCT02138916|Drug|Benralizumab Arm B|Benralizumab subcutaneously on study week 0 until study week 48 inclusive
1613042|NCT02138916|Drug|Placebo|Placebo subcutaneously on study week 0 until study week 48 inclusive
1613043|NCT02138903|Other|trans thoracic echocardiography|
1613044|NCT02138890|Device|APS|Intra-articular Injection
1613045|NCT02138890|Device|Placebo|Intra-articular injection
1613046|NCT02138877|Procedure|After coming stent after dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. The patients who are randomized to the after coming stent arm, an after coming stent is inserted. Distal part of it is positioned in the mid ureter. The proximal end is passed through the renal parenchyma (usually the lower kidney calyx) to be exteriorized through stab wound and fixed to the skin. The size of external stent is 4-5 F.
1613047|NCT02138877|Procedure|Stentless dismembered pyeloplasty|Dismembered pyeloplasty through lumbar incision. No stents are inserted
1613049|NCT02138851|Dietary Supplement|Ficus Carica (300g/day)|Ficus Carica (300g/day), parallel design
1613050|NCT02138851|Dietary Supplement|Placebo (300g/day)|Placebo (300g/day), parallel design
1613051|NCT02138838|Drug|Cinacalcet HCl|Capsules were opened and either sprinkled onto soft food (≥ 5 mg dose) or suspended into a sucrose syrup (≥ 2.5 mg dose) to create a liquid suspension for administration. Tablets were used for doses of 30 mg and higher in participants who could swallow tablets.
1613052|NCT02138838|Dietary Supplement|Standard of Care|Standard of care therapy included the use of vitamin D sterols, calcium supplementation, and phosphate binders.
1613053|NCT02138825|Drug|Riociguat (Adempas, BAY63-2521)|Active drug 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration. The starting dose will be 0.5 mg TID, and the dose will be adjusted every two weeks for ten weeks in 0.5 mg increments up to a maximum dose of 2.5 mg TID based on patient's systolic blood pressure and well-being.
1613054|NCT02138825|Drug|Placebo|Inactive dosed at 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID/day as per individual dose titration for 26 weeks
1613259|NCT02137239|Drug|Tacrolimus(TAC)|
1613055|NCT02138812|Drug|BAY1161909|"Given orally, with a starting dose of 0.75 mg twice daily, on 14 day cycle - D1, D2, D8, D9 and 28 day cycle - D8, D9 D15 and D16 of a 28 day cycle.
FOR PK COHORT ONLY:Given orally at morning dose only on C1D1"
1613056|NCT02138812|Drug|Paclitaxel|"Paclitaxel will be given once per week (intravenous) IV at 75 mg/m2 on D1, D8, and D15 of a 28 day cycle
Paclitaxel will be given once per week (intravenous) IV at 90 mg/m2 on D1, D8, and D15 of a 28 day cycle"
1613057|NCT02138812|Drug|Paclitaxel|"After MTD(75) + BAY1161909 is established:
BAY1161909 will then be refined for the combination with 90 mg/m2 IV paclitaxel MTD(90) following the same dosing schedules as noted in Arm 1 for both drugs."
1613058|NCT02138799|Drug|enzalutamide|oral
1613059|NCT02138799|Drug|rifampin|oral
1613060|NCT02138786|Drug|selinexor|60 mg, may be increased to 80 mg after Cycle 1
1613061|NCT02138773|Drug|Tamsulosin formulation-A|oral
1613062|NCT02138773|Drug|Tamsulosin formulation-B|oral
1613063|NCT02138760|Procedure|MRI UroNav fusion biopsy|
1613064|NCT02138747|Drug|Mirabegron|Oral
1613065|NCT02138747|Drug|Tolterodine ER|Oral
1613066|NCT02138734|Biological|BCG+ALT-803|BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks in phase I and phase II. Phase II includes maintenance treatment consisting of BCG+ALT-803 for 3 consecutive weeks at 3, 6 and 12 months.
1613067|NCT02138734|Biological|BCG|BCG-only will be administered via intravesical instillation weekly for 6 consecutive weeks in phase II. Phase II includes maintenance treatment consisting of BCG for 3 consecutive weeks at 3, 6 and 12 months.
1613068|NCT02138721|Procedure|Radical Prostatectomy (RP)|Radical Prostatectomy with extended Pelvic Lymph Node Dissection within 8 weeks after inclusion.
1613069|NCT02138708|Other|Pharmacological test of pulmonary endothelial|
1613070|NCT02138682|Drug|l-123 Ioflupane|5 millicuries of Ioflupane
1613071|NCT02138669|Device|Intacs|INTACS® prescription inserts are an ophthalmic medical device designed for the reduction or elimination of myopia and astigmatism in patients with keratoconus so that their functional vision may be restored and the need for a corneal transplant procedure can potentially be deferred.
1613072|NCT02138656|Other|Chiropractic|Chiropractic treatment delivered in accordance with clinical protocols developed and agreed with the participant clinicians
1613073|NCT02138656|Other|Best Standard Care|Counselling and advice delivered in accordance with the Map of Medicine care pathway for Infantile colic
1613074|NCT02138643|Procedure|Endoscopic surgery|These will be treated with Endoscopic surgery - Peroral endoscopic myotomy (POEM)
1613075|NCT02138643|Procedure|Laparoscopic surgery|These will be treated with Laparoscopic surgery - Laparoscopic Heller myotomy.
1613076|NCT02138630|Dietary Supplement|Capsaicin|
1613077|NCT02138630|Dietary Supplement|Placebo|Sugar capsule
1613078|NCT02138617|Drug|5-Fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours, Day 1 and Day 15 .
1613079|NCT02138617|Drug|Leucovorin|200-400 mg/m2 IV over 2 hours, Day 1 and Day 15
1613080|NCT02138617|Drug|Irinotecan|IV infusion over 90 minutes, dosed at 180, 260 or 310 mg/m2 based on genotype.
1613081|NCT02138617|Drug|Bevacizumab|Bevacizumab (5 mg/kg IV infused as per institutional policy, IV, Day 1, 15)
1613082|NCT02138591|Procedure|Blood draw pre-operatively|Pre-Operative blood draw of approximately 32ml will check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
1613083|NCT02138591|Procedure|Blood draw post-operative Day 1|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
1613084|NCT02138591|Procedure|Blood draw post-operative Day 2|Blood draw of approximately 32ml to check the following: Vitamin D (25-OHD), Calcium, Cathelicidin and Resistin levels in the blood.
1613087|NCT02138565|Procedure|Gastric by-pass surgery|
1613088|NCT02138552|Drug|Octenidine dihydrochloride|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
1613089|NCT02138552|Drug|Placebo|Mouthrinsing - comparison of different dosages of Octenidine dihydrochloride over 4 days vs. Placebo
1613092|NCT02138526|Drug|pazopanib|pazopanib 800mg OD without food
1613093|NCT02138526|Other|continental breakfast|pazopanib 600mg OD with food
1613094|NCT02138513|Behavioral|Mindfulness Based Cognitive Therapy|This MBCT protocol consists of 8 weekly sessions of 2,5 hours each and a silent day of 6 hours of meditation practice. Similar to group MBCT, in the online MBCT group, participants will be asked to practice at home for 45 minutes, 6 days a week. They will receive files with meditation and yoga exercises to support this.
1613095|NCT02138500|Drug|PF-06372865|Single, oral dose administration of 10 mg PF-06372865 using tablet formulation.
1613096|NCT02138500|Drug|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
1613097|NCT02138500|Drug|PF-06372865|Single, oral dose administration of TBD dose PF-06372865 using tablet/extemprep formulation.
1613098|NCT02138487|Other|liberal postoperative activity|Women will be given specific instructions regarding postoperative activities and will not have any limitations regarding activity.
1613099|NCT02138487|Other|Restricted postoperative activity|Women in this group will be given instructions regarding postoperative activity and will need to abstain from heavy lifting, running, aerobics for 3 months.
1613100|NCT02138474|Other|Lacticum acidum homaccord|Homeopathic remedy, made using sucrose pillules
1613101|NCT02138474|Other|Placebo|Unmedicated sucrose pillules
1613102|NCT02138448|Behavioral|Interactive Preventive Health Record|The interactive preventive healthcare record (IPHR) is a patient-centered application that links patients to their clinician's record, explains information in lay language, displays tailored recommendations and educational resources, and makes preventive care actionable.
1613103|NCT02138435|Other|MRI exercise test|Measuring cardiac output with MRI during exercise on an ergometer bicycle.
1613104|NCT02138435|Other|Gas-exchange exercise test|Measuring cardiac output by gas-exchange, while during exercise on an ergometer bicycle.
1613105|NCT02138422|Biological|Xilonix|
1613106|NCT02138422|Biological|Placebo|
1613107|NCT02138409|Drug|Fentanyl Sublingual Spray (FSS)|Fentanyl sublingual spray (FSS) packaged to deliver 100 µg/spray, 200 µg/spray or 400 µg/spray
1613108|NCT02138409|Drug|Placebo Sublingual Spray (PSS)|Placebo sublingual spray (PSS) packaged to match FSS, but deliver no drug
1613109|NCT02138396|Drug|Fentanyl Sublingual Spray (FSS)|A single dose of fentanyl, 400 mcg per sublingual spray
1613110|NCT02138396|Drug|Fentanyl Citrate Injection (FCI)|A single dose of fentanyl citrate, 100 mcg per intramuscular injection
1613111|NCT02138396|Drug|Naltrexone|Naltrexone is provided as a 50 mg tablet before and after product dosing to minimize unacceptable adverse effects of fentanyl.
1613112|NCT02138383|Drug|Enzalutamide|The starting dose of enzalutamide will be 80 mg (Level 1) daily, taken orally. The dose escalation schedule is a standard 3 + 3 design. In the first part of the study, different doses of enzalutamide will be tested. In the second part of the study, all patients will be started at the same dose of enzalutamide.
1613113|NCT02138383|Drug|Gemcitabine|The starting dose of gemcitabine will be 1000 mg/m^2 administered intravenously on days 1, 8 and 15 of each cycle.
1613114|NCT02138383|Drug|Nab-paclitaxel|The starting dose of nab-paclitaxel will be 125 mg/m^2 administered intravenously on days 1, 8 and 15 of each cycle.
1613115|NCT02138357|Drug|buprenorphine transdermal delivery system (BTDS)|
1613116|NCT02138357|Drug|Placebo for BTDS patch|A placebo patch will be manufactured to mimic the BTDS patch.
1613117|NCT02138331|Biological|MSC exosomes.|Exosomes: (Size) 40-100 nm, (markers) CD63, CD9, Alix, TSG 101, HSP 70 Microvesicles: (Size) 100-1000 nm, (markers) Annexin V, Flotillin-2, selectin, integrin, CD40 metalloproteinase
1613118|NCT02138318|Other|High definition (HD) endoscopy|
1613119|NCT02138318|Other|chromoendoscopy|
1613120|NCT02138305|Device|ComboMap XT Guidewire|Intracoronary pressure and flow measurements
1613121|NCT02138305|Procedure|'SPY' NIRF During CABG|FDA approved use of injection of indocyanine green for the purposes of performing pre and post coronary grafting graft patency and perfusion assessment with the SPY near infra red fluorescence system
1613122|NCT02138292|Drug|Trametinib (2mg)/Digoxin (.25mg)|"Trametinib (2mg) will be administered orally on a daily basis.
Digoxin (0.25mg) will be administered orally on a daily basis.
On a 8 week cycle, duration of treatment can last from 8 to 104 weeks."
1613123|NCT02138266|Device|Topcon Specular Microscope SP-1P|
1613124|NCT02138266|Device|Konan Specular Microscope CELLCHEK XL|
1613125|NCT02138253|Drug|IDN-6556|
1613126|NCT02138253|Drug|Placebo|Placebo control
1613127|NCT02138240|Behavioral|Social network intervention|
1613130|NCT02138214|Procedure|thyroidectomy|Undergo total thyroidectomy
1613131|NCT02138214|Procedure|thyroidectomy|Undergo total thyroidectomy with ipsilateral prophylactic CND
1613132|NCT02138214|Procedure|central lymph node dissection|Undergo total thyroidectomy with ipsilateral prophylactic CND
1613133|NCT02138214|Procedure|quality-of-life assessment|Ancillary studies
1613134|NCT02138162|Drug|enzalutamide|oral
1613135|NCT02138136|Drug|Lubiprostone|12 or 24 mcg capsules twice daily (BID) for 9 months
1613136|NCT02138123|Procedure|IOL-shell technique|Phacoemulsification was performed with the same device and handpieces, using the same phaco chop technique as in the conventional procedure group. What was different was that before the emulsification of the last nuclear fragment, cohesive viscoelastic material was injected below the nuclear fragment and a foldable IOL was implanted into the well inflated capsular bag posterior to the nuclear fragment. The remaining last piece of nuclear fragment was then emulsified and removed within the capsular bag.
1613137|NCT02138123|Procedure|Conventional procedure|In this procedure, a IOL was not implanted until all the nuclear fragments were removed.
1613138|NCT02138110|Device|Neuro-Spinal Scaffold|
1613139|NCT02138084|Drug|BMS-663068|BMS-663068
1613140|NCT02138084|Drug|Rifabutin|Rifabutin
1613141|NCT02138084|Drug|Ritonavir|Ritonavir
1613142|NCT02138058|Drug|Topiramate|
1613143|NCT02138058|Behavioral|Cognitive restructuring intervention|4 sessions of a manualized cognitive restructuring intervention for compulsive buying
1613144|NCT02138045|Drug|Placebo treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
1613145|NCT02138045|Drug|Liraglutide treatment|Treatment continues at highest tolereable dose (minimum 1.2 mg/day). Intervention time 26 weeks at target dose.
1613146|NCT02138032|Behavioral|Gains Framed Message|
1613147|NCT02138032|Behavioral|Loss Framed Message|
1613148|NCT02138019|Procedure|Fibrin Glue assisted external eye surgery|
1613149|NCT02138019|Device|Fibrin glue|
1613150|NCT02138006|Drug|Intensive insulin treatment|Mealtime insulin (Actrapid) Basal insulin (Monotard)
1613151|NCT02138006|Drug|Standard insulin treatment|Insulin Mixtard
1613152|NCT02137993|Drug|A-prexa|A-prexa 5-20 mg for 6 weeks
1613153|NCT02137993|Drug|Zyprexa|Zyprexa 5-20 mg for 6 weeks
1613154|NCT02137967|Procedure|NaOCl pulpotomy|Use 2.5% NaOCl as pulpotomy medicament for primary molars
1613155|NCT02137967|Procedure|FC pulpotomy|Use 20% Formocresol as pulpotomy medicament for primary molars
1613156|NCT02137967|Drug|2.5% NaOCl|
1613157|NCT02137967|Drug|20% Formocresol|
1613158|NCT02137954|Drug|Lidocaine|
1613159|NCT02137954|Drug|Placebo|
1613160|NCT02137941|Behavioral|techniques to optimize potential (TOP)|The TOP consists of learning easy techniques in mental skills to improve cognitive-based problem-solving using respiration, relaxation, and visualization.
1613161|NCT02137941|Behavioral|heart coherence (HC)|The heart coherence (HC) is based on the fact that the heart rhythm becomes more erratic with negative emotions such as anger and anxiety, and more ordered/coherent with sustained positive emotions such as appreciation, love, or compassion, leading to optimal performance and well-being. The HC program uses feedback from a simple pulse sensor to reflect changes of the emotional/psychological state, and to learn how to reduce stress and stabilize emotions.
1613162|NCT02137928|Drug|carboplatin periocular injection|20mg/2ml carboplatin periocular injection together with chemotherapy
1613163|NCT02137928|Drug|chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
1613164|NCT02137915|Biological|Human Central Nervous System Stem Cells|
1613165|NCT02137902|Behavioral|Tobacco/Physical Activity Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation and goal setting for tobacco and physical activity, adherence with nicotine replacement therapy (NRT, patch plus gum or lozenge), and self-monitoring with a pedometer-based walking program.
1613166|NCT02137902|Behavioral|Diet plus BP/CHOL Intervention|Telemedicine stage-tailored counseling intervention focused on increasing intrinsic motivation, goal setting for managing HTN and HCL, and adherence with antihypertensives and statins with supportive dietary changes. Includes a native diet cookbook and medication bag.
1613167|NCT02137889|Drug|VAY736|VAY736 is a human immunoglobulin of the G class (IgG1/k) monoclonal antibody (mAb) designed to specifically bind the BAFF receptor. VAY736 binds primarily to B-cells through its fragment antigen binding (Fab) region, in human whole blood and spleen samples; it does not bind to natural killer (NK) cells, monocytes, dendritic cells, granulocytes, or platelets.
1613168|NCT02137876|Procedure|Blood Draws|Patients will be asked to provide blood for immune tests.Patients will not take any study medications, all the research will be performed on blood donated for the study.Patients will donate about 20mls of blood (2 tbls)to be used to determine the subject's blood group and tissue typing (genetic).Results and the patient's contact information will be maintained in a database that is accessible only by the investigators and study personnel conducting the study.For the duration of this study, the investigator will contact patients by phone to request additional samples when needed. Study staff may ask patients donate more blood on short notice (1 day). This will consist of 60-120 ml (6-12 tbls) of blood.The frequency of blood collection will not exceed more than 2 times per week.The total amount of blood collected from subjects will not exceed 360 ml (1.5 cups) within any eight week period throughout the two year timespan patients may be asked to participate in this study.
1613169|NCT02137863|Drug|Dexmedetomidine|"Intravenously 1μg/kg/10min administered just before the procedure.
1 μg/kg/h administered during the angiography and was continued 1 hour after the angiography."
1613170|NCT02137863|Drug|0.9 % NaCl|During 12 hours before the procedure 3 ml/kg/h 0.9 % NaCl infusion and 1 ml/kg/h during the angioplasty and 12 hours after the procedure.
1613171|NCT02137863|Drug|0.9 % NaCl|"100 ml/10min infusion just before the angiography
1 ml/kg/h infusion during the angiography and was continued 12 hours after the procedure"
1613172|NCT02137850|Drug|turoctocog alfa pegol|For intravenous (i.v.) injection. Frequency and dosage (20-75 U/kg) dependent on whether given as treatment for bleeding episode or as prophylaxis
1613173|NCT02137837|Drug|Fulvestrant|
1613174|NCT02137837|Drug|Anastrozole|
1613175|NCT02137837|Drug|Everolimus|
1613176|NCT02137837|Drug|Placebo - Anastrozole|
1613177|NCT02137837|Drug|Placebo - Everolimus|
1613178|NCT02137824|Procedure|sinus floor elevation|
1613179|NCT02137811|Other|MICK Assay|An automated microculture kinetic (MiCK) assay for measuring drug induced apoptosis in tumor cells; the MiCK assay for apoptosis provides a mechanism-based approach to studying effects of cytotoxic agents on tumor cells.
1613181|NCT02137785|Drug|Aminolevulinic Acid (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
1613182|NCT02137785|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
1613183|NCT02137785|Device|Blue Light Photodynamic Therapy Illuminator (BLU-U)|10 J/cm2 blue light delivered at 10mW/cm2
1613186|NCT02137759|Radiation|Standard Radiation Therapy|Radiation therapy to 60 Gy
1613187|NCT02137759|Drug|Standard Temozolomide|Temozolomide given orally
1613188|NCT02137759|Drug|Belinostat|Belinostat dose to be determined, given intravenously over 30-45 minutes
1613189|NCT02137746|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
1613190|NCT02137733|Drug|Bisoprolol|
1613191|NCT02137733|Drug|Carvedilol|
1613192|NCT02137720|Behavioral|Telephonic Diabetes Self-Management Support|
1613193|NCT02137720|Other|Educational Print Materials|
1613194|NCT02137707|Drug|Gilenya|All patients will receive Gilenya
1613195|NCT02137694|Other|vaginal auto-takings and urinary test|vaginal auto-takings and urinary test
1613196|NCT02137681|Drug|Rituximab|Rituximab was given intravenously at a dose of 375mg/m(2) weekly for 2 consecutive weeks (Day 1, 8) in 2 cycles arm; or 4 consecutive weeks (Day 1, 8, 15, 22) in standard 4 cycles arm
1613197|NCT02137668|Drug|Oral Vancomycin|Oral Vancomycin is given to PSC or BA participants
1613198|NCT02137642|Drug|RM-131|Double blind RM-131 (100 ug) will be delivered once by injection during study procedure.
1613199|NCT02137642|Drug|Placebo|Double blind placebo will be delivered once by injection during study procedure.
1613200|NCT02137629|Drug|Vidaza®|The recommended starting dose for the first treatment for all patients regardless of baseline hematology values is Vidaza® 75mg/m2 subcutaneous(SC) injection or intravenous (IV) infusion, daily for 7 days.
1613201|NCT02137616|Drug|risperidone|Risperdal tablets
1613202|NCT02137616|Drug|olanzapine|olanzapine tablets
1613203|NCT02137616|Drug|Quetiapine|quetiapine tablets
1613204|NCT02137616|Drug|Aripiprazole|Aripiprazole tablets
1613205|NCT02137603|Other|Patients discharged home the same day following appendectomy|Patients are discharged to home on the same day following appendectomy with oral antibiotics.
1613206|NCT02137590|Dietary Supplement|Spanish Black Radish product|
1613207|NCT02137577|Procedure|DEB catheter|DEB catheter (trade name: Litos/Tulip)
1613208|NCT02137577|Procedure|common PTA balloon catheter|common PTA balloon catheter
1613209|NCT02137564|Drug|gamma secretase inhibitor PF-03084014|Given PO
1613210|NCT02137564|Other|pharmacological study|Correlative studies
1613211|NCT02137564|Other|laboratory biomarker analysis|Correlative studies
1613212|NCT02137551|Other|ABM|The ABM involves synchronizing all medications to come due on the same say of the month and the individual receives a pre-appointment phone call from the pharmacy staff to review medications and identify any changes.
1613213|NCT02137538|Drug|Letrozole|
1613214|NCT02137538|Drug|Anastrozole|
1613215|NCT02137525|Drug|Morphine 6 mg|Intravenous infusion - delivering morphine 6 mg
1613216|NCT02137525|Drug|Fentanyl 100 µg|Fentanyl sublingual spray - single unit delivering 100 µg fentanyl
1613217|NCT02137525|Drug|Fentanyl 200 µg|Fentanyl sublingual spray - single unit delivering 200 µg fentanyl
1613218|NCT02137525|Drug|Fentanyl 400 µg|Fentanyl sublingual spray - single unit delivering 400 µg fentanyl
1613219|NCT02137525|Drug|Placebo Sublingual Spray|Matching sublingual spray - single unit delivering 0 µg fentanyl
1613220|NCT02137525|Drug|Intravenous Placebo|Matching intravenous infusion - delivering 0 mg morphine
1613221|NCT02137512|Device|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:
DiAs - a smart-phone medical platform;
Dexcom Dexcom G4 Platinum connected to DiAs via CGM receiver and USB-Bluetooth relay hardware;
Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth;
Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and
Modular Closed-Loop Control Algorithm Running on DiAs, which is of Control-to-Range (CTR) class"
1613222|NCT02137499|Device|geko device|Small transcutaneous electrical stimulator. Manufactured in UK by Firstkind UK Ltd, and licensed for use in humans
1613223|NCT02137473|Other|Human milk-based fortifier|
1613224|NCT02137473|Other|Bovine protein-based fortifier|
1613225|NCT02137447|Device|Negative Pressure treatment|
1613226|NCT02137434|Other|Dietary calcium|Dietary calcium from skimmed milk
1613227|NCT02137434|Dietary Supplement|Supplementary calcium|Supplementary calcium from calcium carbonate
1613228|NCT02137421|Dietary Supplement|Resveratrol (3, 4´, 5 trihydroxystilbene)|Resveratrol (RES) (3, 4´, 5 trihydroxystilbene)
1613229|NCT02137408|Dietary Supplement|Docosahexaenoic acid 200 mg|Participants will be randomized to 200 mg docosahexaenoic acid daily (1-200mg capsule) PO beginning at 18-20 weeks gestation through 6 weeks post-partum.
1613230|NCT02137408|Drug|Docosahexaenoic acid 1000 mg|Participants will be randomized to 1000 mg (5-200mg capsules) docosahexaenoic acid PO daily beginning at 18-20 weeks gestation through 6 weeks post-partum.
1613231|NCT02137395|Drug|Dexamethasone|dexamethasone administration, intravenously
1613232|NCT02137395|Drug|Placebo|saline administration intravenously
1613233|NCT02137382|Drug|Creon®|active comparator
1613234|NCT02137382|Drug|Creon N|experimental drug
1613235|NCT02137369|Drug|Escitalopram|Escitalopram, 20mg-40mg daily for 12 weeks
1613236|NCT02137369|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy, standardized, 16 sessions over 12 weeks.
1613237|NCT02137369|Other|Combination treatment (Escitalopram + CBT)|study participants who do not remit in the first 12 weeks will be offered combination treatment of both treatments for 12 more weeks.
1613238|NCT02137356|Radiation|standard dose pelvic radiation therapy|"radiation therapy to pelvis delivered using standard conformal or IMRT techniques.
50.4-55 Gy"
1613239|NCT02137356|Drug|standard dose capecitabine|825 mg/m2 twice daily, 5 days a week (max dose 2000mg twice daily), only on days when radiation is delivered
1613240|NCT02137356|Drug|dose-escalated selinexor treatment|Selinexor oral drug will be given twice weekly according to the dose escalation schedule described in the protocol. Selinexor will be started on the day radiation begins, until the end of week 6.
1613241|NCT02137343|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/SF/MET-driven activities in cells.
1613242|NCT02137343|Drug|Placebo|Placebo
1613243|NCT02137343|Drug|Cisplatin|A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death)
1613244|NCT02137343|Drug|Capecitabine|A chemo-therapy prodrug that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
1613245|NCT02137330|Device|Swallowable Obalon® Gastric Balloon|
1613246|NCT02137317|Device|LAPPE (locally adapted personal protective equipment)|"Hand: Nitrile gloves flexible enough to grip pesticide container firmly and in a length appropriate for mixing and spraying such as wrist length. They should not contain lining inside. In case, nothing is available disposable plastic bags can provide sufficient protection. In both cases wearing a cotton glove underneath.
Upper and lower body: As thick or as heavy cotton blouse and trousers as can be worn and plastic sheets cut as a long poncho.
Feet: Unlined rubber boots or shoes at least calf height with thick cotton socks underneath with possibility for trousers to be worn outside rubber boots or shoes."
1613247|NCT02137304|Device|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA)|Cough Assist® (JH Emerson Compagny, Cambridge, MA, USA) mechanical insufflation to increase peak cough flow
1613248|NCT02137278|Drug|Vasoactive drug therapies|Continue current vasoactive therapy
1613249|NCT02137278|Other|Stop/reduce vasoactive drugs|Discontinuation of any vasoactive therapy or reduction of vasoactive drug therapies as much as possible according to clinical judgment.
1613252|NCT02137252|Drug|Naltrexone|
1613253|NCT02137252|Drug|Sugar Pill|
1613254|NCT02137239|Drug|Thymoglobulin|
1613255|NCT02137239|Drug|Belatacept|
1613256|NCT02137239|Drug|mycophenolate mofetil(MMF)|
1613262|NCT02137213|Drug|Naloxone|Naloxone will be added to oral methadone preparation in methadone:naloxone ratio of 50:1
1613263|NCT02137213|Drug|Placebo|Normal saline will be added to oral methadone preparations as placebo.
1613264|NCT02137200|Procedure|Immediate pushing|Women in this arm will be instructed to initiate pushing as soon as complete cervical dilation is documented.
1613265|NCT02137200|Procedure|Delayed pushing|Women assigned to delayed pushing will be instructed to wait for 60 minutes from complete cervical dilation before pushing. Women will be allowed to push earlier if they feel an irresistible urge to push, the fetal head is visible at the perineum, or the fetal heart tracing is non-reassuring.
1613266|NCT02137187|Procedure|AV junction ablation|AV junction ablation
1613267|NCT02137187|Device|CRT|Implantation of device for pacing and cardiac resynchronization therapy (CRT-P or CRT-D according to guidelines)
1613268|NCT02137187|Drug|Optimized drug therapy|Optimized drug therapy for heart failure and atrial fibrillation rate control
1613269|NCT02137187|Device|ICD|Implantable defibrillator (in control Group or in association with CRT in study Group) according to guidelines
1613270|NCT02137174|Other|Home and school visits|Each child in the intervention group received, in addition to the standard care at the diabetic clinic, home and school visits by a multidisciplinary team during one year.
1613271|NCT02137161|Drug|Dexamethasone+Tobramycin eye drop|dexamethasone 0.1% and tobramycin 0.3% ophthalmic suspension
1613272|NCT02137161|Drug|Bromfenac eye drop|bromfenac ophthalmic solution 0.09%
1613273|NCT02137148|Device|Use of Ultrasound to assist in needle placement|Use of the Sonic Window handheld Ultrasound device to assist in needle placement by providing a coronal image of the patient anatomy.
1613274|NCT02137135|Other|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
1613275|NCT02137135|Other|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
1613276|NCT02137135|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
1613277|NCT02137122|Device|Sham Stimulation|Administer 30 seconds of 2 mA electrical current to the head through saline soaked electrodes.
1613278|NCT02137122|Device|Transcranial Direct Current Stimulation|Participants will undergo 20 minutes of 2 mA electrical stimulation to the head through saline soaked electrodes.
1613279|NCT02137109|Drug|natalizumab|Administered as specified in the treatment arm.
1613280|NCT02137096|Drug|Etoposide phosphate|Etoposide is one of three drugs used in the high-dose conditioning phase
1613281|NCT02137096|Drug|Carboplatin|Carboplatin is one of the drugs used in the high-dose conditioning phase.
1613282|NCT02137096|Drug|Ifosfamide|Ifosfamide is one of the drugs used in the high-dose conditioning phase
1613283|NCT02137096|Procedure|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation follows the high-dose chemotherapy phase of the arm.
1613284|NCT02137083|Drug|Docetaxel|75mg/m2 D2 every 21 days
1613285|NCT02137083|Drug|Fulvestrant|500mg D1, D15, D29, D57, every 28 days later
1613286|NCT02137070|Procedure|Bariatric Surgery Candidates|Participants who are intending to have bariatric surgery for weight loss
1613287|NCT02137070|Other|Non surgical/Community volunteers|Healthy adults with body mass index >35 who will not undergo bariatric surgery for weight loss
1613288|NCT02137044|Behavioral|Collaborative Care (CC)|Collaborative care (CC) is a systematic and integrated approach to improving the delivery and utilization of effective treatments for chronic pain and depression. The care will be delivered through an interdisciplinary team, organized around a CC manager (CCM) who guides the patient through various aspects of care during the 16-week treatment phase. The team will also include the patient's MS physician and the CC Supervisors, a group of study domain experts. The CCM will offer all subjects care management, collaborative medical management, and psychosocial treatment appropriate to their problem area (i.e., pain, depression, or both) described below. If the patient has both pain and depression, he or she will receive care management and collaborative medical management for both.
1613289|NCT02137031|Device|Mini Link REAL-Time Transmitter|Children used the Mini Link REAL-Time Transmitter to measure glucose continuously for a minimum of three days per week for three months.
1613290|NCT02137018|Device|PPL fixation by BP|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by BP patch. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable stitches on the cutaneous layer.
1613291|NCT02137018|Device|PPL mesh|A surgical scar was performed on the abdominal linea alba and carried out deeply into a pocket between large abdominal muscle and abdominal fascia. A pocket was created between the two layers. 5cm PLL prosthesis was implanted and fixed by absorbable stichtes. The scar was sutured with absorbable stitches on subcutaneous incision and not absorbable suture on the cutaneous layer.
1613292|NCT02136992|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken two tablets 3 times a day during the whole study process.
1613293|NCT02136992|Drug|placebo|placebo will be taken two tablets 3 times a day during the whole study process
1613294|NCT02136966|Other|MNP + IYCN counseling + cooking demonstrations|Growth monitoring and promotion sessions will take place every month at village level for all children 0-23 months of age and will serve as an entry point for all the interventions. During these sessions children under 24 months will be weighed monthly and screened for MAM and uncomplicated SAM for treatment in the community as well as complicated SAM for referral to health facility During the monthly sessions cooking demonstrations will take place in which the community Health workers will instruct the mother how to prepare a good complementary food for 6-23 months olds adding the MNP. These meals will be given to the child during the session. Mothers will be encouraged to prepare the same meal at home During the monthly sessions enhanced IYCN counseling will be given to the mothers of 6-23 months olds, using improved BCI messages developed based on the rapid assessment of practices and foods available in the community and adaptation of the WHO manual.
1613332|NCT02136771|Dietary Supplement|Vitamin D3|The treatment group receives 2,800 IU vitamin D3 per day as oily drops (Oleovit D3, producer: Fresenius Kabi Austria, A-8055 Graz) for 8 weeks
1613333|NCT02136771|Dietary Supplement|Placebo|
1613416|NCT02136082|Behavioral|Asha Support + Food|
1613295|NCT02136953|Behavioral|Exercise|12 weeks of structured aerobic exercise, 3 times a week, following a two-stage graduated regimen: 1) Initial stage (weeks 1-4): 40-60% intensity, 15-30 min duration (+ 5 min warm-up/cool-down), and 2) Improvement stage (weeks 5-12): 60-80% intensity, 30-45 min duration. Adherence measures include self-reported exercise session logs and weekly phone checks by research assistants.
1613296|NCT02136953|Behavioral|Cognitive Behavioural Therapy (CBT)|CBT will be delivered in group format, 2 hours per week, for 12 consecutive weeks with 8-10 participants per group and will be conducted according to a session-by-session treatment manual that incorporates Exposure and Response Prevention (ERP) in the early phases of treatment and then increases emphasis on cognitive approaches for obsessions and compulsions outlined in step-by-step strategies.
1613297|NCT02136940|Drug|AMA0076|
1613298|NCT02136940|Drug|Placebo|
1613299|NCT02136927|Drug|SPARC1210|
1613300|NCT02136927|Drug|Reference1210|
1990854|NCT01745107|Radiation|Prophylactic postoperative radiation therapy|Prescription dose of 95%planning target volume(PTV) 50.4Gy/1.8Gy/28fractions for supraclavicular region and 95%PTV 56Gy/2Gy/28fractions for mediastinum which is delivered in 2 months after surgery.
1613303|NCT02136901|Device|NUsurface® Meniscus Implant|The NUsurface Meniscus Implant is a Polycarbonate-Urethane (PCU)-based device reinforced with high tensile Ultra High Molecular Weight Polyethylene (UHMWPE) fibers. The product is available in different sizes, left and right, and with trials so as to allow the surgeon several size options for implantation. The NUsurface® Meniscus Implant, is designed to be conceptually analogous to the natural meniscus whose structural characteristics include a highly orientated collagen fiber network supports the large hoop stresses to produce better distribution of contact pressures within the knee joint. Restoring the distribution of joint loads post-meniscectomy is thought to reducing joint overload and to reducing pain.
1613304|NCT02136901|Drug|NSAID's and Non-surgical Treatment Options|Non-prescription drugs, creams, vitamins, and supplements, Prescription or Non-Prescriptions NSAIDs, Non-weight bearing and/or open chain physical therapy or self-administered exercise
1613305|NCT02136901|Drug|Intra-Articular Injections with Corticosteroids|Intra-articular injection of a corticosteroid, such as 40 mg of Triamcinolone (e.g. Aristocort or Kenalog).
1613306|NCT02136901|Drug|Intra-Articular Injections with Hyaluronic Acid (HA)|Intra-articular injection of a hyaluronic acid treatment, such as SYNVISC® HA Injections.
1613307|NCT02136888|Drug|Ponesimod Placebo|
1613308|NCT02136888|Drug|Moxifloxacin Placebo|
1613309|NCT02136888|Drug|Ponesimod 10 mg|
1613310|NCT02136888|Drug|Ponesimod 20 mg|
1613311|NCT02136888|Drug|Ponesimod 40 mg|
1613312|NCT02136888|Drug|Ponesimod 60 mg|
1613313|NCT02136888|Drug|Ponesimod 80 mg|
1613314|NCT02136888|Drug|Ponesimod 100 mg|
1613315|NCT02136888|Drug|Moxifloxacin 400 mg|
1613316|NCT02136875|Drug|Double dose of Salmeterol + Fluticasone Propionate|
1613317|NCT02136875|Behavioral|Self-management education on the use of a self-administered prescription for exacerbation.|Patients will be instructed to start treatment within 48 hours of experiencing an acute exacerbation of COPD and/or after starting their self-administered prescription.
1613318|NCT02136875|Drug|Self-administered prescription|"An Acute Exacerbation of COPD (AECOPD) is defined as a sustained worsening of dyspnea, cough or sputum production leading to an increase in the use of maintenance medication and/or supplementation with additional medication. In addition, exacerbations should be defined as either purulent or non-purulent.
Standing prescriptions for exacerbation:
1) Purulent exacerbation - Antibiotic: Avelox 400 mg daily for 5 days. 2a) Mild to moderate exacerbation - Combination therapy (SFP - Advair) to be increased as follows: If regular treatment is Advair 250/50 BID then dose should be increased to Advair 500/100 BID for 10 days; if regular treatment is Advair 500/50 BID then increase to Advair 1000/100 BID for 10 days.
2b) Severe exacerbation - Prednisone (oral): 40 mg once daily for 7-10 days"
1613319|NCT02136823|Drug|sugar pill|
1613320|NCT02136823|Drug|Riluzole|
1613321|NCT02136823|Drug|Isradipine|
1613322|NCT02136823|Drug|Memantine|
1613323|NCT02136823|Procedure|Therapeutic muscle stretching|
1613324|NCT02136797|Genetic|CMVpp65 Specific T-cells|
1613325|NCT02136784|Drug|morphine sulfate|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
1613326|NCT02136784|Drug|hydrocodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
1613327|NCT02136784|Drug|hydromorphone HCI|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
1613328|NCT02136784|Drug|oxycodone|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
1613329|NCT02136784|Drug|buprenorphine|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
1613330|NCT02136784|Drug|oral tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
1613331|NCT02136784|Drug|sublingual tablet placebo|Participants will receive randomly assigned order of study drug (opioid) and then have 7 days of testing with test days at least 3 days apart. Pain testing will utilize cold pressor test, in which the participant submerges his arm and hand in a bath of ice cold water to determine pain threshold and tolerance.
1613334|NCT02136758|Behavioral|CRC lifestyle modification program|Intervention group enrolled in lifestyle program in which they developed individualized therapeutic lifestyle plans to reduce cardiovascular risk.
1613335|NCT02136745|Behavioral|Relaxation Response Mind-Body Intervention|The Relaxation Response Mind-Body Intervention (RR-MBI) involved a 9-week group program conducted by a nurse practitioner or psychologist skilled in MBI, which included a GI-specific session conducted by a physician. The groups met once weekly for 1.5 hours. Three consecutive, mixed-disorder groups, ranging in size from 10 to 18 participants each. The program was multidimensional and included daily elicitation of the RR using a variety of methods (including breath focus, single-pointed focus, imagery, contemplation, yoga, and mindful awareness); cognitive reappraisal skills, health enhancing behaviors, and the promotion of optimism and acceptance. Throughout the course of treatment, participants were asked to elicit the RR at home each day for 15-20 minutes.
1613336|NCT02136732|Other|Active self-management intervention|Participants will set health goals at baseline. They will then receive, at minimum, a visit or a phone call to assess how progress and coaching toward meeting goals on a monthly basis from a nurse and/or social worker. The frequency and exact activities associated with the intervention are dependent on each participant's unique health goals.
1613337|NCT02136732|Other|Attention control phone calls|Participants will be called by a social service aide at 2, 4, 6, 8, 10, and 12 months.
1613338|NCT02136719|Procedure|bimanual uterine compression|bimanual uterine compression immediately after delivery of placenta for 5 minutes
1613339|NCT02136706|Procedure|Myocardial Perfusion imaging with 10 minute waiting period|After the Myocardial Perfusion Imaging testing the investigators will wait 10 minutes to take images and then wait the 30 minute standard of care time to take images.
1613343|NCT02136654|Behavioral|Culturally tailored diabetes program|Includes family member and peer support Includes communication training
1613344|NCT02136641|Drug|Midazolam|Was applied Midazolam 0.03 mg / kg, IV (in the vein), single dose.
1613345|NCT02136641|Drug|Midazolam+Fentanyl Combination|Was applied Midazolam 0.015 mg / Kg + Fentanyl 0.8mcg/kg, IV (in the vein), single dose.
1613346|NCT02136641|Drug|Midazolam+Ketamine Combination|Was applied Midazolam 0,015 mg / Kg + ketamine 0.25 mg / kg, IV (in the vein), single dose.
1613347|NCT02136628|Procedure|Method RTL|"The method consists of two lines of suture, each, over the fascial wound edge. It starts with a suture strand (in this study was used PDS number 0) in one end of the fascial wound where the suture is run longitudinally and parallel to the aponeurotic edge. The needle should go in and out at intervals of 1 cm away and always kept at 0.5 cm from the edge of the fascia. Upon reaching the opposite angle of the wound suture strand another repeating the same process on the fascial edge otherwise used. The ends of the two suture strands are tied in fascial angles.
Thus the fascial wound is sutured with two lines of strengthening its edges. Then proceed to close the wound with continuous súrgete always ensuring that the suture lines remain anchored on suture reinforcement."
1613348|NCT02136589|Drug|dicrofenac and travoprost|dicrofenac drop 3 times a day travoprost 0.005% once daily
1613349|NCT02136576|Device|Sensodyne|Subjects will be instructed to brush with Sensodyne twice daily (2 minutes each time in the morning and the evening) during the duration of the study.
1613350|NCT02136576|Device|Crest Cavity Protection & MI Paste Plus|Subjects will be instructed to brush twice daily (2 minutes each time in the morning and the evening) using Crest Cavity Protection toothpaste. They will be instructed to apply MI Paste Plus (CPP-ACP with fluoride) twice daily to the study teeth after brushing their teeth. MI Paste Plus will be applied to the study teeth with a finger.
1613351|NCT02136576|Device|Clinpro 5000|Subjects will be instructed to brush with Clinpro 5000 twice daily (2 minutes each time in the morning and the evening) during duration of the study.
1613352|NCT02136550|Behavioral|Smoking cessation|Smoking cessation is a program that gives all the support to the subject: orientation, medications, exams, etc
1613353|NCT02136537|Device|Bilateral NMES legs|Stimulation with the geko(TM) device, Firstkind Ltd, UK. 4 hours per day, bilateral, applied to the skin overlying the common peroneal nerve
1613354|NCT02136537|Other|Best medical therapy|Treated according to local NHS protocol. At Imperial College Healthcare Trust, this will include diagnostic tests (medical interview and examination, ultrasound of blood vessels, diagnostic treadmill test, blood tests and Xrays as appropriate). This also includes lifestyle advice, treatment with appropriate drugs such as aspirin and statins, and supervised exercise.
1613355|NCT02136524|Drug|cobimetinib|Single, oral dose given as a tablet on Day 1 after a minimum 8 h fast
1613356|NCT02136524|Drug|cobimetinib|Single, oral dose given as 4 capsules on Day 1 after a minimum 8 h fast
1613357|NCT02136511|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
1613358|NCT02136511|Drug|Rituximab|Rituximab administered intravenously starting at 375 mg/m^2 at Week 0 and continuing with a dose of 500 mg/m^2 at Weeks 2, 4, 6, 8, 12, 16, and 20.
1613359|NCT02136498|Drug|Varenicline|Standard 12 week course of varenicline, provided in both arms
1613360|NCT02136498|Behavioral|Cognitive-behavioral self-help|Standard self-help education for smoking cessation, delivered via mobile-optimized website accessible via smartphone.
1613361|NCT02136498|Behavioral|MyMAP (My Mobile Advice Program)|Same standard self-help intervention as in control arm + automatically-tailored support and advice for managing nicotine withdrawal symptoms + secure messaging with cessation counselor
1613362|NCT02136485|Behavioral|Mindfulness-based stress reduction (MBSR)|8 sessions of MBSR
1613363|NCT02136485|Other|waiting list control|
1613364|NCT02136459|Other|Small Tube size|An endotracheal tube of size 6.5 in females and 7.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
1613365|NCT02136459|Other|Large Tube size|An endotracheal tube of size 7.5 in females and 8.0 in males was used for endotracheal intubation of patients undergoing thyroid surgery
1613368|NCT02136433|Device|Tablet - self exercise|
1613369|NCT02136433|Other|GRASP self exercise|
1613374|NCT02136394|Other|Gastro-esophageal reflux|This is an observational study. The exposure is the gastro-esophageal reflux.
1613375|NCT02136381|Behavioral|LEAP intervention|"LEAP has 5 modules of tools and resources. LEAP is personalised based on information provided at different stages. The user determines the modules to complete (skipping or revisiting modules). Users can choose among 8 animated mentors (4 female; 4 male) to guide them through the intervention.
Users will provide demographic data, health-related information, and current lifestyles in order to tailor the advice to be received.
Advice will focus on adopting elements of a Mediterranean dietary pattern, increase physical activity, and improve social connectedness.
Participants will receive 1) Mediterranean diet recipes; 2) a step counter to monitor physical activity goals; 3) advice in how to enhance social engagement and facilitate social roles"
1613376|NCT02136381|Behavioral|Control|"Thirty participants will be randomised to a minimal intervention comparator condition, where participants will be emailed a direct link to the National Health Service (NHS) choices 'LiveWell' website (http://www.nhs.uk/LiveWell/Pages/Livewellhub.aspx).
The email will encourage the participants to access the health resources and information on the pages labelled men's health 40-60, men's health 60-plus, women's health 40-60, women's health 60-plus, as appropriate.
Participants in the control group will be assessment after two months."
1613377|NCT02136368|Behavioral|Multi-modal exercise|Community-based group exercise classes following Canadian Centre for Activity and Aging exercise guidelines. Exercise classes consist of 5 min warm-up, 20 min aerobic exercise, 5 min aerobic cool-down, 10 min full-body resistance exercise, 5 min stretching (total 45 min)
1613378|NCT02136368|Behavioral|Mind-Motor Exercise|Square Step Exercise involves mimicking a stepping pattern demonstrated by an instructor. The stepping patterns become progressively difficult and involve forward, backward, lateral and diagonal movements on a 250cm long mat with 25cm square grids (15 min).
1613379|NCT02136368|Behavioral|Balance and range of motion exercises|Community-based group exercise designed to improve balance and range of motion of the joints (15 min)
1613380|NCT02136355|Radiation|Stereotactic Body Radiation Therapy plus Surgery|Stereotactic body radiation therapy followed by surgical resection
1613381|NCT02136342|Drug|chlorogenic acid|
1613382|NCT02136329|Drug|Sildenafil|"The active study drug, Revatio®, is the citrate salt of sildenafil, a selective inhibitor of cyclic guanosine monophosphate (cGMP)-specific phosphodiesterase type-5 (PDE5). Sildenafil citrate is designated chemically as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo [4,3-d] pyrimidin-5-yl)-4-ethoxyphenyl] sulfonyl]-4-methylpiperazine citrate.
The active study medication is supplied in single use glass vials and as a clear, colourless, sterile, ready-to-use solution containing 10 mg (12.5 mL) of sildenafil. Each mL of solution contains 1.124 mg sildenafil citrate, 50.5 mg dextrose and water for injection.
Sildenafil is manufactured under Good Manufacturing Practice (EU-GMP) by Pfizer Inc"
1613383|NCT02136316|Drug|ASP7962|Oral
1613384|NCT02136316|Drug|Placebo|Oral
1613385|NCT02136303|Dietary Supplement|S1: Dosage-dependency|kale extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein tagetes extract: placebo, 1 mg lutein, 2 mg lutein, 5 mg lutein, 10 mg lutein
1613386|NCT02136303|Other|S2: Kale extract versus kale purée|
1613387|NCT02136303|Other|S3: Kale extract: AMD-patients|
1613388|NCT02136290|Behavioral|Prepackaged meals|Portion-controlled prepackaged meals
1613389|NCT02136290|Behavioral|Usual Care|Usual care dietary counseling
1613390|NCT02136277|Drug|Hartmann's solution|Administered in 250ml boluses, until cardiac output has been optimised.
1613391|NCT02136264|Other|PCFA interventional dietary counselling|
1613392|NCT02136264|Other|conventional DASH diet counselling|
1613393|NCT02136238|Device|Hosmer 5XA voluntary opening hook|"Voluntary opening prosthetic terminal device (hand)"
1613394|NCT02136238|Device|TRS Grip 3 voluntary closing hook|"Voluntary closing prosthetic terminal device (hand)"
1613395|NCT02136225|Behavioral|Means restriction counseling|Health care providers will counsel parents on the risks of having a gun, particularly an unlocked gun, in the home where youth are present.
1613396|NCT02136212|Behavioral|Approach-positive AAT|
1613397|NCT02136212|Behavioral|Control AAT|
1613398|NCT02136199|Other|Active Implementation of ShareEBM Toolkit|
1613399|NCT02136199|Other|Passive Dissemination of Share EBM|
1613400|NCT02136186|Device|Philips Telehealth|patients will be provided with a philips home telemonitoring system post hospital discharge
1613401|NCT02136173|Device|Heliosphere bag (air filled balloon)|sequential balloons . Heliosphere bag (air filled balloon)
1613402|NCT02136160|Behavioral|attitude change, behavioral change|
1613403|NCT02136160|Behavioral|prevention program|
1613404|NCT02136147|Drug|methylphenidate medication|
1613405|NCT02136147|Drug|atomoxetine medication|
1613406|NCT02136147|Drug|lisdexamphetamine medication|
1613407|NCT02136147|Drug|guanfacine medication|
1613408|NCT02136134|Drug|Daratumumab|Daratumumab will be administered as an IV infusion at a dose of 16 mg/kg weekly for the first 3 cycles, on Day 1 of Cycles 4-9, and then every 4 weeks thereafter.
1613409|NCT02136134|Drug|VELCADE (Bortezomib)|VELCADE will be administered at a dose of 1.3 mg/m2 subcutaneously (SC) on Days 1, 4, 8 and 11 of each 21-day cycle. Eight VELCADE treatment cycles are to be administered.
1613410|NCT02136134|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 VELCADE treatment cycles.
1613411|NCT02136121|Device|da Vinci Sp Surgical System - Robotic|robotic assisted laparoscopic single-port system
1613412|NCT02136108|Other|OPENtext|Participants will receive 12 weeks of daily text messages sent from an automated system. The text messages will assist participants in managing their chronic pain.
1613413|NCT02136108|Other|OPENnav|Particpants will be linked with a RIPN PEER Navigator who will assisted them in managing their health care
1613414|NCT02136095|Procedure|Intraoperative fluorescent cholangiography (IFC)|A standardized protocol with IFC including concomitant angiography was performed during laparoscopic cholecystectomy.
1613415|NCT02136082|Behavioral|Asha Support + Training|
1613417|NCT02136082|Behavioral|Asha Support + Training + Food|
1613418|NCT02136082|Behavioral|Asha Support Only|
1613419|NCT02136069|Drug|etrolizumab|105 mg administered by subcutaneous injection (Q4W) until Week 52
1613420|NCT02136069|Drug|infliximab|5 mg/kg of infliximab will be administered by intravenous (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
1613421|NCT02136069|Other|placebo (IV)|Administered by (IV) infusion at Weeks 0, 2, and 6 and then every 8 weeks until Week 46.
1613422|NCT02136069|Other|placebo (injection)|administered by SC injection Q4W until Week 52
1613423|NCT02136056|Behavioral|Self-management program (SMP)|A self-management course
1613424|NCT02136043|Device|PBASE system 1.1 (active treatment)|
1613425|NCT02136030|Drug|Liposomal amphotericin B|4mg/kg/day, IV infusion
1613426|NCT02136030|Drug|Amphotericin B-deoxycholate|1mg/kg/day, IV infusion
1613428|NCT02135991|Behavioral|Getting To Outcomes|These sites will receive written materials, training, and on site technical assistance to use the Getting To Outcomes process to implement Project CHOICE at their sites.
1613429|NCT02135991|Behavioral|Project CHOICE|Sites will receive standard training for Project CHOICE.
1613430|NCT02135978|Other|Shoulder home exercise program|Patients receive instruction and practice on the shoulder home exercise program, receive a notebook with handouts including pictures and written instructions on how to perform the program, and receive a kit containing the exercise equipment. Patients are asked to perform the exercises at home 3 days a week over the next 3 years.
1613431|NCT02135965|Drug|2mg of Albuterol|2mg of Albuterol on metabolic rate
1613432|NCT02135965|Drug|4mg of Albuterol|4mg of Albuterol on metabolic rate
1613433|NCT02135965|Drug|100mg of Caffeine|100mg of caffeine on metabolic rate
1613434|NCT02135965|Drug|200mg of Caffeine|200mg of Caffeine on metabolic rate
1613435|NCT02135965|Drug|Albuterol 2mg & Caffeine 100mg|Albuterol 2mg and 100mg of Caffeine
1613436|NCT02135965|Drug|Albuterol 2mg and Caffeine 200mg|Albuterol 2mg and Caffeine 200mg on metabolic rate
1613437|NCT02135965|Drug|Albuterol 4mg and Caffeine 100mg|Albuterol 4mg and Caffeine 100mg on metabolic rate
1613438|NCT02135965|Drug|Albuterol 4mg and Caffeine 200mg|Albuterol 4mg and Caffeine 200mg on metabolic rate
1613439|NCT02135952|Procedure|SRP|SRP in four to six appointments lasting approximately 1 h each, using manual curettes and ultrasonic device under local anesthesia.
1613440|NCT02135952|Other|Placebo|Administration of placebo for 14 days started immediately after the first session of SRP.
1613441|NCT02135952|Drug|MTZ+AMX|Administration of antibiotics (metronidazole and amoxicillin) for 14 days started immediately after the first session of SRP.
1613442|NCT02135939|Behavioral|Diet|Whole foods plant based vegan diet vs the American Heart Association-recommended diet
1613443|NCT02135926|Device|Thrombectomy|Stent retriever are intended to restore blood flow in patients with acute ischemic stroke secondary to intracranial occlusive vessel disease by providing temporary bypass across the occlusion and/or by the non-surgical removal of emboli and thrombi. They may be used with aspiration and with the injection or infusion of contrast media and/or other fluids. For subjects enrolled in this protocol who are randomly assigned to undergo the thrombectomy procedure, the device will be used according to the Instructions-for-Use (IFU) that is packaged with the device.
1613444|NCT02135926|Other|Best medical care|Best medical treatment will be performed as detailed in established Standard Operating Procedures, following regional guidelines (American Heart Association (AHA), European Stroke Organisation (ESO), Deutsche Schlaganfall-Gesellschaft (DSG), local country, etc.).
1613445|NCT02135913|Dietary Supplement|Vitamin D|All subjects enrolled into the study will be prescribed standard of care Vitamin D
1613446|NCT02135900|Drug|Heliox|From the onset of sleep until 2:00 am, patients will be placed on heliox 70/30. At 2:00 am patients will be switched to CPAP for titration according to American Academy of Sleep Medicine (AASM) guidelines.
1613447|NCT02135887|Drug|MB-6|6# TID with meal
1613448|NCT02135887|Drug|Placebo|6# TID with meal
1613449|NCT02135874|Drug|Clofarabine|"Induction:
Clofarabine 15 mg/m2 by vein Days 1-4.
Consolidation:
Clofarabine 15 mg/m2 by vein on Days 1-3."
1613450|NCT02135874|Drug|Idarubicin|"Induction:
Idarubicin 10 mg/m2 by vein on Days 1-3.
Consolidation:
Idarubicin 6 mg/m2 by vein on Days 1-2"
1613451|NCT02135874|Drug|Cytarabine|"Induction:
Cytarabine 1,000 mg/m2 by vein on Days 1-4.
Consolidation:
Cytarabine 1,000 mg/m2 by vein on Days 1-3."
1613452|NCT02135874|Drug|Vincristine|"Induction and Consolidation:
Vincristine 2 mg by vein Days 1, 8, and 15."
1613453|NCT02135874|Drug|Rituximab|"For patients with CD20 positive disease:
Induction and Consolidation:
Rituximab 375 mg/m2 by vein on Days 1 and 8."
1613454|NCT02135874|Drug|Dexamethasone|"Induction and Consolidation:
Dexamethasone 40 mg by vein daily for 4 days on days 1 - 4 and days 15 - 18."
1613455|NCT02135861|Procedure|DCE-MRI scans|Subjects will be placed supine in the scanner and will be prepared for intravenous contrast agent administration. The contrast agent is administered using a power injector before imaging.
1613456|NCT02135861|Other|Gadobutrol|Gadobutrol at a dose less than or equal to 0.1 millimoles per kilogram (mmol/kg) will be given intravenously as a bolus using a power injector.
1613459|NCT02135835|Drug|Shenfu Zhusheye|
1613460|NCT02135835|Drug|5% glucose injection|
1613461|NCT02135822|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
1613462|NCT02135822|Drug|gemcitabine|Gemcitabine is given intravenously at 1000 mg/m2 on day 1 and 8 of each 21-day cycle. Number of cycles: 6 cycles.
1613463|NCT02135809|Device|WallFlex Pancreatic Stent|Temporary placement of the WallFlex Pancreatic Stent for treatment of refractory pancreatic duct strictures in patients with painful chronic pancreatitis. Stent will be removed after 3-6 months indwell.
1613464|NCT02135796|Other|Echocardiography|
1613512|NCT02135419|Procedure|thermal ablation therapy|Undergo hyfrecation/electrocautery therapy
1613465|NCT02135783|Procedure|Decompressive Craniectomy|A portion of frontal,temporal, and parietal bone was removed by craniectomy and the size of decompression was about 10x12 cm2.Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical microscope.
1613466|NCT02135783|Procedure|non-Decompressive Craniectomy|a simple hematoma removal by osteoplastic craniotomy group (HR) or Intracerebral hematoma was evacuated by transcortical approach with the aid of a surgical neuroendoscopyand the size of decompression was about 3x2.5 cm2.
1613467|NCT02135770|Drug|Unfractionated heparin|10 unit/kgBW/hour continuous infusion for 72 hours
1613468|NCT02135744|Behavioral|Bundle tool|Tool consists of 1. screening measures to identify the presence of various risk factors for COPD exacerbations and 2. Educational components for the disease of COPD.
1613469|NCT02135731|Other|Medication review software with pictures|The intervention is a self-service software program that displays each prescription on screen along with an image of the pharmaceutical product. Patients must use response buttons to describe adherence patterns and to advance through the questionnaire items.
1613470|NCT02135718|Device|ELLIPTA inhaler|ELLIPTA inhaler, placebo DPIwith 30 doses (2 strips with 30 blisters per strip containing lactose in strip first strip and Lactose blended with magnesium stearate in second strip)
1613471|NCT02135718|Device|Placebo Inhalation Aerosol (MDI)|Placebo inhaler MDI will be supplied containing aerosol propellant
1613472|NCT02135705|Drug|Lomitapide|As prescribed by Physician.
1613473|NCT02135692|Biological|Mepolizumab|Mepolizumab is a fully humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be supplied as a lyophilised cake in sterile vials for individual use.
1613474|NCT02135692|Drug|SOC|Standard of Care (SOC) will differ by participant, however it will generally include oral corticosteroids and an inhaled controller medicine (an inhaled corticosteroid plus a long acting beta agonist) and/or short acting beta agonists
1613475|NCT02135679|Radiation|Radiotherapy|
1613476|NCT02135666|Procedure|Blood sampling|At Years 16 - 20 after first dose of the primary vaccination in HAB-084 (208127/084) study.
1613477|NCT02135653|Radiation|Radiotherapy|
1613478|NCT02135653|Other|Eischens Yoga|
1613479|NCT02135640|Drug|denosumab 60mg|solution
1613480|NCT02135640|Drug|denosumab 120 mg|solution
1613481|NCT02135640|Drug|placebo|solution
1613482|NCT02135627|Drug|TC-325 monotherapy on initial endoscopy ± radiation therapy, angioembolization, and/or surgery.|
1613483|NCT02135627|Other|Current standard therapy|
1613484|NCT02135614|Drug|Presatovir|Presatovir 200 mg (4 x 50 mg tablets) administered orally
1613485|NCT02135614|Drug|Presatovir placebo|Presatovir placebo tablets administered orally
1613487|NCT02135588|Drug|Combination TISSUE PLASMINOGEN ACTIVATOR (TPA) AND DORNASE ALFA (DNASE)|
1613488|NCT02135575|Behavioral|Spinning|After the baseline studies the pre and postmenopausal women will be randomized to spinning training groups and the intervention will last for 3 months. The spinning group will spin three times per week under guidance of a trained instructor. The training is heart rate monitored.
1613489|NCT02135562|Dietary Supplement|Dietary Intervention|Follow the Protein-Sparing Modified Fast (PSMF) intervention. This diet has participants consume enough lean beef, pork, poultry, and seafood to provide 1.2 grams of protein per kilogram of their obesity adjusted ideal body weight.
1613490|NCT02135562|Other|Informational Material|Receive carbohydrate reintroduction handout
1613491|NCT02135562|Other|Dietary Education|Receive education on nutrition label reading for carbohydrates
1613492|NCT02135562|Dietary Supplement|Weight Maintenance|weight maintenance diet consists of gradual addition of previously eliminated carbohydrate containing food groups to the high protein PSMF diet. During weight maintenance, consumption of non-starchy vegetables is unlimited
1613493|NCT02135562|Other|Average score of Obesity and Weight-Loss Quality of Life Questionnaire|Participants will take a tailored quality of life questionnaire. These scores will be averaged and a group mean reported. Higher scores indicate greater quality of life.
1613494|NCT02135549|Dietary Supplement|SugarDown|4 or 8 gram dose in tablet form, before meals, daily for one week
1613495|NCT02135536|Biological|NGM282|NGM282
1613496|NCT02135523|Radiation|involved-field radiation therapy|Participants will receive involved-field radiotherapy (external beam radiotherapy or brachytherapy) over 45Gy for residual or locoregionally recurrent epithelial ovarian cancer after definitive treatment. Patients will be treated with 1.8-2.0Gy fraction, five times per week. It starts 2 weeks later of chemotherapy.
1613497|NCT02135510|Drug|metoclopramide|
1613498|NCT02135510|Drug|dexamethason|
1613499|NCT02135510|Drug|palonosetron|
1613500|NCT02135484|Drug|Alpharadin|50 kBq (0.0014 mCi)/kg body weight, administered by slow intravenous injection over 1 minute every 4 weeks for 6 cycles (6 doses total).
1613501|NCT02135471|Drug|acellular dermal matrix graft|On one side, the previously reflected partial-thickness flaps will be coronally positioned to entirely cover the acellular dermal matrix graft (ADMG), and also sutured with sling sutures using 6-0 bioabsorbable sutures.
1613502|NCT02135471|Drug|enamel matrix derivative|On the other side, the same procedure will be performed, with an additional layer of enamel matrix derivative between the acellular dermal matrix graft (ADMG) and the flap, and between the ADMG and the root surface by using a sterile brush.
1613503|NCT02135458|Other|Telemonitoring|
1613504|NCT02135458|Other|Conventional care|
1613505|NCT02135445|Drug|TAK-385|TAK-385 tablet
1613506|NCT02135445|Drug|Degarelix|Degarelix injection
1613507|NCT02135432|Drug|Ivacaftor|
1613508|NCT02135432|Drug|Placebo|
1613509|NCT02135419|Drug|imiquimod|Applied topically
1613510|NCT02135419|Drug|fluorouracil|Applied topically
1613511|NCT02135419|Procedure|infrared photocoagulation therapy|Undergo infrared coagulation
1613513|NCT02135419|Procedure|laser therapy|Undergo laser therapy
1613514|NCT02135419|Other|clinical observation|Undergo active monitoring
1613515|NCT02135419|Other|laboratory biomarker analysis|Correlative studies
1613516|NCT02135419|Procedure|quality-of-life assessment|Ancillary studies
1613517|NCT02135406|Biological|CART-19 T cells|
1613518|NCT02135393|Dietary Supplement|13C5-folic acid or 13C5-6S-5-FormylTHF|Subjects with an insitu transjugular intrahepatic porto systemic stent shunt assigned to receive either a physiological 500 nmol (220 µg folic acid equivalent) dose of 13C5-folic acid or 13C5-6S-5-FormylTHF at the time of routine shunt venography to check patency followed by portal venous sampling at pre defined time points for 85 minutes and then given 13C5-6S-5-FormylTHF ator 13C5-folic acid at their next annual venography patency check with portal venous sampling at pre defined time points for 85 minutes
1613519|NCT02135380|Biological|Autologous Stromal Vascular Fraction (SVF)|Study arm A subjects will receive single dose of autologous adipose derived Stromal Vascular Fraction (SVF) intravenously.
1613520|NCT02135380|Biological|Autologous Adipose Derived MSCs (ADMSCs)|Study arm B subjects will receive total 3 doses of 2 million per kg body weight adipose tissue derived Ex-vivo expanded Mesenchymal stem cells (MSC) intravenously each. All the three doses will be given at weekly intervals.
1613521|NCT02135380|Other|Control|Standard Therapy
1613522|NCT02135367|Biological|PRP|injections of Platelet rich Plasma
1613523|NCT02135354|Drug|Azithromycin|"From day 1 up to and including day 3: 500 mg azithromycin PO once a day
From day 4 up to and including day 90: 250 mg azithromycin PO once every 2 days"
1613524|NCT02135354|Drug|Placebo|"From day 1 up to and including day 3: 500 mg placebo PO once a day
From day 4 up to and including day 90: 250 mg placebo PO once every 2 days"
1613525|NCT02135341|Drug|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection at 20 sites of bladder wall in single treatment
1613526|NCT02135341|Drug|Botulinum toxin A|BoNT-A 100 units in normal saline 10ml, suburothelial injection 50 U in 10 sites and 50 U urethral injections in 5 sites
1613527|NCT02135328|Behavioral|Radio Story|"For the purposes of this study a Radio Story is an audio recorded story of about a family's success story about type 2 diabetes mellitus prevention and management."
1613528|NCT02135328|Behavioral|Audio brochure|The control participants listened to an adio version of a standard brochure about prevention and management of type 2 diabetes.
1613529|NCT02135315|Drug|Isosorbide Dinitrate|"continuous infusion of Isosorbide dinitrate (40 mg per 40 ml) depending on the systolic blood pressure value.
SBP: under 120 mmHg : no drug SBP: 120 to 130: 1 mg per hour SBP: 130 to 140: 2 mg per hour SBP: 140 to 150: 3 mg per hour SBP: 150 to 160: 4 mg per hour SBP: above 160 mmHg : 6 mg per hour"
1613530|NCT02135315|Drug|Labetalol|"continuous infusion of Labetalol (TRANDATE) is used if the arterial pressure objectives are not reached with the Isosorbide Dinitrate alone.
Dilution Labetalol: 200 mg in 40 ml: 4mg per ml SBP: under 110 mmHg: no drug SBP: 110 to 130: 4 mg per hour SBP: 130 to 150: 8 mg per hour SBP: above 150 mmHg: 16 mg per hour"
1613531|NCT02135302|Drug|eravacycline|Eravacycline (TP-434) is a parenteral and oral antibiotic of the tetracycline class that is highly active in vitro and in established animal infection models against both nosocomial and community-acquired methicillin-susceptible or -resistant Staphylococcus aureus strains, vancomycin-susceptible or -resistant Enterococcus faecium and Enterococcus faecalis, and penicillin-susceptible or -resistant strains of Streptococcus pneumoniae. In addition, eravacycline is highly active against clinically important species of Enterobacteriaceae (including those isolates that produce extended-spectrum β-lactamases and/or are carbapenem-resistant), Acinetobacter baumannii, and anaerobes.
1613532|NCT02135276|Drug|eravacycline|All subjects will receive s single dose of intravenous eravacycline (1.5 mg/kg) administered over 60 minutes on Day 1. This study includes an up to 21-day Screening Period, a 5-day Treatment Period, and an End of Study Visit occurring approximately 2 weeks (±2 days) after study drug administration. Approximately 12 subjects will be enrolled: 6 subjects with ESRD and 6 healthy subjects with normal renal function. Healthy subjects will be matched to renally impaired subjects in gender, age, and body mass index (BMI).
1613533|NCT02135263|Drug|Methylphenidate|10 mg as a single dose followed by blood samples for the next 33 hours
1613534|NCT02135263|Drug|Enalapril|10 mg as a single dose followed by blood samples for the next 72 hours
1613535|NCT02135250|Drug|Xinkeshu tablets|4 Xinkeshu tablets are given three times per day
1613536|NCT02135250|Other|placebo|the placebo is not drug.
1613537|NCT02135237|Behavioral|Prize Contingency Management for Alcohol Abstinence|
1613538|NCT02135237|Behavioral|Standard Care|
1613539|NCT02135224|Drug|Fentanyl|
1613540|NCT02135224|Drug|Normal saline|
1613541|NCT02135211|Behavioral|Lifestyle counseling|
1613542|NCT02135198|Drug|2 mg AZD7325|A single 2 mg oral dose of AZD7325
1613543|NCT02135198|Drug|10 mg AZD7325|A single 10 mg oral dose of AZD7325
1613544|NCT02135198|Drug|Placebo|A single oral dose
1613545|NCT02135185|Other|custom work endurance|Experimental: Rehabilitation effort
1613546|NCT02135185|Behavioral|dietary management adapted to the nutritional status|dietary management adapted to the nutritional status
1613547|NCT02135172|Behavioral|Sitting|
1613548|NCT02135172|Behavioral|Standing|
1613549|NCT02135172|Behavioral|Walking|
1613550|NCT02135159|Drug|TDM1|administration of the TDM1 by IV perfusion
1613551|NCT02135159|Radiation|Brain Sequential RT|local RT
1613552|NCT02135146|Drug|Plasmalyte 3ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 3 ml/kg/hr. and a nexfin monitor placed on them
1613553|NCT02135146|Drug|Plasmalyte 6ml/kg/hr group|This group will have intravenous plasmalyte fluid limited to a rate of 6 ml/kg/hr. and a Nexfix Monitor placed on them
1613554|NCT02135133|Drug|Idelalisib|150 mg BID Oral Daily
1613555|NCT02135133|Drug|Ofatumumab|Ofatumumab will then be administered at 1000 mg weekly to complete 8 weeks (days 64, 71, 78, 85, 92, 99, 106) throughout Cycles 3 and 4. This will be followed by monthly ofatumumab on weeks 20, 24, 28, 32 to complete 4 additional cycles (5-8).
1613556|NCT02135120|Drug|Combined spinal epidural anesthesia technique with intrathecal morphine|
1613557|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block|
1613679|NCT02134288|Drug|Everolimus|
1613558|NCT02135120|Drug|A combination of combined spinal-epidural (with intrathecal morphine) and femoral nerve block as well as sciatic nerve block|
2010331|NCT03007953|Behavioral|Palliative Care|Care delivered by a nurse, including symptom assessment and management, patient education on lung cancer and treatment options, discussion and communication about preferences for care, psychosocial assessment (including referrals to ancillary services), and patient-centered resources. A personalized treatment plan based on the patient's lung cancer stage, treatment, symptoms and psychosocial needs will be developed by the palliative care team (physician, study nurse) with input from the patient and family member. The study nurse will assess patient's symptoms, implement and monitor the treatment plan applying established End-of- Life Nursing Education Consortium (ELNEC) for Veterans protocols.
1613563|NCT02135094|Device|Sam Ultrasonic Diathermy Device (Active Device)|low intensity continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2 for treatment duration of 4 hours per day
1613564|NCT02135094|Device|Sam Ultrasonic Diathermy Device (Placebo Device)|The placebo device appears and operates identically to the active device except that it does not emit ultrasound.
1613565|NCT02135068|Device|Medtronic MiniMed Closed Loop (CL) System|The Medtronic MiniMed Closed Loop (CL) System is an investigational system that uses some commercially available products. An investigational Enlite 2 glucose sensor measures the sensor glucose. The glucose sensor signal is sent to the insulin pump. From the insulin pump the sensor glucose is sent through the translator, which then relays the signal on to a controller. An Android Mobile Device (off the shelf) has the control algorithm installed. This device is known as the controller. The controller serves as the control center for the Android system, receiving data from the sensor and pump components, feeding the data to its control algorithm, issuing delivery commands to the pump to apply the algorithm's recommend therapy, and providing a means to monitor the system.
1613566|NCT02135068|Other|Snacking|Up to 45 g of oral glucose via Gatorade
1613567|NCT02135055|Other|blood sample collection|Patients were included 1 hrs later(before the study drug is administrated), 3 d and 7 d after sedation with midazolam, blood sample is collected. Flow cytometry is performed to test the mHLA-DR and according the value of mHLA-DR, assign the participant to the 4 groups as described in the arm.
1613568|NCT02135055|Drug|Midazolam|The loading dose of midazolam is 0.03-0.3 mg/kg, intravenous injected slowly for 10 minutes, then 0.04-0.2 mg/kg/h for maintenance of sedation.
1613569|NCT02135055|Drug|Morphine|Morphine is the only analgesic drug that permitted to use. 2 mg morphine is given a bolus when the participant feel pain. If the pain is not alleviated, 0.4-1 mg/h morphine is maintained.
1613570|NCT02135055|Procedure|Sedation interruption|Sedation interruption is performed at 8 am every morning.
1613571|NCT02135042|Drug|Cisplatin|Given IV
1613572|NCT02135042|Other|Clinical Observation|Undergo clinical observation
1613573|NCT02135042|Drug|Fluorouracil|Given IV
1613574|NCT02135042|Drug|Gemcitabine Hydrochloride|Given IV
1613575|NCT02135042|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1613576|NCT02135042|Other|Laboratory Biomarker Analysis|Correlative studies
1613577|NCT02135042|Drug|Paclitaxel|Given IV
1613578|NCT02135042|Other|Quality-of-Life Assessment|Ancillary studies
1613583|NCT02135016|Drug|1% lidocaine|epidural anesthesia with 1% lidocaine 10ml before propofol TCI
1613584|NCT02135016|Drug|2% lidocaine|epidural anesthesia with 2% lidocaine 5ml before propofol TCI
1613585|NCT02135016|Drug|0.9% normal saline|epidural anesthesia with 0.9% normal saline 5ml before propofol TCI
1613586|NCT02135003|Other|patient-selected care buddy|Patient-selected Care buddy intervention: In addition to standard of care, pre-ART patients randomized to this arm were requested to choose a care buddy who was aware of the patient's HIV infection and resided in the same household or in close proximity. Care buddies attended at least two HIV health education sessions similar to those provided to study participants. Information on HIV, and the importance of adhering to scheduled clinic visits and to prescribed medications will be emphasized. Buddies were requested to remind participants to take their prophylactic treatments, and remind them of clinic appointments
1613587|NCT02134990|Drug|Oshadi D and Oshadi R|Anti cancer agents
1613588|NCT02134990|Drug|Docetaxel|Chemotheraphy
1613589|NCT02134977|Drug|Leuprorelin Acetate|Leuprorelin Acetate SR 11.25 mg Injection Kit
1613590|NCT02134964|Drug|OLT1177 Capsules|OLT1177 Capsules are an experimental drug.
1613591|NCT02134964|Drug|Placebo Capsules|Placebo Capsules are identical in all ways to the study drug, but contain no active pharmaceutical ingredient.
1613594|NCT02134938|Dietary Supplement|Konjac Glucomannan|Konjac Noodles (Wellbond Import Export Inc.), Vegan Konjac Shrimp (Sophie's Kitchen), Konjac Gel Cubes
1613595|NCT02134925|Other|Laboratory Biomarker Analysis|Correlative studies
1613596|NCT02134925|Biological|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
1613597|NCT02134925|Other|Quality-of-Life Assessment|Ancillary studies
1613598|NCT02134925|Other|Saline|Given SC
1613599|NCT02134912|Drug|crizotinib|Given PO
1613600|NCT02134912|Drug|pemetrexed disodium|Given IV
1613601|NCT02134912|Other|laboratory biomarker analysis|Correlative studies
1613602|NCT02134912|Other|pharmacological study|Correlative studies
1613603|NCT02134899|Drug|Everolimus|Change from a calcineurin inhibitors-based immunosuppression to an everolimus-based immunosuppression
1613604|NCT02134899|Drug|Calcineurin inhibitors maintenance|Usual treatment
1613605|NCT02134886|Drug|Erlotinib Hydrochloride|Given PO
1613606|NCT02134886|Other|Laboratory Biomarker Analysis|Correlative studies
1613607|NCT02134886|Other|Pharmacological Study|Correlative studies
1613608|NCT02134886|Other|Quality-of-Life Assessment|Ancillary studies
1990877|NCT01729858|Device|Ceramic-Ceramic|"Zirconia computer aided design and computer milled cores with press on veneers with different thicknesses, gingival embrasure diameters and connector heights.
Fifty percent of the recruited subjects will be given a ceramic-ceramic bridge at baseline."
1990878|NCT01729858|Device|Metal-Ceramic|"Metal Ceramic prosthesis with press on veneer with different thicknesses, different diameters of curvature of gingival embrasure and connector heights.
Fifty percent of the recruited subjects will receive the metal-ceramic bridges at baseline."
1613609|NCT02134873|Other|sucrose|Sucrose will be administered by a research nurse experienced in neonatal intensive care using a standardized procedure and timing consistent with policies in the participating units, including: (a) administering sucrose 2 minutes prior to the heel lance to ensure peak effects; (b) giving the total volume of sucrose drop by drop via syringe on the anterior surface of the tongue, as tolerated, over a period of up to 1 minute to allow for individual infant swallowing rates and to ensure analgesic effects are sustained during the heel lance procedure; and (c) offering a pacifier for non-nutritive sucking (NNS) immediately following sucrose administration.
1613610|NCT02134860|Other|Bed rest|8 days of full bed rest
1613611|NCT02134860|Other|OGTT|Oral glucose tolerance test with 75 g of glucose before and after bed rest
1613612|NCT02134860|Other|IVGTT|Intravenous glucose tolerance test mimicking the glucose profile from the corresponding OGTT
1613613|NCT02134860|Other|Cognitive testing|Daily testing of memory and concentration using standardized tests
1613614|NCT02134860|Other|Muscle and fat biopsies|Biopsies will be obtained before and after bed rest
1613615|NCT02134860|Other|Dual-energy X-ray Absorptiometry (DXA) scan|DXA scan to evaluate fat and muscle distribution before and after bed rest
1613616|NCT02134860|Other|MRI|Functional MRI to evaluate cognitive function and abdominal MRI to evaluate visceral fat before and after bed rest
1613617|NCT02134847|Other|SCS intervention schedule|
1613618|NCT02134834|Drug|OP0595|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
1613619|NCT02134834|Drug|Placebo|Five cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation
1613620|NCT02134821|Procedure|Surgery for lumbar spinal stenosis|decompression with or without fusion for lumbar spinal stenosis
1613621|NCT02134808|Drug|Creatine|Creatine is a nutritional supplement.
1613622|NCT02134808|Drug|Placebo|The placebo is an inactive ingredient similar in appearance, weight and density to the active treatment.
1613623|NCT02134795|Device|TNM (trade name), a form of brainstem Stimulation|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes. The stimulation is non-invasive and non-electrical. The form of stimulation acts on the brainstem.
1613624|NCT02134782|Behavioral|Individualized Yoga Intervention Group|These children will not receive a study-supplied iPad. Use of child or hospital supplied iPad games, music, movies or books will be permitted without any modification, encouragement or discouragement of these activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
1613625|NCT02134782|Other|iPad Activity Control Group|These children will not receive yoga during the 3 week iPad activity period; instructors will receive specific training to ensure that no yoga occurs during this time frame. Use of child or hospital supplied iPad activities will be permitted instead of the study-supplied iPad activities. There will be no restrictions on concomitant medications. Standardized sleep hygiene recommendations will be provided.
1613626|NCT02134769|Device|Bionecteur|Using Bionecteur at each lumina of the catheter; handling according to institutional guideline
1613627|NCT02134756|Drug|NutraStem Active|
1613628|NCT02134743|Procedure|Implant surgery|Dental implant surgery with two different kinds of implant surface (SLA and modified SLA)
1613629|NCT02134730|Behavioral|FRIENDS for life|Friends for life (FFL). The FFL is a prevention program created by professor Paula Barrett, Brisbane, Australia. It is based on cognitive behavioral treatment strategies, for example the link between thoughts and feelings, negative and positive thoughts, breathing and relaxing exercises, support from others, breaking challenging situation in smaller steps, and problem-solving techniques. The children's workbook comprises practice-sheets for use during class, and homework assignments. The group leader manual comprises detailed instructions to all exercises.
1613630|NCT02134717|Drug|all subjects will receive maraviroc 300mg orally twice a day for 6 weeks|
1613631|NCT02134717|Procedure|Bronchoscopy with bronchoalveolar lavage|Bronchoscopy employs a flexible instrument that is inserted into the trachea and proximal airways after topical anesthesia. Bronchoalveolar lavage involves the instillation of saline solution through the bronchoscope into the airways followed by recovery under suction to collects lung fluid containing cells and proteins.
1613632|NCT02134717|Procedure|venipunctures|Venipunctures will be performed at study entry, after two weeks, and at the end of the study to collect blood for research studies and safety laboratories.
1613633|NCT02134717|Procedure|Skin biopsy|For subjects with sarcoidosis skin lesions, an optional skin biopsy specimen may be collected for research studies.
1613634|NCT02134704|Other|Data recording with all sensors|The sensors will be placed in the child body and will allow the collection of all the data of the trial.
1613635|NCT02134691|Behavioral|Prolonged Exposure|
1613636|NCT02134691|Behavioral|Applied Relaxation|
1613637|NCT02134678|Behavioral|self-system therapy|
1613638|NCT02134678|Behavioral|cognitive therapy|
1613639|NCT02134652|Other|diagnostic bedside ultrasound|"Patients enrolled in this study will undergo bedside ultrasound during their initial presentation to the emergency department. Ultrasound imaging protocols include the following:
FAST Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) sub-xyphoid 2)right upper quadrant (with right thorax) 3)left upper quadrant (with left thorax) and 4) suprapubic
Right Upper Quadrant Exam - Standard images will be obtained using the abdominal transducer. Images include the following: 1) Long axis of the gallbladder 2) Transverse axis of the gallbladder fundus 3) Transverse axis of the gallbladder body and 4) Transverse axis of the gallbladder neck."
1613640|NCT02134639|Procedure|68Ga-DOTATOC PET-CT Imaging|
1613641|NCT02134626|Drug|Simvastatin|40mg / pill, one pill orally once a day for three months
1613642|NCT02134626|Drug|Placebo pill|
1613643|NCT02134613|Other|99mTc-anti-TNF-alpha Scintigraphy|99mTc-anti-TNF-alpha Scintigraphy will be analysed and discussed by physicians who are in charge of the patients.
1613644|NCT02134600|Dietary Supplement|Omega-3 enriched fruit juice|"Different doses of omega-3 will be administered to five different groups:
400, 800, 1200, 2400 and 3000 mg/m2."
1613680|NCT02134275|Behavioral|Whole body vibration training|Each whole body vibration session will consist of a 20 min timed stand on the vibration platform where participants will stand with their knees in a slightly flexed position (120°) while the plate oscillates. The vibration frequency will be set at ranges between 20-40Hz and the amplitude set at 2mm displacement.
1613645|NCT02134587|Other|Multifaceted educational intervention|"Application of questionnaire of knowledge, attitudes and skills in pharmacovigilance.
Lecture regarding the theoretical framework and importance of pharmacovigilance, and distribution of educational material
Distribution of educational material
Practical class to explain the correct fill of adverse drug events form
Reapplication of questionnaire of knowledge, attitudes and skills in pharmacovigilance."
1613646|NCT02134574|Biological|hematologic malignancy|hematologic malignancy with a sampling of blood
1613647|NCT02134561|Behavioral|psychological interview|
1613648|NCT02134561|Radiation|MRI|This MRI is a specific intervention assign to the subjects of the study, that's why it is an interventionnal study
1613649|NCT02134561|Other|cognitive tests|
1613650|NCT02134561|Other|neurological tests|
1613651|NCT02134522|Device|Continuous positive airway pressure (CPAP).|Continuous positive airway pressure is a commonly prescribed therapy for obstructive sleep apnea which is recommended for the treatment of obstructive sleep apnea in children and adults.
1613652|NCT02134509|Behavioral|Experimental App|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach behavioral strategies for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules
1613653|NCT02134509|Behavioral|Active Comparator App|It is comprised of 6 prompts per day asking individuals about their experience, behavior, and smoking habits, for 22-days.
1613654|NCT02134496|Procedure|assessment of motorfunction in PACU|assessment of motorfunction in PACU after spinal anesthesia
1613655|NCT02134483|Biological|Parathyroid allo-transplantation|parathyroid allotransplantation with a new tecnique without immunosuppression
1613656|NCT02134470|Drug|Testosterone supplementation|Low-dose testosterone supplementation will be facilitated by using hormone patches. For pharmacokinetic aspects circadian profiles of saliva/blood/urine will be measured under native conditions and under exogene hormone application. In addition, cross-reactivity of a standardized exercise bout and hormone application will be of further interest.
1613657|NCT02134457|Biological|ranibizumab|
1613658|NCT02134444|Behavioral|Experimental group|Experimental group will receive a game-based exercise program delivered at home. This includes provision of a head-mounted motion mouse. This provides a treatment tool applied to gaze control, and allows incorporation of balance exercises. It also allows many different therapeutic exercises to be coupled to a wide range of inexpensive commercial computer games. Participants will attend 3 clinical sessions during which time the home therapy programs will be established and training in the use of the motion mouse and games will be provided. The treating physiotherapist will attend the participant's home to ensure proper set-up and operation of the computer applications. Participants will be asked to perform their respective home programs four times per week for 20 minutes per session.
1613659|NCT02134444|Behavioral|Control group|Control group will receive a vestibular exercise program which will include the Herdman gaze stabilization exercises and balance training program. This program is presently a standard of vestibular care. Participants will attend an out-patient physical therapy clinic once a week for 12 weeks. The program also includes a 20 minute home exercise program prescribed 4 times per week.
1613660|NCT02134431|Device|flexible sigmoidoscopy or colonoscopy with biopsies|Lower endoscopy with biopsies (specifically either colonoscopy or flexible sigmoidoscopy) in both HIV-positive subjects already on oral tenofovir , as well as HIV negative subjects. Biopsies will be taken to laboratory for quantification of HIV-1 and drug levels of tenofovir.
1613661|NCT02134418|Behavioral|CBT of irony comprehension|Over the course of intervention participants will analyze and discuss short film scenario's that end with an ironic statement, and will experience completing short scenario's that contain irony. Intervention will include 5 sessions, each session will take 40 minutes, 3-5 subjects will participate in each group.
1613662|NCT02134405|Drug|Rebamipide|Rebamipide 100mg tid
1613663|NCT02134405|Drug|Placebo (for Esomeprazole)|Sugar pill manufactured to mimic Esomeprazole
1613664|NCT02134405|Drug|Esomeprazole|Esomeprazole tablets 20mg o.d. for 8 weeks
1613665|NCT02134392|Biological|Fecal Microbiota Transplantation|250 ml of a fecal suspension diluted in saline will be administered via colonoscopy or enema in patients with recurrent c-diff.
1613666|NCT02134379|Device|Medtronic ICDs, CRT-Ds, and CRT-Ps|Any Medtronic implantable cardioverter defibrillator (ICD) or cardiac resynchronization therapy (CRT) device. Device must have capacity to measure thoracic impedance as described in protocol. This includes the majority of FDA-approved Medtronic devices currently in use.
1613667|NCT02134366|Drug|Clobazam|Comparison of AED use in Epilepsia Partialis Continua
1613668|NCT02134366|Drug|Clonazepam|Comparison of AED use in Epilepsia Partialis Continua
1613669|NCT02134366|Drug|Lorazepam|Comparison of AED use in Epilepsia Partialis Continua
1613670|NCT02134353|Drug|Inhaled mannitol|Inhaled mannitol 400 mg BD for 26 weeks
1613671|NCT02134353|Drug|Placebo Comparator: Arm B - Control|Placebo Comparator: Arm B - Control BD for 26 weeks
1613672|NCT02134340|Drug|[I-124]-CPD-1028 Injection|A single intravenous dose of [I-124]-CPD-1028 Injection will be given at Visit 2 (within 21 days of screening Visit 1), and may be followed by whole body PET/CT imaging approximately 3 hours post-injection. PET/CT imaging will occur at Visit 3 (2-3 days after Visit 2) and Visit 4 (5-7 days after Visit 2). PET/CT imaging may also occur at Visit 5 (16-18 days after Visit 2). Visit 6 (28 +/- 2 days after Visit 2) is a follow-up telephone call for a post-treatment safety assessment. At Visits 2-5, whole body biodistribution and tumour uptake will be assessed. At all visits, safety will be assessed.
1613673|NCT02134340|Biological|CPD-1061|[Optional] An intravenous dose of 0.4, 1.4 or 6 mg/kg of body weight of CPD-1061 may be given 1-2 hours prior to injection of [I-124]-CPD-1028 at Visit 2. The decision to use CPD-1061 and the dose amount is based on an adaptive design and is dependent on interim reviews of imaging data.
1613674|NCT02134327|Drug|Combination of Dexmedetomidine with Midazolam|
1613675|NCT02134314|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 50 units/kg IVPB administered on day of transplant, and another dose 24 hours post op. Total: 2 doses
1613676|NCT02134314|Drug|Placebo|Placebo medication identical to study drug (C1 esterase inhibitor) volume will be administered on day of transplant, and another dose 24 hours post op. Total: 2 doses
1613677|NCT02134301|Drug|Oritavancin|
1613678|NCT02134288|Drug|Belatacept|
1613681|NCT02134275|Behavioral|Control group|Participants in this group will be asked to not make any significant changes to their lifestyle behaviors, such as diet and exercise, for the duration of the study.
1613682|NCT02134262|Drug|Cyclophosphamide or Bendamustine|Cyclophosphamide [1.5 g/m^2 x 1 day Intravenous (IV)] or Bendamustine [120 mg/m^2 x 2 days Intravenous (IV)] is administered as Pre-treatment medication of CD19-CAR-T.
1613683|NCT02134262|Genetic|Dose Level -1|CD19-CAR-T [1 x 10^5 cells/kg x 1 day and 2 x 10^5 cells/kg x 1 day Intravenous (IV)] are administered.
1613684|NCT02134262|Genetic|Dose Level 1|CD19-CAR-T [1/3 x 10^6 cells/kg x 1 day and 2/3 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
1613685|NCT02134262|Genetic|Dose Level 2|CD19-CAR-T [1 x 10^6 cells/kg x 1 day and 2 x 10^6 cells/kg x 1 day Intravenous (IV)] are administered.
1613686|NCT02134262|Genetic|Dose Level 3|CD19-CAR-T [1/3 x 10^7 cells/kg x 1 day and 2/3 x 10^7 cells/kg x 1 day Intravenous (IV)] are administered.
1613687|NCT02134249|Drug|Diosmin|2 tab / 8 hs Diosmin ( 500mg) will be given at day of HCG injection and for14 days
1613688|NCT02134249|Drug|Cabergoline|1 tab/day Cabergoline( 0.5 mg) will be given at day of HCG injection and for 8 days
1613689|NCT02134223|Behavioral|Dialectical behavior therapy|"in standard DBT, we will employ all treatment modalities: a weekly individual (1 hour) and group (2 hours) session, available telephone consultation, and DBT consultation team.
DBT participants will be assigned to the next available individual therapist and relevant skills training group.
Groups have a minimum of four members before commencement and a maximum of twelve members. Entry to the skills group occurs only at the commencement of the next skills module."
1613690|NCT02134223|Other|Treatment as Usual: any other drug or psychotherapy offered to participants, except DBT|
1613691|NCT02134210|Drug|Etanercept|Head-to-head comparison
1613692|NCT02134210|Drug|CHS-0214|
2010332|NCT03007030|Drug|Brentuximab Vedotin|"Starting Dose: 2.4 mg/kg by vein over 30 minutes on Day 1 of each 21 Day cycle.
Brentuximab vedotin capped at a maximum dose of 240 mg."
1613694|NCT02134184|Biological|Fluzone® 2012-2013 Formula NDC No 498281-012-50|This vaccine is given intramuscularly
1613695|NCT02134171|Other|Biological and imaging investigations|From day 1 to day 3, specific blood tests will be performed (serum troponin Ic and brain natriuretic peptide [BNP]). A cardiac ultrasonography within the 4 first days and a cerebral MRI within the first 7 days after TMA diagnosis will be performed.
2010333|NCT03004924|Drug|SHP640|Instill 1 drop of SHP640 (0.6% povidone-iodine [PVPI] and 0.1% Dexamethasone ) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
1613697|NCT02134132|Biological|Platelet Gel|Application of platelet gel in patients suffering from diabetic foot ulcers.
1613698|NCT02134132|Other|Placebo|The patients with Diabetic foot ulcer who receive placebo instead of PL Gel.
1613699|NCT02134119|Dietary Supplement|Echinacea-based dietary supplement|Echinacea-based dietary supplement given at 8,000mg/day or 16,000 mg/day by mouth
1613700|NCT02134119|Drug|Placebo|Sugar pill manufactured to mimic dietary supplement
1613701|NCT02134106|Drug|Polymyxin B|Intravenous polymyxin B will be started on a standard dose of 25,000U/kg body weight, in 2 divided doses each day, infused over 2 hours. The duration of intravenous antibiotic treatment for subjects with either bacteremia or VAP or HAP will be at least 10 days. The duration of intravenous polymyxin B can be prolonged based on clinical indication, e.g., deep-seated source of infection, etc. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
1613702|NCT02134106|Drug|Polymyxin B + Doripenem|Standard dose of intravenous polymyxin B at 25,000U/kg body weight will be given in 2 divided doses each day with each dose infused over 2 hours and intravenous doripenem 500mg, with each dose infused over 4 hours. For patients with VAP, nebulized colistin at the dose of 2 MU 8 hourly for 5 days will be prescribed.
1613703|NCT02134093|Drug|Induction of anesthesia,midazolam ,sufentanil,etomidate and rocuronium|Anesthesia induction:midazolam (0.03~0.05 mg/kg), sufentanil(0. 5~0.8 μg/kg), etomidate ( 0.2~0.6mg/kg) and rocuronium(0.6mg/kg)
1613704|NCT02134093|Drug|Dexmedetomidine|Continuous pump infusion dexmedetomidine at 0.5μg/kg （low dose group）or 1μg/kg （high dose group）for 15 minutes before anesthesia induction，then followed by a continuous pump infusion at 0.2 μg/kg/h（low dose group）or 0.4μg/kg/h（high dose group） until the end of surgery.
1613705|NCT02134093|Drug|Normal saline|Continuous pump infusion normal saline with identical volume of dexmedetomidine.
1613706|NCT02134093|Drug|Maintenance of anesthesia , propofol, remifentanil,vecuronium|Continuous infusion of propofol （3~6 mg/kg/h）, remifentanil （0.05~0.3 μg/kg/min）is required to maintain Entropy within 40~60,Mean Arterial Blood Pressure more than 20% of baseline level , Oxygen Saturation more than 90% , airway pressure less than 40 cm H2O, intermittent injection vecuronium （0.05~0.1mg/kg） as needed to maintain muscle relaxation.
1613707|NCT02134080|Drug|PF-04457845|PF-04457845 will be administered orally at 4mg daily for four weeks.
1613708|NCT02134080|Drug|Placebo|Placebo will be administered orally at 4mg daily for four weeks.
1613709|NCT02134067|Drug|TAS-119|
1613710|NCT02134067|Drug|Paclitaxel|A dose of 90 mg/m2 is used in combination with various doses of TAS-119.
1613711|NCT02134041|Other|traumatic brain injury|mild TBI, GCS >/=13 after traumatic brain injury
2010334|NCT03004924|Drug|PVP-I 0.6%|Instill 1 drop of 0.6% PVP-I ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
1990881|NCT01724346|Drug|Arm A - Post-Chlorambucil Therapy Follow-up|Patients remain in this Arm for continue follow-up until PD, unacceptable toxicity, or other reason for treatment discontinuation. All patients in this Arm have completed Chlorambucil therapy.
1613716|NCT02134002|Drug|Disulfiram|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
1613717|NCT02134002|Drug|Placebo|Thirty cocaine dependant patients will be included in this study during their hospitalization for withdrawal. After the inclusion visit, they will be randomized to receive disulfiram 250 mg/day or placebo over the 15 days of their hospitalization.
1613718|NCT02133989|Drug|Ticlopidine + Ginko biloba|ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily
1613719|NCT02133989|Drug|Clopidogrel|clopidogrel bisulfate 97.875mg(75mg as clopidogrel)
1613720|NCT02133976|Behavioral|cognitive therapy|
1613721|NCT02133976|Behavioral|mindfulness training|
1613722|NCT02133976|Behavioral|behavioral therapy|
1613723|NCT02133976|Other|treatment as usual|
1613724|NCT02133950|Procedure|elective cryopreservation of available embryos after PGD|no elective fresh embryo transfer; freeze all
1613725|NCT02133950|Procedure|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD|PGD and elective fresh embryo transfer plus cryopreservation of supernumerary available embryos after PGD
1613726|NCT02133937|Drug|gantenerumab|Single subcutaneous injection of a high concentration liquid formulation
1613727|NCT02133937|Drug|gantenerumab|Single subcutaneous injection of a lyophilized formulation
1613728|NCT02133924|Drug|natalizumab|Natalizumab 300mg on days 0 and 14.
1613729|NCT02133924|Drug|steroids|Prednisone 2mg/kg/d (or methyl-prednisolone IV equivalent)
1613730|NCT02133911|Drug|Ranolazine|
1613731|NCT02133898|Other|L-methylfolate|L-methylfolate, an FDA approved medical food will be administered in 15 mg capsule form once daily for 90 days
1613732|NCT02133885|Drug|Minocycline Group|These subjects will start with minocycline for 16 weeks, followed by a washout period for 3 weeks, then will receive a placebo for 16 weeks, followed by a washout period for 3 weeks, then will finish with minocycline for 16 weeks.
1613733|NCT02133885|Other|Placebo Group|These subjects will start with placebo (tablet looking just like minocycline) for 16 weeks, followed by a washout period for 3 weeks, then will receive minocycline for 16 weeks, followed by a washout period for 3 weeks, then will finish with placebo for 16 weeks.
1613734|NCT02133872|Drug|Minocycline 100mg Group|Subjects will be randomized to receive Minocycline 100mg
1613735|NCT02133872|Drug|Minocycline 200mg Group|Subjects will be randomized to receive Minocycline 200mg.
1613736|NCT02133846|Drug|TPI 287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.Drug: Placebo Drug: Placebo 500mL 0.9% sodium chloride.
1613737|NCT02133846|Drug|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
1613738|NCT02133846|Drug|Placebo|500mL 0.9% sodium chloride
1613739|NCT02133846|Drug|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class
1613740|NCT02133833|Device|Quantum Spectrum Radiation Emitter|The patients receive stimulation treatment of Quantum Spectrum Radiation Emitter (5 quantum chips) daily for three weeks. The emitters are placed around the shoulder.
1613741|NCT02133820|Drug|4 mg 12 hourly capsule - strong pain killer fasted|
1613742|NCT02133820|Drug|4 mg 12 hourly capsule - strong pain killer fed|
1613743|NCT02133820|Drug|12 hourly capsule strong painkiller with antagonist fasted)|
1613744|NCT02133820|Drug|4 mg 12 hourly capsule strong painkiller with antagonist fed|
1613745|NCT02133807|Procedure|Specific Lp(a) apheresis|"Specific Lp(a) apheresis procedures were carried out weekly with Lp(a) Lipopak columns (POCARD Ltd., Moscow, Russia) according to the standard protocol"
1613746|NCT02133794|Device|Tomosynthesis|
1613747|NCT02133781|Biological|Fluzone® 2009-2010 Formula|This vaccine is given intramuscularly
1613748|NCT02133781|Biological|FluMist® 2009-2010 Formula|This vaccine is given intranasally
1613749|NCT02133755|Drug|Bromocriptine|Three month administration of bromocriptine. Baseline ultrasound and laboratory parameters measured. Repeat measures at discontinuation of drug at 3 months.
1613750|NCT02133742|Drug|Axitinib|Axitinib at starting dose of 5 mg and 3 mg BID.
1613751|NCT02133742|Drug|MK-3475|MK-3475 with two dose levels: 2 mg/kg every three weeks to find the maximum tolerated dose and continue treatment in a dose expansion phase.
1613752|NCT02133729|Other|Blood sampling and OGTT|
1613753|NCT02133716|Other|expressed breast milk|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.
A single dose prior to venipuncture of expressed breast milk given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
1613754|NCT02133716|Behavioral|sucrose 24% oral|"The administration will be by direct instillation feeding syringe (maximum capacity 1ml) in the front of the mouth of the infant and accompanied throughout the administration of non-nutritive sucking (pacifier) and manual containing both sucrose treatment oral, as in the oral expressed breastmilk.
A single dose prior to venipuncture of oral sucrose 24% given two minutes in the sequence and then will proceed to the venipuncture care nurse responsible for the child, accompanied at all times provided the technical permitted with non-nutritive sucking and containment."
1613755|NCT02133703|Behavioral|Enhanced Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
1613756|NCT02133703|Behavioral|Internet DA|BRCA1/2 carriers randomized to this arm will have access to Internet-based decision support. This intervention is designed to provide education regarding the available risk management options.
1613757|NCT02133703|Behavioral|Enhanced Print DA|BRCA1/2 carriers randomized to this arm will receive print-based decision support materials which include a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
1613758|NCT02133703|Behavioral|Print DA|BRCA1/2 carriers randomized to this arm will receive print education materials designed to provide information regarding the available risk management options.
1613759|NCT02133703|Behavioral|Inconclusive Results DA|Women who receive uninformative BRCA1/2 results randomized to this arm will have access to Internet-based decision support including a preference clarification tool. This intervention is designed to provide education and decision support regarding the available risk management options.
1613932|NCT02132403|Drug|Gemcitabine|Gemcitabine on days 1, 8, and 15, at assigned doses, of a 28-day (4 week) cycle.
1613933|NCT02132390|Drug|Goserelin|
1613760|NCT02133690|Biological|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV)|Live Attenuated Pentavalent (G1-G2-G3-G4-G9) Human X Bovine Reassortant Rotavirus Vaccine (BRV-PV), at a dosage of ≥ Log10^5.6 fluorescent focus units (FFU)/Serotype/Dose in 2.5 ml of buffered diluent
1613761|NCT02133690|Other|Placebo|Lyophilized minimal essential medium (MEM) + excipients reconstituted in 2.5 ml of buffered diluents
1613762|NCT02133677|Drug|temozolomide 100mg|WBRT: 30 Gy in 15 fractions (2 Gy per fraction, 5 fractions per week) CT: TMZ 200 mg p.o. q.d. x 5 days per week x 3 weeks
1613763|NCT02133664|Drug|lipoic acid and omega-3 fatty acids|alpha lipoic acid as racemic form at 1,200 mg per day omega-3 fatty acids as fish oil concentrate containing a daily dose of 1.35 grams docosahexanoic acid and 1.95 grams of eicosapentaenoic acid
1613764|NCT02133664|Drug|Placebo|placebo lipoic acid and placebo oil
1613765|NCT02133638|Drug|Sevoflurane|Induction of anesthesia: fentanyl 2 µg kg-1 and a bolus inhalation of 8% sevoflurane in an 8 L.min-1 fresh gas flow. Anesthesia maintenance: 1 minimal alveolar concentration (MAC) sevoflurane at a low fresh gas flow of 0.6-0.8 L min-1 in a 60% air-oxygen mixture supplemented with boluses of fentanyl.
1613766|NCT02133638|Drug|Propofol|Induction of anesthesia: propofol 2 mg kg-1 and fentanyl 4 µg kg-1. Maintenance of anesthesia: infusion of propofol 8 mg kg-1 h-1 and boluses of fentanyl 3 µg kg-1.
1613767|NCT02133625|Drug|carboplatin|
1613768|NCT02133625|Drug|pioglitazone|
1613769|NCT02133612|Drug|paclitaxel; cisplatin|The adjuvant chemotherapy regimen consisted of paclitaxel 150mg/m2 intravenously (IV) over 3 hours on day 1, followed by cisplatin 50mg/m2 IV on day 2 every 14 days for 4 to 6 cycles.
1613770|NCT02133599|Drug|IOHEXOL|Patients receive 5 mL of Iohexol prior to cycle 1 and 4 of HDMTX
1613771|NCT02133586|Other|Ozone|Exposure to 300ppb ozone with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or nitrogen dioxide) in a two-exposure series.
1613772|NCT02133586|Other|Nitrogen dioxide|Exposure to 500ppb nitrogen dioxide with intermittent exercise as either the first exposure in a two-exposure series or as the second exposure approximately 22 hours after the first exposure (either clean air or ozone) in a two-exposure series.
1613773|NCT02133573|Drug|Progesterone|Crinone is supplied in a single use, disposable, white polypropylene vaginal applicator with a teal twist-off cap. Each applicator delivers 1.125 grams of Crinone gel containing 90 mg (8% gel) of progesterone in a base containing glycerin, mineral oil, polycarbophil, carbomer 934P, hydrogenated palm oil glyceride, sorbic acid, purified water and may contain sodium hydroxide. Crinone 8% is administered vaginally at a dose of 90 mg twice daily. The rounded tip of the applicator is inserted into the vagina. After insertion, the plunger is pushed to release the gel into the vagina. The applicator is removed.
1613774|NCT02133573|Drug|Vaginal lubricant|Replens Long-Lasting Moisturizer is supplied in pre-filled, sealed and individually wrapped applicators.Replens Long-Lasting Moisturizer will also be dosed at one applicator intravaginally twice daily.
1613775|NCT02133560|Behavioral|Video recording|Subjects will be asked to monitor their daily iron chelator administration by taking a video recording of preparing it and ingesting at least one sip. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
1613776|NCT02133560|Behavioral|Medication Administration Log|Subjects will be asked to monitor their daily iron chelator administration by completing the medication administration log on a daily basis. The data collected will be analyzed to describe patient adherence and comfort level with the process of daily recording of medication management.
1613777|NCT02133560|Behavioral|Education|"During this first six months period a study staff member will see subjects at each scheduled clinic visit they attend for regular blood transfusion.
Subjects will receive educational material and short quizzes related to sickle cell disease, thalassemia, iron overload, or iron chelation."
1613778|NCT02133534|Drug|Atorvastatin|
1613779|NCT02133521|Drug|DLBS1033|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
1613780|NCT02133521|Drug|Placebo|Investigational drug or placebo will be given in addition to the standard therapy, consists of: aspirin enteric-coated tablet 1 x 80 mg daily, simvastatin film-coated tablet 1 x 20 mg daily, and vitamin B complex 1 x 1 tablet
1613781|NCT02133495|Procedure|Non Cadaveric Human Acellular Dermal Tissue|
1613782|NCT02133482|Drug|Placebo|placebo solution
1613783|NCT02133482|Drug|BI 639667|oral solution BI 639667, single rising doses
1613784|NCT02133469|Biological|PCV7 (Pneumococcal 7-Valent Conjugate Vaccine)|injection 0.5 mL, single dose
1613785|NCT02133469|Biological|Hib Vaccine|Single Dose
1613786|NCT02133443|Device|PSV - pressure support ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Pressure support ventilator assistance to obtain a tidal volume of 6-8 ml/kg of ideal body weight.
1613787|NCT02133443|Device|Neurally Adjusted Ventilatory Assist|"Partial ventilator support partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Stepwise implementation of the NAVA level (steps of 25% ), returning to the  optimal  level between each evaluation (PSV 100%, NAVA 100%, 75%, 50%, 125%, 150%)."
1613788|NCT02133430|Device|Bispectral index, as measured by a BIS processor|Comparisons of incidence of postoperative delirium.
1613789|NCT02133417|Device|Quantitative Transmission Ultrasound|Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
1613790|NCT02133404|Drug|ASP7991|oral
1613791|NCT02133404|Drug|Cinacalcet|oral
1613792|NCT02133404|Drug|Placebo|oral
1613793|NCT02133391|Other|Centralized Reminder/Recall (R/R)|Method of increasing immunization delivery using reminder/recall techniques, which are implemented centrally.
1613794|NCT02133391|Other|Practice-based Reminder/Recall|Method of increasing immunization delivery using reminder/recall techniques, which are implemented at the practice level.
1613795|NCT02133378|Device|Hemopatch|Baxter Hemopatch
1613796|NCT02133378|Behavioral|Traditional Hemostasis Techniques (dry or wet gauze compression or similar)|
1613934|NCT02132390|Drug|Toremifene|
1613797|NCT02133365|Behavioral|Mindfulness and Interoceptive Exposure|The Mindfulness and Interoceptive Exposure intervention will be delivered in 4-5 manualized, individualized therapy sessions, of 1.5 hours - 2 hours each. The intervention is comprised of four established cognitive-behavioral strategies: psychoeducation, mindfulness, interoceptive exposure and skills generalization.
1613798|NCT02133352|Drug|Ranolazine|Single arm- ranolazine, initiated at 500 mg BID and increased to 1000 mg BID as tolerated
1613799|NCT02133339|Drug|TRN-157|
1613800|NCT02133339|Drug|Placebo|
1613801|NCT02133326|Drug|Caldolor|Subject will be given Caldolor by IV prior to surgery.
1613802|NCT02133326|Drug|Ofirmev|Subject will be given Ofirmev prior to surgery.
1613803|NCT02133300|Other|electrical stimulation|
1613804|NCT02133287|Device|AVI® Arsenic trioxide drug eluting stent delivery system|
1613805|NCT02133287|Device|Firebird2® sirolimus eluting stent system|
1613806|NCT02133274|Behavioral|Brief Psychosocial Intervention|Five weekly sessions of a Brief Psychosocial Intervention based of Behavioral Cognitive Therapy designed specifically for the present study.
1613807|NCT02133274|Other|Early Palliative Care|Early integration of Palliative Care into the standard oncologic care. Patients starting first line chemotherapy will receive immediately evaluation by the board-certified palliative care physicians.
1613808|NCT02133235|Procedure|conventional|insertion endobronchial blocker with the guidance of fiberoptic bronchoscopy
1613809|NCT02133235|Procedure|auscultation|insertion endobronchial blocker by auscultation, without the guidance of fiberoptic bronchoscopy
1613810|NCT02133222|Procedure|blood sample|
1613811|NCT02133209|Behavioral|Mindfulness Based Stress Reduction|Mindfulness Based Stress Reduction (MBSR) involves focused attention while practicing moment-to-moment nonjudgmental awareness of the self with the goal of achieving emotional balance and clarity of thought. There will be 8 weekly sessions and a half day retreat followed by 4 bi-weekly sessions over a period of 4 months.
1613812|NCT02133209|Behavioral|Stress Management for Headaches|Intervention involves a standardized stress management for headaches (SMH) group intervention that focuses on stress and general stress management skills, headache symptoms and their management, sleep hygiene, and healthy eating. There will be 8 weekly sessions followed by 4 bi-weekly sessions over a period of 4 months.
1613813|NCT02133196|Drug|Aldesleukin|Aldesleukin at 720,000 (cohort 1) or 72,000 (cohort 2) IU/kg IV based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to a maximum of 9 doses in cohort 1 and 12 doses in cohort 2.
1613814|NCT02133196|Drug|Fludarabine|Patients will receive Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1613815|NCT02133196|Drug|Cyclophosphamide|Patients will receive Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
1613816|NCT02133196|Biological|Young TIL|On day 0, TIL will be administered intravenously over 20 to 30 minutes one to four days after last dose of fludarabine.
2010335|NCT03004924|Drug|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye 4 times QID (with a minimum of 2 hours between doses) for 7 days.
2010336|NCT03002428|Drug|Teriparatide (PF708)|Subcutaneous injection
2010337|NCT03002428|Drug|Teriparatide (Forteo)|Subcutaneous injection
1613821|NCT02133170|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|The MBCT program is conducted in HULP (BRV and CBP), which also train therapists from Vitoria, in order to homogenize the intervention. Random sessions are video or audio recorded to be discussed and analyzed by the treatment team. The manualized MBCT therapy consists of 8 weekly sessions of 90 minutes and is applied in groups of approximately 10-15 patients. At least two programs in H. La Paz and two in the hospital de Santiago (Vitoria) will be provided.
1613822|NCT02133170|Behavioral|Psychoeducation|Psychoeducation program will be held in groups of 10 to 15 patients in 90-minute weekly sessions led by two therapists also outside the research team. The specific program of 8 sessions is focused addressing disease awareness, adherence to treatment and early detection of prodromal symptoms. Homework will also be included. The program is based on the Psychoeducation Manual for Bipolar Disorder . F.Colom , E.Vieta . Ars Medica, 2004. Attendance at least 80 % of the sessions of both interventions will be required to be considered complete.
1613823|NCT02133170|Behavioral|Standard treatment|Treatment as usual (TAU), including standard psychiatric care with psychopharmacological treatment.
1613824|NCT02133157|Drug|Sulfatinib|Sulfatinib is a capsule in the form of25, 50mg , 100mg; oral, once a day
1613825|NCT02133144|Behavioral|overeating fat|
1613826|NCT02133144|Behavioral|overeating carbohydrate|
1613827|NCT02133131|Drug|Grazoprevir/Elbasvir FDC|FDC tablet containing grazoprevir 100 mg + elbasvir 50 mg taken q.d. by mouth.
1613828|NCT02133131|Drug|Sofosbuvir|Sofosbuvir 400mg tablet taken q.d. by mouth.
1613829|NCT02133118|Drug|individual SUs, insulin, pioglitazone|
1613830|NCT02133105|Drug|Levosimendan|
1613831|NCT02133105|Drug|Dobutamine|
1613832|NCT02133092|Other|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
1613833|NCT02133079|Biological|autologous gp96 vaccination|vaccination of autologous gp96 derived from tumor tissue + basal treatment
1613834|NCT02133066|Procedure|Bedside Ultrasound-Assisted Site Marking|Patient will receive a bedside ultrasound-assisted site marking of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap using Mindray M7 Ultrasound.
1613835|NCT02133066|Device|Mindray M7 Ultrasound|Patient will receive a bedside ultrasound exam of the most appropriate site for lumbar puncture prior to the clinician completing the spinal tap
1613836|NCT02133066|Procedure|Routine lumbar puncture|Lumbar puncture will be performed per routine standard of care
1613837|NCT02133053|Other|Medical Device, drug-like|Ectoin Allergy Nasal Spray
1613838|NCT02133053|Drug|Beclomethasone|Beclomethasone nasal spray
1613839|NCT02133027|Procedure|Rouviere's sulcus|Dissection may be started safely by division of the peritoneum immediately ventral to the sulcus and continued in a triangle bounded by the liver surface, the neck of the gallbladder and the plane of the sulcus.
1613840|NCT02133027|Device|surgical instruments|surgical instruments used in the laparoscopic cholecystectomy,such as ratcheted grasper,atraumatic grasper ,scissors.
1613841|NCT02133014|Procedure|laparoscopic-assisted percutaneous catheter drainage|Removing necrotic pancreatic organizations and putting the catheter around the region of pancreas.After the surgery,patient's cavity are continuously douched by catheter using 0.5% 5-fluorouracil normal saline
1613842|NCT02133014|Drug|0.5% 5-fluorouracil normal saline|On the one hand,0.5% 5-fluorouracil normal saline directly inhibit DNA synthesis of pancreatic acinar cells which result in the synthesis of amylopsin of and trypsase is restrained.On the other hand,it can induce pancreatic cells apoptosis and alleviate pancreatic necrosis.
1613843|NCT02133001|Drug|Esketamine|Esketamine 84 mg will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25). Dose may be reduced to 56 mg per day based on Investigator's discretion.
1613844|NCT02133001|Drug|Placebo|Matching placebo will be self-administered by participants as intranasal spray as two times a week, for 4 weeks (that is, Day 1,4,8,11,15,18,22,25).
1613845|NCT02132988|Biological|OPT-822/OPT-821|
1613846|NCT02132975|Device|Biopsies using Apollo and UroStation®|Apollo : Motorised probe handler for prostate biopsies
1613847|NCT02132975|Procedure|Biopsies using UroStation® (image fusion)|
1613848|NCT02132962|Dietary Supplement|Amino acid infusion|
1613849|NCT02132962|Other|Bloodsamples, Biopsies.|
1613850|NCT02132949|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 500 mg/m^2 IV on Day 1 of each cycle q3w.
1613851|NCT02132949|Drug|Cyclophosphamide|Participants will receive cyclophosphamide 600 milligrams per square meter (mg/m^2) intravenous (IV) given on Day 1 of each cycle q2w.
1613852|NCT02132949|Drug|Docetaxel|Participants will receive docetaxel at a starting dose of 75 mg/m^2 IV for the first cycle and the dose may be escalated to 100 mg/m^2 for subsequent cycles q3w.
1613853|NCT02132949|Drug|Doxorubicin|Participants will receive doxorubicin 60 mg/m^2 IV on Day 1 of each cycle q2w.
1613854|NCT02132949|Drug|Epirubicin|Participants will receive epirubicin 100 mg/m^2 IV on Day 1 of each cycle q3w.
1613855|NCT02132949|Drug|paclitaxel|Participants will receive paclitaxel 80 mg/m^2 IV given weekly.
1613856|NCT02132949|Drug|Pertuzumab|Participants will receive pertuzumab at a loading dose of 840 milligrams (mg) IV loading dose, then 420 mg IV q3w.
1613857|NCT02132949|Drug|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) IV, then 6 mg/kg IV q3w.
1613858|NCT02132936|Drug|LEO 90100 aerosol foam|
1613859|NCT02132936|Drug|Aerosol foam vehicle|
1613860|NCT02132936|Drug|Calcipotriol BDP gel|
1613861|NCT02132936|Drug|Gel vehicle|
1613862|NCT02132923|Biological|No intervention|This is an observational study. The children hospitalized with lower respiratory tract infection (LRTI) with a laboratory confirmed RSV infection will be monitored for maximum 7 days or until hospital discharge.
2010338|NCT03001297|Biological|Placebo|Participants will receive single dose of placebo matched MEDI5884 injection SC on Day 1
1613864|NCT02132897|Drug|Auration CR Tablets 400 Single Dose-Tegretol CR 400 Single Dose|Carbamazepine CR Tablets 400 milligrams is given orally with 250 mL of water at room temperature.
1613865|NCT02132897|Drug|Tegretol CR 400 Single Dose-Auration CR 400 Single Dose|Auration CR 400 milligrams Single Dose is given orally with 250 mL of water at room temperature.
1613866|NCT02132884|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
1613867|NCT02132884|Procedure|therapeutic procedure|Receive standard of care treatment
1613868|NCT02132884|Drug|targeted therapy|Receive specific targeted therapy
1613869|NCT02132884|Other|laboratory biomarker analysis|Correlative studies
1613870|NCT02132871|Device|Impedance cardiography Physioflow ®|
1613871|NCT02132858|Other|cytology specimen collection procedure|Correlative studies
1613872|NCT02132858|Other|laboratory biomarker analysis|Correlative studies
1613873|NCT02132845|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
1613874|NCT02132845|Drug|targeted therapy|Receive target-directed therapy
1613875|NCT02132845|Procedure|therapeutic procedure|Receive standard of care therapy
1613876|NCT02132845|Other|laboratory biomarker analysis|Correlative studies
1613877|NCT02132832|Drug|Buspirone|Buspirone is an anxiolytic compound marked by modulation of both 5-HT1A and D3 receptors. Buspirone is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks. 10 mg buspirone is administered on days 1-4, then the dose is increased by 10 mg every 3 days to a maximum of 40 mg buspirone on days 10-19.
1613878|NCT02132832|Drug|Placebo|Placebo is administered orally twice per day (9:00 AM and 6:00 PM) for 3 weeks.
1613879|NCT02132819|Other|Withholding feeds|At least 2 feeds before the transfusion, 2 feeds after the transfusion and feeds during the transfusion are withholded
1613880|NCT02132819|Other|feeding during transfusion|The feeding process will be continued during the transfusion
1613881|NCT02132806|Procedure|Piezosurgery with biomaterial mp3 + bracket|
1613882|NCT02132806|Procedure|Piezosurgery with biomaterial mp3|
1613883|NCT02132806|Procedure|Piezosurgery|
1613884|NCT02132793|Behavioral|Anger Management Therapy|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment.
1613885|NCT02132793|Behavioral|Anger Management Therapy & RELAX app|Anger Management Therapy (AMT) is a 12-session manual-driven cognitive-behavioral intervention found efficacious for anger management treatment. RELAX app (1) enables the practice of anger management strategies remotely through mobile phone interfaces; (2) integrates with evidence-based treatments through implementing an existing CBT anger management course; (3) provides information, direction, and feedback through physiological sensors; and (4) supports communication and direction by the therapist through a web-based therapist interface and a remote and secure patient data server.
1613886|NCT02132767|Drug|Amiodarone|"Amiodarone Initial Dose
Oral: 400 mg po TID for 3 days is recommended
For patients incapable of taking oral: 150 mg IV bolus over 10 min, then 1 mg/min over 6 hours followed by 0.5 mg/min over 18 hours Maintenance Dose
Oral: at least 200 mg/day to be continued until 60 days after randomization
If drug cannot be given orally or via NG tube: 0.5 mg/min administered through central line (e.g., PICC) until oral dosing is started"
1613887|NCT02132767|Procedure|DC-cardioversion|DC-Cardioversion - frequency and duration determined by medical professional as medically needed
1613888|NCT02132767|Drug|Rate Control|Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed
2010339|NCT03001297|Biological|MEDI5884 Dose 1|Participants will receive single dose MEDI5884 Dose 1 injection SC on Day 1.
2010340|NCT03001297|Biological|MEDI5884 Dose 2|Participants will receive single dose MEDI5884 Dose 2 injection SC on Day 1
1613891|NCT02132728|Other|Flaxseed or rice raw powder ingestion|The experimental groups received isocaloric diets and different proportions of carbohydrates, and the introduction of 60g of brown flaxseed or rice raw powder. Flaxseed and raw rice were crushed weekly by minimal particle type mill and appropriate sieves for fine grinding grain with a degree to 250 mm/micrometers. After crushing flaxseed and raw rice, they were weighed in semi-analytical balance. The addition of flaxseed or raw rice powder was made in the collation (40 g added to milk) and lunch (20 g added to baked beans). The volunteers received flaxseed or rice raw powder, portioned to be used for 42 days, including the weekends.
1613892|NCT02132715|Behavioral|Resistance Exercise|
1613893|NCT02132715|Behavioral|KAATSU exercise|
1613894|NCT02132702|Device|Ekso|
1613895|NCT02132689|Drug|Actilyse (Thrombolytic therapy)|
1613896|NCT02132689|Drug|Heparine (Standard anticoagulation therapy)|
1613897|NCT02132663|Other|Control: Marketed routine infant formula|
1613898|NCT02132663|Other|An investigational infant formula containing an alternate source of DHA|
1613899|NCT02132650|Behavioral|ACC training|Rehabilitation of walking using accurate (ACC) walking tasks, such as stepping on targets, over obstacles, etc.
1613900|NCT02132650|Behavioral|SS training|Rehabilitation of walking using typical steady state (SS) walking. Conducted overground and on treadmill. 36 sessions of training conducted over the course of 12 weeks. Each session lasts about 1 hour.
1613901|NCT02132637|Drug|Insulin Peglispro|Administered SQ
1613902|NCT02132637|Drug|Insulin Glargine|Administered SQ
1613904|NCT02132611|Device|Diamondback 360® Coronary OAS Micro Crown|The Diamondback 360® Coronary OAS Micro Crown consists of a diamond-coated crown mounted to a shaft. The OAD ablates occlusive material in order to facilitate stent delivery. During orbit, forces press the crown against the coronary plaque, reducing calcified plaque on the vessel wall.
1613905|NCT02132598|Drug|cabozantinib|
1613906|NCT02132585|Procedure|Speckle tracking echocardiography|
1613907|NCT02132572|Device|BIOCELL™ Textured 410 Implant|Previously received a Natrelle BIOCELL™ textured 410 implant for primary breast augmentation.
1613908|NCT02132559|Drug|DHEA|
1613909|NCT02132546|Drug|Chlorhexidine|
1613910|NCT02132533|Drug|Nifedipine|Nifedipine 20 mg orally, then nifedipine 20 mg orally after 90 minutes if still contracting. Continue nifedipine 20 mg orally every 4 hours after the first dose for 48 hours.
1613911|NCT02132533|Drug|Placebo|Placebo orally, then placebo orally after 90 minutes if still contracting. Continue placebo orally every 4 hours after the first dose for 48 hours.
1613912|NCT02132533|Other|Usual care|Usual evaluation, monitoring and care for women with preterm labor.
1613913|NCT02132520|Device|rTMS|Low frequency rTMS (either real or sham) will be applied to the contralesional hemisphere at a rate of 1Hz for 10 minutes.
1613914|NCT02132520|Behavioral|BCI Training|BCI training will consist of a series of EEG-based motor-imagery tasks with virtual feedback presented on a computer screen.
1613915|NCT02132494|Behavioral|Physical activity|
1613916|NCT02132481|Other|EMA Only|The EMA only condition consists of: a) RSAU, b) an Android phone, c) a 6-hour EMA training on how to use the phone, HIV and SUD prevention, self-monitoring, procedures for completing the EMAs (see Appendix), d) an EMA signaling schedule covering 6 EMA prompts over a 16-hour time period per day tailored to each participant's schedule, e) research office visits twice a week during 1st month for staff to check participant's proficiency using the phone and completing EMAs, and f) collecting urine screens.
1613917|NCT02132481|Other|EMI Only|The EMI only condition includes: a) RSAU, b) an Android phone, c) a 6-hour EMI training on how to use the phone, HIV and SUD prevention, how each EMI relates to relapse prevention or HIV risk reduction, and how to access each EMI, d) research office visits twice weekly in 1st month as described above except visits focus on EMIs, and e) collecting urine screens.
1613918|NCT02132481|Other|EMA+EMI|"The combined condition includes: a) RSAU, b) an Android phone, c) the 6-hour EMA training, d) EMA signaling schedule, e) the 6-hour EMI training, f) research office visits 2 times a week during 1st month, and g) feedback following each EMA, which will include participants' current risk of use in the next 7 days ."
1613919|NCT02132481|Other|Neither - RSAU|"The neither smartphone condition will still have access to community recovery support as usual (RSAU). Standard discharge practice is to provide a recovery plan and relevant referrals. A recent RCT indicated that after leaving treatment, 37% of the clients attended self-help in the community, 41% participated in substance-free structured activities, and about 14% returned to treatment within 6 months. They will also participate in office visits twice a week during 1st month to complete non-phone related surveys and provide urine for screens."
2010341|NCT03001297|Biological|MEDI5884 Dose 3|Participants will receive single dose MEDI5884 Dose 3 injection SC on Day 1
1613921|NCT02132455|Procedure|colonoscopy|colonoscopy (colon examination with flexible tube and a camera) is to find early precancerous growth in the colon (polyps) and remove them before they turn into cancer
1613922|NCT02132442|Dietary Supplement|Ergocalciferol, placebo|Ergocalciferol 50000 IU capsules Microcrystalline cellulose
1613923|NCT02132429|Drug|AMG 333|Oral administration available in varying dose strength.
1613924|NCT02132429|Drug|Placebo|Placebo containing no active drug
1613925|NCT02132416|Drug|NSAID|Will be used if tolerated.
1613926|NCT02132416|Drug|Opioids|Initially intravenous administration and when tolerated oral slow-release pils will be used.
1613927|NCT02132416|Drug|Thoracic Epidural anaesthesia|Given by specialists in anaesthesiology and intensive care.
1613928|NCT02132416|Drug|Paracetamol|1g QID will be given to all patients unless allergies.
1613929|NCT02132416|Procedure|Surgical management|Fracture stabilization
1613930|NCT02132403|Drug|BTH1704|BTH1704 at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
1613931|NCT02132403|Drug|IMPRIME PGG|Imprime PGG at assigned doses administered on days 1, 8, 15, and 22 of a 28-day (4 week) cycle.
1613935|NCT02132364|Other|optimised follow-up|optimised follow-up will be done by nursing personnel associated with a caregiving member of his social circle.
1613936|NCT02132338|Behavioral|The Education Health Program|The operation of the educational program for the group under intervention will consist of groups operating with the triad of diabetes mellitus (pathophysiology of the disease, physical activity and diet), to be held in five times (cycles) approach, an interval of three months being held between them . In each session, participants will be the same (under multidisciplinary team intervention), the content will also be the same, however, using different educational strategies. During the intervals between cycles these users will be monitored by phone by equity and / or nursing students of the Federal University of São João Del Rei properly trained to do so. The educational program will be developed in five times (T0, T3, T6, T9, T12) and with an interval of three months. At every moment the educational process will be conducted with three consecutive meetings with one week interval. In summary, 15 educational sessions with the experimental group will be held.
1613937|NCT02132325|Behavioral|Dignity Therapy|Dignity Therapy/Life Plan will be provided by an advanced practice nurse or chaplain (APN/Chap), who has undergone training in provision of Dignity Therapy (offered through a 3-day group workshop by Dr. Harvey Chochinov).
1613938|NCT02132312|Drug|OMS302|
1613939|NCT02132312|Drug|Phenylephrine HCl|
1613940|NCT02132299|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, metabolically active, non-replicating (live, radiation attenuated) cryopreserved Plasmodium falciparum sporozoites (PfSPZ)
1613941|NCT02132299|Biological|Normal Saline (Placebo)|
1613942|NCT02132299|Biological|PfSPZ Challenge|Live, infectious, aseptic, purified, vialed, cryopreserved Plasmodium falciparum sporozoites (PfSPZ) for CHMI
1613943|NCT02132286|Drug|Quetiapine XR (extended release)|Treatment of quetiapine XR ( extended release)in MDD patients with S/Lg alleles
1613944|NCT02132273|Other|Educational Story|Educational story with pictures illustrating overnight polysomnography procedure accompanied by simple narrative.
1613945|NCT02132260|Drug|Naftifine Hydrochloride Cream 2%|Naftifine Hydrochloride Cream 2% (Taro Pharmaceuticals Inc.) applied once-daily for two weeks
1613946|NCT02132260|Drug|Naftin® (Naftifine Hydrochloride) Cream 2%|Naftin® (Naftifine Hydrochloride) Cream 2% (Merz Pharmaceuticals, LLC) applied once-daily for two weeks.
1613947|NCT02132260|Drug|Placebo Topical Cream|Placebo Topical Cream (Taro Pharmaceuticals Inc.) applied once-daily for two weeks.
1613948|NCT02132247|Drug|Diclofenac hydroxyethylpyrrolidine|
1613949|NCT02132234|Drug|Etanercept|biological treatment according to rheumatologic indication
1613950|NCT02132234|Drug|Adalimumab|biological treatment according to rheumatologic indication
1613951|NCT02132234|Drug|Certolizumab|biological treatment according to rheumatologic indication
1613952|NCT02132234|Drug|Infliximab|biological treatment according to rheumatologic indication
1613953|NCT02132221|Behavioral|Cognitive Behavioral Therapy|10- weekly 1h30 group sessions including psychoeducation and group discussions on pain, pain coping, opioid mechanisms, and relationship between mood, sleep, stress and pain.
1613954|NCT02132195|Drug|ACTH|Patients will receive ACTH twice weekly for 6 months, with a 50% dose reduction allowed for side effects. The dose will be reduce by 50% at 6 months and continued for an additional 6 months.
1613955|NCT02132182|Biological|Blood draw|The patient population for this study will be comprised of individuals who present to clinic with newly diagnosed osteosarcoma with or without infection and without known metastasis to the lung. These patients would have a standard-of-care blood draw. For the study we will be drawing an additional 15-20mL of blood (no additional needle stick).
1613956|NCT02132169|Drug|Drug: AC-170 0.24%|
1613957|NCT02132169|Drug|AC-170 0%|
1613958|NCT02132143|Radiation|intensity-modulated radiation|For concurrent chemoradiotherapy, the intensity-modulated radiation therapy(IMRT)will be given at the first day of therapy,total dose of 5000cGy～6000cGy/5-6 Weeks.
1613959|NCT02132143|Radiation|intensity-modulated radiation|For sequential chemoradiotherapy,the intensity-modulated radiation will(IMRT) will be given when patients received adjuvant chemotherapy for four cycles,total dose of 5000cGy～6000cGy/5-6 Weeks.
1613960|NCT02132130|Drug|CGF166|CGF166 is a recombinant adenovirus 5 (Ad5) vector containing the human Atonal transcription factor (Hath1) cDNA for administration via intra-labyrinthine infusion
1613961|NCT02132117|Drug|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% (AGN-199201) applied to the face once daily for 29 days.
1613962|NCT02132117|Drug|Vehicle to Oxymetazoline HCL Cream|Vehicle to Oxymetazoline HCL Cream (AGN-199201) applied to the face once daily for 29 days.
1613963|NCT02132104|Procedure|Uterine application of amnion membrane|Uterine application of amnion membrane following hysteroscopic adhesiolysis.
1613964|NCT02132104|Device|Foley balloon|Uterine application of Foley balloon
1613965|NCT02132104|Drug|Femoston|Hormones treatment after surgery.
1613966|NCT02132091|Other|Intermittent Fasting|The intermittent fasting paradigm used in this study will require participants to alternate between days of feasting (175% of normal caloric intake) and fasting ( 25% of normal caloric intake). Food will be provided by University of Florida Clinical Research Center with macronutrient composition prepared according to the 2010 Dietary Guidelines for Americans.
1613967|NCT02132091|Dietary Supplement|400 IU Vitamin E|once each day in morning; oral pill form
1613968|NCT02132091|Dietary Supplement|1000 mg Vitamin C|500mg twice each day; morning and evening; oral pill form
2010342|NCT03001297|Biological|MEDI5884 Dose 4|Participants will receive single dose MEDI5884 Dose 4 injection SC on Day 1
1613970|NCT02132039|Other|12-step sitting Tai Chi Chuan|The intervention consists of eight home-based sessions on 12-step sitting Tai Chi Chuan. Each session will last for an hour.
1613971|NCT02132039|Other|Control|The control consists of eight home-based sessions on useful health-care information. Each session will last for an hour.
1613972|NCT02132026|Drug|Denosumab|
1613973|NCT02132026|Drug|Alendronic Acid|
1613974|NCT02132026|Drug|Denosumab Placebo|subcutaneous injection of 0.9%Saline at baseline, 6 months, 12 months and 18 months
1613975|NCT02132026|Drug|Alendronic Acid Placebo|Inert Capsule containing lactose monohydrate manufactured and labelled by Investigational Supplies Group (ISG) University of Edinburgh.
2010343|NCT02999906|Drug|Oral Treprostinil|Sustained release oral tablets for three times daily administration
1613976|NCT02132013|Behavioral|Intervention SUBLIME|Intervention: dietary sodium restriction supported by 2 group meetings, structured self-regulation computer program, e-coaching.
1613977|NCT02132000|Drug|toremifene or tamoxifen|
1613978|NCT02131961|Drug|Collagenase ointment|250 collagenase units/g
1613979|NCT02131961|Device|Modified Contact Cast System|1 Unit
1613980|NCT02131948|Drug|Intranasal insulin|Intranasal spray
1613981|NCT02131948|Drug|Intranasal placebo|Intranasal spray
1613982|NCT02131922|Procedure|Intensive Treatment|Intensive Surgical Treatment of Periodontitis
1613983|NCT02131922|Procedure|Dental Hygienization Treatment|
1613984|NCT02131922|Drug|Chlorhexidine (Intensive Treatment)|Chlorhexidine (PerioKIN) (0.2%) implantation in dental pockets
1613985|NCT02131909|Procedure|mirror therapy|During a session, the child performs a series of 10 single, bilateral and synchronous movements while viewing the reflected image
1613986|NCT02131909|Procedure|bimanual rehabilitation exercises|During a session, the child performs a series of 10 single, bilateral and synchronous movements while watching his two hands
1613989|NCT02131883|Behavioral|Group-Cognitive Behavioral Therapy|psychoeducation, stress management, cognitive restructuring, response prevention, exposure, relapse prevention
1613990|NCT02131883|Other|Wait-List with treatment as usual|Intervention typical supportive talks from general practitioner. No restrictions for interventions for patients here.
1613991|NCT02131870|Dietary Supplement|L plantarum DSM 9843 or placebo|
1613992|NCT02131857|Behavioral|active interventional program based on Mindfulness training|active interventional program based on Mindfulness training
1613993|NCT02131844|Other|Facilitated early mobilization|Participants randomized to this group, in addition the preoperative education (usual care), will have early mobilization facilitated by a trained health professional. This health professional will: (1) visit the participant on the day of surgery to reinforce mobilization goals and assist with transfer to a chair and (2) visit the participant three times per day starting from POD 1 to reinforce mobilization goals and walk with the participant (at least the length of the hallway). Targeted walking distances will increase according to the participant's tolerance. This intervention will be undertaken until POD 3 or hospital discharge, whichever comes first.
1613994|NCT02131844|Other|Usual care|Participants randomized to this group will receive instructions about postoperative mobilization in a preoperative education session and will receive a booklet describing mobilization goals for each POD (sit in a chair for 2 hours on the day of surgery, stay out of bed for at least 6 hours/day from POD 1 until hospital discharge)
1613995|NCT02131818|Drug|Amoxicillin|The patient will be received amoxicillin 500 mg 2 capsules orally bid pc for 5 days
1613996|NCT02131818|Drug|Placebo|The patient will be received placebo 2 capsules orally bid pc for 5 days
1990882|NCT01724346|Drug|Arm B - PCI-32765|PCI-32765 will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. PCI-32765 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. PCI-32765 will be dispensed to patients in bottles at every other visit.
1990883|NCT01724346|Drug|Second-line PCI-32765|For patients who experienced PD before other Second-line treatment are eligible to receive PCI-32765.
1613999|NCT02131792|Procedure|Slanted recession of the lateral rectus muscle|All patients who had intermittent exotropia with convergence weakness was enrolled to the slanted lateral rectus muscle recession group.
1614000|NCT02131779|Behavioral|Men's Workshops|Two male Community Health Advisors will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series.
1614001|NCT02131779|Behavioral|Co-Educational Workshops|One male and one female Community Health Advisor will be trained using traditional/classroom methods and provided with technical assistance/support to implement the 4 part workshop series. Two break out sessions will occur in the Health Partner condition with separate discussion sessions for men and female health partners.
1614002|NCT02131766|Device|Diabetes Assistant (DiAs)|DiAs is the central component of our system. It is a standard cell phone running on an Android operating system. The cell phone has been changed to prevent from (1) using it as a phone or browser, (2) changing the volume (3) accidentally shutting it off. The cell phone runs an algorithm and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range and help avoid hypoglycemia during the night.
1614003|NCT02131753|Drug|Cladribine s.c. injection, HCL treatment|Patients with hairy cell leukemia and the need for treatment are given cladribine 0.14 mg/kg for 5 consecutive days as a s. c bolus injection
1614004|NCT02131740|Other|Eye rubbing|eye rubbing for 1 minute in horizontal direction clockwise, 5 second rest & eye rubbing for a further 1 minute.
1614005|NCT02131740|Other|No eye rubbing|This eye will not be rubbed
1614006|NCT02131727|Behavioral|Hand Hygiene Improvement Intervention|Participants received a 4 minute video about protective hand hygiene behaviors and other activities (cough ettiquette, and staying home when ill) to reduce the risk of contracting respiratory tract and GI infections. In addition, motivational posters and hand hygiene supplies were distributed in the work setting.
1614007|NCT02131727|Behavioral|Ask Me 3|"Participants in the control group received a 4 minute training video about the Ask Me 3 program to promote effective communication with health care providers, along with an Ask Me 3 brochure and a key-chain with the Ask Me 3 principles for effective communication with health care providers."
1614008|NCT02131714|Behavioral|counseling and exercises|These individuals were asked about parafunctional habits and the treatment was applied by providing an explanation concerning the role of pain, possible aetiological factors of the patient's TMD, the relationship between chronic pain and psychosocial distress, and its benign character. They also had to perform once daily application of hot packs on both sides of the face for 20 minutes and after that they must perform active free therapeutic exercise of mouth opening for 10 times
1614009|NCT02131714|Behavioral|lifestyle counseling|
1614010|NCT02131701|Behavioral|Physical activity|
1614011|NCT02131688|Drug|Mitoxantrone Hydrochloride Liposome|
1614012|NCT02131675|Dietary Supplement|Boost shake|Blood draw after mixed-meal consumption
1990884|NCT01724346|Drug|Alternative Anticancer Treatment|Specific therapy and treatment regimen are at the investigator's discretion.
1614018|NCT02131649|Device|18F-FCH PET/MRI Scan|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo a PET/MRI scan using 18F-FCH as the radiolabeled tracer. If prostate cancer is detected outside the prostate, patients may undergo a biopsy or follow-up 18F-FCH PET/MRI to confirm the results.
1614019|NCT02131636|Drug|AGN-199201|AGN-199201 applied to the face once daily for 29 days.
1614020|NCT02131636|Drug|Vehicle to AGN-199201|Vehicle to AGN-199201 applied to the face once daily for 29 days.
1614021|NCT02131597|Drug|SGI-110|60 mg/m2 subcutaneously daily for 5 days every 4 weeks.
1614022|NCT02131584|Drug|Ruxolitinib|Starting dose: 10 mg by mouth twice a day.
1614023|NCT02131584|Behavioral|Questionnaire|Symptom questionnaire completed at baseline, then 2 weeks after study dose, and again at 3 months.
1614024|NCT02131558|Procedure|ICG Dye|ICG Dye injections
1614025|NCT02131545|Drug|Quetiapine 25 mg gel applied topically|Quetiapine 25 mg gel applied topically; 9 serum quetiapine levels drawn over the course of 8 hours
1614026|NCT02131545|Drug|Quetiapine 25 mg tablet by mouth|Quetiapine 25 mg tablet administered by mouth; 9 serum quetiapine levels drawn over the course of 8 hours
1614027|NCT02131545|Drug|Quetiapine 25 mg rectal suppository|Quetiapine 25 mg suppository administered rectally; 9 serum quetiapine levels drawn over the course of 8 hours
1614028|NCT02131545|Drug|Quetiapine 25 mg gel applied topically|Quetiapine 75 mg gel applied topically every 4 hours for 24 hours; 6 serum quetiapine levels drawn over the course of 24 hours
1614029|NCT02131532|Behavioral|A brief psychological intervention|This intervention is based on the principle of cognitive-behavioral therapy
1614030|NCT02131519|Procedure|internal jugular vein catheter placement|
1614031|NCT02131506|Drug|Lapatinib, Caelyx|Lapatinib, Caelix: Lapatinib is given at escalating doses orally and continuously on days 1-21. Caelyx is administered at escalating doses in a 60-minute i.v. infusion on day 1. Each cycle is defined as 21 days. Four dose levels are planned. Dose level -1, Caelyx 30 mg/mq & Lapatinib 1000 mg die; dose level 1, Caelyx 30 mg/mq & Lapatinib 1250 mg die; dose level 2, Caelyx 30 mg/mq & Lapatinib 1500 mg die; dose level 3, Caelyx 40 mg/mq & Lapatinib 1500 mg die
1614032|NCT02131493|Drug|S-1, Gemcitabine|
1614033|NCT02131480|Drug|Doxorubicin|60 mg/m²
1614034|NCT02131480|Drug|Trabectedin|1,1 mg/m²
2010344|NCT02999906|Drug|Placebo|Placebo (sugar pill) for three times daily oral administration
1614036|NCT02131454|Other|Inhalation technique training|Training in inhalation technique in asthmatics and COPD patients
1614037|NCT02131441|Procedure|laparoscopic hepatectomy|
1614038|NCT02131441|Procedure|open liver resection|
1614039|NCT02131402|Device|ocufilcon D|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (ocufilcon D) in the contra lateral eye.
1614040|NCT02131402|Device|omafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (omafilcon A) in the contra lateral eye.
1614041|NCT02131402|Device|methafilcon A|Contralateral pair of study lenses. Test lens (enfilcon A) in one eye and a control lens (methafilcon A) in the contra lateral eye.
1614042|NCT02131389|Device|Iconacy Hip System|
1614043|NCT02131376|Procedure|Non-renorrhaphy|The suture closure of the renal cortex after tumor removal is omitted. A base layer running stitch only is performed for hemostasis and urine leak prevention.
1614044|NCT02131376|Procedure|Renorrhaphy|After tumor resection the patient will have both a deep and cortical layer reconstruction
1614045|NCT02131363|Device|Ingrowing Toenail Treatment Kit|detailed in arm description
1614046|NCT02131350|Procedure|Photocoagulation|Photocoagulation include focal/grid laser and/or panretinal photocoagulation
1614047|NCT02131350|Drug|Ranibizumab|
1614048|NCT02131337|Other|Electrophysiology study|after 3 months to check for pulmonary vein isolation (PVI) status
2010345|NCT02999178|Drug|Nintedanib|
2010346|NCT02999178|Drug|Placebo|
1614051|NCT02131311|Device|disposable, single-use pessary|
1614052|NCT02131298|Drug|Palbociclib Alone|A single 125 mg dose of palbociclib free base capsule given orally alone in the fed state, followed by 120 hours of PK sample collection
1614053|NCT02131298|Drug|Palbociclib plus itraconazole|Itraconazole 200 mg once daily with food for a total of 11 days; on Day 5, a single oral 125 mg dose of palbociclib will be given with itraconazole after a meal, followed by 168 hours of PK sample collection.
1614054|NCT02131285|Other|Sensory training|
1614055|NCT02131272|Drug|Insulin detemir|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OAD's i.e. metformin treatment should continue unchanged during the treatment period.
1614056|NCT02131272|Drug|Insulin NPH|Administered subcutaneously (s.c., under the skin) once or twice daily. The subjects' pre-trial OADs i.e. metformin treatment should continue unchanged during the treatment period.
1614057|NCT02131272|Behavioral|Diet/exercise|Intervention will be performed through family based changes in eating and activity behaviours.
1614058|NCT02131259|Drug|Afatinib dimaleate|20mg - 50mg
1614059|NCT02131246|Drug|Faster-acting insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
1614060|NCT02131246|Drug|insulin aspart|Subjects will receive a single dose of either Faster-acting insulin aspart or NovoRapid® at a predefined fixed dose level in connection to intake of a standardised meal. Administered subcutaneously (s.c., under the skin)
1614061|NCT02131233|Drug|Reformulated Raltegravir|Reformulated raltegravir 1200 mg (2x 600 mg tablets) orally once daily
1614062|NCT02131233|Drug|Raltegravir|Raltegravir 400 mg tablet orally twice daily
1614063|NCT02131233|Drug|TRUVADA™|Emtricitabine / tenofovir disoproxil fumarate 200 / 300 mg tablet administered once-daily with food (open-label)
1614064|NCT02131233|Drug|Placebo to Reformulated Raltegravir|Placebo to reformulated raltegravir 2 tablets orally once daily
1614065|NCT02131233|Drug|Placebo to Raltegravir|Placebo to raltegravir 1 tablet orally twice daily
1614066|NCT02131220|Drug|Prourokinase|20mg intracoronary bolus infusion using selective catheter during PCI
1614067|NCT02131220|Drug|Tirofiban|10ug/kg intracoronary bolus infusion using selective catheter during PCI
1614068|NCT02131220|Drug|normal saline|intracoronary bolus infusion using selective catheter during PCI
1614069|NCT02131207|Device|magnetic resonance imaging|Undergo pelvic MRI
1614070|NCT02131207|Procedure|prostate biopsy|Undergo prostate biopsy
1614071|NCT02131194|Dietary Supplement|Lenstatin|Dietary Supplement Lenstatin
1614072|NCT02131194|Drug|Placebo|Placebo sugar pill manufactured to mimic Lenstatin
1614075|NCT02131142|Device|BioFreedom drug coated coronary stent|Placement of a BioFreedom drug coated stent in a narrow coronary artery
1614076|NCT02131129|Device|rTMS|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
Ten sessions over a two week duration"
1614077|NCT02131129|Device|Sham Comparator|"The stimulation sites will be the left and right DLPFC, defined as 5 cm anterior to the scalp positions at which the MTs were determined. Treatments will be delivered within the following stimulation parameters: 110% of MT, 20 Hz, 30 trains, 1.0 second per train, 20 pulses per train, inter-train interval of 30 seconds (600 pulses/hemisphere, for a total of 1200 pulses/session/day).
Ten sessions over a two week duration"
1614078|NCT02131116|Behavioral|Integrated Metacognitive Therapy|Integrated Metacognitive Therapy
1614079|NCT02131116|Behavioral|Treatment as Usual|Treatment as Usual
1614080|NCT02131103|Other|Percutaneous coronary intervention|"All patients received fibrinolysis, aspirin 300 mg and clopidogrel (300 mg for participants 75 years of age or younger or 75 mg for participants older than 75 years of age). Patients older than 75 years of age did not receive enoxaparin.
Patients will be randomly assigned to either the group that received routine early PCI (hereinafter termed the early-PCI group) or the group that received standard treatment (PCI performed after 24-72 hours of successfully fibrinolysis). Randomized will perform within 24 hours after successful fibrinolytic therapy. PCI will be performed when persistent occlusion or substantial stenosis of the infarct-related artery (either stenosis of 70% or more of the diameter of the artery or stenosis of 50-70% with thrombus, ulceration, or spontaneous dissection) was present. In case of multivessel disease, only culprit lesion will be correct."
1614081|NCT02131090|Device|Tegaderm TM|This is a generic adhesive dressing which is commonly used to secure epidural catheters.
1614082|NCT02131090|Device|Lock-it Plus|This dressing is specifically designed for securing epidural catheters. It is adhesive to the patient's back and has a plastic clamp through which the epidural catheter passes. Once closed, the clamp secures the catheter.
1614083|NCT02131090|Device|Epifix|This dressing is specifically designed to secure epidural catheters. It is adhesive to the patient's back and has a foam, moulded mechanism through which the catheter is passed. An adhesive flap folds over the whole mechanism to secure the catheter.
1614084|NCT02131077|Biological|ALLO-ASC-TI|
1614085|NCT02131077|Drug|Placebo|
1614086|NCT02131064|Drug|Carboplatin|Carboplatin IV infusion at a dose to achieve an AUC of 6 mg*min/mL q3w
1614087|NCT02131064|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infusion q3w
1614088|NCT02131064|Drug|Pertuzumab|Pertuzumab 840 mg (loading dose); and 420 mg (maintenance dose) IV infusion q3w
1614089|NCT02131064|Drug|Trastuzumab|Trastuzumab 8 mg/kg (loading dose); and 6 mg/kg (maintenance dose) IV infusion q3w
1614090|NCT02131064|Drug|Trastuzumab Emtansine|Trastuzumab Emtansine 3.6 mg/kg IV infusion q3w
1614091|NCT02131038|Other|Medica device, drug-like|Ectoin (R) Allergy Nasal Spray
1614092|NCT02131012|Drug|Intravitreal Celecoxib|1-4 mg intravitreal celecoxib
1614093|NCT02130999|Drug|tasimelteon 20 mg capsule|
1614094|NCT02130999|Drug|tasimelteon 2 mg I.V.|
1614095|NCT02130986|Other|Procalcitonin level|A procalcitonin (PCT) will be drawn level within one hour after randomization in the ED, and if hospitalized, 6-24 hours after the initial ED blood draw, and on Days 3, 5, and 7. Days 3, 5, and 7 blood draws for procalcitonin will only occur in hospitalized patients on antibiotics and/or at the treating physician's discretion.
1614096|NCT02130986|Other|Results of procalcitonin (PCT) level to treating clinician|In the ED, we will quickly (<1 hour goal) provide clinicians the procalcitonin result.
1614097|NCT02130986|Other|Provide procalcitonin guideline to treating clinician|"Procalcitonin antibiotic guideline --
Procalcitonin level (ug/L) -- Bacterial etiology -- Recommendation
< 0.1 -- Very unlikely -- Antibiotics strongly discouraged(1)
0.1 - 0.25 -- Unlikely -- Antibiotics discouraged(1)
> 0.25 - 0.5 -- Likely -- Antibiotics recommended(2)
> 0.5 -- Very likely -- Antibiotics strongly recommended(2)
Initial antibiotics can be considered for critical illness, Legionella pneumophilia. Procalcitonin should be evaluated in context with all findings and the total clinical status; clinical judgment always necessary.
For outpatients, antibiotic duration based on level (> 0.25-0.5 ug/L:3 days; > 0.5-1.0 ug/L:5 days; >1.0 ug/L:7 days). Physician follow-up is recommended."
1614098|NCT02130986|Other|Telephone Visit|We will collect the number of antibiotic days during telephone visits occurring on or around Day 15 and Day 30
1614099|NCT02130973|Drug|Standard Clinical Practice Regimen|Standard Clinical Practice Regimen
1614100|NCT02130973|Drug|Experimental Cyclic Regimen|Experimental Cyclic Regimen
1614101|NCT02130947|Behavioral|Exercise|
1614102|NCT02130934|Procedure|Cardiac 3D MRI|
1614103|NCT02130921|Behavioral|Intervention to Address Drug Use and HIV in Vietnam|"Intervention for CHWs: 3 sessions will cover the understanding stigma and its impact, self-protection and universal precaution adherence, effective communication with patients and family members, and motivational enhancement for behavioral change.
Intervention for IDUs: CHWs who participate in the intervention will be required to conduct 3 individual sessions with participating IDUs covering the following topics: physical health, risk reduction behaviors, mental health, and community integration.
Intervention for FMs: CHWs who participate in the intervention will be required to conduct 2 group sessions with participating FMs covering the following topics: healthy family routine, coping with caregiver burdens, enhance family relationships, support positive behavior change."
1614104|NCT02130908|Other|Lean fish|Participants consumed 150g of lean fish, five times per week for 4 weeks
1614105|NCT02130908|Other|Fatty fish|Participants consumed 150g of fatty fish, five times per week for 4 weeks
1614106|NCT02130908|Other|Lean meat|Participants consumed 150g of lean meat, five times per week for 4 weeks
1614107|NCT02130895|Other|STOPP Criteria Decision Support Content|"55 previously developed clinical decision support suggestions based on the STOPP criteria will be activated in the physician EMR. Each suggestion provides a patient specific rule that, if triggered will display its title in an existing Clinical Decision Alerts box on the bottom right hand column in the patient's EMR chart. For example, in a patient with diabetes and on a beta blocker then the suggestion Consider: avoiding b-blockers in elderly diabetics with >=1 hypoglycaemic episodes / month will be presented to the physician in the side bar (not a popup). The physician then can decide to review, consider, or ignore the recommendation."
2010347|NCT02997436|Device|Laser speckle flowmetry|"A galvanic current (0.1 mA) will be applied between 2 patches on the forearm of patient and protocol was repeated at 4 minutes.
Microvascular response to current application (CIV) will be recorded by laser speckle flowmetry 10 minutes later.
Measurement of the value of skin blood flow (by laser speckle) at the stimulated area as compare to a non stimulated adjacent skin value taken as a reference Usual treatment will be recorded"
2010348|NCT02998541|Drug|SHP640|Instill 1 drop of SHP640 (0.1 % Dexamethasone and 0.6% PVP-I) ophthalmic suspension in each eye QID (with a minimum of 2 hours between doses) for 7 days.
2010349|NCT02998541|Drug|PVP-I 0.6%|Instill 1 drop of PVP-I ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
2010350|NCT02998541|Drug|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID (with a minimum of 2 hours between doses) for 7 days.
2010351|NCT02997176|Drug|Talazoparib|Daily oral doses of talazoparib 0.5 mg
2010352|NCT02997163|Drug|Talazoparib|Daily oral doses of talazoparib 0.5 mg
2010353|NCT02996474|Drug|Pembrolizumab|200 mg will be administered as a 30 minute IV infusion every 3 weeks. Every effort should be made to target infusion timing to be as close to 30 minutes as possible. However, given the variability of infusion pumps, a window of -5 minutes and +10 minutes is permitted (i.e., infusion time is 30 minutes: -5 min/+10 min).
2010354|NCT02996474|Drug|Decitabine|Will be administered at a dose of 20 mg/m2 by continuous intravenous infusion over 1 hour repeated daily ordinarily on days 8 through 12 and 15 through 19 of alternative cycles (ie: cycles 1, 3, 5, 7). Decitabine should be repeated every 6 weeks.
2010355|NCT02993302|Drug|1α-D3|patients were given PTU and 1α-D3
2010356|NCT02993302|Drug|Placebos|patients were given PTU and placebos
1990893|NCT01713725|Biological|Omalizumab|"Two injections will be administered the first two weeks
The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
1614124|NCT02130856|Device|Neonatal kit|"Contents of the neonatal kit:
Clean birth kit: sterile blade, a clean plastic square, plastic gloves, hand soap, and cord ties/clamp.
4% Chlorhexidine (CHX) lotion (15 mL) and a bag of cotton balls.
Sunflower oil emollient (50 mL)
ThermoSpot
Mylar infant sleeve
Click to heat warmer (http://www.heatinaclick.ca/products/pocket_size.html) in a fitted cloth pouch.
Handheld electric scale with suspended cloth sling. The scale will not be included with the kit but rather one will be issued to each Lady Health Worker."
1614125|NCT02130843|Device|INSERTION OF URETEHRL CATHETER|USE OF A TIEMANN CATHETER TO INSERT THE URODYNAMIC STUDY CATHETER INTO THE BLADDER
1614126|NCT02130830|Drug|Topical 2,5% lidocaine + 2,5% prilocaine gel|The topical gel is administered in the anal canal at the moment of the anoscopy
1614127|NCT02130830|Drug|Placebo|Placebo gel to mimic topical anesthesia administered in the anal canal at the moment of the anoscopy
1614128|NCT02130817|Drug|Belatacept|Belatacept will be added to the standard of care regimen and will be given at days 0,5, weeks 2, 4, 8 and 12 (10 mg/kg) and every 4 weeks (5 mg/kg) for one year.
1614129|NCT02130817|Drug|Tacrolimus withdrawal|Tacrolimus dosing will begin on Days 1 through 5 post transplant at up to 2 mg BID to achieve target trough levels of 9-11 ng/ml. The dose will be tapered through the end of week 2 to achieve a trough level of 4 ng/ml which will be maintained for six weeks. Tacrolimus will be withdrawn at the end of eight weeks post transplant.
1614130|NCT02130817|Procedure|Plasmapheresis/Intravenous Immunoglobulin G|Enrolled patients will start with standard of practice treatment including plasmapheresis and IVIG therapy twice after transplant, on days 2 and 4 and potentially once before transplant. Plasmapheresis and albumin exchange for one volume of blood will be performed in the infusion center at the University of Wisconsin Hospital and Clinics (UWHC). Each pheresis session will be completed by IVIG infusion. While plasmapheresis will help with the removal of circulating Donor Specific Antibodies (DSA), IVIG therapy will provide immunomodulatory characteristics that include sterilizing immunity from infections, inhibiting and scavenging activated complement fragments, modifying cell-mediated immune responses, inducing regulatory T cells and importantly, inhibiting deleterious antibody production.
1614131|NCT02130817|Drug|Thymoglobulin (ATG)|Thymoglobulin (ATG) Induction. Thymoglobulin will be administered to a total cumulative dose of 4.5-6 mg/kg via a peripheral or central vein, starting in the operating room.
1614132|NCT02130817|Drug|Myfortic|Patients will receive 720mg bid of Myfortic throughout the study, starting day 1 after surgery.
1614133|NCT02130817|Drug|Steroids|Patients will receive Dexamethasone IV on the day of surgery (Day 0) with tapered doses through Day 4 followed by prednisone tapered to 10mg/d by day 30.,
1614134|NCT02130804|Drug|Salsalate (4 g/day)|Given orally twice daily
1614135|NCT02130804|Drug|Placebo (4 g/day)|Given orally twice daily
1614136|NCT02130791|Behavioral|Sleep|
1614137|NCT02130778|Drug|Synthetic GLP-1 (1.5 pmol/kg/min) dissolved in 500 ml 0.9% saline|infusion of synthetic GLP-1 (1.5 pmol/kg/min) saline
1614138|NCT02130778|Other|500 ml 0.9% saline|infusion of saline
1614139|NCT02130765|Device|Cardiac catheter ablation with ICD/CRT-D|Cardiac ablation catheter system
1614186|NCT02130453|Drug|Regadenoson|0.4 mg by vein given during nuclear stress testing with echocardiography strain measurements.
1614187|NCT02130440|Drug|Resveratrol nasal spray|
1990894|NCT01713725|Biological|Placebo|"Two injections will be administered the first two weeks
The following three injections will be administered every four weeks Consequently, we will administer 5 doses within 14 weeks"
1614140|NCT02130752|Device|Monopolar electrocautery|During the procedures of the abdominal approach D2 distal gastrectomy, use the monopolar electrocautery (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes .
1614141|NCT02130752|Device|Ultrasonic scalpel|During the procedures of the abdominal approach D2 distal gastrectomy, use ultrasonic scalpel (Device) to coagulation and cut off blood vessel, separate and dissection lymph-nodes
1614142|NCT02130739|Procedure|thoracic epidural anesthesia|thoracic epidural anesthesia following continuous thoracic epidural analgesia for mastectomy
1614143|NCT02130739|Procedure|mastectomy|mastectomy with/without breast reconstruction
1614144|NCT02130739|Drug|Ropivacaine|Thoracic epidural anesthesia performed using 0.375% or 0.5% ropivacaine
1614145|NCT02130739|Drug|Propofol|Thoracic epidural anesthesia performed followed by sedation consisting of propofol
1614146|NCT02130739|Drug|Fentanyl|thoracic epidural analgesia continued; supplemented by a continuous epidural infusion of ropivacaine 0.15%, 2 ml/h with fentanyl 8mcg/h.
1614147|NCT02130726|Procedure|Minimally-invasive gastrectomy|Patients allocated to the 'Minimally-invasive gastrectomy' arm will receive total gastrectomy via laparoscopy.
1614148|NCT02130726|Procedure|Open Gastrectomy|patients allocated to the 'Open gastrectomy' group will receive total gastrectomy via laparotomy
1614149|NCT02130713|Drug|Third generation fluoroquinolone|Prulifloxacin 600 mg
1614150|NCT02130713|Dietary Supplement|Nutritional supplement + third generation fluoroquinolone|Serenoa repens 320 mg, Lactobacillus Sporogens 200 mg, Arbutin 100 mg and prulifloxacin 600 mg
1614151|NCT02130700|Drug|VT-464: given orally twice daily in 28-day cycles|Oral VT-464 given twice daily, in continuous 28-day cycles at the recommended Phase 2 dose
1614152|NCT02130700|Drug|VT-464: given orally once daily in 28-day cycles|Oral VT-464 given once daily, in continuous 28-day cycles at the recommended Phase 2 dose
2010357|NCT02991833|Other|A New Incontinence Care Product|The novel incontinent care product is dressed and removed removed by opening both sides. In the part surrounding the waist and thights of the novel incontinent care product flexibility is achieved by planting rubber bien. When developing new incontinence care products was taken counselling from a faculty member from Department of Textile Engineering of one University Faculty of Engineering. The insurance policies was prepared for each patients attended to the study (Number: 481360).New care product is put on the experimental group. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the novel incontinent care product was changed.
2010358|NCT02991833|Other|Diaper|In patients of the diaper group was used the optimum adult diaper (Pads, Linea TENA, SCA, Hygiene, Goteborg, Sweden) which was available in the market. Perineal care was made to patients twice a day and after each defecation. After each perineal care, the diaper was changed.
2010359|NCT02991859|Drug|Fluticasone furoate (FF) Dry Powder Inhaler|Dry inhalation powder 25 mcg, 100 mcg, and 200 mcg per blister strip will be administered using ELLIPTA for both treatment periods
2010360|NCT02991859|Drug|Fluticasone propionate (FP) Dry Powder Inhaler|Dry Inhalation powder 50 mcg, 100 mcg, 250 mcg, and 500 mcg per blister strip will be administered using DISKUS for both treatment periods
1614157|NCT02130674|Drug|Dipeptiven|two groups: group 1: continuous infusion for 24 hours group 2: continuous infusion for 5 days
1614158|NCT02130661|Drug|Rilapladib 25 mg|White, round, biconvex, film coated tablet of 25 mg. Taken orally along with food.
1614159|NCT02130661|Drug|Rilapladib 250 mg|White, round, biconvex, film coated tablet of 250 mg. Taken orally along with food.
1614160|NCT02130661|Drug|Itraconazole|100 mg capsule with a blue opaque cap and pink transparent body. Taken orally along with food.
1614161|NCT02130648|Other|A sampling of blood|A sampling of blood de 14 ml
1614162|NCT02130635|Drug|GSK2269557 100 MCG|100 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
1614163|NCT02130635|Drug|GSK2269557 500 MCG|500 mcg of GSK2269557 blended with lactose per blister administered using a dry powder inhaler device
1614164|NCT02130635|Drug|PLACEBO|Lactose administered using a matching dry powder inhaler device
1614165|NCT02130622|Drug|Promethazine|
1614166|NCT02130622|Drug|Sugar pill|
1614167|NCT02130609|Device|Skintel|
1614168|NCT02130596|Behavioral|Acceptance-Based Behavioral Intervention|
1614169|NCT02130596|Other|Nutritional Counselling|
1614170|NCT02130583|Behavioral|Positive Affect Skills Training|Individual sessions (3-4) delivered on the inpatient unit, focused on psycho-education regarding positive affect and mood monitoring and teaching of skills to attend to positive affect such as mindfulness, gratitude, and savoring. In-person sessions are followed by weekly phone calls and daily text messages for one month, with option to extend.
1614171|NCT02130583|Behavioral|Treatment as Usual|Participants will follow the intervention plan laid out in their discharge summary, but do not receive any individual sessions regarding positive affect. Upon discharge, they will receive generic text messages regarding healthy habits for one month, with option to extend.
2010361|NCT02991859|Drug|Budesonide (BUD) Turbuhaler|Budesonide comprises white to off-white rounded granules, which disintegrate to a fine powder upon slight pressure, will be administered using Turbuhaler for both treatment periods.
2010362|NCT02991859|Drug|Placebo (ELLIPTA or DISKUS)|Lactose dry powder inhaler will be administered using ELLIPTA or DISKUS for both treatment periods.
2010363|NCT02991430|Device|active neuromodulation for episodic migraine headache|Non-invasive brainstem neuromodulator. Active and placebo devices appear identical
1614175|NCT02130531|Drug|Emixustat HCl Tablet|Tablet for oral administration
1614176|NCT02130531|Other|Placebo Tablet|Tablet for oral administration
1614177|NCT02130518|Drug|Auriclosene Irrigation Solution, 0.2%|
1614178|NCT02130518|Drug|Auriclosene Vehicle Solution|
1614179|NCT02130505|Dietary Supplement|OGTT|Oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
1614180|NCT02130492|Radiation|FDG|The intervention arm consists of treatment with increasing doses of [18F]-Fluorodeoxyglucose.
1614183|NCT02130466|Biological|Pembrolizumab|IV infusion
1614184|NCT02130466|Drug|Dabrafenib|oral capsule
1614185|NCT02130466|Drug|Trametinib|oral tablet
1614188|NCT02130427|Radiation|Radiation Therapy|
1614189|NCT02130414|Drug|Sandimmun® IV|2 mg/kg IV
1614190|NCT02130414|Drug|CyCol® capsules|37.5 mg CyCol® capsules
1614191|NCT02130401|Device|TNM (thermoneuromodulation device)|The device is worn like a music headset and the patient lies on a wedge pillow while the device is active. Each session lasts under 20 minutes.
1614193|NCT02130375|Procedure|the IncontiLaseTM procedure|Utilizing laser (IncontiLaseTM) to treat the anterior vaginal wall area to intensify periurethral tissue and achieve urinary continence
1614194|NCT02130336|Behavioral|Aerobic interval training|
1614195|NCT02130336|Behavioral|Continuous moderate-intensity exercise|
1614196|NCT02130323|Drug|Imiquimod|12.5mg (5%) once a week vaginally for 16 weeks
1614197|NCT02130323|Procedure|Loop Electrosurgical Excision Procedure|Patients with CIN 2-3 will be randomized to receive intervention, CKC or LEEP versus medical therapy with Imiquimod.
1614198|NCT02130310|Biological|CureXcell®|CureXcell® is a cell based therapy obtained from donated whole blood. The blood is collected from healthy young adults, the white blood cells are separated and then activated by hypo-osmotic shock.
1614199|NCT02130310|Other|Placebo injection|Normal saline injected at each centimeter of ulcer bed
1614200|NCT02130297|Device|Laser Treatment|The subject will receive ablative fractional resurfacing with the Deep and Active FXTM platforms of the Lumenis Ultrapulse CO2 laser. The settings for treatment of scars on the face with the Deep platform will be 15% coverage, 15mJ at 150 Hz and 15% coverage, 12.5 mJ at 150 Hz for off the face. The Active platform settings will be 90 mJ with a density of 3 for the face and 70 mJ and a density of 2 for off the face. The DeepFXTM platform will be applied to the scar prior to the ActiveFX TM platform. Half of the excision scar will be treated with the appropriate settings and half will go untreated.
1614201|NCT02130284|Device|Predictive Low Glucose Management Feature in Insulin pump|All subjects will undergo hypoglycemic induction at Visit 2 with target set to 65 mg/dL using the rate of change basal increase algorithm. Low Limit setting when PLGM ON is 65 mg/dL.
1614202|NCT02130271|Drug|Radioactive dye|The radioactive dye [11C]PBR28 will be administered through an intravenous line (IV).
1614203|NCT02130271|Radiation|PET/MRI|All subjects will undergo a simultaneous PET/MRI scan. The scan will be up to 2 hours long.
1614204|NCT02130271|Other|Blood draw|Up to 11 tablespoons of blood will be drawn through an intravenous line (IV-line) for two purposes: 1) testing for the subject's genetic affinity to the radioactive dye, and 2) testing for the presence inflammatory biomarkers.
1614205|NCT02130258|Device|Quantitative Sensory Testing (QST)|Subjects will undergo hot and cold temperature testing using the QST device at two points: 1) Before ESI and 2) after ESI.
1614206|NCT02130245|Procedure|Early cholecystectomy|Early laparoscopic cholecystectomy for acute cholecystitis after admission
1614207|NCT02130245|Procedure|Delayed cholecystectomy|Laparoscopic cholecystectomy well be done after a period on conservation
1614208|NCT02130232|Behavioral|Lifestyle Intervention|
1614209|NCT02130232|Other|Usual Care|
1614210|NCT02130219|Device|Non-invasive intracranial pressure measurement|The noninvasive ICP measurement device Vittamed 205 aICP meter used in this study has been developed in Lithuania. The method is based on two-depth transcranial Doppler technique for simultaneously measuring flow velocity pulsatilities in the intracranial and extracranial segments of the ophthalmic artery (OA). These measurements are made while applying a series of small pressure steps to the tissues surrounding the eye-ball. The intracranial segment of the OA is compressed by ICP and the extracranial segment of the OA is compressed by the externally applied pressure Pe. Blood flow pulsatility parameters in both of these OA segments are monitored.Pulsatilities are approximately the same when Pe = ICP. Two-depth TCD device is used as an indicator of the pressure balance point.
1614211|NCT02130219|Device|Brain MRI/CT|"1.5 T MRI using T1 and T2 regimes, brain MRI angiography, performed for selected patients to analyze anatomical features of ophthalmic artery and optical nerves sheath diameter.
Brain CT performed to evaluate hemorrhage and stroke volume."
1614212|NCT02130219|Procedure|Lumbar puncture and cerebrospinal fluid pressure measurement|Lumbar puncture performed in lateral decubitus position while knees and head flexed. After local antiseptics and anesthesia puncture in lumbar 3/4 or 4/5 intervertebral space performed. As CSF appears legs and head are relaxed and slightly straightened. Spinal manometer graded 0-40 cm H₂O with stopcock connected to the needle. CSF pressure monitored for 10 minutes and recorded. CSF collected for diagnostic test. Spinal needle Number 22 and Rocket Spinal Manometer Set (No. R55990) used for this study.
1614213|NCT02130206|Other|Caries Free|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
1614214|NCT02130206|Other|Caries Active|Gums will be examined. On some visits Saliva and plaque will be collected. Toothpaste assigned will include DenClude 1.5% Arginine.
1614215|NCT02130206|Other|Caries Free - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
1614216|NCT02130206|Other|Caries Active - Placebo|Gums will be examined. On some visits Saliva and plaque will be collected. Marketed Toothpaste will be assigned.
1614217|NCT02130193|Drug|Danirixin|Danirixin is available as 50 or 75 mg white, film coated immediate release tablet.
1614218|NCT02130193|Drug|Placebo|Subjects will receive danirixin matching placebo
1614219|NCT02130167|Drug|Atropine|Compare different concentrations of atropine eye drops (0.01% vs 0.05%) in the efficacy of controlling myopia progression and side effects of atropine
1614220|NCT02130154|Other|18-FDG PET CT scan and 123I-MIBG SPECT scan|
1614221|NCT02130141|Dietary Supplement|Dark chocolate|Mildly hypertensive subject will replace their usual snacks with with 50 g dark chocolate daily for a period of 8 weeks.
1614222|NCT02130141|Other|Dietary counselling|Usual snacks are limited.
1614223|NCT02130128|Device|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
1614224|NCT02130115|Device|LungPoint ATV System|The LungPoint ATV System is an image-guided navigation system used to access tissue samples in the lungs.
1614263|NCT02129686|Procedure|Delayed Acupuncture Group|
1614264|NCT02129673|Drug|VS101 Insert Dose A|Sustained release of latanoprost into the eye
1614265|NCT02129673|Drug|VS101 Insert Dose B|Sustained release of latanoprost into the eye
1614266|NCT02129673|Drug|VS101 Insert Dose C|Sustained release of latanoprost into the eye
1614225|NCT02130102|Device|The ModuLAAr Ambient Assisted Living System|"The system consists of the following modules which will be provided to the volunteers according to their needs:
tablet computer (digital photo album, video telephone, meal ordering system, reminder system), bodyweight scale, blood pressure meter, emergency call system, mobile phone (documentation of personal health-related data), bathroom surveillance system, blood glucose meter, house automation technologies/smart home technologies"
1614226|NCT02130089|Behavioral|Intensive Tailored Education|
1614227|NCT02130063|Drug|iron isomaltoside 1000 (Monofer®)|
1614228|NCT02130063|Drug|iron sucrose (Venofer®)|
1614229|NCT02130037|Behavioral|application|along standard psychotharpy we use a smartphone application that allows the patient to monitor her meals, behaviours, emotions and thoughts and to communicate them directly in real time to their therapists.
1614230|NCT02130037|Other|psychotherapy|standard psychotherapy for eating disorders
2010364|NCT02991430|Device|placebo neuromodulation for episodic migraine headache|Sham non-invasive brainstem neuromodulator. Active and placebo devices appear identical
2010365|NCT02991677|Behavioral|aerobic exercise intervention|Exercise physiologist supervised walking or running on the treadmill 3 times weekly for 12 weeks.
1614233|NCT02130011|Other|with feeding/fluid instruction|No additional intervention besides standard treatment prescription will be added. Investigators foresee daily kV cone beam CT matching (already standard in house). this subgroup of 10 patients will be asked not to eat or drink carbonated fluids three hours before CT simulation and daily treatment
2010366|NCT02991677|Other|control group|weekly contact by study staff with survivorship information offered not related to neuropathy.
1614235|NCT02129985|Drug|Exenatide|Exenatide (10 ug/bid for 3 months)
1614236|NCT02129985|Drug|Metformin|Metformin 850 mg/bid for 3 months
1614237|NCT02129972|Device|Colon videocapsule endoscopy (PillCam colon 2)|"This is a simple blind (blind for the lecture of the CVC record) study to evaluate the diagnostic value of the colon capsule endoscopy for the detection and the control of colon lesions, the feasibility, tolerance and safety of the CVC compared to the conventional colonoscopy under general sedation in children presented with Inflammatory Bowel Disease.
Over one week, the patient will undergo two exams (CVC and colonoscopy under general sedation). The exams will be done by two different physicians.
In order to assess the tolerance, after the completion of both exams, the patients will be asked to answer a comfort score questionnaire.
In order to assess the safety of the CVC, the patients will have a follow-up for adverse events over a 3 weeks period after completion of the CVC and only if the colon video capsule was not recovered during the conventional colonoscopy."
1614238|NCT02129946|Other|Resistant Starch|In a randomized crossover fashion, participants will consume bagels that are made with either high-resistant starch or standard wheat flour, daily for a period of 8 weeks, with a 4 week washout period.
1614239|NCT02129933|Drug|Bevacizumab-IRDye800CW|"Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW 2 days prior to the fluorescence endoscopy procedure.
* amendment June 2015: topical administration bevacizumab-800CW (100ug/ml)"
1614240|NCT02129933|Device|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope to visualize the luminal wall. The fluorescent imaging will be performed prior and post the endoscopic resection (within the same endoscopic session)
1614241|NCT02129920|Other|This is an observational study|
1614243|NCT02129881|Biological|Autologous regulatory T Cell Product|Autologous regulatory T Cell Product (1-10 million cells/kg) infused intravenously 5 days post renal transplantation. Recipients also receive prednisolone, mycophenolate mofetil, and tacrolimus as detailed in the arm description.
1614244|NCT02129868|Device|Closed-loop (Android Closed-Loop platform)|"The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
The Android Closed-Loop platform employs the Medtronic MiniMed Paradigm® Veo™ insulin pump system with CGM capability (use of MiniLink™Transmitter and sensor). A Radiofrequency (RF) translator module translates the RF protocol to Bluetooth® technology. An Android device containing an algorithm will use sensor glucose data to calculate pump strokes."
1614245|NCT02129829|Drug|Tenofovir disoproxil|Tenofovir disoproxil 245 mg once daily
1614247|NCT02129803|Device|High-Flow, 20 LPM (via Optiflow cannula)|Nasal high flow humidification (20LPM) therapy will be administered using Optiflow with Airvo 2.
1614248|NCT02129803|Device|Low FLow, 5 LPM (via Optiflow cannula)|standard humidified wall medical air.
1614249|NCT02129790|Behavioral|Mentalization-Based Therapy|Up to 21 individual MBT-A sessions plus 9 monthly family sessions. MBT-A sessions will focus on the adolescent's recent social experiences and the resulting mental states and managing interpersonal challenges, particularly those involving separation or loss. The goal of this intervention is to improve the adolescent's ability to mentalize: to understand, acknowledge, and predict thoughts and feelings in oneself and others.
1614250|NCT02129777|Drug|Namilumab|Namilumab subcutaneous injection
1614251|NCT02129777|Drug|Placebo|Placebo subcutaneous injection
1614252|NCT02129764|Drug|Prednisone|
1614253|NCT02129764|Drug|Allopurinol|
1614254|NCT02129751|Drug|bupropion hydrobromide|study drug
1614255|NCT02129751|Drug|Placebo|
1614257|NCT02129725|Drug|Sildenafil citrate|Sildenafil citrate 25 mg, 1 capsule three times a day for 3 months
1614258|NCT02129725|Drug|Placebo Oral Capsule|placebo capsules, 1 capsule po three times a day for 3 months
1614259|NCT02129712|Behavioral|Cognitive training|
1614260|NCT02129699|Drug|Denosumab|Denosumab: 120 mg, s.c. every 3-4 weeks (in cycle 1 additional dose on day 8) until unacceptable toxicity, patient refusal or patient's death (max. 4 years 3 months).
1614261|NCT02129699|Other|None, standard chemotherapy only|"Possible standard chemotherapies (3 weeks cycles, duration: 4 - 6 cycles):
Cisplatin 75 mg/m2 as an infusion on day 1 Gemcitabine 1250 mg/m2 as an infusion days 1 and 8 or Carboplatin AUC 5 as an infusion on day 1 Gemcitabine 1000 mg/m2 as an infusion days 1 and 8 or Cisplatin 75 mg/m2 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1 or Carboplatin AUC 5 as an infusion on day 1 Pemetrexed 500 mg/m2 as an infusion on day 1"
1614262|NCT02129686|Procedure|Immediate Acupuncture Group|
1614267|NCT02129673|Drug|Latanoprost 0.005% eye drops|Latanoprost 0.005% eye drops administered once daily on the eye
1614268|NCT02129660|Drug|Dose 1 of DRM04B|
1614269|NCT02129660|Drug|Dose 2 of DRM04B|Not provided
1614270|NCT02129660|Drug|Dose 1 of DRM04|Not provided
1614271|NCT02129660|Drug|Dose 2 of DRM04|
1614272|NCT02129660|Other|Vehicle|
1614273|NCT02129647|Drug|Axitinib|
2010367|NCT02991677|Behavioral|resistive training|Exercise physiologist supervised upper and lower extremity resistive training 3 times weekly for 12 weeks
2010368|NCT02989064|Genetic|Autologous genetically modified MAGE A10ᶜ⁷⁹⁶T cells|
1614276|NCT02129621|Procedure|Urinary and blood lipococalin levels determination|Blood test on an empty stomach. Urinary taking on arrival in the service
1614277|NCT02129621|Drug|Spironolactone|For the group 5, at the time of the V0 visit, a treatment by aldactone will be set up (posology: 1 to 2 mg/kg).
1614278|NCT02129608|Device|LLLT|The LLLT uses 6 diode laser heads - each emitting 17 mW output. Subject will receive 30 minutes of therapy in the frontal central area and 30 minutes of therapy in the back central area, once a week for 12 weeks.
1614279|NCT02129608|Drug|Lorcaserin|10 mg pills twice daily for 12 weeks.
1614280|NCT02129595|Dietary Supplement|placebo|A placebo will given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
1614281|NCT02129595|Dietary Supplement|resveratrol|resveratrol will be given for 30 days or 34 days (if included in brown adipose tissue measurement), twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
1614282|NCT02129582|Radiation|total marrow irradiation|Undergo TMI
1614283|NCT02129582|Drug|fludarabine phosphate|Given IV
1614284|NCT02129582|Drug|busulfan|Given IV or PO
1614285|NCT02129582|Procedure|myeloid progenitor cell transplantation|Undergo allogeneic hematopoietic progenitor cell transplant
1614286|NCT02129582|Biological|anti-thymocyte globulin|Given IV
1614287|NCT02129582|Drug|tacrolimus|Given IV or PO
1614288|NCT02129582|Drug|methotrexate|Given IV
1614289|NCT02129582|Other|laboratory biomarker analysis|Correlative studies
1614290|NCT02129569|Other|Psychoeducational intervention|Receive information about strategies for cognitive self-management of distress
1614291|NCT02129569|Behavioral|behavioral intervention|Receive individualized walking prescription and wear pedometer
1614292|NCT02129569|Other|counseling intervention|Receive supplemental counseling support over the phone
1614293|NCT02129569|Other|educational intervention|Receive NCI educational booklets and a link to the ACS website
1614294|NCT02129569|Other|telephone-based intervention|Receive calls that are primarily social in nature
1614295|NCT02129569|Other|questionnaire administration|Ancillary studies
1614296|NCT02129569|Other|quality-of-life assessment|Ancillary studies
1614297|NCT02129556|Drug|MK-3475|The phase Ib trial will determine the recommended dose from three MK-3475 dose levels: 1mg/kg, 2 mg/kg or 10 mg/kg.
1614298|NCT02129543|Procedure|Blood Draw|Whole blood samples will be collected from study subjects for immune cell and plasma analysis at the following intervals: Within 30 days pre-transplant; Post-transplant Day 30 (+/- 7 business days); Day 60 (+/- 14 business days); Day 100 (+/- 21 business days); 6 months (+/- 21 business days); 1 year (+/- 21 business days) and annually (+/- 21 business days) thereafter
1614299|NCT02129530|Behavioral|Community Social Mobilization program|
1614303|NCT02129504|Device|root coverage comparing two techniques|The aim of this study was to compare and show the benefits of the extended flap technique (new technique) compared to coronal advanced technique (gold standard technique) both techniques using the porcine collagen matrix for root coverage.
1614304|NCT02129478|Drug|Olanzapine|"Patients will receive olanzapine once daily starting just before the first dose of chemotherapy within the study chemotherapy block and continuing until discharge from hospital or for a maximum of 4 doses after the last dose of chemotherapy.
Olanzapine will be dosed at 0.14mg/kg/dose (maximum 10mg/dose) as a single daily oral dose rounded to the nearest increment of a half-tablet (2.5mg)."
1614305|NCT02129439|Drug|SB012|"The treatment phase lasts 28 consecutive days. The IMP will be administered for the first time at the study site in the morning on Day 1 (IMP administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP will be self-administered by the subject at home.
SB012 will be available in this clinical trial in a concentration of 7.5mg/ml hgd40 in 30ml PBS (Maximum daily dose: 225mg)
The IMP is formulated as an enema and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required.
No modifications are permitted to the dosing regimen except for premature study discontinuation."
1614306|NCT02129439|Drug|Placebo|"Intervention of placebo-treated subjects does not vary to SB012-treated subjects.
The treatment phase lasts 28 consecutive days. Placebo will be administered for the first time at the study site in the morning on Day 1 (Administration training by study site staff). The final administration will be performed at the study site in the morning of Day 28. On all other treatment days (Day 2 to Day 27), the IMP/Placebo will be self-administered by the subject at home. Placebo will be administered with a volume of 30ml.
The IMP/Placebo is formulated as an enema (plastic rectal tube) and will be administered in this clinical trial by the rectal route. The enema is a ready-for-use preparation. No further preparation steps are required."
1614307|NCT02129426|Drug|Ketamine|
1614308|NCT02129426|Drug|Midazolam|
1614309|NCT02129426|Drug|Dexmedetomidine|
1614310|NCT02129413|Device|Delta system|
1614311|NCT02129400|Drug|Xenon pro Anaesthesia 100 % (V/V)|Xenon-gas inhalation of indicated concentrations during indicated time
1614312|NCT02129400|Drug|Aer medicinalis Linde 100%|
1614313|NCT02129374|Procedure|Direct repair of pars defect|Direct repair at pars defect was performed with 4.5mm cortical screw in young spondylolytic patients.
1614314|NCT02129361|Behavioral|Adapted Screening and Brief Intervention (Adapted SBI)|
1614315|NCT02129361|Behavioral|Screening & Education Attention Control|
1614318|NCT02129335|Other|stress|stress level and survival
1614319|NCT02129322|Drug|Sorafenib|
1614320|NCT02129322|Drug|S-1|
1614321|NCT02129322|Drug|Oxaliplatin|
1614322|NCT02129309|Procedure|Forearm plethysmography|Dose response study
1614323|NCT02129309|Procedure|Haemodynamic studies|Dose response study
1614324|NCT02129296|Device|Air filled balloon|Balloon filled with air according to the manufacturing company orders
1614325|NCT02129296|Device|Bioenteric BIB® balloon|Balloon filled with saline and methylene blue according to the manufacturing company orders
1614326|NCT02129283|Behavioral|Simulation training|End-of-life simulation training. The simulation training will include training with standardized patients (actors) using 9 essential skills for communication and interpersonal relationships. The control group will have no training.
1614327|NCT02129270|Drug|Lidocaine HCl 2% .|comparison of different dosages of drug
1614328|NCT02129270|Drug|Lidocaine HCl 1%|comparison of different dosages of drug
2010369|NCT02988531|Other|PET/MR scan|Patients to undergo PET/MR scanning after PET/CT scan. Patients will have had an injection of 18F Sodium Fluoride for their PET/CT therefore will not need another dose of radiotracer prior to their PET/MR scan.
2010370|NCT02987894|Device|ACURATE neo™ Aortic Bioprosthesis|TAVI, transcatheter aortic valve replacement. Transfemoral access.
2010371|NCT02987504|Drug|Samalizumab|Dose escalation
1614333|NCT02129244|Other|NCM-Plus|"The NCM will follow the domains of the chronic care model by:
Assuring effective, efficient clinical care and self-management support
Promoting clinical care consistent with scientific evidence and patient preferences
Organizing data to facilitate efficient, effective care
Empowering and preparing patients to manage their health and health-care needs
Mobilizing community resources to meet the needs of patients"
1614334|NCT02129231|Drug|calcined magnesia|We ensured the patient took the drug at night before meals
1614335|NCT02129231|Drug|Ezetimibe/simvastatin|We ensured the patient took the drug at night before meals
1614336|NCT02129231|Drug|Rosuvastatin|We ensured the patient took the drug at night before meals
1614337|NCT02129218|Other|questionnaire administration|Ancillary studies including three day food record, twenty-four hour dietary recall, and a food acceptability questionnaire.
1614338|NCT02129218|Other|laboratory biomarker analysis|Correlative studies
1614339|NCT02129218|Behavioral|Standard Dietary Intervention|Participants will be contacted by a nutritionist, in person every 2 weeks with phone contact on the alternating weeks. At the initial visit, each participant will be given verbal and written patient education materials, including low glycemic load diet recipes, meal plans, food preparation, and grocery shopping information. Individual instruction will be tailored to their baseline dietary preferences (e.g. vegan, allergies, etc).
1614340|NCT02129218|Behavioral|Intensified Dietary Intervention|Patients will be contacted weekly, in person, by a nutritionist . Participants will take part in a cooking demonstration at the time of their initial visit. The demonstration will be hands-on and participants will be able to sample foods and recipes. In addition to grocery shopping information, participants will be accompanied by a nutritionist to their local grocery store to practice new shopping habits for their target dietary glycemic load. Each participant will also receive weekly random phone calls to assess his or her progress.
1614341|NCT02129218|Behavioral|Low glycemic load|
1614342|NCT02129218|Behavioral|Medium Glycemic Load|
1614345|NCT02129192|Drug|Amlodipine 5mg capsule|Amlodipine 5mg capsule
1614346|NCT02129192|Drug|T80/H12.5 mg FDC tablet|Telmisartan 80 mg/Hydrochlorothiazide 12.5 mg FDC tablet
1614347|NCT02129192|Drug|T80/A5/H12.5 mg FDC tablet|Telmisartan 80 mg/Amlodipine 5 mg/Hydrochlorothiazide 12.5 mg FDC tablet
1614348|NCT02129179|Drug|Glucagon-Like Peptide 1|
1614349|NCT02129166|Drug|Dasatinib|In this group, subjects will take dasatinib only. Dose regimen: dasatinib 20 mg single oral dose
1614350|NCT02129166|Drug|Dasatinib+Imatinib|"In this group, subjects will take imatinib prior to dasatinib administration.
Dose regimen: Imatinib: 400 mg single oral dose Dasatinib: 20 mg single oral dose"
1614351|NCT02129153|Behavioral|LIFT (Parent Information)|"Parents will receive specific information about class assignments that the student missed or about poor performance on tests/quizzes. Parents will also be notified about behavioral problems, such as poor attention and class disruption. RA will communicate with parents in Spanish or English by text message, phone, email according to the parents preference for communication
Parents will be invited to parenting seminars to discuss parenting strategies regarding what to do with their child's academic and behavioral information once they receive it from research staff. Sessions will take place at school and last 2 hours. Multiple sessions will be offered throughout the academic year and parents may attend as many sessions as they wish."
1614353|NCT02129127|Device|Paclitaxel Coated Chocolate Balloon Angioplasty|Balloon Angioplasty with the Chocolate Balloon resulting in vessel dilatation and localized delivery of Paclitaxel
1614354|NCT02129114|Device|ReDura Onlay|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of ReDura Onlay.
1614355|NCT02129114|Device|DuraGen|Subject will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of DuraGen.
1614356|NCT02129101|Drug|Azacitidine|Given SC or IV
1614357|NCT02129101|Drug|Decitabine|Given IV
1614358|NCT02129101|Other|Laboratory Biomarker Analysis|Correlative studies
1614359|NCT02129101|Other|Quality-of-Life Assessment|Ancillary studies
1614360|NCT02129101|Drug|Sonidegib|Given PO
1614361|NCT02129088|Drug|Esketamine|Esketamine 14 mg will be self-administered by participants as intranasal spray into each nostril on Day 1 to cohort 1 and cohort 2 in a fixed sequence.
1614362|NCT02129088|Drug|Placebo|Placebo will be self-administered as intranasal spray by participants after 5 and 10 minutes of esketamine administration into each nostril on Day 1 of Treatment period 2 to Cohort 2.
1614462|NCT02128360|Drug|Letrozole, Gonadotropins|
1990901|NCT01702896|Drug|Interleukin-2|Interleukin-2
1614363|NCT02129075|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC or ID
1614364|NCT02129075|Other|Laboratory Biomarker Analysis|Correlative studies
1614365|NCT02129075|Biological|Neoantigen-based Melanoma-Poly-ICLC Vaccine|Given SC
1614366|NCT02129075|Other|Pharmacological Study|Correlative studies
1614367|NCT02129075|Biological|Recombinant Flt3 Ligand|Given SC
1614368|NCT02129062|Drug|Ibrutinib|Given orally 560 mg daily (dispensed as 4 x 140-mg capsules)
1614369|NCT02129062|Other|Laboratory Biomarker Analysis|Correlative studies
1614370|NCT02129049|Other|educational intervention|Participate in the Enhancing Connections Telephone Program
1614371|NCT02129049|Behavioral|telephone-based intervention|Participate in the Enhancing Connections Telephone Program
1614372|NCT02129049|Other|questionnaire administration|Ancillary studies
1614373|NCT02129023|Device|Xbox 360|For each participant in the experimental arm, two Xbox 360 exercise items were randomly selected from the nine items, which are related to user health. Each participant takes the two exercise items in turn.
1614375|NCT02128984|Dietary Supplement|Symbiotic Formula with DHA and antioxidants|6 months intervention.
1614376|NCT02128984|Dietary Supplement|Standard Formula|6 months intervention.
1614377|NCT02128971|Dietary Supplement|Ferrochel® 90 mg|Ferrochel® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
1614378|NCT02128971|Dietary Supplement|Sumalate® 90 mg|Sumalate® capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
1614379|NCT02128971|Dietary Supplement|Ferrous fumarate 90 mg|Ferrous fumarate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
1614380|NCT02128971|Dietary Supplement|Ferrous Sulfate 90 mg|Ferrous Sulfate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
1614381|NCT02128971|Dietary Supplement|Ferric Glycinate 90 mg|Ferric Glycinate capsule 90 mg, administered orally once daily in the morning after breakfast, for 30 days
1614382|NCT02128971|Dietary Supplement|Placebo|Placebo capsule, administered orally once daily in the morning after breakfast, for 30 days
1614383|NCT02128958|Drug|CF102|orally q12h
1614384|NCT02128958|Drug|Placebo|orally q12 hours
1614385|NCT02128945|Other|[18F] - Fludarabine PET/CT|[18F] - Fludarabine PET/CT before treatment
1614386|NCT02128932|Drug|semaglutide|Injected subcutaneously (under the skin) once weekly. Following 4 doses (4 weeks) of 0.25 mg semaglutide weekly subjects will receive 0.5 mg semaglutide weekly for 26 weeks.
1614387|NCT02128932|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Subjects will start on 10 IU once daily and the dose will be adjusted according to fasting plasma glucose.
1614388|NCT02128919|Device|tDCS|Transcranial Direct Current Stimulation
1614389|NCT02128906|Drug|Cisplatin|Cisplatin 40 mg/m2 weekly x 7
1614390|NCT02128906|Radiation|IMRT|IMRT: once daily, M-F, 7 weeks (70 Gy)
1614391|NCT02128906|Drug|Docetaxel|Docetaxel 15 mg/m2 weekly x 7
1614392|NCT02128906|Drug|Cetuximab|Cetuximab 400 mg/m2 load, one week prior to IMRT Cetuximab 250 mg/m2 weekly x 7
1614393|NCT02128893|Drug|Isavuconazole|oral
1614394|NCT02128893|Drug|Esomeprazole|oral
1614395|NCT02128880|Behavioral|CARRII|CARRII is an interactive, personalized and tailored Internet intervention designed to reduce the risk of AEP among drinking women of childbearing age.
1614396|NCT02128880|Behavioral|CARRII Education|CARRII Education provides information on women's health related to drinking and contraception in a static website format.
1614397|NCT02128867|Other|Assisted Autogenic Drainage (AAD)|
1614398|NCT02128867|Other|bouncing and AAD|
1614399|NCT02128867|Other|bouncing|
1614400|NCT02128854|Behavioral|Tablets Intervention|The TABLET intervention adds a novel tablet-based delivery mechanism to provide real-time videoconferencing education about diabetes self-management behaviors to high-risk, low-income African American (AA) adults with diabetes. Cardiovascular disease (CVD) knowledge/ information modules consist of materials developed from a CVD patient education booklet adapted from Maine Heart Center of Maine Health and supplemented by clinical guidelines to specifically address behavioral risk factors. Motivation/behavioral skills training modules consist of patient activation (asking questions to providers), patient empowerment (CVD responsibility contracts, flow charts for lab results), and behavioral skills training (self-monitoring, goal-setting).
1614401|NCT02128841|Drug|Rivaroxaban|Direct Factor Xa Inhibitor
1614403|NCT02128815|Other|Coaching|Care translation - behaviour modification, personalized/tailored diabetes education and psychosocial support
1614404|NCT02128802|Procedure|Gastric Bypass|
1614405|NCT02128802|Other|Weight Loss Program|
1614406|NCT02128789|Other|Elder Tree website|Elder Tree is a private, secure information, support and communication website developed for this study.
1614407|NCT02128776|Other|Comprehensive care medical home|Comprehensive care provided in our High-Risk Children's Clinic as a medical home augmented by measures to prevent serious illness
1614408|NCT02128776|Other|Usual Care|Usual care provided in the offices of private pediatricians or our general pediatrics clinic staffed by faculty-supervised residents.
1614409|NCT02128763|Drug|Omega-3 supplements|2000 mg EPA and 1000 mg DHA per day
1614410|NCT02128763|Drug|Placebo|Olive oil gelcaps manufactured to mimic Omega-3 gelcaps
1614411|NCT02128750|Other|contrast echographie with hexafluorur of sulfur|Echography of contrast after injection of product of contrast (sonovue (r))
1614412|NCT02128737|Behavioral|Sleep|
1614413|NCT02128724|Drug|BKM120|BKM120 is a highly specific inhibitor of phosphatidylinositol 3-kinase (PI3K). BKM120 is supplied as 10mg and 50mg hard gelatin capsules.
1614414|NCT02128698|Dietary Supplement|Protein|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
1614415|NCT02128698|Dietary Supplement|Placebo|Postoperative intake of 25 g per day starting on the first day after hospital discharge until 6 months postoperatively.
1614416|NCT02128698|Behavioral|Computer-assisted exercise|Postoperative regular computer-assisted exercise using Nintendo Wii Mini, Nintendo Wii Balance Board and Wii Fit Plus Software. Exercise is advised to be done 4 times per week.
1614417|NCT02128698|Behavioral|Usual exercise|Postoperative regular exercise using written exercise instructions. Exercise is advised to be done 4 times per week.
1614418|NCT02128685|Drug|Dydrogesterone|
1614419|NCT02128685|Drug|Placebo|
1614420|NCT02128672|Procedure|Spinal Cord Stimulator Lead Placement|
1614421|NCT02128659|Behavioral|SHE Project|Consists of five-sessions, starting on a Monday and ending Friday. Each day involves an approximately 2 hour session.
1614422|NCT02128646|Drug|EXPAREL|
1614423|NCT02128646|Drug|Ketorolac|
1614424|NCT02128646|Procedure|laparoscopic abdominal hernia repair|
1614425|NCT02128646|Procedure|an open surgery for abdominal hernia repair|
1614426|NCT02128633|Drug|placebo gel|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
1614427|NCT02128633|Drug|5% sodium fluoride, potassium oxalate 5%, strontium chloride 10%|Manipulated at Novaderme ®, Santa Maria, RS, Brazil.
1614428|NCT02128633|Drug|Fluoride neutral NaF gel 2 %|The product had similar appearance and viscosity than others.
1614429|NCT02128620|Behavioral|Game-Based Appointment System|Users randomized to the www.sjekkdeg.no B version, consisting in the web app www.sjekkdeg.no including the Game-Based Appointment System
1614430|NCT02128607|Device|SNAG|sustained natural apophyseal glide: SNAG / Mulligan technique
1614431|NCT02128607|Device|Sham|
1614432|NCT02128594|Behavioral|Serosorting Intervention|Single session, behavioral intervention
1614433|NCT02128581|Drug|Exendin-9,39|use Exendin-9,39 @ 750pmol/kg/min and Exendin-9,39 @ 300pmol/kg/min to block endogenous GLP-1 in humans after gastric bypass and determine contribution of GLP to satiety after meal ingestion
1614434|NCT02128581|Other|Saline|
1614435|NCT02128568|Behavioral|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 12 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
1614438|NCT02128542|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
1614439|NCT02128542|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1614440|NCT02128516|Other|oral powder in sachet|
1614441|NCT02128503|Other|HBV DNA level monitoring|HBV DNV level being monitoring regularly
1614442|NCT02128490|Drug|Febuxostat IR|Febuxostat IR over-encapsulated tablets
1614443|NCT02128490|Drug|Febuxostat XR|Febuxostat over-encapsulated capsules
1614444|NCT02128490|Drug|Febuxostat placebo|Febuxostat IR and XR placebo-matching capsules
1614445|NCT02128490|Drug|Colchicine|Colchicine tablets
1614446|NCT02128490|Drug|Naproxen|Naproxen tablets
1614447|NCT02128490|Drug|Lansoprazole|Lansoprazole capsules
1614448|NCT02128464|Procedure|Patient specific cutting guides|Patient specific cutting guides are custom-made for each patient based on Magnetic Resonance Imaging (MRI). Before surgery, MRI of the knee is done and used to create a cutting guide that is formed to the exact shape of the knee. The patient specific cutting guides have platforms that can be attached to the bone, so the rod does not need to be placed in the leg bone.
1614449|NCT02128464|Procedure|Standard knee cutting guides|Standard cutting guides use traditional instrumentation to determine knee implant positions. During surgery, a rod is placed in the leg bone and the cutting guide is attached to that rod.
1614450|NCT02128451|Drug|Meperdine|15ml 0.5% bupivacaine,25 mg of meperdine and 1 ml of clonidine will be injected epidurally in meperdine Group.
1614451|NCT02128451|Drug|Fentanyl|15ml 0.5% bupivacaine, 25 micrograms of fentanyl and 1 ml of clonidine will be injected epidurally in fentanyl Group
1614452|NCT02128425|Drug|FOLFOXIRI|"irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
*reduced in UGT1A1 7/7 patients"
1614453|NCT02128425|Drug|FOLFOX|oxaliplatin 85 mg/m² + leucovorin 400 mg/m² +5-FU 400mg/m² bolus iv.+ 5-FU 2400 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle
1614454|NCT02128412|Device|Oversized stent deployed at low pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
1614455|NCT02128412|Device|Stent deployed at high pressure (Multi-Link Bare Metal Stent or Xience Prime Evenolimus Eluting Stent)|Stent can include both bare metal stents and drug eluting stents. Depending on availabilities, different stent brands may be used.
1614456|NCT02128373|Procedure|Usual care|Health care provided by physician, physician's nurse, and social worker
1614457|NCT02128373|Other|computer-assisted intervention|Caregiver will virtually attend visit using the CLOSER intervention
1614458|NCT02128373|Other|Distress Thermometer|Average score of a one item scale (range 0-10) where higher scores indicate more distress
1614459|NCT02128373|Other|Profile of Mood States (POMS-B)|average score of five items scored 0-4 which describe how someone is feeling. Higher scores indicate increased discomfort
1614460|NCT02128373|Other|Quality of Life: Functional Assessment in Cancer Therapy - (FACT)|Average score of FACT which quantitatively assesses brain cancer patient's physiological functional and quality of life. FACT questions are scored 0-4 with higher numbers indicating more functionality
1614461|NCT02128373|Other|Tension-Anxiety Subscale|six item scale which asks to qualitatively describe which areas in you life are causing stress
1614464|NCT02128347|Other|Electronic Patient Portal|RelayHealth is a web-based application that allows patients and clinicians to communicate through a secure, password protected online electronic portal with data transfer capabilities. The system allows physicians and nurses to view patient questions, patient data and transmit messages to patients in response to questions or after clinic visits in an electronic message. In addition, patients can be made aware of upcoming investigations or clinic visits. Patients can also use the interface to identify any proposed changes (which would minimize recall mistakes after clinic visits) and submit queries pertaining to dialysis. Both patients and clinicians are made aware of new messages through email prompt, which moderates the asynchronous nature of electronic communication. Telephone communication can be maintained, but reserved for more urgent issues that require immediate assistance.
1614465|NCT02128334|Drug|Eligard 45 mg Exposure|Subcutaneous injections
1614466|NCT02128321|Drug|Isavuconazole|oral
1614467|NCT02128321|Drug|Repaglinide|oral
1614468|NCT02128321|Drug|Caffeine|oral
1614469|NCT02128308|Drug|Levofloxacin and Streptomycin added|
1614470|NCT02128308|Drug|Moxifloxacin and Kanamycin added|
1614471|NCT02128295|Device|Electric breast pump - A|
1614472|NCT02128295|Device|Electric breast pump - B|
2010372|NCT02986139|Drug|Commercial formulation of Etanercept/Enbrel (A), New formulation Etanercept/Enbrel (B)|Each dose of etanercept will consist of the complete contents of 1 SureClick autoinjector. If the first injection site occurs on the leg, the second injection site should be performed on the contralateral limb. If the injection occurs in the abdomen, the first injection should be on either the right or left half of the abdomen with the second injection occurring on the opposite side of the abdomen. Each dose will follow the recommended label dosing for subjects with Rheumatoid Arthritis and Psoriatic Arthritis: 50 mg weekly (scheduled approximately 7 days apart).
2010373|NCT02986139|Drug|New formulation Etanercept/Enbrel (B), Commercial formulation of Etanercept/Enbrel (A)|Each dose of etanercept will consist of the complete contents of 1 SureClick autoinjector. If the first injection site occurs on the leg, the second injection site should be performed on the contralateral limb. If the injection occurs in the abdomen, the first injection should be on either the right or left half of the abdomen with the second injection occurring on the opposite side of the abdomen. Each dose will follow the recommended label dosing for subjects with Rheumatoid Arthritis and Psoriatic Arthritis: 50 mg weekly (scheduled approximately 7 days apart).
2010374|NCT02986737|Device|ACURATE neo™ and ACURATE TA™ LP|ACURATE neo™ Aortic Bioprosthesis and ACURATE TA™ LP Transapical Delivery System on patients with severe aortic stenosis where conventional aortic valve replacement (AVR) via open-heart surgery is considered to be high risk
1614476|NCT02128269|Biological|Study Drug- ALXN1007|10 mg/kg IV q 2 weeks x 12 doses
1614477|NCT02128256|Device|Cerament G|
1614478|NCT02128243|Drug|S-1 de-escalation|S-1 30 mg/m² bid d1-14 q21d
1614479|NCT02128243|Drug|Chemotherapy by Investigator's choice|"Polychemotherapy administration as in induction therapy consists of a platinum and fluoropyrimidine compound as well as optional a taxane / an anthracycline compound.
Two-Drug combinations:
FLO / mod. FOLFOX-6; Cisplatin, S-1; Cisplatin, 5-FU; Cisplatin, Capecitabine (XP)
Three-drug combinations:
EOX/EOF FLOT"
2010375|NCT02985866|Device|Artificial Pancreas|Use of CTR at home for 3 months
1614484|NCT02128204|Device|lidocaine contained hyaluronate facial dermal filler|HYADERMIS LA Facial Dermal Implant contains 20 mg/ml hyaluronate and 0.3 % lidocaine.
1614485|NCT02128204|Device|hyaluronate facial dermal filler|Hya-Dermis Facial Dermal Implant contains 20 mg/ml hyaluronate.
1614486|NCT02128191|Drug|Oral ibuprofen|Initial dose of 10 mg/kg of oral ibuprofen, followed by two doses of 5 mg/kg 24 and 48 hours later
1614487|NCT02128191|Drug|Normal saline|Initial dose of normal saline followed by second and third dose 24 and 48 hours later, at equal volume to ibuprofen arm
1614488|NCT02128178|Drug|Enoxaparin 40 mg 2 hours before arm|Enoxaparin 40 mg 2 hours before surgery
1614489|NCT02128178|Drug|Enoxaparin 40 mg 12 hours before arm|Enoxaparin 40 mg 12 hours before surgery
1614490|NCT02128165|Device|BMI more than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI above 45
1614491|NCT02128165|Device|BMI less than 45 BMI|Air filled gastric balloon (Heliosphere) those BMI below 45
1614492|NCT02128152|Device|Ekso exoskeleton|
1614494|NCT02128113|Drug|Placebo|Opthalmic suspension manufactured to mimic RTA 408 suspension
1614495|NCT02128113|Drug|0.5% Omaveloxolone Ophthalmic Suspension|0.5% ophthalmic suspension of RTA 408
1614496|NCT02128113|Drug|1% Omaveloxolone Ophthalmic Suspension|1% ophthalmic suspension of RTA 408
1614497|NCT02128100|Drug|Folfirinox|"Oxaliplatin 85 mg/m² for over 2 hours,
Leucovorin 400n mg/m² for over 2 hours,
Irinotecan 180 mg/m² for over 90 minutes, along with Leucovorin infusion
Fluorouracil 400 mg/m² as a fast infusion over 15 minutes
Fluorouracil 2400 mg/m² as a slow infusion over 46 hours"
1614498|NCT02128100|Radiation|Stereotactic Body Radiation Therapy|5 treatments of stereotactic ablative radiotherapy (SABR) over the course of two weeks with a minimum of 36 hours in between each treatment.
1614499|NCT02128087|Behavioral|Two-way SMS intervention|"Clients will receive a weekly two-way SMS, meaning that the clients in this group will receive the same message as in the one-way SMS study arm, but in addition will be asked how they feel. Clients are required to either press 1 or respond well or press 2 or write 'Unwell in response in the language of their choice within 48 hours. A missing response after 48 hours triggers a second SMS to remind the client to respond. If after 24 more hours the participant still does not respond or if at any point s/he responds unwell then the study coordinator will follow up with a call within 24 hours."
1614500|NCT02128087|Behavioral|One-way SMS intervention group|Clients will receive a weekly one-way SMS message. There will be no prompt for any response.
1614501|NCT02128074|Drug|KRX-0502|1g tablets of KRX-0502
1614502|NCT02128061|Drug|Lenalidomide|
1614503|NCT02128061|Drug|Rituximab|
1614504|NCT02128048|Device|Assessment of body composition and muscle function|Assessment of body composition by DEXA and BIA Measurement of muscle function by hand-grip dynamometer and physical tests Comparison between quitters and continued smokers
1614637|NCT02126852|Device|Acceleromyography (AMG, three-dimensionally)|Neuromuscular monitoring
1614638|NCT02126852|Device|Electromyography (EMG)|Neuromuscular monitoring
1614505|NCT02128035|Procedure|With Lead Shield|"A pelvic lead shield will be draped on patient from umbilicus to knees.
Interventional cardiologists who will perform the procedure will wear a radiation protection cap in all procedures."
1614506|NCT02128022|Drug|GLP-1 (7-36) amide|Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
1614507|NCT02128022|Drug|Glibenclamide|Oral Glibenclamide 5mg
1614508|NCT02128009|Other|osteoporosis|
1614509|NCT02127996|Drug|GLP-1|GLP-1 (7-36) amide infused at 1.2 pmol/Kg/min
1614510|NCT02127996|Drug|placebo|Normal saline
1614511|NCT02127983|Behavioral|Early intervention|"Training non-paid informal healthcare providers (such as store-keepers) in TB and HIV disease recognition, sputum specimen collection, referral to the public health system, and raising community awareness.
Front line public health personnel and community leaders were sensitised to support the intervention"
1614512|NCT02127983|Behavioral|Delayed intervention|Delayed intervention arm, engaging informal providers Received the intervention after one year
1614513|NCT02127970|Drug|Single Dose Dalbavancin|Single dose of dalbavancin 1500 mg on day 1
1614514|NCT02127970|Drug|Two Dose Dalbavancin|Two dose regimen of dalbavancin (1000 mg on Day 1 followed by 500 mg on Day 8)
1614515|NCT02127957|Other|Exercise|Exercise will be prescribed by kinesiologist and will be done 3 times a week for 1 hour by subject. Every 4 weeks subject will be on supervised training session.
1614516|NCT02127931|Device|Groundskeeper|Groundskeeper, a Video Game Diagnostic Tool for ADHD is administered to probands with ADHD and age, gender matched controls without ADHD.
1614517|NCT02127918|Drug|ESES treated with clobazam|The patients that will participate in the protocol will be those that are administered for clinical reasons oral clobazam.
1614518|NCT02127905|Biological|CD34+ selected cells|Compassionate treatment of Fanconi Anemia patients with unrelated bone marrow or peripheral blood HSCT followed by the infusion of CD34+ selected cells using CliniMACS
1614519|NCT02127892|Biological|unrelated BM with T cell depletion|Remaining unmanipulated bone marrow will be processed to isolate CD34+ cells (T cell depleted).
1614520|NCT02127892|Biological|unrelated cord blood|Cord blood will be thawed (and processed if ABO incompatibility) per institutional SOP.
1614521|NCT02127892|Biological|haplo BM with T cell depletion|haplo-identical (parental) bone marrow will be processed for CD34+ cell isolation.
1614522|NCT02127892|Device|unrelated PBSC with T cell depletion|peripheral blood stem cell will be processed for CD34+ cell isolation.
1614523|NCT02127879|Device|Transcranial Magnetic Stimulation|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. pause is between every stimulation session for safety reasons.v
1614524|NCT02127879|Device|Transcranial Magnetic Stimulation with sham coil|16 sessions/4 days (4 sessions per day), 2000 stimuli per one session, 20 trains per session (train interval= 10 sec., intertrain interval= 30sec.), stimulation intensity 110 % related to the individual resting motor threshold; in total 32,000 stimuli, 20 min. Pause is between every stimulation session for safety reasons.
1614525|NCT02127866|Drug|CHF 5259 plus Foster 100/6 µg|Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)
1614526|NCT02127866|Drug|Foster 100/6 µg|"Active comparator
Comparison of different doses of CHF 5259 (on top of Foster 100 /6 µg) versus Foster 100/6 µg over a treatment period of 6 weeks. Each subject will be allocated to 3 ouf of the 4 possible treatments performed in sequence during a cross over design (incomplete block)"
1614527|NCT02127853|Drug|gabapentin|100 mg tid of gabapentin is prescribed to the patient for 1 week after the first eye surgery
1614528|NCT02127853|Drug|placebo|the same regimen of placebo drug is prescribed to the patient for 1 week after the first eye surgery
1614529|NCT02127840|Drug|Synacthen infusion during adrenal venous sampling|Adrenal venous sampling during Synacthen infusion
1614530|NCT02127827|Device|Automated Ambulatory Glycemic Controller (AAGC)|
1614531|NCT02127814|Dietary Supplement|Lactobacillus reuteri|One chewable tablet of 1E8 CFU L. reuteri, once per day
1614532|NCT02127801|Drug|REGN1908-1909|
1614533|NCT02127801|Drug|placebo|
1614534|NCT02127788|Drug|Micafungin|intravenous
1614535|NCT02127775|Drug|Lesinurad 400 mg (manufactured at Site 1)|
1614536|NCT02127775|Drug|Lesinurad 400 mg (manufactured at Site 2)|
1614537|NCT02127762|Behavioral|Mindfulness Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups.
1614538|NCT02127749|Drug|Endotoxin|Both groups will receive 2 ng/kg LPS (endotoxin) intravenously
1614539|NCT02127749|Drug|Vancomycin, Metronidazole, Ciprofloxacin|ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
1614540|NCT02127736|Drug|Amitriptyline|
1614541|NCT02127736|Drug|Placebo|
1614542|NCT02127723|Device|Hyaluronic acid injection (Macroalne VRF30)|Injection of Macrolane subcutaneously in the buttocks area to reduce cellulite
2010376|NCT02985866|Other|Sensor Augmented Therapy|Use of personal pump with study CGM & glucometer at home for 3 months
1614544|NCT02127697|Drug|NVA237|NVA237 capsules for inhalation, delivered via Concept1 once daily
1614545|NCT02127697|Drug|Placebo to NVA237|Placebo to NVA237 delivered via Concept1 once daily
1614546|NCT02127697|Drug|salbutamol/ albuterol|Taken as rescue medication
1614547|NCT02127684|Drug|ranibizumab|ranibizumab 0.3mg intravitreally monthly
1614548|NCT02127684|Drug|ranibizumab|ranibizumab given every 2 weeks for 8 weeks then monthly as needed
1614549|NCT02127671|Other|IDEAL intervention|
1614550|NCT02127671|Other|Control|
1614551|NCT02127658|Other|Hygiene education|Participants will receive specific hygiene instructions according to existing recommendations.
1614639|NCT02126839|Drug|Albuterol MDPI|90 mcg/actuation of the multidose dry powder inhaler (MDPI).
1614640|NCT02126839|Drug|Placebo|Matching Placebo delivered via a multidose dry powder inhaler (MDPI).
1614552|NCT02127658|Other|Hygiene education and Decolonization|Participants in this intervention group will receive the same hygiene instructions as the participants in the first intervention group. In addition, intervention number 2 will include the following for all consented household members: Twice weekly 15 minute soaks in diluted bleach water (2/3 cup of 8.25% sodium hypochlorite [Clorox; The Clorox Company] for a standard 50 gallon tub of water, or a teaspoon for each 1.5 gallons of water used) for the duration of 6 weeks. Application of 2% mupiricin ointment by the use of clean swab to the bilateral anterior nares twice daily for ten days
1614553|NCT02127645|Procedure|SRT-TEM|SRT-TEM underwent 25 Gy RT followed by TEM
1614554|NCT02127645|Procedure|LRT-TEM|TEM following 46 Gy RT
1614555|NCT02127645|Procedure|Transanal Endoscopic Microsurgery (TEM)|Transanal Endoscopic Microsurgery (TEM)
1614556|NCT02127645|Procedure|Total Mesorectal Excision (TME)|Laparoscopic Total Mesorectal Excision
2010377|NCT02984293|Drug|Atorvastatin|Atorvastatin 80 mg once daily for 28 days.
2010378|NCT02984293|Drug|Placebo|Placebo once daily for 28 days.
1614559|NCT02127619|Device|Total knee replacement with the ROCC® knee prosthesis|replacement of an osteoarthritic knee with a total knee prosthesis operation may be for a single knee ( unilateral) or both knees of a patient ( bilateral)
1614560|NCT02127606|Device|Vibration with tilt-table standing|
1614561|NCT02127593|Drug|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Wet Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by wet process will be orally administered on Day 1 of Period 1 or Period 2.
1614562|NCT02127593|Drug|Norgestimate /Ethinyl estradiol tablets (NGM/EE) (Dry Process)|Norgestimate /Ethinyl estradiol tablets (NGM/EE) containing norgestimate 250 mcg and ethinyl estradiol 35 mcg, formulated by dry process will be orally administered on Day 1 of Period 1 or Period 2.
1614563|NCT02127580|Procedure|BAV|
1614564|NCT02127580|Procedure|without BAV|
1614565|NCT02127567|Other|online writing tool|The writing tool contained the main CONSORT item and extension items for non pharmacological treatments along with bullet points indicating key elements to report from the explanation and elaboration publications of the CONSORT. Participants were also instructed to detail information they felt important to report but that was not available in the study protocol they were provided.
1614566|NCT02127567|Other|writing with no specific support|The control tool simply provided the domain or section heading with a space too write. Similar to for the experimental intervention, participants were to indicate information they felt important to report but unavailable in the provided study protocols.
1614567|NCT02127541|Other|Ga -exendin PET/CT, In- exendin SPECT/CT, MRI|Comparison of different imaging modalities
1614568|NCT02127515|Procedure|Non Invasive Prenatal Testing|
1614569|NCT02127515|Procedure|Invasive Prenatal Testing|
1614570|NCT02127489|Drug|1 mL/kg bupivacaine 0.25%.|40 children between 2 and 10 years of ASA I-II were randomized and they received caudal anesthesia under general anesthesia. Patients underwent the application of caudal block in addition with saline and 1 mL/kg bupivacaine 0.25%. In the postoperative period, Group C (n=20) was given 5mL saline and Group M (n=20) was given 0.30 mg/kg rectal midazolam diluted with 5mL saline. Sedation scale and postoperative pain scale (CHIPPS) of the patients were evaluated. The patients were observed for their analgesic need, first analgesic time, and adverse effects for 24 hours.
1614571|NCT02127476|Drug|KHK6640|Single ascending dose and multiple ascending doses administration
1614572|NCT02127476|Drug|Matching Placebo|Single ascending dose and multiple ascending doses administration
1614573|NCT02127463|Drug|MC-1101|Topically, two times a day, morning and bedtime
1614574|NCT02127463|Drug|MC-1101 Vehicle|Topically, two times a day; morning and bedtime
1614575|NCT02127437|Drug|Lanreotide|120 mg, subcutaneously, once every 4 weeks
1614576|NCT02127437|Drug|saline|0,5 ml, subcutaneously, once every 4 weeks
1614577|NCT02127424|Procedure|Nurse-driven HIV targeted screening|
1614578|NCT02127424|Procedure|Current practice|
1614579|NCT02127411|Behavioral|Mindfulness-Based Relapse Prevention|The MBRP is an adjuvant treatment for people that have been treated for drug use related problems
1614580|NCT02127398|Biological|fecal microbiota|fecal microbiota in capsule form
1614581|NCT02127372|Drug|Docetaxel, Cisplatin and STI571|"Treatment will consist of docetaxel plus cisplatin IV every 21days and oral STI571 given on Days -5 to 2 with each chemotherapy cycle. A maximum of 6 cycles will be given.
Phase 1 dose levels are:
Level 1 Docetaxel/Cisplatin 60 mg/m2, STI571 300mg
Level 2 Docetaxel/Cisplatin 60 mg/m2, STI571 400mg
Level 3 Docetaxel/Cisplatin 70 mg/m2, STI571 400mg
Level 4 Docetaxel/Cisplatin 70 mg/m2, STI571 600mg
Level 5 Docetaxel/Cisplatin 75 mg/m2, STI571 600mg
Level 6 Docetaxel/Cisplatin 75 mg/m2, STI571 800mg
Once the MTD level has been established, the previous dose level will be the dosing schedule for Phase II."
1614582|NCT02127372|Drug|Docetaxel|
1614583|NCT02127372|Drug|Cisplatin|
1614584|NCT02127320|Drug|Rosuvastatin 20mg|
1614585|NCT02127320|Drug|Ezetimibe 10mg|
1614586|NCT02127320|Drug|Rosuvastatin 20mg + Ezetimibe 10mg|
1614587|NCT02127294|Device|transcatheter patent foreman ovale closure|
2010379|NCT02984072|Drug|Menthol|Topical menthol in aqueous cream
1614589|NCT02127268|Drug|Thymosin-α1|with Thymosin-α1 1.6mg twice a week
1614590|NCT02127255|Procedure|Manual acupuncture implemented by acupuncturist 1|Manual acupuncture once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 1 has to have more than 15 years of acupuncture clinical practice experience.
1614591|NCT02127255|Procedure|Manual acupuncture implemented by acupuncturist 2|Manual acupuncture given by acupuncturist 2 once per day. Acupuncture treatment regimens (acupoints, needling methods, needle retention time) were decided by acupuncturist 1 according to the syndrome differentiation of patients. Acupuncturist 2 has to have less than 5 years of acupuncture clinical practice experience.
2010380|NCT02984072|Drug|Aqueous Cream|placebo
2010381|NCT02983552|Other|iPad®|Binocular therapy on iPad®
2010382|NCT02983552|Other|Spectacle correction|Spectacle correction for all waking hours, 7 days per week
2010383|NCT02981147|Drug|Phytus (Cisti, Thyme and Ivy Leaves)|Phytus is a medicinal herb containing Ivy leaves, Cisti and Thyme.
2010384|NCT02982486|Drug|Ipilimumab|Ipilimumab 1 mg/kg every 6 weeks
1614592|NCT02127242|Procedure|ureteroscopic air-pressure ballistic lithotripsy|In case of large, hard or impacted stones ureteroscopic air-pressure ballistic lithotripter is used for fragmentation. The probe of the lithotripter target towards the stone and then fragmented.
1614593|NCT02127229|Procedure|Endoscopist informed of cost per procedure|Following each procedure, endoscopists will get a cost report regarding the amount spent on disposable accessories.
1614594|NCT02127216|Behavioral|MOSES|MOSES is an integrated system between a patient, peer patients, and healthcare providers.
1614595|NCT02127190|Drug|CXA-10 emulsion|CXA-10 Injectable Emulsion is a sterile emulsion containing CXA-10 in a formulation containing soybean oil, medium chain triglycerides oil, egg phospholipids, sucrose, and disodium EDTA. CXA-10 Injectable Emulsion will be administered intravenously. The active emulsion will be diluted in a vehicle emulsion.
1614596|NCT02127190|Drug|Placebo|
1614597|NCT02127177|Device|Continuous Positive Airway Pressure Ventilator|CPAP group received fixed-level CPAP titration using an automated pressure setting device for one night. The optimal CPAP pressure for each patient in the CPAP group was set at the minimum pressure required to abolish snoring, obstructive respiratory events, and airflow limitation for 95% of the night, according to a previous validation by our study.
1614598|NCT02127164|Device|"Veraflo device, Dakin's solution"|Veraflo device will be installed on the wound to create negative pressure after surgery. Dakin's solution will be instilled through this device into the wound at the regular intervals.
1614599|NCT02127151|Drug|BMN 673|Starting oral dose of 1.0 mg once daily to be taken until progression, death, unacceptable toxicity, withdrawal consent or any other criterion felt by the Investigator to preclude continuation of treatment.
1614600|NCT02127138|Device|Sirolimus eluting Drug stent|Use the Sirolimus-eluting Drug stents has been approved by the CFDA，But does not allow use taxol-eluting Drug stents and Drug-eluting stent without Polymer.
1614601|NCT02127125|Drug|Maltodextrin|Maltodextrin treatment as a placebo group. Maltodextrin, 6 gm three times a day for 4 weeks.
1614602|NCT02127125|Drug|Synbiotic|Synbiotic [5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming unit (CFU)/g) three times a day) for 4 weeks.
1614603|NCT02127125|Drug|Sevelamer|Sevelamer (1.6 g sevelamer + 4.4 g maltodextrin three times a day), for 4 weeks
1614604|NCT02127112|Procedure|Block Allograft plus Matrix Allograft|A cancellous block allograft plus a demineralized bone matrix allograft will be used as the positive control treatment.
1614605|NCT02127112|Procedure|Moldable Matrix Allograft|The test arm of this study will include a demineralized bone matrix allograft placed over resorbable bone pins.
1614606|NCT02127086|Other|Intervention Group|The PAIN Algorithm and analgesic order sets to be used by nurses to assess and reassess pain and opioid-related side effects will include orders for: 1) managing pain based on MOPAT Behavioral Dimension cut scores, 2) pre-medication before painful procedures, 3) titration of drugs, and 4) managing major opioid side effects. The order sets will start with small doses of opioids that will be titrated upwards for peak analgesic effect and allow for adjustment for patient characteristics and type of pain while simultaneously monitoring for and treating side effects.
1614607|NCT02127073|Drug|Intranasal Oxytocin|Intranasal spray, one spray or 4 IU of oxytocin will be administered into each nostril of each patient about 15-30 minutes before NAF collection
1614608|NCT02127060|Drug|Vitamin C|for 1 month postoperative period, vitamin C was administered orally to the patients.
1614609|NCT02127060|Drug|Placebo drug|for 1 month postoperative period, placebo medication administered orally to the patients.
1614610|NCT02127047|Drug|Sitagliptin|
1614611|NCT02127047|Drug|Exercise|
1614612|NCT02127034|Drug|Mirabegron|oral
1614613|NCT02127034|Drug|Solifenacin|oral
1614614|NCT02127034|Drug|Digoxin|oral
1614615|NCT02127021|Drug|Norzyme® 40000 IU|A kind of pancreatic enzyme supplement containing lipase: 40,000 FIP, amylase: 25,000 FIP, and protease: 1,500 FIP Single capsule of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal
1614616|NCT02127021|Drug|Placebo|Single capsule of placebo drug with the same appearance of Norzyme® 40000 IU will be prescribed three times a day while taking a meal meal.
1614617|NCT02127008|Procedure|Resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was resected.
1614618|NCT02127008|Procedure|No resection of epidural fat|During surgical procedure, the epidural fat with pituitary forcep and rongeur was not resected.
1614619|NCT02126995|Drug|MG01CI extended-release tablet|Metadoxine, MG01CI extended-release tablet taken for 6 weeks treatment. Starting with a dose of 700 mg for 2 weeks followed by a 2 weeks of 1400 mg and then 2 weeks of 700 mg or 1400 mg.
1614620|NCT02126969|Radiation|Low dose fractionated radiation - 80cGy with chemotherapy|Chemotherapy + 80 cGy of RT
1614621|NCT02126969|Drug|Docetaxel and Carboplatin AUC 6|Docetaxel 75 mg/m2 and Carboplatin AUC 6 without Radiation
1614622|NCT02126956|Drug|ACT-128800|ACT-128800 was supplied as a powder mix in hard gelatin capsules for oral administration. The capsules contained a co-precipitated mixture of non-radiolabeled and 14C-labeled ACT-128800 formulated at a dose strength of 40 mg with a maximum radioactive content of 102 μCi (3.79 MBq).
1614623|NCT02126943|Drug|Opsumit (macitentan)|10 mg tablets
1614624|NCT02126930|Other|Pharma consult|Upon hospital discharge, patients randomized to the experimental arm will have a pharmaceutical consultation concerning their anti-infectious treatment.
1614625|NCT02126930|Other|Routine care|Patients randomized to this arm will receive care in the habitual manner.
1614626|NCT02126917|Drug|HC-ER + 40% Alcohol|HC-ER 50 mg + 240 mL solution of 40% alcohol/orange juice in fasted state
1614627|NCT02126917|Drug|HC-ER + 20% Alcohol|HC-ER 50 mg + 240 mL solution of 20% alcohol/orange juice in fasted state
1614628|NCT02126917|Drug|HC-ER + 0% Alcohol|HC-ER 50 mg + 240 mL solution of 0% alcohol/orange juice in fasted state
1614629|NCT02126904|Drug|IVA group|
1614630|NCT02126891|Procedure|Tests|Individual parameters of echocardiography and heart rate variability
1614631|NCT02126878|Drug|Kenalog|
1614632|NCT02126865|Drug|Placebo to BI 1060469|tablet
1614633|NCT02126865|Drug|BI 1060469 Healthy|tablet
1614634|NCT02126865|Drug|Placebo to BI 1060469 asthmatics|tablet
1614635|NCT02126865|Drug|BI 1060469 asthmatics|tablet
1614636|NCT02126852|Device|Acceleromyography (AMG, one-dimensionally)|Neuromuscular monitoring
1614641|NCT02126839|Drug|ProAir HFA inhaler|Rescue medication, ProAir hydrofluoroalkane (HFA) inhaler, was dispensed at the run-in visit for the relief of asthma symptoms to be administered as needed.
1614642|NCT02126826|Drug|BI 1026706|Multiple Rising Doses (oral solution, tablet)
1614643|NCT02126826|Drug|Placebo to BI 1026706|Multiple Rising Doses (oral solution / tablet, identical to active treatment)
1614644|NCT02126813|Procedure|increased interventional threshold for urinary bladder catheterization (800 ml)|
1614645|NCT02126813|Procedure|Current used interventional threshold for urinary bladder catheterization (500 ml)|
1614646|NCT02126813|Device|Intermittent bladder catheter|
1614647|NCT02126787|Behavioral|Intensive Group Analytic Psychotherapy|The form of intensive group analytic therapy to be used in the trial has been manualized by the research team for the study. It is rooted in group analysis tradition (Bion 1961; Foulkes & Anthony, 1965). It is based on two recent group analytic psychotherapy manuals, one developed by Lorentzen (2014), the other by Garland (2010). The manual has been adapted to day treatment setting and also draws on polish psychoanalytical group experiences practiced in a public service. Like in other psychodynamic short-term therapies this approach is more structured and focused on issues relevant to symptoms relief. Thereby additional techniques are used: psychodrama, non-verbal techniques, movie therapy, memoir, summary or relaxation.
1614648|NCT02126787|Behavioral|Intensive transdiagnostic cognitive-behavioral group therapy|GCBT was designed for treatment in naturalistic settings of diagnostically mixed anxiety disorder patients with comorbid Personality Disorders (PD's) (Holas, Szaniawska, Suszek, Błażejewski, & Kokoszka, in prep.). It is based on the transdiagnostic approach to emotional and particularly anxiety disorders that has been developed over the past ten years (Barlow, 2000; Barlow, Allen, & Choate, 2004; Norton, 2006), additionally it includes interventions for personality disorders based of schema therapy and modes of personality disorders. This approach assumes a high overlap between anxiety disorders and is focused on the common aspects of them. Intensive GCBT developed by our group shares the classical assumptions of cognitive-behavioral therapy (Beck, 1976).
1614649|NCT02126761|Biological|Adjuvanted, trivalent subunit influenza vaccine|Group 1 and group 5 are active comparators; group 5 includes placebo comparator as a second injection in contralateral deltoid
1614650|NCT02126761|Biological|Adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 2 and group 6 are experimental; group 2 has double dosage of MF59 in a single injection; group 6 has triple dosage of MF59 and includes placebo comparator in contralateral deltoid
1614651|NCT02126761|Biological|Antigen level modified adjuvanted, trivalent subunit influenza vaccine|Group 3 is experimental with double the usual antigen dosage
1614652|NCT02126761|Biological|Antigen and adjuvant level modified adjuvanted, trivalent subunit influenza vaccine|Group 4 and 7 are experimental; group 4 has one injection with double the antigen and adjuvant; group 7 has two injections with double the antigen and adjuvant
1614653|NCT02126748|Other|inhalation 4ml hypertonic saline 3% 3x/day|
1614654|NCT02126748|Device|Intrapulmonary Percussive Ventilation|
1614655|NCT02126748|Procedure|Assisted Autogenic Drainage|
1614656|NCT02126722|Procedure|Gastroscopy|Gastroscopy with multiple biopsies will be performed in all patients enrolled
1614657|NCT02126722|Device|EndoFaster test|During the gastroscopy the EndoFaster test will be carried out in all patients enrolled.
1614658|NCT02126722|Other|Clo test|During the gastroscopy the Clo test will be carried out in all patients enrolled.
1614659|NCT02126722|Other|Faecal Helicobacter pylori antigen|On the day of the endoscopic procedure all the enrolled patients will bring a stool sample for the detection of Helicobacter pylori antigen.
1614660|NCT02126709|Drug|Repigel|Repigel will be used as the intervention in the treatment group
1614661|NCT02126683|Drug|Hydroxychloroquine|
1614662|NCT02126670|Drug|ACT01|
1614663|NCT02126670|Drug|Comp01|
1614664|NCT02126670|Drug|Comp02|
1614665|NCT02126670|Drug|Comp03|
1614666|NCT02126670|Drug|Comp04|
1614667|NCT02126657|Drug|70% glycolic acid|
1614668|NCT02126644|Drug|70% glycolic acid|
1614669|NCT02126579|Biological|Peptide Vaccine (LPV7) + Tetanus peptide|1.5 mL administered half intradermally and half subcutaneously.
1614670|NCT02126579|Other|PolyICLC|1 mL administered half intradermally and half subcutaneously
1614671|NCT02126579|Other|Resiquimod|500 mg applied to vaccine site after vaccine administration
1614672|NCT02126579|Other|IFA|2 mL administered half intradermally and half subcutaneously
1614673|NCT02126566|Device|Administration of light therapy - measurement of results before and after therapy|
1614674|NCT02126553|Drug|Lenalidomide|Starting dose: 10 mg by mouth on days 1- 28 of a 28 day cycle.
1614675|NCT02126540|Device|Pantheris Atherectomy System|Treatment device in primary cohort arm; OCT image guided directional atherectomy
1614676|NCT02126527|Drug|auranofin|Given PO
1614677|NCT02126527|Drug|sirolimus|Given PO
1614678|NCT02126527|Other|laboratory biomarker analysis|Correlative studies
1614679|NCT02126527|Other|pharmacological study|Correlative studies
1614680|NCT02126514|Drug|AZD3293|7 subjects will receive AZD3293
1614681|NCT02126501|Other|Gradual pressure wean|NCPAP will be removed by gradually decreasing pressure over 24 hours once the weaning is decided
1614682|NCT02126488|Behavioral|treadmill slip perturbation|Group A will receive perturbation training on a treadmill with precisely controlled slip-like displacements and then encounter an unannounced novel slip during over-ground walking.
1614683|NCT02126488|Behavioral|treadmill training placebo|An age-matched control group (Group B) will receive only placebo training (on the same treadmill for the same duration but without perturbation) but encounter an identical novel slip during their over-ground walking.
1614684|NCT02126488|Behavioral|observation training|An age-matched observation-training group (Group C) will watch a training video and slides. When exposed to an identical novel slip in over-ground walking, they will know where and how the slip is going to occur and how to resist a fall.
1614685|NCT02126462|Biological|Na-APR-1 (M74)/Alhydrogel®|
1614686|NCT02126462|Biological|Na-GST-1/Alhydrogel®|
1614687|NCT02126462|Biological|Hepatitis B vaccine|Hepatitis B vaccine co-administered with saline
1614688|NCT02126449|Other|Fasting mimicking diet|
1614797|NCT02125513|Drug|carboplatin and paclitaxel followed by surgery|
1614689|NCT02126436|Other|Acupuncture|"Participants will receive a course of traditional Chinese acupuncture. Acupuncture will be pragmatic but strict guidelines will be adhered to including:
using a combination of body and auricular acupuncture, treating the opposite limb to amputation and possibly the residual limb, using auricular acupuncture points such as shen men, sympathetic, points corresponding to the lower limb, using body acupuncture points around the stump (depending on tissue health and the patient), mirroring local and distal points by needling them on the opposite limb, points on the lower back taking a segmental approach to dermatomal pain, including points such as LI4 + LR3, LR3, GV20, SP10, electro-acupuncture may be used, retaining the needles for 20-30 minutes, treating twice weekly for four weeks."
1614690|NCT02126436|Other|Usual care|The group will receive usual care (including physiotherapy, occupational therapy, medical intervention and any other intervention as deemed appropriate by clinical staff).
1614691|NCT02126423|Other|Conjunctival and nasopharyngeal swabs|For conjunctival samples, a sterile swab is moistened with ophthalmic balanced salt solution and gently swept along the lower fornix from the medial to the lateral canthi, with all attempts to avoid the eyelashes and eyelids. For nasopharyngeal cultures, the sterile swab is inserted 2 cm into the naris and rotated against the anterior nasal mucosa for 3 seconds.
1614692|NCT02126397|Procedure|polyps resection with Laser Diode|resection of endometrial polyps by hysteroscopy without anesthesia
1614693|NCT02126397|Procedure|polyps resection with bipolar electrode|
1614694|NCT02126384|Drug|pneumovax vaccination|vaccination
1614695|NCT02126371|Drug|LEO32731|
1614696|NCT02126358|Drug|Gemigliptin and/or Rosuvastatin|
1614697|NCT02126345|Device|MASTER SL femoral stem and DELTA TT acetabular cup|
1614698|NCT02126332|Other|ropivacaine and sufentanil|Thoracic epidural analgesia will be performed using ropivacaine (2 mg/ml), sufentanil (0.5 microg/ml) administered through a patient-controlled deviced (PCEA : patient-controlled epidural analgesia). PCEA parameters will be fixed as follows : continuous administration of 5 to 15 ml/h and bolus of 3 to 10 ml every 10 minutes. Iterative epidural administration of clonidine (1 mckg/kg) will be allowed to achieve analgesia goals.
1614699|NCT02126332|Other|acetaminophen, nefopam, tramadol, opidoids|Conventional analgesia will include enteral and/or parental administration of usual analgesics, ranging from step 1 to step 3 drugs according to WHO classification (including acetaminophen, nefopam, tramadol, opidoids). The route, dose and frequency of analgesics administrations will be based on participating ICUs protocols.
1614700|NCT02126319|Behavioral|Cognitive Affective preparation|"Forty five minute cognitive-affective preparation session, wherein individuals were encouraged to experience and self-assess their personal reactions to the information they had just received about their prostate cancer risk status, and to anticipate (pre-live) and role play their potential psychological reactions to normal and abnormal test results and associated follow-up diagnostic and management recommendations. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)"
1614701|NCT02126319|Behavioral|General Health Education|A general health educational comparison session administered by research staff in order to equate for factual content, time, and attention. Participants in this session received information of relevance to men at risk for Pca, focusing on recommendations for general health (i.e., diet, exercise, alcohol use, and smoking) and were encouraged to freely probe, explore, and discuss their own attitudes, beliefs, expectations, and feelings about these topics in an interactive format. Combined with standard Prostate Risk Assessment Program (Group Prostate Cancer Education Session, Individual Counseling, Screening feedback)
1614702|NCT02126306|Drug|Beta Glucosylceramide|Beta Glucosylceramide
1614703|NCT02126306|Drug|Placebo|normal saline
1614704|NCT02126293|Drug|Zinc Supplement|
1614705|NCT02126293|Procedure|Repeat blood and urine tests|
1614706|NCT02126280|Other|In vitro estimation of individual reactivity of monocytes|Technique for isolation/separation of monocytes with culture purity more than 95 % CD14-positive cells according to flow cytometry, the share of viable cells at least 98% by trypan blue vital staining, capable of producing TNFa at concentration of at least 50 pg/ml when stimulated with 100 ng/ml IFN-gamma, and CCL18 at concentration at least 30 pg/ml when stimulated with 10 ng/ml interleukin.
1614707|NCT02126267|Procedure|Scaling and root planing|Scaling procedures were performed per quadrant (30 min. per quadrant) at weekly intervals between sessions;
1614708|NCT02126267|Procedure|Full mouth disinfection|Procedures for scaling and root planing were performed in a single stage (24 hours) divided into two sessions (60 min per session) on two consecutive days
1614709|NCT02126267|Drug|Chlorhexidine gel and gluconate|application of chlorhexidine (CX) (1%) gel in pockets after scaling, brushing tongue for 1 min. with CX (1%) gel and mouthwash at the beginning and end of each session with CX 0.2% for 30 seconds (with the form of a gargle in the last 10 seconds)
1614710|NCT02126267|Drug|Chlorhexidine gluconate solution|Home use fo CX 0.2% for 60 consecutive days after the end of the first session of scaling.
1614711|NCT02126267|Drug|Azithromycin|Azithromycin (500 mg) once daily for 3 consecutive days.
1614712|NCT02126254|Device|Hemodynamic group|NICAS guided treatment
1614713|NCT02126241|Other|NICaS guided CRT optimization|"Baseline CO measurement by NICaS
AV delay optimization:
AV delay will be changed (increase and decrease) by 30 ms steps , and for each new AV value, the CO will be real-time measured by NICaS
The AV delay yielding the maximal CO, will be considered the optimal AV delay
The device will be programmed using the optimal AV delay
VV delay optimization:
After Step 2, the baseline VV delay will be changed (increase and decrease; meaning that we will be pacing alternatively the LV before the RV, then the RV before the LV), by 30 ms steps, and for each new VV value, the CO will be real-time measured by NICaS
The VV delay yielding the maximal CO, will be considered the optimal VV delay
The device will be programmed using the optimal VV delay"
1614714|NCT02126215|Procedure|MRI CO2 stress testing|Pre and post operatively
1614715|NCT02126202|Procedure|Coronary angiography and revascularization if feasible|Coronary angiography and revascularization with PCI or CABG (coronary artery bypass grafting) if feasible
1614761|NCT02125786|Device|Photon therapy|Participants will receive one or both: Photon or proton therapy.
1614762|NCT02125786|Device|Proton therapy|Participants will receive one or both: Photon or proton therapy.
1614798|NCT02125500|Drug|Sofosbuvir/Ledipasvir fixed dose|SOF 400 mg/LDV 90 mg FDC tablet administered orally once daily
1614844|NCT02125149|Other|Exercise Intervention|
1614716|NCT02126163|Behavioral|Treatment Group|Responsible Drinking intervention sessions include an internet-based, computer-tailored intervention (CTI) grounded in the Transtheoretical Model of Behavior Change (TTM). The intervention includes stage-matched and tailored feedback on alcohol use, alcohol-related problems, and theoretically identified behavior change strategies, as well as access to a web-based portal with stage-matched interactive activities to reinforce and promote stage progression. Finally, the intervention will include 7 months of stage-matched behavior change SMS messages.
1614717|NCT02126137|Drug|Ezetimibe|
1614718|NCT02126124|Device|Sham Treatment|In the sham treatment, the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the the brain.
1614719|NCT02126124|Device|Active dTMS Treatment|Deep Transcranial Magnetic Stimulation (dTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The Brainsway Coil is a novel dTMS coil desigend to allow deeper brain stimulation without significant increase of electric fields induced in superficial cortical regions.
1614720|NCT02126111|Biological|DEPIGOID phleum|Subcutaneous Immunotherapy with modified extract of Phleum pollen.
1614721|NCT02126111|Biological|DEPIGOID Placebo|Placebo for subcutaneous administration
1614722|NCT02126085|Procedure|Endovascular recanalisation|"Endovascular recanalisation by mechanical thrombectomy with e.g. stent retriever device, possibly following intravenous thrombolysis within a bridging concept"
1614723|NCT02126072|Dietary Supplement|Alcohol|They consume 1gram of alcohol per kilogram of bodyweight in wine (12%)
1614724|NCT02126072|Dietary Supplement|Water|Volunteers consume the same volume of water as the would in wine according toe the protocol.
1614725|NCT02126059|Behavioral|Reminiscence|"The 10 session topics include Happy to seeing you, Childhood stories, Food flavor, Our old songs, Festival, My family, My Carrier, Unforgettable events, My home, and My award.
small group intervention (8-12 per group), expected total number of group is 5."
1614726|NCT02126059|Behavioral|Cognitive stimulation|"The 10 session topics include psycial activities, sound, face, food, word association, number and games, being creative, categorizing objects, orientation, and team qiuz.
small group intervention (8-12 per group), total number of group is 5."
1614727|NCT02126059|Behavioral|Aroma-massage|Researcher will conduct hand and arm massage to a patient, once a week, each time session for 30 mins with natural tested and safe aroma-essential oil.
1614728|NCT02126046|Genetic|unrelated CB following haplo-identical hematopoietic stem cells transplantation|
1614729|NCT02126033|Procedure|take blood samples|
1614730|NCT02126020|Drug|topical infliximab|topical infliximab administered QID for 3 months followed by BID for 9 months
1614731|NCT02126007|Behavioral|Sleep and Rhythm Intervention|
1614732|NCT02126007|Behavioral|Dietary Modifications|
1614733|NCT02125994|Procedure|Interscalene nerve block|
1614734|NCT02125981|Drug|Limaprost|taking Limaprost α-Cyclodextrin Clathrate 1 Tablets (166.67 μg), three times per day
1614735|NCT02125981|Drug|Placebo|taking placebo drug
1614736|NCT02125968|Other|interactive video game|short- and medium-term therapeutic effects
1614737|NCT02125968|Other|therapeutic exercise|short- and medium-term therapeutic effects
2010385|NCT02982486|Drug|Nivolumab|Ninolumab 240 mg IV every 2 weeks
1614740|NCT02125942|Behavioral|Central Meditation and Imagery Therapy|mindfulness, guided imagery, meditation
1614741|NCT02125929|Procedure|Robotic surgery|Robotic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
1614742|NCT02125929|Procedure|Laparoscopic surgery|Laparoscopic surgery: enucleation benign Pancreatic Neuroendocrine Tumors
1614743|NCT02125929|Procedure|Open surgery|Open surgery: enucleation benign Pancreatic Neuroendocrine Tumors
1614744|NCT02125916|Other|oxygen therapy|
1614745|NCT02125903|Drug|Ropivacaine|Regional Anesthesia performed with 0.375% Ropivacaine 15ml (56,25mg)
1614746|NCT02125890|Drug|Tranexamic Acid|two doses of Tranexamic Acid will be given to patients with rupture abdominal aortic aneurysms
1614747|NCT02125877|Drug|Deferasirox dispersible tablet|Deferasirox DT was provided as 125 mg, 250 mg and 500 mg dispersible tablets for oral use.
1614748|NCT02125877|Drug|Defearisox film-coated tablet|Deferasirox FCT was provided as 90 mg, 180 mg and 360 mg film-coated tablets for oral use.
1614749|NCT02125864|Drug|Aflibercept|
1614750|NCT02125851|Other|Xanthan Gum|esophageal mucosal contact time vs sucralose slurry
1614751|NCT02125851|Other|Honey|esophageal mucosal contact time of honey vs sucralose slurry
1614752|NCT02125838|Device|Laryngeal Mask Airway-Supreme|Group LM-S (Laryngeal Mask Airway-Supreme)Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
1614753|NCT02125838|Device|Endotracheal Tube|ETT
1614754|NCT02125812|Other|scaling and systemic moxifloxacin|scaling and root planing (SRP) combined with systemic moxifloxacin
1614755|NCT02125812|Other|scaling and root planing|scaling and root planing
1614756|NCT02125799|Device|Accelerated HF-rTMS (Magstim Rapid 2 stimulator)|Twice daily rTMS sessions involving 10 Hz in 75 trains of 4 seconds duration, with 26 seconds intertrain intervals (6,000 pulses per day) at 120% of the resting motor threshold.
1614757|NCT02125786|Radiation|Irradiation|Radiation therapy on this protocol will be based on extent of disease, extent of resection and location. The allowed treatment modalities include conformal or intensity-modulated radiation therapy using photons or proton therapy using double-scattering or spot-scanning methods. The general goal is to initiate radiation therapy within 12 weeks of last surgery performed at the time of recurrence.
1614758|NCT02125786|Procedure|Surgery|When applicable, surgery will be used to remove metastases. The goal of surgery is to achieve gross total resection of all imaging visible residual tumor.
1614759|NCT02125786|Drug|^1^8F-Fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
1614760|NCT02125786|Drug|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
1614763|NCT02125773|Behavioral|Informed Risk Score|Subjects in the intervention arm will receive an estimate of their risk of HIV infection as estimated by the UCSD calculator. The risk of HIV infection will be based on the subject's responses to the self-reported sexual risk questionnaire and the risk of HIV infection in one year will be extrapolated based on continuation of the same risk behavior. The subjects will also be provided the calculated risk if they were to take PrEP. Subjects in the control arm will not be provided with the results of the risk calculators. Both arms will receive standard of care risk reduction education and information sheets about PrEP.
1614764|NCT02125760|Other|Inspiratory Muscle Training (IMT)|Sham IMT at a fixed workload of 10 cmH2O. 5 sets of 10 repetitions, twice a day, 7 days per week, for 4 weeks.
1614765|NCT02125760|Other|High-intensity IMT|High Intensity IMT. The training load is the maximum inspiratory load defined according to patient tolerance. This load will be equivalent to 10 maximal repetitions (RM) as 10 consecutive inspirations (x 5 sessions), twice a day.
1614766|NCT02125747|Other|No Respiratory Therapy|Patients received conventional treatment.
1614767|NCT02125747|Other|Respiratory Therapy|"Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area.
The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions.
Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period."
1614768|NCT02125734|Drug|QVA149|QVA149 capsules 110/50 µg for inhalation via Concep-1-inhaler device, taken once a day
1614769|NCT02125734|Drug|Tiotropium|Tiotropium 18 µg capsules for inhalation via HandiHaler device taken once a day
1614770|NCT02125721|Drug|CBTD 0-3 gm|Oral CBTD 0-3 gm dose/day for 7 days, dose escalation
1614771|NCT02125708|Device|OvulaRing®|The OvulaRing® is a non-invasive thermometer measuring the intravaginal temperature every 5 minutes. It was originally invented to assess the moment of ovulation and optimize fertility. This plastic ring including a high-tech-sensor thermometer should be placed into the vaginal fornix for a maximum of 30 days, measuring the intravaginal core-temperature 288 times a day.
1614772|NCT02125695|Procedure|Skin Taping|Skin taping from affected and unaffected sites (4 tape harvestings/area plus photograph of taping site)
1614773|NCT02125695|Procedure|Blood Sampling|Sampling for biomarker and basic research in CLE and AD
1614774|NCT02125695|Procedure|Skin Biopsy|As described in the treatment arm
1614775|NCT02125682|Drug|atovastatin 10 mg/day|patients will receive 10 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 80 mg daily for 8 weeks
1614776|NCT02125682|Drug|Atorvastatin 80 mg/day|patients will receive 80 mg of atorvastatin daily for 8 weeks, then wash out for 6 weeks then cross over to atorvastatin 10 mg daily for 8 weeks
1614779|NCT02125656|Other|High Intensity Interval Training|6 sessions in 2 weeks (Monday, Wednesday and Friday). Each training session will consist of repeated high-intensity efforts in a workload that matches the peak oxygen uptake for 60 seconds. These sprints are interspersed with active recovery for 75 seconds on low intensity (30W). The training sessions will have three minutes of heating in 30W. There will be 8 shots in the first and second session, 10 shots in the third and fourth session and 12 shots in the fifth and sixth session.
1614780|NCT02125643|Drug|Caffeine|
1614781|NCT02125643|Other|Flour|Flour will be administered as the placebo.
1614782|NCT02125630|Procedure|Surgery|Surgery to primary tumor
1614783|NCT02125630|Drug|Systemic therapy|Systemic therapy based on tumor phenotype
1614784|NCT02125617|Drug|Abiraterone|1000 mg/day
1614785|NCT02125617|Drug|Prednisolone|10 mg/day
1614786|NCT02125604|Drug|dimethyl fumarate|capsules administered according to the prevailing product label
1614787|NCT02125591|Device|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
1614788|NCT02125591|Device|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
1614789|NCT02125578|Drug|BIIB017 (PEGylated Interferon Beta-1a)|Each participant will receive BIIB017 every other week or every 4 weeks.
1614790|NCT02125578|Drug|Placebo|Each participant will receive placebo every other week or every 4 weeks.
1614791|NCT02125565|Other|Injected subcutaneous local (lidocaine) anaesthesia|Trial of technique
1614792|NCT02125552|Procedure|Ultrasound guidance|The ultrasound machine will be used to guide intravenous line placement in patients randomized to the ultrasound guided intravenous line group
1614793|NCT02125552|Procedure|Traditional intravenous access|Placement by experienced nurse using standard IV techniques
1614794|NCT02125539|Behavioral|Navigating my Journey program|The online relapse prevention program called Navigating my Journey is designed for adolescents who are receiving outpatient treatment for substance abuse. Since the Navigating my Journey program will be available to adolescents 24/7, it is easy for them to access at their convenience. The program functions as an adjunct to treatment and is designed to complement and enhance the work the adolescent does with the counselor during counseling sessions. The core intervention is expected to last for 12 weeks.
1614795|NCT02125539|Behavioral|Attention Control|Client participants in the control group will receive their typical course of counseling and a link to online online health information in PDF form as an attention control.
1614796|NCT02125526|Device|Intra-aortic balloon pump|The intra-aortic balloon pump is placed in the descending thoracic aorta and inflates and deflates in synchrony with the cardiac cycle, providing diastolic augmentation and improving coronary blood flow, while deflating before systole, providing afterload and workload reduction for the myocardium.
1614799|NCT02125487|Behavioral|Teaching using Hybrid Simulation of breast examination|"Students in the intervention/experimental group will receive the regular lecture given at the American University of Beirut and will attend a screening of an educational video on the technique of CBE, in addition to the hybrid simulation teaching activities in the simulation lab (standardized patient wearing breast examination simulator jackets)"
1614800|NCT02125487|Behavioral|Teaching using traditional method|"Students in the control group will receive the regular lecture given at the American University of Beirut and will attend the usual simulation lab teaching activities (single breast silicone model without any actors). The only new introduction to the curriculum is an educational video on the technique of CBE."
1614801|NCT02125474|Radiation|[177Lu] DOTA-TATE|We have designed a one-arm phase II prospective sequential clinical trial to assess the therapeutic efficacy of 177-Lu-[DOTA 0, Tyr 3] octreotate (177-Lu- DOTATATE) applied intravenously in three separate doses to patients with inoperable progressive WDNET.
1614802|NCT02125461|Drug|MEDI4736|MEDI4736 by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
1614803|NCT02125461|Other|PLACEBO|PLACEBO by intravenous infusion. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier . The 2:1 ratio (MEDI4736 to placebo).
1614804|NCT02125448|Device|MRI and PET-CT|
1614805|NCT02125435|Drug|ASP2408|intravenous
1614806|NCT02125435|Drug|Placebo|intravenous
1614807|NCT02125422|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
1614808|NCT02125409|Drug|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily for 7 days.
1614809|NCT02125409|Procedure|Screening colonoscopy|
1614810|NCT02125396|Other|Transarterial chemoembolization|Adjuvant transarterial chemoembolization [5-15 ml lipiodol 5-fluorouracil (500 mg/m2) and adriamycin (30 mg/m2)]
1614811|NCT02125396|Other|Radiotherapy|Adjuvant radiotherapy is used for postoperative curative HCC
1614812|NCT02125383|Procedure|Active tDCS|Anodal tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
1614813|NCT02125383|Procedure|Sham tDCS|Sham tDCS will be applied over motor cortex for 20 minutes, three times during the night while the subject sleeps, each separated by 1 hour
1614814|NCT02125370|Other|Qualitative and survey|
1614815|NCT02125357|Drug|Abiraterone acetate|Abiraterone acetate 1000mg PO OD with prednisone 5mg PO BID or 10mg OD as per standard of care.
1614816|NCT02125357|Drug|Enzalutamide|160mg PO OD as per standard of care.
1614817|NCT02125344|Drug|non-pegylated liposomal doxorubicin|20 mg/m2, i.V. 18 times weekly
1614818|NCT02125344|Drug|Carboplatin|Carboplatin AUC 1.5 18 times weekly (only in patients with triple-negative breast cancer).
1614819|NCT02125344|Drug|Paclitaxel|paclitaxel 80mg/m² 18 times weekly
1614820|NCT02125344|Drug|Epirubicin|150mg/m² every 2 weeks for 3 cycles.
1614821|NCT02125344|Drug|Cyclophosphamide|2000 mg/m² every 2 weeks for 3 cycles.
1614822|NCT02125344|Drug|Pertuzumab|420 (840) mg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
1614823|NCT02125344|Drug|Trastuzumab|Trastuzumab 6 (8) mg/kg every 3 weeks simultaneously to all T and C cycles in the ETC arm and to all cycles in the PM(Cb) arm.
1614824|NCT02125344|Drug|Ferric carboxymaltose|after first anemia grade ≥2 and in case of randomisation: Ferric carboxymaltose i.V. 1000 mg followed 1 week later by an injection of ferric carboxymaltose i.V. 500 mg (if body weight is <70 kg) or 1000 mg (if body weight is ≥70 kg). In case body weight is <50 kg, both dosages will be reduced to 500 mg each.
1614825|NCT02125331|Procedure|Device: Blood pressure monitoring with GE Healthcare CARESCAPE B650 Patient Monitor-Patient Side Module (PSM) or Patient Data Module (PDM)|3-15 Non-Invasive Blood Pressure readings on the CARESCAPE B650 Patient Monitor equipped with PSM-Datex-Ohmeda and PDM-SuperSTAT NIBP measurement devices during non-emergent heart catheterization
1614826|NCT02125318|Drug|Anagrelide CR|Starting dose of 0.5 mg b.i.d. (1.0 mg/day) titrated at weekly intervals, on an individual basis, to achieve the lowest dose required to achieve and maintain a target platelet count of 150 - 400 x 10e9/L, tolerability permitting. The dose will be increased at weekly intervals in steps not exceeding 0.5 mg/day; the rate of dose titration may be reduced (i.e., up to once every 2 weeks) at the discretion of the Investigator.
1614827|NCT02125305|Drug|Metformin|
1614828|NCT02125292|Drug|Mesalamine|
1614829|NCT02125279|Drug|Calcitriol|
1614830|NCT02125266|Drug|V404|Sustained Release
1614831|NCT02125253|Drug|Mometasone Furoate Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate
1614832|NCT02125253|Drug|Nasonex Nasal Spray, 50 mcg|a metered-dose, manual pump spray unit containing an aqueous suspension of mometasone furoate monohydrate
1614833|NCT02125253|Drug|Placebo Nasal Spray|a metered-dose, manual pump spray unit containing an aqueous suspension
1614836|NCT02125227|Drug|Rosuvastatin, Metformin, YH14755|single dose
1614837|NCT02125227|Drug|YH14755|single dose
1614838|NCT02125214|Device|Target Controlled Infusion system (Orchestra Base Primea, Fresenius, France)|Intravenous induction with propofol using the pharmacokinetic model by Schnider et al. The initial cerebral concentration will be 0.5 µg ml-1, which will be increased stepwise by 1.0 µg ml-1 until 2.5 µg ml-1, and then by 0.5 µg ml-1 until loss of consciousness
1614839|NCT02125201|Drug|Fentanyl|A neonate will recieve Fentanyl intranasal or intravenous 5 minutes before the procedure The nurse will check his pain scale If the pain scale will be more than 4 the neonate will recieve the second dose of Fentanyl
1614840|NCT02125188|Drug|Desmopressin|Desmopressin 3ug/kg ivdrip before surgery
1614841|NCT02125188|Drug|saline|saline 100ml ivdrip before surgery
1614842|NCT02125175|Radiation|Hypofractionated IMRT boost Radiotherapy|
1614843|NCT02125162|Drug|BCX4161|Each subject will receive Treatments A, B, and C in an open-label, randomized sequence with a washout period of at least 7 days between each dose
1614845|NCT02125136|Drug|Gem/nab-Pac|"All patient receive:
2 cycles gemcitabine/nab-paclitaxel ([Gem/nab-Pac]; duration of each cycle 28 days)
Then:
Nab-paclitaxel 125 mg/m2, IV infusion over 30 minutes, followed by gemcitabine 1000 mg/m2 as a 30-minute IV infusion on D1, D8, D15 of each 28-day cycle"
1614846|NCT02125136|Drug|FOLFIFINOX|"All patient receive:
2 cycles gemcitabine/nab-paclitaxel ([Gem/nab-Pac]; duration of each cycle 28 days)
Then:
Oxaliplatin 85 mg/m2, given as a 2-hour intravenous infusion D1 Folinic acid 400 mg/m2, given as a 2-hour intravenous infusion D1 Irinotecan 180 mg/m2, given as a 90-minutes intravenous infusion D1 (application through a Y-connector parallel to infusion of folinic acid or 30 minutes after start of folinic acid possible) Fluorouracil 400 mg/m2, administered by intravenous bolus, followed by a continuous intravenous infusion of fluorouracil 2400 mg/m2 over a 46-hour period D1.
To be repeated on D1 of each cycle."
1614847|NCT02125123|Other|Nutritional Supplement and Counseling|Ready-to-feed nutritional supplement and dietary counseling
1614848|NCT02125123|Other|Counseling|Dietary counseling
1614849|NCT02125110|Device|MRI|
1614850|NCT02125110|Other|neuropsychological assessment|
1614851|NCT02125097|Device|Barrel™ Vascular Reconstruction Device (VRD)|Intended for use with embolic coils for the treatment of wide-neck bifurcating or branch intracranial aneurysms arising from a parent vessel with a diameter of ≥ 2.0 mm and ≤ 4 mm, measured by 2D Digital Subtraction Angiography (DSA). Wide-neck is defined as having a neck width ≥ 4 mm or a dome-to-neck ratio < 2.
1614852|NCT02125084|Drug|Everolimus|
1614853|NCT02125084|Drug|Enzalutamide|
1614854|NCT02125071|Other|Blood Sample Collection|Blood Sample Collection before and after the administration of I.V. Hepabig Inj. on LT day(0 day); 1 day after; 1, 4, 12 and 24 weeks after LT.
1614855|NCT02125058|Procedure|Transcutaneous sutures|Conventional excision followed by subcutaneous sutrues and transcutaneous sutures
1614856|NCT02125058|Procedure|Intracutaneous sutures|Conventional excision followed by subcutaneous sutrues and intracutaneous sutures
1614857|NCT02125045|Dietary Supplement|L-GSH|Reduced glutathione is formed by cysteine, glycine and glutamate. It enters into the detoxification processes of endogenous products, such as peroxides which are the final pathway of many reactions caused by cardiovascular risk factors. It also acts on the exogenous compounds, such as pollutants, heavy metals and some drugs.
1614858|NCT02125045|Dietary Supplement|Placebo|Placebo will be prepared using the same excipients of the dietary supplement without active substance.
1614859|NCT02125032|Device|Transcranial low voltage pulsed electromagnetic fields (T-PEMF)|
1614860|NCT02125032|Device|Placebo Transcranial low voltage electromagnetic fields|
1614861|NCT02125006|Behavioral|Mindfulness-Based Stress Reduction|Consists of eight weekly 2.5 hour sessions and one 6 hour session midway through the course. All sessions will be conducted by a psychologist or social worker with experience in chronic pain, formal MBSR training and 5 years of experience leading MBSR groups. To assess therapist adherence to the protocol, sessions will be recorded. A random selection of 50% of sessions will be rated by an MBSR trainer who completed the University of Massachusetts Centre for Mindfulness in Medicine, Health Care and Society Teacher Development Intensive using a checklist of specified treatment components. A percentage score for each session rated will be calculated to determine therapist adherence.
1614862|NCT02124993|Other|Questionnaire|Dr. Ballanger's office will administer a FPQ upon approval of an informed consent. Subjects will be asked to complete the questionnaire at a pre-operative visit and six weeks post-operatively.
1614863|NCT02124980|Behavioral|Recovery Line|
1614864|NCT02124967|Other|Exercise|A one hour exercise class including both aerobic activity and resistance training
1614865|NCT02124954|Drug|TA-8995|
1614866|NCT02124954|Drug|Midazolam|
1614867|NCT02124954|Drug|Digoxin|
1614868|NCT02124941|Drug|N-acetyl cysteine|
1614869|NCT02124941|Drug|riluzole|
1614870|NCT02124941|Drug|pentoxifylline|
1614871|NCT02124941|Drug|13C MRS|
1614872|NCT02124941|Behavioral|Continued abstinence|
1614873|NCT02124928|Procedure|Carotid endarterectomy|Carotid endarterectomy is a surgery used to reduce the risk of stroke, by correcting stenosis in the carotid artery. Endarterectomy is the removal of material on the inside (end-) of an artery.An incision is made on the midline side of the Sternocleidomastoid muscle. The incision is between 5 and 10 cm in length. Then the patients get 5000 IU heparin by the anesthesia. The internal, common and external carotid arteries are carefully identified, controlled with vessel loops, and clamped. The lumen of the internal carotid artery is opened, and the atheromatous plaque removed. The artery is closed using suture. The procedure is performed under local anesthesia. Local anesthesia, opposite to general, allows for direct monitoring of neurological status by intra-operative verbal contact and testing of grip strength.
1614874|NCT02124902|Drug|Docetaxel|
1614875|NCT02124902|Drug|Carboplatin|
1614877|NCT02124863|Device|Intrapulmonary Percussive Ventilation|20 min IPV freq 300/min, p 10cmH2O
1614881|NCT02124837|Behavioral|Park walk during lunch break|
1614882|NCT02124837|Behavioral|Relaxation during lunch break|
1614883|NCT02124824|Drug|BQ-123|Endothelin subtype A antagonist
1614884|NCT02124811|Drug|Minocycline|
1614885|NCT02124798|Device|Belimumab autoinjector|Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
1614886|NCT02124785|Procedure|Blood sampling|At Years 21 to 25 after their second vaccine dose.
1614887|NCT02124772|Drug|Trametinib|Trametinib is available in tablet (0.125mg, 0.5mg, 2mg dose) as well as in powder form for Oral Solution (0.05mg/mL dose). It is recommended that subjects drink 4 to 6 mL of water/kg body weight following dosing.
1614888|NCT02124772|Drug|Dabrafenib|Dabrafenib is available in capsules (50mg and 75mg) as well as in powder form for Oral Suspension (10 mg/mL dose) and taken twice a day. It is recommended that subjects drink approximately 1 ounce (30 mL) of water for every 10 pounds of body weight following dosing.
1615017|NCT02123732|Dietary Supplement|DbXell|
1614889|NCT02124759|Drug|Sevelamer|1.6 g sevelamer + 4.4 g maltodextrin three times a day
1614890|NCT02124759|Drug|Synbiotic|5 g of oligofructose + 1 g Bifidobacterium longum R0175 (4 billion colony forming units (CFU)/g) three times a day.
1614891|NCT02124759|Drug|Maltodextrin|This is a control group. Maltodextrin, 6 g three times a day
1614892|NCT02124746|Drug|Momelotinib|Momelotinib tablets administered orally once daily
1614893|NCT02124733|Procedure|Aminolevulinic acid based photodynamic therapy|The PDT treatments will be done in two stages. ALA (Levulan® Kerastick™) will be applied to the entire treatment area, and then the longer light exposure (lasting up to 1 hr) will be performed on one-half of the treatment area (Side A). After that, a shorter (16 min 40 sec) light exposure will be done on the other half (Side B).
1614894|NCT02124720|Behavioral|iSTIM|Trained research assistants and parents will implement the assessments and interventions recommended by the iSTIM mobile application during sessions lasting between 10 and 60 minutes
1614895|NCT02124707|Drug|Cetuximab|400mg/m2 IV (in the vein) on day 1 of week 1 and 250mg/m2 IV (in the vein) on day 1 of weeks 2-6. Patients with stable disease may continue on maintenance therapy at the 250mg/m2 dose until disease progression.
1614896|NCT02124707|Drug|Paclitaxel|135mg/m2 IV (in the vein) on day 1 of each 1 week for 6 weeks.
1614897|NCT02124707|Drug|Carboplatin|AUC2, IV (in the vein) on day 1 of each 1 week for 6 weeks.
1614898|NCT02124694|Behavioral|HTUG|HTUG is a group psychotherapy...
1614899|NCT02124681|Drug|Hydroxychloroquine|Hydroxychloroquine sulfate 400mg/d PO for 13±1 weeks
1614900|NCT02124681|Other|Placebo|Placebo PO for 13±1 weeks
1614901|NCT02124668|Drug|Enzalutamide|oral
1614902|NCT02124655|Drug|Essential oils|
1614903|NCT02124655|Drug|0.2% chlorhexidine|
1614904|NCT02124655|Drug|Sterile water|
2010386|NCT02980965|Drug|letrozole, leuprorelin, fluorouracil, epirubicin, cyclophosphamide, docetaxel|Postmenopausal patients were treated with letrozole 2.5mg/day p.o until complement of neoadjuvant chemotherapy before surgery, while premenopausal ones received letrozole 2.5mg/day p.o and a subcutaneous injection of the GnRH-a, leuprorelin, as concomitant treatment with neoadjuvant chemotherapy (fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles), letrozole was delivered after 1 week of first dose of leuprorelin injection.
2010387|NCT02980965|Drug|fluorouracil, epirubicin, cyclophosphamide, docetaxel|Patients received fluorouracil 600mg/m2 IV, epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles followed by docetaxel 100mg/m2 IV on day 1 at 3-weekly intervals for 3 cycles; or epirubicin 90mg/m2 IV and cyclophosphamide 600mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles, followed by docetaxel 80mg/m2 IV on day 1 at 2-weekly intervals for 4 cycles.
1614907|NCT02124590|Other|Acute Exercise|Repeated isometric leg exercises at varying intensities for up to twelve minutes per bout. Leg exercises will target the quadriceps muscles.
1614908|NCT02124590|Other|Acute Exercise|Aerobic exercise session on a bike at 50% of peak VO2 for 30 minutes.
2010388|NCT02980731|Drug|Venetoclax|Tablet
1614910|NCT02124525|Drug|N-acetylcysteine|N-acetylcysteine 3000mg a day for 12 weeks versus Placebo for 12 weeks
1614911|NCT02124512|Drug|Rifaximin SSD|Study Drug dosing will be 80 mg SSD once daily
1614912|NCT02124512|Other|Placebo|80 mg placebo once daily
1614913|NCT02124486|Procedure|Bariatric surgery|Participants randomised to the bariatric surgery arm of the trial will be referred to the surgery pathway according to NICE guidelines at Birmingham Heartlands Hospital (BHH), Heart of England NHS Foundation Trust.
1614914|NCT02124486|Behavioral|Dietetic intervention|Participants randomised to the dietetic arm will be given vouchers at baseline, 3, 6 and 9 months that exempt them from paying for consecutive and specified weeks of their local Weight Watchers.
1614915|NCT02124473|Other|Homeopathy|
1614916|NCT02124473|Other|Placebo|
1614917|NCT02124460|Behavioral|Health Coaching|"Parent/child duos enrolled in the intervention group will participate in a total of six visits with a trained health coach. During these visits, the health coach will coach the parent/child duos on improving obesity-related behaviors .
The health coach will also help the family identify supports to assist with behavior change; discuss family health habits and the home environment; and review and encourage use of materials related to both specific target behaviors and available resources in the community.
Following the first call with the health coach, parents will receive semi-weekly text messages designed by the study team. The messages will alternate in structure between 2 types of messages; 1) skills training messages will deliver tips and motivational messages to help their child practice the study's goals and 2) self monitoring messages will ask parents to respond to the message and track health behaviors important to this study."
1614918|NCT02124447|Drug|PEG+E|Split dose 4 liter polyethylene glycol with electrolytes
1614919|NCT02124447|Drug|PEG+Asc|Split dose 2 liter polyethylene glycol with ascorbic acid
1614920|NCT02124447|Drug|P+MC|Split dose sodium picosulfate, magnesium oxide, and anhydrous citric acid
1614921|NCT02124447|Drug|sulfate|Split dose sodium sulfate, magnesium sulfate, and potassium sulfate solution
1614922|NCT02124421|Procedure|Cytoreductive Surgery (CRS)|Cytoreductive surgery
1614923|NCT02124421|Drug|Adjuvant Chemotherapy|Six weeks post-surgery (CRS or CRS/HIPEC) standard combination chemotherapy will be administered every 21 days for 6 cycles
1614924|NCT02124421|Other|Questionnaire|Questionnaires designed to assess quality of life in ovarian cancer patients will be administered to study participants
1614925|NCT02124421|Procedure|Hyperthermic intraperitoneal chemotherapy|Hyperthermic intraperitoneal chemotherapy with carboplatin, AUC=6
1614926|NCT02124421|Drug|Carboplatin|AUC=6 mg/mL/min IV (in the vein), on day 1. Repeat every 21 days for 6 cycles.
1614927|NCT02124421|Drug|Paclitaxel|175 mg/m2 IV (in the vein), day 1. Repeat every 21 days for 6 cycles
1614928|NCT02124421|Drug|Paclitaxel|Day 1: paclitaxel 135 mg/m2 IV (in the vein). Repeat every 21 days for 6 cycles Day 8: paclitaxel 60 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
2010389|NCT02980523|Drug|PRO-157|PRO-157 (Pazufloxacin 0.09%) Laboratories Sophia S.A. de C.V., ophthalmic solution
1614929|NCT02124421|Drug|Cisplatin|Day 2: cisplatin 75 mg/m2 IP (intraperitoneal). Repeat every 21 days for 6 cycles
1614930|NCT02124408|Behavioral|Personalized Behavioral Intervention|
1614931|NCT02124395|Other|Health-related Quality of Life in Rare Kidney Stone Questionnaire|
1614932|NCT02124369|Drug|Abraxane|125mg/m2, IV, on days 1,8 & 15 of each 28 day cycle, up to 6 cycles.
1614933|NCT02124369|Drug|Gemcitabine|1000mg/m2, IV, on days 1,8 & 15 of a 28 day cycle, up to 6 cycles.
1614934|NCT02124356|Other|Evaluation of functional performance|
1614935|NCT02124343|Other|Interval Exercise|
1614936|NCT02124330|Dietary Supplement|montmorillonite 5 g|5g montmorillonite + 15 g protein (ratio 1:3)
1614937|NCT02124330|Dietary Supplement|montmorillonite 3 g|3g MONT+ 15 g protein (ratio 1:5)
1614938|NCT02124330|Dietary Supplement|Montmorillonite 1 g|1g MONT+ 15 g protein (ratio 1:15)
1614939|NCT02124317|Drug|nanoparticle albumin-bound paclitaxel|nanoparticle albumin-bound paclitaxel is given at 120 mg/m2 intravenously on day 1 and 8 of each 21 day cycle. Number of cycles: 6 cycles.
1614940|NCT02124317|Drug|S-1|S-1 is orally administered (40-60 mg according to the body surface, twice a day) on day 1-14 of each 21 day cycle. Number of cycles: 6 cycles.
1614941|NCT02124304|Device|Neck exercises using both manual and Thera-Band elasatic resistance|Exercises will include cervical flexion and extension, and cervical right and left side-bending, and rotation. All 6 exercises will be done with both manual and elastic (Thera-Band) resistance.Manual Resistance is applied by the subject placing their own hand on their head and pushing in to it. Thera-Band bands will be used to provide elastic resistance
1614942|NCT02124291|Device|Mechanical Assisted Hatching|The technique of assisted hatching using partial zona pellucida dissection to create an artificial opening of the zona pellucida of early cleaved embryos. While the embryo is stabilized by a holding pipette of micromanipulator, the zona pellucida is pierced with a microneedle that is pushed tangentially through the space between the zona pellucida and blastomeres until it pierces through the zona pellucida again.
1614943|NCT02124278|Drug|PUL-042 Inhalation Solution|
2010390|NCT02980523|Drug|Vigamox|Vigamox® (Moxifloxacin 0.5%), Alcon Laboratories, S.A. de C.V., ophthalmic solution
1614945|NCT02124252|Behavioral|Community-based testing with standard linkage to care|Women will be offered HPV-based cervical cancer screening followed by standard linkage to care for women who test positive (to subdistrict or district hospitals).
1614946|NCT02124252|Behavioral|Community-based HPV testing with enhanced linkage to care|Women will be offered HPV-based cervical cancer screening followed by enhanced linkage to care using the strategies determined in partnership with the key stakeholders in the communities.
1614947|NCT02124239|Drug|Ingenol mebutate|
2010391|NCT02980523|Drug|Zymar®|Zymar® (Gatifloxacin 0.3%), Allergan, S.A. de C.V., ophthalmic solution
2010392|NCT02980523|Drug|Lagricel Ofteno®|Lagricel Ofteno® Sodium hyaluronate 0.4%, Laboratories Sophia S.A. de C.V., ophthalmic solution
1614950|NCT02124213|Drug|30 mg PF-06412562|Subject will receive a single dose of 30 mg PF-06412562
1614951|NCT02124213|Drug|PF-06412562|The dose will be selected based on the results obtained for Cohort 1. This Cohort is optional.
1614952|NCT02124213|Drug|PF-06412562|"The dose will be selected based on the results obtained for Cohort 1 and Cohort 2.
This Cohort is optional."
1614953|NCT02124200|Device|EGO/CE4, 9mg nicotine|
1614954|NCT02124187|Device|Ecig 24 mg nicotine|eCig 24 mg nicotine for 12 weeks
1614955|NCT02124187|Device|Ecig 0 mg nicotine|eCig 0 mg nicotine for 12 weeks
1614956|NCT02124187|Device|Nicotine free inhalator|eCig 24 mg nicotine for 12 weeks
1614957|NCT02124174|Drug|Vidaza and Valproic Acid|"Days 1-5: 5-Azacytidine 40 mg/m^2 daily Days 1-5: +Valproic acid 15 mg/kg daily Days 6-28: Valproic acid 15 mg/kg daily
*treatments will be repeated on the same days of each cycle for up to 4 total cycles. Each cycle will consist of 28 days."
1614958|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
1614959|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
1614960|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
1614961|NCT02124161|Other|Placebo|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
1614962|NCT02124161|Biological|Seasonal Inactivated Influenza Vaccine|One (1) dose of SIIV will be administered intramuscularly into the right deltoid of all subjects at Visit 1.
1614963|NCT02124161|Biological|13-valent pneumococcal conjugate vaccine|One (1) dose (0.5 mL) will be administered intramuscularly into the left deltoid either at Visit 1 or at Visit 2, depending on the randomization group assigned to the subject.
1614964|NCT02124148|Drug|Prexasertib|Administered IV
1614965|NCT02124148|Drug|Cisplatin|Administered IV
1614966|NCT02124148|Drug|Cetuximab|Administered IV
1614967|NCT02124148|Drug|G-CSF|Administered SC
1614968|NCT02124148|Drug|Pemetrexed|Administered IV
1614969|NCT02124148|Drug|Fluorouracil|Administered IV
1614970|NCT02124148|Drug|LY3023414|Administered PO
1614971|NCT02124148|Drug|Leucovorin|Administered IV
1614972|NCT02124135|Behavioral|Diet/Nutrition Education|"As described elsewhere, all participants will receive 1 phone call and 3 in person sessions with the registered dietitian.
Participants in the clinic arm will receive the education intervention in the clinic.
Participants in the restaurant arm will receive the education intervention while dining in a restaurant."
1614973|NCT02124122|Biological|Lactobacillus reuteri|Probiotic
1614974|NCT02124122|Biological|Placebo|Placebo
2010393|NCT02979691|Radiation|SIB-IMRT|
2010394|NCT02979691|Drug|S-1|
1615018|NCT02123732|Dietary Supplement|Placebo|
1615019|NCT02123719|Other|Surgery|
2010395|NCT02978781|Drug|SAGE-217|
2010396|NCT02978781|Drug|Placebo|
1614977|NCT02124044|Drug|Asunaprevir and Daclatasvir|Oral treatment with Asunaprevir 100mg (ASV), twice daily, and Daclatasvir 60mg (DCV), once daily, for 24 weeks in HIV/HCV genotype 1b patients
1614978|NCT02124044|Drug|Asunaprevir and Daclatasvir with BMS-791325|Oral treatment with Asunaprevir 200mg (ASV), Daclatasvir 30 mg (DCV) and BMS-791325 75 mg in a fixed dose combination pill (FDC), twice daily, for 12 weeks in HIV/HCV genotype 1a or 1b patients
1614979|NCT02124018|Procedure|Programmed ventricular stimulation|Programmed ventricular stimulation in high-risk patients based on non-invasive evaluation
1614980|NCT02124018|Device|ICD implantation|ICD implantation in patients with induced VT in programmed ventricular stimulation
1614981|NCT02124005|Drug|Bupivacaine|
1614982|NCT02123992|Device|Elevate Apical and Posterior|
1614983|NCT02123992|Procedure|Native Tissue Repair for pelvic organ prolapse|
1614984|NCT02123979|Drug|Neupro® transdermal patch/placebo|8mg transdermal patch Neupro® transdermal patch/placebo
1614986|NCT02123953|Drug|TAK-438|TAK-438 tablets
1614987|NCT02123953|Drug|TAK-438 Placebo|TAK-438 placebo-matching tablets
1614988|NCT02123940|Device|lung ultrasound score|Prospective randomized clinical multicentric study on ICU comparing a treatment strategy (nasal humidified high flow therapy and Noninvasive Ventilation) in patients with high-risk of postextubation distress in ICU based on a Lung Ultrasound Score VERSUS standard strategy
1614989|NCT02123927|Drug|TAK-438|TAK-438 tablets
1614990|NCT02123927|Drug|Placebo|TAK-438 placebo-matching tablets
1614991|NCT02123914|Other|Aerobic exercise with Vit. C|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week combined with taking vitamin C supplemented daily with an oral dose of 2,000 mg 2 times/day for 8 weeks.
Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,
Nasal peak flow measurement,
Nasal blood flow measurement,
Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
1614992|NCT02123914|Other|Aerobic exercise|"walking - running on a treadmill at intensity of 65-70% HRR for 30 minutes per session three times a week for 8 weeks.
Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,
Nasal peak flow measurement,
Nasal blood flow measurement,
Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
1614993|NCT02123914|Other|No exercise|"Sedentary control.
Nasal challenge with house dust mites with the evaluation of cytokines in nasal lavage fluid,
Nasal peak flow measurement,
Nasal blood flow measurement,
Exercise training regimen including VO2max measurment at baseline and at the end of the experiment."
1614994|NCT02123901|Other|Walking Meditation|"Walking Meditation training program will be based on aerobic walking exercise combined with Buddhist meditation. The subjects will perform walking on the treadmill while concentrated on foot stepping by voiced Budd and Dha with each foot step that contacted the floor to practice mindfulness while walking. Walking Meditation will be conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week."
1614995|NCT02123901|Other|Walking|Walking training program will be based on aerobic walking exercise. The subjects will perform walking on the treadmill and conducted at mild to moderate intensity (50-60% maximum heart rate) and in phase 2 (week 7-12), the training intensity will be increased to moderate intensity (60-70% maximum heart rate). In both phases the training will be performed for 30 minutes, 3 times per week.
1614996|NCT02123901|Other|No exercise|Sedentary life style.
1614997|NCT02123888|Radiation|Cone Beam Computed Tomography|Simultaneous Cone Beam Computed Tomography acquisition during arc radiotherapy
1614998|NCT02123875|Other|Physiotherapy|
1614999|NCT02123875|Other|Control arm|Routine hospital based physiotherapy
1615000|NCT02123849|Drug|Aspirin|Given PO
1615001|NCT02123849|Other|Laboratory Biomarker Analysis|Correlative studies
1615002|NCT02123849|Other|Placebo|Given PO
1615003|NCT02123836|Biological|NK cells|"7 days of preparatory treatment are given before the NK cell infusion. Chemotherapy will be given over 6 days. This chemotherapy will promote donor NK cells engraftment. After which, a drug called Interleukin-2 (IL-2) will be given as an injection just under the skin three times per week for at least 2 weeks (total of 6 doses). This treatment is used to help keep the donor NK cells alive.
Blood cells will be collected from an eligible and suitable family donor 10 days before infusion. The collection sample will be processed to remove red blood cells and as many T-cells as possible. T-cells from the donor might cause these donor cells to attack the body, usually the skin, liver, and intestines.
NK cells will be activated in the National University Hospital lab and ready for infusion on Day 0.
The NK cells will then be infused into the vein, through a peripheral catheter."
1615012|NCT02123810|Other|CPR|Simulated cardiac arrest on a manikin Chest Compression CPR for 6 minutes
1615013|NCT02123758|Drug|Abiraterone Acetate|Administered orally (by mouth) once daily in morning at a dose of 1000 mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
1615014|NCT02123758|Drug|Prednisone|Administered orally twice a day at a dose of 5mg for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
1615015|NCT02123758|Drug|JNJ-56021927|Administered orally once daily in morning at a dose of 240 mg starting on Day 8, Treatment Cycle 1 for up to the end of treatment (EoT) visit (ie, for up to approximately 18 months).
1615016|NCT02123745|Device|The ivWatch Model 400|The ivWatch Model 400 monitored the site during the course of the infiltration and issued red and/or yellow notifications if an infiltration was detected.
1615020|NCT02123693|Other|Osteopathic manipulative treatment|
1615021|NCT02123693|Other|Sham Therapy|
1615022|NCT02123693|Other|No Intervention|
1615023|NCT02123654|Drug|Daclatasvir|
1615024|NCT02123654|Drug|Asunaprevir|
1615025|NCT02123654|Drug|DCV 3DAA|
1615026|NCT02123654|Other|Placebo for DCV 3DAA|
1615027|NCT02123654|Other|Placebo for Daclatasvir|
1615028|NCT02123654|Other|Placebo for Asunaprevir|
1615029|NCT02123641|Other|Heavy resistance training|Supervised heavy resistance training three times weekly for 52 weeks.
1615030|NCT02123641|Other|Moderate intensity training|Moderate intensity training supervised once weekly and home based unsupervised two times weekly for 52 weeks.
1615031|NCT02123641|Other|Control|No training
1615032|NCT02123628|Drug|duration of the antibiotic therapy|
1615033|NCT02123615|Drug|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subdermally with ASIS Device for 30 patients.
Gadolinium For abdomen Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
1615034|NCT02123615|Drug|Gadolinium For abdomen|"Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subcutaneously for 30 patients.
Gadolinium For abdomen Total Persistent % subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs."
1615035|NCT02123615|Drug|Gadolinium For abdomen|Gadolinium For abdomen Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
1615036|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Total Persistent % subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subdermally with ASIS Device for 30 patients.
1615037|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Total cumulative Persistent % of Gadolinium subcutaneously on MRI at 6 hrs, 12 hrs, and 24 hrs. Gadolinium 1cc/ diluted with 19cc normal saline (for <40kg) or 29cc normal saline (for >40kg) subcutaneously for 30 patients.
1615038|NCT02123615|Drug|Gadolinium For lower back|Gadolinium For lower back Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI .
1615039|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 12.
1615040|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 12.
1615041|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
1615042|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 12.
1615043|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
1615044|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 12.
1615045|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
1615046|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 12.
1615047|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 24.
1615048|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 24.
1615049|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
1615050|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 24.
1615051|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 24.
1615052|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 24
1615053|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
1615054|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 24.
1615055|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) of any infections as Efficacy of Gammagard subcutaneously at Week 36.
1615056|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|Annual rate of any infections as Efficacy of Gammagard subcutaneously at Week 36.
1615057|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
1615058|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subcutaneously at Week 36.
1615059|NCT02123615|Drug|Efficacy of Gammagard subcutaneously at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
1615060|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subcutaneously at Week 36.
1615061|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
1615062|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subcutaneously at Week 36.
1615063|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 12
1615064|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 12
1615065|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
1615066|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 12
1615067|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 12
1615068|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 12
1615069|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 12
1615070|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 12|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 12.
1615071|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 24.
1615072|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 24.
1615073|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
1615074|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 24.
1615075|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 24.
1615076|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 24.
1615077|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
1615078|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 24|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 24.
1615079|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) of any infections as Efficacy of Gammagard subdermally at Week 36.
1615080|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate of any infections as Efficacy of Gammagard subdermally at Week 36.
1615081|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
1615082|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Antibiotic use as Efficacy of Gammagard subdermally at Week 36.
1615083|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|subjects (%) with Days out of work as Efficacy of Gammagard subdermally at Week 36.
1615084|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with Days out of work as Efficacy of Gammagard subdermally at Week 36.
1615085|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|(%) with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
1615086|NCT02123615|Drug|Efficacy of Gammagard subdermally at Week 36|Annual rate with hospitalized infections as Efficacy of Gammagard subdermally at Week 36.
1615087|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 12|Adverse Reactions of Gammagard subcutaneously at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
1615088|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 24|Adverse Reactions of Gammagard subcutaneously at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
1615089|NCT02123615|Drug|Adverse Reactions of Gammagard subcutaneously at Week 36|Adverse Reactions of Gammagard subcutaneously at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
1615090|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 12|Adverse Reactions of Gammagard subdermally at Week 12, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain
1615091|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 24|Adverse Reactions of Gammagard subdermally at Week 24, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
1615092|NCT02123615|Drug|Adverse Reactions of Gammagard subdermally at Week 36|Adverse Reactions of Gammagard subdermally at Week 36, in number of Local Reactions, Headache, Fever, Nausea, Vomiting, Fatigue, Diarrhea, Asthma, Oropharyngeal, and Abdominal Pain.
1615093|NCT02123602|Other|core stabilization|
1615094|NCT02123602|Other|lower extremity training only|
1615095|NCT02123589|Drug|Deep sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl,continuous intravenous infusion ; the target level of sedation,RASS score between -5 and -3
1615096|NCT02123589|Drug|Deep and daily interruption of sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl continuous intravenous infusion ; The target level of sedation,RASS score between -5 and -3. Daily interruption of sedation will be taken from the second day after admitted in ICU
1615097|NCT02123589|Drug|Light sedation(midazolam and fentanyl )|0.05~0.1mg/kg midazolam and 1~2μg/kg fentanyl,IV; 0.05mg/kg.h midazolam and1~2μg/kg.h fentanyl,continuous intravenous infusion ; The target level of sedation,RASS score between -2 and +1;
1615098|NCT02123576|Drug|Pentoxyfylline|
1615099|NCT02123576|Drug|Placebo|
1615100|NCT02123576|Drug|AMO Therapy|Albumin, midodrine and octreotide therapy (standard of care for HRS)
1615101|NCT02123563|Other|Ultrason Essential oils rinse|Test treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a commercially available non-prescription essential-oils solution (20mL, 30 seconds for each rinse) for 3 months. This solution is composed of eucalyptol 0.092%, menthol 0.042%, methyl salicylate 0.060%, thymol 0.064%, zinc chloride and sodium fluoride 0.0221%.
1615136|NCT02123342|Behavioral|Exercise programme plus SMS reminders|Participants will receive SMS reminders for their myPAtHS exercise programme compared to the other group where participants will only receive the myPAtHS exercise programme.
1615102|NCT02123563|Other|Ultrason Placebo rinse|Comparative treatment strategy combined mechanical and chemical procedures. Mechanical procedures were: a) ultrasonic debridement to remove dental plaque, calculus and teeth staining; b) dental polishing and c) oral hygiene instructions related to brushing and flossing. Toothbrush, dental floss and fluoride dentifrice were monthly provided. Within the same visit participants performed at the study center the first supervised rinse. Other rinses were performed at home unsupervised. A diary card was used to register times of rinsing. Participants rinsed twice a day a placebo solution (20mL, 30 seconds for each rinse) for 3 months.
1615103|NCT02123537|Device|Bioness L300 Foot Drop System|Participants will use the Bioness L300 Foot Drop System during waking hours for 12 weeks.
1615104|NCT02123524|Drug|Rivaroxaban|
1615105|NCT02123524|Drug|Placebo|
1615106|NCT02123511|Drug|acetylcysteine|Oral rinse
1615107|NCT02123511|Other|placebo|Oral rinse
1615108|NCT02123511|Other|quality-of-life assessment|Ancillary studies
1615109|NCT02123511|Other|questionnaire administration|Ancillary studies
1615110|NCT02123498|Drug|Omeprazole|40mg, to be taken once daily by mouth, 30-60 minutes before meals, for at least 6 weeks
1615111|NCT02123498|Drug|Ranitidine|300mg, to be taken once daily by mouth, before bedtime, for at least 6 weeks
1615112|NCT02123498|Drug|Pantoprazole|40mg, to be taken twice daily by mouth, 30-60 minutes before meals, for at least 6 weeks. (Alternative intervention if participant cannot tolerate omeprazole, is on an anticoagulant medication, or if on medication contraindicated for omeprazole and ranitidine)
1615113|NCT02123498|Procedure|24-Hour Diagnostic pH-Probe Test|Participants will undergo a routine clinical 24-hour diagnostic pH-probe test to assess quantitative measures for laryngopharyngeal reflux.
1615114|NCT02123498|Procedure|Laryngoscopy|Participants will undergo routine clinical laryngoscopy to assess presence of laryngopharyngeal reflux.
2010397|NCT02978508|Drug|Permethrin Cream, 5%|Subjects on Test product will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
2010398|NCT02978508|Drug|Elimite|Subjects on RLD will receive a maximum of two doses, 60 g each, during the study. The first dose will be applied on Day 1 in an outpatient setting, after the visit to the clinical site (preferably in the evening). The second dose will be applied on Day 14±2 only if retreatment is necessary.
1615117|NCT02123472|Drug|Cephalexin|Administered Orally
1615118|NCT02123459|Drug|Cephalexin|Administered orally
1615119|NCT02123446|Drug|Cephalexin|Administered orally.
1615120|NCT02123433|Biological|pneumococcal conjugate 13 valent vaccine|"Pneumococcal polysaccharide conjugate vaccine(13-valent adsorbed) conjugated to CRM197 carrier protein and adsorbed on aluminum phosphate (0.125 mg of aluminum).
Pharmaceutical form: suspension for injection. Dosage: 0.5 ml, containing 2.2 g of polysaccharide for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F, and 4.4 micrograms for serotype 6B.
Prevenar 13 is administered in two doses,each of 0.5 ml, with an interval of 2 months, injected intramuscularly in the deltoid muscle of the arm."
1615121|NCT02123420|Device|Nobel Replace Tapered Groovy implant; (Nobel Biocare®, Sweden)|"Both sites received tapered implants with an anodised surface, one site received: Nobel Replace Tapered Groovy PS implant; (Nobel Biocare, Goteborg, Sweden), with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (PS group), the contralateral site received Nobel Replace Tapered Groovy implant with Replace Select connection with diameters of 4.3 or 5.0 mm and lengths of 10 or 8 mm, (RP group).
Healing abutments were connected to implants at the same time of surgery , then flaps were sutured with Vicryl 4.0 sutures (Vicryl, Ethicon J&J International, St-Stevens-Woluwe, Belgium)."
1615122|NCT02123407|Drug|Carbon Nanoparticles|Carbon Nanoparticles will be injected into the subserosa of stomach around the tumor.Gastrectomy with D2 dissection will be performed after the injection.
1615123|NCT02123407|Procedure|Gastrectomy with D2 dissection|In the control arm,Gastrectomy with D2 dissection will be performed directly,without any coloring materials.
1615124|NCT02123394|Other|Placebo|The patients allocated to the Placebo group will be treated with detuned pulsed ultrasound therapy for 5 minutes and detuned short wave diathermy in pulsed mode for 25 minutes. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
1615125|NCT02123394|Other|McKenzie method|The patients of the McKenzie group will be treated according to the principles of the method and the choice of therapeutic intervention will be guided by the physical examination findings and classification. Patients will also receive written instructions from the Treat Your Own Back book and will be asked to perform home exercises based on the principles of McKenzie method. The description of the exercises that will be prescribed in this study are already published elsewhere. Compliance with home exercises will be monitored by means of a daily-log that the patient will fill in at home and bring to the therapist at each subsequent session. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week).
1615126|NCT02123381|Radiation|preoperative radiotherapy|"Patients receive intensity modulated radiation therapy(IMRT) or image-guided radiation therapy(IGRT)from week 1 to week 4,once a day, 5 times per week.
Radiotherapy dose：95% gross tumor volume（GTV-T） 40Gy/20f，GTV-N 40Gy/20f，CTV-T 40Gy/20f，CTV-N 40Gy/20f."
1615127|NCT02123381|Drug|cetuximab|400mg/m2/week, 2 hours,iv,at week 1;250mg/m2/week,1hour,iv,at week 2-4
1615131|NCT02123355|Drug|Induction of anesthesia|Midazolam 0.05 mg/kg、Propofol 1.0 mg/kg、Sufentanyl 3μg/kg、Victracurium 0.1 mg/kg sequential intravenous injection
1615132|NCT02123355|Procedure|Intubation|After muscle relaxed and loss of eyelash reflex of the patients, intubation is done,then mechanical ventilation is performed, and maintain the PETCO2于35~40 mmHg，pulse oxygen saturation is more than 95%.
1615133|NCT02123355|Drug|Sevoflurane, remifentanil ,vecuronium|Sevoflurane（1%-2%）is inspirated, and remifentanil 0.1-0.5μg/kg//min is continuously pumped,vecuronium 0.03 mg/kg is injected intermittently.
1615134|NCT02123355|Drug|Dexmedetomidine|Dexmedetomidine is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
1615135|NCT02123355|Drug|Placebo|Normal saline is given at 0.5μg/kg/h by continuous infusion and is stopped to given 30 minutes before the surgery is over.
1615299|NCT02122029|Behavioral|Lifestyle counselling|Behavioral techniques for weight management
2010399|NCT02979119|Drug|Coagulation proteins|Documentation of factor VIII and factor IX products from the first exposure day onwards
2010400|NCT02977507|Other|Lytera 2.0|Lytera 2.0 applied to the affected areas twice a day, morning and evening, everyday for 12 weeks.
1615139|NCT02123316|Biological|Pangramin Plus D. pteronyssinus|Subcutaneous immunotherapy with Dermatophagoides pteronyssinus
1615140|NCT02123316|Biological|Placebo|Placebo for subcutaneous injection
1615141|NCT02123290|Drug|DSM265 400mg|
1615142|NCT02123290|Drug|DSM265 xmg|Dose of DSM265 to be determined based on the results of the first cohort
1615143|NCT02123290|Drug|DSM265 ymg|Dose of DSM265 to be determined based on the results of the second cohort
1615144|NCT02123277|Device|Balloon catheter for the Eustachian tube|Balloon catheter is inserted in the Eustachian tube to dilate it.
1615145|NCT02123264|Drug|Zoledronic acid|Zoledronic acid: 5 mg/year x 2 years
2010401|NCT02977507|Drug|4% Hydroquinone Topical Cream|4% Hydroquinone Topical Cream applied to the affected areas twice a day, morning and evening, everyday for 12 weeks.
2010402|NCT02974868|Drug|PF-06651600|200 mg QD during induction and 50 mg QD during Maintenance
1615148|NCT02123238|Other|bed positioning|
1615149|NCT02123212|Other|Mailer|Henry Ford intentifies patients meeting birth cohort screening criteria and then sends mailers to those individuals. Mailers contained HCV guidelines, the importance of screening, laboratory slips and locations for patients to act directly on their own behalf. If patients do not respond to the initial mailer, Henry Ford sends additional mailers.
1615150|NCT02123212|Other|In-person recruitment|UAB used study coordinators to actively screen and recruit patients who met the inclusion criteria for birth-cohort screening. Study coordinators were located at two internal medicine clinics, where they approached eligible participants in person. A control group was pulled from an additional two internal medicine clinics, which screened using a risk-based strategy. A cross-over approach was used, so that the intervention and control clinics switched at the midpoint of data collection, allowing all four clinics to participate in both arms of the study.
1615151|NCT02123212|Other|EHR Alert|EHR include a Best Practice Alert (BPA) prompting the Medical Assistant and/or clinican to order a Hepatitis C lab test for patients in the birth cohort.
1615152|NCT02123199|Drug|Indacaterol (Onbrez®) /QAB149|
1615153|NCT02123186|Other|newborn screening test for SMA|Routine newborn screening dried blood spots sample is used to test if missing 2 copies of SMN1 gene.
1615154|NCT02123160|Behavioral|Child Parent Psychotherapy (CPP)|Child Parent Psychotherapy (CPP) is a multi-theoretical approach to enhance the caregiver-child relationship in the context of the caregiver's psychiatric history (e.g., depression) and/or caregiver/child exposure to traumatic events. Mother and child's in-session interactions are used to provide developmental guidance, and reinforce reciprocity between parent and child, affect regulation , continuity in daily living, and helping mother and child understand themselves and each other in the context of the maternal psychiatric functioning and/or familial exposure to trauma. When there is a history of trauma exposure for mother and/or child, mother and child create a joint narrative of the trauma, identify and address traumatic triggers, and focus on safety issues.
1615155|NCT02123160|Behavioral|Control (usual treatment)|Following Time 1 (pre-treatment) assessment, mother-child patient dyads randomized to the control group will be referred to usual treatment in the community for psychoeducation, counseling/ therapy for maternal depressive symptoms, and child behavioral/ emotional difficulties. Control patient dyads will be closely monitored through regular contact with the study research assistant and follow up by a licensed study clinician to assess mother/ child's psychiatric functioning and make necessary referrals to alternative treatments or arrange an emergency evaluation, if needed.
1615156|NCT02123134|Drug|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
1615157|NCT02123134|Drug|Placebo|Phosphate buffered saline placebo for injection
1615158|NCT02123121|Drug|Resveratrol 1000 mg/day|Orally consume resveratrol 1000 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
1615159|NCT02123121|Drug|Resveratrol 1500 mg/day|Orally consume resveratrol 1500 mg/day capsule following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
1615160|NCT02123121|Other|Vegetable cellulose|Orally consume placebo vegetable cellulose capsule a day following each main meal (i.e. breakfast, lunch, and dinner), (i.e. take 3 capsules per day) for 90 Days.
1615161|NCT02123121|Other|All groups|All Participants will have the following done: Physical Exams, Physical Measurements, Medical History, Questionnaires, Blood Samples, Tests of physical performance, and muscle tissue samples.
1615162|NCT02123108|Drug|Basiliximab|Peri-operative 40 mg IV dose and 20mg IV postoperative dose will be given in the treatment arm
1615163|NCT02123082|Device|Storz single Lumen Ureteroscope|Single lumen, flexible scope for ureteroscopies
1615164|NCT02123082|Device|Dual Lumen Ureteroscope|Dual lumen, flexible scope for ureteroscopies
1615165|NCT02123069|Device|Brachial artery catheter|A catheter will be placed in the brachial artery by a physician on the study day.
1615166|NCT02123069|Drug|Acetylcholine|Acetylcholine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Acetylcholine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
2010403|NCT02974868|Drug|PF-06700841|60 mg QD during induction and 30 mg QD during maintenance
2010404|NCT02974868|Drug|Placebo|Placebo
2010405|NCT02974621|Biological|Bevacizumab|Given IV
2010406|NCT02974621|Drug|Cediranib Maleate|Given PO
2010407|NCT02974621|Other|Laboratory Biomarker Analysis|Correlative studies
2010408|NCT02974621|Drug|Olaparib|Given PO
2010409|NCT02974023|Device|Pain Gear|PainGear [ActiPatch®] (BioElectronics Corporation, MD, USA) has been recently introduced as an 'topical' analgesic for localized musculoskeletal pain. PainGear is a noninvasive, low power, easy to use, pulsed shortwave therapy device for localized musculo¬skeletal pain.
2010410|NCT02973789|Device|NovoTTF-100L|Patients receive continuous TTFields treatment using the NovoTTF-100L device. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the chest. The treatment enables the patient to maintain regular daily routine.
2010411|NCT02973789|Drug|PD1 inhibitors or docetaxel|Patients receive standard of care with PD1 inhibitors or docetaxel
1615167|NCT02123069|Drug|Nitroprusside|Nitroprusside will be infused into the brachial catheter while blood flow levels in the forearm are measured. Nitroprusside will be infused at the following doses: 0.25, 0.5, 1.0, and 2.0 ug/100 ml tissue/min for 2 minutes each.
1615168|NCT02123069|Drug|Norepinephrine|Norepinephrine will be infused into the brachial catheter while blood flow levels in the forearm are measured. Norepinephrine will be infused at the following doses: 1.0, 2.0, 4.0, and 8.0 ug/100 ml tissue/min for 2 minutes each.
1615169|NCT02123069|Drug|Nitroprusside and phenylephrine|A single dose of nitroprusside (100 ug) will be infused through an IV; one minute later, a single dose of phenylephrine (150 ug) will be infused.
1615170|NCT02123056|Drug|Metoprolol|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
1615171|NCT02123056|Drug|Matching Placebo|the daily dose range is 25mg twice a day to a maximum of 100mg twice a day
1615172|NCT02123043|Behavioral|Motor learning-based training|The motor learning-based training will focus on some of the core concepts in the field of motor learning. The key concepts will include variable practice with respect to speed, feedback (both intrinsic and extrinsic but focusing on extrinsic), feedback focusing on three main variables (wheeling pattern, speed of hand when contacting push rim, push angle), sequential learning (specifically relating to wheeling pattern), and mental imagery (during the rest breaks).
1615173|NCT02123043|Behavioral|Practice wheeling|The practice wheeling will consist of the same amount of wheeling exposure compared to the motor learning-based training group, however no feedback regarding an individuals's wheeling will be provided. Participants randomized to this group will wheel for two 5-minute trials/ visit for 6 visits for a total of 60 minutes of wheeling exposure.
1615174|NCT02123017|Drug|90 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 30 grams crystalline lactulose x 3 doses
1615175|NCT02123017|Drug|135 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 45 grams crystalline lactulose x 3 doses
1615176|NCT02123017|Drug|180 grams of Crystalline Lactulose|15 mg of bisacodyl, plus 60 grams crystalline lactulose x 3 doses
1615177|NCT02123004|Drug|Ticagrelor|180mg loading dose for one day ,and then 90mg per day for 4 weeks
1615178|NCT02123004|Drug|Clopidogrel|300mg loading dose for one day ,and then 75mg per day for 4 weeks
1615179|NCT02122978|Behavioral|Mindfulness Based Cognitive Therapy|MBCT 8 week course delivered by trained facilitator
1615180|NCT02122978|Behavioral|MBSC - minimal contact|8 week course in Mindfulness Based Self Compassion delivered remotely by audio guided MP3
1615181|NCT02122978|Behavioral|Mindfulness Based Self Compassion Therapy|Mindfulness Based Self Compassion Therapy - 8 wee course delivered by trained facilitator
1615182|NCT02122965|Other|Pharmacist-led medication review|Medication review is a structured, critical examination of a patient's medications with the objective of reaching agreement with the patient about treatment, optimizing the medications' impact, and minimizing the number of medication-related problems and adverse drug events.
1615183|NCT02122952|Biological|AVXS-101|Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
1615184|NCT02122939|Drug|Escitalopram|
1615185|NCT02122926|Other|Intensive discharge intervention|"The intervention is a multi-modal program consisting of the following:
Inpatient protocol for adjusting the discharge diabetes regimen;
Nurse practitioner discharge advocate to schedule follow-up appointments, prepare an after-hospital care plan, and patient education and counseling;
Inpatient pharmacist counseling (identifying and addressing previous barriers to medication adherence, performing enhanced medication reconciliation, and patient education);
Visiting nurse intervention after discharge;
Follow-up in a post-discharge clinic with the NP discharge advocate and pharmacist /certified diabetes educator within 3 days of discharge;
Telemonitoring of POC glucose levels to the study CDE, patient's PCP, or endocrinologist as appropriate; and
Follow-up with PCP or endocrinologist within 1 week of discharge."
1615186|NCT02122913|Drug|Larotrectinib|Oral larotrectinib
1615187|NCT02122887|Behavioral|Peace-Building Intervention Process|"The eight sessions include (1) presentation of the self to others members (2) getting familiar with the other culture (3) what is a conflict - how do conflicts come about, what are adaptive and non-adaptive modes of resolving conflict (4) getting to know the Other - preconceived notions about the other side (5) on dialogue- what is dialogue, can dialogue offer means for conflict resolution, what are the benefits of dialogue to inter-cultural and inter-racial conflicts, (6) empathy, generosity, and kindness (7) wrapping up - hopes for the future at the personal and community levels, practical suggestions (8) goodbye and summary - what have we learned ,gift giving, summary of process by group leaders."
1615188|NCT02122874|Device|Percutaneous Neurostimulation (PENS) of dermatome T7|The patients undergo PENS of dermatome T7 and follow a 1200 Kcal diet
1615189|NCT02122874|Other|1200 Kcal diet|
1615190|NCT02122861|Biological|ID-LV305|pembrolizumab
1615191|NCT02122848|Device|BiLevel|The intervention will be performed using BiLevel ventilation mode with EPAP=10 cmH2O and a IPAP which manages 6-8ml/kg tidal volume.
1615192|NCT02122835|Behavioral|aerobic exercise training|12 weeks of supervised aerobic exercise training
1615193|NCT02122822|Biological|gp96|vaccination of autologous gp96 derived from tumor tissue + basal treatment
1615194|NCT02122809|Drug|Chiauranib|Take orally
1615196|NCT02122783|Device|ADR™ brace resistance|
1615197|NCT02122783|Device|Conventional brace resistance (using hard stops)|Conventional polypropylene custom molded ankle foot orthosis (MAFO) with Lawrence style double channel adjustable joints containing pins/springs
1615198|NCT02122770|Drug|MLN4924|MLN4924 Intravenous Solution
1615199|NCT02122770|Drug|Fluconazole|Fluconazole Tablets
1615200|NCT02122770|Drug|Itraconazole|Itraconazole Oral Solution
1615201|NCT02122770|Drug|Docetaxel|Docetaxel Intravenous Solution
1615202|NCT02122770|Drug|Carboplatin|Carboplatin Intravenous Solution
1615203|NCT02122770|Drug|Paclitaxel|Paclitaxel Intravenous Solution
1615204|NCT02122757|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular anodal tDCS increases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
1615300|NCT02122029|Procedure|Bariatric Surgery|Vertical Banding Gastroplasty
1615205|NCT02122744|Device|Super Rapid Magstim Stimulator|"The repetitive transcranial magnetic stimulation (rTMS) is able to modify cortical excitability and reactivity. 1Hz rTMS inhibits the cortex, 10Hz excites it. In particular, a new paradigm of rTMS, the rTMS quadri pulse has a more lasting and effective activity.
The side effects are rare and transient: migraine,contractions of the muscles of the neck due to muscle stimulation by the electromagnetic field of the coil."
1615206|NCT02122731|Drug|Amiloride|5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
1615207|NCT02122718|Drug|Allopurinol|
1615208|NCT02122718|Drug|Placebo|
1615209|NCT02122705|Device|VPIA remifentanil|Vital signs controlled patient assisted intravenous analgesia using remifentanil
1615210|NCT02122692|Drug|Lu AE58054 30 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 1-5, orally
1615211|NCT02122692|Drug|Lu AE58054 30 mg + itraconazole 200 mg|Lu AE58054 encapsulated film-coated tablets, once daily, Day 6-11, orally + itraconazole capsules, once daily, Day 6-11, orally
1615212|NCT02122692|Drug|Itraconazole|Itraconazole capsules, once daily, Day 12-13, orally
1615213|NCT02122679|Drug|Tranexamic Acid|
1615214|NCT02122679|Drug|placebo|
1615215|NCT02122666|Procedure|muscle biopsy|A member of the study team will obtain a small sample of muscle tissue from the patient's thigh (vastus lateralis muscle).
1615216|NCT02122653|Other|Weight training|Participants will perform 4 weeks of Weight training for lower extremities.
1615217|NCT02122653|Device|Electronic muscle stimulator|Participants will perform 4 weeks of electrical stimulation for Quadriceps muscle belly.
1615218|NCT02122627|Drug|Vitamin D|Colecalciferol 16.800 IU per week
1615219|NCT02122627|Drug|Placebo|
1615220|NCT02122614|Behavioral|Pulmonary rehabilitation (PR) plus PA monitoring and feedback from a pedometer|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week). Patients will also receive a pedometer to self-monitor their PA during and after the PR program and individualized step-count goals.
1615221|NCT02122614|Behavioral|Pulmonary rehabilitation (PR)|Patients will enrol in a 12-week PR program comprising exercise training (3 times per week) and psychoeducation sessions (once a week).
1615222|NCT02122601|Drug|LBSA0103 (BDDE cross-linked sodium hyaluronate gel)|
1615225|NCT02122549|Device|HWD1000|Wearable cardioverter-defibrillator designed for inpatient use
1615226|NCT02122536|Drug|Xeomin to right side of face in half of the subjects; Xeomin to left side of face in the other half of subjects|Subjects were randomized to which side of the face would be treated with Xeomin.
1615227|NCT02122536|Drug|Botox to right side of face in half of the subjects (randomized); Botox to the left side of the face in the other half of subjects|Subjects were randomized to which side of the upper face would be treated with Botox
1615228|NCT02122523|Procedure|Near-Infrared (NIR) dye Indocyanin Green (ICG)|
1615229|NCT02122510|Drug|Bupivacine group|Bupivacaine group(n=30) will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
1615230|NCT02122510|Drug|Dexmedetomidine|Dexamedtomedine group will receive post-delivery bilateral TAP block with 10 ml of bupivacaine 0.5 % mixed with 10 ml saline and 10 μg dexmetonedine in 20 ml syringe
1615231|NCT02122497|Procedure|abdominal aortic surgery|
1615232|NCT02122484|Drug|Colchicine|colchicine p.os 0.5 mg bid for two days before undergoing elective CABG surgery and eight days after the operation
1615233|NCT02122471|Drug|Plecanatide|
1615234|NCT02122471|Drug|Placebo|
1615235|NCT02122458|Device|mild-gain hearing aids|open-fit hearing aids with mild amplification in the high frequencies.
1615236|NCT02122445|Device|Cramer Sports Motion Tape|lower body exercises with and without Cramer Sports Motion tape applied to the hip
1615237|NCT02122432|Other|Teledermatology|"General practitioner takes 3 photographs per dermatologic lesion using either a telephone with a 3Mega Pixel minimum camera or a standard camera following recommendations of the practice guidelines for teledermatology (2007) of the American Telemedicine Association.
Photographs are sent by email using a secured mail server with at least the following information=date of symptoms, symptomatology, topography of lesions, description of lesions, extension, recent drug intakes)
Photographs are read and analyzed by a single dermatologist who gives an expert answer (diagnosis and/or treatment). Answer is sent back to the general practitioner by email (using a secured mail server). Answer contains at least the following information= are photographs usable? What is the diagnosis? If necessary, which treatment should the general practitioner begin ? If necessary, does the patient need a consultation with a dermatologist ?"
1615238|NCT02122419|Other|lateral|spinal anesthesia performed during lateral position
1615239|NCT02122419|Other|sitting|spinal anesthesia performed during sitting position
1615240|NCT02122406|Other|Hospital Anxiety and Depression Scale (HADS) questionnaire|Patients filled in the Hospital Anxiety and Depression Scale (HADS) questionnaire
1615241|NCT02122393|Drug|Sertraline|
1615242|NCT02122393|Behavioral|Cognitive Behavioural Therapy|
1615243|NCT02122380|Drug|Sitagliptin|Sitagliptin 100 mg by mouth daily for 30 Days
1615244|NCT02122380|Drug|Placebo|1 placebo pill by mouth per day for 30 days
1615245|NCT02122367|Other|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada)|HES 130/0.4 (VolulyteⓇ, Fresenius Kabi, Canada) 6ml/kg of ideal body weight loading
1615246|NCT02122354|Behavioral|"Hide and Seek videogame"|
1615247|NCT02122341|Device|BackStop|BackStop™ is a FDA approved device. It is intended for use during ureteroscopic lithotripsy to prevent retrograde migration of stones and stone fragments. It is comprised of a solution of a thermosensitive polymer, a purified version of poloxamer 407 having been fractionated in saline. BackStop™, which is injected above the stone, is provided in sterile, pre-filled 2.5ml and 5ml syringes along with and a corresponding injector and a catheter (3F or 5F).
1615248|NCT02122328|Procedure|Sequential laser photocoagulation of communicating vessels.|
1615249|NCT02122328|Procedure|Selective laser photocoagulation of communicating vessels|
1615409|NCT02121262|Procedure|Laser Photocoagulation|Laser photocoagulation on day 1, and on months 3, 6, and 9, if retreatment indicated.
1615250|NCT02122315|Other|Physical therapy plus dry needling|Best-evidence physical therapy intervention in addition to a single session of TrP-DN targeted to active TrPs in the neck-shoulder muscles
1615251|NCT02122315|Other|Physical therapy|Best-evidence physical therapy intervention
1615252|NCT02122302|Device|CarePrep Online Health Assessment|Patients can utilize a web-based self-assessment system to answer questions that address medical, psychological, social, behavioral, and quality-of-life issues that are relevant to pancreatic disease. Patients can enter and track their symptoms over the Internet from home or clinic. The system is also designed to gather clues to identify neuropathic pain, which occurs when the nervous system fails to properly regulate pain signals.
1615253|NCT02122289|Device|Application of Smartphone|Weekly questionnaire on smartphone
1615254|NCT02122289|Other|No application Smartphone|No weekly questionnaire on smartphone
1615255|NCT02122276|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch exercise on ankle.
1615256|NCT02122250|Behavioral|Interactive web-based materials|Interactive web-based materials for self-management of diabetes
1615257|NCT02122250|Behavioral|Static web-based materials|Static web-based materials
2010412|NCT02972788|Drug|Enamel Matrix Proteins Derivative|Enamel matrix proteins derivative will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
1615259|NCT02122224|Other|High fiber breakfast|Breakfast will contain 10-11g fiber.
1615260|NCT02122224|Other|High Protein Breakfast|Breakfast will contain 19-20g of protein.
1615261|NCT02122224|Other|High Protein/High Fiber Breakfast|Breakfast will include 19-22g of protein and 10-12g of fiber.
1615262|NCT02122211|Drug|Betaine supplement|
1615263|NCT02122198|Drug|Leuprolide acetate|Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 9 months. First 6 months under parent study (FAME) protocol (NCT01712230); months 6-9 under sub-study.
1615264|NCT02122198|Drug|Estradiol|Climara transdermal patch 0.075mg/day applied weekly months 6-9
1615265|NCT02122198|Drug|Medroxyprogesterone|Provera 5mg tablets once daily by mouth for 12 days beginning at week 30.
1615266|NCT02122198|Drug|Placebo|placebo
1615267|NCT02122185|Drug|paclitaxel|Given IV
1615268|NCT02122185|Drug|carboplatin|Given IV
1615269|NCT02122185|Drug|docetaxel|Given IV
1615270|NCT02122185|Drug|metformin hydrochloride|Given PO
1615271|NCT02122185|Drug|placebo|Given PO
1615272|NCT02122185|Other|laboratory biomarker analysis|Correlative studies
1615273|NCT02122172|Drug|afatinib dimaleate|Given PO
1615274|NCT02122172|Other|laboratory biomarker analysis|Correlative studies
1615275|NCT02122159|Biological|MA09-hRPE Cellular Therapy|A suspension of either 50,000 MA09-hRPE cells (first cohort), 100,000 MA09-hRPE cells (second cohort), 150,000 MA09-hRPE cells (third cohort) or 200,000 MA09-hRPE cells (fourth cohort) in 150 uL of BSS plus will be implanted over 1 minute in the space created.
2010413|NCT02972788|Other|Saline|Saline will be placed in deep periodontal pocket during routine periodontal maintenance therapy.
2010414|NCT02970981|Biological|Nivolumab|
1615278|NCT02122133|Device|PC 400|
1615279|NCT02122120|Dietary Supplement|HEN|Patients with tube feeding with FSMP for at least twelve months
1615280|NCT02122094|Behavioral|Sexual Health Promotion Intervention|The seven core modules are 1) the Importance of Sexual Health, 2) Sexual Diversity, 3) HIV and other STIs, 4) Behavioral Risk and Risk Reduction, 5) Alcohol and Drugs, 6) Stigma and 7) Health Seeking Practices. The five optional modules are 1) HIV Treatment and Adherence, 2) Stress Reduction, 3) HIV Status Disclosure, 4) MSM/Gay Disclosure, and 5) Other Sexual Health Concerns
2010415|NCT02970981|Biological|Ipilimumab|
2010416|NCT02970864|Device|Polynerve|Polymer biomaterial nerve conduit
2010417|NCT02969356|Drug|AbobotulinumtoxinA (Dysport®)|Dysport® administered in both upper and lower limbs (total dose of 1500 U per injection split between the 2 limbs) plus daily GSC therapy.
2010418|NCT02969044|Drug|Placebo|
2010419|NCT02969044|Drug|PF-06651600|200mg pill every day (QD) for 8 weeks
2010420|NCT02967211|Drug|insulin glargine (U300)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2010421|NCT02967211|Drug|insulin glargine (U100)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2010422|NCT02967211|Drug|NPH insulin|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2010423|NCT02967211|Drug|insulin detemir|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1615290|NCT02122068|Behavioral|Central Meditation and Imagery Therapy|4 week long meditation and mindfulness intervention
1615291|NCT02122068|Behavioral|Relaxation cd|
1615292|NCT02122055|Drug|Fentanyl|Fentanyl 0.7-1μg/kg，prn pain assessment is done every 4 hours，maintain Behavioral Pain Scale（BPS） 0-2.
1615293|NCT02122055|Procedure|Sedation assessment|Sedation assessment is done every 4 hours,maintain the Riker Sedation Agitation Score(SAS) 3-4.
1615294|NCT02122055|Procedure|Screen of weaning|1. Screen of weaning is done at 8:00 every morning. 2 If the patient is successful to wean, stop the Dexmedetomidine sedation. 3. If failed to wean, the patient is ventilated again and try to wean after 24 hours, until it is successful to wean and stop sedation，
1615295|NCT02122055|Drug|Propofol|Propofol is started with dosage of 0.3 mg/kg/h, observe the patient's response, increase 0.3 mg/kg/h propofol every 10 minutes until target sedation level is obtained(Riker Sedation Agitation Score(SAS) 3-4),then 0.3-3 mg/kg/h propofol is maintained.
1615296|NCT02122055|Drug|Midazolam|Midazolam 2 mg is slowly titrated to Riker Sedation Agitation Score(SAS) 3-4 every 10 minutes, then Midazolam 0.02-0.1 mg/kg/h is maintained.
1615297|NCT02122055|Drug|Dexmedetomidine|After the screen of the weaning is passed, change to Dexmedetomidine sedation, the dose is 0.2-0.7 mg/kg/h and continuously pumped, increase the dose 0.1-0.2 mg/kg/h every 30 minutes, titrate to Riker Sedation Agitation Score(SAS) 3-4，the maximum dose is 1 mg/kg/h maintained，and prepare for weaning.
1615298|NCT02122042|Biological|HBOT|
2010424|NCT02967211|Drug|insulin degludec|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2010425|NCT02967523|Device|DEB-TACE with Surefire Precision Infusion System|Subjects have undergone/will undergo DEB-TACE using the Surefire Precision Infusion System.
1615301|NCT02122016|Device|SmartCare|Ventilator with a SmartCare module that is capable of performing a computer-driven weaning trial taking into account patients lung mechanics and exaled CO2.
1615302|NCT02122016|Other|Conventional weaning protocol|A conventional weaning protocol performed by physiotherapist with a daily weaning screen and a spontaneous breathing trial
1615303|NCT02122003|Drug|Sorafenib|Sorafenib 400 mg bid
1615304|NCT02121990|Drug|Paclitaxel,|
1615305|NCT02121990|Drug|Bevacizumab|
1615306|NCT02121990|Drug|Cisplatin|
1615307|NCT02121990|Drug|Olaparib|
1615308|NCT02121977|Device|Elevate Anterior and Apical|
1615309|NCT02121977|Procedure|Native Tissue Repair for pelvic organ prolapse|
1615310|NCT02121964|Procedure|Capsulectomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulectomy during total hip arthroplasty.
1615311|NCT02121964|Procedure|Capsulotomy in Direct Anterior Total Hip Arthroplasty|Surgical intervention in which the surgeon will perform anterior capsulotomy during total hip arthroplasty. Surgeon will repair the joint capsule.
1615312|NCT02121951|Procedure|Local Anesthetic infiltration|Lignocaine infiltration through the nephrostomy track
1615313|NCT02121951|Procedure|Quadratus Lumborum block|A linear 12-MHz ultrasound probe will be placed in the anterior axillary line to visualize the typical triple abdominal layers. Then, the probe will be placed in the midaxillary line and at this point the layers of abdominal layers starte to taper. The probe will be placed in the posterior axillary line, sonoanatomy will show first the transversus abdominis disappearing then the internal oblique and external oblique forming aponeurosis and appearance of QL will be noticed. At the posterior border of the quadratus lumborum muscle and outside the fascia, Touhe needle will be inserted in plane and confirmed its position by injecting saline. Under ultrasound (US) guidance, local anesthetic mixure will be deposited separating the fascia
1615314|NCT02121951|Drug|MAC|Incremental doses are given to the targed sedation and analgesia
2010426|NCT02967133|Drug|Nivolumab|"Arm A: Nivolumab 240 mg via intravenous infusion (IV) over 30 minutes day 1 of each 14 day cycle until disease progression or not tolerated.
Arm B: Nivolumab 360 mg via intravenous infusion (IV) over 30 minutes day 1 of every 21 day treatment cycle until progression or not tolerated."
2010427|NCT02967133|Drug|nab-paclitaxel|Patients in arm B receive nab-paclitaxel at a dose of 100 mg/m2 over intravenous infusion on Days 1 and 8 of each 21 day cycle.
1615317|NCT02121886|Procedure|venous reconstruction with the parietal peritoneum|
1615318|NCT02121873|Device|Nipple aspirator|The subject will undergo nipple aspiration with a suction device designed to elicit fluid from the nipple.
1615319|NCT02121873|Device|Ductal lavage microcatheter|Upon completion of the nipple aspiration procedure, subjects will undergo a nipple block with local anesthesia. The duct will be lavaged with the ductal lavage microcatheter. Samples will be immediately processed for shipping to Covance for WGS. Subjects will be contacted 24 hours and again 2 weeks after the procedure to collect any untoward effects of participating in the study.
1615320|NCT02121873|Device|Blood draw|Blood will be drawn and immediately processed for shipping to Covance for WGS.
1615321|NCT02121860|Drug|IDN-6556|
1615322|NCT02121847|Drug|cyclosporine 0.05% ophthalmic emulsion|Cyclosporine 0.05% ophthalmic emulsion (Restasis®) eye drops administered twice daily for 6 months.
1615323|NCT02121847|Drug|carboxymethylcellulose-based lubricant eye drops|Carboxymethylcellulose-based lubricant eye drops (Refresh OPTIVE® Advanced) administered as needed for 6 months.
2010428|NCT02967224|Drug|insulin glargine (U300)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2010429|NCT02967224|Drug|insulin glargine (U100)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1615326|NCT02121821|Behavioral|SMS reminder messages|The study is prospective and interventional comparing differences between pregnant women who receive reminder messages via the SMS Mother Reminder system to those who are not. Pregnant women will be followed from their first ANC visit at a health facility through delivery. The study will examine the effect of the mobile phone intervention on attendance to ANC appointments and IPTP2 coverage. The intervention group will be composed of pregnant women receiving SMS reminder messages in comparison with a control group of pregnant women receiving no intervention (i.e. no SMS reminders).
2010430|NCT02967224|Drug|NPH insulin|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1615329|NCT02121795|Drug|FTC/TDF|200/300 mg FDC tablets administered orally once daily
1615330|NCT02121795|Drug|F/TAF|Tablets administered orally once daily
1615331|NCT02121795|Drug|Allowed third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir-boosted atazanavir (ATV/r), ritonavir-boosted lopinavir (LPV/r), ritonavir-boosted darunavir (DRV/r), efavirenz (EFV; Sustiva®), rilpivirine (RPV; Edurant®), nevirapine (NVP;Viramune®), raltegravir (RAL; Isentress®), dolutegravir (DTG;Tivicay®), and maraviroc (MVC; Selzentry®).
1615332|NCT02121795|Drug|FTC/TDF Placebo|Tablets administered orally once daily
1615333|NCT02121795|Drug|F/TAF Placebo|Tablets administered orally once daily
1615334|NCT02121782|Biological|Quadrivalent influenza vaccine|GC3110A, 0.5ml, intramuscular, a single dosing at Day 1
1615335|NCT02121782|Biological|Trivalent influenza vaccine|GC Flu Pre-filled Syringe Inj., 0.5ml, intramuscular, a single dosing at Day 1
1615337|NCT02121756|Drug|Dipyridamole|Dipyridamole 100 mg 4 times daily for 24 weeks
1615338|NCT02121756|Drug|Placebo, then Dipyridamole|Dipyridamole placebo 1 capsule 4 times daily for 12 weeks, then Dipyridamole 100 mg 4 times daily for 12 weeks.
1615339|NCT02121743|Device|strattice|use of a strattice
1615340|NCT02121743|Procedure|No strattice|no use of a strattice
1615341|NCT02121717|Drug|Chiglitazar|Take orally
1615342|NCT02121717|Drug|Placebo|Take orally
1615343|NCT02121704|Device|Magnetic Endoscope Imaging (Scope Guide)|
1615344|NCT02121691|Behavioral|Walk by Faith|The Walk by Faith program is aimed at increasing physical activity and improving healthy eating to reduce or maintain healthy BMI among members of the churches.
1615410|NCT02121249|Device|Renaissance, Mazor Robotics Ltd, Caesare, Israel|Renaissance (Mazor Robotics Ltd, Caesare, Israel) is the name of the robot
1615411|NCT02121249|Procedure|free hand technique|"No specific device is necessary in the free hand technique"
1615345|NCT02121678|Other|Resistance training|"Participants do resistance training of selected muscle groups. Resistance are predefined from 1-repetition max (1-RM) and increased during the 12 weeks of training:
Week 0-4: 70-80 % of 1-RM
Week 5-8: 75-86 % of 1-RM
Week 9-12: 80-92% of 1-RM
Participants trains unilateral, the opposite site serves as reference.
MMN patients train elbow (flexion/extension) and wrist (flexion/extension)
CIDP patients train knee (flexion/extension) and elbow (flexion/extension)"
1615346|NCT02121678|Other|Aerobic training|"Participants train on ergometer bicycle 2 times weekly increasing during the first weeks to 3 times weekly. Workload is measured before initiation and VO2-max, heart rate and blood pressure will be measured as well.
Patients train with 60-75 % of VO2-max for 30 minutes per training session. They use heart rate monitor to store data."
1615347|NCT02121665|Drug|Probiotic (Inersan)|Each Inersan lozenge contains not less than 1 billion CFU of Lactobacillus brevis CD2
1615348|NCT02121665|Drug|Placebo|Each placebo lozenge contains all excipients except the active constituent (Lactobacillus brevis CD2)
1615349|NCT02121652|Behavioral|Cognitive behavioral therapy for insomnia|Cognitive behavioral therapy for insomnia includes content on sleep restriction, stimulus control, relaxation, cognitive restructuring and sleep hygiene content delivered in a 90 minute group intervention with two follow up phone calls.
1615350|NCT02121652|Behavioral|Healthy eating control|Healthy eating control involves healthy eating content delivered in a 90 minute group session with two follow up phone calls.
1615351|NCT02121639|Drug|Placebo|
1615352|NCT02121639|Drug|AZD5363|
1615353|NCT02121613|Drug|Permixon® 160 mg|Oral administration - 160 mg twice daily.
1615354|NCT02121613|Drug|Tamsulosine LP|Oral administration - 0.4 mg daily.
1615355|NCT02121613|Drug|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
1615356|NCT02121613|Drug|Placebo matching Tamsulosine LP|Oral administration - daily.
1615357|NCT02121600|Other|[F-18]-FCH|Before the PET/MRI or PET/CT scan, patients will receive an [F-18]-Fluorocholine injection in the arm.
1615358|NCT02121600|Radiation|PET scan|A whole body PET scan will be performed, combined with either whole body MRI or CT scan. This will be performed at baseline and after 12 weeks of treatment
1615359|NCT02121600|Radiation|MRI scan|Whole body MRI scan will be performed. This may be combined with PET scan or may be performed separately. MRI scan will be done at baseline and after 12 weeks of treatment
1615360|NCT02121587|Behavioral|Pain self-management course|This is an observational study of patient-reported outcomes from an experiential pain self-management course which integrates mindfulness and acceptance-based exercises into osteopathic manual therapy treatment. The intervention consists of six, individual, one-hour osteopathic evaluation and treatment sessions which incorporate pain education, the development of mindfulness skills to enhance body awareness, and the identification of personal values to promote compassionate self-care and sustain commitment to active coping strategies. The intervention aims to enhance patients' well-being and resilience through developing psychological and behavioural flexibility in response to persistent pain.
1615361|NCT02121574|Device|Zero flux and ingestible thermometers|
1615362|NCT02121561|Behavioral|Self-Acceptance Group Therapy|SAGT is an 8-week group therapy for persons with high levels of shame focused on providing psychoeducation regarding shame and self-acceptance and teaching skills for effectively responding to shame. SAGT is based on a cognitive-behavioral framework. Group members are taught how to recognize and challenge shame-eliciting thoughts, effectively discuss shame-eliciting topics with others, and build self-acceptance. Group members also complete weekly homework assignments that allow them to practice their new skills. All sessions include a review of homework and previously discussed concepts, introduction of new material, and in-session discussions/activities. The content of SAGT includes: defining self-acceptance and recognizing shame; increasing balanced thinking about oneself; improving social connections; increasing skillful interpersonal disclosure; challenging unhelpful expectations; handling setbacks; review and commitment to future practice.
1615363|NCT02121548|Behavioral|CHW Outreach and HPV Self-sampling|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes. Women who are randomized to this arm will also include information on the alternative screening method. They will be told that cervical self-sampling is an alternative screening technique for the Pap smear and they will be offered the choice of having the HPV screen done during that home visit or have a Pap Smear at the participating FQHC.
1615364|NCT02121548|Behavioral|CHW Outreach|The intervention strategies will involve three overlapping domains 1)provide health education on cervical cancer screening, 2) motivation to encourage women to have screening 3) provide navigation services to obtain the screening. We envision visits lasting no more than 60 minutes.
1615365|NCT02121535|Drug|T80/A5 mg FDC tablet|
1615366|NCT02121535|Drug|T80/A5 mg FDC tablet|A Telmisartan 80 mg/ Amlodipine 5 mg FDC tablet
1615367|NCT02121535|Drug|H12.5 mg tablet|
1615368|NCT02121535|Drug|T80/A5/H12.5 ng FDC tablet|A Telmisartan 80 mg/Amlodipine 5 mg/HCTZ 12.5 mg FDC tablet
1615369|NCT02121535|Drug|H12.5 mf tablet|A HCTZ 12.5 mg tablet
1615370|NCT02121535|Drug|T80/A5/H12.5 mg FDC tablet|
1615371|NCT02121522|Drug|BI 144807|twice daily
1615372|NCT02121509|Drug|Linagliptin|1 x Linagliptin tablet
1615373|NCT02121509|Drug|Linagliptin/Metformin ER FDC|2 x Linagliptin/Metformin ER FDC tablet
1615374|NCT02121509|Drug|Metformin ER|3 x Metformin ER tablets
1615375|NCT02121496|Behavioral|Resources for Postpartum Parenting|The intervention includes four-sessions that targets maternal caregiving of young infants to increase infant sleep and reduce fuss/cry behavior and thereby simultaneously consolidate women's enjoyment of and confidence in their maternal role, this, in turn, promotes a cycle of a mutually re- warding engagement in the mother-infant dyad — the antithesis of a 'toxic' experience, and a strong foundation for improving the chances of a successful psychosocial adjustment, including adequate employment. Investigators believe PREPP holds tremendous promise as an intervention to fill the science-practice gap in the promotion of an optimal emotional environment for the developing infant, particularly for women and children living in poverty and/or facing significant psychosocial hardship.
1615376|NCT02121483|Drug|empagliflozin medium dose|
1615377|NCT02121483|Drug|empagliflozin high dose|
1615378|NCT02121483|Drug|empagliflozin low dose|
1615379|NCT02121457|Dietary Supplement|Brazil nut|Participants of the treatment group were instructed to take one Brazil nut daily during 6 months. Brazil nuts were supplied in 2-month allowances at no cost together with written nutritional information and a calendar to monitor the compliance. Compliance was monitored in intervals of 2 months by checking the calendar and counting returned nuts. Compliance was considered to be adequate if ≥85% of Brazil nuts were consumed. All subjects were instructed to maintain their normal diet and to avoid additional Brazil nuts during the study.
1615380|NCT02121457|Dietary Supplement|selenium|
2010431|NCT02967224|Drug|insulin detemir|"Pharmaceutical form: solution
Route of administration: subcutaneous"
2010432|NCT02967224|Drug|insulin degludec|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1615383|NCT02121431|Behavioral|Triple P--Positive Parenting Program|The Triple P--Positive Parenting Program (Triple P), which has an extensive evidence base, is grounded in a common set of core principles of positive parenting and draws on a broad menu of parenting strategies. A key provision of Triple P is that parents are the decision-makers about program goals and selection/implementation of specific parenting strategies consistent with their preferences and values.
1615384|NCT02121418|Drug|Cytarabine|Given IV
1615385|NCT02121418|Drug|Decitabine|Given IV
1615386|NCT02121418|Other|Laboratory Biomarker Analysis|Correlative studies
1615387|NCT02121405|Procedure|Rectectomy|Include anterior resection or abdominoperineal resection by open or laparoscopy with Total Mesorectal Excision (TME).
1615388|NCT02121405|Radiation|Radiotherapy|45-50 Gy in 25-28 fractions to the pelvis. After 45 Gy a tumor bed boost with a 2 cm margin of 5.4 Gy in 3 fractions for preoperative cancers or 5.4-9.0 Gy in 3-5 fractions for postoperative cancers could be considered. Radiotherapy is used only for patients with pathological confirmed positive circumferential margin in Group primary surgery. Radiotherapy is used to all of the patients in Group preoperative radiochemotherapy.
1615389|NCT02121405|Drug|Capecitabine|Capecitabine 825 mg/m2 twice daily 5 or 7 days/week with concurrent radiotherapy in Group primary surgery and Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 weeks after preoperative radiochemotherapy in Group preoperative radiochemotherapy. Capecitabine 1250 mg/m2 twice daily 1-14 every 3 weeks to a total of 6 months postoperative therapy for a part of stage II patients in Group of primary surgery. Capecitabine 1000 mg/m2 twice daily 1-14 every 3 weeks with oxaliplatin day 1 to a total of 6 months postoperative therapy for stage III patients in Group of primary surgery.
1615390|NCT02121405|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 over 2 hours, day 1, with capecitabine every 3 weeks. Repeat every 3 weeks to total of 6 months postoperative therapy.
1615391|NCT02121392|Device|Adductor Canal Nerve Block Catheter|ACNB catheter will be placed by anesthesia residents under the supervision of board-certified anesthesiologists familiar with regional anesthesia techniques, who are part of the anesthesia pain service. They will be performed at the bedside, aseptically, with the patient's vital signs monitored throughout the procedure. 1% lidocaine will be infiltrated in the skin and subcutaneous tissues overlying the adductor canal as visualized on ultrasound. Via a 17 gauge touhy needle a closed tip non-stimulating, epidural catheter will be placed after 1% lidocaine is used to hydrodissect the space lateral to the superficial femoral artery within the adductor canal. The catheter will be secured to the skin. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The functional ACNB pumps will run 8cc/h.
1615392|NCT02121392|Device|Adductor Canal Nerve Block Sham Catheter|Patients randomized to the sham catheter will have a chlorhexidine prep of the skin and ultrasound examination of the adductor canal on postoperative day #1. To minimize patient risk, a wooden applicator will be used to apply 10 seconds of pressure to the leg followed by catheter securing to the skin with the same tegaderm and paper tape dressing used on functional catheters. All catheters will be connected to infusion pumps with opaque plastic bags covering the pumps. The sham catheter pumps will not be turned on.
1615393|NCT02121392|Drug|Bupivacaine|In the functioning continuous adductor canal block, 0.125% bupivacaine will be infused at a rate of 8cc/hr.
1615394|NCT02121379|Behavioral|pulmonary rehabilitation|
2010433|NCT02966834|Drug|Placebo|GSK2330672 matching placebo will be supplied as white film-coated tablets.
1615396|NCT02121353|Drug|Lucentis|Single‐use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha‐trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra‐vitreal
1615397|NCT02121353|Drug|PF582|Single‐use 2 mL vial designed to deliver 0.05 mL of 10 mg/mL ranibizumab solution. Excipients: Alpha, alpha‐trehalose dihydrate; histidine hydrochloride, monohydrate; histidine; polysorbate 20; water for injections Route of Administration: Intra‐vitreal
1615398|NCT02121340|Behavioral|Behavioral Activation|
1615399|NCT02121327|Other|disease management|disease management program include self management education
1615400|NCT02121327|Other|usual care|usual care group receive regular outpatient treatment
1615401|NCT02121314|Drug|intravenous administration of 1st line TB drugs, day 1|TB drugs IV on day 1 for calculation of bioavailability while fasting or fed
2010434|NCT02966834|Drug|GSK2330672|GSK2330672 will be supplied in 2 dose strengths of 10 mg and 45 mg white film-coated tablets.
2010435|NCT02964104|Drug|insulin 287|Administered once weekly subcutaneously (s.c., under the skin) for 35 days
1615404|NCT02121288|Drug|Ticagrelor|Day 1: Loading dose of ticagrelor 180mg (two 90mg tablets) followed by 90mg dose at 12 hours after loading dose. Subject continues to take ticagrelor 90mg twice a day (morning and evening) for 7 days until next visit (Day 7).
1615405|NCT02121288|Drug|clopidogrel|Day 1: Clopidogrel 75mg oral tablet. Subjects will continue to take clopidogrel 75mg once a day for 7 days until next visit (Day 7/Visit 3). Note: no loading dose is given for the clopidogrel as those subjects are already on chronic dosing.
1615406|NCT02121275|Device|Ultrasound of the lungs|Ultrasound examination of the lungs
1615407|NCT02121275|Device|Electric impedance tomography|Electric impedance tomography (EIT) is a noninvasive tool based on the measurement of electrical impedance changes within the thorax and lung tissue during ventilation and depicts the regional changes in ventilation in real time. To use electric impedance tomography 16 electrodes are applied in a circular fashion around the patient's chest, typically at the level of the 7th intercostal space.
1615408|NCT02121262|Drug|700 μg dexamethasone|700 μg dexamethasone intravitreal injection in the study eye on day 1, month 5, and month 10.
1615412|NCT02121223|Device|post-dilatation with a Quantum Maverick balloon|post-dilatation with a Quantum Maverick balloon at high pressure (>=16atm) for at least 15 seconds.
1615413|NCT02121223|Device|manual thrombus aspiration + Promus Element stent implant|manual thrombus aspiration followed by Promus Element stent implantation at normal pressure
1615414|NCT02121210|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
1615415|NCT02121197|Drug|Ozurdex|
1615416|NCT02121184|Drug|Routine oxytocin|per regular oxytocin protocols
1615417|NCT02121184|Drug|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes initiation of labor analgesia
1615418|NCT02121171|Device|Ologen Collagen Matrix|Use of ologen Collagen Matrix in trabeculectomy (ologen) Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
1615419|NCT02121171|Procedure|Combined trabeculotomy-trabeculectomy|Combined trabeculotomy and trabeculectomy is a standard surgery for congenital glaucoma, however, it has its known complications.
1615420|NCT02121158|Device|Implantable Cardioverter Defibrillator|The ICD and lead(s) will be FDA-approved.
1615421|NCT02121158|Other|Optimal Medical Therapy|Guidance on lifestyle modification, exercise training, and disease management including review of American Heart Association (AHA) Guidelines for Primary Prevention of Cardiovascular Disease and Stroke.
1615422|NCT02121145|Biological|Vivotif|3 oral doses
1615423|NCT02121145|Biological|Typherix|one intramuscular dose
1615424|NCT02121119|Drug|Lidocaine|Continuous block with lidocaine in both legs. Lidocaine infusion starts 0.5% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
1615425|NCT02121119|Drug|Bupivacaine|Continuous block with lidocaine in both legs. Infusion starts bupivacaine 0.1% to 5 ml hour Baxter Infusor elastomeric pump LV 5 ml / hr
1615426|NCT02121106|Behavioral|Cognitive Remediation|
1615427|NCT02121106|Behavioral|Sham Cognitive Remediation|
1615428|NCT02121093|Procedure|vibration|
1615429|NCT02121080|Drug|REGN2222(SAR438584)|
1615430|NCT02121080|Drug|placebo|
1615431|NCT02121067|Drug|Levonorgestrel Intrauterine System (LNG-IUS)|The LNG-IUS will be inserted at two-weeks postpartum (day 14-20 postpartum) in all 50 women enrolled
1615432|NCT02121041|Drug|Amlodipine|Amlodipine 5 mg or 10 mg
1615433|NCT02121041|Drug|Chlorthalidone|Chlorthalidone 12.5 mg or 25 mg
1615434|NCT02121041|Drug|Losartan|Losartan 50 mg or 100 mg
1615435|NCT02121015|Behavioral|Share|
1615436|NCT02121015|Behavioral|Self-Directed|
1615437|NCT02121002|Drug|Diclofenac Sodium Topical Gel, 1%|Opaque, white gel
1615438|NCT02121002|Drug|Voltaren Topical Gel, 1%|Opaque, white gel
1615439|NCT02121002|Drug|Vehicle Diclofenac Sodium Topical Gel|Opaque, white gel
1615440|NCT02120989|Behavioral|Partner-Assisted Cognitive Behavioral Therapy for Insomnia|Study treatment includes partner-assisted Cognitive Behavioral Therapy for Insomnia (CBT-I) and consists of 7-8 weekly group therapy sessions of 2 hours each. Partner-assisted CBT-I focuses on altering patients' sleep schedules and changing their behaviors and patterns around sleeping in order to help them sleep in a single block of time overnight. As part of this treatment, participants will be asked to change, possibly reduce, the amount of time spent in bed and to maintain a specific bed time and wake time, as well as other potential changes depending on his/her specific insomnia pattern. This treatment has been shown to be safe and efficacious for a wide range of patients.
1615441|NCT02120976|Drug|JTT-252 or Placebo|Subjects will receive JTT-252 or Placebo
1615442|NCT02120976|Drug|JTT-252|Subjects will receive JTT-252
1615443|NCT02120963|Behavioral|Person-centered physical therapy intervention program|Comparison of person-centered physical therapy and control group
1957830|NCT02162693|Biological|Sodium Hyaluronate|
1615446|NCT02120937|Behavioral|MBCT-C Therapy|Mindfulness Based Cognitive Therapy for Children is a manualized psychotherapeutic intervention that combines mindfulness techniques with certain features of cognitive behavioral therapy. This particular protocol for youth includes weekly group sessions, regular home practice, and the core curriculum of formal mindfulness practices (e.g., body scan, sitting, movement, and walking meditations).
1615447|NCT02120924|Drug|Azelaic acid|Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
1615448|NCT02120911|Drug|Pertuzumab, trastuzumab|Pertuzumab and trastuzumab will be combined with standard chemoradiation with carboplatin and paclitaxel.
1615449|NCT02120898|Drug|Imiquimod|Subjects will apply the assigned test article to the designated treatment area (full face or balding scalp) identified by the investigator at Visit 1. The assigned test article will be applied once daily for two, 2-week treatment cycles separated by a 2-week no treatment interval.
1615450|NCT02120885|Behavioral|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
1615451|NCT02120872|Drug|Platelet rich fibrin and simvastatin|Three wall intrabony defect sites treated with Open Flap Debridement. 0.1 mL prepared SMV gel (1.2 mg/0.1 mL) was mixed with PRF. The PRF - SMV mixture was delivered to the defect.
1615452|NCT02120872|Biological|Platelet rich fibrin|Three wall intrabony defect sites treated with Open Flap Debridement. PRF was placed into the intrabony defect.
1615453|NCT02120872|Procedure|Open Flap Debridement alone|Three wall intrabony defect sites treated with Open Flap Debridement only. No PRF or SMV was delivered to the defect.
1615605|NCT02119754|Drug|Plurogel PN|
1615454|NCT02120859|Device|FFR - guided DEB angioplasty|DEB-only angioplasty is attempted in all patients. At baseline, quantitative coronary angiography (QCA) and fractional flow reserve (FFR) using an intracoronary standard bolus of adenosine are performed. If FFR at baseline is greater than 0.8, PCI is deferred, otherwise predilation with a non-coated balloon is performed. In case of severe recoil (> 50% residual stenosis) or flow-limiting dissection the procedure is deemed not suitable for DEB-only angioplasty and stent implantation is performed at the discretion of the operator. In all other cases, the lesion is treated using a Sequent Please® paclitaxel-eluting balloon (DEB). QCA and FFR measurements are repeated and the result is considered satisfactory if there is no flow-limiting dissection, residual stenosis < 40% and FFR > 0.8.
1615455|NCT02120859|Device|Provisional bare metal stenting|In case of suboptimal results after the FFR-guided DEB angioplasty described above, a bare metal stent is implanted inside the segment previously treated by DEB.
1615456|NCT02120846|Other|Flywheel leg-press resistance exercise|
1615457|NCT02120833|Device|EpiCeram® Skin Barrier Emulsion|Device (including sham) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
1615458|NCT02120833|Drug|Colloidal Oatmeal Cream|Drug (including placebo) Apply in a thin layer to the affected skin areas 2 times per day (or as needed) and massage gently into the skin as directed.
1615459|NCT02120820|Behavioral|Multisensory environment (MSE)|Participants are staying in multisensory environment (MSE only) for 30 minutes in each session, and twice per week for 10 weeks. An enabler stays with the participant throughout the session.
1615460|NCT02120820|Behavioral|Massage therapy (MT)|A trained massage therapist provides 15 minutes massage therapy (MT) to the participants, twice a week for 10 weeks. The massage therapist acts as an enabler.
1615461|NCT02120820|Other|Control group|Usual residential care will be given to these participants. Only attention and social interactions from the enabler will be provided.
1615462|NCT02120820|Behavioral|Massage therapy in multisensory environment (MT-MSE)|Participants receive 15 minutes massage therapy while staying in multisensory environment for 30 minutes, twice a week for 10 weeks.
1615463|NCT02120807|Drug|Certolizumab|
1615464|NCT02120807|Drug|cisplatin|
1615465|NCT02120807|Drug|pemetrexed|
1615466|NCT02120794|Device|530G Insulin pump|Subjects will use 530G insulin pump with Threshold Suspend (TS) feature for one year.
1615467|NCT02120781|Biological|Azficel-T (autologous fibroblasts)|"Autologous fibroblasts will be cultured from three 3-mm post auricular punch biopsies. Biopsies will be shipped from the clinical sites to the Fibrocell manufacturing site where the cells will be harvested, tested for sterility, endotoxin level, cell identity, viability and concentration. When the desired cell number is reached, cells will be transported to the investigative site as a suspension in shipping media.
Depending upon the clinical circumstances for each subject, the vocal fold(s) will be injected transorally or percutaneously in order to deposit 1.0 mL of study drug into the lamina propria layer of each vocal fold. The injection process will be visualized via a flexible fiberoptic laryngoscope inserted through the nostril."
1615468|NCT02120781|Drug|Placebo|Subjects randomized to placebo will receive injections of sterile saline into the vocal fold(s).
1615469|NCT02120768|Procedure|barrier resection/1cm resection|"For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas."
1615470|NCT02120755|Biological|AmnioClear™ Human Allograft Amniotic Membrane|
1615471|NCT02120742|Behavioral|SMS message reminder|SMS texts will be delivered to study participants over a 6-week period.
1615472|NCT02120729|Other|Genotype-guided care|Pharmacogenetic alerts are furnished to the clinician within 1 day of analysis of patient consent, and 2 days of admission. Buccal cell DNA is analyzed for 19 common CYP2D6 polymorphisms and results quantified into a drug metabolism reserve index to establish levels of sub-normal function (poor metabolizer) or supra-normal function (rapid metabolizer). For the estimated 50% of patients who are poor or rapid metabolizers, CEMS will proscribe medications which are major CYP2D6 substrates.
1615474|NCT02120703|Drug|Pregabalin|Pregablin 75 mg per oral two times a day
1615475|NCT02120703|Drug|Gabapentin|Gabapentin 200 mg twice daily per oral
1615476|NCT02120690|Device|Trigeminal nerve stimulation|10-day TNS interventional protocol over an 10-day follow-up. Subjects will have electrodes (Superior Silver 1.25-in. diameter) placed on their foreheads to stimulate the V1 branches of the trigeminal nerve bilaterally for approximately 30 minutes each day. Current was adjusted to maintain comfortable but perceptible levels of stimulation
1615477|NCT02120677|Drug|Itraconazole|Itraconazole comes in the form of capsules and liquid (oral solution). It is FDA approved for treatment of systemic Blastomycosis, Histoplasmosis and Aspergillosis in immunocompromised and non-immunocompromised patients at doses ranging from 200mg to 400mg daily. The current FDA approved dosage recommendation for treating toenail onychomycosis (nail fungus) is 200mg PO per day for 3 months. Test materials in this study will be prepared as an ointment (compounded in petrolatum jelly).
1615478|NCT02120664|Drug|Florbetapir (18F)|
1615479|NCT02120664|Drug|11C-PiB|
1615480|NCT02120651|Procedure|Fibrin monomer|Fibrin monomer by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
1615481|NCT02120651|Procedure|Hemostatic sponge|Hemostatic sponge by microscopic tympanoplasty, every 4 weeks up to 3 months is evaluated graft integrity by standard audiologic and tympanometric parameters.
1615482|NCT02120638|Drug|Pyrazinamide containing regimen|Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, ＞70kg 2000-2500mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, ＞70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, ＞50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily All treatment is taken daily, for a duration of up to 12 months depending on treatment arm.
1615483|NCT02120638|Drug|Regimen without Pyrazinamide|Isoniazid 600mg daily Amikacin 600mg daily Levofloxacin 33-70kg 750 mg daily, ＞70kg 1000 mg daily Clarithromycin 33-50kg 500 mg daily, ＞50kg 1000 mg daily Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, ＞70kg 1000 mg daily All treatment is taken daily, for a duration of up to 18 months depending on treatment arm.
1615484|NCT02120625|Device|Lumbar MB RFN|Patients will be placed in a prone position and prepped. The C-arm will be adjusted to establish a true anteroposterior image of the target vertebra. The C-arm will then be rotated until the target point at the base of the SAP is clearly visualized. The Nimbus probe, with the tines (filaments) in the retracted position, will be inserted and advanced to the bony target site using a down the beam approach. The probe hub will be rotated to accomplish a full deployment of the tines with a medial or lateral angular bias, as dictated by the SAP anatomy and angle of entry of the NMEE probe. Motor stimulation at 2 Hz up to 2 volts will be administered (safety check). The lesion site will be anesthetized before the radiofrequency (RF) generator is set to achieve a temperature of 80°C for 80 seconds, following 30 second temperature ramp up. Impedance and power will be recorded.
1615485|NCT02120612|Other|Naloxone Education Intervention|"The Naloxone Education Intervention is a curriculum that has been adapted from New York State Department of Health's, Opioid Overdose Prevention program for non-medical responders."
1615486|NCT02120599|Dietary Supplement|ready-to-use supplementary food|
1615487|NCT02120599|Dietary Supplement|corn-soy blend|
1615488|NCT02120599|Dietary Supplement|iron|
1615489|NCT02120599|Dietary Supplement|folic acid|
1615490|NCT02120599|Dietary Supplement|UNIMMAP|
1615491|NCT02120586|Other|Inspiratory Muscle Training (IMT).|"Supervised interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. This protocol is published as a practical guide for clinicians by Hill et al (2010).
The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants will be familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP. Participants remain seated in groups of 8 to 10."
1615492|NCT02120586|Other|Peripheral muscle training|"The supervised training program consists of one cycle of 10 exercises, 12 repetitions each one. The main peripheral muscles to be trained will be those recommended by Cruz-Jentoft et al (2011): brachial biceps and triceps, pectorals, deltoid, hand flexors and extensors, spine extensor muscles, psoas-iliac, quadriceps femoris and sural triceps.
The sessions will take place 3 times per week over a twelve-week period for a total of 36 sessions. All participants were familiarized with the force exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of maximum muscle force. Participants remain seated in groups of 8 to 10."
1615493|NCT02120573|Other|Workshop using Lecture and human model|workshop to teach CPR with lecture and human models
1615494|NCT02120573|Other|Workshop using Educational Film|workshops using film review about CPR
1615495|NCT02120573|Other|Workshop using Lecture, human model as well as Educational Film|using educational films and human model and lecture for training
1615496|NCT02120573|Other|Workshop using Lecture, human model, Educational Film as well as reference book|training volunteers with lecture, films, and human models and giving them reference book for referral
1615497|NCT02120560|Procedure|Atrial Fibrillation Ablation|Both treatment arms will undergo atrial fibrillation ablation.
1615498|NCT02120547|Drug|Cenicriviroc in mild liver impaired|Subjects with mild hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
1615499|NCT02120547|Drug|Cenicriviroc in moderate liver impaired|Subjects with moderate hepatic impairment will receive CVC, 1 tablet once daily, for 14 days. Matching healthy subjects will receive CVC, 1 tablet once daily, for 14 days.
1615500|NCT02120508|Device|rTMS|To test the efficacy of this specific setting.
1615501|NCT02120495|Procedure|condylectomy|The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
1615502|NCT02120482|Device|Combined apheresis|Semiselective immunoadsorption combined with membrane filtration
1957836|NCT02159755|Drug|Ibrutinib|Given PO
1957837|NCT02159755|Other|Laboratory Biomarker Analysis|Correlative studies
1957838|NCT02159755|Drug|Palbociclib|Given PO
1957839|NCT02159755|Other|Pharmacological Study|Correlative studies
1615507|NCT02120456|Drug|LEO 43204|
1615508|NCT02120456|Drug|Placebo|
1615509|NCT02120443|Device|ivWatch Model 400|The ivWatch Model 400 monitored tissue at common IV sites over a 24 hour period.
1615510|NCT02120430|Other|Video|"The video was developed by a multidisciplinary team (psychologists, paediatricians, filmmaker). It was conceived as an aid to parenting in the first year of life, providing opportunities for parents to look at their own experiences. The video lasts 24 minutes and describes the birth of a new relationship between primary caregivers and their babies, in chronological order, starting from late pregnancy to the end of the first year. Caregiver-child interactions are shown from early contact after delivery to common care practices, with an emphasis on four specific activities, which are believed to improve child development and caregiver-child interaction: reading aloud to the baby, exposure to songs, rhymes and music, promotion of early socialization for parents and for children."
1615511|NCT02120417|Drug|Ruxolitinib|"5 mg tablets to be administered by mouth
Ruxolitinib 15 mg BID (starting dose)"
1615512|NCT02120417|Drug|Capecitabine|Capecitabine 2000 mg/m^2 daily given as 1000 mg/m^2 twice a day (BID) (starting dose) Day 1-14 of each 21 day cycle
1615513|NCT02120417|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
1615514|NCT02120404|Drug|Esmolol administration|"Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.
Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.
The titrated dose will be maintained for a total duration of 24 hours."
1615515|NCT02120391|Other|iPhone Application|All subjects will receive the iPhone App on their phone however not all subjects will have the intervention (medication notifications) turned on.
1615516|NCT02120365|Drug|Perampanel|Perampanel is a noncompetitive (allosteric) antagonist of the AMPA-R that is well-absorbed (100% bioavailability), has good blood-brain-barrier penetration, and rapidly reaches peak plasma concentrations (1 hour). To date, there have been no clinical trials of AMPA-R antagonists (e.g., perampanel) for the treatment of alcoholism.
1615517|NCT02120365|Drug|Placebo|Placebo given in place of perampanel during the pre-treatment period and lab session days.
2010651|NCT02907359|Other|Treatment Choice|"BSC: according to standard/institutional practice; includes RBC or platelet transfusions; growth factors, ie, erythropoiesis stimulating agents, granulocyte stimulating factors, iron chelating therapy; broad spectrum antibiotics and/or antifungals.
Low dose cytarabine: 20 mg/m2 SC or IV QD for 14 days in 28-day cycles. Other schedules allowed per institutional practice. Treatment for ≥4 cycles absent disease progression/toxicity. BSC per institutional/standard practice.
Standard Intensive Chemotherapy: recommended 7+3 given as cytarabine 100-200 mg/m2/day continuous infusion for 7 days and an anthracycline for 3 days. Anthracyclines per institutional practice include daunorubicin (45-60 mg/m2/day) or idarubicin (9-12 mg/m2/day) or mitoxantrone (8-12 mg/m2/day) by IV infusion. Subjects with complete or partial response after IC induction should receive ≥1 additional cycles with reduced cytotoxic doses then BSC per standard /institutional practice."
2010652|NCT02907333|Behavioral|Advice to use condoms|
2010653|NCT02907099|Drug|BL-8040|"In cycle 1, a daily dose of BL-8040 1.25 mg/kg administered subcutaneously on Days 1-5 and 8-12.
Cycles 2 and beyond, BL-8040 administered on Days 1, 4, 8, and 11 of each 21 day cycle."
1615523|NCT02120339|Drug|Carvedilol|
1615524|NCT02120326|Device|Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.
Stimulation parameters:
2 mA intensity
Continuous stimulation for 20 min with rise times and fall times of 10 seconds each"
1615525|NCT02120326|Device|simulation of Transcranial direct current stimulation of the motor cortex|"The area of stimulation is determined by by EEG system 10/20. The two electrodes are soaked in saline and then placed on the scalp.
Stimulation parameters:
The intensity of the stimulation current is 2 mA
The current is applied during the first 30 seconds with rise times and fall times of 10 seconds each. Then the session will be continued without actual stimulation."
1615526|NCT02120313|Other|inpatient rehabilitation|
1615527|NCT02120313|Other|outpatient rehabilitation|
1615528|NCT02120300|Drug|LDV/SOF|90/400 mg FDC tablet administered orally
1615529|NCT02120300|Drug|SOF|400 mg tablet administered orally once daily
1615530|NCT02120300|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1615531|NCT02120287|Drug|Bevacizumab|Patients will receive bevacizumab (10 mg/kg) one day before and then at day 14 followed by10 mg/kg/day every 14 days until progression.
1615532|NCT02120287|Procedure|Magnetic Resonance Spectroscopy (MRS)|Subjects will have MRS prior to BZ-SRS.
1615533|NCT02120287|Procedure|Border Zone Stereotactic Radiosurgery (BZ-SRS)|The 'border zone' of the tumor will be targeted by SRS in a single session.
1615534|NCT02120274|Drug|Vitamin D|Oral vitamin D 2,000 IU qd throughout, irrespective of baseline vitamin D level.
1615535|NCT02120274|Drug|Vitamin B 12|Intramuscular vitamin B12 5000 UI will be given weekly in the first 12 weeks followed by a monthly injection until the end of therapy.
1615536|NCT02120261|Procedure|Trigger point injection|study medication mix (1 mL) or Sterile normal saline (1 mL) are injected in the most tender segment (trigger point) of the compromised muscle
1615537|NCT02120248|Other|Telephone-based breastfeeding peer counseling|
1615538|NCT02120222|Drug|selinexor|Given PO
1615539|NCT02120222|Other|Correlative studies|Blood will be collected for pK and pDn analysis pretreatment on day 1 and 8 hours after treatment, on day 1 of cycles 1 and 2.
1615540|NCT02120196|Drug|Rifaximin|rifaximin 1200 mg daily versus norfloxacin 400 mg once daily
1615541|NCT02120196|Drug|Norfloxacin|FDA approved:400mg once daily
1615542|NCT02120183|Behavioral|Psycho-educational support group therapy|"Weekly sessions lasting 60 minutes. Topics addressed each week:
Week 1: Coping with the diagnosis of loved one and dealing with uncertainty
Week 2: Caring for the carer 1: Feeding your body (self-care, stress management, mindfulness concepts)
Week 3: Caring for the carer 2: Feeding your mind (challenging negative thinking habits)
Week 4: The emotions of caregiving (handling emotional reactivity)"
1615543|NCT02120170|Procedure|Colon polypectomy|
1615544|NCT02120157|Drug|Cyclophosphamide|Chemotherapy administration
1615545|NCT02120157|Radiation|TBI|Radiation Therapy
1615546|NCT02120157|Drug|Busulfan|Chemotherapy Administered
1615547|NCT02120157|Other|Unmanipulated Bone Marrow|Bone Marrow Transplant
1615548|NCT02120157|Drug|Tacrolimus|Immunosuppressive Drug Administered
1615549|NCT02120157|Drug|Mycophenolate mofetil|Immunosuppressive Drug Administered
1615550|NCT02120144|Other|Observation & imagination|It is a combination of an observation phase followed by an immediate imagination phase of a straight gait with an imposed cadency.
1615551|NCT02120144|Other|Reading|"A 10 minutes reading phase of François Mauriac's Therese Desqueyroux on a computer"
1615552|NCT02120118|Radiation|Radiation|2Gy/5fx/week for a subtotal of 40Gy/20fx/4 weeks, followed by reduced-field boost with 10Gy/2fx/2 weeks (5Gy once a week during 5th and 6th week), totalling 50Gy/22fx/6 weeks.
1615553|NCT02120118|Other|Hyperthermia|42℃ ± 0.5℃ for 40 minutes within 2hr after irradiation, once a week since the 1st week of radiation for a total of 6 times
1615554|NCT02120118|Drug|Cisplatin|30mg/m2
1615555|NCT02120118|Drug|Taxotere|20mg/m2
1615556|NCT02120092|Drug|Clopidogrel|1x Loading dose 600 mg 6x maintenance dose 150 mg
1615557|NCT02120092|Drug|Ticagrelor|1x Loading dose: 180 mg 6x Maintenance dose: 90 mg bid
1615558|NCT02120092|Drug|ASA|"7x 100mg acetylsalicylic acid (clopidogrel arm)
1x 300 mg acetylsalicylic acid (ticagrelor arm)"
1615559|NCT02120092|Drug|Placebo|7x 300mg acetylsalicylic acid placebo
1615562|NCT02120066|Procedure|Vitrectomy for submacular hemorrhage|
1615563|NCT02120066|Drug|subretinal injection of tissue-plasminogen activator|
1615564|NCT02120053|Device|Conventional protocol|Teeth extractions and conventional immediate complete denture placement
1615565|NCT02120053|Device|Bone substitute material group|Teeth extractions and sockets filling with bone replacement material before immediate complete denture placement
1615566|NCT02120040|Other|evaluation of anxiety with psychosocial scales|
1615567|NCT02120027|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
1615568|NCT02120027|Drug|Placebo|Oral tablet (identical in appearance and weight to ibodutant tablets) to be given once daily.
1615569|NCT02120014|Procedure|blood volume measurement|"Patients will drink a solution 30 minutes prior to the test. They will need to lie still on a flat surface for 15 minutes. During the blood volume analysis portion of the test, a small amount of a radioactive isotope or tracer is injected.Blood samples are taken at 6 time points during the test. The blood volume test is used to measure the amount of blood in the patients body.
A hematocrit measurement is done on the blood samples taken. This blood test calculates the percentage of red blood cells in the bloodstream."
1615570|NCT02120014|Procedure|venous plethysmography|venous plethysmography is a non-invasive test to measure how well your veins and arteries in your forearm and calf work. Cuffs similar to blood pressure cuffs are placed on the upper and lower arm and the thigh and calf. Measurements are taken
1615571|NCT02120001|Device|ETT cleaning maneuver|"EndOclear is a commercially available device. It consists of an endotracheal tube cleaning apparatus with a flexible central tube and a cleaning device at its distal end. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the endotracheal tube. The cleaning apparatus is then pulled out of the endotracheal tube removing mucus deposits and secretions.
We plan to add the use of endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
1615572|NCT02119988|Procedure|TIPS|TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. TIPS revision was planned if any evidence of shunt dysfunction was seen.
1615573|NCT02119988|Procedure|Embolization|Embolization of SPSS was conducted via the same jugular vein before TIPS implantation. The major procedures included (a)angiography of SPSS after successful intrahepatic puncture of a branch of the portal vein and (b)embolization of SPSS with coils of varying diameters, which resulted in the SPSS disappearing at postembolization angiography.
1615574|NCT02119975|Behavioral|Working memory training|
1615575|NCT02119975|Behavioral|Placebo training|
1615576|NCT02119962|Behavioral|Working memory training|
1615577|NCT02119962|Behavioral|Placebo training|
1615578|NCT02119949|Behavioral|Working memory training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the experimental group executed versions of these task that adapt to their working memory capacity, to train their working memory optimally.
1615579|NCT02119949|Behavioral|Placebo training|The working memory training started the day after the pre-test and included 24 sessions of 25 minutes each. Participants trained, under supervision of an experimenter, on weekdays in the clinic. The training consisted of two tasks: the Symmetry Span and the N-back Task. Participants in the placebo group executed easy versions of these task that did not adapt to their level, to prevent training.
2010654|NCT02907099|Drug|Pembrolizumab|Cycles 2 and beyond, Pembrolizumab 200 mg administered by vein Day 1 of each 21 day cycle.
2010655|NCT02907099|Behavioral|Phone Call|Study staff calls to check participant's status 30 days after last dose of study drugs, and thereafter, every 12 weeks.
1615582|NCT02119923|Behavioral|Working memory training|The WM consisted of two tasks; the Number-letter task (Rogers & Monsell, 1995) and an Updating task. The Number-letter task trains the ability to shift between task relevant stimuli. Participants need to shift between four categories. In the Updating task participants receive a set of three words in which they have to compare the two consecutive words on emotional valence (positive or negative) to train their updating skills. Participants executed the training three times a week during four weeks.
1615583|NCT02119923|Behavioral|Placebo training|Both the WM and the placebo training consisted of two tasks; the Number-letter task (Rogers & Monsell, 1995) and an Updating task. To prevent training WM the placebo training was a simplified version of the Number-letter task in which shifting was not required. In the Updating task the placebo group only had to count the number of positive or negative words. Participants executed the training three times a week during four weeks.
1615584|NCT02119910|Behavioral|Technology Supported Manual|
1615585|NCT02119897|Device|Low Level Light Therapy|
2010656|NCT02907619|Biological|PF-06252616|Either 5mg/kg, 20mg/kg or 40mg/kg will be assigned to a subject based on their maximum tolerated dose from B5161002
2010657|NCT02904902|Drug|Adalimumab|Sub-cutaneous Injection
2010658|NCT02905604|Device|dmPFC iTBS|2400 pulses/day over 10 week days over bilateral dmPFC using MagPro X100 and the cool D-B80 A/P coil
2010659|NCT02905604|Device|dmPFC Sham iTBS|Sham iTBS
1615590|NCT02119858|Drug|indocyanine green solution|Given transperineally
1615591|NCT02119858|Other|diffuse optical imaging|Undergo near infrared fluorescence imaging
1615592|NCT02119858|Procedure|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic radical prostatectomy
1615593|NCT02119858|Procedure|therapeutic lymphadenectomy|Undergo lymphadenectomy
1615594|NCT02119845|Device|Endovascular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access.
1615595|NCT02119832|Device|Endovasccular AVF (EndoAVF)|The FLEX System will be used to endovascularly create a fistula in CKD patients who require hemodialysis vascular access
1615596|NCT02119819|Drug|LY2944876|Administered SC
1615597|NCT02119819|Drug|Exenatide extended-release|Administered SC
1615598|NCT02119819|Drug|Placebo|Administered SC
1615599|NCT02119806|Drug|Benzodiazepine|
1615600|NCT02119806|Drug|Fentanyl|
1615601|NCT02119806|Drug|Propofol|
1615602|NCT02119793|Device|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
1615603|NCT02119780|Device|YVOIRE® contour|YVOIRE® contour injection into the anteromedial malar region
1615604|NCT02119780|Device|Restylane SubQ™|Restylane SubQ™ injection into the anteromedial malar region
1615606|NCT02119728|Drug|HPPH|Undergo photodynamic therapy with HPPH
1615607|NCT02119728|Device|Light Infusion Therapy™|Undergo photodynamic therapy with HPPH
1615608|NCT02119728|Procedure|therapeutic conventional surgery|Undergo standard of care surgery
1615609|NCT02119715|Drug|Pegylated rhG-CSF 100μg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
1615610|NCT02119715|Drug|Pegylated rhG-CSF:150 μg/kg|Patients were administered pegylated rhG-CSF 150 ug/kg once at the 3rd day of 2 to 4 chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy).
1615611|NCT02119715|Drug|rhG-CSF 5 μg/kg/day|Patients were administered rhG-CSF 5 ug/kg daily during chemotherapy cycle(epirubicin 75mg/m2+docetaxel 75mg/m2 for neoadjuvant therapy and epirubicin 100mg/m2+cyclophosphamide 600mg/m2 for adjuvant therapy) until (1)continuous injection for 14 days (2)two successive ANC counts exceed 5.0×109/L（3）ANC counts exceed 15×109/L at anytime.
1615612|NCT02119689|Other|Diabetic Patients|measuring CD34 cell function in relation to diabetic retinopathy status
1615613|NCT02119689|Other|Healthy Controls|measuring CD34 cell function
1615614|NCT02119676|Drug|Ruxolitinib|"5 mg tablets to be administered by mouth
Ruxolitinib 20 mg twice a day (BID) (Part 1) (NOTE: The starting dose for the randomized portion of study (Part 2) was 15 mg BID based on results from Part 1.)"
1615615|NCT02119676|Drug|Regorafenib|Regorafenib 160mg once daily for the first 21 days of each 28-day cycle. (NOTE: Dose interruptions and modifications for regorafenib are expected when toxicities occur in which dose interruptions or modifications are appropriate.)
1615616|NCT02119676|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
1615617|NCT02119663|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
1615618|NCT02119663|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth twice daily (BID)
1615619|NCT02119663|Drug|Capecitabine|150 mg or 500 mg tablets to be administered by mouth twice daily (BID)
2010660|NCT02903888|Drug|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Intrauterine delivery system Jaydess (13.5 mg levonorgestrel)
2010661|NCT02903251|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily, day 1-3. 2 insufflations (8 IU of oxytocin total) as needed, max thrice daily, day 3-30.
2010662|NCT02903251|Other|intranasal spray without oxytocin|6 insufflations (24 IU of placebo total) given twice daily, day 1-3. 2 insufflations (8 IU of placebo total) as needed, max thrice daily, day 3-30.
2010663|NCT02902172|Drug|Acetaminophen|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
1615625|NCT02119572|Behavioral|peer support|
1615626|NCT02119572|Other|usual education lectures|
1615627|NCT02119559|Other|Blood analysis by EPISPOT and CellSearch®|
1615628|NCT02119546|Other|Aerobic exercise|Aerobic exercise and dual-task training
1615629|NCT02119546|Other|Stretch exercise|Stretch exercise & sitting balance
1615630|NCT02119520|Drug|Platelet rich fibrin +Atorvastatin|
1615631|NCT02119520|Drug|Platelet rich fibrin|
1615632|NCT02119520|Procedure|open flap debridement|
1615633|NCT02119507|Device|Curodont Repair|Single application on Day 0
1615634|NCT02119507|Other|No treatment - control|
1615635|NCT02119481|Behavioral|Mindfulness-based stress reduction|
1615636|NCT02119481|Behavioral|Expressive writing condition|
1615641|NCT02119455|Device|Vibration Device|Subjects receiving the OrthoAccel Aura device will be instructed to use the device for 20 minutes/day per the manufacturer's instructions during the study period.
1615642|NCT02119442|Device|Transcather Valve Implantation|Transcather Valve Implantation
1615643|NCT02119429|Dietary Supplement|Pumpkin Seed Oil|2 grams per day, everyday for 12 weeks.
1615644|NCT02119429|Dietary Supplement|Wheat Germ Oil|2 grams per day, everyday for 12 weeks.
1615645|NCT02119416|Drug|Placebo Administration first|"All participants received each dose on two days and the order of administration was counterbalanced.
Order of Administration for Visits 1-6: 0mg, 1mg, 2mg, 0mg, 1mg, 2mg"
1615646|NCT02119416|Drug|Low Caffeine Administration first (1mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.
Order of Caffeine Administration for Visits 1-6: 1mg, 2mg, 0mg, 1mg, 2mg, 0mg"
1615647|NCT02119416|Drug|High Caffeine Administration first (2mg/kg body weight)|"On two of the 6 visits, participants received a placebo (flattened sprite) added to their beverage.
Order of Caffeine Administration for Visits 1-6: 2mg, 0mg, 1mg, 2mg, 0mg, 1mg"
1615648|NCT02119403|Other|There are no other inteventions.|This device gives patients the opportunity to receive nitrous oxide where no such opportunity exists. There is no other intervention available that creates immediate short term minimal sedation.
1615649|NCT02119390|Behavioral|Staff-delivered intervention sessions|In addition to standard clinical care, participants in the Pill Trial+ arm will receive staff-delivered intervention sessions individualized for each participant at HAART initiation, 1-month, and 3-month follow-up. Two booster sessions will also be provided at two weeks following intervention session 1 (in clinic) and intervention session 2 (by phone) to assess any difficulties using the created adherence plans.
1615650|NCT02119390|Other|Demographic Questionnaire|Participants will complete a questionnaire developed for the purposes of the current study assessing basic background information.
1615651|NCT02119390|Other|Questionnaires|Self-reported adherence, health-related quality of life and other questionnaire measures will be administered using a password protected laptop the same day as participants' regularly scheduled outpatient clinic appointments.
1615652|NCT02119377|Other|questionnaire|
1615653|NCT02119364|Other|Working memory training|The child will use the computer program at home under parental supervision for 25 sessions, each lasting 30-45 minutes and the family has 6 weeks to complete the training. Each session consists of 8 different tasks presented by an animated robot. The tasks all require the child to hold information in working memory and to manipulate the information.
1615816|NCT02118129|Other|wait listed|
2010664|NCT02902172|Drug|NSAID|Blood pressure will be monitored during postpartum stay (typical 2 days) and then again at 1 week and 6 weeks (standard practice of care) with blood pressure measurements
1615656|NCT02119338|Drug|5-ala|dose of 5-ala will be taken as either 5 mg/kg, 10 mg/kg, or 20 mg/kg approximately 3 hours before going to surgery.
1615657|NCT02119325|Dietary Supplement|25% fibre|Test is a powdered beverage with an active component of 25% of fibre (resistant maltodextrin)
1615658|NCT02119325|Dietary Supplement|0% fibre|Placebo is an energy matched powdered beverage
1615659|NCT02119299|Device|SMART device|Sensor Monitored Alimentary Restriction Therapy (SMART) device
1615660|NCT02119286|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
1615661|NCT02119286|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
1615662|NCT02119286|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
1615663|NCT02119286|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
1615664|NCT02119273|Drug|Prednisone|See arm description
1615665|NCT02119273|Drug|Placebo|See arm description
1615666|NCT02119260|Drug|GSK2798745 solution|Clear, colourless GSK2798745 (0.1 to 0.4mg) solution in aqueous citrate buffer with 4% captisol
1615667|NCT02119260|Drug|GSK2798745 suspension|Aqueous suspension of GSK2798745 (>=0.5 mg)
1615668|NCT02119260|Drug|GSK2798745 capsule|White Opaque granule filled capsules of GSK2798745 (>=0.5 mg)
1615669|NCT02119260|Drug|Placebo solution|Clear, colourless solution of aqueous citrate buffer with 4% captisol
1615670|NCT02119260|Drug|Placebo suspension|Visually matching aqueous suspension of hypromellose acetate succinate powder
1615671|NCT02119260|Drug|Placebo capsule|Matching white opaque placebo blend filled capsule
1615672|NCT02119247|Device|CHF 6001 dry powder for inhalation via NEXThaler®|
1615673|NCT02119247|Device|CHF 6001 DPI capsules for inhalation via Aerolizer|
1615674|NCT02119234|Drug|Beclometasone/formoterol/glycopyrrolate|
1615675|NCT02119234|Drug|Placebo|
1615676|NCT02119221|Drug|Copanlisib (BAY80-6946)|Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 μCi) of [14C]
1615677|NCT02119208|Behavioral|Intensity and timing of exercise|
1615678|NCT02119195|Procedure|Sealant|resin-based sealant (Clinpro Sealant, 3M ESPE)
1615679|NCT02119182|Behavioral|In-Person Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures In-Person at 2 Weeks, 6 Months, and 12 Months, and by Phone at 3 Months.
1615680|NCT02119182|Behavioral|Phone Outcome Assessment|NIH Flexible Outcome Assessment Battery Framework Measures by Phone at 2 Weeks, 3 Months, 6 Months, and 12 Months.
1615681|NCT02119182|Procedure|3T Magnetic Resonance Imaging (MRI)|3T Research MRI at 2 weeks and 6 months.
1615682|NCT02119182|Procedure|Blood Draw for Plasma, DNA, Serum, RNA|Blood draw at baseline, 2 weeks, and 6 months.
1615683|NCT02119169|Device|Pigtail catheter|pigtail catheter for pleural drainage
1615684|NCT02119156|Drug|Belimumab|Monthly intravenous infusions dosed as 10 mg/kg body weight
1615685|NCT02119143|Dietary Supplement|vitamines and minerals|given for 24 weeks, after 4 week wash out of all supplements and dietetic products
1615686|NCT02119143|Dietary Supplement|placebo|given for 24 weeks, after 4 weeks wash out of all supplements and dietetic products
1615687|NCT02119130|Device|QGIT|Seven pairs of clinics will be included in this study. One clinic in each pair will be selected by a computerized randomization program to be the standard of care arm (TST only) and the other will be in the QGIT arm.
1615688|NCT02119117|Dietary Supplement|CoQ10|This is a dietary supplement which will be administered daily to the patient for 3 months prior to IVF
1615689|NCT02119117|Dietary Supplement|Placebo|This is a placebo which will be administered daily to the patient for 3 months prior to IVF.
1615690|NCT02119104|Drug|Prevenar (13v)|Prevenar (13v)
1615691|NCT02119091|Drug|Moxifloxacin|
1615692|NCT02119078|Other|Acute Care of Elders focused geriatric care|Patients admitted to the ACE Service will receive standard care as well as additional use of geriatric-specific order sets and protocols and oversight of care by a geriatric-trained Advanced Practice Provider (APP).
1615693|NCT02119065|Procedure|positron emission tomography|Undergo PET/CT scan
1615694|NCT02119065|Procedure|computed tomography|Undergo PET/CT scan
1615695|NCT02119052|Drug|octeotride|
1615696|NCT02119052|Drug|placebo|
1615697|NCT02119039|Device|RGTA OTR 4120 (CACICOL20)|
1615698|NCT02119039|Device|Genteal HA eye drops|
1615699|NCT02119026|Drug|Capecitabine|"800mg/m2 bid d1-14
± 1000 mg/m2 bid,days 1-14 q3w: maintenance"
1615700|NCT02119026|Drug|Capecitabine|1000mg/m2 bid d1-14,
1615701|NCT02119026|Drug|Bevacizumab|7,5 mg/kg given on d1 q3w
1615702|NCT02119026|Drug|Oxaliplatin|130mg/m2 iv. d 1 q3w
1615703|NCT02119026|Drug|Irinotecan|200mg/m2 iv. d 1 q3w .
1615704|NCT02119013|Drug|Octeotride|
1615705|NCT02119013|Drug|Placebo|
1615706|NCT02119000|Drug|PEG/electrolytes 2L/2L split dose|Polyethylene glycol 17gm X 4 At 18h00 the day prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes On the day of the procedure, 4-5 hours prior the colonoscopy, dilute 2 sachets in 2 L of water and drink 240 mL every 10 minutes
1615707|NCT02119000|Drug|Bisacodyl 15 mg and PEG/electrolytes 1L/1L split dose|"Bisacodyl 15 mg x 3
At 14h00 the day prior the endoscopic procedure: take 3 tablets of Bisacodyl ER (15 mg) orally then 5 hr later:
PEG/electrolytes 1L/1L Polyethylene glycol 17gm Dilute one sachet of Polyethylene glycol 17gm in 1 L of water Start drinking at around 19h00 the night prior the colonoscopy Drink 240 ml every 10 minutes The day of the colonoscopy. At (4 hrs prior the procedure). Dilute on sachet of PEG and drink 240 ml every 10 minutes"
1615708|NCT02118987|Drug|Omalizumab|
1615709|NCT02118974|Procedure|Hysterectomy|Hysterectomy
1615710|NCT02118961|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)|0.5 mL, subcutaneous injection
1616027|NCT02116660|Drug|Lamivudine|Lamivudine (3TC) 150 mg tablets
1615711|NCT02118961|Biological|Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)|0.1 mL, subcutaneous injection
1615712|NCT02118948|Behavioral|Abuse-focused intervention|
1615713|NCT02118948|Behavioral|Sexual behavior-focused intervention|
1615714|NCT02118935|Other|Previously marketed cow's mlik-based infant formula|
1615715|NCT02118935|Other|Marketed cow's milk-based infant formula with prebiotics|
1615716|NCT02118922|Procedure|Brillouin imaging|
1615717|NCT02118909|Drug|Pracinostat|
1615718|NCT02118909|Drug|Itraconazole|
1615719|NCT02118909|Drug|Ciprofloxacin|
1615720|NCT02118896|Drug|FK506E|oral
1615721|NCT02118883|Other|Essentia Water|
1615722|NCT02118883|Other|Bottled water|
1615723|NCT02118870|Drug|Treatment 90 days DAPT|Short term DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 90 days, after which patients will continue.
1615724|NCT02118870|Drug|Treatment 360 days DAPT|Long term (360 days) DAPT arm: will continue DAPT with P2Y12 inhibitors and ASA up to 360 days, after which patients will continue on monotherapy with ASA only, unless contraindications for ASA emerge
1615725|NCT02118857|Other|Omnivore, vegetarian and vegan subjects.|Omnivore, vegetarian and vegan subjects collected the feces, urina and saliva samples for 3 weeks from recruiting.
1615726|NCT02118844|Drug|rocuronium|
1615727|NCT02118831|Biological|Blood Sample Collection|Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.
1615728|NCT02118831|Drug|Aflibercept|an intravitreal injection of Aflibercept administered three times on a monthly basis.
1615729|NCT02118831|Drug|Bevacizumab|an intravitreal injection of Bevacizumab administered three times on a monthly basis.
1615730|NCT02118831|Drug|Ranibizumab|an intravitreal injection of Ranibizumab administered three times on a monthly basis.
1615731|NCT02118818|Genetic|Next generation sequencing|There will be no intervention. This is an observational trial to examine the differences in genetic variants and gene expression between patients with and without RHD.
1615732|NCT02118792|Drug|AN2728 Topical Ointment, 2%|
1615733|NCT02118792|Drug|Matching vehicle control|
1615734|NCT02118779|Behavioral|Behavioural change intervention|The intervention is cognitive behaviour therapy (CBT). The CBT consists of six different modules. All patients will start with individual goal setting and psycho-education about the role of cognitive-behavioural variables in the disabilities patients' experience. The patient formulates his or her treatment goals in concrete terms and later on in the therapy the goals are realised step by step by the patient. The treatment is tailored to the patient's problems: which of the six modules a patient will receive is dependent on the scores on measures that have been collected at baseline assessment. Based on our previous experience with modular interventions we expect that most patients will receive less than four modules.
1615735|NCT02118766|Drug|AN2728 Topical Ointment, 2%|
1615736|NCT02118766|Drug|Matching vehicle control|
1615737|NCT02118753|Drug|Eplerenone|eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
1615738|NCT02118727|Drug|Memantine|All randomized patients will be instructed to take one tablet once a day for the first week from a blinded bottle that contains 5 mg tablets or matching placebo. At week two, patients will be instructed to take one tablet twice a day from the 5 mg bottle or matching placebo. At week three, patients will be instructed to take one tablet in the morning from the 5 mg bottle and one tablet from the 10 mg bottle or the matching placebo bottle in the evening. At week four patients will be instructed to take one pill twice a day from the 10 mg bottle or matching placebo. At week five patients will be instructed to take 2 pills from the 10 mg bottle or matching placebo in the morning and one pill in the evening. At week six patients will start 2 pills twice a day from the 10 mg bottles or matching placebos
1615739|NCT02118727|Drug|Placebo (for Memantine)|All randomized patients will be instructed to take one tablet once a day for the first week from a blinded bottle that contains 5 mg tablets or matching placebo. At week two, patients will be instructed to take one tablet twice a day from the 5 mg bottle or matching placebo. At week three, patients will be instructed to take one tablet in the morning from the 5 mg bottle and one tablet from the 10 mg bottle or the matching placebo bottle in the evening. At week four patients will be instructed to take one pill twice a day from the 10 mg bottle or matching placebo. At week five patients will be instructed to take 2 pills from the 10 mg bottle or matching placebo in the morning and one pill in the evening. At week six patients will start 2 pills twice a day from the 10 mg bottles or matching placebos
1615740|NCT02118714|Drug|Atrasentan|Atrasentan
1615741|NCT02118701|Other|Shared Decision-Making educational training|
1615742|NCT02118688|Drug|Risperidone|
1615743|NCT02118688|Drug|Trazodone|
1615744|NCT02118688|Drug|Placebo|
1615745|NCT02118675|Other|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements. Your BMI will be calculated from these measurements.
1615746|NCT02118675|Other|Body Composition and Circumference measurements|This test is to measure the amount of water in your body. After a fasting urine sample is collected, you will drink a glass of water that has been enriched with an atom called a stable isotope (deuterium). After you drink this non-radioactive heavy water, you will provide urine samples several times over the next 4 hours.
1615747|NCT02118675|Other|Whole Body DXA scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table. You will be carefully positioned on the table, and your legs will be placed together using two Velcro straps. A scanner emitting low energy X-rays and a detector will pass along your body. You will be asked to remain completely still while the scan is in progress. The scan takes approximately ten minutes.
1615748|NCT02118675|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will repeat this procedure on three different BIA systems.
1616118|NCT02115984|Drug|Placebo|
1615749|NCT02118675|Other|BodPod|This test will estimate the amount of fat mass and fat free mass in your body. You will be required to change into a swimsuit and swim cap that we will provide for this procedure. If your swimsuit meets the necessary criteria, you can bring and wear it for the procedure, or PBRC will provide one for you. You will step onto a scale for a quick weight measurement. Next, you will sit inside of the system like you are sitting in a chair. The door of the system will be closed, but you will have a window so that you can see outside of the system while the measurements are completed. The test will be completed in about 15 minutes.
1615750|NCT02118675|Other|Circumferences|This test will measure the circumferences of your waist, hip, neck, arms, and legs and the lengths of your forearm, upper arm, thigh, and lower leg. The circumference measurements will be made by a trained observer using a calibrated tape measure and an automated circumference measurement device (KX-16). These measurements will be made in about 30 minutes.
1615751|NCT02118675|Other|Ultrasound|An ultrasound is a procedure that uses sound waves to create a picture of an organ or soft tissue. This test measures the size of your tissue thicknesses for fat and skeletal muscle. For this procedure, you will be asked to raise your shirt, disrobe from the waist up, or change into a hospital gown and lie flat on your back on an examination table, or sit on a chair, or stand for measuring your leg dimensions. A gel will be spread on the ultrasound probe, and the probe will be applied directly to the skin on your arms, legs, and abdomen. You will feel slight pressure when the probe is applied. The entire procedure will take approximately 30 minutes.
1615752|NCT02118662|Other|Energy Expenditure during seated in an office chair|You will first rest motionless in a chair for 20 minutes. You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
1615753|NCT02118662|Other|Energy Expenditure during seated and typing|You will complete this working conditions for 15 minutes. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
1615754|NCT02118662|Other|Energy Expenditure during Treadmill walking work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
1615755|NCT02118662|Other|Energy Expenditure during cycling work condition|You will complete the working conditions for 15 minutes each at your own self-selected level of effort. A rest period of 5 minutes will be given between each condition. During the working conditions, you will be asked to retype a displayed standard set of text.
1615756|NCT02118649|Behavioral|Game|
2010665|NCT02901431|Drug|Placebo|Participants will receive a matching placebo orally. Approximate treatment duration will be up to 24 weeks.
2010666|NCT02901431|Drug|RO5285119|Participants will receive age-adjusted total daily oral dose approximately equivalent to the adult doses of either 4 mg/d or 10 mg/d of RO5285119. Approximate treatment duration will be up to 24 weeks.
2010667|NCT02899559|Behavioral|Message|Participants will receive one of three messages at the end of a survey, two of which are experimental messages and one of which is a control message.
1615760|NCT02118610|Drug|L-tetrahydropalmatine (30mg)|Active comparator
1615761|NCT02118610|Drug|Sugar pill|Placebo
1615762|NCT02118597|Drug|Boceprevir|Boceprevir administered according to corresponding summary of product characteristics (SmPC).
1615763|NCT02118597|Drug|Simeprevir|Simeprevir administered according to corresponding summary of product characteristics (SmPC).
1615764|NCT02118597|Drug|Pegylated Interferon (Peginterferon) Alfa-2a|Pegylated interferon (peginterferon) alfa-2a according to corresponding summary of product characteristics (SmPC).
1615765|NCT02118597|Drug|Ribavirin|Ribavirin according to corresponding summary of product characteristics (SmPC).
1615766|NCT02118584|Drug|Etrolizumab|Participants will receive etrolizumab 105 milligrams (mg), administered subcutaneously (SC) every 4 weeks for up to 7 years or until either commercial availability or the Sponsor's decision to terminate the study.
1615767|NCT02118558|Device|Negative Pressure Wound Therapy (NPWT)|
1615768|NCT02118558|Drug|standard prophylactic therapy|administration of antibiotics before the first incision, keeping the surgery field sterile and performing several rinsing
1615769|NCT02118532|Device|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter|IN.PACT Admiral Paclitaxel-Eluting Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter originally developed, approved and commercialized by Invatec Technology Center GmbH is the investigational medical device used in the study. Medtronic Inc. acquired Invatec on April 21, 2010. Medtronic
1615770|NCT02118519|Biological|Autologous Mesenchymal Stem Cells|Comparison of clinical outcomes of patients injected by mesenchymal stem cells only with patients injected with mesenchymal stem cells supported by platelet lysate
1615812|NCT02118155|Procedure|Connective tissue graft|Periodontal surgical technique to treat gingival recessions
1615813|NCT02118142|Dietary Supplement|Betaine|6 gram one-time dose of betaine delivered in encapsulated form with an unsweetened beverage
1615814|NCT02118142|Dietary Supplement|Dextrose|6 gram one-time dose of dextrose delivered in encapsulated form with an unsweetened beverage
1615815|NCT02118129|Behavioral|an educational video|
2010668|NCT02899754|Behavioral|Lung Cancer Screening Decision Tool|This will be a lung cancer screening decision support tool that is web based and provides patients with information about the potential benefits and harms associated with lung cancer screening and helps them to consider their personal values when making a decision about whether to initiate or continue with lung cancer screening.
2010669|NCT02899754|Behavioral|Control Intervention|This will be a health message regarding prevention and healthy behavior that is not related to lung cancer screening but delivered in a similar modality and taking approximately the same amount of time as the LCSDecTool.
2010670|NCT02899000|Drug|Adapalene 0.3% / benzoyl peroxide 2.5% emulsion gel|Topical acne therapy
2010671|NCT02899000|Drug|Oral doxycycline hyclate|Tetracycline-class oral antibacterial 200 mg daily (2 tablets [50 mg], twice daily)
2010672|NCT02896725|Device|Keratin dressings|Wool-derived keratin matrix dressings applied with each change of the compression bandage until healing or the trial ends
1615771|NCT02118506|Other|Physical practice|"The control group underwent familiarization of gait phases using cards with gait phases and physical gait training.
Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases. Then, they were submitted to a physical gait training. They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
1615772|NCT02118506|Other|Mental and physical practice|"The experimental group underwent familiarization of gait phases using cards with gait phases, mental practice of gait and physical gait training.
Familiarization with gait cycle: Cards with pictures of an elderly person performing movements related to the adjustment of posture, gait initiation and gait phases were shown to the subjects. They should have organized them sequentially, showing that they learned gait phases.
Then, they were submitted to a mental training of gait. They imagined the gait steps per 400 repetitions. While imagining, they verbalized the gait phases.
Finally, they were submitted to a physical gait training. They executed 400 steps.
They underwent a single training session during 1 hour and 30 minutes and were reassessed 10 minutes and 1 day after the end of the session, in respect of the kinematic gait and mobility."
1615773|NCT02118493|Device|Benign Biliary Stenosis, Laser|Single use of laser to attempt excision of biliary ductal tissue causing stenosis.
1615774|NCT02118480|Other|cognitive remediation program: REHACOP|Specifically, REHACOP group remediation with PD patients consisted of: Attention unit (4 weeks) training sustained, selective, alternant and divided attention; Memory unit (3 weeks) focusing on visual and verbal learning, recall and recognizing memory; Language unit (3 weeks) including grammar, syntax, vocabulary, verbal fluency, verbal comprehension, abstract language; Executive functions unit (2 weeks) training cognitive planning, proverbs, analogies; and Social cognition unit (1 week) exercising theory of mind, social reasoning and moral dilemmas.
1615775|NCT02118480|Other|Occupational Therapy|The activities included drawing, reading the daily news and constructing using different materials (such as paper or wood). These activities were accomplished in a group format and with the same frequency as the implementation of REHACOP in the experimental group.
1615776|NCT02118467|Drug|Norepinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
1615777|NCT02118467|Drug|Epinephrine|Dose range 0.03 to 0.3 mcg/kg/minute, titrated to target blood pressure.
1615778|NCT02118467|Drug|Phenylephrine|Dose range 0.3 to 3.0 mcg/kg/minute, titrated to target blood pressure.
1615779|NCT02118467|Drug|Vasopressin|Dose range 0.1 to 0.6 milliunits/kg/minute, titrated to target blood pressure.
1615780|NCT02118454|Behavioral|Daily IVR Calls Intervention|
1615781|NCT02118454|Behavioral|Weekly IVR Survey Only|
1615782|NCT02118441|Device|Ultrasound-guided Radial Artery Catheter Insertion|
1615783|NCT02118441|Device|Direct Palpation-guided Radial Artery Catheter insertion|
1615786|NCT02118415|Other|Hsp70-peptide TKD/IL-2 activated, autologous NK cells|Adjuvant treatment with Hsp70-peptide TKD/IL-2 activated, autologous NK cells following completion of standard radiochemotherapy (Cisplatin/Vinorelbine)
1615787|NCT02118402|Dietary Supplement|Fortified maize porridge|Maize porridge will be home-fortified with either A) MNP, B) MNP+Fe, C) MNP+Fe+GOS
1615788|NCT02118389|Dietary Supplement|Glucerna|Glucerna 52g meal replacement
1615789|NCT02118376|Drug|Exenatide|5ug bid,Subcutaneous injection
1615790|NCT02118350|Behavioral|Mat Pilates Training|Mat Pilates training performed two times at week for 16 weeks.
1615791|NCT02118337|Biological|MEDI0680|anti-PD-1
1615792|NCT02118337|Biological|Durvalumab|anti-PD-L1
1615793|NCT02118337|Biological|Nivolumab|anti PD-1
1615794|NCT02118324|Behavioral|Exergaming Program|Participants will exercise through exergaming play.
1615795|NCT02118311|Biological|T Regulatory cells|Fixed dose of nTreg cells will be infused on day 0 of transplant after the umbilical cord blood cells
1615796|NCT02118311|Drug|Fludarabine|Fludarabine 30mg/m^2 IV over 1 hour on days -6 through -2 from transplant
1615797|NCT02118311|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg IV over 2 hours on day -6 from transplant
1615798|NCT02118311|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) 200 cGy administered on day -1 in a single fraction will be given at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
1615799|NCT02118285|Drug|Fludarabine|Fludarabine 25 mg/m^2 IV on days -6 through -2 from NK cell infusion
1615800|NCT02118285|Drug|Cyclophosphamide|Cyclophosphamide 30 mg/kg IV on days -5 and -4 from NK cell infusion
1615801|NCT02118285|Biological|NK cells|CD3-/CD19- selected NK cells administered by intraperitoneal (IP) infusion on day 0
1615802|NCT02118285|Biological|IL-2|IL-2 at 6 million units/dose IP 3 times a week x 6 doses with the 1st dose given immediately after the NK cell infusion
1615803|NCT02118285|Drug|INCB024360|INCB024360 at assigned dose by mouth twice a day begin day -2 and continue for 90 days (+/- 3 days)
1615804|NCT02118272|Device|Physica KR|
1615805|NCT02118259|Other|Before-after study|"The before-after study is composed of a first observational phase followed by a proactive phase, and then finally by a second observational phase.
The first observational phase corresponds to retrospective data-collecting for the information necessary for calculating the baseline ADE geriatric risk score.
The proactive phase corresponds to a multidisciplinary review of drug prescriptions (especially long-term drugs) for all included patients in the residence.
During the second observational phase, the same data as in the first observational phase will be collected a second time."
1615806|NCT02118246|Device|Dry Needling|Dry needling was performed for one week, three times a week.
1615807|NCT02118246|Device|Kinesio Tape|Kinesio tape was performed for one week, three times a week.
1615808|NCT02118220|Other|Concussion Questionnaire|
1615809|NCT02118207|Other|Aerobic running exercise|60 min of aerobic intervals completed prior to SCUBA diving
1615810|NCT02118181|Dietary Supplement|HMB|
1615811|NCT02118168|Other|No intervention|No intervention is foreseen in this Observational Study
1615817|NCT02118116|Other|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training is a 2-day, 14-hour intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide. The ASIST program has five learning sections: 1) Preparing - Sets the tone, norms, and expectations of the workshop; 2) Connecting - allows participants to explore their own attitudes towards suicide and creates an understanding of the impact that attitudes have on the intervention process. 3) Understanding - Describes the intervention needs of a person at risk. 4) Assisting - Presents a model for suicide intervention. 5) Networking - Generates information about resources in the local community.
1615818|NCT02118103|Procedure|Spinal Manipulation|Lumbar spinal manipulation
1615819|NCT02118090|Drug|Chloroquine sulfate|Chloroquine sulfate (NIVAQUINE) - 30 mg/kg for 3 days
1615820|NCT02118090|Drug|DHA-PP|DHA-PIP (Duo-Cotecxin®, DHA 40 mg and PP 320 mg, Zhejiang Holley Nanhu Pharamaceutical Co. Ltd, Jiaxing, Zhejiang province, China): one tablet of DHA-PIP contains 40 mg of dihydroartemisinin (DHA) and 320 mg piperaquine (PIP). It is an oral administration, one dose a day for 3 consecutive days. An adult dose (≥40 kg to 60kg body weight or more than 15 years old) consisted of three doses of 3 tablets over consecutive days (Total dose 9 tablets). The approximate total adult dose was 2-4 mg/kg for DHA and 20mg/kg for PP.
1615821|NCT02118077|Biological|G17DT|
1615822|NCT02118064|Biological|G17DT-Irinotecan|500µg dose of G17DT intramuscular injection in combination with 125 mg/m^2 intravenous infusion of Irinotecan over 90 minutes.
1615823|NCT02118051|Drug|Ganirelix 0.25 mg.|Ganirelix 0.25 mg. Route of administration: Subcutaneous use. Dose: 250μg/24h since the day observe a follicle> 14mm.
1615824|NCT02118051|Drug|Recombinant choriogonadotropin alfa|Recombinant choriogonadotropin alfa. Route of administration: Subcutaneous use. Dose: 6,500 IU, pods, when follicles> 17 mm are observed
1615825|NCT02118051|Drug|Micronized natural progesterone.|Micronized natural progesterone. Route of administration: vaginal . Dose: 400mg/24, from embryo transfer until the day of b-hCG.
1615826|NCT02118025|Procedure|Off-pump coronary artery bypass graft|Patients operated with the heart beating, without heart arrest.
1615827|NCT02118025|Procedure|Mini extracorporeal circulation bypass|Patients operated with a modified extracorporeal circulation system
2010673|NCT02896725|Device|Usual care dressings|Dressings chosen from study centres' formulary of non-medicated moist wound dressings (non-adherent dressings, hydrogel, alginate, hydrofibre or polyurethane foam dressings) applied with each change of the compression bandage until healing or the trial ends
2010674|NCT02896777|Other|Transfer embryo from pH 7.21±0.02|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.21±0.02.
2010675|NCT02896777|Other|Transfer embryo from pH 7.29±0.02|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be cultured in pH of 7.29±0.02.
1615832|NCT02117986|Drug|colistin|One arm will receive a loading dose of colistin (6 million international units), and a maintenance dose of 3 million every 8 hours. The other arm will receive a maintenance dose of 3 million international units every 8 hours.
1615833|NCT02117973|Procedure|iAssist Technique using Persona system vs. the conventional technique using Persona system|
1615834|NCT02117960|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
1615835|NCT02117960|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
1615836|NCT02117947|Behavioral|Behavioral Counseling|Behavioral counseling used components of evidence-based smoking intervention treatment to promote maternal smokers efforts in reducing their children's exposure to secondhand smoke.
1615837|NCT02117947|Behavioral|Self-help control|This intervention group received a comprehensive self-help manual that included information and advice about how to protect children from secondhand smoke (e.g., adopting a smokefree home and car.)
1615838|NCT02117934|Biological|HEPLISAV|Intramuscular injections at Week 0 and Week 4, plus a placebo injection at Week 24
1615839|NCT02117934|Biological|Engerix-B|Intramuscular injections at Week 0, Week 4, and Week 24
1615840|NCT02117921|Behavioral|One-on-one interview and educational sessions. Reading material for educational series as below|"A one-on-one interview with the patient and the principal investigator and group educational sessions. Participants will also be provided with the following books during the intervention period:
Healing Back Pain by Dr. John Sarno Unlearn Your Pain by Dr. Howard Schubiner The Mindful Way through Anxiety: Break Free from Chronic Worry and Reclaim Your Life by Susan Orsillo, PhD & Lizabeth Roemer"
1615841|NCT02117908|Device|RESMED AUTOSET S9|Continuous positive pressure during surgery
1615842|NCT02117895|Procedure|Celiac plexus resection|Celiac plexus at the left side of aorta, between celiac trunk and superior mesenteric artery will be resected.
1615843|NCT02117895|Procedure|Pancreatectomy|Standard distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
1615844|NCT02117869|Other|Low furanocoumarin hybrid grapefruit juice|3 consecutive daily doses of 200ml low furanocoumarin grapefruit juice plus midazolam 5mg orally on the third day.
1615845|NCT02117869|Other|Regular grapefruit juice|3 consecutive daily doses of 200ml regular grapefruit juice plus midazolam 5mg orally on the third day.
1615846|NCT02117869|Other|Water (control)|3 consecutive daily doses of 200ml water plus midazolam 5mg orally on the third day.
1615847|NCT02117856|Procedure|1 implant placed surgically in the mandibular midline|Participants receive an implant in the mandibular midline using a surgical flap procedure with local anaesthesia.
1615848|NCT02117856|Procedure|2 implants placed surgically in the mandibular canine sites|Participants receive implants bilaterally in the site of the mandibular canines using a surgical flap procedure with local anaesthesia.
1615849|NCT02117856|Procedure|Soft reline (Coe Comfort) of the existing complete lower denture|Participants receive a soft reline of the existing complete lower denture approximately 10 days after placement of the implant(s).
1616967|NCT02110082|Biological|Cetuximab|
1957867|NCT02130687|Drug|Placebo|"Subjects will receive two capsules of placebo to preserve the blinding of the study.
In a separate period, subjects will receive one capsule of placebo and one capsule of sitagliptin."
1615850|NCT02117856|Device|2.25mm ball patrix placed on 1 healed implant|A 2.25mm ball patrix is screwed onto the 1 implant approximately six weeks after placement of the implant.
1615851|NCT02117856|Device|2.25mm ball patrices placed on 2 healed implants|2.25mm ball patrices are screwed onto the 2 implants approximately six weeks after placement of the implants.
1615852|NCT02117856|Procedure|Reline (Ivoclar acrylic-resin) with 1 retentive matrix in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 1 retentive matrix in the denture-base to retain on the implant.
1615853|NCT02117856|Procedure|Reline (Ivoclar acrylic-resin) with 2 retentive matrices in the lower denture|Participants have their complete lower denture relined with a laboratory-processed acrylic resin to incorporate 2 retentive matrices in the denture-base to retain on the implants
1615854|NCT02117843|Device|AVI® Arsenic trioxide drug eluting stent|AVI® Arsenic trioxide drug eluting stent
1615855|NCT02117830|Drug|Androxal 25 mg capsules|
1615856|NCT02117830|Drug|Androxal 250 Capsules|
1615857|NCT02117830|Drug|Placebo Capsules|
1615858|NCT02117830|Drug|Moxifloxacin 400 mg|
1615859|NCT02117817|Drug|BKM120|
1615860|NCT02117817|Drug|Nabpaclitaxel|Given IV
1615861|NCT02117804|Other|Early Screen for Discharge Planning|This screen is completed by a study coordinator within 24 hours of patient admission to the hospital. The screen measures four variables available from routine hospital admission clinical data (walking limitation, age, living alone prior to admission, and level of disability) that exhibit high sensitivity and specificity (AUC's were .82 and.84) in identifying patients who should receive targeted attention from a DP expert.
1615863|NCT02117778|Procedure|Continuous Nerve Block|
1615864|NCT02117765|Drug|Ustekinumab|
1615865|NCT02117752|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
1615866|NCT02117752|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
1615867|NCT02117752|Drug|sodium lauryl sulfate|Patches containing sodium lauryl sulfate (Positive Control) will be applied to the skin.
1615868|NCT02117752|Drug|Normal saline|Patches containing normal saline (Negative Control) will be applied to the skin.
1615869|NCT02117739|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
1615870|NCT02117739|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
1615871|NCT02117726|Drug|Dexmedetomidine,midazolam|
1615872|NCT02117726|Drug|Propofol,midazolam|
1615873|NCT02117713|Drug|LUM001|Administered orally daily
1615874|NCT02117700|Dietary Supplement|N-acetyl cysteine 600 mg once/day|NAC 600 mg once/day + Placebo once/day for 16 weeks
1615875|NCT02117700|Dietary Supplement|N-acetyl cysteine 600mg twice/day|N-acetyl cysteine 600 mg twice/day for 16 weeks
1615876|NCT02117700|Other|Placebo twice/day|Placebo capsules twice/day for 16 weeks
1615877|NCT02117687|Drug|carboxymethylcellulose 0.5%/glycerin 0.9%|1-2 drops OPTIVE FUSION™ (carboxymethylcellulose 0.5%/glycerin 0.9%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
1615878|NCT02117687|Drug|sodium hyaluronate 0.18%|1-2 drops VISMED® Multi (sodium hyaluronate 0.18%) in each eye as needed at least 2 times and no more than 6 times daily, for 3 months.
1957868|NCT02130687|Drug|Sitagliptin|Subjects will receive sitagliptin 100mg daily for 7 days. In addition, subjects will receive either aprepitant or a capsule of placebo to preserve the blinding of the study.
1957869|NCT02130687|Drug|Aprepitant|Subjects will receive aprepitant (125 mg on the first day followed by 80mg/d) for 7 days along with sitagliptin.
1957870|NCT02130687|Other|Mixed Meal Test (MMT)|The first 18 subjects per arm/ group will undergo a mixed meal test on the 7th day of each medication intervention. This will take place after the first half of the study day at the clinical research center, following a 30 minute rest. Subjects will ingest a shake (combination of fixed carbohydrates/ fat/ protein) and have blood pressure, heart rate, and venous blood sample measurements collected for 4 hours after the meal.
1615882|NCT02117661|Dietary Supplement|L-carnitine capsules|Oral
1615883|NCT02117661|Dietary Supplement|Cellulose capsules|oral
1615886|NCT02117635|Biological|CTX DP|20 million cell dose administered by surgery to the damaged area of the brain
1615887|NCT02117622|Drug|insulin degludec|Treatment according to routine clinical practice at the discretion of the treating physician. The assignment of the patient to Tresiba® is decided in advance of this study
1615888|NCT02117609|Dietary Supplement|New DELICAL formula|3 months with the option of continuing until 6 months.
1615889|NCT02117609|Dietary Supplement|Standard DELICAL formula|3 months with the option of continuing until 6 months.
1615891|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fasting conditions
1615892|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, taken whole, single dose, under fed conditions
1615893|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fasting conditions
1615894|NCT02117583|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, Chewed, single dose, under fed conditions
1615895|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
1615896|NCT02117570|Biological|Clostridium difficile vaccine|0.5 mL intramuscular injection on day 1, day 8, and day 30.
1615897|NCT02117570|Biological|Placebo|Placebo (0.9 percent saline) given as a 0.5 mL intramuscular injection on day 1, day 8, and day 30.
1615898|NCT02117557|Procedure|Single incision laparoscopic surgery|
1615899|NCT02117557|Procedure|Conventional laparoscopic surgery|
1615900|NCT02117544|Device|Lotrafilcon B multifocal contact lenses (new)|
1615901|NCT02117544|Device|Lotrafilcon B multifocal contact lenses|
1615902|NCT02117518|Other|blood drawing|
1615903|NCT02117505|Drug|Formulation 2|Single-dose of JNJ-54781532 formulation 2 will be administered as 150 milligram (mg) oral tablet in one of the treatment periods.
1615904|NCT02117505|Drug|Formulation 1|Single-dose of JNJ-54781532 formulation 1 will be administered as 150 milligram (mg) oral tablet (5*30 mg tablet=150 mg) in one of the treatment periods.
1615905|NCT02117492|Procedure|Cuff Closure|Closure of the vaginal cuff following hysterectomy.
1615906|NCT02117479|Drug|Ruxolitinib|5 mg tablets to be administered by mouth twice daily (BID)
1615907|NCT02117479|Drug|Placebo|5 mg tablets to be administered by mouth twice daily (BID)
1615908|NCT02117479|Drug|Capecitabine|150 and 500 mg tablets to be administered by mouth twice daily (BID)
1615909|NCT02117466|Drug|Dose escalation cetuximab|dose escalation of cetuximab (described in the second arm)
1615910|NCT02117466|Drug|Standard dose cetuximab|500mg/m2 bsa cetuximab (described in the first arm)
1615911|NCT02117453|Drug|Rosuvastatin|Rosuvastatin 20 mg/day
1615912|NCT02117453|Drug|Placebo|Placebo
1615914|NCT02117414|Device|MRI scan sequences of the head and chest regions|Non-diagnostic MRI scans
1615915|NCT02117414|Other|Waiting Period Visit|Waiting period time will equate to 1 hour
1615916|NCT02117401|Drug|mivacurium chloride|intravenously injected during induction with the dose according to allocated group, and intravenously injected with the dose of 0.1 mg/kg when T1 recovers to 25% during period of maintenance.
1615917|NCT02117401|Drug|midazolam|"Before induction: after moving into operating room, oral administration with dose of 0.5 mg/kg or mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children
Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
1615918|NCT02117401|Drug|ketamine|"mixed with ketamine (midazolam 10 mg+ ketamine 100 mg) with dose of 0.1 ml/kg by intramuscular route for uncooperative children
Induction: for children who didn't receive mixture of midazolam and ketamine before induction, it will be given with the dose of 0.05 ml/kg"
1615919|NCT02117401|Drug|propofol|Induction: 2 to 3 mg/kg Maintenance: 50 to 100 mcg/kg/min
1615920|NCT02117401|Drug|Remifentanil|Induction: 2 mcg/kg Maintenance: 0.1 to 0.3 mcg/kg/min
1615921|NCT02117388|Behavioral|Sleep Restriction|Sleep Restriction therapy will limit the time spent in bed in order to make sure participants are sleepy enough to fall asleep quickly.
1615922|NCT02117388|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy is designed to identify incorrect ideas about sleep, challenge their validity, and replace them with correct information. This therapy tries to reduce worry, anxiety, and fear that one won't sleep by providing accurate information about sleep.
1615923|NCT02117388|Behavioral|Combined Therapy|Sleep Restriction and Cognitive Therapy will be combined so that the two therapies reinforce each other.
1615924|NCT02117375|Device|spinal cord MRI follow-up|Evaluation : focal lesions (number, volume, localisation), atrophy, parameters from Diffusion Tensor Imaging and parameters from Magnetization Transfer Ratio
1615925|NCT02117375|Other|clinical follow-up|Relapses, treatments, global disability,walking performance, upper limbs motor performance, sphincter disturbances and walking difficulty
1615926|NCT02117375|Other|brain MRI follow-up|
1615927|NCT02117362|Biological|1 mg/kg GR-MD-02|1 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
1615928|NCT02117362|Biological|2 mg/kg GR-MD-02|2 mg/kg GR-MD-02 on Days 1, 22, 43, and 65.
1615929|NCT02117362|Biological|4 mg/kg GR-MD-02|4 mg/kg GR-MD-02 on Days 1, 22, 43, and 65
1615930|NCT02117362|Biological|8 mg/kg GR-MD-02|8 mg/mg GR-MD-02
1615931|NCT02117362|Biological|Ipilimumab|3 mg/kg ipilimumab on Days 1, 22, 43, and 65
1615932|NCT02117349|Drug|Raplixa plus Gelatin Sponge|During the surgical procedure on Day 1 (Visit 2), subjects will be initially treated with Raplixa plus gelatin sponge at the target bleeding site and the time to stop bleeding will be assessed. Subjects may be retreated with Raplixa and gelatin sponge treatment as necessary during the 5-minute assessment period.
1615933|NCT02117349|Drug|Gelatin Sponge|During the surgical procedure on Day 1 (Visit 2), subjects will be initially treated with a gelatin sponge alone at the target bleeding site and the time to stop bleeding will be assessed. Subjects may be retreated with gelatin sponge during the 5-minute time to stop bleeding assessment period.
1615934|NCT02117336|Drug|P1446A-05|"The study have dose escalation phase, followed by a dose extension phase.
Dose escalation phase: five Dose Levels will be evaluated in the 'dose escalation' phase. The Dose Levels selected are 50 mg (Dose Level 1), 75 mg (Dose Level 2), 125 mg (Dose Level 3), 200 mg (Dose Level 4) and 275 mg (Dose Level 5), once daily. If required, a 25 mg once daily dose (Dose Level -1) will also be studied. For Dose Levels 1, 2 and 3 there will be 2- dosing periods: Single Dose and Continuous Dose. At least 3-patients will be enrolled at each Dose Level. Dosing regimens planned for Dose Level 4 and 5 are 200 and 275 mg once daily. In the continuous dose period, patients will receive P1446A-05 on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity.
Dose Extension Phase: Up to a total of 14 patients will be treated at the MTD of P1446A-05, determined in the dose escalation phase, until the occurrence of disease progression or unacceptable toxicity or death."
1615935|NCT02117310|Drug|indocyanine green|ICG will be administered to identify the blood supply at two distinct stages of endonasal cranial base surgery: during nasoseptal flap harvest and after final positioning of the nasoseptal flap to ensure its viability before ending the case.
1615936|NCT02117297|Drug|Gemtuzumab Ozogamicin|Gemtuzumab, 9.0 mg/m2, will be given IV over 2 hours two times post allogeneic transplantation.
1615937|NCT02117271|Device|continuous positive airway pressure|device to treat obstructive sleep apnea using positive airway pressure with a nasal mask
1615938|NCT02117271|Other|Breathe Right ®|Nasal dilator strip treatment used during sleep to open the nasal airway
1615939|NCT02117258|Drug|Z-360|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while Z-360 (60, 120 or 240 mg) will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
1615940|NCT02117258|Drug|Placebo|Gemcitabine (1,000 mg/m^2) will be given by 30-minute intravenous infusion on Day 1, 8, and 15 followed by a one week rest in all 28-day Cycles, while placebo will be taken orally, twice daily (BID) after a meal. Dosing will continue until the patient fulfills the withdrawal criteria.
1616028|NCT02116660|Drug|Tenofovir|Tenofovir disoproxil fumarate (TDF) 300 mg tablets
1615941|NCT02117232|Device|Visualization balloon|"The Visualization Balloon is a disposable medical device that is used during the advancement of the colonoscope inside the colon. The intended use of the Visualization Balloon is to help insertion of the colonoscope into the colon without the aid of gas (air or CO2) insufflation as with standard colonoscopy. The Visualization Balloon is inserted through the biopsy channel of the colonoscope prior to the colonoscope introduction into the rectum. The Visualization Balloon is an inflatable balloon that opens up the lumen of the gastrointestinal tract, thereby allowing the endoscopist to advance the endoscope inside and to view the gastrointestinal tract through the clear balloon."
1615942|NCT02117232|Device|Traditional CO2 insufflation colonoscopy|"Traditional colonoscopy performed with CO2 insufflation without Visualization balloon"
1615943|NCT02117219|Biological|MEDI4736 Evaluate MEDI4736 in MDS|MEDI4736 will be administered by IV infusion
1615944|NCT02117219|Drug|VIDAZA|VIDAZA will be administered subcutaneously as described on the package insert VIDAZA will be administered in combination with MEDI4736 upon progression from MEDI4736 monotherapy
1615945|NCT02117219|Biological|tremelimumab|tremelimumab will be administered by IV infusion
1615946|NCT02117206|Drug|L-arginine (L-arginine Veyron)|
1615947|NCT02117206|Drug|Nacl|
1615948|NCT02117193|Other|Alcohol intake|The subjects will be drink beer (with or without alcohol) before sleep intervention (normal sleep and sleep deprivation).
1615949|NCT02117193|Other|Sleep deprivation|One night of sleep deprivation or one night of normal sleep.
1615951|NCT02117167|Drug|AZD2014|Target: m-TOR
1615952|NCT02117167|Drug|AZD4547|Target: FGFR
1615953|NCT02117167|Drug|AZD5363|Target: AKT
1615954|NCT02117167|Drug|AZD8931|Target: HER2, EGFR
1615955|NCT02117167|Drug|Selumetinib|Target: MEK
1615956|NCT02117167|Drug|Vandetanib|Target : VEGF, EGFR
1615957|NCT02117167|Drug|Standard maintenance for squamous NSCLC|
1615958|NCT02117167|Drug|Pemetrexed|Standard maintenance for non squamous NSCLC
1615959|NCT02117167|Drug|MEDI4736|Target: PD-L1
1615960|NCT02117154|Device|6-day Continuous Glucose Monitoring System|performed 3 times on a patient, one month apart
1615961|NCT02117141|Drug|HC-ER 20 mg capsule (fasted)|Single oral dose HC-ER 20 mg capsule after overnight fast (fasted)
1615962|NCT02117141|Drug|HC-ER 20 mg capsule (fed)|Single oral dose HC-ER 20 mg capsule after high fat meal (fed)
1615963|NCT02117128|Drug|Tranexamic acid|
1615964|NCT02117115|Radiation|Dynamic contrast-enhanced computed tomography|CT scan performed between Day +7 and Day +14.
1615965|NCT02117115|Drug|Ioversol|To optimize visualization of bowel mucosal, patient will be given 1350 ml, or as much as can be tolerated, of negative oral contrast to distend the small bowel one hour prior to scanning. A weight-based volume of Optiray-350 will be injected at a rate of 4 cc/sec followed by 50 cc of saline flush also at 4 cc/sec.
1615966|NCT02117102|Other|Bladder and lumbar stimulation technic|
1615967|NCT02117089|Device|Electrical Stimulation; Rehabilitation Robot|The recruited subjects will receive 20-session device assisted upper limb training with an intensity of 3 to 5 sessions/week, which will be finished within 7 consecutive weeks. In each session, the subjects will conduct the system assisted and task-oriented upper limb training for 1.5 hours.
1615968|NCT02117076|Drug|Gabapentin immediate release|up to 1200 mg per day
1615969|NCT02117076|Drug|Gabapentin enacarbil extended release|up to 1200 mg per day
1615970|NCT02117063|Behavioral|Go Girls! Fitness Support Group|Go Girls! is a dance-based patient fitness support group offered by the University of Virginia Pediatric Endocrinology division in conjunction with the Center for Research in Reproduction and the Children's Fitness Clinic at the University of Virginia for girls. The goals of the program are to introduce girls to exercise in a fun, non-threatening environment, meet other girls, enable girls to discover and develop a personal enjoyment of exercise, and enable low-pressure interactions with medical care providers.
1615971|NCT02117050|Drug|Rebif®|Rebif® will be administered subcutaneously three times a week at a dose of 8.8 to 44 microgram (mcg) in initial titration schedule (5 weeks), followed by Rebif® 44 mcg subcutaneously three times a week by using Rebif® Rebidose® auto-injector device till Week 24.
1615972|NCT02117037|Other|blood sample|
1615973|NCT02117024|Drug|Viagenpumatucel-L|Vaccine derived from irradiated human lung cancer cells genetically engineered to continually secrete gp96-Ig
1615974|NCT02117024|Drug|Metronomic Cyclophosphamide|One 50mg tablet administered orally daily for 7 days on alternating weeks for a total of 6 weeks of therapy over 12 weeks
1615975|NCT02117024|Drug|Physician's Choice Regimen (Vinorelbine, Erlotinib, Gemcitabine, Paclitaxel, Docetaxel, Pemetrexed)|"Physician will select one of the following to be given in nominal 21 day cycles with dose and route according to investigator's standard practice:
Vinorelbine
Erlotinib
Gemcitabine
Paclitaxel
Docetaxel
Pemetrexed"
1615976|NCT02117011|Other|Physical Activity|Those participants randomized to the exercise group will be required to exercise 5 days/week for 8 weeks coinciding with the radiation treatment sessions. The exercise intervention will consist of aerobic training. Participants will be required to meet and maintain a goal of 75 min/week of aerobic exercise by using portable cycle ergometers; that is; 15 min/day for 5 days/week. The cycle ergometer consists of two cycling pedals mounted to a stationary block that allows patients to exercise while sitting. The tension on the pedals can be adjusted to provide desired tension. Patients can also move the equipment so they can use it conveniently while sitting anywhere and with any chair.
1615977|NCT02116998|Biological|GEN-004 with Aluminum Hydroxide Adjuvant|"GEN-004: 100 µg of each antigen, with adjuvant, 350 µg aluminum hydroxide, administered as a 0.5 mL intramuscular (IM) injection.
GEN-004 is a recombinant S. pneumoniae protein subunit vaccine consisting of 3 recombinant T cell antigens:
GB104: ABC transporter, substrate-binding protein
GB144: Maltose/maltodextrin binding protein, ABC transporter
GB152: Hypothetical protein
GEN-004 is filled in 2 mL vials containing 0.5 mL (350 µg/mL of each antigen).
Aluminum hydroxide adjuvant is filled in 2 mL vials containing 1 mL at a concentration of 5 mg/mL."
1615978|NCT02116998|Biological|Placebo|Placebo: normal saline, 0.5 mL per dose, IM.
1616029|NCT02116660|Drug|Emtricitabine|Emtricitabine (FTC) 200 mg tablets
1616030|NCT02116660|Drug|Lopinavir|Lopinavir (LPV) 200 mg tablets
1615979|NCT02116985|Device|Dual-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
1615980|NCT02116985|Device|manual|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits without using the Narcotrend monitor only depend on the experience of anesthesiologist.
1615981|NCT02116972|Drug|FX006|Single intra-articular injection
1615982|NCT02116972|Drug|Normal saline|Single intra-articular injection
1615983|NCT02116959|Drug|Melphalan|
1615984|NCT02116959|Drug|Carboplatin|
1615985|NCT02116959|Drug|Etoposide|
1615986|NCT02116959|Drug|Vincristine|
1615987|NCT02116946|Biological|Platelet Rich Plasma (PRP)|Injection of Leukocyte-rich or Leukocyte-poor Platelet Rich Plasma prepared by the Angel cPRP System along with a 12 week exercise program for treatment of patients with patellar tendinopathy.
1615988|NCT02116946|Other|Saline + exercise|Peritendinous saline injection plus 12 week exercise program.
1615989|NCT02116933|Procedure|Adipose Derived Stem Cells|Adipose derived stem cells harvested from autologous lipoaspirate
1615990|NCT02116933|Procedure|SVF Enriched Autologous Fat Grafting|Cell assisted lipotransfer
1615991|NCT02116907|Drug|E2007|14C-labeled perampanel dissolved in ethanol and administered using a capsule formulation in a single dose, one day
1615992|NCT02116894|Biological|PF-03446962|PF-03446962 will be an investigational formulation supplied by Pfizer . PF-03446962 injection, 10 mg/mL is presented as a sterile solution for IV administration in a formulation consisting of precedented excipients. We will be administering PF-03446962 intravenously at a starting dose of 4.5 mg/kg and escalating to up to 7 mg/kg.
1615993|NCT02116894|Drug|Regorafenib|We will be administering regorafenib on-label for the indication of metastatic colorectal cancer. The indicated dose is 160 mg once daily for the first 21 days of a 28 day cycle. We will start at a regorafenib dose of 120 mg in the combination therapy, but may increase to 160 mg during dose escalation.
1615994|NCT02116881|Procedure|Colorectal Surgery|Application of postoperative questionnaires will be completed by patients. The intervention is the standard of care.
1615995|NCT02116868|Device|Pupillometry guided analgesia (PP)|Analgesia is guided by pupillary reflex provided by the pupillometer (AlgiScan). The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed (Tailored remifentanil controlled infusion). Administration of antihypertensive drugs or vasopressors is also guided.
1615996|NCT02116868|Drug|Tailored remifentanil controlled infusion|The anesthesiologist in charge must adjust the peroperative remifentanil dose (Target controlled infusion) during surgery according to the algorithm proposed
1615997|NCT02116868|Drug|Tailored antihypertensive drug administration|Administration of antihypertensive drugs or vasopressors is guided by the results of the pupillary reflex.
1615998|NCT02116855|Other|according to the efficacy of AJBRs|
1615999|NCT02116842|Drug|0.1% bupivacaine|Epidural block in early labour.
1616000|NCT02116842|Drug|0.075% bupivacaine|Epidural block in early labour.
1616001|NCT02116842|Drug|40 µg fentanyl|Given with different doses of bupivacaine in epidural block.
1616002|NCT02116829|Other|Danish butter|The effect of butter intake versus olive oil (refined) intake on blood lipids (primarily)
1616003|NCT02116829|Other|Olive oil|
1616004|NCT02116816|Dietary Supplement|Polyphenol|Polyphenol
2010676|NCT02896777|Other|Transfer embryo that cultured in pH of 7.23±0.02 from Day 0 to Day 3 then in pH of 7.32±0.02|Post IVF/ICSI and according to the result of the randomization process, women will receive embryo from their oocytes that will be sequentially cultured in pH of in pH of 7.23±0.02 from Day 0 to Day 3 then in pH of 7.32±0.02
1616007|NCT02116790|Drug|Naproxen|Subjects will take one 250mg Naproxen capsule
1616008|NCT02116790|Drug|Sinemet|Subjects will take one 12.5mg/50mg Sinemet.
1616009|NCT02116790|Drug|Sinemet|Subjects will take one 25mg/100mg Sinemet.
1616010|NCT02116790|Drug|Placebo|Subjects will take two placebos.
1616011|NCT02116777|Other|Laboratory Biomarker Analysis|Correlative studies
1616012|NCT02116777|Other|Pharmacological Study|Correlative studies
1616013|NCT02116777|Drug|Talazoparib|Given PO
1616014|NCT02116777|Drug|Temozolomide|Given PO
1616015|NCT02116738|Procedure|Flap Transposition Procedures|Modified Limberg Flap Transposition Procedure and Lateral Advancement Flap Transposition with Burrow's Triangle Procedure in The treatment of Pilonidal Sinus Diseases
1616019|NCT02116712|Drug|Saracatinib|Saracatinib is escalated as follows: Three dose levels will be administered for 1 month each: 50 mg, 125 mg and 175 mg. Three subjects will be treated at the lowest daily dose of 50 mg. If no subject experiences DLT (dose limiting toxicity), the dose level is escalated to 125 mg/day for the next cohort of 3 different subjects and so on to next dose.
1616020|NCT02116699|Other|oropharyngeal mother's milk|Application of 0.2 mL of own mother's milk onto the infant's oral mucosa, followed by brief swabbing, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
1616021|NCT02116699|Other|oropharyngeal sterile water|Application of 0.2 mL of sterile water onto the infant's oral mucosa, followed by brief swabbing, for an initial treatment period of every 2 hours for 48 hours, followed by an extended treatment period of every 3 hours until 32 weeks corrected gestational age
1616022|NCT02116686|Device|ventilatory polygraphic recordings|Standard nocturnal in-home ventilatory polygraphic recordings were performed using an Embla device (Embla®, Broomfield, USA) and scored according to the AASM recommendations (RemLogic® software, Broomfield, USA).
1616023|NCT02116673|Other|Cognitive rest|The intervention is providing discharge instructions instructing cognitive rest and graduated return to usual activities in patients whom have experienced minor traumatic brain injury.
1616024|NCT02116673|Other|Usual care|These are usual care emergency department discharge instructions provided at emergency department discharge for minor traumatic brain injury.
1616025|NCT02116660|Drug|Raltegravir (MK-0518)|Raltegravir (MK-0518) 400 mg tablets
1616026|NCT02116660|Drug|Nevirapine|Nevirapine (NVP) 200 mg tablets
1616031|NCT02116660|Drug|Ritonavir|Ritonavir (r) 100 mg tablets
1616032|NCT02116660|Drug|Atazanavir|Atazanavir (ATV) 300 mg tablets
1616033|NCT02116660|Drug|Darunavir|Darunavir (DAR) 400 mg tablets
1616034|NCT02116647|Behavioral|Psychoanalytic therapy|
1616035|NCT02116634|Biological|mesenchymal stem cell|intra spinal injection of 1 ×10(8) mesenchymal stem cells +10cc normal saline
1616036|NCT02116621|Behavioral|Trialist Intervention|Clinician and patient set up N-of-1 trial and patient uses Trialist smartphone app to answer daily questions about pain and associated side effects.
1616037|NCT02116621|Device|smartphone|
1616038|NCT02116608|Drug|Betadine|Apply locally as needed.
1616039|NCT02116608|Drug|Silver Nitrate|Arzol Silver Nitrate Applicators may be applied directly to mucous membranes and other moist surfaces. In the case of dry skin, the applicator tip should be dipped in water immediately before use. Apply carefully to the area to be treated.
1616040|NCT02116608|Drug|Hydrocortisone Butyrate Cream, 1.0%|Hydrocortisone butyrate cream, 1.0% should be applied to the affected area as a thin film two or three times daily depending on the severity of the condition.
1616041|NCT02116595|Other|high or low acid diet|high or low acid diets
1616042|NCT02116582|Drug|Enzalutamide|Oral capsules
1616043|NCT02116569|Drug|Daratumumab|Participants will be administered intravenously with daratumumab at a dose of 8 or 16 mg/kg up to 8 weeks (total 7 infusions). After 8 weeks, participants will receive daratumumab intravenously at a same dose, two times in every 2 weeks until Week 24 followed by one time in 4 weeks until study discontinuation. If the dose exceeds 24 mg/kg, then it will be considered as overdose in this study.
1616044|NCT02116556|Drug|Prednisone|Prednisone PO 40mg/day or IV equivalent dosage for 30 days. Patients not responding at 7 days (e.g. Lille Model ≥ 0.45) treatment with Prednisone will be suspended.
1616045|NCT02116556|Drug|Rifaximin|Rifaximin PO 1200 mg/day for 90 days
1616046|NCT02116543|Drug|TD-6450|
1616047|NCT02116543|Drug|Placebo|
1616048|NCT02116530|Drug|Olanzapine|oral
1616049|NCT02116530|Drug|Chemotherapy (cisplatin or cyclophosphamide and doxorubicin)|oral or IV
1616050|NCT02116530|Drug|Antiemetic treatment (ondansetron or granisetron or palonosetron; plus dexamethasone; plus fosaprepitant or aprepitant)|oral or IV
1616051|NCT02116530|Other|Placebo|oral
1616052|NCT02116517|Dietary Supplement|green tea extract|500 mg three times per day
1616053|NCT02116517|Dietary Supplement|Placebo|cellulose 500mg three times a day for 6 weeks
1616054|NCT02116504|Procedure|Sampling of blood|Sampling of blood for dosage of antibodies
1616055|NCT02116491|Device|Visual Sputum Suctioning System|All ES procedures were performed on indication by RICU nurses and according to protocol, according to which Closed suction system was performed which the patient remained connected to the ventilator. The double-lumen catheter of the Visual Sputum Suctioning System integrated with a 0.9-mm micro-imaging fiber was inserted into the endotracheal tube until resistance was met and withdrawn 0.5 cm. A negative pressure of maximum 150mmHg was set, and the catheter was withdrawn while gently rotating. The procedure lasted for a total of 10 seconds. Nonsterile gloves were to be used during all procedures.
1616056|NCT02116478|Procedure|surgical proximal medial gastrocnemius recession|proximal medial gastrocnemius recession
1616057|NCT02116465|Drug|Levodopa Carbidopa immediate release tablets|oral administration
1616058|NCT02116452|Dietary Supplement|Supplemented Formula|50:50 mixture of GOS/PDX formula will be administered
1616059|NCT02116426|Biological|Blood work in the ambulance|Blood sample for copeptin and troponin HS testing is taken during ambulance care.
1616060|NCT02116426|Biological|Blood work upon arrival in the emergency room|Blood in drawn for copeptin and troponin HS testing upon arrival in the emergency room.
1616061|NCT02116426|Biological|Blood work at 3 hours post-arrival in the emergency room|Blood is drawn for troponin HS testing 3 hours after the patient's arrival in the emergency room.
1616062|NCT02116413|Procedure|Fluid challenge|The fluid challenge starts at minute 0 (T0) and consists of 500ml of crystalloids over 10 minutes.
1616063|NCT02116413|Procedure|Cardiac ultrasound|Ultrasound measures are made at T0, T2, T4, T6, T8, T10, T20 and T30.
1616064|NCT02116400|Other|Interview|All patients are interviewed at the BEC. Questionnaires and scores are administered. See endpoints.
1616065|NCT02116400|Other|Neuropsychological testing|Neuropsychological tests are administered (requires computer use). See endpoints.
1616066|NCT02116400|Biological|Serum concentration of lithium or sodium divalproate.|Venous blood is drawn and tested for serum concentration of lithium or sodium divalproate.
1616067|NCT02116387|Other|Routine Physical Therapy|Patients randomized to this arm will participate in a classic physical therapy program (15 weeks, a total of 15 sessions).
1616068|NCT02116387|Device|I-Moove Physical Therapy|Patients randomized to this arm will participate in a physical therapy program using the I-Moove device (15 weeks, a total of 15 sessions).
1616069|NCT02116374|Other|Physiopathology study|
1616070|NCT02116361|Biological|onabotulinumtoxinA|OnabotulinumtoxinA injected into protocol-specified areas on Day 1.
1616071|NCT02116361|Drug|Normal Saline|Placebo (normal saline) injected into protocol-specified areas on Day 1.
1616072|NCT02116348|Drug|Cerebrolysin (Nerve growth factor)|Cerebrolysin will be given to the intervention group
1616073|NCT02116335|Drug|Bosentan|Stress response and vascular function will be assessed 3 days following 125 mg twice per day of Bosentan
1616074|NCT02116335|Drug|Placebo|Stress response and vascular function will be assessed 3 days following twice per day placebo
1616075|NCT02116322|Procedure|EUS-FNA with Corkscrew technique|
1616076|NCT02116322|Device|Expect 19 G Flex needle|
1616079|NCT02116296|Behavioral|ToyBox-intervention|
1616080|NCT02116283|Behavioral|48 hour smoking abstinence|Participants will maintain smoking abstinence for 48 hours
1616081|NCT02116283|Other|Smartphone|Participants will use an Android-based smartphone as their own for one month
1616082|NCT02116270|Biological|Blood sample|3 tubes of 5 ml tubes and 4 of 7 ml for biological assays at t0.
1616083|NCT02116257|Drug|Propacetamol|total 4g of Propacetamol added to patient's PCA regimen
1616084|NCT02116257|Drug|PCA regimen|
1616085|NCT02116244|Drug|Civamide Nasal Spray|
1616086|NCT02116231|Drug|Concurrent chemotherapy with cisplatin|Three cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT
1616087|NCT02116231|Radiation|Intensity modulated radiotherapy|Intensity modulated radiotherapy is a technique of radiotherapy.
1616088|NCT02116218|Procedure|acupuncture|Acupuncture in the Hegu (LI4), Shousanli (LI10), Zusanli (ST36), Yanlinquan (GB34), Taichong (LV3) and Ouch point. Needles would be correctly inserted and manually stimulated until the 'De Qi' sensation is elicited. The needles would stay in place for 15 minutes.
1616089|NCT02116218|Procedure|Vaccaria seed|We put Vaccaria seeds near the acupoints without acupressure as an intervention in control group.
1616090|NCT02116205|Biological|HTNV/PUUV DNA vaccine|HTNV/PUUV DNA vaccine mixture, composed of pWRG/HTN-M(co) and pWRG/PUU-M(s2)
1616091|NCT02116205|Biological|Placebo|0.9% sodium chloride
1616092|NCT02116192|Behavioral|Experimental: Low-fructose, reduced carbohydrate diet|"Low Carbohydrate (Low Fructose and Sucrose) Diet (Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg;40-45% CHO, 20-25% Protein, 30-40% Fat)
● Aim for less than 25g fructose daily."
1616093|NCT02116192|Behavioral|General Healthy Diet|Prescribed Hypocaloric regimen to promote 7% initial weight loss via 25-30kCal/kg; 50-60% CHO, 15-20% Protein, 20-30% Fat
1616094|NCT02116179|Behavioral|DVD Intervention|Participants will be randomly assigned, with a baseline and 3 month follow up assessments
1616095|NCT02116140|Other|[C11]Acetate and HED PET|
1616096|NCT02116127|Device|Active tDCS|The intervention is active 2mA transcranial direct current stimulation (tDCS). Direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and delivered for 30 minutes. The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
1616097|NCT02116127|Device|Sham tDCS|The sham intervention is transcranial direct current stimulation (tDCS). 2mA of direct current will be transferred with a pair of saline soaked sponge electrodes (contact area 5 x 7cm), and the current will be turned off after 54 seconds.The electrodes will be placed over F3 and F4 according to the 10-20 international system for EEG placement.
1616098|NCT02116114|Other|Aerobic training|The program of aquatic exercise training was developed involving the following steps : heating : dynamic stretching exercises aerobic exercises , lasting 10 minutes was performed, aquatic fitness : aerobic training and slowdown. The intensity was prescribed based on the Borg scale score 4-6. Aerobic training was performed at intervals. The duration of aerobic fitness was started with eight 20-minute sessions , progressing to eight sessions of 30 minutes and finished with eight 40-minute sessions. Downturn : global stretching exercises , lasting 10 minutes were performed. During all sessions , the patients were instructed to breath with pursed - lip .
1616099|NCT02116101|Dietary Supplement|Bright Momchilovtsi Yogurt|"Oral consumption of Bright Momchilovtis Yogurt containing 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus
Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo."
1616100|NCT02116101|Dietary Supplement|Bright Dairy Beverage|Oral consumption of Bright Dairy Beverage Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.
1616101|NCT02116088|Behavioral|Teacher Coaching|
1616102|NCT02116075|Procedure|Epidural Prolotherapy|caudal injection of 10mL 5% dextrose
1616103|NCT02116075|Procedure|Epidural Steroid|caudal injection of 1mL 80mg depo-medrol with 9ml of 1% lidocaine
1616104|NCT02116062|Device|1. Amniotic membrane transplantation on the cornea with the Da Vinci Si HD© robot (Inlay or overlay technique)|
1616105|NCT02116062|Device|Pterygium removal and autograft of the conjunctiva with the Da Vinci Si HD© robot (Kenyon technique)|
1616106|NCT02116062|Device|Penetrating keratoplasty using Baron trephine and nylon stitches with the Da Vinci Si HD© robot|
1616107|NCT02116049|Behavioral|Disclosure Intervention|The experimental condition is a 4-session + 3 month booster intervention. Session 1 includes an introduction to the project, goal setting, assessment of disclosure strategies or tactics utilized, and disclosure triggers. Session 2 focuses on the costs and benefits of disclosing to casual sexual partners and previous best and worst disclosure experiences. Session 3 begins with the delivery of the encouraging messages and review of the disclosure strategies already employed. Session 4 is a continuation of session 3 activities with an additional focus on expanding the participant's repertoire of strategies; discussion of methods of sexual negotiation, and rehearsal. The booster session includes a discussion of what strategies have been used in the preceding months, which strategies worked and how can these be enhanced, which strategies did not work with opportunities for troubleshooting, and an examination of rewards experienced or costs encountered.
1616108|NCT02116049|Behavioral|Attention Control Case Management|Comprehensive Risk Counseling and Services (CRCS) will be used to guide the case management activities. CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs. CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance.
1616110|NCT02116023|Other|Orange flavored beverage|
1616111|NCT02116010|Drug|E. coli Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat respectively E. coli burn wound infection
1616112|NCT02116010|Drug|Standard of care : Silver Sulfadiazine|Use of Standard of care : Silver Sulfadiazine, to treat E. coli or P. aeruginosa infected burn wound
1616113|NCT02116010|Drug|P. Aeruginosa, Phages cocktail|Use of Pherecydes Pharma Phages cocktail to treat P. aeruginosa burn wound infection
1616114|NCT02115997|Drug|Methylprednisolone|Methyprednisolone will be administered 1 to 3 pulses at a dose of 1000 milligram (mg) IV at the discretion of the investigator.
1616115|NCT02115997|Drug|Prednisone|Prednisone will be administered orally at tapered dose (start at 1 milligrams per kilogram per day [mg/kg/day]) at the discretion of investigator given daily until participants are off the drug.
1616116|NCT02115997|Drug|Rituximab|Rituximab will be administered at 375 milligrams per meter square (mg/m^2) of body surface area given by IV infusion once weekly from Week 1 to 4.
1616117|NCT02115984|Drug|Panagen|
1616119|NCT02115984|Procedure|Chemotherapy|Chemotherapy course includes 500 mg/m2 cyclophosphan, 50 mg/m2 doxorubicin, and 500 mg/m2 fluorouracil administered intravenously in one day.
1616120|NCT02115971|Other|Jumping exercise|Total 120min exercise
1616121|NCT02115971|Other|Strength exercise|Total 120 min exercise
1616122|NCT02115958|Biological|cancer stem cell vaccine|
1616123|NCT02115945|Other|DN4 test|The DN4 test was used to evaluate neuropathic pain.
1616124|NCT02115945|Other|The SF 12 test|The SF 12 test (SHORT FORM 12) was used to evaluate quality of life.
1616125|NCT02115945|Other|HAD scale|The anxiety/depression scale (HAD) was used to assess anxiety and depression.
1616126|NCT02115945|Other|Visual analogue score|Visual analogue score vas used to evaluate pain.
1616127|NCT02115945|Procedure|femoral block|
1616128|NCT02115945|Procedure|epidural block|
1616129|NCT02115932|Other|Strength & Balance Training|Subjects will be guided through 8 weeks (1 hour per week) of home-based strength and balance training sessions. During each session, a trainer will guide subjects to perform muscle strengthening, range of motion, static balance, dynamic balance and endurance exercises, after an initial warm up. They will also be given advice on continuing such training as well as daily walking for the rest of the week.
1616130|NCT02115919|Drug|Leukocyte Interleukin, Injection 200IU|Cohort A participants will receive 200IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then 14 days off with out any Multikine injections received. After the 14 days without receiving the Investigational Product injections they will begin a second round of 200IU Multikine perilesional injections once daily, Monday through Friday for 14 days.
1616131|NCT02115919|Drug|Leukocyte Interleukin, injection 400IU|Cohort B participants will receive 400IU Multikine perilesional injections once daily, Monday through Friday, for 14 days, then they will not receive any Multikine perilesional injections for 14 days. After the 14 day rest period when the participants did not receive the Investigational Product injections they will begin a second round of 400IU Multikine perilesional injections every day, Monday through Friday, for 14 days.
1616132|NCT02115906|Other|1H/31P Magnetic Resonance Spectroscopy|The 31P-MRS examinations will be performed in a 7 T MR system (Siemens Healthcare, Erlangen, Germany) using a double-tuned (31P/1H) surface coil (Rapid Biomedical Ltd, Rimpar, Germany), with a diameter of 10 cm. Participants will be investigated lying in lateral position with the right lobe of the liver positioned over the coil.
1616133|NCT02115906|Other|oral glucose tolerance testing|"In patients without overt diabetes, glucose tolerance will be assessed by an oral glucose tolerance test, routinely performed at the outpatients clinic. The test will be performed in the morning after an overnight fast of at least 8 hours. Blood will be drawn via a catheter placed in an antecubital vein of one arm. Blood samples for the assessment of glucose, insulin, C-peptide, free fatty acids and growth hormone will be drawn at baseline as well as 30, 60, 90 and 120 minutes after ingestion of 75g glucose in a solution.
Concentrations of glucose, insulin and C-peptide will be used to derive parameters of insulin secretion and insulin sensitivity by mathematical modelling."
1616134|NCT02115906|Other|Thyroid sonography|In acromegalic patients thyroid morphology will be assessed at the outpatient clinic of the Division of Endocrinology and Metabolism, using standard ultrasound technique. Measurements will be performed by a well- experienced physician at baseline and at each follow up examination in an out-patient care setting.
1616135|NCT02115893|Dietary Supplement|Sodium Nitrate|
1616136|NCT02115893|Dietary Supplement|Sodium Chloride|
1616137|NCT02115880|Behavioral|Prevention programme|Based on a group- and family-based cognitive behavioural manual developed by Bruce Compas and colleagues in the USA, and adapted for a German sample. The programme is for parents and children and consists of 8 weekly sessions and 4 monthly booster sessions.
1616138|NCT02115867|Dietary Supplement|Probiotic|Symprove probiotic
1616139|NCT02115854|Other|labial biopsy|
1616140|NCT02115841|Device|"Enraf-Nonius Muscle stimulator"|The order 15Hz TENS stimulation session and sham stimulation session will also be randomized.
1616142|NCT02115815|Biological|Placebo|Participants will receive placebo (sterile saline for human use from commercial source liquid) on Day 1.
1616143|NCT02115815|Biological|RSV sF 20 mcg|Participants will receive single dose of 20 mcg RSV sF by intramuscular injection on Day 1.
1616144|NCT02115815|Biological|MEDI7510 (20 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 20 mcg RSV sF by intramuscular injection on Day 1.
1616145|NCT02115815|Biological|RSV sF 50 mcg|Participants will receive single dose of 50 mcg RSV sF by intramuscular injection on Day 1.
1616146|NCT02115815|Biological|MEDI7510 (50 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 50 mcg RSV sF by intramuscular injection on Day 1.
1616147|NCT02115815|Biological|RSV sF 80 mcg|Participants will receive single dose of 80 mcg RSV sF by intramuscular injection on Day 1.
1616148|NCT02115815|Biological|MEDI7510 (80 mcg RSV sF)|Participants will receive single dose of MEDI7510 containing 80 mcg RSV sF by intramuscular injection on Day 1.
1616149|NCT02115802|Device|Activa PC+S|Subjects will undergo placement of bilateral standard Deep Brain Stimulation (DBS) electrodes (Medtronic model 3387/3389) and implantation of the Activa PC+S, a modified impulse generator (IPG) for DBS with the added technology of neural signal recording.
1616150|NCT02115789|Behavioral|Visual Analog Scale|"Subjects will review examples of both linear and zigzag scars and rate the aesthetic appearance of both configurations of scars on a scale of 1 through 10, with 1 being normal skin and 10 being the worst scar imaginable."
1616151|NCT02115776|Drug|Amoxicillin-Potassium Clavulanate|Administer Amoxicillin-Potassium Clavulanate following endotracheal intubation prior to single tooth-extraction
1616152|NCT02115776|Drug|Amoxicillin|Administer Amoxicillin following endotracheal intubation prior to single tooth-extraction
1616153|NCT02115776|Drug|Chlorhexidine|Administer Chlorhexidine Digluconate following endotracheal intubation prior to single tooth extraction
1616154|NCT02115763|Drug|Caffeine|
1616155|NCT02115763|Drug|Placebo|
1616156|NCT02115750|Drug|Etanercept|Head-to-head comparison
1616157|NCT02115750|Drug|CHS-0214|
1616158|NCT02115737|Behavioral|Dialectical Behavior Therapy Skills Group|
1616159|NCT02115737|Behavioral|Psychoeducation group treatment|
1616347|NCT02114398|Other|usual treatment + sophrology|usual treatment + sophrology
1616160|NCT02115724|Dietary Supplement|Antioxidant cocktail|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
1616161|NCT02115724|Other|Biopsy|Under sterile conditions, a small incision (¼ - ½ inch) by the study doctor will be made and the piece of fat will be taken out. Fat tissue was chosen for this study because it is a big source of small blood vessels which we are studying
1616162|NCT02115724|Other|Placebo|Flow-Mediated Dilation will be determined at baseline and 2 hours following acute antioxidant treatment
1616163|NCT02115724|Drug|NMD; 0.4mg sub-lingual nitroglycerin spray|Nitroglycerin mediated dilation will be measured immediately following an administered 0.4mg dose of nitroglycerin spray, sub-lingual.
1616164|NCT02115711|Behavioral|Community health worker|The intervention is a multi-component one that is tailored to the individual and will target lifestyle changes, health seeking behavior and medication compliance. The CHW, after identifying the cardiovascular risk factors, will give advice about lifestyle interventions and will encourage hypertensives and diabetics to seek a physician. The first phase of the intervention will target hypertension, while the second phase which will be introduced 6 months after the first visit will target diabetes and smoking. The CHW will continue visiting the home of the participants every 2 months to reinforce the previous recommendations, seek to address reasons for non-adherence, address knowledge deficits and encourage physician visits.
1616165|NCT02115698|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
1616166|NCT02115698|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
1616167|NCT02115698|Dietary Supplement|Protein Whey|Two daily 20 g whey protein and 10 g carbohydrate supplementations for 52 weeks.
1616168|NCT02115698|Dietary Supplement|Protein Collagen|Two daily 20 g collagen protein and 10 g carbohydrate supplementations for 52 weeks.
1616169|NCT02115698|Dietary Supplement|Carbohydrate|Two daily 30 g carbohydrate supplementations for 52 weeks.
1616170|NCT02115685|Other|Treadmill Training|Subjects will be randomized to a high intensity and low intensity group. The high intensity group will train at 70-80% of their HRR and the low intensity group will train at 30-40% of their HRR.
1616171|NCT02115672|Drug|BL-8040|BL-8040 will be added to imatinib to improve CML response.
1616172|NCT02115659|Drug|Triptolide-Containing Formulation|Triptolide-Containing Formulation (1mg/kg/d) plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain.
1616173|NCT02115659|Drug|Placebo|Placebo plus standard treatment of complications. Anti-hypertension drug(s) for hypertension; Antibiotics for cyst infections; cause oriented treatment for flank pain, etc.
1616174|NCT02115646|Device|fractionated carbon dioxide laser|patients will have serial laser treatments
1616175|NCT02115633|Device|Walkasins ON|Subjects will be wearing a device that works as intended and provides real-time vibrotactile feedback that reflects center of pressure sway.
1616176|NCT02115633|Device|Walkasins OFF|Subjects will be wearing a device that is turned off.
1616177|NCT02115620|Other|Telemedicine|Daily updates on symptoms, weight, vital signs, and relevant labs will be communicated by phone with cardiology nurses at Providence Heart Clinic. Concerning changes in symptoms or signs will trigger a telemedicine clinic visit with a HF specialist using remote video/audio, virtual stethoscope technology, and VZ Cloud managed hosting. The consult will include a virtual face-face interview and physical examination between patient and HF clinician using Cisco Yabber Video, Littman e-stethoscope, and Verizon managed hosting. Medication changes, laboratory testing, additional virtual visits, or in-person clinic visits can be arranged as appropriate.
2010677|NCT02894957|Drug|Varenicline|: Patients will be randomized either to receive varenicline (uptitrated to 1 mg twice daily) for smoking reduction or smoke as usual for 4-6 weeks before quitting. After quit-day, the two groups will receive standard 12-week varenicline treatment. Non-treatment follow-up will continue to 6 months.
1616179|NCT02115594|Drug|Fulvestrant|
1616180|NCT02115594|Drug|Entinostat|
1616181|NCT02115594|Drug|Placebo|
1616182|NCT02115581|Drug|Coenzyme Q10|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
1616183|NCT02115581|Drug|Placebo|dose of 2 mg/kg/day in 2 or 3 divided doses and increased to the maximum dose of 10 mg/kg/day according to the patient's tolerance
1616184|NCT02115555|Behavioral|HIT-aided approach|Subjects randomized to this approach will be using the HIT-aided monitor.
1616185|NCT02115555|Behavioral|Contracted conflict management system|Subjects randomized to this arm will be using the behavioral contracted conflict management system.
1616186|NCT02115555|Behavioral|HIT plus contracted conflict management|Subjects randomized to this arm will use both the HIT-aided approach and the behavioral contract conflict management system.
2010678|NCT02893930|Drug|Sapanisertib|Given PO
1616188|NCT02115529|Drug|Nabilone|Nabilone (0.5 mg) or placebo given preoperatively
1616189|NCT02115529|Drug|Placebo|Placebo Comparator: identical capsule containing placebo (single dose) given preoperatively
1616190|NCT02115516|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, infectious P. falciparum sporozoites, strain NF54
1616191|NCT02115516|Biological|0.9% Sodium Chloride (Placebo)|
1616192|NCT02115490|Drug|Bisphosphonates|
1616193|NCT02115477|Procedure|Lymphadenectomy|Pelvic and/or paraaortic lymphadenectomy
1616194|NCT02115464|Drug|Metformin plus Chemo-radiotherapy|Metformin 2000 mg a day for 12 months plus cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
1616195|NCT02115464|Radiation|Chemo-radiotherapy|Cisplatin-based chemotherapy with or without consolidation with standard radiotherapy of 60-63 Gy for 6 weeks.
1616196|NCT02115425|Other|Body Measurements|A series of body measurements will be taken by trained staff. These measurements include height and weight. These measurements will be completed twice during this time. You will wear a hospital gown and bathing suit for these measurements.
1616197|NCT02115425|Other|Whole Body DXA Scan|This scan measures the amount of bone, muscle, and fat in your body. The scan will be performed using a whole-body scanner. You will be required to wear a hospital gown, to remove all metal-containing objects from your body, and to lie down on the table.
2010679|NCT02893917|Drug|Cediranib|Given PO
1621788|NCT02073448|Drug|CD0271|
1616198|NCT02115425|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. Once changed and barefoot, you will be asked to stand on a scale (similar to a large gym scale) and to hold on to hand electrodes on each side of the scale. You will be asked to step off of the scale once the measurement is complete (less than one minute). You will also hold on to hand electrodes for three other BIA systems.
1616199|NCT02115425|Other|Bioelectrical Impedance Analysis (BIA)|These tests will measure the amount of fat in your body. You will be asked to change into a hospital gown and to remove all footwear and socks/stockings. You will be asked to hold on to hand electrodes on a hand hold device. You will be asked to complete 3 measurement (less than one minute). You will also hold on to hand electrodes for two other BIA systems.
1616200|NCT02115425|Other|add name here|
1616201|NCT02115386|Drug|Nilotinib|300 mg
1616202|NCT02115373|Drug|MSC2156119J|MSC2156119J tablet will be administered in a total dose of 300 to 500 milligram (mg) orally once daily for repeated 21-day cycles until disease progression, intolerable toxicity, death, or withdrawal from treatment.
1616203|NCT02115360|Drug|Calcitonin|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
1616204|NCT02115360|Drug|Fentanyl|Under full aseptic conditions, the epidural space was identified at the L 2-3 or L 3-4 lumbar interspace using the loss-of-resistance to saline technique using 16-gauge Tuohy needle. A test-dose of 3 mL of a 2% solution of lidocaine with adrenaline (1:200,000) will be given to exclude subarachnoid or intravenous catheter placement. An injection of a2 ml hyperbaric bupivacaine will be injected into the subarachnoid space through 25 gauge spinal needle, then 15ml 0.5% bupivacaine, 100 micrograms of fentanyl and 1ml normal saline will be injected epidurally in Bupivacain- fentanyl (BF) Group, then a 16G Portex catheter was inserted for post- operative analgesia.
1616205|NCT02115347|Drug|Ertugliflozin 15 mg|
1616206|NCT02115334|Behavioral|professional therapists delivering the PHPA|PHPA are delivered by professional therapists, which including gross motor, fine motor, cognition verbal, social interactions, activity of daily living(ADL).
1616207|NCT02115334|Behavioral|parents executing the PHPA|PHPA are executed by parents, which including gross motor, fine motor, cognition verbal, social interactions, ADL.
1616208|NCT02115334|Behavioral|health education|health education of the children with DD.
1616209|NCT02115321|Drug|Grazoprevir|GZR was supplied as two 25 mg tablets in the Part A CP-B arm, or as either one GZR 100 mg tablet or one fixed-dose combination (FDC) tablet containing GZR 100 mg + EBR 50 mg in a single tablet (MK-5172A) in the Part A NC arm. GZR was taken q.d. by mouth.
1616210|NCT02115321|Drug|Elbasvir|EBR was supplied as 50 mg tablets and was taken q.d. by mouth.
1616211|NCT02115321|Drug|MK-5172A|MK-5172A FDC tablet containing GZR 100 mg + EBR 50 mg taken q.d. by mouth.
1616212|NCT02115308|Drug|Regadenoson|Regadenoson injection is a pharmacologic stress agent indicated for radionuclide myocardial perfusion imaging.
1616213|NCT02115295|Drug|Cladribine|"Induction Phase:
Cladribine 5 mg/m2/day by vein on Days 1 - 5.
Consolidation Phase:
Cladribine 5 mg/m2/day by vein on Days 1 - 3."
1616214|NCT02115295|Drug|Cytarabine|"Induction Phase:
Age < 60 years: Cytarabine 2 grams/m2 by vein on Days 1 - 5. Age > or = 60 years: Cytarabine 1.5 grams/m2 by vein on Days 1 - 5
Consolidation Phase:
Cytarabine 1.5 grams/m2 by vein on Days 1 - 3. Age > or = 60 years: Cytarabine 1 grams/m2 by vein on Days 1 - 3."
1616215|NCT02115295|Drug|Idarubicin|"Induction Phase:
Idarubicin 10 mg/m2/day by vein on Days 1 - 3.
Consolidation Phase:
Idarubicin 8 mg/m2/day by vein on Days 1 - 2."
1616216|NCT02115295|Behavioral|Phone Calls|After last dose of study drug, participant called every 6 -12 months by a member of the study staff to ask about any side effects they may be having. The phone call should take about 5-10 minutes.
1616217|NCT02115282|Drug|Entinostat|Given PO
1616218|NCT02115282|Drug|Exemestane|Given PO
1616219|NCT02115282|Drug|Goserelin Acetate|Given SC
1616220|NCT02115282|Other|Laboratory Biomarker Analysis|Correlative studies
1616221|NCT02115282|Other|Pharmacological Study|Correlative studies
1616222|NCT02115282|Other|Placebo|Given PO
1616223|NCT02115282|Other|Quality-of-Life Assessment|Ancillary studies
1616224|NCT02115256|Drug|Intravenous Terbutaline|0.25 mL of Intravenous Terbutaline. This will be followed 3 minutes later by an injection of 0.25 mL IV of normal saline.
1616225|NCT02115256|Drug|Intravenous Nitroglycerine|The dose of IV nitroglycerine will be 100 micrograms three minutes before beginning the procedure, and because of it's short half-life (approximately 3 minutes) will be followed by a second dose 3 minutes later just after the start of the procedure for a total of 200 micrograms.
1616226|NCT02115243|Drug|Ipilimumab|
1616227|NCT02115230|Procedure|Renal denervation + medical therapy|Renal denervation + medical therapy Renal sympathetic denervation with an irrigated radiofrequency catheter with Celsius Thermocool (Biosense Webster, California, USA) + standard optimized medical therapy for diastolic heart failure
1616228|NCT02115217|Device|Leukotape K|All interventions will be performed by a qualified physiotherapist in a standardized manner. Tape will be extended to the recommended length (120%) and applied along the outer side of the leg, along the path of the peroneal muscle. Starting in the middle of the foot arch, the tape ends 1 cm below tibial head.
1616229|NCT02115217|Device|Sham kinesiotape|KT put with no effects
1616230|NCT02115217|Other|Control|absence of tape
1616231|NCT02115204|Drug|Epirubicin|
1616232|NCT02115204|Drug|Cyclophosphamide|
1616233|NCT02115204|Drug|Docetaxel|
1616234|NCT02115204|Drug|Methotrexate|
1616235|NCT02115204|Drug|5-fluorouracil|
1616350|NCT02114359|Drug|Capecitabine/cisplatin|Capecitabine/cisplatin (XP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv over 15min D1, capecitabine 1000mg/m2 (80% dose of 1250mg/m2) po bid D1-14, q 3wks
2010680|NCT02893917|Other|Laboratory Biomarker Analysis|Correlative studies
1616236|NCT02115191|Device|2-octylcyanoacrylate|After sedation with midazolam (0.5 mg/kg orally) a Foley catheterization with a 10 Fr gauge siliconized catheter will be placed, with the balloon inflated with 1.5 ml water to prevent bladder spasm. After this we will apply the adhesive by using dissecting forceps to approximate the edges of the UCF, and then apply it several thin layers of OCA.
1616237|NCT02115191|Procedure|Surgical reintervention|The reoperation will consist on mobilizing dartos flaps and closing the defect in layers with absorbable sutures. Urinary bladder drainage will be provided with a 10 Fr silicone Foley catheter, with the balloon inflated with 1.5 ml water to prevent bladder spasm.
1616238|NCT02115178|Other|Lithotomy or Prone position|The surgery, haemodynamic measurements will be performed in Lithotomy or Prone position
1616239|NCT02115165|Drug|Cabazitaxel|On Day 1 of each cycle, patients will receive cabazitaxel at a dose of 25 mg/m², administered by IV route in 1 hour
1616240|NCT02115152|Drug|fluorouracil|
1616241|NCT02115152|Drug|capecitabine|
1616242|NCT02115152|Drug|cyclophosphamide|
1616243|NCT02115152|Drug|Epirubicin|
1616244|NCT02115139|Drug|Ipilimumab|Ipilimumab 3mg/Kg iv q 3 weeks for 4 cycles
1616245|NCT02115126|Biological|LMP2A-loaded conventional DC vaccine|"Vaccine #1 will be administered 9-13 weeks status post peripheral blood stem cell (PBSC) infusion. At the time of vaccination, ANC must be > 1.5.
Vaccine #2, the booster vaccine, will be administered 4 weeks +/- 7 days status post vaccine #1. At the time of vaccination, ANC must be > 1.5.
Vaccines will be administered following standard institutional practice for IV infusions using a peripheral or central line and following sterile technique. On the day of vaccination, the patient will be given a total dose of 3 x 107 cells in 30ml of normal saline per vaccination."
1616246|NCT02115126|Biological|DUK-CPG-001|"On the day of vaccination, for those patients who are randomized to receive DUK-CPG-001, a single vial will be dispensed to the nurse, upon request, by Duke ICS. DUK-CPG-001 will be thawed at room temperature right before use and 0.5 ml (5 mg) will be injected subcutaneously immediately after vaccination.
DUK-CPG-001 will be stored at -20ºC until use. It will be stored in the Duke Investigational Chemotherapy Service pharmacy.
Using standard institutional guidelines and sterile technique for subcutaneous injections, 5 mg of DUK-CPG-001 will be injected subcutaneously immediately after each vaccination."
2010681|NCT02893917|Drug|Olaparib|Given PO
2010682|NCT02893696|Other|Various sitting time|Various sitting time
2010683|NCT02890303|Device|Zepto System|Anterior Capsulotomy using the Zepto System.
1616250|NCT02115100|Procedure|procedure|Renal ablation+pulmonary vein isolation OR pulmonary vein isolation only
1616251|NCT02115087|Procedure|ultrasound guided rectus sheath block|the application of rectus sheath block with ultrasound guidance
1616252|NCT02115087|Drug|Morphine|
1616253|NCT02115074|Drug|Fluvastatine|"Escalation dose : Level 1: 2mg/kg/day. Level 2: 4mg/kg/day. Level 3: 6mg/kg/day. Level 4: 8mg/kg/day.
Per os from D1 to D14 of each 28 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops."
1616254|NCT02115074|Drug|Celebrex|"Dose levels : 100 mg twice a day (< 20 kg), 200 mg twice a day (20-50 kg), 400 mg twice a day (> 50 kg)
Per os from D1 to D28 of each 28 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops."
1616255|NCT02115061|Device|Treatment: coil + cyanoacrylate|This group had fourteen patients who met all inclusion criteria. These will be treated with coil + cyanoacrylate.
1616256|NCT02115061|Device|Treatment: cyanoacrylate|This group owned fourteen patients who met all the inclusion criteria. These will be treated with cyanoacrylate.
2010684|NCT02890875|Other|Ethanol lock|
2010685|NCT02890875|Other|Heparin lock|
1616259|NCT02115035|Drug|Vermurafenib|960 mg of Vermurafenib twice daily orally on a 28 day schedule
1616260|NCT02114983|Other|compression ultrasonography|CUS in patients with a high pre-test clinical probability of DVT and/or a positive D-dimer
1616261|NCT02114970|Other|Randomized- paper consent|
1616262|NCT02114970|Other|Randomized- Tablet-delivered consent|
1616263|NCT02114970|Other|Focus Group- paper and tablet consent|
1616264|NCT02114957|Dietary Supplement|800mg dietary supplement CognIQTM (4 capsules) by oral at hour 0|
1616265|NCT02114944|Device|NIV|Patients treated, as per attending physician's decision, with noninvasive ventilation
1616266|NCT02114944|Device|CPAP|Patient treated, as per attending physician's decision, with CPAP
1616267|NCT02114944|Device|Standard oxygen|Patient treated, as per attending physician's decision with standard oxygen therapy either as primary respiratory therapy or rest therapy during breaks off CPAP or NIV
1616268|NCT02114944|Device|HFNC|Patients treated, as per attending physician's decision, with high-flow nasal cannula either as primary therapy or rest therapy during breaks off NIV or CPAP
1616269|NCT02114931|Biological|ABP 501|Solution for subcutaneous injection in a syringe containing 40 mg/0.8 mL ABP 501
1616270|NCT02114918|Behavioral|Attention Modification Program|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm has been modified to facilitate an attention bias away from threatening material. In this case, the probe always replaces the neutral word. Thus, although there will be no specific instruction to direct attention away from the threat word, on all trials, the position of the neutral word will indicate the position of the probe."
1616351|NCT02114359|Drug|S-1/cisplatin|S-1/cisplatin (SP) : cisplatin 50mg/m2 (80% dose of 60mg/2m) iv ov 15min D1, S-1 30mg/m2 (80% dose of 40mg/m2) po bid D1-14, q3wks
2010686|NCT02890355|Drug|Fluorouracil|Given IV
1621789|NCT02073448|Drug|CD1579|
2010687|NCT02890355|Drug|Fluorouracil|Given IV bolus
2010688|NCT02890355|Drug|Irinotecan Hydrochloride|Given IV
2010689|NCT02890355|Other|Laboratory Biomarker Analysis|Correlative studies
2010690|NCT02890355|Drug|Leucovorin Calcium|Given IV
2010691|NCT02890355|Drug|Veliparib|Given PO
2010692|NCT02891408|Drug|GS-0976|20 mg (2 x 10 mg) capsule (s) or 5 mg (1 x 5 mg) tablet (s) administered orally on Day 1
1616271|NCT02114918|Behavioral|Attention Control Condition|"Each trial begins with a fixation cross presented in the center of the computer screen for 500 ms. The cross is then replaced by a word pair presented in the center of the screen for 500 ms. The word pair disappears and a probe (i.e., the letter E or F) appears immediately in the location of one of the two words. Participants will be instructed to decide whether the letter is an E or an F and press the corresponding mouse button. This paradigm is not intended to facilitate an attention bias away from threatening material. In this case, the probe randomly replaces the threat or neutral word."
1616272|NCT02114905|Behavioral|OTs Trained and Deliver CBIT|"CBIT is a highly structured therapy that typically takes place on a weekly basis. The patient is taught to perform a specific behavior that makes the tic more difficult to do, as soon as the tic or urge appears. This competing response helps to reduce, and in some cases, even eliminate the tic. The functional intervention (FI), is based on the fact that certain situations or reactions to tics can make them worse than they might otherwise be. The goal of FI is to identify these situations and have the patient and family attempt to change them so the tics aren't made worse unnecessarily."
1616273|NCT02114892|Drug|Resveratrol|Resveratrol capsules of 500 mg three times per day before meals with a total dosis of 1500 mg per day.
1616274|NCT02114892|Drug|Placebo|Calcined magnesia capsules, 500 mg, three times per day before meals with a total dose per day of 1500 mg
1616275|NCT02114879|Behavioral|Enhanced Medical Rehabilitation|Daily PT/OT provided by therapists trained in Enhanced Medical Rehabilitation. This training focuses on improved communication, patient engagement, and intensity.
1616276|NCT02114879|Behavioral|Standard of Care Rehabilitation|Daily PT/OT provided by therapists not trained in the treatment intervention.
1616277|NCT02114840|Procedure|Pronator quadratus preservation after volar plate fixation in wrist fractures|Pronator quadratus preservation after volar plate fixation in wrist fractures
1616278|NCT02114840|Procedure|Pronator quadratus repair after volar plate fixation in wrist fractures|Pronator quadratus repair after volar plate fixation in wrist fractures
1616279|NCT02114840|Procedure|Pronator quadratus nonrepair after volar plate fixation in wrist fractures|Pronator quadratus nonrepair after volar plate fixation in wrist fractures
1616280|NCT02114827|Behavioral|Video|23-minute video
1616281|NCT02114827|Behavioral|FAQ Sheet|
1616282|NCT02114814|Behavioral|Experimental: Diabetes Self Management|
1616283|NCT02114814|Behavioral|General Health Education|
1616284|NCT02114801|Device|manual brushing|Tooth brushing
1616285|NCT02114801|Device|electric toothbrush linked|Tooth brushing
1616286|NCT02114801|Device|off electric toothbrush|Tooth brushing
1616287|NCT02114788|Other|Internet-based|
2010693|NCT02887768|Device|Epicardial Infarct Repair with CorMatrix-ECM|CorMatrix-ECM-biomaterial will be surgically applied to the epicardial surface of the infarct myocardium at the time of coronary artery bypass surgery
2010694|NCT02887768|Procedure|Coronary Artery Bypass Grafting Surgery|All participants will undergo standard coronary artery bypass grafting surgery to treat coronary artery disease
2010695|NCT02886065|Drug|Hiltonol|
1616291|NCT02114762|Procedure|Balloon dilation of the Eustachian tube|Insert a balloon into one Eaustachian tube and inflate it for up to one minute. The balloon is then removed.
1616292|NCT02114749|Device|a set of wearable respiration and cardiac monitoring devices|feasibility of methods for detecting physiological state changes from a set of wearable respiration and cardiac monitoring devices
1616293|NCT02114736|Procedure|Tenotomy of the proximal rectus femoris tendon|Surgical release of the proximal tendon of the rectus femoris
1616294|NCT02114736|Drug|Botulinum Toxin injection in the rectus femoris muscle|Injections of 200U of Botox in the rectus femoris muscle with a 2ml/100U dilution
1616295|NCT02114723|Device|Medical Taping Concept|"The material used is a lengthways tape bandage of cotton with elastic properties, provided with a layer of anti-allergic adhesive in one of its sides that does not contain latex. This layer of glue is applied according to a special pattern so as to allow adequate transpiration.
The bandage is applied at the time that menstrual pain begins and is stuck to the skin for 4-5 days until menstrual pain disappears"
1616296|NCT02114710|Drug|Hydrocortisone|Hydrocortisone hemisuccinate (Roussel-Uclaf, Romainville, France), 50 mg intravenously every 6 hrs
1616297|NCT02114697|Drug|Rosuvastatin|Rosuvastatin 20 mg - drug administered orally, once a day, for the duration of the trial, which is 3 years (to be discontinued on account of unacceptable adverse effects)
1616298|NCT02114697|Behavioral|Lifestyle modification|Lifestyle modification includes a recommended exercise regimen, a healthy diet and decreasing alcohol intake for 3 years.
1616299|NCT02114684|Drug|moxifloxacin|[isoniazid (H), rifampicin (R), pyrazinamide (Z), moxifloxacin (M)]
1616300|NCT02114671|Drug|Faldaprevir high dose|capsules, oral
1616301|NCT02114671|Drug|Placebo|capsule, oral
1616302|NCT02114671|Drug|Ciprofloxacin|tablets, oral
1616303|NCT02114671|Drug|Faldaprevir low dose|capsules, oral
1616304|NCT02114658|Drug|Sorafenib (Nexavar,BAY43-9006)|Sorafenib 400 mg will be administered orally,twice daily in a 28 day cycle
1616305|NCT02114645|Drug|Leuprolide acetate|in experimentals groups,on fifth and tenth day after embryo transfer 0,5mg leuprolide acetate is given subcutaneously as luteal phase support
1616306|NCT02114645|Drug|vaginal progesterone|crinone gel is applied till fetal heart beat is detected
1616307|NCT02114645|Drug|4 mg oral estradiol valerate|estrofem is given twice a day
1616308|NCT02114632|Dietary Supplement|Eye Q|3 months of treatment with a polyunsaturated fatty acids or placebo. At 3 months a one-way treatment crossover of the placebo-group to active treatment was made so that both patient groups received active treatment for the remaining 3 month period.
1616309|NCT02114619|Drug|Low dose of I-131|We wil administer 100 micro currie of iodine per thyroid gram
1616310|NCT02114619|Drug|Intermediate dose|We will administer 150 micro currie of iodine per thyroid gram
1616311|NCT02114619|Drug|High dose|We will administer 200 micro currie of iodine per thyroid gram
1616352|NCT02114359|Drug|Capecitabine/oxaliplatin|Capecitabine+oxaliplatin (XELOX): oxaliplatin 100mg/m2 (80% dose of 130mg/m2)iv ov 120min D1, capecitabine 800mg/m2 (80% dose of 1000mg/m2) po bid D1-14, q3wks
2010696|NCT02886065|Drug|Durvalumab|
2010697|NCT02886065|Drug|Lenalidomide|
2010698|NCT02886065|Biological|PVX-410|
2010699|NCT02886026|Device|Bladder tumor resection using diathermia|Conventional bladder tumor resection using diathermia
1616313|NCT02114593|Behavioral|Parent support program|Parent support program
1616314|NCT02114580|Other|physical training|"Participants in both the aerobic and stretching groups will carry out their activity routines 3 d/wk for 45 to 60 minutes per session for 4 months. Training will be on one on one basis, where each participant will be supervised by an experienced trainer at the participant's home.Aerobic intervention protocol: subjects will practice with stationary bicycle. Exercise intensity will be monitored through wireless HR monitor. Participants will be also monitored for the intensity of their workouts by the Borg's Rating of Perceived Exertion and the talk test (a subjective method for estimating of appropriate cardiorespiratory exercise intensity).
Stretching exercise protocol: Participants in the stretching control group will carry out a prescribed routine of stretching and balance exercises."
1616315|NCT02114567|Other|PEEP titration|In both groups, PEEP was titrated and set to 0, 40%PEEPi, 80%PEEPi, and 120%PEEPi
1616316|NCT02114528|Drug|Antiarrhythmic Drug Therapy|Either one or more of the following antiarrhythmic drugs: sotalol, mexiletine, procainamide, or amiodarone.
1616317|NCT02114528|Procedure|Catheter ablation|Ventricular tachycardia catheter ablation.
2010700|NCT02886026|Device|Diode laser (980 nm) tumor destruction|Laser mediated destruction of bladder tumors (LMD-BT)
2010701|NCT02885246|Other|Data collection|The ICGES database of Panama will be checked for all seasonal influenza A and/or B positive cases reported via influenza surveillance programs from 2010 to 2015.
2010702|NCT02884726|Drug|BMS-986148|Specified dose on specified days
1616321|NCT02114502|Drug|Carfilzomib|27 mg/m2 by vein on Days -7 and -6, then on Days -2 and -1
1616322|NCT02114502|Drug|SAHA|1,000 mg by mouth on Days -8 to -3.
1616323|NCT02114502|Drug|Gemcitabine|Loading dose of 75 mg/m2 followed by continuous infusion of the remaining dose of 1875 mg/m2 by vein on Days -8 and -3.
1616324|NCT02114502|Drug|Busulfan|Test dose of 32 mg/m2 by vein on Day -10 if inpatient, on Day -12 if outpatient, then AUC of 4,000 microMol.min on Days -8 to -5.
1616325|NCT02114502|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
1616326|NCT02114502|Procedure|Stem Cell Transplant (SCT)|Stem cell transplant on Day 0.
1616327|NCT02114502|Drug|Palifermin|60 microgram/kg by vein on Days -12 to -10 and Days 0, +1 and +2.
1616328|NCT02114502|Drug|Dexamethasone|8 mg by vein twice a day from Day -9 PM to Day -2 PM.
1616329|NCT02114502|Drug|Caphosol|30 mL oral rinse four times a day from Day -9 until discharge.
1616330|NCT02114502|Drug|Glutamine|15 g four times a day, swished, gargled and spit on Day -9 until discharge.
1616331|NCT02114502|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
1616332|NCT02114489|Drug|ibandronate|Unique perfusion of ibandronate 3 mg IV
1616333|NCT02114489|Drug|Placebo|
1616334|NCT02114476|Device|progestin implant|two small (2.5 mm × 43 mm) silicone rods each containing 75 mg of levonorgestrel in a polymer matrix
1616335|NCT02114463|Procedure|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
1616336|NCT02114463|Procedure|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
1616337|NCT02114463|Drug|ropivacaine|0.2% ropivacaine
1616338|NCT02114463|Drug|flurbiprofen|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
1616339|NCT02114450|Behavioral|Robot-assisted training with the H2 lower limb powered exoskeleton|The H2 is a powered, robotic lower limb exoskeleton with actuated hips, knees and ankles. A custom control algorithm has been implemented in this device, which allows for provision of assistance to lower limb segments during movement, dependent on user needs.
1616340|NCT02114450|Behavioral|Supervised motor practice|Supervised motor practice involves lower limb rehabilitation, primarily walking and other applicable lower limb exercises performed by participants under the guidance and supervision of a research physical therapist.
1616341|NCT02114437|Device|Closed-loop TCI|the controller in the current study measures and calculates the error(NI error),which is the difference between the set point(NI=36)and the measured NI.If the NI error is different from 0,the controller determines a new propoflo and/or remifentanil concentration.
1616342|NCT02114437|Device|Opened-loop TCI|the investigator modified the effect-site target concentrations of both drugs without minimum or maximum concentration limits to maintain NI at approximately 36 within a range of 26 to 46 to the extent possible.
1616343|NCT02114424|Device|Positional vibrator belt|Belt with vibarator to avoid sleep supine
1616344|NCT02114411|Procedure|GastroPanel test|Dyspeptic patients will be referred for the GastroPanel test, containing four biomarkers specific for the gastric mucosa: 1) Pepsinogen I (P-PGI), 2) Pepsinogen II (P-PGII), 3) Gastrin-17 (P-G-17) and 4) H. pylori antibody (P-HpAb).
1616345|NCT02114411|Procedure|Gastroscopy|Dyspeptic patients will undergo gastroscopy examination, with targeted biopsies from the antrum and corpus, following the protocol of the OLGA classification for chronic gastritis and Sydney Classification.
1616346|NCT02114398|Other|usual treatment|usual treatment
1622034|NCT02071641|Drug|Sunitinib|
2010703|NCT02884206|Drug|LCZ696|LCZ696 50, 100, and 200 mg tablets taken orally twice daily with matching placebo for valsartan
2010704|NCT02884206|Drug|Valsartan|Valsartan 40, 80, and 160 mg tablets taken orally twice daily with matching placebo for LCZ696
2010705|NCT02884206|Drug|Placebo of LCZ696|Placebo to match LCZ696 50 mg, 100 mg, and 200 mg tablets
2010706|NCT02884206|Drug|Placebo of Valsartan|Placebo to match valsartan 40 mg, 80 mg, and 160 mg tablets
2010707|NCT02882633|Drug|30ml bolus of bupivacaine|Local anesthetic
2010708|NCT02883699|Behavioral|Standard endurance training|Continuous vigorous training 2 x per week on a cycle ergometer
1616353|NCT02114359|Drug|5-fluorouracil/oxaliplatin|5-fluorouracil/oxaliplatin (FOLFOX): oxaliplatin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, leucovorin 80mg/m2 (80% dose of 100mg/m2) iv ov 120min, 5-fluorouracil 1900mg/m2 (80% dose of 2400mg/m2) iv ov 46h D1, q 2wks
1616354|NCT02114359|Drug|Capecitabine|Capecitabine : 1250mg/m2 po bid D1-14 q3wks (if Ccr <60ml/min, 1000mg/m2 po bid)
1616355|NCT02114359|Drug|S-1|S-1 : 40mg/m2 po bid D1-14 q3wks (if Ccr <60ml/min, 30mg/m2 po bid)
1616356|NCT02114359|Drug|5-fluorouracil|5-fluorouracil (FL) : leucovorin 100mg/m2 iv ov 2h, 5-fluorouracil 2400mg/m2 iv ov 46h D1, q2wks
1616357|NCT02114346|Drug|Atorvastatin|
1616358|NCT02114346|Drug|Placebo|
1616359|NCT02114346|Drug|0.9% sodium chloride|Patients with estimated glomerular filtration rate of less than 60 mL/min/1.73 m2 are hydrated with 0.9% sodium chloride for 2 hours, from 1 hour before (3 mL/kg/hour) to 1 hour after (1 mL/kg/hour) operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg/hour.
1616360|NCT02114333|Biological|Zostavax|0.65ml, subcutaneous
1616361|NCT02114333|Biological|HZ/su vaccine|0.5ml, intramuscular
1616362|NCT02114333|Biological|Placebo|0.65ml, subcutaneous
1616363|NCT02114320|Device|EUS-BD|EUS-guided hepaticogastrostomy (EUS-HG) will be performed in patients with hilar stricture or altered anatomy such as Roux-en-Y anastomosis, and EUS-guided choledochoduodenostomy (EUS-CD) will be performed in patients with mid to distal extrahepatic bile duct strictures. Because EUS-guided rendezvous technique can be attempted only in patients in whom the papilla is endoscopically accessible. Following bile duct puncture using a 19-gauge fine needle, one-step or graded tract dilatation will be performed. Then, finally we insert a partially or fully covered metallic stent.
1616364|NCT02114307|Device|REVITIVE IX|neuromuscular electrical stimulation device
1616365|NCT02114294|Other|Isolated hip strengthening|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Hip strengthening group will train hip abduction, hip external rotation and hip extension.
1616366|NCT02114294|Other|Quadriceps based training|Exercise program that is carried out by subjects under supervision once a week and then performed at home 2 additional times without supervision for a total of 6 weeks. Quadriceps group will train mini-squat, straight leg raising, terminal extensions.
1616367|NCT02114294|Other|Active control|Patients receive standardised information concerning patellofemoral pain syndrome, but receive no prescribed exercise regime. They are encouraged to remain active.
1616368|NCT02114281|Other|Care|
1616369|NCT02114281|Other|Not care|
1616370|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 300 mg MEDI8897 intravenous infusion on Day 1.
1616371|NCT02114268|Drug|Placebo|Participants received placebo on Day 1.
1616372|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 1000 mg MEDI8897 intravenous infusion on Day 1.
1616373|NCT02114268|Drug|MEDI8897 Intravenous|Participants received a single fixed dose of 3000 mg MEDI8897 intravenous infusion on Day 1.
1616374|NCT02114268|Drug|MEDI8897 Intramuscular|Participants received a single fixed dose of 100 mg MEDI8897 intramuscular injection on Day 1.
1616375|NCT02114268|Drug|MEDI8897 Intramuscular|Participants received a single fixed dose of 300 mg MEDI8897 intramuscular injection on Day 1.
1616376|NCT02114255|Other|Placebo|Administration of 0.9% NaCl.
1616377|NCT02114255|Biological|BCG|Vaccination with the live attenuated BCG vaccine.
1616378|NCT02114242|Other|CSF, blood and urine sampling|PSP and MSA patients will receive CSF and blood sampling at two study visits (baseline and after 12 months).
1616379|NCT02114242|Other|clinical measures of disease severity and progression|Questionnaires (quality of life, motricity scales, cognitive scales, depression scales, scale of sleep quality)
1616380|NCT02114229|Drug|alisertib|Alisertib will be administered orally at 80 mg/m^2 per day for enteric coated tablet formulation and 60 mg/m^2 per day for oral solution formulation.
1616381|NCT02114229|Drug|methotrexate|Methotrexate will be given at a dose of 5 g/m^2/dose as an intravenous infusion over 24 hours on day 1 of each induction cycle except in patients ≤ 31 days of age at enrollment. These young infants will receive methotrexate at a reduced dose of 2.5g/m^2/dose.
1616382|NCT02114229|Drug|cisplatin|Cisplatin will be given intravenously (IV): 75 mg/m^2 IV infusion.
1616383|NCT02114229|Drug|carboplatin|Carboplatin may be substituted for cisplatin during induction for patients having Grade 4 ototoxicity or bi-lateral hearing loss after having prior cisplatin dose reduction. Route of administration is IV.
1616384|NCT02114229|Drug|cyclophosphamide|Cyclophosphamide will be given 1.5 g/m^2 IV infusion during induction and consolidation.
1616385|NCT02114229|Drug|etoposide|"Etoposide will be given 100 mg/m^2 IV infusion.
In case of etoposide reactions, etoposide phosphate will be given 40 mg/kg/day."
1616386|NCT02114229|Drug|topotecan|Topotecan will be administered by intravenous infusion over 4 hours on days 1-5 of each consolidation cycle for Stratum B2 and B3 patients not receiving craniospinal irradiation. The initial dose of Topotecan will be based on patient's age with subsequent doses adjusted, if necessary, to achieve a topotecan lactone area under the curve (AUC) of 140 ± 20 ng/mL*hr.
1616387|NCT02114229|Drug|vincristine|Vincristine will be given 1 mg/m^2 IV via 25 mL normal saline (NS) mini-bag (maximum 2 mg for all patients) or administration per local institutional standards for participating sites.
1616388|NCT02114229|Procedure|Surgical resection|"For patients with localized AT/RT, gross total resection results in a significant survival benefit. Maximal resection that can be achieved without undue risk to the patient should be attempted prior to trial enrollment. Decisions about initial resectability will be at the discretion of the local neurosurgeon. In rare instances, the feasibility of completely resecting residual tumor may change as a result of induction chemotherapy; in these cases a second-look operation is encouraged if and may be performed prior to consolidation therapy."
1616389|NCT02114229|Radiation|Radiation therapy|The guidelines for this protocol were developed to maximize the curative potential of radiation therapy and minimize the risk of treatment complications for children with newly diagnosed CNS AT/RT. Focal irradiation is indicated for children < 36 months with no evidence of metastatic disease. Craniospinal irradiation is indicated for children age > 36 months.
1616390|NCT02114216|Procedure|endoscopic mucosal biopsy|endoscopic mucosal biopsy was undertaken for every participant.
1616395|NCT02114190|Behavioral|Adolescent Mindful Eating Group|Adolescents will learn mindfulness and meditation, how to be mindful when eating, mindful yoga, how to recognize hunger cures, understand emotional eating, trigger foods and how to apply mindful eating in social situations.
1616396|NCT02114190|Behavioral|Parent Integrated Group|Adolescents will receive learn same techniques as adolescents in Adolescent Mindful Eating Group. The group component of the parent intervention is designed for parents only and will be run parallel to the adolescent group. The goal of these sessions is to teach parents skills to support adolescent by developing effective parenting styles, parenting skills, strategies around eating behavior change, productive problem solving, and the role of all other family members with regard to the treatment process. The last five sessions will be dedicated to teaching a slightly reduced MEAL adult protocol to allow parents to learn mindfulness skills as it applies to their own eating behaviors and affective reactivity.
1616397|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 12 weeks in Arm 1.
1616398|NCT02114177|Drug|Simeprevir|150 participants will receive 1 capsule of 150 mg simeprevir orally once daily for 8 weeks in Arm 2
1616399|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks in Arm 1.
1616400|NCT02114177|Drug|Sofosbuvir|150 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 8 weeks in Arm 2.
1616401|NCT02114164|Device|AirSeal System|To analyze the results of patients randomized to either the AirSeal system or Standard Endopath trocar.
1616402|NCT02114164|Device|Standard Endopath|This group receives the Standard Endopath Trocar for intraoperative insufflation.
1616403|NCT02114151|Drug|Simeprevir|100 participants will receive 1 capsule of 150 mg orally once daily for 12 weeks.
1616404|NCT02114151|Drug|Sofosbuvir|100 participants will receive 1 tablet of 400 mg sofosbuvir orally once daily for 12 weeks.
2010709|NCT02883699|Behavioral|Polarized endurance training|Continuous moderate training 1 x per week and aerobic high intensity interval training (HIIT) 1 x per week on the cycle ergometer
2010710|NCT02883699|Behavioral|Standard resistance training|Machine based hypertrophy training 2 x per week
1616407|NCT02114125|Behavioral|Physical Activity|group-based physical activity
1616408|NCT02114125|Behavioral|Cognitive Training|individual-based, multi-domains cognitive training
1616409|NCT02114112|Other|NCPAP cycling|
1616410|NCT02114112|Other|NCPAP continuous|
1616411|NCT02114099|Drug|Atorvastatin|10 mg qd x1 year
1616412|NCT02114073|Drug|Cyclosporine|In study arm, ophthalmic emulsion of cyclosporine A 2% will be prescribed in postoperative phase.
1616413|NCT02114073|Drug|Betamethasone|In control arm, betamethasone eye drop will be prescribed in postoperative period.
2010711|NCT02883699|Behavioral|Daily undulating periodization resistance training|Machine based daily undulating periodization resistance training 1 x per week
2010712|NCT02884089|Drug|Abemaciclib|Administered orally
2010713|NCT02884089|Drug|Metformin|Administered orally
1616417|NCT02114021|Drug|betamethasone gel|betamethasone gel (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
1616418|NCT02114021|Drug|lidocaine jelly|the effect of lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
1616419|NCT02114021|Drug|distilled water|The effect of betamethasone gel and lidocaine jelly (over tracheal tube cuff) compared with distilled water on the post intubation syndrome incidence.
1616420|NCT02114008|Other|Endoscopic examinations|Patients underwent two endoscopic examinations within two weeks. RGV was measured by aspiration of gastric contentes into a graduated cylinder after traditional fasting (at least 8 hours before the test) and after abbreviated fasting (3 hours with 200ml of water containing 25g of 12.5% maltodextrin). All patients received both oral and written information about the protocol at the outpatient clinic.
1616421|NCT02113995|Other|ACERTO protocol vs Traditional care|Three sample blood collections were performed, being one in the anesthesic induction and the others in the next 24 to 48 hours. The blood was sent to the laboratory for dosages of glucose, insulin, C-reactive protein, albumin, prealbumin, alpha 1 acid glycoprotein and interleukin 6. During the anesthesic induction we also collected blood for analize glycosylated hemoglobin.
1616422|NCT02113982|Drug|SL-401|
1616423|NCT02113969|Device|Vaginal Pessary|Pessary fitting session at recruitment, follow up at 1 week, then monthly to complete 1 year follow up. QoL, symptoms and sexual function Surveys will be conducted at recruitment, 6 and 12 month. The absence of bacterial vaginosis (through study of vaginal discharge and pH) will be checked prior to positioning pessary and then each control. At the end of follow up period the success related variables will be determine with a statistical model. This information will be analyzed by an expert panel aiming to identify relevant clinical variables not included. This panel will generate a Standardized Management Protocol for symptomatic pelvic organ prolapse using vaginal pessaries.
1616424|NCT02113956|Behavioral|Guy2Guy (G2G)|"G2G is a text messaging-based healthy sexuality and HIV prevention program specifically for 14-18 year old GBQ adolescent males. Content is guided by the Information-Motivation-Behavioral Skills (IMB) model and focuses on: HIV information, motivations to engage in HIV preventive behavior, communication skills, behavioral skills (e.g., using a condom; HIV testing); and healthy/unhealthy relationships. Behavioral skills content is reinforced using brief online videos. The intervention is 5 weeks long. A booster is delivered 6-weeks post-intervention end and reviews the topics covered in the intervention. G2G content is tailored based upon whether one is abstinent or sexually active."
1616425|NCT02113943|Drug|Citalopram 30mg|
1616470|NCT02113449|Drug|Carbon Dioxide|Nasal administration of carbon dioxide (CO2) through the delivery device for 10 seconds
1616471|NCT02113436|Drug|FP/ SLM HFA MDI 50/25 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate and 25 mcg of salmeterol per inhalation
1626602|NCT02036606|Behavioral|questionary|
2010714|NCT02884089|Drug|Iohexol|Administered intravenously (IV)
2010715|NCT02884089|Drug|Placebo|Administered orally
2010716|NCT02883387|Other|Preoperative CT angiography|Patients will receive a CT scan to map the blood vessels to be used during surgery for breast reconstruction
2010717|NCT02883387|Other|No Preoperative Imaging|No imaging will be done to map blood vessels prior to surgery
2010718|NCT02882282|Drug|Pembrolizumab|200 mg by vein on Day 1 of a 21 day cycle for 4 cycles.
1616426|NCT02113930|Biological|Constitution of a biobank of frozen cells, plasma and serum samples|Depending on clinical presentation and based on previous data obtained by our group, we will investigate the immune responses against Human papilloma virus (HPV), Cryptococcus neoformans,implication of chemokines involved in lymphocyte migration (CXCR4 and CCR7 receptors) and signalisation in response to cytokines controlling LT CD4+ homeostasis (IL-7 et IL-2).
1616427|NCT02113930|Genetic|Genetic study|High rate genome wide genetic screening, investigation of mutations associated with identified primary immune deficiencies (adenosine deaminase et class II MHC)
1616428|NCT02113917|Biological|Identification of biological markers|
2010719|NCT02880059|Device|Cardiorepiratory Polygraphy|Sleep apnea screening by out-of-center polysomnography/polygraphy
1616430|NCT02113891|Drug|Eculizumab|"Eculizumab induction: 900 mg IV every 7 days for 4 doses, a fifth 1200 mg dose 7 days later Eculizumab maintenance: 15 1200 mg doses every 14 days.
(each patient will receive a total of 20 eculizumab doses during the whole treatment period from 3 month to 12 month post-transplant)."
1616431|NCT02113878|Drug|BKM120|BKM120 is a potent and highly specific oral pan-class I PI3K inhibitor.
1616432|NCT02113878|Drug|Cisplatin|Cisplatin is a chemotherapy drug
1616433|NCT02113878|Radiation|Intensity-modulated radiotherapy (IMRT)|IMRT is the medical use of ionizing radiation, generally as part of cancer treatment to control or kill malignant cells
1616434|NCT02113839|Procedure|Spirometry|Before re-breathing (if the patient not performed one 6 months in advance).
1616435|NCT02113839|Procedure|CO Exhaled breath|In current smokers of both arms to confirm that the patient has not smoked in the past three hours and to asses the smoking status (heavy, moderate, light).
1616436|NCT02113839|Procedure|P01|P01 is the negative airway pressure generated during the ﬁrst 100 ms of an occluded inspiration. It's an estimation of the neuromuscular drive to breathe.
1616437|NCT02113839|Procedure|FeNO|The measurement of fraction of exhaled nitric oxide during exacerbations of COPD is higher than normal.
1616438|NCT02113826|Drug|Pazopanib|Pazopanib 800mg qd daily for 4 weeks = 1 cycle
1616441|NCT02113800|Drug|Everolimus (Afinitor®)|Formulation: 10 mg/day Route: oral (tablet)
1616443|NCT02113774|Other|antimicrobial treatment according to in-vitro susceptibility|
1616444|NCT02113748|Other|Downhill walking training|Walk on a treadmill with a negative inclination.
1616445|NCT02113748|Other|Conventional walking training|Walk on a treadmill without inclination. Possible to progress training intensity with positive inclinations
1616446|NCT02113735|Drug|H.P. Acthar® Gel (repository corticotropin injection)|
1616447|NCT02113735|Drug|Placebo|
1616448|NCT02113722|Procedure|Left cardiac sympathetic denervation|Left cardiac sympathetic denervation via a video
1616449|NCT02113722|Procedure|Standard of Care|Medical therapy
1616450|NCT02113709|Device|Occlusion therapy by Eye Patch|The good eye was occluded by a stick-on eye patch to stimulate the amblyopic eye and its neural connections to learn to see again.
1616451|NCT02113709|Device|Occlusion therapy|To see how much improvement in visual acuity occurs by full-time occlusion therapy.
1616452|NCT02113696|Dietary Supplement|Omega 3 intake, morbid obesity|Individuals of both sexes with ages between 18 and 65 years took 3g of omega 3, and 1.8g eicosapentaenoic acid (EPA) and 1.2g docosahexanoic acid (DHA) for 8 weeks.
1616453|NCT02113696|Dietary Supplement|Placebo Capsules|They received gelatin (colorless) capsules. A nutritional evaluation was performed, a 24-h recordatory was applied to verify macro and micronutrients intake, biochemical evaluation before and after the intervention. Macro and micronutrients were calculated using the Avanutri 2.0 system. Clinical history was verified through a questionnaire previously filled out by a physician.
1616454|NCT02113670|Other|SUI 1|instillation of 50ml of air into the urinary bladder before the urodynamic test
1616455|NCT02113657|Drug|Ipilimumab|3 mg/kg by vein once every 3 weeks for a total of 4 doses.
1616456|NCT02113644|Other|Lifestyle intervention|
1616457|NCT02113631|Drug|Telaprevir|
1616458|NCT02113631|Drug|Boceprevir|
1616459|NCT02113631|Drug|Peg-IFN|Administration 45-180mcg in 0.5 ml solution s.c. weekly for 24-48 weeks
1616460|NCT02113631|Drug|Ribavirin|Administration: 200 mg capsules; 800 mg-1200 mg daily for 24-48 weeks
1616461|NCT02113618|Behavioral|Cogmed training|Cogmed® working memory training session consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks (i.e. total training time approximately 12,5 hours). In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program adjusts the difficulty of the different tasks trial-by-trial, which allows for each subject to train at a level adjusted to his or her current Working memory capacity
1616462|NCT02113618|Behavioral|Standard Training|Standard training session in an online training and also consists 90 trials and lasts for approximately 30 minutes per day, 5 days a week and during a total training period of 5 weeks. In order to complete the study each subject must complete 20 - 25 training sessions within maximum 6 weeks. The program does not increase in difficultly level
1616463|NCT02113605|Other|Cognitive behavior therapy|Exposure-based cognitive behavior therapy in a 10 week face-to-face treatment
1616464|NCT02113592|Behavioral|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
1616465|NCT02113579|Device|Experimental Mouth Rinse 12027-033|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
1616466|NCT02113579|Other|Placebo Mouth Rinse|After brushing for at least one-minute using at least one-inch strip of toothpaste, rinse with water and then rinse 60 seconds with 10mL of mouth rinse, twice daily.
1616467|NCT02113566|Drug|Acetaminophen 1000mg|Subjects who require rescue medication between hours 4 and 6 will be allowed to take Dose 2 of the study medication. If the subject chooses to take a rescue analgesic (acetaminophen 1000mg), they will be considered a treatment failure. This intervention will be use for the placebo and Ibuprofen arm.
1616468|NCT02113553|Drug|Triptorelin|Triptorelin administered once every 28 days in addition to chemotherapy
1616469|NCT02113540|Drug|Atorvastatin|
1616472|NCT02113436|Drug|FP HFA MDI 50 mcg|Metered-dose aerosol product containing 50 mcg of fluticasone propionate per inhalation
1616473|NCT02113423|Radiation|3D-CRT, IMRT, BT, BT combined 3D-CRT or IMRT|3D - CRT（3D-Conformal Radiotherapy）: CTV-P 50-60Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) IMRT（Intensity Modulated Radiotherapy）: GTV-P 50-60 Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week) BT(Brachytherapy): 2.5Gy BID*10F one week interval BT combined 3D - CRT or IMRT: First,GTV-P 40Gy(2 Gy or 1.8 Gy per daily fraction, 5 days per week);Then, 2.5Gy BID*2F
1616474|NCT02113410|Behavioral|Sit 'N' Fit Chair Yoga (SNFCY)|Experimental: Sit 'N' Fit Chair Yoga - a twice-weekly, 8-week yoga program of 45-minute sessions. Active Comparator: Health Education Program (HEP), a twice-weekly, 8-week program of 45-minute sessions
1616475|NCT02113410|Behavioral|Health Education Program (HEP)|Willing and eligible subjects randomized to the Health Education Program (HEP) will attend twice-weekly 45-minute health education sessions for 8 weeks, for a total of 16 sessions.
1616476|NCT02113397|Drug|TOBI™ Podhaler™ 112 mg inhaled twice daily|
1616477|NCT02113397|Drug|Colistimethate 75 mg inhaled two times daily|
1616478|NCT02113384|Other|Observational study.|Biobanking of tissue (tumor biopsy, peritoneal lavage, blood specimen) from patients with locally advanced rectum cancer undergoing surgical resection of the primary tumor at the Norwegian Radium Hospital.
1616479|NCT02113371|Behavioral|Intervention|
1616480|NCT02113358|Drug|Intravenous colloid bolus with Voluven|
1616481|NCT02113345|Behavioral|Metamemory Cognitive Intervention|Metamemory Cognitive Intervention
1616482|NCT02113332|Drug|Liraglutide|
1616483|NCT02113332|Drug|Placebo|
1616484|NCT02113319|Drug|dasatinib|dasatinib 50 mg and 20 mg During one year
1616485|NCT02113306|Device|t-VNS|The device that will be used is approved for systematic use by those with epilepsy and depression in the European Union. It has been used in studies of acute stimulation with healthy participants with no significant changes in heart rate or breathing (Kraus et al., 2007; Busch et al., 2013).
1616486|NCT02113306|Device|sham stimulation|electrodes will be put upside down
1616487|NCT02113293|Drug|CyclASol®|Cyclosporine A Solution
1616488|NCT02113293|Drug|Placebo (vehicle)|Vehicle Solution
1616489|NCT02113280|Procedure|Arthroscopy|Patients to receive knee arthroscopy and meniscal debridement
1616490|NCT02113280|Procedure|Physiotherapy|Outpatient standardised physiotherapy regime with focus on exercise therapy
1616491|NCT02113267|Drug|Mometasone furoate|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
1616492|NCT02113267|Drug|Placebo|4 spray doses à 50 micrograms by mouth to be swallowed 4 times daily after meals (9) with no eating or drinking allowed 30 minutes after intake. Duration of treatment is 8 weeks.
1616493|NCT02113254|Other|Corn zeaxanthin|The treatment will consist in a daily consumption of a box of 125g of corn with strong zeaxanthin content during 10 weeks. This corresponds to a daily contribution of at least 1,2 mg of lutein and 2,2 mg de zeaxanthin
1616494|NCT02113241|Drug|Dapagliflozin|Dapagliflozin capsules, 10 mg, one per day before breakfast during 90 days.
1616495|NCT02113241|Drug|Placebo|Placebo capsules, 10 mg, one per day before breakfast during 90 days.
1616496|NCT02113215|Procedure|Stable Isotope Infusion|9-hour infusion of stable isotope tracers
1616497|NCT02113202|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a 4.5 mg, 10 mg or 25 mg of Bevacizumab-IRDye800CW 3 days prior to the fluorescence endoscopy procedure.
1616498|NCT02113202|Device|Near infrared fluorescence endoscopy platform|A flexible fiber-bundle is attached with its proximal end to a camera which can detect near infrared fluorescent light. The distal end is inserted into the working channel of a clinical video endoscope, which is used for the surveillance endoscopy procedure.
1616499|NCT02113189|Other|Walking program with ankle brace|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with the bilateral ankle braces on.
1616500|NCT02113189|Other|Individualized walking program|Walking program will include instructions on walking activities at home such as time of walking
1616501|NCT02113189|Other|Walking program with custom braces.|Walking program will include instructions on walking activities at home such as time of walking. Walking will be done with custom-fabricated ankle braces on.
1616502|NCT02113176|Drug|Minocycline|
1616503|NCT02113163|Drug|Metformin Eicosapentaenoate|
1616504|NCT02113163|Drug|Metformin HCl and Vascepa|
1616505|NCT02113150|Drug|remifentanil|renal function
1616506|NCT02113150|Drug|Ketamine|renal function
1616507|NCT02113137|Drug|group 1: drug: chlorine dioxide|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.
group 1 - additional use of 12ml chlorine dioxide (ClO2) mouthwash two times per day, for three consecutive weeks besides tooth brushing.
At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
1616508|NCT02113137|Device|group 2: device: small tooth brush for tongue cleaning|"First, each group practiced tooth brushing only for one week. After that each group was requested to do the following procedures.
group 2 - additional practice of tongue cleaning by a small tooth brush two times per day, for three consecutive weeks besides tooth brushing.
At last, each group practiced all three methods of tooth brushing, tongue cleaning, mouth washing."
1616509|NCT02113111|Behavioral|Fasting|Fasting therapy was adapted from Buchinger, including a fasting period of 7 days. After 2 prefasting days with 800kcal per day from vegetables and rice/potatoes, fasting starts with the ingestion of an oral laxative. During fasting patients receive small quantities of juice and herbal teas, and a vegetable broth for lunch, altogether no more than 350kcal per day. At the end, fasting is broken by an apple or cooked potato, and for the following 3 days nutrition returns to normocaloric diet.
1616510|NCT02113098|Other|Treadmill, ankle load|The experimental group will perform gait training on a treadmill (Gait Trainer 2®) with added load to the ankle of the non-paretic lower limb, plus physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
1616511|NCT02113098|Other|Treadmill|The control group (active comparator) will perform gait training on a treadmill (Gait Trainer 2®) with physical therapy correction for restore gait symmetry. The intervention will last 30 minutes, in nine sessions for two weeks
1616512|NCT02113085|Behavioral|Self-determination enhancement|Self-determination enhancement through individual coaching and peer mentoring workshops
1616513|NCT02113072|Drug|Beclomethasone|The wheezing infants will be using the inhaled corticosteroid beclomethasone 50mcg - 02 jets per day (100mcg/dia).
1616514|NCT02113072|Drug|Probiotics|Lyophilized form, each sachet containing 1 g of the probiotic, to be used in addition to milk, juice or yoghurt in the first morning meal once daily for 60 days.
1616515|NCT02113072|Drug|Placebo|The placebo will be supplied in the same way with the same organoleptic characteristics of formula with probiotics, 1 g sachet for 60 days, in the juice, milk or yoghurt.
1616516|NCT02113046|Procedure|pancreatico-jejunal anastomosis|
1616517|NCT02113046|Procedure|traditional anastomosis|
1616518|NCT02113033|Device|Equilia® Vagal Nerve Stimulation|Vagal Nerve Stimulation synchronized with cardiac activity
1616519|NCT02113020|Drug|TAK-233|Oral administration of TAK-233
1616520|NCT02113020|Drug|Placebo|Oral admininstration of Placebo
1616521|NCT02113007|Drug|Rituximab plus Temozolomide|Treatment cycles will be repeated every 14 days (2 weeks) for the lead-in portion. If no prohibitive toxicities are observed in the first 6 patients during the first 2 treatment cycles, the study will continue enrolling patients. Treatment cycles for the Phase II portion will be repeated every 14 days (2 weeks) for a total of 12 cycles.
1616522|NCT02112994|Drug|sebelipase alfa|Intravenous infusion of sebelipase alfa: 1mg/kg every other week
1616523|NCT02112981|Device|Sirolimus Eluting Coronary Stent|BioMimeTM Sirolimus Eluting Stent (CE Marked) has cobalt chromium NexGenTM platform (CE Marked) with Tamarin BlueTM balloon Delivery System (CE marked and with FDA clearance under 510k). Stent is coated with combination of Sirolimus drug and Biodegradable PLLA and PDLG polymers.
1616524|NCT02112981|Device|Everolimus-eluting Coronary stent|Xience V/Xience Xpedition/Xience Prime stent is MULTI-LINK MINI VISION or MULTI-LINK VISION platform Cobalt chromium stent with Everolimus (active ingredient) embedded in a non-erodible polymer (inactive ingredient).
1616525|NCT02112968|Procedure|Proscan|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
1616526|NCT02112968|Procedure|Zyoptix|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
1616527|NCT02112968|Procedure|Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
1616528|NCT02112955|Behavioral|Stroke self-management program|A nurse-led community-based self-efficacy enhancing stroke self-management program.
1616529|NCT02112955|Behavioral|Usual care|Usual care such as hospital-based or community-based health education or services.
1616530|NCT02112942|Drug|IDX21459|
1616531|NCT02112942|Drug|Matching Placebo|
1616532|NCT02112929|Drug|Hyperpolarized xenon|Inhalation of up to one litre of polarized xenon gas, up to four inhalations per day are permitted.
2010720|NCT02878941|Procedure|Synovial Fluid Analysis|Synovial fluid aspiration (act of using an 18 gauge needle to obtain synovial fluid from the elbow) in the emergency room for patients with the eligible elbow fracture (as defined in inclusion/exclusion criteria) is performed in conjunction with the anesthetic injection as part of standard of care. The elbow will be prepped as per usual for the anesthetic injection. An 18 gauge needle will be inserted through a lateral approach. The subject's elbow will be aspirated. The syringe with the aspirate would be removed from the needle while the needle would remain in the subject's elbow joint. The syringe with anesthetic would then be connected to the needle, and the anesthetic would be injected into the elbow joint. Therefore, no risks from a separate aspiration would be conferred to the patient.
2010721|NCT02876835|Drug|Daprodustat|The initial dose or oral daprodustat for ESA naïve subjects is based on Hgb and for ESA users is based on prior ESA dose. The dose is adjusted thereafter in order to achieve the target range.
1616550|NCT02112903|Drug|Encapsulated vortioxetine IR tablet, 20 mg|
1616551|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 5.5)|
1616552|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 6.0)|
1616553|NCT02112903|Drug|Vortioxetine MR capsule 20 mg (pH 7.0)|
1616554|NCT02112890|Other|Data collection|Data of the selected subjects (through structured questionnaires and interviews) and stored serum samples obtained from the ENSANUT 2012. A subset database will be designed by the NIPH for the purpose of this study. Extracted data and laboratory results of the selected subjects will be captured in the study database.
1616555|NCT02112877|Device|Veniti Vici™ Venous Stent System|
1616556|NCT02112864|Drug|Dexamethasone|10 mg (2.5 ml)
1616557|NCT02112864|Drug|Normal Saline|2.5 mL normal saline
1616558|NCT02112851|Other|Orange flavored beverage|Intervention involves consumption of one beverage of 240ml following baseline measurements
1616559|NCT02112838|Drug|Fostamatinib 150 mg|Fostamatinib 150 milligram (mg) tablet twice daily by mouth, over the course of 24 weeks
1616560|NCT02112838|Drug|Fostamatinib 100 mg|Fostamatinib 100 mg tablet twice daily by mouth, over the course of 24 weeks
1616561|NCT02112838|Drug|Placebo|Placebo tablet twice daily by mouth, over the course of 24 weeks
1616562|NCT02112825|Behavioral|Exercise|Blended supervised-home based walking exercise 3-4 times per week for 30-45 minutes
1616563|NCT02112812|Drug|Eradication therapy for H.pylori infection|Patients who were positive for H.pylori infection received an eradication therapy consisting of oral esomeprazole 40 md daily, oral clarithromycin 500mg bd and oral amoxicillin 1000mg bd for 14 days.
1616564|NCT02112812|Drug|Eradication of Helcobacter Pylori|Patients who are positive on urea breath test are given eradication therapy for 14 days, Eradication therapy includes esomeprazole 40mg daily, clarithromycin 500mg bd, amoxicillin 1g bd
1616565|NCT02112812|Drug|Eradication therapy for Helicobacter pylori|
1616569|NCT02112786|Device|Intermittent or Continuous Setting RestorePrime Implanted Impulse Generator|This is a routine procedure already performed, we are simply changing a post surgical setting to observe for improvement.
1626740|NCT02035644|Drug|placebo granules|
1616570|NCT02112760|Other|specific stabilization exercise|The specific stabilization exercise refers to an exercise that targets the deep trunk muscle, including the multifidus and transversus abdominis with ultrasound feedback.
1616571|NCT02112747|Other|Patient Navigator|Patients are randomized to receive the assistance of a patient navigator to understand, obtain assistance with following the screening recommendations of the personal prescription given to them by the website survey.
1616572|NCT02112734|Drug|Vitamin D|400 IU/daily for 10 months
1616573|NCT02112734|Drug|placebo|identical placebo daily
1616574|NCT02112721|Dietary Supplement|Vitamin D|
1616575|NCT02112721|Dietary Supplement|Placebo|
1616576|NCT02112708|Other|Rational-Emotive-Behavioral Therapy|A social worker held eight 30 minutes sessions fortnightly. First session is informative about the type of treatment to be performed. The next sessions work events, thoughts and feelings with the goal of changing the dysfunctional thoughts by other more rational ones, measured by scales.
1616577|NCT02112708|Other|Control Group usual care|In the control group the depression is treated as usual with the conventional treatment.
1616579|NCT02112682|Procedure|Completion axillary treatment|Completion axillary treatment according to the Dutch breast cancer guideline
1616580|NCT02112669|Device|VasQ|
1616581|NCT02112656|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
1616582|NCT02112656|Drug|Dummy infusion|Sodium Chloride 0.9% or 5% Dextrose (D5W), Single 30 minute intravenous infusion
1616583|NCT02112643|Dietary Supplement|Sodium selenite|A 100 microgram pill will be orally administered twice a day for 6 months.
1616584|NCT02112643|Dietary Supplement|Sugar pill|The placebo pill will be constructed to look exactly like the selenium pill, but will have no active ingredients. This will be orally administered for 6 months.
1616585|NCT02112630|Drug|P-IFN alfa 2a|P-IFN alfa 2b 0.75 mcg/kg/week
1616586|NCT02112630|Drug|P-IFN alfa 2b|P-IFN alfa 2a 135 mcg/kg/week
1616587|NCT02112630|Drug|Ribavirin|200 mg PO once daily or 200 mg PO three times a week
1616588|NCT02112630|Drug|Boceprevir|800 mg PO three times daily starting at week 4
1616589|NCT02112617|Radiation|Proton Beam Radiation Therapy|Proton radiation will be delivered daily for 3-4 weeks, depending on the dose prescribed by study doctor. Treatment is delivered (Monday - Friday) for 5 days (no weekends or holidays). Each treatment the participant will lie on a table for 30-45 minutes.
1616590|NCT02112604|Device|Ventilator|Mechanical ventilator used to replace or assist spontaneous breathing.
1616591|NCT02112604|Device|Alice PDx|Alice PDx is a polysomnography monitor used to study stages of sleep and detect sleep-disordered breathing. The device monitors PO2, airflow, EEG, EOG and abdominal wall movements to detect sleep apnea.
1616592|NCT02112604|Other|Pulmonary function test|The pulmonary function tests are used to study upper airway patency.
1616593|NCT02112604|Other|Muscle strength tests|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
1616594|NCT02112604|Other|Grip strength measurement|Grip strength has been shown to be an accurate means of assessing muscle function in the critically ill. Muscle weakness may have an impact on upper airway patency.
1616595|NCT02112604|Drug|Sedatives and muscle relaxants given in the ICU|Patients in the ICU are administered sedatives, anesthetics, opiods, anti-pyschotics and neuromuscular blocking agents as part of routine care. We hypothesize that the use of these drugs is associated with sleep-disordered breathing following extubation. We will collect the drug doses from the patient's chart.
1616596|NCT02112591|Procedure|transobturator subtrigonal tape S-TOT|Minimally invasive surgery for placement of suburethral polypropylene tape (TOT), which is widely used around the world and considered the standard of treatment at present, has very limited efficacy when considering the correction of SUI without affecting normal micturition. There is evidence that the placement of autologous fascia tape in subtrigonal position has higher efficacy. Thus, the subtrigonal placement of polypropylene mesh tape through minimally invasive procedures could have higher efficacy.
1616597|NCT02112591|Procedure|Transobturator suburethral tape (TOT)|Minimally invasive procedures in which needles are inserted via transobturator approach for the placement in mid-urethral position of polypropylene tape that is 1.5cm wide for the treatment of SUI
1616598|NCT02112578|Drug|Meclizine|25 mg, 3 times per day up to 30 days
1616599|NCT02112578|Drug|Dimenhydrinate|50 mg, 3 times per day up to 30 days
1616600|NCT02112565|Drug|RNR inhibitor COH29|Given PO
1616601|NCT02112565|Other|laboratory biomarker analysis|Correlative studies
1616602|NCT02112565|Other|pharmacological study|Correlative studies
1616603|NCT02112552|Drug|Paclitaxel|Given IV
1616604|NCT02112552|Drug|Carboplatin|Given IP
1616605|NCT02112552|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal radiation therapy
1616606|NCT02112552|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1616607|NCT02112552|Other|Quality-of-Life Assessment|Ancillary studies
1616608|NCT02112552|Other|Laboratory Biomarker Analysis|Correlative studies
1616609|NCT02112539|Other|platelet aggregation measurement|
1616610|NCT02112526|Drug|ACP-196|
1616611|NCT02112500|Biological|Mesenchymal Stem Cell|Mesenchymal stem cells will be intravenously infused. Mesenchymal stem cells will be cultured and extracted from the bone marrow of the patients.
1616612|NCT02112487|Drug|Macitentan|10 mg once daily
1616613|NCT02112474|Device|Spinal Cord Stimulation|Crossover design whereby subjects will undergo Spinal Cord Stimulation in two arms: low frequency stimulation and high frequency stimulation
1616614|NCT02112474|Device|Group 1|9 days of spinal cord stimulation at 30 Hertz and perceptible paraesthesias
1616615|NCT02112474|Device|Group 2|9 days of spinal cord stimulation with 1000 Hertz and sub-perception paraesthesias
1616655|NCT02112227|Other|PACT-HF Model|PACT-HF Model includes the following 1) comprehensive patient assessment 2) self-care education 3) patient-centered discharge summary 4) early follow up with FP 5) referral of high-risk patients to regional multidisciplinary HF clinic and to nurse-led home care
1616616|NCT02112461|Behavioral|SCP-Hospice Alert|The intervention in Project 1 SCP utilizes a multi-faceted system. The SCP-Hospice symptom management model will include several features: 1) a computer-based telecommunication system to monitor symptoms as perceived and reported by the family caregiver; 2) tailored care management messages that SCP provides directly to the caregivers to promote care management based on the individualized patient symptom profile and caregiver distress; and 3) an automated alerting function that notifies the hospice nurse of unrelieved symptoms that have exceeded a pre-set threshold.
1616617|NCT02112448|Drug|continuous infusion|Continuous morphine/midazolam and 'as needed' doses. Will receive scheduled acetaminophen and ketorolac.
1616618|NCT02112448|Drug|as needed dosing|morphine and midazolam as needed. Will receive scheduled acetaminophen and ketorolac..
1616619|NCT02112448|Drug|Acetaminophen|Acetaminophen will be given every 4 hours for a total of 24 hours.
1616620|NCT02112448|Drug|ketorolac|Ketorolac 0.5 mg/kg will be given every six hours to all subjects in the study.
1616621|NCT02112435|Device|Somnyx ®|Active mandibular advancement splint
1616622|NCT02112435|Device|Narval ORM ® or SomnoDent ®|Mandibular advancement splint
1616623|NCT02112422|Drug|Control|The control group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline immediately prior to skin incision.
1616624|NCT02112422|Drug|Intervention|Patients in the intervention group will receive 0.15 mg/kg of intravenous dexamethasone (maximum dose 20mg) in 100ml normal saline 45-60 minutes prior to the OR.
1616625|NCT02112409|Procedure|cell salvage technique|blood from the surgical field is collected, anti-coagulated, filtered, centrifuged, washed and re-suspended in saline to produce autologous blood with a resultant haematocrit of 50-80% for transfusion back to the patient using specific cell saver device
1616626|NCT02112409|Procedure|acute normovolemic hemodilution|Removal of 500ml whole blood from the patient after induction of anesthesia, with restoration of blood volume with acellular fluid using equivolume of 6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride (voluven) to maintain isovolemia
1616627|NCT02112396|Behavioral|Community Reinforcement and Family Training|The Intervention is based on the CRAFT literature and includes Building and sustaining motivation of CSOs, functional analysis of problem behaviors, domestic violence precautions (if mandatory), improving communication skills of CSOs, use of negative consequences of drinking behavior, positive reinforcement of clean and sober behavior, strategies to enrich CSOs lives, and strategies for inviting the addicted individual to enter treatment.
1616628|NCT02112383|Behavioral|Cognitive behavior group therapy|For participants in the group intervention condition, the modules from a self-help treatment for procrastination will be delivered at four consecutive three-hour sessions at the Student Health Centre at Karolinska Institutet, with approximately two modules given at each session. The sessions will be spaced two weeks apart, during which participants are instructed to complete assignments related to the modules that were in focus of the previous session, e.g., goal-setting, time management, and behavioral experiments, which they are advised to present and discuss with the other participants.
1616629|NCT02112383|Behavioral|Internet-based cognitive behavior therapy|For participants in the Internet-based condition, the modules from a self-help treatment for procrastination will be distributed weekly during the treatment period, with one module given each week, i.e., ten weeks. In comparison to the group condition, participants will not receive a therapist contact or attend any sessions. In addition, the participants are expected to complete both the reading material and the assignments that are included in each module.
1616630|NCT02112370|Drug|Ropivacaine with epinephrine injection|1 mg/mL 1cc epinephrine is diluted in 100cc normal saline and then 7.5 mg/mL 30cc ropivacaine is diluted in the same normal saline. The mixture is injected into the subcutaneous layer for the initial flap dissection for the experiment group.
1616631|NCT02112370|Other|Placebo|100cc normal saline is injected into the subcutaneous layer for the initial flap dissection for the placebo group.
1616632|NCT02112344|Radiation|IMRT|
1616633|NCT02112331|Other|Raw human milk|
1616634|NCT02112331|Other|Pasteurized human milk|
1616635|NCT02112331|Other|Pasteurized-homogenized human milk|
1616636|NCT02112331|Other|Gastric samples|
1616637|NCT02112305|Drug|isotonic magnesium sulphate|2.5 ml of isotonic magnesium sulphate (150 mg, 245 mmol/L) NB on three occasional at 20 minutes interval
1616638|NCT02112305|Drug|50% magnesium sulphate|magnesium sulphate 50mg/kg/dose intravenous drip in 20 minutes for one dose
1616639|NCT02112292|Drug|tetrahydrocannabinol|
1616640|NCT02112292|Drug|cannabidiol|
1616641|NCT02112292|Drug|Placebo|
1616642|NCT02112279|Biological|Donor microbiota applied via colonoscopy.|"B. Preparation of donor sample 1. Instillation via Colonoscopy
1. Stool mixture is administered into the terminal ileum and cecum through the biopsy channel of a colonoscope while the patient is sedated.
Administer 300-700 ml of slurry through biopsy channel of colonoscope with a piston syringe."
1616643|NCT02112266|Other|Mail support|between post treatment and follow up two groups: one with unspecific mail support every 2 weeks one without
1616644|NCT02112266|Other|no mail support|follow-up without mail support
1616645|NCT02112253|Device|Deep brain stimulator ventral electrode up to 2 mA|
1616646|NCT02112253|Device|Deep brain stimulator ventral electrode up to 3 mA|
1616647|NCT02112253|Device|Deep brain stimulator dorsal electrode up to 2 mA|
1616648|NCT02112253|Device|Deep brain stimulator dorsal electrode up to 3 mA|
1616649|NCT02112253|Device|Deep brain stimulator empirical programming|
1616650|NCT02112240|Other|Intraoperative Mobile Gamma Camera imaging|Intraoperative images will be taken with a unique mobile gamma camera to identify sentinel lymph nodes in the rectum.
1616651|NCT02112240|Drug|Endoscopic injection of 99mTc-sulfur colloid|Radiotracer injection around the rectal tumor for pre- and intra-operative imaging.
1616652|NCT02112240|Other|Endoscopic injections of Spot|Dye injection for tattooing rectal tumor prior to surgical resection.
1616653|NCT02112240|Procedure|Preoperative flexible sigmoidoscopy|Flexible sigmoidoscopy prior to surgery to facilitate endoscopic injections of radiotracer and dye.
1616654|NCT02112240|Radiation|SPECT/CT|Preoperative imaging to identify lymph nodes in rectum.
1616832|NCT02111083|Biological|Insulin Lispro|LY275585 administered SC.
1616656|NCT02112214|Drug|10-day bismuth-based quadruple therapy|Bismuth 300 mg (4 times a day), lansoprazole 30 mg (twice a day), metronidazole 500 mg (3 times a day), and tetracycline 500 mg (4 times a day) for 10 days
1616657|NCT02112214|Other|Placebo|Placebo for bismuth-based quadruple therapy
1616658|NCT02112201|Behavioral|Integrated intervention for parents and adolescent girls|The intervention will consist of individually administered preventive curriculum for adolescent girls involved in the juvenile justice system that integrally addresses delinquency, drug abuse, and trauma exposure, along with group-based training and support for parents.
1616659|NCT02112188|Behavioral|In-depth Patient Interviews|
1616660|NCT02112188|Behavioral|Adaptation of IMCP for Chinese Immigrant Cancer Patients|
1616661|NCT02112175|Drug|Lenalidomide|
1616662|NCT02112175|Drug|Placebo|
1616663|NCT02112162|Radiation|fludeoxyglucose F 18|Undergo FDG PET/MRI
1616664|NCT02112162|Device|positron emission tomography|Undergo FDG PET/MRI
1616665|NCT02112162|Device|magnetic resonance imaging|Undergo FDG PET/MRI
1616666|NCT02112162|Other|laboratory biomarker analysis|Correlative studies
1616667|NCT02112149|Behavioral|LIVESTRONG|The LIVESTRONG at the YMCA is a twelve-week, small group (< 16 participants) program designed for adult cancer survivors. YMCA fitness instructors work with each participant to fit the program to their individual needs. The instructors are trained in the elements of cancer, post rehabilitation exercise and supportive cancer care. There are two YMCA fitness instructors overseeing each exercise session. Each session is 90 min in duration, twice per week, for 12-wks (total of 24 sessions). Each session begins with a warm-up, then aerobic exercise (e.g., treadmill) and resistance training exercises, followed by a cool-down period, and follows the recommendations of the American College of Sports Medicine.
1616668|NCT02112136|Other|Blood Collection|Phenotype and Genotype Analysis, Biological Analysis
1616669|NCT02112123|Drug|Icariin|
1616670|NCT02112123|Dietary Supplement|Matching placebo|
1616671|NCT02112110|Drug|BMS-791325|
1616672|NCT02112110|Drug|[13C]-BMS-791325|
1616673|NCT02112097|Drug|Gadolinium|"For Left Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium Magnevist® (gadopentetate dimeglumine)
.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
1616674|NCT02112097|Drug|Gadolinium|"For Left Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium Magnevist® (gadopentetate dimeglumine)
.1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
1616675|NCT02112097|Drug|Gadolinium|For Left Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
1616676|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
1616677|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
1616678|NCT02112097|Drug|Efficacy of Enbrel subcutaneously at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
1616679|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 12|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
1616680|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 24|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
1616681|NCT02112097|Drug|Efficacy of Enbrel subdermally at Week 36|"sPGA 50 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of Proportion of patients who achieve a score of clear or minimal by the Static Physician Global Assessment (sPGA) and the proportion of patients with a reduction of PASI of at least 50% from baseline.
The sPGA is a 6-category scale ranging from 5 = severe to 0 = none indicating the physician's overall assessment of the psoriasis severity focusing on indurations, erythema, and scaling. Treatment success of clear or minimal consists of none or minimal elevation in plaque, up to faint red coloration in erythema, and none or minimal fine scale over < 5% of the plaque."
1616828|NCT02111109|Device|Side Stream Dark Field Microscopy|
1616682|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 12|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
1616683|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 24|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
1616684|NCT02112097|Drug|PASI 75 n(%) subcutaneously at Week 36|PASI 75 n(%) as Efficacy of Enbrel subcutaneously at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
1616685|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 12|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 12, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
1616686|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 24|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 24, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
1616687|NCT02112097|Drug|PASI 75 n(%) subdermally at Week 36|PASI 75 n(%) as Efficacy of Enbrel subdermally at Week 36, in terms of the proportion of patients who achieved a reduction in score of at least 75% from baseline by the PASI.
1616688|NCT02112097|Drug|Adverse Reactions of Enbrel subcutaneously|Adverse Reactions of Enbrel subcutaneously at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
1616689|NCT02112097|Drug|Adverse Reactions of Enbrel subdermally at Week 36|Adverse Reactions of Enbrel subdermally at Week 36, in number of Injection site reactions, Heart failure, Allergic Reactions, Blood problems/low blood counts, Nervous system, Infections, Malignancies, Immunogenicity, and Autoantibodies.
1616690|NCT02112097|Drug|Gadolinium|"For Right Upper Arm Total Persistent % subdermally, on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
1616691|NCT02112097|Drug|Gadolinium|"For Right Upper Arm Total Persistent % subcutaneously, on MRI at 6 hrs, 12 hrs, and 24 hrs.
Gadolinium Magnevist® (gadopentetate dimeglumine) .1cc/ diluted with .9cc normal saline subcutaneously for 30 patients, and subdermally with ASIS Device for 30 patients."
1616692|NCT02112097|Drug|Gadolinium|For Right Upper Arm Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium subcutaneously on MRI.
1616693|NCT02112084|Behavioral|Individualized DPM|The intervention includes 7 LO phone sessions and 7 RO home visits provided by trained interventionists. The primary focus of the LO phone conversations will be on grief work issues, daily functioning, and emotional support. The calls will provide an opportunity to discuss how grief could be interfering with their daily functioning, dealing with grief-related feelings- emotions they are experiencing, the frustrations associated with taking on new responsibilities while still trying to meet their own needs, critical time periods like anniversaries and holidays, unfinished business, coping strategies, including using humor, and having realistic expectations about the bereavement process. The RO home visits will be based specifically on the bereaved partners' skill and knowledge needs.
1616694|NCT02112071|Behavioral|Exercise|Blended supervised-home based walking program 3-4 times per week for at least 30 minutes.
1616695|NCT02112058|Behavioral|A Family-Strengthening Program for Low-Income Families|"The program's central and most intensive component was a series of relationship and marriage education workshops for groups of couples that was offered in the first four to five months of enrollment in the program.
Complementing the workshops was a second component, offered for the year after enrollment, that consisted of supplemental activities: educational and social events that were intended to build on and reinforce lessons from the curricula.
The third component, family support services, paired couples with a specialized staff member who maintained contact with them and facilitated their participation in the other two components throughout the duration of the program."
1616696|NCT02112045|Drug|Granix|
1616697|NCT02112045|Drug|High dose melphalan (HDR)|
1616698|NCT02112045|Procedure|Autologous Stem Cell Transplant (ASCT)|
1616699|NCT02112032|Drug|MK-3475|This is a dose escalation study to determine the serious and non-serious adverse events that occur as the dose increases.
1616700|NCT02112032|Drug|Peginterferon alfa-2b|This is a dose escalation study to determine the serious and non-serious adverse events that occur from the combination of Peginterferon and MK-3475 as the doses increase.
1616701|NCT02112019|Procedure|Sialoendoscopy|
1616702|NCT02112019|Drug|saline|
1616703|NCT02112019|Drug|hydrocortisone|
1616704|NCT02112006|Procedure|0.5% bupivacaine injected in the forearm|Median, Ulnar, and Radial nerve blocks performed in the forearm
1616705|NCT02112006|Procedure|20-30ml of 0.5% bupivacaine.|supraclavicular, infraclavicular, or axillary nerve block using 20-30ml of 0.5% bupivacaine.
2010722|NCT02876835|Drug|Darbepoetin alfa|The initial dose of darbepoetin alfa to be administered for SC injection for ESA naïve subjects is based in Hgb and weight, and for ESA users is based on converting the prior ESA dose to the nearest available study darbepoetin alfa dose. The dose is adjusted thereafter in order to achieve the target range. IV darbepoetin alfa can be considered for participants transitioning to hemodialysis.
2010723|NCT02876835|Drug|Placebo|Oral placebo tablets will be taken from Week -4 up to randomization (Day 1).
2010724|NCT02876835|Drug|Iron Therapy|Participants will receive supplemental iron therapy if ferritin is <=100 ng/mL or TSAT is <=20%. The investigator will choose the route of administration and dose of iron.
1616709|NCT02111967|Other|Questionnaire administration|
1616710|NCT02111967|Other|Laboratory biomarker analysis|
1616711|NCT02111954|Diagnostic Test|1 PET/CT with F-18-FCH + 1 PET/CT with Ga-68-NODAGA-MJ9|Each patient will have two PET/CT
2010725|NCT02877355|Drug|semaglutide|All subjects will receive 3 mg oral semaglutide for five days followed by 7 mg oral semaglutide for five days
2010726|NCT02873650|Drug|dabrafenib|Single dose of 100 mg dabrafenib on Day 1
2010727|NCT02872935|Drug|Glycopyrrolate|.2mg of Glycopyrrolate will be given intravenously with the administration of the spinal dose
2010728|NCT02872935|Drug|Normal Saline|1ml of normal saline will be given intravenously with the administration of the spinal dose
1616714|NCT02111928|Device|NovaTears® Eye Drops|Topical eye drops for lubrication of the ocular surface
1616715|NCT02111915|Behavioral|THPP-P|Trial participant s who are in the THPP group will receive, in addition to Enhanced Usual Care (EUC), 14 sessions of THPP (simplified cognitive behaviour therapy) starting from their recruitment in the third trimester until up to 5 months after child birth.
1616716|NCT02111915|Other|EUC|EUC will comprise communicating the results to the mother's Lady Health Worker and medical officer (MO) at the Basic Health Unit (BHU) of her area, providing the MO with the WHO mental health gap (mhGAP) guidelines for the treatment of depression, and providing guidance on referral of depressed mothers to mental health services.
1616717|NCT02111889|Other|[11C] kinase inhibitor PET [15O]water PET and tumor biopsies.|[11C] kinase inhibitor PET (i.e. sorafenib and erlotinib in this study, with the aim to investigate others in future studies) and [15O]water PET will be performed before and after 2 weeks of treatment. Tumor biopsies will be performed before and after 2 weeks of therapy.
1616718|NCT02111863|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
1616719|NCT02111863|Drug|Fludarabine|Fludarabine 25 mg/m^2/day (intravenous piggyback) IVPB daily X 5 days.(The fludarabine will be started approximately 1-2 hours after the cyclophosphamide on Days -5 and -4)
1616720|NCT02111863|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml 5% dextrose in water (D5W) over 1 hr.
1616721|NCT02111863|Biological|4-1BB Selected Tumor Infiltrating Lymphocytes (TIL)|On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (one to four days after the last dose of fludarabine).
2010729|NCT02872766|Device|CXL Myopia|Applying riboflavin 0,22% to 0,25 % up to 20 minutes . Then, the eyes are exposed to UVA light with the KXL II system according to the programmed treatment pattern.
2010730|NCT02871258|Device|The MetaNeb® System|
2010731|NCT02872038|Drug|Cefepime|Cefepime intraperitoneal continuous dosing
2010732|NCT02872038|Drug|Cefazolin plus Ceftazidime|
1616726|NCT02111837|Other|Standard infant formula|
1616727|NCT02111837|Other|Standard infant formula with PL1|
1616728|NCT02111837|Other|Standard infant formula with PL2|
1616729|NCT02111824|Device|MIMIG System|Minimally Invasive MultiModality Imaging Guidance System (MIMIG)
1616730|NCT02111824|Drug|Indocyanine Green (ICG)|Use of ICG as staining for fiberoptic visualization of lung tissue via introducer needle prior to obtaining tissue samples.
1616731|NCT02111811|Other|Veterans Work and Health Initiative|CBT based intervention focused on work productivity
1616732|NCT02111798|Drug|Bupropion XL|Cocaine dependent methadone maintenance patients will receive usual care at their methadone clinic. All study participants will be able to earn financial incentives throughout the study for stopping cocaine use. In addition, they will receive double blind medication (active vs placebo) daily at the methadone clinic. Active medication is bupropion XL 300mg/day. Participants will see research staff 3 times per week to deliver urine specimens and may be awarded financial incentives if these test cocaine negative.
1616733|NCT02111798|Drug|placebo|Cocaine dependent methadone maintenance patients will receive usual care at their methadone clinic. All study participants will be able to earn financial incentives throughout the study for stopping cocaine use. In addition, they will receive double blind medication (active vs placebo) daily at the methadone clinic. Participants will see research staff 3 times per week to deliver urine specimens and may be awarded financial incentives if these test cocaine negative.
1616734|NCT02111785|Drug|Dexamethasone|
1616735|NCT02111785|Procedure|Burr Hole Craniostomy|
1616736|NCT02111772|Biological|Rhinovirus|
1616737|NCT02111759|Procedure|knee flexion angle 1|0 degrees of knee flexion during ACL graft fixation
1616738|NCT02111759|Procedure|knee flexion angle 2|30 degrees of knee flexion during ACL graft fixation
1616739|NCT02111746|Drug|Exparel®|
1616740|NCT02111746|Drug|Bupivacaine hydrochloride|Standard/regular bupivacaine hydrochloride
1616741|NCT02111733|Other|Hs-TNT dosage|Bloodwork before and after hemodialysis for high sensibility troponins T blood level
2010733|NCT02870491|Behavioral|Free Distribution|Caretakers of children under 5-years-old will have access to free ORS and zinc
2010734|NCT02870491|Behavioral|Preemptive Delivery|Caretakers of children under 5-years-old will have ORS and zinc delivered to their home
2010735|NCT02870478|Drug|Atropine|Dosing frequency comparison, using atropine sulfate 1% solution diluted to 0.01% and 0.05% by Leiter's Compounding Pharmacy
1616745|NCT02111694|Behavioral|Bottle Type|Infants will be fed from a conventional, clear bottle during one feeding and from an opaque, weighted bottle from another feeding
1616746|NCT02111681|Device|Calypso Beacon Implantation|Bronchoscopic Calypso Beacon Implantation
1616829|NCT02111096|Drug|LY2409021|Administered orally
2010736|NCT02869854|Behavioral|Mindfulness|Mindfulness course during 8 weeks with 20 minutes mindfulness exercise each day
2010737|NCT02869854|Behavioral|PAP|Physical Activity on Prescription, after 3 months a new prescription
2010738|NCT02869334|Device|Active Transcranial direct current stimulation (tDCS)|Active tDCS, where an extremely weak electric current passes through the brain
2010739|NCT02869334|Device|Sham Transcranial direct current stimulation (tDCS)|Sham (inactive or placebo) tDCS
2010740|NCT02869334|Behavioral|Auditory Remediation|Computer program designed to improve discrimination between sounds
2010741|NCT02869334|Behavioral|Control computer activities|Computer program (e.g. games), which are not designed to improve discrimination between sounds
2010742|NCT02869295|Drug|NKTR-214|Participants in the dose escalation cohorts will be treated every 21 days (q21d) or every 14 days (q14d) until tumor progression.
2010743|NCT02868606|Other|Physiologic Insulin Therapy|
2010744|NCT02868606|Other|Sliding-Scale Insulin Therapy|
2010745|NCT02868385|Drug|4x Praziquantel|Five consecutive praziquantel treatments (40 mg/kg): at baseline (week 0) and at week 2, 4, 6, and 8.
2010746|NCT02868385|Drug|1x Praziquantel|One praziquantel treatment (40 mg/kg) at baseline
2010747|NCT02867995|Device|Eye Drop Aid|Fabrication Autodrop Eye Drop Guide,Owen Mumford OP 6100 Autosqueeze, and the Simply Touch Eye Drop Applicator
1616747|NCT02111655|Device|Second generation surveillance of AVF|"Doppler ultrasound and transonic dilution method technique will be performed in the experimental group quarterly.
QA will be measured by both techniques and haemodynamic repercussion stenosis will be evaluated by doppler ultrasound."
1616748|NCT02111655|Procedure|vital signs|Effective blood flow, venous pressure, arterial pressure, at the beginning and at the end of the dialysis session
1616749|NCT02111655|Procedure|physical examination of AVF|Predialysis physical examination of AVF every dialysis session.
1616750|NCT02111655|Procedure|ktv test|Weekly ktv measurement using biosensors. In patients who have been dialyzed in monitors with no biosensors, ktv will be measured monthly using monocompartimental Daugirdas equation
1616751|NCT02111655|Procedure|urea method|Quarterly recirculation with urea method.
1616752|NCT02111642|Other|Online risk calculator|A new online risk calculator tool has been developed to predict a woman's individual risk of developing de novo stress urinary incontinence after prolapse surgery. This validated tool has been shown to outperform preoperative prolapse reduction stress testing results and expert predictions when providing risk assessment of de novo stress urinary incontinence after vaginal prolapse surgery. After inputting individual patient characteristics, including patient age, body mass index, number of vaginal deliveries, presence or absence of urgency urinary incontinence and diabetes, and prolapse reduction stress testing results if available, this tool calculates the theoretical risk of postoperative de novo stress urinary incontinence both with and without an anti-incontinence procedure.
1616753|NCT02111629|Drug|Fluconazole and Secnidazole|
1616754|NCT02111616|Behavioral|Survivorship Care Plan (SCP)|Cancer Survivorship Care Plan (SCP) adapted from JourneyForward template. Each SCP is individualized to patient's care regimen. SCP is delivered at the conclusion of cancer treatment and during the patient's transition visit with nurse practitioner or physician assistant.
1616755|NCT02111616|Behavioral|Coordinated PCP visit|Visit with PCP scheduled on behalf of patient at the conclusion of cancer treatment and patient's transition visit.
1616756|NCT02111603|Drug|Colesevelam|Subjects will receive 1875 mg of Colesevelam orally twice daily for 10 days
1616757|NCT02111590|Drug|Immunoglobulins|SCIG dosage is individualized for each patient according to previous IVIG dosage
2010748|NCT02867956|Drug|Apatinib|Apatinib 500mg daily, po, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent.
2010749|NCT02867956|Drug|Etoposide|Etoposide 50mg daily, po, day 1 to day 14, repeat every 21 days for 6 cycles
2010750|NCT02866734|Other|Free screening group|The intervention provide Diabetic Retinopathy screening without charging a fee.
2010751|NCT02866734|Other|Pay screening group ($150)|The intervention is charging HK$150 for the Diabetic Retinopathy screening.
2010752|NCT02866734|Other|Pay screening group ($300)|The intervention is charging HK$300 for the Diabetic Retinopathy screening.
2010753|NCT02865499|Drug|acarbose|acarbose treatment with meals
2010754|NCT02863471|Drug|Gemcitabine|1000 milligram (mg)/square meters (m2) body surface 60 minutes (min) intraperitoneal hyperthermic lavage
1616765|NCT02111551|Drug|DMXB-A 150 mg|
1616766|NCT02111551|Other|placebo|
1616767|NCT02111551|Drug|DMXB-A 75 mg|
1616768|NCT02111538|Other|Dietary advice|Standard dietary advice are provided to all patients at baseline and during the follow-up to all requiring or asking for
1616769|NCT02111512|Drug|Administration of Live attenuated influenza vaccine (LAIV)|
1616770|NCT02111499|Drug|LAS41004-IMP1|daily topical application
1616771|NCT02111499|Drug|LAS41004 IMP2|daily topical application
1616772|NCT02111499|Drug|LAS41004 IMP3|daily topical application
1616773|NCT02111499|Drug|LAS41004 IMP4|daily topical application
1616774|NCT02111499|Drug|LAS41004 IMP6|daily topical application
1616775|NCT02111499|Drug|LAS41004 IMP5|once daily, topical
1616776|NCT02111486|Other|breakfast|
1616777|NCT02111473|Drug|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
1616778|NCT02111460|Radiation|Loco-regional Radiotherapy|with or without Loco-regional Radiotherapy
1616779|NCT02111447|Drug|Propofol|Propofol infusion with nasal oxygen
1616780|NCT02111447|Drug|Propofol|Propofol infusion with an LMA
1616781|NCT02111447|Drug|Sevoflurane|Sevoflurane with an LMA
1616782|NCT02111447|Drug|Isoflurane|Isoflurane with an LMA
1616783|NCT02111434|Drug|Testosterone|Testosterone 250 mg injection per 3-4 weeks for 6 months
1616784|NCT02111421|Drug|Dexmedetomidine 01|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,after the umbilical cord was clapped.The wight used to calculate the dose of dexmedetomidine would be that the total weight of the mother minus the weight of the placenta, amniotic fluid and fetal.
1616785|NCT02111421|Drug|Dexmetomidine 02|Initial dose of dexmedetomidine was 1.0 μg/kg, with dose adjustment intervals of 0.1μg/kg in first three turning points and 0.05μg/kg in the last four turning points,as soon as the spinal anesthesia
1616786|NCT02111382|Other|CV4 Cranial (4th ventricle technique) Osteopathic Manipulative|"The participant will be in supine position during the whole procedure. The practitioner sits behind the participant's head, contacts participant's lateral protuberances of the squama occipitalis (medially to the occipitomastoid suture) with the thenar eminence of both hands.
When the practitioner feels the PRM (a pulsating rhythm caused by liquor production and reabsorption), the flexion phase will be resisted and the extension phase exaggerated. The compressive force is held until the PRM stops (event known as 'Still point'). The compression will be held until the practitioner feels PRM gradual return; the compression will be slowly diminished, and then, the practitioner remove the hands from the occipital bone, laying the participant's head on the table.
The CV4 technique will be performed by an osteopath D.O. - member of the Brazilian Register of Osteopaths."
1616787|NCT02111382|Other|CV4 (4th ventricle technique) manual therapy sham technique|"The participant will be in supine position and the practitioner will be seated behind the participant's head. The practitioner places the fingers (2nd to 5th) under the occipital bone, touching only the squama occipitalis. The practitioner will hold this position for 5 minutes, and after this period the participant's head will be placed on the table.
The CV4 sham will be performed by a registered physiotherapist."
1616830|NCT02111096|Drug|Sitagliptin|Administered orally
1616831|NCT02111096|Drug|Placebo|Administered orally
1616788|NCT02111369|Drug|Propranolol|After a discussion of the risks and benefits of propranolol therapy, the patient will then be given a prescription by the principal investigator for propranolol. This prescription will consist of a starting dose of generic immediate-release at 10 mg three times daily (30 mg each day) with an increase in dose in 5-7 days if there is no effect (60 mg each day) and if the patient had demonstrated no side effects. Dose may be increased to 240 mg each day depending on patient improvement and side effect profile.
1616789|NCT02111369|Procedure|Botulinum Toxin|At the second evaluation, patient will receive botulinum toxin injections. The risks and benefits of botulinum toxin therapy will be explained to the patient, and bilateral injections will take place.
1616790|NCT02111356|Device|Phinhole glasses|Wearing the pinhole glasses (Trayner Pinhole Glasses, Trayner Glasses, U.K.)
1616791|NCT02111343|Other|Computer-based auditory training (CBAT)|"There are 3 listening games (i.e. Doggy, Who-Is-Right, Story-in-noise) that target on speech-in-noise training and 1 listening game (i.e. TATP) that aims to train dichotic listening.
Patient was required to undergo the training for 30 minutes per day, 5 sessions per week, for a duration of 12 weeks. Parents were advised to keep a journal to record child's training hour of the day."
1616792|NCT02111330|Drug|PBF-509|
1616793|NCT02111330|Drug|Placebo|
1616794|NCT02111317|Drug|ASP015K|oral
1616795|NCT02111317|Drug|verapamil|oral
1616796|NCT02111304|Drug|iOWH032|
1616797|NCT02111291|Biological|Collagenase SANTYL® Ointment|Daily application directly to the ulcer bed, approximately 2 mm thick.
1616798|NCT02111291|Biological|Hydrogel (if needed) and foam dressing|Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
1616799|NCT02111278|Other|Lumbar Manipulation|The manipulating therapist performs the lumbar manipulation technique. With the patient supine, the therapist stands opposite the side to be manipulated. The patient is passively side-bent away from the therapist. The therapist rotates the thoracic spine and then delivers a quick posterior and inferior thrust through the anterior superior iliac spine. The manipulation is performed on the side the patient reported to be more symptomatic. If the patient is unable to identify a more painful side, the side to be manipulated is left to the manipulating therapist discretion. If a cavitation is experienced, no more manipulations are performed that session. If no cavitation is produced, the patient is repositioned, and the manipulation is attempted again. If no cavitation is experienced again, the therapist attempts to manipulate the opposite side. A maximum of two attempts per side will be attempted.
1616800|NCT02111278|Other|Sham Manipulation|The manipulating therapist will perform the sham lumbar manipulation technique with the patient side-lying. The therapist passively flexes both hips until slight lumbar flexion is noted at the patient's most painful vertebral level. The therapist will take time palpating patient's spine taking care to avoid rotating the spine. The therapist will then place both hands on the same lumbar spinous process. An equal and opposite force is then applied to the spinous process with both hands. No physiologic motion is expected with this technique. The patient will then be setup for the same sham technique on the opposite side. The sham manipulation technique will be performed in an attempt to blind the patient to group allocation. This technique is designed to provide similar hands on treatment time as the manipulation intervention.
1616801|NCT02111278|Other|Physical Therapy|Patients will receive 4 weeks of physical therapy with 2 visits per week. The treating physical therapist is blinded to group allocation. The treating physical therapist will prescribe exercises based on patient presentation. Therapy visits last approximately 45-60 minutes depending of patient ability to perform exercises. The treating physical therapist will perform no mobilizations or manipulations on the patient.
1616802|NCT02111265|Drug|Remifentanil|"Remifentanil 0.1-0.2μg/ ( kg•min) is continuously pumped at steady speed for analgesia for induction and maintenance of anesthesia.
Remifentanil is stopped before skin closure"
1616803|NCT02111265|Drug|Cisatracurium|"Cisatracurium 0.15 mg/kg for induction and 0.12 mg/kg/h continuous infusion for maintenance of anesthesia.
Cisatracurium is stopped before skin closure."
1616804|NCT02111265|Drug|Sufentanil|Before skin closure, remifentanil is stopped and sufentanyl 0.1μg/kg is given by intravenous injection.
1616805|NCT02111265|Device|Bispectral index(BIS) monitor|BiS is maintained at 40-60 during anesthesia.
1616806|NCT02111252|Drug|TAK-850|TAK-850 injection
1616807|NCT02111239|Device|CTA|pelvic/abdominal CTA scan
1616808|NCT02111239|Device|MRA|pelvic/abdominal MRA scan
1616809|NCT02111226|Other|SMS text messaging|short message service
2010755|NCT02863328|Drug|semaglutide|Oral administration once-daily.
2010756|NCT02863328|Drug|empagliflozin|Oral administration once-daily.
2010757|NCT02862015|Other|Oncothermia|Oncothermia is a kind of hyperthermia treatment. It serves heat energy more selectively than conventional hyperthermia.
2010758|NCT02862015|Drug|FOLFIRINOX or Gemcitabine based chemotherapy|As a standard palliative chemotherapy, FOLFIRINOX or Gemcitabine based chemotherapy will be treated to the patients.
2010759|NCT02859441|Drug|Ranibizumab|Intravitreal injections of the commercially-available 10 mg/mL formulation of ranibizumab. Ranibizumab is formulated as a sterile solution (pH 5.5 with histidine, trehalose and polysorbate 20. The vial contains no preservative. Each vial contains 0.5 mL of 10 mg/mL ranibizumab aqueous solution. The intravitreal injection volume of ranibizumab is 50 (Micro)L, which correlates to 0.5 mg of dry ranibizumab.
1616816|NCT02111174|Device|Scrambler Therapy|
1616817|NCT02111174|Device|Sham Therapy|
1616818|NCT02111161|Drug|IVIG (Privigen)|Three doses of 25 g IVIG (250 ml)
1616819|NCT02111161|Drug|Saline 0.9%|Three doses of Saline 0.9% (250 ml)
1616820|NCT02111148|Procedure|Urea and creatinine|the vagina will be washed with 5ml saline, urea and creatinine will be detected biochemically in the vaginal wash.
1616821|NCT02111148|Procedure|Nitrazine|Nitrazine detection in vaginal wash
1616822|NCT02111148|Drug|5ml saline|the vagina will be washed with 5ml saline and vaginal wash will be collected.
1616823|NCT02111135|Biological|b-OPV|
1616824|NCT02111135|Biological|m-OPV2|
1616825|NCT02111135|Biological|m-IPV HD|
1616826|NCT02111135|Biological|t-IPV|
1616827|NCT02111122|Drug|Sodium Oxybate|
1616833|NCT02111070|Biological|IL-YANG FLU Vaccine|0.5mL
1616834|NCT02111044|Drug|Octreotide|octreotide 100 mcg sc t.i.d. for 4 weeks
1616835|NCT02111044|Drug|ITF2984 500 mcg|ITF2984 500 mcg sc b.i.d for 4 weeks
1616836|NCT02111044|Drug|ITF2984 1000 mcg|ITF2984 1000 mcg sc b.i.d for 4 weeks
1616837|NCT02111044|Drug|ITF2984 2000 mcg|ITF2984 2000 mcg sc b.i.d for 4 weeks
1616838|NCT02111018|Device|CytoSorb Device|
1616839|NCT02111018|Procedure|CVVH|
1616840|NCT02110992|Drug|Docetaxel|Docetaxel 15mg/m2 IV, given days 1, 8, and 15 during SBRT
1616841|NCT02110992|Radiation|Stereotactic Radiation|SBRT will be given over 5 fractions separated by > 48 hours. Dose will be determined based upon dose escalation schedule and will range from 25-40 Gy.
1616842|NCT02110979|Behavioral|Use of a PDA to assist shared decision making|
1616843|NCT02110966|Drug|Mepivacaine|Drug: Tramadol 1.8 ml of Mepivacaine 2% epinephrine 1:100000.
1616844|NCT02110966|Drug|Mepivacaine plus Tramadol|0.5 ml of Tramadol mixed with 1.3 ml of Mepivacaine.
1616845|NCT02110953|Combination Product|irinotecan-eluting beads|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
1616846|NCT02110953|Procedure|hepatic artery embolization|Receive irinotecan hydrochloride-eluting beads via hepatic artery embolization
1616847|NCT02110940|Other|Neurodynamic mobilization exercise|"The mobilization exercise is conducted with 10 repetitions for each action, the action is hold for 5 seconds when subjects had the stretch feeling. The series of exercise is told to perform 2 sets a day, daily practice.
Subjects' conditions will be reviewed at the end of 4th and 8th week. An exercise log book will be provided for each subject to record down the compliance of the exercise."
1616848|NCT02110940|Other|Conservative Physiotherapy|The control group is assigned to received conventional treatment in the physiotherapy department with the standard rehabilitation protocol consisted of electrotherapy for pain relief, strengthening exercise to increase the strength of the thigh
1616849|NCT02110927|Device|Transcutaneous microcurrent|Microcurrent in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensitivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25 Hz to 10 Hz.
1616850|NCT02110927|Device|Aerobic exercise|50 minutes of aerobic moderate-intensity exercise (45-55% of maximal oxygen consumption (VO2 max)) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13), Polar® heart monitors to control heart rate and K4b2 to analyze the quantity of oxygen (O2) consumption and carbon dioxide (CO2) produced during exercise.
1616851|NCT02110914|Behavioral|Coaching|"Coaching is based on the principles of the Co-active coaching model and performed by a certified coach. At the first coaching session the coach and client will make an agreement about the format for subsequent coaching sessions. The first and the last coaching session will always be face to face at the hospital and last 1- 1½ hours. Intervening coaching sessions will be approximately 60 minutes by phone or face to face. In total, ten coaching sessions will be offered, one every 1-2 weeks early in the program and one every 2-4 weeks later in the process. The duration of the coaching intervention will be between 6 and 9 months."
1616852|NCT02110901|Drug|PRT-201|
1616853|NCT02110901|Drug|Placebo|
1616854|NCT02110888|Device|Subcutaneous peripheral nerve stimulation|
1616855|NCT02110888|Other|SCS Only|
1616856|NCT02110862|Other|Transittime. Defecography|
1616857|NCT02110849|Radiation|Proton|Proton Therapy for Prostate Cancer
1616858|NCT02110836|Dietary Supplement|Glucose ingestion|Glucose ingestion during exercise at 1.8 g/min
1616859|NCT02110836|Dietary Supplement|Sucrose ingestion|Sucrose ingestion during exercise at 1.8 g/min
1616860|NCT02110810|Drug|Indomethacin|Indomethacin suppository of 100 mg immediately afterwards while still under sedation
1616861|NCT02110810|Drug|2.6-g suppository of glycerin|to receive a 2.4 g of glycerin suppository immediately afterwards while still under sedation
1616862|NCT02110797|Other|biological markers and evaluation of the mineral density at the lumber spine using DEXA|
1616863|NCT02110784|Drug|Eurartesim tablets|dosage bands: 24 to <36 kg body weight: 2 tablets a day for three consecutive days 36 to <75 kg body weight: 3 tablets a day for three consecutive days 75 to 100 kg body weight: 4 tablets a day for three consecutive days
1616864|NCT02110771|Behavioral|GAÏA - facial affect recognition targeted|"2 sessions of one hour per week with therapist. Intervention proposes 3 stages : 1)discovering and learning facial affects recognition and discrimination criterions for joy, sadness and anger (photos exercises); 2) facial affect recognition training (computer based and role game exercises); 3) generalization to other emotions (photos, role games and computer based exercises).
The therapist chooses the change of stages; 5 sessions or more are proposed for the generalization stage."
1616865|NCT02110771|Behavioral|RECOS - attentional process targeted|2 sessions of one hour per week with therapist the first of those two session is allocated to paper and pen exercises (search and validation of strategies to resolve cognitive training exercises or functional problems). the second session is allocated to computer based exercises.
1616867|NCT02110745|Drug|Sevofluorane|Comparison of different induction drugs and techniques
1616868|NCT02110745|Drug|Propofol|Comparison of different induction drugs and techniques
1616869|NCT02110732|Dietary Supplement|Lactobacillus rhamnosus GG|
1616870|NCT02110719|Drug|Celebrex|
1616871|NCT02110719|Drug|Gabapentin|
1616872|NCT02110719|Drug|IV acetaminophen|
1616873|NCT02110719|Drug|oral acetaminophen|
1616874|NCT02110719|Drug|oral ibuprofen|
1616875|NCT02110719|Drug|percocet|
1616876|NCT02110719|Drug|vicodin|
1616877|NCT02110719|Drug|Oxycodone|
1616878|NCT02110719|Drug|dilaudid|
1616879|NCT02110719|Drug|Dexamethasone|
1616880|NCT02110719|Drug|zofran|
1616881|NCT02110706|Drug|Rituximab|Intervention (rituximab): The treatment group will receive a total of two cycles of rituximab separated by 6 months. Each cycle is defined as one infusion (375mg/m2 IV) per week for four consecutive weeks
1616882|NCT02110706|Drug|Placebo|The placebo group will receive a vehicle control infusion
2010760|NCT02859441|Drug|E10030|E10030 is not a commercially available drug product, and will be provided by Ophthotech Corp. The drug product is provided as a sterile aqueous solution of E10030 at a concentration of 30 mg (oligo weight)/mL. The solution contains monobasic sodium phosphate monohydrate and dibasic sodium phosphate heptahydrate as buffering agents as well as sodium chloride as a tonicity adjuster. The intravitreal injection volume of E10030 is 50 microliter, which correlates to 1.5 mg of dry E10030.
1616885|NCT02110680|Device|Sports TENS 2|transcutaneous electric stimulation
1616886|NCT02110667|Device|Transperineal Ultrasound|
1616887|NCT02110654|Drug|Montelukast|
1616888|NCT02110654|Drug|mometasone furoate nasal spray|
1616889|NCT02110641|Behavioral|Weight Loss Counseling|The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
1616890|NCT02110628|Procedure|Roux-en-Y anastomosis|Roux-en-Y anastomosis
1616891|NCT02110628|Procedure|Roux-en-Y+Pouch anastomosis|Roux-en-Y+Pouch anastomosis
1616892|NCT02110615|Other|Primary Care Practice Changes|The clinical intervention components included (1) advanced training on clinical quality improvement and obesity prevention, assessment, management; (2) computerized, point-of-care decision support tools for clinicians; (3) implementation of multi-disciplinary weight management programs within the community health centers, e.g. Healthy Weight Clinics (HWC); (4) integrating community health workers into the primary care and HWC teams; and (5) health center environmental changes to support behavior change modification.
1616893|NCT02110602|Other|Diet high in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism & Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
1616894|NCT02110602|Other|Diet low in amino acid levels|Meals will be prepared in the Clinical Research Center Metabolism & Nutrition Metabolic Kitchen, and participants will eat only this food during the controlled-diet periods of the study. The diets will contain equivalent calories (matched to the requirements of each participant) and either a low or high percentage of all BCAAs relative to protein content.
1616895|NCT02110589|Device|Epidetect|Topically aplied muscle tonicity monitor (EMG recording)
1616896|NCT02110563|Drug|DCR-MYC|"Dosing: 2 hour IV infusion on Day 1 and 8 of each 21 day cycle.
Starting dose: 0.1mg/kg/dose
Dose escalation: 100%, 50%, or 25% increase in subsequent cohorts depending upon toxicity.
Number of cycles: until progression or unacceptable toxicity develops."
1616897|NCT02110550|Other|IPS.emmax endocrown|
1616898|NCT02110537|Procedure|Active Acupuncture|Active acupuncture treatment group consists of electroacupuncture (EA) and intradermal acupuncture (IDA). For EA treatment, unilateral PC5, PC6, ST36, and ST37 are chosen. Disposable, sterile needles and low frequency electrical stimulator (ES-160, ITO, Japan) are used. Each needle is inserted to the depth of 2 ± 0.5 cm with a 90 degree angle. Thereafter, needles are connected with the pole and electrical stimulation is applied with 2Hz, continuous wave current for 20 minutes. For IDA treatment, bilateral HT7 and TF4 are selected. Disposable, sterile, sticker-type needles (0.18 mm x 1.3 mm x 1.5mm) are used. Attached needles are maintained as long as possible.
1616899|NCT02110537|Procedure|Sham acupuncture|For sham intervention, nonacupuncture points are used. As with active treatment group, two types of acupuncture, sham EA and sham IDA, compose the sham intervention. Electrical acupuncture is connected but electrical stimulation is not given to sham acupuncture group.
1616900|NCT02110537|Drug|flecainide|Both groups commonly take antiarrhythmic medication (flecainide 75 mg twice daily) during study period. Flecainide administration is initiated 2 weeks before electrical cardioversion and maintain during follow up period.
1616901|NCT02110524|Device|Percutaneous Transluminal Angioplasty|
1616902|NCT02110511|Other|blended lentils|blended lentils burritto breakfast
1616903|NCT02110511|Other|whole lentils|whole lentils breakfast burritto
1616904|NCT02110511|Other|no lentils|No lentils control breakfast burritto
1616906|NCT02110472|Device|Corneal inlay|Presbia Flexivue Microlens implantation in corneal pocket created in nondominant eyes of emmetropic presbyopes.
1616907|NCT02110459|Drug|POL7080|Intravenous infusion
1616908|NCT02110446|Drug|SS-1|"The patients will be divided into two groups (A and B) at random and all of them keep the routine treatment in the rheumatology OPD. Group A patients will receive 12 weeks SS-1 treatment first, and then stop the SS-1 for 4 weeks for wash-out phase, and then receive 12weeks placebo treatment. Group B patients receive 12 weeks placebo first, and then stop the placebo treatment for 4 weeks for wash-out phase, and then receive 12weeks SS-1 treatment.
SS-1 is composed of 3 traditional Chinese herbal formula: Gan-Lu-Yin, Sang-Ju-Yin and Xuefu-Zhuyu-Decoction with the ratio of 2:1:1. The placebo is composed with corn starch, pigment and minimal dose of 1% SS-1. Patients in both groups take 6 gram of SS-1/Placebo three times per day."
1616909|NCT02110446|Drug|Placebo|The placebo is composed of corn starch, pigment and minimal dose of 1% SS-1. Patients take 6 gram of experiment medicine three times per day.
1616910|NCT02110433|Device|Placebo group|patient will be managed as recommended by ESC guidelines and follow up will be in accordance to ESC recommendations
1616911|NCT02110433|Device|Cordiva System (R)|Patients have to answer to 8 specific binary questions based on the main precipitating factors for decompensation and measure their body weight every day. If not they will be contact after two missing measures. Patient will be contact by phone call every month in order to reinforce the initial patient therapeutic education and patient-'s compliance. Patient have access to specific printed documents and to a specific web based platform where he can find some PowerPoint presentation on CHF aetiology, signs and therapy and where he can try to answer to monthly quiz in whom questions are based on key messages about CHF according to guidelines and consensus paper on patient therapeutic education.
1616965|NCT02110095|Device|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
1616966|NCT02110082|Biological|Urelumab|
1616912|NCT02110433|Device|BNP heartcheck|Patients had to measure the BNP plasma level using Alere home based BNP device heartcheck in a weekly basis in order to follow this parameter up. In case of clinical signs of CHF or a significant weight increase identified by the tele monitoring or the patient, the nurse will ask to the patient to do an extra measurement of home BNP testing in order to exclude a CHF decompensation (BNP < 100 pg/ml or remaining stable (< 30% increase).
1616913|NCT02110420|Drug|CC-90001|CC-90001 10mg will be administered as a single dose
1616914|NCT02110420|Drug|CC-90001|CC-90001 30mg will be administered as a single dose
1616915|NCT02110420|Drug|CC-90001|CC-90001 60mg will be administered as a single dose
1616916|NCT02110420|Drug|CC-90001|CC-90001 120mg will be administered as a single dose
1616917|NCT02110420|Drug|CC-90001|CC-90001 240mg will be administered as a single dose
1616918|NCT02110420|Drug|CC-90001|CC-90001 10mg will be administered daily for 14 days
1616919|NCT02110420|Drug|CC-90001|CC-90001 30mg will be administered daily for 14 days
1616920|NCT02110420|Drug|CC-90001|CC-90001 60mg will be administered daily for 14 days
1616921|NCT02110420|Drug|CC-90001|CC-90001 120mg will be administered daily for 14 days
1616922|NCT02110420|Drug|CC-90001|CC-90001 240mg will be administered daily for 14 days
1616923|NCT02110420|Drug|Placebo|Placebo will be administered once daily for up to 14 days depending on the Part of the study
1616924|NCT02110420|Drug|CC-90001|CC-90001 480mg will be administered as a single oral dose
1616925|NCT02110420|Drug|CC-90001|CC-90001 720mg will be administered as a single oral dose
1616926|NCT02110420|Drug|CC-90001|CC-90001 480mg will be administered daily for 14 days
1616927|NCT02110407|Device|tDCS|transcranial direct current stimulation (tDCS)
1616928|NCT02110407|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
1616929|NCT02110394|Other|bendamustine|Routine practice
1616930|NCT02110394|Other|rituximab|Routine practice
1616931|NCT02110381|Device|Device guided breathing RESPeRATE|"Participants will use a device called RESPeRATE which will measure how many breaths they take per minute. A strap wraps around the participants chest that measures breathing frequency. Headphones plug into the device to inform participants about their breathing. The device will help guide participants to breathe slowly using musical tones, with a goal of about ten breaths per minute.
Participants will use the breathing device 5 days per week for about 15 minutes each day. Participants will keep a log of their exercises and return it with each visit."
1616932|NCT02110381|Device|Isometric hand grip Zona Plus|"Participants will use a device called the Zona Plus, which they will hold in their hand and squeeze. A session consists of 2 minutes of squeezing the device followed by 1 minute of rest. Participants will do a total of 4 sessions (2 sessions for each hand) for a total of about 12 minutes of exercise.
Participants will do these exercises 5 days per week. Participants will keep a log of their exercise and return it with each visit."
1616933|NCT02110368|Drug|Testosterone Topical Gel, 1.62% Metered Pump|
1616934|NCT02110368|Drug|AndroGel (testosterone gel) 1.62% Metered-Dose Pump|
1616935|NCT02110355|Drug|AMG 232|Given as an oral tablet in escalating doses
1616936|NCT02110355|Drug|Trametinib|Trametinib is an anti-cancer agent
1616937|NCT02110355|Drug|Dabrafenib|Dabrafenib is an anti-cancer agent
1616938|NCT02110342|Drug|[14C] PF-04449913|Single oral dose of 100 mg PF-04449913 + 100µCi of [14C] PF-04449913
1616939|NCT02110329|Genetic|evaluation of the recurrence rate according to molecular analysis|
1616940|NCT02110316|Other|Dosage form of voriconazole|Instead of an oral dose of voriconazole, patients receive one intravenous dose of voriconazole (in the same dose as the oral dose).
2010761|NCT02857023|Behavioral|Cogmed RM|Cogmed consists of 12 increasingly challenging exercises (completed over 25 sessions spanning 5-8 weeks) that target skills involving visuo-spatial and verbal working memory.
1616943|NCT02110277|Device|PAI/ultrasound Diagnostic Group|These patients will include women who are at risk for ovarian cancer and wish to undergo prophylactic oophorectomy, or who have an ovarian mass suggestive of a malignancy and are counseled to undergo oophorectomy.
1616944|NCT02110264|Drug|XR-NTX|Monthly injections of XR-NTX will be administered to participants assigned to either the XR-NTX or XR-NTX+PN groups.
1616945|NCT02110264|Behavioral|XR-NTX+PN|In addition to long-acting naltrexone (XR-NTX), participants assigned to the XR-NTX+PN condition will meet regularly with a patient navigator to assist in accessing psychosocial services when released from jail.
1616946|NCT02110264|Behavioral|ETAU|Participants assigned to the ETAU group will receive drug education.
1616947|NCT02110251|Behavioral|Supervised Exercise Therapy|
1616948|NCT02110238|Device|Supartz|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
1616949|NCT02110238|Device|Euflexxa|Treatment is 3 injections over 2 weeks; Week 0 (baseline), Week 1, and Week 2.
1616950|NCT02110225|Drug|rhNGF 60 µg/ml eye drops solution|rhNGF 60 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
1616951|NCT02110225|Drug|rhNGF 180 µg/ml eye drops solution|rhNGF 180 µg/ml eye drops solution, one drop 3 times a day for 24 weeks in both eyes
1616952|NCT02110225|Drug|Placebo|Placebo eye drops solution, one drop 3 times a day for 24 weeks in both eyes
1616953|NCT02110212|Procedure|U/S Surgery and CCC|Subjects will receive the standard of care for U/S cataract surgery and CCC to facilitate removal of the crystalline lens.
1616954|NCT02110212|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery.
1616955|NCT02110186|Device|Dynamic Stabilization|
1616956|NCT02110186|Procedure|Discectomy|
1616957|NCT02110186|Device|Instrumentation and fusion|
1616958|NCT02110160|Device|FDG PET/CT|
1616959|NCT02110160|Biological|Fluorodeoxyglucose F 18 Injection (FDG)|
1616960|NCT02110147|Drug|uridine triacetate|
1616961|NCT02110134|Device|Revlite Laser System|Revlite Laser System for the Treatment of Melasma
1616962|NCT02110121|Device|Picosure Laser System|Picosure Laser System for the Treatment of Unwanted Tattoos
1616963|NCT02110121|Device|Revlite Laser System|Revlite Laser System for the Treatment of Unwanted Tattoos
1616964|NCT02110108|Device|Revlite Laser System|Revlite Laser System for the Treatment of Facial Solar Lentigines
1616968|NCT02110069|Drug|Vincristine|Vincristine dose dependent upon weight. Weekly for 2 weeks (Induction); Weekly 2 months; every 2 weeks for next 5 months; every 3 weeks for 5 months (Maintenance)
1616969|NCT02110069|Drug|Sirolimus|Continuous dosing to maintain trough level of 10-15ng/ml.
1616970|NCT02110056|Device|tDCS|transcranial direct current stimulation (tDCS)
1616971|NCT02110056|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
1616972|NCT02110043|Device|tDCS|transcranial direct current stimulation (tDCS)
1616973|NCT02110043|Behavioral|training|intensive training of visual-spatial abilities (in LOCATO task)
1616974|NCT02110030|Device|Transcutaneous nerve stimulation|"The group with TENS received electrical stimulation (Endomed 182, Enraf-nonius, Germany) at a frequency of 80 Hz and with a pulse width of 150 ns. The TENS was applied by using 4 surface electrodes (5x5 cm Prim-Trode, Spain) into two channels: supraspinatus fossa and the insertion of the rotator cuff (channel 1) and V deltoid  (channel 2). The current intensity was set 3 times during each session according to each patient's sensitivity. Current was strong but it did not exceed the threshold of pain."
1616975|NCT02110030|Device|Interferential Currents|"The group with IC received a base frequency of 4000 Hz (Endomed 182, Enraf-nonius, Germany) with an amplitude-modulated frequency (AMF) and slope of 1/1 in tetrapolar mode, as previously indicated. For IC, the same number and type of surface electrodes (5x5 cm Prim-Trode, Spain) were placed onto the anterior and posterior deltoid, supraspinatus fossa and V deltoid. Similarly, the intensity of the current was set 3 times per session and the stimulation was strong but comfortable (without exceeding the threshold of pain)."
1616976|NCT02110017|Other|fMRI social cognition task|fMRI social cognition task : each subject will go through 3 runs of a fMRI paradigm, first one verbal then two visual runs, which are meant to activate the theory of mind network.
1616977|NCT02110004|Procedure|Ablation procedure|The primary purpose of the First-In-Man clinical investigation is to assess the Picasso NAV Catheter's ability to collect intra-cardiac signals within the desired chambers (atrial and/or ventricle) in the heart for the analysis of complex arrhythmias.
1616978|NCT02110004|Device|Picasso NAV Catheter|
1616979|NCT02109991|Device|CG-100 device|Colorectal surgery performed per standard of care with deployment of the CG-100 device in the anastomosis site
1616980|NCT02109965|Drug|Dexmedetomidine|Continue infusion (CIF) 0.1 - 0.7 mcg/kg/h Goal of sedation: Richmonad agitation-sedation scale 0 to -2
1616981|NCT02109965|Drug|Midazolam|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
1616982|NCT02109965|Drug|Propofol|CIF Goal of sedation: Richmonad agitation-sedation scale 0 to -2
1616983|NCT02109939|Genetic|GeneSight Psychotropic|"The GeneSight Psychotropic product is a pharmacogenomic decision support tool that helps clinicians to make informed, evidence-based decisions about proper drug selection, based on the testing for clinically important genetic variants in multiple pharmacokinetic and pharmacodynamic genes that affect a patient's ability to tolerate or respond to medications.
The GeneSight Psychotropic product contains the most commonly prescribed antidepressant and antipsychotic medications, including a full representation of the SSRI and SNRI drug classes.
tricyclic antidepressants, an MAOI, and typical and atypical antipsychotics are also represented."
1616984|NCT02109926|Other|Phone interview and blood test|Subjects will be interviewed about environmental, domestic and occupational exposures during several periods of life Two blood samples will be collected at enrollment to study genetic polymorphisms
1616985|NCT02109913|Drug|Everolimus plus Exemestane|Everolimus 10mg, oral, daily; exemestane 25 mg, oral, daily. Number of Cycles: until progression or unacceptable toxicity develops. From all patients, 4 additional blood samples, 6ml each, will be collected and an optional tumor biopsy will be taken, if eligible.
1616986|NCT02109900|Other|Serum Progesterone Levels|
1616987|NCT02109874|Biological|AERAS-404 (mcg H4/nmol IC31)|Dose escalation
1616988|NCT02109874|Biological|Sterile buffer containing 10 mmol/L tris and 169 mmol/L NaCl|
2010762|NCT02855905|Other|Exercise/Rest and cold/neutral temperature|Subjects were either exercising or resting in either cold or neutral environmental temperature
2010763|NCT02855359|Drug|denintuzumab mafodotin|SGN-CD19A at 3 mg/kg will be administered every 6 weeks via intravenous (IV) infusion, up to a maximum of three (3) doses, on Day 1 of Cycles 1, 3, and 5 of 21-day cycles
2010764|NCT02855359|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
1616992|NCT02109809|Radiation|total nodal irradiation|Undergo TLI
1616993|NCT02109809|Other|laboratory biomarker analysis|Correlative studies
1616994|NCT02109809|Other|questionnaire administration|Ancillary studies
1616995|NCT02109796|Device|transcranial Direct current stimulation|
1616996|NCT02109783|Dietary Supplement|Caffeine 2mg|Caffeine 2 mg versus 4 mg/kg or placebo
1616997|NCT02109783|Dietary Supplement|Caffeine 4 mg|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
1616998|NCT02109783|Dietary Supplement|Caffeine 0|To compare exercise performance of 2 or 4 mg of caffeine per kilogram of body weight to placebo within subjects. Subjects will perform 4 exercise tests.
1616999|NCT02109757|Other|Software intervention and education|Personal attenuation rating measurements will be taken before and after educating the patient using software program
1617000|NCT02109757|Other|Education only|
2010765|NCT02855359|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
1617002|NCT02109731|Other|Negative airway pressure delivery|Negative airway pressure delivery (breathing against a vaccuum) in order to improve the tone of the upper airway muscles and make them less susceptible to collapse during sleep.
1617003|NCT02109718|Drug|Open Dressings with Petrolatum Jelly|participants randomized to this arm had their wounds dressed with a thin layer (1mm) of petrolatum gel applied over the burn wound and instructed to reapply the gel as needed in the event of gel coming off.
1617004|NCT02109718|Drug|Silver Sulfadiazine Gauze Dressing Group|Participants randomized to this arm had their wounds dressed using the standard methods at the Burn Center. An initial layer of fine mesh gauze is applied that is laden with a 2mm layer of silver sulfadiazine cream. This is covered with layers of moist gauze and an outer layer of dry gauze, secured by wrapping with rolled gauze. The dressing extends at least 1 inch beyond the wound edge.
1617005|NCT02109692|Other|blood sample|dosage of miRNA
1617006|NCT02109679|Drug|metformin|multiple doses metformin given as tablet
1617007|NCT02109679|Drug|BI 187004|multiple doses BI 187004 given as tablets
1617008|NCT02109679|Drug|BI 187004|multiple doses BI 187004 given as tablets
1617009|NCT02109679|Drug|metformin|multiple doses metformin given as tablet
1617010|NCT02109666|Drug|Abatacept|
1617011|NCT02109653|Drug|LGX818|Oral LGX818 300mg daily
1617012|NCT02109640|Drug|Targinact|Post-operative analgesia
1617013|NCT02109640|Drug|Oxycodone|Postoperative analgesia
1617014|NCT02109640|Procedure|Laparoscopic segmental colectomy|
1617015|NCT02109627|Drug|Ficlatuzumab|5-20 mg/kg; intravenous; Days 0, 14, 28, and 42. Number of cycles: until progression or unacceptable toxicity develops.
1617016|NCT02109627|Drug|Cytarabine|2 g/m2; intravenous; Days 2-7; Number of cycles: until progression or unacceptable toxicity develops.
1617017|NCT02109614|Drug|Extended release Niacin|Arm will be taking 1500-2000mg of niacin daily to see if lipoprotein(a) levels are lowered and aortic stenosis does not increase.
1617018|NCT02109614|Drug|Placebo Comparator|Placebo Comparator arm will be taking 1500mg of the placebo daily
1617019|NCT02109601|Other|Extensive bedside training for accessing patient portal|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
1617020|NCT02109601|Other|Limited bedside training on patient portal use.|EXTENSIVE bedside training from a research assistant on how to access and effectively use their patient portal.
1617021|NCT02109588|Behavioral|A supervised physical exercise program|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60% of heart rate reserve. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate"
1617022|NCT02109575|Diagnostic Test|Blood Draw of up to 10 ml|In a laboratory setting, the blood will be spun for plasma and buffy coat, DNA will be extracted for processing using the diagnostic test. The results of the test are not provided back to the clinical setting.
1617023|NCT02109562|Drug|RBP-7000 90mg|Subcutaneous 90 mg injection on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29. RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner.
1617024|NCT02109562|Drug|Placebo|Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.
1617025|NCT02109562|Drug|Risperidone|Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
1617026|NCT02109562|Drug|RBP-7000 120mg|Subcutaneous 120 mg injection on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29. RBP-7000 is a combination of the ATRIGEL Delivery System and risperidone. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner.
1617027|NCT02109536|Device|Magnetic endoscopic imager.|recognizing loop type accuracy of loop type detection methods of loop reduction assessed by type
1617028|NCT02109523|Behavioral|Motivational Interviewing (MI|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
1617029|NCT02109523|Behavioral|volitional intervention|Five weekly motivational and volitional session sessions and each last about 50 minutes. Five registered psychologists will moderated the session. All MI technique and planing intervention will be used.
1617030|NCT02109523|Behavioral|Routine discharge counseling|
1617031|NCT02109510|Drug|nonintubated sedation anesthesia with dexmedetomidine IV, ketamine IV and intercostal nerve block with lidocaine infiltration|
1617032|NCT02109510|Drug|intubated general anesthesia with propofol IV, rocuronium IV ,sevoflurane and N2O gas|
1617033|NCT02109510|Procedure|single port thoracoscopic bullectomy|Thoracoscopic bullae resection with automated stapler through the single incision (2.0 cm length) at 5th intercostal space.
1617034|NCT02109497|Drug|PBT2|PBT2 250 mg administered
2010766|NCT02855359|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
2010767|NCT02855359|Drug|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
2010768|NCT02855359|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
1617041|NCT02109458|Device|Navigation guided bronchoscopy|Navigation guided transthoracic needle aspiration (N-TTNA) and navigation guided bronchoscopy (NB); guidance system is by Veran Medical Technologies, Inc.
1617042|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Doses: 100 -150 mg BID
1617043|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
1617044|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
1617045|NCT02109445|Drug|PF-03084014|Tablets, orally administered twice daily on a continuous dosing schedule in 28 days cycles. Phase 2 dose will be the recommended phase 2 dose defined in phase 1.
1617046|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
1617047|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
1617048|NCT02109445|Drug|Gemcitabine|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 1000 mg/m2.
1617049|NCT02109445|Drug|Nab-paclitaxel|Intravenously administered on Days 1, 8, 15 in 28 days cycles at the dose of 125 mg/m2.
1617050|NCT02109432|Behavioral|Self-Directed Pedal Desk|participants will have a pedal desk installed in their office and will have access to their daily recorded data but will not have any other form of feedback or goal-setting
1617091|NCT02109185|Drug|Nasonex® Nasal Spray Suspnsn, 50 μg/actuation|
1617051|NCT02109432|Behavioral|Facilitated Pedal Desk|participants are provided with their daily recorded pedal desk data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount
1617052|NCT02109432|Behavioral|Facilitated Pedal Desk with Pedometer|participants will be provided with their daily recorded pedal desk and step count data and additional daily behavioral support from an interventionist (e.g., feedback and goal-setting) to increase their use of the pedal desk by an individually negotiated and agreed upon amount and increase their step count by 3,000 steps/day compared to baseline.
1617053|NCT02109406|Drug|AZD2115 Dose 1|AZD 2115, Dose 1 administered as two inhalations BID
1617054|NCT02109406|Drug|AZD 2115, Dose 2|AZD 2115, Dose 2 administered as two inhalations BID
1617055|NCT02109406|Drug|Placebo MDI|Placebo MDI administered as two inhalations BID
1617056|NCT02109393|Other|MIRT|"It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues, cycloergometer, treadmill-plus. The third is a session of occupational therapy. The last session includes one hour of speech therapy.
All patients undergo 20-minutes treadmill-plus training per day, 5 times a week, for 4 weeks."
1617057|NCT02109393|Other|MIRT+Lokomat|It consists of a 4-weeks physical therapy which entails four daily sessions for five days. All treatments are performed in aerobic condition. The duration of each session, including recovery periods, is about one hour. The first session consists of a one-to-one session with physical therapist. The second session includes aerobic and repetitive exercises to improve balance and gait using different devices: a posturographic platform with visual cues and cycloergometer. The third is a session of occupational therapy to improve autonomy in activities of daily life. The last session includes one hour of speech therapy. All patients undergo 20-minutes Lokomat® training per day in spite of treadmill-plus.
1617058|NCT02109380|Behavioral|Bed rest|
1617059|NCT02109354|Biological|ALVAC-HIV|Formulated as a lyophilized vaccine for injection and is reconstituted with 1.05 mL of sterile Sodium Chloride solution (0.4% NaCl) for a single 1 mL dose of >1.0 x 106 CCID50/mL, to administer intramuscularly (IM).
1617060|NCT02109354|Biological|AIDSVAX B/E|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein adsorbed onto 600 mcg of aluminum hydroxide gel adjuvant. Each vial contains 1.2 mL of sterile suspension, to administer 1 mL IM.
1617061|NCT02109354|Biological|Placebo for ALVAC-HIV|A sterile, lyophilized product that consists of a mixture of virus stabilizer, and freeze drying medium and is reconstituted with 1.05 mL of sterile Sodium Chloride (0.4% NaCl) for a single 1 mL dose, to administer IM.
1617062|NCT02109354|Biological|Placebo for AIDSVAX B/E|Sodium Chloride for Injection, 0.9% administered IM.
1617063|NCT02109354|Biological|Hepatitis B vaccine|Each 1 mL dose contains 20 mcg of hepatitis B surface antigen (HBsAg) adsorbed onto 500 mcg aluminum as aluminum hydroxide, to administer IM.
1617064|NCT02109354|Biological|Tetanus toxoid vaccine|The active ingredient is tetanus toxoid (≥ 40 I.U. / 0.5 mL) adsorbed on aluminium hydroxide dihydrate (600 mcg of aluminium), to administer IM.
1617065|NCT02109354|Biological|Placebo for hepatitis B vaccine|Sodium Chloride for Injection, 0.9% administered IM.
1617066|NCT02109354|Biological|Placebo for tetanus vaccine|Sodium Chloride for Injection, 0.9% administered IM.
1617067|NCT02109341|Drug|Paclitaxel bound albumine|
1617068|NCT02109328|Drug|Alisertib|"SINGLE-ARM, SINGLE-DRUG PHASE: Alisertib will be given PO in a dosage of 50 mg BID for 7 Days (Days 1-7) of each 21 day treatment cycle.
In the randomized phase, Experimental arm will consist of the following drugs:
Alisertib will be given PO in a dosage of 40 mg twice daily on days 1-3, 8-10 and 15-17 of a 28 day cycle.
Paclitaxel: 60 mg/m2 over 60 minutes on Days 1, 8, and 15 in a 28-day cycle."
1617069|NCT02109328|Drug|Paclitaxel|Placebo will be given PO. Paclitaxel will be infused at the dose of 80 mg/m2 IV over a period of 60 minutes on Days 1, 8, and 15 in a 28-day cycle.
1617070|NCT02109328|Drug|Placebo|Placebo oral tablets
1617071|NCT02109315|Drug|Vitamine C|C Vitamine endovenous 1000 mg/5 ml. Infusion dose: 30 mgr/min
1617072|NCT02109315|Drug|Liraglutide 6 mg|Liraglutide endovenous de 0.6 mg. one time a day
1617073|NCT02109302|Procedure|Blood sample|
1617074|NCT02109302|Procedure|Skin biopsy|
1617075|NCT02109302|Other|Questionnaire|
1617076|NCT02109289|Drug|etanercept|Etanercept is a tumor necrosis factor antagonist
1617077|NCT02109276|Device|Spheric Sensar(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
1617078|NCT02109276|Device|Aspheric Tecnis(R) 3-piece IOL|Patients will be randomized to receive either a standard spheric intraocular lens or an aspheric intraocular lens
1617079|NCT02109263|Procedure|saccharose versus breast-feeding|saccharose versus breast-feeding
1617080|NCT02109250|Drug|Caprelsa|Caprelsa® 100 mg or 300 mg film-coated oral tablets. Each film-coated tablet contains 100 mg or 300 mg of vandetanib.
1617081|NCT02109237|Procedure|Assessment of sleep disorders and treatment if required|Assessment of sleep disorders and treatment if required
1617082|NCT02109224|Drug|Ibrutinib|Given PO
1617083|NCT02109224|Other|Laboratory Biomarker Analysis|Correlative studies
1617084|NCT02109224|Other|Pharmacological Study|Correlative studies
1617085|NCT02109211|Device|Intubation with Magill forceps|
1617086|NCT02109211|Device|Intubation with altered Magill forceps|
1617087|NCT02109198|Device|Active CN-NINM PoNS|Delivery of active stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
1617088|NCT02109198|Device|Sham CN-NINM PoNS|Delivery of sham stimulation of the tongue during in-person therapy sessions (1 hour) and during two home sessions (40 minutes) daily on 6 of 7 days per week (120 total sessions). Stimulation sessions will be separated by at least 4 hours.
1617089|NCT02109185|Drug|Mometasone Furoate Monohydrate Nasal Spray, 50 μg/act.|
1617090|NCT02109185|Drug|Nasonex® Nasal Spray, 50 μg/actuation|
1617092|NCT02109185|Drug|Placebo Nasal Spray, 50 μL/actuation|
1617093|NCT02109172|Drug|TD-4208|
1617094|NCT02109172|Drug|Placebo|
1617095|NCT02109159|Other|A short online video with emotional content|
1617096|NCT02109159|Other|A short online video with less emotional content|
1617097|NCT02109146|Drug|Transcatheter Arterial Chemoembolization|Transcatheter Arterial Chemoembolization should be used in the experimental group
1617098|NCT02109146|Other|No intervention No Transcatheter Arterial Chemoembolization|
1617099|NCT02109133|Procedure|deep neuromuscular blockade|deep neuromuscular blockade using rocuronium and reverse with sugammadex
1617100|NCT02109133|Procedure|moderate neuromuscular blockade|moderate neuromuscular blockade using atracurium and reverse with neostigmine
1617101|NCT02109133|Drug|Rocuronium|
1617102|NCT02109133|Drug|Sugammadex|
1617103|NCT02109133|Drug|Atracurium|
1617104|NCT02109133|Drug|Neostigmine|
1617105|NCT02109120|Procedure|vein blood collection|5 ml peripheral vein blood samples were collected from each patient admitted to our study at the following time-points：Pre-operative（morning of surgery），just before declamping，30mins after declamping and post-operative（12h）.
1617106|NCT02109107|Device|Erchonia EZ6 Laser|The Erchonia EZ6 is administered 6 times across 6 consecutive weeks, each administration seven days apart, each treatment lasting 60 minutes.
1617107|NCT02109081|Drug|Dexamethasone|
1617108|NCT02109081|Drug|Placebo|
1617109|NCT02109068|Behavioral|Weight Loss Counseling- Phone|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
1617110|NCT02109068|Behavioral|Weight Loss Counseling- In-Person|"The intervention will be based on the Diabetes Prevention Program weight loss program, which uses a combination of reduced caloric intake, increased physical activity, and behavior therapy. The content of the weight loss program will be similar for the in-person and telephone interventions, but the approach will vary (i.e., in-person vs. telephone counseling). The weight loss intervention will be conducted by a Registered Dietitian, who has training in exercise physiology and behavior modification.
During the 6-month intervention, participants will receive weekly (month 1), then bi-weekly (months 2 and 3), then monthly (months 4, 5, and 6) individualized counseling sessions. An advantage of tapering the frequency of visits from weekly to every other week and then monthly works as a process tool to help transfer the work or responsibility onto the participant for life long change and maintenance of behavior change."
1617111|NCT02109055|Other|Pilates|The exercise program will be held during the period of hospitalization for six days, often two to three sessions per day, totaling 12 sessions.
1617112|NCT02109055|Other|Conventional Physiotherapy|The conventional physiotherapy group will continue with the routine hospital consisting of respiratory physiotherapy, twice daily, six days.
2010769|NCT02853435|Drug|Gepotidacin RC Tablet|The tablet is a capsule shape white film coated tablet with no identifying markings. This is an immediate release tablet containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
1617114|NCT02109029|Drug|LY2605541|Administered IV
1617115|NCT02109029|Drug|Human Insulin|Administered IV
1617116|NCT02109029|Drug|Sinistrin|Administered IV
1617117|NCT02109016|Drug|Lucitanib|"Lucitanib given orally to all patients, once daily (q.d.), on a continuous schedule over 28-day cycles, in fasting conditions (at least 2 hours prior to and 2 hours after any meal), until progressive disease or unacceptable toxicity.
Starting dose is 10 mg/day and can be reduced in 2.5 mg decrements to 5 mg/day based on individual tolerability."
1617118|NCT02109003|Device|Pressure easy® device|Continuous control of tracheal cuff pressure using a mechanical device for 24h followed by manual control of cuff pressure using a manometer.
1617119|NCT02109003|Device|Manual control of Pcuff followed by continuous control.|Control 24h with manual control using a manometer followed by 24h of continuous control using a mechanical device.
1617120|NCT02108990|Drug|Acetaminophen|
2010770|NCT02853435|Drug|Gepotidacin HSWG Tablet|The tablet is an oval shape white film coated tablet with no identifying markings. This is an immediate release tablets containing gepotidacin 750 mg (free base) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing tablets.
1617125|NCT02108925|Drug|Oxygen|supplementary oxygen during exercise
1617126|NCT02108912|Other|ESTT|ESTT is early-standardized task-specific training is a treadmill and over ground gait protocol for gait recovery after stroke
1617127|NCT02108912|Other|Traditional outpatient|Traditional physical therapy includes standard of care for gait recovery after stroke such as pre-gait activities, standing balance activities, strengthening, walking with assistive devices.
1617128|NCT02108899|Behavioral|Retrieval practice effect using descriptive stories and free-call tests without feedback|"In the first phase (encoding), people study 2 short prose passages covering general scientific topics.
In the second phase (initial test), they recall one text or restudy the other one.
In the third phase (final test) which takes place 2 days later, they recall both texts."
1617129|NCT02108886|Drug|Montelukast|10 mg of Montelukast per day, from admission for preterm labor until delivery or 35 weeks of pregnancy.
1617130|NCT02108886|Drug|Placebo|empty capsule filled with sugar
1617131|NCT02108886|Other|urine and vaginal secretions sampling|Urine and vaginal secretions sampling, once a week in both groups
1617132|NCT02108860|Drug|Abatacept|Those randomized to abatacept will receive abatacept 125 mg administered by subcutaneous injection once a week Participants randomized to either the abatacept or the placebo arm who experience a non-severe disease relapse, non-severe disease worsening, or who have not achieved remission by month 6 will have the option of entering an open-label trial period whereby they would receive open-label abatacept. .
1617133|NCT02108860|Drug|placebo|Those randomized to placebo will receive a sterile placebo solution administered by subcutaneous injection once a week.
1617134|NCT02108847|Drug|.2% Ropivacaine|
1617135|NCT02108847|Drug|Saline|
1617136|NCT02108847|Procedure|Fascia Iliaca Block|Ultrasound-guided regional anesthesia block to the groin area.
1617137|NCT02108834|Procedure|nerve block|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.5% ropivacaine in Group 1
1617138|NCT02108834|Procedure|placebo|After general anaesthesia,the patient is placed in a supine position with the head turn away from the side to be blocked, and then the sternocleidomastoid muscle (SCM) is identified by slight head elevation. SCPB(superficial cervical plexus block) is performed with a 26-gauge needle that is inserted at the midpoint of the posterior border of the SCM muscle and the needle is advanced just past the SCM muscle. The mixture is prepared with 20ml of 0.9% saline in Group 2.
1617139|NCT02108821|Biological|Fecal Microbiota Transplantation (FMT)|The process of fecal microbiota transplantation (FMT), where fecal bacteria from a healthy individual is transferred into a recipient as an alternative therapy for individuals affected with these life-altering diseases: Crohn's Disease (CD), and/or Ulcerative Colitis (UC).
1617140|NCT02108808|Drug|Ticagrelor|
1617141|NCT02108808|Drug|Prasugrel or Clopidogrel|
1617142|NCT02108795|Drug|Remifentanil|Children randomised to remifentanil group receive remifentanil 0.05 ug/kg/min. Children randomised to control group receive normal saline (placebo)
1617143|NCT02108795|Drug|Placebo|
1617144|NCT02108782|Drug|dovitinib lactate|Given PO
1617145|NCT02108782|Other|pharmacological study|Correlative studies
1617146|NCT02108782|Other|laboratory biomarker analysis|Correlative studies
1617147|NCT02108769|Behavioral|Yogic Breathing|"Chanting Om
Sharp deep inhalation through nostrils
Slow exhalation through mouth while chanting Om. At this step the subjects will perform a slow and complete exhalation.
Repeat for 10 min. During the whole period of chanting, the subjects keep their eyes closed.
Yogic Breathing:
Check which of the two nostrils exhibit free flow of air. For the explanation purpose the nostril with free flow of air is treated as Nostril 1 and the other one as Nostril 2.
Close Nostril 2 and inhale a sharp deep breath through Nostril 1 and then close both the nostrils so no inhaled air escapes. Air should not escape through mouth either. This inhalation step should take about 4 seconds.
Hold breath in this position for about 16 seconds.
Open Nostril 2 and exhale for about 8 seconds. Complete exhalation is required. Abdomen will slowly curve-in as the subject exhales. This is normal and encouraged. No air should leak through the Nostril 1 or mouth.
Go to step a)."
1617148|NCT02108769|Behavioral|Attention Control|The participants will read a text of their choice for 20 minutes in a one-on-one session with the Yoga Instructor.
1617149|NCT02108756|Drug|L-pantoprazole sodium|2 injection L-pantoprazole sodium (40mg), Bid
1617150|NCT02108756|Drug|Panmeilu|An injection Panmeilu (80 mg) + 1 branch placebo, Bid;
1617151|NCT02108743|Drug|Albuterol.|2.5 mg of albuterol inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
1617152|NCT02108743|Drug|Normal saline placebo|Placebo inhaled via jet nebulizer 15 minutes prior to symptom-limited maximal CPET.
1617153|NCT02108730|Procedure|restrictive pancreatic resection|Restrictive, spleen-preserving resection of the pancreatic tail by laparoscopy
1617154|NCT02108717|Device|Remote CT reading using the iPhone|
1617155|NCT02108717|Device|CT reading using LCD monitor|
1617156|NCT02108704|Drug|Helicobacter pylori eradication therapy|
1617157|NCT02108704|Drug|Placebo|
1617158|NCT02108691|Dietary Supplement|Glycin max(L.) Merr. peel extract|Glycin max(L.) Merr. peel extract (2.5g/day)
1617159|NCT02108691|Dietary Supplement|Placebo|Placebo (2.5g/day)
1617160|NCT02108678|Behavioral|ACT-ME|1 hour discussion about migraine education (ME) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). Migraine education covers topics including migraine symptoms, triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
1617161|NCT02108678|Behavioral|Migraine Education Only|6 hour discussion of migraine education only (MEO). This will involve educating participants about migraine, its natural course, its prodromal symptoms and triggers for symptom worsening, risk for migraine chronification, how to use abortive migraine medications, medication overuse headache, medical and psychological treatments of migraine, migraine comorbidity, and menstrual migraine.
1617162|NCT02108665|Radiation|Radiographic hysterosalpingography|
1617163|NCT02108665|Radiation|Magnetic resonance imaging hysterosalpingography|
1617164|NCT02108652|Drug|Atezolizumab|Atezolizumab 1200 mg given by IV infusion on Day 1 of 21-day cycles until disease progression per RECIST v1.1 criteria/loss of clinical benefit or unmanageable toxicity.
1617165|NCT02108639|Drug|DCV 3DAA FDC|
1617166|NCT02108639|Drug|BMS-791325|
1617167|NCT02108626|Drug|Nicotine|E-Cigarette with nicotine cartridge
1617168|NCT02108626|Drug|Placebo|E-Cigarette with 0mg nicotine cartridge
1617169|NCT02108613|Behavioral|Exercise Sessions|8 weeks of weekly exercise classes taught by a certified exercise physiologist.
1617170|NCT02108613|Behavioral|Nutrition Education|Four monthly education sessions on nutrition topics. Presentations and materials are were created by a BCCA dietitian.
1617171|NCT02108613|Behavioral|Peer Support Volunteer|Participants will be assigned a peer support volunteer who will preform adherence calls to discuss goals and motivations about improving exercise and healthy eating.
1617431|NCT02106559|Drug|porfimer sodium|Given IV
1617172|NCT02108600|Drug|Tocilizumab|Will receive tocilizumab 8 mg/kg intravenously at four-week intervals for a total of 6 doses. In addition, will continue usual immunosuppressive regimen.
1617173|NCT02108587|Device|optical coherence tomography|Undergo optical coherence tomography
1617174|NCT02108574|Device|Placebo Filter|
1617175|NCT02108574|Device|Rhinix Nasal Filter|
1617176|NCT02108561|Other|Post Surgical Her2 testing|Eligible patients will have post surgical Her2 testing on the primary tumor, a satellite lesion and a tumor positive node. The results will be provided to medical oncologist, who will comment as to whether the additional testing will prompt treatment recommendation changes
1617177|NCT02108548|Drug|ASP7657|oral
1617178|NCT02108548|Drug|Placebo|oral
1617179|NCT02108548|Drug|naproxen|oral
1617180|NCT02108535|Drug|Nanocrystalline silver|Flexible polyester low-grip coated nano-crystalline silver layer. The level of silver is 1.64 mg/ cm². This dressing enables the sustained release of silver in humid conditions dynamically and reached a higher plateau than 60 mg / L in less than 2 hours, and maintains a uniform level by 72 hours.
1617181|NCT02108535|Drug|Silver Sulphadiazine|This is at Standard treatment. The cream silver sulphadiazine at 1% was applied on the burn aseptically in a thick layer, approximately 3 to 5 mm, ie 5 g per 80 cm2
1617182|NCT02108522|Biological|Multivirus Specific T cells|
1617183|NCT02108483|Drug|dapsone gel|Patches containing dapsone gel will be applied to the skin.
1617184|NCT02108483|Drug|dapsone gel vehicle|Patches containing dapsone gel vehicle will be applied to the skin.
1617185|NCT02108470|Other|Dental consultation using OHIP|The S-OHIP[M] measure assesses the impact of one's oral health condition on QoL, contributing to 7 domains: functional limitation, physical pain, psychological discomfort, physical disability, psychological disability, social disability, and handicap. Responses of each item are made on a Likert scale and coded as: 1 = never, 2 =hardly ever, 3= occasionally, 4= fairly often, and 5= very often.
1617186|NCT02108457|Radiation|[18F]Fluorothymidine (FLT) PET/CT Imaging|
1617187|NCT02108431|Device|balloon catheter for suprapubic bladder-drainage|suprapubic tube removal was allowed when the anastomosis was watertight, Day 5
1617188|NCT02108431|Device|balloon catheter for transurethral bladder-drainage|transurethral catheter withdrawal was allowed when the anastomosis was watertight, Day 5
1617189|NCT02108418|Drug|TG-2349 as the original formulation|single oral dose under fed condition
1617190|NCT02108418|Drug|TG-2349 as a new capsule formulation|single oral dose under fed condition
1617191|NCT02108379|Device|Rhinix Nasal Filters|
1617192|NCT02108366|Drug|Celecoxib|Celecoxib 200mg daily
1617193|NCT02108366|Drug|Oseltamivir|Oseltamivir 75mg bid
1617194|NCT02108366|Drug|Placebo|Placebo capsule identical in appearance to celecoxib capsule, containing corn starch
1617195|NCT02108353|Drug|Melatonin 2mg|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
1617196|NCT02108353|Drug|Placebo|once daily, 0.5-1 hours before going to bed and 1-2 hours after the last meal for 12 weeks.
1617197|NCT02108340|Procedure|Microwave radiometry|Microwave radiometry of the right lower quadrant in a room temperature of 20-24 degrees celsius, in order to record changes in the temperature of the inflamed appendix.
1617198|NCT02108327|Procedure|surgical blade|Using surgical blade all the time of surgery
1617199|NCT02108327|Procedure|electrocautery|Using electrocautery all the time except at skin incision
1617200|NCT02108314|Behavioral|Video Screening and Counselling|The intervention comprises 1) GP counseling, 2) 3-minute promotional video on mammography and 3) an informational brochure with relevant contact details and information for arranging a mammography screening. Pre- and post-consultation questionnaire were administered to participants to evaluate their health beliefs, with emphasis on breast cancer and mammography.
1617201|NCT02108301|Drug|tacrolimus-cyclosporine A|conversion of immunosuppression from tacrolimus to cyclosporine A in hepatitis C-positive renal transplant recipients
1617202|NCT02108288|Drug|OPC-1085EL ophthalmic solution|
1617203|NCT02108288|Drug|Carteolol long-acting ophthalmic solution|
1617204|NCT02108288|Drug|Latanoprost ophthalmic solution|
1617205|NCT02107170|Drug|Sevoflurane|sevoflurane-based general anesthesia
1617206|NCT02107170|Drug|Propofol|total intravenous anesthesia
1617207|NCT02107170|Drug|Remifentanil|
1617208|NCT02107157|Device|755nm Laser with Cap Array|
1617209|NCT02107144|Drug|trimetazidine|After being randomized to Trimetazidin and cardiac medication vs. only cardiac medication, patient will undergo scheduled PCI of single, new, native coronary artery lesion using balloon predilatation and subsequent stenting.
1617210|NCT02107131|Drug|Intravitreal ranibizumab 0.3mg|
1617211|NCT02107118|Biological|ARM 1: AdMSC: adipose stem cells|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. Cells are returned to the study doctor for installation into the subject every 2 weeks for 3 months.
1617212|NCT02107118|Other|ARM 2: Placebo|Adipose tissue will be harvested from all patients as previously described and stem cells will be cultured. For those subjects in the placebo arm, the stem cells will be frozen for later use after one year when the patients cross over into the treatment arm.
2010771|NCT02853435|Drug|Gepotidacin Capsule|It is a pink gelatin size 00 capsule with no identifying markings containing slightly agglomerated pale yellow to grayish yellow to yellowish gray powder. This is an immediate release capsules containing gepotidacin 500 mg (mesylate salt) and inactive formulation excipients administered orally with 240 mL of water. Up to an additional 100 mL of water may be given to assist in swallowing capsules.
1617215|NCT02107079|Drug|Melatonin|swallowing 1 piece, collecting saliva afterwards
1617216|NCT02107066|Behavioral|Exercise|Weekly telephone counseling to increase aerobic exercise to 150 min/wk for 6 months.
1617217|NCT02107053|Dietary Supplement|PJ|
1617218|NCT02107053|Drug|IV iron|IV iron is routinely administered to dialysis patients worldwide to correct anemia
1617219|NCT02108262|Biological|CSL112|CSL112 is a novel formulation of apolipoprotein A-I (apoA-I) purified from human plasma and reconstituted to form high-density lipoprotein (HDL) particles.
1617220|NCT02108262|Biological|Placebo|0.9% weight/volume sodium chloride solution (ie, normal saline)
1617221|NCT02108249|Device|Annex™ Adjacent Level System|
1617222|NCT02108236|Device|acupuncture|Zhong-wan (RN12), Liang-men (ST21), Shui-fen (RN9) and Qi-hai (RN6) and bilateral acupuncture points Dai-mai (GB26), Tian-shu (ST25), Zu-sanli (ST36), Feng-long(ST40) and Liang-qiu(ST34) will be applied through the skin by acupuncture for 30 minutes every time. Electro-acupuncture apparatus will be connected to both Dai-mai, Zu-sanli and Feng-long, Zhong-wan and Qi-hai for 30 minutes with interrupted waves (2/100HZ).
1617223|NCT02108223|Drug|fix dose r-FSH (Gonal-f)|recombinant follicle stimulation
1617224|NCT02108223|Drug|r-LH supplementation|recombinant luteinizing hormone
1617225|NCT02108223|Drug|r-FSH (Gonal-f)|recombinant follicle stimulation hormone
1617228|NCT02108197|Device|Continuous positive airway pressure (S9, ResMed)|
1617229|NCT02108184|Drug|Sequential therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g) bid for the first 5 days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg ) bid for the next 5 days : Sequential therapy 1
1617230|NCT02108184|Drug|Sequential therapy 14 days|(pantoprazole 40 mg + amoxicillin 1.0 g bid) for the first 7days, subsequently (pantoprazole 40 mg + clarithromycin 500 mg + metronidazole 500 mg bid) for the next 7 days : Sequential therpay 2
1617231|NCT02108184|Drug|Concomitant therapy 10 days|(pantoprazole 40 mg + amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg ) bid for 10 days : Concomitant therapy 1
1617232|NCT02108184|Drug|Concomitant therapy 14 days|(pantoprazole 40 mg +amoxicillin 1.0 g + clarithromycin 500 mg + metronidazole 500 mg bid) for 14 days : Concomitant therapy 2
1617233|NCT02108171|Drug|Dexmedetomidine|intranasal dexmedetomidine 1μg.kg-1，0.9% saline was added to make a final volume of 1 mL.all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
1617234|NCT02108171|Drug|placebo|0.9% saline 1 mL all patients received intranasal medication at approximately 45-60 min before induction of anesthesia.
1617235|NCT02108158|Drug|Azzalure|
1617236|NCT02108145|Procedure|bilateral metal stent insertion|
1617237|NCT02108145|Procedure|unilateral metal stent insertion|
1617238|NCT02108132|Biological|Cellular therapy|bone marrow derived mesenchymal stem cells for normal subjects will be separated and induced to adopt the hepatocyte phenotype then injected through the portal vein to hemophilia patients
1617239|NCT02108132|Biological|cellular therapy|Allogenic bone marrow derived MSCs will be isolated and subjected to induction of hepatic phenotype. After proof of in vitro secretion of albumin and factor 8 from the cell population. It will be injected into the portal vein via the spleen
1617240|NCT02108119|Dietary Supplement|Probiotics|
1617241|NCT02108119|Dietary Supplement|Control placebo|
1617242|NCT02108106|Drug|AG-348|A range of doses of AG-348 will be tested based on assessment of safety and tolerability.
1617243|NCT02108106|Drug|Placebo|
1617244|NCT02108093|Procedure|retrograde autologous priming|Retrograde autologous priming (RAP) is a technique where, the patient's own circulating blood partially replaces the priming solution in the CPB.
1617245|NCT02108015|Procedure|Brain Imaging (PET)|
1617246|NCT02108015|Procedure|Aterial Line|
1617247|NCT02108015|Procedure|Blood Sampling|
1617249|NCT02107963|Biological|Anti-GD2-CAR engineered T cells|Administer anti-GD2 CAR T cells 1 x 105 transduced T cells/kg; 1 x 106 transduced T cells/kg; 3 x 106 transduced T cells/kg; and 1 x 107 transduced T cells/kg
1617250|NCT02107963|Drug|AP1903|If unacceptable toxicity occurs that is possibly, probably or likely related to anti-GD2-CAR T cells, AP1903, a dimerizing agent, may be administered to mediate clearance of the genetically engineered cells and resolve toxicity
1617251|NCT02107963|Drug|Cyclophosphamide|1800mg/m2/d X 2 days as a lymphodepleting regimen
1617252|NCT02107950|Biological|DCVAC/OvCa in parallel with chemotherapy|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Gemcitabine
1617253|NCT02107950|Drug|Standard of Care|Carboplatin and Gemcitabine is Standard of Care First Line Chemotherapy
1617254|NCT02107937|Biological|DCVAC/OvCa with Standard of Care|DCVAC/OvCa is the experimental therapy added on to Carboplatin and Paclitaxel
1617255|NCT02107937|Biological|DCVAC/OvCa sequentially chemotherapy|DCVAC/OvCa added sequentially after Carboplatin and Paclitaxel
1617256|NCT02107937|Drug|Standard of Care|Carboplatin and Paclitaxel is Standard of Care First Line Chemotherapy
1617257|NCT02107924|Procedure|APPI of TKR-Stimulan|
1617258|NCT02107898|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
1617259|NCT02107898|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
1617260|NCT02107898|Drug|Lipid-Modifying Therapy (LMT)|Statin (pravastatin, simvastatin, fluvastatin, atorvastatin, pitavastatin, rosuvastatin) at stable dose with or without other LMT as clinically indicated.
1617261|NCT02107885|Drug|DS-1971|6 subjects in each group will receive DS-1971.
1617262|NCT02107885|Drug|placebo|2 subjects in each group will receive placebo.
1617263|NCT02107872|Drug|REGN1500|
1617264|NCT02107872|Drug|placebo|
1617265|NCT02107859|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (10-, 10-, and 20-mg/kg morning, midday and evening, respectively) for 192 weeks
1617266|NCT02107846|Drug|PRX-112|
1617267|NCT02107833|Drug|OPRX-106|
1617268|NCT02107820|Behavioral|Bladder Training (BT)|All patients randomised to PTNS + BT group will have BT with the nurse for 20 minutes during PTNS sessions (which last 30 minutes). Since BT is recommended by NICE for a duration of 6 weeks. BT will be discussed for the first 6 sessions of the 12 week PTNS treatment cycle.
1617314|NCT02107469|Drug|Sida cordifolia roots|Sida cordifolia roots, crude drug (coarse powder) a plant product 7g (packages prepared) are soaked in 112ml water (measurement cup provided) for 12 hours and then boiled until the level is reduced to 1/4 of hight. Fluid is filtered an drunk after cooling down to room temperature - orally 2 times a day before breakfast and dinner
1617315|NCT02107469|Drug|Phyllanthus niruri|Phyllanthus niruri (whole plant) fine powder 3g three times a day with warm water before meals taken orally.
1617432|NCT02106559|Procedure|therapeutic conventional surgery|Undergo tumor resection and/or radical pleurectomy
1617433|NCT02106559|Drug|photodynamic therapy|Undergo PDT
1617269|NCT02107820|Device|Percutaneous Tibial Nerve stimulation|"A needle electrode insertion site is located on the inner aspect of either leg approximately three fingerbreadths (5 cm or 2) cephalad to the medial malleolus and approximately one fingerbreadth (2 cm or ¾) posterior to the tibia. The needle electrode head is gently tapped to pierce the skin, maintaining a 60° angle, and insert to a depth of approximately 2cm. The electrode is then connected to the stimulator and the current setting needed is determined by the test mode on the stimulator. Once the current setting is known, the stimulator is started on the therapy mode which delivers the current for 30 minutes and shuts off automatically after 30 minutes. The needle is then removed and stimulator disconnected. The treatment involves twelve weekly sessions of 30 minutes each."
1617270|NCT02107807|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
1617271|NCT02107807|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
1617272|NCT02107807|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
1617273|NCT02107807|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
1617274|NCT02107794|Other|Decision Aid|Paper based decision aid will be utilized to facilitate treatment option conversation between clinician and patient.
1617275|NCT02107781|Device|AbViser abdominal compartment pressure measuring device|AbViser AutoValve IAP Monitoring Device will be used on all patient enrolled in the research study.
1617276|NCT02107768|Other|Aerobic exercise|"Other: Aerobic exercise The intervention group will conduct a 12 week training period with two training sessions of 60 minutes per week at a local hospital. The start shall be made within 6 weeks after stroke . The training shall be conducted in a group with a maximum of 10 participants and start running as new participants in the intervention group will be added.The intensity during the exercise program should be individualized and based on the initial tests . Patients should be advised to reach a degree of exertion 13-15/20,Rate of Perceived Exertion (Borg 's RPE scale) .
Two fitness goals was to be achieved during the training session
1. An individual training level corresponded to 50% or more of maximal oxygen uptake for at least 40 min ( Borg 9-11/20 ) . Which corresponds to 70 % of maximum heart rate.
2:nd 80% or more of the estimated maximum oxygen uptake during two periods of 8 minutes( Borg 13-15/20 ) . Which corresponds to 85 % of maximum heart rate."
1617277|NCT02107755|Biological|ipilimumab|Given IV
1617278|NCT02107755|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
1617279|NCT02107755|Other|laboratory biomarker analysis|Blood and tissue samples will be collected for research purposes.
1617280|NCT02107742|Procedure|Normal speed lidocaine injection|30 seconds
1617281|NCT02107742|Procedure|Slow lidocaine injection|speed 45 seconds
1617282|NCT02107742|Procedure|Fast lidocaine injection|speed 15 seconds
1617283|NCT02107729|Procedure|Large needle gauge lidocaine injection|21 G
1617284|NCT02107729|Procedure|Normal needle gauge lidocaine injection|23 G
1617285|NCT02107729|Procedure|Small needle gauge lidocaine injection|27 G
1617286|NCT02107716|Procedure|Lidocaine injection with bicarbonate|bicarbonate added to change pH
1617287|NCT02107716|Procedure|lidocaine injection|Lidocaine injection with pH unchanged
1617288|NCT02107703|Drug|Abemaciclib|Administered Orally
1617289|NCT02107703|Drug|Fulvestrant|Administered IM
1617290|NCT02107703|Drug|Placebo|Administered Orally
1617291|NCT02107690|Procedure|Low temperature lidocaine injection|4 °C
1617292|NCT02107690|Procedure|Room temperature lidocaine injection|20 °C
1617293|NCT02107690|Procedure|Body temperature lidocaine injection|37 °C
1617294|NCT02107664|Radiation|Palliative RT for bone cancer pain|
1617295|NCT02107638|Procedure|OMM treatment arm|"OMM is a gentle hand-on manual therapy. The research team created a protocol coined PARK-OMM protocol. These techniques aim to help treat myofascial restrictions and improve joint range of motion."
1617296|NCT02107638|Other|Counseling|Patients will be counseled on Parkinson's Disease related issues including prevention of falls, medications, diet, nutrition, exercise, tai-chi, yoga, meditation, and mental health.
1617297|NCT02107625|Behavioral|Diet A i.e. Low FODMAP diet|
1617298|NCT02107625|Behavioral|Diet B, i.e. Traditional IBS diet|
1617299|NCT02107612|Device|Integrated system to insert two splinted (bar) mini dental implants for mandibular overdenture|
1617300|NCT02107612|Other|Denture|
1617301|NCT02107599|Drug|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
1617302|NCT02107586|Procedure|Biceps tenotomy|A biceps tenotomy procedure involves cutting of the long head of the biceps just prior to its insertion on the superior labrum of the glenoid.
1617303|NCT02107586|Procedure|Biceps tenodesis|Biceps tenodesis involves detaching the long head of the biceps from it's superior labrum in the shoulder and reattaching it to the humerus bone just below the shoulder.
1617304|NCT02107573|Procedure|Rotator Cuff Repair without Suprascapular Nerve decompression|Traditional rotator cuff repair without Suprascapular nerve decompression
1617305|NCT02107573|Procedure|Rotator Cuff Repair with Suprascapular Nerve decompression|Traditional rotator cuff repair with Suprascapular nerve decompression
1617306|NCT02107547|Procedure|Biceps tenodesis|A biceps tenodesis involves cutting the tendon within the shoulder joint and reattached further down the arm.
1617307|NCT02107547|Procedure|Labral repair|Repair of a Superior Labrum Anterior and Posterior lesion involves placing small anchors in the glenoid to re-attach the torn labrum.
1617308|NCT02107534|Behavioral|parent training (dyslexia)|The intervention program is designed for group sizes of three to ten persons. A cognitive behavioral approach was chosen.
1617309|NCT02107521|Other|Intracytoplasmic morphologically selected sperm injection|Sperm selection for injection will be performed at 6600x magnification
1617310|NCT02107521|Other|Intracytoplasmic sperm injection|sperm selection for injection will be performed under 400x magnification
1617311|NCT02107495|Device|Samsung LABGEO IVD-A20 CHF Test|
1617312|NCT02107482|Device|Levia Narrow Band UVB|The device's spectral output is is Narrow Band UVB (NB-UVB) (NB-Levia): 308-312 nm
1617313|NCT02107482|Device|Levia sham/visible-light source|the light spectrum is in the range of 400-700nm, the light is produced using the same Levia® device. Levia® enable the user to switch off the UVB light and only produce visible light spectrum.
1617316|NCT02107469|Drug|Sida cordifolia roots extract|gelatine capsule with 300mg Sida cordifolia roots spraydry extract 12:1 concentrated normalized to alkaloids (alcoholic/aqueous extract) - 2 capsules taken orally 2 times a day with warm water before meal
1617317|NCT02107469|Drug|Phyllanthus niruri extract|gelatine capsule with 300mg Phyllanthus niruri spray dry extract 5:1 concentrated normalized to bitters (alcohol/aqueous extract) - 2 capsules taken orally 3 times a day with warm water before meal
1617318|NCT02107469|Other|Sida cordifolia placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 2 times a day orally with warm water before meals
1617319|NCT02107469|Other|Phyllanthus niruri placebo|300mg inert Maltodextrin in gelatine capsule. 2 capsules given 3 times a day orally with warm water before meals
1617320|NCT02107456|Device|Dry Needling|Dry needling was performed for one week, three times a week.
1617321|NCT02107443|Other|Informational Intervention|Complete GA summary
1617322|NCT02107443|Other|Questionnaire Administration|Ancillary studies
1617323|NCT02107443|Other|Quality-of-Life Assessment|Ancillary studies
1617324|NCT02107430|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa arm post radiotherapy
1617325|NCT02107430|Radiation|Standard radiotherapy|radiotherapy
1617326|NCT02107417|Device|active TENS|Experimental Group (EG) who will receive the application of active TENS. The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes with the highest tolerable intensity, while still remaining comfortable for the patient.
1617327|NCT02107417|Device|placebo TENS|who will be administering the placebo TENS.The participants of these group will receive TENS within the following parameters: VF mode TENS with a variable frequency between 7 Hz and 65 Hz. It has a pulse width of 200 µs, this is the highest tolerable intensity while still remaining comfortable for the patient. It has an application time of 60 minutes The TENS-placebo will be applied where no current will be emitted. Patients in the placebo group will only feel the tingling for 45 seconds and after this period the device will not emit impulses, but it will work for 1 hour.
1617328|NCT02107404|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa Experimental therapy
1617329|NCT02107391|Biological|Dendritic Cells DCVAC/PCa|Combination therapy with DCVAC/PCA add on to and Standard of Care Hormone Therapy
1617330|NCT02107391|Drug|Leuprolide acetate|Standard of Care Hormone Therapy as an Active Comparator
1617331|NCT02107391|Drug|Goserelin Acetate|Standard of Care Hormone Therapy as an Active Comparator
1617332|NCT02107378|Biological|DCVAC/OvCa|DCVAC/OvCa is the experimental therapy added on to Paclitaxel or topotecan or doxorubicin
1617333|NCT02107378|Drug|Standard of Care (Paclitaxel or topotecan or doxorubicin)|Paclitaxel or topotecan or doxorubicin is Standard of Care First Line Chemotherapy
1617334|NCT02107365|Drug|Asunaprevir|Asunaprevir 100 mg, 1 capsule twice a day from Day 0 to Week 24
1617335|NCT02107365|Drug|Daclatasvir|Daclatasvir 60 mg, 1 tablet once a day from Day 0 to Week 24
1617336|NCT02107365|Drug|Ribavirin|Ribavirin tablets or capsules 200 mg, weight-based daily dose ( <75 kg : 1000 mg ; ≥ 75 kg : 1200 mg), from Day 0 to Week 24
1617337|NCT02107365|Drug|Pegylated Interferon alpha-2a|Pegylated Interferon alpha-2a, by subcutaneous injection 180µg / week, from Day 0 to Week 24
1617338|NCT02107339|Drug|Methadone|Methadone 0.2 mg/kg administered at induction of anesthesia
1617339|NCT02107339|Drug|Hydromorphone|Hydromorphone 2 mg administered at the conclusion of anesthesia
1617341|NCT02107313|Drug|Fed Cohort PBT2|PBT2 250 mg is administered orally following a period of fasting for 10 hours and a high fat breakfast.
1617342|NCT02107313|Drug|Fasted Cohort PBT2|PBT2 250 mg is administered orally after a period of fasting of 10 hours and without food
1617343|NCT02107300|Drug|NeutraSal|NeutraSal is a powder that when dissolved in water creates a supersaturated calcium phosphate rinse.
1617344|NCT02107300|Drug|Placebo (for NeutraSal)|Placebo is a powder consisting of sodium chloride only; chosen to mimic NeutraSal
1617345|NCT02107287|Radiation|IMRT Technique|
1617346|NCT02107274|Drug|Azithromycin|Azithromycin (C38H72N2O12 MW 749) is a 15-membered azalide, a subclass of macrolide antibiotics
1617347|NCT02107274|Drug|Placebo for Azithromycin|In Part One of the study participants will be randomised to receive 12 weeks of either placebo or azithromycin in a 1:1 ratio in a double-blinded fashion. After 12 weeks, in Part Two of the study, all participants will receive placebo in a double-blinded fashion for an additional 12 weeks.
1617348|NCT02107261|Drug|incobotulinumtoxin A|Incobotulinumtoxin A is being used on average doses between 10U and 30 Units per subject, but at no time will any subject receive over 100 Units. Each study visit, the assessing physician will select the muscles and the amounts of medication to be injected.
1617349|NCT02107248|Behavioral|Sleep position: no restrictions|during the first eight weeks after total hip replacement following a posterolateral surgical approach
1617350|NCT02107248|Behavioral|Sleep position: supine|during the first eight weeks after total hip replacement following a posterolateral surgical approach
1617351|NCT02107235|Drug|oral rigosertib|
1617352|NCT02107235|Drug|cisplatin|
1617353|NCT02107235|Radiation|Radiotherapy|
1617354|NCT02107222|Device|CO2-Removal (PALP-Device/MaquetCP)|extracorporeal circuit to remove CO2 out of the blood
1617355|NCT02107209|Procedure|Bronchoscopic Lung volume reduction|Fiberoptic bronchoscopy is used to inject the biological agents into the targeted lung segment
1617356|NCT02107196|Drug|Ibodutant 10 mg|Oral tablet, to be given once daily.
1617357|NCT02107196|Drug|Placebo|Oral tablet, (identical in appearance and weight to ibodutant tablets), to be given once daily.
1617358|NCT02107183|Device|Optiflow (Fisher & Paykel Healthcare)|This device delivers high-flow oxygen through nasal cannula
1617359|NCT02107183|Device|Venturi mask|This device delivers low-flow oxygen at predetermined concentrations
1617428|NCT02106585|Drug|JTT-251 or Placebo|Subjects will receive JTT-251 or Placebo
1617429|NCT02106572|Drug|abnobaVISCUM 900|intravesical instillation of abnobaVISCUM 900 13 times during treatment period
1617430|NCT02106572|Drug|Mitomycin C|intravesical instillation of Mitomycin C 10 times during treatment period
1617360|NCT02107027|Device|nMARQ catheter|"In this arm the circular ablation catheter will be used for a quick mapping of left atrium with Carto system. The catheter will be positioned to pulmonary veins ostium to deliver radiofrequency on 1 to 10 electrodes simultaneous. The same catheter will be used to document pulmonary veins isolation (PVI).
A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) site(s) will be noted."
1617361|NCT02107027|Device|Navistar catheter|"In this arm the conventional catheter will be used. It will be used for a left atrium quick mapping on Carto system. Radiofrequency will be delivered in a sequential manner in pulmonary veins for point by point ablation. Isolation will be guided and confirmed with the Lasso decapolar diagnostic catheter (Biosense Webster, Diamond Bar, USA).
A waiting period of 30 minutes will be observed after PVI to document possible reconnection(s). Adenosine will be injected (except in case of adenosine contraindication) and reconnection(s) sites will be noted."
1617362|NCT02107014|Drug|Low Dose Naltrexone|Naltrexone 4.5 mg p.o. nocte
1617363|NCT02107001|Procedure|Lung ultrasound|Lung ultrasonography performed and interpreted by a physician (Pulmonologist or Emergency Physician) possessing specific knowledge in the procedure and a training of at least 100 thoracic ultrasonographies in accordance to a prespecified protocol.
1617364|NCT02106988|Radiation|Radiation Therapy|Radiation therapy delivered for a total dose of 50.4 to 54 Gy 5 days a week for 28 to 30 treatments.
1617365|NCT02106988|Drug|Dexamethasone|40 mg by vein Days 1-3 in a 21 day cycle.
1617366|NCT02106988|Drug|Etoposide phosphate|67 mg/m2 by vein on Days 1-3 of a 21 day cycle.
1617367|NCT02106988|Drug|Ifosfamide|1 g/m2 by vein on Days 1-3 of a 21 day cycle.
1617368|NCT02106988|Drug|Mesna|0.4 g/m2 by vein on Days 1-3 with Ifosfamide, 0.6 g/m2 by vein over 24 hours daily on Days 1-3 via ambulatory pump.
1617369|NCT02106988|Drug|Carboplatin|200 mg/m2 by vein on Day 1 of a 21 day cycle.
1617370|NCT02106975|Drug|Ascorbic Acid|Intervention
1617371|NCT02106975|Drug|Placebo: 5% Dextrose in water|Placebo
1617372|NCT02106962|Drug|Topical Tranexamic Acid 5% with bacitracin|Selected participants received a fixed amount of tranexamic acid 5 %and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
1617373|NCT02106962|Other|Topical Tranexamic Acid 25% with bacitracin|Selected participants received a fixed amount of tranexamic acid 25%and bacitracin applied with compression up to 3 times (13 minutes total) per hemodialysis fistula needle site.
1617374|NCT02106949|Device|SMS contact with patient after discharge in intervention group|
1617375|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
1617376|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
1617377|NCT02106923|Drug|1 tablet 10 mg Empagliflozin/3 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/3 x Metformin XR tablets
1617378|NCT02106923|Drug|2 tablets 5 mg Empagliflozin/750 Metformin XR|Experimental:2 x low dose Empagliflozin/Metformin XR FDC tablets
1617379|NCT02106923|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1 x Empagliflozin/2x Metformin XR tablets
1617380|NCT02106923|Drug|10 mg Empagliflozin/1000 mg Metformin XR|Experimental: high dose Empagliflozin/Metformin XR, FDC tablet
2010772|NCT02852213|Drug|AAV2-hAADC|"Subjects will be enrolled sequentially into 2 dose groups, Group 1 followed by Group 2. Initially, up to 3 subjects initially will be enrolled in Group 1 and treated with a single dose of AAV2 hAADC (1.3x10 11 vg, delivered as an infusate volume of up to 160 μL of vector at concentration of 8.3x10 11 vg/mL) on Day 0. Enrollment in Group 2 may commence after the last subject in Group 1 is treated and followed through Month 3 post-surgery, with the approval of the data safety monitoring board (DSMB).
The final safety and clinical outcome assessments will be performed 1 year post-surgery. A follow-up analysis will be performed for 2 years post-surgery. Thereafter, subjects will be enrolled in a long-term follow-up study to assess safety and clinical status updates."
2010773|NCT02851693|Device|Optical Coherence Tomography (OCT) with Vivosight|OCT used is Vivosight for diagnosis
2010774|NCT02851693|Device|Optical Coherence Tomography (OCT) with Skintell|OCT used is Skintell for diagnosis
1617384|NCT02106884|Drug|Abraxane (nab-paclitaxel)|
1617385|NCT02106884|Drug|Gemcitabine|
2010775|NCT02851186|Device|Acupuncture|
1617388|NCT02106845|Drug|Digoxin|Single dose of digoxin 0.5 mg (2 tablets 0.25 mg) orally without and with regorafenib
1617389|NCT02106845|Drug|Rosuvastatin|Single dose of rosuvastatin 5mg (1 tablet 5 mg) without and with regorafenib 160 mg q.d. (4 tablets 40 mg)
1617390|NCT02106845|Drug|Regorafenib (Stivarga, BAY73-4506)|Once daily orally 160 mg (4 tablets 40 mg)
1617391|NCT02106832|Drug|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin dry powder for inhalation (DPI) 32.5 mg inhaled twice daily in cycles of 28 days on-treatment and 28 days off-treatment.
1617392|NCT02106832|Drug|Ciprofloxacin (BAYQ3939) dry powder for inhalation|Ciprofloxacin DPI 32.5 mg inhaled twice daily in cycles of 14 days on-treatment and 14 days off-treatment.
1617393|NCT02106832|Drug|Placebo|Matching placebo inhaled twice daily intermittently for 28 days on / 28 days off
1617394|NCT02106832|Drug|Placebo|Matching placebo inhaled twice daily intermittently for 14 days on / 14 days off
1617395|NCT02106819|Behavioral|Testing of emotional communication ability|Assessment of comprehension and expression of emotional facial and prosodic expressions and assessment of emotional reactivity via ratings of emotionally evocative pictures and words.
1617396|NCT02106819|Procedure|magnetic resonance imaging (MRI) of the brain|Cerebellar participants who score at least 1 and a 1/2 standard deviations below the mean on the Florida Affect Battery and who have no contra-indications to scanning will be given an MRI. Healthy control participants who are willing and able to be scanned will also be given an MRI of the brain to use for analysis comparison.
1617397|NCT02106806|Dietary Supplement|Zinc|35 mg of elemental zinc twice daily for 16 weeks
1617398|NCT02106806|Other|Placebo|One capsule, twice daily for 16 weeks
2010776|NCT02851186|Device|Sham acupuncture|
1617399|NCT02106793|Drug|Mitomicin C|Mitomicin C (0.4 mg/ml) will be provided in a sterile vial and prepared by pharmacist at the Faculty of Medicine Ramathibodi Hospital.The treatment solution will be drawn and soaked ono two one inch neurosurgical cotton pledgets. Each pledget will be placed on each side of the nose for 5 minutes. The nurse will set the alarm for removal of the cotton pledgets, then normal saline will be used to irrigate both sides of the nose, using 100 ml on each side.
1617400|NCT02106793|Drug|Identical placebo solution|Identical placebo solution
1617401|NCT02106780|Drug|14C-labeled ASP1707|oral
1617402|NCT02106767|Drug|Rosuvastatin|Rosuvastatin 20mg po x1
1617403|NCT02106767|Drug|Rosuvastatin plus rifampin|Rifampin 600mg IV infused over 30 minutes followed by rosuvastatin 20mg PO x1
1617404|NCT02106754|Behavioral|Brief Intervention|
1617405|NCT02106754|Behavioral|Brief Intervention with Coaching|
1617406|NCT02106754|Behavioral|Treatment as Usual|
1617407|NCT02106741|Behavioral|Relaxation acupressure|"The relaxation acupressure protocol will use a set of nine fixed acupoints: forehead, twixt the eyebrows (unilateral); posterior neck, behind the ears (bilateral); palmer side of hand at wrist (bilateral); inside of lower leg (bilateral); top of foot (bilateral).
A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.
Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
1617408|NCT02106741|Behavioral|Stimulating acupressure|"The stimulating acupressure protocol will use a set of ten fixed acupoints: top of the head (unilateral); below the navel (unilateral); back of the hand (bilateral); outside of lower leg (bilateral); inside of lower leg (bilateral); inside of ankle (bilateral).
A trained acupressure educator will meet with each participant and demonstrate the sites and techniques for self-administered acupressure. Additionally, each participant will receive a demonstration DVD and a laminated handout detailing the locations of each acupoint.
Participants will be asked to perform daily acupressure sessions using the assigned sites. Each site is stimulated for 3 minutes, and the entire session can be completed in approximately 30 minutes."
1617409|NCT02106728|Behavioral|Multi-Family Therapy|Multi-Family Therapy is conducted once per week over the course of 8 weeks for 1.5 hours per session. Therapy is provided to a minimum of 3 families and a maximum of 6 families with the aid of two to three therapist group leaders. Group topics are set and cover material on eating disorder psychoeducation, care-giving styles, meal support, and relapse prevention.
1617410|NCT02106728|Behavioral|Supportive Family Therapy|Supportive Family Therapy is treatment as usual in the eating disorders program at TGH. Families meet independently with a therapist once per week for 1 hour per session. The length of the therapy and the topics of therapy are decided upon collaboratively with the therapist and the family.
1617411|NCT02106715|Other|Training|Two exercises for training of core stability and mobility.
1617412|NCT02106702|Behavioral|Navigator enhanced case-management|Patient navigators are non-clinical, paraprofessional peers who are HIV-infected and have lifetime histories of detention and substance abuse. Working with the patient, they facilitate adherence to a comprehensive care plan designed to address clients' multiple risks and needs. Patients have access to Navigator services for one year after study enrollment.
1617413|NCT02106702|Behavioral|Forensic AIDS Project|The Forensics AIDS Project provides primary care to HIV-infected detainees, as well as up to 90 post-release case-management services which include discharge planning.
1617414|NCT02106689|Device|Needle free system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
1617415|NCT02106689|Device|Standard needle injection system|Approximately 60 patients will be randomized in a 1:1 ratio to either receive their gonadotropin injections using the Comfort-in™ needle free system (treatment group), or through the standard needle and syringe (control group).
1617416|NCT02106663|Procedure|Circumferential Pulmonary Vein Ablation|Contiguous ablation lesions will be performed to encircle the two left and right pulmonary veins (PVs) of the left atrium, guided by 3D electroanatomic mapping. After completion of the circumferential ablation, PV isolation will be confirmed by the mapping catheter, and further focal ablation performed as required until electrical PV isolation is confirmed.
1617417|NCT02106663|Procedure|Segmental Pulmonary Vein Isolation|Electrical potentials recorded in the pulmonary vein (PV) ostium using a circular mapping catheter, representing electrical connections between the left atrium and PVs will be ablated at or just proximal to the PV ostium in the PV antrum. Ablation will be performed segmentally at multiple sites guided by the mapping catheter until mapping demonstrates elimination of all PV potentials.
1617418|NCT02106650|Drug|Folotyn and Leucovorin|
1617419|NCT02106650|Drug|Folic Acid|Folic acid (1.0 mg PO QD) is to be initiated at least 10 days prior to Folotyn administration, or per the USPI for Folotyn.
1617420|NCT02106650|Drug|Vitamin B12|Vitamin B12 (1 mg IM) is to be administered within 10 weeks prior to initiation of Folotyn and can be administered during Screening. Subsequent vitamin B12 injections may be given the same day as treatment with Folotyn and patients are to receive vitamin B12 every 8 to 10 weeks while treated with Folotyn.
1617421|NCT02106637|Drug|Varenicline|drug will be initiated during hospitalization and continued for 12 weeks following discharge
1617422|NCT02106637|Drug|placebo|placebo
1617423|NCT02106624|Other|nitrogen supply|Nitrogen supply could be administered through amino acid in parenteral nutrition, proteins in enteral nutrition.
2010777|NCT02847715|Device|ePRIME|ePRIME is an remote monitoring pathway that includes an online system for patients to self-report symptoms and AE following cancer treatments. ePRIME allows AE reporting from home and enables patient reported data to be integrated into existing EPR to allow for the reports to be used in routine care. In addition the system is capable of generating alerts for serious symptoms to the relevant clinical team and providing patient advice on managing mild and moderate symptoms.
2010778|NCT02848248|Drug|SGN-CD123A|Intravenous infusion in 3-week cycles
2010779|NCT02848131|Drug|Group 2: Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days.
2010780|NCT02848131|Drug|Group 2: Quercetin|Quercetin - take four 250 mg capsules daily (total 1000 mg daily) for 3 consecutive days.
2010781|NCT02847650|Drug|Placebo|
2010782|NCT02847650|Drug|PF-06649751|
2010783|NCT02847091|Drug|Ipragliflozin|Oral administration once daily
2010784|NCT02848703|Device|Magnetic Resonance Imaging (MRI)|
1617438|NCT02106533|Other|Aerobic exercise training|The exercise training program was comprised of three 60-minute exercise sessions per week over a 3-month period. Each exercise session consisted of a 5 minute warm up, 30-50 minutes of aerobic exercise performed on a treadmill and 5 minutes of cool-down exercises. Aerobic exercise intensity was set at the corresponding heart rate between the VAT and RCP. All patients were able to achieve the set aerobic training intensity.
1617439|NCT02106520|Drug|Bevacizumab|
1617440|NCT02106520|Drug|placebo|
1617441|NCT02106507|Drug|apalutamide|apalutamide, 240 mg/day, oral
1617442|NCT02106507|Drug|Everolimus|5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended
1617443|NCT02106494|Drug|APF530|
1617444|NCT02106494|Drug|Ondansetron|
1617445|NCT02106494|Drug|Ondansetron placebo|
1617446|NCT02106494|Drug|APF530 placebo|
1617447|NCT02106494|Drug|Fosaprepitant|
1617448|NCT02106494|Drug|Dexamethasone|
2010785|NCT02848703|Device|phosphorus-31 Magnetic Resonance Spectroscopy|
2010786|NCT02848703|Device|sodium-23 MRI|
1617451|NCT02106468|Drug|Prednisone tablet 5mg|This group included 15 patients who received prednisone (Delta-cortene Fort®, Lepetit, Carmano, Melano, Italy) at 40mg /day (8 tablets/day in divided dose , 4 tablet at morning and 4 at evening) for 6 weeks then 20mg/day for 2 week then to 10 mg/day for 2 week, and finally to 5 mg /day for the last 2 weeks.
1617452|NCT02106468|Drug|Omega-3 soft capsules 1000 mg|This group included 15 patients who received Omega-3 soft gelatin capsules 1000 mg (Super Omega; Technopharma, Cairo, Egypt). The patients received instruction to take one capsule three times daily for 3 months.
1617453|NCT02106455|Drug|Sodium risedronate|Sodium risedronate tablets
1617454|NCT02106442|Drug|Sodium risedronate|Sodium risedronate tablets
2010787|NCT02846077|Other|No intervention. Observation only|No intervention. Observation only
1617456|NCT02106403|Other|Prototype disinfectant spray formulation|0.13% w/w BAC and 1% MGA. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
1617457|NCT02106403|Other|Reference product|0.13% w/w BAC. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
1617458|NCT02106403|Other|Negative control|0.9% w/v sodium chloride solution. After wounding, the product will be held approximately 10 cm above the wounding area, and sprayed twice towards the wound
2010788|NCT02843828|Device|gait rehabilitation with Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation with Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
2010789|NCT02843828|Other|gait rehabilitation without Samsung Hip Assist v1|Participants will participate in 10 sessions of gait rehabilitation without Samsung Hip Assist v1 (5sessions-treadmill gait training / 5sessions-overground gait training), 30min per session
1617461|NCT02106377|Drug|loteprednol etabonate (Lotemax)|Lotemax (loteprednol etabonate) 0.5% is a prescription-only, preserved ophthalmic suspension supplied by Bausch & Lomb, Inc. Lotemax (loteprednol etabonate) 0.5% has been approved by the FDA for treatment of ocular inflammation with a maximum dosing frequency of 24 drops per eye per day. It is a C-20 ester-based corticosteroid, with a potent anti-inflammatory efficacy, but decreased impact on intraocular pressure (IOP) compared to other corticosteroids, which may increase IOP. The medication will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
1617462|NCT02106377|Drug|Soothe Tired Eyes Lubricant Eye Drop|Soothe Tired Eyes Lubricant Eye Drop (Bausch & Lomb Inc.) is a preserved artificial tear whichis used to relieve the dryness of the eye and to prevent further irritation. Its active ingredient is glycerin 1%. The artificial tear will be applied topically to both eyes for 6 weeks with the following regimen: four times a day for 2 weeks, twice daily for 2 weeks, and once daily for 2 weeks.
1617463|NCT02106364|Drug|Insulin Peglispro|Administered SQ
1617464|NCT02106364|Drug|Insulin Glargine|Administered SQ
1617466|NCT02106338|Other|Placebo|Placebo capsules have the same inert components as CRS3123; 2 subjects randomized in each cohorts recieve 200mg, 400mg; and 600mg, or 100mg are planned respectively given orally every 12 hours for 10 days
1617467|NCT02106338|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, formulated in 100 and 200 mg capsules; 8 subjects randomized in Cohorts A through C receive doses of 200 mg, 400 mg; and 600 mg or 100mg are planned respectively given orally every 12 hours for 10 days.
2010790|NCT02844816|Drug|Atezolizumab|Given IV
2010791|NCT02844816|Other|Laboratory Biomarker Analysis|Correlative studies
1617470|NCT02106312|Radiation|dose reduction of preoperative radiotherapy in MLS|A: The primary sarcoma in case of non-metastatic disease for management is with curative intent (regime to be chosen=18 x 2 Gy) B: In case of oligometastatic patients, the metastasis may also be irradiated to a dose of 36 Gy in order to postpone the time interval to next systemic chemotherapy. These patients are usually not operated upon and the total dose may also be reached in 12 times 3 Gy, for convenience purposes.
1617471|NCT02106299|Device|Regen sling|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a Regen sling (medprin).
1617472|NCT02106299|Device|tension-free vaginal tape-obturator(TVT-O)|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (gynecare™, USA).
1617473|NCT02106286|Drug|Bisoprolol|
1628390|NCT02022592|Drug|Lormetazepam|
2010792|NCT02844725|Drug|VVZ-149 injections|Colorless, transparent liquid in water for injection
2010793|NCT02844725|Drug|Placebo|water for injection
1617474|NCT02106273|Device|Bronchial blocker (Coopdech, Arndt)|Using bronchial blocker with LMA
1617475|NCT02106273|Device|LMA-ProsealTM|
1617476|NCT02106260|Drug|CLS003|
1617477|NCT02106247|Drug|BI 1181181 high dose|two tablet
1617478|NCT02106247|Drug|BI 1181181 low dose|one tablet
1617479|NCT02106247|Drug|Placebo|tablet
1617480|NCT02106234|Other|No prophylactic iv hydration|Control group: Patients having been referred for an elective procedure involving intravascular iodinated contrast material administration and for intravenous prophylactic hydration according to current guidelines (but only those patients with an eGFR ≥30ml/min/1.73m2) will NOT receive the standard intravenous prophylactic hydration treatment with normal saline prescribed.
1617481|NCT02106221|Other|Intervention|Will receive payments based on achievement in meeting goals based on specified high value elements as well as effort.
1617482|NCT02106221|Other|Control|Will receive payments based on achievement in meeting goals.
1617483|NCT02106208|Other|Cheese diet|
1617484|NCT02106208|Other|Butter diet|
1617485|NCT02106208|Other|CHO diet|
1617486|NCT02106208|Other|MUFA diet|
1617487|NCT02106208|Other|PUFA diet|
1617488|NCT02106195|Drug|KD025|
1617489|NCT02106182|Drug|Silodosin|
1617490|NCT02106182|Other|Laboratory tests|"Subject's overall health state will be evaluated by clinical laboratory tests.
Serum chemistry test: Creatinine, Blood Urea Nitrogen(BUN), Aspartate aminotransferase(AST), Alanine aminotransferase(ALT) Urinalysis: Urine Specific Gravity, Urine pH, Urine Protein, Urine Glucose, Urine Ketone, Urine Bilirubin, Urine Urobilinogen, Urine Nitrite, Urine Occult Blood(OB), Urine Red Blood Cell(RBC), Urine White Blood Cell(WBC) Immunoassay: Prostate Specific Antigen(PSA)"
1617491|NCT02106182|Other|3-days voiding diary|3-day voiding diaries will be distributed on Visits 1, 2 and 3. Subjects will record incidence of nocturia during 3 days on the diaries within 7 days of Visits 2 (baseline), 3 and 4. The average will be used to confirm the change in incidence of nocturia (at baseline, results from within 1 week from screening may be used but will be excluded for subjects needing wash-out period).
1617492|NCT02106182|Other|12 weeks|
1617493|NCT02106169|Behavioral|Therapeutic education group|
1617494|NCT02106156|Drug|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a administered according to corresponding summary of product characteristics (SmPC).
1617495|NCT02106156|Drug|Ribavirin|Ribavirin administered according to corresponding summary of product characteristics (SmPC).
1617496|NCT02106143|Device|RejuvenAir™ Radial Spray Cryotherapy|Metered dose radial spray cryotherapy treatment
1617497|NCT02106130|Drug|Rebamipide|oral administration, 3 times/day
1617498|NCT02106130|Drug|Mosapride citrate|oral administration, 3 times/day
1617499|NCT02106104|Drug|Linagliptin 5 mg QD (N=24)|Linagliptin 5 mg will be taken orally, once daily for 8 weeks
1617500|NCT02106104|Drug|Glimepiride 1 mg QD (N=24)|Glimepiride 1 mg will be taken orally, once daily for 8 weeks
1617501|NCT02106091|Drug|AFM11|Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 4 weeks.
1617502|NCT02106078|Behavioral|Moderated Discussion Board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone (Mead et al., 2010).
The discussion boards will be moderated by trained clinicians (masters level or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
1617503|NCT02106078|Behavioral|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:
What is bipolar disorder? - Content about symptoms and diagnosis
Stress and triggers of illness
Medication and the biological basis of bipolar disorder
Depression - Symptoms, early detection and helpful strategies
Mania and hypomania - Symptoms, early detection and helpful strategies"
1617504|NCT02106078|Behavioral|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviors, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
1617505|NCT02106065|Behavioral|Education and Skill-Building Rehabilitation (ESBR)|ESBR intervention consists of four, 90-minute sessions over a 4-6 week period. These four sessions are supplemented with booster sessions at 3 and 9 months post-intervention. Each group session (10 or fewer participants) is attended either in-clinic or via video telehealth technology within the VAPAHCS.
1617506|NCT02106065|Other|Supplemental Education Materials|Participants randomized to the Usual Care (UC) group will receive supplemental educational materials related to aging and dementia.
1617507|NCT02106052|Other|Aerobic exercise|The aerobic exercise condition is a graduated program of supervised aerobic exercise up to one hour per day, three days per week, and lasting 6 months. The structured exercise portion of the sessions will initially last for 15-20 minutes at 40-50% heart rate reserve (HRR) and progressively increase up to 35-40 minutes in duration at 65-75% HRR during the last month of the program. The program will focus on large, dynamic movements of the lower extremities (e.g. leg cycling ergometry). There may be some individual variation in adaptations that dictate the exact characteristics of the program.
1617508|NCT02106052|Other|Stretching and toning exercise|The stretching and toning condition is a supervised stretching program with Therabands up to one hour per day, three days per week, and lasting 6 months. The stretching exercises will be based on a manual published by the National Multiple Sclerosis Society (NMSS) that has been standardized, manualized for reproducibility, and the investigators will progressively include more exercises and sets with Therabands for resistance over the course of the 6-month period.
1617509|NCT02106039|Procedure|intensive monitoring|
1617552|NCT02105701|Drug|Grazoprevir + Elbasvir|FDC tablet containing grazoprevir 100 mg and elbasvir 50 mg.
1617510|NCT02106026|Other|Preventive education|The intervention group received education to facilitate successful breastfeeding and symptom management as nipple pain. This was supported by strategies designed to (1) prevent problems associated with breastfeeding (nipple lesions, cracks and mastitis), (2) perform breast-care procedures, (3) strengthen information about the advantages of maternal breastfeeding (nutritional support, importance as food for the baby, availability, post-partum recovery) and (4) provide asepsis and hygiene measures.
1617511|NCT02106000|Device|Inhalation profile recorder|Up to three inhalation profiles will be recorded whilst inhaling with maximal effort
1617512|NCT02105987|Drug|ABC/DTG/3TC FDC|Purple, oval, biconvex tablets containing 702 mg Abacavir sulphate which is equivalent to 600 mg ABC, 52.62 mg Dolutegravir sodium which is equivalent to 50 mg Dolutegravir free acid and 300 mg 3TC
1617513|NCT02105987|Drug|Ongoing cART regimen|Stable cART regimens including boosted PI (or ATV unboosted) + 2 NRTIs; NNRTI + 2 NRTIs, or INI (RAL or EVG)+ 2 NRTIs
1617514|NCT02105974|Drug|Fluticasone Furoate/Vilanterol|100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler
1617515|NCT02105974|Drug|Vilanterol|25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler
1617516|NCT02105961|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
1617517|NCT02105961|Drug|Placebo|Sterile 0.9percent sodium chloride solution
1617518|NCT02105948|Drug|Mepolizumab|Humanised IgG antibody (IgG1, kappa) with human heavy and light chain frameworks, provided as a lyophilised cake in sterile vial. Vial to be reconstituted with Sterile Water for Injection, just prior to use.
1617519|NCT02105948|Drug|Placebo|Sterile 0.9% sodium chloride solution
1617520|NCT02105922|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 3 months.
1617521|NCT02105922|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 3 months.
1617522|NCT02105922|Procedure|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 3 months.
1617523|NCT02105909|Other|GWAS|
1617524|NCT02105883|Other|Use of identification badge during scenarios|
1617525|NCT02105870|Drug|Abciximab|This drug will be administered intracoronary before percutaneous coronary intervention.
1617526|NCT02105857|Other|grade A+ knee mobilization|grade A+ knee mobilization using the joint active systems knee device, 20minutes twice a day in knee extension and knee flexion
1617527|NCT02105831|Other|Contrast ultrasound skeletal muscle perfusion imaging|1. Contrast ultrasound perfusion imaging will be performed in patients in whom LVAD will be placed for clinical indications of severe heart failure.
1617528|NCT02105805|Behavioral|Dietetic group sessions|Group sessions to improve dietary adherence
1617529|NCT02105792|Drug|second- or third-line glucose-lowering diabetes treatment|Observation of response and disease progression following clinician's addition of a glucose-lowering diabetes therapy (Sulphonylurea, DPP-4 inhibitor, GLP-1R agonist, SGLT2 inhibitor or Glitazone) to existing therapy.
1617530|NCT02105779|Other|Targeted Cognitive Training|At present, the TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). [Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (30 hours), and a Visual Module (30 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
1617531|NCT02105779|Other|Social Cognitive Training|We developed a systematic approach to basic training in facial emotion identification and discrimination and simple social perception and theory of mind tasks using components drawn from three commercially available software packages: the MicroExpressions Training Tool and The Subtle Expressions Training Tool (METT and SETT), plus the MindReading program. Training begins with simple emotion identification tasks, and slowly progressed to more difficult tasks that required subjects to discriminate between two subtle emotion expressions, and to correctly interpret the emotional significance of brief social scenes. A total of 10 hours of training occurred over 8 weeks.
1617537|NCT02105753|Device|1210nm Diode Laser treatments|
1617538|NCT02105740|Behavioral|Hypnosis|The hypnosis intervention consists of two 40-minute sessions, with an interval of 7 days between them, emphasizing the pain blocking, the well-being of the patient and the reduction of the symptoms of anxiety and depression of the same.
1617539|NCT02105740|Behavioral|Control|The control and experimental groups respond in 3 different moments to Visual Analogue Scale (VAS) for the evaluation of pain, and to Hospital Anxiety and Depression Scale (HADS) to evaluate depression and the anxiety. The first meeting will be made before the hypnosis. In the second meeting, within an interval of 7 days, the scales will be applied in all patients. Before applying the scales, the hypnosis group will be submitted to the session. The third meeting will occur two weeks later, where the scales will be only applied to compare the groups.
1617540|NCT02105727|Behavioral|Community-based salt reduction|
1617541|NCT02105714|Procedure|Stool culturing for pathogenic bacteria|
1617542|NCT02105714|Procedure|Kato-Katz technique|
1617543|NCT02105714|Procedure|Baermann technique|
1617544|NCT02105714|Device|Mini-FLOTAC|
1617545|NCT02105714|Device|Crypto/Giardia Duo Strip|
1617546|NCT02105714|Procedure|Formalin-ether concentration technique|
1617547|NCT02105714|Device|CCA RDT|
1617548|NCT02105714|Procedure|Koga agar plate culture|
1617549|NCT02105714|Procedure|Kinyoun staining|
1617550|NCT02105714|Device|Multiplex PCR|
1617551|NCT02105714|Procedure|Metagenomics analysis|
1617553|NCT02105701|Drug|Ribavirin|200 mg capsule
1617556|NCT02105675|Biological|Dendritic Cells DCVAC/PCa|DCVAC/PCa is the experimental therapy added on to Docetaxel
1617557|NCT02105675|Drug|Docetaxel|Docetaxel is Standard of Care First Line Chemotherapy
1617558|NCT02105662|Drug|Grazoprevir 100 mg/Elbasvir 50 mg fixed-dose combination tablets|MK-5172A FDC tablet: MK-5172 (100 mg)/MK-8742 (50 mg)
1617559|NCT02105649|Other|Strengthening exercise + Electrical stimulation of calf muscle|
1617560|NCT02105649|Other|selected physical therapy program|
1617561|NCT02105636|Drug|Nivolumab|
1617562|NCT02105636|Drug|Cetuximab|
1617563|NCT02105636|Drug|Methotrexate|
1617564|NCT02105636|Drug|Docetaxel|
1617565|NCT02105623|Behavioral|Standard Therapy|Risk factor control Diet Exercise for 24months
1617566|NCT02105623|Drug|Rosuvastatin|Risk factor control rosuvastatin 5mg/day for 24months
1617567|NCT02105610|Drug|desflurane, isoflurane, sevoflurane|
1617568|NCT02105610|Drug|total intravenous anesthetics|
1617569|NCT02105597|Other|Mobile application|The intervention in this study is a mobile application which will be downloaded into the participant's smartphone.
1617570|NCT02105584|Device|Implantation of LAA closure device|
1617571|NCT02105571|Behavioral|Intervention|
1617572|NCT02105558|Procedure|Epidural|"An epidural involves injecting pain-blocking medication into a space between the
vertebrae and the spinal fluid; it usually takes about 15 minutes to work."
1617573|NCT02105558|Procedure|CSE|Combined Spinal Epidural: A spinal is an injection directly into the spinal fluid; it is given in addition to the epidural technique and takes effect in five minutes. With either an epidural or CSE, the catheter that delivers the drug is left in the epidural space until the baby is born so the medication can be administered continuously.
1617574|NCT02105545|Other|Cancer Treatment Options|Patients may meet, depending on test results, with their physician and a genetic counselor to discuss possible changes in their treatment options and/or lifestyle changes.
1617575|NCT02105532|Other|Restrictive transfusion policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 8 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 8.1-10 g/dL for the duration of hospital stay.
1617576|NCT02105532|Other|Liberal Transfusion Policy|Participants allocated to this group will be eligible for transfusion once their Hb level is ≤ 10 g/dL after presentation to hospital. The objective for the attending clinician is to maintain the Hb level between 10.1-12 g/dL for the duration of hospital stay.
1617577|NCT02105519|Biological|Seasonal influenza vaccine (AdimFlu-S)|Participants receiving 0, 1 and 2 dose of AdimFlu-S during the study period.(a) No vaccination: no any influenza vaccination during the study period.(b) One dose of AdimFlu-S group: patient will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at the initiation of the study.(c)Two doses of AdimFlu-S group: patients will receive one dose of Seasonal influenza vaccine (AdimFlu-S) at week 0 and 4 weeks after the initiation of the study.
1617578|NCT02105506|Drug|Tachosil patch|
1617579|NCT02105493|Drug|500 microgram of Nitroglycerin|500 microgram of Nitroglycerin (in 5 mL saline) given intra-arterially through the sheath at the end of transradial procedure
1617580|NCT02105493|Drug|Saline 5 mL|Saline 5 mL given intra-arterially through the sheath at the end of transradial procedure
1617581|NCT02105480|Device|Computer aided auscultation (CAA)|
1617582|NCT02105467|Drug|Grazoprevir 100mg / Elbasvir 50 mg FDC|
1617583|NCT02105467|Drug|Placebo to Grazoprevir / Elbasvir 50 mg FDC|
1617584|NCT02105454|Drug|Grazoprevir (GZR)|100 mg oral tablet (total daily dose)
1617585|NCT02105454|Drug|Elbasvir (EBR)|10 mg oral capsule (total daily dose = 5 capsules)
1617586|NCT02105454|Drug|Ribavirin (RBV)|200 mg oral capsule (total daily dose = 4-7 capsules)
1617587|NCT02105441|Device|Cochlear implant|Implantable hearing device
1617588|NCT02105428|Behavioral|Aerobic Exercise Training|A progressive increase in duration, frequency and intensity so the last 8 weeks of exercise are performed for 60 min, 5 days per week and at 80% of aerobic capacity. The duration includes a 5 minute warm up and 5 minute cool down. All exercise will be performed on a stationary bicycle (i.e., cycle ergometer).
1617589|NCT02105415|Drug|Ketamine / Propofol Admixture|
1617590|NCT02105415|Drug|Etomidate|
1617591|NCT02105402|Behavioral|PROMPT|The PROMPT approach utilizes a motor-speech hierarchy (MSH) to guide speech language pathologists (SLP) in selecting speech movement goals for treatment. PROMPT treatment generally proceeds systematically in a bottom-up fashion starting with the lowest subsystem in the hierarchy where a child has control issues. Furthermore, in the PROMPT approach specific techniques are used to stimulate sensory input that are assumed to facilitate the formation of sensory-motor pathways required for the acquisition and accurate production of speech movement patterns. As the speech motor behaviors are established, the clinician reduces the number of cues and the frequency and immediacy of feedback and practices transfer and generalization activities.
1617592|NCT02105389|Behavioral|Individualized Yoga Intervention|
1617593|NCT02105376|Device|Trigeminal Nerve Stimulation (TNS)|Trigeminal Nerve Stimulation (TNS)
1617594|NCT02105363|Other|measure of skin movement on surface of the back|
1617595|NCT02105363|Other|Measurement of skin movement on surface of back|
1617596|NCT02105350|Drug|MEK 162|
1617597|NCT02105350|Drug|Gemcitabine|
1617598|NCT02105350|Drug|Oxaliplatin|
1957883|NCT02114060|Biological|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
1957884|NCT02114060|Biological|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
1617601|NCT02105311|Device|Selective laser trabeculoplasty|Selective laser trabeculoplasty platform The Lumenis Selecta® Duet™ (Lumenis Ltd., Yokneam, Israel)
1617602|NCT02105311|Drug|Travoprost|Travoprost benzalkonium-free ophthalmic solution (40 microgram/ml) (Alcon Laboratories, Inc., Fort Worth, TX, USA)
1617603|NCT02105285|Drug|OPC-1085EL ophthalmic solution|
1957885|NCT02114060|Biological|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
1617604|NCT02105285|Drug|Carteolol long-acting ophthalmic solution|
1617605|NCT02105272|Drug|OPC-1085EL ophthalmic solution|
1617606|NCT02105272|Drug|Latanoprost ophthalmic solution|
1617607|NCT02105259|Behavioral|Psychodynamic Internet Treatment|Psychodynamic Internet Treatment for patients social anxiety disorder
1617608|NCT02105259|Other|Waiting list|Waiting list, where participants wait for delayed treatment
1617609|NCT02105246|Behavioral|Home-based cardiac rehabilitation|The intervention is a 12 week, home-based lifestyle intervention that includes counseling regarding heart healthy lifestyle changes.
1617610|NCT02105246|Behavioral|Center-based cardiac rehabilitation|The intervention is a health center-based cardiac rehabilitation program that involves counseling in healthy heart behaviors and exercise delivered in a clinical setting.
1617611|NCT02105233|Biological|brain mimicking fluid|filled into the operation cavity during surgery for glioblastoma
1617612|NCT02105220|Other|Respiratory mechanics assessment|Data collection on respiratory mechanics, end expiratory lung volumes, gas exchanges, work of breathing. Data will be obtained by setting different end expiratory pressures and recording esophageal and airways pressure tracings.
1617613|NCT02105207|Other|Lung Ultrasound|Lung ultrasound evaluation is performed after clinical assessment and before chest radiography
1617614|NCT02105207|Other|Chest Radiography|Chest Radiography is performed after clinical evaluation without using ultrasound assessment
1617615|NCT02105194|Drug|Hyperbaric oxygen therapy|total body exposure to greater than atmospheric pressure oxygen
1617616|NCT02105181|Device|Placement of a FCMS in the biliary tract of the patients|During an ERCP procedure, a fully covered biliary metal stent (FCMS) is placed across a benign biliary stricture
1617617|NCT02105168|Procedure|Blood sample|Optional
1617618|NCT02105168|Procedure|Tumorous biopsy|Optional
1617619|NCT02105168|Procedure|Healthy material sample|Optional
1617620|NCT02105155|Drug|Conversion at day 7 ± 3 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 7±3
1617621|NCT02105155|Drug|Conversion at day 90±5 Prograf® to Advagraf®|Conversion from Prograf® (tacrolimus administered twice daily) to Advagraf® (once-daily prolonged-release tacrolimus) at day 90±5
1617622|NCT02105142|Behavioral|ADHD Group Visits|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians
1617623|NCT02105142|Behavioral|ADHD Group Visits plus Online Discussion Portal|Parents and children attend separate but concurrently run group visits every three months; groups are facilitated by general pediatricians. Parent participants will be granted access to the online discussion portal to allow for communication in between in-person group visits.
1617624|NCT02105142|Behavioral|Computer Decision Support|ADHD Module of the Child Health Improvement through Computer Automation (CHICA) system Designed to facilitate physician adherence to clinical care guidelines for ADHD identification and chronic care management
1617625|NCT02105129|Drug|HMPL-523|HMPL-523: Oral administration with a single dose of 5, 20, 50, 100, 200 and 300 mg in Part A, followed by multiple doses of selected strength in Part B Other Name: NA
1617626|NCT02105129|Drug|Placebo|Oral administration
1957886|NCT02114060|Biological|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
1957887|NCT02114060|Biological|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
1957888|NCT02114060|Biological|Placebo|0.9% Normal Saline (NaCl)
1617632|NCT02105103|Device|Accu-Chek® Insight Insulin Pump|A new insulin pump, the Accu-Chek® Insight insulin pump, will be used by all subjects enrolled in this study. The usability of the Accu-Chek® Insight insulin pump for the intended use has already been investigated in a Human Factor study. The study subjects may encounter the following potential risks of CSII therapy while participating in the study: Possible hypoglycemia; Possible hyperglycemia which might progress to ketosis and DKA; Infusion site reactions (bleeding, bruising, discomfort, pruritus, pain, plaster reactions, inflammation, infection etc.)
1617635|NCT02105077|Drug|Anesthesia with inhalative application of xenon gas|
1617636|NCT02105064|Device|Active rTMS|rTMS over supplementary motor area, 1hz, no pauses, 20 minutes/sessions, 5 sessions/week, 4 weeks. Total 20 sessions.
1617637|NCT02105064|Device|SHAM rTMS|Sham rTMS, without brain stimulation
1617638|NCT02105038|Other|Spinner knob|
1617639|NCT02105038|Other|No Knob|
1617640|NCT02105012|Drug|BD MDI 320 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
1617641|NCT02105012|Drug|BD MDI 160 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
1617642|NCT02105012|Drug|BD MDI 80 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
1617643|NCT02105012|Drug|BD MDI 40 µg|Budesonide Inhalation Aerosol administered as 2 inhalations BID
1617644|NCT02105012|Drug|Placebo MDI|Placebo MDI administered as 2 inhalations BID
1617645|NCT02104999|Device|Point-of-care test for CRP|Device: C Reactive Protein (CRP) measurement on capillary blood using a point-of-care test to determine the CRP level in the blood
1617646|NCT02104986|Drug|Velbe-Bleomycin-Cisplatin|Limitation of the number of chemotherapy courses (≤ 4) after the achievement of a clinical and biological response in NSMGCT patients treated with cisplatin-based chemotherapy, in order to reduce treatment long-term effects
1617647|NCT02104986|Drug|Vepeside-ifosfamide-Cisplatin|
1617648|NCT02104973|Behavioral|Lifestyle counseling|We will intent to modify the diet of the children. The intervention is designed to promote the increase the intake of fruits and vegetables and to reduce the high density foods consumption.
1617649|NCT02104960|Other|Dermatological clinical examination|Clinical pictures, Dermatoscopy, Elastography, Sebumetry
1617650|NCT02104960|Other|Biopsy|Skin biopsy for examinations by confocal microscopy ex vivo and histopathology
1617651|NCT02104960|Other|Confocal microscopy in vivo|Examination by confocal microscopy in vivo
1617652|NCT02104947|Drug|idarucizumab|idarucizumab
1617653|NCT02104934|Procedure|Adductor Canal Block|
1617703|NCT02104583|Drug|Eleclazine|Eleclazine tablets administered orally
1617654|NCT02104908|Procedure|paravertebral nerve|a lumbar, sacral plexus and paravertebral nerve block(LSP) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) , 10ml 0.5%ropivacaine at sacral plexus and 10ml 0.5%ropivacaine at paravertebral nerve(level L1).
1617655|NCT02104908|Procedure|lumbar and sacral plexus block|a lumbar and sacral plexus block(LS) group with 20ml 0.5% ropivacaine at lumbar plexus(level L3-4) and 10ml 0.5%ropivacaine at sacral plexus;
1617656|NCT02104895|Radiation|Accelerated partial breast irradiation (APBI)|Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
1617657|NCT02104895|Radiation|Whole breast irradiation (WBI)|Conventional whole breast irradiation (WBI)
1617658|NCT02104882|Radiation|Intraoperative Radiotherapy (Applicator Surface Dose: 20-40 Gy)|
1617659|NCT02104869|Biological|Trivalent influenza vaccine (inactivated and fragmented).|
1617660|NCT02104856|Device|Alair System (Bronchial Thermoplasty)|
1617661|NCT02104843|Drug|Daclatasvir, Asunaprevir and BMS-791325 FDC|
1617662|NCT02104843|Drug|BMS-791325|
1617663|NCT02104843|Drug|Rosuvastatin|
1617664|NCT02104830|Biological|Empegfilrastim 6 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
1617665|NCT02104830|Biological|Filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
1617666|NCT02104830|Biological|Placebo №1|Placebo №1 is supplied as solution for injection 1.0 ml. Placebo №1 is to be administered 24 h after the chemotherapy at dose of 1.0.
1617667|NCT02104830|Biological|Placebo №2|Placebo №2 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo №2 is supplied as solution for injection 0.0083 ml/kg.
1617668|NCT02104830|Biological|Empegfilrastim 7.5 mg|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 6 mg.
1617669|NCT02104817|Drug|Epanova® (omega-3 carboxylic acids)|Adjunct to statin therapy and diet in high risk adult patients for the prevention and reduction of major adverse cardiovascular events (MACE)
1617670|NCT02104817|Drug|corn oil control|corn oil control arm
1617671|NCT02104804|Drug|Saxagliptin 5mg|Saxagliptin 5mg (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
1617672|NCT02104804|Drug|Placebo for Saxagliptin|Placebo tablets (plus stable insulin dose), given orally once daily (24 weeks); subjects stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue).
1617673|NCT02104791|Drug|procalcitonin|In patient with preterm premature rupture of membrane (PPROM) is the procalcitonin can be used to predict intra-amniotic subclinical infection?
1617674|NCT02104778|Drug|Dexamethasone|In dexamethasone group, dexamethasone 8 mg is added to 0.5% ropivacaine 20 ml for sciatic nerve block.
1617675|NCT02104778|Drug|Epinephrine|Epinephrine 1:200,000 is added to 0.5% ropivacaine 20 ml for sciatic nerve block
1617676|NCT02104765|Drug|LY2951742|Administered subcutaneously.
1617677|NCT02104765|Drug|Placebo|Administered subcutaneously.
1617679|NCT02104739|Drug|Exenatide|Single subcutaneous injection (10 mcg)
1617680|NCT02104739|Drug|Saxagliptin|Single dose orally (5 mg)
1617681|NCT02104739|Drug|Exenatide ER|Subcutaneous injection (2mg) weekly for 6 weeks
1617682|NCT02104739|Other|Placebo|Placebo tablets and Placebo (normal saline) injections
1617683|NCT02104726|Other|Flouroscopy guided steroid injection|We want to compare if there is a difference between the two arms, with the assumption that with flouroscopy will deliver the steroid more accurately and see better outcomes.
1617684|NCT02104726|Other|Blind Steroid Injection|Want to compare it to flouroscopy guided, with assumption that it will be less effective in reducing pain
1617685|NCT02104713|Biological|Allogeneic (MSC's) Application to the Burn Wounds|"Allogeneic (MSC's) Application to the Burn Wounds. The first group of 5 will be started on the lowest dose. If there are no adverse reactions, the second group of 5 will receive a higher dose. This will be repeated for the third and fourth groups with each receiving a higher dose
Initial dose level will be 2.5 x 10³ Allogeneic MSCs cells/square cm.
Second dose level 5 X 10³ Allogeneic MSCs cells/square cm.
Third dose level 1 X 10⁴ Allogeneic MSCs cells/square cm.
Fourth dose level 2 X 10⁴ Allogeneic MSCs cells/square cm.
Up to 2 administrations of cells will be allowed per dose level to be given over a period of no more than 8 weeks. Each administration of cells will be no less than ten days apart and no more than 6 weeks apart."
1617686|NCT02104700|Drug|Rilpivirine/Emtricitabine/Tenofovir|Rilpivirine 25mg/Emtricitiabine 200mg/Tenofovir 300mg FDC qday
1617687|NCT02104687|Procedure|Flow group|After induction, each patient will obtain Transesophageal Dopplerometry probe (CardioQ) in order to monitor the parameters of CI, FTc, PV and SVR.
1617688|NCT02104687|Procedure|Press group|After induction, the parameters of MAP and CVP will be monitored in each of the patients.
1617689|NCT02104674|Drug|lebrikizumab|Given SC on Days 1, 29, and 57
1617690|NCT02104674|Drug|montelukast [Singulair]|10 mg given orally once daily for 12 weeks
1617691|NCT02104674|Other|placebo|SC injection given on Days 1, 29, and 57
1617692|NCT02104661|Drug|Oxcarbazepine|Oxcarbazepine 150mg tablet, over encapsulated and back-filled with Microcrystalline Cellulose/Magnesium Stearate 1%.
1617693|NCT02104661|Drug|Placebo|Placebo in a matched capsule containing Microcrystalline Cellulose/Magnesium Stearate 1%.
1617694|NCT02104648|Other|Placebo RO4602522|Daily oral doses
1617695|NCT02104648|Drug|RO4602522|Daily oral doses
1617696|NCT02104648|Drug|RO4602522|Single, oral dose
1617697|NCT02104648|Drug|moxifloxacin|400 mg oral dose given on Day 1 or 11
1617698|NCT02104648|Other|moxifloxacin placebo|Dose given orally on Days 1 and/or 11
1617699|NCT02104635|Behavioral|Delivery of a Post-Partum Package|
1617700|NCT02104622|Device|ReWalk Rehabilitation 2.0|
1617701|NCT02104609|Drug|Levonorgestrel 1.5mg by mouth once|Levonorgestrel 1.5mg by mouth given on menstrual cycle day 8
1617702|NCT02104596|Device|Xylitol|
1617704|NCT02104583|Drug|Placebo to match eleclazine|Placebo to match eleclazine tablets administered orally
1617705|NCT02104570|Other|Kinesio taping with tension|
1617706|NCT02104570|Other|Kinesio taping without tension|
1617707|NCT02104570|Other|Fatigue protocol|
2010794|NCT02843048|Behavioral|Exercise training program|"Participants allocated to the Exercise training plus standard medical care group will undergo an exercise-training program of 11 months duration, 3 sessions/week, and 60 minutes/session, starting one month after the surgery. Each exercise session will be supervised and will include 5 major components: i) warm-up, ii) multidirectional jumps, iii) balance, iv) strength and, v) cool down. This structure is planned to meet two main objectives: i) enhance bone formation and, ii) reduce fall risk by improving muscle strength, cardiorespiratory fitness and balance."
2010795|NCT02843048|Behavioral|Standard medical care|Standard follow-up medical care following bariatric surgery
2010796|NCT02840695|Drug|bDMARD treatment|Treatment with bDMARD includes registered ATC-codes: L04AA and L04AB.
2010797|NCT02840539|Drug|Bortezomib, Cytarabine, Dexamethasone, Pegteograstim|"Bortezomib: 1.3mg/m2 per day, SC (mixed with normal saline 1.4ml) on day 1, 4, 8, and 11 of each 28-day cycle
Cytarabine: 1.5g/m2 per day, IV (in the vein) over 3 hours on day 2 and 3 of each 28-day cycle for subjects aged less than 65 and 1g/m2 with the same route and schedule for those aged 65 or older
Dexamethasone: 20mg per day, IV (in the vein) or PO on day 1, 4, 8, and 11 of each 28-day cycle
Pegfilgrastim: 6mg once, SC on day 13 of each 28-day cycle Number of cycles: 6 unless progression or unacceptable toxicity develops within 6 cycles"
1617712|NCT02104492|Other|a 12-week Respiratory Muscles Training Program (RMTP)|Every session will be lasted 50 minutes and performed under supervision of a physiotherapist. It will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program which will be supplemented by a 12-week Respiratory Muscles Training Program (RMTP) with ORYGEN Dual® device for 20 minutes. Patients will be instructed to maintain adequate inspiration and expiration while using the Origen-Dual® valve at a rate of 15-20 breaths/minute. Participants will be performed five sets of 10 repetitions followed by 1-2 minutes of unloaded recovery breathing off the device, once a day, 2 days per week, for 12 weeks. The respiratory muscles training will be begun at 30% of MIP achieved at baseline and increased by 5% each week to reach 60% of the baseline assessment MIP.
1617713|NCT02104492|Other|Active Comparator|Every session will be comprised of 30 minutes of progressive aerobic training program followed by peripheric resistive muscle training program and Health Education Program.
1617714|NCT02104466|Procedure|Acupuncture|Acupuncture will be delivered in a group setting, in a common space with multiple reclining chairs. The initial acupuncture treatment will include a one-on-one diagnostic interview with one of the study acupuncturists for up to 30 minutes, followed by administration of acupuncture needles retained for 20-40 minutes. For subsequent group acupuncture treatments, participants will have a 10-15 minute diagnostic intake with the acupuncturist, followed by administration of acupuncture needles retained for 20-40 minutes. Eight to twelve needles will be administered in acupuncture points selected based on a treatment manual developed for the study. All treatments will be administered using sterile, disposable, surgical stainless steel acupuncture needles.
1617715|NCT02104453|Procedure|airway maneuver|"Three-period crossover study: During general anesthesia induction, subjects are assigned to one of the 6 airway maneuver sequences (ABC, CAB, BCA, ACB, CBA, or BAC) in accordance with a randomization schedule. Each maneuver is performed 5 times in a period.
Airway maneuver A: E-C clamp mask holding technique; Airway maneuver B: two-handed mask ventilation with jaw thrust airway maneuver; Airway maneuver C: two-handed mask ventilation with triple airway maneuver(combine jaw thrust and head tilt chin lift)"
1617716|NCT02104440|Biological|"Sequential infusion of allogeneic mesenchymal stem cells expanded in vitro"|
1617721|NCT02104401|Device|tDCS|tDCS will be applied with a Soterix CT tDCS Device with a HD-tDCS 4x1 Multi-Channel Stimulation Interface. During stimulation, a low level of constant DC electrical current (1-2 mA) will be applied via the electrodes. Current will be ramped up over 10-60 seconds, and typically causes very mild tingling and itching sensations. The current will be applied for no more than 20 minutes per session, at which time the current is ramped down over 10-60 seconds. Subjects will be seated in a chair throughout tDCS administration. Subjects will receive tDCS 5 days/week for 4 weeks.
1617722|NCT02104388|Drug|SJP-0035 Ophthalmic Solution|
1617723|NCT02104388|Drug|Vehicle for SJP-0035 Ophthalmic Solution|
1617724|NCT02104375|Dietary Supplement|L-citrulline|2 weeks of L-citrulline supplementation (6g/day).
1617725|NCT02104362|Radiation|exclusive single-fraction irradiation|
1617726|NCT02104349|Behavioral|Mindfulness meditation|One hour training with mindfulness instructor. Listening to mindfulness CD twice a day for 2 weeks prior to spine surgery. Post-operative practice will be at least 1 track per day.
1617727|NCT02104336|Drug|EPI-743|EPI-743 is the quinone oxidation product of alpha-tocotrienol
1617728|NCT02104323|Drug|Endostatin|Method of drug administration:continuous intravenous pumping; Dosage: 7.5mg/m2/d; Course of treatment: 3 months;Total three treatment courses.
1617729|NCT02104310|Drug|Fluorine-18-L-dihydroxyphenylalanine|5 millicuries ± 10%; Intravenous injection; 1 time
1617730|NCT02104297|Drug|deksmedetomidine|deksmedetomidine infused during operation 0.2 mcg/kg/hour
1617731|NCT02104297|Drug|Remifentanil|Remifentanil infused during operation 0.2 mcg/kg/min
1617732|NCT02104297|Drug|Saline|During operation saline infused equal volüme of deksmedetomidine and remifentanil
1617734|NCT02104271|Procedure|Argon Plasma Coagulation|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.
All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
1617820|NCT02103517|Dietary Supplement|Omega -3 fatty acids|Each subject assigned to active treatment group will receive 4 g/day capsule of omega-3 fatty acids.
1618005|NCT02102113|Drug|Low Dose THC|Subjects will receive 0.018 mg/kg over 20 minutes.
1617735|NCT02104271|Procedure|Historical control|"APC was performed during sigmoidoscopy exam. Bowel preparation begins on the eve of the exam associated with waste liquid diet without oral intake of 10mg of bisacodyl (5mg/dragee) at 14 o'clock and 18pm and 130ml of phosfoenema (16g of sodium phosphate monobasic monohydrate and 6g of sodium phosphate dibasic heptahydrate per 100ml) diluted in 100ml of orange juice or lemon to 19h. On the day of the exam is administered 130ml of phosfoenema rectally immediately before the exam.
All patients were previously sedated with fentanyl (0.05mg/ml), midazolam (5mg/5ml) and propofol (10mg/ml) and have intravenous introduction of the flexible colonoscope to the transverse colon to the exchange of gases following the routine of the Department of Endoscopy, Cancer Hospital Barretos."
1617736|NCT02104258|Other|Physiotherapy ASPETAR|Standardized physiotherapy protocol
1617737|NCT02104258|Other|Physiotherapy ASPETAR+|Standardized physiotherapy protocol including early lengthening exercises
1617738|NCT02104245|Drug|Pulmaquin|
1617739|NCT02104245|Drug|Placebo|
1617740|NCT02104232|Behavioral|THPP-I|
1617741|NCT02104232|Behavioral|EUC|
1617742|NCT02104193|Drug|simvastatin in addition to radiation therapy|simvastatin 80 mg tablet once daily during the radiation therapy period in addition to radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
1617743|NCT02104193|Radiation|radiation therapy|radiation therapy 30 Gy delivered in 10 fractions over 2 weeks
2010798|NCT02839902|Drug|TAK-085|A dose of 2 g of omega-3-acid ethyl esters (TAK-085) is orally administered immediately after meal twice a daily.
2010799|NCT02839902|Other|Not treated with omega-3-acid ethyl esters|Not treated with omega-3-acid ethyl esters
1617746|NCT02104167|Device|ROIC interbody cage with VerteBRIDGE plating|
1617747|NCT02104154|Device|Samsung LABGEO PT10 Hepatic Panel|
1617748|NCT02104141|Device|ROIA Interbody Cage with VerteBRIDGE plating|
1617749|NCT02104128|Drug|Bupropion|Bupropion MR will be given open label to all participants in the depression group. Participants will receive 150mg od for one week. The dose will then be increased to 150mg bd for the following 5 weeks. Participants in the control group will recieve no drug. Note that the study is not assessing the safety or efficacy of buprion-- it is using bupropion to assess the neural effects of altering central dopaminergic function in depressed patients.
1617750|NCT02104115|Other|MRI scanners|
1617751|NCT02104115|Other|VAS Symptom scores|
1617752|NCT02104102|Other|Mirror Therapy|Mirror Therapy, which is based on the activation of mirror neurons from the illusion generated by viewing the reflection of a member in a mirror, that is, intended to facilitate the movement through the practice of bilateral symmetric activities, since it is able to stimulate cortical plasticity, promoting reversal of the decrease and the reestablishment of motor function.
1617753|NCT02104102|Other|Kinesiotherapy|Hands movements.
1617754|NCT02104089|Device|Zenith® t-Branch™ Thoracoabdominal Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
1617755|NCT02104076|Device|Evolution® Biliary Stent-Fully Covered|Implantation of the Evolution® Biliary Stent-Fully Covered in the common bile duct utilizing ERCP
1617756|NCT02104063|Procedure|MRI-PET|Participants will have an MRI-PET scan (the Index test) in addition to the procedures they would normally receive as their standard of care (Reference tests). The accuracy of MRI-PET in detecting or ruling out metastatic penile cancer will be compared to the reference tests.
1617757|NCT02104050|Drug|Placebo Gel|6 mL of Placebo Gel administered TID for 6 weeks
1617758|NCT02104050|Drug|OLT1177 Gel|6 mL of OLT1177 Gel (5%) administered TID for 6 weeks
1617759|NCT02104037|Procedure|Lumbar puncture|
1617760|NCT02104024|Other|Contrast Enhanced Ultrasound Scanning|
1617761|NCT02104011|Drug|Propranolol|
1617762|NCT02103998|Drug|thryoid hormone T4 + oral potassium iodide (KI) for 42 days|Continuous infusion of 4 µg/Kg/day T4 with 30 µg/Kg/day oral potassium iodide (KI) for 42 days
1617763|NCT02103998|Drug|D5W - 5% dextrose water|Equivalent volume of infusion as study drug
1617764|NCT02103985|Drug|JNJ-39823277|Participants will receive 100 mg of JNJ-39823277 tablet orally (by mouth) as a single dose.
1617765|NCT02103972|Dietary Supplement|GM080|
1617766|NCT02103972|Dietary Supplement|Maltodextrin|
1617767|NCT02103959|Drug|CMX-2043|Slow bolus IV administration of CMX-2043
1617768|NCT02103959|Drug|Placebo comparator|Slow bolus IV administration of PBS
1617769|NCT02103946|Procedure|Serratus Anterior Muscle Plane block (SAM block)|The US probe is placed in the mid-axillary line at level of the 6th intercostal space. From caudal to cranial, an in-plane approach, the block needle is inserted until the tip is placed between SAM and intercostal muscles and the LA injection will be visualized in real-time. The injection usually consists of 0.4ml/kg of bupivacaine 0.25% plus adrenaline (5ug/ml). Intraoperatively, all subjects will receive a general anesthetic using inhaled anesthetic and oxygen. Intravenous fentanyl will be administered for cardiovascular stability to noxious stimuli.For postoperative analgesia, all subjects will receive oral acetaminophen. Patients will receive a ketorolac IV injection then morphine as a rescue analgesic for breakthrough pain.
1617770|NCT02103946|Procedure|Paravertebral Block|After skin preparation and sterile draping applied. Target paravertebral space will be located using US guidance. The paravertebral space between the third and fourth thoracic vertebrae will be identified in a parasagittal view approximately 3 cm lateral to midline on the side of surgery. A local anesthetic skin wheal will be raised caudal to the ultrasound transducer. A 17-gauge, Tuohy-tip needle will be inserted through the skin wheal in-plane beneath the ultrasound transducer and directed to the paravertebral space. Normal saline (5 mL) will be injected via the needle to help identify the paravertebral space and observe the pleura being displaced anteriorly. 0.4 ml\kg of 0.25% Bupivacaine with epinephrine, 5 μg/mL, will be slowly injected with gentle aspiration every 3 mL.
1617771|NCT02103907|Other|Targeted dynamic balance training|Participants in this study group will complete dynamic balance training exercises four times per week, for ten weeks. Exercise sessions at the university will last approximately one hour, and home exercise sessions will take approximately 30 minutes to complete. Exercises will emphasize dynamic balance control, muscle strength and proprioception and will be progressed over three phases during the ten weeks (with more difficult exercises phased in, and exercises that have been mastered phased out).
1617940|NCT02102646|Procedure|Orchiectomy|Androgen deprivation therapy by bilateral subcapsular orchiectomy
1617772|NCT02103894|Drug|[18F]T807 ([18F]MNI-777)|All enrolled subjects will undergo an [18F]MNI-777 PET imaging visit. For individuals with AD or CTE, [18F]florbetapir imaging may also be performed to serve as a means of correlating disease severity by evaluating the relationship of β-amyloid uptake (measured by [18F]florbetapir imaging) and tau protein uptake (measured by [18F]MNI-777 PET imaging). For individuals with Parkinsonian symptoms, [123I]β-CIT SPECT imaging may be performed to evaluate for a reduction in dopamine transporter uptake.
1617773|NCT02103881|Drug|Ketamine|500 mg of intramuscular ketamine for severe pre-hospital agitation
1617774|NCT02103881|Drug|Haloperidol|Haloperidol 10 mg intramuscular for severe prehospital agitation.
1617775|NCT02103868|Behavioral|Tobacco Cessation Counseling|Doing group and personal counseling for tobacco cessation
1617776|NCT02103855|Drug|Belatacept|
1617777|NCT02103842|Drug|Omega-3 fatty acids|
1617778|NCT02103829|Behavioral|Brief Intervention #1|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
1617779|NCT02103829|Behavioral|Brief Intervention #2|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 1 minute to complete.
1617780|NCT02103829|Behavioral|Brief Intervention #3|Brief online suggestion intended to increase the likelihood of quitting smoking that takes less than 7 minutes to complete.
1617781|NCT02103816|Device|SmartLipo Triplex laser system along with the SideLaze800 hand piece|
1617782|NCT02103790|Device|Home NIV installation|
1617783|NCT02103777|Drug|Caffeine citrate|Caffeine will be given by either high dose in Arm 1 or low dose in Arm 2
1617784|NCT02103764|Drug|Desogestrel|Desogestrel Dosage form : Desogestrel 150 mcg/capsule Dosage : 150 mcg/day Frequency : 1 capsule/day before bed time Duration: 10 day/month
1617785|NCT02103764|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate Dosage form : 10 mg./capsule Dosage : 10 mg./day Frequency : 1 capsule/day before bed time Duration : 10 day/month
1617786|NCT02103738|Other|0.5 mg Ranibizumab intravitreal injections|All eligible patients will initially be treated in a fixed loading phase, consisting of one intravitreal injection of Ranibizumab 0.5 mg per month for 3 consecutive months (Day 1, Month 1, and Month 2). After the loading phase, patients will be treated according to the treatment arm to which they have been assigned, either a continued once monthly dosing regimen, or an extended schedule of Ranibizumab intravitreal injections as described below. The planned duration of total treatment is 24 months.
1617787|NCT02103725|Drug|pimecrolimus 10 mg/g cream|
1617788|NCT02103725|Drug|Vehicle cream|
1617789|NCT02103712|Other|Qualitative|
1617790|NCT02103699|Drug|No intervention|This is an observational study. Patients receiving simeprevir (single capsule of 150 mg once daily) as prescribed by the health care provider will be observed.
1617791|NCT02103686|Drug|Lyrica|
1617792|NCT02103686|Drug|Experimental drug|sustained release formulation of pregabalin
1617793|NCT02103686|Dietary Supplement|High fat meal|
1617794|NCT02103686|Dietary Supplement|fasted|
1617795|NCT02103673|Drug|DAOIB|Intervention drug: DAOIB. Dosage: 250-1500 mg/day by mouth. Duration: 6 weeks
1617796|NCT02103673|Drug|Placebo|Intervention drug: placebo by mouth. Duration: 6 weeks
1617797|NCT02103660|Drug|Depo-Medroxyprogesterone Acetate|150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks
1617798|NCT02103660|Drug|Progestin Contraceptive (Jadelle)|2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
1617799|NCT02103647|Drug|Immediate release capsule(lyrica 150mg * 2/day)|Immediate release capsule
1617800|NCT02103647|Drug|sustained release tablet|sustained release tablet
1617801|NCT02103634|Device|NaF PET/MRI|
1617802|NCT02103634|Device|NaF PET/CT|NaF PET/CT images will be obtained through fusion software. Researchers will fuse the Non AC and AC NaF images with the low dose CT obtained in the FDG PET/CT study.
1617803|NCT02103634|Device|FDG PET/CT|
1617804|NCT02103621|Behavioral|Unified Protocol (UP)|
1617805|NCT02103621|Behavioral|Taper and Monitoring (TAP-M)|
2010800|NCT02838823|Biological|humanized anti-PD-1 monoclonal antibody|humanized anti-PD-1 monoclonal antibody (JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activation of lymphocytes and elimination of malignancy theoretically.
1617807|NCT02103595|Device|Accu-Chek FlexLink|Insulin pump device used for 4-weeks under real life conditions
1617808|NCT02103595|Device|Accu-Chek FlexLink Plus|Insulin pump device used for 4-weeks under real life conditions
2010801|NCT02838758|Device|Cryoablation|A minimally invasive cryoablation device. It delivers focused nitrous oxide to the target tissue via a 22-gauge needle to create an approximately 9.4mm by 5.4mm spherical freezing zone of temperature between -20 to -100° C.
1617810|NCT02103569|Drug|FDC of Daclatasvir, Asunaprevir and BMS-791325|
1617811|NCT02103569|Drug|FDC of Norethindrone and Ethinyl Estradiol|
1617812|NCT02103569|Drug|BMS-791325|
1617813|NCT02103556|Other|Mineral oil|4 ml daily (adjusted as needed), for 4 weeks
1617814|NCT02103556|Dietary Supplement|Olive oil|4 ml daily (adjusted as needed), for 4 weeks
1617815|NCT02103556|Dietary Supplement|Flaxseed oil|4 ml daily (adjusted as needed), for 4 weeks
1617816|NCT02103543|Other|physical therapy|physical therapy consisting of core strengthening, low back stretching and range of motion 3 sessions
1617817|NCT02103543|Procedure|lumbar interlaminar epidural steroid injection|single lumbar interlaminar epidural steroid injection
1617818|NCT02103543|Drug|epidural steroid injection|Dexamethasone 10mg or Depomedrol 40mg, together with Bupivacaine 0.25% (for 3-5mL total injectate volume)
1617819|NCT02103530|Other|FLT PET/CT|All PET/CT scans were performed using a hybrid PET/CT scanner (Gemini TF 64 with Astonish TF, Philips). F-18 FLT (2.96 MBq/kg) in 2-5 mL of normal saline was injected intravenously. One hour after FLT injection, CT began at the vertex and progressed to the upper thigh (120 kVp, 100 mA and 4 mm slice thickness). PET emission data were acquired immediately for 1 min at each bed position followed. The CT data were used for attenuation correction. Images were reconstructed using a standard ordered-subset expectation maximization algorithm with 3 iterations and 33 subsets.
1617941|NCT02102633|Drug|Dabigatran|Dabigatran 150 mg orally
1617821|NCT02103517|Dietary Supplement|Placebo: Corn oil|Each subject assigned to the control group will receive 4 g/day capsule of corn oil.
1617822|NCT02103504|Device|DePuy Attune posterior stabilized fixed bearing total knee replacement|
1617823|NCT02103491|Dietary Supplement|Salt administration|Participants were provided with 3 plastic bags each one containing 4 white capsules (e.g., a total of 12 capsules). In the salt group, the capsules were filled with a commercially available product that contains buffered electrolyte salts (Saltstick caps, Saltstick, California US). The total amount of electrolytes provided in the salt group was: 2580 mg of sodium (113 mmol), 3979 mg of chloride (112 mmol), 756 mg of potassium (19.3 mmol) and 132 mg of magnesium (5.4 mmol). In the control group, participants received the same number of capsules with the exact same appearance but filled with an isocaloric placebo (cellulose). All the participants were instructed to ingest the contents of the first bag in the transition between the swimming and cycling sections, the second bag around the middle of the cycling leg and the third bag during the transition between the cycling and running sections.
1617824|NCT02103491|Dietary Supplement|Placebo administration|
1617825|NCT02103478|Drug|ASTX727 Dose Escalation|Oral investigational product and approved IV decitabine
1617826|NCT02103478|Drug|ASTX727 Dose Confirmation|Randomization cross over design for courses 1 and 2
1617827|NCT02103465|Drug|Rotigotine|transdermal patch
1617828|NCT02103465|Drug|Placebo|transdermal patch
1617829|NCT02103452|Procedure|Ovarian and endometrial samples|Ovarian and endometrial samples were evaluated by hematoxlin &amp;eosin for histopathology (HP) and of oct-4 for immunohistochemistry (IH) for SCE
1617830|NCT02103439|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
1617831|NCT02103439|Drug|PegIntron|1.5 µg/kg of body weight subcutaneously, once a week
1617832|NCT02103426|Drug|ASP0113|intramuscular injection
1617833|NCT02103426|Drug|Placebo|intramuscular injection
1617834|NCT02103413|Device|EUS-BD|When the ERCP was unsuccessful, we tried one-step EUS-BDS using a linear-array echoendoscope (GF-UCT 240-AL 10 or AL 5, Olympus Medical Systems, Tokyo, Japan) at the same ERCP unit on the same session. EUS-BDS was performed by EUS-guided choledocoduodeostomy (EUS-CD) or EUS-guided hepaticogastrostomy (EUS-HG) at the discretion of involved endosonographers. Based on our modified protocol from two our proposed protocols, EUS-BD with transmural stenting was only considered.
1617835|NCT02103413|Device|PTBD|PTBD was performed in selected patients with an 8.5F catheter inserted under fluoroscopic or ultrasound guidance by experienced interventional radiologists or endoscopists.
1617836|NCT02103400|Other|Experimental group|Exercise Training Group
1617837|NCT02103400|Other|Control group|Exercise control group
1617838|NCT02103387|Behavioral|Cognitive Behavioral Training|Cognitive Behavioral Training [CBT] (stress awareness, cognitive restructuring, coping skills training, interpersonal skills training)
1617839|NCT02103387|Behavioral|Relaxation Training|Relaxation Training [RT] (muscle relaxation, deep breathing, guided imagery, meditation)
1617840|NCT02103387|Behavioral|Health Education Control|Health Education control condition (information about breast cancer diagnosis and treatment, side-effect management, recurrence, physical activity and nutrition, and life after breast cancer)
1617841|NCT02103374|Drug|Atrovent + Bricanyl or Atrovent + Ventoline|3 daily inhalations of Atrovent mixture to form Bricanyl or Ventolin form during 48 weeks
1617842|NCT02103374|Drug|Placebo|1 capsule lactose during 48 weeks
1617843|NCT02103335|Drug|pomalidomide|Oral Pomalidomide, days 1-21 of 28 day cycle, dose 3 to 4 mg
1617844|NCT02103335|Drug|marizomib|IV Marizomib, 0.2 to 0.5 mg/m2 on days 1, 4, 8, 11 of 28 day cycle
1617845|NCT02103335|Drug|low-dose dexamethasone|Oral Dexamethasone, days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 22, 23 of 28 day cycle, 5 or 10 mg
1617846|NCT02103322|Drug|Imatinib Mesylate Tablets, 400 mg|Brown, oval, scored, film coated, beveled edge tablet. Debossed with AN on scored side and 795 on the other side.
1617847|NCT02103322|Drug|Imatinib Mesylate Tablets, 400 mg|"Very dark yellow to brownish orange, film-coated tablets, ovaloid, biconvex with bevelled edges, debossed with 400 on one side with score on the other side, and SL on each side of the score."
1617848|NCT02103309|Device|Nelfilcon A contact lenses|
1617849|NCT02103309|Device|Etafilcon A contact lenses|
1617850|NCT02103296|Procedure|Drawing admission labs from cord blood|
1617851|NCT02103296|Procedure|Drawing admission labs from infant blood|
1617852|NCT02103283|Drug|Teprotumumab|Teprotumumab 20mg/kg administered by intravenous infusion every 3 weeks for 3 infusions
1617853|NCT02103270|Drug|Peanut Protein 4,000mg|"Arm A will be defined as clinically tolerant if there is no clinical reactivity at the Week 104 and Week 117 DBPCFC. Clinical reactivity is defined as any reaction ≥ Grade 1 based on the Bock's Criteria (Appendix 4). Individuals in Arm A who meet the definition of clinically tolerant will continue to avoid peanut protein (i.e. continue on 600 mg per day of oat flour) as long as each subsequent DBPCFC (performed every 13 weeks until end of study) shows no clinical reactivity."
1617854|NCT02103270|Drug|Oat Flour|"Arm C will be defined as natural loss of responsiveness if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
1617855|NCT02103270|Drug|Peanut Protein 300 mg|"Arm B will be defined as desensitized to a minimum of 300 mg per day of peanut protein if they show no clinical reactivity at DBPCFCs (week 117 to end of study)."
1617856|NCT02103257|Drug|Sequential Icotinib Plus Chemotherapy|Sequential icotinib plus chemotherapy: pemetrexed 500mg/m2 iv d1, cisplatin 75mg/m2 d1, icotinib 125 mg is administered orally three times per day d 8-21, every 3 weeks for a cycle. After receiving a maximum of 4 cycles treatment, non-progressive patients continue to receive icotinib as maintenance treatment until disease progression or intolerable toxicity.
1617857|NCT02103257|Drug|Icotinib|Icotinib 125 mg is administered orally three times per day until disease progression or intolerable toxicity.
1617858|NCT02103244|Drug|Carboplatin|carboplatin will be dosed according to newly developed dosing algorithm.
1617859|NCT02103218|Behavioral|Education, activities, empowerment, racial pride building|Intervention focuses on information aimed toward reducing or preventing risky sex behaviors of minority adolescent females.
1617860|NCT02103218|Behavioral|General Health education, activities|Intervention focuses on information regarding general health knowledge and healthy behaviors (not including sex).
1617942|NCT02102633|Drug|Bosutinib|Bosutinib 500 mg orally
1617861|NCT02103205|Dietary Supplement|Formula with low iron concentration (2 mg/L) supplemented with bovine lactoferrin|
1617862|NCT02103205|Dietary Supplement|Formula with low iron concentration (2mg/L) without lactoferrin|
1617863|NCT02103205|Dietary Supplement|Formula with normal iron concentration (8 mg/L) without lactoferrin|
1617864|NCT02103192|Other|Anti-Oxidant Drink|
1617865|NCT02103179|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
1617866|NCT02103166|Drug|Hyoscine bromide|20 mg of hyosine bromide diluted in 100 ml of physiological serum (0.9% NaCl).
1617867|NCT02103166|Drug|Physiological serum|100 ml of physiological serum (0.9% NaCl).
1617868|NCT02103153|Device|Picosure Laser System|
1617869|NCT02103140|Behavioral|Facility-based Exercise|Supervised Facility-Based Exercise Intervention Arm The participants randomized to the exercise group will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months. This intervention will use heart rate and rating of perceived exertion (RPE) to define moderate intensity. Participants will exercise for the prescribed duration at a heart rate in the range of 45-65% of their maximal oxygen consumption (VO2 max), as determined during baseline testing, and with an RPE in the range of 11-14 on the 20-point scale. The exercise will primarily utilize treadmills and exercise bikes.
1617870|NCT02103140|Behavioral|Home-based Exercise|Home-Based Exercise Intervention Group The participants randomized to this intervention arm will be required to meet and maintain a goal of 150 min/wk of moderate intensity exercise for 6 months, the same as the supervised intervention group. Their exercise goal will be to achieve a total of 10,000 steps per day, as measured by pedometers. Participants will be required to have a cell phone with text messaging capabilities.
1617871|NCT02103127|Device|755nm Alexandrite laser with lens array|
1617872|NCT02103114|Drug|Anti-thrombin III|"Intraoperatively- (correcting to 100%) according to the following formula:
Units required = ((100%- baseline ATIII level*%) X body weight)/1.4
expressed as a % normal level based on functional ATIII assay"
1617873|NCT02103114|Other|Placebo|Normal saline placebo
1617874|NCT02103101|Other|Measurement of Plasma Concentrations of NOACs|Plasma concentrations of dabigatran, rivaroxaban or apixaban will be measured using High Performance Liquid Chromatography (HPLC) coupled with tandem mass spectrometry (MS/MS). Blood samples will be taken in an EDTA tube and rapidly centrifugated. Plasma will be aliquoted and frozen at minus 80 degrees Celsius for later analysis.
1617875|NCT02103101|Genetic|Identification of ABCB1 polymorphisms coding for P-gp|To investigate the existence of a relation between polymorphisms of ABCB1 and plasma concentrations of new oral anticoagulants, the SNaPshot® Multiplex System will be used enabling multiplexing of SNPs (single nucleotide polymorphisms) of the ABCB1 gene (namely rs4148738, rs2235046, rs1128503, rs10276036, rs1202169, rs1202168, rs1202167).
1617876|NCT02103088|Behavioral|Sexual and urological intervention|Sexual and urological intervention consisting of: i) DVD instruction in pelvic floor muscle training ii) group instructions in pelvic floor muscle training by physiotherapist including three individually follow-up and ii) up to six couple sessions performed by a sexual nurse counselor.
1617877|NCT02103075|Device|Neuromuscular electrical stimulation|All groups received an accumulated 30-minute NMES (25 Hz, on/off: 800ms/800ms) intervention on median nerve.
1617878|NCT02103062|Drug|ABI-007|
1617879|NCT02103049|Drug|Ezetimibe|Patients on standard immunosuppressive therapy with statin will be added ezetimibe for 6 months. Thereafter ezetimibe will be discontinued for three months. Biochemical parameters will be analysed at the time of enrolment, after 3 months, 6 months and 9 months.
1617880|NCT02103036|Procedure|Core Stability Exercises (CSE)|The increase in intra-abdominal pressure stiffens and strengthens the relevant structural support around the spine, compacts the arthrogenic structures and in combination with abdominal contraction, it can encourage a rigid cylinder and stiffness to occur around the spine. The relevant anatomy in these type of exercises are deep muscles like transversus abdominous, multifidus or pelvic floor. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
1617881|NCT02103036|Procedure|Traditional Back School|The back school exercises are based in the traditional activity used for improve the back pain symptoms using the breathing with the stretching of the trunk muscles, the erector spinae reinforcement, the abdominal reinforcement or the postural movements. The participants will have to do 10 different exercises. They will have to perform from 8 to 10 repetitions of every exercise, guided by a physical therapist. They will be recommended about making some series more at home, three days a week, when the treatment was finished.
1617882|NCT02103036|Device|TENS|"Used equipment: MEGASONIC 313 P4 (Carin). Application program number 15: analgesic TENS with stimulation of afferent fibers.
Type of current: two-phase TNS. Width of the impulse: 70µs. Frequency of the impulse: 100Hz. Train: Not. Pause / pause activates: Not. Time of treatment: 20 minutes."
1617883|NCT02103036|Device|Infra-red|Used equipment: INFRA - 2000 (Enraf Nonius) with the following parameters: 230 V / 50-60 Hz / 1.2 A
2010802|NCT02838758|Drug|Lidocaine|Roughly 3cc of lidocaine will be injected near the intermetatarsal neuroma under ultrasound visualization.
2010803|NCT02838758|Drug|Saline|Roughly 3cc of saline will be injected near the intermetatarsal neuroma under ultrasound visualization.
1617888|NCT02102984|Device|covered biliary stents|endoscopic placement of covered biliary stents
1617889|NCT02102984|Device|uncovered biliary stents|endoscopic placement of uncovered biliary stents
1617890|NCT02102971|Procedure|Hepatocellular carcinoma|Participants undergoing a liver resection/liver transplantation surgery. During the liver surgery a small piece of tissue will be removed to undergo additional laboratory testing.
1617891|NCT02102958|Behavioral|DSME with Nonvisual Foot Examination|Diabetes Self-Management Education (DSME) with Nonvisual Foot Examination included comprehensive DSME taught by Certified Diabetes Educators that included instruction in nonvisual self-examination of feet using the senses of touch and smell.
1617943|NCT02102633|Drug|Dabigatran|Dabigatran 150 mg orally
1618001|NCT02102139|Drug|Saline + Propofol|All procedure would be same in DXM+Propofol group except saline loading rather than DXM loading before induction.
1617892|NCT02102958|Behavioral|DSME with Usual Foot Examination Instruction|DSME with usual foot examination instruction was comprehensive diabetes self management education taught by Certified Diabetes Educators that included usual care instructions for examination for feet at home by visually impaired persons, i.e., to have a sighted person check the feet regularly.
1617893|NCT02102945|Procedure|Computed tomography perfusion|Computed tomography perfusion of the head
1617894|NCT02102932|Drug|5 mg empagliflozin/850 mg metformin FDC|5 mg empagliflozin/850 mg metformin FDC
1617895|NCT02102932|Drug|12.5 mg empagliflozin|10 mg empagliflozin tablet and 2.5 mg empagliflozin tablet
1617896|NCT02102932|Drug|12.5 mg empagliflozin|10mg empagliflozin tablet and 2.5 mg empagliflozin tablet
1617897|NCT02102932|Drug|850 mg metformin|850mg metformin tablet
1617898|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
1617899|NCT02102932|Drug|5 mg empagliflozin|5 mg empagliflozin
1617900|NCT02102932|Drug|850 mg metformin|850 mg metformin
1617901|NCT02102932|Drug|12.5 mg empagliflozin/850 mg metformin FDC|12.5 mg empagliflozin/850 mg metformin FDC
1617902|NCT02102932|Drug|12.5 mg empagliflozin/500 mg metformin FDC|12.5 mg empagliflozin/500 mg metformin FDC
1617903|NCT02102932|Drug|5 mg empagliflozin/500 mg metformin FDC|5 mg empagliflozin/500 mg metformin FDC
1617904|NCT02102932|Drug|500 mg metformin|500 mg metformin
1617905|NCT02102932|Drug|500 mg metformin|500 mg metformin
1617906|NCT02102919|Device|SR-WBV|Participants will undergo a training program set over eight weeks, three times a week with 3 to 6 Hz, Noise 4.
1617907|NCT02102919|Device|Virtual Games (VG)|Participants will undergo a training program set from week 5 to 8, three times a week over 20 minutes.
1617908|NCT02102919|Other|SR-WBV|Participants will undergo a training program set over eight weeks three times a week with 1 Hz, Noise 1.
1617909|NCT02102919|Device|Aktiv Tramp (Swiss Frei AG, Switzerland)|Participants will undergo a training program set from the 5 to 8 week, three times a week with 1Hz.
1617910|NCT02102906|Procedure|Transcranial magnetic stimulation|Single pulse TMS - 20 pulses at 120% motor threshold. Using the Magstim rapid 2 stimulator, which has a CE mark and will be used within the indications specified by the CE mark.
1617911|NCT02102880|Genetic|the polymerase chain reaction (PCR)|
1617912|NCT02102854|Drug|rATG|Infusion of horse or rabbit-derived antibodies against human T cells, used to prevent & treat acute rejection in organ transplantation
1617913|NCT02102841|Procedure|Skin biopsy|
1617914|NCT02102841|Procedure|Skin suction blister|
1617915|NCT02102841|Biological|Mantoux test|
1617916|NCT02102828|Device|extended compression & aspirin|Home use of extended compression therapy
1617917|NCT02102828|Drug|Aspirin only|Subjects will receive standard therapy of aspirin; no extended compression
1617918|NCT02102815|Drug|Dexamethasone|Dexamethasone 8-12 mg mixed with NSS up to 50 mL IV slowly push over 5 minutes
1617919|NCT02102815|Drug|Normal saline|NSS 50 mL IV slowly push over 5 minutes
1617920|NCT02102802|Drug|Low or Medium dose MDMA|Participants receiving 30 or 75 mg MDMA
1617921|NCT02102802|Drug|Full dose MDMA|Participants receiving 125 mg MDMA
1617922|NCT02102789|Drug|mFOLFOX6|Patients will receive mFOLFOX6 every 28 days: Oxaliplatin 85 mg/m2 IV over 3 hours on Day 1, 15; Leucovorin (l-LV) 200mg/m2 IV over 2 hours on Day 1, 15; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion on Day 1, 15.
1617923|NCT02102789|Drug|HAI|"Patients will receive HAI every 28 days: 0.12 mg/kg/day floxuridine (FUDR) and 25 mg dexamethasone in normal saline to a total volume of 300 ml will be administered through the HAI pump.
This will be repeated on Day 1 of each 28 day cycle. FUDR administration will be a 14-day continuous infusion using the HAI pump."
1617924|NCT02102776|Procedure|MMC|Standardized cotton soaked in mitomycin C (0.02%) will be applied underneath conjunctiva for 5 minutes after pterygium excision.
1617925|NCT02102776|Procedure|AMT|Amniotic membrane transplantation will be applied to cover the conjunctival defect after pterygium excision.
1617926|NCT02102776|Procedure|CAG|A conjunctival autograft, harvested from the superior bulbar conjunctiva of the operating eye, will be applied to cover the conjunctival defect after pterygium excision.
1617927|NCT02102776|Procedure|Pterygium excision|Pterygium head, minimal conjunctiva and anterior tenon's capsule underneath will be removed in the excision of pterygium tissue.
2010804|NCT02837692|Drug|JNJ-42847922 10 milligram (mg)|JNJ-42847922 will be administered as single tablet of 10 mg, orally, once on Day 1.
1617929|NCT02102737|Drug|6-DIG|injection of 6-DIG
1617930|NCT02102737|Procedure|clamp|hyperinsulinemic euglycemic clamp
1617931|NCT02102724|Dietary Supplement|Fish oil that contains omega-3 fatty acids|Fish oil gelcaps that contain 800 mg of EPA, 600 mg of DHA, 200 mg other omega-3 fatty acids
1617932|NCT02102711|Dietary Supplement|Vitamin A oral drops|
1617933|NCT02102698|Drug|Ecopipam|Ecopipam is a selective antagonist of the dopamine D1 receptor family.
1617934|NCT02102685|Procedure|VAC Therapy|within the first three days the VAC therapy was placed , proceeding as follows : Wound cleaning was performed with irrigating solution and replacement of the sponges every 72 hours according to evolution, photographs were taken to assess the percentage of viable tissue and granulation. A Sample to culture was taken prior to placement of VAC therapy , during the use of it and at the time of removal of the system. When the wound presents clinical signs of improvement (elimination of purulent discharge and granulation tissue ) VAC therapy was withdrawn , and follow by delayed primary closure.
1617935|NCT02102685|Procedure|TRADITIONAL THERAPY|after surgical drainage, a culture was taken, photographs every three days (during hospital stay ) and secretion culture; daily cleaning stipulated by the service was perform. The control of the patients were made until wound closure (presence of epithelialization tissue) .
1617936|NCT02102672|Drug|Trimetazidine|
1617937|NCT02102659|Genetic|Upper Limit Nutrition Support Therapy|"Upper limit nutrition support therapy will be used in patens assigned to this group based on the patient's curve of apoptosis of oral mucosal epithelium"
1617938|NCT02102659|Genetic|Formula Nutrition Support Therapy|"Formula nutrition support therapy will be used in patens assigned in this group based on Harris Bendiest Formula."
1617939|NCT02102646|Drug|Triptorelin|Androgen deprivation therapy by Pamorelin 22,5mg/24 weeks administered intramuscularly.
1618002|NCT02102126|Procedure|Renal denervation|
1617944|NCT02102620|Drug|Intra-articular injection with corticosteroid|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
1617945|NCT02102620|Drug|Intra-articular injection with lidocaine|After rigorous antisepsis with alcoholic 0.5% chlorhexidine. Sterile insulin syringe BD ™ Ultra Fine needles 8 mm x 0.3 mm 30 G) was used in all patients. The anatomical place used for needle entry was located in the dorsal - lateral joint aspect. After the procedure, the injected joint was immobilized for 48 hours.
1617946|NCT02102607|Other|age|subjects stratified according to age: 20-30 years (Group 1), 31-40 years (Group 2), 41-50 years (Group 3), 51-60 years (Group 4), 61-70 years (Group 5), and 71-80 years (Group 6).
1617947|NCT02102594|Drug|Bortezomib|Bortezomib will be subcutaneously applicated in 2 treatment cycles with 4 injections of 1.3 mg Bortezomib /m2 body surface per cycle.
1617948|NCT02102581|Procedure|short time tourniquet|short time tourniquet: the tourniquet starting from the implantation of prosthesis to the completion of the operation.
1617949|NCT02102555|Drug|IV acetaminophen|Single dose of one gram of IV acetaminophen given in pre-operative area
1617950|NCT02102555|Drug|placebo|placebo (IV normal saline)
1617951|NCT02102529|Procedure|laparoscopic colonic surgery|women with typical symptoms including pelvic pain, infertility and endometriotic bowel lesions who underwent laparoscopic surgery including colonic resection performed from 2009 to 2012
1617952|NCT02102516|Drug|SPRIX(intranasal ketorolac tromethamine)|"Dose: Subjects weighing 3.0 kg received 3.15 mg (1 spray/1 nostril), subjects weighing 5.1 - 10.0 kg received 5.25 mg (1 spray/1 nostril), subjects weighing 10.1 - 15.4 kg received 10.5 mg (1 spray/1 nostril), subjects weighing 15.5 - 31.7 kg received 15.75 mg (1 spray/1 nostril), and subjects weighing >=31.8 kg received 31.5 mg (1 spray/2 nostrils).
Duration of Treatment: Subjects received a dose of SPRIX every 6 hours from the day of surgery until the morning of post-operative Day 2. Dosing may have resumed after final PK assessment of the morning of post-operative Day 3 until post-operative Day 4. A follow-up phone interview took place 14 days after the final dose of study drug."
1617953|NCT02102503|Behavioral|Standard Treatment|
1617954|NCT02102503|Behavioral|MI and Medication review|
1617956|NCT02102477|Procedure|Prostatectomy/Surgery|Radical prostatectomy with or without adjuvant or salvage radiotherapy
1617957|NCT02102477|Other|Radiotherapy with adjuvant androgen deprivation therapy|Radiotherapy with adjuvant androgen deprivation therapy
2010805|NCT02837692|Drug|JNJ-42847922 20 mg|JNJ-42847922 will be administered as 1 tablet of 20 mg, orally, once on Day 1.
1617959|NCT02102438|Drug|Trastuzumab|"Trastuzumab (at a loading dose of 4mg/kg and a maintenance dose of 2mg/kg) will be given concomitantly with chemotherapy.
After completion of four chemotherapy cycles, Trastuzumab will be given at a dose of 6mg/kg every 21 days, for a total 14 cycles."
1617960|NCT02102438|Drug|Weekly Paclitaxel|Weekly paclitaxel at 80mg/m2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
1617961|NCT02102438|Drug|Carboplatin|Carboplatin at an Area Under the Curve (AUC) of 2 at D1, D8 and D15 in a 28-day cycle, for a total of 4 treatment cycles.
1617962|NCT02102425|Procedure|Patients with or without bandage over exit site|
1617963|NCT02102412|Biological|screening colonoscopy|performance of a colonoscopy with the experimental device followed by complete conventional colonoscopy
1617964|NCT02102399|Behavioral|Vocal Warm-up|Vocal Warm-up group performed 13 minutes of vocal warm-up exercises everyday before teaching over a course of 6 weeks, with one session exercise per day.
1617965|NCT02102399|Behavioral|Respiratory Muscle Training|Respiratory Muscle Training group performed 13 minutes of Respiratory Muscle Training everyday before teaching over a course of 6 weeks, with one session exercise per day.
1617966|NCT02102373|Device|polyethylene glycol 3350|Patients received a polyethylene glycol 3350 solution starting at afternoon the day before the colonoscopy at a dose of 1000 ml/15 kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
1617967|NCT02102360|Device|Anorganic Bovine Bone|used to improve periodontal regenerative procedures.
1617968|NCT02102360|Device|Enamel Matrix Derivative|used to improve periodontal regenerative procedures.
1617969|NCT02102347|Other|exercise|
1617970|NCT02102347|Other|Phototherapy|
1617971|NCT02102321|Drug|albendazole|
1617972|NCT02102321|Drug|placebo|
1617973|NCT02102308|Other|Exercise|Multicomponent exercise
1617974|NCT02102308|Other|Education classes|
1617975|NCT02102295|Drug|Experimental toothpaste|Experimental toothpaste was containing 0.3% L-ascorbic acid 2-phosphate magnesium salt and 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
1617976|NCT02102295|Drug|Control toothpaste|Control toothpaste was containing 950 ppm fluoride. The registered participants were instructed to brush their teeth twice a day in their customary manner.
1617977|NCT02102269|Device|actimove sling|
1617978|NCT02102269|Device|shoulderlift|
1617979|NCT02102256|Device|Auditory Brainstem Implant|
1617980|NCT02102243|Drug|DEFINITY® infusion|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with agitation, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
1617981|NCT02102243|Drug|Human Recombinant Regular Insulin infusion|The plasma insulin concentration will be acutely raised and maintained at at a steady state by a prime-continuous insulin infusion.
1617982|NCT02102243|Drug|Dextrose infusion|The plasma glucose concentration will be held constant at 90 mg/dl by a variable glucose infusion during euglycemic hyperinsulinemic clamp
1618003|NCT02102113|Drug|Placebo|placebo
1618612|NCT02097875|Drug|BLZ-100|
2010806|NCT02837692|Drug|JNJ-42847922 40 mg|JNJ-42847922 will be administered as 2 tablets of 20 mg, orally, once on Day 1.
1617983|NCT02102243|Procedure|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
1617984|NCT02102243|Procedure|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
1617985|NCT02102243|Procedure|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
1617986|NCT02102243|Procedure|Microneurography|Sympathetic nerve activity from the peroneal nerve measured by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. .The recording needle will remain in position throughout the study.
1617987|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral intervention for insomnia
1617988|NCT02102230|Behavioral|quasi-desensitization|behavioral placebo control
1617989|NCT02102230|Behavioral|Cognitive Behavioral Therapy for Insomnia plus Mobile App|Group-based behavioral intervention for insomnia with adjunct information provided by mobile application
1617990|NCT02102217|Procedure|PRECious|Standardized measurement of serum CRP levels on postoperative day 3,4 and 5.
2010807|NCT02837692|Drug|JNJ-42847922 60 or 80 mg|JNJ-42847922 will be administered as 3 or 4 tablets of 20 mg, orally, once on Day 1. Dose to be determined from Cohort 3, Period 1.
1617992|NCT02102191|Device|e-cigarette|smoking cigarette without tobacco
1617993|NCT02102191|Device|cigarette|smoking cigarette with tobacco
1617994|NCT02102178|Other|Tapestry|"A gauze screen, wool thread appropriate for tapestry and a large needle were used.
The entire screen was filled with a striped pattern made of embroidered half-stitches in the individuals' preferred colors. To fill the screen with half-stitches, the needle was always worked in diagonal movements, point to point. The stitches were started keeping a distance of three points from the four edges."
1617995|NCT02102178|Other|Regular occupation therapy|All the patients were followed up daily for 10 days by a single occupational therapist for around 30 minutes, during which they received guidance regarding how best to perform their ADLs, i.e. how to position themselves when sitting down and standing up, dressing and undressing, feeding themselves, performing personal hygiene and undertaking leisure activities, with the aim of protecting their joints, reducing the pain and expending less energy.
1617996|NCT02102178|Other|Weaving a scarf on a nail frame|"Weaving a scarf on a nail frame: this activity used a rectangular wooden frame (30 cm x 10 cm), with an empty space in the middle and nails distributed at 1 cm intervals along all sides, together with a crochet needle and wool thread.
Procedure: The thread was measured out on the frame and all the fringes were cut to the same length. After this, each thread was knotted, leaving a loop that was placed over each nail. A wool thread was tied to the nail at the corner and a zigzag pattern was woven between alternate nails. On the return, the zigzag weave went via the nails that had initially been missed out. Using the crochet needle, the loop of the fringe was pulled across on top of the zigzag. The scarf went on coming out from under the frame. The zigzag sequence and the needle movement were repeated until the scarf reached the desired length."
1617997|NCT02102178|Other|Domino game|"Each player received seven dominos and kept them concealed from the adversaries' eyes. The player with the double-six (domino with the number six at both ends) started the game. If this domino had not been dealt out to any player, the one with the highest double domino started. Following on from this first player, in clockwise direction, each subsequent player placed one domino at one of the ends of the chain that was formed as the dominos were played. If a player did not have a domino that could be played, he would go to the pile and keep on picking up dominos until getting one that would fit. If no such domino existed, the player would then pass his turn on to the next player. The first player to get rid of all his dominos was the winner. If the game became blocked, i.e. there was no longer any possibility of adding dominos to the chain, the points in each player's hand were counted and the winner was the one with the lowest number of points in his hand."
1617998|NCT02102165|Procedure|metastatic lesion biopsy|a medical test commonly performed by a surgeon or an interventional radiologist in order to collect tissues for examination; in this case from a metastatic lesion
1617999|NCT02102152|Drug|Tobramycin|
1618000|NCT02102139|Drug|DXM + Propofol|"After induction as mentioned at 'arm description', the effect-site propofol concentration was fixed at 5.0 μg mL-1 at the time of diluted epinephrine injection and was unchanged during the entire hydrodissection period in all patients.
The first patients received effect-site concentrations of remifentanil of 4 ng mL -1, respectively. The EC50 of remifentanil for stable hydrodissection was determined by a modification of Dixon's up-and-down method.If the response was success (SBP during the entire hydrodissection period being ±20% from baseline), the next target concentration of remifentanil was decreased by a step of 0.5 ng mL -1. If the response was fail(SBP > ±20% from baseline), the target concentration was increased by 0.5 ng mL-1."
1618004|NCT02102113|Drug|Very Low Dose THC|Subjects will receive 0.010mg/kg.
2010808|NCT02834416|Behavioral|Supervised Group Exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
2010809|NCT02834416|Behavioral|Home Based Exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
2010810|NCT02834013|Procedure|Biospecimen Collection|Undergo optional collection of biopsy tissue and blood
2010811|NCT02834013|Biological|Ipilimumab|Given IV
1618006|NCT02102100|Drug|IV nicotine|Subjects in each arm will receive three infusions in a fixed order one hour apart. The first infusion will be saline, the second infusion will be nicotine (.25 mg / 70kg) and the third infusion will be nicotine (0.5 mg / 70 kg).
1618007|NCT02102100|Drug|Tobacco Flavor|A popular 'Burly' tobacco flavor used in e-cigarettes will be used as the placebo comparator.
1618008|NCT02102100|Drug|Low dose Menthol|A low dose of menthol will be added to the tobacco flavor.
1618009|NCT02102100|Drug|High Dose Menthol|A higher dose of menthol added to tobacco flavor will be an active intervention.
1618010|NCT02102087|Device|Initial Specimen Diversion Device (ISDD)|
1618011|NCT02102087|Device|Lab standard practice (LSP)|
1618012|NCT02102061|Other|multidisciplinary intervention|"a health- and quality of life-oriented program comprising exercise, nutrition advices, and philosophy meetings, without a focus on weight loss, following the philosophical principles from Health at Every Size."
1618013|NCT02102048|Drug|Atazanavir|
1618014|NCT02102035|Procedure|Direct and reversed dorsal digital island flap|The direct dorsal digital island flap is used to cover the defects of adjacent fingers. The reversed dorsal digital island flap is used to cover the defects of the same fingers.
1618015|NCT02102022|Drug|ADI-PEG 20|
1618016|NCT02102009|Dietary Supplement|Complete enteral formula|"Product: Complete nutritional formula in powder enriched with key nutrients to be administered orally (200 ml of water per 57 g product).
Time of intervention: 3 months."
1618017|NCT02102009|Other|Dietary Advise|Patients will receive the usual dietary advise in these patients according hospital clinical practice .
1618018|NCT02101996|Other|high-fat diet|Subjects consume a high-fat diet for three weeks before the in-hospital stay.
1618019|NCT02101983|Drug|Cytarabine|
1618020|NCT02101970|Dietary Supplement|Omega-3 Fatty Acids|Amber 4020 Ethyl Ester (EE) 1000 mg omega-3 capsule contains 420 mg of EPA and 210 mg of DHA both as the ethyl esters (380 mg EPA and 190 mg DHA)
1618021|NCT02101970|Other|Placebo Capsule|
1618022|NCT02101970|Other|Diet and Exercise|Increasing physical activity required over 6 month period to be tracked by a Fitbit. Diet based on caloric intake and eating approved foods.
1618023|NCT02101957|Drug|RP103|
1618024|NCT02101957|Drug|Placebo|
1618025|NCT02101944|Drug|Carfilzomib|Given IV
1618026|NCT02101944|Drug|Dexamethasone|Given IV
1618027|NCT02101944|Other|Laboratory Biomarker Analysis|Correlative studies
1618028|NCT02101944|Biological|Wild-type Reovirus|Given IV
1618029|NCT02101931|Drug|Amino levulinic Acid|The bladder cancer patients is required to swallow a chemical called Amino levulinic Acid, about 10mg/kg body weight. 5ml of blood and one urine samples will be taken before using Amino levulinic Acid. The patient must drink water then the urine will be collected after 4, 8 and 12 hours of taking ALA and the samples will be analyzed by photodynamic diagnostic procedure. ALA gets metabolized into certain types of porphyrins which selectively bind on to the tumor tissues (for a longer time than the normal tissues).
1618030|NCT02101918|Radiation|Computed Tomography Perfusion Imaging|Undergo computed tomography perfusion imaging
1618031|NCT02101918|Other|Laboratory Biomarker Analysis|Correlative studies
1618032|NCT02101918|Biological|Ziv-Aflibercept|Given IV
1618037|NCT02101892|Drug|Amitriptyline|per os, daily, evening
1618038|NCT02101892|Drug|placebo|per os, daily, evening
1618039|NCT02101866|Drug|Vapendavir 300 mg tablet|tablet - single dose
1618040|NCT02101866|Drug|Vapendavir 132 mg capsules|2 capsules - single dose
2010812|NCT02834013|Biological|Nivolumab|Given IV
2010813|NCT02834884|Genetic|Biomarker assessment|Predictive and prognostic biomarker assessment
2010814|NCT02834884|Diagnostic Test|NGS, IHC|Diagnostic tests to check eligibility for a specific targeted trial
2010815|NCT02833766|Drug|anti-EGFR-IL-dox|First-line treatment with anti-EGFR-IL-dox, given at a dose of 50 mg/m2 intravenous, on day 1 of each cycle, cycle length is 28 days
2010816|NCT02833298|Behavioral|Automated reminders|At the time consent is obtained, members of the research team will collect data about how a subject prefers to be contacted for automated reminders (i.e. text messages, postcard, email, MyChart)
2010817|NCT02833298|Behavioral|Patient navigation|The patient navigator will attempt to provide a reminder to the subject one to three days before the scheduled imaging and also offer to accompany the subject to the test.
2010818|NCT02832570|Drug|Sildenafil 100mg single oral dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
2010819|NCT02832570|Drug|Placebo, Oral intake single dose|Measurement of maximal walking distance on a constant load treadmill test (3.12 km/ 10% slope)
2010820|NCT02831959|Device|NovoTTF-100M device|
2010821|NCT02831959|Other|Best Standard of Care|
2010822|NCT02830477|Biological|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973|unmodified, full length recombinant FVIII
2010823|NCT02828124|Biological|BMS-986183|specified dose on specified days
2010824|NCT02828124|Biological|Nivolumab|specified dose on specified days
2010825|NCT02828358|Drug|Azacitidine|Given IV
2010826|NCT02828358|Drug|Cyclophosphamide|Given IV
2010827|NCT02828358|Drug|Cytarabine|Given IV, SC, IT
1618058|NCT02101840|Drug|Apo-Oxycodone CR®|a single 40mg oral dose of the controlled release oxycodone formulation Apo-Oxycodone CR®
1618059|NCT02101840|Drug|OxyNEO®|a single 40mg oral dose of the controlled release oxycodone formulation OxyNEO®
1618060|NCT02101840|Drug|Placebo|a single oral dose of placebo prepared using gelatin capsules and lactose filler with identical looking study capsules as the oxycodone products
1618061|NCT02101814|Procedure|Roux-en-Y gastric bypass (bariatric surgery)|
1618062|NCT02101801|Other|vegetables from fresh or recycled water|
1618063|NCT02101801|Other|receives vegetables from fresh water or recycled waste water farms|
1618073|NCT02101775|Drug|Gemcitabine Hydrochloride|Given IV
1618074|NCT02101775|Other|Laboratory Biomarker Analysis|Correlative studies
1618075|NCT02101775|Other|Pharmacological Study|Correlative studies
1618076|NCT02101775|Other|Placebo|Given PO
1618077|NCT02101775|Other|Questionnaire Administration|Ancillary studies
1618078|NCT02101775|Drug|WEE1 Inhibitor AZD1775|Given PO
1618079|NCT02101749|Biological|trivalent inactivated influenza|intradermal or intramuscular injection in the deltoid area.
1618080|NCT02101736|Drug|Cabozantinib|Open label Phase II clinical trials. All subjects will start cabozantinib at 40 mg. Subjects who tolerate 40 mg for 2 cycles will escalate to 60 mg.
1618081|NCT02101723|Dietary Supplement|MNP + Zn/Fe|Micronutrient powder with 12 mg Fe and 5 mg Zn provided daily from 6-9 months of age
1618082|NCT02101723|Dietary Supplement|MNP + Zn|Micronutrient powder with 5 mg Zn provided daily from 6-9 months of age
1618083|NCT02101723|Dietary Supplement|Placebo|Placebo powder without micronutrients
1618084|NCT02101710|Drug|Elantan SR 60 mg|"Trade Name: Elantan
Active Substance: Isosorbide 5-mononitrate
Pharmaceutical form: Tablet
Concentration: 60 mg
Route of Administration: Oral administration"
1618085|NCT02101710|Drug|Imdur SR 60 mg|"Trade Name: Elantan
Active Substance: Isosorbide 5-mononitrate
Pharmaceutical form: Tablet
Concentration: 60 mg
Route of Administration: Oral administration"
2010828|NCT02828358|Drug|Daunorubicin Hydrochloride|Given IV
1618087|NCT02101684|Drug|Orteronel 300mg BID|
1618088|NCT02101658|Other|clinic-based weight measurements|
1618089|NCT02101645|Procedure|Periodical low intensity direct current (LIDC) stimulation of wound.|Wound is stimulated using LIDC current. Stimulation current magnitude is in micro-ampere range. Stimulation sequence is 1 hour on and 1 hour off for 72 hours or 96 hours.
1618090|NCT02101645|Procedure|Compression therapy of swollen limbs.|Compression bandage is used for reducing swelling of the limbs.
1618091|NCT02101632|Dietary Supplement|Bee Venom Ointment|2 weeks
1618092|NCT02101632|Other|Vaseline Ointment|2 weeks
1618093|NCT02101606|Drug|Tenecteplase (TNK) (0.25 mg/kg, to maximum of 25mg)|TNK will be administered within 30 minutes once MRI and CTP inclusion criteria are determined to have been met.
1618094|NCT02101593|Drug|ADI-PEG 20|
1618095|NCT02101580|Drug|ADI-PEG 20|
1618096|NCT02101567|Drug|Pabal 100 mcg iv infusion over 1 minute given after delivery of fetal head|In the first group of patients, carbitocin 100 mcg will be given iv infusion over one minute after delivery of the head in cesarean section.
1618097|NCT02101567|Drug|Oxytocin 5 IU iv infusion and Methtergine 0.2 mg iv|In the second group of patients oxytocin 5 IU will be given iv infusion and Methergine 0.2 mg iv
1618098|NCT02101554|Drug|Ages 7-11|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
1618099|NCT02101554|Drug|ages 12-17|Oral/Capsule, once per day or twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 6 week Maintenance Treatment duration.
1618100|NCT02101541|Procedure|FIRM ablation|Radiofrequency catheter ablation of atrial fibrillation driving sources detected by sequential bi-atrial panoramic contact mapping.
2010829|NCT02828358|Drug|Dexamethasone|Given PO, NG, IV
1618102|NCT02101502|Other|Questioner|Obstetrics and gynecology health problems questionnaire for patients Educational effectiveness special questionnaire for medical staffs Institutional capacity special questionnaire for institution employees
1618103|NCT02101489|Other|Foley Catheter|20 with intraoperative Foley catheter measurement of the urethral length and 20 without
1618104|NCT02101476|Drug|Percocet|10mg/650mg
1618105|NCT02101476|Drug|Xartemis|15mg/650mg
1618106|NCT02101463|Device|surgeon-modified fenestrated-branched stent-grafts (sm-FBSG)|
1618107|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The uterus will be dragged out of the abdominal cavity, prior to removal of the placenta.
1618108|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The placenta will be manually removed extra-abdominally, with uterine massage as soon as possible.
1618109|NCT02101450|Procedure|Extra-abdominal removal of the placenta|The cesarean incision will be sutured with no. 1 Vicryl ®.
1618110|NCT02101450|Procedure|Extra-abdominal removal of the placenta|Uterus will be replaced in the abdominal cavity.
1618111|NCT02101411|Drug|clopidogrel, ticagrelor, cilostazole|
1618112|NCT02101398|Device|eldith DC-stimulator, configuration F7A|tDCS will be delivered during a 20 minutes speech-language therapy session
1618113|NCT02101398|Device|eldith DC-stimulator, configuration F7C|tDCS will be delivered during a 20 minutes speech-language therapy session
1618114|NCT02101398|Device|eldith DC-stimulator, configuration T5A|tDCS will be delivered during a 20 minutes speech-language therapy session
1618115|NCT02101398|Device|eldith DC-stimulator, configuration T5C|tDCS will be delivered during a 20 minutes speech-language therapy session
1618116|NCT02101398|Device|eldith DC-stimulator, configuration Sham|Sham tDCS will be delivered during a 20 minutes speech-language therapy session
1618117|NCT02101385|Drug|Genomically Directed Monotherapy|Participants randomized to Experimental Arm A will receive an FDA approved drug at standard dose for four cycles (12-16 weeks total duration, depending on cycle length). The CGTB will assign therapy to each participant individually based on biomarkers/pathways identified by DNA sequencing:
1618118|NCT02101385|Other|Observation/Standard Therapy|Currently no standard therapy has proven efficacy in this patient population and thus observation alone would be considered standard of care. Additional therapy is permitted, however, if deemed appropriate by the treating physician.
1618119|NCT02101372|Behavioral|treatment as usual|case management
2010830|NCT02828358|Drug|Hydrocortisone Sodium Succinate|Given IT
2010831|NCT02828358|Other|Laboratory Biomarker Analysis|Correlative studies
2010832|NCT02828358|Drug|Leucovorin Calcium|Given PO, IV
2010833|NCT02828358|Drug|Mercaptopurine|Given PO, NG
2010834|NCT02828358|Drug|Methotrexate|Given IT, IV, PO
2010835|NCT02828358|Drug|Pegaspargase|Given IV
2010836|NCT02828358|Other|Pharmacological Study|Correlative studies
2010837|NCT02828358|Drug|Prednisolone|Given PO, NG
2010838|NCT02828358|Drug|Thioguanine|Given PO, NG
2010839|NCT02828358|Drug|Vincristine Sulfate|Given IV
1618120|NCT02101372|Behavioral|Psychoeducation group treatment|Psychoeducation therapy problem solving focus
1618121|NCT02101359|Drug|T2380|200 microlitres of T2380 will be administrated intracamerally
1618122|NCT02101359|Drug|Mydriatics|3 drops of tropicamide and phenylephrine were instilled 30 minutes before surgery. The second and the third instillation of both phenylephrine and tropicamide will be realised respectively within 20 and 10 minutes before surgery.
1618123|NCT02101359|Drug|Tetracaine|Two drops of tetracaine were instilled in the eye to be operated 5 minutes and 1 minute before surgery
1618124|NCT02101346|Dietary Supplement|Mixed High Fat Diet|Healthy, Round 1
1618125|NCT02101346|Dietary Supplement|Saturated fat diet|Healthy, Round 1 Healthy, Round 2
1618126|NCT02101346|Dietary Supplement|Monounsaturated fat diet|Healthy, Round 1
1618127|NCT02101346|Dietary Supplement|Polyunsaturated fat diet|Healthy, Round 1
1618128|NCT02101346|Dietary Supplement|Triolein 13C|Healthy, Round 2
1618129|NCT02101346|Dietary Supplement|Low fat|Healthy, Round 1
1618130|NCT02101333|Drug|Tocilizumab|intravenous injection 8 mg/kg, monthly during 6 months
1618131|NCT02101320|Device|TRECAM|using the camera during the surgery
1618132|NCT02101294|Device|Interossei Lumbricals Neuro Interface|Finger Relief's keyboard home row layout [actual home row placement order: asdeihotlrn], plus substitutions on the upper row [qwfgjyuk;p] and bottom row [zxcvb'm,.] moves or shifts finger and thumb movement from the elbow muscles to the finger muscles. The movement of finger bending toward the palm is shifted to the interosseous and lumbrical muscles of the hand and fingers from the full flexion and extension muscle control to reduce contraction and expansion of tendons and the movement in the carpal canal adjacent to the median nerve and reduces pressure on the median nerve. Pressure on the median nerve compromises the nerve leading to symptoms of the carpal tunnel syndrome of pain, tingling, and numbness.
1618133|NCT02101294|Device|Standard QWERTY keyboard|Report of onset and severity symptoms of carpal tunnel syndrome when typing with QWERTY keyboard and the Finger Relief device.
1618134|NCT02101281|Biological|Human nerve growth factor 20 µg/mL|1 drop for each eye, twice daily for 28 day
1618135|NCT02101281|Biological|Human nerve growth factor 4 µg/mL or 60 µg/mL|either 4 µg/mL, option 1 or 60 µg/mL, option 2; 1 drop each eye, twice daily for 28 day
1618136|NCT02101268|Drug|Momelotinib|Momelotinib tablet administered orally once daily
1618137|NCT02101268|Drug|Best Available Therapy (BAT)|Regimens for BAT may include but are not limited to chemotherapy (eg hydroxyurea), anagrelide, corticosteroid, hematopoietic growth factor, immunomodulating agent, androgen, interferon, and may include no myelofibrosis treatment.
1618138|NCT02101255|Device|Curodont Repair|"Self-assembling peptide, biomimetic re-mineralisation
Application on Day 0 and Day 360"
1618139|NCT02101255|Device|Fluoride|Application on Day 0, Day 180, Day 360, Day 540
1618140|NCT02101229|Drug|Insulin, Asp(B28)-|"the insulin dose is calculated by the Diabeloop algorithm and then administered to the patient"
2010840|NCT02825394|Other|anti-Xa activity point-of-care testing (aXa-POCT)|
2010841|NCT02825394|Other|ecarin clotting time point-of-care testing (ECT-POCT)|
1618143|NCT02101203|Drug|Placebo|
1618144|NCT02101203|Drug|0.5 mgTestosterone + 10 mg Buspirone|"A total of 28 doses will be provided. Subjects are required to take a minimum of 8 doses over the 8-week treatment period (1 dose/week). The other 20 doses may be taken as desired (ie, on demand) throughout the 8-week treatment period; dosing is permitted every 2 days (ie, on alternate days)."
1618145|NCT02101190|Drug|BIA 9-1067|Opicapone, OPC
1618146|NCT02101164|Biological|denosumab|Treatment Group A - 120 mg SC dose every 4 weeks at Day 1 and week 5 Treatment Group B - 120 mg SC dose every 4 weeks at Week 9 and Week 13
1618147|NCT02101164|Drug|pamidronate|Treatment Group A - 90 mg IV dose every 4 weeks at Week 9 and Week 13 Treatment Group B - 90 mg IV dose every 4 weeks at Day 1 and Week 5
1618148|NCT02101151|Dietary Supplement|Vitamin D3(cholecalciferol)|
2010842|NCT02825251|Drug|Faster-acting insulin aspart|Injected s.c. /subcutaneously (under the skin)
1618150|NCT02101125|Drug|BMS-986020|
1618151|NCT02101125|Drug|Rosuvastatin|
1618152|NCT02101112|Drug|Apixaban|
1618153|NCT02101099|Device|Colonoscopy Force Monitor|Use of Colonoscopy Force Monitoring device (CFM) to measure forces applied to the colonoscope during the procedure.
1618154|NCT02101086|Other|Blood transfusion|Whenever the infant indicated to receive transfusion, a blood product request was sent to the blood bank. This infant was randomly assigned to the autologous or the allogeneic product labeled for each patient at birth in the blood bank
1618155|NCT02101073|Biological|ALX-0061|single dose, intravenous
1618156|NCT02101073|Biological|ALX-0061|single dose, subcutaneous
1618157|NCT02101060|Other|exercise|16-week progressive aerobic and resistance exercise training
1618158|NCT02101047|Drug|Phenylephrine|
1618159|NCT02101034|Biological|Cetuximab|
1618160|NCT02101034|Drug|PD 0332991|
1618161|NCT02101021|Drug|Momelotinib|Momelotinib tablets administered orally once or twice daily
1618162|NCT02101021|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once or twice daily
1618163|NCT02101021|Drug|Nab-paclitaxel|Nab-paclitaxel administered intravenously over approximately 30-40 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
1618164|NCT02101021|Drug|Gemcitabine|Gemcitabine administered intravenously over approximately 30 minutes or as per institutional standard of care on Days 1, 8, and 15 of each cycle
1618165|NCT02101008|Drug|disulfiram and chelated zinc|
1618166|NCT02100995|Behavioral|Intervention Simultaneously Targeting Obesity and Pain|
1618167|NCT02100995|Behavioral|Weight Loss/Weight Self-Management|
1618168|NCT02100995|Behavioral|Chronic Pain Self-Management|
1618169|NCT02100982|Other|Customized Care|Customized Care consists of two components. The first component is a Discussion Prioritization Tool (DPT) which forces patients to make trade-offs between competing concerns to help them determine which are the most important to discuss. The second component is a customized question prompt list (QPL) to help patients communicate their priorities to the PCP. The QPL will be generated after patients use the DPT, and consists of question prompts tailored to the patients' priorities. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
1618170|NCT02100982|Other|Care As Usual|Participants in this condition will interact with the research staff who will help the participant use an iPad in the waiting room to complete baseline health assessments. Consented patient-participants will be told that the subsequent office visit with the PCP will be audio-recorded to assess patient-PCP communication.
1618172|NCT02100956|Drug|oxytocin 100 micrograms|oxytocin 100 micrograms administered intrathecally (IT)
1618173|NCT02100956|Drug|Normal Saline (preservative free)|Normal Saline (preservative free) administered intrathecally (IT)
1618174|NCT02100930|Biological|Anti-GD2 3F8 Monoclonal Antibody|
1618175|NCT02100930|Drug|GM-CSF (granulocyte-macrophage colony-stimulating factor)|
1618176|NCT02100930|Drug|oral isotretinoin|
1618177|NCT02100917|Drug|DMB-3111|
1618178|NCT02100917|Drug|trastuzumab|
1618179|NCT02100904|Procedure|Radiofrequency ablation of fibroids|
2010843|NCT02825251|Drug|insulin aspart|Injected s.c. /subcutaneously (under the skin)
2010844|NCT02824432|Drug|TAK-085|TAK-085 capsules
1618182|NCT02100865|Device|Solar powered oxygen|
1618183|NCT02100865|Device|Oxygen from cylinders|
1618184|NCT02100852|Drug|TGR-1202 + Obinutuzumab + Chlorambucil|TGR-1202: Oral dose Obinutuzumab: IV infusion Chlorambucil: Oral dose
1618185|NCT02100839|Drug|AEM-28|Solution for injection
1618186|NCT02100839|Drug|Normal Saline|0.9% saline for injection
1618187|NCT02100826|Drug|Cephalexin|Administered orally.
1618188|NCT02100813|Drug|LEO 43204|
1618189|NCT02100813|Drug|Placebo|
1618190|NCT02100800|Other|MR and CT measurements of emphysema quantification|
1618191|NCT02100787|Other|TheraTears lubricating drops|A over-the-counter lubricating eye drop to be used 1 drop in both eyes 4 times a day (QID) for 8 weeks
1618192|NCT02100761|Drug|Voriconazole|Patients with creatinine clearance at least 50 ml/min will be treated with voriconazole by intravenous drip infusion at the dose of 6 mg/kg twice daily on the first day (Day 1) and 4 mg/kg twice daily from day 2 onward. The IV treatment is at least 7 days. Then switch to 200 mg orally twice daily between meals. The total treatment duration is at least 14 days Patients with creatinine clearance <50 ml/min will be treated with oral voriconazole (loading dose of 400 mg twice daily followed by maintenance dose of 200 mg twice daily between meals for at least 14.0 days).
1618193|NCT02100748|Drug|TRV130|TRV130 1 - 4 mg will be administered every 4 hours
1618194|NCT02100748|Drug|Morphine|Morphine 4 mg will be administered every 4 hours
1618195|NCT02100748|Drug|Placebo|Placebo will be administered every 4 hours
1618196|NCT02100735|Other|Sedation protocol|
2010845|NCT02823301|Behavioral|VAMOS Program|Active life improving health: all participants that will be assigned to change behavior group will participate of a change behavior program, entitled VAMOS (Active Life Improving Health), for five months. The VAMOS Program is a lifestyle promotion program, that includes physical activity and healthy eating habits. The program is composed by 12 meetings (six weekly meetings and six fortnightly meetings), in group, lasting about 90 min. In each In each weekly meeting, will be discussed guidelines and strategies for physical activities practices in different domains and for adoption of a healthy diet. All aspects and strategies included in the program are based in behavior changes theories.
2010846|NCT02821455|Procedure|Lung Surgery with One-Lung Ventilation|A single cohort of patients undergoing one-lung ventilation during lung surgery
1618199|NCT02100709|Device|BiLevel Noninvasive Ventilation|Positive pressure applied through an oro-nasal mask. The pressure is altered between inspiration and expiration.
1618200|NCT02100696|Drug|Etrozulimab|Participants will receive 105 mg administered by subcutaneous injection every 4 weeks.
1618201|NCT02100696|Drug|Placebo|Participants will receive placebo matched with etrolizumab.
1618202|NCT02100683|Device|PDA Coil|The Nit-Occlud PDA is a permanently implanted prosthesis indicated for percutaneous, transcatheter closure of small to moderate size patent ductus arteriosus with a minimum angiographic diameter < 4 mm.
1618207|NCT02100657|Drug|Plitidepsin|
1618208|NCT02100657|Drug|Bortezomib|
1618209|NCT02100657|Drug|Dexamethasone|
1618210|NCT02100644|Drug|Lamotrigine tablets 25/100 mg|Lamotrigine (LTG) is administered according to the package insert: that is, 25 mg of LTG will be orally administered once every other day for the first 2 weeks and then once daily for the next 2 weeks. Thereafter, the dose will be gradually escalated by 25-50 mg every 1-2 week for once or twice daily administration. During the VPA reduction phase and LTG&amp;VPA maintenance phase, as specified in the information of package insert, maintenance dose of LTG will be administered twice daily.
1618211|NCT02100631|Biological|PXVX0200|
1618212|NCT02100631|Biological|Placebo|
1618213|NCT02100618|Procedure|Blood sampling|Blood samples will be collected from all subjects at Year 6.5
1618214|NCT02100605|Device|Phytosun, decongestant, nasal spray|one time application of the nasal spray
1618215|NCT02100592|Other|Early rehabilitation treatment on Erigo Hocoma|5 weekly sessions of erigo for three weeks. Expected tilt angle up to 60 °
1618216|NCT02100592|Other|Early rehabilitation treatment on Erigo Hocoma|Early verticalization treatment with Erigo Hocoma, a tilt table with stepping system
1618217|NCT02100579|Drug|Bupivacaine|10 ml of 0.25% bupivacaine
1618218|NCT02100579|Drug|Preservative free normal saline|10 ml of preservative free normal saline
1618219|NCT02100566|Behavioral|Counseling (Care giver burden focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on care giver burden as the reason for adoption of the AD.
1618220|NCT02100566|Behavioral|Counseling (patient autonomy focus)|An advance directive (AD) document is provided to the patient along with counseling that focuses on patient autonomy (control) as the reason for adoption of the AD.
1618221|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
1618222|NCT02100553|Drug|Itraconazole|Two 100 mg capsules, once daily for 7 days
1618223|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
1618224|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose
1618225|NCT02100553|Drug|Itraconazole|Two 100 mg capsules, once daily for 7 days
1618226|NCT02100553|Drug|CE/BZA|CE 0.45mg/BZA 20mg tablets, single dose on Day 5
1618227|NCT02100540|Drug|I placebo capsule|I placebo capsule
1618228|NCT02100540|Drug|II RDC 0.3mg capsule|II RDC 0.3mg capsule
1618229|NCT02100540|Drug|III RDC 0.6mg capsule|III RDC 0.6mg capsule
1618230|NCT02100527|Drug|PF-05175157|200 mg (as 2x100 mg tablets) twice a day (BID) for 6 weeks
1618231|NCT02100527|Drug|Placebo|placebo matching 200 mg (as 2x100 mg tablets) BID for 6 weeks
1618232|NCT02100514|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection for 52 weeks.
1618233|NCT02100514|Other|Placebo|Subcutaneous injection every 2 weeks for 52 weeks.
1618234|NCT02100488|Device|Closed-loop insulin infusion system|"Each subject will undergo two Open-loop and two Closed-loop meal tests, each one at 1-2 week intervals, thus completing the 4 experiments in about 6 weeks. The day of the experiment, a standard mixed meal test containing 60 g of carbohydrates (CHO), will be administered. On two occasions, patients will receive in a randomized order the standard insulin bolus based on the individual insulin to CHO ratio (First arm, Open-loop study). On the other two occasions they will receive a Sliding Mode Reference Conditioning (SMRC) Closed-loop insulin administration, based on subcutaneous continuous glucose monitoring (Second arm, Closed-loop study). Commercial insulin infusion systems and continuous glucose monitoring devices will be used."
1618235|NCT02100488|Other|Open-loop insulin infusion system|Standard subcutaneous insulin infusion based on the individual insulin to carbohydrate ratio. Commercial insulin infusion systems and continuous glucose monitoring devices will be used.
1618236|NCT02100475|Drug|insulin degludec/liraglutide|"Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin.
Dose individually adjusted."
1618237|NCT02100475|Drug|insulin aspart|Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
1618238|NCT02100462|Drug|Chlorthalidone 12.5 mg|
1618239|NCT02100462|Drug|Hydrochlorothiazide 25 mg|
1618240|NCT02100462|Drug|Aspirin 81 mg|
1618241|NCT02100449|Other|Lung ultrasound and Doppler (Day 0)|In patients presenting a consolidation of suspected atelectatic nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 only.
1618242|NCT02100449|Other|Lung ultrasound and Doppler (Day 0 and Day 3 to 5)|In patients presenting a consolidation of suspected infectious nature, a lung ultrasound examination using pulsed-wave Doppler will be performed on Day 0 and on Day 3 to 5. A bronchoalveolar lavage will also be performed on Day 0.
1618243|NCT02100436|Biological|Influenza Virus Vaccine, Monovalent A/H3N2v A/Minnesota/11/2010 NYMC X-203|A unadjuvanted subvirion monovalent inactivated split influenza virus vaccine (H3N2v MIV) produced in eggs. Subjects are enrolled in 3 cohorts stratified by age. 6-35 month old subjects receive 2 doses of H3N2v MIV, intramuscularly (IM) as 7.5 micrograms (mcg) of hemagglutinin (HA)/0.25 milliliter (mL) dose, 21 days apart, or 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart. 3-8 year old subjects and 9-17 year old subjects receive 2 doses of H3N2v MIV, IM as 15mcg HA/0.5mL dose, 21 days apart.
1618244|NCT02100423|Dietary Supplement|curcumin|Given PO
1618245|NCT02100423|Dietary Supplement|cholecalciferol|Given PO
1618246|NCT02100423|Other|laboratory biomarker analysis|Correlative studies
1618247|NCT02100423|Other|pharmacological study|Correlative studies
1618248|NCT02100410|Device|Delefilcon A toric contact lens T1|Iteration 2-87-1 with embossed mark
1618249|NCT02100410|Device|Delefilcon A toric contact lens T2|Iteration 2-87-1 without embossed mark
1618250|NCT02100410|Device|Delefilcon A toric contact lens T3|Iteration 2-87-2 with embossed mark
1618251|NCT02100410|Device|Delefilcon A toric contact lens T4|Iteration 2-87-2 without embossed mark
1618252|NCT02100410|Device|Delefilcon A toric contact lens T5|Iteration 2-87-3 with embossed mark
1618253|NCT02100410|Device|Delefilcon A toric contact lens T6|Iteration 2-87-3 without embossed mark
1618254|NCT02100397|Biological|Salmonella enterica serovar Paratyphi A (strain NVGH308)|Ingestion of 1-5x10³ to 1-5x10⁵ colony forming units (CFU) of the challenge strain after bicarbonate buffer solution.
1618255|NCT02100384|Procedure|Peri-implant maintenance|The peri-implant maintenance will be performed by two experienced Registered Dental Hygienists with titanium scalers or ultrasonic instrumentation
1618256|NCT02100371|Drug|BMS-833923|BMS-833923, by mouth, at the dose and schedule administered while enrolled in CA194002.
1618257|NCT02100319|Drug|Azilsartan|Azilsartan tablets
1618258|NCT02100306|Behavioral|Auditory Feedback 100%|Patients will receive constant auditory feedback across training trials.
1618259|NCT02100306|Behavioral|Auditory Feedback 50% alternate|Patients will receive alternating auditory feedback (1 trial auditory feedback; 1 trial no auditory feedback) across trials
1618260|NCT02100293|Drug|magnesium sulfate 30 mg/kg|Patients in each group received the magnesium sulfate 30 mg/kg for 2 min in 0.9% normal saline (total volume 100 ml) intravenously for 5 min before induction of anesthesia
1618261|NCT02100293|Drug|saline|Patients in each group received 0.9% normal saline (total volume 100 ml) alone intravenously for 5 min before induction of anesthesia
1618262|NCT02100280|Drug|deep block|sugammadex 4 mg/kg are administered IV for reversal of neuromuscular block
1618263|NCT02100267|Drug|Methacholine Chloride (SK-1211)|Subjects received saline and 0.039-25 mg/mL of Methacholine chloride
1618264|NCT02100254|Behavioral|behavioral intervention|View personal narrative informational video
1618265|NCT02100254|Behavioral|behavioral intervention|View fact-based informational video
1618266|NCT02100241|Procedure|Active stretching|The participants performed three specific exercises of static active stretching of the hamstring muscles, maintaining the maximum tightness that was tolerable without pain for 15 seconds. Each exercise were performed twice, with a total of six repetitions.
1618267|NCT02100228|Drug|Apixaban|Oral, 2.5 or 5 mg BID
1618268|NCT02100228|Drug|Parenteral heparin and/or oral Vitamin K antagonist|Parenteral heparin and/or locally used oral Vitamin K antagonist e.g. warfarin (excludes other novel oral anticoagulants)
1618269|NCT02100215|Other|Common readings and educational handouts|Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
1618270|NCT02100215|Other|Expert Modeling|70 minutes of expert modeling videos
1618271|NCT02100215|Other|Voice Over Power Point|60 minutes of Voice Over PowerPoint presentations
1618272|NCT02100202|Other|Placebo|
1618273|NCT02100202|Dietary Supplement|BioTurmin (Curcuma longa rhizomes extract)|
1618274|NCT02100202|Dietary Supplement|BioTurmin-WD (Water dispersible curcuminoids)|
1618275|NCT02100202|Dietary Supplement|MaQxan (Tagetes erecta flower extract)|
1618276|NCT02100189|Other|Cytology Specimen Collection Procedure|Undergo esophageal cytology collection
1618277|NCT02100189|Procedure|Esophagogastroduodenoscopy|Undergo standard EGD or endoscopy
1618278|NCT02100189|Other|Laboratory Biomarker Analysis|Correlative studies
1618279|NCT02100176|Other|Multidisciplinary intensive rehabilitation treatment|The first session comprises cardiovascular warm-up activities, relaxation exercises, muscle-stretching exercises, exercises to improve the range of motion of spinal, pelvic and scapular joints, exercises to improve the functionality of the abdominal muscles, and postural changes in supine position. The second session comprises exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill plus. The last session is a session of occupational therapy aimed to improve autonomy in daily living activities.
1618280|NCT02100176|Drug|Rotigotine|Rotigotine 2-8 mg/24 h
1618281|NCT02100163|Behavioral|Virtual Reality Hypnosis|The patient receives virtual reality hypnosis daily.
1618282|NCT02100163|Behavioral|Audio Hypnosis|Patient will listen to an Audio Hypnosis recording daily.
1618283|NCT02100163|Other|Standard treatment|
1618284|NCT02100150|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (3g in 30 milliliter vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
1618285|NCT02100150|Drug|Placebo|Strawberry flavored solution
1618286|NCT02100137|Other|vaginal ultrasound|vaginal ultrasound performed at a routine gyn examination
1957913|NCT02111213|Behavioral|Virtual Advisor|The virtual advisor is named Carmen. She is an animated, computer-generated figure that speaks to participants and gives advice and support for physical activity.
1618290|NCT02100085|Biological|GX-188E|In phase I study, 9 patients were assigned to three dose groups (1mg, 2mg and 4mg) and were administered three times with GX-188E by electroporation during an entire period of study. After the final administration, the follow-up will be conducted to investigate safety and efficacy aspects.
1618291|NCT02100072|Device|Nd:YAG 1440 nm laser|
1618292|NCT02100059|Other|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 40 minutes.
1618293|NCT02100046|Drug|Zarontin® (ethosuximide) and Stodal®|
1618294|NCT02100033|Device|acupuncture|
1618295|NCT02100020|Other|Direct Referral to physical activity|Participants randomized to the Direct Referral Arm will be provided with a referral to a physical activity program in their community and will be closely monitored in this program for 16 wks.
1618296|NCT02100007|Drug|ME-344|"Part 1: ME-344 IV at 10 mg/kg on Days 1, 8, 15, and 22 of each 28-day cycle. Part 2: ME-344 IV at the dose defined in Part 1 on Days 1, 8, 15, and 22 of each 28 day cycle.
Patients will be allowed to continue receiving ME-344 infusions weekly according to the assigned dose level as long as there is clinical benefit to the patient as assessed by the Investigator."
1618297|NCT02100007|Drug|Topotecan|Part 1: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle. Part 2: Topotecan 4 mg/m2 i.v. weekly on Days 1, 8 and 15 of each 28-day cycle.
1618298|NCT02099994|Biological|Ad35-GRIN|intramuscular administration of Ad35-GRIN 5 x 10^10 vp or saline placebo
1618299|NCT02099994|Biological|MVA.HIVconsv|IM administration of MVA.HIVconsv 2 x 10^8 pfu or saline placebo
1618300|NCT02099994|Biological|pSG2.HIVconsv DNA|IM administration of pSG2.HIVconsv DNA 4 mg or saline placebo
1618301|NCT02099994|Biological|Electroporated pSG2.HIVconsv|IM administration of electroporated pSG2.HIVconsv 4mg or saline placebo
1618302|NCT02099981|Drug|Aminoguanidine|
1618303|NCT02099968|Behavioral|Comprehensive Lifestyle Modification|"Vegeterian diet
Fasting (1st week)
Meditation
Yoga
Aerobic exercise"
1618304|NCT02099968|Behavioral|DASH|"DASH diet (dietary approaches to stop hypertension)
Aerobic exercise
Progressive muscle relaxation"
1618305|NCT02099955|Drug|Vitamin D3|4000 IU/day or 2000 IU/day for 12 weeks
1618306|NCT02099942|Device|V8 Balloon Aortic Valvuloplasty (BAV) Catheter|"The V8 device can be used for BAV as follows:
as stand-alone intervention
as a bridge to transcatheter aortic valve replacement (TAVR)
as a bridge to surgical aortic valve replacement (SAVR)
as an intraprocedural predilatation prior to TAVR"
1618307|NCT02099929|Other|Coffee with Sugar|300mL of Coffee with 30g of Sugar
1618308|NCT02099929|Other|Coffee without Sugar|300mL of Coffee without Sugar
1618309|NCT02099929|Other|Decaffeinated Coffee without Sugar|300mL of Decaffeinated Coffee without Sugar
1618310|NCT02099929|Other|Water with Sugar|300mL of Water with 30g of Sugar
1618311|NCT02099929|Other|Water without Sugar|300mL of Water without Sugar
1618312|NCT02099916|Drug|gonadotropins plus DHEA|Women in the DHEA group will received 25 mg of DHEA three times a day for at least 12 weeks.
1618313|NCT02099916|Drug|Gonadotropins|All patients will be stimulated with a fixed GnRH-antagonist protocol. Ovarian stimulation will be initiated with 450 IU of gonadotropins either in the form of a combination of highly purified urinary FSH and LH or with a combination of Rec FSH and Rec LH.
1618314|NCT02099903|Device|transcatheter renal denervation|Renal sympathetic denervation with an irrigated radiofrequency catheter.
1618315|NCT02099890|Dietary Supplement|Omega-3|
1618316|NCT02099890|Dietary Supplement|Vegetation Protein Powder|
1618317|NCT02099890|Dietary Supplement|InflanNox|
1618318|NCT02099890|Dietary Supplement|Anti-oxidant Network|
1618319|NCT02099890|Dietary Supplement|Chlorella|
1618320|NCT02099877|Drug|Fentanyl|Epidural analgesia will be initiated with 100µg of epidural fentanyl
1618321|NCT02099864|Drug|Enzalutamide|Given PO
1618322|NCT02099864|Other|Laboratory Biomarker Analysis|Correlative studies
1618323|NCT02099851|Device|Carotid body ablation (Cibiem)|
1618324|NCT02099838|Drug|Pioglitazone and Metformin|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
1618325|NCT02099838|Drug|Placebo|taking 1 tablet twice a day (before breakfast and before dinner) orally for 12 weeks
2010847|NCT02821247|Drug|VEGF-Trap-Eye (BAY86-5321)|standard treatment patterns as decided by the physician
1618327|NCT02099799|Behavioral|Pedometer and Website|Pedometer and website with feedback, goal setting, educational and motivational content, and community forum.
1618328|NCT02099786|Other|COMP-VA|Hearing testing at each treatment interval by the comp-va audiologist
1618329|NCT02099786|Other|Standard of care|Hearing testing done in the audiology clinic after oncology referral
1618330|NCT02099786|Other|Program evaluation|Hearing test done by the study research audiologist to evaluate the experimental arms
1618331|NCT02099760|Device|STD testing (GC/Ct/trich)|
1618332|NCT02099747|Drug|hATG|
1618333|NCT02099747|Drug|CsA|
1618334|NCT02099747|Drug|Eltrombopag|
1618335|NCT02099734|Behavioral|Questionnaires|
1618336|NCT02099734|Other|sample of blood or saliva|A sample of blood or saliva will be obtained for DNA extraction. Approximately 2-4 tubes of blood will be collected or one tablespoon of saliva. If a participant has already provided a DNA sample for another MSKCC IRB approved protocol, they may not need to provide an additional sample.
1618337|NCT02099721|Device|ICD or CRT-D Device|Subjects who receive an ICD/CRT-D device implant will be implanted and follow protocol-specified programming. The programming is not investigational. Consistent programming is desirable in order to compare groups during statistical analysis.
1618338|NCT02099708|Drug|Lansoprazole|Lansoprazole Capsules 15 mg/ Orally Disintegrating (OD) Tablets 15 mg
1618339|NCT02099695|Drug|Oxybutynin|The doses will increase due to the absence/ lack of therapeutic response of the previous dose assessed during the study visits.
1618340|NCT02099695|Drug|Placebo|The quantity of tablets will increase due to the absence/ lack of therapeutic response.
1618341|NCT02099682|Drug|Lansoprazole|Lansoprazole Capsules 15/ OD Tablets
1618342|NCT02099669|Other|Blood transfusions|
1618343|NCT02099656|Drug|Lebrikizumab|Lebrikizumab will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
1618344|NCT02099656|Drug|Placebo|Lebrikizumab matching placebo will be administered by SC injection on Day 1, Day 8, Week 4, and Week 8.
1618345|NCT02099656|Drug|Inhaled corticposteroids (ICS)|Participants will continue their ICS controller therapy, as they are receiving prior to screening, throughout the study. Protocol does not specify any particular ICS.
1618346|NCT02099656|Drug|Second Asthma Controller Medication|Participants will continue their asthma controller therapy, as they are receiving prior to screening, throughout the study.
1618347|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent|
1618348|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent|
1618349|NCT02099617|Procedure|Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent|
1618350|NCT02099604|Drug|Vitamin D + Pegylated Interferon Alpha 2b + Ribavirin|Vitamin D ARM: 28000UI/week during 4 weeks (lead in phase) then 28000 UI/week associated with PegIFN/RBV during 48 weeks
1618351|NCT02099591|Drug|Naloxegol|
1618352|NCT02099578|Dietary Supplement|25 g of Freeze-dried Strawberry Powder|Participants will be given one packet of 25 g of freeze-dried strawberry powder and one packet of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
1618353|NCT02099578|Dietary Supplement|50 g of Freeze-dried Strawberry Powder|Participants will be given two packets of 25 g of freeze-dried strawberry powder and asked to consume one packet in the morning and one at night.
1618354|NCT02099578|Dietary Supplement|Placebo Powder|Participants will be given two packets of 25 g of placebo powder and asked to consume one packet in the morning and one at night.
1618355|NCT02099539|Biological|ALT-803|Intravenous infusion for cohort 1, 2, 3 and 4; subcutaneous injection for cohort 5, 6 and 7; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
1618356|NCT02099513|Device|The Mobile Health Platform|
1618357|NCT02099500|Procedure|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
1618358|NCT02099500|Other|Stem Cell Injection|Stem cell implantation will be performed using intramuscular injection into the affected ischemic site of interest
1618359|NCT02099487|Radiation|Radiation|hypofractionated IMRT
1618360|NCT02099474|Other|Study of pharmacokinetic properties of raltegravir during the 3rd trimester of pregnancy|Introduction of a catheter for performing 5 blood samples in pregnant women infected by HIV-1, before the raltegravir intake, 0.5, 3, 8 and 12 hours after the intake at each of two visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
1618361|NCT02099461|Drug|Denosumab|Single sucutaneous dose
1618362|NCT02099461|Procedure|Percutaneous core needle breast biopsy|
1618363|NCT02099435|Device|Hemospray|The Hemospray™ device comes in a 7F kit and a 10F kit. Each kit includes two 220 cm Teflon application catheters, a handle with CO2 cartridge and a syringe containing approximately 20 g of the Hemospray™ material. Hemospray™ is a proprietary inorganic mineral powder that acts as a mechanical barrier when sprayed over a bleeding lesion and the surrounding mucosa.
1618364|NCT02099409|Device|FLORENCED2|FLORENCED2 device ensures the closed loop between Freestyle Navigator II and the DANA DIABECARE R
1618365|NCT02099396|Drug|Docetaxel+lobaplatin|
1618366|NCT02099396|Drug|Gemcitabine+lobaplatin|
1618367|NCT02099383|Other|normal saline|intravenous normal saline 20cc per kilogram of body weight over a period of 8 hours
1618368|NCT02099357|Dietary Supplement|Creatine|Daily supplementation with 3g of monohydrate creatine during 8 weeks
1618369|NCT02099357|Dietary Supplement|Placebo|
1618370|NCT02099357|Dietary Supplement|Vitamin D|Vitamin D supplementation with 25000 IU each two weeks during eight weeks
1618371|NCT02099344|Device|Artegraft|Surgical placement of graft for hemodialysis access
1618372|NCT02099344|Device|Propaten|Surgical placement of graft for hemodialysis access
1618373|NCT02099331|Drug|Melatonin|
1618374|NCT02099331|Drug|Placebo (for Melatonin)|Sugar pill manufactured to mimic Melatonin 20 mg
1618613|NCT02097862|Procedure|Adipose Stem Cells|Injection of adipose derived stem cells intra-discally
1618375|NCT02099318|Other|Active SRP cases|The SRP involves preoperative rehearsal and planning. Similarly to the CT/MRI studies, the SRP will be available for surgeons during the surgery for evaluation of optional surgical approaches.
1618376|NCT02099318|Other|Control cases|Control cases will consist of video recorded cases done in the exact same way as they have been performed prior to the implementation of the SRP for neurosurgery cases. Due to the alternation of cases, both the SRP and control cases will take place in the same period.
1618377|NCT02099305|Other|Adolescent Depression Awareness Program (ADAP)|Depression education curriculum delivered by trained school health education teachers or other school personnel
1618378|NCT02099292|Drug|Rituximab and DexaBEAM|combination treatment
1618379|NCT02099279|Device|echocardiography examination|patients underwent echocardiography examination
1618380|NCT02099266|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
1618381|NCT02099253|Drug|Dexmedetomidine 01|Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
1618382|NCT02099253|Drug|Dexmedetomidine 02|Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
1618383|NCT02099240|Drug|oral antibiotics|intravenous antibiotics with early switch to oral antibiotics, antibiotic type will be dependent on bacteria type
1618384|NCT02099240|Procedure|intravenous antibiotics|intravenous antibiotics for the full duration of therapy, antibiotic type will be dependent on bacteria type
2010848|NCT02818764|Procedure|Blood Draw|5 mL of blood from the patients preoperative, postoperative, 1 day and 2 days after surgery for a total of 20 mL.
2010849|NCT02818764|Procedure|Cerebral Spinal Fluid collection|Fluid collected at the time of dural puncture if patients will undergo spinal anesthesia
2010850|NCT02818764|Device|Electroencephalogram|Test used to detect abnormalities related to electrical activity of the brain will be done during surgery.
2010851|NCT02818751|Drug|Escitalopram|Patients being randomized to receive escitalopram.
1618392|NCT02099201|Drug|ACT-389949 40 mg|
1618393|NCT02099201|Drug|ACT-389949 200 mg|Predicted dose
1618394|NCT02099201|Drug|ACT-389949 800 mg|Predicted dose
1618395|NCT02099201|Drug|ACT-389949 (Group C1 dose to be selected)|
1618396|NCT02099201|Drug|ACT-389949 (Group C2 dose to be selected)|
1618397|NCT02099201|Drug|Placebo|
1618398|NCT02099188|Drug|Cisplatin|80 mg/m2 or 33 mg/m2/day or 100 mg/m2 - Concentrate for solution for infusion
1618399|NCT02099188|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
1618400|NCT02099188|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
1618401|NCT02099188|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
1618402|NCT02099188|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
1618403|NCT02099188|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
1618404|NCT02099188|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
1618405|NCT02099188|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.
Particle boost with ENI:
HR-PTV: carbon ions 18 - 21 Gy (relative biological effectiveness, RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.
Photons boost with ENI. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
1618406|NCT02099188|Radiation|Radiotherapy - Patients not needing ENI|"Treatment with particles. IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.
Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
1618407|NCT02099188|Radiation|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.
Particle boost. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.
Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
1618408|NCT02099175|Drug|Cisplatin|80 mg/m2 or 33 mg/m2 or 100 mg/m2 - Concentrate for solution for infusion.
1618409|NCT02099175|Drug|Docetaxel|75 mg/m2 - Concentrate for solution for infusion
1618410|NCT02099175|Drug|5-fluorouracil|800 mg/m2/day - Concentrate for solution for infusion
1618411|NCT02099175|Drug|Etoposide|150 mg/m2/day - Concentrate for solution for infusion
1618412|NCT02099175|Drug|Adriamycin|20 mg/m2/day - Powder for solution for infusion
1618413|NCT02099175|Drug|Ifosfamide|3000 mg/m2/day - Powder for solution for infusion
1618414|NCT02099175|Drug|Leucovorin|250 mg/m2/day - Powder for solution for infusion
1618415|NCT02099175|Radiation|Radiotherapy - Patients needing Elective Nodal Volume (ENI)|"Particle boost with ENI:
HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.
Photons boost with ENI:
HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
1618416|NCT02099175|Radiation|Radiotherapy - Patients not needing ENI|"Treatment with particles IR-PTV: this volume can be larger or equal to HR-PTV according to individual situations. 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed to IR-PTV with protontherapy with concomitant chemotherapy. HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy. The first 3 fractions may be given to the bigger IR-PTV.
Treatment with photons. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 54-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed"
1628391|NCT02022592|Drug|Midazolam|
1618417|NCT02099175|Radiation|Radiotherapy - Patients needing curative neck irradiation|"LR-PTV: 50.4-54 Gy with 1.8-2 Gy per fraction will be prescribed. This volume will always be treated with photons IMRT.
Particle boost:
HR-PTV: carbon ions 18 - 21 Gy (RBE) in fractions of 3 Gy (RBE) without concomitant chemotherapy IR-PTV: this volume is optional, if used it will receive the first 3 fractions i.e. 9 Gy (RBE) of the boost.
Photons boost. HR-PTV: at least 70 Gy with 2-2.12 Gy per fraction and 66 Gy at 2Gy per fraction in radical and postoperative setting will be prescribed. IR-PTV: 59.4-60 Gy with 1.8 Gy-2 Gy per fraction will be prescribed."
1618418|NCT02099162|Device|coronary stents|e.g. Sirolimus eluting stent, Paclitaxel-eluting stent, Zotarolimus-eluting stent, Everolimus-eluting stent, Biolimus eluting stent, EPC(endothelial progenitor cell) Capture stent, etc
1618419|NCT02099136|Procedure|UV Light Therapy|Undergo UV-irradiation
1618420|NCT02099136|Other|Placebo|Given PO
1618421|NCT02099136|Drug|Celecoxib|Given PO
1618422|NCT02099136|Procedure|Biopsy|Undergo skin biopsy
1618423|NCT02099136|Other|Imaging Biomarker Analysis|Correlative studies
1618424|NCT02099123|Drug|Atorvastatin|Atorvastatin 20 mg tablet
1618425|NCT02099123|Drug|Placebo (for Atorvastatin)|Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
2010852|NCT02818751|Other|Placebo|Patients being randomized to receive placebo.
2010853|NCT02817958|Drug|Chemotherapie TIP|Paclitaxel, ifosfamide and cisplatine
2010854|NCT02817841|Drug|15 mg E4/3 mg DRSP|15 mg estetrol and 3 mg drospirenone tablets administered once daily for 13 consecutive cycles following a 24/4-day regimen, i.e. one 15 mg E4/3 mg DRSP active tablet per day for 24 consecutive days followed by one placebo tablet per day for 4 consecutive days.
2010855|NCT02815982|Behavioral|NOURISH-T|Overweight/obesity family intervention
2010856|NCT02815982|Behavioral|Enhanced Usual Care|Publicly available overweight/obesity materials
2010857|NCT02815956|Device|percutaneous tibial nerve stimulation|
2010858|NCT02815956|Device|Placebo|
2010859|NCT02816138|Drug|Nicotine|Open-label transdermal nicotine patch
2010860|NCT02814175|Biological|adalimumab|
1618435|NCT02099097|Other|web-based video game (Quit IT)|
1618436|NCT02099097|Behavioral|Questionnaires|In order to maximize survey the response rate, patients will be mailed a reminder letter approximately two weeks before the 1 month follow up surveys are due. If the survey is not returned, patients will be sent additional reminders on the survey due date as well as two weeks past the due date.
1618437|NCT02099097|Other|Salvia sample|The investigators will inform patients prior to obtaining their self-reports that a saliva test or expired CO sample for those using NRT or electronic cigarettes will be performed to examine recent tobacco exposure.
1618438|NCT02099084|Drug|Teduglutide|Participants will receive Teduglutide 0.05 mg/kg/d administered subcutaneously.
1618439|NCT02099084|Drug|Placebo|Participants will receive placebo matching study drug, administered subcutaneously.
1618440|NCT02099071|Drug|ACT-389949 1 mg|
1618441|NCT02099071|Drug|ACT-389949 5 mg|
1618442|NCT02099071|Drug|ACT-389949 20 mg|
1618443|NCT02099071|Drug|ACT-389949 50 mg|
1618444|NCT02099071|Drug|ACT-389949 100 mg|
1618445|NCT02099071|Drug|ACT-389949 200 mg|
1618446|NCT02099071|Drug|ACT-389949 500 mg|
1618447|NCT02099071|Drug|ACT-389949 1000 mg|
1618448|NCT02099071|Drug|Placebo|
1618449|NCT02099058|Drug|ABBV-399|It is administered by infusion in 21-day dosing cycles.
1618450|NCT02099058|Drug|Erlotinib|It is administered orally everyday.
1618451|NCT02099058|Drug|Cetuximab|It is an intravenous infusion administered every 7 days.
1618452|NCT02099058|Drug|Bevacizumab|It is an intravenous infusion administered every 21 days.
1618453|NCT02099058|Drug|Nivolumab|It is an intravenous infusion administered every 14 days.
1618454|NCT02099058|Drug|ABBV-399|It is administered by infusion in 28-day dosing cycles.
1618455|NCT02099045|Device|Point of Care Ultrasonography|
1618456|NCT02099032|Other|3g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 3g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
1618457|NCT02099032|Other|5g milk polar lipid fortified cheese consumption|Women will have to consume daily 100g of a 5 g milk polar lipid fortified cheese product instead of usual cheese products during four weeks.
1618458|NCT02099032|Other|Unfortified cheese product consumption|Women will have to consume daily 100g of a unfortified cheese product instead of usual cheese products during four weeks
1618459|NCT02099006|Drug|Amitriptyline|Topical application of the drug at a 2% concentration in combination with 2% Baclofen
1618460|NCT02099006|Drug|Baclofen|Used topically at 2% concentration in combination with 2% amitriptyline
1618461|NCT02099006|Drug|Ketoprofen|To be applied topically at a 10% concentration
1618462|NCT02099006|Drug|Ketamine|To be applied topically at a 10% concentration
1618463|NCT02099006|Drug|Loperamide|To be applied topically at a 5% concentration
1618464|NCT02099006|Drug|Gabapentin|To be applied topically at a 6% concentration
1618465|NCT02099006|Drug|placebo|Compounding base to be used alone as a placebo
1618466|NCT02098993|Drug|Unfractionated heparin|
1618467|NCT02098980|Dietary Supplement|Vitamin D|
2010861|NCT02814175|Drug|methotrexate (MTX)|
2010862|NCT02813499|Other|CARE Rule|Evaluation of the clinical suspicion of myocardial infarction, calculation of CARE rule and troponin assay performed by the practitioner.
1618614|NCT02097849|Drug|dimethyl fumarate|Throughout the study participants will remain on their existing, stable dosing regimen of Tecfidera.
2010863|NCT02813356|Drug|naloxegol|non-interventional study where naloxegol is prescribed during normal clinical practice
2010864|NCT02813356|Drug|non-PAMORA|non-interventional study where patients are exposed to non-peripherally acting mu-opioid antagonists during the normal course of clinical practice
2010865|NCT02811783|Drug|Naloxone Hydrochloride Lotion, 0.5%|Topical TID for 2 weeks
2010866|NCT02811783|Drug|Placebo Lotion|Topical TID for 2 weeks
2010867|NCT02811237|Other|HESTIA|"Management based on the HESTIA rule:
If the rule is negative, meaning that patient meet none of the exclusion criteria of the rule, the proposed management will be outpatient care.
In the other cases, the patient will receive in-hospital care.
Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
1618471|NCT02098954|Drug|Gemcitabine platinum combined with erlotinib|patients will received a 28 days gemcitabine platinum combined with erlotinib scheme, after 4 cycles combined chemotherapy, patients will receive erlotinib for maintain treatment until progression disease.Gemcitabine for day 1 and day 8, 1250mg/m2. Platinum for day 1, 75mg/m2. Erlotinib for day 9-21 during combined chemotherapy, 150mg/day, then erlotinib should be used daily until patients develop progression disease.
1618472|NCT02098928|Behavioral|Hand-acupuncture|Use Hand-acupuncture directly. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
1618473|NCT02098928|Device|Electrico-acupuncture|Use Electrico-acupuncture device to therapy. Four acupoints:Tianshu,Zigong,Guanyuan and Sanyinjiao. Every patient are supposed to have 24 times acupuncture treatment. 30 minutes per time.
1618474|NCT02098915|Drug|intravenous metoclopramide|the experimental arm will receive intravenous metoclopramide dosed according to the current Sick Kids guidelines based upon weight and age
1618475|NCT02098915|Other|Placebo|equivalent volume to intravenous metoclopramide (dosed according to the current Sick Kids guidelines based upon weight and age ) of sterile sodium chloride 0.9% injection as a placebo
1618476|NCT02098902|Behavioral|Smart Moms Intervention|Reduction in child sugar-sweetened beverage consumption and maternal caloric beverage consumption, in addition to self-selected 100-calorie dietary and physical activity changes made by the mother to promote modest weight loss. Content will be delivered via one in-person group meeting, weekly online lessons, and weekly text messages. Mothers will self-monitor their weight and their own and their child's beverage consumption via text message every 2-3 days.
1618477|NCT02098889|Drug|hyoscine-N-butyl bromide(HBB)|A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB) versus placebo ( a single dose of 20ml IV NaCl) on the active phase of labor
1618478|NCT02098889|Drug|Saline|placebo ( a single dose of 20ml IV NaCl) versus A single dose intravenously(IV) 20 mg (20ml) hyoscine-N-butyl bromide(HBB)on the active phase of labor
1618479|NCT02098876|Device|Resolute Integrity Zotarolimus eluting stent|PCI with Resolute stent
1618480|NCT02098876|Device|Xience Xpedition everolimus eluting stent|PCI with Xience stent
1618481|NCT02098837|Drug|Dolutegravir|Dolutegravir 50mg once daily
1618482|NCT02098824|Drug|Galantamine|Single administration of capsule containing 16 mg of Galantamine
1618483|NCT02098824|Drug|Methylphenidate|Single administration of capsule containing 10 mg of Methylphenidate
1618484|NCT02098824|Drug|Placebo|Single administration of capsule containing placebo
1618485|NCT02098811|Device|1064nm Laser|Patient will be treated with 1064nm Laser prior to abdominoplasty
1618486|NCT02098811|Device|940nm Laser|Patient will be treated with 940nm Laser prior to abdominoplasty
1618487|NCT02098798|Procedure|HD Colonoscopy|High definition colonoscopy procedure in surveillance colonoscopy
1618488|NCT02098798|Procedure|HD Colonoscopy + iSCAN|
1618489|NCT02098798|Procedure|HD Colonoscopy + dye spray|
1618490|NCT02098785|Drug|Caffeine citrate|Oral solution
1618491|NCT02098772|Drug|Custodiol-N|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
1618492|NCT02098772|Drug|Custodiol|comparison of two cardioplegic solutions, Custodiol-N versus Custodiol, in aortic valve surgery
1618493|NCT02098759|Device|epilepsy early diagnosis protocol|Infants that have epileptiform discharges on vEEG and no clinical seizures, if their parents/caregivers give consent, will enter the randomized part of the study. Those children will be randomized into two groups: group A will be diagnosed as having epilepsy after subclinical (electroencephalographic) epileptiform discharges (based on epilepsy early diagnosis protocol), and the patients in group B will be diagnosed as epileptic after clinical seizures appear. All infants diagnosed with epilepsy will receive standard therapy with recommended first line antiepileptic drug starting from the day of diagnosis.
1618494|NCT02098746|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
1618495|NCT02098733|Drug|Pioglitazone/glimepiride|Pioglitazone/glimepiride combination tablets
1618496|NCT02098720|Drug|Conbercept|
1618497|NCT02098707|Other|Stabilometric Platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
1618498|NCT02098694|Other|Physiotherapy follow-up|"Physiotherapy consultation every 4 months containing assessment of the spine and its mobility, including axial joints, assessment of the patients activity profile.
Instruction in home-exercises and recommendations for optimization of activity profile. Information regarding the disease and the importance of physical activity and exercise."
1618499|NCT02098668|Other|Fertility treatment|Fertility treatment
1618500|NCT02098655|Other|Stabilometric platform|Stabilometric platform is a device used for assessment and training of balance basing on ground reaction force evaluation in static conditions.
1618501|NCT02098642|Other|MIRT|A 4-week cycle of physiotherapy that entailed three daily sessions, 5 days a week. The first session comprised cardiovascular warm-up activities, relaxation exercises, muscle-stretching, exercises to improve the range of motion of spinal, pelvic and scapular joints, and exercises to improve the functionality of abdominal muscles and postural changes in the supine position. The second session included exercises to improve balance and gait using a stabilometric platform with a visual cue and treadmill training associated with auditory and visual cues (treadmill plus). The last was an occupational therapy session with the aim of improving autonomy in daily living activities.
1618502|NCT02098642|Other|Mobilization of the metatarsophalangeal joint of the hallux|MIRT and mobilization of the metatarsophalangeal joint of the hallux
2010868|NCT02811237|Other|sPESI|"Management based on the simplified PESI score:
If the sPESI score =0, the proposed management will be outpatient care.
In the other cases, the patient will receive in-hospital care.
Any reason for management (hospitalization or outpatient treatment) not based on the recommendation will be explained and documented in the e-CRF."
1618615|NCT02097849|Biological|tetanus diphtheria toxoids vaccine|Administered as described in the treatment arm
1618506|NCT02098616|Drug|DCV/ASV/BMS-791325|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) orally twice a day
1618507|NCT02098616|Drug|DCV/ASV/BMS-791325 + RBV|Fixed dose combination (Daclatasvir 30 mg, Asunaprevir 200 mg and BMS-791325 75 mg) tablet orally twice a day plus weight based ribavirin orally twice a day
1618508|NCT02098603|Behavioral|Testing & Intervention|Intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, 30 minute weekly sessions incorporated into a team's usual work time or overtime activities.
1618509|NCT02098590|Biological|CPS-immunization|Subjects will be exposed 3 times to bites from 15 NF54 Plasmodium infected mosquitoes during each immunization, while taking chloroquin prophylaxis.
1618510|NCT02098590|Biological|malaria challenge infection, P. falciparum NF135.C10|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF135.C10 sporozoites.
1618511|NCT02098590|Biological|malaria challenge infection, P. falciparum NF166.C8|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF166.C8 sporozoites.
1618512|NCT02098590|Biological|malaria challenge infection, P. falciparum NF54|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum NF54 sporozoites.
1618513|NCT02098590|Drug|atovaquone/proguanil|All participants will be treated with atovaquone/proguanil when they develop a malaria infection or on day 28 after malaria challenge infection.
1618514|NCT02098577|Other|Crossover|Crossover cycle
1618515|NCT02098577|Other|Stabilometric Platform|This Stabilometric plate allows to assess the balance with an objective and reliable measurement, in both standard static or dynamic unstable condition
1618516|NCT02098564|Other|Joint mobility exercises hand therapy|Joint mobility exercises which are appropriate for their injury, both in the therapy setting and as a home exercise program
1618517|NCT02098564|Other|activity-based hand therapy|intervention involve joint mobility exercises which are appropriate for their injury and training with specific meaningful activities which they performed prior to the hand-related injury. Activity-based hand therapy will be performed both in the therapy setting and as a home exercise program.
1618518|NCT02098551|Other|SPT and APT|"All patients will be tested by skin prick testing (SPT: Histamine, buffer, commercial birch pollen extract, rBet v 1 (20 and 40 μg/ml), rBet v 1 fragment 1 (20 and 40 μg/ml), rBet v 1 fragment 2 (20 and 40 μg/ml), equimolar rBet v 1 fragment mix (20 and 40 μg/ml) in duplets.
Atopy patch testing (APT: birch pollen extract, rBet v 1:160 μg/application, rBet v 1 fragment 1: 160 μg/application, rBet v 1 fragment 2: 160 μg/ml, equimolar mix of rBet v 1 fragments: 160 μg/application; negative control with vaseline alone."
1618519|NCT02098538|Drug|Regorafenib|All eligible patients will receive a starting regorafenib dose of 120 mg daily taken orally for 3 weeks in a 4-week cycle. Patients for whom regorafenib dose reduction was not performed or required may have their treatment dose increased to the FDA-approved dose of 160 mg daily orally for 3 weeks in a 4-week cycle in cycle #2 or beyond (this is not mandatory). RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity
1618520|NCT02098512|Drug|Brentuximab Vedotin|"Brentuximab Vedotin will be administered every 21 days starting on or around Day +42 post allogeneic stem cell transplant for a TOTAL of 4 doses as outlined below:
42 (+/-7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1
63 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1
84 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max = 180 mg) IV x 1
105 (+/- 7 days) Brentuximab Vedotin 1.8 mg/kg (max=180 mg) IV x 1"
1618521|NCT02098512|Procedure|Allogeneic Stem Cell Transplantation|Following conditioning with chemotherapy, patients will receive stem cells from a matched related or unrelated donor.
1618522|NCT02098512|Drug|Reduced Intensity Conditioning|Patients will receive reduced intensity chemotherapy with one of three regimens: Busulfan/Fludarabine; Gemcitabine/Fludarabine/Melphalan; Fludarabine/Cyclophosphamide
1618523|NCT02098499|Drug|Haloperidol|5mg IV
1618524|NCT02098499|Drug|Metoclopramide 10mg|10mg IV
1618525|NCT02098499|Drug|Diphenhydramine|25mg IV
1618526|NCT02098486|Drug|Moxifloxacin|
1618527|NCT02098486|Drug|ceftriaxone|
1618528|NCT02098473|Drug|RPC4046|
1618529|NCT02098473|Drug|Placebo|
1618530|NCT02098460|Drug|Atorvastatin, Probucol, Cilostazol|
1618531|NCT02098447|Device|PrimeStim|
1618532|NCT02098434|Behavioral|Montreal Imaging Stress Task|Math task developed to induce a stress response in a laboratory setting
1618533|NCT02098421|Drug|Oxytocin|Use of oxytocin while the Foley bulb is in place
1618534|NCT02098408|Behavioral|Cognitive remediation|"Neurocognition will be trained using the NEAR model (Medalia et al. 2003), whereas the training of social cognitive skills will be by use of the SCIT manual (Social Cognition and Interaction Training) developed by Roberts et al. 2014.
The intervention consists of 24 group sessions taking place once a week (two hours) and additional neurocognitive training at home. Furthermore, there will be a total of 12 individual sessions aiming at bridging the cognitive training to the everyday functioning of the patients."
1618535|NCT02098408|Behavioral|Standard treatment|Patients allocated to the control condition are free to choose whatever standard treatment they are offered by the clinicians managing their treatment. Usually standard treatment consists of regular contact to health professionals in the in- and outpatient facilities in Copenhagen, Denmark, and encompass different kinds of supportive counselling.
1618616|NCT02097849|Biological|23-valent pneumococcal polysaccharide vaccine|Administered as described in the treatment arm
1618617|NCT02097849|Biological|meningococcal polysaccharide diphtheria conjugate vaccine (quadrivalent)|Administered as described in the treatment arm
1628861|NCT02018861|Drug|Etoposide|
1618536|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
1618537|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
1618538|NCT02098395|Drug|liraglutide|Subjects randomised to 1.8 mg liraglutide treatment as an add-on to their pre-trial insulin treatment will receive 0.6 mg liraglutide for 2 weeks followed by 1.2 mg liraglutide for 2 weeks. After 4 weeks of treatment subjects will receive 1.8 mg liraglutide for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
1618539|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
1618540|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
1618541|NCT02098395|Drug|placebo|Subjects randomised to 0.3 mL liraglutide placebo as an add-on to their pre-trial insulin treatment will receive 0.1 mL for 2 weeks followed by 0.2 mL for 2 weeks. After 4 weeks of liraglutide placebo, subjects will receive 0.3 mL for 22 weeks. Administered subcutaneously (s.c., under the skin) once daily.
1618542|NCT02098382|Device|Dilapan-S|Dilapan-S synthetic osmotic dilator for cervical ripening prior to labor induction
2010869|NCT02809326|Behavioral|17 week Exposure Therapy Control Arm|15 individual VR-assisted exposure therapy sessions and 14 psychoeducational group sessions conducted over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during the Psychoeducational phase.The psychoeducational group therapy, will include topics such as: DSM-IV criteria of PTSD, prevalence of PTSD, risk factors for PTSD, biological and conditioning models of PTSD, PTSD comorbidity, pharmacological treatment of PTSD, the impact of substance abuse, impairment in interpersonal functioning among veterans with PTSD, and issues related to anger control problems and suggested coping strategies
1618547|NCT02098356|Other|Low Bicarbonate|Low bicarbonate hemodialysis - 30 mEq/L dialysate bicarbonate
1618550|NCT02098330|Drug|Ginkgo biloba & Methylprednisolone|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month. Methylprednisolone 48 mg/day(per oral, once a day for first 9 days. And then methylprednisolone tapering was started every 2 days. The entire duration of methylprednisolone treatment was 14 days.
1618551|NCT02098330|Drug|Ginkgo biloba|Ginkgo biloba 160 mg/day (per oral, 80 mg twice a day) for 1 month.
1618552|NCT02098317|Drug|DHA plus Vitamin D|DHA 500 mg plus Vitamin D 800 IU
1618553|NCT02098317|Drug|Placebo|Placebo pearls mimicking pearls with DHA and Vitamin D
1618554|NCT02098304|Device|Calcivis Caries Activity Imaging System|Teeth imaged with the Calcivis Caries Activity Imaging System
1618555|NCT02098291|Drug|G17DT|
1618556|NCT02098278|Drug|CAT-2003|
1618557|NCT02098278|Drug|Placebo|
1618558|NCT02098265|Device|Transcranial Magnetic Stimulation|Electrical stimulation of the brain, through direct cortical stimulation
1618559|NCT02098265|Behavioral|Behavioral Assessments|These assessments will include measures of upper extremity motor assessments, standard stroke scales, and measures of activities of daily living.
1618560|NCT02098265|Other|Magnetic Resonance Imaging|A functional magnetic resonance image will be collected.
1618561|NCT02098265|Other|EEG|EEG electrodes will be attached to the subject's scalp using a standard, commercially available electrode cap. Proper electrode placement is made according to the international 10-20 system, ensuring complete electrode coverage over sensorimotor cortex.
1618562|NCT02098252|Procedure|Neurosurgery|Surgical resection to be used when the lesion is considered by a multidisciplinary team to be safely 'operable'.
1618563|NCT02098252|Radiation|Radiation therapy|when the AVM is smaller than 3 cm, and considered to not be safely 'operable'.
1618564|NCT02098252|Procedure|Embolization|Curative embolization, when the lesion is considered curable by embolization.
1618565|NCT02098239|Drug|G17DT|
1618566|NCT02098213|Other|Immediate spa treatment|soon after randomization: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all participating of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
1618567|NCT02098213|Other|Late Spa treatment|soon after 4,5 months visit: Spa treatment of 3 weeks. Spa treatment : that best adapted to the concerned pathology and common to all of spa resorts (walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower etc)
1618568|NCT02098200|Device|TriCinch System|Percutaneous treatment of Tricuspid Regurgitation
1618569|NCT02098187|Drug|Below target dose MP-3180|MP-3180 0.5 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
1618570|NCT02098187|Drug|At target dose MP-3180|MP-3180 1 µmol/kg (0.186 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
1618571|NCT02098187|Drug|2 times above target dose MP-3180|MP-3180 2 µmol/kg (0.744 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
1618572|NCT02098187|Drug|4 times above target dose MP-3180|MP-3180 4 µmol/kg (1.488 mg/kg) dose (fluorescent tracer agent) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
1619543|NCT02090738|Drug|Standard regimen group|
1618573|NCT02098187|Device|ORFM prototype|The Optical Renal Function Monitor (ORFM) investigational device noninvasively monitors fluorescent light emission from an exogenous tracer agent over time. Prior to administration of MP-3180 and iohexol, ORFM sensor probes were affixed to each of the participants via standard adhesive pads to four locations: forehead, sternum, upper inner arm, side trunk. The administration of the MP-3180 infusion and iohexol infusion occurred at least 15 minutes after the start of the data acquisition software.
1618574|NCT02098187|Other|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) (comparator agent) was administered by IV injection over 2 minutes after MP-3180 injection, followed by a 10 mL saline flush IV over 2 minutes.
1618575|NCT02098174|Drug|MP-3180|MP-3180 (1 µmol/kg or 0.372 mg/kg) (fluorescent tracer agent) was administered by IV injection (2.5 mL to 3.5 mL for participant weights of 70 kg to 91 kg) over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
1618576|NCT02098174|Other|Iohexol comparator|Iohexol (Omnipaque 300, 5 mL) was administered by IV injection over 2 minutes, followed by a 10 mL saline flush IV over 2 minutes.
1618580|NCT02098148|Drug|Xenon|
1618581|NCT02098148|Drug|Placebo|
1618582|NCT02098135|Device|ArmeoSenso|Virtual realty therapy with a touchscreen computer and movement sensors, over 42 days.
1618583|NCT02098109|Drug|XM02 Filgrastim|
1618584|NCT02098109|Drug|Filgrastim|
1618585|NCT02098109|Procedure|Apheresis|
1618586|NCT02098109|Drug|Plerixafor|
1618587|NCT02098109|Procedure|Stem Cell Transplant|
1618588|NCT02098096|Other|Negative Work|"Exercise will be performed twice per week for 12 weeks and exercise intensity will be progressed in three phases. These phases are:
Familiarization
Acclimatization
Progression
Exercise volume will be 3 sets of 10 repetitions (progressing to 4 sets at Week 6) for the knee flexors and extensors.
All exercise will be supervised by a physical therapist and performed on a Biodex isokinetic dynamometer."
1618589|NCT02098096|Other|Stretching|Home exercise program will be performed by the Placebo Comparator group and feature stretching over the 12 week intervention period.
1618590|NCT02098057|Dietary Supplement|Gluten Healthy|Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks.
1618591|NCT02098057|Drug|Placebo|"A total of 24 patients with NCGS and 12 healthy controls will be recruited for this study. The 24 patients with NCGS will be randomized to receive one of two diets (GFD or GCD) in a 1:1 ratio
Assessment of current diet and amount of gluten consumed will be determined by the dietitian and by means of a questionnaire at baseline. Subjects will have a 2-week run in period, in which they will continue or initiate a gluten free diet plan prepared by the dietitians. After the run-in period, participants will be randomized to either a gluten containing diet (GCD) or placebo (GFD) for 4 weeks."
1618592|NCT02098031|Other|Improving nutrition knowledge among mothers|
1618593|NCT02098018|Behavioral|Program 2|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
1618594|NCT02098018|Behavioral|Program 1|A well-established behavioral method for reducing stress. To maintain blinding, details will be given to participants after randomization.
1618595|NCT02098005|Other|usual care evidence-based physiotherapy|Arm 1 (i.e., the control group) will be subjected to a control intervention, including back/neck school and general exercises. 3 sessions of education (session 1: group session; session 2: online module; session 3: individual session) will be given by a physiotherapist, followed by 15 sessions of traditional physiotherapy and general exercises. The 18 sessions will be spread over a period of 3 months.
1618596|NCT02098005|Other|modern neuroscience approach|Arm 2 (i.e., the experimental group) will receive pain neuroscience education (3 sessions of education), followed by 15 sessions of cognition-targeted motor control training (15 sessions). The 18 sessions will be spread over a period of 3 months.
1618597|NCT02097992|Drug|SD placebo and MD roflumilast then MD placebo|SD placebo and MD roflumilast then MD placebo
1618598|NCT02097992|Drug|SD placebo and MD placebo then MD roflumilast|SD placebo and MD placebo then MD roflumilast
1618599|NCT02097992|Drug|SD roflumilast and MD placebo then MD roflumilast|SD roflumilast and MD placebo then MD roflumilast.
1618600|NCT02097992|Drug|SD roflumilast and MD roflumilast then MD placebo|SD roflumilast and MD roflumilast then MD placebo
1618601|NCT02097979|Behavioral|Glaucoma Educational Intervention|
1618602|NCT02097966|Drug|Daclatasvir|
1618603|NCT02097966|Drug|Sofosbuvir|
1618604|NCT02097966|Drug|Ribavirin|
1618605|NCT02097953|Drug|Daptomycin|
1618606|NCT02097953|Drug|Rifampin|
1618607|NCT02097940|Other|proprioceptive exercises|Exercises with movements, jumping and imbalance.
1618608|NCT02097927|Behavioral|Mango-flavour beverage|The study will be a 3-way crossover design: it will assess the impact of a high-energy, sensory-enhanced beverage on energy intake through ad libitum food consumption and subjective feeling of appetite using visual analogue scales (VAS) compared to 2 control beverages following repeated exposures. Each participant will consume each beverage 10 times. This includes 2 satiety-testing sessions on site at Leatherhead Food Research, and 8 occasions consuming the product as a mid-morning snack during the participants' normal routine. Each participant will attend the Nutrition Unit on 6 different occasions before and after repeated exposures to the beverages at home. There will be a two-week washout period in which none of the beverages are consumed between the different beverage manipulations.
1618609|NCT02097914|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
1618610|NCT02097901|Procedure|Microfracture|Rotator Cuff Repair AND Microfracture
1618611|NCT02097901|Procedure|NO microfracture|Rotator Cuff Repair without microfracture
1618618|NCT02097849|Drug|non-pegylated interferon|Throughout the study participants will remain on their existing, stable dosing regimen of non-pegylated IFN.
1618619|NCT02097836|Device|Targeted Training|Custom training devices were imported from The Movement Centre for research purposes. The typical course of treatment involves loaning the customized equipment to each family for use in their home or in their child's educational setting. Training occurs once daily usually for 30-45 minutes. This is done 5 or 6 days per week. Training programs typically involve playing with balls or balloons or video games that motivate the child to hold the head erect and to wave the arms and hands and move the upper body.
1618620|NCT02097823|Drug|Olanzapine|
1618621|NCT02097823|Drug|Aprepitant|
1618622|NCT02097810|Drug|Entrectinib|
1618623|NCT02097797|Other|Fecal Transplantation|Fecal microbiota (50-100g of stool from donor resuspended in 250-350ml of physiological serum and filtered) given by infusion in coecum during colonoscopy
1618624|NCT02097797|Other|Sham Transplantation|250-350ml of physiological serum given by infusion in coecum during colonoscopy
1618625|NCT02097784|Procedure|Echocardiography|
1618626|NCT02097771|Device|LMA SupremeTM|
1618627|NCT02097771|Device|AuraOnceTM|
1618628|NCT02097758|Device|Transcatheter device closure|"Closure of atrial septal defect with device
choosing device size with 3D image and the formula
we do not use sizing balloon for choosing of the device size"
1618629|NCT02097745|Drug|methotrexate|a 10-25 mg stable dose given orally or parenterally throughout study
1618630|NCT02097745|Drug|rituximab [MabThera/Rituxan]|1 g given by intravenous infusion on Days 1 and 15 of each treatment course
1618631|NCT02097732|Drug|Ipilimumab|Ipilimumab 3mg/kg given intravenously over 90 minutes, every 3 weeks for a total of 4 doses.
1618632|NCT02097732|Procedure|Stereotactic Radiosurgery|Stereotactic radiosurgery is a type of focused radiation therapy. It requires the placement of a metal frame on the head for several hours.
1618633|NCT02097719|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
1618634|NCT02097719|Drug|travoprost 0.004%|Travoprost 0.004% administered to both eyes once daily for 12 weeks.
1618635|NCT02097719|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
1618636|NCT02097719|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
1618637|NCT02097706|Drug|NMDA receptor antagonist (active drug)|
1618638|NCT02097706|Other|Lactose packed capsule (inert/inactive arm)|
1618639|NCT02097680|Drug|Letrozole|One Letrozole 2.5 mg capsule every two days during four months
1618640|NCT02097680|Drug|Placebo|One placebo capsule every two days during four months
1618641|NCT02097641|Biological|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously over approximately 60-80 minutes.
1618642|NCT02097641|Biological|Plasma-Lyte A|Plasma-Lyte A placebo will be administered intravenously over approximately 60-80 minutes.
1618643|NCT02097628|Procedure|tidal volume|In the volume controlled ventilation group using laryngeal mask airway Guardian,a tidal volume of 8-12ml/kg,respiratory rate12-16bpm.
1618644|NCT02097628|Procedure|peak airway pressure|In the pressure controlled ventilation group using laryngeal mask airway Guardian,a peak airway pressure that provides a tidal volume of 8-12ml/kg with an upper limit of 35 centimeter water column,respiratory rate12-16bpm.
1618645|NCT02097615|Procedure|chlorhexidine gluconate|chlorhexidine gluconate spray of 0.125% . Application in the area of the ulcer every 24 hours for six weeks
1618646|NCT02097615|Other|deionized water|application every 24 hours six weeks
1618647|NCT02097589|Drug|Atorvastatin|10-person arm receiving treatment for 28 days: 40 mg atorvastatin, taken orally, once daily, for 28 days.
1618648|NCT02097589|Drug|Pneumovax 23|Pneumovax 23 injected once, intramuscularly at Day 7.
1618649|NCT02097589|Other|Placebo (lactose pill)|10-person arm receiving treatment for 28 days: Placebo (lactose pill), taken orally, once daily for 28 days.
1618650|NCT02097576|Other|Saline mixed with Manuka Honey|Saline mixed with MH nasal rinses participants will be instructed how to mix a rounded teaspoon of MH (Wedderspoon® 100% Raw Manuka Honey Active 16+) with 4-6 oz of lukewarm distilled or previously boiled water, to add along with distilled or previously boiled water and the NeilMed® Sinus Rinse packet to the rinse bottle to a final volume of 240 ml. Participants will be instructed to rinse slowly with the MH/saline rinse mixture to maximize contact time with the MH/saline mixture.
1618651|NCT02097576|Other|NeilMed Saline Sinus Rinse|Saline nasal rinses will be performed using a NeilMed® Sinus Rinse 240 ml bottle and one NeilMed® packet containing sodium chloride/sodium bicarbonate at a concentration to make an isotonic solution when mixed with distilled or previously boiled water.
1618652|NCT02097563|Behavioral|High Intensity Training|This is a training method involving a live workshop followed by high intensity technical consultation.
1618653|NCT02097563|Behavioral|Low Intensity Training|Clinicians complete an online workshop in family-focused therapy, followed by technical consultation sessions after every third session.
1618654|NCT02097550|Other|eHealth Intervention|Patients randomized to this arm will receive eHealth materials every 2-4 weeks over the 12-month intervention. However, the exact nature of timing, dose, and delivery channel will be informed by the formative research.
1618655|NCT02097537|Drug|Methacholine Chloride (SK-1211)|
1618656|NCT02097524|Drug|Sarilumab|
1618657|NCT02097524|Drug|Tocilizumab|
1618661|NCT02097498|Other|Directed feedback|Group will receive feedback from an airway management expert while the paramedic review their baseline simulation scenario through recorded video
1618662|NCT02097498|Other|Basic Videolaryngoscopy Videos|Group will watch a series of educational videos related to common airway management errors.
1618663|NCT02097485|Drug|Abametapir Lotion 0.74% w/w|200mL abametapir lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
1630830|NCT02002611|Drug|Lobeglitazone|
1618664|NCT02097485|Drug|Vehicle Lotion|control to abametapir: 200mL Vehicle Lotion topically administered to the scalp and hair and once fully saturated left for 10 minutes and then washed out thoroughly with warm water.
1618665|NCT02097472|Biological|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine adsorbed to Alum
1618666|NCT02097472|Biological|pneumococcal polysaccharide conjugate vaccine (adsorbed)|"1 dose (0.5 mL) contains:
1 μg of each of the following pneumococcal polysaccharide serotypes:
1, 5, 6B, 7F, 9V, 14, and 23 F
And 3 μg of the following pneumococcal polysaccharide serotypes:
4, 18C and 19F.
The serotypes are conjugated to either:
protein D (derived from Non-Typeable Haemophilus influenzae) carrier protein, tetanus toxoid carrier protein or diphtheria toxoid carrier protein"
1618667|NCT02097472|Biological|Diptheria Pertussis Tetanus Hep B Haemophilus b Conjugate|"Each PFS contains 0.5 ml (single dose):
Diphtheria Toxoid 20 Lf to 30 Lf Tetanus Toxoid 2.5 Lf to 10 Lf B. Pertussis 4 IU HBsAg (rDNA) 10 mcg Purified capsular HIB Polysaccharide (PRP) Conjugated to Tetanus Toxoid (carrier protein) 10 mcg Adsorbed on Aluminium Phosphate, AL+++ 1.25 mg Preservative: Thiomersal 0.005 % Dose: O.5ml by intramuscular injection."
1618668|NCT02097472|Other|Saline|0.9% Sodium Chloride Injection, USP
1618669|NCT02097459|Drug|Anastrozole|
1618670|NCT02097459|Drug|Tamoxifen|
1618671|NCT02097459|Drug|Toremifene|
1618672|NCT02097446|Device|Guardix-FL|
1618673|NCT02097446|Device|Interceed|
1618674|NCT02097433|Drug|Dacomitinib|A single 45 mg oral dose of Dacomitinib will be administered under fasted conditions to healthy Chinese volunteers
1618675|NCT02097420|Device|Mitral valve replacement SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve|Implantation of the SJM™ Masters HP™ 15mm Rotatable Mechanical Heart Valve in the mitral and aortic positions
1618676|NCT02097407|Drug|Group C : Saline + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of normal saline. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group C received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.
After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment"
1618677|NCT02097407|Drug|Group D : Dexmedetomidine + propofol group|"All patients were pre-oxygenated with 100% oxygen with spontaneous breathing for 3 min before the end of loading of dexmedetomidine. Anaesthesia was induced with predetermined effect-site propofol concentrations using a target-controlled infusion device (Orchestra; Fresenius-Vial, Brezins, France). The first patient in Group D received an effect-site propofol concentration of 3 and 5 µg mL-1, respectively, over 5 min.
After equilibration of the plasma and effect-site propofol concentrations, i-gel (size 4 for patients weighing 50-90 kg, size 3 for patients weighing 30-50 kg) was inserted using the standard technique by a single anaesthesiologist staff member with expertise in i-gel insertion and who entered the operating room immediately before i-gel insertion to blind him to the group assignment."
1618678|NCT02097394|Drug|Combizym|Combizym( 1 tablet, po, tid)
1618679|NCT02097394|Drug|Bifidobacteri|Bifidobacteri (2 tablet, po, tid)
1618680|NCT02097394|Drug|Combizym + Bifidobacteri|Combizym( 1 tablet, po, tid) + Bifidobacteri (2 tablet, po, tid)
1618681|NCT02097394|Drug|control|have no any drug
1618682|NCT02097381|Drug|Tenofovir-Emtricitabine plus Lopinavir/Ritonavir or Darunavir/Ritonavir|"Conventional antiretroviral therapy started in naïve patients for antiretroviral treatment that met the criteria to start cART according to International Guidelines.
The antiretroviral treatment consisted in a tenofovir-emtricitabine NRTI backbone (TDF/FTC, 300/200 mg/ml, once a day) plus boosted protease inhibitor, lopinavir/ritonavir (LPV/r, 400/100 mg twice a day) or darunavir/ritonavir (DRV/r 800/100mg once a day)."
1618683|NCT02097368|Procedure|tongue strength measurement|tongue strength measurement
1618684|NCT02097368|Procedure|respiratory function measurement|respiratory function measurement
1618685|NCT02097368|Procedure|swallowing tests|swallowing tests
1618686|NCT02097368|Other|Magnetic resonance imaging|Magnetic resonance imaging
1618687|NCT02097355|Other|TriVox for clinical care|Use TriVox disease modules to manage patients
1618688|NCT02097342|Drug|Linagliptin|Tablet Linagliptin (5mg) per oral, once daily will be given to 10 patients for 6 months
1618689|NCT02097342|Drug|Placebo|Tablet placebo per oral, once daily will be given to 10 patients for 6 months
1618690|NCT02097342|Drug|Voglibose|Tablet Voglibose (0.2mg) per oral thrice daily(with meals) to 10 patients for 6 months
1618691|NCT02097329|Drug|palbociclib commercial free base|125 mg oral capsule single dose
1618692|NCT02097329|Drug|famotidine|20 mg oral tablet 10 hours before and 2 hours after palbociclib
1618693|NCT02097329|Drug|rabeprazole|2 x 20 mg oral tablets daily for 6 days then on 7th day, 4 hours after palbociclib
1618694|NCT02097329|Drug|palbociclib commercial free base|125 mg oral capsule single dose
1618695|NCT02097329|Drug|antacid|30 mL orally once (2h before palbociclib)
1618696|NCT02097329|Drug|antacid|30 mL orally once (2h after palbociclib)
1618697|NCT02097316|Device|JewelPump|
1618698|NCT02097316|Device|usual insulin pump|
1618699|NCT02097303|Drug|Concurrent use of Radium Ra 223 dichloride and Abiraterone Acetate plus Prednisone|Radium Ra 223 dichloride - A targeted alpha particle-emitting pharmaceutical (a radiopharmaceutical drug) is a ready-to-use solution for intravenous injection containing the drug substance radium dichloride. The active moiety is the alpha particle emitting nuclide Ra-223, present as a divalent cation (223Ra2+) and Abiraterone Acetate - A CYP17 inhibitor, indicated in combination with prednisone for the treatment of subjects with metastatic castration-resistant prostate cancer. Administration of Abiraterone Acetate may result in mineralocorticoid-related adverse events (AEs), due to CYP17 inhibition. Therefore, Abiraterone Acetate is administered in combination with Prednisone to reduce the frequency of these AEs.
1618700|NCT02097290|Device|CRT-D|For all subjects with the AUTOGEN CRT-D, the autothreshold algorithms will be evaluated
1618701|NCT02097277|Biological|BMS-986036|
1618702|NCT02097277|Biological|Placebo (Matching with BMS-986036)|
1619544|NCT02090725|Drug|3-4 Diaminopyridine|
1618703|NCT02097264|Drug|NNC0109-0012|Solution for injection administered subcutaneously (s.c. - under the skin). 240 mg NNC0109-0012 will be administered weekly for 12 weeks
1618704|NCT02097264|Drug|Adalimumab|Solution for injection administered subcutaneously (s.c. - under the skin). Administered every other week for 12 weeks; Each active treatment involves 1 (one) s.c. injection of adalimumab 40 mg/0,8 mL solution for injection for paediatric use (Humira®)
1618705|NCT02097264|Drug|placebo|"Solution for injection administered subcutaneously (s.c. - under the skin).
1 active adalimumab injection and 2 placebo injections per active treatment (every other week), and 3 placebo injections on placebo visits (alternative weeks)."
1618706|NCT02097251|Drug|UX003|Open Label
1618707|NCT02097238|Drug|Eribulin Mesylate|Given IV
1618708|NCT02097238|Other|Pharmacological Study|Correlative studies
1618709|NCT02097225|Drug|Dabrafenib|Given PO
1618710|NCT02097225|Other|Laboratory Biomarker Analysis|Correlative studies
1618711|NCT02097225|Drug|Onalespib|Given IV
1618712|NCT02097225|Other|Pharmacological Study|Correlative studies
1618713|NCT02097225|Drug|Trametinib|Given PO
1618714|NCT02097199|Other|Increased sports workload|"At least 150 minutes of moderate or 75 minutes of vigorous exercise per week. The Recommendations for Adults From the American College of Sports Medicine and the American Heart Association clearly define physical exercise intensity levels. The present study follows these recommendations. Consequently, moderate physical activity can be reached by e.g. quick walking, slow bicycling, slow swimming...; it is also possible to reach the expected workload by engaging in vigorous exercise (e.g. jogging/running, quick swimming, playing soccer/tennis...). The gain in performance will objectified by performing a bicycle stress test at the beginning and the end of the study."
1618715|NCT02097186|Procedure|Remote ischaemic preconditioning|Ischaemic preconditioning is a phenomenon whereby a brief period of non-lethal ischaemia in a tissue renders it resistant to the effects of a subsequent much longer ischaemic insult. Remote ischaemic preconditioning works on the theory that brief ischaemia in one tissue could confer protection on distant organs.
1618716|NCT02097173|Drug|Methotrexate|
1618717|NCT02097160|Other|Vitamin D fortified yogurt and cheese products|
1618718|NCT02097160|Other|Control Group 1|
1618719|NCT02097147|Drug|Vilazodone 20 mg|Oral administration, once per day.
1618720|NCT02097147|Drug|Vilazodone 40 mg|Oral administration, once per day.
1618721|NCT02097147|Drug|Paroxetine 20 mg|Oral administration, once per day.
1618722|NCT02097147|Drug|Placebo|Oral administration, once per day.
1618723|NCT02097134|Drug|Melphalan|Given IA
1618724|NCT02097121|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
1618725|NCT02097108|Drug|Raltegravir|
1618726|NCT02097082|Device|STANZA Drug-eluting resorbable Scaffold|
1618727|NCT02097069|Dietary Supplement|Folic acid|Folic acid 400 mcg/day
1618728|NCT02097069|Dietary Supplement|Myo-inositol|myo-inositol 2000 mg twice a day
1618729|NCT02097069|Dietary Supplement|D-Chiro-inositol|D-chiro inositol 250 mg twice a day
1618730|NCT02097069|Dietary Supplement|Myo-inositol plus D-chiro inositol|Myo-inositol plus D-chiro inositol 550mg/13,8 mg twice a day
1618731|NCT02097056|Drug|Donepezil HCL|Donepezil HCl 23 mg once daily, just before bed, for 24 weeks
1618732|NCT02097043|Drug|DA-7218|
1618733|NCT02097043|Drug|Placebo|
1618734|NCT02097030|Device|filcon II 3|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
1618735|NCT02097030|Device|etafilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
1618736|NCT02097030|Device|nelfilcon A|Participants wear a first pair of lenses for three days and then crossover and wear a second pair of lenses for three days.
1618737|NCT02097017|Drug|Lidocaine|will local application of lidocaine to the cervix alleviate pain of laminaria insertion
1618738|NCT02097017|Other|placebo comparator|
1618739|NCT02097004|Biological|Peginterferon alfa-2a|once weekly 180 μg subcutaneous injection for 48 weeks
1618740|NCT02097004|Biological|HBV vaccination|1.0 mL (20 μg) intramuscular injection at 4, 8, 12 and 28 weeks
1618741|NCT02097004|Drug|Entecavir|Continue Entecavir(0.5mg) for 100 weeks
1618742|NCT02096991|Other|Can 1|drink the beverage in a can and a glass bottle
1618743|NCT02096991|Other|Can 2|Consume two canned beverage
1618744|NCT02096991|Other|Glass|consume two glass bottled beverage
1618745|NCT02096978|Procedure|Preparing the osteotomy to accept a standard implant device|Preparing the osteotomy with one of two randomly assigned protocols
1618746|NCT02096965|Drug|Tolvaptan|Patients will receive daily dose of 45 mg (30 mg at 8 AM and 15 mg at 4 PM).
1618747|NCT02096965|Drug|Placebo|Patients will receive daily dose at 8 AM and at 4 PM.
1618748|NCT02096952|Drug|Methylphenidate extended-release liquid formulation|
1618749|NCT02096939|Procedure|Adrenal extirpation|
1618750|NCT02096939|Drug|Antihypertensive medication|
1618751|NCT02096926|Drug|Placebo|
1618752|NCT02096926|Drug|Ibuprofen|400 mg PO
1618755|NCT02096900|Drug|zolpidem|Zolpidem will be given one time at 0.25 mg/kg pre-operatively
1618756|NCT02096900|Drug|Midazolam|
1618757|NCT02096887|Behavioral|Patient Education|"Patient Education using the following two instruments:
Framingham Risk Score calculator:
Know your numbers patient booklet"
1619579|NCT02090400|Drug|Bazedoxifene|20 mg Oral daily for 12 months
1618758|NCT02096874|Drug|Bevacizumab|Intravitreal injection of 1.25mg/0.05 cc each 5 weeks for the first 3 months then PRN for six month
1618759|NCT02096861|Biological|CT-P13|CT-P13 (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
1618760|NCT02096861|Biological|Remicade|Remicade (5 mg/kg) by intravenous (IV) infusion administered as a 2 hour IV infusion per dose
1618761|NCT02096835|Device|Transcutaneous electrical acupoint stimulation|A surface electrode will be applied to the P6 acupoint on the dominant upper extremity, located approximately 3cm proximal to the distal wrist crease between the tendons of the flexor carpi radialis and the palmaris longus, and a negative surface electrode placed on the opposing dorsum aspect of the forearm.
1618762|NCT02096835|Device|Sham transcutaneous electrical acupoint stimulation|The same TEAS protocol will be applied unless silicone covers will be attached to both electrodes. The device will also be turned on during the procedure.
1618763|NCT02096835|Drug|Tropisetron|will be given at the start of skin closure
1618764|NCT02096835|Drug|Dexamethasone|will be given after induction
1618765|NCT02096822|Behavioral|Facilitated tucking + non-nutritive sucking|
1618766|NCT02096822|Other|non-nutritive sucking|
1618767|NCT02096809|Procedure|One week loading of Bone Anchored Hearing Aid (BAHA)|Patients in this arm will be fitted with the BAHA one week after surgery.
1618768|NCT02096809|Device|Cochlear Baha BI300/BA400 Implant System|
1618769|NCT02096783|Other|informational intervention|Given scripted intervention
1618770|NCT02096783|Other|counseling intervention|Given standard counseling
1618771|NCT02096783|Other|questionnaire administration|Ancillary studies
1618772|NCT02096757|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
1618773|NCT02096757|Other|Pro-Omega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day 2 weeks prior to surgery and continued for 4 weeks after
1618774|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Oppanol
1618775|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
1618776|NCT02096744|Drug|Intervention 1: Catapres-TTS-3|Catapres-TTS-3 Oppanol
1618777|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
1618778|NCT02096744|Drug|Catapres-TTS-1|Catapres-TTS-1 Vistanex
1618779|NCT02096744|Drug|Intervention 2: Catapres-TTS-3|Catapres-TTS-3 Vistanex
1618780|NCT02096718|Drug|Afatinib healthy|
1618781|NCT02096718|Drug|Afatinib severe renally impaired|
1618782|NCT02096718|Drug|Afatinib moderate renally impaired|
1618783|NCT02096705|Drug|Dapagliflozin|Tablet
1618784|NCT02096705|Drug|Dapagliflozin Placebo|Tablet
1618785|NCT02096692|Device|Patients with a ProMRI ICD System|Tachycardia Fast Heart Beat
1618786|NCT02096692|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine
1618787|NCT02096679|Drug|AZD9291|Volunteer will receive a single oral dose of 20 mg [14C]-AZD9291 as a solution on Day 1
1618788|NCT02096666|Drug|AMG 337|Phase 1- AMG 337 150 mg, 200mg and 300 mg orally daily. Additional 150 mg and 200 mg orally twice daily. Phase 2- AMG 337 (dose determined by Phase 1)
1618789|NCT02096653|Procedure|X-ray SI joint steroid injection|Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
1618790|NCT02096653|Procedure|Landmark-guided SI steroid injection|Injection of steroid into the joint area based on palpation. The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
1618791|NCT02096640|Procedure|Type of surgical teqnique for tracheostomy|
1618792|NCT02096614|Drug|TBI-1201|TBI-1201(5*10^8 or 5*10^9) is administered.
1618793|NCT02096614|Drug|Cyclophosphamide|Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1201
1618794|NCT02096614|Drug|Fludarabine|Fludarabine (20mg/m2 x 5 days Intravenous(IV)) is administered as pre-treatment medication of TBI-1201 in combination with cyclophosphamide.
1618795|NCT02096601|Drug|Levodopa and carbidopa SC solution|Levodopa and carbidopa SC solution
1618796|NCT02096601|Drug|Oral levodopa and carbidopa|Oral levodopa and carbidopa
1618797|NCT02096588|Drug|Simvastatin|Simvastatin will be administered on an outpatient basis orally at a dose of 40 mg once daily.
1618798|NCT02096588|Drug|Doxorubicin/cyclophosphamide|The standard chemotherapy regimen that must be planned for all participants in order to take part in this study. The regimen is given every 2 or 3 weeks per standard of care, at the direction of the treating physician.
1618799|NCT02096575|Other|Nitrous oxide administration|"All participants will receive 800 mg of oral ibuprofen 30 minutes pre-operatively. The NO group will get two placebo pills and the standard care group will get one 5/325 mg Vicodin, and 1 mg of Ativan 30 minutes before the procedure. The standard care group will get oxygen intraoperatively.
NO or oxygen will be administered via a scented nasal mask to blind patients to the intervention.
All patients will get local anesthesia via a standardized PCB."
1618800|NCT02096562|Other|Patients use compression stockings for 10 days after surgery|patients wear compression stocking for 24 hours in the first 2 days after surgery and for at least 8 hours at day 3-10 after surgery
1618801|NCT02096562|Other|normal therapy - no compression stockings|the patients receive the common therapy according to S2 guidelines
1618802|NCT02096536|Drug|Vancomycin|vancomycin administration based on decision of treating physician
1618803|NCT02096523|Other|Blood collection for platelet protein samples|
1618804|NCT02096510|Drug|Solu-Cortef|administration by pump for minimum 2 weeks
1618805|NCT02096510|Drug|Cortef|tablet treatment 2 ro 3 times per day for 14 days
1618806|NCT02096484|Behavioral|Group Metacognitive Therapy|
1618807|NCT02096484|Behavioral|Mindfulness Meditation Therapy|
1618809|NCT02096458|Drug|Dexlansoprazole|Dexlansoprazole delayed-release orally disintegrating tablets
1618810|NCT02096445|Device|robot-assisted neurocognitive therapy of hand function|2 degrees-of-freedom hand rehabilitation robot to train fine motor skills during grasping and forearm rotation.
1618939|NCT02095444|Drug|Menstrual blood stem cells|10*7 cells/kg, intravenous injection for 4 times during two weeks
1618811|NCT02096445|Other|Conventional neurocognitive rehabilitation|Use sensory perception (tactile, proprioception but not vision!) to solve a by the therapist guided (passive) or patient controlled (active) therapy task, e.g. discrimination/identification of different spring resistances, sponges, different sized blocks, etc.
1618812|NCT02096432|Behavioral|Behavior Activation|Behavioral Activation includes the following components: empowering education, referral to treatment, care Management, and behavior activation
1618813|NCT02096432|Behavioral|Usual Community Care|Community standard care as usual
1618814|NCT02096419|Drug|Clopidogrel dose adjustment|"Patients in the interventional arm will receive clopidogrel dose adjustment to maintain optimal platelet reactivity determined by Multiplate function analyzer (19-46U).
They will undergo platelet function testing on day 1,2,3,7,30 and month 2,3,6,9 and 12.
On first two measurements patients will receive up to 2 additional clopidogrel loading doses (600 mg) and put on 150 mg and 75 mg a day if platelet reactivity >18U and <18U, respectively. Maintenance dose will be determined on following measurements - increased by 75 mg if >46U; not changed if 19-46U; decreased by 75 mg if <19U. Minimal dose - 75 mg; maximal dose 300 mg (for patients >70 years 150 mg)"
1618815|NCT02096406|Drug|ACE/ARB continuation|ACE/ARB will be taken the morning of surgery with a sip of water
1618816|NCT02096406|Drug|ACE/ARB withdrawal|ACE/ARB will be stopped 48 hours prior to surgery
1618817|NCT02096393|Device|Zimmer Patient specific instruments|A custom made cutting block will be used during total knee replacement surgery. The cutting block is made specific to patient's anatomy based on MRI scans taken 6 weeks prior to surgery.
1618818|NCT02096393|Device|Standard instrumentation|Standard instrumentation will be used during total knee replacement surgery.
1618819|NCT02096380|Drug|One cycle TPF induction chemotherapy for NPC|"One cycle TPF induction chemotherapy for NPC
Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for single one cycle before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.
A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
1618820|NCT02096380|Drug|Three cycles TPF induction chemotherapy for NPC|"Three cycles TPF induction chemotherapy for NPC
Patients receive docetaxel (60mg/m2 on day 1), cisplatin (20mg/m2 on day 1-4) and fluorouracil (800mg/m2/d, continuous infusion, d1-4) every three weeks for three cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2) every week for six cycles during radiotherapy.
A total dose of 70Gy in 30 fraction to PTV-P, 60Gy in 30 fraction to PTV-1 and 54Gy in 30 fraction to PTV-2."
1618821|NCT02096367|Other|Gait analysis|
1618822|NCT02096367|Other|Kinematic gait analysis in lower limb|
1618823|NCT02096367|Other|Analysis of static posture|
1618824|NCT02096367|Other|Gait on treadmill|Treadmill during 2 minutes
1618825|NCT02096367|Device|Muscle vibration stimulation|Vibration stimulation at a 70 Hz frequency of biceps brachii muscle (sham), posterior neck muscles and gluteus medius muscle on the hemiplegic side
1618826|NCT02096354|Drug|RRx-001|
1618827|NCT02096354|Drug|Regorafenib|
1618828|NCT02096354|Drug|Irinotecan|To be dosed after RRx-001 or regorafenib
1618829|NCT02096341|Drug|RRx-001|"RRx-001 Dose level 1 (16 mg/m2) twice weekly
RRx-001 Dose level 2 (27 mg/m2) twice weekly"
1618830|NCT02096328|Drug|POL7080|Intravenous infusion
1618831|NCT02096315|Drug|POL7080|Intravenous infusion
1618832|NCT02096302|Dietary Supplement|Infant Formula with a novel probiotic CECT7210|Bottle-feeding with a new infant formula enriched with probiotic CECT7210 during the first 3 months of life.
1618833|NCT02096302|Dietary Supplement|Standard formula|Standard formula without probiotics
1618834|NCT02096289|Drug|Thioridazine|
1618835|NCT02096276|Other|Data collection|Initial and follow-up data will be collected using questionnaires
2010870|NCT02809326|Behavioral|Trauma Management Therapy|TMT consists of 29 treatment sessions administered over a period of 17 weeks. After the Education session, treatment occurs three times a week during the Virtual Reality (VR) assisted Exposure phase, and then once a week during Social and Emotional Regulation (SER). Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
1618845|NCT02096250|Other|NaFeEDTA|
1618846|NCT02096250|Other|Ferrous fumarate|
1618847|NCT02096250|Other|NaFeEDTA + ferrous fumarate|
1618848|NCT02096237|Device|IgE adsorber|Two plasma volumes of each patient in the apheresis group will be treated per session
1618849|NCT02096224|Drug|Sevoflurane|Sevoflurane will be used.
1618850|NCT02096224|Drug|Desflurane|Desflurane will be used
1618851|NCT02096211|Device|COC 36mm|Total Hip Replacement with COC 36mm Acetabular Cup System
1618852|NCT02096185|Radiation|3 dimensional tomosynthesis imaging|Each operative specimen will be imaged twice using each condition
1618853|NCT02096185|Radiation|2 dimensional digital imaging|
1618854|NCT02096159|Drug|trimethoprim-sulfamethoxazole|
1618855|NCT02096159|Other|placebo|
1618856|NCT02096146|Procedure|TMT Fusion plate|Patients are treated with TMT Fusion Plate a post-market device to encourage bony fusion of the 1st TMT joint.
1618857|NCT02096146|Procedure|Two crossed screws|Patients are treated with two crossed screws.This procedure is a standard treatment for 1st TMT joint fusion.
1618858|NCT02096133|Drug|Cholecalciferol|Vitamin D3 solution
1618859|NCT02096133|Other|Placebo comparator|Placebo comparator
1618860|NCT02096107|Drug|Everolimus|Convert mycophenolate to everolimus with subsequent reduction in exposure to tacrolimus
1618861|NCT02096107|Other|Standard of Care|Tacrolimus, mycophenolate mofetil and steroids
1619021|NCT02094807|Drug|NSAID|Will be used if other drugs are not tolerated.
1619580|NCT02090400|Drug|Calcium/Vit D|Calcium 500 mg / 400 IU Vit D
1618862|NCT02096094|Procedure|Standardization phase|Prior the principal intervention, each volunteer should complete a standardization phase, which consists in the daily bathing for two weeks with a antiseptic free soap and shampoo. Likewise would avoid chemical showers such as swimming. At the end of this phase a quantification of skin flora will be perform.
1618863|NCT02096094|Procedure|Control bath|Volunteers will be ask to perform full body bath with wipes without impregnation for 3 to 5 days, each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
1618864|NCT02096094|Procedure|Bath with chlorhexidine|Volunteers will be asked to perform full body bath with wipes with 2% chlorhexidine impregnation and with 0.15% chlorhexidine shampoo (for the head and genitalia) for 3 to 5 days. Each day the volunteer will answer a survey regarding side effects (skin reactions) and comfort related to the bath. At the end of the intervention, a skin culture to quantify skin colonization will be performed.
1618867|NCT02096068|Drug|Dexmedetomidine (Dexdor®)|Dexmedetomidine (Dexdor 100 micrograms/ml concentrate for solution for infusion)
1618868|NCT02096068|Drug|0.9% Sodium Chloride|Solution for infusion: Sodium Chloride : 9.0 g/l; Each ml contains 9 mg sodium chloride mmol/l : Na+ : 154. Cl-: 154.
1618869|NCT02096055|Drug|SGI-110|"Group A Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days.
Maintenance Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days.
Group B Induction Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 10 days.
Maintenance Phase: SGI-110 60 mg/m2 subcutaneously (SQ) daily for 5 days."
1618870|NCT02096055|Drug|Idarubicin|"Group B Induction Phase: Idarubicin 6 mg/m2 by vein daily for 2 days.
Maintenance Phase: Idarubicin 6 mg/m2 by vein on Day 1."
1618871|NCT02096042|Drug|Brentuximab Vedotin|"Pilot Phase: Starting dose of Brentuximab Vedotin 1.2 mg/kg intravenous (IV) infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.
Phase I Dose-Escalation Phase: Starting dose of Brentuximab Vedotin 1.0 mg/kg IV (starting dose level 1), or one-dose level lower than the established MTD if the pilot portion of the study establishes a lower MTD, infusion over approximately 30 minutes on days 1, 8, and 15 of each 28-day cycle.
Phase II Dose-Expansion Phase: Patients receive Brentuximab Vedotin at MTD from dose-escalation phase by vein on Days 1, 8, and 15 of each 28-day cycle."
1618872|NCT02096042|Drug|5-Azacytidine|Phase I Dose-Escalation Phase and Phase II Dose-Expansion Phase: 5-Azacytidine at 75 mg/m2/day by vein or subcutaneously on days 1-7 every 28 days.
1618873|NCT02096029|Other|Nicotine Replacement Therapy (NRT) Sampling|2 week supply of 4 mg nicotine lozenge and 14 mg nicotine patch
1618874|NCT02096029|Behavioral|Ask, Advise, Refer (physician brief advice)|
1618875|NCT02096016|Procedure|Human Papilloma Virus test from the vaginal vault|Surveillance after surgical treatment of early stage cervical cancer
1618876|NCT02096003|Drug|Intrathecal morphine|0.25mg intrathecal morphine is the standard opioid medication the investigators use for analgesia for cesarean sections. It is the control arm.
1618877|NCT02096003|Drug|Intrathecal hydromorphone|50mcg intrathecal hydromorphone will be added to 1.5mg 0.75% bupivicaine for single shot spinal anesthesia.
1618878|NCT02095990|Drug|Hydroquinone|
1618879|NCT02095990|Drug|Placebo|
1618880|NCT02095977|Procedure|fluoroscopy|Fluoroscopic evaluation of three different views (left anterior oblique, right anterior oblique and anterior/posterior) and magnification will be performed to check for externalized cables at 15 frames per second using the best visualized angle per screening electrophysiologist.
1618881|NCT02095977|Procedure|synchronized high-voltage shock|"If fluoroscopic evaluation shows externalized conductors or if patient is deemed high-risk, the patient will be consented for synchronized high voltage shock through his/her device. This will be done in the non-invasive electrophysiology lab with conscious sedation as is done during defibrillation threshold testing.
For patients undergoing a generator (ICD) change as part of standard of care, performance of synchronized, high-voltage shock will be performed at the discretion of the electrophysiologist."
1618882|NCT02095977|Procedure|Holter monitor|Participants will be given a 24-hour Holter monitor at baseline and once annually, and will be followed at least every three months throughout the study. Participants who are found to have an electrical abnormality at any point during the study may be given a 24-hour Holter monitor if it is believed that this procedure will provide clinically useful information regarding the integrity of the lead.
1618883|NCT02095951|Drug|Ethanol lock therapy (ELT)|Participants will be randomized to receive early (preemptive) ELT (after 12 hours from time blood culture drawn, but before blood culture positive, R/O sepsis) with systemic antimicrobials versus standard ELT (placed in catheter when blood culture is positive for growth of a germ) with systemic antimicrobials.
1618884|NCT02095938|Drug|amisulpride|Amisulpride (Solian) will be orally administered once or twice daily after meal intake for 8 weeks. Patients initially will receive a low dose of amisulpride (200-400mg/day). The dosage may be adjusted to between 400 and 800mg/day according to the clinical decision by treating physician.
1618885|NCT02095899|Drug|Rufinamide|2x200mg up to max 2x800mg a day Titration over 20days
1618886|NCT02095886|Drug|BMS-955176|BMS-955176
1618887|NCT02095873|Dietary Supplement|Glyoxalase 1 (Glo1) inducer|Dietary bioactive
1618888|NCT02095873|Dietary Supplement|Placebo|Mannitol, 108 mg
1618889|NCT02095860|Drug|DCV 3DAA FDC|Fixed Dose Combination of Daclatasvir (DCV), Asunaprevir (ASV) and BMS-791325
1618890|NCT02095847|Procedure|High-Resolution Microendoscopy Imaging|Once the cervix has been dilated, a hysteroscope will be introduced in the uterine cavity to evaluate for presence of tumor. Location and size of tumor documented. White-light images obtained using the HRME camera introduced through the hysteroscope. Once completed; the hysteroscope will be removed and the uterine cavity will be infused with 10 mL of proflavine (an acridine dye) (0.01% Proflavine (10ml)). A resectoscope will then be introduced in the uterine cavity and fluorescent images obtained using the HRME camera.
1618891|NCT02095847|Drug|Proflavine|After hysteroscopy with HRME camera, uterine cavity infused with 10 mL of Proflavine.
1619022|NCT02094807|Procedure|thoracic epidural anesthesia|Continous epidural anesthesia will be introduced by specialists in Anesthesia and Intensive care.
1618892|NCT02095834|Drug|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of a 28‐day cycle for Cycles 1-12 and on Days 1, 2, 15, and 16 for a 28‐day cycle for maintenance Cycles 13 and higher.
Expansion Cohort Starting Dose: Maximum tolerated dose from Phase I."
1618893|NCT02095834|Drug|Bendamustine|"Phase I Starting Dose: 50 mg/m2 by vein on Days 1 and 2 of cycles 1 - 3 and on Day 1 of each subsequent cycle.
Expansion Cohort Starting Dose: Maximum tolerated dose from Phase I."
1618894|NCT02095834|Drug|Dexamethasone|20 mg by mouth or vein administered weekly on Days 1 , 2, 8, 9, 15, 16, 22 and 23 of cycles 1 - 3, on days 1, 2, 15 and 16 for cycles 4 - 12, then on days 1 and 2 of each subsequent cycle.
1618895|NCT02095808|Procedure|Imaging Biomarkers|Want to see if using 13C-glucose helps in detecting cancer and deciding on a treatment plan.
1618896|NCT02095795|Device|Technological Rehabilitation|The Lokomat (Hocoma, Zurich, Switzerland) is robotic device conformed as an exoskeleton on the lower limbs of the patient. Through active and passive actuators, it realize a proper trajectory with an associated motion profile of the involved limbs. The results are physically guide repetitive, rhythmic, bilateral lower extremity movements in order to simulate a physiological gait cycle.The system uses a dynamic body weight-support system to support the participant above a motorized treadmill synchronized with the Lokomat. Participants were provided verbal encouragement to actively step in conjunction with the movement presented by the Lokomat.
1618897|NCT02095795|Other|Control Rehabilitation|When needed, more than one therapist are employed in the intervention for safety reasons.
1618898|NCT02095782|Drug|Intercalated combination of chemotherapy and erlotinib|"Primary therapy stage:
Paclitaxel Patients receive six cycles of Paclitaxel (175 mg/m² on days 1 of a 4 week cycle, intravenously) plus carboplatin (AUC=5, intravenously on day 1 of a 4 week cycle, intravenously) with sequential erlotinib (150 mg/day) on days 8-21 of each cycle.
Maintenance therapy stage:
Patients, who complete 6 cycles of therapy without progression or intolerable toxicity, receive erlotinib (150 mg/day) as maintenance therapy until progression, intolerable toxicity or death."
1618899|NCT02095756|Other|755nm Alexandrite Laser and Lytera Skin Brightening System (Non-Hydroquinone Topical Therapy)|
1618900|NCT02095756|Other|Lytera Skin Brightening System (Non-hydroquinone topical therapy)|
1618901|NCT02095743|Device|implanted port for chemo administration (X-port isp)|
1618902|NCT02095743|Device|Use of a PICC line for chemo administration (PowerPICC SOLO²)|The description of the device could found on the published marketing authorisation
1618903|NCT02095730|Drug|Epithelium-On Riboflavin|Riboflavin 0.1% Phosphate Sodium solution with Benzalkonium Chloride Preservative
1618904|NCT02095730|Drug|Epithelium-Off Riboflavin|Riboflavin 0.1% Phosphate Sodium solution
1618905|NCT02095730|Device|UV Light - Continuous Beam|5 minutes of constant UV exposure to saturated cornea
1618906|NCT02095730|Device|UV Pulsed Beam|5 minutes of UV exposure to saturated cornea, alternating 1 minute of treatment with 1 minute rest for a total time of 10 minutes
1618907|NCT02095717|Drug|Curcumin|
1618908|NCT02095717|Drug|Placebo|
1618909|NCT02095717|Drug|Taxotere|
1618910|NCT02095704|Drug|paracetamol oral solution|dosage form: paracetamol oral solution;dosage:15.6ml(containing 500 mg of the active ingredient);frequency:single dose
1618911|NCT02095704|Drug|paracetamol tablet|dosage form: paracetamol tablet;dosage: 500 mg;frequency:single dose
1618912|NCT02095691|Device|Celsius® ThermoCool® Renal Denervation|The investigational device is indicated for the treatment of resistant hypertension by renal denervation.
1618913|NCT02095678|Procedure|liver biopsy|patients with HCC or metastatic lesions will have a liver biopsy performed after the experimental MRI. This biopsy will be examined to confirm the imaging results
1618914|NCT02095678|Device|free-breathing MRI|All patients will be asked to come in for an MRI scan using techniques developed which minimize the time a patient has to hold their breath to image the liver to <8 seconds and validate quantifiable techniques which improve liver image quality
1618915|NCT02095665|Drug|Mirabegron|50 mg of Mirabegron daily from stent insertion until removal 5 to 10 days
1618916|NCT02095665|Drug|Tamsulosin|0.4 mg of Tamsulosin daily and 1 tab of Percocet every 4 hours as necessary from stent insertion until removal 5 to 10 days
1618917|NCT02095665|Drug|Tylenol #3|1 tab of Tylenol #3 every 6 hours as necessary from stent insertion until removal 5 to 10 days
1618918|NCT02095626|Drug|AP-301|orally delivered doses of 87.6 mg AP301 (dose per subject, 5 ml nebulizer filling dose) are inhaled every 12 hours for a total of 7 days
1618919|NCT02095626|Drug|saline solution|placebo solution (0.9 % physiologic NaCl, 5 ml nebulizer filling dose) is inhaled every 12 hours for a total of 7 days
1618920|NCT02095613|Other|traditional food|
1618921|NCT02095613|Other|food that is nutrient dense|
1618922|NCT02095600|Radiation|Radiosurgical thalamotomy|
1618923|NCT02095587|Drug|IPI-145|25 mg single oral capsule
1618924|NCT02095574|Drug|[14C]ABT-199 (GDC-0199)|[14C]ABT-199 will be administered as a single oral administration
1618925|NCT02095561|Other|HPV self testing|Community Health Workers instructed women about cervical cancer and HPV testing, advised them on how to seek screening at health centers, and offered them the option of self-testing, providing women with educational materials on how to perform it.
1618926|NCT02095548|Drug|SM04690, 0.03mg/2mL|
1618927|NCT02095548|Drug|SM04690, 0.07mg/2mL|
1618928|NCT02095548|Drug|SM04690, 0.23mg/2mL|
1618929|NCT02095548|Drug|Placebo|
1618930|NCT02095535|Drug|Chlorhexidine gluconate|antiseptic
1618931|NCT02095522|Drug|Colchicine|Colchicine 1mg per day for one month
1618932|NCT02095522|Drug|Placebo|Placebo
1618934|NCT02095496|Device|Intellivent-ASV|12 hours of mechanical ventilation with intellivent-ASV
1618935|NCT02095496|Device|Conventional ventilation|12 hours of mechanical ventilation with pressure support ventilation
1618936|NCT02095470|Device|video laryngoscope|newly developed innovatory device
1618937|NCT02095470|Device|traditional laryngoscope|traditional way for intubation
1618938|NCT02095457|Behavioral|Frequent monitoring and feedback|In the intervention arm, patients routinely fill short monitoring questionnaires, the results of which are fed back to their therapists and staff. The frequency of monitoring is between once a week to once every three months, depending on the type of therapy
1618940|NCT02095418|Drug|Mycophenolate mofetil, Corticosteroids|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1500mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (2 weeks)
1618941|NCT02095418|Drug|Corticosteroids, Mycophenolate mofetil|tacrolimus (low dose, trough level of 5-12ng/ml)+Mycophenolate mofetil(500-1000mg/day*, bid)+ Basiliximab + corticosteroids 500mg to 5mg or above (3 month±2weeks)
1618942|NCT02095405|Drug|Caffeine|"SVT group: Oral tablets of Caffeine prior to the electrophysiology study in patients with SVT.
AF group: Dark chocolate and Caffeinated substances in patients with AF at the time of Ambulatory monitoring."
1618943|NCT02095405|Other|Placebo|"SVT group: Oral tablets of placebo prior to the electrophysiology study in patients with SVT.
AF group: White chocolate and Decaffeinated substances in patients with AF at the time of Ambulatory monitoring."
1618944|NCT02095392|Dietary Supplement|P1000/Ca0|22 subjects consume for 8 weeks a beverage enriched with phosphate [1g phosphorus/d]
1618945|NCT02095392|Dietary Supplement|P1000/Ca500|22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [0,5 g calcium]
1618946|NCT02095392|Dietary Supplement|P1000/Ca1000|22 subjects consume for 8 weeks a beverage enriched with phosphate [1 g phosphorus/d] and calcium [1 g calcium]
1618947|NCT02095392|Dietary Supplement|Placebo|all participants consume two weeks before intervention the beverage without phosphate and calcium
1618948|NCT02095379|Other|oligosecretary|not abvailable
1618949|NCT02095366|Drug|Morphine|"Intravenous administration Patient receives simultaneously IV morphine administration and IN placebo spray.
Pain is controlled by:
at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg
at 10 minutes and if NPRS>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg
at 20 minutes and if NPRS>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
1618950|NCT02095366|Drug|Sufentanil|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV placebo administration and IN sufentanil spray.
Pain is controlled by:
at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV
at 10 minutes and if NPRS>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV
at 20 minutes and if NPRS>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
1618951|NCT02095366|Drug|Placebo|"Intravenous administration Patient receives simultaneously IV placebo administration and IN sufentanil spray.
Pain is controlled by:
at 0 minute : Sufentanil IN 0,3µg/kg (2 sprays, one spray in each nostril) + NaCl 0,9% IV
at 10 minutes and if NPRS>3 : Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV
at 20 minutes and if NPRS>3: Sufentanil IN 0,15µg/kg (1 spray) + NaCl 0,9% IV"
1618952|NCT02095366|Drug|Placebo|"Intranasal spray with one spray, equivalent to an half-dose. Patient receives simultaneously IV morphine administration and IN placebo spray.
Pain is controlled by:
at 0 minute : Placebo IN (2 sprays, one spray in each nostril) + morphine IV 0,1mg/kg
at 10 minutes and if NPRS>3 : Placebo IN (1 spray) + morphine IV 0,05mg/kg
at 20 minutes and if NPRS>3: Pacebo (1 spray) + morphine IV 0,05mg/kg"
1618953|NCT02095340|Other|Positive Interpretation Bias Training|
1618954|NCT02095340|Other|Neutral Interpretation Bias Training|
1618955|NCT02095314|Biological|Pentavalen|Batch 5010613
1618956|NCT02095301|Other|Herbal Beverage|
1618957|NCT02095288|Procedure|Blood draw|This is a single blood donation, no drugs or devices administered
1618958|NCT02095262|Other|reactive auditory training|
1618959|NCT02095262|Other|Interactive auditory training|
1618960|NCT02095249|Drug|Pimonidazole|Pimonidazole is to be administered to patients scheduled for radical prostatectomy one day prior to surgery.
1618961|NCT02095236|Behavioral|organ motion|Three-dimensional intrafractional motion of a fiducial marker or a transponder during a radiotherapy treatment session. Image and/or signal acquisition will be performed by ultrasound, computed tomography, magnetic resonance imaging or by specialized signal detectors.
1618962|NCT02095223|Device|Electromyographic Biofeedback|Electromyographic biofeedback is a device that enables a patient or clinician to measure the intensity of a muscle contraction using electrodes placed on the skin over a muscle of interest. In this study, participants in the electromyographic biofeedback supplemented exercise will also be instructed on correct setup and use of the electromyographic biofeedback unit. These instructions will focus on correct placement of the electromyographic recording electrodes over quadriceps muscle as well as correct tuning of the feedback threshold for each exercise to maximize the benefit of the intervention. Electromyographic biofeedback will be used during all exercises throughout the course of the study for this group.
1618963|NCT02095223|Behavioral|Traditional Exercise|All participants will be asked to complete 3 set of 10 repetitions of isometric quadriceps contractions with a 15 second hold time, supine straight leg raises, body weight squatting, and body weight lunges daily. Participants will be required to complete the single limb exercises on the previously injured limb only.
1618964|NCT02095210|Other|Radiolabeled [68Ga]ABY-025|Single dose of 100 μg ABY-025 labeled with 500 MBq gallium-68, administrated as a slow intravenous injection. All patients will receive the same dose.
1618965|NCT02095197|Drug|Triamcinolone 80mg|C7-T1 Cervical interlaminar epidural steroid injection with Triamcinolone 80mg and 1 mL 1% lidocaine. Total volume is 2 cc.
1618966|NCT02095184|Drug|Anastrozole|1 mg daily
1618967|NCT02095184|Drug|Letrozole|2.5 mg daily
1618968|NCT02095171|Drug|PRX002|
1618969|NCT02095171|Other|Placebo|
1618970|NCT02095158|Drug|Oxymetazoline HCL Cream 1.0%|Oxymetazoline HCL Cream 1.0% applied to the face once daily for 52 weeks.
1618971|NCT02095145|Other|Laboratory Biomarker Analysis|Correlative studies
1618972|NCT02095145|Other|Pharmacological Study|Correlative studies
1618973|NCT02095145|Other|Placebo|Given PO
1618974|NCT02095145|Drug|Pomegranate-Extract Pill|Given PO
1618979|NCT02095119|Drug|Nimotuzumab|Monoclonal antibody Nimotuzumab will be administered alone at a 200mg dose weekly during the first 4 weeks. Posteriorly it will be administered with a maintenance dose of 200 mg every 2 weeks in combination with chemotherapeutic agents Cisplatin in patients with good renal function or Gemcitabine in patients with kidney failure data until exclusion or death occurs. The administration will be intravenously in 250 ml of saline solution in a time period of 30 minutes.
1618980|NCT02095119|Drug|Cisplatin|Cisplatin will be administered at a calculated dose of 50mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, only in patients whose creatinine clearance as defined by the Cockcroft-Gault equation is >/= 60. The administration form will be intravenously.
1618981|NCT02095119|Drug|Gemcitabine|Gemcitabine will be administered at a calculated dose of 800 mg/m2/BSA every 21 days as concomitant therapy to Nimotuzumab, until 6 cycles are completed, exclusion or death occurs, in patients with kidney failure data(Creatinine clearance as defined by the Cockcroft -Gault equation < 60). The administration form will be intravenously.
1618982|NCT02095119|Procedure|CT Scan|A CT Scan will be performed in all patients prior to the beginning of treatment to assess any measurable tumor found by this method. The CT Scan will be repeated once the patient completes the induction phase with Nimotuzumab (4 once a week doses), when the patient has completed 3 full cycles of combination therapy with Nimotuzumab (every 2 weeks)and Gemcitabine or Cisplatin (every 21 days)and once more when the patient has completed 6 full cycles of the aforementioned therapy.
2010871|NCT02809326|Behavioral|Intensive 3-Week Trauma Management Therapy|Intensive 3-Week Trauma Management Therapy consists of 29 treatment sessions administered over a period of 3 weeks. Individual VR-assisted exposure sessions and group sessions are conducted Monday-Friday with individual sessions conducted in the morning and Social and Emotional Regulation (SER) sessions conducted in the afternoon. Education and exposure are implemented individually while SER is administered in small group sessions (3-5 people). All exposure treatment sessions will terminate after a decline of 50% in the highest rating recorded. SER sessions will be 90 minutes. The treatment program as a whole results in approximately 43.5 hours of therapist contact for each patient.
2010872|NCT02807350|Device|Overminus treatment|spectacles with full cycloplegic refraction plus 2.50 D overminus added to the sphere
1618985|NCT02095093|Device|Intellijoint HIP|Intellijoint HIP is an intra-operative, imageless intelligent instrument used to provide real-time information to surgeons about leg length and hip offset changes during total hip replacement surgery.
1618986|NCT02095093|Device|Outrigger|The outrigger is a pin and caliper device that is used to assess leg length and offset during total hip arthroplasty. It is the current standard of care at Mount Sinai Hospital.
1618987|NCT02095080|Dietary Supplement|Leucine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
1618988|NCT02095067|Device|Video consultation|
1618989|NCT02095054|Drug|Regorafenib|"Dose Escalation Group Starting Dose of Regorafenib: 80 mg by mouth once a day for 21 days (5 days on and 2 days off) in a 28 days cycle.
Dose Expansion Group Starting Dose of Regorafenib : MTD from Dose Escalation Group."
1618990|NCT02095054|Drug|Cetuximab|"Dose Escalation Group Starting Dose of Cetuximab: 200 mg/m2 initial dose, then 150 mg/m2 by vein over about 1-2 hours on Days 1, 8, 15, and 22 of each 28 day cycle.
Dose Expansion Group Starting Dose of Cetuximab: MTD from Dose Escalation Group."
1618991|NCT02095054|Behavioral|Questionnaire|Symptom questionnaire completed at each study visit.
1618992|NCT02095028|Behavioral|Dietary and lifestyle intervention|participants in the intervention group were provided with an individualized dietary intake protocol. Patients received a diet of not fewer than 1500 calories per day in the first trimester and not fewer than 1800 calories per day after 13wks of gestation.
1618993|NCT02094989|Other|posture dependence of VCG-ECG-transformation|
1618997|NCT02094963|Drug|Ticagrelor|180mg loading and 90mg bid
1618998|NCT02094963|Drug|Clopidogrel|600mg loading and 75mg qd
1618999|NCT02094950|Procedure|Acupuncture|
1619000|NCT02094937|Drug|Fluticasone Furoate/Vilanterol|FF/VI 100mg/25 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
1619001|NCT02094937|Drug|Fluticasone Furoate 100 mcg|FF 100 mcg is available as a dry white powder to be given once daily in the evening via dry powder inhaler
1619002|NCT02094937|Drug|Fluticasone Propionate 250 mcg|FP 250 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
1619003|NCT02094937|Drug|Fluticasone Propionate 100 mcg|FP 100 mcg is available as a dry white powder to be given twice daily (morning and evening) via dry powder inhaler
1619004|NCT02094937|Drug|Fluticasone Furoate Placebo|Matching placebo of Fluticasone Furoate will be given once daily in the evening via dry powder inhaler
1619005|NCT02094937|Drug|Fluticasone Propionate Placebo|Matching placebo of Fluticasone Propionate will be given twice daily (morning and evening) via dry powder inhaler
1619006|NCT02094924|Drug|GSK587323|Single dose of FDC tablet formulation to be taken orally.
1619007|NCT02094924|Drug|FDC of candesartan cilexetil 16 mg and HCTZ 12.5mg|Single dose of FDC tablet formulation to be taken orally
1619008|NCT02094911|Behavioral|Combined lifestyle intervention|"10-month intervention period with:
weekly group-based sports lessons supervised by a physiotherapist
individual dietary advice by a dietician
case management by practice nurse
maintenance programme to guide subjects to maintain lifestyle behaviour change"
1619009|NCT02094911|Other|Usual care group|Written information on healthy lifestyle was provided at baseline, no individual advice or programme was provided. No additional appointments were scheduled, apart from the visits for follow-up measurements
1619010|NCT02094898|Drug|Ketamine|0.3 mg/kg/hr of ketamine infused for 100 minutes
1619011|NCT02094885|Biological|Bioseal Fibrin Sealant|
1619012|NCT02094885|Other|Manual Compression|
1619013|NCT02094872|Other|cytology specimen collection procedure|Undergo collection of tissue and blood samples
1619014|NCT02094872|Drug|MEK 162 therapy or molecularly targeted therapy|molecularly targeted therapy, MEK 162 therapy
1619015|NCT02094872|Procedure|therapeutic procedure|
1619016|NCT02094872|Other|laboratory biomarker analysis|Correlative studies
1619017|NCT02094872|Other|quality-of-life assessment|Ancillary studies
1619018|NCT02094846|Behavioral|Voice messages|Voice messages reinforced with self-efficacy
1619019|NCT02094833|Biological|DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
1619020|NCT02094833|Biological|DTaP-IPV//PRP~T and Hepatitis B vaccine|0.5 mL, Intramuscular
1619581|NCT02090387|Other|ONS without AN777|2 servings a day
1619023|NCT02094807|Drug|opioids|During firs 24 hours i.v will be used. Then slow releas tabletts will be preferred.
1619024|NCT02094807|Drug|paracetamol|100mg x 4 i.v. during the first 24 hours. Then orally 100mg x 4.
1619025|NCT02094807|Procedure|operative fixation of rib fractures|Fractures will be stabilized on the outside of of the ribs.
1619026|NCT02094794|Drug|etoposide|Given IV
1619027|NCT02094794|Drug|cyclophosphamide|Given IV
1619028|NCT02094794|Radiation|total marrow irradiation|Undergo TMLI
1619029|NCT02094794|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
1619030|NCT02094794|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood stem cell or bone marrow transplant
1619031|NCT02094781|Dietary Supplement|Whey protein and creatine supplement|Each sachet contained 30g whey protein powder and 5g creatine powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
1619032|NCT02094781|Dietary Supplement|Whey protein only supplement|Each sachet contained 30g of whey protein powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
1619033|NCT02094781|Dietary Supplement|Placebo|Each sachet contained 30g of isocaloric carbohydrate powder and 5g of bulking agent powder, administered twice a day. The first serving was consumed with breakfast and the second serving was consumed within 60 minutes of completing training or in the evening on non-training days. Participants also drank at least 2 litres of water per day
1619034|NCT02094768|Dietary Supplement|Reduced Fat Milk|Subjects will be provided with and instructed to consume the equivalent of 20oz. reduced fat milk per day for 3 weeks
1619035|NCT02094768|Dietary Supplement|Sugar Sweetened Soda|Subjects will be provided with and instructed to consume 2 cans (24oz) of sugar sweetened soda per day for 3 weeks
2010873|NCT02807350|Device|Non-overminus treatment|spectacles with full cycloplegic refraction without overminus
1619037|NCT02094742|Procedure|biopsy|
1619038|NCT02094729|Drug|BAN2401 2.5 mg/kg|Cohorts 1: Intravenous infusions of 2.5 mg/kg BAN2401 for 60 +/- 10 minutes.
1619039|NCT02094729|Drug|BAN2401 5 mg/kg|Cohorts 2: Intravenous infusions of 5 mg/kg BAN2401 for 60 +/- 10 minutes.
1619040|NCT02094729|Drug|BAN2401 10 mg/kg|Cohorts 3: Intravenous infusions of 10 mg/kg BAN2401 for 60 +/- 10 minutes
1619041|NCT02094729|Drug|Placebo|Intravenous infusions of placebo for 60 +/- 10 minutes.
1619042|NCT02094716|Drug|Permethrin Foam 4%|Topical application, single whole-body treatment
1619043|NCT02094716|Drug|Permethrin Foam 5%|Topical application, single whole-body treatment
1619044|NCT02094716|Drug|Vehicle Foam|Topical application, single whole-body treatment
1619045|NCT02094703|Drug|Levofloxacin|
1619046|NCT02094703|Drug|Solifenacin succinate|
1619047|NCT02094703|Drug|Placebo (for Solifenacin succinate)|
1619048|NCT02094690|Device|Therabite|10 repetitions holding Therabite for 30 seconds. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
1619049|NCT02094690|Device|Hyperboloid|5 min of bilateral mastication alternated with hyperboloid. The exercises should begin one day before the onset of Radiotherapy and kept until the end of RT. Repeated 4x a day (after breakfast, lunch, dinner and before going to bed).
1619050|NCT02094677|Device|filcon II 3|Participants were randomized to wear filcon II 3 test lens.
1619051|NCT02094677|Device|etafilcon A|Participants were randomized to wear etafilcon A control lens.
1619052|NCT02094677|Device|nelfilcon A|Participants were randomized to wear nelfilcon A control lens.
1619054|NCT02094651|Drug|divalproex sodium|The drug is an FDA approved medication for seizures but has not been approved for the treatment of epileptiform EEG abnormalities in the absence of clinical seizures.
1619055|NCT02094651|Other|Placebo|The placebo is an inactive substance that looks like the active drug.
1619056|NCT02094625|Drug|N-Acetylcysteine|"NAC will be administered intravenously over ~30 minutes starting 4 hours following completion of cisplatin for the first 3 cycles of chemotherapy. Patients will have the option to continue with NAC for any remaining cycles.
Three dose levels have been pre-determined:
Dose Level 1: 225 mg/kg Dose Level 2: 300 mg/kg Dose Level 3: 450 mg/kg
Should Dose Level 3 exceed the MTD, the study will examine blood levels of NAC and if below the target blood level necessary for hearing protection, the study will de-escalate from Dose Level 3 to an intermediate Dose Level 2.5 and test a dose of 375 mg/kg."
1619057|NCT02094612|Device|Quotient®|Patients will be randomized once at the time of ADHD assessment to either usual clinic ADHD care or usual clinic ADHD care plus the Quotient using computer-generated random numbers.
1619058|NCT02094612|Behavioral|Usual Clinic ADHD Care|Usual ADHD care as provided by the clinic
1619059|NCT02094599|Drug|Dronabinol 10 mg|Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.
1619060|NCT02094599|Drug|Dronabinol 30 mg|Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.
1619061|NCT02094599|Drug|Placebo|Matching placebo provided in capsules or as an oral solution in syringes.
1619062|NCT02094586|Biological|PXVX0200|comparing 3 lots of PXVX0200
1619063|NCT02094586|Biological|Placebo|
1619064|NCT02094573|Drug|Brigatinib|Brigatinib tablets
1619065|NCT02094560|Drug|CAP7.1|CAP7.1 is a prodrug of Etoposide released after via specific carboxyesterase
1619066|NCT02094547|Dietary Supplement|New infant formula|New infant formula
1619067|NCT02094547|Dietary Supplement|Standard infant formula|Standard infant formula
1619068|NCT02094534|Biological|ORMD-0801 Capsules|API (recombinant human insulin USP), in Oramed's proprietary formulation in capsules.
1619069|NCT02094534|Other|Placebo|Fish oil capsules, identical in appearance to the experimental intervention.
1619113|NCT02094157|Drug|Tapered warfarin regimen|This intervention is assigned to the experimental arm - Tapered warfarin regimen
1619582|NCT02090387|Other|ONS containing AN777|2 servings a day
1619070|NCT02094521|Drug|NNC0113-0987|For oral administration. All subjects will be treated for 10 consecutive days with five days on 5 mg NNC0113-0987 followed by five days on 10 mg NNC0113-0987. Dose escalation is chosen to increase gastrointestinal tolerability.
1619071|NCT02094482|Device|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate.|The IMD is a resilient palatal implant which is introduced through a stab incision into the palate. Two implants are placed underneath the rostral part of the palatal bone and continue into the upper part of the soft palate
1619072|NCT02094469|Drug|Cilostazol|Oral, Bid, 24 weeks
1619073|NCT02094456|Procedure|Endoscopic clipping of diverticula|Colonoscopy with identification of each individual colonic diverticula and endoscopic clipping.
1619074|NCT02094456|Procedure|Follow-up colonoscopy|Patients will undergo a repeat colonoscopy 6 months after endoscopic clipping procedure.
1619075|NCT02094443|Drug|Alisporivir|ALV 100 and 200 mg soft gel capsules administered orally
1619076|NCT02094443|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
1619077|NCT02094430|Drug|biological: human fibrinogen concentrate|
1619078|NCT02094417|Drug|AMG531|Subcutaneous, weekly injection
1619079|NCT02094391|Drug|Ipilimumab|Ipilimumab is to be administered as an IV infusion with a 1.2μm in-line filter (see current version of Investigator's Brochure), using a volumetric pump, at the 3 mg/kg dose, at the ratio and rate specified in the pharmacy manual, to complete the infusion in 90 minutes with a 100 cc normal saline flush at the end. The total dose needed should be diluted to a total volume of 250 mL in 0.9% sodium chloride injection, USP or 5% Dextrose Injection, USP.. The total dose must be calculated using the most recent subject weight (obtained on the same day of, and prior to, the infusion). If the patient weighs more than 125,0 kg, the Coordinating Investigator needs to be contacted to discuss the total infusion volume, infusion rate and duration. Ipilimumab 3 mg/kg will be administered as a single dose intravenously over 90 minutes every 3 weeks for 4 cycles (Weeks W1, W4, W7, W10). A time interval of +/- 3 days is allowed for Ipilimumab administration.
1619080|NCT02094378|Drug|Esketamine|84 mg esketamine administered intranasally
1619081|NCT02094378|Drug|Placebo|Placebo administered intranasally
1619082|NCT02094365|Drug|ALS-008176|
1619083|NCT02094365|Drug|vehicle|
1619084|NCT02094352|Drug|Ketamine Infusion + Epidural Infusion|The ketamine and epidural infusions will be administered over 96 hours with appropriate titration.
1619085|NCT02094352|Drug|Control Group + Epidural infusion|The saline and epidural infusions will be administered over 96 hours with appropriate titration.
1619086|NCT02094352|Drug|Ketamine Booster Infusion|Patients will receive three ketamine booster infusions over the course of three months.
1619087|NCT02094352|Drug|Control Group Booster Infusion|Patients will receive three saline booster infusions over the course of three months.
1619088|NCT02094339|Procedure|Local analgesic|Patient will be performed under combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.At the end of surgery,two catheters are left in the wound.One is intraarticular and the other is on the surface of articular cavity.And then a pump elastomeric infusion pump will be connected with the catheters, which runs 5mL every hours.
1619089|NCT02094339|Procedure|Nerve Block|Combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine will be performed before the surgery.After the a bolus of 30mL ropivacaine around lumbar plexus,a catheter will be left in Psoas gap with 6cm.A pump elastomeric infusion pump running 5mL every hours will also be connected with the catheters at the end of the operation.
1619090|NCT02094339|Procedure|Intravenous analgesic|People in this group will also receive an anesthesia of combined lumbar plexus and sciatic nerve block with 0.33% ropivacaine.An intravenous electronic analgesia pump infusion of flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg will will provide postoperative pain management.The patients will received a 2 mL/h continuous basal infusion and 1 mL boluses with a lockout time of 30 min after a 5 mL Loading dose at the end of the surgery.
1619091|NCT02094339|Drug|ropivacaine|0.2% ropivacaine
1619092|NCT02094339|Drug|ropivacaine|0.2% ropivacaine
1619093|NCT02094339|Drug|opioid|flurbiprofen axetil 250mg,palonosetron 0.5mg,pentazocine 240mg.dezocine 30mg
1619094|NCT02094313|Drug|Atorvastatin|The aim of this pilot study is to evaluate the efficacy and the safety of a decrease of cholesterol blood levels, induced by taking atorvastatin, on sperm quality of normocholesterolaemic and healthy men without confounding factors.
1619095|NCT02094300|Device|Zenith® Dissection Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guide the study device(s) into place in the aorta.
1619096|NCT02094287|Drug|dimetindene|receiving either dimetindene or a placebo (saline) via infusion
1619097|NCT02094287|Behavioral|instruction|information about the drug dimetindene and its efficacy versus no information and unawareness of treatment influencing expectations of an efficient treatment
1619098|NCT02094287|Other|conditioning|classical conditioning; experiencing and observing the efficiency of a drug manipulated by a conditioning process versus no learning experience.
1619099|NCT02094274|Drug|LAS40468|
1619100|NCT02094274|Drug|Salmeterol/fluticasone propionate|
1619101|NCT02094274|Drug|Placebo|
1619102|NCT02094261|Drug|AZD9291|Once daily tablet 80 mg
1619103|NCT02094248|Drug|TPO|rhTPO（Recombinant Human Thrombopoietin，TPIAO®, Shenyang Sunshine Pharmaceutical Company Limited [SUNSHINE], Shenyang, China）， 15000U/ml, s.c injection
1619104|NCT02094248|Drug|control|Normal saline，1ml/day, s.c injection
1619105|NCT02094235|Drug|E6005 0.05%|
1619106|NCT02094235|Drug|Placebo|0.5 g placebo ointment
1619107|NCT02094235|Drug|E6005 0.2%|
1619109|NCT02094209|Device|SmartFix|AO Fracture Monitor attached postoperatively to a connection rod of the external fixator. The device continuously measures deformation of the fixator frame due to weight bearing for up to 4 months by means of a strain gauge.
1619110|NCT02094196|Other|Alcohol detoxification|Detoxified alcohol- dependent patients in an inpatient setting
1619111|NCT02094183|Other|GLP-1|GLP-1
1619112|NCT02094183|Dietary Supplement|low calorie diet|low calorie diet
1619202|NCT02093468|Drug|MST-188|
1619114|NCT02094157|Drug|Bridged regimen Low-molecular-weight heparin|This intervention is assigned to the active control arm - Bridged regimen
1619115|NCT02094144|Other|Brisk walking program|The intervention consists on achieve 40 minutes of brisk walking 3d/wk for 6 months (two supervised sessions and one session performed one their own per week with a detailed program). The intensity of the program is adapted to the heart rate work and gradually increases over the 6-month program
1619116|NCT02094144|Other|physical activity habit|The Intervention consists on maintain the lifestyle and especially their physical activity habits during 6 months
1619117|NCT02094131|Other|Voldyne group (VG)|"VG: slow deep breaths through the mouthpiece of the incentive Voldyne5000® were conducted from the tidal volume (TV) until the total lung capacity (TLC), holding the maximum inspiration. All individuals should maintain yellow cup (yellow flow cup) at a range of flow Best in as long as possible. The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
1619118|NCT02094131|Other|Cliniflo group (CG)|"CG: slow deep breaths through the mouthpiece of the incentive Cliniflo® from tidal volume (TV) were performed until the total lung capacity (TLC), holding the maximum inspiration. The volume flow of 100 ml / s for Cliniflo® was standardized, being envisaged to keep the yellow indicator behind the happy face for all individuals.The training lasted approximately 50 minutes, were held twice a week on alternate days, for five consecutive weeks, totaling 10 sessions. Performed three sets of 15 repetitions."
1619119|NCT02094118|Biological|Point-of-care washed red blood cell transfusion.|
1619120|NCT02094118|Biological|Standard of care red blood cell transfusion.|
1619121|NCT02094105|Procedure|Endoscopy examination with iodine staining|Endoscopy examination with Lugol's iodine staining and questionnaire once time and early treatment on precancerous lesions was undergone for the intervention group.
1619122|NCT02094092|Other|ProTectis drops (five drops per day) for 21 days|
1619123|NCT02094092|Other|Placebo drops (five drops per day) for 21 days|
1619124|NCT02094079|Other|biomedical outcomes|Evaluation of abnormal blodtests (evaluating thyroid function) from predefined control program
1619125|NCT02094066|Drug|tranexamic acid|preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes
1619126|NCT02094066|Drug|serum physiologic|preoperative 100 cc ıv serum physiologic
1619127|NCT02094053|Drug|E2020-Donepezil hydrochloride|3 mg of E2020 (oral) once daily, for 24 weeks
1619128|NCT02094053|Drug|E2020-Donepezil hydrochloride|5 mg of E2020 (oral) once daily, for 24 weeks
1619129|NCT02094053|Drug|Placebo|placebo (oral) once daily, for 24 weeks
1619130|NCT02094040|Behavioral|Receive municipality-based follow-up visit|Systematic electronic referral from hospital to municipality of high risk people at discharge from a medical ward. Contact from municipality service to primary physician and citizen, to arrange first home visit within 7 days with focus on: medication, rehabilitation plan and health care appointments, functional level and need for further health care initiatives. The visit is concluded by planning of further visits (up till tree) and division of responsibilities between primary physician and the municipality service.
1619131|NCT02094027|Behavioral|Guided Self Help|A behaviourally orientated guided self help book designed to reduce binge eating prior to surgery
1619132|NCT02094027|Other|Treatment As Usual|Binge eating disordered participants receive treatment as usual in the form of bariatric surgery (i.e. no pre-operative intervention to reduce binge eating)
1619133|NCT02094014|Behavioral|Normal Auditory Feedback|Participants will produce sentences under normal speaking conditions, able to hear their own speech.
1619134|NCT02094014|Behavioral|Masked Auditory Feedback|Participants will produce sentences while listening to speech-shaped noise at 85 decibels (sound pressure level) to mask ability to hear their own speech.
1619135|NCT02094014|Behavioral|Altered Auditory Feedback|Participants will produce sentences while listening to their speech shifted up one octave and delayed.
1619136|NCT02094001|Radiation|Cardiac PET imaging using F-18-FDG, N-13 ammonia( NH3)|After an overnight fast, patients will undergo a 20 minute dynamic PET scan with injection of 3 MBq/kg of N-13 ammonia (NH3) to measure myocardial perfusion. Followed by a 60 min dynamic PET scan with injection of 3MBq/kg of F-18-FDG to measure glucose uptake.
1619137|NCT02093988|Drug|Topical TXA|
1619138|NCT02093988|Drug|Intravenous TXA|
1619139|NCT02093975|Device|iPad air with 4G/3G SIM card|"iPad air with 4G/3G SIM card is used as device for videoconferencing. LifeSizeClearSea solution is used for videoconferencing.
Video consultation"
1619140|NCT02093962|Drug|TH-302 combination with pemetrexed|"400 mg/m2 of TH-302 will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.
Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after TH-302 administration."
1619141|NCT02093962|Drug|Matched placebo in combination with pemetrexed|"Matched placebo will be administered by IV infusion over 30 - 60 minutes on Day 1 and Day 8 of a 21-day cycle.
Pemetrexed (500 mg/m2) will be administered as an IV infusion on Day 1 two - four hours after placebo administration."
1619142|NCT02093949|Procedure|Routine substrate ablation without pulmonary vein Isolation|
1619143|NCT02093949|Procedure|Routine conventional ablation with pulmonary vein Isolation|
1619144|NCT02093923|Drug|DX-2930|DX-2930 is a recombinant, Chinese hamster ovary (CHO) cell expressed, fully human immunoglobulin IgG1, kappa light chain, monoclonal antibody
1619145|NCT02093923|Drug|Placebo|Placebo
1619146|NCT02093910|Drug|Monosialotetrahexosylganglioside|
1619147|NCT02093897|Biological|rVIII-SingleChain|
1619148|NCT02093884|Other|Text Messaging Intervention|
1619149|NCT02093884|Other|Standard Referral|
1619150|NCT02093871|Device|ThermalCore Hyperthermia System|Patients will undergo 6 cycles of therapeutic hyperthermia with the ThermalCore Perfusion Induced Systemic Hyperthermia System every 28 days
1619151|NCT02093845|Device|Biomatrix NeoFlex coronary stent|Percutaneous coronary intervention involving use of stent
1619152|NCT02093845|Device|SYNERGY stent|Percutaneous coronary intervention involving use of stent
1619153|NCT02093832|Other|There are no specific Intervention|are no specific Intervention
1619154|NCT02093819|Drug|Placebo to BI 416970|single rising doses
1619155|NCT02093819|Drug|BI 416970|single rising doses
1619156|NCT02093806|Other|measurment|
1619203|NCT02093468|Drug|Saline|
1619157|NCT02093793|Device|PRECISION SCS Adapted for High-Rate SCS|Comparison of spinal cord stimulation parameters
1619158|NCT02093780|Behavioral|Alberta Anti-inflammatory diet|Patients randomized to Alberta Anti-inflammatory diet will follow a strict menu plan designed by certified dietitian for 6 months.
1619159|NCT02093780|Behavioral|Canada's Food Guide Diet|Patients randomized to Canada's Food Guide diet will receive counseling by certified dietitian for 6 months and will design their own diet following Canada's Food Guide.
1619160|NCT02093767|Dietary Supplement|Synergy1|The prebiotic preparation, Synergy-1, consists of 1:1 inulin and oligosaccharide. The chicory derived inulin has a degree of polymerization (DP) of 10 to 60 (average DP of 25). The oligofructose is produced by partial enzymatic hydrolysis of chicory derived inulin and has a DP ranging between 3 and 7 (average DP of 4).
1619161|NCT02093754|Procedure|MRI and biopsy|
2010874|NCT02806674|Device|The eradication times of the patients|The patients who have failed more than 2 eradication courses with standardized treatment were the refractory infection of H. pylori group,and patients who succeeded at the first standardized treatment were the successful treatment group
1619163|NCT02093728|Drug|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 1, treatment A
1619164|NCT02093728|Drug|itraconazole|Volunteers will receive oral doses of itraconazole 200 mg twice daily on Day 1 to Day 7 in sequence 1 treatment B:
1619165|NCT02093728|Drug|itraconazole|Volunteers will recieve a single morning dose of 200mg itraconazole on Day 8 and twice daily doses of 200mg itraconazole on Day 8 to Day 11; sequence 1 treatment C.
1619166|NCT02093728|Drug|selumetinib|Volunteers willl recieve a single oral dose of 25 mg selumetinib (4 hours fasted state) on Day 8; sequence 1 treatment C.
1619167|NCT02093728|Drug|selumetinib|Volunteers will recieve single oral dose of 25mg selumetinib in sequence 2, treatment A.
1619168|NCT02093728|Drug|fluconazole|Volunteers will recieve a single dose of 400 mg fluconazole on Day 1 and daily doses of 200 mg fluconazole on Day 2 to Day 7; sequence 2 treatment D.
1619169|NCT02093728|Drug|fluconazole|Volunteers will receive a morning dose of 200mg fluconazole on Day 8 and daily doses of 200mg fluconazole on Day 8 to Day 11; sequence 2 treatment E
1619170|NCT02093728|Drug|selumetinib|Volunteers will receive a single dose of 25mg selumetinib (4 hours fasted state) on Day 8; sequence 2 treatment E
1619171|NCT02093702|Behavioral|Physical activity and exercise education and behaviour counseling from a Registered Kinesiologist and a YMCA Wellness Coach|
1619172|NCT02093702|Behavioral|Unstructured Physical Activity and Exercise Education|
2010875|NCT02806674|Device|The result of 13C-urea breath test after treatment|The intervention focused on the results from the result of 13C-urea breath test after treatment.The two groups were treatment based on the antibiotic susceptibility testing. Eight weeks after treatment,a 13C-urea breath test was performed on patients.The successful treatment group were patients with negative in 13C-urea breath tests in the first treatment. The refractory infection of H. pylori group were treatment failure patients after the second standardized treatment.
2010876|NCT02808312|Drug|GS-9674|GS-9674 10 mg tablet administered orally
1619175|NCT02093676|Behavioral|"experimental protocol treatment The New Authority"|
1619176|NCT02093663|Drug|MMX Mesalamine/Mesalazine (Low Dose)|Once daily, tablets - the amount depends on the subjects weight<br>&lt;br&gt;-900 mg/day for subjects weighing 18 to less than or equal to 23kg<br>&lt;br&gt;-1200 mg/day for subjects weighing &gt;23 to less than or equal to35kg<br>&lt;br&gt;-1800 mg/day for subjects weighing &gt;35 to less than or equal to 50kg<br>&lt;br&gt;-2400 mg/day for subjects weighing &gt;50 to less than or equal to 90kg.
1619177|NCT02093663|Drug|MMX Mesalamine/Mesalazine (High Dose)|Once daily, tablets - the amount depends on the subjects weight<br>&lt;br&gt;<br>&lt;br&gt;•1800 mg/day for subjects weighing 18 to less than or equal to 23kg<br>&lt;br&gt;•2400 mg/day for subjects weighing &gt;23 to less than or equal to35kg<br>&lt;br&gt;•3600 mg/day for subjects weighing &gt;35 to less than or equal to 50kg<br>&lt;br&gt;•4800 mg/day for subjects weighing &gt;50 to less than or equal to 90kg.
1619178|NCT02093650|Drug|black cohosh extract|Black cohosh extract 80 mg
1619179|NCT02093650|Drug|Placebo|Soy bean oil
1619180|NCT02093637|Other|Placebo acupuncture|Placebo Comparator
1619181|NCT02093637|Other|Battlefield Acupuncture|Experimental
1619182|NCT02093611|Dietary Supplement|Placebo|
1619183|NCT02093611|Dietary Supplement|ATP|400 mg of ATP
1619184|NCT02093598|Drug|Temsirolimus|
1619185|NCT02093585|Drug|abacavir (600 mg QD)|
1619186|NCT02093585|Drug|tenofovir (245 mg QD)|
1619187|NCT02093572|Other|3 standard meals/day|
1619188|NCT02093572|Other|2 meals/day (omit breakfast)|
1619189|NCT02093559|Behavioral|Brief counseling Intervention|The brief counseling intervention will utilize MI and skills-building techniques to modify personal overdose risk behaviors and develop skills as a peer responder for witnessed overdose. The counselor will draw upon themes of safer substance use to address HIV risk behaviors and determine readiness for change in substance use.
1619192|NCT02093520|Procedure|MILD Procedure|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
1619193|NCT02093520|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
1619194|NCT02093507|Other|parents manipulation|parents perform manipulation the child foot to correct the deformity
1619195|NCT02093494|Device|Initial Specimen Diversion Device (ISDD)|
1619196|NCT02093494|Procedure|Lab standard practice (LSP)|
1619197|NCT02093494|Device|Peripheral Intravenous Catheters (PIVC)|
1619198|NCT02093481|Other|Test meal|
1619199|NCT02093481|Other|Reference|
1619200|NCT02093481|Other|Priming|The reference or test meal was eaten 3 days prior to measurements of variables.
1619201|NCT02093481|Other|No priming|The reference or test meal was eaten 1 days prior to measurements of variables.
1957914|NCT02111213|Behavioral|Promotora for physical activity|A promotora is a trained, lay health worker. Promotoras will be trained and supervised to provide advice, support and guidance to people to encourage them to be more physically active. They work with people face to face and by telephone to offer support and advice.
1619204|NCT02093455|Dietary Supplement|Chardonnay Seed Flour (CSF)|CSF is made from wine grape skins and seeds.
1619205|NCT02093455|Dietary Supplement|Placebo|
1619206|NCT02093442|Procedure|Endometrial injury|Endometrial biopsy using a pipelle de Cornier
1619207|NCT02093429|Drug|INCB047986|INCB047986 will be supplied as tablets.
1619208|NCT02093403|Drug|decitabine|Given IV
1619209|NCT02093403|Drug|selinexor|Given PO
1619210|NCT02093403|Other|pharmacological study|Correlative studies
1619211|NCT02093403|Other|laboratory biomarker analysis|Correlative studies
1619212|NCT02093390|Drug|TAK-385|TAK-385 tablets
1619213|NCT02093390|Drug|Fluconazole|Fluconazole tablets
1619214|NCT02093390|Drug|Atorvastatin|Atorvastatin tablets
1619215|NCT02093377|Device|Adaptive servo-ventilation|Adaptive servo-ventilation (ASV, most recent technology of AutoSetCS device, ResMed, Sydney, Australia)
1619216|NCT02093351|Drug|Olaparib|2 x 150mg tablets, twice daily Day 1-5, and Day 27 onwards (Cohort 1), Day 20 onwards (Cohort 2) or Day 39 onwards (Cohort 3)
1619217|NCT02093351|Drug|Tamoxifen|60mg Tamoxifen once daily, Day 10 - Day 13; 20mg Tamoxifen once daily, Day 14 - Day 31
1619218|NCT02093351|Drug|Anastrozole|1mg Anastrozole once daily Day 10 - Day 24
1619219|NCT02093351|Drug|Letrozole|2.5mg Letrozole once daily Day 10 - Day 43
1619220|NCT02093351|Procedure|Pharmacokinetic sampling|Blood sampling over 12-24 hour period for pharmacokinetic analysis
1619221|NCT02093338|Dietary Supplement|Lactobacillus fermentum CECT5716|
1619222|NCT02093338|Other|Placebo Comparator: maltodextrin|Placebo
2010877|NCT02806232|Drug|Biltricide (racemate praziquantel) oral tablets|Biltricide supplied will be of 600 mg strength oral tablet. The tablets will be split in 4 if necessary to adjust the dose and then crushed, suspended in water and ingested.
2010878|NCT02806232|Drug|Racemate Praziquantel ODT|Racemate Praziquantel (PZQ) supplied will be of 150 mg strength ODT. The tablets will be suspended in water and ingested.
1619225|NCT02093312|Dietary Supplement|Home food-delivery service|A home food-delivery service is offered the intervention group of cancer patients
1619226|NCT02093299|Drug|Clopidogrel|a blood sample is drawn on all patients to determine responder status
1619227|NCT02093273|Biological|tOPV pilot batch|the tOPV vaccine is given orally
1619228|NCT02093273|Biological|tOPV commercial batch|tOPV vaccine is given orally
1619229|NCT02093260|Biological|Vaccine|"Flubio (Influenza HA) Vaccine
The vaccine will be given intramuscularly."
1619230|NCT02093234|Behavioral|mobile health care application|mobile health application for cell phones to assist patients in managing their diabetes.
1619231|NCT02093234|Behavioral|CHWs and mobile health care application|CHWs will assist diabetic patients in managing their health in conjunction with the mobile health care application.
1619232|NCT02093234|Behavioral|Community Health Worker (CHW)|CHWs assist patients in managing their diabetes in various ways.
1619236|NCT02093195|Drug|Bosentan|
1619237|NCT02093195|Drug|Symbicort turbuhaler|
1619238|NCT02093169|Drug|Part A: Lu AF35700|One 30 mg single dose for one day; orally
1619239|NCT02093169|Drug|Part B: Lu AF35700|Daily dosing: 10 mg for 3 days, 20 mg for 3 days, 45 mg on Day 7; orally
1619240|NCT02093156|Other|Bowel preparation instructions|The same-day preparation method was used as previously reported. Briefly, all patients were instructed to have a regular diet for breakfast and lunch, but only clear liquids for dinner on the day before the colonoscopy. They were asked to drink two bags of PEG-ELP (polyethylene glycol electrolyte powder) dissolved in 2 L of water, or 45 mL of sodium phosphate be diluted in 240 mL of cool water follow with at least 1.5 L of water at 05:00-06:00 h within 2 h on the day of colonoscopy. Patients were encouraged to drink more clear liquids after purgatives for adequate hydration before colonoscopy.
1619241|NCT02093143|Drug|Remifentanil|Target-controlled infusion of remifentanil 50 µg/ml using the pharmacologic model of Minto et al. to achieve a theorical brain concentration of 1.5 ng/ml.
1619242|NCT02093130|Dietary Supplement|Pomegranate Juice|
1619243|NCT02093130|Dietary Supplement|Placebo|
1619244|NCT02093117|Procedure|Recruitment maneuver|continuous positive airway pressure of 30 cm of water for 30 seconds
1619245|NCT02093117|Procedure|Sham recruitment maneuver|Continuous positive airway pressure of 5 cm of water for 30 seconds
1619246|NCT02093091|Procedure|Dental caries was removed from primary molars and was filled with the recent filling material; Ketac Nano.|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The recent nano-filled RMGI filling (Ketac Nano) was used to fill these cavities.
1619247|NCT02093091|Procedure|Dental caries was removed from primary molars and was filled with the conventional filling material;Vitremer|Class I carious primary molars were selected. Dental caries was removed and cavities were prepared. The conventional RMGI filling (Vitremer) was used to fill these cavities.
1619248|NCT02093078|Behavioral|CARD|"Intervention: CARD
This group will be introduced to the CARD protocol which focuses on clarification of individual roles and distribution of tasks. It relies on large identification cards specially designed for each team member's profession and role. Each card worn by a team member identifies the specific tasks associated with that individual's role. CARD enables the team leader and other team members to quickly recognize everyone's role at the code, and each team member can commence their assigned tasks without delay."
1619249|NCT02093052|Behavioral|Attachment and Biobehavioral Catch-up|Enhance nurturance and following the lead among parents. In-home intervention with parents and children present.
1619250|NCT02093052|Behavioral|Developmental Education for Families|Enhance children's cognitive development. In-home intervention with parents and children present.
1619251|NCT02093039|Device|decision aid group|The paper-based leaflet DECIDEO is a 12-page pocket leaflet providing scientific information about the advantages and disadvantages of participating in the national breast screening program, understandable by all, constructed to conform with the International Patient Decision Aid Standards
1619252|NCT02093026|Drug|Rituximab|Participants will receive rituximab 1 gram IV on Days 1 and 15 of each course of retreatment.
1619253|NCT02093026|Drug|Methotrexate|Participants will receive methotrexate 10-25 mg/week orally or parenterally.
2010879|NCT02806232|Drug|Levo Praziquantel ODT|Levo PZQ supplied will be of 150 mg strength ODT. The tablets will be suspended in water and ingested.
1619254|NCT02093026|Drug|Methylprednisolone|Participants will receive methylprednisolone 100 mg IV 30 minutes prior to each rituximab infusion.
1619255|NCT02093026|Drug|Folic Acid|Participants will receive folic acid >= 5 mg/week or equivalent.
1619256|NCT02093013|Other|Integrated care program|Integrated care program meant in effect, calling on the family medicine group (FMG) nurses to evaluate and support asthmatic patients. The FMG and asthma education centre (AEC) nurses received special training and followed a protocol based on the theoretical model and the Canadian asthma management recommendations then in force. The protocol had five main aspects: 1) asthma assessment, 2) self-management, 3) environment and lifestyle, 4) collaborative care plan, and 5) information sharing and follow-up.
1619257|NCT02093000|Drug|Bevacizumab|Participants will receive bevacizumab 7.5 milligrams per kilograms (mg/kg) intravenously according to bevacizumab summary of product characteristics/local labeling.
2010880|NCT02803554|Other|Plasma|Blood plasma from donors aged 25 years or younger
2010881|NCT02804386|Drug|Sofosbuvir|Sofosbuvir (formerly known as GS-7977) is a direct-acting nucleotide polymerase inhibitor that is being developed as an oral drug for the treatment of chronic HCV infection
1619260|NCT02092974|Procedure|tDCS|
1619261|NCT02092974|Drug|Citalopram|
1619262|NCT02092974|Other|sham-tDCS + placebo|
1619263|NCT02092961|Drug|Fostamatinib|Fostamatinib 100mg twice daily.
1619264|NCT02092961|Drug|Adalimumab|Adalimumab 40 mg by subcutaneous injection every 2 weeks for 24 weeks.
1619265|NCT02092961|Drug|Placebo of Fostamatinib|Placebo bid for 6 weeks.
1619266|NCT02092961|Drug|Placebo of Adalimumab|Placebo injection once every two weeks.
1619267|NCT02092948|Radiation|[124I] PSCA-Minibody PET/CT imaging of the whole body|
1619268|NCT02092935|Drug|SMT19969|
1619269|NCT02092935|Drug|Vancomycin|
1619270|NCT02092922|Drug|Filanesib, KSP (Eg5) inhibitor; intravenous|multiple dose, single schedule
1619271|NCT02092922|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
1619272|NCT02092909|Drug|IMO-8400|
1619273|NCT02092896|Drug|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
1619274|NCT02092896|Drug|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 1 is performed.
1619275|NCT02092896|Drug|Liraglutide|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
1619276|NCT02092896|Drug|Placebo|Subjects randomised to 1.2 mg liraglutide treatment or liraglutide placebo will receive 0.6 mg for 1 weeks followed by 1.2 mg for 11 weeks. At baseline and week 12 study 2 is performed.
1619277|NCT02092883|Drug|ACTH|PK PET scan before and after ACTH treatment
1619278|NCT02092870|Drug|Adipose derived stem cells|ASCs harvested from autologous lipoaspirate
1619279|NCT02092857|Dietary Supplement|Arachidonic acid (25 mg/100 kcal )|
1619280|NCT02092857|Dietary Supplement|Arachidonic acid (34 mg/100 kcal)|
1619281|NCT02092857|Dietary Supplement|Placebo|10 weeks exclusive infant formula feeding (without supplemental arachidonic acid).
1619282|NCT02092844|Behavioral|CBT for Menopausal Insomnia (CBTMI)|Cognitive Behavioral Therapy for Menopausal Insomnia (CBTMI) includes education about sleep, sleep restriction, stimulus control, cognitive restructuring of sleep interfering thoughts, and relapse prevention; while also addressing women's beliefs about and reactions to hot flashes.
1619283|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 1
1619284|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 2
1619285|NCT02092831|Drug|GDC-0941|Single dose market image tablet of hardness 3
1619286|NCT02092831|Drug|GDC-0941|Single dose Phase 2 tablet formulation
2010882|NCT02802345|Drug|Nintedanib|
1619288|NCT02092805|Procedure|Real rTMS(20 Hz, 10 trains, inter train interval 30 sc with total pulses 2000, intensity 80% of motor threshold) daily for 10 consecutive days (5 days/week)|
1619289|NCT02092805|Procedure|Sham rTMS (same parameters but with coil elevated and angled away from the head) every day for 10 consecutive days (5 days/week).|
1619290|NCT02092792|Drug|DLYE5953A|Escalating doses of DLYE5953A
1619291|NCT02092792|Drug|DLYE5953A|Administration of DLYE5953A at the recommended phase II dose (RP2D)
1619292|NCT02092766|Drug|artesunate|
1619293|NCT02092766|Drug|quinine|
1619294|NCT02092753|Other|Standard diet (SD)|Nutrition intervention following the recommendations of the germans society for nutrition (DGE)
1619295|NCT02092753|Other|Experimental 1: Ketogenic diet (KD).|Nutritional intervention: recommendations to follow a ketogenic diet
1619296|NCT02092753|Other|"Experimental 2: Low glycämic and insulinemic diet (LOGI)"|"Nutritional intervention: patients were instructed to follow the LOGI diet regimen"
1619297|NCT02092727|Behavioral|Behavioral Interventions for Dialysis Facilities|"Educational seminars and monthly educational webinars
Peer-to-peer mentoring program
Bulletin boards about transplantation
Facility-specific feedback reports detailing transplant referral data for their center compared to state average
Formulate a facility-specific improvement plan to increase transplant referrals.
Requirement to form a Patient and Family Advisory Group to increase outreach about transplant education within the facility.
Monthly monitoring and reporting of patient referrals to ESRD Network
Conduct a patient and family education session about transplantation
Host a movie day to show Living ACTS (About Choices in Transplantation & Sharing) video"
1619298|NCT02092714|Other|laboratory biomarker analysis|Correlative studies
1619299|NCT02092701|Drug|Cholecalciferol|
1619338|NCT02092428|Other|Diagnostic Accuracy|Both groups are eligible for all combinations of interventions. This arm will also include collection of conventional x-ray angiography.
1619583|NCT02090374|Other|TLR Agonist|Preceding incremental ascending dose study to be used to assess top safe dose.
2010883|NCT02802345|Drug|Placebo|
2010884|NCT02802345|Drug|Sildenafil|
1619300|NCT02092688|Device|novel kit for the detection of PAMG-1|The novel kit for the detection of PAMG-1 is a diagnostic device employing monoclonal antibodies that detect Placental α1 Microglobulin present in cervico-vaginal secretions manufactured by AmniSure® International, LLC, Boston, MA. The in vivo sensitivity detection threshold is 4ng/ml. During the test procedure, PAMG-1 from the sample sequentially binds to monoclonal antibody conjugated with labeled particles, then to monoclonal antibody immobilized on an insoluble carrier. The test requires a 30 second swab saturation in the vagina (a sterile speculum examination is not required), a 30 second active washing step whereby the swab just removed from the vagina is actively rotated in a solvent filled vial and lastly, a 5 minute waiting period from the time the swab is removed and the test strip is inserted if two testing lines do not appear sooner.
1619301|NCT02092662|Other|stroke|task-oriented therapy: physical and occupational therapy emphasizing integration of the patients needs, environment and context
1619302|NCT02092662|Other|Healthy controls|no treatment
1619303|NCT02092649|Dietary Supplement|Omega-3 Complete|
1619304|NCT02092649|Dietary Supplement|Placebo Pill|
1619305|NCT02092636|Other|NIR/US Diagnostic Group|Patients receiving an ultrasound-guided biopsy will participate in one study visit on the day of the biopsy. The NIR/US scan will be completed immediately prior to the biopsy procedure and takes about 5-10 minutes to perform.
1619306|NCT02092636|Other|NIR/US Neoadjuvant Chemotherapy Group|Patients may have the NIR/US scan performed at the time of their initial ultrasound-guided biopsy. In addition, patients in this group may also have NIR/US performed according the schedule in Table 1. The number of NIR/US study visits for these subjects will vary from 1-11 depending on the subject's treatment regimen. The expected duration of study participation for these patients is approximately 6 months.
1619307|NCT02092636|Other|NIR/US Process Validation Group|Patients who present with visible lumps at initial ultrasound but do not have ultrasound visible lumps on the day of the biopsy procedure will not require a biopsy. NIR/US scan will be performed. Data from the NIR/US scan will be used to validate instrument measurements.
1619308|NCT02092623|Device|Transvaginal posterior mesh|A trocar-free fixation system with low-weight mesh
1619309|NCT02092610|Device|Novel Implant BI300|The Novel Implant BI300 was the new titanium implant and abutment for the Baha system developed by Cochlear Bone Anchored Solutions AB. The novel implant is 4.5 mm wide and 4.0 mm long.
1619310|NCT02092610|Device|Standard Implant BI300|The Standard Implant BI300 was the standard titanium implant and abutment in the Baha system developed by Cochlear Bone Anchored Solutions AB. The implant is 3.75 mm wide and 4.0 mm long
1619311|NCT02092597|Drug|Exenatide|
1619312|NCT02092597|Drug|Linagliptin|
1619313|NCT02092597|Drug|Gliclazide|
1619314|NCT02092584|Dietary Supplement|Omega-3|4 cap 1 g Omega-3 per day for 2 months
1619315|NCT02092584|Dietary Supplement|Placebo|4 cap 1 g Placebo(paraffin) per day for 2 months
1619316|NCT02092571|Drug|Progesterone vaginal ring,|Participants will be randomized to receive treatments in 1 of 2 treatment sequences (AB or BA)
1619317|NCT02092558|Drug|Second-generation cephalosporin, nitrofurantoin, 1% aminoglycoside solution|
1619318|NCT02092558|Drug|cephalosporin with chemotherapeutics|Second-generation cephalosporin was prescribed for 10 days, and then treatment crossover with chemotherapeutics in therapeutic dose (change in every week) during 3 months
1619319|NCT02092545|Other|Ketogenic diet|
1619320|NCT02092532|Drug|Rescue Intravitreal Aflibercept Injection|Patients can receive additional IAI treatment (Months 3, 5, 7, 9, and 11) if the re-treatment criteria are met.
1619321|NCT02092532|Procedure|Rescue Therapy with PDT, Laser or Intravitreal Steroids|Starting at Month 3, patients can receive non-anti VEGF rescue therapy (ie: PDT, laser, intravitreal steroids) if the pre-defined criteria are met.
1619322|NCT02092519|Device|Needle with sideport (NA-230H-8020)|EUSFNA using needle with sideport
1619323|NCT02092519|Device|Needle without sideport (NA-220H-8022)|EUSFNA using needle without sideport
1619324|NCT02092506|Drug|10 day triple therapy|10 day triple therapy
1619325|NCT02092506|Drug|10 day sequential therapy|10 day sequential therapy
1619326|NCT02092506|Drug|10 day concomitant therapy|10 day concomitant therapy
1619327|NCT02092493|Device|ScopeGuide|These patient will have their procedure undertake with the use of ScopeGuide, which provides a 3d configuration of the colonoscope in the patient
1619328|NCT02092480|Behavioral|If I Were Jack|The If I Were Jack intervention is a classroom-based RSE resource designed to be delivered by teachers over four weeks. It is composed of: (i) An interactive video drama which asks pupils to put themselves in Jack's shoes and consider how they would feel and what they would do if they were Jack; (ii) Classroom materials for teachers containing detailed lesson plans with specific classroom-based and homework activities; (iii) 60-minute training session for teachers wishing to implement the intervention; (iv) 60-minute information and discussion session for parents/guardians delivered by RSE teachers; (v) Brochures and factsheets about the intervention and unintended teenage pregnancy for schools, teachers, teacher trainers, young people and parents.
1619329|NCT02092467|Drug|tofacitinib|Oral tablet, 5 mg BID
1619330|NCT02092467|Drug|tofacitinib|Oral tablet, 10 mg BID
1619331|NCT02092467|Biological|adalimumab|Pre-filled syringe, 40 mg subcutaneous injection, every other week
1619332|NCT02092467|Biological|etanercept|Pre-filled syringe, 50 mg subcutaneous injection, every week
1619333|NCT02092454|Drug|Benzocaine|topical otic solution
1619334|NCT02092454|Drug|Placebo|topical otic solution
1619335|NCT02092441|Other|Alcohol prep pad group|Subjects inhale scent of alcohol pad
1619336|NCT02092441|Other|Normal Saline prep pad|Subjects inhale scent of placebo (normal saline) pads
1619337|NCT02092428|Other|Image Quality|"The following procedures may be conducted as part of this study:
Coronary MRI scan with no contrast
Coronary MRI scan enhanced with a gadolinium-based contrast agent (Optimark, MultiHance, Ablavar) administered intravenously at a total dose of up to 0.2 mmol/kg
MRI scan with an oral beta blocker (metoprolol)
Cardiac Stress Test MRI scan with a pharmacologic stress drug; either adenosine (dosage depends on the subject's weight and is set at 140mcg/kg/min) or regadenoson (0.4mg/5ml bolus)
Determination of study drugs will be made depending upon study focus, subjects' health conditions, blood pressure, heart rate and concomitant medications. Both groups are eligible for all combinations of interventions."
1619837|NCT02088385|Device|Combined Conventional Technique|
1619339|NCT02092415|Device|Application of a Junctional Tourniquet|All subjects will be studied at baseline and after placement of a junctional tourniquet to the femoral artery.
1619340|NCT02092402|Other|Fecal transplantation|
1619341|NCT02092376|Drug|Cholecalciferol|
1619342|NCT02092376|Drug|Placebo|
1619343|NCT02092363|Drug|OMP-54F28, Paclitaxel and Carboplatin|
1619344|NCT02092350|Drug|Grazoprevir|Grazoprevir 100 mg tablet
1619345|NCT02092350|Drug|Elbasvir|Elbasvir 50 mg tablet
1619346|NCT02092350|Drug|Placebo to Grazoprevir|Placebo tablet matched to grazoprevir
1619347|NCT02092350|Drug|Placebo to Elbasvir|Placebo tablet matched to elbasvir
1619348|NCT02092337|Other|computer-assisted speech training|
1619349|NCT02092324|Other|Laboratory Biomarker Analysis|Correlative studies
1619350|NCT02092324|Other|Quality-of-Life Assessment|Ancillary studies
1619351|NCT02092324|Drug|Ruxolitinib Phosphate|Given PO
1619352|NCT02092311|Procedure|Combined Microscopic Varicocelectomy|After making a mini-incision at inguinal level, veins are evaluated, and if the including criteria (Complexity and tortuosity of the veins and/or existence of veins that are contiguous with arteries so that separating and ligation of the veins could jeopardize the artery) are existed, only external spermatic vein, if dilated, is ligated at the depth of the inguinal canal, and other veins are left alone for prevention of damage to the artery. Subsequently, another mini-incision is made at high inguinal level and the rest of surgery is conducted by retroperitoneal approach, which is also done microscopically
1619353|NCT02092311|Procedure|Inguinal and Subinguinal varicocelectomy|Microscopic Inguinal and Sub inguinal varicocelectomy, recommended by Goldstein and associates, are currently popular approaches. In this approach the spermatic cord structures are pulled up and out of the wound so that the testicular artery, lymphatics, and small periarterial veins may be more easily identified. In addition, an inguinal or subinguinal approach allows access to external spermatic and even gubernacular veins.
1619354|NCT02092298|Drug|Mitomycin C|Mitomycin C 30 mg delivered laparoscopically for 60 minutes.
1619355|NCT02092298|Drug|Cisplatin|Cisplatin 200 mg delivered laparoscopically 60 minutes, 2-8 weeks after completion of systemic chemotherapy.
1619356|NCT02092298|Drug|Sodium Thiosulfate|Loading dose of 7.5 gm/M2 of Sodium Thiosulfate infused prior to addition of Cisplatin to the peritoneal perfusion circuit. Then a maintenance infusion of Sodium Thiosulfate 25.56 gm/M2 delivered by continuous infusion pump over 12 hours.
2010885|NCT02802059|Drug|EcN-Suspension|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administerd within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).
Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administerd within 10 days (1 ampoulle per day)."
1619358|NCT02092272|Behavioral|instructional exercise video source|instructional exercise video source
1619359|NCT02092246|Device|Ultrasound machine|Use of ultrasound machine guidance for accurate needle placement into the knee joint
1619360|NCT02092246|Device|Unguided injection|Needle placement will take place without ultrasound machine guidance
1619363|NCT02092207|Drug|KL7016 900mg|oral administration, 150mg 3tab, bid
1619364|NCT02092207|Drug|KL7016 600mg|oral administration, 150mg 3tab, bid
1619365|NCT02092207|Drug|Placebo|oral administration, 150mg 3tab, bid
1619366|NCT02092194|Procedure|High Dose Online HDF|Convection volume; 33-43 L/treatment (140-180 mL/min)
1619367|NCT02092194|Procedure|Standard Dose Online HDF|convection volume; 16.8-21.5 L/treatment (70-90 mL/min)
1619368|NCT02092181|Drug|Mirabegron|25 mg po daily for 32-40 days. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
1619369|NCT02092181|Drug|Placebo|Placebo 25 mg po daily. Following up-titration to 50 mg po daily. This is pending no adverse events on the 25 mg dose.
1619370|NCT02092168|Drug|BIA 9-1067|
1619372|NCT02092116|Drug|Romidepsin|Latency reversing agent
1619373|NCT02092116|Biological|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
1619374|NCT02092116|Biological|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
1619375|NCT02092103|Procedure|Cord Milking|See description in cord milking arm.
1619376|NCT02092090|Behavioral|Dietary sodium reduction|Ongoing dietary advice and a supply of a reduced-sodium added-potassium salt substitute
1619377|NCT02092077|Drug|TV-1106|TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg
1619378|NCT02092077|Drug|somatropin|Dose may be adjusted as required
1619379|NCT02092051|Device|Continuous glucose monitoring with DexCom G4 platina|
1619380|NCT02092038|Drug|Temozolomide|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
1619381|NCT02092038|Radiation|partial brain irradiation|Neoadjuvant treatment with concurrent temozolomide and radiation therapy, followed by surgery and then further temozolomide.
1619382|NCT02092038|Procedure|stereotactic biopsy of brain tumor|will be assessed for tumor type and tumor markers
1619383|NCT02092038|Procedure|craniotomy and tumor resection|maximal safe resection
1619385|NCT02092012|Drug|dexketoprofen trometamol|ıv 50 mg dexketoprofen trometamol after anaesthesia induction
1619386|NCT02092012|Drug|Dexmedetomidine|ıv 1 mcg/kg dexmedetomidine after anaesthesia induction
1619387|NCT02091999|Drug|ASG-22CE|intravenous (IV) infusion
1619388|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/2.25 µg, 2 acuations twice daily
1619389|NCT02091986|Drug|Symbicort pMDI|Budesonide/formoterol pMDI 80/4.5µg, 2 acuations twice daily
1619390|NCT02091986|Other|Budesonide pMDI|Budesonide pMDI 80µg, 2 acuations twice daily
1619391|NCT02091973|Drug|Everolimus|Everolimus dosing to target tough level 6-10 mg/ml
1619392|NCT02091973|Drug|Tacrolimus|Tacrolimus dosing to target tough level 5-10 ng/ml
1619393|NCT02091960|Drug|enzalutamide|oral
1619394|NCT02091960|Drug|trastuzumab|Intravenous infusion (IV) or subcutaneous if it is standard of care within a country
1619395|NCT02091947|Device|FMS (Magstim rapid2)|5 Hz FMS, over bilateral sacral roots.
1619396|NCT02091934|Procedure|Wavefront-guided PRK|Wavefront-guided PRK
1619397|NCT02091934|Procedure|Wavefront-optimized PRK|Wavefront-optimized PRK
2010886|NCT02802059|Drug|Placebo|"Initial administration not later than 120h after birth. 14 ampoules a 1 ml are administerd within a time of 3 weeks (1 ampoule per day within first week and 1 ampoule every second day within the following two weeks).
Subsequent re-administration after 6 and 12 months. 10 ampoules a 1 ml are administerd within 10 days (1 ampoulle per day)."
1619399|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
1619400|NCT02091908|Biological|Novartis Investigational H5N1 vaccine|2 doses of 0.5 ml, 3 weeks apart
1619401|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
1619402|NCT02091908|Biological|Novartis Seasonal Influenza Vaccine|2 doses of 0.5 ml, 3 weeks apart
1619403|NCT02091895|Procedure|probe-based confocal laser endomicroscopy|"After shooting 10% fluorescein sodium in,2.5-5 .0 ml to the object with colorectal disease, the lesion will observed and evaluated with pCLE in real-time and also stored the inspection images.
Then, determines the treatment plan to determine which is applied currently in clinical, Sensitivity, specificity, accuracy, amphoteric predict of pCLE diagnosis, and calculate the agreement of prediction compared to the pathological findings of lesions Based on the inspection image stored, using Delphi approach tests, two or more are discussed, to derive a significant technical phrases.
Check diagnostic agreement of technical phrases which are derived, the matching degree between observers, and developed a new classification method based on this."
1619404|NCT02091882|Device|MIND1 System|Following placement of the Patch by clinic staff, subjects will ingest one IEM tablet approximately every 2 hours, for a total of 4 ingestions. The subject will ingest one 10 mg aripiprazole-embedded IEM tablet without food (Hour 0), one placebo-embedded IEM tablet without food (approximately Hour 2), one placebo-embedded IEM tablet with a high fat meal (approximately Hour 4), and one placebo-embedded IEM tablet without food (approximately Hour 6). Aripiprazole-embedded IEM tablets are being tested along with the placebo-embedded IEM tables to assess any differences in accuracy of IEM detection and latency. The time of ingestion will be recorded by clinic staff, and the time of IEM detection by the MIND1 System phone will be evaluated to determine the period of latency.
2010887|NCT02801825|Procedure|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.|Real-time ultrasound-guided in-plane infraclavicular axillary artery cannulation.
2010888|NCT02801825|Procedure|Real-time ultrasound-guided out-of-plane femoral artery cannulation|
1619407|NCT02091856|Behavioral|Cognitive Behavioral Therapy (CBT)|Cognitive behavioral therapy (CBT) represents a psychotherapeutic approach that helps patients understand the thoughts and feelings that influence behaviors. The underlying concept behind CBT is that thoughts and feelings play a fundamental role in behavior. Beyond the conventional CBT techniques proven effective for MDD, the Positive CBT intervention includes set of exercises devised from the positive psychology paradigm. Similarly, the Christian CBT intervention includes a comparable set of exercises rooted on the general Christian belief.
1619408|NCT02091843|Procedure|DBS of the Basolateral Nucleus of the Amygdala|
1619409|NCT02091843|Device|Medtronic Activa PC DBS of the Basolateral Nucleus of the Amygdala|
1619410|NCT02091830|Drug|Paracetamol and nonsteroidal antiinflammatory drug (NSAID)|
1619411|NCT02091830|Other|Physiotherapy|
1619412|NCT02091830|Drug|Cortisone Injection|
1619413|NCT02091830|Other|Others|
1619414|NCT02091817|Drug|Oxytocin|Intervention will be examined on control group, and on experimental group as well.
1619415|NCT02091817|Drug|Placebo|Placebo will be given to control group and experimental group as well.
2010889|NCT02796508|Behavioral|Experimental: Non-action video game training|PSI2013-41409R. Effects of video game training on behavioral and neuroimaging measures of attention and memory
2010890|NCT02796508|Behavioral|Active Comparator: Non-cognitive video game training|16 training sessions with The Sims over 8-10 weeks in small groups
1619418|NCT02091791|Procedure|Traction sessions|
1619419|NCT02091778|Device|Fast gelling dressing|
1619420|NCT02091765|Behavioral|Internet-based cognitive behavioral therapy.|
1619421|NCT02091752|Drug|Ruxolitinib|Starting dose was based on reason for previous discontinuation of ruxolitinib (i.e. loss of response or AE) and baseline platelet count. For participants who previously discontinued ruxolitinib due to loss of response, the starting dose was determined based on baseline platelet counts as follows: participants with a baseline platelet count of ≥ 200 x 109/L began dosing at 20 mg po bid; participants with a baseline platelet count of 100 x 109/L to <200 x 109/L began dosing at 15 mg po bid. Participants who previously discontinued ruxolitinib due to an AE initiated therapy at a total daily dose 5 mg lower than the total daily dose prior to discontinuation.
1619422|NCT02091739|Drug|IncobotulinumtoxinA (100 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
1619423|NCT02091739|Drug|IncobotulinumtoxinA (75 Units)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
1619424|NCT02091739|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
1619425|NCT02091726|Procedure|Unicirc instrument plus cyanoacrylate tissue adhesive|Volunteers will be circumcised using the Unicirc surgical instrument and the incision will be sealed using cyanoacrylate tissue adhesive
1619668|NCT02089581|Drug|MRXXX and MR1XXX|MRXXX and MR1XXX in fed and fasted state
2010891|NCT02795767|Drug|Emicizumab|Emicizumab will be administered as per the schedule specified in the respective arm.
2010892|NCT02796326|Device|improved tracheal balloon dilatation|Treatment for laryngotracheal stenosis using a modified tracheal dilatation balloon
2010893|NCT02793219|Biological|Sipuleucel-T|
2010894|NCT02793219|Drug|Docetaxel|
2010895|NCT02793765|Drug|Docetaxel|
2010896|NCT02793765|Biological|Sipuleucel-T|
2010897|NCT02792725|Drug|Abemaciclib|Administered orally
2010898|NCT02792179|Drug|[18F]RO6958948|Radiolabeled low molecular weight compound, administered as single IV injection. The mass dose of [18F]RO6958948 injected will be less than or equal to (</=) 10 micrograms (µg), injection volume </=20 mL. Target injected activity for [18F]RO6958948 will be 370 megaBecquerel (MBq) (10 millicurie [mCi]).
2010899|NCT02789774|Procedure|Posterior fusion C1-C2|Posterior access and screws in C1 (atlas) and C2 (axis) and fusion with addition of iliac crest bone graft. No postoperative collar.
1619426|NCT02091713|Other|Functional movement screen|The subjects will undergo movement and balance screens, measures of power, demographic data and biopsychosocial measures. Injury data will be collected through physician exam, self-report, profile data, and healthcare utilization data. Injury data will be collected at baseline and for six iterations, every 60 days, over the course of one year following baseline. Based on the data collected, clinical prediction rules will be used to develop computerized algorithm to predict injury risk in these populations.
1619427|NCT02091700|Other|Indocyanine Green ICG|
2010900|NCT02789774|Procedure|Rigid cervical collar|External immobilization of cervical spine in a rigid collar for 12 weeks.
1619429|NCT02091661|Procedure|Radical retropubic prostatectomy|The surgery arm underwent radical retropubic prostatectomy, performed by a technique described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible. The degree to which the surgeon preserve the nerves is categorized as non-nerve-sparing, unilateral nerve-sparing, or bilateral nerve-sparing. Pelvic lymph node dissection is performed if feasible. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 6 to 9 days to facilitate bladder emptying.
1619430|NCT02091661|Radiation|External beam radiotherapy|External beam radiotherapy is carried out with intensity-modulated radiation technique. The treatment is designed to maximize the radiation dose to the prostate and seminal vesicles and minimize exposure to surrounding structures, including the bladder and rectum. Radiation to the prostate was delivered in fractionated doses divided over multiple treatments (180 to 200 centigray (cGy) daily fractions, 5 days per week) for a total dose to the prostate of 68 to 77 gray (Gy), prescribed at 90% to 100% of the isodose line.
1619431|NCT02091648|Behavioral|I Can Cope Intervention|"Participants randomized to the I Can Cope condition will receive 6 face-to-face individualized sessions over a 2-month period. Each session will last 50 minutes and take place at the child's school either during approved times during the school day or as part of the after-school program. Sessions are psychoeducational and experiential and include opportunities for the child with asthma to: (1) learn about the pathophysiology of asthma; (2) understand the biological impact of stress on the body; (3) learn the relationship among thoughts, feelings, actions, and asthma; (4) acquire a set of coping skills to help deal with asthma-related and day-to-day stressors in their lives, and (5) receive training in biofeedback-assisted relaxation techniques."
1619432|NCT02091648|Behavioral|Standard Education Intervention|"This group will receive the standard American Lung Association (ALA)Open Airways for Schools program. This program includes six 40-minute sessions covering the National Heart Lung and Blood Institute's recommendations for asthma education."
1619433|NCT02091635|Drug|Placebo (for Motilitone)|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
1619434|NCT02091635|Drug|Motilitone|Eligible subjects were randomly allocated in a 1 : 1 ratio to receive either 60 mg motilitone (motilitone group) or placebo (placebo group) three times daily (before meals) for 5 days (days 1-5).
1619435|NCT02091622|Other|Educative intervention|Two municipalities (in charge of nursing homes) and two hospitals were randomized to receive an interactive half-day course about ITEOL for physicians and nurses.
1619436|NCT02091609|Other|dental interproximal brush|use of this to maintain oral hygiene
1619437|NCT02091609|Other|dental floss|use of this to maintain oral hygiene
1619438|NCT02091596|Drug|PluroGel N|Study Drug
1619439|NCT02091596|Drug|PluroGel|PluroGel Vehicle Placebo Comparator
2010901|NCT02787005|Biological|Pembrolizumab|Intravenous infusion
2010902|NCT02787005|Drug|Enzalutamide|Oral capsules
2010903|NCT02786953|Behavioral|Sleep Promotion|Behavioral intervention to improve sleep quality and duration.
1619444|NCT02091570|Other|Nutrition Bar|Intervention involves consumption of one nutrition bar of approximately 50 g in the beginning of each visit of the crossover sequence
1619445|NCT02091557|Drug|GnRH-analogue|
1619446|NCT02091544|Other|Lifestyle intervention|
1619447|NCT02091531|Drug|MLN0128|
1619448|NCT02091518|Behavioral|MR Screening Questionnaire|All participants will complete the MR Screening Questionnaire before the MRI exam. During the MRI exam, all participants will be observed through the window from the operator console. Verbal communication will be kept with the participant throughout the exam via a speaker system.
1619449|NCT02091518|Device|Magnetic Resonance Imaging Acquisition and Analysis|MRI Studies: The MRI scans will be performed on a 1.5T or 3T MRI scanner. Conventional MRI studies will be performed using the standard clinical sequences. The new research sequences will be performed.at any point during the clinical exam. Total imaging time for volunteers will be 30-45 minutes.
1619450|NCT02091505|Drug|Ranibizumab|
1619451|NCT02091492|Drug|Teriparatide|Teriparatide 20 µg sc (subcutaneous injection) each day for 12 weeks
1619452|NCT02091492|Drug|Placebo|Placebo teriparatide sc (subcutaneous injection) each day for 12 weeks
1619453|NCT02091479|Drug|UFH Early group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).
Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
1619454|NCT02091479|Drug|UFH Late group|"Either curative dose, intravenous unfractionated heparin (UFH) so as to reach an anti-Xa activity between 0.3 and 0.7 IU/mL, lengthening the activated prothrombin time as determined by each centre according to the treatment area (depending on the coagulometer and reactants).
Or low-molecular-weight, curative dose, subcutaneous heparin (LMWH) so as to reach an anti-Xa activity corresponding to treatment areas as determined for each type of molecule (about 0.5 to 1 anti-Xa IU for most LMWHs, administered via 2 daily injections, and about 0.5 to 1.5 anti-Xa IU for tinzaparin, 1 injection daily)."
1619455|NCT02091466|Device|pre-warming|warming patients 30 minutes prior to anesthesia
1619495|NCT02091154|Behavioral|USDA Regulations|"Implement new USDA regulations assigned school cafeterias.
Fruit or vegetable on every tray
Meet requirements for vegetable varieties
50% of all grains must be whole grain
Milk must be 1% or skim; flavored milk must be skim"
1620239|NCT02085408|Other|questionnaire administration|Ancillary studies
1619456|NCT02091453|Behavioral|APT training|APT training was used as intensive area-specific cognitive training at four levels: sustained, selective, divided and alternating attention. The APT also includes education in acquired attention deficits and training for generalization. Each session took 45-90 minutes to perform. The APT-test was used to determine the level of difficulty for the attention training.
1619457|NCT02091453|Behavioral|Multiprofessional rehabilitation|Attention training in activities included standard occupational training within an interdisciplinary rehabilitation programme. The programme consisted of training and the use of compensatory strategies in attention-demanding activities of daily living, performing independent work with attention-demanding tasks at individual level and group activities
2010904|NCT02787655|Behavioral|Aerobic exercise|stationary bicycling
1619459|NCT02091414|Drug|mycophenolate mofetil (MMF)|1.0 g PO BID
1619460|NCT02091414|Drug|cyclosporine A (CsA)|Initial loading dose of 4 to 6 mg/kg within 48 hours of transplantation, adjusted thereafter to a blood trough concentration of 150 to 300 ng/mL
1619461|NCT02091414|Drug|corticosteroids|As per the practice of each participating center
2010905|NCT02787655|Behavioral|Cognitive training|20 minutes of cognitive training using Mindfit program
2010906|NCT02784795|Drug|LY3039478|Administered orally
2010907|NCT02784795|Drug|Taladegib|Administered orally
1619465|NCT02091388|Drug|LY03004|
1619466|NCT02091388|Drug|Risperdal® Consta®|
1619467|NCT02091375|Drug|GWP42003-P|GWP42003-P is an oral solution presented as an oily solution containing 25 mg/mL cannabidiol (CBD: FT0086) or 100 mg/mL CBD (FT0095) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1619468|NCT02091375|Drug|Placebo control|Placebo oral solution contains the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1619469|NCT02091362|Drug|LY2409021|Administered orally
1619470|NCT02091362|Drug|Placebo|Administered orally
1619471|NCT02091349|Other|polydextrose|polydextrose- 7, 14, or 21 grams/day 3X3 latin square with 3 periods
1619472|NCT02091349|Other|soluble corn fiber|nutirose- 7, 14, or 21 grams/day
1619473|NCT02091336|Drug|Metformin|patients treatment
1619474|NCT02091336|Drug|Glyburide|patients treatment
1619475|NCT02091323|Procedure|gastric bypass surgery|With the patient under intubation and general anesthesia, a pneumoperitoneum was created and the pressure was set to 15 mmHg. All LRYGB operations were performed using four trocars. Separate cardiac angle and hepatogastric ligament from the left gastric artery between 2 and 3 branch by hanging liver on the abdominal wall so as to enter into the lesser sac. Reveal the ligament of Treitz, lift the jejunum from the Treitz ligament 75 ~ 150 cm, connect the distal jejunum to the posterior wall of the stomach with a linear cutting staple by an end-to-side anastomosis and suture the common opening at last.
1619476|NCT02091310|Drug|Placebo|
1619477|NCT02091310|Drug|GFT505|
1619478|NCT02091310|Drug|Moxifloxacin 400 mg|
1619479|NCT02091297|Drug|TAP Block|This intervention of a TAP block will be compared to the intervention of Common Care and to the intervention of Patient Controlled Epidural Analgesia
1619480|NCT02091297|Drug|Ropivacaine|The intervention of the Patient Controlled Epidural Analgesia will be compared to the intervention of a TAP block and the intervention of Common Care
1619481|NCT02091297|Drug|Acetaminophen|"Common ways to treat pain control after Cesarean Section include oral and IV opioids, non-narcotic adjuncts such as non-steroidal anti-inflammatory drugs and acetaminophen, and long-acting spinal or epidural opioids such as morphine. Due to the potential issues such as ineffectiveness and fear of respiratory depression, increasing the dosing of these opioids may not be ideal.
The intervention of Common Care will be compared to the intervention of a TAP block and the intervention of Patient Controlled Epidural Analgesia"
1619482|NCT02091297|Drug|Morphine|
1619483|NCT02091284|Device|transcranial Direct Current Stimulation|Direct currents will be transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode will be placed over F3 according to the 10-20 international system while the anode will be placed over the contralateral F4 region. The currents will flow continuously for 20 minutes with an intensity of 2 milliamperes.
1619484|NCT02091245|Drug|KPT-330|
2010908|NCT02784795|Drug|Abemaciclib|Administered orally
1619486|NCT02091219|Drug|Vitamin D|2400 IU/day by mouth for 16 weeks
1619487|NCT02091219|Drug|25(OH)D3|20 micrograms/day by mouth for 16 weeks
1619488|NCT02091206|Drug|GWP42003-P|"GWP42003-P is an oral solution presented as an oily solution containing 25 mg/mL cannabidiol (CBD: FT0086) or 100 mg/mL CBD (FT0095) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Subjects will be randomly assigned to receive either 5, 10 or 20 mg/kg/day."
1619489|NCT02091206|Drug|Placebo control|Placebo oral solution contains the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1619490|NCT02091193|Dietary Supplement|Krill Oil (Supplement A)|
1619491|NCT02091193|Dietary Supplement|Placebo (Supplement B)|
1619492|NCT02091180|Drug|Mannitol|0.5g/kg of 20% intravenous (i.v.) mannitol infusion over 10 minutes immediately before induction of anesthesia
1619493|NCT02091180|Drug|Control|Saline infusion
1619494|NCT02091167|Device|transcranial Direct Current Stimulation|Direct currents will be transferred via a pair of carbonated-silicone electrodes (35 cm2) with a thick layer of high conductive gel for EEG underneath them. The electric current will be delivered by an electric stimulator. To stimulate the left DLPFC, the cathode electrode will be placed over F3 according to the 10-20 international system while the anode will be placed over the contralateral F4 region. The currents will flow continuously for 20 minutes with an intensity of 2 milliamperes.
1619541|NCT02090764|Drug|Placebo|
1619542|NCT02090738|Drug|Acetazolamide group|
2010909|NCT02784795|Drug|Cisplatin|Administered IV
2010910|NCT02784795|Drug|Gemcitabine|Administered IV
2010911|NCT02784795|Drug|Carboplatin|Administered IV
2010912|NCT02784795|Drug|LY3023414|Administered orally
1619496|NCT02091154|Behavioral|Marketing Kit|"This marketing tool kit is designed to encourage purchasing of school lunches. The marketing tool kit included the following components:
56''x72'' vinyl sign with the words [school mascot] Cafe
8.5''x11'' signs describing the foods offered on a specific day
2''x4'' signs used to name all foods. These were to be placed in a visible location near the corresponding food.
Magnetic board displaying a tray onto which magnets shaped as food can be placed to show what foods were being offered during a specific lunch shift."
1619497|NCT02091154|Behavioral|Smarter Lunchrooms Makeover (SLM)|"Implement three basic Smarter Lunchrooms techniques. It consists of the following components:
Place fruit in an attractive bowl or serving dish and set on two places on the line. One of the places should be at or near the register.
Give all vegetables descriptive names and write or type them on a 2''x4'' card. These cards should be visible and placed near the corresponding food.
Make white milk the most prominent milk in the milk coolers by making it the most available milk and easiest to take."
2010913|NCT02783417|Other|Strength Training|"G1: will be three series of repetitions to the concentric failure with occlusion pressure, with the two-second intervals for the concentric phase and two seconds for the eccentric phase (Moore et al., 2004;. LAURENTINO et al, 2012), with 30% of 1RM and intermittent vascular occlusion members. Will be provided one-minute intervals between sets and exercises (with the exception of the interval between the exercises of upper and lower; being provided at present a three-minute break for removal and installation of restrictive cuffs).
G2: will be three series of repetitions to the concentric failure, with cadence of movement and intervals similar to the G1. The intensity will be 80% of 1RM without occlusion."
2010914|NCT02783521|Behavioral|Counseling sessions|During the first 12 weeks, intervention participants will attend weekly 30-45-minute individual counseling sessions guided by a trained bilingual Hispanic male lifestyle coach. Counseling sessions will be tailored to the needs of the participants (e.g., evening/weekend sessions, waiting/childcare area). After 12 weeks, intervention group participants will receive bi-weekly phone calls across a 12-week follow-up. Phone calls will last approximately 10 minutes in duration and study staff will follow a script to review current body weight, eating and activity behaviors, and specific barriers for weight loss/maintenance or diet/physical activity behaviors.
2010915|NCT02783521|Behavioral|Wait List Control|After 12 weeks, the wait list control will receive the weight loss intervention plus mHealth technology support. It will include tailored, targeted text messaging and real-time self-monitoring support including beverage tracking cups, which provide the amount of calories users are consuming through beverages on a daily basis, and wearable activity monitors.Behavioral constructs used for the intervention group will be maintained during this intervention delivery thereby ensuring all participants have the appropriate tools to continue weight loss efforts regardless of mHealth use.
1619506|NCT02091115|Dietary Supplement|dairy drink with probiotic culture|The participants were instructed to consume the dairy drink with probiotic culture containing animalis bifidobacterium with 3.2 x 107 UFC for 60 days and a glass of 150 ml daily.
1619507|NCT02091115|Dietary Supplement|Dairy drink|
1619508|NCT02091102|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for the treatment of Wrinkles
1619509|NCT02091089|Device|755nm Alexandrite laser|755nm Alexandrite laser for the treatment of wrinkles
1619510|NCT02091076|Device|Silk fibroin with bioactive coating layer dressing|
1619511|NCT02091076|Device|Bactigras wound dressing|
1619512|NCT02091063|Drug|ACY-1215|All patients will take the oral ACY-1215 160mg for 28 consecutive days on a 28-day treatment cycle. Each dose will be administered at least 1 hour after ingestion of food and followed by at least 4 ounces of water. Patients will be instructed not to ingest food or other oral medication for at least 2 hours after each ACY-1215 dose.
1619513|NCT02091050|Other|2D HDR planning|HDR planning using simple radiograph (2D)
1619514|NCT02091050|Other|3D HDR planning|HDR planning using computed homograph (3D)
1619515|NCT02091024|Dietary Supplement|ECE (Ecklonia cava extract)|ECE 200mg, twice a day
1619516|NCT02091024|Dietary Supplement|Placebo|Placebo 200mg, twice a day
1619520|NCT02090959|Drug|Ataluren|
1619521|NCT02090933|Drug|Celecoxib|Given PO
1619522|NCT02090933|Other|Laboratory Biomarker Analysis|Correlative studies
1619523|NCT02090933|Procedure|UV Light Therapy|Undergo UV-irradiation
1619524|NCT02090920|Drug|Nifedipine|Nifedipine 10 mg immediate release tablet by mouth loading dose Nifedipine administered orally every 15-20 minutes for the first hour to a maximum loading dose of 30 mg, followed by a maintenance dose of 10-20 mg immediate release nifedipine administered orally every 6 hours
1619525|NCT02090907|Drug|Levothyroxine|
1619526|NCT02090907|Drug|Placebo|
1619527|NCT02090894|Device|UV Light (Laser Genesis)|
1619528|NCT02090881|Other|Ultrasound scan|Trans cranial Doppler ultrasound examination of cerebral arterial blood flow
1619529|NCT02090868|Other|Oral Intake Screening Tool|A screening tool developed from a literature review and expert opinion. It will be used by nurses to assess patients receiving non-invasive ventilation ability to eat and drink orally and suggest what actions should be taken if they are unable to do so
1619530|NCT02090842|Dietary Supplement|Ca-caseinate|
1619531|NCT02090842|Dietary Supplement|Maltodextrin|
1619532|NCT02090842|Dietary Supplement|Whey protein isolate|
1619533|NCT02090829|Drug|Syntocinon (synthetic oxytocin)|Syntocinon is a nine residue cyclic peptide; the hormone is prepared synthetically to avoid possible contamination with vasopressin and other small polypeptides with biologic activity.
1619534|NCT02090829|Other|Placebo|"Placebo Comparator: Intranasal Placebo Intranasal placebo The placebo is identical to the oxytocin formulation with the exception of the active compound.
Route of administration: Intranasal Planned exposure: Each participant will receive one dose of intranasal placebo per day for 5 days.
One dose equals 6 spray puffs (3 puffs in each nostril)."
1619535|NCT02090816|Procedure|Surgery of liver and lung|Simultaneous resection of liver and right lung metastases in a single surgical session through a new approach
1619536|NCT02090790|Drug|iv dexamethasone|2 ml 8 mg iv dexamethasone
1619537|NCT02090790|Drug|femoral dexamethasone|2ml 8mg dexamethasone administration added 30 ml 0,5 % bupivacain
1619538|NCT02090790|Drug|serum physiologic|2 ml iv serum physiologic
1619539|NCT02090777|Behavioral|Health Coach|
1619540|NCT02090764|Drug|Ozenoxacin|
1619545|NCT02090712|Procedure|PCI|Balloon dilatation of the culprit artery followed by stent implantation will be made immediately for patients not receiving thrombolysis or after 3 to 24 hours after thrombolysis, under clinical indication and current practice patterns, in the setting of acute myocardial infarction
1619546|NCT02090686|Device|Pulsatile Cupping|"8 cupping sessions (each 8 minutes) in 4 weeks (-150 to -350 mbar), interval 2 seconds.
Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day)"
1619547|NCT02090686|Device|Minimal Cupping|8 cupping sessions (each 8 minutes) in 4 weeks witth (-60 to -70 mbar). Paracetamol on demand as rescue medication (maximum dosage 4 x500 mg/day).
1619548|NCT02090673|Drug|Exenatide|
1619549|NCT02090660|Other|ICG Localization with Spy thoracoscope localization|
1619550|NCT02090647|Behavioral|aesthetic outcome|
1619551|NCT02090634|Behavioral|Psychoeducation|Participants will also receive daily text messages to evaluate mood, but these messages will not remind participants about medication adherence.
1619552|NCT02090634|Behavioral|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who have bipolar disorder (BD+). Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART and psychotropic medications among HIV+/BD+ persons above and beyond an active comparator group.
1619553|NCT02090621|Procedure|Extracorporeal photopheresis|Extracorporeal photopheresis with Methoxsalen(UVADEX)and immunosuppression reduction Extracorporeal photopheresis (ECP) is an immunomodulatory excellent technical tolerated initially designed for the treatment of cutaneous T-cell lymphoma and various autoimmune diseases, which has been proven effective in reversing episodes acute heart transplants, kidney and lung rejection, and in the treatment of Disease graft versus host both acute and chronic.
1619554|NCT02090608|Drug|Paricalcitol|Paricalcitol was administered at the dose of 1 mcg/die
1619555|NCT02090595|Behavioral|MBCT-C|A 12 week group therapy program for children with anxiety disorders. This involves teaching the children the pay attention to anxiety related cues with openness and non-judgment. Group leaders begin each session with: sitting meditation, review of the previous session and home practices, teaching a new mindfulness exercise, reading a group poem or story, distributing handouts, etc. There will be a new theme each week.
1619556|NCT02090595|Behavioral|Waitlist Control|Waitlist Control (WC) will be the comparison condition. Some of the children in the study will initially participate in a 12 week WC prior to their participation in the MBCT-C. At each visit during the waitlist control period, participants and their families will receive materials about mood and anxiety disorders in youth, bipolar disorders, familial risk for bipolar disorder and treatment strategies for anxiety and depression in youth.
1619557|NCT02090582|Other|Structured Palliative Care|Structured palliative care approach, defined as the gynecologic oncology team performing comprehensive symptom assessment with the Quality Data Collection Tool Palliative Care (QDACT-PC) and providing interventions based on National Comprehensive Cancer Network (NCCN) guidelines. Symptom scores above the acceptable threshold in the QDACT-PC tool that occur after two consecutive visits will automatically trigger palliative care consultation.
1619558|NCT02090582|Other|Usual Care|Usual care described as current practice by the gynecologic oncology team with referral to PC specialist at provider discretion or at the request of the patient or their families.
2010916|NCT02782507|Behavioral|CBT for Distressing visual hallucinations|"Eight to ten sessions of manualised CBT for distressing visual hallucinations based on existing treatment manuals (ie. Kingdon & Turkington, 2004, Morrison et al., 2005), delivered over 8 to 12 weeks by CBT therapists.
Subjects will continue to receive treatment as usual throughout the therapy period and will receive appropriate prescription of medication if requested or clinically indicated."
1619561|NCT02090543|Drug|Phenprocoumon (Marcumar)|common use, no requirements (real life situation)
1619562|NCT02090543|Drug|Rivaroxaban (Xarelto, BAY-59 7939)|common use, no requirements (real life situation)
1619563|NCT02090530|Other|Biospecimen collection|Specimens to be collected include a fresh tumor biopsy, previously obtained tumor specimens or blocks (if available), whole blood, serum, plasma and buccal smear.
1619564|NCT02090517|Device|Pulsed Dye Laser|Pulsed dye laser treatments will be performed with a 595 nanometer wavelength, 20 millisecond pulse duration, at 10 Joules/cm2, with a 10 millimeter spot size.
1619565|NCT02090517|Device|Long Pulsed Alexandrite Laser|Alexandrite laser will be used with a 755 nanometer wavelength, 40 millisecond pulse duration, at 88Joules/cm2, with a 6 millimeter spot size.
1619566|NCT02090517|Device|Pulsed Dye Laser Plus Nd:YAG Laser|The Cynergy with MultiPlex will be used with a multiplex mode system with a pulse dye laser at 585 nanometer wavelength, 20 milliseconds pulse duration, at 7 Joules/cm2 with a 7 millimeter spot size, with a short delay, followed by a Nd:YAG 1064 nanometer wavelength, 20 millisecond pulse duration, at 50 Joules/cm2 with a 7 millimeter spot size.
1619567|NCT02090517|Procedure|Electrodesiccation|A curette is used to scrape off the cancer down to the dermis. The scraping is then paused while an electrosurgical device like a hyfrecator is used next. Electrodesiccation is performed over the raw surgical ulcer to denature a layer of the dermis and the curette is used again over the surgical ulcer to remove denatured dermis down to living tissue.
1619568|NCT02090504|Drug|Sodium Oxybate (SMO)|
1619569|NCT02090504|Drug|Oxazepam|
1619570|NCT02090478|Other|Low sugar diet|All subjects followed their usual diet during month 1. For months 2-4: sham diet intervention for the control group, 40% reduction in sugar calories for the experimental group. All subjects were allowed to chose any diet they wished during month 5.
1619571|NCT02090478|Other|Sham diet manipulation|Subjects in the control group will meet with a dietician and discuss diet records, but the dietician will not instruct the control subjects to reduce the number of calories from simple sugars in the diet
1619572|NCT02090465|Drug|Ingenol Mebutate|No intervention: observation of routine use of Picato®
1619573|NCT02090452|Device|Real time transmission of patient related data. Device used: MobiMed 3.1, manufactured by Ortivus AB Sweden|
1619574|NCT02090439|Drug|Silodosin|
1619575|NCT02090426|Other|Link2Care|
1619576|NCT02090413|Drug|dimethyl fumarate|
1619577|NCT02090413|Drug|acetylsalicylic acid|enteric-coated capsule
1619578|NCT02090413|Drug|ASA-Placebo|matched placebo
1619584|NCT02090374|Other|Tuberculin nasal challenge|Preceding incremental ascending dose study to be used to assess safe top dose.
1619585|NCT02090374|Other|Timothy Grass Pollen|Dose: 5000 SQ-U/100µl
1619586|NCT02090361|Procedure|skin graft|Epidermization of the defect by applying a thin layer of autologous epidermis
1619587|NCT02090348|Drug|dimethyl fumarate|Administered as specified in the treatment arm
1619588|NCT02090335|Behavioral|In SHAPE|In SHAPE is a health promotion intervention consisting of a fitness club membership and a health promotion coach with basic certification as a fitness trainer, instruction on principles of healthy eating and nutrition, and training in tailoring individual wellness plans to the needs of persons with serious mental illness.
1619589|NCT02090335|Behavioral|Fitness Club Membership|Fitness club membership with education in using the exercise equipment.
1619590|NCT02090322|Procedure|Injection of bevacizumab intravitreal (Avastin)|"The treatment of Retinopathy of prematurity is with bevacizumab intravitreal for resolution of the illness.
When there is a Retinopathy of prematurity type 1, is the indication for the infection"
1619591|NCT02090309|Drug|Hydrocortisone|100 mg IV (in the vein) injection as a single bolus of hydrocortisone for the study group.
1619592|NCT02090309|Drug|normal saline 0.9%|IV injection of 5 ml normal saline 0.9% as a single bolus.
1619594|NCT02090283|Drug|SD-101 dermal cream (6%)|applied topically once a day to the entire body for the duration of the study.
1619595|NCT02090257|Behavioral|TRANSIT|Educational Modules, staff follow up.
1619596|NCT02090244|Drug|Teriparatide|Daily injections with teriparatide 20 µg (PTH 1-34 (Forteo®)) during four weeks
1619597|NCT02090231|Device|rTMS, Magstim Rapid2|5 Hz rTMS
1619598|NCT02090218|Device|I-Gel|I-Gel supraglottic airway device
1619599|NCT02090218|Device|LTS, ETI or current airway management practice|Laryngeal tube, endotracheal tube, bag-mask-ventilation
1619600|NCT02090205|Procedure|Non-ventilation during CPB|Patients that will not be ventilated during cardio-pulmonary bypass
1619601|NCT02090205|Procedure|Ventilation with CPAP|These patients will receive CPAP (at least 5 cmH2O and FiO2 50%-80%)
1619602|NCT02090205|Procedure|Ventilation with 5 act/minute|These patients will receive mechanical ventilation (5 acts/minute) during CPB
1619603|NCT02090205|Device|CPAP|Continuous Positive Air Pressure, applicated during cardio-pulmonary bypass
1619604|NCT02090205|Device|Ventilator: 5 act/minute|Tidal volume = 2-3 ml/kg + PEEP = 3-5 cmH2O.
1619605|NCT02090192|Procedure|WBV training|
1619606|NCT02090192|Procedure|PRT training|
1619607|NCT02090166|Other|Blood test|a blood test will be taken from each patient
1619608|NCT02090153|Drug|S-1|40~60mg bid，d1~7 q2W
1619609|NCT02090153|Drug|LV|LV is given simultaneously at a ﬁxed dose of 25 mg b.i.d. on days 1-7, followed by a 7 day rest.
1619610|NCT02090140|Procedure|ADSC Application|Patients will undergo arthroscopic resection of approximately 5cc of the infrapatellar fat pad, which will be collected for processing for a population of ADSCs. Patients will undergo arthroscopy and preparation of the chondral defect and removal of the calcified cartilage layer. Tisseel Fibrin glue will be placed at the base of the defect side, followed by the application of the acellular collagen dermal matrix, ADSCs, and an additional layer of fibrin glue.
1619611|NCT02090140|Procedure|Microfracture|Microfracture surgery is the standard of care for articular cartilage lesions. Patients will undergo arthroscopy with standard technique of microfracture preparation, including the creation of vertical, stable defect edges and removal of the calcified cartilage layer. A microfracture awl will then be used to perform the microfracture technique (6mm below the subchondral plate).
1619612|NCT02090127|Drug|ficlatuzumab|humanized anti-hepatocyte growth factor (HGF) monoclonal antibody IV administration at 16.5mg/kg every 2 weeks with a ±2 day window around dosing dates, as long as subject is deriving clinical benefit as determined by the Investigator
1619613|NCT02090114|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
1619614|NCT02090114|Drug|Testosterone Enanthate|Testosterone Enanthate Injection, for intramuscular injection, contains testosterone enanthate which is the oil-soluble ester of the androgenic hormone testosterone. Enanthate Injection is available as a colorless to pale yellow solution. Each mL contains 200 mg testosterone enanthate in sesame oil with 5 mg chlorobutanol as a preservative.
1619615|NCT02090114|Drug|Abiraterone acetate|Abiraterone is an inhibitor of CYP17 (17α-hydroxylase/C17,20-lyase). Each ZYTIGA tablet contains 250 mg of abiraterone acetate.
1619616|NCT02090114|Drug|Enzalutamide (Cohort A = CLOSED TO ACCRUAL)|XTANDI is provided as liquid-filled soft gelatin capsules for oral administration. Each capsule contains 40 mg of enzalutamide as a solution in caprylocaproyl polyoxylglycerides.
1619617|NCT02090101|Drug|ANAKINRA|
1619618|NCT02090088|Drug|Not applicable- observational study|
1619619|NCT02090075|Drug|apixaban|5 po or 2.5 po bid.
1619620|NCT02090075|Drug|warfarin|
1619621|NCT02090049|Dietary Supplement|Puravita Breakfast|The study was done in duplicate i.e two different days each meal (control and experimental) separated at least one week in time. Subjects were instructed to consume the test meal within 10 min from commencement. They subsequently completed VAS on appetite sensation every 30 min until a total of 4 hours. At the end of the test day, an ad libitum lunch consisting of a standardized pizza (17E% protein, 34E% fat and 49E% carbohydrate) and water (300 ml) was served. The subjects were instructed to eat until comfortably satisfied. Food intake was registered and energy intake (EI) calculated afterwards.
1619622|NCT02090049|Dietary Supplement|Control|The control breakfast consisted of white bread (85 g), jam (10 g) and margarine (2 g) to adjust for energy density, fat and sugar levels.
1619623|NCT02090036|Drug|Primaquine (For artemether-lumefantrine+primaquine arm)|A 0.25 mg/kg single-dose primaquine will be administered concomitantly with the first dose of artemether-lumefantrine in all patients randomized into the artemether-lumefantrine+primaquine arm.
1619624|NCT02090036|Drug|Placebo (For artemether-lumefantrine arm)|Volume of normal saline mixed with coloured fruit juice measured based on weight bands will be given orally concomitantly with first dose of artemether-lumefantrine.
2010917|NCT02782403|Drug|Axitinib|"Chronic Phase CML with T315I Mutation Group and Chronic Phase CML with No T315I Mutation Group: Axitinib 5 mg twice a day by mouth.
Blast Phase or Accelerated Phase CML Group: Phase I Dose Escalation Phase Starting Dose of Axitinib 3 mg/day by mouth twice daily. Phase II Dose Expansion Phase Starting Dose of Axitinib is maximum tolerated dose from Phase I Dose Escalation Phase."
1619628|NCT02089984|Behavioral|Internet Based CBT Training|
1619629|NCT02089958|Procedure|Laparoscopic incisional hernia repair|Standardized laparoscopic incisional hernia repair with mesh
1619630|NCT02089932|Drug|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound guided femoral nerve block with injection of 25 ml bupivacaine 0.5% perineurally with 1 ml dexmedetomidine 25, 50, or 75 microgram perineurally.
After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia."
1619631|NCT02089932|Drug|Placebo|
1619632|NCT02089919|Biological|cancer stem cell vaccine|
1619633|NCT02089880|Device|C-brace|The participant will receive 6 sessions of training over a one month period in using the C-brace in all levels of functional gait. The participant will then continue use of the C-brace for one month following training. The C-Brace from Otto Bock is an orthosis that controls throughout stance and swing phases of gait with a micro-processor (MP) controlled knee.
1619634|NCT02089880|Device|Stance control orthosis|The participant will receive 6 sessions of training over a one month period in using his current stance control knee-ankle-foot orthosis (SCO) in all levels of functional gait. The participant will then continue use of the SCO for one month following training. The SCO controls the knee by maintaining it straight and extended during the stance phase of gait.
1619635|NCT02089867|Other|Ezetimibe + plant sterols|The ezetimibe + plant sterols group will receive ezetimibe 10 mg/day + spread enriched with 2g daily of plant sterols for 6 weeks
1619636|NCT02089867|Drug|Ezetimibe|The ezetimibe group will receive 10 mg/day ezetimibe for 6 weeks.
1619637|NCT02089867|Dietary Supplement|Plant sterols|The plant sterol group will receive spread enriched with 2g daily of plant sterols for 6 weeks
1619638|NCT02089854|Drug|Toremifene; Anastrozole|Toremifene 60mg PO. per day for premenopausal and perimenopausal patients; Anastrozole 1mg PO. per day for postmenopausal patients
1619639|NCT02089841|Drug|Artemether-lumefantrine|Blood samples will be collected on blood slides and filter papers for asexual parasites assessment both by microscope and molecular genotyping respectively following treatment with artemether-lumefantrine, to assess its efficacy.
1619640|NCT02089828|Other|autologous purified CD34+ cells|
1619641|NCT02089828|Other|autologous peripheral blood mononuclear cells|
1619642|NCT02089815|Behavioral|Home based exercise|modified Otago exercise program to simple designed home based exercise program
1619643|NCT02089815|Other|fall prevention education and counseling|
1619644|NCT02089802|Drug|Pazopanib|
1619645|NCT02089763|Biological|pegylated recombinant human arginase|
1619646|NCT02089750|Other|Orthotics|
1619647|NCT02089750|Other|Orthotics Plus Chiropractic Care|The six week Chiropractic Care portion of this intervention may include the use of ice packs, hot packs, massage, and chiropractic manipulations to the spine or lower extremities (utilizing High Velocity Low Amplitude and/or Flexion Distraction manipulations).
1619648|NCT02089750|Other|Wait List|
1619649|NCT02089737|Drug|Panitumumab|Panitumumab for intravenous infusion
1619650|NCT02089698|Device|Mini-flared|Mini-flared Kelman tip
1619651|NCT02089698|Device|Reversed tip|Reversed Kelman tip
1619652|NCT02089685|Biological|Pembrolizumab|
1619653|NCT02089685|Biological|PegIFN-2b|
1619654|NCT02089685|Biological|Ipilimumab|
1619655|NCT02089672|Device|Catheter ablation|This is observational trial studying the effects of a standard intervention of a catheter ablation procedure.
1619656|NCT02089659|Drug|doravirine|
1619657|NCT02089633|Biological|PACOX|Pegylated recombinant human arginase 1 in combination with Oxaliplatin and Capecitabine
1619658|NCT02089620|Drug|Yasmin|will be used every 21 days for three months by the patient
1619659|NCT02089620|Dietary Supplement|Calver|Calver will be given daily for 3 months
1619660|NCT02089620|Drug|Placebo 1|Patients will receive a daily placebo similar in size and structure to calvar.
1619661|NCT02089620|Drug|Placebo 2|Women will receive an oral placebo similar to COC for 21 days starting from the 3rd day of menstruation
1619662|NCT02089607|Device|Zenith Fenestrated-Branched System|"The Zenith Fenestrated-Branched System is a tubular graft made of polyester fabric sewn to stainless steel stents that keep the graft open. The graft will be inserted through arteries in the leg (called endovascular repair). This procedure uses catheters that go inside the blood vessel to place a stent graft above and below the aneurysm.
The upper portion of the graft includes 1 to 5 small holes (fenestrations) or cuffs (side branches) that allow the graft to be located above the renal arteries without blocking blood flow to them. This is needed when there is not enough healthy aorta below the renal arteries. At least one artery may also be treated with an alignment stent to help keep the arteries open and aligned with the fenestrations or branches."
1619663|NCT02089594|Drug|Hyperbaric Oxygen|HBOT Group: Pressurization will proceed with 100% oxygen at 1.0 pounds per square inch (psi) per minute, the minimal pressurization rate, to 1.5 ATA (atmospheres absolute) or 7.35 psi and will take approximately 7 minutes. Pressurization will then resume until the final depth of 1.5 ATA is achieved. The patient will remain at depth for approximately 45 minutes and the subject will be informed of the onset of depressurization, which will occur at the same rate as pressurization. Total dive time will be 60 minutes.
1619664|NCT02089594|Drug|No Hyperbaric Oxygen|Subjects will receive their usual care during the equivalent eight-week HBOT treatment period. There will be no hyperbaric chamber experience. At the conclusion of the eight-week control period both control and experimental subjects will be retested and the control group will be crossed over to receive the identical 40 HBOTs of the HBOT group.
1619665|NCT02089581|Drug|Active comparator MR2XXX|comparison of two new oral formulations with existing formulation
1619666|NCT02089581|Drug|MRXXX|MRXXX
1619667|NCT02089581|Drug|MR1XXX|
1619669|NCT02089568|Drug|Co-Amoxiclav|Will receive 1.2g co-amoxiclav at induction
1619670|NCT02089568|Drug|Normal Saline|Placebo - 0.9% saline
1619671|NCT02089555|Procedure|Lumbar puncture|Cerebrospinal fluid (CSF) will be collected via lumbar puncture. During lumbar puncture, a needle is inserted between two lumbar bones (vertebrae) to remove a sample of cerebrospinal fluid. The procedure involves inserting a thin, hollow needle between the two lower vertebrae (lumbar region), through the spinal membrane (dura) and into the spinal canal and extracting a small amount of fluid. The procedure takes about 45 minutes.
1619672|NCT02089555|Procedure|Blood draw|One tube of blood will be collected in an ethylenediaminetetraacetic acid (EDTA)-K2 plasma tube for DNA analysis.
1619673|NCT02089555|Procedure|Magnetic Resonance Imaging (MRI)|Each participant will undergo Magnetic Resonance Imaging (MRI) analysis using a modified Alzheimer's Disease Neuroimaging Initiative (ADNI) protocol with a 3 Tesla (3T) MRI Scan. The exam takes approximately 20 minutes.
1619674|NCT02089542|Other|MB and fluorescent imaging|Single arm study for the development of a protocol stipulating the optimum dose and time to peak near infra-red fluorescence from intraoperative injection of low dose Methylthioninium chloride
1619675|NCT02089529|Drug|Ibuprofen|Ibuprofen/Ibumetin with no information, positive information and neutral information
1619676|NCT02089529|Drug|Placebo|Placebo with no information, positive information and neutral information
2010918|NCT02782403|Drug|Bosutinib|"Chronic Phase CML with T315I Mutation Group and Chronic Phase CML with No T315I Mutation Group: Bosutinib 500 mg by mouth daily.
Blast Phase or Accelerated Phase CML Group: Phase I Dose Escalation Phase Starting Dose of Bosutinib 400 mg/day by mouth once daily. Phase II Dose Expansion Phase Starting Dose of Bosutinib is maximum tolerated dose from Phase I Dose Escalation Phase."
1619678|NCT02089490|Device|NEVELIA® implantation|Skin substitute implantation followed by ultra-thin epidermal graft
1619679|NCT02089477|Other|Support group|"The participants in the intervention group receives the intervention and support consisting of:
Individual Goal Setting: 2-3 functional goals related to everyday life evaluated every 4th week.
SMS send every Sunday with 5 possible responses. depending on the answer of the participant it will cause a telephone call from a project about motivation and barriers for interval walking."
1619680|NCT02089464|Device|NBS-guided rTMS|
1619681|NCT02089464|Device|Sham rTMS|
1619682|NCT02089464|Procedure|Task oriented rehabilitation|
1619683|NCT02089451|Drug|Faster-acting insulin aspart|Drug: insulin aspart (faster acting insulin aspart) Subjects will receive five single dose level of faster acting insulin aspart. Three single dose s.c under the skin (abdomen, deltoid/upper arm, thigh), one single dose i.m. (intramuscularly, into the muscle) and one single dose i.v. (intravenously, into the vein)
1619684|NCT02089438|Drug|Saxagliptin|Saxagliptin (5 mg) is given before breakfast
1619685|NCT02089438|Drug|Vildagliptin|Vildagliptin (50mg) is given before breakfast and dinner
1619686|NCT02089438|Drug|Sitagliptin|Sitagliptin (100 mg) is given before breakfast
1619687|NCT02089425|Drug|K-103-IP|
1619688|NCT02089425|Drug|Placebo|Placebo comparator
1619689|NCT02089412|Drug|E2006|
1619690|NCT02089399|Drug|Sevikar(amlodipne/olmesartan)|Treatment AB
1619691|NCT02089399|Drug|crestor(Rosuvastatin)|Treatment AB/Treatment C
1619692|NCT02089386|Drug|Tamoxifen|
1619693|NCT02089386|Procedure|Endoscopy|
1619694|NCT02089373|Procedure|Probe-based confocal laser endomicroscopy|In this arm1, an investigator observes a cancerous lesion using white light endoscopy. In addition, contrast dye for confocal laser endomicorscopy (fluorescein sodium 0.1mL/kg) is administered. Then, the cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy would be done 5 times at the most suspcious parts of the cancerous lesion.
1619695|NCT02089373|Procedure|White light endoscopy|In this arm2, an invesigator observes a cancerous lesion using white light endoscopy. The biopsy would be done 5 times at the most suspicious parts of the cancerous lesion.
1619696|NCT02089347|Biological|Tdap: Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|0.5 mL, intramuscularly.
1619697|NCT02089347|Biological|Diphtheria and Tetanus toxoids adsorbed|0.1 mL, Subcutaneously
1619698|NCT02089334|Drug|RX-0201|"RX-0201 will be administered in a dose up to 250mg/m^2/day as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles in Stage 1.
In Stage 2, RX-0201 will be administered the dose determined in Stage 1 as a continuous infusion for a cycle of 21 days (14 days infused followed by 7 days off) for up to 8 cycles."
1619699|NCT02089308|Drug|Test treatment : V0116 transdermal patch|
1619700|NCT02089308|Drug|Reference treatment : Nicotine transdermal patch|
1619701|NCT02089295|Drug|Oxycodone|One capsule of 5 mg PF-00345439 Formulation K, single dose, under fed conditions
1619702|NCT02089295|Drug|Oxycodone|One capsule of 20 mg PF-00345439 Formulation K, single dose, under fed conditions
1619703|NCT02089295|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
1619704|NCT02089282|Device|Ultrasound|
1619705|NCT02089256|Drug|Liraglutide|"Graded glucose infusion test (GGIT)will be performed on baseline. 1 week later treatment with liraglutide 0.6mg/day (injected between 21.00-23.00) will be initiated.
GGIT will be repeated 12 hours after first injection and after 21 days on-treatment (12 hours after last injection)."
1619706|NCT02089243|Procedure|Vagus nerve stimulation therapy|The adjustments in device parameters were performed, individually, and solely at the discretion of the primary epileptologist with a formal protocol guiding changes.
1619707|NCT02089243|Procedure|Resective surgery|The experienced neurosurgery are responsible for the selection of surgical techniques employed for medically refractory medial temporal lobe epilepsy that provide an effective treatment with significant preservation of neurological function and acceptable surgical risks.
1619708|NCT02089230|Drug|MEK 162|"Phase I Starting Dose of MEK 162: 15 mg by mouth twice a day in a 28 day cycle.
Phase II Starting Dose of MEK 162: Maximum tolerated dose from Phase I."
2010919|NCT02782325|Biological|Fecal microbiota transplantation|Endoscopic FMT followed by 2 weeks of oral FMT with evaluation of primary and secondary endpoints at week 4, 8 and 16.
1619826|NCT02088463|Procedure|Placebo mobilization|placebo mobilization is a tactile stimulation at the same level L3 without application of any force.
1619923|NCT02087748|Drug|1% diclofenac sodium gel|Diclofenac sodium 1% gel 4 grams applied topically Q6 hour for 48 hours
1619713|NCT02089204|Radiation|FMISO-PET/CT|Fluorine-18-labeled fluoromisonidazole PET/CT-guided dose escalation chemoradiotherapy (group C). Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
1619714|NCT02089204|Radiation|FDG-PET/CT|18F-FDG PET/CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy.
1619715|NCT02089204|Radiation|contrast-enhanced CT|contrast-enhanced CT -guided dose escalation chemoradiotherapy. Radiotherapy was delivered using the simultaneous modulated accelerated radiation therapy (SMART) technique in the dose-escalation treatment arms. Patients received concurrent and adjuvant chemotherapy
1619716|NCT02089191|Device|Nelfilcon A contact lenses|
1619717|NCT02089191|Device|Stenfilcon A contact lenses|
1619718|NCT02089178|Procedure|intravenous anesthesia|total intravenous anesthesia group: propofol-remifentanil
1619719|NCT02089178|Procedure|inhalation anesthesia|inhalation anesthesia group: sevoflurane-remifentanil
1619720|NCT02089178|Drug|propofol-remifentanil|
1619721|NCT02089178|Drug|sevoflurane-remifentanil|
1619722|NCT02089165|Dietary Supplement|Krill oil|Krill oil from Antarctic krill, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
1619723|NCT02089165|Dietary Supplement|Krill meal|Krill meal, granular meal from Antarctic krill, per oral, targeted daily n-3 PUFA dose of 1 700 mg, single administration
1619724|NCT02089165|Dietary Supplement|Fish oil|Fish oil, per oral, capsule, targeted daily n-3 PUFA dose of 1 700 mg, single administration
1619725|NCT02089152|Other|An educational programme for prevention of melioidosis|The intervention will be randomly implemented at 10, 10 and 10 diabetic clinics at the end of years 1, 2 and 3, respectively. The education will be conducted using small group education, in which 20 to 25 participants at a time will attend group sessions conducted by the study team.
1619726|NCT02089139|Device|Discogel|DiscoGel is a sterile viscous solution containing ethyl alcohol, cellulose derivative product and tungsten (radio-opaque element)
1619727|NCT02089139|Other|conventional treatment|"Conventional treatment based on current guidelines regarding the management of discogenic low back pain, including but not limited to:
medications (analgesics, NSAIDs, muscle relaxants),
physical therapy,
manual techniques,
transcutaneous electrical nerve stimulation (TENS),
blocks"
1619728|NCT02089126|Drug|Gemigliptin/Glimepiride combination|
1619729|NCT02089113|Drug|Dexamethasone|
1619730|NCT02089113|Device|Punctum Plug|
1619731|NCT02089100|Radiation|stereotactic body radiation therapy|
1619732|NCT02089100|Radiation|Systemic treatment|
1619733|NCT02089087|Biological|CFZ533|Single dose at varying dosage levels depending on treatment assignment
1619734|NCT02089087|Drug|Placebo|
1619735|NCT02089074|Behavioral|Drug use counselling|
1619736|NCT02089061|Drug|BMS-919373|
1619737|NCT02089061|Drug|Rosuvastatin|
1619738|NCT02089061|Drug|Atorvastatin|
1619739|NCT02089048|Drug|Auranofin|Auranofin is a gold-containing chemical salt available as 3mg capsules. Cohort 1 receives 6mg oral dose of auranofin once every 24 hours for 7 days
1619740|NCT02089035|Dietary Supplement|MUFA-rich dairy products (UHT milk, cheese and butter)|
1619741|NCT02089035|Dietary Supplement|Conventional dairy products (UHT milk, cheese, butter)|
1619742|NCT02089022|Other|Physiotherapy resources|The application of ice has been accomplished by means of a plastic bag containing 1.5 kg of crushed ice. The duration of the application was 30 minutes. The use of shortwave diathermy was performed by means of rectangular electrodes having a duration of 20 minutes.
1619743|NCT02089009|Other|Retinal imaging|Retinal imaging by using non-mydriatic camera devices
1619744|NCT02089009|Other|Vessel measurements|Vessel measurements based on the taken images by the use of a specialized software
1619745|NCT02089009|Other|Change in vessel diameters|Change of vessel diameters before and after delivery based on the taken images by the use of a specialized software
1619746|NCT02088996|Device|longwave diathermy on high power and interferential therapy|
1619747|NCT02088996|Device|longwave diathermy on low power|
1619748|NCT02088983|Dietary Supplement|CDP-Choline|Capsule
1619749|NCT02088983|Dietary Supplement|Cellulose|Capsule
1619750|NCT02088970|Device|Crosslinking|"The procedure of the cross linking is standard:combined riboflavin(Ricrolin®)-ultraviolet type A rays (UVA) collagen cross-linking. Radiant energy was 3 milliwatts/cm2 or 5.4 joule/cm2 for a 30-minute exposure irradiation of the cornea.
Patients are checked every days during the hospitalisation and one week, one month and 3 months after the hospitalisation."
1619751|NCT02088970|Drug|antibiotic treatment|"If not the contact lens wearer -> Cocci Gram positive cocci
Vancomycin + Fortum
If contact lens wearer -> Gram negative bacillus
Fortum + Amiklin
If corticosteroids, immunosuppression, latent evolution -> Fungus.
= Fortum + vancomycin + Fungizone"
1619752|NCT02088957|Drug|Brivaracetam intravenous solution|"Active Substance: Brivaracetam
Pharmaceutical Form: Solution for infusion
Concentration: 10 mg/mL
Route of Administration: Intravenous bolus use"
1619753|NCT02088957|Drug|Brivaracetam oral tablets|"Active Substance: Brivaracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 10 mg and 25 mg tablets; Daily Dose: 200 mg/day (100 mg bid)
Route of Administration: Oral use"
1619754|NCT02088957|Drug|Phenytoin intravenous solution|"Active Substance: Phenytoin
Pharmaceutical Form: Solution for infusion
Concentration: 50 mg/mL
Route of Administration: Intravenous use"
1619755|NCT02088957|Drug|Phenytoin oral tablets|"Active Substance: Phenytoin
Pharmaceutical Form: Tablet
Concentration: Weight based
Route of Administration: Oral use"
1619756|NCT02088944|Drug|Infliximab|
1619827|NCT02088463|Device|Ultrasound and infrared devices|ultrasound and infrared are the traditional treatment for low back pain , they are electrical modalities used in the field of physiotherapy to decrease the inflammation and the pain in musculoskeletal systems
1619828|NCT02088450|Drug|Active treatment with nitrendipine (10-40 mg/day).|If necessary, the dihydropyridine calcium-channel blocker was combined with or replaced by enalapril maleate (5-20 mg/day), hydrochlorothiazide (12.5-25 mg/day), or both drugs.
1619924|NCT02087748|Drug|Placebo|Placebo gel 4gm applied topically Q6 hour for 48 hours
1620240|NCT02085395|Drug|SR-T100 ® Gel|
1619757|NCT02088931|Biological|Treg infusion|At the time of Treg infusion (day 0), maintenance immunosuppression will remain unchanged which consists of TAC, MPA and steroids. On follow-up biopsy 2 weeks after Treg infusion, the inflammatory load will be assessed by computer assisted image analysis looking at the number of infiltrating cells per square mm as well as the percentage of renal cortex infiltrated with lymphocytes. If the inflammatory load has decreased by ≥50% and infused Tregs are observed in the allograft, everolimus will be started at 1.5 mg bid and the dose of tacrolimus will be decreased by 50%. After 2 weeks, tacrolimus will be discontinued. These patients will remain on everolimus, mycophenolic acid and prednisone through the end of the study and the follow-up period. If on the 2-week follow-up biopsy, there is no decrease in the inflammatory load or there is a decrease <50%, no change will be made to the maintenance immunosuppressive regimen consisting of TAC, MPA and prednisone.
1619758|NCT02088918|Drug|Nateglinide|
1619759|NCT02088918|Drug|Nateglinide/Metformin|
1619760|NCT02088918|Drug|Metformin|
2010920|NCT02782325|Biological|Open Label FMT - Extension phase|In case the study patient does not achieve clinical remission at week 4 or experiences a flare of disease on day 15-28 after start of the study he/she will be offered the possibility to participate in open label extension with an additional endoscopic FMT followed by 2 weeks of oral FMT and clinical follow up at week 10, 14 and 22.
1619762|NCT02088892|Drug|BCG SSI|Intradermal injection
1619763|NCT02088892|Drug|BCG Tice|Intradermal injection
1619764|NCT02088879|Behavioral|chest compression with kneeling position|
1619765|NCT02088879|Behavioral|chest compression with standing position|
1619766|NCT02088866|Drug|Transdermal Lidocaine|The intervention will use 5% commercially available transdermal lidocaine in clinical practice for the treatment of tinnitus. This dose will be tailored to patient preference.
1619767|NCT02088853|Dietary Supplement|high fat diet (hfd)|Sixty % of the energy content is based on fat.
1619768|NCT02088853|Dietary Supplement|high carb diet|Sixty % of the energy content is based on carbohydrates.
1619769|NCT02088827|Other|Inactivity|Subjects will remain inactive (lying on a bed) for 4 hours.
1619770|NCT02088827|Other|Activity|Subjects will spend 4 hours of inactivity (lying on a bed) broken up by 2 minutes of moderate intensity biking (on a stationary bike) every 20 minutes.
1619771|NCT02088814|Behavioral|'EPICAP'|standardized, secondary preventive psychological intervention with parents of children ages 1-4 with acute burn injuries, consisting of psychoeducation, trauma narrative, storybook, provision of coping skills
1619772|NCT02088801|Device|Airtraq, blade without channel for tracheal tube intubation|Intubation
1619773|NCT02088801|Device|KingVision , blade without channel for tracheal tube intubation|
1619774|NCT02088801|Device|A.P. Advance, blade without channel for tracheal tube intubation|
1619775|NCT02088801|Device|Macintosh|
1619776|NCT02088788|Device|Board|Also has radio-dense pelvic shielding
1619777|NCT02088788|Device|No Board|Radio-lucent armboard for radial access with radio-dense drape across pelvis
1619778|NCT02088775|Procedure|PET scan|Undergo PET-CT scan
1619779|NCT02088775|Procedure|CT Scan|Undergo PET-CT scan
1619780|NCT02088775|Procedure|hepatic artery embolization|Undergo standard radioembolization
1619781|NCT02088762|Procedure|surgical excision|comparison of safety margin 1 versus 2 cm
1619782|NCT02088749|Behavioral|lifestyle intervention for obesity|
1619783|NCT02088736|Device|Intraosseous|
1619784|NCT02088736|Device|Intravenous|
1619785|NCT02088723|Behavioral|Head of bed elevation|head of bed elevation elevation the head of the bed with 15 cm (head of bed elevation) and compare the apnea-hypopnea index with the standard polysomnography
1619786|NCT02088710|Behavioral|Enhanced information about endocrine therapy|Enhanced information about endocrine therapy, extending clinical routine information
1619787|NCT02088697|Drug|Placebo|
1619788|NCT02088697|Drug|ASC-01|
1619789|NCT02088684|Drug|LEE011|LEE011: supplied as capsules of dosage strength of 50 mg or 200 mg. The capsules will be differentiated through different sizes
1619790|NCT02088684|Drug|BYL719|BYL719: supplied as tablets of dosage strength of 10 mg, 50 mg or 200 mg. Tablets will be differentiated through different sizes and/or colors.
1619791|NCT02088684|Drug|fulvestrant|Fulvestrant will be supplied according to local practice and regulation. Fulvestrant is a commercially available product, comes in 500 mg dose and is an injection for intramuscular (i.m.) administration.
1619792|NCT02088684|Drug|BKM120|BKM120: supplied as 10 mg or 50 mg capsules. The capsules will be differentiated through different sizes.
1619793|NCT02088671|Drug|Propofol induction followed by randomized doses of desflurane|Anesthesia in all patients will be induced with iv propofol 1.5 mg/kg with extra 0.5 mg/kg doses as needed. Anesthesia will be maintained using inhaled desflurane in oxygen/air with the initial desflurane concentration of 1.2 MAC, which will be changed in steps of ±0.4 MAC after reaching the post-intubation steady state. The step changes will be initiated every 7.5 min, as follows: at every level of MAC there is a 1/3 chance in remaining at this level and a 2/3 chance of changing it. The anesthesiologist can accept the change to move to the new level. However, he/she can also reject it to remain at the current level for another 7.5 min. This scheme yields 3 possible desflurane levels: 0.8, 1.2 and 1.6 MAC. The anesthesiologist can also leave the randomization schedule at anytime if clinically indicated, and later re-start it at his/her discretion. All anesthetic doses and their changes fall within conventional dosing.
1619829|NCT02088437|Other|Intensive physiotherapy|additional once daily physiotherapy and once daily allied health assistant intervention (equals two more treatments) whilst an inpatient in acute hospital
1619830|NCT02088437|Other|Usual Care|once daily physiotherapy whilst acute hospital inpatient
1619831|NCT02088424|Other|insulin resistance(fasting glucose/fasting insulin)|insulin resistance(fasting glucose/fasting insulin )
1619832|NCT02088411|Drug|Diclofenac|
1619833|NCT02088411|Dietary Supplement|Wobenzym|
1619834|NCT02088411|Other|Placebo|
1619835|NCT02088398|Drug|ACY-1215|
2010921|NCT02782325|Biological|Placebo|Endoscopic placebo FMT followed by 2 weeks of oral placebo FMT with evaluation of primary and secondary endpoints at week 4, 8 and 16.
2010922|NCT02782299|Other|Decision Aid|Decision aid which is still under revision will include unbiased information to assist is clarifying values and informing patients with distal radius fractures.
1619794|NCT02088671|Device|Recording of EEG using NeuroSENSE|"The NeuroSENSE NS-701 system is a 2-channel device for brain activity monitoring in the operating room, intensive care unit, emergency room and other clinical settings. The system acquires and processes electroencephalograms (EEGs) via noninvasive electrodes placed on a patient's forehead. The acquired raw EEG signals and processed EEG variables are continuously displayed for interpretation by the clinician.
The proprietary processed variable, WAVcns, quantifies the patient's brain activity, which is typically affected by anesthetic drugs. The system displays processed variables based on 2 bilateral channels (1 per brain hemisphere) for use as a supplement to the anesthesia standard of care.
Note: the indications provided by the NeuroSENSE monitor are not used for anesthesia dosing or patient assessment in this study, and the anesthesia provider is blinded to the monitor readings. The device is used only for acquisition of EEG signals and may be used to log the events of interest."
1619795|NCT02088671|Other|Data collection|"Non-invasive blood pressure (BP), heart rate (HR), respiratory rate (RR) and electroencephalogram (EEG) will be recorded during the surgery in all subjects. Also, information about all medically significant events, all study-related events (incl. patient's reactions, responses, observations and assessments) and administered medications (incl. end-tidal (ET) desflurane concentration) will be recorded along with time stamps.
The anesthesia and physiological parameters (e.g., BP, HR, RR, ET agent concentration) outputted from the anesthesia monitor will be recorded electronically during the surgery by the anesthesia monitoring system (data-points will be recorded at least every 3 min for BP and every 10 sec for other variables).
The EEG signal will be continuously recorded by NeuroSENSE NS-701 Monitor (described under a separate intervention).
The CRC will also be present in the Operating Room (OR) to record and manage the recording of all the required information."
1619796|NCT02088671|Other|Drug: Emergence by stepping down the desflurane ET|Anesthesia will be reduced to facilitate rapid recovery at the discretion of the anesthesiologist, about 20 minutes before the end of surgery. The desflurane ET will be stepped down from 0.8 MAC by steps of 0.2 MAC approximately every 5 min during the Emergence.
1619797|NCT02088658|Behavioral|Technology Intensified|The intervention is based on the Information-Motivation-Behavioral Skills (IMB) model and provides information, motivation, and behavioral skills training (using motivational enhancement techniques). Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse educators will have access to a secure server to which the uploaded measurements are stored in real time. The glucose and BP readings will be used to tailor and reinforce behavior change during weekly telephone-delivered diabetes education sessions.
1619798|NCT02088645|Drug|177Lu-PP-F11N|
1619799|NCT02088632|Biological|Incobotulinumtoxina|Incobotulinumtoxina (Xeomin) is botulinum toxin type A and is administered via intramuscular injection.
1619800|NCT02088632|Other|Placebo Comparator|Normal saline is sterile sodium chloride without and preservatives.
1619801|NCT02088619|Behavioral|Quality of Life Therapy (QOLT)|
1619802|NCT02088619|Behavioral|Heart Healthy Education (HHE)|
1619803|NCT02088606|Device|TactiCath Quartz treatment|Catheter ablation for the treatment of paroxysmal atrial fibrillation
1619804|NCT02088593|Device|Simulated Dawn Light Box|per3 model of Naturebright It was set at the participants habitual wake time, and automatically began ramping between 30 and 90 minutes prior to that time (based upon participant preference). The ramp increased in a curvilinear fashion, mimicking sunrise during the summer at 45 degrees North latitude and reached a maximum light intensity of 300lux. They were allowed to switch the lamp off during the ramp period, and sleep in on off days, but were asked to allow the light to begin its ramp.
1619805|NCT02088593|Behavioral|Sleep Hygiene instructions|Sleep Hygiene instructions read aloud
1619806|NCT02088580|Procedure|Triple Chronotherapy|
1619807|NCT02088567|Procedure|Total Knee Arthroplasty|Total knee arthroplasty, per the usual practice of the physician.
1619808|NCT02088567|Other|Application of dHACM|Application of dHACM at end of procedure before closing wound between the underlying fascia and the overlying skin layers to reduce scar formation
1619810|NCT02088541|Drug|Selinexor|
1619811|NCT02088541|Drug|Hydroxyurea|
1619812|NCT02088541|Drug|Ara-C|
1619813|NCT02088541|Drug|azacitidine|
1619814|NCT02088541|Drug|Decitabine|
1619815|NCT02088528|Device|Aurolab glaucoma drainage device|Patients undergoing surgery will receive an implant
1619816|NCT02088528|Procedure|Trabeculectomy with mitomycin-c|Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.
1619817|NCT02088515|Drug|Nedaplatin|
1619818|NCT02088515|Drug|Cisplatin|
1619819|NCT02088515|Drug|Docetaxel|
1619820|NCT02088502|Drug|N-acetylcysteine|
1619821|NCT02088502|Drug|Theophylline|
1619822|NCT02088502|Drug|0.9% sodium chloride|All patients are hydrated with 0.9% sodium chloride (1 mL/kg/hour) for 24 hours, 12 hours before operation. Patients with left ventricular ejection fraction less than 40% or New York Heart Association functional class III-IV, are hydrated with 0.5 mL/kg per hour.
1619823|NCT02088489|Device|Atrial flutter irrigated catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with conventional irrigated Thermocool® (Biosense Webster, Diamond Bar, CA) catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
1619824|NCT02088489|Device|Atrial flutter porous tip catheter|A duodecapolar isthmic curve catheter will be introduced to demonstrate cavo-tricuspidal bidirectional block. We performed atrial flutter ablation with Porous tip Thermocool® SF(Biosense Webster, Diamond Bar, CA)irrigated catheter Continuous lesions from tricuspidal annulus to inferior vena cava will be realized and then complete isthmic block will be confirmed by bidirectional stimulation
1619825|NCT02088463|Procedure|mobilization (manual therapy)|mobilization is one of the manual therapy or treatments with the application of a gentle oscillatory passive movement to the spinal region specifically at the level of L3 in this study at the posterio-anterior direction.
1619836|NCT02088385|Device|Hemospray|
1619838|NCT02088372|Device|Vanguard with E1 PS Bearing|Evaluate Clinical Performance of Vanguard Knee with E1 Bearing in Korean Patient Population
1619839|NCT02088359|Other|Cycled light|We covered the incubator with blanket for darkness approximately 12 hours.
1619840|NCT02088359|Other|Continue near darkness|We covered the incubator with blanket all days.
1619841|NCT02088346|Other|Telemedicine consultation system|Telemedicine consultation system based on portable hardwares
1619842|NCT02088333|Behavioral|mCRC intervention|a multilevel intervention consisting of tablet-based patient education about CRC screening, post-visit patient electronic messaging, and clinic protocols to facilitate ordering of screening tests
1619843|NCT02088333|Behavioral|Healthy Lifestyles video|a brief video about healthy lifestyle habits displayed on a tablet device
1619844|NCT02088307|Dietary Supplement|CardioLife|Participants randomized to treatment arm will take dietary supplement as instructed.
1619845|NCT02088294|Behavioral|Lifestyle Education (LS)|See arm description
1619846|NCT02088294|Behavioral|LS + Stress Reduction Guided Imagery|See Arm Description
1619847|NCT02088294|Behavioral|LS + Activity/Eating Guided Imagery|See arm description
1619848|NCT02088281|Drug|Indigo naturalis extract in oil ointment|Apply 0.5 g of INEO ointment per 10 x 10 cm psoriasis lesion twice daily.
1619849|NCT02088268|Other|wound healing|wound healing
1619850|NCT02088255|Procedure|Static surface|During all session time the subject will walk on the floor with partial body weight support. This protocol will be repeated in all sessions.
1619851|NCT02088255|Procedure|Dynamic surface|During all session time the subject will walk on the treadmill with partial body weight support. This protocol will be repeated in all sessions.
1619852|NCT02088242|Drug|Astaxanthin|Oral supplementation with the food supplement Astaxanthin. Subjects receiving Astaxanthin will be asked to ingest 3 capsules containing 4mg of Astaxanthin each (a daily dose of 12mg).
1619853|NCT02088242|Drug|Placebo|3 capsules identical in shape, colour and size to the Astaxanthin capsules, which contain only the inactive ingredients of the same formulation.
1619854|NCT02088216|Drug|N-acetylcysteine|600mg po twice a day for 12 months
1619855|NCT02088216|Drug|Placebo|Oral tablet po twice a day for 12 months
1619856|NCT02088203|Dietary Supplement|Dose 1|Russian Tarragon Nutrasorb 0.3 g
1619857|NCT02088203|Dietary Supplement|Dose 2|Russian Tarragon Nutrasorb 1 g
1619858|NCT02088203|Dietary Supplement|Dose 0|Placebo
1619859|NCT02088203|Dietary Supplement|Dose 3|Russian Tarragon Nutrasorb 3 g
1619860|NCT02088203|Dietary Supplement|Dose 4|Russian Tarragon Nutrasorb 10 g
1619861|NCT02088203|Dietary Supplement|Dose 5|Russian Tarragon Nutrasorb 20 g
1619862|NCT02088203|Dietary Supplement|Dose 6|Russian Tarragon Nutrasorb 30 g
1619863|NCT02088190|Procedure|Sleeve gastrectomy|Type of bariatric surgery
1619864|NCT02088177|Drug|Long-acting injectable naltrexone|Vivitrol is a long-acting opioid antagonist which blocks opioid agonists from binding at opioid receptors. It be administered as described above.
1619865|NCT02088151|Device|Selective retinal pigment epithelium laser therapy using the R:GEN Laser System|Patients receive selective retinal pigment epithelium laser treatment using the R:GEN Laser System by Lutronic Corporation, Korea.
1619866|NCT02088138|Device|Functional Electrical Stimulation|Functional electrical stimulation twice per week for eight weeks totaling sixteen sessions.
1619867|NCT02088138|Device|Functional Electrical Stimulation placebo|Functional electrical stimulation in the sensory threshold level, twice a week for eight weeks, totaling sixteen sessions.
1619868|NCT02088125|Other|Breath Stacking|Breath Stacking A mask was used with two one-way valves (inspiratory limb and expiratory limb), which was coupled to the patient's face allowing only inspiration, while the expiratory branch remained occluded for the individual only perform successive inspiratory efforts.
1619869|NCT02088125|Other|Incentive Spirometry|The Incentive Spirometry was characterized by the use of the incentive spirometer volume, in which volunteer used a nasal clip and was instructed to inhale slowly and deeply through the mouthpiece of the equipment from functional residual capacity to total lung capacity.
1619870|NCT02088112|Drug|Gefitinib|Gefitinib QD
1619871|NCT02088112|Drug|MEDI4736|MEDI4736 IV Q2W
2010923|NCT02781688|Behavioral|Physical Activity|"Self-monitoring: Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.
Active Living counseling: The Active Living counseling program will consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, social support, and time management.
Facility Access: Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.)."
2010924|NCT02781051|Behavioral|Print-based education|All subjects will be given a copy of Exercise for Health: An Exercise Guide for Breast Cancer Survivors. Topics covered within the book include benefits of exercise in breast cancer survivors; recommendations on type, duration, frequency and intensity of exercise; goal-setting; and advice on overcoming barriers.
1619874|NCT02088086|Behavioral|BMI screening|Students in grades 3-8 will have their heights and weights measured annually at school and their BMIs calculated.
1619875|NCT02088086|Behavioral|BMI reporting|Schools will send a report home to parents that provides their child's height, weight, and BMI results.
1619876|NCT02088086|Behavioral|Fitness testing|Students in grades 5-8 will participate in five fitness assessments (curl-ups, sit-ups, push-ups, sit-and-reach, and the PACER test or mile run) annually at school.
2010925|NCT02781051|Device|Fitbit|Subjects will be provided with a commercially available activity monitor (i.e., Fitbit) and instructed to wear the device daily.
1619880|NCT02088060|Drug|Cannabidiol|Cannabidiol tablets
1619881|NCT02088060|Drug|Olanzapine|Olanzapine capsules
1619882|NCT02088060|Drug|Placebo Cannabidiol|Placebo cannabidiol tablets
1619883|NCT02088060|Drug|Placebo Olanzapine|Placebo olanzapine capsule
1619966|NCT02087475|Drug|5-fluorouracil|
1619967|NCT02087475|Radiation|Local radiotherapy|
1619884|NCT02088047|Device|ProFoveate|ProFoveate™ intervention for nystagmus is a management approach comprised of non-magnetic, 1.2 mm spheres that can be made from either stainless steel, gold plated stainless steel or titanium, placed strategically about the face and ears and a set of exercises designed to support improved vision for patients with nystagmus.The spheres (i.e., stimulating press balls or pellets) are supplied in packages of 20 with each sphere supplied on a transparent hypoallergenic adhesive tape approximately 7.6 mm in diameter. Within each package, all spheres are individually contained on a single paper backing measuring approximately 8.5 cm by 1.7 cm. Individual pellets (with adhesive tape) are removed from the backing as needed according to the prescribed treatment regimen.
2010926|NCT02781051|Behavioral|Active Living counseling|The Active Living counseling program consists of 12 weekly group educational sessions, facilitated by project interventionists. These sessions will involve discussion of topics related to increasing physical activity, including: identifying and overcoming barriers, setting goals, and time management.
2010927|NCT02781051|Other|Facility Access|Subjects will have access to the exercise lab in the UT Southwestern Depression Center consisting of equipment for aerobic exercise (treadmills, stationary bikes, etc.).
2010928|NCT02781038|Behavioral|Teaching intervention|Subjects will receive a pamphlet which describes the relationship between smoking and negative outcomes in fracture healing.
1619888|NCT02088021|Device|Portico Transcatheter Aortic Valve|Placement of the SJM Portico aortic valve with a ALC delivery system
1619889|NCT02088008|Drug|cinidipine, valsartan|
1619890|NCT02087995|Device|Continuous Glucose Monitoring|A prescribed clinic session day for participating subjects.
1619891|NCT02087969|Procedure|Dry Needling|
1619892|NCT02087969|Procedure|Stretching|
2010929|NCT02781038|Behavioral|Control|Subjects in this group will not receive the pamphlet
2010930|NCT02780713|Drug|AZD9496 (Reference)|AZD9496 (Reference)
1619895|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
1619896|NCT02087943|Drug|Apremilast|Orally twice a day (BID)
1619897|NCT02087943|Drug|Placebo|Orally twice a day (BID)
1619898|NCT02087943|Drug|Placebo|Orally twice a day (BID)
1619899|NCT02087930|Dietary Supplement|EHCF + LGG|EXtensively hydolyzed casein formula plus Lactobacillus GG
1619900|NCT02087930|Dietary Supplement|EHCF|
1619901|NCT02087917|Drug|HS-25|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
1619902|NCT02087917|Drug|Placebo|Assigned study drug (HS-25 or placebo) is to be administered orally once daily in the morning with or without food. Treatment duration 4 weeks.
1619903|NCT02087904|Biological|ABT-981|
1619904|NCT02087904|Other|Placebo|
1619905|NCT02087891|Behavioral|Web-based Stress Management Program (WSM)|The intervention, developed by the Cleveland Clinic, is an 8-week online, interactive, educational program based on mindfulness meditation. Briefly, each week subjects are introduced to the (1) weekly audio introduction to the mindfulness theme or particular meditation technique of the week, (2) weekly audio meditation techniques for relaxation, (3) daily articles providing scientific evidence and merits of meditation, and (4) bi-weekly email reminders. The introductory talks and meditation exercises were also provided on compact discs (CD) in mp3 format.
1619906|NCT02087891|Behavioral|Group Support (WSMg1)|Subjects will meet once per week for 1 hour during the 8-week duration and practice 2-minutes of deep breathing exercises, listen to 10-minutes audio recording of the weekly lesson and practice 20-30 minutes guided meditation exercise. The remainder of the time will be used to foster sharing experiences and answering specific questions related to the weekly lesson.
1619907|NCT02087891|Behavioral|Clinical Expert Support (WSMg2)|A clinical psychologist will replace the non-expert facilitator during 4 group support sessions.
1619908|NCT02087865|Drug|donepezil HCL|
1619909|NCT02087865|Drug|Placebo|
1619910|NCT02087852|Other|salvia for germline DNA|
1619911|NCT02087852|Behavioral|the Kidney Cancer Questionnaire|
1619912|NCT02087852|Behavioral|Family History Questionnaire (when applicable)|
1619913|NCT02087839|Drug|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
1619914|NCT02087839|Radiation|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.
Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
1619915|NCT02087826|Other|Mixed Meal Tolerance Test|The meal will provide a standard amount of total calories, protein, fat, and carbohydrate to each participant at both study visits. Pre-packaged and prepared food, weighed to the nearest gram, will be used.
1619916|NCT02087826|Drug|Metformin|Metformin will be administered during this study. This medication is safely prescribed at a maximum dose of 1000 mg twice daily for the treatment or prevention of type 2 diabetes, as well as for other metabolic conditions. To minimize potential side effects of metformin (e.g., GI upset), participants will take ½ the maximum dose of this medication (500 mg twice daily) and for only 5 days. Participants will be informed of the potential side effects of metformin. They will be asked to contact study staff and discontinue the medication if symptoms are very uncomfortable.
1619917|NCT02087813|Drug|Alpha1-antitrypsin|
1619918|NCT02087813|Drug|methylprednisolone|3-5 days 1000mg IV methylprednisolone at first presentation with acute attack.
1619919|NCT02087800|Behavioral|F phase lab session|F phase sessions will occur three to seven days post the onset of menses. It will include blood draws, an acute stressor and completion of questionnaires.
1619920|NCT02087800|Behavioral|L phase lab session|L phase sessions will occur six to ten days prior to the onset of the next expected menses. It will include blood draws, an acute stressor and completion of questionnaires.
1619921|NCT02087787|Behavioral|BMT Legal Clinic|2 hour consultation with an attorney in the BMT Legal Clinic with potential follow-up as needed.
1619922|NCT02087774|Behavioral|6 minutes activity|Group added 6 minutes of physical activity daily during school day.
1619968|NCT02087475|Procedure|R0 resection|
2010931|NCT02780713|Drug|AZD9496 Variant A|AZD9496 Variant A.
2010932|NCT02780713|Drug|AZD9496 Variant B|AZD9496 Variant B
2010933|NCT02780713|Drug|AZD9496 Variant C|AZD9496 Variant C
2010934|NCT02780713|Drug|AZD9496 Variant D|AZD9496 Variant D
2010935|NCT02778685|Other|Laboratory Biomarker Analysis|Correlative studies
2010936|NCT02778685|Drug|Letrozole|Given PO
1619925|NCT02087735|Dietary Supplement|Cranberry extract|The aim of this pilot study is to evaluate the urinary catabolites of PACs as a biomarker of consumption of cranberry extracts within 9 hours of intercourse. Once a week, for 3 weeks, the women will receive a sequence of 3 different cranberry extracts (72 mg, 36 mg and 2mg (placebo)). The participant will have to collect its urine for a period of 9 hours in 3 different containers (one different container for 3 hours).
1619926|NCT02087722|Drug|KI1001|
1619927|NCT02087722|Drug|Placebo|
1619928|NCT02087709|Other|Low-calorie diet|
1619929|NCT02087696|Drug|Tocilizumab|Tocilizumab dose 8mg/kg administered every 4 weeks during 24 weeks.
1619930|NCT02087683|Other|Vitamin D Supplementation|Participants in this group will receive vitamin D supplements of 5 000 International units per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologist, whom will give them the vitamin supply for a month.
1619931|NCT02087683|Other|Control group (Placebo)|Participants in this group will receive a placebo made of gelatin and corn oil per day for 12 months. Each patient will attend their respective clinic for clinical evaluation by their cardiologists, whom will give the vitamin supply for a month.
1619932|NCT02087670|Other|controlled, supervised exercise protocol|exercise program within a cardiac rehabilitation program
1619933|NCT02087670|Other|exercise protocol no supervised|Exercise program at the community
1619934|NCT02087657|Device|Administration of hyperbaric oxygen|Hyperbaric oxygen at 2.5 atmospheres absolute (ATA) for a total of 2 hours
1619935|NCT02087644|Biological|CYT003|Injections
1619936|NCT02087644|Biological|Placebo|Injections
1619937|NCT02087631|Drug|Extended-release quetiapine fumarate|Dosing schedule for RRMS: Group 1: Day 1-3:50 mg Day 4-6:100 mg Day 7-28:150 mg Day 29-30:100mg Day 31-32:50mg; Group 2: Day 1-2:50 mg Day 3-4:150 mg Day 5-6:200 mg Day 7-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg; Group 3: Day 1:50 mg Day 2:100 mg Day 3:200 mg Day 4-28:300 mg Day 29-30:250mg Day 31-32:200mg Day 33-34:150mg Day 35-36:100mg Day 37-38:50mg Dosing schedule for progressive MS: Group 1: Day 1-14: 50 mg Day 15-28: 100 mg Day 29-30: 50mg; Group 2: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 150 mg Day 16-28: 200 mg Day 29-30: 150mg Day 31-32: 100mg Day 33-34: 50mg; Group 3: Day 1-5: 50 mg Day 6-10: 100 mg Day 11-15: 200 mg Day 16-28: 300 mg Day 29-30: 250mg Day 31-32: 200mg Day 33-34: 150mg Day 35-36: 100mg Day 37-38: 50mg
1619938|NCT02087618|Other|Kodro+|Kodro+ participants will utilize Kodro Solution on a tablet for 30 minutes a day for 36 weeks
1619939|NCT02087618|Other|Kodro+D|Kodro+D participants will utilize the Kodro Solution program 12-weeks post-baseline for 30 minutes per day for 24-weeks
1619940|NCT02087592|Behavioral|Structured exercise training plus mediterranean diet|
1619941|NCT02087579|Drug|Aripiprazole, oral formulation|Aripiprazole tablets will be administered orally (by mouth), at no dose restriction, as per the locally approved label indications.
1619942|NCT02087579|Drug|Olanzapine, oral formulation|Olanzapine tablets will be administered orally, at no dose restriction as per the locally approved label indications.
1619943|NCT02087579|Drug|Paliperidone, oral formulation|Paliperidone prolonged-release/extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
1619944|NCT02087579|Drug|Paliperidone, LAI|Paliperidone long-acting injectable (LAI) i.e., paliperidone palmitate injections, will be administered per the locally approved label indications.
1619945|NCT02087579|Drug|Quetiapine, oral formulation|Quetiapine immediate-release (IR) formulation or extended-release (XR) formulation tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
1619946|NCT02087579|Drug|Risperidone, oral formulation|Risperidone tablets will be administered orally, at no dose restriction, as per the locally approved label indications.
1619947|NCT02087579|Drug|Risperidone, LAI|Risperidone LAI injections will be administered will be administered per the locally approved label indications.
1619948|NCT02087566|Drug|600 mg linezolid|
1619949|NCT02087553|Biological|Transfusion of red blood cells|(non-experimental) PRBC transfusion
1619950|NCT02087553|Biological|Infusion of albumin/saline|(non-experimental) albumin/saline infusion
1619951|NCT02087540|Drug|Telmisartan 80mg|
1619952|NCT02087540|Drug|Rosuvastatin 20mg|
1619953|NCT02087540|Drug|Rosuvastatin 10mg|
1619954|NCT02087540|Drug|Placebo(for Telmisartan 80mg)|
1619955|NCT02087540|Drug|Placebo(for Rosuvastatin 20mg)|
1619956|NCT02087540|Drug|Placebo(for Rosuvastatin 10mg)|
1619957|NCT02087527|Drug|Dexamethasone|IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours
1619958|NCT02087527|Drug|Normal Saline|IV normal saline every 6 hours for 48 hours
1619959|NCT02087514|Procedure|Blood Transfusion|A routine medical procedure in which blood is given through an intravenous (IV) line a blood vessel.
1619960|NCT02087514|Biological|Packed red blood cells|"Red blood cells that have been collected, processed, and stored in bags as blood product units available for blood transfusion.
A standard autologous leukoreduced packed red blood cell unit will be collected and stored in AS-3 solution in the Columbia University Medical Center blood bank.
The number of weeks in storage are as follows:
1 week
2 weeks
3 weeks
4 weeks
5 weeks
6 weeks"
1619961|NCT02087501|Device|Horizon™ Abdominal Aortic Aneurysm Stent Graft System|All patient eligible to undergo stent implantation will receive the Horizon™ Abdominal Aortic Aneurysm Stent Graft System and its designated Delivery System.
1619962|NCT02087488|Other|auricular acupuncture(AA)|"Auricular acupoints: Shenmen (TF4), Heart (CO15), Subcortex (AT4), modifying points according to different patterns.
Auricular attachment material: disposable Seirin Pyonex Needle Seirin Pyonex Needle manufacturer: Seirin Corporation, a Japanese company. Medical Device Certification number: No. 15500BZZ00806000.
Treatment frequency: every 3 days.
Duration: 4 weeks."
1619963|NCT02087488|Other|placebo AA|"Auricular acupoints: Wrist (SF1), Clavicle (SF6), Shoulder (SF4、5), Tooth (LO1), Tonsil (LO7, 8, 9).
Auricular attachment material: the disposable Pyonex Zero Needle Pyonex Zero Needle manufacturer: Seirin Corporation, a Japanese company.
Treatment frequency: every 3 days.
Duration: 4 weeks."
1619964|NCT02087488|Drug|Eszopiclone|"Dosage form: tablet.
Dosage: 1 piece (3mg).
Drug manufacturer: Kanghong pharmaceutical limited liability company, Chengdu.
Production license: NO. H20100074 approved by the state.
Treatment frequency: 15 mins before going to bed everyday.
Duration: 4 weeks."
1619965|NCT02087475|Drug|Irinotecan|
1619969|NCT02087462|Other|Electroacupuncture (EA)|"Main acupoints: Da chang shu (BL25), Huan tiao (GB30), bilateral Jiaji point of attacked lumbar vertebra, Ashi points, modifying points according to different patterns.
Electroacupuncture: choose the dilatational wave, frequency is 2Hz/100Hz, electric current ranges from 0.1mA to 1.0mA, 30 mins per time.
Treatment frequency: 5 times per week in the first 2 weeks, 3 times per week in the 3rd and 4th week, 2 times per week in the 5th and 6th week.
Duration: 6 weeks."
1619970|NCT02087462|Other|Traction|An electric pelvis traction in supine position will be applied. The treatment frequency and duration are the same as EA.
1619971|NCT02087462|Drug|Voltaren|"Medication: 50 mg, twice per day
Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.
Duration: 6 weeks."
1619972|NCT02087462|Drug|Vitamin B1|"Medication: 10mg, twice per day.
Treatment frequency: In the first 2 weeks, take medicine for continuous 5 days with a 2-day interval each week; in the 3rd and 4th week, take medicine every 2 days, totally 3 times each week; in the 5th and 6th week, take medicine every 3 days, totally 2 times each week.
Duration: 6 weeks."
1619973|NCT02087449|Device|E1-Hip Bearing|Vitamin E doping of highly cross-linked polyethylene is a proposed method for insuring long-term oxidative stability of highly cross-linked ultra-high molecular weight polyethylene for use in total joint arthroplasty. In vitro research and development studies have shown that this material has improved wear performance, retention of mechanical properties, and a high resistance to oxidation due to the anti-oxidative properties of Vitamin E.
1619974|NCT02087436|Device|Taperloc Complete Microplasty|Taperloc Complete Microplsty cementless stem is designed to transmit load to the proximal femur, thereby preserving bone density, and preventing long term instability and loosening secondary to proximal bone resorption.
1619975|NCT02087436|Device|Taperloc Complete Standard|Taperloc Complete Standard is designed after the philosophy of a flat tapered wedge. It has evolved to incorporate the Reduced Distal and Microplasty stems to better address all patient anatomies, and facilitate multiple surgical techniques.
2010937|NCT02778685|Drug|Palbociclib|Given PO
1619977|NCT02087397|Other|Liposuction|Liposuction using aspiration syringe and tumescent local anesthesia
1619978|NCT02087397|Biological|AD-SVF Cell Injection|Stem cell implantation will be performed using direct injection into the Corpus Cavernosum with local anesthesia
1619979|NCT02087384|Biological|Gardasil|Intramuscular Gardasil vaccination at 0, 2 and 6 months.
1619980|NCT02087384|Drug|Placebo|injection of 0.9% saline
1619981|NCT02087332|Drug|Prolonged release Torasemide (Britomar)|
1619982|NCT02087332|Drug|Torasemide (Diuver)|
1619983|NCT02087319|Other|hair loss, baldness (patient's own platelet-rich plasma)|hair loss, baldness
1619984|NCT02087306|Drug|CMX001|CMX001 administered twice weekly, dose depending on weight.
1619985|NCT02087293|Behavioral|Intervention arm - automated call and phone-based pharmacist counseling|patients receive automated phone call with questions about side effects and an opportunity to speak with a pharmacist
1619986|NCT02087267|Procedure|1- or 2-level spinal fusion|1- or 2-level lumbar or lumbar-sacral spinal fusion with the icotec CF/PEEK Pedicle System in combination with the icotec CF/PEEK TLIF Cage ETurn™
1619987|NCT02087241|Drug|AZD1775|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
1619988|NCT02087241|Drug|AZD1775 Matching Placebo|AZD1775 is a highly selective, adenosine-triphosphate (ATP) competitive, small molecule inhibitor of the WEE 1 kinase that sensitizes tumor cells to cytotoxic agents and is being developed for the treatment of advanced solid tumors and p53 pathway deficient malignancies
1619989|NCT02087241|Drug|pemetrexed|This drug is a part of a general group of chemotherapy drugs called anti-metabolites. It prevents cells from using folate to make DNA and RNA. Because cancer cells need these substances to make new cells, this drug helps to stop the growth of cancer cells.
1619990|NCT02087241|Drug|carboplatin|This drug is a platinum chemotherapy drug that acts like an alkylating agent. It stops the growth of cancer cells, causing the cells to die.
1619991|NCT02087228|Device|Genesys HydroTherm Ablator|Heated water is circulated inside the uterus to destroy the lining of the uterus
1619992|NCT02087228|Device|radiofrequency energy ablation device|
1619993|NCT02087215|Drug|boron gel|application of a formulation gel: addition of borate as sodium penta boric acid pentahydrate 3% (w/v) and two different copolymer as pluronic block namely F68 2% (w/v) and f127 2% (w/v) to diabetic foot ulcers.
1619994|NCT02087215|Drug|Placebo|
1619995|NCT02087202|Drug|Magnesium Sulfate|magnesium sulfate is added to the patients
1619996|NCT02087202|Drug|ketamine|ketamine is added to the patients.
1619997|NCT02087189|Device|First ICD/CRT-D implantation or upgrade from pacemaker|
1619998|NCT02087176|Drug|AZD1775|AZD 1775 + antimitotic agent+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
1619999|NCT02087176|Drug|AZD1775 Placebo|Placebo (to match dose) + antimitotic+ pegfilgrastim, restage every 2 cycles; continue until disease progression or unacceptable toxicity
1620000|NCT02087176|Drug|Antimitotic Agent|The antimitotic is a drug that stops cells from dividing. This leads to cell death. Because cancer cells divide faster than normal cells, they are more likely than normal cells to be affected by this drug.
1620001|NCT02087176|Drug|pegfiligrastim|Pegfilgrastim is a man-made version of a protein called granulocyte-colony stimulating factor (G-CSF). This protein is made by cells in the body to stimulate the bone marrow to make more infection-fighting white blood cells.Pegfilgrastim is made by attaching filgrastim to a molecule called polyethylene glycol (PEG). This addition helps it stay in the body longer than filgrastim, which means it can be given less often.
1620002|NCT02087163|Device|Movement Enhancement Technique|Conventional Orthodontic treatment
1620003|NCT02087163|Device|Clear Aligner|Orthodontic treatment with Clear Aligner
1620004|NCT02087150|Device|Acclarent Eustachian Tube Balloon Catheter (ETBC)|
1620005|NCT02087137|Behavioral|Memory and Aging Program|
1620153|NCT02085967|Drug|midazolam 2 mg with bupropion 75 mg|
2010938|NCT02778685|Biological|Pembrolizumab|Given IV
1620006|NCT02087124|Other|Whey protein|Different amounts of whey protein dissolved in 200 mL water.
1620007|NCT02087111|Drug|Telaprevir|375 mg film coated tablets
1620008|NCT02087111|Drug|40 Kd Pegylated interferon alfa 2a|180 µg in pre-filled syringe for sub-cutaneous injection
1620009|NCT02087111|Drug|Ribavirin|200 mg tablets
1620010|NCT02087098|Drug|Solifenacin|Patients with residual OAB symptoms (urge urinary incontinence, urgency, and frequency) after treatment with other antimuscarinics
1620011|NCT02087085|Drug|400 µg Brimonidine Implant|400 µg brimonidine implant in the study eye on Day 1, and every 3 months through Month 21.
1620012|NCT02087085|Other|Sham|Sham treatment with needleless applicator (no implant) to the study eye on Day 1, and every 3 months through Month 21.
1620013|NCT02087072|Other|Collaborative visit with provider and pharmacist|
1620014|NCT02087059|Drug|Ruxolitinib|
1620016|NCT02087033|Dietary Supplement|ritmonutra|2 tablets a day by mouth for 4 weeks
1620017|NCT02087033|Dietary Supplement|placebo|sugar pill manufactured to simulated ritmonutra: 2 tablets a day for 4 weeks
1620018|NCT02087020|Procedure|Debridement, antibiotics and implant retention|DAIR treatment protocol embodies an extensive surgical debridement and a radical excision of infected tissue. This is followed by exchange of modular components (articulating surfaces of the implant such as the femoral head, acetabular liner in total hip arthroplasty and the tibial insert, the polyethylene meniscus, in total knee arthroplasty). The wound is then copiously irrigated (> 9 litre) with 0.9 % sodium chloride and then closed.
1620019|NCT02087007|Drug|Cilostazol|100mg oral tablets bid during 2 weeks after dosing of 50mg oral tablets bid during 2 weeks
1620020|NCT02087007|Drug|placebo|100mg oral placebo tablets bid during 2 weeks after dosing of 50mg oral placebo tablets bid during 2 weeks
1620021|NCT02086994|Drug|misoprostol|given after the delivery of the anterior shoulder of the baby.
1620022|NCT02086994|Drug|carbetocin|given after delivery of anterior shoulder
1620023|NCT02086968|Drug|Injectafer|2 doses of Injectafer, at 15mg/kg for a maximum single dose of 750mg given on days 0 and 7 for a total of up to 1500mg
1620024|NCT02086968|Drug|Ferrous Sulfate tablets|325mg (1 tablet) three times a day for 28 days
1620025|NCT02086955|Behavioral|Nursing counseling|The participants who are randomized in the intervention group receive standardized education regarding diabetic foot care. The nurse-led outpatient intervention lasts five weeks. During a period of five weeks, the participants are provided with weekly skill training, and counseling sessions on foot care. Each participant receives a foot care kit with essential foot care material and a foot care diary.
1620026|NCT02086942|Drug|Bortezomib|Induction therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,4 cycle Intensive therapy：1.6mg/m2 or 1.3mg/m2 SC,Days 1, 6, 11, 16 of each 28 day cycles,5 cycles.
1620027|NCT02086942|Drug|cyclophosphamide|Induction therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,4 cycles. Intensive therapy：300mg/m2 VD Days 1-3 of each 28 day cycles,5 cycles. Maintenance treatment with CP: 200mg PO Days 1-14 of each 28 day cycles,12 cycles.
1620028|NCT02086942|Drug|Dexamethasone|Induction therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,4 cycles Intensive therapy：40 mg/d VD Days 1,6,11,16 of each 28 day cycles,5 cycles.
1620029|NCT02086929|Drug|Trazodone|
1620030|NCT02086929|Drug|Venlafaxine|
1620031|NCT02086903|Drug|Ticagrelor 90 mg|The subjects administer Ticagrelor 90 mg as loading dose (LD) follow by 90 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Clopidogrel 600 mg as LD follow by 75 mg/day as MD for 5 days).
1620032|NCT02086903|Drug|Clopidogrel 600 mg|The subjects administer Clopidogrel 600 as loading dose (LD) follow by 75 mg/day as maintenance dose (MD) for 5 days, following a 2-week washout period, to receive the alternate thienopyridine (Ticagrelor 90 mg/day as LD, follow by 90 mg/day as MD for 5 days).
1620033|NCT02086890|Device|Electro-acupuncture|
1620034|NCT02086890|Device|Laser Acupuncture|
1620035|NCT02086890|Device|Transcorneal Electrical Stimulation|
1620036|NCT02086890|Device|Sham Electro-acupuncture|
1620037|NCT02086890|Device|Sham laser acupuncture|
1620038|NCT02086890|Device|Sham transcorneal electrical stimulation|
1620039|NCT02086864|Drug|lactose/sucrose granule (Individualized homeopathic medicine treatment)|The homeopathic remedy (study medication) for each patient will be chosen from among the homeopathic medicines manufactured by Boiron Canada and currently approved for sale in Canada by Health Canada. As per classical homeopathy practice, once the most appropriate homeopathic remedy has been chosen, it will be prescribed by the homeopath according to her/his clinical judgment (maximum on a daily basis, 3 times per day, minimum 1 dose (or zero doses on the second consult or later)) with administration instructions given to the parent and patient as appropriate. Water dosing, in which a lactose/sucrose granule remedy is dissolved in 250 ml of water will be used based on the homeopath's clinical judgment. Only one remedy will be administered at a time.
1620040|NCT02086864|Drug|Placebo lactose/sucrose pill|
1620041|NCT02086864|Behavioral|Homeopathic consultation|
1620042|NCT02086851|Behavioral|Lifestyle Intervention|
1620043|NCT02086851|Behavioral|Parent Motivational Interviewing|
1620044|NCT02086838|Drug|Theragran Hematinic|
1620045|NCT02086838|Drug|low molecular weight iron dextran|
1620046|NCT02086825|Drug|Rifaximin|(Xifaxin®, Salix Pharmaceuticals) 550mg tablet twice daily.
1620047|NCT02086825|Drug|Lactulose|20g dose titrated
1620048|NCT02086799|Drug|IV thyroxin|Patients will receive treatment with intra-venous thyroxine 100mcg once on admission and additional 100mcg after 12 hours.
1620049|NCT02086799|Drug|Placebo|Patients will receive treatment with normal saline 100ml once on admission and additional 100ml after 12 hours
1620050|NCT02086786|Drug|Risperidone ISM|"Four doses of 75 mg of Risperidone ISM as intramuscular (IM) injection into the deltoid muscle at 28-day intervals.
Four doses of 75 mg of Risperidone ISM as intramuscular injections into the gluteal muscle at 28-day intervals."
1620051|NCT02086773|Procedure|RBC Transfusion: restrictive threshold (7 g/dL Hb)|RBC transfusion with transfusion threshold of 7g/dL Hb.
1620052|NCT02086773|Procedure|RBC transfusion: standard threshold (8 g/dL Hb)|RBC transfusion with transfusion threshold of 8g/dL Hb
1620053|NCT02086760|Other|Ultrasonography with oral hydration|Before, 30 min and 90 min following oral hydration
1620054|NCT02086760|Radiation|Scintigraphy|
1620055|NCT02086747|Drug|Acetaminophen|100 ml iv, 4 times a day for 72 hours
1620056|NCT02086747|Drug|Isotonic|100 ml iv, 4 times a day for 72 hours
1620057|NCT02086734|Other|Perfusion-CT|"Baseline Perfusion CT-Scan (before AAT)
Follow-Up I Perfusion-CT Scan 7 days after start with AAT
Follow-Up II Perfusion-CT Scan 8 weeks after start with AAT"
1620058|NCT02086721|Drug|L19-IL2|"Patients receive a schedule of 1 x 30 Gy, 3 x 15-20 Gy; 5 x 12 Gy; 8 x 7.5 Gy; to the 80 % or 100 % isodose.
Step -1: Toxicity of 10 Mio IU of L19-IL2 (n=3-6)10 Mio IU of L19-IL2 (max. 6 cycles) via i.v. bolus injection.
Toxicity scored at every i.v. drug administration and on day 7, 14 and 21. Step 1: Toxicity of 15 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.
Step 2: Toxicity of 22.5 Mio IU of L19-IL2 (n=3-6)(max. 6 cycles) via i.v. bolus injection.
Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle.
Step 3: Expansion cohort of the maximally tolerable dose (n=10) Administration of the maximally tolerable dose of L19-IL2(max. 6 cycles) via i.v. bolus injection.
Toxicity scored at every i.v. drug administration and on day 7, 14 and 21 of the cycle."
1620059|NCT02086708|Device|Shear Wave sonoelastography|Shear Wave Sonoelastography as a ultrasound technique to measure liver fibrosis is performed on patients scheduled for non-focal liver biopsy. Results are compared with pathological score of fibrosis from liver biopsy.
1620060|NCT02086669|Procedure|Pneumatic dilatation|
1620061|NCT02086669|Procedure|Laparoscopic myotomy|
1620062|NCT02086656|Drug|capecitabine, oxaliplatin, irinotecan and bevacizumab|perioperative COI-B
1620063|NCT02086643|Procedure|Retroclavicular block|Retroclavicular ultrasound guided nerve block with total injection of 40 ml of a mixture of 20 ml ropivacaine 0,5% (5 mg/ml) + 20 ml mepivacaine 1,5% (15 mg/ml) + epinephrine 1 : 400 000 (2,5 mcg/ml). Incremental injections of 5 ml separated by an aspiration test.
1620064|NCT02086630|Behavioral|Heart to Heart|
1620065|NCT02086617|Other|ultrasound of aorta|
1620066|NCT02086604|Drug|Brentuximab vedotin|
1620067|NCT02086604|Drug|Lenalidomide|
1620068|NCT02086591|Drug|Doxycycline|
1620069|NCT02086578|Device|Breast MRI|
1620070|NCT02086578|Behavioral|Breast-Q© questionnaire|
1620071|NCT02086578|Radiation|Multi-Beam IMRT|The radiation dose (50-50.4 Gy/25-28 fractions in approximately 5-6 weeks), treatment-planning and delivery aspects are according to departmental guidelines for breast IMRT.
1620072|NCT02086565|Behavioral|Portal training and home visits|patient portal training and home visits by CHW to coordinate care
1620073|NCT02086565|Behavioral|Portal training|training in use of patient portal
1620077|NCT02086539|Other|Large Envelope|
1620078|NCT02086539|Other|Priority Mail|
1620079|NCT02086539|Other|Amazon|
1620080|NCT02086526|Drug|Metformin|Approximately 37 patients will start metformin therapy 3 months after their visit 2. All other patients will receive metformin therapy at their visit 2.
1620081|NCT02086513|Drug|LDE225|Treatment with LDE225
1620082|NCT02086500|Drug|Tranexamic Acid|1 gram of prehospital Tranexamic Acid
1620083|NCT02086500|Other|Saline control|Saline Control
1620084|NCT02086487|Drug|Nilotinib 300 mg.|"Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:
Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript > 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at > 12 months; i.e (BCR-ABL1 0.1 -1%)"
1620085|NCT02086474|Drug|Hyaluronan|Intra-articular injection
1620086|NCT02086474|Drug|Bupivacaine|Extra-capsular injection
1620087|NCT02086461|Device|Pneumatic pyloric dilatation|
1620088|NCT02086461|Other|15 mm pyloric balloon dilatation|
1620089|NCT02086448|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevents apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
1620090|NCT02086448|Device|sham-CPAP|
1620091|NCT02086448|Other|Sleep hygiene|Information about sleep apnea and healthy sleep. Information about local sleep resources
1620092|NCT02086435|Procedure|Extracorporeal morcellation|"patients treated with protected removal by endobag and extracorporeal myoma morcellation with cold scissors and scalpel blade or with power morcellator used inside the bag itself"
1620093|NCT02086435|Procedure|Intracorporeal morcellation|patients treated with standard intracorporeal morcellation, using reusable electronic device
1620094|NCT02086422|Drug|ivabradine|
1620095|NCT02086422|Drug|Placebo|
1620096|NCT02086422|Other|Exercise|
1620097|NCT02086409|Dietary Supplement|Yogurt supplemented with vitamin D and calcium|The product is a yogurt containing 200 IU of vitamin D and 400 mg of calcium. Participants take 2 yogurts per day.
1620098|NCT02086409|Dietary Supplement|Yogurt not supplemented with vitamin D and calcium|The comparator is represented by a yogurt not supplemented with vitamin D and calcium.Participants take 2 yogurts per day.
1620099|NCT02086396|Dietary Supplement|pumpkin seed flour|The pumpkin seed flour group received 20g/day of pumpkin seed flour during 12 weeks
1620100|NCT02086396|Dietary Supplement|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored) received 20g/day of cassava flour flavored during 12 weeks.
1620101|NCT02086370|Procedure|Standard PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of the posterior tubal margin, sparing the mesosalpinx.
1620154|NCT02085967|Drug|E2006|
1620155|NCT02085941|Procedure|Cryoablation|Type and number (Mean 3, range 1-10) of cryoprobe(s) used depend on size and shape of target lesion
1620102|NCT02086370|Procedure|Radical PBS|the tube will be removed by coagulation and section of the tissue beginning from the very distal fimbrial and proceeding toward the uterine cornu. The resection will be performed at the level of ovarian margin and the uterus-ovarian ligament, including the mesosalpinx removal.
1620103|NCT02086357|Procedure|SWUE|
1620104|NCT02086344|Procedure|PBS|TLH plus PBS
1620105|NCT02086344|Procedure|TLH _adnexal preservation|TLH without PBS
1620106|NCT02086331|Procedure|Contrast enhanced ultrasound|Infusion of microbubbles to enhance blood vessels in the leg for ultrasound
1620107|NCT02086331|Behavioral|Treadmill test|Exposes you to exercise in a controlled environment. We will see if we can detect this change with our new ultrasound protocol
1620108|NCT02086331|Procedure|Contrast enhanced ultrasound|
1620109|NCT02086318|Other|OvAge assessment|Basal serum anti-Mullerian hormone (AMH), Follicle-stimulating hormone (FSH) and Estradiol (E2), antral follicle count (AFC), ovarian volume, Vascularization Index (VI), Flow Index (FI) and Vascularization Flow Index (VFI) will be measured in all women between day 1 and day 4 of menstrual cycle. Evaluation can be repeated after every kind of intervention regarding ovaries, both medical or surgical. Evaluation can be repeated also at interval of 3-6-12 months in order to study the modification of ovarian age when time passes.
1620110|NCT02086305|Behavioral|Transitional Care Model|Symptom assessment and management, care goal setting, post-discharge support
1620111|NCT02086305|Behavioral|Usual care|Usual care is the routine practice in the hospital
1620112|NCT02086292|Procedure|2 ml 1% Lidocaine|
1620113|NCT02086292|Procedure|1 ml 2% Lidocaine|
1620114|NCT02086279|Drug|GnRH analogue|"Patients with uterine myoma, endometriosis, fibromatous uterus, chronic pelvic pain in list for laparoscopic surgery or laparotomy are usually pharmacologically treated by administration of GnRHa, 11.25 mg at 21° day of the menstrual cycle and repeated after 3 months. This treatment is part of our preoperative routine in order to reduce pain symptoms, menstrual blood loss, uterine or fibroids vascularization and size, during the months spent on surgery waiting list.
Patients who will satisfy inclusion and exclusion criteria will be enrolled in this study protocol and will be subjected to valuation of ovarian reserve: specifically, serum levels of AMH and antral follicle count (AFC) between first and fourth days of the menstrual cycle will be measured."
1620115|NCT02086266|Other|PILATES|
1620116|NCT02086266|Other|PFMT and AES|
1620117|NCT02086253|Drug|BQ-788 and/or BQ-123|
1620118|NCT02086240|Drug|XBD173|XBD173 (Emapunil is an anxiolytic drug which acts as a selective agonist at the peripheral benzodiazepine receptor), a drug which binds the TSPO with high affinity.
1620119|NCT02086227|Drug|Glucagon for Injection (Fresenius Kabi USA)|Test product: A 1 mg (1 IU/ml) Glucagon for Injection (Fresenius Kabi USA)
1620120|NCT02086227|Drug|Glucagon for Injection (Bedford Laboratories)|Reference product: B 1 mg (1 IU/ml) of GlucaGen® for Injection (Bedford Laboratories)
1620121|NCT02086214|Device|Proprioceptive pressure therapy|Proprioceptive pressure therapy using a a LYCRA® compressive sleeve initially used in burn therapy : 15 to 25 mmHg.
1620122|NCT02086214|Device|Control|LYCRA® non-compressive sleeve initially used in burn therapy : < 5 mmHg.
1620123|NCT02086201|Behavioral|Problem Solving Therapy|PST is a behavioral intervention for depression that is delivered by trained therapists over a 9 week period. It consists of a process to help patients understand and then solve the problems in their lives they feel is contributing to their depression.
1620124|NCT02086201|Behavioral|Engage|Engage is a weekly behavioral intervention that is delivered over a 9 week period of time by trained therapists. The focus of Engage is to help patient reconnect with activities that they have lost interest in pursuing due to depression.
1620125|NCT02086188|Drug|Mirabegron|see detailed information in associated Arm Description
1620126|NCT02086188|Drug|Placebo|Sugar pill manufactured to mimic Mirabegron 25mg tablet.
1620127|NCT02086175|Drug|Imprime PGG|
1620128|NCT02086175|Drug|Rituximab|
1620129|NCT02086162|Behavioral|Web-based motivational decision support system|
1620130|NCT02086162|Behavioral|NCI Education|
1620131|NCT02086149|Behavioral|Aerobic Exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals. Two month course of the nicotine patch initiated during week 5.
1620132|NCT02086149|Behavioral|Health Education|12-week health education control. Weekly sessions about 12 different topics related to the health effects of smoking, led by an expert in smoking cessation.
1620133|NCT02086123|Procedure|Epidural Analgesia|Bupivacaine + Fentanyl
1620134|NCT02086123|Procedure|Parenteral Analgesia (Intravenous)|Dilaudid 0.2 -0.4 mg IV every 3 hours
1620135|NCT02086110|Dietary Supplement|Synbiotic|
1620136|NCT02086110|Dietary Supplement|Prebiotic|
1620137|NCT02086097|Drug|Dexketoprofen trometamol|25m of dexketoprofen (oral intake) every 8 hours
1620138|NCT02086097|Drug|Ibuprofen|600 mg of Ibuprofen (Oral Intake) every 8 hours
1620139|NCT02086097|Drug|PLACEBO|INACTIVE SUGAR PILLS
1620140|NCT02086084|Device|NIV|Standard care
1620141|NCT02086084|Device|ECCO2R|Application of ECCO2R in addition to NIV
1620142|NCT02086071|Procedure|re biopsy|re biopsy depending on the location of the pathology
1620143|NCT02086045|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold System|percutaneous coronary
1620144|NCT02086032|Drug|1mg 17 beta-estradiol|Comparing sleeping quality between micronized progesterone and dydrogesterone users.
1620145|NCT02086032|Drug|Dydrogesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users.
1620146|NCT02086032|Drug|micronized progesterone|Comparing sleeping quality between micronised progesterone and dydrogesterone users
1620147|NCT02086019|Drug|Conservative Arm|crossover to angiogram only if predefined criteria met
1620148|NCT02086019|Procedure|Invasive Arm|angiogram with PCI or CABG revascularisation if appropriate
1620149|NCT02086006|Device|DESolve Novolimus Eluting Bioresorbable Coronary Scaffold|
1620150|NCT02085980|Device|Laser treatment|The laser handpiece (probe) will be deposited in the vaginal canal and the laser energy will be delivered through the handpiece
1620151|NCT02085967|Drug|rifampin 600 mg|
1620152|NCT02085967|Drug|itraconazole 200 mg|
1620156|NCT02085941|Device|Biopsy|If target lesion has not been previously biopsied, a core biopsy may be taken prior to the cryoablation.
1620157|NCT02085928|Other|Intratissue percutaneous electrolysis, associated with eccentric exercise and stretching|"The EPI technique was performed under ultrasound-guidance on the clinically relevant area (or areas of maximum tenderness to palpation and with ultrasonographic degenerative tendon changes) using an intensity of 4-6 mA during 3 seconds, approximately 3 times. We used the EPI machine (Cesmar Electromedicina S.L., Barcelona, Spain) and a GE Logiq E Portable Ultrasound Machine with GE Linear probe 12L-RS (5-13 mhz) (GE Healthcare, Wisconsin, EEUU).
The eccentric exercise program consisted of three series of up to 10 repetitions of eccentric work, repeated twice daily (morning and afternoon), under maximum load (initially with one kilogram) in an optimal and functional pain-free range.
The stretching program consisted of a stretching exercise for the epicondylar muscles consisting in three series of 7 repetitions twice a day (morning and afternoon."
1620158|NCT02085915|Other|strip Peri Screen|
1620159|NCT02085902|Drug|Ropivacaine|
1620160|NCT02085889|Other|no intervention: observational study|
1620161|NCT02085876|Other|2 additional MRI sequences|
1620162|NCT02085876|Other|An additional blood sample|
1620163|NCT02085863|Drug|laquinimod|Oral laquinimod 0.6 mg capsules (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
1620164|NCT02085863|Drug|Placebo|Placebo (with oral contraceptives tablets containing 30 μg ethinylestradiol and 150 μg levonorgestrel (Microgynon®)
1620165|NCT02085837|Other|Education|Additional education will be provided by nurses to improve communication and reduce fragmentation of care.
1620166|NCT02085837|Other|Daily weight measurement and monitoring|Monitor weight to avoid problems related to hypervolemia.
1620167|NCT02085837|Other|Universal Dietary education|To improve diet and health
1620168|NCT02085837|Other|Medication review|Medication will be reviewed by nurses to detect any discrepancies to reduce medication error.
1620169|NCT02085837|Other|Focused advanced directive program|Education will be provided to increase awareness and encourage patients to have advanced directive.
1620170|NCT02085837|Other|Countdown to fistula program|To reduce the number of patients starting dialysis with catheter in place, comprehensive stepwise intervention will be provided by nurses to ensure arterio-venous (AV) fistula placement in all appropriate patients, with coordinated follow up and failure recovery processes.
1620171|NCT02085824|Drug|Enoxaparin|
1620172|NCT02085824|Drug|rivaroxaban|
1620173|NCT02085824|Drug|dabigatran|
1620174|NCT02085811|Other|radiography standard|
1620175|NCT02085798|Other|Either Wait and See, or Supportive Treatment, or Active Treatment at physician discretion|As described above
1620176|NCT02085785|Behavioral|Coached group|Participants randomized to the coached arm will receive 1) education and self-monitoring materials [e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)], 2) a home visit by an exercise specialist, and 3) 11 telephone calls (over a 20-week period) by a health coach who will utilize motivational interviewing techniques to help the participant set eating and activity goals and trouble shoot problems when they occur
1620177|NCT02085785|Behavioral|Self-directed control group|Participants randomized to the self-directed control arm will receive the same educational and self-monitoring materials as the coached group [e.g., a booklet, calorie count book, pedometer, and scale (if they do not have one)], but no home visit and no coaching calls. They will be encouraged to make behavior changes on their own.
1620178|NCT02085785|Other|Screened only|Screened only - No intervention -- individuals who are contacted and/or screened for eligibility
1620179|NCT02085772|Other|Blood samples at 37-38 Weeks of amenorrhea|
1620180|NCT02085772|Other|Blood samples at 41 Weeks of amenorrhea if prolonged pregnancy|
1620181|NCT02085746|Other|Defining Sexual Activity Questionnaire|
1620182|NCT02085720|Device|CPAP therapy|As OSA may increase the risk of cardiovascular mortality, all elderly subjects with AHI ≥ 15 or those with AHI ≥ 5 plus either cardiovascular risk factors or ESS score ≥ 10 received patient education program. Elderly subjects who agree for home CPAP treatment were prescribed nasal CPAP units with time clocks to assess objective compliance (run time). ESS, sleep apnea specific quality of life index (SAQLI), and cognitive function tests were performed at baseline, 3 months, 6 months and 12 months after CPAP treatment.
1620183|NCT02085707|Procedure|Total hip replacement arthroplasty|treatment with total hip replacement arthroplasty with the implant chosen by the institution
1620184|NCT02085707|Procedure|Closed reduction and internal fixation|treatment with closed reduction and internal fixation with 2 cannulated hip pins
1620185|NCT02085694|Drug|Lactobacillus brevis CD2|
1620186|NCT02085681|Other|Tele-medicine|Patients at the diabetes clinics will be subjected to non-mydriatic retinal imaging and the images will be transferred to the eye hospital via internet using a specified software - Aravind Diabetic Retinopathy Evaluation Software (ADRES) that enables a retinal specialist to read and grad the image and send the feedback immediately to the diabetes clinic. Based on the presence or absence of DR the patients will be referred to the eye hospital for detailed retinal examination.
1620187|NCT02085681|Other|Conventional referral|All eligible patients in the conventional arm will be counselled on the importance of eye screening and will be referred to the eye hospital
1620188|NCT02085668|Device|Renal denervation (Symplicity™)|Delivery of radiofrequency through the wall of the renal artery to disrupt the surrounding renal nerves under angiography control
1620189|NCT02085655|Drug|pegaspargase|pegaspargase: 2000U/m2 im on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1620190|NCT02085655|Drug|Gemcitabine|1000mg/m2, ivd on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1620191|NCT02085655|Drug|Oxaliplatin|100mg/m2 ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops
1620192|NCT02085655|Drug|Methotrexate|3000m g/m2 civ 6-hour on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1620193|NCT02085655|Drug|Dexamethasone|40mg ivd on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1620194|NCT02085655|Drug|Thalidomide|100-200mg, PO, after chemotherapy
1620195|NCT02085642|Other|Acupuncture|Single disposal needle to be used, 0.02 mm x 25 mm in length
1620196|NCT02085642|Other|Sham needle|Retractable needle with no skin puncture
1620197|NCT02085629|Biological|Donor M reg (Mreg_UKR)|"Experimental: M reg treatment
Donor M reg (2.5-7.5 million cells/kg) IV infused (6-7d before Tx) into recipients of a living donor renal Tx. Recipients also receive prednisolone, mycophenolate mofetil and tacrolimus background immunosuppression (as described in detail in the arm description)."
1620198|NCT02085616|Behavioral|Proactive service|In the proactive service the callers to the quitline are offered a number of callbacks.
1620199|NCT02085616|Behavioral|Reactive service|In the reactive service the callers to the quitline are informed that they can themselves call back whenever they like.
1620200|NCT02085603|Drug|Saracatinib|
1620201|NCT02085603|Drug|Placebo|
1620202|NCT02085590|Biological|BCG vaccine|
1620203|NCT02085590|Biological|Lipopolysaccharide (LPS) E. Coli 1 ng/kg intravenously|
1620204|NCT02085577|Drug|(S)-(+)-Ketamine Hydrochloride Solution 25 mg/ml|Ketamine (25 mg/ml) bolus 0.5 mg/kg administered immediately after induction of anesthesia, followed by infusion ketamine 0,25 mg/kg/hour that is terminated when the last suture to the skin has been performed.
1620205|NCT02085577|Drug|Isotonic sodium chloride 0.9 percent|Isotonic sodium chloride 0.9 percent 0.02 ml/kg administered immediately after induction of anesthesia, followed by infusion isotonic sodium chloride 0.01 ml/kg/hour that is terminated when the last suture to the skin has been performed.
1620206|NCT02085577|Drug|Paracetamol 1 g|Paracetamol 1 g orally 1 hour preoperatively and every 6 hours after extubation time during the first 24 hours.
1620207|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml administered as patient-controlled analgesia (PCA, bolus 2.5 mg, lockout 5 minutes) 0-24 hours postoperatively
1620208|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 2.5 mg administered by the PACU nurse on request of the patient for the first hour postoperatively.
1620209|NCT02085577|Drug|Ondansetron 2 mg/ml|Ondansetron 2 mg/ml 4 mg iv in case of moderate to severe nausea, supplemented by Ondansetron 1 mg iv if needed
1620210|NCT02085577|Drug|Usual daily opioids|The patients usual daily opioid consumption are administered during the study period
1620211|NCT02085577|Drug|Morphine Sulphate 1 mg/ml|Morphine Sulphate 1 mg/ml, bolus 0.4 mg/kg administered 45 minutes before expected awakening.
1620212|NCT02085577|Drug|Sufentanil 5 microgram/ml|Sufentanil 5 microgram/ml, bolus 5 micrograms administered by the anaesthetic nurse in the operating room if the patient is in pain upon awakening.
1620213|NCT02085564|Procedure|Peritoneal washing cytology|The methode is describes in the detailed study description
1620214|NCT02085551|Device|Mechanical Thrombectomy by the Indigo System|
1620215|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
1620216|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
1620217|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
1620218|NCT02085538|Drug|palbociclib|palbociclib 125 mg oral capsule with food once
1620219|NCT02085525|Other|Nurse Practitioner Clinic|"The nurse practitioner (NP) clinic is staffed by two NPs, one registered nurse, and several medical assistants. Patients can be seen by either NP during their treatment course. Patients will be scheduled to be seen in the (NP) clinic based on randomization assignment.
Each clinic visit focuses on specific concerns and toxicities of the patient and their significant other. This will include physical as well as psychological, social and spiritual needs."
1620220|NCT02085512|Procedure|Neurocognitive retraining|
2010939|NCT02778282|Other|MySafeRx™|The MySafeRx™ platform is a combination of several key components, including daily videoconferencing check-ins with motivational interviewing-based recovery coaching, text-messaging reminders, secure storage of buprenorphine medication within a secure electronic pill dispenser, and a standardized protocol for supervising self-administration of medication via videoconferencing.
2010940|NCT02777762|Behavioral|Fun First|8 weekly interactive small-group sessions with a health coach
1620223|NCT02085486|Device|Ultrasound-assisted puncture|Portable ultrasound device
1620224|NCT02085486|Other|Standard|Standard inspection, palpation.
2010941|NCT02777762|Behavioral|Close at Hand|8 weekly check-ins with a state of the art, engaging mobile app
1620226|NCT02085460|Drug|Placebo|
1620227|NCT02085460|Drug|2% Rebamipide liquid|
1620228|NCT02085460|Drug|4% Rebamipide liquid|
1620229|NCT02085447|Behavioral|CAE-L|Eight sessions of the manualized intervention, Customized Adherence Enhancement (CAE), will be delivered along with a long-acting injectable antipsychotic (either haloperidol decanoate or paliperidone palmitate dosed per package insert) over the course of six weeks. Study staff will also communicate with the participant's mental health provider to help ensure treatment continuation after study end.
1620230|NCT02085434|Behavioral|FITLINE practice-based referral program|The FITLINE practice-based referral program provides pediatric practices an easily accessible resource to help families make AAP-recommended Stage 1 lifestyle changes. The program includes a pediatric practice-based component (systems to identify overweight and obese children ages 8-12, a brief pediatric provider-delivered intervention, referral to the FITLINE counseling program, and feedback from the FITLINE nutritionist) and a parent support component(eight weekly FITLINE counseling telephone calls delivered by centrally located nutritionists). Providers receive a summary from the nutritionist of the progress made by families so they may support maintenance of an improved lifestyle, or refer for additional intervention.
1620231|NCT02085421|Device|tDCS|Transcranial direct current stimulation (tDCS) is a form of non-invasive neuromodulation that has been shown to enhance learning. tDCS is applied with current intensity of 1-2 mA of direct current and can be applied both before and during each cognitive remediation treatment session. Two saline soaked electrode sponges will be applied to the scalp.
1620232|NCT02085408|Drug|clofarabine|Given IV
1620233|NCT02085408|Drug|daunorubicin hydrochloride|Given IV
1620234|NCT02085408|Other|clinical observation|Undergo clinical observation
1620235|NCT02085408|Drug|cytarabine|Given IV
1620236|NCT02085408|Drug|decitabine|Given IV
1620237|NCT02085408|Other|laboratory biomarker analysis|Correlative studies
1620238|NCT02085408|Procedure|quality-of-life assessment|Ancillary studies
2010942|NCT02775812|Drug|Cisplatin|Given IV
2010943|NCT02775812|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1620241|NCT02085382|Procedure|Kangaroo Mother Care|"The infants were placed on continuous skin to skin contact between the mother and the baby as soon as possible. The mother kept her newborn infant between the breast, in close contact with her body and covered with the kangaroo tube. Infants wore diaper and a cap during the procedure. Breastfeeding was the standard feeding method.
When the baby was not in KMC, the baby was placed in the bassinet under warm lamp, if needed, adequately clothed and covered."
1620242|NCT02085382|Procedure|Conventional Mother Care|"This is generally included: an artificial warming system (heated room overhead lamp warmers). Breastfeeding was also the standard feeding method but if indicated, babies can also be fed through tube or cup feeding. The mothers were allowed to visit their babies anytime but skin to skin contact was not allowed.
Babies in both groups were monitored hourly. Their heart rate, respiratory rate and temperature were monitored and recorded. Any untoward events like hypothermia, hypoglycemia, apnea, signs of sepsis, and feeding problems were also noted."
1620243|NCT02085356|Behavioral|Protect your family|"Protect Your Family intervention is a manualized, closed, structured behavioral risk reduction program targeting HIV, stigma, disclosure, communication, intimate partner violence (IPV), PMTCT knowledge, safer conception, family planning and dual method sexual barrier use.
Intervention participants will attend 3 prenatal weekly 2 hour gender-specific (male or female, 5-7 participants) group sessions followed by 1 individual counseling session and 2 monthly couples or individual (women-only) counseling sessions (1 prenatal, 2 postpartum) led by study-trained clinic staff (e.g., nurses, HIV counseling and testing (HCT) counselors) plus standard of care (PMTCT)"
1620244|NCT02085343|Behavioral|EXP|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement throughout supporting efforts at exposure. An instructional set will be provided prior to treatment presenting the rationale for exposure as an effective means of reducing pathological fear.
1620245|NCT02085343|Behavioral|EXP + SBF|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided prior to treatment explaining how safety behaviors serve to maintain fear, and how their elimination may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment.
1620246|NCT02085343|Behavioral|EXP + SBF + AA|Participants will receive one-session exposure therapy consisting of six-6 minute trials of exposure to heights, involving ascending a 9-landing flight of outdoor stairs. Participants will be asked to ascend, accompanied by the therapist who will provide verbal encouragement supporting efforts at exposure. An instructional set will be provided explaining the rationale for eliminating safety behaviors, and how engagement in anti-phobic actions may enhance fear reduction. Additionally, the therapist will identify safety behaviors and prompt participants to reduce their utilization of them during treatment, and will instruct participants to enact a series of progressively challenging anti-phobic actions which oppose the prototypical fear response.
1620247|NCT02085330|Device|Hyperbaric oxygen therapy|100%, 2 ATA, 90 minutes
1620248|NCT02085317|Drug|acetylcholine Iontophoresis|Using a protocol similar to the one developed by Rossi and co-workers (Rossi et al., 2008), ACh (Acetylcholine - Sigma-Aldrich, St. Louis, USA) was delivered by 9 iontophoretic pulses of 0.1 mA for 20 s with 60 s interval between pulses using a drug delivery electrode filled with 0.1 ml of 1% ACh solution, attached to the dorsal aspect of the second left finger by a double-sided adhesive disc.
1620249|NCT02085317|Drug|sodium nitroprusside Iontophoresis|After Ach, SNP (Nipride® 10mg/ml - Biolab, São Paulo, Brazil) was delivered by 7 iontophoretic pulses of 0.2 mA for 20 s with 180 s interval between pulses using another drug delivery electrode filled with 0.1 ml of 1% SNP solution, attached to the dorsal aspect of the third left finger. In both situations, an indifferent electrode was attached on the dorsal aspect of the left hand. Endothelial-dependent and independent skin vasodilator response to each iontophoresis pulse was measured in PUs, as mean value during each interval from one pulse to the following one.
1620250|NCT02085304|Procedure|Gross total resection and Gliadel(R) wafers implanted|Complete removal of tumor and implant of Gliadel(R) wafers that are small, dime-sized wafers designed to deliver the chemo drug, carmustine, directly into the cavity made when the brain tumor was removed.
1620251|NCT02085304|Radiation|GammaKnife(R) stereotactic Radiosurgery|GammaKnife® (GK) radiosurgery dose of 15 Gy in one fraction to the resection cavity margin
1620252|NCT02085304|Radiation|Standard fractionated radiation therapy|standard fractionated RT of 60 Gy in 30 fractions (over approximately six weeks)
1620253|NCT02085304|Drug|Temozolomide|temozolomide 75 mg/m2 daily for 42 days, will be administered to all patients beginning within 24 hours of GK/RT initiation as is routine clinical care. There will be a one month drug holiday following the 42 days before adjuvant chemotherapy begins. Adjuvant temozolomide administered 5 days monthly at 150-200 mg/m2/day will be administered for 12 months as is routine clinical care.
1620254|NCT02085291|Drug|NE|NE infusion to titrate MAP to usual level
1620255|NCT02085291|Drug|Saline|Fluid resuscitation to titrate MAP to usual level
1620256|NCT02085278|Device|Apollo Micro Catheter device|Detachable Tip Micro catheter
1620257|NCT02085265|Drug|Perindopril|Perindopril 2 mg, 4 mg or 8 mg/day (depending on kidney function and tolerability)
1620258|NCT02085265|Drug|Telmisartan|Telmisartan 40 mg or 80 mg/day (depending on age and tolerability)
1620259|NCT02085252|Drug|Leuprorelin|Solution for injection
1620260|NCT02085252|Drug|bicalutamide|Bicalutamide tablets
1620261|NCT02085239|Drug|Lidocaine Ropivacaine|"8-10 ml of Lidocaine given by subcutaneous injection
8-10 ml of Ropivacaine given by subcutaneous injection"
1620262|NCT02085239|Drug|Lidocaine alone|
1620294|NCT02084992|Other|Expanded technology disease management|Tablet computers loaded with a web-based disease management program will be given to patients for the duration of the study.
1620295|NCT02084992|Other|Telephonic disease management|
1620296|NCT02084979|Behavioral|telepsychiatry evaluation|telepsychiatry evaluation and consultation to primary care
1620297|NCT02084966|Procedure|Procedure/Surgery: Transplantation: OCT of Kidney Transplant|Device: Optical Coherence Tomography of Kidney Transplant
1620298|NCT02084953|Drug|BMS-791325|
1620299|NCT02084953|Drug|Moxifloxacin|
1620263|NCT02085226|Other|Creative Engagement Intervention|"The CEI has 5 component stages which map the participant's journey with the Artist
Meeting with Artist, discuss interests, stroke and explore initial creative goals.
Introduction to materials and mark making to create interpretations of established images.
From mark making and interpretations to developing personal project ideas.
Turning personal project ideas into creative finished pieces.
Review of completed work, mounting and display of work, future plans.
It is recognised that participants will progress differently. Components may be repeated or retuned to or may be addressed simultaneously. Participants may progress rapidly and so move from stage 5 back to stages 2, 3 or 4 to progress new work or experience new materials or processes."
1620264|NCT02085226|Other|Portfolio Group|The Portfolio group will receive conventional rehabilitation activity at each site. In addition, to control for effects of art related attention received by the intervention group, after baseline assessment and randomisation, this group will receive from the research assistant, a portfolio of work produced by previous participants of the Tayside CEI, with details of community programmes that people with stroke can attend after hospital discharge. Participants will be invited to view the portfolio during their stay. Prior to outcome assessment, the research assistant will visit participants again to answer questions and to discuss options for community programmes, if the person is interested.
1620265|NCT02085213|Drug|Glyceryl Trinitrate|
1620266|NCT02085213|Drug|Matched Placebo|
1620267|NCT02085200|Other|horizontal adduction stretch with scapular stabilization|Scapular is stabilized during manual horizontal adduction stretch
1620268|NCT02085200|Other|Horizontal adduction stretch without scapular stabilization|Scapula stabilization is not performed during horizontal adduction stretch
1620269|NCT02085187|Other|Telemedicine training and counselling|"Training and counselling by the physiotherapist consisted of 3 weekly sessions, lasting 30-45 minutes, over a 3 week period, i.e. a total of 9 supervised sessions. Heart rate and oxygen saturation were monitored during the exercise training. This included thoracic mobilization exercises, cardio training, strength training and breathing exercises. The training intensity was progressed continuously.
There were 1-2 sessions with the occupational therapist, which consisted of training and counselling on energy conservation techniques. The first session was 60 minutes long and included assessment, counselling and training. This session was delivered in the second week of the intervention. The intervention concluded in the third week, with sessions of 30 minutes as required."
1620270|NCT02085161|Drug|placebo to tiotropium + olodaterol|comparator
1620271|NCT02085161|Drug|tiotropium+olodaterol|tiotropium 5 mcg once daily
1620272|NCT02085161|Drug|tiotropium +olodaterol|olodaterol 5 mcg once daily fixed dose combination
1620273|NCT02085161|Drug|tiotropium|tiotropium 5 mcg once daily fixed dose combination
1620277|NCT02085135|Drug|ALKS 5461|Sublingual tablet taken once daily
1620278|NCT02085122|Other|noninvasive ventilation|Ventilatory support with bilevel positive pressure was held for 30 minutes with the volunteer sitting comfortably. A fan with two pressure levels (Vivo 40 Bi-Level, General Electric Company), which was attached to the face of the individual through a face Macara ( Respironics), was initially adopted one of 15 cmH2O IPAP and EPAP was used 5 cmH2O, making admissible pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
1620279|NCT02085109|Dietary Supplement|Fat milkshake|
1620280|NCT02085109|Dietary Supplement|Theobromine|
1620281|NCT02085096|Behavioral|Problem-Solving Therapy|Problem-solving therapy programs have been shown to be effective among parents of children diagnosed with cancer. Efforts have been made to apply this same strategy to spouses/significant others of men diagnosed with prostate cancer. The purpose of this study is to test the efficacy of problem-solving therapy on the spouses of prostate cancer patients.
1620282|NCT02085083|Behavioral|Telephone and email correspondence with an Inflammatory Bowel Disease Nurse|"The IBD pediatric-adult transition nurse will send an email each month containing:
Brief Questionnaire: A link to a secured website will be provided where participants will respond to a questionnaire.
Direct Nurse Contact: Telephone and email correspondence with an Inflammatory Bowel Disease Nurse
Educational module: Every other month, we will include in the email another link to an optional educational module that will be part of a curriculum to facilitate transition readiness.
MyHealth Passport
Study Questionnaire: A personalized link to a more comprehensive study questionnaire similar to the baseline questionnaire will be emailed in the 6th and 12th (final) email."
1620283|NCT02085083|Behavioral|Minimal Intervention Arm|Patients randomized to the control group will have receive email based questionnaires and information relating to the MyHealth Passport application. This intervention is not expected to significantly improve outcomes.
1620284|NCT02085070|Drug|MK-3475|IV MK-3475
1620285|NCT02085057|Procedure|Functional Magnetic Resonance Imaging|
1620286|NCT02085044|Dietary Supplement|Ready-to-Used Supplement Food administration|
1620287|NCT02085031|Procedure|Intracorporeal Roux-en-Y esophagojejunostomy|During totally laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy intracorporeally using a transorally inserted anvil (OrVil™) will be performed.
1620288|NCT02085031|Procedure|Extracorporeal Roux-en-Y esophagojejunostomy|During laparoscopic total gastrectomy, Roux-en-Y esophagojejunostomy extracorporeally using a transabdominally inserted anvil will be performed.
1620289|NCT02085018|Drug|Omeprazole|Drug
1620290|NCT02085018|Drug|Matched placebo|Matched placebo
1620291|NCT02085005|Drug|Capecitabine|Pharmaceutical form:tablet Route of administration: oral
1620292|NCT02085005|Drug|Aflibercept AVE0005|Pharmaceutical form:concentrate for infusion Route of administration: intravenous
1620293|NCT02085005|Drug|Oxaliplatin SR96669|Pharmaceutical form:solution for infusion Route of administration: intravenous
1620300|NCT02084953|Drug|Placebo matching BMS-791325|
1620301|NCT02084940|Drug|GnRH antagonist depot Degarelix|Women receive 20 mg of Degarelix on the first day of menstrual cycle followed by a fixed dose of 225 IU of recombinant FSH on the second day until the day of ovulation triggering
1620302|NCT02084927|Biological|HBOT|HBOT of 2 ATA for 90 minutes, for 60 treatments
1620303|NCT02084914|Procedure|Endometrial scratching|Group A: pipelle Group B: sound
1620304|NCT02084901|Device|Drug-eluting biodegradable stent Orsiro implantation|Drug-eluting biodegradable stent Orsiro implantation
1620305|NCT02084901|Device|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation|Drug-eluting biodegradable stent BioMatrix or BioMatrix Flex implantation
1620306|NCT02084875|Drug|tofacitinib modified-release (MR) formulation|A single dose of tofacitinib modified release 11 mg tablet after receiving the standard FDA high fat/high calorie meal.
1620307|NCT02084875|Drug|tofacitinib modified-release (MR) formulation|tofacitinib modified release (MR) 11 mg tablet after a 10 hour overnight fast.
1620308|NCT02084862|Device|Ultrasound guided percutaneous tracheostomy|Ultrasound guided percutaneous tracheostomy
1620309|NCT02084862|Device|Bronchoscopy guided percutaneous tracheostomy|Bronchoscopy guided percutaneous tracheostomy
1620310|NCT02084836|Other|Functional Magnetic Resonance Imaging|
1620311|NCT02084823|Biological|cancer stem cell vaccine|
1620312|NCT02084810|Drug|activated recombinant human factor VII|"All subjects will receive one i.v. (intravenous, into the vein) injection of 90μg/kg.
Each subject will be allocated to two treatment periods separated by a wash-out period of a week."
1620313|NCT02084810|Drug|eptacog alfa (activated)|All subjects will receive one i.v. injection of 90μg/kg. Each subject will be allocated to two treatment periods separated by a wash-out period of a week.
1620314|NCT02084797|Drug|V2R (Vasopressin 2 receptor)|All ten subjects were used as their own controls in this double-blind, randomized controlled trial assessing the effect of the V2R on sweat sodium concentration via use of a V2R blocker (antagonist), stimulator (agonist), against a placebo (drug naive state).
1620315|NCT02084784|Drug|Indocyanine green|Subcutaneous injection around the areola with 2-4 points Indocyanine green with 1ml of 0.5%
1620316|NCT02084784|Drug|methylene blue|Subcutaneous injection around the areola with 2-4 points Methylene blue with 1ml of 1%
1620317|NCT02084771|Drug|Intravenous Saline|Patients randomized to this arm will receive intravenous isotonic (0.9%) saline. The rate of isotonic saline will be 3 mL/kg given the one hour before CT and 1 mL/kg/hour for 6 hours post-CT as per Canadian guidelines. Patients weighing more than 110 kg will receive the rate as per a 110 kg patient. The dose will be rounded up to the nearest 5 mL.
1620318|NCT02084771|Biological|Oral Salt and Water|Oral salt capsules and water, based on patient weight
1620319|NCT02084758|Dietary Supplement|Nitrate supplementation|7 days of supplementation with sodium nitrate solution
1620320|NCT02084758|Dietary Supplement|Placebo supplementation|7 days of supplementation with sodium chloride solution
1620321|NCT02084745|Device|Boston keratoprosthesis type 1|The Boston KPro, purchased from Massachusetts Eye and Ear infirmary (Boston, MA), is implanted using the usual standard technique.
1620322|NCT02084745|Device|Glaucoma drainage device|The GDD that will be used is the Ahmed implant (New World Medical, Rancho Cucamonga, CA). The Ahmed implant will be implanted using the standard technique either at the time of KPro surgery in group 1, or 6 months following KPro in group 2.
1620323|NCT02084732|Drug|Sorafenib|drug
1620324|NCT02084719|Device|Oraquick HCV Rapid Antibody Test|
1620325|NCT02084719|Device|Standard algorithm|
1620326|NCT02084706|Procedure|Triamcinolone (20 g) and 2% Lidocaine injection over the A1 pulley|
1620327|NCT02084706|Drug|2% Lidocaine|
1620328|NCT02084706|Drug|Triamcinolone (20 g)|
1620329|NCT02084706|Procedure|J-tip lidocaine administration|
1620330|NCT02084706|Procedure|Triamcinolone (20 g) Injection over the A1 pulley.|
1620331|NCT02084693|Device|COMPREHENSIVE|Comprehensive® Reverse Shoulder products are indicated for use in patients whose shoulder joint has a grossly deficient rotator cuff with severe arthropathy and/or previously failed shoulder joint replacement with a grossly deficient rotator cuff.
1620332|NCT02084680|Behavioral|community health workers|community health workers offering individual prenatal education to pregnant women
1620333|NCT02084654|Drug|Exenatide 5 and 10 mcg 2 times a day|
1620334|NCT02084654|Drug|placebo|
1620335|NCT02084641|Other|Over feeding|Study participants will be given low saturated fat snacks, an additional 750-1000 calories to gain 6-8 lbs over 4 weeks
1620336|NCT02084628|Drug|Gadoxetate disodium (Eovist/Primovist, BAY86-4873)|Participants to receive single dose of Eovist/Primovist as a manual injection at a dose of 0.1 milliliter per kilogram (mL/kg) body weight (BW) (0.025 millimole [mmol]/kg BW), followed by a flush of at least 5 mL saline (sodium chloride 0.9 percent [%] solution) manually.
1620337|NCT02084615|Drug|Aspirin|Subjects will undergo open inguinal hernia repairs while taking their normal dose of 81mg, 325mg, or no aspirin
1620338|NCT02084602|Drug|Artesunate|Orally administration of artesunate 4mg/Kg by three days
1620339|NCT02084602|Drug|Mefloquine|Orally administration of mefloquine 15mg/Kg in the fourth day Orally administration of mefloquine 10mg/Kg in the fifth day
1620340|NCT02084589|Other|PCEA with basal infusion and demand dose using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
1620341|NCT02084589|Other|PCEA without basal infusion (demand only) using ropivacaine 0,15% and fentanyl 2μg/ml for pain relief in labor|
1620342|NCT02084576|Drug|Nepafenac|One drop in the study eye 3 times daily for 30 days
1620343|NCT02084576|Drug|Ketorolac|One drop in the study eye 4 times daily for 30 days
1620344|NCT02084563|Drug|Induction Chemotherapy|"Induction chemotherapy for patients with AML eligible for intensive chemotherapy:
Cytarabine 200 mg/m2 IV continuous infusion days 1-7
Daunorubicin 90 mg/m2 intravenous piggyback days 1-3"
1620345|NCT02084563|Drug|Consolidation Chemotherapy|"Consolidation chemotherapy for patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:
-Cytarabine 1.5 g/m2 IV in 3 hours days 1, 3 and 5 for 3 cycles"
1620384|NCT02084381|Device|Revaclear 400|hemodialysis
1620506|NCT02083380|Drug|Artefenomel 800mg: piperaquine 960mg|Active, loose combination
1620346|NCT02084563|Drug|Autologous Stem Cell Transplantation|"Autologous Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with low-risk AML or patients with intermediate-/high-risk AML who do not have matched donors:
Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4
Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2"
1620347|NCT02084563|Drug|Allogeneic Stem Cell Transplantation|"Allogeneic Stem Cell Transplantation for consolidation of patients eligible for intensive chemotherapy with intermediate-/high-risk AML
Conditioning regimen:
Busulfan 1 mg/Kg PO q6h or 130 mg/m2 IV once daily days -7 to -4
Cyclophosphamide 60 mg/Kg IV once daily days -3 and -2 or Fludarabine 40 mg/m2 IV once daily days -7 to -4"
1620348|NCT02084563|Drug|Low Dose Cytarabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:
Cytarabine 60 mg/m2 subcutaneous (SQ) bid days 1-5 (until CR or maximum 4 cycles)
Cytarabine 40 mg/m2 SQ bid days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
1620349|NCT02084563|Drug|Decitabine|"Chemotherapy for patients with AML who are not fit for intensive chemotherapy:
Decitabine 20 mg/m2 IV once daily days 1-10 (until CR or maximum 4 cycles)
Decitabine 20 mg/m2 IV once daily days 1-5 (after CR, until a maximum of 3 years of therapy or relapse, whichever comes first)"
1620350|NCT02084550|Dietary Supplement|Vaminolac|Vaminolac with an amino acid content corresponding humane breast milk.
1620351|NCT02084550|Other|Saline|Intravenous isotonic saline with a sodium chloride content of 9mg/ml.
1620352|NCT02084537|Procedure|Endoscopic treatment|Treated by single transmural cystogastrostomy, 12mm balloon dilation (10mm if cystoduodenostomy), two 7fr double pigtail plastic stents and nasocystic drainage catheter.
1620353|NCT02084537|Procedure|Minimally invasive surgical necrosectomy|"First line approach is video assisted retroperitoneal debridement (VARD), or transperitoneal tract debridement.
If this is not possible due to the location of the collection, second line approach is a laparoscopic approach. This includes transperitoneal laparoscopy cystgastrostomy, or transgastric cystgastrostomy with internal debridement. If percutaneous tract access and debridement is planned, surgery is to be performed no later than 48 hours after interventional radiology insert percutaneous drain."
1620354|NCT02084524|Procedure|Malnutrition screening and perioperative nutritional support|"Multidisciplinary training sessions for malnutrition and malnutrition risk screening, postoperative nutritional procedures according to the ESPEN Guidelines
Preoperative Geriatric evaluation : eligibility criteria, nutritional status, previous history, comorbidities, clinical examination, activities of daily living (ADL) and Instrumental activities of daily living (IADL)
Implementation of an adapted nutritional support based on ESPEN Guidelines"
1620355|NCT02084511|Drug|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
1620356|NCT02084511|Drug|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
1620357|NCT02084511|Drug|BI 1026706|BI 1026706
1620358|NCT02084511|Drug|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
1620359|NCT02084511|Drug|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
1620360|NCT02084511|Drug|Placebo to BI 1026706 solution|Placebo to BI 1026706 solution
1620361|NCT02084511|Drug|BI 1026706|BI 1026706
1620362|NCT02084511|Drug|Placebo to BI 1026706 tablet|Placebo to BI 1026706 tablet
1620363|NCT02084511|Drug|Celecoxib|Celecoxib capsule
1620364|NCT02084498|Device|Automated bolus calculator|Training in Advanced Carbohydrate Counting and the use of an automated bolus calculator according to the BolusCal concept.
1620365|NCT02084498|Behavioral|Advanced Carbohydrate Counting|Training in advanced carbohydrate counting.
1620366|NCT02084485|Drug|PH-797804|30 MG Single dose
1620367|NCT02084485|Drug|Placebo|matching placebo
1620368|NCT02084472|Other|Baby oil|patient in study 1, arm B washed unscented liquid paraffin (baby oil) in place of aqueous cream
1620369|NCT02084472|Other|petroleum jelly|patients in this arm, use petroleum jelly (vaseline), replacing emulsifying ointment as a moisturiser
1620370|NCT02084472|Other|Glycerine:petroleum jelly 2:1|patients in this arm use glycerine and petroleum jelly mixed at a ratio of 2:1 in place of cetomacrogol as a moisturiser
1620371|NCT02084459|Behavioral|Autonomy-supportive counselling (GSD)|GSD, an educational method, comprising 32 semi-structured reflection sheets inviting the patients in groups of 4 through 8 sessions of 150 minutes' duration to reflect on the patient's own situation and to be active in co-operation with the nurses.
1620372|NCT02084446|Drug|Everolimus|Everolimus: initial dose of 1 mg twice a day starting at Day 1. Dose will be adjusted to keep everolimus trough levels between 3 and 8 ng/mL.
1620373|NCT02084446|Drug|Very Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL during the first 3 months and 2 and 4 ng/mL thereafter.
1620374|NCT02084446|Drug|Low Tacrolimus|Tacrolimus: initial dose of 0.05 mg/kg twice a day starting at Day 1. Dose will be adjusted to keep tacrolimus trough levels between 4 and 7 ng/mL.
1620375|NCT02084446|Drug|Steroids|Corticoids: endovenous Methylprednisolone will be administered 30-60 minutes before the first 3 doses of r-ATG: 250 mg (D0) and 125 mg (D2 and D4); Prednisone, 10 mg per oral, will be administered before the last dose of r-ATG (D6). Maintenance with Prednisone at post-transplant period will be performed in accordance with center local practice, i.e., only in patients with chronic previous use of corticosteroids, as well as in patients with autoimmune disease (systemic lupus erythematous, rheumatoid arthritis, etc).
1620376|NCT02084446|Drug|Thymoglobulin|All patients will receive induction with rabbit Thymoglobulin (r-ATG) in four doses of 1.5 mg/kg (maximum total dose of 6 mg/kg), administered according to center local practice (before graft revascularization and at days 2, 4, and 6 post-transplant).
1620377|NCT02084446|Drug|Sodium Mycophenolate|Sodium Mycophenolate: initial dose of 720 mg twice a day starting at Day 1.
1620378|NCT02084433|Procedure|intraosseous anaesthesia using a computerized system|"1 / Anesthesia of periosteum (Articaine 1/100000) 2 / penetration of the needle rotated to the apex 3 / osteocentral injection "
1620379|NCT02084433|Procedure|conventional anasthesia|para-apical maxillary and locoregional mandibular (Articaine 1/100000) anaesthesia
1620380|NCT02084420|Drug|Ilaprazole|10mg 2 BID( 2 times / day), before breakfast and dinner
1620381|NCT02084420|Drug|Pantoprazole|40mg, BID(2 times / day), before breakfast and dinner
1620382|NCT02084407|Other|Clinical examination, skin biopsy, blood and urine sampling|
1620383|NCT02084381|Device|MCO-Ci 400|hemodialysis
1620385|NCT02084368|Procedure|Nerve block|Patients in this group were assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacaine 30ml guided by PNS
1620386|NCT02084368|Procedure|Combined spinal and epidural anesthesia|Combined spinal and epidural anesthesia were performed in patients of this group with 0.5% hyperbaric bupivacaine 8~10mg at L2-3 or L3-4.
1620387|NCT02084368|Drug|Ropivacaine|Patients will be assigned to receive lumbar plexus block and sciatic nerve block both using 0.33% ropivacain 30ml guided by PNS.
1620388|NCT02084368|Drug|Bupivacaine|Combined spinal and epidural anesthesia will be performed in patients with 0.5% hyperbaric bupivacaine 8~10mg.
1620389|NCT02084355|Drug|oral oxycodone|
1620390|NCT02084355|Drug|oral hydromorphone|
1620391|NCT02084355|Drug|fentanyl patch|
1620392|NCT02084342|Drug|tranexamic acid and sodium chloride injection|10mg/kg, IV (in the vein) for 30min, before incision. then at 1mg/kg/h, IV pump, until the surgery is over.
1620393|NCT02084342|Drug|normal saline|100ml, IV for 30min,before incision.
1620394|NCT02084342|Drug|desmopressin acetate injection|0.3μg/kg dissolved in 100ml NS，IV for 30min，before incision.
1620395|NCT02084329|Device|Weighted Compression Vest|
1620396|NCT02084316|Behavioral|One4All|Participants with HIV-positive screening results on EIA will immediately have their blood drawn for CD4 and VL tests. Participants will receive post-screening test counseling. Two venous blood samples will be collected-one for immediate numeration of CD4 T-lymphocytes in the same hospital lave using PIMA POC CD4 analyzer and the other for later VL testing at the province CDC which takes 10-15 days. Participant will be notified in person of their CD4 results on the same day and provided post-CD4 test counseling. Counseling in the One4all intervention has been modified from the national SOC guidelines due to the different order of tests and the shortened time period between screening and CD4 testing. The participant will be provided with a tentative assessment of ART eligibility based on CD4 results and other factors. Those who are eligible for ART are encouraged to seek HIV care at the study hospitals via China's National Free ART program.
1620397|NCT02084316|Behavioral|Standard of Care|"The control condition is the current standard of care (SOC) utilized within the county hospitals in Guangxi China. This SOC has some variability between counties but in general follows the national policies. After the initial positive screening on EIA and subsequent repeat screening, participants will receive post-screening test counseling. Participants will then be tested by WB either at the same visit or a subsequent visit. The WB is sent offsite.
After WB test results are reported to the hospital, the health care provider will contact the participant by phone. The participant will be asked to return to the hospital for results and post-WB test counseling. At this visit, a blood sample will be collected for CD4 testing, and an initial epidemiological investigation will be carried out.
Once CD4 test results are available, participants must be located again to inform them of their results and ART eligibility and to provide post-CD4 test counseling."
1620398|NCT02084303|Other|Ferumoxytol injection after focal epileptic seizure followed by iron-sensitive MRI|
1620399|NCT02084290|Behavioral|Shared Decision Making Program|This study is cluster randomized by study-site, Subjects enrolled at intervention sites will access an educational program and risk prediction tool. Their decisions about treatments will be compared to subjects that did not view the educational program or risk prediction tool.
1620400|NCT02084277|Device|Self-ligating brackets (SLB)|
1620401|NCT02084277|Device|Conventional brackets (CB)|
1620402|NCT02084251|Drug|PB-119|
1620403|NCT02084238|Drug|Interleukin-2|Patients receive low dose recombinant human Interleukin-2（HrIL-2） (1 million units every other day subcutaneously (HrIL-2 1X 106, ip, Qod) for a period of 14 days. After a 14-day rest, another cycle started) for 3-6 courses according to the situation of the disease.
1620404|NCT02084225|Procedure|ultrasound guided regional nerve block|participants were the physicians performing the procedure
1620405|NCT02084212|Other|Microperimetry|
1620406|NCT02084199|Drug|GLPG0634|100 mg oral tablet, intake once daily for 10 days
1620407|NCT02084186|Other|herb-partitioned moxibustion|Ignited moxa cones are placed upon herbal cake. Herbs are smashed into powder. Every 2.8g medicine powder mix with 3g millet wine and then be pressed into herbal cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the herbal cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
1620408|NCT02084186|Other|bran-partitioned moxibustion|Ignited moxa cones are placed upon bran cake. Every 2.8g bran powder mix with 3g millet wine and then be pressed into bran cakes which are 28mm in diameter and 7mm in high with a specific mould. Then the bran cake with a moxa cone will be fixed on Tianshu and Shangjuxu.
1620409|NCT02084173|Behavioral|MET + CRA|
1620413|NCT02084134|Drug|hydrocortisone|100mg at the time of surgery
1620414|NCT02084134|Drug|dexamethasone|0.5mg every 6 hours for a total of four doses
2010944|NCT02775812|Other|Laboratory Biomarker Analysis|Correlative studies
1620416|NCT02084108|Other|intervention|intervention group that will be provided, in addition, in-home multidimensional geriatric assessment with access to a 24h/7 day a week call service, and coordinated long-term follow-up.
1620417|NCT02084082|Drug|Linagliptin/Metformin ER FDC|1x Linagliptin/Metformin FDC tablet
1620418|NCT02084082|Drug|Linagliptin|1x Linagliptin tablet
1620419|NCT02084082|Drug|Metformin ER|2x Metformin ER tablets
1620420|NCT02084069|Drug|Atorvastatin|
1620421|NCT02084056|Drug|Linagliptin|Linagliptin
1620422|NCT02084056|Drug|Metformin|Metformin
1620423|NCT02084056|Drug|Linagliptin/Metformin FDC|Linagliptin/Metformin FDC
1620424|NCT02084043|Drug|Nebulization of Amikacin during NIV (RR: 15 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 15 cycles/minute
1620502|NCT02083406|Drug|800mg OZ439 prototype formulation 2|
1620503|NCT02083406|Drug|800mg OZ439 prototype formulation 3|
1620504|NCT02083406|Drug|960mg PQP|
1630831|NCT02002611|Drug|Warfarin|
2010945|NCT02775812|Biological|Pembrolizumab|Given IV
2010946|NCT02775708|Device|Pillcam endoscopy system|
2010947|NCT02775435|Biological|Pembrolizumab|IV infusion
1620425|NCT02084043|Drug|Nebulization of Amikacin during NIV (RR: 25 cycles/minute)|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds. The NIV is set with an IPAP of 15 cmH2O and EPAP of 5 cmH2O. The lung model is simulated with a respiratory rate of 25 cycles/minute
1620426|NCT02084017|Device|Prevena (Negative Pressure Wound Therapy Device)|No other details required.
1620427|NCT02084017|Device|Standard Tegaderm (3M Healthcare, St. Paul, MN) adhesive dressing|
1620428|NCT02084004|Drug|Bifidobacterium viable pharmaceutics|
1620429|NCT02084004|Drug|Berberine Hydrochloride|
1620430|NCT02083991|Drug|Steroid-free low TAC-arm: Thymoglobulin Standard low-TAC arm: Simulect, prednisolon|
1620431|NCT02083978|Other|MRI scanning|
1620432|NCT02083965|Biological|rFVIIIFc|Administered as specified in the treatment arm.
1620433|NCT02083952|Other|Swaddle Blanket|Two arms involve varying time spent in blanket
1620434|NCT02083926|Drug|Ketamine|Ketamine (a single 0.5mg/kg intravenously over 40 minutes).
1620435|NCT02083926|Drug|Saline|Saline (a single 0.5mg/kg intravenously over 40 minutes).
2010948|NCT02775435|Drug|Paclitaxel|IV infusion
1620437|NCT02083900|Device|Banana Leaf Dressing|Banana leaf dressing will be prepared by cutting the mid rib of the leaf cutting the leaf into standard size of 12 x 12 inches to facilitate packing. The leaves are rolled and packed in polypropelene bags and subject to gamma irradiation or packed in paper bags for autoclaving. The Banana Leaf Dressing site will receive a single layer of banana leaf without any topical antibiotic applied to the wound followed by a layer of dry gauze for absorption of exudates. The dressing is secured with cling wrap to maintain an occlusive environment. This is then covered by rolled gauze and elastic bandage.
1620438|NCT02083900|Drug|Hydrocolloid Dressing (DuoDERM CGF)|The donor under HCD was covered with hydrocolloid (DuoDERM CGF). The hydrocolloid dressing was cut to the size of the donor site with an overlap of at least 2 centimeter around the wound edge. After pulling off the adhesive backing, care was taken to ensure that the adhesive was in direct contact with the raw surface. This was likewise covered with a top dressing of gauze for absorption of exudates and an elastic bandage to secure dressing.
1620439|NCT02083887|Biological|ChAd63 ME-TRAP / MVA ME-TRAP|Intramuscular administration of ChAd63 ME-TRAP 5 x 10^10 vp and MVA ME-TRAP 1 x 10^8 pfu
1620440|NCT02083874|Drug|CBD|
2010949|NCT02775435|Drug|Nab-paclitaxel|IV infusion
1620442|NCT02083848|Other|7T MRI|Ultra high field magnetic resonance imaging
1620443|NCT02083822|Procedure|term MRI, executive EF functions testing|An MRI will be realized at term born between 25 and 32 weeks GA
1620444|NCT02083809|Drug|intravenous oxytocin|30 units of oxytocin added to 500ml of inert IV fluid (saline, lactated ringer)
1620445|NCT02083809|Drug|Intravenous Fluids and Electrolytes|500 ml of inert IV fluid
1620446|NCT02083796|Procedure|Shoulder impingement_TSM|A physiotherapist with 4 years of experience in manual therapy will administer the TSM targeting the middle thoracic spine of the subjects.
1620447|NCT02083796|Procedure|Asymptomatic_TSM|A physiotherapist with 4 years of experience in manual therapy administered the TSM targeting the middle thoracic spine of the subjects.
1620448|NCT02083796|Procedure|Shoulder impingement_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
1620449|NCT02083796|Procedure|Asymptomatic_sham|A physiotherapist with 4 years of experience in manual therapy administered the sham intervention targeting the middle thoracic spine of the subjects.
1620450|NCT02083783|Drug|TRI102|formulation containing active moiety
1620451|NCT02083783|Other|Placebo|formulation without active moiety
1620452|NCT02083770|Behavioral|Cancer Clinical Trials Education Program|Hispanic Americans are underrepresented in cancer clinical trials. The purpose of this study is to develop and test programs designed to reduce barriers and increase facilitators associated with cancer clinical trials participation for Hispanic Americans.
1620453|NCT02083744|Behavioral|PsychoEducational Support|
1620454|NCT02083744|Behavioral|Usual Care|Standard Heart Failure Care
1620455|NCT02083731|Biological|MSCs|
1620456|NCT02083718|Biological|PBSC|
1620457|NCT02083718|Biological|MSCs|
1620458|NCT02083705|Procedure|CC+SI|Chest compression will be superimposed by sustained inflation during CPR
1620459|NCT02083705|Procedure|3:1 CPR|CPR using 3:1 ratio (control group)
1620460|NCT02083692|Drug|Metformin|
1620461|NCT02083679|Drug|Part 1: Sym004 6 mg/kg + Cisplatin/Gemcitabine|Sym004 will be administered as an intravenous infusion at a dose of 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the investigational medicinal product (IMP) in combination with platinum-doublet chemotherapy regimen of cisplatin/gemcitabine (cisplatin 75 mg/m^2 on Day 1 plus gemcitabine 1250 mg/m^2 on Days 1 and 8 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
1620462|NCT02083679|Drug|Part 1: Sym004 6 mg/kg + Cisplatin/Pemetrexed|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of cisplatin/pemetrexed (cisplatin 75 mg/m^2 plus pemetrexed 500 mg/m^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
1620463|NCT02083679|Drug|Part 1: Sym004 6 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg weekly until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin area under the concentration-time curve (AUC) = 6 milligram per millilitre per minute [mg/mL/min] plus paclitaxel 225 mg/m^2 on Day 1 of 3-Week cycle intravenously for a maximum of 6 treatment cycles).
1620505|NCT02083380|Drug|Artefenomel 800mg: piperaquine 640mg|Active, loose combination
1632432|NCT01990092|Other|Placebo|
2010950|NCT02775435|Drug|Carboplatin|IV infusion
2010951|NCT02775435|Drug|Saline placebo for pembrolizumab|IV infusion
2010952|NCT02775006|Drug|Docetaxel|75mg/m2
1620464|NCT02083679|Drug|Part 1: Sym004 6/12 mg/kg + Carboplatin/Paclitaxel|Sym004 will be administered as an intravenous infusion at a dose 6 mg/kg on Day 1 and 12 mg/kg on Day 8 of a 3-Week cycle until unacceptable toxicity, progressive disease, withdrawal of consent, or until the subject meets any of the criteria for subject withdrawal, or withdrawal from the IMP in combination with platinum-doublet chemotherapy regimen of carboplatin/paclitaxel (carboplatin AUC = 6 mg/mL/min plus paclitaxel 225 mg/m^2 on Day 1 of every 3-Week cycle intravenously for a maximum of 6 treatment cycles).
1620465|NCT02083666|Drug|SOBI002|Test Product
1620466|NCT02083666|Drug|Placebo|Reference product
1620467|NCT02083653|Drug|Sym004|Sym004 is a 1:1 mixture of two mAbs which bind to two non-overlapping epitopes of the EGFR
1620468|NCT02083653|Drug|Sym004|Sym004 is a 1:1 mixture of two mAbs which bind to two non-overlapping epitopes of the EGFR
1620469|NCT02083653|Other|Best supportive care (BSC)|BSC will be provided at the Investigator's discretion and may include antibiotics, analgesics, antiemetics, blood transfusions and nutritional support.
1620470|NCT02083653|Drug|Fluorouracil (5-FU)|5-FU will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
1620471|NCT02083653|Drug|Capecitabine|Capecitabine will be administered at doses and schedules as per Investigator's discretion and in line with the local package insert.
1620472|NCT02083640|Drug|Palbociclib Formulation Reference|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 1, which is representative of the intended commercial hard gelatin capsule.
1620473|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 41 micrometer API particle size and dissolution level 1
1620474|NCT02083640|Drug|Palbociclib Formulation Test|125 mg single dose of palbociclib formulation with 16 micrometer API particle size and dissolution level 2
1620475|NCT02083627|Drug|rosuvastatin|Oral
1620476|NCT02083627|Drug|fidaxomicin|Oral
2010953|NCT02775006|Drug|Erlotinib|150mg/day
1620478|NCT02083601|Behavioral|Parent Forum|In-person psychoeducational workshop that provides education (including problem-solving training) and psychological/peer support for caregivers of youth with SCI.
1620479|NCT02083601|Behavioral|Psychological support|Outreach from a mental health professional in the form of monthly phone calls for 12 months.
1620480|NCT02083588|Device|dTMS|All subjects will receive prefrontal deep rTMS of H1 Coil (75 trains of 2 seconds, 20 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold, a total of 3000 pulses per session), for 4 weeks, 5 days a week, overall 20 sessions.
1620481|NCT02083575|Drug|Vitamin C, Defriprone, deferisarox|adjuvant vitamin c with iron chelator.
1620482|NCT02083575|Drug|deferiprone , deferesarox|iron chelator
1620483|NCT02083549|Other|Blood collection|After transfusion of each shipment of blood products outlined in the current Massive Transfusion Protocol one 2.7mL citrated blood sample will be collected from the subject through the 5th shipment of blood products. A final sample will be collected 24 hours following the discontinuation of the massive transfusion protocol.
1620484|NCT02083536|Radiation|Low Dose Fractionated Whole Abdominal Radiation Therapy|A single fraction of LDFWART will be given 6-8 hours after the start of morning administration of Docetaxel for 6 cycles (the time of the start Docetaxel will be counted as the frame of reference for when the LDFWART can be given).
1620485|NCT02083536|Drug|Docetaxel|Chemotherapy will consist of 6 cycles of Docetaxel. Each cycle will follow standard of care and will be scheduled every 3 weeks ± 3 days. Chemotherapy should be administered in the morning to allow 6-8 hours before Radiation Therapy. On Day 1 of each cycle, chemotherapy will consist of Docetaxel 60 mg/m² infused intravenously over 30-60 minutes (with premedication of dexamethasone 10 mg given IV 30-60 minutes prior to docetaxel administration).
1620486|NCT02083523|Behavioral|Motivational Interview with Normative Feedback|NOrmative Feedback (NF) contrasts and individual's substance use to available norms for one's reference group (i.e., descriptive norms.) Essentially, NF highlights how an individual's behavior is non-normative, which in turn, is thought to lead to reduced substance use.
1620487|NCT02083523|Behavioral|Motivational Interview|The Motivational Interview (MI) addresses ambivalence about change. It's effects are mediated by how well counselors evoke change talk, or in-session client utterances about the: need for; commitment to; ability to; or steps needed, to change.
1620488|NCT02083510|Drug|Colchicine|
1620489|NCT02083497|Other|rigid bandage|
1620490|NCT02083497|Other|elastic bands|
1620491|NCT02083497|Other|without the use of banding|
1620492|NCT02083484|Biological|Pembrolizumab|Each participant will receive pembrolizumab every 3 weeks for up to 2 years or until confirmed radiographic disease progression, unacceptable toxicity, confirmed positive pregnancy test, withdrawal of consent, or pembrolizumab approval in the participant's country.
1620493|NCT02083471|Dietary Supplement|Specific Oral Tolerance Induction with Egg or Cow's milk|
1620494|NCT02083458|Procedure|Catheterization of the axillary vein.|
1620495|NCT02083445|Other|cognitive activities|Participants followed a day of cognitive activities 1 day (1 hour/day) per week during 12 weeks.
1620496|NCT02083445|Other|Exercise program|Exercise program of endurance, resistance and proprioception exercises, comprising three sessions per week and muscle electro-stimulation was applied using the Compex Vitality® vascular and capillarization program with electrodes fixed in quadriceps and abdominal muscles or cycling exercise.
1620497|NCT02083445|Device|Muscle electro-stimulation|A program of intermittent hypobaric hypoxia and muscle electro-stimulation of 3 days (3 hours/day) per week during 12 weeks
1620498|NCT02083445|Other|Intermittent hypobaric hypoxia|
1620499|NCT02083432|Behavioral|5 session of CBT performed by specially trained dentists|"A total of 60 participants are randomly assigned to a 5-weeks waiting list Control Group or directly enrolled to the 5-session of CBT treatment Group.
The participants in the waiting list Control Group are enrolled to the treatment Group (5 sessions of CBT) after 5 weeks if they still meet the diagnostic criteria of a specific phobia (according to DSM-IV)."
1620500|NCT02083419|Device|LVAD CRT|The following procedures will be performed: limited echocardiogram, an adjustment to the CRT device's programmed settings, follow-up in 30 days to adjust the CRT device's programmed settings. In addition, quality of life questionnaires will be filled out and a 6 minute walk test will be completed.
1620501|NCT02083406|Drug|800mg OZ439 prototype formulation 1|
1620507|NCT02083380|Drug|Artefenomel 800mg: piperaquine 1440mg|Active, loose combination
1620508|NCT02083354|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules. Each capsule will contain 50 mg or 75 mg of free base (present as the mesylate salt)
1620509|NCT02083354|Drug|Trametinib|Trametinib study medication will be provided as 0.5 mg and 2.0 mg tablets. Each tablet will contain 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
1620510|NCT02083341|Device|Lelo® Siri vibrator|external vibration device
1620511|NCT02083341|Device|Lelo® Siri vibrator with vibration component removed|external vibration device - sham
1620512|NCT02083328|Dietary Supplement|Caffeine|Caffeine will be filled in gelatine capsules and administrated in a dosage of 6mg per kg body mass
1620513|NCT02083328|Dietary Supplement|Placebo (Mannitol)|Mannitol filled in gelatine capsules
1620514|NCT02083315|Drug|TRV130 1.5 mg|TRV130 1.5 mg IV x 1 dose
1620515|NCT02083315|Drug|TRV130 3 mg|TRV130 3 mg IV x 1 dose
1620516|NCT02083315|Drug|TRV130 4.5 mg|TRV130 4.5 mg IV x 1 dose
1620517|NCT02083315|Drug|Morphine 10 mg|Morphine 10 mg IV x 1 dose
1620518|NCT02083315|Drug|Placebo|Dextrose 5% in water IV x 1 dose
1620519|NCT02083302|Behavioral|SCREAM Theater Dose 1|Intervention 1: A three part program: a skit acted out by peer educators that depicts a sexual assault; an in-character question and answer session; and an out-of-character information session.
1620520|NCT02083302|Behavioral|SCREAM Theater Doses 2 & SCREAM Theater Dose 3|"Dose 2: Scenes from the skit from Session 1 are re-created with small groups of students, but stop at certain points to allow audience members to explore different bystander intervention possibilities.
Dose 3: The six scenes outlined in Session 2 are presented individually to small groups of student participants; specifically outlining potential points of bystander intervention."
1620521|NCT02083302|Behavioral|SCREAM Theater Dose 4|Booster Session
1620522|NCT02083289|Drug|ONO-9054|
1620523|NCT02083289|Drug|Latanoprost|
1620524|NCT02083276|Drug|Pivmecillinamhydrochlorid|PO 400 mg x3 for 7 days
1620525|NCT02083263|Device|Bilevel|3 months
1620526|NCT02083263|Device|PEP mask|3 months
1620527|NCT02083250|Drug|Fludarabine|10 mg/m2 by vein on Days -6 to -3.
1620528|NCT02083250|Drug|Clofarabine|40 mg/m2 by vein on Days -6 to -3.
1620529|NCT02083250|Drug|Busulfan|Busulfan test dose, 32 mg/m2, administered within 10 days prior to admission as an outpatient or as an inpatient on Day -8. Busulfan pharmacokinetics performed with the test dose and the first dose on Day-6. Busulfan adjusted dose determined to achieve a systemic exposure represented by an average daily AUC of 5500 µMol-min ± 5% for the entire 4-day treatment period, Days -6 to -3. If pharmacokinetic analysis cannot be completed for any reason, Busulfan given in a dose of 130 mg/m2 daily.
1620530|NCT02083250|Drug|SAHA|Starting dose of SAHA: 200 mg by mouth daily on Days -6 to -3, within one hour prior to fludarabine administration for total 4 doses.
1620531|NCT02083250|Procedure|Stem Cell Infusion (SCT)|Stem cell infusion on Day 0.
1620532|NCT02083250|Drug|Thymoglobulin|Participants who receive a graft from an unrelated donor receive 0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1.
1620533|NCT02083237|Behavioral|Behavioural Intervention Program|People with MCI and their close family member (80% spouses) participate jointly in the first hour, which provides education about MCI, lifestyle influences on cognitive health, and community resources. During the second hour, family members participate in a separate psychosocial group intervention, while the individuals with MCI participate in memory training. The first 6 of the 8 sessions occur weekly, the 7th occurs as a 1-month follow-up session and the 8th as a 3-month follow-up session. These follow-up sessions provide support to sustain positive outcomes and provide further assistance with resolving continued challenges.
1620534|NCT02083211|Drug|mAb Nimotuzumab|This group will receive a dose of 200 mg mAb hR3 (weekly over 18 weeks) plus chemotherapy (6 cycles every 21 days of Cisplatin (CDDP) 50 mg/m2 on day 1/, Vinorelbine 30 mg/m2 on day 1 and day 8)
1620535|NCT02083211|Device|Placebo|This group will receive a placebo in addition to chemotherapy in a similar regimen. Once the chemotherapy is completed a maintenance dose will be administered with 200 mg/dose of mAb hR3 every 14 days until progression.
1620536|NCT02083185|Drug|TAK-385, 80 mg|
1620537|NCT02083185|Drug|TAK-385, 120 mg|
1620538|NCT02083185|Drug|Leuprorelin|
1620539|NCT02083172|Device|Ultrasound Cardiac Output Monitor and 2 D-Echo|Hemodynamic measurements obtained by 2D-Echo and USCOM will be compared.
1620540|NCT02083120|Device|NHF therapy|AIRVO 2 device therapy is either a humidifier with integrated flow generator that delivers warmed and humidified respiratory gases to spontaneously breathing patients through a variety of patient interfaces. Flow rates up to 60 L/min are available to the user, depending on the patient interface and mode of operation.In this study, flow rates of 20 L/min and 35 L/min will be compared.
1620541|NCT02083120|Other|Long term Oxygen Therapy (LOT)|Oxygen will individually be added to NHF in order to achieve stable oxygen saturation by pulse oximetry (SpO2) values of 88% to 92%.
1620542|NCT02083107|Drug|Misoprostol|Comparison of different routes of administration of 400 micro gram misoprostol
1620543|NCT02083107|Other|Placebo|
1620544|NCT02083081|Behavioral|Community level intervention|Community intervention plus individual counseling
1620545|NCT02083068|Biological|Vaccine PvCS N+C+R|Vaccine PvCS N+C+R 60 mcg, freeze dried powder, Batch n°P0RGB, Exp: 18.10.2015 At month 2 and 4
1620546|NCT02083068|Biological|Vaccine PvCS N+C|Vaccine PvCS N+C 60 mcg, freeze dried powder, Batch n°P0RGA, Exp: 18.10.2015
1620547|NCT02083068|Biological|SSN Montanide ISA-51|SSN Montanide ISA-51 1 mL
1620548|NCT02083055|Drug|Dexmedetomidine|controlled hypotensive anesthesia with dexmedetomidine compare with nitroglycerin on anesthetic outcome such as analgesic use, time to eye opening, follow verbal command, extubation and early postoperative pain
1620549|NCT02083055|Drug|Nitroglycerin|controlled hypotensive anesthesia with nitroglycerin compared with dexmedetomidine on anesthetic outcomes such as analgesic use, time to eye opening, follow verbal command, extubation, and early postoperative pain.
1620550|NCT02083029|Procedure|Simulated dive reflex|All subjects undergo simulated dive reflex, with 30s facial immersion and continuous HR and BP monitoring with Nexfin over a period of 6 minutes.
1620551|NCT02083016|Device|Ablation guided by conventional mapping.|Substrate mapping and ablation of ventricular tachycardia.
1620552|NCT02083016|Device|Ablation guided by ultra-high density mapping with multielectrode catheter.|Substrate mapping and ablation of ventricular tachycardia.
1620553|NCT02083003|Dietary Supplement|Polyamine low-diet|
1620554|NCT02083003|Dietary Supplement|Liberal alimentation|
1620555|NCT02082990|Behavioral|Face-to-Face Brief Intervention|One face-to-face Brief Intervention which is provided by General Practitioner or Nurse
1620556|NCT02082990|Behavioral|Online Brief Intervention|Primary care-based facilitated access to an alcohol reduction website (Brief Intervention)
1620557|NCT02082977|Drug|GSK2816126|GSK2816126 will be supplied as a solution containing 15 milligram per milliliter (mg/mL) GSK2816126 in water for injection.
1620558|NCT02082964|Other|SCIM|after lecture students had rotation in 6 groups through 6 stations, trained and practiced under supervision of 6 instructors about Initial Steps, Positive Pressure Ventilation(PPV), Intubation, Chest Compressions, Medications and management of advanced resuscitation
1620559|NCT02082964|Other|video|video about neonatal resuscitation presented then students repeated the video. Workshops was based on NRP and lasted 6 hours for each group the contentof the video was based on the educational content of the course
1620560|NCT02082951|Behavioral|Empathic behaviour by nurses.|The empathic behaviour in group 1 was performed by a trained nurse.
1620561|NCT02082951|Behavioral|Empathic behaviour by family.|Considered the empathic behaviour performed by family as a hospital visit with greater than 45 minutes duration, a person with whom the patient had a good relationship, he considered it to be important and welcome. It is emphasized that these families did not have any prior training and after the visit, patients were asked about how the visit had been seeking to detect the presence of any conversations that have been unpleasant for patients and, if present, the patients were excluded from the study.
1620562|NCT02082938|Device|Bracing|Twice a week, for a period of 5 weeks, before the sessions in the physiotherapy clinic the patients participating in the study were asked to walk at a self-selected speed on flat ground along a corridor 50 meters long, with the brace being used for fifteen minutes of gait retraining of the affected side.
1620563|NCT02082925|Other|Patient has to get up his hand when he defined his dyspnea threshold during 6MWT|
1620564|NCT02082912|Drug|D-cycloserine|D-cycloserine 100mg PO twice weekly (Monday and Wednesday) for three weeks
1620565|NCT02082912|Other|Placebo|Placebo pill PO twice weekly (Monday and Wednesday) for three weeks
1620566|NCT02082912|Device|HandMentor Pro|The HandMentor Pro (Kinetic Muscles Inc.) is a robotic device that has recording electrodes. The device gives feedback during various activities requiring varying levels of wrist control. The main goal of the hand robot is to improve active range of motion about the wrist and fingers and wrist control. The robotic therapy will be done over 3 consecutive weeks for 2 hours each session (days 1, 3, 5, 8, 10, 12, 15, 17 and 19, for 18 hours total).
1620567|NCT02082899|Drug|Active Comparator EBI-005 5 mg/mL|
1620568|NCT02082899|Drug|Placebo Comparator|
1620569|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 1|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
1620570|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 2|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
1620571|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 3|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
1620572|NCT02082860|Genetic|rAAV2/5-PBGD vector dosage 4|Intravenous injection of rAAV2/5-PBGD vector, single administration on Day 1.
1620573|NCT02082834|Other|abdominal MDCT examination|
1620574|NCT02082808|Drug|DTG|DTG is provided as 9 millimetre white, film-coated, round tablets debossed with SV 572 on one side and 50 on the other side
1620575|NCT02082808|Drug|DCV|DCV is provided as a plain, green, biconvex, pentagonal film-coated tablet
1620576|NCT02082782|Procedure|Irreversible electroporation (IRE)|Percutaneous (CT-guided) or open (US-guided) irreversible electroporation of central colorectal liver metastasis.
1620577|NCT02082769|Drug|Febuxostat|
1620578|NCT02082769|Drug|Allopurinol|
1620579|NCT02082756|Drug|Bifidobacterium viable pharmaceutics|
1620580|NCT02082756|Drug|Berberine Hydrochloride|
1620581|NCT02082743|Behavioral|Outdoor activity in recess time|Outdoor activity in recess time
1620582|NCT02082730|Device|ASARM|The ASARM system combines objective and subjective measurements of sleep, rest and activity patterns by using a combination of low-cost devices and technologies. The patient wears a wrist-mounted Actigraphy device to measure their energy expenditure, and carries an electronic diary (a Smartphone app) for recording their activities and their subjective measures of mood and energy level. These synchronise daily with a remote server, accessible by the clinician through a web interface, to allow monitoring, data analysis and feedback to the patient.
1620583|NCT02082717|Drug|potassium chloride replacement|
1620584|NCT02082717|Drug|Experimental - 4% Sodium Bicarbonate|
1620585|NCT02082704|Behavioral|SE Game on DSME|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
1620586|NCT02082704|Behavioral|SE Game on American History|Investigators created an online educational game by incorporating game mechanics into an evidence-based form of online education, termed 'spaced education' (SE). Based upon two psychology research findings (the spacing and testing effects), SE has been shown in randomized trials to improves knowledge acquisition, boosts learning retention for up to two years, and durably improves clinical behavior.
1620587|NCT02082691|Drug|G-202|Patient will receive G-202 for 3 days in a row, followed by 25 days without taking G-202. This cycle will be repeated every 28 days. Patient will receive G-202 as long as his/her cancer does not grow and the investigational drug side effects are tolerable.
1620588|NCT02082678|Drug|Ondansetron|Ondansetron is a serotonin receptor antagonist that is FDA-approved to treat nausea and vomiting caused by cancer therapy and surgery.
1620589|NCT02082678|Drug|Placebo|Inactive ingredient matching the active medication in appearance
1620590|NCT02082665|Drug|Rosuvastatin10 mg tablet|Commercially available Rosuvastatin 10 mg tablets will be supplied. Single oral dose of Rosuvastatin 10 mg will be administered on Day 1, 8 and 22
1620678|NCT02081989|Procedure|Renal denervation|Renal denervation
1620591|NCT02082665|Drug|Midazolam 3 mg syrup|Commercially available Midazolam syrup will be supplied.Single oral dose of Midazolam 3 mg syrup will be administered on Days 1, 8 and 22
1620592|NCT02082665|Drug|Dabrafenib 75 mg capsule|Dabrafenib 75mg will be supplied in the form of capsules. Oral dose Dabrafenib 150 mg (2 x 75 mg) BID will be administered at 12 h apart on Days 8 through 22 and 150 mg (2 x 75 mg) OD on Day 23.
1620593|NCT02082652|Drug|Etonogestrel|Etonogestrel single-rod subdermal implant (68mg/rod) is placed upon enrollment (day 0) and remains in place until participant requests removal or for the duration of active drug (currently approved for 3 years of use).
1620594|NCT02082639|Biological|Cervarix™|2 doses intramuscularly in the deltoid muscle of the non-dominant arm
1620595|NCT02082639|Biological|Havrix|2 doses intramuscularly in the deltoid muscle of the dominant arm
1620596|NCT02082626|Drug|Eribulin mesylate|
1620597|NCT02082613|Procedure|Lord´s procedure|
1620598|NCT02082613|Procedure|Sclerotherapy|
1620599|NCT02082600|Other|Sleep deprivation|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and than will keep awake for 60 hours (2 nights), followed by 1 night of sleep, all inside the lab. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
1620600|NCT02082600|Other|Normal sleep|This group will perform 24 sets of 10 maximum repetitions of eccentric contractions for quadriceps and and will be able to sleep the 3 nights. During whole protocol, it will be collected several blood samples for evaluation of hormones, cytokines and muscle damage parameters. It will be also evaluated isometric strength and pain.
1620601|NCT02082561|Behavioral|Transdiagnostic Treatment (F-SET)|F-SET treatment consisted of five weekly individual sessions (approximately 50 minutes each). The participants learn to techniques and skills to help them reduce their anxiety. F-SET protocol is consistent with current CBT protocols for anxiety disorders.
1620602|NCT02082548|Other|Educational Intervention|This intervention will contain educational materials for both patients and providers that are specific to the needs in each participating country
1620603|NCT02082522|Drug|Photodynamic therapy-Photofrin|Photodynamic therapy (PDT) involves the i.v. injection of Photofrin (2 mg/kg) followed by the illumination of the tumor using a fiber optic device during an endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC). Two days after the injection, a laser light (180 J/cm(2)) will be applied to the tumor. A second light application will be given 96-120 hours after Photofrin injection if PDT could not initially be performed on all sides of the tumor. Post illumination, all patients will undergo stenting as part of standard medical care procedure. Up to 3 additional courses of PDT using a light dose of 120 J/cm(2) may be given at 3-month intervals.
1620604|NCT02082522|Procedure|Stenting procedure|As per standard medical procedures, stenting procedure consists in the placement of stents above the main tumors of the right and left hepatic bile ducts via endoscopic retrograde cholangiopancreatography (ERCP) or percutaneous transhepatic cholangiography (PTC) when the ERCP approach has been unsuccessful.
1620605|NCT02082522|Drug|Chemotherapy regimen|The regimen will comprise gemcitabine (1 000 mg/m(2)) followed by cisplatin (25 mg/m(2)), each administered on days 1 and 8 every 3 weeks (21 day-cycle) for four cycles. An additional 12 weeks of the same chemotherapy regimen may be administered if there is no disease progression or intolerable toxicity.
2010954|NCT02774876|Device|Patient's insulin pump|The patient's insulin pump will be used to regulate glucose levels.
1620607|NCT02082483|Other|Selective Screening|Patients randomized to selective-use of screening tests will not routinely undergo Myocardial Perfusion Scintography or Dobutamine Stress Echocardiography. If patients develop symptoms of CAD at any time, they will undergo investigations as per the usual standard of care.
1620608|NCT02082470|Other|follow-up care|Undergo survivorship care planning
1620609|NCT02082470|Other|active surveillance|Undergo cancer surveillance
1620610|NCT02082470|Other|questionnaire administration|Ancillary studies
1620611|NCT02082457|Drug|YKP10811 5mg|
1620612|NCT02082457|Drug|YKP10811 20mg|
1620613|NCT02082457|Drug|YKP10811 placebo|
1620614|NCT02082444|Other|Skipping lunch|
1620615|NCT02082418|Dietary Supplement|Alpha-lactalbumin|Subjects will ingest the liquid meal containing alpha-lactalbumin and carbohydrates (0.6 g/kg FFM protein + 0.3 g/kg FFM carbohydrates).
1620616|NCT02082418|Dietary Supplement|Whey|commercially available whey protein
1620617|NCT02082418|Dietary Supplement|Casein|commercially available casein protein
1620618|NCT02082405|Drug|bortezomib|Given SC or IV
1620619|NCT02082405|Drug|cyclophosphamide|Given PO
1620620|NCT02082405|Drug|dexamethasone|Given PO
1620621|NCT02082405|Other|laboratory biomarker analysis|Optional correlative studies
1620622|NCT02082405|Other|quality-of-life assessment|Ancillary studies
1620623|NCT02082392|Drug|Escitalopram|
1620624|NCT02082379|Behavioral|inhaled normal saline using different interfaces.|A Hudson nebulizer will be loaded with 3 mls of normal saline and operated at 7 L/min of wall air for 3 minutes with each scenario with a 5-minute interval between interfaces. The infants will be videotape while they receive inhaled aerosol, and sound will be captured. The camera will be positioned so the face of the parent holding the child will not be visible.
1620625|NCT02082366|Device|TCD monitoring of microembolic signal during procedure|monitoring of microembolic signal during procedure
1620626|NCT02082340|Behavioral|TB knowledge and socio-psychological counseling session|TB patients and their family members will participate in one-day counseling session provided by a trained psychologist and a TB nurse
1620627|NCT02082340|Other|SMS text messages|TB patients will receive SMS text messages every morning (except Sunday) during the whole ambulatory TB treatment phase as a reminder for taking the TB medication prescribed and provided by the TB physician
1620628|NCT02082340|Other|phone calls|Family members of the TB patients will receive phone calls every evening (except Sunday) during the whole ambulatory TB treatment phase to assure that the patient takes the medication prescribed and provided by the TB physician and to collect information on treatment adherence and possible side effects.
2010955|NCT02774876|Drug|Insulin|Patient's usual fast-acting insulin analog will be used.
1632553|NCT01989299|Device|ILR implantation|
1620629|NCT02082340|Behavioral|Self-administered drug intake strategy|Once a week TB patients will receive the TB medication from their local outpatient TB centers and will use the medication every day (six days a week, except Sunday according to the TB treatment protocol) at home under supervision of a family member in charge.
1620630|NCT02082340|Behavioral|Educational leaflet|Educational leaflet containing information on TB infection; infection control measures; importance of TB treatment adherence and family support will be provided to all TB patients at the end of the counselling session
1620631|NCT02082327|Drug|IV migalastat HCl|
1620632|NCT02082327|Drug|IV placebo|
1620633|NCT02082327|Drug|oral migalastat HCl|
1620634|NCT02082314|Procedure|RFA Vertebroplasty|
1620635|NCT02082288|Other|Edessy ICSI Outcome Embryo Score|"EIOS:
Age (ys) >35 (0) 30-35 (1) <30 (2) No of retrived oocyte <5 (0) 5-9 (1) ≥ 10 (2) No of EC embryos <2 (0) 2-4 (1) >4 (2) No of good quality embryos <3 (0) 3-5 (1) >5 (2) No of embryos transferred -------- (0) ≤2 (1) >2 (2)"
1620636|NCT02082275|Other|OB Nest|"Reduction in the number of clinic office visits
Assignment to a specific nursing care team
Support and direct interaction available through tools which supports mom's empowerment to address her concerns, care for herself and connect with OB as necessary between clinic visits.
Empower and enable mothers to complete at home measurements for fetal heart rate, weight, and blood pressures.
Augmentation of in-person visits between care providers and patients with video conversations.
Maternal outcomes will be monitored through surveys and questionnaires."
1620637|NCT02082262|Drug|AGN-229666|One to two drops of AGN-229666 twice daily in each eye for 10 weeks.
2010956|NCT02774876|Device|Dexcom G4 Platinum glucose sensor|The Dexcom G4 Platinum glucose sensor will be used to measure glucose levels.
1620639|NCT02082236|Drug|Treatment Arm A: Sufenta®|Sufenta® intravenous (IV) (50 mcg/mL) 30 mcg infused over 1 minute
1620640|NCT02082236|Drug|Treatment B: Sufentanil SSM 30 mcg|single-dose SSM 30 mcg
1620641|NCT02082236|Drug|Treatment C: SSM 15 mcg|2 consecutive doses of SSM 15 mcg administered 20 minutes apart
1620642|NCT02082236|Drug|Treatment D: SSM 30 mcg|12 consecutive doses of SSM 30 mcg administered 1 hour apart
1620643|NCT02082223|Behavioral|Interventions to improve preop QOL/resilience deficits|Identify patients' and patients' care givers quality of life/resilience deficits and supply information and resources prior to undergoing complex GI surgery.
1620644|NCT02082210|Drug|LY2875358|Administered Intravenously (IV)
1620645|NCT02082210|Drug|Ramucirumab|Administered Intravenously (IV)
1620646|NCT02082197|Drug|ABT-SLV176|ABT-SLV176 administered daily
1620647|NCT02082184|Device|Sensor Based Glucose Monitoring System|"Subjects will wear the Abbott Sensor Based Glucose Monitoring System (unmasked) for 6 months to monitor their glucose levels. Post completion of the 6 month intervention, subjects participating in this arm of the study will be given a further 6 month period of open access to the device.
All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
1620648|NCT02082184|Device|Standard Blood Glucose Monitoring|"Subjects will use an Abbott Blood Glucose Monitoring System (standard blood glucose meter) for 6 months to monitor their glucose levels. A 14-day masked wear of the Abbott Sensor Based Glucose Monitoring System is included for these subjects at the 6 month time point, to collect glycaemic variability data for comparison to the intervention group of the study.
All subjects will wear a masked Abbott Sensor Based Glucose Monitoring System, for 14 days prior to randomisation."
1620649|NCT02082171|Other|Multidomain intervention|Multidomain preventive intervention designed by a multidisciplinary team on the basis of results of a comprehensive geriatric assessment
1620650|NCT02082158|Other|Study Procedures|Study activities include fit-testing, wearing the respirator while performing a series of motions that simulate healthcare worker tasks and completing a survey on the comfort and tolerability of the respirator worn.
1620651|NCT02082145|Device|NMES|Application of NMES device bilaterally, once a day, 5 times a week, for 10 weeks
1620653|NCT02082106|Other|Alpine skiing|
1620654|NCT02082106|Other|cross country skiing|
1620655|NCT02082106|Other|Indoor training (cycling)|
1620656|NCT02082093|Device|Telemedicine System|
1620657|NCT02082080|Other|Education|
1620658|NCT02082080|Other|Social support|
1620659|NCT02082067|Procedure|Adductor canal|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert in adductor canal through tuohy needle (18G, 100mm length) under ultrasound guidance.
1620660|NCT02082067|Procedure|Femoral|Perinervous catheter (stimulong sono- Pajunk, Germany) will be insert between femoral nerve and femoral artery through tuohy needle (18G, 100mm length) under ultrasound guidance.
1620661|NCT02082067|Procedure|Spinal Anesthesia|Spinal anesthesia will be perform at L3-L4 or L4-L5 level. Levobupivacaine 0,5% 12mg will be injected.
1620662|NCT02082067|Procedure|Local anesthetic infusion|Continuous infusion of levobupivacaine 0,125% at 8ml/h rate through perinervous catheter until 5th postoperative day.
1620663|NCT02082067|Procedure|Intravenous analgesia|Ketorolac 30mg 3 times/day and morphine Patients Control Analgesia (1mg/h, max 4mg/h) administered.
1620664|NCT02082067|Drug|Ropivacaine 0,75%|
1620665|NCT02082067|Drug|Levobupivacaine 0,5%|
1620666|NCT02082067|Drug|Levobupivacaine 0,125%|
1620667|NCT02082067|Drug|Ketorolac 30mg|
1620668|NCT02082067|Drug|Morphine|
1620669|NCT02082067|Device|stimulong sono, Pajunk, Germany|
1620670|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.36 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.36 mg white, scored, tablets with M27 on scored side and plain on the other side"
1620671|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.24 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
1620672|NCT02082054|Drug|PSE 120 mg, CM 8 mg, Atr 0.12 mg|"Pseudoephedrine 120 mg, chlorpheniramine 8 mg, atropine 0.12 mg white, scored, tablets with M27 on scored side and plain on the other side"
1620673|NCT02082054|Drug|PSE 120 mg, CM 8 mg|Pseudoephedrine 120 mg, chlorpheniramine 8 mg tablets dosed BID
1620674|NCT02082054|Drug|Atropine 0.24 mg|"Atropine sulfate 0.24 mg white, scored, tablets with M27 on scored side and plain on the other side"
1620675|NCT02082028|Device|BGStar|
1620676|NCT02082028|Device|glucose meter|
1634034|NCT01977664|Other|no intervention|
1620679|NCT02081976|Behavioral|Integrated Care Group|The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.
1620680|NCT02081976|Other|Standard Care Group|The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
1620681|NCT02081963|Drug|Amikacin|Nebulized 0.2g of amikacin and 2 mL of normal saline twice a day for 14 days in combination with standard treatment.
1620682|NCT02081963|Drug|Normal saline|Nebulized 3 mL of normal saline twice a day for 14 days in combination with standard treatment.
1620683|NCT02081950|Biological|Enoxaparin sodium|comparison of 2 different administration of drug
1620684|NCT02081937|Biological|anti-CD19-CAR vector-transduced T cells|
1620685|NCT02081924|Other|Kisspeptin|Kisspeptin / placebo will be administered via a subcutaneous pump device for up to 3 months.
1620686|NCT02081924|Other|Saline|Kisspeptin / placebo will be administered via a subcutaneous pump device for up to 3 months.
1620687|NCT02081911|Procedure|High Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of 30 mL 0.25% bupivacaine/ epinephrine
1620688|NCT02081911|Procedure|Low Volume Adductor Canal Block|Adductor canal block performed in the distal thigh (1/3 of the total distance between the superior border of the patella and the femoral crease, cephalad to the patella) utilizing an injectate volume of of 10 mL 0.75% bupivacaine/ epinephrine
1620689|NCT02081911|Procedure|Femoral Nerve Block|Femoral nerve block with 10 mL 0.75 % bupivacaine/epinephrine
1620690|NCT02081898|Dietary Supplement|LCD|approximate 100 kcal/d caloric deficit
1620691|NCT02081885|Procedure|Tricalcium Phosphate / Chitosan|
1620692|NCT02081885|Procedure|Autologous Graft|
1620693|NCT02081859|Device|Embryoscope|The embryoscope is a microscope that allows for continuous time-lapse monitoring.
1620694|NCT02081859|Other|Conventional Criteria|
1620695|NCT02081846|Other|Nurse Home Visit|We will complete a single center, parallel, randomized, standard-of-care-controlled prospective study to determine the efficacy of a nurse home visit program, an intervention adapted from those studied in other populations (i.e., adults, high-risk infants) and re-engineered through Aim 2, in improving pediatric patient transitions from hospital to home
1620696|NCT02081846|Other|Standard of Care|Control patients will be randomized to receive standard-of-care at discharge. This care at our institution includes pediatric hospitalist to PCP (primary care physician) verbal and written communication prior to discharge, written documentation for the family regarding prescribed medication regimen, recommended follow-up with outpatient PCP and relevant consultant(s), and delivery of prescribed medications from the hospital pharmacy to the patient's bedside.
1620697|NCT02081794|Other|Tailored education intervention|Receive 2 minute video-assisted intervention on the risk and prevention of falls with tailored hand-outs depending on participant answers about fall risks
1620698|NCT02081794|Other|Standard fall care|Patient are given a generic handout on falling and receive standard care by nurses comprising of a fall risk assessment and verbal education
1620699|NCT02081781|Procedure|Probing|"A punctal dilator was used for dilating the punctum. The nasolacrimal system was irrigated through either the lower or upper punctum with a hollow 23-gauge irrigating cannula attached to a syringe. A #0 (or #00) Bowman probe was passed through either the lower or upper canaliculus into the lacrimal sac and then directed downward through the nasolacrimal duct into nasal cavity. A Hard resistance could be felt as the probe touched the end of the nasolacrimal duct. A Pop tactile sensation might be noted while the probe passing through an obstruction at the valve of Hasner."
1620700|NCT02081768|Radiation|90yttrium colloid|90yttrium colloid will be inserted into a sellar/parasellar cyst
1620701|NCT02081755|Drug|Everolimus|Everolimus Dosing: 1.5 mg BID (3.0 mg/day) for 24 months
1620702|NCT02081755|Drug|Tacrolimus|Tacrolimus Dosing: 0.05 mg/kg BID for 24 months
1620703|NCT02081755|Drug|Myfortic|Myfortic®: 360 mg to 1080 mg BID for 24 months
1620704|NCT02081755|Drug|CellCept|CellCept: 500 mg to 1500 mg BID for 24 months
1620705|NCT02081755|Drug|Imuran|0.5 mg/kg to 2 mg/kg QD
1620706|NCT02081703|Drug|AYX1 Injection 660 mg / 6 mL|6 mL solution for intrathecal injection with 660 mg of AYX1
1620707|NCT02081703|Drug|AYX1 Injection 1100 mg / 10 mL|10 mL solution for intrathecal injection with 1100 mg of AYX1
1620708|NCT02081703|Drug|Placebo Injection 6 mL|6 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
1620709|NCT02081703|Drug|Placebo Injection 10 mL|10 mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
1620711|NCT02081677|Device|ACUVUE 2|worn in a daily wear modality; lenses will be replaced after 2 weeks
1620712|NCT02081677|Device|Prototype E1|worn in a daily wear modality; lenses will be replaced after 2 weeks
1620713|NCT02081677|Device|Prototype E2|worn in a daily wear modality; lenses will be replaced after 2 weeks
1620714|NCT02081677|Device|Prototype E3|worn in a daily wear modality; lenses will be replaced after 2 weeks
1620715|NCT02081664|Behavioral|lifestyle intervention|
1620716|NCT02081651|Dietary Supplement|Parmigiano Reggiano cheese|
1620719|NCT02081625|Drug|NS-065/NCNP-01|"NS-065/NCNP-01 for Infusion is packaged as 25 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline as follows:
Cohort 1: 1.25mg/kg once weekly for 12 weeks; Cohort 2: 5.0mg/kg once weekly for 12 weeks; Cohort 3: 20.0mg/kg once weekly for 12 weeks"
1620720|NCT02081612|Behavioral|Nutrition Education|12 educational weight management group session each addressing a different weight loss topic
1620721|NCT02081612|Procedure|Acupuncture|12 weight loss acupuncture session using both body and auricular points.
1620722|NCT02081599|Drug|Teneli (Teneligliptin)|
1620723|NCT02081599|Drug|Placebo|
1620724|NCT02081599|Drug|Insulin|
1620725|NCT02081586|Behavioral|CBT|Therapists will work with patients to identify non-constructive thinking patterns that are serving as barriers to adequate self-management of Type 2 Diabetes.
1620726|NCT02081586|Device|Smartphone app|Smartphone app developed to assist patients practice CBT skills throughout the week
1620727|NCT02081586|Other|Standard Diabetes Care at PCP|Patients receive ADA standard of Care with physician at PCP office
2010957|NCT02774876|Other|Single-hormone closed-loop|Interventions will be undertaken 1 to 5 days after sensor insertion. Subjects will be admitted at IRCM at 6:30 am in a fasting state. At 7:00, single-hormone closed-loop will be initiated. At 8:00, if glucose levels are between 3.5 and 12.5 mmol/L, the meal will be served. Patients will have 20 minutes to consume the meal. If glucose levels are not in this target range, the meal will be delayed for a maximum of 45 minutes. If after 45 minutes, glucoses levels are still not between 3.5 and 12.5 mmol/L, the test will be cancelled and rescheduled. The test meals will be: 1) 75g of CHO; 2) 75g of CHO + 35g of protein; 3) 75g of CHO + 35g of fat; or 4) 75g of CHO + 35g of protein + 35g of fat. The intervention day will end at 13:00.
1620729|NCT02081560|Drug|Colistin|Colistin i.v. three times daily as long a necessary for infection treatment
1620730|NCT02081534|Drug|AZD1722|AZD1722, oral tablet
1620731|NCT02081534|Drug|Placebo|Placebo bid, double dummy technique
1620732|NCT02081521|Behavioral|Community behaviour change campaign|Community campaign targeting exclusive breastfeeding, handwashing with soap, and use of ORS and zinc to manage child diarrhoea. Includes a range of activities within the community (large events and small group sessions); clinic activities (ORS preparation), radio adverts.
1620733|NCT02081508|Behavioral|Interference onset|Temporal duration of interference onset.
1620734|NCT02081495|Drug|DOXIL/CAELYX reference product (Treatment A)|Participants will receive DOXIL/CAELYX reference product 50 mg/m2 as an intravenous (into a vein) infusion over 90 minutes on Day 1.
1620735|NCT02081495|Drug|DOXIL/CAELYX test product (Treatment B)|Participants will receive DOXIL/CAELYX test product 50 mg/m2 as an intravenous infusion over 90 minutes on Day 1.
1620736|NCT02081482|Radiation|18F-FDG PET|
1620737|NCT02081469|Other|TDF|To compare extend TDF 24 wks versus 48 wks prophylaxis efficacy in chemotherapy CHB patients
2010958|NCT02772068|Drug|Istaroxime|Subjects will be given Istaroxime, a novel SERCA2a activator one hour prior and during exercise.
2010959|NCT02772068|Other|Exercise|
1620740|NCT02081443|Drug|Ticagrelor 180mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
1620741|NCT02081443|Drug|Ticagrelor 90mg|The proposed study will have a prospective, randomized, parallel design in which patients on chronic ticagrelor therapy will be assigned to receive a reloading dose of 90 or 180 mg ticagrelor. Platelet function assays will be done following in vitro incubation with and without 500 nM cangrelor.
1620742|NCT02081430|Procedure|CT Manipulation|
1620743|NCT02081430|Procedure|Upper trapezius stretch|
2010960|NCT02770807|Drug|EDS-EP dose range of ~5-10 mg DSP/infusion|infusion
1620745|NCT02081404|Drug|Esomeprazole|standard dose of proton pump inhibitor by mouth once a day for 30 days
1620746|NCT02081404|Drug|Placebo|placebo
1620747|NCT02081391|Drug|Tapentadol 4 mg/mL|Participants aged from 6 months to less than 18 years with body weight less than 20 kg will receive tapentadol 4 mg/mL solution orally (by mouth) every 4 hours for up to 72 hours. The dose during the first 24 hours will be 1.25 mg/kg. After 24 hours, the dose can be reduced to 1.0 mg/kg, based on investigator's judgment. Dose of tapentadol 4 mg/mL solution for participants aged birth to less than 2 years with body weight less than 20 kg will be decided based on the forthcoming pharmacokinetic (PK) [what the body does to a medication] data.
1620748|NCT02081391|Drug|Tapentadol 20 mg/mL|Participants aged from 6 months to less than 18 years with body weight greater than or equal to 20 kg will receive tapentadol 20 mg/mL solution orally every 4 hours for up to 72 hours. The dose during the first 24 hours will be 1.25 mg/kg. After 24 hours, the dose can be reduced to 1.0 mg/kg, based on investigator's judgment. Dose of tapentadol 20 mg/mL solution for participants aged birth to less than 2 years with body weight greater than or equal to 20 kg will be decided based on the forthcoming PK data.
1620749|NCT02081391|Other|Placebo|Matching placebo solution will be administered orally every 4 hours up to 72 hours.
2010961|NCT02770807|Drug|EDS-EP dose range of ~14-22 mg DSP/infusion|infusion
2010962|NCT02770807|Drug|Placebo|infusion
2010963|NCT02770612|Other|Prescribed opioids|Making a shared decision with post-cesarean delivery mothers about quantity of opioids prescribed at discharge
2010964|NCT02765191|Drug|Norepinephrine|Norepinephrine will be titrated to achieve a MAP of 60-65 mmHg and 75-80 mmHg respectively.
1620755|NCT02081365|Behavioral|Computerized Dental Anxiety Treatment|The Computerized Dental Anxiety Treatment Program consists of treatment modules that are be delivered through a computer. The modules use Cognitive Behavioral Therapy (CBT) to assist the participant in preparing a personal plan for managing his/her dental anxiety. The program incorporates a range of CBT techniques, including cognitive restructuring, exposure, and motivational interviewing.
1620756|NCT02081352|Other|DermaPure™|"A minimally manipulated human tissue regulated as human cells, tissues, and cellular and tissue-based products (HCT/Ps)"
1620757|NCT02081352|Other|Standard care|
1620758|NCT02081339|Drug|ranibizumab, aflibercept, pegaptanib, verteporphin|
1620759|NCT02081326|Biological|Bacillus Calmette-Guérin|2 BCG vaccinations spaced 4 weeks apart during the first year and then 1 vaccination every year for the next 4 years
1620760|NCT02081326|Biological|Saline injection|2 injections spaced 4 weeks apart during the first year, then 1 injection per year for the next 4 years
1620761|NCT02081313|Other|Biopsy|
1620762|NCT02081313|Other|Blood sample|
2010965|NCT02765191|Drug|Ringer's Acetate|7,5 ml/kg mL Ringer's acetate during 10 minutes will be administered
1620765|NCT02081287|Drug|IP6|IP6 2,000 -3,000 mg per day given orally in two doses
1620766|NCT02081287|Drug|Lamotrigine|Dose up to 200 mg per day over 10 weeks
1620767|NCT02081274|Procedure|Surgery for congenital heart disease|
1620768|NCT02081261|Procedure|Coronary artery bypass surgery|coronary artery bypass surgery
2010966|NCT02764151|Drug|PF-06840003|Daily Oral PF-06840003
2010967|NCT02761057|Drug|Cabozantinib S-malate|Given PO
1620771|NCT02081235|Procedure|surgery for congenital heart disease|surgery for congenital heart disease
1620772|NCT02081222|Procedure|surgery for congenital heart disease with cardiopulmonary bypass|surgery for congenital heart disease with cardiopulmonary bypass
1620773|NCT02081209|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1620774|NCT02081196|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1620775|NCT02081183|Drug|Mycophenolate mofetil (MMF)|1 g/day, PO BID for 2 weeks; 1.5 g/day PO TID for the next 2 weeks; and 2 g/day PO BID for the remainder of the Maintenance Phase.
1620776|NCT02081183|Drug|Cyclophosphamide, Maintenance Phase|0.5-1 g/m^2 IV pulse once every 3 months
1620777|NCT02081183|Drug|Cyclophosphamide, Induction Phase|0.5 - 1 g/m^2 IV pulse once per month
1620778|NCT02081183|Drug|Prednisone|1 mg/kg PO once per day; reduced by 5 mg every 2 weeks up to 20 mg/day; followed by a reduction of 2.5 mg every 2 weeks until reaching the maintenance phase of 10 mg/day.
1620779|NCT02081170|Procedure|Autologous platelet concentrate|"pars plana vitrectomy
internal limiting membrane removal
Fluid-air exchange
Intravitreal autologous platelet concentrate injection
Intravitreal gas (14% C3F8) injection
Keep prone position for 7-14 days after surgery"
1620780|NCT02081157|Device|GalaFlex Mesh|
1620781|NCT02081144|Other|Smokefree TXT Program|The SmokeFreeTxt program is a library consisting of ~130 brief messages that can be proactively sent to smokers' cellphones using software developed and maintained by NCI. The message content is informed by principles of cognitive behavioral therapy. They are sent to smokers at random times of day (during normal waking hours), up to 5 messages per day.
1620782|NCT02081144|Drug|nicotine replacement patches|Subject will be given 4 weeks of Nicotine Replacement Patches, based on the amount he/she is smoking at baseline.
1620783|NCT02081144|Drug|Nicotine Replacement Gum|Subjects will be given 10 pieces of 2mg Nicotine Replacement Gum x 28 days.
1620784|NCT02081144|Behavioral|Faxed Referral CT Smokers Quitline|A faxed referral will be sent to the CT Smokers Quitline for the subject.
1620785|NCT02081131|Procedure|Open surgery|pancreatic head resection by open method
1620786|NCT02081131|Procedure|Laparoscopic surgery|laparoscopic pancreatoduodenectomy
1620787|NCT02081118|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
1620788|NCT02081118|Drug|Placebo|Placebo for HM11260C
1620789|NCT02081105|Other|PEEP of 5 or 15 cm H2O|PEEP of 5 or 15 cm H2O set at the respirator and applied to the patient for 10 minutes. Then, measurements are made at each PEEP in the following order: arterial blood gas, CXR, pressure-volume curve.
1620790|NCT02081079|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
1620791|NCT02081066|Other|cardiovascular risk factors|
1620792|NCT02081053|Device|STAR™ Tumor Ablation System and StabiliT® Vertebral Augmentation System|Radiofrequency targeted radiofrequency ablation (t-RFA) and targeted vertebral augmentation (RF-TVA)
1620793|NCT02081040|Other|Not applicable (observational study with no active intervention)|
1620794|NCT02081027|Drug|Riluzole|
1620795|NCT02081027|Drug|placebo|
1620796|NCT02081014|Drug|G-Pen Mini™ (glucagon injection)|stable, pre-mixed, liquid glucagon for subcutaneous injection
1620797|NCT02081001|Drug|Novo Nordisk GlucaGen®|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
1620798|NCT02081001|Drug|G-Pump™ (glucagon infusion)|single subcutaneous infusion doses at 0.3 μg/kg, 1.2 μg/kg and 2.0 μg/kg
1620799|NCT02080975|Other|Data Collection During Atrial Flutter Ablation|All enrolled patients are clinically indicated for an atrial flutter ablation. The patients who consent for this study will have additional electrocardiograms taken during their procedure for future review, as well as ultrasound images form inside their heart. This will lengthen the ablation by approximately 10 minutes, but is not a separate procedure.
1620800|NCT02080962|Radiation|30 Gy in 5 fractions|5 fractions of 600 cGy, once a day, five times a week - TDF: 89
1620801|NCT02080962|Radiation|40 Gy in 10 fractions|tumors > 2-5 cm in diameter: 10 fractions of 400 cGy, once a day, five times a week - TDF: 96
1620802|NCT02080949|Radiation|4fx x 5Gy|It'll be recruited 3 patients to the initial scheme of 4 fractions of 5 Gy on each brain metastasis with HSRT and if no patient has unacceptable toxicity, more 3 patients for subsequent scheme will be recruited. If 2 patients had unacceptable toxicity, the study ends and it'll be considered the study initiated with toxic regimen. If 1 patient has unacceptable toxicity, it'll be recruited 3 more patients for this scheme and if 1 or more patients had unacceptable toxicity, the scheme will be considered toxic and the study will be closed. If no patient develops unacceptable toxicity, the study will follow to the next cohort of 3 more patients with next dose level. The same criteria of recruitment will be performed till any scheme reach the MTD or up to the scheme of 4 fractions of 9 Gy.
1620803|NCT02080923|Behavioral|Brief Motivational Interview|The intervention is exclusively focused on Adolescent Dating Aggression and will always be delivered by a human interventionist. It is theory-based and its success as an intervention method for substance abuse and several other health-related issues is well established.
1620804|NCT02080910|Behavioral|Psychoeducation|
2010968|NCT02761057|Drug|Crizotinib|Given PO
1620806|NCT02080858|Drug|Ticagrelor + Apixaban + ASA|
2010969|NCT02761057|Other|Laboratory Biomarker Analysis|Correlative studies
2010970|NCT02761057|Drug|Sunitinib Malate|Given PO
2010971|NCT02761057|Drug|Volitinib|Given PO
2010972|NCT02760329|Procedure|Blood draw|Biomarkers analyses
2010973|NCT02760329|Procedure|Urine|Biomarker analyses
2010974|NCT02760329|Procedure|Lung function measurements|FEV1, FVC, PEF, FEF25-75%, IC, calculated FEV1/FVC ratio and calculated FEV1 % predicted
1620807|NCT02080858|Drug|Ticagrelor + Apixaban|
1620808|NCT02080845|Dietary Supplement|no caffeine|
1620809|NCT02080845|Dietary Supplement|high caffeine|
1620810|NCT02080845|Dietary Supplement|no theobromine|
1620811|NCT02080845|Dietary Supplement|low theobromine|
1620812|NCT02080845|Dietary Supplement|high theobromine|
2010975|NCT02760329|Procedure|Fractional Exhaled Nitric Oxide (FENO)|Measures level of exhaled nitric oxide.
2010976|NCT02760238|Other|Observational|
1620815|NCT02080819|Drug|levodopa/carbidopa 400/100 BID|"Levodopa dose escalation (1 week): Days 1-2, one 50/12.5 mg tablet BID; Days 3-4, one 100/25 mg tablet BID; Days 5-6, one 200/50 mg tablet BID; Day 7, one 400/100 mg tablet BID.
Maintenance phase (7 weeks): One 400/100 mg Levodopa/Carbidopa tablet BID or placebo in conjunction with once weekly individual cognitive behavioral therapy plus contingency management for attendance."
1620816|NCT02080806|Device|Mechanical Insufflation Exsufflation|Mechanical Insufflation Exsufflation -Each patient received daily treatments by means of a light-weight, elastic oronasal mask. Treatments were divided between morning and afternoon and were carried out 5 times a week. A total of 20 sessions were carried out by a a trained respiratory therapist.
1620817|NCT02080793|Other|Questionnaire|
1620818|NCT02080780|Drug|Clarithromycin XL|Clarithromycin XL administered once daily on Days 4 through 9 as 2 x 500 mg tablets, 1000 mg per day, for a total of 6000 mg
1620819|NCT02080780|Drug|2% Diltiazem|2% Diltiazem Hydrochloride Cream applied on Day 1 & Day 8 to the perianal area (~2.5 cm [1 inch]; ~8.5 mg)
1620820|NCT02080767|Drug|Tecovirimat|Oral tablet 600mg daily dose(three capsules, 200 mg/capsule)
1620821|NCT02080754|Other|effective sellick maneuver|Sellick maneuver is applied, as originally described by Sellick et al .
1620822|NCT02080754|Other|sham sellick maneuver|The operator who applied the maneuver is the only person who knows the arm inclusion of the patient. Thus, he sets his fingers as described in Sellick arms without exerting pressure on the cricoid cartilage.
1620823|NCT02080741|Other|Blood sample of 12 ml|
1620824|NCT02080728|Drug|Ropivacaine 500mg/100ml Naropeine|
1620825|NCT02080728|Drug|0.9% sodium chloride BAXTER|
1620826|NCT02080715|Drug|Tolcapone|2 x 100mg Tolcapone compared to placebo (randomized, double-blind, cross-over)
1620827|NCT02080715|Drug|Placebo|
1620828|NCT02080702|Device|Monosyn|Monosyn will be used to perform the gastrointestinal anastomoses
1620829|NCT02080689|Other|Decipher|
1620830|NCT02080663|Procedure|Proximal row carpectomy|
1620831|NCT02080650|Device|Mesenchymal-marker based ferrofluid (c-MET)|
1620832|NCT02080650|Device|Epithelial cell adhesion molecule (EpCAM) ferrofluid|
1620833|NCT02080637|Drug|Ambrisentan|Once daily oral dosing
1620834|NCT02080637|Other|Placebo|
1620835|NCT02080624|Drug|Drug: Topical Rapamycin|"After signing this consent form, you will be asked to undergo some screening tests or procedures to find out if you can be in the research study.
A medical history, which involves questions about your health history, any medications you are taking or plan to take, any allergies and the treatments you received for your CM.
A physical exam, during which you will be asked about any problems that you might be having. Additionally, your clinician will check your vital signs (blood pressure, heart rate, weight and height). The doctor will also evaluate your performance status, which indicates how much your illness affects your activity level.
Blood tests, which will be done to make sure your hemogram, triglyceride and cholesterol levels are normal.
A pregnancy test for females will be done to check that you are not pregnant. If theses tests show that you are eligible to participate in the research study, you will begin the study treatment."
1620836|NCT02080598|Behavioral|2 cigarettes in 15 minutes|
1620837|NCT02080585|Behavioral|Physical Activity advice.|Subjects receive advice regarding physical activities.
1620838|NCT02080559|Biological|4CMenB|0.5ml IM
1620839|NCT02080546|Procedure|Cut-Coag|"Incision using electrothermal cautery, with an attempt made to use the cut (continuous low-voltage, high-current) for colpotomy incision following the initial scoring of the cervico-vaginal tissue on the coag (pulsed high-voltage, low-current) mode."
1620840|NCT02080546|Procedure|V-mode|"Incision using electrothermal cautery in the V mode. The V mode combines real-time tissue sensing technology with the cut and coag waveforms to reduce the amount of thermal spread to the tissue without sacrificing hemostasis during monopolar electrothermal procedures."
1620841|NCT02080546|Device|Valleylab G3000 Electrosurgical Device|Use of surgical device Valleylab G3000 Electrosurgical Device
1620842|NCT02080533|Other|Slow-paced respiration therapy|The FDA-approved RESPeRATE device contains headphones and a sensor that attaches to the chest to detect inhalation and exhalation. Musical tones synchronize with the respiratory cycle to slowly guide the user to decrease respirations.
1620843|NCT02080520|Dietary Supplement|Nattokinase|
1620844|NCT02080520|Dietary Supplement|Placebo|
1620845|NCT02080507|Device|Active Neuronetics rTMS stimulator|In the active group, magnetic power output will be delivered to the subject through the coils.
1620846|NCT02080507|Device|Inactive Neuronetics rTMS stimulator|In the inactive group, no magnetic power output will be delivered to the subject through the coils.
1620847|NCT02080494|Drug|Tranexamic Acid|
1620848|NCT02080481|Device|Infiniti Plus needle guidance system|The Infiniti Plus needle guidance system is designed to help physicians perform ultrasound guided nerve blocks.
1620849|NCT02080481|Device|Conventional block needle|conventional block needle used for insertion of femoral nerve catheters.
2010977|NCT02759315|Drug|Uprifosbuvir 450 mg|450 mg administered as 3 x 150 mg oral tablets
2010978|NCT02759315|Drug|Ruzasvir 60 mg|60 mg administered as 6 x 10 mg oral capsules
2010979|NCT02757638|Other|Stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
1620854|NCT02080442|Other|Balance training|Training will consist of 30 minute sessions 2-3 times/week for a total of 18-24 sessions, in keeping with best practice guidelines for older adults.12 Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
1620855|NCT02080429|Procedure|Passive Descent|
1620856|NCT02080429|Procedure|Pushing|
1620857|NCT02080416|Drug|Nelfinavir|Nelfinavir will be given 3000 mg orally twice daily on days 1-14 of a 14-day cycle. NFV will be continued in patients tolerating therapy for 4 cycles (8 weeks).
1620858|NCT02080403|Drug|2.5 mg Chlorhexidine gluconate chip|Subgingival debridement will be carried out for each one of the target implant. Upon completion of the debridement a PerioChip® will be inserted in each one of the target implant.
1620859|NCT02080390|Procedure|Transthoracic echocardiogram (ultrasound)|Any transthoracic echocardiogram (ultrasound) of the heart, performed as part of standard clinical care, will be further evaluated for special parameters that may help to detect weakening.
1620860|NCT02080377|Drug|Glibenclamide|
1620861|NCT02080377|Drug|Insulin|
1620862|NCT02080364|Drug|Azeliragon|Azeliragon 5mg administered orally, once daily for 18 months
1620863|NCT02080364|Drug|Placebo|Placebo administered orally, once daily for 18 months
1620864|NCT02080351|Behavioral|Simple cognitive task|
1620865|NCT02080338|Device|Orthodontic bracket slot system|Orthodontic treatment using different orthodontic bracket slot systems
1620866|NCT02080325|Other|High Protein-Weight loss-Soy diet|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the soya version based on soya protein or soya-tvp (textured vegetable protein).
1620867|NCT02080325|Other|High Protein-Weight loss-Meat|• The high protein (HP) weight loss diet will be fed to 100% resting metabolic rate (RMR) on a 5 day rotation menu, fed as three meals a day, 30% protein, 30% fat and 40% carbohydrate; the meat version will be based on chicken and beef meat.
1620868|NCT02080312|Drug|Magnevist (gadopentetate dimeglumine)|
1620869|NCT02080299|Procedure|Remote ischemic preconditioning (RIPC)|3 circles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion, preceding TAVI procedure.
1620870|NCT02080299|Procedure|Placebo|Prior to TAVI-procedure, the blood pressure cuff remains uninflated for 30 min.
2010980|NCT02758093|Behavioral|Speed of Processing Training|These are specific computerized exercises that are designed to increase the rate in which people can process visual information.
2010981|NCT02758093|Other|Internet Navigational|This is a sham condition in which participants will receive the same amount of social and computer contact as those randomized to receive the 10 hours of speed of processing training. In this condition, participants will learn how to do various activities on the internet.
2010982|NCT02755818|Drug|Heparin|This is not an interventional study. The investigators use heparin at 50unit/kg of body weight to release enzyme lipoprotein lipase (LPL) from the body. LPL level will be used as part of calculation of lipid analysis and measurements
1620874|NCT02080273|Drug|Colgate Cavitity Protection toothpaste|0.76% monofluorophosphate (1000 ppm MFP), control toothpaste
1620875|NCT02080273|Drug|Colgate Total toothpaste|0.32% sodium fluoride (1450 ppm NaF) and 0.3% triclosan. active comparator toothpaste
1620876|NCT02080273|Drug|Parodontax toothpaste|1400 ppm sodium fluoride (NaF), active comparator toothpaste
1620877|NCT02080260|Drug|regorafenib|Single agent drug therapy with regorafenib
1620878|NCT02080247|Drug|Skin care regimen with Calmoseptine ointment|Application of Calmoseptine Ointment for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters).
1620879|NCT02080247|Drug|Skin care regimen with Destin ointment|Application of Destin for 6 days will be applied on the affected area that will be calculated by multiplying the longest portion of the affected area measured in a head to toe orientation by the widest portion of the affected area measured from side to side(in Centimeters). Patients will receive treatment with Destin Maximum Strength 40% Zinc Oxide Diaper Rash Paste (Destin) for 6 days as part of a structured skin care regimen.
1620880|NCT02080234|Drug|GELOX|gemcitabine ：1250mg/m2 (ivdrip) on days 1, oxaliplatin :85 mg/m2 (ivdrip) on day 1, and pegaspargase : 2500 IU/m2 (intramuscular injection) on day 1.Cycle is repeated every 14 days
1620881|NCT02080234|Radiation|IFRT|IFRT is delivered using 6-MeV linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions
1620882|NCT02080221|Drug|FOLFOXA|
1620883|NCT02080208|Device|Optiflow|patients receive oxygen via high flow oxygen therapy during 20 minutes
1620884|NCT02080195|Drug|Cyclophosphamide|Cyclophosphamide (alkylating agent) conditioning regimen and post transplantation cyclophosphamide with matched, partially matched, haplo-identical or unrelated donors
1620885|NCT02080195|Drug|Sodium-2-mercapto ethane sulphonate|Antineoplastic detoxifying agent
1620886|NCT02080195|Drug|Fludarabine monophosphate|Purine antimetabolite
1620887|NCT02080195|Drug|Tacrolimus|Calcineurin inhibitor
1620888|NCT02080195|Drug|Mofetil|Immunosuppressant
1620889|NCT02080195|Drug|Rabbit antithymocyte globulin|Selective immunosuppressant
1620890|NCT02080182|Drug|Acetylcysteine|
1620891|NCT02080182|Drug|placebo acetylcysteine|
1620892|NCT02080169|Drug|midazolam|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.
If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
1620893|NCT02080169|Drug|Dexmedetomidine|"If the target sedation level is not obtained using the above recommended dosage, midazolam 0.01-0.05 mg/kg is added every 10-15min, until the target sedation level is obtained.
If it is over sedation (RASS -3 to -5), and reduction of the dosage of the sedation drug could not ease the situation, and then stop the sedation until the target sedation level is obtained."
1620894|NCT02080169|Drug|Fentanyl|Fentanyl is used as analgesic drug in order to obtain the VAS <3.
1620895|NCT02080156|Device|CPAP|
1620896|NCT02080143|Device|Thermal Adhesion Patch|
1620897|NCT02080143|Device|Thermal Adhesion Patch|
1620898|NCT02080130|Dietary Supplement|Saccharomyces boulardii|FLORATIL®. Saccharomyces boulardii 200 mg sachet. One sachet orally, BID, for 5 days.
2010983|NCT02753101|Drug|[18F]-FTC-146|10 mCi± 1 mCi of [18F]FTC-146 intravenously
1620899|NCT02080130|Dietary Supplement|Probiotics combination|LACTIPAN®. Probiotics combination sachet. One sachet orally, BID, for 5 days. Lactobacillus acidophilus............. 1.00 x 109 cfu Lactobacillus casei........................ 1.00 x 109 cfu Lactobacillus rhamnosus............. 4.40 x 108 cfu Lactobacillus plantarum............... 1.76 x 108 cfu Bifidobacterium infantis................ 2.76 x 107 cfu Streptococcus thermophillus....... 6.66 x 105 cfu
1620900|NCT02080130|Other|Placebo|Placebo
1620901|NCT02080117|Procedure|kidney transplantation, living or deceased donor|
1620902|NCT02080104|Drug|intarvenous and intramusculer 10 IU oxytocin|intarvenous and intramusculer 10 IU oxytocin
1620903|NCT02080078|Drug|Theophylline|
1620904|NCT02080078|Drug|Erlotinib|
1620905|NCT02080065|Procedure|living donor liver transplantation|
1620906|NCT02080052|Device|Robot-assisted prostate biopsy|
1620907|NCT02080039|Device|Electrical Stimulation|
1620908|NCT02080026|Biological|CPS-immunization|Subjects will receive four 'immunizations' with bites from 15 Plasmodium infected mosquitoes during each immunization, while taking chloroquine prophylaxis.
1620909|NCT02080026|Biological|Controlled Human Malaria Infection|Subjects will receive bites from 5 Anopheles mosquitoes infected with Plasmodium falciparum, NF54 strain.
1620910|NCT02080026|Drug|chloroquine|Registered for prophylaxis against infection with Plasmodium falciparum and the treatment of acute infections.
1620911|NCT02080026|Drug|atovaquone/proguanil|"Registered for use as an antimalarial agent for the treatment of acute infections with Plasmodium falciparum.
One tablet contains: atovaquone 250 mg, proguanil(hydrochloride) 100 mg"
1620912|NCT02080013|Other|radiofrequency|ClosureFAST
1620913|NCT02080000|Other|Optimisation of V-V timing using R wave on surface ECG|
1620914|NCT02080000|Other|Standard V-V timing settings|
2010984|NCT02751112|Biological|Predictor' kit|Realization of the Predictor' kit on the blood of donor of HSC, in the frame of a graft, to predict a aGvH reaction on recipient patient.
2010985|NCT02749968|Drug|Liposomal bupivacaine|1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
1620917|NCT02079974|Drug|Pravastatin|20 mg pravastatin sodium daily for 3 months
1620918|NCT02079961|Dietary Supplement|Micronutrient-fortified yoghurt|A iron-fortified yogurt targeted to children 24-59 months old will be provided through the logistics of an existing value chain, to see if in return this can enhance the reliability of producers supply within this value chain.
1620919|NCT02079961|Behavioral|BCC|"Behavior Change Campaign (BCC)
A behavior change campaign will be conducted during all the duration of the intervention to increase knowledge about good infant feeding practices and health."
1620920|NCT02079948|Drug|Methotrexate + Folic Acid|"Participants in the methotrexate + folic acid condition will have a
Blood draw at each monthly visit
Cognitive performance testing to assess memory performance
Physical function testing to assess walking speed and measure muscle endurance
Pain assessment testing to assess the presence and location of daily pain
Self-reported function and quality of life to measure disability and mobility limitations, and
Depression assessment testing to assess participants' level of depression."
1620921|NCT02079948|Drug|Placebo + Folic Acid|"Participants in the placebo + folic acid condition will have a
Blood draw at each monthly visit
Cognitive performance testing to assess memory performance
Physical function testing to assess walking speed and measure muscle endurance
Pain assessment testing to assess the presence and location of daily pain
Self-reported function and quality of life to measure disability and mobility limitations, and
Depression assessment testing to assess participants' level of depression"
1620922|NCT02079948|Procedure|Functional MRI Experimental Tasks|Participants who are randomly assigned to the fMRI scan wil receive their study drugs at the the Baseline fMRI visit. Participants who are randomly assigned to the fMRI will also attend complete their last visit at the 6 month period.
1620923|NCT02079948|Procedure|Muscle Biopsy|Participants who are randomly assigned to the muscle biopsy assessment of the study will receive their study drugs at the Baseline muscle biopsy visit. Participants who are randomly assigned to the muscle biopsy portion of the study will also complete their last visit at the 6 month period.
1620924|NCT02079935|Behavioral|Cognitive Behaviour Therapy|Following group-modified protocol for cognitive behavioral therapy, CBT, first described by Fairburn 2008, modified by Modum Bad, Norway.
1620925|NCT02079935|Behavioral|Physical Activity and Dietary Therapy|Guided physical activity and dietary therapy, to (re-)introduce a more healthy lifestyle and help stabilizing a healthy weight. A detailed manual will be published.
1620926|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
1620927|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
1620928|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
1620929|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
1620930|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
1620931|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
1620932|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
1620933|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days.
1620934|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
1620935|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
1621290|NCT02077231|Drug|carbomer eye gel|use one drop in the eye
2010986|NCT02749968|Drug|0.9% sodium chloride|1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position
2010987|NCT02748057|Drug|Ezetimibe|
2010988|NCT02748057|Drug|Rosuvastatin|
1620936|NCT02079922|Drug|PF-06678552|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
1620937|NCT02079922|Drug|Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution either once daily (QD), every 12 hours (Q12H), or every 8 hours (Q8H) for 14 days.
1620938|NCT02079909|Drug|T-817MA-H|224 mg or 448 mg T-817 MA once daily
1620939|NCT02079909|Drug|T-817MA-L|224 mg T-817 MA once daily
1620940|NCT02079909|Drug|Placebo|Placebo
1620941|NCT02079896|Drug|Lexaptepid pegol (NOX-H94)|anti-hepcidin L-RNA-aptamer (Spiegelmer)
1620942|NCT02079896|Drug|Placebo|
2010989|NCT02748161|Procedure|DEB-TACE|Transarterial chemoembolization with doxorubicin-eluting beads.
2010990|NCT02748278|Procedure|Transvaginal ultrasound-guided oocyte retrieval|Transvaginal ultrasound-guided oocyte retrieval will be performed 34-36 hours after hCG injection.
2010991|NCT02748278|Procedure|Embryo transfer|One or two embryos will be replaced on day 2-5 after oocyte retrieval.
2010992|NCT02746419|Device|Vessix|Renal denervation using radio-ablation
2010993|NCT02745769|Drug|Ramucirumab|Administered IV
1620948|NCT02079844|Drug|Roflumilast|Roflumilast tablets
1620949|NCT02079844|Drug|Placebo|Roflumilast placebo-matching tablets
1620950|NCT02079844|Drug|Second generation antipsychotic|Second Generation Antipsychotic (SGA) medication for standard of care therapy will be sourced and managed locally by the site.
2010994|NCT02745769|Drug|Merestinib|Administered orally
2010995|NCT02745769|Drug|Abemaciclib|Administered orally
2010996|NCT02745119|Drug|Lampalizumab|Lampalizumab 10 mg will be administered every 4 or 6 weeks according to the frequency given during participation in the parent study.
1620954|NCT02079818|Device|Penumbra Ruby Coil System|The Penumbra Ruby™ Coil is a new generation of detachable coils developed by Penumbra Inc. This coil system is specifically designed for the occlusion of aneurysms and vessels that is equivalent to standard platinum coils. This system consists of: an implantable Coil attached to a Detachment Pusher as well as a Detachment Handle. The Detachment Pusher is comprised of a shaft with a radiopaque positioning marker, a Distal Detachment Tip, and a pull wire. The Detachment Handle is used to detach the Coil Implant from the Detachment Pusher. The Penumbra Ruby Coil is designed for endovascular embolization in the peripheral vasculature. Intended users for this device are physicians who have received appropriate training in interventional radiology and endovascular intervention.
1620955|NCT02079805|Drug|Azilsartan|Azilsartan tablets
1620956|NCT02079805|Drug|Telmisartan|Telmisartan tablets
1620957|NCT02079792|Procedure|Lying Head Back Position|Subjects randomized to the LHB position will be instructed to lay supine on the clinical table, with their head hanging over the edge of the bed as far as possible without discomfort.
1620958|NCT02079792|Procedure|Head Down and Forward Position|Subjects randomized to the HDF position will be instructed to kneel down, placing the top of their head on the ground and forehead close to the knees with the nostrils facing upwards.
1620959|NCT02079779|Other|Robotic-assisted therapy|The robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient performance (i.e. quality of movements).
1620960|NCT02079779|Other|Classical therapy|Conventional therapy will be performed by therapists specialized in neuro-rehabilitation
1620961|NCT02079766|Drug|florbetapir F 18|
1620962|NCT02079766|Drug|18F-AV-1451|
1620963|NCT02079753|Device|Inogen|single pulse dose concentrator (Inogen One G2 portable. Inogen) device for 24 hours
1620964|NCT02079753|Device|Combination system of a portable and a stationary device.|"Combination system of a portable and a stationary device (reservoir of liquid oxygen Liberator 30, Caire and a liquid Stroller oxygen pack Caire for patients using previously liquid oxygen, or a VisionAire5 Airsep stationary concentrator and an Inogen One G2 portable Inogen concentrator for patients using previously concentrators)"
1620965|NCT02079740|Other|Laboratory Biomarker Analysis|Correlative studies
1620966|NCT02079740|Biological|Navitoclax|Given PO
1620967|NCT02079740|Other|Pharmacological Study|Correlative studies
1620968|NCT02079740|Drug|Trametinib|Given PO
1620969|NCT02079727|Drug|chondroitin sulfate|
1620970|NCT02079727|Drug|celecoxib|
1620971|NCT02079727|Drug|placebo|
1620972|NCT02079701|Biological|23-valent pneumococcal vaccine|randomization, based upon a random-number (block design) double-blind enrollment sequence. 1:1 ratio.
1620973|NCT02079701|Biological|Placebo|
1620974|NCT02079688|Drug|SB011, 2 % (Water/Oil/Water) emulsion of hgd40|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).
Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.
Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
2010997|NCT02744534|Drug|FACBC PET-CT Scan|"One hour prior to scanning, participants will drink one glass (450 ml) of oral contrast to allow for better pictures of abdomen and pelvic organs. The participants will have their temperature taken before and after the injection of the FACBC. Blood pressure and pulse will be taken every 15 minutes during the PET scan.
Participants will lie on a scanning bed and the bed will move slowly through the PET/CT scanner. This portion usually takes about one minute. Following this the FACBC will by administered by an intravenous (IV) catheter and the PET scan portion of the exam will begin. The table moves slowly through the scanner and many sets of PET-CT images are produced. When the imaging is complete, the scanner will send the results to a computer. The computer then generates a number of images that will be reviewed by a specially trained radiologist."
1620975|NCT02079688|Drug|Multiple W/O/W formulation, active ingredient-free vehicle|"Treatment will be performed BID on 14 consecutive days and one single last application at the site on Day 15 (29 applications in total).
Two preferably disseminated and contralateral, comparable lesional treatment areas of approximately 50 cm2 each and located on arms, legs, chest, stomach or neck will be chosen. All patients will perform treatment with both formulation SB011 containing 2% hgd40 and the active ingredient-free vehicle. Comparison of the IMPs will be performed intraindividually.
Approximately 5 mg/cm2 (250 μl) of SB011 (2% hgd40) and the vehicle will be applied to the respective treatment areas. The time between the two applications should include min. 8 hours and max. 16 hours. Patients compliance will be controlled by weighing of the IMPs at each visit. On day 1 the application of the IMPs will be demonstrated to the patients at the clinical site. The first treatment as well as the morning treatment on Days 3, 5, 8, 12, and 15 will be carried out at the clinical site"
1620976|NCT02079675|Drug|SKI3246 Low Dose|SKI3246 Low Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
1620977|NCT02079675|Drug|SKI3246 High Dose|SKI3246 High Dose will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
1620978|NCT02079675|Drug|Placebo|SKI3246 Placebo will be taken for a 4-week duration (28 days) as 4 capsules a day: two capsules in the morning and two capsule in the evening
1620979|NCT02079662|Behavioral|Aerobic Activity|30-60 minutes of moderate-to-vigorous intensity aerobic activity up to 6 days/week.
1620980|NCT02079662|Behavioral|Dietician Counseling|Weekly meeting with dietician during radiotherapy to learn how to shop and cook during radiation therapy.
1620981|NCT02079662|Behavioral|Yoga|Yoga based biweekly sessions with a mind-body instructor for about an hour.
1620982|NCT02079662|Behavioral|Cognitive Behavior Therapy|Participants meet with a psychologist once a week during radiation treatment, during which time they take part in cognitive behavioral therapy to help support behavior changes.
1620983|NCT02079662|Behavioral|Smoking Cessation Counseling|Smoking cessation treatment offered if participant smokes.
1620984|NCT02079662|Behavioral|Questionnaires|Questionnaire completion at baseline, at end of radiation treatment, and at 3, 6, 12, 18, and 24 months after the end of radiation treatment, and then once a year for up to 3 years. This should take about 60-80 minutes.
1620985|NCT02079662|Other|Saliva Samples|Saliva samples collected 4 times a day for 3 days in a row at baseline and in follow up.
1620986|NCT02079662|Behavioral|Dietary Assessment|Within 2 weeks of consent date, participant contacted by telephone on 3 random days for a dietary recall.
1620987|NCT02079662|Procedure|Blood Samples|At baseline and follow ups, blood drawn to measure hormones and immune system responses.
1620988|NCT02079649|Drug|AL-53817 Ophthalmic Solution, 0.1%|
1620989|NCT02079649|Drug|AL-78843 Ophthalmic Solution, 0.03%|
1620990|NCT02079649|Drug|Dexamethasone Ophthalmic Suspension, 0.1%|
1620991|NCT02079649|Drug|AL-53817 Vehicle|Inactive ingredients used for masking purposes
1620992|NCT02079636|Drug|Abemaciclib|Administered orally
1620993|NCT02079636|Drug|Pemetrexed|Administered IV
1620994|NCT02079636|Drug|Gemcitabine|Administered IV
1620995|NCT02079636|Drug|Ramucirumab|Administered IV
1620996|NCT02079636|Drug|LY3023414|Administered orally
1620997|NCT02079636|Drug|Pembrolizumab|Administered IV
1620998|NCT02079623|Procedure|Electroporation/ Nano knife treatment|
1620999|NCT02079623|Device|NanoKnife|
1621000|NCT02079610|Behavioral|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
1621001|NCT02079610|Behavioral|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories.
1621002|NCT02079571|Dietary Supplement|Coconut water|250 ml Coconut water for each subject
1621003|NCT02079571|Dietary Supplement|ginger tea|250 ml for each subject
1621006|NCT02079545|Drug|Sirukumab (IV infusion)|Participants will receive a single IV infusion of 100 mg sirukumab.
1621007|NCT02079545|Drug|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-U.
1621008|NCT02079545|Drug|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 50 mg sirukumab with PFS-AI.
1621009|NCT02079545|Drug|Sirukumab (SC injection with PFS-U)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-U.
1621010|NCT02079545|Drug|Sirukumab (SC injection with PFS-AI)|Participants will receive a single SC injection of 100 mg sirukumab with PFS-AI.
1621011|NCT02079532|Drug|rituximab [MabThera]|1 g was given by intravenous infusion on Days 1 and 15
1621012|NCT02079519|Drug|Bevacizumab|Bevacizumab was provided as a concentrate in vials.
1621013|NCT02079506|Drug|Candesartan|
1621014|NCT02079506|Drug|Rosuvastatin|
1621016|NCT02079480|Drug|BMS-986090|
1621017|NCT02079480|Drug|Placebo matching with BMS-986090|
1621018|NCT02079480|Drug|Keyhole limpet hemocyanin|
1621019|NCT02079467|Procedure|Unrestricted rehabilitation|Standard care range of motion restrictions will not be used
1621020|NCT02079467|Procedure|Standard rehabilitation|Standard care range of motion restrictions will remain in place
1621021|NCT02079428|Other|No interventions|
1621022|NCT02079415|Other|Prevention of complications in infants of diabetic mothers|strict glycemic control in diabetic pregnancies
1621023|NCT02079402|Drug|Isotonic crystalloids|
1621162|NCT02078284|Biological|LSP|
1621163|NCT02078271|Other|FBDG group|The group received food based dietary guidelines for complementary feeding
1621164|NCT02078271|Other|Stimulation|The group received psychosocial stimulation
1621024|NCT02079389|Device|Lap+Lus|"In the standard arm (Lap) the conditions at the abdomen is only assessed by laparoscopy immediately prior to the resection. In the intervention arm the intra-abdominal conditions are also assessed by laparoscopy, but then supplemented with a laparoscopic ultrasound examination of the primary tumor, liver and retroperitoneum.
All patients are given an CT scan of the abdomen after 3 months."
1621025|NCT02079376|Device|DIAMOND System|DIAMOND Implantable Pulse Generator (IPG)
1621026|NCT02079363|Other|No interventions, this is an observational study|
1621027|NCT02079350|Drug|%6 HES and %4 Gelofusine|
1621028|NCT02079337|Drug|Rocuronium|
1621029|NCT02079337|Drug|sugammadex|
1621030|NCT02079337|Drug|placebo|
1621031|NCT02079324|Biological|GX-051|intratumoral injection
1621032|NCT02079311|Device|Active self warming blanket|BARRIER® EasyWarm is a disposable self-warming blanket that produces heat via an exothermic chemical reaction initiated by exposure to air, resulting from the oxidation of iron.
1621033|NCT02079311|Device|Forced air warming device|Forced air warming is a temperature management unit, where heated air is used to warm subjects through convection.
1621034|NCT02079298|Drug|Treatment with fluconazole.|
1621035|NCT02079298|Drug|2. Treatment with both fluconazole and Ibuprofen.|
1621036|NCT02079298|Drug|3. Treatment with ibuprofen.|
1621037|NCT02079298|Other|4. No treatment with either fluconazole nor ibuprofen.|
1621038|NCT02079285|Procedure|EUS-FNA|
1621039|NCT02079272|Other|Helical tomotherapy for breast cancer|"At baseline, before helical tomotherapy is performed, for each included woman will have:
measures of biomarkers of cardiac injury based on blood samples (including CRP, NT-Pro BNP, …, microparticles and miRNA)
cardiologic examination including echocardiography for measurement of strain and strain rate
a CT coronary angiogram for measurement of coronary plaque indexes
Helical tomotherapy will be performed for all women included in the cohort.
At the end of tomotherapy, follow-up will include:
measures of biomarkers: at the end of radiotherapy, 6 months and 24 months after radiotherapy
cardiologic examinations including a echocardiography 6 and 24 months after radiotherapy
A CT coronary angiogram 24 months after radiotherapy"
1621040|NCT02079259|Procedure|Ultrafiltration|
1621041|NCT02079246|Drug|Idalopirdine (Lu AE58054) 60 mg (or 30 mg)|once daily, encapsulated tablets, orally
1621042|NCT02079246|Drug|Memantine|Memantine immediate-release (IR) 20 mg/day (recommended target dose), once or twice daily, tables for oral use; or memantine extended-release (XR) 28 mg/day (recommended target dose), once daily, capsules for oral use; or patient's individualised maintenance dose
1621043|NCT02079233|Drug|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 7 consecutive days.
1621044|NCT02079220|Drug|Arm A|"Capecitabine
Oxaliplatin
Ziv-aflibercept"
1621045|NCT02079220|Drug|Arm B|Capecitabine Oxaliplatin Ziv-aflibercept
1621046|NCT02079207|Biological|NBP606|13-valent peumococcal conjugate vaccine(13vPnC)
1621047|NCT02079207|Biological|Prodiax-23|23-valent peumococcal polysaccharide vaccine(23vPS)
1621048|NCT02079194|Drug|P2Y12 antagonist monotherapy|
1621049|NCT02079194|Drug|aspirin plus P2Y12 antagonist|
1621050|NCT02079181|Radiation|fluorine F 18 d-FMAU|Given IV
1621051|NCT02079181|Procedure|positron emission tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
1621052|NCT02079181|Procedure|computed tomography|Undergo fluorine F 18 d-FMAU PET/CT scan
1621053|NCT02079168|Drug|RXI-109|
1621054|NCT02079168|Drug|Placebo|
1621055|NCT02079155|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
1621056|NCT02079155|Procedure|robot-assisted laparoscopic surgery|Undergo R-LESS RP
1621057|NCT02079155|Other|laboratory biomarker analysis|Correlative studies
1621058|NCT02079155|Other|quality-of-life assessment|Ancillary studies
1621059|NCT02079155|Other|questionnaire administration|Ancillary studies
1621060|NCT02079142|Behavioral|High Intensity Strategy: Train-the-trainer|"Trainers in the high intensity condition will attend two separate workshops at Washington University in St. Louis designed to teach participants to conduct IPT and then to train IPT.
Following participation in the first, two-day workshop, each trainer will return to their site and be encouraged to treat at least two cases with eating disorders or depression, audio recording each session.
Trainers will then return to Washington University to be trained in how to train their other staff members in IPT."
1621061|NCT02079142|Behavioral|Low Intensity Strategy: Expert Consultation|We will provide a two-day workshop on IPT at each site randomized to this condition to train therapists to use IPT for the treatment of Eating Disorders and depresion.
1621062|NCT02079116|Other|60 grams of fat plus water solution|"A solution composed by 60 grams of fat and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:
300 mL final volume of the solution.
Time of oral ingestion inferior than 2 minutes.
60 minutes before the radiopharmaceutical injection.
12 hours fasting minimum."
1621063|NCT02079116|Other|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:
300 mL final volume of the solution.
Time of oral ingestion inferior than 2 minutes.
30 minutes before the radiopharmaceutical injection.
12 hours fasting minimum."
1621064|NCT02079103|Device|Virtual Reality|During a 4 weeks period the patients will be offered 4-5 Virtual reality training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The Virtual reality training will be supervised by a physical or an occupational therapist. Virtual reality gaming parameters are adapted according to improving arm motor function.
1621065|NCT02079103|Behavioral|Conventional arm training|During a 4 weeks period the patients will be offered 4-5 supervised self-training sessions weekly of 45-60 minutes duration in addition to other rehabilitation. The training will be task-related and supervised by a physical or an occupational therapist. Exercises increase in difficulty according to improving arm motor function.
1621068|NCT02079077|Drug|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg. oral daily for two months
1621069|NCT02079077|Drug|Hydroxychloroquine (HCQ)|Hydroxychloroquine (HCQ) 200 mg. oral, daily for two months.
1621072|NCT02079051|Behavioral|Moderate intensity weight loss|A calorie restricted diet based on estimates of total energy expenditure (TEE) obtained from the measured resting metabolic rate (RMR) during a wt stable period. TEE will be estimated by multiplying RMR by a factor of 1.1-1.3 to cover activity energy expenditure based on an assessment of physical activity levels at baseline using accelerometry. We will use the TEE to create an individualized dietary rx for each pt, subtracting up to 500 calories from the estimated TEE. To ensure micronutrient needs are being met, total calories will not be decreased below 1200 kcal per day, regardless of the estimated TEE. They will receive a standard exercise program that will be designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per week.
1621073|NCT02079051|Behavioral|High intensity medical weight loss|Placed on complete meal replacement (MR) using the OPTIFAST medical wt loss protocol. Pts will consume a min of 86 g of protein daily in 5-6 servings of MR. Min caloric intake will be 960 kcal/day with adjustments in intake made based on BMI and activity levels, holding the percent of calories from protein constant at 35%. The MRs provide 100% of daily recommended needs for micronutrients and will be supplied weekly at clinic visits by the study. Pts will begin to incorporate food into their routine beginning at week 13 with guidance from a dietitian. From weeks 13-26, caloric prescriptions will be between 1100 to 1600 kcal/day, using a combo of MRs and food. Will receive an exercise program designed to promote exercise energy expenditure of approximately 1200 kcal/week. We will prescribe resistance training for 2 days per week with a loading intensity of 60% of 1 rep max and volume of 3 sets at 8 reps per exercise. Aerobic training will be prescribed for 3 days per wk.
1621074|NCT02079038|Device|Totalis|
1621075|NCT02079038|Device|Sham|
1621076|NCT02079025|Device|High-resolution ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using ultra-high resolution ultrasound system
1621077|NCT02079025|Device|Standard ultrasound guided prostate biopsy|Ultrasound guided prostate biopsy using standard of care ultrasound system
1621078|NCT02079012|Behavioral|10-week walking program|
1621079|NCT02078986|Other|Whole Body Electromyostimulation|Supervised WB-EMS, 3 sessions in 2 weeks (1,5 sessions/week) for 14 weeks
1621080|NCT02078986|Other|High Intensity Resistance Exercise Training|Supervised High Intensity Resistance Exercise Training (HIT) 2-3 sessions/week for 14 weeks
1621081|NCT02078973|Drug|15 mg tolvaptan|15 mg pr day for 1 day
1621082|NCT02078973|Drug|30 mg tolvaptan|30 mg pr day for 1 day
1621083|NCT02078973|Drug|45 mg tolvaptan|45 mg pr day for 1 day
1621084|NCT02078973|Drug|Placebo|1 tablet Unikalk pr day for 1 day
1621085|NCT02078960|Drug|Omacetaxine mepesuccinate|3.5 mg omacetaxine mepesuccinate and 10 mg mannitol; The first dose of the day for cycle 1 will be administered at the investigational center. Subsequent doses (in prefilled syringes) may be administered on an outpatient basis after training takes place
1621086|NCT02078947|Behavioral|High Intensity Exercise|
1621087|NCT02078947|Behavioral|Moderate Continuous Exercise|
1621088|NCT02078947|Behavioral|Usual Care|
1621089|NCT02078934|Procedure|Endoscopic Gastric Plication|Evaluate the efficacy of endoscopic suturing for weight loss
1621090|NCT02078921|Drug|Sodium Nitrate|
1621091|NCT02078921|Drug|Placebo|
1621092|NCT02078908|Drug|Sodium nitrite, 40 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 40 micrograms/kg/hour
1621093|NCT02078908|Drug|Sodium nitrite, 120 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 120 micrograms/kg/hour
1621094|NCT02078908|Drug|Sodium nitrite, 240 micrograms/kg/hour|Continuous 2 hour infusion of sodium nitrite, 240 micrograms/kg/hour
1621095|NCT02078908|Drug|Placebo|Continuous 2 hour infusion of sodium chloride, 25 ml/hour
1621096|NCT02078895|Drug|Botox|Peri-Ureteral and Intradetrusor Injection of Botulinum Toxin Type A
1621097|NCT02078882|Biological|abatacept|125 mg subcutaneously each week for 24 weeks
1621098|NCT02078869|Drug|Progesterone in oil|
1621099|NCT02078869|Drug|vaginal progesterone suppositories|
1621100|NCT02078856|Drug|A3384|
1621101|NCT02078843|Drug|Gallium-68-DOTATATE PET/CT (index test)|Somatostatin-based imaging tracer
1621102|NCT02078843|Drug|Indium-111-Octreoscan (standard test)|Somatostatin-based imaging tracer
1621103|NCT02078830|Device|3M™ Tegaderm™ CHG I.V. Securement Dressing|Chlorhexidine gluconate (CHG) has been dissolved into a soft gel pad (3x4 cm) to provide a reservoir for consistent and continuous antimicrobial action over time. The gel pad is active on contact without requiring additional moisture. CHG migrates under the catheter to provide continuous circumferential antimicrobial protection at the insertion site. Soft and conformable, the gel pad moulds around the catheter and hub.
1621104|NCT02078830|Device|Placebo Comparator: 3M™ Tegaderm™ I.V. Advanced Dressing|Placebo Dressing with the same shape like the CHG-Dressing without CHG.
1621105|NCT02078817|Drug|Ketamine|IV infusions of 0.5mg/kg of Ketamine hydrochloride over a 40-minute infusion period. Participants will receive a total of 6 doses over a 2-week period.
1621106|NCT02078804|Procedure|Colonoscopy|20 000 individuals will be randomised to a primary screening colonoscopy and 60 000 to take a feces test for occult blood (FIT) and if positive (10% of individuals) they will be offered a follow-up colonoscopy.
1621107|NCT02078791|Drug|Botox infiltration|botox cervical infiltration in a group
1621108|NCT02078791|Behavioral|Psychology therapy|Psychology problem solving therapy lead by specialized nurses.
1621109|NCT02078791|Other|Botox infiltration & psychology therapy|Botox infiltration in cervical region and psychology problem solving therapy lead by specialized nurses.
1621110|NCT02078778|Device|CPAP|3 months of CPAP treatment
1621111|NCT02078752|Drug|PF-06647263|Part 1- PF-06647263 will be administered intravenously in either a 21 day cycle or weekly in cohorts of 2 or more patients starting at a dose of 0.015 mg/kg. Increases in dose will continue until MTD is determined.
1621112|NCT02078752|Drug|PF-06647263|Part 2- Patients with triple negative breast cancer will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
1621113|NCT02078739|Behavioral|Yoga Program at home using internet technology|
1621114|NCT02078726|Drug|Glucagon|glucagon (hormone produced by the body)
1621115|NCT02078726|Drug|Placebo|
1636837|NCT01956409|Drug|18F-FCH|
1621117|NCT02078700|Other|The early palliative care programme|The intervention consists of an early integration of a palliative care programme with the standard care performed by the oncologists-pneumologists that are following the cancer patients. The intervention will be delivered by the specialised Palliative Care Unit (PCU) of the hospital. Each patient meets the professionals of the PCU by 30 days by cancer diagnosis and at least monthly thereafter in the outpatint settings.
1621118|NCT02078687|Dietary Supplement|Enfamil HM fortifier, Mead Johnson|Enfamil was added to a small amount of mothers expressed milk and given in a bottle or with a small cup every day. Group 2 (HMF) received 5 packets each day for 4 month containing; 17.5 kcal, 1.375 g protein/ 5 packets
1621119|NCT02078687|Dietary Supplement|Enfalac Premature Formula, Mead Johnson Nutritionals|"Group 3 received Enfalac containing:
68 kcal, 2 g protein, 7.4 g carbohydrate, 3.5 g fat/ 100 ml"
1621120|NCT02078687|Dietary Supplement|Mothers own milk|Group 1 received mothers own milk without fortification
1621121|NCT02078674|Biological|Monovalent Avian Influenza VLP (H7N9)|
1621122|NCT02078674|Biological|Matrix-M1™ adjuvant|
1621123|NCT02078674|Biological|Placebo|
1621125|NCT02078648|Biological|SL-701; poly-ICLC (polyinosinic-polycytidylic acid stabilized with polylysine and carboxymethyl cellulose)|Within 20 minutes following the administration of the SL-701 emulsion, poly-ICLC should be administered as an IM injection in the same extremity (within 3 cm whenever possible) as was administered the SL-701 (deltoid muscle, unless contraindicated).
1621126|NCT02078648|Drug|Bevacizumab|Following the administration of SL-701 and poly-ICLC, bevacizumab will be administered IV at a dose of 10 mg/kg. Bevacizumab infusions may occur over 30, 60 or 90 minutes in accordance with institutional practices and guidelines.
1621127|NCT02078635|Behavioral|Portfolio Plus Diet|Foods on the Portfolio Plus plan will contribute 9 g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran bread and soups) and psyllium (cereal), 1 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese) and additional sources of plant proteins from pulses (eg. lentils, chickpeas, beans, etc); and 22.5 g almonds or equivalent of other nuts/1000 kcal and increase MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale)
1621128|NCT02078635|Behavioral|DASH-like (high fibre) dietary advice|Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce red meat consumption, choose low fat dairy foods and a control margarine
1621129|NCT02078622|Other|Respiratory Therapist Education and Case Management|Respiratory Therapists will conduct home care visits over a period of one-year at two-week intervals
1621130|NCT02078609|Drug|LGH447|LGH447 in patients with AML or MDS
1621131|NCT02078609|Drug|LGH447 + midostaurin|LGH447 + midostaurin in patients with AML
1621132|NCT02078596|Drug|Divalproex|Patients were randomly assigned to receive divalproex or placebo first, follow by the converse treatment, for six weeks each
1621133|NCT02078583|Drug|Fentanyl|
1621134|NCT02078583|Drug|Remifentanil|
1621135|NCT02078583|Drug|Normal saline|
1621136|NCT02078557|Drug|MK-8892|
1621137|NCT02078544|Other|Integrated Molecular Analysis|
1621138|NCT02078518|Other|Questionnaires|
1621139|NCT02078505|Behavioral|diet|Carbohydrate poor diet
1621140|NCT02078492|Drug|10 mg of Ketorolac|Patients will receive 10 mg of Ketorolac for pain control.
1621141|NCT02078492|Drug|15 mg of Ketorolac|Patients will receive 15mg of Ketorolac for pain control.
1621142|NCT02078492|Drug|30 mg of Ketorolac|Patients will receive 30mg of Ketorolac for pain control.
1621143|NCT02078479|Procedure|20 Hz, 10 s, 10 trains with inter-train interval 30 s 2000 pulses , intensity 80% over hand area daily for 10 consecutive days (5 days/week).|
1621144|NCT02078479|Procedure|sham rTMS (same parameters but with coil elevated and angled away from the head)every day for ten consecutive days (5 days/week).|
1621145|NCT02078466|Other|Assessment of functional ability and follow-up at home|Assessment of functional ability and follow-up at home
1621146|NCT02078453|Procedure|Dental treatment|Dental treatment of all dental needs present in the children related or not to the dental caries.
1621147|NCT02078440|Drug|Bromocriptine mesylate|Cycloset (bromocriptine mesylate quick release) 0.8 mg tablets, weight adjusted 1.6 mg- 4.8 mg
1621149|NCT02078388|Drug|Doxorubicin|
1621150|NCT02078375|Dietary Supplement|Protein|whey protein plus casein protein
1621151|NCT02078375|Dietary Supplement|Carbohydrate (Placebo)|The twice daily placebo will consist of a carbohydrate and a small amount of protein
1621152|NCT02078375|Other|Resistance Exercise Program|All participants will be enrolled in an individually supervised twice weekly (for 16 weeks) resistance exercise program
1621153|NCT02078349|Drug|KPT-330|Each dose will consist of KPT-330 (Selinexor) for oral administration on an mg/m2 basis, and should be based on the patient's actual calculated body surface area (BSA) at baseline. Patients with a BSA >2.5 m(2) will receive a dose based upon a 2.5 m(2) BSA.
1621154|NCT02078336|Drug|Midazolam Mylan|
1621155|NCT02078336|Drug|Lorazepam Mylan|
1621156|NCT02078336|Drug|Valium + Akineton + Dehydrobenzperidol + Atropine sulfate|
1621157|NCT02078323|Drug|Linaclotide|
1621158|NCT02078323|Drug|Placebo|
1621159|NCT02078310|Drug|ITI-007|
1621160|NCT02078310|Drug|Placebo|
1621161|NCT02078284|Biological|CPP|One unit of frozen CPP contains approximately 3.4 x 10^11 irradiated platelets and approximately 6% DMSO in sterile 0.9% sodium chloride solution (total volume of 20 mL to 35 mL) stored frozen at ≤ -65°C.
1621165|NCT02078271|Other|Combinded FBDG and stimulation|The group received both FBDG and psychosocial stimulation
1621166|NCT02078271|Other|Control group|
1621167|NCT02078258|Behavioral|dot-probe task|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition.
1621168|NCT02078245|Other|MRI|MRI
1621169|NCT02078232|Device|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.
randomization: puncture with either 22G needle or 19G flex needle"
1621170|NCT02078232|Device|puncture of head of pancreas|"puncture of head of pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control.
randomization: puncture with either 22G needle or 19G flex needle"
1621171|NCT02078219|Drug|RDEA3170|Oral Treatment
1621172|NCT02078219|Drug|Allopurinol|Oral Treatment
1621173|NCT02078219|Drug|Placebo|Oral Treatment
1621174|NCT02078206|Other|Neurocognitive stimulation|
1621175|NCT02078193|Drug|Belatacept|Patients will be converted from their MMF to Belatacept
1621176|NCT02078180|Drug|generic bupropion|We are comparing different formulations of bupropion that release this drug at different rates. The abbreviation IR75 means immediate release and the number is the dose in mg. The other abbreviations represent SR for sustained-release and XL for extended release, which release the drug slower than the IR formulation.
1621177|NCT02078167|Other|nutraceutical combination (red yeast rice, policosanols and berberine)|
1621178|NCT02078141|Drug|18F-deoxyglucose (FDG)|18F-deoxyglucose (FDG) One injection of 3.5 MBq/kg of 18FDG with a minimum of 220 MBq and a maximum of 400 MBq
1621179|NCT02078128|Dietary Supplement|oral beta-glucans|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
1621180|NCT02078128|Drug|oral sugar powder|30 mg/kg, oral every day until wound healed completes or unacceptable toxicity develops.
1621181|NCT02078102|Drug|Meloxicam|15 mg tablets of Meloxicam will be taken orally in the morning, with or without food.
1621182|NCT02078102|Drug|Filgrastim|Filgrastim will be subcutaneously injected in one or two sites at home.
1621183|NCT02078089|Drug|Morphine|Morphine will be given to patients as part of their standard care
1621184|NCT02078089|Drug|Oxcarbazepine|Can be taken with or without food at the same time as morphine. Morphine will be provided to patients free of charge.
1621185|NCT02078076|Device|Magnetic Resonance Cardiac Imaging (with Gadolinium)|
1621186|NCT02078063|Drug|Mepivacaine|10 ml of Mepivacaine for injection (Carbocain®) 10 mg/ml instilled into the uterus through a hydrosonography catheter
1621187|NCT02078063|Drug|Placebo|10 ml of NaCl 0.9 mg/ml instilled into the uterus through a hydrosonography catheter
1621188|NCT02078050|Other|Phrenic nerves magnetic stimulations|
1621189|NCT02078037|Device|Arctic Sun cooling device|The Arctic Sun® 5000 Temperature management systems (Bard Medical), a non- invasive, surface cooling technology that allows rapid and precise manipulation of core body temperature will be employed to maintain normothermia (normal temperature) in patients with ICH randomized to the treatment group.
1621190|NCT02078037|Other|Standard of Care|Patient will be given standard fever management (acetaminophen + cooling blanket at the discretion of the treating physician)
1621191|NCT02078024|Drug|IVM plus ALB|
1621192|NCT02078024|Drug|IVM|
1621193|NCT02078011|Device|High Intensity Focused Ultrasound|The Echopulse device is a computer driven system which uses ultrasound to guide a high intensity focused ultrasound beam to a targeted area (the fibroadenoma in the breast).
1621194|NCT02077998|Radiation|carbon C 14 oxaliplatin|Given IV
1621195|NCT02077998|Drug|oxaliplatin|Given IV
1621196|NCT02077998|Other|laboratory biomarker analysis|Correlative studies
1621197|NCT02077985|Behavioral|Sensory Adapted Dental Environment|See study arm description.
1621198|NCT02077972|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
1621199|NCT02077959|Drug|lenalidomide|Given PO
1621200|NCT02077959|Biological|pidilizumab|Given IV
1621201|NCT02077959|Other|pharmacological study|Correlative studies
1621202|NCT02077959|Other|laboratory biomarker analysis|Correlative studies
1621203|NCT02077946|Drug|liraglutide|No treatment given.
1621204|NCT02077946|Drug|sitagliptin|No treatment given.
1621205|NCT02077933|Drug|alpelisib|"alpelisib is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 8 of Cycle 1 in the dose escalation and Day 1 of Cycle 1 in the dose expansion.
In the doublet dose escalation, the alpelisib starting dose is 300 mg. The alpelisib dose may be escalated or de-escalated, as needed.
In the triplet dose escalation part, the alpelisib starting dose is one dose level lower of the MTD as determined during the doublet escalation. The alpelisib dose may be escalated or de-escalated, as needed.
In the doublet dose expansion and triplet dose expansion (patients assigned to alpelisib, everolimus and exemestane), alpelisib is administered at the recommended dose determined in the dose escalation.
In the triplet dose expansion (patients assigned to alpelisib and exemestane), alpelisib is administered at a dose of 250 mg daily."
1621206|NCT02077933|Drug|everolimus|"everolimus is administered orally once a day on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 1 of cycle 1 in both the dose escalation and dose expansion parts.
In the dose escalation part, the everolimus starting dose is 2,5 mg. In the dose expansion part, everolimus is administered at the recommended dose determined in the dose escalation."
1621207|NCT02077933|Drug|exemestane|exemestane is administered orally once a day on a continuous dose of 25 mg starting on Day 1 of Cycle 1 in both the dose escalation and dose expansion.
1621288|NCT02077244|Behavioral|Follow up talks|Nurse led follow up talks at the ward and one and two months later.
1621208|NCT02077920|Drug|Chlorhexidine|"SFDA Approval No. H21020748; Jinzhou Jiu Tai Pharmaceutical Co., Ltd., Liaoning, China
Drug administration and preparation:
Drug administration: oropharyngeal rinsing and suctioning of subglottic secretions
Drug preparation: 0.12% chlorhexidine solution prepared with distilled water that has been sterilized by autoclaving"
1621209|NCT02077920|Drug|0.9% sodium chloride injection|SFDA Approval No. H20045252; Shenyang Zhiying Pharmaceutical Co., Ltd., Liaoning, China
1621210|NCT02077920|Device|Endotracheal tube|Type 5-10115; size 7.0 mm, 7.5 mm, or 8.0 mm; purchased from Teleflex Medical (USA).
1621211|NCT02077920|Device|Fiber bronchoscope|For suctioning of subglottic secretions. BF-P30 (Olympus, Japan); BF-1T20 (Olympus, Japan); or FB-18BS (Pentax, Japan).
1621212|NCT02077907|Dietary Supplement|Super Cereal Plus (SC+)|
1621213|NCT02077907|Dietary Supplement|Super Cereal (SC), fortified oil, sugar|
1621214|NCT02077907|Dietary Supplement|Plumpy Sup|
1621215|NCT02077907|Dietary Supplement|Corn Soy Blend 14 (CSB14) and fortified oil|
1621216|NCT02077881|Drug|Nab-Paclitaxel|Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
1621217|NCT02077881|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest. Patients will continue until they experience disease progression or significant toxicity.
1621218|NCT02077881|Drug|Indoximod|"Indoximod will be administered in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth
Indoximod in the form of 200 mg capsules will be given (3, 5, and 6 capsules depending on the escalated dose). Indoximod should be taken with water by mouth one hour before breakfast and one hour prior to dinner. The medication should be taken twice daily for 28 days each cycle. Patients will continue until they experience disease progression or toxicity."
1621219|NCT02077868|Other|Usual Maintenance|Usual maintenance therapy according to local investigator's practice, e.g. treatment break, reduced treatment, continued treatment, and other
1621220|NCT02077868|Drug|MGN1703 treatment|MGN1703 will be used as single agent maintenance treatment
1621221|NCT02077842|Device|Nasal Continuous Positive Airway Pressure|Nasal continuous positive airway pressure at 10 cmH2O
1621222|NCT02077842|Device|Low Flow Oxygen|Low flow oxygen delivered via face mask at 8 litres per minute
1621223|NCT02077829|Behavioral|Illness Management and Recovery|Evidence-based practice given individually or in groups, weekly for 10-12 months.
1621224|NCT02077803|Drug|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
1621225|NCT02077803|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
1621226|NCT02077803|Drug|CANA/MET XR FDC, Formulation 1, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 1, to be taken orally.
1621227|NCT02077803|Drug|CANA/MET XR FDC, Formulation 2, 50 mg/1000 mg|Each tablet contains 50 mg of canagliflozin and 1000 mg of metformin HCl granulate, formulation 2, to be taken orally.
1957915|NCT02111213|Behavioral|Food Literacy and Nutrition|In a small group format, participants will participate in educational sessions to learn the components of a 'heart healthy' diet, and learn how food choices are influenced by individual, social and environmental factors.
1621229|NCT02077777|Drug|Mesalazine|Mesalazine cpr 800 mg t.i.d. for 3 months
1621230|NCT02077764|Procedure|OCT and coronary angiography|
1621231|NCT02077764|Procedure|Right heart cat.|
1621232|NCT02077764|Radiation|PET|
1621233|NCT02077764|Procedure|Echocardiography|
1621234|NCT02077764|Procedure|exercise test|
1621235|NCT02077764|Other|blood samples|
1621236|NCT02077751|Drug|biotin labelled RBCs|Autologous red blood cells are biotin labelled and transfused to the subject. Survival of these red blood cells is tracked through examination of blood samples until no biotin labelled red blood cells remain.
1621237|NCT02077738|Device|HFCWO (Hill-Rom Vest™ Airway Clearance System)|study subjects in the HFCWO group received HFCWO for 15 min twice a day for 5 days after extubation
1621238|NCT02077725|Other|interdisciplinary polypharmacy clinic visit|
1621239|NCT02077712|Drug|intranasal dexmedetomidine|1 or 2 ug/kg of intranasal dexmedetomidine
1621240|NCT02077699|Dietary Supplement|Lactobacillus casei DG|Lactobacillus casei DG (24 billion of live cells per pill) - 2 pills b.i.d. for 4 weeks
1621241|NCT02077686|Behavioral|Education - Diabetes and Travel|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Travel was created. The module covers specific and detailed aspects of the topic travel such as insulin adaption to intercontinental flights, dealing with exotic food, and treatment goals during vacation. With this module, a more comprehensive education of patients with specific interest is possible."
1621242|NCT02077660|Dietary Supplement|Four green tea bags per day for 12 weeks|Four green tea bags per day for 12 weeks
1621243|NCT02077660|Other|4 daily placebo tea bags for 12 weeks|4 daily placebo tea bags for 12 weeks
1621244|NCT02077634|Drug|abiraterone acetate + prednisone + LHRH-therapy|Hormon therapy will go on
1621245|NCT02077634|Drug|abiraterone acetate + prednisone|ormon therapy will be stopped
1621246|NCT02077621|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline
1621247|NCT02077621|Drug|Placebo|500 mL normal saline
1621248|NCT02077595|Device|transcutaneous electrical nerve stimulation, TENS|Then participants will receive stimulation for 20 minutes.
1621249|NCT02077569|Drug|AZD5363|Stage 1: AZD5363 480mg or placebo twice daily oral dosing for 4 and 1/2 days (9 doses) Stage 2: AZD5363 360mg or 240mg daily oral dosing for 4 and 1/2 days (9 doses)
1621250|NCT02077556|Drug|Everolimus|Everolimus: 1 mg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 3-8 ng/mL
1621251|NCT02077556|Drug|Mycophenolate mofetil|Mycophenolate mofetil: 10-15 mg/kg orally every 12 hours from post-operation day 1 (decrease 50% dose if white blood cell < 4000/mcL)
1621252|NCT02077556|Drug|Tacrolimus|Tacrolimus: 0.05-0.075 mg/kg orally every 12 hours from post-operation day 1 to achieve trough concentrations of 8-12 ng/mL
1621289|NCT02077231|Drug|Vitamin A|use one drop in the eye
1957916|NCT02111941|Other|Laboratory Biomarker Analysis|Correlative studies
1621253|NCT02077556|Drug|Methylprednisolone|Methylprednisolone: 50 mg iv every 6 hours on post-operation day 1, 40 mg iv every 6 hours on post-operation day 2, 30 mg iv every 6 hours on post-operation day 3, 20 mg iv every 6 hours on post-operation day 4, 20 mg iv every 8 hours on post-operation day 5, 20 mg iv every 12 hours on post-operation day 6, 20 mg iv on post-operation day 7
1621254|NCT02077556|Drug|Prednisolone|Prednisolone: 20 mg orally once a day from post-operation day 8 to post-operation week 4, then titrated gradually
1621255|NCT02077543|Device|Molecular and cellular tumor print Medical Device (ProTool)|Proteomic, genomic and cellular culture
1621256|NCT02077517|Procedure|Roux en Y Gastric Bypass|
1621257|NCT02077504|Other|MEG and MRI|CONDUCTOME
1621258|NCT02077491|Other|High-protein diet and resistance training|The intervention includes 1.7g/kg/day during admission combined with resistance training and a daily protein and energy supplement after discharge.
1621259|NCT02077478|Device|Remifentanil and propofol administration using TCI|
1621260|NCT02077478|Device|Remifentanil and propofol administration using MCI|
1621261|NCT02077465|Drug|GS-5745|400 mg GS-5745 administered intravenously
1621262|NCT02077465|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered intravenously
1621263|NCT02077452|Drug|HMS5552|
1621264|NCT02077452|Drug|Placebo|
1621265|NCT02077439|Device|Hand Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
1621266|NCT02077439|Device|Hand and Arm Robotic Training|Training for 20 sessions for one hour, 3-5 times per week.
1621267|NCT02077439|Other|Conventional therapy|Training for 20 sessions for one hour, 3-5 times per week.
1621268|NCT02077426|Other|Regional Specific Training (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
1621269|NCT02077413|Procedure|Healthy Muscle Group|Six subjects will be enrolled in this group. MRI measures will be performed at baseline and 48 hours post-exercise, when the largest amount of muscle damage is typically observed. They will be tested for maximum strength of the dorsiflexors and then undergo an eccentric exercise protocol for both lower legs on the Biodex with varying loads. Approximately two days after the exercise protocol, the participants will have another MRI of the lower legs to assess any change in T2 relaxation time as a construct of muscle edema/damage.
1621270|NCT02077413|Procedure|Stretch-Contract Pre-rehabilitation Group|"All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors. They will also receive the stretch-contract protocol on one leg consisting of the following: a 5 second passive stretch of the dorsiflexors, followed immediately by a 5 second active isometric contraction of the dorsiflexors, and a 5 second rest/relaxation period. This cycle will continue for a duration of ~5 minutes."
1621271|NCT02077413|Procedure|Stretch-Contract Control Group|All subjects will be tested initially with an MRI, blood work for creatine kinase levels (CK), subjective report of pain, range of motion (ROM) of the lower leg/ankle, and maximum strength of the dorsiflexors.
1621272|NCT02077413|Procedure|Muscle Atrophy|These subjects will undergo MRI and strength testing at baseline and will also be assessed for CK levels, pain report, and ROM. They will then receive an eccentric loading paradigm for the dorsiflexor muscles of the involved leg using an isokinetic dynamometer with varying loads. Approximately two days after the exercise protocol, follow-up assessment of MRI, CK levels, pain report, ROM, and strength will be done.
1621273|NCT02077400|Drug|Cephazolin|Cephazolin
1621274|NCT02077387|Behavioral|CHild Inhibitory Control (CHIC) Play|CHIC Play paradigm: Children will exposed to several play paradigms that enhance inhibitory control around snack foods. Children will receive the intervention in the preschool setting over a 3 week period.
1621275|NCT02077387|Behavioral|Attention control|Children will receive an equal amount of time with the RA, but focus on other healthy behaviors and not use inhibitory control skills training techniques
1621276|NCT02077374|Drug|IDN-6556|25 mg BID for 28 days
1621277|NCT02077374|Other|Placebo|Placebo BID for 28 Days
1621279|NCT02077348|Drug|Insulin withdrawal|Withdrawal of usual (evening) insulin, replaced by Insuman Rapid (10% of the amount of usual evening insulin) as a continuous IV- administration overnight until 8 o'clock on the study day.
1621280|NCT02077348|Drug|Norditropin|0,4 mg of GH administered at 7.05 A.M. on the study day.
1621281|NCT02077335|Radiation|HDR brachytherapy monotherapy|"Radiation therapy in the study consists of treatment with 2 separate interstitial HDR brachytherapy procedures with temporary interstitial catheters, each with one fraction of 13.5 Gray (Gy). Both procedures will be done in an identical manner. The 2 procedures will be separated by an interval of 7-14 days Treatments will be done with interstitial catheters inserted transperineally with transrectal ultrasound guidance under sterile conditions. Optimization of treatment plan will be done with Brachyvision software (Varian, Palo Alto CA) based on CT-scan imaging done post-implant. Optimization parameters will be the following:
Prostate :
V100 > 95%
V150 30-35%
V200 < 15%
D90 > 90% (12,15Gy)
Bladder
• V75 < 1cc
Rectum
• V75 < 1cc
Urethra
V125 = 0cc D10 < 120%
Treatments will be carried out with an Iridium-192 afterloader. Source and all catheters will be removed from the patient at the end of the procedure."
1621282|NCT02077322|Device|Silastic Spacer|The Silastic spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
1621283|NCT02077322|Device|Merocel Spacer|The Merocel spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 to 14 days following surgery.
1621284|NCT02077309|Drug|Linagliptin|
1621285|NCT02077309|Drug|Placebo|
1621286|NCT02077270|Procedure|electroacupuncture|Patients allocated to this arm will receive electro-acupuncture bilaterally on the following points which are considered relevant both for sedation and abdominal distention:LI4 (Hegu),ii. St36 (Zusanli), Sp6 (Sanyinjiao), St25 (Tianshuv),. Du20 (Baihui),
1621287|NCT02077257|Drug|Rosuvastatin|Rosuvastatin 20 mg/d compared to 10 mg/day
1621291|NCT02077218|Procedure|computed tomography|Undergo cardiac CT
1621292|NCT02077218|Other|cytology specimen collection procedure|Undergo collection of blood samples
1621293|NCT02077218|Other|laboratory biomarker analysis|Correlative studies
1621294|NCT02077218|Other|questionnaire administration|Ancillary studies
1621295|NCT02077205|Behavioral|Manualised Cognitive Behavioral Therapy|16 Sessions of Manualised Cognitive Behavioral Therapy in a Routine Care Setting
1621296|NCT02077192|Drug|Fostamatinib Disodium|Fostamatinib Disodium tablet 100 mg or 150 mg by mouth twice a day
1621297|NCT02077179|Behavioral|HIP Program|"The entirety of the HIP Program is delivered through an interactive mobile website.
The physical activity portion of the program consists of daily step counting, prescribed aerobic activity, structured strength and toning workouts, and daily stretching. The program was designed by a local trainer, specializing in postnatal exercise, to increase gradually in intensity, while encouraging a more active lifestyle. The program is designed to be completed at home with minimal equipment.
The nutrition portion of the program consists of 16 video tutorials developed by a local Registered Dietitian and weekly diet logs. The video tutorials cover all aspects of healthy eating, from the basics of Canada's Food Guide, to smart snacking, to eating healthy over the holidays."
1621301|NCT02077153|Behavioral|Reminiscence therapy|
1621302|NCT02077153|Behavioral|Active participation in group setting|
1957917|NCT02111941|Biological|Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine|Given ID
1621305|NCT02077114|Biological|Vaccine consisting of a peptide derived from the protein IDO|All patients will receive seven vaccines containing IDOlong
1621306|NCT02077101|Other|Questionnaire|
1621307|NCT02077101|Other|Interview|
1621308|NCT02077088|Other|galactooligosaccharide|addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides
1621309|NCT02077075|Behavioral|Web-based weight loss program|A 4-week web-based wellness program.
1621310|NCT02077075|Behavioral|On-line health coaching|A 4-week web-based wellness program with weekly personalized on-line health coaching.
1621311|NCT02077049|Device|serious games|"Execution of computer-based games that stimulate patient's mobility. The game is displayed on a Television (TV) screen and the patient's movements are detected by the sensors of the Kinect® camera, requiring therefore no game console.
The Fit Bit®, a mobility tracker device, is attached at the patient's belt the whole day and measure all the trips performed and stairs climbed.
This serious games program is instructed individually by experienced physiotherapists."
1621312|NCT02077049|Other|Conventional self-training|Participants perform conventional physical exercises that train their balance capabilities. There are instructed by experienced physiotherapists and are adapted to each patient's physical abilities. Detailed handouts are distributed to each participants.
1621313|NCT02077036|Device|Kinetic Oscillation Stimulation Device|
1621314|NCT02077036|Device|Kinetic Oscillation Stimulation Device in placebo mode|
1621315|NCT02077010|Drug|Milrinone|Milrinone is both the active comparison and experimental arm. The intervention arm will receive milrinone via inhalation of a nebulizer solution. The active comparison arm will receive milrinone via a continuous intravenous infusion.
1621316|NCT02076997|Drug|Methotrexate|"Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood."
1621317|NCT02076984|Procedure|Laparoscopic incisional or ventral hernia repair|
1621318|NCT02076958|Behavioral|Community Health Advisor education|
1621319|NCT02076945|Procedure|US-guided sciatic block at the popliteal crease (30 mL1:1 mixture of lidocaine 1% and bupivacaine 0.5%)|
1621320|NCT02076932|Behavioral|Spinning|After the baseline studies, the women will perform Spinning three times a week. Two of the sessions are performed on our location by trained instructors and the third training is self-training in a local fitness center where we provide free membership. All trainings are heart rate monitored.
1621321|NCT02076919|Drug|LHA510 Ophthalmic Suspension|Ophthalmic suspension in 4 concentration levels topically administered in Part 1 and Part 2
1621322|NCT02076919|Drug|LHA510 Vehicle|Inactive ingredients used for masking purposes
1621323|NCT02076906|Device|Magnetic Resonance High Intensity Focused Ultrasound|MR-High intensity focused ultrasound (HIFU) is an ultrasound based technology which allows for non-invasive thermal ablation of tumors under the guidance of MR thermography.
1621324|NCT02076893|Drug|gabapentin|The active comparator arm will receive gabapentin as per dosing specifics listed in the study arm description.
1621325|NCT02076893|Drug|Tramadol|Both study arms will receive tramadol per dosing details listed in the study arm descriptions.
1621326|NCT02076893|Drug|Ibuprofen|Both study arms will receive as needed (PRN) ibuprofen to take home.
1621327|NCT02076893|Drug|Placebo|Simple syrup suspension
1621328|NCT02076880|Other|Caloric restriction|"Caloric restriction of 1000 kcal per day compared to the usual food intake.
usual breakfast of the patient (possibly limited in quantity)
midday and evening meals from mixed and dehydrated meals, soups with protein and dairy desserts sweetened"
1621329|NCT02076880|Other|No caloric restriction|No change in eating habits to patients in this arm
1621330|NCT02076867|Behavioral|Intensive Short-Term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation and perpetuation of somatic symptoms. Treatment will be provided according to manualized recommendations. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and somatic presentation. The research protocol calls for the treatment duration to be initially agreed at 8 weeks and then reviewed. Treatment should be delivered as a maximum 20-session time-limited format. The first session is an extended 2-3 hour appointment; then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Treatment progress is reviewed, specifically at sessions 4 and 8 to clarify the goal and objectives of further sessions. Patients are informed of the maximum treatment length. Termination in fewer sessions is based upon agreement between therapist and patient.
1621375|NCT02076503|Procedure|histology (gold standard)|histopathological classification of co-located dissected lymph nodes
1621636|NCT02074384|Other|Clinician|Survey of clinicians after study visits
1621331|NCT02076867|Behavioral|Medical Care As Usual (MCAU)|This Medical Care As Usual (MCAU) was selected to control for both the role of emergency department care and family doctors care, as well as the passage of time and the natural emergence and reduction in symptoms before further intervention. Participants allocated to this group are advised that care will continue to be provided to them by the ED and they will be contacted with an appointment to see a therapist in 8 weeks should they so wish. They are advised to contact their family physician for routine care where necessary
1621332|NCT02076854|Behavioral|Text-Message Intervention|
1621333|NCT02076841|Device|interferon beta-1a|Administered as specified in the treatment arm
1621334|NCT02076828|Drug|Ferro Sanol® sp|The children with IDA that included in Fe-S (Ferro Sanol® sp.)(Group I) were treated with a therapeutic dose Ferro Sanol® sp as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
1621335|NCT02076828|Drug|Santafer® sp.|The children with IDA that included in Fe-OH-PM (Santafer® sp.)(Group II) were treated with a therapeutic dose Santafer® as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
1621336|NCT02076828|Drug|Ferro Zinc® sp|The children with IDA that included in Fe-Zn (Ferro Zinc® sp.)(Group III) were treated with a therapeutic dose Ferro Zinc® sp. as 6 mg/kg/day in the first 2 months and followed by maintenance treatment at a dosage of 2 mg/kg/day for the next 2 months.
1621337|NCT02076815|Drug|Anagrelide retard|Overencapsulated tablets or matched placebo, twice daily, 2-12 weeks titration to achieve stable platelet count, followed by 4 more weeks
1621338|NCT02076815|Drug|Thromboreductin|Overencapsulated capsule, twice daily, 2-12 weeks titration to achieve the stable platelet count, followed by 4 more weeks
1621339|NCT02076802|Behavioral|physical exercises|
1621340|NCT02076776|Behavioral|Repetitive Task Practice (RTP)|This group will preform arm and hand therapy.
1621341|NCT02076776|Behavioral|Voluntary cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
1621342|NCT02076776|Behavioral|Assisted cycling + RTP|This group will preform arm and hand therapy and cycle on a bike.
1621343|NCT02076750|Dietary Supplement|Vitamin D3 (cholecalciferol)|
1621344|NCT02076737|Device|Model-based iterative reconstruction (MB-IR VEOTM) on CT Discovery 750HD (GE Healthcare, Milwaukee, WI)|
1621345|NCT02076724|Device|Biological mesh|
1621346|NCT02076724|Device|Synthetic mesh|
1621347|NCT02076711|Drug|Metoprololsuccinate|
1621348|NCT02076711|Drug|Placebo|Placebo
1621349|NCT02076698|Procedure|AN-DBS|Electrode and one multichannel stimulator surgical time: 4 to 6 hours 3 visits of adjustment
1621350|NCT02076698|Drug|Usual treatment|usual treatment of epilepsy Vagus nerve stimulation: maintained
1621351|NCT02076685|Drug|isoniazid|dose adjustment according to the pharmacogenomic results
1621352|NCT02076672|Drug|Artichoke WPC|
1621353|NCT02076659|Drug|F8IL10|"Weekly administration of F8IL10 (from 6 to 600 μg/kg), starting from 6 μg/kg cohort 1. The cohort 10 represents the last dose-level of the study.
F8IL10 will be administered as subcutaneous (s.c.) injections. Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
1621354|NCT02076659|Drug|Methotrexate|"Methotrexate will be administered at a fixed dose of 10-15 mg on Day 1, orally (p.o.), subcutaneously (s.c.) or intramuscularly (i.m.).
Patients will receive 4 cycles of treatment unless there is unacceptable toxicity or withdrawal of consent."
1621355|NCT02076646|Drug|L19IL2 - Ph I|During phase I part of the study, increasing dose of L19IL2 from one cohort to the next will be performed in steps of 160,000 IU/kg starting at 480,000 IU/kg (i.e., 0.48; 0.64; 0.80 MioIU/kg until MTD is reached).
1621356|NCT02076646|Drug|L19IL2 at RD - Ph II|L19IL2 at RD will be administered to Arm 1 patients during phase II part of the study.
1621357|NCT02076646|Drug|DTIC|Dacarbazine: 1 hour intravenous infusion on day 1 of each 21-cycle at a dosage of 1000 mg/m2 (fixed dose).
1621358|NCT02076633|Drug|L19IL2+L19TNF|Patients will be treated with intratumoral injections of 10 MioIU L19IL2 and 312μg L19TNF once weekly for up to 4 weeks.
1621359|NCT02076620|Drug|L19TNFα|L19TNFα will be administered as a 2 hours i.v. infusion on days 1, 3, and 5 of each 3-week cycle.
1621360|NCT02076620|Drug|Doxorubicin|Doxorubicin will be administered as a 15 minutes i.v. infusion on day 1 of each 3-week cycle prior L19TNFα administration.
1621361|NCT02076607|Procedure|Arthrodesis|Posterior approach to toracolumbar spine fusion.
1621362|NCT02076607|Device|Brace|Toracolumbar imobilization
1621363|NCT02076594|Drug|Docetaxel|Powder for solution for infusion
1621364|NCT02076594|Drug|Epirubicin|Solution for infusion
1621365|NCT02076594|Drug|Oxaliplatin|Powder for solution for infusion
1621366|NCT02076594|Drug|Capecitabine|Film coated tablets
1621367|NCT02076568|Behavioral|Education - Diabetes and Partnership|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Partnership was created. The module covers specific and detailed aspects of the topic partnership such as dealing with hypoglycemia, late complications, and talking about diabetes in a relationship. With this module, a more comprehensive education of patients with specific interest in these topics is possible."
1621368|NCT02076555|Behavioral|Education - Diabetes and Social Issues|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Social Issues was created. The module covers specific and detailed aspects of the topic social issues such as driver licence, hypoglycemia when driving, and the pass for severly handicapped persons. With this module, a more comprehensive education of patients with specific interest is possible."
1621369|NCT02076542|Behavioral|Education - Diabetes and Sports|"Based on the treatment and education programme PRIMAS a problem-specific education module regarding Diabetes and Sports was created. The module covers specific and detailed aspects of the topic sports such as insulin reduction, hypoglycemia awareness during physical activity, and blood glucose values prior to physical activity. With this module, a more comprehensive education of patients with specific interest is possible."
1621370|NCT02076529|Drug|Ramosetron 0.3mg|
1621371|NCT02076529|Drug|Ramosetron 0.45mg|
1621372|NCT02076529|Drug|Ramosetron 0.6mg|
1621373|NCT02076516|Device|Drug-eluting stent: CORACTO®|
1621374|NCT02076503|Procedure|PET-MR 18f-FACBC|
1621637|NCT02074358|Drug|Apixaban|
1636838|NCT01956409|Drug|Magnevist|
1621376|NCT02076490|Other|Physical/Occupational therapy|At least 10 individual sessions over the clinical intervention period of 4 weeks followed by a 6 weeks self-management phase.
1621377|NCT02076477|Radiation|concurrent chemoradiotherapy|Radiation（image-guided radiotherapy）：（1）primary tumors≤3cm，Hypofractionated radiation therapy，accumulated dose BED ≥80Gy （central lung cancer），BED ≥100Gy（Peripheral lung cancer）.（2）primary tumors〉3cm，conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（3） regional lymph node:conventional fractionated radiotherapy，accumulated dose BED=60-66Gy/30-33f.（4） Brain metastases： whole brain radiation therapy，36Gy/12f,Intracranial metastases，48Gy/12f.（5） bone metastasis：36 Gy/12f.
1621378|NCT02076477|Drug|Docetaxel|Docetaxel:60mg/m2 d1,Given IV
1621379|NCT02076477|Drug|pemetrexed|pemetrexed: 500mg/m2 d1,Given IV
1621380|NCT02076477|Drug|Cisplatin|Cisplatin：25mg/m2 d1-3，Given IV
1621381|NCT02076464|Behavioral|StudentBodies - Eating Disorders|The intervention is a structured, cognitive-behavioral guided self-help program, derived from manual-based cognitive-behavioral therapy. The intervention targets the core eating disorder pathology (e.g., extreme dietary restraint, overvaluation of shape and weight, binge eating, compensatory behaviors), focusing on helping users develop regular eating patterns, self-control strategies, problem-solving skills, and relapse prevention tools for maintenance of behavior change. The program includes daily symptom checklists, journal exercises and activities, and an asynchronous moderated online discussion group.
1621382|NCT02076451|Drug|DS-8273a|DS-8273a will be administered as an intravenous (IV) solution. Subjects will receive DS-8273a on Day 1 of a 21 day cycle (once every 3 weeks
1621383|NCT02076438|Dietary Supplement|Probiotics|Randomized to receive probiotics or placebo
1621384|NCT02076425|Behavioral|PCIT-ED|
1621385|NCT02076412|Drug|Fostamatinib Disodium 100mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) over the course of 24 weeks.
1621386|NCT02076412|Drug|Placebo|Placebo tablet PO bid (morning and evening)
1621387|NCT02076412|Drug|Fostamatinib Disodium 150mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening) over the course of 24 weeks.
1621388|NCT02076399|Drug|Fostamatinib Disodium 100mg|Fostamatinib Disodium tablet 100 mg PO bid (morning and evening) over the course of 24 weeks.
1621389|NCT02076399|Drug|Placebo|Placebo tablet PO bid (morning and evening) over the course of 24 weeks
1621390|NCT02076399|Drug|Fostamatinib Disodium 150mg|Fostamatinib Disodium tablet 150 mg PO bid (morning and evening) over the course of 24 weeks.
2010998|NCT02744534|Procedure|Three-dimensional ultrasound-guided biopsy|"A lubricated rectal probe will be inserted and a local anesthetic to numb the prostate will be administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images. The probe connects to a computer that will link to the FACBC PET-CT scan results that the participant has already had performed. These combined images will provide a three-dimensional (3D) image from the FACBC PET-CT scan previously obtained as well as real-time, 2D ultrasound images, resulting in an improved visualization tool to target the biopsy needle to a suspicious lesion.
The needle tip position for each biopsy sample will be recorded on the real-time ultrasound images; this information allows the physician to either re-biopsy the same area for a follow-up examination or not to re-biopsy the same region if the original biopsy was negative.
This biopsy process is estimated to take about 10 minutes."
1621392|NCT02076373|Drug|recombinant human Erythropoietin|i.v. administration
1621393|NCT02076373|Drug|Placebo|i.v. administration
1621394|NCT02076360|Behavioral|Preoperative Video|Patients will watch preoperative instructional video
1621395|NCT02076347|Behavioral|Office visit intervention|Pharmacist communicates monitoring recommendations to physician through the electronic medical record prior to a scheduled patient office visit
1621396|NCT02076347|Behavioral|Electronic Message Intervention|Pharmacist communicates need for monitoring directly to patients and instructs them to obtain monitoring on their own time without need for an office visit with physician
1621397|NCT02076334|Other|Far Infrared Fabric|
1621398|NCT02076334|Other|Spandex|
1621399|NCT02076321|Drug|Acetaminophen|acetaminophen for pain control with dose and frequency of 10-15mg/kg/dose, Maximum dose 1000mg. Maximum amount per day: 75mg/kg (not to exceed 4g/day).
1621400|NCT02076321|Drug|Ibuprofen|ibuprofen for pain control with dose and frequency 4-10mg/kg/dose. Maximum of 40mg/kg/day, not to exceed 3,200mg/day. Maximum one-time dose of 800mg.
1621401|NCT02076308|Other|Electroacupuncture and physical therapy|real electroacupuncture
1621402|NCT02076308|Other|Sham-electroacupuncture and physical therapy|Sham electroacupuncture
1621403|NCT02076282|Other|1 MRI scan|"For healthy volunteers: 1 MRI scan without contrast
For patients: 1 MRI scan with contrast"
1621404|NCT02076269|Other|No Intervention|Patients are receiving no treatment in this study and there is no investigational product involved
1621405|NCT02076256|Behavioral|The helping relationships intervention program|
1621410|NCT02076217|Drug|Copper T-380 IUD|
1621411|NCT02076217|Drug|LNG IUD|
1621412|NCT02076217|Device|Contraceptive implant Nexplanon|
1621413|NCT02076217|Drug|Depo-Provera|
1621414|NCT02076204|Behavioral|Home visiting|MIHOPE-Strong Start will examine local programs that use either of two home visiting service models that have shown previous evidence of improving birth outcomes: Healthy Families America (HFA) and Nurse-Family Partnership (NFP). HFA and NFP provide disadvantaged expectant mothers with individualized in-home services, including assessment of prenatal and postnatal risks to child well-being; referrals to needed health care or social services; and direct education of parents by home visitors on such topics as healthy prenatal behaviors, parenting, and child development.
1621415|NCT02076191|Drug|Ruxolitinib|Ruxolitinib will be administered at doses of 5mg, 10mg, 15mg, or 25 mg taken orally every 12 hours throughout the treatment cycle.
1621443|NCT02075970|Drug|Biotinylated Red Blood Cells|Biotinylated red blood cells will be transfused to infants to determine red blood cell lifespan.
1621444|NCT02075944|Behavioral|High intensity aerobic exercise|
1621416|NCT02076191|Drug|Decitabine|Decitabine is administered intravenously at a dose of 20 mg/m2 daily for 5 days. Subsequent cycles of decitabine may be administered at 4 week intervals as clinically tolerated. Decitabine treatment may be deferred for up to 2 weeks to allow recovery from non-hematologic toxicity during the first 6 cycles and up to 2 weeks thereafter for hematologic toxicities as well. The first treatment cycle will last 35 days and will be the evaluable period for DLTs and RPTD determination for patients enrolled in the phase I portion only. Subsequent treatment cycles will be 4-6 weeks in duration as defined by decitabine administration.
1621421|NCT02076165|Behavioral|Behavioral treatment for insomnia-Group I|Participants will attend 5 individual sessions with a trained instructor.
1621422|NCT02076165|Behavioral|Behavioral treatment for insomnia-Group II|Participants will attend in 5 individual sessions with a trained instructor.
1621423|NCT02076152|Device|FMISO PET|
1621424|NCT02076152|Device|MRI|"MR scans will be performed with the same sequences and in the same order during each visit, including T1- and T2-weighted volumetric images, fluid attenuated inversion recovery (FLAIR), contrast agent enhanced T1-weighted permeability, diffusion tensor imaging (DTI), T2/T2*-weighted perfusion scans, and MR Spectroscopy. The Autoalign package available from the manufacturer will be used to achieve the same slice prescription in the same patient at each visit. Each MRI will last 60-75 minutes versus 45 minutes for standard brain MRIs."
1621425|NCT02076152|Drug|Bevacizumab|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
1621426|NCT02076152|Drug|CCNU|A cycle is defined as 28 days (1 month). The study duration is 12 months (12 cycles). Patients will be treated after 12 months or at the time of progression per discretion of their responsible physician.
1621427|NCT02076139|Dietary Supplement|Nyaditum resae® 10e4|
1621428|NCT02076139|Dietary Supplement|Nyaditum resae® 10e5|
1621429|NCT02076139|Other|Distilled water|
1621430|NCT02076113|Procedure|Ventral (Front) decompression with Fusion|Ventral decompression and fusion will be performed using a multi-level discectomy (including partial or single level corpectomy) with fusion and plating. Allograft will be used at each disc space and all compressive osteophytes will be removed using the operating microscope. Fixation will be performed with rigid, semi-constrained, or dynamic titanium plates to optimize fusion and minimize complications.
1621431|NCT02076113|Procedure|Dorsal (Back) Decompression with Fusion|Dorsal decompression and fusion will be performed using midline cervical laminectomy with the application of lateral mass screws and rods for rigid fixation. All surgeons will use local bone and allograft as needed to perform a lateral mass fusion, which typically will include one level rostral to the levels decompressed.
1621432|NCT02076113|Procedure|Dorsal (back) Laminoplasty|Laminoplasty will be performed using an open-door approach with the application of plates and screws at each treated level. Ceramic or allograft laminar spacers (surgeon's choice) can be used with plates and screws to expand the canal diameter.
1621433|NCT02076100|Drug|Ruzasvir|Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.
1621434|NCT02076087|Procedure|Liposuction/lipectomy|Subcutaneous adipose tissue will be obtained from liposuction/lipectomy to determine the types of immune cells
1621435|NCT02076074|Radiation|accelerated partial breast irradiation|Undergo HG-PBI
1621436|NCT02076022|Device|Enhanced Fat Grafting|"The stromal vascular fraction (SVF) cell suspension (device output) will be processed using the Tissue Genesis Cell Isolation System™
The Standard graft material and the stromal vascular fraction cells will be mixed and subsequently injected into the amputated stump at a concentration of 2.0 - 3.0 x 10 6 stromal vascular cells/ml of injected fat graft to each site. The volume of each injected fat graft will depend on the volume requirements for each injured extremity.
To manually combine the standard fat graft material and the SVF suspension (device output), each of the syringes will be connected via luer to luer lock. The contents of the lipoaspirate syringe are transferred to the SVF syringe and the cell suspension will be injected slowly back and forth between the two (2) syringes. The final 1 mL SVF-fat graft syringe is now considered cell-enriched and ready for injection into the subject."
1621437|NCT02076022|Procedure|Standard fat graft|Aspirated fat tissue will be processed as standard graft material. It will be divided into small aliquots and centrifuged in a sterile rotor (3000 rpm for 3 minutes/1200g), and top fluid oil layer from the fat tissue fractions were removed, and transferred into 1ml syringes and injected into the amputation stump. This graft preparation will be performed in the operating room. Standard fat graft material will serve as a control treatment and will be injected into limb using specialized injection cannulas
1621438|NCT02076009|Drug|Daratumumab|Daratumumab 16mg/kg will be administered as an intravenous (IV) infusion (into the vein) as per the following schedule: once a week during treatment cycles 1 and 2; every 2 weeks during treatment cycles 3 to 6; once only (on Day 1) during treatment cycles 7 onwards.
1621439|NCT02076009|Drug|Lenalidomide|Lenalidomide will be administered at a dose of 25 mg orally (by mouth) on Days 1 through 21 of each treatment cycle.
1621440|NCT02076009|Drug|Dexamethasone|Dexamethasone (or equivalent in accordance with local standards) will be administered as a total dose of 40 mg weekly (or 20 mg weekly for participants > 75 years old or with a body mass index < 8.5).
1621441|NCT02075983|Biological|GTU®-multiHIV B clade|The investigational HIV-1 vaccine GTU®-MultiHIV B clade encodes for a MultiHIV antigen (synthetic fusion protein built up by full-length polypeptides of Rev, Nef, Tat, p17 and p24 with more than 20 Th and CTL epitopes of protease, reverse transcriptase (RT) and gp160 regions of the HAN2 HIV-1 B clade.
1621442|NCT02075970|Drug|Epoetin Alpha|"Infant study 1: VLBW infant study subjects (weighing 1.0 to 1.5 kg at birth) who are otherwise receiving standard clinical care will be treated with Epoetin Alpha according to a dosing algorithm.
Infant study 2:
Dosing algorithm will be determined by results of Infant Study 1."
1621445|NCT02075944|Behavioral|Low intensity aerobic exercise|
1636922|NCT01955720|Drug|Placebo|
1621446|NCT02075931|Other|Physical activity feedback with group meetings|Physical activity feedback
1621447|NCT02075931|Other|Control|No intervention
1621448|NCT02075892|Dietary Supplement|Mushroom Blend|Scivation
1621449|NCT02075892|Dietary Supplement|Placebo|
1621450|NCT02075879|Behavioral|Nurse-led interviewing|Participants in experimental arm received regular face-to-face interviews during dialysis sessions conducted by the designated case managers every week for 6 weeks and biweekly for another 6 weeks.
1621451|NCT02075879|Other|Brief group exercise|Participants in this arm only participated in the brief in-center exercise training. They received usual care from the nurse without the interviews and mutual goals developed.
1621452|NCT02075840|Drug|Alectinib|Participants will receive alectinib 600 mg orally (four 150 mg capsules) BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
1621453|NCT02075840|Drug|Crizotinib|Participants will receive crizotinib 250 mg capsules orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
1621454|NCT02075827|Behavioral|Competitive video game|1 hour playing video game
1621455|NCT02075827|Behavioral|Little Big Planet|1 hour playing video game
1621456|NCT02075801|Other|Sealing of amalgam margin defects|Comparison between sealing of amalgam margins defects, replacement and non treated groups.
1621457|NCT02075801|Other|Sealing of amalgam margin defects|"A.Sealing of amalgam margin defects: were acid etched with 35% phosphoric acid for 15 seconds. A resin-based sealant (Clinpro Sealant, 3MESPE) was applied over the defective area. The sealant was polymerized with a photocuring unit (Curing Light 2500, 3M ESPE) for 40 seconds. Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.
B.Replacement Group: The clinician totally removed and replaces the defective restoration with a new amalgam (Tytin, Kerr Corporation, Orange, CA, USA). Rubber dam isolation was used for this procedure. All treatments were applied by the same clinician.
C.Control Group: The defective restorations did not receive any treatment."
1621458|NCT02075788|Other|Commercial white bread|
1621459|NCT02075788|Other|Corn based products (porridge etc.)|
1621460|NCT02075788|Other|Millet based products (porridge etc.)|
1621461|NCT02075762|Procedure|Transbronchial biopsy|
1621462|NCT02075762|Procedure|Cryoprobe biopsy|
1621463|NCT02075762|Procedure|VATS biopsy|
1621464|NCT02075749|Drug|Triamcinolone Acetonide|
1621465|NCT02075749|Drug|licorice mucoadhesive films|30 patients received licorice mucoadhesive films
1621466|NCT02075736|Procedure|KTP laser|
1621467|NCT02075736|Procedure|TUR-P|device
1621468|NCT02075723|Dietary Supplement|Overfeeding (130 % of energy requirements )|Overfeeding (130 % of energy requirements )
1621469|NCT02075723|Behavioral|Sleep restriction (4 hours per night)|Sleep restriction (4 hours per night)
1621470|NCT02075710|Other|High sugar/meal feed|Weight-maintaining diet relatively high in sugar fed as two large meals daily
1621471|NCT02075710|Other|High sugar/nibble|Weight-maintaining diet relatively high in sugar fed as 8 meals daily
1621472|NCT02075710|Other|High fat/meal feed|Weight-maintaining diet relatively high in fat fed as two large meals daily
1621473|NCT02075710|Other|High fat/nibble|Weight-maintaining diet relatively high in fat fed as 8 small meals daily
1621474|NCT02075710|Other|High sugar/ 3 meals a day|Weight-maintaining diet relatively high in sugar fed as 3 meals daily
1621475|NCT02075710|Other|High fat/ 3 meals a day|Weight-maintaining diet relatively high in fat fed as 3 meals daily
1621476|NCT02075684|Procedure|Renal Biopsy|
1621477|NCT02075671|Drug|Aminolevulinic acid topical solution 20%|Intervention used in the experimental arm only
1621478|NCT02075671|Device|Blu-U Light Therapy|Intervention used in experimental and sham arms
1621479|NCT02075671|Other|Placebo vehicle only|Intervention only includes the placebo vehicle solution
2010999|NCT02744534|Procedure|Standard transrectal ultrasound (TRUS) guided biopsy|A lubricated ultrasound probe of about 2.5 cm in diameter is gently inserted into the rectum and a local anesthetic to numb the prostate is administered. The ultrasound probe allows visualization of the prostate in two-dimensional (2D) images and allows for the placement of a biopsy needle that collects samples of the prostate. Usually, a total of 12 biopsy specimens are collected. The procedure takes about 20 minutes. This TRUS-guided biopsy is considered as the standard method for prostate cancer diagnosis.
1621482|NCT02075645|Other|Team training course|"A 1-day simulation-based team-training course. There will be 4 simulated resuscitation events. Simulation #1 will be the pre-course team performance and simulation #4 will be the post-course performance."
1621483|NCT02075632|Drug|Alclometasone dipropionate cream|Alclometasone dipropionate cream 0.05% (15 g)
1621484|NCT02075619|Drug|Amlodipine+Rosuvastatin|Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
1621485|NCT02075619|Drug|GSK3074477 FDC - 1|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
1621486|NCT02075619|Drug|GSK3074477 FDC - 2|GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
1621487|NCT02075606|Drug|lanreotide acetate|Somatuline Autogel injection 120mg for first 3 months then 120, 90 or 60 mg administered via the deep subcutaneous route every 28 days
1621488|NCT02075593|Drug|DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablets|The DTG 50 mg /ABC 600 mg /3TC 300 mg FDC tablet is a purple, oval, biconvex tablets. The tablet contains 52.6 mg DTG sodium which is equivalent to 50 mg DTG free acid, 702 mg ABC sulphate which is equivalent to 600 mg ABC and 300 mg 3TC.
1621489|NCT02075580|Behavioral|psychological support (interactive/cognitive strategies)|"cognitive/behavioural intervention (6 times starting from hospital admission, in 90 days; for arm of intervention)
metacognitive techniques (6 times starting from hospital admission, in 90 days; for arm of intervention)
psychoeducational intervention (6 times starting from hospital admission; for arm of intervention)
questionnaires: EORTC questionnaires and a written structured interview (3 times: hospital admission,15 days after surgical intervention, 90 days after intervention; in both arms)"
1621490|NCT02075567|Procedure|Experimental|
1621491|NCT02075554|Device|CALIBER|Expandable interbody spacer
1636923|NCT01955720|Drug|BI 655075|
1621492|NCT02075541|Biological|NTHi-10-AS01E|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1621493|NCT02075541|Drug|NaCl Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1621494|NCT02075528|Drug|Paliperidone ER|9 mg/d of paliperidone ER was administered during the first 2 weeks, after which the dose was adjusted clinically
1621495|NCT02075515|Biological|Herpes Zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
1621496|NCT02075502|Behavioral|Exercise therapy|The exercise therapy program with training, monitoring and coaching enhanced by community-based participatory research (CBPR) (TMC+) is a comprehensive approach to community-based walking exercise for improving PAD patient outcomes. The components of TMC+ are optimal training guidelines for patients (i.e., T), monitoring from both investigators and patient self-monitoring (i.e., M), coaching from investigators on how to improve patients' walking ability (i.e., C), and finally enhancements from CBPR practices (+).
1621497|NCT02075502|Procedure|lower extremity ET|catheter-based revascularization of peripheral arteries (background treatment part of standard clinical care at hospital)
1621498|NCT02075502|Procedure|peripheral open intervention|revascularization of lower extremities with open bypass surgery (background treatment part of standard clinical care at hospital)
2011000|NCT02744352|Drug|20ml bolus of 0.5% ropivicaine|Local anesthetic
2011001|NCT02744352|Drug|0.2% of ropivacaine at 8 milliliter/hour|Local anesthetic
1621501|NCT02075476|Procedure|Hemiarthroplasty|
1621502|NCT02075476|Procedure|reverse arthroplasty|
1621503|NCT02075463|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg or 25 mg of GSK1278863
1621504|NCT02075463|Drug|Placebo|Matching placebo tablet for GSK1278863
1621505|NCT02075450|Device|CPRcard|CPR Card in place during chest compressions to provide immediate visual feedback.
1621506|NCT02075450|Other|Just in Time Video|CPR Just in Time training video administered before the simulation case
1621507|NCT02075437|Behavioral|Feeling and Body Investigators with Functional Abdominal Pain|"Investigator's ten session intervention trains children to be Feeling and Body Investigators. Half of the sessions will be done in clinic and half at home via web-camera to facilitate generalization. During the treatment child/caregiver dyads will 1) gather body clues (Learn), 2) investigate (Experience: perform interoceptive mystery missions to explore a body sensation), 3) organize body clues (Contextualize: recall other context that evoke similar sensations), and 4) go on increasingly daring missions (Challenge: decrease avoidance and safety behaviors).
If successful, young children with FAP who complete the FBI early intervention will learn to experience changes in the viscera as fun and fascinating, rather than scary, and will develop new capacities for pain management, adaptive functioning, and emotion regulation."
1621508|NCT02075437|Behavioral|Treatment Strategies|"identify strategies with unique patterns of neural circuit maturation associated with early visceral pain on the gut-brain axis:
adapt acceptance-based behavioral strategies used to address psychopathology in older children to younger children;
incorporate caregivers as role models and facilitators based on attachment research."
1621509|NCT02075424|Other|salivary sampling by a biomnis swab|"Each call operator will have a series of salivary sampling taken when assigned to call reception, to the unit deployment station and to the assessment station.
Only one sampling will occur to doctors who are assigned to a single workstation.
Sampling will be taken every 15 minutes during one hour and half and one last sample will be taken 2 hours after the call.
To improve interpretation of the results, a series of control-samples will be taken among the call operators and doctors during a day off and not during a security break.
There will be 4x8 samples taken for each call operator and 2x8 samples per doctor.
They will also be frozen at a temperature of -4°C and sent to the laboratory of the CHR Metz Thionville."
1621510|NCT02075411|Drug|bupivacaine|"Adolescent males receive the single shot femoral and sciatic nerve blocks prior to ACL repair.
Males Single shot peripheral nerve block"
1621511|NCT02075411|Drug|bupivacaine|"Adolescent females receive the single shot femoral and sciatic nerve blocks prior to ACL repair.
Females Single shot peripheral nerve block"
1621512|NCT02075411|Device|continuous perineural infusion catheter|Adolescent males receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
1621513|NCT02075411|Device|continuous perineural infusion catheter|Adolescent females receive the continuous peripheral nerve block infusion catheter prior to ACL repair.
1621514|NCT02075385|Procedure|pre, during and pos-treatment swallowing exercises|Speech pathology therapy
1621515|NCT02075372|Other|Data registration|Patients diagnosed with the presence of one or more chronic total occlusions (CTOs) and who will receive treatment via percutaneous coronary intervention (PCI), which is standard medical practice for these types of lesions. This study will collect data on the patients' demographics, CTO characteristics, procedure and outcome. This will be done in the form of a registry
1621516|NCT02075333|Dietary Supplement|Ingestion of solution|Participants will ingest the solution
1621517|NCT02075333|Dietary Supplement|Rinising of solution|Participants rinse the solution in the oral cavity
2011002|NCT02744092|Drug|Rivaroxaban|Anticoagulation therapy.
1621638|NCT02074358|Drug|Cofact (4-Factor PCC)|
1621639|NCT02074358|Drug|Beriplex P/N (4-Factor PCC)|
2011003|NCT02744092|Drug|Apixaban|Anticoagulation therapy.
2011004|NCT02744092|Drug|Edoxaban|Anticoagulation therapy.
2011005|NCT02744092|Drug|Dabigatran|Anticoagulation therapy.
2011006|NCT02744092|Drug|Warfarin|Anticoagulation therapy.
2011007|NCT02744092|Drug|Dalteparin|Anticoagulation therapy.
2011008|NCT02744092|Drug|Enoxaparin|Anticoagulation therapy.
2011009|NCT02744092|Drug|Fondaparinux|Anticoagulation therapy.
2011010|NCT02743858|Other|Bilateral arm measurements|will be obtained using the Perometer (Model 350 NT Perometer, Per-System) circumferential arm measurements with elastic tape taken at 4-cm intervals from the wrist to the shoulder, and the L-Dex U400 (Impedimed, Brisbane, Australia) for bioimpedance measurements.
2011011|NCT02743858|Other|Body mass index (BMI)|Height and weight will be obtained for each patient at baseline and at each scheduled visit for the purpose of calculating BMI. BMI will be correlated with the presence of inflammatory biomarkers in the tissue, as well as with lymphedema development.
2011012|NCT02743858|Behavioral|Quality of Life Questionnaire|
2011013|NCT02743923|Drug|carboplatin|AUC 6
1621518|NCT02075320|Device|Stationary Digital Chest Tomosynthesis|"The study scan, s-DCT, will be performed within two weeks of his/her clinical evaluations by chest CT and CR. There cannot be any intervening therapies or procedures (i.e. biopsy or excision of lesions) done in between the SOC imaging and the s-DCT. In the event that CRs are not included in the SOC imaging or are unusable (outside of acceptable window or poor quality), the scout image acquired by CT will be used in place of a CR.
Images will be acquired by a trained radiologist technologist. The technologist will comfortably position the patient in the supine position on the imaging table. Then, all patients will have a breath held s-DCT scan in an anterior-posterior direction."
1621519|NCT02075307|Dietary Supplement|Blueberry Powder|
1621520|NCT02075307|Dietary Supplement|Placebo|
1621521|NCT02075294|Drug|Adefovir dipivoxil or Entecavir|"Adefovir tablet, 10mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines.
Entecavir tablet, 0.5mg, take orally, once per day, more than 3years, exact duration depend on specific conditions and guidelines"
1621522|NCT02075281|Biological|HM11260C|Glucagon-like peptide-1 analogue
1621523|NCT02075281|Biological|Placebo|
1621524|NCT02075268|Drug|prasugrel|prausugrel 10 or 30 mg will be administrated as single dose under overnight fast.
2011014|NCT02743923|Drug|paclitaxel|200mg/m2
2011015|NCT02743923|Drug|Bevacizumab|15 mg/kg
2011016|NCT02743923|Drug|Pemetrexed|500 mg/m2
1621528|NCT02075242|Drug|Mycophenolate Mofetil|experimental group receive Tacrolimus as a main immunosuppressants and assistant is My-rept capsule®(Mycophenolate Mofetil),
1621529|NCT02075242|Drug|Tacrolimus|control group receive same immunosuppressants except for My-rept capsule®(Mycophenolate Mofetil- investigational product
1621530|NCT02075229|Device|Cochlear implant|A cochlear implant consists of an implantable device that electrically stimulates surviving nerve fibers within the inner ear to produce perceptions of sound in patients with significant sensorineural hearing loss.. The implanted device is controlled by an external sound processor that converts acoustic sound signals into patterns of electrical stimulation that result in sound perception for the user.
1621531|NCT02075216|Procedure|Myoblast Transplantation|For each patient 4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope. The suspension will be injected in the area of the external sphincter and along the posterior urethra proximal to the verumontanum, aiming to attain visual occlusion of the urethral lumen.
1621532|NCT02075216|Biological|Neonatal Cystourethroscope Injection|4-7 Million cells per ml will be injected into 8 to 10 sites through a cystoscopic injection needle with a 10 mm long, 21 gauge needle connected to a 30 cm long plastic tube, using a 6.75Fr neonatal cystourethroscope.
2011017|NCT02743923|Drug|cisplatin|75 mg/m2
2011018|NCT02742038|Other|Fluoride varnish plus education|Biannual varnish every 6 month/ 24 months plus educational component
2011019|NCT02740491|Other|Remission Consultation|"At the end of adjuvant treatment (adjuvant chemotherapy and / or radiotherapy), the patient is seen by a referent oncologist and included in the study. A Remission consultation with a psychotherapist is then proposed and its purpose explained to the patient. The patient agrees or refuses take advantage of the Remission consultation; in case of refusal, the reasons are documented and further information is provided, thus giving the opportunity for the patient to benefit from further psychological counseling if desired.
If approval is given, the patient will be scheduled for the Remission consultation (duration 1 hour) . The latter includes a first phase evaluating the mental state of the patient, and then a proposal of individualized care if necessary and according to several methods, depending on the choice of the patient."
1621536|NCT02075190|Other|Computerized intervention|
1621537|NCT02075177|Drug|Fenretinide Lym-X-Sorb Oral Powder|Fenretinide Lym-X-Sorb 1500 mg/m2/day, daily for 7 days every 3 weeks
1621538|NCT02075177|Drug|Ketoconazole|Ketoconazole 6 mg/kg/day, daily for 7 days every 3 weeks.
1621539|NCT02075164|Dietary Supplement|Fructose|High oral Fructose challenge (150g per day for 56 days)
1621540|NCT02075164|Dietary Supplement|Glucose|Dietary Supplement: High oral Fructose challenge (167g per day for 56 days)
1621541|NCT02075151|Procedure|Bronchial Thermoplasty|Bronchial thermoplasty
1621542|NCT02075125|Drug|Prasugrel 60 mg|Patient administer prasugrel 60 mg as loading dose followed by 10 mg/day as maintenance dose.
1621543|NCT02075125|Drug|Ticagrelor 180 mg|Patients administer ticagrelor 180 mg as loading dose followed by 90 mg bid as maintenance dose.
1621544|NCT02075112|Drug|Soy isoflavone|Patients will receive genistein 150 mg daily for the duration of radiation treatment. If a patient is experiencing significant side effects attributable to genistein, the treating physician has the option to reduce genistein to 150 mg every other day.
1621545|NCT02075112|Radiation|Radiation|All patients will undergo computed tomography (CT) simulation with intravenous (IV) contrast unless medical contraindications to IV contrast exist. Gross disease will be treated to 70 Gy in 2 Gy/day.
1621546|NCT02075112|Drug|Cisplatin|Cisplatin chemotherapy 100 mg/m² on days 1, 22, and 43 of radiation treatment.
1621547|NCT02075099|Other|tensing exercises|Donors will do tensing exercises during blood donation
1621548|NCT02075099|Other|No tensing exercises|Donors will not do tensing exercises during blood donation - control arm
1621549|NCT02075086|Drug|Xelox or Xeliri Bevacizumab|Chemotherapy treatment
1621550|NCT02075073|Biological|SB3|
1621551|NCT02075073|Biological|EU sourced Herceptin®|
1621552|NCT02075073|Biological|US sourced Herceptin®|
1621553|NCT02075060|Procedure|IPOI (pre-operative)|
1621554|NCT02075060|Procedure|IPOP (post-operative)|
1621629|NCT02074423|Dietary Supplement|Placebo|Acute administration of 1 g PO (2 capsules of 500 mg)
1621630|NCT02074410|Drug|OMS643762|
2011020|NCT02738034|Other|Cogmed|The Cogmed is computer software designed to train visuospatial and audio-verbal working memory, and other functions associated with working memory: attention, focus and impulsiveness. It has three versions adapted to different age groups: Cogmed for younger children, about 4-7 years, which are not yet so familiar with numbers and letters; Cogmed for children over 7 years and adolescents; and Cogmed for youth and adults over 18 years. In this study we will use the version for youth and adults over 18 years.
2011021|NCT02734862|Drug|CD101|Intravenous antifungal therapy
2011022|NCT02734862|Drug|Caspofungin|Intravenous antifungal therapy
1621557|NCT02075034|Drug|rigosertib|Rigosertib will be supplied as soft gel capsules in strengths of 280 mg and 70 mg.
1621558|NCT02075021|Drug|Lenalidomide|
1621559|NCT02075021|Drug|nab-paclitaxel|
1621560|NCT02075008|Drug|QGE031|QGE031 120 mg/mL solution for subcutaneous injection
1621561|NCT02074995|Biological|BVS857|Group 1A&1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
1621562|NCT02074995|Other|placebo|Group 1B receive first dose as IV then remaining doses as SC. Groups 2, 3 and 4 receive only SC doses.
1621563|NCT02074982|Drug|AIN457 300 mg|
1621564|NCT02074982|Drug|ustekinumab 45/90 mg|
1621565|NCT02074982|Drug|placebo secukinumab|Placebo
1621566|NCT02074969|Device|Gamma Nail 3|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by Gamma Nail 3.
1621567|NCT02074969|Device|PFNA|Patients who have sustained an unstable pertrochanteric hip fracture are getting treated by PFNA.
1621568|NCT02074956|Biological|AERAS-404|AERAS-404 is comprised of the H4 antigen, a fusion protein of Mycobacterium tuberculosis antigens 85B and TB10.4; and IC31 adjuvant, a combination of a leucine-rich peptide and a synthetic oligonucleotide.
1621569|NCT02074956|Biological|Placebo|Sterile buffer containing 10 mmol Tris and 169 mmol of NaCl in 0.8 mL of aqueous solution. This is the identical buffer solution in which H4 and IC31 are formulated.
1621570|NCT02074943|Biological|PRP|PRP will be inject to half head. The other half will be injected with normal saline.
1621571|NCT02074930|Device|Microporation by P.L.E.A.S.E. Professional / Prick needle|
1621572|NCT02074917|Procedure|Anatomical ACL reconstruction|Anatomical anterior cruciate ligament reconstruction in the anteromedial or central tunnels positions.
1621575|NCT02074891|Drug|coformulated TDF/FTC|Daily oral dose of coformulated TDF/FTC
1621576|NCT02074878|Drug|Crixotinib 200 mg and Sunitinib Cohort 1|Crizotinib 200 mg, twice daily with Sunitinib 25.0 mg once a day
1621577|NCT02074878|Drug|Crixotinib 250 mg and Sunitinib Cohort 2|Crizotinib 250 mg, twice daily with Sunitinib 25.0 mg once a day
1621578|NCT02074878|Drug|Crizotinib & Sunitinib 37.5 mg Cohort 3|Crizotinib 250 mg, twice daily with Sunitinib 37.5 mg once a day
1621579|NCT02074865|Biological|biological samples|
1621580|NCT02074852|Other|Foley urethral catheter|
1621581|NCT02074839|Drug|AG-120|AG-120 administered continuously as a single agent dosed orally every day of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression, development of other unacceptable toxicity or hematopoietic stem cell transplant.
1621582|NCT02074813|Other|Inspiratory muscle training|Inspiratory muscle training
1621583|NCT02074800|Drug|CNTO 328 (Sp2/0-derived)|Participants will receive a single-dose of Sp2/0-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
1621584|NCT02074800|Drug|CNTO 328 (CHO-derived)|Participants will receive a single-dose of CHO-derived CNTO 328 intravenously (into the vein) either 1.4 or 2.8 mg/kg in Part 1 and 1.4 mg/kg in Part 2.
1621585|NCT02074800|Drug|Placebo|Participants will receive a single-dose of matching placebo intravenously in Part 1.
1621586|NCT02074787|Device|Thermography|Standard thermographic images
1621587|NCT02074787|Device|Laser Doppler|standard laser doppler analysis
1621588|NCT02074787|Device|Spectrophotometric Intracutaneous analysis|standard SIA scope imaging
1621589|NCT02074774|Device|Aeolus|Automated FiO2 regulator that responds to pulse oximetry measures
1621590|NCT02074774|Other|Manual control|Standard practice of manually titrating FiO2 as needed.
2011023|NCT02734862|Drug|Fluconazole|oral antifungal therapy
1621592|NCT02074735|Drug|Placebo|Inactive ingredient matching the active comparator in appearance
1621593|NCT02074735|Drug|Citicoline|Citicoline is an over-the-counter nutritional supplement that is used for neuroprotective effects. It is a naturally occurring neurochemical in the human body.
1621594|NCT02074709|Drug|Plain bupivacaine|"Intraoperative: TAP block with plain bupivacaine + Acetaminophen 1000 mg IV + Ketorolac 30 mg IV .
First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine.
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h,prn"
1621595|NCT02074709|Drug|Liposomal bupivacaine|"Group intraoperative: Wound infiltration with liposomal bupivacaine (Exparel) + IV acetaminophen 1000 mg IV + Ketorolac 30 mg IV
First 24-h Postoperative: Ketorolac 30 mg, IV 3 more doses, + acetaminophen 1000 mg 3 more doses, + IV-PCA morphine
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
1621596|NCT02074683|Procedure|Year A Pathway|Fat Grafting Operative Procedure followed by Standard of Care Follow-up.
1621597|NCT02074683|Procedure|Year B Pathway|Standard of Care Followed by Fat Grafting Operative Procedure
1621598|NCT02074670|Other|Treadmill gait training|Five days a week, 40 sessions of Kinesiotherapy (passive and active mobilizations, muscle lengthening), Body Weight Supported Treadmill Training, bicycle, manual therapy (with and without assistance of a mechanical device) and daily life activities training.
1621599|NCT02074657|Biological|Activated and expanded natural killer cells (NKAEs)|Activated and expanded natural killer cells (NKAEs) from haploidentical donor
1621631|NCT02074410|Drug|Placebo|
1621632|NCT02074397|Procedure|Distant extrafascial injection|
1621633|NCT02074397|Procedure|Subfascial injection|
1621634|NCT02074384|Device|Continuous Glucose Monitor|CGM device for measurement of interstitial glucose on a 24/7 continuous cycle.
1621635|NCT02074384|Device|Self Monitoring Blood Glucose|Participants will use their own SMBG device.
1638140|NCT01946477|Drug|Dexamethasone|
2011024|NCT02734862|Drug|intravenous placebo|normal saline
2011025|NCT02734862|Drug|oral placebo|microcrystalline cellulose
2011026|NCT02732821|Procedure|Gastric POEM|Patients will receive Per Oral Endoscopic Gastric Myotomy for Gastroparesis.
2011027|NCT02732964|Other|Pandora Music|Patients enrolled will be exposed to Pandora music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
1621600|NCT02074644|Procedure|Prostatic Arterial Embolization|"The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. Bead Block 300-500 or PVA 100+200 micra particles are slowly injected under fluoroscopic control until the end point is reached. Embolization is considered finished when there is near stasis in the prostatic vessels with interruption of the arterial flow and prostatic gland opacification checked in both oblique and AP views. Upon finishing the embolization of the left prostatic arteries, the right prostatic arteries are embolized in the same way."
1621601|NCT02074644|Procedure|Sham procedure|The prostatic arteries are selectively catheterized with a Progreat 2.7 microcatheter and an angiography is performed to confirm that the catheter is in the prostatic artery. The catheter is removed and no particles are injected.
1621604|NCT02074618|Other|Physical exercise.|Physical exercises were held three times a week on alternate days to hemodialysis sessions, with duration of 45 to 90 minute, supervised by a physiotherapist. In all the sessions the following measurements were performed: body weight and blood pressure, heart rate and peripheral oxygen saturation in the pre, during and post session. The exercises were: heating and stretching during 5 minutes, followed by aerobic physical exercise on treadmill and/or bike (about 30 minutes), muscle strengthening exercises (15 to 20 minutes), cooling and stretching (5 minutes). The time for aerobic and strengthening varied according to the tolerance of the patient. The resistance exercises have been conducted for the major muscle groups of the lower limbs.
1621605|NCT02074605|Biological|Interferon alpha|
1621606|NCT02074592|Behavioral|Self assessment of ultrasound fetal biometry images|self assessment of ultrasound fetal biometry images followed by automatically generated feedback
1621607|NCT02074592|Behavioral|assessment of ultrasound fetal biometry images by expert|assessment of ultrasound fetal biometry images by expert, followed by automatically generated feedback
1621608|NCT02074579|Drug|TU-100|15g daily, orally as 5g three times daily for 4 consecutive weeks
1621609|NCT02074579|Drug|Placebo|Matching placebo given 5g three times daily orally for 4 consecutive weeks
1621610|NCT02074566|Other|Cryoballoon ablation|PVI using cryoballoon
1621611|NCT02074553|Drug|Part 1 (Fasted): Treatment A|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment A (capsule formulation containing 50% SLS) on Day 1 of any of the four intervention periods in Part 1.
1621612|NCT02074553|Drug|Part 1 (Fasted): Treatment B|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment B (capsule formulation containing 25% SLS) on Day 1 of any of the four intervention periods in Part 1.
1621613|NCT02074553|Drug|Part 1 (Fasted): Treatment C|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment C (capsule formulation containing 12.5% SLS) on Day 1 of any of the four intervention periods in Part 1.
1621614|NCT02074553|Drug|Part 1 (Fasted): Treatment D|Participants following an overnight fast of at least 10 hours will receive 600 mg of alectinib orally as Treatment D (capsule formulation containing 3% SLS) on Day 1 of any of the four intervention periods in Part 1.
1621615|NCT02074553|Drug|Part 2 (Fed): Treatment A|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment A (capsule formulation containing 50% SLS) on Day 1 of any of the four intervention periods in Part 2.
1621616|NCT02074553|Drug|Part 2 (Fed): Treatment B|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment B (capsule formulation containing 25% SLS) on Day 1 of any of the four intervention periods in Part 2.
1621617|NCT02074553|Drug|Part 2 (Fed): Treatment C|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment C (capsule formulation containing 12.5% SLS) on Day 1 of any of the four intervention periods in Part 2.
1621618|NCT02074553|Drug|Part 2 (Fed): Treatment D|Participants following an overnight fast of at least 10 hours will eat a high-fat, high-calorie meal in 30 minutes or less and 30 minutes after the start of the meal will receive 600 mg of alectinib orally as Treatment D (capsule formulation containing 3% SLS) on Day 1 of any of the four intervention periods in Part 2.
1621619|NCT02074540|Other|Questionnaire|Questionnaire that is based on socio-demographic characteristics, Morisky's Four-Item Self-Reported Adherence Measure, Becker's Theory of Health Beliefs and Mishel's Theory of Uncertainty
1621620|NCT02074514|Drug|Sofosbuvir|400 mg tablet administered orally once daily
1621621|NCT02074514|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1621622|NCT02074501|Other|training capacity in caregivers|"The participants of the InCARE programme (intervention group) will receive, additionally, intervention based on: (i) empowering caregivers to put hands on caring, which will be the key-point of the pilot programme; (ii) training handling techniques: mobility, bathing, (un)dressing, transferring, positioning, eating and drinking using technical aids, after 1 week, 1 month and 3 months, post hospital discharge."
1621623|NCT02074488|Other|Balancing Act exercise curriculum|"Balance improvement exercise curriculum titled Balancing Act"
1621624|NCT02074488|Other|Informational Brochure|Informational Brochure on falls prevention
1621625|NCT02074475|Other|Control group|A group of no Monitoring patients from larger AoA study with no adequacy of anaesthesia monitoring
1621626|NCT02074436|Drug|EACA|EACA 1000 mg twice a day. Patients will receive platelet transfusion in case of grade ≥ 2 bleeding.
1621627|NCT02074436|Other|Platelet transfusion|Prophylactic platelet transfusion. Additional platelet transfusions will be administered in case of grade ≥ 2 bleeding.
1621628|NCT02074423|Dietary Supplement|MealShape cinnamon extract|Acute administration of 1 g PO (2 capsules of 500 mg)
1638141|NCT01946477|Drug|Daratumumab|
1621640|NCT02074358|Drug|Placebo (Saline solution)|
1621641|NCT02074345|Biological|TAK-816|TAK-816 intramuscular injection
1621642|NCT02074332|Behavioral|Physical activity guidance|Physical education class amelioration Additional physical activities for overweight&obese students Family physical activities Parent involvement
1621643|NCT02074332|Behavioral|Health education|Knowledge of obesity prevention and control
1621644|NCT02074319|Drug|Methotrexate|Treatment as usual or standard treatment for psychosis will be common in all arms
2011028|NCT02732964|Other|Mozart Music|Patients enrolled will be exposed to Mozart music for 30 minutes prior to their spinal anesthesia and cesarean delivery, and throughout their surgery.
2011029|NCT02733302|Behavioral|Hope theory|Adapted Physical Activity
1621647|NCT02074293|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
1621648|NCT02074293|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs.
1621649|NCT02074293|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
1621650|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
1621651|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox intramuscularly at Week 12, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
1621652|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Percent of Patients with Improved PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, Change from Baseline in Pain Intensity, Change from Baseline in CDSS (Cervical Dystonia Severity Scale).
1621653|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
1621654|NCT02074293|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
1621655|NCT02074293|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
1621656|NCT02074293|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
1621657|NCT02074293|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
1621658|NCT02074293|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
1621659|NCT02074293|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of improvement on the Physician Global Assessment Scale, and Change from Baseline in Pain Frequency, and Pain Intensity, as well as Cervical Dystonia Severity Scale (CDSS).
1621660|NCT02074293|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
1621661|NCT02074293|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
1621662|NCT02074280|Drug|rifaximin|Rifaximin is an antibiotic that is virtually non-absorbed after oral administration and exhibits broad spectrum antimicrobial activity against both aerobic and anaerobic gram-positive and gram-negative microorganisms within the gastrointestinal tract.
1621663|NCT02074267|Drug|Carbatin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.
The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
1621664|NCT02074267|Drug|Neurontin|"Carbatin® or Neurontin® is initiated at 100 mg at night and slowly titrated to 300~800 mg three times/day over 4 to 25 days.
The dose of Carbatin® or Neurontin® taken by each patient will amount to 100 to 2400 mg /day oral if the pain intensity reaches a VAS score ≧4. The maintenance dose of Carbatin® or Neurontin® will throughout for at least 14 days of the treatment period."
1621665|NCT02074241|Other|Expression analysis|Analysis of the expression of DNA repair genes (XPC, XPF, Brca1, Rad51,SNF5, etc.) in bladder cancer specimens.
1621666|NCT02074228|Drug|Methylphenidate (Concerta)|
1621667|NCT02074215|Other|Aerobic exercises|Aerobic exercises + dual task
1621668|NCT02074215|Other|Stretch exercise|Stretch exercise
1621669|NCT02074202|Drug|18F- fluorocholine|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan.
1621742|NCT02073747|Drug|Normal Saline|One hour inhaled normal saline
2011030|NCT02731820|Dietary Supplement|Potassium citrate|Kcitr 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
1621670|NCT02074202|Drug|18F- fluorodeoxyglucose|To compare the diagnostic efficacy of FCH PET scan to FDG PET scan
1621671|NCT02074189|Drug|Gemcitabine, Cisplatin|Gemcitabine 1000 mg/m2 iv,D1,D8,D15;cisplatin 70 mg/m2 iv,D2.With 4 cycles. Treatment begins between 1-5 weeks after radical operation (within 42 days is recommended)
1621672|NCT02074163|Drug|Gadolinium|Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients. Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs.
1621673|NCT02074163|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
1621674|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
1621675|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 12|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
1621676|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
1621677|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 24,|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
1621678|NCT02074163|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
1621679|NCT02074163|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 6, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
1621680|NCT02074163|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 12, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
1621681|NCT02074163|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 18, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
1621682|NCT02074163|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 24, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
1621683|NCT02074163|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox (onabotulinumtoxinA) subdermally at Week 30, in terms of Change in frequency of headache days, and Change in hrs of HA on HA days.
1621684|NCT02074163|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
1621685|NCT02074163|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
1621686|NCT02074150|Drug|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS intramuscularly with ASIS Device for 30 patients.
Total cumulative Persistent % of Gadolinium intramuscularly on MRI at 6 hrs, 12 hrs, and 24 hrs."
1621687|NCT02074150|Drug|Gadolinium|"Gadolinium .1cc/ diluted with .9ccNS subdermally with ASIS Device for 30 patients.
Total cumulative Persistent % of Gadolinium subdermally on MRI at 6 hrs, 12 hrs, and 24 hrs."
1621688|NCT02074150|Drug|Gadolinium|Relative Prolongation Ability Score or total Persistent % of Gadolinium subdermally over total Persistent % of Gadolinium intramuscularly on MRI.
1621689|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 6|Efficacy of Botox intramuscularly at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
1621690|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 12,|Efficacy of Botox intramuscularly at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
1621691|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 18|Efficacy of Botox intramuscularly at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
1621692|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 24|Efficacy of Botox intramuscularly at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
1621693|NCT02074150|Drug|Efficacy of Botox intramuscularly at Week 30|Efficacy of Botox intramuscularly at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
1621694|NCT02074150|Drug|Efficacy of Botox subdermally at Week 6|Efficacy of Botox subdermally at Week 6, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
1621695|NCT02074150|Drug|Efficacy of Botox subdermally at Week 12|Efficacy of Botox subdermally at Week 12, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
1621696|NCT02074150|Drug|Efficacy of Botox subdermally at Week 18|Efficacy of Botox subdermally at Week 18, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
1621697|NCT02074150|Drug|Efficacy of Botox subdermally at Week 24|Efficacy of Botox subdermally at Week 24, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
1621698|NCT02074150|Drug|Efficacy of Botox subdermally at Week 30|Efficacy of Botox subdermally at Week 30, in terms of Change from Baseline in PGAS, or improvement on the Physician Global Assessment Scale, and Change from Baseline in Elbow Ashworth, Change from Baseline in Wrist Ashworth, Change from Baseline in Finger Ashworth, and Change from Baseline in Thumb Ashworth.
1621699|NCT02074150|Drug|Adverse Reactions of Botox intramuscularly|Adverse Reactions of Botox (onabotulinumtoxinA) intramuscularly at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
1621700|NCT02074150|Drug|Adverse Reactions of Botox subdermally|Adverse Reactions of Botox (onabotulinumtoxinA) subdermally at Week 30, in number of Headache Migraine, Facial paresis, Eyelid ptosis, Bronchitis, Neck pain Musculoskeletal stiffness, Muscular weakness Myalgia, Musculoskeletal pain, Muscle spasms, Injection site pain, and Hypertension.
1621701|NCT02074137|Drug|CABAZITAXEL XRP6258|Pharmaceutical form:Solution Route of administration: Intravenous
1621702|NCT02074137|Drug|Prednisone|Pharmaceutical form:Tablet Route of administration: Oral
1621703|NCT02074137|Drug|Prednisolone|Pharmaceutical form:Tablet Route of administration: Oral
1621704|NCT02074098|Device|Macintosh laryngoscope|Direct Laryngoscope
1621705|NCT02074098|Device|Glidescope|Videolaryngoscope-1
1621706|NCT02074098|Device|Airwayscope|Videolaryngoscope-2
1621707|NCT02074072|Device|15 degree left-lateral tilt wedges|The wedges are made of aluminium
1621708|NCT02074072|Device|30 degree left-lateral tilt wedges|The wedges are made of aluminium
1621709|NCT02074059|Drug|Lucinactant for Inhalation|Lucinactant for Inhalation refers to the active investigational agent, lucinactant, in combination with the investigational delivery device (drug-device combination product)
1621710|NCT02074059|Device|nCPAP alone|nCPAP therapy
1621711|NCT02074046|Biological|cancer stem cell vaccine|
1621712|NCT02074020|Drug|Blisibimod|Administered via subcutaneous injection once per week
1621713|NCT02074020|Drug|Placebo|Administered via subcutaneous injection once per week
1621714|NCT02074007|Drug|AR01|drops administered as needed for pain
1621715|NCT02074007|Drug|Placebo Comparator|Glycerin ear drops (placebo) drops administered as needed for ear pain
1621716|NCT02073994|Drug|AG-120|AG-120 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Subjects may continue treatment with AG-120 until disease progression or development of other unacceptable toxicity
1621717|NCT02073968|Drug|Carboplatin|Given IV
1621718|NCT02073968|Procedure|Computed Tomography|Undergo PET-adjusted IMRT
1621719|NCT02073968|Radiation|Intensity-Modulated Radiation Therapy|Undergo PET-adjusted IMRT
1621720|NCT02073968|Drug|Paclitaxel|Given IV
1621721|NCT02073968|Procedure|Positron Emission Tomography|Undergo PET-adjusted IMRT
1621722|NCT02073968|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
2011031|NCT02731820|Dietary Supplement|Placebo|Excipients: 3.064 milligrams daily in two tablets by mouth (1.032 milligrams every 12 hours)
2011032|NCT02731820|Dietary Supplement|Vitamin D3|400 IU/die Vitamin D3 daily by mouth
1621725|NCT02073916|Drug|TDM1|•Drug: abraxane Intravenous repeating dose weekly
1621726|NCT02073916|Drug|Lapatinib|Oral repeating dose daily
1621727|NCT02073916|Drug|Abraxane|Intravenous repeating dose weekly
1621728|NCT02073903|Behavioral|Patient Survey|
1621729|NCT02073903|Behavioral|Provider Survey|
1621730|NCT02073851|Device|TriGuard™HDH|TriGuard™HDH Embolic Deflection Device in patients undergoing Transcatheter Aortic Valve Replacement (TAVR)
1621731|NCT02073838|Drug|Ribavirin|
1621732|NCT02073838|Drug|Vismodegib|
1621733|NCT02073838|Drug|Decitabine|
1621734|NCT02073825|Behavioral|Web Brief Intervention (WBI)|4-session WBI
1621735|NCT02073812|Drug|RPX7009 and RPX2014|The study is designed to enroll approximately 25 healthy subjects. The study will evaluate the plasma, epithelial lining fluid, and alveolar macrophage concentrations of Carbavance (RPX7009/RPX2014)
1621736|NCT02073799|Procedure|Laser prostatectomy (Photoselective vaporization of the prostate or Holmium laser enucleation of the prostate)|
1621737|NCT02073786|Device|Conventional lightwand intubation|Conventional lightwand intubation technique will perform during intubation
1621738|NCT02073786|Device|Rigid video stylet|Rigid video stylet will inserted through endotracheal tube before induction. After induction with propofol and remifentanil using TIVA infusion pump, rocuronium 0.6mg/kg were used to facilitate intubation. After 2minutes, board-certificated anesthesiologist perform intubation using Optiscope.
1621739|NCT02073773|Drug|Levodopa|"Levodopa 100mg with benserazide 25mg will be administered 3 hours prior to the start of the daily PT/OT session to maximize its pharmacokinetic window ie. blood plasma levels in the narrow window during which functional rewiring of neural circuits is thought to occur.
Levodopa at the lowest available dose (100mg P.O qd) has been shown to improve motor function of stroke patients and their corresponding quality of life. The treatment proposed can be incorporated into their daily rehabilitation routine. Early intervention (within 7-21 days of the infarct) raises the chance for neuroplasticity and improved recovery of their motor function in the short and long run. Levodopa has been proven to be safe to be used in stroke patients (Lancet. 2001 Sep 8;358(9284):787-90., Arch Phys Med Rehabil. 2008 Sep;89(9):1633-41.), however, the side effects of this medication may include nausea, unusual tiredness, dizziness, excessive watering of mouth."
1621740|NCT02073773|Other|Virtual Reality based therapy|The VR therapy session consists of the subject interacting with a computer-based program in which they guide an avatar to gather items by using flexion and extension gestures of the affected upper limb. VR therapy sessions will last for 15-30 minutes depending on the subject's tolerance and participation. For patients who are unable to overcome gravity fully, they can still participate in this therapy by resting their arm on a table.
2011033|NCT02731820|Dietary Supplement|Calcium carbonate|500 mg/die calcium carbonate daily by mouth
1621743|NCT02073747|Drug|Albuterol|One hour inhaled ten milligrams of albuterol
1621744|NCT02073734|Drug|Dexamethasone|Dexamethasone 8mg/IV
1621745|NCT02073734|Drug|Placebo|Placebo given IV
1621746|NCT02073721|Other|electrostimulation with exercises MAPs|this group will make the electrostimulation with exercises of the pelvic floor muscles with a focus on strengthening the pelvic floor muscles.the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
1621747|NCT02073721|Other|exercises MAPs|This group will focus exercises of the pelvic floor muscles with strengthening the muscles of the pelvic floor. the frequency will be 20 sessions, 2 times per week, lasting 30 minutes.
1621748|NCT02073695|Procedure|Operative procedure to fix proximal humeral|Operative fixation by the shoulder team at Torbay Hospital
1621749|NCT02073695|Device|Neutral Rotation Brace|Performed at the end of the surgical procedure at Torbay Hospital
1621750|NCT02073695|Other|Physiotherapy review|Physiotherapy review on day of surgery, and post-surgery at 6 weeks, 3 months and 1 year.
1621751|NCT02073695|Other|Functional outcome forms filled in|
1621752|NCT02073695|Other|Postal functional outcome scores|Sent to patient at 9 weeks post surgery
1621753|NCT02073695|Other|Post-operative Radiographs|Performed at 6 weeks and 3 months at shoulder clinic appointment at Torbay Hospital
2011034|NCT02731729|Drug|ipilimumab|
2011035|NCT02731729|Drug|nivolumab|
2011036|NCT02730377|Drug|liraglutide|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
1621757|NCT02073656|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
1621758|NCT02073656|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1621759|NCT02073630|Other|active cerebellar stimulation|
1621760|NCT02073630|Other|sham cerebellar stimulation|
1621761|NCT02073617|Radiation|Real-time 3-dimensional DynaCT|After coronary angiography is performed, a 6Fr pigtail catheter will be placed in the aorta and 40cc of 50% contrast media diluted normal saline will be delivered using standard automated injection during dynaCT cardiac image acquisition. Intravenous delivery of contrast as alternative.
1621762|NCT02073604|Other|Healthy volunteers|Morphological and functional brain MRI; transcranial magnetic stimulation
1621763|NCT02073604|Other|Congenital mirror movements|Morphological and functional brain MRI; transcranial magnetic stimulation
1621764|NCT02073591|Other|Ceradan Cream|
1621765|NCT02073591|Other|Ceradan Wash|
1621766|NCT02073578|Procedure|Peroral Endoscopic Myotomy (POEM)|Endoscopy myotomy for treatment of achalasia
1621767|NCT02073565|Device|OrbusNeich Combo stent™|The Combo Stent is composed of the OrbusNeich R stent™, with an abluminal coating of a bioabsorbable polymer matrix formulated with sirolimus for sustained release, and an anti-CD34 antibody cell capture coating on the luminal surface.
1621768|NCT02073565|Device|Everolimus Eluting Stent (EES)|Everolimus Eluting Stent (EES) (Xience V, Xience Prime, Xience Xpedition stents, Abbott Vascular/Abbott Vascular Japan). Xience Prime inherited the clinical result of Xience V and is a product that obtains efficiency essentially equal to Xience V.
1621769|NCT02073552|Drug|Polyethylene glycol 4000|- Polyethylene glycol 4000: 16 envelopes (70 g of powder each). It includes electrolytes and sodium sulfate. These substances make PEG metabolically inert, achieving a suitable osmotic balance, despite having a high molecular weight. The preparation passes along the gastrointestinal tract without causing net absorption of fluid or electrolytes. It is routinely used in clinical practice for bowel cleansing, before abdominal surgery, barium enema and other colorectal and genitourinary tract tests. Participants will divide the whole doses in 4 liters of water taking half the day before the examination starting at 20.00 h and the other half at 6.00 pm on the day of the examination.
1621770|NCT02073552|Drug|Macrogol 3350 plus ascorbic acid|- Macrogol 3350 plus ascorbic acid: 4 envelopes, 2 containing 112 g polyethylene glycol and electrolytes and 2 with 2 g of ascorbic acid. The properties of the polyethylene glycol are the same as those mentioned previously, while ascorbic acid generates an osmotic gradient potentiating the effect of polyethylene glycol. It is used routinely as a bowel prep. Participants will divide the doses in 2 liters of water taking half the day before (112 g of PEG and an 11 g of ascorbic acid) the examination at 20.00 h and the other half at 6.00 pm on the day of the examination
1621771|NCT02073539|Device|Stryker ST104-747|760 x 2110 mm, 228 kg, Stryker Co., Kalamazoo, Michigan, US
1621772|NCT02073539|Device|Shinchang SB-34p|, 850 x 2080 mm,Shinchang Co.,Busan,ROK
1621773|NCT02073526|Drug|Infliximab, adalimumab, certolizumab pegol|Patients are treated with the above mentioned drugs decided by clinicians
1621774|NCT02073513|Device|Kinesiotape plus thenar pressure (PPTG)|"In the kinesiotape plus thenar pressure (PPTG). Kinesiotape was applied to control the cortical thumb sign. In addition a piece of plastazote aiming to give thenar pressure was also applied.
The amount of pressure was regulated so that the child felt the pressure without being irritated and without restriction in grasping functions."
1621775|NCT02073513|Device|Taping Group (TG)|In the taping group (TG) kinesiotape was applied to control the cortical thumb sign.
1621776|NCT02073500|Other|Observational study.|"Analysis of metastatic tissue and blood specimens collected from patients with PSM undergoing CRS-HIPEC. CRS: Removal of all macroscopically detectable tumor.
HIPEC: Instillation of heated chemotherapy in the abdominal cavity to remove residual cancer disease."
1621777|NCT02073487|Drug|Trastuzumab Emtansine|trastuzumab emtansine [Kadcyla] Intravenous repeating dose every 3 weeks
1621778|NCT02073487|Drug|Trastuzumab|Trastuzumab (Herceptin) Intravenous repeating dose weekly
1621779|NCT02073487|Drug|Lapatinib|Lapatinib repeating dose taken orally every day for 6 weeks
1621780|NCT02073487|Drug|Abraxane|Abraxane repeating dose weekly IV for up to 12 weeks
1621781|NCT02073487|Drug|Paclitaxel|Paclitaxel IV repeating dose weekly for up to 12 weeks
1621782|NCT02073487|Drug|Pertuzumab|Pertuzumab repeating dose weekly IV for up to 12 weeks
2011037|NCT02730377|Drug|alpha-glucosidase inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
1621784|NCT02073461|Drug|CD1579 2.5%|
1621785|NCT02073461|Drug|CD1579 5%|
1621786|NCT02073461|Drug|Vehicle|
1621787|NCT02073448|Drug|GK530G|
1621790|NCT02073435|Behavioral|donor pain management/ Pre-operative OR Set-up|"The evidence-based donor pain management solution entails the following elements:Preoperative Assessment and Management (OSA assessment etc.); At the end of the case in OR (Local anesthetics etc.); Post operative Management (CO2 monitoring etc.)
Standardization and Optimization of the Pre-operative OR Set-up Process The four participating A2ALL Deux TCs will need to engage in additional review of the detailed assessment of the preoperative OR set-up process and will collaboratively design a standardized and optimized preoperative OR set-up solution to reduce the frequency of medical errors medical errors, resource wastage, and team burden and improve LDLT care (anticipated implementation February 2014)."
1621791|NCT02073422|Device|Fractional flow reserve|Guidewire-based index of coronary artery stenosis severity measured when coronary microvascular resistance is minimised by administration of a vasodilator drug.
1621792|NCT02073422|Other|Magnetic resonance imaging|Cardiac magnetic resonance imaging at 3.0 Tesla, including perfusion MRI at rest and during pharmacological stress with intravenous adenosine (140-210 ug/kg/min).
1621793|NCT02073396|Other|Global Thrombosis Test|Patients will undergo the Global Thrombosis Test, before and after stabilisation of their cardiac condition. Cardiac stabilisation will be provided by clinical cardiac teams, outside and independently from the study. The Global Thrombosis Test assesses thrombotic and thrombolytic status, by measuring the time of thrombus (occlusion time, OT), and time needed for lysis of the thrombus (lysis time, LT).
1621794|NCT02073383|Procedure|Axillary brachial plexus block|
1621795|NCT02073357|Procedure|Light general anaesthesia (BIS = 50)|
1621796|NCT02073357|Procedure|deep general anaesthesia (BIS = 35)|
1621797|NCT02073344|Procedure|Renal replacement therapy|intermittent hemodialysis or peritoneal dialysis
1621798|NCT02073344|Other|no intervention|no renal replacement therapy
1621799|NCT02073318|Other|Task-oriented balance training|4 weeks individualized task-oriented balance training, twice a week and 1 hour each session
1621800|NCT02073318|Other|Upper extremities exercise|"4 weeks upper extremities exercise in sitting position, twice a week and 1 hour each session
weeks"
1621801|NCT02073305|Other|No Sleep Apnea|No intervention
1621802|NCT02073305|Other|Sleep Apnea - untreated|No intervention
1621803|NCT02073305|Device|Sleep Apnea - treated|Sleep Apnea treatment by positive pression ventilation (CPAP/BIPAP) or sleep apnea oral appliance
1621804|NCT02073292|Procedure|c-RFA|
1621805|NCT02073292|Procedure|tRFA|
1621808|NCT02073266|Procedure|Macular hole surgery using a 25 G pars plana vitrectomy, ILM peeling, fluid-air exchange followed by air-gas exchange with SF6 or C3F8.|
1621809|NCT02073253|Other|Noninvasive ventilation|In the experimental phase with NIV ventilatory support with bilevel positive pressure was used for 30 minutes with the subject comfortably seated. The NIV (Vivo 40 Bi-Level, General Electric Company) was fitted to the face of volunteer through a face mask, was initially adopted an inspiratory pressure (IPAP) of 15 cm H2O and an expiratory pressure (PEEP) of 5 cmH2O, resulting in a variation in pressure of 10 cm H2O, where the IPAP would be increased, subject to the comfort of the patient until the patient reached a tidal volume of 6-8 ml / kg, not exceeding the maximum of 20 cmH2O for IPAP.
1621810|NCT02073240|Behavioral|Enhanced TB IC Package|"Facilities randomized to the intervention group will receive:
Skills-based training addressing the hierarchy of TB IC measures, how to conduct a facility TB IC /risk assessment; and development, implementation, and monitoring of an operational TB IC plan for the facility
Audits and Feedback of performance
A TB IC collaborative membership
A standardized unit-level daily checklist of critical IC activities"
1621811|NCT02073227|Drug|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
1621812|NCT02073227|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
1621813|NCT02073227|Drug|CANA/MET XR FDC, Formulation 1, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
1621814|NCT02073227|Drug|CANA/MET XR FDC, Formulation 2, 150 mg/1,000 mg|Each tablet contains 150 mg of canagliflozin and 1,000 mg of metformin HCl granulate formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
1621815|NCT02073214|Other|Probiotic|Standard treatment plus probiotic
1621816|NCT02073214|Other|Placebo|Standard treatment plus placebo
1621817|NCT02073201|Other|High-functioning older adults|Participants with a SPPB score ≥ 11 will be categorized as high-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
1621818|NCT02073201|Other|Lower-functioning older adults|Participants with a SPPB score ≤ 8 will be categorized as lower-functioning. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
1621819|NCT02073201|Other|Young adults|Participants between the 20 - 30 years of age. The following test will be performed: Health and Quality of Life questionnaires, Mobility Assessments, Accelerometry, Body Composition (DEXA scan), Strength assessments, Neuromuscular stimulation, and Magnetic resonance imaging (MRI).
1621820|NCT02073188|Device|iBGStar|
1621821|NCT02073188|Device|Traditional Glucometer|
1621822|NCT02073175|Drug|Motherwell|The interventions involves a dietary supplement called Motherwell, at current stage, to reduce the intensity of sadness in women vulnerable to sadness.
1621823|NCT02073162|Procedure|Major Abdominal Surgery|•All types of open or lap-assisted abdominal or pelvic surgery with an expected duration of at least 2 hours, and an expected hospital stay of at least 3 days (for example, oesophagectomy, gastrectomy, pancreatectomy, colectomy, aortic or aorto-femoral vascular surgery, nephrectomy, cystectomy, open prostatectomy, radical hysterectomy, and abdominal incisional hernia repair)
1621824|NCT02073149|Dietary Supplement|Low-dose iron as NaFeEDTA|Daily home fortification for 30 days with 3 mg iron as NaFeEDTA, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
1621876|NCT02072811|Drug|Consolidation, III HiDAraC cycle|"Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days
2-CdA 5 mg/m2 2h infusion iv on 1,3,5 days, 2h before Ara-C"
1621825|NCT02073149|Dietary Supplement|Conventional dose iron as ferrous salt|Daily home fortification for 30 days with 12.5 mg iron as encapsulated ferrous fumarate, vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
1621826|NCT02073149|Dietary Supplement|Placebo|Daily home fortification for 30 days with vitamin A (300 RE μg as retinyl palmitate) and 5 mg zinc (as gluconate)
1621827|NCT02073136|Other|Diet with phosphate containing additives|
1621828|NCT02073136|Other|Diet without phosphate containing additives|
1621829|NCT02073123|Drug|Indoximod|"Initial dose of 600mg BID by mouth with escalation planned to 1200mg BID by mouth
Dose escalation:
If 0 of the 3 subjects forming the first cohort experience RLT, 1200mg BID cohort will be enrolled
If 1 of the 3 subjects in any cohort experiences a RLT, then enrollment into that cohort will increase to a total of 6 subjects
If > 1 of the 3-6 subjects experience a RLT, then the MTD has been exceeded and further enrollment into the cohort will cease
If >1 subject at 600mg BID experiences a RLT, the dose will be de-escalated to 400mg BID. If >1 subject at this level experiences a RLT, one additional de-escalation to 200mg BID is allowed
Dosing cycles are 21 days in length during the combination immunotherapy component (first 4 cycles) and 28 days during indoximod monotherapy. Patients will continue until they experience disease progression or limiting toxicity
Phase 2 Treatment Plan (Cohort 2) Will receive fixed dose of indoximod determined in phase 1"
1621830|NCT02073123|Drug|Ipilimumab|Ipilimumab administered intravenously at 3 mg/kg every three weeks for a total of four doses.
1621831|NCT02073123|Drug|Nivolumab|Nivolumab administered intravenously at 3 mg/kg every three weeks
1621832|NCT02073123|Drug|Pembrolizumab|Pembrolizumab administered intravenously at 2 mg/kg every three weeks
1621833|NCT02073110|Device|Percutaneous Optical Biopsy (OCT and DRS)|
1621834|NCT02073097|Drug|carfilzomib|Given IV
1621835|NCT02073097|Biological|rituximab|Given IV
1621836|NCT02073097|Drug|cyclophosphamide|Given IV
1621837|NCT02073097|Drug|doxorubicin hydrochloride|Given IV
1621838|NCT02073097|Drug|vincristine sulfate|Given IV
1621839|NCT02073097|Drug|prednisone|Given PO
1621840|NCT02073097|Other|laboratory biomarker analysis|Correlative studies
1621841|NCT02073084|Drug|K-877 Low Dose|K-877 Low Dose
1621842|NCT02073084|Drug|Moxifloxacin|
1621843|NCT02073084|Other|Placebo|
1621844|NCT02073084|Drug|K-877 High Dose|K-877 High Dose
1621845|NCT02073071|Other|Preterm infant formula per standard of care|Commercially available preterm infant formula
1621846|NCT02073058|Device|No treatment|
1621847|NCT02073045|Other|educational intervention|Receive educational handouts
1621848|NCT02073045|Other|lymphedema survey|Ancillary studies
1621849|NCT02073032|Other|No intervention, only observation|
1621850|NCT02073019|Drug|BL-8040|
1621851|NCT02073019|Drug|Placebo|
1621852|NCT02073006|Dietary Supplement|Natural Fibre Supplement|Natural Fibre Supplement 2 doses per day for 4 weeks
1621853|NCT02072993|Drug|AZD1979|Single dose, oral solution administration
1621854|NCT02072993|Drug|Placebo to match|Single dose, oral solution administration
1621855|NCT02072980|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses
1621856|NCT02072967|Other|Ribomustin|Routine practice
1621857|NCT02072967|Other|rituximab|Routine practice
1621858|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|White to off-white, round, uncoated,unscored, flat-faced radius edge tablet. Debossed with A on one side and 17 on the other side
1621859|NCT02072954|Drug|Asenapine Sublingual Tablets 10 mg|"Round, white to off-white sublingual tablets, with 10 on one side within a circle"
1621860|NCT02072941|Behavioral|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning (ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
2011038|NCT02730377|Drug|DPP-4 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
1621862|NCT02072915|Procedure|Suction|
1621863|NCT02072889|Other|Neck Angle|Ultrasound guided measures of the neck of subjects undergoing cardiac surgery who need internal jugular vein cannulated
1621864|NCT02072863|Drug|Oprozomib|Study subjects will receive oprozomib administered orally.
1621865|NCT02072863|Drug|Melphalan|Study subjects will receive melphalan 9 mg/m2.
1621866|NCT02072863|Drug|Prednisone|Study subjects will receive prednisone 60 mg/m2.
1621867|NCT02072850|Device|Coronary pressure wire|Guidewire-based coronary pressure- and temperature recordings (coronary thermodilution) with and without hyperaemia induced by intravenous administration of adenosine (140 ug/kg/min) in patients with acute ST-elevation myocardial infarction treated by emergency PCI.
1621868|NCT02072850|Other|Magnetic resonance imaging of the heart|Cardiac magnetic resonance imaging (MRI) with gadolinium contrast imaging at baseline (~ day 2) and 6 months (all participants) and in 30 subjects at 4 time-points (< 12 hours, days 2, 7-10 and at 6 months).
2011039|NCT02730377|Drug|meglitinides|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
2011040|NCT02730377|Drug|SGLT-2 inhibitors|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
2011041|NCT02730377|Drug|sulphonylurea|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
1621872|NCT02072811|Drug|DAC|"DNR 60 mg/m2 0,5h infusion iv on 1-3 days
2-CdA 5 mg/m2 2h. infusion iv on 1-5 days
Ara-C 200 mg/m2 12h infusion iv 2h after end of infusion with 2CdA on 1-7 days"
1621873|NCT02072811|Drug|CLAG|"G-CSF 30MU sc, on 0-5 days
Mitoxantrone 10mg/m2 30 min infusion iv, on 1-3 days
Cladribine 5mg/m2 in 2h infusion iv, on 1-5 days
Ara-C 2000mg/m2 4h infusion iv, infusion start after 2h of Cladribine infusion end, on 1-5 day"
1621874|NCT02072811|Drug|Consolidation, I HAM cycle|"Ara-C 3g/m2; 3h infusion iv every 12h on 1,2,3 days
Mitoxantrone 10mg/m2; 0,5h infusion iv on 3,4,5 days"
1621875|NCT02072811|Drug|II Consolidation HiDAraC|• Ara-C 3g/m2 every 12h; 3h infusion iv on 1,3,5 days (+ mobilization of CD34+)
2011042|NCT02730377|Drug|thiazolidinediones|Trial product will be prescribed by the investigator and dispensed by pharmacy or similar.
2011043|NCT02730299|Drug|NiCord®|
1621877|NCT02072798|Drug|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
1621878|NCT02072785|Drug|Vincristine Sulfate Liposome|
1621879|NCT02072785|Drug|Vincristine Sulfate|
1621880|NCT02072772|Behavioral|Positively Smoke Free group treatment|See Arm Description
1621881|NCT02072772|Behavioral|Standard Care|See Arm Description
1621882|NCT02072759|Dietary Supplement|Carnitine supplement|"Carnitine supplement (oral ingestion with meals)
Total dosage of 2g carnitine per day for 36 days.
1 carnitine supplement at breakfast (500mg)
1 carnitine supplement at lunch (500mg)
2 carnitine supplements at diner (2x 500mg=1000mg)"
1621883|NCT02072759|Dietary Supplement|Placebo|
1621884|NCT02072746|Dietary Supplement|Zinc|
1621885|NCT02072746|Dietary Supplement|Placebo|
1621886|NCT02072733|Other|Comprehensive geriatric assessment|Intervention is planned to be based on the findings of the geriatric assessment and could include optimizing on comorbidity, planning of physical exercise, improvement of the social situation and nutritional status.
1621887|NCT02072720|Drug|Bevacizumab|patients will receive bevacizumab (3mg/kg/wk) starting from the identified induction time point of VEGF expression
1621888|NCT02072707|Procedure|Epicardial VT ablation|Combined Epicardial and Endocardial VT Ablation
1621889|NCT02072707|Procedure|Endocardial VT Ablation|Endocardial Only VT ablation
1621890|NCT02072694|Other|75 grams of glucose plus water solution|"A solution composed by 75 grams of glucose and water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:
300 mL final volume of the solution.
Time of oral ingestion inferior than 2 minutes.
30 minutes before the radiopharmaceutical injection.
12 hours fasting minimum."
1621891|NCT02072694|Other|Pure water|"Pure water at ambient temperature is administered to each volunteer, being of the with obesity group or the without obesity group, as follow:
300 mL final volume of the solution.
Time of oral ingestion inferior than 2 minutes.
30 minutes before the radiopharmaceutical injection.
12 hours fasting minimum."
1621894|NCT02072655|Procedure|socio-aesthetic care|"care of the face
skin cleansing with cleansing milk to remove impurities
a gentle scrub to exfoliate and cleanse the skin
a relaxing massage
moisturizing mask
application of a moisturizer suited to specific patient skin: skin reactivity, dehydration ...
care manicure / pedicure,
massages
makeup, advice (scarves, wigs care products adapted to the skin changes ...) and helping relationship."
1621895|NCT02072642|Device|active light therapy : Light therapy: DayVia lamp 10000 lux|4 weeks of active light therapy with DayVia lamp 10000 lux
1621896|NCT02072642|Device|Placebo light therapy|4 weeks with Placebo light therapy
1621897|NCT02072629|Other|Training of VHVs in iCCM|Village Health Volunteers will be trained in Integrated Community Case Management (iCCM) of childhood illness
1621898|NCT02072616|Other|Pancreatic adenocarcinoma diagnosis|
1621899|NCT02072603|Other|HITSystem|"Online, automated program designed to overcome current EID barriers by providing efficient prospective tracking of HIV-exposed infants and triggering electronic action alerts for both EID providers and lab technicians when time sensitive interventions are overdue for specific infants."
1621900|NCT02072603|Other|Standard of Care|current procedures that follow Kenyan National EID guidelines to diagnose and manage HIV infection among HIV-exposed infants.
1621901|NCT02072577|Behavioral|Video|"The student watched the video prepared individually in the ward where they were interned.
After this step, the student demonstrated again the procedure for oral hygiene.
At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially."
1621902|NCT02072564|Other|Questionnaire|Questionnaire with 100 questions divided into different groups: general data, work, physical activity, character, hobbies, disease and diet.
1621903|NCT02072525|Biological|Menveo®|One dose administered intramuscularly (IM) in the upper left deltoid of the arm.
1621904|NCT02072525|Biological|Boostrix®|One dose administered intramuscularly (IM) in the upper right deltoid of the arm.
1621905|NCT02072525|Biological|Pneumovax 23®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
1621906|NCT02072525|Biological|Prevnar 13®|One dose administered intramuscularly (IM) in the non-dominant deltoid of the arm.
1621907|NCT02072512|Drug|Fulvestrant|Fulvestrant 500mg I.M. Once/28days,until progression or unacceptable toxicity develops
1621908|NCT02072512|Drug|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
1621909|NCT02072512|Drug|Anastrozole|Anastrozole 1mg P.O. once daily, until progression or unacceptable toxicity develops
1621910|NCT02072512|Drug|Goserelin|goserelin 3.6mg subcutaneously every 28(± 3) days
1621911|NCT02072499|Procedure|KTP Green Light Prostatectomy|
1621912|NCT02072499|Device|Green Light|
1621913|NCT02072499|Procedure|Open prostatectomy|
1621914|NCT02072486|Other|Laboratory Biomarker Analysis|Correlative studies
1621915|NCT02072486|Drug|Sorafenib Tosylate|Given PO
1621916|NCT02072473|Procedure|Coronary sinus / left-sided slow pathway ablation|"Patients with unsuccessful right-sided slow pathway ablation attempt will undergo a stepwise:
coronary sinus slow pathway ablation, which, if unsuccessful, will be followed by
left-sided slow pathway ablation, using trans-septal approach."
1621917|NCT02072460|Other|electromyography|
1621918|NCT02072460|Other|electroencephalography|
1621919|NCT02072460|Other|approaches from psychophysics|
1621920|NCT02072447|Drug|YH4808 PO and [14C]-YH4808 IV|
1621921|NCT02072434|Drug|edoxaban|Factor Xa inhibitor anticoagulant, oral, edoxaban tablet, 60 or 30 mg once-daily (QD), 28-49 days dosing
1621922|NCT02072434|Drug|Enoxaparin|Vitamin K antagonist, sq, 100mg/kg, 28-49 days
1621923|NCT02072434|Drug|Warfarin|Vitamin K antagonist, oral, 1 or 2.5 mg tablet QD, 28-49 days
1621924|NCT02072421|Procedure|PCI|
1621925|NCT02072408|Drug|aflibercept|"Three monthly intravitreal aflibercept (2mg) injections
Five bimonthly intravitreal aflibercept (2mg) injections
Rescue treatment: Verteporfin photodynamic therapy
Loss of five ETDRS letters or one Snellen line of vision from baseline
Presence of subretinal fluid or intraretinal fluid despite three consecutive (monthly or bimonthly) aflibercept injection
Presence of active polyp on indocyanine green angiography"
1621926|NCT02072395|Procedure|Plication|Plication of the stomach will be performed in conjunction with placement of a gastric band.
1621927|NCT02072382|Drug|Metformin|metformin 850mg twice a day for eight weeks
1621928|NCT02072382|Drug|Placebo|
1621929|NCT02072369|Other|VAEDA Glove|Voice And EMG-Driven Actuated glove used during training
1621930|NCT02072369|Other|Occupational Therapy|novel upper extremity occupational therapy focused on the hand
1621931|NCT02072356|Radiation|yttrium Y 90 glass microspheres|Given Interartrial
1621932|NCT02072356|Other|laboratory biomarker analysis|Alpha-fetoprotein assay
1621933|NCT02072343|Device|No-DCCM|
1621934|NCT02072343|Device|DCCM|
1621935|NCT02072343|Other|Water 5ml in tracheal tube|
1621936|NCT02072343|Other|Water 10ml in tracheal tube|
1621937|NCT02072330|Drug|TAK-536CCB|TAK-536CCB 20 mg/5 mg ＋Hydrochlorothiazide placebo tablets
1621938|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets
1621939|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets
1621940|NCT02072330|Drug|Hydrochlorothiazide|TAK-536CCB placebo and Hydrochlorothiazide 6.25 mg tablets x2
1621941|NCT02072330|Drug|TAK-536CCB + Hydrochlorothiazide|TAK-536CCB 20 mg/5 mg and Hydrochlorothiazide 6.25 mg tablets x2
1621942|NCT02072317|Drug|taxel plus raltitrexed|taxol 135 mg/m2, raltitrexed 3 mg/m2 ivgtt d1, every three weeks for a cycle
1621943|NCT02072317|Drug|taxol|taxol 135 mg/m2, every three weeks for a cycle
1621944|NCT02072304|Behavioral|web-based CBT|A cognitive behavioral program in 8 weeks that will provide participants with the following: online interactive tools to do their homeworks and guidance on using cognitive and behavioral strategies to help reduce depressive symptoms, information about the depressive symptoms and cognitive behavioral therapy
1621945|NCT02072304|Behavioral|supportive care|supportive care group will receive supportive care for treating depression by e-mail per a week for 8 weeks with the following: psychoeducation about depression, stigma of mental illness, distraction technique, emotional regulation, active scheduling.
1621946|NCT02072291|Drug|Nifedipine|PO Nifedipine 5mg single dose
1621947|NCT02072278|Drug|Vortioxetine 10 mg|
1621948|NCT02072278|Drug|Vortioxetine 20 mg|
1621949|NCT02072278|Drug|Escitalopram 15 mg|
1621950|NCT02072278|Drug|Placebo|
1621951|NCT02072265|Device|Infrared thermal images|
1621952|NCT02072252|Behavioral|Mobile Phone Application|Mobile phone app teaching cognitive behavioral skills
1621953|NCT02072239|Device|Angioshield|The Angioshield wrap provides external structural support for the saphenous vein graft used in CABG surgery and is intended to prevent over distention of the graft under arterial pressure, potentially improving graft patency and reducing the likelihood of graft failure.
1621954|NCT02072226|Drug|Alteplase|Single dose of alteplase will be administered at 0.9 milligrams per kilogram (mg/kg) IV (maximal dose of 90 mg).
1621955|NCT02072226|Drug|Alteplase Placebo|Single dose of alteplase placebo will be administered as IV injection.
1621956|NCT02072226|Drug|Aspirin|Single dose of aspirin will be administered at 325 mg orally.
1621957|NCT02072226|Drug|Aspirin Placebo|Single dose of aspirin placebo will be administered orally.
1621958|NCT02072213|Drug|GL2702 GLARS-NF1|0.4mg once a day
1621959|NCT02072213|Drug|Omix Ocas|0.4mg once a day
1621960|NCT02072200|Drug|Lodotra®|Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response
1621961|NCT02072187|Dietary Supplement|Active|
1621962|NCT02072187|Dietary Supplement|Placebo|
1621963|NCT02072174|Drug|Anaferon for children|Efficiency of tablet dosage form
1621964|NCT02072174|Drug|Placebo|Efficiency of tablet dosage form
1621965|NCT02072161|Drug|ETC-1002|ETC-1002 capsules, taken once daily oral
1621966|NCT02072161|Drug|Placebo|Placebo capsules, taken once daily oral
1621967|NCT02072161|Drug|Statin Therapy|Patients remained on ongoing statin therapy (not study provided) of either Atorvastatin 10mg or 20mg; Simvastatin 5mg, 10mg or 20mg; Rosuvastatin 5mg or 10mg; or Pravastatin 10mg, 20mg or 40mg.
1621968|NCT02072148|Procedure|PET/CT|PET scan or CT scan q 4 months for 5 years
1621969|NCT02072148|Radiation|Radiotherapy|Postoperative XRT 5000 cGy
1621970|NCT02072148|Radiation|Concurrent Chemoradiation|"CCRT with cisplatin 40mg/m2/week IV over approximately 30 minutes, mixed in 250ml normal saline Weekly on Monday or Tuesday any time, or Wednesday prior to radiation
Postoperative XRT 5600 cGy"
2011044|NCT02730299|Other|Cord Blood Unit|Cord blood unit
1621972|NCT02072096|Drug|Glimepiride|Administered orally
1621973|NCT02072096|Drug|Metformin|Administered orally
1621974|NCT02072096|Drug|Pioglitazone|Administered orally
1621975|NCT02072096|Drug|Acarbose|Administered orally
1621976|NCT02072096|Drug|Linagliptin|Administered orally
1621977|NCT02072096|Drug|Sitagliptin|Administered orally
1621978|NCT02072096|Drug|Liraglutide|Administered subcutaneously (SC)
1621979|NCT02072096|Drug|Insulin Glargine|Administered SC
1621980|NCT02072096|Drug|Exenatide once weekly (QW)|Administered SC
1621981|NCT02072096|Drug|Exenatide twice daily (BID)|Administered SC
1621982|NCT02072083|Drug|Dexmedetomidine|via intranasal route 1 mcg/kg
1621983|NCT02072083|Drug|Ketamine|via intranasal route 7,5 mg/kg ketamine and 0,1 mg/kg midazolam
1621984|NCT02072070|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
1621985|NCT02072070|Drug|Placebo|Placebo control(Normal Saline)
1621986|NCT02072057|Drug|Ruxolitinib|
1621987|NCT02072044|Drug|Anlotinib|Anlotinib p.o. qd
1621988|NCT02072031|Drug|Anlotinib|Anlotinib p.o. qd
1621989|NCT02072031|Drug|Sunitinib maleate|Sunitinib 50 mg p.o. qd
1621990|NCT02072018|Drug|H-100|H-100 is a new compound to be applied to Peyronie's disease tissue with the intention of reducing disease symptoms.
1621991|NCT02072018|Drug|Placebo|Placebo is an established, standard compound to be applied to Peyronie's disease tissue that will have no effect on disease symptoms.
1621992|NCT02072005|Other|mSMART smartphone application|This application is an interface that provides subjects with information and questionnaires related to their medication.
1621993|NCT02071979|Device|Autologous PRP Gel|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then activated (by mixing with thrombin and calcium chloride) and sprayed directly on the area to be treated.
1621994|NCT02071979|Device|Autologous PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and platelet concentrate (platelet rich plasma) from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then drawn into multiple small syringes and injected directly into the wound bed or the skin surrounding it.
1621995|NCT02071979|Device|Autologous PRP Gel plus PRP Injections|Autologous PRP Gel is prepared using the Arteriocyte Magellan® System (510(k) approved), an Autologous Platelet Separator Instrument, which is a microprocessor-controlled centrifuge designed to be used in the clinical laboratory or intraoperatively at point of care for the safe and rapid preparation of platelet poor plasma and PRP from a small sample of blood. The Arteriocyte Magellan® automatically and quickly separates PRP from anticoagulated blood and dispenses it into a separate sterile syringe. The prepared PRP is then divided into equal parts and half is drawn into multiple small syringes and injected directly into the skin surrounding the wound bed, half is activated (by mixing with thrombin and calcium chloride) and sprayed the wound bed.
1621996|NCT02071979|Procedure|Standard Wound Care|Subjects in the control group will receive Standard Wound Care treatment for chronic wounds according to accepted medical practices.
1621997|NCT02071966|Drug|Ticagrelor|Comparison of Ticagrelor with another anti-platelet drug (Clopidogrel)
1621998|NCT02071966|Drug|Clopidogrel|Comparison of Clopidogrel with another anti-platelet drug (Ticagrelor)
1622001|NCT02071940|Drug|PLX3397|PLX3397 capsules 1000mg/day as monotherapy
1622002|NCT02071927|Drug|CB-839|Single-agent CB-839
1622003|NCT02071927|Drug|CB-Aza|CB-839 in combination with standard dose azacitidine
1622004|NCT02071914|Drug|CT-P27|
1622005|NCT02071914|Drug|Placebo|
1622006|NCT02071901|Drug|eltrombopag olamine|Given PO
1622007|NCT02071888|Drug|CB-839|Glutaminase inhibitor
1622008|NCT02071888|Drug|CB-839 and low dose dexamethasone|CB-839 and low dose dexamethasone
1622009|NCT02071888|Drug|CB-839, pomalidomide, and low dose dexamethasone|CB-839, pomalidomide, and low dose dexamethasone
1622010|NCT02071875|Device|Nautilus NeuroWaveTM recording|Nautilus NeuroWaveTM recording 15 minute recording with Nautilus NeuroWave Neurodiagnostic .
1622011|NCT02071862|Drug|CB-839|CB-839 monotherapy
1622012|NCT02071862|Drug|Pac-CB|CB-839 in combination with standard dose paclitaxel
1622013|NCT02071862|Drug|CBE|CB-839 in combination with standard dose everolimus
1622014|NCT02071862|Drug|CB-Erl|CB-839 in combination with standard dose erlotnib
1622015|NCT02071862|Drug|CBD|CB-839 in combination with standard dose docetaxel
1622016|NCT02071862|Drug|CB-Cabo|CB-839 in combination with standard dose cabozantinib
1622017|NCT02071849|Device|HAART 200 Aortic Valve Annuloplasty Device|Surgical repair of bicuspid aortic valve using the HAART 200 Aortic Valve Annuloplasty Device .
1622018|NCT02071836|Behavioral|Right Turns web application|
1622019|NCT02071836|Behavioral|Treatment as usual|
1622020|NCT02071823|Drug|BIA 9-1067|A single oral dose of 50 mg (2 x 25 mg capsules) was administered in the morning of each study period under fasting or fed conditions. The two single dose administrations were separated by a wash-out of 7 days.
1622021|NCT02071810|Drug|BIA 9-1067|
1622022|NCT02071810|Drug|Placebo|
1622023|NCT02071797|Device|Induced Therapeutic Hypothermia|Head to head, direct comparator of two standard care devices/treatments (RhinoChill versus Blanketroll lll) to assess time to induced therapeutic hypothermia
1622024|NCT02071771|Device|Nelfilcon A toric contact lenses|
1622025|NCT02071771|Device|Etafilcon A toric contact lenses|
1622026|NCT02071758|Biological|LEISH-F3 + SLA-SE|
1622027|NCT02071758|Biological|LEISH-F3 + GLA-SE|
1622028|NCT02071732|Device|real repetitive Transcranial Magnetic Stimulation|
1622029|NCT02071732|Device|sham repetitive Transcranial Magnetic Stimulation|This sham stimulation is not true stimulation.
1622031|NCT02071680|Other|Iodine-123 Meta-iodobenzylguanidine|"A single injection of the 123I-mIBG will be given. Imaging will be done twice following injection: at 0120 minutes and 3-5 hours. The timing is dependent on the specific participant and imaging characteristics.
The imaging is done for approximately 24 minutes at each time point."
1622032|NCT02071667|Other|Blood draw|
1622033|NCT02071654|Device|Venus P-valve transcatheter implantation|Percutaneous implantation of Venus-P valve to treat RVOT stenosis patients
1622035|NCT02071615|Drug|Methylphenidate 20 mg tablet given once by mouth|3-arm, single-drug dosage comparison study
1622036|NCT02071615|Drug|modafinil 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
1622037|NCT02071615|Drug|caffein 200mg tablet given once by mouth|3-arm, single-drug dosage comparison study
1622038|NCT02071615|Drug|placebo|
1622039|NCT02071602|Drug|CD-NP|Randomized 1:1:1
1622040|NCT02071589|Drug|Nifedipine soft gelatine capsules|3 Adalat capsules of 10 mg each one
1622041|NCT02071589|Drug|Nifedipine oral solution|6 mL of Nife Par solution
1622042|NCT02071576|Device|Proscan|One device (500 Hz Excimer Laser - TENEO) with one intervention (Proscan)
2011045|NCT02729311|Behavioral|Paired PLIÉ Program|The Paired PLIÉ Program is a novel, multimodal, movement program that focuses on abilities that are well maintained in people with dementia, including training procedural ('muscle') memory for basic daily movements, in-the-moment mindful body awareness, and social engagement. Group classes are held with affected individuals, care partners and instructors together. A monthly home visit also is provided.
2011046|NCT02730455|Drug|natalizumab|Administered as specified in the treatment arm
2011047|NCT02730455|Drug|Placebo|Matched placebo
1622046|NCT02071550|Device|FORESİGHT cerebral oxygen monitor and INVOS cerebral oxygen monitor|
1622047|NCT02071550|Device|FORESIGHT and INVOS monitor|
1622048|NCT02071537|Drug|Chloroquine|Dose is 50, 100, 150, and 200 mg per day cohorts. It is given one week prior to the initiation of chemotherapy and then given for four 21 day cycles in combination with chemotherapy.
1622049|NCT02071537|Drug|Carboplatin|Administered day 1 of each 21 day cycle for 4-6 cycles.
1622050|NCT02071537|Drug|Gemcitabine|Administered days 1 and 8 of each 21 day cycle for 4-6 cycles.
1622051|NCT02071524|Drug|Group Colloid|Group Colloid: cristalloid 1:2 (gelofusine: ringer lactate)
1622052|NCT02071524|Drug|Cristalloid administration|Only Ringer Lactate administration
1622053|NCT02071511|Procedure|Ablation of ventricular arrhythmias|control group: Ablation of ventricular arrhythmias
1622054|NCT02071511|Procedure|Ablation of ventricular arrhythmias + renal denervation|Intervention group: Ablation of ventricular arrhythmias + renal denervation
1622055|NCT02071498|Device|Pillbox app named ALICE|Participants in the experimental group were given a BQ tablet or an iPad with the ALICE app installed and personalised according to the medications they had been prescribed as listed in their medical record
1622056|NCT02071498|Other|oral and written information|oral and written information about the most common errors of patients
1622057|NCT02071472|Other|DP medication reconciliation|
1622058|NCT02071459|Drug|L-Threo DOPS|initial dose titration period (4 weeks) followed by 8 weeks at the max tolerated dose
1622059|NCT02071459|Drug|placebo|initial period (4 weeks) followed by 8 weeks
1622060|NCT02071433|Procedure|Saphenous nerve blockade|
1622061|NCT02071433|Procedure|Femoral nerve blockade|
2011048|NCT02728284|Procedure|CMR|
2011049|NCT02728284|Procedure|Conventional Cardiologic Evaluation|
2011050|NCT02728245|Drug|Dienogest|Dienogest 2mg po qd
2011051|NCT02728245|Drug|Placebo drug|Placebo 1 table po qd
1622066|NCT02071407|Drug|Midazolam|"For patients allocated into group N2, 2 mg midazolam will be injected intravenously, and then it will be given at 0.05-0.1 mg/(kg·h) by intravenous infusion. If a surgery is needed, infusion of midazolam will begin 3 hours after the operation and continue for at least 72 hours. During the sedation with midazolam, BIS should be kept at 60 to 80.
Morphine can be used to supply adequate analgesia."
1622067|NCT02071407|Drug|Placebo|
1622068|NCT02071394|Drug|Xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours, including during transport for outborn babies, starting within 5 hours after birth.
1622069|NCT02071394|Other|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment), including during transport for outborn babies, starting within 3 hours after birth.
1622070|NCT02071381|Drug|DW330SR 45mg|
1622071|NCT02071381|Drug|DW1030 75mg|
1622072|NCT02071368|Drug|Canagliflozin, 300 mg|Each tablet contains canagliflozin (CANA) of 300 mg to be taken orally (by mouth).
1622073|NCT02071368|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
1622074|NCT02071368|Drug|CANA/MET XR FDC, Formulation 1, 150 mg/500|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, to be taken orally.
1622075|NCT02071368|Drug|CANA/MET XR FDC, Formulation 2, 150 mg/500 mg|Each tablet contains 150 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, to be taken orally.
1622076|NCT02071355|Drug|TMC435 100 mg|Participants will receive TMC435 100 mg capsule once daily from Day 1 to Day 7 after food.
1622077|NCT02071355|Drug|TMC435 150 mg|Participants will receive TMC435 150 mg capsule once daily from Day 1 to Day 7 after food.
1622078|NCT02071342|Procedure|angioplasty|patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.
1622079|NCT02071329|Drug|Vaccine FP-01.1|
1622080|NCT02071329|Drug|Placebo|
1622081|NCT02071329|Other|Virus Challenge|
1622082|NCT02071316|Drug|Hexacapron( Tranexamic acid)|1. Treatment group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously with concurrent hexacapron( Tranexamic acid) I.V. every 6 hours until 72 hours and then the patient continue oral treatment 6 g /day for 7 days.
1622083|NCT02071316|Drug|esomeprazole|2. Standard of care group - receive I.V. Esomeprazole 80 mg once and then 8mg/h continuously
1622084|NCT02071303|Drug|Tramadol|Tramadol 100mg will be given to 70 women before the procedure.
1622085|NCT02071303|Drug|Celecoxib|Celecoxib 200mg will be given to 70 women before the procedure.
1622086|NCT02071303|Drug|Placebo|A placebo will be given to 70 women before the procedure.
2011052|NCT02728245|Procedure|Surgery|conservative surgery without intent to oophorectomy
1622303|NCT02069665|Drug|Ibuprofen Suspension|taken under prescription
2011053|NCT02728180|Drug|Xingnaojing injection|Xingnaojing injection (20 ml), IV (in the vein), every 12 hours for 10 days.
2011054|NCT02728180|Other|Standard care|Guidelines-based standard care for acute ischemic stroke.
1622088|NCT02071277|Other|Pressure targeted modes|Intervention involving three different pressure-targeted modes (APRV, BIPAP, and BIPAPassist) each in a random order generated by a computer on one ventilator. Each mode will be studied for 20 minutes.
1622089|NCT02071264|Behavioral|HIV/STI intervention|The intervention covers HIV101 information, reproductive health and human rights national policies, goal setting activities as individuals and as a group, results of prior research on ethics of doing research with sex workers.
1622090|NCT02071251|Procedure|Prospective wound complication protocol|The skin and subcutaneous tissues were incised using a scalpel or cutting electrocautery. Use of coagulation current on the skin or subcutaneous tissues was not allowed, except focally to attain hemostasis. At the conclusion of surgery, a 7mm Jackson-Pratt drain was placed below Camper's fascia, which in turn was closed with 3-0 plain catgut suture. The skin was closed with staples. Dressings were retained for at least twenty-four hours. Staples were to be retained for at least two weeks.
1622091|NCT02071238|Behavioral|Pamphlet|Written pamphlet outlining the risks of surgery as discussed in consultation.
1622092|NCT02071238|Behavioral|Group Consultation|Informed consent discussion in group-format
2011055|NCT02725411|Drug|Celecoxib|Orally administered Celecoxib 100 mg twice daily for 56 weeks
1622095|NCT02071212|Drug|Ticagrelor|Loading dose 180 mg . Maintainance dose 90 mg BID
1622096|NCT02071199|Drug|1X ACCS (Amnion-derived Cellular Cytokine Solution)|1X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
1622097|NCT02071199|Drug|Normal saline|Saline will be applied to the gingival margin daily 5 days per week for 2 weeks
1622098|NCT02071199|Drug|0.3X ACCS|0.3X ACCS will be applied to the gingival margin daily 5 days per week for 2 weeks
1622099|NCT02071186|Device|Virtual Reality training|"Subjects will train with the VR system at the Tel Aviv Sourasky Medical Center 3 times per week for 6 weeks with each session lasting approximately 30 minutes.
To assure participants' safety and maintaining progress, training with the VR will be individual and provided by qualified physiotherapists, who use the system on a daily basis."
1622100|NCT02071186|Other|Computerized Cognitive Remediation|Subjects in this study will train with the AttenGo program at home 3-5 times per week for 6 weeks with each session lasting approximately 30 minutes.
1622101|NCT02071186|Other|Standard of care|
1622102|NCT02071173|Device|CRT-D, quadripolar coronary venous lead, defibrillation lead|
1622103|NCT02071160|Drug|Melatonin|Melatonin is administered to the melatonin/hypothermia group (n=15) in a dose of 10 mg/kg daily for a total of 5 doses starting immediately at enrollment. Melatonin tablets (1 or 3 mg/tablet) (Puritan's Pride,Oakdale, NY, USA) are crushed, then dissolved in 5-10 ml of distilled water , then administered via an orogastric tube.
1622104|NCT02071147|Other|No Clinical Follow up|
1622105|NCT02071147|Other|Quality of Life questionnaire|
1622106|NCT02071147|Other|Patient satisfaction Questionnaire|Conducted at Research clinic.
1622107|NCT02071134|Device|Deep Brain Stimulation (DBS)|Subjects receiving Deep Brain Stimulation (DBS) for the treatment of their Parkinson's disease symptoms will be offered participation in this registry.
1622108|NCT02071121|Drug|BIIB061|BIIB061 capsules for oral administration
1622109|NCT02071121|Drug|Placebo|BIIB061 matching placebo capsules
1622110|NCT02071121|Drug|14C-BIIB061|Radiolabeled containing 14C-BIIB061 ≤ 500 nCi.
1622111|NCT02071108|Device|Shockwave Lithoplasty System|
1622112|NCT02071095|Drug|Arm A: Poly-ICLC|Poly-ICLC (Hiltonol®, Oncovir) Administration - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with 1.4 mg of Poly-ICLC (Hiltonol®, Oncovir). Each subject will receive a total of 2 SC doses of Poly-ICLC. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
1622113|NCT02071095|Drug|Arm B: Normal Saline|Normal Saline - On days 1 and 2, patients randomized to this arm will be injected subcutaneously in the arm with normal saline obtained from the Rockefeller University Pharmacy. Each subject will receive a total of 2 SC doses of normal saline. The volume of each injection is 0.7ml. The investigators who are blinded will not be present at the time of injection by the study nurse.
1622114|NCT02071082|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily with food
1622115|NCT02071069|Drug|Cetuximab|400mg/m2 d1,250mg/m2 every week or 500mg/m2 every 2 weeks
1622116|NCT02071069|Drug|irinotecan|180 mg/m2 IV every 2 weeks
1622117|NCT02071069|Drug|fluorouracil|400mg/m2 on day 1 and 2400mg/m2 civ46h every 2 weeks
1957924|NCT02105688|Drug|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet (MK-5172A)|Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
1622120|NCT02071030|Procedure|Third molar removal|Surgically removing the third molar in the lower jaw
1622121|NCT02071004|Drug|DS-1040b|IV of 6 mg given once over 30 minutes
1622122|NCT02071004|Drug|Aspirin|Dispersible tablet, 300mg & 75 mg, once daily for 5 days
1622123|NCT02070991|Drug|Macitentan|oral tablet, 10 mg once daily
1622124|NCT02070991|Drug|Placebo|matching placebo
1622125|NCT02070978|Drug|Atacicept 75 mg|Subjects who received 75 mg atacicept in the ADDRESS II trial, will continue receiving 75 mg atacicept as subcutaneous injection once weekly for 96 weeks in this trial.
1622126|NCT02070978|Drug|Atacicept 150 mg|Subjects who received placebo or 150 mg atacicept in the ADDRESS II trial, will receive 150 mg atacicept as subcutaneous injection once weekly for 96 weeks in this trial.
1622127|NCT02070965|Drug|DFD01 Spray|
1622128|NCT02070965|Drug|Comp01 Lotion|
1622129|NCT02070952|Radiation|CyberKnife Stereotactic Ablative Body Radiation Therapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
1622130|NCT02070939|Drug|PF-06260414|Subjects will receive single doses of 1,3,6,30,100,200, 400 mg of PF-06260414 (solution) in a dose escalating format
1622131|NCT02070939|Drug|Placebo|Subjects will receive single doses of PF-06260414 matching placebo (solution) in a dose escalation format
1957925|NCT02105688|Drug|Placebo to Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet|Placebo Grazoprevir 100 mg/Elbasvir 50 mg FDC tablet, taken once daily by mouth for 12 weeks.
1957926|NCT02104427|Drug|TG-0054 combined with G-CSF|
1622132|NCT02070939|Drug|PF-06260414|Subjects will receive PF-06260414 doses (solution) twice daily for 14 days
1622133|NCT02070939|Drug|Placebo|Subjects will receive PF-06260414 matching placebo doses (solution) of 3, 10, 30, 100mg BID and 60 mg QD for 14 days
1622134|NCT02070939|Drug|PF-06260414|Japanese subjects may receive the highest dose of PF-06460414 tested in non Japanese cohort twice daily for 14 days
1622135|NCT02070939|Drug|Placebo|Japanese subjects may receive PF-06260414 matching placebo doses (solution) twice daily for 14 days
1622136|NCT02070900|Device|POC CD4|Point of Care device for CD4 count testing (to be used as a clinical monitoring tool)
1622137|NCT02070900|Other|Programmatic Mentoring|Programmatic Mentoring aimed at messaging around CD4 count to encourage retention on lifelong ART for PMTCT patients, administered by trained clinical mentors
1622138|NCT02070874|Behavioral|telehealth enhanced pain management|
1622139|NCT02070861|Procedure|Changes in cardiac output|
1622140|NCT02070848|Other|Session 1-4|Familiarization sessions to knee-extensor exercise separated by 72h recovery
1622141|NCT02070848|Other|Session 4|After the last familiarization session, 1 maximal incremental test on a bicycle, followed by 72h rest
1622142|NCT02070848|Other|Session 5|2 maximal incremental tests of knee-extension exercise (concentric vs eccentric), separated by 3h rest.
1622143|NCT02070835|Device|ReCell®|ReCell® and skin graft
1622144|NCT02070835|Procedure|skin graft|split-thickness skin graft
1622145|NCT02070809|Procedure|tissue-engineered skin method|This method is composite of skin grafting over human acellular dermal matrix scaffold the investigators used before with skin basal cell as seed cells, moreover it was finished in the surgery without culturing the cells
1622146|NCT02070809|Procedure|split-thickness skin graft method|This method is traditional split-thickness skin graft
1622147|NCT02070796|Drug|Rotigotine PR2.2.1|"Treatment A:
Rotigotine Transdermal patch 2 mg/24 hr (10 cm^2) Test drug product PR2.2.1. Single application of 1 patch for 24 hours."
1622148|NCT02070796|Drug|Rotigotine PR2.1.1|"Treatment B:
Rotigotine Transdermal patch 2 mg/24 hr (10 cm^2) Reference drug product PR2.1.1. Single application of 1 patch for 24 hours."
1622149|NCT02070783|Drug|ARA290|
1622150|NCT02070783|Drug|Placebo|
1622151|NCT02070770|Dietary Supplement|Very low calorie diet|
1622152|NCT02070770|Other|Standard weight loss diet|
2011056|NCT02725411|Biological|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
2011057|NCT02725411|Biological|Tanezumab 10 mg|Subcutaneous injection of tanezumab 10 mg every 8 weeks for 56 weeks
1622155|NCT02070744|Drug|VX-661|
1622156|NCT02070744|Drug|ivacaftor|
1622157|NCT02070744|Drug|VX-661 placebo|
1622158|NCT02070744|Drug|ivacaftor placebo|
1622159|NCT02070731|Device|TriGuard HDH|TAVI with the TriGuard HDH embolic deflection device
1622160|NCT02070718|Drug|Standard Dose Kappa Agonist|
1622161|NCT02070718|Drug|Half Dose Kappa Agonist|
1622162|NCT02070718|Other|Placebo|
1622163|NCT02070705|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
1622164|NCT02070692|Drug|Tamoxifen|7 day course of tamoxifen during an episode of irregular vaginal bleeding
1622165|NCT02070692|Drug|Placebo|7 day course of placebo during an episode of irregular vaginal bleeding
1622166|NCT02070679|Drug|Vitamin E|
1622167|NCT02070666|Behavioral|Protective mechanical ventilation|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode; a minimum of 5 cmH2O level of support should be used; in case the resulting tidal volume exceeds 6 mL/kg PBW this is accepted. This is not a reason to use more sedation and/or muscle relaxants, or to switch the ventilator to a controlled mode of ventilation).
Tidal volume: 6 mL/Kg PBW, decreasing 1 mL/kg PBW each step if necessary (steps of 5 minutes), to maintain plateau pressure < 25 cmH2O until a minimum tidal volume of 4 mL/Kg PBW, unless the patient suffers from severe dyspnea or unacceptable acidosis.
Fraction of inspired oxygen inspired oxygen fraction (FiO2) > 0.21 to maintain oxygen saturation 90-92%.
PEEP ≥ 5 cmH2O, and optimized to maintain Oxygen saturation (SpO2) 90-92% (left to the discretion of the attending physician).
Plateau pressure ≤ 25 cmH2O"
1622168|NCT02070666|Behavioral|Control group|"Ventilation mode: volume control, pressure control, dual modes (It is allowed to change to a spontaneous mode, with the level of support adjusted to reach tidal volumes minimum of 8 mL/kg predicted body weight PBW; if it is not possible, the data collection should be continue and an intention-to-treat analysis will be done).
Tidal volume: minimum 8 mL/kg PBW. It is possible to increase until 10 mL/kg PBW unless plateau pressure increases above 25 cmH2O.
· FiO2 > 0.21 to maintain oxygen saturation 90-92%.
PEEP ≥ 5 cmH2O, and optimized to maintain SpO2 90-92% (left to the discretion of the attending physician).
Plateau pressure ≤ 25 cm H2O."
1622169|NCT02070666|Other|Dead space|Volumetric capnography will be used. Dead space (Vd/Vt) measurements will be taken at baseline and daily after initiation of mechanical ventilation. Nursing and respiratory care activities (including changes to ventilator settings) will be suspended for at least 5 minutes prior to all Vd/Vt measurements.
1622170|NCT02070653|Drug|Ticagrelor|
1622171|NCT02070653|Drug|Placebo|
1622172|NCT02070640|Drug|Injection of indocyanine green (ICG)|2.5 mg of of ICG will be injected intravenously 60-30 minutes prior to surgery in order to visualize the biliary tree using a near-infrared light source and camera. An additional 2.5 mg of IV ICG may be given intraoperatively if fluorescence has faded prior to visualization.
1622173|NCT02070640|Device|Near Infrared Cholangiography Fluorescence (NIRF-C)|These devices are used to identify anatomy, using infrared light that causes the ICG to fluoresce.
1622174|NCT02070627|Drug|Indocyanine Green (ICG)|60-30 minutes prior to cholecystectomy, 2.5 mg of indocyanine green (ICG) will be injected intravenously. An additional 2.5 mg of ICG may be injected intraoperatively if the fluorescence fades prior to imaging.
1622175|NCT02070627|Device|Near Infrared Fluorescence Cholangiography (NIRF-C)|Near infrared fluorescence cholangiography will be performed intraoperatively in order to image anatomy.
1622176|NCT02070588|Device|MRI|MR Diagnostic Imaging will be performed on both TBI subjects and Non TBI subjects
2011058|NCT02725411|Drug|Placebo for celecoxib|Orally administered the placebo twice daily for 56 weeks
2011059|NCT02725411|Biological|Placebo for tanezumab|Subcutaneous injection of the placebo every 8 weeks for 56 weeks
1622177|NCT02070575|Other|blood draw|Venous blood will be collected in an EDTA Vacutainer tubeup to 10 mL and will be immediately put on ice. This sample may be drawn as a stand-alone blood draw. Samples will be centrifuged at 1900g (3000-3200 RPM) for 15 Minutes and the serum aliquoted into freezer vials and stored at -80°C until analysis. In addition patients who have not received treatment for biochemical recurrence after their first draw are eligible for subsequent draws to determine the reproducibility of the test over time.
2011060|NCT02724215|Device|Sleep Apnea Screening (Out of Center Polysomnography Device)|
1622182|NCT02070536|Other|sRAGE|
1622183|NCT02070523|Drug|VDCLD regimen|
1622184|NCT02070510|Drug|semaglutide|For oral administration once daily. Doses of 5 mg and 10 mg, respectively, will be given for 7 days followed by 20 mg administered on days 43-84.
1622185|NCT02070510|Drug|lisinopril|For oral administration. A single dose of 20 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 1, 15 and 71).
1622186|NCT02070510|Drug|warfarin|For oral administration. A single dose of 5 mg is administered three times either alone or conconmitantly with a perpetrator compound (days 8, 22 and 78).
1622187|NCT02070510|Drug|placebo|A single dose of SNAC is administered conconmitantly with victim compounds (days 15 and 22).
1622188|NCT02070497|Other|case management|case management group will accept the case manager's service; the control group will just accept the routine care
1622189|NCT02070484|Biological|NuCel|
1622190|NCT02070484|Biological|Demineralized Bone Matrix|
1622191|NCT02070471|Drug|Placebo|Placebo
1622192|NCT02070471|Drug|LC28-0126 Dose A|LC28-0126 Dose A
1622193|NCT02070471|Drug|LC28-0126 Dose B|LC28-0126 Dose B
1622194|NCT02070471|Drug|LC28-0126 Dose C|LC28-0126 Dose C
1622195|NCT02070458|Drug|ixazomib|Given PO
1622196|NCT02070458|Drug|mitoxantrone hydrochloride|Given IV
1622197|NCT02070458|Drug|etoposide|Given IV
1622198|NCT02070458|Drug|cytarabine|Given IV
1622199|NCT02070432|Drug|LUZ11|LUZ11 i.v. administration followed by laser light irradiation
1622200|NCT02070419|Procedure|transarterial chemoembolization|Undergo TACE with doxorubicin-eluting beads
1622201|NCT02070419|Radiation|stereotactic radiosurgery|Undergo SBRT
1622202|NCT02070406|Drug|cyclophosphamide|Given IV
1622203|NCT02070406|Drug|fludarabine phosphate|Given IV
1622204|NCT02070406|Biological|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Given NY-ESO-1 reactive TCR retroviral vector transduced autologous T cells IV
1622205|NCT02070406|Biological|dendritic cell vaccine therapy|NY-ESO-1157-165 peptide pulsed DC vaccine given ID
1622206|NCT02070406|Biological|aldesleukin|Given SC
1622207|NCT02070406|Radiation|fludeoxyglucose F 18|Correlative studies
1622208|NCT02070406|Procedure|positron emission tomography|Correlative studies
1622209|NCT02070406|Other|laboratory biomarker analysis|Correlative studies
1622210|NCT02070393|Radiation|Proton|14-24 Radiation treatments using Protons
1622211|NCT02070380|Drug|MultiHance 0.1 mmol/kg|MultiHance administered at 0.1 mmol/kg
1622212|NCT02070380|Drug|Dotarem|Dotarem administered at 0.1 mmol/kg
1622213|NCT02070380|Drug|MultiHance 0.05 mmol/kg|MultiHance administered at 0.05 mmol/kg
1622214|NCT02070367|Other|Somatosensory rehabilitation|
1622215|NCT02070367|Other|Usual treatment: physiotherapy|
1622216|NCT02070341|Drug|Polyethylene Glycol|
1622217|NCT02070341|Drug|Picosalax|
1622218|NCT02070328|Other|Registry|
1622219|NCT02070302|Drug|Botulinum Toxin Type A|40 units of BOTOX® (onabotulinumtoxin A) divided into two injection sites of 20 units each
1622220|NCT02070302|Drug|Placebo|Placebo (Normal Saline) divided into 2 injections of .4cc each
1622221|NCT02070289|Drug|PF-06372865|Tablets, 2.5 mg BID, 14 days
1622222|NCT02070289|Drug|Placebo|Tablets, BID, 14 days
1622223|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
1622224|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
1622225|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
1622226|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
1622227|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
1622228|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
1622229|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
1622230|NCT02070289|Drug|Placebo|Tablets, BID or titration, 14 days
1622231|NCT02070289|Drug|PF-06372865|Tablets, to be decided dose, BID or titration, 14 days
1622232|NCT02070276|Procedure|Trans-thoracic echocardiography|Subcostal evaluation of inferior vena cava dimensions and colorability with cyclic spontaneous breathing in order to determine if the patients will be fluid responsive or not.
1622233|NCT02070276|Procedure|Passive Leg Raising Test|Application of this test in a standard manner in order to determine if our spontaneous breathing patients are fluid responsive before spinal anesthesia.
1622234|NCT02070250|Behavioral|From Cancer to Health (C2H-D)|From Cancer to Health gives people with cancer the information and tools they need to manage their stress to improve their health throughout the cancer journey. Each institution involved in this study will implement the core techniques of the C2H-D Intervention but may alter the format somewhat to meet their patient population needs (e.g., shorten hourly 18 week intervention into 2-hour 9 week intervention).
1622235|NCT02070237|Drug|Enoxaparin|Enoxaparin will be given in either once daily or twice daily doses. One arm will receive 40 mg enoxaparin subcutaneous injection daily. The other arm will receive 0.5 mg/kg dosed subcutaneously twice daily. This medication will be started 8-12 hours after cesarean section and will be continued while the patient is admitted. It will be stopped at the time of discharge.
1622236|NCT02070224|Other|Serum and urine samples collections|Serum and urine samples will be collected at baseline, 3 month, 6 month, 12 month to assess the predictive value of cartilage-specific biomarkers Coll2-1/Coll2-1NO2 on OA progression (MRI, Clinical and radiological progression)
1622304|NCT02069665|Drug|salbutamol|taken under prescription
1622237|NCT02070224|Other|Imaging (x-rays and MRI)|MRI will be done at baseline and 12 month and x-rays will be done at baseline
1622238|NCT02070211|Dietary Supplement|omega-3 PUFAs|4 capsules (2 in the morning; 2 in the evening) for a period of 12 weeks. The active treatment is a supplement of yellow gelatine 0.625 g capsules containing concentrated marine fish oil. The daily dose of 4 capsules will provide approximately 700 mg of eicosapentaenoic acid (EPA, 20:5n3), 480 mg of docosahexaenoic acid (DHA, 22:6n3), and 7.6 mg of Vitamin E.
1622239|NCT02070211|Other|Standard care|Standard care includes management by a psychiatrist or resident psychiatrist and non-neuroleptic pharmacotherapy as clinically indicated. Specifically, Cognitive-behavioural therapy (CBT) embedded within case management will be administered. The CBT will be based on the models developed at the PACE Clinic in Melbourne, in the EDIE trial, and in Cologne, as these have proven to be effective in RCTs. The number of sessions delivered will be captured for each client. In addition, fidelity will be monitored by therapists rating their own sessions on an established checklist of therapeutic interventions.
1622240|NCT02070211|Dietary Supplement|placebo|4 capsules of 0.7g of paraffin oil (which is not absorbed by the gastrointestinal tract) per day.
1622241|NCT02070198|Drug|Long acting FSH and GnRH antagonist|Woman in long acting FSH and GnRH antagonist arm receive an initial dose of 150 mcg Corifollitropin alfa on second day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards. On the ninth day of the cycle, a daily fixed dose of 300 IU of recombinant FSH will be administered until the day of ovulation triggering.
1622242|NCT02070198|Drug|Daily FSH and GnRH antagonist|Woman in daily FSH and GnRH antagonist arm receive a fixed dose of 300 IU of recombinantFSH starting 3 day of the menstrual cycle followed by a fixed daily dose of 0.25 mg of GnRH antagonist on day 7 of the cycle onwards until the day of ovulation triggering.
1622243|NCT02070198|Drug|Triptorelin and recombinant FSH|Women in Triptorelin and recombinant FSH arm receive a fixed dose of 0.05 mg of Triprorelin from the 1 day of the menstrual cycle followed by a fixed dose of 300 IU of recombinant FSH starting 3 day untill the day of HCG administration.
1622244|NCT02070185|Behavioral|2 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).
During a 4-wk conditioning period, children were exposed either 2 times to each beverage.
After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
1622245|NCT02070185|Behavioral|7 exposures arm|"During this study, children were exposed to 2 flavored sweetened beverages: a high energy version (HE: 150kcal) and a no energy version (NE: 0kcal).
During a 4-wk conditioning period, children were exposed either 7 times to each beverage.
After a 3-wk stability period without exposure, children were exposed 3 times to both beverages in which the association between the flavor and the energy density had been switched (4-wk extinction period)."
1622246|NCT02070159|Drug|Clopidogrel 600 mg|Patients administer 600 mg of clopidogrel as conventional loading dose of clopidogrel
1622247|NCT02070159|Drug|Prasugrel 30 mg|Patients administer 30 mg of prasugrel as lower loading dose of prasugrel.
1622248|NCT02070159|Drug|Prasugrel 60 mg|Patients take 60 mg of prasugrel as conventional loading dose of prasugrel.
1622249|NCT02070133|Drug|Simvastatin|Simvastatin 40 mg once a day during 12 weeks
1622250|NCT02070133|Drug|Placebo|Placebo once a day during 12 weeks
1622251|NCT02070120|Drug|Mitomycin C|Patients assigned to the chemoresection group will receive 4 once weekly intravesical instillations of 40mg MMC as outpatients.
1622252|NCT02070120|Procedure|Surgical Management|Patients in this group should be treated according to local practice. Surgical interventions may include transurethral resection (TUR) or ablation.
1622253|NCT02070107|Other|On Plan|"On Plan is a highly customizable software package developed by our co-investigator at the University of Louisville for a variety of applications related to compliance."
1622254|NCT02070081|Procedure|Roux-en-Y gastric bypass surgery or sleeve surgery|
1622255|NCT02070068|Device|PINPOINT System|
1622256|NCT02070055|Other|No intervention|
1622257|NCT02070042|Drug|Omega 3 Fatty Acid|Trunature® Triple Strength Omega-3, given twice a day. Each capsule contains 647 mg Eicosapentaenoic Acid (EPA) and 253 mg Docosahexaenoic Acid (DHA).
1622258|NCT02070042|Drug|Placebo|Placebo capsules (olive oil) twice a day
1622259|NCT02070029|Procedure|Acupuncture|"Acupuncture Therapy - Initial Evaluation History including: chief complaint, diet, level of diaphoresis, water intake, digestive function, menstrual cycling, sleep habits, overall mood.
Physical Exam: inspection of tongue and palpation of central and peripheral pulses.
Chinese Diagnoses for Female Sexual Dysfunction: Kidney Yang Deficiency; Liver Qi Stagnation; Generalized Blood Deficiency; Spleen Yang Deficiency; Heart Fire
- Subsequent Sessions 25 minute sessions, twice weekly, for 5 weeks = total 10 sessions Needle usage = 8-20, average 14 per session Typically placed on the scalp, lower abdomen, elbows and knees"
1622260|NCT02070016|Device|Transcranial Magnetic Stimulation|
1622261|NCT02070003|Behavioral|Motivational Interviewing and Physician Guided Opioid Weaning|
1622262|NCT02069990|Drug|Cholecalciferol|
1622263|NCT02069977|Drug|Aripiprazole|
1622264|NCT02069951|Other|Practice a procedural module on a simulator|
1622265|NCT02069925|Behavioral|Early Detection (ED)|This intervention consists of educational campaigns directed at patients & families (who have yet to seek care) and professionals in educational and clinical settings to hasten referral of individuals with new onset psychosis to an established, best-practice first-episode service (i.e. STEP). Interleaved with this educational campaign will be procedures to make the STEP clinic more rapidly responsive to referrals to further shorten the duration of untreated psychosis
1622266|NCT02069925|Behavioral|Usual Detection|This intervention will provide equivalent best practice care without the benefit of an early detection campaign
1622267|NCT02069912|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are culturally and health literacy adapted for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
1638229|NCT01945853|Device|7 Tesla MRI|
1622268|NCT02069899|Drug|NI-0501|In the event that NI-0501 treatment needs to be prolonged beyond Week 8 foreseen in the previous study, and upon request of the treating physician, patients will continue receiving NI-0501 in the context of this study.
1622269|NCT02069886|Drug|deferasirox|125, 250, 500 mg dispersable tablets
1622270|NCT02069873|Behavioral|16-Week Group Treatment|Within the 16-week group treatment, the cognitive block will contain 5 sessions, the exposure block will contain 5 sessions, and the skills block will contain 4 sessions.
1622271|NCT02069860|Device|Bone Anchored Port System (BAP)|The port body will be implanted onto the petrous bone, a sealing cap, a twofold valve system and a catheter connected to the port body. The catheter is tunneled under the skin, enters the internal jugular vein and ends in the right atrium of the heart. The novelty of the access lies in its location (retro auricular on petrous bone) and its bone fixation
1622272|NCT02069847|Drug|Budesonide|"Participants will be instructed to swallow budesonide 3mg twice daily for eight consecutive weeks following endotherapy with EMR or ESD. Budesonide will be provided in a capsule containing 3mg budesonide only by Mayo Clinic Pharmacy with full 8 weeks supply.
The patient will require opening the capsule and mixing the budesonide powder in 10ml (2 teaspoons) honey, or pancake syrup.
Patients will be instructed not to ingest any solid or liquids for 30 minutes before and after taking the budesonide. For purposes of this study, budesonide is used off-label but according to the same dose and efficacy as has been demonstrated in other esophageal inflammatory conditions. Patients will receive a handout with exact instructions how and when to take Budesonide."
1622273|NCT02069834|Drug|Arm 1 (intervention)|Dolutegravir 50 mg/j + Rilpivirine 25 mg/j qd orally (intake during meal)
1622274|NCT02069834|Drug|Arm 2 (control)|Continuation of existing HAART at the time of randomization
1622275|NCT02069821|Drug|combination administration|combination administration : amlodipine/valsartan 10/160mg and atorvastatin 40mg, qd, 10days(oral)
1622276|NCT02069808|Drug|Follistim|Follicle stimulating hormone promotes recruitment of follicles for ovulation.
1622277|NCT02069808|Drug|Ganirelix|GnRH antagonist preventing a problematic risk of premature LH surge during ovulation induction therapy.
1622278|NCT02069808|Drug|Menotropins|Combination of follicle stimulating hormone and Luteinizing hormone activity promotes recruitment of follicles for ovulation. Absence or presence of this medication is the difference being tested between the two arms of the study.
1622279|NCT02069808|Drug|Leuprolide|Promotes endogenous LH surge signaling oocyte maturation followed by ovulation. This controls timing for oocyte collection.
1622280|NCT02069808|Procedure|Transvaginal ultrasound guided needle aspiration of oocytes|
1622281|NCT02069795|Other|Voice recording|
1622282|NCT02069782|Other|Home visiting|Home visits are used to assess family needs, provide support and education, and make referrals to relevant community services. The goals of the programs are to improve child health and development, promote positive parenting, prevent child maltreatment, improve maternal and child health, and increasing parental self-sufficiency.
1622283|NCT02069769|Behavioral|communication with oncology team|Oncology team will contact patients and families via telephone at specific intervals
1622284|NCT02069743|Other|ePAL Mobile Application|A mobile application designed to help cancer patients better self-manage cancer pain.
1622285|NCT02069730|Drug|Selinexor|
1622286|NCT02069730|Drug|EGFR or HER2 Inhibitor|
1622287|NCT02069730|Drug|FGFR Inhibitor|
1622288|NCT02069730|Drug|C-KIT Inhibitor|
1622289|NCT02069730|Drug|Anti-androgen|
1622290|NCT02069730|Drug|NOTCH Inhibitor|
1622291|NCT02069730|Drug|MEK or PI3K Inhibitor|
1622292|NCT02069717|Other|Not applicable-observational study|
1622293|NCT02069704|Drug|Bevacizumab biosimilar (BEVZ92)|"Bevacizumab biosimilar (BEVZ92), Active ingredient Bevacizumab 25 mg/mL (strength = 100mg/mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).
FOLFIRI = Folinic Acid + Fluorouracil + Irinitecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).
*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.
The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
1622294|NCT02069704|Drug|Avastin® (bevacizumab, reference product)|"Avastin® (bevacizumab, reference product). Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).
*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.
The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care."
1622295|NCT02069691|Device|virtual reality-cycling training system|
1622296|NCT02069665|Other|Fuxiong San|external application; 8-10cm wide, 0.3-0.5cm thick; 10mins for patient aged 1 to 3-year old; 15mins for those aged 3 to 5-year old; once daily
1622297|NCT02069665|Drug|Xiyanping injection|ivd. 5 to 10 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
1622298|NCT02069665|Drug|Ribavirin Injection|ivd. 10 to 20 mg/(kg•d), plus 5% Glucose Injection, 80 to 100 ml, ivd. Once a day injection.
1622299|NCT02069665|Drug|Xiaoer Qingfei Heji (mixture)|children aged 6 months to 1 year old: 10 ml, orally taken three times daily; children aged 1 to 3 year old: 15 ml, orally taken three times daily; children aged 3 to 5 year old: 20 ml, orally taken three times daily;
1622300|NCT02069665|Drug|Zhi Ke San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
1622301|NCT02069665|Drug|Hua Tan San|children aged 6 months to 1 year old: 0.5g, orally taken three times daily; children aged 1 to 3 year old: 1.5g, orally taken three times daily; children aged 3 to 5 year old: 2.0g, orally taken three times daily;
1622302|NCT02069665|Drug|Guaifenesin Syrup|children aged 6 months to 1 year old: 3ml, orally taken three times daily; children aged 1 to 3 year old: 5ml, orally taken three times daily; children aged 3 to 5 year old: 8ml, orally taken three times daily;
1639890|NCT01932775|Device|GlucoTab System|
1622305|NCT02069652|Behavioral|Lifestyle Counseling|Lifestyle Counseling
1622306|NCT02069639|Other|no treatment|
1622307|NCT02069626|Procedure|compression time of the laparoscopic linear stapler|
1622308|NCT02069600|Device|Continuous Positive Airway Pressure|"CPAP applies a positive pressure into the airway to avoid its collapse during sleep.
The pressure used in each patient is calculate by an auto CPAP device during 3 months. This device calculate the pressure that avoid 95% of sleep-disordered breathing"
1622309|NCT02069587|Dietary Supplement|pomegranate|
1622310|NCT02069574|Procedure|non-surgical periodontal therapy|
1622311|NCT02069561|Dietary Supplement|Eicosapentaenoic Acid|Twenty patients with long-standing ulcerative colitis undergoing the usual colonoscopic surveillance + biopsy sampling will be recruited. At entry six extra biopsy samples will be collected from the colon. We will also collect blood (for serum, plasma and red cells isolation), urine and stools. Subjects will then receive 2 g/day of Eicosapentaenoic Acid (ALFA ™, SLA Pharma AG, Switzerland) as a supplement for 90 days. At the end of the study each subject will undergo sigmoidoscopy for the collection of 6 biopsies. Blood, urine and stools will be obtained prior to the procedure.
1622312|NCT02069535|Biological|AVANZ Cupressus|AVANZ Cupressus
1622313|NCT02069522|Other|Standard Milk-based Formula Containing Carotenoid|Fed ad libitum
1622314|NCT02069522|Other|Investigational Milk-based Formula Containing Carotenoid|Fed ad libitum
1622315|NCT02069496|Biological|Arepanrix®|Injected according to the prescribing information in the locally approved label by the authorities.
1622316|NCT02069483|Behavioral|Motivational Interviewing|Subjects will engage in motivational interviewing in order to generate motivating messages related to quitting smoking.
1622317|NCT02069483|Behavioral|Tailored Feedback|Subjects will self-generate reasons they want to quit smoking during the baseline survey and record these reasons during the in-person activity.
1622318|NCT02069470|Behavioral|Continuing Medical Education|3-hour after work meeting. Multifaceted form. Content: Cancer symptoms positive predictive values, pit falls, reflections on barriers and attitudes towards early cancer diagnosis.
1622319|NCT02069444|Procedure|Macintosh laryngoscope|intubation criterias withMacintosh laryngoscopein pediatric patients
1622320|NCT02069444|Procedure|Truview EVO2 laryngoscope|intubation criterias with Truview EVO2 laryngoscope in pediatric patients
1622323|NCT02069418|Radiation|18F-FLT-TEP|Patients are going to have two 18F-FLT-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
1622324|NCT02069418|Radiation|18F-FDG-TEP|Patients are going to have two 18F-FDG-TEP : one during the two weeks before the beginning of erlotinib and the second one will occur during the second week after the initiation of erlotinib.
1622325|NCT02069405|Other|Relaxation Music|
1622326|NCT02069392|Behavioral|Cognitive remediation training|
1622327|NCT02069392|Drug|Nicotine polacrilex lozenge|Of interest are the effects of nicotine on cognitive remediation training benefits.
1622328|NCT02069379|Drug|Metformin|Women classified as insulin resistant will participate in both a placebo and a metformin treatment arm, each lasting about 16 weeks. Women will be randomized to order of treatment arms.
1622329|NCT02069379|Drug|Placebo|Placebo capsules prepared identically to Metformin capsules
1622330|NCT02069366|Drug|Dronabinol|Dronabinol (7.5mg) is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and is placed in opaque capsules with dextrose filler. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive dronabinol.
1622331|NCT02069366|Drug|Placebo|Placebo is administered only once (approximately 120 min prior to fMRI scanning in Visit 3) by the oral route and contains only dextrose in opaque capsules. Half of the participants in each diagnostic group [HC = 20; PTSD = 20; TEC = 20] will receive placebo.
1622334|NCT02069340|Drug|zoledronic acid|Given IV
1622335|NCT02069340|Other|pharmacological study|Correlative studies
1622336|NCT02069314|Dietary Supplement|Whey protein supplementation|subjects are asked to consume a smoothie with whey protein added
1622337|NCT02069314|Dietary Supplement|Carbohydrate (polycose) supplementation|Subjects are asked to consume a beverage with polycose added
1622338|NCT02069301|Behavioral|Behavioral Activation and Problem Solving Group Therapy|LIFE-DM depression group, uses behavior activation and problem solving therapy skills to teach patients how to manage mood and reach livelihood goals.
1622339|NCT02069301|Drug|Guideline Antidepressant Care|Guideline antidepressant care
1622340|NCT02069301|Other|LIvelihood Support|Livelihood support, including group-based loans to develop small enterprise, personal finance management education, business management skills, vocational training, and rotating-credit savings program.
1622341|NCT02069288|Drug|Fludrocortisone|50 µg of fludrocortisone per os
1622342|NCT02069288|Drug|Placebo|1 tablet of placebo per os
1622343|NCT02069275|Other|Immediate mobilization|Patients are mobilized immediate after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device. Heparin reverted with Protaminsulphate
1622344|NCT02069275|Other|Two hours bedrest|Patients is following the usual regimen, two hours bedrest after coronary angiography and percutaneous coronary intervention via femoral access and closed with Angio-seal closing device before mobilization. Heparin is reverted with Protaminsulphate
1622345|NCT02069262|Other|rebleeding|Those who developed rebleeding during the observation would be crossed over to the other investigation modality.
1622385|NCT02068859|Drug|Diclofenac Cream 8%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
1622386|NCT02068859|Drug|Diclofenac Gel 1%|Subjects will be given instructions to apply the study drug topically 3-4 times daily to the affected knee. Application instructions will also be printed on the tubes of products.
1622346|NCT02069249|Behavioral|Healthy Sleep intervention|Healthy Sleep Intervention (HSI)- This online interactive e-learning system will include information for parents on the following topics: (a) establishing appropriate bedtime, including how to assess the sleep needs of their child, how to establish regular bedtime and overall sleep schedule, how to deal with daytime naps; (b) establishing a regular and enjoyable bedtime routine (e.g. bedtime stories); (c) coping with bedtime resistance, setting limits to excessive demands, rewarding appropriate sleep related behaviors; (d) coping with bedtime and nighttime fears, strategies to deal with separation anxieties, fears of darkness, scary imaginative creatures etc; (e) coping with excessive night-wakings and eliminating potential reinforcing consequences; (f) coping with nightmares, night terrors and other parasomnias (e.g., night-walking).
1622347|NCT02069249|Behavioral|Healthy Nutrition intervention|Healthy Nutrition Intervention (HNI)- This online system will include information for parents on the following issues: (a) increasing awareness and making healthy food choices; (b) increasing appeal of healthy food by games, rewards, and child involvement in preparation and cooking; (c) setting rules regarding proper eating environment, family meals and schedules; (d) limiting the presence of unhealthy food and beverage temptations at home; (e) limiting TV and other screen time and increasing physical activities; (f) encouraging parents to be positive role models for all these principles.
1622348|NCT02069236|Other|G6PD Test|All subjects are tested by multiple G6PD tests
1622349|NCT02069223|Procedure|Gastrectomy|
1622350|NCT02069223|Procedure|BPD-DS|
1622351|NCT02069210|Other|Blood transfusion|Intraoperative blood transfusion
1622352|NCT02069197|Other|Ketogenic diet|ketogenic diet will consist of 3:1[fat]:[protein+carbohydrate]weight ratio with 1600 kcal restriction. Diet will last 9 months.
1622353|NCT02069197|Drug|Orlistat|Orlistat 120 mg TID for 9 months; life style intervention with recommended caloric goal of 1600 kcal/day.
1622354|NCT02069197|Other|Standardized diet|Standardized diet treatment for 9 months with recommended caloric goal of 1600kcal/day.
2011061|NCT02724956|Device|Ambu AuraGain|Pre-curved, rigid airway tube, SGAD. Third generation Ambu laryngeal mask satisfying 3 fundamental airway management needs by integrating gastric access and intubation capability in an anatomically curved single-use device that facilitates rapid establishment of a safe airway. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
2011062|NCT02724956|Device|Teleflex LMA Protector|Pre-curved, rigid airway tube, SGAD: A next-generation, single-use laryngeal mask with a dual gastric drainage channel and pharyngeal chamber. A SGAD used for ventilation, and a conduit for intubation. SGAD insertion followed by fiber-optic evaluation using Ambu aScope.
1622357|NCT02069158|Drug|PF-05212384|iv administrartion
1622358|NCT02069158|Drug|Paclitaxel|iv administration
1622359|NCT02069158|Drug|Carboplatin|iv administration
1622360|NCT02069145|Drug|OMP-54F28 with Sorafenib|
1622361|NCT02069132|Drug|Warfarin|warfarin treatment will be determined by treating physicians according to in-hospital guidelines, blindly to genotype assessment.
2011063|NCT02724956|Device|Ambu aScope|Flexible scope which will be introduced into airway tube and guided through the SGAD until it will be possible to view the vocal cords. Description of the maximal optical view will be measured by the Percentage of Glottic Opening (POGO).
1622364|NCT02069106|Dietary Supplement|Pro-Omega LDL|
1622365|NCT02069106|Other|Placebo|
1622366|NCT02069093|Drug|Dexamethasone based mouthwash|Dexamethasone steroid-based oral solution, comprised of 0.5 milligrams per 5mL of alcohol-free dexamethasone.
1622367|NCT02069093|Drug|Everolimus|Commercially available everolimus 10 mg was prescribed to participants by the Investigator according to local regulations.
1622368|NCT02069093|Drug|Exemestane|Commercially available exemestane 25 mg was prescribed to participants by the Investigator according to local regulations.
1622372|NCT02069015|Behavioral|Patient education|Patient education on hypertension delivered through a touchscreen kiosk.
1622373|NCT02069002|Behavioral|Cognitive-Behavioral Therapy (CBT)|
1622374|NCT02069002|Behavioral|Applied relaxation group therapy|
1622375|NCT02069002|Behavioral|Information session (psychoeducation)|
1622376|NCT02068950|Behavioral|Progressive resistance training|A 12-week, supervised, group based, progressive resistance training program involving the major muscle groups of the body will be tested. Details of the program: 12 weeks, 3 sessions per week, 7 exercises (leg press, leg curl, hamstring curl, chest press, lateral pull down, sit-ups and back extensions). In general 2-3 sets of 8-15 repetitions will be performed following a progression plan starting with more repetitions at lower intensity progressing to fewer repetitions at higher intensity during the 12-week period (American College of Sports Medicine Position Stand)
1622377|NCT02068937|Drug|Furosemide and Phone contact|The intervention group is conducted by a nurse in a systematic way during one time per week. If signs and symptoms of congestion, the dose of diuretic ( furosemide ) is revised , nonpharmacological guidelines are provided. According to the algorithm 1KG weight changes are indicative of modifying the diuretic dose , with the addition or reduction 1 tablet a day (1 tablet equivalent to 40 milligrams of furosemide)
1622378|NCT02068937|Drug|Furosemide|This group received just diuretic adjusted (Furosemide 40 milligrams) by the doctor on the baseline.
1622379|NCT02068924|Other|Slow freezing versus vitrification|
1622380|NCT02068911|Device|Monitoring of ETCO2 and PTCO2|Concomitant monitoring of ETCO2 and PTCO2
1622381|NCT02068898|Drug|XS003|
1622382|NCT02068898|Drug|Tasigna|
1622383|NCT02068885|Behavioral|Feeding study|Food provision throughout the study to all 3 dietary arms, with the following phases: 1) Weight loss; 2) Weight maintenance; 3) Ad libitum
1622384|NCT02068872|Procedure|Sleeve Gastrectomy|To assess the safety, tolerability and feasibility of sleeve gastrectomy in the perioperative period following liver transplantation in obese (BMI of > 40 or > 35 kg/m2 in the presence of at least one major obesity related co-morbidities (e.g. type 2 diabetes, hypertension, sleep apnea, heart disease, etc) adult subjects aged 18-75 years of age.
1622387|NCT02068846|Drug|Ciprofloxacin|20 (SGDHIV) Participants will be randomized to either Ciprofloxacin or a Placebo arm. Ciprofloxacin 500mg will be over encapsulated and taken 2x daily for 28days, Placebo will also be over encapsulated and taken 2x daily for 28days. This study is double blinded. Each study participant will be consented and be required to complete study questionnaires.
1622388|NCT02068846|Drug|Placebo|
1622389|NCT02068833|Procedure|Gastrectomy|
1622390|NCT02068833|Procedure|BPD-DS|
1622391|NCT02068820|Device|ISB dye and standard white light imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system and ISB dye with standard white light imaging.
1622392|NCT02068820|Device|ICG dye and FireFly fluorescence imaging|Sentinel lymph node mapping utilizing the da Vinci surgical system with ICG dye and FireFly fluorescence imaging.
1622393|NCT02068807|Dietary Supplement|Lutein drops|After randomisation, the infant received orally a total dose of 0.28 mg of lutein in two doses: within 6 hours after birth and at 36 hours of life
1622394|NCT02068807|Dietary Supplement|Glucose drops|After randomization, newborns received 0.5 mL of 5% glucose solution in two doses: within 6 hours (hrs) after birth and at 36 hrs of life.
1622398|NCT02068781|Dietary Supplement|Low-sodium diet|50 mmol NaCl per 24h
1622399|NCT02068781|Dietary Supplement|High-sodium diet|250 mmol NaCl per 24h
1622400|NCT02068768|Device|Avenue® L Interbody Fusion System (LDR Spine)|PEEK, intervertebral cage for interbody fusion of the lumbar spine
1622401|NCT02068742|Other|battery neuropsychological tests|Application of the scores will be on the day 0 (the day before the surgery), day 2 and day 4 (after the surgery).
1622402|NCT02068703|Behavioral|Sleep Education Presentation|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep WITHOUT a demonstration of tools to improve sleep.
1622403|NCT02068703|Behavioral|Sleep Tool Demonstration|Subjects will receive a 10 minute presentation, aimed at educating on the value of sleep PLUS a demonstration of tools to improve sleep.
1622404|NCT02068690|Drug|BI 425809 PfOS|BI 425809 PfOS
1622405|NCT02068690|Drug|Placebo|Placebo
1622406|NCT02068690|Drug|Placebo|Placebo
1622407|NCT02068690|Drug|BI 425809 tablet|BI 425809 tablet
1622408|NCT02068690|Drug|BI 425809 PfOS|BI 425809 PfOS
1622409|NCT02068677|Other|Sympathetic response|Sympathetic response will be defined as change in heart rate by >10 bpm and change in BP <10mmHg.
1622410|NCT02068677|Other|no sympathetic response|no Sympathetic response will be defined as change in heart rate by <10 bpm and change in BP <10mmHg.
1622411|NCT02068664|Behavioral|prism adaptation treatment|Prism goggles shift the image one sees toward the left (because the thicker portion of the glass lens is on the right). This will change the perception of where the image is in space, causing the person to adapt. The after-effects of the treatment is what is important. It has been shown to make it easier for people to move in the right space (if have right neglect) or improves ability to complete other functional tasks.
1622412|NCT02068651|Behavioral|Advance care planning programme|It is a multi-faceted programme which includes an educational component with support of multimedia materials, reflection on personal values and a facilitated discussion between patient and family carer over future care. It will be delivered to each pair of participant and family carer on individual basis. By the end of the programme, each participant will have a personal workbook summarising the advance care planning process for record.
1622413|NCT02068638|Procedure|IHE first, CONT second|IHE: intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes. CONT (occurring after a washout period of 2-8 weeks): continuous moderate intensity exercise of 90 minutes
1622414|NCT02068638|Procedure|CONT first, IHE second|CONT: continuous moderate intensity exercise of 90 minutes. IHE (occurring after a washout period of 2-8 weeks): intermittent high intensity exercise: integration of 10 s maximal sprints every 10 minutes in a continuous low to moderate intensity exercise of 90 minutes
1622415|NCT02068638|Procedure|GLU first, GLU-FRU second|: ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU FRU (occurring after a washout period of 2-8 weeks): ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes
1622416|NCT02068638|Procedure|GLU-FRU first, GLU second|GLU-FRU : ingestion of a 12% carbohydrate solution (consisting of 90 g glucose + 90 g fructose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes. GLU (occurring after a washout period of 2-8 weeks): : ingestion of a 6% carbohydrate solution (consisting of 90 g glucose dissolved in 1500 ml tap water) over a continuous moderate exercise of 90 minutes.
1622417|NCT02068625|Drug|Rasagiline|Rasagiline 1mg daily orally for 7 days
1622418|NCT02068625|Drug|Placebo|Oral treatment with placebo for 7 days
1622419|NCT02068612|Behavioral|Moderate Intensity Continuous Training+Interval Training|
1622420|NCT02068612|Behavioral|Low Intensity Continuous Training|
1622421|NCT02068599|Drug|TV-45070|TV-45070 ointment 4% and 8%
1622422|NCT02068599|Drug|Placebo|Matching placebo
1622425|NCT02068573|Device|Ventilation|The ventilation system is placed outside the house and provides filtered conditioned air to the child's bedroom, through insulated pipes mounted in a window opening. The window opening was built specifically for this purpose in form of a thermo plate replacing the window glass. The unit provides the bedroom with at least 2-3 air changes per hour
1622426|NCT02068573|Device|Placebo Ventilation|The placebo unit (DUPLEX 370) is a completely similar installation to the active ventilation unit, but it only recirculates the air in the room instead of replacing it with fresh conditioned air.
1622427|NCT02068560|Drug|dDAVP infusion|
1622428|NCT02068547|Biological|locally harvested autograft, demineralized bone matrix, and cadaveric allograft|
1622429|NCT02068547|Biological|Bone Marrow Aspirate|
1622430|NCT02068521|Drug|somavaratan|Subcutaneous injection
1641681|NCT01919346|Drug|Normal Saline|
1622433|NCT02068482|Drug|Rifaximin|Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months
1622434|NCT02068456|Drug|Roflumilast|
1622435|NCT02068443|Drug|Alogliptin|Alogliptin tablets
1622436|NCT02068443|Drug|Metformin hydrochloride|Metformin hydrochloride tablets
1622437|NCT02068443|Drug|Metformin hydrochloride Placebo|Metformin hydrochloride placebo-matching tablets
1622438|NCT02068430|Drug|Riboflavin 0.1%|After topical anesthesia, 1 drop of Riboﬂavin 0.1% ophthalmic solution will be instilled topically in the eye every 2 minutes for 30 minutes. At the end of the 30 minute riboﬂavin pre-treatment period, the eye will be examined with blue light for the presence of a yellow ﬂare in the anterior chamber.
1622439|NCT02068430|Other|UV-X™ Illumination System|When the yellow ﬂare in the anterior chamber is conﬁrmed, the eye will be aligned under the UV-X™ light with the treatment plane at a working distance that is 50mm from the UV-X™ beam aperture. The correct aperture setting will be selected for the size of the eye (7.5 , 9.5, or 11 mm), and the eye will be irradiated for 30 minutes, during which time instillation of riboﬂavin will continue (1 drop every 2 minutes). At the end of 30 minutes, the UV light source will automatically switch to the off position. The operator will keep track of irradiation time independently to conﬁrm the actual treatment time.
1622440|NCT02068417|Device|shock waves|extracorporeal shock waves: Verum: 0.1 mJ/mm2 Placebo: placebo stand-off
1622441|NCT02068404|Drug|Nifedipine|
1622442|NCT02068391|Behavioral|Stretching Program|The 'Stretching Program' will teach stretching for the upper and lower limbs, and the trunk, as well as breathing exercises for relaxation. Supervised group activities will be performed once per week (45 minutes) and self-directed stretching will be encouraged 4 days per week and monitored by an activity journal. The intensity of stretching and number of stretches will be progressed every 2 weeks. Heart rate and perceived exertion will be monitored. The program will last 6 months.
1622443|NCT02068391|Behavioral|Exercise Program|The 'Exercise Program' will prescribe specific aerobic exercise to the participants. Supervised group exercise will be performed once per week (60 minutes) and self-directed exercise will be encouraged 4 days per week and monitored by an activity journal. The initial walking prescription will be set at ~1.6 km and an intensity equivalent to the anaerobic threshold and/or 60% of peak oxygen uptake. Progressions will be made every 2 weeks, increasing distance to a maximum of 6.4 km and then increasing to a max intensity of 80% of peak oxygen uptake and/or max duration of 60 minutes. Heart rate and perceived exertion will be monitored. The program will last 6 months.
1622444|NCT02068378|Device|CMPE Optical Sensor Device|Christie Medical Physics & Enginieering visual feedback with optical sensing device.
1622445|NCT02068365|Drug|Pegyinterferon-alfa-2a|Pegyinterferon-alfa-2a 180mcq weekly for 48 weeks
1622446|NCT02068352|Drug|OPA-15406|0.3% or 1% OPA-15406 topical ointment, applied twice daily for 8 weeks
1622447|NCT02068352|Drug|Placebo|
1622448|NCT02068339|Drug|Oltipraz 1 (90mg)|
1622449|NCT02068339|Drug|Placebo|
1622450|NCT02068339|Drug|Oltipraz 2 (120mg)|
1622451|NCT02068326|Behavioral|Mentalization Based Treatment|
1622452|NCT02068326|Behavioral|Treatment As Usual|Treatment As Usual
1622453|NCT02068313|Radiation|Toxicity and outcome measures of IMRT|
1622454|NCT02068287|Drug|Esmolol|After, at least six hours of hemodynamic optimization, patients with an hyper dynamic shock received a conventional management with a continuous infusion of Esmolol titrated to gain a 20% reduction in heart rate. This infusion is maintained for six hours.
1622455|NCT02068261|Behavioral|Computerized Cogmed working memory training|Computerized working memory training with Cogmed QM software. The QM software consists of a set of verbal and visual working memory tasks which is trained for 25-40 minutes each session.
1622456|NCT02068261|Behavioral|Treatment as usual|Treatment as usual can consist of medication, psychotherapy, counseling, and psychological assessment.
1622457|NCT02068248|Dietary Supplement|Soluble Fibre|
1622458|NCT02068235|Drug|Ponesimod 5mg i.v.|
1622459|NCT02068235|Drug|Ponesimod i.v.|Dose and infusion rate will be adjusted according to the results of the pilot phase
1622460|NCT02068235|Drug|Ponesimod 10 mg tablet|
1622461|NCT02068222|Drug|ABT-450/ritonavir (r)|Tablet
1622462|NCT02068222|Drug|ABT-530|Tablet
1622463|NCT02068222|Drug|Ribavirin (RBV)|Tablet
1622464|NCT02068209|Drug|Tramadol|patients will receive Tramadol 50mg orally 1 hour before outpatient hysteroscopy.
1622465|NCT02068209|Drug|Placebo|patients will receive a placebo 1 hour before outpatient hysteroscopy
1622466|NCT02068196|Procedure|Blood sampling for Pre-existing immunity|Identify predictive biomarkers of long term study survivors who have substantially benefited from ipilimumab therapy
1622467|NCT02068196|Drug|Ipilimumab|
1622468|NCT02068170|Drug|Haloperidol, azi/clari/erythromycin, levo/moxifloxacin, co-trimoxazole, vori/keto/flu/itraconazole, methadone, tacrolimus, sunitinib|
1622472|NCT02068144|Dietary Supplement|Cranberry Extract|Participants will drink one 15.2 oz bottle of Cranberry Extract beverage daily for 8 weeks.
1622473|NCT02068144|Other|Placebo|Participants will drink one 15.2oz bottle of placebo beverage daily for 8 weeks.
1622474|NCT02068131|Drug|Novaferon|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, 3 times per week for first 2 weeks, followed by 20μg,im, 3 times per week after 2 weeks.
1622475|NCT02068131|Drug|Capecitabine|The dose of capecitabine is 1250 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2500 mg/m2).
1622476|NCT02068118|Device|Telecardiology program|"The telecardiology program is a combination of a scale, a device asking the patients questions about the symptoms associated with their heart failure, and regular phone calls made by nurses.
Automatic algorithms have been built-up in order to detect early the need for a hospitalization due to heart failure."
1622477|NCT02068105|Drug|ALKS 5461|Sublingual tablet
1622478|NCT02068105|Drug|Placebo|Sublingual tablet
1622479|NCT02068092|Drug|Hydroxytyrosol|
1622480|NCT02068079|Drug|Vemurafenib and Trientine|
1622481|NCT02068053|Drug|[14C] BMS-986020|
1622482|NCT02068040|Dietary Supplement|CocoaVia|CocoaVia contains flavanols found natrually in cocoa beans. Capsules will contain 250mg of flavanol
1622483|NCT02068027|Drug|Clonidine Gel 0.1%|
1622484|NCT02068027|Drug|Placebo|
1622485|NCT02068001|Procedure|Roux-en-Y Gastric Bypass|
1622486|NCT02067988|Device|Holmium-166 microspheres hepatic radioembolization.|Holmium-166 microspheres hepatic radioembolization.
1622487|NCT02067975|Drug|Tryptophan|
1622488|NCT02067975|Drug|Placebo|
1622489|NCT02067962|Biological|Blood sample|Blood sample
1622490|NCT02067949|Drug|Simvastatin|single oral tablet 40 mg / day If the patient is able to swallow; the tablet will be given orally. Otherwise, it will be crushed, suspended in water and administered via any existing enteral feeding or gastric drainage tube
1622491|NCT02067936|Drug|Group A propofol + remifentanil|Predicted TOL90% according to Bouillon model
1622492|NCT02067936|Drug|Group B propofol + remifentanil|TOL 90% according to the Bouillon interaction model
1622493|NCT02067936|Drug|Group C propofol + remifentanil|TOL 90% according to the Bouillon interaction model
1622494|NCT02067936|Drug|group D propofol + remifentanil|TOL 90% according to the Bouillon interaction model
1622495|NCT02067910|Drug|Abatacept SC|Weekly subcutaneous administration of 125 mg Abatacept
1622496|NCT02067884|Procedure|dynamic contrast-enhanced ultrasound imaging|Undergo CEUS
1622497|NCT02067884|Procedure|shear wave elastography|Undergo SWE
1622498|NCT02067884|Drug|Definity, (Lipid Microspheres) Intravenous Suspension|Participant will receive contrast agent by intravenous administration
1622499|NCT02067884|Device|Philips Shear Wave Elastography|Equipment used for SWE
1622500|NCT02067871|Other|Laser Therapy|Low-level laser therapy was administered twice a week with a minimum of 48h between sessions over a period of eight weeks.
1622501|NCT02067871|Other|Electrical Stimulation|Neuromuscular electrical stimulation was administered twice a week with a minimum of 48h between sessions over a period of eight weeks and with progressive intensity and volume.
1622502|NCT02067858|Radiation|Stereotactic Radiosurgery|
1622503|NCT02067845|Behavioral|Adapted Many Men, Many Voices (3MV) group level intervention|"The intervention will adapt the Many Men, Many Voices (3MV) group level intervention for MSM to address individual and social determinants of HIV/STI risk and vulnerability. This intervention involves 6 consecutive 2-3 hours sessions conducted at a weekend retreat. We will have 1 retreat in Calgary and 1 retreat in Toronto; each retreat will include 20 persons.
Based on the 3MV format, a draft template includes: Session 1: Intersectionality; Session 2: STI/HIV Prevention Among WSW and LBQ Women; Session 3: STI/HIV Risk Assessment and Prevention Options; Session 4: Relationship Issues; Session 5: Self-efficacy, Resilient Coping and Capacity for Change; Session 6: Social Support and Problem Solving to Maintain Change.
Delivery methods include discussion, role-plays and risk-reduction planning."
1622504|NCT02067845|Behavioral|A group-based HIV/STI prevention intervention for women who have sex with women|
1622505|NCT02067819|Device|Active Oral Orthotic Treatment|Active treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
1622506|NCT02067819|Device|Placebo Oral Orthotic Treatment|After two weeks, this treatment group will receive an occlusal splint adjusted to the appropriate therapeutic height (based on an initial fitting). Participants will be instructed to wear the orthotic 24/7 (or as close as possible) for the duration of the study.
1622507|NCT02067806|Drug|Spinal administration of chloroprocaine|
1622508|NCT02067793|Drug|NRX-1074 1 mg|Single intravenous administration of 1 mg into arm on Day 0
1622509|NCT02067793|Drug|Placebo|Single intravenous injection into the arm on Day 0
1622510|NCT02067793|Drug|NRX-1074 5 mg|Single intravenous injection of 5 mg into the arm on Day 0
1622511|NCT02067793|Drug|NRX-1074 10 mg|Single intravenous injection of 10 mg into the arm on Day 0
1622512|NCT02067780|Drug|Levofloxacin 500mg|One tablet per day for 7days.
1622513|NCT02067767|Drug|Abacavir/Lamivudine/Dolutegravir|"At Day 1 (D1):
group 1 will switch their ongoing treatment of ABC/3TC + NVP to ABC/3TC/DTG ;
group 2 will continue NVP and switch ABC/3TC to ABC/3TC/DTG for 6 days (D-5 to D0), then stop NVP from D1."
1622515|NCT02067728|Behavioral|FNPA tool|Intervention practice will train to use FNPA screening paired with Brief Action Planning. They will implement this approach during well child visits.
1622516|NCT02067728|Behavioral|Usual Care|Practices not undergoing intervention with FNPA tool will provide usual care to patients during well-child visits.
1622517|NCT02067715|Drug|Tooth bleaching|The bleaching agent will be used in a single-application of 45 minutes.
1622518|NCT02067702|Procedure|Limb Cooling Assessment of ET|The non-pharmacological treatment assessments of limb cooling will take place for the subjects which will include the upper limbs. Both clinical and physiological recordings will be measured for a difference in tremors at three different temperatures. 1)baseline assessment maintaining a normal body temperature (96-98°F). 2) at a temperature of 59°F and 3) at a temperature of 80°F for a period of 10 minutes. The clinical assessments will include the Tremor Rating Scale (TRS), Handwriting Assessment Battery (HAB) and the Functional Dexterity Test (FDT). In addition, the Bagnoli and Trigno EMG systems to record surface EMG signals from muscles and accelerometer readings.
1622519|NCT02067689|Device|Transcranial Direct Current Stimulation|Application of a weak electrical current to the scalp
1622522|NCT02067663|Device|Paragard|The IUD will be placed as part of standard clinical care.
1622523|NCT02067663|Drug|Mirena|The IUD will be placed as part of standard clinical care.
1622524|NCT02067624|Other|Thai massage|
1622525|NCT02067611|Drug|X0002|Parallel Assignment
1622526|NCT02067611|Drug|Placebo|Parallel Assignment
1622527|NCT02067598|Other|scapular exercise|
1622650|NCT02066727|Drug|Dexmedetomidine|Dexmedetomidine is administrated as an adjuvant of lidocaine at a dose of 1.0 μg/ kg.
1622528|NCT02067585|Dietary Supplement|Standardized Lipid meals|Standardized Lipid meals: 240 ml of Hormel Great Shake Plus liquid nutritional supplement, 203 Kcal/100mL; 49% calories from fat, mostly unsaturated fatty acids of soy origin; 38% calories from carbohydrates, 13% calories from proteins.
1622529|NCT02067572|Other|Saline mouthwash|
1622530|NCT02067572|Other|Salvia mouthwash|
1622531|NCT02067559|Behavioral|ICU Diary|Creation of an ICU diary: A bound empty journal will be stored at the patient's bedside near the nurse charting area. All family members and ICU staff are invited to write in the ICU diary at any time. Procedure for diary writing will follow previous research (see www.icu-diary.org).
1622532|NCT02067559|Behavioral|Psychoeducation|The psychoeducation brochure will describe procedures in the ICU (sedation, ventilation), and the delirium, hallucinations, and trauma that may result; as well as symptoms of PTSD post-ICU. It will provide instructions for follow-up, information, and emergency care. The brochure will instruct participants to contact their follow-up healthcare provider if they have any questions.
1622533|NCT02067546|Device|Experimental toilet seat|
1622534|NCT02067546|Device|Standard toilet seat|
1622535|NCT02067533|Procedure|soft tissue repair in flexion position|
1622536|NCT02067533|Procedure|soft tissue repair in extension position|
1622538|NCT02067507|Behavioral|Tailored education and referral|LACDPH Site: 5-minute tailored educational messages and clinic referral for vaccine plus tailored small media
1622539|NCT02067507|Behavioral|Clinic training and patient reminders|AltaMed Health Services Corporation Site: (1) Health care provider training on the importance of HPV vaccination, strategies to appropriately frame the HPV vaccine conversation, and recommended processes and procedures for vaccine delivery; (2) Staff training on the importance of HPV vaccination, strategies to promote uptake of the vaccine, and recommended processes and procedures for vaccine delivery; and (3) Patient education materials and reminders to promote completion of the three-dose vaccine series.
1622540|NCT02067507|Behavioral|Clinic-level reminder systems|Northeast Valley Health Corporation Site: Mailed letter, automated/robo telephone call, or text message reminder
1622541|NCT02067494|Other|Myofascial Soft Tissue Release|Protocol: Myofascial release on thoracolumbar fascia, Myofascial release on diaphragm, Myofascial release in the psoas fascia, Indirect Myofascial release restrictions in the public area, Myofascial release in lumbo-sacral decompression, Myofascial release on sacrum, and Myofascial release on the lumbar fascia.
1622542|NCT02067494|Other|Kinesio taping treatment|"Two bands in I, with anchor onset in sacrum, on paravertebral muscles. Furthermore a strip will be applies on correction space point of maximum pain."
1622543|NCT02067481|Behavioral|Weight loss intervention|This single-arm pre-post study, that involved one-hourly weekly diet sessions delivered by a dietician and 75-minute bi-weekly Physical Activity (PA) sessions of moderate-to-high intensity led by PA monitors, was offered to overweight and obese BC survivors shortly after treatment. Before and after the intervention, anthropometry, dietary information, Quality of Life (QoL) and cardiorespiratory fitness (CRF) were collected.
1622544|NCT02067468|Device|HPV test|QIAGEN - The Digene HPV test®
1622545|NCT02067468|Procedure|COLPOSCOPY|Colposcopy routine health services
1622546|NCT02067468|Device|cytology|Cytology routine health services
1622547|NCT02067455|Other|adding 2 cardiopulmonary exercise testings : peak oxygen consumption (VO2 max) and stress echocardiography|
1622548|NCT02067442|Drug|oral acetaminophen|1000 milligrams given orally before surgery
1622549|NCT02067442|Drug|intravenous acetaminophen|1000 milligrams of intravenous acetaminophen given before surgery
1622550|NCT02067429|Procedure|Limbal Relaxing Incisions|
1622551|NCT02067429|Device|Toric Intraocular Lens|
1622552|NCT02067416|Drug|Anthracycline based chemotherapy|standard of care neoadjuvant treatment with anthracycline based chemotherapy
1622553|NCT02067416|Drug|taxane-based chemotherapy|neoadjuvant taxane based chemotherapy given as standard of care
1622554|NCT02067403|Other|Pressure-support Eadi optimization|
1622555|NCT02067377|Dietary Supplement|Serum bovine immunoglobulin (SBI) medical food|Serum bovine immunoglobulin (SBI) is an FDA regulated, orally administered prescription medical food intended for the nutritional management of patients who are unable to absorb necessary nutrients as a result of therapeutic or chronic medical problems.
1622556|NCT02067377|Dietary Supplement|Placebo (for serum bovine immunoglobulin)|
1622557|NCT02067364|Device|Fit & Function test|
1622558|NCT02067351|Behavioral|Mindfulness|Meditation, body scan, yoga.
1622559|NCT02067338|Drug|1 mg morphine soak in epidural oxidized cellulose|During posterior lumbar spinal surgery , patients received 1 mg morphine-soaked in epidural oxidized cellulose.
1622560|NCT02067338|Drug|normal saline|During posterior lumbar spinal surgery , patients received NSS -soaked in epidural oxidized cellulose.
1622561|NCT02067325|Other|Thai massage|
1622562|NCT02067312|Other|Thai massage|
1622563|NCT02067299|Drug|JNJ-42847922|Participants will receive suspension of JNJ-42847922 (10 mg, 20 mg, and 40 mg) orally on Day 1 of the appropriate treatment periods.
1622564|NCT02067299|Other|Placebo|Participants will receive placebo orally on Day 1 of the appropriate treatment periods.
1622565|NCT02067273|Device|Transcranial Magnetic Stimulation (TMS)|
1622566|NCT02067260|Device|X5 HairLaser|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
1622567|NCT02067260|Device|X5 Hair Laser Sham Device|Treatment consists of three, 10-15 minute, at-home treatments per week (on nonconcurrent days) for 26 weeks.
1622568|NCT02067247|Device|BeamMed Speed-of-Sound bone strength test at forearm|BeamMed Speed-of-Sound bone strength test at forearm in addition to the DEXA test
1622569|NCT02067234|Other|Routine Care/Education|Nursing staff will spend time educating the patient and family about therapy involved in medically treating atopic dermatitis. This might include different topical therapy to use as well as how often to apply and when to apply.
1622570|NCT02067234|Behavioral|Psychoeducation/Coping Prevention|In addition to routine care, the psychologist will meet with family to review psychoeducation about the mind-body connection as well as introduce and review different strategies regarding coping with stress, sleep strategies, and behavior strategies.
1622651|NCT02066727|Drug|Normal Saline|Normal Saline is administrated as an adjuvant of lidocaine.
1622571|NCT02067221|Device|RIRS|"RIRS arm
Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract"
1622572|NCT02067221|Device|MPCNL|"MPCNL arm
A new technique that reduced the size of percutaneous tract to make renal stone into small pieces."
1622573|NCT02067208|Device|wedged insole|Wedged insoles are designed to reduce frontal plane knee joint mechanical loads during gait. Specifically, they can alter the knee adduction moment during gait - a variable associated with progression of knee osteoarthritis. In the experimental arm of this study, participants will undergo biomechanical gait analysis to identify the wedged insole that reduces the moments the most. The two options are medial wedge, where the medial aspect of the foot is elevated relative to the lateral aspect, and the lateral wedge, where the lateral wedge is elevated relative to the medial aspect.
1622574|NCT02067195|Drug|Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride)|No hydration for patients without chronic kidney disease(CrCl<60ml/min),or Receiving hydration with a 1 mL/kg bolus of intravenous isotonic saline (0.9% sodium chloride) after diagnosis of chronic kidney disease until 24 hours after PCI. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
1622575|NCT02067195|Drug|3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride)|Receiving hydration with a 3 mL/kg.hour bolus of intravenous isotonic saline (0.9% sodium chloride) from randomization to the end of the procedure, the measurement of LVEDP was conducted after the procedure, a sliding-scale hydration was employed in the LVEDP-guided hydration arm that was based on LVEDP for 2 hours: 5 ml/kg/hr for LVEDP <13 mmHg, 3 ml/kg/hr for LVEDP 13-18 mmHg, and >1.5 ml/kg/hr for LVEDP >18 mmHg, whereas,0.5 ml/kg/hr for LVEDP >20 mmHg, continue hydration with a 1 mL/kg until 24 hours after procedure. Hydration rate was reduced to 0.5 mL/kg per hour in patients with New York Heart Association class III or KillipⅡ/Ⅲ.
1622576|NCT02067182|Drug|Dabigatran|"Antral pulmonary vein ablation for patients with AF
left atrial fibrosis/electrical scar assessment by electroanatomical mapping
followed by 6 months OAC (3 months blanking period + 3 months observation period)
in case of AF-recurrence in month 4-6: re- pulmonary vein ablation
followed again by 6 months OAC (3 months blanking period + 3 months observation period)
AF-free patients as assessed by 72h Holter ECG and symptoms wil be random-izedals to the following two interventional arms:
Experimental arm (group A): OAC with dabigatran for 12 months
Control arm (group B): No OAC (no placebo medication) for 12 months - Cerebral MRI at randomisation and 12 months later"
1622577|NCT02067169|Biological|CMV Infection|Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for . Resistance testing towards any antiviral available by genotype and phenotype (when an isolate is obtained) when resistance criteria are fulfilled. Plasma collection at treatment initiation, and in case of neutropenia, for antiviral dosage.
1622578|NCT02067156|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
1622579|NCT02067143|Drug|Prephase PDN + CY|
1622580|NCT02067143|Drug|Cycle 1 Induction|
1622581|NCT02067143|Drug|Cycle 2 Induction / Early consolidation|
1622582|NCT02067143|Drug|Cycle 3 Early consolidation|
1622583|NCT02067143|Drug|Cycle 4 Consolidation|
1622584|NCT02067143|Drug|Cycle 5 Consolidation|
1622585|NCT02067143|Drug|Cycle 6 Consolidation|
1622586|NCT02067143|Drug|Cycle 7 Consolidation|
1622587|NCT02067143|Drug|Cycle 8 Reinduction|
1622588|NCT02067143|Drug|Maintenance|If MRD negative MRD u/k SR
1622589|NCT02067143|Procedure|Allogeneic SCT or Autologous SCT|If MRD positive MRD u/k HR
1622590|NCT02067130|Procedure|Fibroscan|Transient elastography (Fibroscan®) is an affordable and noninvasive tool for measuring liver stiffness as a predictor of liver fibrosis. Since Fibroscan® measures liver's stiffness, its utility is not limited to fibrosis, and has been extended to other conditions that would increase the liver's stiffness, such as amyloidosis (Loustaud-Ratti et al. Amyloid 2011) and perhaps iron overload.
1622591|NCT02067117|Drug|GC FLU® Injection, GC FLU® Pre-filled Syringe Injection|
1622592|NCT02067104|Drug|Vismodegib|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
1622593|NCT02067104|Drug|Placebo|Pulse therapy pattern of 2 months of daily treatment and 2 months of no treatment for 24 months.
1622594|NCT02067091|Device|stent implant in a coronary artery|"Implantation of device called a stent in a coronary artery
Percutaneous coronary intervention"
1622595|NCT02067078|Drug|Dexamethasone 4 mg + Clonidine 75 microgram + Marcaine 90 mg + Adrenaline 90 microgram|Dexamethasone 4 mg Clonidine 75 microgram Marcaine 90 mg Adrenaline 90 microgram
1622596|NCT02067078|Drug|Dexamethasone 2 mg + Clonidine 37,5 microgram + Marcaine 45 mg + Adrenaline 45 microgram|Dexamethasone 2 mg Clonidine 37,5 microgram Marcaine 45 mg Adrenaline 45 microgram
1622597|NCT02067078|Drug|Ropivacaine + Toradol + Adrenaline|Ropivacaine 300 mg + Toradol 45 mg + Adrenaline 0,75 mg
1622598|NCT02067065|Drug|Non-anesthesiologist propofol sedation|Bolus propofol sedation administered according to non-anesthesiologist propofol sedation guidelines of the European Society of Gastrointestinal Endoscopy
1622599|NCT02067065|Drug|Propofol sedation administered by an anesthesiologist|Propofol sedation by an anesthesiologist
1622600|NCT02067065|Procedure|Colonoscopy|Elective total colonoscopy with or without biopsies, polypectomies or mucosal resection, as clinically indicated
1622601|NCT02067052|Procedure|Surgery, radiotherapy and chemotherapy|Surgery: vulvectomy and lymphadenectomy Radiotherapy: 180 cGy / day per 5 days untill maximum dose 4500 - 5940 cGy Chemotherapy: vulvectomy, lymphadenectomy
1622602|NCT02067052|Procedure|Surgery|Vulvectomy & lymphadenectomy
1622603|NCT02067039|Device|OraQuick in home & Sure Check HIV tests|Provision of OraQuick in home & Sure Check HIV tests
1622604|NCT02067026|Dietary Supplement|Aleurone|
1622605|NCT02067026|Dietary Supplement|Placebo|
1622606|NCT02067013|Drug|Ranibizumab|Subjects in the Ranibizumab arm will receive an injection of drug within 2 weeks prior to their surgery.
1622607|NCT02067013|Other|No Ranibizumab|Subjects in the control arm will NOT receive an injection of drug within 2 weeks prior to their surgery.
1622652|NCT02066688|Drug|folic acid|Patients receive oral folic acid 1mg daily for 36 months in the absence of unacceptable toxicity or any other adverse effects.
1622609|NCT02066987|Behavioral|Implementation intention|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.
If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth! If it is _____ (WHEN) at or in _______ (WHERE) before/after ______ (ACTIVITY), then I will brush my teeth!"
1622610|NCT02066987|Behavioral|Action planning|"It may be helpful for you to plan when and where you will brush your teeth each day over the next month. Please write below when, where, and after what activity you will brush your teeth (e.g., at 8.00 a.m. and 9.00 p.m. in the bathroom after eating breakfast/dinner). Because you should brush your teeth twice a day, please make two plans.
I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY).
I will brush my teeth at ___(WHEN) at or in ____(WHERE) before/after ___ (ACTIVITY)."
1622611|NCT02066987|Behavioral|active control group|Participants in the active control group will receive an educational pamphlet containing what it is dental brushing, why it is done, and how it is done.
1622612|NCT02066974|Genetic|hepatoma requiring radiotherapy|hepatoma requiring radiotherapy
1622613|NCT02066948|Other|wt loss|subjects will consume a 750 reduced calorie daily diet based on current ht. wt and age
1622614|NCT02066948|Other|Meal Pattern|Even or skewed distribution of protein for a 16 week period of wt loss.
1622615|NCT02066948|Other|meal pattern|skew or even
1622616|NCT02066948|Dietary Supplement|even|even amount of protein distributed between each meal
1622617|NCT02066948|Dietary Supplement|skew|a skewed amount of protein is distributed between each meal
1622618|NCT02066935|Other|kidney transplant patient|kidney transplanted patients for at least one year
1622619|NCT02066922|Device|Delefilcon A contact lens|Commercially available silicone hydrogel contact lens
1622620|NCT02066922|Device|Narafilcon A contact lens|Commercially available silicone hydrogel contact lens
1622621|NCT02066922|Device|Spectacles|Incremental prescription worn over contact lenses if needed to provide acceptable vision
1622622|NCT02066909|Drug|0.15 mg PF-06649751|Oral dosing of 0.15 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
1622623|NCT02066909|Drug|0.5 mg PF-06649751|Oral dosing of 0.5 mg PF-06649751 extemporaneously-prepared solution given once-daily for 14 days.
1622624|NCT02066909|Drug|0.5 mg PF-06649751|Oral dosing of tablets up to 0.5 mg PF-06649751 given once-daily for 14 days.
1622625|NCT02066909|Drug|1.5 mg PF-06649751|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days.
1622626|NCT02066909|Drug|1.5 mg PF-06649751 21 Days|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 21 days.
1622627|NCT02066909|Drug|3.0 mg PF-06649751|Oral dosing of tablets up to 3.0 mg PF-06649751 given once-daily for 28 days.
1622628|NCT02066909|Drug|5.0 mg PF-06649751|Oral dosing of tablets up to 5.0 mg PF-06649751 given once-daily for 28 days.
1622629|NCT02066909|Drug|8.0 mg PF-06649751|Oral dosing of tablets up to 8.0 mg PF-06649751 given once-daily for 28 days.
1622630|NCT02066909|Drug|1.5 mg PF-06649751 in healthy Japanese subjects|Oral dosing of tablets up to 1.5 mg PF-06649751 given once-daily for 14 days given in healthy Japanese subjects.
1622631|NCT02066896|Device|Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide). The laser beam applied bilaterally in non contact mode to each salivary gland area, extra orally to the parotid and submandibular glands and intramurally to the sublingual gland/ 4 Joules/cm2 each point (active group)
1622632|NCT02066896|Device|Sham Lasertherapy|Laser 808 wave length infrared Ga AlAs(gallium-aluminum-arsenide).The device will be applied with the laser pen closed by aluminium foil (placebo group).
1622633|NCT02066870|Drug|Icotinib|Icotinib is administered orally 125 mg three times per day, until disease progression or untolerated toxicity.
1622634|NCT02066870|Drug|Arsenic trioxide|"Arsenic trioxide is administered by intravenous injection with an initial dose of 4mg/m2 per day for day 1 to day 14 every 21 days.
Three dose levels, 4mg/m2, 6mg/m2 and 8mg/m2 will be evaluated according to predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 2 patients developed a DLT. There was no further dose escalation when this dose was achieved."
1622635|NCT02066857|Device|Cast made of generic plaster or fiberglass cast material|Patients will randomly receive a generic plaster or fiberglass cast for treatment of non-displaced distal radius fracture.
1622636|NCT02066857|Device|"Generic off the shelf removable splint"|"Patients will be randomized to receive a generic off the shelf removable splint for treatment of a non-displaced distal radius fracture."
1622639|NCT02066831|Behavioral|Telemedical coaching|
1622640|NCT02066831|Other|Telemedicine|
1622641|NCT02066818|Drug|Lidocaine/tetracaine patch|
1622642|NCT02066818|Drug|1% lidocaine|
1622643|NCT02066805|Drug|Database assessment of off-label XGEVA use|No intervention is planned during this study as it involves analyses of patient electronic records from Northern Jutland Region and Copenhagen
1622644|NCT02066792|Drug|D-Cycloserine|D-cycloserine is a medication thought to be associated with fear extinction.
1622645|NCT02066792|Drug|Placebo|Sugar pill
1622646|NCT02066792|Behavioral|Cognitive Behavioral Therapy|This will be a 5-session version of a group CBT protocol with 4-6 patients and 2 therapists per group emphasizing repeated exposure practices. Session 1 involves an introduction and orientation to the CBT model. Sessions 2-5 emphasize repeated exposure tasks, which consist of role-play activities to confront fearful situations in a group setting while disputing cognitive distortions (coupled with the fading of safety behaviors). At the conclusion of each exposure session, patients will be encouraged to continue to apply home-practice strategies (such as giving speeches in front of a mirror). Continued practice of the interventions will be considered part of treatment, and patients will be asked to refrain from alternative treatment for four weeks following completion of the last treatment session.
1622647|NCT02066766|Other|No treatment given|Patients will fill out a questionnaire by interview.
1622648|NCT02066753|Procedure|Mild therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature between 32-34°C.
1622649|NCT02066740|Device|EverFlex™ stent with Entrust™ delivery system|
1622653|NCT02066688|Drug|folic acid calcium vitamin D3|Patients receive oral folic acid 1mg + calcium 1200mg +vitamin D3 250 IU daily for 36 months in the absence of unacceptable toxicity or any other adverse effects .
1622654|NCT02066688|Drug|calcium|calcium 1200mg/d + vitamin D3 250 IU/d daily supplements
1622655|NCT02066675|Drug|Trabectedin|Each patients will receive intravenous trabectedin (1.5 mg/mq-1.3 mg/mq) over 24 hours every 3 weeks
1622656|NCT02066662|Drug|Rivaroxaban or Marcumar|"Arm A: Rivaroxaban (tablet) for patients with atrial fibrillation: with 20 mg once daily for patients with eGFR > 49 ml per minute and 15 mg rivaroxaban once daily for patients with eGFR of 15 to 49 ml. Rivaroxaban (tablet) for patients with pulmonary embolism : 2x a day 15 mg at day 1-21 and 1x 20 mg from day 22 ongoing;
Arm B: Adjusted dose coumadin/phenprocoumon (tablet) titrated according to target international normalized ratio (INR) with a target range 2.0 to 3.0."
1622657|NCT02066649|Drug|Carvedilol|Administering carvedilol to patients diagnosed with large varices on endoscopy
1622658|NCT02066649|Procedure|Variceal band ligation|Performing variceal band ligation during endoscopy after diagnosis of large varices on endoscopy
1622659|NCT02066636|Drug|Nivolumab|
1622660|NCT02066623|Device|ABSORB Scaffold|Implantation of a drug-eluting vascular scaffold, which is completely resorbable to improve the blood flow in coronary arteries in the presence of stenosis
1622661|NCT02066610|Other|selenium and sodium selenate supplementation|Parenteral nutrition with selenium and sodium selenate supplementation of infant formula
1622662|NCT02066610|Other|selenium and sodium selenite supplementation|Parenteral nutrition with selenium and sodium selenite supplementation of infant formula
1622663|NCT02066610|Other|Without selenium and sodium selenate supplementation|Parenteral nutrition without selenium and sodium selenate supplementation of infant formula
1622664|NCT02066610|Other|Without selenium and sodium selenite supplementation|Parenteral nutrition without selenium and sodium selenite supplementation of infant formula
1622665|NCT02066597|Device|Thrombectomy|Within 96 hours of enrolment, patients will be treated with a single session of PMT using an AngioJet catheter without adjuvant thrombolysis . Venous access will be obtained at the popliteal vein in all patients with a 5-F sheath through which all subsequent venography procedures will be performed. The AngioJet catheter will then be passed over the guide wire and moved from proximal to distal to remove thrombus. Completion venography will be performed through the sheath in all patients. After the completion of the procedure patients are expected to remain in hospital for no more than six hours (1 hour in post-anaesthesia care unit followed by transfer to the surgical daycare unit from where they will be discharged).
1622666|NCT02066584|Other|Sibling oocyte incubation|
1622667|NCT02066571|Drug|Droxidopa|Droxidopa will be supplied in 100 and 200 mg pill sizes. The proposed dosing is 100mg twice daily at baseline, then titrate to 200 mg twice daily at day 7 and then titrate to 300mg twice daily at day 14. Subjects will stay on the 600mg daily for 2 weeks. Total exposure 28 days of study drug.
1622668|NCT02066571|Drug|sugar pill|Sugar pill or placebo will be supplied in pill sizes matched to droxidopa formulation. The study titration will be the same. Sugar pills will be used for 5 weeks during the study.
1622669|NCT02066558|Other|Carbon monoxide|carbon monoxide, 4.7, Purity 99.997, inhalation of carbon monoxide in a volume corresponding to carboxyhemoglobin 10 and 20%, calculated from baseline Hg and body mass.
1622670|NCT02066558|Other|Placebo|
1622671|NCT02066545|Drug|CLS001 Topical Gel|
1622672|NCT02066545|Drug|CLS001 Topical Gel Vehicle|
1622673|NCT02066532|Drug|Ruxolitinib|25 mg bid, 20 mg bid, 15 mg bid, or 10 mg bid, (oral, twice a day) on days 1 through 21 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1622674|NCT02066532|Drug|Trastuzumab|6 mg/kg every 3 weeks (cycle = 21 days). If no trastuzumab > 28 days, patients will be initially re-loaded at 8 mg/kg, then 6 mg/kg.
1622675|NCT02066519|Behavioral|Physical exercise programme using a rowing machine|3 sessions per week of individualized physical training using a rowing machine during 3 months.
1622676|NCT02066506|Other|asymptomatic group|2 visits with MRI
1622677|NCT02066506|Other|symptomatic group|2 visits with MRI
1622678|NCT02066467|Device|Left Ventricular lead implant: ACUITY X4® Lead Family|Implantation of (cardiac re-synchronization therapy with defibrillator) CRT-D devices for heartfailure treatment
1622679|NCT02066454|Drug|Apixaban|2.5mg x 2 per day during 6 months
1622680|NCT02066441|Dietary Supplement|Bio-D-Mulsion Forte®|According to the company's literature, Bio-D-Mulsion Forte® contains: vitamin D (as cholecalciferol), a water and gum Arabic emulsifier base, and sesame oil. This product is documented online at the following web address: http://www.bioticsresearch.com/node/1570
1622681|NCT02066441|Other|Placebo|
1622682|NCT02066428|Biological|AERAS-404|AERAS 404 (H4:IC31) contains a fusion protein of 2 mycobacterial antigens (Ag85B and TB 10.4) formulated in IC31 adjuvant.
1622683|NCT02066428|Biological|Placebo|Tris buffer saline consisting (10mM Tris and 169mM NaCI at pH7.4)
1622684|NCT02066415|Drug|AMG 334|Investigational Product
1622685|NCT02066415|Drug|Placebo|Placebo Comparator
1622686|NCT02066402|Drug|Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Tedizolid once daily i.v to oral from 1-6 days
1622687|NCT02066402|Drug|Placebo Tedizolid (BAY119-2631)|50 % of the participants will be randomized to this arm and will receive 200 mg Placebo Tedizolid once daily i.v to oral from 7-10 days
1622688|NCT02066402|Drug|Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Linezolid twice daily i.v. to oral from 1-10 days
1622689|NCT02066402|Drug|Placebo Linezolid|50 % of the participants will be randomized to this arm and will receive 600 mg Placebo Linezolid twice daily i.v. to oral from 1-10 days
1622690|NCT02066389|Drug|ABT-494|
1622691|NCT02066389|Drug|Placebo|
1622692|NCT02066363|Dietary Supplement|Dietician advise|Dietician advise 5 times, during 24weeks. Prescription of a diet plan if wanted from the patient.
1622693|NCT02066363|Dietary Supplement|Parenteral nutrition|Supportive parenteral nutrition.
1622694|NCT02066350|Procedure|Single pancreas transplantation|
1622695|NCT02066337|Procedure|scaling and root planing|
1622696|NCT02066337|Drug|placebo gel|
1622697|NCT02066337|Drug|Ozonated olive oil gel|
1622698|NCT02066311|Drug|Nelfinavir|
1641718|NCT01919008|Drug|FK949E|Oral
1622699|NCT02066298|Drug|Mometasone 220mcg BID|Mometasone is an ICS
1622700|NCT02066298|Drug|Tiotropium Respimat 5mcg QD|Tiotropium is a LMA
1622701|NCT02066298|Drug|Placebo|
1622702|NCT02066285|Drug|Pazopanib|Treatment will continue until disease progression, development of unacceptable toxicity, non-compliance, withdrawal of consent by the patient or investigator decision.
1622703|NCT02066246|Device|AirSeal|100 patients are treated with the AirSeal insufflation and trocar system
1622704|NCT02066246|Device|Olympus UHI-3|100 patients are treated with a conventional insufflation and trocar system
1622705|NCT02066233|Device|EG Scan II (transnasal endoscopy)|
1622706|NCT02066233|Procedure|Standard Endoscopy|
1622707|NCT02066220|Radiation|Radiotherapy without Carboplatin|"Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks
LR Arm after Amendment (Protocol version 11- 17 Nov 2014):
Brain - 18.0 Gy in 10 daily fractions of 1.80 Gy Spine - 18.0 Gy in 10 daily fractions of 1.80 Gy Primary tumour boost - 36.0 Gy in 20 daily fractions of 1.80 Gy Total dose - 54 Gy Duration of radiotherapy 6 weeks"
1622708|NCT02066220|Drug|Reduced-intensity maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 6 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15, Regimen B: (cycles 2, 4, 6): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.
Interval after cycle A: 6 weeks, after cycle B: 3 weeks, for a total duration of 27 weeks.
Cumulative doses of chemotherapy drugs: cisplatin 210 mg/m2, lomustine (CCNU) 225 mg/m2, vincristine 18 mg/m2, cyclophosphamide 6 g/m2."
1622709|NCT02066220|Radiation|Radiotherapy with Carboplatin|Brain - 23.40 Gy in 13 daily fractions of 1.80 Gy Spine - 23.40 Gy in 13 daily fractions of 1.80 Gy Primary tumour boost - 30.60 Gy in 17 daily fractions of 1.80 Gy Total dose - 54 G Carboplatin 35 mg/m2 5 times/week.
1622710|NCT02066220|Drug|Maintenance chemotherapy|"Starts 6 weeks after radiotherapy. 8 cycles alternating Regimen A and Regimen B. Regimen A (cycles 1, 3, 5, 7): cisplatin 70 mg/m2 day 1, CCNU 75 mg/m2 day 1, vincristine 1.5 mg/m2 days 1, 8 and 15 Regimen B: (cycles 2, 4, 6, 8): cyclophosphamide 1 x 1000 mg/m2 days 1-2, vincristine 1.5 mg/m2 day 1.
Interval after cycle A: 6 weeks, after cycle B: 3 weeks. Duration 36 weeks. Cumulative doses of chemotherapy drugs: cisplatin 280 mg/m2, lomustine (CCNU) 300 mg/m2, vincristine 24 mg/m2, cyclophosphamide 8 g/m2, carboplatin 1050 mg/m2 (in randomized patients)."
1622711|NCT02066207|Drug|Fenofibrate|
1622712|NCT02066207|Drug|Atorvastatin|
1622713|NCT02066194|Procedure|Electroacupuncture|
1622718|NCT02066155|Behavioral|Parish nurse|On-going support following diabetes self-management education provided by Parish Nurse
1622719|NCT02066155|Behavioral|Peer Support|On-going support following diabetes self-management education provided by a trained person with diabetes
1622720|NCT02066142|Device|3D mammography (Tomosynthesis)|Tomosynthesis will be used as normally employed in clinical practice
1622721|NCT02066142|Device|Ultrasound|
1622722|NCT02066129|Drug|Fluticasone 44 mcg|Fluticasone is an inhaled corticosteroid
1622723|NCT02066129|Drug|Fluticasone 220 mcg|Fluticasone is an inhaled corticosteroid
1622724|NCT02066116|Procedure|Kinect-based rehabilitation plus occupational therapy|The developed kinect-based rehabilitation system will be used for 30min/session. Conventional 30min occupational therapy also will be applied for the patient enrolled.
1622725|NCT02066116|Other|sham virtual rehabilitation education plus occupational therapy|For the sham virtual rehabilitation, computer-based cognitive rehabilitation program will be used. Patients will be encouraged to use their affected arm to push the button but the motion will be minimal and not related to the concept of upper extremity rehabilitation.
1622726|NCT02066103|Drug|Paclitaxel|
1622727|NCT02066090|Device|Real acupuncture|"manual acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + electroacupuncture (middle CV6, CV12), twice a week, for 6 weeks
common approaches for the treatment of obesity used by doctors of Korean medicine in Korea today"
1622728|NCT02066090|Device|Sham acupuncture|"sham acupuncture (bilateral LI4, LI11, SP6, ST25, ST28, ST36) + placebo acupuncture without electrical stimulation (middle CV6, CV12), twice a week, for 6 weeks
sham acupuncture (0.25mm diameter x 40mm length, stainless steel, Acuprime, UK) as control for manual acupuncture (0.25mm diameter x 40mm length, stainless steel, Dongbangacupuncture Inc., Korea)
placebo acupuncture without electrical stimulation as control for electroacupuncture (0.25mm diameter x 90mm length, stainless steel, Dongbangacupuncture Inc., Korea)"
1622729|NCT02066077|Drug|Etomidate|
1622730|NCT02066077|Drug|Propofol|
1622731|NCT02066077|Device|Bilateral temporal MECT|
1622732|NCT02066077|Device|The right temporal MECT|
1622733|NCT02066077|Device|Bilateral frontal MECT|
1622734|NCT02066064|Procedure|Standard Colonoscopy|Standard Colonoscopy
1622735|NCT02066064|Procedure|G-EYE(TM) Colonoscopy|G-EYE(TM) Colonoscopy
1622736|NCT02066051|Device|IPL|Intense Pulsed Light (IPL) treatment from Quadra Q4 Platinum Series, made by DermaMed Solutions. With the eyes patched closed the IPL was applied to the surface of the skin by the way of a hand-held wand in 30 spots over the skin in the lower lid, cheek area, and nose area starting and ending from in front of each ear.
1622737|NCT02066051|Procedure|Meibomian Gland Expression|After the IPL was applied, the eyes were numbed for 15 minutes with a numbing drop, and a sterile cotton swab was used to squeeze the eyelids and express clogged oil secretions from the miebomian glands.
1622738|NCT02066038|Drug|Erlotinib|150mg po on days 2-15 of each 3 week cycle for 4 cycles and 150mg po per day after 4 cycles until disease progression
1622739|NCT02066012|Other|dysmetabolic iron overload syndrome|
1622740|NCT02065986|Drug|Truvada (once daily tablet containing 300mg tenofovir disoproxil (TDF) and 200mg of emtricitabine (FTC)|
1622741|NCT02065973|Biological|R-enantiomer of 1,2-dioleoyl-3-trimethylammonium-propane chloride + Peptides from HPV-16 E6 and E7|
1622742|NCT02065960|Radiation|Stereotactic body radiotherapy (SBRT)|
1622743|NCT02065947|Procedure|paravertebral block|catheter with 3-level-injection
1622744|NCT02065947|Drug|fentanyl, propofol, atracurium|endotracheal intubation
1622745|NCT02065947|Drug|lidocaine , adrenaline, ketamine bolus, midazolam|a mixture of 10 ml bupivacaine 0.5% plus 20 ml lidocaine 2% with adrenaline 1:200,000, ketamine bolus 0.5 mg/kg, midazolam 2-3 mg and continuous propofol using target-controlled infusion (TCI) system aiming at effect site concentration (Ce) of 1-1.5 mcg/mL
1622746|NCT02065947|Device|catheter with 3-level-injection|
1622747|NCT02065947|Drug|sevoflurane and 50% oxygen in air|
1622748|NCT02065934|Other|cardio-pulmonary resuscitation|
2011064|NCT02723864|Drug|Veliparib + VX-970 + Cisplatin|ATR protein kinase is central to the DNA damage response and homologous recombination, activating a series of phosphorylation cascades, culminating in cell cycle arrest to allow time for DNA repair. PARP plays a pivotal role in base-excision repair of single strand breaks formed either due to direct genotoxic stress or during the processing of double strand breaks. Preclinical studies show ATR inhibitor VX-970 synergizes with cisplatin to induce DNA damage and antitumor activity. The addition of PARP inhibitor veliparib with VX-970 allows for impairment of DNA repair, induction of a BRCA null phenotype, and potentiation of the antitumor activity of cisplatin.
1622752|NCT02065882|Biological|BT524 (fibrinogen concentrate from human plasma)|single intravenous infusion
1622753|NCT02065869|Biological|BPX-501 T cells and AP1903|Biological: T cells transduced with CaspaCIDe suicide gene
1622754|NCT02065869|Drug|AP1903|AP1903 administered to treat GVHD
1622755|NCT02065856|Biological|AVANZ Salsola|AVANZ Salsola
1622756|NCT02065843|Drug|Mulungu|500 mg/single dose/1 hour before dental surgery
1622757|NCT02065843|Drug|Placebo|500 mg/single dose/1 hour before dental surgery
1622758|NCT02065843|Drug|Passiflora incarnata|100 mg/single dose/1 hour before dental surgery
1622759|NCT02065843|Drug|midazolam|15 mg/single dose/1 hour before dental surgery
1622760|NCT02065830|Device|EKSO|"The subjects will undergo inpatient rehabilitation consisting of a treatment cycle of 30/40 training section using the robot EKSO system device, according to individually tailored exercise scheduling.
The practice will include robot-assisted walking at variable speeds for 45/60 min and balance training."
1622761|NCT02065817|Other|stable isotope of cholesterol|
1622763|NCT02065791|Drug|Canagliflozin|One 100 mg over-encapsulated tablet orally once daily
1622764|NCT02065791|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily
1622765|NCT02065778|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in chronic stroke patients
1622766|NCT02065765|Biological|Ramucirumab|Administered intravenously (IV)
1622767|NCT02065752|Drug|Canagliflozin, 100 mg|Each tablet contains canagliflozin (CANA) of 100 mg to be taken orally (by mouth).
1622768|NCT02065752|Drug|Metformin XR, 500 mg|Each tablet contains metformin extended release (MET XR), 500 mg, to be taken orally (by mouth).
1622769|NCT02065752|Drug|CANA/MET XR FDC, Formulation 1, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 1, in release-controlling polymers to obtain the XR granulation, to be taken orally.
1622770|NCT02065752|Drug|CANA/MET XR FDC, Formulation 2, 50 mg/500 mg|Each tablet contains 50 mg of canagliflozin and 500 mg of metformin HCl granulate, formulation 2, in release-controlling polymers to obtain the XR granulation, to be taken orally.
1622771|NCT02065739|Drug|JNJ-42165279|Participants will receive a single 30-mg (6 mL of oral suspension) dose of JNJ-42165279 orally (by mouth) on Day 1 (Period 1) and on Day 8 (Period 2).
1622772|NCT02065739|Drug|Itraconazole|Participants will receive itraconazole 200 mg (2 capsules) once a day orally on Days 4, 5, 6, 7, 8, 9, and 10 (Period 2).
1622773|NCT02065726|Dietary Supplement|Whey protein|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician + 20 g (2 x 10 g) of whey proteins
1622774|NCT02065726|Other|Nutritional counseling|Nutritional counseling consists in a personalized dietary prescription and regular (monthly) dietetic advise by a registered dietician
1622775|NCT02065713|Drug|Golimumab|Prefilled syringe with golimumab 50mg (Simponi®) administrated subcutaneously, once monthly, for 24 weeks.
1622776|NCT02065713|Drug|Methotrexate|MTX started at 15mg/weekly at baseline, increased to 20mg/weekly at week 4 and to 25mg/weekly at week 8, maintaining the dose of 25mg/weekly throughout the trial period of 24 weeks, except in case of intolerance or toxicity
1622777|NCT02065713|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously, once monthly, for 24 weeks.
1622779|NCT02065687|Drug|Carboplatin|Given IV
1622780|NCT02065687|Other|Laboratory Biomarker Analysis|Correlative studies
1622781|NCT02065687|Drug|Metformin Hydrochloride|Given PO
1622782|NCT02065687|Drug|Paclitaxel|Given IV
1622783|NCT02065687|Other|Placebo|Given PO
1622784|NCT02065687|Other|Quality-of-Life Assessment|Ancillary studies
1622785|NCT02065687|Other|Questionnaire Administration|Ancillary studies
1622786|NCT02065674|Drug|Abroma Augusta Q (mother tincture)|30 drops in 1 cup of water three times a day for 3 months
1622787|NCT02065635|Procedure|maintenance with sevoflurane|in patients allocated to the sevoflurane group, general anesthesia will be maintained with sevoflurane
1622788|NCT02065635|Procedure|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
1622791|NCT02065609|Drug|89Zr-Trastuzumab Human Dosimetry and Safety|PET Imaging following administration of 89Zr labeled Trastuzumab for calculation of human dosimetry and overall safety
1622792|NCT02065609|Drug|HER2 Positive Lesion Detection and Safety|Detection of HER2 Positive Breast Cancer with 89Zr Labeled Trastuzumab and PET imaging
1622793|NCT02065596|Drug|Fludarabine|the study will begin with enrollment of an initial safety cohort of at least 10 subjects at the lowest dose, after which enrollment will pause until the dose-limiting toxicity (DLT) period has been completed. If a patient experiences DLT, defined as failure to engraft. In which case, the patient may be advanced to two higher doses.
1622794|NCT02065596|Procedure|Hematopoietic Stem Cell Transplant (HSCT)|Three weeks after Immunomodulation patients will be infused with matched bone marrow from a sibling, unrelated donor, haploidentical donor, or cord blood. Patients will be followed for the following year.
1642410|NCT01913665|Other|Placebo|
2011065|NCT02722369|Drug|Gemcitabine|Chemotherapy
2011066|NCT02722369|Drug|Carboplatin|Chemotherapy
1622798|NCT02065544|Behavioral|behavioral weight loss and exercise|Weight loss and exercise counseling
1622799|NCT02065531|Other|Myofascial Soft Tissue Release|Protocol: Transverse Plane-Level Clavicular Release. Diaphragmatic Transverse Plane Release. Square the Lumbar Fascia Release. Gluteal Fascia Release. Hint Of Pubic Region Release. Fascia Psoas Release. Lumbo-sacral Decompression. Pelvic Floor Release.
1622800|NCT02065531|Other|Mobilization with impulse technique.|Subject in lateral decubitus with extension and lower limb traction contact the couch with contralateral lower limb was performed triple flexion and left trunk rotation. This technique reduces the slack (tension joints) of the ventral pelvis, head and into the contralateral side of the sacrum support (base) with the forearm.
1622801|NCT02065518|Device|NMES|Participants will train at 15-20% of maximal voluntary contraction (MVC) during weeks 1-3, 20-30% of MVC during weeks 3-6 and 30-40% of MVC during weeks 6-9, 40-50% of MVC during weeks 9-12, then sustain 50% of MVC during weeks 12-18. Incremental increases will be made at the 3, 6, 9, and 12-week clinic visits.
1622802|NCT02065518|Behavioral|Strength Walking|Strength Walking participants will maintain a daily training log. Pedometer readings will form the basis for setting activity goals. Initial step goals will be 10% above the average 3-day pedometer step count taken at baseline, with a 10% increase every other week, and then a gradual increase when 30% above the baseline step count has been achieved.At week 7, participants will be given a vest to begin the strengthening component. Participants will be instructed to wear the vest during their 30-minute walk, 3 to 4 days a week. The beginning weight load for the vest will be calculated using 2% of baseline body weight and it will be increased by that same amount every week thereafter until the end of the 12 weeks.
1622803|NCT02065518|Behavioral|Standard Rehabilitation Protocol|All participants will receive the current standard of care at the 2 military sites (Walter Reed National Military Medical Center (WRNMMC) and Malcolm Grow Medical Clinics and Surgery Center (MGMCSC)) of the physical therapy rehabilitation protocol for knee injuries. This program includes treatment with a physical therapist at WRNMMC and MGMCSC physical therapy clinic.
1622804|NCT02065505|Other|Mat Pilates|
1622805|NCT02065505|Other|Water Pilates|
1622806|NCT02065492|Drug|Standard Chelation|This will comprise of standard chelation drugs (Deferasirox or Deferoxamine or Combination of Deferoxamine and Deferiprone).The dosage and drug used will depend on ferritin levels and individual requirement, as determined by the treating hematologist and will be in accordance with the Iron chelation guidelines from Pakistan Thalassemia Society.
1622807|NCT02065492|Drug|Amlodipine|doses of 0.2 to 0.25 mg/kg/day PO would be given during this trial
2011067|NCT02722369|Drug|Etoposide|Chemotherapy
2011068|NCT02722369|Drug|Hydroxychloroquine|Maintenance Agent
1622810|NCT02065466|Drug|nab-paclitaxel|
1622811|NCT02065466|Drug|Temozolomide|
1622812|NCT02065466|Drug|Bevacizumab|
1622813|NCT02065453|Device|disposable device (Ligasure, Covidien)|"One side of the uterine attachments would be transected using the disposable device (Ligasure, Covidien). . We will randomize the side for each energy source used on each side for every case. The number of sides performed by the attending surgeon will equal that of the less experienced resident surgeon."
1622814|NCT02065453|Device|Reusable device|One side of the uterine attachments would be transected using the reusable Robi bipolar and Storz laparoscopic
1622815|NCT02065440|Drug|Rhinoebastel|Rhinoebastel(ebastine 10mg/pseudoephedrine 120mg) 1 cap/day for 1 week unless progression or unacceptable toxicity develops.
1622816|NCT02065440|Drug|Placebo|Placebo 1 cap/day for 1 week unless progression or unacceptable toxicity develops
1622817|NCT02065427|Behavioral|Social Support|a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
1622818|NCT02065414|Other|Listerine Advance Gum Defense|
1622819|NCT02065414|Other|Mouth rinse containing Chlorhexidine|
1622820|NCT02065414|Other|Mouth rinse containing 5% Hydroalcohol|
1622821|NCT02065401|Drug|Deferitazole (disodium salt, granule)|Single oral dose of 1500 mg administered on Day 1
1622822|NCT02065401|Drug|Deferitazole (disodium salt, tablet)|Single oral dose of 1500 mg administered on Day 1
1622823|NCT02065401|Drug|Deferitazole (magnesium hydroxide salt)|Single oral dose of 2400 mg administered on Day 1
1622824|NCT02065388|Behavioral|Standard of care dosing for warfarin|
1622825|NCT02065388|Genetic|Genotype-guided dosingTaiwan algorithm for warfarin|
1622826|NCT02065388|Genetic|Genotype-guided dosing IWPC algorithm for warfarin|
1622827|NCT02065375|Drug|RTA 408 0.5% Ophthalmic Suspension|
1622828|NCT02065375|Drug|RTA 408 1.0% Ophthalmic Suspension|
1622829|NCT02065375|Drug|Placebo|
1622830|NCT02065362|Biological|DNR.NPC-specific T cells|"Each patient will receive 2 infusions, 14 days apart, according to the following dosing schedule:
Dose Level 1:
Day 0: 2 x 10^7 cells/m^2
Day 14: 2 x 10^7 cells/m^2
The doses are calculated according to the total T cell number."
1622831|NCT02065362|Biological|DNR.NPC-specific T cells + cyclophosphamide + fludarabine|"Patients will receive cyclophosphamide and fludarabine for 3 days before receiving the DNR.NPC-specific T cells.
Each patient will receive infusions according to the following dosing schedule:
Dose Level 2:
Cy/Flu on Days -4 to -2 and then 4 x 10^7 cells/m^2 on Day 0, Day 1 or Day 2
Dose Level 3:
Cy/Flu on Days -4 to -2 and then 1 x 10^8 cells/m^2 on Day 0, Day 1, or Day 2"
1622832|NCT02065349|Drug|ASP8477|oral
1622833|NCT02065349|Drug|Placebo|oral
1622834|NCT02065336|Drug|ARC-520|
1622835|NCT02065336|Drug|Placebo|
1622836|NCT02065323|Drug|Standard ADT|Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
1622837|NCT02065323|Drug|Dovitinib|Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
2011069|NCT02721732|Drug|Pembrolizumab|200 mg by vein every 3 weeks (21 days).
1622838|NCT02065310|Other|N2-(1-carboxyethyl)-2'deoxyguanosine (CEdG)|"Glucose and its adducts, such as HbA1c, decompose non-enzymatically to yield α-oxo-aldehydes are up to 20,000 x more reactive than the parent molecule. Amounts of an α-oxo-aldehyde, methylglyoxal (MG), are elevated up to 6-fold in patients with Type 1 dm. Quantitation of MG, but MG does form stable, irreversible adducts termed advanced glycation endproducts (AGEs) that can be measured. MG also reacts with DNA to yield primarily one stable DNA-AGE, CEdG, and suggests that measuring CEdG might allow for a direct method for assessing glycemic status and α-oxo-aldehyde burden.
Investigators have shown that CEdG levels are significantly elevated in urine and tissue of Type 1 & 2 dm animal models. DNA-AGE may correlate with the development of diabetes complications and identify patients at higher risk. Therefore, the investigators hypothesize that CEdG, a DNA-AGE, can be used as a marker of diabetes control and complications."
1622839|NCT02065297|Other|1 blood sample|
1622840|NCT02065297|Other|2 to 3 blood samples (at inclusion, at 3 months and at 6 months in cases of relapse)|
1622841|NCT02065284|Other|Rhythmic Auditory Stimulation (RAS)|Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
1622842|NCT02065271|Dietary Supplement|herbal supplement|
1622843|NCT02065271|Other|placebo supplement|
1622844|NCT02065258|Other|Breathing exercise|"It will be based on Yoga´s breathing technique (Eliade, 1996) and will be focus on to stimulate nasal and diaphragmatic breathings, to increase expiratory time, to slow respiratory flow and to regulate the breathing rhythm. Breathing exercises will be divided into 3 phases (lasting one month each) with progressive intensity every 8 sessions.
All participants will be required to maintain their normal medical regimens during the interventions. Will be part of the routine of breathing exercises the following exercises: I) Kapalabhati, II) Uddhiyana"
1622845|NCT02065258|Other|Aerobic exercise|Exercise will be performed on a treadmill (Imbramed Export Plus, Brazil) with the initial intensity of 60% of the maximum predicted heart rate for patient´s age (Tanaka et al, 2001) reaching a maximal of 80% during the training. The intensity values will be calculated using Karvonen's formule (1957). Exercise intensity will be increased if the patient do not present any increase in asthma symptoms during the exercise for 2 consecutive training days. Before and after every session, patients will perform a peak expiratory flow test and if values were lower than 70% of the patient´s maximum value, they will be advised to use the rescue dose of bronchodilator prescribed the their physician
1622846|NCT02065245|Biological|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)|Allogeneic Human Mesenchymal Stem Cells (allo-hMSCs)
1622847|NCT02065245|Biological|Placebo|Placebo
1622848|NCT02065232|Drug|Tilmanocept|
1622849|NCT02065232|Drug|Sulfur Colloid|
1622850|NCT02065219|Drug|Bupivacaine|10 ml of bupivacaine 2.5 mg/ml deposited by ultra-sound guidance around the spermatic cord
1622851|NCT02065219|Drug|Placebo|10 ml 0.9% physiological saline deposited by ultra-sound guidance around the spermatic cord
1622852|NCT02065193|Behavioral|ADOS/ADI-R/Clinical assessment|
1622853|NCT02065180|Dietary Supplement|commercially available nutrition supplement|the food supplement contains red rice yeast and olive extract
1622854|NCT02065180|Dietary Supplement|placebo|
2011070|NCT02721732|Behavioral|Phone Call Follow-Up|Every 12 weeks after participant's last dose of pembrolizumab, study staff will contact them by phone to ask about their status. The call should take about 15-20 minutes.
1622857|NCT02065141|Other|sip feeding with stable isotope infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
1622858|NCT02065128|Other|Capsaicin cough challenge test|The capsaicin cough challenge testing will be conducted in the pulmonary function laboratory at SMH by a pulmonary function technologist. The test involves having the participant inhale increasing concentrations of capsaicin solutions and assessing their response. The tidal breathing method and solution preparation presented by Nejla, et al. 12 will be used to conduct this testing. The tidal breathing method is preferred to the alternative dosimeter method as it produces similar results with lower capsaicin concentrations thereby resulting in less throat irritation for the participant. The technique is detailed in the following sections.
1622859|NCT02065115|Other|Cryotherapy (ice pack)|
1622860|NCT02065089|Other|playing the ipad quiz game|Individualized education to the patient via the quiz game, with optional additional education provided by medical providers.
1622861|NCT02065076|Drug|Sodium polystyrene sulfonate|
1622862|NCT02065076|Drug|Lactose with carob gum|
1622863|NCT02065063|Drug|Trametinib|Trametinib is available as a 0.5 mg yellow oval tablet or as a 2.0 mg pink round tablet.
1622864|NCT02065063|Drug|Palbociclib|Palbociclib is available as a 75 mg (size 2 sunset yellow) or 100 mg (size 1 sunset yellow/caramel) or 125 mg (size 0 caramel) capsule.
1622865|NCT02065050|Other|team-based care|Patients in the eDMS arm are called at least every month for their diabetes treatment.
1622866|NCT02065037|Device|room temperature air insufflation|control arm
1622867|NCT02065037|Device|warmed carbon dioxide insufflation|comparator arm
1622868|NCT02065024|Dietary Supplement|b-cryptoxanthin plus phytosterols|
2011071|NCT02720887|Procedure|Nanoparticles load|Pregnant women will have a sampling of amniotic fluid to measure load and composition of nanoparticles.
1622870|NCT02064998|Behavioral|Promillekoll|Smartphone app monitoring alcohol use with feedback on eBAC level.
1622871|NCT02064998|Behavioral|PartyPlanner|Smartphone-adapted web-based app for simulating an event with alcohol consumption in advance, real time monitoring of alcohol use with eBAC feedback during the event and later possibility of comparison between the plan and the event.
1622872|NCT02064998|Behavioral|TeleCoach|Smartphone app providing exercises and vignettes for reducing or abstaining from alcohol consumption.
1622873|NCT02064985|Drug|"Inhibition of Platelet Aggregation by Brilinta(Ticagrelor)"|To determine the Inhibition of Platelet Aggregation (IPA) profiles of single and multiple doses of ticagrelor 45, 60, and 90 mg in Chinese patients with stable coronary heart disease (CHD) on chronic low dose ASA (75-100mg daily).
1622874|NCT02064972|Other|Patients undergoing allo-HSCT, who manifest GvHD.|Changes in CEC counts in relation to GvHD ONSET
2011072|NCT02720068|Drug|MK-4280|IV infusion
1642411|NCT01913652|Drug|Cabazitaxel|
2011073|NCT02720068|Biological|Pembrolizumab|IV infusion
1622878|NCT02064920|Drug|Placebo|Placebo for donepezil hydrochloride capsule
1622879|NCT02064920|Drug|Donepezil|5 mg donepezil hydrochloride capsule.
1622880|NCT02064920|Drug|Donepezil|10 mg donepezil hydrochloride capsule.
1622881|NCT02064907|Drug|Dexlansoprazole Delayed Release Orally Disintegrating Tablets|Dexlansoprazole delayed-release, orally disintegrating (OD) tablets
1622882|NCT02064907|Drug|Dexlansoprazole Delayed Release Capsules|Dexlansoprazole delayed-release capsules
1622883|NCT02064894|Drug|oral morphine and oral ibuprofen|The combination of oral morphine and oral ibuprofen is one of the Experimental arm group
1622884|NCT02064894|Drug|Oral morphine|Oral morphine 0.2 mg/kg (syrup) up to a maximum dosage of 15 mg, administered once during the study
1622885|NCT02064894|Drug|Oral ibuprofen|oral ibuprofen combine to a placebo is the active comparator
1622886|NCT02064881|Drug|Metformin glycinate|
1622887|NCT02064881|Drug|Metformin Hydrochloride|
1622888|NCT02064868|Drug|Serelaxin|30 µg/kg/day IV infusion
1622889|NCT02064868|Drug|Standard of Care|This treatment can include but is not limited to intravenous and/or oral diuretics, angiotensin-converting enzyme (ACE) inhibitors/angiotensin receptor antagonists, blockers and aldosterone receptor antagonists, etc.
1622890|NCT02064842|Drug|TMC647055|TMC647055 150 mg (1 capsule), 450 mg (3 capsules), 600 mg (4 capsules) taken orally (by mouth) once daily on Day 1 in Part 1. TMC647055 450 mg (3 capsules), and 600 mg (4 capsules) taken orally once daily on Days 1 to 7 in Part 2
1622891|NCT02064842|Drug|TMC435|TMC435 1 capsule of 75 mg, 100 mg, and 150 mg taken orally on Days 1 to 7 in Part 2
1622892|NCT02064842|Drug|Placebo|Placebo capsule once daily taken orally on Day 1 in Part 1
1622893|NCT02064842|Drug|Ritonavir (RTV)|RTV 30 mg (ie, 0.38 mL oral solution of RTV [80 mg/mL strength]) taken orally on Day 1 in Part 1 and on Days 1 to 7 in Part 2
1622894|NCT02064829|Drug|Nab-paclitaxel|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
1622895|NCT02064829|Drug|IG-001|260 mg/m2 administered intravenously over 30 minutes on Day 1 every 3 weeks
1622896|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 microgram (mcg) subcutaneously three times a week in the morning using RebiSmart® self-injector device for 12 weeks.
1622897|NCT02064816|Drug|Rebif®|Rebif® will be administered at a dose of 44 mcg subcutaneously three times a week in the evening using RebiSmart® self-injector device for 12 weeks.
1622898|NCT02064803|Procedure|Gastro-entero anastomosis only|Gastro-entero anastomosis only
1622899|NCT02064803|Procedure|Gastric partitioning Plus Gastro-entero anastomosis|Gastric partitioning Plus Gastro-entero anastomosis
1622900|NCT02064777|Drug|Tacrolimus|
2011074|NCT02717949|Drug|sofosbuvir/ledipasvir|sofosbuvir ledipasvir fixed dose combination given once a day by mouth
2011075|NCT02717949|Drug|sofosbuvir|sofosbuvir 400 mg given one a daily orally and weight-based ribavirin given twice a day orally
1622903|NCT02064751|Device|CRT with MultiPoint Pacing|
1622904|NCT02064751|Procedure|Hemodynamic measurements for CRT device programming|
1622905|NCT02064738|Behavioral|Restricting daily intake of omega-6 fatty acids to less than 4 grams and increasing omega-3 fatty acids to 3 grams|
1622906|NCT02064725|Drug|Sodium cridanimod|Eligible patients will be enrolled into the study and administered sodium cridanimod (500 mg i.m./ twice a week) in combination with megestrol acetate (160 mg p.o./ day) or medroxyprogesterone acetate (200 mg p.o./ day).
1622907|NCT02064712|Other|Low CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
1622908|NCT02064712|Other|High CPAP Wean|Infants receive NCPAP by Hudson nasal prongs.
1622909|NCT02064699|Biological|CMV Infection|"Routine follow-up (viral load, creatininaemia, neutrophil count, isolation of CMV strains when possible) and biological sample collection for.
Using the QuantiFERON-CMV test for predicting the risk of CMV infection in the transplanted immune against CMV."
1622910|NCT02064686|Other|Exhaled breath temperature|
1622911|NCT02064673|Drug|Curcumin|Curcumin or placebo 500mg by mouth twice a day for 6 months
1622912|NCT02064673|Drug|placebo|placebo orally twice a day
1622913|NCT02064660|Device|massager|The patients will be doing self-stimulation using acupressure device, The acupuncture treatment will be applied two times per day for six months. Acupressure divice will stimulate for 14 minutes. Examples of acupuncture points to be used might include GB1, GB14, TE23, ST1, ST2, BL01, BL02, the Extra-point Tae-yang, In-dang.
1622914|NCT02064647|Other|Trend Arrow Adjustment Tool|The Trend Arrow Adjustment Tool formula is: if CGM shows a single arrow up or down: adjust bolus by +/- (1.5/ISF) and for 2 arrows up or down +/- (3/ISF). Where ISF is the patients own insulin sensitivity factor.
1622915|NCT02064647|Other|10/20% bolus adjustment|The 10/20% bolus adjustment formula is: if CGM shows a single arrow up or down: adjust bolus by +/- 10% and for 2 arrows up or down +/- 20%.
1622916|NCT02064621|Drug|Candesartan 32mg|Candesartan 32mg 1T, PO, QD for 9days
1622917|NCT02064621|Drug|Candesartan 32mg/Amlodipine 10mg|Candesartan 32mg 1T, PO, QD for 9days/Amlodipine 10mg 1T, PO, QD for 9days
1622918|NCT02064608|Drug|AZD2014|mTOR inhibitor
1622919|NCT02064595|Procedure|External fixator|Treatment with external fixation
1622920|NCT02064595|Procedure|Intramedullary nail|Fracture treated with intramedullary nail
1622921|NCT02064582|Drug|Enzalutamide|160mg by mouth each day
1622922|NCT02064582|Drug|Leuprolide acetate|22.5 mg intramuscular every 3 months or 45mg intramuscular every 6 months
1622923|NCT02064582|Radiation|radiation|External beam radiation will be delivered as per standard radiation therapy protocol
1622924|NCT02064569|Genetic|GS010|
1622925|NCT02064556|Drug|Amlodipine 10mg|Amlodipine 10mg 1T, PO, QD for 9days
1622926|NCT02064556|Drug|Amlodipine 10mg/Candesartan 32mg|Amlodipine 10mg 1T, PO, QD for 9days/Candesartan 32mg 1T, PO, QD for 9days
1622927|NCT02064543|Other|GAITRite|mobility test assessing gait parameters
1622928|NCT02064543|Other|ADPM|mobility test assessing gait parameters
1622929|NCT02064530|Drug|Bupivacaine|21 ml 0.5 %bupivacaine is applied interfasially
1622930|NCT02064530|Drug|Dexmedetomidine|1 ml dexmedetomidin + 20 ml 0.5 % bupivacaine are applied interfasially
1622931|NCT02064530|Drug|serum physiologic|21 ml serum physiologic is applied interfasially
1622934|NCT02064504|Drug|GSK961081|Dry white to off white powder
1622935|NCT02064504|Drug|Fluticasone furoate|Dry white powder
1622936|NCT02064491|Drug|Erlotinib|
1622937|NCT02064491|Drug|Chemotherapy|
1622938|NCT02064465|Drug|Lamotrigine Dispersible/Chewable tablet|Single dose of lamotrigine dispersible/chewable 100mg tablet at Day1
1622939|NCT02064465|Drug|Lamotrigine Compressed tablet|Single dose of lamotrigine compressed 100mg tablet at Day1
1622940|NCT02064452|Other|Triple P Online System|The Triple P Online System (TPOS) is an online parenting support program designed to assist parents in developing effective parenting practices for handling their children's problem behaviors. Content focuses on positive attention and praise, teaching strategies, effective discipline, antecedent strategies to avoid problems in high-risk situations, and applying these principles to specific situations. TPOS integrates 3 different levels of program intensity to meet different levels of family need, based on severity of children's behavior problems.
1622941|NCT02064452|Behavioral|Placebo Comparator|Enhanced Usual Community Care-Waitlist
1957954|NCT02098967|Drug|RO6839921|Non-escalating IV doses given on Days 1-5 of Cycle 1.
1957955|NCT02098967|Drug|RO6839921|Escalating IV doses of RO6839921 in solid tumor patients. Dose escalation will be calculated using the new Continual Reassessment Method (nCRM). RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
1622945|NCT02064426|Drug|Molidustat (BAY85-3934)|Subjects will continue with the same treatment they were receiving in the parent study (16208). BAY85-3934 will be administered daily as oral tablets. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits, the dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose. Total treatment time is up to 36 months. Planned doses include 15, 25, 50, 75, 100, and 150 mg once daily.
1622946|NCT02064426|Biological|Epoetin alfa/beta|Subjects will continue with the same treatment they were receiving in the parent study (16208). Epoetin alfa / beta will be administered as intravenous (IV) or subcutaneous (SC) injections per individual subject regimen according to the local label. Dose assessments will be made every 4 (± 1) weeks. At the scheduled visits,dose may be titrated on an individualized basis taking into account the subject's Hb response and the tolerability of the previous dose.Total treatment time is up to 36 months.
1622947|NCT02064413|Device|ESS310 (BAY1454032)|
1622948|NCT02064400|Other|Musculoskeletal Ultrasound|7-joint musculoskeletal ultrasound scan
1622949|NCT02064400|Other|Semi-structured patient interview|Semi-structured patient interview
1622951|NCT02064374|Drug|Metformin 500 mg q12h|Metformin will be supplied as 500 mg tablet to be administered orally.
1622952|NCT02064374|Drug|Dolutegravir 50 mg q24h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken once a day in the morning in Period 2 (Total daily dose 50 mg per day for Cohort 1 only)
1622953|NCT02064374|Drug|Dolutegravir 50 mg q12h|Dolutegravir will be supplied as 50 mg tablet to be administered orally. To be taken 50 mg tablets every 12 hours in Period 2 (Total daily dose 100 mg per day for Cohort 2 only).
1622954|NCT02064361|Other|High intensity exercise|Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.
1622955|NCT02064348|Drug|semaglutide|Solution for subcutaneous (s.c., under the skin) injection. Dose escalation to 1.5 mg.
1622956|NCT02064348|Drug|placebo|Solution for s.c. injection or tablets for oral administration
1622957|NCT02064348|Drug|moxifloxacin|Tablets for oral administration
1622958|NCT02064335|Behavioral|Physical activity coaching|Comparison the effects of physical activity coaching and no coaching on different health parameters in diabetic subjects
1622959|NCT02064322|Device|SImmetry Implant|"The SImmetry system is commercially available. The implanted devices consist of a range of thread-tapping cannulated implants designed to transfix the sacrum and ilim, providing stability for intra-articular fusion.
The SImmetry Surgical Instruments include standard manual surgical instruments used to access and prepare the sacroiliac joint space for intra-articular fusion."
1622961|NCT02064296|Device|Needle acupuncture (Traditional Acupuncture)|This group will receive needle acupuncture at 3 pairs of sites. The needles will be stimulated with low intensity, low frequency electric current using a constant-current electro-acupuncture device.
1622962|NCT02064296|Device|Laser acupuncture (Non-traditional Acupuncture)|For non-traditional acupuncture, a laser acupuncture device will be positioned over all of the same acupoints used in EA. There will be no palpation prior to positioning these devices, and there will be no physical contact between device and skin.
1622963|NCT02064283|Procedure|Diffusion MRI|
1622964|NCT02064270|Device|Single-Use Negative Pressure Wound Therapy|Application of PICO Single-Use Negative Pressure Wound Therapy
1622965|NCT02064270|Device|Standard postsurgical dressings|Use of Standard postsurgical dressings
1622966|NCT02064257|Behavioral|Listening Project Protocol|The intervention will consist of listening to computer-altered acoustic stimulation, designed to modulate the frequency band of vocal music passed to the participant. The frequency characteristics of the acoustic stimulation are selected to emphasize the relative importance of specific frequencies in conveying the information embedded in human speech. Modulation of the acoustic energy within the frequencies of human voice, similar to an exaggerated vocal prosody, are hypothesized to recruit and modulate the neural regulation of the middle ear muscles and to functionally reduce sound hypersensitivities and improve auditory processing.
1622967|NCT02064244|Other|Ultrasound for measurement of Inferior Vena Cava size.|Focused bedside ultrasound will be performed for each patient as part of their routine care and initial assessment. The IVC size will be measured at the subcostal window, during inspiration and expiration, using the Sonosite cardiac probe P-21 (5-1 MHZ). The measurement is obtained by applying the M-mode, perpendicular to the IVC axis and 2 cm caudal from its junction with the right atrium.
1622968|NCT02064231|Device|Coloplast Test A|Coloplast Test A is a new ostomy appliance developed by Coloplast A/S
1622969|NCT02064231|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance developed by Coloplast A/S
1622970|NCT02064231|Device|Own product|Own product is tested to get baseline results. Own product can be any 2-piece product that is commercially available. The manufactures can be Coloplast, Hollister, Convatec, Dansac, B. Braun and others.
1622971|NCT02064231|Device|Coloplast Test C|Coloplast Test C is a new ostomy appliance developed by Coloplast A/S
1622972|NCT02064231|Device|Coloplast Test D|Coloplast Test D is a new ostomy appliance developed by Coloplast A/S
1622973|NCT02064218|Drug|Anti-hypertensive drugs|
1622974|NCT02064205|Dietary Supplement|12.5 g polydextrose|Appetite suppressing supplement is added in yogurt and provided with breakfast (four hours before lunch) or 1.5h before lunch. Also yogurt with control (glucose syrup) is tested for its satiating effect.
1622975|NCT02064205|Dietary Supplement|glucose syrup|Glucose syrup is used a control product for the polydextrose
1622976|NCT02064166|Drug|Intranasal Insulin|"treatment arm: Insulin, 40 international units daily, intranasally, for 4 weeks;
placebo arm: normal saline, daily, intranasally, for 4 weeks."
1622977|NCT02064153|Procedure|Cool dialysate|Each recruited patient undergoes a cool dialysate session ( 35.5ºC) and a warm dialysate session (37ºC). The sessions are minimum a week apart to remove the carryover effect.
1622978|NCT02064153|Procedure|Warm dialysate|All recruited patients will undergo two study sessions - Cool dialysis (35.5ºC) and Warm dialysis (37ºC)
1622979|NCT02064140|Drug|Rocuronium|
1622980|NCT02064114|Procedure|Intervention group|Start of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
1622981|NCT02064114|Procedure|control group|Followed for a period of 3,6 and 12 months after the procedure.
1622982|NCT02064101|Procedure|Spinal Fusion|The investigators are studying the use of triggered EMG via the IPC POWEREASE screwdriver (Product Codes HBE, HWE, GWF) during spinal fusion surgery in adolescent idiopathic scoliosis by comparing it to the traditional triggered EMG OrthoMon probe system (Product Codes GWF, IKN).
1622983|NCT02064088|Drug|Injection of 0,2 ml/kg of 0,2% levobupivacaine for small volume group|Ultrasound guided administration of 0,2 ml/kg of 0,2% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
1622984|NCT02064088|Drug|Injection of 0,4 ml/kg of 0,1% lévobupivacaine for high volume group|Ultrasound guided administration of 0,4 ml/kg of 0,1% lévobupivacaine in the plane between the internal oblique and transversus abdominis muscles
1622985|NCT02064075|Drug|Lactated Ringer's solution|15-50 ml/kg Lactated-Ringer's solution was given intravenously every day until discharge.
1622986|NCT02064075|Drug|Hydroxyethyl starch|15 ml/kg Lactated-Ringer's and 15-50 ml/kg hydroxyethyl starch solution was given intravenously every day until discharge.
1622987|NCT02064062|Biological|Autologous Mesenchymal Stem Cells|
1622988|NCT02064049|Drug|Sofosbuvir/velpatasvir|The treatment phase will commence in year 2. This is 12 weeks of the pangenotypic sofosbuvir/velpatasvir 400/100mg, coformulated into one tablet daily.
1622989|NCT02064036|Radiation|Stereotactic Radiosurgical Boost|Intensity Modulated Radiotherapy (IMRT)2 with Concurrent Androgen Blockade to Whole Pelvis, Prostate, and Seminal Vesicles Followed by: Stereotactic Radiosurgical Boost3 to the Prostate with Implanted Electromagnetic Transponder Beacon Intrafraction Guidance
1622990|NCT02064036|Drug|Casodex|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
1622991|NCT02064036|Drug|Leuprolide|Neoadjuvant Androgen Blockade before radiation therapy and Adjuvant Androgen Blockade after radiation therapy
1622994|NCT02064010|Drug|SNC-102|Acamprosate calcium (SNC-102) tablet, administered orally for 4 weeks
1622995|NCT02064010|Drug|Placebo|Placebo tablet, administered orally for 4 weeks
1622996|NCT02063997|Drug|Arhalofenate 600 mg|Arhalofenate 600 mg tablets once daily for 12 weeks
1622997|NCT02063997|Drug|Allopurinol 300 mg|Allopurinol 300 mg tablets once daily for 12 weeks
1622998|NCT02063997|Drug|Colchicine 0.6 mg|Colchicine 0.6 mg over-encapsulated tablets once daily for 12 weeks
1622999|NCT02063997|Drug|Placebo|Placebo tablets once daily for 12 weeks
1623000|NCT02063997|Drug|Arhalofenate 800 mg|Arhalofenate 800 mg tablets once daily for 12 weeks
1623001|NCT02063984|Behavioral|Behavior Therapy|Weekly individual counseling sessions with teen and parent(s) to review and discuss contingency management abstinence-based incentives
1623002|NCT02063984|Behavioral|Working Memory Training|25 computer-delivered sessions of neurocognitive training
1623003|NCT02063971|Other|Soothing (formulation number: F#1048-082) and antiaging creams (F#841-020 and F#1374-002)|
1623004|NCT02063958|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety not to exceed a dose of 100 mg/m2. Maintenance therapy of SNX-5422 at the MTD will be allowed for all patients not experiencing significant toxicity.
1623005|NCT02063945|Drug|Methylphenidate|
1623006|NCT02063945|Drug|Risperidone|
1623007|NCT02063932|Other|endomicroscopy, targeted biopsy and 16s rRNA gene sequencing|
1623008|NCT02063919|Other|the mucosal microbiome in the biopsy specimen was analysed|
1623009|NCT02063880|Other|Urgent ART|Children will be started on HAART <48 hours after enrollment.
1623010|NCT02063880|Other|Early ART|Children will be started on ART after stabilization 7-14 days after enrollment.
1623011|NCT02063867|Drug|Arm 2: Decolonization|"Daily chlorhexidine (CHG) shower or CHG cloth bath for all non-critical care patients.
Topical intranasal mupirocin ointment (bilateral nares, twice daily) x5 days if non-critical care patients are MRSA+ by history, culture, or screen."
1623012|NCT02063854|Drug|NE-58095 IR|NE-58095 IR tablets
1623013|NCT02063854|Drug|NE-58095 IR Placebo|NE-58095 IR placebo-matching tablets
1623014|NCT02063854|Drug|NE-58095 DR|NE-58095 DR tablets
1623015|NCT02063854|Drug|NE-58095 DR Placebo|NE-58095 DR placebo-matching tablets
1623016|NCT02063841|Device|lead-free protective drape containing bismuth and antimony (RADPAD®)|
1623017|NCT02063841|Device|sterile identical sham drape|
1623018|NCT02063828|Device|Group A - Device guided breathing low dose|Group A: 15 minutes once a day, 5 days a week for 8 weeks.
1642538|NCT01912677|Drug|Methyldopa|
1623019|NCT02063828|Device|Group B - Device guided breathing high dose|Group B - 15 minutes twice a day, 5 days a week for 8 weeks.
1623020|NCT02063828|Device|Group C - Usual Breathing Control Group|Group C - 15 minutes per day, 5 days a week for 8 weeks.
1623021|NCT02063815|Procedure|Fissure sealant application|
2011076|NCT02717949|Drug|Ribavirin|ribavirin 1200 mg given orally in divided dose for those >75kg and 1000 mg in divided dose for those <75 kg.
2011077|NCT02716662|Dietary Supplement|Axona|medical powder, supplement food
2011078|NCT02712320|Drug|LMIS 50 mg|Subcutaneous injection of 50 mg Leuprolide Mesylate
2011079|NCT02709161|Behavioral|real-time fMRI neurofeedback: Amygdala|Participants are shown activity from their left amygdala in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
1623026|NCT02063789|Drug|Human immunoglobulin intravenous|After GC5107A Intravenous injection, evaluate platelet increase
1623027|NCT02063750|Other|strengthening exercises using a Swiss ball|"This group performed eight muscle strengthening exercises using a Swiss ball of 65 cm diameter and dumbbells with different loads.
Each training session was 40 minutes long and was performed three times a week for 12 weeks. The exercises were performed in three sets of 12 repetitions, with an interval of one to two minutes of recovery between exercises, which alternated between upper limbs, lower limbs and abdomen. The load used was 60 % of one repetition maximum (1RM)."
1623028|NCT02063750|Other|strengthening exercises|The stretching group performed stretching exercises that targeted the same muscles trained in the IG. The participants remained in the stretched position for three sets of 30 s for each exercise. The total session time was 40 minutes.
1623029|NCT02063737|Behavioral|Text-message assessments only|Text message assessments only. No intervention for high level fatigue.
1623030|NCT02063737|Behavioral|Text-message interventions for high level fatigue|Intervention messages to promote alertness while on duty at work including activities. Additionally at the end of the shift, participants were queried on their adoption of the suggested activities and perception of the activities' effectiveness.
1623031|NCT02063724|Biological|HER-2 pulsed Dendritic Cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines followed by 3 booster vaccines once every 3 months. Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
1623032|NCT02063711|Behavioral|Yoga intervention|
1623033|NCT02063698|Drug|auranofin|Given PO
1623034|NCT02063698|Other|placebo|Given PO
1623035|NCT02063698|Other|questionnaire administration|Ancillary studies
2011080|NCT02709161|Behavioral|real-time fMRI neurofeedback: HIPS|Participants are shown activity from their left horizontal segment of the intraparietal sulcus in real time and are instructed to increase the level of activity in that region by thinking of positive autobiographical memories
2011081|NCT02709083|Drug|Dasatinib|Given orally
2011082|NCT02709083|Drug|Imatinib Mesylate|Given orally
2011083|NCT02709083|Drug|Nilotinib|Given orally
2011084|NCT02709057|Behavioral|Lifestyle intervention|Life-style intervention includes 7-9 group sessions (two additional group sessions for participants whose body mass index exceeds 28 kg/m2) on diet (healthy diet according to Nordic and Finnish nutrition recommendations emphasizing appropriate energy intake, meal frequency, consumption of fruits, vegetables and berries, quality of dietary fat and carbohydrates, including sugar and fiber intake) and physical exercise (brisk walking a minimum of 30 minutes per day at least five days a week or other types of exercise, e.g. cycling, cross-country skiing, housework such as leafs raking, resistance training).
1623041|NCT02063672|Device|Lutonix DCB|
1623042|NCT02063672|Device|Standard Uncoated Balloon Angioplasty Catheter|PTA Catheter
1623043|NCT02063659|Drug|Telotristat etiprate tablets (250 mg)|Telotristat etiprate (250 mg) in tablet form.
1623044|NCT02063659|Drug|Placebo|Matching placebo in tablet form
1623045|NCT02063646|Dietary Supplement|Polyphenol-rich extract|Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product.
1623046|NCT02063646|Dietary Supplement|Placebo|"The placebo is a capsule with same appearance and organoleptic properties as the active product, containing no active component.
Two groups, each of 102 volunteers, are studied. For 24 weeks, one group of volunteers will consume the active product (polyphenol-rich extract) while the other one will consume the placebo product."
1623047|NCT02063620|Drug|Ketamine HCL|ketamine HCL is using as adjuvant agent with local anesthetic agent in regional intravenous anesthesia procedure routinely
1623048|NCT02063607|Biological|Peginterferon lambda|
1623049|NCT02063594|Drug|NCTX (PEGylated Liposomal Iodixanol Injection)|Single dose of NCTX (PEGylated Liposomal Iodixanol Injection) administered at escalating doses from 9 mg I/kg up to 110 mg I/kg
1623050|NCT02063594|Drug|Saline Placebo|Single dose of 0.9% Sodium Chloride Injection, USP administered similarly and at an equivalent dose volume as the active drug
1623051|NCT02063581|Drug|ipatasertib (Capsule)|Orally administered single dose of Ipatasertib formulated as a capsule.
1623052|NCT02063581|Drug|ipatasertib (Tablet)|Orally administered single dose of Ipatasertib formulated as a tablet.
1623053|NCT02063568|Drug|Oxytocin|
1623054|NCT02063555|Biological|DAR-901|
1623055|NCT02063555|Biological|BCG|
1623056|NCT02063555|Biological|Sterile saline|
1623057|NCT02063529|Drug|FOLFOXIRI + Cetuximab|Cetuximab 500mg/m² + irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
1623058|NCT02063529|Drug|FOLFOXIRI|Irinotecan* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
1623103|NCT02063139|Drug|Fluticasone 50 ug (2puffs bid) pMDI|
1623104|NCT02063139|Drug|Beclometasone Autohaler 50 ug (2 puffs bid)|
1623176|NCT02062541|Other|Funct. assessment+usual rehabilitation|
2011085|NCT02707588|Drug|Pembrolizumab|"200mg IV infusion every 3 weeks, i.e. on day 1, 22, 43 during the course of radiotherapy.
Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
1623059|NCT02063516|Device|Guardian Laryngeal Mask|Guardian Laryngeal Mask: The Guardian Laryngeal Mask (Ultimate Medical Pty Ltd, Richmond, Vic, Australia) is a new silicone-based single-use extraglottic airway device that forms a seal with the glottis for ventilation and with the hypopharynx for airway protection, and provides a gastric drainage port. In addition, it has a port for suctioning material from the hypopharynx and a pilot balloon valve that constantly monitors intracuff pressure. In the following randomized, non-crossover study, the investigators test if oropharyngeal leak pressures differed between the Guardian Laryngeal Mask and the LMA proseal in paralysed, anaesthetised patients.
1623060|NCT02063516|Device|Proseal Laryngeal Mask Airway|Proseal Laryngeal Mask Airway: Silicon based, reusable, modified dorsal cuff and drainage tube
1623061|NCT02063503|Other|physiotherapy|every group receives 2 treatments every week during 9 consecutive weeks
1623062|NCT02063490|Behavioral|Adherence support|"One-time preparatory intervention offering adherence prerequisites (knowledge, social support and skills)
+ One-year monthly individualised counselling sessions with a standardised intervention sheet listing the most prevalent problems with possible solutions"
1623063|NCT02063477|Dietary Supplement|Placebo|The placebo composition is for 1 gelule: 250 mg maltodextrin + 30 mg magnesium stearate; total weight: 280 mg/gelule
1623064|NCT02063477|Dietary Supplement|Oligopin®|"Oligopin® PUR' expert (%) is a red brown powder extracted from the bark of the Maritime Pine (Pinus pinaster) with composition:
- TOTAL POLYPHENOL CONTENT > 96
MONOMERS + PHENOLIC ACIDS 30
DIMERS >15
OTHER OLIGOMERS 50
PROCYANIDINS CONTENT (GPC) > 67
The Oligopin composition is for 1 gelule: 75 mg Oligopin + 175 mg maltodextrine + 30 mg magnesium stearate: total weight: 280 mg/gelule"
1623065|NCT02063451|Dietary Supplement|Very Low Calorie Diet (VLCD)|Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.
1623066|NCT02063438|Procedure|Pericostal suture technique|
1623067|NCT02063438|Procedure|Intracostal suture technique|
2011086|NCT02707588|Drug|Cetuximab|"Loading dose of 400 mg/m² IV on Day-8, followed by weekly dose of 250 mg/m² IV during the whole course of radiotherapy.
Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions)."
1623070|NCT02063386|Drug|AZD1722|Single oral dose 15 mg of [14C]AZD1722
1623071|NCT02063373|Other|Hyaluronic acid|treatment: Weekly intra-articular hyaluronic acid injection (20 MG / 2ML) into both knees for five weeks.
1623072|NCT02063360|Drug|BMS-663068|BMS-663068
1623073|NCT02063360|Drug|Darunavir (DRV)|Darunavir (DRV)
1623074|NCT02063360|Drug|Ritonavir (RTV)|Ritonavir (RTV)
1623075|NCT02063360|Drug|Etravirine (ETR)|Etravirine (ETR)
1623076|NCT02063334|Dietary Supplement|Vitamin D3|In total 25 pills will be taken by the subjects, each containing 80 micrograms of vitamin D3 or placebo. Of the 25 pills, 13 will be taken in the morning with breakfast and 12 with lunch.
1623077|NCT02063334|Dietary Supplement|Placebo|
1623078|NCT02063308|Dietary Supplement|Oxaloacetate (OAA)|
1623079|NCT02063295|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
1623080|NCT02063295|Drug|ZGN-440 for injectable suspension|
1623081|NCT02063269|Drug|Rivastigmine|9-18mg/rivastigmine for 52 weeks
1623082|NCT02063256|Dietary Supplement|7 nuts a day|add 7 nuts a day (whole shelled weight 75 grams) to standard diet
1623083|NCT02063256|Other|Diet modification|modify the diet allowing more intake of PUFA rich food and cutting the consumption of saturated fatty acids
1623084|NCT02063243|Procedure|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
1623085|NCT02063230|Drug|Selumetinib 50mg|HV and hepatic impaired patients with mild and moderat severity will recived selumetinib 50mg orally on day 1
1623086|NCT02063230|Drug|Selumetinib 25mg|Severe (Child Pugh C) hepatic impaired patients will receive selumetinib 25mg orally on Day 1
1623089|NCT02063204|Drug|selumetinib|selumetinib 50 mg (2x25mg) administered by mouth as capsules
1623090|NCT02063178|Behavioral|Phone-based sessions (28 total) on a structured schedule|28 sessions will be reviewed weekly and then bi-weekly with a trained motivational interviewing counselor for those individuals randomly assigned to the counselor-initiated condition.
1623091|NCT02063178|Behavioral|Phone-based sessions upon request|For those individuals randomly assigned to the self-paced condition, the 28 sessions are still available to them, the participant has to call to initiate sessions.
1623092|NCT02063178|Behavioral|Weight self-monitoring|Each randomized participant will be given a Body Trace scale that will electronically record their weight.
1623093|NCT02063178|Behavioral|Dietary and physical activity self-monitoring|Each randomized participant will be given a free account to Lose It! Premium, an online food/activity diary for self-monitoring.
1623094|NCT02063178|Behavioral|Scheduled tailored interventionist feedback|Randomly assigned participants to the counselor-initiated condition will receive feedback on their progress throughout their sessions with their assigned interventionist.
1623095|NCT02063178|Behavioral|Dietary goals|Each randomized participant will receive a daily calorie goal range based on their current weight, gender, and BMI.
1623096|NCT02063178|Behavioral|Meal replacements|Randomized participants will receive coupons for meal replacements including oatmeal and popcorn.
1623097|NCT02063178|Behavioral|Physical activity goals|Each participant will complete the Global Physical Activity Questionnaire which will determine their weekly exercise goals.
1623098|NCT02063178|Behavioral|Toolbox|The toolbox includes additional treatment options for those who wish to take advantage of them. Items may include: food scales, cookbooks, etc. These items may be checked out and must be returned prior to the completion of the study.
1623099|NCT02063178|Behavioral|Challenges|There will be several challenges designed to increase participant interest and provide a specific goal (e.g., increase self-monitoring). Participants who successfully completed the challenges will be given a small award.
1623100|NCT02063178|Behavioral|Tailored interventionist feedback upon request|Randomly assigned participants to the self-paced condition have the option to receive feedback on their progress upon request.
1623101|NCT02063165|Dietary Supplement|High Linoleic Safflower Oil|2 tsp per day (~10g of oil)
1623102|NCT02063139|Drug|Flutiform 50/5 ug (2 puffs bid) pMDI|
1623105|NCT02063126|Dietary Supplement|ReConnect (NADH plus CoQ10)|"ReConnect supplementation (NADH: 20 mg/day plus CoQ10: 200mg/day) divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)
Placebo supplementation divided into two daily dose ( 2 tablets/ before breakfast and 2 tablets/ before lunch)"
1623106|NCT02063126|Dietary Supplement|placebo|placebo (phosphoserine/serine plus vitamin C) supplementation divided in two daily doses (2 tablets/before brekfast and 2 tablets/before lunch)
1623107|NCT02063113|Other|Vulnerability and therapeutic changes in older patients with multiple myeloma.|
1623108|NCT02063100|Drug|Shenyankangfu tablets|Shenyankangfu tablets 2.4g, po, 3/day and Losartan potassium placebo 2 tab, po, 1/day,all drugs and placebo are taken for 48 weeks.
1623109|NCT02063100|Drug|Losartan potassium 50mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab,po, 1/day, all drugs and placebo are taken for 48 weeks.
1623110|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 50mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg,po, 1/day and losartan potassium placebo1 tab, po, 1/day, all drugs and placebo are taken for 48 weeks.
1623111|NCT02063100|Drug|Shenyankangfu tablets and Losartan potassium 100mg|Shenyankangfu tablets 2.4g, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
1623112|NCT02063100|Drug|Losartan potassium 100mg|Shenyankangfu tablets placebo 5 tab, po, 3/day and losartan potassium 50mg×2,po, 1/day, all drugs and placebo are taken for 48 weeks.
2011087|NCT02707588|Radiation|Radiotherapy|Radiotherapy will be delivered daily for 5 days per week to a total dose of 69.96 Gy in 2.12 Gy daily fractions over 6.5 weeks (33 fractions).
1623114|NCT02063061|Device|Sham treatment|Patients will receive simulated treatment, with the same ESWT unit as in other arm. Placebo gel-pad is design to prevent shockwaves emission. Looks identical as active gel-pad.
1623115|NCT02063061|Device|ESWT treatment|ESWT treatment group will receive 600 low-energy, linear shockwaves against erectile dysfunction per week in 10 weeks.
1623116|NCT02063048|Behavioral|Text Message Based Weight Loss Support|
1623117|NCT02063035|Drug|Tranexamic Acid|A single topical application of 3 grams (g) of Tranexamic acid in 100 milliliter (mL) saline.
1623118|NCT02063035|Drug|Placebo|A single topical application of matching placebo, which is 100 mL of normal saline.
1623119|NCT02063022|Drug|Standard treatment (as per protocol ISG SSG III)|Induction treatment with: 4 cycle of Vincristine (9mg/,2), Dactinomycin (6mg/m2), Doxorubicin (160mg/m2), Cyclophosphamide (2.4g/m2), Ifosfamide (18g/M2) and Etoposide (450mg/m2) given every 3 weeks Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Dactinomycin (1.5mg/m2), Doxorubicin (320mg/m2), Ifosfamide (27g/m2), Cyclophosphamide (8.8g/m2), Etoposide (1.5g/m2) and peripheral Cells Steam Transplant after Busulfan and Melphalan treatment Maintenance treatment (37 week) for good responder: Vincristine (18mg/m2), Dactinomycin (6mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Cyclosphosphamide(6g/m2), Etoposide (1.8 g/m2)
1623120|NCT02063022|Drug|Intensified chemotherapy|"Induction treatment with: 4 cycle of Vincristine (10.5 mg/m2), Doxorubicin (320 mg/m2) and Ifosfamide (36 mg/m2) given every 3 weeks
Maintenance treatment for poor responder (25 weeks): Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (63g/m2), Cyclophosphamide (4g/m2), Etoposide (1.5g/m2) and Cells Steam Transplant after Busulfan and Melphalan treatment
Maintenance treatment (25 week) for good responder: Vincristine (12mg/m2), Doxorubicin (400mg/m2), Ifosfamide (72g/m2), Etoposide (1.8g/m2)"
1623121|NCT02062996|Drug|Oxymetazoline|
1623122|NCT02062983|Drug|Herceptin|"Herceptin will be administered in different way per each setting as follow::total herceptin cycles are 18.
Neu Adjuvant : chemo+herceptin, Surgery (hold herceptin) , Resume herceptin for 1 year period Adjuvant : Surgery, chemo+herceptin for 1 year period Metastatic : chemo+herceptin until progression."
1623123|NCT02062970|Biological|blood draw|
1623124|NCT02062944|Drug|Sirolimus|SRL minimization will be performed if clinically, biochemically and histologically stable. Patients entering the minimization phases will be reduced every month by 50% of total dose of Sirolimus until they reach .5mg daily for one month. Then .5 mg every other day, then twice weekly, the once weekly dosing. This should take approximately 6 month to complete minimization. Liver function tests will be monitored every 2 weeks. For any patient developing liver dysfunction, liver biopsy will be performed. Patients will then be completely withdrawn and followed post-withdrawal for 12 months.
1623125|NCT02062931|Biological|Stem Cell Preparation and Injection|"Stem Cells 60 ml of bone marrow will aspirated using local anathesia and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared.
Blood sample drawn from venous blood centrifuged and then platelets rich plasma (PRP) collected. The purified and collected stem cells suspended in platelets rich plasma (PRP) using GMP rules and finally injected into ovarian tissues and ligaments .
Stem Cell Dose: 3-5 Million Autologous MSCs Injected into Ovarian tissue."
1623126|NCT02062918|Device|Abdominal belt|
1623127|NCT02062905|Drug|OTX-DP treatment|
1623128|NCT02062905|Device|Placebo Plug with no drug|
1623129|NCT02062892|Drug|Everolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/everolimus arm of the study will be switched from sirolimus to everolimus 1:1 (same sirolimus as everolimus dose). Everolimus doses will be adjusted so that trough blood concentrations are within 3-8 ng/mL. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, twice a day) in combination with Everolimus (Zortress, 0.25, 0.5 and 0.75 tablets).
1623130|NCT02062892|Drug|Sirolimus|Patients will be stable kidney transplant patients who are receiving an immunosuppressive drug regimen based on tacrolimus and sirolimus. 24 hours after the last sirolimus dose, the patients randomized to the tacrolimus/sirolimus arm of the study will remain on tacrolimus/sirolimus. In detail: Tacrolimus (Prograf or FDA approved generic 0.5 mg, 1 mg or 5 mg capsules, once a day) in combination with Sirolimus (Rapamune, 0.5, 1, and 2mg tablets).
1623131|NCT02062879|Drug|Ketamine|Ketamine administered as patient-controlled analgesia.
1623132|NCT02062879|Drug|Hydromorphone|Hydromorphone administered as patient-controlled analgesia.
1623175|NCT02062541|Other|Funct. assessment+fast rehabilitation|
1643169|NCT01908270|Behavioral|Yoga|
2011088|NCT02706834|Drug|Group A1= TAK-828 0.1 mg+TAK-828 3 mg +TAK-828 20 mg +Placebo|TAK-828 oral solution, fasted.
1623133|NCT02062866|Procedure|Purse-String|"The wound will be closed using one, long, continuous suture which will enter and exit run through the skin along the inner edge of the wound. The start and stopping point will be adjacent to one another. The suture will then be pulled on either side to essentially cinch down the wound, decreasing the size of the wound."
1623134|NCT02062866|Procedure|Second Intent|The wound will not be sutured, and allowed to heal on its own.
1623135|NCT02062853|Other|Video Group|Subjects will view a brief video today (about 5 minutes long) that provides information on the cream medication that will be used for treatment of your actinic keratoses.
1623136|NCT02062853|Other|Verbal Group|The physician will provide information about the cream medication for the treatment of actinic keratoses through a regular conversation.
1623137|NCT02062840|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
1623138|NCT02062840|Device|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
1623139|NCT02062840|Device|Functional Magnetic Resonance Imaging (fMRI) and electrocardiogram (EKG)|A standard magnetic resonance imaging (fMRI) machine will be used to take images of the brain. An standard EKG (compatible with the fMRI machine) will be used to take measurements of cardiac vagal control.
1623140|NCT02062840|Other|Questionnaires|Weekly questionnaires to assess changes in depression, mood, perceptions of self and quality of life will be administered.
1623142|NCT02062801|Drug|Ephedrine|Patients received additional doses of ephedrine 10mg IV to a maximum of 30mg if BP remained low (<90mmHg systolic) and/was associated with persistent fetal bradycardia or maternal symptoms of dizziness and nausea
1623143|NCT02062801|Drug|Placebo|Patients received normal saline (placebo) administered immediately after combined spinal epidural (CSE) placement
1623144|NCT02062788|Dietary Supplement|Oral rehydration solution|Preoperative day #1: able to drink Oral rehydration solution (ORS) freely On day of Surgery: Allowed administration until 2hrs prior to surgery. 8AM patients(the first patients to undergo surgery of the day) are recommended to administer ORS at 5:30AM
2011089|NCT02706834|Drug|Group B1= TAK-828 0.1 mg+TAK-828 3 mg+Placebo+TAK-828 100 mg|TAK-828 oral solution, fasted.
2011090|NCT02706834|Drug|Group C1= TAK-828 0.1 mg+Placebo+TAK-828 20 mg+TAK-828 100 mg|TAK-828 oral solution, fasted.
2011091|NCT02706834|Drug|Group D1= Placebo+TAK-828 3 mg+TAK-828 20 mg+TAK-828 100 mg|TAK-828 oral solution, fasted.
1623148|NCT02062762|Behavioral|Online-MBSR|8 week mindfulness based stress reduction online
1623149|NCT02062762|Behavioral|Expressive Writing Online|Online distributed expressive writing intervention as active control
1623150|NCT02062749|Drug|Oxaliplatin|Starting dose of Oxaliplatin is 175 mg/m2 delivered by hyperthermic intraperitoneal chemotherapy over 90 minutes.
1623151|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; dextromethorophan; placebo|diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg; placebo.
1623152|NCT02062710|Drug|diphenhydramine/phenylephrine/cocoa; placebo; dextromethorphan|diphenhydramine 25 mg and phenylephrine 10 mg; placebo; dextromethorphan 30 mg.
1623153|NCT02062710|Drug|dextromethorphan; diphenhydramine/phenylephrine/cocoa; placebo|dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg; placebo
1623154|NCT02062710|Drug|dextromethorophan; placebo; diphenhydramine/phenylephrine/cocoa|dextromethorphan 30 mg; placebo; diphenhydramine 25 mg and phenylephrine 10 mg
1623155|NCT02062710|Drug|placebo; diphenhydramine/phenylephrine/cocoa; dextromethorphan|placebo; diphenhydramine 25 mg and phenylephrine 10 mg; dextromethorphan 30 mg
1623156|NCT02062710|Drug|placebo; dextromethorphan; diphenhydramine/phenylephrine/cocoa|placebo; dextromethorphan 30 mg; diphenhydramine 25 mg and phenylephrine 10 mg
1623157|NCT02062697|Procedure|Lavage of the Cavum uteri and proximal fallopian tubes|
1623158|NCT02062697|Procedure|Liquid-PAP smear|
1623159|NCT02062684|Drug|Blisibimod|
1623160|NCT02062684|Drug|Placebo|
1623161|NCT02062671|Procedure|renal denervation|
1623162|NCT02062658|Drug|Ketamine|0.5mg/kg IV
1623163|NCT02062658|Behavioral|Exposure and Response Prevention|A type of Cognitive Behavioral Therapy called Exposure and Response Prevention.
1623164|NCT02062645|Drug|amlodipine/valsartan|Fixed combination of amlodipine and valsartan in tablet; 5/160/mg, 10/160 mg
1623165|NCT02062632|Drug|Doxepin Hydrochloride|Given orally
1623166|NCT02062632|Other|Placebo|Given orally
1623167|NCT02062632|Other|Quality-of-Life Assessment|Ancillary studies
1623168|NCT02062632|Other|Questionnaire Administration|Ancillary studies
1623169|NCT02062619|Behavioral|Computer-based behavioural word reading therapy|"Each patient participates in two blocks of reading training (one with real tDCS, one with sham tDCS). Different words will be trained in each training block.
Each training block comprises 10 hours of reading therapy per week for four weeks (three 1-hour sessions/week at research site; 1-hour of training/day at home)"
1623170|NCT02062619|Other|Real tDCS|Real tDCS 20 minutes per session, three times per week
1623171|NCT02062619|Other|Sham tDCS|Sham tDCS, 20 minutes per session, 3 sessions per week
1623172|NCT02062606|Device|MESA Rail™ Deformity System|MESA Rail™ (cross-sectioned rod) with MESA pedicle screws compared to traditional rod use in the literature
1623173|NCT02062593|Procedure|Coronary angioplasty|Percutaneous coronary intervention with drug-eluting stents and modern techniques
1623174|NCT02062580|Biological|BCG|
2011092|NCT02706834|Drug|Group A2: TAK-828 0.5 mg+TAK-828 10 mg+TAK-828 40 mg+Placebo|TAK-828 oral solution, fasted.
2011093|NCT02706834|Drug|Group B2: TAK-828 0.5 mg+TAK-828 10 mg+Placebo+TAK-828 200 mg|TAK-828 oral solution, fasted.
1623177|NCT02062541|Other|usual assessment+fast rehabilitation|
1623178|NCT02062528|Dietary Supplement|omega-3 fatty acids|highly dosed in EPA
1623179|NCT02062528|Dietary Supplement|placebo|
1623180|NCT02062515|Drug|icotinib|Icotinib is administered orally 125 mg three times per day continuously for four weeks
1623181|NCT02062502|Biological|VARIVAX™ New Seed Process|Varicella virus vaccine live manufactured with a new seed process
1623182|NCT02062502|Biological|VARIVAX™ 2007 process|Varicella virus vaccine live manufactured with the 2007 process
1623183|NCT02062502|Biological|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
1623184|NCT02062489|Drug|Tamoxifen|20 mg(2#)/day, PO, daily
1623185|NCT02062489|Drug|Placebo|2#/day, PO, daily
1623186|NCT02062476|Dietary Supplement|Lactobacillus GG|
1623187|NCT02062463|Drug|Budesonide and formoterol fumarate dehydrate (BF) SPIROMAX|SPIROMAX (BF) Budesonide and formoterol fumarate dehydrate (160/4.5 and 320/9 mcg)
1623188|NCT02062463|Drug|SYMBICORT TURBOHALER budesonide and formoterol fumarate|SYMBICORT® TURBOHALER® (200/6 and 400/12 mcg)
1623189|NCT02062450|Device|Primary surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
1623190|NCT02062450|Device|Revision surgery with Dual Mobility Cup|Hip joint replacement with a hip prosthesis including a Dual Mobility cup to replace the acetabular component.
1623191|NCT02062424|Other|DIPI|
1623192|NCT02062411|Behavioral|CBT only|Participants will learn 12 sessions including educational information about ADHD and skills in organization and plan, reducing distractibility, and adaptive thinking.
1623193|NCT02062411|Behavioral|CBT with booster sessions|Participants are provided with the same CBT programme and additional 3 booster sessions which summarize and extend the 3 main topics of the CBT programme in order to improve the skills practice ability.
1623194|NCT02062398|Device|The Reprieve System|BlueWind Medical neurostimulator for the treatment of neuropathic pain
1623195|NCT02062385|Biological|V260|V260 (RotaTeq™; live, oral, pentavalent rotavirus vaccine)
1623196|NCT02062385|Biological|Placebo to V260|Placebo control
1623197|NCT02062385|Biological|OPV|Oral poliovirus vaccine administered according to the standard of care
1623198|NCT02062385|Biological|DTaP|Diphtheria, Tetanus, Acellular Pertussis vaccine administered according to the standard of care
1623199|NCT02062372|Device|7 T MRI|Overview Technical DetailsField strength: 7 Tesla Bore size: 60 cm System length: 317,5 cm RF power: 7,5 kW / 8x1 kW Gradient strength: SC 72 Gradients (max. 70 mT/m @ 200 T/m/s) Helium Consumption: Zero Helium boil-off technology
1623200|NCT02062372|Procedure|Biopsy|During surgery patients will receive standard biopsies plus one study biopsy from a region of interest. The neuro-surgeon will determine the feasibility of the extra biopsy and the optimal biopsy tract. A screen capture from the neuronavigation system will be saved for each biopsy to relate the findings on 3T and 7T MRI to histopathology.
1623201|NCT02062359|Biological|Anti-NY ESO-1 T cell receptor (TCR) cluster of differentiation 62L (CD62L)+ cells|"Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T cell receptor (TCR) CD62L+ cells and high dose aldesleukin.
On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes."
1623202|NCT02062359|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
1623203|NCT02062359|Drug|Cyclophosphamide|On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
1623204|NCT02062359|Drug|Fludarabine|On days -5 to -1: Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
1623206|NCT02062333|Drug|Dexmedetomidine|1 mcg/kg dexmedetomidine is applied bolus and 0.2 mcg/kg/h dexmedetomidine is applied iv infusion
1623207|NCT02062333|Drug|esmolol|500 mcg/kg brevibloc is applied bolus and 100 mcg/kg/h iv infusion
1623208|NCT02062281|Biological|23-valent pneumococcal polysaccharide vaccine|Single 0.5ml 23-valent pneumococcal polysaccharide vaccine was administered intramuscularly (IM)
1623209|NCT02062281|Biological|trivalent influenza vaccine|Single 0.5ml trivalent influenza vaccine was administered IM
1623210|NCT02062281|Biological|23vPPV+TIV|Single 0.5 ml 23-valent pneumococcal polysaccharide vaccine (23vPPV) and a single 0.5 ml trivalent inactivated influenza vaccine (TIV) were administered IM, in one day.
1623211|NCT02062268|Behavioral|health education & law enforcement|
1623212|NCT02062255|Drug|Aspirin|
1623213|NCT02062255|Dietary Supplement|Omega 3 FFA|
1623214|NCT02062242|Other|Transvaginal electrical stimulation|The current employed is biphasic and the stimulation parameters are: frequency of 50 Hz, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds and relaxation time (Toff) of 10 seconds. The current intensity is defined according to the tolerance of patient and the total stimulation time is 20 minutes.
1623215|NCT02062242|Other|Palpation|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
1623216|NCT02062242|Other|Palpation with posterior pelvic tilt|The patient is positioned supine with the lower limbs bent and feet flat on the stretcher. The examiner will hold vaginal palpation and to request her the contraction of PFM associated with posterior pelvic tilt and contraction of accessory muscles. It will be requested 3 sets of 10 contractions with a rest period between contractions. There are two minutes a rest period between sets.
1623217|NCT02062242|Other|Control|The patient receive verbal instructions related to the pelvic floor and its contraction.
1623218|NCT02062203|Drug|AKB-6548 (therapeutic dose)|Single oral dose of AKB-6548 at a therapeutic dose level
1623219|NCT02062203|Drug|AKB-6548 (supratherapeutic dose)|Single oral dose of AKB-6548 at a supratherapeutic dose level
1623220|NCT02062203|Drug|Placebo|Single oral dose of placebo
1623221|NCT02062203|Drug|Moxifloxacin|Single oral dose of 400 mg moxifloxacin
1623222|NCT02062190|Drug|resveratrol|"100mg 2x/day
1 month"
1623223|NCT02062177|Drug|Propofol|70 patients (35 upper endoscopy - 35 colonoscopy) are sedated with propofol TCI (Target Controlled Infusion) pump (concentration 1.2-1.6 mcg/ml).
1623224|NCT02062177|Drug|Midazolam|70 patients (35 upper endoscopy - 35 colonoscopy) in group midazolam are sedated with midazolam 0.04 mg/Kg if aged < 70, 0.03 mg/Kg if aged > 70.
1623225|NCT02062164|Procedure|bariatric surgery|The intervention takes place in the clinical care setting. The decision for surgery is made by a multidisciplinary team, according to the international guidelines and the recommendations of the German working group on obesity (AGA, www.a.g.a.de). The choice of procedure is made on an individual basis taking into consideration patient inherent factors as well as the recommendations of the operating center. Operations are conducted at certified bariatric centers according to the policies of the German working group on bariatric surgery (CAADIP), and in the context of a structured preparation and follow-up program. The program is offered by a multidisciplinary team (pediatrician, endocrinologist, surgeon, dietician, psychologist/psychiatrist, social worker) and comprises preparation for and education about the surgery and expected lifestyle changes, as well as a structured, multidisciplinary follow-up plan. Subjects sign a contract agreeing to adhere to the recommended follow-up schedule.
1623226|NCT02062164|Other|conservative care|Subjects will be seen by a trained study physician every 6 months. Stuctured health assessments will be conducted, and individual treatment recommendations will be made based on the patients motivation and ability(e.g. inpatient obesity rehab, exercise, dietary or behavioral intervention etc.)
1623227|NCT02062151|Other|Acupuncture|Acupuncture
1623228|NCT02062138|Other|continuous passive motion (CPM)|standard-of-care therapy (control intervention); Patients receive three 30 minutes CPM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
1623229|NCT02062138|Other|controlled active motion (CAM I)|Patients receive three 30 minutes CAM applications (unilateral op-leg) each day from the second postoperative day until 1 day prior to discharge.
1623230|NCT02062138|Other|controlled active motion (CAM II)|Patients receive three 30 minutes CAM applications (bilateral alternating) each day from the second postoperative day until 1 day prior to discharge.
1623231|NCT02062112|Other|Pattern of flavoring of bowel laxative|Unflavored bowel laxative versus entire bowel laxative flavored versus liberal flavoring as decided by patient
1623232|NCT02062099|Drug|[18F]DPA-714 PET/ [18F]AV-45 PET/neuropsychological assessment|
1623233|NCT02062086|Dietary Supplement|deuterated creatine 30 mg|Study participants will take a single oral dose of deuterated creatine 30 mg in capsule form
1623234|NCT02062073|Drug|Abametapir Lotion 0.74% w/w|
1623235|NCT02062073|Other|0.1% sodium lauryl sulfate|
1623236|NCT02062073|Other|saline 0.9%|
1623237|NCT02062073|Other|Vehicle Lotion|
1623238|NCT02062060|Drug|Abametapir Lotion 0.74% w/w|
1623239|NCT02062060|Drug|Vehicle Lotion|
1623240|NCT02062047|Procedure|FMSRP|FMSRP in a maximum of 24 hours.
1623241|NCT02062047|Drug|Chlorhexidine|Application and irrigation of chlorhexidine, rinsing chlorhexidine solution during 60 days
1623242|NCT02062047|Procedure|PMSRP|Scaling and root planing in 4-6 sessions in a maximum of 2 weeks
1623243|NCT02062047|Other|Placebo|Application and irrigation of placebo, rinsing placebo solution during 60 days
2011094|NCT02706834|Drug|Group C2: TAK-828 0.5 mg+Placebo+TAK-828 40 mg+TAK-828 200 mg|TAK-828 oral solution, fasted.
2011095|NCT02706834|Drug|Group D2: Placebo+TAK-828 10 mg+TAK-828 40 mg+TAK-828 200 mg|TAK-828 oral solution, fasted.
2011096|NCT02706834|Drug|Group A3: TAK-828 3 mg +TAK-828 20 mg +Placebo|TAK-828 oral solution, fasted.
1623247|NCT02062021|Other|No intervention|
1623248|NCT02062008|Device|PET-MRI|PET-MRI with intravenous Gadolinium and FDG. The entire study will take approximately one hour.
1623249|NCT02061995|Drug|PREOB® Intravenous Infusion|Each patient will undergo a single intravenous administration of PREOB®.
1623250|NCT02061982|Dietary Supplement|Coffee consumption|Coffee is consumed before cognitive tests. One cup of instant coffee with 75 mg of caffeine or 0 mg caffeine and will be prepared with 150-200 mL of hot water.
1623251|NCT02061969|Drug|linagliptin|5mg linagliptin tablets
1623252|NCT02061969|Drug|insulin glargine|
1623253|NCT02061930|Procedure|single crowns supported by implants|The implant placement procedures were planned based on clinical and radiographic evaluation. During the surgeries, the mid-crestal incision and intra-crevicular incision were made following local articaine infiltration anesthesia. No releasing incisions were made. After full-thickness flaps were elevated labially and lingually to expose the alveolar ridge, the implants were placed according to the standard surgical procedures defined by the manufacturer. After a healing time of 10-16 weeks, implant-level impressions were taken. The porcelain (Ivoclar-Vivadent AG, Schaan, Lichtenstein) fused to noble metal crowns were fabricated. Abutment screws were torqued to 15 Ncm. Crowns were cemented with HY-bond Glassionomer Cement
1623254|NCT02061917|Other|Tobacco-Heating Cigarette|Smokers switched to a tobacco-heating cigarette for 24 weeks
1623255|NCT02061917|Other|Snus (Smokeless Tobacco)|Smokers switched to snus product for 24 weeks
1623256|NCT02061917|Other|Tobacco-Burning Cigarette|Smokers switched to a tobacco-burning cigarette for 24 weeks
1623257|NCT02061904|Radiation|DEXA: dual energy X-ray absorptiometry|Bone mineral density development measured with dual energy X-ray absorptiometry
1623258|NCT02061904|Other|Short Form Health Survey 12|questionnaire for general health monitoring
1623259|NCT02061904|Other|VAS-satisfaction|questionnaire for intervention satisfaction monitoring
1623260|NCT02061904|Other|VAS-pain|questionnaire for pain monitoring
1623261|NCT02061904|Other|Harris Hip Score|questionnaire for hip function monitoring
1623262|NCT02061891|Procedure|Invasive coronary evaluation (Deferred)|Invasive coronary angiography and revascularization (PCI/CABG)
1623263|NCT02061891|Procedure|Invasive coronary evaluation (Acute)|Invasive coronary angiography and revascularization (PCI/CABG)
1623264|NCT02061878|Drug|Bexarotene|Marketed product Targretin® soft gelatin capsule (75mg/capsule) is over-encapsulated in a size AA-el Swedish orange capsule. The subjects will be administered three (3) capsules of Targretin™ (75 mg/capsule) on a twice daily basis (450 mg/day) for five days.
1623565|NCT02059603|Procedure|Electroacupuncture|
2011097|NCT02706834|Drug|Group B3: TAK-828 3 mg+Placebo+TAK-828 100 mg|TAK-828 oral solution, fasted.
1623265|NCT02061878|Drug|Placebo|The subjects will be administered three (3) capsules of Avicel PH on a twice daily basis (450 mg/day) for five days.
1623266|NCT02061865|Drug|REGN2176-3|
1623267|NCT02061852|Device|Simeox|
1623268|NCT02061852|Procedure|Physiotherapy|
1623269|NCT02061839|Other|Sunscream with visible light protection|
1623270|NCT02061839|Other|Sunscream|
1623271|NCT02061813|Drug|Abametapir Lotion 0.74% w/w|applied 0.2 mL topically under occlusive condition
1623272|NCT02061813|Drug|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate is prepared as a 0.2% aqueous solution by the site for topical administration, and applied 21 times over consecutive days under occlusive conditions, will serve as a positive control.
1623273|NCT02061813|Drug|Saline 0.9%|A solution of 0.9% saline for topical administration, applied 21 times over consecutive days under occlusive conditions, will serve as a negative control
1623274|NCT02061813|Drug|Placebo|
1623275|NCT02061800|Device|CliniMACS CD34+ Reagent System|The CliniMACS® Reagent System (Miltenyi Biotec, Germany), is a semi-automated immunomagnetic cell selection medical device that is used in vitro to select and enrich specific cell populations in a closed, sterile environment. The system is comprised of a computer controlled medical device containing a permanent magnet, a closed-system sterile tubing set containing columns coated with a ferromagnetic matrix, and a magnetic cell specific labeling reagent.
1623276|NCT02061800|Drug|Thiotepa|Standard of care: Thiotepa should be diluted in normal saline (NS) (1-5 mg/ml) and infused over 2 hrs on Days -5, -4. IV fluids should be at maintenance rate (1500 ml/m2). It is recommended that total parental nutrition not being used during Thiotepa administration as amino acid infusions may interfere with Thiotepa metabolism.
1623277|NCT02061800|Drug|Cyclophosphamide|Standard of care: Cyclophosphamide (Cytoxan) should be infused over one hour. The drug can be diluted in dextrose water solvent (D5W), NS, or other solutions (250cc) to a maximum concentration of 20 mg/mL.
1623278|NCT02061800|Drug|Alemtuzumab|Standard of care: Each dose of alemtuzumab is to be diluted in D5W or NS (maximum concentration: 0.3 mg/mL) for IV infusion over two hours.
1623279|NCT02061800|Drug|Tacrolimus|Standard of care: Tacrolimus dosing will be 0.03mg/kg/24 hours as continuous IV infusion or 0.12 mg/kg/day po divided Q8-12 hr
1623280|NCT02061800|Drug|Melphalan|Standard of care: Melphalan 45mg/m2 (1.5 mg/kg IV for children <1 year of age or <10 kg) diluted in 0.9% NS to a concentration of 0.1- 0.45mg/ml, given IV over 30 minutes.
1623281|NCT02061800|Drug|Busulfan|Standard of care: Busulfan will be given IV in 0.9% sodium chloride or D5W to a final solution for infusion equal to 10 times the volume of diluent to Busulfex (to a concentration >0.5 mg/mL), through a central venous access device over 2 hours.
1623282|NCT02061800|Drug|Fludarabine|Standard of care: Fludarabine will be given IV in 50-100 ml of D5W or 0.9% sodium chloride, over 30 minutes.
1623283|NCT02061800|Drug|Methylprednisolone|Standard of care: Methylprednisolone will be give IV slow infusion over 15-30 minutes.
2011098|NCT02706834|Drug|Group C3: Placebo+TAK-828 20 mg+TAK-828 100 mg|TAK-828 oral solution, fasted.
1623286|NCT02061761|Biological|BMS-986016|
1623287|NCT02061761|Biological|BMS-936558|
1623288|NCT02061748|Drug|Observational|Retrospective Chart Review
1623289|NCT02061722|Radiation|PET Imaging with [18F]MNI-659|"The radioligands [11C]raclopride and [18F]MNI-659 will be administered at doses less than 10 micrograms, i.e. within the micro dosing concept, and no pharmacological effects are expected.
The injected radioactivity of [11C]raclopride will be 300 MBq/70 kg of body weight ± 10%.
The injected radioactivity of [18F]MNI-659 will be 185 MBq/70 kg of body weight ± 10%."
1623290|NCT02061709|Biological|Ragweed-SPIRE|
1623291|NCT02061709|Biological|Placebo|
1623292|NCT02061696|Device|Vascular Access Device|AXERA 2 Access System with Reduced Manual Compression
1623293|NCT02061696|Procedure|Standard Manual Compression|Closure procedure by Manual Compression
1623294|NCT02061683|Drug|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN®) 1 drop in the affected eye(s) once daily as monotherapy or adjunctive therapy for 3 months.
1623295|NCT02061670|Biological|Ragweed-SPIRE|Intradermal injection
1623296|NCT02061670|Biological|Placebo|
1623297|NCT02061657|Drug|Misoprostol|25 patients undergoing myomectomy operation will receive two tablets of misoprostol (400 mcg) rectally two hours before the operation
1623298|NCT02061657|Drug|Placebo( for misoprostol)|Include 25 patients undergoing myomectomy operation will not receive misoprostol before the operation.
1623299|NCT02061644|Other|Spinal anesthesia|Routine spinal anesthesia procedure will be made to the patients for surgical anesthesia.
1623300|NCT02061631|Drug|Cisplatin|Pharmaceutical form:solution Route of administration: intravenous
1623301|NCT02061631|Drug|DOCETAXEL XRP6976|Pharmaceutical form:solution Route of administration: intravenous
1623302|NCT02061631|Drug|Dexamethasone|Pharmaceutical form:tablet Route of administration: oral
1623303|NCT02061631|Drug|Dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
1623304|NCT02061618|Behavioral|Bollywood Dance Exercise|
1623305|NCT02061605|Device|Laser Tissue Welding Device|Laparoscopic partial nephrectomy will be robotically assisted using the second generation da Vinci® Surgical System. Once the tumor is resected with laparoscopic scissors with a margin of healthy tissue, the solder will be dripped onto the cut surface of the parenchyma. A laparoscopic rigid 5mm spot-size laser hand-piece will be passed through the 10-mm port. The diode laser will be then used to weld a thin layer of solder onto the cut parenchymal surface. The 60 Watt 810-nm diode laser will be set to deliver continuous energy. During soldering, the tip of the laparoscopic laser hand-piece will be maintained 1 to 2 cm from the renal surface to generate a spot size of approximately 5 mm. Each spot will be treated with the laser until the color of the solder changes from green to white. The renal pedicle clamp will be removed to allow renal blood supply to be restored and the surgical site inspected for evidence of bleeding for 10 minutes prior to completing the surgical procedure.
1623306|NCT02061592|Device|etafilcon A|
1623307|NCT02061592|Device|etafilcon A|
1623560|NCT02059629|Device|Sentus BP lead|over-the-wire (OTW), bipolar (BP), L-shaped (L), 4.8 French left ventricular lead
1623308|NCT02061579|Behavioral|Structured Group Exercise|The study intervention is a 6-month exercise program with structured group sessions conducted in a clinical setting. Group sessions include Aerobic Training and Combined Training. Once-Weekly participants will attend one Combined Training session while thrice-weekly participants will attend two Combined Training sessions and one Aerobic Training session per week. Participants in both groups will attend three exercise evaluations during the intervention period. Participants will also use provided logs to track their daily exercise activities outside of group sessions. Physical activity will be assessed by group session attendance, exercise resistance and intensity, and exercise frequency data collected from exercise logs, surveys, and evaluations.
1623309|NCT02061553|Behavioral|Intention|Implementation intentions are created collaboratively by participants and therapists in a single 2-hour session that uses principles of brief BA (the translation of important life values into the planning of rewarding activities that support those values). BA-based implementation intentions will then be delivered daily by text for 8 weeks.
1623310|NCT02061553|Behavioral|Motivation|Control condition in which participants receive a single 2-hour session with education on the importance of self-confidence and motivation, followed by 8 weeks of daily SMS messages with self-selected motivational statements .
1623311|NCT02061540|Drug|LUM001|LUM001 oral dose
1623312|NCT02061527|Procedure|Reconstruction with ADM.|If the patient wishes to undergo immediate implant based reconstruction, and meets the selection criteria for entering the study, she is randomly selected to be treated according to Group A or Group B. Group A (no intervention) will be reconstructed with expander or anatomical gel implant without ADM, using complete muscle coverage. Group B (Intervention) will be reconstructed with expander or anatomical gel implant using partial muscle coverage in conjunction with ADM.
1623313|NCT02061527|Procedure|Skin or nipple sparing mastectomy|Mastectomy for invasive or pre-invasive breast cancer
1623314|NCT02061527|Procedure|Reconstruction with implant|Immediate breast reconstruction with implant
1623315|NCT02061527|Procedure|Total submuscular coverage|Implant based breast reconstruction with total submuscular coverage
1623316|NCT02061527|Procedure|Partial submuscular coverage|Implant based breast reconstruction with partial submuscular coverage
1623317|NCT02061514|Procedure|maintenance with desflurane|in patients allocated to the desflurane group, general anesthesia will be maintained with desflurane
1623318|NCT02061514|Procedure|maintenance with propofol|in patients allocated to the propofol group, general anesthesia will be maintained with propofol
1623319|NCT02061501|Other|Optometric therapy during 6 months|Optometric therapy during 6 months, once a week
1623320|NCT02061501|Other|Optometric therapy during 12 months|Optometric therapy once a week, during 12 months
1623321|NCT02061488|Other|open-loop night|During the open-loop night the patient is using his insulin pump as usual
1623322|NCT02061488|Other|closed-loop night|During the closed-loop night glucose values measured by the sensor are collected every 15 minutes. The data are entered into the SP-MPC controler that calculate the insulin dose to be delivered. A diabetologist validates the insulin dose before the infusion (manually bolus infusion)
1623323|NCT02061475|Drug|Lidocaine Patches|
1623324|NCT02061462|Procedure|EVLP-DCD Group|Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy
1623325|NCT02061449|Drug|Romidepsin|
1623326|NCT02061449|Drug|Poly ICLC|
1623327|NCT02061449|Radiation|Focal lesional radiation|
1623328|NCT02061423|Biological|HER-2 pulsed Dendritic Cell Vaccine|Each dose will consist of between 1.0-2.0 x 10^7 cells and will be injected into 1-2 different normal groin lymph nodes or axillary nodes.
1623329|NCT02061410|Device|Neuromuscular Electrical Stimlation (NMES)|The intervention was performed with subjects seated on a regular chair (hip and knee angles maintained at approximately 908), 3 times/week for a period of 8 weeks. NMES parameters included: rectangular biphasic symmetric current, pulse duration of 400 ms and stimulation frequency of 80 Hz.
1623330|NCT02061397|Drug|Simvastatin|Eligible patients will be assigned to receive 20 mg of simvastatin once daily for a period of two months. If tolerated, the dosage of simvastatin will be advanced to 40 mg once daily in months 3 and 4.
1623331|NCT02061384|Drug|13-cis retinoic acid|Accutane is used for the treatment of severe acne
1623332|NCT02061384|Drug|Calcitriol|Calcitriol is a form of vitamin D given twice daily (BID)
1623333|NCT02061371|Other|virtual therapy|
1623334|NCT02061371|Other|conventional physiotherapy|
1623335|NCT02061358|Drug|UV-4B 3 mg|Oral solution, single dose
1623336|NCT02061358|Drug|UV-4B 10 mg|Oral solution, single dose
1623337|NCT02061358|Drug|UV-4B 30 mg|Oral solution, single dose
1623338|NCT02061358|Drug|UV-4B 90 mg|Oral solution, single dose
1623339|NCT02061358|Drug|UV-4B 180 mg|Oral solution, single dose
1623340|NCT02061358|Drug|UV-4B 360 mg|Oral solution, single dose
1623341|NCT02061358|Drug|UV-4B 720 mg|Oral solution, single dose
1623342|NCT02061358|Drug|UV-4B 1000 mg|Oral solution, single dose
1623343|NCT02061358|Drug|Placebo|Oral solution, single dose
1623344|NCT02061332|Biological|HER-2 Pulsed Dendritic cell Vaccine|6 weekly HER-2 pulsed dendritic cell vaccines will be administered to subjects in each of the 3 arms.
1623345|NCT02061319|Behavioral|Nordic Walking|Participants in the Nordic walking group will be provided with walking poles (GymstickTM Nordic Walking Poles, Gymstick International OY, Lahti, Finland) for the duration of the study. They will attend on-site exercise classes twice weekly for 12 weeks. The on-site exercise training classes will be one hour in length and include the following components: a 15 minute chair warm-up that excludes resistance exercises; 10-15 minutes of walking with Nordic walking poles for the first 3 weeks, progressing to 30 minutes of continuous walking with poles for the remaining 9 weeks; and 15 minutes of cool down exercises. Participants will be instructed to take the walking poles home and perform 200-400 minutes of Nordic walking per week for 12 weeks
1623346|NCT02061293|Drug|Psilocybin|
1623347|NCT02061293|Drug|Diphenhydramine|
1623561|NCT02059616|Drug|Amlodipine 5mg|Daily oral administration for 8 weeks
1623348|NCT02061293|Behavioral|Motivational Enhancement and Taking Action (META)|Manualized psychosocial intervention based on motivational enhancement therapy, functional analysis, and implementation of a change plan.
1623349|NCT02061280|Procedure|MICT|Participants randomized to MICT will complete study procedures using an iPad for data entry and FaceTime visits rather than coming into the study site for onsite visits. Participants will perform spirometry at home using a handheld spirometer, EasyOne Plus.
1623350|NCT02061280|Procedure|LASST|Participants randomized to LASST will complete study procedures in the traditional format in which all study visits are conducted at the study site, all questionnaires are completed by pen/paper, and all spirometry is performed at the clinic site.
1623351|NCT02061280|Device|iPad|Participants randomized to MICT will receive an iPad for data entry and FaceTime visits. This form of study participation will be compared with traditional trial participation by the LASST participants
1623352|NCT02061280|Procedure|Parallel MICT|The process for obtaining informed consent will be entirely web-based with electronic documentation of consent.
1623353|NCT02061280|Procedure|Parallel LASST|The process for obtaining informed consent will be conducted at the clinic site by conventional face-to-face interaction and paper signing of consent documents.
1623354|NCT02061280|Drug|Advair Diskus 250/50 Dry Powder Inhaler, 60 ACTUAT|Participants will receive Advair Diskus 250/50 Dry Powder Inhaler, 60 ACTUAT administered twice daily for 12 weeks after randomization
1623355|NCT02061280|Drug|Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT|Participants will receive Advair Diskus 100/50 Dry Powder Inhaler, 60 ACTUAT administered twice daily for 12 weeks after randomization
1623356|NCT02061280|Drug|Flovent Diskus, 100 Mcg Inhalation Powder|Participants will receive FloventDiskus 100 Dry Powder Inhaler, 60 ACTUAT administered twice daily for 12 weeks after randomization
1623357|NCT02061267|Dietary Supplement|Niacin|The subjects will receive a vitamin B3 supplement (2 g)
1623358|NCT02061267|Dietary Supplement|Saturated meal|Test meal with high-fat (containing 72% saturated fat, 22% carbohydrate, and 6% protein)
1623359|NCT02061267|Dietary Supplement|Monounsaturated meal|Test meal with high-fat (containing 72% monounsaturated fat, 22% carbohydrate, and 6% protein)
1623360|NCT02061267|Dietary Supplement|Polyunsaturated meal|Test meal with high-fat (containing 72% polyunsaturated omega-3 fat, 22% carbohydrate, and 6% protein)
1623361|NCT02061254|Device|Cutometer|3 measures by cutometer on each area: the mean value will be the final value
1623362|NCT02061254|Device|High resolution ultrasonography (echography)|Cutaneous echography on the 3 areas, in order to measure skin thickness and echogenicity Measures are blinded to cutometer (by a different investigator)
1623363|NCT02061254|Device|Elastography|10 measures on the 3 areas (central measures will be doubled) Measures will be performed blinded to cutometer
1623364|NCT02061254|Procedure|Skin biopsy|Skin biopsy of 3 mm in diameter, for 30 participants, to evaluate histological fibrosis
1623365|NCT02061241|Procedure|Pacing in vein at site of latest mechanical activation|Pacing in vein at site of latest mechanical activation
1623366|NCT02061241|Procedure|Pacing in other suitable vein|Pacing in other suitable vein
1623367|NCT02061228|Device|Pipelle de Cornier®|Women in the intervention group will undergo an endometrial biopsy on the 6th day of ovarian stimulation using a Pipelle de Cornier® (CCD International, Paris, France). This class I individually and sterile-packaged medical device, complies with Directive 93/42/European Economic Community (EEC) and is routinely used in our centre for endometrial sampling. It is comprised of a flexible disposable polypropylene suction cannula with an outer diameter of 3.1 mm and a 2.4 mm diameter opening on the distal end, on one side of the cannula. An inner plunger creates a vacuum essential for the blind endometrial biopsy. After the introduction of the Pipelle into the uterine cavity, it will be rotated 360 degrees and moved up and down four times after withdrawing the piston.
1623368|NCT02061215|Other|CMV viral load|
1623369|NCT02061202|Drug|Mometasone Furoate|inhaled cortico-steroid (ICS) with a dosage of 220mcg once daily for 16 weeks
1623370|NCT02061202|Drug|Placebo|placebo training inhaler with the same instructions as the experimental group.
1623371|NCT02061189|Other|Physical exercise in a swimming pool during 6 months|10 patients will undergo a training program of physical exercise in a swimming pool, 3 days per week during 6 months. Each session will last for 20 minutes.
1623372|NCT02061176|Procedure|Transanal Haemorrhoidal Dearterialization|
1623373|NCT02061176|Procedure|Open Haemorrhoidectomy|
1623374|NCT02061163|Device|Contrast Enhanced Ultrasound|Subjects with Crohn's disease will undergo contrast enhanced ultrasound imaging with shear wave elastography. Both CEUS and shear wave elastography will be performed using FDA approved ultrasound machines.
1623375|NCT02061163|Drug|Optison|Optison is a microbubble contrast agent (dye) that will be injected during the CEUS imaging. Optison is FDA-approved for use in heart ultrasounds but not approved for use in bowel ultrasounds. Its use in this study is considered investigational (off-label).
1623376|NCT02061137|Drug|fingolimod (FTY720)|0.5 or 0.25 mg fingolimod orally daily for each of 6 patients with rett syndrome for 12 months
1623377|NCT02061124|Drug|Sevelamer 1600 mg TID for 7 days|
1623378|NCT02061124|Drug|Placebo 1600 mg TID for 7 days|
1623379|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group A|Group A will consume 1 daily capsule of pomegranate extract for 3 weeks
1623380|NCT02061098|Dietary Supplement|Placebo-first dose-Group B|Group B will consume 1 daily capsules of placebo for 3 weeks.
1623381|NCT02061098|Dietary Supplement|Pomegranate extract-first dose-Group B|After 3 weeks of washout, group B will consume 1 daily capsule of pomegranate extract for 3 weeks.
1623382|NCT02061098|Dietary Supplement|Placebo-first dose-Group A|After 3 weeks of washout, group A will consume 1 daily capsule of placebo for 3 weeks.
1623383|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of pomegranate extract for 3 weeks.
1623384|NCT02061098|Dietary Supplement|Placebo-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of placebo for 3 weeks.
1623385|NCT02061098|Dietary Supplement|Pomegranate extract-second dose-Group B|After 3 weeks of washout, group B will consume 4 daily capsules of pomegranate extract for 3 weeks.
1623386|NCT02061098|Dietary Supplement|Placebo-second dose-Group A|After 3 weeks of washout, group A will consume 4 daily capsules of placebo for 3 weeks.
1623387|NCT02061085|Drug|Eribulina|
1623388|NCT02061072|Device|Population pharmacokinetic estimation|Pre-existing individual PK data will be used to derive population PK models. Sparse concentration time data, acquired via a website, will be used to estimate individual pharmacokinetic parameters
1623389|NCT02061059|Other|block 1|shoemaker 1 produces shoes according to standard methods, shoemaker 2 uses plantar pressure measurements
1623390|NCT02061059|Other|block 2|shoemaker 2 produces shoes according to standard methods, shoemaker 1 uses plantar pressure measurements
1623391|NCT02061059|Other|standard|patient wears shoes produced with standard method
1623392|NCT02061059|Other|with measurements|patient wears shoes produced with plantar pressure measurements
1623393|NCT02061046|Device|CPAP therapy|8 weeks of CPAP therapy
1623394|NCT02061020|Drug|Cannabis (THC) in cigarettes of 30mg, 10mg and placebo|"Smoked THC containing cigarettes. Randomly allocated dosage 30mg, 10mg et placebo.
Both chronic and occasional cannabis consuming volunteers will be allocated to smoking a cigarette containing (1) no THC (placebo), (2) a joint containing 1% THC (10 mg THC, i.e. low-dose) and (3) a joint containing 3% (30 mg THC) mixed with 1 g tobacco.
Each cigarette will be followed by 24 hours testing in laboratory conditions. Each period is separated by 7 days (3 testing periods over 3 weeks). Each volunteer will undergo performance testing (driving simulator and PVT) before administration of the substance (T0).
Blood samples and repeat performance testing will be carried out at 1 hour, 2 hours, 4 hours, 6 hours, 8 hours, 12 hours and 24 hours."
1623395|NCT02061007|Drug|Pimonidazole hydrochloride (Hypoxyprobe™-1)|Prior to surgery, patients will be administered a single dose of 0.5 g/m^2 (approximately 13 mg/kg) of oral Hypoxyprobe™-1 (pimonidazole, HCl).
1623396|NCT02061007|Drug|Optional 18F-FMISO PET scan (18F-fluoromisonidazole)|All patients will be offered the opportunity to receive an additional 18F-FMISO-PET scan, until 18 such scans are administered.
1623397|NCT02061007|Procedure|Surgical Resection of Melanoma Metastases|Participants will undergo surgical resection of melanoma metastases within 16 - 24 hours of consuming oral pimonidazole. Pimonidazole staining will be done on formalin-fixed and paraffin-embedded (FFPE) tissues for pimonidazole analysis. All participants will be contacted 24-72 hours post-surgery to be assessed for any adverse events (AEs) related to surgery, pimonidazole consumption and 18F-FMISO (when applicable).
1623398|NCT02060994|Other|No intervention|No intervention
1623399|NCT02060981|Behavioral|Control|Control group patients will then be mailed an American Heart Association brochure regarding hypertension and a brief, 5-question, paper-based survey.
1623400|NCT02060981|Behavioral|Interview Only|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension.
1623401|NCT02060981|Behavioral|Interview plus decision support tool|Patients will be asked to participate in an interview regarding their views on hypertension and taking medications to treat hypertension and to provide feedback regarding a new decision support tool for helping patients learn more about their medications.
1623402|NCT02060968|Device|Promus PREMIER|
1623403|NCT02060955|Biological|ALECSAT|The ALECSAT will be administered at week 4, 9, 14, 26 and week 46. Cells are re-suspended in a plasmalyte injection fluid up to a total volume of 20 ml. The 20 ml cell suspension will contain between 10 million and 1 billion cells. Each dose is supplied in a sterile 20 ml syringe and should be injected intravenously.
1623404|NCT02060955|Drug|Bevacizumab/Irinotecan|Patients allocated to the Bevacizumab/Irinotecan (control group) will receive treatment according to standard praxis, i.e. up to 16 treatment cycles with 4 weeks duration. Each cycle consist of 2 dosing days; day 1 and day 15 in the cycle.
1623405|NCT02060929|Drug|Esketamine|Participants will self administer 1 spray of esketamine solution using a intranasal device with a nasal guide in Treatment A regimen and without nasal guide inTreatment B regimen at time 0 and repeated twice every 5 minutes (total dose: 84 mg).
1623406|NCT02060916|Drug|PAZ320|Single-center pilot study, open label dose escalation design
1623407|NCT02060903|Drug|Abametapir Lotion 0.74% w/w|
1623408|NCT02060903|Drug|Vehicle Lotion|
1623410|NCT02060877|Other|observational study: use of patient questionnaires|observational study, there is no study intervention, only patient questionnaires
1623411|NCT02060864|Dietary Supplement|AN-PEP|Two pills are consumed in the morning with a breakfast
1623412|NCT02060864|Dietary Supplement|Placebo|
1623413|NCT02060851|Drug|Iron sucrose|
1623414|NCT02060851|Drug|EPO|
1623415|NCT02060838|Procedure|Acute normovolemic hemodilution (ANH)|Blood is drawn from our patients pre-bypass after obtaining the arterial line and administered back to the patient after separation from cardiopulmonary bypass (CPB) and reversal of heparin with protamine.
1623416|NCT02060825|Device|Regional saturation monitor|
1623417|NCT02060812|Procedure|Group I, SSNB & ANB|Suprascapular nerve block (SSNB) and axillary nerve block(ANB) were performed by one anesthesiologist under sono-guidance. 23 gauge spinal needle was used. SSNB was done at first and the entry site was the mid point between an anterolateral angle of acromion and medial end of scapular spine. With the linear probe, the suprascapular notch was identified and the block was performed penetrating the transverse scapular ligament because the scapular nerve and artery were located at the suprascapular notch. Just after the SSNB, ANB was performed and the entry site was the point 1.5 cm medial and 2cm inferior to posterolateral angle of acromion. With the linear probe, posterior circumflex artery was identified and the block was done at just above the artery.
1623418|NCT02060812|Procedure|Group II, SSNB alone|This is same as the Group I, SSNB & ANB, but ANB was performed with placebo(10mL normal saline).
1623419|NCT02060786|Drug|generic clopidogrel (Plavitor® )|
1623420|NCT02060786|Drug|original clopidogrel (Plavix® )|
1623421|NCT02060747|Behavioral|Coordinator-based post fracture program|
1623422|NCT02060734|Procedure|Lidocaine|Lidocaine injection 3-5 points in experimental group( using 25 gauge, 40mm long needle, pre-filled with 1% lidocaine inserting into the site of the trigger point).
1623423|NCT02060734|Other|Saline|The control group will receive a 25 gauge, 40mm long needle, pre-filled with saline inserting to subcutis.
1623424|NCT02060721|Drug|Macitentan|Macitentan 10mg, oral tablet, once daily
1623562|NCT02059616|Drug|Amlodipine 10mg|Daily oral administration for 8 weeks
1623707|NCT02058784|Drug|pracinostat|
1623425|NCT02060708|Device|HD-tDCS|HD-tDCS non-invasive brain stimulation using this same device (Soterix) has been designated a 'non-significant risk' by the US FDA.
1623426|NCT02060682|Device|Navvus Catheter FFR|Navvus Catheter provides Fractional Flow Reserve (FFR) measurement for each lesion identified according to standard of care of the center and the Instructions for Use (IFU).
1623427|NCT02060669|Drug|Xeloda|Xeloda
1623428|NCT02060656|Drug|Gemcitabine|1000mg/m2 IV D1, D8, D15 every 28 days
1623429|NCT02060656|Drug|Methylprednisolone|1000mg/m2 IV or PO D1-5 every 28 days
1623430|NCT02060656|Drug|Rituximab|375mg/m2 IV D1, D15 every 28 days
1623431|NCT02060656|Drug|Cisplatin|100mg/m2 IV D15 every 28 days
1623432|NCT02060656|Drug|Lenalidomide|25mg PO D1-21 every 28 days
1623433|NCT02060630|Procedure|Open surgical revascularization|
1623434|NCT02060630|Device|Endovascular revascularization|A variety of FDA approved devices will be used within this treatment arm. The trial will submit a proof-of-concept IDE application to the FDA to cover all devices.
1623435|NCT02060617|Behavioral|Patient Education|All subjects will receive education that back pain is common but rarely harmful in nature, that pain does not necessarily mean that there is structural damage to their back, and that they should try to remain as active as they are able within the limits of their pain. In addition, individualized education regarding posture, body mechanics, sleeping positions, or other concerns of the patient will be provided on a pragmatic basis as deemed appropriate by the treating clinician.
1623436|NCT02060617|Procedure|Manual therapy of the thoracolumbosacral spine and hips|Thrust and/or non-thrust manipulation and soft tissue mobilization as determined by mobility impairments identified on clinical examination.
1623437|NCT02060617|Procedure|Motor control exercises|Motor control exercises as determined by motor control impairments identified on clinical examination.
1623438|NCT02060617|Procedure|Treatment-Based Classification intervention|Lumbopelvic manipulation and range of motion exercise, spinal stabilization exercises, direction specific exercises, and/or traction will be applied as determined by the Treatment-Based Classification (TBC) Algorithm.
1623439|NCT02060604|Drug|Ketorolac + Ranibizumab|3 monthly ranibizumab, then as needed Ketorolac TID
1623440|NCT02060604|Drug|Ranibizumab|3 monthly ranibizumab, then as needed
1623441|NCT02060591|Drug|Exparel|
1623442|NCT02060591|Drug|Marcaine|
1623443|NCT02060578|Other|Questionnaire and interview|Questionnaire completed by the parents Interview with the parents and the psychologist (University Rennes 2)
1623444|NCT02060552|Drug|Diacerein|oral administration of IL-1βinhibitory
1623445|NCT02060552|Drug|Colchicine|"Colchicine is a toxic natural product and secondary metabolite, originally extracted from plants of the genus Colchicum (autumn crocus, Colchicum autumnale, also known as meadow saffron). It was used originally to treat rheumatic complaints, especially gout as the positive control"
1623446|NCT02060552|Drug|Febuxostat|A urate lowering drug, an inhibitor of xanthine oxidase that is indicated for use in the treatment of hyperuricemia and gout
1623447|NCT02060539|Device|Biofinity XR|
1623448|NCT02060526|Drug|Recombinant human heparan N-sulfatase [rhHNS]|Recombinant human heparan N-sulfatase [rhHNS]
2011099|NCT02706327|Device|CAD/CAM Insole|A computer numerical control machine was used to product insoles according to pedobarographic pressure data;35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
1623453|NCT02060474|Drug|Triac|Triac is a naturally occuring T3 metabolite with similar bioactivity and receptor binding profile.
2011100|NCT02706327|Device|Semi-custom Insole|Plantar surfaces of each patient's metatarsophalangeal joints were marked with a thick broad marker, and the participants were asked to stand on a clean paper. The borders of the foot were then drawn, and the medial longitudinal arch length was marked from the anterior aspect of the heel to the first metatarsophalangeal joint. These marks were used in designing and production. 35 Shore A hardness ethyl vinyl acetate was used for the main insole, and 3 mm, 15 Shore A hardness ethyl vinyl acetate was used for covering. Orthotic insoles have been implemented in a pair of sports shoes.
1623455|NCT02060448|Behavioral|Emotion awareness training|Four weekly individual treatment sessions focused on increasing awareness of one's emotions.
1623456|NCT02060448|Behavioral|Cognitive reappraisal|Four weekly individual treatment sessions focused on thinking about stimuli in a way that diminishes one's emotions.
1623457|NCT02060435|Other|EBER|EBV RNA was detected by an in situ hybridization (ISH) technique using the EBV ISH kit (Leica Microsystems, Bannockburn, IL, USA).
1623458|NCT02060422|Behavioral|Mindfulness-based therapy|Mindfulness-based therapy is a four biweekly two-and-a-half-hour psychotherapy tailored for patients with drug-resistant epilepsy. The aims of this therapy are to introduce and practice mindfulness-based stress reduction techniques in coping with drug-resistant epilepsy.
1623459|NCT02060422|Behavioral|Social support group|Social support group is an attention-placebo with the same contact hours (four bi-weekly two-and-a-half-hour) as the experimental group, but without active treatment input. The aim of the social support group is to provide a supportive group atmosphere for patients with drug-resistant epilepsy.
1623460|NCT02060409|Genetic|spliceosome|spliceosome mutations
1623461|NCT02060396|Drug|Acetylsalicylic acid|One tablet of Adiro 100 mg will be administered daily orally for 7 days.
2011101|NCT02706327|Other|Control|15 Shore A hardness ethyl vinyl acetate, implemented in a pair of sports shoes as a placebo insole.
1623468|NCT02060370|Drug|Sunitinib|"Starting dose: 50 mg by mouth daily given for 2 weeks on followed by 1 week off. 1 cycle is 6 weeks."
1623469|NCT02060370|Behavioral|Questionnaire|Questionnaire completion on Day 1 of Cycle 1, and on Day 35 of Cycles 2, 4, and 6.
1623470|NCT02060357|Device|Optical coherence tomography|
1623563|NCT02059616|Drug|Candesartan Cilexetil 8mg|Daily oral administration for 8 weeks
1643170|NCT01908270|Other|Usual care|
1623471|NCT02060318|Drug|Infliximab|The patients are included in the study when the decision to treat with Infliximab is already made. This study is observational, and all treatment and clinical follow-up are according to national guidelines.
1623472|NCT02060305|Drug|Bevacizumab intra-articular injection|Bevacizumab, 20~40mg, intra-articular injection every month for 2~ 4 cycles
1623473|NCT02060279|Other|Lifestyle intervention and carotenoid supplements|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take Jarrow Formulas CaroteneAll® (5000 IU) supplement while at the intervention site for 2 weeks and then will continue to take the supplements for up to 6 months until their participation in the study is complete. Two capsules of supplement will be consumed daily with a meal with 6 oz. of water.
1623474|NCT02060279|Other|Lifestyle intervention and placebo|2 week intervention partial hospitalization program followed by 8 bi-monthly sessions of a lifestyle intervention group run by a psychologist or health coach (research assistant). The entire intervention will last approximately 6 months. Children will participate in all aspects of the intervention including: dietary groups, life coaching, art and music therapy, school based learning, group therapy, physical activity, cooking, preparing meals, family therapy sessions, and yoga. The participants randomized to this study arm will also take a gel-cap placebo while at the intervention site for 2 weeks and then will continue to take the placebo for up to 6 months until their participation in the study is complete. Two capsules of placebo will be consumed daily with a meal with 6 oz. of water.
1623475|NCT02060266|Drug|semaglutide|Subjects will receive a single dose subcutaneously (s.c., under the skin).
1623476|NCT02060253|Drug|ganetespib|Given IV
1623477|NCT02060253|Drug|paclitaxel|Given IV
1623478|NCT02060253|Biological|trastuzumab|Given IV
1623479|NCT02060253|Biological|pertuzumab|Given IV
1623480|NCT02060240|Behavioral|High Activity|The high activity group will undergo a 12 week ramped exercise protocol.
1623481|NCT02060227|Procedure|Open Latarjet procedure|
1623482|NCT02060227|Procedure|Arthroscopic Bankart repair|
1623483|NCT02060201|Drug|Saxagliptin|
1623484|NCT02060201|Drug|Dapagliflozin|
1623485|NCT02060201|Drug|Saxagliptin/Dapagliflozin FDC|
1623486|NCT02060188|Drug|Ipilimumab|
1623487|NCT02060188|Drug|Nivolumab|
1623488|NCT02060188|Drug|Cobimetinib|
1623489|NCT02060188|Drug|Daratumumab|
1623490|NCT02060188|Drug|anti-LAG-3 antibody|
1623491|NCT02060175|Device|Cilotax drug-eluting stents implantation|
1623492|NCT02060175|Device|DESyne drug-eluting stents implantation|
1623493|NCT02060162|Other|Standard of care|routine standard of care per Ministry of Health protocol including blood draws and examinations.
1623494|NCT02060149|Drug|C/S plus minocycline.|Cefoperazone/ sulbactam 3.0g（intravenous infusion, q8h or q6h) combined with minocycline doxycycline 100mg (oral, q12h).
1623495|NCT02060149|Drug|nebulization with pH 7.4 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.4 (Each time the volume of aerosol solution is 5ml, q8h).
1623496|NCT02060149|Drug|nebulization with pH 7.8 solution|Patients will receive the nebulization with Sodium Bicarbonate of pH 7.8 (Each time the volume of aerosol solution is 5ml, q8h).
1623497|NCT02060149|Drug|No nebulization|No nebulization will be given to the patients.
1623498|NCT02060123|Behavioral|Qigong training|"a total of 103 hours over a period of 5.5 months, consisting of:
Group learning and practice: a 2-hour qigong exercise training session will be provided by a qigong master twice a week for six consecutive weeks (24 hours),
Weekly group follow-up: a 1-hour qigong exercise will be conducted with reinforcement of learning and remedial teaching by a qigong master once a week for four consecutive months (16 hours) after the group learning and practice, and
Self-practice: participant will engage in qigong exercise for 30 minutes every day for the whole intervention period lasting 5.5 months (63 hours)."
1623499|NCT02060123|Other|Wait-list control- Health talks|Monthly health education talks unrelated to qigong will be provided starting from the point when the intervention group starts the qigong weekly follow-up.Once the intervention group has completed the qigong intervention program, the wait-list control group will receive the qigong exercise training.
1623500|NCT02060110|Device|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study|
1623501|NCT02060110|Device|MADIT-CRT ICD ONLY ARM|
1623502|NCT02060097|Dietary Supplement|Cocoa flavanol beverage|
1623503|NCT02060097|Dietary Supplement|Placebo beverage|
1623504|NCT02060084|Drug|a control group|the same dose of luke warm water
1623505|NCT02060084|Drug|a probiotic-supplemented group|was orally administered starting from day 2 after birth, at a dose of 0.5g (the numbers of Long Bifidobacterium, Lactobacillus acidophilus and Enterococcus faecalis in live>0.5*107CFU), twice per day, for 2 weeks
1623506|NCT02060071|Other|Blood test|Blood test
2011102|NCT02704403|Drug|Elafibranor|
1623508|NCT02060045|Other|Bundle implementation|
1623509|NCT02060032|Drug|1.2% Atorvastatin local drug delivery|
1623510|NCT02060032|Drug|1.2% simvastatin local drug delivery|
1623511|NCT02060032|Drug|Placebo local drug delivery|
1623512|NCT02060019|Drug|administration of exforge 10/160mg for 3days. Next 7days administration of exforge 10/160mg and crestor 20mg.|
1623513|NCT02060006|Drug|Meloxicam 7.5mg daily for 8 weeks|Meloxicam 7.5mg daily for 8 weeks
1623564|NCT02059616|Drug|Candesartan cilexetil 16mg|Daily oral administration for 8 weeks
2011103|NCT02704403|Drug|Placebo|
2011104|NCT02704260|Genetic|GENETIC ANALYSIS|prélevement blood to search for a genetic cause of vascular endofibrose. Search genetic mutations in 5 subjects.
2011105|NCT02703662|Device|Strattice biologic mesh|Patients randomized to this group will be inserted one or more Strattice biologic meshes during the abdominal wall reconstruction surgical procedure.
1623514|NCT02059993|Device|continuous positive airway pressure|mean continuous positive airway pressure use was at least 4 hours per night;continuous positive airway pressure group received fixed-level continuous positive airway pressure titration using an automated pressure
2011106|NCT02703662|Device|Permacol biologic mesh|Patients randomized to this group will be inserted one or more Permacol biologic meshes during the abdominal wall reconstruction surgical procedure.
2011107|NCT02702869|Procedure|cleft lip repair|
1623517|NCT02059967|Drug|Paclitaxel|Given IV
1623518|NCT02059967|Radiation|image-guided adaptive radiation therapy|Undergo IGART
1623519|NCT02059967|Drug|carboplatin|Given IV
1623520|NCT02059954|Procedure|Hysterectomy|
1623521|NCT02059928|Device|Intraosseous Device|
1623522|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fed conditions
1623523|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
1623524|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
1623525|NCT02059915|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
1623526|NCT02059902|Drug|Lidocaine|Lidocaine infusion runs for a total of 24 hours
1623527|NCT02059902|Other|Placebo|Normal saline runs for a total of 24 hours
1623528|NCT02059889|Device|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
1623529|NCT02059889|Device|4-dimensional computed tomography|Undergo 4D CT
1623530|NCT02059889|Radiation|fludeoxyglucose F 18|Undergo FDG-PET
1623531|NCT02059889|Device|FDG-PET|Undergo FDG-PET
2011108|NCT02702869|Procedure|cleft palate repair|
1623533|NCT02059863|Behavioral|SPRING|SPRING package: Home visits by community based agents carried out from pregnancy to 2 years of age to encourage key behaviours to promote child growth, survival and development together with regular supervision
1623534|NCT02059850|Biological|Autologous NY-ESO-1-specific CD8-positive T Lymphocytes|Given IV
1623535|NCT02059850|Drug|Cyclophosphamide|Given IV
1623536|NCT02059850|Other|Laboratory Biomarker Analysis|Correlative studies
1623537|NCT02059837|Procedure|recurrent pterygium excision and following grafting|The excision of recurrent pterygial tissue and autograft of conjunctiva was done.
1623538|NCT02059824|Device|Aesthesiometer|"The eyelid sensation will be tested on every third by applying the tip of the aesthesiometer filament perpendicular to the eyelid skin and tarsal plate until the filament bent slightly. The filament length will be set at 6 cm (longest length) and applied to the test site 3 times. This process will be repeated 3 times and if the patient verbally responded to the 3rd touch, the number 6 will be recorder.
If the patient responded less than 3 of the 3 times, the filament will be shortened by 0.5 cm and the test will be repeated. This process will be continued by shortening the filament 0.5 cm each time, until the patient feels the filament touch 3 of 3 times. This filament length number will be recorded as the touch reading for that time period."
1623539|NCT02059811|Other|DASH Diet|The DASH diet is a nutritional intervention that is low in cholesterol and saturated fat and emphasizes high intake of the following: fruits, vegetables, low-fat dairy products, whole grains, fiber, and protein derived mostly from plant sources.
1623540|NCT02059811|Other|Control Diet|The control diet, which is a diet typical of most Americans, is relatively high in total and saturated fat and cholesterol, and low in servings of fruits, vegetables and low fat dairy products.
1623541|NCT02059785|Drug|Pinocembrin for Injection|
1623542|NCT02059772|Drug|ranibizumab|
1623543|NCT02059772|Procedure|micropulse diode laser|
1623544|NCT02059759|Drug|Placebo|Patients in this arm will receive sub-cutaneous injections of placebo (same vehicle as for experimental arms, and same volume) for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
1623545|NCT02059759|Drug|1.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 1.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
1623546|NCT02059759|Drug|2.0 MIU IL-2 per day|Patients in this arm will receive sub-cutaneous injections corresponding to 2.0 MIU of IL-2 per injection for 5 consecutive days at the beginning of three consecutive months (a total of 15 injections, 5 per month for 3 months).
1623547|NCT02059746|Other|Questionnaires sent by mail|The questionnaires necessary for the study are mailed to patients at 3 and 12 months post-partum.
1623548|NCT02059733|Drug|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-DTBZ immediately prior to imaging.
The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
1623549|NCT02059720|Procedure|HSCT|Patients randomly assigned in to either of groups will receive either autologous SCT or haplo-SCT after CR1 is achieved.
1623550|NCT02059707|Device|LARIAT RS Suture Delivery Device|LARIAT RS Suture Delivery Device
1623551|NCT02059694|Drug|Hyaluronidase|
1623552|NCT02059694|Other|2 mL of lidocaine 2% with epinephrine 1:100,000 without rHuPH20|
1623553|NCT02059681|Other|Autologous bone marrow derived-CD133+ cells|Cell therapy
1623554|NCT02059668|Biological|Biomarker analyses head & neck cancer tissue, blood specimen|For biomarker analyses, tumor tissues from previous biopsies and surgery and blood specimens taken during treatment at the treating institution will be used.
1623555|NCT02059655|Drug|Bimatoprost|
1623556|NCT02059655|Drug|Eye drop solution|Artificial tear drops
1623557|NCT02059642|Drug|MG01CI (1400 mg)|MG01CI (Metadoxine Immediate-release/Slow-release, Bilayer Caplet) 1400 mg administered orally once daily
1623558|NCT02059642|Drug|placebo|Placebo 1400 mg administered orally once daily
1623559|NCT02059629|Device|Eluna pacemaker family|"New pacemaker generation with new functions, like wandless RF telemetry SafeSync"
2011109|NCT02702869|Procedure|oronasal fistula repair|
2011110|NCT02702869|Procedure|pharyngoplasty|
2011111|NCT02702869|Procedure|gingivoperiosteoplasty|
2011112|NCT02702869|Procedure|LeFort-1 maxillary repositioning|
1623566|NCT02059603|Procedure|Fast-track program|
1623567|NCT02059590|Drug|Pyridinylmethyl-14C-labeled isavuconazonium sulfate|Intravenous
1623568|NCT02059577|Dietary Supplement|Nutritional and Dietary Interventions|Day 0: Vitamin/Mineral supplementation begins. Day 30: Essential Fatty Acid supplementation begins. Day 60: Epsom Salt baths begin (2x/week) Day 90: Carnitine supplementation begins Day 180 Digestive Enzyme supplementation begins; Day 210: Healthy, casein-free, gluten-free diet is begun.
1623569|NCT02059564|Drug|HM11260C|doses of 6 mg, 16 mg
1623570|NCT02059564|Drug|Placebo|Normal saline solution
1623571|NCT02059564|Drug|Victoza|doses of 1.8 mg
1623572|NCT02059551|Procedure|MRI combined with venous ultrasonography of the legs|In case of positive D-dimer testing or in patients with a high probability of PE, MRI and a venous ultrasonography of the legs are done.MRI protocol includes 2 sequences: 1-Unenhanced steady-state-free precession sequences (SSFP) are acquired first without ECG-gating or breath-holding in the axial plane in the multiphase cine mode, with 6 phases per location.The acquisition is repeated to cover 2-3 of the thorax, from the roof of the aorta to the diaphragm. 2- A pulmonary gradient recalled echo (GRE) sequence is performed in the axial plane.The acquisition is triggered to start when contrast enhancement occurred in the right ventricle.Two acquisitions are necessary to cover the anatomy. For each acquisition, 0.15 mL kg-1 body weight of DOTAREM Gadolinium is injected at a rate of 3 mL s-1 followed by an injection of 15 mL of normal saline at 3 mL s-1.Venous ultrasonography of the legs: the examination consists of a real-time B-mode examination of the common femoral and popliteal veins.
1623573|NCT02059538|Other|Adipose tissue biopsies (omental and subcutaneous) liver|
1623574|NCT02059538|Radiation|CT-scan|
1623575|NCT02059538|Other|Stools sampling|
1623576|NCT02059538|Other|DNA sampling|
1623577|NCT02059538|Other|Blood sampling|
1623578|NCT02059538|Other|Urine sampling|
1623579|NCT02059538|Radiation|Dual energy X-ray absorptiometry-scan (DEXA-scan)|
1623580|NCT02059512|Procedure|coronary artery bypass grafting with administration of autologous bone marrow stem cells|
1623581|NCT02059512|Procedure|coronary artery bypass grafting with administration of 0.9 % NaCl (sodium chloride) 0.2 ml|
2011113|NCT02702869|Procedure|rhinoplasty|
2011114|NCT02702869|Procedure|myringotomy and tympanostomy tube placement|
2011115|NCT02702869|Other|speech therapy|
2011116|NCT02702869|Procedure|orthodontia|
1623586|NCT02059486|Behavioral|Teen Choice|The curriculum provides sexual education on topics such as anatomy, puberty, sexually transmitted infections, and contraceptive methods (including abstinence). It also covers topics such as gender and sex roles, sexual orientation, decision making and conflict resolution, adult-teen relationships, rape and sexual assault, and coping with stress.
1623587|NCT02059473|Procedure|Rotator cuff repair|Physiotherapy & Surgery
1623588|NCT02059473|Procedure|Physiotherapy|
2011117|NCT02702869|Procedure|presurgical orthopedics|
2011118|NCT02702141|Drug|SGN-CD19B|Given intravenously Day 1 of 28-day or 42-day cycles
1623591|NCT02059447|Other|No treatment waiting period|All subjects undergo a no treatment waiting period before being randomly allocated to either Mindfulness Based Cognitive Therapy or Relaxation Therapy
1623592|NCT02059447|Behavioral|Mindfulness Based Cognitive Therapy|
1623593|NCT02059447|Behavioral|Relaxation Therapy|
2011119|NCT02702401|Biological|Pembrolizumab|IV infusion
2011120|NCT02702401|Drug|Placebo|0.90% w/v sodium chloride IV infusion
2011121|NCT02702401|Other|Best Supportive Care|Best supportive care will include pain management and management of other potential complications including ascites per local standards of care.
2011122|NCT02700360|Dietary Supplement|high-fat diet|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900~1,000 kcal, contains 50~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects.
1623605|NCT02059421|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|"- Therapy session administered by a clinical psychologist using web-based video conferencing software.
Therapy sessions will include:
Sleep restriction therapy
Stimulus control instructions
Sleep hygiene education"
1623606|NCT02059421|Other|Johrei therapy|"Therapy will be administered by a senior Johrei administrator at the University of Arizona or the patient's residence.
Therapy sessions will consist of 3 sessions per week lasting 30 minutes each.
Therapist will wash his hands and and pray for 1 minute while facing the subject at a distance.
Therapy will be administered without physical contact.
During therapy the administrator will sit adjacent to the patient and channel energy from his palm towards the patient."
1623607|NCT02059408|Other|Screen-Educate|A targeted, automated CKD clinical decision support system (CDSS) designed to improve bloodpressure (BP) level, disease awareness, staging, processes of care, and knowledge among persons with documented reduced eGFRcreat (creatinine-based estimated glomerular filtration rate) in primary care setting.
1623608|NCT02059408|Other|Screen-Educate and Intensify Treatment|The CKD CDSS plus pharmacist (CDSS PLUS) extends beyond CDSS alone. PCPs randomized to this arm will have the additional option to refer their higher-risk patients to a clinical pharmacist-led CKD management program with education. A primary care clinical pharmacist will schedule a series of appointments with patients found to have confirmed higher-risk CKD (defined as eGFRcreat-cys <45, or eGFR 45-59 and ACR ≥ 30 mg/g). The pharmacist will follow treatment algorithms recommended by the 2012 KDIGO international CKD guidelines, and designed by a team of internists and nephrologists.
1623611|NCT02059382|Behavioral|ChiRunning training|
1623612|NCT02059382|Behavioral|unblinded accelerometer|
1623613|NCT02059382|Behavioral|participation in online social network|
1623614|NCT02059382|Behavioral|participation in study website|
1623615|NCT02059382|Behavioral|Technology support for behavior change|
1623616|NCT02059369|Procedure|PVI+CFAE+DCC|pulmonary vein Isolation (PVI), CFAE for substrate modification and direct current cardioversion (DCC) if AF persists
1623617|NCT02059369|Procedure|PVI, CFAE, anterior and roof line, DCC|PVI, CFAE ablation. If AF persists linear lesions (anterior and roof line), cardioversion if AF persists
1623618|NCT02059330|Drug|Palbociclib 75mg|In Period 1, Japanese subjects will receive a single oral 75mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
1623619|NCT02059330|Drug|Palbociclib 125mg|In Period 2, Japanese subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
1623620|NCT02059330|Drug|Palbociclib 100mg|In Period 3, Japanese subjects will receive a single oral 100mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
1623621|NCT02059330|Drug|Palbociclib|In Period 4, Japanese subjects will receive a single oral dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours. The amount of the dose will be determined based on an interim analysis of the PK data from Periods 1 and 2.
1623622|NCT02059330|Drug|Palbociclib 125mg|In Period 1, healthy non-Asian subjects will receive a single oral 125mg dose of palbociclib with food. Serial PK assessments will be collected over the next 120 hours.
1623623|NCT02059317|Other|Flexion-extension in the sagittal plane|The movement required is a flexion - extension where the subject touches a target (adapted to his/her morphology) with both index fingers: the target is positioned in front of the subject, inline with his/her outstretched arms and at knee height. This movement simulates a lifting task without weight. The movement is repeated 30 times with a return to the initial position at a frequency of 0.32Hz.
1623624|NCT02059317|Other|Rotation in a transverse plane|The movement required of the subject is a rotational movement where the subject alternately touches with his/her left and right hands two targets. The latter are positioned horizontally on either side of the subject at shoulder height and at arm's length. The movement is repeated 30 times at a frequency of 0.28 Hz.
1623625|NCT02059317|Other|Complex movement in three dimensions|The subject is required to successively touch 4 targets situated (i) at knee height to the left of the subject, (ii) at shoulder height to the right of the subject, (iii) at shoulder height to the left of the patient, and (iv) at knee height to the right of the patient. The movement is repeated 30 times at a frequency of 0.16 Hz.
1623626|NCT02059304|Device|Measurement of cervical length with embryo transfer catheter|
1623627|NCT02059291|Drug|Canakinumab|Canakinumab solution for subcutaneous injection in vial which contained 150mg/mL canakinumab in 1 mL solution.
1623628|NCT02059291|Drug|Placebo|Matching placebo to canakinumab solution for subcutaneous injection
1623629|NCT02059278|Drug|T-2345|T-2345 Ophthalmic Solution
1623630|NCT02059278|Drug|Xalatan|Xalatan (latanoprost 0.005% ophthalmic solution)
1623631|NCT02059265|Drug|Dasatinib|Given PO
1623632|NCT02059265|Other|Laboratory Biomarker Analysis|Correlative studies
1623633|NCT02059252|Device|SmartMatrix dermal replacement scaffold|SmartMatrix dermal replacement scaffold
1623634|NCT02059239|Drug|Bendamustine|Days - 24 and Day - 23 followed by a short break of 10 - 14 days.
1623635|NCT02059239|Drug|Carmustine|300 mg/m2 on Day -6
1623636|NCT02059239|Drug|Etoposide|100 mg/m2 on days -5 to -2
1623637|NCT02059239|Drug|Melphalan|140mg/m2 on Day -1
1623638|NCT02059239|Drug|Cytarabine|200 mg/m2 on days -5 to -2
1623639|NCT02059239|Drug|Alemtuzumab|20 mg/m2 days -6 to -2 for UNRELATED donors, and 20 mg/m2 days -4 to -2 for RELATED donors
1623640|NCT02059239|Biological|Autologous Stem Cell Transplantation|
1623641|NCT02059239|Biological|Allogeneic Stem Cell Transplantation|
1623642|NCT02059239|Drug|Rituximab|Only to be administered in subjects with B-cell malignancies. Dose is 375 mg/m2 on Days 1 and 8 post-transplant
1623643|NCT02059226|Behavioral|cognitive behavioural therapy|Internet-based CBT
1623644|NCT02059226|Other|Internet-based resource page|Static webpage
1623645|NCT02059213|Drug|Ibrance|
1623646|NCT02059213|Drug|Bicalutamide|
1623647|NCT02059213|Drug|Zoladex|
1623648|NCT02059213|Drug|Lupron Depot|
1623649|NCT02059200|Behavioral|Mindfulness Based Compassionate Living|The MBCL program consists of eight biweekly group sessions of 2.5 hours, in which the participants get formal meditation exercises, some theoretical information and participate in inquiry on the meditation exercises and homework assignments. Homework assignments are given after every session, consisting of formal and informal meditation exercises primarily and some diary instructions.
1623650|NCT02059187|Drug|MK-1293|MK-1293 (insulin glargine) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate MK-1293 at 10 units daily. Participants taking insulin will initiate MK-1293 at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
1623651|NCT02059187|Drug|Lantus™|Lantus™ (insulin glargine [rDNA origin]) 100 units/mL administered subcutaneously once daily for 24 weeks. Participants not taking insulin at study entry will initiate Lantus™ at 10 units daily. Participants taking insulin will initiate Lantus™ at an appropriate dose based on prior insulin dosing. After initiation, the dose will be titrated to the suggested target for fasting finger stick glucose. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
1623652|NCT02059187|Drug|Prandial insulin|Participants taking prandial insulin will continue their current prandial insulin regimen during the insulin glargine titration. After the insulin glargine titration phase, the prandial insulin may be adjusted if the investigator determines it to be necessary for glucose control.
1623653|NCT02059174|Drug|MK-1293|MK-1293 0.4 units/kg administered subcutaneously
1623654|NCT02059174|Drug|EU-Lantus™|EU-Lantus™ 0.4 units/kg administered subcutaneously
1623655|NCT02059174|Drug|Novolog™|Participants will receive an intravenous infusion of insulin aspart (Novolog™ or other rapid-acting insulin analog) for several hours prior to MK-1293 or EU-Lantus™ dosing in each dosing period to meet basal insulin requirements
1623708|NCT02058758|Device|Magnetic Resonance Imaging|MRI scanning with novel acquisition, reconstruction, and/or analysis methods.
1623747|NCT02058459|Device|Holaira™ Lung Denervation System with energy delivery|
1623748|NCT02058459|Device|Holaira™ Lung Denervation System without energy delivery|
1623656|NCT02059161|Drug|MK-1293|MK-1293 dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. MK-1293 dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
1623657|NCT02059161|Drug|Lantus™|Lantus™ dosed subcutaneously once daily at bedtime for 52 weeks. Initial dose will be determined based on the participant's previous insulin therapy. Thereafter, the dose will be titrated to the suggested target for fasting fingerstick glucose levels. Lantus™ dosing once daily at times other than bedtime will be permitted for participants with a previously established dosing time.
1623658|NCT02059161|Drug|Prandial Insulin|Participants will continue their prandial insulin during the study.
1623660|NCT02059135|Biological|Recombinant human antithrombin (ATryn)|Atryn 250 mg loading dose over 15 minutes, immediately followed by continuous infusion of 2000 mg per 24 hours. Total daily dose is 2250 mg for the first day and 2000 mg on subsequent days
1623661|NCT02059135|Other|Normal Saline 0.9%|Placebo Comparator: Normal Saline 0.9%
1623662|NCT02059109|Procedure|Hands on Assembly of Belmont Rapid Infuser|Participants will work individually or in pairs to assemble the Belmont Rapid Infuser in addition to completing the traditional training methods.
1623663|NCT02059096|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
1623664|NCT02059083|Behavioral|Heart rate variability biofeedback|
1623665|NCT02059083|Behavioral|CBT|
1623666|NCT02059070|Drug|Ropivacaine|Post-operative epidural 0.125% Ropivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
1623667|NCT02059070|Drug|Bupivacaine|Post-operative epidural 0.125% Bupivacaine Interscalene brachial plexus block, 20-28 hrs post surgery.
1623668|NCT02059057|Device|LVRC System|
1623669|NCT02059044|Other|ISTOP-ADE|Interactive Voice Response System + Pharmacist
1623670|NCT02059031|Drug|GSK1265744 Reference formulation|GSK1265744 (micronized) reference formulation is available as 30 mg tablet to be orally administered with 240 mL of water
1623671|NCT02059031|Drug|GSK1265744 New formulation 1|GSK1265744 (micronized) New formulation 1 is available as 30 mg tablet to be orally administered with 240 mL of water
1623672|NCT02059031|Drug|GSK1265744 New formulation 2|GSK1265744 (un-micronized) New formulation 2 is available as 30 mg tablet to be orally administered with 240 mL of water
1623673|NCT02059018|Drug|COX-inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
1623674|NCT02059018|Drug|Nitroglycerin|Oral administration of tablet nitroglycerin 0,5mg 5 minutes before recordings of diameter changes of retinal vessels are initiated
1623675|NCT02059018|Drug|COX-inhibitor + Nitroglycerin|Combination of COX-inhibitor and nitroglycerin interventions.
2011123|NCT02700360|Drug|EC-18|This trial is conducted as a randomized, open-label, single -dose, crossover, phase I to evaluate the effect of food on the safety, tolerability and pharmacokinetics of EC-18. EC-18 is given at an oral, once daily in condition of empty stomach and a high fat diet(900~1,000 kcal, contains 50~60%lipid).This trial is divided into Part 1(1,000mg dose) and Part 2(500mg dose and 2,000mg dose), 12 subjects are included in each dose and cross-over period is 7 days. After Part 1 study, If primary PK parameters of EC-18 is affected by food and AEs meeting study discontinuation criteria are not reported, Part 2 will proceed in consecutive order with registering new subjects
2011124|NCT02698930|Drug|dexmedetomidine|Randomly selected patients of the dexmedetomidine group are given intravenous 0.4mcg/kg/h of dexmedetomidine from the beginning of the anesthesia to postoperative 1 day.
1623678|NCT02058992|Drug|Ramelteon|Ramelteon 8 mg tablets
1623679|NCT02058979|Drug|BOLUS INFUSION (Ancef)|Bolus Infusion of antibiotics
1623680|NCT02058979|Drug|CONTINUOUS INFUSION (Ancef)|Continuous Infusion of ANCEF with infusion pump
1623684|NCT02058953|Procedure|Craniotomy scheduled|Resection of affected brain tissue
1623685|NCT02058953|Procedure|Collection for non-craniotomy|CSF, Blood, biopsy
1623686|NCT02058940|Drug|Exenatide|50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours
1623687|NCT02058927|Drug|Measles vaccine|measles revaccination administered at 12 months from start of ART
1623688|NCT02058914|Dietary Supplement|high fructose sweetened beverage|710 ml per day of a HF-sweetened beverage
1623689|NCT02058914|Dietary Supplement|High Glucose sweetened beverage|HG-sweetened beverage
1623690|NCT02058901|Drug|Sunitinib|
1623691|NCT02058875|Drug|Myfortic®|
1623692|NCT02058875|Drug|Neoral®|
1623693|NCT02058875|Drug|Cellcept®|
1623694|NCT02058875|Drug|Prednisone|
1623695|NCT02058849|Drug|Beetroot|10g Beetroot powder mixed with 4-8 oz.
1623696|NCT02058849|Other|Placebo|Placebo
1623697|NCT02058836|Drug|Botox Injection|One-time injection of 100 Units of Botox in 10 mL of saline. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
1623698|NCT02058836|Procedure|Normal saline injection|One-time injection of 10 mL of 0.9% sodium chloride (normal saline) solution. The 10 mL injection will be distributed in 4 areas around the spermatic cord and testicle of the affected side with 2.5 mL being injected at each area.
1623699|NCT02058823|Drug|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
1623700|NCT02058823|Drug|Placebo|The subjects receive 1 oral pill of placebo each morning during the second week of the two periods, so 14 pills in all.
1623701|NCT02058823|Drug|Valsartan|The subjects receive 1 oral pill of Valsartan each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 40 mg.
1623702|NCT02058823|Drug|Amlodipine|The subjects receive 1 oral pill of Amlodipine each morning during the second week of the two periods, so 14 pills in all. 1 pill equal 6,944 mg of amlodipine besilate with 5 mg of amlodipine.
1623703|NCT02058810|Device|Nasal high flow|
1623704|NCT02058810|Device|Conventional nasal oxygen|
1623705|NCT02058797|Behavioral|Coherence Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
1623706|NCT02058797|Behavioral|Cognitive Behavioral Therapy|Manualized individual treatment (3 + 1 one-hour sessions)
1623709|NCT02058745|Behavioral|CAU+ (Enhanced Care as Usual)|"CAU+ is defined as the care received from the care recipient's oncologist supplemented by unlimited access to three components of the study website: caregiver guides, links to web-based resources, and a basic friends and family page. These resources are routinely available on the Internet. We provide these as a one-stop shopping resource in order to standardize care as usual for caregivers. All caregivers will be sent personalized e-mails from the project director every week during the intervention period."
1623710|NCT02058745|Behavioral|Beating the Blues|"Beating the Blues is an established, self-directed, web-based cognitive behavioral therapy program for managing depressive symptoms. Caregivers are asked to complete 8 weekly sessions, each lasting approximately 50 minutes. Participants are also given simple homework after each lesson."
1623711|NCT02058745|Behavioral|SmartCare|SmartCare is a web-based, nurse guided intervention for caregivers based on the Representational Approach of symptom management. The RA builds on traditional cognitive-behavioral interventions by promoting in depth reflection of previous and current experiences, beliefs, and knowledge (referred to as representations) prior to providing new information or engaging in problem-solving.
1623712|NCT02058732|Other|MRI|Subjects will have an MRI that lasts approximately 60 minutes at the same time points as during the stem cell study schedule; once before the stem cell surgery, and again at 1, 6, 12, 18, 24, 36, and 48 months after receiving stem cells. This magnetic resonance imaging(MRI)scan will be of the cervical spine and brain.
1623713|NCT02058706|Drug|enzalutamide|Given PO
1623714|NCT02058706|Drug|bicalutamide|Given PO
1623715|NCT02058706|Procedure|orchiectomy|Undergo orchiectomy or receive LHRH analogue therapy
1623716|NCT02058706|Drug|leuprolide acetate|Undergo orchiectomy or receive LHRH analogue therapy
1623717|NCT02058706|Drug|goserelin acetate|Undergo orchiectomy or receive LHRH analogue therapy
1623718|NCT02058706|Other|laboratory biomarker analysis|Correlative studies
1623719|NCT02058693|Drug|mixed salts amphetamine|adjunctive to ADT
1623720|NCT02058680|Biological|PSA/IL-2/GM-CSF|"In Stage 1 (Phase 1A), patients receive intradermal injections of PSA/IL-2/GM-CSF vaccine at Weeks 1, 2, 3, 7, 11, and 15.
In Stage 2 (Phase 1B), patients will receive the same course of vaccine (induction as in Phase 1A; this will be followed in eligible patients by maintenance vaccinations alternating between IL-2 alone at Weeks 23, 31, and 39) and complete vaccine (PSA/IL-2/GM-CSF) at Weeks 27, 35, and 43."
1623721|NCT02058667|Radiation|Paclitaxel+Initial Radiation+Boost|Paclitaxel twice weekly + Initial Fields Radiation + Boost Radiation (10Gy)
1623722|NCT02058654|Drug|Creatine|Creatine powder (5 g)
1623723|NCT02058654|Drug|Placebo|Bulking agent powder (5 g)
1623724|NCT02058641|Drug|Darapladib|EC tablet with a unit dose strength of 160 mg administered once daily orally for 11 days.
1623725|NCT02058628|Drug|Clindamycin + BPO|Gel containing 1.2% clindamycin and 3% BPO for once daily application
1623726|NCT02058628|Drug|Azelaic acid|Cream containing 20% azelaic acid for twice daily application
1623727|NCT02058615|Behavioral|Male Spouse Transition Toolkit|
1623728|NCT02058602|Other|Assessment of Idiopathic Pulmonary Fibrosis over a period of up to 6 months|Patients are receiving no treatment on this study and there is no investigational product involved.
1623729|NCT02058589|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
1623730|NCT02058589|Drug|Placebo|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
1623731|NCT02058576|Drug|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fed condition.
1623732|NCT02058576|Drug|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fed condition
1623733|NCT02058563|Biological|Priorix®|1 dose administered as a subcutaneous (SC) injection.
1623734|NCT02058563|Biological|Merck's M-M-R®II, Measles, Mumps, and Rubella Virus Vaccine|1 dose administered subcutaneously.
1623735|NCT02058550|Other|survey administration|Receive reminder email survey
1623736|NCT02058550|Other|computer-assisted intervention|Receive reminder email survey
1623737|NCT02058550|Behavioral|telephone-based intervention|Receive reminder phone call
1623738|NCT02058537|Drug|Bethanechol|Due to the fact that this study has only 1 arm and all study subjects will receive the study drug in the same manner and dose, there are no other details to cover.
1623739|NCT02058524|Biological|fecal microbiota transplantation|
2011125|NCT02698930|Drug|Normal saline|Group given intravenous 0.4mcg/kg/h of normal saline from the beginning of the anesthesia to postoperative 1 day.
2011126|NCT02698917|Other|Low normal PaCO2|4.5-4.7 kPa
1623742|NCT02058498|Behavioral|Physical activity|Participants will be provided physical activity walking instructions and asked to record their daily activity on an activity log. Participants will be given the International Physical Activity Questionnaire and asked about their quality of life at baseline, at 6 weeks and at 4 months.
1623743|NCT02058485|Drug|Midazolam|Midazolam was calculated by actual body weight of patients that had been diluted with saline to 40 ml. It was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.025 mg.kg-1
1623744|NCT02058485|Drug|Dexmedetomidine|Dexmedetomidine was calculated by actual body weight of patients that had been diluted with saline to 40 ml. Dexmedetomidine was administered 15 min before induction of anesthesia via intravenous infusion. at a dose of 0.5 µg.kg-1
1623745|NCT02058472|Drug|G3041|
1623746|NCT02058472|Drug|SEVIKAR®|
1643171|NCT01908257|Drug|lesinurad 400 mg|
2011127|NCT02698917|Other|High normal PaCO2|5.8-6.0 kPa
2011128|NCT02698917|Other|Low normal PaO2|10-15 kPa
2011129|NCT02698917|Other|High normal PaO2|20-25 kPa
2011130|NCT02698917|Other|Low normal MAP|65-75 mmHg
2011131|NCT02698917|Other|High normal MAP|80-100 mmHg
2011132|NCT02699749|Drug|TAK-931|TAK-931 oral capsules.
2011133|NCT02698410|Drug|Lanreotide (Autogel formulation) and Temozolomide|
2011134|NCT02698163|Device|Nanodiamond reinforced Gutta Percha|Gutta percha reinforced with 5 nm diameter nanodiamonds 5 wt % (NDGP).
1623749|NCT02058446|Drug|Amlodipine/Valsartan|Amlodipine/Valsartan: 5 mg/80 mg
1623750|NCT02058433|Other|dosage of paclitaxel|Based on pharmacokinetics. Observe the toxicity in an individual patient after a fixed Paclitaxel dose depending on BSA and then the dosage of Paclitaxel is adjusted depending on pharmacokinetics follow up to avoid excess toxicity in subsequent cycles.
1623751|NCT02058433|Other|dosage of paclitaxel|Based on body surface area. The dosage of Paclitaxel is based on the BSA of the patient. Paclitaxel/carboplatin up to 4 cycles or disease progression or intolerable toxicity.
1623752|NCT02058420|Drug|Low tocotrienols group|300 mg tocotrienols daily
1623753|NCT02058420|Drug|High tocotrienols group|600 mg tocotrienols daily
1623754|NCT02058407|Drug|GSK2793660 solution|Clear, colourless solution at a unit dose strength of 0.1 mg/mL, in a glass bottle
1623755|NCT02058407|Drug|GSK2793660 capsule|Size zero swedish orange capsule at a unit dose of 3 mg, 10 mg, 20 mg and 50 mg
1623756|NCT02058407|Drug|Placebo solution|Matching placebo to GSK2793660 solution
1623757|NCT02058407|Drug|Placebo capsule|Matching placebo to GSK2793660 capsule
1623758|NCT02058394|Procedure|Phacoemulsification|Subjects will be recruited serially from eligible candidates on the basis of presentation for cataract evaluation and subsequent cataract surgery with phacoemulsification.
2011135|NCT02698163|Device|Gutta Percha|Gutta percha is a device made from coagulated sap of certain tropical trees intended to fill the root canal of a tooth. The gutta percha is softened by heat and inserted into the root canal, where it hardens as it cools. Gutta percha is classified as Class I (general controls).
1623761|NCT02058368|Drug|Dutasteride 0.5mg capsules|Dutasteride 0.5mg capsules will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
1623762|NCT02058368|Drug|Dutasteride placebo capsules|Dutasteride placebo will be supplied as plain, oblong, opaque, dull yellow soft gelatin capsules.
1623763|NCT02058368|Drug|Tamsulosin 0.2mg tablets|Commercially available tamsulosin 0.2mg tablets will be supplied.
1623764|NCT02058368|Drug|Disintegrating placebo tamsulosin tablet|Disintegrating placebo tamsulosin tablet will be supplied for the run-in period.
1623765|NCT02058355|Behavioral|Consequences List Feedback|
1623766|NCT02058355|Behavioral|Personalized Normative Feedback|
1623767|NCT02058342|Behavioral|Active Play at Home|The Active Play at Home (APAH) curriculum includes age-appropriate goal-oriented physical activities that combine playground and video games using the Nintendo Wii™ with exercises targeting: muscular strength and endurance, aerobic endurance, flexibility, balance, agility, and motor coordination. APAH was designed for children ages 8-11 without disability and ages 8-15 years with PWS. The playground games and interactive console-based games are to be performed twice weekly each. The activity is progressed from 25 to 45 minutes of moderate to vigorous physical activity throughout the 24 weeks period. Parents and children are trained to use the curriculum hands-on at baseline.
1623768|NCT02058329|Other|Home Visit|A geriatric fellow will conduct a comprehensive in hospital post discharge assessment of hip fracture patients discharged to home in the intervention group.Follow up home visits will occur at 1,3 and 6 months post discharge.Any problems will be referred to the patient's primary care physician.
1623769|NCT02058316|Device|Lateral Flow Device Test|Testing of leftover BAL samples from clinical routine by the lateral flow device test
1623770|NCT02058303|Drug|Exparel Forearm block|20-30 mL Mepivacaine will be used for the supraclavicular block following the forearm block.
1623771|NCT02058303|Drug|Bupivacaine supraclavicular block|20-30mL 0.5% bupivacaine
1623772|NCT02058290|Drug|IV morphine sulfate or Sponsor-approved equivalent|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to a floor if the stay in the PACU is less than one hour.
1623773|NCT02058290|Drug|EXPAREL|"Patients will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 40 cc administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
All patients will be offered rescue analgesia, as needed."
1623774|NCT02058277|Drug|bosutinib or bosutinib + aprepitant|Single dose of bosutinib (500 mg) or single dose of bosutinib (500 mg) and aprepitant (125 mg)
1623775|NCT02058264|Drug|BBI-4000|
1623776|NCT02058251|Drug|Oxytocin|One 40 IU dose of intranasal oxytocin will be self-administered (5 puffs in each nostril) by participants.
1623777|NCT02058251|Drug|Placebo|Each participant will self-administer a 40 IU dose of intranasal saline.
1623778|NCT02058212|Drug|ascorbate 1000mg, vitamin E 400, zinc and selenium|anti oxidant in the form of ascorbate 1000mg, vitamin E 400, zinc and selenium) are given to half patients only before IVF , plasma level of ROS are detected before and on day of oocyte retrieval then correlated to pregnancy outcome
1623779|NCT02058199|Drug|rivaroxaban|Single dose pharmacodynamic study
1623780|NCT02058186|Drug|oral vitamin D|
1623781|NCT02058186|Drug|Placebo|
1623782|NCT02058173|Drug|150 mg/daily chloroquine compare to placebo for 12 week|
1623783|NCT02058173|Drug|Chloroquine|
1623784|NCT02058173|Drug|placebo|
1623785|NCT02058160|Drug|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Insulin glargine/lixisenatide FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using one of 2 SoloStar® pen-injectors: Pen A (ratio of 2 Units (U) of insulin glargine U 100:1 mcg of lixisenatide) or Pen B (ratio of 3 U of insulin glargine U 100:1 mcg of lixisenatide). After run-in, the FRC was initiated at a dose of either 20 U/10 mcg with Pen A or 30 U/10 mcg with Pen B, depending on participant's dose of Insulin glargine on the day prior to randomization.
Dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L). Pen A was used for administration of doses up to 40 U/20 mcg and Pen B for administration of doses from 30 U/10 mcg up to 60 U/20 mcg."
1623823|NCT02057874|Drug|Magnevist® (Intravenous (IV) administration of MRI contrast agent)|For the acquisition of DCE-MR data, the FDA-approved contrast agent Magnevist® (gadopentetate dimeglumine, 0.1 mmol/kg) will be delivered intravenously by the MR technologist at a rate of 2 mL/sec (followed by a saline flush) via a power injector after the acquisition of a set of baseline dynamic scans. The entire sequence lasts approximately 8 minutes.
1623786|NCT02058160|Drug|Insulin glargine (HOE901)|"Insulin glargine was self-administered QD by SC injection at approximately the same time every day.
After screening, eligible participants entered 6 week run-in phase during which they were switched (if necessary) to insulin glargine and dose was stabilized. The first dose after randomization was same as the one administered on the day prior to randomization and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L)."
1623787|NCT02058160|Drug|Metformin (Background Drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration
1623788|NCT02058147|Drug|Insulin glargine/lixisenatide Fixed Ratio Combination|Insulin glargine/Lixisenatide FRC was self-administered by subcutaneous (SC) injection in the morning within one hour before breakfast using one of the 2 prefilled disposable SoloStar® pen-injectors: Pen A containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 50 mcg/mL lixisenatide in a ratio of 2 U:1 mcg, used for administration of doses from 10 U to 40 U (10 U/5mcg to 40 U/20mcg). Pen B containing 100 U/mL insulin glargine (Lantus, 100 U/mL) and 33 mcg/mL lixisenatide in a ratio of 3 U:1 mcg, used to administer doses from 41 U to 60 U (41 U/13 mcg to 60 U/20 mcg). The starting dose was 10 U/5 mcg. Dose was then adjusted individually to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
1623789|NCT02058147|Drug|Insulin glargine (HOE901)|Insulin glargine (100 U/mL) was self-administered by SC injection at approximately the same time every day. Dose was adjusted individually to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L) while avoiding hypoglycemia.
1623790|NCT02058147|Drug|Lixisenatide (AVE0010)|Lixisenatide was self-administered by SC injection within 0 to 60 minutes before breakfast or evening meal. If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 10 mcg.
1623791|NCT02058147|Drug|Metformin|Pharmaceutical form: Tablet; Route of administration: Oral administration.
1623792|NCT02058134|Device|cardioPAT cell saver|
1623793|NCT02058121|Behavioral|Acceptance and Commitment Therapy|ACT is provided in 12 weekly two hour long sessions in a group setting
1623794|NCT02058121|Behavioral|Treatment as usual|Treatment as usual contains different interventions available at the clinic, such as individual therapy, group therapy, or contact with a dietician and/or physiotherapist.
1623795|NCT02058108|Drug|Telbivudine|Patients of any age and weight< 30kg: telbivudine oral solution (20 mg/mL): 20 mg/kg up to 600 mg q.d corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight≥ 30kg: telbivudine oral solution (20mg/mL), 600 mg/day corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: telbivudine film-coated tablet, 600 mg/day, corresponding to 1 tablet p.o. once daily
1623796|NCT02058108|Drug|Placebo|Patients of any age and weight < 30kg: placebo oral solution corresponding to weight (kg) x1mL, p.o. once daily Patients < 12 years old and weight ≥ 30kg: placebo oral solution corresponding to 30 mL p.o. once daily Patients ≥ 12 years old and weight ≥ 30kg: placebo tablet, corresponding to 1 tablet p.o. once daily
1623797|NCT02058095|Drug|Tadalafil|Tadalafil 5 mg tablet
1623798|NCT02058095|Drug|Placebo|Placebo tablet
1623799|NCT02058082|Procedure|Intracytoplasmic sperm injection|
1623800|NCT02058069|Device|Robotic Arm Assisted Total Knee Arthroplasty|The total knee implant system used for this study was the Kinetis implant system (MAKO Surgical Corp.).
1623801|NCT02058056|Radiation|Irradiation: HA-PCI|25 Gy in 10 daily factions, five times a week
1623802|NCT02058030|Device|Insertion of ProSeal laryngeal mask airway|"The patient's head was placed on the 3 cm or 6 cm height of a pillow in supine and PLMA was inserted using a standard method in the sniffing position.
The success rate at first and second attempt, insertion time, Seal pressure, hemodynamic variables, complications(blood staining on cuff, sore throat and hoarseness) were assessed"
1623803|NCT02058017|Drug|OPB-51602|
1623804|NCT02058004|Procedure|Cricoid pressure|Firm pressure on the cricoid cartilage with the goal of occluding the esophagus during endotracheal intubation.
1623805|NCT02057991|Other|educational intervention|Watch an educational video
1623806|NCT02057991|Procedure|CAM exercise therapy|Watch a mindfulness exercise video
1623807|NCT02057991|Other|caregiver-related intervention or procedure|Watch mindfulness exercise video and/or educational video
1623808|NCT02057991|Other|questionnaire administration|Ancillary studies
1623809|NCT02057991|Other|laboratory biomarker analysis|Correlative studies
1623810|NCT02057978|Procedure|EXCEL DES implatation|Implant DES for CAD cases
1623811|NCT02057978|Procedure|EXCEL-II DES implantation|Implant DES for CAD cases
1623812|NCT02057965|Drug|Mesenchymal Stromal Cells|Two doses of autologous bone marrow (BM) derived MSCs IV, 7 days apart, 6 and 7 weeks after transplantation. Doses of MSCs will be 1-2x10^6 million MSCs per/kg body weight
2011136|NCT02697383|Drug|Ixazomib (MLN9708)|
1623814|NCT02057939|Drug|enzalutamide|160 mg orally once daily for six months
1623815|NCT02057939|Drug|Androgen Deprivation|Two injections each lasting three months, for a total of six months of androgen deprivation therapy. Doctor will help determine which androgen deprivation drug to use.
1623816|NCT02057939|Radiation|Radiation Therapy|Daily (Monday-Friday) for 6-8 weeks, final dose of approximately 66 Gy
1623817|NCT02057926|Drug|The effect of tetracycline in degradation and permeability of collagen membranes.|
1623818|NCT02057913|Drug|Vinflunine|All patients will receive on Day 1 of a 21 day cycle, vinflunine 320mg/m2 via intravenous infusion in either 100ml sodium chloride 0.9% or glucose 5% over 20 minutes; four cycles to be given in total prior to formal re-staging.
1623819|NCT02057900|Biological|Human embryonic stem cell-derived CD15+ Isl-1+ progenitors|Epicardial delivery of a fibrin patch embedding human embryonic stem cell-derived CD15+ Isl-1+ progenitors
1623820|NCT02057887|Drug|HM10660A|
1623821|NCT02057887|Drug|Pegasys|180 mcg Pegasys SC once weekly
1623822|NCT02057874|Device|3 Tesla Magnetic Resonance Imaging|3T MRI consists of a series of radiofrequency (RF) pulse sequences optimized for acquiring CEST-, MT-, DW-, and DCE-MRI data in one seamless imaging examination. For DCE, MR contrast agent will be intravenously administered.
1623869|NCT02057536|Other|Arm A Directed exercise program|
1623870|NCT02057536|Other|Observation|
1624241|NCT02054793|Drug|Itraconazole|100 mg 200 mg 300 mg
2011137|NCT02697383|Drug|Dexamethasone|
1623824|NCT02057848|Other|low amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
1623825|NCT02057848|Other|high amount of carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
1623826|NCT02057848|Other|Rapid-acting carbohydrates|different regimens of carbohydrate administration to prevent hypoglycaemia during a standardized bout of moderate physical activity in patients with type 1 diabetes
1623827|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
1623828|NCT02057835|Drug|BI 691751 high dose|BI 691751 high dose
1623829|NCT02057835|Drug|BI 691751 middle dose|BI 691751 middle dose
1623830|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
1623831|NCT02057835|Drug|BI 691751 low dose 1|BI 691751 low dose 1
1623832|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
1623833|NCT02057835|Drug|Placebo to BI 691751|Placebo to BI 691751
1623834|NCT02057835|Drug|BI 691751 low dose 2|BI 691751 low dose 2
1623835|NCT02057822|Procedure|Cytokins assay in tears|
1623836|NCT02057796|Device|Xpert MTB/RIF®, Determine TB LAM, Chest X-ray|"The following point-of-care TB tests will be systematically performed:
Xpert MTB/RIF® on sputum (in all patients able to provide sputum; no sputum induction will be requested in others), Urine LAM (all patients). Depending on clinical presentation, Xpert MTB/RIF® will also be performed on any relevant extra-pulmonary specimen.
TB treatment will depend on the result of the tests:
Criteria met for confirmed or probable TB : TB treatment will be initiated immediately (Visit 1) followed by ART initiation 2 weeks later (Visit 2); No evidence of confirmed or probable TB: ART will be started immediately (Visit 1)."
1623837|NCT02057796|Drug|ART (Atripla, Truvada, Efavirenz, Combivir)|"ART (TDF-3TC/FTC or AZT-3TC + efavirenz) will be started immediately after randomization in patients not put on TB treatment, and 2 weeks after initiation of TB treatment in others.
ART will be initiated 2 weeks after the onset of TB treatment (V2) for Arm 2"
1623838|NCT02057796|Drug|Rifampin, isoniazid, pyrazinamide, ethambutol|Arm 1: Only patients who meet standardized criteria for TB at inclusion or during follow-up will receive a standard TB treatment (2ERHZ/4RH); Arm 2: • All patients will start a 6-month standard TB treatment (2ERHZ/4RH) at randomization
1623839|NCT02057783|Other|Physical activity|Physical activity will carry out 3 times per week during 12 weeks for intervention arm
1623840|NCT02057770|Drug|busulfan|
1623841|NCT02057770|Drug|fludarabine phosphate|
1623842|NCT02057770|Radiation|total-body irradiation (TBI)|
1623843|NCT02057770|Procedure|Stem cell transplant|
1623844|NCT02057770|Drug|cyclophosphamide|
1623845|NCT02057770|Drug|tocilizumab|
1623846|NCT02057757|Drug|Nitazoxanide (NTZ)|"Participants 1 to 3 years old: 5 mL oral suspension (100 mg NTZ) every 12 hours for 5 days.
Participants 4 to 11 years old: 10 mL oral suspension (200 mg NTZ) every 12 hours for 5 days.
Participants 12 years and older: two 300-mg NTZ tablets orally twice daily for 5 days."
1623847|NCT02057757|Drug|Placebo|"Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.
Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.
Participants 12 years and older: two placebo tablets orally twice daily for 5 days."
1623848|NCT02057731|Genetic|Glycogen Storage Disease markers|Blood and urine tests will be performed on all groups to measure markers of GSD. A saliva DNA test will be used to determine the specific mutation the carrier has or to ensure noncarrier status. A questionnaire will also be filled out.
1623849|NCT02057718|Drug|LUM001|LUM001 oral dose up to twice a day (BID).
1623850|NCT02057692|Drug|LUM001|LUM001 administered orally
1623851|NCT02057692|Drug|Placebo|Placebo administered orally
1623852|NCT02057679|Drug|Amoxicillin clavulanic|3 g per day divided into 3 oral intakes of 1 g each (2 pill of Amoxicillin Clavulanic every 8 hrs). This treatment will begin on postoperative day 1 for 5 days.
1623853|NCT02057679|Drug|Placebo|1 pill of the same characteristics as Amoxicillin clavulanic every 8 hs. This will begin on postoperative day 1 for 5 days.
1623856|NCT02057640|Drug|Panobinostat|20mg, on day 1, 3, 5, 15, 17, 19, 28
1623857|NCT02057640|Drug|Dexamethasone|20mg, on day 1, 2, 8, 9, 15, 16, 28
1623858|NCT02057640|Drug|MLN9708|4mg on day 1, 8, 15, 28
1623859|NCT02057627|Behavioral|Perinatal Dyadic Psychotherapy|8-session mother-infant psychotherapy (Perinatal Dyadic Psychotherapy) delivered by nurse-interventionists in participant's homes over 3 months
1623860|NCT02057627|Behavioral|Placebo Comparator|Standard care plus depression monitoring by phone
1623861|NCT02057601|Drug|Levobupivacaine infiltration group|The patients in the intervention group will receive peri-surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline.
1623862|NCT02057588|Procedure|LV pacing site|Patient will be paced in VVI mode from Left ventricle specific position for a short period of time per position in order to cover spontaneous ventricular activity
1623863|NCT02057575|Drug|PG324 Ophthalmic Solution 0.01%|1 drop daily (evening)
1623864|NCT02057575|Drug|PG324 Ophthalmic Solution 0.02%|1 drop daily (evening)
1623865|NCT02057575|Drug|Netarsudil (AR-13324) Ophthalmic Solution|1 drop daily (evening)
1623866|NCT02057575|Drug|Latanoprost Ophthalmic Solution|1 drop daily (evening)
1623867|NCT02057549|Drug|Haloperidol|Intravenous dose of haloperidol 5 mg.
1623868|NCT02057549|Drug|Conventional Therapy|Conventional Therapy includes hydration via IV fluids, pain control with analgesics (usually opiates) frequently requiring multiple doses, also antiemetics (often requires multiple doses and different agents in attempts to control nausea and vomiting within this population), in addition to electrolytes abnormalities corrections as needed.
1624242|NCT02054793|Drug|Orteronel|300 mg
1623871|NCT02057523|Drug|Acthar|Those interested will be started on Acthar 80 units twice weekly for 6 months. Those with minor adverse effects such as weight gain, worsening hypertension, or glucose intolerance will have their doses reduced to 40 unit twice weekly. Those with major adverse effects such as allergy or infection will discontinue the medication. If the primary endpoint of 50% reduction in proteinuria or total proteinuria less than 150mg/day is not reached, therapy may be continued for a total of 12 months.
1623873|NCT02057471|Drug|Intravenous ferric carboxymaltose|1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
1623874|NCT02057458|Drug|Acute (1 hour) Sildenafil|Exercise capacity and vascular function will be assessed 1 hour following oral ingestion of sildenafil (50 mg)
1623875|NCT02057458|Drug|Sub-Chronic (4 weeks) Sildenafil|Exercise capacity and vascular function will be assessed 4 weeks following 20 mg three times per day (TID) of sildenafil for four weeks
1623876|NCT02057458|Drug|Placebo|Sugar pill designed to mimic the sildenafil treatment
1623877|NCT02057445|Drug|EBV CTL's|Eligible patients with a matched cell line will be infused with 3rd party CTLs and monitored for adverse events and response. Patients who show a response and tolerate the infusion well may receive up to 5 infusions total 4-6 weeks apart.
1623878|NCT02057445|Other|Peripheral Blood Donor|Donors who are EBV+ and meet the eligibility criteria will be consented to provide 60-120 ml peripheral blood once for future use for this and other clinical trials using 3rd party CTLs.
1623879|NCT02057432|Device|intra-operative MRI|Patients will undergo an MRI during surgery.
1623880|NCT02057406|Drug|2:1 EPA/DHA|400 Eicosapentaenoic acid/200 docosahexaenoic acid fish oil 2 grams
1623881|NCT02057406|Drug|High EPA|
1623882|NCT02057406|Other|Placebo|
1623883|NCT02057393|Drug|Indocyanine green|Subjects receive 0.9ml of ICG subcutaneously about the primary melanoma. The ICG has an infrared signal that is detected with the SPY Elite system (Lifecell). The ICG travels through the lymphatics to the sentinel node.
1623884|NCT02057393|Drug|Technetium99|Technetium99 is a standard, widely used radiopharmaceutical that is injected subcutaneoulsy about the primary melanoma site. Lymphoscintigraphy is performed to identify the draining nodal basin, and a gamma probe is used in the operating room to track the radioactive signal and find the sentinel node.
1623885|NCT02057393|Drug|Methylene blue|Subjects receive 0.5-2ml of methylene blue subcutaneously about the primary melanoma at the time of surgery. The sentinel node should turn blue, which is visible with the naked eye.
1623886|NCT02057380|Drug|linsitinib|oral
1623887|NCT02057380|Drug|erlotinib|oral
1623888|NCT02057380|Drug|paclitaxel|Intravenous (IV) infusion
1623889|NCT02057380|Drug|Bortezomib|Subcutaneous or IV
1623890|NCT02057380|Drug|Dexamethasone|IV, Oral
1623891|NCT02057367|Drug|Scalp block with 0.5% plain Marcaine|Anterior scalp block will be done by using 0.5% plain Marcaine 20 ml.
1623892|NCT02057367|Drug|Scalp block with 0.9% normal saline|Anterior scalp block will be done by using 0.9% normal saline 20 ml.
1623895|NCT02057341|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
1623896|NCT02057328|Drug|TELMISARTAN|Patients of the group of telmisartan will take 40 mg of telmisartan daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients still classified in the stage I hypertensive range will receive 80 mg of telmisartan daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range will continue on the same medication scheme. For patients still classified in the stage I hypertensive range12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project.
1623897|NCT02057328|Drug|NEBIVOLOL|Patients will take 5 mg of nebivolol daily in the morning. At the end of the first month of treatment, patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. Patients classified in the stage I hypertensive range the nebivolol group will receive 10 mg of nebivolol daily in the morning. At the end of the 6th month from the beginning of the study patients classified in the normal BP range based on the results of ABPM will continue on the same medication scheme. For patients classified in the stage I hypertensive range 12,5 mg of hydrochlorothiazide will be added. The end of the 12-month period from the beginning of the study indicates the completion of the project
1623898|NCT02057315|Drug|ELS-M11|One dose of 5% ELS-M11 over 3 bilateral applications.
1623899|NCT02057315|Drug|Placebo|One dose of matching placebo over 3 bilateral applications.
1623900|NCT02057302|Drug|Xuezhikang capsule|
1623902|NCT02057276|Device|Repetitive Transcranial Magnetic Stimulation|We will use a specific rTMS paradigm called Continuous Theta Burst Stimulation (cTBS) for this study.
1623903|NCT02057276|Device|Sham Repetitive Transcranial Magnetic Stimulation|
1623904|NCT02057276|Other|Occupational Therapy|
1623905|NCT02057263|Drug|Alendronate|Participants will receive 4 doses of alendronate during the course of the study.
1623906|NCT02057263|Drug|Hepatitis B Vaccine|Participants will receive 3 Hepatitis B vaccinations, according to the schedule outlined by the CDC.
1623907|NCT02057263|Drug|Placebo|Participants will receive 4 doses of placebo during the course of the study.
1623908|NCT02057250|Drug|Sarilumab|Pharmaceutical form: Solution Route of administration: Subcutaneous
1623909|NCT02057250|Device|Auto-Injector Device (AID)|
1623910|NCT02057250|Device|Pre-filled Syringe (PFS)|
1643172|NCT01908257|Drug|ranitidine 150 mg|
1623911|NCT02057250|Drug|Methotrexate|Dispensed according to local practice.
1623912|NCT02057250|Drug|Sulfasalazine|Dispensed according to local practice.
1623913|NCT02057250|Drug|Leflunomide|Dispensed according to local practice.
1623914|NCT02057250|Drug|Hydroxychloroquine|Dispensed according to local practice.
1623915|NCT02057237|Drug|Mitotane|Mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance every 3rd day by 0.5 g up to a maximal dose of 5.0 g and then adjusted according to blood concentrations monthly and tolerability, up to a maximum of 10g daily
1623916|NCT02057224|Procedure|Renal denervation using Medtronic Symplicity System (mono-electrode)|Secondary hypertension is excluded by an extensive preoperative clinical investigation and the renal artery anatomy is visualized by computer tomography (with contrast). By cannulating the femoral artery both renal arteries are treated by a radiofrequency-catheter, 4-6 ablations in each artery.
2011138|NCT02696122|Procedure|Local Group|General anesthesia willl be induced with propofol 2 mg mg. kg-1 and alfentanyl 30 mcg.kg-1. Once an appropriate depth of anesthesia had been obtained, a laryngeal mask airway (LMA) will be positioned. The anesthesia will be maintained by propofol 4 to 5 mg. kg-1.h-1. Ventilation will controlled by adjusting the flow volume and respiratory rate to keep the end-tidal CO2 level (PETCO2) between 30 and 40 mmHg. For local anesthesia, approximately 50 ml of 0.5% ropivacaive will infiltrated along the line of incision in the subcutaneous plane, followed by peripheral nerve block technique (e.g., ilioinguinal-hypogastric nerve block) and local wound infiltration at the fascial level.
2011139|NCT02696122|Procedure|Spinal anesthesia|Spinal puncture will be performed with the patient in the sitting position, using 27G disposable Quincke needles (B. Braun, Meisungen, AG). After obtaining CSF, 15 mg of 0.5% hyperbaric bupivacaine will be injected.
1623919|NCT02057198|Drug|Fidaxomicin|
1623920|NCT02057198|Drug|Metronidazole|
1623921|NCT02057198|Drug|Vancomycin|
2011140|NCT02696811|Dietary Supplement|White carrots|White carrots contain compounds called polyacetylenes, including falcarinol, falcarindiol and falcarindiol-3-acetate.
2011141|NCT02696811|Dietary Supplement|Oat biscuits|The 3 oat biscuits contain the same amount of fibre and sugar as the white carrot but without the polyacetylenes.
1623924|NCT02057172|Drug|HM11260C|HM11260C is a novel long-acting form of CA Exendin-4 (an Exendin-4 analogue)
1623925|NCT02057172|Drug|liraglutide|Liraglutide is a GLP-1 agonist.
1623926|NCT02057172|Drug|Placebo|Placebo
1623927|NCT02057159|Biological|NeuroVax|
1623928|NCT02057159|Biological|IFA Placebo|IFA Placebo
1623929|NCT02057146|Procedure|Duodenoscopy, pancreatoscopy, cholangioscopy, confocal microscopy|The intervention consists of mother-baby endoscopy of the bile and/or pancreatic duct with visual inspection, confocal laser microscopy, collection of fluid for cytology, and eventually biopsy.
1623930|NCT02057133|Drug|LY2835219|Administered orally.
1623931|NCT02057133|Drug|Letrozole|Administered orally.
1623932|NCT02057133|Drug|Anastrozole|Administered orally.
1623933|NCT02057133|Drug|Tamoxifen|Administered orally.
1623934|NCT02057133|Drug|Exemestane|Administered orally.
1623935|NCT02057133|Drug|Everolimus|Administered orally.
1623936|NCT02057133|Drug|Trastuzumab|Administered IV infusion.
1623937|NCT02057133|Drug|LY3023414|Administered orally
1623938|NCT02057133|Drug|Fulvestrant|Administered IM
2011142|NCT02694263|Drug|Canagliflozin|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide, Pioglitazone, Gliclazide or Glimepiride) for the treatment of Type 2 Diabetes.
1623941|NCT02057107|Radiation|SBRT|8.8-10 Gy per fraction (total: 44-50 Gy)
1623942|NCT02057107|Drug|Cetuximab|"Day -7 (One week prior to commencement of stereotactic radiosurgery):
Cetuximab, 400 mg/m2
Days 0 and 8 (The 1st and 2nd week of radiosurgery):
Cetuximab, 250 mg/m2 Cetuximab, 250 mg/m2 will be given weekly ( following radiosurgery)"
1623943|NCT02057107|Drug|Docetaxel|Days 0 and 8 (The 1st and 2nd week of radiosurgery) Docetaxel, 25 mg/m2 Docetaxel, 25 mg/m2 will be given weekly (following radiosurgery)
1623944|NCT02057094|Dietary Supplement|Protein, High-Protein, and Control|
1623945|NCT02057081|Behavioral|Multifamily Group for mTBI for Couples|MFG-mTBI-C uses a structured problem-solving and skills training approach to provide Veterans and partners with tools and information to improve coping and help couples reconnect through positive behavioral exchanges.
1623946|NCT02057081|Behavioral|Group Health Education (GHE)|GHE is a 14-session, highly structured educational intervention providing general information on health problems that are common among the general OEF/OIF cohort including sleep and sleep problems, physical activity and exercise, and alcohol and drug use, as well as guidelines for improving health behavior in these areas.
1623948|NCT02057055|Other|Soap 300000027003|
1623949|NCT02057055|Other|Soap 300000029240|
1623950|NCT02057042|Behavioral|Peer-assisted computerized CBT|Patients in the PS-cCBT intervention will receive usual depression care and will also receive: 1) access to Beating the Blues (BTB), an online cCBT program, 2) support of a peer specialists for 12 weeks, 3) a copy of the Depression Helpbook by Wayne Katon and colleagues
1623951|NCT02057042|Behavioral|Enhanced usual care|Patients randomized to EUC will receive the following enhancements: 1) patient education regarding the symptoms of depression and evidence-based depression treatments, 2) a copy of the Depression Helpbook by Wayne Katon and colleagues 3) information about how to access local VA mental health depression treatment resources (groups, individual psychotherapy, etc), and 4) bi-weekly study mailings with depression management tips.
1623952|NCT02057029|Behavioral|BCI Assay Results|The nature of the intervention is to utilize the BCI results in the decision making process for ER-positive breast cancer patients and their physicians.
1623953|NCT02057003|Drug|DAA against HCV|
1623954|NCT02056990|Other|Advice|
1623955|NCT02056977|Other|Titration|Individualized PEEP according to PEEP titration monitored by EIT
1623956|NCT02056977|Other|control|PEEP selected according to a PaO2/FIO2 table as in the routines of the institution
1623957|NCT02056951|Procedure|Multidisciplinary rehabilitation|"Multidisciplinary rehabilitation includes interventions from the physical and psychological dimensions:
health education
exercise therapy
back school
physical treatments
psychological interventions in groups and individual counselling
rehabilitation/social counselling."
1623958|NCT02056951|Procedure|Interprofessional rehabilitation|"Interprofessional rehabilitation includes also interventions from the physical and psychological dimensions:
education about low back pain
behavioural exercise therapy
coping with pain
relaxation
work related informations"
1623959|NCT02056938|Drug|Anti-Thymocyte Globulins treatment|
1623960|NCT02056938|Drug|Basiliximab treatment|
1623961|NCT02056925|Other|Echocardiography|
1623962|NCT02056912|Genetic|Amplification by PCR and direct sequencing on the entire coding sequence and intron-exons boundaries of the candidate gene|
1623963|NCT02056912|Biological|Perform blood cells and fibroblasts biochemical and immuno-labeled investigations|Performed only in the two index patients enrolled in the sub-study
1623964|NCT02056899|Drug|Gabapentin|
1623965|NCT02056886|Procedure|SLN detection +/- complementary axillary lymphadenectomy|breast cancer surgery with SLN detection +/- complementary axillary lymphadenectomy Whatever the detection method used in the lab (Arm A: OSNA; Arm B: Pathological Examination; Arm C: Extemporaneous) to assess the positivity of sentinel lymph-node invasion, if negative result (no tumor invasion in the sentinel LN), a complementary lymph-node dissection is not mandatory if positive result (tumor invasion in the sentinel LN), a complementary lymph-node dissection is performed, either immediately (Arm A and C) or in a second surgical procedure (Arm B)
1623966|NCT02056873|Device|DBS System|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.
The DBS system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for DBS. At 6 months, the investigators will determine whether or not the subject is a candidate for responsive brain stimulation (RBS). Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. Subjects who do not qualify or do not participate will continue to receive this intervention for the duration of the study. These subjects will been seen every 6 months for evaluation as part of normal clinical care for DBS."
1623967|NCT02056873|Device|DBS System (RBS Setting)|"The DBS system includes an implantable neurostimulator, CM thalamic leads, and Electrocorticography (ECOG) strips.
Six months post-surgery, the DBS system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for DBS.
Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention."
1623968|NCT02056860|Procedure|Group 1 will receive 15 Hz|Group 1 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 15 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 15 Hz at 1.25 cm.
1623969|NCT02056860|Procedure|Group 2 will receive 30 Hz|Group 2 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 30 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 30 Hz 1.25 cm.
1623970|NCT02056860|Procedure|Group 3 will receive 60 Hz|Group 3 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 60 Hz .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 60 Hz at 1.25 cm.
1623971|NCT02056860|Procedure|Group 4 will receive 100 Hz|Group 4 (n=30), these subjects will receive 10 minutes of High Frequency Oscillation at 100 Hz at .75 cm on day 1. Then will have a 24 hour washout. On day 2 will receive 10 minutes of low Frequency Oscillation at 100 Hz at 1.25 cm.
1623972|NCT02056860|Procedure|Phase II Optimal Frequency|Participants in Phase II will undergo 10 minutes of HFO at the optimal frequency as determined during Phase I.
1623973|NCT02056847|Drug|Pitavastatin calcium 4mg|taking once a day
1623974|NCT02056847|Drug|Pitavastatin calcium 2mg|Taking once a day
1623975|NCT02056834|Device|chronOS Inject|chronOS Inject is used as bone void filler in internal fixation of proximal tibial fractures
1623976|NCT02056808|Drug|SMT C1100|Comparison of safety and pharmacokinetic of different dosages of drug
1623977|NCT02056795|Device|Asia-Med Special No 16 (0.30x30mm) needles|Subjects will do balance assessment in lab. In treatment room, practitioner will clean insertion area with alcohol swab, allow adequate time to dry, and insert 2 Asia-Med Special No 16 (0.30x30mm) needles: one at proximal insertion of fibularis longus anterior to fibular neck, in proximity to common fibular nerve (GB-34); one over sinus tarsi and lateral ligaments of ankle mortise (GB-40). Needles will be inserted approximately 1-2cm, connected for 10 min at 2Hz to electrical stimulation (ITO ES-130, 500 ohm test load, 1 to 500Hz). Needles will disposed of in sharps container. Area will be wiped with long handled cotton swab, pressure will be applied for 2 seconds. Subjects will be asked to slowly get up from table and return to lab for second balance assessment.
1623978|NCT02056795|Device|Streitberger placebo needles (Asia-Med, 0.03 x 30 mm)|As with experimental group, controls will do balance assessment pre- and post-intervention. Streitberger placebo needles (Asia-Med, 0.03 x 30 mm), blunted with a telescoping mechanism, will be used. Subjects will feel slight prick, and shaft will telescope into handle, creating illusion of skin penetration. Needles will be held in place by plastic ring covered by a bandage. They are validated for blinding. They will be placed over non-traditional acupuncture points on medial aspect of leg, in direct opposition to treatment group needles. Needle placement is not intended to produce therapeutic outcome. The needles will be connected to a wire, which will be turned on for 10 minutes but no stimulation will be felt.
2011143|NCT02694263|Drug|Repaglinide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Repaglinide) for the treatment of Type 2 Diabetes.
1623980|NCT02056769|Radiation|CT Perfusion|Quantitative CT Perfusion imaging
1623981|NCT02056756|Drug|Carfilzomib|
1644661|NCT01896843|Drug|STX107|
2011144|NCT02694263|Drug|Pioglitazone|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Pioglitazone) for the treatment of Type 2 Diabetes.
2011145|NCT02694263|Drug|Gliclazide|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Gliclazide) for the treatment of Type 2 Diabetes.
2011146|NCT02694263|Drug|Glimepiride|Comparison of Canagliflozin (Invokana™) vs. standard dual therapy (Glimepiride) for the treatment of Type 2 Diabetes.
2011147|NCT02690272|Behavioral|Psychic processes|Quantitative and qualitative aprroche of the psychic process
2011148|NCT02690233|Procedure|Elective Surgery|Elective laparoscopic inguinal hernia repair
1623982|NCT02056743|Drug|CYP cocktail|Each group administered CYP cocktail (Caffeine 200mg + Losartan 50mg + Omeprazole 20mg + Dextromethorphan 30mg + Midazolam 7.5mg) under fasting conditions.
1623983|NCT02056743|Drug|Fexofenadine 30mg|Each group administered Fexofenadine 30mg under fasting conditions.
1623984|NCT02056743|Dietary Supplement|Red ginseng|During 4~17th days, end of the period 1, the group of red ginseng administered red ginseng extract.
1623985|NCT02056743|Dietary Supplement|Fermented-red ginseng|During 4~17th days, end of the period 1, the group of fermented-red ginseng administered fermented-red ginseng extract.
1623986|NCT02056730|Drug|calcium sensing receptor agonist|For the Regpara those taking 25 mg per day to get the default dose and the dose is adjusted according to the levels of calcium and parathyroid hormone. By adjusting the dose of 25 mg every 3 weeks for a period of 12 weeks, the drug is between 25-75 mg dose, with a maximum dose of not more than 100 mg per day (weeks 3, 6, 9).
1623987|NCT02056717|Drug|Dexamethasone|Administration of dexamethasone 10 mg IV 1 h before UAE
1623988|NCT02056717|Drug|Normal saline|Administration of normal saline 2 mL IV 1 h before UAE
1623989|NCT02056704|Device|Angiography with IVUS|The use of IVUS to evaluate dialysis access failure.
1623990|NCT02056691|Procedure|Exercise programme|The exercise regime consists of 10 sessions of exercise against a constant load, each lasting 60 seconds, separated by 60 seconds of recovery eliciting 90% maximal heart rate. The 6 sessions are held over a 2 week period.
1623991|NCT02056691|Procedure|Muscle biopsy|muscle biopsy under local anaesthetic taken from the thigh, again for analysis and storage 3 times: before, during and after the exercise programme
1623992|NCT02056678|Drug|acetaminophen, IV preparation|
1623993|NCT02056665|Drug|MINOCYCLINE|Pill Minocycline 50 mg capsule
1623994|NCT02056665|Drug|PLACEBO (for Minocycline)|Pill manufactured to mimic Minocycline 50 mg capsule
2011149|NCT02690207|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
2011150|NCT02690181|Biological|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 in subjects who received GBS No Adj in parent study.
1623997|NCT02056626|Drug|carvedilol|
1623998|NCT02056600|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
1623999|NCT02056600|Drug|gemigliptin/metformin HCl sustained release|Administration of combination of gemigliptin 50mg/metformin HCl sustained release 1000mg, for 1day.
1624000|NCT02056587|Drug|Everolimus|All patients with metastatic renal cell carcinoma progressing on prior treatment with bevacizumab ± interferon enrolled into this study will receive everolimus in the dose of 10 mg daily until the disease progression or unacceptable toxicity.
1624001|NCT02056574|Drug|NA-1|
1624002|NCT02056574|Drug|Placebo|
1624003|NCT02056535|Behavioral|Brief Motivational Intervention|A short discussion is held with patients identifying pros and cons of their drinking, readiness for change is assessed, and a brief prescription drawn for behavior change signed by the patient.
1624004|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with low punicalagin:EA ratio (PE-1). After 2 weeks of washout, the same group will also consume the other extract with high punicalagin: EA ratio (PE-2).
1624005|NCT02056496|Dietary Supplement|Pomegranate extract|Crossover study: The group will consume the pomegranate extract with high punicalagin:EA ratio (PE-2) after 2 weeks of washout. The same group will also consume the other extract with low punicalagin: EA ratio (PE-1).
1624006|NCT02056483|Other|Screening-based nurse navigation|Screening-based nurse navigation for breast cancer rehabilitation
1624007|NCT02056470|Device|Freedom Total Knee|The Freedom Total Knee System is being implanted in subjects suitable for a total knee replacement
1624008|NCT02056470|Device|Total Knee Replacement|total Knee replacement implant
1624009|NCT02056470|Device|Freedom Total Knee System|Total Knee replacement implant
1624010|NCT02056457|Behavioral|Responsible Fatherhood or Healthy Marriage Program|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
1624011|NCT02056457|Behavioral|Other services in the community|RF grantees funded by the most recent re-authorization of the program must offer services in each of three categories: (1) healthy marriage; (2) responsible parenting; and (3) economic stability. HM grantees must provide one or more of eight allowable activities, which include marriage and relationship skills programs, mentoring, divorce reduction programs, and education in high schools on the value of marriage, relationships skills, and budgeting.
1624012|NCT02056444|Drug|Tranexamic Acid|
1624014|NCT02056418|Dietary Supplement|enteral nutrition|enteral nutrition only (Nutrison Fibre, 20-30kcal/kg/day)
1624015|NCT02056418|Drug|corticosteroid|corticosteroid(equal dose to prednisone 0.75mg/kg/day,4 weeks)
1624016|NCT02056405|Drug|Mosapride|15 mg per day divided into 3 oral intakes of 5 mg each (1 pill of Mosapride every 8 hs with 30 ml tap water). This treatment will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
1624017|NCT02056405|Drug|Placebo|1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
1624018|NCT02056392|Drug|Selumetinib|Volunteers will receive 75 mg selumetinib oral dose (Treatment A)
1624019|NCT02056392|Drug|Moxifloxacin|Volunteers will receive 400 mg Moxifloxacin oral dose (Treatment B)
1624020|NCT02056392|Drug|selumetinib placebo|Volunteers will receive selumetinib placebo oral dose (Treatment C)
1624090|NCT02055963|Drug|Minocycline|100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
1624091|NCT02055963|Drug|Placebo|Placebo 100 mg given orally every 12 hours on Day -2, (i.e., 2 days prior to surgery) and continuing for 3 weeks postsurgery.
1645670|NCT01888978|Drug|Gem-OX|
1624021|NCT02056379|Drug|Budesonide|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 2 mg of inhaled budesonide and 3 ml of IV normal saline. If there is an improvement the following maintenance therapy will be instituted for 48 hs and the subjects will receive 2 mg of budesonide q12hs and 3 ml of IV NS q6hs.
1624022|NCT02056379|Drug|Dexamethasone|The subjects will receive a 5 ml normal saline inhalation right after extubation and will be re-evaluated in 5 to 10 minutes. The ones who develop upper airway obstruction and stridor with a Downes-Raphaelly score of 2 or higher will receive 0.5 ml/kg of inhaled epinephrine 1:1000 diluted to a final volume of 5 ml with a maximum dose of 2.5 ml in children up to 4 years and 5 ml in children with 5 years and above, as recommended by the American Academy of Pediatrics. The subjects who do not show an improvement after the epinephrine treatment will then be randomized to receive 8 ml of inhaled normal saline and 0.6 mg/kg of IV dexamethasone. The dexamethasone group will receive 8 ml of inhaled NS q12hs and 0.15 mg/kg/dose of dexamethasone q6hs.
1624023|NCT02056366|Drug|α-lipoic acid|α-lipoic acid 600mg PO medication,Per day, For 6weeks α-lipoic acid 1200mg PO medication,Per day, For 6weeks
1624024|NCT02056353|Device|LOGIC-Insulin algorithm|
1624025|NCT02056353|Device|Paper protocol|
1624026|NCT02056340|Drug|Atorvastatin|
1624027|NCT02056340|Drug|Placebo|
1624028|NCT02056327|Device|A novel monitoring suite of sensors will be inserted into the standard oral device.|
1624031|NCT02056301|Drug|Hydromorphone|In keeping with standard practice at the TCH, the position of the thoracic epidural catheter tip will be confirmed by real time fluoroscopy and a single injection of 1 ml of omnipaque 180 mg/mL contrast. In keeping with current practice, a bolus of 0.2% ropivacaine 0.3 ml per kg (maximum dose 20 ml) will be administered in the epidural space to the patients in the TEA group at least 10 minutes prior to surgical incision.
1624032|NCT02056301|Drug|Morphine|This device runs a basal infusion of pain medicine (morphine) intravenously with additional allowable patient controlled doses every 10 minutes
1624033|NCT02056288|Drug|Fentanyl|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction.
1624034|NCT02056288|Drug|Ropivacaine|Patients randomized to the systemic analgesia group will receive 1mcg/kg of fentanyl IV after induction. Patients randomized to the supraclavicular block group will receive an ultrasound guided nerve block with 0.2 ml/kg ropivacaine 0.5% (maximum 10 ml).
1624035|NCT02056275|Other|Nutrition supplement + dietary counseling|Nutritionally balanced nutritional supplement providing 1.0 kcal/ml.
1624036|NCT02056275|Other|Dietary Counseling|Dietary counseling provided at each study visit by study dietitian.
1624037|NCT02056262|Other|Dental cavity evaluation|The dental cavities present will be evaluated using the ICDAS (International Caries Detection and Assessment System).
1624038|NCT02056262|Biological|Saliva sampling|A saliva sample will be harvested.
1624039|NCT02056262|Biological|Plaque sampling|Plaque samples from a healthy tooth and a tooth with a cavity will be harvested.
1624040|NCT02056249|Other|Norepinephrine Transporter (NET) ligand|Norepinephrine Transporter (NET) ligand for iv administration during Positron Emission Tomography scan to measure changes in brain NET concentration based on insulin levels.
2011151|NCT02690181|Biological|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 in subjects who received GBS Alum in parent study.
2011152|NCT02690181|Biological|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 in subjects who received GBS MF59 Full in parent study.
1624043|NCT02056223|Drug|Intravenous paracetamol|15 mg/Kg every 6 hours for three days
1624044|NCT02056223|Drug|Intravenous ibuprofen|10 -5-5 mg/Kg once a day for three days
1624045|NCT02056210|Drug|Mozobil|Subcutaneous injection of 0.24 mg/kg Mozobil once at 8:30am
1624046|NCT02056197|Other|Placebo|Shortwave
1624047|NCT02056197|Other|Stable surface exercises|Stable surface exercises
1624048|NCT02056197|Other|Unstable surface exercises|
1624049|NCT02056184|Drug|Adalimumab|
2011153|NCT02690181|Biological|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 in subjects who received GBS MF59 Half in parent study.
2011154|NCT02690181|Biological|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 in subjects who received Placebo in parent study.
1624052|NCT02056145|Procedure|LFCNB|LFCNB - Normal Saline solution 10 cc
1624053|NCT02056145|Procedure|FNB|FNB - Normal saline solution 10 cc
1624054|NCT02056145|Procedure|LFCNB|LFCNB - Chirocaine 0.25%, 20 cc
1624055|NCT02056145|Procedure|FNB|FNB - Chirocaine 0.25%, 20 cc
1624056|NCT02056132|Other|Exhaled Breath Condensate|Lab results of Exhaled Breath Condensate
1624158|NCT02055547|Drug|Placebo|Placebo sc injection once each day for 10 days (Part 2)
2011155|NCT02690181|Biological|GBS Trivalent Vaccine|Administration of lyophilized formulation of a GBS trivalent vaccine containing 5 µg of each polysaccharide capsules from serotypes Ia, Ib, and III of Group B Streptococcus conjugated to CRM-197 in subjects who were not part of parent study.
1624057|NCT02056119|Device|Vibrating Mesh Nebulizer Arm|"Physician order received for subject, randomization to vibrating mesh nebulizer occurred.
Aeroneb® Solo (Aerogen, Galway, Ireland) vibrating mesh nebulizer to be placed before the heater on the dry side of the heater water chamber on the inspiratory ventilator circuit.
Aerosol treatment delivered per physician order.
Mesh nebulizer to be replaced every 30 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
1624058|NCT02056119|Device|Jet Nebulizer Arm|"Physician order received for subject, randomization to jet nebulizer occurred.
Jet nebulizer, Misty Max 10™ (Carefusion, CA), placed into spring loaded t-piece between the humidifier and the ventilator (approximately 15 cm from the gas outlet).
Aerosol treatment delivered per physician order at flow rates of 8-10 L/min.
Jet nebulizer to be replaced every 3 days per hospital protocol. a. Prior to every nebulizer change or every 3 days, study staff to be notified in order to obtain cultures."
1624059|NCT02056106|Drug|antidepressant therapy|
1624060|NCT02056093|Device|PSV mode|Application of PSV in all patients
1624061|NCT02056093|Device|PAV mode|Application of PAV mode in all patients
1624062|NCT02056093|Device|NAVA|
1624063|NCT02056067|Behavioral|Exercise|The exercise intervention group will receive social, behavioral support and research staff contact time to encourage them to increase their activity level to include twice weekly strength-training sessions and 150 min of walking/week (e.g., three 50-min walking sessions or five 30-min walking sessions) over 12 months.
1624064|NCT02056067|Behavioral|Attention Control (Health Education)|The Attention Control Group will be provided written information that emphasizes the importance of a healthy lifestyle. Participants will be encouraged to follow the NCI and ACS physical activity guidelines. This procedure was followed in our exercise trials, with no increase in physical activity levels observed at follow-up among women in the usual care group. Attention Control participants will also receive frequent contacts throughout the 12 month intervention. Each month, women randomized to attention control will be contacted by phone to discuss a health education topic of interest
1624065|NCT02056054|Other|Pediatric transplant subject with d-AIH|30 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws will depend on the patient's pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
1624066|NCT02056054|Other|Pediatric transplant subject with acute rejection|Recipients with acute rejection will have blood drawn at time of diagnosis before treatment for rejection is instituted.
1624067|NCT02056054|Other|Pediatric transplant subject with chronic rejection|Recipients with chronic rejection will have blood drawn either at diagnosis before treatment is instituted or for those with ongoing chronic rejection at the time of enrollment.
1624068|NCT02056054|Other|Adult non-transplant patients with auto-immune hepatitis|"75 ml of blood will be collected during periods of disease quiescence and activity in non transplanted subjects with AIH who are enrolled. Research blood draws will be drawn along with clinical blood draws.
The exact number of blood draws for each subject will depend on his or her pattern of disease activity. No more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2 year study period will be 8.
Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.
In the event that any enrolled subject undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
1624069|NCT02056054|Other|Adult non-transplant subjects with chronic hepatitis C virus|"For enrolled patients with chronic hepatitis C, 75 ml of blood will be collected before the start of treatment. This will be a onetime blood draw prior to treatment. Liver tissue (2 mm) will be obtained at the time a clinically indicated liver biopsy is performed.
In the event that any enrolled patient undergoes liver transplantation, a portion of the explanted liver will be obtained and stored in special media."
1624070|NCT02056054|Other|Pediatric control subjects|2 tablespoons of blood (30 ml) will be collected at each blood draw over a 2-year period. . The maximum amount of blood draws will be 3 however there will be no more than 1 blood draw within an 8-week period.
1624071|NCT02056054|Other|Adult transplanted subjects with de novo autoimmune hepatitis|75 ml of blood will be collected during periods of disease quiescence and activity in recipients with d-AIH who are enrolled. The exact number of blood draws for each subject will depend on his or her pattern of disease activity. However, no more than one blood draw will take place during an 8-week period. The maximum amount of blood draws over the 2-year study period will be 8.
1624072|NCT02056041|Procedure|Hepatectomy|
1624073|NCT02056028|Procedure|Hepatic resection|
1624074|NCT02056015|Drug|[68Ga]MLN6907|IV Administration of [68Ga]MLN6907 on Day 1
2011156|NCT02688075|Other|No Intervention|Participants who are receiving Canagliflozin +/- other AHA as per usual clinical practice will be observed for effectiveness, safety and PRO.
2011157|NCT02685488|Device|Transcranial Ultrasound|Transcranial ultrasound will be to stimulate at the right fronto-temporal cortex. 30 seconds of stimulation at 500 kHZ with duty cycle 0.24% and pulse rate frequency at 40 Hz.
2011158|NCT02684292|Biological|pembrolizumab|IV infusion
2011159|NCT02684292|Biological|brentuximab vedotin|IV infusion
1624079|NCT02055989|Radiation|Dose-escalated radiotherapy level 1|
1624080|NCT02055989|Radiation|Sequential dose-escalated radiotherapy level 2|
2011160|NCT02684227|Drug|Enzalutamide|"Safety Lead-in Phase (Part A) Starting Dose: 160 mg by mouth daily of a 21 day cycle.
Phase II (Part B) Starting Dose: Maximum tolerated dose (MTD) from Safety Lead-in Phase (Part A). Enzalutamide taken every day by itself during the first cycle (called Cycle 0)."
2011161|NCT02684227|Drug|Carboplatin|"Safety Lead-in Phase (Part A) Starting Dose: Area under curve (AUC)= 5 by vein on Day 1 of Cycles 1 - 9 of a 21 day cycle.
Phase II (Part B) Starting Dose: Maximum tolerated dose (MTD) from Safety Lead-in Phase (Part A). Carboplatin given by vein on Day 1 of Cycles 1 - 9."
2011162|NCT02684227|Drug|Paclitaxel|"Safety Lead-in Phase (Part A) Starting Dose: 175 mg/m2 by vein on Day 1 of Cycles 1 - 9 of a 21 day cycle.
Phase II (Part B) Starting Dose: Maximum tolerated dose (MTD) from Safety Lead-in Phase (Part A). Paclitaxel given by vein on Day 1 of Cycles 1 - 9."
2011163|NCT02684032|Drug|Gedatolisib|Gedatolisib weekly intravenous starting at 180 mg/week in a 4 week cycle.
2011164|NCT02684032|Drug|Palbociclib|Palbociclib initiated at 125 mg daily: 3 out of 4 weeks in a 4 week cycle.
1624092|NCT02055963|Behavioral|Questionnaires|Questionnaire completion 2 days before surgery, on day of surgery, 1 and 3 days after surgery, then twice a week until follow up visit on day 21.
1624093|NCT02055950|Procedure|Storage of kidney in refrigerated solution|
1624094|NCT02055950|Procedure|Kidney perfused by pulsatile machine|
1624095|NCT02055937|Procedure|immediate implant breast reconstruction|Eligible patients will undergo radical mastectomy with axillary lymph nodes sampling followed by immediate and single-stage breast reconstruction using the acellular dermal matrix Strattice™
1624096|NCT02055924|Drug|Ibrutinib and immunochemotherapies|Combination of immunochemotherapies (R-DHAP or R-DHAOx) and ibrutinib
1624097|NCT02055911|Drug|Ranibizumab|monthly ranibizumab (0,5 mg injected intravitreally in a standard fashion) until maximum visual acuity (VA) is achieved and remains stable for three consecutive months (for a minimum of 3 initial injections).
1624098|NCT02055898|Drug|Sodium Oxybate|
1624099|NCT02055898|Other|placebo (fresh potable water)|
1624100|NCT02055872|Drug|Intravenous albumin|
1624101|NCT02055872|Drug|Normal saline|
1624102|NCT02055859|Radiation|Radiosurgery|
1624103|NCT02055846|Procedure|Realisation of blood sample, urinary sample and tumor biopsy|
1624104|NCT02055833|Dietary Supplement|Intensive nutritional counseling|Intensive nutritional counseling: nutritional counseling + oral nutritional supplements
1624105|NCT02055833|Other|Nutritional counseling|Nutritional counseling
1624106|NCT02055820|Drug|Venetoclax|Venetoclax 200 to 800 milligrams (mg) tablets will be administered orally once daily (QD) during Phase I and MTD will be administered during Phase II.
1624107|NCT02055820|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square meter (mg/m^2) administered intravenously (IV) on Day 1 of each 21-day cycle up to Cycle 6.
1624108|NCT02055820|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion as an absolute dose of 1000 mg on Days 1, 8, 15 of Cycle 1 and Day 1 of Cycles 2-8 (cycle length = 21 days).
1624109|NCT02055820|Drug|Rituximab|Rituximab 375 mg/m^2 dose will be administered IV on Day 1 of every 21-day cycle.
1624110|NCT02055820|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 administered IV on Day 1 of each 21-day cycle up to Cycle 6.
1624111|NCT02055820|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) administered IV on Day 1 of each 21-day cycle up to Cycle 6.
1624112|NCT02055820|Drug|Prednisone|Prednisone 100 mg per day orally on Days 1-5 of each 21-day cycle up to Cycle 6.
1624113|NCT02055807|Other|PEEP and recruitment maneuvers|
1624114|NCT02055807|Other|ZEEP (no PEEP nor recruitment maneuver)|
1624115|NCT02055794|Procedure|Suturing of the perineal skin|
1624116|NCT02055794|Procedure|Closing perineal skin with surgical glue|
1624117|NCT02055794|Procedure|No suturing of the perineal skin|
1624118|NCT02055781|Drug|Pacritinib|
1624119|NCT02055781|Drug|Best Available Therapy|
1624120|NCT02055742|Device|illumigene CT and NG assays, illumipro-10|
1624121|NCT02055729|Biological|3mm tissue punch biopsy|Bacterial samples will be collected using deep level tissue biopsy using a Steifel punch of 3 mm in diameter (days 0 and 28).
1624122|NCT02055729|Biological|Superficial bedsore sample|Bacterial samples will be taken from the surface of the bedsore via swabbing. (days 0 & 28)
1624123|NCT02055729|Biological|Stool sample|Stool samples will be collected on days 0 and 28.
1624124|NCT02055729|Biological|Urine sample|Urine samples will be collected on days 0 and 28.
1624125|NCT02055716|Drug|Sulforadex|
1624126|NCT02055716|Drug|alpha-cyclodextrin|
1624127|NCT02055703|Drug|E2609|
1624128|NCT02055703|Drug|itraconazole|
1624129|NCT02055703|Drug|rifampin|
1624130|NCT02055703|Drug|digoxin|
1624131|NCT02055703|Drug|donepezil|
1624132|NCT02055690|Drug|Pazopanib|Tyrosine Kinase Inhibitor
1624133|NCT02055690|Drug|Fosbretabulin|Vascular Disrupting Agent
1624134|NCT02055664|Drug|Ropivacaine 0.2%|
1624135|NCT02055664|Drug|Chlorure de sodium 0.9%|
1624136|NCT02055651|Behavioral|Examination and survey|Routine medical examination as required by law and follow-up for lifestyle change program
1624137|NCT02055638|Drug|SRX246|capsules
1624138|NCT02055638|Drug|Placebo|
1624139|NCT02055625|Biological|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells will be injected directly underneath the mucosal lesions at one side under local anesthetic at 2.5-4 million cells/ml. A total of approximately 1.7 ml will be injected divided in 2-3 injections around the lesion. Patients will be followed every second day up to 7 days afterwards and then routinely at 14 days, 1 month, 2 months and 6 months to assess the healing process.
1624140|NCT02055586|Other|fluorine F 18 fluorothymidine|Undergo FLT-PET/MRI
1624141|NCT02055586|Device|positron emission tomography|Undergo FLT-PET/MRI
1624142|NCT02055586|Device|magnetic resonance imaging|Undergo FLT-PET/MRI
1624143|NCT02055573|Other|Ready To Learn (RTL)|See arm description
1624144|NCT02055573|Other|All Babies Cry (ABC)|See arm description
1624145|NCT02055547|Drug|MK-8521|Single dose 100 mcg sc injection in a treatment period (Part 1)
1624146|NCT02055547|Drug|MK-8521|Single dose 150 mcg sc injection in a treatment period (Part 1)
1624147|NCT02055547|Drug|MK-8521|Single dose 300 mcg sc injection in a treatment period (Part 1)
1624148|NCT02055547|Drug|MK-8521|Single dose 200 mcg sc injection in a treatment period (Part 1)
1624149|NCT02055547|Drug|Mk-8521|Single dose 175 mcg sc injection in a treatment period (Part 1)
1624150|NCT02055547|Drug|Placebo|Single dose placebo sc injection in a treatment period (Part 1)
1624151|NCT02055547|Drug|MK-8521|50 mcg sc injection once each day for 5 days (Part 2)
1624152|NCT02055547|Drug|MK-8521|74 mcg sc injection once each day for 5 days (Part 2)
1624153|NCT02055547|Drug|MK-8521|100 mcg sc injection once each day for 5 days (Part 2)
1624154|NCT02055547|Drug|MK-8521|125 mcg sc injection once each day for 5 days (Part 2)
1624155|NCT02055547|Drug|MK-8521|150 mcg sc injection once each day for 5 days (Part 2)
1624156|NCT02055547|Drug|MK-8521|72 mcg sc injection once each day for 7 days (Part 2)
1624157|NCT02055547|Drug|MK-8521|125 mcg sc injection once each day for 7 days (Part 2)
1624159|NCT02055547|Drug|Placebo|Placebo sc injection once each day for 14 days (Part 2)
1624160|NCT02055547|Drug|MK-8521|Single low dose sc injection in a treatment period (Part 3)
1624161|NCT02055547|Drug|MK-8521|Single high dose sc injection in a treatment period (Part 3)
1624162|NCT02055547|Drug|Placebo|Single Placebo sc injection in a treatment period (Part 3)
1624163|NCT02055534|Other|Nutritional counseling|Nutritional counseling consists in: personalized dietary prescription associated with regular (every 3 weeks) dietetic advise by a registered dietician. Follow-up evaluations take place also during the visits scheduled by the oncologists
1624164|NCT02055534|Other|General dietary advices|General dietary advices are provided. Follow-up evaluations take place during the visits scheduled by the oncologists
1624165|NCT02055521|Procedure|Blood sample, biopsy|
1624166|NCT02055508|Behavioral|Exercise Intervention|
1624167|NCT02055508|Other|Care-Management-Phone-Calls|
1624168|NCT02055482|Drug|BAY85-3934|BAY85-3934 will be titrated at the scheduled dose control visits to maintain the Hb in the target range of 10.0 to 12.0 g/dL. Available doses include 15, 25, 50, 75, 100, and 150 mg/day OD. Treatment will be for minimum of 6 months to up to a maximum of 36 months.
1624169|NCT02055482|Biological|Darbepoetin|Darbepoetin will be administered according to the local label and titrated at the scheduled dose by intravenous injection. Treatment will be for a minimum of 6 months to up to a maximum of 36 months.
1624170|NCT02055456|Drug|Nandrolone Decanoate|
1624171|NCT02055443|Other|12-lead holter monitor application|"-- The study coordinator will then obtain a 5-minute baseline high resolution (1000 samples/second), 12-lead resting ECG stream using H12+ holter ECG machine (Mortara Instruments, Milwaukee, WI). This ECG will be performed before the subject completed their clinical stress test.
The patient will then complete the scheduled nuclear stress test that involves exercise treadmill testing followed by single-photon emission computerized tomography (SPECT) scan as per hospital protocols. The exercise treadmill test and SPECT nuclear imaging scan are clinical in nature, and therefore, separate from the research study.
After completing the scheduled exam, the study coordinator will obtain another 5-minute 12-lead ECG stream prior to removing the chest electrodes but before their nuclear scan."
1624172|NCT02055430|Procedure|percutaneous nephrostomy insertion|The 1st arm was drained by PCN. This was performed under general anesthesia (GA) and fluoroscopic guidance.
1624173|NCT02055430|Procedure|bilateral double J ureteric stent|The 2nd arm was drained by bilateral JJ . This was performed under general anesthesia (GA) and fluoroscopic guidance.
1624174|NCT02055430|Procedure|Definitive stone management|(shockwave lithotripsy, chemodissolution therapy, ureteroscopy or open surgery) for clearance of stones.
1624175|NCT02055417|Behavioral|Personal Approaches to Treatment Choices for HIV|
1624176|NCT02055417|Behavioral|Stress Reduction Skills Program|
1624177|NCT02055404|Device|Delefilcon A spherical contact lens with molded marks|Silicone hydrogel contact lens with 9 different molded marks of varying widths and depths indented into the front surface (S1, S2, S3, S4, S5, S6, S7, S8, and S9). Each lens contained all 9 marks.
1624178|NCT02055404|Device|Etafilcon A toric contact lens|Hydrogel toric contact lens for daily wear, daily disposable use
1624179|NCT02055391|Behavioral|Behavioral Weight Loss|Weekly group meetings addressing behavioral weight loss skills including calorie counting, exercise, behavior modification, environmental changes, and coping with triggers.
1624180|NCT02055391|Behavioral|Enhanced Behavioral Weight Loss|Weekly group meetings that combine behavioral weight loss skills (calorie counting, exercise, behavior modification, environmental changes) with skills to decrease emotional eating by learning ways to manage and cope with emotions without eating.
1624181|NCT02055378|Drug|Atropine|topical 0.125% atropine eye drops
1624182|NCT02055378|Device|auricular acupoint stimulation|Five auricular acupoints (Shenmen, Xin, Yan, Mu 1 and Mu 2) Tapping stimulation was administered by using a 1-mm alloy ball (Magrain®; Sakamura, Kyoto, Japan) three times a day, each time for five minutes.
1624183|NCT02055365|Biological|Hepatitis B Vaccine (Recombinant)|All subjects will receive the standard 3-dose course of Recombivax HB (Merck) - Hepatitis B Vaccine (Recombinant).
1624184|NCT02055352|Drug|Budesonide|Budesonide 400 mcg twice a day via Breezhaler® device
1624185|NCT02055352|Drug|Fluticasone|Fluticasone 250 mcg twice daily via Accuhaler® device
1624186|NCT02055352|Drug|Indacaterol|Indacaterol 150 mcg once daily via Breezhaler® device
1624187|NCT02055352|Drug|Salmeterol|Salmeterol 50 mcg twice daily via Diskus® device
1624188|NCT02055339|Device|Fisher & Paykel heated humidified high flow nasal cannula|
1624189|NCT02055339|Device|InfantFlow/RAM nasal continuous positive airway pressure|
1624190|NCT02055326|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|one hour weekly for 8 weeks. Cognitive behavioral therapy for smoking cessation
1624191|NCT02055326|Behavioral|Yoga|One hour, twice weekly for 8 weeks of vinyasa yoga
1624192|NCT02055326|Behavioral|Health & Wellness|Lectures, handouts and printed materials on general health and wellness topics including healthy eating, cancer prevention and cardiovascular disease prevention.
1624193|NCT02055300|Drug|LY03005|
1624194|NCT02055300|Drug|Placebo|
1624195|NCT02055300|Other|Meal|
1624196|NCT02055300|Drug|Pristiq|
1624197|NCT02055287|Drug|LY03004|
1624198|NCT02055274|Drug|LY03003|
1624199|NCT02055274|Drug|Neupro|
1624200|NCT02055261|Device|Low frequency DBS of the pedunculopontine nucleus|
1624201|NCT02055196|Biological|carboxylesterase-expressing allogeneic neural stem cells|Given via intracerebral catheter
1624202|NCT02055196|Drug|irinotecan hydrochloride|Given IV
1624203|NCT02055196|Other|laboratory biomarker analysis|Correlative studies
1624204|NCT02055183|Drug|BAT|Noninterventional, retrospective, observational phase 4 patient Registry
1624205|NCT02055170|Drug|finasteride 5mg oral daily|
1624206|NCT02055157|Drug|BMN 111|BMN 111 will be administered daily for 24 months in an open-label sequential dose adjustment fashion.
1624207|NCT02055131|Drug|aspirin|
1624208|NCT02055118|Biological|idursulfase-IT|10mg
1624209|NCT02055118|Other|No IT treatment|Standard of Care
1624210|NCT02055105|Procedure|miRNA in Sepsis|miRNA in Sepsis
2011165|NCT02684032|Drug|Letrozole|Letrozole at 2.5 mg daily
1624211|NCT02055079|Drug|Sirolimus|Fixed oral dose of 3 mg sirolimus (blinded) once weekly for 24 months.
1624212|NCT02055079|Drug|Placebo|Fixed oral dose of 3 mg placebo (blinded) once weekly for 24 months.
1624213|NCT02055066|Drug|ARGX-111|
1624214|NCT02055053|Drug|0.5% Bupivicaine|Local anesthetic
1624215|NCT02055027|Other|Comparison between groups|Comparison between the two groups (adherent and non-adherent patients) in order to discover criteria of non-adherence
1624216|NCT02055014|Drug|Liraglutide|
1624217|NCT02055014|Device|Duodenal-jejunal bypass liner - Endobarrier device|
1624218|NCT02054988|Other|caffeine|"After 5 day coffee wash-out period, patients were randomly assigned to caffeine for 10 days. At baseline: 2 cups of coffee consecutively after 5 hour by clopidogrel or prasugrel intake. Afterwards, 3 cups of coffee daily for 10 days.
Platelet reactivity (expressed as P2Y(12) reaction units (PRU) by the point-of-care VerifyNow assay [Accumetrics, San Diego, California]) was measured at baseline and after 10-days of coffee intake."
1624219|NCT02054988|Other|not caffeine|evaluate the platelet reactivity after 10 days of no caffeine intake
1624220|NCT02054975|Drug|Vitamin D2 + vitamin D3|higher dose vitamin D
1624221|NCT02054975|Drug|Vitamin D3|lower dose vitamin D
1624222|NCT02054949|Drug|N-Acetyl Cysteine (NAC)|NAC will be started at 500 mg by mouth twice daily for the first 2 weeks, then increased to 500 mg in the am and 1000 mg in the pm for week 3, and then increased to 1000 mg am and pm for weeks 4 through 8. Subjects will be maintained at the highest tolerated dose.
1624223|NCT02054936|Drug|Rivaroxaban (Xarelto)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
1624224|NCT02054936|Drug|Warfarin (Coumadin)|To date there has been little attention to evaluating differences in wound complications following TJA among patients treated with rivaroxaban compared to warfarin.
1624225|NCT02054923|Procedure|Implementation of routine videorecording|All screening centres (clusters) assigned to the routine video recording group will receive an appropriate number of video recorders and DVDs for each colonoscopy room. Screening centre coordinators will be responsible for the implementation of routine video recording of all screening colonoscopies (only withdrawal) in the centres. Every three months screening centre coordinators will be asked to send back all recorded DVDs. All the recorded DVDs will be reviewed to verify ceacal intubation and withdrawal time by the PCSP team and then stored.
1624226|NCT02054923|Behavioral|No routine videorecording|Screening centres (clusters) assigned to the control group will not receive video recorders and DVDs but will be allowed to record colonoscopies on demand.
1624227|NCT02054910|Procedure|Celiac Plexus Block|Patients will receive celiac plexus block during endoscopy.
1624228|NCT02054910|Procedure|Sham|Patients will not receive celiac plexus block during endoscopy.
1624229|NCT02054897|Drug|semaglutide|Once weekly, administrated subcutaneously (s.c. under the skin)
1624230|NCT02054897|Drug|placebo|Once weekly, administrated subcutaneously (s.c. under the skin)
1624231|NCT02054884|Drug|Arm A: F16IL2 in combination with paclitaxel|"Intravenous (i.v.) 1 hour infusions of paclitaxel 90 mg/m^2 followed, after 30 min pause, by 3 hour i.v. infusions of F16IL2 35 Mio IU on days 1, 8, 15 of each 28 day cycle.
Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
1624232|NCT02054884|Drug|Arm B: Paclitaxel|"Intravenous (i.v.) 1 hour infusions of Paclitaxel 90 mg/m^2 on days 1, 8, 15 of each 28 day cycle.
Patients will receive 4 week cycles of study therapy for a maximum of 24 weeks, or until disease progression, unacceptable toxicity or withdrawal of consent."
1624233|NCT02054871|Procedure|RIPC|A standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 3 ischaemia-reperfusion cycles. Additional, blood and urine samples will be collected on Day 1, Day 2 and Day 3 post procedure.
1624234|NCT02054858|Procedure|RIPC|Remote ischaemic preconditioning (RIPC) is a simple technique whereby brief periods of skeletal muscle ischaemia and reperfusion triggers a period of resistance to ischaemia-reperfusion injury in distant tissues eg. heart or kidney. In this study preconditioning will be performed Immediately prior to the patient undergoing a CT scan. A CE-approved blood pressure cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles.
2011166|NCT02684032|Drug|Fulvestrant|Fulvestrant administered intramuscularly at 500 mg on Day 1, 15 and 28 and then every 28 days.
2011167|NCT02684006|Drug|Avelumab (MSB0010718C)|IV treatment Avelumab administered at 10 mg/kg IV every two weeks
1624237|NCT02054832|Dietary Supplement|Glycosade|
1624238|NCT02054819|Other|Induction chemotherapy and concurrent radiation|Cycle 1: irinotecan 65mg/m2 and cisplatin 30 mg/m2 on Day 1 and 8 Q 21 days Cycles 2-4: irinotecan 65 mg/m2, and cisplatin 30 mg/m2 Day 1 and 8 Q 21 days PLUS radiation therapy 66 Gy/7weeks/33 daily fractions
1624239|NCT02054819|Other|Consolidation: Radiation therapy to metastatic sites|At least 60 Gy total (taking into account a possible 3 Gy x 4 pre-treatment or equivalent) to all metastatic sites. For brain, 2.5 Gy x 14 to whole brain to follow stereotactic radiosurgery (SRS).
2011168|NCT02684006|Drug|Axitinib (AG-013736)|Oral treatment Axitinib given 5 mg PO BID
2011169|NCT02684006|Drug|Sunitinib|Oral treatment Sunitinib given at 50 mg PO QD on schedule 4/2
2011170|NCT02683941|Drug|Lanreotide (Autogel formulation)|120mg every 28 days until disease progression
2011171|NCT02683941|Drug|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days until disease progression.
2011172|NCT02683694|Device|iOCT|the number of subjects that can be peeled without dye are assessed
1624243|NCT02054780|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|We propose using TF-CBT to address stress related problems (SRP) and reduce HIV risk behaviors. OVC lack behavioral and cognitive skills and intention necessary to use the available information and resources to prevent HIV. For example, internalizing problems are related to HIV risk through low self-efficacy, poor assertiveness skills, and reduced ability to negotiate safe sex. Given evidence on the link between abuse/trauma and elevated HIV risk, researchers have called for overlap between evidence-based mental health treatments like TF-CBT and HIV prevention programs. Some studies have found that skills-oriented interventions reduced HIV-risk behaviors among minority and troubled youths. An intervention study using CBT increased condom use and decreased high-risk sexual behaviors among runaway youths in a short-term follow-up evaluation. However, these studies were done in Western countries; their relevance to OVC in Africa is unproven.
1624244|NCT02054780|Behavioral|Psychosocial Counseling|"The curriculum Psychosocial Care and Counseling was developed for HIV Infected Children and Adolescents. The goal is to enable health care providers to provide safe supportive counseling and support services to HIV infected youth and their families. The course materials are designed to be adapted to different cultures and needs. The 14 modules cover child development, family systems, communicating with children, disclosure and adherence and legal/ethical issues. The course teaches basic counseling skills with children such as listening and play. It explores and challenges barriers to care such as caregivers' fear and reluctance to disclose an HIV positive diagnosis to a child, discussing adolescent sexuality, and practical issues such as inadequate legislation governing child rights. The curriculum was adapted for Zambia and endorsed by the MoH."
1624245|NCT02054767|Drug|Intervention: inferior alveolar nerve block injection|-22 patients received inferior alveolar nerve block injections of 3.6 mL (equivalent to 2 cartridges)
1624246|NCT02054754|Drug|Dexanabinol Dose Level 1|Oral formulation of dexanabinol
1624247|NCT02054754|Drug|Dexanabinol Dose Level 2|Oral formulation of dexanabinol
1624248|NCT02054754|Drug|Dexanabinol Dose Level 3|Oral formulation of dexanabinol
1624249|NCT02054754|Drug|Dexanabinol Dose Level 4|Oral formulation of dexanabinol
1624250|NCT02054754|Drug|Dexanabinol Dose Level 5|Oral formulation of dexanabinol
1624251|NCT02054754|Drug|Placebo|
1624252|NCT02054741|Other|Comprehensive Geriatric Assessment|Complete geriatric assessment
1624253|NCT02054741|Other|Quality-of-Life Assessment|Ancillary studies
1624254|NCT02054741|Other|Survey Administration|Ancillary studies
1624255|NCT02054728|Other|RHC and IMT|"Eligible patients subjected to RHC will be instructed on how to do RMT using the Threshold IMT® two days in advance. RMT will be conducted with 20-30% of individual inspiratory muscle strength, which will be measured beforehand. A single training session consists of 7 cycles with 2 min inspiratory training each, followed by a 1 min break (total duration 21 min).
The actual intervention consists of inspiratory muscle training (IMT) during right-heart catheterization for at least 2 min or as long as is necessary to measure all specified parameters."
1624256|NCT02054715|Behavioral|print educational intervention|print educational intervention
1624257|NCT02054715|Behavioral|multimedia psychoeducational intervention|multimedia psychoeducational intervention
1624258|NCT02054702|Drug|Brexpiprazole|Treatment (6 weeks) Up to 4 mg/day, once daily dose, tablets, orally
1624259|NCT02054702|Drug|Aripiprazole|Up to 20 mg/day, once daily dose, tablets, orally
1624260|NCT02054689|Radiation|Fractionated Stereotactic Radiosurgery|SRS SBRT CyberKnife Trilogy True Beam Radiosurgery
1624261|NCT02054676|Radiation|Cone-Beam Computed Tomography preoperative evaluation.|"Procedure: Cone-beam computed tomography (CBCT) preoperative evaluation (e.g. i-CAT, Imaging Sciences International, Hatfield, Pennsylvania, USA). CBCT voxel size is about 0,2 - 0,25 mm . Manufacturer recommended software is used. CBCT evaluation of partially edentulous jaw segments are made during preoperative stage (see Appendix 1):
Non aesthetic and aesthetic zone edentulous jaw segment parameters (height, width, length, mandibular canal walls identification/jawbone quality type visual identification) evaluation;
Every edentulous jaw segment parameter should be graded following: Type I (low risk), Type II (moderate risk), Type III (high risk).
All graded measurements provide overall risk evaluation for implant treatment in non aesthetic and aesthetic zone without aesthetic parameters evaluation. Dental implant is selected if surgery is possible."
1624262|NCT02054676|Procedure|Intraoperative edentulous jaw segment parameters evaluation.|"Surgery is planned preliminary according to preoperative stage edentulous jaw segment evaluation results.
Intervention related study parameters are provided on Appendix 2. Aesthetic parameters related to implant treatment success are evaluated after mucoperiosteal flap elevation: alveolar ridge vertical position, mesial and distal interproximal bone peak height (in the aesthetic zone).
The additional parameters (non aesthetic) are evaluated after dental implant osteotomy preparation and implant placement:
implant drill slippage deeper than planned;
implant threads coverage;
etc."
1624263|NCT02054676|Device|Endosseous dental implant placement.|"Endosseous dental implant (e.g. Bone Level SLA implant, Straumann AG, Basel, Switzerland) is placed if possible during intraoperative stage according to study protocol in the aesthetic or non aesthetic zone edentulous jaw segment. Optimally positioned dental implant is surrounded by at least 1 mm of bone for successful treatment outcome in the non aesthetic zone.
Aesthetic zone implant is placed in the optimal three dimensional position. It is surrounded by bone at least 1 mm from lingual side and at least 2 mm from buccal side for successful treatment outcome.
Dental implant apex is at least 2 mm away from anatomically important jaw vital structures.
Dental implant parameters (length, width) are individual (depends on edentulous jaw segment parameters).
Bone and soft tissue augmentation are made if necessary after dental implant placement."
1624264|NCT02054676|Radiation|Dental implant position evaluation.|"Periapical radiograph (e.g. Kodak RVG 6100 Intraoral Digital Imaging System, Carestream Health, Rochester, NY) evaluation is necessary (Appendix 2) to examine implant apex distance to anatomically important vital structures (possible injury) (mandibular canal, nose base) during early postoperative stage.
Digital periapical radiographs are used to assess the edentulous jaw segment after implant placement. The long cone paralleling technique should be used for taking periapical X-ray (prevention of possible creation of foreshortening and elongation).
Postoperative patient's neurosensory evaluation is necessary to assess possible inferior alveolar nerve and lingual nerve injury. After finishing of local anaesthesia patient should be contacted and if there are some sensory deficit complains, patient should be examined."
1624295|NCT02054468|Drug|Rocuronium (0.07mg/kg/body mass)|Rocuronium (0.07mg/kg/body mass)
1645671|NCT01888978|Drug|Gem-5FU|
1624265|NCT02054676|Drug|Medications.|"Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.
Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.
Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days."
1624266|NCT02054676|Procedure|Late postoperative soft tissue evaluation.|"Mesial and distal papillae appearance, vertical soft tissue deficiency (Appendix 3) evaluation during late postoperative stage is necessary for classification accuracy assessment during final single-tooth implant crown placement in the region of aesthetic zone (both parameters are evaluated) and non aesthetic zone (soft tissue vertical deficiency) edentulous jaw segment.
The time after surgery is case depending before provisional and final crown placement.
Peri-implant soft tissue conditioning is recommended with screw retained provisional single-tooth implant crown for approximately 4 - 8 weeks.
Healing abutment placement after dental implant osseointegration is not recommended because of the treatment time saving."
1624267|NCT02054663|Drug|Clopidogrel|Patients on ticagrelor following an acute coronary syndrome, being transitioned to clopidogrel will be randomized to either a one time 600mg bolous dose of clopidogrel followed by 75mg daily or just starting at 75mg daily without a bolous dose.
1624268|NCT02054650|Other|Osteopathic Manual Treatment (OMT)|Osteopathic Manual Treatment (OMT) is a system of hands-on techniques used by osteopathic physicians to increase function and reduce pain.
1624269|NCT02054650|Other|Sham OMT|Sham OMT involves hand contact, active and passive range of motion, and sham techniques that simulate OMT, but that utilize such maneuvers as light touch, improper patient positioning, purposely misdirected movements, and diminished provider force.
1624270|NCT02054637|Drug|Lanreotide|
1624271|NCT02054624|Behavioral|Lifestyle intervention|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
Phase 1 will be 4 months of weight loss treatment
Phase 2 will be 12 months of follow-up contact by group telephone call.
The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
During Phase 2 you will receive two phone calls per month from your group leader for the first 6 months, and one phone call per month for the next 6 months."
1624272|NCT02054624|Behavioral|Health education control|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
Phase 1 will be 4 months of weight loss treatment
Phase 2 will be 12 months of follow-up contact by email.
The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
During Phase 2 you will receive you will receive a specially prepared newsletter two times per month. The newsletter will contain educational information about proper eating and physical activity. The newsletters will include low-fat and low-calorie recipes, along with tip sheets that describe strategies to help you maintain lost weight."
1624273|NCT02054624|Behavioral|Individual|"The weight-loss treatments will include two phases. Phase 1 will last 4 months and Phase 2 will last 12 more months.
Phase 1 will be 4 months of weight loss treatment
Phase 2 will be 12 months of follow-up contact by on-on-one telephone call.
The participants will learn about nutrition, physical activity, and safe methods to lose weight during Phase 1.
During Phase 2 you will receive two phone calls per month from your group leader for the first 6 months, and one phone call per month for the next 6 months."
1624274|NCT02054624|Behavioral|All Groups|All participants will receive the following: Questionnaires, height, weight, waist measurement, blood pressure, heart rate, electrocardiogram, blood sample, urine sample, urine pregnancy test (for females only), 400 meter walking test, accelerometer (an armband device the size of a deck of cards to record physical activity and movement each day).
1624275|NCT02054611|Other|Online Educational Module|A descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review.
1624276|NCT02054611|Other|Evaluation First (Placebo)|The respondents will view the descriptive video detailing the diagnosis of ARDS according to the Berlin Definition, along with online educational materials available for review only after they have completed the evaluation.
1624277|NCT02054598|Behavioral|Decision aid and navigation|Patients in the intervention group will receive a combined intervention consisting of a CRC screening decision aid and assistance from a trained patient navigator.
1624278|NCT02054585|Other|NaCl 0.9%|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.
Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
1624279|NCT02054585|Other|NaCl 0.9 +5% dextrose|"Children will be included in each group in a randomized way using SAS (Statistical Analysis System) program.
Intervention: In this arm children will receive 20 ml/kg bolus of IV NaCl 0.9% + 5% dextrose. The bags will be identical and the content will be 1 liter. This way if a second bolus is administrated before hospitalization or discharge is decided, the child will still receive the same fluid."
1624280|NCT02054572|Drug|[¹⁴C]Etelcalcetide|750 nCi of [¹⁴C]etelcalcetide formulated as a single 10 mg dose of etelcaletide in 2 mL liquid solution for bolus intravenous (IV) administration at the end of hemodialysis.
1624281|NCT02054559|Drug|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone (or prednisolone))
1624282|NCT02054559|Radiation|Radiotherapy|
1624283|NCT02054520|Drug|HyperAcute®-Melanoma (HAM) Immunotherapy|
1624284|NCT02054520|Drug|Ipilimumab|
1624285|NCT02054520|Drug|Pembrolizumab|
1624286|NCT02054520|Drug|Nivolumab|
1624287|NCT02054507|Behavioral|Cognitive evaluation (Wechsler IV tests)|Children born prematurely in a level III referral Center will undergo psychometric evaluation at 8 to 11 years of age by routine test (WISC IV). The relationship between cognitive scores and neonatal characteristics will be determined and compared with the results of schoolmate control children, born at term.
1624288|NCT02054481|Drug|BI 655066|Medium dose
1624289|NCT02054481|Drug|BI 655066|High dose
1624290|NCT02054481|Drug|Ustekinumab|
1624291|NCT02054481|Drug|BI 655066|Low dose
1624292|NCT02054468|Drug|Single-Shot Propofol|Single-shot propofol induction dose (1.5-2.5mg/kg body mass)
1624293|NCT02054468|Drug|30min infusion Propofol|30min of propofol infusion (4-6mg/kg/h)
1624294|NCT02054468|Drug|Remifentanil infusion|Remifentanil infusion (0.1-0.2µg/kg/min)
1624296|NCT02054468|Drug|Rocuronium (0.1mg/kg/body mass)|Rocuronium (0.1mg/kg/body mass)
1624297|NCT02054468|Drug|Rocuronium (0.15mg/kg/body mass)|Rocuronium (0.15mg/kg/body mass)
1624298|NCT02054468|Drug|Rocuronium (0.2mg/kg/body mass)|Rocuronium (0.2mg/kg/body mass)
1624299|NCT02054468|Drug|Rocuronium (0.3mg/kg/body mass)|Rocuronium (0.3mg/kg/body mass)
1624300|NCT02054468|Drug|Rocuronium (0.45mg/kg/body mass)|Rocuronium (0.45mg/kg/body mass)
1624301|NCT02054455|Dietary Supplement|Lactobacillus paracasei F19|25x10E9 live bacterial cells for 3 days/week for 6 months
1624302|NCT02054455|Dietary Supplement|Placebo|Placebo will consist of a preparation similar to that of probiotic but with no added microorganisms.
1624303|NCT02054442|Drug|Cetuximab|We will perform a randomized phase II study to investigate in first line if the addition of cetuximab to MTX is beneficial, i.e. improvement in the PFS, for the patient.
1624304|NCT02054442|Drug|Methotrexate|
1624305|NCT02054429|Drug|Insulin|Intensive Insulin Therapy (IIT) will be given to you by two IV infusions. The insulin infusion will be started immediately after you are moved to the intensive care unit (ICU) after endovascular therapy and continued for 48 hours
1624306|NCT02054416|Device|ArtAssist© Device|The study intervention will consist of one hour of IPC with the ArtAssist© device to the remaining leg, three times a day for a three month period. We will obtain the usage data from the device when the subject returns the device (the device has an internal device that stores the usage data) to evaluate subject compliance.
1624307|NCT02054377|Other|Tai chi|"Tai Chi, a Chinese form of mindful exercise, may help alleviate CF symptoms, encourage active self-management and provide a practical way to relieve and manage stress for patients and carers. It involves gentle physical exercises, combined with breathing techniques and mindful awareness.
It will be taught by qualified instructors either face to face in the participant's home or over videoconferencing technology e.g. Skype.
A DVD of the Tai Chi was developed in Phase 1 which was successful for teaching adults, and will be used here, along with a child-friendly DVD. This will be filmed with and aimed at children aged 6-18. Teaching support materials, incorporating child-specific guidance such as animal-based Tai Chi movements, will be prepared for use in conjunction with the DVD."
1624308|NCT02054364|Behavioral|FBT and CRT|
1624309|NCT02054364|Behavioral|FBT and art therapy|
1624310|NCT02054351|Drug|IMAB027|Stage 1 (Intrapatient dose escalation): The starting dose is set to 1 mg/m2, followed by 10 mg/m2, 30 mg/m2 and 100 mg/m2 Stage 2 (Interpatient dose escalation): 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2 Extension period: 4 dose level 100 mg/m2, 300 mg/m2, 600 mg/m2, 1000 mg/m2
1624311|NCT02054338|Drug|vinflunine 320 mg/m² as a 20-minute infusion on day 1 of each cycle repeated every 3 weeks gemcitabine 1000 mg/m² IV on day 1 and 8 repeated every 3 weeks|
1624312|NCT02054338|Drug|vinflunine plus gemcitabine|320 mg/m² IV on day 1 plus gemcitabine 1000 mg/m² on days 1 and 8 of each cycle repeated every 3 weeks
1624313|NCT02054338|Drug|paclitaxel plus gemcitabine|paclitaxel 175 mg/m² on day 1 plus gemcitabine 1250 mg/m² on days 1
1624314|NCT02054325|Drug|Polidocanol with Glucose|An application session 0.2% Polidocanol + 70% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
1624315|NCT02054325|Drug|Glucose|An application session 75% Glucose to treat reticular veins of the lower limb selected, with a maximum volume of 5 ml. Return to a week to investigate the adverse effects and 2 months for proof of efficacy and adverse effects
1624316|NCT02054312|Behavioral|Family Based Interpersonal Psychotherapy (FB-IPT)|
1624317|NCT02054312|Behavioral|Client Centered Therapy (CCT)|
1624318|NCT02054299|Drug|Drug application Amitriptyline|Amitriptyline: 25 mg, single oral application
1624319|NCT02054299|Drug|Drug application Desvenlafaxine|Desvenlafaxine: 50 mg, single oral application
1624320|NCT02054299|Drug|Drug application Sumatriptan|Sumatriptan: 50 mg, single oral application
1624321|NCT02054299|Drug|Drug application Proguanil|Proguanil: 200mg, single oral application
1624322|NCT02054299|Drug|Drug application Fenoterol|Fenoterol: 180 mcg, single intravenous application
1624323|NCT02054299|Drug|Drug application Thiamine|Thiamine: 200mg, single oral application
1624324|NCT02054286|Biological|THV01-1|Intramuscular injection of THV01-1 (week 0)
1624325|NCT02054286|Biological|THV01-2|Intramuscular injection of THV01-2 (week 8)
1624326|NCT02054286|Biological|Placebo|Intramuscular injection of placebo matching THV01-1 and THV01-2
1624327|NCT02054260|Drug|Surgicel|
2011173|NCT02683356|Other|OCT-guided PCI|Patients assigned to the OCT-guided PCI strategy will undergo OCT prior to PCI to determine vessel and lesion dimensions and treatment strategy. OCT will be repeated at the end of the procedure and corrective PCI will aim to optimize the PCI result according to pre-specified criteria in terms of minimal lumen area, scaffold expansion, apposition, residual dissections or intra-scaffold thrombus formation
1624331|NCT02054221|Procedure|myoectomy|The scheme of Extended septal myectomy: Two parallel incisions were made into the septal bulge and connected to remove the muscle mass. Myectomy was extended to the base of the papillary muscles, when midseptal thickening was present. The papillary muscles were grasped and pushed medially to visualize the abnormal connections between the papillary muscles and the anterior wall of the ventricle. A blade was used to divide the thickened abnormal attachments. A pituitary rongeur may be used to resect a portion of the junction of the papillary and lateral wall. This reduces the diameter of the papillary muscle and allows for posterior displacement of the anterior mitral leaflet. Division of abnormal attachments and thinning of the papillary muscles is critical for the treatment of SAM.
1624332|NCT02054221|Procedure|Mitral valve surgery|41 patients will be performed mitral valve replacement with complete excision of the subvalvular apparatus.
1624333|NCT02054221|Procedure|Mitral valve surgery|41 patients will be performed mitral valve repair. Results of mitral valve repair will be more appreciated intraoperatively. In case of unsatisfactory MV repair will reconnect the device artificial circulation and mitral valve replacement. There after, patients will be moved to the first group.
1624377|NCT02053883|Drug|Cethrin (BA-210)|High or low doses of Cethrin administered extradurally in a fibrin sealant during spinal decompression/stabilization surgery.
1624865|NCT02049801|Drug|MEK inhibitor MEK162|Given PO
1624334|NCT02054208|Biological|human umbilical cord blood derived mesenchymal stem cells|"Low dose: 1 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals
High dose: 3 x 10^7cells/2mL 3 repeated intraventricular administrations via an Ommaya Reservoir at 4 week intervals"
1624335|NCT02054208|Other|Normal saline 2mL|Intraventricular administrations of 2mL Normal Saline at 4 week intervals via an Ommaya Reservoir, for a total of 3 administrations
1624336|NCT02054195|Behavioral|Training|Training model is consist of effort to provide intra uterine device post placental by organising a special guided training model for post-placental IUD insertion by pushing the head of IUD using index and middle finger close enough to fundal part of uterus to prevent expulsion.
1624337|NCT02054195|Behavioral|No Training|Control of Training model is without training on effort of pushing the head of IUD using index and middle finger to uterine fundus.
1624338|NCT02054182|Drug|Vitamin D|Vitamin D 2 500 IU daily from enrolment (within 24 hours of hospitalization) until discharge from hospital
1624339|NCT02054156|Drug|azithromycin|3 times weekly, oral suspension, 10 mg/kg/dose up to 500 mg, for 18 months
1624340|NCT02054156|Drug|placebo|3 times weekly, oral suspension, volume-matched to azithromycin, for 18 months
1624341|NCT02054156|Drug|Tobramycin solution for inhalation|300 mg, twice daily for 28 days when respiratory cultures are found positive for Pa at study visits for 18 months
1624342|NCT02054143|Procedure|Partial pressure of CO2 at the end of an exhaled breath|Three previously defined EtCO2 levels (partial pressure of CO2 at the end of an exhaled breath) were adjusted during anesthesia.
1624343|NCT02054143|Drug|Sevoflurane|Sevoflurane was administered to all patients at 1 minimal alveolar concentration (MAC) during the whole operation.
2011174|NCT02683356|Other|Angiography-guided PCI|Patients assigned to the OCT-guided PCI strategy will only undergo OCT after PCI to determine vessel and lesion dimensions and treatment strategy.
2011175|NCT02682836|Behavioral|Walk with Ease|
2011176|NCT02680847|Drug|ALO-02|Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
2011177|NCT02679716|Other|MRI of the cerebral arteries|MRI of the cerebral arteries is performed
1624348|NCT02054117|Other|Intracerebral Hemorrhage|Spontaneous intracranial or intraparenchymal hemorrhage that occurred in a supratentorial location.
2011178|NCT02679170|Drug|Crizotinib|Treatment with crizotinib following routine clinical practice
2011179|NCT02678702|Behavioral|CBT-I|CBT-I
2011180|NCT02678702|Behavioral|Treatment as usual|Treatment as usual
1624352|NCT02054091|Dietary Supplement|Bovine colostrum|The BC powder to be used in this study is donated from a Danish company, Biofiber Damino. The raw colostrum used for production is collected within 1-2 milking from healthy Danish dairy cows (Danish Holstein). Antibiotic residues are screened upon collection and those tested positive are not used for production. Intact colostrum is pasteurized, low temperature spray-dried, and sterilized by γ-irradiation.
1624353|NCT02054078|Drug|Bevacizumab|Bevacizumab200mg by intrapleural administration
1624354|NCT02054078|Drug|Pulvis talci|Pulvis talci 4g by intrapleural administration
1624355|NCT02054065|Other|CAUTI Decision Support|Decision support used to prevent Catheter Associated Urinary Tract Infections
1624356|NCT02054052|Drug|Bevacizumab|Bevacizumab 100 mg, intrapleural injection treating MPE after the drainage of MPE
1624357|NCT02054039|Device|Incentive spirometry (IS)|Mechanical devices activated by an inspiratory effort, which is viewed by the elevation of a plateau or balls in a transparent cylinder having a calibrated scale that displays the inspired flow.
1624358|NCT02054039|Device|Breath Stacking (BS)|Equipment with a one-way valve that masks and promotes the accumulation of successive inspiratory volumes, preventing expiration
1624359|NCT02054026|Behavioral|Reducing the Risk|
1624360|NCT02054013|Procedure|Prostatic artery embolization|
1624361|NCT02054013|Procedure|monopolar transurethral prostatectomy|
1624362|NCT02054000|Drug|Tirofiban|Intracoronary administering of Tirofiban
1624363|NCT02054000|Other|Placebo|Intracoronary serum physiologic
1624364|NCT02053987|Other|Intensive rehabilitation in the home.|
1624365|NCT02053974|Drug|Spironolactone|Spironolactone
1624366|NCT02053974|Other|Placebo|Placebo
1624367|NCT02053961|Device|Deep Transcranial Magnetic Stimulation|1Hz dTMS real treatment
1624368|NCT02053961|Device|Deep Transcranial Magnetic Stimulation|1Hz dTMS SHAM treatment
1624369|NCT02053948|Procedure|Pursestring Wound Closure|
1624370|NCT02053948|Procedure|Gunsight Skin Incision and Closure Technique|
1624371|NCT02053935|Drug|Dopamine|Each subject will receive a priming dose of dextrose 20% to increase their glucose concentration by 125 mg/dl in the first 15 minutes. Then they will receive variable rates of dextrose 20% infusion to maintain glucose level at 180-220 mg/dl. Then, dopamine (200mg/250ml) will be titrated up to 5 mcg/kg/min with care not to increase blood pressure greater than 160 systolic. Dopamine will be infused for 3 hours.
1624372|NCT02053922|Drug|Syntocinon|Syntocinon ampoules (10 IU Oxytocin). (Novartis Pharma, Egypt) One ampoule 10 IU diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS, followed by an intravenous drip of 20 IU oxytocin in 500 ml saline over 4 hours.
1624373|NCT02053922|Drug|Carbetocin|Carbetocin (Ampoule 100 μg/ml) . [Pabal, Marketing Authorization Holder: Ferring GmbH (Gesellschaft mit beschränkter Haftung), Kiel ,Germany. Manufactured by DRAXIS Pharma , a division of specialty Pharmaceuticals Inc. Montreal ,Canada] ,diluted in 10 ml normal saline and administered slowly (over 30- 60 seconds) intravenously just after delivery of the neonate during CS.
1624374|NCT02053922|Drug|Misoprostol|Misoprostol (200 mcg Tablet) [Misotac, Sigma Pharmaceutical Industries, SAE, Egypt] Two tablets (400 mcg) in the buccal space just after delivery of the neonate during CS.
1624375|NCT02053909|Drug|Aspirin|
1624376|NCT02053909|Drug|Ticagrelor|
2011181|NCT02679755|Drug|Palbociclib|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
2011182|NCT02679755|Drug|Letrozole|2.5 mg/d tablets orally on a continuous regimen
1624378|NCT02053883|Drug|Placebo|Fibrin sealant alone administered extradurally during spinal decompression/stabilization surgery.
1624379|NCT02053870|Other|Physiotherapy+conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks. Additionally, they will be involved in 9 sessions (3 times a week during 2 weeks) of respiratory physiotherapy including breathing retraining and chest clearance techniques, exercises for thoracic mobility, expansion and flexibility, cardiorespiratory exercise training and education about the disease.
1624380|NCT02053870|Drug|Conventional treatment|Patients will be treated with daily medication prescribed by the physician, during 3 weeks.
1624381|NCT02053857|Dietary Supplement|RUTF|
1624382|NCT02053857|Dietary Supplement|RUTF-P|
1624383|NCT02053857|Drug|Amoxicillin|
1624384|NCT02053844|Other|lottery for tool users to win a $500 prize|Intervention group is eligible to enter a monthly lottery to win a $500 gift card if they use the tool each month.
1624385|NCT02053844|Other|enhanced promotion of the tool to employers and members|Intervention group also receives extra promotion of the tool through mailings, employer outreach, and automated phone calls
1624386|NCT02053818|Drug|Remifentanil|Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
1624387|NCT02053818|Drug|Sufentanil|Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
2011183|NCT02677766|Other|occupational therapy|an intervention phase in the period of hospitalization for rehabilitation in the hospital, aimed mainly at achieving objectives related to the area of self-care and, secondly, the objectives in the areas of productivity and leisure, identified at T0; plus an intervention in the post-discharge at the patient's home, aimed primarily at achieving objectives related to the areas of productivity and leisure time and, secondly, to possible targets in residues of self-care, identified in T0.
2011184|NCT02677766|Other|Usual care|Usual care consists in rehabilitation treatment delivered by a multidisciplinary team
2011185|NCT02677714|Radiation|99mTc-rhAnnexin V-128|
2011186|NCT02677844|Drug|Abemaciclib|Administered orally
2011187|NCT02677844|Drug|Placebo|Administered orally
2011188|NCT02677844|Drug|Loperamide|Administered orally
2011189|NCT02674386|Drug|Investigational Medical Product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen or diclofenac administered in parent study.
1624395|NCT02053779|Drug|Triptorelin 0.1mg|Triptorelin 0.1 mg administered subcutaneously 6 days after ovum pick-up (OPU) in IVF/ICSI cycles triggered by triptorelin 0.2 mg followed by hCG 1500 iu the day of OPU.
1624396|NCT02053766|Drug|Sevoflurane|Sevoflurane up to 8% will be administered to study subjects
1624397|NCT02053766|Drug|Dexmedetomidine|Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.
1624398|NCT02053766|Drug|Propofol|Propofol up to 50 mcg/ kg/min will be administered to study subjects.
2011190|NCT02672423|Drug|Abemaciclib Capsules (Reference Formulation)|Administered orally
2011191|NCT02672423|Drug|Abemaciclib Tablet(s) (Test Formulation)|Administered orally
1624401|NCT02053740|Drug|Add R-S-Y-R-T (500 mg 3 times per day) for 6 months|
1624402|NCT02053740|Drug|Routine western medicine|
1624403|NCT02053727|Drug|Abatacept|Abatacept Injection, 125 mg/Syringe (125 mg/mL), is a sterile solution for SC administration, which contains approximately 126 mg abatacept.
1624404|NCT02053727|Drug|Placebo|
1624405|NCT02053714|Behavioral|Diabetes self-management and education|
1624406|NCT02053688|Device|Astigmatic Correction Lens (Nexis ACCL lenses)|Astigmatic refractive error correction
1624407|NCT02053688|Device|Toric Soft Contact Lenses|astigmatism correction using toric optics
1624408|NCT02053675|Drug|Vasopressin infusion|
1624409|NCT02053662|Procedure|Sample Collection|A collection of donated cancer and normal adjacent tissues, blood and urine which will be prospectively obtained from patients through the Tissue Procurement Shared Resources (TPSR) and The Ohio State University Comprehensive Cancer Center Biospecimen and Biorepository Resource (BBR) as needed.
1624410|NCT02053649|Behavioral|Triple Chronotherapy|triple chronotherapy (TC will consist of bright light therapy, sleep phase advance, and sleep deprivation/restriction
1624411|NCT02053649|Other|Usual Care|UC will consist of medication administered by a perinatal psychiatrist and/or psychotherapy
1624412|NCT02053636|Drug|lucitanib|
1624413|NCT02053610|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
1624414|NCT02053610|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
1624415|NCT02053610|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle
1624416|NCT02053597|Drug|Doxorubicin|All patients will receive four cycles of doxorubicin (A) (50 mg/m2)
1624417|NCT02053597|Drug|paclitaxel|All patients will receive four cycles paclitaxel (P) (200 mg/m2), given on a three-weekly basis for four cycles, followed by weekly paclitaxel (P) (80 mg/m2) for twelve weeks.
1624420|NCT02053571|Procedure|TIPS with 3D Overlay|
1624421|NCT02053558|Drug|Systemic lidocaine|Systemic lidocaine group will receive a lidocaine 1.5 mg/kg bolus after induction of anesthesia followed by a 2mg/kg/hr infusion and sham bilateral TAP blocks with normal saline 15mL on each side.
1624422|NCT02053558|Drug|TAP BLOCK with ropivacaine|TAP block group will receive bilateral TAP blocks using ultrasound guidance with 0.5% ropivacaine 15mL on each side and a bolus and infusion of normal saline after induction of anesthesia.
1624423|NCT02053545|Drug|Conditioning Regimen & GVHD Prophylaxis|"Stratum 1 (Refractory disease, relapse after previous transplant): Radiation Therapy (if patient had prior Central Nervous System (CNS) disease), Clofarabine, Melphalan,Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus and MMF
Stratum 2 (Myeloid in remission): Radiation Therapy (if patient had prior CNS disease), Busulfan, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF
Stratum 3 (Lymphoid in remission): Radiation Therapy (if patient had prior CNS disease), TBI, Fludarabine, Thiotepa, Stem Cell Transplant, Cyclophosphamide, Mesna, Tacrolimus, MMF"
1624866|NCT02049801|Drug|idarubicin|Given IV
1624424|NCT02053532|Procedure|Positron emission tomography/magnetic resonance imaging|Positron emission tomography/magnetic resonance (PET/MR) imaging using 18-F-fluorodeoxyglucose (FDG) as radio tracer
1624425|NCT02053519|Drug|Active Comparator: Vigantol Oil (Vitamin D3)|Vitamin D Oral oil 100.000iu in 5 mls
1624426|NCT02053519|Drug|Mygliol Oil|Matched placebo comparator
1624427|NCT02053506|Dietary Supplement|Immune-enhancing nutritional beverage|Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.
1624428|NCT02053506|Dietary Supplement|Probiotics (BB-12)|Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.
1624429|NCT02053506|Dietary Supplement|Placebo (for nutritional beverage and probiotic)|Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
1624430|NCT02053493|Drug|Isosorbide Mononitrate|"Dispense phase 1 study drug:
Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg ISMN Week 4: 60 mg ISMN Weeks 5 and 6: 120 mg ISMN
Dispense phase-2 study drug:
Weeks 7 and 8: No study drug (washout) Week 9: 30 mg ISMN Week 10: 60 mg ISMN Weeks 11 and 12: 120 mg ISMN"
1624431|NCT02053493|Drug|Placebo|"Dispense phase 1 study drug:
Weeks 1 and 2: No study drug (baseline) Week 3: 30 mg Placebo Week 4: 60 mg Placebo Weeks 5 and 6: 120 mg Placebo
Dispense phase-2 study drug:
Weeks 7 and 8: No study drug (washout) Week 9: 30 mg Placebo Week 10: 60 mg Placebo Weeks 11 and 12: 120 mg Placebo"
1624432|NCT02053467|Other|Champlain BASE eConsult Service|Building on a recent successful pilot project, and using a pre-existing secure web-based collaboration space, primary care providers will submit a patient-specific clinical question to a specialist using a standardized electronic form that permits attachments (e.g., laboratory results, digital images). The specialist responds within one week by either: i) directly answering the question (negating the need for referral), ii) asking for additional patient information, or iii) requesting an in-person referral.
1624433|NCT02053454|Drug|patisiran (ALN-TTR02)|Ascending doses administered by intravenous (IV) infusion
1624434|NCT02053454|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
1624435|NCT02053428|Procedure|percutaneous image-guided gastrostomy|
1624436|NCT02053415|Dietary Supplement|Krill oil low dose|3 capsules krill oil per day
1624437|NCT02053415|Dietary Supplement|Krill oil high dose|9 capsules krill oil per day
1624438|NCT02053402|Drug|Vitamin D|Vitamin D daily for six months
1624439|NCT02053389|Behavioral|DVD Decision Aid|"The decision aid, Discussing the Choice: Talking with your Doctor about Early Stage Prostate Cancer is a DVD modeling patient communication strategies. The DVD includes vignettes with actors depicting patient-physician discussions of prostate cancer treatments. In these vignettes, the patient models communication strategies designed to facilitate patient activation."
1624440|NCT02053389|Behavioral|Written decision aid|"A written decision aid entitled Making the Choice: Deciding What to Do About Early Stage Prostate Cancer that describes treatment options for early stage prostate cancer."
1624441|NCT02053376|Drug|Regorafenib|regorafenib (120 mg) orally once daily 21 days (3 weeks) on and 7 days (1 week) off in the 28-day (4-week) cycle.
1624442|NCT02053363|Drug|Tranexamic Acid (Cyklokapron)|
1624443|NCT02053350|Drug|Alanyl-glutamine|Alanyl-glutamine, 44g, taken by mouth daily for 10 days
1624444|NCT02053337|Device|Self adhesive foam dressing|Self adhesive foam dressing
1624445|NCT02053324|Combination Product|AvidinOX/ST2210|One intralesion injection of AvidinOX followed by an intravenous infusion of ST2210
1624446|NCT02053311|Drug|Orteronel|300mg orteronel
1624447|NCT02053311|Drug|Placebo|Placebo
1624448|NCT02053298|Drug|Timolol & Dorzolamide|Topical preservative-free fixed combination of timolol 0.5%+dorzolamide 2% to be applied bid for 1 month
1624449|NCT02053272|Drug|GWP42004|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
1624450|NCT02053272|Drug|Placebo|The total dose administered within any 24-hour interval will be two capsules (typically 12 hours apart).
1624451|NCT02053259|Behavioral|Adaptive Goals|
1624452|NCT02053259|Behavioral|Reinforcement|
1624453|NCT02053259|Behavioral|Static Goals|
1624454|NCT02053246|Drug|Nebivolol|Nebivolol will be started at 2.5 mg by mouth daily if on a beta-blocker the dose will start at 5mg, and titrated up to 10 mg daily, as tolerated.
2011192|NCT02671929|Behavioral|self-help program|Access to the internet-based self-help program
2011193|NCT02671929|Behavioral|therapeutic feedback|Therapeutic feedback on the written information sent to the online therapist
1624457|NCT02053220|Biological|Colo-Ad1|Oncolytic virus
1624458|NCT02053207|Behavioral|Cog-Train Intervention|Twenty-one days prior to surgery, patients will begin self-administering the intervention using an iPad tablet. This intervention will consist with daily sessions of at least 20 minutes of the Cog-Train task (the task and regimen used to obtain robust effects in previous studies by members of our group). Cog-Train is an n-back task - an adaptive working memory computer game that extends players' working memory capacity by getting progressively more difficult as the player's performance increases.
1624459|NCT02053194|Behavioral|Pharmacist-led educational intervention|1) Educational material to participants in the form of a written educational brochure on inappropriate prescriptions that was developed and tested during the EMPOWER study. 2) Evidence-based pharmaceutical opinions sent to the treating physicians.
1624514|NCT02052726|Biological|placebo|Placebo administered at Day 1, 8, and 30.
1624867|NCT02049801|Drug|cytarabine|Given IV
2011194|NCT02670447|Procedure|MRI|Magnetic Resonance Imagery will be performed on patients attempted by schizophrenia. The aim of this intervention is an early detection of the non-answering patients to the primary cares.
2011195|NCT02668250|Procedure|OPTI-AGED|OPTI-AGED is composed of a multi-parametric optimization strategy.
2011196|NCT02668250|Procedure|Usual Care|Patients receive the usual care.
2011197|NCT02668783|Drug|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 or 6 cycles of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
1624460|NCT02053181|Drug|Cadazolid|Cadazolid was provided as dry powder for oral suspension (Amber glass bottles of 60 mL). The powder was reconstituted with tap water by a pharmacist immediately prior to dispensing to subjects.
1624461|NCT02053168|Device|Resorbable Mesh|Phasix Mesh
1624462|NCT02053155|Behavioral|Computer based patient education|
1624463|NCT02053142|Drug|Acyclovir|Single dose of acyclovir 200mg was given for pk study
1624464|NCT02053142|Drug|Placebo|
1624465|NCT02053129|Other|TB screening Questionnaire|All subjects will be screened with the questionnaire which assesses TB symptoms.
1624466|NCT02053129|Other|Sputum smear and culture (only in HIV negative women who are symptomatic)|specimens for sputum microscopy and culture collected and processed in accordance with WHO TB Infection Control Guidelines
1624467|NCT02053116|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
1624468|NCT02053116|Drug|Placebo|Tablet, 0 mg, twice daily, 2 weeks
1624469|NCT02053103|Drug|PF-05175157|Tablet, 200 mg, twice daily, 6 weeks
1624470|NCT02053103|Drug|Placebo|Tablet, 0 mg, twice daily, 6 weeks
1624471|NCT02053090|Behavioral|Group Education and Stretching|
1624472|NCT02053090|Procedure|Group Acupuncture|
1624473|NCT02053064|Genetic|SAF-301|
1624474|NCT02053051|Device|ABC4D|Advanced Bolus Calculator for Type 1 Diabetes (ABC4D) to calculate pre-meal insulin boluses
1624475|NCT02053051|Drug|Novorapid|Multiple daily injections(MDI) of insulin
1624476|NCT02053038|Device|iFR|Treatment guided by instantaneous wave-free ratio
1624477|NCT02053038|Device|FFR|Treatment guided by Fractional Flow Reserve
1624478|NCT02053025|Dietary Supplement|mycoprotein|
1624479|NCT02053025|Dietary Supplement|control protein|
1624480|NCT02053012|Device|PVT-192|PVT-192 Psychomotor Vigilance Task Monitor is a hand-held, self-contained system used for repetitive reaction time measurement.
1624481|NCT02052999|Drug|PAC-14028 cream 1%|Participants received topical PAC-14028 cream 1% twice daily for 8 weeks
1624482|NCT02052999|Other|Vehicle|Participants received topical Vehicle twice daily for 8 weeks
1624483|NCT02052999|Drug|Rozex gel 0.75%|Participants received topical Rozex gel 0.75% twice daily for 8 weeks
1624484|NCT02052986|Other|VASCAZEN|All enrolled subjects will receive 4 capsules daily of VASCAZEN which delivers 3.0 grams of EPA and DHA
1624485|NCT02052973|Other|Propolis varnish|Saliva and oral biofilm will be collected before and in regular times after the application of the propolis varnish. This data will be compared in order to evaluate the probable reduction of Streptococcus mutans in saliva and oral biofilm.
1624486|NCT02052960|Drug|Tomuzotuximab|720 mg i.v. weekly
1624487|NCT02052960|Drug|Cetuximab|250 mg/sqm BSA i.v. weekly
1624488|NCT02052960|Drug|Chemotherapy|Combination of Cisplatin and 5-Fluorouracil (Carboplatin may substitute Cisplatin following the 1st cycle of therapy in case of toxicity)
1624489|NCT02052947|Radiation|SPECT-DaTscan|"Measurement of fixation of DaTscan® in the caudate and lenticular nucleus
LP (Lumbar Puncture): the LP will follow the last guidelines published in 2011 (Armand Perret-Liaudet is co-author of these guidelines; Perret-Liaudet A. et al, Cerebrospinal Fluid Collection Tubes: a critical issue for Alzheimer Disease diagnosis. Clin Chem, 2012, accepted)."
1624490|NCT02052934|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral entertoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5 cohorts receive 3 doses ranging from 1 mcg to 50 mcg.
1624491|NCT02052934|Biological|Recombinant Double Mutant Heat-Labile Toxin LT(R192G/L211A) (dmLT) Oral entertoxigenic Escherichia coli (ETEC) Vaccine|Attenuated, Recombinant Double Mutant Heat-Labile Toxin (dmLT) from Enterotoxigenic Escherichia coli (ETEC), LT(R192G/L211A); lot 1575. Subjects in 5b cohort receive 3 doses of 25 mcg.
1624492|NCT02052921|Procedure|Rectal resection|Surgical rectal resection
1624493|NCT02052921|Other|Observation|
1624494|NCT02052908|Other|Laboratory Biomarker Analysis|Correlative studies
1624495|NCT02052908|Drug|Naproxen|Given PO
1624496|NCT02052908|Other|Placebo|Given PO
1624497|NCT02052882|Biological|romiplostim|
1624498|NCT02052869|Procedure|esophagus intubation|In these patients, automatic pressure waveform analysis is performed during the first three test ventilations on both the tracheal and oesophageal tube. ventilations will be performed by a blinded person. Subsequently, three conventional thoracic pushes will be performed.
1624499|NCT02052843|Behavioral|Steps to Success|
1624500|NCT02052843|Behavioral|Traditional Healthy Families|
1624501|NCT02052830|Behavioral|Wise Guys|Multi-session curriculum delivered in different formats that range in length from 5 to 12 weeks and topics covered include communication and masculinity, dating violence, abstinence and contraception, and sexually transmitted infections.
1624502|NCT02052817|Device|Optimal Medical Therapy Debridement + Toad Brace|
1624503|NCT02052817|Other|Optimal Medical Therapy - Debridement|
1624504|NCT02052791|Drug|nusinersen|Administered by intrathecal (IT) injection
1624505|NCT02052778|Drug|TAS-120|
1624506|NCT02052765|Device|ECG continuous recording (Analyze ST)|During the ajmaline test, continuous ECG recording was forced to record ST shift
1624507|NCT02052752|Drug|3% Benzoyl Peroxide|Test product contained 3% benzoyl peroxide in the form of a gel. It was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
1624508|NCT02052752|Drug|3% Benzoyl Peroxide Placebo|The vehicle gel was similar to the test product except that it did not contain 3% benzoyl peroxide. The vehicle gel served as the negative control and was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
1624509|NCT02052752|Drug|Neutrogena Rapid Clear®|A commercial product containing 2% salicylic acid that reportedly improves acne lesions was applied on participant's face once-daily at approximately the same time on Days 0, 1, 2 and 3.
1624510|NCT02052739|Drug|SAGE-547|Intravenous
1624511|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at Month 0, 1, and 3.
1624512|NCT02052726|Biological|Placebo|Placebo administered at Month 0, 1, and 3.
1624513|NCT02052726|Biological|C. difficile vaccine with adjuvant|C. difficile vaccine with adjuvant administered at day 1, 8, 30.
1624515|NCT02052713|Drug|Commercially available combination of dutasteride 0.5 mg and tamsulosin HCL 0.4 mg|Commercially available, orange and brown, hard shell capsule, administered orally as a single dose on Day 1 under fasted condition.
1624516|NCT02052713|Drug|Second generation dutasteride 0.5 mg and tamsulosin HCL 0.4 mg combination capsule|Orange and brown, hard shell capsule, administered orally, as a single-dose on Day 1 under fasted condition.
1624517|NCT02052687|Drug|LFX453 H1|LFX453 high dose cream 1
1624518|NCT02052687|Drug|LFX453 L1|LFX453 low dose cream 1
1624519|NCT02052687|Drug|LFX453 H2|LFX453 high dose cream 2
1624520|NCT02052687|Drug|LFX453 L2|LFX453 low dose cream 2
1624521|NCT02052687|Drug|Imiquimod|Imiquimod cream
1624522|NCT02052687|Drug|Placebo 1|Placebo cream 1
1624523|NCT02052687|Drug|Placebo 2|Placebo cream 2
1624524|NCT02052674|Device|Vented urinary drainage system|This group will be catheterized with a vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
1624525|NCT02052674|Device|Non-vented urinary drainage system|This group will be catheterized with a non-vented urinary drainage system. Several data sets will be evaluated to compare the two arms of the study: retained urine volume, the difference (ΔH) in meniscus heights in the dependent loops, time necessary for drainage of dependent loops, and incidence of bacteriuria.
1624526|NCT02052661|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in deltoid region of non-dominant arm.
1624527|NCT02052648|Drug|Indoximod|
1624528|NCT02052648|Drug|Temozolomide|
1624529|NCT02052648|Drug|Bevacizumab|
1624530|NCT02052648|Radiation|Stereotactic Radiation|
1624531|NCT02052635|Drug|ticagrelor|Single loading dose of 180mg of ticagrelor at time of bivalirudin administration. Beginning 12 hrs following study drug administration, all pts in the ticagrelor arm will receive ticagrelor 90 mg (maintenance dose) approximately every 12 hrs until Follow-up telephone contact.
1624532|NCT02052635|Drug|clopidogrel|Single loading oral dose of 600 mg of clopidogrel will be given at time of bivalirudin administration. Beginning 4 hrs following study drug administration, all pts in the clopidorgrel arm will receive ticagrelor 180 mg for the loading dose, followed by 90 mg maintenance dose approximately every 12 hours until the Follow-up telephone contact.
1624533|NCT02052622|Procedure|Examinations and surveys|Clinical evaluation, measurement of fat deposit beneath the chin by skinfold caliper, patient-reported outcome questionnaires, photographs, recording of adverse events
1624534|NCT02052609|Drug|KHK4827 140mg SC|Experimental1:KHK4827 140mg subcutaneous injection
1624535|NCT02052609|Drug|KHK4827 210mg SC|Experimental2:KHK4827 210mg subcutaneous injection
2011198|NCT02668783|Drug|Placebo vaginal ring|Up to 4 or 6 cycles of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
2011199|NCT02668783|Drug|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping.
1624538|NCT02052583|Procedure|therapeutic hypothermia at 32 ° C|
1624539|NCT02052583|Procedure|therapeutic hypothermia at 34 ° C|
1624540|NCT02052557|Drug|Bupivacaine|30ml of bupivacaine were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
1624541|NCT02052557|Drug|Bupivacaine liposome suspension|30ml of Bupivacaine liposome injectable suspension were injecting into the subcutaneous tissue at the incision sites after surgery in the OR
1624542|NCT02052531|Drug|PAC-14028|Participants received topical PAC-14028 cream 0.3 or 1% twice daily for 4 weeks
1624543|NCT02052531|Other|Vehicle|Participants received topical Vehicle twice daily for 4 weeks
1624544|NCT02052518|Behavioral|Experimental|These participants will receive the enhanced intervention including decision support and problem solving skills in addition to the standard of care for the individuals in the Nuturing Family Network Home Visition Program
1624545|NCT02052505|Procedure|Medication review|The medication review will be based on the nurses experience, clinical knowledge and predefined categories of inappropriate prescribing
1624546|NCT02052492|Drug|EF-022 (Modified Vitamin D Binding Protein Macrophage Activator)|
1624547|NCT02052479|Other|Frequently Sampled Intravenous Glucose Tolerance Test (FSIVGTT)|
1624548|NCT02052440|Drug|Baclofen|Treatment arm: baclofen 10mg tid
1624549|NCT02052440|Drug|Placebo|Sugar pill by mouth three times daily
1624550|NCT02052427|Device|Celution System|ADRCs processed by the Celution System for reintroduction into the myocardium
1624551|NCT02052427|Device|Placebo|Physiological solution made of Lactated Ringers solution and a small amount (<1mL) of autologous blood
1624552|NCT02052414|Drug|Gabapentin ER|"Patient who are on gralise will report efficacy by rating his or her pain rating on a digital pain scale (11 points) from 0 to 10 on each scheduled clinical visits, which will be compared to their pain level at baseline.
In addition, patients will also record the doses and any adverse effects that might arise during the trial in a diary provided by the study. All information will be recorded in a paper diary that will be followed by coordinator during each follow up visits."
1624553|NCT02052401|Other|Domiciliary Intervention|Two time domiciliary application of an standardized protocol consisting of: a) evaluation of pharmacological and non pharmacological therapies adherence. b) application of a Checklist of home safety measures. c) development of a patient oriented occupational routine d) education in strategies for elderly global stimulation e) education strategies for identifying red flags and for correct use of health services.
1624554|NCT02052388|Drug|Daptomycin|Active Comparator
1624555|NCT02052388|Drug|Brilacidin|Experimental Drug
1624556|NCT02052375|Drug|ASP2408|subcutaneous injection
1624557|NCT02052375|Drug|Placebo|subcutaneous injection
1624558|NCT02052362|Drug|ABT-450/r/ABT-267|ABT-450, ABT-267 and ritonavir
1624559|NCT02052349|Drug|ABT-333|Dose of ABT-333
1624560|NCT02052336|Drug|CJ-12420 200mg + Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
1624597|NCT02052024|Drug|MYOBLOC|Treatment group will receive 5,000 units of MYOBLOC and subjects will receive 1-3 injections per muscle at each visit.
1624561|NCT02052336|Drug|CJ-12420 200mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
1624562|NCT02052336|Drug|Clarithromycin 500mg|To assess the effect of the coadministration of multiple dose of CJ-12420 and clarithromycin on the pharmacokinetics (PK) of CJ-12420 or clarithromycin.
1624563|NCT02052323|Drug|Artesunate/mefloquine (AS/MQ)|"artesunate (AS) 4mg/kg by mouth once daily at 0, 24 and 48 hours
mefloquine (MQ) 15mg/kg by mouth once at 72 hours, and 10mg/kg once by mouth at 84-96 hours
primaquine (PQ) 0.5mg/kg single dose by mouth at 84-96 hours"
1624564|NCT02052310|Drug|FG-4592 (roxadustat)|Drug will be dosed orally three times a week.
1624565|NCT02052310|Drug|Epoetin Alfa|The drug will be dispensed per the package insert or the country-specific product labeling.
1624566|NCT02052297|Other|GSK2634673F|GSK2634673F is a synthetic peptide derived from the foot and mouth disease virus (FMDV2). GSK2634673F will be injected into a cubital or forearm vein intravenously and emission data acquired for up to 240 minutes. This radioactive ligand binds potently and specifically to the integrin alpha(V)beta6.
1624567|NCT02052284|Other|Sterile water application|Nurses are trained in proper dispensing and application of water in a sterile gentle way that will minimize shear force on the skin, risk for skin injury, and the potential for spread of fecal flora.
1624568|NCT02052271|Device|Cathodal cerebellar transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation cerebellum;
1624569|NCT02052258|Drug|Oxytocin|
1624570|NCT02052232|Other|Experimental protein powder sachet|mixed with 8 oz. water
1624571|NCT02052232|Other|Control protein powder sachet|mixed with 8 oz. water
1624572|NCT02052219|Drug|Blisibimod|Blisibimod administered subcutaneously
1624573|NCT02052219|Drug|Placebo|Placebo administered subcutaneously
1624574|NCT02052206|Procedure|Shoulder replacement surgery|
1624575|NCT02052193|Drug|Dabrafenib|Measurement of toxicity related to UV exposure
1624576|NCT02052193|Drug|Vemurafenib|Measurement of toxicity related to UV exposure
1624577|NCT02052180|Drug|Exparel|EXPAREL arm: one vial (266 mg/20 mL) of EXPAREL (Bupivicaine Extended-Release Liposome, 13.3mg/ml), undiluted, will be administered for each of the specified procedures.
1624578|NCT02052180|Drug|Marcaine (Control)|15 cc of Marcaine 0.5% (Bupivacaine 0.5%, 5mg/ml) will be administered into the wrist per the Surgeon's Standard practice.
1624579|NCT02052167|Drug|methotrexate prefilled pen|
1624580|NCT02052154|Biological|Prime-boost pneumococcal immunization|2 months between the 2 vaccines
1624581|NCT02052141|Biological|CINRYZE 500|500 Units of CINRYZE administered by IV injection
1624582|NCT02052141|Biological|CINRYZE 1000|1000 Units of CINRYZE administered by IV injection
1624583|NCT02052128|Drug|onapristone|
1624584|NCT02052115|Behavioral|12 month exercise and weight loss intervention|
1624585|NCT02052102|Radiation|Radiation therapy|
1624586|NCT02052089|Procedure|physiotherapy|Physiotherapy is the treatment of a wide range of conditions and injuries to the body through the use of various forms of passive mobilisation, massage, electrotherapy and exercises.
1624587|NCT02052089|Procedure|extracorporeal shockwave therapy|Extracorporeal shockwave therapy (ESWT) is noninvasive procedure, and has been shown to be effective in the treatment of chronic tendon pathology in the elbow, shoulder and plantar fascia. Shock wave therapy is traditionally categorized as either low energy (<0.2 mJ/mm2) or high energy (>0.2 mJ/mm2). Rompe, et al have hypothesized that there is an overstimulation of nerve fibers, resulting in an immediate analgesic effect (hyperstimulation analgesia). Physical effects on cell permeability and induction of diffusible radicals have also been postulated to cause disruption of the tendon tissue, resulting in induction of a healing process.
1624588|NCT02052089|Procedure|prolotherapy|Prolotherapy has been defined as the iatrogenic stimulation of wound healing and tissue repair through the injection of an irritant solution into damaged ligaments and tendons. Prolotherapy solutions are purported to initiate an inflammatory cascade at the site of injection, which induces fibroblast proliferation and subsequent collagen synthesis, resulting in a tighter and stronger ligament or tendon. The primary mechanism of action of prolotherapy is to induce a small inflammatory response to promote adequate healing or more viable scar tissue formation that results in stronger fibrous tissue at the lateral epicondyle, which leads to improved function and reduced pain.
1624589|NCT02052089|Procedure|platelet-rich plasma|Platelet-rich plasma (PRP) is defined as an autologous concentration of human platelets in a small volume of plasma which is mechanically treated to increase the concentration of platelets compared to whole blood. The supraphysiological concentration of platelets will provide a locally increased concentration of growth factors and cytokines that are contained within the platelets themselves.Based on these concepts, it is believed that PRP can augment or stimulate healing with the same biologic healing process that normally occurs in the human body after injury.
1624590|NCT02052076|Behavioral|Meal pattern|
1624591|NCT02052063|Device|stapled transanal rectal resection|transanal rectal resection using staple will be done for rectocele
1624592|NCT02052063|Device|Anal compliance measure with Endoflip system|Anal compliance will be measured using Endoflip system
1624593|NCT02052050|Other|core stability|
1624594|NCT02052037|Dietary Supplement|Egg inclusion|Participants will meet with a registered dietitian and receive instructions for including 2 eggs per day (10 to 14 eggs/week)in their meal plan, while preserving an isocaloric condition relative to the egg exclusion phase. The study dietitian will provide individualized guidance to participants on how to make room for eggs in their diet, while giving them latitude in determining how to adjust for the extra calories from the eggs, to better approximate real-world conditions. Treatment phase will last for 12 weeks.
1624595|NCT02052037|Dietary Supplement|Egg exclusion|"Participants will meet with the dietitian and receive relevant meal planning guidance and instructions to avoid eggs and specific egg-containing products.
During both intervention phases, study participants will be advised to eat to their usual state of fullness, and dietary monitoring and weighing will be conducted to ensure that an isocaloric condition is maintained. Treatment phase will last for 12 weeks."
1624596|NCT02052024|Drug|Botox|Treatment group will receive 100 units of BOTOX and subjects will receive 1-3 injections per muscle at each visit.
1624640|NCT02051712|Behavioral|Adherence measures|Measures to increase adherence to exercise training
1624598|NCT02052011|Drug|Ranolazine|Subjects will take the extended-release Ranolazine for a total of 4 weeks. Subjects will take 500 mg twice daily for the first week and then 1000 mg twice daily for remaining period (Dosing will be adjusted with concomitant use of diltiazem, verapamil, erythromycin, simvastatin or metformin).
1624599|NCT02052011|Drug|Placebo|
1624600|NCT02051985|Other|Aerobic exercise training|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).
Days 3-4: as days 1-2 + unloaded bedside cycle ergometer (3 sessions/day, each 5-6 minutes duration).
Days 5-6: as days 1-2 + bedside cycle ergometer at 10 W (3 sessions/day, each 15-20 minutes duration).
Days 7-12: as days 1-2 + bedside cycle ergometer at 10-20 W (3 sessions/day, each 15-20 minutes duration).
In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
1624601|NCT02051985|Other|Standard physical therapy|"Days 1-2: active assisted mobilization (2 sessions/day, each 30 minutes duration).
Days 3-12: active assisted mobilization (1 session/day, 30 minutes duration).
In addition, when possible according to their clinical conditions, patients will undergo one assisted ambulation session of 15-20 minutes per day."
2011200|NCT02666872|Behavioral|Motivational interviewing|
1624603|NCT02051959|Device|Anodal stimulation of M1 + sham|8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area) followed by 8 sham treatments.
1624604|NCT02051959|Device|Sham + Anodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA anodal stimulation of M1 for 20 minutes (over the relevant cortex area).
1624605|NCT02051959|Device|Cathodal stimulation of M1 + sham|8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area) , followed by 8 sham treatments.
1624606|NCT02051959|Device|Sham + Cathodal stimulation of M1|8 sham treatments followed by 8 active treatmments: 2mA cathodal stimulation of M1 for 20 minutes (over the relevant cortex area).
1624607|NCT02051946|Device|Retroject Device|
1624608|NCT02051946|Drug|ethacrynic acid injection|
1624609|NCT02051946|Drug|balanced salt solution|
2011201|NCT02664753|Drug|56 days of weight-adjusted L-Carnitine treatment|"Patients in the experimental arm will receive 10 days of intravenous L-carnitine treatment followed by 46 days of oral L-Carnitine treatment.
Day 1: a first bolus of 6g of L-Carnitine is administered in a 50 ml isotonic saline mini-perfusion bag.
Day 2 to Day 10: Two mini-perfusions are prepared each day, corresponding to 1 administration every 12 hours. 50 mg/kg/day (rounded up to the next gram) L-Carnitine is added to each mini-perfusion For the next 46 days, patients will take oral doses of L-Carnitine at 50mg/kg/day (rounded up to the next gram)"
2011202|NCT02664753|Drug|10 days of intravenous placebo (isotonic saline)|"Patients in the placebo arm will receive 10 days of intravenous isotonic saline in a fashion analogous to the experimental arm (they study is thus blinded for the first 10 days and then open there afterwards).
Day 1: 1 50ml isotonic saline mini-perfusion bag + an additional 30 ml of saline solution.
Day 2 to Day 10 : Two mini-perfusions are prepared each day, one during the morning and one during the evening. Saline solution is added to each mini-perfusion."
1624612|NCT02051907|Device|KAM1403 Gel|
1624613|NCT02051907|Device|aloevera gel|
1624614|NCT02051894|Drug|Dobutamine|"Infants will receive treatment according to the preference of the responsible physician. As is common practice, dobutamine, dopamine and/or other treatments (including other cardiovascular drugs and/or volume replacement therapy with normal saline) will be administered.
If dobutamine is used we will take a maximum of two blood samples from the baby for pharmacokinetic analysis."
1624615|NCT02051881|Other|Taking intestinal biopsies|
1624616|NCT02051868|Drug|Cisplatin|Cisplatin 60 mg/m2 as a 1 hour i.v. infusion once every 3 weeks.
1624617|NCT02051868|Drug|5-Fluorouracil (5-FU)|5-FU 1000 mg/m2/24h as a 96-hour continuous infusion over days 1 to 4 every 3 weeks.
1624618|NCT02051868|Drug|Carboplatin|Carboplatin 1-hour i.v. infusion to an area under the curve (AUC) of 5 once every 4 weeks.
1624619|NCT02051868|Drug|Paclitaxel|Paclitaxel 80 mg/m2 as a 1-hour i.v. infusion on day 1,8 and 15 of each (4-weekly) cycle.
1624620|NCT02051842|Drug|Metadoxine|
1624621|NCT02051829|Other|Comparison of the four screening score|Comparison of the four screening score, for patient making a preoperative assessment for SLBO (clinique Saint-Luc de BOuge)
1624622|NCT02051816|Device|Video Laryngoscopy|
1624623|NCT02051816|Device|Apneic Oxygenation|
1624624|NCT02051816|Device|Direct Laryngoscopy|
1624625|NCT02051816|Device|No Apneic Oxygenation|
1624626|NCT02051803|Behavioral|Distress Tolerance Treatment for Weight Concern (DT-W)|
1624627|NCT02051803|Behavioral|Health Education (HE)|
1624628|NCT02051790|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in the course of clinical practice.
1624629|NCT02051777|Dietary Supplement|Oral Nutritional Supplement 1|Containing macro and micronutrients
1624630|NCT02051777|Dietary Supplement|Oral Nutritional Supplement 2|Containing macro and micronutrients
1624631|NCT02051777|Dietary Supplement|Dietary Advice|
1624632|NCT02051764|Drug|18F-AV-1451|
1624633|NCT02051764|Drug|Florbetapir F 18|
1624634|NCT02051751|Drug|BYL719|BYL719 will be administered orally once daily on a continuous dosing schedule and dosed on a flat-fixed dose and not adjusted by body weight or body surface area, starting on Day 2 in the dose escalation part and Day 1 in the dose expansion part. In the dose escalation part, the BYL719 starting dose will be 300mg, with anticipated dose escalation to 350mg. In the dose expansion part, BYL719 will be administered at the recommended dose determined in the dose escalation part.
1624635|NCT02051751|Drug|Paclitaxel|Paclitaxel will be administered once weekly at a dose of 80 mg/m2 i.v. (days 1, 8, 15 and 22) in a 28 day cycle in both dose escalation and expansion.
1624636|NCT02051738|Drug|Mebendazole - fasted state (Treatment A)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fasted condition.
1624637|NCT02051738|Drug|Mebendazole - fed state (Treatment B)|Participants will receive a single 500 mg dose of mebendazole fast-disintegrating chewable tablet in the fed condition.
1624638|NCT02051725|Other|Active life-style intervention|
1624639|NCT02051712|Behavioral|exercise training|individualized exercise training
1624641|NCT02051699|Procedure|radiographic of standing knee|the patients stand on their one leg with pillar support and both-leg then shoot the x-ray beam to their knee
1624642|NCT02051686|Drug|Tranexamic Acid|10 mg/kg TXA loading dose approximately 15 minutes before surgical start time and then 1 mg/kg/h TXA infusion over 10 hours.
1624643|NCT02051686|Drug|Placebo|The control group will receive a similar volume load of normal saline and maintenance doses.
1624644|NCT02051673|Biological|Biological/Vaccine: Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
1624645|NCT02051660|Behavioral|Manualized CALM intervention|Managing Cancer and Living Meaning Cancer (CALM) is a short-term individual psychotherapy for patients with advanced disease.
1624646|NCT02051660|Behavioral|Non-manualized supportive intervention.|Supportive psycho-oncological intervention.
1624647|NCT02051634|Drug|Fermented Papaya Preparation (FPP)|A total of 9 grams of FPP per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing FPP per day - once 30-40 min before breakfast, once 30-40 min before lunch, and once 30-40 min before dinner. Participants will open the sachet, slowly empty contents into their mouth, and let it dissolve before swallowing.
1624648|NCT02051634|Drug|Sugar Pill|A total of 9 grams of placebo (sugar) per day (divided into three 3 gram doses) will be consumed for 8 weeks. Participants will consume three 3g sachets containing placebo per day - once with breakfast, once with lunch, and once with dinner. Participants will open the sachet, empty contents into their mouth, and let it dissolve before swallowing.
1624649|NCT02051621|Drug|Antiarrhythmic drug|medical treatment of atrial flutter with either flecainide (Tambocor ®) 100 mg twice daily, propafenone (Rytmonorm ®) up to 150 mg 3 times daily) or amiodarone (Cordarex®) 200 mg daily electrical cardioversion as needed
1624650|NCT02051621|Procedure|Cavo-tricuspid-isthmus-ablation|irrigated radiofrequency (RF)-ablation of the cavo-tricuspid-isthmus catheter used: Thermocool R (F-type), Biosense Webster, Diamond Bar, CA, USA
1624651|NCT02051621|Procedure|Pulmonary vein isolation|pulmonary vein angiography followed by antral pulmonary vein isolation using 3D-electroanatomical Mapping mapping system: Carto 3 (Biosense Webster, Diamond Bar, CA, USA) catheter used for irrigated RF-ablation: Navistar Thermocool R (D, E or F-type according to atrial dimensions), Biosense Webster, Diamond Bar, CA, USA
1624652|NCT02051608|Drug|Florbetapir|IV injection of florbetapir [Amyvid] up to 370 mega Becquerel (MBq) (10 millicurie [mCi]) of florbetapir and imaging for up to 15 minutes per PET scan conducted at screening and on 3 subsequent time points per protocol
1624653|NCT02051608|Drug|Gantenerumab|Participants will receive gantenerumab as SC injection q4w up to Week 100
1624654|NCT02051608|Drug|Placebo|Participants will receive placebo as SC injection q4w up to Week 100q4w
1624655|NCT02051595|Other|Vancomycin concentrations|Up to ten blood samples testing for vancomycin concentrations will be collected in subjects administered vancomycin as prophylaxis before cardiac surgery with cardiopulmonary bypass and modified ultrafiltration.
1624656|NCT02051582|Procedure|Surgeons using fluoroscopy with laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped with a laser pointer.
A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.
Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
1624657|NCT02051582|Procedure|Surgeons using fluoroscopy without laser pointer|"Surgeons will attempt to obtain a perfect anterior-posterior (AP) and axillary views of a cadaver wrist using a mini-fluoroscopy unit equipped without a laser pointer.
A perfect view is considered the ability to obtain perfect circle views through a cannulated mini acutrak screw that will have been placed into the cadaver prior to data collection.
Surgeons will also be asked to wear three dosimeter badges: one on the collar, one on the waist, and a ring badge under a pair of regular sterile surgical gloves."
1624658|NCT02051569|Dietary Supplement|Tryptophan|Tryptophan and placebo are given in a crossover design, based on randomisation.
2011203|NCT02664220|Drug|Povidone-iodine irrigation|"Povidone-iodine (PVI) is an antiseptic solution consisting of polyvinylpyrrolidone with water, iodide, and 1% available iodine. It has bactericidal ability against a large array of pathogens, including those pathogens which commonly cause postoperative IAA in children with perforated appendicitis.
1% PVI will be used. Once the appendix has been removed and hemostasis ensured, the surgeon will perform the irrigation with 10cc/kg (minimum 100ml and maximum 1000ml) of 1% PVI. After completing the irrigation, the surgeon will suction out all intra-abdominal fluid into a suction canister."
2011204|NCT02664220|Procedure|No irrigation|Patients allocated to the control group will not undergo intra-abdominal irrigation.
2011205|NCT02664155|Drug|Apixaban|Direct Oral Anticoagulant
1624662|NCT02051543|Behavioral|Brief Behavioral Treatment of Insomnia -Military Version|
1624663|NCT02051530|Dietary Supplement|tryptophan depletion|tryptophan depletion involves the ingestion of an amino acid mixture that is devoid of tryptophan. on the other day participants receive placebo, being the same mixture but including tryptophan
1624664|NCT02051504|Behavioral|Incremental maximal exercise|The exercise test starts 2-4h after a standardised breakfast. After a 2-min resting period sitting on the cycle ergometer (Excalibur Sport, Lode B.V, Medical Technology, Groningen, Netherlands), the test starts at 30 watts with a 20 watts increment every 2min until exhaustion.
1624665|NCT02051504|Dietary Supplement|Oral Glucose Tolerance Test|The subjects arrive after an overnight fast and have a 75g Glucose Oral Charge.
1624666|NCT02051504|Procedure|Muscle biopsy|A sample of vastus lateralis (less than 150mg) is taken with a specific needle under local anesthesia.
1624667|NCT02051504|Procedure|Combined DLCO-DLNO|Lung carbon monoxide and nitric oxide diffusion capacities are assessed at rest in a sitting position.
1624668|NCT02051504|Procedure|Dual energy X-ray absorptiometry|Body composition is measured using dual energy X-ray absorptiometry at rest.
1624669|NCT02051504|Procedure|Accelerometry over one week|The subjects wear an uniaxial accelerometer over one week to assess their usual physical activity level
1624670|NCT02051504|Other|Questionnaires|Diet questionnaire, quality-of-life questionnaires, physical activity questionnaires
2011206|NCT02664155|Drug|Rivaroxaban|Direct Oral Anticoagulant
2011207|NCT02664155|Drug|Heparin|Standard Of Care
2011208|NCT02664155|Drug|VKA|Standard Of Care
1624671|NCT02051491|Device|BP-NCPAP|Initial settings of BP-NCPAP will be a lower level PEEP of 5 cm H2O and a higher level PEEP of 8 cm H2O at a cycle rate of 20 per minute with 1 second at the higher PEEP per cycle. The settings can then be adjusted and titrated up to a maximum of 7 and 10 cm H2O for the lower and higher PEEPs respectively at a maximum rate of 30 cycles per second based on FiO2 requirements.
1624672|NCT02051491|Device|NIHFV|The initial settings will be a MAP of 8 cm H2O, frequency of 10 Hz, and amplitude of 20 cm H2O. The maximum allowable MAP will be 10 cm of H2O. The range of frequency allowed will be 6 - 14 Hz. Both frequency and amplitude will be adjusted to try and achieve palpable/visible chest movement and to achieve target CO2 levels for the particular patient.
1624673|NCT02051478|Other|Thoracic mobilization|Patients will receive 20 seconds bouts of grade III-IV of central posterior-anterior (PA) non-thrust mobilization from T3 to T6 spinous process as described by Maitland et al for an overall intervention time of approximately 2 minutes
1624674|NCT02051478|Other|Thoracic manipulation|A high-velocity, end range, anterior-posterior thrust applied through the elbows to the mid-thoracic spine will be applied
1624675|NCT02051465|Device|LumenR Retractor|Polyp removal using LumenR Retractor Modified overtube
1624676|NCT02051465|Device|Removal without overtube|Endoscopic removal of polyp without overtube
1624677|NCT02051452|Drug|Methylphenidate|
1624678|NCT02051452|Other|Saline|
1624679|NCT02051439|Procedure|Valsava|The patients were randomized to 2 groups. The first group performed conventional Valsava 3 times before balloon assisted Valsava 3 times. The second group performed balloon assisted Valsava 3 times before conventional Valsava 3 times for venous reflux examination by duplex scan.
1624680|NCT02051426|Other|D-serine|single P.O. administration of D-serine (2.1g)
1624681|NCT02051426|Other|Placebo|single P.O. administration of Placebo
1624682|NCT02051413|Drug|Venlafaxine extended release|antidepressant drug
1624683|NCT02051400|Device|the McGrath® MAC video laryngoscope|
1624684|NCT02051400|Device|the GlidesScope® Ranger video laryngoscope|
1624685|NCT02051400|Device|the Macintosh laryngoscope|
1624686|NCT02051387|Drug|Cannabidiol CR|
1624687|NCT02051387|Drug|Cannabidiol|
1624688|NCT02051387|Drug|Amisulpride|
1624689|NCT02051387|Drug|Olanzapine|
1624690|NCT02051387|Drug|Quetiapine|
1624691|NCT02051387|Drug|Risperidone|
1624692|NCT02051387|Drug|Placebo|
1624693|NCT02051374|Procedure|Decompression alone|
1624694|NCT02051374|Procedure|Decompression followed by fusion with instrumentation|
1624695|NCT02051348|Biological|Pylopass|Pylopass
1624696|NCT02051348|Biological|Placebo|Placebo
1624697|NCT02051335|Drug|Roflumilast|Roflumilast tablets
1624698|NCT02051335|Drug|Roflumilast placebo|Roflumilast placebo-matching tablets
1624699|NCT02051335|Drug|Donepezil|Donepezil overencapsulated tablets
1624700|NCT02051335|Drug|Donepezil placebo|Donepezil placebo-matching overencapsulated tablets
1624701|NCT02051335|Drug|Scopolamine|Scopolamine subcutaneous injection
1624702|NCT02051322|Device|Jet Nebulizer|
1624703|NCT02051322|Device|Trunk Mask Nebulizer|
1624704|NCT02051322|Device|Aerobika Nebulizer|
1624705|NCT02051309|Drug|Guanfacine|6mg/day ER with 3-week lead-in period. Maintained at steady state throughout 8 week treatment phase. After treatment phase, given taper supply of medication. Follow up at 1 month, 2 months and 6 months.
1624706|NCT02051309|Drug|Placebo|
1624709|NCT02051283|Other|RFA|RFA
1624710|NCT02051270|Other|Descriptive study|More than 65 years old elders
1624711|NCT02051257|Biological|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
1624712|NCT02051257|Biological|Autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes|Given IV
1624713|NCT02051257|Other|Laboratory Biomarker Analysis|Correlative studies
1624714|NCT02051231|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
1624715|NCT02051218|Drug|Denosumab (reduced dosing)|3x Denosumab 120mg (XGEVA®) sc. q4w followed by Denosumab 120mg (XGEVA®) sc. q12w
1624716|NCT02051218|Drug|Denosumab (standard dosing)|Denosumab 120mg (XGEVA®) sc. q4w
1624717|NCT02051192|Behavioral|Parent-Led Exposure Therapy|Therapists will work with families for 10 sessions, twice weekly. The first treatment session will be a 90 minute parent only psychoeducation and treatment preparation session. Each subsequent session will last up to 60 minutes and will consist of exposure therapy using developmentally appropriate modulated behavioral approaches such as Participant modeling (PM) and Reinforced practice (RP).
1624718|NCT02051192|Other|Treatment As Usual|Patients randomized to the TAU arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice. These participants may also elect to receive no treatment at all during the TAU period.
1624719|NCT02051153|Drug|Modafinil|Modafinil (2-[(Diphenylmethyl) sulfinyl]acetamide (Provigil, 1997)) is a novel drug which has a demonstrable efficacy in the treatment of daytime sleepiness associated with narcolepsy (Benerjee et al., 2004). Studies on healthy volunteers show that modafinil improves neuropsychological task performance in some healthy individuals (Turner et al., 2004; Baranski et al., 2004; MÜller et al., 2004; Randall et al., 2005) and in patients with neuropsychiatric disorders (Minzenberg & Carter, 2008).
1624720|NCT02051153|Drug|Placebo|
1624721|NCT02051140|Dietary Supplement|Freeze-dried Strawberry|12g freeze-dried strawberry (powder), twice daily with water, for 90 days
1624722|NCT02051140|Dietary Supplement|Strawberry Placebo|12g blue, strawberry-flavored powder, twice daily with water, for 90 days
1624723|NCT02051127|Other|Exercise|Physical training Duration: 45-60 minutes Frequency: 3 times per week Intensity: mean heart rate > 75% of maximum heart rate determined by exercise test before start of the intervention
1624724|NCT02051101|Other|Biopsy sample from Port Wine Stain Birthmark|Biopsy sample from Port Wine Stain Birthmark
1624943|NCT02049164|Drug|AR08|
1624725|NCT02051088|Procedure|Revascularization with drug-eluting technology|Endovascular intervention with the use of drug-eluting devices (drug-coated balloons and/or drug-eluting stents).
1624726|NCT02051088|Procedure|Revascularization without drug-eluting technology|Endovascular intervention without using drug-eluting balloons or stents
1624727|NCT02051088|Device|drug-coated balloons and/or drug-eluting stents|
1624728|NCT02051075|Biological|PXN sperm treatment|immotile sperm activation with PXN
1624729|NCT02051075|Biological|Sperm activation with PXN and oocyte activation|
1624730|NCT02051062|Biological|One 5 mL of blood will be collected.|The blood sample should be collected no later than 24 hours post BAT® administration. To ensure sufficient detectable circulating levels of BAT® for pharmacokinetic analysis the target window of time for collection should be between 6 and 24 hours post-BAT® administration.
1624731|NCT02051036|Procedure|Moxibustion|"In the moxibustion treatment group, 5 moxibustion points (bilateral SP6, LV3 and unilateral CV4) will be heated with indirect moxibustion (KangHwa, Korea).
The moxa pillars will be removed when the patient feel hotness and require to remove them.
The moxibustion will be conducted repeatedly unless patients feel the sense of heat up to seven times per session."
1624732|NCT02051023|Drug|FML 0.1% eyedrops|Ocular topical application of fluorometholone 0.1% 4 times a day during 22 days
1624733|NCT02051023|Drug|Liquifilm artificial tears eyedrops|Liquifilm instillation 4 times a day for 22 days
1624734|NCT02050971|Biological|Umbilical Cord Blood Infusion|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of autologous cord blood within the first 5 postnatal days.
1624735|NCT02050971|Biological|Intravenous Infusion of Peripheral Blood or its Components|Regular treatment of neonatal anemia with peripheral blood or its components transfusion.
1624736|NCT02050958|Drug|OXP001|
1624737|NCT02050958|Drug|Ibuprofen|
1624738|NCT02050945|Behavioral|Resistance training|
1624739|NCT02050945|Behavioral|Endurance training|
1624740|NCT02050932|Dietary Supplement|60 mg Fe as FeSO4 with stable isotopic labels|Subjects will receive FeSo4 supplements labeled with stable isotopic labels (54Fe, 57Fe, 58Fe) and iron absorption will be measured for each administration
1624741|NCT02050919|Drug|Epirubicin Hydrochloride|Given IV
1624742|NCT02050919|Radiation|External Beam Radiation Therapy|Undergo EBRT
1624743|NCT02050919|Drug|Ifosfamide|Given IV
1624744|NCT02050919|Other|Laboratory Biomarker Analysis|Correlative studies
1624745|NCT02050919|Drug|Sorafenib Tosylate|Given PO
1624746|NCT02050919|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
1624747|NCT02050906|Behavioral|behavioral dietary intervention|Patients undergo nutritional counseling over 30 minutes once weekly during months 1-2 and then every 2 weeks via telephone calls during month 3.
1624748|NCT02050906|Behavioral|exercise intervention|Patients undergo 1 hour of intensive exercise comprising 30 minutes of aerobic exercise and 30 minutes of resistance exercise twice weekly during weeks 1-6, once weekly during weeks 7-8, and independently during weeks 7-12.
1624749|NCT02050906|Other|behavioral activity counseling|Undergo behavioral activity and nutritional counseling
1624750|NCT02050906|Behavioral|telephone based counseling|Undergo behavioral activity and nutritional counseling
1624751|NCT02050906|Procedure|quality-of-life assessment|Ancillary studies
1624752|NCT02050906|Other|questionnaire administration|Ancillary studies
1624753|NCT02050893|Drug|sedatives(Midazolam and Propofol)|
1624754|NCT02050841|Biological|octaplas|Octaplas S/D Plasma
1624755|NCT02050828|Drug|AKB-9778|
1624756|NCT02050828|Drug|ranibizumab|
1624757|NCT02050828|Drug|Placebo|
1624758|NCT02050828|Drug|Sham|
1624759|NCT02050815|Drug|MEK162|
1624760|NCT02050802|Drug|Moxifloxacin 400 mg|
1624761|NCT02050802|Drug|Macitentan 10 mg|
1624762|NCT02050802|Drug|Macitentan 30 mg|
1624763|NCT02050802|Other|Placebo|
1624764|NCT02050789|Behavioral|flexible duty hours|If a hospital is assigned to the intervention arm, all categorical and preliminary general surgery residents in that general surgery program will switch to the flexible duty hours while at an enrolled hospital.
1624765|NCT02050776|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally and intramuscularly in limb girdle muscular dystrophy patients
1624766|NCT02050763|Behavioral|The SHARE Project|"SHARE aimed to reduce IPV and used methodologies from two proven successful violence prevention frameworks: Stepping Stones (Welbourn, 1995) and the Resource Guide for Mobilizing Communities to Prevent Domestic Violence (Michau & Naker, 2003). SHARE promoted a process of social change based on the Transtheoretical Model's Stages of Change Theory (Prochaska & DiClemente, 1983; Prochaska & Velicer, 1997) which posits that although people realize they need to make changes in their life, they do it in stages instead of one major life change. There are five main stages of change: (1) pre-contemplation, (2) contemplation, (3) preparation for action, (4) action and (5) maintenance.
We hypothesized that repeated exposure to the ideas included in SHARE would encourage men and women to begin a process of change that results in preventive behavior."
1624767|NCT02050724|Drug|Radioactive labelling of pulmonary nodules|Application directly into a pulmonary nodule
1624768|NCT02050724|Device|CT guided radioactive labelling|CT guided puncture is a standard procedure in radiology. In this study it is used to mark pulmonary nodules for the following thoracoscopic surgery, done with a handheld-SPECT device.
1624769|NCT02050724|Device|Electromagnetic guided bronchoscopic radioactive labelling|Electromagnetic guided bronchoscopy is a standard procedure. In this study it is used to mark pulmonary nodules.
1624770|NCT02050711|Behavioral|Pulmonary rehabilitation|
1624771|NCT02050711|Other|Usual care|
1624772|NCT02050698|Procedure|Protected weightbearing in a hard-soled shoe|Patients allocated to experiment group are allowed tolerable weightbearing in a hard-soled shoe after one week of immobilization in a posterior splint
1624773|NCT02050698|Procedure|Protected weightbearing in a short leg walking cast|Patients allocated to control group are allowed tolerable weightbearing in a short leg walking cast after one week of immobilization in a posterior splint
1624812|NCT02050295|Procedure|Sham washout|Infusion of saline to maintain catheter patency.
1624813|NCT02050295|Drug|Saline|
1624774|NCT02050685|Other|All patients incoming in the sleep study centre for a PSG|All patients incoming in the sleep study centre for a PSG. Comparison between screening score and AHI derived from PSG.
1624775|NCT02050672|Dietary Supplement|Myo-inositol|
1624776|NCT02050672|Other|untreated|
1624777|NCT02050646|Other|Low Salt Diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
1624778|NCT02050646|Other|Liberal salt diet|On Day 0, patients will be randomized to one of the two crossover liberal/low or low/liberal salt diet groups. Each subject will complete two controlled dietary phases: 10-days of low salt diet, a washout period of 3-days, and 10-days of liberal salt diet.
1624779|NCT02050607|Other|fecal microbiota transplantation from healthy lean donors|fecal microbiota transplantation from healthy lean donors
1624780|NCT02050594|Drug|Ipilimumab|
1624781|NCT02050555|Dietary Supplement|Placebo|
1624782|NCT02050555|Dietary Supplement|Koji-extracted beverage fermented with Pediococcus pentosaceus LP28|
1624783|NCT02050542|Procedure|systematic biopsies|90 patients will have to undergo 12 systematic transrectal ultrasound-guided biopsies of the prostate
1624784|NCT02050542|Procedure|Targeted biopsies guided by a fusion of MRI and ultrasound- images|Immediately after the 12 systematic biopsies, the same patients will have to undergo 3 additional targeted biopsies on the suspicious image detected by IRM, guided by a fusion of MRI and ultrasound- images with the Koelis ® system
1624785|NCT02050529|Drug|Labetalol|Group A( Labetalol) will be receive intravenous labetalol bolus doses as specified in protocol summary.
1624786|NCT02050529|Drug|Hydralazine|Group B(Hydralazine) will serve as control and will receive active comparator Hydralazine intravenous bolus doses as specified in summary.
1624787|NCT02050516|Other|micro-well group culture dish|an embryo culture dish containing nine micro-wells in the middle.
1624788|NCT02050477|Procedure|Laparoscopic Vertical Gastroplasty|The Magenstrasse and Mill procedure is a conservative vertical gastroplasty described in 1987 through a laparotomy. A tubular gastric pouch is created by a vertical stapling extending from the antrum to the angle of Hiss. In this study, we evaluate the laparoscopic technique of the procedure.
1624789|NCT02050451|Dietary Supplement|Ensure Plus®|
1624790|NCT02050451|Dietary Supplement|Multivitamin|
1624791|NCT02050438|Procedure|Total Knee Arthroplasty|
1624792|NCT02050425|Device|Placebo-CPAP device|short-term CPAP withdrawal by the use of Placebo-CPAP
1624793|NCT02050425|Device|CPAP|Patients continue therapeutic CPAP therapy
1624794|NCT02050412|Other|Cat fur scratch test|
1624795|NCT02050399|Other|Isometric exercise|The isometric protocol (handgrip) will be performed into 4 percentages of MVC (15, 30, 45 and 60%) to exhaustion in 3 postures (supine, seated and standing position). The percentages and the postures will be randomized. In the first day of exercise protocol the subjects will be at rest during 10 minutes and will perform 3 MVC during 5 seconds, with 5 minutes of recovery. The higher value of MVC will be used to prescribe the percentages. The subjects will perform two contractions until exhaustion in one posture in each day.
1624796|NCT02050386|Other|Cold pressor stimulation|Immersion of the foot in 0-2 degrees C water for 50 seconds
1624797|NCT02050386|Other|Sham Stimulation|Immersion of the foot in room temperature water for 50 seconds
2011209|NCT02660138|Drug|AbobotulinumtoxinA|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
1624799|NCT02050360|Drug|Sildenafil 40 mg|
1624800|NCT02050360|Drug|Sildenafil 80 mg|
1624801|NCT02050360|Drug|Placebo|
1624802|NCT02050347|Genetic|CD19.CAR-CD28Z T Cells - dose escalation 2|"Patients will receive one of the following dose levels:
Dose Level 1: 5 ×10^5 cells/kg
Dose Level 2: 1×10^6 cells/kg
Dose Level 3: 5×10^6 cells/kg"
1624803|NCT02050347|Genetic|CD19.CAR-CD28Z T Cells - dose escalation 1|"Patients will receive one of the following doses:
Dose Level one: 1x10^5 cells/kg
Dose Level 2: 5x10^5 cells/kg
Dose Level 3: 1x10^6 cells/kg"
1624804|NCT02050334|Drug|CC100|CC100 reconstituted in diluent
1624805|NCT02050334|Drug|Placebo|Diluent. Amount to match CC100 dose.
1624806|NCT02050321|Drug|Acitretin|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
1624807|NCT02050321|Drug|Vemurafenib|A combination of Acitretin and Vemurafenib will be administered to determine if it reduces the incidence of biopsy-confirmed cSCC at 6 months
2011210|NCT02660138|Drug|AbobotulinumtoxinA|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
2011211|NCT02660138|Drug|AbobotulinumtoxinA Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
2011212|NCT02660138|Drug|AbobotulinumtoxinA Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
1624811|NCT02050295|Procedure|Nerve block washout|Saline will be infused through the perineural catheter to reverse motor block.
1624944|NCT02049164|Drug|Placebo|
2011213|NCT02660112|Drug|(+)-Epicatechin|25mg (+)-Epicatechin capsules. Starting dose 75mg total daily dose (one 25mg cap taken three times per day). Dose escalation at 12 weeks for non-responders to 150mg total daily dose (two 25mg caps taken three times per day)
2011214|NCT02660359|Drug|AbobotulinumtoxinA|600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points.
2011215|NCT02660359|Drug|AbobotulinumtoxinA|800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
2011216|NCT02660359|Drug|AbobotulinumtoxinA Placebo|AbobotulinumtoxinA Placebo 600 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
2011217|NCT02660359|Drug|AbobotulinumtoxinA Placebo|AbobotulinumtoxinA Placebo 800 U intra detrusor injection in two treatment periods (Initial and Retreatment phase) delivered at 30 injection points
2011218|NCT02659631|Drug|PF-06671008|Dose Escalation Phase - Part 1
2011219|NCT02659631|Drug|PF-06671008|Dose Expansion Phase - Part 2
2011220|NCT02658890|Drug|BMS-986205|
1624814|NCT02050282|Other|Supplementary NT-proBNP measurement|In patients randomized to the strategy with supplementary measurement of NT-proBNP, a blood sample will be drawn from the peripheral venous catheter that is routinely inserted and analyzed immediately using a COBAS H232 and Roche Diagnostics NT-proBNP assay.
1624815|NCT02050269|Drug|Iohexol|Iohexol, 300 mg/mL
1624816|NCT02050256|Other|continuing medical education and electronic decision support|
1624817|NCT02050256|Other|education and electronic support|Continuing medical education and electronic decision support to General Practitioners.
1624818|NCT02050243|Drug|5ALA|20mg/kg of oral suspension of 5ALA
1624819|NCT02050230|Biological|Blood transfusion|One unit of red blood cells will be transfused over the course of 20 minutes
1624820|NCT02050217|Procedure|Neurally Adjusted Ventilatory Assist|
1624821|NCT02050204|Behavioral|Intervention|The intervention was a 3-month structural and social change process designed to increase employee control over work time and family supportive supervisory behaviors (Kossek et al., in press). The change process was an integration of two previously evaluated interventions (Hammer et al., 2011; Kelly et al., 2011). A facilitator led 8 hrs of participatory sessions to transition employees from a time-based to a results-based work culture. Supervisors participated in all change activities plus 4hrs of training in supportive supervision. Training in family supportive supervision was implemented with behavioral computer-based training (cTRAIN, NWeta, Lake Oswego, OR) followed by 2 rounds of goal-setting and behavioral self-monitoring using an iPod Touch (Habitrack, OHSU, Portland, OR).
1624822|NCT02050191|Behavioral|www.princetonlivingwell.com|
1624823|NCT02050178|Drug|OMP-54F28, Nab-Paclitaxel and Gemcitabine|
1624824|NCT02050165|Dietary Supplement|KIND Bars|Consumption of KIND Bars for 12 weeks
1624825|NCT02050165|Dietary Supplement|Typical American Snack|Consumption of typical American snacks for 12 weeks
1624826|NCT02050152|Behavioral|Explicit and Implicit memory|Explicit and implicit memory will be tested visually (showing an animal) and auditory (telling a joke, stating a food type that starts with the letter B) and smell recall (bad smell of anesthesia)
1624827|NCT02050152|Drug|0% nitrous oxide, 30% nitrous oxide and 60% nitrous oxide|
1624828|NCT02050139|Dietary Supplement|L-cysteine|
1624829|NCT02050139|Other|Placebo|
1624830|NCT02050126|Device|Lumenis UltraPulse Encore.|Treatment using Lumenis UltraPulse Encore.
1624831|NCT02050113|Device|Physician modified stent graft|The surgeon will modify commercially available stent grafts to match the anatomy of the patient being treated. Small fenestrations (holes) will be made in the stent graft so that additional stents can be inserted through the fenestration and into the blood vessels that lead to the kidneys, intestines or liver. These stents allow blood to flow freely to these organs. This surgery is done through small incisions in the groin.
1624832|NCT02050087|Device|Simple sling.|
1624833|NCT02050087|Device|Neutral brace|
1624834|NCT02050074|Drug|Colesevelam|
1624835|NCT02050074|Drug|Metformin|
1624836|NCT02050074|Other|Placebo|
1624837|NCT02050061|Other|compression stocking|study the impact of compression stocking
1624838|NCT02050048|Other|Administration of Lactated Ringer's (LR) Solution|"Patients will be randomized to low volume or high volume group. Patient in the low volume group will receive fluids via infusion at a rate of 1.5 cc/kg/hr. Fluid administration may be continued through the 90 minute post-procedure observation period. Patients in the high volume group will receive fluids via infusion by the following weight based regimen:
initial bolus of LR prior to ERCP of 7.5 cc/kg over 1 hour
LR fluid infusion during the procedure at 5 cc/kg/hr
Post-procedure bolus of 20 cc/kg over 90 minutes"
1624839|NCT02050035|Other|Aerobic Exercise Training|Supervised outpatient moderate to vigorous aerobic training at 60% - 85% heart rate reserve, carried out for 45 minutes, three times per week over a twelve week period.
1624840|NCT02050009|Drug|metformin hydrochloride|Given PO
1624841|NCT02050009|Drug|carboplatin|Given IV
1624842|NCT02050009|Drug|paclitaxel|Given IV
1624843|NCT02050009|Other|laboratory biomarker analysis|Correlative studies
1624844|NCT02049983|Device|Use of Levita Magnetics Grasper|
1624845|NCT02049970|Drug|dexmedetomidine|1 ml 100 mcg dexmedetomidine+ 15 ml 0.25 % bupivacaine are applied around brachial plexus
1624846|NCT02049970|Drug|bupivacaine|30 ml 0.25 % bupivacaine is applied around brachial plexus
1624847|NCT02049957|Drug|MLN0128|Phase 1B: 2, 3, 4, or 5 mg once daily; Phase 2: dose determined after Phase 1B
1624848|NCT02049957|Drug|Fulvestrant|Phase 1B: 500 mg monthly; Phase 2: 250 or 500 mg monthly
1624849|NCT02049957|Drug|Exemestane|25 mg once daily
1624850|NCT02049944|Drug|Cefazolin|Participants who are undergoing an elective cesarean section at term will receive 3 grams of Cefazolin at least 30, but no more than 60 minutes prior to skin incision administered through an intravenous line.
1624851|NCT02049931|Device|No brace treatment|Patients in the no brace group were allowed to ambulate without any braces as long as it would be tolerable.
1624852|NCT02049931|Device|Rigid brace|In rigid brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the rigid brace for a total of 8 weeks.
1624853|NCT02049931|Device|Soft brace|In soft brace group, brace is required to be worn at all times except when lying. All patients were instructed to wear the soft brace for a total of 8 weeks.
1624854|NCT02049905|Drug|Aldoxorubicin|
1624855|NCT02049905|Drug|Investigator's Choice Treatment (Darcabazine, Pazopanib, Gemcitabine + Docetaxel, Doxorubicin, Ifosfamide)|
1624856|NCT02049892|Other|Metal Ion Levels|
1624857|NCT02049879|Drug|Corticosteroids injection|A solution of triamcinolone 40 mg (Kenalog) mixed with 3 cc of 2% xylocaine without epinephrine.
1624858|NCT02049866|Drug|Denosumab|Denosumab 60mg, administered every 6 months by subcutaneous injection for 36 months
1624859|NCT02049853|Device|"NTproBNP measurement with point of care device Cobash232 in the POCT group"|
1624860|NCT02049840|Device|Altis Single Incision Sling System|Altis Single Incision Sling (SIS) System is a permanently implantable synthetic sling for the surgical treatment of Stress Urinary Incontinence
1624861|NCT02049827|Other|participation in the study|
1624862|NCT02049814|Drug|Metformin|Metformin tablets
1624863|NCT02049814|Drug|Voglibose|Voglibose tablets
1624864|NCT02049814|Drug|Acarbose|Acarbose tablets
1624868|NCT02049801|Other|pharmacological study|Correlative studies
1624869|NCT02049801|Other|laboratory biomarker analysis|Correlative studies
1624870|NCT02049788|Behavioral|low calorie/fat diet|Conventional behavioural lifestyle modification instructions x 1/month for 6 months about low-calorie (approximately 1200-1300 kcal/day), low-fat (25% of total calories from fat) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3 times/week, increase physical activity in their routine and decrease sedentary activity).
1624871|NCT02049788|Behavioral|Low glycaemic index diet|Experimental behavioural lifestyle modification instructions x 1/month for 6 months about low glycaemic index diet (selection of low-GI carbohydrates with the caloric distribution of carbohydrate 50-55%: protein 15-20%: fat 30-35%, instruction by two-hour small classes with parental participation low GI cooking demonstration and food labeling guidance) and about physical activity (increase non-weight bearing exercise 30 minutes/day at least x 3/week, increase physical activity in their routine and decrease sedentary activity).
1624872|NCT02049775|Procedure|NBI|
1624873|NCT02049762|Drug|Aspirin|Aspirin 100 mg vs. placebo in ACS patients on P2Y12 inhibitors a month following PCI.
2011221|NCT02658890|Drug|Nivolumab|
1624875|NCT02049736|Drug|Telbivudine|
1624876|NCT02049710|Behavioral|Seventeen Days|Interactive video includes highlighting salience of active choices in sexual decision making, modeling different responses to sexual situations, cognitive rehearsal of preventive behaviors, and information about hormonal and non-hormonal contraception
1624877|NCT02049710|Behavioral|Driving Skills for Life|Interactive video includes guidance and practice for safe driving techniques, driver and car care tips, an eco-driving learning module, and interactive driving games.
1624878|NCT02049697|Drug|14C-JNJ-39823277|Participants will receive a single oral dose of 25 mg 14C-JNJ-39823277 as a 50-mL solution.
1624879|NCT02049684|Procedure|Patch|
1624880|NCT02049671|Drug|Growth Hormone Therapy|
1624881|NCT02049632|Procedure|Omission of axillary clearance|
1624882|NCT02049619|Device|pharyngeal pack|Following endotracheal intubation, one saline soaked, gauze pharyngeal pack was inserted into the hypopharynx under direct vision using McGill's forceps. The packs were tied to the endotracheal tube and their placements were documented on the scrub nurse's count board.
1624883|NCT02049606|Drug|LAYLA tablet|1 Tablet twice a day
1624884|NCT02049606|Drug|CENATONE tablet|2 Tablets once a day
1624885|NCT02049593|Drug|PARP inhibitor BMN-673|Given PO
1624886|NCT02049593|Drug|temozolomide|Given PO
1624887|NCT02049593|Drug|irinotecan hydrochloride|Given IV
1624888|NCT02049593|Other|pharmacological study|Correlative studies
1624889|NCT02049593|Other|laboratory biomarker analysis|Correlative studies
1624890|NCT02049580|Drug|Thiotepa|Thiotepa (10 mg/kg /day) will be administered every 12 h, at day -6
1624891|NCT02049580|Drug|Fludarabine|"Fludarabine (30mg/m2/day x 4 days) will be dosed according to renal function. For decreased creatinine clearance (CCr) (≤ 61 mL/min) Fludarabine dosage should be reduced as follows:
CCr 46-60 mL/min, fludarabine = 24 mg/ m2/day"
1624892|NCT02049580|Drug|Cyclophosphamide|"Pre-transplantation Cyclophosphamide(Cy) 30 mg/kg/day will be administered as a 1-2 hour intravenous infusion with a high volume fluid flush on Days -5.
Cy will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125% of IBW, in which case the drug will be dosed according to the Adjusted IBW (AIBW)
Cyclophosphamide [50 mg/kg/day IBW] will be given on Day 3 post-transplant (between 60 and 72 hours after marrow infusion) and on Day 4 post-transplant (approximately 24 hours after Day 3 cyclophosphamide). Cyclophosphamide will be given as an IV infusion over 1-2 hours (depending on volume)."
1624893|NCT02049567|Device|Intraocular Lens Implantation|Use of accommodating lens to restore visual function at all distances.
1624894|NCT02049554|Other|Preconception Care Screener|
1624895|NCT02049541|Drug|PI3K inhibitor BKM120|Will be supplied to each patient on the first day of each cycle. It will subsequently be self administered by the patient themselves daily on days 1-28 of every 28 day cycle
1624896|NCT02049541|Biological|rituximab|Given IV (intervenously) on days 2, 8, 15, and 22 of cycle 1, and subsequently on day 1 of cycles 3, 5, 7, 9, and 11.
1624897|NCT02049541|Other|Pharmacodynamics|Pharmacodynamic samples from peripheral blood (for those with peripheral blood involvement) and bone marrow aspirate (for all patients) are drawn at baseline.
1624898|NCT02049541|Other|Correlative studies|Patients will undergo correlative studies to include bone marrow biopsy at study enrollment, and at the time of complete remission. In addition, patients with peripheral blood involvement at enrollment will have peripheral blood drawn for all planned research correlates.
1624899|NCT02049528|Drug|CC-122|CC-122
1624900|NCT02049528|Drug|CC-122|CC-122
1624901|NCT02049528|Drug|CC-122|CC-122
1624902|NCT02049515|Drug|IPI-145 (duvelisib)|PI3K Inhibitor
1624903|NCT02049515|Drug|Ofatumumab|
1624904|NCT02049502|Biological|biologically active human fecal microbiota|instillation of biologically active human fecal microbiota material via flexible sigmoidoscopy
1624905|NCT02049502|Procedure|sigmoidoscopy|
1624906|NCT02049489|Biological|ICT-121 DC vaccine|autologous dendritic cells pulsed with peptide antigens
1624907|NCT02049476|Drug|Dexamethasone pellet|"Dexamethasone pellet placement occurs within 14 days of baseline examination; for patients with bilaterally active uveitis, placement of a dexamethasone pellet in the second eye should occur within 14 days of the first implantation or within 30 day of the baseline examination.
Repeated placement is permitted every 3 months based on the best clinical judgment of the doctor and the study protocol."
1624986|NCT02048917|Drug|Low Intensity Counseling + bupropion + PRN NRT|Low Intensity Counseling + bupropion + PRN NRT
2011222|NCT02658890|Drug|Ipilimumab|
2011223|NCT02656082|Drug|Etanercept|Treatment with etanercept is intended for remission induction of DLE only and not for maintenance purpose.
2011224|NCT02655263|Drug|Somatropin|Somatropin infusion (Genotropin®)
2011225|NCT02655263|Other|Ketone bodies|ketone bodies infusion
2011226|NCT02654145|Drug|Mepolizumab 100mg SC|At Visit 2 (Week 0) eligible subjects will receive mepolizumab 100mg SC into the upper arm or thigh every 4 weeks over a period of 28 weeks.
2011227|NCT02654145|Drug|Albuterol/salbutamol MDIs|Albuterol/salbutamol metered dose inhalers (MDIs) will be provided as rescue medication during treatment period.
1624908|NCT02049450|Drug|ruxolitinib|Ruxolitinib was taken at a starting dose of 10 mg twice daily with dose adjustments within the range of 5 to 25 mg twice daily.
1624909|NCT02049437|Drug|tocilizumab|"Subjects will be randomized 1:1 to one of the following arms:
ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 and 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
1624910|NCT02049437|Drug|Placebo|"Subjects will be randomized 1:1 to one of the following arms:
ARM A: TCZ, 4 mg/Kg by IV infusion over 60 minutes (not to exceed 400 mg) once at study entry, followed by TCZ, 8 mg/Kg by IV infusion over 60 minutes (not to exceed 800 mg) at weeks 4 aned 8, and THEN placebo by IV infusion at weeks 20, 24, and 28.
ARM B: Placebo by IV infusion at study entry followed by placebo by IV infusion at weeks 4 and 8, and THEN TCZ, 4 mg/Kg (not to exceed 400 mg) by IV infusion over 60 minutes once at week 20, followed by TCZ, 8 mg/Kg (not to exceed 800 mg) by IV infusion over 60 minutes at weeks 24 and 28."
1624911|NCT02049411|Drug|Ketamine|Ketamine: (dose 0.3 mcg/kg) included in physiological solution at 0.9% (250 ml) during 2 hours, intravenously.
1624912|NCT02049411|Drug|physiological solution|physiological solution at 0.9% (250 ml) during 2 hours, intravenously, with the same physical characteristics of ketamine.
2011228|NCT02654145|Drug|Omalizumab|Subjects receiving omalizumab will enter in a run-in period and will continue to receive omalizumab throughout the run-in period. At Visit 2 (week 0) subjects will discontinue omalizumab.
1624916|NCT02049346|Drug|Epoetin alpha or beta (Epoetin group)|"Erythropoetin doses in that were adjusted according to the approved prescribing information, without additional restrictions.
Doses of erythropoetin were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. erythropoetin doses were increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.
The doses for all patients were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
1624917|NCT02049346|Drug|Darbepoetin alfa|"Subjects in that group received Darbepoetin alfa once every week or every 2 weeks as per protocol. Doses of Darbepoetin alfa were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. Darbepoetin alfa doses and increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.
The doses were adjusted so that haemoglobin concentrations were remain within a target range of 11-12 g/dL during the study.
If a dose of Epoetin alpha/ beta does not equate exactly to a unit dose of Darbepoetin alfa at switching, then the nearest available unit dose of Darbepoetin alfa was used."
1624918|NCT02049346|Drug|Methoxy polyethylene glycol-epoetin beta|"Patients in that arm received Intravenous MIRCERA monthly. The initial dose was 120 mcg, 200 mcg or 360 mcg, for patients had previously received a weekly dose of Epoetin alpha/ beta of less than 8000 IU, between 8000 to16 000 IU or more than16000IU respectively. MIRCERA doses were adjusted according to the approved prescribing information, without additional restrictions.
Doses of MIRCERA were decreased by 25% for Hb values >12 and ≤13 g/dL and increased by 25% for Hb <11 and ≥10 g/dL. MIRCERA doses were increased by 50% for Hb <10 g/dL. Treatment was interrupted temporarily if Hb exceeds 13 g/dL.
The doses of MIRCERA were adjusted so that haemoglobin concentrations were maintained within a target range of 11-12 g/dL during the study."
1624919|NCT02049333|Procedure|Phacoemulsification|
1624920|NCT02049333|Procedure|Endoscopic Cycloplasty (ECPL)|
1624921|NCT02049320|Drug|Remifentanil|
1624922|NCT02049307|Drug|Losartan 100mg daily|
1624923|NCT02049307|Drug|Matching placebo|
1624924|NCT02049294|Biological|Omalizumab (Xolair)|
1624925|NCT02049294|Drug|Placebo|
1624926|NCT02049281|Drug|Vintafolide|Intravenous (IV) bolus, starting dose 1.4 mg, on Days 1, 3, 5, 15, 17, and 19 of each 28-day cycle for up to 6 cycles.
1624927|NCT02049268|Drug|Nicotine + Alcohol|14 mg nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach blood alcohol level (BAL) = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
1624928|NCT02049268|Drug|Placebo Nicotine + Alcohol|Placebo nicotine patch applied in combination with vodka and orange juice alcoholic beverage (to reach BAL = 0.08 based on subject weight, which is approximately 2-3 drinks for 400 mL volume)
1624929|NCT02049268|Drug|Nicotine + Placebo Alcohol|14 mg nicotine patch applied in combination with 400 mL orange juice beverage with a trace of alcohol to create placebo alcohol mixture.
1624930|NCT02049255|Drug|Chloroprocaine|"The Group Chloroprocaine will receive: Chloroprocaine: 50 mg in rachianesthesia"
1624931|NCT02049255|Drug|Marcaine|"The Group Marcaine will receive: Marcaine: 12,5 mg in rachianesthesia"
1624932|NCT02049242|Procedure|triple tourniquet|"Triple tourniquet consist of two tourniquet applied both infundibulopelvic ligaments and one uterine isthmus to occlude the left and right ovarian vessels and to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
Through the same openings in the broad ligament each side a Foley catheter looped around the infundibulopelvic ligament lateral to the fallopian tube and ovary."
1624933|NCT02049242|Procedure|Single tourniquet|Single tourniquet is tourniquet applied uterine isthmus to occlude the uterine arteries. For this purpose, a small opening is made in the avascular place of the broad ligament on either side of the uterine isthmus superior to the uterine vessels. A pediatric Foley catheter is threaded through the two holes and tied tightly anteriorly around the cervix at the level of the internal os.
1624934|NCT02049229|Device|percutaneous coronary intervention|Optimax-stent implantation
1624935|NCT02049229|Device|percutaneous coronary intervention|Synergy stent implantation
1624936|NCT02049216|Other|Flexible tape|Flexible, elasticised, adhesive athletic tape
1624937|NCT02049216|Other|Fixomull|
1624938|NCT02049216|Other|Exercise|Participants in both groups will be prescribed a home exercise program to complete.
1624939|NCT02049203|Drug|Ataciguat|
1624940|NCT02049203|Drug|Placebo|
1624941|NCT02049190|Drug|onapristone|
1624942|NCT02049190|Drug|abiraterone|
1624945|NCT02049151|Drug|Tecemotide|Tecemotide injection will be administered once weekly subcutaneously at a dose of 806 microgram up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
1624946|NCT02049151|Drug|Placebo|Matching placebo injection will be administered once weekly subcutaneously up to Week 8 and from Week 14, every 6 weeks until end-of-trial, or until NSCLC progression.
1624947|NCT02049151|Drug|Cyclophosphamide (CPA)|CPA injection will be administered as a single intravenous infusion at a dose of 300 milligram per square meter (mg/m^2) (to a maximum of 600 mg) 3 days before the first injection of tecemotide.
1624948|NCT02049151|Drug|Saline (sodium chloride)|Matching placebo (saline) injection will be administered as a single intravenous (0.9 percent [%] sodium chloride) infusion 3 days before the first injection of tecemotide-matching placebo.
2011229|NCT02651740|Drug|Rifaximin|400mg tid* 3d
2011230|NCT02651740|Procedure|Fecal microbiota transplantation|Using filtered fresh donor stool, 100-200ml per time throuth enteral nutrition tube for at least one time
2011231|NCT02652442|Behavioral|Gaze stability exercises|Gaze stability exercises include adaptation and substitution exercises. Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Substitution exercises specifically attempt to facilitate use of alternative strategies, rather than teaching the specific strategies. For example, during active eye-head exercise, a large eye movement to a target is made prior to the head moving to the target, potentially facilitating preprogrammed eye movements.
1624953|NCT02049086|Behavioral|SBIRT-PM|Screening, Brief Intervention and Referral to Treatment with Pain-Management advice (SBIRT-PM)
1624954|NCT02049086|Behavioral|Pain Module|The pain module of SBIRT-PM with no substance abuse focus (Pain Module Only)
1624955|NCT02049073|Drug|Zonisamide|Zonisamide 100 mg or 200 mg pill administered orally every day for 2 weeks
1624956|NCT02049073|Drug|Methylprednisolone|Methylprednisolone 32 mg or 64 mg pill administered orally once
1624957|NCT02049060|Drug|Tivantinib|"•- 1 level: Tivantinib 120 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
•0 level: Tivantinib 240 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks
•+ 1 level: Tivantinib 360 mg p.o. BID + Carboplatin AUC 5 i.v. day 1 every 3 weeks + Pemetrexed 500 mg/mq i.v. day 1 every 3 weeks"
1624958|NCT02049047|Drug|Everolimus|Everolimus will be orally administered at the dosage of 10 mg once daily. Each cycle will be considered as 21 days of treatment. Tumor assessment will be done every two cycles.Treatment should be administered until documented disease progression, unacceptable toxicity, or patient refusal.
1624959|NCT02049034|Other|Lixisenatide|"Lixisenatide and placebo are considered as investigational medicinal product (IMP). Metformin is not considered an investigational product but concomitant allowed antidiabetic medications.
Lixisenatide is supplied as disposable pre-filled pen for subcutaneous injection: 10mcg Lixisenatide green pens; 20 mcg Lixisenatide purple pens. Dose titration-10mcg Lixisenatide for 14 days, 20 mcg for 14 days."
1624960|NCT02049034|Other|Placebo|Placebo for lixisenatide is supplied as green and purple colored disposable pen-injectors containing 3 mL of a sterile aqueous solution.
1624961|NCT02049021|Device|MECTA SPECTRUM 5000Q ECT|
1624962|NCT02049021|Procedure|Sham ECT|Sedation using propofol or etomidate and usual ECT preparation (no stimulation)
1624963|NCT02049008|Other|Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected to receive antimicrobial photodynamic therapy (aPDT) will be irrigated with distilled water. Shortly thereafter, the dye will be applied (phenothiazine hydrochloride- 10mg/mL) from the bottom of the pocket. After 1 minute, irrigation will be performed with distilled water to remove the excess of dye. The stained area will be irradiated with a diode laser (660 nm and a 60 mW/cm²). Six sites per tooth under treatment will be irradiated (10 seconds/ site). The applications of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
1624964|NCT02049008|Other|Sham Photodynamic Therapy|After a full-mouth scaling and root planning (SRP), the periodontal pockets of teeth selected will receive a simulation of antimicrobial photodynamic therapy (aPDT): irrigation with distilled water and simulated laser application. The simulations of aPDT will be repeated in the same way until the second week (days: 2, 7,14). Before the application, the supragingival plaque will be removed.
1624965|NCT02048982|Behavioral|Guideline|Physicians will receive information on the Choosing Wisely Guideline
1624966|NCT02048982|Behavioral|Cost|Physicians will receive cost information.
1624967|NCT02048982|Behavioral|Victim|Physicians will receive information on an identifiable victim.
1624970|NCT02048956|Other|Hydrotherapy intervention|Participants randomized to the exercise programme received a training in a swimming pool focused on dance therapy.
1624971|NCT02048956|Other|Control group|Standard exercises of hydrotherapy
1624972|NCT02048943|Drug|dovitinib lactate|Given PO
1624973|NCT02048943|Drug|gemcitabine hydrochloride|Given IV
1624974|NCT02048943|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1624975|NCT02048943|Other|pharmacological study|Correlative studies
1624976|NCT02048943|Other|laboratory biomarker analysis|Correlative studies
1624977|NCT02048930|Device|Budesonide Easyhaler|
1624978|NCT02048930|Device|Budesonide dry powder inhaler|
1624979|NCT02048917|Drug|High Intensity Counseling + Long Acting NRT + PRN NRT|High Intensity Counseling + Long Acting NRT + PRN NRT
1624980|NCT02048917|Drug|High Intensity Counseling + bupropion + PRN NRT|High Intensity Counseling + bupropion + PRN NRT
1624981|NCT02048917|Drug|High Intensity Counseling + varenicline + PRN NRT|High Intensity Counseling + varenicline + PRN NRT
1624982|NCT02048917|Drug|High Intensity Counseling + Long Acting NRT|High Intensity Counseling + Long Acting NRT
1624983|NCT02048917|Drug|High Intensity Counseling + bupropion|High Intensity Counseling + bupropion
1624984|NCT02048917|Drug|High Intensity Counseling + varenicline|High Intensity Counseling + varenicline
1624985|NCT02048917|Drug|Low Intensity Counseling + Long Acting NRT + PRN NRT|Low Intensity Counseling + Long Acting NRT + PRN NRT
1624987|NCT02048917|Drug|Low Intensity Counseling + varenicline + PRN NRT|Low Intensity Counseling + varenicline + PRN NRT
1624988|NCT02048917|Drug|Low Intensity Counseling + Long Acting NRT|Low Intensity Counseling + Long Acting NRT
1624989|NCT02048917|Drug|Low Intensity Counseling + bupropion|Low Intensity Counseling + bupropion
1624990|NCT02048917|Drug|Low Intensity Counseling + varenicline|Low Intensity Counseling + varenicline
1624991|NCT02048904|Drug|Sitagliptin|Sitagliptin 100 mg/day for 3 months
1624992|NCT02048904|Drug|Placebo|Placebo 1 pill/day for 3 months
1624993|NCT02048891|Drug|GnRH agonist trigger|
1624994|NCT02048891|Drug|hCG trigger|
1624995|NCT02048865|Drug|Apixaban|Apixaban 2.5 mg tablets BID for 6 months
1624996|NCT02048865|Drug|Placebo drug|placebo drug 2.5mg BID for 6 months
2011232|NCT02652442|Behavioral|Centrifugation|Participants will be rotated in a darkened rotary chair booth with 1 ear positioned 7-8 cm off-axis and the other ear positioned on-axis. Following a 5-minute rest period, the procedure will be repeated with the opposite ear positioned off-axis. Participants will receive 10 sessions in a 4-week period.
2011233|NCT02652442|Behavioral|Balance rehabilitation|All participants will perform balance and gait exercises and will be provided a written home exercise program consisting of exercises designed to improve postural stability and mobility with progressively more challenging tasks.
2011234|NCT02651987|Drug|Lanreotide autogel 120 mg|
2011235|NCT02650193|Drug|HSP-130|Dosage will vary per each cohort: (Five independent cohorts) Cycle 0 Regimen A - 3 mg Cycle 0 Regimen B - 6 mg Cycles 1-4 Regimen B - 6 mg Cycles 1-4 Regimen A (Potential)- 3 mg Cycles 1-4 Regimen C (Conditional)- 12 mg
2011236|NCT02648607|Device|Customised Dynamic Elastomeric Fabric Orthosis (DEFO)|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthosis (DEFO). Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
2011237|NCT02648048|Drug|Pirfenidone|Pirfenidone will be administered as per the dosage schedule mentioned in arm description.
2011238|NCT02648048|Drug|Vismodegib|Vismodegib will be administered as per the dosage schedule mentioned in arm description.
2011239|NCT02644629|Drug|Placebo|Saline 0.9%, Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
2011240|NCT02644629|Drug|Ketamine (1st phase)|Administration of 0.2mg/kg (IV Push) or 50mg (IN, 5 doses, alternating nostrils)
1625011|NCT02048800|Drug|Treosulfan|Treosulfan will be administered over 3 days prior to HSCT at the following dose: 10 g/m2 (children aged < 3months) or 12 g/m2 (children aged 3/12 months) or 14 g/m2 (children aged > 12 months)
1625012|NCT02048787|Drug|Buparlisib|Subjects will receive a single dose of 50 mg buparlisib.
1625013|NCT02048774|Behavioral|Designation of Social Positioning|
1625014|NCT02048761|Drug|Placebo gel|After debridement, a single dose of the placebo gel was applied into the periodontal pockets with a syringe and a blunt canula
1625015|NCT02048761|Drug|1 % Metformin gel|After debridement, 1% Metformin gel gel was applied into the periodontal pockets with a syringe and a blunt canula.
1625016|NCT02048748|Device|Weight and blood pressure device|Weight and blood pressure device integrated in a home telemonitoring kit. The weight scale is Withings The Smart Bodyscale. The blood pressure device is MEDISANA iHealth BP3.
1625017|NCT02048748|Device|Home telemonitoring device|An iPad 2 WiFi 16GB (Model A1395) tablet integrating the telemonitoring kit.
1625018|NCT02048722|Drug|regorafenib|Given PO
1625019|NCT02048709|Drug|GDC-0919|Supplied in 50 mg and 200 mg capsules. To be taken every 12 hours with water by mouth on an empty stomach (no food or drink other than water for 2 hours prior to dose). Taken twice daily for 21 days each cycle, followed by 7 days off; or taken twice daily on 28 consecutive days of a 28-day cycle
1625020|NCT02048696|Other|Secondary prevention and cardiac rehabilitation clinic|Secondary prevention and cardiac rehabilitation clinic of the Montreal Heart Institute. Subjects will undergo twice weekly exercise training with high intensity interval training for a period of 12 weeks.
1625021|NCT02048683|Drug|Short term sedation with sevoflurane in ICU|
1625022|NCT02048670|Device|Balance Belt|Vestibular habituation therapy for sensitivity to visual motion, visual complex environments, head movements and visual patterns. The exercises will have 3-5 repetitions for each of the head movement or visual stimuli that cause and increase in the symptoms of unsteadiness or self motion. These exercises will be done while wearing the Balance Belt for feedback information as to how much the patient is swaying.
1625023|NCT02048657|Device|Foley Airway Stylet Tool|
1625024|NCT02048657|Device|introducer-tool|
1625025|NCT02048644|Drug|fostair|beclometasone dipropionate 200mcg and formoterol 12 mcg delivered by inhaler, twice a day for 28 days
1625026|NCT02048644|Drug|placebo|placebo matched inhaler 2puffs to be taken twice a day for 28 days
1625027|NCT02048618|Drug|GLPG0634|100 mg oral tablet, intake once daily for 20 weeks
1625028|NCT02048618|Drug|Placebo|placebo oral tablets, intake once daily for 20 weeks
1625029|NCT02048605|Behavioral|Psycho-social CBT based training|Number of Sessions: 9x Content: cognitive behavioral group-training-program to reduce stress and augment quality of life.
1625030|NCT02048605|Behavioral|Unspecific group training|Number of sessions: 9x Content: Music or Art Therapy Nutrition Education around Food Functional Movement Physical Activity Group discussion
1625031|NCT02048592|Dietary Supplement|Impact-Nutridrink|"IMPACT (immunonutrition) will be given in the first 8 weeks. Afterwards the patients will be returned to their previous nutrition support |(Nutridrink) for another 8 weeks."
1625032|NCT02048592|Dietary Supplement|Nutridrink-Impact|In this group of patients - the study starts with period of 8 weeks with no change of previous nutrition support (Nutridrink). After 8 weeks the laboratory results will be examined ant the patients will switch to immunonutrition (Impact) for another 8 weeks. After the laboratory examination including oxidative stress parameters will be evaluated.
1625033|NCT02048579|Behavioral|Behavior Therapy + Motivational Interviewing|
1625064|NCT02048358|Drug|Methylprednisolone hemisuccinate|
1625065|NCT02048345|Drug|Suspension Fasted State|
1625066|NCT02048345|Drug|Suspension Fed State|
1625067|NCT02048345|Drug|Solution Fasted State|
1625068|NCT02048345|Drug|Solution Fed State|
1645672|NCT01888978|Drug|Gem-Tax|
1625034|NCT02048566|Device|ImaCor PM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorPM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, at the time of occurrence of defined new organ system deterioration and/or at least every 4 hours during the first 72h after study inclusion or until one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
1625035|NCT02048566|Device|ImaCor SM|The ImaCor ClariTEE (hTEE) device is a transesophageal echocardiography system. It produces a single-plane two-dimensional image. The ImaCor probe is a 5.5 mm detachable probe; it can remain in situ for up to 72h and allows for reassessment of the patient's hemodynamic progress and the effect of selected interventions at any time. The probe is connected to a dedicated echocardiographic system which allows the for the recording of digital loops and performance of basic two-dimensional measurements. ImaCorSM subjects will receive echocardiography-guided hemodynamic management (hTEE) at the time of inclusion, follow-up assessment intervals are at the discretion of the treating physician for the first 72h after study inclusion. hTEE monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
1625036|NCT02048566|Other|Control PM|Group Control protocolized monitoring (ControlPM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, at the time of occurrence of defined new organ system deterioration or at least every 4 hours for the first 72h after study inclusion. Protocolized monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
1625037|NCT02048566|Other|Control SM|Group Control standard monitoring (ControlSM) will receive any hemodynamic monitoring of choice of the treating physician except ImaCor. Protocolized hemodynamic assessments will be performed at the time of inclusion, follow-up measurement intervals are at the discretion of the treating physician for the first 72h. Data collection from standard monitoring is discontinued if one of the following events occurs: study primary endpoints reached, patient is extubated, withdrawal of active treatment.
1625038|NCT02048553|Device|Tablet-guided ventriculostomy|"In patients of the treatment group, ventriculostomy will be performed using a mini-tablet-guided assistance based on preoperative CT imaging. Any patient meeting the inclusion criteria and not violating the exclusion criteria may participate in the TABGUIDE study and be randomized to either a guided or freehand ventriculostomy, thus defining the two distinct groups  guided  or  freehand )."
1625039|NCT02048553|Procedure|Freehand|Patients in the control group will receive standard free-hand ventriculostomy using anatomical landmarks. The catheter may be placed for external drainage or internal (ventriculoperitoneal) shunting in both groups.
1625040|NCT02048540|Biological|Bevacizumab|Bev (5 mg/kg, d1) every 3 weeks, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
1625041|NCT02048540|Drug|docetaxel oxaliplatin 5-FU CF|docetaxel, 75 mg/m2, iv, d1; oxaliplatin, 85 mg/m2, iv, d1; 5-FU, iv infusion 600 mg/m2 and iv injection 400mg/m2, d1-2; CF, 200 mg/m2, d1 and d2 each 3-week, up to 2-4 cycles preoperation, and another 2-4 cycles postoperation up to total 6 cycles.
1625042|NCT02048540|Procedure|Gastrectomy|
1625043|NCT02048527|Other|Global|Single medium for the culture of embryos from Day1 to Day 5
1625044|NCT02048527|Other|Origio|Sequential media medium for the culture of embryos from Day1 to Day 3 (ISM1) and from Day 3 to Day 5 (BlastAssist)
1625045|NCT02048514|Device|The Nellix® EndoVascular Aneurysm Sealing System|
1625046|NCT02048501|Other|Resting Metabolic Rate (RMR)|Each subject will have their resting metabolic rate (RMR) measured. The RMR is assessed by indirect calorimetry measured with the metabolic cart. Oxygen consumption is converted into kilocalories. Subjects will be advised to avoid strenuous exercise for at least 48 hours prior to participation in the study and to sleep at least 6-8 hours the night before. Smoking and consuming caffeine will be prohibited 12 hours before the study begins.
1625047|NCT02048501|Other|Duel-energy x-ray absorptiometry (DEXA)|During a separate appointment on the same day, or within 7 business days if same day is not possible, a body compositions analysis, including fat mass and fat free mass, will be assessed by dual-energy x-ray absorptiometry (DEXA), using a Hologic system.
1625048|NCT02048501|Other|Visual Analog Scale (VAS)|Subjects will be asked to complete a 100-mm Visual Analog scale (VAS) to assess their appetite. The VAS will be completed prior to the meal stimulation test and at 30-minutes, 1-hour, 90 minutes and 2-hours after the meal. The VAS will contain questions assessing food intake, appetite, and hunger.
1625049|NCT02048501|Other|Meal Stimulation Test|Subjects will consume a mixed-nutrient liquid meal 240-ml in 20 minutes. Prior to the meal stimulation test, a baseline 10-ml blood sample will be collected. The, during the meal stimulation test, 10-ml venous blood sample will be collected at 30 minute intervals up to two hours, for a total of 5 samples including the baseline sample. The blood samples will be used to measure fasting blood glucose, adipokines, myokines, gut hormones, amino acids, bile acids, vitamin B and vitamin D analysis with the appropriate assay method.
1625050|NCT02048488|Drug|TSR-011|Number of cycles until progression or unacceptable toxicity develops.
1625051|NCT02048475|Other|desflurane|changing concentration
1625053|NCT02048410|Dietary Supplement|Lactobacillus paracasei B21060|combination of probiotic (Lactobacillus paracasei B21060) and prebiotics (arabinogalactans, xyloooligosaccarides) and amine (L-glutamine)
1625054|NCT02048410|Other|low satured diet|
1625055|NCT02048397|Other|Pulmonary Rehabilitation|
1625056|NCT02048397|Dietary Supplement|Hyperproteic oral nutritional supplement enriched with beta-hydroxy-beta-methylbutyrate|
1625057|NCT02048384|Drug|metformin alone (Arm A)|metformin alone
1625058|NCT02048384|Drug|metformin (Arm B)|rapamycin + metformin
1625059|NCT02048384|Drug|rapamycin (Arm B)|rapamycin + metformin
1625060|NCT02048371|Drug|Regorafenib|
1625061|NCT02048371|Drug|Placebo|
1625062|NCT02048358|Drug|2B3-201|
1625063|NCT02048358|Drug|Placebo|
1625069|NCT02048332|Biological|Viral specific CTL Infusion|"CTL's will be infused into stem cell transplant recipients who have evidence of viral infection or reactivation defined as any of the following:
Blood adenovirus PCR ≥ 1,000
Blood CMV PCR ≥ 500
Blood EBV PCR ≥ 18,000
Evidence of invasive adenovirus infection or disease, defined as the presence of adenoviral positivity in one or more sites.
Evidence of invasive CMV infection, eg pneumonitis, retinitis, colitis
Evidence of EBV-associated lymphoproliferation (EBV-LPD) defined as an elevated EBV DNA level in the blood associated with clinical symptoms (adenopathy or fever or masses on imaging) but without biopsy confirmation."
1625070|NCT02048319|Drug|Pasireotide LAR 60 mg|Pasireotide long acting release, intramuscular injection
1625071|NCT02048319|Procedure|Aspiration sclerotherapy|Percutaneous drainage of the hepatic cyst with subsequent ethanol instillation
1625072|NCT02048319|Drug|Placebo|Saline solution, injected as placebo
1625073|NCT02048306|Behavioral|Family-based PR program|The 12-week Family-based PR program will consist of psychoeducation for patients and family members (once a week) and exercise training for patients (3 times a week). The psychoeducation component aims to empower the family with strategies to facilitate a functional and healthy adjustment to the disease and includes educational and psychosocial support components.
1625074|NCT02048306|Behavioral|Conventional PR program|The 12-week Conventional PR program will consist of psychoeducation (once a week) and exercise training (3 times a week) for patients only.
1625075|NCT02048293|Drug|Remifentanyl, Ultiva®|Anesthetic induction for orotracheal intubation. Group O
1625076|NCT02048293|Drug|Remifentanil Laboratorios Chalver de Colombia S.A.|Anesthetic induction for orotracheal intubation. Group A
1625077|NCT02048293|Drug|Fada Remifentanilo|Anesthetic induction for orotracheal intubation. Group B
1625078|NCT02048280|Procedure|NAVA level|Peak inspiratory pressure will be measured at each NAVA level
1625079|NCT02048280|Other|NAVA level|Increase NAVA level every 3 minutes
1625080|NCT02048267|Procedure|Frey's procedure/Pylorus preserving pancreatoduodenectomy|Duodenum preserving head resection
1625081|NCT02048254|Radiation|brachytherapy|
1625082|NCT02048254|Radiation|IMRT|
2011241|NCT02644629|Drug|Ketamine (2st phase)|Patients failing to achieve response (<50% MADRS score) in the parallal phase, will be offered additional 4 session (twice a week, 2 weeks) of 0.5 mg/kg ketamine over 40 minutes.
1625086|NCT02048228|Drug|genotyping guided therapy Ticagrelor, Clopidogrel|CYP2C19*2 carriers will be given 90 mg ticagrelor twice daily, and non-carriers and patients in the standard treatment group will be given 75 mg clopidogrel daily.
1625087|NCT02048228|Drug|standard therapy clopidogrel|All patients will be administrated with clopidogrel 75 mg daily for 5 consecutive days.
1625088|NCT02048215|Drug|Caffeine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
1625089|NCT02048215|Drug|Placebo|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
1625090|NCT02048215|Drug|Ephedrine|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
1625091|NCT02048215|Other|Hypocaloric diet|Patients are randomised to 30-day treatment with either EC (200/20mg t.i.d.) or placebo. The EC administration starts with an initial dose of 100/10 mg t.i.d. for the first week and then proceeds with the full dose of 200/20 mg t.i.d. Patients are hospitalised during the whole treatment period, at the metabolic unit of San Giuseppe Hospital-Istituto Auxologico Italiano at Piancavallo (VB, Italy). During the treatment period all patients are fed a hypocaloric diet (total energy content of ~70% of energy expenditure, as measured by indirect calorimetry), and containing 20% proteins, 55% carbohydrates, 25% fat half of which was monounsaturated, and 35 g/day fibres.
1625092|NCT02048189|Drug|LEVEMIR|
1625093|NCT02048189|Drug|APIDRA|
1625094|NCT02048150|Biological|anti-PSMA monoclonal antibody MDX1201-A488|Given IV
1625095|NCT02048150|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
1625096|NCT02048150|Other|diffuse optical imaging|Undergo IOOI
1625097|NCT02048150|Other|pharmacological study|Correlative studies
1625098|NCT02048150|Other|Laboratory Biomarker|Correlative studies
1625099|NCT02048150|Other|Questionnaire|Ancillary studies
1625100|NCT02048137|Device|Transcranial direct current stimulation|
1625101|NCT02048124|Device|25g standard needle|
1625102|NCT02048124|Device|25d ProCor needle|
1625140|NCT02047734|Drug|RPC1063 0.5 mg|oral capsule, daily for 24 months
1625141|NCT02047734|Drug|RPC1063 1 mg|oral capsule, daily for 24 months
1625142|NCT02047734|Drug|RPC1063 placebo|oral capsule, daily for 24 months
1625143|NCT02047734|Drug|Interferon β-1a|intramuscular injection, 30 µg, weekly for 24 months
1625103|NCT02048111|Biological|IB1001|"Prophylaxis (during Treatment and Continuation phases): 40 - 75 IU/kg twice weekly.
The starting dose for prophylaxis may be based on previous recombinant factor IX product use. The recommended starting prophylaxis dose is 40 - 60 IU/kg twice weekly, however, the investigator may prescribe up to 75 IU/kg twice weekly at their discretion (after clinically assessing the subject) and discretion of the subject.
The dose or the frequency of IB1001 prophylaxis may be adjusted at the discretion of the investigator."
1625104|NCT02048098|Drug|Vaginal misoprostol|400 µg vaginal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg vaginal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
1625105|NCT02048098|Drug|Buccal misoprostol|400 µg buccal misoprostol per 3 hours up to 6 doses. The treatment will be withold if the patient has strong uterine contractions. If abortion had not occured in 24 hour after the start of the study a second course of 400 µg buccal misoprostol per 3 hours up to 6 doses will be administered. If abortion had not occured in 48 hour after the start of the study it will be considered treatment failure and patient will be offered another induction/delivery method or to continue protocol.
1625106|NCT02048085|Drug|Ticagrelor|For ticagrelor arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with ticagrelor 180 mg prior to PCI followed by maintenance dose of 90 mg bid.
1625107|NCT02048085|Drug|Clopidogrel|For clopdigrel arm, randomized STEMI patients with a history of fibrinolysis within last 24-48 and undergoing PCI will be loaded with clopidogrel 300 mg prior to PCI followed by maintenance dose of 75 mg QD
1625108|NCT02048072|Drug|Gilenya|Autonomic testing during first dose administration of Gilenya.
1625109|NCT02048059|Drug|ANG1005|
1625110|NCT02048033|Device|Endogastric suturing|The Apollo Endosurgery OverStitch is an endoscopic equipment which involves the suturing by endogastric way to decrease the size of the anastomosis gastrojujenal or gastric pouch
1625111|NCT02048020|Drug|paclitaxel|Given IV
1625112|NCT02048020|Drug|carboplatin|Given IV
1625113|NCT02048020|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1625114|NCT02048020|Procedure|quality-of-life assessment|Ancillary studies
1625115|NCT02048007|Drug|Azithromycin|Biannual mass oral azithromycin to children, annual mass oral azithromycin to everyone
1625116|NCT02048007|Drug|Placebo|Biannual mass oral placebo to children
1625117|NCT02047994|Drug|Triple therapy|"Participants who are positive with Helicobacter pylori in Group1 will receive triple therapy.
Esomeprazole 40 mg bid for 10 days
Clarithromycin 500 mg bid for 10 days
Amoxicillin 1000 mg bid for 10 days"
1625118|NCT02047981|Drug|Azithromycin|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral azithromycin suspension every 6 months for 2 years
1625119|NCT02047981|Drug|Placebo|Children aged 1 month to 60 months per community will be offered weight or height-based, directly observed, oral placebo every 6 months for 2 years
1625120|NCT02047968|Behavioral|wake therapy|
1625121|NCT02047942|Behavioral|Center-based cardiac rehabilitation|
1625122|NCT02047942|Behavioral|Home-based training with telemonitoring guidance|
2011242|NCT02644564|Other|Ultrasonography|One doctor does the clinical examination, another does ultrasonography. Both doctors and patient are blinded until results have been registered on written forms. The results are then disclosed to the patient and doctors in order to plan further treatment.
1625124|NCT02047903|Drug|Afatinib|50, 40, 30 or 20 mg
1625127|NCT02047864|Dietary Supplement|Creatine monohydrate|
1625128|NCT02047851|Other|Acupuncture|Patients are randomized to real acupuncture or sham acupuncture if they are in the intervention group
1625129|NCT02047838|Other|Anti-mullerian hormone (AMH) level dosage.|
1625130|NCT02047838|Other|Follicle-stimulating hormone (FSH) level dosage.|
1625131|NCT02047838|Other|Antral follicle count (AFC).|
1625132|NCT02047825|Other|Upper limbs intervention|An 8-week intervention with different exercises will be performed. This intervention will focus on upper limbs. The exercises will include plaster of resistance, elastic bands and other exercises.
1625133|NCT02047825|Other|Usual treatment|Occupational therapy and physiotherapy, twice a week, as usual.
1625134|NCT02047799|Dietary Supplement|Calcitriol|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Calcitriol (1000 UI)
1625135|NCT02047799|Dietary Supplement|Control|Subjects whom were enrolled for 6 weeks of treatment with a daily dose of Placebo
1625136|NCT02047773|Other|Duration|If bacterial load checked on day 7 is less than 10^6 cfu/ml then antibiotics will be stopped on day 8 (results take 24hrs). If bacterial load remains higher than this then patients will continue on intravenous antibiotics. Bacterial load will be checked again on day 10. If bacterial load is less than 10^6 cfu/ml then antibiotics will be stopped on day 11. If bacterial load remains higher than this then the patient will complete a 14day course of antibiotics. All patients will be seen and bacterial load assessed on day 1, day 7, day 10, day 14 and day 21.
1625137|NCT02047773|Drug|Colomycin|If there is a clinical deterioration a second antibiotic to augment treatment (Colomycin) will be added for both arms of the study.
1625138|NCT02047773|Drug|Meropenem|
1625139|NCT02047747|Drug|Dacomitinib|Dacomitinib 45 mg will be administered orally daily. Treatment cycles will consist of 28 days.
2011243|NCT02643381|Drug|Etomidate|Patients randomized to this group will receive etomidate immediately prior to emergency endotracheal intubation.
2011244|NCT02643381|Drug|Ketamine|Patients randomized to this group will receive ketamine immediately prior to emergency endotracheal intubation.
2011245|NCT02643381|Procedure|Emergency Endotracheal Intubation|Patients enrolled in the study will be endotracheally intubated. (A breathing tube will be placed into the patient's mouth and trachea). This procedure is being done as part of standard emergency care. Standard endotracheal tubes will be used. Our hospital uses primarily Mallinckrodt (TM) brand endotracheal tubes.
1625144|NCT02047734|Drug|IFN β-1a placebo|intramuscular injection, weekly for 24 months
1625145|NCT02047721|Behavioral|Exercise|The intervention gradually increases EE from 150-200 kcal/day 5 days per week to a target of 400 kcal/d 5 days per week and will last a total of 12 weeks.
1625146|NCT02047721|Behavioral|Diet|A supervised diet program which has been successfully implemented by our group with a goal being to reduce energy intake by ~2000 kcal/week.
1625148|NCT02047682|Behavioral|Biopsychosocial|
1625149|NCT02047682|Behavioral|Reference|
1625150|NCT02047669|Behavioral|Biopsychosocial|
1625151|NCT02047669|Behavioral|Reference|
1625152|NCT02047656|Drug|LFF269|LFF269 capsules twice daily (b.i.d)
1625153|NCT02047656|Drug|Placebo to LFF269|Placebo LFF269 b.i.d for 10 days in healthy volunteers
1625154|NCT02047643|Device|Algorithm ON|See Arm description.
1625155|NCT02047630|Drug|Generic latanoprost|
1625156|NCT02047630|Drug|Brand-name latanoprost|
1625157|NCT02047617|Device|the standard physiotherapy group|Mobilization and rehabilitation program is progressively introduced after clinical stabilization
1625158|NCT02047617|Device|standing table group|The protocol involved a stepwise process to gradually raise the subject into a standing position on the standing table platform
1625159|NCT02047604|Drug|SAN-300|
1625160|NCT02047604|Drug|Placebo|
1625161|NCT02047578|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
1625162|NCT02047565|Drug|60mg edoxaban|
1625163|NCT02047565|Drug|180mg edoxaban|
1625164|NCT02047565|Drug|50 IU/kg Beriplex P/N|
1625165|NCT02047565|Drug|25 IU/kg Beriplex P/N|
1625166|NCT02047565|Drug|10 IU/kg Beriplex P/N|
1625167|NCT02047552|Drug|Iron sucrose|Iron sucrose 100 mg IV will be dosed daily for up to seven days if, on morning laboratory analysis, (1) TSAT < 25%, (2) Serum iron concentration < 150 ug/mL, and (3) Serum ferritin concentration < 1,500 ng/mL. Thus, the maximum possible cumulative dose of iron sucrose over the one-week dosing period will be 700 mg.
1625168|NCT02047552|Drug|Oxandrolone|10 mg PO Q12 hours for seven days
1625169|NCT02047552|Other|IV iron placebo|100 mL normal saline.
1625170|NCT02047552|Other|Oxandrolone placebo|similar color and size sugar pill
1625171|NCT02047539|Drug|Aspirin|1000 mg/day of aspirin 1000 mg/day of sugar pill
1625172|NCT02047539|Drug|Placebo|
1625173|NCT02047513|Drug|perioperative nab-paclitaxel/gemcitabine|2 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles) followed by 3 weeks of rest and subsequent tumor surgery. Starting within 12 weeks after surgery adjuvant chemotherapy with 4 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles)
1625174|NCT02047513|Drug|adjuvant nab-paclitaxel/gemcitabine|Tumor surgery followed by adjuvant chemotherapy with 6 cycles of nab-paclitaxel/gemcitabine (nab-paclitaxel 125 mg/m2, gemcitabine 1000 mg/m2 on day 1, 8 and 15 of an 28 day-cycles, starting within 12 weeks after surgery)
2011246|NCT02643381|Device|Mechanical Ventilation|Patients enrolled in the study will be mechanically ventilated, using a standard ventilator used in our hospital. The mechanical ventilator is attached to the patient's endotracheal tube and helps sustain the patient's life. Our hospital uses several brands of mechanical ventilators.
2011247|NCT02642042|Drug|Docetaxel|Given IV
2011248|NCT02642042|Other|Laboratory Biomarker Analysis|Correlative studies
1625178|NCT02047474|Drug|oxaliplatin|Given IV
1625179|NCT02047474|Drug|leucovorin calcium|Given IV
1625180|NCT02047474|Drug|irinotecan hydrochloride|Given IV
1625181|NCT02047474|Drug|fluorouracil|Given IV
1625182|NCT02047474|Procedure|therapeutic conventional surgery|Undergo surgical resection
1625183|NCT02047474|Other|laboratory biomarker analysis|Correlative studies
1625184|NCT02047461|Drug|ALXN1101|IV infusion
1625185|NCT02047448|Procedure|Pharmacist Counseling|The hospital pharmacist will meet with the patient and complete medication reconciliation, assess the patient's understanding of the medications, and identify medication-related problems. The hospital pharmacist will complete a pharmacist discharge care plan and a copy will be sent to the participating community pharmacist. The patients will be scheduled for the first meeting with their community pharmacist within 1 week of hospital discharge. The community pharmacist will interview the patient about their general health and any current symptoms of heart failure or COPD, identify any additional medication-related problems, follow-up on any issues as described in the pharmacist discharge care plan, and provide patient education. The patients will then meet with their community pharmacist for counseling and patient education at monthly intervals for 6 months following hospital discharge.
1625186|NCT02047435|Behavioral|Information, event and workshops at a cartoon museum|"An event at the Storm P. Museum consisting of:
A guided tour at the museum
A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.
The museum serves a refreshment and offer participants a season pass to the museum.
And
Workshops at The Storm P. museum, for up to 12 months with approximately two workshops a months. In collaboration with the museum the participants create memory material for nursing home resident with dementia. The workshop will use narrative as a method to give participants a mutual relationship that is perceived as meaningful and rewarding for each participant and in the dialogues a mutual understanding is created. The museum staff facilitates the process of storytelling using events, significant stories and artistic works by Storm P., to encourage the participants, via the method known as narrative interview, to share similar stories from their life."
1625187|NCT02047435|Behavioral|Information and event at a cartoon museum|"1. An event at the Storm P. Museum consisting of:
A guided tour at the museum
A representative from the municipal DaneAge Association will tell about the municipality's activities for the elderly.
The museum serves a refreshment and offer participants a season pass to the museum."
2011249|NCT02642042|Drug|Trametinib|Given PO
2011250|NCT02641093|Drug|Pembrolizumab|Pembrolizumab administered one week prior to surgery and then every three weeks in the adjuvant setting for a total of 7 doses.
2011251|NCT02641093|Procedure|Surgery|gross total surgical resection
1625188|NCT02047422|Drug|Furosemide|furosemide (doubling previous furosemide dose)
1625189|NCT02047422|Drug|metolazone|metolazone (add 2.5mg qod)
1625190|NCT02047422|Drug|furosemid/spironolactone|spironolactone (doubling previous spironoalctone dose or add 12.5mg BID if previous non-user)
1625191|NCT02047422|Drug|metolazone/spironolactone|no spironolactone (maintaining previous spironolactone dose or not add spironolactone if previous non-user)
1625192|NCT02047383|Other|Respiratory infection|An assessment of the patients included in the study will be conducted
1625193|NCT02047370|Other|Diaphragm stretching|The therapist stands behind the patient and passes his hands around the thoracic cage, carefully introducing fingers under the costal margins. The patient slightly rounds the trunk in order to relax rectus abdominis. During the exhalation of the patient the therapist grasps the lower ribs and costal margin and eases the hands caudally. This traction was maintained during 5-7 minutes.
1625194|NCT02047370|Other|Placebo|The same therapist, patient position and duration of the technique, but using disconnected ultrasound
1625196|NCT02047344|Drug|Antroquinonol|patients will receive one 12 week cycle of antroquinonol 200 mg t.i.d. or until disease progression, unacceptable toxicity, non compliance or withdrawal of consent by the patient, or the investigator decides to discontinue treatment, whichever comes first.
1625197|NCT02047331|Procedure|periarticular injection|patients were performed bupivacaine solution to the periarticular soft tissues during surgery by the surgeon.
1625198|NCT02047331|Procedure|fascia iliaca block|patients were performed fascia iliaca block with bupivacaine solution before surgery.
1625199|NCT02047318|Drug|LUM001|Dosing of LUM001 with the objective of achieving optimal control of pruritus at a dose level that is tolerated by the subject and up to a maximum daily dose of 280 μg/kg LUM001 or 20 mg total dose.
1625200|NCT02047305|Device|Radiofrequency Ablation|Patients with a histopathological diagnosis of moderate-grade intra-epithelial neoplasia (MGIN), high-grade intra-epithelial neoplasia (HGIN) and/or early flat-type SCCA of the esophagus, are treated with radiofrequency ablation, with repeat endoscopy and follow-up treatment at 3 month intervals.
1625201|NCT02047292|Device|THA Corail PinnacleCoC28|Uncemented THA with Corail stem and Pinnacle acetabular cup with CoC 28 mm head
1625202|NCT02047292|Device|THA Corail DeltaMotion36|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 36 mm head
1625203|NCT02047292|Device|THA Corail DeltaMotion40|Uncemented THA with Corail stem and DeltaMotion acetabular cup with 40 mm head
1625204|NCT02047279|Procedure|maze procedure|"The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases."
1625205|NCT02047279|Procedure|mitral valve surgery|For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
1625206|NCT02047279|Procedure|left atrial reduction|The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape.
1625207|NCT02047266|Procedure|MICS CABG|Minimally invasive coronary artery bypass grafting - beating heart multi-vessel procedure in which the anastomoses are performed under direct vision through a lateral left mini-thoracotomy. The left internal thoracic artery is used to graft the left anterior descending artery or circumflex artery territories. Radial artery or saphenous vein are used (Y - grafts) to graft another myocardial territories. Right internal thoracic artery can be used as free Y-graft, as in-situ graft with radial artery (extension technique) or as in-situ graft without composite technique. Right gastroepiploic artery can be used to graft right coronary artery territory. Hybrid approach (MICS CABG + PCI), parallel transfemoral extracorporeal circulation without cardioplegia and CABG from the ascending aorta are acceptable for achievement of the complete revascularization.
1625208|NCT02047266|Procedure|OPCABG|Off-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Mechanical Devices are used for coronary artery stabilization and heart positioning. Pericardial traction sutures are used to position the heart where appropriate. Blowers and Intracoronary shunts are used routinely. Anticoagulation is obtained using sodium heparin at a dose of 2mg/kg with supplemental doses to maintain adequate heparinisation (Activated clotting time>250seconds).
1625209|NCT02047266|Procedure|ONCABG|On-pump coronary artery bypass grafting via sternotomy (aortocoronary bypass grafting or aortic no-touch technique composite grafting). Normothermic cardiopulmonary bypass and complex blood ante-retrograde cardioplegia are used. All patients are cannulated with an proximal aortic cannula and two-stage right atrial cannula. Extracorporeal circulation is provided by the Terumo System-1 heart-lung machine using cardiopulmonary bypass systems with physiological surfaces and opened venous reservoirs. The left internal thoracic artery is used to graft the left anterior descending artery, and radial artery or saphenous vein segments are used to graft another myocardial territories. Anticoagulation is obtained using sodium heparin at a dose of 3mg/kg (ACT, activated clotting time>450seconds).
1625210|NCT02047266|Device|Octopus® Nuvo, Starfish® Non-Sternotomy, thoracic retractor (ThoraTrak®)|Octopus® Nuvo - MICS CABG tissue stabilizer available for minimally invasive procedures. It minimizes the motion of a small area of the heart while the rest of the heart continues to beat normally and allows to perform anastomosis through a small incision. Starfish® Non-Sternotomy (NS) - MICS CABG heart positioner available for minimally invasive procedures. It allows for the positioning of the beating heart through a small incision, bringing coronary targets into the operative thoracotomy window. ThoraTrak® - a reusable, stainless steel MICS thoracic retractor system for minimally invasive heart surgery with multiple interchangeable blades, which allows to harvest left internal thoracic artery and to perform anastomosis through a small left thoracotomy(Medtronic, Inc., Minneapolis, MN).
1625211|NCT02047266|Device|Starfish®, Octopus®, Clearview® blower, ClearView® Shunt|Starfish® - heart positioner is designed to position and to hold the heart to give the surgeon easy access to the vessel requiring the bypass graft. Octopus® - tissue stabilizer minimizes / limits the motion of a small area of the heart while the rest of the heart continues to beat normally. This allows the surgeon to perform CABG surgery without stopping of the heart and without using the heart-lung machine. ClearView® Blower is designed to improve visualization of the surgical site. An irrigation mist gently clears blood from the site, improving visualization without drying or desiccating delicate tissue. The ClearView® shunt - Intracoronary shunt provides a clear anastomotic site during the procedure while providing blood flow to the distal myocardium (Medtronic, Inc., Minneapolis, MN)
2011252|NCT02641093|Radiation|Radiation Therapy|60-66 Gy over 6 weeks
2011253|NCT02641093|Drug|Cisplatin|Weekly during radiation therapy for 6 doses only for patients with high risk pathological features
2011254|NCT02639182|Drug|AGS-16C3F|Intravenous (IV) infusion
1625215|NCT02047227|Drug|Pergoveris®|Pergoveris (follitropin alfa and lutropin alfa) was administered subcutaneously once daily with a starting dose of 300 International Unit (IU) recombinant human follicular stimulating hormone (rhFSH)/ 150 IU recombinant human luteinizing hormone (rhLH) after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 millimeter (mm); 250 microgram (mcg) of r-hCG (Ovidrel) was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments while maintaining the 2:1 ratio of r hFSH to r-hLH in the Pergoveris group based on the subject's response per site standard clinical practice.
1625216|NCT02047227|Drug|GONAL-f®|GONAL-f (r-hFSH) was self-administered subcutaneously once daily at a starting dose of 300 IU after confirmation of down regulation up to 21 days. After follicle attained mean diameter of 17-18 mm; 250 mcg of r-hCG was administered once subcutaneously to trigger final follicular maturation as per site standard practice. The dose adjustment for r-hFSH was allowed in 75 IU increments based on the subject's response per site standard clinical practice.
1625217|NCT02047227|Drug|Recombinant human chorionic gonadotrophin (r-hCG)|On r-hCG day, 250 mcg of r-hCG was administered once subcutaneously
1625218|NCT02047214|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
1625219|NCT02047214|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
1625220|NCT02047201|Radiation|IMRT|IMRT treatment planning using FDG-PET/CT images after induction chemotherapy (IC).
1625221|NCT02047201|Radiation|PET/CT|Assessing tumor response using FDG-PET/CT.
1625222|NCT02047201|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
1625223|NCT02047201|Drug|Fluorouracil|750 mg/m2 continuous infusion for 120 h IV (in the vein) every 3 weeks. Number of cycles: 3.
1625224|NCT02047201|Drug|Cisplatin|75 mg/m2, IV (in the vein) on day 1 every 3 weeks. Number of cycles: 3.
1625225|NCT02047175|Drug|Telmisartan/S-Amlodipine|Telmisartan/S-Amlodipine 40/2.5mg 2T PO, QD for 9days
1625226|NCT02047175|Drug|Rosuvastatin|Rosuvastatin 20mg 1T PO, QD for 5days
1625227|NCT02047175|Drug|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 5days
1625228|NCT02047175|Drug|Telmisartan/S-Amlodipine + Rosuvastatin|Telmisartan/S-Amlodipine 40/2.5mg 2T + Rosuvastatin 20mg 1T PO, QD for 9days
1625229|NCT02047162|Drug|Bismuth subsalicylate|
1625230|NCT02047162|Other|Placebo|Chewable tablets identical to intervention tablets, but missing the bismuth subsalicylate
1625231|NCT02047149|Drug|Zileuton (Zyflo®) Dasatinib (Sprycel®)|To determine the maximum dose of zileuton/dasatinib in subjects with CML
1625232|NCT02047149|Drug|Dosing with Zileuton/Dasatinib in CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
1625233|NCT02047149|Drug|Daily dosing of Zileuton/Dasatinib|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
1625234|NCT02047149|Drug|Daily dosing with Zileuton/Dasatinib for CML|Three dose levels of daily zileuton will be studied in conjunction with dasatinib to define the MTD
1625235|NCT02047136|Other|Treatment group (on low histamine diet)|78 subjects who come to Allergy Centre for treatment of idiopathic urticaria, with or without angioedema and pruritus (U/A/P), will be randomized into two parallel groups; treatment group (TG) will be asked to follow a histamine-restricted diet for 4 weeks and the control group (CG) will be asked to follow a well-balanced diet instructed by a dietitian for 4 weeks. A well-balanced diet for the CG subject is tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
1625236|NCT02047136|Other|Well-balanced diet|Diet tailor-made by the dietitian according to subject's usual intake to ensure that the subject's energy requirement is met and all food groups are consumed.
1625237|NCT02047123|Dietary Supplement|Raw Flaxseed|The participants were randomly single blind controlled trial distributed into three groups: (1, n =30), (2, n =32), (3, n =27). For 30 days, participants in group 1 took with 15g flaxseed mixed with yoghurt and diet,(the 15g of flaxseed that was provided in addition to the linen package spoon so all would take far it) group 2 took yoghurt and diet, and group 3 only received the diet.
1625238|NCT02047110|Drug|Placebo|Placebo
1625239|NCT02047110|Drug|BI 655066|Medium Dose
1625240|NCT02047110|Drug|BI 655066|Low Dose
1625241|NCT02047110|Drug|BI 655066|High Dose
1625242|NCT02047097|Drug|dimethyl fumarate|Provided under routine clinical care
1625243|NCT02047071|Device|Continuous positive airways pressure|Optimal Continuous positive airways pressure treatment every night plus standard care for OSA consisting of hygienic-dietary advice and lifestyle counseling.
1625244|NCT02047045|Procedure|acupuncture|Electro-acupuncture at bilateral ST25, SP14 ,and ST37. Patients will be treated once per day for 30 minutes, 5 times/week for the first 2 weeks and 3 times/week for the next 6 weeks. Each treatment cycle will include 28 sessions for continuous 8 weeks.
1625326|NCT02046499|Drug|Oxytocin|Oxytocin will be administered intravenously as per standard protocol
1625245|NCT02047045|Drug|Prucalopride|Prucalopride Succinate will be taken orally at the dose of 2mg/day in the morning before breakfast. Each treatment cycle will be given for continuous 8 weeks.
1625246|NCT02047032|Procedure|acupuncture|For BL33, the needle (75mm) will be inserted at the point upper and outside of BL33. Insert the needle with a 30-45°angle to a depth of 50-60 mm. The needle will be manipulated with an even lifting, thrusting and twisting method and the sense of soreness and distention will radiate to the perineal region or the anus. For BL35, the needle will be inserted upward and outward slightly with an even lifting, thrusting and twisting method. The sense of soreness and distention will radiate to the perineal region or the anus. The electric stimulator will be put on the two pair of points with a spare-dense wave, 10/50 Hz, 0.1-5.0 mA. The current intensity will be increased until the participant can not stand.
1625247|NCT02047032|Drug|solifenacin|Solifenacin used in this trial is produced by Astellas Pharma Europe B.V.(Country medicine accurate character No. J20090109 )
1625248|NCT02047032|Procedure|PFMT|Intensity of the PFMT exercises will conform to the guideline of National Institute for Health and Clinical Excellence (NICE).
1625249|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 30/16 mg, tablet, orally, once daily
1625250|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16 mg, tablet, orally, once daily
1625251|NCT02047019|Drug|Candesartan Cilexetil|Candesartan Cilexetil, 16 mg, capsule, orally, once daily
1625252|NCT02047019|Drug|Candesartan matching placebo|Candesartan matching placebo, capsule, orally, once daily
1625253|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106) 30/16mg matching placebo, tablet, orally, once daily
1625254|NCT02047019|Drug|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106)|Nifedipine GITS/Candesartan Cilexetil FDC(BAY98-7106), 60/16mg matching placebo, tablet, orally, once daily
1625255|NCT02047006|Drug|Rivaroxaban 10 mg|"Measurement of AUC of rivaroxaban and effect on coagulation assays:
Venous blood samples (8.5 ml) are collected immediately before (t=0) and at t= 0,5, 1, 2, 4, 8, 12, 24, 36 and 44 hours after administration of rivaroxaban.
Effect of dialysis on levels of rivaroxaban:
Venous blood samples (8.5 ml) are collected at the start of dialysis (t=0) and at t=1, 2, 3 and 4 hours."
1625256|NCT02046993|Behavioral|Smart phone telemonitoring HBP + enhanced usual care|Smart phone telemonitoring home Blood pressure (HBP) Patients input their HBP readings to their smart phone which is sent to the data center regulary
1625257|NCT02046993|Behavioral|Enhanced usual care|Encouraged to do HBP measurement and record BP readings in paper diary
1625258|NCT02046980|Procedure|Gufoni|
1625259|NCT02046980|Procedure|Vibration|
1625260|NCT02046980|Procedure|Sham|
1625261|NCT02046967|Procedure|Endovenous laser ablation with 940 nm bare fiber|Endovenous laser ablation with 940 nm Diode laser using a bare fiber for treating the Great Saphenous Vein.
1625262|NCT02046967|Procedure|Endovenous steam ablation with steam vein sclerosis system.|Endovenous steam ablation with steam vein sclerosis.
1625263|NCT02046941|Behavioral|Speech Production Treatment|This treatment employs a response-contingent hierarchy made up of verbal modeling/repetition, graphic cueing, integral stimulation, and articulatory placement instruction.
1625264|NCT02046928|Drug|A6|A6 is self-administered subcutaneously two times a day for 6 cycles (1 cycle = 28 days).
1625268|NCT02046889|Behavioral|Bicycle Training Intervention|
1625269|NCT02046876|Other|Multimodal Physiotherapy Program|Multimodal Physiotherapy Program integrates: physical land-based therapeutic exercise, adapted swimming and health education
1625270|NCT02046863|Device|Automated Programming|Prototype DBS-Expert software will be used to guide a clinician through DBS programming.
1625271|NCT02046850|Drug|selumetinib|Volunteers will receive a single oral dose of 75 mg selumetinib on day 1 (Treatment A).
1625272|NCT02046850|Drug|rifampicin|Volunteers will receive single, daily, oral doses of 600 mg rifampicin on Days 4 to 11 (Treatment B).
1625273|NCT02046850|Drug|selumetinib|On day 12 volunteers will receive a single oral dose of 75 mg selumetinib (Treatment C).
1625274|NCT02046850|Drug|rifampicin|On day 12 volunteers will receive a single oral dose of 600 mg rifampicin. Once daily rifampicin administrations will continue through to Day 14 (Treatment C).
1625275|NCT02046837|Behavioral|Supervised 1:1 exercise|The exercise program will be delivered in a personal training (1:1) format by a certified exercise specialist.
1625276|NCT02046837|Behavioral|Supervised group exercise|The exercise program will be delivered in a group format (4-8 participants per group) by a certified exercise specialist.
1625277|NCT02046837|Behavioral|Home-based exercise|The exercise program will be executed independently by participants in a home-based setting. Home-based participants will be supported with remote health coaching and smartphone technology.
1625278|NCT02046824|Device|Xtra®, Sorin cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
1625279|NCT02046824|Device|C.A.T.S.®, Fresenius cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
1625280|NCT02046824|Device|CardioPAT®, Haemonetics, cellsaver|when at least 750 mL of wound blood is collected in the reservoir during the operation, the washing process will be started using one of the three cell savers (see above). Samples will be taken from before and after the washing process. Thereafter, the blood will be retransfused to the patient.
1625281|NCT02046824|Other|no use of cell saver|When less than 750 ml of wound blood is collected in the reservoir at the end of the operation, patients will be automatically allocated to the control group. The collected blood will be cast away according to daily clinical practice and recommendations of the manufacturers.
2011255|NCT02639182|Drug|Axitinib|Oral
2011256|NCT02636322|Drug|Rituximab|"Smart Start: Rituximab 375 mg/m2 by vein once.
At completion of Smart Start Participants on R-EPOCH: Rituximab 375 mg/m2 by vein on Day 1 of a 21 day cycle for 6 cycles.
At completion of Smart Start Participants on R-CHOP: Rituximab 375 mg/m2 by vein on Day 1 of a 21 day cycle for 6 cycles."
2011257|NCT02636322|Drug|Ibrutinib|"Smart Start: Ibrutinib 560 mg by mouth 1 time every day in a 21 day cycle for 2 cycles.
At completion of Smart Start Participants on R-EPOCH: Ibrutinib 560 mg by mouth 1 time every day in a 21 day cycle for 6 cycles."
2011258|NCT02636322|Drug|Lenalidomide|"Smart Start: Lenalidomide 25 mg by mouth 1 time every day on Days 1-10 of each 21 day cycle for 2 cycles.
At completion of Smart Start Participants on R-EPOCH: Lenalidomide 25 mg by mouth 1 time every day on Days 1 - 10 of each 21 day cycle for 6 cycles."
1625285|NCT02046798|Drug|ASP3652|oral
1625286|NCT02046785|Other|0.9% saline solution|comparing values obtained before and after administration of 500 ml of 0.9% salin
1625287|NCT02046772|Drug|Bupivacaine low dose|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
1625288|NCT02046772|Drug|Bupivacaine standard dose|Single intradural standard dose of bupivacaine
1625289|NCT02046772|Drug|Morphine Chloride|A dose of morphine chloride added to a low dose solution of bupivacaine administered intradural
1625290|NCT02046759|Other|Pharmacist- Intervention|Patients received additional education on basic facts about asthma, role of medications, the difference between long-term control medications and quick-relief medications, as well as patient skills in the first visit then reinforcement every two weeks.. The importance of proper inhaler technique, avoidance of asthma triggers and self-monitoring of asthma were also highlighted. Visual aids, physical demonstration as well as written information resources were supplied. Asthma care plans were tailored to patient needs and preferences. Patients were informed how to detect early signs of worsening asthma, when and how to seek medical care as appropriate.
1625291|NCT02046759|Other|Routine Care|Patients received usual care delivered by physician without pharmacist intervention. Patients were prescribed asthma medication with summarized basic information on asthma and medication use. Follow-up visits were not planned on consistent basis, but rather individually according to the disease status. No asthma action plans were provided.
1625292|NCT02046746|Other|Oral Nutritional Supplement (ONS)|renal specific commercially available ONS
1625293|NCT02046733|Drug|Ipilimumab|Induction phase: i.v. 3 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation)
1625294|NCT02046733|Drug|Nivolumab|Induction phase: Nivolumab i.v. 1 mg/kg, once every 3 weeks × 4 cycles, to start within 6-8 weeks (42-56 days) from start of chemotherapy cycle 4, and not more than 2 weeks (14 days) after the date of randomisation) Maintenance Phase: Nivolumab 240 mg i.v once every 2 weeks for a maximum of 12 months from start of maintenance (the first dose of maintenance nivolumab will be administered 3 weeks after the last IMP doses of induction Phase).
1625295|NCT02046720|Drug|Propofol induced sedation|"Propofol was administered using a commercially available target-controlled infusion with an incorporated pharmacokinetic model developed by Schnider (Base Primea , Fresenius-Kabi, Brezins, FRANCE)12. The initial effect-site target concentration of propofol (0.5 μg/ml) was incremented by 0.5 μg/ml every 5 minutes to ensure equilibration between plasma concentration and effect site, until loss of eyelash reflex. From the beginning of infusion until LOER patients received no other agent besides propofol for the duration of the trial.
The BIS index was compared between a young population (18 to 64 years old) and an elderly population (65 and more)"
1625296|NCT02046707|Other|initial evaluation|
1625297|NCT02046707|Other|Period of cardiac rehabilitation|
1625298|NCT02046707|Other|final evaluation|
1625299|NCT02046707|Other|Concentric and eccentric exercise sessions|
1625300|NCT02046694|Drug|Allopurinol|At week 1, patients will begin allopurinol daily (100 mg for weight >30 kg, 50 mg for weight ≤30 kg) and will restart 6-MP and methotrexate at 50 percent of the most recent dose. Patients will continue taking allopurinol in combination with 6-MP and methotrexate for the duration of the study (total of 8 weeks).
2011259|NCT02636322|Drug|Etoposide|At completion of Smart Start Participants on R-EPOCH: Etoposide 50 mg/m2 by vein on Days 1 - 4 of each 21 day cycle for 6 cycles.
1625302|NCT02046655|Drug|Corifollitropin alfa|
1625303|NCT02046655|Drug|rFSH|
1625304|NCT02046642|Behavioral|Maternal rest in left lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their left sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
1625305|NCT02046642|Behavioral|Maternal rest in right lateral position|After initial amniotic fluid index measurements, the participating pregnant women were instructed to turn their right sides and rest in that position for 15 minutes before a second amniotic fluid index measurement
1625306|NCT02046629|Drug|Teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
1625307|NCT02046629|Drug|cholestyramine|Pharmaceutical form:power Route of administration: oral
2011260|NCT02636322|Drug|Prednisone|"At completion of Smart Start Participants on R-EPOCH: Prednisone 100 mg by mouth on Days 1 - 5 of each 21 day cycle for 6 cycles.
At completion of Smart Start Participants on R-CHOP: Prednisone 100 mg by mouth on Days 1 - 5 of each 21 day cycle for 6 cycles."
2011261|NCT02636322|Drug|Vincristine|"At completion of Smart Start Participants on R-EPOCH: Vincristine 0.4 mg/m2 by vein on Days 1 - 4 of each 21 day cycle for 6 cycles.
At completion of Smart Start Participants on R-CHOP: Vincristine 1.4 mg/m2 by vein on Days 1 of each 21 day cycle for 6 cycles."
1625312|NCT02046590|Drug|Propofol|
1625313|NCT02046590|Other|General anesthesia|
1625314|NCT02046577|Dietary Supplement|Vitamin D3|Cholecalciferol administration
1625315|NCT02046577|Dietary Supplement|Placebo|Placebo liquid
1625318|NCT02046551|Drug|Atomoxetine|
1625319|NCT02046551|Drug|Placebo|
1625320|NCT02046538|Drug|Leucovorin|400 mg/m2 IV over two hours (or administered concurrently with oxaliplatin or irinotecan, depending on the assigned regimen)
1625321|NCT02046538|Drug|Oxaliplatin|85 mg/m2 IV over two hours
1625322|NCT02046538|Drug|5-FU|400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
1625323|NCT02046538|Drug|Irinotecan|180 mg/m2 IV over 90 minutes
1625324|NCT02046525|Biological|Autologous fecal microbiota therapy|
1625325|NCT02046512|Dietary Supplement|Probiotic|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
1625327|NCT02046499|Drug|Oxytocin ergometrine|Oxytocin ergometrine will be administered intra-musculalry
1625328|NCT02046486|Drug|Ticagrelor 180mg whole tablets|
1625329|NCT02046486|Drug|Ticagrelor 180mg crushed and dispersed|
1625330|NCT02046473|Procedure|Volumetric Flow in TIPS|Subjects who have a TIPS (transjugular intrahepatic portal-systemic shunt) for portal hypertension will undergo a clinical 3D ultrasound to determine if the TIPS is working properly. Additional ultrasounds will be obtained during the subject's clinically ordered ultrasound(s). These measurements will be taken by using a second ultrasound probe (plastic hand held device that is rubbed along the subject's abdomen). 15 minutes will be added to your clinically ordered exams that are completed 4 times a year.
1625331|NCT02046460|Drug|Acetylsalicylic acid|acetylsalicylic acid, 300mg o.p.d.
1625332|NCT02046460|Drug|vitamin K-antagonist|vitamin K-antagonist, dosage according to INR 2.0-3.0
1625333|NCT02046447|Drug|Primary Cervical Dystonia (Trihexyphenidyl)|After the baseline testing these subjects will receive a dose of trihexyphenidyl 2 mg an hour prior to the second functional magnetic resonance imaging (fMRI) scan. This is to test the change in cerebral blood flow based on blood-oxygen-level dependent (BOLD) contrast during a precision gripping task after administration of trihexyphenidyl compared to change in BOLD contrast during a precision gripping task. The subjects will be done with the study after the second MRI scan has been completed.
1625334|NCT02046447|Other|Controls Primary Cervical Dystonia (Trihexyphenidyl)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
1625335|NCT02046447|Other|DYT 1 Dystonia (Healthy Control)|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
1625336|NCT02046447|Other|DYT 1 Dystonia|These subjects will receive the following: 1) data about clinical movement disorder history, age, gender, height, weight, and other medical conditions; 2) clinical neurological examination; 3) tests assessing cognitive abilities including: the Montreal Cognitive Assessment, Stroop, Digit Span, and Brief Test of Attention (BTA); 4) measures of anxiety and depression: the Beck Depression Index (BDI II). Only participants aged 18+ will be given the BDI; and 5) Functional magnetic resonance imaging (fMRI) and structural MRI will be performed.
1625337|NCT02046434|Drug|Glycerol Phenylbutyrate|
1625338|NCT02046421|Drug|mifepristone|Given PO
1625339|NCT02046421|Drug|carboplatin|Given IV
1625340|NCT02046421|Drug|gemcitabine hydrochloride|Given IV
1625341|NCT02046421|Other|laboratory biomarker analysis|Correlative studies
1625342|NCT02046421|Other|pharmacological study|Correlative studies
1625343|NCT02046408|Other|Computer Tablet|
1625344|NCT02046395|Drug|amlodipine, hydralazine, terazosin or hydrochlorothiazide|In the washout period, the Ace Inh or ARB classes of medicine(s) that are part of the patient's antihypertensive regimen will be discontinued. The patient will be started on alternative therapy with medications that are approved by the Food and Drug Administration for treatment of high blood pressure (such as amlodipine, hydralazine, terazosin or Hydrochlorothiazide) for control of their blood pressure.
1625345|NCT02046382|Drug|IV Acetaminophen|1000mg dose of IV acetaminophen in 100mL solution every 8 hours for 48 hours. The first dose will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
1625346|NCT02046382|Drug|Placebo|100 mL of Normal Saline every 8 hours for 48 hours. The first does will be administered intraoperatively following delivery of the baby. A total of 6 doses will be given.
1625349|NCT02046343|Behavioral|Health education|Group health education sessions delivered by a promotora approximately 90 minutes in length. In the PA arm, health education incorporates at least 30 minutes group exercise.
1625350|NCT02046343|Behavioral|Telephone Counseling|Brief (10 minute) telephone counseling calls delivered by promotoras using motivational interviewing techniques. The counseling calls will emphasize behavior change strategies, including self-monitoring, goal setting, reinforcement, problem solving, stimulus control, and enlisting social support.
1625351|NCT02046343|Other|Newsletter|Educational, motivational and informational newsletters tailored for each community and hand-delivered by promotoras to participant homes.
1625352|NCT02046343|Other|Environmental Change|Create a site atmosphere that promotes PA and increases the number of PA program offerings.
1625353|NCT02046330|Device|Deep Brain Stimulation Model 3387 Model 3389|Implantation of all devices will be performed at a single session. Lead implantation will take place under local anesthesia, with implanted pulse generator (IPG) implantation under general anesthesia. The stereotaxic frame will be fitted on the day of surgery, following standard stereotactic surgical procedure. The leads will be inserted so that the stimulation sites span superolateral median forebrain bundle.
1625354|NCT02046317|Drug|Femoral Nerve Block|Femoral Nerve Block for isolated femur fractures
1625355|NCT02046304|Drug|Gemcitabine|Starting dose: 400 mg/m2 by vein on days 1, 8, 22, 29, 43, and 50.
1625356|NCT02046304|Radiation|Radiation Therapy|Radiation therapy dose of 50 Gy in 25 fractions at 2.0 Gy per fraction. Radiotherapy given once daily (Monday through Friday) for 5 weeks.
1625357|NCT02046291|Drug|Romiplostim|Romiplostim at the assigned dose will be administered subcutaneously (SQ) once a week for 6 weeks. The dose will be assigned at the time of subject registration. This is a dose escalation to determine the maximum tolerated dose. The doses include 4 mcg/kg/dose, 6 mcg/kg/dose, 8 mcg/kg/dose, and 10 mcg/kg/dose.
1625358|NCT02046278|Device|LifeSeal™ Kit|
1625359|NCT02046265|Behavioral|Step Up to Prevention|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
1625360|NCT02046265|Behavioral|Step Up to Prevention: knowledge|Participant receives an individual computer-delivered information session and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
1625361|NCT02046265|Behavioral|Step Up to Prevention:belief|Participant receives a one-on-one tailored educational session with a trained study team member and participant is offered the HPV vaccine only by their nurse practitioner in clinic.
1625362|NCT02046265|Behavioral|Offered HPV vaccine only|Participant is offered the HPV vaccine only by their nurse practitioner in clinic.
1625363|NCT02046252|Drug|Oral naltrexone|50 mg/day
1625364|NCT02046252|Drug|Naltrexone implant|monthly
1625365|NCT02046239|Procedure|Suture Group|
1625366|NCT02046239|Biological|Staple Group (control)|
1625367|NCT02046226|Device|Oxygenesys(TM) Dissolved Oxygen Dressing|OxyGenesys(TM) Dissolved Oxygen Dressing
1625368|NCT02046213|Drug|E2006|Single oral 10mg dose of 100 uCi [14C]E2006
1625369|NCT02046200|Drug|Ivermectin|Ivermectin is a semi-synthetic macrocyclic lactone used worldwide as a broad-spectrum antiparasitic avermectin.
1625370|NCT02046200|Drug|Placebo|Matched placebo
1625371|NCT02046200|Drug|Alcohol|
1625372|NCT02046187|Dietary Supplement|Ketogenic Diet|Patients/families meet with the study dietician after surgery to discuss the ketogenic diet (KD), ask questions and plan clinic visits. Before radiation and chemotherapy begins, training takes place about the diet, meal planning and ketone/glucose monitoring. Ketosis will begin with the help of the dietitian one week before radiation begins. The patient will follow a classic 4/1 KD during chemo-radiation, followed by a modified Atkins diet during monthly chemotherapy. At the end of this period patients will follow a normal low carbohydrate diet similar to a Diabetic diet. The dietitian will follow the patient over the course of treatment. The patient will take and record ketone and glucose blood levels daily from start to end of treatment MRI scan, and meet with the dietitian weekly during radiation, at follow-up visits and on an as-needed basis.
1625373|NCT02046187|Radiation|Radiation therapy|Patients receive standard dose (60Gy/30 fractions) external beam radiation
1625374|NCT02046187|Drug|Temozolomide|patients receive standard dose (75 mg/kg/day) temozolomide by mouth daily with radiation for 6 weeks. patients will also have standard maintenance dose (150-200 mg/kg/day) for five days each month for 12 cycles following radiation course.
1625375|NCT02046174|Biological|RENCA macrobeads|
1625376|NCT02046161|Procedure|colonoscopic examination in colon cleansing room|All patients drink two liter PEG-ELS in the colon cleansing room which is a in-hospital setting for colon preparation at 8:00 AM on the day of colonoscopy.
2011262|NCT02636322|Drug|Cyclophosphamide|"At completion of Smart Start Participants on R-EPOCH: Cyclophosphamide 750 mg/m2 by vein on Day 5 of each 21 day cycle for 6 cycles.
At completion of Smart Start Participants on R-CHOP: Cyclophosphamide 750 mg/m2 by vein on Day 1 of each 21 day cycle for 6 cycles."
2011263|NCT02636322|Drug|Doxorubicin|"At completion of Smart Start Participants on R-EPOCH: Doxorubicin 10 mg/m2 by vein on Days 1 - 4 of each 21 day cycle for 6 cycles.
At completion of Smart Start Participants on R-CHOP: Doxorubicin 50mg/m2 by vein on Day 1 of each 21 day cycle for 6 cycles."
1625379|NCT02046135|Drug|Sodium Bicarbonate|
1625380|NCT02046135|Drug|Sodium Chloride|
1625381|NCT02046122|Drug|Idarubicin|"Eligible subjects will receive induction chemotherapy with idarubicin (12 mg/m2 intravenously for 3 days) and cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.
Subjects who experience no remission or partial remission will receive a second course of the identical induction chemotherapy."
1625382|NCT02046122|Drug|Cytarabine|"Cytarabine (100 mg/m2 intravenously for 7 days) starting Day 1 and ending Day 7. Patients 80 years or older will only receive 2 and 5 days of idarubicin and cytarabine respectively starting Day 1 and ending Day 5.
Subjects who achieve a complete remission (CR) will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
1625383|NCT02046122|Biological|DLI|"HLA-mismatched DLI will be administered Day 9, approximately 24-48 hours following completion of chemotherapy at a dose of 1x10^8 cluster of differentiation 3 (CD3+) cells; however, due to logistics of planning infusions with staffing, donor availability, weekends/holidays, etc., it may be necessary to postpone cell infusion up to 96 hours.
Given the time constraints presented by the need to start induction chemotherapy as soon as possible, in some cases, it may not be logistically possible to administer cells with induction. In these cases, patients would just receive standard induction chemotherapy and cells would be administered after consolidation 1 in addition to consolidation 2
Subjects who achieve a CR will receive 2 further courses of cytarabine postremission chemotherapy (consolidation) at 1.0 g/m2 for 6 dosages followed by HLA-mismatched DLI after the second consolidation."
1625384|NCT02046109|Procedure|Repair|
1625385|NCT02046109|Procedure|Replace|
1625386|NCT02046096|Device|Günther Tulip® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
1625387|NCT02046096|Device|Cook Celect® Vena Cava Filter|Temporary or permanent filter placement for the prevention of pulmonary embolism
1625388|NCT02046083|Drug|arachid|
1625392|NCT02046057|Procedure|PNB of SLN|Percutaneous biopsy of sentinel node
1625393|NCT02046044|Drug|Digoxin|
1625394|NCT02046044|Drug|Ivabradine|
1625395|NCT02046031|Drug|Ginkgolides Meglumine Injection|25 mg, ivdrip, once.
1625396|NCT02046018|Other|ICCM delivered by VHT|VHT's deliver ICCM to children under five in their communities
1625397|NCT02046018|Other|ICCM delivered by VHT with Cell Phone|ICCM delivered to children under 5 by VHT trained in ICCM and given cell phones
1625398|NCT02046018|Other|No intervention|VHT's selected by no ICCM training given and no drugs or cell phones.
1625399|NCT02046005|Behavioral|PRE-RA|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information.
1625400|NCT02046005|Behavioral|PRE-RA Plus|Personalized Risk Estimator for Rheumatoid Arthritis (PRE-RA) is an online tool that provides education about RA, collects data about demographics and behaviors, and presents personalized RA risk information. In addition, participants in this arm receive education from a health educator.
1645673|NCT01888978|Drug|Modified FOLFOX-6|
1625401|NCT02046005|Behavioral|General Rheumatoid Arthritis Education|Participants will receive general information about signs and symptoms of rheumatoid arthritis.
1625402|NCT02045992|Dietary Supplement|caffeine|Five doses of 100mg of caffeine diluted in 100 ml of decaffeinated coffee. One dose every hour for five hours
2011264|NCT02634333|Procedure|Prompt Sham|A sham injection (syringe without a needle pressed against the injection site) is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
1625406|NCT02045966|Drug|Cocktail|Cocktail = Caffeine 200 mg, Metoprolol 50 mg, Montelukast 10 mg, Flurbiprofen 50 mg, Omeprazole 40 mg, Midazolam 5 mg, Digoxin 0.25 mg, and Pravastatin 40 mg
1625407|NCT02045966|Drug|DCV 3DAA FDC|DCV 30 mg + ASV 200 mg + BMS-791325 75 mg
1625408|NCT02045966|Drug|BMS-791325|
1625409|NCT02045953|Device|VENTOLIN Mini-Spacer|VENTOLIN mini-spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
1625410|NCT02045953|Device|Aerochamber Plus spacer|Aerochamber Plus spacer will be used to dispense the SERETIDE Evohaler and FLIXOTIDE Evohaler
1625411|NCT02045940|Drug|GSK2881078|Hot melt solution within Capsule for oral single ascending doses or repeat dose administration with planned dose level and strength of 0.1, 0.3, 1.0, 2.0, 4.0, 8.0, and 10.0 mg
1625412|NCT02045940|Drug|Placebo|Hot melt solution within Capsule for oral single ascending doses or repeat doses administration.
1625413|NCT02045927|Other|sedation monitoring with RASS score|
1625414|NCT02045927|Other|sedation monitoring with BIS-Guided monitoring|
1625415|NCT02045914|Other|calcium ionophore solution|After microinjection of sperm into the oocyte, oocytes are incubated for 15 minutes in a 30 microlitre droplet of calcium ionomycin solution
1625416|NCT02045901|Drug|Diclegis|On Day 1, all participants will take 2 tablets of Diclegis at bedtime. On Days 2 to 14, participants will take 2 tablets of Diclegis at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
1625417|NCT02045901|Drug|Placebo (Sugar Pill)|On Day 1, all participants will take 2 tablets of Placebo at bedtime. On Days 2 to 14, participants will take 2 tablets of Placebo at bedtime. The minimum dosage will be 2 tablets daily at bedtime, increasing, when indicated, to the maximal dosage of 4 tablets per day on Days 3 to 14.
1625418|NCT02045888|Device|ADRCs prepared by investigational Celution Device|ADRCs (low dose and high dose) to be used in investigational treatment will be prepared using the investigational Celution Device which is being investigated under IDE 15363
1625419|NCT02045888|Biological|Placebo|Placebo is visually matched solution
1625420|NCT02045875|Drug|Dulera|Dulera is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, FDA approved and indicated for treatment of asthma in patients 12 years of age and older.
1625421|NCT02045862|Drug|Solifenacin Succinate|oral
1625422|NCT02045862|Drug|Mirabegron|oral
1625423|NCT02045862|Drug|Placebo to match solifenacin|oral
1625424|NCT02045862|Drug|Placebo to match mirabegron|oral
1625425|NCT02045849|Drug|GSK2140944 capsule|Immediate release capsule containing GSK2140944 and inactive formulation excipients with a unit dose strength of 500 mg
1625426|NCT02045849|Drug|GSK2140944 tablet|Immediate release tablet containing GSK2140944 and inactive formulation excipients with a unit dose strength of 750 mg
1625427|NCT02045849|Drug|Itraconazole capsule|Capsule containing Itraconazole with a unit dose strength of 100 mg
1625428|NCT02045836|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
1625429|NCT02045836|Biological|Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™|One dose administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
1625430|NCT02045810|Drug|Levobupivacaine|
1625431|NCT02045810|Drug|Saline|
1625432|NCT02045797|Drug|GSK2140944 Lyophile|GSK2140944 Lyophile (pale yellow to grayish yellow cake) containing 750 mg of GSK2140944 (as free base) per vial for IV infusion.
1625433|NCT02045797|Drug|GSK2140944 Capsules|GSK2140944 500 mg capsules will be supplied as pink hard gelatin capsule with no external markings filled with slightly agglomerated pale yellow to grayish yellow powder.
1625434|NCT02045784|Dietary Supplement|Infant formula|To establish dose-response relationships, formula-fed infants will be randomly allocated to three 11-day cross-over periods of exclusive consumption of infant formula providing different amounts of iodine. All iodine levels are within the required iodine levels for infant formula following the regulations of the United States, the European Union, Switzerland and New Zealand.
1625435|NCT02045784|Other|Breast milk|Unlimited breast feeding
1625436|NCT02045771|Behavioral|Behavioral Activation|"Behavioral activation is a therapy, which has been shown to be quite effective in the treatment of depression (Kanter, Manos et al. 2010; Martell, Dimidjian et al. 2010). Although previous therapies have focused more on the cognitive element, behavioural activation on its own has also been significantly effective for depression treatment (Jacobson, Dobson et al. 1996). The treatment works by increasing behaviours that help a patient with depression interact with an environment and providing consequences to positively reinforce antidepressant behaviour (Martell, Dimidjian et al. 2010)."
1625437|NCT02045771|Behavioral|Support Group|In addition to usual care, the control group will be offered a support group therapy format delivered at the same place, same visit frequency and duration of program as the intervention group. This support group is intended to simulate the intervention group format to minimize risk of biased estimate of BA effectiveness by reducing the potential placebo effect which can be seen due to frequent clinic visits and having additional attention beyond usual care.
1625438|NCT02045758|Device|Fingerstick|
1625439|NCT02045758|Device|TAP20-C|
1625440|NCT02045745|Biological|"Implantation of autologous mesenchymal stem cells (CSM) expanded in vitro and administered directly into the lung suture line"|Patients at risk of prolonged postoperative air leak will be treated by local administration of autologous mesenchymal cells expanded in vitro
1625441|NCT02045732|Biological|PF-06342674 0.25 mg/kg|Bi-Weekly Subcutaneous Injections X 6
1625442|NCT02045732|Biological|Placebo|Bi-Weekly Subcutaneous Injections X 6
1625443|NCT02045732|Biological|PF-06342674 1.5 mg/kg|Bi-Weekly Subcutaneous Injections X 6
1626193|NCT02039492|Procedure|Sympathetic Renal Denervation|
1625444|NCT02045732|Biological|PF-06342674 6.0 mg/kg|Bi-Weekly Subcutaneous Injections X 6
1625445|NCT02045719|Drug|uncaria tomentosa (cat´s claw)|
1625446|NCT02045706|Other|Community Health Worker Trainings|
1625447|NCT02045693|Drug|Methadone|
1625448|NCT02045693|Drug|DCV 3DAA FDC|
1625449|NCT02045693|Drug|BMS-791325|
1625450|NCT02045693|Drug|Buprenorphine|
1625451|NCT02045693|Drug|Naloxone|
1625452|NCT02045667|Drug|Mexiletine|"Mexiletine is a lidocaine-derivate and belongs to the class of 1B antiarrhythmic agents (Vaughan-Williams Classification of Antiarrhytmica). Class I antiarrhythmics have membrane-stabilizing properties. Drugs in this class work by interfering with the fast influx of sodium by inhibition of sodium ionchannels during the fast depolarization phase, thereby decreasing the maximal voltage and upshoot phase of the action potential.
Mexiletine study-medication will be purchased from Stabilimento Chimico Farmaceutico Militare, Firenze, Italy."
1625453|NCT02045667|Drug|Placebo|Placebo tablets do not contain any active medicinal component.
1625454|NCT02045641|Procedure|pleuracentesis|Direct needle drainage of pleural effusions with dynamic ultrasound technique
1625455|NCT02045628|Behavioral|Investment intervention|Those in the investment group will complete carefully framed questions designed to raise the salience of the investment they have made in their procedure at baseline and 3 months follow up. The content of this intervention will be tailored to the recent experiences of the patient (ie pre or post surgery).
1625456|NCT02045615|Procedure|Proposed technique for removal of the Wichita Fusion Nail|
1625457|NCT02045602|Genetic|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
1625458|NCT02045602|Drug|Gemcitabine|1000 mg/m2 intravenous administration
1625459|NCT02045602|Drug|Abraxane®|125 mg/m2 intravenous administration
1625460|NCT02045589|Genetic|VCN-01|Genetically modified human adenovirus encoding human PH20 hyaluronidase
1625461|NCT02045589|Drug|Gemcitabine|1000 mg/m2 intravenous administration
1625462|NCT02045589|Drug|Abraxane®|125 mg/m2 intravenous administration
1625463|NCT02045576|Device|sleep position trainer|
1625464|NCT02045576|Device|Oral Appliance Therapy|
1625465|NCT02045563|Other|prise de sang|
1625466|NCT02045563|Other|magnetic resonance imaging and magnetic resonance spectroscopy|
1625467|NCT02045550|Drug|Prospan Syrup|2.5 ml twice daily for 4 weeks
1625468|NCT02045524|Other|Deep muscle injection|
1625469|NCT02045524|Other|Sub-Q Injection|
1625470|NCT02045511|Behavioral|Baltimore HEARS|Tailored aural rehabilitation for participant and communication partner
1625471|NCT02045511|Device|Baltimore HEARS|Tailored fitting and programming of a personal sound amplifier. This will be accompanied by a component of aural rehabilitation.
1625472|NCT02045498|Device|capnography feedback|capnography feedback was used for management of the resuscitation and quality of cpr performance in rescuers and outcomes of the patients was measured.
1625473|NCT02045472|Drug|VIS410|
1625474|NCT02045472|Drug|Placebo|
1625475|NCT02045459|Behavioral|Exercise Program|Subject will be exercising on a treadmill 3x/week. Subjects progress will dictate increases/decreases in time of exercise and pace.
1625476|NCT02045459|Drug|Medical Therapy|Subjects will be given medications listed above. They will be contacted periodically throughout the study to maximize effectiveness and to manage side effects if they occur.
1625477|NCT02045446|Radiation|Stereotactic Body Radiation Therapy|
1625478|NCT02045446|Drug|Maintenance chemotherapy|Maintenance chemotherapy
1625479|NCT02045433|Radiation|SABR Boost Therapy|
1625480|NCT02045394|Other|Chest X-ray|
1625481|NCT02045394|Other|computed tomography of the chest|
1625482|NCT02045394|Procedure|Bronchoscopy|In patients with haemoptysis bronchoscopy will be performed with flexible bronchoscope. A systemic research of bleeding site and causes will be done. Microbiological or pathological sampling will be executed if clinically required. In selected patients, bronchoscopy might be performed with the rigid instrument or the flexible bronchoscope in intubated patients.
2011265|NCT02634333|Drug|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept is performed on the day of randomization and visits at 1, 2, and 4 months and then every 4 months thereafter.
1625484|NCT02045368|Drug|IGF-Methotrexate conjugate|IV infusion at the assigned dose administered on days 1, 8, and 15 of a 28 day (4 week) cycle. Up to 7 dose levels will be tested, starting with 0.05 µequivalents per kg and up to 2.5 µequivalents per kg.
1625485|NCT02045355|Other|Fish intervention|The intervention will compare fish intake with a correspondent amount of meat. The basis for the comparison will be the estimated protein intake from fish and meat and should be almost similar both from fish and from meat. To ensure compliance and to add more variety to the diet, different fish types will be included in the intervention group and different meat sources in the control group. The types of fish (and that of meat in the control diet) that will be used will be accurately documented and will be similar for all participants included.
1625486|NCT02045342|Other|Carbohydrate drink|Ingest 500ml (1g/kg) prior to metabolic measures.
1625487|NCT02045342|Other|Placebo|Ingest 500ml of placebo prior to metabolic measures.
1625490|NCT02045290|Drug|Metformin|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in the morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
1625491|NCT02045290|Drug|Placebo|
1625492|NCT02045277|Drug|IDP-118 Lotion|Lotion
1625493|NCT02045277|Drug|IDP-118 Monad HP Lotion|Active Comparator
1625494|NCT02045277|Drug|IDP-118 Monad Taz Lotion|Active Comparator
1625495|NCT02045277|Drug|IDP-118 Vehicle Lotion|Vehicle
1625496|NCT02045264|Drug|Icatibant (30 mg)|On Day 1, subjects will receive a single 30mg subcutaneous injection of icatibant in their abdominal area. Subjects will be discharged from the study on Day 3 after collection of study related assessments
1626194|NCT02039492|Drug|Treatment with aldactone|
1625497|NCT02045251|Drug|Pylera based reduced regimen|Patients with H. pylori infection will be treated with a 10 day course of reduced Pylera based regimen.
1625498|NCT02045238|Drug|Hypertonic Saline|Sodium Chloride 3% solution, previously prepared in 5 mL syringes.
1625499|NCT02045238|Radiation|Chest X-Ray|
1625500|NCT02045238|Other|Respiratory virus screening test|Immunofluorescence analysis of nasal aspirate
1625501|NCT02045225|Behavioral|Reduction of social anxiety & substance use in gay/bi men|The study will provide Phase I trial data for a novel and innovative HIV prevention intervention for MSM built upon empirically supported interventions to reduce HIV risk among MSM and cognitive-behavioural therapy to reduce social anxiety. This study will test a novel integrated HIV prevention intervention that combines empirically supported treatments for social anxiety with HIV risk reduction counseling to reduce HIV sexual risk behaviour. Study objectives: 1) to provide data on the acceptability/feasibility of the intervention, 2) to provide data to test the intervention, and 3) to provide data that will allow for a RCT that will test intervention efficacy relative to HIV prevention interventions that do not reduce social anxiety or substance use in sexual situations.
1625502|NCT02045212|Drug|RPh201|SC injection twice a week during 13/26 weeks
1625503|NCT02045212|Drug|Placebo|SC injection twice a week during 13/26 weeks
1625504|NCT02045199|Device|Tested product : V0111 cream|Application twice a day during 28 days
1625505|NCT02045199|Device|Placebo|Application twice a day during 28 days
1625506|NCT02045186|Other|Assessment of Oral HPV Infection|"Saliva and exfoliated oral epithelial cells will be collected with collection supplies provided by OralDNA Labs. Patients will swish and gargle a saline solution for 30 seconds and expectorate it into a funneled collection tube. The collected specimen will be sent to OralDNA Labs. Three diagnostic tests will be performed on each sample to assess oral HPV infection:
Polymerase chain reaction (PCR) for HPV DNA.
Fluorescent in-situ hybridization (FISH).
Viral expression: The test is based on the measurement of the viral RNA levels by methods of detection of the fluorochrome labeled HPV probes by flow cytometry."
1625507|NCT02045173|Other|Apneascan TM|Autoscoring algorithms with automatical detection of sleep apnea by the Apneascan TM
1625508|NCT02045173|Device|Polysomnography/polygraphy|1 night polysomnography/polygraphy
1625509|NCT02045147|Behavioral|Grp 1 Low Cognition, Low Activation|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation."
1625510|NCT02045147|Behavioral|Grp 2 Low Cognition, High Activation|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided at a 5th grade reading level. The teach back method is used to validate knowledge, skills and confidence. Once knowledge is validated, the interventions focused on motivation and handling stressful situations."
1625511|NCT02045147|Behavioral|Grp 3 Normal Cognition, Low Activation|"The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Education is provided for areas of misunderstanding. The teach back method is used to validate knowledge, skills and confidence. Interventions are focused on motivation and developing personal behavioral goals."
1625512|NCT02045147|Behavioral|Grp 4 Normal Cognition, High Activation|The intervention is focused on knowledge, skills, confidence and creating a partnership with the health care provider. Focus is on maintaining behaviors during hardship and stress. Empowering, motivating and validating are strategies utilized.
1625513|NCT02045134|Dietary Supplement|Placebo|Soluble corn flour not rich in anthocyanins
1625514|NCT02045134|Dietary Supplement|High-anthocyanin rich corn flour|Soluble corn flour at high content in anthocyanins
1625515|NCT02045121|Device|Indwelling Pleural Catheter|
1625516|NCT02045121|Procedure|Talc Pleurodesis|
1625517|NCT02045108|Behavioral|Active Retraining|
1625518|NCT02045108|Device|Sham TDCS|
1625519|NCT02045108|Device|Active TDCS|
1625520|NCT02045108|Behavioral|Sham Retraining|
1625521|NCT02045095|Drug|MLN7243|"Dose escalation stage Schedule A: IV infusion on days 1, 4, 8, 11 for a 21-day treatment cycle Schedule B: IV infusion on days 1, 8, 15 for a 28-day treatment cycle
Dose expansion stage: MLN7243 will be administered following schedule A (twice-weekly, 21-day dosing) and/or B (once-weekly, 28-day dosing)"
1625522|NCT02045082|Procedure|Corneal sampling|Slit lamp corneal sampling with a Swab
1625523|NCT02045069|Drug|2 days Ivermectin|200-400 µg/kg once daily for 2 days and placebo once daily at D3
1625524|NCT02045069|Drug|3 days Ivermectin|200 -400 µg/kg once daily for 3 days
1625525|NCT02045069|Drug|Placebo|Placebo once daily for 3 days
1625526|NCT02045056|Drug|Gemfibrozil|
1625527|NCT02045056|Drug|Placebo|
1625528|NCT02045030|Drug|aflibercept + FOLFIRI|Aflibercept (Sanofi and Regeneron) targets the Vascular endothelial growth factor (VEGF) pathway that is a composite decoy receptor based on VEGFR-1 and VEGFR-2 fused to an Fc segment of IgG1. In pre-clinical assessments, aflibercept results in stronger angiogenesis inhibition than bevacizumab, exhibiting at least 100-1000 times higher affinity to the circulating VEGFs. It is postulated that in vivo, the binding of these ligands to aflibercept results in the blockade of tumor angiogenesis along with pruning of existing tumor vascular elements and reduction of VEGF-driven vascular permeability. The expected outcome is reduced growth of primary and metastatic tumors by impeding the density of tumor vasculature and diminishing the abnormal leakiness of tumor vessels that supply matrix components to the cancer.
1625529|NCT02045017|Drug|Pomalidomide and Dexamethasone|
1625530|NCT02044991|Drug|Corticosteroid|40mg of a non-fluorinated injectable glucocorticoid, methylprednisolone acetate (1cc) combined with 1cc of 1% Lidocaine
1625531|NCT02044991|Drug|Placebo Injection|A placebo injection
1625532|NCT02044978|Device|Zoledronate-coated dental implant|
1625533|NCT02044965|Other|Antibiotic|2 mg/kg per day via oral ingestion.
1625534|NCT02044965|Drug|Probiotic|2 capsules; 5 billion total organisms of L. rhamnosus GR-1 and L. reuteri RC-14 per capsule
1625535|NCT02044952|Drug|Mesalazine, Tripterygium glycosides|tripterygium glycosides: 2mg/kg/d, oral Mesalazine: 4g/d, oral
1625536|NCT02044939|Other|Pulmonary rehabilitation program|Pulmonary rehabilitation program should follow ATS/ERS Guidelines (2006)
1645674|NCT01888978|Drug|Ox-Tax|
1625537|NCT02044913|Behavioral|Phone-based Aftercare-Coordination|After inpatient treatment patients receive six phone contacts of aftercare-coordination at intervals of two weeks carried out by therapists for 12 weeks. The intervention is case-management orientated and aims at supporting the patients in finding and organising an adequate aftercare treatment.
1625538|NCT02044887|Other|physical activity|The characteristics of the PCD and CF and motivation will be evaluated to increase the AF through the (Test Prochaska-Diclemente). For 3 months will receive instructions to perform AF autonomously (walking, preferably in the vicinity of the place of residence). The intervention will be conducted by a professional of the health center so only couples of the intervention group will have knowledge of the specific recommendations of the AFISDEMYF. It is an intervention that has demonstrated its effectiveness in the PEPAF study (large, Sanchez et al. 2009) adapted, designed and implemented by primary care professionals for patients with dementia and for family members who care for them.
2011266|NCT02634333|Procedure|Deferred laser|Laser (either focal/grid laser for diabetic macular edema or panretinal photocoagulation for proliferative diabetic retinopathy) is added following initiation of anti-vascular endothelial growth factor injections for center-involved diabetic macular edema or proliferative diabetic retinopathy only if certain criteria are met
2011267|NCT02634333|Drug|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once proliferative diabetic retinopathy or center-involved diabetic macular edema develops and then up to every 4 weeks using defined treatment criteria.
1625541|NCT02044861|Drug|PFK-158|IV dose escalation
1625542|NCT02044848|Drug|Secukinumab|
1625543|NCT02044848|Drug|Placebo|Placebo
1625544|NCT02044835|Drug|Fu-zheng-qu-zhuo oral liquid|Fu-zheng-qu-zhuo oral liquid was composed of Ginseng, Astragalus, Angelica root, Tuckahoe, Rhubarb, etc. It was producted by manufacturing laboratory of Guang'anmen Hospital, China Academy of Chinese Medical Science (License code: 京药制字Z20063242)
1625545|NCT02044822|Drug|Idelalisib|150 mg tablets administered orally twice daily
1625546|NCT02044822|Drug|Rituximab|375 mg/m^2 administered intravenously once weekly x 8 weeks
1625549|NCT02044796|Drug|Cladribine|Given IV
1625550|NCT02044796|Drug|Cytarabine|Given IV
1625551|NCT02044796|Biological|Filgrastim|Given SC
1625552|NCT02044796|Other|Laboratory Biomarker Analysis|Correlative studies
1625553|NCT02044796|Drug|Mitoxantrone Hydrochloride|Given IV
1625554|NCT02044783|Behavioral|Behavioral Counseling|
1625555|NCT02044757|Behavioral|SSB withdrawal|During days 1-5, participants will drink the beverages they normally consume (no intervention). On days 6-8, participants will be instructed to drink only water and unflavored milk during the withdrawal period (days 6-8).
1625556|NCT02044744|Behavioral|Physical activity referral|Provision of a primary care referral to at least one community-based physical activity program that is a good match for the participant's needs and preferences and patient follow-up on enrollment.
1625557|NCT02044731|Behavioral|Active and Healthy Families|A pediatric overweight/obesity intervention delivered through five bi-weekly family-based group sessions.
1625558|NCT02044705|Behavioral|Active and Healthy Families|Pediatric obesity intervention delivered through five bi-weekly Active and Healthy Families family-based group medical appointments (i.e., sessions).
1625559|NCT02044679|Other|Water|
1625560|NCT02044679|Other|No intervention|
1625561|NCT02044666|Device|Micronized Small Intestinal Submucosa (SIS)|Micronized Small Intestinal Submucosa (SIS)
1625567|NCT02044640|Procedure|Appendectomy|
1625568|NCT02044627|Drug|[14C-ETC-1002]|
1625569|NCT02044614|Other|Adjuvant Peritoneal Dialysis in the context of ongoing Hemodialysis|
1625570|NCT02044601|Drug|Onartuzumab|"Phase I: Starting dose of Onartuzumab 10 mg/kg by vein on Day 1 of each 3 week cycle.
Phase II: Maximum tolerated dose from Phase I."
1625571|NCT02044601|Drug|Erlotinib|Phase I and II: 150 mg by mouth every day throughout radiation, except for chemotherapy day.
1625572|NCT02044601|Drug|Paclitaxel|Phase I and II: 45 mg/m2 by vein once a week throughout radiation for 7 weeks.
1625573|NCT02044601|Drug|Carboplatin|Phase I and II: AUC 2 by vein once a week throughout radiation for 7 weeks.
1625574|NCT02044601|Radiation|Radiation Therapy|Phase I and II: Radiation therapy at 66 Gy in 33 fractions delivered 5 days a week for 7 weeks, or proton therapy delivered at biological equivalent to 66 Gy (RBE) (RBE = 1.1) in 33 fractions 5 days a week for 7 weeks.
1625575|NCT02044588|Biological|HBsAg positive kidney allograft donor|
1625576|NCT02044562|Dietary Supplement|nitrate supplementation|A 70 ml beetroot juice containing 0.45g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
1625577|NCT02044562|Dietary Supplement|Placebo|A 70 ml placebo containing 0 g nitrate will be provided to the patients for 7 days at the end of the radiotherapy.
1625578|NCT02044549|Drug|carbetocin|Oxycontin analogue
1625579|NCT02044549|Drug|Syntometrine|Uterotonins
1625580|NCT02044536|Other|No intervention|No intervention (retrospective data review)
1625581|NCT02044523|Device|Transient elastography, acoustic radiation force impulse, magnetic resonance elastography|Transient elastography (Fibroscan) Acoustic Radiation Force Impulse (ARFI) Magnetic Resonance Elastography (MRE)
1625582|NCT02044510|Drug|Mirabegron|Mirabegron 25mg PO daily for 2 weeks, with dose increase to Mirabegron 50mg PO daily for the remaining 8 weeks.
1625583|NCT02044510|Drug|Placebo|Matched placebo capsules to the intervention arm
1625584|NCT02044497|Drug|oral oxycodone|
1625585|NCT02044484|Behavioral|Multi-component intervention|"The computer-based intervention (CBI) is offered to patients whose viral load exceeds 1000 copies/mL at enrollment.
Counseling is offered to patients whose viral load does not drop 1-log after the first CBI or remains above 200 copies/mL after completing two CBIs.
The behavioral screener will be conducted of all patients at primary care visits. The patient completes the screener before seeing the provider. Responses are given to their provider who can use it in clinical care of the patient.
At primary care visits, all patients are given a palm card containing 1 of 15 empowering messages before they leave the clinic. Messages cover three domains: adhering to antiretroviral therapy, regular care, and safer sex."
1625586|NCT02044471|Other|Remote Ischemic Conditioning (using Sphygmomanometer)|"Patients in experimental arm will have validated protocol of Remote Ischemic Conditioning (using Sphygmomanometer): 5 minutes with blood pressure cuff inflated at 200 mmHg, then deflated for 5 minutes; repeated for 3 cycles.
Patient in control group will not perform this."
1625587|NCT02044458|Device|Stylette|use of stylette for successful insertion of foley catheter for induction of labor
1625588|NCT02044445|Procedure|Oocyte retrieval will be performed 36 h or 38 h after hCG administration|Oocyte retrieval will be performed 36 h or 38 h after hCG administration
1625589|NCT02044432|Other|ginger compress|Kidney ginger compress
1625591|NCT02044406|Drug|BI 1181181|single dose (low to high dose)
1625592|NCT02044406|Drug|BI 1181181, R|powder for oral solution
1625593|NCT02044406|Drug|BI 1181181, T2|tablet, fasted
1625594|NCT02044406|Drug|Placebo to BI 1181181|Placebo to BI 1181181
1625595|NCT02044406|Drug|BI 1181181, T1|tablet, fed
1625596|NCT02044393|Drug|itraconazole|multiple doses of itraconazole given as capsules
1625597|NCT02044393|Drug|BI 691751|single dose BI 691751 given as tablet
1625598|NCT02044393|Drug|BI 691751|single dose BI 691751 given as tablet
1625599|NCT02044380|Drug|Afatinib|40, 30, or 20mg tablets taken once daily, dosage depending on tolerability
1625600|NCT02044367|Drug|Dabigatran etexilate|Pellets (multiple dose of dabigatran)
1625601|NCT02044367|Drug|Dabigatran etexilate|Granules resolved in reconstitution solution (multiple dose of dabigatran)
1625602|NCT02044367|Drug|Dabigatran etexilate|Hard capsule (multiple dose of dabigatran)
1625603|NCT02044354|Drug|Taxotere|
1625604|NCT02044354|Drug|Jevtana|
1625605|NCT02044341|Drug|AR01|drops administered an needed for pain
1625606|NCT02044341|Drug|Glycerin ear drops|placebo drops administered for ear pain
1625607|NCT02044328|Drug|Icotinib|Icotinib is administered 125 mg three times per day.
1625608|NCT02044315|Device|ICD programming|
1625609|NCT02044302|Drug|Bupivacaine|
1625610|NCT02044302|Drug|Botulinum Toxins|
1625611|NCT02044302|Drug|Analgesics|
1625612|NCT02044276|Drug|lipegfilgrastim|6 mg
1625613|NCT02044276|Drug|pegfilgrastim|6 mg
1625614|NCT02044263|Behavioral|Internet CBT-i SHUTi|Computer program SHUTi is based on the same theoretical model of insomnia and involves the same interventions as ordinary CBT-I: a structured treatment focusing on education, behaviors and cognitions. Specifically, CBT-I usually consists of one or more of the following: psychoeducation about sleep, sleep restriction therapy, stimulus control, relaxation techniques, and challenging beliefs and perception of sleep.
1625615|NCT02044263|Behavioral|face-to-face CBT-i|
1625616|NCT02044250|Drug|Clopidogrel|Clopidogrel 75mg 1tab P.O. daily
1625617|NCT02044250|Drug|Aspirin|Aspirin 100~200mg 1~2tab P.O. daily
1625618|NCT02044237|Behavioral|Decoupling|
1625619|NCT02044237|Behavioral|Progressive relaxation|
1625620|NCT02044224|Drug|Dexmedetomidine|"Dexmedetomidine 0.4 µg/kg/hr infusion (from the start of anaesthesia until the end of anaesthesia).
Anaesthesia induction: propofol 2 mg/kg, rocuronium 0.6 mg/kg iv, and fentanyl 2-3 mikrogram/kg.
Anaesthesia maintenance: sevoflurane and oxygen 50%, rocuronium 0.1-0.2 mg/kg iv, fentanyl 1 mikrogram/kg as required"
1625621|NCT02044211|Behavioral|Collaborative Care for Heart Failure|"Nurse care managers will provide patients with education for their heart failure to facilitate self-management for their condition. In addition, the nurse will telephone the patient to review with their medical history, medications, diet, activity and sleep patterns, and plans for follow-up medical appointments, and offer basic care coordination relative to heart failure care including assistance attaining authorization for home health services in concert with the patient's primary care physician (PCP), and follow-up appointments.
After case review with a study internist, the care manager may send treatment recommendations to the patient's physician(s) regarding guideline-indicated care. Afterwards, the care manager will telephone the patient approximately every other week to monitor and promote adherence with recommended care, and suggest adjustments in treatment as applicable following discussion with the clinical team and notification of the patient's PCP and cardiologist."
1625622|NCT02044211|Behavioral|Collaborative Care for Depression|"The care manager will telephone patients randomized to blended care patient to review their psychiatric history including use of antidepressant pharmacotherapy, herbal supplements, and alcohol possibly used to self-medicate depressive symptoms; provide basic psychoeducation about depression and its impact on cardiac disease; recommend various self-management strategies (e.g., sufficient rest and exercise); and describe treatment options. They will include: (1) use of a workbook or computer program to enhance patients' understanding and ability to self-care; (2) initiation or adjustment of antidepressant pharmacotherapy prescribed under their primary care physicians' direction; or (3) referral to a local mental health specialist. The nurse will then telephone the patient to monitor symptoms and pharmacotherapy use, practice skills imparted through workbook assignments, promote adherence with recommended care, and suggest adjustments in treatment as applicable."
1625623|NCT02044198|Biological|FMP2.1/AS01B|50 µg FMP2.1 in 0.5 mL of the adjuvant AS01B (containing 50 mcg MPL + 50 mcg QS21) is administered via intramuscular (IM) injection in the deltoid region of the non-dominant arm
1625624|NCT02044185|Drug|salvage chemotherapy, total body irradiation|there are no direct interventions to our patients.
1625625|NCT02044172|Procedure|Radical prostatectomy|radical prostatectomy
1625626|NCT02044172|Radiation|Conformal radiation therapy|Conformal radiation therapy, external beam
1625627|NCT02044172|Other|Active monitoring|Active monitoring of Prostate specific antigen levels and disease surveillance
1625628|NCT02044159|Drug|Hydrocortisone|Hydrocortisone will be made up as a 10 mg/ml solution so the volume of added fluid will be very small (2 to 10 mls even for the initial dose of 2 mg/kg).
1625629|NCT02044159|Other|Placebo|The placebo (normal saline) will be identical in appearance, volume and smell to the active study drug (hydrocortisone).
1625630|NCT02044146|Drug|Ticagrelor, Prasugrel, Clopidogrel|
1625631|NCT02044133|Other|Dosage Vitamine D|
1625632|NCT02044120|Drug|niraparib|
1625633|NCT02044120|Drug|Temozolomide|
1625634|NCT02044120|Drug|Irinotecan|
1626195|NCT02039479|Drug|Lithium Carbonate|Lithium as Add on to every necessary treatment as usual
1625635|NCT02044107|Behavioral|Co-packaging and counseling messages|The intervention involves co-packaging in 2 distinct packages: 1) for diarrhea treatment to package zinc & ORS for the treatment of diarrhea using a plastic bag with printed messages that were pre-tested in formative research; and 2) for pneumonia treatment to co-package zinc & antibiotics in a plastic bag with printed messages that were pre-tested in a formative research phase. Pre-tested zinc treatment messages will be on posters displayed in the intervention health centers. Orientation will be provided to health facility staff in control and intervention areas.
1625636|NCT02044094|Drug|Buprenorphine|A depot of buprenorphine 300 mg delivered using the ATRIGEL® Delivery System on study days 1 and 29. As the depot degrades, buprenorphine is released into the systemic circulation at a consistent rate over an approximately 28-day period.
1625637|NCT02044094|Drug|buprenorphine and naloxone|Buprenorphine and naloxone (SUBOXONE® sublingual film) is given to participants on days -14 to day -1 (the SUBOXONE Film stabilization period) as soon as they start to experience withdrawal symptoms. SUBOXONE is initially administered several times daily until the stable dose of between 8 mg and 24 mg daily is established.
1625638|NCT02044094|Drug|hydromorphone|"Hydromorphone challenges are administered during the screening period (days -17 to -15), on days -3 to -1 during the buprenorphine and naloxone (SUBOXONE film) stabilization period, and weekly during the 12-week treatment period after administration of RBP-6000. Each challenge consists of 3 days during which participants are administered 0 mg (placebo), 6 mg and 18 mg hydromorphone via intramuscular injection daily in varying blinded sequences.
Hydromorphone can also be earned during the Reinforcing effects tasks and up to the same randomized dose received in the hydromorphone challenge that morning can be earned (or money can be chosen)."
1625639|NCT02044094|Drug|placebo|Placebo for hydromorphone administered via intramuscular injection during each challenge.
1625640|NCT02044081|Drug|C16G2 Rinse|Active rinses are 1.6 mg/mL C16G2.
1625641|NCT02044081|Drug|Placebo|Placebo is the vehicle without C16G2
1625642|NCT02044081|Drug|C16G2 Gel|Active C16G2 Gel is 3.2 mg/mL
1625643|NCT02044003|Device|Innovasc Tack Intravascular Staple System (Tack)|Tack-It Dissection repair
1625644|NCT02043990|Device|Noninvasive NAVA ventilation|Noninvasive NAVA Ventilation versus conventional noninvasive Pressure Support Ventilation
1625645|NCT02043977|Drug|propofol injectable emulsion|
1625646|NCT02043964|Procedure|tears and cerebrospinal fluid sampling|All patients recruited in this study will undergo a cerebrospinal fluid sampling which is an invasive procedure included in the actual routine practice. In addition a sampling from eyes will be obtain using the Schirmer test to get tears from the lacrimal gland.
1625647|NCT02043951|Device|Lutonix Drug Coated Balloon Catheter|
1625648|NCT02043925|Drug|drugs linked with QT-prolongation|all the drugs that are mentioned in the lists of QT-prolonging drugs of CredibleMeds (www.crediblemeds.org)
1625649|NCT02043912|Drug|Haloperidol|
1625650|NCT02043899|Drug|[124I]meta-Iodobenzylguanidine|Single intravenous administration of [124I]mIBG Solution for Injection on Day 1 with a maximum radioactive dose of 1.42 MBq/kg (±10%) and a maximum injected dose of 50 MBq [124I]mIBG equating to a maximum chemical dose of 10 micrograms of stable mIBG. The activity to paediatric patients will be scaled by weight based upon the EANM paediatric dose card (Lassmann et al., 2007). This will result in an activity between 10 MBq and 50 MBq depending on the patient's weight.
1625651|NCT02043886|Drug|Acarbose|Acarbose 50 mg by mouth given during Meal Test
1625652|NCT02043886|Drug|Placebo|Non active substance matched to look like Acarbose 50 mg tablets. Taken by mouth during Meal Test.
1625653|NCT02043860|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total body irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, 9Gy, or 12Gy.
1625654|NCT02043860|Procedure|Autologous Transplant|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with escalating doses of total marrow irradiation prior to autologous stem cell rescue.
1625655|NCT02043860|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant.
1625656|NCT02043860|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm^3 over period of 3 days.
1625657|NCT02043847|Radiation|Total Marrow Irradiation|Subjects in this trial will receive total marrow irradiation (3Gy) per day for up to four days and as little as one day. Total IMT doses: 3Gy, 6Gy, or 9Gy.
1625658|NCT02043847|Drug|Melphalan|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning therapy prior to transplant.
1625659|NCT02043847|Drug|Filgrastim (G-CSF)|Subjects to begin GCSF 5 μg/kg/d SC or IV on Day 5 and continue until ANC > 1000/mm^3 over period of 3 days.
1625660|NCT02043847|Procedure|Autologous transplant|Subjects will receive standard melphalan 200mg/m^2 (100mg/m^2 day-2 and day-1) conditioning with autologous stem cell rescue.
1625661|NCT02043834|Other|Balance Training|"Balance training will be conducted individually two times per week for 4 weeks. Each training session will include virtual reality tasks such as ankle reaching and obstacle crossing using a virtual obstacle shown on a computer screen. Each session will last 30 - 45 minutes."
1625662|NCT02043821|Drug|Capecitabine|14days
1625663|NCT02043821|Other|placebo|14 days
1625664|NCT02043795|Device|BVS, Abbott Vascular|The aim of this study is to study the safety and clinical efficacy of a novel Bioabsorbable Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS, Abbott Vascular).
1625665|NCT02043782|Device|Coloplast Test|Newly developed 1-piece convex ostomy product
1625666|NCT02043782|Device|Own product|The subjects Own product is used as baseline performance in this investigation. The products are commercial and available on the market, and are products manufactured by manufactures who produce convex ostomy products i.e. Coloplast, Convatec, Dansac, B.Braun, Hollister and more.
1625667|NCT02043782|Device|Competitor soft convex|A commercially available soft convex product
1625668|NCT02043756|Drug|Mitoxantrone Hydrochloride Liposome|6-16mg/m2, IV ,one time of each 28 day cycle,3 cycles
1625669|NCT02043756|Drug|Mitoxantrone|10mg/m2, IV ,on day 1 of each 28 day,3 cycles
1625670|NCT02043743|Biological|Biological: Stem Cells|Biological: Stem Cells 60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally 3-5 million MSCs injected into ovarian tissue.
1645675|NCT01888978|Drug|FOLFIRI|
1625671|NCT02043730|Drug|Nab-paclitaxel and Gemcitabine|Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle
1625672|NCT02043730|Drug|Gemcitabine|gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.
1625673|NCT02043717|Dietary Supplement|Vitamin D|"Supplementing oral cholecalciferol according to the new guidelines by:
Tangpricha V, Kelly a, Stephenson a, Maguiness K, Enders J, Robinson K a, et al. An update on the screening, diagnosis, management, and treatment of vitamin D deficiency in individuals with cystic fibrosis: evidence-based recommendations from the Cystic Fibrosis Foundation. The Journal of clinical endocrinology and metabolism [Internet]. 2012 May [cited 2012 Oct 31];97(4):1082-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22399505"
2011268|NCT02634281|Drug|Varenicline|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
2011269|NCT02634281|Drug|placebo|Subjects in Group A will receive varenicline for six weeks while those in group B will receive placebo for 5 weeks and varenicline for 1 week. During this phase, subjects in both groups will be asked to reduce cigarette smoking by 50 percent. At week 6 all participants will be instructed to stop smoking before receiving 12 weeks of varenicline treatment
2011270|NCT02632721|Drug|Decitabine|
2011271|NCT02632721|Drug|BI 836858|BI 836858 weekly i.v. infusion
1625678|NCT02043678|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|50 kBq/kg body weight, intravenous injection (IV-slow bolus), every 4 weeks for 6 cycles.(nominal change to 55 kBq/kg after implementation of National Institute of Standards and Technology (NIST) update)
1625679|NCT02043678|Drug|Matching placebo (normal saline)|Intravenous injection ( IV-slow bolus), every 4 weeks for 6 cycles
1625680|NCT02043678|Drug|Abiraterone|All study subjects will receive treatment with oral abiraterone acetate (1000 mg once daily),with best supportive care
1625681|NCT02043678|Drug|Prednisone/Prednisolone|All study subjects will receive treatment with oral prednisone/prednisolone (5 mg twice daily), with best supportive care
1625682|NCT02043665|Biological|CVA21|
2011272|NCT02632175|Biological|Adalimumab|every other week or weekly subcutaneous injection
2011273|NCT02632500|Other|Quality of chest compressions|
1625685|NCT02043626|Other|DISTRICT WELLNESS COMMITTEE|Three Targeted Schools (N+PA) will expand the District's school based wellness initiative, PAW-Physical Activity and Wellness. With District support, PAW schools develop School Wellness Teams (SWTs) to identify school health priorities, implement and sustain health initiatives through school campaigns, promote healthy behavior, and support wellness policies. Results from a 3-year evaluation suggest significant and sustained positive impact on school health culture, student behavior, time-on-task, and increased physical activity among students.
1625686|NCT02043626|Other|NUTRITIONAL QUALITY OF FOODS AND BEVERAGES ON CAMPUS|Policy changes will focus on 6 target schools. District will expand nutrition education by integrating other opportunities to learn and practice healthy behaviors across disciplines. Farm-to-School programs will include school visits by farmers to teach students about agriculture, healthy foods and nutrition, coinciding with Farmer's Market Menu Days. Schools will receive four 45 minute nutrition workshops per year. Community educators will offer culturally appropriate, interactive nutrition workshops and cooking demonstrations. Cafeterias will receive youth friendly nutritional messaging, regular promotion of new menu foods, and a variety of monthly nutrition-focused activities. The goals are to: increase number of students who try new menu items regularly, increase acceptance of healthy foods, and improve nutrition literacy. Policy states schools will limit celebrations that involve food to no more than 1 per class/month: 6 schools will pilot alternatives to food for celebrations.
1625687|NCT02043626|Other|HEALTH PROMOTION AND MARKETING|SWP addresses health promotion and marketing by limiting product marketing in schools, expanding nutrition education and broadening health communication with parents. In 3 targeted schools, we expand to include Staff Wellness Promotion. Adults in schools are trusted and influential role models for students; by increasing their positive health behaviors, students may be influenced to adopt similar behaviors. The District will work with the City's Employee Wellness Program to increase school staff participation.
1625688|NCT02043626|Other|OPPORTUNITIES FOR PHYSICAL ACTIVITY|District-wide policies include mandates for daily physical activity and PE and development of policies that prohibit withholding PE for punitive reasons. To further increase physical activity, the School Wellness Policy specifies expanding programs/activities that meet need, interest, and abilities of students. Exer-gaming consoles will be provided to 6 schools and will be integrated into 5th-8th grade PE classes and after-school programs. New and innovate gym equipment will be purchased for the 6 target schools for use in gym class and after school programming. Various pedometer and interactive programs encouraging physical activity in and outside of school are planned for the 6th grade.
1625689|NCT02043613|Other|Contextually enhanced physical surroundings of exercise|"Different physical surroundings of exercise may affects the patients differently and consequently influence the effect of exercise. The exercise rooms are different from each other on parameters such as source of lighting, acoustics, materials and decorations.
The differences with the physical surroundings of exercise is the primary intervention for this study."
1625690|NCT02043613|Other|Neuromuscular exercise|The neuromuscular exercise program is the same across the two exercise groups. Consequently, this intervention is not the primary intervention of this study. The exercise program is based on the previously reported NEMEX program designed for patients with hip or knee osteoarthritis, originally published by Ageberg et al, 2010 in BMCMusculoskeletal Disorders.
1625691|NCT02043600|Behavioral|Yoga|12-week Hatha Yoga intervention 90 minutes once a week
1625692|NCT02043600|Behavioral|Self-care|Self-care books are provided for self-directed use
1625693|NCT02043587|Drug|DNR|Daunorubicin 60 mg/m2 IV (in the vein) daily 1,2,3 Courses 1A, 2A
2011274|NCT02630654|Other|This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.|
2011275|NCT02630030|Drug|Ixazomib|Given PO
1625694|NCT02043587|Drug|VCR|1.4 mg/m2 IV, days 1, 8, 15, 22 (cap at 2mg for ages >50) during Courses 1A, 2A; Maintenance: Day 1 during months 2-12
1625695|NCT02043587|Drug|PEG-asp|2,000 IU/m2 IV for ages </= 50, age > 50, 1000 IU/m2 IV Day 16, Courses 1A & 2A; Day 18, Course 1B; Day 17, Course 2B; Day 16, Maintenance, Month 1
1625696|NCT02043587|Drug|CTX|750 mg/m2 IV, days 1 &15 for subjects <40 year of age, substitute cyclophosphamide 500 mg/m2 IV over 60 minutes every 12 hours for 4 doses on days 15 & 16 for subjects < 40 years of age if day 14 bone marrow M2 or M3; Courses 1A & 2A
1625697|NCT02043587|Drug|Prednisone|60 mg/m2 orally once daily on days 1-28 during Courses 1A & 2A; Maintenance: Monthly, days 1-5
1625698|NCT02043587|Drug|Liposomal AraC|25 mg intrathecal (IT), on days 1 & 15 during Courses 1A & 2A; 50 mg intrathecal on day 1 during Maintenance Months 1 through 4
1625699|NCT02043587|Drug|MTX|220 mg/m2 IV bolus over 15 minutes then 60 mg/m2/hour for 36 hours once on days 2-3 and 16-17 during Courses 1B & 2B; 20 mg/m2 orally one day per week every 7 days during Maintenance Months
1625700|NCT02043587|Drug|LCV|50 mg/m2 IV over 15-30 minutes every 6 hours for 3 doses to begin immediately after completion of methotrexate infusion, then 10 mg/m2 orally or IV over 15-30 minutes every 6 hours until methotrexate level less than 0.1 micromolar during Courses 1B & 2B
1625701|NCT02043587|Drug|AraC|2,000 mg/m2 IV, days 1-4 during Courses 1C & 2C
1625702|NCT02043587|Drug|Etoposide|500 mg/m2 IV over 3 hours once daily on days 1-4 during Courses 1C & 2C
1625703|NCT02043587|Drug|Dasatinib|140 mg orally daily if BCR/ABL positive and/or Ph+
1625704|NCT02043587|Drug|Rituximab|375 mg/m2 IV once daily on days 1 & 15 (precursor B-cell ALL only, administer per institutional protocol) during Courses 1A, 1B, 1C & 2A
1625705|NCT02043587|Drug|Hydrocortisone|Randomize patients proceeding to Course 1B to hydrocortisone versus placebo prior to PEG-asparaginase treatments in Courses 1B, 2B, 3B, and Maintenance month 1
1625706|NCT02043574|Behavioral|Stretching (control)|Stretch controls will be enrolled in supervised stretching program for 2 days/week for 1 hour sessions. The stretch program will focus on basic mobility skills, including balance, endurance, sit-to-stand, weight shifting, leg strength, and truncal stability-coordination. Stretching will be done in groups up to 6 participants. Exercises will be performed in standing, seated, and lying positions. A log book on the stretching exercise participation and progression will be maintained and reviewed by the instructor with the participant at each session.
1625707|NCT02043574|Behavioral|Treadmill Exercise|Training will be started conservatively with a goal of 15 minutes total duration at 40-50% HRR. Training target HR = %(HRmax - HRrest) + HRrest. HR max is defined as peak HR based on 2 maximal exercise tests at baseline. Individuals unable to walk continuously will exercise intermittently for several minutes as tolerated, with rest intervals, and advanced as tolerated with HR, blood pressure monitoring, and Borg Perceived Exertion to assess subjective cardiopulmonary exercise tolerance, as previously described. Treadmill training velocity will advance as tolerated by week 6 to a target intensity of 70-80% maximal HRR. Duration will similarly advance to a target of 30 minutes by week 6. Following week 6, the progressive training protocol will continue with attempts to increase velocity on a weekly basis and increase duration by 5 minutes bi-weekly to peak at 50 minutes. After week 6, the target HR goal will be 75-85% of HRR as tolerated by the subject.
1625708|NCT02043561|Other|induction of urge by rectal distension|
1625711|NCT02043535|Device|Delivery of precise levels of carbon dioxide with the RespirAct™ Gen4 sequential gas delivery system|"All participants will undergo a baseline rest Rb-82 positron emission tomography (PET) myocardial perfusion imaging scan (MPI) with low-dose computed tomography. Following this baseline study, serial Rb-82 PET MPI using three target levels of carbon dioxide (CO2) (50 mmHg, 55 mmHg, and 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A rest/stress Rb-82 PET MPI will be performed after return to normal CO2 levels (normocapnea) using adenosine as the stress agent.
Myocardial perfusion stress testing"
1625712|NCT02043535|Device|Delivery of rubidium radioisotope (Rb-82) using the automated pump/elution system|All participants will undergo a baseline rest Rb-82 positron emission tomography myocardial perfusion imaging scan (PET MPI) with low-dose CT. Following this baseline study, serial Rb-82 PET MPI using three target levels of pulmonary end-tidal carbon dioxide tension (PetCO2) (50 mmHg, 55 mmHg, and 60 mmHg (± 3 mmHg)) as a stress agent will be performed. The 60 mmHg level will be repeated following a minimum 10 minute rest. A second rest Rb-82 PET MPI will be performed after return to normocapnea, followed by a pharmacologic adenosine stress Rb-82 PET MPI.
1625713|NCT02043522|Drug|Radioisotope|One dose of 10 mCi (370 mBq:± 10%, calibrated to time of injection) of 123I-mIBG (AdreView) administered as a single intravenous bolus over 1 or 2 minutes, followed by a saline flush.
1625714|NCT02043509|Behavioral|MiQuit|MiQuit is an automated responsive text message support programme lasting 12 weeks which provides tailored smoking cessation support and advice to the participant's mobile phone. This support includes motivational messages, advice about preparing for a quit attempt, how to manage cravings and withdrawal, dealing with trigger situations, information about how smoking affects babies and general encouragement.
1625715|NCT02043496|Behavioral|Integrative Cognitive-Affective Therapy|Integrative Cognitive-Affective Therapy is a psychotherapy treatment for binge eating that focuses on changing behaviors, feelings, thoughts, and relationships
1625716|NCT02043496|Behavioral|CBT-Guided Self Help|CBT-Guided Self Help focuses on changing behavior patterns through the use of reading and homework assignments along with sessions with a therapist.
1625717|NCT02043457|Other|phenotyping|
1625718|NCT02043444|Radiation|FDG PET-CT|
1625719|NCT02043405|Behavioral|Weight loss and exercise training|
1625757|NCT02043158|Behavioral|Interview|Interview asking questions about the amount of stress participant may be having or have had in the past. It should take about 25-30 minutes to complete the interview.
1625758|NCT02043145|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) as prescribed according to standard of care in clinical practice.
1625780|NCT02042989|Drug|Vorinostat|"Dose Escalation Phase - Starting Dose of Vorinostat: 100 mg by mouth twice a day, total of 200 mg/day Days 1 to 21.
Dose Expansion Phase Starting Dose of Vorinostat: Maximum tolerated dose from Dose Escalation Phase."
1645676|NCT01888978|Drug|Tax-Iri|
1625720|NCT02043392|Device|Magnamosis|Single-use, sterile device enables creation of a circular compression intestinal anastomosis. Device is comprised of matched pair of self-centering rare earth magnets encased in medical grade polycarbonate. Geometry of magnets' mating surfaces applies force on inside of mated rings to produce compression necrosis of intervening intestinal walls. Lesser force on outside of mated rings produces inflammatory healing of the two co-apted intestinal walls. Internal lumen creates patency of the anastomosis to prevent intestinal obstruction during compression anastomosis creation. In 5-10 days, mated rings with necrotic tissue falls into intestinal lumen and is naturally expelled with stool, leaving a well-healed anastomosis.
1625721|NCT02043379|Drug|IVIG|Those randomized to the study arm will receive a one time dose of IVIG at 12 our post-Cardiopulmonary bypass. This is significantly early than our current standard of care.
1625722|NCT02043379|Other|Placebo|If the subject is randomized to the placebo group they will receive a volume of normal saline that is equivalent to the volume of IVIG to be administered based on their weight.
1625723|NCT02043366|Drug|Normal Saline|Normal Saline is intravenously administrated before anesthesia induction
1625724|NCT02043366|Drug|Butorphanol|Butorphanol is intravenously administrated
1625725|NCT02043366|Drug|Flurbiprofen axetil|Flurbiprofen axetil is intravenously administrated
1625726|NCT02043366|Drug|Remifentanil|Remifentanil is intravenously administrated
1625727|NCT02043366|Drug|Sufentanil|Sufentanil is intravenously administrated
2011276|NCT02629068|Behavioral|PURPOSE|"The first week of the intervention will focus on welcoming everyone to the facebook group and laying down the ground rules for participation. Each additional week of the intervention will focus on a specific topic to promote discussion and learning of each particular skill; however, questions and discussions on other relevant topics are always welcome and encouraged.
Week 1: Welcome Week Week 2: SUD Basics Week 3: Problem of Stigma Week 4: Communication Skills Week 5: Parental Monitoring Week 6: Stress Management Week 7: Family and Valued Directions Week 8: Putting It All Together"
2011277|NCT02623556|Biological|ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in left arm and TB-PPD in right arm respectively. Two drug must use at the same participant and in different arms.
2011278|NCT02623556|Biological|ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm|All subjects including TB subjects and non-TB subjects with lung disease inject ESAT6-CFP10 (10ug/ml) in right arm and TB-PPD in left arm respectively. Two drug must use at the same participant and in different arms.
1625731|NCT02043314|Drug|Isoniazida|
2011279|NCT02622854|Procedure|plasma exchange|see arm description
2011280|NCT02622854|Drug|conservative treatment|see arm description
2011281|NCT02622074|Biological|Pembrolizumab|IV infusion
1625735|NCT02043288|Drug|NC-6004|"Study group (3 week/cycle):
NC-6004 90 mg/m2 i.v. inf. over 60 min on Day 1"
1625736|NCT02043288|Drug|Gemcitabine|"Study group (3 week/cycle):
Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1 and Day 8 (follow by administration of NC-6004)
Control group (4 week/cycle):
Gemcitabine 1000 mg/m2 i.v. inf. over 30 min on Day 1, Day 8 and Day 15"
1625737|NCT02043275|Other|Leg training|Lower body resistance training twice per week for one hour each time.
1625738|NCT02043275|Other|Arm training|Upper body resistance training twice per week for one hour each time.
1625739|NCT02043262|Behavioral|Reablement|The intervention deals with improving function in daily activities the person defines as important in the areas of self-care, productivity and leisure.
1625740|NCT02043262|Behavioral|Standard treatment|The control intervention is standard home-based treatment/care in Norway.
1625741|NCT02043249|Other|CORD MILKING|MILKING OF UMBILICAL CORD OF THE BABY
1625742|NCT02043236|Behavioral|Healthy bones pamphlet|written educational material
1625743|NCT02043236|Behavioral|Bone Health Care Coordinator|The Bone Health Care Coordinator reviews educational materials with participant and facilitates ordering BMD.
1625744|NCT02043236|Behavioral|Letter to GP|The letter to the General Practitioner contains information about the study, recommendations for bone health, guidelines of Osteoporosis Canada, and the identical educational material that the participant received.
1625745|NCT02043223|Dietary Supplement|Vitamin A (<3-day postpartum)|Single dose 200,000 IU vitamin A supplementation at <3-day and placebo supplementation at 6-wk postpartum.
1625746|NCT02043223|Dietary Supplement|Vitamin A (6 wk postpartum)|Placebo supplementation at <3-day and single dose 200,000 IU vitamin A supplementation at 6-wk postpartum.
1625747|NCT02043223|Dietary Supplement|Vitamin A (<3-day and 6 wk postpartum)|200,000 IU vitamin A supplementation, both at <3-day and 6-wk postpartum
1625748|NCT02043223|Dietary Supplement|Placebo|Placebo supplementation, both at <3-day and 6-wk postpartum.
1625749|NCT02043210|Behavioral|Standard Treatment as Usual|Treatment normally offered at this clinic which could include individual or group substance use counseling sessions one time per week lasting one hour each time.
1625750|NCT02043210|Behavioral|CBT4CBT plus Standard treatment as usual|Subjects work with a computerized program in Spanish that teaches skills for stopping substance use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus Standard treatment as usual
1625751|NCT02043184|Behavioral|Interactive Voice Response (IVR) Reminders|Reminders tailored to the oral cancer medication(s) the patients are receiving delivered by interactive voice response system with referral to a self-management guide when symptoms exceed thresholds.
1625752|NCT02043171|Dietary Supplement|Placebo|A Placebo comparator
1625753|NCT02043171|Drug|HMB plus Vitamin D|Active comparator of HMB (3 g/d) plus Vitamin D (2,000 IU/d)
1625754|NCT02043171|Behavioral|Non-Exercise|This group will not participate in 3 times per week strength training
1625755|NCT02043171|Behavioral|Exercise|This group will participate in a supervised 3 times per week strength training program
1625756|NCT02043158|Behavioral|Questionnaire|Questionnaire completion asking questions about quality of life, mood, social support, stress, diet, lifestyle, and demographic information. Questionnaire should take about 60-90 minutes to complete.
2011282|NCT02622074|Drug|Nab-paclitaxel|IV infusion
2011283|NCT02622074|Drug|Anthracycline (doxorubicin)|IV injection
2011284|NCT02622074|Drug|Cyclophosphamide|IV infusion
2011285|NCT02622074|Drug|Carboplatin|IV infusion
1625759|NCT02043132|Drug|Tranexamic Acid|Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
1625760|NCT02043132|Drug|Placebo|Patients randomized to placebo receive an infusion of 10 mg/kg of normal saline within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
1625761|NCT02043119|Behavioral|Breastfeeding Clinic|
1625762|NCT02043106|Other|plantar vibration|
1625763|NCT02043093|Behavioral|Sources of Strength|"Sources of Strength (http://www.sourcesofstrength.com/) has three phases:
Introduction to school and community partners. Staff advisors for the program are identified and trained.
A standard process is used for nominating student peer leaders, who are trained through a 4-hour interactive workshop. A major focus is on increasing knowledge of 'sources of strength' and skills for increasing use of those resources for themselves and other students.
Peer Leaders plan and conduct messaging with Adult Advisor mentoring. A school-wide messaging phase involves presentations; media campaigns through posters, public service announcements, videos."
1625764|NCT02043080|Other|Xpert MTB/RIF Tuberculosis diagnostic tool|This is s new diagnostic tool that has been approved by WHO for the diagnosis of TB in HIV-infected patients in resource limited settings
1625765|NCT02043067|Other|Comprehensive TB screening|All enrollees will receive a comprehensive TB screening regardless of symptom presentation.
1625766|NCT02043054|Drug|Liraglutide|"Liraglutide (Victoza®, Novo Nordisk) is a stable analogue of the natural hormone glucagon-like peptide-1 (GLP-1). Liraglutide is licensed for use within the United Kingdom and recommended by NICE in combination with metformin, and/or sulphonylurea and/or thiazolidinedione if the following conditions are satisfied.
BMI ≥ 35 kg/m2 in those of European descent (with appropriate adjustment for other ethnic groups) and specific psychological or medical problems associated with high body weight, or
BMI < 35 kg/m2, and therapy with insulin would have significant occupational implications or weight loss would benefit other significant obesity-related comorbidities."
1625767|NCT02043054|Drug|Sitagliptin|Sitagliptin (Januvia®, Merck & Co) is an enzyme-inhibiting drug used to inhibit the natural enzyme dipeptidyl peptidase-4 (DPP-4). It is an oral antihyperglycaemic agent used in the treatment of T2DM. Sitagliptin is licensed to be used either alone or in combination with other oral antihyperglycemic agents (such as metformin or a sulphonylurea) and is recommended by NICE as a second line therapy.
1625768|NCT02043041|Other|Number of DBS Spots|The number of DBS spots on the card constitutes the experimental condition.
1625769|NCT02043028|Device|Chest compression with a step stool|Participants compress the chest of a manikin with a standing posture using a step stool during 5 minutes
1625770|NCT02043028|Device|Chest compression with a kneeling stool|Participants compress the chest of a manikin with kneeling posture using a kneeling stool during 5 minutes
2011286|NCT02622074|Drug|Paclitaxel|IV infusion
2011287|NCT02621710|Other|Questionnaire 3 months post-operatively|
2011288|NCT02620787|Drug|Tedizolid|
2011289|NCT02620787|Procedure|Microdiaylsis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
2011290|NCT02620774|Drug|Ceftolozane/tazobactam|3 or more doses of ceftolozane/tazobactam intravenously administered over 60 minutes every 8 hours
2011291|NCT02620774|Procedure|Microdialysis Catheter Insertion|A 20 kila-Dalton microdialysis probe (63 MD catheter; MDialysis Inc., N. Chelmsford, MA) will be inserted into the subcutaneous tissue at the margin of the wound (patient group) or in the thigh tissue (healthy volunteers). The probe will be left in place for the final dose and all tissue sampling procedures thereafter. This probe is perfused with a physiologic solution to collect interstitial fluid samples. The probe will then be removed after completion of sample collection.
2011292|NCT02620683|Drug|Lidocaine|See above
1625778|NCT02043002|Procedure|18F-FDG-PET scan|
1625779|NCT02042989|Drug|MLN9708|"Dose Escalation Phase - Starting Dose of MLN9708: 3 mg by mouth on day 1, 8 and 15.
Dose Expansion Phase Starting Dose of MLN9708: Maximum tolerated dose from Dose Escalation Phase."
1625781|NCT02042976|Behavioral|Mindfulness-based cognitive therapy|
1625782|NCT02042976|Behavioral|Pulmonary rehabilitation|
1646366|NCT01883700|Other|Boiled Pasta|
2011293|NCT02618915|Genetic|AAVrh10FIX|non-replicating recombinant AAVrh10 encoding human FIX (hFIX)
2011294|NCT02618915|Genetic|AAVrh10FIX|non-replicating recombinant AAVrh10 encoding human FIX (hFIX)
2011295|NCT02618915|Genetic|AAVrh10FIX|non-replicating recombinant AAVrh10 encoding human FIX (hFIX)
2011296|NCT02618915|Genetic|AAVrh10FIX|non-replicating recombinant AAVrh10 encoding human FIX (hFIX)
2011297|NCT02618096|Drug|Oxytocin|
2011298|NCT02618096|Drug|Dinoprostone|
2011299|NCT02618096|Procedure|Membrane sweeping|
2011300|NCT02614833|Biological|IMP321|In the placebo-controlled, double-blind randomisation stage, paclitaxel + IMP321 at the RPTD will be compared to paclitaxel + placebo
2011301|NCT02614833|Drug|Placebo|In the placebo-controlled, double-blind randomisation stage, paclitaxel + placebo will be compared to paclitaxel + IMP321 at the RPTD
2011302|NCT02614833|Drug|Paclitaxel|Paclitaxel will be given in both treatment arms (classified as Non IMP)
2011303|NCT02609828|Drug|Tanezumab|Subcutaneous study treatment (tanezumab 20 mg or matched placebo) dosed at 8 week intervals.
2011304|NCT02610439|Other|Laboratory Biomarker Analysis|Correlative studies
2011305|NCT02609607|Drug|Bisacodyl|Rectal suppository
2011306|NCT02609607|Other|Placebo|Rectal suppository
2011307|NCT02609191|Device|"Whole body exam using the Discovery A"|"Whole body exam using the Discovery A machine made by Hologic."
2011308|NCT02609191|Device|"First whole body exam using the Stratos DR"|"First whole body exam using the Stratos DR machine made by the DMS group."
1625783|NCT02042950|Drug|Carfilzomib|Starting dose: 20 mg/m2 by vein on Days 1 and 2 in Cycle 1 followed by 56 mg/m^2 for each subsequent dose thereafter) on days 1 and 2, 8 and 9, 15 and 16 of a 28-day cycle (following cycle 12 carfilzomib given on days 1 and 2 and 15 and 16 only).
1625784|NCT02042937|Other|Exercise|Exercise to improve gluteus maximus recruitment
1625785|NCT02042924|Radiation|FLT PET/CT|Functional marrow imaging using the FLT PET/CT will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
1625786|NCT02042924|Device|MRI|MRI imaging will be performed prior to preparative for HSCT and approximately 3 months post-transplant (Day 100 +/- 5 days).
1625787|NCT02042911|Drug|SyB L-0501|SyB L-0501 is administered at 100 mg/m2/day by intravenous infusion on Day 1 and Day 2 followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 cycles. Dose administration can be delayed or discontinued from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle, but dose reduction is permitted from the 3rd cycle.
1625788|NCT02042898|Other|Restrictive Transfusion Strategy|
1625789|NCT02042898|Other|Liberal transfusion strategy|
1625790|NCT02042885|Drug|OPB-111001|
1625791|NCT02042872|Drug|Zoledronic acid|At baseline, study subjects in the treatment group will receive 5 mg of zoledronic acid (Reclast: 5 mg; Novartis Pharmaceuticals Inc., East Hanover, NJ) by intravenous infusion over 30 minutes.
1625792|NCT02042859|Device|Endoscopic Bipolar RadioFrequency Probe used to remove tumors in bile duct to manage Pancreatic Cancer|
1625793|NCT02042846|Device|SportWelding Fiji Anchor|
2011309|NCT02609191|Device|"Second whole body exam using the Stratos DR"|"Second whole body exam using the Stratos DR machine made by the DMS group. This second exam is required for reproducibility purposes."
1625795|NCT02042807|Drug|Placebo|
1625796|NCT02042807|Drug|MCS®|
1625798|NCT02042755|Device|trifocal intraocular lens|Standard cataract surgery
1625799|NCT02042742|Dietary Supplement|punicalagin and hydroxytyrosol mixture|Antioxidant Supplement (punicalagin and hydroxytyrosol mixture) During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
1625800|NCT02042742|Dietary Supplement|Control supplement (maltodextrin)|During one period of crossover study (I or II) volunteers consume daily of functional supplement during 8 weeks. Additionally, volunteers must follow guidelines for healthy diet and physical activity.
1625801|NCT02042729|Drug|E2022- Current Formula Tape|"Cohort I: E2022 current formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.
Cohort II: E2022 current formula tape administered to skin application site and evaluated for 20 days."
1625802|NCT02042729|Drug|E2022- New Formula Tape|"Cohort I: E2022 new formula tape administered on a skin application site and evaluated for 10 days during the introductory skin patch test.
Cohort II: E2022 new formula tape administered to skin application site and evaluated for 20 days."
1625803|NCT02042729|Drug|E2022 Matching Placebo- Current Formula Tape|
1625804|NCT02042729|Drug|E2022 Matching Placebo- New Formula Tape|
1625805|NCT02042716|Other|diagnosis of white matter damage in preterm infants|Added value of supersonic shear imaging in the diagnosis of white matter damage in preterm infants
1625806|NCT02042703|Device|anterior segment OCT|
1625807|NCT02042690|Procedure|Haplo-identical HSCT|Haplo-identical Protocol: GIAC regimen. GVHD prevention regimen: CSA/MMF/MTX, CSA 1.25mg/kg/d, i.v administrated in two doses from day -109 until bowel function returned to normal, at which time patients receive oral CSA until 12months after HRD-HSC and then gradually tapered. Every 12h, 0.5g MMF(0.25g for children) was administrated orally from day -10 to +30 and subsequently 0.25g from days +30 to +60. MTX was administrated at a dose of 15mg/m2 on day +1 and 10mg/m2 on days +3,+6, and +11.
1625808|NCT02042690|Drug|Chemotherapy|Patients receive 6 cycles of consolidation chemotherapy after randomization, including Hyper-CVAD-B regimen-Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen/Hyper-CVAD-B regimen/Hyper-CVAD-A regimen.Maintenance treatment includes MTX 20mg/m2/w，po，6-mercaptopurine 60 mg/m2/d，po，d1-d28，VP（VDS 4mg,d1, Prednisone 1mg/kg d1-7) every one month for 2 years.
1625809|NCT02042664|Drug|BYETTA treatment|
1625810|NCT02042664|Drug|Metformine|
1625811|NCT02042651|Device|Low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The energy level applied will range between 0.25 and 0.40 mJ/mm2 with a frequency of 3 Hz for a total of 3000 shockwaves per treatment session
1625812|NCT02042651|Device|Sham low intensity extracorporeal shockwave therapy|Shockwaves will be applied to the perineum a total of 6 times once per week. The shockwaves will be blocked by a medium on the handheld applicator.
1625813|NCT02042638|Drug|hCG 1500 IU three times a week|
1625814|NCT02042638|Drug|Pregnyl (hCG) ampule 1500 IU/three times a week|
1625815|NCT02042625|Procedure|Nasopharyngeal|
1625816|NCT02042612|Drug|Sedation with sevoflurane during 48-hr in ICU|
1625817|NCT02042599|Drug|Sedation with sevoflurane during 48-hr in ICU|
1625818|NCT02042586|Other|Analysis of movement before total hip replacement|
1625819|NCT02042586|Other|Analysis of movement after total hip replacement|
1625820|NCT02042573|Device|rTMS|
1625821|NCT02042573|Drug|SSRI (SEROPLEX ou ZOLOFT)|
1625822|NCT02042573|Other|Genetic samples|
1625823|NCT02042560|Other|Blood samples|
1625824|NCT02042560|Other|Spleen samples|
1625825|NCT02042547|Other|Tissue samples from the right atrium|
1625826|NCT02042547|Other|Blood samples|
1625827|NCT02042534|Drug|Rivaroxaban|"Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.
The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety."
1625863|NCT02042248|Biological|AGS-004|All participants in both arms will receive the same treatment and doses of AGS-004 in Step 2 at weeks 0, 4, 8, and 12.
1625828|NCT02042534|Drug|Warfarin|To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
1625829|NCT02042521|Drug|Dietary Supplement|The active evening dietary supplement is taken at 22:00. The active morning dietary supplement is taken at 8:00-8:15. The active evening dietary supplement is taken first. The active morning and evening dietary supplements are taken within 12 hours in time points as specified above.
1625830|NCT02042521|Drug|Lactose Placebo|This research study involves a placebo dietary supplement that does not have any of or only partial of the active ingredients in the active dietary supplement. The placebo dietary supplement will be given in identical time points to match that of the active dietary supplements.
1625831|NCT02042508|Other|strengthening|
1625832|NCT02042508|Other|hybrid training programme|
1625833|NCT02042495|Drug|Metformin|
1625834|NCT02042482|Dietary Supplement|Coenzyme Q10U, L-carnitine|
1625835|NCT02042456|Device|Digital Breast Tomosynthesis|digital breast tomosynthesis technology
1625836|NCT02042456|Device|Automated Whole Breast Ultrasound|Automated Whole Breast Ultrasound
1625837|NCT02042456|Device|Full Field Digital Mammography|
1625838|NCT02042443|Drug|Capecitabine|Given PO
1625839|NCT02042443|Drug|Fluorouracil|Given IV
1625840|NCT02042443|Other|Laboratory Biomarker Analysis|Correlative studies
1625841|NCT02042443|Drug|Leucovorin Calcium|Given IV
1625842|NCT02042443|Drug|Trametinib|Given PO
1625843|NCT02042430|Drug|Epacadostat|Given PO
1625844|NCT02042430|Other|Laboratory Biomarker Analysis|Correlative studies
1625845|NCT02042430|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1625846|NCT02042417|Device|INRatio2 and CoaguChek|
1625847|NCT02042404|Device|Sound amplification provided via EarLens System.|The EarLens System has two primary components: 1) an external Behind the Ear (BTE) Sound Processing Unit, and 2) a Tympanic Membrane Transducer (TM Transducer). In this system, light is used to wirelessly transmit both signal and power from the BTE Sound Processor to the TM Transducer. The BTE is designed to be able to be removed, reprogrammed, and have the battery recharged as needed, similar to a BTE for an air conduction hearing aid. The removable TM Transducer is customized for each patient, is placed and removed by a physician in an office visit procedure, and is designed to reside in the ear in a safe and stable manner for long periods of time.
1625848|NCT02042391|Drug|Rituximab sc|All patients will receive 4 courses of rituximab on days 1, 8, 15 and 22. Rituximab will be administered as a single therapeutic agent at a standard dosage of 375 mg/m2 infused intravenously at day 1. Three subsequent single therapeutic agent applications of rituximab will be administered subcutaneously at a fixed dose of 1400 mg once a week for 3 weeks at days 8, 15 and 22.
1625849|NCT02042391|Drug|Rituximab sc consolidation|Patients considered low-risk will receive four more single therapeutic agent applications of rituximab administered subcutaneously at a fixed dose of 1400 mg once every three weeks at days 50, 71, 92 and 113.
1625850|NCT02042391|Drug|Rituximab sc combined with CHOP chemotherapy|Patients considered high-risk will receive four more applications of rituximab administered subcutaneously at a fixed dose of 1400 mg combined with CHOP chemotherapy every 3 weeks at days 50, 71, 92 and 113. CHOP chemotherapy will be administered at standard doses: cyclophosphamide 750 mg/m2, adriamycine 50 mg/m2, vincristine 1.4mg/m2 (maximum total dose: 2mg) and prednisone 100mg (at day 1 to 5 of each cycle). Cyclophosphamid, adriamycine and vincristine will be infused intravenously. Prednison will be administered orally in a single dose. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
1625851|NCT02042391|Drug|Rituximab sc combined with alternating chemotherapy with CHOP and DHAOx|Patients considered very high-risk will receive six more applications of rituximab sc at a fixed dose of 1400 mg combined with chemotherapy every 3 weeks. Chemotherapy is CHOP at days 50, 92 and 134 (cyclophosphamide IV 750 mg/m2, adriamycine IV 50 mg/m2, vincristine IV 1.4mg/m2 (maximum total dose: 2mg) and prednisone PO 100mg (at day 1 to 5 of each cycles). Chemotherapy is DHAOx at days 71, 113 and 155 (oxaliplatin (130 mg/m2, day 1) and cytarabine (ARA-C, 2x 1000 mg/m2 at day 2) dexamethasone PO (40 mg/m2, day 1)), as per institutional practice. At day 3-4 of each treatment cycle either a single dose of 6 mg Peg-GCSF or repetitive doses of 5 µg/kg GCSF until recovery of WBC will be applied subcutaneously, as per institutional practice.
1625852|NCT02042378|Drug|Rucaparib|All patients will take oral tablets twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
1625853|NCT02042365|Procedure|ERAS (Enhanced recovery after surgery)|
1625854|NCT02042352|Other|pH glove|
1625855|NCT02042339|Drug|Hyperbaric oxygen|The treatment will be applied in a large walk-in drive-in hyperbaric chamber. Depending on their general condition, the patients will sit in comfortable chairs or remain in their own wheelchair or bed in relaxed position. They will be accompanied by a medical attendant or by a hyperbaric physician if necessary due to their general condition. Oxygen 100% will be distributed over a tight fitting oxygen-mask connected to the overboard-dumping system. The treatment will be administered according to the so-called problem-wound schedule once a day for six consecutive weeks. On weekends and on public holidays the patients will be off therapy.
1625856|NCT02042326|Drug|Sirolimus|For patients with swallowing problems, and for children under 6 years and / or who have an inability to swallow tablets, the 1mg/ml solution form should be used.
1625857|NCT02042313|Other|continuous epidural infusion|
1625858|NCT02042313|Other|combined paravertebral infusion and single shot of TAP block|
1625859|NCT02042300|Device|XIENCE Xpedition/Alpine|
1625860|NCT02042287|Device|Vaginal lactic acid and glycogen gel|Medical device (registration number: 10-355-717, first licensed 12.08.2010)
1625861|NCT02042287|Drug|Metronidazole|Oral antibiotic
1625862|NCT02042274|Dietary Supplement|Fish oil supplement|Participants are instructed to consume fish oil supplements on a daily basis for a 3-month period.
1626017|NCT02040987|Drug|Moxifloxacin|Moxifloxacin tablet - one single dose
1625864|NCT02042235|Behavioral|Parent-implemented intervention|In order to achieve the programme of parent-implemented language intervention, a detailed protocol for speech therapists recruited and trained for the present study has been established. The techniques and attitudes favouring use of oral language will be taught to the parents during 15 sessions with the parent(s) and child.
1625865|NCT02042222|Drug|Hydroxyurea|
1625866|NCT02042196|Drug|KUVAN|KUVAN will be given orally at 10mg/kg dose per body weight. KUVAN will be dissolved in 4-8oz water and consumed within 15 minutes.
1625867|NCT02042196|Drug|Placebo|Placebo pills designed to match the dissolvable KUVAN pills
1625868|NCT02042196|Drug|Cetrotide|Cetrotide (0.25mg/d) will be taken daily for 10 days via abdominal subcutaneous injection.
1625869|NCT02042196|Drug|Climara|0.075mg/d transdermal patch will be placed on skin.
1625870|NCT02042196|Drug|Placebo transdermal patch|Inactive transdermal patch
1625871|NCT02042183|Drug|Lubiprostone|12 mcg or 24 mcg administered orally twice daily (BID)
1625872|NCT02042183|Drug|Placebo|Matching placebo, 0 mcg administered orally twice daily (BID)
1625873|NCT02042170|Drug|human growth hormone self-injection|
2011310|NCT02610218|Other|CTC and cfDNA analysis|The enumeration of CTCs as well as the detection of HER2 expression will be achieved via the integrated subtraction enrichment (SET) and immunostaining-fluorescence in situ hybridization (iFISH) platform. Further, for the geneomic analysis, the enriched single CTC will be isolated for single-cell targeted sequencing. While for cfDNA analysis, extracted DNA from plasma will be directly subjected to targeted sequencing. Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol.
1625876|NCT02042144|Drug|Stivarga (Regorafenib, BAY73-4506)|Patients diagnosed with mCRC who have been previously treated with, or are not considered candidates for, other locally approved standard treatment(s) and for whom the decision has been made per investigator's routine treatment practice to prescribe regorafenib
1625877|NCT02042131|Behavioral|Treatment As Usual (TAU)|
1625878|NCT02042131|Behavioral|Standard Crisis Response Plan (S-CRP)|
1625879|NCT02042131|Behavioral|Enhanced Crisis Response Plan (E-CRP)|
1625880|NCT02042118|Device|Laryngeal Mask Airway|Laryngeal mask airway (LMA) ventilation will be provided for newborns in this arm during the first 2.5 minutes.
1625881|NCT02042118|Device|Face mask ventilation|Face-mask ventilation (FMV) will be provided for newborns in this arm during the first 2.5 minutes.
1625882|NCT02042092|Device|Ultrasound|
1625883|NCT02042092|Device|MRA|
1625884|NCT02042079|Procedure|EFTR with LA|(Endoscopic full-thickness resection with laparoscopic assistance)
1625885|NCT02042066|Device|Omnispec model Vascuspec|Energy Density: 0.09 - 0.1 mJ/mm2 Extracorporeal Shockwave Therapy
1625886|NCT02042053|Device|PET/CT|
1625887|NCT02042053|Device|PET/MRI|
1625888|NCT02042027|Drug|Gamunex-C|Patients will receive 50 mg (0.5 mL) subconjunctival Gamunex-C injection in addition to standard of care treatment (steroids and cyclosporine)
1625890|NCT02042001|Drug|Immediate switch to TDF/FTC/RPV|
1625891|NCT02042001|Drug|Switch to TDF/FTC/RPV after 12 weeks|Patients will continue current EFV-containing regimen up to week 12 and then will be switched to TDF/FTC/RPV
1625892|NCT02041975|Dietary Supplement|Nutriose FB06|Wheat dextrin soluble fibre
1625893|NCT02041975|Dietary Supplement|Placebo|
1625894|NCT02041962|Behavioral|Chronic Care Model for Mood Disorders|"The mood disorders CCM intervention (Life Goals Collaborative Care) consists of: (a) a web-based patient self-management skills enhancement (CCM-1), (b) enhanced information flow and continuity of care via a care manager (CCM-2), and (c) decision support, or situation-specific evidence-based clinical practice guideline recommendations for providers (CCM-3). The CCM will be implemented utilizing telephonic contact with patients and providers by an Aetna care managers.The care managers will also use the Life Goals web portal as a guide for each session."
1625895|NCT02041962|Other|Educational Control|
1625896|NCT02041936|Device|NanoKnife IRE System|
1625898|NCT02041910|Biological|Stem Cells|MSCs injection intratesticular
1625899|NCT02041910|Biological|Stem Cells|60 ml of Bone marrow will aspirated for stem cells isolation and preparation. 5 ml of stem cells prepared according to GMP rules injected into testis.
1625900|NCT02041897|Procedure|EUS-FNA|Only one puncture will be performed. First the fluid will be aspirated out for biochemical analysis and cytology. Then the tissue will be aspirated out from the solid part of the lesion for pathology.
1625901|NCT02041884|Behavioral|iCBT for Adults with ADHD|A skill training internet-based treatment program based on CBT and DBT interventions .
1625902|NCT02041884|Behavioral|Internet stress-reduction|Internet-based psychoeducation, stress-reduction, and Applied Relaxation based on CBT (control group)
1625903|NCT02041884|Other|Treatment as usual (TAU)/waiting list|Treatment as usual (usually medications for ADHD), will be offered treatment after the FU3 (week 24)
1625904|NCT02041871|Dietary Supplement|Oral immunonutrition|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
1625905|NCT02041871|Dietary Supplement|Placebo|Powder 74g within 250ml of water, 3 times per day during 7 days before surgery
1625906|NCT02041858|Other|Altered Alarm Settings|An altered set of alarm parameter settings
1625907|NCT02041845|Radiation|45 Gy in 30 fractions|3D conformal thoracic radiotherapy at a total dose of 45 Gy in 30 fractions, 2 fractions per day, 5 days a week
1625908|NCT02041845|Radiation|60 Gy in 40 fractions|3D conformal thoracic radiotherapy at a total dose of 60 Gy in 40 fractions, 2 fractions per day, 5 days a week. If doses to organs at risk exceed normal tissue tolerance, the dose may be lowered to a minimum of 54 Gy.
1625909|NCT02041832|Other|Conventional Holter monitoring|Patients undergo 72h Holter monitoring
1625910|NCT02041832|Device|Implantable loop recorder|Implantation of loop recorder with follow-up by remote monitoring
1625911|NCT02041819|Drug|Nimotuzumab|Nimotuzumab: 200mg,IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
1625912|NCT02041793|Procedure|Laparoscopic cystogastrostomy|Patients undergo drainage of pseudocyst by laparoscopic technique
1647359|NCT01875718|Drug|Placebo|
1625913|NCT02041793|Procedure|Endoscopic cystogastrostomy|Endoscopic cystogastrostomy or cystoduodenostomy will be performed either under direct endoscopic or endosonography guidance
1625914|NCT02041780|Procedure|Shearwave electrography|
1625915|NCT02041767|Drug|Ertapenem|One single injection of 1g of ertapenem before surgery
1625916|NCT02041754|Device|IQP-AK-102|
1625917|NCT02041754|Device|Placebo|
1625918|NCT02041741|Behavioral|Weekly tips|Participants in this condition receive weekly a more in-depth tip to increase feelings of happiness involving a (doing and experiencing) task
1625919|NCT02041741|Behavioral|Daily Tips|Participants in this condition receive daily a set of small tips aimed at increasing happiness
1625920|NCT02041715|Drug|TKM-100802 for Injection|IV infusion
1625921|NCT02041715|Drug|Placebo|IV infusion
2011311|NCT02608554|Behavioral|Taichi|The program of Taichi training consisted of 60 minutes exercise sessions, 3 days per week for 12 weeks, based on their original level of physical activity. Each session comprised 40 minutes of Taichi training plus a 10-minute warm-up and cool-down. The Taichi training was instructed by the same experienced Taichi instructors who were qualified in the teaching of Taichi. The 24 forms of simplified Taichi recommended as the popular health sport by the General Administration of Sport of China were applied.
1625924|NCT02041689|Behavioral|Interview|Each participant will complete two interview sessions with the primary investigator. Each interview will be conducted in a private, quiet room. Parents may choose to remain with the child during the interview if they would like, but only the responses of the child will be analyzed. Each interview session will last no more than one hour; if the child is not able to respond to each of the primary interview questions during this time, a second follow-up session will be scheduled so that the remainder of the questions can be answered. All interviews will be audio-recorded and transcribed.
1625925|NCT02041689|Behavioral|Observations|Observations help to give insights about interpersonal interactions, actions, non-verbal cues, and the activities and function of areas within the hospital. Three kinds of observation will be used: participant observation, non-participant observation, and guided activities. These observations will be conducted to learn more about the hospital environment as it intersects with the learning experiences of the participants.
1625926|NCT02041689|Behavioral|Guided Activities|"This study will use three different types of arts and play-based activities to give participants a variety of ways to express their thoughts and perceptions of what it is like to learn about their cancer diagnosis and treatment.
The first activity will be a guided medical play opportunity that prompts the child to use actual medical equipment while taking care of a doll.
For the second activity, the child will be given a digital camera to use and a prompt that asks them to photograph things and individuals in the hospital that have helped them to learn about their diagnosis and treatment.
The third activity will be an open-ended art prompt in which the child will create an artistic representation of what it means to have cancer and get treatment."
1625927|NCT02041676|Procedure|Chest physiotherapy|
1625928|NCT02041676|Procedure|Usual surveillance|Usual surveillance of the non invasive ventilation without chest physiotherapy.
1625929|NCT02041663|Biological|BNP|Repeated brain natriuretic peptide dosages and cardiac echographies up to day 5
1625930|NCT02041650|Drug|Ticagrelor|
1625931|NCT02041611|Procedure|Blood collections|pts will have 6 blood collections (30ml/collection) throughout course of standard treatment
1625933|NCT02041572|Behavioral|Attentional bias retraining|Participants complete a computer-based intervention, which is designed to correct cognitive biases associated with PTSD by training to attend to neutral information rather than the trauma-related cue words.
1625934|NCT02041546|Drug|Lung lavage with surfactant|
1625935|NCT02041546|Drug|Bolus surfactant|
1625936|NCT02041533|Biological|Nivolumab|
1625937|NCT02041533|Drug|Gemcitabine|
1625938|NCT02041533|Drug|Cisplatin|
1625939|NCT02041533|Drug|Carboplatin|
1625940|NCT02041533|Drug|Paclitaxel|
1625941|NCT02041533|Drug|Pemetrexed|
1625942|NCT02041520|Drug|omega 3 fatty acids|omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
1625943|NCT02041520|Other|placebo|olive oil in similar presentation of omega 3 fatty acids will be administered until progression or unacceptable toxicity develops during 6 months follow up.
1625944|NCT02041507|Other|Air insufflation method.|Air insufflation colonoscopy.
1625945|NCT02041507|Other|Water Immersion method.|Water Immersion during insertion, air insufflation during withdrawal.
1625946|NCT02041507|Other|Water Exchange method.|Water Exchange during insertion, air insufflation during withdrawal.
1625949|NCT02041481|Drug|MEK inhibitor MEK162|Given PO
1625950|NCT02041481|Drug|leucovorin calcium|Given IV
1625951|NCT02041481|Drug|fluorouracil|Given IV
1625952|NCT02041481|Drug|oxaliplatin|Given IV
1625953|NCT02041481|Other|pharmacological study|Correlative studies
1625954|NCT02041481|Other|Laboratory Biomarker Analysis|Correlative Studies
1625955|NCT02041455|Drug|Melatonin and Placebo|
1625956|NCT02041455|Drug|Amitriptyline and Placebo|
1625957|NCT02041455|Drug|Melatonin and Amitriptylin|
1625958|NCT02041442|Procedure|Electrical mapping of the urinary bladder|
1625959|NCT02041429|Drug|Ruxolitinib|
1625960|NCT02041429|Drug|Paclitaxel|
1625961|NCT02041390|Other|SMS reminder|Each month after stent implantation, one investigator sent a text massage by SMS to inform patients the necessity of regular stent removal/exchange and the disadvantage of delayed management, and to remind them the appropriate date back to the hospital for stent management. Patients were requested to response by SMS and were encouraged to contact with the investigator if they had any questions about stent management.
1625962|NCT02041390|Other|Conventional reminder|After stent implantation, all patients received oral instruction about further management. If single or multiple plastic stents were inserted, patients were informed back to our hospital at 3 months for stent removal/exchange; if FCSEMS was inserted, they were informed back to the hospital at 6 months.
1626018|NCT02040961|Device|ETView Double-Lumen Tube|Tracheal intubation is performed using a ETView Double-Lumen Tube
1626196|NCT02039479|Drug|Placebo|Placebo as ADD-on to every necessary treatment as usual
1625963|NCT02041377|Device|Karajishi TS Investigational Blood Glucose Monitoring System|Subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi TS Investigational Blood Glucose Monitoring System with no training. All BG results were compared to reference method results obtained from subject capillary plasma. Also, study staff tested subject venous blood and BG results were compared to reference method results obtained from subject venous plasma.
1625964|NCT02041351|Drug|Docetaxel|evaluate the activity of docetaxel on, metastatic lesions when measured after 4 cycles of chemotherapy
1625965|NCT02041338|Drug|Paclitaxel and carboplatin|
1625966|NCT02041338|Drug|Paclitaxel|
1625967|NCT02041338|Drug|Epirubicin and Paclitaxel|
1625968|NCT02041325|Drug|Lenalidomide|Subjects will receive oral CC-5013 (lenalidomide) at 25 mg qd for 7 days prior to and 7 days after the vaccine.
1625969|NCT02041325|Drug|Placebo|Subjects will receive placebo for 7 days prior to and 7 days after the vaccine.
1625970|NCT02041312|Other|No intervention|No intervention will be needed.
1625971|NCT02041299|Drug|Deferiprone|
1625972|NCT02041299|Drug|Deferoxamine|
1625973|NCT02041286|Device|Karajishi Contour Investigational BG Monitoring System|Subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Karajishi Contour Investigational BG Monitoring System with no training. All BG results are compared to reference method results obtained from subject capillary plasma. Also, study staff test subject venous blood and BG results are compared to reference method results obtained from subject venous plasma.
1625974|NCT02041273|Drug|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under overnight fasting conditions
1625975|NCT02041273|Drug|palbociclib isethionate (phase 1 and 2 studies)|125 mg palbociclib isethionate salt under minimal fasting conditions (1 hr before palbociclib administration and 2 hrs post dose)
1625976|NCT02041273|Drug|palbociclib commercial free base capsule|125 mg palbociclib commercial free base capsule under fed conditions ( moderate fat meal)
1625977|NCT02041260|Drug|Cabozantinib|
1625978|NCT02041247|Biological|VAC-3S|VAC-3S is administered via intra-muscular route in the arm.
1625979|NCT02041234|Procedure|Roux-en-Y Gastric Bypass (RYGB)|Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.
1625980|NCT02041234|Drug|Incretin analogues|Incretin analogues: Liraglutide up to 1.8 mg daily
1625981|NCT02041234|Drug|Xenical|Xenical: Up to 120 mg tds
1625982|NCT02041234|Drug|SGLT2 inhibitors|SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily
1625983|NCT02041234|Drug|DPP-4 Inhibitors|Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
1625984|NCT02041221|Drug|SPARC1316 Dose 1|The subjects will receive SPARC1316.
1625985|NCT02041221|Drug|Placebo|
1625986|NCT02041221|Drug|SPARC1316 Dose 2|
1625987|NCT02041221|Drug|SPARC1316 Dose 3|
1625988|NCT02041221|Drug|SPARC1316 Dose 4|
1625989|NCT02041221|Drug|SPARC1316 Dose 5|
1625990|NCT02041208|Procedure|kidney transplantation|kidney transplantation
1625991|NCT02041195|Drug|RM-493|
1625992|NCT02041195|Drug|Placebo|
1625993|NCT02041182|Behavioral|Pre-Visit Questionnaire|
1625994|NCT02041169|Other|Subsequent walking performance|Subsequent walking performance
1625995|NCT02041156|Other|aerobic and resistance training|
1625996|NCT02041156|Other|aerobic combined with balance training|
1625997|NCT02041143|Dietary Supplement|Milk protein|Study product will provide 25 g of protein to subjects.
1625998|NCT02041143|Dietary Supplement|Placebo|Product with no protein
1625999|NCT02041130|Device|Renal Denervation|
1626000|NCT02041117|Drug|Rosuvastatin|Rosuvastatin, 10mg for 4-weeks, then according to the results of the LDL-C, adjust dose of rosuvastatin, maximum to 20 mg/d, to reduce LDL-C under 70 mg/dl for two years.
1626001|NCT02041104|Dietary Supplement|Bread with added beta-glucans|Participants will daily consume bread with high content of beta-glucans. They will approximately consume 6 g beta-glucans per day in 200 g of bread. Intervention period will be 8 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics
1626002|NCT02041104|Dietary Supplement|Placebo Comparator: Bread without added beta-glucans|Participants will daily consume placebo bread without any added beta-glucans (approximately 200 g per day). Intervention period will be 8 weeks. Meanwhile the participants will remain their usual eating habits except consuming any pro- or pre-biotics.
1626003|NCT02041091|Drug|Tabalumab Auto-Injector|Administered SC
1626004|NCT02041091|Drug|Tabalumab Prefilled Syringe|Administered SC
1626005|NCT02041078|Procedure|Intrahepatic division of the right hepatic vein.|Ligation and division of the entrance of the right hepatic vein into the suprarenal cava vein are done at the end of transection of the liver parenchyma with CUSA.
1626006|NCT02041078|Procedure|Extrahepatic vein division|Standard surgical procedure with extrahepatic ligation/division of the right hepatic vein prior to parenchymal division with CUSA.
1626007|NCT02041065|Device|Waterjet induced dissection|Waterjet induced dissection of the liver during resection.Waterjet dissection device mechanically separates hepatic tissue from bile ducts and vessels, the latter two to be separately ligated.
1626008|NCT02041065|Device|CUSA induced dissection|Ultrasound based destruction of the liver
1626009|NCT02041052|Procedure|Subtotal gastrectomy as an adjunct to traditional whipple procedure.|Subtotal gastrectomy as an adjunct to traditional whipple procedure.
1626010|NCT02041052|Procedure|Conventional whipple procedure|All patients undergoing whipple procedure without risk for pancreaticojejunal anastomosis leakage.
1626011|NCT02041026|Dietary Supplement|probiotic yoghurt|The probiotic yoghurt will be prepared using lactobacillus NN20 isolated from Kimere (a traditional fermented food product) consumed in eastern part of kenya
1626012|NCT02041013|Other|Taking Card|Recordable greeting card-style discharge instruction card
1626013|NCT02041000|Other|Adipose Derived Stem Cells|
1626014|NCT02040987|Drug|AZD3293|AZD3293 oral solution - one single dose (low dose).
1626015|NCT02040987|Drug|AZD3293|AZD3293 oral solution - one single dose (high dose).
1626016|NCT02040987|Drug|Placebo|Placebo oral solution - one single dose
1626019|NCT02040948|Device|- Nexfin (Pulse Pressure Variation) - Radical 7 (Pleth Variability Index) - CardioQ (stroke volume)|
1626020|NCT02040935|Drug|Trastuzumab|600 mg SC Q3W by SID
1626021|NCT02040909|Drug|Propofol|Propofol, an anesthetic agent, is used to sedate the patients before endotracheal intubation. The propofol starting dose in all age groups will be 1.0 mg propofol/kg. After 5 patients per age group the next dose will be determined. Dose will be increased or decreased with 0.5 mg/kg for the next 5 patients. The study will be continued untill an adequate dose, that results in adequate sedation, good intubation conditions without hypotension, is determined. That dose will be valideted in another 5 patients per age group.
1626022|NCT02040883|Drug|Risperidone/Olanzapine/Quetiapine/Ziprasidone/Aripiprazole|Treated with a stable dose of an AAPD for at least three months before enrollment, which is suggested to attain the stable cognitive status.
1626023|NCT02040883|Drug|Tandospirone|Tandospirone，30mg per day
1626024|NCT02040870|Drug|LDK378|750 mg once daily
1626025|NCT02040857|Drug|Palbociclib|CDK 4/6 inhibitor
1626026|NCT02040857|Drug|Endocrine Therapy|Endocrine Therapy
1626027|NCT02040844|Drug|Received Cat-PAD Treatment 1 in Study CP007 [NCT01620762]|
1626028|NCT02040844|Drug|Received Cat-PAD Treatment 2 in Study CP007 [NCT01620762]|
1626029|NCT02040844|Drug|Received Cat-PAD Treatment 3 in Study CP007 [NCT01620762]|
1626030|NCT02040831|Biological|RSV LID ΔM2-2 Vaccine|10^5.0 plaque forming units (PFU); 0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
1626031|NCT02040831|Biological|Placebo Vaccine|0.5 mL dose delivered as nose drops (approximately 0.25 mL per nostril)
1626032|NCT02040818|Drug|tigecycline, N-acetylcysteine, heparin combination|
1626033|NCT02040818|Device|guide-wire exchange|
2011312|NCT02608554|Behavioral|Self-monitored exercise|Exercise was self-monitored and consisted of brisk walking, cycling, jogging, or any other aerobic exercise for 60 mins. 3 days per week for 12 weeks.
2011313|NCT02607891|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1626036|NCT02040792|Drug|TD-4208|
1626037|NCT02040792|Drug|Placebo|
2011314|NCT02607891|Drug|Placebo|Clear, colorless to yellow solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
2011315|NCT02607904|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol (CBD) dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
2011316|NCT02606279|Drug|valsartan|Valsartan will be given in increasing doses (from 40 mg to 80 mg) to those in the valsartan arm.
1626041|NCT02040766|Drug|Beclomethasone dipropionate|Participants are instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
1626042|NCT02040766|Drug|Placebo|Participants are instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
1626043|NCT02040766|Drug|albuterol/salbutamol 90 mcg|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
1626044|NCT02040753|Behavioral|Intensive Lifestyle Intervention|Intensive Lifestyle intervention at Ubberup Folk High School for 10-14 weeks. Daily exercise for 1-3hrs. Calorie restriction. Education within Nutrition, exercise and healthy living in general.
1626045|NCT02040727|Behavioral|Resistance Training|Supervised strength training 3 days per week for 24 weeks
1626046|NCT02040727|Behavioral|No Resistance Training|No supervised strength training throughout the study
1626047|NCT02040714|Procedure|osteotomy|Surgical procedures that improve femoral head containment
1626048|NCT02040714|Procedure|multiple epiphyseal drilling|Multiple epiphyseal drilling is a procedure that creates small holes in the femoral head growth plate to increase blood flow into the femoral head.
1626049|NCT02040662|Procedure|Continuous Thoracic Epidural Block|Before anesthesia, continuous thoracic epidural block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (air). A catheter is advanced ca. 3-5 cm, and test dose with 2 ml of lidocaine 2% i injected. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 6 ml bolus is injected, followed by an infusion of the same mixture at 0,06 ml/kg/h for postoperative pain management.
1626050|NCT02040662|Procedure|Continuous Thoracic Paravertebral Block|Before anesthesia, continuous thoracic paravertebral block of T5/T6 is performed (Portex Epidural Minipack set). Identification of paravertebral space by loss of resistance technique (normal saline). After injection of 5-10 ml of normal saline a catheter is advanced medially ca. 5 cm. At the end of surgery syringe with 0,25% bupivacaine with epinephrine 1:200.000 is connected to catheter and 20 ml bolus is injected, followed by an infusion of the same mixture at 0,08 ml/kg/h for postoperative pain management
1626051|NCT02040662|Procedure|Patient-Controlled Analgesia with Morphine|"Once arrived at the PACU all patients are placed on a postoperative analgesia regimen, that include:
patient-controlled analgesia with morphine (bolus dose 2 mg, lockout time 10 min)
paracetamol 1000 mg iv every 8 hrs
ketoprofen 100 mg iv every 12 hrs"
2011317|NCT02606279|Other|Placebo|
2011318|NCT02604225|Drug|Methoxyflurane|Participants randomised to the experimental arm will inhale methoxyflurane administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
1626188|NCT02039531|Drug|Hyaluronic Acid|
2011319|NCT02604225|Drug|Placebo|Participants randomised to the control arm will inhale 0.9% saline administered through the Penthrox® inhaler starting approximately one minute before insertion of the rectal probe.
2011320|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
2011321|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X2 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression.
1991915|NCT00290355|Biological|GSK 249553 vaccine|Intramuscular injection, 13 doses
1991916|NCT00290355|Biological|Placebo|Intramuscular administration, 13 doses
1626054|NCT02040636|Biological|Tetanus and Diphtheria Toxoids Adsorbed Combined with Component Pertussis Vaccine and IPV|0.5 mL, Intramuscular
1626055|NCT02040636|Biological|Hepatitis B vaccine|0.5 ml, Intramuscular
1626056|NCT02040623|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution 0.2% 2 drops per eye twice a day
1626057|NCT02040623|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 2 drops per eye twice a day
1626058|NCT02040623|Other|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution 2 drops per eye twice a day
1626059|NCT02040610|Radiation|Hypofractionated Proton Therapy|
1626060|NCT02040597|Drug|Beclometasone/Formoterol/Glycopyrrolate|
1626061|NCT02040584|Drug|Minimisation of TAC|•EVR: Treatment will be started at a total daily dose of 2 mg within 24 hours after randomisation. The dose of EVR will be adjusted upon reaching trough levels (C-0h) in whole blood of 3-8 ng/mL. The daily dose (in two administrations) of EVR may be modified to maintain trough levels (C-0h) in whole blood of 3-8 ng/mL until Week 52 post-transplant. •TAC: Once confirmation is obtained, beginning in Week 5, that trough levels (C-0h) in whole blood of EVR are between 3-8 ng/mL, minimisation of TAC will begin, in order to reach trough levels (C-0h) of TAC in whole blood of ≤5 ng/mL no later than four weeks after randomisation (Week 8), which are levels that should be maintained until Week 52 post-transplant. •MMF will be withdrawn at the same time that EVR is introduced. •oral corticosteroids will be administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids is permitted
1626062|NCT02040584|Drug|TAC + MMF + corticosteroids|•Dose of TAC: Trough levels (C-0h) of TAC in whole blood should be maintained between 6-10 ng/mL until Week 52 post-transplant. •Dose of MMF: Doses of 500-1000 mg/12 hrs will be maintained until Week 52. •Corticosteroids: During the study, oral corticosteroids will be administered in accordance with local clinical practice, although a therapeutic strategy free of corticosteroids is permitted (e.g. in patients with a history of HCV). It is recommended in any case that corticosteroids not be administered beyond Week 24 post-transplant except in cases of hepatopathy of autoimmune origin. At each centre all patients should follow the same administration protocol for corticosteroids based on history of HCV.
1626063|NCT02040571|Device|Closed Loop|A total of 24 participants with T1 Diabetes with sensor augmented insulin pump therapy (SAPT) experience will be recruited from four tertiary hospitals and will enter an un-masked randomised-control crossover trial, with a run-in period followed by two phases (in-hospital and at-home) in each of two stages (Closed Loop and Open Loop in random order). Closed Loop will be the intervention for this study, and its performance will be assessed compared to Open Loop (control treatment).
1626064|NCT02040571|Device|Open Loop|"The performance of closed loop system will be compared to open loop system (Sensor Augmented Pump Therapy). Therefore, the Open Loop system will be the control treatment.
In stage 1 of study, participants are randomized to either closed loop (CL) or open loop (OL). In stage 2, all participants will be crossed to the opposite study arm.
Throughout the study, those who randomised to OL will receive exactly the same medical attention as the CL participants."
1626065|NCT02040558|Drug|MNK-010|
1626066|NCT02040532|Drug|Gabapentin|The study is a 7-week intervention study using open-label gabapentin at bedtime with a scheduled dose titration from 100-mg for one week, followed by 300-mg for 3 weeks, and then 600-mg for 3 weeks.
1626067|NCT02040519|Behavioral|Filling out voiding diaries.|
1626068|NCT02040506|Drug|IGN523|Given intravenously every week for 8 weeks. Dosing beyond 8 weeks will be permitted for subjects meeting criteria for ongoing clinical benefit and acceptable safety.
1626069|NCT02040493|Radiation|Intra-operative radiation therapy (IORT)|All subjects will receive IORT at the time of lumpectomy.
1626070|NCT02040480|Drug|GSK2110183 Gelatin Capsule|White opaque hard gelatin capsule with a unit dose strength of 25 milligrams (mg) for oral administration
1626071|NCT02040480|Drug|GSK2110183 IR Tablet|White round biconvex film coated IR tablet with a unit dose strength of 25 mg for oral administration
1626072|NCT02040454|Drug|Paclitaxel|
1626073|NCT02040454|Procedure|Standard Therapy|
1626074|NCT02040441|Drug|Spironolactone|
1626075|NCT02040441|Drug|Placebo|
1626076|NCT02040441|Drug|Standard care|Standard diabetes care
1626077|NCT02040428|Biological|EVARREST™ Fibrin Sealant Patch|
1626078|NCT02040428|Biological|Topical hemostat|
1626079|NCT02040415|Drug|DW-1030(eperisone HCl) 75mg|
1626080|NCT02040415|Drug|Myonal Tab.(eperisone HCl) 50mg|
1626081|NCT02040415|Drug|Placebo drug of DW-1030|
1626082|NCT02040415|Drug|Placebo drug of Myonal Tab.|
1626083|NCT02040402|Biological|7-valent pneumococcal conjugated vaccine|Pneumococcal vaccine 3+1 and 2+1 schedule comparison
1626084|NCT02040402|Biological|7-valent pneumococcal conjugated vaccine|3+1 doses vs 2+1 doses
1626085|NCT02040389|Behavioral|Picture book|Arm with showing and explaining for parents about perioperative typical surgery site/wound view by study's team
1626086|NCT02040389|Behavioral|Standard preoperative education|Arm with standard, verbal explaining for a parents about perioperative site/wound view
1626087|NCT02040376|Drug|Metformin|Metformin and placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
1626088|NCT02040376|Drug|Placebo|Metformin and placebo doses will be 500 mg/m2 po daily given in 2 doses for one week and if there are no concerns increased to 1000 mg/m2 po daily given in 2 doses for the rest of the 12 week trial. The investigators will use the closest dose according to body surface area (250-500-750-1000) BID.
1626089|NCT02040363|Procedure|Muscular biopsy|
1626090|NCT02040363|Other|5-10 weeks sport training|
1626091|NCT02040350|Drug|Pralidoxime|Pralidoxime was compared to placebo to study the effects of the drug on mortatlity
1626092|NCT02040324|Device|Laryngeal mask with gastric access|
1626093|NCT02040324|Device|Endotracheal tube|
1626094|NCT02040311|Drug|Topiramate 96 mg daily|
1626095|NCT02040311|Drug|Topiramate 192 mg daily|
1626096|NCT02040311|Drug|Placebo|
1626097|NCT02040298|Drug|Clemastine|4mg tablet twice daily
1626098|NCT02040298|Drug|Placebo|Placebo tablet twice daily
1626189|NCT02039518|Drug|gemcitabine|gemcitabine 1000mg/m2，d1，d8，Q3W
1626099|NCT02040285|Drug|Bisacodyl & PEG-CS|"the day before the CTC:
low fiber diet
at 15.00: 2 tablets of bisacodyl (5 mg)
at 17.00: 1 litre of PEG-CS
liquid diet
the day of the exam:
at home: 2 tablets of bisacodyl (5 mg)
at the Hospital (3 hours after tablets intake): 90 ml of Iopamidol in 500 ml of water
at the Hospital (5 minutes after Iopamidol intake): 10 mg of Metoclopramide mono chlorohydrate monohydrate im"
1626100|NCT02040285|Drug|Iopamidol|"the day before CTC:
low fiber diet
at 15.00: 90 ml of Iopamidol in 250 ml of water
at 17.00: 90 ml of Iopamidol in 250 ml of water
at 20.00: start liquid diet"
1626101|NCT02040272|Procedure|(Extended) pleurectomy decortication|
1626102|NCT02040246|Drug|Repaglinide|Initial dose of repaglinide 0.5 mg once daily. During the dose titration period of 1 week, the dose of repaglinide could be titrated up to 1 mg three times daily, according to fasting glucose values. The minimal dose was repaglinide 0.5 mg three times daily.
1626103|NCT02040246|Drug|Metformin|Initial dose of metformin 250mg once daily. During the dose titration period of 1 week, the dose could be titrated up to metformin 500 mg three times daily, according to fasting glucose values.
1626104|NCT02040233|Drug|BAY1067197 (10 mg)|10 mg BAY1067197 for 7 d treatment once daily as oral application
1626105|NCT02040233|Drug|BAY1067197|The dose escalation to the second dose step will proceed only if the previous dose step has shown acceptable safety and tolerability 5 mg / or 10 mg / or 20 mg BAY1067197 for 7 d treatment as oral application.
1626106|NCT02040233|Drug|Placebo (10 mg)|10 mg Placebo for 7 d treatment once daily as oral application
1626107|NCT02040233|Drug|Placebo|5 mg / or 10 mg / or 20 mg Placebo for 7 d treatment once daily as oral application
1626108|NCT02040220|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|2 mg of Eylea will be treated per one injection at more than one months interval usually.
1626109|NCT02040207|Drug|AM-101|AM-101 gel for intratympanic injection
1626110|NCT02040194|Drug|AM-101|AM-101 gel for intratympanic injection
1626111|NCT02040194|Drug|Placebo|Placebo gel for intratympanic injection
1626112|NCT02040155|Device|Novel nano-scintillator fiber-optic dosimeter (nanoFOD)|This is an observational study whose purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
1626113|NCT02040142|Procedure|HIPEC|
1626114|NCT02040129|Device|Acrysof Toric IOL|Lens implantation following cataract surgery
1626115|NCT02040116|Drug|Rituximab Infusion|Participants will receive their first infusion of rituximab at the standard infusion rate provided in the manufacturer labeling. If they tolerate this infusion with a grade 2 of less infusion-related reaction, the next infusion will be administered as a 90 minute rapid infusion.
1626116|NCT02040103|Device|pneumatic compression|All IPC devices intended for DVT prophylaxis are acceptable in the study. Sequential devices (cuffs have several chambers) are preferred, but non-sequential (cuffs have single chambers) are acceptable.
1626117|NCT02040090|Drug|Active rabies vaccine (US-FDA approved)|A 1.0 ml dose of active vaccine (2.5 IU/ml), will be given on 5 occasions, on Days 0, 3, 7, 14, and 28 On day 0, the day when the HRIG is given, the first vaccine dose could be given within few minutes from the time of HRIG injection was given and never be administered into the same anatomical site as the HRIG.
1626118|NCT02040090|Biological|KamRAB|
1626119|NCT02040090|Biological|FDA approved commercially available HRIG product|
1626120|NCT02040077|Behavioral|Computer + Fluency|
1626121|NCT02040077|Behavioral|Computer Only|
1626122|NCT02040077|Behavioral|Treatment as Usual|
1626123|NCT02040064|Drug|Gefitinib|Oral tablet
1626124|NCT02040064|Drug|Tremelimumab|IV
1626125|NCT02040051|Behavioral|Sound isolation / Music therapy|"Sound isolation: we will used headphones Noise Candelling HI-FI Polk Audio UF 8000 Control Talk for sound isolation.
Music therapy: we will used relaxing Zen music. Light Reiki Touch (Album: Merlin's Magic; Composer: Andreas Mock. Published in 1995 by Inner Worl Music)"
1626126|NCT02040038|Behavioral|LIVE|3-D Virtual Environment for DSMT/S
1626127|NCT02040038|Behavioral|Website|2-D Website participation for DSMT/S
1626128|NCT02040012|Drug|AZP-531|
1626129|NCT02040012|Drug|Placebo|
1626130|NCT02039999|Other|Nebulised citric acid in serial dilutions|Citric acid will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
1626131|NCT02039999|Other|Nebulised ATP solution in serial dilutions|ATP solution will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
1626132|NCT02039999|Other|Nebulised TRPA1 agonist solution in serial dilutions|TRPA1 agonist will be delivered in serial dilutions as per the clinical trials unit standard operating procedure for cough challenge using KoKo Digidoser, based on ERS guidelines. Challenge will be repeated until C5 (5 coughs in 30 seconds following challenge) is elicited.
1626133|NCT02039973|Behavioral|Task-sharing approach to group therapy|"Participants will also identify, select and clarify common concerns/problems; provide orientation to steps in problem-solving; break down identified problems into manageable pieces; choose pieces of problem to address in facilitated discussion of problem solving for implementing solutions; support the sharing of feedback of strategies used in problem-solving and maintaining pleasurable activities.
Additionally, the intervention to aim to effect behavior by: explaining the links between problems, negative thoughts, choices made on a day-to-day basis, behaviors, and mood (symptoms of depression); facilitate sharing of practical skills to tackle problems, to change mood-related thoughts, choices and/or behaviors; offer and provide feedback on homework assignments to encourage practice of skills; and help participants attribute reported improvements to the use of new skills during feedback sessions."
1626134|NCT02039973|Behavioral|Enhanced standard of care|
1626135|NCT02039960|Drug|Bupropion|Bupropion is a weak catecholamine reuptake inhibitor predominantly affecting serotonin, norepinephrine and dopamine and is approved for depression, smoking cessation and seasonal affective disorder.
1626136|NCT02039947|Drug|Dabrafenib|Dabrafenib will be provided as 50 mg and 75 mg capsules
1626137|NCT02039947|Drug|Trametinib|Trametinib will be provided as 0.5 mg and 2.0 mg tablets
1626190|NCT02039518|Other|observation group|observation group
1626138|NCT02039934|Other|High intensity interval training|"The intervention consists of 30 minute sessions of high-intensity interval training on a bicycle ergometer three times per week.
Training program: After 5 minutes of warm-up the subject cycles for 10 intervals of 60 s. at 90 % maximum effort separated 60 s at 20% maximum effort, based on a previously performed spiroergometry, followed by 5 minutes of cool-down."
1626139|NCT02039908|Drug|Methylphenidate|Children will receive a double-blind assessment to determine their optimal starting dose of Concerta. Doses will be adjusted over the course of the school year and inceased if tolerance to the medication is detected.
1626140|NCT02039895|Radiation|HITS|Helical irradiation of the total skin by helical tomotherapy
1626141|NCT02039869|Device|Confocal endomicroscopy|The probe allows microscopic evaluation of tissue in real time during endoscopy.
1626142|NCT02039869|Drug|Proton pump inhibitor|Acid suppressing medication (over the counter)
1626143|NCT02039869|Drug|Sucralfate|Coating agent for damaged intestinal lining.
2011322|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 3 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
2011323|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X3 mg IV every 2 weeks to optimize dosing for expansion. Treatment with avelumab will continue until disease progression
1626146|NCT02039843|Other|Service Dog or Emotional Support Dog|"Emotional Support Dog. Service Dog - an assistance dog specifically trained to perform tasks that are specific to the person's disability and has public access privileges.
-Emotional Support Dog - a dog that has earned AKC Good Canine Citizen certification and provides emotional support and comfort to the Veteran."
1626147|NCT02039843|Other|Emotional Support Dog|-Emotional Support Dog - a dog that has earned AKC Good Canine Citizen certification and provides emotional support and comfort to the Veteran.
1626148|NCT02039830|Behavioral|Group physiotherapy|Multimodal Group physiotherapy 12 weeks of weekly Group physiotherapy treatments including education and pelvic floor muscle exercises
1626149|NCT02039830|Behavioral|Individual one-on-one physiotherapy|Multimodal Individual physiotherapy 12 weeks of weekly Individual physiotherapy treatments including education and pelvic floor muscle exercises
1626150|NCT02039817|Drug|IDN-6556|
1626151|NCT02039804|Drug|Corticosteroids|Intra-bursal injection
1626152|NCT02039804|Device|Hyaluronic acid|Intra-bursal injection
1626153|NCT02039791|Biological|Nimotuzumab|200mg/w,weekly, 6 weeks
1626154|NCT02039791|Drug|Carboplatin|AUC 6, d1，1 cycle/21d, 2 cycles
1626155|NCT02039791|Drug|Paclitaxel|"175 mg/m2, d1
1 cycle/21d, 2 cycles."
1626156|NCT02039778|Radiation|Stem Cell Radiotherapy (ScRT) and Temozolomide|"Stem Cell Radiotherapy (ScRT) and Temozolomide:
The postoperative surgical bed + edema + margin & the ipsilateral subventricular zone (contoured as a 5mm rim of tissue around the ipsilateral lateral ventricles) will be included within the initial target volume and treated to 46 Gy in 23 fractions. After 46 Gy, the conedown or boost volume (surgical cavity + margin) will be treated to a total of 60 Gy, with seven additional fractions of 2 Gy each (14Gy boost dose).
Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2. The drug will be administered orally on an empty stomach, the first dose to be given the night prior or morning of the first radiation fraction, and continued until the last radiation fraction is completed (including weekends and holidays)."
1626157|NCT02039765|Drug|Brimonidine tartrate|
1626158|NCT02039752|Other|Treatment|
1626159|NCT02039739|Device|Orsiro™ Drug Eluting Stent group|
1626160|NCT02039726|Drug|Quizartinib|no details to specify
1626161|NCT02039726|Drug|Salvage Chemotherapy|No details to specify.
1626162|NCT02039713|Device|DeSyne drug eluting stent group|
1626163|NCT02039700|Drug|Lesinurad 400 mg|
1626164|NCT02039700|Drug|[14C]lesinurad (100 μg per 10 mL)|
1626165|NCT02039687|Drug|ARA 290|A small peptide that activates the innate repair receptor to induce anti-inflammatory and tissue repair mechanisms.
1626166|NCT02039687|Other|Placebo|Formulation buffer
1626175|NCT02039661|Drug|Lidocaine Spray|These patients received 2 puff lidocaine spray
1626176|NCT02039661|Drug|Placebo|
1626177|NCT02039648|Other|Rumex acetosa L. extract|
1626178|NCT02039648|Other|Placebo|
1626179|NCT02039635|Dietary Supplement|Korean Red Ginseng|Given Orally
1626180|NCT02039635|Dietary Supplement|Placebo|Given Orally
1626181|NCT02039596|Other|Diet|
1626182|NCT02039583|Other|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces were by law required to be smoke-free. More detail can be found via the link provided at the end of this protocol.
1626183|NCT02039570|Other|Transvaginal scan|transvaginal scan conducted using duplex ultrasonography
1626184|NCT02039557|Genetic|NiCord|
1626185|NCT02039544|Drug|Xuebi formula|
1626186|NCT02039544|Drug|placebo|
1626187|NCT02039531|Biological|Plasma rich in growth factors|
2011324|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X mg IV every 2 weeks. Treatment with avelumab will continue until disease progression
2011325|NCT02603419|Drug|Avelumab|Anti-PD-L1 antibody at X1 mg IV every 2 weeks which can be escalated to X4 mg every 2 weeks based on safety and efficacy. Treatment with avelumab will continue until disease progression.
2011326|NCT02602860|Radiation|[11C]UCB-J|"Pharmaceutical form: Sterile solution for intravenous infusion
Concentration: 20 mCi
Route of Administration: iv"
2011327|NCT02602860|Drug|Brivaracetam|"Pharmaceutical form: Sterile solution for intravenous infusion
Concentration: 10 mg/ml
Route of Administration: iv"
1626197|NCT02039466|Procedure|volume controlled ventilation|
1626198|NCT02039466|Procedure|pressure controlled ventilation|
1626199|NCT02039453|Drug|fentanyl doses|fentanyl doses 50μg (37.5kg to 62.5kg), 75μg (62.5kg to 87.5kg), 100μg (>87.5kg), single use Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
1626200|NCT02039453|Drug|pethidine dose|pethidine dose 50mg, IV bolus (25mg if < 50kg or >70 years or significant co-morbidity), Propofol doses 1.0mg/kg IV bolus loading, 20mg, IV bolus, titration (up to MOAAS 5)
1626201|NCT02039440|Other|Blood draw|One-time blood draw
1626202|NCT02039427|Drug|Ketorolac|ketorolac 30 mg mixed with normal saline 1 ml : total volume of 2 ml
1626203|NCT02039427|Other|Dexamethasone|dexamethasone acetate10 mg : total volume of 2 ml
1626204|NCT02039427|Drug|Placebo|Normal saline 2 ml
1626205|NCT02039401|Genetic|VM202|
1626206|NCT02039388|Procedure|Lavage of the Cavum uteri and proximal Fallopian tubes, performed in the luteal phase of the female cycle|
1626207|NCT02039375|Other|"Hopkins post tPA for ischemic stroke monitoring protocol"|"The Hopkins post tPA monitoring protocol includes: vital signs and neurochecks, per standard of care for the first two hours (every 15 minutes), then on arrival to unit, in one hour, every 2 hours for 8 hours, and every 4 hours to complete 24 hours."
1626208|NCT02039362|Drug|Tenofovir DF|Tenofovir DF will be started at week 28 of pregnancy and stopped or not, according to the physician's decision, at week 12 after birth
1626209|NCT02039349|Drug|PF-05190457|
1626210|NCT02039336|Drug|Dacomitinib|
1626211|NCT02039336|Drug|PD-0325901|
1626212|NCT02039336|Drug|Docetaxel|
1626213|NCT02039323|Drug|Tenofovir|
1626214|NCT02039323|Drug|Maraviroc|
1626216|NCT02039284|Device|SES|SES group received the SES training in addition to traditional rehabilitation. Each SES session involved electrical stimulation followed by UE training in addition to home program.The novel SES programs were conducted three times per week, for 12 weeks. Each SES session involved electrical stimulation followed by UE training in addition to home program. The SES was applied to the forearm and whole hand with mesh glove for 20-30 minutes and arm with wrap for 20-30 minutes. The pulse width was set to 300 us for all stimulation levels. The frequency was set to 40-50 Hz.
1626217|NCT02039284|Device|VCT|The UE VCT programs were conducted three times per week, for 12 weeks. Each UE VCT session involved upper limb cycling training followed by UE training in addition to home program. The cycling program consisted of a warm-up exercise, twenty repetitions of hand push-up movements in the sitting position, UE cycling, and a cool-down exercise. The warm-up and cool-down exercises involved stretching and relaxing the head, neck, and the upper and lower body.
1626218|NCT02039284|Device|VRCIT|VRCIT group received the VRCIT training in addition to traditional rehabilitation, conducted three times per week, for 12 weeks. Each VRCIT session involved practice of functional tasks with the more affected UE followed by virtual-reality based eye-hand coordination tasks with the more affected UE for, in addition to home program, and restraint of the less affected UE for 3.5 to 4 hours per day. The functional training of the more affected UE focused on massive practice of functional activities using the more affected arm, with the principles of shaping and repetitive task practice applied during training.
1626219|NCT02039284|Device|traditional rehabilitation program|The absence of muscle contractions was controlled by the investigator the sham stimulation was carried out identically, but the stimulation amplitude was set to 0 milliampere(mA). Subjects were not informed about the stimulation level and were instructed to distract attention from the stimulation.
1626220|NCT02039271|Other|Music therapy|This will include 30 minutes before and after ambulation on post-op days 1 and 2. This will be contingent on when the participant had surgery the day prior and when they are ready and able to begin ambulating. Participants in the intervention group will do a VAS prior to listening to music and then afterward while those in the control group will do a VAS prior to and after each ambulation. Participants will be ambulating twice a day, in the AM and PM so the intervention will be given twice a day.
1626221|NCT02039258|Drug|CANA/MET XR FDC|Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) tablet of 150 mg/1,000 mg
1626222|NCT02039245|Drug|CANA/MET XR FDC|Each tablet contains Canagliflozin/extended release Metformin (CANA/MET XR) fixed dose combination (FDC) of 150 mg/1,000 mg, to be taken orally (by mouth)
1626223|NCT02039232|Device|Pedicle screw system|
1626224|NCT02039219|Drug|Placebo|1 tablet of placebo, taken orally daily with water, approximately 30 minutes prior to breakfast for 6 weeks.
1626225|NCT02039219|Drug|10 mg Obeticholic Acid (OCA)|10 mg Obeticholic Acid (OCA) Study medication will be administered orally, once daily, approximately 30 minutes prior to breakfast for 6 weeks.
1626226|NCT02039206|Device|Deep TMS|1Hz Stimulation
1626227|NCT02039193|Behavioral|Cognitive behavioral therapy|CBT-manual (Zinbarg et al., 2006): Traditional cognitive-behavioral therapy (CBT) for GAD typically consists of psycho education of generalized anxiety disorder, relaxation training (RT), cognitive restructuring (CR) and with some in-vivo situational exposure for patients with overt behavioral avoidance (e.g., Barlow, Rapee, & Brown, 1992; Borkovec & Costello, 1993). Furthermore, imagery exposure as a GAD-specific form of in-sensu exposition will be applied to reduce experiential avoidance based on a well-introduced CBT-manual (Zinbarg et al., 2006). The manualized therapy follows an usual treatment format of 14 sessions to 50 minutes and a booster session after 6-months.
1626228|NCT02039180|Drug|AZD3293 oral solution|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and solution as a single dose on Day 1, Day 8 or Day 15.
1626229|NCT02039180|Drug|AZD3293 tablet formulation A|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8, or Day 15.
1626230|NCT02039180|Drug|AZD3293 tablet formulation B|Subjects will receive AZD3293 as a tablet (Formulation A; Formulation B) and a solution as a single dose on Day 1, Day 8 or Day 15.
1626231|NCT02039167|Device|Left atrial appendage occlusion|Percutaneous left atrial appendage closure using the WATCHMAN device.
1626269|NCT02038881|Biological|IMVAMUNE®|0.5 ml Modified Vaccinia Ankara Strain - Bavarian Nordic (MVA-BN®) smallpox vaccine containing at least 1 x 10E8 TCID50 per ml
1626270|NCT02038868|Drug|ASP4901|oral
1626271|NCT02038868|Drug|Tamsulosin|oral
1626272|NCT02038868|Drug|Placebo|oral
1626232|NCT02039154|Behavioral|Aerobic and strength training group|A exercise training program will be developed individually for each subject with the goal of increasing duration and intensity consistent with modern training techniques. Workouts will vary with respect to mode (walk, cycle, swim), duration (30-60 minutes), and intensity (base, interval, recovery) to optimize the training response. Each subject will be assigned a personal trainer and a heart rate monitor so that every session is carefully tracked and recorded. For intervals, we will use the novel high intensity aerobic intervals (HAIT). Subjects will also perform strength training 1-2 days/week.
1626233|NCT02039154|Behavioral|Balance and flexibility group|For the balance and flexibility group, subjects will be encouraged to participate in yoga/tai chi/pilates classes that is approved by one of the exercise physiologists on the research team. The goal for this group is exercise classes that will be of benefit to them, but that will not include sustained aerobic, endurance exercise. In place of a group exercise class, subjects will have the option of purchasing videos for home use. The subjects will be encouraged to participate in some form of non-endurance training at least 3 days per week. Each subject will receive an exercise log in which they will be expected to record their training.
1626234|NCT02039141|Other|Every Little Step Counts Intervention|"Youth participants randomized to participate in the experimental group will attend weekly healthy lifestyles education session with their parent(s)/guardian(s) and will also attend exercise sessions 3 times a week for 12 weeks. The education sessions will cover topics such as healthy eating choices, roles and responsibilities of both parents and youth in the realm of the family unit as well as in youth's own health, and self esteem among other topics. The exercise sessions will incorporate both aerobic and resistance training as well as other free-play physical activities i.e. basketball, volleyball etc."
1626235|NCT02039128|Dietary Supplement|Krill oil or Fish oil|
1626236|NCT02039128|Dietary Supplement|Placebo|
1626237|NCT02039115|Drug|prednisone|6 weeks of prednisone and placebo therapy will be given over 6 weeks after both the first and second stage complete Barretts Excision.
1626238|NCT02039115|Drug|placebo|6 weeks of placebo therapy will be given in the same manner as the prednisone arm after the first and second stage complete Barretts excision.
1626239|NCT02039089|Drug|E2006 2.5 mg|
1626240|NCT02039089|Drug|E2006 10 mg|
1626241|NCT02039089|Drug|E2006 25 mg|
1626242|NCT02039089|Drug|Placebo|
1626243|NCT02039076|Drug|avatrombopag|
1626244|NCT02039063|Drug|E6011 2 mg/kg|
1626245|NCT02039063|Drug|E6011 5 mg/kg|
1626246|NCT02039063|Drug|E6011 10 mg/kg|
1626247|NCT02039063|Drug|E6011 15 mg/kg|
1626248|NCT02039050|Drug|Tiotropium|
1626249|NCT02039050|Drug|Aclidinium|
1626250|NCT02039037|Device|Acupuncture|Acupuncture Group, which will hold acupuncture needles brand Dong Bang 20x15 in specific spots for the treatment of low back pain.
1626251|NCT02039037|Device|Electroacupuncture (device 585)|Electro will be added through the use of electrical stimulation to the Electro Accurate use of the device 585 at the same points Pulse.
1626252|NCT02039024|Drug|18F- DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) 18F- DTBZ immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.
During this study, subjects will receive a single i.v. administration of approximately 370MBq (10 mCi) florbetapir F-18 immediately prior to imaging. The dosage of DTBZ is 10 nmole. The effective dose in human body is about 5.6 mSV.
The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG (Lin 2010)."
1626253|NCT02039011|Drug|Indacaterol|Participants receive indacaterol for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
1626254|NCT02039011|Drug|Indacaterol and tiotropium|Participants receive indacaterol and tiotropium for 2 to 4 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
1626255|NCT02038998|Device|Exer-Rest® TL|Exer-Rest® TL is a therapeutic motorized platform that allows the application of pGz forces to a patient. The typical application would provide an acceleration of 0.4 Gz.
1626256|NCT02038985|Other|Participants will receive ICG Dye|Participants will receive ICG Dye preoperatively for use in the Visual Diagnosis of Endometriosis
1626257|NCT02038972|Genetic|Autologous Stem Cells|The subjects autologous stem cells banked at Cord Blood Registry will be infused intravenously by gravity.
1626258|NCT02038959|Other|Virtual Visits|Virtual visits will be completed using HIPAA-compliant video conferencing software from SBR Health and Vidyo, designed specifically for use in the healthcare industry. The software is available for Windows and Mac OS, as well as iOS devices (iPad and iPhone).
1626259|NCT02038946|Drug|Nivolumab|
1626260|NCT02038933|Drug|Nivolumab|
1626263|NCT02038907|Biological|Hepatitis A Vaccine|Hepatitis A Vaccine IM injection
1626264|NCT02038907|Biological|Norovirus Bivalent VLP Vaccine|Norovirus GI.1/GII.4 bivalent VLP vaccine IM injection
1626265|NCT02038894|Drug|Intubated with Sevoflurane (IS)|Anesthesia will be maintained with sevoflurane 3% in oxygen at 2 L/min. The endoscopist will begin the procedure. The sevoflurane inspired concentration will be adjusted between 1 to 2 times the minimum alveolar concentration (MAC) by the attending anesthesiologist to maintain an appropriate level of anesthesia.
1626266|NCT02038894|Drug|Intubated with Propofol (IP)|Anesthetic maintenance will be with 2 L/min flow of oxygen through the endotracheal tube and a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg and an increase in the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist if necessary to provide adequate anesthesia.
1626267|NCT02038894|Drug|Zofran - no intubation|A nasal cannula will be placed with oxygen administered at a rate of 3 L/min, and a bite block will be inserted. Zofran will be administered. Anesthesia will be maintained with a continuous propofol infusion at a rate of 250 mcg/kg/min. A maximum of two bolus doses of propofol 0.5 to 1 mg/kg, and an increase of the continuous infusion to 300 mcg/kg/min may be given at the discretion of the anesthetist.
1626268|NCT02038894|Drug|Propofol|
1626273|NCT02038855|Behavioral|Integrated Intervention for Dual Problems and Early Action|Integrated Intervention for Dual Problems and Early Action (IIDEA) includes psycho-education, Cognitive Behavioral Therapy and mindfulness; identifies triggers and challenging thoughts; provides motivational techniques for reducing substance use and/or smoking cravings; incorporates cognitive restructuring to identify and correct negative thinking patterns influenced by depression, anxiety and/or trauma; and includes self-monitoring of thoughts and risk behaviors that contribute to substance use, smoking and increased HIV risk.
1626274|NCT02038842|Biological|LIPO-5|LIPO-5: 1mL IntraMuscular, 2 shots;
1626275|NCT02038842|Biological|MVA HIV-B (MVATG17401)|MVA HIV-B (MVATG17401): 0.5mL IntraMuscular, 2 shots;
1626276|NCT02038842|Biological|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots|GTU®-MultiHIV B: 0.5 mL IM via Biojector® 2000 and 0.5mL IntraDermic, 3 shots
1626277|NCT02038829|Drug|Placebo|Placebo
1626278|NCT02038829|Drug|SUN101 3 mcg|SUN-101 3 mcg bid
1626279|NCT02038829|Drug|SUN-101 6.25 mcg|SUN-101 6.25 mcg bid
1626280|NCT02038829|Drug|SUN-101 12.5 mcg|SUN-101 12.5 mcg bid
1626281|NCT02038829|Drug|SUN-101 50 mcg|SUN-101 50 mcg bid
1626282|NCT02038829|Drug|Aclidinium|Aclidinium 400 mcg bid
1626283|NCT02038816|Drug|Deferasirox + Azacitidine|"Deferasirox:
20 mg/kg/d for < 14ml/kg/mo pRBCs (~ <4U/mo), 30mg/kg/d for ≥14ml/kg/mo pRBCs(≥4U/mo), 10mg/kg/d for transfusion-independent patients"
1626284|NCT02038816|Drug|Azacitidine|Azacitidine 75mg/m2 sc daily X 7 days (5-2-2 schedule permitted) on a 28 day cycle for 6 cycles
1626285|NCT02038790|Drug|Suboxone Sublingual Film|A single Suboxone sublingual film strip containing 8mg buprenorphine and 2mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
1626286|NCT02038790|Drug|Zubsolv sublingual tablets|A single Zubsolv sublingual tablet containing 5.7mg buprenorphine and 1.4mg naloxone taken sublingually on either Day 0 or Day 1, depending on randomized treatment arm assignment. Study drug will be administered by designated qualified study personnel at the site in the morning prior to 9:00 a.m. under fasting conditions.
2011328|NCT02602860|Drug|Levetiracetam|"Pharmaceutical form: Sterile solution for intravenous infusion
Concentration: 100 mg/ml
Route of Administration: iv"
2011329|NCT02602860|Drug|Brivaracetam|"Pharmaceutical form: Tablets for oral intake
Concentration: 25 mg
Route of Administration: oral"
2011330|NCT02602171|Other|Oldenburger sentence test, localization test|
2011331|NCT02601209|Drug|Pazopanib Hydrochloride|Given PO
2011332|NCT02601209|Drug|Sapanisertib|Given PO
1626300|NCT02038738|Drug|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography.|
1626301|NCT02038712|Dietary Supplement|Fed Condition|Subjects will consume a 600mL 600kcal liquid test meal
1626302|NCT02038712|Dietary Supplement|Fasted condition|Subjects will consume 600mL plain water.
1626303|NCT02038712|Procedure|Blood samples|Blood samples will be collected at -15, 0, 10, 30, 60, 90, 120 min
1626304|NCT02038712|Behavioral|Subjective appetite ratings|Appetite ratings will be collected at -15, 0, 10, 30, 60, 90, 120 min.
1626305|NCT02038712|Procedure|fMRI scan|Blood Oxygen Dependent (BOLD) signal response to pictures and words of food and non-food items will be measured using functional magnetic resonance imaging (fMRI).
1626306|NCT02038699|Drug|ONC201|ONC201 capsules will be administered orally once every three weeks with flat dosing. Dosage will be given according to a modified Fibonacci sequence with the anticipated starting dose being 125 mg.
1626307|NCT02038686|Device|PFN-A|
1626308|NCT02038673|Drug|ASP5878|oral
1626309|NCT02038660|Device|Balloon angioplasty|
1626310|NCT02038647|Drug|Alisertib|Alisertib tablets
1626311|NCT02038647|Drug|Placebo|Placebo matching tablets
1626312|NCT02038647|Drug|Paclitaxel|Paclitaxel tablets
1626313|NCT02038634|Drug|Betamethasone|
1626314|NCT02038634|Device|Ultrasound|Ultrasound guided injection using GE Healthcare LOGIQ e Ultrasound
1626315|NCT02038621|Drug|Paclitaxel|
1626316|NCT02038621|Drug|Oxaliplatin and Capecitabine|Before randomization,all enrolled patients underwent 3 cycles XELOX chemotheray. After patients' disease achieved CR\PR\SD,then randomized into this clinical trial.
1626317|NCT02038608|Device|PET|
1626318|NCT02038595|Radiation|PET imaging|
1626319|NCT02038582|Other|POC CD4 Testing|Point of Care CD4 testing
1626320|NCT02038582|Other|CD4 Referral|Referral to CD4 testing
1626321|NCT02038582|Behavioral|Lay Counselor Follow-up|Follow-up from a lay counselor
1626322|NCT02038582|Behavioral|Clinic Accompaniment|Accompaniment to the clinic by a counselor
1626323|NCT02038582|Behavioral|Clinic Referral|Referral to clinic
1626324|NCT02038582|Behavioral|SMS Reminder|SMS reminder for male circumcision
1626325|NCT02038582|Behavioral|Circumcision Promotion|Promotion of male circumcision at the time of HIV testing
1626326|NCT02038582|Other|POC VL|POC VL testing for HIV infected persons on ART
1626327|NCT02038582|Other|Laboratory based VL assay|Laboratory based viral load testing for HIV infected persons on ART
1626328|NCT02038569|Drug|LEO 80185|
1626329|NCT02038556|Behavioral|cognitive behaviorial therapy -Insomnia|
1626372|NCT02038153|Other|Laboratory Biomarker Analysis|Correlative studies
1626373|NCT02038140|Device|Zimmer Trabecular Metal Total Ankle System|Primary or revision total ankle replacement
1626467|NCT02037477|Drug|Rabeprazole sodium|Rabeprazole sodium tablets
2011333|NCT02600949|Biological|Peptide Vaccine|"Vaccine given in a total volume of up to 1.0ml/shot consisting of a peptide cocktail injected subcutaneously into two to three separate sites of the subject's thighs for a total of up to 1.0ml per vaccination per cocktail. If subject is prescribed two cocktails then up to four to six sites on the subject's thighs may be used, provided that each vaccine cocktail is administered into different thighs. The total amount of peptide delivered will vary (range from approximately 200µg to 2.0mg) depending on how many peptides are identified and prescribed (range 1-5 per peptide cocktail, 2 total cocktails possible, maximum of 10 peptides).
Vaccinations given on Day 1 of Weeks 0, 1, 3, 4, 6 and then every 3 weeks until Week 30, then at Weeks 39 and 51."
1626330|NCT02038543|Drug|Hydroxyproline and Leucine|Subjects will be infused with 13C5-hydroxyproline and 2H3-leucine for 6 hrs in the CRTU. The metabolic flux of 2H3-leucine has been well characterized, and is used as a control when studying the metabolism of trace infusions of labeled amino acids 3. Blood samples will be obtained every 30 min to determine the enrichment of plasma with 13C5-hydroxyproline and 2H3-leucine. Urine collections will be obtained hourly. The fluxes of whole body hydroxyproline and leucine will be calculated
1626331|NCT02038491|Procedure|regional anesthesia|Spinal, epidural, combined spinal epidural, nerve blocks
1626332|NCT02038478|Biological|Donor Stem Cell Transplantation|One day after they complete their radiation and Campath-1H treatments and have begun their Sirolimus, the donor blood stem cells described above are transfused through the central line. This process takes approximately 30 minutes to 2 hours and is normally completely without side effects.
1626333|NCT02038465|Device|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for patient
1626334|NCT02038465|Device|Questionary|Test the effectiveness of two techniques of cognitive remediation of autobiographical memory using an innovative tool called SenseCam ® for healthy volunteers
1626335|NCT02038452|Drug|Depo-Medrone|Steroid Injection
1626336|NCT02038452|Device|Wrist Splint|Simple wrist splint
1626337|NCT02038439|Behavioral|Intervention A - Online Clinical Questions Recorder|Clinicians allocated to this intervention will receive access to an online recorder for the clinical questions at the point of care. The recorder is accessible across a wide range of devices including phones, tablets, and desktop computers.
1626338|NCT02038439|Behavioral|Intervention B - Online Evidence Retrieval Coach|Clinicians allocated to this intervention will receive online guidance, embedded in the MPFS search engine, in the form of short videos, animations, demos and tips and tricks regarding evidence retrieval.
1626339|NCT02038439|Behavioral|Intervention C - Online Audit and Feedback|Clinicians allocated to this intervention will receive feedback on their current search performance compared to their peers, both online when using MPFS as well as by e-mail.
1626340|NCT02038426|Biological|BLOOD SAMPLES|
1626341|NCT02038426|Device|Radiographs of the sacroiliac joints|
1626342|NCT02038426|Device|Radiographs of heels|
1626343|NCT02038426|Device|SCAN|
1626344|NCT02038400|Device|KINETUBE medical Device|
1626345|NCT02038400|Device|insertion of tympanic ventilation tubes (tympanostomy)|
1626346|NCT02038387|Behavioral|normocaloric low cholesterol diet|
1626347|NCT02038374|Procedure|biopsies|
1626348|NCT02038361|Genetic|blood draw|
1626349|NCT02038348|Device|PET with 18F-FDOPA|
1626350|NCT02038335|Drug|DMPA|Depot medroxyprogesterone acetate
1626351|NCT02038335|Drug|NET-EN|Norethisterone enantate
1626352|NCT02038335|Drug|MPA/E2|Medroxyprogesterone acetate and estradiol cypionate
1626353|NCT02038335|Device|LNG-I|Levonorgestrel subdermal implant
1626354|NCT02038335|Device|ENG-I|Etonogestrel subdermal implant
1626355|NCT02038335|Device|Cu-IUD|Copper IUD
1626357|NCT02038296|Procedure|transarterial chemoembolization|
1626358|NCT02038257|Procedure|MKTP (melanocyte keratinocyte transplant procedure)|Each subject will have the melanocyte keratinocyte transplant procedure on 4 distinct areas using the two different techniques being studied (carbon dioxide laser and dermabrasion) and the two different dressings being studied (vaseline impregnated gauze and collagen dressing).
1626359|NCT02038257|Device|Collagen Dressing|Each subject will have MKTP on 4 distinct areas. Two of these areas will be dressed with a collagen dressing.
1626360|NCT02038257|Device|Vaseline Impregnated Gauze|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be dressed with vaseline impregnated gauze.
1626361|NCT02038257|Device|Carbon Dioxide Laser|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using a carbon dioxide laser.
1626362|NCT02038257|Device|Dermabrasion|Each subject will have MKTP on 4 distinct areas of depigmented skin. Two of these areas will be de-epithelialized using dermabrasion.
1626363|NCT02038244|Other|Multimodal integrative medicine inpatient treatment program|
1626364|NCT02038231|Behavioral|Parenting Mindfully Program|see Arm Description.
1626365|NCT02038231|Other|Parent Education Program|See Arm Description.
1626366|NCT02038218|Drug|4-Demethyl-4-cholestryloxycarbonylpenclomedine|"This will be an open-label, uncontrolled two-arm, multi-center study in patients with CNS involvement from melanoma, breast, lung cancers or primary malignancies of the CNS. Patients can be previously treated with radiation and systemic therapies and are eligible if they also have other sites of cancer involvement.
Two Cohorts of patients will be treated every 21 days with a single infusion of DM-CHOC-PEN as an out-patient:
Cohort 1: Patients with liver involvement or history of disease will be treated at a dose of 85.8 mg/m2 and;
Cohort 2: Patients without liver involvement or history of liver disease, will be treated at a dose of 98.7 mg/m2.
Patients in both cohorts will discontinue dosing with DM-CHOC-PEN when there are any unacceptable toxicities, progression of cancer or patient compliance."
1626367|NCT02038192|Behavioral|Living with Hope Program|"The Living with Hope Program is based on the research team's grounded theory study Hope and Connection. The film  Connecting with Hope reflects the findings of the grounded theory study. Stories of the Present has been utilized in the team's previous research with family caregivers of persons with advanced cancer."
1626368|NCT02038192|Behavioral|Stories of the Present|Stories of the Present is a directed journaling activity in which participants write in a journal at the end of the day their challenges, hope and hope for tomorrow
1626369|NCT02038179|Drug|Allopurinol|The subjects will be randomized to receive allopurinol as ULT, at a daily dose of 300 mg once daily by mouth or placebo. Participants will be asked to take 4 weeks of allopurinol or placebo, then will crossover to the other drug (after 4 week washout period) and take either allopurinol or placebo for an additional 4 weeks.
1626370|NCT02038179|Drug|Placebo|The subjects will be randomized to receive allopurinol as ULT, at a daily dose of 300 mg once daily by mouth or placebo. Participants will be asked to take 4 weeks of allopurinol or placebo, then will crossover to the other drug (after 4 week washout period) and take either allopurinol or placebo for an additional 4 weeks.
1626371|NCT02038153|Drug|Lenalidomide|Given PO
1626374|NCT02038114|Behavioral|Instructed to read patient education pamphlets|The intervention in this study is the administration of patient education pamphlets and instructions to read them. Half of all patients who participate in this study will be required to read pamphlets on symptoms that are relevant to them (i.e. symptoms that they are experiencing). Subsequent to reading pamphlets, patients will complete study questionnaires to assess their impact.
1626375|NCT02038101|Behavioral|Education and Feedback|"Formal Rounds on AUC for TTE
Appropriate Use for TTE Application for Smartphone
Individualized Feedback Reports provided by email"
1626376|NCT02038075|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|
1626377|NCT02038075|Behavioral|Treatment As Usual (TAU)|
1626378|NCT02038062|Procedure|Sevoflurane preconditioning|Preconditioning by transient application of sevoflurane
1626379|NCT02038049|Drug|VAY736|
1626380|NCT02038049|Drug|Placebo|Placebo to VAY736
1626381|NCT02038036|Drug|Best Available Therapy|Best Available Therapy as selected by the investigator from the below: 1. Hydroxyurea 2. IFN/PEG-IFN 3. Pipobroman 4. Anagrelide 5. IMIDs 6. Observation only
1626382|NCT02038036|Drug|ruxolitinib|Supplied as tablets. Starting dose of 10 mg bid. Based on efficacy and safety parameters, dose may be increased or decreased. Maximum dose allowed is 25mg bid.
1626383|NCT02038023|Drug|Intravaneous iron(low molecular weight iron dextran)|1000 mg of Iron dextran administered over one hour
1626384|NCT02038010|Drug|PI3K inhibitor BYL719|Given PO
1626385|NCT02038010|Biological|ado-trastuzumab emtansine|Given IV
1626386|NCT02038010|Other|pharmacological study|Correlative studies
1626387|NCT02038010|Other|laboratory biomarker analysis|Optional correlative studies
1626388|NCT02037997|Drug|docetaxel|docetaxel 75mg/m2 ivgtt D1
1626389|NCT02037997|Drug|pemetrexed|pemetrexed 500mg/m2 ivgtt D1
1626390|NCT02037997|Drug|Erlotinib|Erlotinib 150mg qd
1626391|NCT02037984|Biological|V114|A 0.5-mL intramuscular dose
1626392|NCT02037984|Biological|Prevnar 13|A 0.5-mL intramuscular dose
1626393|NCT02037971|Procedure|Aerobic Exercise|From 1st week up to and including 4th week, subjects will do: 5 minutes warm-up, then 15-30 minutes low to moderate (55-65% VO2) exercise, then 15 minutes stretching. From 5th week up to and including 16th week, subjects will do: 5 minutes warm-up, then intermittent training for between 30-40 minutes, then 10 minutes stretching.
1626394|NCT02037971|Other|Control Group|The control group will have monthly meetings to learn about: good sleep habits, Systemic Lupus Erythematosus (their disease) and general good health.
1626395|NCT02037958|Device|Laryngeal Mask Airway-Supreme|Patients who receive the LMA-S
1626396|NCT02037958|Device|Endotracheal Tube|Patients who receive endotracheal intubation
1626397|NCT02037945|Procedure|18F-FCH PET Scan|
1626398|NCT02037932|Device|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.|Balloon Assisted Coiling using MicroVention second-generation hydrogel coils and MicroVention Scepter Occlusion Balloon Catheter.
1626399|NCT02037919|Other|Immediate Nexplanon Insertion|Patient will have a Nexplanon inserted within 15 minutes of her abortion
1626400|NCT02037919|Other|Post-op Nexplanon Insertion|Place Nexplanon at post operative visit rather than at surgery
1626401|NCT02037906|Radiation|Escalating Energy SWL|Dose escalation, 1500 SW at 18 kv, followed by 1500 SW at 20 kv and the following 1500 SW at 22 kv.
1626402|NCT02037906|Radiation|Constant Energy SWL|Constant dose at 20 kv
1626403|NCT02037906|Radiation|Reduction Energy SWL|Dose reduction, 1500 SW at 22 kv, followed by 1500 SW at 20 kv and the following at 18 kv.
1626404|NCT02037893|Drug|Antipyrine and Benzocaine otic solution|
1626405|NCT02037893|Drug|Antipyrine Otic Solution|
1626406|NCT02037893|Drug|Benzocaine Otic Solution|
1626407|NCT02037893|Drug|Placebo Otic solution|
1626408|NCT02037880|Procedure|Lumbar puncture|
1626409|NCT02037880|Device|Magnetic Resonance Imaging (MRI) of the brain|
1626410|NCT02037867|Device|Fibrosis Biomarkers|Liver disease stratification with liver stiffness scan (Transient Elastography) Analysis of diagnostic performance of serum fibrosis markers (as listed above) Whole blood samples obtained for DNA analysis
1626411|NCT02037854|Other|Nutrient formulation|
1626412|NCT02037841|Other|Nursing-driven clinical pathway for management of inpatient asthma|
1626413|NCT02037815|Drug|20% mannitol solution, 125 ml, IV infusion in 15 min|
1626414|NCT02037815|Drug|3.1% sodium chloride solution, 125 ml, IV infusion in 15 min|
1626415|NCT02037802|Device|B-Braun, Perifix® ONE Paed, Germany|caudal epidural catheterization bupivacaine fentanyl
1626416|NCT02037802|Drug|Pethidine|pethidine intravenous at a dose 1mg/kg when pain score more than 5 postoperative rescue analgesia
1626417|NCT02037802|Drug|Propofol|fentanyl propofol atracurium besylate
1626418|NCT02037802|Drug|Bupivacaine|
1626419|NCT02037802|Drug|Fentanyl|
1626420|NCT02037776|Drug|Rikkunshito|- Oral administration of rikkunshito (2.5 g t.i.d) before meals for 8 weeks
1626421|NCT02037776|Drug|Rikkunshito placebo|- Oral administration of rikkunshito placebo (2.5 g t.i.d) before meals for 8 weeks
1626422|NCT02037750|Behavioral|LINKS|"In the LINKS, foster/kin parents will participate in weekly group meetings led by well-trained and supervised paraprofessional facilitators (school behavioral aids and foster parents) where the curriculum is based on parent management training (PMT). In previous studies, attendance at such groups has been high, averaging about 75-80%. Missed sessions will be made up with an in-person visit to the foster/kin home during the week of the original session. In addition, youth in the intervention condition will receive individual skill building sessions from a Life Skills Coach to increase their competency at goal setting, refusal skills, and peer relations."
1626424|NCT02037724|Dietary Supplement|supplement containing 60 mg iron sulfate|control agent
1626425|NCT02037724|Dietary Supplement|iron rich food supplement (60 mg iron)|contains 60 mg of iron
1626426|NCT02037724|Dietary Supplement|iron rich food supplement (10 mg iron)|contains 10 mg iron
1626427|NCT02037724|Dietary Supplement|supplement containing 10 mg iron sulfate|control agent
1626466|NCT02037477|Drug|Esomeprazole|Esomeprazole capsules
1647715|NCT01873053|Drug|Placebo|
1626428|NCT02037711|Drug|Levobupivacaine 0.5%|Group I (Chirocaine group) (n=20): Levobupivacaine 0.5% will be instilled during insufflations of CO2 at the beginning of surgery at a dose of 2mg/kg.
1626429|NCT02037711|Drug|Normal saline|Group II (control group) (n=20): laparoscopy done with instillation of normal saline instead of levobupivacain
1626430|NCT02037698|Device|Pre-PCI coronary CT scan|Coronary CT scan before CTO PCI
1626431|NCT02037685|Behavioral|Motivational Interviewing (MINT)|"MINT has the following basic structure and goals:
Establishing a connection and reinforcing autonomy: open ended questions regarding the health status or well being of the participant to establish an empathetic connection with the subject via reflective listening.
Empathizing with ambivalence and rolling with resistance. The counselor will help the subject express the ambivalence they may have regarding taking their statins.
Coach the subject towards expressions of commitment. Commitment is predictive of change. Speaking commitment out loud to an other enhances the likelihood that the commitment will be acted upon"
1626432|NCT02037685|Other|Usual Care|We selected American Heart Association brochures on a variety of risk factors, including dyslipidemia and mailed them to subjects in the usual care.
1626433|NCT02037672|Drug|metformin|
1626434|NCT02037672|Drug|metformin and roflumilast|
1626435|NCT02037659|Procedure|DermaBond treatment of Gastric Varices|Endoscopic Ultrasound (EUS) administration of DermaBond glue to control bleeding gastric varices.
2011334|NCT02600949|Behavioral|Phone Call|Participant called 2 times by study staff in the 6 months after last dose of vaccine and asked about any side effects experienced since the end-of-study visit. Each call should take about 10 minutes.
2011335|NCT02600949|Drug|Pembrolizumab|Pembrolizumab administered as a fixed dose of 200 mg infusion every three weeks over approximately 30 minutes until week 51.
2011336|NCT02598583|Biological|Study Drug - ALXN1210|"Cohort 1: Intrapatient dose escalation to therapeutic dose level.
At Day 477, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen, as follows:
≥ 40 to <60 kg: 3000 mg every 8 weeks
≥ 60 to <100 kg: 3300 mg every 8 weeks
≥100 kg: 3600 mg every 8 weeks"
2011337|NCT02598583|Biological|Study Drug - ALXN1210|"Cohort 2: Intrapatient dose escalation to therapeutic dose level.
At Day 477, the dose and dosing interval for all patients will change to an every 8 week, weight-based regimen, as follows:
≥ 40 to <60 kg: 3000 mg every 8 weeks
≥ 60 to <100 kg: 3300 mg every 8 weeks
≥100 kg: 3600 mg every 8 weeks"
2011338|NCT02598960|Drug|BMS-986156|
2011339|NCT02598960|Drug|Nivolumab|
1626442|NCT02037633|Drug|Fentanyl|Fentanyl IV
1626443|NCT02037633|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block using ropivacaine
1626444|NCT02037633|Drug|ropivacaine|
1626445|NCT02037620|Device|5-6-5 Specify electrode|
1626446|NCT02037620|Device|Restore Advance Pulse Generator|
1626447|NCT02037594|Behavioral|Sexual Health Counseling|This brief intervention presents PrEP within the context of a patient's comprehensive sexual health plan and is designed to enhance decision-making around PrEP use and decrease sexual risk taking.
1626448|NCT02037594|Behavioral|Enhanced Adherence Intervention|This brief intervention is provides standard of care PrEP adherence information plus specific counseling, troubleshooting, and support.
1626449|NCT02037594|Behavioral|PrEP Information (Active Control)|Standard of Care Information about PrEP
1626450|NCT02037594|Behavioral|Standard of Care Adherence Support (Active Control)|Standard of care information and instruction about PrEP adherence.
1626451|NCT02037581|Behavioral|Early detection and Integrated Care|Patients receive integrated care including therapeutic Assertive Community Treatment (TACT)
1626452|NCT02037581|Behavioral|Standard Care|Standard care as being offered by private psychiatrists
2011340|NCT02597933|Drug|Nintedanib|
1626454|NCT02037555|Biological|AT-III (Human)|AT-III (Human) is an antithrombin concentrate prepared from pooled human plasma. AT-III (Human) is provided as a freeze-dried preparation for intravenous use. The AT-III (Human) preparation is reconstituted in 10 or 20 mL of sterile water for injection prior to intravenous administration.
1626455|NCT02037555|Other|Placebo|0.9% Sodium Chloride for Injection, United States Pharmacopeia
1626456|NCT02037542|Behavioral|Diet and exercise|Upon enrollment, the patient will be asked to meet with a dietitian to assess the individual patient's current diet and exercise routines. In the first session, the dietitian will provide individual counseling and together with the patient devise weight loss / exercise strategies that fit the patients' lifestyle. Following the initial assessment, patients will embark on a weekly program, with weekly meetings lasting 30min - 1h. Patients will be asked to record meal portions weekly in a Food Log (Appendix B), according to the established goal. At each meeting, the dietitian will review the Food Log with the patient and evaluate progress.
1626457|NCT02037529|Drug|Eribulin|
1626458|NCT02037529|Drug|Paclitaxel|
1626459|NCT02037516|Device|Accelomyography|quantitative measurement of the train-of-four with the TOF Watch to determine timing of administration of neostigmine and extubation To assure patient flow the time to reversal administration will be limited to approximately 30 minutes after achieving 4 twitches in qualitative monitoring
1626460|NCT02037516|Drug|Neostigmine|Neostigmine is used to reverse the effects of neuromuscular blocking agents
1626461|NCT02037516|Device|Qualitative Monitor|Qualitative (tactile or visual) assessment of residual neuromuscular paralysis
1626462|NCT02037503|Drug|Ketamine|
1626463|NCT02037503|Drug|Saline|
1626464|NCT02037490|Behavioral|Grow2Gether|"Participants in this intervention will:
Participate in Facebook group of 6-12 peers for about 8 months, led by a professional group mentor.
Complete an intervention video activity approximately weekly:
View educational videos addressing topics related to healthy infant growth
Create photos/videos modeling healthy behaviors and post them to the group
Provide and receive feedback on posts
Be encouraged to share information with key caregivers of their child
Attend group party soon after enrollment, to meet peers and group leader in person."
1626465|NCT02037477|Drug|Vonoprazan|Vonoprazan tablets
1649313|NCT01860729|Drug|Placebo|
2011341|NCT02597933|Drug|Placebo|
2011342|NCT02596438|Other|Hepatitis B|Hepatitis B Surface Antigen, Hepatitis B Surface Antibody and Hepatitis B Core AB, Total Testing
2011343|NCT02595944|Other|Laboratory Biomarker Analysis|Correlative studies
2011344|NCT02595944|Biological|Nivolumab|Given IV
2011345|NCT02595905|Drug|Cisplatin|Given IV
1626468|NCT02037464|Dietary Supplement|Capsaicin Supplement (Cayenne by Nature's Way)|One capsule of the supplement to be taken twice daily.
1626469|NCT02037451|Procedure|rhythmic auditory stimulation|Participants perform the finger tapping at the same time give rhythmic auditory stimulation ,and need to execute tapping with auditory stimulation.
2011346|NCT02595905|Other|Laboratory Biomarker Analysis|Correlative studies
2011347|NCT02595905|Other|Placebo|Given PO
1626472|NCT02037425|Drug|onabotulinumtoxinA|BOTOX® (Formulation Number 9060X) contains 200 International Units (IU) of Clostridium botulinum Toxin Type A, reconstituted with 4 cc of normal saline providing 5 units per 0.1 cc. At visit 2, subjects will receive their first treatment at Day 29 (+/-3 days). All subjects will receive 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas. Injections will be repeated at day 113 (+/- 3 days) and at day 197 (+/- 3 days).
1626473|NCT02037412|Drug|Ticagrelor|Ticagrelor - 180 mg loading and 90 mg bid maintenance for 3 months
1626474|NCT02037412|Drug|Clopidogrel|Clopidogrel - 600 mg loading and 75 mg qd maintenance for 3 months
1626475|NCT02037399|Drug|intravenous dexamethasone|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous dexamethasone (0.15 mg/kg) immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including dexamethasone was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.
At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
1626476|NCT02037399|Drug|intravenous normal saline|"Patients were enrolled in outpatient settings after evaluating appropriate ESD indications. A single study coordinator performed a randomization process by using a table of random numbers. The patients were allocated to receive intravenous normal saline as placebo immediately after ESD. The patients with an odd number were assigned into DEXA group, and the patients with an even number were assigned into placebo group. The syringe including placebo was completely covered with a paper sticker to mask treatment assignment. The operator and assisting nurse were also blinded to the study.
At the day and next day of ESD, intravenous proton pump inhibitor was routinely administered to prevent complications including bleeding. At 3rd day of ESD, all patients started to take 40mg oral lansoprazole once a day and sucralfate suspension 3 times a day for 28 days."
1626477|NCT02037386|Device|H-side branch stent|Implantation of H-side branch stent at coronary bifurcation stenotic lesion
1626478|NCT02037373|Biological|Octaplas™|Octaplas™ infusion solution for IV administration as prescribed by the treating physician.
1626479|NCT02037373|Biological|Plasma|Plasma as prescribed by the treating physician.
1626480|NCT02037360|Behavioral|Active Comparator App/Training|This is a free smoking cessation smartphone app using the latest evidence-based smoking cessation methods and behavior change theory. The app allows users to set a quit date, financial goals, and reminders, track daily smoking habits with an easy-to-use calendar, see graphs tracking money saved and number of packs not smoked, receive health milestones and craving tips to stay motivated, connect with social networks to give milestone updates, create a video diary, and watch personalized video messages from loved ones
1626481|NCT02037360|Behavioral|Experimental App/Training|It is comprised of twenty-two modules of 10-15 minutes each, designed to teach mindfulness for smoking cessation using psychoeducation-based audio and videos, animations to reinforce key concepts, and in vivo exercises. In addition, 5 bonus modules become available upon completion of earlier modules; these may be accessed for additional practices to bolster other modules.
1626482|NCT02037347|Drug|Palifermin|
1626483|NCT02037334|Device|CERVICAL ASPIRATOR 3.2|No intervention is done except for measuring the stiffness of the cervix in pregnant women
1626484|NCT02037308|Dietary Supplement|Bread|
2011348|NCT02595905|Drug|Veliparib|Given PO
2011349|NCT02594163|Drug|Brentuximab Vedotin|
1626487|NCT02037282|Drug|Anti-influenza IVIG|
1626488|NCT02037256|Drug|bortezomib|Given IV
1626489|NCT02037256|Biological|filgrastim|Given SC
1626490|NCT02037256|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
1626491|NCT02037243|Behavioral|Standard Public Health Intervention with Water Treatment|Compound level meeting
1626492|NCT02037243|Behavioral|Standard Public Health Intervention with Water Treatment & Hand Washing|Compound level meeting
1626493|NCT02037243|Behavioral|Disgust and Shame Based Intervention with Water Treatment|Compound level meeting
1626494|NCT02037243|Behavioral|Disgust and Shame Based Intervention with Water Treatment & Hand Washing|Compound level meeting
1626495|NCT02037230|Drug|MK-1775|MK-1775 will be given as an oral capsule on days 1 and 2, and on days 8 and 9 of every 3-week cycle .
1626496|NCT02037230|Drug|Gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1 and 8 of a 3 -week treatment cycle.
1626497|NCT02037230|Radiation|Radiation Therapy|52.5Gy in 25 fractions (2.1Gy/fraction), using intensity modulated radiation therapy (IMRT). Radiation therapy will be administered after chemotherapy.
1626498|NCT02037217|Device|ExAblate Transcranial MRgFUS System|
2011350|NCT02594163|Drug|Rituximab|
2011351|NCT02594163|Drug|Bendamustine|
2011352|NCT02594072|Radiation|stereotactic ablative radiotherapy|Linac-based prostate stereotactic radiotherapy, using Volumetric Modulated Arc Therapy planning and delivery, with fiducial marker and cone-beam CT based image guidance.
1957956|NCT02098967|Drug|RO6839921|Escalating IV doses of RO6839921 in AML patients. Escalation will follow an adapted rolling 6 design. Starting dose </= dose inducing Grade 2 toxicity in patients with solid tumors. RO6839921 will be given on Days 1-5 of 28-day cycles. Treatment will continue until disease progression, unacceptable toxicity or study discontinuation.
2011353|NCT02594072|Radiation|external beam radiation therapy|Conventional intensity modulated radiotherapy, with fiducial marker or cone-beam CT based image guidance.
1626500|NCT02037191|Drug|Methotrexate|"Non responder patients in arm A will be re-randomized to receive from month 6 to the end of the study (month 12):
methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
1626501|NCT02037191|Drug|Placebo|"Non responder patients in arm B will be re-randomized to receive from month 6 to the end of the study (month 12):
methotrexate alone or methotrexate associated with prednisone 0.3 mg/Kg/day"
1626502|NCT02037178|Other|First ultrasound reading|First ultrasound reading of the sub-renal abdominal aorta by a general practitioner.
1626503|NCT02037178|Other|Second ultrasound interpretation|The untrasound images recorded by general practitioners will be interpreted a second time by an expert in vascular medecine, and evaluated for their image quality.
1626504|NCT02037165|Drug|Placebo to BI 1026706|Placebo tablet
1626505|NCT02037165|Drug|Placebo to BI 1026706|Placebo oral solution
1626506|NCT02037165|Drug|Pregabalin|Pregabalin hard capsule
1626507|NCT02037165|Drug|Placebo to BI 1026706|Placebo oral solution
1626508|NCT02037165|Drug|Placebo to BI 1026706|Placebo oral solution
1626509|NCT02037165|Drug|Placebo to BI 1026706|Placebo tablet
1626510|NCT02037165|Drug|Placebo to BI 1026706|Placebo tablet
1626511|NCT02037165|Drug|BI 1026706|BI 1026706 oral solution
1626512|NCT02037165|Drug|BI 1026706|BI 1026706 oral solution
1626513|NCT02037165|Drug|Placebo to BI 1026706|Placebo oral solution
1626514|NCT02037165|Drug|Celecoxib|Celecoxib hard capsule
1626515|NCT02037152|Behavioral|Body scan exercise|"The body scan includes 20 minutes of guided audio-- the pre-recorded voice of a narrator instructs the user to systematically direct attention to various parts of the body. The audio content is adapted from the body scan exercises traditionally taught in evidence-based mindfulness interventions."
2011354|NCT02594072|Drug|Zoladex ®|The preferred agent for the protocol is goserelin acetate (Zoladex ®) 3-month depot, but other LHRH agonists are permitted. The total duration of ADT will be 6 months for men with intermediate risk disease, and 18 months for those with high risk disease. ADT is to be initiated prior to the start of RT.
2011355|NCT02592824|Drug|glutamate infusion|Intravenous infusion of 0.125M L-glutamic acid solution at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
1626519|NCT02037126|Drug|Psilocybin|this has been used in treating obsessive-compulsive disorders, cluster headaches, anxiety, and drug dependence.
1626520|NCT02037126|Drug|Diphenhydramine|This drug will be used as the control. Diphenhydramine is a histamine blocker.
1626521|NCT02037087|Behavioral|Good household prenatal practice|Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression
1626522|NCT02037087|Behavioral|Care seeking|"Danger-sign recognition
Reminders for government projects"
1626523|NCT02037087|Behavioral|Full bank of SMS|"Danger-sign recognition
Reminders for government projects
Knowledge on nutrition, labor, non-medical pain management, breastfeeding and depression"
1626524|NCT02037074|Drug|Drug: EVP-6308|Arms 1, 2, 3
1626525|NCT02037074|Drug|Placebo|Arm 4
1626528|NCT02037048|Drug|oxaliplatin|Given IV
1626529|NCT02037048|Drug|leucovorin calcium|Given IV
1626530|NCT02037048|Drug|fluorouracil|Given IV
1626531|NCT02037048|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
1626532|NCT02037048|Radiation|radiation therapy|Undergo radiation therapy
1626533|NCT02037048|Drug|carboplatin|Given IV
1626534|NCT02037048|Drug|paclitaxel|Given IV
1626535|NCT02037035|Drug|Ketamine|
1626536|NCT02037022|Behavioral|Pivotal Response Treatment Package (PRT-P)|
1626537|NCT02037009|Other|Health care organization (anesthetic surveillance)|
1626538|NCT02036983|Procedure|Transversus abdominis plane block (TAP BLOCK)|Ultrasound guided TAP block with local anesthetics and dexamethasone.
1626539|NCT02036983|Procedure|Instillation of surgical site with local anesthetic.|Instillation of surgical site with local anesthetics and dexamethasone.
1626540|NCT02036983|Procedure|Opioid IV medications (Control)|Standard anesthetic technique.
1626541|NCT02036970|Drug|Bardoxolone methyl|
1626542|NCT02036970|Drug|Placebo|
1626543|NCT02036957|Procedure|BALM ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
1626544|NCT02036957|Procedure|PLACEBO ARM|The product will be applied throughout the body in abundant quantity to achieve that the skin be perfectly hydrated. The product will be applied twice a day (after showering in the morning and at night), massaging the area until completely absorption. Treatment will last three months, and at this time, We will measure toxicologic toxicity in both arms.
1626545|NCT02036931|Device|Metal on Polyethylene articulation|G7 Acetabular Cup System with Metal head on Polyethylene liner articulation (MOP)
1626546|NCT02036931|Drug|Ceramic on Polyethylene articulation|G7 Acetabular Cup System with Ceramic head on Polyethylene liner articulation (COP)
1626547|NCT02036931|Device|Ceramic on Ceramic articulation|G7 Acetabular Cup System with Ceramic head on Ceramic linear articulation (COC) - Outside the United States ONLY
1626548|NCT02036918|Drug|Sipuleucel-T|
1626549|NCT02036918|Procedure|Lymph Node Biopsy|
1626550|NCT02036905|Other|Cervical and thoracic mobilization|Described in arm description
1626551|NCT02036905|Other|cervical and thoracic manipulation|described in arm description
1626552|NCT02036892|Behavioral|Lifestyle counseling with smartphone|Lifestyle counseling with health promoting smartphone software
1626553|NCT02036892|Behavioral|Lifestyle counseling|Lifestyle counseling
1626554|NCT02036879|Drug|Loestrin (norethindrone acetate and ethinyl estradiol)|This is an optional substudy that females participating in the main study can choose to participate in. Loestrin, an oral contraceptive or birth control pill, will be prescribed and taken daily for approximately 2 months.
1626555|NCT02036866|Other|Transcutaneous Electrical Nerve Stimulation|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. A continuous biphasic pulsatile current (150 Hz, phase duration 150 µs) will be applied at an intensity that produces a comfortable sensation but not a muscle contraction. The duration of intervention will be 8 hours per day for 1 week.
1626556|NCT02036866|Other|Physical Therapy Exercises|Patients will be given detailed verbal and hands-on instruction in a home exercise program. This program will consist of 6 exercises modeled from established protocols focuses on improving lower extremity strength. Patients will be instructed to do the exercises daily and to progress the exercises over the week for a maximum of 30 repetitions per day for 1 week.
1626557|NCT02036866|Other|No Intervention|Patients will be instructed to maintain their usual activity level.
1626558|NCT02036853|Drug|Triheptanoin|"Schedule A: Subjects previously treated with triheptanoin will continue to dose at approximately 35% of total daily calories (~1-4g/kg/day, depending on age).
Schedule B: Subjects who are naïve to triheptanoin will begin a 2-week fixed titration schedule up until they have reached 35% of total daily calories (~1-4 g/kg/day depending on age). If a subject has not reached the target of 35% of total daily calories, by the end of the 2-week fixed titration period, dose titration should continue until achieved or until the maximally tolerated dose has been established."
1626559|NCT02036840|Drug|Antibiotic|
1626560|NCT02036827|Drug|Rocuronium|We will administrate neuromuscular blocking agent until moderate or deep neuromuscular blockade stabilized.
1626561|NCT02036814|Behavioral|Program Health Education|
1626562|NCT02036801|Other|Lung specific elastance|Measurement of lung specific elastance and lung mechanical characteristics at different PEEP levels and tidal volumes
1626563|NCT02036788|Other|Occlusion test|Occlusion test to assess the correct positioning of esophageal balloon catheter when the patient is breathing spontaneously.
1626564|NCT02036788|Other|Thoraco-abdominal compressions|Thoraco-abdominal compressions to assess the correct positioning of esophageal balloon catheter when the patient is sedated and paralyzed.
1626565|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
1626566|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
1626567|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
1626568|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
1626569|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
1626570|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
1626571|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
1626572|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
1626573|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
1626574|NCT02036775|Drug|Lasolvan prolonged-released capsules|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
1626575|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
1626576|NCT02036775|Drug|Lasolvan tablet|One Lasolvan tablet 30 mg twice daily for 5 days.
1626577|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
1626578|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
1626579|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
1626580|NCT02036775|Drug|Lasolvan prolonged-release hard capsule|One Lasolvan prolonged-release hard capsule 75 mg once daily for 5 days
1626581|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
1626582|NCT02036775|Drug|Lasolvan effervescent tablet|One-half Lasolvan effervescent tablet 60mg twice daily for 5 days.
1626583|NCT02036762|Other|Stretching Exercises|The group submitted to stretching exercises in the respiratory muscles and treadmill exercises
1626584|NCT02036749|Procedure|nerve block|quadratus lumborum block
1626585|NCT02036736|Drug|Intraoperative anesthetic strategy by Propofol|"1- Arm Propofol: Propofol TCI induction target between 2 and 6 mg / mL
Sufentanil (0.15 mg / kg intravenously (IV))
Atracurium (0.5 mg / kg IV) Maintenance mode by Propofol TCI target between 2 and 4 micrograms / mL tune to 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
1626586|NCT02036736|Drug|Intraoperative anesthetic strategy by Desflurane|"2- Arm Desflurane Desflurane induction (2-3 mg / kg)
Sufentanil (0.15 mg / kg IV)
Atracurium (0.5 mg / kg IV)) Desflurane closed by maintenance target with minimal alveolar concentration (MAC) to adapt the circuit to obtain a figure 40 <BIS <60 Sufentanil bolus according to intraoperative analgesia Atracurium bolus according to the level of neuromuscular blockade"
1626587|NCT02036723|Drug|Bevacizumab|Patients will receive bevacizumab at a dose 1.25 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
1626588|NCT02036723|Drug|Ranibizumab|Patients will receive ranibizumab at a dose 0.50 mg (in 0.05 ml of solution) as an intravitreal injection on day 1 and then every 28 days during 12 months.
1626589|NCT02036697|Drug|Bupivacaine 4.5|Bupivacaine hyperbaric, 4.5 mg
1626590|NCT02036697|Drug|Bupivacaine 9|Bupivacaine hyperbaric, 9 mg
1626591|NCT02036697|Drug|Morphine|morphine 150 mcg.
1626592|NCT02036697|Drug|Fentanyl|15 mcg
1626593|NCT02036684|Behavioral|Prehabilitation (PREHAB)|
1626594|NCT02036671|Device|The FLEX System will be used to percutaneously create a fistula in CKD patients who require hemodialysis vascular access|
1626595|NCT02036658|Behavioral|Cognitive Behavioral Group Therapy|Cognitive Behavioral Group Therapy for social anxiety disorder is a 12-week treatment that involves psychoeducation, cognitive restructuring and exposure to social situations.
1626596|NCT02036658|Behavioral|Mindfulness-Based Stress Reduction|Mindfulness-Based Stress Reduction is completed in 12 weeks in the study and includes enhancing one's awareness non-judgmentally by focusing on the present moment through the use of mindfulness meditation.
1626601|NCT02036632|Device|Eye Patching|
1626603|NCT02036593|Behavioral|Walk Your Heart to Health|Walking group sessions conducted 3 times per week for 32 weeks.
1626604|NCT02036580|Biological|tralokinumab cohort 1|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
1626605|NCT02036580|Biological|tralokinumab cohort 2|Tralokinumab is a human recombinant monoclonal antibody (MAb) of the subclass that specifically binds human IL-13, blocking interactions with the IL-13 receptor
1626606|NCT02036580|Other|Placebo|
1626607|NCT02036554|Drug|Everolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
1626608|NCT02036554|Drug|Tacrolimus|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
1626609|NCT02036554|Drug|Mycophenolic acid|Decrease the level of Tacrolimus and add on Everolimus instead of Mycophenolic acid which is standard treatment.
1626610|NCT02036541|Device|AqueSys XEN 45 Glaucoma Implant|Placement of the AqueSys XEN 45 Glaucoma Implant in the study eye
1626611|NCT02036528|Drug|Gentamicin Topical Gel|
1626612|NCT02036528|Drug|Ciprofloxacin|
1626613|NCT02036528|Drug|Doxycycline|
1626614|NCT02036515|Drug|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
1626615|NCT02036515|Drug|Ertugliflozin 15 mg|Ertugliflozin, oral, 5 mg and 10 mg tablet once daily for 52 weeks
1626616|NCT02036515|Drug|Placebo for ertugliflozin 5 mg|Matching placebo for ertugliflozin 5 mg, oral, once daily for 52 weeks
1626617|NCT02036515|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period.
1626618|NCT02036515|Drug|Sitagliptin|Participants are to remain on their stable doses of sitagliptin (oral, 100 mg once daily) while receiving blinded investigational product during the double-blind treatment period.
1626619|NCT02036515|Drug|Glimepiride|Glimepiride rescue medication, oral, once daily, open-label glimepiride; dose determined per the investigator's discretion
1626620|NCT02036515|Biological|Insulin|Insulin glargine rescue medication, injectable, as required. In the event that an investigator considers use of glimepiride to not be appropriate for a participant meeting protocol specified glycemic rescue criteria, insulin glargine can be initiated as the rescue medication, and managed by the investigator according to clinical practice guidelines of the local country.
1626621|NCT02036515|Drug|Placebo for ertugliflozin 10 mg|Matching placebo for ertugliflozin 10 mg, oral, once daily for 52 weeks
1626622|NCT02036502|Biological|Pembrolizumab|Intravenous (IV) infusion
1626623|NCT02036502|Drug|Lenalidomide|Oral capsule
1626624|NCT02036502|Drug|Dexamethasone|Oral tablet
1626625|NCT02036502|Drug|Carfilzomib|IV infusion
1626626|NCT02036489|Drug|Vincristine|
1626627|NCT02036489|Drug|Daunorubicin|
1626628|NCT02036489|Drug|Prednisone|
1626629|NCT02036489|Drug|L-asparaginase|
1626630|NCT02036489|Drug|Ciclophosphamide|
1626631|NCT02036489|Drug|Metotrexate|
1626632|NCT02036489|Drug|ARA-C|
1626633|NCT02036489|Drug|Hidrocortisone|
1626634|NCT02036489|Drug|Mercaptopurine|
1626635|NCT02036489|Drug|VP-16|
1626636|NCT02036489|Drug|Dexametasone|
1626637|NCT02036476|Drug|Cabozantinib|Cabozantinib 60 mg Oral Daily 28 days (4 weeks)
1626638|NCT02036463|Drug|Prednisone|
1626639|NCT02036463|Drug|Placebo|
1626640|NCT02036450|Device|LOOP recorder (Medtronic LINQ device)|A LOOP recorder will be implanted in a 1:3 randomization
1626641|NCT02036437|Drug|Misotac® Sigma Pharmaceutical Industries|The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
1626642|NCT02036437|Drug|Dinoprostone 3 mg|Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
1626643|NCT02036424|Drug|Ozurdex|intravitreal steroid
1626644|NCT02036424|Drug|Bevacizumab|antiVEGF
1626645|NCT02036398|Device|Double J stent without nephrostomy|Double J stent only left at the end of the procedure without placement of a nephrostomy tube
1626646|NCT02036398|Device|nephrostomy tube and double J stent|Double J stent and nephrostomy tube left at end of procedure
1626647|NCT02036372|Drug|Liraglutide|
1626648|NCT02036372|Drug|Insulin bolus|
1626649|NCT02036372|Drug|GIK infusion|continuous infusion
1626650|NCT02036359|Drug|erlotinib|150mg/day for 9 weeks unless disease progression, unacceptable toxicity or death.
1626651|NCT02036359|Drug|docetaxel|receive 3 cycles (9 weeks) of chemotherapy with docetaxel 35mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 8.
1626652|NCT02036346|Dietary Supplement|Oral Rehydration Solution|Oral rehydration solution containing: sodium chloride, sodium citrate, glucose, magnesium gluconate and water.
1626653|NCT02036346|Other|Advise on calculated oral fluid requirements|
1626654|NCT02036346|Other|No nutritional advice will be given|
1626655|NCT02036320|Device|etafilcon A|Each study subject will be exposed to both test lenses following a washout period of five minutes between test periods.
1626656|NCT02036307|Dietary Supplement|DHA-enriched|DHA 3g + 600 mg EPA in 6 g of fish oil/day given for 4 weeks
1626657|NCT02036307|Dietary Supplement|EPA-enriched|EPA 2.4 g + DHA 600mg in 6 g of fish oil/day for 4 weeks
1991927|NCT00243152|Drug|Lamotrigine|: 25mg and 50mg tablets
2011356|NCT02592824|Drug|saline infusion|Intravenous infusion of saline at a rate of 1.65 ml/kg BW and hour commencing at or up to 20 minutes before the release of aortic cross-clamp. The infusion is continued for two hours after declamping the aorta after which an additional 50 ml is given at a halved infusion rate.
1626660|NCT02036281|Drug|Substance P-Saporin|
1626661|NCT02036268|Behavioral|Standard|Standard ostomy education
1626662|NCT02036268|Behavioral|Pre-operative Education|In addition to standard ostomy education, an additional pre-operative ostomy education session will be conducted with the subject.
1626663|NCT02036268|Behavioral|Two-week Post Operative Education|In addition to standard ostomy education and an additional pre-operative ostomy education session, another ostomy education session will be conducted with the subject two weeks post-op.
1626664|NCT02036255|Drug|Taurolidine Urokinase|
1626665|NCT02036255|Drug|Taurolidine Heparin|
1626666|NCT02036242|Drug|Sole local anesthetic|0.125% ropivacaine 10-15 ml every 1h during labor delivery
1626667|NCT02036242|Drug|Sufentanil (Opioid plus local anesthetic)|Sufentanil combined with 0.125% ropivacaine, 10-15 ml every 1h during labor delivery
1626668|NCT02036242|Drug|Ropivacaine|
1626669|NCT02036229|Drug|ivermectin cream 0.5%|Each participant will be treated with topical ivermectin cream 0.5% qd for one half of the face and with a vehicle cream qd for the other half of the face for 1 month. In the second month all patients will be treated with ivermectin cream for the entire skin involvement.
1626670|NCT02036203|Device|SCu300A IUB|Spherical copper contraceptive
1626671|NCT02036203|Device|TCu380A IUD|T-shaped copper IUD
1626672|NCT02036177|Device|SCu300A IUB intrauterine device|Spherical copper IUD
1626673|NCT02036177|Device|T380A IUD|T-shaped copper IUD
1626674|NCT02036164|Radiation|Pelvic radiation|"Radiation:
Pelvic radiation 1.8 Gy/ day, 5 days/ week, 6 weeks
Brachytherapy 30-35 Gy for 4-5 times"
1626675|NCT02036164|Drug|Cisplatin|Cisplatin 40 mg/m2 i.v.
1626676|NCT02036164|Drug|Paclitaxel|Paclitaxel 175 mg m2 i.v.
1626677|NCT02036164|Drug|Carboplatin|Carboplatin AUC 5 i.v.
1626678|NCT02036151|Drug|xylitol|Mothers in the experimental group were instructed to chew 1 pellet of xylitol gum (Fennobon Oy, Yrittäjäntie, Finneland -gum, 3 times ) for a period of 3 months. control mothers did not receive any medications. All mothers received oral hygiene instructions and restorative treatment when needed. Offspring of both the experimental and control groups did not receive any medication and were followed for at 6,12, 18 and 24 month from initiation of mothers consumption. month
1626679|NCT02036151|Drug|fluoride varnish application|The control group participated in a preventive program under the supervision of the Pediatric Dentistry Department. The program activities consisted of oral hygiene instructions, fluoride varnish application (Duraphat 5% Na F ,Ultradent Products, Utah, USA) and restorative treatment when needed.
1626680|NCT02036138|Procedure|Laparoscopic Sleeve Gastrectomy|
1626681|NCT02036138|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
1626682|NCT02036138|Drug|Advanced Medical Therapy|
1626683|NCT02036125|Device|Ultrasound|Subjects will receive an ultrasound guided injection of 40 mg of methylprednisolone.
1626684|NCT02036125|Drug|methylprednisolone|Subjects will receive a blind injection of 40 mg of methylprednisolone.
1626685|NCT02036112|Procedure|conventional ELAPE|device
1626686|NCT02036112|Procedure|Individual ELAPE|device
1626687|NCT02036099|Other|Driving in Mild Dementia Decision Tool|Study participants will be screening patients for fitness to drive using our DMD-DT, instead of using their usual care strategies.
1626688|NCT02036086|Drug|Vemurafenib|Drug
1626689|NCT02036086|Drug|Cobimetinib|Drug
1626690|NCT02036073|Drug|recombinant human erythropoietin|rhEPO 500U/kg was injected within 24h after birth, subsequent injection was given each other day fro 2 weeks.
2011357|NCT02593097|Drug|Metformin|Metformin 500mg twice daily
1626693|NCT02036047|Device|exclusive cold polypectomy snare (Exacto cold snare, product number 00711115)|
1626694|NCT02036047|Device|Regular polypectomy snare (Snare Master, SD-210U-10)|
1626695|NCT02036034|Device|forced air warmer (Bair Hugger)|forced air warmer placed under the chin before draping, forced air warmer inflated after draping is completed.
1626696|NCT02036034|Device|warming blanket|warming blanket placed on torso of patient under the drape.
1626697|NCT02036008|Other|Liver MRI with Gdfos|"Participants will receive Gdfos at a dose of 10 mL of 0.25mmol/mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.
Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase.
This study will be performed within 4 weeks of the MRI study with EcGd."
1626698|NCT02036008|Other|Liver MRI with EcGd|"Participants will receive a liver MRI with EcGd as per clinical institutional protocol.
Participants will receive EcGd at a dose of 0.1 mL/kg body mass up to 10 mL. This will be administered automatically using an MRI-compatible power injector, as a bolus through an intravenous line placed in an antecubital vein at a rate of 1.5 mL/s followed by 25 mL of 0.9% saline flush.
Participants will be imaged using a 3.0 T MRI scanner with an 8 channel body phased array coil utilized covering the entire liver. Images of the liver will be obtained including: axial precontrast phase, axial arterial phase, axial portovenous phase, axial 5 minute delayed phase, axial 10 minute delayed phase, axial 20 minute delayed phase. Additional noncontrast images will be obtained as per institutional protocol, including diffusion weighted imaging, in/out of phase imaging, and T2 weighted imaging."
1626699|NCT02035995|Other|Pregnant volunteers with GDM|
1626700|NCT02035982|Drug|Cholinesterase Inhibitor|"For participants randomized into the active treatment arm, they will be provided with the following study medications:
Donepezil - 5 mg or 10 mg Galantamine - 8 mg and 16 mg and 24 mg Rivastigmine - 1.5 mg and 3 mg
The type of study medication provided will depend on the type and dosage of the cholinesterase inhibitor they have been receiving for the last 3 months of their regular treatment. For example, if that have been taking Donepezil - 5 mg daily, they will continue on that same medication, dosage and frequency."
1626876|NCT02034669|Device|Intradural space|ADSCs injection into Intradural space at damage site
1626701|NCT02035982|Drug|Placebo|For participants randomized into the placebo intervention, placebo capsules will match capsules in the active intervention.
1626702|NCT02035969|Behavioral|Enhanced Treatment Support (ETS)|"Peer supporters, who are also caregivers of HIV-infected children, organize peer support group meetings. In the meetings one peer supporter discusses problems related to adherence with caretakers and provides them with information. Another supporter provides children above 3 years of age with age relevant information about their disease and treatment as well as games and play to enhance group bounds. The supporter will also have weekly telephone contact with all caretakers to assess the condition of the child.
For children with poor adherence individual support to caretakers and patients will be arranged to assess the child's condition and reason for poor adherence, in case of complications the supporter gives advice or refers the child for medical checkup."
1626703|NCT02035956|Biological|IVAC MUTANOME, RBL001/RBL002|Each patient will receive multiple repeated intranodal injections of IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002.
1626704|NCT02035943|Dietary Supplement|Insulin separated|separate continuos infusion of insulin
1626705|NCT02035943|Dietary Supplement|Insulin added to parenteral nutrition|Insulin added to parenteral nutrition
1626706|NCT02035930|Drug|dexmedetomidine|
2011358|NCT02593097|Drug|Matching Placebo|Matching Placebo twice daily
2011359|NCT02592876|Drug|denintuzumab mafodotin|Denintuzumab mafodotin 3 mg/kg by intravenous (IV) infusion, every 3 weeks for up to 3 cycles.
1626709|NCT02035904|Drug|Levobupivacaine PCIA (Patient Controlled Intrawound Analgesia)|patient controlled infusion from the 2nd day after surgery
1626710|NCT02035904|Drug|saline|patient controlled infusion from the 2nd day after surgery
1626711|NCT02035904|Drug|Levobupivacaine continuous infusion|Continuous infusion Levobupivacaine 0,25% 5ml/h for 24 hs in all patients
1626712|NCT02035904|Device|intrawound infusion catheter|placed by surgeon at the end surgery in all patients
1626713|NCT02035904|Drug|morphine|PCA with morphine: 0,5 mg/ml bolus 1 mg lock-out 5 min max 20 mg in 4 hs - for the first 24 hs as rescue analgesia
1626714|NCT02035904|Drug|Patrol|tramadol-paracetamol 37,5/325 mg oral fix combination-rescue analgesia from 2nd day (after morphine PCA removal)
1626715|NCT02035891|Drug|colchicine 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
1626716|NCT02035891|Drug|placebo 0.5mg/d|on the basis of standard therapy to manage hyperglycemia, hypertension,dislipidemia etc.
1626717|NCT02035878|Other|Probiotics|probiotic intervention: 400mg of probiotic capsule
1626718|NCT02035878|Drug|Placebo|placebo comparator
1626719|NCT02035852|Other|MRI|3T MRI vs. 7T MRI
1626720|NCT02035839|Device|Target Temperature Management of 34°C|In hospital target temperature management to achieve core body temperature of 34°C for 24 hours.
1626721|NCT02035839|Device|Target Temperature Management of 32°C|In hospital target temperature management to achieve core body temperature of 32°C for 24 hours.
1626722|NCT02035839|Device|Target Temperature Management of 33°C|In hospital target temperature management to achieve core body temperature of 33°C for 24 hours.
1626723|NCT02035826|Behavioral|Behavioral Economics Intervention|Patients will receive an active intervention for 3 months followed by 3 months of observation. Incentives will be awarded at the end of the first 3 months, based on an improvement of at least 10 mg/dl in LDL relative to the patient's baseline LDL or achieving or sustaining LDL of 100, depending on baseline LDL and FRS. Adherence in all groups will be measured using Vitality GlowCaps as a recording device. Patients in all arms will be given the GlowCaps and instructions on use. Patients will receive adherence feedback electronically with daily lottery awards to match the timing of their task.
1626724|NCT02035813|Drug|Everolimus|Everolimus in combination with endocrine therapy
1626725|NCT02035813|Drug|Eribulin|
1626726|NCT02035800|Drug|Adalimumab|Patient will received medication as standard of care
1626727|NCT02035787|Drug|Metformin|Metformin added to standard non-surgical treatment with levonorgestrel-Releasing Intrauterine Device.
1626728|NCT02035774|Procedure|LSIB + SSNB|Patients will receive LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml Ropivacaine 5 mg/ml) or LSIB (31 ml ropivacaine 7.5 mg/ml)+ SSNB (4 ml placebo, saline)
1626729|NCT02035748|Drug|Ocriplasmin|0.5 mg/0.2 mL solution for injection
1626730|NCT02035735|Procedure|WL and NBI|For each patient with a suspicion of squamous cell carcinoma of the oropharynx, hypopharynx or larynx for whom a laryngoscopy under general anesthesia (LGA) is expected benefit the day before a transnasal endoscopy with white lamp (WL) and NBI by two different operators. Suspected mucosal abnormalities showed by one or the two technics are reported in a table wich describes the different areas of the pharynx and the larynx. During the LGA, several biopsies are performed and identified (WL and/or NBI).
1626731|NCT02035722|Behavioral|Printed materials|AMD-related information is presented to patients in the form of a brochure (i.e. printed materials)
1626732|NCT02035722|Behavioral|Video|AMD-related information is presented as in the form of a video
1626733|NCT02035709|Drug|Hydromorphone|Hydromorphone is given by PCA or TCI-PCA. The TCI-PCA System steer the hydromorphone infusion pump to achieve plasma concentrations of hydromorphone in predefined increasing steps on patient request and in predefined decreasing steps on lack of patient request within predefined plasma concentration range, lock times and infusion speed.
1626736|NCT02035683|Procedure|PET/CT|PET/CT scan at baseline and 3 weeks after first cycle chemotherapy
1626737|NCT02035670|Other|Two-step diagnostic strategy|"The first step is to differentiate FUO according to the onset of disease and invasive pathogens. Apart from collecting detailed present medical history and careful physical examination, it focuses on seeking the clues of bacterial invasion two weeks before the fever onset from five aspects.To finish this part, the doctor needs to ask for informations following a list we already made, which covers more than forty definite items. If some of these items were proved existed, result of first step would be positive.
The second step is calculating the integral score of inflammatory biomarkers and vital diagnostic clues, WBC& N, ESR, CRP, LDH, SF, ANCA, ANA, RF, PCT and T-Spot, as well as the clinical findings were included in this integrating system.The results of these items will be recorded and calculated with certain interval of time. If the score were more than nine, this part would be considered. positive."
1626738|NCT02035657|Biological|GLA-SE|Glucopyranosyl Lipid A in Stable Emulsion
1626739|NCT02035644|Drug|Jinlida granules|
1626741|NCT02035631|Behavioral|Diet|The dietary component, aimed to reduce calorie intake according to individual requirements, will be structured in 1-hour weekly sessions led by trained nutritionists. Sessions will concentrate on teaching participants about food groups, the food pyramid and Mediterranean diet, how to chose, prepare and cook hypo-caloric meals.
1626742|NCT02035631|Behavioral|Physical activity|The physical activity component will include two sessions per week led by trained physical activity monitors including aerobic exercise of high/moderate intensity, and instruction about the at-home exercise activities (3 more sessions).
1626743|NCT02035631|Behavioral|Minimal diet intervention|Some basic diet recommendations
1626744|NCT02035631|Behavioral|Minimal physical activity intervention|Some basic recommendations on physical activity
1626745|NCT02035618|Other|Exercises|Strengthening and stretching
1626746|NCT02035618|Other|Exercises + Manual Therapy|Mobilization; massage; post-isometric relaxation; strengthening; stretching
1626747|NCT02035605|Drug|ALN-AT3SC|Ascending doses of ALN-AT3SC by subcutaneous (sc) injection
1626748|NCT02035605|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
1626749|NCT02035592|Other|Full dose blueberry|"Full dose: 26g of freeze dried blueberry powder to be incorporated into the habitual diet.
Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
1626750|NCT02035592|Other|Half dose blueberry|"Half dose: 26g of freeze dried powder (containing 13g of freeze dried blueberry powder and 13g of placebo comparator material) to be incorporated into the habitual diet.
Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
1626751|NCT02035592|Other|Control|"Control: 26g of placebo comparator material to be incorporated into the habitual diet.
Dietary restrictions will be observed (i.e. avoidance of blueberry, and restricted intake of anthocyanin rich foods) for 21 days prior to the first assessment visit and throughout the study."
1626752|NCT02035579|Behavioral|Aerobic Training Intervention|
1626753|NCT02035579|Behavioral|Stretching Intervention|
1626754|NCT02035566|Other|Telehome Care Monitoring|Telehome care monitoring over a 60-day period wherein patients transmit health measurements to their health care professional on a daily basis
2011360|NCT02592876|Drug|rituximab|375 mg/m2 by IV infusion, every 3 weeks for up to 3 cycles
2011361|NCT02592876|Drug|ifosfamide|5000 mg/m2 by IV infusion over a 24-hour period, every 3 weeks for up to 3 cycles
1626757|NCT02035540|Other|Decellularized human valves|
1626758|NCT02035527|Drug|sorafenib tosylate|Given daily PO in the a.m.
1626759|NCT02035527|Drug|cisplatin|Given IV over 1 hour following Docetaxel administration
1626760|NCT02035527|Drug|docetaxel|Given IV 1 hour prior to cisplatin administration
1626761|NCT02035527|Other|Correlative Studies|Correlative studies will be performed at the following time points. A total of three biopsies (blood and tumor samples) will be obtained in consenting patients.Pre-treatment biopsy to establish diagnosis and baseline data, Research biopsy obtained at the end of a two week period of sorafenib monotherapy just prior to administration of cycle1 with cisplatin and docetaxel, Research biopsy obtained at the end of two chemotherapy cycles.
1626762|NCT02035514|Biological|Bone marrow autologous mesenchymal stem cells transplantation|
1626763|NCT02035501|Drug|L-Tyrosine|
1626764|NCT02035501|Drug|Placebo|
1626765|NCT02035488|Drug|Tobramycin|Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
1626766|NCT02035475|Device|Intuitive Vessel Sealer|Investigators intend to use this device unilaterally so the contralateral side can serve as an internal control.
1626767|NCT02035449|Device|McGrath MAC|McGrath MAC is a videolaryngoscope
2011362|NCT02592876|Drug|carboplatin|AUC 5 by IV infusion, every 3 weeks for up to 3 cycles
2011363|NCT02592876|Drug|etoposide|100 mg/m2 per day by IV infusion for 3 days, every 3 weeks for up to 3 cycles
1626770|NCT02035423|Dietary Supplement|120 IU milk|Daily consumption of milk fortified with 120 IU vitamin D
1626771|NCT02035423|Dietary Supplement|200 IU Milk|Daily Consumption of milk fortified with 200 IU vitamin D
1626772|NCT02035423|Dietary Supplement|Non-Fortified Milk|Daily consumption of non-fortified milk
1626773|NCT02035410|Procedure|Hydrogen peroxide pretreatment group|Hydrogen peroxide pretreatment perform before cardiac devices Implantation. It disinfects the cardiac devices pocket using Hydrogen peroxide gauze.
1626774|NCT02035397|Drug|Botulinum Toxin Type A|
1626775|NCT02035397|Drug|Saline solution|
2011364|NCT02590263|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
1626777|NCT02035371|Drug|Faster-acting insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
1626778|NCT02035371|Drug|insulin aspart|A single dose will be administered subcutaneously (s.c. under the skin)
1626779|NCT02035358|Biological|HyperAcute®-Renal (HAR) Immunotherapy|"HyperAcute®-Renal Immunotherapy consisting of equal cell doses of each of two allogeneic renal cell cancer cell lines (HAR1 and HAR2) engineered to express the murine α(1,3)GT gene.
Cells will be injected intradermally every 1 week x 4 weeks and then every 2 weeks for 10 immunizations to total 14 immunizations. Dose Cohort 1 will receive 150 million cells per immunization; Dose Cohort 2 will receive 300 million cells per immunization."
1626780|NCT02035345|Drug|Carboplatin|
1626781|NCT02035332|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
1626782|NCT02035306|Other|non invasive co-oximetry haemaglobin measurement|
1626783|NCT02035293|Other|PEP|
1626784|NCT02035267|Drug|ATX-101|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
1626785|NCT02035267|Drug|Placebo|Phosphate buffered saline placebo for injection.
1626786|NCT02035254|Other|Web-based Wellness Program|Web-based educational modules and physical activity and/or health weight challenges
2011365|NCT02590263|Drug|Temozolomide|Temozolomide will be administered per label.
2011366|NCT02590263|Radiation|Whole Brain Radiation|Whole Brain Radiation will be administered in over 30 fractions as per the procedure in each study site.
2011367|NCT02588261|Drug|naquotinib|oral
1626787|NCT02035241|Dietary Supplement|Spices 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
1626788|NCT02035241|Dietary Supplement|Spices 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
1626789|NCT02035241|Dietary Supplement|Spices 3|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of spices 3. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
1626790|NCT02035241|Dietary Supplement|Herbs 1|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 1. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
1626791|NCT02035241|Dietary Supplement|Herbs 2|In this study, subjects are asked to consume 200 ml beverage drinks contain certain amounts of herbs 2. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
1626792|NCT02035241|Dietary Supplement|Control drink|As a control, subjects are asked to consume 200 ml control drinks. Following 10 min. beverage consumption, subjects will be given standardized breakfast corresponding to 50 g carbohydrate.
1626793|NCT02035228|Device|Abdominal Stimulation - low / early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at low stimulation current for the first half of exhalation"
1626794|NCT02035228|Device|Abdominal stimulation - low/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at low stimulation current for the second half of exhalation"
1626795|NCT02035228|Device|Abdominal Stimulation - low/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at low stimulation current throughout exhalation"
1626796|NCT02035228|Device|Abdominal stimulation - med/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at medium stimulation current for the first half of exhalation"
1626797|NCT02035228|Device|Abdominal stimulation - med/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at medium stimulation current for the second half of exhalation"
1626798|NCT02035228|Device|Abdominal Stimulation - med/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at medium stimulation current throughout exhalation"
1626799|NCT02035228|Device|Abdominal Stimulation - high/early|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at high stimulation current for the first half of exhalation"
1626800|NCT02035228|Device|Abdominal Stimulation - high/late|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at hig stimulation current for the second half of exhalation"
1626801|NCT02035228|Device|Abdominal Stimulation - high/full|"Transcutaneous electrical stimulation applied to the abdominal wall muscles in synchronous with volitional exhalation.
Stimulation is applied at high stimulation current throughout exhalation"
1626802|NCT02035215|Drug|Atorvastatin 20mg|
1626803|NCT02035215|Drug|Omega-3-acids ethylesters 90 4g|
1626804|NCT02035215|Other|Placebo(Omega-3-acids ethylesters 90)|
1626805|NCT02035202|Behavioral|CBT2go|CBT administered using mobile intervention.
1626806|NCT02035202|Device|Smartphone|A smartphone platform will be used to deliver the CBT2go behavioral intervention and the surveys in the EMA-only arm.
1626807|NCT02035163|Procedure|Two sites cryoablation|Two ganglionic plexi around atrium was performed with 90-second cryoablation.
1626808|NCT02035150|Dietary Supplement|Oatmeal|A breakfast consisting of oatmeal
1626809|NCT02035150|Dietary Supplement|Frosted Flakes|A breakfast consisting of Frosted Flakes and milk
1626810|NCT02035150|Dietary Supplement|No Breakfast|A breakfast consisting of plain water
1626811|NCT02035137|Radiation|131I-MIBG|
1626812|NCT02035137|Drug|Vincristine|
1626813|NCT02035137|Drug|Irinotecan|
1626814|NCT02035137|Drug|Vorinostat|
1626815|NCT02035124|Drug|BKM 120|
1626816|NCT02035124|Drug|Cabazitaxel|
1626817|NCT02035111|Drug|Tianshu capsule|
1626818|NCT02035111|Drug|Sugar pill|
1626819|NCT02035098|Other|the Pac-IFicO programme|The Pac-IFicO programme is a complex interventions with multiple components. It includes focus group with ward professionals for identifying possible local obstacles to optimal pain control, informative material for the patients, an educational programs performed through guides from the wards, and an organisational intervention to the ward.
1626820|NCT02035085|Drug|CS-1000 labeled SVF cells|Patients will undergo autologous transplantation of CS-1000 labelled SVF cells in a sterile environment.
1626821|NCT02035072|Drug|Gemcitabine|Gemcitabine 1000 mg/m2
1626822|NCT02035072|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2
1626823|NCT02035072|Radiation|Hypofractionated RT|Hypofractionated radiotherapy (35 Gy in 7 fractions)
1626824|NCT02035046|Procedure|Samplings of blood|
1626825|NCT02035046|Procedure|Sampling of urine|
1626826|NCT02035046|Procedure|Measure of the blood pressure|
1626827|NCT02035046|Procedure|glycemia test|
1626828|NCT02035020|Drug|gamma interferon|IFN gamma 1b (Immukin ®) will be administered by subcutaneous route at day 0, 14 and 28 at a dose of 100, 150 and 200 ug respectively.
1626829|NCT02035007|Device|PiCCO Catheter (Pulsiocath 5F)|Measuring of PiCCO derived values
1626873|NCT02034682|Drug|Volulyte 6%|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Volulyte 6% to the cardiopulmonary bypass circuit.
1626874|NCT02034682|Drug|Geloplasma|During elective coronary artery bypass grafting surgery, patients need to be attached to a cardiopulmonary bypass circuit. Administration of Geloplasma to the cardiopulmonary bypass circuit.
1626959|NCT02034045|Other|Usual Care|
1626830|NCT02034994|Behavioral|Eating behavior and physical activity change|A combination of two prevention school based programs will be addressed to schoolchildren over one year. Primary prevention will be developed monthly in order to reduce cookies and sugar sweetened beverages consumption, reduction of sedentary activities, increase meal consumption frequency and quality etc, in all children from 6th and 7th grades. Overweight and obese children will be invited to participate on a secondary prevention program in which daily physical activity classes will be performed by physical education teachers in school facilities.
1626831|NCT02034981|Drug|Crizotinib|"Patients will receive oral crizotinib, daily continuously, until progression or unacceptable toxicity develops.
-250 mg twice daily for adults ≥ 18 years of age
280 mg/m2 twice daily for children and adolescents aged from 1 to 17 (except ALCL).
165 mg/m² twice daily for ALCL patients aged from 1 to 17."
1626832|NCT02034968|Drug|Nimotuzumab|Nimotuzumab: 200mg,IV once a week during chemotherapy.
1626833|NCT02034955|Radiation|Post-operative Adaptive Radiation Therapy|
2011368|NCT02588261|Drug|Erlotinib|oral
2011369|NCT02588261|Drug|Gefitinib|oral
1626836|NCT02034929|Device|EndoCuff-assisted colonoscopy|EC-assisted colonoscopy
1626837|NCT02034929|Device|Standard colonoscopy|Standard colonoscopy
1626839|NCT02034903|Other|Feedings warmed with commercial warmer|
1626840|NCT02034890|Drug|Hyaluronic Acid|intravesical instillation of 40 mg of hyaluronic acid in 6 specific time points: 1,2,3 and 4 weeks postoperatively (After radical cystectomy and orthotopic neobladder reconstruction) 2 and 3 months postoperatively
1626841|NCT02034877|Biological|13-valent Pneumococcal conjugate vaccine|1 dose (0.5 mL/ pre-filed syringe) of 13vPnC administered at visit 1
1626842|NCT02034877|Procedure|Blood sample collection|10 mL of blood will be collected just before and approximately 1 month after vaccination.
1626843|NCT02034864|Other|Osteopathic manipulative treatment|A standardized manipulative treatment according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized manipulative treatment.
1626844|NCT02034864|Other|Placebo of osteopathic manipulative treatment|"A standardized placebo of manipulative treatment consisting in light touch and according to the results of a physical examination including 7 anatomical areas will be given by trained osteopaths during 6 sessions (with an interval of 2 weeks between 2 sessions). Each session will last 45 minutes. Osteopaths will have 3 days of training in standardized placebo of manipulative treatment."
1626845|NCT02034838|Drug|atazanavir 300mg boosted with ritonavir 50 mg|"atazanavir 300 mg with ritonavir 100 mg once a day at 8:00 am for study day 1 and 9.
atazanavir 300 mg with ritonavir 50 mg once a day at 8:00 am for 7 consecutive days (study days 2-8)"
1626846|NCT02034825|Other|Decipher Questionnaire|Each participant will complete the pre and post-Decipher eCRQs for a minimum of 5 cases, and a maximum of 25 cases.
1626847|NCT02034812|Other|Decipher Questionnaire|Pathological data from 12 de-identified patient cases will be reviewed by at least 25 Radiation Oncologists before and after exposure to the Decipher test results. Given the number of patient cases, reviewed by each participant, this allows for assessment of decision making based on 300 patient case reviews at each time point, immediately following RP and at the time of PSA rise.
1626850|NCT02034786|Procedure|Adipose tissue collection|"Only the patients selected for the Test Group will go through the procedure. The adipose tissue collection will occur in an elective surgery liposuction, in patients who meet the inclusion criteria, after signing the informed consent form. Thus, the material that would be disposed after surgery will be donated to the study.
The material for the study will be collected by the tumescent liposuction technique, which involves the removal of subcutaneous fat under local anesthesia."
1626851|NCT02034786|Biological|Transdermal injection|Transdermal injection of the filler agent composed of mesenchymal stem cells derived from autologous adipose tissue associated with hyaluronic acid.
1626852|NCT02034786|Procedure|Transdermal injection|Transdermal injection of hyaluronic acid only.
1626853|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered once daily for 14 days
1626854|NCT02034773|Drug|CC-220|CC-220 1mg will be administered once daily for 28 days + 1 dose of tetanus toxoid vaccination and 1 dose of pneumococcal vaccination
1626855|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered once daily for 28 days
1626856|NCT02034773|Drug|CC-220|CC-220 1mg will be administered once daily for 7 days on 2 separate occasions, with a 7-day washout in between, for a total of 14 days of dosing
1626857|NCT02034773|Drug|Placebo|Placebo will be administered once daily for up to 28 days
1626858|NCT02034773|Drug|CC-220|CC-220 0.3mg will be administered every 3 days for 14 days (5 total doses)
1626859|NCT02034773|Drug|CC-220|CC-220 1mg (once every 7 days for 28 days)
1626860|NCT02034773|Drug|CC-220|CC-220 1mg will be administered as a single dose in each of 2 study periods; once as a formulated capsule and once as two reference capsules
1626861|NCT02034760|Procedure|Heavy Resistance Training|Supervised Heavy Resistance Training three times weekly for 52 weeks.
1626862|NCT02034760|Procedure|Light Intensity Training|Home-based Light Intensity Training three-five times weekly for 52 weeks.
1626863|NCT02034760|Dietary Supplement|Protein Whey|Two daily 20g whey protein and 10g carbohydrate supplementations for 52 weeks.
1626864|NCT02034760|Dietary Supplement|Protein Collagen|Two daily 20g collagen protein and 10g carbohydrate supplementations for 52 weeks.
1626865|NCT02034760|Dietary Supplement|Carbohydrate|Two daily 30g carbohydrate supplementations for 52 weeks.
1626866|NCT02034747|Drug|Advagraf|oral
1626867|NCT02034747|Drug|Corticosteroid|oral
1626868|NCT02034734|Drug|ASP3652|oral
1626869|NCT02034721|Dietary Supplement|Protein supplement|24 g protein before, 12 g during, and 24 g after eccentric exercise
1626870|NCT02034721|Dietary Supplement|Placebo|Placebo
1626871|NCT02034708|Drug|Dotarem®|Dotarem® 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus.
1626872|NCT02034708|Drug|Gadovist®/Gadavist®|Gadovist®/Gadavist®, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus.
1626875|NCT02034669|Device|Laminectomy|surgical laminectomy with glial scar resection
1626877|NCT02034669|Device|Intrathecal|ADSCs Intrathecal into lumbar puncture
1626878|NCT02034669|Device|Intravenous|ADSCs intravenous
1626879|NCT02034643|Procedure|balloon pressure adjustment|Tracheal cuff pressure was adjusted to 18 mmHg (25 cmH2O) before TEE probe insertion
1626880|NCT02034630|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
1626881|NCT02034617|Behavioral|LiMoNid|One LiMoNid observation will be performed on day 1-3 post birth, one in time of discharge, and one in the home when the infant has reached 40 weeks (+/- 2 week). All observations are performed in presence of and in collaboration with the parents with the outspoken aim to guide the parents to learn how to read and respond to their infant' signals
1626882|NCT02034604|Drug|Naftofidil|
1626883|NCT02034604|Drug|Tamsulosin|
1626884|NCT02034591|Drug|Apixaban|
1626885|NCT02034591|Dietary Supplement|Boost Plus|
1626886|NCT02034578|Drug|Apixaban|
1626887|NCT02034565|Drug|Apixaban|
1626888|NCT02034552|Drug|Radium-223 dichloride (Xofigo,BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg (55 kBq/kg after implementation of NIST update) every 4 weeks x 6 doses intravenous slow bolus
1626889|NCT02034552|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) taken orally once daily for up to two years following last dose of radium-223 dichloride
1626890|NCT02034552|Drug|Prednisone|Prednisone 5 mg capsule taken orally twice daily for up to two years following last dose of radium-223 dichloride
1626891|NCT02034552|Drug|Enzalutamide|Enzalutamide 160 mg (four 40 mg capsules) taken orally once daily for up to two years following last dose of radium-223 dichloride
1626892|NCT02034539|Device|VADOplex system|intermittent automatic pneumatic compression of the sole of the foot by the VADOplex system
1626893|NCT02034526|Device|DDDR-60|DDDR, lower pacing rate 60 bpm, RR activated (low-moderate)
1626894|NCT02034526|Device|DDD-40|DDD, lower pacing rate 40 bpm, RR function off
1626895|NCT02034513|Drug|insulin degludec|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
1626896|NCT02034513|Drug|insulin glargine|Administered once daily, injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
1626897|NCT02034513|Drug|insulin aspart|Administered 2-4 times daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
1626900|NCT02034487|Other|retrospective data collection|
1626901|NCT02034474|Drug|Tocilizumab|8mg/kg intravenously via iv drip over 60 min
1626902|NCT02034474|Drug|Placebo|intravenously via iv drip over 60 min
1626903|NCT02034461|Device|Utah Slanted Electrode Array|This study is using the microelectrode array device for scientific purposes only. This device will not be promoted or test marketed, and is not available for commercial distribution. There will be no costs to the participants for this device. This study is not aimed at collecting data for pre-market approval.
1626904|NCT02034448|Procedure|Continuous Renal Replacement Therapy|
1626905|NCT02034435|Other|glucose and insulin testing|
1626906|NCT02034422|Dietary Supplement|Oral Antioxidant|Consisting of vitamins C, E and alpha lipoic acid.
1626907|NCT02034422|Other|Exercise rehabilitation|8 weeks of exercise rehabilitation
1626910|NCT02034396|Procedure|Blood Draw|One blood draw at enrollment
1626911|NCT02034383|Other|Control|Controlled diet for 3 weeks with 0 servings/day of almonds.
1626912|NCT02034383|Other|Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of whole, natural almonds.
1626913|NCT02034383|Other|Roasted Whole Almonds|Controlled diet for 3 weeks with 1.5 servings/day of roasted whole almonds.
1626914|NCT02034383|Other|Diced Almonds|Controlled diet for 3 weeks with 1.5 servings/day of diced almonds.
1626915|NCT02034383|Other|Almond Butter|Controlled diet for 3 weeks with 1.5 servings/day of almond butter.
1626916|NCT02034370|Device|Lung-function spirometry test|5 minute lung function test performed once preoperatively and once postoperatively
1626917|NCT02034370|Device|Overnight sleep test|Somte sleep monitor to be worn two nights before and the night of surgery.
1626918|NCT02034357|Other|Neurocognitive function|Each eligible participant will complete a neuro-cognitive assessment as measured by CVLT at the beginning of the study. Neurocognitive evaluations will be repeated at 4-month and 1-year follow-up.
1626919|NCT02034357|Other|Sleep evaluations|Each eligible participant will complete sleep questionnaires and undergo a baseline sleep study at the beginning of the study. The sleep questionnaires will be repeated at 4-month and 1-year follow-up.
1626920|NCT02034344|Procedure|Skin biopsy|Participants with LE will have 2 adjacent 4 mm punch biopsies collected from involved and uninvolved skin at one timepoint and again from the involved skin site approximately 12 weeks later. Healthy participants will have 2 adjacent 4 mm punch biopsies taken at one timepoint.
1626921|NCT02034344|Procedure|Blood collection|Blood for serum analyses will be taken from all participants. Blood for DNA analysis will only be taken from participants who consent to this separately.
1626922|NCT02034344|Procedure|Urine collection|Urine will be collected from all participants.
1626923|NCT02034331|Drug|Insulin iontophoresis|For insulin iontophoresis, the cathode electrode will contain 0.2 ml of liquid insulin. For preparation and instrumentation, the arms will be uncovered below the elbow; the participant's lower extremities will be uncovered below knee for leg evaluations. The laser Doppler flowmetry (LDF) lead will be placed bilaterally, 2 inches proximal to the lateral malleolus over the peroneus longus muscle. For arm evaluations, a lead will be placed (and secured with dual-sided transparent tape) bilaterally, 2 inches distal to the lateral epicondyle over the flexor carpi ulnaris muscle along the midline with the ulnar process. Baseline and peak cutaneous blood flow responses to application of insulin iontophoresis will be determined for each LDF lead during the evaluation.
1626960|NCT02034032|Procedure|Regenexx SD|stem cell treatment
1626961|NCT02034032|Behavioral|Exercise Therapy|exercise therapy control
1626924|NCT02034331|Drug|Placebo Iontophoresis|For placebo iontophoresis, the cathode electrode will contain 0.2 ml of preservative-free normal saline; the anode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
1626925|NCT02034331|Drug|Acetylcholine Iontophoresis|For acetylcholine iontophoresis, the anode electrode will contain 0.2 ml of 1% acetylcholine chloride; the cathode electrode will contain a medical grade adhesive for skin placement and last 20 minutes. Preparation, instrumentation and data collection for this intervention are the same as the insulin iontophoresis.
1626926|NCT02034331|Other|Heat application|For the provocation with heat, an insulated thermal heat pack (~106°F) will be applied to the exposed arm or leg for 18 minutes. The thermal heat pack is comparable to what is routinely used as a heat therapy in conventional rehabilitation settings. LDF leads and temperature sensors will be placed in the previously specified locations to evaluate the changes.
1626927|NCT02034292|Drug|Clopidogrel|
1626928|NCT02034292|Drug|Aspirin|
1626929|NCT02034292|Drug|APD791|
1626930|NCT02034292|Drug|Placebo|
1626931|NCT02034279|Drug|Albumin|Intravenous infusion of 20% albumin
1626932|NCT02034266|Dietary Supplement|Omega-3 supplementation|5 mL twice daily, administered under the tongue
1626933|NCT02034253|Drug|Risperidone|Patients with psychosis will be provided a 16 week regimen of the antipsychotic drug Risperidone in accordance with standard care.
1626934|NCT02034227|Drug|SG2000|intravenous doses given on Days 1, 2, and 3 of each 21-day cycle (1 to 6 cycles).
1626935|NCT02034214|Behavioral|Life skills education|The life skills curriculum drew upon Stepping Stones and CDC-Zimbabwe Talk Time, developed with input from the target population. It consisted of 14 modules delivered to groups of 25 over 4-6 weeks on: HIV/STI and reproductive health; relationship negotiation; strategies to avoid violence;and identification of safe and risky places in the community. Participants also attended a six-weeks-long home-based care training conducted through Red Cross Zimbabwe, to gain skills on safely caring for people living with HIV.
1626936|NCT02034214|Other|Reproductive health services|All participants were provided a health screening at every study visit and were treated for treatable STIs and minor ailments. They received condoms, and contraceptive pills or injectable free upon request. Participants who tested positive for HIV were referred to local clinics, where the study team assisted with ART registration including payment for CD4 tests required for enrolment.
1626937|NCT02034214|Behavioral|Economic livelihoods|The Livelihoods intervention consisted of financial literacy and a choice of vocational training at local training institutes. Courses were 6-months-long, conducted in English, with a practical and a theoretical component. In spite of encouragement to venture outside of accepted gender norms, the most popular courses were hairdressing, garment-making, and receptionist/secretarial and nurse-aid training. Participants who passed developed business plans that were supported with a micro-grant valued at $100US in the form of capital equipment, supplies or additional training.
1626938|NCT02034201|Drug|Lisdexamfetamine|
1626939|NCT02034201|Drug|Placebo|
1626940|NCT02034188|Biological|Umbilical cord mesenchymal stem cells|
1626941|NCT02034162|Drug|Mebendazole|Mebendazole will be administered as a single-dose 500 mg chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
1626942|NCT02034162|Drug|Placebo|Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to <36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
2011370|NCT02588001|Drug|Enzalutamide|All patients will receive enzalutamide 160 mg (four 40 mg capsules) orally once daily. The treatment will be started at Visit 0 within one week after enrollment. Visit 1 is at 2 weeks after the treatment started; clinical assessments are conducted on adverse events and the Japanese version of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scales. Patients who are considered to be adequate by the investigator can continue the treatment with 12-week cycle visit (counted from initial dose) until patients meet withdrawal criteria. Patients will be followed up at 2 and 3 years after enrollment and at 3 years after the last participant enrollment.
2011371|NCT02584634|Drug|Avelumab|Administered by IV once every two weeks in doses of either 5 mg/kg or 10 mg/kg
1626946|NCT02034136|Dietary Supplement|Ginsenoside|3.0 g/ d for 28 days
1626947|NCT02034136|Dietary Supplement|Dietary fiber fill|3g/day, 28days
1626948|NCT02034123|Drug|GSK2879552|Subjects will receive GSK2879552orally with approximately 200 milliliter (mL) of water.
1626949|NCT02034110|Drug|Dabrafenib|Dabrafenib is a 150 mg twice daily capsule administered orally on a continuous basis.
1626950|NCT02034110|Drug|Trametinib|Trametinib is a 2 mg once daily tablet administered orally on a continuous basis.
1626951|NCT02034097|Drug|Foretinib|Round yellow tablet containing 15 mg of foretinib will be orally administered in a dose level of 45 mg (3 x 15 mg) or 60 mg (4 x 15 mg) OD until disease progression
1626952|NCT02034097|Drug|Erlotinib|Round white tablet containing either 25 mg, 100 mg, or 150 mg of erlotinib will be orally administered in a dose level of 150 mg OD until disease progression
1626953|NCT02034084|Procedure|left radial approach|Coronary diagnostic procedures performed through left radial approach
1626954|NCT02034084|Procedure|Right radial approach|coronary diagnostic procedures performed through right radial approach
1626955|NCT02034071|Drug|DCCR|
1626956|NCT02034071|Drug|Placebo|
1626957|NCT02034058|Device|Wingspan Stent System|The Wingspan Stent System is used with the Gateway PTA Balloon Catheter. The Wingspan Stent System is a self-expanding, Nitinol stent and delivery system intended for use in the treatment of intracranial atherosclerotic disease. The Gateway PTA Balloon Catheter is an over-the-wire balloon catheter intended for the pre-dilation of the lesion prior to insertion and deployment of the Wingspan Stent System.
1626958|NCT02034045|Other|Community Paramedicine|
2011372|NCT02584634|Drug|PF-06463922|Tablets taken orally once every day in doses of either 100mg, 75mg, or 50mg.
1626965|NCT02033993|Drug|Nab-Paclitaxel|
1626966|NCT02033993|Drug|Paclitaxel|
1626967|NCT02033980|Device|NBI|All detected colorectal lesions will be examined by high-definition NBI. For type 2 and type 3 lesions, subsequent magnifying NBI examination will be performed.
1626968|NCT02033967|Procedure|vasodilator induced hypovolemia|
2011373|NCT02584634|Drug|Crizotinib|Capsules. Taken orally once or twice every day in doses of either 200mg or 250mg.
2011374|NCT02583867|Behavioral|Exercise|Subjects will engage in supervised exercise sessions for 12 weeks. Each week will consist of at least three exercise sessions with a total duration of weekly exercise of approximately 150 minutes.
1626971|NCT02033915|Other|Interactive discussion group|The investigators adopt the group intervention that provide interactive discussions regarding the assessment of suicide risk among inpatients in a general hospital.
1626972|NCT02033902|Drug|Perampanel|Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment
1626973|NCT02033889|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg orally (1 ertugliflozin 5 mg tablet and 1 placebo ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
1626974|NCT02033889|Drug|Ertugliflozin 15 mg|Ertugliflozin 15 mg orally (1 ertugliflozin 5 mg tablet and 1 ertugliflozin 10 mg tablet), once daily from Day 1 to Week 104.
1626975|NCT02033889|Drug|Placebo to Ertugliflozin|Placebo to ertuglioflozin (1 placebo ertugliflozin 5 mg tablet and/or 1 placebo ertugliflozin 10 mg tablet), orally once daily from Day 1 to Week 104.
1626976|NCT02033889|Other|Glimepiride|Glimepiride will be used for glycemic rescue therapy (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride) in the 26-week initial period. Blinded Glimepiride (up to a maximum of 6 or 8 mg per day, based on the local label of glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of blinded glimepiride is at the discretion of the investigator.
1626977|NCT02033889|Drug|Placebo to Glimepiride|Placebo to glimepiride will be used in the 78-week extension period in participants who were not rescued with open-label glimepiride during the 26-week initial period. Dosing and titration of placebo to glimepiride is at the discretion of the investigator.
1626978|NCT02033889|Biological|Basal Insulin|Basal insulin will be used for participants requiring rescue therapy in Phase B. Dosing and titration of basal insulin is at the discretion of the Investigator.
1626979|NCT02033889|Drug|Metformin|Metformin >=1500 mg/day, orally, once a day
1626980|NCT02033876|Drug|Ursodiol|
1626981|NCT02033850|Behavioral|Attention Process Training-II|Rehabilitation of attention using the Attention Process Training-II
1626982|NCT02033824|Other|dHACM|A piece of dHACM placed over any dural defect or dural closure during craniectomy.
1626983|NCT02033824|Procedure|Craniectomy|Removal of the skull flap followed by closure techniques per current SOC.
1626984|NCT02033798|Drug|Tamsulosin|Once Daily 0.2mg per oral for 6 months
1626985|NCT02033772|Procedure|Thoracoscopic surgery|
1626986|NCT02033759|Device|Bio-Impedance Testing|Participants in the BIA Arm will also undergo bio-impedance testing with this device.
1626987|NCT02033759|Other|Anxiety Questionnaire|21 item questionnaire
1626988|NCT02033759|Other|Traditional Circumferential Measurements|
1626989|NCT02033746|Device|Han's Acupoint Nerve Stimulator|frequency delivery(3 seconds of 2 Hz followed by 3 seconds of 100 Hz(dense disperse method).
1626990|NCT02033733|Drug|Cisatracurium infusion|"This group will include postcardiac arrest patients that have received a cisatracurium infusion as part of their therapeutic hypothermia protocol. It will only include patients that had their infusion started within 2 hours from protocol initiation. Patients that received an infusion as a rescue measure (beyond the first 2 hours) or did not receive and infusion at all will not be included in this group.
Most patients admitted to our ICU postcardiac arrest prior to October 2011, will likely belong to this group (the cisatracurium infusion group)."
1626991|NCT02033733|Drug|Cisatracurium prn bolus|Patients that have not received a cisatracurium infusion within the first 2 hours from protocol initiation will be in this group. These are likely to be patients admitted to our ICU after October 2011 (when the protocol change happened).
1626992|NCT02033720|Other|No treatment|No therapeutic hypothermia was induced.
1626993|NCT02033720|Other|Therapeutic hypothermia|Hypothermia was induced after successful resuscitation from cardiac arrest.
1626994|NCT02033707|Drug|Hallucinogens and psychoactive substances|"One of the following or placebo will be given:
Hallucinogens: DMT, 4-phosphoryloloxy-N-diethyltryptamine, dipropyltryptamine (DPT), ketamine, dextromethorphan, mescaline, PCP, psilocybin, salvinorin-A, LSD, d-lysergic acid amide (LSA), MDMA, cannabis
Sedatives/anxiolytics: alprazolam, diazepam, lorazepam, secobarbital, temazepam, triazolam, zolpidem
Antihistamines: diphenhydramine, chlorpheniramine
Stimulants: d-amphetamine, caffeine, ephedrine, methylphenidate, diethylproprion
Opioids: heroin, morphine, oxycodone, hydrocodone, methadone, codeine
Other: alcohol, scopolamine, nicotine
Each volunteer will receive a hallucinogen on at least one of five sessions. More drugs are listed than will be administered to increase the degree to which volunteers are blind to the drugs being studied. It is important that the volunteer and research staff be blinded to specific drug conditions to minimize confounding the results with expectations about the nature of drug effects."
1626995|NCT02033681|Procedure|"One-per-mil Tumescent Solution Injection"|"One-per-mil tumescent solution containing 1:1,000,000 epinephrine concentration in saline solution, is injected to the finger."
1626996|NCT02033681|Procedure|Saline Solution|Saline solution is injected into the tissue as a placebo control.
1626997|NCT02033668|Drug|GSK933776 for SQ administration|Antibody solution for subcutaneous injection with unit dose strength of 50mg/mL administered as 200 mg single dose or as repeat dose of 50 mg weekly for 4 weeks
1626998|NCT02033668|Drug|GSK933776 for IM administration|Antibody solution for intramuscular injection with unit dose strength of 50mg/mL administered as 200 mg single dose
1627587|NCT02029196|Other|Conventional cigarette|Smokers of conventional cigarettes who continue smoking conventional cigarettes.
1626999|NCT02033668|Drug|GSK933776 for IV administration|Antibody solution for intravenous injection with unit dose strength of 50mg/mL administered as 200 mg single dose through an IV catheter over approximately 1 hour
1627000|NCT02033655|Dietary Supplement|Protein supplementation|> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from lean pork.
1627001|NCT02033655|Behavioral|Diet counseling and group education lessons|Participants meet once a week for 6 months to participate in group lessons and counseling.
1627002|NCT02033642|Behavioral|Family Based Behavioral Intervention|Family Based Behavioral Intervention (FBBI) is a 24-session lifestyle intervention designed to train parents or family members of adolescent/young adult participants with intellectual disability to monitor diet and physical activity behavior, set goals, provide support and reinforcement, and assess and make changes to the home environment.
1627003|NCT02033642|Behavioral|Maintenance|The Maintenance condition in this study is a 12-session intervention for parent/family member of adolescents with intellectual disability, designed to teach families to continue lifestyle behaviors, generalize healthful behaviors to new environments, find additional social and community supports and prevent relapse.
1627004|NCT02033629|Drug|Ce 1 ng/ml|TCI Remifentanil Ce 1 ng/ml
1627005|NCT02033629|Drug|Ce 2 ng/ml|TCI Remifentanil Ce 2 ng/ml
1627006|NCT02033629|Drug|Ce 3 ng/ml|TCI Remifentanil Ce 3 ng/ml
2011375|NCT02581878|Drug|BAY1862864|Radiopharmaceutical, injection Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. In this dose-escalation part of the study, the radioactivity dose will start at 1.4 MBq and increase in steps of 1.4 MBq, with a protein dose of 2 or 10 mg.
2011376|NCT02581878|Drug|BAY1862864|Radiopharmaceutical, injection Up to four treatment cycles lasting six weeks each; in each cycle, a single treatment on Day 1. The dose for this expansion part of the study will be selected on the basis of all available information from the dose-escalation part and will not necessarily be the MTD.
1627009|NCT02033603|Drug|Ropivacaine|30mls of 0.5% ropivacaine
2011377|NCT02581137|Other|Laboratory Biomarker Analysis|Correlative studies
1627011|NCT02033577|Procedure|Distal gastrojejunal bypass|RYGB with 200 cm BP limb and 150 cm common limb, effect on EWL, QoL and complications
1627012|NCT02033577|Procedure|RYGB|RYGB with 60 cm BP limb and 150 cm alimentary limb, effect on
1627013|NCT02033564|Device|Macintosh/Miller Laryngoscope|
1627014|NCT02033564|Device|Glidescope Laryngoscope|
1627015|NCT02033551|Drug|Veliparib|
1627016|NCT02033551|Drug|Carboplatin|
1627017|NCT02033551|Drug|Paclitaxel|
1627018|NCT02033551|Drug|FOLFIRI|combination of Fluorouracil, leucovorin and irinotecan
1627019|NCT02033538|Drug|nanoparticle albumin-bound paclitaxel|Paclitaxel protein-bound particles for injectable suspension (albumin-bound) 125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
1627020|NCT02033525|Drug|XCEL-M-ALPHA and standard rehabilitation|Intraarticular infusion of autologous bone marrow derived ex vivo expanded mesenchymal stromal cells produced at Xcelia (Advanced Therapies Division of the Blood and Tissue Bank)
1627021|NCT02033525|Other|Rehabilitation|Standard rehabilitation program
1627022|NCT02033512|Drug|Transdermal Hormone Replacement Therapy|"The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal progesterone was prescribed. The patients were evaluated 3 months after THRT treatment protocol.
All the patients were instructed about how to use the progesterone pump for transdermal application, performed in the presence of an experienced physician, in order to guarantee standardization and correct use of the THRT. Compliance was defined as completing seventy percent or more of the transdermal applications."
1627023|NCT02033512|Drug|Transdermal Nanoformulation|The Blood samples were collected from the subjects early in the morning after an overnight fast. After serum testing, the identification hormone deficiencies, was determined and then, if necessary, additional transdermal hormones were prescribed.
1627024|NCT02033512|Drug|Transdermal formulation|66 patients completed the study. In the present analysis, the subjects received daily in the right and left forearm a transdermal nanostructured formulation of Estriol (0.1%) + Estradiol (0.25%) and Progesterone (10%) respectively (Biolipid B2®, Evidence, SP, Brazil) for sixty months. The effects of transdermal hormone formulation were analyzed.
2011378|NCT02581137|Drug|Metformin Hydrochloride|Given PO
1627026|NCT02033486|Device|TOBI + DBT|
1627027|NCT02033473|Drug|Apelin|An apelin clamp in which an apelin infusion will be administered
1627028|NCT02033473|Drug|Placebo|A clamp reference during which a placebo solution (saline solution) will be administered
1627029|NCT02033460|Other|Manual Therapy and Education|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective will add to manual therapy treatment.
1627030|NCT02033460|Other|Manual Therapy|Manual therapy will consist on Traction oscillatory, Maintained traction in the craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral C1- C2 ( 2 minutes) , C2 -C3, and C5 -C6 and High-velocity technique in dorsal region.
1627031|NCT02033460|Other|Manual therapy, Education and Exercise|Manual therapy will consist on Traction oscillatory,craniocervical region, Mobilization of upper cervical region in flexion, Side glide roll, Mobilization upper cervical anteroposterior with Wedge, Sliding lateral techniques and High-velocity technique in dorsal region. And Education of the physiology of pain and Education about cognitive behavioral perspective and Craniocervical exercise will add to this arm.
1627032|NCT02033447|Other|Magnetic Nanoparticle Injection|
1627033|NCT02033434|Drug|Intranasal Ketamine|Atomized Intranasal Ketamine, 50mg
1627034|NCT02033408|Drug|AB (antibiotics)|"PO Vancomycin 250mgX4/d for 3 weeks
PO Amoxycillin 50mg/Kg divided by 3 (up to 500mgX3/d) - for 3 weeks
PO Doxycycline 2mg/kg X2/d (up to 100mgX2/d) - for 3 weeks; OR- For children younger than 8 years: PO Ciprofloxacin 10mg/Kg X2/2 (up to 250mgX2/d) for 3 weeks
Patients with known allergy to one of the drugs may be treated with oral Gentamycin (2.5mg/KgX3/d) for 3 weeks instead of the allergenic drug."
1627035|NCT02033408|Drug|CS (corticosteroids) Only|"methylprednisolone (1.5mg/kg up to 60mg daily in two divided doses)
PO Metronidazole 5mg/Kg X3/d (up to 250mgX3/d) - for 3 weeks"
1627037|NCT02033356|Procedure|Adductor canal block with lidocaine 1%|US-guided adductor canal block
1627038|NCT02033356|Drug|Lidocaine|
1627039|NCT02033343|Radiation|Prostate cancer radiotherapy using real-time tracking|Radiotherapy delivered using Calypso radiofrequency emitting beacon guided real-time prostate localisation and beam adjustment using Dynamic Multi-leaf Collimator tracking software.
1627040|NCT02033330|Dietary Supplement|phenolics form orange peel|
1627041|NCT02033317|Drug|patiromer|15 grams/day (5 grams 3 times daily) administered orally
1627042|NCT02033291|Procedure|Dynamic contrast enhanced Brain MRI|DCE-MRI is used to quantify the BBB permeability
1627043|NCT02033278|Drug|Infusion of autologous mononuclear bone marrow cells|Infusion of autologous mononuclear bone marrow cells more conventional medical treatment
1627044|NCT02033278|Drug|Placebo infusion|Placebo infusion more conventional medical treatment
1627045|NCT02033265|Procedure|Brachial plexus block|Ultrasound guided axillary brachial plexus block
1627046|NCT02033252|Device|Acupuncture|In the acupuncture treatment group, 10 acupuncture points (bilateral LI4, TE23, ST36, unilateral EHN-1, GV23, LI20 and LI4) will be inserted with 0.20 mm in diameter x 30 mm in length disposal needles. The needle will be inserted to a depth of 10 - 30 mm, according to the points selected. The participating acupuncture doctors will manually manipulate the acupuncture needles with de-qi sensation and maintain the needles for 10 minutes with two times of manual stimulation, at the beginning and at the end.
1627047|NCT02033239|Drug|Faster-acting insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
1627048|NCT02033239|Drug|insulin aspart|Subjects will receive different dose levels of faster acting insulin aspart and NovoRapid®. Single dose of trial products will be administered subcutaneously (s.c. under the skin).
1627049|NCT02033226|Device|Amniotic Membrane|AM strongly resembles the oral mucosal basement membrane and possesses several types of laminins, which can promote regeneration, accelerate tissue adhesion, and preserve tissues, all of which play a key role in improved healing of periodontal lesions and might result in reduction in probing pocket depth (PPD) and decrease in clinical attachment loss (CAL)
1627050|NCT02033226|Device|Control group (Hydroxyapatite only)|The placebo group was treated with Hydroxyapatite graft placement only.
1627051|NCT02033213|Other|Restrictive group|"A group of patients who received ≤ 8ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid administered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
1627052|NCT02033213|Other|Liberal group|"A group of patients who received > 8 ml/kg/h of intraoperative fluid during esophageal carcinoma surgery.
The fluid admnistered: Plasma-Lyte 148 (pH 7.4; Viaflo, Baxter, US), 10% Aminoven (Fresenius Kabi AG, Bad Homburg, Germany) at 0.5 ml/kg/h, 5 ml/kg of colloid (6% Voluven 130/0.4, Fresenius Kabi AG, Bad Homburg, Germany), packed red blood cells."
1627053|NCT02033200|Drug|Stendra 200 mg|
1627054|NCT02033200|Drug|Placebo|
1627055|NCT02033187|Other|Chlorhexidine bathing|Patients in an ICU randomized to treatment arm 1 will be bathed with single use, no rinse, disposable cloths impregnated with 2% chlorhexidine gluconate solution (Sage® 2% Chlorhexidine Gluconate Cloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current practice in each intensive care unit.
1627056|NCT02033187|Other|Non-chlorhexidine bathing|Patients in an ICU randomized to treatment arm 2 will be bathed with single use, no rinse, disposable cloths that do not contain chlorhexidine gluconate solution (Sage Comfort Bath® Cleansing Washcloths). Bathing of the skin of the arms, chest, abdomen, back, both legs, perineum, and buttocks will be performed daily and as needed after patients become soiled. The face and neck will not be bathed in this manner but will be bathed with water-moistened washcloths. All other infection control and cleaning procedures will be performed per the current protocols in each intensive care unit.
1627057|NCT02033174|Other|Oral fat diet plus water with sugar|All participants were assigned to receive and oral fat diet plus sugar water. Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. Sugar water has equivalent caloric intakes as alcoholic beverages.
1627058|NCT02033174|Other|Oral fat diet plus alcoholic beverages|Oral fat diet contained 1487 kcal/m2 with 654 kcal/m2 (44%) as fat. In all cases, alcohol represented a daily total amount of 16 g/m2. The content of alcohol was 12% in red wine, 37% in rum, and 35% in brandy.Vodka was tri-distilled and contained 40% alcohol.
1627059|NCT02033161|Behavioral|Internet-delivered CBT|"The internet-treatment consisted of six modules during 8 weeks. Part 1: education about FGID and the treatment model. Part 2: individual symptom behavior. Part 3: toilet habits, or other common symptom behavior. Part 4 and Part 5: Exposure during 4 weeks. Part 6: relapse prevention.
Parents received four modules over 8 weeks consisting of psycho-education about FGID and the treatment model, increased positive time with the child in order to reduce attention to pain, parental symptom behavior, support child exposure and relapse prevention.
The therapists gave feedback weekly . All participants had at least 1 telephone call from their therapist during the fifth and sixth week of treatment."
1627060|NCT02033148|Drug|icotinib hydrochloride|Given PO
1627061|NCT02033148|Other|laboratory biomarker analysis|Correlative studies
1627062|NCT02033148|Other|pharmacological study|Correlative studies
1627063|NCT02033135|Procedure|Angioplasty with Zilver PTX|Angioplasty and stenting with a polymer free paclitaxel-eluting stent (Zilver-PTX)
1627064|NCT02033135|Other|Best medical treatment|Treatment with antiplatelet and statins, smoking cessation advice and unsupervised walking exercise.
1627065|NCT02033135|Device|Zilver PTX|
1627066|NCT02033122|Other|Aerobic training|the intervention will be an aerobic training program. For the TG subjects, breathing exercises will have duration of 30 minutes and will be always followed by aerobic training sessions that will consist in 35 minutes divided in 5 minutes of warm-up, 25 minutes of aerobic training and 5 minutes of cool down. Initially, aerobic training will be performed at the heart rate (HR) corresponding to one third of the difference between the anaerobic threshold (AnT) and the respiratory compensation point (RCP) obtained in the incremental cardiopulmonary testing (CPET) and after two weeks of the adaptation, the intensity will increased to two thirds of the difference between AnT and RCP. The program will be performed twice a week, for 3 months.
1627067|NCT02033122|Other|Breathing exercise|Patients from the control group will be taught breathing exercises with 30 min per session , twice a week , during 3 months. Every exercise will be performed in sets of 3 (2 min each) and 60 s of rest .
1627068|NCT02033109|Drug|PC-1005|Intravaginal use
1627069|NCT02033109|Drug|HEC gel|
1627070|NCT02033096|Drug|stannsoporfin|
1627071|NCT02033083|Device|Laminaria|
1627072|NCT02033083|Device|Dilapan-S|
1627073|NCT02033057|Procedure|Muscular electrostimulation and percutaneus muscular biopsy.|Muscular electrostimulation everyday and percutaneus muscular biopsy weekly.
1627074|NCT02033044|Other|cognitive remediation|Cognitive Rehabilitation (CR). Consisted on group sessions (5 individuals per group) of 120-minutes, twice a week during a total period of 16 weeks (32 sessions). The exercises addressed neurocognitive issues related to sustained attention, processing speed, memory and executive functioning. The whole program aimed at getting new strategies to improve functional adaptation, thus tasks were carried out in the clinical setting and at home. Some homework tasks were based on their daily life difficulties and problems. The main objective of this program was the generalization of rehabilitated cognitive functions to daily life activities. Most of the techniques were based on a previous program for bipolar disorder.
1627075|NCT02033044|Other|Psychoeducation|Psychoeducation (PE). The psychoeducation intervention consisted of 16 weekly group sessions of 5 individuals of 120 minutes each (16 sessions). This therapy aimed at improving illness' consciousness , interpersonal abilities, family balance, therapeutical adherence, emotional management in frustrating situations, problems resolutions, and lifestyle regularity. On this intervention, no homework tasks were required. This intervention was based on the Systems Training for Emotional Predictability and Problem Solving (STEPPS) program therapy.
1627076|NCT02033031|Drug|Lucentis intravitreal injection|Lucentis intravitreal injection
1627077|NCT02033031|Drug|Avastin intravitreal injection|Avastin intravitreal injection
1627078|NCT02033018|Drug|Aflibercept Injection|Aflibercept intravitreal injection
1627079|NCT02032979|Behavioral|Psychiatric test|
1627080|NCT02032966|Procedure|Nonsurgical|"Randomized to nonsurgical: patient will receive surgical treatment of the inside portion (medial malleolus) of the tibia fracture only; the fibula fracture (and posterior malleolus fracture, if present) will be closed reduced (not repaired surgically)."
1627081|NCT02032966|Procedure|Surgical|"Randomized to surgical: patient will receive surgical treatment of both the inside portion (medial malleolus) of the tibia fracture, as well as the fibula fracture (lateral malleolus). Fixation of the posterior side of the tibia (posterior malleolus) may or may not be performed based upon intraoperative x-rays."
1627082|NCT02032953|Dietary Supplement|Travasol (amino acid injection)|an amino acid supplementation infused intravenously containing essential and non-essential amino acids
1627083|NCT02032953|Drug|Insulin|After the insertion of an arterial catheter and obtaining a baseline arterial blood glucose value, 2 units of insluin will be administered iv followed by an infusion of 2 microunits/kg*min. Ten minuts after starting the insulin, and when the the blood glucose is<6 mmol/L, dextrose 20% supplemented with phosphate (30mmol/L) will be infused. Blood glucose levels measured every 15 minutes and the dextrose infusion rate adjusted to maintain arterial glycemia between 4 and 6 mmol/L until end of study.
1627084|NCT02032927|Drug|Codeine/paracetamol|"Randomization to one of the two treatments will be done through appropriate randomization list.
During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.
The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
1627085|NCT02032927|Drug|Oxycodone/naloxone|"Randomization to one of the two treatments will be done through appropriate randomization list.
During the first 15 days of treatment in the event of failure of efficacy, understood as the average pain intensity higher than 4 (monitored with NRS) with the need to take more than two rescue doses of paracetamol per day, and in the absence of side effects, the patients will be instructed on how to proceed with dosage adjustments according to specific guidelines.
The patient will be evaluated at 15 days, 1 month, 2 months and three months. Your health care professional who administer the assessment scales (WOMAC, SF-12, BFI, TMT) will not know in any way which treatment the patient is taking."
1627086|NCT02032901|Drug|Daclatasvir|
1627087|NCT02032901|Drug|Sofosbuvir|
1627088|NCT02032888|Drug|Daclatasvir|
1627089|NCT02032888|Drug|Sofosbuvir|
1627090|NCT02032875|Drug|Daclatasvir|
1627091|NCT02032875|Drug|Sofosbuvir|
1627092|NCT02032875|Drug|Ribavirin|
1627093|NCT02032862|Drug|Sage extract, 3400 mg , DER 1:17|
1627094|NCT02032849|Procedure|Manual air-impingement operation|A method which we invented to clear subglottic secretion
1627095|NCT02032849|Device|subglottic secretion drainage|The conventional method with a special tube to drainage subglottic secretion
1627249|NCT02031614|Procedure|Phlebotomy|Withdrawal of 500 mL of whole blood.
1650768|NCT01849770|Drug|Mexiletine|
1627100|NCT02032810|Drug|Panobinostat|Participants will be assigned to receive a certain dose of panobinostat (5, 10, 15, or 20 mg). The dose of panobinostat will depend on the time point the participant enters the study and the side effects of other participants already on the study.
1627101|NCT02032810|Drug|Ipilimumab|Dose of ipilimumab of 3 mg per kg (mg/kg) of body weight.
1627102|NCT02032797|Drug|Progesterone|
1627105|NCT02032771|Device|M22 IPL and ResurFX|The procedure will include an intense pulse light (M22 IPL) treatment followed by fractional non-ablative (M22 ResurFX) treatment.
1627106|NCT02032758|Drug|Propranolol|Single oral dose of 10 mg propranolol
1627107|NCT02032758|Device|Opal Device|The Opal Device (APDM, Inc.) will be used to measure wrist movement.
1627108|NCT02032758|Procedure|Science and Motion PuttLab (SAM)|The SAM will be used to study putter stroke movement and ball movement.
1627109|NCT02032758|Device|Surface Electromyography EMG|The surface EMG will be used to evaluate co-contraction of the wrist flexor/extensor muscle groups and the wrist pronator/supinator muscle groups.
1627110|NCT02032732|Other|leukocyte esterase test|leukocyte esterase test on fluid removed by intra-articular aspiration
1627111|NCT02032719|Behavioral|smartphone-assisted health coaching|smartphone with software provides self monitoring of exercise, diet and stress reduction; provision of timely reminders; photo-journaling of meals; secure text messaging
1627112|NCT02032719|Behavioral|Lifestyle counseling|Lifestyle counseling
1627113|NCT02032706|Device|Deliver therapy when the supine position is detected|Application of vibrotactile feedback to the neck when the supine position is detected
1627114|NCT02032693|Dietary Supplement|Everycell™|
1627115|NCT02032693|Other|Placebo|
1627116|NCT02032680|Behavioral|Web-based multi-family psychoeducational treatment|This intervention uses a website to provide multi-family psychoeducational treatment to Veterans and their family members or other supporters.
1627117|NCT02032680|Behavioral|In-persons multi-family psycho-educational treatment|This intervention will provide the VA's evidence-based, in-person delivered, multi-family psychoeducational treatment, termed Multi-Family group (MFG). This intervention is delivered to Veterans and their families or other supporters using an in-person format.
1627118|NCT02032680|Other|Treatment as usual (TAU)|Treatment as Usual (TAU) is considered the usual care at the VA. Participants assigned to be in the Treatment as Usual arm will complete assessments at all data collection time points, (baseline, 6, 12, and 15 months.) These participants will not receive any study treatment but will continue to receive their treatment as usual through the VA.
1627119|NCT02032667|Behavioral|Multi-player condition|Children in the multi-player condition will be able to play with and compete against other children in real time.
1627122|NCT02032641|Device|Laser treatment|Non-ablative, non-fractional, microsecond-pulsed Nd:YAG laser 500-1000 pulses, 0.3 msec pulse duration, 10-14 J/cm2, 5 mm spot size
1627123|NCT02032628|Behavioral|Exercise|The investigators will measure changes in DNA methylation as a result of four different intervention groups, i.e, high/longer, low/longer, high/shorter, low/shorter.
1627124|NCT02032615|Dietary Supplement|Education plus Gudness Nutritional Bar|
1627125|NCT02032615|Other|Education|
1627126|NCT02032602|Other|Deep Dry Needling|
1627127|NCT02032589|Behavioral|Self-generation treatment|self-generation treatment is a cognitive rehabilitation strategy aimed to improve memory. The self-generation strategy treatment, embedded within practice of various activities will consists of six individualized intervention sessions administered over 2-3 weeks
1627128|NCT02032576|Device|ECT for depressed patients|electroconvulsive therapy with a bipolar brief pulse square wave
1627129|NCT02032563|Drug|Indocyanine Green|intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
1627130|NCT02032550|Other|Preference Based Decision Aid|The objective of the preference based decision aid is to assess the treatment preferences of prostate cancer patients. The investigators will analyze the association between preferences, treatment choice and objective and subjective outcomes. The preference based decision aid will lead to a values-based patient centered treatment decision making. This will ultimately improve clinical decision making, clinical policy process, enhance patient centered care and improve prostate cancer outcomes.
1627131|NCT02032537|Drug|Callmax cream application over affected skin|Callmax cream application over affected skin Callmax cream or topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity.
1627132|NCT02032537|Drug|Placebo|Topical water containing emollient (placebo) will be applied by the patient on the affected skin area whenever the pruritus starts including night time. The frequency of application will be regulated by individual patients and increased according to pruritus severity. The data on efficacy, duration of effect and frequency of application will be collected.during the study.
1627133|NCT02032524|Drug|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
1627134|NCT02032498|Drug|Indocyanine Green|Superficial injection of ICG in combination with deep injection of 99mTc-HSA to evaluate the complementarity of the two techniques
1627135|NCT02032485|Drug|Indocyanine Green|An iv injection will be performed for the colorectal cancer patient before the operation.
1627136|NCT02032472|Other|Measurement of Arterial Pressure|Pharmacies cooperate in measuring blood pressure of patients
1627137|NCT02032446|Biological|UMBILICAL CORD DERIVED MESENCHYMAL STROMAL CELLS (UC-MSC)|"pentostatin, dose 1 mg/m2
§ MSC doses:
3 patients → 3 infusions of 1x106 cells /kg
3 patients → 3 infusions of 2x106 cells /kg
3 patients → 3 infusions of 3x106 cells /kg"
1627138|NCT02032433|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®)
1627139|NCT02032433|Drug|Buprenorphine-Naloxone|Buprenorphine-Naloxone (Suboxone®)
1627140|NCT02032420|Behavioral|STAR|
1627141|NCT02032420|Behavioral|ART|
1627142|NCT02032407|Drug|Dapsone Gel|Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.
1627143|NCT02032394|Drug|Povidone-iodine|15 ml 10%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
1627144|NCT02032394|Drug|Chlorhexidine|15 ml .2%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
1627145|NCT02032394|Drug|Normal saline|15 ml .9%, 3 imes a day for 10 days /external use for Washing perinea area and catheter first 5 centimeters
1627146|NCT02032381|Other|late pulmonary complications occurring in children treated with allogeneic hematopoietic stem cells.|
1627147|NCT02032368|Procedure|transarterial chemoembolization (TACE)|
1627148|NCT02032355|Procedure|spinal anesthesia|
1627149|NCT02032342|Device|Endobronchial double lumen tube|Endobronchial double lumen tube for one lug ventilation
1627150|NCT02032342|Device|Arndt® blocker|Arndt® blocker for selective lobar deflation
1627151|NCT02032342|Device|Cohen blocker|Cohen blocker for selective lobar deflation
1627152|NCT02032342|Device|Fuji Uni-blocker|Fuji Uni-blocker foe selective lobar deflation
1627153|NCT02032329|Device|FastFES|Fast treadmill walking supplemented with FES to ankle plantarflexor and dorsiflexor muscles, using a VFT stimulation pattern. 12 weeks of 2-3x/week. Stimulation delivered using the customKYnetics study device.
1627154|NCT02032316|Device|Post-Ureteroscopy ADVA-Tec Uriprene™ Degradable Temporary Ureteral Stent|Renal stent placed after uncomplicated uteroscopy
1627155|NCT02032303|Procedure|Assessment of coronary flow reserve|
1627156|NCT02032303|Procedure|Percutaneous Coronary Intervention|
1627157|NCT02032303|Drug|Ticagrelor loading|
1627158|NCT02032303|Drug|Prasugrel loading|
1627159|NCT02032290|Procedure|Assessment of Coronary Flow Reserve|
1627160|NCT02032290|Procedure|Percutaneous coronary intervention|
1627161|NCT02032290|Drug|ticagrelor loading|
1627162|NCT02032290|Drug|Clopidogrel loading|
2011379|NCT02578758|Behavioral|Transdiagnostic internet-based protocol|Transdiagnostic internet-based protocol is an Internet-based Protocol for ED, which will allow the individual to learn and practice adaptive ways to regulate their emotions from a transdiagnostic perspective. The protocol contains the following components: present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention, which are organized in 12 modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; and Relapse Prevention.
1627170|NCT02032264|Other|Comprehensive Chromosome Screening|On day 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS), will be performed via next generation sequencing and results will be available at the time of study completion.
1627171|NCT02032264|Other|Morphologically Best|Patients in this arm of the study will not receive CCS in selection of their embryo for transfer. The best looking embryo (morphology) will be transferred
1627172|NCT02032251|Drug|oral administration of ginger|Oral administration of ginger in patients with infertility.
1627173|NCT02032251|Drug|Placebo|
1627174|NCT02032238|Device|laser photocoagulation|Standard bevacizumab Injections will be combined with laser photocoagulation in a pre-defined manner
1627175|NCT02032225|Other|Skin biopsy|
1627176|NCT02032212|Other|EVP unflavoured|
1627177|NCT02032212|Other|EVP flavoured|
1627178|NCT02032212|Other|Nicotine inhalator|15 mg nicotine Nicorette
1627179|NCT02032212|Other|Conventional cigarette|
1627180|NCT02032186|Drug|Magnesium citrate|Oral Mg++citrate, 160 mg twice daily. Each capsule will contained 160 mg of elemental magnesium citrate. The participants will be instructed to take one capsule twice daily until delivery.
1627182|NCT02032160|Biological|Engerix B IM injection - 20ug|Engerix B IM injection - 20ug At 0, 1 and 6 months
1627183|NCT02032160|Biological|Fendrix IM injection - 20ug|Fendrix IM injection - 20ug At 0, 1 and 6 months
1627184|NCT02032147|Drug|NGF group|This group will be treated with NGF 18u per day im for 60 days
1627186|NCT02032121|Procedure|Blood specimen|
1627187|NCT02032121|Procedure|Echocardiography|
1627188|NCT02032108|Behavioral|lifestyle counselling|"A 45-min lifestyle educational session will be delivered to the subjects randomized to the intervention group every month for one year.
Lifestyle intervention will consist in group counselling on dietary habits, effects of regular physical activity, importance of adherence to medications, diabetes complications, actions to control blood sugar and ways of coping with stress."
1627189|NCT02032095|Drug|GB-0998|
1627190|NCT02032082|Other|Carbone monoxide|
1627191|NCT02032069|Other|no intervention|
1627192|NCT02032056|Dietary Supplement|Probiotic (10^9 CFU/day)|
1627193|NCT02032056|Dietary Supplement|Probiotic (10^8 CFU/day)|
1627194|NCT02032043|Drug|Annual versus Semiannual Albendazole plus Ivermectin MDA|Annual or semiannual Albendazole plus Ivermectin, administered by the Ivorian Ministry of Health.
1627195|NCT02032017|Procedure|Ceramic on ceramic couple|All patients will get a standard total hip replacement (cementless hydroxyapatite coated cup and a titanium plasmasprayed stem) with a ceramic on ceramic (third generation biolox delta) couple. Preoperative leg length and offset are marked to reconstruct the preoperative leg length and to obtain the optimal offset.
1627196|NCT02032017|Procedure|Percutaneous assisted approach|
1627197|NCT02032017|Procedure|Anterolateral approach|
1991937|NCT00193739|Drug|NACT|3 cycles of neoadjuvant chemotherapy
1627198|NCT02032017|Other|Usual care|Both groups will receive usual care (UC) after surgery. This includes standard physiotherapy care consisting of mobilizing and strengthening techniques. All patients will receive a booklet containing information about the surgery, weight bearing after the surgery, and rehabilitation in general.
1627199|NCT02032004|Biological|Allogeneic Mesenchymal Precursor Cells (MPC)|Rexlemestrolcel-L consists of human bone marrow-derived allogeneic MPCs isolated from bone mononuclear cells with anti-STRO-3 antibodies, expanded ex vivo,and cryopreserved
1627200|NCT02032004|Other|Sham Comparator|The sham procedure will be staged to script and will not include actual cardiac mapping or delivery of rexlemestrocel-L.
1627201|NCT02031991|Biological|PF-06439535|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
1627202|NCT02031991|Biological|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
1627203|NCT02031991|Biological|Avastin|Solution for intravenous infusion, single dose of 5mg/kg, administered as 90-minute infusion.
1627204|NCT02031965|Biological|oncolytic HSV-1716|Given IT
1627205|NCT02031965|Drug|dexamethasone|Given IV
1627206|NCT02031965|Procedure|therapeutic conventional surgery|Undergo surgical resection
1627207|NCT02031965|Other|laboratory biomarker analysis|Correlative studies
1627208|NCT02031952|Procedure|hepatectomy combined with lymphadenectomy|
1627209|NCT02031952|Procedure|hepatectomy alone|
1627210|NCT02031939|Drug|Induction and gap chemotherapy (Capecitabine combine with oxaliplatin)|All rectal cancer patients in this group will receive induction, gap chemotherapy(capecitabine combine with oxaliplatin) alone with standard chemoradiotherapy before surgery.
1627211|NCT02031939|Radiation|standard chemoradiotherapy|All rectal patients in this group will receive standard chemoradiotherapy and surgical resection.
1627212|NCT02031926|Device|Positive expiratory pressure|
1627213|NCT02031900|Device|NvisionVLE Imaging System: NvisionVLE Imaging Console, NvisionVLE Optical Probe and Inflation Accessory Kit|The NvisionVLE Imaging System is indicated for use as an imaging tool in the evaluation of human tissue microstructure, including esophageal tissue microstructure, by providing two-dimensional, cross-sectional, real-time depth visualization.
1627214|NCT02031887|Dietary Supplement|formula with synbiotics|
1627215|NCT02031887|Dietary Supplement|formula without synbiotics|
1627216|NCT02031861|Drug|nifedipine CR tablets (Xin Ran)|
1627217|NCT02031861|Drug|nifedipine CR tablets (Adalat)|
1627218|NCT02031848|Other|Diet Intervention|
1627219|NCT02031848|Other|Assessments and Diet Intake|
1627220|NCT02031835|Procedure|BWSTT (3 days a week for maximum of 20 minutes session)|
2011380|NCT02578758|Behavioral|Transdiagnostic internet-based protocol + positive affect component|Transdiagnostic internet-based protocol + positive affect component is an Internet-based protocol for ED. This protocol contains several transdiagnostic components (present-focused emotional awareness, cognitive flexibility, emotional avoidance and emotion-driven behaviors, interoceptive and situation-based emotion exposure, psychoeducation about emotions, motivational enhancement and relapse prevention) and a specific positive affect regulation component. These components are organized in 16 treatment modules: Emotional disorders and emotion regulation; Motivation for change; Understanding the role of emotions; The acceptance of emotional experiences; Practicing the acceptance; Learning to be flexible; Practicing the cognitive flexibility; The emotional avoidance; Emotion driven behaviors; Accepting and facing physical sensations; Facing emotions in the contexts in which they occur; Learning to move on; Learning to enjoy; Learning to live; Living and learning; and Relapse Prevention.
1627222|NCT02031796|Other|CAVAREC Image Processing algorithm|After deployment of the TAVI prosthesis but before the patient care episode is completed, a set of rotational x-ray angiography images will be acquired and reconstructed using the clinical DyanCT and research CAVAREC algorithms.
1627223|NCT02031783|Dietary Supplement|Mixture of glucose and fructose|
1627224|NCT02031783|Dietary Supplement|glucose|
1627225|NCT02031770|Drug|Sodium bicarbonate|Subjects will be treated with oral sodium bicarbonate two to three times per day for a goal serum bicarbonate (HCO3-) of ≥ 23 meq/L.
1627226|NCT02031770|Other|Control|subjects will receive no treatment
1627227|NCT02031757|Other|perturbation training|training utilizing a system that provides small, controlled and unpredictable perturbations during treadmill walking.
1627228|NCT02031757|Other|balance exercises|specific exercises regularly used in rehabilitation aiming to improve balance
1627229|NCT02031744|Drug|erlotinib [Tarceva]|150 mg oral administration once daily
1627230|NCT02031744|Drug|Placebo|15 mg/kg intravenous administration every 3 weeks
1627231|NCT02031744|Drug|Onartuzumab [MetMAb]|15 mg/kg intravenous administration every 3 weeks
1627232|NCT02031731|Drug|4 mg/kg Onartuzumab (MetMAb)|4 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
1627233|NCT02031731|Drug|15 mg/kg Onartuzumab (MetMAb)|15 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
1627234|NCT02031731|Drug|30 mg/kg Onartuzumab (MetMAb)|30 mg/kg Onartuzumab (MetMAb) will be administered intravenously every 3 weeks.
1627235|NCT02031718|Behavioral|Virtual Counseling|
1627236|NCT02031705|Procedure|cavotricuspid isthmus ablation|Isthmus ablation was performed in paroxysmal atrial fibrillation patients.
1627237|NCT02031705|Procedure|control group|Control group was performed no additional cavotricuspid isthmus ablation.
1627238|NCT02031692|Drug|400IU cholecalciferol and 500mg of elemental calcium as calcium carbonate|The patients allocated to the intervention group will have a test for serum vitamin D, and receive 800 IU of vitamin D and 1000 mg of calcium as calcium carbonate when the serum vitamin D is decreased. The patients in the control group will be followed up without intervention for one year.
1627239|NCT02031679|Drug|AZD1981|AZD1981 is an oral, potent, selective, reversible antagonist of CRTh2 (Chemoattractant Receptor Homologous Molecule expressed on Th2 cells).
1627240|NCT02031679|Drug|Placebo|Sugar pill manufactured to mimic AZD1981 10 mg tablet
1627241|NCT02031666|Drug|JNJ-56021927 capsule|Participants will receive oral soft gel capsules providing a total dose of 240 mg JNJ-56021927 on Day 1.
1627242|NCT02031666|Drug|JNJ-56021927 tablet|Participants will receive oral tablets providing a total dose of 240 mg JNJ-56021927 on Day 1.
1627250|NCT02031601|Drug|Erlotinib|150mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive erlotinib150mg po once a day daily until progression
1627251|NCT02031601|Drug|Gefitinib|250mg po once a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive gefitinib 250mg po once a day daily until progression
1627252|NCT02031601|Drug|Icotinib|125mg po three time a day on days 2-15 of each 3 week cycle for 4 cycles; then continue to receive icotinib 125mg po three time a day daily until progression
1627253|NCT02031601|Drug|Docetaxel|75 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
1627254|NCT02031601|Drug|Pemetrexed|500 mg/m2 ivgtt on days 1 of each 3 week cycle for 4 cycles
1627255|NCT02031601|Drug|Platinum (cisplatin or carboplatin)|cisplatin -- 75mg/m2 ivgtt on day 1 of each 3 week cycle for 4 cycles or carboplatin -- 5 x AUC ivgtt on day 1 of each 3 week cycle for 4 cycles
1627256|NCT02031601|Drug|Erlotinib|150mg po once a day daily until disease progression
1627257|NCT02031601|Drug|Gefitinib|250mg po once a day daily until disease progression
1627258|NCT02031601|Drug|Icotinib|125mg po three times a day daily until disease progression
1627259|NCT02031575|Behavioral|Interactive Treatment|Mobile phone text messaging service about reproductive health
1627260|NCT02031575|Behavioral|Basic Treatment|Mobile phone text messaging service about reproductive health
1627261|NCT02031575|Other|Control, comparator arm|
1627262|NCT02031562|Other|chiropractic|chiropractic
1627263|NCT02031562|Other|physical therapy|physical therapy
1627264|NCT02031549|Other|SpermComet assay|Measurement of DNA fragmentation in samples of surplus sperm (diagnostic, not an intervention).
1627268|NCT02031523|Drug|Sanjie analgesic capsule|Oral, four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle.or follow the doctor's advice.
1627269|NCT02031523|Drug|placebo|oral，four each time, 3 times a day, on the first day of menstruation to start taking, taking three consecutive menstrual cycle. Or Follow the doctor's advice.
1627270|NCT02031510|Drug|placebo|transversus abdominis plane block with saline 0.9%
1627271|NCT02031510|Drug|bupivacaine|transversus abdominis plane block bupivacaine 0.25%
1627272|NCT02031510|Drug|bupivacaine-dexmedetomidine|transversus abdominis plane block with bupivacaine 0.25% with dexmedetomidine 1 µg Kg-1
1627273|NCT02031497|Dietary Supplement|Drink with sweeteners|Subjects will have to consume a 330ml can of a drink with sweeteners twice per day as part of their usual fluid intake for 12 weeks.
1627274|NCT02031497|Dietary Supplement|Drink without sweeteners|Subjects will have to consume a 330ml can of a drink without sweeteners twice per day as part of their usual fluid intake for 12 weeks.
1627275|NCT02031471|Drug|tocilizumab|Fixed dose of 162 mg subcutaneously weekly
1627276|NCT02031458|Drug|Atezolizumab|1200 mg IV every 3 weeks
1627277|NCT02031445|Drug|MRX-6|
1627278|NCT02031445|Other|Placebo|
1627279|NCT02031432|Drug|Cebranopadol|Cebranopadol 200 µg to 1000 µg per day taken once a day in the morning.
1627280|NCT02031419|Drug|CC-122|2mg or 3 mg administered orally once daily
1627281|NCT02031419|Drug|CC-223|20mg or 30mg administered orally once daily.
1627282|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
1627283|NCT02031419|Drug|CC-122|2mg or 3mg administered orally once daily.
1627284|NCT02031419|Drug|CC-292|500 mg twice a day administered orally.
1627285|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
1627286|NCT02031419|Drug|CC-223|20mg or 30mg per day administered orally daily.
1627287|NCT02031419|Drug|CC-292|500 mg twice a day administered orally.
1627288|NCT02031419|Drug|Rituximab|375 mg/m2 administered intravenously once every 28 days
1627289|NCT02031406|Other|Post-discharge counseling on medication adherence & literacy|
1627290|NCT02031380|Device|Open angle glaucoma - iDropper device|The iDropper system is an eye drop dispensing device and medication monitor designed to optimize adherence behaviors for glaucoma patients.
1627291|NCT02031367|Drug|Triamcinolone Acetonide|Corticosteroid arm
1627292|NCT02031367|Other|Platelet Rich Plasma|Platelet Rich Plasma
1627293|NCT02031354|Dietary Supplement|Lysine Chloride|Administration of 21g of lysine chloride (7g three times daily) for a period of time of 3 days
1627294|NCT02031328|Radiation|Stereotactic Ablative Radiation|
1627295|NCT02031302|Device|Lotus Valve System|The Lotus Valve System is indicated to improve aortic valve function for symptomatic subjects with severe calcific aortic stenosis (aortic valve area [AVA] of <1.0 cm2 or index of <0.6 cm2/m2) who are at high risk for standard surgical valve replacement.
1627296|NCT02031289|Drug|Erythropoietin/Ferric carboxymaltose/Vitamin B12/Folic Acid|"Treatment ) will be given the day before the operation (day -1) or a maximum of 2 days prior to the operation (day -2) in iron deficiency patients and a maximum of 3 days prior to the operation in anemic patients (day -3).
Erythropoietin alpha (Eprex, Janssen-Cilag AG, Baar) 40'000 U sc. Ferric carboxymaltose (Ferinject, Vifor (International) AG, St. Gallen) 1000 mg in 100 ml NaCl over 30 min.
Vitamin B12 (Vitarubin®-superconc., Streuli Pharma AG, Uznach) 1 mg sc. Folic acid (Acidum folicum, Streuli Pharma AG, Uznach) 5 mg po."
1627297|NCT02031276|Drug|ABBV-066|ABBV-066 administered by IV infusion
1627298|NCT02031276|Drug|ABBV-066|ABBV-066 administered by SC injection
1627299|NCT02031276|Drug|Placebo|Placebo for ABBV-066
1627300|NCT02031263|Procedure|bronchial thermoplasty system|Check on the quality of life, emergency room uses, and sudden progress of the disease of the patients before and after the treatment by using bronchial thermoplasty system by using paired t test.
1627301|NCT02031250|Drug|Cisplatin|Cisplatin 40mg/m2 administered as an IV infusion prior to radiotherapy on day 1 of each week of chemo-irradiation
1627302|NCT02031250|Drug|Carboplatin|Patients considered medically unfit to receive Cisplatin as determined by the prescribing physician, will receive Carboplatin via IV infusion on day 1 of each week of chemo-irradiation
1627303|NCT02031250|Radiation|IMRT (Intensity-Modulated Radiation Therapy)|
1627304|NCT02031250|Radiation|Boost Radiation to Hypoperfused Volumes|
2011381|NCT02578758|Other|Waiting List Control Group|Participants in a 18-week waiting list control condition. They will be offered the possibility of receiving the online treatment protocol after the wating list period.
2011382|NCT02576574|Drug|Avelumab|Subjects will be administered with avelumab at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (IV) infusion once every 2 weeks until disease progression or unacceptable toxicities.
2011383|NCT02576574|Drug|Pemetrexed|Pemetrexed 500 mg per square meter (mg/m^2) by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
1627309|NCT02031224|Behavioral|Conventional low protein diet|
1627310|NCT02031224|Dietary Supplement|Very low protein diet supplemented with Ketosteril|
1627311|NCT02031211|Drug|Etanercept|The patient will receive 0.4 ml/kg as the 25mg/ml preparation subcutaneously.
1627312|NCT02031211|Drug|Placebo|The patient will receive 0.4 ml/kg of Normal Saline injected subcutaneously.
1627313|NCT02031198|Drug|AADvac1|Active immunization against pathological Alzheimer's disease tau protein
1627314|NCT02031185|Behavioral|FitBit only|Participants will use the FitBit device
1627315|NCT02031185|Behavioral|FitBit and Text Messages|Participants will use the FitBit device and receive daily affective text messages
1627316|NCT02031146|Procedure|Lumbar puncture|
1627317|NCT02031133|Drug|Miravirsen|
1627318|NCT02031107|Device|cTBS|
1627319|NCT02031107|Device|cathodal tDCS|
1627320|NCT02031107|Device|sham stimulation|
1627321|NCT02031094|Other|Observational study: Sense Wear armband and indirect calorimetry used to measure resting energy expenditure|Observational methods of measuring resting energy expenditure
1627322|NCT02031081|Drug|Prucalopride|2 X 2 mg tablets (encapsulated) by mouth once daily for 28 days
1627323|NCT02031081|Drug|Placebo|2 X 100mg tablets (encapsulated) by mouth once daily for 28 days
1627324|NCT02031068|Behavioral|Active Rehabilitation Program|"The active rehabilitation program will be implemented for a maximum of 6-8 weeks. Each participant will be followed by regular weekly telephone calls or personal follow-up relating to outcome from concussion and managing symptoms. The participant will receive TAU (above) in addition to the 4 components listed below:
Sub-maximal aerobic training for up to 15 minutes
Light coordination and sport-specific exercises for up to 10 minutes
Visualization and imagery techniques
Home program
A physiotherapist will supervise the rehabilitation."
1627325|NCT02031068|Behavioral|Treatment-as-usual (TAU)|"The TAU program will be implemented after the initial assessment. It will consist of 2 components:
An initial education session by an occupational therapist, relating to outcome from concussion and managing symptoms A school consultation to provide teacher education, recommend accommodations, and facilitate return to school"
1627326|NCT02031055|Drug|TAS-102 with a light tracer dose of [14C]FTD|A single dose of 60 mg TAS-102 with a light tracer dose (200 nCi, approximately 1.2 μg) of [14C]FTD administered as an oral solution on Day 1 (mass balance part)
1627327|NCT02031055|Drug|TAS-102 with a light tracer dose of [14C] TPI|A single dose of 60 mg TAS-102 with a light tracer dose (1000 nCi, approximately 5.6 μg) of [14C]TPI administered as an oral solution on Day 1 (mass balance part)
1627328|NCT02031055|Drug|TAS-102 tablets|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met. Treatment starts during study extension part (day 9 of the study).
1627329|NCT02031016|Drug|Fentanyl|"fentanyl bolus injections on an as needed base, NEXT TO the fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium."
1627330|NCT02031016|Drug|Remifentanil|starting with 0.15 ug/IBW(kg)/min, next to fentanyl bolus injections (200-500 ug) on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
1627331|NCT02031016|Drug|Fentanyl|fentanyl bolus injections on predetermined times; before incision, at sternotomy, at aorta canulation and at opening of the pericardium.
1627332|NCT02031003|Dietary Supplement|Infant formula|Infant formula
1627333|NCT02030990|Drug|Mitomycin-C|0.01% applied to cornea with a sponge during PRK
1627334|NCT02030990|Drug|Fluorometholone 1% topical ocular steroid|topical steroid drops applied to the cornea after PRK
1627335|NCT02030977|Dietary Supplement|Resveratrol|
1627336|NCT02030977|Other|placebo|
1627337|NCT02030964|Drug|DFMO|
1627338|NCT02030964|Drug|Celecoxib|
1627339|NCT02030964|Drug|Cyclophosphamide|
1627340|NCT02030964|Drug|Topotecan|
1627341|NCT02030938|Device|SERI® Surgical Scaffold|Standard revision augmentation (with or without implant exchange) with the adjunctive use of SERI® Surgical Scaffold placed intra- or extra-capsularly.
1627342|NCT02030925|Drug|IW-3718|
1627343|NCT02030925|Drug|Matching Placebo|
1627344|NCT02030912|Drug|3 doses of amoxicillin daily for 7 days|
1627345|NCT02030912|Drug|2 doses of minocycline daily for five days|
1627346|NCT02030912|Other|2 doses of placebo daily for five days|
1627347|NCT02030899|Procedure|Cage fusion|Randomized selection of surgery type
1627348|NCT02030899|Procedure|Plate fusion|Randomized selection of surgery type
1627349|NCT02030886|Device|Sensimed Triggersfish®|All subjects will be monitored by Sensimed Triggerfish for 24 hours.
1627350|NCT02030873|Other|Virtual simulation training|Virtual simulation training in the Visible Ear Simulator.
1627351|NCT02030860|Drug|Paricalcitol|Dose: 25 micrograms Route: IV Frequency (within a 28 day cycle):Three times weekly for one cycle beginning day 1 of therapy until the day before surgery (+/- 3 days) (for subjects randomized to receive paricalcitol), then three times weekly for 3 cycles post-operatively (for all subjects).
1627352|NCT02030860|Drug|Abraxane|Dose: 125mg/m2 Route: IV infusion over 30 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
1627353|NCT02030860|Drug|Gemcitabine|Dose: 1000mg/m2 Route: IV infusion over 30-100 minutes Frequency (within a 28 day cycle): Day 1, 8, 15
1627354|NCT02030847|Biological|CART-19|CART-19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCR:41BB administered by a single i.v. infusion of 1 to 5 x 108 transduced CAR T cells
1627435|NCT02030132|Behavioral|Feedback compared to 75th percentile|
1627436|NCT02030132|Behavioral|Forgiveness|
1627355|NCT02030834|Biological|CART-19|Single infusion of CART-19 cells administered by i.v. injection (total dose of 1 - 5 x108 CART-19 cells, calculated as a range of 2-50% transduced cells in total cells).
1627356|NCT02030821|Drug|Amicar|Subjects randomized to receive Amicar will receive this during surgical intervention
1627357|NCT02030821|Drug|TXA|Subjects randomized to receive TXA will receive this during surgical intervention
1627358|NCT02030808|Drug|Muscle Relaxants (MR) group|patients received 0.2 mL/kg cisatracurium® (Nimbex) 0.2%, and a left-sided endobronchial double-lumen tube was placed when the TOF revealed one or two twitches
1627359|NCT02030808|Drug|Non- Muscle Relaxants (NMR) group|No cisatracurium® (Nimbex) will be administered
1627360|NCT02030795|Other|Disconnection group|The blocker cuff was deflated, the single lumen tube was disconnected from the ventilator for 60 s allowing the surgical lung to collapse, then the cuff was re-inflated with the same amount of air as determined previously and the ventilator was reconnected to the single lumen tube
1627361|NCT02030795|Other|Bronchial Suction group|The barrel part of a 1-mL insulin syringe was attached to the suction port of the bronchial blocker, and connected to -30 cm H2O of suction.
1627362|NCT02030782|Other|Quality Improvement (QI) for depression|Major intervention components included a) expert leader teams who planned and implemented the intervention at each clinic, b) care managers who supported primary care clinicians with depression evaluation and management, c) access to cognitive-behavior therapy for depression within each primary care clinic, and d) patient and provider choice regarding treatment modality.
1627363|NCT02030782|Other|Usual Care|Usual care enhanced by provider education regarding depression evaluation and management
1627364|NCT02030769|Drug|Pronase|use pronase to improve visibility during endoscopical iodine staining
1627365|NCT02030769|Drug|Control|No pronase plus Dimethicone and sodium bicarbonate. use without pronase to compare visibility during endoscopical iodiine staining
1627366|NCT02030756|Device|vibrating capsule|patients will receive vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
1627367|NCT02030756|Device|sham vibrating capsule|patients will receive sham vibrating capsule for 8 weeks of treatment [1 every 3 days (+/- 1 day)].
1627368|NCT02030743|Other|Visual training|6 training sessions with computerised visual attention paradigm
1627369|NCT02030730|Behavioral|Triple P Seminar Series|The intervention was delivered by the researcher and an accredited TripleP practitioner. The seminars took place in a conference room located within a bookshop. The seminars were re-offered for parents who could not attend the scheduled day.
1627370|NCT02030717|Drug|klonidin|spinal injection of 12 mg bupivacain,160 ug morfin och klonidin, according to age
1627371|NCT02030717|Drug|epidural anesthesia|epidural anesthesia: patients get an continuous infusion of a solution with bupivacain 1 mg/ml, fentanyl 1 ug/ml and adrenalin 1 ug/ml
1627372|NCT02030691|Device|Nasal continuous airway positive pressure (nCPAP)|
1627373|NCT02030691|Device|Nasal high frequency percussive ventilation (nHFPV)|
1627374|NCT02030678|Drug|irinotecan|irinotecan , 100mg/m2,day1,day 8;21days a cycle;at least 3cycles.
1627375|NCT02030665|Behavioral|Contingency Management|Reinforcement provided contingent upon demonstration of negative drug tests
1627376|NCT02030665|Behavioral|Individualized Assessment & Treatment|Tailored Cognitive-Behavioral Treatment based on detailed records of patient behavior
1627377|NCT02030665|Behavioral|Cognitive-Behavioral Treatment|Standard psychoeducational approach to coping skills training
1627378|NCT02030652|Procedure|Intermittent nasal positive pressure positive ventilation.|
1627379|NCT02030652|Procedure|CPAP|Nasal continuous positive airway pressure
1627380|NCT02030639|Drug|rigosertib|A single dose of 450 mg of rigosertib containing 250 microcuries of carbon 14-labeled rigosertib ([14C]-rigosertib) administered as a continuous intravenous (CIV) infusion over 24 hours to healthy volunteers.
1627381|NCT02030626|Device|active or placebo rTMS or active or placebo tDCS|
1627382|NCT02030613|Genetic|Blood test|
1627383|NCT02030600|Drug|insulin degludec|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
1627384|NCT02030600|Drug|insulin glargine|Administered once daily injected s.c. / subcutaneously (under the skin). Dose is individually adjusted.
1627385|NCT02030587|Procedure|Radiofrequency Ablation|
1627386|NCT02030587|Procedure|Laparoscopic Adrenalectomy|
1627387|NCT02030574|Drug|Gemcitabine and fractionated cisplatin (combination treatment)|1 Cycle = 21 days. GC x 4 cycles ----> cystectomy Gemcitabine: 1000mg/m2, days 1 and 8 Cisplatin: 35mg/m2, days 1 and 8
1627388|NCT02030561|Drug|Trastuzumab + NK cells|
1627389|NCT02030535|Drug|olodaterol|free combination with tiotropium
1627390|NCT02030535|Drug|tiotropium|free combination with olodaterol
1627391|NCT02030535|Drug|Placebo|
1627392|NCT02030535|Drug|tiotropium|fixed dose combination with olodaterol
1627393|NCT02030535|Drug|olodaterol|fixed dose combination with tiotropium
1627394|NCT02030522|Behavioral|Accelerated Resolution Therapy (ART)|"The ART protocol will be delivered in 2-5 sessions. Imaginal Exposure (IE) will be used whereby service members and veterans will be asked to recall (verbally or non-verbally) details of the traumatic event(s) while focusing their attention on physiological sensations, thoughts, and emotions. This short period of exposure to the memory will be followed by identification and diminishment of the emergence of any uncomfortable emotional or somatic symptoms. Imagery Rescripting (IR) will be used to change (replace) negative traumatic images to positive images. The service member/veteran will imagine and play out an affectively-driven solution to change sensory components of the memory, as if they were the director of the movie of the memory they are working on."
1627395|NCT02030509|Other|Quick diagnosis program|
1627437|NCT02030132|Behavioral|Financial Incentive|For the first three months of the study, a weekly lottery will be held. Teams whose average daily step count for that week is ≥ 7000 will be eligible to collect their lottery winnings. Teams whose average daily step count is less than 7000 will receive messages about how much they would have won had the team met its goal.
1627438|NCT02030132|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
1650769|NCT01849770|Drug|Placebo|
1627396|NCT02030496|Procedure|open reduction and internal fixation|The surgery will be performed by a certified trauma surgeon. After the fracture site is exposed, the fracture will be reduced and provisionally fixed with K-Wires and reduction forceps. An appropriate volar locking plate which best suits the anatomy of the wrist and the fracture type will be selected. Screw placement and fracture reduction will be confirmed intra-operatively by radiographic images. No post-operative fixation will be applied and patients will be instructed to use the affected extremity in daily activities as pain allows. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
1627397|NCT02030496|Other|Closed reduction and plaster|Closed reduction will be performed according to the Robert-Jones method. This involves increasing the deformity first, then applying continuous traction and immobilising wrist and hand in the reduced position. Additional radiographs will be performed to verify the quality of the reduction. After this has been confirmed, the wrist will be immobilised according to Dutch guidelines: a splint for one week followed by a circular cast for another four weeks. According to Dutch treatment standards, vitamin C 500 milligrams will be prescribed to all patients at initial presentation and for a duration of two months in order to prevent Complex Regional Pain Syndrome.
1627398|NCT02030483|Drug|Palbociclib|Palbociclb will be given at predefined dose level of 75 mg, 100 mg, 125 mg, or 150 mg days 1-14 every 28 days (days 0-14 for cycle 1 only).
1627399|NCT02030483|Drug|Dexamethasone|20 mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle (Day 1 dosing is omitted for cycle 1 only).
1627400|NCT02030483|Drug|Lenalidomide|Lenalidomide at predefined dose level of 5mg, 10 mg, 15 mg, 25 mg daily for days 8-21 (or days 1-21, depending on dose level cohort).
1627401|NCT02030470|Other|Fotosan®630. LED lamp. Toluidinblue. Photoactivated disinfection|
1627402|NCT02030457|Drug|Beclomethasone dipropionate BAI|Breath Activated Inhaler (BAI)
1627403|NCT02030457|Drug|Beclomethasone dipropionate MDI|Metered Dose Inhaler (MDI)
1627404|NCT02030444|Procedure|PET-MRI and EBUS-TBNA|
1627405|NCT02030431|Device|Dynaloc|
1627406|NCT02030431|Device|Cancellous screws|
1627407|NCT02030418|Device|Leadless Pacemaker|Patients will undergo an attempted leadless pacemaker implant
1627408|NCT02030405|Drug|ixazomib|Given PO
1627409|NCT02030392|Behavioral|Intervention group|Cognitive-behavioral intervention
1627410|NCT02030392|Behavioral|Active control group|Education and information
1627411|NCT02030379|Behavioral|QPL-CT|Use the QPL-CT to prioritize questions
1627412|NCT02030353|Behavioral|Self-regulation plus activity monitoring|Individual in-person session, digital smart scale, online intervention, and an activity monitor.
1627413|NCT02030353|Behavioral|Self-regulation|Individual in-person session, digital smart scale, and online intervention.
1627414|NCT02030340|Procedure|lower urinary tract dysfunction|Urodynamic investigation with a double (two systems: air-charged and water filled) catheter system
1627415|NCT02030314|Drug|Chlorthalidone|treatment of resistant hypertension in kidney transplant patients
1627416|NCT02030301|Biological|VCL-HB01|Plasmid DNA vaccine encoding two HSV-2 proteins; formulated with Vaxfectin®
1627417|NCT02030301|Biological|VCL-HM01|Plasmid DNA vaccine encoding one HSV-2 protein; formulated with Vaxfectin®
1627418|NCT02030301|Biological|PBS|Phosphate-buffered saline
1627419|NCT02030288|Behavioral|Relational Agent Intervention|"Relational Agents are on-screen characters that speak to the patient and establish a relationship with them. They have been used to improve several health behaviors including diet and exercise, and can overcome communication barriers related to low levels of computer literacy. The Relational Agent can be placed on a desktop or tablet computer with a touch screen, on which patients indicate their responses. Using Motivational Interviewing and behavior change principles, the Relational Agent guides patients to consider change."
1627420|NCT02030275|Drug|RXI-109|surgery.
1627421|NCT02030275|Drug|Placebo|surgery.
1627422|NCT02030262|Procedure|Epiretinal membrane peeling with fluid-air exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be air. The remaining of the intervention is the same between the two arms.
1627423|NCT02030262|Procedure|Epiretinal membrane peeling with fluid-SF6 exchange|The intervention starts with a pars plana vitrectomy and then a epiretinal membrane peeling is performed. During the fluid-gaz exchange, the gaz used will be SF6 (sulfur hexafluoride). The remaining of the intervention is the same between the two arms.
2011384|NCT02576574|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 by IV infusion on Day 1 of 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
2011385|NCT02576574|Drug|Gemcitabine|Gemcitabine 1250 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles when combined with cisplatin of IV injection until disease progression or unacceptable toxicities.
1627427|NCT02030236|Device|Cooling|Temperature reached Duration of exposure to cold.
1627428|NCT02030223|Procedure|Transversus abdominis plane block|ultrasound guided transversus abdominis plane block
1627429|NCT02030197|Behavioral|CRISP Program|Educational program to improve self-efficacy, loneliness and depression
1627430|NCT02030197|Other|Control Group|no treatment
1627431|NCT02030184|Drug|Rhenium Re 188-P2045|Topotecan at 1.0 mg/m2 or 1.5 mg/m2 for 3 days, followed by single dose of Rhenium Re 188-P2045, at one of the following dosage levels based on the Phase I Maximum Tolerated Dose (MTD): 40% of MTD; 50% of MTD; 75% of MTD; 85% of MTD or 100% of MTD.
1627432|NCT02030171|Other|functionnal reeducation|Specific functionnal reeducation for chronic low back pain
1627433|NCT02030145|Procedure|Compressive Thoracic Lymphatic Pump|This technique is a modification of the Classic Thoracic Lymphatic Pump where some pressure is maintained on the chest wall at the end of each exhalation and at the end of the third or fourth breathing cycle, during the inhalation phase, the hands are slowly removed from the chest wall, gradually releasing pressure on the chest without causing a sudden change in intrathoracic pressures.
1627434|NCT02030145|Procedure|Classic Thoracic Lymphatic Pump|This technique is well described in Chapter 68 of the Foundations for Osteopathic Medicine, 2nd Edition.
1627441|NCT02030093|Behavioral|Telephone-based counseling|Telephone-based continuing care wil be provided to patients in different frequency
2011386|NCT02576574|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 on Day 1 and Day 8 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with carboplatin until disease progression or unacceptable toxicities.
2011387|NCT02576574|Drug|Carboplatin|Carboplatin AUC 5 mg/mL*min in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with gemcitabine until disease progression or unacceptable toxicities.
2011388|NCT02576574|Drug|Cisplatin|Cisplatin 75 mg/m^2 by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection until disease progression or unacceptable toxicities.
1627446|NCT02030067|Drug|RX-3117|escalating doses
1627447|NCT02030054|Drug|Atorvastatin|Patients were randomly assigned to atorvastatin (40 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
1627448|NCT02030054|Drug|Rosuvastatin|Patients were randomly assigned to rosuvastatin (20 mg day) for 30 days. After 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days.
1627449|NCT02030041|Drug|Vitamin D|Vitamin D will be given to achieve normal serum levels
1627450|NCT02030041|Drug|Simvastatin|Simvastatin in a dose of 40 mg will be provided to the study participants
1627451|NCT02030041|Drug|Placebo|Placebo will be provided to the study participants
1627452|NCT02030028|Drug|ACTHAR gel|Subjects are given the ACTHAR gel subcutaneously twice per week for 12 weeks.
1627455|NCT02030002|Device|APC Flash-Free Adhesive Coated Appliance System|APC Flash-Free Adhesive Coated Appliance System
1627456|NCT02030002|Device|APC II Adhesive Coated Appliance System|APC II Adhesive Coated Appliance System
1627457|NCT02029989|Device|Glucose and lipids|"Point-of-care (POCT) screening for diabetes and dyslipidemia.
Glucose and Lipids"
1627458|NCT02029989|Device|Glycosylated Hemoglobin A1c|"Point-of-care (POCT) screening for diabetes
Glycosylated Hemoglobin A1c"
1627459|NCT02029989|Device|Blood Pressure and Heart Rate|"Point-of-care (POCT) screening for hypertension
Blood Pressure and Heart Rate"
1627460|NCT02029989|Device|Body mass index|Height and weight measurement used to calculate BMI = Mass(kg)/(height (m))squared
1627461|NCT02029989|Device|Waist and Hip circumference|"Measurement for Central Obesity
Waist and Hip circumference"
1627462|NCT02029989|Behavioral|Comprehensive Medication Management|Defined at http://www.pcpcc.org/guide/patient-health-through-medication-management
1627463|NCT02029976|Behavioral|SNAPSHOT (Student, Nurses and Parents Seeking Healthy Options Together)|attention control condition after school weight management program
1627464|NCT02029976|Behavioral|Mailed monthly newsletters|Newsletters
1627465|NCT02029963|Device|Transcranial Magnetic Stimulation (rTMS)|A non-invasive method for brain stimulation
1627466|NCT02029963|Behavioral|Treatment as Usual|An individually-tailored maintenance plan as determined by a psychiatrist or primary care provider
1627467|NCT02029950|Drug|Cytarabine|Given IV
1627468|NCT02029950|Drug|Daunorubicin Hydrochloride|Given IV
1627469|NCT02029950|Drug|Etoposide|Given IV
1627470|NCT02029950|Drug|Idarubicin Hydrochloride|Given IV
1627471|NCT02029950|Other|Laboratory Biomarker Analysis|Correlative studies
1627472|NCT02029950|Other|Pharmacological Study|Correlative studies
1627473|NCT02029950|Drug|Pomalidomide|Given PO
1627474|NCT02029937|Drug|Proflavine, high resolution imaging|5-10 ml of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the endoscope and gently placed against the mucosa. Imaging of abnormal tissues will be performed.
1627475|NCT02029924|Drug|BioChaperone insulin lispro|Single dose of 0.2 U/Kg body weight injected subcutaneously (under the skin)
1627476|NCT02029924|Drug|Humalog®|Single dose of 0.2 /Kg body weight injected subcutaneously (under the skin)
1627477|NCT02029911|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
1627478|NCT02029898|Drug|Remifentanil|
1627479|NCT02029898|Drug|sodium chloride 0,9%|
1627480|NCT02029885|Device|Investigational Therapy (Surround Sound)|
1627481|NCT02029885|Device|Sham Control|
1627482|NCT02029872|Drug|Chlorhexidine gluconate soap|4% chlorhexidine gluconate (soap)
1627483|NCT02029872|Drug|Chlorhexidine gluconate oral rinse|chlorhexidine gluconate oral rinse 0.12%
1627484|NCT02029872|Drug|Mupirocin calcium 2 % ointment|nasal mupirocin calcium 2% ointment
1627485|NCT02029859|Procedure|Polygraphic examination|Polygraphic examination between 30 and 36 weeks of amenorhea
1627486|NCT02029846|Drug|Standard Treatment|traditional drugs only
1627487|NCT02029846|Drug|Incretin-Based Treatment|incretin-based drugs
1627488|NCT02029833|Other|Regular Canola Oil|
1627489|NCT02029833|Other|High Oleic Canola Oil|
1627490|NCT02029833|Other|Western Type Diet - Common Dietary Oils|
1627491|NCT02029820|Device|RenalGuard|Intravenous saline hydration matched with urine output, using the device Renalguard
1627492|NCT02029794|Procedure|HPV self-colleciton|Women will self-collect a cervical sample that will be provided to an outreach worker and then labelled and sent to laboratories in Kampala for HPV testing. Women who test positive for HPV will be contacted by phone and provided with follow-up instructions.
1627493|NCT02029794|Procedure|visual inspection with acetic acid (VIA)|
1627494|NCT02029794|Drug|3-5% acetic acid|
1627495|NCT02029781|Procedure|LAPP score|Use of the LAPP score during a diagnostic laparoscopy.
1627496|NCT02029755|Procedure|transversus abdominis plane block|bilateral ultrasound-guided transversus abdominis plane block, with 20 ml of 0.25% ropivacaine at each side after the induction of general anesthesia
1627497|NCT02029755|Procedure|local infiltration|local anesthetics infiltration at surgical wound with 20 ml of 0.5% ropivacaine before wound closure
1627498|NCT02029755|Procedure|Patient controlled analgesia|postoperative analgesia with intravenous patient controlled analgesia with morphine
1627584|NCT02029209|Drug|Anlotinib|Anlotinib QD
1627585|NCT02029209|Drug|Placebo Capsule|Placebo capsule QD
1627499|NCT02029742|Behavioral|Community Health Worker (CHW)|CHWs will have scheduled interactions with subjects at home, by telephone or at Community League of the Heights (CLOTH), our partner community-based organization (CBO). CHWs will customize text messaging jointly with each youth and parent (Month 3) and text message reminders to both parent and youth will be implemented during Months 4-6. Subjects lacking a mobile phone or sufficient cell phone plan will be compensated to purchase or upgrade plans to accommodate texts.
1627500|NCT02029742|Behavioral|Education|Dyads randomized to the control group will continue usual clinic-based care, including monitoring and review of HbF levels, and similar frequency of clinic visits and access to sickle cell team staff. They will be provided with educational materials about sickle cell disease and hydroxyurea use for children.
1627501|NCT02029729|Drug|omaveloxolone|
1627502|NCT02029716|Drug|RTA 408 Lotion 0.5%, 1%, 3%|
1627503|NCT02029716|Drug|Lotion vehicle/placebo|
1627504|NCT02029703|Device|Synvisc-One Injection|
1627505|NCT02029703|Other|Sham Injection|
1627506|NCT02029690|Drug|ADI-PEG 20|
1627507|NCT02029664|Device|Visual distortion increment based on the gait pattern|
2011389|NCT02576574|Drug|Carboplatin|Carboplatin AUC 6 mg/mL*min by IV infusion in 3-Week cycle up to a maximum of 6 cycles of IV injection when combined with pemetrexed, or paclitaxel until disease progression or unacceptable toxicities.
1627510|NCT02029638|Biological|Antithymocyte globulin (ATG)|An initial dose of 0.5 mg/kg IV will be administered over 6 hours on Day -9. Thereafter the daily dose will be increased to 2 mg/kg IV given over 4 hours on Days -8 and -7. No more than 150 mg of ATG may be administered per day.
1627511|NCT02029638|Drug|Fludarabine|Fludarabine at dose 30 mg/m2 will be administered daily by intravenous infusion over 30 minutes on Day -6 to Day -2.
1627512|NCT02029638|Drug|Low dose Pre-transplant cyclophosphamide|Pre-transplant cyclophosphamide will be administered as an intravenous infusion over 1- 2 hours, (depending on volume) on Days -6 and -5. The dose of pre-transplantation cyclophosphamide is 14.5 mg/kg/day.
1627513|NCT02029638|Radiation|Total Body Irradiation|Total body irradiation, consisting of 200 centigray (cGy) Anterior-Posterior/Posterior-Anterior (AP/PA) with 4 Megavolts (MV) or 6 MV photons at 8-12 cGy/min at the point of prescription will be administered in a single day on Day -1.
1627514|NCT02029638|Drug|Acetaminophen|650 mg orally prior to antithymocyte globulin infusion
1627515|NCT02029638|Drug|Diphenhydramine|25mg diphenhydramine orally prior to antithymocyte globulin infusion.
1627516|NCT02029638|Drug|Methylprednisolone|On Days -9 to -7 methylprednisolone 1mg/kg IV 1 hour prior ATG. This dose may be repeated once 3 hours after the first dose of steroids. On Day -6 and -5, methylprednisolone 0.75 mg/kg/ IV as a single dose; on Days -4 and -3, methylprednisolone 0.5 mg/kg/ IV as a single dose; on Day -2 methylprednisolone 0.25 mg/kg/ IV as a single dose.
1627517|NCT02029638|Biological|Bone Marrow|Unprocessed, unmanipulated bone marrow will be harvested from the donor and infused into the recipient on Day 0
1627518|NCT02029638|Drug|MESNA|A series of MESNA doses will be administered for each dose of high dose, post-transplant cyclophosphamide. The total daily dose of MESNA is equal to 80% of the total daily dose of cyclophosphamide.
1627519|NCT02029638|Drug|Mycophenolate mofetil (MMF)|MMF will be administered at a dose of 15 mg/kg orally three times per day based upon actual body weight, with the maximum of 3 grams a day from Day 5 to 35. The dose will then be reduced to the standard 1 g twice daily thereafter.
1627520|NCT02029638|Drug|Prednisone|Prednisone will be administered at a dose of 10 mg orally daily from Day 5 for 12 weeks. Thereafter the dose will be reduced to 5 mg orally daily.
1627521|NCT02029638|Drug|Filgrastim|All recipients will receive 5 microgram/kg per day of filgrastim as a single, subcutaneous injection from Day -5 until the absolute neutrophil count is greater than 1000/µl on three consecutive measurements over at least 2 days.
1627522|NCT02029638|Drug|High dose post-transplant cyclophosphamide|High dose post- transplant cyclophosphamide [50mg/kg (Ideal Body Weight)] will be administered on Day 3 post-transplant (within 60 to 72 hours of marrow infusion) and on Day 4 post-transplant. Cyclophosphamide will be given as an IV infusion over 1-2 hours depending on volume.
1627523|NCT02029625|Drug|NVP-1205|rosuvastatin/ezetimibe fixed dose combination orally, once daily on Period 1 or Period 2
1627524|NCT02029625|Drug|rosuvastatin and ezetimibe|coadministration of rosuvastatin and ezetimibe orally, once daily on Period 1 or Period 2
1627525|NCT02029612|Drug|Nicotine Patch|10 week supply of nicotine patches given to participants at baseline.
1627526|NCT02029612|Behavioral|Phone Counseling|Each participant counseled on quitting smoking at baseline.
1627527|NCT02029612|Behavioral|Questionnaires|Questionnaires completed at baseline, 3 months, and at 6 months.
1627528|NCT02029612|Behavioral|Breath Test|Breath test performed at 3 month and 6 month visit.
1627529|NCT02029612|Behavioral|Proactive Cell Phone Smoking Cessation Counseling|Participant receives 11 phone calls from study staff over a 6-month period.
1627530|NCT02029612|Behavioral|Text Message Smoking Cessation Support|Participants receive text messages for support about quitting smoking over a 6 month period.
1627531|NCT02029599|Drug|Fang yi qing feng shi granule|10g, Oral,Three each time, 3 times a day,for 3 months;
1627532|NCT02029599|Drug|placebo|10g, Oral,Three each time, 3 times a day,for 3 months
1627533|NCT02029599|Drug|Methotrexate|7.5-15mg per week，All patients should be used
1627534|NCT02029599|Drug|Acetaminophen tablets|Oral,0.5g, 1~2 times a day, when vas=10
1627535|NCT02029586|Drug|MB12066 200mg|oral administration, 100mg bid
1627536|NCT02029586|Drug|Placebo|oral administration, 100mg bid
1627537|NCT02029573|Drug|Atorvastatin|80 mg po daily until disease progression or unacceptable toxicity. (starting dose of 40 mg po daily for the first 21 days)
1627538|NCT02029573|Drug|Temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
1627539|NCT02029573|Radiation|Radiotherapy|60 Gy in 30 fractions
1627540|NCT02029547|Drug|Florbetapir (18F)|No Florbetapir (18F) will be administered in this study.
1627541|NCT02029534|Drug|Atorvastatin 20 mg|
1627542|NCT02029534|Drug|Atorvastatin 80 mg|
1627586|NCT02029196|Other|E-vapour product|Smokers of conventional cigarettes who switch to use an e-vapour product.
1627721|NCT02028156|Other|Partially Hydrolyzed Infant Formula|Commercially available infant formula
1627543|NCT02029521|Dietary Supplement|Oral reduced l-glutathione|The treatment was pharmaceutical-grade Reduced L-Glutathione (GSH) with a daily dose of 65 mg/kg. The placebo was calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
1627544|NCT02029521|Dietary Supplement|Placebo|calcium citrate with a daily dose of 65 mg/kg. The daily dose of each substance was divided into three doses given at mealtime.
1627545|NCT02029508|Procedure|Modified Epley maneuver|For Modified Epley maneuver, the patient was placed in the upright position with the head turned 45 degrees toward the affected ear. And then the patient was rapidly laid back to the supine head-hanging position for 1 minute. Next, the head was turned 90 degrees toward the other (unaffected) side for 1 minute. Next, the head is turned a further 90 degrees (usually necessitating the patient's body to also move from the supine position to the lateral decubitus position) such that the patient' head is nearly in the facedown position for 1 minute. The patient is then brought into the upright sitting position for 1 minute, completing the maneuver.
1627546|NCT02029508|Procedure|Semont maneuver|Patient's head was turned 45 degrees toward the healthy side. And then patient was rapidly moved to affected side-lying position and sustained for 2 minutes. Next, Patient is rapidly taken to the opposite side-lying position without pausing in the sitting position or changing the head position relative to the shoulder for 2 minutes. Next, Patient returns slowly with the head still tilted and fixed until the seated position for 1 minute.
1627547|NCT02029508|Procedure|Reverse Epley maneuver|Like the modified Epley maneuver, but the direction was reverse.
1627548|NCT02029495|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection
1627549|NCT02029495|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection
1627550|NCT02029495|Drug|Placebo|Placebo administered via subcutaneous injection until week 24.
1627551|NCT02029482|Drug|ACT-128800|
1627552|NCT02029482|Drug|Placebo|
1627553|NCT02029469|Device|Ascension HRA device|Patients who are treated with the Ascension® HRA for resurfacing of humeral head.
1627554|NCT02029456|Drug|25 mg Actilyse ( Boehringer Ingelheim, Germany) infusion in 6 hours|
1627555|NCT02029443|Drug|acalabrutinib|
1627556|NCT02029430|Drug|aldoxorubicin|
1627557|NCT02029417|Drug|cytarabine|Given SC
1627558|NCT02029417|Drug|omacetaxine mepesuccinate|Given SC
1627559|NCT02029417|Drug|decitabine|Given IV
1627560|NCT02029417|Other|laboratory biomarker analysis|Correlative studies
1627561|NCT02029404|Procedure|Tibial nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution, Micrel Medical Devices) with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be > 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.
An information sheet will be released at the discharge and the medical indication for any rescue doses at home.
The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
1627562|NCT02029404|Procedure|Tibial peroneal nerve group|"After the recovery of the sensitivity we will start the continuous infusion of levobupivacaine 0,125% with a portable pump (Mini Rythmic Evolution ,Micrel Medical Devices )with a flow basal rate 2 ml/h and a rescue bolus doses of 2 ml (lock out 20 minutes). Before the discharge from the hospital, if the NRS will be > 4, a bolus of 10 ml of Mepivacaine 1% through the catheter could be administered.
An information sheet will be released at the discharge and the medical indication for any rescue doses at home.
The patients will be contacted by phone at POD 1-2 and will allowed to answer to a questionnaire (see endpoint) At POD 3 the patients will come in our ambulatory where we will remove the catheter and they will return the pump"
1627563|NCT02029391|Other|Manual pressure release|Therapist applied non-painful pressure with slowly increase over the myofascial trigger point until he felts a tissue resistance barrier.
1627564|NCT02029391|Other|Kinesio tape|Kinesio tape was adhered from insertion to origin of the upper trapezius muscle
1627565|NCT02029378|Drug|Eculizumab|
1627566|NCT02029365|Other|Autoquestionnary|autoquestionnary completed during the consultation for infertility
1627567|NCT02029365|Other|semi-structured interview|phone interview
1627568|NCT02029352|Drug|Sinecatechins 10%|
1627569|NCT02029352|Drug|Placebo|Composition, apart from the active substance, is otherwise identical to the investigational medical product.
1627570|NCT02029339|Device|Continuous topical triple-tube irrigation and suction|"The triple-tube device was continuous operated: instilled the topical solution through the washing tube, delivered negative pressure therapy at 100 - 125 mmHg continuously through the inner tube of sleeve tubes through the central negative pressure device in the wall of the ward. The outer tube was used for normalize and balance the distribution of the negative pressure around the inner tube to allow the solution to penetrate through the dressing to cover the wound, and protecting the inner tube from getting stuck with the sucked tissue. All tubes are all commercially available (Medical Silicone Tubing, Forbest Manufacturing Co., Ltd, China)."
1627571|NCT02029339|Device|SOC|Debridement, offloading, standard moist wound care, and conventional NPWT without continuous irrigation are the fundamental SOC for Open Abdomen with complicated abdominal infections.
1627572|NCT02029313|Drug|Montelukast|
1627573|NCT02029313|Drug|Montelukast sodium|
1627574|NCT02029300|Other|Fiberoptic Intubation through the nasal route|
1627575|NCT02029300|Other|Fiberoptic intubation through the oral route|
1627576|NCT02029287|Other|Hospital-Community-Family-Care Management Platform Online|Hospital-Community-Family-Care Management Platform Online: the remote monitoring service platform on line based on community and family for subjects with CHF under the guidance of the regional central hospital
2011390|NCT02576574|Drug|Avelumab|Subjects will be administered with avelumab at a dose of 10 milligram per kilogram (mg/kg) 1-hour intravenous (IV) infusion once a week for 12 weeks and then once every 2 weeks until disease progression or unacceptable toxicities.
1627581|NCT02029248|Other|Quality of life questionnaire|
1627582|NCT02029235|Drug|Acetaminophen/Hydrocodone|Patients will be treated with acetaminophen 325 mg / Hydrocodone 5 mg
1627583|NCT02029235|Drug|Acetaminophen/Ibuprofen|Acetaminophen 500 mg / Ibuprofen 400 mg
1627588|NCT02029183|Device|Bi level positive pressure ventilation|Bi level positive pressure ventilation should be given for subject for 6 hours per night ，total 7 times.
1627589|NCT02029183|Device|bi-level positive airway pressure|
1627590|NCT02029170|Procedure|Early weightbearing|Patients allocated to early weightbearing group are allowed to weightbear after stitch out and application of a walking cast
1627591|NCT02029170|Procedure|Non-weightbearing|Patients allocated to non-weightbearing group are kept non-weightbearing till 6 weeks post-operative
1627594|NCT02029131|Behavioral|Exercise|Educated exercise training for the trunk 3 times per week, each for 20 min. Recommendation of additional fitness courses as offered by the local healthy insurance company.
1627595|NCT02029118|Drug|Herbal plaster ( styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech)|Application containing herbal medicine that mainly include styrax, borneol, frankincense, santalum,trichosanthes kirilowii Maxim, allium macrostemon Bunge, leech and other herbal medicine.
1627596|NCT02029118|Device|acupoint|select acupoint according to traditional Chinese medicine
1627597|NCT02029118|Drug|Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn.|foundation treatment
1627598|NCT02029105|Biological|Mesothelin, hyaluronan, osteopontin, syndecan-1|We compere the serum levels of the tumor markers in patients with pleural diseases according to the groups for the diagnosis and differential diagnosis of the diseases.
1627599|NCT02029079|Dietary Supplement|E+|300 ml E+ per day (525 kcal, 22.5 gram protein) for 35 days.
1627600|NCT02029066|Drug|SR-T100 gel|2g of SR-T100 will topical apply on 100 cm^2 once for 24 hours.
1627601|NCT02029053|Device|Vaginal Lubrication Ring for Vaginal Dryness|"Participants will be asked to complete 4 study visits and one final follow-up phone call. Each study visit will include a brief vaginal exam where vaginal fluid levels and pH levels are checked and questionnaires are completed. Daily diaries will be completed at home and returned to the study staff at subsequent visits.
Participants will self-insert the Intravaginal ring on the 1st study visit. The 2nd study visit will occur 3-4 days later.
The 3rd study visit will occur approximately 7 days after the 1st visit. Participants will remove the device and self-insert a new intravaginal ring.
The 4th study visit will occur approximately 14 days after the first visit. Participants will remove the intravaginal ring and undergo a final vaginal exam.
Participants will be called approximately 7 days after the last visit and will be asked about their current vaginal dryness symptoms and how they felt about the device during the study."
1627602|NCT02029040|Drug|3% Hypertonic Saline versus 0.9 % normal saline|Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.
1627603|NCT02029027|Device|GYNEFFIK(R)|Vaginal electro-stimulation medical device
1627604|NCT02029027|Other|Usual Care|Any treatment / physiotherapy sessions / muscular training ... usually recommended and/or prescribed by the patient's general practitioner or gynaecologist with the exception of vaginal electro-stimulation
1627605|NCT02029014|Device|LAA closure system|
1627606|NCT02029001|Drug|Nilotinib (400 mg BID)|Patients whose tumor harbors mutations of ABL1, KIT, PDGFRA, PDGFRB, DDR1, DDR2, CSF1R, or amplification/translocation of the genes and/or of the ligands.
1627607|NCT02029001|Drug|Everolimus (10 mg QD)|Patients whose tumor harbors mutations or amplification of the PIK3CA, PIK3R1, AKT1, AKT2, mTOR genes, or with TSC1, TSC2 or PTEN loss (defined as complete loss of both gene copies OR loss of one copy + mutation on the other copy).
1627608|NCT02029001|Drug|Sorafenib (400 mg BID)|Patients whose tumor harbors mutations of VEGFR1-3, PDFGRB, FLT3, BRAF (other than V600 mutations), CRAF, KRAS or RET or amplification/translocation of the genes and/or of the ligands.
1627609|NCT02029001|Drug|Lapatinib (1500 mg QD)|Patients whose tumor harbors mutations or amplifications of HER2
1627610|NCT02029001|Drug|Pazopanib (800 mg QD)|Patients whose tumor harbors mutations of VEGFR1-3, PDGFRA, PDGFRB or KIT* or amplification /translocation of the genes and/or of the ligands.
1627611|NCT02028988|Drug|Enzalutamide|
1627612|NCT02028988|Radiation|External Beam Radiation|"Dose will be normalized such that exactly 98% of the PTV (planned target volume) receives the prescription dose and will be scored as per protocol. The maximum allowable dose within the PTV is 107% of the prescribed dose to a volume that is at least 0.03 cc. The minimum allowable dose within the PTV is >95% of the prescribed dose to a volume that is at least 0.03 cc.
EBRT shall receive prescription doses to the PTV 75.6- 79.2 Gy delivered in 1.8 Gy fractions."
1627613|NCT02028975|Other|Measure the threshold of detection for linoleic acid|
1627614|NCT02028975|Other|Oral stimulation tests|
1627615|NCT02028975|Other|Venous blood samples|
1627616|NCT02028975|Other|Samples for genetic studies (ancillary study)|
1627617|NCT02028962|Behavioral|Lifestyle counseling|
1627618|NCT02028949|Drug|Zavedos®|
1627619|NCT02028949|Other|Blood samples|
1627620|NCT02028936|Other|Grape juice R@isol|
1627621|NCT02028936|Other|Commercially-available grape juice|
1627622|NCT02028923|Drug|Morphine gel|Topical
1627623|NCT02028923|Other|Neutral gel|Topical
1627624|NCT02028910|Drug|Ondansetron|"The treatment is administered orally in a single dose of 2.5 ml = 2 mg per 5 kg weight of the child, not to exceed the maximum dose of 10mg. A second dose, the same dose is given back if the child vomits within 15 minutes after the first administration.
The bottle contains at least 2 doses of up to 10 mg for a second dose can be given back in case of vomiting within 15 minutes after the first dose in children weighing more than 25 kg.
The dosage should be adjusted according to the weight of the child"
1627625|NCT02028897|Other|Conventional embryo culture|
1627626|NCT02028897|Other|Enclosed embryo culture|
1627629|NCT02028871|Drug|Intranasal Insulin|
1627630|NCT02028871|Drug|Placebo|
1628148|NCT02024594|Drug|Nitrous Oxide-Oxygen conscious sedation|
1627631|NCT02028845|Device|Biliary cannulation with loop guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
1627632|NCT02028845|Device|Biliary cannulation with straight guidewire|Selective biliary cannulation during endoscopic retrograde cholangiopancreatography
1627633|NCT02028832|Procedure|PIM consult and service provision|If service is requested, treatment options include acupuncture/acupressure, massage, and reiki
1627634|NCT02028832|Procedure|Usual care|Usual care consists of all conventional care options in pediatric oncology including medication and other therapies.
1627635|NCT02028819|Drug|Dolutegravir Sodium Monohydrate|Dolutegravir taken 50mg orally twice daily
1627636|NCT02028819|Drug|Ibalizumab|Ibalizumab will be administered intravenously at a dose of 800mg once every two weeks.
1627637|NCT02028806|Drug|mFOLFIRINOX|Patients will receive mFOLFIRINOX every 2 weeks: Oxaliplatin 65 mg/m2 IV over 3 hours on Day 1; Irinotecan 150 mg/m2 IV over 90 minutes on Day 1; Leucovorin(l-LV) 200 mg/m2 IV over 2 hours on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
1627638|NCT02028780|Drug|Placebo to dose|placebo
1627639|NCT02028780|Drug|Idarucizumab|short infusion
1627640|NCT02028780|Drug|Placebo to Idarucizumab|Placebo to Idarucizumab
1627641|NCT02028780|Drug|dabigatran|2 capsules dabigatran
1627642|NCT02028780|Drug|Idarucizumab|short infusion
1627643|NCT02028767|Drug|Empagliflozin 2.5 mg|Empagliflozin 2.5 mg tablet
1627644|NCT02028767|Drug|Empagliflozin 10 mg|Empagliflozin 10 mg tablet
1627645|NCT02028767|Drug|Metformin 500 mg|Metformin 500 mg tablet
1627646|NCT02028767|Drug|Empagliflozin/Metformin FDC|12.5 mg Empagliflozin / 500 mg Metformin
1627647|NCT02028754|Drug|Sodium Carboxymethylcellulose|Sodium carboxymethylcellulose (Refresh Liquigel®) 1 drop in the study eye 4 times a day for 30 days post-cataract surgery.
1627648|NCT02028754|Drug|Levofloxacin|Levofloxacin 1 drop in the study eye 3 times a day for 7 days post-cataract surgery.
1627649|NCT02028754|Drug|Prednisolone|Prednisolone 1 drop in the study eye 4 times a day for the 1st week post surgery, 3 times a day for the 2nd week post surgery, 2 times a day for the 3rd week post surgery, and 1 time a day for the 4th week post surgery.
1627650|NCT02028741|Other|Transverse vertebral pressures|Graded transverse mobilization directed to the thoracic spine
1627651|NCT02028715|Drug|Placebo (normal saline)|Normal saline (100cc) will be given IV as the placebo medication every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
1627652|NCT02028715|Drug|IV acetaminophen|IV acetaminophen (1,000mg) will be given every six hours for a total of eight doses with the first dose being given at time of anesthesia induction.
1627653|NCT02028702|Dietary Supplement|Placebo|water with color
1627654|NCT02028702|Dietary Supplement|Red Clover extract|Red Clover extract containing 80 mg Isoflavones. Dosage: 2 X 75 ml/day
1627655|NCT02028689|Drug|Lesinurad 400 mg|
1627656|NCT02028689|Drug|Metformin 850 mg|
1627657|NCT02028689|Drug|Furosemide 40 mg|
1627658|NCT02028676|Other|Clinically Driven Monitoring (CDM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. Screening results were used to assess eligibility. All subsequent results at and after randomisation were only returned if requested for clinical management (authorised by centre project leaders); haemoglobin results at week 8 were automatically returned on the basis of early anaemia in a previous adult trial as were grade 4 laboratory toxicities (protocol safety criteria). Total lymphocytes and CD4 tests were never returned for CDM participants, but for all children other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
1627659|NCT02028676|Other|Laboratory plus Clinical Monitoring (LCM)|Participants were examined by a doctor and had routine full blood count with white cell differential, lymphocyte subsets (CD4, CD8), biochemistry tests (bilirubin, urea, creatinine, aspartate aminotransferase, alanine aminotransferase) at screening, randomisation (lymphocytes only), weeks 4, 8, and 12, then every 12 weeks. All results were returned to physicians for patient management. Other investigations (including tests from the routine panels) could be requested and concomitant drugs prescribed, as clinically indicated at extra patient-initiated or scheduled visits.
1627660|NCT02028676|Drug|Arm A: ABC+3TC+NNRTI|Children received a standard WHO-recommended regimen of open-label lamivudine, abacavir, plus NNRTI continuously. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
1627661|NCT02028676|Drug|Arm B: ZDV+ABC+3TC+NNRTI->ABC+3TC+NNRTI maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus NNRTI subsequently. The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
1627662|NCT02028676|Drug|Arm C: ZDV+ABC+3TC+NNRTI->ZDV+ABC+3TC maintenance|Children initiated ART using an induction-maintenance approach, starting with open-label four-drug lamivudine, abacavir, NNRTI, plus zidovudine for 36 weeks, then open-label lamivudine, abacavir, plus zidovudine subsequently (triple NRTI maintenance). The NNRTI (nevirapine or efavirenz) was chosen by clinicians according to local availability and age.
1627663|NCT02028676|Drug|Once-daily ABC+3TC|
1627664|NCT02028676|Drug|Twice-daily ABC+3TC|
1627665|NCT02028676|Drug|Continued cotrimoxazole prophylaxis|
1627666|NCT02028676|Other|Stopped cotrimoxazole prophylaxis|
1627667|NCT02028663|Drug|CJ-12420|Once daily, Oral administration
1627668|NCT02028663|Drug|Esomeprazole|Once daily, Oral administration
1627669|NCT02028650|Biological|the first donor's stem cell|HLA-matched stem cell infusion
1627670|NCT02028650|Biological|the second donor's stem cell|HLA-mismatched, the second donor's stem cell infusion
1627671|NCT02028637|Other|TLRs|Recently it has involved the role of TLR (toll-like receptors) in the pathogenesis of asthma.The possible role that TLRs play in the asthma and its recognition as a new endotype asthma, could open new therapeutic expectations.
1627720|NCT02028182|Biological|Lyral®|T.R.U.E. Test allergen panel (0.40 mg/cm^2, 0.20 mg/cm^2, 0.10 mg/cm^2 and negative control)
1628149|NCT02024594|Behavioral|cognitive-behavioral therapy|
1627672|NCT02028624|Behavioral|Nutrition counseling|Patients received nutrition counseling, through one-to-one sessions conducted once a month, until the 6-month evaluation. Nutrition counseling was based on goal-setting and aimed at increasing adherence to Mediterannean diet.
1627673|NCT02028598|Drug|Treatment 1|An oral single dose administration
1627674|NCT02028598|Drug|Treatment 2|An oral single dose administration
1627675|NCT02028598|Drug|Treatment 3|Co-administration of oral single doses
1627676|NCT02028585|Dietary Supplement|Low-fat milk group|
1627677|NCT02028559|Device|Propulse 1|Move kidney stones with Propulse 1 device.
1627678|NCT02028546|Procedure|bathing and moisturizer application|"regimen 1: soaking an arm for 10 minutes, no moisturizer application regimen 2: soaking an arm for 10 minutes,immediate moisturizer application regimen 3: soaking an arm for 10 minutes, delayed moisturizer application for 30 min.
regimen 4: wait for 10 minutes,no soaking, moisturizer application (moisturizer alone) (All regimens were completed in all patients with 2 visits (7 days interval))"
1627679|NCT02028533|Drug|Oxytocin|
1627680|NCT02028533|Drug|Placebo|
1627681|NCT02028507|Drug|Palbociclib|
1627682|NCT02028507|Drug|Capecitabine|
1627683|NCT02028507|Drug|Exemestane|
1627684|NCT02028507|Drug|Fulvestrant|
1627685|NCT02028494|Drug|Capecitabine|Two dosages comparison
1627686|NCT02028481|Procedure|Postoperative air tamponade|Pars plana vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
1627687|NCT02028468|Procedure|hemiarthroplasty|
1627688|NCT02028455|Biological|Patient Derived CD19 specific CAR T cells also expressing an EGFRt|Defined Composition CD4 and CD8 T cells Lentivirally Transduced to Express a Second Generation 4-1BB:zeta CD19 CAR and EGFRt
1627689|NCT02028442|Biological|Enadenotucirev|Oncolytic virus
1627690|NCT02028429|Drug|Sildenafil.|Arm 1 :Sildenafil Drug Dosage: 25 mg once a day for one week followed by 25 mg twice daily for two weeks then 25 mg thrice daily for one week.
1627691|NCT02028416|Drug|ATG-fresenius|"we will create 2 arms as per randomization table. Both arms will receive ATG-Fresenius but with 2 different regimens.
the first arm will receive ATG-F @10mg/kg for 3 days and second arm will receive ATG-F same dose but for 5 days"
1627692|NCT02028403|Drug|BMS-936559|0.3 mg/kg, 1 mg/kg, 3 mg/kg, or 10 mg/kg of BMS-936559, depending on which cohort participants are enrolled in, administered as an intravenous (IV) infusion
1627693|NCT02028403|Drug|Placebo for BMS-936559|Sodium chloride for injection 0.9%, USP, administered as an IV infusion
1627694|NCT02028390|Device|Scout takes visual and thermal images of external wounds|All images are taken after the wound has acclimated.
1627695|NCT02028390|Device|ImageReview's visual perimeter trace of the external wound|Trace is drawn by the study staff using the ImageReview software.
1627696|NCT02028390|Device|ImageReview's External Wound Trace Overlay|Study staff overlay the trace of the visual external wound's perimeter onto the corresponding thermal image of the external wound.
1627697|NCT02028390|Device|ImageReview's unaffected reference area selected|Study Staff select an unaffected reference area of an adjacent body surface.
1627698|NCT02028390|Device|Adjacent tissue trace of the wound trace overlay|Study staff select an adjacent tissue trace of the wound trace overlay
1627699|NCT02028377|Procedure|PET/MRI|PET/MRI
1627700|NCT02028364|Drug|Everolimus|10mg orally daily
1627701|NCT02028364|Drug|Exemestane|25mg orally daily
1627702|NCT02028338|Device|placebo ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
1627703|NCT02028338|Drug|dapivirine ring|intravaginal ring silicone elastomer intravaginal ring containing no drug product
1627704|NCT02028325|Drug|Fluorescein Sodium|All patients enrolled in the study will prepare for surgery as per standard neurosurgical indications, procedures and institution protocols. At the time of the anesthesia induction, with the patient under general anesthesia, Fluorescein Sodium 10% (100mg/1mL) at a dose of 3-20 mg/kg will be administered intravenously (the optimal dosage will be determined within the study as the most minimal dose for adequate visualization will be used). For vascular lesions, fluorescein sodium 10% (100mg/1mL) will be injected and used to assess its application after the conventional methods have confirmed the exclusion of the aneurysm. No patient's care will be affected by the results of the Fluorescein angiography.
1627705|NCT02028312|Drug|Loteprednol etabonate|
1627706|NCT02028312|Drug|Artificial Tears|
1627707|NCT02028312|Drug|Restasis|
1627708|NCT02028299|Procedure|2D doppler echo with Definity solution|Correlate right heart catheterization results with results from 2D doppler echo with Definity Solution
1627709|NCT02028286|Drug|CLS001|
1627710|NCT02028260|Drug|Modafinil|200 mg daily
1627711|NCT02028260|Drug|Placebo|similar appearing inert tablet
1627712|NCT02028247|Behavioral|Personalized Cognitive-behavioral therapy|
1627713|NCT02028247|Behavioral|Standard Practice Cognitive-behavioral therapy|
1627714|NCT02028234|Drug|Pantoprazole,|os, 20 mg, once per day, for 30 days
1627715|NCT02028234|Drug|Omeprazole|os, 20 mg, once per day, for 30 days
2011391|NCT02574455|Drug|Sacituzumab govitecan|Sacituzumab govitecan (10 mg/kg on Days 1 and 8 of 21-day cycles)
2011392|NCT02574455|Drug|Eribulin|Eribulin (1.4 mg/m2 intravenously on Days 1 and 8 of a 21-day cycle)
1627718|NCT02028208|Biological|Mercury, Aluminum, Palladium|T.R.U.E. Test metal allergen panels containing ascending doses of mercury, aluminum or palladium
1627719|NCT02028195|Other|Health check|"The program includes four components:
Invitation: All participants receive invitation by mail and a prefixed appointment time. A web-based questionnaire including self-reported health (SF12), physical activity, smoking habits and alcohol use/behaviour has to be answered before Health Examination (HE).
The HE include: Blood pressure, waist, weight, lung function test, lipid profile, HbA1c and fitness (Aastrand).
Health profile pamphlet: The participant receives a pamphlet with the results. The persons are stratified into three groups (I) referral to a consultation in general practice (GP) (II) targeted behavioural programs at the health centre (HC) or (III ) no identified need for health promoting follow-up.
Follow-up according to risk-profile: If referred to GP treatment of risk conditions or diseases will follow national guidelines. The GPs were paid 50 Euros per health interview."
1627722|NCT02028143|Device|Biosense Webster irrigated tip catheter|The second group (study group) will have the ICE catheter placed through one of two existing 8F sheaths already in the left atrium. The ICE catheter will be exchanged in the sheath utilizing the lasso multipolar mapping catheter during left pulmonary vein ablation lines. During exchange, suction and irrigation techniques will be utilized to avoid any air or thrombus embolization. All patients will have standard anticoagulation during the procedure with heparin infusion adjusted to an activated clotting time (ACT) of 350-400. The left sided ICE catheter will be adjusted to visualize left sided structures, ablation tip and tissue interface, and adjacent noncardiac structures such as the esophagus during radiofrequency ablation of the left pulmonary vein system.
1627723|NCT02028143|Device|Biosense Webster irrigated tip catheter|Group 1 will receive standard pulmonary vein isolation (PVI) procedure utilizing intracardiac guided ultrasound (ICE) placed within the right atrium via the femoral vein.
1627724|NCT02028143|Procedure|Pulmonary vein isolation|
1627725|NCT02028143|Procedure|ICE catheter placed through one of two existing 8F sheaths|
1627726|NCT02028130|Procedure|LAA electrical isolation + occlusion|LAA electrical isolation + Watchman device implantation to occlude LAA
1627727|NCT02028117|Biological|Enadenotucirev|Oncolytic Virus
1627728|NCT02028104|Biological|Autologous bone marrow mononuclear cell transplantation|bone marrow derived mononuclear cells are administered intrathecally in traumatic brain injury patients
1627729|NCT02028078|Drug|Insulin human|Induces hypoglycaemia
1627730|NCT02028065|Drug|Sugammadex|Sugammadex 4 mg/kg or 16 mg/kg administered as a single IV bolus over 10 seconds
1627731|NCT02028065|Drug|Placebo|Placebo administered as a single IV bolus over 10 seconds
1627732|NCT02028052|Procedure|ROSE|The procedure will proceed with conventional EBUS-TBNA sampling of the target lesion with 22 gauge Vizishot needles. Each subject will be randomized to either ROSE by cytopathologist or no ROSE.
1627733|NCT02028052|Device|22 gauge Vizishot needles|
1627734|NCT02028039|Drug|IPI-145|75 mg orally twice daily for 4 weeks.
1627735|NCT02028039|Behavioral|Follow-up Visit/Call|Follow-up visit 30 days after last dose of study drug. If patient cannot make it to the clinic for this visit, they may speak by phone with a member of the study staff. This phone call should last about 10 minutes.
1627736|NCT02028026|Drug|Vilazodone|10mg/day for 1 week, 20 mg/day for 1 week, and then 40 mg/day for 6 weeks.
1627737|NCT02028026|Drug|Citalopram|20 mg/day for 2 weeks and then 40 mg/day for 6 weeks
2011393|NCT02574455|Drug|Capecitabine|Capecitabine (1250 mg/m2 orally twice daily for 2 weeks followed by a 1 week rest period given as a 21-day cycle)
2011394|NCT02574455|Drug|Gemcitabine|Gemcitabine (1250 mg/m2 intravenously on Days 1 and 8 of a 21-day cycle)
2011395|NCT02574455|Drug|Vinorelbine|Vinorelbine (30 mg/m2) weekly IV injection
1627741|NCT02027987|Drug|valproate acid|valproate acid is a common drug which is applied for epilepsy prevention and treatment.
1627742|NCT02027974|Device|Iconacy Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
1627743|NCT02027974|Device|Stryker Accolade Hip System|Comparison of Iconacy I-Hip system to the Stryker Accolade hip system using a randomized study.
2011396|NCT02574247|Procedure|Computerized auditory training|10 sessions of computerized auditory training (1.5 hr/session) across a 15-week span.
2011397|NCT02573259|Drug|PF-06801591|IV every 21 days (Part 1)
2011398|NCT02573259|Drug|PF-06801591|300 mg SC every 28 days (Part 1 and 2)
1627747|NCT02027948|Other|nutritional and functional assessments|"Patients will undergo nutritional & functional assessments along the continuum of their chemoradiotherapy treatment. The initial assessment will be measurements of height, weight, & baseline weight loss. Patients will receive chemotherapy & radiation as per standard practice at MSKCC, which is induction chemotherapy for approximately 3 weeks, followed by concurrent chemoradiotherapy. A commonly used regimen is weekly carboplatin (AUC 2) with paclitaxel (50 mg/m2) & radiation consisting of 5040 cGy over 28 fractions. Patients in this study will undergo assessments at three time points (at baseline, after induction chemotherapy, & post-treatment.) At baseline, all patients will complete the functional assessment, dysphagia scale, & Mini- Nutritional Assessment (MNA). According to the baseline MNA score, patients will be categorized as normal nutrition, at risk for malnutrition, or malnourished & receive the appropriate intervention."
1627748|NCT02027935|Drug|Cyclophosphamide|300 mg/m2 by vein 2 days prior to T cell infusion.
1627749|NCT02027935|Procedure|CD8+ T Cells|T cells administered at a dose of 10^10 cells/m2 by vein on Day 0.
1627750|NCT02027935|Drug|Interleukin-2|250,000 U/m2 administered subcutaneously every 12 hours begins within 6 hours of T cell infusion and continues for a total of 14 days On Day 0 to Day +14.
1627751|NCT02027935|Drug|Ipilimumab|3 mg/kg by vein 24 hours after T cell infusion. Subsequent infusions administered on Days +22, +43 and +64.
1627752|NCT02027922|Other|Fluor Protector S|Fluor Protector S intervention group A (25 ml) Duraphat group B (25ml)
1627753|NCT02027909|Device|Reprogramming dual chamber pacemaker|Reprogramming rate response feature in the Medtronic pacemaker to each arm with crossover
1627754|NCT02027896|Other|Accelerated medical clearance and surgery|Rapid medical clearance with targeted arrival to the operating room within 6 hours of diagnosis of a hip fracture requiring surgical repair.
1627755|NCT02027883|Device|Nominal T shock setting|Nominal Parameter Set 1 Programming Values for EnTrust
1627756|NCT02027883|Device|Educated T shock setting|Experimental Parameter Set 2 Programming Values
1627757|NCT02027870|Device|EXCEL-II biodegradable polymer sirolimus-eluting stent|EXCEL-II biodegradable polymer sirolimus-eluting stent implantation
1627758|NCT02027857|Device|EIT monitoring|
1627759|NCT02027857|Device|non-invasive ICP monitoring|
1627760|NCT02027844|Behavioral|Cartoon|Cartoon watching by children during inhalational induction of sevoflurane
1627761|NCT02027844|Behavioral|parental presence|parental presence during inhalational induction of sevoflurane
1627762|NCT02027831|Drug|Indocyanine Green|
1627763|NCT02027818|Drug|Indocyanine Green|Observation of the correlation between fluorescence and margins of the tumour after IV injection of ICG
1627764|NCT02027805|Biological|T-Guard|
1627765|NCT02027792|Other|Cabbage leave wraps|
1627766|NCT02027792|Drug|Diclofenac Gel|
2011399|NCT02572947|Drug|Dolutegravir|
1627767|NCT02027779|Biological|GreenGene™ F|"Prophylaxis safety and efficacy substudy:
intra venous infusion, 30 ± 10 IU/kg infusions 3 times per week with dose escalation to 45 ± 10 IU/kg if appropriate, for 50 exposure days"
1627768|NCT02027779|Biological|GreenGene™ F|"On-demand safety and efficacy substudy:
minor bleed = 20 ± 10 IU/kg moderate bleed = 30 ± 10 IU/kg major bleed = 30 - 50 IU/kg"
1627769|NCT02027766|Other|Calf muscle stretching|
1627770|NCT02027753|Drug|INSULIN GLARGINE|Pharmaceutical form: solution Route of administration: subcutaneous
1627771|NCT02027753|Drug|Metformin|Pharmaceutical form: tablet Route of administration: oral
1627772|NCT02027753|Drug|DPP-4 inhibitor|Pharmaceutical form: tablet Route of administration: oral
1627773|NCT02027753|Drug|Sulphonylurea|Pharmaceutical form: tablet Route of administration: oral
1627774|NCT02027740|Dietary Supplement|almond|
1627775|NCT02027727|Other|No Intervention|no intervention- tihs is an observational study
1627777|NCT02027688|Other|q6 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 6 hours.
1627778|NCT02027688|Other|q3 hour oral feeding schedule|The intervention is the schedule under which stable infants are offered oral feeding attempts: every 3 hours.
1627779|NCT02027675|Other|High fat poor micronutrient meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an high fat poor micronutrient meal.
1627780|NCT02027675|Other|Mediterranean meal|The meal will be prepared by a team of nutritionist in order to comply with the demand characteristics of an Mediterranean meal
1627781|NCT02027662|Drug|Osvaren Granules|
1627782|NCT02027662|Drug|Osvaren film-coated tablets|
1627783|NCT02027636|Behavioral|Engagement and Counseling for Latinos (ECLA-F)|The Engagement and Counseling for Latinos - Face-to-face (ECLA-F) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered in person. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and help with transportation. This intervention was identical to the telephone (ECLA-F) intervention, except for the delivery method.
1627784|NCT02027636|Behavioral|Engagement and Counseling for Latinos (ECLA-T)|The Engagement and Counseling for Latinos - Telephone (ECLA-T) intervention is a cognitive behavioral therapy (CBT) plus care-management intervention delivered via telephone. The CBT component consists of 6-8 sessions, delivered by a Master's level clinician, and focusing on self-management techniques, problem-solving, and techniques for managing depression and stress. The care-management component of the intervention consisted of monitoring, assistance in scheduling appointments, and technical assistance. This intervention was identical to the face-to-face (ECLA-F) intervention, except for the delivery method.
1627785|NCT02027623|Behavioral|Motor skill training|The participant will assist in selecting both simple and complex functional activities to practice. Difficulty will be graded to match the participant's motor capabilities. Three activities will be practiced per session. Within the practice of activities the training will emphasize 1) contraction of groups of specific trunk muscles, 2) earlier and greater movement of the hip, knee, and/or thoracic spine relative to the lumbar spine, 3) later and less movement of the lumbar spine relative to other regions. Within each activity the conditions of practice will vary based on 1) the participant's ability to perform the activity, and 2) the level of challenge the participant is faced with when performing the activity during his day. Equipment will be provided as needed.
1627786|NCT02027623|Behavioral|Strength and flexibility exercise|Exercises based on best evidence for effectiveness in people with chronic low back pain will be prescribed. Strengthening exercises will target all trunk muscles. Flexibility exercises will target all trunk and hip motions. All exercises will be performed at the intensity appropriate for the person's musculoskeletal fitness level based on the American College of Sports Medicine guidelines. Difficulty level, frequency, and number of repetitions will be modified based on guidelines described in the literature. Equipment will be provided as needed.
1627787|NCT02027597|Other|Attack of the S. Mutans|A research assistant led groups of students through the Attack of the S. Mutans exhibit. All participants played all the games and viewed all the graphical content of the exhibit.
1627788|NCT02027597|Other|Follow-up|This group experienced the Attack of the S. Mutans! exhibit and 3 doses of follow-up booster content at a web site.
1627789|NCT02027597|Other|SnowWorld|SnowWorld is a 3D first-person-shooter game developed by Firsthand Technology. In SnowWorld, the player shoots snowballs at penguins, polar bears, and other features of a frozen landscape. The game is designed to help burn victims cope with pain, and has no oral health messages.
1627790|NCT02027584|Other|collection of remnant of clinically indicated blood sample|collection of remnant of clinically indicated blood sample
1627791|NCT02027571|Behavioral|Intensive Lifestyle Intervention (ILI)|ILI consists of weight loss ( > 10%); caloric reduction; physical activity (180 min/week); monthly visits for group counseling for 6 months, followed by quarterly visits; and meal replacements.
1627792|NCT02027558|Behavioral|Behavioral Education Intervention I|Manual-based education program focusing on sleep and sleep apnea provided by allied health personnel in individual sessions.
1627793|NCT02027558|Behavioral|Behavioral Education Intervention II|Manual-based education program focusing on sleep and sleep apnea provided by allied health personnel in individual sessions.
1627794|NCT02027545|Behavioral|Decision Aid|Printed booklet comprising educational information about benefits and harms of screening, individualized estimates of benefits and harms of screening, and values clarification exercise
1627795|NCT02027545|Behavioral|Provider Education|Providers of patients in both arms of the study will be given an educational module about recent data on the benefits and harms of screening how these data fit in with existing population-centered guidelines.
1627796|NCT02027545|Behavioral|Performance Measure Modification|The clinical reminder system will be modified so to facilitate documentation of informed decision making about CRC screening, including specific reasons for not screening. Additionally, providers who indicate a specific exception for not screening (using the modified clinical reminder) will be considered as satisfying the requirements and will not be penalized in terms of performance pay, and will be removed from feedback reports that encourage population screening.
1650905|NCT01848743|Drug|lamivudine|
1627797|NCT02027545|Behavioral|Simple Informational Booklet|A simple informational booklet explaining colorectal cancer screening and current screening recommendations.
1627798|NCT02027532|Drug|Cefazolin|
1627799|NCT02027532|Drug|Vancomycin|
1627800|NCT02027519|Other|HIV Self-testing with Standard Counseling and Testing (SCT) Confirmation|"Partners of the index participants and other household members will be offered HIV self-testing by the mobile testing team. Those who consent to HIV self-testing with SCT confirmation will complete the following procedures:
Undergo standardized pre-test counseling and demonstration of use of HIV rapid test kit by trained study staff, including how to determine test results
Self-administer HIV rapid test and read test results
Provide study staff with self-testing result
Undergo confirmatory testing as well as post-test counseling by study staff (SCT) if the initial self-test is positive, there is any doubt about the results, or the test reveals couple discordance"
1627801|NCT02027493|Drug|Reiferon R|subcutaneous injection of 100 μg/m2
1627802|NCT02027493|Drug|Ribavirin|15 mg/kg daily on two divided doses
1627803|NCT02027467|Dietary Supplement|StemAlive®|
1627804|NCT02027467|Dietary Supplement|Placebo (For StemAlive®)|
1627805|NCT02027454|Drug|GSK1265744|White to slightly colored film coated tablet with unit dose strength of 30 mg and dose level of 150mg (5 tablets of 3 mg) administered orally every 12hours for 3 doses.
1627806|NCT02027454|Drug|GSK1265744 matching placebo|GSK1265744 matching placebo tablets administered orally every 12hours for 3 doses (5 tablets per dose).
1627807|NCT02027454|Drug|Moxifloxacin|Dull red, oblong, convex film coated tablets with unit dose strength of 400 mg administered orally as a single dose.
1627808|NCT02027441|Other|Standard Counseling and Testing|"Individuals who opt for standard counseling and testing will complete the following procedures:
• Standardized pre- and post-test counseling and HIV testing using HIV rapid test per approved national guidelines"
2011400|NCT02570984|Drug|Omalizumab|anti-ige injection
2011401|NCT02570984|Drug|Placebo|placebo comparator arm, injection similar to active
2011402|NCT02570386|Procedure|Fresh embryo transfer|Women allocated to the control arm will either undergo embryo transfer at cleavage stage or extended culture and transfer at blastocyst stage according to local policy. A maximum of 2 embryos or blastocysts will be replaced according to the standard protocol under transabdominal ultrasound guidance. Luteal phase support is given according to local protocols.
2011403|NCT02570386|Procedure|Frozen embryo transfer|Fresh embryo transfer will not be undertaken. Embryos will be frozen by vitrification or slow freezing at cleavage or blastocyst stage according to standard agreed local protocols. Women will be contacted after 4 weeks and arrangements made for frozen embryo transfer.
2011404|NCT02569840|Dietary Supplement|Amino Acid Feed|Each child will receive the amino acid based feed for a period of up to 4 weeks (28 days). The feed prescription will be determined on an individual basis by the Dietitian responsible for the child's nutritional management. The child will take the feed orally or via a pre-existing naso-gastric, gastrostomy or jejunostomy tube.
2011405|NCT02570139|Device|Cavilon Advanced Skin Protectant|The liquid barrier film flows from the applicator and dries quickly on the skin. It is durable for 72-96 hours under conditions of incontinence.
2011406|NCT02570139|Device|ConvaTec Sensi-Care Protective Barrier|Sensi-Care is commercial paste product applied to protect denuded and weeping skin from incontinence.
1627816|NCT02027415|Dietary Supplement|Beet juice|2 cups of beet juice will be given before the car ride
1627817|NCT02027415|Dietary Supplement|Orange juice|2 cups of orange juice will be given before the car ride
1627818|NCT02027402|Procedure|Laparoscopic cholecystectomy with drain insertion|In the drain insertion group, investigators use the closed suction drain through a lateral 5-mm trocar and placed it in right subhepatic space
1627821|NCT02027363|Drug|Capecitabine|maintenance with apecitabine，1,000 mg/m2 twice a day， days1-15，every 3 weeks，until progression, unacceptable toxicity, or patient withdrawal.
1627822|NCT02027363|Other|Observation|Patients with metastatic colorectal cancer who achieved objective response or stable disease after 4-6 months first-line chemotherapy would stop the chemotherapy and observation
1627823|NCT02027350|Device|CD Leycom/Millar Instruments conductance catheter|Conductance catheter-Pressure volume relationship
1627824|NCT02027337|Drug|20 mcg ethinylestradiol /3 mg drospirenone|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
1627825|NCT02027337|Drug|20 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
1627826|NCT02027337|Drug|30 mcg ethinylestradiol/3 mg drospirenone|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12
1627827|NCT02027337|Drug|30 mcg ethinylestradiol/3 mg drospirenone and Selmevit|One contraceptive pill in each of 21 days, than 7 days break. Number of Cycles: 12 Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
1627828|NCT02027337|Drug|35 mcg ethinylestradiol/2 mg cyproterone|1 contraceptive pill in each day of 28 day cycle. Number of Cycles: 12
1627829|NCT02027337|Drug|35 mcg ethinylestradiol/2 mg cyproterone and Selmevit|One contraceptive pill in each day of 28 day cycle. Number of Cycles: 12. Two pills of Selmevit in each day during 30 days, repeat of the course every 3 months.
1627830|NCT02027324|Drug|Chlorhexidine-alcohol group|2% chlorhexidine in 70% isopropyl alcohol in accordance with manufacturer's instructions for safe usage.
1627831|NCT02027324|Drug|Povidone-Iodine Group|10% Povidone-Iodine for surgical antisepsis according to manufacturer's instructions.
1627832|NCT02027311|Drug|Etomidate|This cohort would be administered etomidate with meperidine. The initial dose of etomidate is 0.1mg/kg IV and meperidine, 25mg. Additional dose of etomidate is 2mg(1cc). In old age cased, more than 65 years old, 30% of initial dose discounted.
1627833|NCT02027311|Drug|Midazolam|This cohort would be administered midazolam with meperidine. The initial dose of midazolam is 0.06mg/kg IV and meperidine 50mg IV. Additional dose is 1mg of midazolam. In the elders, more than 65 years old, initial dose was declined to 70%.
1627834|NCT02027311|Drug|Meperidine|Both groups were administered same dose of meperidinie 50mg. Then elders > 80 years old were administered 25mg iv bolus.
1627835|NCT02027298|Drug|Abatacept|by SC injection of 125 mg weekly for 6 months
1627872|NCT02027012|Device|Percutaneous renal denervation with the Vessix™ Renal Denervation System|
1627836|NCT02027285|Dietary Supplement|fortified milk|"FortifiedUltra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose <0.5%) produced by Granarolo s.p.a. supplemented with long chain unsaturated fatty acids DHA (Docosahexaenoic acid) +EPA (Eicosapentaenoic acid), vitamin D, B12, B6, B9, E,C, Zinc and Selenium versus placebo Ultra-high temperature (UHT), partly-skimmed milk (1.6% fat), highly digestible (lactose <0.5%) of the same manufacturer.
The nutrients added are: DHA + EPA 1.4 mg/ml; vitamin D3 0.068 mcg/ml; B6 6.4 mcg/ml; B12 0.01 mcg/ml; B9 (folic acid) 0.80 mcg/ml; vitamin E 0.05 mg/ml; vitamin C 0.19 mg/ml; Zinc 0.04 mg/ml; Selenium 0.22 mcg/ml. The protein content of the milk is 0.04 g/ml."
1627837|NCT02027272|Drug|Dexamethasone|Intravenous Dexamethasone 12 mg, 2 doses, 12 hours apart
1627838|NCT02027259|Behavioral|Behavioral activation (BA)|The addition of Behavioral activation (BA) to our group visits in patients with DM and depression will consist of 4 weekly group visits of 2-hour duration followed by monthly booster group visits for 6 months to prevent relapse.
1627839|NCT02027246|Biological|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
1627840|NCT02027233|Other|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
1627841|NCT02027220|Drug|G-CSF|G-CSF Intracutaneous injection (IC) on days 0, 1, 7, 8, 14, 15, 21 and 22, every four weeks.
1627842|NCT02027220|Drug|Bortezomib|Bortezomib Intravenous injection (IV) on days 1, 8, 15 and 22, every four weeks.
1627843|NCT02027220|Drug|Cyclophosphamide|Cyclophosphamide, Continuously Intravenous injection (CIV) on days 1, 8, 15 and 22, every four weeks.
1627844|NCT02027220|Drug|Dexamethasone|Dexamethasone Intravenous injection (IV) on days 1, 2, 8, 9, 15, 16, 22 and 23, every four weeks.
1627845|NCT02027207|Biological|Shanchol|"We will use the killed whole cell oral cholera vaccine, Shanchol that will be manufactured by Shantha Biotechnics, in Hyderabad, India for the study. The vaccine is registered in India and is prequalified by the WHO. Shanchol is available in a single dose vial. Vaccine will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive vaccine.Pregnancy status will be enquired verbally for all married women of child bearing age during the census update as well as before vaccination to exclude them from the study.
Prior to vaccination, informed consent will be taken from the adults and guardians of minor participants .Each dose of vaccine will be 1.5 ml in volume."
1627846|NCT02027207|Biological|Placebo|Placebo will be transported from the manufacturer and will be maintained at 2-8oC. Each participant over the age of one year and non pregnant females living in communities will be individually randomized to receive placebo.Each dose of placebo will be 1.5 ml in volume.Placebo will be dispensed in liquid form in identical vials.
1627847|NCT02027194|Drug|Cure-Allergic Rhinitis Syrup|Delivered one bottle for two weeks to the participants twice
1627848|NCT02027194|Drug|Yu-ping-fung San|Delivered one bottle for 2-week usage to the participants twice
1627849|NCT02027194|Drug|Placebo|Delivered one bottle (wheat power with favors) for 2-week usage to the participants twice
1627850|NCT02027181|Device|Device FreeO2 v2.0|"Automatic adjustment of oxygen through the Free O2 device.
FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
1627851|NCT02027181|Device|Device FreeO2 v2.0|"Manual adjustment of oxygen without the assistance of the FreeO2 device.
Only FreeO2 device in mode medical data collecting(SpO2,EtCO2...)."
1627852|NCT02027168|Other|CPA|Site specific, patient centered manual physical therapy regimen focused on restoring function to the entire body
1627853|NCT02027155|Drug|AR09 solution|moderate levels of sedation
1627854|NCT02027155|Drug|placebo|Sterile Saline, USP
1627855|NCT02027142|Other|Pittsburgh Sleep Quality Index.|"Pittsburgh Sleep Quality Index is an effective instrument used to measure the quality and patterns of sleep of patients. It allows evaluating poor from good sleep by assessing seven domains. A total score ≤ 5 indicated good sleep quality while a total score > 5 was indicated poor sleep quality."
1627856|NCT02027142|Other|Epworth sleepiness scale.|Epworth sleepiness scale is an 8-item questionnaire developed to measure average daytime sleepiness. A total score ≥ 10 indicates excessive daytime sleepiness.
1627857|NCT02027142|Other|Insomnia Severity Index.|Insomnia Severity Index is a 7-item questionnaire developed to measure insomnia. A total score between 0 and 7 correspond to not clinically significant insomnia, between 8 and 14 to subthreshold insomnia, between 15 and 21 to clinical insomnia (moderate), between 22 and 28 to clinical insomnia (severe).
1627858|NCT02027142|Other|The Endometriosis Health Profile.|The Endometriosis Health Profile is a patient generated instrument that evaluates disease-specific health-related quality of life in patients with endometriosis. The questionnaire is administrable to all patients with endometriosis and it consists in 30 items divided in 5 domains (pain, control and powerlessness, emotional well-being, social support and self-image). Each scale for each domain is comprised between 0 (indicating the best health status) and 100 (indicating the worst health status).
1627859|NCT02027129|Other|High Frequency Oscillation|Comparison of low frequency HFO/HFO-TGI with cuff leak and high frequency HFO without cuff leak on right ventricular function
1627860|NCT02027116|Biological|VGX-6150|Plasmid DNA delivered via IM injection with electroporation
1627861|NCT02027103|Drug|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
1627862|NCT02027103|Drug|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
1627863|NCT02027090|Drug|Routine dose icotinib|Icotinib is administered 125 mg three times daily.
1627864|NCT02027090|Drug|Higher dose icotinib|After 8-week induction of icotinib with a dose of 125 mg three times daily, icotinib is administered 375 mg three times per day.
1627865|NCT02027077|Behavioral|Control group|No prescribed intervention/ Participants asked to follow normal initiatives to engage in physical activity a healthful diet behaviors for the duration of the intervention
1627866|NCT02027077|Behavioral|Lifestyle counselling|Participants will follow a prescribed behavioral intervention program seeking small changes in both physical activity and diet for the duration of the intervention.
1627867|NCT02027064|Drug|Interferon-alpha|
1627868|NCT02027038|Device|Pelvic belt application|
1627869|NCT02027025|Drug|SPARC1103 I|
1627870|NCT02027025|Drug|SPARC1103 II|
1627871|NCT02027025|Drug|SPARC Placebo|
1991938|NCT00193739|Procedure|Radical abdominal hysterectomy (class III), BPLND & lower para aortic lymph node sampling|NACT followed by surgery
1627874|NCT02026973|Drug|Fulvestrant|
1627875|NCT02026973|Drug|Anastrozole|
1627876|NCT02026973|Drug|Placebo|
1627877|NCT02026973|Drug|Somatostatin|
1627878|NCT02026960|Device|RNA extraction and amplification from biopsy specimens|
1627879|NCT02026947|Drug|Sodium Benzoate|0.5 g/day during the first week, 1.0 g/day for the next 11 weeks. One capsule at the morning for the first week. One capsule at the morning and one at the evening for 2-12 weeks.
1627880|NCT02026947|Drug|Placebo|
1627881|NCT02026934|Device|CliniMACS CD34 Reagent System|Following screening and enrollment, peripheral blood or bone marrow collection will be performed on the donor followed by subsequent CD34+ cell selection using the Miltenyi CliniMACS device. There is no limit to the number of CD34+ progenitors that can be administered. The CD34+ selected cells will be infused within 12 hours of the initiation of processing.
1627882|NCT02026921|Drug|Carboplatin|Carboplatin, AUC5, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops
1627883|NCT02026921|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
1991939|NCT00193739|Drug|Inj.Cisplatin|Concurrent chemo radiotherapy
1627885|NCT02026895|Genetic|Genetic blood sample|
1627886|NCT02026882|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway. Preoxygenation, rapid sequence induction and cricoid pressure. Induction of general anaesthesia.
1627887|NCT02026869|Drug|Metformin|Metformin is taken either orally or vaginally every 12 hours
1627888|NCT02026856|Drug|sodium selenite pentahydrate|
1627889|NCT02026856|Other|placebo - continuous saline NaCl 50 ml|
1627890|NCT02026817|Drug|HCP1201 750/10mg|750mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
1627891|NCT02026817|Drug|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
1627892|NCT02026817|Drug|Rosuvastatin 10mg|Co-administration of Metformin 750mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
1627893|NCT02026791|Device|I-gel|"The patient was monitored at 1-5 minute intervals.
While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.
After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).
Then, with the assistance of another anesthesiologist, I-gel prepared in advance was inserted."
1627894|NCT02026791|Device|Supreme-LMA|"The patient was monitored at 1-5 minute intervals.
While supplying oxygen through a mask, propofol 1.0mg/kg and remifentanil 0.5ug/kg were intravenously injected to induce anesthesia. When consciousness was not lost, propofol 0.5mg/kg was additionally injected. After consciousness was lost and spontaneous respiration disappeared, rocuronium 0.3 mg/kg was intravenously injected while performing manual ventilation.
After injecting an anesthetic and muscle relaxant, the injection concentration of fresh gas including 6 L/min oxygen and desflurane was regulated to maintain BIS between 40 and 60. A train of four (TOF) was performed with a nerve stimulator for muscle relaxation monitoring to verify that a muscular contraction did not take place (TOF=0).
Then, with the assistance of another anesthesiologist, Supreme LMA prepared in advance was inserted."
1627895|NCT02026778|Drug|ondansetron|"The ondansetron group is given placebo (pyridoxin) instead of betahistine.
The ondansetron group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
1627896|NCT02026778|Drug|ondansetron-betahistine|"The ondansetron-betahistine group is given betahistine 18mg orally in the morning of surgery and postoperative day 1.
The ondansetron-betahistine group is given ondansetron 4 mg bolus at the end of surgery and ondansetron 8 mg added to the IV-PCA."
1627897|NCT02026765|Device|traditional lens|A random eyes with traditional lens
1627898|NCT02026765|Device|heparin surface modified aspheric lens|the other eye implant heparin surface modified aspheric lens
1627899|NCT02026739|Procedure|low supplemental oxygen concentration|low supplemental oxygen concentration would be used during the surgery
1627900|NCT02026739|Procedure|high supplemental oxygen concentration (conventional)|high supplemental oxygen concentration would be used during the surgery
1627901|NCT02026713|Other|quit smoking for a 2 weeks period|evaluate the platelet reactivity after 15 days by quit smoking
1627902|NCT02026700|Device|bariederm cream|patients are asked to apply twice a day a barrier cream on their hands for 3 weeks only
1627903|NCT02026687|Procedure|Epidural|
1627904|NCT02026687|Procedure|Intrathecal|
1627905|NCT02026674|Device|FloRite|Disposable home use urine flow meter.
1627906|NCT02026622|Behavioral|psychometric tests|NEO-PI, MADRS, MINI depression, MMSE, STAI-E, ERD, Anhedonia
1627907|NCT02026622|Device|MRI|ASL, rest f-MRI, FLAIR, white matter hyper intensities load
1627908|NCT02026622|Device|transcranial doppler and TPI|transcranial doppler TPI
1627909|NCT02026622|Behavioral|explicitative interview|
1627910|NCT02026609|Other|Oral glutamine challenge|Blood ammonia determination before, 30-, 60-, and 90-minute, after intake of 10 g of L-glutamine
1627911|NCT02026609|Other|Psychometric Tests|PHES (portosystemic hepatic encephalopathy score) and ICT (inhibitory control test)
1627914|NCT02026583|Drug|Simvastatin|
1627915|NCT02026570|Behavioral|Internal Focus of Attention|Providing instructions for the user to manipulate their residual limb in space during standing and walking tasks.
1628197|NCT02024191|Dietary Supplement|Glutamine|
1628198|NCT02024178|Procedure|Ultrasound Imaging|
1627916|NCT02026570|Behavioral|External Focus of Attention|Providing instructions for the user to manipulate their prosthetic foot in space during standing and walking tasks.
1627917|NCT02026544|Device|Low Frequency Therapeutic Ultrasound|29 kHz (kilohertz) low frequency therapeutic ultrasound delivered transcutaneously
1627918|NCT02026531|Other|3-Helium gas|3-Helium gas for MRI contrast
1627919|NCT02026518|Dietary Supplement|Soy isoflavones|
1627920|NCT02026518|Dietary Supplement|cholecalciferol|
1627921|NCT02026518|Dietary Supplement|Placebo of soy isoflavones|
1627922|NCT02026518|Dietary Supplement|placebo of cholecalciferol|
1627923|NCT02026505|Drug|Bortezomib|
1627924|NCT02026492|Other|Exercise challenge in a cold chamber|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in a cold chamber.
1627925|NCT02026492|Other|Methacholine challenge|nebulized metacholine administered at following doses: 0,01mg, 0,1mg, 0,4mg, 0,8mg und 1,6mg
1627926|NCT02026492|Other|Exercise challenge in room temperature|Exercise challenge is defined as running on a treadmill for 6-8 minutes on submaximal work load in room temperature.
1627927|NCT02026479|Drug|Dexamethasone Phosphate|5mg; postauricular injection
1627928|NCT02026479|Drug|Dexamethasone Phosphate|10mg; postauricular injection
1627929|NCT02026479|Drug|Ginaton|40mg/pill, 3times/day,oral
1627930|NCT02026453|Other|Pharmacist obtains admission medication history|
1627931|NCT02026453|Other|Pharmacy technician obtains admission medication history|
1627932|NCT02026414|Dietary Supplement|PrimaVie|Subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) twice a day for the first 8 weeks they are enrolled in the study. For the last 4 weeks of the study, subjects will take 250 mg of PrimaVie (herbal supplement manufactured by Natreon, Inc) supplement twice a day while also completing supervised exercise on a treadmill (70-75% of maximum Heart Rate for 20 mins, plus 5 minutes of warm up and 5 minutes of cool down exercises for a total of 30 minutes a day 3 days a week). Subjects will participate for a total of 12 weeks and come for three total visits. At each visit, subjects will have muscle biopsies taken from their thigh or calf as well as approximately 2 tablespoons of blood drawn.
1627933|NCT02026414|Other|Exercise|
1627934|NCT02026401|Biological|NGM282|
1627935|NCT02026401|Biological|Placebo|
2011407|NCT02569437|Drug|Doxycycline|Doxycycline (200 mg PO X 1 dose on Day 1, then 100 mg PO daily) for Day 2-20
2011408|NCT02569437|Drug|methylprednisolone|oral methylprednisolone: 32 mg x 5 days, 16 mg x 5 days, 8 mg x 10 days
1627938|NCT02026349|Drug|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.
Day 1: 1800 mg twice daily (loading doses)
Days 2 through 5: 800 mg twice daily"
1627939|NCT02026349|Drug|Placebo|Administered twice daily over 5 consecutive days for a total of 10 doses.
1627940|NCT02026336|Other|electronic nose|"Exhaled gas to assess e-nose VOC profiles was collected as described. Briefly, patients breathed through a mouthpiece into a 2-way nonrebreathing valve (Hans rudolph 2700, Hans rudolph, Kansas City, Mo) with an inspiratory VOC filter and an expiratory silica reservoir to dry the expired air. Expiratory air was collected in a 10-L Tedlar bag. Within not more than 10 minutes, the bag was connected to the e-nose device (Cyranose 320®; Smith Detections, Pasadena, CA), provided with a 32 organic polymeric nano-composite sensor array, for 5 minutes and changes in the nano-sensor electrical resistance generated a breath-print VOC profile."
1627941|NCT02026323|Other|acupuncture|acupuncture
1627942|NCT02026310|Drug|glimepiride|on the basis of metformin and glargine, glimepiride is added; with the maximun dose of glimepiride, if the targeted FPG is not reached, glargine dose will be increased.
1627943|NCT02026310|Drug|glargine and metformin|
2011409|NCT02569437|Drug|nasal saline spray|nasal saline sprays: 2 sprays each nostril three times a day
2011410|NCT02569437|Drug|Flonase|daily nasal steroid sprays (Flonase, 2 sprays each nostril daily).
1627946|NCT02026284|Other|Questionnaire|A questionnaire was performed to gravid women who are to deliver, regarding theri anesthesia preferences.
1627947|NCT02026271|Biological|INXN-2001|"2.0 x 10^11 viral particles (vp) per injection or 1.0 x 10^12 viral particles (vp) per injection
one intratumoral injection of INXN-2001"
1627948|NCT02026271|Drug|veledimex|"4 doses (20mg/day, 40mg/day, 80mg/day, and 120mg/day)
14 oral daily doses of INXN-1001
1 Expansion cohort at a single dose level at or below MTD"
1627949|NCT02026258|Procedure|Piezotome-Corticision|Local anesthetic will be administered to the labial sulcus of the mandibular incisors. A scalpel will be used to make three vertical incisions through the gingiva, 4mm below the interdental papilla, interproximally between mandibular canines and lateral incisors, and central incisors on the labial aspect of the mandible. The incisions will be 4mm in length. A piezosurgery knife will be used to create the cortical alveolar incisions to a depth of 1mm within the cortical bone. The depth of the cortical incision will be limited to 1mm for a safety margin. Postoperatively, subjects will be advised to rinse with chlorhexidine mouthwash twice a day for one week and take acetaminophen as needed.
1627950|NCT02026258|Device|Orthodontics|Subjects will be followed every 4-5 weeks after the first wire placement until full alignment of the lower arch (irregularity index 0-2mm). The archwire sequence will be 0.014-in Cu-NiTi wire for the first two visits followed by a 0.014 X 0.025-in Cu-NiTi wire until completion of alignment.
1627951|NCT02026245|Device|Data gloves to perform movements|"Using the electronic data gloves to perform a set routine of movements:
5DT 'dataglove 14 Ultra' Electronic glove (commercially available)
New 'Tyndall/UU' developmental dataglove"
1627952|NCT02026232|Drug|Hydroxychloroquine|200mg twice daily
1627953|NCT02026232|Other|Hydroxychloroquine Placebo|200mg placebo twice daily
1627954|NCT02026219|Drug|Clopidogrel|Clopidogrel 600mg loading
1627955|NCT02026219|Drug|Ticagrelor|Ticagrelor 180mg loading
1627956|NCT02026206|Device|low-level light therapy|we used a skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
1628199|NCT02024152|Drug|JDP-205 IV high dose|
1628200|NCT02024152|Drug|JDP-205 IV low dose|
2011411|NCT02569437|Drug|sugar pill|placebo pill to match doxycline
1627957|NCT02026206|Device|Placebo|we used a placebo skin-adhesive LLLT device called the Color DNA-WSF (Color Seven Co., Seoul, Korea) which consists of body for power supply and two microprocessor-controlled light-emitting diodes. We selected two acupuncture points, conception vessel 4 (CV4; Guanyuan) and CV6 (Qihai), for treating dysmenorrhea. The participants attached the placebo skin-adhesive LLLT device probes to both acupuncture points according to treatment schedule.
1627958|NCT02026193|Procedure|oocyte vitrification|
1627959|NCT02026193|Procedure|embryo freezing|
1627960|NCT02026180|Device|Micropuncture Access|Femoral arterial access will be obtained either with a 21G micropuncture needle kit or an 18G standard access needle.
1627961|NCT02026167|Behavioral|Collaborative Care|Addition of a Health Care Assistant to treatment team, case review by expert panel of supervisors, non-medical interventions
1627962|NCT02026141|Drug|Dexmedetomidine|
1627963|NCT02026141|Drug|Normal Saline Placebo|
1627964|NCT02026115|Behavioral|PAINReportIt|PAINReportIt is a software program first developed with an electronic MPQ (1970 version) and now includes questions about analgesics used by the patient and a shortened version of the pain Barriers Questionnaire (BQ). PAINReportIt is designed as an interactive, touch screen method for assessment of pain. It can be self-administered and requires little or no patient computer experience and minimal or no provider time for administration. Directions for self-administration allow the patient to read instructions on-screen and practice making all types of selection responses that are available in the program. Directions from the paper and pencil tools were modified to address the touch screen method of recording patient responses. The copyright is owned by Dr. Ronald Melzack for the MPQ and Dr. Sandra Ward for the BQ. Both of these individuals have authorized the modifications, presentation format, and computerized use of their tools.
1627965|NCT02026115|Behavioral|PAINConsultN|PAINConsultN for hospice nurses. Our previous studies support the feasibility and clinical effect of PAINConsultN. This narrative and graphic tool provides decision support for the nurse's clinical decisions regarding management of the patient's pain. Based on the PAINReportIt output and published cancer pain guidelines, PAINConsultN generates an algorithm-based consultation report with a list of recommendations that could be useful to provide improved pain relief. If the patient's PAINReportIt output indicates the pain level is consistent with the patient's goals for pain management and represents no pain or a mild pain level, the consultation report acknowledges the therapy plan and reinforces its consistency with pain guidelines.
1627966|NCT02026115|Behavioral|PAINUCope|We tested the prototype of the PAINUCope component of the intervention in three completed studies. PAINUCope is a multimedia, computer generated tool that provides tailored patient information to overcome their misconceptions about pain and to help them engage in self-care activities that contribute to reducing their pain. PAINUCope focuses on two crucial aspects of pain management: 1) reporting cancer pain; and 2) safe and effective use of pain medicines. All the educational materials were written at a 6th grade reading level and presented as 21st Century best-practices, evidence-based facts or scripts for the person living with cancer or sickle cell disease (in one study). The facts or scripts are customized to the patient's need for this type of health information. The patient's responses on PAINReportIt govern the specific health information that is shared with the patient via PAINUCope.
1627967|NCT02026102|Behavioral|ICD Decision Aid Toolkit|Research assistants will provide patients with a toolkit of decision aids. Participants will have the option of using all of the decision aids or just some of the decision aids.
1627968|NCT02026089|Biological|Varicella vaccine|Varivax 0.5ml subcutaneous injection
1627969|NCT02026076|Other|mechanical lumbar traction|15 minutes at up to 50% body weight lumbar traction in supine hooklying with split table open
1627970|NCT02026063|Drug|Telotristat etiprate tablets (250 mg)|
1627971|NCT02026050|Procedure|intraarticular dexamethasone|2ml 8 mg dexamethasone administration for intraarticular
1627972|NCT02026050|Procedure|interscalene dexamethasone|2ml 8 mg dexamethasone administration interscalene brachial plexus added 30 ml 0.5 % bupivacaine
1627973|NCT02026050|Procedure|serum phsyologic|interscalene brachial plexus block was preoperative performed 30 ml 0.5 % bupivacaine+ 2ml serum phsyologic and after surgery 10 ml serum phsyologic administration for intraarticular
1627974|NCT02026037|Behavioral|Brief Treatment for Acutely Burned Patients (BTBP)|Brief Treatment for Acutely Burned Patients (BTBP) adapts CBT principles that have been validated with non-burn trauma survivors to the treatment of hospitalized burn patients. BTBP consists of three 1 to 1½ hour sessions per week for two weeks, as well as two sessions for family members or partners/spouses.
1627975|NCT02026011|Drug|Naltrexone|Naltrexone is an opioid receptor antagonist with highest affinity for mu opioid receptors
1627976|NCT02026011|Drug|Placebo|Sugar pill, matched to the active study medication in capsule size and color
1627977|NCT02025998|Drug|Ibudilast|Ibudilast is a glial cell modulator that inhibits phosphodiesterases -4 and -10 and macrophage migration inhibitory factor.
1627978|NCT02025998|Other|Matched placebo|A matched placebo (suggar pill) will be administered as a control condition.
1627979|NCT02025985|Drug|Selinexor|35 mg/m2 twice weekly, 50 mg/m2 twice weekly, 50 mg/m2 once weekly, or 60 mg/m2 twice weekly. Cycles are 4 weeks.
1627981|NCT02025959|Behavioral|Educating hospital staff on good sleep hygiene for patients and screening for sleep disorders|
1627982|NCT02025933|Other|Salmon Group|The children are advised to eat at least 75g of salmon per serving, but no more than 150g
1627983|NCT02025933|Other|Cod Group|The children are advised to eat at least 75g of cod per serving, but no more than 150g
1627984|NCT02025933|Other|Meat Group|The children are advised to eat at least 75g of meat per serving, but no more than 150g
1627985|NCT02025920|Other|Salmon Group|
1627986|NCT02025920|Other|Cod Group|
1627987|NCT02025920|Other|Meat Group|
1627988|NCT02025907|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily.
1627989|NCT02025907|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily.
1627990|NCT02025907|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily.
1628096|NCT02024932|Drug|BVS857|BVS857 lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
1628201|NCT02024152|Drug|JDP-205 IM|
1628202|NCT02024152|Drug|Control: Zyrtec|
1627991|NCT02025881|Drug|Carboplatin + etoposide|"Carboplatin 160 mg/m2 Day 1 to day 5 As an intravenous infusion over 1 hour. Dilution in 5 % glucose saline or sodium chloride 9 mg/ml (0.9%).
Etoposide 100 mg/m2 D ay 1 to day 5 As an intravenous infusion over 1 hour. Dilution in physiological saline or 5 % glucose saline while not exceeding a concentration of 0.4 mg/ml etoposide in the infusion bottle."
1627992|NCT02025881|Drug|Thiotepa|Thiotepa 200 mg/m² Day-3 to day-1 As an intravenously infusion over 1 hour dilution in 200 ml/m² of 5% glucose saline or sodium chloride 9 mg/ml (0.9%)
1627993|NCT02025881|Drug|Cyclophosphamide + Busilvex|"Cyclophosphamide Level 1 20 mg/kg/day Level 2 30 mg/kg/day Level 3 40 mg/kg/day Level 4 50 mg/kg/day
Busilvex < 9 kgs 0.8 mg/kg/dose - 3.2 mg/kg/day 9 à < 16 kgs 0.96 mg/kg/dose - 3.84 mg/kg/day 16 à 23 kgs 0.88 mg/kg/dose - 3.52 mg/kg/day > 23 à 34 kgs 0.76 mg/kg/dose - 3.04 mg/kg/day > 34 kgs 0.64 mg/kg/dose"
1627994|NCT02025868|Behavioral|adherence reinforcement|Directly observed treatment at home (family or relatives DOT); pillboxes; phone calls; SMS; home visits; adherence reinforcement sessions by trained health workers.
1627995|NCT02025868|Drug|Antiretroviral Therapy Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)|"Second-line ART regimen : ongoing regimen at the time of inclusion will be continued.
Third-line ART regimen : Darunavir/r + Raltegravir + 2 NRTIs (as chosen by the investigators)"
1627996|NCT02025855|Drug|Methadone|
1627997|NCT02025855|Drug|Placebo|
1627998|NCT02025803|Drug|TAS-114/capecitabine|"Part 1 (dose-escalation phase):
Treatment cycles of TAS-114 and capecitabine orally BID for 14 days followed by 7 days rest until at least one of the discontinuation criteria are met TAS-114 dose starting at 20mg/m2/day with capecitabine dose of 760 mg/m2/day. TAS-114 doses will be escalated for each cohort up to 480mg/m2/day. If MTD is not reached by TAS-114 dose of 480mg/m2/day, the capecitabine dose will be escalated
Part 2 (expansion phase):
TAS-114 and capecitabine MTD established in Part 1 administered BID for 14 days followed by 7-day recovery period (21-day cycle)."
1627999|NCT02025790|Procedure|Per Oral Endoscopic Myotomy (POEM)|"Mucosal incision - After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 12 cm proximal to the gastroesophageal junction (GEJ).
Submucosal tunneling. A long submucosal tunnel is created to 3 cm distal to the GEJ.
Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.
Long endoscopic myotomy is performed 10 cm proximal to GEJ extending
Closure of mucosal entry: the mucosal incision is closed using hemostatic clips"
1628000|NCT02025790|Procedure|Pneumatic Dilatation|Pneumatic dilatation using a Rigiflex balloon up to 35 mm at 8 psi for 1 minute.
1628001|NCT02025777|Device|Capsule Endoscopy|
1628002|NCT02025751|Drug|Metoclopramide Nasal Spray|One 10 mg spray dose 30 minutes before meals and before bed for 28 days (QID)
1628003|NCT02025751|Drug|Placebo Nasal Spray|One placebo spray dose 30 minutes before meals and before bed for 28 days (QID)
1628004|NCT02025738|Device|MAGNET APPLICATION|
1628005|NCT02025738|Device|REPROGRAMING|
1628006|NCT02025738|Device|NO ACTION|
1628007|NCT02025725|Drug|Metoclopramide Nasal Spray|nasal spray formulation of metoclopramide
1628008|NCT02025725|Drug|Placebo Nasal Spray|nasal spray formulation with vehicle only
1628009|NCT02025712|Drug|Exemestane|Commercially available exemestane was supplied to sites as 25-mg tablets according to local regulations.
1628010|NCT02025712|Drug|Everolimus|Everolimus was administered by continuous oral dosing of two 5-mg tablets or one 10-mg tablets.
1628011|NCT02025686|Drug|Hyperbaric Oxygen|Subjects will breathe oxygen (FIO2 = 1.0) at 2.4 ATA in a hyperbaric chamber after the tonic heat stimulations. The duration of oxygen exposure is 90 min.
1628012|NCT02025686|Other|Normal ambient conditions|Normal ambient conditions (1 ATA, FIO2 = 0.21)
1628013|NCT02025660|Drug|Mw, 0.3ml x three days sc|
1628014|NCT02025660|Drug|Placebo|
1991940|NCT00193739|Radiation|Concurrent chemo radiotherapy|Radiation therapy will be administered to the whole pelvis region followed by intracavitary brachytherapy.
1628017|NCT02025621|Drug|Levosimendan|
1628018|NCT02025621|Drug|Placebo|matching placebo
1628019|NCT02025608|Drug|Pramipexole|
1628020|NCT02025608|Drug|Placebo|
1628021|NCT02025582|Device|Kinesio Tape of the Ankle|Tibialis anterior facilitation/ gastrocnemius inhibition: Taping to be worn 3-5 days and repeated x 1
1628022|NCT02025569|Other|Strain Counterstrain|
1628023|NCT02025569|Other|Sham strain counterstrain|
1628024|NCT02025556|Biological|LBR-101 High Dose|Subcutaneously Administered High Dose LBR-101 Monthly x 3
1628025|NCT02025556|Biological|LBR-101 Low Dose|Subcutaneously Administered Low Dose LBR-101 Monthly x 3
1628026|NCT02025556|Biological|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
1628027|NCT02025543|Other|MRI|R2 MRI scan
1628029|NCT02025517|Other|Cognitive Tasks.|The Experimental Group underwent treadmill gait training simultaneously to a protocol of cognitive tasks created specifically for this study, based on cognitive activities proposed in previous studies. The training sessions lasted 20 minutes. The first three minutes allowed subjects to familiarize themselves with the treadmill. From the 4th minute onward, the volunteer walked for 1 minute while performing cognitive tasks, and in the following minute, only walked. Thus, the 17 remaining minutes on the treadmill alternated between one minute of treadmill training combined with a cognitive task and the following minute only treadmill training. Treadmill gait speed was that reported by the patient as the fastest possible speed while maintaining a suitable comfort level.
1628030|NCT02025504|Device|ColoWrap|ColoWrap is an abdominal binder intended as an accessory to facilitate colonoscopy.
1628031|NCT02025491|Drug|Liposomal Amphotericin B|Liposomal Amphotericin B will be administered by intravenous route, 3 to 5 mg/kg/day, during 7 to 14 days of treatment. Complete hemogram, aminotransferases (AST, ALT), blood urea and creatinine will be determined in all patients on days -1, and three times/week up to the end of therapy. Patients will bemonitored for side effects daily. Patients will be followed-up at 1, 2, 3, 4 and 6 months post-therapy. Clinical and laboratory adverse events will be graded according to the Common Toxicity Criteria (CTC) of the National Cancer Institute.
1628032|NCT02025478|Biological|Breastmilk|"A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.
If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician."
1628033|NCT02025465|Drug|Metoprolol|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF/FL rate control.
Conversion of intravenous to oral, chronic management will be left to the discretion of the ED or managing medical team."
1628034|NCT02025465|Drug|Diltiazem|"The attending ED physician may use higher or lower intravenous doses depending on patient response as this is the norm in clinical practice for these two medications used for decades for AF rate control.
Conversion of intravenous to oral medication for rate control for chronic management will be left to the discretion of the ED or managing medical team."
1628035|NCT02025452|Other|Rapid diagnostic|Specimens from rectal mucosa will be obtained using flocked swabs at enrolment. Those in 'rapid diagnostic' groups will have them tested using multiplex PCR the day of enrolment and participants with treatable pathogens will have antimicrobials provided. Those in 'delayed diagnostic' groups will have the swabs batched at tested at the conclusion of the study, being treated as per standard of care.
1628036|NCT02025452|Dietary Supplement|Probiotic|Lactobacillus reuteri suspended in vegetable oil, 5 drops/day (1 x 10e8 CFU) x 2 months
1628037|NCT02025452|Other|Placebo|Identical in appearance to L. reuteri probiotic (same bottle), but simply vegetable oil. Dose is 5 drops/day x 2 months.
1628038|NCT02025439|Device|rTMS|
1628039|NCT02025439|Drug|Amantadine|
1628040|NCT02025426|Drug|Phenylephrine|
1628041|NCT02025426|Drug|Ephedrine|
1628042|NCT02025413|Device|Mesenchymal-marker based ferrofluid (N-cadherin or O-cadherin based)|
1628043|NCT02025400|Other|eRehab|"Growth in e-Health applications, defined as any computer or Internet application integrated into health services, has resulted in the development of treatment strategies to improve healthcare while reducing costs. The utilization of e-Health to provide a rehabilitative intervention has recently been identified in the cardiac literature as e-rehabilitation or eRehab. This study specifically compares an orthopedic eRehab Internet application to standard outpatient physical therapy as an adjunct in the treatment of non-complicated knee and shoulder disorders."
1628044|NCT02025400|Other|Formal Physical Therapy|This intervention involves referral to a licensed physical therapist or supervised ATC-L.
1628047|NCT02025374|Drug|Hyperbaric levobupivacaine|
1628048|NCT02025374|Drug|Hyperbaric bupivacaine % 0.5|
1628049|NCT02025361|Drug|intrarectal lidocaine gel anesthesia|
1628050|NCT02025361|Drug|periprostatic nerve blockade|
1628051|NCT02025348|Drug|IntelliCap|Drug release from the IntelliCap® system will be actuated post-gastric emptying of IntelliCap® capsule.
2011412|NCT02567292|Other|Breast Milk|Participants will receive breast milk (fortified with Prolacta if required per doctor's discretion) for regular feedings while in the neonatal intensive care unit (NICU).
1628053|NCT02025309|Device|Neuromuscular monitorisation|
1628054|NCT02025296|Device|U-healthcare|use of a public switched telephone network (PSTN)-connected glucometer to measure their blood glucose level at the same frequency as the SMBG group
1628055|NCT02025283|Procedure|Group Decompression or Group Nucleoplasty|Group Decompression: Decompression with flexible intradiscal decompression catheter (SpineCATH®, Smith & Nephew, Memphis, TN) Group Nucleoplasty: Nucleoplasty with radiofrequency-compatible needle (Coblation: Perc DLE SpineWandTM [ArthroCare Spine, Sunnyvale, CA]
1628056|NCT02025270|Biological|Stem Cells|60 ml of bone marrow will aspirated and used for stem cells isolation. Then stem cells will cultured using autologous serum, characterized and prepared using GMP rules and finally injected into rete testis.
1628057|NCT02025257|Other|Exercise|Individually prescribed hospital based exercise in group two times a week, home-based exercise once a week. The exercise intervention consists of interval based aerobic exercise on a bicycle ergometer 30 minutes with intensity level at 13-17 at Borg scale, resistance exercises and balance exercises
1628058|NCT02025244|Procedure|Key Hole Biopsy ( KHB)|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are, according to randomization, allocated to undergo esophagogastroduodenoscopy with Key Hole Biopsy consisting of forceps biopsy through mucosal incision by a needle knife, with subsequent cytological /histological and immunohistochemical evaluation of specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine the mitotic activity is evaluated.
1628059|NCT02025244|Procedure|EUS-FNA|Patients with endoscopically detected Upper Gastrointestinal Submucosal Tumors with diameter ≥ 2cm are after randomization allocated to undergo endosonography-guided fine-needle-aspiration biopsy (EUS-FNA) by 22G needle, with subsequent cytological /histological and immunohistochemical examination of the specimen. In the case of Gastrointestinal Stromal Tumors (GIST), the possibility to determine mitotic activity is evaluated. In case of failure of this method, the second one is performed.
1628060|NCT02025231|Radiation|External beam radiotherapy|Study group 1: 3.5 Gray x 10, 5 fractions per week. Study group 2: 3.5 Gray x 10 + 7 Gray boost to biological target volume, 5 fractions per week. Study group 3: 5.9 Gray x 10, 5 fractions per week. Study group 4 (planning target volumes: 100 millilitres - 300 millilitres): 3.5 Gray x 10, 5 fractions per week. Phase II dosis: to be chosen based on results of phase I study.
1628061|NCT02025218|Drug|Gefitinib standard dose|
2011413|NCT02564900|Drug|DS-8201a|
2011414|NCT02565615|Other|No intervention|Because this is a non-interventional study, there is no intervention here.
2011415|NCT02564042|Drug|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
2011416|NCT02564042|Drug|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
2011417|NCT02564042|Drug|Vehicle cream|White to off-white vehicle cream base to be applied topically
1628063|NCT02025192|Drug|Tucatinib|Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) and capecitabine, tucatinib (ONT-380) and trastuzumab, and tucatinib (ONT-380), capecitabine and trastuzumab until disease progression or unacceptable toxicity. Tucatinib (ONT-380) and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
1628064|NCT02025192|Drug|Capecitabine|Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) and capecitabine, tucatinib (ONT-380) and trastuzumab, and tucatinib (ONT-380), capecitabine and trastuzumab until disease progression or unacceptable toxicity. Tucatinib (ONT-380) and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
1628065|NCT02025192|Drug|Trastuzumab|Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) and capecitabine, tucatinib (ONT-380) and trastuzumab, and tucatinib (ONT-380), capecitabine and trastuzumab until disease progression or unacceptable toxicity. Tucatinib (ONT-380) and capecitabine are administered twice per day, orally. Trastuzumab is administered at a loading dose of 8 mg/kg IV followed by 6 mg/kg once every 21 days.
1628066|NCT02025179|Drug|Teriparatide|Teriparatide 20 ug daily Sub-Q over 12 months
1628067|NCT02025179|Device|Vibration|Vibration 10 min/day for 12 months
1628068|NCT02025166|Drug|Paracetamol|"Pain treatment with aniline analgesics (paracetamol) at the time of the procedure"
1628069|NCT02025166|Drug|lornoxicam|"Pain treatment with NSAID (lornoxicam) at the time of the procedure"
1628070|NCT02025153|Other|pain testing|physical testing, psychological testing, genetics testing and functional brain imaging
1628071|NCT02025140|Device|Computer controlled anesthesia|The IANB by the computer controlled local anesthetic device CCLAD and periodontal ligament anesthesia by the CCLAD
1628072|NCT02025140|Device|conventional anesthesia syringe|Active control
1628073|NCT02025127|Other|Enteral nutrition|Enteral nutrition introduced via a feeding tube
1628074|NCT02025114|Drug|selumetinib|The starting dose of selumetinib in combination with the standard dose of gefitinib (250mg QD) on a continuous dosing schedule will be 50mg QD. Total 3 doses of selumetinib will be tested (50mg QD, 50mg BID and 75mg BID).
1628075|NCT02025088|Procedure|Laser|Patients of this arm will undergo three sessions of laser treatment with an interval of six weeks between them. In each laser session, the non-ablative fractional erbium laser 1340 nm ProDeep (Etheria ® platform/Industra) with tip 100mtz/cm ² will be applied across the face, with a power of 120mJ/mtz time and pulse time of 5ms.
1628076|NCT02025088|Procedure|Microneedling|"Patients in this arm will undergo three sessions with microneedling, with an interval of six weeks between them. In the microneedling sessions, the instrument contains 192 microneedles with 2 mm depth, which will be applied to the face in four different directions, making up about 20 movements of coming and going in each direction."
1628077|NCT02025075|Drug|Rocuronium|Rocuronium 0.6 - 1.2 mg/kg with the dose adjusted to achieve 1-2 post-tetanic counts (Deep NMB) or 1-2 twitches in the train-on-four (Moderate NMB).
1628078|NCT02025062|Other|CGA and geriatric follow-up|The CGA is a multidimensional assessment of general health status, using validated scales. It produces an inventory of problems which can then serve to develop an individualized geriatric intervention plan of care and follow-up
1628079|NCT02025049|Drug|DP-b99|DP-b99 is a lipophilic analog of the divalent metal ion chelator O,O'-Bis(2-aminophenyl) ethyleneglycol-N,N,N',N'-tetraacetic acid (BAPTA)
1628080|NCT02025049|Drug|Placebo|mannitol-based DP-b99 look-alike
1628081|NCT02025036|Drug|Capecitabine(Aibin)|capecitabine(Aibin)：625mg/m2, bid d1-5; q1w, po,5 weeks in total
1628082|NCT02025036|Drug|Oxaliplatin(Aiheng)|Oxaliplatin(Aiheng)：65mg/m2，d1，8, 22, 29,I.V.
1628083|NCT02025036|Radiation|Radiotherapy|concurrent radiotherapy： 50Gy in total，2 Gy/d，5d/w，Until disease progression or unacceptable toxicity
1628084|NCT02025023|Drug|5-fluorouracil Injection|If the chalazion is present at follow-up visit, another injection of 5-FU will be given.
1628085|NCT02025023|Drug|Triamcinolone Acetonide|If chalazion present at follow-up, another Triamcinolone injection will be done.
1628086|NCT02025023|Procedure|Incision and Curettage|If chalazion present at follow-up visit, patient will be randomized to receive local injection of either triamcinolone, 5-FU, or triamcinolone/5-FU mixture.
1628087|NCT02025023|Drug|Triamcinolone Acetonide/5-fluorouracil mixture|If chalazion persists at follow-up visit, another injection of triamcinolone/5-FU mixture will be done.
1628088|NCT02025010|Drug|abiraterone acetate|Daily four 250 mg tablets (1,000 mg) of AA taken orally for 28 day cycles. No food should be consumed for at least two hours before the dose and for at least one hour after the dose. The tablets should be swallowed whole with water. Tablets should not be crushed or chewed.
1628089|NCT02025010|Drug|prednisone|Take with food 5 mg Oral Twice daily
1628090|NCT02025010|Procedure|pre-treatment and progression tumor biopsies|Participants will undergo pre-treatment and progression tumor biopsies. After the progression biopsy is performed, protocol therapy will be discontinued. Participants who stop protocol therapy before receiving four cycles of AA will not be asked to undergo the second biopsy.
1628091|NCT02025010|Genetic|assessment of serum corticosteroid intermediates and ACTH|•Participants will undergo assessment of serum corticosteroid intermediates and ACTH at baseline and subsequent treatment visits for correlation with symptoms of mineralocorticoid excess.
1628092|NCT02024997|Other|Magnetic Resonance Imaging (MRI)|
1628093|NCT02024984|Drug|Clomiphene Citrate|"Group A (study group) 'Luteal Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting on day 2 of the cycle induced by MPA for another menstrual cycle.
Group B (control group)'Follicular Clomid': will include 45 patients to whom 100 mg of CC will be administrated daily for five days starting on day 2 of the cycle induced by MPA, for one menstrual cycle, then a wash out period for another menstrual cycle, then the group treatment plan is shifted to administration of 100 mg of CC daily for five days starting the next day after finishing MPA (medroxyprogesterone acetate) 10 mg tablet for five days for another menstrual cycle."
1628094|NCT02024971|Drug|Pioglitazone/metformin hydrochloride|Pioglitazone/metformin hydrochloride combination tablets
1628095|NCT02024945|Drug|Propiverine|Propiverine 15 mg tablets or 30 mg regulated release capsules
1628097|NCT02024932|Drug|Placebo|Placebo lyophilisate in vial; the lyophilisate was reconstituted with sterile water for injection, diluted as appropriate, and administered either i.v. or s.c..
1628098|NCT02024919|Drug|intracoronary administration of diltiazem|
1628099|NCT02024919|Drug|intracoronary injection of 5 mL saline|
1628100|NCT02024906|Dietary Supplement|soy protein isolate (SPI)|
1628101|NCT02024906|Dietary Supplement|milk protein isolate (MPI)|
1628102|NCT02024893|Other|Observational study|"Observation and type of data collected are listged in detail under 'description"
1628105|NCT02024867|Drug|Trimethoprim-Sulfamethoxazole|3 versus 10 days of drug
1628106|NCT02024854|Behavioral|skin-to-skin|
1628107|NCT02024854|Behavioral|standard care|
1628108|NCT02024841|Drug|Intraperitoneal docetaxel|Intraperitoneal docetaxel, intravenous cisplatin and oral TS-ONE every 3 weeks for 3 cycles then stop
1628109|NCT02024828|Other|Early/Slow|
1628110|NCT02024828|Other|Early/Fast|
1628111|NCT02024828|Other|Late/Slow|
1628112|NCT02024828|Other|Late/Fast|
1628113|NCT02024815|Radiation|External Beam radiotherapy|External Beam radiotherapy
2011418|NCT02562456|Procedure|ART with Fuji IX|Occlusal and occlusal-proximal ART restorations in primary molars using the high viscosity GIC Fuji IX will be performed. No local anesthesia will be used. Infected carious tissue will be removed with hand instruments, and the cavities restored with GIC (Glass Ionomer Cement). The cavity will be filled with GIC. After the press-finger technique, the excess of material will be removed and occlusion will be checked.
1628117|NCT02024776|Behavioral|Prehabilitation|Tailored exercise training program
1628118|NCT02024763|Behavioral|Educational Intervention|Intervention was applied to classroom teachers by the multidisciplinary team of the RRIDA Project. Training lasted six weeks, 12 hours devoted to physical activity and 18 hours to nutritional content. Modules of educational activities to classroom teachers were to be replicated at PE classes to children from 1st and 2nd grades of three exposed schools. The physical activity module was based on a theoretical approach of physical activity benefits and risks for health, children's physical fitness and activity patterns, physical education and change behavior models.
1628119|NCT02024750|Behavioral|Tailored Resources|Based upon PRISM screening tool results that identifies self-management barriers, patient/family will receive self-management resources matched to their barriers. These resources could be focused on: 1. Understanding and organizing care; 2. Motivation to self-manage; and 3. Family Teamwork. Group session of about 6 families with the same barrier will meet four times fo 75-minutes over a year, at the clinic site on same date as routine clinic visit.
1628120|NCT02024737|Other|MRI lung imaging (not an intervention per se but the focus of the study)|"The purpose of this pilot study is to determine short and long term reproducibility of a comprehensive set of functional imaging data; using hyperpolarised gas MRI, conventional MRI and lung physiology measurements in patients with moderate to severe COPD. In addition,how sensitive the imaging techniques are to changes in lung function after treatment with a standard (bronchodilator) inhaler will also be assessed (the bronchodilator foradil is a non-investigative medicinal product as it is a medicine with a known effect which will be used to induce a known response).
This pilot study will serve as a platform for future larger scale studies, aimed at better understanding of and intervention in early COPD."
1628121|NCT02024724|Drug|Bupivacaine|4 mL of 0.25% bupivacaine
1628122|NCT02024724|Drug|Triamcinolone|40 mg of Triamcinolone
1628123|NCT02024724|Drug|Dexamethasone|4 mg of Dexamethasone
1628124|NCT02024711|Device|EYEFILL® C.-US Viscoelastic|A comparison between EYEFILL ® C.-US and Healon® Viscoelastic (CONTROL) for the identical use during cataract extraction.
1628125|NCT02024711|Device|Healon® Viscoelastic (CONTROL)|
1628126|NCT02024698|Device|omafilcon A|contact lens
1628127|NCT02024698|Device|etafilcon A|contact lens
1628128|NCT02024685|Behavioral|Personalized Treatment Recommendations|This is a psychosocial/behavioral study. It will use a randomized trial to test the hypothesis that a decision analysis model that provides individualized estimates of quality-adjusted disease-free survival for each of the treatment options for clinically localized prostate cancer will lead to higher quality treatment decisions congruent with a patient's values leading to improved decisional regret and treatment satisfaction. In this trial, all patients would be evaluated at baseline for their utilities for various clinically important health states. The primary endpoint of this study will be regret-free survival at 2 years after treatment. There will be a 1:1 randomization. A random permuted design will be used to assure approximate balanced number of patients in the two groups over time.
1628129|NCT02024685|Behavioral|Standard patient-physician counseling interaction|Both patients and physicians will be unaware of the decision analysis recommendation and the patients will receive standard treatment counseling alone. After the patient has made a treatment decision he will be given a short questionnaire to assess decisional conflict. If after one month no treatment decision information is available, a letter and form requesting treatment information along with the decisional conflict questionnaire will be sent to patients.
1628131|NCT02024659|Drug|budesonide|Patients receive 1mg/2ml budesonide twice daily via transnasal nebulization for 14 days.
1628132|NCT02024659|Other|placebo|patients receive placebo (saline solution) 2ml twice daily for 14 days.
1628136|NCT02024633|Drug|icotinib|Three dose levels of icotinib are designed to be evaluated, 125 mg three times per day, 250 mg three times per day, and 375 mg three times per day. Dose escalations are based on predefined dose escalation decision rules. The Maximum Administered Dose (MAD) was reached at the dose level when at least 30% patients developed a dose limited toxicity.
1628137|NCT02024633|Drug|Gemcitabine|Gemcitabine: 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration every 4 weeks.
1628138|NCT02024620|Behavioral|Behavioral activation plus mobile app|
1628139|NCT02024620|Behavioral|Standard behavioral activation|
2011419|NCT02562456|Procedure|Restoration with Filtek Z-350 composite resin|Occlusal and occlusal-proximal composite resin restorations in primary molars using the Scotchbond Multi-purpose adhesive system and the Filtek Z-350 composite resin wil be performed. Local anesthesia will be used. Absolute isolation will be performed using rubber dam and clamp. Access to caries lesion will be done using a round bur. Infected carious tissue will be removed with hand instruments. The cavity will be etched using 37% phosphoric acid for 15 seconds followed by rising and drying for the same amount of time. The cavity will be restored with composite resin. Occlusion will be checked.
2011420|NCT02560857|Other|Quantiferon-Monitor assay|The QFT-Monitor assay is a recently developed non-pathogen specific immune assay based on immune activation of both innate and adaptive immunity.
1628152|NCT02024568|Drug|Pregabalin|See arm description
1628153|NCT02024568|Drug|Placebo|See arm description
1628154|NCT02024555|Drug|Levofloxacin|
1628155|NCT02024555|Drug|Ethambutol|
1628156|NCT02024555|Drug|Azithromycin|
1628157|NCT02024555|Drug|Rifampin|
1628158|NCT02024555|Drug|Placebo|This will serve as a placebo to the antibiotics used in antimycobacterial therapy.
1628159|NCT02024542|Other|Surgery|Patients wishing to participate in the research will complete all necessary pre-operative work-up labs, testing & counseling, complete and sign the informed consent. During weight loss surgery a small amount of subcutaneous and omental fat will be collected for analysis, with subsequent blood collection post surgery for analysis.
1628160|NCT02024529|Biological|Ampion|kDa ultrafiltrate of 5% human serum albumin
1628161|NCT02024516|Other|50 gr concentrated pomegranate juice|
1628162|NCT02024477|Drug|Saxagliptin|5 mg tablet once daily for 12 weeks
1628163|NCT02024477|Drug|Placebo|1 tablet daily for 12 weeks
1628164|NCT02024464|Device|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
1628165|NCT02024464|Device|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
1628166|NCT02024451|Device|Radial shock wave|radial shock wave: Treatment point is the origin attachment of upper trapezius at the external occipital protuberance. Radial shock wave therapy will be performed once per week, and will be continued for 3 weeks. Acetaminophen will be prescribed as rescue medication, and the amount given will be recorded at the end of the study.
1628167|NCT02024451|Device|Acupuncture|Acupuncture is performed at Fenfchi (GB20) point over upper back by the same physiatrist to all patients.
1628168|NCT02024438|Drug|monosialotetrahexosylganglioside Sodium|it is extracted from pig's brain,shenjie is the brand name
1628169|NCT02024438|Other|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
1628170|NCT02024425|Dietary Supplement|Functional bioactive supplement|1,25g of antioxidant extracted from rosemary, 18g of oligosaccharides derived from lactulosa and 1,25g of bioactive peptides
1628171|NCT02024425|Dietary Supplement|Control supplement|
1628172|NCT02024412|Drug|monosialotetrahexosylganglioside Sodium|it is a component extract from pig's brain,shenjie is the brand name
1628173|NCT02024412|Other|placebo|saline of the same appearance as monosialotetrahexosylganglioside Sodium
1628174|NCT02024399|Other|Exercise|Strength training, aerobic exercise and core strengthening, running
1628175|NCT02024386|Drug|Riociguat|After completion of first V02 max test at altitude, subjects will have a 3-hour rest period. Riociguat will be administered at the 90-minute mark of this rest period.
1628176|NCT02024373|Drug|Atorvastatin|20 mg (every evening orally) for 8 weeks
1628177|NCT02024373|Drug|placebo|20 mg (every evening orally) for 8 weeks
1628178|NCT02024360|Behavioral|Patient navigation|16 session (25 hour) home-based intervention with patient navigators encouraging families to adopt healthy eating, active living and parental skill building
1628179|NCT02024334|Drug|Leflunomide|
1628182|NCT02024295|Drug|Ademethionine|ademethionine 1000mg ivgtt qd for 2 weeks, then orally 1000mg bid for 4 weeks.
1628183|NCT02024295|Drug|Polyene Phosphatidyl choline|Polyene Phosphatidyl choline 10ml ivgtt qd for 2 weeks, then Polyene Phosphatidyl choline 456 mg tid orally for 4 weeks.
1628184|NCT02024295|Drug|Ademethionine|after 6 weeks of core treatment stage, then ademethionine 1000mg bid or qd orally for 42 weeks
1628185|NCT02024282|Device|Use of C-reactive protein (CRP) point of care test|
1628186|NCT02024282|Other|Brief intervention and parent leaflet|"Brief interventions are commonly used to give opportunistic advice, discussion, negotiation or encouragement. Mostly they take between 5 to 10 minutes. We developed a brief intervention: we'll ask the clinicians to ask 3 specific questions, namely Are you concerned?, What exactly concerns you? and Why does this concern you?. This intervention is easy to implement in daily practice and no additional training is required.
We developed a parent information leaflet that gives information about what they can do when their child is ill, which signs are important to follow up and when they really should get advice from a clinician. This could make it easier for them to cope with an ill child. The clinician could use this leaflet to give advice and make clear when they have to re-consult their physician to re-evaluate the child. Our hypothesis is that through creating this safety net, the improper demand for antibiotics could be reduced."
1628187|NCT02024282|Device|Finger Pulse Oximeter|All physicians will be asked to perform a measurement of the oxygen saturation on all children and enter the results on the case report form. The selected device is a clip-on system suitable for use in children, which measures oxygen saturation in the capillary blood as well as the pulse rate.
1628188|NCT02024269|Biological|Adipose Derived Stem Cells|
1628189|NCT02024256|Other|Cold pads soaked in Magnesium sulfate solution|
1628190|NCT02024256|Other|Cold pads soaked in water|
1628191|NCT02024243|Procedure|Punch Tissue Biopsy|Subjects will have two 3 mm punch tissue biopsies of the same wound/ulcer (for OCT & infection) collected on days 0, 14, and 28. Biopsies will not be collected if the wound has closed by day 14 or 28.
1628192|NCT02024230|Drug|Warfarin or Rivaroxaban|No limitations of previous medication (Warfarin or new oral anticoagulant drugs or no anticoagulant drug) and type of stent (bare metal stent or drug eluting stent) in both arms
1628193|NCT02024217|Radiation|S1，oxaliplatin，radiation|Radiation: 180 (cGy) /day, D1-5;S1: 50mg/m2,D1-5;
1628203|NCT02024139|Other|Chewing Sugarless Gum|Chewing sugar free gum three times per day for 5-10 minutes
1628204|NCT02024139|Other|Using Mouthwash|Rinse mouth with plax sensitive fluoridated mouthwash for 30 seconds, three times per day
1628205|NCT02024126|Other|Exercise therapy|Exercise therapy
1628206|NCT02024113|Other|Venous blood sample|Collection of a venous blood sample to investigate metabolic changes in blood
1628207|NCT02024087|Drug|Dalantercept plus sorafenib|Subcutaneous (SC) injection of dalantercept once every 3 weeks and oral sorafenib daily.
1628208|NCT02024074|Other|Sestamibi (Tc-MBI) scan of the breast|Patients will be given 8mCi of Sestamibi intravenously. following which Sestamibi scan will be performed on the breast. Sestamibi scan will be done prior to any surgical procedure..
1628209|NCT02024061|Behavioral|Peer support|
1628210|NCT02024061|Behavioral|Regular treatment|The participants in this arm will receive the regular obesity treatment provided by the hospital and university (interactive sessions and physical activity).
1628211|NCT02024048|Other|OCT|Optical coherence tomography in enhanced depth imaging mode
1628212|NCT02024035|Radiation|Radiotherapy|
1628213|NCT02024022|Drug|Standard approach|bowel cleansing with either 4L PEG or sodium picosulphate/magnesium citrate
1628214|NCT02024022|Drug|Individualized approach|
1628215|NCT02024009|Drug|nab-paclitaxel|Abraxane is a proprietary solvent-free, protein-stabilized formulation of paclitaxel comprised of paclitaxel and human albumin in a noncrystalline amorphous state
1628216|NCT02024009|Radiation|60Gy in 30#|
1628217|NCT02024009|Radiation|50.4Gy in 28#|
1628218|NCT02024009|Drug|Nelfinavir|VIRACEPT® (nelfinavir mesylate) is an inhibitor of the human immunodeficiency virus (HIV) protease.
1628219|NCT02024009|Drug|Capecitabine|Given in combination with gemcitabine, known as GemCap.
1628220|NCT02024009|Drug|Gemcitabine|Gemcitabine is indicated for treatment of patients with locally advanced or metastatic adenocarcinoma of the pancreas. It is administered as an infusion
1628221|NCT02023996|Radiation|89Zr-DFO-trastuzumab|
1628222|NCT02023996|Device|PET imaging|
2011421|NCT02560051|Drug|Doxorubicin|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive doxorubicin (20 mg/m2 as a 24-hour intravenous infusion on day 1 of each applicable week)
2011422|NCT02560051|Drug|Ketoconazole|In weeks 1, 3, and 5 of each 8-week cycle, participants will receive ketoconazole (400 mg orally 3 times daily for 7 days)
1628225|NCT02023970|Device|Patients receiving animal-derived bioprosthetic heart valves.|
1628226|NCT02023970|Other|Echocardiography (1)|
1628227|NCT02023970|Other|Echocardiography (2)|
1628228|NCT02023970|Other|Echocardiography (3)|
1628229|NCT02023970|Biological|Blood sample (1)|
1628230|NCT02023970|Biological|Blood sample (2)|
1628231|NCT02023970|Biological|Blood sample (3)|
1628232|NCT02023957|Behavioral|Interactive computer-assisted screening (iCAS)|
1628233|NCT02023944|Other|Memory and Aging Course|This is a 12-week course that will provide participants with an understanding of what normal and pathological aging processes look like. It will also provide participants with methods to maintain healthy lifestyles as they continue to grow older.
1628234|NCT02023931|Drug|Broccoli Sprout Extract (BSE)|"The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.
The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.
The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane."
1628235|NCT02023918|Drug|pegvisomant|Pegvisomant 20 mg subcutaneously Qday will be administered by the study subject for 28 days during this study.
1628236|NCT02023905|Drug|Everolimus|
1628237|NCT02023905|Drug|Temozolomide|
1628238|NCT02023892|Drug|atorvastatin|
1628239|NCT02023892|Drug|placebo|
1628240|NCT02023879|Drug|Alirocumab|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
1628241|NCT02023879|Drug|Placebo (for Alirocumab)|Solution for injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre-filled pen).
1628242|NCT02023879|Drug|Non-statin LMT|Ezetimibe or Fenofibrate at stable dose as background therapy.
1628243|NCT02023879|Other|Diet Alone|Stable cholesterol-lowering diet as background therapy.
2011423|NCT02560051|Drug|Docetaxel|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive docetaxel (35 mg/m2 intravenously on day 1 of each applicable week)
1628245|NCT02023853|Procedure|ultrasonic|
1628246|NCT02023853|Procedure|erythritol|
1628247|NCT02023853|Drug|metronidazole gel|
1628248|NCT02023840|Drug|metronidazole gel|
1628249|NCT02023840|Procedure|ultrasonics|
1628250|NCT02023840|Procedure|erythritol|
1628251|NCT02023840|Drug|placebo|
1628252|NCT02023827|Behavioral|RAYS Intervention|The Rise Above Your Situation program (RAYS) is a multimedia computer-tailored intervention that relies on the Transtheoretical Model of Behavior Change (TTM) and expert system technology to deliver assessments, feedback, printed reports, and helpgiver reports with intervention ideas. Helpgivers (probation officers in this case) use the reports to guide 1/2 hour follow-up discussions to reinforce intervention ideas and provide support.
1628253|NCT02023801|Device|Aurora Endometrial Ablation System|Ablation of the endometrial lining of the uterus using the Aurora System
1628254|NCT02023788|Biological|PNEUMOSTEM|"A single intratracheal administration
Low Dose Group (3 patients): 1.0 x 10^7 cells/kg High Dose Group (6 patients): 2.0 x 10^7 cells/kg
* The subjects were administered with Pneumostem in the earlier part of the Phase I study. No drug/biologics will be administered to any subject during this part of the study."
1628255|NCT02023775|Device|Melody valve implantation|
1628256|NCT02023749|Dietary Supplement|Nut group|
1628353|NCT02022930|Device|Hydros|
1628257|NCT02023736|Other|Systemic Therapy Inventory of Change (STIC)|The STIC is a computerized measurement and feedback system for use in psychotherapy. The measurement system consists of weekly questionnaires, completed on the computer, that target symptoms and functioning in a variety of domains of a clients life (e.g., individual symptoms, couple functioning, family functioning, relationship with children). The feedback system consists of a web-portal where therapists may access their clients' STIC responses, for the purposes of planning treatment, assessing progress, and discussing change with clients.
1628258|NCT02023736|Other|Treatment as Usual|Clients receive psychotherapy treatment as planned and implemented by their psychotherapists. Exact type of treatment varies by therapist and according to client need.
1628259|NCT02023723|Dietary Supplement|Monster Energy Drink|16oz Monster Energy drinks - 2 consumed within 60 minutes
1628260|NCT02023723|Dietary Supplement|Active Control|16oz control drink: Caffeine 160mg, Sucrose 115g consume 2 - 16oz drinks within 60 minutes
1628261|NCT02023710|Drug|Paclitaxel|175 mg/m^2 by IV infusion on the first day of each 4-week cycle (dose was based on patient's weight and could be adjusted for weight change)
1628262|NCT02023710|Drug|Carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 4-week cycle
1628263|NCT02023710|Drug|Bevacizumab|5mg/kg by intravenous (IV) infusion every two weeks of each 4-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
1628265|NCT02023684|Drug|control saline|Surgical bed irrigation with saline 40ml
1628266|NCT02023684|Drug|Lidocaine|surgical bed Irrigation Lidocaine 0.5%, 40ml
1628267|NCT02023684|Drug|Ropivacaine|surgical bed Irrigation Ropivacaine 0.2%, 40ml
1628268|NCT02023658|Other|pMTCT systems analysis and improvement|Five-step systems analysis and iterative improvement cycles carried out over a six-month period in intervention facilities.
1628269|NCT02023645|Dietary Supplement|active supplement|tablet
1628270|NCT02023645|Other|placebo|tablet
1628271|NCT02023632|Behavioral|Similar-Age-Same-Gender (SASG)|The core feature of the program is that it is exclusively for those of a similar age and same gender. Such an environment was reported to provide opportunities for social connectedness, as well as personal comfort. Secondly, exercise class instructors are volunteers- both providing 'similar-models' to enhance efficacy as well as reduce costs associated with instructors. Consistent with social identity and self-categorization perspectives, the program also makes use of a series of strategies to foster intra-group attraction and group identity. For many of the participants a major draw of the program is that it provides opportunities for the older adults to connect with one another after the classes have ended.
1628272|NCT02023632|Behavioral|Similar-Age-Mixed-Gender (SAMG)|The SAMG physical activity condition will mirror the SASG group condition, but will be open to older adults from both genders. The same strategies to those used within the SASG condition will also be utilized (development of a unique program name, T-shirts, opportunities to socialize after the program), and will be offered three days per week (Mon, Wed, Fri, or Tues, Thurs, Sat). Older adults will also be recruited to be instructors for the group classes (= 65 years), with both males and females invited to occupy these instructional roles. (As with the SASG condition, training will take place between September and December 2013, through the respective YMCA centres. The YMCA will oversee the training of these volunteers through their Fitness Leader Training Program).
1628273|NCT02023632|Behavioral|Mixed-Age-Mixed-Gender (MASG)|The third condition utilized within the RCT is designed to reflect 'standard' group based exercises that one sees in typical physical activity centres. Specifically, these classes are not restricted to participants on the basis of age or gender, and as such older adults will be participating in groups comprised of people younger than themselves as well as those of both gender.
1628274|NCT02023606|Drug|SPN-810M|
1628275|NCT02023593|Drug|FOLFIRI|Patients will receive FOLFIRI every 2 weeks: Irinotecan 180mg/m2 IV over 90 minutes on Day 1; Leucovorin IV over 2 hours on Day 1(l-LV 200 mg/m2 or dl-LV 400 mg/m2 ); 5-Fluorouracil 400 mg/m2 IV bolus on Day 1; followed by 5-Fluorouracil 2.4 g/m2 for 46 hours continuous infusion.
1628276|NCT02023580|Behavioral|Video treatments|"The treatment video vignettes to be delivered between Baseline and 3 Months include: 1) Condom use/anal sex without HIV status disclosure (potentially SDUAI); 2) Condom use/anal sex without HIV status disclosure and perceived responsibility; 3) Discussion of nondisclosure of HIV status prior to sex and perceived responsibility, STIs; 4) Stigma associated with disclosing HIV status to sex partners; 5) HIV/STI testing; and 6) Diagnosis of an STI; STI disclosure to sex partners and perceived responsibility.
Video boosters to be delivered weekly for 4 weeks between 6 and 9 Months include: 7) HIV status disclosure, condom use, STIs; 8) STI disclosure to sex partners, disclosure to friends, serodiscordant partnerships; 9 & 10) Support of HIV disclosure and perceived responsibility."
1628277|NCT02023567|Drug|SSRIs|fluoxertine hydrochloride 20-60mg/day, paroxetine hydrochloride 20-60mg/day, sertraline hydrochloride 50-200mg/day, citalopram 20-60mg/day, escitalopram 10-20mg/day, fluvoxamine 50-300mg/day
1628278|NCT02023554|Drug|Theophylline with azithromycin|"Drug: Theophylline(100mg,sustained release tablets). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 1 to day 7.
Drug:Azithromycin(250mg, capsules). Multi-dose of azithromycin(500mg,once daily) will administered at 8 pm from day 1 to day 7."
1628279|NCT02023554|Drug|Theophylline alone|Drug: Theophylline(100mg,sustained release tablet). Multi-dose of theophylline(100mg,twice daily) will administered at 8 am and 8 pm from day 8 to day 14.
1628280|NCT02023541|Radiation|Proton beam therapy|
1628281|NCT02023515|Behavioral|Emotional brain training|Stress management based program
1628282|NCT02023515|Behavioral|Behavioral weight loss|Standard behavioral weight loss
1628283|NCT02023502|Other|collection of urine and blood sample|
1628284|NCT02023489|Device|1H/ 13C and 31P Magnetic Resonance Spectroscopy|Study participants will be studied in the fasting state after an overnight fast of at least 10 h. Participants will arrive at the MR-Centre in the morning of the study. Between 6:30 and 10:00 a.m., 1H MRI (3T) will be performed for the assessment abdominal adipose tissue distribution and composition as well as myocardial functional parameters. 1H/13C MRS examinations (7T) will be performed for measurements of myocardial, skeletal muscle and liver lipid content and composition as well as glycogen content. Additionally, ATP synthesis and energy metabolism will be assessed.
1628354|NCT02022930|Device|Hydros-TA|
1628285|NCT02023489|Other|Meal Tolerance Test|"A meal tolerance test meal tolerance test according to Petersen et al. (PNAS, Vol 104, 2007) will be performed. After MRI and MRS examinations subjects will be returned at our outpatients clinic, where small polyethylene catheter will be inserted in an antecubital vein for hourly blood sampling. At 10:30 a.m. and 1:30 p.m. two liquid high carbohydrate meals of equal size containing all the required daily energy (30 kcal/kg of body weight; 55% carbohydrate, 10% protein, and 35% fat) with an additional 25% of the daily energy requirements added in the form of sucrose will be served.
At 5 p.m. subjects will be returned at the MR - Centre for postprandial 1H / 13C MRS (7T) of muscle, liver and myocardial lipid and glycogen contents. Myocardial function parameters and abdominal fat distribution will be assessed again by 1H MRI (3T)."
1628286|NCT02023489|Other|Hyperglycemic-hyperinsulinemic clamp|"All volunteers will be admitted in the morning and basal 13C tracer enrichment will be assessed.
At 8:00a.m. (0 min) a hyperglycemic-hyperinsulinemic-pancreatic clamp test will be initiated by somatostatin (-5-300 min: 0.1 µg·kg-1·min-1, UCB Pharma, Vienna, Austria) and insulin (0 - 8 min: 80 mU·min-1·m-2 body surface area; 8 -300 min: 40 mU·min-1·m-2 body surface area) infusion. Plasma glucose will be raised and maintained at ~180 mg·dL-1 by primed (0.2 g·kg-1)-variable dextrose infusion (20%w/v) enriched with [1-13C]glucose (40%w/w). A second catheter will be placed into an antecubital vein of the other arm and blood samples for the measurement of glucose, insulin and c-peptide. Glucose concentrations will be analysed immediately every 5 minutes, employing a glucose analyser. Myocardial glycogen concentrations will be measured before the clamp (-60 - 0 min) and from 90 min to 180 min during the clamp employing 13C MRS."
1628287|NCT02023476|Radiation|MRI|MRI- imaging on the upper arm
1628288|NCT02023463|Drug|Enzalutamide|Given PO
1628289|NCT02023463|Drug|Goserelin acetate|Given SC
1628290|NCT02023463|Drug|Leuprolide acetate|Given IM or SC
1628291|NCT02023463|Radiation|Radiation therapy|Undergo image-guided radiation therapy
1628292|NCT02023450|Drug|saquinavir and ritonavir|micro and low dose
1628293|NCT02023450|Drug|saquinavir and ritonavir|standard dose
1628294|NCT02023437|Device|Femtosecond laser cataract surgery|The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
1628295|NCT02023437|Device|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
1628296|NCT02023424|Drug|Glatiramer Acetate (Copaxone®)|GA is a potent inducer of Th2-cells and modulates these immune cells to secrete high levels of neurotrophic factors, particularly BDNF. The induced cells cross the blood brain barrier (BBB), accumulate in the CNS and express BDNF and other regulatory substances in situ.
1628297|NCT02023411|Drug|Teriparatide|recombinant human parathyroid hormone (1-34) subcutaneously every day at 8-9 pm
1628298|NCT02023411|Other|Placebo|Placebo
1628299|NCT02023398|Device|BTL-9000 HFT|Deep tissue heating with the BTL-9000 HFT for HFT group
1628300|NCT02023398|Device|sham BTL-9000 HFT|sham deep tissue heating with BTL-9000 HFT in Placebo group
2011424|NCT02560051|Drug|Estramustine|In weeks 2, 4, and 6 of each 8-week cycle, participants will receive estramustine (280 mg orally 3 times daily for 7 days)
2011425|NCT02560051|Drug|Degarelix|The starting dose (240 mg given as two injections of 120 mg each) is followed by maintenance doses of 80 mg administered as a single injection every 28 days
1628303|NCT02023372|Biological|NuCel with Autograft|NuCel is a minimally manipulated allograft product derived from amniotic membrane along with cells from amniotic fluid. Local autograft is bone that comes from the patient's own vertebrae and surrounding bony structures.
1628304|NCT02023359|Drug|Everolimus and exemestane|
1628305|NCT02023346|Behavioral|surveys and cognitive tests|
1628306|NCT02023333|Drug|Regorafenib|All patients that meet the eligibility criteria who have signed informed consent and have enrolled on the trial will be treated with regorafenib, daily 3 weeks on 1 week off for all cycles. Dose will be escalated to 120 mg in week 2 of cycle 1 and all remaining cycles if no excess toxicity is experienced by the patient at the discretion of the treating physician.
1628307|NCT02023320|Dietary Supplement|Low dose of blueberry dry powder|
1628308|NCT02023320|Dietary Supplement|High dose of blueberry dry powder|
1628309|NCT02023307|Device|V-Loc Suture|
1628310|NCT02023294|Procedure|Convetional laparoscopic Sleeve Gastrectomy|Convetional laparoscopic sleeve gastrectomy using 5 ports (incisions) in the abdominal wall
1628311|NCT02023294|Procedure|SILS Sleeve gastrectomy|Single incision Sleeve gastrectomy using only one port (incision) on the abdominal wall assisted by an special Traction Device for single port surgery (Endograb)
2011426|NCT02560038|Drug|Gemcitabine|1000 mg/m2 will be administered as an IV infusion over 10 mg/minute on Days 1 and 8 of each cycle (each cycle is 21 days).
1628313|NCT02023268|Device|T2762|1 drop in each eye 3 to 6 times daily during 84 days
1628314|NCT02023268|Device|Vismed®|1 drop in each eye 3 to 6 times daily during 84 days
1628315|NCT02023255|Drug|JNJ-39393406|In Part A of the study, participants will receive single dose of JNJ-39393406 50 mg, 150 mg, 450 mg, 1,350 mg, and 2,700 mg once daily for 7 consecutive days. In Part B of the study, participants will receive single dose of JNJ-39393406 based on the PK data from Part A of the study once daily for 13 consecutive days.
1628316|NCT02023255|Other|Placebo|In Part A of the study, participants will receive placebo for 7 consecutive days and in Part B of the study, participants will receive placebo for 13 consecutive days.
1628317|NCT02023242|Device|Hydrus Microstent|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
1628318|NCT02023242|Device|iStent Trabecular Micro Bypass|Device inserted into Schlemm's canal to enhance aqueous flow from the anterior chamber.
1628319|NCT02023229|Dietary Supplement|Branched-chain aminoacids|
1628320|NCT02023229|Other|High-fiber high protein diet|
1628355|NCT02022930|Drug|Triamcinolone Acetonide|
1628357|NCT02022904|Device|Near infrared (NIR) emissive nanotechnology|
2011427|NCT02560038|Drug|Paclitaxel|175 mg/m2 will be administered as an IVPB over 3 hours on Day 2 of each cycle (each cycle is 21 days).
2011428|NCT02560038|Drug|Cisplatin|70 mg/m2 will be administered as an IVPB over 2 hours on Day 2 of each cycle (each cycle is 21 days).
1628321|NCT02023216|Device|Pacifier|The effect of NNS on GER features will be evaluated in preterm infants suffering from GER symptoms, for which a 24-hour pH-MII monitoring has been scheduled. During the monitoring period each infant will receive 8 meals: 4 meals will be followed by NNS, applied by pacifier, while the other 4 not. The sequence of NNS application will be consecutively alternated in study participants. At least 2 hours of NNS are required for the validity of each post-prandial evaluation; measures to fix the pacifier will be strictly forbidden. In the subgroup of babies with recurrent desaturations a simultaneous non-invasive 6-hour PSG monitoring comprehensive of 2 meals (one followed by NNS, the other not), will be performed to evaluate the effect of NNS on apneas, bradycardias and hypoxic episodes.
1628322|NCT02023203|Procedure|Totally Extraperitoneal laparoscopic inguinal hernia repair|Laparoscopic hernioplasty
1628323|NCT02023164|Drug|JDP-205 Injection|
1628324|NCT02023164|Drug|Diphenhydramine|
1628327|NCT02023138|Other|Focus group|Two hours focus group to allow the participants to modify a clinical practice guideline recommendation
1628328|NCT02023138|Other|Wiki|A specially tailored interactive communication website (Wiki) to allow the participants to modify a clinical practice guideline recommendation
1628329|NCT02023125|Drug|Alectinib|A single 600-mg oral dose of alectinib will be administered in a fasted or fed condition.
1628330|NCT02023125|Drug|Esomeprazole|Esomeprazole 40 mg will be administered orally once daily for 6 days prior to alectinib administration.
1628331|NCT02023125|Other|High Fat and Calorie Meal|High fat and calorie meal served prior to alectinib administration
1628332|NCT02023125|Other|Standard Meal|Standard meal served prior to alectinib administration
1628333|NCT02023112|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
1628334|NCT02023112|Drug|Ribavirin|Capsule
1628335|NCT02023099|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
1628336|NCT02023099|Drug|Placebo|Tablet
1628337|NCT02023086|Procedure|Contrast sensitivity measurement|Contrast sensitivity test is made with targets alternating black and white lines. The larger the lines are, easier it is to see them. Targets are distributed in 5 rows, each oriented at a different angle. Contrast sensitivity level is determined by the smallest target seen by the participant, line by line. This test is done under dim lightning with the habitual visual correction worn.
1628338|NCT02023086|Procedure|Slit Lamp assessment and intra-ocular pressure measurement|Slit lamp is used to assess the presence of significant lens opacities known as Fabry cataracts. In fact, these opacities can induced a bias on the contrast sensitivity measurement and can increase the symptoms felt by the patient. A grade 2 (CFDI grading chart) of lens opacities is considered clinically significant and this will become an exclusion criteria for the following of the study. Intra-ocular pressure will be measured with a non contact tonometer (air pulsed) (Ocular Response Analyser, Reichert Instrumentation.)
1628339|NCT02023086|Procedure|Visual field testing|"Visual field will be assessed with an automated perimeter (Humphrey, Texas) using a threshold strategy. This implies that the subject has to identify not only if he perceives the visual stimulus but the minimal level of this stimulus (in decibels), to be seen, is also recorded. Visual field will be tested up to 30 degrees from the central point of fixation.
In order to measure immediate variability of the visual testing among Fabry subjects, this test will be done at the beginning of the testing session (in the morning) and another time 1h00 later."
1628340|NCT02023086|Procedure|Oxygen flow at the optic nerve head measurement|"Pupils will be dilated with 1 drop of 1% tropicamide. The procedure is similar to the one used for taking a photo of the retina. Each measurement session represents a continuous recording of 20 simultaneous functions of reflectometry from the optic nerve area during 10 seconds.
During all recording sessions, the systemic arterial oxygen saturation will be also monitored at the right index finger using a pulse oximeter (Escort M10, Invivo, Orlando, USA). Arterial blood pressure will be also monitored before and after the testing using a manual sphygmomanometer."
1628341|NCT02023086|Drug|Tropicamide|Used to dilate patient's pupil during testing
1628342|NCT02023086|Device|OSOME|The OSOME system is the only technology able to perform on line and real time capillaries blood oxygenation measurement in the eye. The system operates with 1200 discreet wavelengths between 400 nm to 700 nm with 500 millisecond integration times. It is not invasive, functioning just like a fundus camera.
1628343|NCT02023047|Drug|Nifedipine 12 mg coated suppositories|
1628344|NCT02023034|Other|Virtual exercises|The exercises will be performed with the Nintendo ® Wii Balance Board ® platform, and consist in: 1) Table Tilt; 2) Obstacle Course; 3) Tilt City; 4) Basic step; 5) Penguin; 6) Heading Soccer; 7) Basic Run. All patients underwent 12 sessions, twice a week for a period of 06 weeks.
1628345|NCT02023021|Drug|nab-paclitaxel|Patients firstly receive nab-paclitaxel 100 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
1628346|NCT02023021|Drug|gemcitabine|Patients secondly receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
1628347|NCT02023008|Procedure|yoga therapy|Undergo integral yoga intervention with videoconferencing
1628348|NCT02023008|Other|internet-based intervention|Undergo integral yoga intervention with videoconferencing
1628349|NCT02023008|Other|questionnaire administration|Ancillary studies
1628350|NCT02022982|Drug|Palbociclib|Palbociclib will be administered orally once daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 75 mg daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. No pre-medications for palbociclib are required. It should be administered without food with patients fasting for 1 hour prior and 2 hours post drug administration.
1628351|NCT02022982|Drug|PD-0325901|PD-0325901 will be administered orally twice daily, 3 weeks out of every 4 in each cycle. The initial dose for phase 1 of the study will be 2 mg twice daily. Dosing will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. PD-0325901 will be administered using a flat-dosing plan. No premedications are required. As the effect of food on PD-0325901 is uncertain, patients will be permitted to dose either fasting or after food.
1628352|NCT02022956|Drug|Lorcaserin|
1628358|NCT02022891|Behavioral|systematic psychological care|Prevention treatment plan that provides systematic medical and psychological care at routine pediatric consultations for SCD. Bio-psychosocial paradigm applied at pediatric consultations.
1628359|NCT02022878|Procedure|PCI of CTO|
1628360|NCT02022852|Drug|Capecitabine|50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy. Rest for 8 weeks and surgery followed.
1628361|NCT02022852|Drug|XELOX|XELOX 2 cycles (oxaliplatin 130mg/m2 ivgtt 2-6h day 1,capecitabine 1000 mg/m2 bid day 1-14 repeat every 3 weeks) → 50Gy, 2Gy/day per time, 5 days a week, for 5 weeks+capecitabine 850mg/m2 bid on the day accept radiotherapy → XELOX 1 cycle. Rest for 2 weeks and surgery followed.
2011429|NCT02558140|Biological|RO6874813|RO6874813 will be administered at a single low dose of 0.5 mg/kg via IV infusion in a 7- day PK run-in period (Cycle 0). Dose level for RO6874813 will be escalated to determine MTD and RP2D for RO6874813.
1628363|NCT02022813|Dietary Supplement|Supplemental parenteral nutrition (SPN)|The amount of energy delivered by SPN will depend on the indirect calorimetry measurement and actual enteral feed delivery. SPN will be reduced with progressing EN
1628364|NCT02022800|Other|PET 18FDOPA|contribution of PET 18FDOPAimagery in high level glioma diagnosis
1628365|NCT02022787|Other|patients with renal cell carcinoma|Chemokines that may be elevated in patients with RCC
1628366|NCT02022774|Drug|Fimasartan|Fimasartan 60 ~ 120 mg/po take one tablet once a day
1628367|NCT02022761|Drug|Laninamivir octanoate|40 mg dose consists of 2 laninamivir octanoate TwinCaps® DPI 80 mg dose consists of 4 laninamivir octanoate TwinCaps® DPI (2 administered 12 hours apart)
1628368|NCT02022748|Drug|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 1, subjects will receive treatment A in Period 1 and treatment B in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 1. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
1628369|NCT02022748|Drug|ticagrelor|Group A is hemodialysis subjects. Crossover design will be implemented for Group A subjects. Group A will be randomized into 2 sequences, Sequence 1 and Sequence 2. In Sequence 2, subjects will receive treatment B in Period 1 and treatment A in Period 2. Washout period of at least 7 days between Period 1 and Period 2 in Sequence 2. Treatment A and Treatment B are defined as follows: Treatment A subjects will be dosed with oral 90 mg ticagrelor tablet 1 day following the dialysis session but 2 days before the next dialysis session. Treatment B will be dosed with oral 90 mg ticagrelor tablet just prior to dialysis session.
1628370|NCT02022748|Drug|ticagrelor|Group B is healthy subjects. Group B healthy subjects will receive oral 90 mg ticagrelor referred to as Treatment H.
1628371|NCT02022735|Device|Deep Brain Stimulation|
2011430|NCT02558140|Biological|RO6874813|RO6874813 at RP2D will be administered by IV infusion as per dosing schedule determined in Part 1.
1628374|NCT02022709|Drug|Fluoxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
1628375|NCT02022709|Drug|Sertraline|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
1628376|NCT02022709|Drug|Paroxetine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
1628377|NCT02022709|Drug|Citalopram|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
1628378|NCT02022709|Drug|Fluvoxamine|The dosage depends on clinician's judgement ,but not over the maximum tolerated dosage.
1628379|NCT02022709|Behavioral|Exposure and Response Prevention|8 exposure and response prevention (ERP) sessions,once a week
1628380|NCT02022696|Genetic|Lentiviral Gene Transfer|
1628381|NCT02022683|Device|ELVR (Endoscopic Lung Volume Reduction) with Zephyr valve|Standard Medical Care
1628382|NCT02022670|Drug|Placebo|Sugar pill manufactured to mimic sodium nitrite capsules
1628383|NCT02022670|Drug|Sodium Nitrite|80 mg/d or 160 mg/d
1628384|NCT02022657|Drug|Truvada|Truvada is a combination pill consisting of tenofovir and emtricitabine used in PrEP
1628385|NCT02022644|Drug|nanoliposomal irinotecan|
1628386|NCT02022631|Other|Alternative summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
1628387|NCT02022631|Other|Current summary of findings table format|Investigators will compare one SoF table with alternative formats (Table A) against one SoF table with the current formats (Table B). In both tables, the clinical question in terms of patients and setting, intervention, comparator, and outcomes informed by the tables, and the complementary information included as footnotes will be the same. The only differences between the current and alternative SoF table formats will be different methods to either show the same data in a different way or to provide complementary data to the one showed in the current format (i.e. supplementary data as risk difference).
1628388|NCT02022605|Device|Hands-on EMS training|A trainer (SAH) gave a series of demonstrations of the proper techniques of ERCP step by step on the EMS. The demonstration included selective cannulation, sphincterotomy, guidewire exchange, balloon dilation, stone extraction and stent insertion. Then trainees practiced each technique with hands-on coaching from the trainer on the EMS. Each trainee could repeate the practice with the trainer giving only verbal correction of any errors for about 30min.
1628389|NCT02022605|Other|Standard training|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of CBD or PD. During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within 10min, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation.
1628392|NCT02022579|Procedure|DCE-MRI and DWI|DCE-MRI defined lesion(s) compared with biopsy results or 1-year follow up
1628393|NCT02022566|Behavioral|A supported self management of osteoarthritis program|Three theoretical sessions, each of about 90 minutes, held as group sessions with about 10 participants in each group. After the intervention patients are offered an individual exercise program, and the opportunity to practice this program together with others under supervision of a physical therapist for 6 weeks.
1628394|NCT02022553|Procedure|usual rectal cancer surgery|
1628395|NCT02022553|Procedure|RACHEL|
1628396|NCT02022540|Drug|PAN-90806 Ophthalmic Solution|
1628397|NCT02022540|Drug|Lucentis|
1628398|NCT02022527|Drug|Acetyl Salicylic Acid|
1628399|NCT02022527|Drug|Warfarin|
1628400|NCT02022527|Drug|Placebo (for Aspirin)|Sugar pill manufactured to mimic 75 mg Aspirin
1628401|NCT02022514|Other|Mononuclear cells from autologous bone marrow|Mononuclear bone marrow cells autologous intracoronary
1628402|NCT02022514|Drug|Conventional medical treatment|
1628403|NCT02022501|Drug|DE-120|
1628404|NCT02022488|Drug|midazolam|Group M
1628405|NCT02022488|Drug|alfentanil|Group MA
1628406|NCT02022488|Drug|ketamine|Group MK
1628407|NCT02022475|Drug|Vitamin D|100 000 units oral vitamin D as 2 capsules 50 000 units each
1628408|NCT02022475|Other|placebo|2 placebo capsules will be applied as a single dose
1628409|NCT02022462|Behavioral|Health Navigation|"Experimental: Immediate peer health navigator intervention vs. waitlist control.
The immediate peer health navigator intervention group will receive assistance for 6 months and then followed up with after an additional 6 months. Participants will receive training in how to self-manage their physical health and healthcare. The intervention is individualized and the number of contacts by the navigator will be determined by their need level. The waitlist control group will complete a baseline assessment and then wait for 6 months before receiving the peer health navigator intervention. They will complete a follow-up assessment after 6 months of the intervention."
1628410|NCT02022449|Behavioral|Stress management|Cognitive behavioral stress management Cognitive and emotionally focused coping enhancement strategies Progressive muscle relaxation Social support Strategies for parenting a child with cancer
1628411|NCT02022436|Drug|contrast ultrasound|Definity® is the contrast agent that will be administered by intravenous injection by a registered nurse during the ultrasound (contrast enhanced ultrasound (CUS). The purpose is to assist in identifying differences in AAA characteristics based on gender and AAA stability and growth.
1628414|NCT02022410|Other|CAS after primary and revision TKA|CAS and RAPT
1628415|NCT02022384|Other|Blood sample and life quality questionnaires|Blood will be drawn at distinct time points during and after radio(chemo)therapy
1628416|NCT02022371|Procedure|Targeted biopsies of the prostate|Multiple biopsies from a MRI lesion for analysis of intratumour heterogeneity
1628417|NCT02022358|Drug|Glucarpidase|Glucarpidase rescue (50 units/kg x 1, intravenously)
1628418|NCT02022358|Drug|Methotrexate|Methotrexate (12 g/m2 x 1, intravenously)
1628419|NCT02022358|Drug|Folinic Acid|Folinic acid rescue 15mg/m2 four times daily adjusted according to methotrexate levels
1628420|NCT02022345|Procedure|Percutaneous Coronary Intervention|
1628421|NCT02022319|Device|Ultrasonographic Shear Wave Elastography|
1628422|NCT02022306|Drug|TD-6450|
1628423|NCT02022306|Drug|Placebo|
1628424|NCT02022293|Drug|Atorvastatin|Patients in this group will take 20mg per night.
1628425|NCT02022293|Other|Placebo|
1628426|NCT02022280|Drug|Lansoprazole|
1628427|NCT02022254|Drug|semaglutide|Subjects will initiate treatment with 0.25 mg for the first four weeks followed by dose doubling every four weeks up to a dose of 1.0 mg.
1628428|NCT02022254|Drug|placebo|Semaglutide placebo will be administered s.c.
1628429|NCT02022254|Drug|metformin|For oral administration twice daily, in two periods, each of 3.5 days duration. The first period is initiated before semaglutide treatment and the second period is initiated at the end of semaglutide treatment.
1628430|NCT02022254|Drug|warfarin|For oral administration, given as a single dose. The first dose is given before semaglutide treatment and the second dose is given at the end of semaglutide treatment.
1628431|NCT02022241|Drug|triptorelin|0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
1628432|NCT02022228|Drug|triptorelin|0.2 mg triptorelin, ih
1628433|NCT02022228|Drug|hCG|1000 IU hCG, im
1628434|NCT02022228|Drug|hCG|500IU hCG, im
1628435|NCT02022215|Drug|ME1111 Solution, Low strength|ME1111 Solution, Low strength, applied once daily for 48 weeks
1628436|NCT02022215|Drug|ME1111 Solution, High strength|ME1111 Solution, High strength, applied once daily for 48 weeks
1628437|NCT02022215|Drug|Matching Vehicle Solution|Matching Vehicle Solution, applied once daily for 48 weeks
1628438|NCT02022189|Procedure|Renal Biopsy|
1628439|NCT02022176|Other|Glucose Uptake|Glucose uptake is measured by oral glucose tolerance test and euglycemic clamp
1628440|NCT02022176|Other|Resting metabolic rate|Resting metabolic rate is measured by indirect calorimetry after an over-night fast
1628441|NCT02022176|Other|Nitrite infusion|Sodium nitrite or saline was infused at escalating doses at a rate of 1, 10 or 100 nmol kg-1 min-1 (10 minutes per dose) in a randomized, double blinded cross-over fashion
1628442|NCT02022163|Biological|Low dose of H7 VLP vaccine + Alhydrogel|Low dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
1628443|NCT02022163|Biological|Med dose of H7 VLP vaccine + Alhydrogel|Med dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
1628444|NCT02022163|Biological|High dose of H7 VLP vaccine + Alhydrogel|High dose of H7 VLP vaccine mixed with Alhydrogel, 2 doses given 21 days apart
1628445|NCT02022163|Biological|High dose of H7 VLP vaccine|High dose of H7 VLP vaccine, 2 doses given 21 days apart
1628446|NCT02022163|Biological|Placebo|Placebo, 2 doses given 21 days apart
1628447|NCT02022150|Behavioral|Body composition in paracentesis|Takin blood samples and bioelectrical impedance measurmeent, Neuropsychological tests evaluation
1628448|NCT02022137|Dietary Supplement|Red cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
1628449|NCT02022137|Dietary Supplement|Green cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
1628450|NCT02022137|Dietary Supplement|White cereal bar|Consumption of the cereal bar with agave fructans or lactitol or lactose added each bar with 10 grams of dietary fiber and 1.2 grams of protein by weight and 20 to 30 grams of fiber.
1628451|NCT02022124|Drug|Microcrystalline cellulose (open-label inert substance)|The intervention will be an inert substance, microcrystalline cellulose in a capsule. Participants will take two capsules daily.
1628452|NCT02022111|Behavioral|Patient Education and Behavioral Activation|To stimulate and motivate sustained, effective self-care, patient education materials and behavioral activation techniques that are adapted for the Indian population will be used by care coordinators. Behavioral activation strategies are brief, structured psychological interventions that are based on extensive theoretical and clinical literature, can be delivered by non-specialist providers, can be combined with antidepressant medications, and emphasize reinforcing behaviors to produce improvements in thoughts, mood, and quality of life.
1628453|NCT02022111|Behavioral|Supporting Self-Care (care coordinators)|Care coordinators will: (a) meet with intervention arm patients and collaboratively set treatment goals; (b) provide verbal education regarding diabetes and depression self-care ;(c) will use motivational interviewing and self-efficacy enhancement strategies to promote monitoring of depressive symptoms, glucose, BP; (d) will proactively follow-up to externally monitor depression symptoms and CVD indicators; (e) will enter updated patient indicators into decision-support electronic health record and utilize software outputs to prioritize patients for review; (g) will convene case review meetings with supervising physicians; and (h) will communicate physician-recommended treatment changes to patients and their routine providers.
1628454|NCT02022111|Other|Psychiatrist and Diabetologist Reviews|Senior psychiatrist and endocrinologist/diabetologist will be involved in weekly offline case review meetings with care coordinators. Case review meetings will be structured: the decision-support electronic health record will help prioritize cases that are new (within 3 weeks of randomization); have moderate/severe depression symptoms (based on Patient Health Questionnaire (PHQ)-9) ≥6 weeks after most recent treatment changes, or continued poor HbA1c, home glucose, BP, or LDL-c control in past 4 weeks; or have not been reviewed for 3 months. Based on patient indicators and current therapies, physicians will recommend treatment changes (initiation, increases, or simplification of medication regimens) which will be communicated by care coordinators to patientsand their usual care providers.
1628455|NCT02022111|Other|Decision-support Electronic Health Record System|The decision-support electronic health record will store patient indicators entered by the Nurse Case Managers (NCM) and provide diabetes and depression care prompts based on an evidence-based treatment algorithm developed from recommended guidelines for control of diabetes and depression, Indian formularies, and TeamCare investigators. The decision-supported electronic health record (DS-EHR) will prioritize patients (new; poorly-controlled; or well-controlled but not reviewed ≥3 months) for case review meetings and promote accountability (physicians must justify rejecting electronic care prompts).
1628456|NCT02022111|Other|Standard of Care|Participants randomized to the control arm will receive the existing standard care and treatment for their diabetes that is provided routinely at each Clinic Site and their care provider will be notified regarding their depressive symptoms. The physicians treating the control arm will also be provided with trainings regarding identification and care for people with depression. The control participants will have no contact with care coordinators and will only be contacted at 6-monthly intervals for assessment by the blinded outcomes assessor.
1628461|NCT02022085|Device|Baha Attract System|The Cochlear Baha Attract System incorporates both implantable and external parts. The implantable parts include the BI300 Implant and the BIM400 Implant Magnet, which is intended to be fixated to the BI300 Implant. The external parts include the Sound Processor Magnet (SP Magnet), which, together with the Implant Magnet, constitute the transcutaneous coupling. The SP Magnet incorporates a soft material (Soft pad) at the tissue facing surface that is designed to distribute the pressure over the skin. The Baha Sound Processor attaches to the SP Magnet via a snap coupling.
1628462|NCT02022072|Device|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)|measures of assisted vital capacity by a mechanical insufflation/exsufflation (Cough Assist®)
1628463|NCT02022059|Drug|Lidocaine = group A|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by spray of lidocaïne during the insertion (group A = lidocaine)
1628464|NCT02022059|Drug|Group B placebo|Patient requiring a SNG for nutrition entérale benefiting from a pre-medication by placebo during the insertion
1628465|NCT02022046|Other|Methylation biosignature|Methylation biosignature, CKD staging, assessment of cardiovascular function, and traditional/uremia-related risk factors will be performed.
1628466|NCT02022033|Drug|FOLFOXA|"Abraxane: 150mg/m2 IV over 30 minutes, day 1 (administered first) every 14 days.
Oxaliplatin: 85mg/m2, IV over 2 hours, day 1 every 14 days Leucovorin: 400mg/m2, IV over 2 hours, day 1 every 14 days 5-FU infusion:1200mg/m2/day, as a continuous IV infusion over 2 days, day 1 and day 2 (for a total dose of 2400mg/m2 over 46 hours.)"
1628467|NCT02022007|Drug|Metformin XR|"Start 2 pills (2 pills of 500 mg =1000mg XR) for 3 weeks
Increase to 4 pills as tolerated (4 pills of 500 mg XR =2000 mg XR) for remainder of study"
1628468|NCT02022007|Drug|Saxagliptin|"Start 1 pill (5 mg)) for 3 weeks
Remain at 1 pill (5mg dose) for remainder of study"
1628469|NCT02022007|Drug|Saxagliptin-Metformin XR|"Start 1 pill (2.5 mg/ 1000mg XR) for 3 weeks
Increase to 2 pills as tolerated (5mg/2000 mg XR) for remainder of study"
1628470|NCT02021968|Biological|TetraVax-DV-TV003|TetraVax-DV-TV003 is a live attenuated recombinant tetravalent dengue virus vaccine, which will be administered as a 0.5 mL dose containing 10^3.0 plaque forming units (PFUs) each of DENV-1, DENV-2, DENV-3, and DENV-4. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
1628471|NCT02021968|Biological|rDEN2∆30-7169|The challenge virus, rDEN2∆30-7169, is a live recombinant attenuated DENV-2 candidate vaccine virus and will be administered as a 0.5 mL dose containing 10^3 PFUs of rDEN2∆30-7169. It will be delivered by subcutaneous injection in the deltoid region of the upper arm.
1628472|NCT02021968|Biological|Placebo|The placebo vaccine is the vaccine diluent 1X L-15, which will be administered as a 0.5 mL dose delivered by subcutaneous injection in the deltoid region of the upper arm.
2011431|NCT02558075|Behavioral|MoodLifters Sessions|This program consists of 12 different sessions with a different topic for each session. These sessions will occur once a week for 12 weeks and will last approximately an hour each. These topics will be in one of five theoretically important areas: biological, cognitive, affective, behavioral and social. Each subsequent week will involve an in-depth exploration of each topic, including why it is important to mental well-being and practical ideas about how to implement positive changes into one's everyday life. Following the facilitator's brief presentation, group members will be invited to share their experiences, challenges, and provide peer support.
2011432|NCT02554812|Drug|Avelumab|Anti-PD-L1 antibody given until disease progression.
1628475|NCT02021929|Drug|Sorafenib|"Sorafenib is a kinase inhibitor indicated for the treatment of:
Unresectable hepatocellular carcinoma
Advanced renal cell carcinoma
Locally recurrent or metastatic, progressive, differentiated thyroid carcinoma refractory to radioactive iodine treatment"
1628476|NCT02021929|Drug|Placebo|
1628477|NCT02021903|Other|V1: HGPO + meal and V2: placebo + meal|"Ambulatory polysomnography for the night preceding each test
Usual antiparkinsonian treatments at their usual dose and timing
Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test
During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :
continuous digital blood pressure monitoring by Nexfin®
blood pressure monitoring at brachial artery
continuous polysomnographic recording
synchronized continuous digital audiovisual recording
glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
1628478|NCT02021903|Other|V1: placebo 75mg + meal and V2: HGPO 75mg + meal|"Ambulatory polysomnography for the night preceding each test
Usual antiparkinsonian treatments at their usual dose and timing
Randomisation to receive an oral solution of glucose load or a placebo (fructose). Standard meal 4 hours after the test
During two hours following the oral solution administration and the standardized meal, we will perform the followings for each patient :
continuous digital blood pressure monitoring by Nexfin®
blood pressure monitoring at brachial artery
continuous polysomnographic recording
synchronized continuous digital audiovisual recording
glucose and insulin blood level monitoring Additional blood samples will be taken in order to assay the intestine-pancreatic neuropeptides including incretins GLP- 1 and GIP"
1628479|NCT02021890|Behavioral|Dance program|two-hour dancing session twice a week, led by instructors in a private hall of a disco. Both solo and partner and group dances were performed during each session: an initial one-hour activity, chaired by two instructors who taught new steps and choreographies to patients (both individually and in group), was followed by a second hour, when patients danced in pairs both Latin and standard ballroom music
1628480|NCT02021890|Behavioral|Self-selected physical activity|gym sessions (with the support of sports associations), exercising at home (cycling, stepping) or walking, jogging or cycling outside with/without group support
1628481|NCT02021864|Drug|vitamin D3 50,000 unit|vitamin D3 50,000 unit/week for 8 weeks
1628482|NCT02021864|Drug|prenatal multivitamin|daily prenatal multivitamin containing elemental calcium 250 mg/day and vitamin D3 400 unit
1628483|NCT02021851|Drug|Dexamethasone and aprepitant|
1628484|NCT02021851|Drug|Dexamethasone and ondansetron|
1628485|NCT02021838|Other|Lethality Assessment Program|
1628486|NCT02021838|Other|Domestic Violence High Risk Team|
1628487|NCT02021825|Drug|Mitoxantrone|The treatment protocol consisted of 12 mg/m2 MITO intravenous infusions every 3 months for 2 years. Dosage was adjusted according to side effects.
1628488|NCT02021812|Device|Branched TAG® Device|
1628489|NCT02021799|Dietary Supplement|Moringa and Lactobacillus rhamnosus GR-1|
1628490|NCT02021786|Behavioral|Mobile phone based intervention|Parents in the intervention group receive a six month mHealth program (the MINISTOP app) based on social cognitive theory with strategies to change unhealthy diet and physical activity behaviors. The program includes information, advice, and strategies to change unhealty behaviours and the possibility to register the child's intake of fruits, vegetables, candy, sweetened beverages, moderate-to-vigorous physical activity, and sedentary time. Feedback is then provided on reported variables. In addition, the parents are able to ask questions through the app to a dietician and a psychologist.
1628491|NCT02021773|Biological|LBR-101 High Dose|Subcutaneously Administered LBR-101 Monthly x 3
1628492|NCT02021773|Biological|LBR-101 Low Dose|Subcutaneously Administered LBR-101 Monthly x 3
1628493|NCT02021773|Biological|Placebo|Subcutaneously Administered Placebo (Vehicle) Monthly x 3
1628494|NCT02021760|Procedure|Primary Percutaneous Coronary Intervention|Primary Percutanous Coronary Intervention is performed in both Groups.
1628495|NCT02021669|Drug|Omega-3 supplement|Two grams of the EPA form of omega-3 daily and 50 mgs of sertraline daily for 10 weeks
1628496|NCT02021669|Drug|Placebo|Two grams of corn oil plus 50 mg of sertraline daily for 10 weeks.
1628501|NCT02021630|Other|Outcomes|No intervention will occur during this study. Evaluation of changes in patients' family after having patient has bariatric surgery.
1628524|NCT02021435|Dietary Supplement|salt substitute|Free salt substitute provided
1628525|NCT02021422|Drug|anakinra|Dosage Route Administration 100 mg SC Every Other Day
1628526|NCT02021422|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 2-4 hours
1628527|NCT02021422|Drug|Irinotecan|Irinotecan 180 mg/m2 90 minutes
1628528|NCT02021422|Drug|fluorouracil|fluorouracil 2400 mg/m2 48 hours
1650906|NCT01848730|Drug|CNV2197944|
1628502|NCT02021617|Device|Intraosseous access|The EZ-IO Intraosseous Vascular Access System (Vidacare Corporation, Shavano Park, TX, USA) has been cleared by the U.S. Food and Drug Administration, Health Canada, and the European Union for the administration of drugs and fluids anytime vascular access is difficult to obtain in emergent, urgent, or medically necessary cases. It consists of a driver—a small battery-powered drill—and a needle set designed for insertion into the IO space of the proximal tibia, distal tibia, or proximal humerus. Needles are 15 gauge and available in three lengths: 15 mm, 25 mm, and 45 mm. In this study the 45 mm EZ-IO needle set will be used for all humeral placements and the 25 mm needle set will be used for all tibial placements.
1628503|NCT02021604|Drug|Fluorodopa F 18|A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.
1628504|NCT02021591|Behavioral|Early Mobile Diabetes Detective (MoDD)|"Study participants will be given access to the MODD application and instructions for use for 4 weeks at the beginning of the study. After the initial 4 weeks of access to the MODD application, participants will be offered an option to continue using MODD for the duration of the study.
MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior."
1628505|NCT02021591|Behavioral|Late Mobile Diabetes Detective (MoDD)|"Study participants will be given access to the MODD application at the end of the study. Instructions on how to use the MODD will be provided by site staff.
MoDD is a web-based application that is designed to help individuals with diabetes identify specific problems related to glycemic control, and engage in problem-solving process. MoDD includes a number of messages that explain its users the nature of various problems related to glycemic control, aspects of individuals' behaviors that might have contributed to these problems, and alternative behaviors that could help to improve glycemic control. In addition to these messages displayed on the MoDD website, study participants may receive SMS messages with reminders to test blood glucose, or to follow the selected new behavior."
1628506|NCT02021578|Behavioral|Family Cognitive Behavioral Prevention|Parent training and cognitive behavioral intervention with parents. Coping skills training with children.
1628507|NCT02021578|Behavioral|Written information|Reading materials about depression
2011433|NCT02554812|Drug|Utomilumab|Anti-4-1BB antibody at 1 of 3 dose levels to optimize the combination with avelumab. Treatment with the combination of avelumab and PF-05082566 will continue until disease progression.
1628509|NCT02021552|Other|blood sampling|5 ml blood sampling
1628510|NCT02021539|Procedure|Cervical ultrasound +elastography 1|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
1628511|NCT02021539|Biological|Vaginal fibronectin measurement|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
1628512|NCT02021539|Drug|Tocolytic treatment for 2 hours|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
1628513|NCT02021539|Procedure|Cervical ultrasound +elastography 2|Included patients will have a cervical ultrasound upon arrival in the maternity ward. This latter exam will include elastographic measurements, and will be followed by a vaginal fibronectin measurement. Patients will then be treated via a tocolytic (anti-contraction treatment), and two hours later a second cervial ultrasound including elastographic measures will be performed.
1628514|NCT02021526|Drug|Triheptanoin|Triheptanoin (C7 oil) is a 7-carbon medium chain triglyceride.
1628515|NCT02021513|Dietary Supplement|Fish Oil|Fish Oil (2.25gm EPA and 2.25gm DHA total)
1628516|NCT02021513|Dietary Supplement|Olive Oil|Placebo group
1628517|NCT02021500|Drug|ABI-007|No intervention is being given in this extension study which is gathering survival information on participants of study NCT 00844649 (Celgene study CA046) who were known to be alive as of March 2013)
1628518|NCT02021474|Drug|Histamine Dihydrochloride|
1628519|NCT02021474|Drug|Subcutaneous placebo (Evan's solution = phenol 0.4%, isotonic sodium chloride).|
1628520|NCT02021461|Drug|ESL Banana taste|oral suspension with Banana flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
1628521|NCT02021461|Drug|ESL Grape taste|oral suspension with Grape flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
1628522|NCT02021461|Drug|ESL Tutti-Frutti taste|oral suspension with Tutti-Frutti flavor at a concentration of 50 mg/mL and was administered in 2.5 mL doses.
1628523|NCT02021448|Other|Annual visits among 3 years. During each visit different testings are performed in order to detect an obesity-hypoventilation syndrome (OHS)|Polygraphy/Polysomnography,Blood sampling, EKG,Lung function testing,Arterial blood gases,Thoracic radiography,Six-minute walk test,Respiratory questionnaires
1628605|NCT02020798|Other|Dietary Intervention|
2011434|NCT02554812|Drug|PF-04518600|PF-04518600 will be administered at increasing dose levels in combination with avelumab.
2011435|NCT02554812|Drug|PD 0360324|PD 0360324 will be administered at increasing dose levels in combination with avelumab.
2011436|NCT02554890|Drug|sacubitril/valsartan (LCZ696)|sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
1628529|NCT02021409|Drug|BAY85-3934|Oral doses of BAY 85-3934 will be available in multiples of 5, 25, and 75 mg tablets
1628530|NCT02021409|Biological|Darbepoetin alfa|
1628531|NCT02021396|Procedure|Embolisation|this arm of the study was interventional (embolization) the scans of the inclusion (D0, to validate the inclusion criteria) in one month (J30-validating the primary endpoint) and 6 months (D180).
1628532|NCT02021383|Behavioral|Bi-weekly in person meetings with a Registered Dietician|"Participants in the Contest Plus group had the opportunity to receive 5 in person meetings with a Registered Dietician. These meetings took place bi-weekly and gave the participants a chance to discuss food consumption, physical activity, meal planning and assessed the participant's weight at each visit.
Participants in the Contest only and Control group were not eligible to receive these meetings."
1628533|NCT02021383|Behavioral|Financial incentives for weight loss maintenance|Participants in the Contest Plus and Contest Only groups were eligible for a lottery based financial incentive for maintaining their weight lost during phase 1 (Baseline to week 10) of the trial. There were three, month-long follow up assessments (weeks 16, 20 and 24) that participants were eligible for. The lottery prize was contingent upon the length of time they maintained their weight loss.
1628534|NCT02021370|Drug|BAY85-3934|25mg Tablet
1628535|NCT02021370|Drug|Placebo|Matching placebo tablet
1628536|NCT02021357|Behavioral|hyperboloid associated with the exercise of proprioceptive|
1628537|NCT02021357|Other|hyperboloid|
1628538|NCT02021344|Behavioral|Mental Health First Aid|Originally developed in 2001, MHFA is a 12-hour course comprised of six modules, covering depression, anxiety, psychosis, substance abuse, eating disorders, and self-harm. Each module includes information about the mental health-related problems (e.g., signs and symptoms), advice on how to respond appropriately, and interactive activities to enhance the learning process. Some modules include videos with perspectives of individuals recovering from mental disorders and examples of how to effectively use the MHFA intervention. Program participants learn how to help individuals in crisis and also how to recognize early warning signs and intervene before mental health problems progress to crises.
1628539|NCT02021331|Device|immediate implant placement without provisionalization|
1628540|NCT02021331|Device|immediate implant placement with immediate provisionalization|
1628541|NCT02021318|Drug|Roxadustat|oral
1628542|NCT02021318|Drug|darbepoetin alfa|subcutaneous or intravenous injection
2011437|NCT02554890|Drug|Enalapril|Enalapril tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
1628545|NCT02021279|Device|MatriStem Pelvic Floor Matrix|
1628546|NCT02021279|Procedure|native tissue repair|
1628547|NCT02021266|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
1628548|NCT02021253|Dietary Supplement|Probiotic|Lactibiane TOLERANCE vs Placebo
1628549|NCT02021253|Dietary Supplement|Placebo|
1628550|NCT02021240|Drug|Ketamine|
1628551|NCT02021240|Drug|Dexamethasone|
1628552|NCT02021240|Drug|Normal Saline|
1628553|NCT02021227|Procedure|Early chair sitting exercise|A chair sitting exercise will be done at least once a day and for > 1 hour
1628554|NCT02021214|Drug|Methylphenidate|
1628555|NCT02021214|Drug|Placebo|
1628556|NCT02021201|Drug|risperidone|Patients with schizophrenia will be treated for 10 weeks treatment with risperidone
1628557|NCT02021201|Drug|Sertindole|Patients with schizophrenia will be treated for 10 weeks treatment with serindole
1628558|NCT02021175|Behavioral|Tailored CBME Therapy via Technology|6 Sessions of tailored interactive Cognitive-Behavioral Motivational Enhancement Therapy delivered through internet and cell phones
1628559|NCT02021175|Other|Standard of Care|Referral to currently available resources for 6 sessions of a standard smoking cessation approach
1628560|NCT02021149|Device|High intensity whole-body infrared heating|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat. Core body temperatures will be raised to those comparable to a mild fever 37.8-38.5°C.
1628561|NCT02021149|Behavioral|Psychotherapy|Weekly psychotherapy using cognitive behavioral therapy sessions with a therapist.
1628562|NCT02021149|Other|Questionnaires|Weekly questionnaires to assess changes in mood, perceptions of self and perceptions of effectiveness of the therapist/patient bond will be administered.
1628563|NCT02021149|Device|Low intensity whole-body infrared heating|Attenuated heating using only heating coils at the bottom of the Heckel device. This results in only a minor increase in skin temperature and no increase in core body temperature. The participant will still feel heat and will see similar lighting and hear similar sounds as those occurring during actual WBH, and will be in the chamber for the same period of time.
1628564|NCT02021136|Device|Rebel Reliever|Rebel Reliever knee brace + usual antalgic treatment + physical exercises recommendations
1628565|NCT02021136|Other|Control|Usual antalgic treatment + physical exercises recommendations
1628566|NCT02021123|Drug|Anidulafungin 100mg single dose iv|Anidulafungin 100mg single dose iv pre-surgery (gastric bypass)
1628567|NCT02021110|Drug|Ursodeoxycholic Acid|The intervention group will receive 15-20mg/kg/day UDCA for 24 weeks
1628568|NCT02021097|Drug|Levonorgestrel 100 mcg and Ethinyl Estradiol 20 mcg|Tablet, orally, opd
1628569|NCT02021097|Drug|Levonorgestrel 150 mcg and Ethinyl Estradiol 30 mcg|Tablet, orally, opd
1628570|NCT02021084|Dietary Supplement|probiotic|Probiotics group - patients will received probiotics Bio -25 including 11 types of bacteria total of 25 billion germs in each capsule, patients will received one capsule a day for 3 month.
1628571|NCT02021084|Dietary Supplement|Placebo|Placebo group - patients will received placebo patients will received one capsule a day for 3 month.
1628572|NCT02021071|Radiation|XperGuide|Live 3D image needle guidance which overlays live fluoroscopy and 3D soft tissue imaging data from previous acquired CT, MR or XperCT.
1628573|NCT02021071|Radiation|XperGuide with virtual path planning|Instrument guidance allowing certain tasks that would normally occur using continuous X-ray guidance to be performed with reduced dose for patient and staff.
1628574|NCT02021058|Other|Experimental Formula|Experimental formula
1628575|NCT02021058|Other|Standard control formula|Standard Infant formula
1628576|NCT02021045|Device|Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)|Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.
1628577|NCT02021032|Device|Prolieve|Prolieve® is a transurethral microwave therapy device equipped with automated controls designed to deliver microwave energy to the prostate and balloon-administered compression for the treatment of symptomatic BPH. This device utilizes a transurethral catheter with microwave antenna to heat the prostate, with simultaneous 46 Fr. prostatic urethral catheter balloon-administered compression.
1628578|NCT02021019|Procedure|Renal Denervation|Renal Denervation
1628579|NCT02021006|Drug|nitrofurantoin|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs
Physicians can chose one the following schedules:
nitrofurantoin 1.5-2 mg/kg per day
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)
cefixime 2 mg/kg per day
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
1628580|NCT02021006|Other|No prophylaxis|children will be followed, but no antibiotic prophylaxis will be administered
1628581|NCT02021006|Drug|Amoxicillin-Potassium Clavulanate Combination|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs
Physicians can chose one the following schedules:
nitrofurantoin 1.5-2 mg/kg per day
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)
cefixime 2 mg/kg per day
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
1628582|NCT02021006|Drug|Trimethoprim/sulfamethoxazole|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs
Physicians can chose one the following schedules:
nitrofurantoin 1.5-2 mg/kg per day
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)
cefixime 2 mg/kg per day
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
1628583|NCT02021006|Drug|Cefixime|"antibiotic prophylaxis of urinary tract infections The antibiotic for prophylaxis will be chosen by Physicians according to the local resistance spectrum of bacteria responsible of UTIs
Physicians can chose one the following schedules:
nitrofurantoin 1.5-2 mg/kg per day
amoxicilline/clavulanic acid 15 mg/kg per day (dose expressed in units equivalent to amoxicilline)
cefixime 2 mg/kg per day
trimethoprim/sulfamethoxazole 2.5 mg/kg per day (dose expressed in units equivalent to trimethoprim)"
1628584|NCT02020980|Drug|Botulinum Toxin Type A (BoNT-A) Injection|"This is an observational study designed to reflect the clinical practice in real life as closely as possible.
Botulinum Toxin Type A (BoNT-A) injection administered according to the local Summary of Product Characteristics (SmPC) and the locally agreed treatment guidelines."
1628585|NCT02020967|Other|Non-interventional cross-sectional survey|This is a survey which does not involve any intervention into routine clinical practice, including the use of any investigational therapy or special examination methods.
1628586|NCT02020954|Procedure|ECG, echocardiography, cardiac MRI, sera biomarkers|
1628587|NCT02020941|Drug|carfilzomib|Given IV
1628588|NCT02020941|Drug|dexamethasone|Given IV or PO
1628589|NCT02020941|Other|laboratory biomarker analysis|Correlative studies
1628590|NCT02020928|Device|Low level laser therapy|Low level laser therapy: Laser Therapy XT (DMC) having red light with a wave length of 660 nm (± 10 nm) and infrared light with a wavelength of 808 nm (± 10 nm) is used, both power of 100 mW (± 20%), applied in a timely manner.
1628591|NCT02020915|Procedure|lateral sphincterotomy|
1628592|NCT02020915|Procedure|ultrasound guided lateral sphincterotomy|
1628593|NCT02020902|Other|Cetrizine hydrochloride|As provided on the patient information leaflet
2011438|NCT02554890|Drug|sacubitril/valsartan (LCZ696) matching placebo|matching placebo of sacubitril/valsartan (LCZ696) tablet with minimum dose 24/26 mg, maximum dose 97/103 mg twice daily administered orally.
2011439|NCT02554890|Drug|enalapril matching placebo|enalapril matching placebo tablet with minimum dose 2.5 mg, maximum dose 10 mg twice daily administered orally.
1628596|NCT02020876|Other|DECIPHER Questionnaire|Participants are asked to complete a questionnaire to assess the impact of Decipher on physicians' treatment recommendation. All participants use the same data collection instrument. Each participant opinion is collected based on a random selection of cases.
1628597|NCT02020863|Device|Closed Loop|Fluid management in the closed loop group will be performed via a closed loop (automated) system that will use an infusion pump (Q-Core) and a controller (a computer run index and algorithm developed by Sironis) to make frequent, regular and accurate adjustments to the amount of fluid the patient receives using feedback from standard operating room monitors.
1628599|NCT02020824|Behavioral|Exposure to anxiogenous environments|"The anxiogenous environments are defined by several levels of possible anxiety classified progressively and independently by each patient at the beginning of the study. The exposure is applied during the 8 sessions for each of the arms Exposure to anxiogenous environments (with or without control)."
1628600|NCT02020824|Other|Imagery with functional MRI initial|Subjects will be submitted to 1 session of fMRI during their first visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
1628601|NCT02020824|Other|Imagery with PET-scanner initial|Subjects will be submitted to 1 session of PET-scanner during their first visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
1628602|NCT02020824|Other|Imagery with functional MRI final|Patients will be submitted to 1 session of fMRI during a follow-up visit, in order to identify and evaluate the activation of cerebral fields involved during the exposure to anxiogenous environments.
1628603|NCT02020824|Other|Imagery with PET-scanner final|Patients will be submitted to 1 session of PET-scanner during a follow-up visit, in order to measure the synaptic activity during the exposure to anxiogenous environments.
1628604|NCT02020811|Device|Sentinel|
1628606|NCT02020785|Behavioral|Dietary Education on Phosphorus Additives|All participants at the beginning of the study will receive dietary education to reduce their baseline consumption of phosphorus to a goal of ~1gm/d by receiving education on avoiding phosphorus-based additives
1628607|NCT02020785|Other|Higher phosphorus period|Commercially-available unaltered food/beverage products containing phosphorus additives (~1gm/d of phosphorus) will be given for 3 weeks
1628608|NCT02020785|Other|Lower phosphorus period|Commercially-available unaltered food/beverage products without phosphorus additives (<10mg/d of phosphorus) will be given for 3 weeks
1628609|NCT02020772|Other|coordinating primary health care|
1628610|NCT02020772|Other|usual primary health care|
1628611|NCT02020759|Device|Transcranial Doppler Ultrasound|Transcranial Doppler Ultrasound is used to monitor cerebral embolism Near-Infrared Spectroscopy is used to detect cerebral hypoperfusion
1628612|NCT02020746|Drug|EscharEx|
1628613|NCT02020746|Drug|Gel Vehicle|
1628614|NCT02020733|Device|Balloon catheter|
1628615|NCT02020733|Device|metal cannula|
1628616|NCT02020720|Procedure|Biopsy|Undergo image-guided biopsy
1628617|NCT02020720|Procedure|Computed Tomography|Undergo 18F-DOPA-PET/CT
1628618|NCT02020720|Procedure|Diffusion Weighted Imaging|Undergo DTI
1628619|NCT02020720|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET/CT
1628620|NCT02020720|Other|Laboratory Biomarker Analysis|Correlative studies
1628621|NCT02020720|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
1628622|NCT02020720|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET/CT
1628623|NCT02020720|Procedure|Therapeutic Conventional Surgery|Undergo stereotactic craniotomy
1628624|NCT02020707|Biological|Bevacizumab|Given IV
1628625|NCT02020707|Other|Laboratory Biomarker Analysis|Correlative studies
1628626|NCT02020707|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1628627|NCT02020707|Other|Pharmacological Study|Correlative studies
1628628|NCT02020694|Drug|Vitamin D|
1628629|NCT02020694|Drug|Placebo (for vitamin D)|
1628630|NCT02020681|Device|Curodont Repair|Self-assembling peptide, biomimetic re-mineralisation
1628631|NCT02020681|Other|Placebo|Formulation of Curodont Repair without the peptide P11-4
1628632|NCT02020681|Device|Fluoride|Single application on day D90
1628633|NCT02020668|Other|Physiotherapy|
1628634|NCT02020668|Other|Wait list control|
1628635|NCT02020655|Other|Shear- force model|Shear- force model
1628636|NCT02020642|Procedure|Renal transplantation|Renal transplantation from cadaveric or live donor
1628637|NCT02020629|Drug|Lixisenatide|Lixisenatide is given for 6 weeks whereafter a hypoglycemia clamp is undertaken
2011440|NCT02553616|Behavioral|Intervention to Promote Healthy Behaviors|Six individualized sessions (30 minutes each) are delivered to each participant randomized to receive the intervention.
2011441|NCT02550639|Other|BIOMARKER- elispot test|ELISPOT TEST
1628641|NCT02020603|Device|epinephrine injection plus soft coagulation using hemostatic forceps|
1628642|NCT02020603|Device|epinephrine injection plus argon plasma coagulation|
1628643|NCT02020590|Drug|ALLOB® implantation|Each patient will undergo a single administration of ALLOB® into the delayed-union site under anesthesia.
1628644|NCT02020577|Drug|Cetuximab( erbitux®)|once per week
1628645|NCT02020577|Drug|Afatinib|once per day
1628646|NCT02020564|Behavioral|Speed of Processing Training|
1628647|NCT02020551|Drug|Lidocaine Spray|
1628648|NCT02020551|Drug|Placebo|
1628649|NCT02020538|Other|Low-chloride perioperative intravenous fluid strategy|The low-chloride perioperative IV fluid strategy will include the use of PlasmaLyte 148 or Hartmann's solution as the crystalloid of choice and 20% albumin as the colloid of choice.
1628650|NCT02020525|Procedure|restrictive transfusion strategy|Patients allocated to the restrictive transfusion strategy were transfused only when their hemoglobin concentration decreased below 7.7 g d dL-1 and were then maintained at hemoglobin concentrations between 7.7 and 9.9 g d dL-1.
1628651|NCT02020525|Procedure|liberal transfusion strategy|Patients assigned to the liberal strategy were transfused when their hemoglobin concentration fell below 9.9 g dL-1, aiming at maintaining hemoglobin at or above 10 g dL-1.
1628652|NCT02020512|Drug|0.03% Bimatoprost|0.03% bimatoprost (LUMIGAN®) 1 drop in the affected eye once daily in the evening as monotherapy or adjunctive therapy for 5 weeks.
1628653|NCT02020499|Drug|Somatuline Autogel® (lanreotide) 60, 90, 120 mg.|Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.
1628654|NCT02020486|Drug|Perampanel|2 mg up to 4 mg
1628655|NCT02020486|Drug|Perampanel|2 mg up to 6 mg
1628656|NCT02020460|Device|Subdural trial lead|
1628657|NCT02020460|Device|Epidural trial lead|
1628658|NCT02020434|Drug|RPX7009 and RPX2014|The study is designed to enroll approximately 32 subjects. There will be approximately 24 subjects with varying degrees of renal insufficiency and approximately 8 subjects with normal renal function.
1628659|NCT02020421|Device|rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the center of the right Pars Triangularis for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 90% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
1628660|NCT02020421|Device|tDCS|2mA cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. tDCS will start immediately before the speech-language therapy session and last throughout the session.
1628661|NCT02020421|Device|Sham rTMS|Low frequency (1Hz) repetitive transcranial magnetic stimulation (rTMS) over the Vertex for 15 minutes (900 pulses) prior to each Speech-Language therapy session. Stimulation intensity will be set at 10% of the resting motor threshold (RMT) of the left first dorsal interosseous (FDI) muscle.
1628773|NCT02019485|Drug|Tapentadol Prolonged-Release Formulation 2 (PR2)|Participants will receive a single dose of tapentadol PR2 100 mg tablet orally in treatment sequences AB and BA appropriately.
1628662|NCT02020421|Device|Sham tDCS|Sham cathodal transcranial direct current stimulation (tDCS) over the right Pars Triangularis. The anode will be placed on the forehead over the contralateral eye. To elicit the typical skin sensation of real tDCS (tingling sensation on the skin when tDCS is turned on and off), the current will be turned on for 30 seconds and then turned off for the duration of the speech-language therapy session. The same procedure will be done at the end of the session.
1628663|NCT02020408|Drug|[11C]raclopride|1.[11C]raclopride -The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND
1628664|NCT02020408|Drug|[11C]DASB|BPND of [11C]DASB.
1628665|NCT02020408|Drug|amphetamine|The change (Δ) in BPND (the difference between the [11C]raclopride BPND at baseline and post-AMPH treatment normalized to the baseline BPND.
1628666|NCT02020395|Dietary Supplement|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
1628667|NCT02020395|Dietary Supplement|test meal (500 kcal)|whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
1628668|NCT02020382|Device|qPCR diagnostic KIT of microRNAS|testing qPCR diagnostic KIT of microRNAS from colonic biopsies
1628669|NCT02020369|Biological|Coagulation Factor VIIa (Recombinant)|A cross over design to assess the efficacy of 2 separate dose regimens (75µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII/IX
2011442|NCT02550444|Drug|Intrathecal Clonidine|Intrathecal Adjuvant Clonidine 75 mcg; Intravenous Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
2011443|NCT02550444|Drug|Intravenous Clonidine|Intravenous Clonidine 75 mcg; Intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
1628672|NCT02020343|Behavioral|taste tests|"Subjects undergo sham feeding in which they take a bit of food, chew it and spit it out. This test should engage sensory mechanisms which may affect intestinal signaling."
1628673|NCT02020330|Drug|Artemether-lumefantrine 3 days|One tablet contains 20mg artemether and 120mg lumefantrine. The standard regimen is twice daily for 3 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 3 days arm.
1628674|NCT02020330|Drug|Artemether-lumefantrine 5 days|One tablet contains 20mg artemether and 120mg lumefantrine. The experiment regimen is twice daily for 5 days with a delay of at least 8 hours between the first and second dose. It is dosed by weight categories. One gram of fish oil will be given to half of the participants in the 5 days arm.
1628675|NCT02020317|Behavioral|decision support in potassium-inc. drug-drug-interactions|display of computer-based reminders for serum potassium monitoring and hyperkalemia alerts
1628676|NCT02020304|Drug|combined spinal epidural|Combined Spinal Epidural
1628677|NCT02020291|Drug|Foxy-5|
1628679|NCT02020265|Device|EEG neurofeedback|
1628680|NCT02020252|Other|Touchscreen Computer Program|A program which allows patients to see information on a computer screen regarding cancer care, and specifically clinical trials
1628681|NCT02020239|Other|Exercise|
2011444|NCT02550444|Drug|Placebo|Intravenous and intrathecal Placebo (Saline 0,9%); Intrathecal heavy Bupivacaine 0,5% (15mg), morphine 0,02 (80mcg) and fentanyl (10mcg).
1628683|NCT02020213|Drug|Posaconazole|400 mg po bid for 8 weeks
1628684|NCT02020200|Drug|MPH|MPH dosage will be determined according to participants' body weight: dosage: 10 mg in case weight<40 kg; 30 mg in case weight>90 kg; otherwise 20 mg.
1628685|NCT02020200|Drug|Placebo|
1628686|NCT02020187|Other|Exercise on a cycle-ergometer|Home training on an ergometer-cycle 30 minutes every other day or at least three times a week. Subject will exercise in a pulse interval corresponding to 70% of their maximal VO2.
1628687|NCT02020161|Drug|Atra|
1628688|NCT02020161|Drug|Idarubicin|
1628689|NCT02020161|Drug|methotrexate|
1628690|NCT02020135|Drug|PSMA ADC|Upon recommendation from the PI and after Sponsor approval, a subject benefiting from treatment could have received up to eight additional doses Q3W. Subjects were weighed prior to each cycle and dosing was calculated on a mg/kg basis prior to each dose, with a maximum weight of 100 kg for dosing calculations.
1628691|NCT02020122|Drug|Duloxetine|duloxetine 60mg
1628692|NCT02020122|Drug|Pregabalin|pregabalin 150mg
1628693|NCT02020122|Drug|Placebo|non active placebo
1628694|NCT02020109|Radiation|splenic irradiation|
1628695|NCT02020096|Procedure|Ultrasound and nerve stimulator guided lumbar plexus block|An insulated nerve block needle connected to a nerve stimulator that was delivering a current of 1.5 mA at a frequency of 2 Hz was then inserted in the long axis (in- plane) of the ultrasound transducer towards the the hypoechoic psoas compartment. If the quadriceps contraction which produces patella twitching was elicited with an initial current of 1.5mA,then the current should be reduced until contraction is still present between 0.5 and 1.0 mA .Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.2mA, otherwise intraneural needle position should be suspected.
1628696|NCT02020096|Procedure|Nerve stimulator guided lumbar plexus block|The block was conducted following traditional Winnie approach. The accepted end point for the lumbar plexus is stimulation of the femoral nerve component, observed by contraction of the quadriceps muscle. Quadriceps contraction which produces patella twitching should be sought with an initial current of 1.5mA, and once elicited the current should be reduced until contraction is still present between 0.5 and 1.0 mA. Afterward, the lumbar plexus nerve block was performed by using 30mL of 0.5% ropivacaine. Contraction should stop below a current of 0.2mA, otherwise intraneural needle position should be suspected.
1628772|NCT02019485|Drug|Tapentadol Extended Release (ER) Tamper-Resistant Formulation (TRF)|Participants will receive a single dose of tapentadol ER TRF 100 mg tablet orally (by mouth) in treatment sequences AB and BA appropriately.
2011445|NCT02549170|Biological|HYQVIA|Dosing regimen for HYQVIA/HyQvia will be the same as the participant's pre-randomization monthly equivalent IgG dose when administered every 2, 3, or 4 weeks.
1650907|NCT01848730|Drug|Placebo|
2011446|NCT02549170|Biological|0.25% albumin placebo solution with rHuPH20|Dosing regimen for placebo treatment will be the same as the participant's pre-randomization monthly equivalent IgG infusion volume when administered every 2, 3, or 4 weeks.
1628697|NCT02020096|Procedure|Nerve stimulator guided sciatic nerve block|We performed the sciatic nerve block using the classic Labat's approach. The stimulating needle was inserted with a 90° angle to the skin and advanced until stimulation of the tibial nerve (plantar flexion of the foot) was obtained. The intensity of the stimulating current, initially set to deliver 2 mA, was gradually decreased to 0.5 mA while the appropriate motor response was maintained. Then,20 mL of 0.5% ropivacaine was injected slowly after careful intermittent aspirations. If dorsiflexion was elicited as a result of stimulation of the common peroneal nerve, the needle was withdrawn and redirected 2-3mm more deeply and medially. Contraction should stop below a current of 0.2mA, otherwise intraneural needle position should be suspected.
1628698|NCT02020070|Drug|Degarelix|
1628699|NCT02020070|Drug|Ipilimumab|
1628700|NCT02020070|Procedure|Radical Prostatectomy|
1628701|NCT02020057|Procedure|Total knee arthroplasty|Total knee arthroplasty with standard incision and approach, and cement fixation. Zimmer Nexgen posterior stabilized total knee implants are used.
1628702|NCT02020044|Other|Endothelial Keratoplasty|
1628703|NCT02020031|Drug|Vancomycin|
1628704|NCT02020018|Device|wound VAC (Prevena)|negative pressure therapy that will be applied instead of the regular dressing immediately postoperatively in high risk patients and kept for 6-7 days
1628705|NCT02020018|Other|standard wound dressing|regular dressing that is applied immediately postoperatively for high risk patients in the operating room after strenotomy
2011447|NCT02549170|Biological|IGIV|IGIV treatment will consist of an induction dose of 2 g/kg, followed by maintenance infusions at the same monthly dose as the participant's pre-randomization IgG dose, every 3 weeks.
2011448|NCT02548234|Other|Mirror therapy|Mirror therapy group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
2011449|NCT02548234|Other|Bilateral arm training|Bilateral arm training group received training for 1.5 hours/day, 3 days/week, for 4 weeks and home programs for 30-40 min/day, 5 days/week.
2011450|NCT02546661|Drug|AZD4547|AZD4547 Monotherapy vs. Durvalumab + AZD4547 1:1 Randomization.
2011451|NCT02546661|Drug|Durvalumab|Durvalumab
1991946|NCT00156013|Drug|CLOFARABINE|4 mg/m^2 days 1-5 of every cycle for a maximum of 6 cycles
1628712|NCT02019979|Drug|metformin|Addition of metformin 1000 mg po bid to standard of care platinum based chemotherapy
1628713|NCT02019979|Behavioral|carbohydrate restricted diet|addition of dietary counseling and metformin 1000 mg po bid to platinum based chemotherapy
1628714|NCT02019953|Other|Yoga|The yoga intervention, which is taught based on Hatha yoga, will be offered to study participants in Study Arms 1, 2, and 3, is a combination of asanas (poses), pranayams (breathing exercises), and meditation. Blood pressure and heart rate measurements are taken before and after each session.
1628715|NCT02019953|Other|Walking|The walking intervention, which is Study Arm 4 includes, three guided walking sessions per week for 24 weeks. Each class is an hour in length and will include a minimum of 30 minutes of walking at the equivalent of a minimum of three miles per hour. Each session includes a ten-minute warm-up and ten-minute cool-down period of some stretches and walking at a leisurely pace. Blood pressure and heart rate measurements are taken before and after each session.
1628716|NCT02019953|Other|Healthy Lifestyles Education|Participants randomly assigned to the fifth study arm attend one 60-minute healthy lifestyles class per week for 24 weeks. The Healthy Lifestyles curriculum includes 24 independent lesson modules, which allows participants to begin their intervention at any time during the course schedule. Blood pressure and heart rate measurements are taken before and after each session.
1628717|NCT02019940|Drug|Riluzole|
1628718|NCT02019927|Device|Transcorneal Electrical Stimulation|The clinical trial will investigate whether Transcorneal Electrical Stimulation delivered by the Okuvision Stimulation Set manufactured by Okuvision GmbH, Reutlingen, Germany, is a potentially effective therapy for the restoration and rehabilitation of vision loss as measured by improvements in visual acuity in the following three patient populations: patients with ocular trauma, patients with optic neuritis associated with multiple sclerosis and patients with Non-arteritic Anterior Ischemic Optic Neuropathy.
1628719|NCT02019901|Other|Nurse-led clinic|
2011452|NCT02546661|Drug|Olaparib|Durvalumab + Olaparib
2011453|NCT02546661|Drug|AZD1775|Durvalumab + AZD1775
1628724|NCT02019862|Device|TRJ® Total Hip Arthroplasty|
1628725|NCT02019849|Device|Plasmafit® Total Hip Arthroplasty|
1628726|NCT02019836|Other|Determining maternal and neonatal vitamin D levels|
1628727|NCT02019823|Behavioral|Informational SMS-text|
1628728|NCT02019823|Behavioral|Interactive SMS-text|
1628729|NCT02019823|Behavioral|Enhanced usual care|
1628730|NCT02019810|Drug|Norepinephrine|
1628731|NCT02019810|Drug|Dobutamine and norepinephrine|
1628732|NCT02019797|Drug|Desflurane|Patients are assigned to desflurane group (Des) or propofol group (Prop). Des receives desflurane (1-2 MAC) inhalation between the induction of anesthesia and before cardiopulmonary bypass (CPB). After the induction of CPB, the anesthesia in Des is switched to a total intravenous anesthesia (TIVA) with propofol. Prop receives a propofol during the surgery.
1628733|NCT02019784|Drug|Rifaximin-α|Rifaximin-α will be compared to placebo with the various outcome measures assessed at baseline (pre-randomisation), and then at 30 days and 90 days.
1628734|NCT02019784|Drug|Placebo Oral Tablet|Placebo Oral Tablet
1628739|NCT02019745|Biological|LAIV|Standard dose of LAIV administered by a licensed health care providers.
1628740|NCT02019732|Other|Data collection|Data collection from existing electronic healthcare databases (Marketscan Commercial database, MarketScan Medicare Supplemental database).
1991947|NCT00140738|Biological|GSK Biologicals' 719125|Patients receive six vaccinations at two-week intervals
1628743|NCT02019706|Drug|F-DOPA PET Scan|
1628744|NCT02019706|Drug|Mifepristone|
1628745|NCT02019706|Drug|Ga-DOTATATE|
1628746|NCT02019706|Drug|Octreoscan|
1628747|NCT02019706|Other|CT, MRI|
1991954|NCT00116428|Device|NAVISTAR® THERMOCOOL® Catheter|The Biosense Webster NAVISTAR® THERMOCOOL® Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
1628753|NCT02019628|Dietary Supplement|Rice Bran Arabinoxylan Compound (RBAC)|Participants enrolled in the study will receive BRM4 at a dosage level of either 1 gram/day or 3 gram/day for the 60-day period. Subjects will be instructed to not consume any known immune-active pharmaceutical agents, nutritional supplements containing vitamins C and D, and/or any mushroom products for two weeks prior to having the baseline assessments and until the conclusion of the 60-day period. According to the company's literature, RBAC is a water soluble extract of rice bran that has been acted upon by an enzyme complex extracted from Shiitake mushroom. BRM4 contains: microcrystalline cellulose, hypromellose, sucrose fatty acid ester, gellan gum, and potassium acetate.
1628754|NCT02019615|Device|transcranial direct current stimulation|anodal transcranial direct current stimulation on the left dorsolateral prefrontal cortex for the anodal session and sham stimulation (5secondes of tDCS) for the sham session
1628755|NCT02019602|Procedure|Blood sampling from mother|A blood sample from the mother will be taken within 24 hours before/after the delivery.
1628756|NCT02019602|Procedure|Blood sampling from infant|Blood samples from the infant will be taken within 24 hours after birth, at Week 4 and at Week 8.
1628757|NCT02019602|Procedure|Blood sampling from umbilical cord|A blood sample from the umbilical cord will be taken directly (within 1 hour ) after delivery.
1628758|NCT02019602|Biological|Certolizumab Pegol|"Mothers who decided to continue on, or to start treatment with, CZP for an approved indication with their treating physician prior to participation into this study. The mother is responsible for procuring her own supply of commercial CZP. The CZP dose and administration schedule will be as per the locally approved label.
Active Substance: Certolizumab Pegol
Pharmaceutical Form: Solution for injection
Concentration: 200 mg/ml
Route of Administration: Subcutaneous Use"
1628760|NCT02019576|Radiation|Stereotactic radiotherapy|SRT to all areas of oligo-progression as follows: BRAIN: 20-24 Gy in 1 fraction if < 2 cm,18 Gy in 1 fraction if 2-3 cm,15 Gy in 1 fraction for 3-4 cm, alternatively 25-30 Gy in 5 fractions can be used; SPINE: 18-24 Gy in 1-2 fractions,24 Gy in 3 fractions or 30-40 Gy in 5 fractions; NON-SPINE BONE: 30-40 Gy in 5 fractions; LUNG: 48-60 Gy in 4 fractions or 54-60 Gy in 3 fractions for peripheral lung tumours,50 Gy in 5 fractions or 60 Gy in 8 fractions for central lung tumours; LIVER: 30-60 Gy in 3-6 fractions,higher doses for central liver lesions and lower doses for peripheral liver lesions depending on proximity to adjacent organ (stomach, small bowel, large bowel or kidney); ADRENAL OR KIDNEY TUMOURS: 30-40 Gy in 5 fractions; LYMPHADENOPATHY: 30-40 Gy in 5 fractions.
1628761|NCT02019563|Procedure|RCT Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and the pulp tissue removed. The canal will be irrigated with water and then filled with non-reinforced ZOE.
1628762|NCT02019563|Procedure|MTA/FS pulpotomy Group|After complete removal of all caries, if a pulp exposure is detected the pulp chamber will be opened and vital coronal pulp to a depth of 2mm below free gingival margin will be removed. A solution of ferric sulfate will be applied to the amputated pulp surface and then flushed with water. MTA paste is then used to cover over the exposed amputated pulp surface.
1628763|NCT02019550|Device|Rebif Rebidose|Rebif 44 mcg will be injected subcutaneously three times a week using Rebif Rebidose self-injector device.
1628764|NCT02019550|Device|Rebiject II|Rebif 44 mcg will be injected subcutaneously three times a week using Rebiject II self-injector device.
1628765|NCT02019537|Procedure|Steroid injection into the subacromial space|"Group: Steroid
Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)
The number of injections : only once during the study period
Injection site : subacromial space
Material : 25-gauze spinal needle
Subacromial injections were performed using ultrasonographic guidance."
1628766|NCT02019537|Procedure|Allogeneic PRP injection into the subacromial space|"Group: Allogeneic PRP
Total volume of injection drugs: 4ml
The number of injections : only once during the study period
Injection site : subacromial space
Material : 25-gauze spinal needle
Subacromial injections were performed using ultrasonographic guidance."
1628767|NCT02019524|Biological|E39 peptide vaccine|500mcg of lyophilized E39 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the E39 peptide vaccine. For patients randomized to the E39 vaccine arm, the primary vaccine series (PVS) consists of E39 vaccine administered intradermally every three to four weeks for six total vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive one inoculation of either the E39 vaccine or the J65 vaccine.
1628768|NCT02019524|Biological|E39 vaccine then J65 vaccine|The E39 vaccine is prepared as noted above. For the J65 vaccine, 500mcg J65 peptide is suspended in bacteriostatic saline for injection and then frozen. At the time of vaccine administration, one vial of frozen suspended E39 peptide is thawed and mixed with 250mcg GM-CSF in the syringe. This constitutes the J65 vaccine. For patients randomized to this arm, the primary vaccine series (PVS) consists of the E39 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the J65 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
1628769|NCT02019524|Biological|J65 vaccine then E39 vaccine|The E39 and J65 vaccines are prepared as noted above. For patients randomized to this arm, the primary vaccine series (PVS) consists of the J65 vaccine administered intradermally every 3-4 weeks for 3 total vaccinations. Patients are then administered the E39 vaccine every 3-4 weeks for a total of 3 vaccinations. After completion of the PVS, patients are assessed for significant residual immunity (SRI). Patients with SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine. Patients without SRI will be randomized to receive 1 inoculation of either the E39 vaccine or the J65 vaccine.
1628770|NCT02019498|Behavioral|Relaxation exercise|Participants allocated to the relaxation group will apply daily but at least five days a week a 15-minutes relaxation exercise, guided by a smartphone application (App). On a daily basis, participants can select one out of the three exercises (guided imagery, mindfulness based training, autogenic training) which they want to apply
1628771|NCT02019498|Other|ususal care|Participants allocated to the usual care waiting list group will continue with their usual care without receiving any additional therapy
2011454|NCT02546661|Drug|Vistusertib|Durvalumab + Vistusertib
2011455|NCT02546661|Drug|AZD9150|Durvalumab + AZD9150
1628778|NCT02019459|Other|Very low nicotine content cigarettes|
1628779|NCT02019459|Other|standard nicotine content cigarettes|
1628780|NCT02019446|Device|Laser Treatment YAG laser|YAG Laser / FOX Laser
1628781|NCT02019446|Drug|Standard Treatment (control group) terbinafine hydrochloride tablets|Terbinafine hydrochloride tablets tablets
1628782|NCT02019433|Device|Structan®|
2011456|NCT02543398|Procedure|Ridge preservation|Ridge preservation is a procedure which consists in grafting the tooth extraction socket with a bone grafting material and cover the site with a membrane to protect the site.
2011457|NCT02542865|Dietary Supplement|Fortified malt based food|Fortified malt based food
1628785|NCT02019407|Procedure|PVI, CTI block|"PVI (pulmonary isolation)
Catheter ablation of cavo-tricuspid isthmus line for treatment of atrial fibrillation
Catheter is inserted into inferior venacava (IVC) and right atrium (RA) via femoral vein. And the procedure is to block bidirectionally between inferior venacava (IVC) and the annulus of tricuspid valve (TV) by using electrical energy of catheter tip."
1628786|NCT02019407|Procedure|PVI|PVI (pulmonary isolation)
1628787|NCT02019394|Drug|Lu AE58054|"Oral dosing: 90 mg Lu AE58054 as a single dose once and after a 3 days washout period, once daily for 7 days.
Intravenous dosing: 90 μg/not more than (NMT) 1000 nCi/37 kBq 14C-Lu AE58054 for intravenous infusion once on Day 10."
1628788|NCT02019381|Dietary Supplement|Endocrine Society UL Dosage Vitamin D|Endocrine Upper limit arm will get 10,000IU Vitamin D and 1200mg Calcium
1628789|NCT02019381|Dietary Supplement|Institute of Medicine Dosage Vitamin D|IOM arm will get 600 IU Vitamin D and 1,200 mg Calcium
1628790|NCT02019381|Dietary Supplement|Calcium|1200mg of CaCO3 supplementation will be given to each participant in both groups
1628791|NCT02019368|Dietary Supplement|Placebo|
1628792|NCT02019368|Dietary Supplement|Aged garlic extract|
1628793|NCT02019355|Drug|5-fluorouracil 5% cream|
1628794|NCT02019355|Drug|Calcipotriol 0.005% ointment|
1628795|NCT02019355|Drug|Vaseline|
1628796|NCT02019342|Other|FACE quality improvement initiative (see below)|Feedback (F): Regular feedback to practitioners; MAP Alerts (A): Change in electronic alert systems for high and low mean arterial pressure with patient specific alerts; Checklist (C): Interactive checklist in relation to the quality improvement initiative; Education campaign (E): Education campaigns about best intraoperative management of blood pressure.
1628797|NCT02019342|Other|Pre-quality improvement initiative|Patients in the pre-quality improvement initiative arm would receive current standard practice.
1628798|NCT02019329|Other|Placebo|Oral daily administration from Days 1-12
1628799|NCT02019329|Drug|RO5545965|Oral daily administration from Days 1-12
1628800|NCT02019329|Drug|risperidone|13 day run-in phase until 4 mg daily dose level is reached. 4 mg daily oral dose until Day 17 of study, for a total of 30 days. Dose may be increased up to 6 mg at the investigator's discretion. After study treatment, risperidone dosage may be decreased, increased or omitted at the investigator's discretion during a wash-out phase while patients return to their chronic antipsychotic treatment. Patient response during wash-out will be monitored in-house for 48 hours after the last dose of RO5545965 or placebo is administered. This in-house observation may be extended as needed by the investigator.
1628801|NCT02019316|Dietary Supplement|BioSteel Sports Drink|Participants will ingest 500ml of BioSteel Sports Drink 3 times during an exercise session.
1628802|NCT02019316|Dietary Supplement|Isoenergetic Control|Participants will ingest 500ml of Gatorade 3 times during an exercise session.
1628803|NCT02019303|Procedure|FNA and Core biopsy|Both procedures will be performed on the same lymph node
2011458|NCT02541292|Other|No intervention, observational|
2011459|NCT02540967|Drug|Gadovist (Gadobutrol, BAY86-4875)|Gadovist dosage following summary of product characteristics
2011460|NCT02538484|Drug|Letrozole|Aromatase inhibitor
2011461|NCT02538484|Dietary Supplement|Fish Oil|Omega-3 free fatty acid
2011462|NCT02536573|Other|Radlink Surgical Positioning Software|
2011463|NCT02535624|Procedure|PACKING|By retroperitoneal access the space in front of the pelvic fracture is compressed with surgical towels, which stops effectively venous bleeding
2011464|NCT02535624|Procedure|ANGIO|Using en endovascular approach, bleeding arteries are identified and clotted using embolizing agents, or coils.
1628811|NCT02019264|Drug|APD356-Lorcaserin hydrochloride|APD356 10 mg twice daily
1628812|NCT02019264|Drug|Placebo|Placebo twice daily
1628813|NCT02019251|Drug|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time with the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
1628814|NCT02019251|Device|MRI|
1628815|NCT02019238|Other|Pulmonary Vein Isolation procedure|comparing the efficacy of PVI ablation vs PVI combined with empiric ablation
1628816|NCT02019225|Other|Dialysis session of at least 4.25 hours|Facilities randomized to the Intervention arm will adopt the practice of recommending dialysis session durations of at least 4.25 hours for all patients initiating hemodialysis treatment regardless of body size or dialysis solute clearance measurements.
1628817|NCT02019186|Dietary Supplement|Vitamin C|<30 kg 250 mg 30-60 kg 500 mg >60 kg 750 mg
1628818|NCT02019186|Dietary Supplement|Vitamin E|<30 kg 100 IU, 30-60 kg 200 IU, >60 kg 300 IU
1628820|NCT02019160|Drug|25% AgNO3 solution followed by 5% NaF varnish|Dosage of 4.4μg±1.4μg fluoride per use
1628821|NCT02019160|Drug|38% SDF solution followed by placebo varnish|Dosage of 8.8μg±2.8μg fluoride per use
1628822|NCT02019134|Behavioral|relaxation exercise|relaxation exercise
1628823|NCT02019134|Other|ususal care|
1628856|NCT02018861|Drug|INCB050465|
1628857|NCT02018861|Drug|itacitinib|
1628858|NCT02018861|Drug|Rituximab|
1628859|NCT02018861|Drug|Ifosfamide|
1628860|NCT02018861|Drug|Carboplatin|
1628824|NCT02019108|Other|Progressive walking program with toe-out gait modification|Participants in this study group will perform continuous treadmill walking for a minimum of 30 minutes at each session, but the emphasis will be to increase toe-out angle by 10 degrees over that exhibited at baseline. A mirror will be provided for biofeedback and participants will be instructed on its use for achieving the target toe-out angle. Increased walking time and distance will be encouraged the same as for the control group.
1628825|NCT02019108|Other|Progressive walking program|At each scheduled visit, participants will perform treadmill walking for a minimum of 30 minutes depending on the individual's baseline activity level and the stage of the intervention. Emphasis will be solely on increasing walking time and distance to achieve the target of a 40% increase in daily activity.
1628826|NCT02019095|Other|Bronchoscopy for the sampling of bronchoalveolar lavage (BAL) fluid|
1628827|NCT02019082|Device|Electrical Stimulation (BTL-5000 series, United Kingdom)|Direct current ES
1628828|NCT02019082|Device|placebo|the intervention procedure was the same as that the ES group, but the current intensity was zero
1628829|NCT02019069|Drug|liposomal cytarabine-daunorubicin CPX-351|Given IV
1628830|NCT02019069|Other|laboratory biomarker analysis|Correlative studies
1628831|NCT02019056|Drug|Placebo /bid P.O|
1628832|NCT02019056|Drug|MG-1|
1628833|NCT02019056|Drug|MG-2 : MG1000mg, Placebo /bid P.O|
1628834|NCT02019056|Drug|metadoxine|
1628835|NCT02019043|Other|Syphilis testing with routine HIV bloodwork|The intervention condition will be implemented as standing orders for syphilis serology whenever patients undergo their standard battery of follow-up bloodwork, i.e., when there is an order for HIV viral load or CD4 cell count. It is standard practice for HIV patients to undergo such tests every 3-6 months. We anticipate that the change in practice will be straightforward, involving minimal training of clinic staff. Team members who are physicians at these clinics will guide the specific approach that will be appropriate and sustainable for their setting. Options are quite simple. They include pre-printing a checkmark for 'syphilis serology' onto existing pre-printed requisitions for routine bloodwork; addition of the serology request form to the routine blood work package; or programming 'syphilis serology' into existing computerized routine order sets.
1628836|NCT02019017|Drug|Botulinum Toxin Type A 25 IU|
1628837|NCT02019017|Drug|Botulinum Toxin Type A 50 IU|
1628838|NCT02019004|Drug|Onabotulinum Toxin A|
1628839|NCT02019004|Drug|Incobotulinum Toxin A|
1628840|NCT02018991|Procedure|Everolimus-Eluting Stent (EES)|Patients treated with EES
1628841|NCT02018991|Procedure|Zotarolimus-Eluting-Stent (ZES)|Patients treated with ZES
1628842|NCT02018991|Procedure|Biolimus-Eluting-Stent (BES)|Patients treated with BES
2011465|NCT02533921|Other|Interdisciplinary outpatient palliative care|Interdisciplinary outpatient palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. Palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease.
1628844|NCT02018965|Drug|Niacin|"• Group 1: This group will receive an initial dose of ER niacin 500 mg by mouth, the first evening from week 0 to week 4 then increase it to 1000 mg once a day from week 5 to week 8, then increase to 1500 mg from week 9 to week 12 then increase to 2000 mg until weeks 24 and then stopped.
Participants will continue to take their ART treatment as prescribed throughout the study."
1628845|NCT02018965|Drug|Niacin|"• Group 2: This group will not receive ER niacin for the first 24 weeks. This group will receive an initial dose of ER niacin 500 mg the first evening at week 25 by mouth from week 25 to week 28 then increase it to 1000 mg once a day from week 29 to week 32, then increase to 1500 mg from week 33 to week 36 then increase to 2000 mg until week 48 and then stopped.
Participants will continue to take their ART treatment as prescribed throughout the study."
1628846|NCT02018952|Other|Ultrasonography assessment|"All patients will be seen at day 0, day 4, day 15 and at 3 months. These visits are usually programmed. Only monitoring ultrasonography, a non invasive exam, and self-administered questionnaires will be made, additional to standard exams for all patients included (no control group).
Day 0 :
Information of patient and no opposition getting
Clinical exam
Laboratory tests
Radiography of the targeted joint
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)
Day 4 :
Clinical exam
Laboratory tests
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)
Day15 :
Clinical exam
Laboratory tests
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)
M3 :
Clinical exam
Laboratory tests
Radiography of the targeted joint
Ultrasonography of the targeted joint and controlateral joint (about 20 minutes)
Functional outcome"
1628847|NCT02018939|Other|Pharmacokinetic profiling|Pharmacokinetic samples are taken from each Patient receiving Doripenem in each arm. No other interventions are performed during this trial. Doripenem is not administered due to the trial.
1628848|NCT02018926|Drug|Mocetinostat|Mocetinostat (a histone deacetylase [HDAC] inhibitor) 70 mg or 90 mg dose, oral capsules 3 times weekly beginning on day 5, for 10 doses in each 28 day cycle
1628849|NCT02018926|Drug|Azacitidine|Azacitidine (a hypomethylating agent [HMA]) 75 mg/m2 dose, by intravenous (IV) infusion or subcutaneous (SC) injection beginning on day 1 for 7 doses in each 28 day cycle
1628850|NCT02018900|Dietary Supplement|Ecologic 825/scFOS|
1628851|NCT02018900|Dietary Supplement|Placebo|
2011466|NCT02533921|Other|Standard of Care|Usual care defined as including both a PCP and neurologist
2011467|NCT02533505|Drug|Budesonide 160 mcg and formoterol fumarate dehydrate 4.5 mcg Inhalation aerosol|Subjects will receive a single dose (2 inhalations) of Symbicort pMDI 160/4.5 μg (2 inhalations; total dosage 320/9.0 μg) or placebo (with a spacer) in a cross-over design (a total of 2 doses of Symbicort and 2 doses of placebo over the duration of the study), and assessments will be made before and after dosing at specified timepoints
1628854|NCT02018874|Drug|LY2780301|"LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :
Dose level -1: 300 mg Q.D.
Dose level -0.5: 400 mg Q.D.
Dose level 1: 400 mg Q.D.
Dose level 1.5: 500 mg Q.D.
Dose level 2 : 500 mg Q.D."
1628855|NCT02018874|Drug|Gemcitabine|The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
1628862|NCT02018848|Behavioral|Attention Training Program|
1628863|NCT02018835|Device|MRI|
1628864|NCT02018835|Device|cardiac echography transthoracic|
2011468|NCT02533505|Drug|Matching Placebo pMDI 160/4.5 μg|Placebo will be given according at the same dose and schedule as the active comparator - cross-over design.
2011469|NCT02532179|Biological|Mouse Allergenic Extract|Subjects will receive escalating doses of glycerinated mouse allergenic extract administered subcutaneously up to a maximum study dose (MSD) of 0.4 mL of extract at a concentration of 1:10 wt/vol., per protocol.
1628867|NCT02018809|Behavioral|Medication Adherence Partner|
1628868|NCT02018809|Device|Electronic pill bottle|This device can remotely track medication taking and will be used by subjects to store once-a-day statin medication already prescribed pre-trial.
1628869|NCT02018796|Drug|Mifepristone, misoprostol|200 mifepristone, followed 24 to 48 hours later by 600 mcg misoprostol
1628870|NCT02018783|Procedure|Colgate|Slow-speed handpiece with a Robson brush for 3 seconds by repeating the procedure
1628871|NCT02018783|Procedure|Sensodyne|Digital application for 60 seconds.
1628872|NCT02018783|Procedure|Nano P|Slow-speed handpiece with a Robson brush for 10 seconds
1628873|NCT02018783|Procedure|Cocorico|Digital application for 60 seconds
2011470|NCT02529930|Biological|VB10.16 Immunotherapy (DNA vaccine)|Patients will receive 3 vaccinations of 3 mg VB10.16 at the pre-specified time points. VB10.16 will be administered intramuscularly in the area over the lateral deltoid muscle.
1628876|NCT02018757|Drug|TACE containing As2O3|transarterial chemoembolization containing a mixture of 20mg of arsenic trioxide, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
1628877|NCT02018757|Drug|TACE containing placebo|transarterial chemoembolization containing a mixture of 20mg of placebo, 40mg of adriamycin and some dose of 40% ultra-fluid lipiodol
1628878|NCT02018731|Drug|Metformin and Metformin & L-Citrulline|
1628879|NCT02018731|Drug|L-Citrulline and Metformin & L-Citrulline|
1628880|NCT02018718|Device|Magnetic Resonance Imaging (MRI)|
1628881|NCT02018692|Dietary Supplement|Alga Dunaliella Bardawil powder|9 cis beta carotene rich Alga Dunaliella Bardawil powder
1628882|NCT02018692|Dietary Supplement|Placebo:Starch|Starch powder
1628883|NCT02018679|Procedure|Er:YAG AFL-PDT|AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
1628884|NCT02018679|Procedure|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
1628885|NCT02018666|Device|NAVA endotracheal tube|
1628889|NCT02018627|Drug|Xeris glucagon|The subject is given an injection of xeris glucagon
1628890|NCT02018627|Drug|Lilly glucagon|The subject is given an injection of lilly glucagon
1628891|NCT02018614|Other|algoplus|
1628892|NCT02018601|Procedure|BRILMA|
1628893|NCT02018601|Procedure|paravertebral block|
1628894|NCT02018601|Drug|dexketoprofen|
1628895|NCT02018601|Drug|paracetamol|
1628896|NCT02018588|Dietary Supplement|tryptophan|graded levels of tryptophan will be given to each subject
1628897|NCT02018575|Dietary Supplement|Crystalline Lysine Amino Acid Mix|Crystalline Lysine from Amino Acid Mixture in amount of 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
1628898|NCT02018575|Dietary Supplement|White corn meal porridge|A cornmeal porridge including 29, 37, 46 and 54% of the mean Lysine requirement of 35 mg/kg/d will be given to subjects.
1628899|NCT02018562|Device|Portex Blueline Ultra Suctionaid Tracheostomy Tube|
1628900|NCT02018549|Device|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
1628901|NCT02018536|Drug|GSK2336805 30 mg|A single dose of 1 tablet of 30 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
1628902|NCT02018536|Drug|GSK2336805 60 mg|A single dose of 2 tablets of 30 mg ie, 60 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
1628903|NCT02018536|Drug|GSK2336805 120 mg|A single dose of 4 tablets of 30 mg ie, 120 mg of GSK2336805 taken orally (by mouth) on Day 1 under fasted conditions.
1628904|NCT02018536|Drug|TMC435 150 mg (Treatment A)|1 capsule of TMC435 150 mg taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
1628905|NCT02018536|Drug|GSK2336805 60 mg (Treatment B and part of Treatment C and D)|2 tablets of 30 mg GSK2336805 ie, 60 mg of GSK2336805 taken once daily orally (by mouth) on Days 1 to 7 under fed conditions.
1628906|NCT02018536|Drug|TMC435 100 mg (part of Treatment C)|1 capsule of TMC435 100 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
1628907|NCT02018536|Drug|TMC435 150 mg (part of treatment D)|1 capsule of TMC435 150 mg taken orally (by mouth) on Days 1 to 7 under fed conditions.
1628908|NCT02018523|Drug|Lenalidomide|lenalidomide 10mg/day orally until disease progression
1628909|NCT02018510|Biological|1 mg/kg, single dose IV administration of 3BNC117|1 mg/kg, single dose IV administration of 3BNC117
1650908|NCT01848717|Device|MINTLIFT®|
1991955|NCT00116428|Drug|Antiarrhythmic drug|Subjects randomized to the antiarrhythmic drug (control) arm will be prescribed to a not previously administered class I or class III antiarrhythmic drug that is currently approved in the U.S. for treating atrial fibrillation.
1628910|NCT02018510|Biological|3 mg/kg, single dose IV administration of 3BNC117|3 mg/kg, single dose IV administration of 3BNC117
1628911|NCT02018510|Biological|10 mg/kg, single dose IV administration of 3BNC117|10 mg/kg, single dose IV administration of 3BNC117
1628912|NCT02018510|Biological|30 mg/kg, single dose IV administration of 3BNC117|30 mg/kg, single dose IV administration of 3BNC117
1628913|NCT02018510|Biological|10 mg/kg, two doses IV of 3BNC117|10 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
1628914|NCT02018510|Biological|30 mg/kg, two doses IV of 3BNC117|30 mg/kg, two IV administrations of 3BNC117 at weeks 0 and 12
1628915|NCT02018484|Procedure|Unicompartmental Knee Replacement|
1628916|NCT02018471|Behavioral|Psychoeducative training|The Psychological education was inspired by the technique, Systematic Desensitization (SD), a therapeutic procedure that seeks to eliminate fear and avoidance behaviour
1628917|NCT02018458|Biological|LA TNBC: DC vaccine+Preop chemo|LA TNBC patients will receive standard preop AC followed by TCb chemo for 24 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous for 4 times prior surgery. During the AC cycles, vaccines will be given on any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on any day between Days 11-15 of Cycles 1 and 3 of TCb. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. After this, patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after the surgery and prior to radiation; 2nd will occur 30 days ± 3 days after radiation; the 3rd will occur 90 days ± 3 days after the 2nd boost.
1628918|NCT02018458|Biological|ER+/HER2-BC:DC vaccine+Preop chemo|ER+/HER2- BC patients will receive standard preop AC followed by weekly T given for 22 weeks. Chemo and DC vaccinations will be given intratumoral and subcutaneous, for 4 times prior surgery. During the AC cycles, vaccines will be given any day between Days 9-12 of Cycles 1 and 3 of AC. Vaccines will be given on Day 1 during Cycle 2 or Cycle 3 and on Day 1 during either Cycle 8 or Cycle 9 of T. Vaccine will be given after T infusion is completed. Patients will undergo biopsies of their cancer prior to treatment and 1-2 days prior to or on Day 1 of Cycle 4 of AC. Patients will have surgery, locoregional radiation therapy to the breast or chest wall and regional lymphatics per standard of care, and will receive 3 boost DC vaccinations subcutaneously, rotating injection sites in the upper arm. The 1st vaccination will occur after surgery and prior to radiation; the 2nd will occur 30 days ± 3 days after radiation; and the 3rd will occur 90 days ± 3 days after the 2nd boost.
1628919|NCT02018445|Device|Accell Evo3 Demineralized Bone Matrix|
1628920|NCT02018432|Drug|Roflumilast escalation dosage|"This is a randomized, prospective, open label, comparative study to assess whether the administration of roflumilast by dose escalation varies the incidence of discontinuations due to adverse events when compared with the usual dosage in severe and very severe COPD patients.
Roflumilast 250 μg once daily for 4 weeks and then increased dose of Roflumilast 500 μg once daily for 12 weeks"
1628921|NCT02018432|Drug|Roflumilast conventional dosage|Roflumilast 500 μg once daily for 12 weeks
1628922|NCT02018419|Biological|AlloStim|AlloStim is derived from the blood of normal blood donors and is intentionally mismatched to the recipient.
1628923|NCT02018419|Procedure|Cryoablation|Percutaneous ablation of a single metastatic tumor lesion usually in liver or bone. The procedure is conducted under CT or ultrasound image-guidance.
1628924|NCT02018406|Drug|Combination injection of EPO and G-CSF|Subcutaneous EPO(300 U/kg)+G-CSF(10 μg/kg) injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
1628925|NCT02018406|Drug|Injection of normal saline|Subcutaneous normal saline injection once a day, 5 times a cycle (a week), total 3 cycles for 3 months.
1628926|NCT02018380|Other|Shock Absorbing Insole (SofSole Athletes Plus)|The shock absorbing insole used in this study was the SofSole Athletes Plus, (Implus Inc, Durham, NC), recommended by the manufacturer for repetitive activities such as running and walking. It is readily available in most athletic shoe stores, retailing for under $20.00. The insole is full-length with a curved last made of Implus XP that has a shore A durometer reading of 60 (0 = softest to 100 = hardest).
1628927|NCT02018367|Drug|Proflavine, high resolution imaging|5-10mL of proflavine hemisulfate (0.01%) will be sprayed on the esophageal mucosa. The HRME will then be inserted through the biopsy channel of the endoscope and gently placed against the mucosa. The endoscopist will image each discrete lesion observed during white light endoscopy. For each HRME imaged area, an optical read will be obtained followed by a tissue biopsy.
1628928|NCT02018354|Procedure|Lateral Extra-Articular Tenodesis (LET)|Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith & Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.
1628929|NCT02018354|Procedure|ACL Reconstruction|Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
1628930|NCT02018341|Other|homeopathic remedy in 30C potency|
1628931|NCT02018341|Other|Placebo|
1628932|NCT02018328|Dietary Supplement|Curcumin|
1628933|NCT02018315|Drug|Triheptanoin|Triheptanoin is a 7-carbon medium chain triglyceride
1628934|NCT02018302|Drug|Triheptanoin|
1628935|NCT02018289|Procedure|Triclosan coated suture|Suture of the abdominal wall with triclosan coated suture
1628936|NCT02018289|Procedure|No triclosan|Suture of the abdominal wall with suture without triclosan coat
1628937|NCT02018276|Drug|Lidocaine|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Lidocaine Group, 1% lidocaine 40 mL was prepared in a 50 mL syringe
1628938|NCT02018276|Drug|Magnesium|The administered drugs for each group were prepared by an anesthetist who did not participate in the study according to directions given by the patient in charge of the study. (for Magnesium Group, MgSO4 4g 40 mL was prepared in a 50 mL syringe)
1628939|NCT02018263|Drug|Cocaine hydrochloride|
1628940|NCT02018263|Behavioral|Exercise|
1628941|NCT02018263|Drug|Nicotine|
2011471|NCT02528253|Biological|Placebo to Week 16; tanezumab 5mg SC|Placebo SC injection every 8 weeks for 2 injections followed by tanezumab 5 mg injection every 8 weeks for 5 injections
2011472|NCT02528253|Biological|Placebo to Week 16, tanezumab 10 mg SC|Placebo SC injection every 8 weeks for 2 injections, followed by tanezumab 10 mg SC injection for 5 injections
1628944|NCT02018237|Behavioral|High fructose corn syrup diet|Subjects will consume a high fructose corn syrup diet for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
1628945|NCT02018237|Behavioral|Standard diet (low in high fructose corn syrup)|Subjects will consume a standard diet (low in high fructose corn syrup) for 4 weeks. The food will be prepared by the bio-nutrition kitchen, and meals will be picked up every 3-4 days.
1628946|NCT02018224|Procedure|End-to-end suturation without augmentation|End-to-end suturation without augmentation; Irregular tendon ends were cleaned and repaired by the Krackow technique with two separate 0-gauge absorbable sutures.
1628947|NCT02018224|Procedure|End-to-end suturation with augmentation.|End-to-end suturation with augmentation; End-to-end suturation as above with a 10 mm wide central gastrocnemius aponeurosis flap, as proposed by Silfverskjöld.
1628948|NCT02018211|Other|control|passive recovery following exercise test
1628949|NCT02018211|Device|graduated compression socks|graduated compression socks worn after test exercise
1628950|NCT02018211|Device|neuromuscular electrical stimulation device|neuromuscular electrical stimulation device worn after test exercise
1628951|NCT02018198|Diagnostic Test|FebriDx|
1628952|NCT02018185|Device|Transcranial Magnetic Stimulation|A non-invasive method for brain stimulation
1628953|NCT02018185|Device|Sham Transcranial Magnetic Stimulation|Sham stimulation of the brain.
1628954|NCT02018172|Drug|somatropin|
1628955|NCT02018159|Drug|menotropin|
1628956|NCT02018146|Other|Mask then nasopharyngeal|Patients will be randomly assigned to Mask ventilation followed by naso-pharyngeal ventilation
1628957|NCT02018146|Other|Nasopharyngeal then mask|Patients will be randomly assigned to naso-pharyngeal ventilation followed by mask ventilation.
1628958|NCT02018133|Drug|Vitamin D 2mg daily for 2 weeks oral paricalcitol|vitamin D 2 capsules daily
1628959|NCT02018133|Drug|Placebo|
1628960|NCT02018120|Procedure|connective tissue graft|
1628961|NCT02018120|Procedure|platelet rich fibrin|
1628962|NCT02018107|Radiation|N-13 ammonia or F-18 fluorodeoxyglucose|PET tracer
1628963|NCT02018107|Diagnostic Test|PET scan|PET scan
1628964|NCT02018094|Drug|Co-amoxiclav|Augmentin 1.2g IV three times daily for 24 hours. If the patient is randomised to the 5-day duration antibiotic arm then Augmentin 625mg oral tablets three times daily are added to the 24 hour course for a further 4 days.
1628965|NCT02018094|Drug|Iodine|Intra-operative skin preparation prior to incision to skin.
1628966|NCT02018094|Drug|Metronidazole|500mg IV three times daily for 24 hours. If the patient is randomised to 5-day duration arm, then another 4 days of oral metronidazole at 400mg three times daily is added to the course
1628967|NCT02018094|Drug|Chlorhexidine|Alcoholic Chlorhexidine skin pre-op preparation
1628968|NCT02018094|Drug|Teicoplanin|Teicoplanin 400mg on induction. If penicillin allergic and on 5-day antibiotic arm then add clindamycin 300mg 4 times daily for further 4 days
1628969|NCT02018094|Drug|Clindamycin|Clindamycin 300mg 4 times daily orally to be used in case of penicillin allergy
1628970|NCT02018081|Drug|Levofloxacin|8 blood sampling by patients between the 48th and 60th
1628971|NCT02018068|Other|Remote control|When pain or sensory and motor block evaluation exceed the thresholds, the patient enters the data in the PCA (patient Control Analgesia) pump. The investigator is alerted by SMS on his smartphone and makes the necessary programming changes by remote control on the Micrel Care TM site. Systematic assessments via the PCA pump are scheduled for 9:00, 13:00 and 19:00 every day during 48 to 72 hours. The patient can alert his physician through his PCA pump of any additional requests (pain, motor blockade, numbness). The anesthesiologist receives an SMS alert and can make any necessary programming changes to the pump via the remote control.
1628972|NCT02018068|Other|At bedside care|When pain or sensory and motor block evaluation exceed the thresholds, the nurse contacts the physician and she will be able to modify the pump settings according to the anesthesiologist prescription. The delay between the call of the patient and the programming changes, the duration of the procedure are reported. Systematic evaluations via the PCA (Patient Control Analgesia) pump are done when the patient arrives in this surgical ward and at 9:00, 13:00 and 19:00 every day for 48 to 72 hours.Throughout the study, if necessary, the nurse or referring physician performs the programming changes directly on the PCA pump and notes the delay in treatment. All the reasons and the duration of any bedside visit are reported.
1628973|NCT02018055|Drug|Ticagrelor|
1628974|NCT02018055|Drug|Clopidogrel|
1628975|NCT02018042|Drug|Abatacept|"After the screening period, subjects will begin weekly self-administered subcutaneous abatacept and will continue treatment for 6 months. Patients will be instructed in self-administration of study medication at baseline (week zero) and will be observed self-administering medication at each visit. Instructions regarding study drug administration will be reinforced as needed.
The 6-month treatment period is expected to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with moderate to severe AAP. Responders will then be followed for 6 months off drug."
1628976|NCT02018029|Other|cardiac resynchronisation therapy|
1628977|NCT02017964|Drug|Vincristine Sulfate|Given IV
1628978|NCT02017964|Drug|Cyclophosphamide|Given IV
1628979|NCT02017964|Drug|Methotrexate|Given IV
1628980|NCT02017964|Drug|Etoposide|Given IV
1628981|NCT02017964|Drug|Carboplatin|Given IV
1628982|NCT02017964|Other|Laboratory Biomarker Analysis|Correlative studies
1628983|NCT02017964|Other|Cognitive Assessment|Optional ancillary studies
1628984|NCT02017938|Procedure|Virtual Reality anti-fatigue ergo cycling training (Self-made)|To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.
1628985|NCT02017925|Behavioral|exercise intervention|Undergo pulmonary rehabilitation
2011473|NCT02528253|Biological|Tanezumab 5 mg SC|Tanezumab 5 mg SC
1628986|NCT02017925|Procedure|pulmonary complications management/prevention|Undergo pulmonary rehabilitation
1628987|NCT02017925|Procedure|quality-of-life assessment|Ancillary studies
1628988|NCT02017925|Other|questionnaire administration|Ancillary studies
1628989|NCT02017912|Biological|Autologous MSC-NTF cells|Single autologous MSC-NTF cells treatment by combined intramuscular and intrathecal administration
1628990|NCT02017912|Biological|Placebo|Excipient administration by combined intramuscular and intrathecal administration
2011474|NCT02528253|Biological|Tanezumab 10 mg SC|Tanezumab 10 mg SC
2011475|NCT02528253|Biological|Tramadol PR oral|Tramadol PR oral
1628993|NCT02017886|Dietary Supplement|L. reuteri DSM 17938/ATCC PTA|L. reuteri DSM 17938/ATCC PTA twice daily for three weeks
1628994|NCT02017886|Dietary Supplement|Placebo|Placebo tablet twice daily for three weeks
1628995|NCT02017873|Drug|Peroxide Carbamide 10% - Dental bleaching treatment|During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
1628996|NCT02017860|Drug|Everolimus|Everolimus will be provided by the investigator in 2.5 mg or 5 mg tablets for daily oral administration
1628997|NCT02017834|Procedure|surgical resection|neck dissection and tumour resection will be performed either with or without the harmonic scalpel as an adjunct.
1628998|NCT02017821|Behavioral|high intensity aerobic training|
2011476|NCT02528188|Drug|NSAID|Orally administered NSAID (naproxen 500 mg, celecoxib 100 mg or diclofenac 75 mg) twice daily for 56 weeks
2011477|NCT02528188|Biological|Tanezumab 2.5 mg|Subcutaneous injection of tanezumab 2.5 mg every 8 weeks for 56 weeks
1629001|NCT02017782|Device|Dust|Dust (250-300µg/m3),
1629002|NCT02017782|Device|Ozone|(0,1ppm ozone),
1629003|NCT02017782|Device|Dust and Ozone|Active Dust (250-300 ug/m3)+Ozone(0,1ppm)
1629004|NCT02017782|Device|Placebo (Filtered air)|Placebo treatment (Filtered air <20 ug/m3)
1629005|NCT02017730|Drug|BMS-986020|
1629006|NCT02017730|Drug|[11C]BMT-136088|
1629010|NCT02017704|Radiation|Endo-HDR (if randomized to this arm)|Patients will be treated with a daily dose of 6.5 Gy over four consecutive days for a total of 26 Gy
1629011|NCT02017704|Drug|capecitabine and IMRT (if randomized to this arm)|Capecitabine shall be delivered at 825mg/m2 BID during IMRT radiotherapy
1629012|NCT02017704|Radiation|IMRT (intensity modulated radiation therapy)|Patients will receive IMRT along with capecitabine. External radiotherapy will be based on contouring guidelines from the RTOG atlas and Radiation Therapy Oncology Group (RTOG 0822) with some modifications
1629013|NCT02017704|Drug|FOLFOX6|"Oxaliplatin - 85 mg/m² in 500ml glucose 5% solution, 2-h infusion
Leucovorin - bolus 400mg/m² following the oxaliplatin/FA infusions
5 Fluorouracil (5FU) - 2400 mg/m², 46-h infusion following the 5-FU bolus An outpatient, 46 hour continuous IV infusion provided by a home IV infusion company. The 5FU is delivered by a small pump worn in a fanny pack around the waist. The home IV infusion company will arrange your disconnect at the end of the infusion."
1629014|NCT02017704|Procedure|Surgery|"After the patient has been identified as a candidate for the trial, the surgeon will assess the patient and will determine:
Exact height and location of tumor with regards to the anal margin as measured by a rigid or flexible proctoscope and/or digital exam.
Mobility of tumor as assessed if possible by rectal exam Type of surgical procedure: Abdominoperineal resection vs. sphincter saving procedures, which will include colo-anal with mucosectomy vs. stapled anastomosis."
1629015|NCT02017691|Device|Near Infrared Spectroscopy|If crSO2 is <10th centile, CPAP via face mask will be started or oxygen support will be increased depending SpO2, on the infants breathing efforts and the heart rate. If crSO2 remains stable >10th centile, or if crSO2 is > 90th centile CPAP via face mask will be stopped or FiO2 will be reduced depending on SpO2, the infants breathing efforts and the heart rate.
1629016|NCT02017691|Device|Pulse-oximetry|If SpO2 remains <10th centile, respiratory support via face mask will be started or FiO2 will be increased depending on the infants breathing efforts and the heart rate. If SpO2 remains stable or if SpO2 is >90th centile respiratory support via face mask will be stopped or FiO2 will be reduced depending on the infants breathing efforts and the heart rate.
1629017|NCT02017678|Biological|JX-594|5 weekly IV infusions of JX-594 followed by laparoscopy and biopsy on day 10 or 38.
1629018|NCT02017639|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:Prefilled syringe of sarilumab solution Route of administration: Subcutaneous injection
1629019|NCT02017639|Drug|simvastatin|Pharmaceutical form:Film-coated 20 mg Tablet Route of administration: oral
1629020|NCT02017626|Biological|mCyp c 1|2 patient groups with different doses of allergen.
1629021|NCT02017613|Drug|RP6530|Escalating doses starting at 25 mg BID
1629022|NCT02017600|Drug|ND-420|ND-420 50 mg/m2 on day1
1629023|NCT02017600|Procedure|Surgery|After induction chemotherapy, participants will be receive right or left thoracotomy for curative resection by total or subtotal thoracic esophagectomy.
1629024|NCT02017600|Drug|Cisplatin|cisplatin 70 mg/m2 on day1
1629025|NCT02017600|Drug|fluorouracil|fluorouracil 700 mg/m2 daily, day1 to day4
1629026|NCT02017574|Behavioral|Reaching Task|Learn a reaching task that requires coordination of the arm segments
1629027|NCT02017561|Behavioral|Lifestyle Counseling|Written and individualized information during the interview in all clinic visits, emphasizing the importance of a healthy lifestyle, engaging on regular moderate-intensity physical activity and eating an healthy diet.
1629028|NCT02017561|Drug|Metformin|Metformin treatment titrated to a maximum dose of 1000mg twice a day. Metformin treatment will start with 500mg at breakfast during the first week and, if well tolerated, increased to 500mg twice a day (breakfast and dinner) in the second week, 1000mg at breakfast and 500mg at dinner in the third week and finally for the target dose of 1000mg twice a day.
1629029|NCT02017548|Behavioral|Life-extension default advance directive|
1629030|NCT02017548|Behavioral|Comfort default advance directive|
1629031|NCT02017535|Drug|Fluoxetine|Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter.
2011478|NCT02528188|Biological|Tanezumab 5 mg|Subcutaneous injection of tanezumab 5 mg every 8 weeks for 56 weeks
1629032|NCT02017535|Behavioral|Interpersonal Psychotherapy|Adolescent randomized to an increase in therapy (4 extra therapy sessions)
1629033|NCT02017522|Device|11C-PBR PET|"Subjects will have a positron emission tomography (PET) CT scan using 11C-PBR28 as a radiotracer. This study will evaluate inflammation due to cardiac sarcoidosis. The CT scan will improve the images. The total scan time will be about 30 minutes. There will also be some time required for prep, such as inserting an intravenous (IV) catheter in an arm or forearm. Including prep time, the scan will take approximately two hours.
Subjects will also undergo a cardiac MRI. Cardiac MRI uses strong magnetic fields to make pictures of the heart. We will use gadolinium containing contrast material, given through an intravenous (IV) catheter to highlight areas of scar in your heart which may be due to cardiac sarcoidosis. This scan will take about 60 minutes."
1629034|NCT02017509|Procedure|Diagnostic Biopsy and Surgical Procedure|A tumor sample from the diagnostic biopsy and surgical procedure will be used for research.
1629035|NCT02017509|Procedure|Intravoxel incoherent motion MRI (IVIM)|At the end of a standard MRI, we will perform IVIM, which is a diffusion-weighted imaging sequence that simultaneously characterizes the microscopic diffusivity of water and the macroscopic transport of water via bulk flow. IVIM may more accurately reflect the properties of the tumor microenvironment including vascular permeability, interstitial fluid pressure, and response to neoadjuvant therapy.
1629036|NCT02017509|Procedure|Dynamic Contrast Enhanced MRI (DCE-MRI)|Following a standard MRI scan, Dynamic Contrast Enhanced MRI (DCE-MRI) will be done. DCE-MRI is an indicator-dilution experiment in which the delivery and transcapillary transfer of a contrast agent, typically one of a number of gadolinium-based contrast agents (GBCA), is used to assess a number of parameters characterizing tissue physiology. In locally advanced rectal cancer patients, use of DCE-MRI for determining pathologic response has produced equivocal results but more promising data has been published recently in the cervical cancer literature.
1629037|NCT02017509|Genetic|RNA gene expression analysis|RNA will be collected from biopsy and surgical tissue for gene expression analysis.
1629038|NCT02017470|Other|Gender-tailored women's heart health outpatient programme|
2011479|NCT02527434|Biological|Tremelimumab monotherapy|IV infusion
2011480|NCT02527434|Biological|MEDI4736 monotherapy|IV infusion
1629041|NCT02017444|Drug|AZD4017|
1629042|NCT02017444|Other|Placebo|Matched placebo (matched to AZD4017 arm)
1629043|NCT02017431|Other|Allergen|Subject specific allergen is inhaled on day 1 of the triad
1629044|NCT02017431|Other|Saline|Saline is inhaled on day 1 of the triad
1629045|NCT02017431|Other|Particle depleted diesel exhaust|High-efficiency particulate filtration of diesel exhaust
1629046|NCT02017418|Dietary Supplement|zeaxanthin|softgel
1629047|NCT02017418|Dietary Supplement|combinatory supplement|softgel
2011481|NCT02527434|Biological|MEDI4736 + tremelimumab combination therapy|IV infusion
2011482|NCT02526290|Device|Intranasal Lacrimal Neurostimulator (Oculeve)|Neurostimulation device
1629050|NCT02017392|Drug|Compound Lidocaine Cream|Compound Lidocaine Cream ,1-2 grams per person.
1629051|NCT02017379|Drug|Erythromycin|
1629052|NCT02017379|Drug|Metoclopromide|
1629053|NCT02017366|Other|Enteral feeding|Target of 1000 kCal/day enteral feeding or glucose 20%, perferably given overnight.
1629054|NCT02017353|Dietary Supplement|Curcuphyt|
1629055|NCT02017340|Drug|Nilvadipine|8mg of Nilvadipine taken once a day at lunch time for 78 weeks
1629056|NCT02017340|Drug|Placebo|8mg Placebo tablet taken once a day at lunch time for 78 weeks
1629057|NCT02017327|Drug|Monoprost|Monoprost®: Latanoprost 0.005% ophthalmic preparation is a sterile unpreserved oil-based solution for topical ophthalmic use. It is supplied in 0.30 ml single use polyethylene containers. The batch numbers and reanalysis dates will be stated in the certificate of analysis.
1629058|NCT02017327|Drug|Lumigan 0.01%|Lumigan® 0.01%: Bimatoprost eye drop solution is supplied in 3 ml multidose container.
1629059|NCT02017327|Drug|Lumigan 0.03% Unit Dose|Lumigan® 0.03% Unit Dose: Bimatoprost eye drop solution is supplied in 0.4 ml single use low density polyethylene (LDPE) containers.
1629060|NCT02017314|Drug|Morphine|
1629061|NCT02017301|Other|Nutritional assessment|Daily nutritional assessment with bioelectrical impedance vector analysis, phase angle and mid-arm muscle circumference
1629062|NCT02017275|Device|BuMA|This group will contain 1175 subjects.
1629063|NCT02017275|Device|EXCEL|This group will contain 1175 subjects.
1629064|NCT02017262|Behavioral|Self-management group|8 weekly sessions of group self-management
1629065|NCT02017262|Behavioral|Enhanced usual care|Usual care by primary care provider, plus educational pamphlet about depression, list of local mental health resources, and letter for provider advising him/her of depression diagnosis
1629066|NCT02017249|Drug|arginine in powder form|
1629067|NCT02017236|Drug|Volitinib|600mg Volitinib ,single dose,oral
2011483|NCT02523586|Device|Simple mask|Subjects will breathe room air for 90 seconds. FiO2 will be measured for 30 seconds. Testing of masks will be performed with oxygen set at high flow through simple mask, non-rebreather mask, OxyMaskTM, and anesthesia mask with headstrap and Jackson-Rees circuit. After placement of each mask and starting oxygen, subjects will breathe normally for 90 seconds. FiO2 will be measured for 30 seconds. After each trial, subjects will take one vital capacity breath. Between testing each mask, subjects will breathe room air for 5 minutes to confirm stability of hemodynamic status. Respiratory rate and FiO2 data will be recorded during each breath to determine oxygen percentages. At the end of the 30 second sampling period, a final measurement will be taken during a forced vital capacity breath.
2011484|NCT02522780|Drug|Mesalamine|
2011485|NCT02522780|Drug|Placebo|
2011486|NCT02522299|Drug|GSK2269557|GSK2269557 500 mcg blended with lactose per blister and will be administered using a DISKUS dry powder inhaler device
2011487|NCT02522299|Drug|Placebo|Lactose will be administered using a DISKUS dry powder inhaler device
2011488|NCT02522299|Device|DISKUS|It is multi-dose dry powder inhaler containing one foil strip of drug with 60 blisters
2011489|NCT02519439|Drug|ganaxolone|225 mg capsules 450 mg to 900 mg 2x/day
2011490|NCT02519634|Procedure|Super-Mini Percutaneous Nephrolithotomy|Patients undergo Super-Mini Percutaneous Nephrolithotomy
2011491|NCT02519634|Procedure|Retrograde Intrarenal Surgery|Patients undergo Retrograde Intrarenal Surgery
1629069|NCT02017210|Other|Longitudinal study|Metabolic health, anthropometry, body fat distribution, liver lipid will be followed up in individuals previously studied at the Clinical Research Facility.
1629070|NCT02017197|Drug|Marevan®|Branded warfarin sodium tablets (manufacturer União Química Farmacêutica Nacional S/A, Brazil) by mouth; dose adjusted according to INR and medical judgement.
1629071|NCT02017197|Drug|generic warfarin #1|Generic warfarin sodium tablets, manufacturer (União Química Farmacêutica Nacional S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
1629072|NCT02017197|Drug|generic warfarin #2|Generic warfarin sodium tablets, manufacturer (Laboratório Teuto Brasileiro S/A, Brazil), by mouth; dose adjusted according to INR and medical judgement.
1629073|NCT02017184|Biological|Noninvasive core temperature thermistor|
1629074|NCT02017171|Drug|Allopurinol|
1629075|NCT02017171|Drug|Placebo|Inactive oral tablets identical in appearance to allopurinol tablets.
1629076|NCT02017158|Other|Virtual Sprouts|The Virtual Sprouts intervention group will play Virtual Sprouts in a school-based implementation of the game.
1629078|NCT02017132|Dietary Supplement|Pomegranate extract|
1629079|NCT02017119|Drug|Comparison between Lactulose and Lactulose-Paraffin|
1629080|NCT02017106|Procedure|Endovenous Laser ablation and concomitant phlebectomies|
1629081|NCT02017106|Procedure|Endovenous Laser ablation and sequential phlebectomies|
1629082|NCT02017093|Device|Error Enhancement|Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
1629083|NCT02017093|Device|control treatment|Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
1629084|NCT02017067|Procedure|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 7 types of equipments for different part of strength training.
1629085|NCT02017054|Other|Cath|No intervention - registry
1629086|NCT02017041|Device|Medsignals|MedSignals (www.medsignals.com) is a cellular communicating medication management device designed to improve adherence. It will be used to track when medication is removed from the device at dosing times and deliver audible and visual alerts at dosing times and to relay adherence data securely to patient files. Participants will use this device throughout the 5-week trial. It is a Class I device.
1629087|NCT02017041|Device|smartphone app|The smartphone app being evaluated in this study is designed to support effective medication management of opioid substitution patients taking buprenorphine/naloxone.
1629088|NCT02017015|Drug|nab-paclitaxel|nab-paclitaxel at 125 mg/m^2, by IV infusion over 30 to 40 minutes (maximum infusion time not to exceed 40 minutes)
1629089|NCT02017015|Drug|Gemcitabine|Gemcitabine at 1000 mg/m^2 IV infusion over 30 to 40 minutes given once weekly for 3 weeks (Days 1, 8 and 15) followed by a week of rest (28 day cycle).
1629090|NCT02017002|Procedure|Ivor Lewis|for the patients with lower-to mid third esophageal cancer, some surgeon performed Ivor lewis esophagectomy, which performing the esophago-gastrostomy in the chest after gastric mobilization without cervical incision wound
1629091|NCT02017002|Procedure|Tri-incision|a cervical incision was required for esophagogastrostomy after esophagectomy and gastric mobilization
1629092|NCT02016989|Device|RGTA OTR4120 (CACICOL20)|
1629093|NCT02016989|Device|physiological salt solution|
1629094|NCT02016976|Drug|EMLA Analgesic Cream|
1629095|NCT02016976|Drug|Dormicum 2.5 mg and Pethidine 25 mg|Routine anesthesia and analgesia ( Dormicum 2.5 mg and Pethidine 25 mg )normally given to patients before and during pacemaker implantation
1629096|NCT02016963|Biological|Raxibacumab|Raxibacumab will be supplied in 50 milliliter (mL) sterile, single-use vials containing 34.9 mL of liquid formulation per vial. Each vial contains 50 milligram (mg)/mL raxibacumab in 0.13 mg/mL citric acid, 2.8 mg/mL sodium citrate, 10 mg/mL sucrose, 18 mg/mL glycine, 0.2 mg/mL polysorbate 80, pH 6.5
1629097|NCT02016924|Drug|ATV|Capsules or powder administered once daily according to dosing recommendations per product monograph
1629098|NCT02016924|Drug|DRV|Tablets or liquid oral suspension administered once daily according to dosing recommendations per product monograph
1629099|NCT02016924|Drug|Cobicistat|Tablets or dispersible tablets as an oral suspension administered orally once daily with food
1629100|NCT02016924|Drug|BR|Background regimen (BR) must include 2 nucleoside reverse transcriptase inhibitors (NRTI). The BR may contain additional antiretroviral agents except for the following disallowed agents: saquinavir, indinavir, nelfinavir, double protease inhibitor (PI) regimens, raltegravir, elvitegravir, efavirenz, nevirapine, delavirdine, maraviroc, etravirine, rilpivirine, dolutegravir, and investigational antiretroviral agents.
1629101|NCT02016911|Drug|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
1629102|NCT02016898|Procedure|Placement of the sponge|
1629103|NCT02016898|Drug|Mitomycin-C|
1629104|NCT02016885|Drug|DRM04B, 1.0%|DRM04B, 1.0%
1629105|NCT02016885|Drug|DRM04B, 2.0%|DRM04, 2.0%
1629106|NCT02016885|Drug|DRM04B, 3.0%|DRM04B, 3.0%
1629107|NCT02016885|Drug|DRM04B, 4.0%|DRM04B, 4.0%
1629108|NCT02016885|Other|Vehicle|Vehicle
1629109|NCT02016872|Drug|18F-FMISO|
1629110|NCT02016872|Other|PET/CT|
1629111|NCT02016859|Other|Immature Platelet Fraction|
1629112|NCT02016846|Drug|Liraglutide|
1629113|NCT02016846|Drug|Placebo|
1629114|NCT02016833|Procedure|Blood Sampling|Sampling of 80mL of whole blood
1629115|NCT02016820|Drug|Omeprazole (suspension)|1 mg/kg/day
1629116|NCT02016820|Other|Lifestyle Modification|Standard lifestyle modification: small meals, upright feeding, elevation of the head of the bed
1629163|NCT02016430|Behavioral|TLC Dietary intervention|Standard American Heart Association (AHA) recommendations for dietary counseling
1629164|NCT02016430|Behavioral|MeLT dietary intervention with TMAO|Mediterranean diet containing food with low TMAO content with TMAO levels provided to the subject for guidance.
1629805|NCT02011126|Other|laboratory biomarker analysis|Optional correlative studies
1651149|NCT01846923|Biological|PCV13|
1629117|NCT02016807|Device|ProThelial|August 2013, the FDA cleared the use of ProThelial, a polymerized high potency sucralfate paste, as a device for the management of oral mucositis.Standard potency non-polymerized sucralfate is not recommended by MASCC/ISOO for the treatment or prevention of mucositis, oral or alimentary. However high potency polymerized sucralfate has been associated with rapid amelioration and prevention of both oral and alimentary mucositis in a patient with advanced head neck cancer treated simultaneously with high dose chemo-radiation. High potency sucralfate is standard sucralfate polymerized into 'sucralfate sheets' that adhere and orderly layer upon the mucosa achieving and maintaining elevated concentrations of sucralfate long after the initial dose administration. Three hours following administration, high potency sucralfate maintains a 7 fold greater surface concentration of sucralfate on normal lining and a 23 fold greater concentration on inflamed, ulcerated mucosa.
1629118|NCT02016781|Procedure|Allogeneic Hematopoietic Cell Transplant|Bone marrow or peripheral blood stem cell transplant.
1629119|NCT02016781|Procedure|Hypomethylating Therapy / Best Supportive Care|The specific non-transplant treatment regimen will be at the discretion of the treating physician.
1629120|NCT02016781|Drug|Reduced Intensity Conditioning|The specific transplant treatment regimen will be at the discretion of the treating physician.
1629121|NCT02016768|Procedure|decompressive cervical surgery|To make decompressive cervical surgery, either anterior cervical discectomy and fusion or posterior laminoplasty on the patients suffering from cervical spondylotic myelopathy and hypertension.
1629122|NCT02016755|Biological|HGF Plasmid|Intramuscular injection in the affected limb.
1629123|NCT02016742|Drug|RDC5|
1629124|NCT02016729|Drug|AMG 232|Given an an oral tablet in escalating doses.
1629125|NCT02016729|Drug|Trametinib|Trametinib is an oral tablet given in a fixed dose.
1629126|NCT02016716|Drug|Romosozumab 90 mg/mL|Administered as 2 SC injections of a 90 mg/mL concentration in a 1.17 mL crystal zenith resin prefilled syringe (PFS).
1629127|NCT02016716|Drug|Placebo 90 mg/mL|Placebo administered as 2 SC injections with the 1.17 mL crystal zenith resin PFS.
1629128|NCT02016716|Drug|Romosozumab 70 mg/mL|Administered as 3 SC injections of a 70 mg/mL concentration in a 1.0 mL glass PFS.
1629129|NCT02016716|Drug|Placebo 70 mg/mL|Placebo administered as 3 SC injections with the 1.0 mL glass PFS.
1629130|NCT02016703|Other|Erythritol drink|
1629131|NCT02016703|Other|Placebo drink|
1629132|NCT02016664|Drug|Ketamine|The St.Joseph's Heath Care Pharmacy will supply the compounded oral ketamine capsules. Patients who are going to participate in this study are already taking this oral ketamine as a part of their chronic pain medications. No new patient will start oral ketamine for the sake of this study. Two doses of oral ketamine will be used for the same patient, 10 mg and 20 mg every 8 hours. These doses are the standard doses in our clinic. Other clinics using much higher doses.
1629133|NCT02016651|Behavioral|Right side position|Enrolled infants are positioned on their back or right side. Tracheal aspirate is assessed for pepsin concentration as an index of aspiration.
1629134|NCT02016638|Other|Polysomnography and ambulatory blood pressure recording|
1629135|NCT02016625|Drug|Faldaprevir|
1629136|NCT02016625|Drug|Faldaprevir|
1629137|NCT02016625|Drug|Cyclosporine|
1629138|NCT02016625|Drug|Tacrolimus|
1629140|NCT02016599|Other|Monitoring and biospecimen collection|The study team will use monitoring methods normally used in the NICU (physical exams, echocardiograms, and ECG) and some new monitoring methods (Near-infrared spectroscopy or NIRS) to find out all the changes that a baby's heart and lungs go through during the first week after delivery. In addition, blood samples will be taken to assess lactate levels.
1629141|NCT02016586|Dietary Supplement|Maternal Nutritional Supplement|S348S0
1629142|NCT02016573|Device|Renal Denervation|Renal Denervation Catheter
1629143|NCT02016560|Drug|florbetapir F 18|
1629144|NCT02016560|Drug|18F-AV-1451|
1629145|NCT02016547|Procedure|abciximab IV and thrombectomy|
1629146|NCT02016547|Drug|alteplase 0.9mg/kg (10% by IV bolus following by 90% by 1 hour IV drip)|
1629147|NCT02016534|Drug|AMG 337|AMG 337 300mg orally daily.
1629148|NCT02016521|Other|Cooling Fabric|Garment made of 100% nylon and consisting of long sleeved shirt and full trouser.
1629149|NCT02016521|Other|Placebo Garment|Garment made of 100% polyester consisting of long sleeved shirt and full trouser
1629150|NCT02016508|Drug|autologous bone marrow derived stem cells|intravitreal injection of autologous bone marrow stem cells in 0.1 ml volume
1629151|NCT02016495|Dietary Supplement|Magnesium plus alpha-lipoic acid|
1629152|NCT02016495|Drug|Placebo|
1629153|NCT02016482|Biological|Adalimumab|
1629154|NCT02016482|Other|Placebo|
1629155|NCT02016469|Other|co-transplantation of FMT and pectin|300ml Bacterial suspension (from 60g fresh stool )for fecal microbiota transplantation the first day and 20g pectin given continuously for total five days
1629156|NCT02016469|Other|single fecal microbiota transplantation|single fecal microbiota transplantation once the first day
1629157|NCT02016469|Dietary Supplement|pure give pectin 20g/d for five days|pure give pectin 20g/d for five days
1629158|NCT02016456|Device|Theta-Burst Stimulation|At 80% motor threshold determined using single pulse stimuli. Depending on the hemisphere determined by connectivity analysis and neuronavigation in each individual, either continuous (left prefrontal) or intermittent (right prefrontal) train of pulses will be delivered.
1629159|NCT02016456|Device|High frequency stimulation|Left prefrontal stimulation. 120% motor threshold with a pulse sequence of 10 Hz for 4 seconds, followed by a 26 second quiet period. Treatment will last for a total of 37.5 minutes this is a total of 3,000 pulses
1629160|NCT02016443|Drug|Tizanidine|Group Tizanidine (Group T) will receive 4 mg tizanidine per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
1629161|NCT02016443|Drug|Placebo|Group Placebo (Group P) will receive a placebo per oral twice a day during the postoperative first week and the first dose will be administered 1 hour before surgery
1629162|NCT02016430|Behavioral|MeLT Dietary intervention|Mediterranean diet containing food with low TMAO content.
1654943|NCT01817426|Other|Placebo|
1629165|NCT02016417|Drug|A combination of Gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
1629166|NCT02016417|Drug|A combination of Docetaxel, cisplatin and 5-Fluorouracil|The TPF regimen consists of docetaxel at a dose of 60 mg/m2/day on day 1, cisplatin 60 mg/m2 by i.v. infusion for 4 h on day 1-3, plus 5-Fluorouracil 600 mg/m2 CIV over 120 hours. The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 100 mg/m2 starting on the first day of IMRT.
1629167|NCT02016404|Other|Low-sodium, high-potassium salt|Iodized low-sodium, high-potassium botcanh (a traditional mixture of salt, MSG, sugar and herbs) plus and iodized low-sodium, high-potassium salt for home food preparation
1629168|NCT02016404|Other|Regular salt|Regular iodized high-sodium botcanh (a traditional mixture of salt, MSG, sugar and herbs) and high-sodium salt
1629169|NCT02016391|Drug|Dexmedetomidine|Dexmedetomidine 0.4 µg/kg/hr infusion during RF procedure
1629170|NCT02016378|Behavioral|Bias retraining|Participants will view pictures of drug (e.g., alcohol) and non-drug stimuli (e.g., soft drinks) on a computer. Participants will then use the computer to make the drug pictures smaller and the non-drug pictures larger.
1629171|NCT02016378|Behavioral|Sham retraining|Participants will view pictures of drug and non-drug related stimuli on a computer. Participants will then use the computer to make the pictures larger or smaller based on the tilt of the picture (slightly to the left or right), but without regard to the content of the picture.
1629172|NCT02016365|Drug|Doxycycline|200 mg/day (100 mg twice daily, orally) for 4 weeks with a pause of 2 weeks in combination with UDCA
1629173|NCT02016365|Drug|Ursodeoxycholic acid|750 mg/day (500 mg +250mg orally) continuously
1629174|NCT02016352|Biological|patient CSF extraction with hydrocephalus|CSF extraction
1629175|NCT02016352|Biological|witness CSF extraction|CSF extraction from patient not suffering from hydrocephalus
1629176|NCT02016339|Behavioral|Standard care|24-h consultation telephone line to the sleep nurses to answer questions regarding CPAP usage. Patients were reviewed at 1 month and at 3 month intervals during the first year and every 6 months thereafter in the CPAP clinic by the nurse. Additional visits or phone calls by sleep specialist if doubts about a patient's compliance or willingness to continue with the therapy.
1629177|NCT02016339|Behavioral|Intensive care|Standard group care plus: Involvement of the patient's partner or family necessary. Extra education on sleep apnea and CPAP by sleep specialists via a 15-min videotape. 10- to 15-min lecture from the sleep clinic's nurses after CPAP titration study. Phone calls by nurses at 2 and 7 days. Early review of patients by sleep specialists at 15 and 30 days. Home visits by sleep nurses, if there doubts about a patients adherence
1629178|NCT02016326|Device|HD Colon|High Definition White Light
1629179|NCT02016326|Device|I-scan 1|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
1629180|NCT02016326|Device|I-Scan 2|I-Scan 1 has Contrast Enhancement(CE), Surface Enhancement(SE)and Tone Enhancement(TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail. CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities. TE provides a uniform color image and is intended for detailed inspection of distinct lesions.
1629181|NCT02016313|Other|physiotherapy|
1629182|NCT02016300|Device|Unloader Bracing|The bracing arm patients will be randomly selected and will wear an unloader brace post-operatively during the study period.
1629183|NCT02016300|Device|Non-Bracing|Microfracture performed with no post-operative unloader bracing
1629184|NCT02016287|Other|Sequential chemotherapy （paclitaxel 80mg/m2 d1,d8) and radiotherapy|Sequential paclitaxel chemotherapy and radiotherapy
1629185|NCT02016274|Other|Sequential chemotherapy (paclitaxel 175mg/m2 d1; cisplatin 37.5mg/m2 d1,d2) and radiotherapy|Sequential paclitaxel/cisplatin chemotherapy and radiotherapy
1629186|NCT02016261|Drug|Fluvoxamine|The subjects will be prescribed Fluvoxamine treatment for 24 weeks with dose 50-300 mg
1629187|NCT02016248|Radiation|Stereotactic Ablative Body Radiotherapy as Monotherapy|The prescribed planned tumor volume (PTV) dose of 36.25 Gy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland.
1629188|NCT02016248|Radiation|Stereotactic Ablative Body Radiotherapy as a Boost|The prescribed planned tumor volume (PTV) dose of 27.5 cGy shall be given in 5 fractions using CyberKnife Hypofractionated Stereotactic Ablative Body Radiation Therapy as a boost following 5040 cGy with external beam. PTV will be defined per parameters outlined in the protocol and will at minimum include the entire prostate gland. Hormonal therapy will given as indicated in the protocol.
1629189|NCT02016235|Drug|Phosphorus Supplement|250 mg po qid
1629190|NCT02016222|Procedure|tears sampling|
1629191|NCT02016209|Drug|nanoparticle albumin-bound paclitaxel|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel in stage Ⅱ B and IIIA non-small cell lung cancer
2011492|NCT02518698|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Therapies used to treat prostate cancer and more specifically castrate resistant prostate cancer inclusively Xofigo (Radium-223 dichloride, BAY88-8223)
2011493|NCT02516553|Drug|BI 894999|day 1 to day 21 in 3-week cycles
2011494|NCT02516553|Drug|BI 894999|day 1 to day 14 followed by a week off in 3-week cycles in schedule B
1629195|NCT02016170|Drug|Ticagrelor 180mg|"After providing written informed consent, eligible patients on maintenance prasugrel meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:
A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.
B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily maintenance dose for 7±2 days"
2011495|NCT02516397|Dietary Supplement|Omnia|12weeks of treatment
1629279|NCT02015598|Device|Continuous Positive Airway Pressure|Patients will interviewed after 3 weeks and the end of trial.We will check their compliance to device memory download , record adverse events and pressure .
1629196|NCT02016170|Drug|Prasugrel 10mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:
A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.
B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
1629197|NCT02016170|Drug|Ticagrelor 90mg|"After providing written informed consent, eligible patients on maintenance prasugrel therapy meeting inclusion and exclusion criteria will be randomized in a 1:1:1 fashion to one of the following treatment arms:
A. Ticagrelor 180 mg loading dose (two 90mg ticagrelor tablets) followed by 90 mg BID maintenance dose for 7±2 days.
B. Ticagrelor 90 mg (one 90mg ticagrelor tablet) followed by 90 mg BID maintenance dose for 7±2 days C. Prasugrel 10 mg once daily MD for 7±2 days"
1629198|NCT02016157|Drug|Moxifloxacin|TO ASSESS THE EFFICACY OF MOXIFLOXACIN IN SITU GEL IN THE TREATMENT OF PERIODONTAL POCKET.
1629199|NCT02016118|Device|Ialuril|The treatment is an intravesical administration of combined hyaluronic acid (HA) 1.6% and chondroitin sulphate (CS) 2.0% once per week for the first month, followed by one instillation every two weeks for the second month and one instillation per month until stable remission of the symptoms.
1629200|NCT02016105|Drug|GP2017 Adalimumab|
1629201|NCT02016105|Drug|Humira ® Adalimumab|
1629202|NCT02016079|Dietary Supplement|omega-3|200 ml fruit drink containing omega-3
1629203|NCT02016066|Drug|CR6261|CR6261 50 mg/kg solution will be administered as a single 2-hour intravenous infusion
1629204|NCT02016066|Drug|Placebo|Placebo will be administered as a single 2-hour intravenous infusion
1629205|NCT02016040|Procedure|High Intensity Focused Ultrasound|
1629206|NCT02016027|Drug|Carica folia|
1629207|NCT02016014|Device|Smartphone with APP|Smartphone with APP (EVIDENT) for 3 months
1629208|NCT02016014|Behavioral|Counseling on lifestyles|Counseling on physical activity and mediterranean diet
1629209|NCT02016001|Other|toothpaste 1 with maximum fluoride concentration|tooth paste 1 will be the tested intervention with maximum fluoride concentration (1500 ppm), which will be provided to the case group. They will brush the teeth twice daily for 2 minutes
1629210|NCT02016001|Other|toothpaste 2 with 1000 ppm of fluoride|tooth paste 2 will be the intervention with 1000ppm of fluoride, will be used by the control group. They will brush the teeth twice daily for 2 minutes
1629211|NCT02015988|Drug|Fenofibrate|
1629212|NCT02015988|Drug|Simvastatin|
1629213|NCT02015962|Drug|Intravenous potassium chloride|
1629214|NCT02015962|Drug|Oral potassium chloride|
1629215|NCT02015949|Drug|Methylphenidate|Cross-over design comparing methylphenidate 0.3 mg/kg (to nearest 5mg) twice daily to placebo
1629216|NCT02015949|Drug|Placebo|Twice daily placebo tablet for two weeks
2011496|NCT02516397|Dietary Supplement|Placebo|12weeks of treatment
2011497|NCT02516202|Drug|Vagifem|One tablet is to be inserted vaginally daily for 2 weeks, then 2 days/week for the remaining 10 weeks of the study.
1629219|NCT02015923|Procedure|Colonic resection|Colonic cancer resection, R0 No surgical intervention on metastasis
1629220|NCT02015923|Drug|Chemotherapy- scheme|Chemotherapy, specified in each center with or without biological drugs
1629221|NCT02015910|Drug|Sitagliptin|Comparison of Sitagliptin a dipeptidyl-peptidase four (DPP-4) inhibitor 100mg pill with placebo comparator
1629222|NCT02015910|Drug|Placebo|Sugar pill manufactured to mimick Sitagliptin 100mg pill.
1629223|NCT02015897|Procedure|Physical TherapyA|"Group A:
Skin care
Manual lymphatic drainage
Bandaging using Coban™2Lite
Guidance on physical activity"
1629224|NCT02015897|Procedure|Physical TherapyB|"Group B:
Skin care
Bandaging using Coban™2Lite
Guidance on physical activity"
1629225|NCT02015871|Drug|Degarelix|
1629226|NCT02015858|Procedure|Chest drain withdrawal|
1629227|NCT02015858|Device|Pain Monitor|
1629228|NCT02015845|Device|Accuvein|
1629229|NCT02015845|Device|Routine technique|Placement of peripheral intravenous catheters using the routine technique
1629230|NCT02015832|Device|Coronary stent|
1629231|NCT02015832|Radiation|Multi Slice Computed Tomography|A coronary non-invasive Multi Slice Computed Tomography will be performed in patients
1629232|NCT02015832|Device|instantaneous wave-free ratio|Pressure-derived, adenosine-free index on physiological assessment of stenosis severity
1629233|NCT02015832|Device|Fractional flow reserve|Pressure-derived index on physiological assessment of stenosis severity
1629234|NCT02015832|Device|Intravascular Ultrasound|Allows the application of ultrasound technology to see from inside blood vessels out through the surrounding blood column, visualizing the inner wall of blood vessels
2011498|NCT02516202|Drug|Replens|2.5 gm to be applied vaginally every 3 days over 12 weeks.
2011499|NCT02516202|Other|Placebo|Dispensed in visually identical bottle and tablet form.
2011500|NCT02516202|Other|Placebo|Dispensed in visually identical tube and gel form.
2011501|NCT02515916|Other|Not Interventional|This will be a prospective, non-randomized, uncontrolled study examining the effects of oncology treatments in women at risk for treatment induced ovarian failure.
2011502|NCT02514525|Device|CryoBalloon Ablation System|CryoBalloon Ablation System, a balloon-based cryotherapy device, provides controlled ablation for the treatment of BE. Deployed through the working channel of an endoscope, the Balloon is simultaneously inflated and cooled with an inert cryogen (nitrous oxide) delivered from the handle that ablates the BE cells upon contact with the esophagus.
1629240|NCT02015806|Behavioral|RxTimerCap|The RxTimerCap is a pill bottle cap with a digital timer that shows the time elapsed since the medication was last taken. Patients randomized to receive the RxTimerCap will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
1629278|NCT02015598|Drug|Carbocysteine|carbocisteine (2×250 mg, three times daily) for 6 weeks. The tablets are provided by Baiyunshan Pharmaceutical, China. patients will interviewed after 3 weeks to check their adherence to the study regimen by collecting and counting the number of remaining tablets, record adverse events, and refill study tablets for the next 3 weeks.
1658693|NCT01787708|Procedure|Red light|
1629241|NCT02015806|Behavioral|Take-N-Slide|The Take-N-Slide device is a patented strip with toggles for each day of the week which are meant to be slid after taking a medication. Each Take-N-Slide can be removed and reused for the next prescription bottle. Patients randomized to receive Take-N-Slide will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
1629242|NCT02015806|Behavioral|Pillbox|The standard pillbox is a plastic organization box with one compartment for every day of the week. Patients randomized to receive a pillbox will receive a one-time mailing with one device for each of the maintenance medications they were using at the time of identification for study eligibility; additionally, patients will receive an information card explaining the device's use which includes a telephone number at which they can get additional information.
1629243|NCT02015793|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
1629244|NCT02015793|Biological|Placebo for adalimumab|Placebo for adalimumab pre-filled syringe, administered by subcutaneous injection to maintain double-blind.
1629245|NCT02015780|Drug|Fasiglifam|Fasiglifam tablets
1629246|NCT02015780|Drug|Placebo|Fasiglifam placebo-matching tablets
1629247|NCT02015780|Drug|Antihyperglycemic therapy|Including any of the following alone or in combination: insulin, sulfonylurea, thiazolidinediones, glucagon-like peptide-1 (GLP-1) receptor agonists, meglitinides, alpha-glucosidase inhibitors or dipeptidyl peptidase-4 (DPP-4) inhibitors acceptable by local practice guidelines.
2011503|NCT02514434|Radiation|Ultrasonography|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
2011504|NCT02514434|Radiation|non-contrast MRI|Subjects will be randomly allocated to either Ultrasonography arm or Non-contrast MRI arm for their surveillance method.
2011505|NCT02514447|Drug|Trilaciclib|
1629251|NCT02015741|Device|EEG monitoring with Bispectral Index and NeuroSENSE|
1629252|NCT02015741|Behavioral|Clinical observation|Patients will be observed during awake periods and during natural sleep.
1629253|NCT02015728|Device|Tumor biology testing|"Tumor biology studies will be performed in a CLIA-approved clinical pathology laboratory using standard procedures. Immunohistochemical (IHC) testing will be performed on formalin fixed tumor obtained at the time of diagnosis and/or relapse. Results will be interpreted by a qualified pediatric pathologist and will be scored on a scale of 0 to 4+ commenting on both percentage of positive cells and intensity of staining. Results will further be reported as a binary result (positive/negative). If more than one tumor specimen is available from different surgical procedures (e.g. initial diagnosis and relapse), the results from the relapse specimen will be prioritized. Results will determine kinase inhibitor treatment arm assignment which will be administered in addition to the best available combination of low-dose oral cytotoxic agents, including temozolomide and etoposide."
1629254|NCT02015728|Drug|Temozolomide|"Temozolomide combined with Etoposide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
1629255|NCT02015728|Drug|Etoposide|"Etoposide combined with Temozolomide is considered the best available combination of low-dose oral cytotoxic agents for patients with refractory or recurrent CNS tumors."
1629256|NCT02015728|Drug|Sorafenib|Sorafenib is a broad-spectrum kinase inhibitor.
1629257|NCT02015728|Drug|Everolimus|Everolimus is an mTOR pathway inhibitor.
1629258|NCT02015728|Drug|Erlotinib|Erlotinib is a tyrosine kinase inhibitor of the ERBB family of proteins.
1629259|NCT02015728|Drug|Dasatinib|Dasatinib is a broad spectrum SRC inhibitor.
1629260|NCT02015715|Drug|RO6864018|A single oral ascending dose of RO6864018 capsules on Day 1.
1629261|NCT02015715|Drug|Placebo|A single oral dose of placebo matching RO6864018 capsules on Day 1.
1629262|NCT02015702|Other|One-on-one physician training|Physicians in the experimental arm were visited by a instructing physician at a computer while performing clinical duties who had observed others to identify best practices. Instructors watched subjects' work, looking for a specific tip that could be applied to the current work, then demonstrated the tip, and answered any questions the subject had about using or applying this new technique .
1629263|NCT02015702|Other|Usual training|Usual training included online e-modules, 12 hours of classroom time, practice in the EPIC Playground, user acceptability training classes,non-physician technical support on all of the floors, and a physician-only help line.
1629264|NCT02015689|Behavioral|Benefits to Child|CDC VIS + message emphasizing benefits to child of MMR vaccine
1629265|NCT02015689|Behavioral|Benefits to Society|CDC VIS + message emphasizing benefits to society of MMR vaccine
1629266|NCT02015689|Behavioral|Benefits to Child and Society|CDC VIS + message emphasizing benefits both to child and to society of MMR vaccine
1629267|NCT02015689|Behavioral|CDC VIS|CDC Vaccine Information Statement (VIS)
1629268|NCT02015676|Drug|trastuzumab|Initial loading does of 4 mg/kg IV, followed by 2 mg/kg IV weekly, until disease progression
1629269|NCT02015676|Drug|paclitaxel|60 mg/m^2 IV weekly; dose increased to 70 mg/m^2, and subsequently 80 mg/m^2, after 2 treatment cycles with no evidence of DLT until disease progression
1629270|NCT02015676|Drug|Myocet|40 mg/m^2 IV weekly; dose increased to 50 mg/m^2 IV after 2 treatment cycles with no evidence of DLT for 6 cycles
1629271|NCT02015663|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm
1629272|NCT02015650|Drug|Cetuximab|Patients in treatment group A will receive Cetuximab at a loading dose of 400 mg/m2 (administered over 120 minutes) and weekly maintenance doses of 250 mg/m2 (administered over 60 minutes) in combination with radiation therapy.
1629273|NCT02015650|Drug|Mitomycin-C/ 5-Fluorouracil|Patients in treatment group B will receive 7 weeks of radiation therapy concomitant with Mitomycin-C 10mg/m² (max. 15mg/m²) d 8 and d 43 and 5-Fluorouracil 1000mg/m²/24h (max. 1500mg/m²/24h) d 8 - 12 and d 43 - 47. Radiation therapy will begin on day 8.
1629274|NCT02015637|Drug|Delafloxacin|single dose
1629275|NCT02015637|Drug|Ceftriaxone|single dose
2011506|NCT02514447|Drug|Placebos|
2011507|NCT02514447|Drug|Topotecan|
1629280|NCT02015585|Procedure|interocclusal appliance|Patients will be submitted to the treatment with interocclusal appliances 30 days before the replacement of their complete dentures.
1629281|NCT02015585|Procedure|Relining of the complete dentures|Patients will be submitted to the relining of their old dentures 30 days before the replacement of their complete dentures.
1629282|NCT02015585|Procedure|Complete denture rehabilitation|All patients will be rehabilitated with new complete dentures in the study
1629283|NCT02015572|Behavioral|Occupational intervention|Early coordinated occupational intervention and supervision in physically activities by a physiotherapist.
1629284|NCT02015572|Other|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist coordinated by the patient's general physician
1629285|NCT02015559|Drug|mucoadhesive oral wound rinse|Given PO
1629286|NCT02015559|Other|laboratory biomarker analysis|Correlative studies
1629287|NCT02015546|Drug|Vilazodone|All subjects will receive Vilazodone at 10, 20 or 40mg.
1629288|NCT02015533|Drug|CR8020|CR8020 50 mg/kg solution will be administered as a single 2-hour intravenous infusion.
1629289|NCT02015533|Drug|Placebo|Placebo will be administered as a single 2-hour intravenous infusion.
1629290|NCT02015520|Drug|Clazakizumab|
1629291|NCT02015520|Drug|Placebo (Matching with Clazakizumab)|
1629292|NCT02015507|Drug|ivacaftor|
1629293|NCT02015507|Drug|VX-661|
1629294|NCT02015507|Drug|ciprofloxacin|
1629295|NCT02015494|Biological|VAX2012Q|Recombinant influenza HA vaccine delivered IM
2011508|NCT02513303|Drug|Sirolimus|Subjects in the treatment group will receive a single prophylactic dose of sirolimus delivered locally to the vessel wall at and around the site of the anastomosis of an AV fistula, immediately following completion of a successful AV fistula surgery. Control group subjects will have surgery for creation of the AV fistula but will not receive the drug.
1629297|NCT02015468|Other|Early mobilization|Early weightbearing and physiotherapy
1629298|NCT02015468|Other|Late mobilization|Late mobilization, none-weightbearing and home exercises
1629299|NCT02015455|Other|Epidemiologic benchmarks included in lumbar imaging reports|Epidemiologic benchmarks inserted into lumbar imaging reports
1629300|NCT02015442|Dietary Supplement|Sucrose|
1629301|NCT02015429|Dietary Supplement|Pasta meal with added fractions or control with no fractions|
1629302|NCT02015416|Biological|IDC-G305|NY-ESO-1 recombinant protein together with GLA-SE
1629303|NCT02015403|Drug|Standard Care + NAC (N -ACETYLCYSTEINE)|
1629304|NCT02015403|Drug|Standard Care (in control arm)|
1629305|NCT02015390|Procedure|Iliac crest autogenous bone grafting|
1629306|NCT02015390|Procedure|Reamer-Irrigator-Aspirator autogenous bone grafting|
1629307|NCT02015377|Other|High sugar versus low sugar meals|Participants visit our lab for two 8-hour periods with a minimum of two weeks washout in between. In one visit they receive high sugar low fiber meals, in the other they receive low sugar, high fiber meals. The order of meals is randomized
1629308|NCT02015364|Procedure|Controlled early mobilization|1. The intervention group: Must perform controlled mobilization-exercises from the beginning of week 3 - 8.
1629309|NCT02015351|Drug|bevacizumab|Injection technique: After lid speculum insertion and irrigation of the conjunctiva with 5% povidone-iodine, 0,05ml of bevacizumab will be inserted through the pars plana 3.5mm to 4.0mm posterior to the surgical limbus using a 30 gauge needle. After injection, topical antibiotics will be immediately applied in the injected eye. Immunosuppression: Corticosteroids will be prescribed (1mg/Kg/d) with tapering along 5 months. Immunosuppressive drug of choice is cyclosporine (3-5mg/Kg/d). In case of contraindication to cyclosporine use, azathioprine or mycophenolate mofetil will be prescribed.
1629310|NCT02015325|Behavioral|Planet Water Foundation's Program|Planet Water Foundation's Program (PWP) provides a school-based program with an aim to improve health outcomes in children using three components: (a) access to safe water, (b) access to hand washing facilities, and (c) access to water-health and hygiene education. As part of the PWP, access to safe water is provided through the use of an AquaTower, which incorporates an Ultra Filtration (UF) system. WASH messaging is also posted around the AquaTower as derived from PWP's school-based four week Water-Health & Hygiene education program.
2011509|NCT02513043|Drug|medical abortion|medical abortion
1629313|NCT02015299|Drug|Linagliptin|one tablet linagliptin 5 mg/day for 26 weeks
1629314|NCT02015299|Drug|placebo|one tablet matching placebo/day for 26 weeks
1629315|NCT02015286|Device|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
1629316|NCT02015273|Device|easypod™|Saizen® (Somatropin) as per Summary of Product Characteristics administered by easypod™
1629317|NCT02015260|Drug|Topical NO|Varying doses of sodium nitrite and citric acid co-applied to warts
1629318|NCT02015260|Drug|Placebo|Placebo
1629319|NCT02015247|Procedure|computer-assisted surgery|use of computer-assisted navigation during periacetabular osteotomy
1629320|NCT02015234|Drug|TNX-102 SL|TNX-102 SL 2.8 mg taken daily at bedtime.
1629321|NCT02015221|Device|Dual Action Pneumatic Compression Device|A novel dual action pneumatic compression device that provides both sustained compression while ambulatory, and intermittent pneumatic compression when connected to an AC outlet.
1629322|NCT02015221|Device|Standard Compression Garments|Compression stockings with a 30-40mmHg level of compression.
1629323|NCT02015208|Drug|Ruxolitinib|20 mg orally on day 1 to 21 of each 28 day cycle. Number of Cycles: 7 or until progression or unacceptable toxicity develops.
1629324|NCT02015195|Other|Acetic Acid (5%)|
1629325|NCT02015195|Other|Sodium Bicarbonate Slurry (50%)|
1629326|NCT02015195|Other|Papain Slurry (70%)|
1629327|NCT02015195|Other|Ammonia (10%)|
1629328|NCT02015195|Drug|Lidocaine (4%)|
1629329|NCT02015195|Other|Isopropyl Alcohol (70%)|
1629330|NCT02015195|Other|Hot Tap Water (40 degrees Celsius)|
1629331|NCT02015195|Other|No treatment|
1629425|NCT02014415|Procedure|Liver Biopsy (Biopsy Group Only)|A percutaneous (needle) liver biopsy will be performed on subjects in the Liver Biopsy Group, in Year 1 and Year 5 of the study.
1629426|NCT02014402|Biological|Human thrombin|Thrombin purified from human plasma reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
1629332|NCT02015182|Other|Blood sample for bupivicaine pharmacokinetics|"Bupivacaine levels will be measured with an assay developed on the 4000 QTrap Tandem Mass Spectrometer (Applied Biosystems/ MDS Sciex).
Data will be collected and analyzed using the Agilent ChemStation software (Rev A.10.02). The analytical column is an Agilent Zorbax Eclipse XDB-C8 (4.6 x 150mm, 5µm).Quantification of bupivacaine is based on analyzing a six point calibration curve (0 to 4.0 mg/L). An internal standard (Prilocaine 221.2/86.1) is included with each calibrator, quality control or patient sample. Instrumentation and Chromatographic conditions: The HPLC system consists of a Specta-System P1000 Isocratic Pump and an AS3000 Autosampler (Thermo Electron Corporation, Waltham MA)."
1629333|NCT02015169|Drug|Lapatinib|lapatinib 1250mg qd daily up to 8 cycles (3 weeks * 8 cycles = 24 weeks)
1629334|NCT02015156|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
1629335|NCT02015156|Biological|Herceptin®|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on Day 1
1629336|NCT02015130|Other|Individual treatment|See detailed description
2011510|NCT02512562|Drug|AL-335|AL-335 is a prodrug being developed as an orally administered anti-HCV therapeutic.
2011511|NCT02512562|Drug|ACH-3102|ACH-3102 is an NS5A inhibitor being developed as an orally administered anti-HCV therapeutic.
2011512|NCT02512562|Drug|Simeprevir|Simeprevir is an orally active, small molecule inhibitor of the NS3/4A protease of HCV and indicated for the treatment of chronic HCV infection as a component of a combination antiviral treatment regimen.
2011513|NCT02512068|Drug|SYR-472 25 mg|SYR-472 25 mg Tablets
2011514|NCT02512068|Drug|Placebo + SYR-472 25 mg|Placebo Tablets + SYR-472 25 mg Tablets
2011515|NCT02511184|Drug|Crizotinib|To test 3 dose levels of crizotinib in combination with pembrolizumab 200 mg iv infusion every 3 weeks
2011516|NCT02511184|Drug|Pembrolizumab|To test pembrolizumab at 200 mg every 3 weeks in combination with crizotinib at 3 dose levels.
1629344|NCT02015091|Biological|PfSPZ Vaccine|The PfSPZ Vaccine is composed of radiation-attenuated Plasmodium falciparum sporozoites (PfSPZ) and is designed to prevent malaria in adults, children, and infants. It is formulated in phosphate buffered saline (PBS) with 1% human serum albumin (HSA). Sanaria Incorporated (Sanaria), Rockville, Maryland, developed and produced the PfSPZ Vaccine.
2011517|NCT02510547|Procedure|CrossBoss Catheter|Upfront use of the CrossBoss catheter for CTO lesion crossing
1629346|NCT02015039|Drug|BoNT Injections|
1629347|NCT02015039|Procedure|Occupational Therapy|
2011518|NCT02510547|Procedure|Antegrade Wire Escalation Strategy|Upfront guidewire escalation strategy for CTO lesion crossing
1629349|NCT02014987|Behavioral|Training programmes|"Runners with a high body mass index follow two types of training programmes:
a running programme of 3 kilometres per week
a running programme 6 kilometres per week
The amount of running will be increased with 10 % per week."
1629350|NCT02014961|Procedure|Dermal biopsy|Skin biopsy
1629351|NCT02014961|Behavioral|Gastro-intestinal questionnaire|Pagi-Sym, Bristol Stool Chart, gastrointestinal symptom rating scale (GSRS)
1629352|NCT02014961|Genetic|Whole-exome sequencing|Whole-exome sequencing (WES)
1629353|NCT02014948|Other|Exercises|The individuals who make up this group performed exercises for 10 consecutive sessions.
1629354|NCT02014935|Other|Low intensity laser|"The study wants to evaluate the use of low intensity laser on the spastic muscle.
Want to assess whether the Low level laser prove change in muscle performace of the individual but also alters muscle activity and blood lactate."
1629355|NCT02014922|Drug|TheraTears® Lubricant Eye Drop|
1629356|NCT02014922|Drug|TheraTears® preservative-free single-use containers|
1629357|NCT02014922|Dietary Supplement|TheraTears® Nutrition|
1629358|NCT02014922|Other|TheraTears® TheraLid® Eyelid Cleanser|
1629359|NCT02014909|Biological|KTN3379|Single agent KTN3379 or in combination administered until unacceptable toxicity or progressive disease
1629360|NCT02014896|Other|Biomarker blood draw|Comparison of gene expression profiles using RNA isolated from whole blood.
1629361|NCT02014883|Drug|GLUT1 DS|
1629362|NCT02014870|Other|1:1000 Live wild-type A/California/H1N1 2009|1:1000 dilution of neat virus
1629363|NCT02014870|Other|1:100 Live wild-type A/California/H1N1 2009|1:100 dilution of neat virus
1629364|NCT02014870|Other|1:10 Live wild-type A/California/H1N1 2009|1:10 dilution of neat virus
1629365|NCT02014857|Procedure|Gingival Crevicular Fluid Sampling|
1629366|NCT02014844|Drug|aldoxorubicin|
1629367|NCT02014831|Drug|Cetuximab|"Cetuximab treatment will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :
CETUXIMAB I.V infusion of 400 mg/m2 on cycle 1 Day 0 for 2 hours, then 250 mg/m2 for subsequent infusions for 1 hour on Day 8, Day 15 and next cycles Day1, Day8, Day15.
In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
1629368|NCT02014831|Drug|TIP|"The TIP combination of treatments will be administered on specific days within a 21-days-cycle and for a maximum of 6 cycles as follow :
PACLITAXEL I.V infusion of 175 mg/m2, for 3 hours, on Day 1 of the cycle.
IFOSFAMIDE I.V infusion of 1200 mg/m2, for 2 hours, on Day 1, Day 2, Day 3 of the cycle.
CISPLATINE I.V infusion of 25 mg/m2, for 1 hour, on Day 1, Day 2, Day 3.
In case of documented toxicities, 2 drugs doses reductions are allowed according specific algorithms indicated in protocol"
2011519|NCT02509741|Behavioral|Education|
1629370|NCT02014805|Radiation|radiotherapy|postoperative conformal radiotherapy for Masaoka stage II-III B type thymoma
1629371|NCT02014779|Behavioral|eChange|A web-based relapse intervention program consisting of 14 modules. The patient will have access to therapist support through a secure messaging system
1629372|NCT02014779|Behavioral|Face-to-face therapy|Face-to-face psychotherapy, consisting of 20 sessions. The content will be different for different therapists, but all have an evidence based approach to therapy
1629373|NCT02014766|Procedure|Interscalene block|Ultrasound-guided interscalene block is performed.
1629374|NCT02014766|Procedure|Supraclavicular block|Ultrasound-guided supraclavicular block is performed
1629375|NCT02014753|Device|cobalt-chromium everolimus-eluting stent (CoCr-EES)|
1629806|NCT02011113|Drug|Pomalidomide|4 mg oral pomalidomide once daily Days 1-21 of each 28-day cycle
2011520|NCT02509741|Dietary Supplement|Food replacement|
1629376|NCT02014740|Drug|Liraglutide|Liraglutide (Victoza) is an acylated analogue of glucagon-like peptide-1 (GLP-1) indicated for the treatment of type 2 diabetes mellitus• L-group will be started and dose-escalated to 1.8mg sc once daily according to below schedule: Liraglutide will be administered with a starting dose of 0.6 mg (after a least one week) and subsequent increments to 1.2 mg (after a least one week) and to 1.8 mg (after at least a week on 1.2 mg). L-group subjects will need to achieve the final dose of 1.8 mg by at least three weeks from the starting dose. Subjects who would not be able to achieve the dose of 1.8 mg (due to potential side effects) will be advised to lower the dose to 1.2 mg. Metformin regimen will be continued. .
1629377|NCT02014740|Drug|Metformin|
1629378|NCT02014727|Biological|Group A1 : 50µg AMA1-DiCo + Alhydrogel|
1629379|NCT02014727|Biological|Group A2 : 50 µg AMA1-DiCo+ GLA-SE|
1629380|NCT02014727|Biological|Group B2 : Placebo|
1629381|NCT02014714|Drug|Morphine|Drug: Morphine Depending on the randomization schedule, 0.1mg of morphine or will be added to the intrathecal mixture.
1629382|NCT02014714|Drug|Fentanyl|Drug: Fentanyl 40mcg Depending on the randomization schedule, 40μg of fentanyl will be added to the intrathecal mixture.
1629383|NCT02014701|Procedure|Echocardiogram|"Contrast echocardiography with Optison for assessment of regional wall motion. This will be performed immediately following the resting echocardiogram by a sonographer specifically trained in myocardial contrast echocardiography.
Contrast echocardiogram with Optison for assessment of myocardial perfusion. This will be performed using a continuous infusion of Optison using low mechanical index power-modulation imaging of the myocardium and blood pool. Myocardial perfusion will be assessed offline using video intensity analysis software."
1629384|NCT02014675|Device|SD01 ICD lead|
1629385|NCT02014662|Other|Eccentric exercise|Each subject will perform eccentric exercise against a predefined personal maximal strength of their non-dominant leg on day 1. Changes on strength, biomarker concentrations and muscle protein synthesis during damage and recovery will be measured over 22 days.
2011521|NCT02509741|Behavioral|IOT monitoring|
1629389|NCT02014636|Drug|Pazopanib|Pazopanib is an orally administered 200 mg tablet available in the dose range of 400 to 800 mg
1629390|NCT02014636|Drug|MK-3475|MK 3475 is an intravenously administered 100 mg/ 4mL solution available in the potential dose range of 1 to 10 mg/kg.
1629391|NCT02014623|Other|Grass pollen sublingual immunotherapy tablet|
1629392|NCT02014623|Drug|Control|
1629393|NCT02014597|Device|HOCD|comparison of HOCD results between subjects with and without glaucoma
1629394|NCT02014584|Drug|Dutasteride|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of dutasteride to be administered orally.
1629395|NCT02014584|Drug|Placebo|Dutasteride matching placebo will be supplied as capsules to be administered orally.
1629396|NCT02014571|Drug|GSK2878175|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose.
1629397|NCT02014571|Drug|Placebo|Round tablets (5.0mg) given once daily repeated (to 2 days), oral dose visually matching GSK2878175.
1629399|NCT02014545|Drug|Lucanthone|The dose of lucanthone to be administered will be calculated based on the patient's body weight. The dose to be given will be 250 bid, 250 tid or 375 tid dependent upon study progression.
1629400|NCT02014545|Other|Placebo|Only standard treatment of whole brain radiation therapy is done.
1629401|NCT02014532|Drug|Montelukast|Patients in Montelukast Group were treated with scaling and root planing (SRP) along with Montelukast (Montair 10mg), 1 tablet twice daily for 3 weeks.
1629402|NCT02014532|Drug|Placebo|Patients in Placebo Group were treated with scaling and root planing (SRP) along with Placebo therapy, 1 tablet twice daily for 3 weeks.
1629405|NCT02014506|Drug|Fludarabine|40mg/M2 once daily IV on days -7 to -2
1629406|NCT02014506|Drug|Cyclophosphamide|50 mg/kg IV on day -3 and -2
1629407|NCT02014506|Biological|anti-thymocyte globulin|
1629408|NCT02014506|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
1629409|NCT02014506|Radiation|Total body irradiation|200 cGy per day on D-6 to -4 (eligible disease except aplastic anemia) 200 cGy per day on D-5 & -4 (severe aplastic anemia)
1629410|NCT02014506|Procedure|TCRαβ-depleted hematopoietic cell transplantation|
1629411|NCT02014506|Device|CliniMACS|Immunogenetic depletion of TCRαβ cells
1629412|NCT02014493|Procedure|High Flow Nasal Cannulae (HFNC)|HFNC 6 l/pr.min
1629413|NCT02014493|Procedure|Continuous Positive Airway Pressure (CPAP)|CPAP 6 l/pr.min
1629414|NCT02014480|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via NDPI.
1629415|NCT02014480|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via NDPI.
1629416|NCT02014480|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via NDPI.
1629417|NCT02014467|Drug|Denosumab|Injection
1629418|NCT02014467|Drug|Placebo|Injection
1629419|NCT02014467|Dietary Supplement|Elemental Calcium|Oral, at least 600 mg
1629420|NCT02014467|Dietary Supplement|Vitamin D|Oral, at least 400 IU
1629421|NCT02014454|Drug|Propranolol eye drops|"All the enrolled preterm newborns will receive propranolol as ophthalmic solution (0,1%): 3 microdrops of 6 microliters (μL) propranolol solution (= 6 μg propranolol/microdrop) will be topically applied with a calibrated pipette, in each eye, three times daily (every 8 hours).The treatment will continue until the complete development of retinal vascularisation, but no more than 60 days.
The propranolol treatment will be always associated to the conventional approach adopted by the ETROP Cooperative Group."
1629422|NCT02014441|Drug|Talimogene laherparepvec|Talimogene laherparepvec will be administered by intralesion injection at an initial dose of up to 4.0 mL of 10^6 PFU/mL. The second and subsequent doses will will be up to 4.0 mL 10^8 PFU/mL. The second dose should be administered 21 days from the initial dose. All subsequent doses should be given every 14 days.
1629423|NCT02014428|Dietary Supplement|Hyaluronic acid|
1629424|NCT02014428|Drug|Placebo|
1630562|NCT02004886|Drug|Placebo|Placebo tablets matching MK-0893
1629427|NCT02014402|Biological|Bovine thrombin|Thrombin of bovine origin reconstituted as a 1000 IU/mL solution in blinded syringes and applied using Gelfoam® sponges
2011522|NCT02508129|Behavioral|Brief Behavioral Treatment for Insomnia|BBTI employs behavioral strategies for treating insomnia, including stimulus control and sleep restriction. The BBTI interventionist contacts occur by telephone or web conferencing. It is administered in an initial session, followed by 3 brief weekly contacts, each guided by a printed workbook. During an initial 60 minute session, the sleep interventionist will review the participant's insomnia symptoms, discuss sleep regulation, and develop an individualized prescription of sleep wake times.
1629431|NCT02014363|Drug|ETS6103 (low dose)|
1629432|NCT02014363|Drug|ETS6103 (high dose)|
1629433|NCT02014363|Drug|Amitriptyline|
1629434|NCT02014350|Device|DePuy Delta Xtend Reverse TSA|
1629436|NCT02014324|Procedure|Endosonography|"Complete endosonographic mediastinal staging is performed in 2 steps:
Systematic EBUS (airways)
Systematic EUS-B (esophagus)"
1629437|NCT02014311|Procedure|CTA+CTP guided treatment strategy|CTA+CTP guided treatment strategy
1629438|NCT02014311|Procedure|CTA guided treatment strategy|CTA guided treatment strategy
1629439|NCT02014298|Radiation|non-ablative fractional laser|3 treatments with 4-6 weeks interval
1629440|NCT02014298|Other|control|observation, comparison to laser-treated area
1629441|NCT02014285|Procedure|Muscle Ultrasound and Muscle Sample|The muscles to undergo ultrasound will include the biceps brachii, wrist extensors, quadriceps, and tibialis anterior. A muscle sample will be taken from the rectus femoris.
1629442|NCT02014272|Drug|RIN 150|Each subject will receive a single oral dose of 4 fixed dose combination tablets (RIN 150) each contains 150 rifampicin and 75 mg isoniazid.
1629443|NCT02014272|Drug|reference drugs|Each subject will receive a single oral dose of 4 x 150 mg rifampicin capsules and 3 x 100 mg isoniazid capsules.
1629444|NCT02014259|Drug|semaglutide|Once daily oral administration of semaglutide formulated with SNAC. Dose escalation, with 5 days on 5 mg followed by 5 days on 10 mg
1629445|NCT02014233|Dietary Supplement|Omega-3|
1629446|NCT02014233|Dietary Supplement|Olive oil|
1629447|NCT02014220|Other|dietary treatment|
1629448|NCT02014207|Other|dietary treatment|
1629449|NCT02014194|Behavioral|attentional bias modification treatment|The attentional bias modification treatment is a behavioral computerized program (software e-prime)
1629450|NCT02014181|Dietary Supplement|finely ground flaxseed powder|40 grams finely ground flaxseed powder daily for one month to patients with cystic fibrosis
1629451|NCT02014168|Biological|Viroflu® and MVA-NP+M1|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.
MVA-NP+M1 manufactured by by IDT Biologika GmbH, Germany. Each vial of MVA-NP+M1 contains 700 microlitres volume at a concentration of 1.3 x108 pfu/ml in 10mM Tris buffer. The dose of MVA-NP+M1 to be used in this study will be 1.5 x108 pfu."
1629452|NCT02014168|Biological|Viroflu® and saline placebo|"2013-2014 season Viroflu, manufactured by Crucell. Contains 15 microgrammes of haemagglutinin (HA) from an H1N1 subtype influenza A virus, an H3N2 subtype influenza A virus and an influenza B virus per 0.5 ml dose.
0.9% saline placebo."
1629453|NCT02014155|Other|Inspiratory Muscle Training|Will be held inspiratory muscle training associated with a pulmonary rehabilitation program. The inspiratory muscle training is performed with a load of 40 to 50% of the muscle strength of the subjects.
1629454|NCT02014155|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation consists of isotonic exercises of upper and lower limbs, 20-minute workout on cycle ergometer in standard deflation (expiration at the time of muscle contraction), is performed three times a week for eight weeks.
1629455|NCT02014142|Drug|Latanoprost Punctal Plug Delivery System (L-PPDS)|Latanoprost Punctal Plug Delivery System (L-PPDS)
1629456|NCT02014129|Drug|LY2835219|Administered orally
1629458|NCT02014103|Drug|Tacrolimus|Administration of each formulation will be determined by sequence.
1629459|NCT02014090|Other|Hemodynamic and biological measurements|by MCE, PWA, Doppler, Multiplex, FACS
1629460|NCT02014077|Procedure|VATS ( Video-Assisted Thoracoscopy )|the patients were randomized to a Video-Assisted thoracoscopy for retained haemothorax
1629461|NCT02014077|Procedure|Thoracostomy Tube reinsertion|the patient is randomized to reinsertion of a Thoracostomy Tube for retained haemothorax
1629462|NCT02014064|Drug|Atomoxetine|"MA Group: Dispense 1 cap @ 8 AM on Treatment day 9 and 10 (total daily dose 40mg or 0); 1 cap SID @ 8 AM and 4 PM on day 11,12, and 13 (total daily dose 80mg or 0); 1 cap @ 8 AM on day 14 (total daily dose, 40mg or 0).
Control Group Schedule:
Day 1: 40mg @ 8:00am
Day 2: 40mg @ 8:00am
Day 3: 40mg @ 8:00am, 40mg @ 8:00pm
Day 4: 40mg @ 8:00am, 40mg @ 8:00pm
Day 5: 40mg @ 8:00am, 40mg @ 8:00pm
Day 6: 40mg @ 8:00am = Testing day (fMRI scan & cognitive testing session)"
1629463|NCT02014064|Other|Placebo|Control Group: Day 1: 40mg @ 8am Day 2: 40mg @ 8am Day 3: 40mg @ 8am, 40mg @ 8pm Day 4: 40 mg @ 8am, 40mg @ 8pm Day 5: 40mg @ 8am, 40 mg @ 8pm Day 6: 40 mg @ 8am = Testing day (fMRI scan & cognitive testing session)
1629464|NCT02014051|Drug|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered to two cohorts at either 280 mg/day or 560 mg/day.
The dose will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.
The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied. However, treatment will be limited to a maximum of 6 cycles including the first cycle."
1629465|NCT02014025|Procedure|Open hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery A and D district is Group A ,they will accept Open Hepatectomy: tumors are totally resected by conventional laparotomy.
1629466|NCT02014025|Procedure|Laparoscope hepatectomy|We let the 45 patients who are meet the inclusion criteria .Hospital in hepatobiliary surgery E district is Group B ,they will accept Laparoscopic Hepatectomy: tumors are totally resected through laparoscopic.
1629467|NCT02013999|Other|Virtual reality program for upper extremity rehabilitation|
1629468|NCT02013999|Other|standard occupational therapy|
2011523|NCT02508129|Behavioral|Sleep Healthy Using the Internet|"SHUTi is a self-guided, automated, interactive, and tailored web-based program modeled on the primary tenets of Cognitive Behavioral Treatment for Insomnia (CBT-I): sleep restriction, stimulus control, cognitive restructuring, sleep hygiene, and relapse prevention. Intervention content is metered out over 6 Cores based on a time and event-based schedule. SHUTi uses online sleep diaries to track progress and to tailor treatment (e.g., assign a sleep restriction window). Each Core acts as an online analog for the weekly sessions of traditional CBT-I and follows the same structure."
1629472|NCT02013973|Other|AMH-analysis|At the first visit to the IVF-clinic a blood sample for serum-AMH is taken and frozen for later analysis in the AMH-group. The AMH assay used is the Beckman Coulter AMH Gene II assay. The analysis result will be added to the algorthm deciding what starting gonadotropin dose the patient is having.
1629473|NCT02013960|Drug|Cytotec|Cytotec medication compared with cytotec and laminaria
1629474|NCT02013947|Other|2 weeks of exercise in low and moderate altitude|"Group A will spend 2 weeks at an altitude of 1900m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate).
Group B will spend spend 2 weeks at an altitude of 400m and participants absolve a training program (3h, 4x a week, total training time 24h, training intensity 55-65% of maximal heart rate)."
1629475|NCT02013934|Dietary Supplement|Probiotic|
1629476|NCT02013934|Dietary Supplement|Placebo|
1629477|NCT02013921|Other|Physical activity|
1629478|NCT02013908|Procedure|Acupuncture plus standard ED management|
1629479|NCT02013908|Procedure|Standard ED management alone|
1629480|NCT02013895|Device|99mTc-GSA|
1629481|NCT02013882|Procedure|1-1-12 wash-in|wash-in phase during start of low flow anesthesia
1629482|NCT02013869|Device|Flow-I|Desflurane Dialed setting 18 %
1629483|NCT02013869|Device|Asys|Desflurane dialed 18%
1629484|NCT02013856|Dietary Supplement|Low Epicatechin and procyanidin|70 mg epicatechin and 65 mg procyanidins once daily for 28 days
1629485|NCT02013856|Dietary Supplement|High Epicatechin and procyanidin|140 mg epicatechin and 130 mg procyanidins once daily for 28 days
1629486|NCT02013856|Dietary Supplement|High procyanidin|No epicatechin and 130 mg procyanidins once daily for 28 days
1629487|NCT02013856|Dietary Supplement|Placebo|Placebo control once daily for 28 days
1629488|NCT02013843|Behavioral|Community-based treatment of overweight and obesity|"Community based treatment of overweight and obese children using the Holbaek-method."
1629489|NCT02013830|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle.
1629490|NCT02013830|Drug|capecitabine [Xeloda]|1600mg/m2/day po in 2 divided doses, on days 1 to 14 of each 3 week cycle.
1629491|NCT02013817|Drug|rituximab [MabThera/Rituxan]|Every 4 weeks for 6 cycles of induction, followed by maintenance therapy every 3 months x 8
1629492|NCT02013817|Drug|fludarabine|Every 4 weeks, 6 cycles
1629493|NCT02013817|Drug|cyclophosphamide|Every 4 weeks, 3 cycles
1629494|NCT02013804|Drug|MEDI0680 (AMP-514)|Study has planned dose escalation cohorts
1629495|NCT02013791|Drug|Placebo|Vehicle of cyclosporine administered as per protocol on Day 1
1629496|NCT02013791|Other|Sham|Sham administered to non-study eye as per protocol on Day 1
1629497|NCT02013791|Drug|Cyclosporine New Ophthalmic Formulation|Cyclosporine New Ophthalmic Formulation administered as per protocol
1629498|NCT02013778|Drug|HCQ|
1629499|NCT02013765|Drug|trastuzumab|Initial dose of 4 mg/kg i.v on Day 1, followed by weekly doses of 2 mg/kg i.v. beginning on Day 8 and continuing for up to 37 weeks.
1629500|NCT02013752|Device|Perineal protection device.|A device used to reduce perineal tears during delivery of the baby.
1629501|NCT02013726|Device|MBI Scan: The LumaGEM®|The LumaGEM Scanner is a dual-head, MBI scanner that has previously been cleared for medical marketing (510(k) number K111791), and has been used to image more than 5,000 patients to date. The LumaGEM MBI scanner is used as a diagnostic adjunct to mammography screening for problem cases The efficacy of MBI has been well documented in clinical trials. The LumaGEM MBI scanner is a dual-head, small field-of-view (FOV) device for developing an MBI image of Tc99m-Sestamibi uptake within the breast. The device consists of solid-state detectors, a data acquisition system, and a computer. The detectors are also used to immobilize the breast during image acquisition by mild compression. The detectors are housed in two heads that are positioned on both sides of a compressed breast.
1629502|NCT02013726|Device|3D Mammogram/Breast Tomosynthesis Scan: Selenia® Dimensions®|The breast tomosynthesis procedure involves x-ray imaging of the breast using a moving x-ray source and digital detectors composed of cesium iodide crystals on an amorphous silicon layer or of solely selenium in order to produce an image of the breast. This procedure is considered to basically be a modification of mammography and also is used as a diagnostic adjunct to mammography screening for problem cases.
1629505|NCT02013687|Biological|Pfs25 VLP- FhCMB|
1629507|NCT02013661|Procedure|Periodontal resective surgery|surgical periodontal debridement is performed after periodontal phase I
1629508|NCT02013648|Drug|Dasatinib|
1629509|NCT02013648|Drug|Cytarabine|
1629510|NCT02013648|Drug|Daunorubicin|
1629511|NCT02013622|Drug|Brexpiprazole|Treatment (16 weeks) Up to 4 mg/day, once daily dose, tablets, orally
1629512|NCT02013609|Drug|Brexpiprazole|Treatment 12 weeks) - Up to 3 mg/day, once daily dose, tablets, orally
1629513|NCT02013596|Other|TEAS pretreatment|Electric stimulation was given through electrode attached to specific acupoints for 30mins before anesthesia induction
1629514|NCT02013596|Other|TEAS treatment|Transcutaneous Electrical Acupoint Stimulation was given to the patient at the same time of the start of anesthesia induction for 30mins
1629515|NCT02013583|Other|No intervention|This is an observational registry. No interventions are required or provided.
1629517|NCT02013557|Behavioral|Text-message reminder|
1629518|NCT02013544|Drug|Placebo|
1629519|NCT02013544|Drug|Prasterone (DHEA)|
1629520|NCT02013531|Drug|Brexpiprazole|Treatment (6 weeks) - Up to 3mg/day, once daily dose, tablets, orally
1629672|NCT02012244|Drug|fentanyl-based analgesia|fentanyl based patient-controlled analgesia + additional pethidine for postoperative 48 hour
1629521|NCT02013518|Behavioral|Cognitive Behavioural Therapy|11 standardised weekly one-hour sessions/6 modules: Module one - introduction to the programme. Module two - pleasant activities to improve mood and depressive symptoms. Module three - the use of external memory aids to help the patients to maintain independence in their daily life. Module four - establishing behavioural routines to reduce demands on memory. Module five - stimulates patients to actively engage in reminiscence and memories to improve mood and well-being. Module six - review of the programme and individual treatment goals.
1629522|NCT02013505|Other|Educational video|An educational video was developed based on the current paper instructions for bowel preparation. The video included a physician explaining the process, using more images and short clip videos of the example. The script of the video was approved by the patient education department of the University Hospital and language adjusted to 6th grade level.
1629523|NCT02013492|Drug|propranolol hydrochloride|Given PO
1629524|NCT02013492|Other|Correlative Studies|"Correlative studies will be conducted using the following materials:
Plasma derived from peripheral blood.
Peripheral blood mononuclear cells (PBMC) derived from patient blood
Tumor tissue obtained at the time of core needle biopsy at the 2 month time point.
Paraffin-embedded tumor tissue obtained pre-therapy to make the diagnosis of metastatic disease."
1629525|NCT02013479|Dietary Supplement|SelenoPRECISE|Produced by Pharma Nord ApS, Vejle, Denmark
1629526|NCT02013479|Dietary Supplement|Placebo|Produced by Pharma Nord ApS, Vejle, Denmark
1629527|NCT02013466|Dietary Supplement|Bolus ONS A|High-whey protein, leucine-rich, low-caloric ONS in powder format
1629528|NCT02013466|Dietary Supplement|Bolus ONS B|High casein-protein, low-caloric control product (isocaloric to product A)
1629529|NCT02013466|Dietary Supplement|Bolus ONS C|High casein-protein, high-caloric control product.
1629530|NCT02013466|Dietary Supplement|Bolus ONS D|high whey-protein, leucine-rich, high-caloric control product (isocaloric to product C)
1629531|NCT02013453|Drug|Omeprazole|40mg of Omeprazole will be administered daily by mouth.
1629532|NCT02013453|Drug|Carboplatin|Carboplatin will be administered over 30 minutes by continuous infusion.
1629533|NCT02013453|Drug|5FU|Administered by infusion.
1629534|NCT02013453|Drug|Paclitaxel|Administered by infusion.
1629535|NCT02013453|Drug|Pemetrexed|Administered by infusion.
1629536|NCT02013427|Drug|Naproxen|Take one 500mg naproxen capsule twice a day.
1629537|NCT02013427|Drug|Placebo|Take one placebo capsule twice a day.
1629538|NCT02013427|Drug|Omeprazole|Take one 20mg omeprazole capsule twice a day.
1629540|NCT02013388|Drug|N91115|Given PO daily for 14 days
1629541|NCT02013388|Drug|Placebo|Given PO daily for 14 days
1629542|NCT02013388|Drug|N91115|Given PO only on Day 1
1629543|NCT02013388|Drug|Placebo-Day 1 only|Given PO- only on Day 1 (single dosed to match single dose treatments)
1629544|NCT02013375|Procedure|Haploidentical Transplant|All subjects will undergo pre-conditioning treatment with alemtuzumab (0.3 mg/kg Day -5, Day -4, Day -3) and total body irradiation (300cGy), followed by stem cell transplant, and post-transplant treatment with cyclophosphamide (50mg/kg/day) and sirolimus (target trough level of 10-15ng/mL).
1629545|NCT02013375|Drug|Alemtuzumab|On Day -7, the first test dose of alemtuzumab (0.03 mg/kg) will be administered and on Day -6, the second test dose of alemtuzumab (0.1 mg/kg) will be administered. Alemtuzumab (0.3 mg/kg) will be infused daily on Day -5, -4, and -3.
1629546|NCT02013375|Radiation|Total Body Irradiation|A 300cGy dose of TBI will be administered in a single fraction on Day -2.
1629547|NCT02013375|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg IBW) IV, over approximately 1-2 hours, is given on Day 3 post-transplantation (ideally between 60 and 72 hours after marrow infusion) and on Day 4 (approximately 24 hours after Day 3 cyclophosphamide).
1629548|NCT02013375|Drug|Sirolimus|Sirolimus will be started on Day +5 (at least 24 hours after the completion of the cyclophosphamide infusion). The starting dose will be 12mg followed by 4mg PO daily. Doses will be adjusted to achieve a whole blood trough level of 4 - 12ng/mL.
1629549|NCT02013362|Drug|Pralatrexate injection|
1629550|NCT02013362|Dietary Supplement|Vitamin B12|
1629551|NCT02013362|Dietary Supplement|Folic Acid|
1629552|NCT02013349|Device|coronary intervention|
1629553|NCT02013336|Drug|MM-398 (Irinotecan Sucrosofate Liposome Injection) plus cyclophosphamide|
1629554|NCT02013323|Drug|Scaling and root planing, and Septilin for 7 days|Subjects in septilin group received Septilin tablets (Septilin tablets, Himalaya Drug Company, India), 500 mg of 2 tablets to be taken thrice daily for 7 days after scaling and root planing and checked for clinical and micrbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months.
1629555|NCT02013323|Drug|Scaling and root planing, and Placebo drug for 7 days|Subjects in placebo group received placebo tablets taken thrice daily for 7 days and checked for clinical and microbiological parameters at baseline, 10 days, 1 month, 3 months and 6 months
1629556|NCT02013310|Drug|HT-0712|
1629557|NCT02013310|Drug|Placebo|
1629558|NCT02013297|Radiation|SBRT treatment|"For Brain metastasis the SBRT treatment consists on 3 fractions of 8 Gy or 5 fractions of 7 Gy or 1 fraction of 18 Gy for a single metastasis which is less than 20 mm.
For primary or secondary pulmonary tumors the SBRT treatment consists on 3 fractions of 15 Gy or 5 fractions of 10 Gy for peripheral lesions and on 5 fractions of 8 Gy for proximal lesions.
For primary or secondary spinal or para-spinal tumors the SBRT treatment consists on 3 fractions of 9 Gy or 5 fractions of 7 Gy.
For previously irradiated tumors (same locations) the SBRT treatment consists on 5 to 8 fractions of 5 Gy.
For relapsed Ependymoma previously irradiated the SBRT treatment will be allocated by surgical stratified randomization and consists on either 3 fractions of 8 Gy or 5 fractions of 5 Gy."
1957964|NCT02092142|Biological|Q fever Vaccine|Subcutaneous 0.5 mL Q fever Vaccine, Phase I, Inactivated, Dried, NDBR 105
1629560|NCT02013258|Drug|Intranasal oxytocin|This is a double-blind placebo controlled 2x2 study. Subjects will receive OT for 5 consecutive days during their 7 day stay. This will be followed by a wash out period of 4-6 weeks.
1658871|NCT01786330|Other|Standard of Care|
1629561|NCT02013258|Other|Placebo|This is a double-blind placebo controlled 2x2 study. Placebo will be given via intranasal spray, one spray in each nostril daily x 5 days. One month interval between arms of treatment.
1629562|NCT02013245|Biological|MTBVAC live vaccine|Live-attenuated Mycobacterium tuberculosis vaccine
1629563|NCT02013245|Biological|Commercially available BCG live vaccine|Live-attenuated Mycobacterium bovis vaccine
1629564|NCT02013232|Drug|Aripiprazole|
1629565|NCT02013219|Drug|Alectinib|Participants will receive 600 mg PO alectinib BID for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter (21-day cycles from Cycle 2 onwards) in Stage 1 and RP2D PO BID in Stage 2.
1629566|NCT02013219|Drug|Atezolizumab|Participants will receive 1200 mg atezolizumab IV infusion q3w on Day 8 of Cycle 1 and on Day 1 of each cycle thereafter in Stage 1 and in Stage 2.
1629567|NCT02013219|Drug|Erlotinib|Participants will receive 150 mg erlotinib PO QD for 28 consecutive days during Cycle 1 and on Days 1-21 of each cycle thereafter in Stage 1 (21-day cycles from Cycle 2 onwards) and RP2D PO QD in Stage 2.
1629568|NCT02013206|Drug|erlotinib [Tarceva]|Erlotinib tablets taken orally once daily in the morning.
1629569|NCT02013193|Device|Ranger DCB|After successful pre-dilatation the index lesion is treated with one or two Ranger DCB devices that completely cover the lesion. If two devices are deployed, overlap shall be minimal.
1629570|NCT02013193|Device|uncoated PTA balloon|The index lesion is treated with one or more uncoated standard PTA balloons that completely cover the lesion.
1629571|NCT02013167|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV).
1629572|NCT02013167|Drug|Standard of Care Chemotherapy|"FLAG (fludarabine, cytarabine arabinoside, and granulocyte colony-stimulating factor) ± anthracycline-based regimen (e.g. idarubicin 10 mg/m² days 1 & 3; fludarabine 30 mg/m² days 1-5; cytarabine arabinoside 2 g/m² days 1-5). Patients > 60 years: Idarubicin 5 mg/m² day 1 & 3; fludarabine 20 mg/m² day 1-5; cytarabine arabinoside 1 g/m² day 1-5
HiDAC (high-dose cytarabine arabinoside) - based regimen ≥1 g/m²/day ± anthracycline and/or in combination with other drugs such as native Escherichia coli asparaginase, polyethylene glycol linked to asparaginase (PEG-asparaginase), vinca alkaloids, steroids, etoposide or alkylating agents
High-dose methotrexate-based regimen (HDMTX; 500 mg/m² to 3 g/m² infused up to 24 hours) in combination with native E. coli asparaginase, PEG-asparaginase, vinca alkaloids, steroids, etoposide or alkylating agents.
Clofarabine as a single agent as recommended in the prescribing information or clofarabine-based regimens with 20 mg/m²/day for up to 5 days."
1629573|NCT02013154|Drug|DKN-01|Administered by IV infusion
1629574|NCT02013154|Drug|Paclitaxel|Administered by IV infusion
1629575|NCT02013141|Drug|Telavancin|
1629576|NCT02013128|Drug|Ublituximab|Ublituximab (IV infusion)
1629577|NCT02013128|Drug|Ibrutinib|Ibrutinib oral daily dose
1629578|NCT02013115|Drug|Budesonide|Experimental: Cursurf and Budesonide The baby with respiratory distress syndrome was given Cursurf and Budesonide through intubation
1629579|NCT02013102|Drug|Decitabine Injection|Decitabine Injection 20mg/m2/d*5d, IV> 1h, one cycles per 4 weeks; Decitabine Injection 12mg/m2/d*8d, IV> 1h, one cycles per 4 weeks.
1629580|NCT02013089|Drug|Erlotinib or Gefitinib|Erlotinib 150mg talbet or Gefitinib 250 mg tablet per day for patients with EGFR gene alternation
1629581|NCT02013089|Drug|Everolimus|Everolimus 10 mg orally once daily every day for patients with mTOR gene alternation
1629582|NCT02013089|Drug|Imatinib|Imatinib 400 mg tablet orally per day for patietns with KIT, PDGFR, ABL gene alternation
1629583|NCT02013089|Drug|Sorafenib or Sunitinib|Sorafenib 400 mg twice a day at least one hour before or two hours after eating or Sunitinib 50 mg orally once a day with or without food for patients with VEGFR, KIT, RAF gene alternation
1629584|NCT02013089|Drug|Vandetanib|Vandetanib 300 mg orally once daily for patients with RET gene fusion.
1629585|NCT02013050|Drug|SGX942|
1629586|NCT02013050|Drug|Placebo|
1629587|NCT02013037|Drug|Eculizumab|"At the time of transplantation, 1200mg of Eculizumab will be administered via a 35 minute IV infusion, followed by thymoglobulin 1.5 mg/kg intravenous piggyback (IVPB). The administration of thymoglobulin will be repeated (if blood counts permit) for a total of five doses.
On Day 1 post-transplant, 900 mg of Eculizumab will be given via an IV infusion.
On Day 5 post-transplant, intravenous immunoglobulin (IVIG) 1 gram/kg will be administered daily for two consecutive days.
On post-transplant days 7, 14, and 21 (+/- 2 days) 900mg of Eculizumab will be given via an IV infusion at each scheduled visit.
On post-transplant days 28, 42, and 56 (+/- 2 days) 1200 mg of Eculizumab will be given via an IV infusion at each scheduled visit."
1629588|NCT02013024|Other|cryopreservation technique|
1629590|NCT02012998|Biological|HBVAXPRO 5µg|0.5mL intramuscular injection
1629591|NCT02012985|Biological|Oxabact OC5 capsules|The dose will be not less than (NLT) 1E+09 colony forming units (CFU) twice daily for 8 to 10 weeks. The dose (an enteric-coated size 4 capsule) will be administered orally with breakfast and dinner.
1629592|NCT02012985|Drug|Placebo capsules|An enteric-coated placebo capsule manufactured to mimic the OC5 capsule. The capsule will be administered orally with breakfast and dinner twice daily for 8 to 10 weeks.
1629595|NCT02012946|Drug|Levosimendan|patient receiving levosimendan
1629596|NCT02012946|Drug|Dobutamine|patient receiving dobutamine
1629597|NCT02012933|Drug|3,4-diaminopyridine|10mg tablets for up to 100mg per day
1629598|NCT02012920|Drug|Seviteronel: given orally once daily in 28 day cycles|
1629599|NCT02012881|Behavioral|Physical activity intervention|Physical activity during recess, in academic subjects, active transportation and PA home work
1629600|NCT02012881|Behavioral|Usual practice|Normal curriculum
1629601|NCT02012868|Procedure|bariatric surgery|
1629602|NCT02012855|Behavioral|Exercise|
1629603|NCT02012855|Other|Diet (meal type)|
1629759|NCT02011568|Other|Therapeutic Hypothermia|
1629760|NCT02011542|Drug|Visbiome|This is a probiotic mixture
1629604|NCT02012842|Other|Non surgical periodontal treatment|Treatment of gingivitis: excavation and sealing of cavities, removal of overhanging restorations, extraction of hopeless teeth, supragingival calculus removal. Oral hygiene instruction, training and motivation will be given at each appointment. Treatment of periodontitis: subgingival scaling and root planing under local anesthesia.
1629605|NCT02012829|Behavioral|GPs communication skills and CRC screening|GPs of the intervention group received a four hours educational training focused on patients' centered care to improve GPs communication skills and enhance patients'participation in CRC mass screening . Triangulation of all qualitative data was performed in order to develop educational material and training based on the six components of the Patient-Centered Clinical Method . Two different scenarios were developed: one for a compliant patient, another for a non-compliant patient. Two videos were made with doctor and simulated patient. Interactive methods were used to elaborate educational training including role playing, the presentation of the video followed by an interactive discussion.
1629606|NCT02012816|Other|Peer‐referral incentive program to increase VMMC uptake|The proposed intervention will allow men coming for male circumcision in randomly selected intervention clinics to refer up to 5 uncircumcised men in their social network and receive a monetary reward for each referred man who undergoes male circumcision. Men who come for circumcision will each be given 5 referral vouchers that they can then provide to uncircumcised men in their social network who may be interested in undergoing VMMC. If these uncircumcised men come to the CIDRZ VMMC clinics and undergo the circumcision procedure, they can present the referral voucher to clinic staff who will then retain the voucher until the man who made the referral comes to collect his incentive payment.
1629607|NCT02012803|Procedure|End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture|Operative treatment of achilles tendon rupture; End to end suturation by Krackow locking loop surgical technique with 2-Fiber-Wire suture and after operation identical protocol as conservative treatment.
1629608|NCT02012803|Other|Conservative treatment of achilles tendon rupture|Conservative treatment of achilles tendon rupture; 1 week equinus-cast without bearing, and then 6 week Vacoped orthosis with different equinus degrees and full weight bearing.
1629610|NCT02012777|Drug|propranolol|Propranolol hydrochloride is a synthetic beta-adrenergic receptor-blocking agent. This will be administered in an open-label single administration to 3 cohorts (10mg, 20mg, and 40mg) of children with sickle cell disease. Patient blood will be evaluated for red cell adhesion and patient data evaluated for safety monitoring.
1629611|NCT02012751|Device|Nevus doctor program|The Nevus doctor program supplies a diagnostic category of pigmented skin lesions based on dermatoscopy images.
1629612|NCT02012738|Behavioral|FORNET|"8 individual sessions:
1 lifeline
6 exposure sessions
1 outlook"
1629613|NCT02012738|Behavioral|CBT|"7 individual sessions, according to the Integrated cognitive behavior change program manual, Bush et al., 1997, National Institute of Corrections, US Dept. of Justice."
1629614|NCT02012738|Other|Waiting List Control Group (camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
1629615|NCT02012738|Other|Waiting List Control Group (no camp)|Participants, if still meeting the criteria and interested, will receive FORNET by local counsellors after the 8-months follow up.
1629616|NCT02012725|Drug|Arm 1 MRI with gadolinium|Healthy volunteers will not receive gadolinium
1629617|NCT02012712|Behavioral|Personal Health Record (PHR)|"Iowa PHR is a Web-based application that features a tabbed interface design. Users can enter, view, and print their current and past medicines, allergies, health conditions, and health event tracking over time. An embedded tutorial video provides assistance with the system. The PHR was developed and refined using participatory design and focus group sessions as well as evaluation in a usability laboratory. The resulting design emphasizes the reduction of physical and cognitive demands on users, focusing on simplicity, readability, and quick navigation.
Iowa PHR displayed a message when a user entered a medication with an associated Assessing Care of Vulnerable Elders project (ACOVE‐3) safety concern. This included 16 safety issues for 12 drugs or drug classes with safety concerns. We also adapted four general medication use patient safety indicators from the ACOVE project and displayed them to all users on a rotating basis upon login."
1629618|NCT02012686|Device|TENS|transcutaneous electric nerve stimulation frequency of 100 Hz pulse duration of 200 µs wih stimulation intensity of feeling strong but non-painful paresthesia in the upper trapezius
1629619|NCT02012673|Device|Bronchoscopic lung volume reduction|Bronchoscopic lung volume reduction with the RePneu Lung Volume Reduction Coil system. The RePneu LVRC is an implantable device, delivered through a fiber-optic bronchoscope, designed specifically to treat patients suffering from emphysema. The Coil is intended to compress the most damaged parenchyma and tension the surrounding tissue, which increases elastic recoil, reduces hyperinflation and redirects air to healthier portions of the lung for more effective ventilation.
1629620|NCT02012660|Other|Seasonality|The impact of high temperature during summer months on the prevalence of hyponatremia will be explores.
1629621|NCT02012647|Procedure|Transcranial Magnetic Stimulation (TMS)|Participants sit in a chair that looks like one in a dentist's office. A magnetic coil will be placed on the scalp on one side of the head, overlying the brain's motor cortex to stimulate the brain's output to the muscles in the opposite hand. A second magnetic coil will be placed on the scalp of the opposite side. Recordings from both hands will be made using the magnetic coils placed on scalp. Results will be compared for participants with and without Parkinson's Disease.
1629622|NCT02012647|Procedure|Motor Physiology Testing|Participants will be asked to move their upper and lower limbs while seated in a chair. Wireless EMG sensors placed on arm and leg muscles will record measurements during this procedure. Upper and lower limb testing will be performed separately.
1629623|NCT02012608|Drug|Glutamine|Oral glutamine for subjects undergoing breast conserving therapy
1629624|NCT02012608|Drug|Placebo|For subjects undergoing breast conserving therapy
1629625|NCT02012595|Other|[11C]donepezil PET|Positon Emission Tomography (PET) imaging of acetylcholinesterase using the ligand [11C]donepezil
1629626|NCT02012582|Drug|VAS203|i.v. infusion
1629627|NCT02012582|Drug|Saline|i.v. infusion
1629670|NCT02012270|Procedure|Conventional group|the fascia will be closed with the current method by the surgeons. There will be a great variation in sutures and techniques used. Study group: the fascia will be closed according
1629628|NCT02012569|Drug|TT-173|Bleeding of the lesion will be evaluated after each product application and will be recorded as bleeding vs. not bleeding. The product will be applied at 4 times for about 1 minute apart each application after skin graft obtention.
1629629|NCT02012569|Drug|Placebo|
1629630|NCT02012556|Drug|Tesamorelin|
1629631|NCT02012543|Dietary Supplement|Agar jelly|
1629632|NCT02012530|Procedure|HA|HA is widely applied in clinical practice with good results in many studies. HA forms part of the inflammatory process that can lead to the regeneration of cartilage in defective areas of the knee.
1629633|NCT02012530|Procedure|PRP|PRP uses reparative growth factors taken from the patient's own blood to create an environment in the knee conducive to wound healing that can fill cartilage defects. It's autologous origin, easy preparation and safety profile makes it a potentially ground breaking treatment option for knee cartilage defects and osteoarthritis.
1629634|NCT02012517|Drug|Prolonged antibiotic treatment|
1629635|NCT02012517|Drug|Short antibiotic course (standard of care)|
1629636|NCT02012491|Drug|Misoprostol|
1629637|NCT02012491|Drug|Mifepristone|
1629639|NCT02012465|Biological|Insulin protocol|"Within 24 hours of admission for diabetic participants, the inpatient oncology team will consult the endocrine team to apply the following part of the protocol, confirm NPH insulin dosing, and ensure that oral hypoglycemics are held.
The following basal-bolus protocol is standard of care for inpatient diabetics requiring insulin at Barnes Jewish Hospital. The alternative practice has been to use 60-80% of the home insulin regimen while patients are hospitalized. For patients using home insulin, the admitting oncology team will enact one of these methods while awaiting the endocrine service's formal recommendations.
Determine basal-bolus insulin requirement for the patient based on body weight: Patient weight (kg) x 0.5-0.7 Units/kg = Units of total insulin per 24 hours
The TDD can be divided into 50% basal (glargine) and 50% meal time (lispro) insulin, plus sliding scale insulin (lispro)."
1629640|NCT02012452|Behavioral|Tobacco treatment|participants will be provided contingency management and cognitive behavioral therapy to help them quit tobacco prior to PTSD treatment
1629641|NCT02012452|Behavioral|Health Education|Participants will be provided education on a variety of health topics and will set health goals around each topic
1629642|NCT02012439|Behavioral|Mindfulness Based Cognitive Therapy|
1629643|NCT02012439|Behavioral|Cognitive Therapy|
1629644|NCT02012426|Behavioral|Weight management program|
1629645|NCT02012413|Device|PST - Pulsed Signal Therapy|PST application is a painless over-the-skin eletromagnetic field application. 9 sessions of application of electromagnetic therapy - PST - during 60 minutes
1629646|NCT02012413|Device|Placebo - Sham PST|"Placebo PST will be performed by applying the same device over the patient knee. The machine is not applying the PST but it appears to be on. In this way, patients are blinded to the intervation.
9 sessions of application of Sham PST - during 60 minutes"
1629647|NCT02012400|Other|Exercise|The exercise group is given a 24-week individualized training program, including aerobic exercise, muscular training, relaxation exercises and stretching. Patients are asked to observe their asthma control daily and to mark in their diary asthma symptoms and activity limitations as well as duration, intensity and form of exercising on daily basis. They are also asked to perform PEF-measurements twice a day for one-week period every 4 weeks. The control group receives ordinary instructions.
1629651|NCT02012374|Behavioral|Intensive Language Action Therapy|
1629652|NCT02012361|Procedure|Control Group|This group will be treated as any other patient would. Their anesthesia will be conducted as per routine with a target FiO2 of 0.25, (25%oxygen / 75%nitrogen) the only exception being that they will not be treated with inspired heliox.
1629653|NCT02012361|Procedure|Single-Dose Heliox Group|This group will be treated with a single dose of inspired 75/25 heliox (75% helium 25% oxygen) breathed continuously for 15 minutes over any convenient window prior to the inflation of the surgical tourniquet. This will be the only change in their clinical care. Their anesthesia will be conducted as per routine and as the anesthesia team sees fit with a target FiO2 of 0.25, the only exception being that they will receive 75/25 heliox prior to the inflation of the tourniquet.
1629654|NCT02012361|Procedure|Muscle Biopsy|During the course of the operation a small muscle biopsy will be collected.
1629655|NCT02012348|Other|Antibacterial soap with triclocarban|
1629656|NCT02012348|Other|Antibacterial soap + benzalkonium chloride|
1629657|NCT02012348|Other|Control soap|
1629658|NCT02012335|Drug|ECT + Ketamine|Brief pulse ECT with 0.05 mg/kg ketamine infusion in each session
1629659|NCT02012322|Dietary Supplement|Coenzyme Q10|100mg/day for three months
1629660|NCT02012322|Dietary Supplement|Coenzyme Q10|300mg/day for three months
1629661|NCT02012322|Dietary Supplement|Placebo|Three month period
1629662|NCT02012309|Biological|PCV-13|
1629663|NCT02012309|Biological|PPSV-23|
1629664|NCT02012296|Drug|enzalutamide|Given PO
1629665|NCT02012296|Drug|mifepristone|Given PO
1629666|NCT02012296|Other|laboratory biomarker analysis|Correlative studies
1629667|NCT02012296|Other|pharmacological study|Correlative studies
1629668|NCT02012283|Other|Food consumption|Cooked vegetables with spices or without spices
1629669|NCT02012270|Procedure|PRINCIPLES technique|"Principles technique for closure of midline laparotomy incisions
closure with a running suture of a slowly absorbable monofilament suture- Monomax 2/0 of 150 cm length with a taper needle point ((1/2 circle, size: 30mm) (B.Braun, reference 0041453)
the suture is started and ended with a self-locking knot, if more than one suture is used sutures are knotted separately, only the fascia will be sutured with small stitches close to each other
the SL/WL ratio should be at least 4/1
SL/WL = (150cm x number of sutures used) - (the suture remnants)
the mean stitch length should be less than 4 cm (suture length / number of stitches placed)"
1629671|NCT02012257|Procedure|AMSA nerve block injectio|Sites of injection
1629673|NCT02012244|Drug|local anesthetic wound infiltration-based anlagesia|continuous wound inflitration with ropivacaine + tramadol patient-controlled analgesia + additional ketorolac or propacetamol for postoperative 48 hour
1629674|NCT02012231|Drug|PLX8394|PLX8394 is a next-generation, orally available, small-molecule, selective inhibitor of BRAF.
1629675|NCT02012218|Drug|ADT|
1629676|NCT02012218|Drug|Brexpiprazole|
1629677|NCT02012205|Procedure|wet cupping|Participants assigned to the treatment group will receive wet-cupping therapy 3 times per week for 2 weeks
1629678|NCT02012192|Drug|Ganetespib|
1629679|NCT02012192|Drug|Paclitaxel|
1629680|NCT02012179|Other|Low sodium diet|Low sodium diet (65 mmol or 1500 mg/day)
1629681|NCT02012166|Drug|MK-0893 10 mg|MK-0893 10 mg administered orally in 240 mL of water
1629682|NCT02012166|Drug|MK-0893 40 mg|MK-0893 40 mg administered orally in 240 mL of water
1629683|NCT02012166|Drug|MK-0893 200 mg|MK-0893 200 mg administered orally in 240 mL of water
1629684|NCT02012166|Drug|MK-0893 1000 mg|MK-0893 1000 mg administered orally in 240 mL of water
1629685|NCT02012166|Drug|Placebo|Placebo administered orally in 240 mL of water
1629686|NCT02012166|Biological|Sandostatine®|Sandostatine® is a somatostatin analogue. At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous Sandostatine® will be administered at 30 ng/kg/min.
1629687|NCT02012166|Biological|Insulin|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous insulin will be administered at 0.10 milli-international unit (mIU)/kg/min.
1629688|NCT02012166|Biological|Glucagon|At 24 and at 72 (Part I) or 120 (Part II) hours postdose, simultaneous infusions of the Sandostatine®, insulin, and glucagon will be administered over a 2-hour period. These compounds are IV compatible and will be combined in one syringe. Intravenous glucagon will be administered at 3 ng/kg/min.
1629689|NCT02012153|Biological|Mesenchymal Stromal Cells|
1629690|NCT02012140|Drug|ticagrelor|
1629691|NCT02012114|Other|Cysteamine bitartrate|No intervention
1629692|NCT02012101|Device|niv plus oxygen therapy|NIV given on Philips Respironics BiPAP Vision apparatus.
1629693|NCT02012101|Device|oxygen therapy|
1629694|NCT02012088|Drug|RCOMP|Day 1: Rituximab 375 mg/m2; Myocet® 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
1629695|NCT02012088|Drug|RCHOP|Day 1: Rituximab 375 mg/m2; Doxorubicin 50 mg/m2; cyclophosphamide 750 mg/m2; vincristine 1.4 mg/m2 (maximum 2 mg); prednisone 60 mg/m2 Days 2-5: Prednisone, 60 mg/m2 Administered every 21 days × 6 cycles
1629696|NCT02012075|Drug|Extended-Release Carvedilol Sulfate|
1629697|NCT02012075|Drug|Sustained-release Metoprolol Succinate|
1629698|NCT02012062|Drug|TPF neoadjuvant chemotherapy|
1629699|NCT02012062|Drug|Concurrent chemotherapy with cisplatin during radiotherapy|
1629700|NCT02012062|Drug|Concurrent nimotuzumab during radiotherapy|
1629701|NCT02012062|Radiation|Radical radiotherapy|
1629702|NCT02012049|Drug|Risperdal OD Tab. 2mg|1 tablet Risperdal OD 2 mg administered orally.
1629703|NCT02012049|Drug|Risperdal Quicklet Tab. 2mg|1 tablet Risperdal Quicklet Tab. 2mg administered orally.
1629704|NCT02012036|Drug|Hexvix|"As this is a non-interventional study, detection of NMIBC with Hexvix is in a pre-defined group, chosen prior to and independently from the decision to enrol the subject in this study.
The detection with Hexvix should be in accordance with local Summary of Product Characteristics [SmPC].
Subjects will be treated in accordance with usual medical practice during their participation in this study, no additional assessment or tests will be required."
1629705|NCT02012023|Device|Low anterior resection|
1629706|NCT02012023|Device|tube ileostomy|
1629707|NCT02012023|Device|loop ileostomy|
1629708|NCT02012023|Device|accept reversal operation|
1629709|NCT02012023|Device|remove the tube ileostomy|
1629710|NCT02012010|Procedure|Manual syringe infusion method|Infuse the distension medium of hysteroscopy by manual syringe infusion method
1629711|NCT02012010|Procedure|Pump infusion method|Infuse the distension medium of hysteroscopy by pump infusion method
1629712|NCT02011997|Procedure|patients undergo cVATS segmentectomy|
1629713|NCT02011997|Procedure|Patients undergo cVATS lobectomy|
1629714|NCT02011971|Drug|Vinpocetine|Vinpocetine is a chemical obtained from the leaves of the Lesser Periwinkle. It has been shown to improve cerebral metabolism and memory in animals and humans. In addition, it has been shown to enhance long-term potentiation, which has been linked to memory mechanisms. Furthermore, vinpocetine has been shown to have anticonvulsant effects and is more potent than several commonly used antiepileptic drug
1629715|NCT02011958|Drug|Liposomal Amphotericin B|"40 mg/kg total dose: IV infusion of 5mg/kg per day on day 1 to 5, 10,17,24 (when administered as a monotherapy)
30 mg/kg total dose: IV infusion 5 mg/kg per day on day 1, 3, 5, 7, 9, 11 (when administered in combination with Miltefosine)"
1629716|NCT02011958|Drug|Miltefosine|"Orally taken every day during 28 days
1 x 50 mg capsule per day if the patient weights less or equal to 25 kg
2 x 50 mg capsules per day if the patient weights more than 25 kg (1 capsule in the morning / 1 capsule in the evening)"
1629720|NCT02011906|Dietary Supplement|omega 3|
1629721|NCT02011906|Dietary Supplement|vitamin E|
1629722|NCT02011906|Dietary Supplement|placebo of omega 3|
1629723|NCT02011906|Dietary Supplement|placebo of vitamin E|
1629724|NCT02011893|Device|Tonic Stimulation|Prodigy Neurostimulation System with associated components
1629725|NCT02011893|Device|Burst Stimulation|Prodigy Neurostimulation System with associated components
1629761|NCT02011542|Drug|Placebo|This is a pill with inactive ingredients.
1629807|NCT02011113|Drug|Dexamethasone|40 mg or 20 mg oral dexamethasone once daily on Days 1, 8, 15, 22 of each 28-day cycle
1629808|NCT02011100|Dietary Supplement|Carnosine|
1629726|NCT02011880|Dietary Supplement|Chinese Herbs|"Dietary Supplement:Experiment group:
Fructus Cnidii,Psoralea Corylifolin L.，monkshood
-Granules,Oral(add into the breast cancer postoperative prescription solution),A Pack(Fructus Cnidii 9g，Psoralea Corylifolin L. 15g，monkshood 9g),Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity
Breast Cancer Postoperative Prescription
-Water Decoction,Oral,200ml,Bid Days,3 Periods(a month is a period),Until progression/unacceptable toxicity
Dietary Supplement:Contrast Group:
Breast Cancer Postoperative Prescription
-Water Decoction,Oral,200ml,Bid Days,3 Periods( a month is a period),Until progression/unacceptable toxicity"
1629728|NCT02011854|Device|rehabilitation|rehabilitation,To treat five times a week,Total course is eight weeks
1629729|NCT02011854|Device|Acupuncture|
1629730|NCT02011841|Drug|Rifaximin|rifaximin 1200 mg/day orally for 6 months
1629731|NCT02011841|Drug|Ciprofloxacin|ciprofloxacin 500 mg/day orally for 6 months
1629732|NCT02011828|Drug|Ergocalciferol|50,000 IU/week
1629733|NCT02011828|Drug|Placebo|Placebo tablet
1629734|NCT02011802|Device|Algosteril TM|
1629735|NCT02011802|Device|Sorbact TM|
1629736|NCT02011789|Dietary Supplement|Citrus Limonoid Beverage|The limonoid containing beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C, 11 mg riboflavin and 250 mg limonin glucoside.
1629737|NCT02011789|Dietary Supplement|Placebo beverage|The placebo beverage will be 12-oz buffered, sterile, orange flavored, artificially sweetened, containing 60 mg vitamin C and 11 mg riboflavin.
1629738|NCT02011763|Biological|Avaxim 80U Pediatric: Inactivated Hepatitis A Virus|0.5 mL, Intramuscular (2 injection 6 months apart)
1629739|NCT02011750|Drug|Sodium Valproate treatment|Sodium Valproate treatment:During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either Sodium Valproate (Depakote, DEP) or placebo (PLA) group in a 1:1 proportion. For the Sodium Valproate treatment group, this will be followed by a two week period to adjust the dose of DEP and attain therapeutic levels (50-100 µg/mL). Then DEP treatment will continue for 16 more weeks, after which DEP will be discontinued. Subject will be followed up for four weeks post-DEP discontinuation to monitor delayed adverse side effects.
1629740|NCT02011750|Drug|Placebo|Placebo: During the entry period, all patients will have a placebo run-in for two weeks after which they will be evaluated for the outcome variables and then randomized to either the experimental Sodium Valproate (Depakote, or DEP) or placebo (PLA) group in a 1:1 proportion. For the PLA group, this will be followed by a two week period of placebo during which members of the experimental Sodium Valproate (Depakote/DEP) will have DEP dose adjusted to attain therapeutic levels (50-100 µg/mL). Then PLA treatment will continue for 16 more weeks. Subjects will be followed up for four weeks post PLA-discontinuation to monitor for delayed adverse side effects.
1629741|NCT02011737|Drug|naftopidil 75mg|
1629743|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of absorbale sutures for mesh fixation|
1629744|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of non absorbable sutures for mesh fixation|
1629745|NCT02011698|Procedure|Lichtenstein technique groin hernia repair with mesh. Use of fibrin biological glue for mesh fixation|
1629746|NCT02011685|Behavioral|Home BP Telemonitoring (HBPTM)|Participants will take home BP readings 3 days per week (morning and evening), one week out of every month for 12 months. BP readings will be transmitted wirelessly to a secure server. Patients' physicians will receive home BP reports via secure email before every scheduled appointment for the duration of the study to facilitate necessary treatment intensification and medication adjustments.
1629747|NCT02011685|Behavioral|Nurse Case Management (NCM)|Participants will complete 20 counseling phone calls with a nurse case manager (NCM) during the 12-month intervention: weekly calls for Months 1-2; biweekly calls for Months 3-4; and monthly calls for Months 5-12. The NCMs will provide self-management education, medication and appointment reminders, and will facilitate patient-provider communication. They will counsel patients on specific self-management behaviors using problem solving and motivational interviewing techniques. Target behaviors will include dietary changes, physical activity, weight loss, medication adherence, and smoking cessation. NCMs will also review patients' clinical information and provide feedback about abnormal lab results, and will communicate with the patient's physician as needed (e.g., regarding barriers).
1629748|NCT02011672|Other|nutrient-enriched milk|
1629749|NCT02011672|Other|regular milk|
1629750|NCT02011659|Drug|Ramosetron|
1629751|NCT02011646|Behavioral|Healthy Weight|The PI will train 4 group leaders to deliver the intervention. Groups will be offered four times per week and consist of approximately 10 participants. Each group will be led by 2 group leaders and each group leader will lead two sessions per week during the 2.5 mo intervention period. Group leaders will digitally video-record all sessions of the first two groups they deliver so the PI can provide supervision and rate fidelity and competence for a random selection of 6 of these 12 sessions. Group leaders will transmit the video recordings via an encrypted, secure internet connection to Dr. Ochner (who was trained by Dr. Eric Stice, the creator of the intervention) within 3 d for supervision, and competence and fidelity assessments.
1629752|NCT02011646|Behavioral|Controlled Intervention|"The Weight of the World is a 51 min documentary focusing on the topics of obesity and healthy living. Via information presented by medical professionals and lifestyle experts, this film delves into issues related to preventing and combating obesity. Major topics include the importance of healthy eating and exercise behaviors and the changes that can be made by communities to reshape our lifestyles. Participants will be given a copy of the DVD. They will also be given the choice to stream it free on the web."
1629753|NCT02011633|Drug|HCP1201 500/10mg|500mg Metformin/10mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
1629754|NCT02011633|Drug|Metformin SR 500mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
1629755|NCT02011633|Drug|Rosuvastatin 10mg|Co-administration of Metformin 500mg and Rosuvastatin 10mg orally in the morning on day1 or day8.
1629756|NCT02011620|Other|Isosorbide-5-mononitrate|Tablet Isosorbide mononitrate 20 mg; 1 tablet to be taken daily at night for a total duration of 6 months.
1629757|NCT02011594|Drug|Nimotuzumab|400mg Q2W intravenously
1629758|NCT02011594|Drug|Placebo|Normal saline
1629762|NCT02011529|Other|TEAMcare treatment of diabetes|TEAMcare is an evidence-based collaborative care approach to the treatment of diabetes and psychiatric illness. It involves structured visits with a study nurse to monitor psychiatric symptoms, control of medical disease, and self-care activities. The nurses use motivational coaching to help patients solve problems and set goals for improved self-care and medication adherence. Medications for diabetes, hypertension, and hyperlipidemia are monitored and therapy intensified based on treat-to-target guidelines. All of these process and outcome measures are tracked in a registry designed for the study, and the nurses receive weekly supervision with a psychiatrist, an endocrinologist and a psychologist in order to review new cases and to track progress. Once a patient achieves targeted levels for relevant measures, the patient and the nurse develop a maintenance plan.
1629763|NCT02011516|Drug|Baclofen|
1629764|NCT02011516|Behavioral|Psychosocial|
1629765|NCT02011516|Drug|Placebo|
1629766|NCT02011503|Procedure|Multi-layer compression therapy|Application of multi-layer compression therapy.
1629767|NCT02011503|Other|Application of dHACM|Application of dHACM to ulcer.
1629768|NCT02011490|Drug|sugammadex|sugammadex 4 mg/kg IV bolus
1629769|NCT02011477|Other|Neural Glide|This technique involves two movements, throughout several joints to glide the nerves. The subject sit on a couch with the right lower limb extended and the left lower limb flexed. The therapist will take the subject's head by putting his hands on the suboccipital and front region. In the initial movement, performe craniocervical flexion in the subject, while he helped with his right elbow to rectify the dorsal spine of the subject; at the same time, the subject performed dorsiflexion of the right ankle. In the final movement, the subject must increase thoracic kyphosis at the same time as performing plantarflexion in the right ankle; also, the therapist performed craniocervical extension in the subject
1629770|NCT02011477|Other|Neural stretching|In the start position, the subject was supine on a couch, with knees bent with the right leg above the left, and supported with the popliteal zone. Both hands were crossed over the chest. The therapist was on the subject´s side, with his knee below the subject's head, bringing stability. One hand was placed on the occipital, and the other hand was placed over the crossed hands of the subject
1629771|NCT02011464|Drug|Exparel|Exparel is infiltrated into posterior compartment for pain control
1629772|NCT02011464|Other|Saline|Saline is infiltrated into posterior compartment for control
1629773|NCT02011451|Drug|95% Pure ECGC capsules 200mg|Theaphenon 95% 95% Pure EGCG
1629774|NCT02011451|Drug|Placebo Comparator:|
1629775|NCT02011438|Behavioral|UTalk|Prevention intervention delivered in group format adapted from IPT-AST, for adolescents who experience peer victimization and who are at risk for developing social anxiety and depression.
1629776|NCT02011425|Device|mandibular advancement appliance|mandibular advancement appliance
1629777|NCT02011399|Procedure|Brain Computer Interface for Mu Rhythm|"Device: Brain Computer Interface Subjects will wear an EEG (electrode) cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate a computer. Subjects will be asked to participate in 4-20 sessions.
Arms: Brain Computer Interface Keyboard"
1629778|NCT02011386|Drug|Treatment|
1629779|NCT02011373|Procedure|fixation technique using a sterile synthetic liquid tissue glue: IFABOND™|
1629780|NCT02011360|Other|Low Carbohydrate diet|Low carbohydrate diet: 15%carb; 65%fat; 20% protein
1629781|NCT02011360|Other|Low Fat diet|Low Fat diet: 65%carb; 15%fat; 20% protein
1629782|NCT02011347|Drug|Ketamine|
1629783|NCT02011347|Drug|Placebo|
1629784|NCT02011334|Drug|tocilizumab [RoActemra/Actemra]|162 mg will be administered once weekly by subcutaneous injection.
1629785|NCT02011321|Drug|clevidipine|clevidipine infusion x4 hours
1629786|NCT02011308|Device|Green light Laser|Laser vs TURP
1629787|NCT02011308|Device|Transurethral Resection of the Prostate (TURP)|Laser vs TURP
1629788|NCT02011295|Procedure|ankle arthroscopy with debridement and microfracture of the OLT|ankle arthroscopy with debridement and microfracture of the OLT
1629789|NCT02011295|Other|Bone Marrow Aspirate injection|
1629790|NCT02011282|Other|Patients will receive daily sessions of electro-neuro-stimulation in the quadriceps muscle for 10 days|
1629791|NCT02011269|Biological|Trichuris Suis Ova|
1629792|NCT02011256|Device|Implantable loop-recorder|All patients not diagnosed with atrial fibrillation with regular ECG or 72-hour Holter-monitoring will receive an ILR for 3 years.
1629793|NCT02011230|Other|Hoist Group|Hoist is a commercially available drink that is sold locally. This solution is isotonic meaning that it contains similar concentrations of salt and sugar that are found in the human body
1629794|NCT02011217|Other|Rye crisp bread A|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
1629795|NCT02011217|Other|Rye crisp bread B|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
1629796|NCT02011217|Other|Wheat crisp bread C|In a randomized cross-over design each subject receive one of three iso-caloric breakfasts on three different occasions, separated by 1 week wash-out period.
1629797|NCT02011204|Device|Electrical impedance myography (EIM)|"In EIM, high-frequency alternating electrical current is applied to localized areas of muscle via surface electrodes and the consequent surface voltage patterns analyzed.
EIM is very sensitive to the compositional and structural elements of muscle. Data from both human subjects and animal disease models, including ALS, spinal muscular atrophy (SMA), and Duchenne muscular dystrophy (DMD), show that EIM may be sensitive to a variety of pathological states. It is anticipated that EIM will thus likely be able to assist in quantifying the severity of the disease affecting various muscle groups as well as in measuring changes in the disease over time."
1629798|NCT02011191|Dietary Supplement|Biotin Supplementation|10,000 micrograms biotin supplement daily for 8 weeks
1629799|NCT02011191|Dietary Supplement|Sugar Pill|Identical sugar pill, identical bottle as the biotin supplementation group
1629800|NCT02011178|Procedure|Optimal medical treatment and surgery|
1629801|NCT02011178|Procedure|Optimal medical treatment|
1629802|NCT02011165|Procedure|Positioning measuring device|A tennis ball in the night shirt will prevent supine position during sleep.
1629803|NCT02011139|Behavioral|Cognitive-behavioral group therapy|
1629804|NCT02011126|Drug|imetelstat sodium|Given IV
1629809|NCT02011087|Procedure|bioelectric impedance analysis|Undergo bioelectric impedance analysis
1629810|NCT02011048|Procedure|Endoscopic components separation|Endoscopic components separation hernia repair
1629811|NCT02011022|Drug|3g MTX|The group of patients which are treated with 3g/m2 MTX, low risk ALL or NHL
1629812|NCT02011022|Drug|5g MTX|The group of patients which are treated with 5g/m2 MTX, they are high or middle risk ALL patients
1629813|NCT02011009|Other|HIV seropositive patients|During a routine visit, a self-administered anal swab will be proposed as well as an anonymous questionnaire about sexual practices. In addition to usual outpatient treatment an examination and an evaluation of a possible sexually transmitted infection (STI) will be realized. Some questions about risk factors traditionally associated with carriage of resistant bacteria will also be investigated with the aid of the questionnaire such as: use of antibiotics during the year, travel in areas at risk.
1629814|NCT02010996|Procedure|vacuum assisted closure|Vacuum assisted closure (also called vacuum therapy, vacuum sealing or topical negative pressure therapy) is a sophisticated development of a standard surgical procedure, the use of vacuum assisted drainage to remove blood or serous fluid from a wound or operation site.
1629815|NCT02010996|Procedure|Axillary dissection|Axillary dissection is a surgical procedure that incises (opens) the armpit (axilla or axillary) to identify, examine, or remove lymph nodes (small glands, part of the lymphatic system, which filters cellular fluids).
1629816|NCT02010983|Other|chromoendoscopy|chromoendoscopy (lugol stain and virtual chromoendoscopy)
1629817|NCT02010970|Drug|Group 1 AZD3293|AZD3293 oral solution
1629818|NCT02010970|Drug|Group 2 AZD3293|AZD3293 oral solution
1629819|NCT02010970|Drug|Group 3 AZD3293|AZD3293 oral solution
1629820|NCT02010970|Drug|Group 1 Itraconazole|itraconazole capsule
1629821|NCT02010970|Drug|Group 2 Diltiazem|Diltiazem ER tablet
1629822|NCT02010970|Drug|Group 3 Midazolam|midazolam syrup
1629823|NCT02010957|Other|FDG positron emission tomography|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
1629824|NCT02010957|Other|Iodometomidate imaging|2 consecutive imaging studies (diagnostic study) within 1-2 weeks: FDG-PET and 123I-Iodometomidate imaging in patients with an indeterminate adrenal neoplasm
1629825|NCT02010944|Drug|solifenacin succinate|oral
1629826|NCT02010944|Drug|mirabegron|oral
1629827|NCT02010944|Drug|mirabegron/solifenacin succinate|oral
1629828|NCT02010918|Drug|glucosamine sulfate /chondroitin sulfate - capsules|500 mg glucosamine sulfate + 400 mg chondroitin sulfate - capsules; One capsule, three times daily.
1629829|NCT02010918|Drug|glucosamine sulfate /chondroitin sulfate - sachet|1500 mg glucosamine sulfate / 1200 mg chondroitin sulfate - sachet; One sachet preparation, once daily.
1629830|NCT02010918|Drug|Cosamin DS®|500 mg glucosamine hydrochloride + 400 mg chondroitin sulfate - Capsules; One capsule, three times daily.
1629831|NCT02010905|Drug|Losartan|
1629832|NCT02010905|Drug|Placebo|
1629833|NCT02010892|Procedure|Stent Grafting (ESR)|
1629834|NCT02010892|Procedure|Open Surgery (OSR)|
1629835|NCT02010866|Behavioral|counseling|in-person counseling through RFWP offered to distressed respondents on the ISP
1629836|NCT02010853|Other|IRMf|"evaluation in resting state fMRI during three successive visits:
During the acute phase within 24 hours
In 72 hours
In 3 months"
1629837|NCT02010840|Behavioral|Psychoeducation program|
1629838|NCT02010827|Biological|isoglycemic intravenous glucose infusion and Glucagon infusion, day C|Infusion of 0.8ng/kg/min glucagon from time 0-25min
1629839|NCT02010827|Biological|Oral glucose tolerance test, day A|
1629840|NCT02010827|Biological|intravenous iv glucose infusion, day B|
1629841|NCT02010801|Procedure|irreversible electroporation|
1629842|NCT02010801|Device|nanoknife AngioDynamics US Ltd|
1629843|NCT02010788|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for Neurogenic Detrusor Overactivity or Overactive Bladder as per local standard of care in clinical practice.
1629844|NCT02010775|Biological|botulinum toxin Type A|Botulinum toxin Type A (BOTOX®) administered intramuscularly to the bilateral masseter muscles on Day 1 and retreatment at Day 180 if applicable.
1629845|NCT02010775|Drug|Normal saline|Normal saline (placebo) administered intramuscularly to the bilateral masseter muscles.
1629846|NCT02010762|Drug|Vitamin D|25.000 IU oral drops
1629847|NCT02010762|Drug|Placebo|placebo oral drops
1629848|NCT02010736|Other|Single treadmill gait training with additional loading|
1629849|NCT02010723|Procedure|surgery|crossectomy and avulsion of the varicose anterior accessory great saphenous vein (AAGSV) under local anesthesia
1629850|NCT02010723|Drug|sclerotherapy with aethoxysclerol foam|foam sclerotherapy with aethoxysclerol foam
1629851|NCT02010710|Device|INFANT software|The decision-support software to be evaluated in INFANT has been designed to run on the K2 data collection system (Guardian®). The data collection system (Guardian®) is a system for managing information from labour monitoring. It displays the CTG on a computer screen alongside other clinical data which are collected as part of routine clinical care. As such, it replaces conventional paper labour notes, the CTG machine and other recording systems for documenting care during labour.
1629852|NCT02010697|Behavioral|Messages targeting nonsmokers|
1629853|NCT02010697|Behavioral|Messages targeting smokers|
1629854|NCT02010684|Behavioral|Empowerment and CBT Classes|"Participants randomized to the intervention arm will receive a manual with 3 CBT modules and 1 Diabetes Empowerment module. CBT Module 1 covers Understanding Depression and Diabetes, Module 2 How Thoughts Affect Your Mood and Diabetes Care, Module 3 How Activities Affect Your Mood and Diabetes Care. The Diabetes Empowerment Module covers topics including the following: food, exercise, medicine, diabetes and your health, social support, communication skills, and community resources."
1629855|NCT02010671|Other|Survey|Survey
1629856|NCT02010658|Other|Cognitive Aid|
1629857|NCT02010645|Drug|Eltrombopag|Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
1629858|NCT02010645|Drug|Decitabine|Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.
1630171|NCT02008110|Drug|CA125 guided strategy|Consider statins in all patients in the active arm
1629859|NCT02010632|Drug|Generic clopidogrel product Apolets®|"Clopidogrel 75 mg once daily for 7 days
Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
1629860|NCT02010632|Drug|Original clopidogrel product Plavix®|"Clopidogrel 75 mg once daily for 7 days
Blood collection at 0 (before dosing), 1, 2, 4, 6, 8, 12, 24 hours after the last dose, administered at day 7"
1629861|NCT02010619|Behavioral|Cognitive behavior therapy|
1629862|NCT02010619|Behavioral|Supportive therapy|
1629863|NCT02010606|Biological|Dendritic cell vaccination, in addition to standard temozolomide chemotherapy and involved field radiation therapy|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. In addition to the investigative treatment, patients with newly diagnosed glioblastoma will receive standard temozolomide chemotherapy and radiation treatment, with the vaccine Induction phase beginning at the conclusion of radiation.
1629864|NCT02010606|Biological|Dendritic cell vaccination, with optional bevacizumab treatment for patients previously treated with bevacizumab|Patients will receive a series of four vaccines given weekly during the Induction phase, followed by vaccinations every 8 weeks during the Maintenance phase for as long as patients remain on the study or until the vaccine supply is depleted. Patients with recurrent glioblastoma will not receive additional treatment other than the investigative treatment as long as they remain on study, unless they were previously treated with bevacizumab, in which case they will be allowed to continue receiving bevacizumab
1629865|NCT02010593|Drug|Dapivirine Vaginal Ring|Dapivirine, a non-nucleoside reverse-transcriptase inhibitor (NNRTI), is a substituted amino- pyrimidine (DAPY) derivative with potent antiviral activity against HIV-1. Dapivirine is chemically described as 4-[[4-[(2,4,6-trimethylphenyl)amino]-2- pyrimidinyl]amino]benzonitrile.6 The dapivirine matrix VR is a flexible ring containing 25 mg of drug substance dispersed in a platinum-catalyzed-cured silicone matrix. Dapivirine is known to be well-suited for delivery via VR,
1629866|NCT02010593|Drug|Placebo Vaginal Ring|The placebo VR is a flexible, platinum-catalyzed-cured silicone matrix ring, identical to dapivirine Ring-004, containing no active drug.
2011524|NCT02508129|Behavioral|Enhanced Usual Care|Participants randomized to EUC will complete the standard panel of self-report assessments and home blood pressure monitoring at baseline. The study team will generate an individualized report based, which will be sent to the participant and physician. The report will also contain publically-available educational resources (websites, books) and contact information for treatment resources. Participants in EUC will be given a link to a website containing an educational video on insomnia and its treatment, produced by Emmi Solutions, Inc. Participants in EUC will complete outcome assessments on the same schedule as participants in the other conditions. Participants who complete the EUC intervention will be offered the CBT-I/ SHUTi intervention following study completion.
2011525|NCT02508155|Biological|MEDI7352 for IV infusion|MEDI7352 for IV infusion
2011526|NCT02508155|Biological|Placebo for IV infusion|IV Placebo infusion
2011527|NCT02508155|Biological|MEDI7352 for Subcutaneous Injection|MEDI7352 for subcutaneous injection
1629871|NCT02010554|Behavioral|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
1629872|NCT02010554|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
1629873|NCT02010502|Dietary Supplement|Beetroot juice|
1629874|NCT02010502|Dietary Supplement|Beetroot powder|
1629875|NCT02010502|Dietary Supplement|Placebo|
1629876|NCT02010489|Other|12 week Exercise Program|Patients will be provided with a tour of the Reh-Fit Centre, exercise prescription, and supervised exercise session. The exercise prescription consists of 3 weekly 60-minute sessions, each with 10 minutes warm-up, 30 minutes endurance, 20 minutes strength training and 5 minutes cool-down. The program is overseen by an accredited Exercise Physiologist. Initial exercise intensity is determined by the kinesiologist and based on the patient's baseline fitness level. Goal intensity of endurance activity is based on the heart rate reserve (HRR) method. This is captured with a heart rate monitor at initial assessment and recorded on exercise logs. There are check-ins at each exercise session to determine progress (time, reps, weight, sets, etc). Endurance activities include treadmill, elliptical, walking, and aerobics. Strength training includes upper body, lower body, and trunk circuits. Patients will be asked to attend three weekly sessions at the Reh-Fit Centre.
1629877|NCT02010463|Other|Exercise|
1629878|NCT02010450|Other|Wearable Blanket (Sleep Sack)|
1629879|NCT02010450|Other|Incentive Item|
1629880|NCT02010437|Drug|Sodium Tetradecyl Sulphate (STS)|
1629881|NCT02010424|Other|control group|standard IVF protocol
1629882|NCT02010424|Device|Primo Vision embryo culture dish (CE labeled, Vitrolife)|
1629883|NCT02010411|Drug|Prolastin (drug)|Outcomes compared to saline or no intervention in each subject.
1629884|NCT02010398|Other|Cross-Training healthy subjects|The phase of intervention will consist of a 6-week cross-training of the stronger limb employing an isokinetic contraction regimen at maximal intensity.
1629885|NCT02010398|Other|Cross-Training multiple sclerosis|The phase of intervention will consist of a 6-week cross-training of the less-impaired limb employing an isokinetic contraction regimen at maximal intensity.
1629886|NCT02010398|Other|Standard-training multiple sclerosis|The phase of intervention will consist of a 6-week standard strength training of the more-impaired limb employing an isokinetic contraction regimen performed at maximal intensity.
1629887|NCT02010385|Drug|Octreotide|
1629888|NCT02010385|Drug|Saline|
1629889|NCT02010372|Other|Reminder Recall Report|Practices (administrators) that are randomized to this intervention will receive training in how to run reminder recall reports for patients due to receive any dose of HPV vaccine. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
1630172|NCT02008110|Drug|CA125 guided strategy|Consider omega-3 polyunsaturated fatty acids in the active arm
1658941|NCT01785810|Drug|Maraviroc 300 mg|
2011528|NCT02508155|Biological|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
2011529|NCT02508246|Drug|Cisplatin|Given IV
2011530|NCT02508246|Drug|Docetaxel|Given IV
2011531|NCT02508246|Other|Laboratory Biomarker Analysis|Correlative studies
1629890|NCT02010372|Other|Audit-Feedback/Immunization Forecasting Reports|Practices (administrators) that are randomized to this intervention will receive training in how to run audit-feedback/immunization forecasting reports for patients due to receive any dose of HPV vaccine and to determine the % of patients in their practice who have received at least one dose of HPV vaccine within the study period. After the training has been completed, administrators will be asked to continue running regularly scheduled reports over the course of one year. A tracking log will be sent regularly to the research team.
1629891|NCT02010359|Drug|Lovaza|
1629892|NCT02010359|Drug|Placebo|
1629893|NCT02010346|Procedure|Early headgear treatment|The treatment with headgear is done as early treatment, beginning at ages 7-8 (Arm 1), or later, durning the maximal growth (arm 2)
1629894|NCT02010333|Drug|Ha44 Gel 0.74% w/w|
1629895|NCT02010320|Other|Computer dosing|Pharmacokinetic population model for individual dose estimations of tacrolimus based on concentrations measurements and inclusion of relevant covariates
1629896|NCT02010320|Other|Standard dose determination|Tacrolimus dose determination according to trough concentrations and standard TDM at the clinic
1629897|NCT02010307|Other|blood extraction|6 ml blood extraction from each patients in all 3 arms of the study
1629898|NCT02010294|Genetic|DNA samples, GAS strains|DNA samples,GAS strains
2011532|NCT02508246|Other|Pharmacological Study|Correlative studies
1629900|NCT02010268|Other|Collection of stool samples|A stool sample will be collected once a week from birth until discharge from the hospital, and every day during digestive episodes, that is to say during an interruption of enteral nutrition for more than 48 hours.
1629901|NCT02010255|Drug|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
1629902|NCT02010255|Drug|RBV|RBV tablets administered orally in a divided daily dose
1629903|NCT02010242|Drug|GKT137831|1 capsule of 100 mg twice a day for the first 6 weeks of treatment, and 2 capsules of 100 mg twice a day for next 6 weeks of treatment
1629904|NCT02010242|Drug|Placebo|1 capsule of Placebo, twice a day, oral treatment self-administered by the patient for the 12 weeks of treatment.
1629905|NCT02010216|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg by intravenous infusion every 4 weeks
1629906|NCT02010203|Biological|HS-410|Vaccine derived from irradiated cancer cells genetically engineered to continually secrete gp96
1629907|NCT02010203|Biological|Placebo|Injection containing sterile solution but no cells
1629908|NCT02010203|Biological|BCG|Vaccine derived from a live bacterium
1629909|NCT02010164|Dietary Supplement|Co-enzyme Q10|600mg for 3 months
2011533|NCT02508246|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1629911|NCT02010138|Procedure|small-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 0.75-disc diameter radius (1.5-disc diameter in total) centering at the center of the macular hole.
1629912|NCT02010138|Procedure|large-extent peeling|The internal limiting membrane was peeled in round shape with the radius of 1.5-disc diameter radius (3.0-disc diameter in total) centering at the center of the macular hole.
1629913|NCT02010112|Other|Breath Test Collection bags|Breath Collection bags will be used to collect breath of subjects before and after ingestion of 13-C breath test substrate
1629914|NCT02010099|Drug|PP110 Gel|
1629915|NCT02010099|Drug|PP110 Medicated wipes|
1629916|NCT02010099|Drug|Preparation-H Cream|
1629917|NCT02010086|Behavioral|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes, implementing the CBT manual for children with ASD (Wood et al., 2007).
1629918|NCT02010086|Behavioral|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to provide a standard community therapy treatment.
1629919|NCT02010060|Behavioral|Aerobic Exercise Training|Individuals randomized to the aerobic exercise training group will participate in 6 months of supervised exercise training. Exercise dose (expressed in kilocalories per kg per week [KKW]) during aerobic training will be 8KKW in week 1, 10KKW in week 2 and 12 KKW in week 3. the exercise dose of 12KKW will be maintained throughout the intervention. Pedometers will be worn by participant in blind-mode throughout the intervention, and removed during exercise training sessions. Participants will enter information about whether they wore their pedometer on the study website. Aerobic exercise group participants will be told to make no conscious alterations to their physical activity or dietary habits
1629920|NCT02010060|Behavioral|Aerobic Exercise+ Physical Activity|The Aerobic Exercise+ Physical Activity Group will participate in the same supervised exercise training intervention as the Aerobic Exercise Group, but will also increase the amount of non-exercise physical activity in their daily lives. After week 6 of intervention, participants will incrementally increase Non-Ex PA until they reach an average of 3,000 steps/day above baseline. Non-Ex PA will be increased with moderate physical activity consistent with daily living (i.e. leisurely walking in the evening, walking the dog etc.). Participants will also periodically have life-style counseling sessions with instructors with expertise in behavioral change support to their dietary habits
1629921|NCT02010047|Device|ALK qPCR assay|72 IHC ALK-negative and 72 IHC ALK-positive FFPE samples will tested with FISH and qPCR to determine the sensitivity and specificity of the ALK qPCR assay.
1629922|NCT02010034|Drug|Omegaven|Omegaven will be used in place of soy oil Intralipid
1629923|NCT02010021|Drug|Letrozole|Patients will receive Letrozole for 10-21 days prior to surgical resection of tumor tissue. This tissue will be used ex-vivo to study cell growth signaling pathway. The results will be compared to arm of the study with no intervention.
1629924|NCT02010008|Behavioral|Motivational Interviewing Intervention|An individual-level intervention that implements a motivational interviewing intervention led by a promotora
1629968|NCT02009566|Radiation|Abdominal radiographs with microfabricated tags|Subjects will have 2 x-rays of their lower thorax/ abdomen taken. For each x-ray, a microfabricated tag or no tag will be placed in a different position. The x-rays will take approximately 15 minutes to complete.
1629969|NCT02009553|Other|Information sheet|
1629970|NCT02009553|Other|No information sheet|
1630258|NCT02007408|Drug|Paracervical block|
2011534|NCT02508246|Drug|WEE1 Inhibitor AZD1775|Given PO
2011535|NCT02508194|Biological|MEDI7510|RSV sF antigen plus adjuvant
2011536|NCT02508194|Biological|IIV|Marketed Inactivated Influenza Vaccine
1629925|NCT02009995|Behavioral|Aerobic Training (AT)|All subjects will participate in a 10-week ramp-in period with the goal of achieving 150 minutes of moderate-to-vigorous physical activity per week. Walking and jogging will be the primary modes of achieving the prescribed aerobic activity as these are the modes of aerobic exercise that are most accurately recorded by an accelerometer. Subjects will use the Rate of Perceived Exertion (RPE) to guide aerobic exercise intensity. Aerobic activity will be objectively monitored by the Technogym MyWellness Key (MWK) accelerometer, which is a lightweight device worn on the waistband.
1629926|NCT02009995|Behavioral|AT plus Primarily Home-Based Resistance Band Training|"The bands + AT group will engage in RBT 3 times per week, progressing to 3 sets of 10-15 repetitions of 12 exercises. The exercises will be: chair squat, sitting chest press, seated rear fly, seated row, overhead press, lateral raise, biceps curl, triceps extension, leg extension, hamstring curl, gluteal extension, and abdominals. The resistance band exercise sessions will be between 25-60 minutes.
Participants in this group will attend supervised group sessions weekly in weeks 1-4, every 2 weeks in weeks 5-8, and every 4 weeks thereafter to ensure proper form and appropriate progression. Participants in this group will be responsible to complete all remaining sessions (a total of 3 per week, including supervised sessions) at home on their own time."
1629927|NCT02009982|Procedure|Cardioneuroablation|Catheter Ablation of Vagal Inputs in Left Atrium
1629928|NCT02009982|Device|Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter|This is the device that will be used to perform the Cardioneuroablation procedure
1629929|NCT02009956|Device|Subjects receiving DESyne Novolimus Eluting CSS - Arm A|
1629930|NCT02009956|Device|Subjects receiving DESyne BD Novolimus Eluting CSS - Arm B|
1629931|NCT02009943|Drug|Ferric carboxymaltose|
1629932|NCT02009943|Drug|Iron sucrose|
1629933|NCT02009878|Drug|tolvaptan|Subjects will receive a single dose of 3.75, 7.5 or 15 mg of tolvaptan on study Day 1
1629934|NCT02009865|Drug|Epanova|Epanova will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
1629935|NCT02009865|Drug|Olive Oil|Olive oil will be provided in 1 g polyacrylate-coated soft gel capsules. Two capsules will be taken once per day, without regard to meals, for 12 weeks. At clinic visits, study drug will be administered at the clinic after fasting blood draws are complete.
1629936|NCT02009839|Behavioral|Meeky Mouse program|
1629937|NCT02009839|Other|Computer Games|
1629938|NCT02009826|Radiation|[18F]-PBR111 Positron Emission Tomography (PET)|[18F]-PBR111 radioligand to assess binding to TSPO
1629939|NCT02009826|Behavioral|Cognitive and psychomotor tasks|Cognitive and psychomotor tasks on digitizing tablet
1629940|NCT02009826|Biological|Blood sampling|Blood sampling for peripheral inflammatory and neurotoxicity markers
1629941|NCT02009813|Procedure|Hyperbaric Oxygen Therapy|Participants will undergo 2 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere. During this time, patients will be treated with 100% oxygen delivered via a hood system.
1629942|NCT02009800|Biological|Quadrivalent HPV vaccine|One dose of Gardasil administered in the intervention group
1629943|NCT02009787|Drug|vitamin D3 tablets|2000 IU vitamin D3 tablets were taken daily for 6 months
1629944|NCT02009787|Drug|placebo tablets|2000 IU placebo tablets were taken daily for 6 months
1629945|NCT02009774|Procedure|NBI Function|
1629946|NCT02009761|Drug|BI 655064|subcutaneous injection
1629947|NCT02009748|Dietary Supplement|Vitamin D supplementation|oral administration of colecalciferol 2.800 IU once daily
1629948|NCT02009748|Dietary Supplement|Placebo|oral administration of placebo (vehicle) once daily
1629949|NCT02009735|Device|virosensor|"virosensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-influenza-virus (or anti-EV71-virus) and its influenza virus antigen (or EV71 antigen) present in patients and normal samples.
The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
1629950|NCT02009722|Drug|Morphine|Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
1629951|NCT02009722|Drug|Hydromorphone|Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
1629952|NCT02009709|Drug|Riboflavin 0.1% ophthalmic solution|Instillation of 0.1% riboflavin ophthalmic solution, one drop every 3 minutes for 30 minutes before the procedure and one drop every 3 minutes during the procedure.
1629953|NCT02009709|Device|CCL-VARIO UV lamp|Application of ultraviolet light on the eye to be treated at an irradiance of 9 mW/cm2 for 10 minutes
1629954|NCT02009709|Device|CCL-VARIO at 18 mW/cm2|Application of ultraviolet light on the eye to be treated at an irradiance of 18 mW/cm2 for 5 minutes.
1629955|NCT02009696|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
1629956|NCT02009696|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of heart/chest or thoracic spine.
1629957|NCT02009670|Dietary Supplement|13C inulin|Oral 13C inulin
1629958|NCT02009670|Other|Placebo|Oral maltodextrin
1629959|NCT02009644|Device|Subjects who receive the Treovance stent-graft|Eligible subjects will be implanted with the Treovance Stent-Graft
1629960|NCT02009631|Drug|Veliparib (ABT-888)|
1629961|NCT02009631|Drug|Placebo|
1629962|NCT02009618|Drug|Rifaximin|Rifaximin tablet is given as 200 mg 3x2/daily, for 10 days.
1629963|NCT02009618|Drug|placebo|
1629964|NCT02009605|Drug|Icotinib|125mg, oral administration, three times per day.
1629965|NCT02009592|Drug|Rifaximin|Both arms receive Rifaximin
1629966|NCT02009579|Drug|Nintedanib|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and Nintedanib 200 mg BID followed by Nintedanib maintenance until progression or for a total maximum duration of 120 weeks.
1629967|NCT02009579|Drug|Placebo|Subjects will receive 6 cycles of 3-weekly carboplatin (AUC 5) + paclitaxel (175 mg/m2) and placebo 200 mg BID followed by placebo maintenance until progression or for a total maximum duration of 120 weeks.
1630134|NCT02008422|Drug|Endostar injection|7.5 mg/m2/d, 2 mL/h continuous pumping into vein, d1-10, 21 d as a cycle.
1629971|NCT02009540|Drug|Botulinum toxin injected to bladder body|arm will receive 100u of onaBoNT-A in 20x1ml aliquots (5u/ml). 20 injections will be given into the bladder wall, sparing the trigone. Injections will be given through all layers of the bladder eg suburothelially and intradetrusor. The intervention will be performed under local anaesthetic using a flexible cystoscope.
1629972|NCT02009540|Drug|Botulinum toxin injected into trigone|Arm B will receive 100u onaBoNT-A injected into 10x1ml suburothelial peri-trigonal sites (aliquot dose 10u/ml). The procedure will be performed under local anaesthetic by flexible cystoscopy.
1629973|NCT02009527|Drug|N-hydroxy-nor-arginine|
1629974|NCT02009527|Drug|NaCl|
1629975|NCT02009514|Other|Glucose-containing compared to glucose-free hemodialysate|Comparison of effects on glucose variation
1629976|NCT02009501|Device|VAC VeraFlo with Dakins Instillation|VAC VeraFlo with Dakins instillation will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
1629977|NCT02009501|Device|VAC Ulta Therapy|VAC ULTA will be placed in the operating room after surgical debridement. Biopsies will be obtained prior to surgical debridement, after surgical debridement, on day 4, and on day 7.
1629978|NCT02009488|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
1629979|NCT02009488|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
1629980|NCT02009488|Drug|Placebo|One placebo capsule (inactive medication) once daily.
1629981|NCT02009475|Other|Interval exercise training|
1629982|NCT02009475|Other|Continues aerobic training|
1629983|NCT02009462|Drug|Artefill dermal filler|Four treatment visits will be scheduled at baseline and at weeks 4, 12, and 24. Each treatment session will utilize no more than 8 mL of Artefill and no more than 30 syringes of Artefill.
1629984|NCT02009449|Drug|AM0010|Daily subcutaneous injections of AM0010 up to 12 months
1629985|NCT02009449|Drug|Paclitaxel or Docetaxel and Carboplatin or Cisplatin|Day 1 of every 21 day cycle
1629986|NCT02009449|Drug|FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)|Intravenous administration on Day 1 and 2 of every 14 day cycle
1629987|NCT02009449|Drug|gemcitabine/nab-paclitaxel|Intravenous administration of the gemcitabine/nab-paclitaxel regimen on Day 1, 8 and 15 of each 28 day treatment cycle.
1629988|NCT02009449|Drug|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
1629989|NCT02009449|Drug|Pazopanib|Pazopanib will be administered orally daily continuously
1629990|NCT02009449|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously on Day 1 of every 21 day cycle.
1629991|NCT02009449|Drug|Paclitaxel|"Paclitaxel will be administered intravenously on Days 1, 8, 15 of each cycle (28 days= 1 cycle)
• Paclitaxel 80 mg/ m2 IV"
1629992|NCT02009449|Drug|nivolumab|Nivolumab on Day 1 of each cycle (14 days = 1 cycle)
1629993|NCT02009449|Drug|Gemcitabine/carboplatin|gemcitabine and carboplatin on Days 1, 8 of each cycle (21 days = 1 cycle)
1629994|NCT02009436|Drug|Azacitidine|Given via nebulizer
1629995|NCT02009436|Other|Laboratory Biomarker Analysis|Correlative studies
1629996|NCT02009436|Other|Pharmacological Study|Correlative studies
1629997|NCT02009423|Drug|Masitinib|
1629998|NCT02009423|Drug|Placebo|
1629999|NCT02009410|Drug|Creon|Creon 25000 (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
1630000|NCT02009410|Drug|Creon 25000 matching Placebo|Creon 25000 placebo matching capsules (2 capsules per meal 3 times per day and 1 capsule/snack 2 times per day) during 12 weeks
1630001|NCT02009397|Drug|Ipilimumab|
1630002|NCT02009397|Drug|GM-CSF|
1957971|NCT02086552|Other|Laboratory Biomarker Analysis|Correlative studies
1630004|NCT02009371|Device|Bright Light therapy|In this group, participants will be exposed to the LED treatment device (lightbox) which delivers bright light and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
1630005|NCT02009371|Device|dim Red Light therapy|In this group, participants will be exposed to the same LED treatment device (light box) which delivers dim red light,which is considered to be biologically inactive, and meanwhile medicated with just one particular antipsychotics drug(a mood stabilizer or an atypical antipsychotic drug)except of antidepressants.
1630006|NCT02009358|Other|mental health promotion|
1630007|NCT02009332|Drug|ABI-009|
1630008|NCT02009306|Drug|PecFent and Epistatus|"PecFent will be supplied by Archimedes Pharma as two strengths of nasal spray solution at 1000 or 4000 mcg/mL fentanyl (as citrate). One spray contains 100 mcg or 400 mcg fentanyl (as citrate). Each bottle contains 1.55 ml ensuring delivery of 8 sprays of 100 or 400 mcg fentanyl (as citrate). PecFent is a commercially available product and packaging will be in accordance with the manufacturing authorisations (EU/1/10/644/001, EU/1/10/644/002, EU/1/10/644/005, EU/1/10/644/003, EU/1/10/644/004, EU/1/10/644/006).
Epistatus will be supplied by Special Products Ltd. as buccal solution, packed in bottles containing solution for up to 4 x 1 ml doses, as per Specials licence. A pack also includes 4 x oral syringes used to administer the solution to the buccal cavity on either side of the mouth."
1630009|NCT02009306|Drug|Standard subcutaneous medication|"Subcutaneous as needed medication will include:
Opioids for pain or dyspnoea
Diamorphine
Oxycodone
Fentanyl
Benzodiazepine and / or anti-psychotic for agitation
Midazolam
Levomepromazine
Haloperidol Anti-emetic for nausea
Cyclizine
Metoclopramide
Haloperidol
Levomepromazine
Anti-secretory drug for respiratory secretions
Glycopyrronium
Hyoscine butylbromide
Hyoscine hydrobromide"
1630010|NCT02009293|Other|Cough monitor|questionnaires about cough and quality of life
1630011|NCT02009280|Drug|Administration of anesthesia: Propofol|Maintenance of anesthesia with the propofol
1630012|NCT02009280|Drug|Administration of anesthesia: Sevoflurane|Maintenance of anesthesia with the sevoflurane
1630013|NCT02009267|Device|Patient controlled analgesia|A programable electronically controlled infusion pump that delivers an amount of intravenous analgesic when the patient presses a button.
1630014|NCT02009267|Procedure|Continuous thoracic epidural infusions|Continuous thoracic epidural infusions (TE) involves continuous infusion of drugs through a catheter placed into the epidural space, resulting in a loss of sensation—including the sensation of pain—by blocking the transmission of signals through nerve fibers in or near the spinal cord.
1630259|NCT02007408|Drug|Lidocaine spray|
1630015|NCT02009267|Procedure|Continuous paravertebral blockade|Continuous paravertebral blockade (PVB) is the technique of injecting local anesthetic adjacent to the thoracic vertebra that anesthetizes the spinal nerve roots after they exit the spinal canal.
1630016|NCT02009254|Other|Dietary treatment|
1630017|NCT02009241|Other|Pulmonary Rehabilitation|
1630018|NCT02009228|Procedure|Ovarian cystectomy|
1630019|NCT02009215|Drug|Dihydroartemisinin-piperaquine (DP)|Intermittent preventive treatment (IPT) with dihyroartemisinin-piperaquine (DP) will be delivered to participating students monthly, for up to 6 rounds of treatment during one school year. DP will be given once a day for 3 days, using full strength tablets (40/320mg) according to weight-based guidelines. Treatment will be directly observed, and will not be blinded.
1630020|NCT02009202|Drug|polyethylene glycol|
1630021|NCT02009202|Drug|picosulphate|
1630022|NCT02009189|Drug|2% Taurolidine Lock|Catheter lock with 2% Taurolidine
1630023|NCT02009189|Drug|1.35% Taurolidine|Catheter lock with 1.35% Taurolidine + citrate
1630024|NCT02009176|Procedure|Laparoscopic Anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group A is Laparoscopic Anatomical Hepatectomy: Anatomy the corresponding liver segment pedicle and hepatectomy along the Glisson fiber sheath
1630025|NCT02009176|Procedure|Laparoscopic Aon-anatomical Hepatectomy|We let the 110 patients divide into A, B groups randomly who are meet the inclusion criteria .Group B is Laparoscopic Aon-anatomical Hepatectomy:1 to 2 cm along the edge of the tumor complete hepatectomy
1630026|NCT02009163|Drug|Lisdexamfetamine dimesylate|SDP489 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
1630027|NCT02009163|Other|Placebo|Placebo capsule once per day (double-blind period)
1630028|NCT02009137|Device|EVERA|EVERA apply for 12 weeks
1630029|NCT02009137|Device|ESTES|ESTES apply for 12 weeks
1630030|NCT02009124|Biological|Autologous bone marrow mononuclear cell transplantation|Bone marrow is aspirated by a standard procedure. Mononuclear cells are separated by density gradient method and then injected intrathecally by a standard lumbar puncture procedure
1630031|NCT02009111|Behavioral|Couple CARE for Parents|Couple CARE for Parents is a skill-based relationship enhancement program based on a self-regulatory model. It consists of seven sessions and two follow-up booster sessions that occur over the baby's first eight months of life. The first home visit is scheduled 7 — 14 days following recruitment. The next two sessions are scheduled in two week intervals. Sessions 4 through 7 are scheduled in three week intervals. Home visits are expected to last 1.5 to 2 hrs. Out-of-session viewing of the video and completing the exercises typically requires 45 min to 1 hr. The typical phone consultation lasts 15- to 30- min per person. Thus, the program lasts a minimum of 8 to 12 hours. The program will also include two booster sessions (beyond the 8 — 12 hrs).
1630032|NCT02009098|Drug|Cefuroxime|iv Cefuroxime 1,5g administered 15-60 minutes before incision versus iv Cefuroxime 1,5g administered after umbilical cord clamping
1630033|NCT02009072|Procedure|Sutureless and glue free limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutureless and glue free conjunctival autograft in 50 eyes of 50 patients (group 1)
1630034|NCT02009072|Procedure|Sutured limbal conjunctival autograft|Simple pterygium excision under local anesthesia was performed then closure of the bare sclera by sutured limbal conjunctival autograft in 100 eyes of 100 patients (group 2).
1630035|NCT02009059|Device|Non-invasive temperature in hypothermia|accuracy of non-invasive temperature measurement in deep hypothermia compared to core temperature
2011537|NCT02508194|Other|Placebo|Sterile Saline
2011538|NCT02506153|Biological|Ipilimumab|Given IV
2011539|NCT02506153|Other|Laboratory Biomarker Analysis|Correlative studies
2011540|NCT02506153|Biological|Pembrolizumab|Given IV
1630040|NCT02009033|Drug|Lactated Ringer|When normovolæmic status of the patient is secured, 35 ml/kg of the allocated fluid is infused during the operation (estimated time for this type of operation is 180 minutes), however max. 3500 ml.Lactated Ringer is the interventional medication.
1630041|NCT02009033|Drug|Hydroxyethylstarch|
2011541|NCT02506153|Other|Pharmacological Study|Correlative studies
2011542|NCT02506153|Other|Quality-of-Life Assessment|Ancillary studies
1630044|NCT02008994|Other|Genomic and Proteomic Profiling|Following review of targets by the Treatment Selection Committee, the treating physician will decide whether to continue with planned therapy or alter the course of treatment based on the genomic results.
1630045|NCT02008981|Drug|Curcuma longa|Curcuma longa in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
1630170|NCT02008110|Drug|CA125 guided strategy|Up titration of loop diuretics according to plasma levels of CA125 in the active arm
2011543|NCT02506153|Biological|Recombinant Interferon Alfa-2b|Given IV and SC
2011544|NCT02507388|Drug|Brolucizumab 3 mg/50 μL|Administered as an intravitreal injection
2011545|NCT02507388|Drug|Brolucizumab 6 mg/50 μL|Administered as an intravitreal injection
2011546|NCT02503592|Other|Vestibular testing|Patients who have received a cochlear implant within 90 days, and had vestibular testing pre-operatively, will undergo post-op vestibular testing
2011547|NCT02502266|Drug|Cediranib Maleate|Given PO
2011548|NCT02502266|Other|Laboratory Biomarker Analysis|Correlative studies
1957972|NCT02086552|Drug|Lenalidomide|Given PO
2011549|NCT02502266|Drug|Olaparib|Given PO
2011550|NCT02502266|Drug|Paclitaxel|Given IV
2011551|NCT02502266|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
2011552|NCT02502266|Other|Questionnaire Administration|Ancillary studies
2011553|NCT02502266|Drug|Topotecan Hydrochloride|Given IV
2011554|NCT02501928|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 28 or 40 weeks
2011555|NCT02501928|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 28 or 40 weeks
2011556|NCT02501928|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 28 weeks
2011557|NCT02501928|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 28 weeks
2011558|NCT02501902|Drug|Palbociclib|Palbociclib oral dosing on Days 1 to 21 of each 28-day cycle.
1630046|NCT02008981|Drug|Angelica sinensis|Angelicae sinensis in capsule form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
1630047|NCT02008981|Drug|Siwu Tang|"TCM formulation Siwu Tang consisting of 4 herbs ( Ligustici chuangxiong, Angelicae sinensis, Rehmanniae praeparata and Paeoniae alba) in tablet form will be given with actual or placebo aspirin, each for a 3 week period. Clotting profile and platelet function test will be done before and after."
1630048|NCT02008981|Drug|Aspirin|Aspirin (enteric-coated) at 100mg daily will be given one of the actual herb or placebo herb, each for a 3 week period. Clotting profile and platelet function test will be done before and after.
1630049|NCT02008968|Drug|allopurinol 300 mg./day|
1630050|NCT02008968|Other|No intervention|
1630051|NCT02008968|Drug|Normouricemic|
1630052|NCT02008955|Dietary Supplement|Lysine intake provided as a milkshake|
1630053|NCT02008942|Drug|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 10 days
1630054|NCT02008942|Drug|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 10 days
1630055|NCT02008929|Biological|MG4101|Ex vivo expanded allogeneic NK cell
1630056|NCT02008916|Drug|Secukinumab|Eligible patients are randomised to each of the three treatment arms in a 1:1:1 ratio.
1630057|NCT02008916|Drug|Secukinumab|Eligible patients are randomised to each of the three treatment arms in a 1:1:1 ratio.
1630058|NCT02008916|Drug|Placebo secukinumab|Eligible patients are randomised to each of the three treatment arms in a 1:1:1 ratio.
1630059|NCT02008890|Biological|Secucinumab|Secucinumab will be used as 150 mg pre-filled syringes in a double-blinded fashion. Until Week 16 patients will perform a self-administration under the supervision of the investigator. After Week 16 patients will have regular office visits and apply the treatment under supervision of the investigator and in between office visits apply treatment at home. The investigator must emphazie compliance and instruct patients to take the treatment exactly as described.
1630060|NCT02008890|Drug|Placebo|matching placebo
2011559|NCT02501902|Drug|Nab-Paclitaxel|Nab-paclitaxel IV dosing on Days -2, 6, and 13 of Cycle 1, and on Days 1, 8, and 15 of subsequent cycles.
2011560|NCT02501408|Device|propriofoot prosthesis|Adaptation of the device and evaluation after 1 month at home using the studied device
1630063|NCT02008864|Drug|Senna|(7.5 mg of sennosoides A and B) Senna tablet/ 2 times per day
1630064|NCT02008864|Drug|Placebo|Placebo tablet/ 2 times per day
1630065|NCT02008851|Biological|Neo-kidney augment|Injection of 3.0 x 10e6 selected renal cells into the left kidney of the patient
1630066|NCT02008838|Dietary Supplement|Synbiotic|
1630067|NCT02008838|Dietary Supplement|Placebo|
1630068|NCT02008825|Device|Utilization of ViSiGi calibration tube|Utilization of ViSiGi calibration tube
1630069|NCT02008825|Device|Usual non suction Bougie|Usual non suction Bougie
1630070|NCT02008812|Device|Ad sensor|"Ad sensor, which was developed for the rapid and sensitive detection of viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-Adenovirus and its Adenovirus antigen present in patients and normal samples.
The system incorporates the use of chip formats. In antibody probing, antibodies are bound as a suitable probe, which specifically and selectively binds targeted molecules (virus antigen) in the test specimens."
1630071|NCT02008799|Procedure|Bone marrow stem cell injection|Injection should be in testis and testicular artery
1630072|NCT02008786|Drug|ramipril|5-10mg (starting dose 5mg titrating up to 10mg if tolerated after 1 week)
1630073|NCT02008786|Drug|rosuvastatin|10-20mg (suggested dose 10mg for Asians, 20mg for everyone else)
1630074|NCT02008786|Drug|placebo|Placebo
2011561|NCT02501954|Drug|Cisplatin|Given IV
2011562|NCT02501954|Drug|Carboplatin|Given IV
1630077|NCT02008760|Dietary Supplement|Omega Krill with D3|
1630078|NCT02008747|Drug|Magnesium sulphate|Continuous application of magnesium sulphate applied 40 mg/kg ideal body weight by bolus before the operation started, followed by a continuous infusion of 10 mg/kg ideal body weight/h for 24 hours
1630079|NCT02008734|Drug|PD0332991|
1630080|NCT02008721|Drug|EGCG as putative neuroprotective agent|Treatment with 800 mg - 1200 mg EGCG as putative neuroprotective agent
1630081|NCT02008721|Drug|Placebo|Placebo
1630082|NCT02008708|Behavioral|Livestock Microfinance|Participants randomized to the microfinance group receive the pig loan.
1630083|NCT02008708|Other|Delayed Control Group|Participants enrolled in delayed control receive their pig loan 12 months after the intervention group.
1630084|NCT02008695|Behavioral|adult microfinance|"Female piglet provided to household member. Participants agrees to repay their loan by giving two piglets (one to repay the loan and one for the interest on the loan) to the association from the first litter of piglets (on average 6-12 piglets). These piglets are then given to other village member households"
1630085|NCT02008695|Behavioral|Youth microfinance only|One child (10-15 years) receive rabbits loan. The child is mentored by microfinance and community mentors. The child repays the loan to program and other children in the family and community are provided a loan from the repayment.
1630086|NCT02008695|Behavioral|youth and adult micro finance|One child and adult member of household receive animal loan. The child and adult are mentored and repayment of the loan to the program is provided and the repayment animal is provided to other members of the community
1630087|NCT02008682|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily as add-on to the subject's stable pre-trial metformin dose.
1630088|NCT02008682|Drug|sitagliptin|Administered orally once daily as add-on to the subject's stable pre-trial metformin dose.
1630089|NCT02008669|Procedure|Blood sampling|A blood sample will be taken from each patient and the following parameters will be assessed : magnesium, albumin, Vitamin B12, Vitamin D, Calcium, Iron.
1630090|NCT02008669|Other|Gustatory sensitivity test using Taste strips|"16 Taste Strips impregnated with 4 flavors (sweet, sour, salty, bitter, each flavor present at 4 different concentrations), are offered to the patient one after the other in a so-called pseudorandomized sequence. The task of the patient is to choose one of the following answers: sweet / sour / salty / bitter / no taste.
Each correct answer is granted one point. In addition to the impregnated strips, two tasteless strips can be integrated in the examination at any point of time (no point)"
1660314|NCT01774474|Drug|Bevacizumab|
1630091|NCT02008669|Other|Questionnaires|"Evaluation of the following parameters by validated questionnaires (name of the questionnaire in bracket):
Fatigue (EMIF-SEP)
Dysphagia (DYMUS)
Food intake (semi-structured questionnaire)
Depression (BDI-II)
Daily energy expenditure (NAP)
Visual analog scale to study quality of sleep"
1630092|NCT02008656|Drug|Oxaliplatin (OXAL)|
1630093|NCT02008656|Drug|5-Fluorouracil (5-FU)|
1630094|NCT02008656|Drug|Leucovorin|
1630095|NCT02008656|Drug|Capecitabine (Xeloda®)|
1630096|NCT02008656|Radiation|intensity modulated radiotherapy (IMRT)|
1630097|NCT02008656|Behavioral|Quality of Life Questionnaires|
1630098|NCT02008656|Procedure|DRE-Endoscopy|
1630099|NCT02008643|Other|filling questionnary to quality of life|filling questionnary to quality of life
1630100|NCT02008630|Other|Animal-assisted activity|
1630101|NCT02008630|Other|Animal-assisted therapy|
1630102|NCT02008617|Drug|Bupivacaine|30mL of Bupivicaine 0.20% with epinephrine 1:300,000
1630103|NCT02008617|Drug|Preservative free normal saline|Ultrasound guided posterior genicular nerve infiltration posterior knee with 30mL of preservative free normal saline
1630104|NCT02008591|Procedure|Epidural Technique versus Dural Puncture Epidural Technique versus Combined Spinal Epidural Technique|Three different techniques, using the same medications (bupivacaine and fentanyl)
1630105|NCT02008578|Biological|Intravenous hyperimmune immunoglobulin (Flu-IVIG)|
1630106|NCT02008578|Biological|Placebo|
1630107|NCT02008565|Drug|Loperamide|Participants randomized to the loperamide group will begin with 2mg of loperamide/day. The participant will be administered the Patient Global Symptom Control rating scale (PGSC) to determine dose escalation. Participants who report inadequate control of stool leakage on the PGSC will be instructed to increase the daily dose of loperamide by 2 mg up to a maximum of 8 mg per day (1-4 capsules). Bothersome adverse events and resulting dose reduction will be based exclusively on the result of the Patient Global Tolerability Scale (PGTS). The daily dose will be decreased by 2mg to a minimum of 2mg every other day. If a PGSC score indicates inadequate control of stool leakage combined with a PGTS score indicating bothersome side effects, the participant will discontinue the study medication.
1630108|NCT02008565|Drug|Placebo|Participants randomized to the placebo arm will begin the a dose of one capsule per day and will be dose increased or dose decreased using the same algorithm described for the loperamide arm.
1630109|NCT02008565|Behavioral|Anal exercises with biofeedback|Participants will receive a formal anal exercises training program that can be easily applied in an office setting with minimal participant burden. Participants will attend six anal exercises with biofeedback sessions with trained personnel over a 12-week period for the 24-week study. Sessions will include introduction, standard patient education, and exercises using anal manometry-assisted biofeedback introducing concepts such as shaping, generalization and termination. The protocol uses strength and sensory training including urge resistance training. During the final twelve weeks, participants will perform anal exercises on their own. The sessions with interventionists will occur every other week for 12 weeks (total 6 supervised sessions).
1630110|NCT02008565|Behavioral|Usual Care|Usual care consists of patients receiving an educational pamphlet on fecal incontinence created by the National Institute of Diabetes and Digestive and Kidney Diseases.
1630111|NCT02008552|Genetic|Sampling of blood|Sampling of blood was taken and analyse to research factor genetic
1630112|NCT02008539|Drug|MSC_apceth_101|
1630113|NCT02008526|Behavioral|Text Messages Transmitted by Peer Health Educators (TXT-PHE)|"Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. Participants who respond to the pre-written text messages or initiate queries or requests for support (pull) are sent additional real-time messages back from the PHE. Text messages are transmitted and responded to in real time, at the peak hours of high-risk activities. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days."
1630114|NCT02008526|Behavioral|Text Messages Transmitted by Automation (TXT-Auto)|Participants receive five gay-specific, theory-based pre-written messages per day sent on a predetermined schedule. During the 8-week intervention, participants receive a brief weekly text-based assessment on their methamphetamine use and HIV sexual behaviors in the previous seven days.
2011563|NCT02501954|Drug|Paclitaxel|Given IV
1630117|NCT02008500|Other|placebo mouthwash|15 ml placebo mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
1630118|NCT02008500|Other|Herbal Mouthwash|15 ml Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
1630119|NCT02008500|Other|Non Herbal Mouthwash|15 ml Non Herbal mouthwash prescribed and VAS score assessed at Baseline, 3 weeks, 6 weeks and 12 weeks
1630120|NCT02008487|Other|Wound powder application|Powder application to wound per protocol.
1630121|NCT02008474|Behavioral|Online weight loss + incentives for behavior 3 months|Participants will receive monetary incentives for submitting their behavior change information into a study website
1630122|NCT02008474|Behavioral|Online weight loss + incentives for weight loss at month 3|Participants will receive an incentive for meeting their weight loss goal at month 3.
1630123|NCT02008474|Behavioral|Online weight loss + Incentives for behavior 12 months|Participants will receive incentives for submitting behavior change information over the course of 12 months.
1630124|NCT02008474|Behavioral|Online weight loss + Incentives for weight loss 12 months|Participants will be receive monetary incentives for reaching their weight loss goal at months 3 and 12.
1630125|NCT02008461|Procedure|radiofrequency ablation|
1630126|NCT02008461|Drug|botulinum toxin injection|
1630127|NCT02008448|Procedure|Pulmonary vein isolation|
1630128|NCT02008448|Procedure|Linear Lesion Ablation|
1630129|NCT02008448|Drug|BT injection|
1630130|NCT02008435|Behavioral|Enriched GLB|Habit formation techniques, namely if-then plans and their mental practice are being added to the standard Group Lifestyle Balance program.
1630131|NCT02008435|Behavioral|Standard GLB|This arm is the standard Group Lifestyle Balance program
1630132|NCT02008422|Drug|Oxaliplatin|130mg/m2 , iv, 3-4h, d1, 21 d as a cycle.
1630133|NCT02008422|Drug|Gimeracil and Oteracil Potassium Capsule|40 mg/m2, po., Bid., d1-14, 21 d as a cycle.
1661878|NCT01762319|Drug|Misoprostol|
1630135|NCT02008409|Device|EndoLift Liver Retractor|"During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends."
1630136|NCT02008396|Drug|Placebo|Subjects will receive capsules of lactose of identical appearance to MDMA capsules during each of two experimental sessions. Capsules will be administered along with therapeutic activities during experimental sessions .
1630137|NCT02008396|Drug|MDMA|Participants receive a capsule of 75 or 100 mg during the first of two experimental sessions and a capsule of 100 or 125 mg MDMA on the second of two experimental sessions. They will receive MDMA along with selected therapeutic activities during each experimental session.
1630138|NCT02008383|Biological|Panitumumab|The FDA approved dose for panitumumab is 6mg/kg IV, every two weeks. This is the dose and schedule that will be used in this study.
1630139|NCT02008383|Drug|Cabozantinib|"There will be three parts to this phase I study: 1) the Combination Dose Finding cohort; 2) the Combination Expansion cohort; and 3) the Monotherapy MET Amplified cohort.
Cabozantinib will start at a dose of 60 mg daily with reductions to 40 and 20 mg daily possible in the dose finding cohort. The combination expansion cohort dose will determined by the dose finding cohort. The Monotherapy MET Amplified cohort will recieve 60 mg Cabozantinib daily."
1630140|NCT02008370|Drug|Exparel infiltration|Exparel infiltrated into wound and chest tube sites
2011564|NCT02501954|Radiation|Radiation Therapy|Undergo Radiation Therapy
1630143|NCT02008344|Drug|favipiravir|"Administered twice daily over 5 consecutive days for a total of 10 doses.
Day 1: 1800 mg twice daily (loading doses)
Days 2 through 5: 800 mg twice daily"
1630144|NCT02008344|Drug|placebo|"Administered twice daily over 5 consecutive days for a total of 10 doses.
Day 1: 1800 mg twice daily (loading doses)
Days 2 through 5: 800 mg twice daily"
1630145|NCT02008331|Dietary Supplement|SYNBIOTIC|"INTERVENTION: Probinul neutro® assumed three times a day far from meals as 5 g powder packets dissolved in water. Probinul neutro® contains 5×109 Lactobacillus plantarum, 2×109 Lactobacillus casei subp. rhamnosus and 2×109 Lactobacillus gasseri, 1×109 Bifidobacterium infantis and 1×109 Bifidobacterium longum, 1×109 Lactobacillus acidophilus, 1×109 Lactobacillus salivarus and 1×109 Lactobacillus sporogenes and 5×109 Streptococcus termophilus, prebiotic inulin (2.2 g; VB Beneo Synergy 1) and 1.3 g of tapioca-resistant starch.
PLACEBO: Tapioca-resistant starch powder similar in colour, texture and taste to the symbiotic mixture, assumed three times a day far from meals as 5 g powder packets dissolved in water."
1630148|NCT02008305|Device|protocol of optimization ALARA|
1630149|NCT02008305|Device|protocol of optimization Philips|
1630150|NCT02008292|Drug|Physostigmine|All subjects will receive physostigmine to induce elevated ACh levels in the brain.
1630151|NCT02008279|Biological|100 mg CNTO 3157|A single subcutaneous (SC) (under the skin) injection of 100 mg CNTO 3157
1630152|NCT02008279|Biological|300 mg CNTO 3157|2 SC injections of CNTO 3157 providing a total dose of 300 mg
1630153|NCT02008279|Biological|600 mg CNTO 3157|4 SC injections of CNTO 3157 providing a total dose of 600 mg
1630154|NCT02008279|Biological|300 mg CNTO 3157|300 mg of CNTO 3157 as an intravenous (IV) infusion (into a vein) administered over a period of 30 minutes
1630155|NCT02008279|Drug|Placebo|SC injections of placebo (number of injections to equal number of injections of CNTO 3157)
1630156|NCT02008253|Procedure|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Main outcome measures included UCVA, BCVA, refraction, keratometry and computerized analysis of corneal topography.
1630157|NCT02008240|Procedure|Needle aspiration of hydrosalpinx|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
1630158|NCT02008240|Procedure|Salpingectomy|laparoscopic surgical removal of affected tube is done with bipolar electrocoagulation for hemostasis. The mesosalpinx is coagulated as close a possible to the fallopian tube to avoid any compromise in the ovarian blood supply . In cases with marked adhesion, proximal ligation and a distal fenestration is done .
1630159|NCT02008227|Drug|Atezolizumab|1200 mg IV infusion on Day 1 of each 21-day cycle
1630160|NCT02008227|Drug|Docetaxel|75 mg/m^2 IV infusion on Day 1 of each 21-day cycle
1630161|NCT02008214|Drug|Pentoxifylline|Addition of pentoxifylline to current HCV treatment
1630162|NCT02008214|Drug|Placebo|Placebo matching pentoxifylline dosage
1630163|NCT02008201|Dietary Supplement|vitamin D|
1630164|NCT02008188|Device|Closed Loop Control with the Advisory/Automated Adaptive (AAA) Control system|During the experimental week, subjects will wear a standard CGM and insulin pump during the day and will follow their usual diabetes care. During the nighttime hours, the subjects will return to the study site and will resume closed-loop control overnight from 23:00-07:00. This study design will also allow for testing of system transitions from CGM-augmented pump therapy to closed loop control and back to CGM-augmented pump therapy.
1630165|NCT02008175|Radiation|Conventional CXL|Crosslinking was done according to the standard protocol using hypo-osmolar riboflavin (<0.1%) to saturate the cornea following epithelial debridement and ultra - violet light of 370nm with energy density of 3 milliwatts/cm2 with riboflavin and distilled water alternated every 2 minutes was used for the procedure..
1630166|NCT02008162|Drug|Bronchodilators|Administration of both albuterol and tiotropium bromide after a 48h period of washout from all bronchodilators, followed by spirometry and plethysmography
1630167|NCT02008149|Other|Rowing exercise|Individuals with SCI will use the rowing exerciser to see if there is a benefit to skeletal health in the lower limbs.
1630168|NCT02008136|Drug|Botulinum Toxins|intramuscular injections
1630169|NCT02008123|Drug|Primidone|Primidone is an antiepileptic used for the management of generalized tonic-clonic seizures and for the management of complex partial seizures. One of primidone's active metabolite is phenobarbital, which is a potent cytochrome P450 inducer. In this study, primidone will be used to induce CYP 1A2 in order to provide more efficient metabolism of clopidogrel to its active form
1661879|NCT01762319|Drug|Vitamin B6|
1630173|NCT02008110|Other|CA125 guided strategy|Frequency of monitoring according plasma evolution of CA125 in the active arm.
1630174|NCT02008110|Drug|Standard treatment strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, aldosterone antagonists, diuretics, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, statins, omega-3 polyunsaturated fatty acids, digoxin, nitrates and vasoactive group).
1630175|NCT02008110|Drug|CA125 guided strategy|All patients should be treated following standard european guidelines regarding angiotensin converting enzyme inhibitors, angiotensin receptor blockers, beta-blockers, ivabradine and other treatments such as (diet, anticoagulants, antiarrhythmics, digoxin, nitrates and vasoactive group).
1630176|NCT02008097|Device|GE LOGIQ E9 Ultrasound System|"Subjects will have an ultrasound exam using the GE LOGIQ E9 Ultrasound System which has computer software that combines the color-flow image and B-mode image to produce the new B-Flow method of ultrasound."
1630177|NCT02008084|Drug|TRIA-662|Following Baseline randomized to active TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then active TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
1630178|NCT02008084|Drug|Placebo|Following Baseline randomized to placebo TRIA-662 2 x 500 mg tablets, three times daily with meals for 2 weeks and then placebo TRIA-662 2 x 1000 mg tablets, three times daily with meals for 12 weeks.
1630179|NCT02008071|Behavioral|Daily step goal financial incentive|Participants' daily activity was incentivized. Reaching a predetermined/individualized step goal each day resulted in 1.00 per day.
1630180|NCT02008071|Behavioral|Standard of Care|Standard payment of 70.00 at the beginning of the study. Participants' daily activity was not incentivized.
1630181|NCT02008058|Behavioral|Survey|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study. Patients will remain on study for up to 26 months (slightly longer than the expected median survival in this population based on data from docetaxel, abiraterone, and MDV3100 pivotal phase 3 trials).
1630184|NCT02008032|Device|Stationary Breast Tomosynthesis|The patient will have the SDBT study performed in a similar manner as conventional mammography in the mediolateral oblique and cranio-caudal plane. The participant will stand up and the mammography research technologist, ensuring patient comfort, will assist in positioning their breast in the breast tomosynthesis unit with standard compression. Once positioned, the total scan time is approximately 10 seconds. Both the left and right breast will be imaged. The length of time for the positioning and examination of a subject's breast may vary but it is expected that the entire imaging procedure will take about 5-10 min, including positioning time.
1630185|NCT02008019|Drug|Everolimus 2.5 mg/day|Comparison between 2,5 mg/day of Everolimus per os to 10 mg/day, or to no treatment, taken during 30 days before chondrosarcoma surgery
1630186|NCT02008019|Drug|Everolimus 10 mg/day|Comparison between 10 mg/day of Everolimus per os to 2.5 mg/day, or to no treatment taken during 30 days before chondrosarcoma surgery
1630187|NCT02008006|Drug|BeEAM|"High Dose Chemotherapy (HDT) containing :
Bendamustine 160 mg/m2 for 2 days (D-8 and D-7)
Etoposide 200 mg/m2 and Cytarabine 400 mg/m2 for 4 days (D-6 to D-3)
Melphalan 140 mg/m2 on D-2
HDT will be followed by an Autologous Stem Cell Transplantation on D0"
1630188|NCT02007993|Other|PDT|"A single session of PDT will be performed with the Chimiolux® photosensitizer at a concentration of 0.005% applied over the middle and posterior thirds of the dorsum of the tongue.
Nine points will be irradiated, the device will be previously calibrated with a wavelength of 660 nm, power of 100 mW, energy of 9 joules for 90 seconds per point in Groups 2 and 4 and 12 joules for 120 second per point in Groups 3 and 5"
1630189|NCT02007993|Other|Tongue Scraper|The pacient will scrap the tongue 10 times.
1630190|NCT02007954|Device|DEBDOX|DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
1630191|NCT02007941|Drug|CKD-501|From day 1 to day 3, Once(Day1) CKD-501 0.5mg is administered .
1630192|NCT02007928|Other|Rispéridone, aripiprazole, olanzapine|"Study:
We propose a prospective, interventional multicenter study.
Method:
Both in and out patients may be included in the study Patients will be recruited over a period of 24 months. They will be followed up for 12 months. Each patient will receive one year of therapeutic monitoring after the introduction of the antipsychotic drug.
The therapeutic monitoring will include clinical, electrocardiographical, and laboratory assessments. These assessments are performed at baseline (before prescribing treatment) and at 1 month (M1), at 3 months (M3), 6 months (M6), 9 months (M9), and at 12 months (M12) after the first prescription of the antipsychotic drug."
2011565|NCT02501330|Drug|Bosutinib|The usual adult dosage of once 500 mg per day postprandial oral administration as bosutinib. The dosage may be adjusted according to the patient's condition, but can be increased to once 600 mg 1 day.
1630194|NCT02007902|Other|Evaluation of the relationship plasma protein levels - neonatal hemodynamics|"Patient inclusion at birth
Total plasma protein values measurement on cord blood sample at birth
Hemodynamic evaluation at 6 hours after birth with colour doppler echocardiography and organ blood flow colour doppler
Total plasma protein and albumin values measurement on plasma sample at 12 hours after birth
Blood pressure, heart rate, O2 saturation, capillary refill time, rSO2 [regional (cerebral and somatic) tissue oxygenation by NIRS - near infrared spectroscopy] will be monitored over 24 hours after birth."
2011566|NCT02500797|Biological|Ipilimumab|Given IV
1957973|NCT02086552|Drug|Sonidegib|Given PO
2011567|NCT02500797|Other|Laboratory Biomarker Analysis|Correlative studies
2011568|NCT02500797|Biological|Nivolumab|Given IV
2011569|NCT02500797|Other|Quality-of-Life Assessment|Ancillary studies
1630195|NCT02007889|Drug|L-carnitine|50 mg/kg/day carnitine in divided 2-3 times/day (maximum 3 g/day) in addition to antibiotic regimens
1630196|NCT02007876|Behavioral|Mobility and Activity Training|"Pre-operative: Transfer training: bed and chair transferring exercises rising with and without use of hand assistance including supine to sit in or to the side in bed, and sit to stand from a normal and low height chair. GCS exercises: 1) supine pelvic bracing with transverse abdominal recruitment 2) hip bridges with abductor squeeze 3) supine bent leg abduction with light theraband and 4) supine isometric core and pelvic stabilization with legs flexed and shoulder flexion to raise arms over head with advancement to using theraband. For patients able to stand safely 5) standing mini squats against the wall.
Post-operative: Early mobilization to include standard physical therapy techniques to enhance bed mobility, facilitated sit to stand and walking with therapist assist as needed. All GCS exercises begin 24 hr post op with goal of 5-10 reps and progressing to 3 sets of 10 reps. Participants will be encouraged to move from a roll to the side first supine to sit strategy by week 2."
1630197|NCT02007863|Procedure|Umbilical Cord Blood Transfusion|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. Umbilical Cord Blood Transfusion will occur on Day 0
1630198|NCT02007863|Drug|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -13 through -9 for a total of 5 doses. Fludarabine will not be dose adjusted for body weight.
1630199|NCT02007863|Drug|Busulfan|Busulfan IV (Busulfex) will be administered IV every 6 hours on days -8 through -5 for a total of 16 doses. Seizure prophylaxis prior to first dose of busulfan till Day -3 will be administered.
1630200|NCT02007863|Drug|Melphalan|Melphalan 45 mg/m2/day will be administered over 60 minutes intravenous infusion on Days -4 through -2 for a total of 3 doses.
1630201|NCT02007850|Drug|ropivacaine|Patients receive 15 ml of 0.25% ropivacaine pre-operatively through femoral block catheter, followed by 0.2% ropivacaine continuous mode or patient controlled mode for 2 days after surgery
1630202|NCT02007837|Drug|Combined aspirin and multinutrient supplement|Single capsule with 80mg low-dose aspirin, 1.2 grams calcium, 600 IU vitamin D, 5mg folic acid and 1000 ug vitamin B12 mixed.
1630203|NCT02007837|Other|Daily text reminder text messages|
1630204|NCT02007824|Device|ULSD-12D|wound cleansing and debridement using ULSD-12D
1630205|NCT02007824|Device|SONOCA-180|wound cleansing and debridement using SONOCA-180
1630206|NCT02007811|Biological|allogeneic donor derived B-lymphocytes|CD3+-depleted, CD19+-enriched, cryopreserved (single administration after day 120 following allogeneic stem cell transplantation, donor-identical) in 4 groups with escalating doses
1630207|NCT02007798|Drug|dexmedetomidine|2 ml of dexmedetomidine at a concentration of 100 ug/ml is diluted by 98 ml normal saline to a concentration of 2 ug/ml. The required amount of experimental drugs is confirmed according to the weight and grouping, and diluted using normal saline to 20 ml.
1630208|NCT02007798|Drug|normal saline|100 ml per bag
1630209|NCT02007785|Behavioral|CO-OP treatment protocol|Participants with Parkinson's disease will be participating in up to 12 one-on-one treatment sessions with 2 sessions per week, for up to 6 weeks. Each session will last 45-60 minutes. During these treatment sessions, each participant will be taught a problem-solving strategy that teaches individuals to monitor and adjust their own actions. Participants will be guided by the principal investigator to select 5 individual treatment goals to work on during treatment. Sessions will continue until all 5 treatment goals have been met or until 12 sessions have been completed, whichever occurs earlier. Initially, each participant's respective primary caregiver will be required to attend treatment sessions, so that the caregiver may be familiar with the treatment strategy in order to coach the participant with Parkinson's disease when you he or she uses the strategy at home.
1630210|NCT02007772|Device|nHF|nasal high-flow is used over a period of 6 weeks (outpatient)
1630211|NCT02007772|Device|BiPAP|BiPAP is used over a period of 6 weeks (outpatient)
1630212|NCT02007759|Device|VitalStim|This group will receive active VitalStim treatment.
1630213|NCT02007759|Device|Sham VitalStim|This group will receive a sham VitalStim intervention.
1630214|NCT02007746|Other|Liver transient elastography (Fibroscan)|Fibroscan will be performed as a measure of liver stiffness. The study will be obtained free of charge in this study.
1630215|NCT02007746|Other|Ferriscan|Ferriscan will be done to assess the quantity of liver iron in iron overloaded subjects.
1630216|NCT02007746|Procedure|Liver biopsy in iron overloaded subjects.|Liver biopsy will be done and the results will be compared to Fibroscan results.
2011570|NCT02501395|Other|No intervention, observational|
2011571|NCT02499783|Biological|Adalimumab|Subjects will be given subcutaneous injections of adalimumab.
2011572|NCT02499783|Other|Placebo|Subjects will be given subcutaneous injections of placebo
1630220|NCT02007720|Drug|Serelaxin|Intravenous infusion
1630221|NCT02007720|Drug|Placebo|Intravenous infusion
1630222|NCT02007720|Other|Standard of CareTherapy|This treatment can include but is not limited to intravenous and/or oral diuretics, ACE inhibitors/angiotensin receptor antagonists, β blockers, and aldosterone receptor antagonists, etc.
1630223|NCT02007707|Behavioral|Tobacco LHW|Quit Smoking For a Healthy Family - This is a family-based psycho-education intervention using lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about tobacco and health, and smoking cessation resources through 2 small-group education sessions and 2 individual phone calls over a 2-month period.
1630224|NCT02007707|Behavioral|Healthy Eating|Eating Healthy and Physically Active for You and Your Family - This is a attention-control comparison group using a family-based psycho-education intervention delivered through lay health worker (LHW) outreach. LHW will be trained to recruit smoke-family dyads and provide education and information about healthy eating and physical activity through 2 small-group education sessions and 2 individual phone calls over a 2-month period. Participants will receive writing information about smoking cessation resources.
1630225|NCT02007694|Behavioral|Virtual Reality Exposure Therapy (VRET)|Graded exposure to feared specific stimulus by computer-generated 3D virtual environments.
1630260|NCT02007408|Drug|Paracervical block + lidocaine spray|
1630563|NCT02004886|Drug|Placebo|Placebo tablets matching metformin
1630226|NCT02007681|Behavioral|Reduction of sedentary time by breaking it with low intensity physical activity|One 5-10 minute break per hour during the work day using a software that alert the participant, and perform 6000 steps above the baseline number of steps/day (previously evaluated), by adopting several domain specific strategies, during 7 days.
1630227|NCT02007668|Other|Kinesio Taping|Kinesio taping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the lumbar spine.
1630228|NCT02007655|Drug|Eliquis|
1630229|NCT02007642|Procedure|Blood sampling / Body fluid sampling|"During the hospitalization of the patient, when a sampling is done for classic follow-up and diagnosis, additionnal blood sampling will be done, for the PATHOQUEST method.
Other body fluids might be taken (if the sampling is done for the classic follow-up), such as cerebrospinal fluid, ascite..."
1630230|NCT02007629|Drug|Riociguat (Adempas, BAY63-2521)|Riociguat / BAY63-2521 film-coated tablets will be used in this study at a dosage of either 0.5, 1.0, 1.5, 2.0, and 2.5 mg. 3 times daily
1630231|NCT02007616|Other|Non-action video game training|Based on cognitive training Lumosity
1630232|NCT02007603|Drug|Administration of Amoxicillin / clavulanic acid|Patients receive amoxicillin / clavulanic acid due to clinical necessity
1630233|NCT02007603|Drug|Ampicillin / sulbactam|Patients receive ampicillin / sulbactam due to clinical necessity
1630234|NCT02007603|Procedure|Blooddraws for pharmacokinetic profiling|Blood will be sampled at multiple timepoints during multiple hemodialysis sessions
1630235|NCT02007590|Device|Aerosure 25 Hz|Active Aerosure device
1630236|NCT02007590|Device|Aerosure Sham|Device designed to appear identical to active device but with HFAO mechanism disabled
1630237|NCT02007577|Drug|salsalate|Participants will take 3, 500 mg tablets with breakfast and 4, 500 mg tablets with dinner
1630238|NCT02007577|Drug|Placebo|Participants will take 3 tablets with breakfast and 4 tablets with dinner
1630239|NCT02007564|Behavioral|LIFE Intervention|RSVs received intensive training in the manualized intervention, including practice opportunities. The manual and accompanying workbook consist of instructions about using the steps of problem solving to decide on a period of life and creative activity project; constructing a project; evaluation of the activity; and additional questions. With the help of the RSV, dyads narrow the focus to one time period in the patients' life that could be adequately represented in one tangible project (scrapbook, audiotapes). The RSV and dyad brainstormed ways to portray the life story and then narrowed the focus to one meaningful project. The dyad gathered all necessary materials (such as pictures) and actively worked on completing a portion of the project between sessions.
1630240|NCT02007551|Behavioral|Mealtime Intervention|The mealtime intervention constitutes once a week visits from a trained volunteer for 8 weeks, each visit lasting 90 minutes and comprising of preparing and sharing a meal together with the participant.
1630241|NCT02007525|Behavioral|Yoga intervention|Participants will attend one weekly 60 minute hatha yoga class taught by a certified yoga instructor for 6 weeks. Each participant is to practice yoga at home 3-5 days per week. Paper logs will be provided to record date, time and duration of yoga practice each week.
2011573|NCT02499731|Behavioral|Strong Hearts, Healthy Communities|"We will evaluate the efficacy of the SHHC curriculum in a 24-week community-based randomized controlled intervention trial. We will compare changes in CVD-related anthropometric, physiologic, behavioral, and psychosocial parameters between subjects in 8 intervention and 8 control communities. In addition, we will evaluate changes in behavior, attitudes, and knowledge among SHHC intervention subjects' social network."
1630246|NCT02007486|Other|Cardiopulmonary Exercise Testing|Symptom-limited incremental exercise testing (10 watts/min) on an electronically braked cycle ergometer
1630247|NCT02007460|Behavioral|Exercise|multidirectional unilateral hopping exercise
1630248|NCT02007447|Drug|OCYTOCINA - SPRAY NASAL|The initial sample is divided into two groups (A and B): group A receive oxytocin intranasal for 8 weeks 24UI twice a day (3 applications per nostril 4UI 12/12 hours); group B will receive placebo for 8 weeks
1630249|NCT02007434|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
1630250|NCT02007434|Drug|Placebo|Phosphate buffered saline placebo for injection
1630251|NCT02007434|Other|Cold Compress|A cold compress was applied to the injection area for 10 minutes before dosing and for 15 minutes after dosing.
1630252|NCT02007434|Drug|Lidocaine / Epinephrine|Lidocaine 4% topical cream applied 45 minutes prior to dosing across the area to be treated, followed by 0.4 mL SC injections of lidocaine HCl 1% / epinephrine 1:100,000 around the perimeter of the treatment area and across the treatment area in a regular pattern 25 minutes before dosing.
1630253|NCT02007434|Drug|Loratadine|Loratadine 10 mg orally from Day -7 until Day 7
1630254|NCT02007434|Drug|Ibuprofen|Ibuprofen 600 mg at least 1 hour prior to dosing and 600 mg 3 times a day for at least 3 days after dosing.
1630255|NCT02007434|Other|Compression Chin Strap|A compression chin strap was applied 15 minutes after dosing for at least 24 hours.
1630256|NCT02007421|Procedure|Participants asked questions about recent experiences of anal intercourse in the last six months.|"Therefore, it is proposed we conduct a longitudinal study of the epidemiology of low risk and high risk HPV infection and related low grade and high grade anal cancers in HIV negative and HIV positive homosexual men who are 35 years or older. Participants are asked questions about recent experiences of anal intercourse in the last six months.
At baseline, all men (both HIV positive and HIV negative)will undergo a behavioural questionnaire, and anal swabs which will be tested for HPV and cytology. An HRA will also be performed on all men. Blood will be collected for HIV testing for HIV negative participants, syphilis and storage. Participants will be followed up for three years with one six-monthly visit in the first year then annually. A 6th study visit to discuss all study results will take place 2-3 months after the 5th study visit. A behavioural questionnaire, an anal swab, and HRA will be administered at all follow up interviews."
1630257|NCT02007421|Procedure|High Resolution Anoscopy|The HRA is performed on HIV positive and HIV negative participants by study doctor after an examination of the perianal region and perineum. The plastic anoscope is inserted into the anal canal and visualised under high resolution magnification. Biopsy samples will be taken by the clinician for histological assessment if there are any detected abnormalities.
1630261|NCT02007369|Behavioral|WhatsApp|Intervention arm with relapse prevention intervention in the social group via the social networking service WhatsApp and the duration of the intervention will be 8 weeks.
1630262|NCT02007369|Behavioral|Facebook|Another intervention arm with the same intervention content, but the platform for the participants to share and receive quitting advice is Facebook and the duration of the intervention will be 8 weeks.
1630263|NCT02007356|Biological|IFN-γ positive selected T-cells|
1630264|NCT02007330|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion (0.1mg/kg) for 1minutes after induction of anesthesia. After 1 minutes, lidocaine infusion continued at rate of 1.5mg/kg/hr during operation, and discontinued before move the patients to PACU.
1630265|NCT02007330|Drug|Normal saline infusion|In group C, the patients receive same volume of normal saline
1630266|NCT02007317|Drug|Oshadi D & Oshadi R|Anti tumor agents
1630267|NCT02007304|Behavioral|Eccentric exercise training|12 weeks of lower leg eccentric training
1630268|NCT02007278|Drug|vildagliptin and metformin (combination)|vildagliptin and metformin combination therapy as 50mg/850mg bid or 50mg/1000mg bid
1630269|NCT02007278|Drug|glimepiride|
1630270|NCT02007278|Drug|Metformin|
1630271|NCT02007252|Drug|ACZ885|ACZ885 150 mg liquid pre-filled syringes were administered s.c..
1630272|NCT02007252|Drug|Placebo|Matching placebo liquid pre-filled syringes were administered s.c..
1630273|NCT02007239|Drug|tocilizumab|single dose of tocilizumab (8mg/kg intravenously) within 24 hours of administration of standard immunochemotherapy.
1630274|NCT02007200|Other|Laboratory Biomarker Analysis|Correlative studies
1630275|NCT02007200|Drug|Soy Isoflavones|Given PO
1630276|NCT02007200|Other|Survey Administration|Ancillary studies
1630277|NCT02007187|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
1630278|NCT02007187|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of unstable angina (UA) and non-ST-elevation myocardial infarction (NSTEMI) (2007) issued by Chinese Society of Cardiology of Chinese Medical Association
1630279|NCT02007187|Drug|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
1630280|NCT02007174|Drug|Bevacizumab|
1630281|NCT02007161|Drug|Diclofenac potassium 50 mg|Diclofenac potassium 50 mg
1630282|NCT02007148|Drug|capecitabine|twice a day
1630283|NCT02007148|Drug|Docetaxel|cycles repeated every 3 weeks
1630284|NCT02007122|Other|Ceftaroline in CRRT|Plasma levels of ceftaroline will be measured in patients receiving CRRT
1630285|NCT02007122|Other|Ceftaroline in IRRT|Ceftaroline plasma levels will be measured in patients receiving intermittent renal replacement therapy
2011574|NCT02499731|Behavioral|Strong Hearts, Healthy Women|"The Strong Hearts, Healthy Women (minimal intervention) will meet once per month for an hour each time for 6 months.
Participants will learn and discuss techniques and strategies to improve personal health."
2011575|NCT02499120|Drug|palbociclib|Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
1630291|NCT02007070|Biological|Pembrolizumab|Intravenous infusion
1630292|NCT02007057|Procedure|Suprascapular nerve block|
1630293|NCT02007057|Procedure|Interscalene nerve block|
1630296|NCT02007018|Device|Negative Pressure Wound Therapy|Prevena™ Incision Management System (PIMS) (Kinetic Concepts Inc. (KCI), San Antonio, TX) is an incisional vacuum assisted closure (PIMS) device intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudates via the application of negative pressure wound therapy The PIMS applies continuous pressure to the closed surgical site at 125 mm Hg and is attached to a 45 mL canister for collection of exudate.
1630297|NCT02007018|Other|Usual Care of Surgical Wound|Patients will receive pre-operative antibiotics consisting of 1g cefazolin (or in the case of an allergy, an alternative e.g. ciprofloxacin/vancomycin) and 500 mg metronidazole given intravenously within the 30 minute prior to beginning the operative procedure. In cases extending > 4 hours, a second dose of each of the antibiotics will be administered. Hair at the operative site will be removed, if required, immediately prior to the skin incision using electric clippers. The abdomen will be prepped using 2% Chlorhexidiene solution (or 10% povidone if allergic). After closure of the skin, the surgical wound will be covered with a sterile adhesive dressing (Tegaderm), which will remain in place until the morning of post-operative day (POD)#2, unless saturated, in which case it is standard practice to change the dressing if the physician is in agreement. On POD#2, the surgical team will remove the initial dressing and daily dressing changes with standard gauze will be initiated.
1630298|NCT02007005|Drug|abnobaVISCUM Fraxini|intravesical instillation 6 times, once weekly, in increasing dosages until dose-limiting-toxicity occurs
1630299|NCT02006992|Other|RTF Infant Formula|a RTF extensively hydrolyzed infant formula
1630300|NCT02006992|Other|Powder Infant Formula|a powdered extensively hydrolyzed infant formula.
1630301|NCT02006979|Other|exercise|An acute bout of exercise performed 24 hours prior to every anthracycline infusion.
1630302|NCT02006966|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
1630303|NCT02006966|Drug|Normal saline infusion|In group C, the patients receive same volume of normal saline
1630304|NCT02006953|Procedure|Bolus feeding schedule following gastrostomy tube placement|
1991996|NCT00062985|Behavioral|Mail-based weight loss intervention|
1991997|NCT00062985|Behavioral|Phone-based weight loss intervention|
1992002|NCT00019682|Biological|Aldesleukin|Given IV
1992003|NCT00019682|Biological|gp100 Antigen|Given SC
1992004|NCT00019682|Drug|Montanide ISA 51 VG|Given SC
1630305|NCT02006953|Procedure|Continuous chimney feeds following gastrostomy tube placement|
1630307|NCT02006927|Device|Nerve Stimulation|Placement and stimulation of implantable neurostimulation device/leads post radical robotic prostatectomy
1630308|NCT02006914|Dietary Supplement|Chromium Picolinate|Subjects will be asked to take chromium picolinate; 2 tablets per day, 1000 mcg or a placebo for a total of 8 weeks.
1630309|NCT02006901|Procedure|microdecompression|a minimal invasive surgical technique
1630310|NCT02006901|Procedure|laminectomy|The traditional open surgical technique: decompression with removal of the spinous process, lamina and often the medial facets
1992005|NCT00019682|Other|Quality-of-Life Assessment|Ancillary studies
1630313|NCT02006875|Device|rTMS|Interventions started on the next weekday after pretest and were performed once a day for 15 consecutive weekdays. Participants in the E and C groups received rTMS (either real or sham, 1 Hz, 15 minutes), followed by a session of physical therapy for 45 minutes.
1630314|NCT02006849|Drug|Acthar|FDA approved drug being used in this study for sub-nephrotic proteinuria. Given Investigational New Drug (IND) exemption by FDA.
1630315|NCT02006836|Dietary Supplement|Pomelo|The sugar content of the pomelo was 5.86% of full weight, and we use 922g Majia pomelos which contained about 50g sugar equal to 50g glucose for GI measurement.
1630316|NCT02006836|Dietary Supplement|Glucose|We dissolved 50 g of glucose in 200 ml water.
1630317|NCT02006836|Other|Blank|For the self-control period the diabetic patients underwent 3-day CSII treatment without change of insulin dose and we did not applied any intervention.
1630318|NCT02006836|Drug|Insulin|Patients who were included in the test of glycemic responses to postprandial pomelo consumption were hospitalized with the treatment of Continuous Subcutaneous Insulin Infusion(CSII), and the insulin for CSII was insulin aspart(NovoRapid).
1630319|NCT02006836|Drug|met or diet|In diabetic group, 20 diabetic patients were included for GI measurement , 18 of whom were on metformin treatment. Only 2 patients were on diet control due to the early stage of this disease.
1630320|NCT02006810|Behavioral|Induction of endothelial function variations|
1630321|NCT02006797|Other|reconciliation|medication reconciliation at discharge and communication of this intervention to patient's community pharmacist
1630322|NCT02006771|Other|Southern Chinese meal|White rice (1 bowl), stir fried choi sum (0.5 bowl) and stir fried lean pork (0.5 bowl) cooked with maize oil
1630323|NCT02006771|Other|Northern Chinese meal|Noodles (1 bowl) and shredded pork with sweet bean sauce (0.5 bowl) cooked with blend oil
1630324|NCT02006771|Other|American meal|Hamburger with cheese (1 piece), French fries (117 g) cooked with canola blend oil and Coca-cola classic (21 fluid ounces)
1630325|NCT02006771|Other|South Indian meal|Basmati rice (1 bowl), chicken curry dish (0.5 bowl), dry vegetable dish (i.e. green beans mixed with herbs) (0.5 bowl), yogurt made with milk powder mainly (0.5 bowl), pickle made with lemon, salt, chilli powder, Asafoetida and vegetable based oil (1 tablespoon)
1630327|NCT02006745|Drug|Ribavirin|24 weeks in those achieving RVR (undetectable HCV RNA at 4 weeks) or 48 weeks in those not achieving RVR
1630328|NCT02006745|Drug|Telaprevir|12 weeks in those achieving RVR, 24 weeks in those not achieving RVR (HCV RNA >25 but <1000 iU/mL at week 4) or 48 weeks in those not achieving RVR (HCV RNA >1000 iU/mL at week 4).
1630329|NCT02006732|Drug|olodaterol|fixed dose combination
1630330|NCT02006732|Drug|tiotropium|fixed dose combination
1630331|NCT02006732|Drug|placebo|
1630332|NCT02006719|Biological|Collagenase Clostridium Histolyticum|Treatment of Adhesive Capsulitis
1630333|NCT02006719|Other|Placebo|Placebo injection
1630334|NCT02006706|Drug|rituximab [MabThera/Rituxan]|1000 mg iv Days 1 and 15
1630335|NCT02006706|Drug|methotrexate|10 - 25 mg/week
1630336|NCT02006706|Drug|methylprednisolone|iv administration on Day 1 and 15 prior to MabThera/Rituxan infusion
1630337|NCT02006693|Device|XEN Gel Stent|The XEN Gel Stent will be placed as a standalone procedure.
1630338|NCT02006693|Device|XEN Gel Stent with cataract surgery|Patient has been diagnosed with a cataract and has elected to have cataract surgery. The XEN Gel Stent will be placed along with cataract surgery.
1630339|NCT02006667|Drug|trastuzumab|4 mg/kg i.v., Day 3 of Cycle 1, followed by weekly doses of 2 mg/kg i.v., Day 1 of Cycle 2 until disease progression
1630340|NCT02006667|Drug|gemcitabine|1200 mg/m2 i.v. on Days 1, 8, and 15 of Cycle 1 through 6
1630341|NCT02006667|Drug|cisplatin|70 mg/m2 i.v. on Day 2 of Cycles 1 through 6
1630342|NCT02006654|Drug|Placebo|Once daily, matching placebo capsules, orally
1630343|NCT02006654|Drug|Lu AE58054|Once daily, encapsulated tablets, orally
1630344|NCT02006641|Drug|Placebo|Once daily, matching placebo capsules, orally
1630345|NCT02006641|Drug|Lu AE58054|Once daily, encapsulated tablets, orally
1630346|NCT02006628|Drug|Placebo|Patients will self-administer their allocated randomised treatment twice daily (in the morning and in the evening) for six weeks using the dosing spoons provided with each bottle. Study medication will be swallowed and may be taken with other concomitant medications, as directed by the investigator.
1630347|NCT02006628|Drug|GWP42003|Patients will self-administer their allocated randomised treatment twice daily (in the morning and in the evening) for six weeks using the dosing spoons provided with each bottle. Study medication will be swallowed and may be taken with other concomitant medications, as directed by the investigator.
1630348|NCT02006615|Device|rTMS|5Hz rTMS over M1 and inferior frontal lobe
1630349|NCT02006602|Drug|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 16 mg will be supplied as round, biconvex white tablets with PX 16 embossed in one face and scored in the other face.
1630390|NCT02006277|Drug|crizotinib oral solution|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
1992006|NCT00019682|Other|Questionnaire Administration|Ancillary studies
1992007|NCT00019682|Other|Laboratory Biomarker Analysis|Correlative studies
1992008|NCT00003659|Biological|filgrastim|Filgrastim (300 μg for patients ≤ 70 kg or 480 μg for patients > 70 kg) will be administered beginning two days after each cyclophosphamide dose and given for a total of eight subcutaneous daily doses.
1630350|NCT02006602|Drug|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 16 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (016 embossment in the plain face and A CH in the scored face).
1630351|NCT02006589|Drug|Candesartan cilexetil (GW615775, Test formulation)|Test formulation candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets with PX 8 embossed in one face.
1630352|NCT02006589|Drug|Candesartan cilexetil (Reference treatment)|Reference treatment of candesartan cilexetil 8 mg will be supplied as round, biconvex pink tablets, scored in one face and with embossment in both faces (008 embossment in the plain face and A CG in the scored face).
1630353|NCT02006576|Drug|600 mg ibuprofen three times daily for 48 weeks|
1630354|NCT02006576|Other|Placebo three times daily|
1630355|NCT02006537|Drug|GSK2256294|GSK2256294 is a 5 mg capsule administered orally as a 10 mg dose in the fasted or fed state
1630356|NCT02006524|Device|`MyDiagnostick|
1630357|NCT02006511|Device|Incisional Neg Pressure Wound Therapy (Prevena™)|Negative pressure wound therapy dressing applied over closed surgical incision
1630358|NCT02006511|Other|Standard of Care wound therapy|Gauze type dressing.
1630359|NCT02006498|Drug|Sillymarin|Sillymarin is derived from the milk thistle plant, Silybum marianum, a herbal remedy that has been used for centuries for diseases of the liver. It is a complex mixture of 6 major flavonolignans (silybins A and B, isosilybins A and B, silychristin, and silydianin), as well as other minor polyphenolic compounds.
1630360|NCT02006498|Drug|Placebo|Placebo capsule with same appearances as study drug
1630361|NCT02006485|Drug|Ublituximab + TGR-1202|Ublituximab IV infusion TGR-1202 oral daily dose
1630362|NCT02006485|Drug|Ublituximab + TGR-1202 + ibrutinib|Ublituximab IV infusion TGR-1202 oral daily dose Ibrutinib oral daily dose
1630363|NCT02006485|Drug|Ublituximab + TGR-1202 + bendamustine|Ublituximab IV infusion TGR-1202 oral daily dose Bendamustine IV infusion
1630364|NCT02006472|Drug|Pridopidine|22.5 mg and 45 mg capsules
1630365|NCT02006472|Other|Placebo|Capsules matching drug
1630366|NCT02006433|Device|Deep Brain Stimulation|Local anesthesis, MRI and CT scan of the brain followed by implantation of the stimulation device
1630367|NCT02006420|Device|ARFI-SVI Ultrasound|Ultrasound imaging of arm and leg lasting approximately 5-10 minutes. Participants will also undergo durometer scoring on the forearm and thigh as part of the study. This lasts approximately 5-10 minutes.
1630368|NCT02006407|Radiation|Cranial Radiotherapy|Standard cranial radiotherapy administered dependent upon patient and brain tumor type.
1630369|NCT02006407|Device|MRI with Diffusion Tensor Imaging (DTI)|Magnetic Resonance Imaging (MRI) with Diffusion Tensor Imaging (DTI)
1630370|NCT02006407|Behavioral|Neuro-cognitive Testing (CogState)|CogState is a computerized software testing system that offers various cognitive assessments based traditional expansive neurocognitive tests.
1630371|NCT02006394|Dietary Supplement|Fish Oil|fish oil capsules
1630372|NCT02006394|Dietary Supplement|Polyphenol Capsules|delphinidin polyphenol capsules
1630373|NCT02006394|Dietary Supplement|Corn Oil Capsules|Corn Oil Capsules
1630374|NCT02006394|Dietary Supplement|Corn starch capsules|Maltodextrin capsules
1630375|NCT02006394|Other|Reduced glycemic index bread products|Made by Zone Labs
1630376|NCT02006394|Other|Market variety bread products|placebo bread products
1630377|NCT02006368|Other|Blood Collection and autologous re-infusion|"Subjects will donate one unit of whole blood. This unit will be stored at 4°C for a predefined storage period. A variety of in vitro metabolic and functional platelet assays will be performed on the stored unit.
After the storage period, an aliquot from the whole blood unit will be processed to obtain platelets. The subject will return and donate a fresh sample of whole blood (43 mls) from which a fresh aliquot of platelets will be obtained. The stored and fresh platelets will each be labeled with a different radioisotope (either Chromium-51 or Indium-111) and reinfused into the subject. Using two different radioisotopes enables separate tracking of both the stored and fresh platelets. Follow-up blood samples will be drawn at 2 hours and on days 1, 2, 3, 5, 7±1 and 10±2. Stored and Fresh platelet recoveries and survivals will be calculated."
1630378|NCT02006355|Drug|Ropivacaine|
1630379|NCT02006342|Drug|Insulin Glargine|
1630380|NCT02006342|Drug|Regular Insulin|
1630381|NCT02006329|Device|acupuncture|
1630382|NCT02006316|Procedure|Microsurgical subinguinal varicocelectomy|
1630383|NCT02006303|Procedure|Green light PVP|The green light laser has a wavelength of 532 nm which is strongly absorbed by red tissues and hemoglobin; this renders a blood rich organ such as the prostate gland to be an excellent target. The procedure uses the technology of high-powered laser light combined with fiber optics to vaporize the overgrowth of prostate cells quickly and accurately. As the surgeon directs the laser at the prostate, the intense pulses of light emitted from the fiber are absorbed by the blood. Within moments, the temperature of the blood becomes so great it causes the nearby cells to vaporize. Once the procedure is completed, patients have immediate post-operative symptom relief and dramatic improvements in symptoms, urinary flow rates, and bladder emptying.
1630384|NCT02006303|Procedure|Prostatic artery embolization|Prostatic artery embolization consists of gaining access into the patients arterial system via a common femoral artery puncture using a small needle and sheath. Once the access is established, a micro-catheter is navigated through the arterial system using X-ray guidance into the arteries feeding the prostate. There, small polyvynil alcohol plastic beads are injected to block the blood flow to the prostate. By doing so, the prostate undergoes an ischemic injury and there is reduction in gland size and relief of obstructive symtpoms.
1630385|NCT02006290|Drug|PF-06412562|single oral split dose 30+20 mg QD
1630386|NCT02006290|Drug|Placebo|tablet, matching placebo, QD
1630387|NCT02006277|Drug|Crizotinib prototype microsphere 0.529 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
1630388|NCT02006277|Drug|crizotinib prototype microsphere 0.470 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
1630389|NCT02006277|Drug|crizotinib prototype microsphere 0.420 mg/mg|Subjects will take each sample into their mouths, swirl the sample for approximately 30 seconds, and then expectorate into an empty cup.
1630433|NCT02005848|Biological|Alpha-1 Antitrypsin|
1630391|NCT02006277|Drug|crizotinib prototype microsphere 0.529 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
1630392|NCT02006277|Drug|crizotinib prototype microsphere 0.470 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
1630393|NCT02006277|Drug|crizotinib prototype microsphere 0.420 mg/mg|Subjects will receive a single 250-mg oral dose of crizotinib.
1630394|NCT02006277|Drug|crizotinib capsule|Subjects will receive a single 250-mg oral dose of crizotinib.
1630395|NCT02006277|Drug|crizotinib oral solution|Subjects will receive a single 250-mg oral dose of crizotinib.
1630396|NCT02006264|Drug|TDF Intravaginal Ring|
1630397|NCT02006264|Drug|Placebo Intravaginal Ring|
1630398|NCT02006238|Device|Farabloc|The participants will be randomly received Farabloc (experimental) for one week, followed by a 7 day washout and then crossed over to received the Nylon fabric (placebo) for one week.
1630399|NCT02006238|Device|Nylon Fabric|The participants will be randomly received Nylon fabric (placebo) for one week, followed by a 7 day washout and then crossed over to receive Farabloc (experimental) for one week.
1630400|NCT02006225|Drug|Plerixafor|
1630401|NCT02006212|Procedure|If any intraoperative EEG abnormality and/or asymmetry is detected a cerebral CT scan will be performed in the immediate postoperative period|
1630402|NCT02006199|Behavioral|mindfulness meditation|8 weeks of mindfulness meditation specified for OCD patient
1630403|NCT02006186|Behavioral|Bicycle Train|The Bicycle Train intervention consists of research staff members who bike to and from school with enrolled participants
1630404|NCT02006173|Drug|Lidocaine|Xylocaine is a 2 % lidocaine hydrochloride contained liquid anesthesia
1630405|NCT02006173|Drug|Normal Saline|
1630406|NCT02006160|Drug|dalfampridine|10 mg bid
1630407|NCT02006160|Drug|placebo|10 mg bid
1630408|NCT02006147|Drug|TLC399(ProDex)|
1630409|NCT02006121|Drug|Apomorphine hydrochloride|Apomorphine hydrochloride 5 mg/ml solution for infusion in pre-filled syringe
1630410|NCT02006121|Drug|Placebo|Sodium chloride 9 mg/ml
1630411|NCT02006108|Drug|Feraheme|Therapeutic classification: iron preparations. Use: Off-label use of ultrasmall paramagnetic iron nanoparticle as contrast agent for magnetic resonance imaging
1630412|NCT02006108|Other|MRI-GE Healthcare 3 Tesla magnet|All patients will undergo
1630413|NCT02006095|Other|Magnetic resonance imaging|arterial spin labeling, diffusion tensor imaging, and diffusion weighted imaging sequences will be used
1630414|NCT02006095|Behavioral|Neuropsychological testing|
1630415|NCT02006082|Device|Telemedicine video-consultation (TVC)|All patients enrolled in the study, were previously monitored by TVC, and the number and length of hospital stays within 6 and 12 months following TVC were compared to similar numbers before TVC in comparable time periods. Thus, TVC is actually not to be considered as an intervention.
2011576|NCT02499120|Drug|Cetuximab|Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
2011577|NCT02499120|Drug|Placebo|"Placebo for palbociclib will be indistinguishable from the palbociclib capsules and will be supplied as capsules matching in size and color the various palbociclib formulations.
Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle."
2011578|NCT02496208|Drug|Cabozantinib S-malate|Given PO
1630419|NCT02006043|Drug|Erlotinib 150mg|
1630420|NCT02006030|Drug|ADI-PEG 20|
1630421|NCT02006017|Other|Evidence summary alone plus a recommendation|
1630422|NCT02006017|Other|Evidence summary alone|
1630423|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 70 mg PF-0521377 using a capsule formulation.
1630424|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 20 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arm 1.
1630425|NCT02005991|Drug|PF-05212377|Single, oral dose administration of 10 mg PF-0521377 using a capsule formulation. This dose is an estimate. The exact dose for Arm 2 will be based on the results from Arms 1 and 2.
1630426|NCT02005939|Dietary Supplement|Pomegranate extract|All randomised participants to the intervention arm receive one pomegranate capsule daily for 4 weeks
1630427|NCT02005926|Procedure|Wire-localized abnormal node|Before the sentinel lymph node biopsy (SLNB) operation, a hookwire was placed at the suspicious axillary lymph node by ultrasound guidance to localize the abnormal node. In the SLNB operation, radioactive nodes and wire-localized nodes were removed and labeled separately for pathological examination.
1630428|NCT02005900|Drug|Docosahexaenoic acid (DHA) administration to modulate Triglycerides in HIV patients under HAART|Multicenter, prospective, double-blind, randomized study of 48 weeks duration, in which the effect of 4 g daily of DHA vs 4 g daily of placebo (oleic acid) are studied on modulation of the Triglycerides and other lipids in patients with HIV infection under HAART treatment.
1630429|NCT02005887|Drug|triptorelin|Triptorelin 3.75 mg injected into the muscle on day 1 every 28 days for 6 cycles (1 cycle= 28 days)
1630430|NCT02005887|Drug|degarelix|Degarelix 240 mg injected under the skin given as two injections of 120 mg on the first day of treatment, followed by injection of 80 mg on day 1 of cycles 2 to 6 (1 cycle=28 days)
1630431|NCT02005887|Drug|Letrozole|Letrozole 2.5 mg orally every day for 6 cycles
1630432|NCT02005861|Procedure|bone marrow cells transplantation on collagen scaffold|"120 ml of venous blood will be collected for the platelet gel production. The day of the surgery, 60 ml of bone marrow will be aspirate from the posterior iliac crest and concentrated. a standard ankle arthroscopy will be performed, with the patient in the supine position. The lesion will be detected and cleaned.
An equine collagen type 1 scaffold (IOR-G1, Novagenit, Mezzolombardo, TN, Italy) will be loaded with 2 ml of bone marrow concentrate and cut into an appropriate shape to fit the lesion.
After the scaffold implantation 2 ml of platelet gel will be loaded on the top of implant, in order to provide growth factors and to improve the stability of the implant."
1630434|NCT02005848|Other|Placebo|Placebo
2011579|NCT02496208|Biological|Ipilimumab|Given IV
2011580|NCT02496208|Other|Laboratory Biomarker Analysis|Correlative studies
2011581|NCT02496208|Biological|Nivolumab|Given IV
1630435|NCT02005835|Other|Community based peer support|"Community-based Support from Peer Mothers (Expert mothers):
Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support in community prior to each visit Monthly support groups in community Home visits for each missed appointment"
1630436|NCT02005835|Other|Facility-based Peer Support|"Facility-based Peer Support to provide the following at the clinic
Routine standard clinical care based on the MoH guidelines Mentor mothers provide education and psychosocial support at facility Weekly support groups provided in clinic Phone call, SMS, or home visit for each missed appointment"
1630437|NCT02005822|Drug|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
1630438|NCT02005809|Procedure|second look endoscopy|Second look endoscopy includes observation or prophylactic bleeding control of ESD site.
1630439|NCT02005796|Other|Dietary intervention|
1630440|NCT02005783|Drug|DBD|DBD:one dose of medicine twice per day, orally
1630441|NCT02005783|Drug|Epirubicin|Epirubicin:90mg/m2, d1, q3w*4
1630442|NCT02005783|Drug|Cyclophosphamide|Cyclophosphamide:600mg/m2, d1, q3w*4
1630443|NCT02005783|Drug|Docetaxel|Docetaxel:75mg/m2, d1, q3w*4
1630444|NCT02005770|Drug|Sevoflurane|
1630445|NCT02005770|Drug|Propofol|
1630446|NCT02005757|Drug|Bredinin tablet 150mg|Bredinin 150mg qd vs Bredinin 50mg tid
1630447|NCT02005757|Drug|Bredinin tablet 50mg|Bredinin 150mg qd vs Bredinin 50mg tid
1630448|NCT02005744|Drug|CKD-501|CKD-501 0.5mg, PO(per oral), once
1630449|NCT02005731|Device|Low intensity linear focused shockwave device ('Renova')|
2011582|NCT02495610|Other|Gait analysis and MRI:|"Gait analysis: Treadmill with pressure sensors (FDM-THM-M-System; 'Zebris' medical GmbH), study-specific, but routine procedures.
MRI: Performed in a scanner at the University Hospital with standard MRI compatibility procedures; study specific is only the additional MRI after the CSF release with spinal tap or drainage."
1630451|NCT02005705|Other|Outpatient Management of Low-risk Patients|"Labs will be obtained within 2-3 days of discharge from ED
Clinic visit will be scheduled within 3 days of discharge from ED
EGD will be scheduled within 7 days of discharge from ED
Phone follow-up at day 7 and 30"
1630452|NCT02005705|Other|Inpatient Management of Low-risk Patients|"Labs will be obtained on day of discharge or day 2-3
EGD will be performed in the hospital
Phone follow-up at day 7 and 30"
1630453|NCT02005692|Device|DynaSense sensor|
1630454|NCT02005679|Behavioral|application of the mini-mental state test|
1630455|NCT02005666|Drug|Clindamycin Phosphate 1.2% / Benzoyl Peroxide 5% Gel|Drug:-1.2% Clindamycin Phosphate/ 5% Benzoyl Peroxide Gel of Cadila healthcare limited Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
1630456|NCT02005666|Drug|DUAC® Gel|Drug:-DUAC® Gel Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
1630457|NCT02005666|Drug|Placebo|Drug:-Placebo, Dosage Form:-Gel Dosage:-Thin Layer/Pea sized Frequency:-Once a day ,every evening Duration:-77 consecutive days
1630458|NCT02005653|Drug|Diethylcarbamazine|Diethylcarbamazine 300 mg tablet as single dose per day for 12 days
1630459|NCT02005653|Drug|Albendazole|Experimental
1630460|NCT02005653|Drug|Doxycycline|Experimental
1630461|NCT02005627|Drug|Grazax|The active treatment arm will receive active grass pollen immunotherapy tablet (AIT), Grazax Oral Lyophilisate 75,000 SQ-T once daily.
1630462|NCT02005627|Drug|Grazax Placebo|This arm will receive Grazax placebo once daily which contains the same composition as in the active Grazax tablet with the only difference being the exclusion of the grass pollen allergen extract.
1630464|NCT02005601|Drug|Placebo|Patients will receive placebo drug with no active ingredients per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
1630465|NCT02005601|Drug|Duloxetine 60mg|Patients will receive 60mg of duloxetine per dose. 1 capsule will be taken pre-operatively. One capsule once a day until end of POD14.
1630466|NCT02005588|Drug|amino acid chelated iron|the drug will be given to pregnant women 14-18 weeks' gestation who prove to have iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily. for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
1630467|NCT02005588|Drug|iron salt (ferrous fumarate)|this drug will be given to pregnant women 14-18 weeks' gestation with iron deficiency anemia. the dose will be given according to hemoglobin level. for hemoglobin 7-9 g/dl, 2 capsules will be given daily, and for hemoglobin 9.1-11 g/dl, 1 capsule will be given daily. complete blood picture and serum ferritin will be measured at 22-23, 29-30 and 36-37 weeks' gestation.
1630470|NCT02005562|Drug|mycophenolate mofetil|3 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52, adapted to MPA by AUC on Weeks 2, 6, 12, 26, and 52 to obtain AUC0-12 of 50 milligrams (mg) multiplied by (*) height (h)/ liter(L).
1630471|NCT02005562|Drug|mycophenolate mofetil|2 g p.o. in divided doses q12h beginning on the day of renal transplant, Day 0, or the day before, Day -1, and continuing to Week 52.
1630472|NCT02005562|Drug|anti-IL-2R|Induction by IL-2R was administered at Day 0 per standard of care at the site at the investigators discretion.
1630473|NCT02005562|Drug|methylprednisolone|500 mg intravenous (i.v.) was administered before or after the transplantation, and 0.5 mg/kg p.o. daily from Day 1 to Day 7.
1630474|NCT02005562|Drug|cyclosporine|100-1500 nanograms (ng) per milliliter (mL) from Day 0 to Week 4, 800-1200 ng/mL from Week 4 to Week 12 and 500-800 ng/mL from Week 12 to Week 52
1630475|NCT02005549|Drug|bevacizumab [Avastin]|15 mg/kg iv on Day 1 of each 3-week cycle, 5 cycles
1630476|NCT02005549|Drug|docetaxel|75 mg/m2 on Day 1 of each 3-week cycle, 6 cycles
1630477|NCT02005549|Drug|capecitabine [Xeloda]|950 mg/m2, orally twice daily, evening of Day 1 until morning of Day 15, followed by a 7 day rest period, every 3 weeks
1630478|NCT02005536|Biological|IMOVAX POLIO®: Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
1630479|NCT02005523|Drug|RNS60|
1630480|NCT02005523|Drug|Saline|
1630481|NCT02005510|Behavioral|Mailed in-home high-risk HPV testing kit|
1630482|NCT02005510|Other|Usual care|
1630484|NCT02005484|Drug|Trastuzumab|4 mg/kg initial dose, followed by 2 mg/kg
1630485|NCT02005471|Drug|Bendamustine|Bendamustine will be administered as described in the reporting arm groups.
1630486|NCT02005471|Drug|Venetoclax|Venetoclax will be administered as described in the reporting arm groups.
1630487|NCT02005471|Drug|Rituximab|Rituximab will be administered as described in the reporting arm groups.
1630488|NCT02005458|Drug|YPEG-rhG-CSF, 20μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
1630489|NCT02005458|Drug|YPEG-rhG-CSF, 30μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
1630490|NCT02005458|Drug|YPEG-rhG-CSF, 45μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
1630491|NCT02005458|Drug|PEG-rhG-CSF, 100μg/kg, single s.c. at 48hrs after chemotherapy for each experimental cycle|
1630492|NCT02005445|Device|CPAP|Continuous positive airway pressure
1630493|NCT02005445|Behavioral|HLSE|Healthy living and sleep education
1630494|NCT02005432|Drug|Intravitreal Ranibizumabe|Intravitreal injection 0,05ml Ranibizumabe
1630495|NCT02005432|Drug|panfotocoagulation (PASCAL)|
1630496|NCT02005432|Drug|panfotocoagulation (PRP) single shoot (ETDRS)|
1630497|NCT02005419|Drug|Gemcitabine|Patients receive gemcitabine 1000 mg/m^2 (iv, 30 minutes) on days 1, 8, and 15 for 3 weeks, followed by one week without treatment, and also receive placebo (Arm I)/ metformin (Arm II) on days 1-28. Treatment repeats every 4 weeks for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
1630498|NCT02005419|Drug|Metformin|Metformin will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
1630499|NCT02005419|Drug|placebo|Placebo will be administered at a dose of 500 mg twice daily. If well tolerated, the dose will be increased to 1000 mg twice daily in the second week. Treatment repeats every 4 weeks (2 g on days 1-28) for up to 6 circles in the absence of disease recurrence or unacceptable toxicity.
1630500|NCT02005406|Device|Experimental group and control groupl|JET
1630501|NCT02005393|Device|FICE Image Acquisition followed by NBI Image Acquisition|Images Captured with FICE Device, followed by same locations imaged with NBI Image Acquisition System
1630502|NCT02005380|Other|Text-based task|Participants are required to take text-based exercise.
1630503|NCT02005380|Other|Graphic-based Task|Participants are required to take the graphic-based exercise.
1630504|NCT02005367|Behavioral|Natural Recovery-Horticulture|"Participants in Natural Recovery-Horticulture received a one-hour small group therapy session during the week using Horticulture modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time.
Natural Recovery participants also pursued four hours of gardening on each weekend day while DAP-CP attended large-group lectures."
1630505|NCT02005367|Behavioral|Natural Recovery-Art/Music|Participants in Natural Recovery-Art/Music received a one-hour small group therapy session during the week using Art/Music modules with a staff facilitator while DAP-CP participants attended a large psychoeducational group at that time. Natural Recovery participants also pursued four hours of art or music on each weekend day while DAP-CP attended large-group lectures.
1630508|NCT02005341|Device|nanOSS|
1630509|NCT02005341|Device|Autograft|
1630510|NCT02005328|Device|Tested product : DC161-DP0291|Application of product in the mouth twice daily
1630511|NCT02005328|Device|Tested product : DC161-DP0292|Application of product in the mouth twice daily
1630512|NCT02005328|Device|Tested product : DC161-DP0293|Application of product in the mouth twice daily
1630513|NCT02005328|Device|Reference product: solution for oromucosal sprays|Application of product in the mouth twice daily
1630514|NCT02005315|Drug|Vantictumab|Administered intravenous (IV) infusion.
1630515|NCT02005315|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered by intravenous (IV) infusion.
1630516|NCT02005315|Drug|Gemcitabine|Gemcitabine will be administered by intravenous (IV) infusion.
1630517|NCT02005302|Drug|1,25(OH)2 Vitamin D3|Oral 1,25(OH)2 Vitamin D3 by 0.25 microgram once daily at start and regulate the dose according to the changes of blood levels of 25(OH)Vit D, calcium, phosphorus, and intact parathyroid hormone.
1630518|NCT02005302|Drug|Vitamin D2|Oral Vit D2 1.25mg(50,000 unit) once weekly as a start and maintain 1.25mg(50,000 unit) once monthly according to the blood 25(OH)vitamin D level.
1630519|NCT02005302|Dietary Supplement|low protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of 0.6g-0.8g/kg/d.
1630520|NCT02005302|Dietary Supplement|normal protein diet|Using nutritious software to make meals recipes and give dietary guidance for patients to reach the DPI goal of more than 0.8g/kg/d.
1630521|NCT02005289|Biological|MOR00208|Given by IV infusion
1630522|NCT02005289|Drug|lenalidomide|Given PO
1630523|NCT02005289|Other|Correlative Studies|Correlative studies associated with this trial will focus on the effects of MOR00208 alone and in combination with lenalidomide on immune effector cell number and function.
1630524|NCT02005276|Behavioral|Basic Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5. Expected value is about $1.40 per person per day.
1630561|NCT02004886|Drug|Metformin|500 mg metformin tablets
1663706|NCT01747551|Drug|Folinic Acid|
1630525|NCT02005276|Behavioral|Combined Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 4 chance of winning $5 and a 1 in 100 chance of winning $50. Expected value is about $1.40 per person per day.
1630526|NCT02005276|Behavioral|Jackpot Lottery|Participants who meet their daily step goals will be eligible for a daily lottery. They will have about a 1 in 400 chance of winning $500. Expected value is about $1.40 per person per day.
1630527|NCT02005263|Procedure|Salpingography|Infusion of typically 1-2 mL of air bubbles in to the uterine cavity to assess whether they disappear through the ostia in to the Fallopian tubes.
1630528|NCT02005237|Behavioral|Aerobic Exercise|3-months exercise program tailored to the individual level of aerobic fitness. Patients will exercise on a bicycle ergometer (2-3 session per week) according to a predefined training plan with increasing duration and intensity
1630529|NCT02005224|Other|LCHF diet and a bout of exercise|Low-carbohydrate/high-fat diet; effect on insulin sensitivity, lipid profile, weight and body composition. Participants ingested LCHF diet for three weeks before undergoing an oral glucose tolerance test. The same afternoon the participated in an one hour indoor bicycle training at 75% at HFpeak. The following morning they underwent a new oral glucose tolerance test. Body composition and weight were measured before and after the intervention. Oral glucose tolerance test was also performed before the intervention for baseline. Blood samples were collected before and after the intervention for lipid profile analyses.
1630530|NCT02005211|Drug|AZD3293|Oral solution
1630531|NCT02005211|Drug|Placebo|Oral solution
1630532|NCT02005198|Other|No treatment given|Subject will only fill out a questionnaire when entering the non-interventional study
1630533|NCT02005172|Device|Alivecor monitor and 14 day event monitor|Alivecor monitor and 14 day event monitor
1630534|NCT02005159|Other|Microbiological studies|
1630535|NCT02005120|Drug|Bevacizumab|Intrapleural administration of bevacizumab
1630536|NCT02005120|Drug|recombinant human endostatin|Intrapleural administration of recombinant human endostatin
1630537|NCT02005107|Drug|Venlafaxine IR and Venlafaxine XR|
1630538|NCT02005081|Device|Actifuse SHAPE|Actifuse Synthetic Bone Graft substitutes mixed with bone marrow aspirate in cervical spine fusion. Actifuse is a synthetic, porous, silicate-substituted hydroxyapatite and has shown that this maximizes a favorable bony response.
1630539|NCT02005081|Device|Autograft with Demineralized Bone Matrix|autograft mixed with demineralized bone matrix in cervical spine fusion.
1630540|NCT02005068|Drug|Ceftaroline|The duration of treatment will vary based on type of infection (acute osteomyelitis or joint infection) and if MRSA positive or negative.
1630541|NCT02005055|Procedure|Surgical excision with adjuvant high-dose-rate brachytherapy|The keloid was excised extralesionally and subsequently a metal tipped Varisource catheter was positioned between the dermal edges of the wound, 5 mm below the surface of the skin and extending out of the skin beyond the wound. Primary wound closure was performed and patients were transferred to the radiation department, where the catheter was connected to the Iridium-192 remote control afterloader. The planning target volume was defined as a cylinder along the axis of the scar, with a central diameter of 5mm. Patients received 2 fractions of HighDoseRate brachytherapy. Within 4 hours after the resection, the first brachytherapy fraction of 6 Gy at 5mm of the source axis was given. Within 24 hours after the first fraction a second fraction of 6Gy was administered to a total dose of 12Gy in 2 days. After the second fraction the catheter was gently removed.
1630542|NCT02005042|Behavioral|Feedback on smartphone|Receive personalized feedback (EMI) on smartphone regarding physical activity
1630543|NCT02005029|Drug|Erythromycin|
1630544|NCT02005029|Drug|placebo|
1630545|NCT02005016|Behavioral|Naming therapy|Participants will receive behavioral therapy which is designed to stimulate semantic (meaning) representations which are required for successful naming (word production). Therapy will be administered for 4 weeks on an intensive schedule (5 days a week, approximately 4.5 hours per day).
1630546|NCT02005003|Behavioral|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
1630547|NCT02005003|Procedure|Blood samples|Hormone levels will be analyzed from blood samples obtained before and after a caloric preload given at each visit
1630548|NCT02005003|Biological|Feces collection|Feces samples will be collected on the morning of each visit, before and after each 2-week intervention period, as well as after each 2-week washout period following each intervention period.
1630549|NCT02005003|Procedure|Caloric preload|A caloric preload will be given to participants, following which blood will be taken at 65 minutes later (specified in Blood sampling) following the ingestion of the caloric preload.
1630550|NCT02005003|Behavioral|Food selection task|Participants are given the opportunity to write and use a computer program to specify amount and type of food would ideally like to consume
1630551|NCT02005003|Behavioral|Memory task|Participants perform short memory tasks on each visit
1630552|NCT02005003|Behavioral|Food consumption task|Participants are given a selection of food items to consume on each visit
1630553|NCT02004990|Procedure|Single cleansing procedure of 10% Povidone Iodine|Single cleansing procedure of 10% Povidone Iodine prior to an in-office 5% Sodium Fluoride varnish application
1630554|NCT02004977|Behavioral|Improve access to the school breakfast program|Access to the school breakfast program is defined as implementation of a grab-n-go cart outside of the school cafeteria, policy change allowing students to eat in the hallway and marketing of the program. in rural high schools.
1630555|NCT02004951|Device|Misago RX|
1630556|NCT02004951|Device|Zilver PTX|
1630557|NCT02004938|Device|Sonosite Titan Ultrasound Machine|
1630558|NCT02004912|Other|Mentoring intervention|The mentoring intervention involves periodic supportive visits and education to health center staff by nurse mentors.
1630559|NCT02004899|Drug|Fentanyl|After obtaining informed consent, patients are randomized into one of two treatment groups or a control group by a computer generated random number table. After confirmation of epidural placement following test dose administration, a loading dose of 10 ml 0.08% Bupivacaine containing 20 mcg Fentanyl is administered after adding 1.6 ml 0.9% NaCl (Sodium Chloride) in the control group (F20).
1630560|NCT02004886|Drug|MK-0893|10 mg and 100 mg tablets
1630564|NCT02004873|Device|Micra Pacemaker Implant|
1630565|NCT02004860|Drug|Protopic (R)|Protopic® 0.1% ointment - 2 applications per week for 6 months
1630566|NCT02004860|Drug|Mycoster (R)|Mycoster 1% - 2 applications per week for 6 months
1630567|NCT02004847|Device|PSO-CT02|The PSO-CT02 device is a non CE marked investigational medical device that is worn on the affected skin area where it irradiates the Psoriasis plaque for 30 minutes with blue light.
1630568|NCT02004834|Drug|levobupivacaine|Comparing: 0,5% levobupivacaine with 2% lidocaine
1630569|NCT02004821|Dietary Supplement|Renutryl® Booster, an oral nutritional supplement in a 300 ml bottle (600 kcal, 30 g protein, 72 g carbohydrate, 21 g fat). One bottle per day during 14 days.|
1630570|NCT02004795|Radiation|BNCT + IG-IMRT|Single faction of BNCT (20 Gy) plus IG-IMRT (40 Gy/20 fractions)
1630571|NCT02004782|Drug|Prednisolone|
1630572|NCT02004769|Drug|Trastuzumab|Trastuzumab (Herceptin) will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks (q3w), until disease progress or intolerable toxicity.
1630573|NCT02004769|Drug|Docetaxel|Docetaxel 60mg/m2 (on day 1) every 3 weeks for 6 cycles.
1630574|NCT02004769|Drug|Capecitabine|Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
1630575|NCT02004756|Other|Exercise Program|The Fontan cohort will subsequently complete a 12-week moderate intensity exercise intervention whereby individualized activity-based home interventions will be prescribed (i.e., sample activities: walking, jogging, swimming, cycling, soccer). More specifically, individualized weekly exercise programs for participants will be provided incorporating two specific exercise components.
1630576|NCT02004743|Behavioral|Intervention|"Psychological guidelines and PET
Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD."
1630577|NCT02004743|Other|Treatment as usual|"Participants will experience treatment as usual.
Patients will receive questionnaires at recruitment, 1 month, 3 months and 6 months based on the timeline of Diagnostic and Statistical Manual (DSM) -IV criteria for PTSD"
1630578|NCT02004730|Device|ABSORB implantation|ABSORB implantation for long (> 24mm) single vessel disease
1630579|NCT02004717|Drug|DS-8895a|
2011583|NCT02495038|Drug|10% reduction of combination of Esmeron® and Nimbex®|Patients were randomly assigned to each group by opening of sealed allocation envelope. After collection of data, allocation number was matched with each group. The participants matched at Group S were administered with NMBAs reduced 10% of each ED95. Before patients arrived in the operating room, rocuronium and cisatracurium were prepared by a nurse who was not involved in this study. Each drug dosage was determined by allocation number. The syringe containing each study drug was conveyed to the performer of this study as the status of shielding the scale. The syringes of rocuronium and cisatracurium used each other syringe.
2011584|NCT02495038|Drug|20% reduction of combination of Esmeron® and Nimbex®|The participants matched at Group L were administered with NMBAs reduced 20% of each ED95.
1630583|NCT02004678|Drug|DS-1150b|
1630584|NCT02004678|Other|Placebo|
1630585|NCT02004652|Drug|Prucalopride|Prucalopride, 2mg, tablet. First given 24 hours after surgery beginning on POD 1,until bowel movements or for a maximum of 7 days of postoperative treatment
1630586|NCT02004652|Drug|Placebo|Vitamin, 50mg, tablet.
1630587|NCT02004639|Radiation|Masticators sparing techniques|
1630588|NCT02004639|Other|electro-acupunture treatment|electro-acupunture treatment and sham-EA
1630589|NCT02004626|Drug|Collagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.
Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.
Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).
Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.
Photographic records."
1630590|NCT02004626|Drug|Kollagenase|"Conduction of security tests: complete coagulation and glycosylated hemoglobin. Volunteers in childbearing age, with β-HCG (human chorionic gonadotropin) test.
Verification of anthropometric data, clinical evaluation, PU evaluation, randomization and treatment start.
Wash the wound with 0.9 % sterile saline solution; Apply of the investigational product directly in the devitalized tissue (necrotic tissue and Slough).
Cover the wound with sterile gauze and dry transparent film. The procedures for the exchange of bandages must be done every day, twice a day until the total debridement of devitalized tissue.
Photographic records."
1630591|NCT02004613|Drug|Dexmedetomidine|Dexmedetomidine
1630592|NCT02004613|Drug|Placebo|Normal saline administration matching dexmedetomidine rate of infusion
1630593|NCT02004600|Procedure|Photodynamic therapy (PDT)|1 session of Photodynamic therapy (PDT) on epidermis dysplasia
1630594|NCT02004587|Drug|Gemigliptin|Gemigliptin is administered to each hepatic impairment subject for single oral dose. Also it is administered to healthy volunteer for single and multiple doses.
1630596|NCT02004548|Drug|Metatinib Tromethamine|
1630597|NCT02004535|Procedure|Cochlear Implantation|The standard surgical procedure for a cochlear implant will be used. The asymmetric participant will receive the cochlear implant in the deaf ear.
1630598|NCT02004522|Drug|IPI-145 (duvelisib)|
1630599|NCT02004522|Drug|Ofatumumab|
1630600|NCT02004509|Drug|anticoagulant by physician criteria|Anticoagulant treatment will be started in case of subclinical atrial fibrillation (>5,5 hours per day) be diagnosed by cardiac implantable electronic device at intervention group, or clinical atrial fibrillation in both groups.
1630601|NCT02004496|Device|Consilium|Patients use a mobile application to track their subjective well-being and adverse events (AE) while ambulant chemotherapy. The mobile app supports the patients in the structured and standardized entry of their data and is developed specifically for this study.
1630654|NCT02004080|Other|Intensive Care treatment|intensive care treatment
1663707|NCT01747551|Drug|5-Fluorouracil|
1630602|NCT02004483|Procedure|Percutaneous Coronary Intervention|Percutaneous coronary intervention is performed according to standard practice. Direct stenting is required for the procedure as it is done in most coronary interventions today. After insertion of the non-inflated stent into the coronary lesion there should still be flow to the distal vessel. The stent should be implanted at high-pressure with balloon inflation lasting for 60 seconds to allow adequate expansion of the stent. Post-dilatation should be performed if required. However, this should be done more than 5 minutes after stent implantation.
1630603|NCT02004470|Procedure|Active lavage and suction|Active lavage and suction of the right upper quadrant will be performed as the laparoscopic procedure is about to be terminated.
1630604|NCT02004457|Behavioral|ABBT|
1630605|NCT02004457|Other|TAU|
1630606|NCT02004418|Radiation|11C-Choline|
1630607|NCT02004405|Other|strengthening exercise|"The experimental group (STRE) will receive strengthening training in Station for lifting weight exercises (Flex Mega 8, Flex Fitness Equipment Brand) using the recommendations of the American College of Sports Medicine (ACMS, 2010), twice a week, during 45 minutes for 16 weeks."
1630608|NCT02004405|Other|flexibility exercise|The control group (FLEX) will receive stretching and flexibility exercise training according to the protocol of prescription and previously tested and described in appendix F (Valim et al., 2003), twice a week, during 45 minutes for 16 weeks.
1630609|NCT02004392|Drug|EVP-6124|
1630610|NCT02004366|Drug|Linagliptin|Linagliptin once daily + correction doses of rapid acting insulin if needed
1630611|NCT02004366|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
1630612|NCT02004366|Drug|Linagliptin|Patients with admission A1C < 7% will be discharged on same pharmacologic regimen (oral agents, insulin therapy) or linagliptin 5 mg/day for 3 months.
1630613|NCT02004366|Drug|Linagliptin + 50% Glargine dose on discharge|Patients with admission HbA1c between 7% and 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 50% of daily hospital dose for 3 months.
1630614|NCT02004366|Drug|Linagliptin + 80% Glargine|Patients with admission HbA1c ≥ 9% will be discharged on previous oral anti-diabetic agents plus linagliptin, and consider glargine insulin at 80% of daily hospital dose for 3 months.
1630615|NCT02004353|Device|Cochlear® Hearing Implants|Market approved hearing implants including: Nucleus Cochlear implants, Nucleus Auditory Brainstem Implants, Cochlear Baha implants, Cochlear Acoustic Implants
1630616|NCT02004340|Device|ear vagus nerve stimulator|
1630617|NCT02004327|Drug|DW1029M300mg|DW1029M300mg PO Once
1630618|NCT02004327|Drug|DW1029M600mg|DW1029M300mg 2 tablets Once
1630619|NCT02004327|Drug|DW1029M1200mg|DW1029M300mg 4 tablets PO Once
1630620|NCT02004314|Drug|Chloroquine|
1630621|NCT02004301|Drug|Radiolabelled T4 Tablet|
1630622|NCT02004301|Drug|Radiolabelled T6 Tablet|
1630623|NCT02004288|Dietary Supplement|Lactobacillus reuteri Protectis DSM17938|One chewable tablet with L. reuteri or placebo taken once a day for 3 months. After the 3 month therapy both groups will be monitored for the next 3 months.
1630624|NCT02004275|Drug|pomalidomide|given PO
1630625|NCT02004275|Drug|ixazomib|given PO
1630626|NCT02004275|Drug|dexamethasone|given PO
1630627|NCT02004262|Biological|GVAX Pancreas Vaccine|
1630628|NCT02004262|Biological|CRS-207|
1630629|NCT02004262|Drug|gemcitabine, capecitabine, 5-FU, irinotecan or erlotinib|
1630630|NCT02004262|Drug|cyclophosphamide|
1630634|NCT02004223|Radiation|Dose escalation using stereotactic boost|"This is a dose escalation study. Participants will be allocated to the current dose level, or if the current dose level has been filled and acceptable toxicity has been established, they will be enrolled into the next dose level.
The first dose level will be 20Gy in 2 fractions to PTV and 25Gy to Gross Target Volume (GTV) if identified. The second dose level will be 22Gy in 2 fractions to PTV and 27.5Gy to GTV if identified. The dose level will be 24 Gy in 2 fractions to PTV and 30Gy to GTV if identified.
Following stereotactic boost, all participants will receive 46Gy in 23 fractions radiotherapy to the prostate / seminal vesicles +/- lymph nodes."
1630635|NCT02004210|Procedure|transarterial radioembolization (TARE)|transarterial radioembolization
1630636|NCT02004210|Procedure|transarterial chemoembolization (TACE)|transarterial chemoembolization
1630637|NCT02004197|Drug|Quadruple Allopathic therapy|
1630638|NCT02004197|Drug|Pylorex plus|
1630639|NCT02004184|Drug|maintenance pemetrexed|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
1630640|NCT02004184|Drug|pemetrexed at progression|500 mg/m2 Body Surface Area is administered intravenously every 3 weeks
1630641|NCT02004171|Other|electronic cigarette|V2 Cigs with 24 mg nicotine cartridges
1630642|NCT02004171|Drug|nicotine inhaler|nicotine inhaler with 10 mg nicotine cartridges
1630643|NCT02004158|Behavioral|Positive psychology intervention|
1630644|NCT02004145|Behavioral|Positive Psychology|The Positive Psychology intervention consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
1630645|NCT02004145|Behavioral|Control Condition|The Control Condition consists of 6 exercises that will be completed by the participant with the guidance of a trainer.
1630646|NCT02004132|Drug|Axiron|Solution administered topically using pump and applicator
1630647|NCT02004119|Drug|KHK4577|
1630648|NCT02004119|Drug|Placebo|
1630649|NCT02004106|Drug|RO6895882|Participants will receive RO6895882 at different dose levels and schedules defined in respective arms as IV infusion.
1630650|NCT02004093|Drug|pertuzumab|Loading dose of 840 mg IV, followed by 420 mg IV every 3 weeks
1630651|NCT02004093|Drug|paclitaxel|175 mg/m2 IV every 3 weeks for 6 cycles
1630652|NCT02004093|Drug|gemcitabine|1000 mg/m2 IV Day 1 and 8 of each cycle for 6 cycles
1630653|NCT02004093|Drug|carboplatin|Target AUC of 5 following paclitaxel or AUC of 4 following gemcitabine IV every 3 weeks for 6 cycles
1630655|NCT02004067|Drug|Restasis|Restasis is an ophthalmic emulsion containing cyclosporine 0.5 mg/mL, produced by Allergan Inc.
1630656|NCT02004067|Drug|Refresh Endura|Refresh Endura is a topical lubricant produced by Allergan, Inc.
1630657|NCT02004054|Other|measure of pupil diameter|The measure will use infra-red cameras
1630658|NCT02004041|Drug|VLY-686|capsules containing 50 mg VLY-686
1630659|NCT02004041|Drug|Placebo|Sugar capsule to mimic VLY-686 50 mg capsule
1630660|NCT02004028|Drug|VS-6063|
1630661|NCT02004015|Drug|injection of placebo|0.5 mg/kg milligram(s)/kilogram
1630662|NCT02004015|Drug|injection of NMBA|
1630663|NCT02004002|Behavioral|Weight maintenance with normal protein intake|Control group will consume 1.4 g/kg/d of protein; consistent with the average protein intake in the US population.
1630664|NCT02004002|Behavioral|Weight maintenance with protein restriction|Protein restriction group will receive the Institute of Medicine RDA of 0.8 g protein/kg body wt/d.
1630665|NCT02003989|Other|ophthalmologic examination and MRI|thorough investigation of patients, not included in usual care.
1630666|NCT02003976|Procedure|Medial Opening Wedge High Tibial Osteotomy (HTO)|A lower limb realignment surgery to redistribute load away from the most affected portion of the knee.
1630667|NCT02003976|Other|Non-Surgical Treatment Program|A 12-week optimized non-surgical treatment program consisting of medication, physiotherapy and nutritional seminars.
1630668|NCT02003963|Behavioral|Klub Kinect|"Dance Central and Just Dance are a series of rhythm games developed by Harmonix Music Systems exclusively for the Xbox 360 Kinect. The Dance Central suite of games (Dance Central 1, 2, and 3) and Just Dance will be played on the Xbox 360+ Kinect gaming console, which employs whole body movement using an infrared sensor that tracks body movements such that an external controller device is not required. The player performs dance moves demonstrated by on-screen characters and set to popular music, with a choice of over 650 dance moves, 90 dance routines, and over 300 songs.
The exergaming condition will wear a pedometer to record total steps during game play, and they will participate in private weigh-ins at each session to track body weight over the 12-week intervention."
1630669|NCT02003950|Other|Snack Condition Specification|Individuals recieve a different snack for every week of the study. This is viewed as 4 phases. Phase 1 measures of habitual chocolate candy consumption (1 week), Phase 2 assesses participants' chocolate consumption while anticipating an oncoming chocolate candy restriction (1 week), Phase 3 is the total chocolate candy restriction period, but participants will be given 3 non-chocolate-candy snack substitutes in a random order (1 week per snack type, 3 weeks total), and Phase 4 examines participants' chocolate candy consumption when the 3-week restriction is lifted (1 week).
1630670|NCT02003937|Behavioral|Aerobic conditioning|Subjects performed 12 weeks of aerobic training on a stationary cycle ergometer. Subjects compleeted a total of 42 training sessions of 30min. exercise at an individually adjusted moderate workload.
1630671|NCT02003924|Drug|Enzalutamide|160 mg by mouth once daily
1630672|NCT02003924|Drug|Placebo|Sugar pill to mimic enzalutamide
1630673|NCT02003911|Drug|Azithromycin|Azithromycin suspension (200mg/5mL)
1630674|NCT02003911|Drug|Placebo|
1630675|NCT02003898|Device|Medtronic MiniMed 530G Insulin Pump|
1630676|NCT02003885|Drug|increment of desflurane|"After achieving stable hemodynamics and BIS 40-60 with desflurnae 0.5 MAC and remifentanil 0.7-1.0 mcg/kg/min (T1), data including S', E', A', EF, E, A and BIS are determined.
After 10 min exposure to the increased desflurane dosage 1.0 MAC (T2), data are determiend. After 10 min exposure to the increased desflurane dosage 1.5 MAC (T3), data are determined.
Reduction of BP is managed by the increment of phenylephrine infusion"
1630677|NCT02003872|Device|Spatz 3 intragastric balloon|Intra gastric balloon implanted using gastroscopy
1630678|NCT02003833|Device|Poly-L-lactic acid|Sculptra injections
1630679|NCT02003833|Device|Placebo comparator|saline injections
1630680|NCT02003820|Behavioral|video modeled social story|Patient will watch a Youtube compatible video of a child in the same age range as the study participants demonstrating proper brushing technique. The video will be paired with written subtitles created using the Social Story format. The subtitles will be read to the participant as the video plays. The patient will watch the video immediately before each brushing session morning and night for the three week intervention. After the intervention period the video will be made available on Youtube.com for the participants to use as they wish.
1630681|NCT02003794|Drug|0.9% NaCl solution|0.9% NaCl solution intravenous infusion: 100 ml/hr for three days.
1630682|NCT02003768|Drug|Propofol|80 patients are randomly allocated into two groups: In TIVA group, propofol based total intravenous anesthesia is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
1630683|NCT02003768|Drug|Desflurane|80 patients are randomly allocated into two groups : In Des group, inhalation anesthesia using desflurane is used to induce and maintain anesthesia for laparoscopic cholescystectomy.
1630684|NCT02003755|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
1630685|NCT02003742|Drug|NX-1207|Single TRUS-guided intraprostatic injection of 2.5 mg of NX-1207
1630686|NCT02003742|Drug|Tamsulosin|1 film coated, prolonged release tablet of tamsulosin 0.4 mg, to be taken orally (p.o.) QD
1630687|NCT02003729|Device|Portable Sleep Monitor|ApneaDx™ is a new PM that uses a microphone to record breath sounds and an acoustical analysis algorithm of breath sounds to determine the AHI.
1630688|NCT02003703|Biological|Recombinant Hepatitis B Virus Vaccine|
1630689|NCT02003690|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy
1630690|NCT02003690|Behavioral|Standard of Care Psychotherapy|Standard of Care Psychotherapy
1630691|NCT02003690|Drug|Pharmacotherapy|Standard of Care Pharmacotherapy
1630692|NCT02003677|Drug|Faster-acting insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
1630693|NCT02003677|Drug|insulin aspart|Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
1630694|NCT02003664|Drug|Baclofen ER|Comparison of Baclofen ER to placebo using a 2 to 1 chance of receiving Baclofen ER, the medication
1630695|NCT02003664|Drug|Placebo|Comparison of placebo to Baclofen ER using a 1 in 3 chance of receiving placebo
1630696|NCT02003651|Dietary Supplement|Quick Defense|Echinacea product from Gaia Herbs.
1630697|NCT02003651|Dietary Supplement|Placebo|Placebo
1630698|NCT02003638|Drug|Niacin|Niacin titrated to 6000 mg daily
1630699|NCT02003638|Drug|Placebo|Placebo provided in the same pill quantity as niacin arm
1630700|NCT02003625|Drug|GCSF|
1630701|NCT02003625|Drug|meloxicam|
1630702|NCT02003625|Drug|Placebo|
1630703|NCT02003612|Other|Not applicable - observational study|No intervention exists as this is a retrospective observational study
1630704|NCT02003599|Device|Laser therapy|The low level laser therapy used in this trial will be Photon Lase III (DMC, approved by ANVISA for medicinal purposes). This InGaAIP laser emits a pulsed 660 nanometer beam with an average output of 80 milliwatts and the average energy density delivered to the breast will be 3 J/cm2.
1630705|NCT02003599|Device|Placebo|In the control group, 26 patients will be submitted to a laser, but the laser will be disabled without affecting its apparent function , five days a week before radiotherapy .
1630706|NCT02003586|Dietary Supplement|plant-based ingredient|
1630707|NCT02003586|Dietary Supplement|No plant-based ingredient|
1630708|NCT02003573|Drug|decitabine iv|decitabine iv fixed dose
1630709|NCT02003573|Drug|volasertib iv infusion|volasertib iv infusion (Body Surface Area (BSA) based dosing)
1630710|NCT02003560|Radiation|accelerated partial breast irradiation|9 x 4.1 Gy accelerated partial breast irradiation delivered by 3D-CRT or IMRT over 5 consecutive days, using twice-a-day fractionation.
1630711|NCT02003547|Drug|AMA0076|
1630712|NCT02003547|Drug|Placebo|
1630713|NCT02003534|Drug|0.15% Brimonidine Tartrate|0.15% Brimonidine Tartrate (Alphagan® P) 1 drop in the affected eye 3 times daily for 3 months.
1630714|NCT02003521|Device|Lung Flute|A low frequency wave is generated at the mouth by exhaling through a mouthpiece over a laminar surface (Reed) inside the Lung Flute®. The resulting low frequency acoustic wave that is produced travels retrograde into the lower airways and lung parenchyma and increases mucociliary clearance. Patients expel air with the force required to blow out a single candle. Patients concentrate on producing a low tone through the device while breathing in a proscribed pattern. Twenty repetitions of a single two-breath pattern are performed with the device to complete a diagnostic session.
1630715|NCT02003495|Biological|MCV-ACYW135 Vaccine Group|0.5ml, intramuscular
1630716|NCT02003495|Biological|MPV-ACYW135 Vaccine Group|0.5ml, intramuscular
1630717|NCT02003495|Biological|MPV-A Vaccine Group|0.5ml, intramuscular
1630718|NCT02003495|Biological|MCV-AC Vaccine Group|0.5ml, intramuscular
1630719|NCT02003495|Biological|Hib Vaccine Group|0.5ml, intramuscular
1630720|NCT02003482|Radiation|Postop IMRT for head/neck cancer|Patients will be enrolled in study through the duration of their radiation therapy, approximately 6-8 weeks. After which time no further evaluations will be made.
1630721|NCT02003482|Device|CT for Radiation Treatment Planning|Treatment planning CT scans will be required to define tumor, clinical, and planning target volumes. This study requires CT scans prior to initiation of treatment then again on the third and sixth week of radiation treatment
1630722|NCT02003469|Device|Ambulatory Blood Pressure Monitoring|All enrolled patients have an ambulatory blood pressure monitor placed, pre-transplant/donation, again at 3 months and finally at 12 months post-transplant/donation to measure blood pressure and blood pressure patterns
1630723|NCT02003456|Drug|Cardiac PET scan w/18F-Fluorodeoxyglucose and rubidium-82|Study subjects will undergo a Cardiac PET scan that will take approximately 20 minutes to complete. In addition to standard clinical rubidium-82/18F-fluorodeoxyglucose (FDG) PET imaging, during a separate imaging session, participants will be infused with a second dose of the radio-tracer rubidium-82 during FDG imaging scan that will take an additional 10 to 15 minutes to complete.
1630724|NCT02003443|Behavioral|Self-Administered Acupressure|The intervention involves teaching and supporting subjects to administer acupressure on themselves.
1630725|NCT02003404|Device|Control Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
1630726|NCT02003404|Device|Peristomal Abdominal Skin|Three barrier materials will be peeled from abdominal skin after a set period at a set rate.
1630727|NCT02003391|Drug|Beta-blocker monotherapy|Per participant's current prescribed therapy
1630728|NCT02003391|Drug|Travoprost 0.004% / timolol 0.5% fixed combination ophthalmic solution|
1630729|NCT02003378|Device|Pacemaker sensor set to MV|Pacemaker sensor set to minute ventilation
1630730|NCT02003378|Device|Pacemaker sensor set to XL|Pacemaker sensor set to accelerometer
1630734|NCT02003352|Procedure|Functional Neurological Rehabilitation|Functional Neurological Rehabilitation Includes vestibular rehabilitation and physical rehabilitation. Vestibular rehabilitation utilizes strategies that involves movement of the head and eyes at various speeds and directions while the subject looks at a target. Physical rehabilitation involves exercises to increase mobility and increase strength.
1630735|NCT02003339|Other|Additional RMIs|
1630736|NCT02003326|Other|Inflammatory markers|
1630737|NCT02003313|Biological|Group T|0.5ml, Intramuscular
1630738|NCT02003313|Biological|Group C|0.5ml, Intramuscular
1630739|NCT02003287|Other|VFSS|Videofluoroscopic Swallow Study
1630740|NCT02003287|Other|FEES|Fiberoptic Endoscopic Swallow Study
1630741|NCT02003274|Other|Clamp-Mixed Meal|"Standard clinical parameters will be assessed in all patients.
Metabolic tests:
A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out in type 1 diabetic patients to assess insulin sensitivity, as previously described (1).
B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump
This test will determine the time courses of:
1. plasma glucose, 2. 13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
1630792|NCT02002949|Procedure|Conventional hemodialysis|3 treatments per week for approximately 4 hours (range 3 hours and 30 minutes to 4 hours) per treatment, to be performed in a dialysis clinic using any hemodialysis machine as chosen by the responsible clinicians in each participating center
1663708|NCT01747551|Drug|Ziv-aflibercept|
1630742|NCT02003274|Other|IVGTT-Mixed Meal Arm|"Standard clinical parameters will be assessed in all subjects.
Metabolic tests:
A. IVGTT. A frequently sampled intravenous glucose tolerance test (IVGTT) in healthy controls will be carried out in study 1 and study 3 to assess insulin sensitivity.
B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter.
This test will determine the time courses of:
1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
1630743|NCT02003261|Behavioral|Unified Protocol with Treatment As Usual|"Unified Protocol(UP) is a transdiagnostic cognitive-behavioral therapy for depressive and anxiety disorders, which is developed by Dr. Barlow and his colleagues at Boston university.
UP is weekly, face to face, individual psychotherapy consisting of 9 to 20 sessions. Average session number is 16 sessions. Contents of the treatment includes motivational enhancement, psychoeducation of treatment rationale and emotion, emotion awareness training, cognitive reappraisal, avoidance and emotion driven behaviors, interoceptive exposure and emotion exposure."
1630744|NCT02003261|Other|Treatment As Usual|Most of the TAU will be drug therapy or nonsystematic supportive psychotherapy.
1630745|NCT02003248|Device|transcranial magnetic resonance guided focused ultrasound pallidotomy|Focused ultrasound is an attractive method for non-invasive thermal ablation of soft tissue, including functional brain targets. Treatment begins by acquiring a series of MR images of the target organ. The physician then identifies a target volume in the MR images, and delineates the treatment contours on the images. Therapy planning software calculates the parameters required to effectively treat the defined target volume. During the treatment, an ultrasound transducer generates a point of focused ultrasound energy, called a sonication. The sonication raises the tissue temperature within a well-defined region, enabling neurophysiological assessment in the low range, and thermal coagulation at higher ranges. MR images acquired during sonication provide a quantitative, real-time temperature map of the target area to confirm the location of the sonication and the size of the affected region.
1630746|NCT02003235|Device|Daily watching videos using Reviview™, a dichoptic video display device, for 60 min|
2011585|NCT02494258|Drug|CC-486|The subject will continue at the same dose, frequency and schedule used for the last dose of CC-486 given in the preceding CC-486 study. Subjects are allowed to rollover after the last cycle is finished and before the new cycle begins in the parent protocol. There is a 7 day window from End of Study on the parent protocol and when the participant will start Day 1 of the rollover study.
2011586|NCT02494076|Drug|EzPAP|
2011587|NCT02494076|Other|Standard Care|
2011588|NCT02493855|Drug|Ombitasvir/ABT-450/Ritonavir|Ombitasvir/ABT-450/ritonavir combination tablets
2011589|NCT02493855|Drug|Dasabuvir|Dasabuvir tablets
2011590|NCT02493855|Drug|Ribavirin (RBV)|Ribavirin tablets
2011591|NCT02494713|Drug|Degarelix|Subcutaneous injection, once/month for 4 months
2011592|NCT02494713|Drug|Doxorubicin|20 mg/m2 as a 24-hour intravenous infusion on day 1 each week, weeks 1, 3, and 5
2011593|NCT02494713|Drug|Ketoconazole|400 mg orally 3 times daily for 7 days, in weeks 1, 3, and 5
2011594|NCT02494713|Drug|Docetaxel|35 mg/m2 intravenously on day 1 of each week, weeks 2, 4, and 6
2011595|NCT02494713|Drug|Estramustine|280 mg orally 3 times daily for 7 days, in weeks 2, 4, and 6
2011596|NCT02489669|Device|RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA)|Patients in the RenalGuard group will be treated by hydration with normal saline controlled by the RenalGuard system™® (PLC Medical Systems, Inc. Franklin, MA, USA). The RenalGuard system includes a) a closed loop fluid management system; b) a high volume fluid pump, c) a high accuracy dual weight measuring system; d) motion detection artifact reduction; e) a single use intravenous set and urine collection system that interfaces with a standard Foley catheter; f) real-time display of urine and replacement fluid volume; g) a timely alerts to drain the urine bag or to replace the hydration fluid bag; f) and safety features such as automatic air and occlusion detection.
1630772|NCT02003183|Radiation|[F-18]FDDNP|[F-18]FDDNP is a molecular imaging probe for PET, with high in vitro binding affinity to NFTs and of the fibrillar tau deposits as shown with fluorescent microscopy with non-radioactive FDDNP.
1630773|NCT02003157|Procedure|hypnosis during embryo transfer or usual transfer procedure|
1630774|NCT02003144|Biological|eculizumab|
1630775|NCT02003131|Biological|Trophic factors from umbilical cord mesenchymal stem cells|
1630778|NCT02003092|Drug|RX-5902|escalating doses (mg)
1630779|NCT02003079|Behavioral|Cystic Fibrosis Questionnaire (Revised) for Teens/Adults|
1630780|NCT02003066|Procedure|Standard fluid therapy|In Standard fluid therapy group, the administration of fluid will be guided to maintain mean blood pressure more than 65 mmHg, urine output more than 0.5 ml/kg/hr, and central venous pressure less than 14 mmHg.
1630781|NCT02003066|Procedure|Conservative fluid therapy|In Goal directed fluid therapy group, the administration of fluid will be guided by stroke volume variation. The anesthesiologist will infuse volulyte (Fresenius Kabi, Bad Homburg, Germany) 200 ml if stroke volume variation is over 12%. If cardiac index is below 2.5 l/min/m2 and stroke volume variation is below 12%, start dobutamine.
1630783|NCT02003040|Device|Mespere Venus 1000 CVP System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject. A CVP measurement is recorded at time of patient's hospital admission and discharge. CVP readings will remain concealed from the treating team.
1630784|NCT02003027|Drug|BT injection|
1630785|NCT02003014|Drug|Pioglitazone|Pioglitazone Tablets
1630786|NCT02003001|Drug|Botulinum Toxin|
1630787|NCT02002988|Procedure|endomyocardial BT injection|
1630788|NCT02002975|Drug|Pioglitazone|Pioglitazone tablets
1630789|NCT02002962|Procedure|radiofrequency ablation|
1630790|NCT02002962|Drug|Botulinum Toxin Type A injection|
1630791|NCT02002949|Procedure|Short daily hemodialysis|5 or 6 treatments per week for approximately 3 hours (range 2 to 4 hours) per treatment, to be performed at the patient's home, using any hemodialysis machine as chosen by the responsible clinician in each participating center
1630827|NCT02002637|Device|Latella Knee Implant System|
1630828|NCT02002624|Device|PSI|
1630829|NCT02002624|Device|Conventional instrumentation|
1630793|NCT02002936|Drug|SyB C-1101|"SyB C-1101（rigosertib sodium） will be administered orally twice daily for 14 consecutive days, followed by 7-day observation period. The treatment period of 21 days (14 days of administration + 7 days of observation) constitutes 1 cycle.
The dose at cycle 6 in the study 2012002 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 7).
From cycle 8 on, the dose of SyB C-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle."
1630794|NCT02002923|Procedure|Pulmonary vein isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
1630795|NCT02002923|Drug|Botulinum Toxin|Transseptal puncture is performed by used standard endovascular approach. Injection of the botulinum toxin is performed in main anatomical zones of ganglionated plexuses of left atrium using Myostar catheter (Biosense Webster).
2011597|NCT02486640|Drug|Interferon beta-1b (Betaferon, BAY86-5046)|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector.
2011598|NCT02486640|Device|Betaconnect Autoinjector|Multiple Sclerosis patients who are treated with Betaferon and who are using the Betaconnect auto-injector.
2011599|NCT02486224|Dietary Supplement|Kona Deep|Subjects will receive Kona Deep post exercise
2011600|NCT02486224|Dietary Supplement|Spring Water|Subjects will receive Spring Water post exercise
2011601|NCT02486224|Dietary Supplement|Sports Drink|Subjects will receive Sports Drink post exercise
1630801|NCT02002871|Device|PSO-CT02 device|The PSO-CT02 device is worn on the affected skin area where it irradiates the target Eczema area for 30 minutes with blue light. A contralateral eczema area is left untreated and serves as control.
1630802|NCT02002858|Drug|Nicotine Patch|
1630803|NCT02002858|Behavioral|Depression and Anxiety Smoking Cessation Treatment|Cognitive-behavioral treatment program that blends smoking cessation, anxiety, and depression management/reduction treatment strategies
1630804|NCT02002858|Behavioral|Educational-Support Psychotherapy|Educational-based psychotherapy and standard smoking cessation treatment program
1630805|NCT02002845|Device|robotic surgery using the da Vinci Surgical System|
1630806|NCT02002832|Drug|Lurasidone tablets|40 or 80mg, dose escalation
1630807|NCT02002832|Drug|Risperidone tablets|2-6 mg, dose escalation
1630808|NCT02002819|Drug|levetiracetam|
1630809|NCT02002806|Other|Alcohol Injection|Celiac plexus neurolysis by alcohol injection
1630810|NCT02002806|Other|Placebo Injection|
1630811|NCT02002793|Other|Early stage abdominal drainage|Ultrasound/CT/GUS guided abdominocentesis and drainage with single-chamber deep venous catheters shoule be implemented and the catheter should be removed when abdominal drainage flow≤100ml in two successive days;
1630812|NCT02002793|Other|Late stage abdominal drainage|Despite that it matches one of the cirteria as the study group:1．Intravesical pressure≥20cmH2O or 2．CT scan:acute peripancreatic liquid collection, the patients continue acquire prearranged integrative treatment and will not accept early stage abdominal drainage until any of the followings emerge:1.Intra-abdominal apartment syndrome; 2. Pancreatic pseudocyst;3. Pancreatic or peripancreatic necrosis;
1630813|NCT02002780|Behavioral|Day Camp|"The intervention will be delivered using a day camp structure, on a weekend or during school break in July 2011. Separate interventions will be offered for boys and girls. Each intervention will include two full days (0900 to 1600) of group activities lead by the researchers. Details of the camp activities will be developed by the researchers, based on the types of psychosocial stress identified during the screening phase of the project."
1630814|NCT02002767|Drug|GS-5816|GS-5816 100 mg (2 x 50 mg tablets) administered orally
2011602|NCT02487199|Drug|Ombitasvir/Paritaprevir/Ritonavir|
1630816|NCT02002741|Drug|Paracetamol|Ibuprofen 3 doses administered q24h + Paracetamol 12 doses administered q 6h
1630817|NCT02002741|Drug|Placebo|Ibuprofen 3 doses administered q24h + Placebo : 12 doses administered q 6h
1630818|NCT02002715|Drug|Inhaled budesonide|inhaled Budesonide 2puff Q12h,total 400µg/day for 4 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 8 weeks inhaled Budesonide 2puff Q12h,total 400µg/day for 16 weeks
1630819|NCT02002702|Drug|Serelaxin|Intravenous infusion
1630820|NCT02002702|Drug|Placebo|Placebo
1630821|NCT02002689|Drug|LDE225|LDE225 800 mg (hard gelatin capsules) will be administered orally once daily on a continuous dosing schedule
1630822|NCT02002663|Drug|ropivacaine 0.2%|PCA morphine 0.5 mg/ml bolus 1 mg LO 5 min max 20 mg in 4 hs
1630823|NCT02002663|Drug|Methylprednisolone 1mg/kg|
1630824|NCT02002663|Drug|saline 0.9%|
1630825|NCT02002650|Drug|Pre-ERCP rectal Indomethacin|Rectal Indomethacin was administrated within 30min before ERCP in all patients.
1630826|NCT02002650|Drug|Post-operational Rectal Indomethacin|Rectal Indomethacin was administrated immediately after ERCP in high-risk patients, while average risk patients did not.
2011603|NCT02487199|Drug|Dasabuvir|
2011604|NCT02484443|Biological|Dinutuximab|Given IV
2011605|NCT02484443|Other|Laboratory Biomarker Analysis|Correlative studies
2011606|NCT02484443|Other|Pharmacological Study|Correlative studies
2011607|NCT02484443|Biological|Sargramostim|Given SC
2011608|NCT02483455|Drug|2014-ALC-919-US|A topical solution to be applied twice daily for the treatment of Common Warts
2011609|NCT02483455|Drug|Vehicle-Control Topical Solution|A topical solution to be applied twice daily for the treatment of Common Warts
2011610|NCT02482935|Drug|Abemaciclib|Administered orally
2011611|NCT02481830|Drug|Nivolumab|
2011612|NCT02481830|Drug|Topotecan|
2011613|NCT02481830|Drug|Amrubicin|
1630832|NCT02002598|Drug|Bendamustine|"Bendamustine will be administered IV on days 1 and 2 with dose escalation up to 90 mg/m2 of each 28-day cycle.
Dose escalation is as follows:
-1 | 60 mg/m2
| 70 mg/m2
| 70 mg/m2
| 90 mg/m2
| 90mg/m2
| 90 mg/m2"
1630833|NCT02002598|Drug|Carfilzomib|"Carfilzomib will be administered IV on Days 1, 2, 8, 9, 15, and 16 every 28 days.
Dose Escalation is as follows:
-1 | 27 mg/m2
| 27 mg/m2
| 36 mg/m2
| 36 mg/m2
| 45 mg/m2
| 56 mg/m2"
1630834|NCT02002598|Drug|Dexamethasone|Dexamethasone will be administered PO or IV, 20 mg, on 1, 2, 8, 9, 15, 16 and 22, 23 of each 28-day cycle.
1630835|NCT02002585|Procedure|Renal denervation|Catheter based renal sympathetic denervation is a endovascular method used for the treatment of resistent hypertension.
1630836|NCT02002572|Other|Magnetic Resonance Imaging (MRI), Surface scan, Motion capture, Digital Image Correlation|
2011614|NCT02480153|Biological|PF-06410293|PF-06410293 will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
1630841|NCT02002507|Other|comparison of different neurosurgical position|in 2 of 3 positions (supine, plus either prone or park bench) with both left and right internal jugular vein cross-sectional area of vein, doppler velocity, internal jugular venous flow, position of internal jugular vein in relation to carotid artery (All measured with the use of ultrasound)
1630842|NCT02002494|Other|Different positions|Jugular venous blood flow in healthy volunteers in 3 different positions- supine, prone and park bench
1630843|NCT02002481|Other|transport|The manikin will be resuscitated during a transport in a vessel by a professional team (emergency physician / paramedic).
1630844|NCT02002468|Other|Test result sent by letter|
1630845|NCT02002468|Other|Test result conveyed by general practitioners|
1630846|NCT02002455|Device|PET/CT, PET/MRI, mpMRI|FACBC dose 370 megabecquerel (MBq)
1630847|NCT02002442|Other|Mouthwash|An investigator will give the patient the assigned mouthwash based on the randomized group allocation. 30ml of the mouthwash will be given to the subject in a sterilized calibrated tube. The subject will be asked to rinse for 60 seconds. Then, the patient will spit the mouthwash.
1630848|NCT02002429|Procedure|Intra-articular injection|Intra-articular injection into the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
1630849|NCT02002429|Procedure|Medial branch block|Medial branch blocks at the nerves that supply the affected facet joint(s) with 0.5 ml of a 50:50 solution containing 10 mg of depo-methylprednisolone and 0.5% bupivacaine. If the subject has a positive block a radiofrequency denervation will be performed at the affected joint.
1630850|NCT02002429|Procedure|Saline injection|Injection into the affected facet joint(s) with 0.5 ml of normal saline. All subjects in the group will receive radiofrequency denervation.
1630851|NCT02002403|Drug|Danazol|
1630852|NCT02002390|Drug|Fingolimod|A sphingosine-1-phosphate receptor regulator
1630853|NCT02002377|Drug|Aflibercept|Aflibercept 2 mg (0.05 mL or 50 microliters) will be administered by intravitreal injection every 4 weeks for the first 8 weeks, followed by 2 mg (0.05 mL) via intravitreal injection once every 8 weeks for 36 weeks
1630854|NCT02002364|Procedure|tracheal intubation|
1630855|NCT02002325|Drug|Tissue-type plasminogen activator (alteplase)|Intravenous tissue-type plasminogen activator (alteplase) 0.6mg/kg body-weight up to a maximum of 60 mg, 10% as bolus, 90% over 1 hour as infusion (plus other standard treatment if needed)
1630856|NCT02002325|Other|Standard care|Standard treatment for acute stroke without intravenous alteplase.
1630857|NCT02002312|Drug|Lu-177-DOTA-girentuximab|"Drug: In-111-DOTA-girentuximab At day 1, every patient received girentuximab at a dose of 10 mg coupled to DOTA and labeled with 5 mCi of In-111.
Drug: Lu-177-DOTA-girentuximab At day 8-10, every patient receives girentuximab at a dose of 10 mg coupled to DOTA and labeled with 65 mCi/m2 of Lu-177. If eligible, patients are retreated at a dose 75% of the previous dose, for a total of not more than three treatments."
1630858|NCT02002286|Drug|Tripterygium Wilfordii Hook F extract (TwHF extract)|The extract Tripterygium wilfordii Hook F (TwHF), a traditional Chinese medication, has been used as anti-inflammatory therapy to treat autoimmune diseases including rheumatoid arthritis and Crohn's disease.
1630859|NCT02002286|Drug|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
1630860|NCT02002273|Procedure|Switching level of suction|
1630861|NCT02002260|Device|Levonorgestrel intrauterine system|
1630862|NCT02002260|Drug|Combined oral contraceptives|
1630863|NCT02002247|Drug|sodium selenite|All subjects will receive an IV bolus of 2000µg selenium within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of 2000µg selenium. Then on every further morning during ICU-stay, patients will receive an IV bolus of 1000µg selenium via central or peripheral venous access until death, discharge from ICU to the ward, or for a maximum of 10 days.
1630864|NCT02002247|Drug|Placebo|All patients will receive an IV bolus of normal saline (equals to 40ml prepared solution) within 30min after induction of anesthesia via the central venous catheter. After termination of surgery, immediately after admission to the ICU, all patients will receive a second bolus of normal saline accordingly. Then on every further morning during ICU-stay, patients will receive an IV bolus of normal saline via central or peripheral venous access until death, discharge from ICU to the ward (treatment may continue in a step down or intermediate care unit), or for a maximum of 10 days.
1630865|NCT02002234|Procedure|Hemicraniotomy|Hemicraniotomy involves removing a large bone flap at least 12 cm in diameter and included parts of the frontal, temporal, parietal and occipital bones, with further craniectomy to the floor of the temporal fossa. The dura was opened widely and duraplasty was performed using periosteum and temporalis fascia. The bone flap was either stored in a subcutaneous pocket in the abdomen or placed in the bone bank.
1630866|NCT02002234|Procedure|Standard medical treatment|Standard medical treatment involves elevation of the head of bed at 30°, intermittent hyperventilation administered, and intravenous mannitol. Mean arterial pressure was maintained above 90 mm Hg. Hemoglobin concentration was maintained at all times above 90 g/L.
1630867|NCT02002221|Drug|Vildagliptin (LAF237)|Corresponds to vildagliptin (LAF237) 50 mg tablets twice daily
1630868|NCT02002221|Drug|Placebo|Matching placebo of vildagliptin 50 mg twice daily
1630869|NCT02002221|Drug|Insulin|"Patients continued their prescribed insulin dose. The dose of insulin remained within a 10% increase of the baseline dose throughout the trial (with no change in frequency or insulin type) unless dose adjustments were required for safety reasons.
The insulin dose was allowed to be decreased for safety reasons at anytime without specific dose limits at the Investigator's discretion."
1630870|NCT02002221|Drug|Metformin|Patients continued their prescribed metformin dose, if applicable.
1630871|NCT02002208|Drug|OC000459|Oral CRTH2 antagonist
1630872|NCT02002195|Drug|FOLFOX|Oxaliplatin 85 mg/m2 is given as a 2 hours intravenous infusion, concomitant to and S-leucovorin 200 mg/m2, and followed by 5-FU 2,400 mg/m2 as a 46 hours continuous infusion.
1630873|NCT02002195|Drug|Capecitabine|Capecitabine 1,000 mg twice a day will be administered until disease progression, unacceptable toxicity or treatment refusal by the patient.
1630874|NCT02002182|Biological|ADXS11-001 (ADXS-HPV)|ADXS11-001 (ADXS-HPV) is a live attenuated Listeria monocytogenes (Lm)-LLO immunotherapy developed for the treatment of HPV-associated dysplasia and malignancy.
1630875|NCT02002169|Other|Shower Technique Protocol|Video and educational pamphlets of the STP will be used to assist in training participants randomized to this intervention. The participant must successfully demonstrate the STP on a training mannequin and be deemed by the study coordinator as ready to independently and correctly perform it before proceeding.
1630876|NCT02002169|Other|Standard CVC Care|Nuanced differences may be present at participating units; however, the key components of the intervention are 1) HD nurse delivery of CVC care 2) chlorhexidine or povidone cleansing 3) dry gauze dressing 4) standardized frequency. For both STP and control arms, participants whose HD centre uses polysporin triple ointment as part of standard CVC care will continue to have it applied as per program policy.
1630877|NCT02002156|Biological|BCG, NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at birth and all routine vaccinations.
1630878|NCT02002156|Biological|BCG, NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®|This group will receive BCG at three months old and all routine vaccinations.
1630879|NCT02002156|Biological|NeisVac‐C®, Pediacel®, Infanrix™, Prevenar‐13®, Menitorix®, Priorix®, Rotarix®|This group will receive no BCG but will receive all routine vaccinations.
1630880|NCT02002143|Behavioral|Group Appointments|"Participants randomly assigned to the intervention group will participate in GAs of 8 patients for 1.5 hours, every 3 months for 2 years. The 3-member Care Team (MD, nurse, behaviorist) will attend each session. The nurse facilitates the session and curriculum. The MD responds to specific health questions. Patients may schedule time before or after to review their clinical results with the MD/nurse (e.g. HbAIC).
Key elements include 1) completed pre-appt questionnaires used to identify a patient's educational needs; 2) patients use goal setting and action plans to initiate and maintain healthy behaviors; 3) each class has a designated purpose and learning objectives; 4) sessional feedback, which is used to adapt the next class (3 months later) based on patient needs."
1630881|NCT02002143|Behavioral|Individual Appointments (IAs)|"Participants randomly assigned to the IAs group will receive eight traditional 1-to-1 appointments, seeing their physician quarterly as per standard care in BC. They will be referred to ancillary services such as nutrition advice, counseling, and physical activity promotion according to 'usual care' practice. In addition, we will organize 4 1-hour social events for these participants annually. The 4 social events will be 1) a potluck lunch; 2) a movie night; 3) an event chosen by participants; and 4) a talent show. From our experience, these events enhance compliance to reporting and minimize dropouts. These events also serve to minimize 'socialization bias' that may otherwise potentially influence health measures including quality of life."
2011615|NCT02480153|Biological|Adalimumab|Adalimumab will be administered with a uniform dose regimen, which is SC injection at a dose of 40 mg every other week, throughout the study treatment.
2011616|NCT02478905|Other|Influenza|
2011617|NCT02476994|Drug|Clinolipid|
2011618|NCT02476994|Drug|Intralipid|Standard-of-Care Soybean Oil-Based Lipid Emulsion
1630886|NCT02002117|Other|DNA mass|DNA mass spectrometry
1630887|NCT02002091|Other|no specific treatment|lifestyle counseling, antihypertensive drugs, antidiabetic drugs (oral and / or insulin)treatment of comorbidity or complications of diabetes.
1630888|NCT02002078|Drug|methylprednisolon|
1630889|NCT02002065|Biological|Inactivated HAV vaccine|Inactivated vaccine: 0.5 ml per dose containing 250 u antigen, one dose
1630890|NCT02002065|Biological|Attenuated alive HAV vaccine|Attenuated alive vaccine: 1.0 ml per dose containing 6.50 lgCCID50 alive virus, one dose
1630891|NCT02002052|Drug|Concurrent platinum-based chemotherapy|Platinum-based concurrent chemotherapy in both arms
1630892|NCT02002052|Radiation|Standard Radiotherapy, 60 Gy in 30 fractions.|
1630893|NCT02002052|Radiation|Functional Lung Avoidance Radiotherapy, 60 Gy in 30 fractions|
1630894|NCT02002039|Drug|Erythropoietin|500 units /kg /day every other day for 5 doses
1630895|NCT02002026|Procedure|Uterine artery ligation|Uterine artery ligation during cesarean section before delivery of the baby
1630896|NCT02002000|Drug|vitamin D (cholecalciferol)|Patients from the vitamin D arm will receive an orally supplementation of 600 000 UI cholecalciferol in 3 doses: 200 000 UI at baseline (day 1), 200 000 UI on day 15 and 200 000 UI on day 30. Cholecalciferol will be presented in blisters, in a non-differentiable form in appearance and taste from placebo, either for the patient or the doctor
1630897|NCT02002000|Drug|Placebo, similar in appearance and taste to cholecalciferol|Patients from the placebo arm will receive 3 doses of placebo to be taken orally: one at baseline (day 1), one on day 15, one on day 30. Placebo will be presented in blisters in a non-differentiable form in appearance and taste from cholecalciferol either for the patient or the doctor.
2011619|NCT02474160|Other|Cytology Specimen Collection Procedure|Procurement of tissue and blood samples
1630899|NCT02001974|Drug|Paclitaxel+Reparixin|Association of Paclitaxel at fixed dosage with three increasing dosage of Reparixin
1630900|NCT02001948|Drug|intrathecal morphine 0.1 mg combined with intrathecal heavy bupivacaine 7.5 mg|
1630901|NCT02001948|Drug|intrathecal morphine 0.4 mg combined with intrathecal heavy bupivacaine 7.5 mg|
1630902|NCT02001948|Device|standard monitoring with Datex Ohmeda anesthesia monitor, GE, Finland|electrocardiography, heart rate, pulse oximetry and noninvasive arterial blood pressure
1630903|NCT02001948|Drug|intravenous cannulation and premedication|18-gauge intravenous cannula was inserted at the forearm opposite to the surgical side and routine iv premedication (midazolam 0.03 mg/kg) was given
1630904|NCT02001935|Drug|theophylline|After oral theophylline 200mg per day for two weeks,bood sample will be collected for determining plasma concentrations of theophylline and it's metabolites and the genotypes of CYP1A2 and CYP2E1
1630905|NCT02001922|Other|COPD integrated care|The intervention will target COPD integrated care, and include a combination of patient-related, professional and organizational elements. It will be centered on patients' needs and focus on self-management education, proactive follow-up (scheduled visits and/or phone contacts), team work, healthcare professionals' training, promotion of pulmonary rehabilitation, physical activity and smoking cessation.
1630906|NCT02001909|Drug|Regorafenib (Stivarga, BAY73-4506)|single oral dose (s.d.) 160 mg (four 40 mg tablets) of regorafenib on two occasions (Day 1, Period 1, and Day 1, Period 2) separated by a washout period of at least 14 days
1630907|NCT02001909|Drug|Neomycin|1 g tid (three times a day) regimen of Neomycin (oral) on five days in Period 2 starting 4 days before regorafenib intake on day 1 in period 2.
1630908|NCT02001896|Drug|gemcitabine; cisplatin or carboplatin; erlotinib|
1630909|NCT02001896|Drug|erlotinib|
1630910|NCT02001883|Drug|Association low-dose statin and nutraceuticals|
2011620|NCT02473497|Drug|Crizotinib|For adult patients, crizotinib 250 mg BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing. For pediatric patients, crizotinib 280 mg/m2 BID will be administered orally at approximately the same time each day on a continuous daily dosing schedule, ie, without break in dosing.
2011621|NCT02473640|Drug|SYN-004|
1630913|NCT02001857|Drug|1 TachoSil hemostatic sponge (9,5 cm x 4,8 cm) placed on each side on the external iliac artery.|at the end of surgery
2011622|NCT02473640|Drug|Esomeprazole|
2011623|NCT02473640|Drug|Ceftriaxone|
1630916|NCT02001831|Dietary Supplement|Supplement|
1630917|NCT02001831|Dietary Supplement|Placebo|
1630918|NCT02001818|Drug|Nilotinib, Pegylated interferon alpha-2b, Imatinib|All patients joining the study will receive treatment with oral nilotinib at 300mg twice daily. This will be given as monotherapy for 3 months initially, prior to commencement of combination therapy with Pegylated interferon alpha-2b added to nilotinib. Patients intolerant of nilotinib will have the option of switching to imatinib.
1630919|NCT02001792|Procedure|Position the patient during colonoscopy|Position the patient either in a left lateral position during colonoscopy
1630920|NCT02001792|Device|pulse oximeter|
1630921|NCT02001779|Device|Biliary SEMS loaded with 125I seeds|A self-expandable metallic biliary stent loaded with 125 iodine seeds is inserted in patients with inoperable malignant biliary obstruction.
1630922|NCT02001779|Device|Conventional biliary SEMS|A self-expandable metallic stent is inserted in patients with inoperable malignant biliary obstruction.
1630923|NCT02001766|Behavioral|Exercise training|
1630924|NCT02001753|Device|CMR|
1630925|NCT02001740|Drug|Triamcinalone (steroid) and lidocaine|receive once
1630926|NCT02001740|Other|Lidocaine|receive once
1630927|NCT02001727|Other|13C-Urea breath test for Helicobacter Pylori|
1630928|NCT02001727|Other|Questionaire|
2011624|NCT02471326|Biological|VRC-HIVMAB060-00-AB (VRC01)|A potent HIV-specific monoclonal antibody
1630930|NCT02001701|Procedure|Intravitreal Injection of sulfahexafluoride gas|After the appropriate sterile and anesthetic preparation of the surgical field, the investigator will administer a single intravitreal injection of 0.3 to 0.5 cc of sulfahexafluoride gas in the study eye. An anterior chamber paracentesis may be performed if necessary. Following the procedure, the optic nerve will be monitored for perfusion.
1630931|NCT02001688|Biological|Kamada-API for Inhalation, 80mg|
1630932|NCT02001688|Drug|Placebo|
1630933|NCT02001688|Biological|Kamada-API for Inhalation, 160mg|
1630934|NCT02001675|Device|magnetic resonance imaging (MRI)|
1630935|NCT02001675|Device|31-phosphorous magnetic resonance spectroscopy (MRS-P31)|
1630936|NCT02001662|Procedure|Intervention group, block no. 1 - Ropivacain|Intervention group: 1. block ropivacaine - 2. block saline
1630937|NCT02001662|Procedure|Control group: 1. block - saline|Control group: 1. block saline - 2. block ropivacaine
1630938|NCT02001649|Genetic|SNP Genotyping|Individuals were genotyped at a total 96 SNP from 15 candidate gene
1630939|NCT02001649|Genetic|SNP genotyping|
1630940|NCT02001636|Drug|Resource Instant Protein 88|Protein product: Resource Instant Protein 88, Nestlé Health Nutrition; postoperative intake of 30 - 35 g powder per day over 6 months.
1630941|NCT02001636|Drug|Resource Maltodextrin|Placebo product (Resource Maltodextrin, Nestlé Health Nutrition). Postoperative intake of 30 - 35 g powder per day over 6 months.
1630942|NCT02001623|Drug|Tisotumab Vedotin (HuMax-TF-ADC)|
1631032|NCT02000882|Drug|BKM120|
1631033|NCT02000882|Drug|capecitabine|
1631034|NCT02000882|Drug|Trastuzumab|
2011625|NCT02472418|Drug|DFN15A|
2011626|NCT02472418|Drug|DFN15B|
2011627|NCT02472418|Other|Placebo|
2011628|NCT02469272|Drug|Fecal Microbiota Transplantation|Administration of frozen fecal materials into gastrointestinal tract
2011629|NCT02469220|Other|Low FODMAP diet|
2011630|NCT02468960|Device|Predilatation with OPN NC balloon catheter.|Target lesion will be prepared by predilatation with OPN NC balloon catheter.
2011631|NCT02468960|Device|Predilatation with standard compliant balloon.|Target lesion will be prepared by predilatation with standard balloon catheter (compliant).
2011632|NCT02468960|Device|Absorb BVS implantation.|After lesion preparation implantation of BVS Absorb scaffold will be performed.
2011633|NCT02468960|Procedure|Treated segment visualization by OCT.|Finally treated segment will be visualized by Intravascular Optical Coherence Tomography (OCT).
2011634|NCT02468960|Other|Clinical FU at 12 months.|All patients will be clinically followed for 12 months.
2011635|NCT02468700|Drug|Sustained release dexamethasone, 0.4mg|
2011636|NCT02468700|Device|Placebo punctum plug, no drug|
1630943|NCT02001610|Dietary Supplement|Acidophilus pearls|"Acidophilus pearls are encapsulated using patented process
Subjects take one capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
1630944|NCT02001610|Dietary Supplement|Hard shell gelatin capsules|"Hard-shelled gelatin capsule with same microbial formulation as pearl supplement
Subjects consume one capsule (containing at least 1 x 10^9 colony forming units) every morning for 12 days"
1630945|NCT02001584|Drug|Baclofen|
1630946|NCT02001584|Drug|Memantine|
1630947|NCT02001584|Drug|Placebo|
1630948|NCT02001571|Drug|Abiraterone acetate|On the morning of Day 1, each participant was given four 250 mg tablets of abiraterone acetate with 240 mL of room temperature tap water. Dosing followed at least a 10-hour fast from food (not including water).
2011637|NCT02466971|Drug|Cisplatin|Given IV
2011638|NCT02466971|Radiation|External Beam Radiation Therapy|Undergo EBRT
1630951|NCT02001519|Drug|AC4-CDDP4|4 cycles of Adriamycin 60 mg/m2 and Cyclophosphamide 600 mg/m2 every 3 weeks 4 cycles of cisplatin 75 mg/m2 every 3 weeks
1630952|NCT02001506|Drug|FEC3-D3|"Fluorouracil 500 mg/m2, every 3 weeks Epirubicin 100 mg/m2, every 3 weeks Cyclophosphamide 500, every 3 weeks
Docetaxel 75 mg/m2, every 3 weeks"
1630953|NCT02001480|Device|12 lead Holter|12 lead Holter measurements will be performed for 7 days
1630954|NCT02001480|Device|CGM Continuous Glucose Monitoring|CGM will be performed continously for 7 days
1630955|NCT02001467|Other|Simulation-based training|
1630956|NCT02001428|Drug|dihydroartemisinin-piperaquine|Participating infants with uncomplicated malaria will be treated with a three day course (1 dose/day) of DHP (containing 40 mg dihydroartemisinin and 320 mg piperaquine) administered as a total dose over three days of 6mg/kg of dihydroartemisinin and 57 mg/kg of piperaquine.
1630957|NCT02001415|Other|Spectacles|Normal spectacle lenses were used to correct myopia as the control group.
1630958|NCT02001415|Other|Myovision|Myovision is a kind of specially designed spectacle glasses that could control the peripheral refraction of myopia patients. It is commercially available.
1630959|NCT02001415|Other|Orthokeratology|Orthokeratology lenses.
1630960|NCT02001389|Drug|EVP-6308|Arms 1, 2, 3, 4
1630961|NCT02001376|Other|Intensive exercise|The intensive exercise group will receive moderate aerobic exercise and strengthening exercise three times a week for three months.
1630962|NCT02001376|Other|Home exercise|The home-based exercise group will receive exercise instruction biweekly for three months
1630963|NCT02001376|Other|Control group live as usual|Control group means no any intervention for them. The control group who with metabolic syndrome risk factors just live as usual.
1630964|NCT02001363|Drug|liraglutide (Novo Nordisk, Bagsværd, Denmark)|once-daily subcutaneous liraglutide 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide 1.2 mg for 2 days ,once-daily subcutaneous liraglutide 1.8 mg for 3 days
1630965|NCT02001363|Drug|liraglutide placebo (Novo Nordisk)|once-daily subcutaneous liraglutide placebo 0.6 mg for 2 days, then gradually increase the dosage, once-daily subcutaneous liraglutide placebo 1.2 mg for 2 days ,once-daily subcutaneous liraglutide placebo 1.8 mg for 3 days
1630966|NCT02001350|Other|Ultrasonography|
1630967|NCT02001337|Other|medical chart review|baseline, quarterly follow-up for 24 months
1630968|NCT02001337|Other|survey administration|baseline
1630969|NCT02001337|Other|Specimen collection|baseline
1630970|NCT02001324|Other|Web-based data collection|
1630971|NCT02001324|Other|Paper-based data collection|
1630972|NCT02001311|Drug|Chlorhexidine gluconate|
2011639|NCT02466971|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
2011640|NCT02466971|Radiation|Internal Radiation Therapy|Undergo brachytherapy
1630975|NCT02001285|Drug|Remifentanil|During intubation, remifentanil will be infused to prevent change arterial blood pressure and heart rate.
1630976|NCT02001272|Drug|Paclitaxel + Carboplatin every 3 weeks|Patients will receive a premedication of 130mg prednisolone the day before (22 pm) and the morning (7 am). A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel administration. At H0, Paclitaxel is administered at 175mg/m² in 3 hours then Carboplatin is administered at AUC 5mg/mL/min.
1630977|NCT02001272|Drug|Carboplatin monotherapy every 3 weeks|A pretreatment using setrons in accordance with local standards of care will be administered 30 minutes before Carboplatin at AUC 5 to 6mg/mL/min in 1 hour.
1630978|NCT02001272|Drug|Weekly Paclitaxel and Carboplatin|A pretreatment using corticosteroids, antihistamines and H2 antagonists and setrons in accordance with local standards of care will be administered 30 minutes before Paclitaxel 60mg/m² in 1 hour followed by Carboplatin at AUC 2mg/mL/min in 1 hour.
1630979|NCT02001259|Drug|epidural triamsinolone|add drugs into catheter at 48 hr after surgery
1630980|NCT02001259|Drug|epidural lidocaine|add into catheter at 48 hr after surgery
1630981|NCT02001246|Behavioral|Real Deal program for Anger Management|Real Deal is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
1630982|NCT02001246|Behavioral|Mind-body Bridging (MBB) program|MBB is an eight week program with sessions one day per week. Each session is approximately 2 hr long.
1630983|NCT02001233|Biological|EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
2011641|NCT02466971|Other|Laboratory Biomarker Analysis|Correlative studies
1631035|NCT02000856|Dietary Supplement|Beetroot juice|
1631258|NCT01999192|Drug|Tregalizumab|humanized anti-CD4 mAb
2011642|NCT02466971|Radiation|Radiation Therapy|Undergo conventional RT
2011643|NCT02466971|Drug|Triapine|Given IV
2011644|NCT02466841|Procedure|Cubital tunnel release|Patients undergoing cubital tunnel release for ulnar nerve compression at elbow
2011645|NCT02464215|Procedure|open surgery|Subtotal gastectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dessection(around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically.
2011646|NCT02464215|Procedure|laparoscopic surgery|Patients in this arm undergo radical resection of gastric cancer in laparoscopic surgery.10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. Dissected stomach and lymph node are collected through additional 5-10 cm incision at the preexisting epigastric incision.
1630986|NCT02001207|Other|Salivary cortisol test|
1630987|NCT02001194|Behavioral|Individual Incentives|
1630988|NCT02001194|Behavioral|Team Incentives|
1630989|NCT02001194|Behavioral|Individual plus Team Incentives|
1630990|NCT02001181|Drug|Tofacitinib ointment 20mg/g|Tofacitinib ointment 20mg/g twice daily (BID) for 4 weeks
1630991|NCT02001181|Drug|Placebo ointment (Vehicle)|Placebo ointment (vehicle) twice daily (BID) for 4 weeks
1630992|NCT02001168|Drug|Pemetrexed|Pemetrexed 500 mg/m2, d1, 21 d as a cycle.
1630993|NCT02001168|Drug|Docetaxel|Docetaxel 60mg/m2 d1＋Cis-platinum 60mg/m2, d1, 21 d as a cycle.
1630994|NCT02001168|Drug|rh-Endostatin|rh-Endostatin 7.5mg/m2 d1-14; 21 d as a cycle.
1630995|NCT02001168|Drug|Cis-platinum|Cis-platinum 60mg/m2, d1, 21 d as a cycle.
1630996|NCT02001155|Procedure|Water Drinking Test|The Water Drinking test has been identified as a reliable and safe tool to predict maximum intraocular pressure values during a diurnal tension curve and to assess the efficacy of surgical interventions. Participants are asked to drink 10 ml/kg water (or approximately 0.33 ounces of water for every 2.2 pounds of weight or about 2.5 cups for a 150 lb. individual) over 15 minutes. Intraocular pressure is assessed every 15 minutes for one hour.
1630997|NCT02001142|Other|Exercise|single session of exercise
1630998|NCT02001129|Behavioral|Automated Telephone System|Participants receive automated reminder phone calls.
1630999|NCT02001129|Behavioral|Personalized Telephone Call|Participants receive reminder phone calls by study staff.
1631000|NCT02001129|Behavioral|Usual Care|Participants receive a standard reminder letter in the mail.
1631001|NCT02001116|Other|Quality Improvement intervention|"Training for local trainers and medical staff on the National Adaptation of the WHO guidelines Pocket Book of Hospital Care for Children.
Regular supporting supervision and monitoring at hospital level aimed at a sustainable improvement of the quality of the paediatric hospital care"
1631002|NCT02001103|Drug|Memantine|"Pills of memantine, including 5 or 10 mg, all prepared in the same capsules as used in the placebo arm.
The Memantine 10 mg intervention arm will take 1 capsule of memantine and 1 capsule of placebo going into week 3."
1631003|NCT02001103|Drug|Placebo|Capsules with starch inside manufactured using the same capsules as used in the other 2 arms.
1631004|NCT02001077|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|
1631005|NCT02001077|Behavioral|Cognitive Behavioral Therapy for Pain (CBT-P)|
1631006|NCT02001064|Behavioral|Application + Standard of care|Care4Today mobile application will send automated medication alert messages to HIV+ persons. The alert messages are customizable and automated, and real-time results are viewable within the application. The Care4Today intervention is designed to improve adherence to ART medications among HIV+ persons who experience adherence difficulties over standard of care.
2011647|NCT02465060|Drug|Afatinib|Given PO
2011648|NCT02465060|Drug|Akt inhibitor AZD5363|Given PO
1631009|NCT02001038|Other|Survey|
1631010|NCT02001025|Device|Absorb scaffold|
1631011|NCT02001025|Device|Xience stent|
1631012|NCT02001012|Drug|Artemether-lumefantrine combination|
1631013|NCT02001012|Drug|Chloroquine|
1631014|NCT02000999|Other|brushing of bile duct strictures for cytology|
1631015|NCT02000986|Behavioral|Specimen Collection/Risk Factor Assessment -> Diet/Exercise -> Chemotherapy|Participants will be taught by a registered dietician about energy balance and how body weight relates to energy intake and expenditure, although specific calorie prescriptions will not be given. An exercise physiologist will create a personalized exercise plan and prescription which is tailored to his / her needs and current level of activity and fitness
1631016|NCT02000973|Drug|Lidocaine|General anesthesia combined with thoracic epidural 1% lidocaine
1631017|NCT02000973|Drug|Bupivacaine|General anesthesia combined with thoracic epidural 0.25% bupivacaine
1631018|NCT02000973|Drug|Ropivacaine|General anesthesia combined with thoracic epidural 0.3% ropivacaine
1631019|NCT02000973|Drug|Normal Saline|General anesthesia combined with thoracic epidural 0.9% normal saline
1631020|NCT02000960|Drug|Triheptanoin|Triheptanoin (C7 oil) is a triglyceride of the anaplerotic odd-chain fatty acid heptonate.
1631021|NCT02000947|Drug|MEDI4736|MEDI4736 is an anti-PD-L1 monoclonal antibody (MAb).
1631022|NCT02000947|Drug|Tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
1631023|NCT02000947|Drug|tremelimumab|Tremelimumab is an anti-CTLA4 monoclonal antibody (mAb).
1631024|NCT02000934|Drug|TAK-659|"Dose escalation stage (Part A) Modified 3+3 dose escalation in participants with advanced solid tumor/lymphoma, with no effective treatment available projected.
Dose expansion stage (Part B) CLL, DLBCL, iNHL, MCL, and PTLD Expansion Cohorts in participants with relapsed or refractory diseases."
1631025|NCT02000921|Other|VLNC cigarettes|Modified risk tobacco product
1631026|NCT02000921|Other|Combusted Products|Options for combusted tobacco products include cigars, cigarillos, and little cigars, .
1631027|NCT02000921|Other|Non-combusted products|Options for non-combusted tobacco products include smokeless tobacco, novel snus products, e-cigarettes and medicinal nicotine.
1631028|NCT02000921|Other|CN cigarettes|Experimental cigarettes with conventional nicotine content.
2011649|NCT02465060|Drug|Binimetinib|Given PO
2011650|NCT02465060|Drug|Crizotinib|Given PO
1667477|NCT01718145|Drug|Asunaprevir|
2011651|NCT02465060|Other|Cytology Specimen Collection Procedure|Optional correlative studies
2011652|NCT02465060|Drug|Dabrafenib|Given PO
2011653|NCT02465060|Drug|Dasatinib|Given PO
2011654|NCT02465060|Drug|Defactinib|Given PO
1631036|NCT02000843|Procedure|tympanoplasty -- conchal cavum approach|Incision is made inside the ear canal. It is extended into the conchal cavum. The incision allows a direct approach to the eardrum, and also allow easy harvesting of the perichondrium to be used as graft material.
1631037|NCT02000830|Drug|stannsoporofin|
1631038|NCT02000817|Biological|Otelixizumab|Otelixizumab is available at unit dose strength of 5 milligram/mL provided as 1 mL solution per vial to be diluted to 0.1 mg/mL in 0.9% sodium chloride. The 0.1 mg/mL solution is to be administered by intravenous infusion using a syringe pump and an in-line 0.2 micron filter by study personnel following specified regimens
1631039|NCT02000817|Biological|Placebo|Placebo is available 0.9% w/v sodium chloride
1631040|NCT02000804|Drug|darapladib 160mg|drug
1631041|NCT02000791|Other|Comparison of fibreoptic view|
1631042|NCT02000778|Drug|EC17|
1631043|NCT02000765|Drug|GSK2140944 for Injection|GSK2140944 (1 gram) for Injection will be supplied as powder for injection containing [14C] GSK2140944. Non sterile powder is to be dissolved aseptically in sterile water for injection to a concentration of 4 mg/mL free base equivalent. IV solution is prepared by sterile filtration. 250 mL of IV solution, equivalent to 1000 mg GSK2140944, is then administered intravenously.
1631044|NCT02000765|Drug|GSK2140944 Capsule|GSK2140944 Capsule (2 gram) will be supplied as powder in capsule containing [14C] GSK2140944. Powder is to be filled in empty capsule to achieve 200-400 mg strength per capsules as free base equivalent. Sufficient capsules are administered to provide the required total dose of 2 gram as free base.
1631045|NCT02000752|Device|Acupuncture|
1631046|NCT02000752|Device|Sham acupuncture|Sham point acupuncture
1631047|NCT02000739|Genetic|Genetically Informed Therapy|If there is a genetic mutation that can be identified with current DNA sequencing and a drug has been developed for this mutation, participants may be able to receive that drug. If there is more than one drug available, the participant and his/her oncologist will decide which is the best one for the participant.
1631048|NCT02000726|Drug|Placebo|
1631049|NCT02000726|Drug|Citalopram|
1631050|NCT02000726|Drug|Fast acting antidepressant-like treatment. administered i.v. during the fMRI scanning session|Fast acting antidepressant-like treatment administered intravenously for 35 min. during the fMRI scanning session.
1631051|NCT02000713|Other|MRI|Subjects will have magnetic resonance imaging(MRI)scans of the cervical spine(neck). This involves lying on a table and sliding into a scanner consisting of a large magnet. This will take approximately one hour to complete. All subjects will be instructed to remove all jewelry and other metal-containing objects for the scan. During the MRI scan loud noises may be heard. Subjects may have a soft brace for the neck for positioning purposes.
1631052|NCT02000713|Other|Clinical Exam|Brief neurological exam will be performed.
1631053|NCT02000700|Drug|Canagliflozin 100 mg|One 100-mg tablet of canagliflozin orally administered daily for 14 days.
1631054|NCT02000700|Drug|Canagliflozin 50 mg|One 50-mg tablet of canagliflozin orally administered daily for 14 days.
1631055|NCT02000700|Drug|Canagliflozin 300 mg|One 300-mg tablet of canagliflozin orally administered daily for 14 days.
1631056|NCT02000700|Drug|Placebo|One matching placebo tablet orally administered at baseline phase.
1631057|NCT02000674|Drug|Succinylcholine : 1mg/kg|
1631058|NCT02000674|Drug|Rocuronium : 1.2 mg/kg|
1631059|NCT02000661|Device|Fractional Flow Reserve (FFR)|Fractional Flow Reserve (FFR) performed per guidelines to guide PCI
1631060|NCT02000635|Other|Quantitative PCR performed at H0 , H24, H48 , H72, 7th day and 14th day|
1631061|NCT02000622|Drug|Olaparib|Patients will be administered olaparib orally twice daily (bid) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 mL of water.
1631062|NCT02000622|Drug|Physician's choice chemotherapy|"Investigators will declare one of the following regimens:
Capecitabine 2500 mg/m2 po daily (divided in 2 doses) x 14 days, repeat every 21 days
Vinorelbine 30 mg/m2 IV Day 1 and Day 8, repeat every 21 days
Eribulin 1.4 mg/m2 IV Day 1 and Day 8, repeat every 21 days"
1631063|NCT02000609|Drug|CHF 1535 NEXThaler 800/48|
1631064|NCT02000609|Drug|CHF 1535 NEXThaler 200/12|
1631065|NCT02000609|Drug|CHF 1535 NEXThaler PLACEBO|
1631066|NCT02000609|Drug|CHF 1535 pMDI 200/12|
1631067|NCT02000609|Drug|CHF1535 pMDI 800/48|
1631068|NCT02000596|Drug|Trastuzumab plus Pertuzumab|
1631069|NCT02000596|Drug|Hormonal Therapy with Anastrozole and Fulvestrant|Anastrozole 1mg by mouth daily FULVESTRANT 500mg i.m. D1, D15, D28 then every 28-30 days
1631070|NCT02000596|Drug|Chemotherapy with Eribulin|
1631071|NCT02000583|Other|Aerobic Exercise|Aerobic group participants will engage in 150 minutes of aerobic exercise over 4-5 days per week for 52 weeks
1631072|NCT02000583|Other|Standard of Care|Control group participants will be provided educational materials on starting an exercise program, but will receive no formal support for their exercise program.
1631073|NCT02000570|Procedure|Sitting position (neurosurgery)|
1631074|NCT02000544|Device|Modular Cardiopulmonary Bypass Circuit|Open heart surgery with a novel hybrid modular extracorporeal circulation circuit that comprises which is a closed cardiopulmonary bypass circuit with enhanced safety as it can be instantly converted to an open circuit.
1631075|NCT02000531|Drug|Erlotinib|150 mg oral dose of erlotinib given once daily
1631076|NCT02000531|Drug|Chemotherapy|Cisplatin (75 mg/m^2 intravenously [IV]) on Day 1 and gemcitabine (1250 mg/m^2 IV) on Days 1 and 8 of 3-week chemotherapy cycles until disease progression, unacceptable toxicity or up to 4 cycles (whichever comes first)
1631077|NCT02000518|Radiation|external beam radiotherapy|
1631078|NCT02000505|Device|PocketCPR|5 minutes chest-compression-only CPR, using Zoll PocketCPR
1631079|NCT02000505|Device|Metronome|5 minutes chest-compression-only CPR, using a metronome
1631080|NCT02000505|Device|110bpm Song|5 minutes chest-compression-only CPR, using a song with 110bpm for support
1631081|NCT02000492|Behavioral|Football|
1631082|NCT02000492|Behavioral|Running|
1631083|NCT02000492|Behavioral|Circuit training|
1631084|NCT02000479|Other|training|
1631085|NCT02000466|Other|Data collection|Initial and follow-up data will be collected using questionnaires
1631259|NCT01999192|Drug|Placebo|identical end formulation buffer
1667478|NCT01718145|Drug|Ribavirin|
1631086|NCT02000453|Drug|GSK2586184 400mg|White film coated round biconvex GSK2586184 200 mg tablets, administered 2 X twice daily. Tablet containing GSK2586184A, with the following excipients: microcrystalline cellulose, lactose, hypromellose, croscarmellose sodium, magnesium stearate and titanium dioxide.
1631087|NCT02000440|Drug|Losmapimod|Losmapimod (micronized GW856553X) will be supplied as a film coated white, 7 mm round, biconvex, plain faced, tablet. Oral doses of losmapimod, 7.5 mg (1 tablet) or 15 mg (2 tablets), will be taken twice daily (BID) with food and swallowed whole (not chewed or crushed)
1631088|NCT02000427|Drug|Blinatumomab|Blinatumomab is administered as a continuous intravenous infusion (CIV). A single cycle of blinatumomab treatment is 6 weeks in duration, which includes 4 weeks of blinatumomab followed by a 2-week treatment-free interval.
1631089|NCT02000414|Drug|intraperitoneal daptomycin|intraperitoneal daptomycin administartion and study of daptomycin kinetics
1631090|NCT02000401|Drug|Ketorolac Tromethamine|
1631091|NCT02000388|Drug|Ketorolac Tromethamine|
1631092|NCT02000388|Other|Standard of Care|
1631093|NCT02000375|Drug|DHEA|DHEA: Daily oral administration of DHEA(Dehydroepiandrosterone) at the dosage of 100 mg/die in combination with a daily oral administration of anastrozole at dosage of 1 mg/die or letrozole at the dosage of 2.5 mg/die or exemestane at the dosage of 25 mg/die without interruption.
1631094|NCT02000362|Biological|Stem cells|
1631095|NCT02000349|Other|PGD|PGD using Next generation sequencing
1631096|NCT02000336|Drug|Prednisolone|To compare two standard p.o. GC starting dosages and the non-use of GCs in the treatment of patients with early active RA on the background of the established 'anchor' therapy with methotrexate (MTX).
1631097|NCT02000336|Drug|Placebo|
1631098|NCT02000323|Other|early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.
The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.
• After catharsis, Standard enteral nutrition liquid regimen will be used step by step.
Patients are targeted to receive calories for 25 kcal/kg/day.
nutrition form: short peptide ,1 kcal/ml,target 200k kcal/day"
1631099|NCT02000323|Other|modified early enteral nutrition|"Naso-gastro-jejunal tube will be set up by X-ray within 24 hours of admission.
The distal end of the feeding tube would be placed at the remote end of Treitz ligament, and verified by X-ray.
After catharsis, Only Normal Saline were given through nasojejunal tube until 2 or more followed requirements were meted (mean arterial pressure≥65mmHg; oxygenation index≥ 300;APCHEII≤8; intra-abdominal pressure <20mmHg).Then Standard enteral nutrition liquid regimen (Peptisorb Liquid) will be used step by step.
Patients are targeted to receive calories for 25 kcal/kg/day."
1631100|NCT02000297|Procedure|Allogenic bone graft|Patients in this arm is treated with allogenic bone graft to fill the bone defect created with medial open wedge high tibial osteotomy
1631101|NCT02000297|Procedure|Synthetic bone substitute (geneX®)|Patients in this arm is treated with synthetic bone substitute (geneX®) to fill the bone defect created with medial open wedge high tibial osteotomy
1631102|NCT02000271|Procedure|Vaginal packing|
1631103|NCT02000271|Procedure|No vaginal packing|
1631104|NCT02000258|Procedure|Double-bundle ACL reconstruction|
1631105|NCT02000258|Device|Magnetic resonance imaging (MRI)|MRI sequences were as follows: sagittal T1-weighted, proton density (PD)-weighted and T2-weighted fast spin echo (FSE) images with 4 mm slice and 1 mm gap, coronal T1-weighted and fat-saturated T2-weighted FSE images with 4 mm slice and 1 mm gap, axial fat saturated PD FSE images with 4 mm slice and 1 mm gap and oblique sagittal and oblique coronal T1 FSE images along AM graft plane with 3 mm slice and 0.3 mm gap.
1631106|NCT02000245|Behavioral|verbal expression for compassion|The doctor going to perform bronchoscopy tells a short sentence to a patient. (Hello, I'm Dr.OO. During this test, I will keep an eye on you. Don't worry)
1631107|NCT02000245|Behavioral|touch|The doctor going to perform bronchoscopy puts a hand on the patient's shoulder
1631108|NCT02000219|Biological|Oxalobacter formigenes|The dose will be (not less than) NLT ≥1E+09 colony forming units (CFU) twice daily for 6 weeks. The dose (an enteric-coated capsule) will be administered orally with breakfast and dinner
1631109|NCT02000206|Drug|Propofol|
1631110|NCT02000206|Drug|Ketamine|
1631111|NCT02000206|Drug|Alfentanil|
1631112|NCT02000193|Drug|fulvestrant|"Eligible patients will receive fulvestrant 500 mg intramuscular injection on day 1, 15, and 29， then every 28 days.
The treatment will continue until disease progression or intolerable AE."
2011655|NCT02465060|Drug|FGFR Inhibitor AZD4547|Given PO
1631114|NCT02000154|Drug|SyB L-1101|SyB L-1101 (rigosertib sodium) will be administered intravenously 72 continuous hours (3 days), followed by 25-day observation period. The treatment period of 28 days (3 days of administration + 25 days of observation) constitutes 1 cycle. The dose at cycle 8 in the study 2011005 will be the dose (if needed, the dose can be reduced) at the first cycle in this study (cycle 9). From cycle 10 on, the dose of SyB L-1101 will be reduced, delayed, or discontinued according to adverse events and results of observation at the previous cycle.
1631115|NCT02000141|Procedure|Endoscopic Mucosal Resection|
1631116|NCT02000128|Device|bioimpedance monitoring|To assess the body composition using Multi-frequency bioelectrical impedance analysis
1631117|NCT02000128|Other|clinical monitoring|clinical symptom and examination,such as edema, body weight, blood pressure, cardial function
1631118|NCT02000115|Device|Portico transcatheter aortic valve|St. Jude Medical transcatheter Portico aortic valve
1631119|NCT02000115|Device|Commercially available transcatheter aortic valve|Commercially available transcatheter aortic valve
1631120|NCT02000102|Drug|Intravitreal Injection of Aflibercept|
1631121|NCT02000089|Drug|Human synthetic secretin|I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion. This intervention offered for all cohorts
2011656|NCT02465060|Other|Laboratory Biomarker Analysis|Undergo molecular analysis
1631165|NCT01999842|Biological|Investigational H7N9 vaccine GSK3206641A|One dose of GSK3206641A H7N9 vaccine administered intramuscularly (IM) in the deltoid region of arm at Day 0 and the second dose of GSK3206641A H7N9 vaccine administered IM in the deltoid region of arm at Day 21
2011657|NCT02465060|Drug|Larotrectinib|Given PO
2011658|NCT02465060|Biological|Nivolumab|Given IV
2011659|NCT02465060|Drug|Osimertinib|Given PO
2011660|NCT02465060|Drug|Palbociclib|Given PO
2011661|NCT02465060|Biological|Pertuzumab|Given IV
2011662|NCT02465060|Drug|PI3K-beta Inhibitor GSK2636771|Given PO
1631124|NCT02000050|Drug|FOLFOX4|FOLFOX4
1631125|NCT02000050|Radiation|Tomotherapy|Tomotherapy
1631126|NCT02000050|Procedure|TME (Total Mesorectal Excision)|TME (Total Mesorectal Excision)
1631127|NCT02000037|Device|IR Reflexotherapy|"18 IR reflexotherapy sessions :
Once a week for 12 weeks at the beginning of the study
Once a week for 3 weeks, 9 months after the beginning of the study
Once a week for 3 weeks, 15 months after the beginning of the study"
1631128|NCT02000037|Behavioral|Dietary care|Dietary consultation 1, 2, 3, 6, 9, 12, 15 and 18 months after the beginning of the study
1631129|NCT02000024|Behavioral|Weight Watchers|"The standard Weight Watchers program will serve as the base curriculum. Persons with increased risk for developing type 2 diabetes will be exposed to an initial orientation session designed to frame the rationale for participation in the program and to encourage attendance to a core series of sessions. This orientation session will reinforce the pre-diabetes status of participants and present the rationale for lifestyle modification as a means to reduce diabetes risk. In addition, this session will highlight the recommended sessions and topics that are needed to help reduce risk."
1631130|NCT02000024|Behavioral|National Diabetes Education Program|
1631131|NCT02000011|Other|comprehensive geriatric assessment (CGA)|
1631132|NCT02000011|Other|Geriatric intervention plan (GIP)|
1631133|NCT01999998|Radiation|Radiotherapy|
1631134|NCT01999985|Drug|Dasatinib - 1A|1A: Begins Day 8. Level 1 - 100 mg, Level 2 - 100 mg, Level 3 - 140 mg.
1631135|NCT01999985|Drug|Afatinib - 1A|1A: Begins Day 1. Level 1 - 30 mg, Level 2 - 40 mg, Level 3 - 40 mg.
1631136|NCT01999985|Drug|Dasatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
1631137|NCT01999985|Drug|Afatinib - 1B|In Phase 1B, a mutationally selected 20 participants (total) will be treated at the recommended dose to confirm tolerability and evaluate for early response signal.
1631138|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage range 2 - 5 mg, given orally twice daily on a continuous dosing schedule in 28 days cycles.
1631139|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage range 200-250 mg, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
1631140|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
1631141|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
1631142|NCT01999972|Drug|axitinib|Axitinib: tablets, dosage be defined based on Arm 1 results, given orally twice daily on a continuous dosing schedule in 28 days cycles.
1631143|NCT01999972|Drug|crizotinib|Crizotinib: capsules, dosage be defined based on Arm 1 results, given orally twice daily or every day on a continuous dosing schedule in 28 days cycle.
1631144|NCT01999959|Procedure|Pertubation|a lavage procedure of the intrauterine cavity and bilateral fallopian tubes
1631145|NCT01999946|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol®), 380mg administered 1x/month by intramuscular injection.
1631146|NCT01999933|Radiation|Radiation|Arm1, Arm2 and Arm3 patients should received the whole pelvic radiation.
1631147|NCT01999933|Drug|cisplatin（DDP） weekly|concurrent chemotherapy with cisplatin（DDP） weekly(40mg/m2),begin with radiation
1631148|NCT01999933|Drug|docetaxel plus cisplatin|concurrent docetaxel plus cisplatin tri-weekly (75mg/m2),2 cycles, begin with radiation
1631149|NCT01999933|Drug|docetaxel plus cisplatin|adjuvant chemotherapy with docetaxel plus cisplatin tri-weekly (75mg/m2), 4 cycles after radiation
2011663|NCT02465060|Drug|Sapanisertib|Given PO
2011664|NCT02465060|Drug|Sunitinib Malate|Given PO
1631152|NCT01999907|Dietary Supplement|Vitamin D|100,000IU cholecalciferol given in a 2ml dose by mouth at baseline.
1631153|NCT01999907|Dietary Supplement|daily vitamin D supplement|Each group receives a daily vitamin D supplement for 6 months, providing 400IU per day.
1631154|NCT01999907|Other|Placebo|placebo given in a 2ml dose by mouth at baseline.
1631155|NCT01999894|Drug|Memantine HCl|Memantine extended release 3- and 6-mg capsules; dose ranging 3 - 18 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for 48 weeks.
1631156|NCT01999881|Behavioral|exercise intervention|Receive aerobic and exercise intervention
1631157|NCT01999881|Procedure|standard follow-up care|Receive usual care
1631158|NCT01999881|Procedure|quality-of-life assessment|Ancillary studies
1631159|NCT01999881|Other|laboratory biomarker analysis|Correlative studies
2011665|NCT02465060|Drug|Taselisib|Given PO
2011666|NCT02465060|Drug|Trametinib|Given PO
2011667|NCT02465060|Biological|Trastuzumab Emtansine|Given IV
2011668|NCT02465060|Drug|Vismodegib|Given PO
1631164|NCT01999855|Other|Phoniatric tests|
1631218|NCT01999452|Behavioral|Diabetes diet|
1631301|NCT01998919|Drug|gemcitabine|1250 mg/m2 iv Days 1 and 8 of each 4-week cycle, 6 cycles
2011669|NCT02465060|Drug|WEE1 Inhibitor AZD1775|Given PO
2011670|NCT02465697|Behavioral|Reappraisal Training|
2011671|NCT02465515|Biological|Albiglutide 30 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
2011672|NCT02465515|Biological|Albiglutide 50 mg|Once weekly subcutaneous injection. Starting dose 30 mg may be increased to 50 mg if needed.
2011673|NCT02465515|Biological|Albiglutide matching placebo|Once weekly subcutaneous injection. Matched to 30 mg and 50 mg albiglutide.
2011674|NCT02462486|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
2011675|NCT02462486|Drug|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 96.
2011676|NCT02462486|Other|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
2011677|NCT02462928|Drug|abicipar pegol|Abicipar pegol administered to the study eye by intravitreal injection at the visits noted per protocol.
2011678|NCT02462928|Drug|ranibizumab|Ranibizumab (Lucentis®) administered to the study eye by intravitreal injection every 4 weeks from day 1 through week 96.
1631166|NCT01999842|Biological|Investigational H7N9 vaccine GSK3206640A|One dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 0 and the second dose of GSK3206640A H7N9 vaccine administered IM at the deltoid region of arm at Day 21
1631167|NCT01999842|Biological|Placebo|One dose of placebo administered IM at the deltoid region of arm at Day 0 and the second dose of placebo administered IM at the deltoid region of arm at Day 21
1631168|NCT01999829|Drug|citrate of caffeine|
1631169|NCT01999829|Drug|placebo|
1631170|NCT01999816|Behavioral|Lifestyle Redesign|Individualized program for lifestyle redesign aimed at decreasing the risk of medically serious pressure ulcers led by licensed occupational therapists trained in the implementation of the lifestyle redesign program
1631171|NCT01999803|Drug|sNN0029|
1631172|NCT01999803|Drug|Placebo|
1631173|NCT01999790|Procedure|blepharotomy|upper eyelid surgery by blepharotomy
1631174|NCT01999790|Procedure|posterior approach|upper eyelid surgery by posterior approach
1631175|NCT01999777|Drug|USL261|
1631176|NCT01999777|Drug|Placebo|
1631177|NCT01999764|Drug|QLT091001|QLT091001 administered orally at multiple time points.
1631178|NCT01999764|Other|Placebo|Placebo is administered orally at multiple time points.
1631179|NCT01999751|Device|MRI Scan|Clinically indicated MRI scan of patients with pacemaker or implantable cardioverter-defibrillator in situ.
1631180|NCT01999738|Drug|EC1456 and EC20|"EC1456 is small molecule drug conjugate of folic acid and tubulysin B hydrazide (TubBH) that specifically binds to the membrane-bound FR and gains entry into the cell via endocytosis.
EC20 is Etarfolatide, a conjugate of folic acid and a tripeptide moiety that can efficiently chelate the radioisotope 99mTechnetium (99mTc). When etarfolatide is labeled with 99mTc, the product (99mTc-etarfolatide) is able to quantify FR expressing tissues with SPECT imaging."
1631181|NCT01999725|Drug|EDP-788|EDP-788 Capsules and matching placebo capsules. EDP-788 Liquid Suspension and matching placebo. All interventions are given as single doses
1631182|NCT01999725|Drug|Placebo|Matching placebo capsules or matching suspension
1631183|NCT01999712|Procedure|Echocardiography|Patients will undergo an echocardiogram at baseline (preoperative) and at 30 and 90 days after LVAD implantation
1631184|NCT01999699|Biological|HEPLISAV|
1631185|NCT01999686|Drug|DLBS3233|
1631186|NCT01999686|Drug|Metformin XR|
1631187|NCT01999686|Drug|Placebo metformin|Placebo metformin has the same ingredients with Metformin XR caplet, except that it does not contain the active substance (metformin).
1631188|NCT01999686|Drug|Placebo DLBS3233|Placebo DLBS3233 has the same ingredients with DLBS3233 capsule, except that it does not contain the active substance (DLBS3233).
1631189|NCT01999673|Biological|bavituximab|
1631190|NCT01999673|Drug|Docetaxel|
1631191|NCT01999673|Other|Placebo (for bavituximab)|
1631192|NCT01999660|Device|SpaceOAR™ implantation|
1631193|NCT01999647|Procedure|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.
Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
1631194|NCT01999647|Procedure|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.
Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
1631195|NCT01999647|Procedure|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
1631196|NCT01999647|Procedure|Patient-Controlled Postoperative Analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
1631197|NCT01999647|Drug|Ropivacaine|Thirty milliliters of 0.75% (wt/vol) ropivacaine will be used for the sciatic nerve block.
1631198|NCT01999634|Device|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
1631199|NCT01999595|Device|Sham TENS|"TENS with no current while applied with the participant told TENS is at a turn-on level whether or not you feel it"
1631200|NCT01999595|Device|High frequency (80 Hz) TENS|High frequency TENS is defined as the transcutaneous electrical nerve stimulation delivered at 80Hz
1631201|NCT01999595|Device|Low frequency TENS|Low frequency TENS is defined as the transcutaneous electrical nerve stimulation delivered at 3Hz
1631202|NCT01999595|Device|Large pads|5cm x10cm each
1631203|NCT01999595|Device|small pads|2.5cm x2.5cm each
1631204|NCT01999582|Biological|Sotatercept|Sotatercept is dosed intravenously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
1631205|NCT01999582|Biological|Sotatercept|Sotatercept is dosed subcutaneously every 14 days. The dose a subject receives will depend on the randomization arm and the dose group.
2011679|NCT02462928|Other|sham procedure|Sham procedure to the study eye at the visits noted per protocol.
1631207|NCT01999543|Dietary Supplement|plant-based dietary supplement|
1631208|NCT01999543|Other|Placebo|
2011680|NCT02462122|Drug|IDP-118 Lotion|Lotion
1631210|NCT01999517|Drug|Intravenous Nitroglycerin|
1631211|NCT01999517|Drug|IV Fluids|
1631212|NCT01999504|Other|PAL-2|meal
1631213|NCT01999504|Other|TFH-1|Meal
1631214|NCT01999504|Other|Reference|Meal
1631215|NCT01999465|Device|Standard NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.
Rate(35 Hz)
Width (300 us)
Ch1 Ramp+ (2 seconds)
On Time 1 (10 seconds)
Ch1 Ramp - (2 seconds)"
1631216|NCT01999465|Device|Sham NMES device|"Blinded parents will follow the NMES parent instructions and place the NMES on the biceps muscle of their child for 30 minutes every day for three months.
Rate(35 Hz)
Width (48 us)
Ch1 Ramp+ (0 seconds)
On Time 1 (0 seconds)
Ch1 Ramp - (0 seconds)"
1631217|NCT01999452|Behavioral|Paleolithic diet|
2011681|NCT02462122|Drug|IDP-118 Vehicle Lotion|Lotion
1631219|NCT01999439|Procedure|Eosinophilic Esophagitis with Dysphagia|"An upper endoscopy with biopsy at the time of diagnosis(which is a standard procedure to diagnose eosinophilic esophagitis. This will be done with sedation or general anesthesia, also a standard procedure. At the time of the anesthesia a small amount of blood will be drawn to measure markers of inflammation and fibrosis. This procedure will take approximately 45 minutes to complete. This endoscopy with biopsy will be repeated in 6 months.
Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete."
1631220|NCT01999439|Procedure|Eosinophilic Esophagitis with Dysphagia|Subjects will also complete a magnetic resonance imaging(MRI)scan with 2 weeks of the initial clinical endoscopy with biopsy, prior to the initiation of your medical treatment. This MRI will be repeated in 6 months. Each magnetic resonance imaging(MRI)scan will take approximately 2 hours to complete.
1631221|NCT01999426|Other|Airway clearance intervention|Both respiratory and non-respiratory on-call physiotherapists provide similar airway clearance treatments, the precise components and delivery of which will vary between physiotherapists
1631222|NCT01999413|Drug|OMEGAVEN|AML Study treatment induction phase
1631223|NCT01999413|Drug|Daunorubicin|AML Study treatment induction phase
1631224|NCT01999413|Drug|Cytarabine|AML Study treatment induction phase
1631225|NCT01999400|Drug|Pentasa 500 mg capsule x 2 with 240 mL water; single dose|
1631226|NCT01999400|Drug|Apriso 375 mg capsule x 3 with 240 mL water; single dose|
1631227|NCT01999400|Drug|Lialda 1200 mg tablet x 1 with 240 mL water; single dose|
1631228|NCT01999400|Drug|Delzicol 100 mg mesalamine x 1 with 245 mL water; single dose|
1631229|NCT01999387|Dietary Supplement|Allergenic food|
2011682|NCT02461251|Device|Rotational Thromboelastometry (ROTEM)|A Point-of-care blood coagulation test tool is used to guide the treatment of major obstetric bleeding.
1631231|NCT01999348|Drug|Fixed Combination Bimatoprost and Timolol|Patients with POAG or OHT treated with GANFORT® UD (fixed combination bimatoprost and timolol) administered in accordance with physician standard practice for up to 12 weeks.
1631232|NCT01999335|Drug|Oprozomib|Study subjects will receive oprozomib tablets once daily on Days 1-5 and 15-19 (QD × 5 bimonthly schedule) of each 28-day treatment cycle.
1631233|NCT01999335|Drug|Pomalidomide|Study subjects will receive pomalidomide once-daily on Days 1-21 of every 28-day cycle.
1631234|NCT01999335|Drug|Dexamethasone|Study subjects will receive dexamethasone once daily on days 1-2, 8-9, 15-16, and 22-23 of every 28-day cycle.
1631237|NCT01999309|Drug|Simvastatin|The lipid-lowering drug simvastatin is added to normal antipsychotic treatment. One 40 mg simvastatin tablet daily for the treatment period of one year.
1631238|NCT01999309|Drug|Placebo|Placebo is added to normal antipsychotic treatment. One identical looking placebo tablet daily for the treatment period of one year.
1631239|NCT01999296|Device|Use of Thunderbeat (TM) in laparoscopic surgery|
1631240|NCT01999283|Other|Yoga Group Exercise|Yoga poses and postures modified to diminish stress on the cervical region and improve flexibility. Breathing and mind-body focus to address stress-related discomfort. A general Hatha yoga style will be used with components from Ashtanga Yoga. Intensity and range of motion will be progressively increased as tolerated.
1631241|NCT01999283|Other|Pilates Group Mat Exercise|The Pilates mat exercises focus on both spinal muscle activation and stability, progressive endurance of the stabilizing muscles with arm and leg challenges and dynamic mobility. The exercises are progressed from more supported to anti-gravity position, slow increases in arm weights and flexibility.
1631242|NCT01999270|Drug|Irinotecan|"Irinotecan IV over 90 minutes on Days 1, 15, and 29 of each cycle (except Cycle 1, when it will be started on Day 29)
Note: Irinotecan can be removed from the treatment plan at the discretion of the healthcare provider."
1631243|NCT01999270|Drug|Bevacizumab|Bevacizumab will be given intravenously AFTER the irinotecan infusion is complete on Days 1, 15, and 29 of each cycle. The first dose will be given over 90 minutes, but doses after that may be given over 30-60 minutes.
1631244|NCT01999270|Device|FDOPA-PET/MRI imaging|FDOPA-PET/MRI imaging Baseline (before beginning Cycle 1 treatment) Cycle 1, Day 29 (before receiving your treatment with bevacizumab) and end of treatment or time of relapse
1631245|NCT01999257|Other|Online pre-test genetic education tool|See Arm Descriptions above.
1631246|NCT01999244|Behavioral|Self-monitoring skills|
1631247|NCT01999244|Behavioral|Technology|
1631248|NCT01999244|Behavioral|Interventionist Contact|
1631249|NCT01999231|Biological|ESAT6-CFP10|32 healthy subjects who meet the standard of protocol are allocated four different groups according to dosages of ESAT6-CFP10 :1μg/ml ESAT6-CFP10、5μg/ml ESAT6-CFP10、10μg/ml ESAT6-CFP10、20μg/ml ESAT6-CFP10.Each dose group have six healthy subjects(three male and three female) , at the same time set up two people for substitute (one male and one female) . ESAT6-CFP10 administered intradermally by the mantoux injection technique. Each receives only one dosage in right or left arm .
1631250|NCT01999218|Drug|Ertugliflozin 5 mg|Ertugliflozin, 5 mg, oral, once daily, from Day 1 to Week 104
1631251|NCT01999218|Drug|Ertugliflozin 10 mg|Ertugliflozin, 10 mg, oral, once daily from Day 1 to Week 104.
1631252|NCT01999218|Drug|Glimerpiride|Glimepiride, oral tablets, initiated at 1 mg daily and titrated up to the maximum approved dose (8 mg daily based on the local country label) or maximum tolerated dose
1631253|NCT01999218|Drug|Placebo to Ertugliflozin|Matching placebo to ertugliflozin, 5 mg and/or 10 mg, oral, once daily, from Day 1 to Week 104
1631254|NCT01999218|Drug|Placebo to Glimepiride|Matching placebo to glimepiride, 1 mg or 2 mg, oral, once daily, from Day 1 to Week 104.
1631255|NCT01999218|Drug|Metformin|Participants are to remain on their stable doses of metformin (oral, >=1500 mg/day) while receiving blinded investigational product during the double-blind treatment period. Participants on metformin <1500 at screening are up-titrated to >= 1500 daily.
1631256|NCT01999218|Drug|Sitagliptin|Open label, oral, once daily, rescue medication as required.
1631257|NCT01999205|Behavioral|Physical activity promotion|A nominated team in each participating company develops a plan to promote physical activity and to reduce sedentary behavior of the employees.
1631260|NCT01999179|Drug|Heparin, Low-Molecular-Weight|Cancer patients will be treated with enoxaparin 1 mg/kg subcutaneously every 12 hours for one month following catheter removal or alternate enoxaparin dose or interval based on anti-factor Xa testing obtained by the clinical team following a catheter related blood clot
1631261|NCT01999166|Radiation|radiography (X-ray)|
1631262|NCT01999166|Genetic|DNA sampling|
1631263|NCT01999153|Drug|20 mL topically used during alginate dressing NAROPEINE|20 mL topically used during alginate dressing
1631264|NCT01999153|Drug|20 mL topically used during alginate dressing NaCl|20 mL topically used during alginate dressing
2011683|NCT02459626|Other|Diagnostic P-V-loops and MRI|Invasive assessment of P-V-loops during catheterization for suspected CAD Magnetic resonance Imaging for assessment of myocardial fibrosis and biventricular function
1631269|NCT01999101|Drug|Px-104|28 days treatment
1631270|NCT01999088|Other|Functional Meet|During the I period, volunteers weekly consumed three 150g/serving Functional Meat (FM) products (cooked Ham and Turkey breast). It was firmly recommended that all other meats and meat derivatives had to be excluded from the diet.
1631271|NCT01999088|Other|Control Meat|During the C period, volunteers consumed identical amounts of meat products that did not include functional ingredients (Control Meat (CM)).
1631272|NCT01999075|Device|Lung Volume Recruitment (LVR)|LVR will be used twice per day
1631273|NCT01999075|Other|Conventional Treatment|This may include: a. Physiotherapy, consisting of percussion, active cycle of breathing and/or postural drainage; b. Nutritional support, consisting of oral or tube-fed dietary supplements; c. Antibiotics (oral or intravenous), if there is evidence of respiratory infection; d. Non-invasive positive pressure ventilation, if there is evidence of nocturnal hypoventilation or sleep-disordered breathing; e. Systemic steroids
1631274|NCT01999062|Other|IMRT + CT + MR scan|
1631275|NCT01999023|Dietary Supplement|Low protein formula group|Low protein formula formula (28.5 g) twice a day
1631276|NCT01999010|Device|MHT|MHT and visualizer contains mood information about the patient themselves, which allows for self management of the mood disorder. Self-management interventions promote early recognition of mood episodes, medication adherence and self-management skills which have shown to improve outcomes in depression. MHT encourages patients to take an active role by engaging in mood journaling, while making this information available in explorable form to the patient and his / her team of clinicians.
1631277|NCT01998997|Behavioral|Family educational intervention|The intervention is an educational intervention directed towards delirium prevention specifically for family members of hospitalized seniors. Family members will be encouraged to perform specific interventions that may decrease incident delirium.
1631278|NCT01998984|Drug|ingenol mebutate|
1631279|NCT01998984|Other|Placebo|
1631280|NCT01998971|Drug|Daratumumab|Administered by intravenous infusion in combination with the applicable backbone treatment.
1631281|NCT01998971|Drug|Velcade|Administered subcutaneously in accordance with product labeling and local standards.
1631282|NCT01998971|Drug|Pomalidomide|Administered orally in accordance with product labeling and local standards.
1631283|NCT01998971|Drug|Dexamethasone|Administered intravenously or orally in accordance with product labeling and local standards.
1631284|NCT01998971|Drug|Melphalan|Administered orally in accordance with product labeling and local standards.
1631285|NCT01998971|Drug|Prednisone|Administered intravenously or orally in accordance with product labeling and local standards.
1631286|NCT01998971|Drug|Thalidomide|Administered orally in accordance with product labeling and local standards.
1631287|NCT01998971|Drug|Diphenhydramine|Administered in prophylactic doses intravenously (or equivalent) in accordance with product labeling and local standards.
1631288|NCT01998971|Drug|Acetaminophen|Administered in prophylactic doses by mouth in accordance with product labeling and local standards.
1631289|NCT01998971|Drug|Carfilzomib|Administered intravenously in accordance with product labeling and local standards.
1631290|NCT01998971|Drug|Lenalidomide|Administered orally in accordance with product labeling and local standards.
1631291|NCT01998971|Drug|Montelukast|Administered intravenously or orally only with the first daratumumab dose in accordance with product labeling and local standards.
1631292|NCT01998958|Drug|Esketamine 14 mg|1 to 6 sprays of esketamine 14 mg self-administered as an intranasal formulation for 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable during the optional open-label phase for up to 4 days
1631293|NCT01998958|Drug|Esketamine 28 mg|1 to 6 sprays of esketamine 28 mg self-administered as an intranasal formulation for 4 days (Days 1,4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
1631294|NCT01998958|Drug|Esketamine 56 mg|1 to 6 sprays of esketamine 56 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
1631295|NCT01998958|Drug|Esketamine 84 mg|1 to 6 sprays of esketamine 84 mg self-administered as an intranasal formulation for up to 4 days (Days 1, 4, 8, 11) during the double-blind phase and if applicable, during the optional open-label phase for up to 9 days
1631296|NCT01998958|Drug|Placebo|1 to 6 sprays of placebo self-administered as an intranasal formulation for 2 days (Days 1 and 4) or depending on response on Day 8, for 4 days (Days 1,4, 8, 11) during the double-blind phase
1631297|NCT01998945|Behavioral|Exposure-based Cognitive Behavioral Therapy|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of exposure-based cognitive behavioral therapy, a time-limited treatment that focuses on confronting avoided memories and situations and identifying and managing distressing thoughts.
1631298|NCT01998945|Behavioral|Relaxation Training|Eight 75-minute, in-home sessions delivered twice weekly for 4 weeks of Relaxation Training, that focus on muscle relaxation and diaphragmatic breathing to address the physical symptoms of anxiety.
1631299|NCT01998919|Drug|erlotinib [Tarceva]|150 mg orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by 150 mg orally daily
1631300|NCT01998919|Drug|placebo|orally daily Days 15 to 28 of each 4-week cycle for 6 cycles, followed by daily oral application
1667479|NCT01718145|Biological|pegIFNα-2b|
1631302|NCT01998919|Drug|cisplatin|75 mg/m2 iv Day 1 of each 4.wek cycle, 6 cycles; or carboplatin
1631303|NCT01998919|Drug|carboplatin|5 x AUC iv Day 1 of each 4.week cycle, 6 cycles; or cisplatin
1631304|NCT01998906|Drug|Trastuzumab|8mg/kg IV on Day 1 of Cycle 1, followed by 6 mg/kg on Day 1 of Cycle 2 up a maximum of Cycle 17
1631305|NCT01998906|Drug|Doxorubicin|60 mg/m2 IV on Day 1 of Cycles 1 through 3
1631306|NCT01998906|Drug|Paclitaxel|150 mg/m2 IV on Day 1 of Cycles 1 through 3, followed by 175 mg/m2 IV on Day 1 of Cycles 4 through 7
1631307|NCT01998906|Drug|CMF|CMF: Cyclophosphamide (600 mg/m2 IV bolus), methotrexate (40 mg/m2 IV bolus), 5-fluorouracil (600 mg/m2 IV bolus) on Day 1 of Cycles 8 through 10
1631308|NCT01998893|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv weekly for 4 weeks; for responders to first course of therapy a second course is possible after relapse
1631309|NCT01998880|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
1631310|NCT01998880|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
1631311|NCT01998880|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
1631312|NCT01998854|Device|VizAblate System|The VizAblate System is indicated for use in transcervical intrauterine-guided radio frequency ablation of uterine fibroids
1631313|NCT01998841|Drug|Crenezumab|Crenezumab will be administered subcutaneously every 2 weeks.
1631314|NCT01998841|Drug|Placebo|Placebo will be administered subcutaneously every 2 weeks.
1631315|NCT01998828|Drug|Momelotinib|Momelotinib tablet administered orally once daily
1631316|NCT01998815|Procedure|Laparoscopic Roux-en-Y gastric bypass surgery|
1631317|NCT01998802|Drug|Active Comparator EBI-005|
1631318|NCT01998802|Drug|Placebo Comparator|
1631319|NCT01998789|Drug|Everolimus|Everolimus will be initiated within 24 hours of baseline at a dose of 1 mg po BID (2 mg/day).
1631320|NCT01998789|Drug|Standard Tacrolimus|"Subjects will be maintained on standard maintenance immunosuppression per local protocol, consisting of a tacrolimus plus enteric coated mycophenolic acid. Oral corticosteroids may not be eliminated sooner than 180 days post transplantation.
Tacrolimus doses will be adjusted based on local lab results of tacrolimus trough levels."
1631321|NCT01998776|Drug|Misoprostol|Misoprostol 200ug four times daily
1631322|NCT01998776|Drug|Placebo|Placebo Starch four times daily
1631323|NCT01998763|Dietary Supplement|Placebo|placebo capsules have similar appearance and smell as 400 IU vitamin D3 capsules,
1631324|NCT01998763|Dietary Supplement|Vitamin D3|Vitamin D3 2000 IU per day
1631325|NCT01998724|Behavioral|Tai Chi|24 week tai chi intervention designed for individuals with COPD
1631326|NCT01998724|Behavioral|Group Walking|24 week group walking intervention
1631327|NCT01998711|Behavioral|Memory group|Five 1-1.5 hour weekly session of memory training
1631328|NCT01998698|Procedure|Phacoemulsification surgery|Phacoemulsification surgery with intraocular lens implantation and monovision correction
1631329|NCT01998698|Procedure|Phacoemulsification surgery|Phacoemulsification surgery with multifocal intraocular lens implantation
1631330|NCT01998685|Drug|Propofol|
1631331|NCT01998685|Drug|remifentanyl|
1631332|NCT01998685|Drug|Midazolam|
1631333|NCT01998685|Drug|Fentanyl|
1631334|NCT01998685|Drug|Sevoflurane|
1631335|NCT01998672|Drug|Px-102|Px-102 drinking solution, 0.5 mg/kg, 1.0 mg/kg and 1.5 mg/kg
1631336|NCT01998672|Drug|Placebo|Drinking solution
1631337|NCT01998659|Drug|Px-102|Px-102 drinking solution, 7 single ascending doses from 0.15 mg/kg up to 4.5 mg/kg
1631338|NCT01998659|Drug|Placebo|Oral drinking solution
1631339|NCT01998646|Drug|ASP4058|Oral tablet
1631340|NCT01998646|Drug|Placebo|Oral tablet
2011684|NCT02457156|Procedure|Blumgart Anastomosis|"Trans pancreatic suture U stich incorporating pancreatic parenchyma and jejunal serosa, left loose.
Pancreatic duct to jejunal mucosa sutures, inserted and tied.
Trans pancreatic suture U stich brought back through the jejuanl serosa anteriorly, tied."
1631342|NCT01998620|Drug|Ademetionine 2|Ademetionine 1000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 500mg po bid with general antiviral treatment for 8 weeks
1631343|NCT01998620|Drug|Ademetionine 1|Ademetionine 2000mg ivgtt qd with general antiviral treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
1631344|NCT01998620|Drug|Ademetionine 3|no treatment for 2 weeks, then Ademetionine 1000mg bid po with general antiviral treatment for 8 weeks
1631345|NCT01998607|Other|Physician Survey|Eligible physicians will be contacted to perform the physician survey. A standardised online questionnaire will be used to collect information about the physician's awareness of the Summary of Product characteristics (SPC) pertaining to osteonecrosis of the jaw (ONJ) in the last 6-18 months.
1631346|NCT01998594|Procedure|Arthroplasty|A longitudinal dorsoradial incision is made from the base of the first metacarpal to the radial styloid for access to the thumb CMC joint. Trapeziectomy is performed piecemeal using sharp and blunt dissection. The base of the first metacarpal is then decorticated with a sagittal saw. A 4x7 cm sheet of thin FlexHD (HADM) is fashioned by a 4-0 monocryl suture imbrication into the size and shape of the subject's trapezium, keeping the dermal side exposed as much as possible. The allograft is secured with multiple interrupted 3-0 Ticron sutures and the bundle is placed into the post-trapeziectomy space. Additional suture fixation is performed between the FlexHD and the volar capsule of the trapezium, and base of the thumb metacarpal using 4-0 Mersilene sutures. The control treatment group will have the same trapeziectomy but without the placement of the FlexHD acellular dermal matrix.
1631347|NCT01998581|Device|JUVEDERM VOLBELLA® XC|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL. Up to 6.0 mL allowed for repeat treatment.
1667480|NCT01718145|Drug|Telaprevir|
2011685|NCT02457156|Procedure|Cattell-Warren Anastomosis|"Posterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied.
Pancreatic duct to jejunal mucosa sutures, inserted and tied.
Anterior row of sutures from pancreatic parenchyma to jejunal serosa, inserted and tied."
1631348|NCT01998581|Device|Restylane-L®|Up to 1.5 mL per lip (upper and lower) at each treatment (initial, touch-up, and repeat treatment). Additional product may be injected into the perioral area, as long as the total injection volume does not exceed 6.0 mL.. Up to 6.0 mL allowed for repeat treatment.
1631349|NCT01998568|Other|Intraocular pressure measurement|Using different tonometers for intraocular pressure measurement
1631350|NCT01998555|Other|CBT|
1631351|NCT01998542|Biological|AlloVax|Personalized anti-cancer vaccine Intradermal injection AlloSimt followed immediately by the intradermal injection of CRCL
1631352|NCT01998542|Biological|CRCL|autologous tumor-derived chaperone protein mixture
1631353|NCT01998542|Biological|AlloStim|AlloStim (ID) injection AlloStim (IV) infusion
1631354|NCT01998542|Other|PlasmaLyteA with 1% human serum albumin|PlasmaLyteA with 1% human serum albumin, packaged, labeled and shipped to appear the same as the active experimental products and under the same storage conditions.
1631355|NCT01998529|Drug|Cisplatin|Starting dose of hyperthermic cisplatin 120 mg/m2. Perfusion continued for 60 minutes after adding the cisplatin at a target temperature of 41 C (+0.5 C).
1631356|NCT01998529|Drug|Amifostine|Amifostine administered intravenously over 15 minutes beginning 30 minutes (+ 15 minutes) after the cisplatin perfusion.
1631357|NCT01998503|Drug|Bortezomib|
1631358|NCT01998503|Drug|dexamethasone|Given orally
1631359|NCT01998503|Biological|filgrastim|Given subcutaneous
1631360|NCT01998503|Procedure|autologous hematopoietic stem cell transplantation (ASCT)|Given on day 0
1631361|NCT01998503|Drug|Melphalan|
1631362|NCT01998490|Other|Animal-assisted activity|
1631363|NCT01998490|Other|Robot-assisted activity|
1631364|NCT01998477|Biological|TIVc|Madin Darby Canine Kidney (MDCK) cell culture derived subunit influenza vaccine TIVc contained the purified viral envelope glycoproteins, hemagglutinin (HA) and neuraminidase (NA) derived from 3 strains (including HA for each strain [A/H1N1-like, A/H3N2-like, and B-like]) intramuscular (IM) injection recommended by the WHO for the 2013-2014 influenza season in the Northern Hemisphere
1631365|NCT01998477|Biological|TIV|A conventional egg derived subunit influenza vaccine (TIV) contained the purified viral envelope-glycoproteins, HA and NA derived from 3 strains (including HA for each strain [A/ H1N1-like, A/H3N2-like, and B-like]) IM injection recommended by the WHO for the 2013‑2014 influenza season in the Northern Hemisphere.
1631366|NCT01998451|Drug|Tauroursodeoxycholic acid|patients from double sphincter group and general gallbladder sphincter group all received Tauroursodeoxycholic acid after surgery for 6 months.
1631367|NCT01998438|Drug|Tranexamic Acid|The loading doses were given in 15 minutes when incision.
1631368|NCT01998399|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg BID for 90 days
1631369|NCT01998399|Drug|Placebo|Placebo 180 mg loading dose followed by 90 mg BID for 90 days.
1631370|NCT01998386|Other|Placebo gel without hydrogen peroxide|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with the gel one hour a day for seven days. Thirty days after the beginning of treatment, the volunteers in this group will receive the whitening treatment with 6.0% hydrogen peroxide - White Class with calcium.
1631371|NCT01998386|Other|6.0% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 6.0% hydrogen peroxide - White Class with calcium and will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
1631372|NCT01998386|Other|7.5% hydrogen peroxide - White Class|Castings will be made of the upper and lower arches of the volunteers and plaster will be poured into the molds. Individual plastic molds (vacuum form, flexible acetate 1 mm in thickness) will be made for each arch using the plaster models. After fitting the molds in the oral cavity, the volunteers will receive oral and written instructions on how to use the whitening gel 7.5% hydrogen peroxide - White Class with calciumand will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening agent. The volunteers will be instructed to use the molds with whitening gel one hour a day for seven days.
1631373|NCT01998386|Other|7.5% hydrogen peroxide - Oral-B 3D White|The participants in this group will receive four disposable whitening 7.5% hydrogen peroxide - Oral-B 3D White strips for daily individual use. The volunteers will be instructed to perform proper oral hygiene with dental floss and a tooth brush prior to the application of the whitening strips. The volunteers will receive oral and written instructions on how to use the whitening strips, which will be placed on the surface of the teeth for 30 minutes twice a day for seven days.
1631374|NCT01998373|Behavioral|training leaflet and oral training|The intervention consisted of training leaflet and oral training. All of the patients were new cases and were divided into 2 groups. All patients were treated with routine medication, no addition medication for two groups were done, the case group attended the workshops and were trained In addition to medical therapy, continuing education and training workshop. The result of the effect of workshop was also filling out a questionnaire before and after training. Finally, two groups with statistical analysis were compared.
1631375|NCT01998360|Procedure|Surgical Control|The study is quasi-experimental, because the open surgical controls are not contemporaneous. They were performed at the same center as part of Unicirc 001 trial with the same conditions as the subsequent 50 Unicirc circumcisions.
1631376|NCT01998360|Procedure|Unicirc with tissue adhesive|Excision of foreskin with Unicirc device and wound sealing with tissue adhesive
1631377|NCT01998347|Drug|Paclitaxel liposome|
1631378|NCT01998347|Drug|Cisplatin|
1631379|NCT01998347|Drug|5-fluorouracil|
1631380|NCT01998334|Other|CVVH 6h|CVVH 6h for first three days
1631381|NCT01998334|Other|CVVH 10h|CVVH 10h for first three days
1668055|NCT01713556|Drug|placebo|
1631382|NCT01998334|Other|CVVHDF 6h|CVVHDF 6h for first three days
1631383|NCT01998321|Other|Patient specific instrument|A special software with the ability to perform 3D planning including sizing, alignment, bone cutting, positioning of implants, simulation & PSI designing and PSI production
1631384|NCT01998321|Other|conventional technique for TKA|
1631385|NCT01998308|Drug|Crespine gel|50 Knees will have single injection of Crespine gel
1631386|NCT01998308|Drug|Intragel|50 Knees will have single injection of 2 ampules of Intragel
1631387|NCT01998308|Drug|Crespine plus gel|50 Knees will have single injection of Crespine Plus Gel
1631388|NCT01998308|Drug|Monovisc|50 Knees will have single injection of Monovisc
1631389|NCT01998295|Drug|Artemether/lumefantrine|Medication was given at 0, 8, 24, 36, 48 and 60 hours. Food was given to all patients prior to medication to ensure proper absorption of the drug.
1631390|NCT01998256|Device|AV optimization|Iterative DFT (diastolic filling time) method for AV optimization. Optimal AV delay for both atrial sensed and atrial paced settings was defined by two experienced echocardiographists, after 3 separate measurements.
2011686|NCT02457156|Drug|Octreotide|Octrotide (100ug) to be administered on the evening before surgery and then 100ug three times daily on the day of surgery and post operative days 1 - 6.
1631392|NCT01998230|Dietary Supplement|early oral feeding|In the early oral feeding group, the patients are encouraged to intake liquid food on post operative day 1.
1631393|NCT01998217|Drug|Remifentanil|Patients in Rem group receive sedation and analgesia with remifentanil, dose of which will be determined by the up-and-down method.
1631394|NCT01998217|Drug|Flurbiprofen and remifentanil|Patients in this group receive sedation and analgesia with flurbiprofen and remifentanil, dose of which was determined by the up-and-down method.
1631395|NCT01998191|Other|Explicit case note review checklist (nurse)|"A checklist to be used to screen notes for features of avoidable death used by nurses.
to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
1631396|NCT01998191|Other|Explicit case note review checklist (physician)|"A checklist to be used to screen notes for features of avoidable death, used by a nurse.
to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
1631397|NCT01998191|Other|Explicit case note review checklist (MDT)|"A checklist to be used to screen notes for features of avoidable death used by a nurse and an expert physician.
to be compared with 'Implicit Case note review (physician)' 'Implicit Case note review (MDT)' 'Implicit Case note review (nurse)' and the other two intervention arms."
1631398|NCT01998165|Drug|Remifentanil|After intubation, continuous intravenous infusion of remifentanil (0.25 µg/kg/min) is started, while anesthesia is maintained with inhaled or intravenous anesthetics. In cases where sedation by general anesthetics and analgesia by lidocaine does not seem to provide a sufficient means of analgesia at the time of intubation, remifentanil may be used, beginning before intubation. The rate of infusion may be adjusted while monitoring the subject's general condition in 25% to 100% increments or in 25% to 50% decrements every 2 to 5 minutes, but should not exceed 1.3 µg/kg/min.
1631399|NCT01998152|Procedure|Nutritional counseling|Patients in the intervention-arm will receive individualized nutritional counseling by a registered dietitian during standard treatment with chemotherapy. The main goals of the nutritional intervention will be to enable every patient to achieve sufficient protein and energy intake with attention for sufficient intake of micronutrients and a sufficient physical activity level.
1631400|NCT01998126|Drug|Ipilimumab|Ipilimumab 3 mg/kg x 4 (given with standard Erlotinib or Crizotinib based on mutation)
1631401|NCT01998126|Drug|Erlotinib|Erlotinib 150 mg once daily or current tolerable dose (given with Ipilimumab)
1631402|NCT01998126|Drug|Crizotinib|Crizotinib 250 mg twice daily or current tolerable dose (given with Ipilimumab)
1631403|NCT01998126|Drug|Nivolumab|
1631404|NCT01998113|Drug|Glyburide vs Insulin trials|Affecting groups 1 and 2
1631405|NCT01998113|Drug|Metformin vs Insulin trials|Affecting groups 3 and 4
1631406|NCT01998113|Drug|Metformin vs Glyburide trials|Affecting groups 5 and 6
1631407|NCT01998100|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
1631408|NCT01998100|Behavioral|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
1631409|NCT01998087|Behavioral|Breastfeeding support|A breastfeeding brochure will be distributed to expectant mothers from 20 weeks gestation during their regular antenatal visit. This will be followed 2 weeks later by a phone call offering clarification/explanation of the brochure. Three phone calls, offering breastfeeding support, will be conducted at 2,6 and 10 weeks following the birth of the baby.
1631410|NCT01998074|Dietary Supplement|extensively hydrolyzed rice protein formula|
1631411|NCT01998061|Drug|EGFR tyrosine kinase inhibitor|Arm A
1631412|NCT01998061|Drug|EGFR tyrosine kinase inhibitor with chemotherapy|Arm B
1631413|NCT01998048|Procedure|Latarjet|A diagnostic arthroscopy is performed before the Latarjet operation in general anaesthesia. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeons' decision by inserting 1 to 2 more suture anchors according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect. Thereafter an open Latarjet operation is performed using standard techniques described by Walch or de Beer. A deltopectoral incision is used. The coracoid process is osteotomized and ventrally prepared to bleeding bone. The coracoid process is then transferred through the middle of the subscapularis and re-attached on to the freshened neck of the glenoid, just medial to the joint line with two screws and washers, according to the surgeon's preference.
2011687|NCT02457221|Drug|Tacrolimus capsules|oral
1631454|NCT01997697|Other|behavior change program|behavior change program among patients with obesity
1631484|NCT01997385|Procedure|KAPD-C|KAPD-C is a treatment prescribed 2000 mL fill volume per each 4 cycles of dialysis session with an exchange cycle of 90 minutes.
2011688|NCT02457221|Drug|Cyclophosphamide injections|intravenous injection
2011689|NCT02457221|Drug|Prednisone|oral
1631414|NCT01998048|Procedure|Bankart|An arthroscopic Bankart operation is performed in general anaesthesia according to current practise (Provencher 2010). The intra-articular findings are recorded and the anteroinferior labrum and the IGHL are mobilized until subscapular muscle fibers can be seen. The IGHL complex is then re-attached to the freshened neck of the glenoid with 2 to 3 suture anchors according to surgeon's preference to re-create labral bumper and capsular tension. In case of a significant Hill-Sachs defect an additional remplissage procedure may be performed according to surgeon's decision by inserting 1 to 2 more suture anchors, according to surgeon's preference into the deepest portion of the Hill-Sachs defect and tying the infraspinatus tendon down to fill the bony defect.
1631415|NCT01998035|Drug|Romidepsin|"Romidepsin is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. Romidepsin is classified as a Histone Deacetylase Inhibitor.
Dose escalation (10, 14 mg/m2)"
1631416|NCT01998035|Drug|Oral 5-Azacitidine|"A pyrimidine nucleoside analogue of cytidine with antineoplastic activity.
Dose escalation (100, 200, 300 mg)"
1631417|NCT01998009|Other|fecal occult blood tests|
1631418|NCT01997983|Device|TC-3 Gel mixed with Botox (BTX)|TC-3 gel mixed with Botox (BTX). Single intravesical instillations of 40 ml of TC-3 mixed with 200 units of preconstitued BTX, using catheter
1631419|NCT01997970|Behavioral|Treadmill workstation|The intervention group will receive a treadmill workstation for 12 months. They will use this at self-selected speed and will be recommended to use this for at least 1 hour per day. Participants in the control group will continue with conventional office work at their regular desk. Participants in the intervention group will receive four boosting e-mails during the study period, in which they will be encouraged to use the treadmill.
1631420|NCT01997970|Behavioral|Health talk|Participants in both groups will receive a health talk with recommendations about diet and physical activity habits.
1631421|NCT01997957|Drug|S-1|Begin oral administration of S-1 from the 2nd day after TACE therapy plus arterial indwelling catheter chemotherapy (Oxaliplatin)
1631422|NCT01997944|Biological|Human Serum ALbumin/interferon alpha2a|600,750 or 900 mcg dosing every 2 weeks
1631423|NCT01997944|Biological|Pegasys|180 mcg dosing every week
1631424|NCT01997931|Device|Bispectral Index Sedation monitor|
1631425|NCT01997905|Device|AtriClip LAA Exclusion Device|
1631426|NCT01997879|Drug|AR-13324 Ophthalmic Solution, 0.02%|Eyedrop
1631427|NCT01997866|Other|STOP-BANG Scoring Model|Patients with Congestive Heart Failure on non-Intensive Care Unit Medical Services and/or visiting our outpatient Congestive Heart Failure Clinic will be administered the STOP-BANG Scoring Model to determine whether they are considered high-risk or low-risk for Sleep Apnea.
1631428|NCT01997866|Other|Polysomnogram Sleep Study|Patients determined by the STOP-BANG Scoring Model to be high-risk for Sleep Apnea will be referred to the Sleep Center physicians for evaluation and treatment. If medically indicated, a Polysomnogram Sleep Study will be performed.
1631429|NCT01997853|Drug|Omega 3 fatty acid|Patients with Chronic Periodontitis in Test Group were prescribed Omega 3 fatty acid tablets 300mg once daily for 12 weeks and SRP at baseline
1631430|NCT01997853|Drug|Placebo|Patients with Chronic Periodontitis in Control Group were prescribed Placebo tablets once daily for 12 weeks and SRP
2011690|NCT02455310|Behavioral|Educational activities to improve dementia care|The multicomponent intervention included active dissemination of educational resources and optional participation in specialist consultation sessions for up to 6 months. The standard intervention included education through a website or conferences, including clinical tools to support implementation of best practices.
1631432|NCT01997827|Device|metal-ceramic RBFDP|Rehabilitation of tooth loss with a metal-ceramic RBFDP
1631433|NCT01997827|Device|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
1631434|NCT01997814|Drug|herbal immunomodulator|Patients in Test Group were treated with scaling and root planing (SRP) along with Herbal Immunomodulators (Septilin) therapy, 2 tablets twice daily for 3 weeks.
1631435|NCT01997814|Drug|Placebo|Patients in Control Group were treated with scaling and root planing (SRP) along with Placebo therapy, 2 tablets twice daily for 3 weeks.
1631436|NCT01997801|Drug|Ketamine infusion|Ketamine will be infused intraoperatively (0.25 mg/kg intravenous bolus following continuous infusion of 100 mcg/kg/hr).
1631437|NCT01997801|Drug|NS infusion|Normal saline will be infused intraoperatively.
1631438|NCT01997788|Drug|The intrathecal morphine injection|A single injection of morphine intrathecally
1631439|NCT01997788|Drug|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
1631440|NCT01997788|Drug|Demerol on demand|Demerol 25 mg intravenously when pain scores more than 5.
1631441|NCT01997775|Drug|METFORMIN|Participants enrolled in this study will be treated with either chemotherapy (Cisplatin 75mg/m2 plus Pemetrexed 500mg/m2 on D1) for 4 cycles or targeted therapy (Gefitinib 250mg/d) till disease progression according to physicians' decision. For participants with plasma IL-6 > 2.0 pg/mL after 2 cycles of chemotherapy or targeted therapy, Metformin 500mg orally qd will be given on Day 1 of cycle 3. If patient could tolerate it well, metformin will be titrated to 500mg bid in the following week (Cycle 3 D8) and 500mg tid in the 3rd week (Cycle 3 D15). For patients receiving chemotherapy, metformin will be used for total 12 weeks and plasma IL-6 level will be checked at the end of metformin treatment. For patients receiving targeted therapy, metformin will be used till disease progression and plasma IL-6 level will be measured after use of metformin for 12 weeks.
1631442|NCT01997762|Dietary Supplement|Resveratrol|gel-coated capsules to be taken twice a day; one with breakfast and dinner
1631443|NCT01997762|Dietary Supplement|Placebo|
1631444|NCT01997749|Dietary Supplement|Ketocal 4:1 (Nutricia)|
1631445|NCT01997749|Dietary Supplement|Control diet: Regular diet offered at the hospitals|
1631446|NCT01997749|Dietary Supplement|Ketogenic meals|
1631447|NCT01997736|Device|Ablation|
1631448|NCT01997723|Device|Portable monitoring|A device applied over 1 arm (on the wrist and finger), worn overnight by patients to detect OSA.
1631449|NCT01997723|Other|Polysomnography|One attended diagnostic sleep study.
1631450|NCT01997723|Device|Home portable monitoring|Portable monitoring with WP200 device - applied by participants once at home.
1631451|NCT01997723|Device|Laboratory portable monitoring|Portable monitoring with WP200 device - applied by technologist once in the laboratory simultaneously with polysomnography.
1631455|NCT01997684|Procedure|Colonic Stenting with Elective Surgery|"After preparation of the distal colon with an enema, the colonoscope will be introduced up to the site of the obstruction. The colonic stent will be placed along a guide wire through the lesion under radiologic or endoscopic guidance. A colonic stent will be chosen which was at least 3 cm longer than the lesion (1.5 cm at either end). When the colonic stent did not cover the entire length of the lesion, a second overlapping stent will be placed.
If the colonic stenting failed (technical failure) or symptoms of colonic obstruction did not resolve within 3 days (clinical failure), patients were indicated for emergency surgery.
Candidates for elective surgery were preferably operated on 5-14 days after colonic stenting, and no later than 4 weeks.
Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis."
1631456|NCT01997684|Procedure|Emergency Surgery|Type and extent of the surgery were selected by the surgeon, including but not limited to: loop colostomy, Hartmann's procedure, and (sub) total colectomy with ileostomy or ileorectal anastomosis.
1631457|NCT01997671|Other|Information Support System|Practitioners in the intervention group may have access, whenever they want and through the computerized medical record program, to personalized information on their assigned patients who have started treatment of cardiovascular primary prevention with lipid-lowering. This information is updated monthly for 12 consecutive months.Information will be presented in two different and complementary ways to each practitioner: asynchronous information (the patient is not present when the practitioner receives the information) and synchronous information (the patient is present when the practitioner receives the information).
2011691|NCT02454335|Procedure|Peroral Endoscopic Myotomy|The intervention is the POEM procedure performed by either anterior approach or posterior approach orientation of the incision for mucosal entry.
1631460|NCT01997645|Procedure|LIFT|
1631461|NCT01997645|Procedure|RAF|
1631462|NCT01997632|Biological|a single dose of monovalent high-dose inactivated poliovirus type 2 vaccine (m-IPV2 HD)|a single dose m-IPV2 HD (study vaccine), 0,5ml
1631463|NCT01997632|Biological|a single dose of the standard trivalent inactivated poliovirus vaccine (IPV)(Imovax Polio®).|a single 0.5 ml dose Imovax Polio (control vaccine)
1631464|NCT01997606|Other|use of Purotex treated bedding covers|Purotex is a textile treatment that uses five 100% natural bacteria or probiotics, selected for their ability to clean up house dust mite allergen along with other allergen types. The active probiotics are placed inside of millions of capsules and are introduced during the textile production. These human friendly bacteria remain non-active until friction force is created between the mattress/pillow and the sleeper's body. Under the friction force a small part of the capsules is opened and probiotics become active. They saturate the bacterial capacity of the textile and by doing so, reduce the risk of dust mite allergen development and growth of molds and harmful bacteria. The patients will apply the covers around their mattress and around their pillow. On top of these covers the patients will apply their own fitted sheet and pillowcase (which they will change every 4 weeks).
1631465|NCT01997606|Other|placebo|
1631466|NCT01997593|Drug|intraperitoneal infiltration of ropivacaine|intraperitoneal infiltration of ropivacaine by a special equipment
1631467|NCT01997580|Drug|escitalopram|SSRI antidepressant
1631468|NCT01997567|Drug|Ropivacaine|Subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of ropivacaine 0.5% with epinephrine 1:200,000 (150mcg) as a tracer for intravascular injection (total 30 ml)
1631469|NCT01997567|Drug|Placebo|Group 2 consented subjects will receive for their hip arthroscopy procedures general anesthesia (sevoflurane) with single femoral and lateral femoral cutaneous nerve blocks under ultrasound guidance, with 20 ml solution for the femoral block and 10 ml for lateral femoral cutaneous block, for a total of 30 ml solution of saline with epinephrine 1:200,000 (150 mcg) (total 30 ml)
1631470|NCT01997554|Other|Blood sample|An extra blood sample of 10 ml is collected
1631471|NCT01997528|Device|Change of blood flow or sweep gas flow ( ILA Activve)|
1631472|NCT01997515|Drug|Ketamine|Group K (ketamine) will receive 0.5mg /kg of ketamine bolus followed by an infusion of 0.5 mg/kg/hour of ketamine throughout the intraoperative period (Adjusted body weight).
1631473|NCT01997515|Drug|placebo|Group P (placebo) will receive the same amount of saline.
1631474|NCT01997502|Device|Pulse CO-Oximetry Technology|"In addition to the standard pulse oximeter used for clinical care, up to six SpHb finger sensors will be applied to the patient. Additional sensors may also be applied to the forehead, neck, chest and ears.
Masimo FDA cleared pulse CO-Oximeter devices: Radical-7, Rad-87, Rad-57, Pronto, Pronto-7, for the noninvasive measurement of SpO2, PR, PI, PVI, SpCO, SpMet, and SpHb, total hemoglobin and respiratory rate.
No treatment decisions will be made based on the new technology and no extra medical procedures are required for the study."
1631475|NCT01997502|Other|Blood draw|4mL arterial blood samples (up to 1 per hour), outside standard of care, are drawn throughout the surgical procedure and sent to UCDMC lab/Masimo lab for analysis.
1631476|NCT01997489|Drug|Enzyme replacement|Observational study of current treatment and with no comparative groups
1631477|NCT01997476|Procedure|Combined EUS, e-PFT and sEUS Testing|"advantage of combined EUS, ePFT & sEUS testing to provide a more definitive diagnostic assessment, rather than each test alone.
Establish the advantage of reduced time and cost of combining EUS and ePFT, rather than when done separately."
1631478|NCT01997463|Drug|Supervised asthma therapy in schools|Therapy observed daily in school. Asthma education by American Lung Association
1631479|NCT01997437|Device|Stem-cell seeded bioartificial tracheal scaffold|Seeding the synthetic scaffold with autologous stem cells; scaffold' cultivation within 48-72 hours in bioreactor, injection of growth factors into scaffold in the first and last stages of the cultivation, replacement of the damaged trachea by generated tissue-engineered organ
1631480|NCT01997424|Device|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
1631481|NCT01997424|Device|FibroScan, Echosens, Paris, France|
1631482|NCT01997411|Drug|Intranasal Glucagon|
1631483|NCT01997411|Drug|Glucagon|
1631927|NCT01993888|Biological|EVARREST® Fibrin Sealant Patch|
1631485|NCT01997385|Procedure|KAPD-A|KAPD-A is a treatment initially prescribed 1500 mL fill volume per each 2 cycles of dialysis session with an exchange cycle of 45 minutes and followed by 2 cycles of 2500 mL fill volume with an exchange cycle of 135 minutes.
1631486|NCT01997372|Drug|ATG|Drug ATG:2.5mg/kg/d or 3.75mg/kg/d for 5 days; Drug Cyclosporine A (CSA):3-10mg/kg/d ,Adjust the dose to maintain drug levels between 150 and 300ng/ml; Drug prednisone:1mg/kg/d,d1-21 from the first dosage of ATG; Drug Granulocyte Colony-Stimulating Factor(G-CSF):5ug/kg/d until absolute neutrophil count (ANC) ＞1×109/L.
1631487|NCT01997333|Drug|CDX-011|
1631488|NCT01997333|Drug|Capecitabine|
1631489|NCT01997320|Other|Heavy resistance exercise and nutrition|Heavy resistance exercise of the lower extremities three times weekly for 12 weeks.
1631490|NCT01997320|Other|Nutrition supplement|Two daily administrations of nutrient supplementation, each containing 20g of milk protein.
1631491|NCT01997294|Drug|Sequential therapy of atorvastatin|80mg atorvastatin before PPCI and 40mg/d for 7 days after PPCI
1631492|NCT01997281|Dietary Supplement|dietary fiber-enriched cereal|"provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)
amount: 79g for dinner and breakfast, 38.5g for night snack (10 p.m.)
one serving of steamed egg is added for dinner and breakfast"
1631493|NCT01997281|Other|conventional cereal|"provided with 300 mL (150 mL at 10 p.m.) of milk, total 3 times (day 1: 6 p.m. and 10 p.m., day 2: 8 a.m.)
amount: 80 g for dinner and breakfast, 40 g for night snack (10 p.m.)
one serving (40g) of steamed egg is added for dinner and breakfast"
1631494|NCT01997268|Drug|Placebo|Corn Oil
1631495|NCT01997268|Drug|SC401B 2 capsules|
1631496|NCT01997268|Drug|SC401B 4 capsules|
1631497|NCT01997268|Drug|SC401B 6 capsules|
1631498|NCT01997255|Drug|Everolimus|Afinitor tablets will be administered at a starting dosage of 5 mg/ m2/ day, dosed once per day in the morning. To achieve appropriate doses for all subjects 2mg, 3mg, 5mg of everolimus Disperz tablets will be used. Subjects will take one or more of these tablets in combination to achieve the required dose. Dosages will be rounded to the nearest 2 mg when calculating doses for individual subjects.
1631499|NCT01997229|Biological|Eculizumab|Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every 2 weeks during Weeks 4-26
1631500|NCT01997229|Drug|Placebo|Placebo
1631501|NCT01997216|Device|Delefilcon A multifocal contact lens|Investigational silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
1631502|NCT01997216|Device|Lotrafilcon B multifocal contact lens|Commercially marketed silicone hydrogel contact lens dispensed in low, medium, or high ADD per current AIR OPTIX® AQUA MULTIFOCAL fitting guidelines
1631503|NCT01997203|Drug|Vitamin D|vitamin D was given to 50 patients (HCV under treatment)
1631504|NCT01997190|Biological|AdV-tk + valacyclovir|AdV-tk will be administered intrapleural through pleural catheter followed by oral valacyclovir. Valacyclovir will be administered orally at a fixed dose for 14 days after each AdV-tk administration.
1631505|NCT01997164|Drug|REGN910-3|
1631506|NCT01997164|Drug|REGN910|
1631507|NCT01997164|Drug|Intravitreal Aflibercept Injection (IAI)|
1631508|NCT01997151|Behavioral|Healthy Pregnancy: Step by Step|
1631509|NCT01997138|Drug|Anakinra 100 mg in 2 ml saline IA|
1631510|NCT01997125|Device|Neural Bridge System|Implanted device
1631511|NCT01997112|Drug|Paracetamol|
1631512|NCT01997112|Drug|Placebo oral capsule|
1631513|NCT01997099|Device|CADD®-Solis VIP Pump|
1631514|NCT01997099|Device|CADD™ Solis Medication Safety Software Administrator|
1631515|NCT01997086|Procedure|Percutaneous transforaminal endoscopic discectomy (PTED)|Percutaneous transforaminal endoscopic discectomy
1631516|NCT01997086|Procedure|Microendoscopic discectomy (MED)|Microendoscopic discectomy
1631517|NCT01997060|Behavioral|Intensive Lifestyle Intervention|
1631518|NCT01997034|Behavioral|Intensive Lifestyle Intervention|The included subjects has previously participated in the Intensive Lifestyle Intervention intervention at Ubberup Folk High School. This intervention includes daily exercise and a hypocaloric diet (app. -700KCal/day) for 10-14 weeks. Furthermore theoretical and practical education within e.g. Nutrition, exercise and motivational psychology.
1631519|NCT01997021|Other|US|US is a 5-hour intervention/condition where participants will be required to sit quietly for 5 consecutive hours.
1631520|NCT01997021|Other|IW|IW is a 24-hour intervention/condition where participants interrupt sedentary time with short 1.5 minute walking bout.
1631521|NCT01997021|Other|CW|CW is a 24-hour intervention/condition where participants perform a 36 minute continuous walking bout and are seated the remainder of the time.
1631522|NCT01997008|Behavioral|Intervention|Positive Affect Skills Training
1631523|NCT01996995|Device|Nd:YAG laser pulse therapy|
1631524|NCT01996995|Device|Sham procedure|Sham procedure
1631525|NCT01996982|Device|CCS Device|Core Cooling System Device
1631526|NCT01996969|Drug|Regorafenib|Regorafenib will be given 160mg once daily for 3 weeks, followed by a 1 week rest. Treatment will be continued until disease progression or unacceptable toxicity occurs. Response evaluation (CT scans) will be performed every 2 cycles.
1631527|NCT01996956|Other|volume expansion|fluid loading of 10 ml/kg colloid or blood product
1631530|NCT01996930|Drug|Haelan tape (steroid impregnated tape)|Medicated plaster applied daily. Max daily dose = 0.1mg (25cm squared per day)Maximum duration of treatment = 28 days
1631531|NCT01996930|Drug|Silver Nitrate|Cautery with silver nitrate cutaneous stick undertaken twice weekly for a maximum duration of treatment = 28 days
1631532|NCT01996917|Device|Prineo|After a Wise pattern breast reduction, one breast will have final layer closure with Prineo, while the other breast will be closed in the standard fashion with sutures.
1631568|NCT01996605|Drug|Oxytocin 150 mcg|Oxytocin 150 mcg will be administered spinally
1631569|NCT01996605|Drug|Placebo|placebo will be administered spinally
1631714|NCT01995474|Other|Conventional Technique|syringe is exchanged for the needle stylet and negative pressure is applied allowing acquisition of a cytology specimen.
1631928|NCT01993888|Other|Standard of Care (SoC)|
1631533|NCT01996904|Procedure|arthroscopic repair|If the subscapularis tendon was not sufficiently mobile, further anterior interval release between subscapularis and scapula was performed. LHB (long head of biceps tendon) was either treated with a biceps tenodesis or by tenotomy when there was tear or subluxation of it. The footprint area of the subscapularis tendon, which is trapezoidal in shape on the proximal part of the lesser tuberosity, was thoroughly cleaned of soft tissue and meticulous bone preparation was done prior to placement of anchor sutures.
1631534|NCT01996904|Procedure|arthroscopic debridement|Anterosuperior portal was made initially for debridement (capsulectomy and anterior bursectomy). A systematic release of the glenohumeral ligaments and the overlying subscapularis bursa was performed.The superior aspect of the tendon was freed from the surrounding structures (the coracohumeral and superior glenohumeral ligaments). The middle glenohumeral ligament was always released to identify the upper border of the subscapularis tendon.
1631535|NCT01996891|Other|Anti-Inflammatory Diet|The anti-inflammatory diet will focus on reducing glycemic load, and increasing fiber, fruits, vegetables, legumes and food-based omega-3 fatty acid content.
1631536|NCT01996865|Drug|Lenalidomide|
1631537|NCT01996865|Drug|Rituximab|
1631538|NCT01996852|Behavioral|Cognitive-behavioral Meetings|"The cognitive-behavioral intervention will consist of six monthly in-person meetings and five telephone follow-ups. In-person meetings include a 90-minute educational group session and five 60-minute therapeutic couple-based meetings which partners are asked to attend. The telephone follow-ups last 15-30 minutes and take place two weeks after each in-person meeting. They will review progress and provide support.
Each monthly meeting has a focused topic: Introduction, Guided imagery, Sensate focus, Communication and relationship issues, and Review.
Homework will be assigned at the end of each meeting. Generally, participants are instructed (a) practice guided imagery daily, (b) engage in sexual activity 1-2 times/ week after sildenafil intake and (c) use the pump every day for 10min."
1631539|NCT01996852|Drug|sildenafil citrate|"100mg of sildenafil citrate will be given twice a week to interested patients. Participants may start Sildenafil at a lower dose when needed.
To increase external validity, participants will be given the choice of using Sildenafil in the study."
1631540|NCT01996852|Device|Vacuum Constriction Device|"The medical treatment entails a 10-minute daily use of VCD (pump).
The VCD (pump) is a FDA approved marketing product and has a brochure and DVD that explain its usage. The clinical trials unit (CTU) nurse will dispense the VCD at the drug pick-up time and document it on a Device Accountability Form. The study coordinator has received manufacturer's training and can address questions that a subject may have about VCD on site or through a phone call."
1631541|NCT01996839|Drug|Loteprednol Etabonate Gel (BID)|One drop of LE gel instilled into the study eye two times per day (BID) for 14 days
1631542|NCT01996839|Drug|Loteprednol Etabonate Gel (TID)|One drop of LE gel instilled into the study eye three times per day (TID) for 14 days.
1631543|NCT01996839|Drug|Vehicle (BID)|One drop of vehicle instilled into the study eye two times per day (BID) for 14 days
1631544|NCT01996839|Drug|Vehicle (TID)|One drop of vehicle instilled into the study eye three times per day (TID) for 14 days
1631545|NCT01996826|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
1631546|NCT01996826|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
1631547|NCT01996813|Device|Compression Hose|Intervention in this case is placement of compression hose on patients
1631548|NCT01996800|Procedure|Spinal Manipulative Therapy (SMT)|Spinal manipulation is a therapeutic intervention performed on spinal articulations which are synovial joints. These articulations in the spine that are amenable to spinal manipulative therapy include the z-joints, the atlanto-occipital, atlanto-axial, lumbosacral, sacroiliac, costotransverse and costovertebral joints.
1631549|NCT01996800|Procedure|SMT and Neuromuscular Reeducation|Neuromuscular reeducation is a general term that refers to techniques that attempt to retrain the neuromuscular system to function properly. The basis of this idea is that the formation of certain patterns of communication between muscles and nerves allow people to perform simple everyday acts such as climbing stairs.
1631550|NCT01996787|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
1631551|NCT01996787|Device|Clariti with Handling Tint|Lenses will be worn on a daily wear basis (i.e. removed at night and stored in solution) and worn in the normal way. Lenses will be worn for one month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
1631552|NCT01996761|Drug|porcine brain peptide (Cerebrolysin)|
1631553|NCT01996761|Drug|Placebo|
1631554|NCT01996748|Drug|DF277|Two administrations daily for 7 days
1631555|NCT01996748|Drug|Placebo|Two administrations daily for 7 days
1631556|NCT01996735|Drug|Ticagrelor 180 mg single dose|
1631557|NCT01996735|Drug|Placebo|
1631558|NCT01996709|Device|Hydrogen peroxide-based contact lens solution|
1631559|NCT01996709|Device|Habitual contact lens solution|Biguanide-preserved
1631560|NCT01996709|Device|Habitual contact lenses|Silicone hydrogel contact lenses with a biweekly or monthly replacement schedule
1631561|NCT01996696|Drug|Metformin|Metformin 500 mg PO TID x 30-36 months
1631562|NCT01996696|Drug|Placebo|Identical placebo TID x 30-36 months
1631563|NCT01996683|Drug|desferal, ferriprox, blood transfusion|"Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.
Arm 2 will only recieve blood transfusion with no chelation"
1631564|NCT01996657|Drug|Warfarin|
1631566|NCT01996618|Drug|Ranolazine|After the initial 6 days of treatment with ranolazine, 500 mg twice daily or matched placebo, subjects will undergo repeat 24 hour electrocardiographic monitoring. If tolerated, the subjects will then have their study medication increased (Ranolazine 1,000 mg twice daily) with the plan to then undergo a repeat 24 hour ambulatory electrocardiographic monitoring in 6 days.
1631567|NCT01996605|Drug|Oxytocin 15 mcg|Oxytocin 15 mcg will be administered spinally
1631570|NCT01996579|Dietary Supplement|Lactoferrin|Lactoferrin is an 80 kilodalton (kD) naturally occurring multifunctional glycoprotein of the transferrin family which is an important component of the human innate immune system. Lactoferrin is distributed widely in humans with the main sources of production being exocrine glands and specific granules of neutrophils. It is present in virtually all human secretions. The highest concentrations are found in milk and colostrum. Lactoferrin has multiple biological functions which make it of interest as a therapeutic agent in the critically ill. These include the ability to bind iron, antimicrobial activity including antibacterial, antifungal, antiviral properties, the ability to bind endotoxin, promotion of beneficial bacteria in the gastro-intestinal tract and immunomodulatory activity.
1631571|NCT01996579|Other|Placebo|Sterile water will be utilized as the placebo control in this double blind randomized-controlled trial.
1631572|NCT01996540|Other|Interventional arm: Early best palliative care|Patients will receive standard oncologic care and will be assigned to early systematic best palliative care. They will meet a member of the palliative care team within 2 weeks after enrolment. Thereafter, they shall be visited by a palliative care team member every 2 weeks until death.
1631573|NCT01996527|Device|3-Tesla magnetic resonance imaging|3-Tesla MRI is a multiparametric imaging exam that includes MR pulse sequences for CEST-MRI, DW-MRI, DCE-MRI, and DSC-MRI
1631574|NCT01996527|Device|CEST-MRI|Undergo CEST-MRI
1631575|NCT01996527|Device|DW-MRI|Undergo DWI-MRI
1631576|NCT01996527|Device|DCE-MRI|Undergo DCE-MRI
1631577|NCT01996527|Device|DSC-MRI|Undergo DSC-MRI
1631578|NCT01996527|Drug|IV administration of gadolinium-containing contrast agent|Gadolinium-containing paramagnetic contrast agent (Magnevist®; Berlex Lab, Wayne, New Jersey) in delivered via intravenous (IV) infusion to achieve DCE and DSC contrast
1631579|NCT01996514|Dietary Supplement|Glucose with water|Glucose (1.0 g•kg-1 body weight ) in 250 mL of water 30 min before meal
1631580|NCT01996514|Dietary Supplement|non-caloric sweetener with water|0.15 g of the high-intensity sweetener, Splenda sucralose in 250 mL of water 30 min before meal
1631581|NCT01996514|Behavioral|TV program with non-food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
1631582|NCT01996514|Behavioral|TV program with food advertisements while feeding|30 minutes of TV program containing non-food ads during a meal
1631583|NCT01996501|Drug|Olanzapine Orally Disintegrating 5mg Tablets|
2011692|NCT02452892|Device|LFMS|Low field magnetic stimulation (1 kHz oscillating magnetic field) will be administered using a portable tabletop device capable of generating time-varying electromagnetic fields of LFMS. For sham therapy, the device will be on; however, no magnetic field stimulation will be delivered.
1631585|NCT01996475|Drug|Escitalopram Oxalate Tablets|
1631586|NCT01996462|Drug|Escitalopram Oxalate Tablets|
1631587|NCT01996449|Drug|Eplerenone|The subject will be started on Eplerenone (Inspra) 50-200mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued
1631588|NCT01996449|Drug|Amlodipine|The subject will be started on Amlodipine (Norvasc) 2.5 -10mg daily, which he or she will continue for a period of 8 weeks. Following the 8-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
1631589|NCT01996449|Procedure|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
1631590|NCT01996449|Procedure|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% or 45% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise
1631591|NCT01996449|Procedure|Sustained hand grip|Subjects will perform a sustained handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
1631592|NCT01996449|Procedure|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following sustained handgrip exercise
1631593|NCT01996449|Procedure|Arm cycling exercise|Subjects will perform a cycling arm exercise with a stationary cycling device. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this exercise.
1631594|NCT01996449|Procedure|Cold Pressor test|Subjects will place hand in cold water with ice for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline, during and 2 minutes after the test.
1631595|NCT01996436|Drug|Nicardipine|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
1631596|NCT01996436|Drug|Verapamil|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
1631597|NCT01996436|Drug|Nicardipine + Verapamil + Nitroglycerin|Pharmacological angioplasty: intra-arterial drug infusion via catheter to treat cerebral vasospasm
1631598|NCT01996423|Dietary Supplement|Vitamin D3|
1631599|NCT01996423|Dietary Supplement|Placebo|
1631600|NCT01996410|Device|Acupuncture|
1631601|NCT01996397|Procedure|Cardiac resynchronization therapy device implantation|
1631701|NCT01995565|Other|PLR|
1631702|NCT01995552|Device|External Loop Recorder|
1631703|NCT01995539|Device|Second iPro2 test|
1631704|NCT01995526|Drug|Insulin Peglispro|Administered subcutaneously
2011693|NCT02452528|Drug|ARC-520|
2011694|NCT02452528|Drug|Placebo|
1631602|NCT01996384|Procedure|Classical Acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are 0.18x30-40mm, manufactured by Dong Bae Corporation (DBC), Korea. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
1631603|NCT01996384|Procedure|Non-classical acupuncture|Very thin needles (0.18mm) will be inserted into locations either on the front or the back of the body and may be placed near or far from the affected area. No needles will be inserted into the genital region. Locations needled will be in non-classical acupuncture points. On even-numbered visits, the needles may be electrically stimulated via an electro-acupuncture machine. Needles will be retained for 30 minutes per study visit. Acupuncture needles used are DBC Brand, Korea, 0.18x30-40mm. The electrical acupuncture device is Pantheon Research Electrical Stimulator 8c, United States.
1631604|NCT01996384|Drug|Lidocaine|Study participants will gently apply 5% lidocaine cream four times daily to vulvar area.
1631605|NCT01996371|Device|Pedicle Screw|
1631606|NCT01996358|Drug|Succinylcholine|Anaesthesia is induced and maintained with propofol (1-2 mg/kg) and remifentanil (0,5 µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. After induction of anaesthesia the patient receives muscle relaxant according to the study group.
1631607|NCT01996358|Drug|Rocuronium 0,3|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
1631608|NCT01996358|Drug|Rocuronium 0,6|General anaesthesia is induced and maintained with propofol (1-2mg/kg) and remifentanil (0,5µg/kg). The study arm is immobilized and after cleaning the skin a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. The Patient receives the muscle relaxant according to the study group.
1631609|NCT01996345|Procedure|Cervical Pessary Placement|For the patients assigned to receive a cervical pessary, they will be evaluated and fitted for a pessary by the physician within 3-4 days unless exclusion criteria develop. After it is placed she will be evaluated for comfort. She will be asked to leave it in at all times but informed that removal and withdrawal from the study is always her option.
1631610|NCT01996332|Drug|erlotinib [Tarceva]|150 mg/day until progressive disease or unacceptable toxicity
1631611|NCT01996319|Drug|QVA149|QVA149 (110/50 µg) once a day via Breezhaler® device
1631612|NCT01996319|Drug|Placebo|Placebo once a day via Breezhaler® device
1631613|NCT01996306|Biological|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle.
1631614|NCT01996306|Drug|CPT-11 (Irinotecan)|150-180 mg/m2 intravenously administered over 90 minutes on day 1 of a 2-week cycle.
1631615|NCT01996306|Drug|5-FU Bolus|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle.
1631616|NCT01996306|Drug|5-FU Infusion|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle.
1631617|NCT01996306|Drug|l-LV (dl-LV)|200 (dl-LV: 400) mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle.
1631618|NCT01996306|Biological|bevacizumab|7.5mg/kg IV intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on Day 1 of a 3-week cycle.
1631619|NCT01996306|Drug|CPT-11 (Irinotecan)|150-200 mg/m2 intravenously administered over 90 minutes on day 1 of a 3-week cycle.
1631620|NCT01996306|Drug|Capecitabine|1600mg/m2/day oral on day 1 (evening) to day 15 (morning)of a 3-week cycle.
1631621|NCT01996293|Drug|lamotrigine|Lamotrigine will be observed in women who have already under the guidance of a physician decide to continue lamotrigine for the treatment of Bipolar Disorder
1631622|NCT01996280|Behavioral|Motivational Interviewing|The MI is a single brief motivational intervention lasting 1.5 hrs. The MI includes MI structured strategies tailored to the patient's readiness to change such as: the Typical Day exercise, the use of personal feedback reports (e.g., normative feedback about their drinking), discussions about the pros and cons of use, and completion of a change plan; It is designed to follow MI principles of invoking autonomy and emphasizing collaboration with the interventionist.
1631623|NCT01996280|Behavioral|Culturally Tailored MI|CTMI is a single brief motivational intervention lasting 1.5hrs. The CTMI follows the same sequence of structured strategies as the MI arm, and while the components in CTMI and MI are parallel, the focus within them is different. CTMI components culturally relevant material, such as acculturation stress. The CTMI components, which are MI structured strategies, are culturally tailored to address relevant concerns and issues. There are also culturally tailored feedback element, such as ethnic normative feedback related to drinking.
1631624|NCT01996267|Drug|PTC+Pertuzumab|Cycle repeated every 21 days
1631625|NCT01996267|Drug|FEC-T+Pertuzumab|Cycle is repeated every 21 days
1631626|NCT01996254|Device|SPRINT Peripheral Nerve Stimulation (PNS) System|"The SPRINT System is an Investigational Device which delivers mild electrical stimulation to nerves in the residual limb. The SPRINT System includes a small wire (called a Lead) that is placed through the skin in the upper leg. It also includes a device worn on the body that delivers stimulation (called the SPRINT Stimulator)."
1631627|NCT01996241|Behavioral|Educational enhancement intervention|Receive educational enhancement intervention
1631628|NCT01996228|Device|Stem Cell Educator|
1631629|NCT01996202|Drug|Ipilumimab|
1631630|NCT01996202|Radiation|Radiation|
1631631|NCT01996189|Device|Standard needle BBraun Sterican® 23G and 25mm in length|Arterial puncture using the hypodermic needle (BBraun Sterican® 23G and 25mm in length) attached to a 3 ml syringe.
1631632|NCT01996189|Device|Insulin|Arterial puncture using the insulin syringe (Terumo®- 0.5 ml with attached needle 29G and 13mm in length)
2011695|NCT02452528|Drug|Entecavir|0.5 or 1.0 mg/day orally
1631709|NCT01995500|Device|BioNIR|drug-eluting stent
1631710|NCT01995500|Device|Resolute|drug-eluting stent
1672740|NCT01677351|Drug|placebo|
1631633|NCT01996176|Behavioral|Intervention group|"The intervention consists of four components, which as described below:
Information about sedentary behaviour and health: Delivered at the kick-off workshop, in a leaflet and the project website.
Local adaptation: Participants adapt the intervention to their personal and local environment setting individual and common goals. Local ambassadors are chosen and support from the management is emphasised.
Structural changes: Facilities for standing meetings, both formal and informal. Routes for walking meetings should be defined.
Individual support: At the kick-off workshop participants set individual goals. The individual can choose to receive e-mails and text messages (SMS)from the project. The individual receives a post-it block and a postcard to remind them of the project."
1631634|NCT01996176|Behavioral|Control group|The control group receives the intervention after the last follow-up, the exact time will be settled together with each workplace in the control group.
1631635|NCT01996150|Drug|bleach bath (sodium hypochlorite)|Subjects will take diluted bleach bath (0.005% Sodium Hypochlorite) for 5-10 minutes twice a week for 12 weeks.
1631636|NCT01996137|Device|VASST|Stroke patients with hemiparesis undergo gait training via VASST
1631637|NCT01996124|Drug|Indacaterol Fumarate|150 mcg inhalation powder, hard capsules, once daily
1631638|NCT01996124|Drug|Placebo|Fructose, dry inhalation powder, hard capsules via breezhaler
1631639|NCT01996111|Procedure|Injection of 1.0 cc of 0.9% Saline|Injection of 1.0 cc of 0.9% Saline into affected area
1631640|NCT01996111|Procedure|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 10 mg/ml micrograft dHACM suspension into affected area
1631641|NCT01996111|Procedure|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 20 mg/ml micrograft dHACM suspension into affected area
1631642|NCT01996111|Procedure|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension|Injection of 1.0 cc of 40 mg/ml micrograft dHACM suspension into affected area
2011696|NCT02452528|Drug|Tenofovir|300 mg/day orally
2011697|NCT02452528|Drug|diphenhydramine|50 mg orally as pretreatment antihistamine
1631645|NCT01996085|Drug|lisinopril|"Angiotensin converting enzyme inhibitor recommended in case of:
hyperconstrictive profile (SVRI > 2500-2800 dyn•s•cm-5•m2)
hyperdynamic profile (CI > 4.2 l/min/m2 and/or HR > 80/min) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with nebivolol)
hypervolemic profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and/or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with diuretic)
balanced profile"
1631646|NCT01996085|Drug|Telmisartan|Angiotensin receptor blocker recommended in terms as for lisinopril in case of its intolerance (e.i. cough)
1631647|NCT01996085|Drug|Nebivolol|"Beta-blocker recommended in case of:
1.hyperdynamic profile (CI > 4.2 l/min/m2 and/or HR > 80/min)"
1631648|NCT01996085|Drug|Indapamide/hydrochlorothiazide|"hypervolemic profile (man - TFC > 34 1/kOhm; women - TFC > 24 1/kOhm)
hyperconstrictive profile (SVRI > 2500-2800 dyn•s•cm-5•m2) and office SBP ≥ 160 mm Hg and/or DBP ≥ 100 mmHg and or 24-h mean SBP ≥ 140 mm Hg and/or 24-h mean DBP ≥ 90 mm Hg (in combination with lisinopril/telmisartan)"
1631649|NCT01996085|Drug|Amlodipine|1/ SVRI > 2800 dyn•s•cm-5•m2 (in combination with lisinopril/telmisartan)
1631650|NCT01996085|Drug|lisinopril|Drug choice at the discretion of physician (blinded to ICG)
1631651|NCT01996085|Drug|Telmisartan|Angiotensin receptor blocker recommended as for lisinopril in case of its intolerance (e.i. cough)
1631652|NCT01996085|Drug|Nebivolol|Drug choice at the discretion of physician (blinded to ICG)
1631653|NCT01996085|Drug|Indapamide/hydrochlorothiazide|Drug choice at the discretion of physician (blinded to ICG)
1631654|NCT01996085|Drug|Amlodipine|Drug choice at the discretion of physician (blinded to ICG)
1631655|NCT01996072|Drug|EC17|
1631656|NCT01996059|Procedure|Functional Jejunal Interposition|First, an end-to-side esophagojejunostomy was performed at 40 cm anal to Treitz's ligament. Then, an end-to-side duodenojejunostomy was created at the efferent limb 35 cm distal to the esophagojejunostomy, followed by a side-to-side jejunostomy at 5 cm distal to duodenojejunostomy and 20 cm distal to Treitz's ligament. Finally, 2 jejunal proper ligations were made at 5 cm oral to esophagojejunostomy and 2 cm distal to duodenojejunostomy.
1631657|NCT01996059|Procedure|Roux-en-Y|The distal end of the duodenum was closed. The jejunum was separated 15-20cm distal to the Treitz's ligament, and an end-to-side esophagojejunostomy was done at the distal side of the jejunum. Then, the continuity of the jejunum was reconstructed with side-to-end jejunojejunostomy at 40-45cm distal to esophagojejunostomy.
1631658|NCT01996046|Other|FDG PET/CT scan|[18F] FDG PET/CT scan at 4 weeks after starting new hormonal therapy
1631659|NCT01995981|Drug|Pazopanib|
1631660|NCT01995968|Other|Antenatal identification of fetal growth restriction|"FGR is considered as identified if:
FGR was mentioned in medical charts
OR at least one ultrasound fetometry had indicated an estimated fetal weight or an abdominal diameter below the 10th percentile (whatever the reference curve used)
OR no (or insufficient) weight gain between two ultrasounds mentioned in medical charts
OR pathological Doppler examination of the umbilical artery (absent or reversed blood flow at the end of diastole)
OR utero-placental Doppler ultrasound indicated for suspicion of growth failure"
1631661|NCT01995955|Procedure|a new non-invasive imaging technique|a new non-invasive imaging technique for evaluation of cardiac microciculation in coronary artery disease
1631662|NCT01995929|Procedure|transnasal functional endoscopy|
1631663|NCT01995916|Behavioral|Mindfulness Intervention|The Mindfulness Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
1631664|NCT01995916|Behavioral|Social Support Group|The Social Support Group will meet once a week for 2.5 hours for 8 weeks with a half day retreat.
1631665|NCT01995903|Diagnostic Test|MRI(magnetic resonance imaging)|Subjects with amyotrophic lateral sclerosis and lower neuron motor skills and healthy subjects will undergo an MRI(magnetic resonance imaging)scans of the brain to assess neurologic condition. The brain scans will take approximately 60 minutes to complete.
1631666|NCT01995890|Drug|nepafenac|
1631711|NCT01995487|Device|BioNIR|drug-eluting stent
1631712|NCT01995487|Device|Resolute|drug-eluting stent
1631713|NCT01995474|Other|Twisted Syringe|briefly disconnecting the syringe from the biopsy channel after a specimen is obtained and then reconnecting it
2011698|NCT02451553|Drug|Afatinib Dimaleate|Given PO
1631667|NCT01995877|Procedure|Subjects scheduled for IVC filter placement|"Subjects will have an intra vascular ultrasound (IVUS) performed while lying down on the exam table; this will be performed before and after the IVC (inferior vena cava) filter is placed. During the ultrasound, measurements of the diameter of different areas of the IVC will be taken. The table will then be moved so that you are in a standing position and the measurements will be taken again.
The ultrasound will be done by the physician performing your procedure. When you are lying down, a sheath (small catheter) will be inserted into a vein in your groin. The IVUS (intra vascular ultrasound) catheter will be inserted through the sheath and used to measure the size of the IVC at various places.
The IVUS procedure will add about 30-45 minutes to the filter placement procedure."
1631668|NCT01995864|Behavioral|CTI-TS|"The following briefly describes the three phases of CTI-TS:
Phase 1: Initiation: The client and CTI-TS team formulate a treatment plan that focuses on selected areas identified as crucial for strengthening stability and facilitating the assimilation of the individual into community living.
Phase 2: The Try-Out phase is devoted to testing and adjusting the support systems that have been established in the community.
Phase 3: The final phase, Transfer of Care, is devoted to making any necessary improvements in the network of supports of the individual."
1631669|NCT01995838|Drug|E2006|E2006 1 mg, 2.5 mg, 5 mg, 10 mg, 15 mg, or 25 mg, in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
1631670|NCT01995838|Drug|Placebo|E2006-matched placebo in tablet form, taken orally, 30 minutes prior to bedtime, each night for 15 consecutive nights
2011699|NCT02451553|Drug|Capecitabine|Given PO
1631672|NCT01995812|Behavioral|Hula and heart health education|
1631673|NCT01995799|Device|Ferumoxytol enhanced MRI|Ferumoxytol enhanced MRI scan
1631674|NCT01995786|Device|Goal Directed Fluid Therapy FloTrac/Vigileo|
1631675|NCT01995734|Drug|Pasireotide long acting release formulation|Pasireotide LAR will be administered intramuscularly (i.m.) every 28 days until pasireotide becomes commercially available and reimbursed or until 31 December 2015, whichever occurs first.
1631676|NCT01995721|Biological|4-valent HPV vaccine|Vaccination with 4-valent HPV vaccine in months 0., 2., 6.
1631677|NCT01995708|Biological|CT7, MAGE-A3, and WT1 mRNA-electroporated Langerhans cells ( LCs)|Patients receive CT7/MAGE-A3/WT1 mRNA-electroporated autologous Langerhans-type dendritic cells ID on days 12, 30, and 90 after autologous stem cell transplant. Patients on the vaccine arm of the study will receive a total of 3 vaccinations, comprising a primary immunization on day +12 after ASCT followed by two boosters at days +30 and +90. Vaccines will be dosed at 9x10^6 LCs per vaccine x 3.
1631678|NCT01995708|Other|Standard of care|No vaccines
1631679|NCT01995695|Biological|Live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine|Participants will receive approximately 10^7.0 focus forming units (FFU) of the live attenuated H7N9 A/Anhui/13 ca influenza virus vaccine. The vaccine will be delivered by an Accuspray nasal spray device (0.25 mL per nostril for a total of 0.5 mL of vaccine).
1631680|NCT01995695|Biological|Inactivated subvirion H7N9 influenza vaccine|Participants will receive 30 mcg of the inactivated subvirion H7N9 vaccine by intramuscular injection.
1631681|NCT01995669|Drug|Lenalidomide|"Phase I Starting Dose: 10 mg by mouth on Days 2-22 of Cycles 1-6. Each cycle is 28 days. Participants with diagnosis of small lymphocytic lymphoma (SLL) begin cycle #1 at a maximum dose of 10 mg total daily on days 2 to 22 of a 28 day cycle. Dose escalated by 5 mg each cycle up to MTD if no toxicity is encountered.
Phase II: Lenalidomide administered orally at maximum tolerated dose (MTD) from Phase I on days 2 to 22 of a 28 day cycle in participants with follicular lymphoma and marginal zone lymphoma."
1631682|NCT01995669|Drug|Obinutuzumab (GA101)|"Phase I: 1000 mg by vein on Day 1, 8, 15, and 22 of cycle one and on day 1 of each subsequent cycle up to 6 cycles during lenalidomide dosing.
Phase II and Maintenance: 1000 mg by vein - Extended dosing of obinutuzumab begins after 6 cycles of combination therapy if participant demonstrates at least stable disease on response assessment. In extended dosing schedule, obinutuzumab administered every 2 months, and in absence of progression, dosed for maximum of 30 months (combination + maintenance)."
1631683|NCT01995656|Drug|Placebo - Capsule|Administered orally
1631684|NCT01995656|Drug|LY3108743 - Capsule|Administered orally
1631685|NCT01995656|Drug|Placebo - Solution|Administered orally
1631686|NCT01995656|Drug|LY3108743 - Solution|Administered orally
1631687|NCT01995643|Dietary Supplement|Active Capsule|GSE Capsule
1631688|NCT01995643|Dietary Supplement|Placebo Capsule|Placebo Capsule
1631689|NCT01995630|Device|AMO Tecnis ZA9003|
1631690|NCT01995630|Device|AMO Sensar AR40e|
1631691|NCT01995617|Biological|Placebo|normal saline, 0.5 mL per dose
1631692|NCT01995617|Biological|GEN-004 Low Dose|The GEN-004 Low Dose contains 10µg of each of the three antigens.
1631693|NCT01995617|Biological|GEN-004 Low Dose + Adjuvant|The GEN-004 Low Dose contains 10µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
1631694|NCT01995617|Biological|GEN-004 Mid Dose|The GEN-004 Mid Dose contains 30µg of each of the three antigens.
1631695|NCT01995617|Biological|GEN-004 Mid Dose + Adjuvant|The GEN-004 Mid Dose contains 30µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
1631696|NCT01995617|Biological|GEN-004 High Dose|The GEN-004 High Dose contains 100µg of each of the three antigens.
1631697|NCT01995617|Biological|GEN-004 High Dose + Adjuvant|The GEN-004 High Dose contains 100µg of each of the three antigens in combination with 350µg of aluminum hydroxide adjuvant.
1631698|NCT01995604|Other|Application of Sterile 0.9% Saline Solution|Application of Sterile 0.9% Saline Solution to half of face after UltraPulse laser therapy.
1631699|NCT01995604|Other|Application of dHACM|Application of dHACM to half of face after UltraPulse laser therapy.
1631700|NCT01995578|Drug|low dose 5'-azacitidine|5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle). Dose de-escalation will be permitted for hematologic and non- hematologic toxicities. Patients will start taking the study drug between days 60-120 post TCD allogeneic hematopoietic stem cell transplant and up to a year post-transplant or until there is a toxicity that requires cessation of therapy. Therefore patients will get between 8-10 cycles. Patients who come off-study for reasons unrelated to toxicities before completing 4 cycles will be replaced Since most cases of relapse occur early post transplant, in the first year, this is the most appropriate time to intervene. Treatment will start as soon as possible.
1631715|NCT01995461|Drug|bilateral transforaminal epidural steroid injections|BTESI with local anesthetic and steroid, and the use of x-ray contrast, under fluoroscopy guidance performed by the PI. 10mg of dexamethasone (1cc) mixed with 1cc of 2% preservative-free xylocaine (lidocaine) will be injected on each side of the stenotic segment under fluoroscopic guidance after confirming epidural x-ray contrast (1-2cc) spread right before the steroid mixed with local anesthetic injection. The injection may be repeated, but not before 2 weeks after the first injection.
1631716|NCT01995448|Biological|Blood test|Residue of blood further to NFS.
1631717|NCT01995435|Device|Telemedicine refraction|
1631718|NCT01995435|Device|Traditional refraction|
1631719|NCT01995422|Other|Physical activity program|One hour sessions of active walking occurring three times a week during three months
1631720|NCT01995409|Behavioral|No smoking material provided in households with newborn infants|
1631721|NCT01995396|Procedure|APE with intersphincteric dissection|Abdominal operation where the rectum is resected down to the levator and then the anus is resected by an intersphincteric dissection and order to leave the outer sfincter and levator in place to avoid a large wound and a high rate of infectious complications.
1631722|NCT01995396|Procedure|Hartmann´s procedure|Abdominal operation where the rectum is resected and stapled off distally and a stoma is created
1631723|NCT01995383|Other|LS followed by NS diet condition|LS diet period followed by NS diet period
1631724|NCT01995383|Other|NS followed by LS diet condition|NS diet period followed by LS diet period
1631725|NCT01995383|Drug|Placebo|Single oral administrations
1631726|NCT01995383|Drug|Placebo|2 single oral administrations
1631727|NCT01995383|Drug|RO6836191|Orally administered, single ascending doses
1631728|NCT01995383|Drug|RO6836191|2 single oral doses
1631729|NCT01995383|Drug|RO6836191|Intravenous administration
1631730|NCT01995370|Drug|aspirin|Aspirin (81mg or 100mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
1631731|NCT01995370|Drug|clopidogrel|Clopidogrel (50mg or 75mg) will be orally administered once daily.The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
1631732|NCT01995370|Drug|cilostazol|Cilostazol (100mg twice daily) will be orally administered. The treatment period will begin with the first visit of the first subject and end one year after the first visit of the last subject.
1631733|NCT01995357|Device|Coloplast Test A|Coloplast Test A is a newly developed ostomy appliance
1631734|NCT01995357|Device|Coloplast Test B|Coloplast Test B is a newly developed ostomy appliance.
1631735|NCT01995357|Device|Standard product|Standard product is the subjects usual product. Only subjects that usually use the CE-marked commercially available SenSura 1-piece flat and SenSura Mio 1-piece are included in the investigation.
1631736|NCT01995344|Drug|Cyclophosphamide|
1631737|NCT01995344|Drug|Fludarabine|
1631738|NCT01995344|Genetic|Tumour Infiltrating Lymphocytes|
1631739|NCT01995344|Drug|Interleukin-2|
1631740|NCT01995331|Drug|cyclophosphamide,cyclosporine A|"Drug,cyclophosphamide,cyclophosphamide (30 mg/kg/day) administered intravenously (IV) over 1 hr for 4 consecutive days Drug,cyclosporine A,5mg-12mg/kg.d,CSA was administered orally 40 days after the fourth dose of cyclophosphamide and maintained for 3 years. The dose of CSA was adjusted to maintain trough drug concentration above 150 μg/L and peak drug concentration above 300 μg/L.
Drug, human granulocyte colony-stimulating factor (rhG-CSF), 5 μg/kg/day subcutaneously starting 24 hrs after the fourth dose of cyclophosphamide, and it was withdrawed when ANC was >1×109/L."
1631741|NCT01995318|Other|Kinesiotaping|Application of anti-edema type kinesiotaping to injured ankle.
1631742|NCT01995305|Genetic|human whole exome|he exome is the part of the genome formed by exons, coding portions of genes in the genome that are used in the synthesis of proteins, therefore, it is most likely to contribute to the phenotype of an organism. The exome of the human genome, is estimated to comprise 1.5% of the total genome (The human exome is about 30 MB).
1631743|NCT01995305|Genetic|whole genomic|This study propose to find the genes that are sensitive to DNA crosslink repair, and genes that have key roles in hematopoietic cell development and maturation.
1631744|NCT01995292|Device|bronchoscope|
1631745|NCT01995292|Device|Enk Fiberoptic Atomizer|
1631746|NCT01995279|Device|French ear acupuncture|Single session (20 minutes) of French ear acupuncture at specific location used to reduce low back pain.
1631747|NCT01995279|Other|Sham Ultrasound|Ultrasound turned off.
1631748|NCT01995266|Drug|Asunaprevir|
1631749|NCT01995266|Drug|Daclatasvir|
1631750|NCT01995253|Device|Energy expenditure estimation in controlled conditions|Volunteers were asked to perform several activities such as walking at different paces, running, sitting, standing still or taking public transportation for about 3h30 They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
1631751|NCT01995253|Device|Energy expenditure estimation in free-living conditions|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
1631752|NCT01995240|Drug|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
1631753|NCT01995227|Biological|AlloVax|Personalized anti-cancer vaccine
1631754|NCT01995227|Biological|CRCL|Personalized anti-cancer vaccine
1631755|NCT01995227|Biological|AlloStim|ID injections IV infusion
1631756|NCT01995214|Drug|Propofol|Anesthesia maintenance with propofol+remifentanil guided by Narcotrend index monitoring.
1631757|NCT01995214|Drug|Sevoflurane|Anesthesia maintenance with sevoflurane+remifentanil guided by Narcrotrend index monitoring.
2011700|NCT02451553|Other|Laboratory Biomarker Analysis|Correlative studies
2011701|NCT02451514|Biological|MenABCWY+OMV vaccine|Intramuscular injection of a single dose at Day 1 to subjects in the MenABCWY+OMV Group or as a 2 doses at Day 1 and Day 31, one month apart, to subjects in the MenACWY and vaccine-naive Groups.
1673627|NCT01670084|Drug|nilotinib|Given PO
1631763|NCT01995188|Drug|Bevacizumab|Bevacizumab 15 milligrams per kilogram (mg/kg) administered via IV infusion on Day 1 of each 21-day cycle until disease progression or death, whichever occurs first.
1631764|NCT01995188|Drug|Carboplatin|Carboplatin fixed dose of AUC=6 mg/mL*min administered by IV infusion on Day 1 of each 21-day dose escalation and expansion cycles. Carboplatin will be administered for a maximum of 6 cycles or until disease progression or unacceptable toxicity, whichever is first.
1631765|NCT01995188|Drug|DNIB0600A|DNIB0600A at an initial dose of 1.2 mg/kg will be administered via IV infusion further following a dose-escalation until DLT under consultation of the investigator on Day 1 of 21 day dose-escalation cycle. RP2D will be administered further in dose-expansion for until disease progression or death, whichever occurs first.
1631766|NCT01995175|Procedure|Nasal swab sampling|Nasal swab samples will be collected from subjects at each examination visit, if they develop respiratory tract infection symptoms with difficulty in breathing and are called for an examination visit in the study.
1631767|NCT01995175|Procedure|Blood sampling|A single blood sample will be collected from a sub-cohort consisting of the first 2000 enrolled subjects when they are either 2, 4, 6, 12, 18 or 24 months old.
1631768|NCT01995175|Other|Diary cards|Diary cards will be provided to parents or LARs of the subjects to record RTI/LRTI, wheeze and asthma symptoms.
1631769|NCT01995162|Device|Energy expenditure estimation|Volunteers were asked to wear sensors during about 12 hours, one day. They wore 2 research sensors that estimate energy expenditure: Armband and Actiheart. They also wore a smartphone (in a front pant pocket) that collected accelerometry data.
1631770|NCT01995149|Behavioral|Weight loss and dietary intervention|The weight loss intervention had a total duration of 6 months. Each participant's caloric prescription represented a deficit of 600 kcal per day as calculated from the person's resting energy expenditure and activity level using the Harris-Benedict equation. In general, prescribed energy intake was between 1200 kcal and 1600 kcal/day. Dietary composition consisted on 50-55% of carbohydrates, 15-20% of protein and 30% of fat and included a wide variety of foods typical of a Mediterranean diet. Patients were also provided with recipes and shopping counselling to improve intervention compliance and to achieve the weight loss goal. Individual consultations with a nutritionist were performed twice a month to motivate the weight loss and reinforce the intervention.
1631771|NCT01995136|Drug|Travoprost Ophthalmic Solution 0.004%|benzalkonium chloride (BAC) free
1631772|NCT01995123|Behavioral|Behavioral Activation Therapy|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
1631773|NCT01995123|Behavioral|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
1631774|NCT01995123|Behavioral|Standard Smoking Cessation Therapy|Standard smoking cessation therapy will be delivered in eight, 20-minute individual sessions over an 8-week period.
1631775|NCT01995110|Other|high-fat meal A|
1631776|NCT01995110|Other|high-fat meal B|
1631777|NCT01995110|Other|high-fat meal C|
2011702|NCT02451410|Other|Nutrition and physical activity|The investigators will design an educational and behavioral program focused on health promotion. Didactic material will be developed for teachers and educational material will be developed for parents. For children, the investigators will design educational and playtime materials that encourage healthy eating and physical activity.
2011703|NCT02448368|Drug|RDEA3170,10 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
1631780|NCT01995084|Drug|[F-18]HX4|400 MBq [F-18]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
1631786|NCT01995058|Drug|cabozantinib|Tablets taken orally
1631787|NCT01995058|Drug|abiraterone|Tablets taken orally daily
1631788|NCT01995058|Drug|prednisone|Tablets taken orally twice daily
1631789|NCT01995045|Drug|Triamcinolone|Retrobulbar anesthesia
1631790|NCT01995045|Drug|Bupivicaine Hydrochloride|Retrobulbar anesthesia
1631791|NCT01995032|Drug|750 mg metformin and 7.5 g L-citrulline daily p.o.|
1631792|NCT01995032|Drug|Placebo|
1631793|NCT01995019|Drug|Methylprednisolone|1 ml single dose Intra-articular Depo-Medrol 40 mg/ml
1631794|NCT01995019|Drug|Physiologic saline|1 ml intra-articular placebo
1631795|NCT01995006|Drug|metamizole|metamizol tablets (500mg): 1000mg TID during 7 days
1631796|NCT01995006|Drug|Naproxen|Naproxen tablets (500mg): 500 mg BID during 7 days
1631797|NCT01994993|Drug|ampicillin and metronidazole and gentamicin|IV infusion of ampicillin and metronidazole and gentamicin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
1631798|NCT01994993|Drug|ampicillin and gentamicin and clindamycin|IV infusion of ampicillin and gentamicin and clindamycin for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
1631799|NCT01994993|Drug|gentamicin and Piperacillin- tazobactam|IV infusion of gentamicin and Piperacillin- tazobactam for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
1631800|NCT01994993|Drug|standard of care antibiotics and metronidazole|IV infusion of standard of care antibiotics and metronidazole for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
1631801|NCT01994993|Drug|metronidazole, clindamycin, or piperacillin-tazobactam|IV infusion of metronidazole, clindamycin, or piperacillin-tazobactam with scheduled CSF procedures per standard of care. Study drug will be given for for a total of 10 days. Dose based on postnatal age (PNA) and gestational age(GA)
1631802|NCT01994980|Drug|Default 4 days antibiotic therapy|The intervention for this trial involves a shorter duration of antibiotic therapy. Specifically, a default of 4 vs. 8 days.
1631803|NCT01994967|Drug|Levobupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
1631804|NCT01994967|Drug|Bupivacaine|Will be administered 3 ml of the investigational anesthetic in combination with morphine through the subarachnoid via.
1631805|NCT01994954|Other|RHO|Recorded oximetry data will be downloaded from home oximeters, analyzed, and used to assist in supplemental oxygen weaning decisions.
1684004|NCT01587807|Drug|LPS|50 μg
1631806|NCT01994941|Drug|Clopidogrel|"A platelet aggregation inhibitor. Also a P2Y12 Receptor Blocker of a drug class Thienopyridine.
Increasing evidence has shown that clopidogrel has wide inter-individual variability in pharmacokinetic and pharmacodynamic actions which lead to suboptimal antiplatelet effect especially in Asian population.
A standard loading dose of 300mg or 600mg(according to clinical protocol) will be given to patients."
1631807|NCT01994941|Drug|Ticagrelor|"A platelet aggregation inhibitor.
Though this agent has better anti-ischemic effects, it is associated with increased bleeding risk especially in Chinese patients whom are considered to be more prone to bleeding complications.
A loading dose of 180mg will be used."
1631808|NCT01994928|Device|Nose-mouth mask|Preoxygenation using a nose-mouth mask.
1631809|NCT01994928|Device|High flow nasal cannula oxygen|Preoxygenation using high flow nasal cannula oxygen.
1631810|NCT01994928|Procedure|Intubation|Intubation
1631811|NCT01994915|Other|Occupational therapy|Patients included in this group are going to receive an occupational therapy intervention 3 sessions after hospital discharge. The intervention is based on energy conservation techniques improving the execution of the activities of daily living.
1631812|NCT01994902|Device|Coloplast test product|The Coloplast test product is a newly developed ostomy appliance
1631813|NCT01994902|Device|SenSura Convex Light|The comparator product is SenSura Convex Light, which is CE-marked and commercially available.
1631814|NCT01994889|Drug|Tafamidis|Tafamidis 20 mg in soft gel capsules administered once a day for 30 months
1631815|NCT01994889|Drug|Tafamidis|Tafamidis 80 mg in soft gel capsules administered once a day for 30 months
1631816|NCT01994889|Drug|Placebo|Placebo in soft gel capsules administered once a day for 30 months
1631817|NCT01994876|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 1-piece convex ostomy appliance
1631818|NCT01994876|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 1-piece convex ostomy appliance
1631819|NCT01994863|Device|Coloplast Test product|Coloplast test product is a newly developed 1-piece ostomy appliance
1631820|NCT01994863|Device|Standard Care|"Standard care consists of three already marketed 1-piece ostomy products
Coloplast SenSura Hollister Moderma/Moderma Flex B.Braun Flexima/Softima"
1631821|NCT01994850|Drug|brentuximab vedotin|
1631822|NCT01994837|Drug|ABT-199|Tablet
1631823|NCT01994824|Drug|rabbit antithymocyte globulin|Thymoglobulin, 3 mg/kg, will be given on day 8 posttransplant to patients at high risk of significant GVHD per day 7 IL15 and IL2Ra levels.
1631824|NCT01994785|Diagnostic Test|Capnographic Monitoring|Capnographic Monitoring: Patients will undergo procedures with real-time capnographic monitoring
1631825|NCT01994772|Procedure|Targeted controlled temperature between 32.5 and 33.5°C|Therapeutic hypothermia ie targeted controlled temperature between 32.5° and 33.5°C will be induced in the active group. Usual method of controlled temperature will be use in ICU: internal active method or external active method.
1631826|NCT01994772|Procedure|Targeted controlled temperature between 36.5 and 37.5°C|Temperature was maintain between 36.5° and 37.5°C in the control group. In case of temperature superior to 37.5°C or inferior to 36.5°C, a pharmaceutical treatment and/or active cooling or warming was introduce to maintain temperature between the range of 36.5 - 37.5°C.
1631827|NCT01994759|Other|Training|Patients are instructed to carry out strengthening exercises for the fascia plantaris 3 days a week and stretching exercises every day. Four times in the first 2 months supervised training in groups is carried out with a physiotherapist supervising the exercises and instructing in progression and new exercises, and all participants are instructed to carry out a specific training program daily at home. The amount of training performed by each patient, is registered in a diary weekly
1631828|NCT01994759|Drug|Glucocorticosteroid injection|"Ultra sound guided injection af 1 ml og Glucocorticosteroid (methylprednisolone 40 mg) and 1 ml of lidocaine 5mg/ml from the medial side profound to the thickened part of the fascia plantaris.
Glucocorticosteroid injections are given every month until the aponeurosis thickness is less than 4 mm as determined by ultrasonography (max 3 injections)."
1631829|NCT01994759|Behavioral|Reduction in impact|advocate reduction in standing, walking, running, jumping. advocate shock absorbing shoes advocate prefabricated insoles advocate taping in special occasions.
1631830|NCT01994746|Drug|Intranasal Glucagon|
1631831|NCT01994746|Drug|Intramuscular Glucagon|
1631832|NCT01994733|Drug|Calcium carbonate ( Intensive phosphate control)|Individuals randomized to this arm will be exposed to a treatment strategy that targets a P of < 1.50 mmol/L, reflecting the recommendations of current guidelines. Titration of the calcium carbonate dose will be the core of this approach and this will be complemented by usual recommendations regarding dietary P restriction. Dietitians will be available to provide counseling with regards to any aspect of the end-stage renal disease diet, as per usual dialysis unit practice
1631833|NCT01994733|Drug|Calcium carbonate (Liberalized phosphate control)|"Individuals in this arm will be exposed to a treatment strategy that allows P to rise above 2.00 mmol/L. This will be accomplished through structured reduction of P binders already in use (as per the algorithm detailed below). Rescue P binding will be instituted if P rises above 2.50 mmol/L. Dietitians will be available to provide counseling regarding any aspect of the end-stage renal disease diet, as per usual dialysis unit practice, but will not provide counseling on dietary P restriction unless the P rises above 2.50 mmol/L."
1631834|NCT01994720|Drug|ticagrelor|ticagrelor, 180 mg (two tablets of 90 mg) loading dose on Day 1 followed by 90 mg twice daily.
1631835|NCT01994720|Drug|Acetylsalicylic acid (ASA)|ASA, 300 mg (three tablets of 100 mg) on Day 1, followed by 100 mg once daily.
1631836|NCT01994707|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation
1631837|NCT01994707|Procedure|Placebo|Deflated cuff on arm for 30 minutes.
1631838|NCT01994668|Drug|Lorazepam|A single intravenous administration of 2 mg lorazepam over 1 minute
1631839|NCT01994668|Drug|Placebo|A single intravenous administration of 0.9% saline over 1 minute
1631840|NCT01994655|Other|Doing exercise|We want to investigate the effects of exercise on climacteric symptoms
1631841|NCT01994655|Other|Doing exercise|Doing exercise at least 6 months including walking, running, yoga etc.
1631842|NCT01994642|Drug|Ciprofloxacin 0.3%/dexamethasone 0.1% sterile otic suspension|
1631843|NCT01994642|Drug|CIPRODEX® (ciprofloxacin 0.3%/dexamethasone 0.1%)|
1631844|NCT01994642|Drug|Placebo Sterile Otic Suspension|
1693864|NCT01511822|Drug|placebo|
1631847|NCT01994616|Procedure|Intralesional cryotherapy|Intralesional (IL) cryotherapy is a treatment for keloids and hypertrophic scars, in which the scar is frozen from inside with the use of a cryoneedle
1631848|NCT01994603|Behavioral|Opt-in or Opt-out testing|Study participants will be offered a health screening onsite.
1631849|NCT01994603|Behavioral|Focus Group|Study participants will be invited to participate in a focus group discussion.
1631850|NCT01994590|Drug|Dovitinib|Starting dose will be 400 mg by mouth daily on Days 1-5, 8-12, 15-19, and 22-26 of each 28 day cycle.
1631851|NCT01994590|Drug|Abiraterone Acetate|4 tablets (250 mg each) by mouth daily.
1631852|NCT01994590|Drug|Prednisone|5 mg by mouth twice daily.
1631853|NCT01994538|Other|Longer therapy duration|14 days of antimicrobial treatment
1631854|NCT01994538|Other|Shorter therapy duration|7 days of antimicrobial treatment
2011704|NCT02448368|Drug|RDEA3170, 2.5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
2011705|NCT02448368|Drug|RDEA3170, 5 mg|Approximately 20 subjects will be randomized to 1 of 10 treatment sequences with single doses occurring on Days 1, 5, 9, 13, and 17.
2011706|NCT02446600|Drug|Carboplatin|Given IV
1631858|NCT01994512|Procedure|Decompression without fusion|Decompressive surgery of both central and lateral component of the stenosis.
1631859|NCT01994512|Procedure|Decompression with fusion|Decompressive surgery of both central and lateral component of the stenosis AND concomitant instrumented or uninstrumented posterior fusion of decompressed segments.
1631860|NCT01994499|Device|Videothoracoscopy drainage|videothoracoscopy drainage of pleural effusion
1631861|NCT01994499|Drug|Medical drainage|Medical pleural drainage
1631862|NCT01994486|Drug|Telaprevir and Sofosbuvir|All subjects will have time to read and discuss IRB approved consent form prior to any study procedures. Following proper consenting, subjects will undergo physical exam including ECG and bloodwork prior to baseline visit. Subjects will return for research visits (vitals, collection of AEs, bloodwork, drug accountability) on Day 3, Weeks 1, 2, 3, 4, 6, 8, 10 and 12 of treatment and 4, 12, and 24 weeks after end of treatment. PK samples will be collected at week 2 and week 10.
1631863|NCT01994473|Drug|SEP-363856|SEP-36385625 as a single oral dose of 10, 25, 50, and 100 mcg
1631864|NCT01994473|Drug|Placebo|single oral dose placebo
1631865|NCT01994473|Drug|SEP-363856 Open Label|75 mg SEP-363856 given once-daily
1631866|NCT01994460|Drug|Linezolid|
1631867|NCT01994460|Drug|Ethambutol|
1631868|NCT01994447|Other|Student Enrollment|The standard informed consent process is for research nurses to provide verbal explanations of studies. In the intervention arm trained research students will use DVD's made by the studies principal investigator to explain study information in the informed consent process.
1631869|NCT01994434|Procedure|Decompression of the ulnar nerve|Surgical decompression of the Guyon's canal and ganglion excision
1631870|NCT01994421|Other|Kinesiotape|
1631871|NCT01994408|Other|default intensification|The investigators will determine which blood pressure medications to use. No specific drug will be tested but rather the automatic intensification of medications is the intervention. Examples of drugs used in this study are calcium channel blockers (e.g., amlodipine 2.5 mg to 10 mg) or ACE-inhibitors (e.g., lisinopril 5 mg to 40 mg) or diuretics (HCTZ 25 mg).
2011707|NCT02446600|Drug|Cediranib Maleate|Given PO
2011708|NCT02446600|Drug|Gemcitabine Hydrochloride|Given IV
1631874|NCT01994382|Drug|Cerdulatinib (PRT062070)|
1631875|NCT01994369|Drug|EC17|
1631876|NCT01994356|Behavioral|Physician self-disclosure of personal IUC use|Physicians self-disclosed personal intrauterine contraceptive use to subjects in intervention arm of study during contraceptive counseling
1631877|NCT01994356|Behavioral|Usual contraceptive counseling|all subjects recieved usual contraceptive counseling
1631878|NCT01994343|Other|Assessment|An assessment of the women is performed.
1631879|NCT01994330|Drug|desmopressin|0.3 mcg per kilogram administered in 30 minutes a half hour previous to surgical incision
1631880|NCT01994317|Other|Algorithm|IV sedation dosing calculated by algorithm
1631881|NCT01994317|Other|Standard care|IV sedation dosing calculated by standard care.
1631882|NCT01994304|Behavioral|SCC|The intervention involves introducing and orienting health providers on the SCC, facilitating availability of a specific set of commodities and regular targeted supervision. These are expected to improve adherence to life saving interventions immediately before, during and after birth, and reduce intrapartum mortality (still births and very early neonatal deaths).
1631883|NCT01994291|Drug|Ranibizumab|"Intravitreal Injection supplied as:
10 mg/mL in a 0.2 mL vial with instructions on preparation and administration of the 0.5 mg (0.05 mL) dose.
6 mg/mL in a single use vial with instructions on preparation and administration of the 0.3 mg (0.05 mL) dose.
Adminstered once a month for 12 weeks"
1631884|NCT01994291|Drug|Placebo|"Oral Placebo is provided in tablet form to match the 50mg dose of PF-04634817.
Dose is 4 tablets each day for 12 weeks"
1631885|NCT01994291|Drug|PF-04634817|Four 50mg tablets PF-04634817 once a day for 12 weeks.
1631886|NCT01994291|Drug|Masked Sham Therapy|Empty, needle-less syringe is used by the unmasked team once a month.
1631887|NCT01994278|Device|Peri Clean|
2011709|NCT02446600|Other|Laboratory Biomarker Analysis|Correlative studies
2011710|NCT02446600|Drug|Olaparib|Given PO
1631890|NCT01994252|Device|Optimal Medical therapy plus ICD|
1631891|NCT01994252|Device|Optimal Medical therapy plus CRT/ICD|
1957980|NCT02071225|Drug|bendamustine|70 milligrams per square meter (mg/m^2) given by IV infusion on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of subsequent cycles.
1957981|NCT02071225|Drug|obinutuzumab|1000 mg given by intravenous (IV) infusion on Days 1, 8, and 15 of Cycle 1 and on Day 1 of subsequent cycles.
2011711|NCT02446600|Drug|Paclitaxel|Given IV
2011712|NCT02446600|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
2011713|NCT02446600|Other|Pharmacological Study|Correlative studies
2011714|NCT02446600|Other|Quality-of-Life Assessment|Ancillary studies
2011715|NCT02445586|Drug|Docetaxel|Participants will receive docetaxel in line with locally approved Prescribing Information. After Cycle 6 (cycle length = 21 days), continuation of docetaxel treatment will be at the discretion of the investigator. Docetaxel will be administered after pertuzumab and trastuzumab.
2011716|NCT02445586|Drug|Pertuzumab|Participants will receive pertuzumab at an initial dose of 840 milligrams (mg) as a 60-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 420 mg as a 30 to 60-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
1631896|NCT01994213|Drug|Famitinib|Famitinib 25 mg p.o. qd
1631897|NCT01994200|Other|Interdisciplinary Team-Based Approach|Three meetings will be scheduled with the oncology dedicated-nurse. First meeting: information about the physical illness; the emotional impact of being newly diagnosed with thyroid cancer; as well as surgery and its' short- and long-term consequences. Second meeting: information on radioactive iodine treatments and its associated safety precautions, nutrition and dietary considerations. Third meeting: how the cancer diagnosis can be an opportunity to make important lifestyle changes and establish new life-priorities. The dedicated nurse, in collaboration with the Department of Nursing and ENT, will develop and implement an interdisciplinary team-based approached developed for this study according to guidelines of the Programme québécois de lutte contre le cancer (PQLC).
1631898|NCT01994200|Other|Usual Care Control|Patients in the control group will be provided with usual care, comprised of meetings with surgeons and endocrinologists. All patients in this study will be provided with an information website containing information on their cancer, treatments, and treatment side-effects.
1631899|NCT01994187|Procedure|Carotid endarterectomy|
1631900|NCT01994187|Procedure|carotid angioplasty|
1631901|NCT01994161|Procedure|intracranial stenting|all the participants in this group will be performed with intracranial stenting
2011717|NCT02445586|Drug|Trastuzumab|Participants will receive trastuzumab at an initial dose of 8 milligrams per kilogram (mg/kg) as a 90-minute intravenous infusion on Cycle 1 Day 1 (cycle length = 21 days), followed by every 3 weeks at a dose of 6 mg/kg as a 30 to 90-minute intravenous infusion until disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first.
1631903|NCT01994135|Other|Reference food|Reference food will be used to which test food samples will be compared to.
1631904|NCT01994135|Other|Test food dose 1|Will contain low dose of a mixture of polyphenols in addition to the reference food
1631905|NCT01994135|Other|Test food dose 2|Will contain high dose (twice of the low dose) of a mixture of polyphenols in addition to the reference food
2011718|NCT02445326|Drug|OTX-DP treatment|
1631908|NCT01994096|Drug|Caspofungin|
1631909|NCT01994083|Drug|Placebo|Administered orally
1631910|NCT01994083|Drug|IX-01|Administered orally
1631911|NCT01994070|Drug|Electrical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient. If atrial fibrillation is maintained, the patient will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient, otherwise a cardiologist will be consulted.
1631912|NCT01994070|Drug|Chemical-first|Patients will be placed on cardiopulmonary blood pressure monitoring, and will receive intravenous procainamide 17 mg / kg over 30 minutes. If the rhythm has changed from atrial fibrillation to normal sinus within one hour, the attending physician may discharge the patient. If the rhythm has not changed, then the patient will be continue to have cardiopulmonary monitoring, but also be attended by a respiratory therapist. The patient will be sedated with propofol 0.5 - 1.0 mg / kg. Once a Ramsay Sedation Scale score of 5 or greater is reached, the physician will attempt synchronized electrical cardioversion with 100 J, 200 J, 200 J. If the patient converts to normal sinus rhythm by the third shock, the physician may discharge the patient, otherwise a cardiologist will be consulted.
1631913|NCT01994044|Procedure|Cervical fusion|
1631914|NCT01994031|Drug|Paclitaxel liposome injection|
1631915|NCT01994031|Drug|Paclitaxel injection|
1631916|NCT01994005|Behavioral|Facebook|Facebook page with contraception information used for counseling
1631917|NCT01994005|Behavioral|Pamphlet|Contraceptive knowledge pamphlets
1631918|NCT01993979|Drug|Chemotherapy|
1631919|NCT01993979|Other|Surveillance|Patients will be closely monitored for early signs of recurrence, for which they will receive treatment as decided in discussion between the clinician and patient. This may include chemotherapy.
1631920|NCT01993953|Other|BodyPump|Participants will be offered BP sessions at fitness centers in Oslo/Akershus. They will exercise three times a week. The instructors at all centers have a BP license from Les Mills, and the same program will be conducted at all centers at all times. The project manager has been in contact with Les Mills Scandinavia and has been given permission to use the training concept for research.
1631921|NCT01993953|Other|Personal training|Participants in this group will be offered training with a PT at the Norwegian School of Sports Sciences. They will exercise with their PT three times per week. The training program for this group will be based on the exercises in the BP class, but repetitions will vary between 3-15, and series between 2-4.
1631922|NCT01993953|Other|Resistance training with instructor|Participants in this group will be invited to train on their own, three times a week, at the Norwegian School of Sports Science. Prior to the intervention period they will receive a training manual, instructions of the exercises and advice about progression during the intervention period. They will also have a follow-up with the same instructor after six weeks. The training program for this group will be the same as for group B. The PT`s from group B will also serve as training instructors.
1631923|NCT01993940|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
1631924|NCT01993940|Drug|Placebo|Placebo tablet taken orally once a day
1631926|NCT01993901|Other|CSRT led telephone follow up|Patients in the intervention group will be telephoned by the CSRT 4-6 weeks after completion of their treatment to assess any symptoms. A second follow up telephone call will be made at 12 weeks post treatment if required in order to address treatment related side effects that were identified during the first call and any interventions that were recommended
1631929|NCT01993875|Drug|Lubiprostone|Liquid formulation, 12 mcg x 2 pumps administered orally twice daily (BID)
1631930|NCT01993875|Drug|Placebo|Matching liquid placebo, 0 mcg x 2 pumps administered orally twice daily (BID)
1631931|NCT01993862|Other|Same Day Discharge|Patients will send device data remotely to their physician on the day of discharge from the hospital and again 24 hours after discharge from the hospital.
1631932|NCT01993849|Drug|N-Acetylcysteine (NAC)|
1631933|NCT01993849|Other|Placebo|
1631934|NCT01993836|Drug|Total intravenous anesthesia with propofol|
1631935|NCT01993836|Drug|General anesthesia with isoflurane|
1631936|NCT01993823|Drug|G238|Five drops into the ear canal twice daily for 14 days
1631937|NCT01993823|Drug|Clotrimazole|Five drops into the ear canal twice daily for 14 days
1631938|NCT01993810|Radiation|photon beam radiation therapy|Undergo photon beam radiation therapy
1631939|NCT01993810|Radiation|proton beam radiation therapy|Undergo proton beam radiation therapy
1631940|NCT01993810|Drug|paclitaxel|Given IV
1631941|NCT01993810|Drug|carboplatin|Given IV
1631942|NCT01993810|Drug|etoposide|Given IV
1631943|NCT01993810|Drug|cisplatin|Given IV
1631944|NCT01993810|Procedure|quality-of-life assessment|Ancillary studies
1631945|NCT01993810|Other|questionnaire administration|Ancillary studies
1631946|NCT01993797|Other|Lung US|
1631947|NCT01993784|Drug|nimotuzumab|
1631948|NCT01993771|Procedure|Surgery with general anaesthesia.|
1631949|NCT01993771|Procedure|Raw EEG|
1631950|NCT01993758|Procedure|Low tourniquet pressure|Tourniquet pressure set as 120mmHg above the systolic blood pressure just before tourniquet inflation
1631951|NCT01993758|Procedure|Conventional tourniquet pressure|Tourniquet pressure set as 150mmHg above the systolic blood pressure just before tourniquet inflation
1631952|NCT01993732|Procedure|Retrieval and Cryopreservation|Females undergoing therapeutic procedures that will potentially lead to the irreversible loss of ovarian function will have their ovarian tissue retrieved and cryopreserved. Ideally, after treatment, the cryopreserved ovarian tissue can be thawed and auto-transplanted and ovarian function resumed.
2011719|NCT02445326|Device|Placebo Plug with no drug|
2011720|NCT02444793|Drug|PF-05082566|Part 1: PF-05082566 dose escalation; Increased doses of PF-05082566 IV are administered at appropriate intervals. Part 2: MTD of PF-05082566 IV established in Part 1 is administered.
2011721|NCT02444793|Drug|KW-0761|Part 1: KW-0761 IV administered at appropriate intervals. Part 2: KW-0761 IV administered at appropriate intervals at the MTD dose for the combination.
2011722|NCT02444598|Device|Vaccum Assisted Closure device|Negative-pressure wound therapy
2011723|NCT02444598|Procedure|Conventional wound dressings|Conventional wound dressings
1631958|NCT01993706|Drug|VRC-HIVMAB060-00-AB|
1631959|NCT01993693|Device|Ultrasonic Diathermy Device|The Ultrasonic Diathermy Device provides low intensity therapeutic ultrasound to musculoskeletal tissues and joints for the purpose of pain relief, relief of muscle spasm, treatment of joint contraction, and local increase of circulation. The device is FDA-cleared for up to 4 hours of continuous use per treatment. It is a stationary hands-free device.
1631960|NCT01993693|Device|Sham Ultrasonic Diathermy Device|Sham therapy delivered by Ultrasonic Diathermy Device that appears identical to active device but does not deliver ultrasound
1631961|NCT01993680|Drug|Pyridostigmine bromide|"Drug doses during the trial:
Pyridostigmine bromide: 30mg p.o. 1-1-1 to 2-2-2 given for 14 days"
1631962|NCT01993680|Drug|fludrocortisone|drug dose during the trial Fludrocortisone: 0,1mg p.o. 1-0-0 to 2-0-0 given for 14 days
1631963|NCT01993667|Drug|Acetazolamide|Administration of low dose acetazolamide
1631964|NCT01993654|Procedure|HRT III with Non-Contact Cornea Rostock Module|Confocal imaging of the conjunctival lesion
1631965|NCT01993641|Drug|pracinostat|Histone deacetylase inhibitor (HDACi) Pracinostat is to be taken before HMA administration 3 times/week (e.g., Monday, Wednesday, and Friday) for 3 weeks, followed by 1 week of rest as a 28-day cycle. Pracinostat administration will be at the clinic on Day 1 of Cycles 1 and 2 and subject will self-administer at home on all other days
1631966|NCT01993641|Drug|Azacitidine|All patients will receive the dose and schedule of azacitadine to which they previously failed to respond. (e.g. 75 mg/m2 via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable; 7 days of each 28 day cycle, either Days 1-7, or Days 1-5, rest on Days 6-7, and azacitadine dosing on Days 8-9)
1631967|NCT01993641|Drug|Decitabine|"All patients will receive the dose and schedule of decitabine to which they previously failed to respond. Common 28 day treatment regimens include: 20 mg/m2 IV for either 5 or 10 days of each 28-day cycle, 10 mg/m2 given intravenously daily for first 10 days of each 28 day cycle, or 20 mg/m2 given subcutaneously daily for the first 5 days of each 28 day cycle.
The 6-week regimen utilizes a dose of 15 mg/m2 by continuous intravenous infusion over 3 hours repeated every 8 hours for 3 days repeated every 6 weeks."
1631968|NCT01993628|Other|Rey figure test|
1631969|NCT01993628|Other|MRI|
1631970|NCT01993615|Procedure|Arthroscopic Surgery|The hip arthroscopy will consist of acetabular rim trimming, labral repair or debridement and femoroplasty, all as indicated based on the surgeon's clinical judgment with input from pre-operative imaging, exam findings and intra-operative findings.
1632016|NCT01993264|Other|Fetal Echocardiogram|Subjects will then have sequential, abbreviated fetal echocardiograms performed by designated, highly trained, and experienced sonographers every 4 weeks, from 20-36 weeks.
1698492|NCT01477073|Drug|Placebo|
2011724|NCT02443883|Drug|Ramucirumab|Administered IV
2011725|NCT02441881|Device|Venefit|Endovenous radiofrequency device
2011726|NCT02441881|Device|Radiofrequency Induced Thermal Therapy|Endovenous radiofrequency device
2011727|NCT02441881|Device|Endovenous Radiofrequency|Endovenous radiofrequency device
2011728|NCT02441946|Drug|Abemaciclib|Administered orally
2011729|NCT02441946|Drug|Loperamide|Administered orally
2011730|NCT02441946|Drug|Anastrozole|Administered orally
2011731|NCT02437864|Device|Supplemental oxygen via nasal cannula|
2011732|NCT02437461|Drug|Triamcinolone hexacetonide|intraarticular knee injection
2011733|NCT02433483|Drug|Cytarabine|Given by either intrathecal (IT) or intravenous (IV) route.
1631971|NCT01993615|Procedure|Physical Therapy|Subjects will participate in two 45-minute sessions for six weeks (total of 12 sessions). The physical therapy treatment plan will be based on individual impairments identified during the initial evaluation, and include manual therapy to the hip, lumbar spine, and pelvis, as well as therapeutic exercise all tailored to individual patient impairments.
1631972|NCT01993602|Procedure|Breathing exercises|"The intervention groups (CPAP, VIS, FIS and DB) used the specific device (or not) according to the group allocation.
The intervention was performed 3 times per day, from 1 to 5 postoperative day. Patients performed 5 sets of 10 repetitions of the specific breathing exercise, with 30 seconds rest between each set.
The sessions were held in the morning, early afternoon and early evening, always supervised by a physiotherapist.
Before starting each session, the patient reported the sensation of pain, and if he quantify pain intensity more than 3 in the visual numeric scale (0 to 10) was asked the doctor to administer analgesics aiming that him to perform properly the breathing exercise."
1631973|NCT01993589|Drug|comparison of pain relievers during curattage|
1631974|NCT01993589|Drug|comparison of pain relievers|
1631975|NCT01993589|Drug|comparison of pain relievers during curattage|
1631976|NCT01993589|Drug|comparison of pain relievers during curattage|
1631977|NCT01993589|Drug|comparison of pain relievers during curattage|
1631978|NCT01993576|Drug|Indocyanine Green|Intravenous injection of 0.25 mg/kg Indocyanine Green (ICG) before the surgery
1631979|NCT01993563|Other|Graded Motor Imagery|"GMI program includes three steps: Implicit Motor Imagery (IMI); Explicit Motor Imagery (EMI) and Mirror Box Therapy (MT).
IMI included a training based on Hand Laterality Discrimination Tasks. During these tasks 60 pictures of right and left hands are projected randomly on a 15 screen. Patients are asked to choose whether the images seen are right or left and therefore to click respectively the right or the left button on a mouse.
EMI training consists in imagining a movement without actual performing it. It will be introduced during IMI's last two sessions and gradually enhanced increasing the complexity of motor skills to be imagined. The therapist shows or explains in details the movements the patient have to mentally rehearsed.
MT treatments will start with simply watching the unaffected hand in the mirror and increased toward functional movement. When possible, gentle movement with the affected hand will be encouraged behind the reflecting part of the mirror."
1631980|NCT01993563|Other|Standard treatment|Patients will undergo to a standard treatment, that is thought to be the best option for that specific patients. In our hospital, treatment options include: motor training, functional training, occupational therapy, bilateral arm training or motor treatment using virtual reality devices.
1631981|NCT01993550|Behavioral|Telephone counseling|
1631982|NCT01993550|Behavioral|Education|
1631983|NCT01993537|Drug|Vitamin D|
1631984|NCT01993524|Dietary Supplement|probiotic|antibiotic plus probiotic
1631985|NCT01993524|Other|placebo|antibiotic plus placebo
1631986|NCT01993498|Procedure|blood sampling|blood samples collection
1631987|NCT01993472|Drug|Andrographolides|comparison of efficacy of Andrographolides combined with Capecitabine or Capecitabine alone in treatment of colorectal cancer
1631988|NCT01993472|Drug|Capecitabine|
1631989|NCT01993459|Drug|Midazolam|We will administer Midazolam 3mg intravenously once pre-operatively to patients just before they undergo surgery
1631990|NCT01993459|Drug|NaCl (sodium chloride) 0,9%|We will administer NaCl (sodium chloride) 0,9% 3ml intravenously once pre-operatively to patients just before they undergo surgery
1631991|NCT01993446|Drug|DRM02|
1631992|NCT01993446|Other|Vehicle|
1631993|NCT01993433|Drug|DRM02|
1631994|NCT01993433|Other|Vehicle|
1631995|NCT01993420|Drug|DRM02|
1631996|NCT01993420|Other|Vehicle|
1631997|NCT01993407|Behavioral|Task Switching Training|Participants will complete four, one-hour training sessions in which they will practice switching between tasks within an alternating runs task switching paradigm.
1631998|NCT01993407|Behavioral|Control Task|Participants will complete four, one-hour training sessions in which they will perform a single task each session
1631999|NCT01993394|Other|hypergravity|1hr sitting rest followed by 10 min of hypergravity (2 centrifuge runs)
1632000|NCT01993394|Other|gas mixture|breathing air, 44.5%O2 or 100%O2
1632001|NCT01993368|Other|flow cytometry|"These populations will be identified by different combinations of antibodies to identify:
T cell subsets (CD45, CD3, CD4, CD8, CD45RA, CD69, CD28, TCRαβ, TCRγδ, CD197, CD25, FoxP3), B cells (CD45, CD19, HLA-DR, IgA), cells NK (CD45, CD3, CD56).
Monocyte subsets (CD45, CD11b, CD14, CD16, CD1c, HLA-DR)
Mesenchymal stromal cells (CD45, HLA-ABC, CD105, CD90, CD73)"
1632002|NCT01993355|Other|Physiotherapy|Physical therapy exercise program for CLBP patients. Its goal is to reduce pain and improve patients' health-related quality of life, functional capacity and well-being.
1632003|NCT01993355|Other|Intervention 1|Relaxation techniques-sophrology consists of a set of physical and relaxation exercises that include breathing methods, visualization, modification of states of consciousness, etc. with the goal to enhance balance between body and mind to improve health-related quality of life, reduce pain and foster patients' well-being.
1632004|NCT01993355|Behavioral|Intervention 2|Cognitive-behavioral therapy (in combination with motivational interviewing principles) is aimed to facilitate psychological adjustment and self-management of CLBP with the ultimate goal of increasing patients' health-related quality of life and well-being.
1632005|NCT01993342|Other|arthrocentesis|The made a diagnostic arthrocentesis to all patient we included
1632006|NCT01993342|Other|ultrasonography of the knee|We explored the affected knee with an ultrasound explanation in order to describe inflammatory changes based on standard examination.
1632007|NCT01993329|Drug|Gefapixant 50 mg|
1632008|NCT01993329|Drug|Gefapixant 300 mg|
1632009|NCT01993329|Drug|Placebo (for AF219)|sugar pill manufactured to mimic gefapixant 50 mg and 300 mg tablets
1632010|NCT01993316|Device|Mitsar 201 neurofeedback|
1632011|NCT01993290|Drug|Ropivacaine|20 ml in total of 0,75% Ropivacaine is administered to each patient in all three arms.
1632012|NCT01993277|Device|Nexalin Brain Stimulator|
1632013|NCT01993277|Device|Fischer Wallace Stimulator|
1632014|NCT01993277|Device|David Delight Stimulator|
1632015|NCT01993277|Behavioral|Relaxation Therapy|
2011734|NCT02433483|Drug|Intrathecal Triples|given IT.
1632017|NCT01993251|Drug|melatonin|one capsule, melatonin 0.5 mg, oral, once a day, 30 minutes before bedtime
1632018|NCT01993251|Drug|Melatonin|one capsule, melatonin 2 mg, oral, once a day, 30 minutes before bedtime
1632019|NCT01993251|Drug|Melatonin|one capsule, melatonin 6 mg, oral, once a day, 30 minutes before bedtime
1632020|NCT01993251|Drug|placebo|one capsule, placebo, oral, once a day, 30 minutes before bedtime
1632021|NCT01993238|Device|Liposonix System (Model 2)|Treatment of subcutaneous adipose tissue of the abdomen using high intensity focused ultrasound (Liposonix System Model 2).
1632022|NCT01993238|Drug|Pre-treatment analgesia|Pre-treatment analgesia (combination of ondansetron, ketorolac, and hydromorphone)
1632023|NCT01993225|Drug|Androxal 12.5 mg/25 mg|
1632024|NCT01993225|Drug|Placebo Capsules|
1632025|NCT01993225|Drug|AndroGel 1.62%|
1632026|NCT01993225|Drug|Placebo Gel|
1632027|NCT01993212|Drug|Androxal 12.5 mg or 25 mg|
1632028|NCT01993212|Drug|AndroGel 1.62%|
1632029|NCT01993212|Drug|Placebo Capsules|
1632030|NCT01993212|Drug|Placebo Gel|
1632031|NCT01993199|Procedure|deep biopsy via ESD technique|
1632032|NCT01993186|Drug|UX007 (triheptanoin)|Triheptanoin is a triglyceride composed of three heptanoate (C7 fatty acid) esters. UX007 is manufactured by chemical synthesis from glycerol and heptanoic acid. UX007 (triheptanoin) is a liquid, intended for oral (PO) administration.
1632033|NCT01993186|Drug|Placebo Oil|
1632034|NCT01993173|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL)|0.5 mL, Intramuscular
1632035|NCT01993173|Biological|DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed)|0.5 mL, Intramuscular
1632036|NCT01993173|Biological|Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)|0.5 mL, Intramuscular
1632037|NCT01993160|Drug|Fluorocholine (18F-FCH) Injection|Before the PET-CT scan, the tracer (fluorocholine/FCH) will be injected into a vein in your arm just before the scan. This is the agent we are investigating in this study (not part of the standard procedure)
1632038|NCT01993160|Radiation|PET scan|A whole body PET scan will be performed, integrated with either whole body low dose CT or whole body MRI
1632039|NCT01993160|Radiation|Whole body MRI|A whole body MRI scan will be performed. This may be integrated with PET scan or performed separately.
1632040|NCT01993147|Drug|Methylphenidate|20mgs of methlyphenidate or placebo to be administered one hour before fMRI and task performance.
1632041|NCT01993147|Drug|Placebo|20mgs of methylphenidate or a placebo to be administered one hour before fMRI and task performance.
1632042|NCT01993134|Procedure|Cefazolin|Cefazolin, 2g/IV, prior to surgery, and after surgery recieved 4 aditional doses 1g/IV of Cefazolin.
1632043|NCT01993134|Procedure|Cefazolin Single Dose|Patients received 2g of Cefazolin (Cefazolin Sodium - Ampoule- 1g - Genéricos Brasil), administered intravenously but none was administered in the post-operative period
1632044|NCT01993121|Other|Supervised Exercise Training|All subjects will perform three months of supervised exercise training.
1632045|NCT01993108|Drug|Methylphenidate|All study participants will receive one dose of any three of the following drug compounds 1 hour before fMRI scan and task performance: 40mgs of methylphenidate, 40mgs of naltrexone, or a placebo. There are a total of three scans per participant, therefore all participants will receive one dose of all three drug compounds for any given scan during their participation in the study.
1632046|NCT01993108|Drug|Naltrexone|All study participants will receive one dose of any three of the following drug compounds 1 hour before fMRI scan and task performance: 40mgs of methylphenidate, 40mgs of naltrexone, or a placebo. There are a total of three scans per participant, therefore all participants will receive one dose of all three drug compounds for any given scan during their participation in the study
1632047|NCT01993108|Drug|Placebo|All study participants will receive one dose of any three of the following drug compounds 1 hour before fMRI scan and task performance: 40mgs of methylphenidate, 40mgs of naltrexone, or a placebo. There are a total of three scans per participant, therefore all participants will receive one dose of all three drug compounds for any given scan during their participation in the study
1632048|NCT01993095|Behavioral|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week.
1632049|NCT01993095|Behavioral|Behavioral: Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD after the completion of the 6-month follow-up testing.
1632050|NCT01993082|Behavioral|Aerobic Training Intervention|"For 24 weeks, subjects randomized into the aerobic training group will be asked to increase their physical activity level to meet the Centers for Disease Control and Prevention recommendations for physical activity of 150 minutes per week of moderate activity.
A first visit with a fitness coach support provider, followed by weekly coaching texts and phone calls, will provide the framework for the activities in which participants should engage."
1632051|NCT01993069|Behavioral|Iyengar-based Yoga Training|6 weekly Iyengar-based yoga classes
1632052|NCT01993056|Behavioral|"FIFA 11+"|
1632053|NCT01993056|Behavioral|"no FIFA 11+"|
1632054|NCT01993030|Device|HQ® Matrix Medical Wound Dressing|
1632055|NCT01993030|Device|Sidaiyi® wound dressing|
2011735|NCT02433483|Biological|HPC-A|Given IV.
1632156|NCT01992224|Other|Conventional Mechanical Ventilation|other group who don't start early mechanical ventilation and fulfillment four criteria below: respiratory rate > 28 bpm dyspnea PaO2/FiO2 Index <200 mmHg Chest X-ray: lung infiltration exclude chronic heart failure and pulmonary disease
1632157|NCT01992211|Drug|Rosuvastatin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
2011736|NCT02432365|Drug|paclitaxel|7-day cycle schedule of paclitaxel (60 mg/m2)
2011737|NCT02432365|Drug|cisplatin|7-day cycle schedule of cisplatin (40 mg/m2)
2011738|NCT02432365|Procedure|Radical hysterectomy and bilateral pelvic lymphadenectomy|2 weeks after last course of neoadjuvant chemotherapy
2011739|NCT02428985|Drug|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information
2011740|NCT02429856|Device|SCORPIO™|subjects randomized at surgery to receive 1 of the 2 specified implants
2011741|NCT02425488|Behavioral|Nursing therapeutics education|"Educational intervention will focus on
Appropriate lifestyles
Early recognition of signs/prodromal symptoms of HF
Early recognition of signs of inflammation of the ICD-pocket
Good management of the device
1) Therapy, body weight, diet, smoking, alcohol, rest, exercise, job and sex 2) Dyspnea, edema and fovea, rapid weight gain, loss of appetite, fatigue, asthenia, insomnia, mental confusion 3) Signs and symptoms of inflammation: hyperpyrexia, rubor, dolor, calor and tumor 4) Identification tag, vibration, metal detectors, air travel, use of electronic devices, diagnostic PET and MRI"
2011742|NCT02423083|Drug|Guanabenz|
1632061|NCT01992991|Device|Transcranial direct current stimulation|Transcranial direct current stimulation of motor cortex
1632062|NCT01992978|Procedure|Radiofrequency-assisted Hepatectomy|Radiofrequency-assisted resection: separating the tumor from liver by using the probe of radiofrequency to block the arterial and vessels before parenchymal transection.
1632063|NCT01992978|Procedure|Conventional Hepatectomy|Hepatectomy was conducted without RF assisted during parenchymal transection. Separating and dissecting the tumor with the routine clamp-crushing technical.
1632064|NCT01992965|Other|Different methods of blood glucose monitoring between groups|Finger prick blood glucose in conventional group versus real-time continuous glucose monitoring system of continuous glucose monitoring group
1632068|NCT01992939|Other|Specialized pulse oximetry probe with external heat pack|Pulse oximetry will be obtained using the specialized pulse oximetry probe with external heat pack for 45 minutes.
1632069|NCT01992939|Other|Standard of Care Pulse Oximetry Probe|Pulse oximetry will be obtained using a standard of care pulse oximetry probe for 45 minutes.
1632070|NCT01992926|Behavioral|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
1632071|NCT01992913|Behavioral|integrated Cognitive Behavioral Therapy|Novel CBT paradigm for schizophrenia/schizoaffective disorder
1632072|NCT01992913|Other|Usual Care|The usual care that Veterans receive - not limited in scope (i.e., subjects may participate in any/all available treatments, outside the study condition)
1632073|NCT01992913|Behavioral|Computerized cognitive remediation (CCR)|Part of the iCBT paradigm, a four month block of bi-weekly computerized cognitive remediation using BrainHQ program.
1632074|NCT01992900|Drug|Eurartesim dispersible oral tablet|The first dose of Eurartesim dispersible oral tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. Eurartesim tablet will be dispersed in about 10 mL of water.
1632075|NCT01992900|Drug|eurartesim film coated tablet|The first dose of Eurartesim film coated tablet will be administered immediately after randomization. the other two doses will be administered with an interval of 24 hours. tablet will be crushed and dispersed in a few amount of water (about 10 ml).
1632076|NCT01992874|Drug|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 milligram (mg) orally on Day 1 in Part A.
1632077|NCT01992874|Drug|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 3 in Part A.
1632078|NCT01992874|Drug|Pimasertib Tablet (Part A)|Pimasertib tablet administration at a single dose of 60 mg orally on Day 1 in Part A.
1632079|NCT01992874|Drug|Pimasertib Capsule (Part A)|Pimasertib capsule administration at a single dose of 60 mg orally on Day 3 in Part A.
1632080|NCT01992874|Drug|Pimasertib Capsule (Part B and trial extension phase)|Subjects completing Part A to receive pimasertib capsule at a dose of 60 mg orally twice daily in cycles of 21 days each in Part B and trial extension phase until disease progression, intolerable toxicity, subject withdrawal, loss to follow-up or death.
1632081|NCT01992861|Procedure|Computed Tomography|Undergo FDG PET/CT
1632082|NCT01992861|Procedure|Diffusion Weighted Imaging|Undergo DW MRI
1632083|NCT01992861|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
1632084|NCT01992861|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
1632085|NCT01992861|Procedure|Magnetic Resonance Spectroscopic Imaging|Undergo MR spectroscopy
1632086|NCT01992861|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
1632087|NCT01992848|Other|Venous blood sampling|40ml venous blood sampling will be undertaken during participants' attendance for CT coronary angiography (the latter being performed as part of routine clinical investigation).
1632088|NCT01992848|Other|4-day food diary|
1632089|NCT01992848|Other|1 week UV dosimeter|To be worn on outerwear for one week week prior to attendance for pQCT
1632090|NCT01992848|Radiation|Peripheral Quantitative Computed Tomography of the radius|To be performed within one month of attendance for CT coronary angiography
1632091|NCT01992835|Other|Grass pollen allergen extract|Each subject will be challenged with a grass pollen allergen extract and with placebo.
1632092|NCT01992835|Other|placebo|
1632093|NCT01992822|Other|experimental pain induction|application of a pre-fixed pressure (160 kPa) on the forearm.
1632094|NCT01992809|Dietary Supplement|Omega 3|Omega-3 group (n=30) received capsules containing 945 mg of Omega-3 PUFA [α linolenic acid/ 64%, eicosapentaenoic acid (EPA)/16% and docosahexaenoic acid (DHA)/21%], in 3 capsules/ day
1632095|NCT01992796|Drug|Irbesartan|75 mg/per os/for 15 days
1632096|NCT01992783|Dietary Supplement|Hi-maize resistant starch|13.5 g/day
1632097|NCT01992783|Dietary Supplement|Maltodextrin|13.5 g/day
1632098|NCT01992770|Behavioral|Hierarchical graded exposure|"Individual Behavioural goal identification, depending on risk profile
(1a). Catastrophising and/or fear-avoidance (2); hierarchical graded exposure, organized with individual coaching in connection to the physical training sessions, based on activities that each participant fear and/or avoid."
1632275|NCT01991509|Biological|LBR-101 IV|LBR-101 Administered Intravenously
1632099|NCT01992770|Behavioral|Graded activity|"Individual Behavioural goal identification, depending on risk profile
(1b) Graded activity;(2) self-monitoring of everyday life activities (3) functional behavioural analyses to describe, predict, and verify factors controlling patient's current and future activity performance (4) training of motor skills, cognitive skills, and strategies to organise everyday life including social support. (5) gradual application of acquired skills in everyday life situations as formulated by Specific, Measureable, Activity-related, Realistic, and Time- specified (SMART) goal setting (6) generalisation of skills to additional activities and challenging situations, and (7) strategies for maintenance and relapse prevention."
1632100|NCT01992770|Behavioral|Physical exercises|Participants will be scheduled for supervised, regular physical training twice a week during eight weeks 8
1632101|NCT01992731|Other|Drug: Follitropine Bèta|
2011743|NCT02421679|Drug|TNX-102 SL|TNX-102 Sublingual tablets
2011744|NCT02420860|Drug|Elotuzumab|10 mg/kg by vein on Days 1, 8, 15, and 21 for the first 2 cycles, then on Days 1 and 15 only during Cycles 3-6, and then on Day 1 each cycle after that. Cycles beyond 6, once per cycle at 20 mg/kg on Day 1 of each cycle.
1632104|NCT01992705|Other|Chemotherapy(FOLFIRINOX) + SBRT prior to surgery if applicable|Patients will receive chemotherapy (21d/cycle for a total of 4 cycles) plus SBRT before screening for surgical resection of the pancreas.
1632105|NCT01992705|Drug|-Oxaliplatin 85 mg/m2 IV on Day 1|Oxaliplatin 85 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
1632106|NCT01992705|Drug|-Irinotecan 180 mg/m2 IV on Day 1|Irinotecan 180 mg/m2 IV on Day 1 of each cycle (21d/cycle for a total of 4 cycles).
1632107|NCT01992705|Drug|-5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours|5-FU (Fluorouracil) 2,400 mg/m2 IV over 46-48 hours of each cycle (21d/cycle for a total of 4 cycles.
1632108|NCT01992679|Behavioral|Exercise group|The BWSTT program will consist of biweekly training sessions for 20 weeks. Per neurorecovery network guidelines, each training session will include a minimum of 20 minutes of locomotor training and 20 minutes of balance training. Training will take place on a Therastride which consists of a treadmill with an air pressure powered pulley system connected to a harness system. The locomotor training strategy focuses on proper gait mechanics, including weight bearing, shifting and maintaining body positioning. Manipulating the participant's legs is done in such a way as to provide appropriate sensory-motor cues that facilitate the development and refinement of walking pattern.
1632109|NCT01992666|Genetic|Blood sampling|Immunologic and genetic analysis from a single blood sample.
1632110|NCT01992653|Drug|Cyclophosphamide|Cyclophosphamide will be administered at 750 milligrams per square meter (mg/m^2) IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
1632111|NCT01992653|Drug|Doxorubicin|Doxorubicin will be administered at 50 mg/m^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
1632112|NCT01992653|Drug|Obinutuzumab|Obinutuzumab will be administered at 1000 milligrams (mg) IV on Cycle 1 Days 1, 8, and 15 and on Day 1 of Cycles 3-8.
1632113|NCT01992653|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered at escalating doses (at a starting dose of 1 mg/kg) IV every 3 weeks, for 6 or 8 cycles.
1632114|NCT01992653|Drug|Prednisolone|Prednisolone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
1632115|NCT01992653|Drug|Prednisone|Prednisone will be administered at 100 mg orally daily for 5 days every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles. Prednisone at 100 mg orally from Day -7 to Day -1 may be given at the discretion of the treating investigator physician.
1632116|NCT01992653|Drug|Rituximab|Rituximab will be administered at 375 mg/m^2 IV every 3 weeks (starting from Cycle 1 Day 1), for 6 or 8 cycles.
1632117|NCT01992627|Device|HILTERAPIA HIRO 3.0|High-intensity laser therapy (HILT), which involves higher-intensity laser radiation and which causes minor and slow light absorption by chromophores. This absorption is obtained not with concentrated light but with diffuse light in all directions (the scattering phenomenon), increasing the mitochondrial oxidative reaction and adenosine triphosphate, RNA, or DNA production (photochemistry effects) and resulting in the phenomenon of tissue stimulation called photobiology.
1632118|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
1632119|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
1632120|NCT01992614|Drug|PF-06678552 or Placebo|PF-06678552 or placebo will be administered as an extemporaneously prepared solution once in each period.
1632121|NCT01992601|Drug|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg)|"For co-administration, Crestor 1 tablet and Micardis 1 tablet a day for 6 days in each period.
For separate administration, Crestor 1 tablet a day for 6 days and Micardis 1 tablet a day for 6 days in each period."
1632122|NCT01992588|Drug|Faster-acting insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.
The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
1632123|NCT01992588|Drug|insulin aspart|"Subjects - in a euglycaemic clamp setting - will receive a priming (initial) dose followed by a continuous basal rate infusion and finally a bolus dose on top of the basal rate infusion.
The trial products will be administered subcutaneously (s.c. under the skin) by means of an insulin pump."
1632124|NCT01992562|Drug|Ziconotide|
1632125|NCT01992562|Drug|placebo|
1632126|NCT01992549|Biological|Human-cl rhFVIII|
1632127|NCT01992536|Biological|MenABCWY+OMV|"Vaccine contains rMenB (50 µg per antigen) with 25 µg of OMV (a full dose) plus the fully lyophilized MenACWY vaccine"
1632128|NCT01992536|Biological|MenABCWY+¼OMV|Vaccine contains rMenB (50 µg per antigen) with 6.25 µg OMV (1/4 dose) plus the fully lyophilized MenACWY vaccine
1632129|NCT01992536|Biological|Placebo|Saline solution for injection (0.5mL)
2011745|NCT02420860|Drug|Dexamethasone acetate|28 mg by mouth between 3-24 hours prior to the start of Elotuzumab infusion. Dexamethasone 8 mg by vein on day of Elotuzumab infusion prior to the start of infusion.
2011746|NCT02420860|Drug|Diphenhydramine|12.5-50 mg mouth or vein prior to Elotuzumab.
2011747|NCT02420860|Drug|Famotidine|20 mg by vein prior to Elotuzumab.
1632130|NCT01992523|Drug|Ticagrelor mashed pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor). Mashed pills administration will be prepared placing 2 ticagrelor pills in a mortar and mashing for 60 seconds using a pestle. The total contents of the mortar will be transferred to the dosing cup, 50 mL of purify water will be added, and the suspension mixed up before drinking. Afterwards, 100 mL of purify water will be administered to the patient.
1632131|NCT01992523|Drug|Ticagrelor integral pills|The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In all case before the end of the PCI (percutaneous coronary intervention) . In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered (90 mg Ticagrelor).
1632132|NCT01992497|Dietary Supplement|Probiotic|
1632133|NCT01992471|Behavioral|Pre-test Assessment|Subjects who consent to the study will complete a pre-test instrument that elucidates their baseline response to genetic testing (BRCA1/2) as measured by the Multidimensional Impact of Cancer Risk Assessment (MICRA), and their current cancer surveillance and prevention behaviors, as well asintentions to undergo surveillance and prevention in the next 6 months. The instrument will either be completed at the time of the counseling for multiplex testing, or by phone within approximately 7 days of sample donation.
1632134|NCT01992471|Behavioral|Pre test Counseling|Subjects will receive appropriate pre-test counseling that will describe the range of outcomes that may results from the multiplex testing. The subject will be asked for permission to audiotape the session for later qualitative review. An outline of the pretest counseling that will be provided. In addition to a description of the genes and syndromes being tested, subjects will receive specific education regarding the following categories and subcategories of possible results a. Definitive (informative) results, b. Variants of uncertain clinical significance (VUCS), c. Uninformative negative test results, d. d. Incidental results. Then Post-counseling selection of desired information After counseling, subjects will complete an instrument indicating which genetic test results they wish to receive. They will complete this instrument in the presence of a genetic counselor, so that the subject may ask questions in order to make the choice most consistent with their preferences.
1632135|NCT01992471|Other|Blood draw|After choosing the information they wish to receive, subjects will provide a blood sample (2 x 7 cc EDTA tubes, which will be sent to Myriad Genetics Laboratory for analysis.
1632136|NCT01992471|Behavioral|Post-test counseling, and post-test assessment|When results are available, subjects will be asked to return for in-person communication of the results. Results will be disclosed after confirmation of information preferences in a standard genetic counseling session.
1632137|NCT01992471|Behavioral|Follow-up assessments (6 and 12 months)|At 6 and 12 months post-results transmission (+/- 4 weeks), subjects will be contacted by telephone by the study RSA to complete follow-up instruments (Assessments 3 and 4; They will complete, by phone, the MICRA. They will also describe the surveillance and prevention behaviors of the preceding 6 months, and their intentions for the next 6 months. Subjects who express a high degree of distress will be offered referral to the Counseling Service, facilitated by Dr. Hay.
1632138|NCT01992393|Behavioral|TIME|TIME consists of 12 group sessions in which patients with epilepsy and mental illness will be coached on techniques to help manage their conditions. There will also be four follow-up telephone sessions after the series of group sessions is completed. In addition, approximately half of the participants will participate in qualitative interviews.
1632139|NCT01992380|Drug|18F-AV-1451|
1632140|NCT01992367|Drug|ASLAN003 ACTIVE|This is a single-centre, placebo-controlled, randomised, double-blind study involving SAD and MAD of ASLAN003 in healthy subjects.
1632141|NCT01992354|Device|PET MR Device|GE PET/MRI system
1632142|NCT01992341|Drug|AMG 386|Weekly 15 mg/kg of AMG 386 in combination with three weeks on/ one week off 80mg/m2 of paclitaxel. Continued therapy with AMG 386 with or without paclitaxel until progression, unacceptable toxicity develops, or study withdrawal.
1632143|NCT01992341|Drug|Paclitaxel|Three weeks on/ one week off 80mg/m2 of paclitaxel in combination with weekly 15 mg/kg of AMG 386 . Continued therapy with AMG 386 until progression, unacceptable toxicity develops, or study withdrawal. A cycle consists of 3 weeks on / 1 week off of paclitaxel.
1632144|NCT01992328|Drug|Immune Globulin|6 months once a month intravenous immunoglobulin (400mg/kg/4weeks)
1632145|NCT01992315|Device|Adipose-derived ECM|Each syringe of adipose-derived ECM will hold 2mL and will be for single use only. Up to 3 syringes (6mL total) may be used for each patient. Injections will be made under local anesthesia and sterile conditions using a 23-gauge needle. All injections will be performed in an outpatient clinic setting at study site by the principal investigator who will determine the method, depth, and volume of each implant. Decellularized adipose tissue-derived matrix will be infiltrated into the defect and the underlying musculature as well as the subcutaneous tissue surrounding the defect, with the goal of creating a smooth transition from surrounding structures to the filled defect. This will be performed using a series of multiple punctures or a single puncture with a fanning or threading technique. After the injection is completed, the treatment area will be massaged to conform to the contour of the surrounding tissue and ice will be applied as needed for swelling.
1632146|NCT01992289|Drug|EDI200|Long-term follow-up study of subjects that received EDI200 as part of protocol ECP-002
1632147|NCT01992276|Biological|CR8020|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
1632148|NCT01992276|Biological|CR6261|30 mg/kg administered as a single 2-hour intravenous infusion on Day 1
1632149|NCT01992276|Biological|Placebo|Administered as a single 2-hour intravenous infusion on Day 1
1632150|NCT01992263|Dietary Supplement|Vitamin D (600 IU)|Daily oral dose for 12 months
1632151|NCT01992263|Dietary Supplement|Vitamin D (2000 IU)|Daily oral dose for 12 months
1632152|NCT01992263|Dietary Supplement|Vitamin D (4000 IU)|Daily oral dose for 12 months
1632153|NCT01992263|Other|Placebo|Daily oral dose for 12 months
1632155|NCT01992224|Other|early mechanical Ventilation|"Fulfillment of three or more criteria below:
respiratory rate > 28 per minute serum lactate > 3 mmol/L PaO2/FiO2 Index <300 mmHg SvO2 < 65% lung infiltration or atelectasis, pleural exudation"
1632158|NCT01992211|Drug|Metformin|Participants will be co-administered a single oral dose of Rosuvastatin 10mg and Metformin SR 1000mg under Fed condition.
1632159|NCT01992211|Drug|BCWP_C003|Participant will be administered a single oral dose of BCWP_C003 under Fasting condition or Fed condition according to sequence.
1632160|NCT01992198|Drug|cefoperazone + metronidazole|"1.Clinical parameters (2 of 3):
1)temperature<37.8℃ or 2)HR <100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):
1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC <12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed <30% compared to that of 72h"
1632161|NCT01992198|Procedure|oral care by chlorhexidine gluconate|oral care by 0.2% chlorhexidine gluconate twice daily
1632162|NCT01992198|Procedure|enteral nutrition|
1632163|NCT01992198|Drug|Somatostatin|
1632164|NCT01992198|Drug|Meropenem|"All patients in cefo-group do not meet 1 of 3 laboratory parameter or image parameter or 2 of 3 clinical parameters.
1.Clinical parameters (2 of 3):
1)temperature<37.8℃ or 2)HR <100bpm or 3)SpO2 >95% 2.Laboratory parameters (3 of 3):
1)CRP or 2)PCT reduction 70% compared to zenith for 2 consecutive samples 3)WBC <12×10E9/L for 2 consecutive samples 3.Image parameter (1 of 1): liquid collection developed <30% compared to that of 72h"
1632165|NCT01992185|Drug|Photocil for Vitiligo|Photocil for Vitiligo
1632166|NCT01992185|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
1632167|NCT01992172|Drug|Photocil for Atopic Dermatitis|Photocil for Atopic Dermatitis
1632168|NCT01992172|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
1632169|NCT01992159|Drug|Romosozumab|Administered by subcutaneous injection
1632170|NCT01992159|Drug|Placebo|Administered by subcutaneous injection
1632171|NCT01992146|Drug|Target-controlled naloxone-infusion|
1632172|NCT01992146|Drug|Placebo|
1632173|NCT01992133|Dietary Supplement|Vitamin D3|
1632174|NCT01992133|Dietary Supplement|Placebo|
1632175|NCT01992120|Other|Debriefing of high-fidelity sepsis simulation scenarios|Educational intervention
1632176|NCT01992120|Other|Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios|
1632177|NCT01992107|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
1632178|NCT01992107|Biological|TIV1c|Licensed Influenza Vaccine
1632179|NCT01992107|Biological|TIV2c|Novartis Investigational Vaccine
1632180|NCT01992094|Biological|QIVc|Novartis Investigational Quadrivalent Vaccine
1632181|NCT01992094|Biological|TIV1c|Licensed Influenza Vaccine
1632182|NCT01992094|Biological|TIV2c|Novartis Investigational Vaccine
1632183|NCT01992081|Device|Automated telehealth system|The automated telehealth system (used within its intended use) comprises of CE marked medical devices and a CE marked step counter (Fitbug®), all being used within their intended use. Coaching by investigators is performed during the study visits and is aimed to enhance physical activity in patients across a spectrum of COPD severity, in addition to the usual care.
1632184|NCT01992081|Other|Usual care|Participants will receive usual care associated with Chronic Obstructive Pulmonary Disease (COPD)
1632185|NCT01992055|Behavioral|Goal Management Training|Participants will be randomly assigned to the GMT Treatment. The GMT cognitive rehabilitation intervention program will be administered in group format, consisting of 8 sessions, including structured psychoeducation, relaxation training, and stepwise learning of GMT.
1632186|NCT01992055|Behavioral|Education & relaxation training|The Education & Relaxation Training Control Group program will also be administered in group format, consisting of two sessions, including structured psychoeducation and relaxation training. Participants assigned to the Control condition will be offered the opportunity to complete the full GMT program following the completion of the study.
1632189|NCT01992029|Other|Clinical evaluation|Clinical evaluation using MRC scale, Norris bulbar scale, ALSFRS score and respiratory evaluation ( Vital Capacity, PiMax and SNIP) at M0, M4, M8, M12
1632190|NCT01992029|Procedure|Muscular biopsy|Muscular biopsy at M0
1632191|NCT01992029|Procedure|Lumbar puncture|Lumbar puncture at M0 and M12
1632192|NCT01992029|Procedure|Blood sampling|Blood sampling at M0, M4, M4, M8 and M12
1632193|NCT01992029|Other|Neurological assessments|Neurological assessments (MRC score and cognitive scales: MMS and BREF)
1632194|NCT01992029|Procedure|Neuro-muscular biopsy and lumbar puncture|Neuro-muscular biopsy and lumbar puncture for patients explored for peripheral neuropathy
1632195|NCT01992029|Procedure|Muscular biopsy|Muscular biopsy for patient explored for myopathy
1632196|NCT01992029|Procedure|Blood sample|Blood sample for qRT PCR, detection and quantification for miRNA
1632197|NCT01992029|Device|Cervical spinal cord and brain MRI|ALS patients : MRI at inclusion and Month 8 Control patients suffering from neuropathy : MRI at inclusion and Month 8 Control patients suffering from myopathy : MRI at inclusion Control subjects : MRI at inclusion
1632198|NCT01992016|Drug|Ranolazine|1000mg given orally twice daily for 1 day (2 doses).
1632199|NCT01991990|Drug|placebo|Single i.v. infusion
1632200|NCT01991990|Drug|tocilizumab [RoActemra/Actemra]|Single 8 mg/kg i.v. infusion
1632201|NCT01991977|Procedure|Diffusion Weighted Imaging|Undergo DTI
1632202|NCT01991977|Drug|Fluorine F 18 Fluorodopa|Undergo 18F-DOPA-PET
1632203|NCT01991977|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1632204|NCT01991977|Procedure|Perfusion Magnetic Resonance Imaging|Undergo pMRI
1632205|NCT01991977|Procedure|Positron Emission Tomography|Undergo 18F-DOPA-PET
1632206|NCT01991977|Other|Quality-of-Life Assessment|Ancillary studies
1632207|NCT01991977|Drug|Temozolomide|Receive temozolomide
1632208|NCT01991964|Other|laryngeal ultrasound|
1632209|NCT01991951|Drug|warfarin|
1632210|NCT01991938|Drug|VS-5584|
1632211|NCT01991925|Other|Interviews, questionaires, RAND-modified delphi method round|phase 1: RAND-modified delphi method round with experts in hereditary haemochromatosis phase 2: patient interviews, questionaires and focusgroup interviews
1632212|NCT01991912|Procedure|open lumbar decompression|A posterior midline incision is performed over the affected levels. Bilateral subperiosteal dissection of the paraspinal muscles is performed. Bilateral hemilaminotomies, foraminotomies and lateral recess decompression is performed followed by wound closure
1700505|NCT01462318|Other|Vitamin K|10 mg
1632213|NCT01991899|Biological|MMR Bio-Manguinhos|1170 children will receive 100% produced by Bio-Manguinhos, 3 diferents lots. Application of a 0.5 ml dose, subcutaneous 390 children will receive 0,5 ml, subcutaneous, MMR GlaxoSmithKline
1632214|NCT01991899|Biological|MMR GlaxoSmithKline|390 children will receive 0,5 ml MMR GlaxoSmithKline
1632215|NCT01991886|Device|Vapotherm Precision Flow|Application of nasal High Flow using 6-7 l/min delivered by nasal prongs from birth
1632216|NCT01991873|Drug|Maintenance Chemotherapy|
1632217|NCT01991873|Drug|Panitumumab (Within maintenance phase)|
1632218|NCT01991873|Drug|mFOLFOX6 (Within re-induction phase)|
1632219|NCT01991873|Drug|Panitumumab (Within re-induction phase)|
1632220|NCT01991860|Drug|APD421|
1632221|NCT01991860|Drug|Placebo|
1632222|NCT01991847|Behavioral|Physical activity|The patients will perform increasing volumes of moderate intensity endurance (e.g. walking, cycling) exercise, leading up to 18 MET-hours per week by the end of three months. Patients will then maintain this activity level for the remaining 9 months, with reduced supervision.
1632223|NCT01991834|Procedure|gynecologic laparoscopy|Gynecological laparoscopy without opening hollow viscera.
1632224|NCT01991834|Drug|Cefazolin|Intravenous administration of 1 g of cefazolin
1632225|NCT01991834|Drug|Placebo|Intravenous administration of saline sterile solution
1632226|NCT01991821|Drug|APD421|
1632227|NCT01991821|Drug|Placebo|
1632228|NCT01991808|Radiation|Radiotherapy|
1632229|NCT01991795|Drug|Ticagrelor 60 mg|Ticagrelor 60 mg bd taken orally as tablets
1632230|NCT01991795|Drug|Ticagrelor placebo|Ticagrelor placebo bd taken orally as tablets
1632231|NCT01991782|Other|Telemedicine|Patients in the telemedicine cohort will have two follow-up visits (at 6 weeks and 6 months) through video calls.
1632232|NCT01991769|Behavioral|47 min moderate intensity training|
1632233|NCT01991769|Behavioral|exercise healthy volunteers|
1632234|NCT01991769|Behavioral|control; no exercise training|
1632235|NCT01991756|Device|Altura Endograft System|Subjects with a documented untreated, unruptured, infrarenal abdominal aorto-iliac aneurysm.
1632236|NCT01991743|Drug|Group 2.5|Administration of bupivacaine 2.5 mg.
1632237|NCT01991743|Drug|Group 5|Administration of 5 mg bupivacaine
1632238|NCT01991743|Drug|Group 7.5|Administration of 7.5 mg bupivacaine
1632239|NCT01991743|Drug|Group 10|Administration of 10mg bupivacaine.
1632240|NCT01991717|Device|Victus|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
1632241|NCT01991717|Device|Conventional Phaco|The capsulotomy as well as the lens fragmentation is performed manually.
1632242|NCT01991691|Device|Tablet-based questionnaire|tablet-based patient reported outcomes (TabPRO)
1632243|NCT01991678|Drug|145 mg/m2 NKTR 102|
1632244|NCT01991678|Drug|120 mg/m2 NKTR 102|
1632245|NCT01991678|Drug|50 mg/m2 NKTR 102|
1632246|NCT01991665|Other|Digital examination|
1632247|NCT01991665|Other|Sonography evaluation|
1632248|NCT01991639|Other|Nutritional and physical activity intervention|Buddies visit malnourished, frail, elderly subjects twice a week for approximately one hour and they perform nutritional and physical activity interventions.
1632249|NCT01991626|Dietary Supplement|micronutrient powder|
1632250|NCT01991626|Dietary Supplement|micronutrient powder (containing FeSO4), phytase|
1632251|NCT01991626|Dietary Supplement|Iron pyrophosphate (FePP)|
1632252|NCT01991626|Dietary Supplement|Iron sulphate|
1632253|NCT01991613|Dietary Supplement|liquid protein supplement|The liquid protein supplement is already in use. The purpose of this study is to determine whether using the supplement earlier will lead to improved growth.
1632254|NCT01991600|Dietary Supplement|ferrous sulphate|
1632255|NCT01991600|Dietary Supplement|ferric iron oxide-organic acid (Fe-OA)|
1632256|NCT01991587|Biological|Low dose of quadrivalent VLP vaccine|A single low dose of quadrivalent VLP vaccine
1632257|NCT01991587|Biological|Medium dose of quadrivalent VLP vaccine|A single medium dose of quadrivalent VLP vaccine
1632258|NCT01991587|Biological|High dose of quadrivalent VLP vaccine|A single high dose of quadrivalent VLP vaccine
1632259|NCT01991587|Biological|Placebo|A single dose of placebo
1632260|NCT01991574|Drug|Calcium acetate|
1632261|NCT01991574|Dietary Supplement|Iron Hydroxide Adipate|
1632262|NCT01991574|Drug|Placebo|methylcellulose capsules
1632263|NCT01991561|Biological|Low dose of H5 VLP vaccine + Alhydrogel|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with Alhydrogel
1632264|NCT01991561|Biological|Med dose of H5 VLP vaccine + Alhydrogel|Biological:Med dose of H5 VLP vaccine 2 doses given 21 days apart of Med dose H5 VLP vaccine mixed with Alhydrogel
1632265|NCT01991561|Biological|High dose of H5 VLP vaccine + Alhydrogel|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with Alhydrogel
1632266|NCT01991561|Biological|Low dose of H5 VLP vaccine + GLA-SE|Biological: low dose of H5 VLP vaccine 2 doses given 21 days apart of low dose of H5 VLP vaccine mixed with GLA-SE
1632267|NCT01991561|Biological|High dose of H5 VLP vaccine + GLA-SE|Biological: High dose of H5 VLP vaccine 2 doses given 21 days apart of High dose of H5 VLP vaccine mixed with GLA-SE
1632268|NCT01991561|Biological|Placebo comparator: Placebo|Biological: Placebo 2 doses given 21 days apart of the placebo
1632269|NCT01991548|Device|MiniMed® 640G Insulin Pump and Guardian® Link Transmitter|
1632270|NCT01991535|Device|Spontaneous Ventilation Mode|"Respiratory rate and duration of inspiration are controlled by the patient.
Device model: Stellar 150® (ResMed, Australia)."
1632271|NCT01991535|Device|Controlled Ventilation Mode|"Ventilator maintains the positive end-expiratory pressure until the patient inspires. At that point, the ventilator reaches the support pressure in a predetermined time. The patient fixes the respiratory rate and the duration of inspiration, triggering all the cycles.
Device model: Stellar 150® (ResMed, Australia)."
1632272|NCT01991535|Device|Simulator Ventilation Mode|"Ventilator maintains a continuous positive airway pressure during the entire cycle.
Device model: Stellar 150® (ResMed, Australia)."
1700506|NCT01462318|Drug|Omeprazole|40 mg
1632276|NCT01991509|Biological|LBR-101 SC|LBR-101 Administered Subcutaneously
2011748|NCT02420860|Drug|Lenalidomide|10 mg/day; after three cycles, provided the ANC is >/= 1000/mL, platelet count >/= 100,000/mL and all non-hematologic toxicity is </= grade 1, dose may be increased to 15 mg/day at discretion of physician.
2011749|NCT02420860|Behavioral|Symptom Questionnaire|Symptom questionnaire completion on Day 1.
1632279|NCT01991470|Device|Sensor|Subject wears both enlite and enlite 3 sensors
1632280|NCT01991457|Drug|Fludarabine|
1632281|NCT01991457|Procedure|Total Body Irradiation|
1632282|NCT01991444|Other|TAVI|no Intervention planned, Observation only
1632283|NCT01991405|Device|Computerized Working Memory Training.|"Auditive and visual Working Memory tasks, administrated on a computer under guidance. 5 x 45 minutes per week, for 5 weeks. The intervention group will train at an adaptive level that is not to difficult nor to easy, which is hypothesized as optimal for learning and training effect. The placebo group will train with a sham program that is fixed (non-adaptive in difficulty level), but otherwise identical."
1632284|NCT01991392|Device|Nasogastric tube|For nasogastric decompression.
1632285|NCT01991392|Device|No nasogastric tube|For nasogastric decompression.
2011750|NCT02420847|Drug|Ixazomib|"Phase I Starting Dose of Ixazomib: 4.0 mg by mouth on Day 1 of every 14-day cycle.
Phase II Starting Dose of Ixazomib: MTD from Phase I."
2011751|NCT02420847|Drug|Gemcitabine|"Phase I Starting Dose of Gemcitabine: 10 mg/m2/min by vein on Day 1 of each 14 day cycle.
Phase II Starting Dose of Gemcitabine: MTD from Phase I."
2011752|NCT02420847|Drug|Doxorubicin|"Phase I Starting Dose of Doxorubicin: 33 mg/m2 by vein on Day 1 of each 14 day cycle.
Phase II Starting Dose of Doxorubicin: MTD from Phase I."
2011753|NCT02421510|Drug|Sotagliflozin|High dose Sotagliflozin, once daily, before the first meal of the day
1632290|NCT01991353|Procedure|With PRP|Following meniscal repair, PRFM will be delivered arthroscopically into the tear site using a portal skid, arthroscopic canula and arthroscopic atraumatic tissue grasper into the interface of the repair site.
1632291|NCT01991353|Procedure|Without PRP|Standard of care meniscal repair without augmentation.
1632292|NCT01991327|Drug|Androxal|
1632293|NCT01991327|Drug|Placebo|
1632294|NCT01991314|Drug|Ferrous sulphate|200mg tablets.
1632295|NCT01991301|Drug|carfilzumib|carfilzumib will be added to the standard regimen of drugs for prevention of graft-versus-host disease.
1632296|NCT01991288|Procedure|SNB Saphenous Nerve Block|Patients in group SNB received an ultrasound guided SNB (a sub sartorial approach) by a single operator with 10 mls 0.5% bupivacaine. At the end of surgery periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline was performed in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
1632297|NCT01991288|Procedure|NSNB Non Saphenous Nerve Block|All patients at the end of surgery received periarticular knee infiltration of 30 mls 0.5% levobupivacaine + 70 mls 0.9% saline + 0.5 mg adrenaline, in a staged fashion by the surgeon, beginning with infiltration of the deep structures on tibial surface at 1mm depth around all exposed tissues, medial and lateral collateral ligament origin, all cut surfaces of extensor mechanism, all cut surface of skin and subcutaneous tissue
1632298|NCT01991275|Drug|The intravenous patient-controlled analgesia|The intravenous injection of morphine using the patient-controlled analgesia machine
1632299|NCT01991275|Drug|The intrathecal morphine injection|A single injection of morphine intrathecally
1632300|NCT01991249|Other|blood draw|
1632301|NCT01991236|Behavioral|Video|Educational video discussing risks and benefits of chronic use of systemic corticosteroids.
1632302|NCT01991236|Behavioral|Standard Script|Standard scripted discussion of risks and benefits of chronic corticosteroid usage read to patients.
1632303|NCT01991223|Drug|Dex infusion|Dexmedetomidine will be injected (1 mcg/kg for 10 minutes and afterward 0.3 mcg/kg/hr)
1632304|NCT01991223|Drug|NS infusion|Normal saline will be infused during surgery
1632305|NCT01991210|Drug|DNIB0600A|DNIB0600A will be administered at a dose of 2.4 mg/kg IV every 3 weeks.
1632306|NCT01991210|Drug|PLD|PLD will be administered at a dose of 40 mg/m^2 IV every 4 weeks.
1632307|NCT01991197|Drug|Sitagliptin|"Week 0-16: Two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the double-blind phase.
Week 16-32: Then two 50mg tablets (or one 50mg tablet for participants with moderate kidney disease) once daily for 16 weeks during the open-label phase of the trial."
1632308|NCT01991197|Drug|Gliclazide|"Double-blind phase (week 0-16):
One 80mg capsule once daily for 4 weeks. The if no severe hypoglycaemic episodes one 80mg capsule twice daily for 4 weeks.
Then if no severe hypoglycaemic episodes two 80mg capsules twice daily for 8 weeks."
1632309|NCT01991197|Drug|Sitagliptin matched placebo|Week 0-16: Two tablets (or one tablet for those with moderate kidney disease) daily for 16 weeks during the double-blind phase.
1632310|NCT01991197|Drug|Gliclazide matched placebo capsule|"Double-blind phase (week 0-16):
One capsule daily for 4 weeks. Then if no severe hypoglycaemic episodes one capsule twice daily for 4 weeks. Then if no severe hypoglycaemic episodes two capsules twice daily for 8 weeks."
2011754|NCT02421510|Drug|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
1632312|NCT01991171|Other|Kinesio Taping|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the quadriceps muscle.
1632313|NCT01991158|Drug|High dose of methotrexate|Methotrexate 3.0g/Kg, intravenous drip D1
1632314|NCT01991158|Drug|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
1632315|NCT01991158|Drug|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
1632316|NCT01991158|Drug|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
2011755|NCT02421510|Drug|Placebo|Placebo, once daily, before the first meal of the day
1632322|NCT01991132|Other|MediView 2.0 software|
1632323|NCT01991119|Drug|Propafenone|
1632324|NCT01991119|Drug|Dronedarone|
1632658|NCT01988389|Dietary Supplement|apple juice (AJ)|
1632325|NCT01991106|Behavioral|High intensity interval training|Twelve weeks of 2-3 supervised training sessions each week.
1632326|NCT01991106|Behavioral|Moderate intensity continuous training|Twelve weeks of 2-3 supervised training sessions each week.
1632327|NCT01991106|Dietary Supplement|Nutritional advice|healthy food choices, portion sizes and regular mealtimes
1632328|NCT01991080|Behavioral|biofeedback|Patients will go through biofeedback sessions
1632329|NCT01991080|Drug|Wheatgerm juice|Patient will drink wheatgerm juice
1632330|NCT01991067|Biological|TBE virus vaccine|TBE virus vaccine FSME Immun is used in both arms for the study population and the control group
1632331|NCT01991054|Dietary Supplement|vitamin D3|
1632332|NCT01991028|Drug|Radiolabelled OligoG CF-5/20 DPI|Inhalation with dry powder by Mia Monodose Inhaler
1632333|NCT01991028|Drug|Radiolabelled OligoG CF-5/20 6% Solution|Inhalation with aerosolised solution by nebuliser
1632334|NCT01991002|Behavioral|14/21 diet|"Diet program is divided into 3 periods: 1. Low carb diet for 14 days; 2. Low carb and regular diet in alternating days for 21 days; 3. Individual carbohydrate-rich diet for 21 days.
The diet consists of a free choice of food ingredients from a detailed list of foods in each category (proteins, carbohydrates, vegetables, fat etc.). The participants are free to choose the types of food as long as they are within the specified allowance (quantity) for each food group."
1632335|NCT01990976|Device|MRI|In Paris centre, a total body NMR imaging will be done with standard T2- and T1-weighted images.
1632336|NCT01990976|Procedure|Biopsy|biopsy of the vastus lateralis muscle
1632337|NCT01990950|Device|Zenith® Fenestrated AAA Endovascular Graft|The Zenith® Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneursyms having morphology suitable for endovascular repair
1632338|NCT01990937|Drug|Oral midazolam|5 mg in 15 mL of apple juice, orally 30 minutes before undergoing EGD
1632339|NCT01990924|Radiation|15 FPS|X-ray pictures
1632340|NCT01990924|Radiation|7.5 FPS|X-ray pictures
1632341|NCT01990911|Device|Renal denervation|In patients randomized to intervention both renal arteries will be treated with radio-frequency energy as per standard Symplicity protocol.In patients randomized to medical-treatment group only, sham renal denervation will be performed by only injecting contrast agent into both renal arteries.
1632342|NCT01990911|Drug|Medical therapy|Subjects will continue on their standard medical therapy as prescribed by their treating physician
1632343|NCT01990898|Drug|Cyclosporine|Drug will be provided to patient's at study visit. Drug is to be taken twice daily. Dosage will be calculated at study visit and provided to patient.
1632344|NCT01990885|Drug|BL-7010|
1632345|NCT01990885|Drug|Placebo|
1632346|NCT01990872|Dietary Supplement|Vitamin D3 (20 micrograms/day)|Vitamin D3 (20 micrograms/day)
1632347|NCT01990872|Dietary Supplement|Placebo|Placebo (0 micrograms vitamin D3/day)
1632348|NCT01990859|Biological|Ipilimumab|
1632349|NCT01990846|Drug|Flufirvitide 3|
1632350|NCT01990846|Drug|Placebo for Flufirvitide-3|
1632351|NCT01990820|Device|Acclarent Relieva Balloon Sinuplasty|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the balloon catheter device will be inserted and the wire/balloon will be threaded through the maxillary sinus ostia. Confirmation of location will be per manufacturer's recommendation with either fluoroscopy or illumination. Following confirmation, the balloon will be dilated under visualization per manufacture's recommendation. After the visualization of the dilated ostia, cultures for aerobic/anerobic examination will be taken and irrigation with 10ml of isotonic sodium chloride will be performed.
Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner."
1632352|NCT01990820|Procedure|Adenoidectomy + Maxillary Sinus Irrigation|"A rigid nasal endoscopy will be performed. After decongesting with oxymetazoline hydrochloride, the maxillary sinuses will be entered via middle meati punctures using either a sterile spinal needle or a curved suction. Sinus contents will be aspirated and sent for aerobic/anaerobic cultures. Irrigation with 10ml of isotonic sodium chloride will be performed. If no material is aspirated initially, the sinus contents will be re-aspirated after irrigation and sent for aerobic/anaerobic cultures.
Adenoidectomy will be performed using either the microdebrider or suction electrocautery in the usual manner.
After adequate hemostasis, the patient will be awakened and brought to the recovery room. Depending on the recovery, the child will either be admitted or discharged home."
1632353|NCT01990807|Drug|Idarubicin(IDA)|6mg/M2 IV(in the vein) on day 16,22,29 of induction therapy, until progression or unacceptable toxicity develops.
1632354|NCT01990781|Drug|LD: Lidocaine and dexamethasone|LD: intravenous lidocaine 1.5 mg/kg and dexamethasone 8 mg before induction of anesthesia
1632355|NCT01990781|Drug|L:Lidocaine|Intravenous lidocaine 1.5 mg/kg before induction of anesthesia
1632356|NCT01990781|Drug|D: Dexamethasone|D:intravenous dexamethasone 8 mg before induction of anesthesia
1632357|NCT01990781|Drug|N: Normal saline (placebo)|Normal saline: 2ml
1632358|NCT01990768|Drug|1 gram Tranexamic Acid (TXA)|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
1632359|NCT01990768|Drug|2 grams TXA|TXA produces an antifibrinolytic effect by competitively inhibiting the activation of plasminogen to plasmin.
1632360|NCT01990768|Drug|0.9% Sodium Chloride injectable|Loading dose of 0.9% Sodium Chloride solution given prior to hospital arrival followed by a placebo of 0.9% Sodium Chloride solution infusion over 8 hours after hospital arrival. No active drug is added to the solution.
1632361|NCT01990755|Behavioral|CBT (Cognitive Behavioral Therapy)|It is a worldwide known form of psychotherapy for eating disorders
1632362|NCT01990755|Other|IBPP (individual psychology brief psychotherapy)|It is a worldwide known form of psychotherapy for eating disorders
1632363|NCT01990755|Drug|CBT + OLANZAPINE|It is a worldwide known form of psychotherapy for eating disorders associated with a new antipsychotic with good efficacy on anorexia nervosa
1632364|NCT01990755|Dietary Supplement|nutritional rehabilitation|all patients were followed-up monthly with nutritionist and dietitian visits
1632365|NCT01990755|Drug|delorazepam|all patients were followed-up with psychiatric visits with symptomatic drug administration (tranquillizer: delorazepam) where necessary
1632367|NCT01990729|Dietary Supplement|ARTRA|ARTRA (glucosamine and chondroitin sulfate)
1632368|NCT01990716|Other|Colonic Biopsy|"Colonoscopy or coloscopy can provide a visual diagnosis and grants the opportunity for biopsy or removal of suspected colorectal cancer lesions.
The endoscope is then passed through the anus up the rectum, the colon, and ultimately the terminal ileum. The endoscope has a movable tip and multiple channels for instrumentation, air, suction and light. Biopsies are frequently taken for histology, needed for cancer or IBD diagnosis.
Extra-biopsies for research purpose will only be performed if the clinician decides that they are necessary for the clinical diagnosis or for the disease follow-up.
For this protocol, collecting these extra biopsies should last under 5 minutes and should not extend the procedure by more than this time."
1632369|NCT01990703|Drug|Levonorgestrel IUD|Timing of IUD insertion
1632370|NCT01990690|Drug|anti oxidant omega 3|"Soft gelatineous capsule (Sedico medical company) each capsule contains:
Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.
Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).
Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks."
1632371|NCT01990677|Drug|25mg Eplerenone|Patients will be given 25mg Eplerenone (or 50mg Eplerenone) or placebo throughout the study and the dosage will be based on the serum potassium/creatine levels. Patients will be randomized 2:1 such that 36 patients in each group will receive eplerenone and 16 patients in each group will receive placebo
1632372|NCT01990677|Drug|Placebo|Patients will be given placebo throughout the study from day one, other patients may be tapered down to placebo based on the serum potassium/creatine levels. 16 patients in each group will receive placebo.
1632373|NCT01990664|Device|senofilcon A|
1632374|NCT01990664|Device|senofilcon A for Astigmatism|
1632375|NCT01990638|Other|exercise capacity test|
1632376|NCT01990625|Device|Antenatal Ultrasound Scan|Women in the intervention arm will be provided two ultrasound scans to screen for pregnancy complications.
1632377|NCT01990612|Procedure|Elective Induction of Labor|Women randomized to induction of labor will undergo induction via oxytocin at 39 weeks 0 days to 39 weeks 4 days. Those with an unfavorable cervix (modified Bishop score < 5) will first undergo cervical ripening (method left to the discretion of the patient's physician) in conjunction with or followed by oxytocin stimulation unless a contraindication arises.
1632378|NCT01990599|Other|Nasopharyngeal Tube|
1632379|NCT01990586|Drug|Rabeprazole sodium 20 mg Delayed Release tablet|
1632380|NCT01990573|Drug|0.3mg/kg IV methadone HCl|Group I will receive 0.3mg/kg IV methadone HCl
1632381|NCT01990573|Drug|0.5mg/kg IV methadon HCl|Group II will receive 0.5mg/kg IV methadone HCl.
1632382|NCT01990573|Other|control no methadone|The control group will not receive methadone.
2011756|NCT02420262|Drug|insulin degludec/liraglutide|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
1632384|NCT01990534|Drug|Brentuximab vedotin|Brentuximab vedotin IV infusion
1632385|NCT01990521|Procedure|MS3TMRI / TRUS Guided Biopsy|Patients would undergo MS3TMRI and then have a transrectal ultrasound (TRUS) biopsy performed within one month after the MRI. The initial cores would be obtained using TRUS without MRI information (TRUSBx). During the same biopsy session, the MS3TMRI information would be given to the physician performing the biopsy and additional cores specifically targeted to suspicious areas would be performed (MS3TMRI-TRUSBx).
1632386|NCT01990521|Device|MS3TMRI / TRUS Guided Biopsy|"Multispectral 3T MRI (MS3TMRI) is a device that uses a 3T MRI system without an endorectal receiver coil and with a surface phased array coil. 3T MRI in addition to established computer aided diagnosis (CAD) has been used to perform guided biopsies in an active surveillance population and demonstrated a positive predictive value and negative predictive value of 83% and 81%.
A recently completed a study looking at repeat prostate biopsies in men followed on an active surveillance population at Sunnybrook has shown that the PPV of MS3TMRI guided biopsy to be 85%, while the negative predictive value was 100% (Haider, Vesprini and Milot, unpublished)."
1632387|NCT01990508|Behavioral|Targeted beverage education and financial incentives|
1632388|NCT01990508|Behavioral|Traffic-light labeling of all beverages in store|All beverages in the supermarket will be labeled as red, yellow, or green
1632389|NCT01990495|Other|Exercise training|Subjects will participate in a center-based and home exercise training program for 3 months.
1632390|NCT01990495|Other|Usual Care|This group will serve as control subjects. They will receive only usual clinical care.
1632391|NCT01990482|Dietary Supplement|caffe|
1632392|NCT01990482|Dietary Supplement|Water|
1632393|NCT01990469|Drug|Gemigliptin|DPP-4 inhibitor
1632394|NCT01990469|Drug|Gemigliptin placebo|Placebo of Gemigliptin
1632395|NCT01990456|Device|PHASE 1: impact of tidal ventilation on VILI|PHASE 1A - Baseline - Standard Ventilation Protocol (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1B - CPAP Strategy - CPAP 10 cmH2O for 1 hour PHASE 1C - Higher Tidal Ventilation Strategy (PCV 20 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 1D - Return to Baseline - Standard Ventilation Protocol
1632396|NCT01990456|Device|PHASE 2: impact of PEEP on VILI|PHASE 2A - Baseline - Standard Ventilation Protocol - (PCV 10 cmH2O, PEEP 10 cmH2O, RR 10, FiO2 0.30) PHASE 2B - Decremental PEEP Trial PHASE 2C - CPAP set at best compliance of respiratory system (as per decremental PEEP Trial) PHASE 2D - ZEEP PHASE 2E - Return to Baseline - Standard Ventilation Protocol
1632397|NCT01990443|Drug|Reslizumab IV|Reslizumab 220-mg intravenous (IV)
1632398|NCT01990443|Drug|Reslizumab SC|Reslizumab 220 mg administered subcutaneous (SC)
1632426|NCT01990144|Drug|Bendamustine+Rituximab|"Patients will receive :
Rituximab 375 mg/m2 intravenously on day 1*
Bendamustine 90 mg/m2 intravenously on days 2 and 3** Treatment will be administered on a 28-day cycle basis.
Administration of rituximab during cycle 1 is postponed to day 8, thereafter on day 1.
After the first cycle, bendamustine can be administered on days 1-2 or days 2-3 according to Institutional/patient/physician choice."
1632427|NCT01990131|Other|Cognitive Anxiety Sensitivity Treatment|
1632428|NCT01990131|Other|Physical Health Education Training|
1632429|NCT01990118|Drug|Neoral|Neoral® capsule containing 25mg or 100mg cyclosporine
1633460|NCT01982448|Drug|Cisplatin|75 mg/m2 IV q 3 weeks x 4 cycles
1632399|NCT01990430|Behavioral|Exercise Intervention|"Intervention: The sessions included instructions in training exercises, as well as included time to speak about their fears and doubts with other patients, who were in the same situation. The intervention lasted 12 weeks (24 sessions). The training intensity was progressively increased from 65% to 85% of heart rate with control by a POLAR FT7 heart rate monitor for aerobic activities, and by 8-15 repetitions in 2-3 sets for the strength activities. Exercise intensity was prescribed using Karvonen equation.
The nutrition program consisted of three theoretical and practice classes. The first class explained the different groups of nutrients, their functions in the organism and for which group of aliments these can be obtained. The second class was a practical class about how to interpret food labels and relating measurements of food portions with recommendations for a healthy diet. Final session spoke about the ten best and the ten worst aliments, which prevent and promote cancer."
1632400|NCT01990417|Other|Passive stretching|Passive stretching of the hamstrings was performed only once, lasting 30 seconds, and initiated on the right leg. Participants were in supine position with head, trunk and arms aligned along the body. The researcher remained ipsilateral to the subject´s leg being stretched and applied external force to the limit tolerated by the participant. The researcher performed a hip flexion, knee extension, and dorsiflexion of the ankle while the opposite leg remained extended on the ground.
2011757|NCT02420262|Drug|insulin glargine|Once daily injected s.c./subcutaneously (under the skin) in combination with metformin.
2011758|NCT02420262|Drug|insulin aspart|Injected s.c./subcutaneously (under the skin) before each main meal.
1632403|NCT01990391|Dietary Supplement|Brazil nut flour|The Brazil nut group received 13g/day of Brazil nut flour during three months.
1632404|NCT01990391|Dietary Supplement|Placebo (cassava flavored flour)|The group placebo (cassava flour flavored)received 9g/day of cassava flour flavored during three months
1632405|NCT01990378|Drug|Rabeprazole sodium 20 mg Delayed Release tablet|
1632406|NCT01990352|Drug|Pegylated liposomal doxorubicin|
1632407|NCT01990339|Drug|Lansoprazole|"• Reflux esophagitis The usual adult dosage is 30 mg of lansoprazole administered orally once daily for up to 8 weeks.
For maintenance therapy of repeatedly recurring/relapsing reflux esophagitis, the dosage is 15 mg of lansoprazole administered orally once daily. If insufficient efficacy is observed, the dosage may be increased to 30 mg administered orally once daily.
• Nonerosive gastroesophageal reflux disease Non-erosive gastroesophageal reflux disease The usual adult dosage is 15 mg of lansoprazole administered orally once daily for up to 4 weeks."
1632408|NCT01990326|Drug|XAF5 Gel|
1632409|NCT01990326|Drug|Placebo Gel|
1632410|NCT01990313|Device|Activa PC+S|The Model 37604 Activa PC+S is a multiprogrammable device that can deliver therapeutic electrical stimulation and record bioelectric signals from leads implanted in the brain.
1632411|NCT01990300|Drug|Alogliptin/pioglitazone|Alogliptin/pioglitazone combination tablets
2011759|NCT02419599|Other|HE ONS|High energy density, low volume oral nutritional supplement (HE ONS) in addition to appropriate nutritional management
2011760|NCT02419599|Other|SE ONS|Standard energy density oral nutritional supplement (SE ONS) in addition to appropriate nutritional management
1632414|NCT01990274|Procedure|GeneXpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
1632415|NCT01990274|Procedure|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
1632416|NCT01990261|Drug|Erlotinib|Erlotinib at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
1632417|NCT01990235|Behavioral|PREPARE Intervention|At week 1, 3, 6, and 12 months, interviews (telephone or in person based on preference) by blinded staff will assess engagement in advance care planning(ACP), self-efficacy with ACP, and activation in and satisfaction with decision making. Blinded telephone interviews will also assess surrogate reports of patient engagement in ACP.
1632418|NCT01990209|Drug|Orteronel|
1632419|NCT01990196|Drug|degarelix|"Every 4-week Treatment: A starting dose of 240 mg of Degarelix is taken subcutaneously (SQ) -placed under the skin by injection- the first month. Doses continue every 4 weeks at 80 mg SQ.
Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
1632420|NCT01990196|Drug|enzalutamide|"Once Daily Treatment: A starting dose of 160 mg of Enzalutamide is taken by mouth once daily.
Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician."
1632421|NCT01990196|Drug|trametinib|"Once Daily Treatment: If randomized into Group 2, then 2mg of Trametinib is taken by mouth daily.
Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
1632422|NCT01990196|Drug|dasatinib|"Once Daily Treatment: If randomized into Group 3, then 100mg of Dasatinib is taken by mouth daily.
Dose for a drug may have to be modified based on development of adverse events on a case by case basis as per the judgment of treating physician"
1632423|NCT01990183|Device|CareToy|Infants randomized in the Intervention Group will begin the habilitation intervention immediately after evaluation at baseline. Rehabilitation staff, in accordance with each infant's needs and clinical characteristics, will set up the CareToy System to perform individualized intervention packages and its user's manual. So a personalized CareToy System will be delivered at infant's home. Moreover parents will attend a training course to use it. During each daily home ‐ session (about 30 - 45 minutes overall) it will be proposed to the child various interactive activities in supine, prone and sitting position. The intervention phase lasts 4 weeks and each session will be remotely monitored by the rehabilitation staff.
1632424|NCT01990183|Other|Standard Care|Current care advices in the management of preterm infants in the first months of life
1632425|NCT01990157|Drug|TAB08|Weekly intravenous administration in escalating doses.
1632430|NCT01990118|Drug|Gengraf® capsule containing 25mg or 100mg cyclosporine|Transplant patients who were stable on Neoral were converted to Gengraf
1632431|NCT01990092|Other|Metanx|Metanx is a prescription medical food.
2011761|NCT02418000|Drug|E6201|Single Group Assignment
2011762|NCT02417337|Procedure|Root Canal Treatment|A standardized endodontic procedures performed.
2011763|NCT02417337|Drug|Paracetamol|
2011764|NCT02417337|Drug|Ibuprofen|
2011765|NCT02417337|Drug|Mefenamic acid|
2011766|NCT02417337|Drug|Diclofenac|
1632433|NCT01990079|Drug|Bupropion|All participants who are medically eligible will be prescribed bupropion, which they will start two weeks prior to their quit day. Dosage will be 150 mg/daily for days 1-7 and 300 mg/daily (administered in two daily doses) until the 3-month follow-up.
1632434|NCT01990079|Drug|nicotine replacement therapy|Participants will be prescribed NRT patch and one nicotine rescue method (e.g., nicotine gum, lozenge, inhaler) for use during the post-quit phase of the study. Participants will be given the choice between nicotine gum, nicotine inhaler, or nicotine nasal spray, and will be instructed to use the rescue method as needed to reduce cigarette cravings
1632435|NCT01990079|Other|Smoking cessation counseling|Participants will receive four 20-minute smoking cessation counseling sessions and a participant manual. The four sessions are based on standard cognitive-behavioral therapy techniques shown to be efficacious for smoking cessation.
1632436|NCT01990079|Behavioral|mobile contingency management|Participants will be asked to provide video recordings of themselves taking carbon monoxide readings in order to confirm smoking abstinence. Participants are asked to upload these videos to the study's secured server, and are provided monetary reward for videos that suggest smoking abstinence.
1632437|NCT01990079|Other|Stay Quit Coach|Stay Quit Coach is a smart phone application that serves as a source of readily available support and information for adults who are already in treatment to quit smoking and to help them stay quit after treatment. The app guides user in creating tailored plans that include their personal reasons for quitting, interactive tools to help users cope with urges to smoke, motivational messages, support contacts to help users stay smoke free and how to address lapses. Participants assigned to this condition will be asked to use Stay Quit Coach from Session 2 through the 6-month follow-up.
1632438|NCT01990066|Behavioral|Home Based Exercise|Subjects randomized to intervention will receive Physical Therapist instructed exercise teaching. They will receive a home exercise DVD and flip ring of exercises. Subjects will be asked to perform home exercise 3 days weekly consisting of 13 strengthening/stretching exercises and 20 mins of aerobic exercise, walking or seated aerobics using ergometer. Subjects will record their exercise on a log and return on day 1 of every cycle.
1632439|NCT01990053|Behavioral|Beating the Blues|The BtB program guides patients through a series of 8 fully automated online lessons intended to help them identify and change problematic patterns of thinking and behavior that maintain depression. Support will be provided by licensed professional therapists over the phone or via email.
1632440|NCT01990001|Other|enrollment in online reminder system|Study personnel enrolled members in the online reminder system during their office visit.
1632441|NCT01989988|Procedure|LMGB|
1632442|NCT01989988|Procedure|LRYGB|
1632443|NCT01989988|Procedure|SADJB|
1632444|NCT01989962|Other|E4E intervention|The E4E intervention consists of a one-day face-to-face workshop and a series of follow-up online learning modules. Workshop and online content will be tailored to meet individual participants' needs determined by a pre-program needs assessment. E4E intervention will emphasize clinically based case scenarios and are designed to reinforce the workshop concepts and stimulate reflection. Participating family physicians will attend the workshop and engage in reflections and small-group interactions.
1632445|NCT01989949|Drug|TP-434 (Eravacycline) reconstituted and administered via an IV infusion|
1632446|NCT01989936|Drug|Placebo|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
1632447|NCT01989936|Drug|Eletriptan 40 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
1632448|NCT01989936|Drug|Eletriptan 80 mg|Subjects were randomized to one of the 3 treatment groups (eletriptan 40 mg, eletriptan 80 mg, or placebo) in a 2:2:1 ratio and were given sufficient medication to treat 3 migraine attacks (including a second dose for each attack for recurrence) within 18 weeks of the initial visit. Subjects were instructed to treat a moderate to severe migraine within 6 hours of the onset of pain provided the headache was not decreasing in severity, the aura phase had ended and they had taken no analgesic or antiemetic within 6 hours. Efficacy data was collected in a diary. Subjects were allowed to take rescue medication if they had no response to the study medication within 4 hours of onset.
1632449|NCT01989923|Other|Nicotine Replacement Therapy|Patients will use one patch per day for 6 weeks for a total of 42 patches - they will receive 7 the first visit and then the additional 35 at the second visit. Women will receive 3 weeks of original strength nicotine patches, and will receive patches half as strong during the last 3 weeks of the study. This will allow for a lower strength of nicotine as each woman continues with smoking cessation.
1632450|NCT01989923|Device|Electronic Cigarettes|The number of cartridges for the electronic cigarettes is determined by asking each patient the number of packs currently smoked per day, and multiplying 1.5 times the number of packs smoked per day. We plan to decrease the strength of the cartridges by one half after three weeks of intervention. We will give each women supplies and instructions accordingly. This will allow for a lower strength of nicotine as each woman continues with smoking cessation
1632451|NCT01989910|Drug|Raltegravir|Raltegravir 400mg oral twice daily
1632452|NCT01989910|Drug|Efavirenz|Efavirenz 600mg oral at bedtime
1632453|NCT01989897|Drug|saline with 1mg/ml Histamine base|
1632454|NCT01989897|Drug|diluent, saline with HSA--phenol|
1632455|NCT01989884|Drug|Ortataxel|75 mg/m2, IV (in the vein) every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
1632456|NCT01989871|Behavioral|Adjusted individual feeding|Feeding every 2-4 hours, starting with ques of hunger and finished upon infant signs.
1701439|NCT01455090|Drug|Ribavirin|
1632457|NCT01989858|Other|peri-operative cht|"CHT treatment have to be chosen between the following associations:
Chemotherapy regimen containing epirubicin, cisplatin and capecitabine (EOX) E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously
or
Chemotherapy regimen containing epirubicin, cisplatin and 5-fluorouracil (ECF) E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line."
1632458|NCT01989858|Other|post-operative CHT|"CHT treatment have to be chosen between the following associations:
EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously
or ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5fluorouracil (5FU) 200 mg/m² daily by continuous infusion via central line."
1632459|NCT01989858|Other|peri-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:
EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or
ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.
The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:
5FU 225 mg/m² given as a continuous iv infusion or
capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
1632460|NCT01989858|Other|post-operative cht + post-operative cht-rtx|"CHT treatment have to be chosen between the following associations:
EOX E: epirubicin 50 mg/m² intravenous (iv) bolus, day 1 every 3 weeks O: oxaliplatin 130 mg/m² iv infusion, day 1 in 2-3 hours every 3 weeks X: capecitabine 625 mg/m² bis in die (bid), day 1 per os (po) continuously or
ECF E: epirubicin 50 mg/m² iv bolus, day 1 every 3 weeks C: cisplatin 60 mg/m² iv with standard hydration day 1 every 3 weeks F: 5FU 200 mg/m² daily by continuous infusion via central line.
The prescribed RTX dose to clinical target volume should be 45 gray (Gy) delivered in daily fraction of 1.8 Gy, five times per week for six weeks. RTX will be administered concurrently with CHT. The choice of the associated CHT should be between the following schedules:
5FU 225 mg/m² given as a continuous iv infusion or
capecitabine 825 mg/m² bid given as a continuous oral administration during the entire course of RTX."
1632461|NCT01989845|Drug|Rivaroxaban|Rivaroxaban 15mg twice daily for the first 3 weeks, followed by 20mg once daily during 6 months
1632462|NCT01989819|Other|skin biopsy|
1632463|NCT01989806|Device|Robotic-assisted body weight supported treadmill training (Lokomat V6, Hocoma AG, Switzerland)|
1632464|NCT01989806|Device|Passive lower limbs mobilization training (Motomed Vivo 2, RECK, Germany)|
2011767|NCT02414165|Biological|Toca 511|Toca 511 consists of a purified retroviral replicating vector encoding a modified yeast cytosine deaminase (CD) gene. The CD gene converts the antifungal 5-flurocytosine (5FC) to the anticancer drug 5-FU in cells that have been infected by the Toca 511 vector.
2011768|NCT02414165|Drug|Toca FC|Toca FC is an extended-release formulation of flucytosine and is supplied as 500 mg tablets
1632467|NCT01989780|Drug|Paclitaxel|
1632468|NCT01989780|Drug|Bevacizumab|
1632469|NCT01989780|Drug|Letrozole|
1632470|NCT01989780|Drug|Anastrozole|
1632471|NCT01989780|Drug|Exemestane|
1632472|NCT01989780|Drug|Fulvestrant|
1632473|NCT01989780|Drug|Goserelin|
1632474|NCT01989780|Drug|leuprorelin|
1632475|NCT01989780|Drug|LHRH Analogs + Aromatase inhibitors|
1632476|NCT01989767|Behavioral|control Rehabilitation as usual|Rehabilitation as usual
1632477|NCT01989767|Behavioral|education|Education as add on to to rehabilitation as usual
1632478|NCT01989754|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily for 156 weeks
1632479|NCT01989754|Drug|Canagliflozin, 100 mg|One 100 mg capsule taken orally (by mouth) once daily
1632480|NCT01989754|Drug|Canagliflozin, 300 mg|One 300 mg capsule taken orally (by mouth) once daily
2011769|NCT02414165|Drug|Lomustine|
1632482|NCT01989728|Procedure|psychiatric examination and feedback|
1632483|NCT01989715|Other|analyzing the position of the body, muscle activity|
1632484|NCT01989702|Other|Fermented blueberry drink|
1632485|NCT01989702|Other|Placebo drink|
1632486|NCT01989702|Other|Sachets with probiotic bacterial powder|
1632487|NCT01989702|Other|Sachets with placebo powder|
1632488|NCT01989689|Drug|Etanercept|Etanercept 50mg twice weekly
1632489|NCT01989689|Drug|Placebo|
2011770|NCT02414165|Drug|Temozolomide|
2011771|NCT02414165|Biological|Bevacizumab|
2011772|NCT02413645|Biological|TriMix_100|100 μg of TriMix in
2011773|NCT02413645|Biological|TriMix_300|300 μg of TriMix in
2011774|NCT02413645|Biological|600μg mRNA (300 μg HIV mRNA+300 μg TriMix mRNA)|600 μg of mRNA (300 μg TriMix + 300 μg HIVACAT)
2011775|NCT02413645|Biological|900μg mRNA (600 μg HIV mRNA+300 μg TriMix mRNA)|900 μg of mRNA (300 μg TriMix + 600 μg HIVACAT)
2011776|NCT02413645|Biological|1200μg mRNA (900 μg HIV mRNA+300 μg TriMix mRNA)|1200 μg of mRNA (300 μg TriMix + 900 μg HIVACAT)
2011777|NCT02413320|Drug|Paclitaxel|
2011778|NCT02413320|Drug|Carboplatin|
2011779|NCT02413320|Drug|Doxorubicin|
2011780|NCT02413320|Drug|Cyclophosphamide|
2011781|NCT02413320|Drug|Docetaxel|
2011782|NCT02410876|Procedure|Bladder biopsy|Small biopsy of the bladder is taken with cold-cup tongs.
2011783|NCT02410876|Procedure|Urodynamic study|Assessment of bladder function through intravesical and intrabdominal pressure measurements according to International Continence Society standards.
2011784|NCT02410213|Drug|Ferric Carboxymaltose (FCM)|
2011785|NCT02409303|Behavioral|Screen-Refer-Treat Intervention|This intervention is healthcare system intervention that trains providers on validated screening tools (Online M-CHAT-R/F and STAT) and an evidence-based behavioral intervention (RIT). PCPs receive a 2-hour training workshop on the Online M-CHAT-R/F and EI Providers receive 2 day-long training workshops, one on the STAT/expedited assessment and one RIT.
1632494|NCT01989663|Drug|1% vaginally applied tenofovir gel|
1632495|NCT01989663|Drug|Tenofovir film- 10mg|
1632496|NCT01989663|Drug|Tenofovir Film-40 mg|
1632497|NCT01989663|Other|HEC Placebo Gel|
1632498|NCT01989663|Other|Placebo Vaginal Film|
1632499|NCT01989650|Other|Break|A break of 15 minute will be provided after 3rd colonoscopy in a session of 6 colonoscopies in total
1632500|NCT01989650|Other|No break|No break will be provided
1632501|NCT01989637|Dietary Supplement|Strawberry Meal|High-fat meal (50 g total fat) with 40 g freeze dried strawberry powder
1632502|NCT01989637|Dietary Supplement|Control Meal|High-fat meal (50 g total fat) with a matched placebo powder containing no strawberry bioactives
1632503|NCT01989611|Drug|emtricitabine / tenofovir 200/300 mg|Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
2011786|NCT02407704|Drug|Venlafaxine XR|
2011787|NCT02407704|Other|Aerobic Exercise|
2011788|NCT02407704|Drug|Lorazepam|Lorazepam may be used in the study for patients who either are already on this drug or who need it for sleep and/or anxiety. Patients taking another benzodiazepine will be asked to convert from their current benzodiazepine to an equivalent dose of Lorazepam (2mg or less in 24 hours). This will be administered in pill form.
2011789|NCT02407093|Behavioral|High-Intensity Functional Training|Constantly varied functional movements performed at a high intensity and incorporating monostructural (aerobic), gymnastics (body weight) and/or weightlifting movements. CrossFit is a good model of HIFT for the military because of its emphasis on general physical preparedness and functional movements and because it is open source and programming is available at no cost (see www.crossfit.com). Sixty-minute HIFT sessions will include a warm-up, workout and cool down. Workouts will average 15 minutes in duration (range = 5-45 minutes) for a total of 50-100 minutes per week.
1632508|NCT01989585|Drug|Dabrafenib|Given PO
1632509|NCT01989585|Other|Laboratory Biomarker Analysis|Correlative studies
1632510|NCT01989585|Biological|Navitoclax|Given PO
1632511|NCT01989585|Other|Pharmacological Study|Correlative studies
1632512|NCT01989585|Drug|Trametinib|Given PO
1632513|NCT01989572|Biological|sargramostim|Given SC
1632514|NCT01989572|Biological|peptide vaccine|Given SC
1632515|NCT01989572|Other|GM-CSF placebo|Given SC
1632516|NCT01989572|Other|peptide placebo|Given SC
1632517|NCT01989559|Biological|gp100:209-217(210M) Peptide Vaccine|Given SC
1632518|NCT01989559|Biological|HPV 16 E7:12-20 Peptide Vaccine|Given SC
1632519|NCT01989559|Other|Laboratory Biomarker Analysis|Correlative studies
2011790|NCT02407093|Behavioral|Army Physical Readiness Training|Usual physical training program for Army personnel from directive FM 7-22, using the Reset phase. Exercises will address strength, endurance, and mobility training. APRT is designed to be completed in 60-90 minute sessions, 5 days/week for a total dose of 300-450 minutes per week.
2011791|NCT02404584|Genetic|Blood drawn for genotyping|Blood will be drawn for genotyping (predefined list of genes) just before the start of sunitinib (baseline).
1632523|NCT01989520|Drug|Phase IIb formulation|Single oral dose 45mg AZD5069
1632524|NCT01989520|Drug|Putative phase III formulation|Single oral dose 45mg AZD5069
1632525|NCT01989520|Drug|Slow dissolution variant 1|Single oral dose 45mg AZD5069
1632526|NCT01989520|Drug|Slow dissolution variant 2|Single oral dose 45mg AZD 5069
1632527|NCT01989520|Drug|Test treatment E|Tablet formulation E, 45 mg (intermediate dissolution variant) of AZD5069
1632528|NCT01989507|Drug|Nicotine|
1632529|NCT01989507|Behavioral|behavioral counseling for smoking cessation|Brief session of Brief advice. Assess smoking and provide assistance with quitting via coping skills.
1632530|NCT01989494|Device|Pedometer|All groups will receive a pedometer to measure their daily steps
1632531|NCT01989468|Biological|Secukinumab|Eligible subjects are randomised to each of three treatment arms in a 1:1:1 ratio
1632532|NCT01989468|Biological|Placebo|Eligible subjects are randomized to each of the three treatment arms in a 1:1:1 ratio
1632533|NCT01989455|Drug|Deferiprone|"Deferiprone for infusion, 10mg/mL for intravenous infusion.
Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)"
1632534|NCT01989455|Drug|Placebo|Placebo: normal saline solution.
1632535|NCT01989442|Device|binasal prongs|patients randomized to binasal prongs for NIV will use binasal prongs as an interface during continuous positive airway pressure support
1632536|NCT01989442|Device|nasal mask|patients randomized to nasal mask for NIV will use nasal mask as an interface during continuous positive airway pressure support
1632537|NCT01989429|Drug|M518101|8-week comparative treatment period ( twice daily application) followed by a maximum 8-week period to evaluate time to relapse
1632538|NCT01989416|Drug|2% chlorhexidine wipe|The ICU patients will be bathing with 2% chlorhexidine wipe
1632539|NCT01989416|Drug|Soap|The ICU patients will be bathing with Soap
1632540|NCT01989403|Other|herbal medicine, acupuncture, bee-venom acupuncture, and Chuna manipulation|
1632541|NCT01989325|Drug|Carfilzomib, proteasome inhibitor; intravenous|multiple dose, single schedule
1632542|NCT01989325|Drug|Filanesib, KSP(Eg5) inhibitor; intravenous|multiple dose, single schedule
1632543|NCT01989325|Drug|Dexamethasone, steroid; oral or intravenous|as indicated, per the carfilzomib prescribing information
1632544|NCT01989325|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|standard of care
1632554|NCT01989286|Other|Assessment|The posture, motor development and balance are going to be assessed.
1632555|NCT01989273|Device|Ultrasound of inferior vena cava|
1632556|NCT01989260|Device|Anti-adhesive gel|4mls of anti-adhesive gel coated to the randomized ovary
1632557|NCT01989247|Behavioral|Self-management programme|Seven weekly group-based sessions for people with anxiety and depressive symptoms
1632558|NCT01989234|Drug|YKP10811|
1632559|NCT01989234|Drug|Placebo|
1632560|NCT01989221|Drug|Sancuso®|Drug: Placebo
2011792|NCT02404584|Biological|Blood drawn for pharmacokinetic measures|"Blood will be drawn for pharmacokinetic measures between CmD15 and CmD28 of each sunitinib cycle.*
*Each patient will undergo several cycles of treatment with sunitinib during the monitoring period as part of routine care (= 18 months; the number of cycles per patient can vary, which is normal). Each cycle and each day of the cycle will be annotated with the letters C and D, respectively, followed by a number in chronological order. Thus C1D1 refers to to the first day of the first cycle; CmDn will be the nth day of the mth cycle."
1632562|NCT01989195|Drug|'SEEMORE' - MANGANESE-ENHANCED MRI CONTRAST REAGENT|"EACH SUBJECT UNDERWENT 2 CARDIAC MRI PROCEDURES: ONE WITH MAGNEVIST (GADOLINIUM), ONE WITH SEEMORE (MANGANESE) REAGENT
CARDIAC MRI USING STANDARD DOSE OF 0.2mMOL/KG MAGNEVIST IV (IN THE VEIN)
CARDIAC MRI USING SEEMORE REAGENT, DOSE: 0.35CC/KG IV (IN THE VEIN) 1 WEEK AFTER GADOLINIUM MRI"
1632563|NCT01989182|Device|Spiration Valve System|
1632564|NCT01989182|Other|Medical Management|
1632565|NCT01989169|Drug|Midazolam|
1632566|NCT01989169|Drug|SSP-004184SS|
2011793|NCT02404376|Drug|Exenatide|Intravenous administration of Exenatide
1632570|NCT01989143|Drug|PF-06480605|Subjects will receive single intravenous doses of 1, 3, 10, 30, 100, 300, 600 or 800 mg of PF-06480605 solution in a dose escalation format.
1632571|NCT01989143|Drug|Placebo|Subjects will receive single intravenous doses of PF-06480605 matching placebo solution in a dose escalation format.
1632572|NCT01989143|Drug|PF-06480605|Subjects will receive three subcutaneous doses of 30, 100, or 300 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
1632573|NCT01989143|Drug|Placebo|Subjects will receive three subcutaneous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
1632574|NCT01989143|Drug|PF-06480605|Subjects will receive three intravenous doses of 500 mg of PF-06480605 solution in a dose escalation format of one dose every 2 weeks (q2wk).
1632575|NCT01989143|Drug|Placebo|Subjects will receive three intravenous doses of PF-06480605 matching placebo solution in a dose escalation format of one dose every 2 weeks (q2wk).
1632576|NCT01989130|Device|Roche AMPLICOR CT/NG|
1632577|NCT01989130|Device|Cepheid Xpert CT/NG Test|
1632578|NCT01989091|Device|B-Lock|Antimicrobial Catheter Lock Solution
1632579|NCT01989091|Drug|Heparin 5,000 U/mL|Standard of Care Catheter Lock Solution
1632580|NCT01989078|Drug|Losartan|"Adults and Children >50 kg:
Those with systolic blood pressure (SBP) ≥ 100 mm Hg at entry will start with 50 mg of oral losartan once daily. At the week 2 visit, losartan will be increased to 100 mg daily.
Those with SBP <100 mm Hg at entry will start with 25 mg of oral losartan once daily. Participants will return after 1 week for titration to 50 mg daily, if tolerated (i.e. SBP not lower than pre-losartan measurement by 10 mm Hg or more), and after 2 weeks to monitor blood pressure.
Children <50 kg weight:
Treatment will start with 25 mg oral Losartan once daily given as a morning dose. At the 2 week visit, Losartan will be increased to 50 mg daily. The dose will be increased to 100 mg once a body weight of 50 kg is achieved."
1632581|NCT01989065|Behavioral|Lifestyle counseling|see arm description
1632582|NCT01989065|Behavioral|Text Messaging|See Arm Description
1632583|NCT01989052|Drug|CTO|
1632584|NCT01989052|Drug|Lomustine|
1632585|NCT01989026|Biological|BCG|
1632586|NCT01989013|Other|biweekly treatment intervention|
1632587|NCT01989000|Drug|Gadobutrol|0.1 ml/kg Gadovist is administered at 5 ml/s followed by a 15 ml saline flush
1632588|NCT01989000|Drug|[F-18]HX4|400 MBq [F-18]HX4, is administered in a single intravenous bolus injection, followed by a saline flush.
1632589|NCT01989000|Drug|Gemcitabine|1000 mg/m2/dose on day 1 and 8 in 2 cycles of 21 days (three weeks) each, one cycle before and one cycle after radiochemotherapy. During radiotherapy gemcitabine is administered at 1000 mg/m2/dose on day 1, 8 and 15.
1632590|NCT01989000|Radiation|Radiotherapy|A hypofractionated scheme of 15 fractions of 2.4 Gy in three weeks will be applied, combined with the second course of gemcitabine.
1632591|NCT01989000|Procedure|Pancreaticoduodenectomy|
1632592|NCT01988987|Other|Inpatient Postpartum GTT|Women with gestational diabetes will undergo a 75 gram, 2 hour, oral glucose tolerance test 2-4 days postpartum prior to hospital discharge, in addition to undergoing the standard of care, outpatient glucose tolerance test performed 6-12 weeks postpartum
1632593|NCT01988974|Behavioral|Alert for Atrial Fibrillation Program|Participants' baseline knowledge of AF symptoms, and attitudes and beliefs about AF will be assessed using the KABAFS, and patients will receive cognitive-behavioral training directed toward survey responses associated with delay of treatment. Training will incorporate the content developed by the American College of Cardiology Foundation (ACCF), and participants will receive education about how to recognize an irregular pulse, and how to record the pulse rhythm in a daily log. The PI/RN coordinator will review the completed KABAFS to assess knowledge deficits, and identify attitudes and beliefs about AF that may hinder early treatment-seeking.
1632594|NCT01988974|Behavioral|Healthy Sleep|Participants will receive a 45 minute face to face instruction about sleep hygiene
1632595|NCT01988961|Biological|Golimumab|SC injections
1632596|NCT01988948|Other|Various biological sampling|
1632597|NCT01988935|Behavioral|Prolonged Exposure|Weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders.
1632598|NCT01988935|Behavioral|Smoking Cessation|Weekly smoking cessation counseling (cognitive behavioral therapy) plus the nicotine patch to reduce withdrawal symptoms.
1632599|NCT01988922|Drug|ketamine|0.4 mg/kg oral racemic ketamine
1632600|NCT01988909|Drug|WR 279,396|Paromomycin + Gentamicin Topical Cream
1632601|NCT01988896|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose as specified via IV infusion.
1704298|NCT01433393|Drug|TAK-875|
1632602|NCT01988896|Drug|Cobimetinib|Cobimetinib will be administered orally at an escalating dose during Stage 1 and at RP2D during Stage 2.
1632603|NCT01988883|Drug|Placebo|Locking gelatin capsules filled with microcrystalline cellulose
1632604|NCT01988883|Drug|Modafinil|Modafinil is a wakefulness-promoting or psychostimulant drug. It will be administered as a single 200 mg oral tablet.
1632605|NCT01988883|Drug|Propranolol|Propranolol is a non-selective beta adrenergic antagonist.It will be administered as a single 20 mg oral tablet.
1632606|NCT01988870|Radiation|Intra-operative Radiation Therapy (IORT)|IORT is a form of APBI (accelerated partial breast irradiation) that allows for a high degree of dose homogeneity, exclusion of non-affected structures, and reduction of the volume of breast tissue exposed.
1632607|NCT01988857|Biological|Boostrix™|Single-dose administered intramuscularly in the deltoid region of non-dominant arm.
1632608|NCT01988844|Other|Assessment|The children with cerebral palsy were assessed. Different measures evaluating the upper limbs functionality are used.
1632609|NCT01988831|Drug|Propranolol hydrochloride|This intervention apply to Propranolol group
1632610|NCT01988831|Drug|Placebo pill|We use placebo pills alike propranolol commercial pills to ensure blindness of the subjects during the study.
1632611|NCT01988818|Device|Mepilex® Border Post-Op|wound dressing with Mepilex® Border Post-Op with Safetac®Technology, self-adherent soft silicone surgical dressing
1632612|NCT01988818|Device|standard wound dressing|standard wound dressing after hip-knee or spinal surgery
1632613|NCT01988805|Other|Blood Draw|
1632614|NCT01988792|Dietary Supplement|Human milk fortifiers|
1632617|NCT01988714|Other|(TCT) plus evidence-based SE|Targeted cognitive computer training (TCT) plus evidence-based SE in a community setting
1632618|NCT01988714|Other|(CG) plus evidence-based SE|(CG) plus evidence-based SE
1632619|NCT01988701|Other|Ancillary-Correlative|Blood samples are analyzed for activation status of B lymphocytes, T lymphocytes, and NK lymphocytes via flow cytometry, ELISA, ELISPOT, immunoblot, and microarray assays.
1632620|NCT01988688|Device|Deep Brain Stimulation (DBS)|Deep Brain Stimulation (DBS) bilaterally in area LC.
1632621|NCT01988675|Radiation|Whole Brain Irradiation|
1632622|NCT01988675|Radiation|Partial Brain Irradiation|
1632623|NCT01988675|Behavioral|Neuropsychological Testing|
1632624|NCT01988675|Behavioral|Quality of Life Questionnaire|
1632625|NCT01988675|Device|Magnetic Resonance Imaging (MRI) Assessments|MRI Assessments include Diffusion Tensor Imaging (DTI)and Gd-DTPA (Diethylenetriamine Pentaacetic Acid - a radioactive tracer injected into the patient and viewed on images).
1632626|NCT01988662|Procedure|Neovascular Age-related Macular Degeneration|Blood measurement
1632627|NCT01988649|Drug|Intranasal Oxytocin|Administration of intranasal Oxytocin
1632628|NCT01988649|Drug|Placebo (saline)|Administration of normal saline intranasally.
1632629|NCT01988636|Biological|PfSPZ Vaccine|Aseptic, purified, vialed, cryopreserved, radiation attenuated NF54 p.falciparum sporozoites produced by Sanaria, Inc.
1632630|NCT01988636|Drug|Placebo|Placebo
1632631|NCT01988623|Behavioral|Pivotal Response Treatment (PRT)|
1632632|NCT01988610|Drug|28 days treatment with Mifepristone.|
1632633|NCT01988597|Other|Dry eyes|
1632634|NCT01988584|Biological|Autologous Stem Cells|
1632635|NCT01988584|Other|Saline Infusion (Placebo)|
1632636|NCT01988571|Drug|Atorvastatin|40 mg tablet taken by mouth each morning for 24 months.
1632637|NCT01988571|Drug|Placebo|One placebo tablet taken each morning orally for 24 months.
1632638|NCT01988558|Drug|DL - Lactic Acid|Treated group to receive DL - Lactic Acid Syrup (Raspberry flavored)
1632639|NCT01988558|Dietary Supplement|Raspberry flavored syrup|Placebo group to receive Raspberry flavored Syrup
1632640|NCT01988545|Other|1,5 nmol/kg,GLP-1 sc injection|
1632641|NCT01988545|Other|1,5 nmol/kg GLP-1 9-36amide, sc injection|
1632642|NCT01988545|Other|Exendin-4 ;10 ug,sc injection|
1632643|NCT01988545|Other|saline|
1632644|NCT01988532|Other|No treatment given|Subject will only fill out a questionnaire
1632645|NCT01988519|Procedure|Closed gravity drain|passive tube drains (PFM Medical, Köln, Germany)
1632646|NCT01988519|Procedure|closed suction drain|BLAKE Silicon drains (Ethicon, USA)
1632647|NCT01988506|Drug|Interleukin 2|Induction period: repeated administration of low-dose IL-2 (1MUI/day, sc) during 5 consecutive days.Maintenance period: treatment with IL-2, 1MUI once every 15 days (except systemic lupus erythematosus's patients every 7 days) for 6 months
1632648|NCT01988493|Drug|MSC2156119J|MSC2156119J will be administered at a total dose range of 300-500 milligram (mg) orally once daily over a 21-day cycle until disease progression, intolerable toxicity or subject withdrawal. Dose adjustment will be done as per investigator's discretion based upon individual subject's tolerability.
1632649|NCT01988493|Drug|Sorafenib|Sorafenib will be administered at a dose of 400 mg orally twice daily over a 21-day cycle until disease progression, intolerable toxicity or subject withdrawal. Dose adjustment will be as per investigator's discretion based upon clinical circumstance, taking references to the description in the package insert.
1632650|NCT01988480|Procedure|Image-guided surgery|Placement on residual bone around the implant
1632651|NCT01988480|Procedure|Sinus lift surgery|Allograft bone
1632652|NCT01988467|Other|exposure to second hand smoking|The duration of the exposure to second hand smoke both days was for 20 minutes within a 250mgr/m3 concentration box room. A smoking machine was used, which mimics the smoker (up to 6 breaths per minute in tobacco volume 80ml for each inhalation). The exposure was sometimes with closed mouth and others with closed nose in random sequence.
1632653|NCT01988428|Drug|Ceftriaxone 2000 mg|Ceftriaxone 2000 mg
1632654|NCT01988415|Device|VSS-Rx1 OPM vs Commercial iDesign Treatment|Commercially available iDesign treatment planning software used to calculate the LASIK treatment profile vs VSS-Rx1 OPM (includes a modified algorithm designed to reduce the induction of postoperative spherical aberration).
1632655|NCT01988402|Drug|allopurinol|
1632656|NCT01988402|Drug|Placebo (sugar pill)|
1632657|NCT01988389|Dietary Supplement|whole apples (WA)|
1704299|NCT01433393|Drug|TAK-875|
2011794|NCT02404376|Other|Remote Ischemic Conditioning (RIC)|Remote ischemic conditioning with a cuff in the arm
2011795|NCT02404376|Drug|Placebo|Intrevenous administration of Placebo
1632661|NCT01988363|Procedure|GON injection at C2 location|GON will be identified at the novel, proximal C2 location on the symptomatic side via ultrasound guidance. Prior to injection, an independent examiner will perform a sensory exam of the involved dermatome. A 25 gauge spinal needle will be inserted into the symptomatic side after locating the GON via ultrasound at the C2 level. Subjects will be injected with treatment medication. Thirty minutes after injection, an independent examiner will test for anesthesia over the desired dermatome. VAS will be assessed pre-injection, 30 post-injection, 2 weeks post-injection and 1 month post-injection. The 2 week and 1 month assessments will be conducted by telephone.
1632662|NCT01988337|Device|Icon resin Infiltration|One tooth will randomly receive the infiltrating resin (Icon) while the other will receive a placebo. Teeth will be isolated with a rubber dam, the tooth surface cleaned with non-fluoride prophylactic paste and pumice. The Icon material will be applied following the manufacturer's instructions and light cured with S 10 curing light (3M ESPE, St Paul, MN). Output from the curing light will be measured and recorded weekly. The Icon infiltrating resin will be polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN). Subjects will be given a letter to take to their local dentist asking them not to treat the selected lesions without informing the investigator first.
1632663|NCT01988337|Other|mock|Teeth will be isolated with a rubber dam, the tooth surface cleaned with non-fluoride prophylactic paste and pumice. Syringes identical to the Icon materials will be supplied by DMG for the placebo procedure. The syringes will be filled with the solutions having the same consistency and color as the Icon material. The placebo material will be applied following the manufacturer's instructions and light cured with an S 10 curing light (3M ESPE, St Paul, MN). Output from the curing light will be measured and recorded weekly. The placebo material and the Icon infiltrating resin will be polished using interproximal finishing/polishing strips (Sof Lex, 3M ESPE, St Paul, MN).
1632664|NCT01988324|Other|FDHT-PET scan|
1632665|NCT01988324|Other|FES-PET scan|
1632666|NCT01988324|Other|CT-scan|
1632667|NCT01988324|Other|Bone scintigraphy|
1632668|NCT01988324|Other|Tumor biopsy|
1632669|NCT01988311|Drug|psilocybin|dose manipulation as described in the protocol
1632670|NCT01988298|Drug|Ibuprofen|Ibuprofen 400 mg each 8 hours
1632671|NCT01988298|Drug|Acetaminophen|Control group
1632672|NCT01988272|Device|SPECT/CT imaging|Patients will undergo scanning on the above system.
1632673|NCT01988259|Procedure|Bilateral approach for Laminoplasty|Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis
1632674|NCT01988259|Procedure|Unilateral approach for laminoplasty|Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.
1632675|NCT01988259|Procedure|Subperiosteal approach for foraminotomy|Unilateral subperiostal approach for single level foraminotomy
1632676|NCT01988259|Procedure|Transmuscular approach for foraminotomy|Unilateral transmuscular approach for single level foraminotomy
1632677|NCT01988246|Drug|Aflibercept|Patients will be assigned to treatment with 2 mg intravitreal Aflibercept injection (0.05 mL or 50 microliters) administered at the time of surgery (post cataract excision) or sham injection.
1632678|NCT01988246|Drug|Sham|Sham injection. No actual injection. No medication is used.
1632681|NCT01988220|Other|sensory retraining|
1632682|NCT01988220|Other|repeated sensory input|sensory stimulation without attentive learning focus
1632683|NCT01988207|Behavioral|Vocal Hygiene Training|Patients will receive education on how to care for their voices on three factors: 1) hydration, 2) exogenous inflammation control, and 3) abstinence of yelling and screaming.
1632684|NCT01988207|Behavioral|Flow Phonation Exercises|Three exercises are employed: gargling, cup bubble blowing, and stretch and flow (tissue blowing). Each is done without voicing, with voicing, and then with variations in pitch and verbalization.
1632685|NCT01988194|Device|Acupuncture|Acupuncture treatments will be provided in patient rooms up to four days per week for the duration of their hospital stay. Treatments will be consistent with how acupuncture is typically practiced: acupuncturists will diagnosis patients according to principles of traditional Chinese medicine (TCM); and treatments will be individualized to the patients. Duration of assessment, needle placement and retention will be 20-30 minutes.
1632686|NCT01988181|Device|BVM-UF biofeedback|The Fresenius 5008 uses an ultrasound and temperature monitor incorporated into the machine to detect ultrasonic velocity and temperature changes to derive the total protein concentration, which is a sum of total plasma proteins and hemoglobin. The relative blood volume is calculated at by dividing the initial concentration of total protein by the total protein concentration at any given time, multiplied by 100. The HD software is based on the critical blood volume entered at the beginning of the dialysis session for each individual patient. The UF rate is adjusted based on the changes in the relative blood volume to the patient's critical relative blood volume.
1632687|NCT01988181|Device|Fresenius 5008 HD machine (Fresenius Medical Care, Bad Homburg, Germany)|For an 8-week period, patients in the best clinical practice (control) phase will use their same prescription as the run-in phase, dialysate sodium of 138mmol/L, dialysate calcium of 1.25mmol/L, dialysate temperature of 36oC, and constant UF rate. BVM will be disabled in this group.
1632688|NCT01988168|Procedure|Suture closure|A running subcuticular suture is placed by taking horizontal bites through the papillary dermis on alternating sides of the wound. An absorbable suture is used and left in place until degraded and absorbed by the patient's tissues.
1632689|NCT01988168|Procedure|Staples closure|Surgical stapling devices re-appose skin edges with stainless steel or titanium staples. A second operator everts the wound skin edges while the operator applies staples along the incision. Staples can be removed on post-operative day 2 or 3, or delayed further according the surgeon preference based on patient characteristics.
1632729|NCT01987817|Biological|Placebo powder provided in capsules|Study product formulated to contain only inactive ingredients for use as defined in the protocol
1632730|NCT01987804|Drug|Oxytocin 100 i.u.|
1632731|NCT01987804|Drug|Oxytocin 400 i.u.|
1632732|NCT01987804|Drug|Placebo|
1632774|NCT01987518|Procedure|quality of life after different type of surgery|
2011796|NCT02403661|Procedure|Post surgical electrical stimulation|Post surgical electrical stimulation immediately after surgical nerve repair
1632690|NCT01988155|Other|Eccentric Exercise|Subjects in the eccentric exercise group will be instructed to perform the modified Alfredson eccentric protocol for insertional Achilles tendinopathy. To perform the eccentric exercise, subjects will be instructed to stand upright with one hand on the wall or a chair for support as needed. A heel raise exercise is then performed with the non-painful leg. Once in the elevated position, subjects are instructed to transfer all of their body weight to the painful leg and slowly lower their heel to the floor while keeping their knee extended. The eccentric exercise program will consist of 3 sets of 15 repetitions performed per session. Subjects will perform 2 sessions per day for a total of 12 weeks and a log will be kept to monitor compliance. In order to partially control for the effect of regular contact with a therapist, subjects in the control group will be contacted by telephone one time per week to discuss their progress with the program and address any questions they may have.
1632691|NCT01988155|Other|Astym|In addition to performing the same eccentric protocol as the eccentric exercise group, subjects in the Astym group will also be seen in the clinic two times per week. Astym treatment will be performed per the foot, ankle, and knee protocol as described in the Astym clinical manual. During the first visit each week, the eccentric exercise protocol will be orally reviewed to match the one time per week phone education received by the eccentric only group. Astym treatment will continue for up to six weeks but may be discontinued early if a subject scores 90 or above on the VISA-A. Subjects in the Astym group will be required to continue with the eccentric exercise protocol for the full 12 weeks even in Astym is discontinued early.
1632692|NCT01988142|Procedure|Ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
1632693|NCT01988129|Other|Sleep disorders education and screening|Firefighters were instructed to attend an education presentation as operations allowed which provided information on firefighter mortality, fatigue-related health hazards and discussed the importance of sleep, and also included strategies to improve sleep hygiene and how to use caffeine and naps effectively to promote alertness. Firefighters were then invited to complete a voluntary sleep disorders screening survey. This survey used validated, self-report screening tools for obstructive sleep apnea, moderate to severe insomnia, restless legs syndrome and shift work disorder. All of those who screened positive for a high risk of any sleep disorder were notified by letter as to their risk and provided with contact information for a partnering sleep clinic if they chose to follow-up.
1632694|NCT01988116|Drug|Oral Calcitriol 0.5 mcg once daily for 6 weeks|
1632695|NCT01988116|Drug|Placebo|
1632699|NCT01988090|Drug|800 IU Vitamin D Supplement|Standard Dose
1632700|NCT01988090|Drug|50,000 IU Vitamin D supplement|High Dose
1632701|NCT01988077|Biological|Adoptive cell transfer|Adoptive cell transfer
1632702|NCT01988077|Drug|Ipilimumab 5 MG/ML Injection [Yervoy]|2 treatments of Ipilimumab before transfer of TIL and 2 treatments of Ipilimumab after TIL
1632703|NCT01988064|Other|Face-to-face training|One-to-one face-to-face training on calculating the pulse rate and detecting abnormalities.
1632704|NCT01988064|Other|Group training|Group training using a tutorial film on calculating the pulse rate and detecting abnormalities.
1632705|NCT01988012|Biological|tocilizumab|162 milligram (mg) administered subcutaneously once weekly for 24 weeks
1632706|NCT01987999|Dietary Supplement|Acetogenins|
1632707|NCT01987986|Biological|Collagenase Clostridium Histolyticum|injectible intervention
1632708|NCT01987986|Biological|Placebo|
1632709|NCT01987973|Procedure|Partial Rotator Cuff Repair|This is the control group. The bursa will be debrided thoroughly and rotator cuff edges will be shaved down to stable tissue. If possible, rip-stop sutures will be employed to stabilize the tear. The subacromial space will then be thoroughly irrigated.
1632710|NCT01987973|Procedure|Partial Rotator Cuff Repair with Allograft Augmentation|Patients in this arm will undergo a partial rotator cuff repair (debridement), followed by an allograft augmentation. An Allopatch HD patch will be rehydrated in saline solution for 15 minutes. The patch is then sewn in place with braided polyester suture material. Multiple sutures, approximately 5 to 10 mm apart from one another will be used. The medial sutures are placed at least 3 cm medial to the tendon-bone attachment site. The patch is stretched to remove the manufacturing surface irregularities. The patch is then attached to the greater tuberosity at the tendon-bone attachment site with arthroscopic bone anchors. The subacromial space will then be thoroughly irrigated.
1632711|NCT01987960|Drug|Placebo|Once daily, tablets, orally
1632712|NCT01987960|Drug|Brexpiprazole|1 to 3 mg/day, once daily dose, tablets, orally
1632713|NCT01987947|Drug|Placebo|Two administrations by subcutaneous injection
1632714|NCT01987947|Drug|Quilizumab|Two administrations by subcutaneous injection
1632717|NCT01987895|Drug|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
1632718|NCT01987895|Drug|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily.
1632719|NCT01987895|Drug|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
1632720|NCT01987895|Drug|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
1632721|NCT01987856|Procedure|Blastocyst morphology|microscopic examination only
1632722|NCT01987843|Drug|MT-1303-Low|
1632723|NCT01987843|Drug|MT-1303-Middle|
1632724|NCT01987843|Drug|MT-1303-High|
1632725|NCT01987843|Drug|Placebo|
1632726|NCT01987830|Device|MRI-PET|"[11C] temozolomide for PET scan and a contrast dye for the MRI scan
Drawing blood to assess the radioactivity of [11C] temozolomide"
1632727|NCT01987830|Device|TMZ-PET|The PET scan will take approximately 90 minutes. You will receive one injection of [11C] temozolomide. Following the injection of the radioactive substance, blood samples will be taken from the second IV line.
1632728|NCT01987817|Biological|AR101 powder provided in capsules|Study product formulated to contain peanut protein at different dosage strengths for use as defined in the protocol
1632773|NCT01987518|Other|Procedure surgery behavioral and genetic diagnosis|Observational Study
1632733|NCT01987778|Other|Resistance training|Resistance training supervised and individualized by an experienced physiotherapist. First the relative load will be lighter during three weeks, thereafter the intensity and load will be increased over another 12 weeks.
1632734|NCT01987765|Drug|Relestat Ophthalmic Solution 0.05%|Relestat Ophthalmic Solution 0.05% prescribed as local standard of care in clinical practice.
1632735|NCT01987752|Drug|brimonidine tartrate/timolol maleate Ophthalmic Solution|brimonidine tartrate/timolol maleate (Combigan®) Ophthalmic Solution as per local standard of care in clinical practice.
1632736|NCT01987739|Drug|200 mg almorexant|
1632737|NCT01987739|Drug|400 mg almorexant|
1632738|NCT01987739|Drug|1000 mg almorexant|
1632739|NCT01987739|Drug|20 mg zolpidem|
1632740|NCT01987739|Drug|40 mg zolpidem|
1632741|NCT01987739|Drug|placebo|
1632742|NCT01987726|Other|cytology specimen collection procedure|Undergo collection of CTCs for NGS and FMI testing, respectively.The most recent tumor sample collected from the patient with enough tissue to perform NGS testing will be selected. Tumor from a metastatic or recurrent cancer lesion is preferred but not required. Tumor collection is for standard of care purposes and thus not detailed in this protocol.For each tissue specimen, a representative H&E stained section will be evaluated by a qualified pathologist to confirm the histopathological diagnosis of cancer and to make a quantitative estimate of the proportion of the specimen that is tumor-related cells and the proportion that is non-tumor cells.
1632743|NCT01987726|Other|laboratory biomarker analysis|2 tubes of 7.5 mL blood samples each will be collected at time tumor tissue is sent to FMI and sent to Cynvenio Biosystems, Inc for CTC isolation and analysis. Patient CTCs will be recovered using Cynvenio CTC flow cell technology (Cynvenio Biosystems, Inc.) and enumerated using a combination of CD45, DAPI and cytokeratin staining.1 DNA will be isolated from CTCs and amplified using Φ-29 whole genome amplification (GE Healthcare). Sequencing to be performed by FoundationOne™ protocol.
1632744|NCT01987713|Behavioral|lifestyle intervention|the intervention strength (amount, frequency, duration) including a reduction in energy intake and an increase in physical activity level will be reported. The guidance/description of the treatment protocol, preparation and training of intervener, techniques to retain the research subjects will be covered to prevent the lack of intervention integrity. Besides, the schooler admitted in a university hospital will be invited to explore their health lifestyles and receive the intervention.
1632745|NCT01987700|Device|FLEX-HD|
1632746|NCT01987700|Device|Strattice|
1632747|NCT01987687|Behavioral|Exercise|Exercise at 55% of maximum power output for 30 min.
1632748|NCT01987687|Behavioral|Rest|Rest for 30 min
1632749|NCT01987687|Behavioral|Delay|Delay between exercise and OGTT
1632750|NCT01987674|Dietary Supplement|Pre-meal protein drink|
1632751|NCT01987674|Other|Water drink|
1632752|NCT01987661|Device|BIPAP ST|non invasive ventilation, individually titrated for each patient, if necessary combined with oxygen, to improve hypercapnic respiratory failure.
1632753|NCT01987661|Device|Airtrap|"Addional to the individally titrated BiPAP ventilation parameters the function AirTrap Control is added.
AirTrap Control helps to prevent dynamic hyperinflation and makes it possible for VENTImotion 2 to automatically regulate to the best frequency and expiration time."
1632754|NCT01987648|Procedure|Elective Craniotomy Patients|Patients who receive an elective craniotomy (no biopsy, no awake surgery, no re-operation)
1632755|NCT01987635|Device|MEMO 3D ring|The experimental MEMO 3D ring is placed.
1632756|NCT01987635|Device|Standard use of rigid ring.|The rigid ring is placed, which is standard procedure.
1632757|NCT01987635|Procedure|3D Echocardiography|
1632758|NCT01987622|Procedure|Acupuncture|The patients in this group will receive individualized acupuncture prescribed by a certified Korean Medicine Doctor (KMD) with at least three years of clinical experience. The acupuncture formulas will be determined based on the individual patient's symptoms and at the KMD's discretion. The acupuncture treatment will be applied one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). Acupuncture will be manually stimulated at first, and then electrical stimulation will be allowed at the KMD's discretion. Retention time will be equal to or less than 20 minutes. Examples of acupuncture points to be used might include LI4, LI11, TE5, SI3, TE3, ST36, SP6, SP9, LR3, GB34, Gb39, BL40, BL57, EX-B2, and BL23.
1632759|NCT01987622|Procedure|Usual care|Usual care consists of patient education for a healthier lifestyle, including diet, exercise, self-management of symptoms, and the use of other treatments as needed. Participants will receive a three-page leaflet of patient education material. Optional regular physical therapies, including interferential current therapy (ICT) and local heat application, will be provided only for the control group at the participants' request . Physical therapy will be provided one to three times a week for six weeks (a total of 12 sessions and an additional four sessions are allowed). All kinds of conservative interventions for lumbar spinal stenosis, including analgesics and non-study physical treatments,will be allowed. However, surgical treatments, non-study acupuncture, or herbal medicine will not be allowed.
1632760|NCT01987609|Drug|Hylenex|
1632761|NCT01987609|Drug|Normal Saline|
1632762|NCT01987596|Biological|filgrastim|Given SC once daily starting on day 1 after chemotherapy in Arm I (fixed) and on any day when ANC drops below 1000/mcl in Arm II (flexible)
1632763|NCT01987583|Procedure|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin.
1632764|NCT01987583|Other|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
1632765|NCT01987570|Drug|Allopurinol|
1632766|NCT01987570|Drug|Placebo|
1632767|NCT01987557|Behavioral|rate group|walking with a high cadence (steps per minute)
1632768|NCT01987557|Behavioral|magnitude treadmill group|
1632769|NCT01987557|Behavioral|regular treadmill walking|
1632770|NCT01987544|Other|Ergometer Training|
1632771|NCT01987544|Other|Motivation|
1632772|NCT01987531|Other|left ventricular epicardial pacing lead|
1632775|NCT01987505|Drug|rituximab [MabThera/Rituxan]|1400 mg injected subcutaneously (SC)
1632776|NCT01987492|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injections every 4 weeks at dose and schedule described in arm description.
1632777|NCT01987492|Drug|Placebo|Placebo matching to lebrikizumab will be administered as SC injections every 4 weeks as per schedule described in arm description.
1632778|NCT01987479|Drug|Non-Biologic DMARDs|Treatment with non-biologic DMARDs, at a stable dose that was initiated at least 4 weeks prior to baseline, is permitted during the study and is at the investigator's discretion.
1632779|NCT01987479|Drug|Tocilizumab|Tocilizumab 162 mg will be administered once a week by SC injection and as a single fixed dose, irrespective of body weight, for the treatment duration of 24 weeks.
1632780|NCT01987479|Drug|Methotrexate|Methotrexate will be administered per investigator's discretion.
1632781|NCT01987466|Biological|Serum NGAL level|Investigators will check the plasma NGAL level after 4 hour from resuscitation. The plasma NGAL level is measured in ng/mg
1632782|NCT01987453|Drug|LDV/SOF|Tablet(s) administered orally once daily
1632783|NCT01987453|Drug|RBV|"Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
Participants in the LDV/SOF+RBV 24 weeks group will dose adjust RBV according to hemoglobin and renal status as stated in the RBV package insert."
1632784|NCT01987440|Drug|lubricating gel|
1632785|NCT01987427|Drug|lorcaserin + phentermine placebo|lorcaserin 10 mg BID + phentermine placebo BID
1632786|NCT01987427|Drug|lorcaserin + phentermine-HCl + phentermine placebo|lorcaserin 10 mg BID + phentermine-HCl 15 mg QD + phentermine placebo QD
1632787|NCT01987427|Drug|lorcaserin + phentermine-HCl|lorcaserin 10 mg BID + phentermine-HCl 15 mg BID
1632788|NCT01987414|Behavioral|occupational therapy task-oriented approach|It is a standard treatment in occupational therapy for persons post-stroke or other neurological conditions. It is an approach that emphasizes client-centered, goal-directed, and functional training for restoration of life roles.
1632789|NCT01987414|Device|Forearm rotation orthosis|The forearm rotation orthosis is made of Latex-free material and is a custom-molded orthosis designed to assist forearm rotation without limiting functional elbow flexion and extension.
1632790|NCT01987414|Other|No treatment|Participants will maintain their daily routines during the no treatment period.
1632791|NCT01987388|Other|High Intensity Exercise|While in the calorimeter, each subject will complete four bouts of exercise. Each bout is approximately 5 minutes in duration at a predetermined speed and elevation to achieve an intensity of 85% of VO2 max according to their fitness level test described previously. Subjects then sit quietly until either the next meal or the next exercise bout.
1632792|NCT01987388|Other|Low Intensity Exercise|While in the calorimeter, each subject completes one exercise bout approximately 40 minutes in duration, at a predetermined speed and elevation, to achieve an intensity of 65% of VO2 max. Subjects then sit quietly until the next meal.
1632793|NCT01987388|Other|High Carbohydrate Beverage|Participants will consume a high carbohydrate beverage (750 g) with the following composition: 2.13 MJ/d, 113g carbohydrate, 4g fat, 6g protein.
1632794|NCT01987388|Other|High Fat Beverage|Participants will consume a high fat beverage (750 g) with the following composition: 2.11 MJ/d, 8g carbohydrate, 50g fat, 7g protein.
1632795|NCT01987375|Drug|Cetuximab-IRDye800|a single dose of the study drug following a single loading dose of unlabeled cetuximab
1632796|NCT01987362|Drug|RO6870810|Participants will receive RO6870810 at different planned doses with a starting dose of 0.03 mg/kg to a maximum dose of 0.85 mg/kg SC on Days 1 to 14 in a 21-day treatment cycle or on Days 1 to 21 in a 28-day treatment cycle.
1632797|NCT01987349|Biological|Fluzone® (intramuscular)|Licensed seasonal trivalent inactivated influenza vaccine (IIV3)
1632798|NCT01987349|Biological|FluMist® (intranasal)|Licensed trivalent seasonal live attenuated influenza vaccine (LAIV3)
1632799|NCT01987323|Drug|Subconjunctival injection of liposomal latanoprost|
1632800|NCT01987310|Drug|atorvastatin|atorvastatin 20 mg per day for 6 months
1632801|NCT01987310|Behavioral|lifestyle counseling|lifestyle modification by dietician counseling and follow up
1632802|NCT01987297|Drug|ATRA+arsenic|experimental
1632803|NCT01987297|Drug|ATRA+chemo|control
1632804|NCT01987284|Drug|SER100|
1632805|NCT01987284|Drug|Placebo|
1632806|NCT01987271|Device|Noninvasive Ventilation|A randomized plan define the order in which patients would execute the 6MWT, with or without NIV.
1632807|NCT01987258|Behavioral|Interval Walking|
1632808|NCT01987258|Behavioral|Continuous walking|
1632809|NCT01987232|Drug|Carfilzomib|Administered by intravenous infusion.
1632810|NCT01987232|Drug|Carboplatin|Administered by intravenous infusion.
1632811|NCT01987232|Drug|Etoposide|Administered by intravenous infusion.
1632812|NCT01987219|Drug|Albuterol-sulphate|Beta-2-adrenergic agonist 2.5 mg 3 cc inhalation Peak effect 15 - 30 mins. Mean duration of effect 3 hours
1632813|NCT01987219|Drug|Ipratropium-bromide|Anti-cholinergic 500 mcg 3 cc inhalation Peak effect 30 - 90 mins. Duration of effect 2 - 4 hours.
1632814|NCT01987219|Other|placebo|Saline solution 3 cc NA
1632815|NCT01987206|Device|MPC control algorithm|
1632816|NCT01987206|Device|PID control algorithm|
1632817|NCT01987167|Drug|ACTHAR|Injectable Gel
1632818|NCT01987154|Other|Marketed cow milk-based premature infant formula|
1632819|NCT01987154|Other|Marketed extensively hydrolyzed casein infant formula|
1632820|NCT01987141|Other|EMR Intervention|Electronic medical record flag/notification in the patient's chart
1632821|NCT01987128|Procedure|Intraneural injection|BBraun Ropivacaine 1% 12ml injection divided in each sciatic components under echographic guidance with a PAJUNK SonoPlex 22G needle.
1632822|NCT01987128|Procedure|Extraneural injection|BBraun Ropivacaine 1% 12ml extraneural injection around sciatic nerve under echographic guidance with a PAJUNK SonoPlex 22G needle.
1632823|NCT01987128|Drug|Ropivacaine|
1632824|NCT01987128|Device|PAJUNK SonoPlex 22G needle.|
1704300|NCT01433393|Drug|Placebo|
1632825|NCT01987115|Procedure|Fascial manipulation|Group will receive fascial manipulation at 3 centers of coordination (C.C) at: 1. C.C above the pronator teres muscle. (M.F unit of INTRA-CUBITUS), 2. C.C above proximal part of pronator quadratus muscle, between the palmaris longus and the flexor carpi radialis tendons (M.F unit of INTRA-CARPUS), 3. C.C in the mid-palmar region between metacarpus 3-4 (M.F unit of INTRA-DIGIT).4. C.C. over the muscle belly of Ext. Digit and Ext. Pollicis Longus (M.F unit of EXTRA-CARPUS).
1632826|NCT01987115|Procedure|Traditional physiotherapy|Group will receive U.S. treatment delivered to the A1 pulley area (3 Megahertz, over 1cm², for 5 minutes), Metacarpophalangeal and Proximal interphalangeal joint mobilization (for 5 minutes), eccentric stretching, and self exercises at home (self-stretch and self-massage).
1632827|NCT01987102|Drug|Leucovorin|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug Calcium Folinate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.
All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
1632828|NCT01987102|Drug|[6R] 5,10-methylenetetrahydrofolate|"The enrolled patients will be treated according to the MAP schedule and will receive the study drug [6R] 5,10-methylenetetrahydrofolate commencing 24 hours after the administration of HDMTX and then every 6 hours (q6h) thereafter until the S-MTX levels are ≤ 0.1 µmol/L, in accordance with COG management recommendations.
All patients will receive standard o care (SOC) in the two (2) first HDMTX courses and [6R] 5,10-methylenetetrahydrofolate in the two (2) following courses. Patients will be enrolled in two (2) [6R] 5,10-methylenetetrahydrofolate® dose cohort groups: with [6R] 5,10-methylenetetrahydrofolate start dose of 15 mg/m2 (i.e. the same as for SOC rescue) the first cohort will be administered, and 7.5 or 30 mg/m2 in the second cohort."
1632829|NCT01987089|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Eight Session CBT-I: Cognitive Behavioral therapy is conducted in 8 individual sessions with the study clinician.
1632830|NCT01987076|Drug|Prednisone|"Prednisone:
Day 0 to day 30: 0.5mg/kg/day Day 30 to day 180: doses decreasing from 15 to 25% every 15 days until Day75 and 10 to 15% every 15 days."
1632831|NCT01987076|Drug|Clobetasol|Clobetasol: cream 0.05% Day 0 to day 30: 30 grams per day Day 30 to day 45: 20 grams per day Day 45 to day 60: 20 grams every other day Day 60 to day 120: 20 grams biweekly Day 120 to day 150: 20 grams one a week
1632832|NCT01987050|Drug|Intranasal oxytocin|
2011797|NCT02404285|Drug|Next Science Acne Gel|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
1632834|NCT01987024|Device|Actim Partus® test|
1632835|NCT01987024|Other|usual procedure|
1632836|NCT01987011|Biological|MG1109|
1632837|NCT01987011|Biological|Placebo|
1632838|NCT01986998|Drug|Methylprednisolone 1250 mg/24h x3 days|Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)
1632839|NCT01986998|Drug|Oral Methylprednisolone 625 mg/24h x3 days|Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
1632840|NCT01986985|Device|PET/MRI system|Compared to PET CT
1632841|NCT01986972|Other|Toothbrushing With Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
1632842|NCT01986972|Other|Toothbrushing Without Dentifrice|The participants were instructed to interrupt any chemical and/or mechanical oral hygiene procedure for 72 hours. Then, dental plaque was stained by a 2% erithrosin solution, followed by a mouth rinsing with water for 1 minute. Next, the set of dental quadrants (1-3 and 2-4) were randomly allocated to experimental groups by the flip of a coin. One of the sets was brushed with multi bristle brush without the use of dentifrice and the second set was brushed with multi bristle brush using dentifrice. Toothbrushing was performed by the individual's regular technique timed. Two minutes was used for each set. After toothbrushing, the dental biofilm was again stained and evaluated by the same examiner, who was blind to the quadrants brushed with or without dentifrice.
1632843|NCT01986959|Procedure|With Periodontal dressing|After surgery,the dressing was mixed with a sterile spatula on a sterile glass plate following the manufacturer's instructions (2 cm of each paste measured with a sterile endodontic ruler). Coe-PakTM Regular was the dressing employed. Mixing and placement were performed only by the specialists in periodontics to ensure standardization. The dressing was inserted into the surgical wounds and molded to the necessary shape after setting sufficiently. The removal of the periodontal dressing was done after seven days.
1632844|NCT01986959|Procedure|Without Periodontal dressing|The dressing was not inserted.
1632845|NCT01986946|Other|Epidural Catheter - Dilaudid|Placement of an epidural catheter to administer local anesthetic and opioid (dilaudid) to the epidural space will be studied as compared to use of intravenous opioid (dilaudid) for pain control following lumbar spine fusion surgery.
1632846|NCT01986946|Drug|Dilaudid|Patients in this arm will receive intravenous patient-controlled opioid analgesia (Dilaudid).
1632847|NCT01986933|Drug|nemolizumab (CIM331)|
1632848|NCT01986933|Other|Placebo|
2011798|NCT02404285|Drug|Vehicle|Subjects will be instructed to apply a thin layer of the product to the entire face every evening after washing with Cetaphil cleanser and gently patting the skin dry. Product should not be applied around the eyes or near the mucous membranes. No other acne treatments will be applied to the face during study participation. Hands should be washed following application of study gel.
1632854|NCT01986894|Drug|Placebo|Single oral dose of Placebo
1632855|NCT01986894|Drug|Pomalidomide|Single oral dose of 4 mg pomalidomide
1632856|NCT01986894|Drug|Pomalidomide|Single oral dose of 20 mg pomalidomide
1632857|NCT01986894|Drug|Moxifloxacin|Single oral dose of 400 mg moxifloxacin tablet
1632858|NCT01986881|Drug|Ertugliflozin|Oral, once daily, up to 6.1 years
1632859|NCT01986881|Drug|Placebo|Matching placebo to ertugliflozin administered orally once daily for up to 6.1 years
1632860|NCT01986868|Other|Coronary MR Angiography (CMRA)|Stable patients who have undergone a clinically indicated CCTA study for suspected Coronary Artery Disease will undergo a research CMRA with contrast (Multihance or Optimark)total dose of up to 0.2 mmol/kg IV. Possible administration of oral beta-blocker (metoprolol)intravenous doses of 5mg IV metoprolol may be given every 2 minutes up to a maximal dose of 15 mg IV.
1632861|NCT01986855|Drug|Ertugliflozin 5 mg|Ertugliflozin, oral, 5 mg tablet once daily for 52 weeks
1632862|NCT01986855|Drug|Placebo 5 mg|Placebo to ertugliflozin, oral, tablet, 5 mg tablet once daily for 52 weeks
1632863|NCT01986855|Drug|Ertugliflozin 10 mg|Ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
1632864|NCT01986855|Drug|Placebo 10 mg|Placebo to ertugliflozin, oral, tablet, 10 mg tablet once daily for 52 weeks
1632865|NCT01986842|Dietary Supplement|Protein diet|Subjects will receive either a low protein or a high protein diet for 14 days. High protein will be realized with protein supplements.
1632866|NCT01986829|Device|Microwave ablation|"Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.
Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
1632867|NCT01986829|Device|Cryoablation|"Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.
Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction."
1632868|NCT01986829|Device|Radiofrequency ablation|-Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.
1632869|NCT01986829|Other|BPI-Short form|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
1632870|NCT01986829|Other|FACT-G7|-Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
1632871|NCT01986803|Device|Percutaneous Coronary Intervention|"Implanting a device (Xience Xpedition stent or Abbott Vascular ABSORBTM everolimus eluting bioresorbable vascular scaffold system (BVS) to open a diseased coronary artery by going to the coronary artery subcutaneously through the arteries from the radial or femoral artery access point."
1632872|NCT01986790|Behavioral|Plain Language|
1632873|NCT01986790|Behavioral|Plain Language + Visuals|
1632874|NCT01986790|Behavioral|Plain Language + Narratives|
1632875|NCT01986777|Drug|lisdexamfetamine|
1632876|NCT01986777|Drug|Placebo|The placebo capsules will be filled with lactose.
1632877|NCT01986764|Drug|Lisdexamfetamine|
1632878|NCT01986764|Drug|Estradiol|
1632879|NCT01986764|Drug|Placebo|Placebo capsules will be filled with lactose powder.
1632880|NCT01986751|Drug|Clonidine|
1632881|NCT01986751|Drug|ropivacaine|
1632882|NCT01986738|Radiation|Standard Radiation Therapy|Radiotherapy will be planned and delivered according to institutional standard of care.
1632883|NCT01986738|Device|Active Breathing Control Device (ABC)|
1632884|NCT01986738|Device|Computed Tomography Scan (CT)|
1632885|NCT01986725|Behavioral|standardized care (Intervention I)|During treatment and routine follow-up consultations, patients randomized to standard care will be provided with usual care and a predefined set of additional written information leaflets about supportive care options in the early treatment phase designed for the study.Usual care includes treatment during hospitalization by the gynecologist and the nurses according to the existing guidelines. At each follow-up visit, the gynecologist will conduct a physical examination. The follow-ups include also treatment of adverse effects of the therapy and rehabilitation.
1632886|NCT01986725|Behavioral|Standardized care + WOMAN-PRO II program (Intervention II)|This intervention is in addition to standard care. Nurse-led follow-up consultations with the WOMAN-PRO II program complementary to physician appointments have the goal to support women's self-management abilities in order to deal with occurring symptoms and related distress. Content of the WOMAN-PRO II program designed for this study is summarized in a handbook for professionals including patient clinical pathways and nurse interventions, supplemented by a patient booklet (paper based and electronic version) with tailored information according to patients' needs. The program includes five consultations with an approximate total duration of two hours.
1632887|NCT01986699|Procedure|Laparoscopic Assisted Polypectomy|
1632888|NCT01986673|Drug|5% Sildenafil Cream (SST-6006)|5 % Sildenafil Cream
1632889|NCT01986673|Drug|Oral Sildenafil 50 mg|Oral Sildenafil 50 mg
1632890|NCT01986660|Drug|Ibuprofen Cream (SST-0225)|
2011799|NCT02402270|Drug|NuLYTELY® (PEG 3350)|
2011800|NCT02402270|Drug|ECP-019|
1711397|NCT01376297|Drug|Palonosetron|
2011801|NCT02402270|Drug|MoviPrep® (PEG 3350)|
1632893|NCT01986634|Device|Laser Treatment|Patient will have split face laser resurfacing. One side of the face will be treated with a standardized single depth laser peel. The other side of the perioral area will be treated with variant, deeper treatment to perioral rhytids.
1632894|NCT01986608|Drug|Lacosamide infusion|"Strength: 10 mg/mL for infusion
Form: solution for infusion
Dosage: 200 mg, single dose
Duration: 30-minute infusion or 60-minute infusion"
1632895|NCT01986608|Drug|Lacosamide oral|"Strength: 200 mg
Form: film-coated tablet
Dosage: 200 mg, single dose
Duration: single oral intake"
1632896|NCT01986582|Drug|Oxymetazoline|Intranasal application
1632897|NCT01986582|Other|Hydroxyl-propyl-methyl cellulose powder|Intranasal application
1632898|NCT01986582|Other|Placebo (lactose powder)|Intranasal application
1632899|NCT01986569|Drug|[18F]fluoroestradiol (FES)|[18F]FES PET/CT will be performed 90 min (± 10 min) after administration of [18F]FES. Patients will undergo core needle biopsy or surgery within 15 days after [18F]FES PET; or patients will undergo core needle biopsy within 30 days before [18F]FES PET. Experienced pathologists will determine metastatic/recurrent disease, and tumor histology including IHC. Patient will undergo surgery, radiation therapy or systemic therapy according to the results of staging workup, histology and biomarkers.
1632900|NCT01986556|Drug|Lesinurad 400 mg (Site 1)|
1632901|NCT01986556|Drug|Lesinurad 400 mg (Site 2, Lot A)|
1632902|NCT01986556|Drug|Lesinurad 400 mg (Site 2, Lot B)|
1632903|NCT01986543|Drug|drug administration|
1632904|NCT01986530|Dietary Supplement|Boost|After an overnight fast, blood samples will be obtained before as well as 30 min after standardized mixed meal ingestion
1632905|NCT01986530|Other|Aerobic exercise|After an overnight fast and rest, blood samples will be obtained before as well as 30 min after aerobic exercise
1632906|NCT01986517|Behavioral|No feedback|Therapists will receive no feedback.
1632907|NCT01986517|Behavioral|Feedback after every fourth session|
1632908|NCT01986491|Drug|JNJ 39393406 30 mg solid X|Participants will receive JNJ 39393406 30 mg solid X formulation as a tablet orally (by mouth).
1632909|NCT01986491|Drug|JNJ 39393406 30 mg solid Y|Participants will receive JNJ 39393406 30 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
1632910|NCT01986491|Drug|JNJ 39393406 120 mg solid X|Participants will receive JNJ 39393406 120 mg solid X formulation as a tablet orally (by mouth).
1632911|NCT01986491|Drug|JNJ 39393406 120 mg solid Y|Participants will receive JNJ 39393406 120 mg solid Y formulation as a hard gelatin capsule orally (by mouth).
1632912|NCT01986491|Drug|JNJ 39393406 30 mg solution|Participants will receive JNJ 39393406 30 mg/mL solution orally (by mouth).
1632913|NCT01986465|Drug|Depomedrol|
1632914|NCT01986465|Drug|Placebo|
1632915|NCT01986452|Device|CPAP therapy|
1632916|NCT01986452|Other|Support|
1632917|NCT01986426|Drug|LTX-315 consecutive lesions|"Dose escalation:
Cohort 1: 2 mg twice per day (4 mg) Cohort 2: 3 mg twice per day (6 mg) Cohort 3: 4 mg twice per day (8 mg)"
1632918|NCT01986426|Drug|LTX-315|"Dose escalation:
Cohort 1: 3 mg per injection Cohort 2: 4 mg per injection Cohort 3: 5 mg per injection"
1632919|NCT01986426|Drug|LTX-315 + ipilimumab|Cohort 1: 3 mg per injection + 3 mg/kg ipilumumab Cohort 2: 4 mg per injection + 3 mg/kg ipilumumab Cohort 3: 5 mg per injection + 3 mg/kg ipilumumab
1632920|NCT01986426|Drug|LTX-315 + pembrolizumab|Cohort 1: 3 mg per injection + 200 mg pembrolizumab Cohort 2: 4 mg per injection + 200 mg pembrolizumab Cohort 3: 5 mg per injection + 200 mg pembrolizumab
1632921|NCT01986413|Device|pressure controlled ventilation BIPAP ST|spontaneous timed pressure controled bilevel ventilation
1632922|NCT01986413|Device|volume assured pressure support IVAPS|intelligent volume assured Pressure Support
1632923|NCT01986413|Device|NIV|Patients with COPD and chronic hypercapnic respiratory failure will spent two nights on NIV, one with spontaneous timed pressure controlled bilevel ventilation (BiPAP ST) and one with the advanced mode of intelligent volume assured pressure support (IVAPS). Patients will spend the treatment nights in randomized order under polysomnographic surveillance, including transcutaneous PCO2 measurement.
1632924|NCT01986400|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
1632925|NCT01986387|Behavioral|Virtual Peer-to-Peer Support Mentoring|The mentorship program will encourage mentored participants to develop and engage in self-management and transition skills and support their practice of these skills. The mentors will present information to mentored participants in a monitored virtual interaction using Skype for 8 weeks (10 total Skype sessions of 30-60 minutes each) to encourage participation in skill building tailored to their needs. All mentors will complete a paid 2.5 day training course and will be supported throughout the duration of the study (consultations with research staff to deal with unforeseen concerns). Mentored participants will complete online outcome measures prior to randomization (T1) and upon study completion (T2).
1632926|NCT01986374|Drug|HCG is introduced|must have good blastocysts
1632927|NCT01986361|Drug|flurbiprofen|A single flurbiprofen 8.75 mg lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
1632928|NCT01986361|Drug|placebo|A single placebo lozenge which also contains 1 mg of menthol in its vehicle base for flavour and taste purposes (blinding). Lozenge is sucked until dissolved, and not chewed, bit or swallowed.
1632929|NCT01986348|Drug|Selinexor|One cycle is 28 days (4 weeks).
1632930|NCT01986335|Biological|DTP/HB/Hib Vaccine|DPT/HB/Hib vaccine (Bio Farma)
1632931|NCT01986322|Biological|DTP/HB/Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
1632932|NCT01986322|Biological|DTP/HB and Hib vaccine|Dosage equal to 0.5 mL administered intramuscularly
1632933|NCT01986309|Drug|Lidocaine|Bolus 1.5 mg/kg over 5 minutes, then an infusion of 2 mg/kg/h
1632934|NCT01986309|Drug|Normal saline|Sodium Chloride 0.9% infusion
1632935|NCT01986296|Device|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
1632936|NCT01986283|Drug|Capsule|Taken once
1632937|NCT01986283|Drug|PF-00345439|40 mg capsule swallowed whole, taken once
1632938|NCT01986283|Drug|PF-00345439|40 mg capsule chewed, taken once
1632939|NCT01986283|Drug|oxycodone|40 mg solution, taken once
1632940|NCT01986270|Drug|Placebo|Matching Placebo
1632941|NCT01986270|Drug|Eletriptan 40 mg|40mg oral
1632942|NCT01986270|Drug|Eletriptan 80 mg|80mg oral
1632943|NCT01986270|Drug|Sumatriptan 25 mg|25mg oral
1632944|NCT01986270|Drug|Sumatriptan 50 mg|50mg oral
1632945|NCT01986257|Behavioral|Emotion Regulation Group Therapy (ERGT).|
1632946|NCT01986231|Drug|Glucagon|Subjects will receive 8 doses of glucagon, each dose will be 2.0 mcg per kg. Glucagon will be reconstituted immediately prior to administration and each dose will be administered subcutaneously via syringe/needle. The first glucagon dose is at hour 17, second at hour 22, third at hour 24, fourth at hour 27, fifth at hour 29, sixth at hour 31, seventh at hour 33, eighth at hour 35.
1632947|NCT01986218|Drug|BMS-986115|
1632948|NCT01986205|Combination Product|Hyperbaric Oxygen|Hyperbaric oxygen (USP oxygen >99%) delivered in a hyperbaric chamber pressurized to 1.5 atmospheres absolute.
1632949|NCT01986205|Combination Product|Pressurized Air (1.2)|Room air delivered in a hyperbaric chamber pressurized to 1.2 atmospheres absolute.
1632950|NCT01986205|Combination Product|Minimal pressure air|Room air delivered in a hyperbaric chamber with minimal pressurization.
1632951|NCT01986192|Drug|rivaroxaban|
1632952|NCT01986192|Drug|Warfarin|
1632953|NCT01986179|Other|Telephone Interpretation|Professional interpretation provided over the phone by a national network of certified medical interpreters
1632954|NCT01986179|Other|Video Interpretation|Professional interpretation provided over video by a national network of certified medical interpreters
1632955|NCT01986166|Drug|Cobimetinib|In Stage 1, cobimetinib will be administered at a starting dose of 80 mg q2w. The doses will be escalated to identify MTD. In Stage 2, participants will receive cobimetinib at the established MTD.
1632956|NCT01986166|Drug|MEHD7945A|MEHD7945A will be administered as IV infusion at a dose of 1100 mg q2w until disease progression or unacceptable toxicity.
1632957|NCT01986140|Device|PAXMAN Orbis Scalp Cooler|Treatment with Orbis scalp cooling cap
1632958|NCT01986140|Other|Control No treatment|No treatment to prevent hair loss
1632959|NCT01986127|Drug|Adalimumab|single intralesional administration during endoscopy process
1632960|NCT01986127|Drug|placebo|single intralesional administration during endoscopy
1632961|NCT01986114|Drug|SM-13496 (lurasidone HCl)|SM-13496 20-120mg
1632962|NCT01986101|Drug|SM-13496 (lurasidone HCl)|SM-13496 20-60mg, SM-13496 80-120mg
1632963|NCT01986101|Drug|Placebo|
1632964|NCT01986088|Drug|Placebo|matching placebo
1632965|NCT01986088|Drug|Eletriptan 40 mg|40mg oral
1632966|NCT01986088|Drug|Eletriptan 80 mg|80mg oral
1632967|NCT01986088|Drug|Sumatriptan 50 mg|50mg oral
1632968|NCT01986088|Drug|Sumatriptan 100 mg|100mg oral
1632969|NCT01986075|Behavioral|Computer-assisted behavior therapy|TES is a computer-assisted therapy program delivered via effective informational and multimedia technologies, includes 32 core interactive, multimedia modules, beginning with basic cognitive behavioral relapse prevention skills (e.g. drug refusal skills) and moving on to improving psychosocial functioning, (e.g. employment status, social relations) and HIV risk reduction.
1632970|NCT01986075|Drug|Mixed amphetamine salts|80 mg/day of Adderall-XR
1632971|NCT01986075|Drug|Computer-assisted CBT plus placebo|Will receive computer -assisted CBT and placebo (instead of active Adderall-XR)
1632972|NCT01986062|Drug|AR11|
1632973|NCT01986062|Drug|Placebo|
1632974|NCT01986049|Drug|Bupivacaine|
1632975|NCT01986036|Dietary Supplement|Protein|Milk-Protein
1632976|NCT01986036|Dietary Supplement|Calcium|Soluble calcium powder.
1632977|NCT01986036|Dietary Supplement|Porridge-based breakfast.|Oats and water.
1632978|NCT01986023|Behavioral|SMS- Short Messaging Service|
1632979|NCT01986010|Biological|V160 Low Dose IM|V160 administered as a 0.75 mL intramuscular injection
1632980|NCT01986010|Biological|V160 Medium Dose IM|V160 administered as a 0.75 mL intramuscular injection
1632981|NCT01986010|Biological|V160 High Dose IM|V160 administered as a 0.75 mL intramuscular injection
1632982|NCT01986010|Biological|V160 Medium Dose plus Merck Aluminum Phosphate Adjuvant (MAPA) 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
1632983|NCT01986010|Biological|V160 High Dose plus MAPA 225 µg /dose IM|V160 plus MAPA administered as a 0.75 mL intramuscular injection
1632984|NCT01986010|Biological|V160 Maximum Dose IM|V160 administered as a 0.75 mL intramuscular injection
1632985|NCT01986010|Other|Placebo IM|Placebo administered as a 0.75 mL intramuscular injection
1632986|NCT01986010|Biological|V160 Medium Dose ID|V160 administered as a 0.1 mL intradermal injection
1632987|NCT01986010|Other|Placebo ID|Placebo administered as a 0.1 mL intradermal injection
1632988|NCT01985984|Radiation|Radiation alone|Radiation alone
1632989|NCT01985984|Radiation|Radiation in combination with systemic therapy|Radiation in combination with systemic therapy
1632990|NCT01985971|Radiation|PET/CT Imaging|
1632991|NCT01985958|Device|Radiation therapy|
1632992|NCT01985945|Other|Yoga|
1632993|NCT01985932|Device|MRI|
1632994|NCT01985919|Other|Obtaining human tissue for basic research or biospecimen bank|
1632995|NCT01985906|Procedure|Multiple overlapping uncovered stents|Endovascular management of complex aortic aneurysms with multiple overlapping uncovered stents
1632996|NCT01985906|Device|Uncovered stents|The number of uncovered stents implanted was determined by intraoperative angiography with the criterion that a decrease of velocity in the aneurysmal sac was achieved. Side branches, including segmental arteries and visceral branches, were covered wherever necessary.
1632997|NCT01985893|Drug|Lapatinib plus trastuzumab|Comparison of the safety and efficacy of lapatinib plus trastuzumab and lapatinib plus capecitabine.
1633461|NCT01982448|Drug|Paclitaxel|80mg/m2 weekly x 12 weeks (4 cycles).
2011802|NCT02401711|Behavioral|Education - BIPS course|The guiding principles behind the BIPS program include: (1) explaining how complex systems cause human error and how human error can lead to patient harm in complex systems; (2) diagnosing human error and identifying a prevention behavior for each of the three types: skill, rule, and knowledge; and (3) preventing error by promoting safety behaviors, such as having attention to detail, communicating clearly, having a questioning attitude, and speaking up for safety
1633000|NCT01985854|Drug|Propofol|
1633001|NCT01985854|Drug|Desflurane|
1633002|NCT01985841|Drug|Bevacizumb|Avastin
1633003|NCT01985841|Drug|5-Fluorouracil|5-FU
1633004|NCT01985841|Drug|Epirubicin|Farmorubicin
1633005|NCT01985841|Drug|Cyclophosphamide|Endoxan
1633006|NCT01985841|Drug|Docetaxel|Taxotere
1633007|NCT01985828|Radiation|CyberKnife|
1633008|NCT01985828|Other|Androgen Deprivation Therapy (ADT)|
1633009|NCT01985828|Radiation|Intensity Modulated radiation therapy (IMRT)|Per current standard of care
1633010|NCT01985815|Device|VC/VS stimulation|
1633011|NCT01985802|Other|Pacing|
1633012|NCT01985789|Drug|Diphenhydramine|
1633013|NCT01985789|Drug|cetirizine|
1633014|NCT01985789|Drug|desloratadine|
1633015|NCT01985789|Drug|placebo|
1633016|NCT01985776|Procedure|Exercise intervention|Functional stabilisation exercise for the trunk.
1633017|NCT01985776|Procedure|Exercise and e-stim|Functional stabilisation exercise for the trunk and electrical stimulation at the same time.
1633018|NCT01985763|Drug|Genistein|Genistein combined with FOLFOX or FOLFOX-Avastin
1633019|NCT01985750|Drug|d-cycloserine|250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation.
1633020|NCT01985750|Drug|placebo|"Other Names:
comparison of d-cycloserine or placebo on enhancing the beneficial effects of pulmonary rehabilitation on breathlessness perception
250mg d-cycloserine or identical placebo given immediately to the first 4 sessions of a 6-week course pulmonary rehabilitation"
1633021|NCT01985737|Other|Sample collection|
1633022|NCT01985724|Drug|Docetaxel|ARM A: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 2 weeks for 4 cycles ARM B: Docetaxel 75 mg/m2 as an IV infusion over 1h on day 1 every 3 weeks for 6 cycles
1633023|NCT01985724|Drug|Epirubicin|ARM A: Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
1633024|NCT01985724|Drug|Cyclophosphamide|ARM A: Cyclophosphamide 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles ARM B: Cyclophosphamide 600 mg/m2 IV push on day 1 every 3 weeks for 6 cycles
1633025|NCT01985724|Drug|5-fluoruracil|ARM A: 5-fluoruracil 500 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
1633026|NCT01985724|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
1633027|NCT01985711|Device|web-based collaborative care|"Firstly ,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
Secondly, usual diabetes outpatient care for 6 months."
1633028|NCT01985711|Other|wait-list|Firstly ,usual diabetes outpatient care for 6 months. Secondly,24 weekly 40-minute web-based collaborative care plus usual diabetes outpatient care for 6months.
1633029|NCT01985711|Behavioral|usual diabetes outpatient care|
1633030|NCT01985698|Procedure|Robotic-assisted resection.|Robotic-assisted abdominoperineal resection.
1633031|NCT01985698|Procedure|Laparoscopic resection|Laparoscopic abdominoperineal resection
1633032|NCT01985698|Procedure|Open surgery|Open abdominoperineal resection
1633033|NCT01985685|Drug|Thiamine|200 mg IV thiamine
1633034|NCT01985672|Procedure|Frozen embryo transfer|Embryo transfer of frozen/thawed embryos after IVF/ICSI
1633035|NCT01985646|Procedure|surgery treatment|one staged pull-through left-colectomy
1633036|NCT01985646|Behavioral|anal dilation|anal dilation
1633037|NCT01985646|Behavioral|colonic lavage|colonic lavage
1633038|NCT01985646|Drug|oral probiotic|oral probiotic
1633039|NCT01985633|Biological|Mesenchymal stem cell suspension|About 8-10ml of bone marrow would be aspirated under strict aseptic precautions, cell fractionationated with Ficoll sol,centrifuged at 1100rpm for 20-30 mins. Buffy layer will be centrifuged again at 1100 rpm for another 20-30 mins. The pellet thus formed will be suspended in 5ml of culture medium. The nucleated stem cells thus isolated, will be incubated at 37deg.C under 5%CO2 in culture flasks for about 4-6weeks. Those cells adherent to flask removed with 0.05% trypsin-EDTA sol and characterised . Those positive for CD90 and CD105 and negative for CD45 and CD34 will be the mesenchymal stem cells. These will then be expanded to 10×106 for use.
1633040|NCT01985633|Biological|PRP|Twelve patients will be placed in supine position with knee in full extension and under full aseptic precautions 8-10 ml of platelet rich plasma would be injected by lateral approach with an 18-20 G needle.
1633041|NCT01985620|Behavioral|Educational intervention|
1633042|NCT01985607|Dietary Supplement|new extensively hydrolysed formula|
1633043|NCT01985607|Dietary Supplement|Extensively hydrolysed formula|
1633044|NCT01985594|Drug|utrogestan|Oral Tablet Utrogestan 400 mg daily for 2 days
1633045|NCT01985594|Drug|Nifedipine|Tablet Nifedipine 20 mg stat then 20 mg after 30 minutes if contraction persist and another 20mg after 30 minutes if contraction still persist followed by 10 mg three times daily for 2 days
1633046|NCT01985581|Drug|Guanfacine extended release|
1633047|NCT01985581|Drug|Placebo|
1633048|NCT01985581|Drug|Stimulant therapy|patient will continue to take stable dosage of usual stimulant therapy (Ritalin, Ritalin SR, Biphentin, Concerta, Vyvanse, Adderall or Dexedrine)
1633049|NCT01985568|Behavioral|Sequential BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Sequential BT will be asked not to begin exercise during months 0-6. They will receive a progressive exercise program and exercise behavior support during months 7-12.
1633084|NCT01985321|Drug|ethanol/glycolic acid solution|ethanol/glycolic acid solution
1633085|NCT01985321|Drug|Placebo/Ethanol|ethanol solution
1633050|NCT01985568|Behavioral|Standard BT|Both study arms (Standard BT and Sequential BT) will receive an identical 6 month group-based weight loss program, followed by an identical 6 month group-based weight maintenance program, followed by an identical 6 months of weight maintenance phone support. Both groups will also receive an identical 6 month exercise intervention. Groups will differ only in the timing of exercise initiation. Standard BT will begin exercise immediately upon starting the 6 month dietary weight loss intervention. They will receive a progressive exercise program and exercise behavior support during months 0-6.
1633051|NCT01985555|Drug|Volitinib(HMPL-504)|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mg and 200 mg,oral,once daily or 2 times a day.
1633052|NCT01985542|Drug|birch pollen subcutaneous immunotherapy|birch pollen subcutaneous immunotherapy
1633053|NCT01985529|Other|Exercise|
1633054|NCT01985516|Other|Instillation into the urethra|5mL of 2% lidocaine gel will be instilled directly into the urethra 5 minutes before catheterization
1633055|NCT01985516|Other|pouring the gel on the catheter's tip|5mL of 2% lidocaine gel will be poured on the distal part of the catheter (from the distal tip to 10 cm proximally).
1633056|NCT01985490|Procedure|epiretinal membrane and internal limiting membrane removal|fluorescein angiography is performed before, 1 week, 3months and 6months after the epiretinal membrane and internal limiting membrane removal.
1633057|NCT01985477|Drug|Lenalidomide|"Phase I All Patients - Induction: Lenalidomide starting dose 25 mg by mouth 1 time every day on Day 1-21.
Phase II Group A: Lenalidomide starting dose: Dose tolerated prior to enrollment.
Maintenance Therapy: Phase I and Phase II Group A: Maintenance therapy lenalidomide at dose level tolerated at completion of cycle 3 for 21/28 days.
Phase II Group B: Lenalidomide will be given as a single oral dose at the level patient was on at the time of progression on single agent lenalidomide prior to study enrollment."
1633058|NCT01985477|Drug|Dexamethasone|"Phase I All Patients - Induction: Dexamethasone starting dose 40 mg by mouth on Days 1,8,15,22.
Phase II Group A: Dexamethasone starting dose: Dose previously on when progressing prior to study entry.
Maintenance Therapy: Phase I and Phase II Group A: Dexamethasone at last tolerated dose on Days 1, 8, 15 and 22."
1633059|NCT01985477|Drug|All-Trans Retinoic Acid (ATRA)|"Phase I All Patients - Induction: ATRA starting dose 25 mg/m2 by mouth 2 times each day on Days 1-21.
Phase II Group A: ATRA starting dose: MTD from Phase I.
Maintenance Therapy: Phase I and Phase II Group A: ATRA at dose determined in Phase I for 14/28 days.
Phase II Group B: All-Trans Retinoic Acid (ATRA) starting dose: MTD from Phase I.
Maintenance Therapy Group B: ATRA at the dose determined in the Phase I portion of the trial for 14/28 days."
1633060|NCT01985464|Biological|Umbilical cord mesenchymal stem cells|
1633061|NCT01985451|Drug|Pemetrexe|Patients with relapsed PCNSL patients were treated with high-dose pemetrexed (900mg/m²).
1633062|NCT01985451|Drug|Temozolomide|Patients with relapsed PCNSL patients were treated with temozolomide (200mg/m² day 1-5,28).
1633063|NCT01985438|Procedure|percutaneous endoscopic gastrostomy tube placement|A 20 Fr PEG tube (Cook Medical, or Boston Scientific) will be placed endoscopically using Ponsky's pull technique, under conscious sedation, as a day-case procedure. A single dose of a prophylactic intravenous antibiotic (1.2g co-amoxiclav, 30 minutes prior to the procedure, unless evidence of penicillin allergy) will be given to all patients undergoing PEG tube insertion. Patients will be monitored for one hour prior to discharge following PEG tube insertion.
1633064|NCT01985438|Procedure|nasogastric tube placement|All nasogastric tubes will be inserted in a standard manner by a Gastroenterology Fellow or an Internal Medicine resident. Ordinarily, a 14 Fr, fine-bore NG feeding tube will be inserted at the bedside or, if unsuccessful, inserted under radiological guidance. A post-procedure abdominal x-ray will be performed to confirm correct placement of all NG tubes.
1633065|NCT01985425|Drug|Colchicine|
1633066|NCT01985425|Drug|Colchicine Placebo|
1633067|NCT01985399|Behavioral|Neuropsychological testing|Neuropsychological testing
1633068|NCT01985386|Dietary Supplement|GDS capsule with meal|GDS capsule with meal
1633069|NCT01985386|Dietary Supplement|Ferrous sulfate with meal|Ferrous sulfate with meal
1633070|NCT01985373|Drug|Intravenous immunoglobulin infusion|Blood samples are drawn before infusion with Nanogam 50 and Nanogam 100 mg/ml and IgG levels are determined to study PK
2011803|NCT02401711|Behavioral|Formal safety curriculum|The educational program is designed to improve patient safety by informing residents about safe operating room behaviors.
2011804|NCT02401711|Behavioral|Ongoing evaluation and feedback|The feedback program is designed to encourage the use of safe behaviors and to discourage unsafe behaviors taught in the workshops.
2011805|NCT02400580|Drug|IV acetaminophen|
2011806|NCT02400580|Drug|placebo|
2011807|NCT02398656|Drug|Tenecteplase|TNK will be administered as a single intravenous bolus over 1-2 minutes within 90 minutes of the CT scan.
1633076|NCT01985347|Device|CPAP|Continuous positive airway pressure( CPAP)
2011808|NCT02398656|Drug|Antiplatelet treatment|Low dose aspirin (single agent) will be the choice of most physicians, some Investigators will chose to use the combination of aspirin and clopidogrel.
2011809|NCT02397720|Drug|5-azacytidine|"Dose Escalation Phase Starting Dose: 75 mg/m2 subcutaneously (SQ) or intravenously (IV) on Days 1 - 7 of every 28 day cycle.
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
2011810|NCT02397720|Drug|Nivolumab|"Dose Escalation Phase Starting Dose: 3.0 mg/kg by vein on Day 1 and Day 14 of each 5-azacytidine cycle for the first 4 cycles or until complete response (CR) (whichever occurs earlier) followed by a maintenance regimen (one dose of nivolumab on day 1 of each cycle of 5-azacytidine).
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
2011811|NCT02397720|Behavioral|Phone Call|Participant called about 30 days after end-of-study visit. If disease appears to be getting better while taking study drugs, participant called every 3-6 months for up to 5 years.
2011812|NCT02397720|Drug|Ipilimumab|"Dose Escalation Phase Starting Dose: 1.0 mg/kg by vein every 12 weeks.
Dose Expansion Phase Starting Dose: Maximum tolerated dose from Dose Escalation Phase."
2011813|NCT02394951|Drug|Pregabalin|Anticonvulsant
2011814|NCT02394951|Drug|Placebo|Identical, matching inactive substance
2011815|NCT02393690|Radiation|Iodine I-131|Given PO
2011816|NCT02393690|Other|Laboratory Biomarker Analysis|Correlative studies
2011817|NCT02393690|Other|Placebo|Given PO
1633088|NCT01985295|Drug|pazopanib|A dose escalation trial of Pazopanib, starting at 400mg daily, orally in combination with the standard 25 x 2Gy preoperative radiotherapy in newly diagnosed extremity sarcoma patients. Dose of pazopanib will be escalated via 600mg to maximally 800mg. Overall treatment time of pazopanib is 40 days.
1633089|NCT01985282|Behavioral|Nutrition Status Questionnaires and Physicial Function Test|Nutrition status questionnaires will be administered, Physical functional status will be tested
1633090|NCT01985269|Other|Home visits|The participants' vital signs (blood pressure, temperature, pulse rate, respiratory rate, and arterial oxygen saturation) will be taken and a limited physical examination (e.g. oral cavity for thrush, Kaposi's lesions, ulcers and dehydration; skin for rash, herpes zoster and dehydration; eyes for jaundice and pallor, gross neurological function such as ability to walk without difficulty, presence of facial droop, one-sided body weakness etc.) conducted. The nurse will then review medications adherence before observing the study participant swallow their pills (antiretrovirals, anti-TB, antibiotics, and analgesics).
1633091|NCT01985256|Biological|Toca 511|All subjects will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene, intravenously and then intracranially. CD converts the antibiotic 5-fluorocytosine (5-FC) to the anti-cancer drug 5-fluorouracil (5-FU) in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after second administration of Toca 511, subjects will take a 7-day course of oral 5-FC. These 7-day courses of 5-FC are repeated every 4 weeks for the duration of the study.
1633092|NCT01985243|Behavioral|Nutrition and agriculture|The intervention includes two components: (1) nutrition education on infant and young child nutrition, and (2) agriculture and small animal husbandry intervention to increase women's income and the accessibility of animal source foods for infants and young children.
1633093|NCT01985243|Behavioral|Iron-rich food & business literacy|The intervention includes two components: (1) a behavioural change intervention to improve school meals and increase the available iron in adolescents' diets, (2) savings & business literacy program for young female adolescents to encourage them to stay in school.
1633094|NCT01985230|Device|ReActiv8 Implantable Stimulation System implanted and activated.|
1633095|NCT01985204|Dietary Supplement|Iodine tablet|Iodine tablets containing 200 ug iodine as potassium iodate
1633096|NCT01985204|Dietary Supplement|Placebo tablet|Placebo tablet without iodine
1633097|NCT01985191|Drug|SAR405838|"Pharmaceutical form:capsule
Route of administration: oral"
1633098|NCT01985191|Drug|Pimasertib|"Pharmaceutical form: capsule
Route of administration: oral"
1633099|NCT01985178|Dietary Supplement|Omega-3 Fatty Acid Supplement|
1633100|NCT01985165|Drug|Imrecoxib|
1633101|NCT01985152|Drug|Azilsartan Trimethylethanolamine|
1633102|NCT01985152|Drug|Placebo|
1633103|NCT01985139|Behavioral|Computer-based tasks|Computer-based tasks designed to assess size and time discrimination capacities
1633104|NCT01985139|Biological|Blood sampling|Blood drawn for the measurement of circulating endocannabinoids concentrations
1633105|NCT01985126|Drug|Daratumumab 16 mg/kg (Part 1)|Daratumumab 16 mg/kg administered at weekly intervals (QW) for 8 weeks, then every 2 weeks (Q2W) for an additional 16 weeks, then every 4 weeks (Q4W) thereafter by intravenous infusion
1633106|NCT01985126|Drug|Daratumumab 8 mg/kg (Part 1)|Daratumumab 8 mg/kg every 4 weeks (Q4W) continuously by intravenous infusion
1633107|NCT01985126|Drug|Methylprednisolone|Administered in prophylactic doses intravenously (or equivalent in accordance with local standards) prior to and after study drug administration. Intravenous administration is preferred, but oral steroids may be substituted
1633108|NCT01985126|Drug|Acetaminophen|650 to 1000 mg administered in prophylactic doses by mouth prior to study drug administration.
1633109|NCT01985126|Drug|Diphenhydramine|25 to 50 mg administered in prophylactic doses by mouth (or equivalent in accordance with local standards) prior to and after study drug administration.
1633110|NCT01985126|Drug|Daratumumab (Part 2)|Based on the Part 1 response rate, Group A or B treatment will be selected as the treatment regimen for participants enrolled in Part 2.
2011818|NCT02393690|Drug|Selumetinib|Given PO
1633112|NCT01985087|Radiation|Hypofractionated radiotherapy|Treatment of 3.4 Gy will be given daily 5 days per week over 2 weeks.
1633113|NCT01985087|Drug|Temozolomide|During concomitant phase Temozolomide will be administered orally at 75 mg/m2 for 2 weeks concomitant with radiotherapy. During the adjuvant phase Temozolomide will be administered orally at 150 mg/m2 on days 1 through day 5 of each 28 day cycle for a maximum of 6 cycles.
1633114|NCT01985074|Behavioral|Case-management intervention|The participants in the intervention group receives a nurse-managed case-management intervention that is regularly delivered by telephone or, when necessary, in person.
1633115|NCT01985061|Drug|BX2|
1633116|NCT01985061|Drug|BX3|
1633117|NCT01985061|Drug|BX4|
1633118|NCT01985035|Behavioral|Diet|Reduction of energy intake in order to weight loss
1633119|NCT01985022|Behavioral|PII with IES|This is an individualized parent-implemented intervention (PII) offered weekly to teach parents how to embed strategies to support social communication skills for 25 hours a week within everyday routines, activities, and places for 9 months. In addition parent will receive twice weekly the IES condition of the study.
1633120|NCT01985022|Behavioral|IES|Parents will receive information, education, and support. They once a week for 75 minutes.
1633121|NCT01985009|Device|FibroScan® examination.|The study involves adults' patients with suspected Non-Alcoholic Fatty Liver Disease(NAFLD). The FibroScan® is a device equipped with probes (M+ or XL+), each of which consists of an ultrasonic transducer mounted on the axis of a mechanical vibrator. Liver stiffness and CAP measurements are performed on the right lobe of the liver with the patient in a dorsal decubitus and maximal abduction position. The procedure is non-invasive and painless.
1633122|NCT01984996|Device|Freedom ProFlor Inguinal Hernia Implant|
1633123|NCT01984983|Biological|Venezuelan Equine Encephalitis Virus DNA Vaccine Candidate|
1633124|NCT01984983|Other|0.9% saline placebo|
1633125|NCT01984970|Device|videolaryngoscope|McGrath Series 5 videolaryngoscope is one kind of portable videolaryngoscopes, which has been usde in both unexpected and anticipated difficult intubation.
1633126|NCT01984957|Procedure|Muscle biopsy|open muscular biopsy of the deltoid under local anaesthesia
1633456|NCT01982474|Biological|Grass pollen extract|Grass pollen extract injected intralymphatically q 4 weeks x 3
1633127|NCT01984944|Other|Autistic functional exploration|"50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer
25 childs with urinary sample, Circadian rhythms assessed with actometer"
1633128|NCT01984944|Other|Control functional exploration|"50 adults with urinary sample, core body temperature rhythm, Circadian rhythms assessed with actometer
25 childs with urinary sample, Circadian rhythms assessed with actometer"
1633129|NCT01984931|Drug|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)|Trimebutine Maleate (NEWBUTIN SR 300 mg Tab)is a noncompetitive spasmolytic agent. It possesses moderate opiate receptor affinity and has marked anti-serotonin activity especially on'M' receptors. A single dose of NEWBUTIN SR 300 mg Tab orally will be given one hour prior to the said operation time and another 300 mg orally as soon as the patient wakes post operatively.
1633130|NCT01984931|Drug|Metoclopramide hydrochloride monohydrate|
1633131|NCT01984918|Other|SMS|A SMS reminder will be sent to patients 7 - 10 days before his colonoscopy appointment
1633132|NCT01984918|Other|No SMS|No SMS reminder will be sent
2011819|NCT02393352|Other|Dry Needling Therapy|The dry needling therapy will be applied on active trigger points in occipital muscle, splenius capitis, sternocleidomastoid muscle, scalene muscles, trapezius, supraspinatus, infraspinatus muscle, latissimus dorsi, iliocostalis muscle, multifidus muscles, and quadratus lumbourm muscles.
1633134|NCT01984879|Other|Survey with structured questionnaire form for inflammatory bowel disease patient group|For patients with inflammatory bowel disease, survey with structured questionnaire form is carried out.
1633135|NCT01984853|Other|OBSERVATIONAL REGISTRY|
1633136|NCT01984840|Device|Telemedicine|
1633137|NCT01984827|Drug|Moxifloxacin|"a single oral dose of 400mg Moxifloxacin plus a hyper-glycaemic clamp for 4 hours
a single oral dose of 400mg Moxifloxacin plus C-peptide
a single oral dose of 400mg Moxifloxacin
placebo
Oral doses of placebo and moxifloxacin will be administered by a Research Physician or Pharmacy staff member between 08:00 a.m. and 10:00 a.m."
1633138|NCT01984827|Other|hyper-glycaemic clamp|a hyper-glycaemic clamp only for 2 hours followed by a hyper-glycaemic clamp plus C-peptide for 2 hours
1633139|NCT01984814|Biological|Stem cell|Autologous bone marrow derived mononuclear cells were administered via intrathecal and intramuscular routes.
1633140|NCT01984801|Drug|0.3% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
1633141|NCT01984801|Drug|1% GSK1940029 gel|200 mg of the gel will be applied to individual patches by using a spatula
1633142|NCT01984801|Drug|0.3%/1% vehicle gel only|200 mg of the gel will be applied to individual patches by using a spatula
1633143|NCT01984801|Other|Sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
1633144|NCT01984801|Other|0.5% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
1633145|NCT01984801|Other|0.1% SLS in sterile distilled water|200 µL of the solution will be applied to individual patches by using a pipette or syringe
1633146|NCT01984801|Other|Patch only|Only patch will be applied
1633147|NCT01984788|Drug|BCX4161|
1633148|NCT01984788|Drug|Placebo|
1633149|NCT01984775|Drug|GSK2894512 cream|GSK2894512 is a white to off-white cream that will be applied topically in 3 different concentrations (0.5% [5 milligram (mg)/gram (g)], 1% [10 mg/g], and 2% [20 mg/g]).
1633150|NCT01984775|Drug|Vehicle cream|Vehicle cream does not contain any active pharmaceutical ingredient.
1633151|NCT01984775|Drug|Positive control|Positive control contains sodium lauryl sulfate solution 0.1% (1 mg/g).
1633152|NCT01984775|Drug|Negative control|Negative control contains petrolatum.
1633153|NCT01984762|Procedure|Roux-en-Y gastric bypass|RYGBP=Roux-en-Y gastric bypass
1633154|NCT01984762|Procedure|sleeve gastrectomy|SG = sleeve gastrectomy
1633155|NCT01984749|Drug|Febuxostat|"Febuxostat will be taken once daily after breakfast (generally within 30 minutes after eating) but can be taken around the time of breakfast even if no food has been eaten. When the dose is to be increased, the principal or sub-investigator will carry out any required examinations and tests as needed.
The starting dose of the investigational product (febuxostat) will be 10 mg/day.
The dose will be increased to 20 mg/day at Week 4.
The aim is to increase the dose to 40 mg/day at Week 8."
1633156|NCT01984736|Drug|Experimental: EVP-6124|
1633157|NCT01984723|Drug|Experimental: EVP-6124|
1633158|NCT01984710|Device|Medtronic Activa PC+S System|
1633159|NCT01984697|Biological|V503 (9-valent Human Papillomavirus [HPV] L1 Virus-Like Particle [VLP] vaccine)|V503, a 9-valent HPV (Types 6, 11, 16, 18, 31, 33, 45, 52, 58) administered as a 0.5-mL intramuscular injection
1633160|NCT01984684|Drug|delafloxacin|
1633161|NCT01984684|Drug|vancomycin|
1633162|NCT01984684|Drug|aztreonam|
1633163|NCT01984671|Behavioral|Mobile Pain Coping Skills Training|
1633164|NCT01984658|Biological|Alecsat|The ALECSAT CBMP will be administered as single dose at week 4, 7 and week 10 which is considered an appropriate time for ALECSAT CBMP to strengthen the immune system and thus have the ability to kill tumour cells. It is the aim that the patients will receive three doses during the study period however, if the patient wish and it is recommended by the investigator, patients may receive more than three doses, continuing until progression or as judged by the Investigator. Continued treatment after the 24 week study period is only possible under the condition that no safety issues have been discovered. The interval between injections for continued treatment will be decided based on e.g. tumour response and clinical examinations.
1633165|NCT01984645|Other|Notification|Providers in the intervention group will receive a secure electronic notification when their patients are visited in the emergency department or admitted as an inpatient.
1633166|NCT01984632|Procedure|Single-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture (control group) in terms of operative time (esp. suturing time).
2011820|NCT02393352|Other|Electrical Stimulation Therapy|
2011821|NCT02392351|Device|Renal Denervation (Vessix)|Percutaneous renal denervation using the Vessix Reduce™ Catheter and Vessix™ Generator
2011822|NCT02392351|Device|Renal Angiography|Percutaneous renal angiography
2011823|NCT02390219|Drug|Lumacaftor|
2011824|NCT02390219|Drug|Ivacaftor|
2011825|NCT02389816|Drug|Placebo|Placebo tablets
1633167|NCT01984632|Procedure|Multi-port laparoscopic myomectomy|The aim of this study is to compare single-port laparoscopic myomectomy using barbed suture (experimental group) with multi-port laparoscopic myomectomy using barbed suture(control group) in terms of operative time (esp. suturing time).
1633168|NCT01984619|Device|Cryotherapy for the utilization of wrinkle reduction (iovera)|
1633169|NCT01984606|Drug|Empagliflozin|Empagliflozin once daily
1633170|NCT01984606|Drug|Placebo|Placebo matching empagliflozin
1633171|NCT01984606|Drug|Sitagliptin|Sitagliptin once daily
1633172|NCT01984606|Drug|Placebo|Placebo matching sitagliptin
1633173|NCT01984593|Other|Yoga|"The participants in the Yoga group will get a private doctors appointment (20 minutes) where they get instructions for two yoga exercises to perform at home 15 minutes twice a day.
The two yoga exercises were:
Left nostril breathing - deep breaths in and out through the left nostril while sitting or lying down, with the right nostril closed off by the right thumb or an earplug (about 11 minutes); and
Spinal flex - movement that alternates between flexing the spine forwards (arching) and relaxing the spine back in time with deep breaths while sitting in a chair (about 4 minutes)."
1633174|NCT01984580|Drug|zinc gluconate|26.6 mg zinc BID (as zinc gluconate)
1633175|NCT01984567|Dietary Supplement|Vitamin E|Daily consumption of vitamin E capsules, 3 capsules of 268 mg daily, in total daily consumption of 804 mg
1633176|NCT01984567|Dietary Supplement|Lipoic acid|Daily consumption of lipoic acid capsules, 3 capsules of 200 mg daily, in total daily consumption of 600 mg
1633177|NCT01984567|Dietary Supplement|Control|Daily consumption of 3 placebo capsules
1633178|NCT01984541|Biological|Artemisia vulgaris|Four concentrations of Artemisia vulgaris allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
1633179|NCT01984528|Biological|four differente concentrations of Alternaria alternata allergen extract, positive control and negative control|This concentrations will be tested in every patient in duplicate on the volar surface of the forearm.
1633180|NCT01984515|Behavioral|Referral Management System|"Referral Management System (RMS) will address patient-level barriers with the delivery of a 1-session cognitive behavioral therapy (CBT) intervention to identify and change treatment seeking beliefs that serve as an barrier to treatment engagement, including specific negative beliefs about EBP (e.g., talking about past trauma will be too difficult for me). RMS will address system-level barriers by tracking the progress of RMS referrals and contacting Veterans who have not followed thought on their chosen referral options. Primary Care staff will also be trained with simple scripts on how to address PTSD symptoms and make appropriate referrals based on VA/DoD Clinical Practice Guidelines for PTSD."
1633181|NCT01984502|Radiation|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy|CyberKnife Accelerated Hemilarynx Stereotactic Radiotherapy
1633182|NCT01984489|Drug|Placebo|
1633183|NCT01984489|Drug|SHR117887|
1633184|NCT01984463|Drug|Fentanyl|Patients will receive an epidural bolus dose of 100 mcg of fentanyl followed by an infusion of epidural bupivacaine 0.1% and fentanyl 2 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
1633185|NCT01984463|Drug|Morphine|Patients will receive an epidural bolus dose of 3 mg of morphine followed by an infusion of epidural bupivacaine 0.1% and morphine 50 mcg/mL continued postoperatively until the surgical drains are removed or for a maximum of five days.
1633186|NCT01984450|Procedure|ACIC|"Autologous Collagen Induced Chondrogenesis (ACIC):
ACIC is a single stage arthroscopic procedure. It is done as a day case procedure. The cartilage defect is debrided and implanted with a collagen + fibrin gel mixture under CO2 insufflation."
1633187|NCT01984450|Procedure|MCIC|"Mesenchymal Cell Induced Chondrogenesis (MCIC):
MCIC is a single stage arthroscopic procedure. It is done as a day case procedure. BMAC is harvested intraoperatively and concentrated. It is then mixed with a fibrin gel and implanted under CO2 insufflation."
1633188|NCT01984450|Device|implant with a collagen + fibrin gel mixture|
1633189|NCT01984424|Drug|Part A, Atorvastatin|Subjects will receive atorvastatin daily
1633190|NCT01984424|Other|Part A, Placebo (administered orally)|Subjects will receive oral placebo daily
1633191|NCT01984424|Drug|Part B, Evolocumab|Subjects will receive subcutaneous evolocumab every month
1633192|NCT01984424|Other|Part B, Placebo (administered orally)|Subjects will receive oral placebo every day
1633193|NCT01984424|Drug|Part B, Ezetimibe|Subjects will receive oral ezetimibe daily
1633194|NCT01984424|Other|Part B, Placebo (administered subcutaneously)|Subjects will receive subcutaneous placebo every month.
1633195|NCT01984424|Drug|Part C, Evolocumab|Subjects will receive subcutaneous evolocumab every 2 weeks or monthly
1633196|NCT01984411|Procedure|Radial Technical|Vascular Access for cardiac catheterization
1633197|NCT01984411|Procedure|Femoral Technical|Vascular Access for cardiac catheterization
1633198|NCT01984411|Drug|Omnipaque|
2011826|NCT02389816|Drug|Lu AA21004|Lu AA21004 tablets
2011827|NCT02389153|Behavioral|collaborative care CHD|Over a time span of 6 months participants receive individualized treatment to reduce risk factors and improve quality of life, based on their preferences following a health plan, which they developed with their health coach.
2011828|NCT02387814|Drug|Abemaciclib|Administered Orally
2011829|NCT02387892|Dietary Supplement|Cheese & yogurt + Vitamin D|cheese & yogurt with added 420 IU cholecalciferol
1633203|NCT01984372|Drug|insulin degludec|Frequency and timing of visits are based on normal clinical practice for patients with diabetes mellitus requiring insulin therapy.
1633204|NCT01984359|Other|Obtaining Human tissue|
2011830|NCT02387892|Dietary Supplement|Cheese & yogurt|Cheese & yogurt without added vitamin D
1633237|NCT01984086|Drug|Salbutamol Sulphate 250mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 250mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
1633238|NCT01984086|Drug|Salbutamol Sulphate 200mcg UD-DPI Blister(1% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
1634027|NCT01977703|Other|Traditional ICD Programming|
1633208|NCT01984320|Procedure|ICSI|Long luteal GnRH agonist protocol: patients will receive GnRH agonist from day 21 of the previous cycle of stimulation and then on day 3 of the stimulation cycle they will start hMG injections with 225 IU/day. Folliculometry will start on day 6 stimulation by vaginal ultrasound. Estradiol levels will be measured on day 8, 10 and 12 of stimulation if appropriate. According to ultrasound and estradiol level patients will be randomized to either one of the study arms. When ready final triggering will be done by human chorionic gonadotropin (10000 IU) and oocyte collection is done at 36 hour from triggering. Embryo transfer is then done 3 days afterwards with ultrasound guidance.
1633209|NCT01984294|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) 90/400 mg FDC tablet administered orally once daily
1633210|NCT01984294|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1633211|NCT01984294|Drug|GS-9669|GS-9669 tablet(s) administered orally once daily
1633212|NCT01984281|Behavioral|Pedometer-based physical activity prescription|After baseline assessments, both groups will receive a educational session, regarding important aspects of asthma plus a unsupervised exercise prescription (walking, 5 times per week, for at least 30 minutes). Only the experimental group will receive a pedometer-based physical activity prescription, consisting of targets (steps per day) to be achieved. The initial target will be determined based on the average of steps per day assessed during the baseline assessments plus 1000 steps. The targets will be biweekly. Both groups will be contact once a week (by phone) and will be asked to return for asthma control assessments once a month.
1633213|NCT01984268|Drug|ACTHAR|
1633214|NCT01984255|Drug|Arm A-Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV|Bavituximab 3mg/kg IV over 90 minutes weekly x 3 followed by Bavituximab 3mg/kg IV over 90 minutes weekly x 12 plus ipilimumab 3mg/kg IV over 90 minutes every 3 weeks x 4. Total number of treated patients will be 16.
1633215|NCT01984255|Drug|Arm B-Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3.|Ipilimumab 3mg/kg IV over 90 minutes day 1 followed three weeks later by ipilimumab every 3 weeks x 3. Total number of treated patients will be 8.
1633219|NCT01984229|Drug|Alectinib|Alectinib will be administered as a single oral dose on Day 1 (Period 1) and Day 15 (Period 3) with an identical standardized meal (identical meal on Day 1 and Day 15 across all participants).
1633220|NCT01984229|Drug|Posaconazole|Posaconazole will be administered as a 400-mg BID oral dose after a high-fat meal on Days 8 to 14 (Period 2) and Days 15 to 18 or 21 (Period 3).
1633221|NCT01984216|Procedure|Roux-en-Y for the gastrojejunostomy reconstruction|
1633222|NCT01984216|Procedure|Billroth II for the gastrojejunostomy reconstruction|
1633223|NCT01984203|Other|Low Load Exercises|"All rotator cuff and scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).
The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
1633224|NCT01984203|Other|Progressive Heavy Strength Exercises|"All scapular exercises are performed with 3 sets of 20 repetitions 3 times per week for 12 weeks. The load is set at around 60% of 1 RM (20 reps).
The rotator cuff exercises are performed with 4 sets of gradually progressive loading and decreasing the repetitions performed in each set.
Week 1: 15reps (70% 1RM) Week 2-3: 12 reps (75% 1RM) Week 4-5: 10 reps (80% 1RM) Week 6-8: 8 reps (85% 1RM) Week 9-12: 6 reps (90% 1RM)
The glenohumeral/postural corrective exercises are performed with 3 sets of 5 repetitions (The position is held for 15 seconds per repetition)."
1633225|NCT01984177|Drug|Corticotropin-Releasing Hormone|Each subject will receive a single dose of Corticotropin-Releasing Hormone corticorelin on a single occasion, and a volume-matched saline injection on a second occasion. Corticorelin will be administered as an intravenous infusion over a 30- to 60-second interval at a dose of 1 ug/kg body weight. ~15 minutes after Corticorelin/saline injection, [11C]-(+)-PHNO will be administered followed by 90 minutes of PET scanning. Primary outcome measure ([11C]-(+)-PHNO) as well as Secondary outcome measures (self reported feeling, hormones and physiological measures) will be obtained before saline or Corticorelin/saline injection and for 90-120 minutes following injection.
1633226|NCT01984164|Drug|Candesartan|blinded
1633227|NCT01984164|Drug|Lisinopril|Blinded
1633228|NCT01984138|Drug|ESTRING|ESTRING (estradiol vaginal ring) is a slightly opaque ring with a whitish core containing a drug reservoir of 2 mg estradiol. Estradiol, silicone polymers and barium sulfate are combined to form the ring. When placed in the vagina, ESTRING releases estradiol, approximately 7.5 mcg per 24 hours, in a consistent stable manner over 90 days. ESTRING has the following dimensions: outer diameter 55 mm; cross-sectional diameter 9 mm; core diameter 2 mm. One ESTRING should be inserted into the upper third of the vaginal vault, to be worn continuously for three months.
1633229|NCT01984138|Drug|Replens|Replens should be applied vaginally, with a supplied applicator, three times each week.
1633230|NCT01984125|Other|Point-of-Care Prompt|
1633231|NCT01984112|Device|Locked plate|Osteosynthesis with philos plate, through deltopectoral approach and rotator cuff augmentation with inabsorbable poliester suture
1633232|NCT01984112|Device|Intramedullary locked nail|Intramedullary locked nail performed by antero-lateral transdeltoid minimally invasive approach and rotator cuff augmentation with inabsorbable poliester suture
1633233|NCT01984099|Drug|Methotrexate|Patients will be given a single course of methotrexate within fourteen days from molar evacuation.
1633234|NCT01984099|Drug|Vitamin B Complex|Patients will be given a placebo in a form of Vitamin B Complex (Bee ALL), intramuscularly or intravenously.
1633235|NCT01984086|Drug|Salbutamol Sulphate 150mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 150mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
1633236|NCT01984086|Drug|Salbutamol Sulphate 200mcg UD-DPI Blister(1.6% blend)|Salbutamol Sulphate 200mcg UD-DPI will be supplied as blister containing a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
1633457|NCT01982474|Other|Placebo injection|Normal saline injected intralymphatically q 4 weeks x 3
1633458|NCT01982461|Drug|Rosuvastatin|10mg,once daily
1633239|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister|Salbutamol Diskus 200mcg will be supplied as blister strip contained within the Diskus device. Each blister contains a small quantity of powder comprising of a blend of salbutamol sulphate (micronized) and excipients
1633240|NCT01984086|Drug|Salbutamol MDI 100mcg|Salbutamol MDI 100mcg will be supplied as formulation of salbutamol sulphate (micronized) in propellant contained within the pressurised MDI device
1633241|NCT01984086|Drug|Salbutamol Sulphate UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
1633242|NCT01984086|Drug|Salbutamol Sulphate 250mcg UD-DPI Blister (selected from Part A)|Formulation will be determined depending on the outcome of Part A.
1633243|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister without activated charcoal|Formulation will be determined depending on the outcome of Part A.
1633244|NCT01984086|Drug|Salbutamol Diskus 200mcg Blister with activated charcoal|Formulation will be determined depending on the outcome of Part A.
1633245|NCT01984086|Drug|Salbutamol MDI 100mcg without activated charcoal|Formulation will be determined depending on the outcome of Part A.
1633246|NCT01984086|Drug|Salbutamol MDI 100mcg with activated charcoal|Formulation will be determined depending on the outcome of Part A.
1633247|NCT01984073|Drug|ER Niacin Oral Fat Challenge|Extended release niacin 2000 mg at hour 0, followed by oral fat challenge at hour 1.
1633248|NCT01984073|Drug|IR Niacin Oral Fat Challenge|Nialor(R) 500mg or Placebo at hour 0, 2, 4, and 6. Oral fat challenge at hour 1 (one hour after first dose of immediate-release niacin)
1633249|NCT01984073|Other|Placebo Oral Fat Challenge|Placebo at hour 0. Oral fat challenge at hour 1, followed by placebo at hours 2,4,and 6
1633250|NCT01984060|Other|HOME-EX|"Motivational Counseling: The first session will be an hour face-to-face interview to establish a rapport with subjects, assess motives and competence. The rest will be 30 min. phone calls to assess week's performance and agree on an action plan for next 2 weeks.
Exercise Intervention: Using the average number of steps for each subject from their baseline assessment, the targeted number of steps the subject needs to walk every day will be calculated. The individualized strength training exercise will target the upper and lower body. If possible, they will be encouraged to progressively increase from their individual baseline sets and repetitions to a maximum of 4 sets of 15 repetitions for each exercise"
1633251|NCT01984047|Drug|GSK3050002|GSK3050002 is a white to off-white lyophilized powder that will be reconstituted with sterile water for intravenous infusion. It is available in the concentrations of 0.1 milligram (mg)/kg, 0.5 mg/kg, 1 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg.
1633252|NCT01984047|Drug|Placebo|Placebo contains normal saline (0.9% sodium chloride) for intravenous infusion
1633253|NCT01984034|Behavioral|Educational Outreach Visits|The 3 members of the steering committee completed training regarding delivery of visits with the National Resource Center for Academic Detailing (Boston, MA). The other detailers were trained locally by this committee, with pre-training study assignments, and 12 hours of face-to-face training which included the principles of academic detailing, role-play, video-recording and feedback, discussion of the scientific content of each guideline, and knowledge assessment. To ensure consistency, the contents of each visit have been prepared in advanced by the committee and were used in the training sessions. Whenever possible, a single detailer will perform all three visits to the same doctor.
1633254|NCT01984034|Other|Passive Dissemination|Usual guideline implementation consists of passive dissemination by their publication on the National Health Directorate's website. Doctors in units randomized to the control group will be offered an unrelated training session (coding with the International Classification of Primary Care, second edition) as a token of good will for participating in the trial.
1633255|NCT01984021|Device|Acupuncture|
1633256|NCT01984021|Device|Sham acupuncture|
1633257|NCT01984008|Drug|Picosulfate sodium, magnesium oxide, citric acid|
1633258|NCT01983969|Drug|Azacitidine|Starting dose 15 mg/ m2 by vein on Day -11.
1633259|NCT01983969|Drug|Vorinostat|1000 mg by vein on Day -11 through Day -2.
1633260|NCT01983969|Drug|Gemcitabine|Loading dose 75 mg/m2 by vein followed by 22775 mg/m2 by vein on Day -8.
1633261|NCT01983969|Drug|Busulfan|Busulfan test dose 32 mg/m2 by vein either as outpatient before Day -12 or as inpatient on Day -11. Busulfan pharmacokinetics performed with test dose and first dose on Day -8. Doses on Days -6 and -5 adjusted to target an AUC of 4,000 microMol.min-1.
1633262|NCT01983969|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
1633263|NCT01983969|Drug|Dexamethasone|8 mg by vein twice a day from Day -11 AM to Day -2 PM.
1633264|NCT01983969|Other|Caphosol|Caphosol oral rinses 30 mL four times a day used from Day -9.
1633265|NCT01983969|Drug|Glutamine|Oral glutamine, 15 g four times a day, swished, gargled and swallowed from Day -9.
1633266|NCT01983969|Drug|Pyridoxine|100 mg by vein or mouth three times a day from Day -1.
1633267|NCT01983969|Drug|Rituximab|375 mg/m2 by vein on Days -9.
1633268|NCT01983956|Behavioral|SENS model|Palliative care with a structured approach (SENS model) based on the bio-psycho-social-spiritual model of care, the WHO definitions of palliative care as well as the National Comprehensive Cancer Networks (NCCN) Practice Guidelines for Palliative Care. The approach supports the assessment of areas and complexity of concerns from the patient perspective, determines the priority and structures the support needed. The intervention is performed by palliative care physicians and nurses collaboratively. It is utilized as baseline assessment and afterwards integrated in each routine oncology care out-patient and in-patient visit. Depending on the goals it may be applied between routine visits. In addition, patients will receive usual oncology care throughout the study period.
1633269|NCT01983943|Dietary Supplement|Hydroxytyrosol, the active ingredient in olive oil.|A 40mg capsule will be taken once daily for 6 months.
1633270|NCT01983943|Dietary Supplement|Placebo|A 40mg placebo will be taken once per day for 6 months.
1633271|NCT01983943|Behavioral|Nutrition counseling|Nutrition counseling on eating a healthy diet will be offered once at baseline.
1633272|NCT01983943|Device|Endopat|An endopat test will be administered twice, once and baseline and once after 6 months of supplementation, to test endothelial function. This is a non-invasive test that takes about 15 minutes.
1634028|NCT01977690|Device|Clavicle Brace|
2011831|NCT02383147|Device|Tomographic Neurofeedback|EEG-Electrodes are placed on the patients head to record the brain activity, EEG-recordings are processed by the standardized Low Resolution Brain Electromagnetic Tomography algorithm (sLORETA) to calculate the frequency spectrum in the auditory cortex and deliver feedback for the patient
1633275|NCT01983917|Behavioral|Diabetes Mobile Application|
2011832|NCT02383147|Device|Non Tomographic Neurofeedback|EEG-electrodes are placed on the patients head, but only 4 electrodes (Fc1, Fc2, F3 and F4 of a 10-10 EEG-system) record the surface activity and generate the feedback for the patient.
1633277|NCT01983891|Other|Cooking course|6-week nutrition education and cooking course
1633278|NCT01983878|Drug|Ramucirumab|Administered IV
1633279|NCT01983865|Other|Exposure to birch pollen|
1633280|NCT01983826|Dietary Supplement|Sodium Nitrate|Sodium Nitrate (1g/day) for 8 weeks
1633281|NCT01983826|Other|Placebo|Microcrystalline cellulose (daily) for 8 weeks
1633282|NCT01983813|Other|PHCVRS Intervention|"A clinical pharmacist at the PHCVRS will follow each participant in the PHCVRS arm for 12 months, including:
Contact via email, phone or text every 2-4 weeks
Assessment and counseling for medication adherence, side effects, and lifestyle modifications to decrease risk of cardiovascular disease.
Collaborative communication with the participant's physician to address gaps in screening or therapy, update medication list, and recommend medication changes.
Each participant in this arm will also have access to an online Personal Health Record that can be used to track medications, diagnosed conditions and laboratory values related to cardiovascular disease risk."
1633283|NCT01983813|Other|Personal Health Record|Participant will be able to access an online Personal Health Record for tracking medications and diagnosed conditions
1633284|NCT01983800|Drug|Isoflurane|
1633285|NCT01983800|Drug|Propofol/midazolam|
1633286|NCT01983774|Drug|Esomeprazole|
1633287|NCT01983774|Drug|Placebo|Sugar pill
1633290|NCT01983748|Biological|Autologous Dendritic Cells loaded with autologous Tumor RNA|
1633291|NCT01983735|Drug|TELMINUVO Tab. (80/2.5mg)|"Fixed dose combination of Telmisartan 80mg and S-amlodipine 2.5mg QD 2 weeks.
With the others investigation product placebo 1 tab QD 2 weeks."
1633292|NCT01983735|Drug|TELMINUVO Tab. (80/5mg)|"Fixed dose combination of Telmisartan 80mg and S-amlodipine 5mg QD 6 weeks.
With the others investigation product placebo 1 tab QD 6 weeks."
1633293|NCT01983735|Drug|S-amlodipine 2.5mg|"S-amlodipine 2.5mg QD 2 weeks
With the others investigation product placebo 1 tab QD 2 weeks."
1633294|NCT01983735|Drug|S-amlodipine 5mg|"S-amlodipine 5mg QD 6weeks
With the others investigation product placebo 1 tab QD 6 weeks."
1633295|NCT01983722|Drug|Stiripentol|
1633296|NCT01983709|Biological|Allogeneic Human Mesenchymal Stem Cells|"This will be a dose escalation study. The first 3 subjects will receive a single dose of 1 x 10^6 cells/kg or a maximum dose of 1 x 10^8 total cells IV 4 days prior to undergoing a planned prostatectomy.
The remaining subjects will receive a single dose of 2 x 10^6 cells/kg or a maximum dose of 2 x 10^8 total cells IV either 4 or 6 days prior to the planned prostatectomy, and if additional doses of MSCs are able to be expanded, up to 6 additional men will be enrolled with a plan to treat them 8 days prior to the prostatectomy."
1633297|NCT01983696|Other|5% oxygen concentration|the oocytes and embryos are cultured in the incubator with concentrations of 6% CO2,5%O2, and 89% N2
1633298|NCT01983683|Drug|Cadazolid|Cadazolid 250 mg as oral suspension twice daily.
1633299|NCT01983683|Drug|Vancomycin|Vancomycin 125 mg as oral capsules 4 times daily
1633300|NCT01983683|Drug|Cadazolid-matching placebo|Placebo matching cadazolid and administered orally twice daily
1633301|NCT01983683|Drug|Vancomycin-matching placebo|Placebo capsules matching vancomycin and administered orally 4 times per day
1633302|NCT01983670|Other|Temporal electrical stimulation|
1633303|NCT01983657|Drug|rhGM-CSF|GM-CSF will be given subcutaneously according to the rule in different groups.
1633304|NCT01983657|Procedure|Whole Lung Lavage(WLL)|using double lumen endotracheal tube (DLT) to selectively lavage one lung
1633305|NCT01983644|Device|RECO flow restoration device|RECO flow restoration device is a novel, self-expanding stent retriever designed to yield rapid flow restoration in acute cerebral ischaemia.
1633306|NCT01983644|Device|Solitaire FR flow restoration device|Solitaire FR flow restoration device has been approved by the FDA and CFDA.
1633307|NCT01983631|Other|Whole body vibration training|
1633308|NCT01983618|Procedure|Interscalene nerve block and catheter|
1633309|NCT01983618|Procedure|Interscalene catheter|
1633310|NCT01983605|Device|LARIAT Suture Delivery Device|LAA exclusion procedure
1633311|NCT01983592|Other|Homeopathic medicine|Intervention must begin within 5 days of chemotherapy cycle completion. Intervention will continue until the next cycle of chemotherapy. The initial consultation will involve a verbal interview between the homeopath and the participant. The practitioner will then choose a single homeopathic remedy that will focus on the reduction of fatigue. Only one homeopathic remedy and potency will be administered at a given time. The participant will be asked to take the study medication at least 30 minutes before or after taking other medications, food and strong smelling substances.
1633312|NCT01983592|Other|Unmedicated lactose/sucrose globule|
1633313|NCT01983579|Procedure|Intraocular anti-VEGF injection|
1633314|NCT01983579|Device|SENSIMED Triggerfish|
1633315|NCT01983566|Drug|BI 207127 high fat|BI 207127 as a single dose after a high fat breakfast
1633316|NCT01983566|Drug|BI 207127 with Omeprazole|BI 207127 as a single dose after 4 days treatment of Omeprazole 40 mg once a day
1633317|NCT01983566|Drug|BI 207127|BI 207127 as a single dose in fasted state
1633318|NCT01983566|Drug|BI 207127 low fat|BI 207127 as a single dose after a low fat breakfast
1633319|NCT01983540|Biological|DTaP-IPV-Hep B- PRP~T + Prevenar + Rotarix vaccine|DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster of the same investigational vaccine concomitantly with Prevenar (PCV7) at 12 to 24 months of age in a previous study
1633320|NCT01983540|Biological|DTaP- IPV-Hep B-PRP~T + Prevenar + Rotarix + Infanrix hexa vaccine|DTaP-IPV-Hep B-PRP~T vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age) and a booster dose of Infanrix hexa vaccine with Prevnar at 12 to 24 months of age in a previous study.
1633459|NCT01982461|Drug|Crestor®|10mg,once daily
1633321|NCT01983540|Biological|Infanrix hexa + Prevenar + Rotarix vaccine|Infanrix hexa vaccine at 2, 4, 6 months of age concomitantly with Prevenar and Rotarix (2 doses at 2 and 4 months of age), and a booster dose of DTaP-IPV-Hep B-PRP~T vaccine concomitantly with Prevenar vaccine concomitantly with Prevenar at 12 to 24 months of age in a previous study.
1633322|NCT01983527|Procedure|Arthrographic distention|Arthrographic distention of the glenohumeral joint with injection of 5 ml contrast, 15 ml local anaesthetic (Prilocaine) and up to 15 ml saline.
1633323|NCT01983527|Drug|Intra-articular corticosteroid Depo Medrol|Intra-articular injection of 1 ml (40 mg) Depo Medrol(Methylprednisolone Acetate Injectable Suspension)
1633324|NCT01983514|Drug|8IU intranasal oxytocin|
1633325|NCT01983514|Drug|24 IU intranasal oxytocin|
1633326|NCT01983514|Drug|1 IU intravenous oxytocin|
1633327|NCT01983514|Drug|Placebo|
1633328|NCT01983501|Drug|tucatinib (ONT-380)|Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) (administered twice per day, orally) and T-DM1 (administered intravenously once every 21 days) until disease progression or unacceptable toxicity.
1633329|NCT01983501|Drug|T-DM1|Phase 1b dose escalation: 21-day cycles of tucatinib (ONT-380) (administered twice per day, orally) and T-DM1 (administered intravenously once every 21 days) until disease progression or unacceptable toxicity.
1633330|NCT01983475|Drug|Denosumab|In clinical trials, denosumab (Amgen Inc., Thousand Oaks, CA), has been shown to be more potent in reducing osteoclastosis and function than bisphosphonates.39,40 The rate of bone loss in the lower extremity at sites of interest in patients with acute SCI has been reported to be several-fold greater than the rate of bone loss in postmenopausal women not prescribed antiresorptive medications, which is about 3-5% per year.11,50,51 The dose of denosumab chosen for our protocol in patients after acute SCI will be the same dose that has been shown to be efficacious to treat postmenopausal osteoporosis (60 mg SQ q 6 months).
1633331|NCT01983475|Drug|Placebo (identical Denosumab volume of normal saline)|The placebo group will receive the identical volume of normal saline at parallel time points.
1633332|NCT01983462|Drug|Clonidine|
1633333|NCT01983462|Drug|Hydrochlorothiazide|
1633334|NCT01983462|Drug|Placebo|
1633335|NCT01983449|Drug|Dexamethasone Sodium Phosphate Injection, USP|Adventitial infusion of dexamethasone after angioplasty or atherectomy-based revascularization of the superficial femoral or popliteal artery.
1633336|NCT01983436|Other|Manual Lymphatic drainage|Manual lymphatic drainage of the face and the neck is a massage technique that aims to remove an edema of this anatomical region. The technique consists to stimulate the lymph nodes in order to accelerate the lymph flow and to achieve a specific massage to promote the entry of lymph nodes in the initial lymphatics. Massages follow anatomical pathways of vessels and of lymph nodes of the head and the neck. The technique should be smooth and painless.
1633337|NCT01983423|Device|Endometrial Biopsy|An endometrial biopsy is performed using a sampling device known as a pipelle catheter which is introduced into the uterine cavity. The inner core is withdrawn creating suctional pressure into the hollow bore of the cavity, which allows acquisition of endometrial tissue upon rotation in the cavity. This is removed and the tissue sent for pathologic examination.
1633338|NCT01983410|Behavioral|The risk assessment questionnaire|
1633339|NCT01983410|Other|Blood specimens|
1633340|NCT01983410|Other|tumor tissue samples will be requested|
1633341|NCT01983397|Other|Multicomponent training|The multicomponent training consisted of individuals subjected to a multicomponent exercise program: 5 minute warm up, 20 minutes of aerobic exercise, 15-20 minutes of strength exercises, 10 minutes of coordination, agility and balance exercises and 5 minute of cool-down.
1633342|NCT01983397|Other|Resistance training|The resistance training was subjected to a strength training using weight machines adapted for elderly. The protocol followed three sets of 10 to 12 maximal repetitions, moderate speed (two seconds for the shortening phase and three seconds for the elongation phase) and one minute for rest interval between sets.
1633343|NCT01983384|Other|Anesthetic depth|Investigators will undertake a randomized control trial in a cohort of older patients undergoing major non-cardiac surgery to receive either a control vs. an intervention of anesthesia as determined by a processed electroencephalogram
1633344|NCT01983371|Drug|Ferumoxytol|All study patients will receive a dose of ferumoxytol for the MRI. Ferumoxytol will be administered intravenously at a dose of 6 mg/kg, for a maximum dose of 510 mg.
1633345|NCT01983371|Other|Magnetic Resonance Imaging|All study patients will undergo a ferumoxytol-enhanced MRI in addition to any other ongoing care for colorectal cancer. Histopathologic analysis of lymph nodes will be the gold standard for determining lymph node status.
1633346|NCT01983358|Drug|JPI-289|PARP-1 inhibitor
1633347|NCT01983358|Other|Placebo|Placebo
1633348|NCT01983345|Procedure|prenatal surgical repair of fetal myelomeningocele|open surgical repair of myelomeningocele before 26 weeks gestational age
1633349|NCT01983319|Device|active anodal transcranial Direct Current Stimulation (tDCS)|Anodal transcranial Direct Current Stimulation 1.5 mA in 30 minutes with CIMT
1633350|NCT01983319|Device|sham transcranial Direct Current Stimulation|sham transcranial Direct Current Stimulation 30 min with CIMT
1633351|NCT01983319|Behavioral|Constraint Induced Movement Therapy (CIMT)|2 weeks of CIMT
1633352|NCT01983306|Drug|SP-333 1 mg|Tablet
1633353|NCT01983306|Drug|SP-333 3 mg|Tablet
1633354|NCT01983306|Drug|SP-333 6 mg|Tablet
1633355|NCT01983306|Drug|Placebo|Tablet
1633356|NCT01983293|Other|QLV based implant strategy|
1633357|NCT01983293|Other|Standard of care implant strategy|
1633358|NCT01983280|Other|Healing Touch|
1633359|NCT01983267|Drug|cannabis|use of cannabis oil or cigarets
1633360|NCT01983254|Behavioral|coping skills training|6-session coping skills training program delivered by telephone w/ web augmentation
1633361|NCT01983254|Other|education program|web-based, ICU-specific education program
1633362|NCT01983241|Biological|Alpha1-proteinase inhibitor (human), modified process (Alpha-1 MP)|
1633363|NCT01983241|Other|0.9% Sodium Chloride for Injection, USP|
1633403|NCT01982877|Behavioral|Four Supports Intervention|The Four Supports Intervention is a multi-faceted intervention involving the addition of a trained nurse/social worker interventionist to the patient's care team who delivers four kinds of support: emotional support, communication support, decision support, and anticipatory grief support.
2011833|NCT02382796|Drug|Dacomitinib|Starting at the current dose level in the prior study. Dose reductions and re-escalations are allowed based on tolerability. Patients may continue to be treated with dacomitinib on this protocol as long as there is evidence of clinical benefit in the judgment of the investigator.
1633365|NCT01983215|Device|Prevena vac|
1633366|NCT01983189|Procedure|transcranial magnetic stimulation|1 hz transcranial magnetic stimulation
1633367|NCT01983163|Other|Ketogenic diet (2.5 to 4:1)|Minimum ratio (2.5 to4:1) ketogenic diet causing ketosis will be given
1633368|NCT01983163|Other|Modified Atkin's diet|1:1 fixed ketogenic ratio Modified atkins diet will be given
1633369|NCT01983150|Behavioral|Crush the Crave Application|Crush the Crave (CTC) allows users to customize a quit plan by choosing a quit date and then deciding whether to quit now or cut down the number of cigarettes they smoke every week up to the quit date. CTC reminds users of money saved and health improvements. Based on contingency reinforcement, rewards are provided, which smokers can then choose to share with their social network via Facebook. Supportive text messages tailored to their specific quit plan and where they are in the quitting experience are provided. CTC allows tracking of daily smoking habits and cravings as well as craving triggers or psychosocial determinants by recording when, where and why smoking occurred. Online distractions to help smokers deal with cravings are provided.
1633370|NCT01983150|Behavioral|On the Road to Quitting - Self Help|"The control group will receive an evidence-based self-help guide known as On the Road to Quitting that has been developed by Health Canada for young adult smokers. Participants will be able to both view the self-help guide via the internet and will receive a printed version of the guide."
1633371|NCT01983137|Drug|Targinact® (oxycodone/naloxone)|
1633372|NCT01983124|Drug|Fotemustine + Vemurafenib|"Fotemustine 100mg/m2 IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity.
Vemurafenib administered continuous oral dosing 960 mg twice daily or dose administered at time of progression since progression or unacceptable toxicity."
1633373|NCT01983111|Drug|buprenorphine|Dosage and administration: This one patch should be attached every 7 days.
1633374|NCT01983111|Drug|tramadol/acetaminophen|"Amount of drug ingredients
: Acetaminophen 325 mg and Tramadol hydrochloride 37.5 mg in 1 tablet of this drug.
Dosage and administration:
Adjust dose depending on a patient's pain severity and treatment response. Starting at the initial dose of 2 tablets, usually administer 4 tablets per dose, twice daily. At a dosing interval of at least 12 hr, the daily dose should not exceed 8 tablets."
1633375|NCT01983085|Device|NOx dressing|The NOx dressing should be changed at least every 2 days.
1633376|NCT01983085|Device|Standard of Care|Dressing changed as per normal clinical practice
1633377|NCT01983072|Dietary Supplement|Infant formula|
1633378|NCT01983072|Other|Breastfeeding|Breastfeeding
1633379|NCT01983046|Drug|Three different mixture of acetate, butyrate and propionate and palcebo|
1633380|NCT01983033|Behavioral|Drop It training session|8 training sessions in group, sessions of 90 minutes, 7 sessions weekly, plus 1 session after 1 month
1633381|NCT01983033|Behavioral|treatment as usual|12 weeks of no intervention other than treatment as usual
1633382|NCT01983020|Drug|Lidocaine|
1633383|NCT01983020|Drug|Ketamine|
1633384|NCT01983020|Other|Saline|
1633385|NCT01983007|Procedure|High-intensity exercise|Performance of high-intensity exercise
1633386|NCT01983007|Procedure|Low-intensity exercise|Performance of low-intensity exercise
1633387|NCT01982994|Behavioral|Education/Daily Planning|"In this study, we will use educational materials delivered at the initial enrollment session and in daily facts of the day presented electronically to heighten awareness of (1) the risks of insufficient physical activity and excessive sedentary behavior, and (2) the expected beneficial outcomes of increased physical activity and reduced sedentary behavior. These messages should are designed to increase intentions to engage in physical activity and to limit sedentary behavior (motivational phase)"
1633388|NCT01982981|Other|water provision|perception behavioral change at the beginning and at the end of the intervention
1633389|NCT01982981|Other|Water provision|After participants are recruited, drink 2L of water for 8 weeks.
1633390|NCT01982968|Procedure|Surgery|Full fundoplication surgery for the treatment of abnormal GER
1633391|NCT01982955|Drug|Tepotinib|Tepotinib will be administered at a dose range of 300 or 500 milligram (mg) (Phase 1b) and the recommended phase II dose (RP2D) determined in the Phase 1b in Phase II orally once daily over a 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment. RP2D will be determined as per safety monitoring committee (SMC) discretion.
1633392|NCT01982955|Drug|Gefitinib|Gefitinib will be administered at a dose of 250 mg orally as once daily over a 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment.
1633393|NCT01982955|Drug|Pemetrexed|Pemetrexed will be administered at a dose of 500 milligram per square meter (mg/m^2) as intravenous infusion over 10 minutes on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
1633394|NCT01982955|Drug|Cisplatin|Cisplatin will be administered at a dose of 75 mg/m^2 as intravenous infusion over 2 hours on Day 1 of each 21-day cycle until progressive disease, intolerable toxicity, subject's withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered.
1633395|NCT01982955|Drug|Carboplatin|Carboplatin will be administered intravenously on Day 1 of each 21-day cycle at a dose of area under curve (AUC) 5 or AUC6 at the discretion of the Investigator until progressive disease, intolerable toxicity, subject's withdrawal from treatment or up to 6 cycles if pemetrexed maintenance is not considered
1633396|NCT01982942|Drug|ibudilast|
1633397|NCT01982942|Drug|Placebo|
1633398|NCT01982929|Procedure|TAP block (Bupivacaine 0.25% with epinephrine 1:400,000 50 cc), & Oral Meds: Paracetamol 1000 mg PO Q8H, diclofenac 50 mg PO Q8H X 24 hours.|
1633399|NCT01982916|Drug|AGR tablet|
1633400|NCT01982916|Drug|Placebo (for AGR tablet and/or Active Comparator)|
1633401|NCT01982916|Drug|Active Comparator|
1633402|NCT01982890|Other|Control|No intervention as this group is simply followed prospectively.
1633454|NCT01982487|Other|laboratory biomarker analysis|Correlative studies
1633455|NCT01982487|Other|pharmacological study|Correlative studies
2011834|NCT02379247|Drug|BYL719|Oral PI3K inhibitor
1633404|NCT01982877|Behavioral|Educational Control Intervention|In addition to usual care, enrolled surrogates will receive two 15-minute education sessions about critical illness and mechanical ventilation on days 2 and 5, delivered by a research staff coordinator with education in critical care nursing.
1633405|NCT01982864|Drug|Gentamicin|"The decision to introduce the antibiotic is made during a session or between two sessions according to both the clinicians usual procedure.
Depending on the number of injections, 8 to 10 blood samples will be drawn per patient. Clinical and biological data will be concomitantly collected (e.g., hemodialysis session duration, creatinine clearance…).
The number of blood sampling and the time schedule will be adapted to the prescription and the possible follow-up of the treatment after the first injection. Whatever the time is between the first injection and the following dialysis session, a sampling will be performed 30 minutes after the end of the injection (T1), 8h after the end of the injection (T2), juste before (TAD), in the middle (TMD) and at the end of the dialysis (TFD)."
1633406|NCT01982851|Procedure|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
1633407|NCT01982851|Procedure|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
1633408|NCT01982838|Procedure|Epidural de novo|Patients will have the epidural space identified with a loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. The epidural catheter will be inserted 5 cm into the epidural space. Epidural analgesia will be initiated with fentanyl 100mcg + bupivacaine 0.125% 10-20 mL (in divided doses). Maintenance epidural analgesia will then be initiated.
1633409|NCT01982838|Procedure|CSE|The epidural space will be located using the loss-of-resistance technique utilizing a 17-G Tuohy epidural needle. Patients will receive the intrathecal study drug via a 27-G pencil-point spinal needle utilizing the standard needle-through-needle technique. A 19-G epidural catheter will be inserted 5 cm in the epidural space. Maintenance epidural analgesia will then be initiated.
1633410|NCT01982825|Behavioral|Online intervention arm|See online intervention arm
1633411|NCT01982825|Behavioral|Online control arm|See online control arm
1633412|NCT01982812|Drug|Oral Levetiracetam|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days
1633413|NCT01982812|Drug|Standard AED|Active comparitor, Standard AED
1633414|NCT01982799|Drug|Oral placebo|placebo
1633415|NCT01982799|Drug|Oral ibuprofen|Ibuprofen
1633416|NCT01982799|Drug|oral naproxen|naproxen
1633417|NCT01982799|Drug|oral acetaminophen/hydrocodone + ibuprofen|vicodin/ibuprofen
2011835|NCT02379247|Drug|Nab-paclitaxel|IV taxane
2011836|NCT02377466|Drug|Retosiban IV infusion|Retosiban for IV administration will be supplied as solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram per milliliter (mg/mL).
2011837|NCT02377466|Drug|Placebo IV infusion|0.9% NaCl matched for the retosiban loading dose and continuous infusion rates
2011838|NCT02376699|Drug|SEA-CD40 monotherapy regimen|Given intravenously on Day 1 every 3 weeks; or Days 1 and 8 every 3 weeks for 2 cycles, and then Day 1 every 3 weeks in subsequent cycles. Number of cycles: until progression or unacceptable toxicity develops.
1633422|NCT01982760|Drug|DDAVP|Patients Receiving DDAVP prior to operation
1633423|NCT01982747|Drug|MGN-Placebo|
1633424|NCT01982747|Drug|Placebo-MGN|
1633425|NCT01982734|Dietary Supplement|curcumin|80 mg curcumin were given orally either as native powder, native powder plus phytochemicals,micelles or micelles plus phytochemicals
1633426|NCT01982721|Device|Locking mechanism for prosthetic knee|
1633427|NCT01982695|Drug|Losartan|
1633428|NCT01982695|Drug|Lisinopril|
1633429|NCT01982682|Radiation|Total-Body Irradiation (TBI)|Undergo TBI
1633430|NCT01982682|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
1633431|NCT01982682|Drug|Cyclophosphamide|Given IV
1633432|NCT01982682|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo CD34+ selected allogeneic HSCT
1633433|NCT01982682|Drug|Mycophenolate mofetil|Given IV
1633434|NCT01982669|Other|No Intervention|
1633435|NCT01982656|Other|Massage|twenty minute massage intervention prior to bedtime (1900-2100), to be started after day 3 of admission for a minimum of 5 consecutive days and up to fourteen days. The massage will be conducted by an RN trained in massage technique that is not caring for the patient in a direct nursing role.
1633437|NCT01982630|Drug|MK-8521|
1633438|NCT01982630|Drug|Liraglutide|
1633439|NCT01982630|Drug|Placebo|
1633440|NCT01982617|Other|Motivational Interviewing|
1633441|NCT01982617|Other|Psychoeducation|
1633442|NCT01982604|Drug|TI-Inhalation Powder A|Inhaled Insulin
1633443|NCT01982604|Drug|TI-Inhalation Powder B|Inhaled Insulin
1633444|NCT01982591|Other|laboratory biomarker analysis|Correlative studies
1633445|NCT01982591|Other|questionnaire administration|Ancillary studies
1633446|NCT01982578|Dietary Supplement|Genistein|Subjects will be randomized 1:1 to receive 180 days of double blind treatment of genistein.
1633447|NCT01982578|Other|Placebo|180 days of double blind treatment of placebo.
1633448|NCT01982565|Device|NOx dressing|The NOx dressing should be changed at least every 2 days.
1633449|NCT01982565|Other|Standard of Care|The clinician/podiatrist is free to use whichever treatment they would choose to use on the patient in their current clinical practice.
1633450|NCT01982539|Drug|Zipsor®|Administration of Zipsor® (liquid filled capsules) to patients with mild to moderate acute pain: 25 mg/every 6 hours/up to 4 days treament. Drug taken by mouth.
1633451|NCT01982513|Device|Ultrasound|The IVC will be visualized and images obtained using the intercostal window in both longitudinal and transverse planes.
1633452|NCT01982487|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
1633453|NCT01982487|Drug|IDO1 inhibitor INCB024360|Given PO
1633462|NCT01982435|Drug|Ranibizumab|Monthly injections of Intravitreal Ranibizumab 0.3 mg for 12 months in patients previously treated with Avastin for Diabetic Macular Edema.
1633463|NCT01982435|Drug|Ranibizumab|Three Monthly injections of Intravitreal Ranibizumab 0.3 mg in patients previously treated with Avastin for Diabetic Macular Edema. Then follow-up visits may be extended by 2 weeks for a total of 12 months.
1633464|NCT01982422|Behavioral|Whole Food, Nutrient-Dense Dietary Intervention|The dietary intervention will be a whole food, nutrient-dense diet which restricts processed foods high in food additives while optimizing micronutrient intake.
1633465|NCT01982409|Biological|Live Attenuated Varicella Vaccine|
1633466|NCT01982396|Drug|ABC Twice Daily|
1633467|NCT01982396|Drug|ABC Once Daily|
1633468|NCT01982396|Drug|3TC Once Daily|
1633469|NCT01982396|Drug|3TC Twice Daily|
1633470|NCT01982383|Device|Micropulse Laser Treatment|
1633471|NCT01982357|Device|Laser Speckle Imaging and Diffuse Optical Spectroscopy|Laser Speckle Imaging and Diffuse Optical Spectroscopy
1633472|NCT01982344|Device|mini-exchange-room|
1633473|NCT01982331|Biological|LAIV H2N2|vaccine is delivered intranasally, .25 cc to each nostril at day 0 and day 28
1633474|NCT01982331|Other|Placebo|placebo delivered intranasally. .25cc to each nostril at day 0 and day 28
1633475|NCT01982318|Drug|VitroGro® ECM|
1633476|NCT01982318|Drug|Dulbecco's Phosphate Buffered Saline|
1633477|NCT01982305|Procedure|Simulator|Axillary nerve anatomy lecture plus training with the simulator.
1633478|NCT01982305|Procedure|Cadaver|Axillary nerve anatomy lecture plus training with the cadaver model.
1633479|NCT01982292|Drug|RLX030 (serelaxin)|RLX030 (serelaxin) was administered according to a weight-range adjusted dosing regimen at a nominal dose of 30 μg/kg/day as a continuous IV infusion for 48 hours.
1633480|NCT01982292|Drug|Placebo|Matching placebo of serelaxin was administered as a continuous IV infusion for 48 hours.
1633481|NCT01982266|Device|GRADION™ Hip Total Cartilage Replacement (TCR)™|
1633482|NCT01982253|Drug|Fasiglifam|Fasiglifam tablets
1633483|NCT01982253|Drug|Placebo to fasiglifam|Fasiglifam placebo-matching tablets
1633484|NCT01982240|Drug|Plecanatide|
1633485|NCT01982240|Drug|Placebo|
1633486|NCT01982227|Drug|indocyanine green|intravenous injection (0.25mg/kg) of the indocyanine green 24h before the surgery.
1633487|NCT01982214|Device|sedentary|No intervention
1633488|NCT01982214|Device|Vibration|Subjects will be submitted to the WBV for 5 to 20 minutes, 2 or 3 times a week with frequencies between 35 to 50 Hz while 12 months
1633489|NCT01982201|Drug|Lesinurad 400 mg|
1633490|NCT01982201|Drug|Tums 500 mg and 750 mg|
1633491|NCT01982201|Drug|MINTOX 10 mL|
1633492|NCT01982175|Biological|Alemtuzumab|"Escalation Phase: Initial Doses of Alemtuzumab 3mg/day by intravenous(IV) infusion until tolerated, then Alemtuzumab 10mg/day IV infusion until tolerated, then Alemtuzumab 30mg IV infusion until tolerated.
Escalation to 30mg/day should be accomplished in 3~7 days.
Stable dose Phase: Once 30mg/day infusion of Alemtuzumab was tolerated, then continue 3 times per week. The total duration of Alemtuzumab therapy including escalation and stable dose phase is 12 weeks.
More than 30mg daily or 90mg weekly dose is prohibited"
1633493|NCT01982149|Genetic|Group 1|Perform gene expression studies of airway epithelium to correlate findings in the gene expression of nasal bronchial epithelium
1633494|NCT01982149|Genetic|Group 2|Correlate gene expression data from nasal and bronchial epithelium
1633495|NCT01982149|Genetic|Group 3|Correlated nasal epithelial gene expression with the ultimate diagnosis (by biopsy or surgery)
1633496|NCT01982136|Procedure|end-to-end urethroplasty|
1633497|NCT01982136|Procedure|substitution urethroplasty (buccal mucosa)|
1633498|NCT01982136|Procedure|substitution urethroplasty (pedicled skin flap)|
1633499|NCT01982123|Procedure|Computed Tomography|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
1633500|NCT01982123|Procedure|Computed Tomography|Undergo 18F FDG PET/CT
1633501|NCT01982123|Radiation|Fludeoxyglucose F-18|Undergo 18F FDG PET/CT
1633502|NCT01982123|Procedure|Positron Emission Tomography|Undergo 18F FDG PET/CT
1633503|NCT01982123|Procedure|Single Photon Emission Computed Tomography|Undergo 99mTc-MAA and 99mTc-DTPA SPECT/CT
1633504|NCT01982123|Radiation|Technetium Tc-99m Albumin Aggregated|Undergo 99mTc-MAA SPECT/CT
1633505|NCT01982123|Drug|Technetium Tc-99m DTPA|Undergo 99mTc-DTPA SPECT/CT
1633506|NCT01982110|Behavioral|Mindfulness based smoking cessation|Mindfulness based interventions are provided via a mobile phone application.
1633507|NCT01982110|Behavioral|Behavioral Smoking Cessation intervention|Behavioral Smoking Cessation intervention is a behaviorally based intervention is provided via a mobile phone application.
1633508|NCT01982097|Drug|Sorafenib (Nexavar, BAY 43-9006)|The patients under routine treatment of metastatic RCC with Nexavar before and after cytoreductive nephrectomy meeting the criteria of inclusion.
1633509|NCT01982071|Drug|Micafungin|Intravenous (IV)
1633510|NCT01982058|Other|communication intervention|
1633511|NCT01982058|Other|counseling intervention|
1633512|NCT01982058|Other|nutrition intervention|
1633513|NCT01982058|Other|questionnaire administration|
2011839|NCT02376699|Drug|Pembrolizumab|Given intravenously on Day 2 every 3 weeks. Number of cycles: until progression or unacceptable toxicity develops.
1633516|NCT01982032|Procedure|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement
1633517|NCT01982032|Device|Medtronic CoreValve system|Transcatheter aortic valve replacement with the Medtronic CoreValve system
1633518|NCT01982032|Device|Edwards SAPIEN bioprosthesis|Transcatheter aortic valve replacement with an Edwards SAPIEN bioprosthesis
1633519|NCT01982019|Behavioral|Meal test taking and hormones measure including 26RFa|Meal test taking and blood sampling for the measure of 26RFa and classical hormones implicated in glucose control and obesity
1633682|NCT01980654|Drug|Ibrutinib|All subjects will receive 560 mg of Ibrutinib orally.
1633520|NCT01982006|Procedure|Cataract surgery with Phacoemulsification|"Each patients randomized in the phaco arm will undergo a conventional cataract surgery.
Corneal incisions will be manually performed using the same calibrated blade and at the same location for all procedures of one surgeon.
Phacoemulsification machine used to perform cataract surgery in each center will be the same for all patients included in the center. The IOL (IntraOcular Lens) used in each center will be the same for all patients treated in the center."
1633521|NCT01982006|Device|Femtosecond laser-assisted cataract surgery|"Each patients randomized in the femto arm will undergo a femtosecond laser assisted cataract surgery.
Corneal incisions will be performed by the laser. Number, size and location of the incisions must be the same than in the phaco arm for all patients treated by one surgeon.
Phacoemulsification machine used to remove the liquefied lens will be the same than in the phaco arm The IOL used in each center will be the same than in the phaco arm"
1633522|NCT01981993|Biological|Urinary proteomic analysis|
1633523|NCT01981980|Other|Carboxytherapy|Carboxytherapy was performed on the right side and RF on the left side. CA was administered using the beveled end of a 30G ½ needle introduced in the skin in an angle of approximately 30ºC and delivered at a velocity of 40 mL/min. The total quantity of CO2 infused was approximately 20 mL (0,3 to 0,6 mL/kg of patient's body weight) encompassing the whole delimited area.
1633524|NCT01981980|Other|Radiofrequency|The epidermal temperature was controlled using an infrared thermometer monitored to reach 40ºC and treatment time was of five minutes starting after having reached this temperature.
1633525|NCT01981967|Biological|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
1633526|NCT01981967|Biological|IMOJEV®: Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous.
1633527|NCT01981954|Drug|Solifenacin succinate|Oral suspension
1633528|NCT01981941|Drug|Gabapentin enacarbil|Oral
1633529|NCT01981928|Drug|ASP7962|Oral
1633530|NCT01981928|Drug|Placebo|Oral
1633531|NCT01981915|Procedure|IPPB|Lung insufflation with positive pressure using IPPB up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
1633532|NCT01981915|Procedure|LIAM|Lung insufflation using the Lung Insufflation Assist maneuver of the Ventilogic LS mechanical ventilator (Weinmann Germany) with positive pressure up from 10 to 40 mbar in 5 mbar increments and consecutive measurement of the insufflation volume
1633533|NCT01981902|Device|Non-Invasive Optical Spectroscopic|Non-Invasive Optical Spectroscopic
1633534|NCT01981889|Drug|Prednisone|Participants will be started on oral prednisone 40mg/day for two weeks as per standard of practice in IBD management, before starting a tapering course.
1633535|NCT01981863|Drug|Epsilonaminocaproic acid|One group receives Epsilonaminocaproic acid, 10 gr IV bolus, followed by 1 gr/hr. Second group receives placebo.
1633536|NCT01981863|Drug|Placebo|Placebo administered in same volume as in experimental arm.
1633537|NCT01981850|Biological|PRM-151|IV infusion
1633538|NCT01981837|Drug|ALN-TTRSC (revusiran) for subcutaneous administration|
1633539|NCT01981811|Drug|Aripiprazole|
1633540|NCT01981811|Device|Ingestible Event Marker (IEM)|
1633541|NCT01981798|Behavioral|Physiotherapy and occupational therapy|Members of the training group received 9 units of physiotherapy and 2 units of occupational therapy, each with a duration of one hour. Every patient of the IG was trained to perform a neck or back intervention program specifically suited to his/her needs. The training was conducted in a single session by one of three experienced physiotherapists (with mean work experience of 6 years). After this training the patients completed eight group training units consisting a maximum number of 8 participants, each unit with a duration of one hour, over a maximum period of six weeks.
1633544|NCT01981759|Drug|D-Cycloserine|Participants will receive 10 administrations of 50 mg of D-Cycloserine by mouth one hour before CBT sessions, weekly, in weeks 3-12.
1633545|NCT01981759|Drug|Placebo|Participants will receive 12 weekly administrations of 50mg placebo by mouth 1 hour before CBT sessions, from weeks 1-12.
1633546|NCT01981759|Behavioral|Cognitive Behavioral Therapy|Participants will engage in a Cognitive Behavioral Therapy treatment plan designed for psychotic delusions. The program will consist of 12 one hour sessions, once weekly from study week 1-week 12.
1633547|NCT01981746|Procedure|Adductor canal block with ropivacaine 0.1%|US-guided adductor canal block
1633548|NCT01981733|Device|geko|The geko is a neuromuscular stimulator device, which when applied stimulates the common peroneal nerve
1633549|NCT01981720|Drug|PRX-102|
1633550|NCT01981707|Device|F-Choline-PET|
1633551|NCT01981694|Drug|PF-06649751|Single doses, given by oral solution, starting at 0.25 mg up to a possible maximum of 7.5 mg. The subject will have been fasted for 10 hours prior to the single dose. For each dosing period, 3 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
1633552|NCT01981694|Drug|PF-06649751|It is believed that the maximum tolerated dose of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 5 subjects will be given a placebo as a comparator.
1633553|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
1633554|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (2.28 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back.
1633555|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
1633556|NCT01981681|Drug|Placebo|Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
1633557|NCT01981681|Drug|PF-06263726|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
1633635|NCT01981005|Drug|RO5424802|Single oral doses followed by IV or oral administration of a 14C-labeled tracer
1634029|NCT01977677|Radiation|radiation therapy|Undergo radiation therapy
1633558|NCT01981681|Drug|Placebo|Subjects will receive dose strength of 4% PF-06263276 (22.8 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back.
1633559|NCT01981668|Drug|cabazitaxel|Concurrent cabazitaxel, radiotherapy and Eligard for 3 years
1633560|NCT01981655|Drug|0.5M Sodium lactate|A bolus of 0.5M Sodium lactate of 3 ml per kg BW is administered in 15 minutes, followed by a continuous infusion with 1 ml per kg per hour for 24 hours, i.e. in total 27 ml per kg over 24 hours
1633561|NCT01981655|Drug|Hartmann's solution|Hartmann's solution of 3 ml per kg BW is administered in 15 minutes, No infusion thereafter i.e. in total 3 ml per kg over 24 hours
1633562|NCT01981642|Other|Recording of LVAD data during routine visits and daily life.|Noninvasive diagnostic intervention.
1633563|NCT01981642|Other|Recording of daily activity using wristwatch accelerometers.|Noninvasive diagnostic intervention.
1633564|NCT01981629|Device|USCOM|The USCOM device will be used in addition to cardiac ultrasound in patients with shock.
1633565|NCT01981616|Drug|Vedolizumab|Vedolizumab for intravenous infusion
1633566|NCT01981616|Drug|Placebo|Placebo intravenous infusion
1633567|NCT01981616|Biological|Hepatitis B vaccine|
1633568|NCT01981616|Biological|Oral cholera vaccine|
1633569|NCT01981603|Other|navigator|
1633570|NCT01981590|Device|Stimulating the phrenic nerve intravenously using high frequency electrical pulses using an EP catheter connected to external pulse stimulator.|Intravenously stimulating the phrenic nerve with an EP catheter using high frequency electrical pulses as generated by the model 19039 external neurostimulator.
1633571|NCT01981564|Behavioral|Asthma Express Intervention|Asthma Express clinic visit for asthma education + nurse home visit
1633572|NCT01981564|Behavioral|Asthma Express Control Arm|Asthma Express home nurse visits for asthma education
2011840|NCT02377635|Dietary Supplement|Anhydrous selenite|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
2011841|NCT02377635|Dietary Supplement|Sodium chloride|40 volunteer sufferers will be housed in a local private in-patient clinic where they will follow a fixed, communal diet consisting of drinking water and meals from their village. On a 6th day we will give a single dose of placebo (sodium chloride) or anhydrous sodium selenite (0.8mg selenium) labelled with a non-radioactive naturally occurring isotope (77Se), to distinguish it from selenium already in the body.
1633575|NCT01981499|Drug|PF-05180999|Ascending single oral doses of 120, 240, and 420 mg modified-release tablets
1633576|NCT01981499|Drug|Placebo|Placebo tablets
1633577|NCT01981499|Drug|120 mg MR PF-05180999|Single 120 mg dose administered as modified release formulation
1633578|NCT01981499|Drug|360 mg MR PF-05180999|Single 360 mg dose administered as modified release formulation
1633579|NCT01981499|Drug|10 mg cetirizine|Single 10 mg dose of cetirizine
1633580|NCT01981499|Drug|Placebo|Placebo tablets
1633581|NCT01981486|Drug|Placebo Tablets|BID modified-release tablets
1633582|NCT01981486|Drug|PF-05180999 Tablets|BID modified-release tablets (20 to 240 mg BID)
1633583|NCT01981473|Other|no intervention|
1633584|NCT01981473|Other|no intervention|
1633585|NCT01981473|Other|no intervention|
1633586|NCT01981460|Procedure|Methylene blue and light treatment|Methylene blue and light treatment for 17 minutes are done twice over 1 week intervals.
1633587|NCT01981447|Drug|IV Lacosamide|Lacosamide administered intravenously over 15 or 30 minutes, depending on study arm, to patients with epilepsy.
1633589|NCT01981408|Drug|[^14C]-LY2801653|Administered orally
1633590|NCT01981395|Drug|Fenobam|Fenobam 150 mg will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
1633591|NCT01981395|Drug|Placebo|A placebo will be administered and subjects will be monitored for up to 8 hours. During the study day questionnaires will be administered, blood will be drawn a testing site will be marked and pain testing and heat/capsaicin sensitization will be measured.
1633592|NCT01981369|Drug|Dexmedetomidine|Intravenous sedation with dexmedetomidine
1633593|NCT01981369|Drug|Propofol|Intravenous sedation with propofol
1633594|NCT01981369|Procedure|Infraclavicular block|All patients will receive ultrasound guided infraclavicular block with the standard protocol of the Block Room in St. Joseph Hospital.
1633595|NCT01981356|Behavioral|Acceptance and Commitment Therapy|"The goal of ACT is to help the patient increase psychological flexibility, a core component of mental health and well-being. ACT teaches clients to be mindfully aware but nonreactive to delusions/ hallucinations and to increase willingness to
experience associated distressing emotions while simultaneously engaging in meaningful behavioral actions.
Patients expand their repertoire of behaviors to live according to their values and to pursue valued goals, thereby increasing adaptive functioning and quality of life."
1633596|NCT01981356|Other|Treatment as Usual (TAU)|All patients admitted to the acute psychiatry unit are administered anti-psychotic and/or other psychotropic medication during their inpatient stay. Patients participate in standard milieu therapy on the unit (group and activities therapies, and individual therapy as needed). Therapy on the unit focuses on psycho-education about illness, symptom identification, mood management techniques, stress reduction, and relapse prevention. Patients also receive unstructured individual therapy and case management as appropriate.
1633597|NCT01981343|Dietary Supplement|A-F Betafood|
1633598|NCT01981343|Other|Placebo|
1633599|NCT01981330|Biological|aMSC|aMSC injected into the vocal fold of the patient
1633600|NCT01981330|Biological|aMSC+hyaluronan gel|aMSC+ hyaluronan gel is injected into the patients vocal fold
1633601|NCT01981317|Behavioral|Stepped Care Cognitive Behavioral Therapy|
1633602|NCT01981317|Behavioral|Cognitive Behavioral Therapy|
1633681|NCT01980667|Drug|Cisplatin|vials containing 1 mg/ml concentrate for solution for infusion
1711398|NCT01376297|Drug|Dexamethasone|
1633603|NCT01981291|Procedure|Intraneural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle penetrates the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if nerve cross section expansion and a reduction in echogenicity are observed.
Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
1633604|NCT01981291|Procedure|Perineural Injection for Subgluteal Sciatic Nerve Block|"The injection will start as the needle indents the outermost discernible layer of the nerve (epineurium) under ultrasound guidance. The injection will be adjudicated as intraneural if the drug infiltrates the space between the epimysium of the surrounding muscles and the outer epineurium of the sciatic nerve.
Short-axis real-time ultrasound imaging will be used, with an in-plane needle approach."
1633605|NCT01981291|Procedure|Femoral Nerve Block|Patients will receive an ultrasound-guided femoral nerve block using a short- or long-acting local anesthetic, as deemed indicated.
1633606|NCT01981291|Procedure|Patient-controlled postoperative analgesia|Patients will receive a patient-controlled intravenous or perineural catheter-based analgesia, depending on their preference and the anesthesiologist's indication.
1633607|NCT01981291|Drug|Mepivacaine|Thirty milliliters of 1.5% (wt/vol) mepivacaine will be used for the sciatic nerve block.
1633608|NCT01981278|Drug|Tapentadol ER 250-mg TRF tablet|Participants will receive single oral dose of tapentadol ER 250-mg TRF tablet on Day 1 of each treatment period.
1633609|NCT01981278|Drug|Tapentadol ER 250-mg PR2 tablet|Participants will receive single oral dose of tapentadol PR2 250-mg tablet on Day 1 of each treatment period.
1633610|NCT01981252|Device|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
1633611|NCT01981239|Device|VFSS|VFSS was perfomred one day before or after the voice sampling in the same patients according to the guideline of modified Longeman's protocol.
1633612|NCT01981226|Device|Extracoporeal shock wave|Extracoporeal shock wave, 3000 shots/time, once a week for 3 weeks, treatment duration:30 minutes/time, shock wave freqency：2-4Hz, energy level:0.8-1.0 mJ/mm2
1633613|NCT01981200|Other|Resistance training in AECOPD|The patients begin training on day 1 of admittance. The training consists of knee extension performed in the sitting position on the bed with a 90 degrees of flexion of the knees. The weight cuffs are tired to the angles with a weight corresponding to 10 RM (the weight lifted 10 times). The weights and exercises are subjected to supervision on daily basis by the physiotherapist. The weight is increased after every set of training if more than 10 rep. can be performed with a given weight. Limitations to exercise is also recorded along with the degree of dyspnoea as assessed by the Borg CR10, possible oxygen supplementation and saturation is recorded before and following exercise.
1633614|NCT01981187|Drug|LGX818|LGX818 will be dosed on a flat scale of 300 mg (e.g., 3 x 100 mg capsules) once daily on a continuous dosing cycle. A complete treatment cycle is defined as 28 days. There will be no breaks between dosing cycles.
1633615|NCT01981174|Procedure|30-gauge needle|
1633616|NCT01981174|Procedure|32-gauge needle|
1633617|NCT01981161|Procedure|biological samples and clinical data|
1633618|NCT01981148|Device|Fluorescence lifetime ophthalmoscope|All patients and healthy subjects will be imaged with the fluorescence lifetime ophthalmoscope
1633619|NCT01981135|Other|Clean Air|Each subject will be exposed to clean air for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
1633620|NCT01981135|Other|Ozone|Each subject will be exposed up to 0.3ppm ozone for 2 hours. The exposure atmosphere will be at a temperature between 31-34oC (88-93 oF) and approximately 40 + 10% RH. Subjects will exercise on a bike. Each exercise session will consist of a 15 minute exercise interval at a level of up to 25 L/min/m2BSA followed by a 15 minute rest period.
1633621|NCT01981122|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
1633622|NCT01981122|Drug|enzalutamide|Enzalutamide is an androgen receptor inhibitor. It is indicated for the treatment of patients with mCRPC who have previously received docetaxel. The enzalutamide dose used in this study will be 160 mg orally once daily.
1633623|NCT01981096|Behavioral|Fibromyalgia integrative training|Combined intervention with neuromuscular exercise training and cognitive behavioral therapy
1633624|NCT01981096|Behavioral|Cognitive Behavioral Therapy|Therapy focused on training in behavioral pain coping skills
1633625|NCT01981083|Dietary Supplement|Egg albumin-based protein supplement|
1633626|NCT01981083|Dietary Supplement|Renal-specific oral supplement|
1633627|NCT01981070|Behavioral|Mindfulness Intervention for Parents|See Study Arms
1633628|NCT01981070|Behavioral|Support and Information for Parents|See Study Arms
2011842|NCT02373800|Device|Cervical ultrasound with elastography|Following routine vaginal exam with determination of Bishop's score, cervical ultrasound with elastography will be used to determine a cervical hardness score varying from 1 to 10. Patients are then hospitalized and labor induced 12 to 48 hours after the elastography.
1633632|NCT01981031|Drug|BioChaperone® Combo|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
1633633|NCT01981031|Drug|Humalog® Mix25|Single dose of 0.8U/kg body weight injected subcutaneously (under the skin)
1633634|NCT01981018|Other|Imagery-focused Cognitive Therapy (ImCT - psychotherapy based on CBT principles)|"ImCT Therapy is carried out by a team of 2 co-therapists and comprises of:
Mapping: Therapists and patient collaboratively map out difficulties and pinpoint a treatment focus, with regards to imagery symptoms and anxiety co-morbidity that impact on bipolar mood instability. This leads to an individualised formulation of the patient's current problem.
Target: Follows the rationale, timing and objectives identified collaboratively in Mapping. It is structured around imagery-based techniques, such as imagery rescripting, which are used to address problematic imagery, to promote management of mood and boost self-care. This results into the acquisition of imagery-based mood- and anxiety-regulating strategies to be integrated into the patient's already existing coping strategies.
Consolidation: Consist of fine tuning the strategies devised during Target based on experience gained after testing them out in real life situations and includes a video blue print."
1633636|NCT01980992|Drug|Wheat OIT|Vital Wheat Gluten dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
1633637|NCT01980979|Drug|Remodulin|Subcutaneous (SQ) remodulin will be initiated at 1.25 ng/kg/min, and increased by 2-6 ng/kg/min weekly to a target dose of 40 ng/kg/min. If the initial infusion rate cannot be tolerated it will be reduced to 0.625 ng/kg/min. If subjects cannot tolerate the SQ therapy, we will attempt to switch to IV therapy.
1633638|NCT01980966|Drug|MHAA549A|IV dose
1633639|NCT01980966|Drug|Placebo|IV dose
1633640|NCT01980966|Drug|oseltamivir [Tamiflu]|Orally b.i.d, 5 days
1633641|NCT01980953|Drug|GDC-0032 Phase III Tablet|Participants will receive 2 mg or 3 mg Phase III tablet after 10 hour fasting from food.
1633642|NCT01980953|Drug|GDC-0032 Tablet|Participants will receive 3 mg Tablet A or Tablet B formulation after 10 hour fasting from food.
1633643|NCT01980953|Drug|GDC-0032 Capsule|Participants will receive 3 mg GDC-0032 capsule formulation after 10 hour fasting from food.
1633644|NCT01980940|Drug|Etoricoxib 75 mg 4% DMSO Gel|Etoricoxib 75 mg 4% DMSO gel applied topically.
1633645|NCT01980940|Drug|Etoricoxib 75 mg 4% PG Gel|Etoricoxib 75 4% PG gel applied topically.
1633646|NCT01980940|Drug|Etoricoxib 150 mg 4% DMSO Gel|Etoricoxib 150 mg 4% DMSO gel applied topically.
1633647|NCT01980940|Drug|Etoricoxib 150 mg 4% PG Gel|Etoricoxib 150 mg 4% PG gel applied topically.
1633648|NCT01980940|Drug|Etoricoxib 163 mg 4% DMSO gel|Etoricoxib 163 mg 4% DMSO gel applied topically
1633649|NCT01980940|Drug|Placebo|Placebo gel applied topically.
1633650|NCT01980940|Drug|Etoricoxib 50 mg 4% DMSO|Etoricoxib 50 mg 4% DMSO gel applied topically.
1633651|NCT01980940|Drug|Matching Placebo to Etoricoxib 50 mg 4% DMSO Gel|Matching Placebo to Etoricoxib 50 mg 4% DMSO gel applied topically.
1633652|NCT01980927|Procedure|NUCCA atlas correction|"A chiropractic procedure involving correcting a misalignment of the atlas or top vertebra in the spine."
1633653|NCT01980901|Device|Ovation™/Ovation Prime™ Abdominal Stent Graft System|Single occurence permanent implant of AAA device.
2011843|NCT02370901|Device|Helmet|Custom fitting helmet, FDA approved, to allow reshaping of the infant skull
2011844|NCT02370901|Behavioral|home therapies|parents will be instructed to do home neck stretching exercises, as well as repositioning techniques to keep baby off the flat spot. They will also be offered reassurance.
1633658|NCT01980875|Drug|Idelalisib|150 mg tablet administered orally twice daily
1633659|NCT01980875|Drug|Chlorambucil|2 mg tablets administered at a dose of 0.5 mg/kg orally every other week for a total of 12 doses
1633660|NCT01980875|Drug|Obinutuzumab|1000 mg/40 mL single-use vials administered intravenously for a total of 8 doses over 21 weeks
1633661|NCT01980849|Drug|Nadroparin, long term|
1633662|NCT01980849|Drug|Nadroparin: short-term|
1633663|NCT01980836|Biological|Seasonal influenza vaccine|
1633664|NCT01980823|Drug|Metformin|"Metformin is an oral diabetes medicine that helps control blood sugar levels.
Dosage/Frequency: 1500 mg per day: divided 500 mg in the morning and 1000 mg in the evening
Metformin is for people with type 2 diabetes. Metformin is sometimes used in combination with insulin or other medications, but it is not for treating type 1 diabetes."
1633665|NCT01980823|Drug|Atorvastatin|"Atorvastatin is in a group of drugs called statins. Atorvastatin reduces levels of bad cholesterol (low-density lipoprotein, or LDL) and triglycerides in the blood while increasing levels of good cholesterol (high-density lipoprotein, or HDL).
Dosage/Frequency: 80 mg once a day at bedtime
Atorvastatin is used to treat high cholesterol, and to lower the risk of stroke, heart attack, or other heart complications in people with type 2 diabetes, coronary heart disease, or other risk factors."
1633666|NCT01980823|Procedure|Breast surgery|(Non-experimental) Female subjects with histologically-confirmed operable invasive breast cancer or DCIS will undergo core needle biopsy with a plan of surgical excision.
1633667|NCT01980810|Drug|albumin-bounded paclitaxel|200mg iv d1, repeat every 2 weeks,until disease progression,or up to 9 cycles
1633668|NCT01980810|Drug|S-1|40mg/m2 po, bid,d1-10,repeated every 2 weeks until disease progression
1633669|NCT01980771|Behavioral|BTWB intervention|Men work in groups to complete a intervention that takes approximately two hours to complete.
1633670|NCT01980771|Behavioral|Cancer prevention and screening|Men are provided health education about cancer screening and prevention
1633671|NCT01980758|Procedure|Laparoscopic Gastric Plication|The study will examine the effects of a type of weight loss surgery on obese adolescents age 14-19. ) The study protocol includes pre-treatment assessments followed by a 2-month education and lifestyle modification treatment program. Following surgery, comprehensive follow-up care will be provided over a 3 year period.
1633672|NCT01980745|Drug|Chloroquine diphosphate 250mg|Sugar pill (placebo) one pill per day for 1110 days Chloroquine diphosphate 250mg per day for 1110 days
1633673|NCT01980745|Drug|Placebo|
1633674|NCT01980732|Drug|68Ga-DOTA TATE|Patients with somatostatin receptor positive tumors will be evaluated with 68Ga-DOTA TATE PET/CT in addition to conventional imaging.
1633675|NCT01980706|Drug|Baclofen|Baclofen is a GABA-B agonist
1633676|NCT01980706|Drug|Placebo|Pill containing no pharmacologically active substance.
1633677|NCT01980693|Device|SonicBone ultrasound|The device measure BA using ultrasound technology by measurement of speed of sound in three different sites : wrist bones, Phalanx III, Metacarpal bones.The device sends a short US pulse and measures the distance between a transmitter probe and a receiver probe, located at the bone measured area.The US probe converts electrical pulse to US pulse and US wave via tested bone arrives from transmitter to Receiver. Simultaneously with US pulse, controller start timer to calculate time between US pulse and the moment that US wave arrives to receiver. The accepted US signal of selected probe via amplifiers arrives to comparators that read timer value. The microcontroller calculates SOS using distance between probes and US time of flight.
1633678|NCT01980680|Drug|hCG|
1633679|NCT01980680|Drug|Progesterone and Estradiol|
1633680|NCT01980667|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
1633683|NCT01980654|Drug|rituximab|All subjects will receive rituximab 375 mg/m2 intravenously
1633684|NCT01980641|Behavioral|Educational intervention|All subjects received an educational intervention consist in an educational advice provides by the therapist to improve the adherence of the treatment.
1633685|NCT01980641|Device|Smartphone-based application|Smartphone-based application group (SG) sample will have a reminder. The app will provide the advice previously given by the therapist in the participants' homes.
1633686|NCT01980628|Drug|ibrutinib|
1633687|NCT01980615|Drug|Inhaled BGF (PT010) Dose 1|
1633688|NCT01980615|Drug|Inhaled BGF (PT010) Dose 2|
1633689|NCT01980615|Drug|Inhaled BGF (PT010) Dose 3|
1633690|NCT01980615|Drug|Inhaled GFF (PT003)|
1633691|NCT01980615|Drug|Inhaled Symbicort Dose 1|
1633692|NCT01980615|Drug|Inhaled Symbicort Dose 2|
1633693|NCT01980602|Procedure|Supervised Exercise program|
1633694|NCT01980589|Drug|Carfilzomib|Carfilzomib administered as a 30-minute intravenous (IV) infusion on Days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. On Days 1 and 2 of Cycle 1, all participants received carfilzomib at 20 mg/m².
1633695|NCT01980589|Drug|Cyclophosphamide|Cyclophosphamide administered orally (PO) at the dose of 300 mg/m² on Days 1, 8, and 15 of each 28-day cycle.
1633696|NCT01980589|Drug|Dexamethasone|Dexamethasone administered PO or IV at 40 mg on Days 1, 8, 15, and 22 of each 28-day cycle.
1633697|NCT01980563|Procedure|ultrasound|
1633698|NCT01980563|Procedure|combined monitoring|
1633699|NCT01980550|Drug|sublingual nicotine|The nicotine sublingual tablet is Smokers were recommended to use one or two tablets per hour, up to a maximum of 20 tablets per day. Subjects were advised to use the full treatment dose for 4 weeks. After this time-point, treatment could be tapered off up to the 8-week visit. During the next 4-week follow-up phase, no further medication was dispensed. Staff, who dispensed medications, were not involved in treating the subjects. During each patient visit, the importance of adequate dosing with study medication was emphasized. The medication was free of charge. In addition, all participants received six sessions of standardized behavioral group counseling focusing on self-monitoring and behavioral modification approaches.
1633700|NCT01980537|Procedure|Magnetic wire navigation|
1633701|NCT01980537|Procedure|Conventional wire navigation|
1633702|NCT01980524|Drug|acipimox|
1633703|NCT01980524|Drug|Placebo Oral Capsule|
1633704|NCT01980498|Drug|Fentanyl pectin nasal spray (FPNS)|The first dose of FPNS will be 100 mcg dose. It will be increased until 800 mcg dose.
1633705|NCT01980498|Drug|Physician choice-Usual care (PC-UC)|"The PC-UC will be started at a dose according to the physician choice. If this dose of PC-UC is effective on pain control, at the following meal the patient will take the same dose of PC-UC.
If the dose of PC-UC results non effective on pain control, at the following meal the patient will take an increased dose of the same PC-UC drug or change the PC-UC drug, according to the physician choice."
1633706|NCT01980485|Behavioral|Lung Age feedback and exhaled carbon monoxide|"In the intervention group, if the lung age is equal to or less than the individual's chronological age, he or she will be briefly informed that the test result was normal and that it is important to avoid potential future lung problems by stopping smoking. For those in the intervention group with a normal FEV-1, the intervention will focus on their exhaled carbon-monoxide.
If their lung age is greater than their chronological age, they will be given their lung age in years, and provided with a graph describing the possible decline in lung age if they continued to smoke and a full explanation.
Those in the Intervention Group will have their exhaled carbon-monoxide (CO) result explained in more detail. Non-smokers typically have an exhaled carbon-monoxide level of 0-4 parts per million, whereas smokers typically have a CO level of 8-50 ppm. CO levels return to normal within a few days of stopping smoking. Participants are provided with a full explanation."
1633707|NCT01980485|Behavioral|No Lung Age Feedback|Those allocated to the control group will simply be informed of their scores on the spirometry.
1633708|NCT01980472|Biological|bevacizumab, carboplatin and paclitaxel|4-6 initial cycles of bevacizumab, carboplatin and paclitaxel bevacizumab until progression or toxicity
1633709|NCT01980459|Dietary Supplement|magnesium lactate|Patient will be given 4 tablets a day of study supplement (Magnesium Lactate) for 3 months. Magnesium cellular and serum levels will be compared prior and post intervention.
1633710|NCT01980446|Procedure|Auditory-evoked potentials|cortical auditory-evoked potentials are performed to all included patients at inclusion, at day 5 to day 10, day without sedation (up to 1 year), day of awakening
1633711|NCT01980433|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Inhibitory 1 Hz rTMS, delivered to left somatosensory cortex during rest. Intervention is delivered during 20 minutes in one single session.
1633712|NCT01980433|Other|pre and post-rTMS electroencephalogram|to verify the absence of infraclinical seizures
1633713|NCT01980433|Other|WCRS|Writer's cramp rating scale
1633714|NCT01980433|Other|handwriting scale DPRE|handwriting in development and being evaluated by the NRC Wilson
1633715|NCT01980433|Other|visual analog scale of discomfort writing and parameters collected on touchpad|
1633716|NCT01980420|Procedure|Laparoscopic sleeve gastrectomy|Conventional laparoscopic sleeve gastrectomy using EndoFLIP® probe to provide measures on the distensibility of gastro-esophageal junction (GEJ) and gastric tube.
1633717|NCT01980407|Drug|S-1, leucovorin, oxaliplatin|S-1 (20mg), capsule, 40-60mg, bid, p.o., day1-14； Leucovorin (15 mg), tablet, 30mg,Bid, p.o., day1-14; Oxaliplatin (50 mg), injection 85mg/m2, day1.
1633718|NCT01980394|Procedure|Esophageal Stump Washout|a washout of the closed esophageal stump with Ringer-solution (10 times 30ml) is performed by means of a transorally inserted 24F-Foley catheter. The first, fifth and tenth portion of the lavage fluid are collected and sent to cytological examination
1633719|NCT01980381|Other|Tree Theme Method ® (TTM)|The TTM method is based on creative activities and occupational life story telling, implies that the paints trees representing different life periods, looking back and forward, as well as the present.
1633720|NCT01980368|Other|Educational Intervention|Receive readings and attend book club
1633721|NCT01980368|Behavioral|Exercise Intervention|Receive Tai Chi Easy class, DVD, and exercise manual
1633722|NCT01980368|Other|Questionnaire Administration|Ancillary studies
1634030|NCT01977677|Drug|temozolomide|Given PO
1633725|NCT01980342|Drug|Efavirenz|Healthy women who are using Nexplanon will be asked to take a 2-week course of reduced-dose efavirenz (400 mg daily).
1633726|NCT01980329|Drug|Maraviroc|
1633727|NCT01980316|Drug|Argatroban|Argatroban in patients undergoing load 250μg/kg, followed by 15μg/kg/min continuous intravenous infusion.5 days after surgery, take 10mg intravenous infusion of speed 2/day
1633728|NCT01980316|Drug|non-argatroban treated group|Patients in control group will receive Unfractionated heparin treatment
1633729|NCT01980303|Drug|Esketamine|Fourteen percent esketamine solution (14 mg of esketamine per 100 microliter) will be administered intranasally by nasal spray pump.
1633730|NCT01980277|Drug|LY2780301 + paclitaxel|Continuous daily PO LY2780301 (400 mg, 500 mg or 300 mg) QD + weekly paclitaxel (70 or 80 mg/m²/week) for 21 days cycle until progression or toxicity
1633731|NCT01980264|Device|Harmonic generation optical biopsy|
1633732|NCT01980238|Device|cannula ileostomy|
1633733|NCT01980238|Device|loop ileostomy|
1633734|NCT01980238|Device|LAR|
1633735|NCT01980225|Procedure|Collapse|inducing collapse (= artificial shrinkage) by applying 1 or 2 laser pulses between trophectoderm cells of the blastocyst to be vitrified
1633736|NCT01980199|Drug|Fexinidazole|"600 mg tablets given orally, after the main daily meal
at the daily dose of 1800 mg (3 tablets) once a day for 4 days
continued by 1200mg (2 tablets)once a day for 6 days"
1633737|NCT01980186|Device|TUS transcranial 2D ultrasound|
1633738|NCT01980173|Procedure|Routine care|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm of the study will continue to have routine care.
1633739|NCT01980173|Device|Bakri balloon|Following diagnosis with post-partum hemorrhage, an initial 30 minute phase corresponding to current recommendations, an injection of sulprostone, a demonstrated inefficacy of sulprostone 20 minutes after the injection and finally randomization, patients in this arm will be treated with the immediate placement of a Bakri balloon, followed by routine care if necessary.
1633740|NCT01980160|Device|Activated Nometex Device|Nometex Device that is activated so will be sending electrical pulses to the median nerve which will travel through afferent nerve fibers to the emetic centers of the brain. It is in these areas that the neurotransmitters modulate signals going to the stomach via the Vagus nerve. These electrical signals normalize the stomach rhythms, thereby alleviating nausea and vomiting.
1633741|NCT01980160|Device|Unactivated Nometex Device|
1633742|NCT01980147|Behavioral|maCBT|Multimodal Antecedent-focussed Cognitive-behavioural Training (maCBT) is an individual manualized psychological intervention. It follows an integrated model focussed on normalisation of the unusual experiences, their re-appraisal, exploring helpfulness of current coping, and developing a repertoire of strategies to decrease the impact of these experiences on the young person's life. The maCBT follows a manual describing obligatory and optional therapeutic elements, proposed list of modules, outline of a therapeutic session, and the integrated cognitive model. The intervention will be delivered in 8 to 16 one-hour sessions in an individual format. Sessions will be initially weekly, and then spaced out to once every two weeks in the latter stages of the intervention.
1633743|NCT01980121|Device|Ultrasound|Two-dimensional portable ultrasound unit with a low frequency (2-5 MHz) curved array transducer
1633744|NCT01980108|Other|water|water
1633745|NCT01980095|Drug|RHB-105|"The intended dose is RHB-105 (12.5 mg rifabutin, 250 mg amoxicillin, and 10 mg omeprazole capsules) 4 capsules every eight hours, equivalent to a total daily dose of:
Rifabutin 150 mg
Amoxicillin 3000 mg
Omeprazole 120 mg
Subjects will take study drug every 8 hours with food for 14 consecutive days."
1633746|NCT01980095|Drug|Placebo|Subjects will take 4 placebo capsules every 8 hours with food for 14 days.
1633747|NCT01980082|Drug|Cefazolin|Antibiotic
1633748|NCT01980082|Drug|Placebo|Placebo
1633749|NCT01980069|Drug|Sugammadex|In sugammadex group, sugammadex (Bridion, Merck Shart and Dohme (MSD), Oss, the Netherlands) will be administered intravenously in different doses according to the degree of muscle relaxation. Sugammadex 8 mg/kg will be administered if there is no response on post-tetanic count (PTC) stimulus. Sugammadex 4 mg/kg will be administered if PTC is more than 1 or 2. Sugammadex 2 mg/kg will be administered if T2 response appears on train-of-four (TOF) stimulus.
1633750|NCT01980069|Drug|Neostigmine|In neostigmine group, neostigmine 50 ㎍/kg will be administered intravenously with glycopyrrolate 10 ㎍/kg when the T2 response appears on TOF stimuli.
1633751|NCT01980056|Drug|Vosaroxin|Dose level 1: Vosaroxin 50 mg/m2 IV on Days 1 and 4 of 28 day cycle Dose level 2: Vosaroxin 72 mg/m2 IV on Days 1 and 4 of 28 day cycle Dose level 3: Vosaroxin 50 mg/m2 IV on Days 1, 4, 8 and 11 of 28 day cycle Dose level 4: Vosaroxin 72 mg/m2 IV on Days 1, 4, 8 and 11 of 28 day cycle
1633752|NCT01980043|Procedure|endoluminal rectal prolapse repair under sedation|endoluminal rectal prolapse repair under sedation
1633753|NCT01980030|Drug|Romiplostim|
1633754|NCT01980017|Behavioral|Ottawa Model for Smoking Cessation|
1633755|NCT01980004|Dietary Supplement|Potassium Citrate Supplementation|20 mEq taken twice daily
1633756|NCT01980004|Other|Dietary Education|Dietary counseling will include both a verbal discussion in the clinic regarding increased fluid intake, a moderate calcium rich diet and lemonade therapy as well as receiving a written handout on these topics.
1633757|NCT01979991|Procedure|CT Imaging and Reconstruction|"Patients will be consented for their permission to save and use the sinogram from their CT chest/lung scan. The sinogram will be de-identified and sent to an archive system for storage.
Later it will be exported to a computer for processing using MBIR (model based image reconstruction). The newly processed images will then be read by blinded readers. The quality of the images will be reviewed to determine if they are as readable and accurate as CT images created with the software that is currently being used."
1633795|NCT01979653|Drug|dexmedetomidine alone or dexmedetomidine + midazolam|
1633796|NCT01979640|Procedure|39 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
1711461|NCT01375816|Drug|leucovorin calcium|
2011845|NCT02369627|Device|Rapid HIV Self-Test (OraQuick® In-home HIV Test)|The participant will utilize materials and directions contained within the OraQuick In-Home HIV Test kit to properly perform a rapid HIV self-test. The participant will first swab his upper and lower gums using an Oral Swab Test Stick. The participant will then place this device in a test tube, and the results will be displayed in the Test Window within 20 minutes. Test results expire after 40 minutes.
1633759|NCT01979965|Drug|Ranolazine (Active drug)|Ranolazine therapy for three months
1633760|NCT01979965|Drug|Placebo|Placebo therapy for three months
1633763|NCT01979939|Drug|DCV/ASV/BMS-791325|
1633764|NCT01979926|Drug|Combination of Broussonetia spp and Lonicera spp|600 mg/ day or 1200 mg/ day for 7 days
1633765|NCT01979913|Drug|Saflutan® 15 microgram/ml Augentropfen im Einzeldosisbehältnis|
1633766|NCT01979900|Drug|Vaccae|One vial of Vaccae diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well, once every 2 weeks, 6 times totally.
1633767|NCT01979900|Drug|placebo|One vial of placebo diluted with 1.0ml sterile water for injection, take deep coxal muscle injection after shaking well，once every 2 weeks, 6 times totally.
1633768|NCT01979887|Procedure|Meibum Expression|Meibum expression as per protocol. No investigational drug is administered in this study.
1633769|NCT01979874|Dietary Supplement|Pro-Omega|Pro-Omega (Nordic Naturals, Watsonville, CA, USA). Each ProOmega capsule contains 325mg of EPA and 225mg of DHA. 4.4gm/day x 3 months
1633770|NCT01979874|Other|ProOmega Placebo|Placebo Comparator: soybean (Nordic Naturals, Watsonville, CA, USA); 4.4gm/day x 3 months
1633771|NCT01979861|Device|AEGEA Vapor System(TM)|vapor endometrial ablation
1633772|NCT01979835|Device|GyneFix Viz|insertion of GyneFix Viz and measurment of the SA distance
1633773|NCT01979822|Other|PH patients with LenusPro pump|Observation/measurement of complications in PH patients with LenusPro pump in the frist six month after implantation of pump
1633774|NCT01979809|Behavioral|MENU GenY|Participants will assess eligibility, complete consent and baseline survey to enroll online, then be randomized to one of 3 arms: Control Arm 1 - a non-tailored intervention with no age targeting; Arm 2 -age targeted, tailored website set to appeal to young adults and offer a varety of support using muli-media to improve dietary intake of fruit, vegetables and whole grains, and decrease sweet drinks. Arm 3 utilizes the same intervention as Arm 2, and has support via email from eCoaches who use a Motivational Interview approach to support to help change dietary patterns. All arms are active for 4 months with occasionalemail contact throughout the following 8 mo. Follow-up surveys occur at 3 mo, 6 mo, and primary outcome at 12 months.
1633775|NCT01979796|Device|Ecig 24 mg nicotine|Cigalike
1633776|NCT01979796|Device|Ecig 0 mg nicotine|Cigalike
1633777|NCT01979796|Device|Nicotine free inhalator|Plastic CIG a Like
1633778|NCT01979757|Other|Puregraft|
1633779|NCT01979757|Other|Centrifugation|
1633780|NCT01979744|Procedure|IVUS guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
1633781|NCT01979744|Device|Angiography guided percutaneous coronary angioplasty with Resolute integrity stent insertion|Resolute integrity stent implantation (diameter from 2.5mm to 3.5mm, length 30, 34, 38mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
1633782|NCT01979744|Device|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. Additional stent implantation or post dilation will be allowed according to attending physician's discrete. IVUS will be not used in this arm.
1633783|NCT01979744|Procedure|Angiography guided percutaneous coronary angioplasty with Promus element stent implantation|Promus element stent implantation (diameter from 2.5mm to 3.5mm, length 28, 32, 36mm) The size and number of stents and post-dilation will be determined on physician's discrete within the range allowed in this study protocol. All procedure will be performed according to current standard technique. IVUS will be used to assess the anatomic characteristics of lesion and determine appropriate stent size and length. Additional stent implantation or post dilation will be allowed according to attending physician's discrete based on IVUS results.
1633784|NCT01979731|Other|Job rotation|The intervention group will perform rotation function, switching between tasks with low, moderate and high ergonomic risk and different requests for ergonomic body region added to ergonomic guidelines.
1633785|NCT01979731|Other|Guidelines ergonomics|Orientation about manual material handling, posture, furniture, rest break and others in general.
1633786|NCT01979718|Device|Mirrored Virtual reality|Patients are required to look at the images of both lower extremities ranged from the perineal area to the foot. Virtual reality system records in real-time method both lower extremities. Following the validity assessement mirrored image of the surgeried lower extremity is re-formed using the virtusal reality system flipping the image of lower extremity not-surgeried and being calibration for the symmetricity.
1633787|NCT01979692|Procedure|confocal laser microscopy CLM at trans thoracic needle biopsy TTNB|
1633788|NCT01979692|Device|CT guided trans thoracic needle biopsy|
1633789|NCT01979679|Drug|Lurasidone 80 mg|
1633790|NCT01979679|Drug|Lurasidone 120 mg|
1633791|NCT01979679|Drug|Lurasidone 160 mg|
1633797|NCT01979640|Procedure|37 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
1633798|NCT01979640|Procedure|35 Fr double lumen tube group|additional bronchial cuff volume is decided according to up-and-down biased coin design sequential method, by incremental volume of 0.1 ml
1633799|NCT01979627|Procedure|transulnar approach interventional procedure|
1633800|NCT01979627|Procedure|transradial approach interventional procedure|
2011846|NCT02369627|Device|Conventional Home-Based HIV Test (Home Access Express)|The participant will utilize materials and directions contained within the Home Access Express HIV-1 Test System to properly perform a conventional home-based HIV test. The participant is required to gather a blood sample by lancing his finger. Blood samples are collected by placing drops of blood on a packaged specimen card. The participant will then mail his blood sample to the Home Access laboratory using a self-addressed, pre-paid shipping envelope. The Home Access laboratory will process the blood sample, and the participant is required to call the facility to learn his HIV test result.
1633803|NCT01979601|Drug|LGT209|150 mg lyophilized powder in glass vial
1633804|NCT01979601|Drug|Placebo|Placebo comparator
1633805|NCT01979588|Other|What's Going Around tool|Provider has access to the What's Going Around tool
1633806|NCT01979588|Other|Control|Provider does not have access to the What's Going Around tool but received information regarding the tool prior to study initiation
1633817|NCT01979523|Drug|Akt Inhibitor GSK2141795|Given PO
1633818|NCT01979523|Other|Laboratory Biomarker Analysis|Correlative studies
1633819|NCT01979523|Other|Pharmacological Study|Correlative studies
1633820|NCT01979523|Drug|Trametinib|Given PO
1633821|NCT01979510|Drug|MK-0663B|MK-0663B once daily for 8 days.
1633822|NCT01979510|Drug|DOLOCAM PLUS®|DOLOCAM PLUS® once daily for 8 days.
1633823|NCT01979510|Drug|Acetaminophen 500 mg|Acetaminophen 500 mg up to 4 times daily for up to 8 days as required for uncontrolled breakthrough pain.
1633824|NCT01979497|Procedure|Suture with Adhesive Stripping|
1633825|NCT01979497|Procedure|Suture without Adhesive Stripping|
1633826|NCT01979484|Drug|PPI-668 capsule|
1633827|NCT01979484|Drug|PPI-668 tablet|
1633829|NCT01979458|Device|PSE|
1633830|NCT01979445|Drug|Cangrelor|Cangrelor administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours
1633831|NCT01979445|Drug|Clopidogrel|Clopidogrel 600 mg single dose
1633832|NCT01979445|Drug|Prasugrel|Prasugrel 60mg single dose
1633833|NCT01979432|Other|Cardiovascular evaluation|
1633834|NCT01979406|Biological|AVA|Anthrax Vaccine Adsorbed (0.5 mL) as the placebo control on Days 1, 15 and 29
1633835|NCT01979406|Biological|Ad4-PA-1|Ad4-PA will be given at 10^9, 10^10 and 10^11 on Day, followed by an oral placebo on Day 15 and an AVA boost on Day 29
1633836|NCT01979406|Biological|Ad4-PA-GPI-1|"Given at 10^9, 10^10 and 10^11 viral particles
Ad4 PA-GPI at Day 1 + oral placebo on Day 29 + AVA boost at Day 15"
1633837|NCT01979393|Drug|Cabozantinib|
1633838|NCT01979393|Drug|Placebo|
1633839|NCT01979380|Drug|KD101|200mg (1casule), 600mg (3 capsule), 1000mg (5 capsule), 1400mg (7 capsule) PO, once in the morning
1633840|NCT01979380|Drug|placebo|PO, once in the morning
1633841|NCT01979367|Device|Anodyne|Subjects will be treated with MIRE therapy using the Anodyne® device within 72 hours of previous treatments, and in accordance with the Anodyne® package insert indications for use 30 to 45 minutes professional units on power setting of 8,. In addition, patients will undergo TENS therapy with the use of either the Avazzia® Pro Sport or TENS 3000 (for no less than 30 mins, both on label) in accordance with the indications for use of each TENS device, for a minimum of 15 minutes at the subjective site for pain and each vertebrae nerve base, when impairment is confirmed with the objective Small Pain Fiber (SPF) Nerve Conduction Study (NCS) test performed.
1633842|NCT01979354|Drug|Spinal morphine|0.15 mg spinal morphine
1633843|NCT01979341|Procedure|final oocyte maturation trigger|when ≥3 follicles reach 17mm patients will be randomized to receive one of two types of trigger for final oocyte maturation; dual trigger: GnRH agonist plus hCG (both full doses) hCG only: full dose of hCG only
1633844|NCT01979328|Device|geko|
1633845|NCT01979328|Device|Plaster cast|
1633846|NCT01979302|Other|Depression CAREPATH|Nurses receive training and agency support in depression assessment and depression care management
1633847|NCT01979302|Other|Usual Care|Nurses receive training in depression assessment and review of usual care procedures.
1633848|NCT01979289|Other|computerized cognitive remediation|
1633849|NCT01979289|Other|computerized cognitive remediation:Control|
1633853|NCT01979263|Other|Attention Bias Modification Computer Task|Computer task aimed at actively modifying attention bias
1633854|NCT01979263|Other|Placebo Computer Task|Computer task that does not actively modify attention bias
1634031|NCT01977677|Drug|plerixafor|Given IV
1633855|NCT01979250|Procedure|DSAEK surgery|"Corneal endothelial transplantation by Descemet's stripping automated endothelial keratoplasty (DSAEK)."
1633856|NCT01979237|Procedure|SPASO method and FARES method|SPASO method and FARES method as shoulder dislocation reduction methods
1633857|NCT01979224|Other|Educational intervention for parents|educational sessions once a week two hours for a month and later educational reinforcement and monitoring asthma control monthly for nine months
1633858|NCT01979211|Drug|Cetuximab|400 mg/m2 IV over 120 minutes week 1; 250 mg/m2 IV over 60 minutes weekly weeks 2-7
1633859|NCT01979211|Radiation|Radiation Therapy|Radiation Therapy 60-66 Gy in 2 Gy fractions starting week 2 of Cetuximab
1633860|NCT01979185|Drug|Simvastatin|
1633861|NCT01979185|Drug|SSP-004184SS|
1633862|NCT01979159|Behavioral|Combined Aphasia and Apraxia of Speech Treatment (CAAST)|Therapy is delivered in a face-to-face format. The therapist uses picture stimuli, verbal modeling, feedback, reinforcement, forward-chaining to increase verbal production. For speech errors that occur, the therapist uses modeling, feedback, reinforcement, simultaneous production, articulatory instruction, and repeated practice to improve articulation.
1633863|NCT01979146|Other|Provider Unrelieved Symptom Alert|The Provider Unrelieved Symptom Alert intervention sent an automatic symptom report to oncology providers (both physician and nurse) when the patient reported symptoms at a moderate to severe level (4-10 on a 0-10 scale). The oncology providers used their clinical judgement in terms of what they did with the information received. There was no prescribed response as part of the intervention.
1633864|NCT01979133|Drug|Icariin|Participants will receive 20% icariin (100 mg/day) in a commercially available over-the-counter Horny Goat Weed supplement. A dose titration from 100 mg/day to 200 mg/day will be allowed at week 3 participants with less than a 30% reduction in HAMD and/or still using cocaine or alcohol or have a positive urine drug screen. An additional dose titration to 300 mg/day will be allowed at week 6 for participants with less than a 50% reduction in HAMD scores and/or still using cocaine or alcohol or have a positive urine drug screen.
1633865|NCT01979107|Behavioral|Proactive action by the general practitioner|"Individuals allocated to the intervention group will receive a personal invitation to an appointed health check from their general practitioner. Three days before the appointment participants will be reminded by phone about the appointment.
At the health check a follow-up consultation will be scheduled. At the follow-up consultation the results of the health check will be reviewed. All participants with abnormal screens at the health check will, depending of the severity, either receive the offer of a referral to the municipality health center for a lifestyle change program and/or follow the procedures for diagnostics and treatment. This will follow the usual medical standards in general practice. For individuals with abnormal screens or health behavior amenable to intervention at the first health check an additional health check will be scheduled six months after the first health check with a follow-up consultation for review of the results."
1633866|NCT01979081|Other|Tailored advice from a physiotherapist and/or an occupational therapist through the myOSCAR patient portal|
1633867|NCT01979055|Behavioral|Self-regulation intervention|6 session educational intervention (3 telephone, 3 In-person), led by a health educator
1633868|NCT01979055|Behavioral|Telephone follow-up|Usual care group, will also receive 3 telephone calls to assess any questions they may have about asthma
1633869|NCT01979029|Procedure|preserving the left colic artery|The root of the inferior mesenteric artery(IMA) was carefully dissected and the artery wall was exposed all the way to the bifurcation of the left colic artery(LCA) and the superior rectal artery (SRA), exposing the LCA from its root until the inferior mesenteric vein (IMV) was recognized. Subsequently, dissection was continued along the IMV up to the level of the root of the IMA. Then the sigmoid mesentery was transected from the root of the IMA to the IMV, and the IMV and the root of the SRA were ligated. Finally, the adipose tissue with the lymph nodes in the area surrounded by the IMA, IMV, and LCA was dissected, with preservation of the LCA .
1633870|NCT01979029|Procedure|not preserving the left colic artery|The root of the IMA was exposed and the fatty tissue around the root of the IMA was swept in order to maximize the lymph node retrieval rate. Subsequently, the IMA was ligated 1 cm from the aorta to avoid damaging the nerves.
1633871|NCT01979016|Drug|dupilumab|"Dupilumab is an anti-interleukin 4 monoclonal antibody (Anti-IL-4R alpha mAb) that is being studied for the treatment of moderate-to-severe eczema.
[In addition to active dupilumab treatment, patients are also required to apply a topical emollient twice daily from day -7 through day 8 as background treatment.]"
1633872|NCT01979016|Drug|placebo|"Placebo is a look-alike substance with no active medication
[In addition to receiving placebo, patients are also required to apply a topical emollient twice daily from day -7 through day 8 as background treatment]"
1633873|NCT01979003|Drug|Fluorescein|
1633874|NCT01978964|Biological|ONT-10|ONT-10 is a liposomal synthetic glycopolypeptide antigen formulated with PET Lipid A adjuvant
1633875|NCT01978951|Behavioral|Integrated Chronic Kidney Disease care|Activities of integrated CKD care program, which will be provided during each hospital visit and quarterly home visits, are live demonstration about treatment and optimal diets for CKD patients, monitor drug compliance.
1633876|NCT01978951|Behavioral|Conventional CKD care|group counselling about optimal diets for CKD patients
1633877|NCT01978938|Drug|Eravacycline|
1633878|NCT01978938|Drug|Levofloxacin|
1633879|NCT01978925|Other|Pharmaceutical care|"The clinical pharmacist will provide a structured 30-minute intervention for enhancing their medication adherence.
The recommendations include: discussion on hypertension and/or diabetes, risk of complications, prescribed drug therapy, correct use of medications and proper dosage, possible adverse effects, route of administration, schedule of administration and correct storage. The pharmacist will also emphasize the importance of lifestyle modifications. Printed educational material, with information on hypertension and/ or diabetes medications, including suggested lifestyle interventions was prepared to assist in the intervention and will be handed to patients in the end of the session."
1633880|NCT01978912|Drug|KTP-001|KTP-001 is one time dose intradiscally.
1633881|NCT01978899|Behavioral|Immediate Weight Loss Program Group|Participation in 15-week Healthy Living Program.
1633882|NCT01978899|Behavioral|Delayed Weight Loss Program Group|Participation in 15-week Healthy Living Program following 15-week wait period.
1633883|NCT01978873|Drug|Cabazitaxel + Androgen deprivation therapy|Cabazitaxel + LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
1633884|NCT01978873|Drug|Androgen deprivation therapy|LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
1633885|NCT01978860|Device|NovaCross, CTO|evaluate the safety and performance of the NovaCross™ micro-catheter in respect to providing additional guidewire support that is expected to allow easier crossing of Chronic Total Occlusion (CTO) lesions in coronary arteries.
1633886|NCT01978821|Procedure|Autologous bone marrow mononuclear cell transplantation|
1633887|NCT01978795|Other|Brain 101 website|Brain 101: The Concussion Play book is a web-based, stand-alone guide for school leaders on effective policies and practices in concussion management. Consistent with the literature on effective school-based change efforts, the website offers a comprehensive, school-wide approach to preventing and managing sports concussion, including training for educators, athletics staff, students, and parents. The website presents guidelines for creating a concussion management team (CMT) that meets regularly to support students as they return to academics, extra-curricular activities, and athletics. It also includes information on strategies for supporting students in the classroom following concussion (e.g., designing reduced school schedules, monitoring school performance following concussion).
1633888|NCT01978795|Other|Control|At control schools, parents viewed Centers for Disease Control materials on safe teen drivers. Athletes viewed web-based materials about teens staying safe on the job.
1633889|NCT01978782|Drug|raltegravir|
1633890|NCT01978782|Drug|citalopram|
1633891|NCT01978756|Other|Outpatient clinic|The participants are seen at the outpatient clinic by a physician or a physician assistant. To analyse fibrosis clinical examination of the breast will be performed. To analyse shoulder function anteversion / retroversion, abduction / adduction and internal / external rotation will be measured. To analyse edema the arm circumference will be measured 15 cm above and below the medial epicondyle (both sides). Also, a photograph of the breast will be made for cosmetic analysis using standardized procedures. Finally a blood sample or saliva will be obtained, if the patient has given written informed consent to participate in the Biobank.
1633892|NCT01978743|Drug|Raltegravir|Switch from Atripla to Raltegravir 400mg BID + Truvada (FTC/TDF) for total of 8 weeks
2011847|NCT02369627|Other|Community/Medical-Based HIV Test|The participant will receive a link to a CDC website (https://gettested.cdc.gov) to search for HIV testing locations in his surroudning community. This resource website will provide the participant with places that offer HIV testing for free or at a low cost. The participant also has the option of going to places that can use his insurance or charge for testing. The pariticant is responsible to pay for any testing costs.
2011848|NCT02369146|Drug|UB-421|The UB-421 (dB4C7 mAb) will be supplied at a concentration of 10 mg/mL (100 mg in 10 mL vial). Subjects will receive 8 doses of the UB-421 by intravenous infusion at 10 mg/kg weekly (Cohort 1, 8 weeks) or 25 mg/kg bi-weekly (Cohort 2, 16 weeks).
2011849|NCT02368119|Biological|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(10) vp)
1633896|NCT01978717|Procedure|epidural anesthesia|
1633897|NCT01978717|Procedure|general anesthesia|Patients received general anesthesia for surgery
1633898|NCT01978704|Other|Adjustment of pre-prandial insulin doses on the bases of glycaemic load of the meal|
1633899|NCT01978704|Other|Adjustment of pre-prandial insulin doses on the bases of carbohydrates content of the meal|
1633900|NCT01978691|Dietary Supplement|Bifidobacterium animalis ssp. lactis 420|Studied as a probiotic bacteria
1633901|NCT01978691|Dietary Supplement|Polydextrose|Studied as a prebiotic
1633902|NCT01978691|Other|Placebo|Control
1633903|NCT01978678|Drug|Pulmicort|
1633904|NCT01978665|Drug|prednisone|
1633905|NCT01978652|Biological|Peginterferon Beta-1a|As specified in the treatment arm
1633906|NCT01978626|Behavioral|App modules|
1633907|NCT01978626|Behavioral|Traditional CBT-I|
1633908|NCT01978613|Drug|NNC0113-0987|Tablets for once-daily oral administration. Multiple doses with sequential dose increments over 10 weeks. The end-dose levels and the dose levels during the escalation regime may be adapted during trial conduct based on safety evaluations.
1633909|NCT01978613|Drug|placebo|Tablets for one-daily oral administration.
1633910|NCT01978600|Drug|Brinzolamide 1%/Brimonidine 0.2% ophthalmic suspension|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
1633911|NCT01978600|Drug|Timolol Maleate 0.5%|Commercially marketed and approved for lowering IOP in patients with open-angle glaucoma and ocular hypertension.
1633912|NCT01978587|Drug|JTZ-951|
1633913|NCT01978574|Behavioral|Intellectual Enrichment daily activities|A daily program of intellectually enriching, iPad/tablet-based activities: games, reading/writing, hobby activities, or a documentary video (control).
1633914|NCT01978574|Behavioral|Intellectual Enrichment documentary videos|Participants watch daily documentary videos.
1633915|NCT01978561|Biological|Post dosing with NT100|
1633916|NCT01978561|Other|Post dosing with Placebo|
1633917|NCT01978548|Drug|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as two 5 mg oral tablets once daily.
1633918|NCT01978548|Drug|JNJ-54861911 50 mg|JNJ-54861911 50 mg will be administered as two 25 mg oral tablets once daily.
1633919|NCT01978548|Drug|Placebo|Matching placebo will be administered as 2 oral tablets once daily.
2011850|NCT02368119|Biological|VRC-EBOADC069-00-vp|IM Injection of cAd3-EBO bivalent (Zaire plus Sudan) vaccine (2 x 10(11) vp)
2011851|NCT02368119|Biological|MVA-EbolaZ|IM injection of MVA-EbolaZ vaccine
1633922|NCT01978522|Other|Randomisation of questionnaire receipt.|"The self-completion questionnaire will be delivered to the participants via post a week after completing the CAPI.
Self-completion questionnaire handed to participants immediately after completing the CAPI."
1633923|NCT01978509|Drug|Low volume prep (Prepopik)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
1633924|NCT01978509|Drug|Moderate volume prep (Moviprep)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
2011852|NCT02368119|Other|Placebo|IM injection injection of Phosphate Buffered Saline
1633925|NCT01978509|Drug|High volume prep (Golytely)|Hospitalized patients will be randomized to receive either large volume bowel preparation (Golytely), moderate volume bowel prep (Moviprep) or low volume bowel preparation (Prepopik) in a split dose manner for bowel cleansing prior to colonoscopy.
1633926|NCT01978496|Drug|Placebo|matching placebo
1633927|NCT01978496|Drug|Eletriptan 20 mg|20mg oral
1633928|NCT01978496|Drug|Eletriptan 40 mg|40mg oral
1633929|NCT01978496|Drug|Eletriptan 80 mg|80mg oral
1633930|NCT01978483|Drug|Denosumab|
1633931|NCT01978483|Radiation|UVB exposure|
1633932|NCT01978483|Drug|Diphenylcyclopropenone|
1633933|NCT01978483|Drug|Normal Saline|
1633934|NCT01978470|Device|External Trigeminal Nerve Stimulation (eTNS)|External stimulation of the trigeminal nerve.
1633935|NCT01978457|Drug|cocaine hydrochloride|
1633936|NCT01978457|Drug|propranolol|
1633937|NCT01978457|Drug|placebo|
1633938|NCT01978444|Procedure|Laparoscopic D2 lymphadenectomy plus CME|
1633939|NCT01978444|Procedure|Laparoscopic D2 lymphadenectomy|
1633940|NCT01978431|Drug|cocaine hydrochloride|
1633941|NCT01978431|Drug|methylphenidate|
1633942|NCT01978418|Drug|salbutamol|Medication given once as a dose of 4 puffs at 30-60 minutes of age
1633943|NCT01978418|Drug|Placebo|Placebo given once as a dose of four puffs at 30-60 minutes of age
1633944|NCT01978405|Drug|Alpha lipoic acid|
1633945|NCT01978392|Behavioral|Self-management group workshops|This intervention consists of multiple group workshop sessions (10 hours total) led by a specially trained facilitator and provided over a span of approximately 2-3 months. The intervention incorporates standard elements of existing evidence-based pain and illness self-management efforts, but tailoring key messages and discussion elements to apply to workplace problems most relevant to workers with chronic medical conditions. Each session is focused on different self-management strategies, with each session containing a mix of facilitator presentation, group discussion, case illustrations, role-play, completion of in-session self-assessments and activities, and brief homework assignments. Approximately equal time is allocated to the topics of improving comfort, modifying work, communicating effectively, applying systematic problem-solving strategies, and dealing with negative thoughts and emotions.
1633946|NCT01978366|Drug|HT-100|May be administered in either fed or fasted state
1633947|NCT01978353|Behavioral|Memory Training|Participants receive memory training to facilitate learning and memory of face-name associations
1633948|NCT01978353|Behavioral|Psychoeducation|Participants receive information about memory functioning and aging
1633949|NCT01978327|Drug|GSK2647544|repeat dose
1633950|NCT01978327|Drug|drug-drug interaction|drug-drug interaction
2011853|NCT02367456|Drug|PF-04449913 (Glasdegib)|Daily dose of PF-04449913 100mg tablet in a continuous regimen of 28 day cycles
1633952|NCT01978301|Drug|Triamcinolone acetonide|Triamcinolone acetonide will be administered as intra-lesional injection in the keloid(s).
1633953|NCT01978301|Drug|Placebo|Placebo will supplied as commercial injectable saline, and will be administered as intra-lesional injection in the keloid(s).
1633954|NCT01978275|Device|stimulong 100, pajunk, germany|simulating catheter
1633955|NCT01978275|Device|plexolong 100, pajunk, germany|nonstimulating catheter
1633956|NCT01978262|Biological|Seasonal Inactivated Influenza Vaccine|Quadrivalent seasonal inactivated influenza vaccine, 0.5 mL intramuscularly
1633957|NCT01978249|Procedure|Systemic chemotherapy|
1633958|NCT01978249|Procedure|primary tumor resection (PTR)|primary tumor resection (PTR) using open or laparoscopy or robotic surgery
1633959|NCT01978236|Drug|Dabrafenib 150 mg|Dabrafenib will be provided for oral administration as 50 mg and 75 mg capsules. Dabrafenib will be dosed orally with approximately 200 mL of water, twice a day. Dabrafenib should be administered under fasting conditions.
1633960|NCT01978236|Drug|Trametinib 2.0 mg|Trametinib study treatment will be provided as 0.5 mg and 2.0 mg tablets. should be taken orally with approximately 200 mL of water under fasting conditions, either one hour before or two hours after a meal.
1633961|NCT01978223|Procedure|Stool sample collection|Stool samples will be collected from all children enrolled in the study, within 48 hours of admission to the hospital/ ED. Stool samples will be tested to determine the presence or absence of rotavirus (RV). Additionally, for RV-positive cases, the stool samples will be tested to determine the RV genotypes.
1633962|NCT01978210|Device|Wireless Moisture Pager (WMP)|The WMP is composed of a three key components: (1) the disposable sensor; (2) the transmitter; and (3) the receiver. The disposable sensor is placed by the parent in the child's underwear and detects small amounts of urine. The transmitter is housed in hardened plastic, attached to the disposable sensor, and, upon activation, emits a radio signal to the receiver. The receiver is an iPod-based app that emits an audible and/or vibration signal to the parent and child at the onset of a toileting accident. A step-by-step manualized curriculum is used to teach parents how to incorporate the device in the toilet training of their child.
1633963|NCT01978184|Drug|gemcitabine|
1633964|NCT01978184|Drug|abraxane|
1633965|NCT01978184|Drug|hydroxychloroquine|
1633966|NCT01978158|Drug|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects
1633967|NCT01978145|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device -or multi-dose dry powder inhalation device BID for each treatment periods
1633968|NCT01978145|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment periods
2011854|NCT02367456|Drug|Azacitidine|75mg/m2 on Days 1-7 of a 28 day cycle or on Days 1-5, 8-9 of a 28 day cycle
1633970|NCT01978119|Drug|FSC|Subject will be administered FSC 250 mcg/50 mcg via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
1633971|NCT01978119|Drug|Placebo|Subject will be administered placebo via dry powder inhalation device or multi-dose dry powder inhalation device BID for each treatment period
2011855|NCT02367456|Drug|PF-04449913 (Glasdegib) Placebo|Daily dose of the Placebo for PF-04449913 100 mg tablet in a continuous regimen of 28 day cycles.
1634032|NCT01977677|Other|laboratory biomarker analysis|Correlative studies
1634033|NCT01977677|Other|pharmacological study|Correlative studies
2011856|NCT02366663|Radiation|Yttrium Y 90 Ibritumomab tiuxetan|0.4 mCi/kg given IV
2011857|NCT02366663|Drug|Carmustine|Given IV
2011858|NCT02366663|Drug|Etoposide|Given IV
2011859|NCT02366663|Drug|Cytarabine|Given IV
2011860|NCT02366663|Drug|Melphalan|Given IV
2011861|NCT02366663|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo AHCT
1633979|NCT01978067|Procedure|transvaginal resection of Uterine Scar|Expose, grasp and traction the cervix. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted.into the vaginal incision to retract the bladder upwards. The PCSD was identified as a'fornix' located in the anterior part of the lower uterine segment. A transverse incision was made to remove the scar deficiency, and the edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed.
1633980|NCT01978054|Other|Dissemination of public health knowledge|State health department chronic disease units will be involved with developing and choosing dissemination activities to spread public health knowledge and information on population-based public health strategies that have been shown to reduce risk factors for cancer and other chronic diseases. Example of activities include: multi-day in-person training workshops and electronic information exchange modalities.
1633981|NCT01978041|Other|Meal prepared with non fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with purified water containing a fluoride dose of 0.8 ug of fluoride/kg body weight (resulting of the natural fluoride concentration in foods).
1633982|NCT01978041|Other|Meal prepared with fluoridated water|Ingestion of a typical brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with fluoridated water (1 ug of fluoride/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
1633983|NCT01978041|Other|Non fluoridated water|Ingestion of purified water with addition of fluoride to provide a total intake of approximately 0.8 ug of fluoride/kg body weight, which represented the same fluoride ingestion dose of the experimental phase with meal prepared with non fluoridated water.
1633984|NCT01978041|Other|Fluoridated water|Ingestion of fluoridated water (1 ug F/mL), to provide a total intake of approximately 12 ug of fluoride/kg body weight.
1633985|NCT01978041|Other|Meal prepared to provide a fluoride dose of 60 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
1633986|NCT01978041|Other|Meal prepared to provide a fluoride dose of 120 ug F/kg|Ingestion of a typical Brazilian meal (rice, beans, meat, french beans, carrots, gelatin and juice) prepared with non-fluoridated water, with sodium fluoride solution added to the juice to provide a total intake of approximately 60 ug of fluoride/kg body weight.
1633987|NCT01978028|Drug|ferric carboxymaltose|
1633988|NCT01978028|Drug|placebo|
1633989|NCT01978015|Drug|travoprost and timolol maleate fixed combination|travoprost 0.004% and timolol maleate 0,5%, 1 eye drop at 8p.m. for 6 months
1633990|NCT01978015|Drug|latanoprost and maleate timolol fixed combination|Latanoprost 0.005% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
1633991|NCT01978015|Drug|bimatoprost and timolol maleate fixed combination|bimatoprost0.03% and timolol maleate 0,5%, 1 eye drop at 8 p.m for 6 months
1633992|NCT01978015|Drug|dextran and hypromellose|Dextran 70 and hypromellose, lubricant eye drop at 8 a.m and 8 p.m for 6 months
1633993|NCT01978002|Behavioral|Pain sensitivity testing|
1633994|NCT01978002|Behavioral|Urodynamic testing|
1633995|NCT01977989|Drug|Vancomycin Powder|For surgeries involving 3 contiguous spinal segments or less, 500mg of vancomycin will be applied topically. For surgeries involving more than 3 contiguous spinal segments, 1gm of vancomycin will be applied topically to the surgical site.
1633996|NCT01977976|Procedure|Endometrial aspiration by pipelle|Endometrial aspiration by pipelle is to be performed on LH+7 in the cycle preceding scheduled IVF treatment
1633997|NCT01977937|Drug|Gabapentin|
1633998|NCT01977937|Drug|Simple Syrup|
1633999|NCT01977924|Dietary Supplement|one month polyphenols supplementation (600mg)|
1634000|NCT01977924|Dietary Supplement|placebo (microcrystalline cellulose)|
1634001|NCT01977911|Other|Stem cell based tissue engineered partial laryngeal implants|Stem cells from the patient receiving the implant are removed from the bone marrow, and are then grown on the scaffold in the laboratory. These cells will form the cartilage in the wall of the scaffold. The implant can be considered 'living' due to the cells grown on it, and this type of treatment is referred to as 'tissue engineering' or 'regenerative medicine'. Once these cells have attached and started to grow on the scaffold, it is ready to be implanted into the patient and a two separate operative stages can occur. The final stage of the operation involves removing the narrow section of voicebox or upper windpipe and implanting the scaffold to reconstruct it.
1634002|NCT01977898|Drug|Morphine|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
1634025|NCT01977729|Behavioral|Cognitive Behavioral Therapy|Youth are given instructions in each session that they may stop whenever they want and they do not need to attempt the task unless they so desire. Therapists have been carefully and thoroughly trained in providing reassurance and/or crisis treatments if needed. Therapists also have been trained to contact one of the PIs immediately in the event of a crisis.
2011862|NCT02366663|Biological|Rituximab|Given IV
2011863|NCT02366663|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
2011864|NCT02366663|Other|Laboratory Biomarker Analysis|
2011865|NCT02365584|Drug|lanreotide (Autogel formulation)|Lanreotide Autogel 120 mg by deep subcutaneous route, at the maximal scheduled standard dose of 120 mg/28 days, just for 1 administration.
1634003|NCT01977898|Drug|Saline|The drug will be prepared in tuberculin syringes. After thoroughly sanitizing the catheter port with a Chloroprep wipe and allowing adequate time for drying of the Chloroprep, the anesthesiologist will first attach a 3-mL syringe to the catheter port and aspirate to a volume of 1 mL. This syringe will then be removed from the port. The study drug will then be administered through the intrathecal catheter via the tuberculin syringe. The 3-mL syringe containing the aspirate will then be injected via the catheter, effectively flushing the study drug through the catheter. The intrathecal catheter will be removed immediately following the injection.
1634004|NCT01977885|Behavioral|High Protein Diet|All participants will be individually counseled by an RD for ~ 4 sessions (30 to 60 minutes)to meet weight loss goals. During the duration of the study, participants will be required to attend a 30 to 60 minute group educational/motivational meeting weekly (first 1 to 2 months) and then biweekly (for the remainder of the study). Diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. This amount of lean cooked beef provides an average of ~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). This combined with reducing energy from carbohydrates and fat from other sources will create an overall energy deficit of 500 kcal/day. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit
1634005|NCT01977885|Behavioral|Exercise|Participants will be prescribed a supervised exercise program with required attendance of 3 nonconsecutive days per week (75 minutes each session). A program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. With specific regard to strength training, 50% of the resistance work will involve primary muscle groups of the lower body with the main focus being the gluteal and quadriceps groups (squats, lunges, etc.). The remaining 50% of work will dedicate 25% to the core stabilizers with the final 25% being the upper body. Transitions between segments of training will be used for recovery and social support enhancement. Note that all aspects of the exercise intervention will be progressive in intensity (i.e., starting at lower end of intensity or ~50% of maximal capacity), and duration (i.e., from 15 minutes to 35 minutes of exercise and adding a few minutes each session).
1634006|NCT01977872|Behavioral|A worksite activity-diet intervention|
1634009|NCT01977833|Other|High Calorie Breakfast (BTdiet)|High Caloric Breakfast Test Diet (BTdiet): in which the majority of energy load will be consumed in the morning and with reduced dinner
1634010|NCT01977833|Other|High Caloric Dinner (DTdiet)|High Caloric Dinner (DTdiet): resembling a skipping breakfast plan, in which the majority of energy load will be consumed in the evening with minimal caloric content at breakfast
1634011|NCT01977820|Drug|Sapropterin|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and 24-Week study period.
1634012|NCT01977820|Drug|Placebo|Sapropterin tablets will be administered orally once daily at a dose of 20 milligram per kilogram (mg/kg) during both the 2-Week response test period and Placebo tablets matching to sapropterin will be administered orally once daily during the 24-Week study period.
1634013|NCT01977807|Device|Proscan, Zyoptix and Supracor|One device (500 Hz Excimer Laser) with three interventions (Proscan, Zyoptix and Supracor as algorithms)
1634014|NCT01977794|Drug|Bisoprolol/Amlodipine (Bisoprolol failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 mg/5 mg once daily for 6 weeks. If blood pressure (BP) is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
1634015|NCT01977794|Drug|Bisoprolol/Amlodipine (Amlodipine failed group)|Bisoprolol/Amlodipine FDC tablet will be orally administered at an initial dose of 5 milligram (mg)/5 mg once daily for 6 weeks. If BP is controlled at Week 6 (Day 43), the same dose will continue for next 6 weeks. If the BP is not controlled at Day 43, the dose will be increased to Bisoprolol/Amlodipine 5mg/10mg or 10mg/5mg for next 6 weeks. Subjects who have controlled BP at Week 12 (Day 85), will continue with the same dose for next 6 weeks. If their BP is not controlled at Day 85, dose will be increased to the next level (Bisoprolol/Amlodipine 5mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/5mg dose and Bisoprolol/Amlodipine and 10mg/10mg for subjects receiving Bisoprolol/Amlodipine 5mg/10mg dose) until Week 18 (Day 127).
1634016|NCT01977781|Drug|Tacrolimus|Topical bilateral application of 0.05% Tacrolimus BID for 10 weeks
1634017|NCT01977781|Drug|Methylprednisolone Sodium Succinate|Topical bilateral application of 0.5% methylprednisolone sodium succinate BID for 10 weeks
1634018|NCT01977768|Biological|V7|One pill of V7 once daily for 30 days together with standard of care TB drugs
1634019|NCT01977768|Biological|Placebo|
1634020|NCT01977755|Drug|danegaptide|
1634021|NCT01977755|Drug|Placebo|
1634022|NCT01977742|Other|Supervised exercise program|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks; after 8 weeks will add a specific sudden rest-exercise training protocol, three times a week. The cardiac vagal index will be measured at every 8 weeks.
1634023|NCT01977742|Other|Supervised exercise program together with a specific sudden rest-exercise training protocol|Aerobic, strength and flexibility exercises in a supervised exercise program for 8 weeks together with a specific sudden rest-exercise training protocol, three times a week After 8 weeks will discontinue the specific sudden rest-exercise training protocol. The cardiac vagal index will be measured at every 8 weeks.
1634024|NCT01977729|Drug|Sertraline|"Medication will be administered daily using a fixed-flexible strategy beginning at 25mg, titrating to 200mg across 8 wks (i.e., wks 9-17). We expect patients' medication dose will be adjusted upward in 50 mg/day increments if clinician-rated CGI-S anxiety severity is 3 (mild) or greater. The dose will be held or adjusted downward if patients have few anxiety symptoms (CGI-S<3) or impairing Adverse Events. Patients will be maintained at 200mg per day during wks 18-20."
1634026|NCT01977703|Other|Ultra Conservative ICD Programming|
1634036|NCT01977638|Drug|CXD101|Capsules, administered orally
1634037|NCT01977625|Drug|Lisdexamfetamine|The overall objective of this study is to assess the effects of LDX on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
1634038|NCT01977625|Other|Placebo|To assess the effects of a placebo pill on brain activation patterns during tasks of sustained attention and working memory in menopausal women.
1634039|NCT01977612|Device|4-0 monofilament suture|Skin closure using 4-0 monofilament suture
1634040|NCT01977612|Device|Stainless steel staples|Skin closure using stainless steel staples.
1634041|NCT01977599|Other|Text Message Reminder for Breast Screening Appointment|Non-clinical/administrative.
1634042|NCT01977586|Other|Magnetic Resonance Imaging (MRI)|
1634043|NCT01977573|Drug|GSK1278863|Film-coated tablets containing 0.5 mg, 1 mg, 2 mg, 5mg or matching placebo
1634044|NCT01977573|Drug|rhEPO|Locally sourced rhEPO. All subjects who are randomized to the Control arm will receive rhEPO (epoetins or their biosimilars, or darbepoetin) as necessary per standard of care, to maintain Hgb levels within the target range. The decision around whether a subject requires rhEPO, selection of the type of rhEPO and rhEPO dose should be based on Investigator clinical judgment, with the historical rhEPO dose (where applicable) and the current Hgb value being considered..
1634045|NCT01977560|Behavioral|Optimum Lifestyle Intervention|Participants will follow a high-protein, low-carbohydrate diet and participate in supervised exercise.
1634046|NCT01977560|Behavioral|Standard Care|Participants will be given advice on exercise and the American Diabetes Association diet, as if they went to a Diabetes clinic.
1634047|NCT01977547|Biological|Short storage RBC age|IND obtained to cover the expiration date on the red blood cell unit
1634048|NCT01977534|Device|Absorb BVS|The Absorb BVS System is a bioresorbable poly(L-lactide) (PLLA) scaffold with a drug and bioresorbable polymer coating [formulation of everolimus in a bioresorbable poly(D,L-lactide) (PDLLA) coating].
1634049|NCT01977521|Device|Eldith DC Stimulator stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). Stimulation will consist of 2 mA for 20 minutes per session.
1634050|NCT01977521|Device|Eldith DC Stimulator sham stimulation|The anodal electrode will be placed with the middle of the electrode over a point midway between F3 and FP1 (left prefrontal cortex: dorsolateral prefrontal cortex and the cathodal electrode located over a point midway between T3 and P3 (left temporo-parietal junction). In the sham condition, after 40 seconds of real stimulation (2 mA), only a small current pulse will occur every 550 msec (110 mA over 15 msec) through the remainder of the 20-minute period.
1634051|NCT01977508|Device|ePTFE vascular access grafts|
1634052|NCT01977495|Behavioral|Financial Incentive: Fixed Lottery|Every day of the 91 day intervention period participants will be asked to use each of their biometric devices. A daily lottery will be conducted automatically by the study website. Participants must use each of their two devices daily to be eligible for the lottery the following day. Winning lottery numbers will be identified by a fixed-position match between the automatically generated winning number and a participant ID number, which each participant will pick at enrollment.
1634053|NCT01977482|Drug|GSK1278863|Film coated tablets containing 1 mg, 2 mg, 5 mg, or 25 mg of GSK1278863
1634054|NCT01977482|Drug|Placebo|Matching placebo tablet for GSK1278863
1634055|NCT01977482|Drug|rhEPO|rhEPO will be procured from local market
1634057|NCT01977456|Drug|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
1634058|NCT01977443|Drug|APD-209 Eye drops|
1634059|NCT01977443|Drug|APD-209 Placebo Eye drops|
1634060|NCT01977430|Drug|Hydrochlorothiazide and furosemide|This clinical trial is cross-over study. The diuretic arm's patients will receive combined diuretic treatment for 1 month: 20 mg of furosemide three times daily and 50 mg of hydrochlorothiazide twice daily
1634061|NCT01977417|Drug|Salsalate|
1634062|NCT01977417|Drug|Placebo|
1634063|NCT01977378|Drug|Sustained-Release Desvenlafaxine Hydrochloride|
1634064|NCT01977378|Drug|Sustained-Release Venlafaxine Hydrochloride|
1634065|NCT01977365|Behavioral|Growth promotion based on child centered approach|"- Preventive consultations will be reorganized. From the child birth, a follow-up schedule will be establish in agreement with the mother, and the subsequent appointment will be renew at each meeting.
Ten contacts will be organized for children under two years. During the first year, the number of contacts will be limited to 6 at birth , 2 , 3, 4 and 9 months to complete the vaccination schedule and an additional contact at 7 months to allow monitoring during the introduction of complementary foods.
Four contacts will be held for the second year to 12, 15, 18 and 24 months to monitor the transition from complementary food to the family diet.
- Inclusion of Child Centered growth promotion approach. During preventive consultations, specific messages according to the child age, health and nutritional status will be developed, based on scientific evidences and adapted to the experience and knowledge of health workers."
1634068|NCT01977339|Drug|Liposome Bupivacaine|10 cc of 266 mg liposome bupivacaine with 10 cc of Normal Saline
1634069|NCT01977339|Drug|Bupivacaine|20 cc of 0.25% bupivacaine
1634070|NCT01977326|Behavioral|basic counselling by lay-health workers|6 sessions of manual based counselling by trained lay health workers
1634071|NCT01977326|Other|Enhanced usual care|3 monthly phone calls by trained lay health workers (without counselling)
1634072|NCT01977300|Drug|Valproate|serum level of 50 to 125 ug/L
1634073|NCT01977300|Drug|Lithium|serum levels of 0.6 to 1.2 mmol/L
1634074|NCT01977300|Drug|Risperidone|1 to 6 mg/day
1634075|NCT01977300|Drug|Olanzapine|5 to 25 mg/day
1634076|NCT01977300|Other|Placebo|manufactured to mimic risperidone and olanzapine
1634077|NCT01977287|Device|Functional Electrical Stimulation|
1634078|NCT01977287|Device|Ankle Foot Orthosis|
1634079|NCT01977274|Other|gynecological cancer|blood and tumor samples
1634080|NCT01977261|Procedure|Opening-wedge HTO|Opening-wedge high tibial osteotomy fixated with a Puddu plate
1634081|NCT01977261|Procedure|Closing-wedge HTO|Closing-wedge high tibial osteotomy fixated with two staples
1634082|NCT01977248|Behavioral|Sensorimotor Affect Relationship-based Therapy (SMART)|The SMART Program is an interdisciplinary program that teaches children ages 2-12.5 the fundamental skills necessary to build and maintain relationships. Sessions last for 12 weeks at a time and address skills such as: tolerance for sitting and structure, joint attention, eye contact, transitions between activities, participation in group activities, communication skills, and play skills.
1634083|NCT01977235|Drug|Irinotecan|
1634084|NCT01977235|Drug|Cisplatin|
1634086|NCT01977209|Drug|Gossypol|
1634087|NCT01977209|Drug|Placebo|
1634088|NCT01977196|Biological|DPT/HepatitisB/Hib vaccine|DPT/HepatitisB/Hib vaccine (Bio Farma)
1634089|NCT01977183|Dietary Supplement|MSPrebiotic|Potato Resistant Starch
1634090|NCT01977170|Biological|Hib/PRP-T vaccine|Hib liquid vaccine
1634091|NCT01977157|Device|bioimpedance mesurements|Bioimpedance measurements were conducted with a BIS device (SFB7, ImpediMed, Pinkeba, Australia) covering a frequency range between 5 kHz and 1 MHz and an ICG device (Niccomo, medis, Ilmenau, Germany)
1634092|NCT01977144|Other|Comprehensive Chromosomal Screening|
1634093|NCT01977131|Other|Cells|
1634094|NCT01977118|Drug|streptokinase|50000U of injection streptokinase dissolved in 100ml of diluent instilled in to the pancreatic and/or peripancreatic collections via percutaneous catheters and clamped for 2 hours in Streptokinase group. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days.
1634095|NCT01977118|Other|Saline irrigation|100 ml of normal saline will be instilled through percutaneous catheters in the pancreatic and/or peripancreatic collections and clamped for 2 hours. After release of clamp, cavity will be irrigated with 100-500ml of saline. This procedure will be performed thrice daily for five days
1634096|NCT01977105|Behavioral|Grow Together peer group|"Participants in this intervention will:
Participate in Facebook group of 6-10 peers for about 8 weeks, led by a professional group mentor.
Complete an intervention video activity approximately weekly:
1. View educational videos addressing topics related to healthy infant growth
2. Create photos/videos modeling healthy behaviors and post them to the group
3. Provide and receive feedback on posts
4. Be encouraged to share information with key caregivers of their child
Attend group party soon after enrollment, to meet peers and group leader in person.
Receive text message reminders, 1) to schedule recommended primary care visits for their infant, and 2) to attend appointments scheduled in CHOP Care Network.
Have basic program information provided to pediatrician to enhance conversation during office visits."
1634097|NCT01977092|Behavioral|Motivational interviewing case management|
1634098|NCT01977092|Behavioral|Resource referrals|
1634099|NCT01977079|Other|procalcitonin|
1634100|NCT01977066|Behavioral|Six months supervised resistance training|progressive resistance training (2x/week), starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery with only low-to-moderate-intensity training during the first 4 weeks.
1634101|NCT01977066|Behavioral|Six months home-based exercise training|Home-based exercise training (2x/week) with initial counseling and weekly telephone contact starting at the earliest 8 weeks after surgery until maximum 12 months after the surgery.
1634102|NCT01977053|Other|Clinical and psychosocial phone calls|"The standard medical supervision is defined as follows:
Prescription of prophylactics medication (corticoid, antiemetic, cream, mouthwash, etc) at each cycle of chemotherapy.
Nominative notebook containing details of chemotherapy administered and medical contacts.
Consultations with psycho-oncologist or psychiatrist (if necessary).
The intervention further comprises: nurse phone calls the 3rd and the 8th day of the first three cycles of treatment, and personalized medical care according to toxicities reported."
1634104|NCT01977001|Device|MigraineBoxTM|
1634105|NCT01976988|Drug|Heparin|Subcutaneous Heparin 5000 Units given in the preoperative area one hour prior to surgery and continued every 8 hours for the remainder of the patients hospital course
1634106|NCT01976962|Radiation|Stereotactic body RT with MR-guided boost|
1634107|NCT01976949|Behavioral|online social-networking intervention|
1634108|NCT01976936|Drug|Low Dose Lovastatin|80 mg daily for 3 days
1634109|NCT01976936|Other|Placebo|Placebo for 3 days
1634110|NCT01976936|Drug|High Dose Lovastatin|640 mg daily for 3 days
1634111|NCT01976923|Drug|Intravitreal bevacizumab|A sterile lid speculum is used to separate the lids. A subconjunctival injection of 1% lidocaine is applied to the inferotemporal quadrant. A 5% povidone iodine solution is used to disinfect the entire conjunctival surface. 1.25 mg / 0.05 mL of bevacizumab is injected using a 30-gauge needle inserted through the inferotemporal pars plana 3.5 mm from the limbus.
1634112|NCT01976923|Procedure|Small-gauge pars plana vitrectomy|
1634113|NCT01976910|Drug|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.
At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.
The MTD will be where 2 DLTs are noted and the study is discontinued."
1634114|NCT01976897|Other|Knee flexion measurement 1|The angle of knee flexion during resting, supine position is measured by a first person.
1634115|NCT01976897|Other|Knee flexion measurement 2|The angle of knee flexion during resting, supine position is measured by a second person.
1992009|NCT00003659|Biological|rituximab|Approximately four weeks after the completion of the last cyclophosphamide dose, patients will receive rituximab 375mg/m2 as an intravenous infusion once weekly for four doses.
1992010|NCT00003659|Drug|cyclophosphamide|Cyclophosphamide 3000mg/m2 will be given intravenously q 2 - 3 weeks x 3 doses.
1992011|NCT00003659|Drug|fludarabine phosphate|Fludarabine will be administered intravenously at a dose of 25 mg/m2 per day x 5 days every 4 weeks.
1992014|NCT00038727|Behavioral|DPPOS Group Lifestyle|Quarterly group lifestyle sessions
1634116|NCT01976897|Other|Heel - interface pressure measurements|"The pressure analysis system used is the X Sensor X3 model (Xsensor Technology Corporation, Calgary, Canada). The sensor mat is made up of transducer cells, each measuring 1.6 cm^2. The digital signal is transmitted to a PC via a USB port at a sampling frequency of 10Hz. Before each measurement, the sensor mat is calibrated from 10 to 220 mm Hg, according to the manufacturer's recommendations.
The sheet of pressure sensors is disposed on the dedicated bed. The patient is then asked to take his/her usual position in the supine position and a latency of 5 minutes is observed. The recording time pressure is then performed for 90 seconds in the optical observing time to adapt to changes in media."
1634117|NCT01976871|Drug|Rotigotine|Rotigotine is FDA approved for the treatment of Restless Legs Syndrome at doses of 1 mg/24h, 2 mg/24h, and 3 mg/24h. The prescribed dose of rotigotine may be achieved using single or multiple patches. Subjects will titrate the dose based on discussions with the investigator.
1634118|NCT01976858|Drug|PEX168|A injection administered subcutaneously
1634119|NCT01976845|Drug|Midazolam|Midazolam (20mg) 2 ml IV, in the pre-op area as a premedication
1634120|NCT01976845|Drug|Propofol|Propofol (20mg) 2 ml IV, in the pre-op area as a premedication
1634121|NCT01976845|Drug|Saline|Saline 2 ml IV, in the pre-op area as a premedication
1634122|NCT01976832|Behavioral|Music with movement|Participants in the intervention group will receive the intervention delivered by their family member according to the validated 8-week music with movement (MWM) intervention protocol.
1634123|NCT01976832|Behavioral|Social interaction|"The control group will receive a protocol for social interaction as the control condition, where caregivers were asked to discuss up to date news with PWeD.
The design of the control condition will be highly similar to the MWM protocol in terms of the frequency and duration of the sessions, the number of people involved, and the total intervention period."
1634124|NCT01976819|Device|TW speaking valve/HME|The TW speaking valve with HME will be used during the day, whereas during sleep patients will use an HME without an automatic speaking valve. Data from TW15 and TW22 will be combined.
1634125|NCT01976806|Drug|Aspirin|
1634126|NCT01976806|Drug|Docosahexaenoic acid|
1634127|NCT01976806|Drug|Placebo (for Docosahexaenoic acid)|Placebo (corn/soybean oil) capsules manufactured to look identical to DHA capsules
1634128|NCT01976780|Drug|Artesunate|
1634129|NCT01976780|Drug|Artemether Lumefantrine|
1634130|NCT01976780|Drug|Mefloquine|
1634131|NCT01976754|Drug|Dexmedetomidine|Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h) dexmedetomidine.
1992015|NCT00038727|Drug|Metformin|Administered as 850mg twice per day, masked in DPP and open label in DPPOS
1634137|NCT01976702|Behavioral|Enhanced Behavioral Skills Training|
1634138|NCT01976676|Dietary Supplement|5-methyltetrahydrofolate|
1634139|NCT01976676|Dietary Supplement|folic Acid|
1634140|NCT01976663|Device|JUVEDERM VOLIFT® XC|Up to 4 mLs JUVEDERM VOLIFT® XC injected intradermally in one NLF (total; including initial and touch-up treatments) and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. For asymmetric correction, only the more severe NLF is eligible for asymmetric correction.
1634141|NCT01976663|Device|Control|Up to 4 mLs Control injected intradermally in opposite NLF (total; including initial and touch-up treatments). Up to 4 mLs JUVEDERM VOLIFT XC is allowed for asymmetry correction and up to 4 mLs JUVEDERM VOLIFT XC is allowed for repeat treatment. Only the more severe NLF is eligible for asymmetric correction.
1634142|NCT01976650|Drug|dexamethasone 700 ㎍ intravitreal implant|dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.
1634145|NCT01976624|Drug|bimatoprost/timolol|Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.
1634146|NCT01976611|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment for chronic migraine as per local standard of care in clinical practice.
1634147|NCT01976598|Other|Sub-Sensory Stimulation|Sub-Sensory Stimulation using Boston Scientific Spinal Cord Stimulation System in patients currently implanted with the system .
1634148|NCT01976585|Drug|rhuFlt3L/CDX-301|"rhuFlt3L/CDX-301 is a truncated, soluble, recombinant human fms-like tyrosine kinase-3 ligand (Flt3L), expressed in a Chinese hamster ovary cell.
RhuFlt3L/CDX-301 is formulated as a sterile solution intended for single-use parenteral administration. Each vial contains 2.5 mg/mL rhuFlt3L/CDX-301 in a 1 mL of buffered solution composed of Sodium Phosphate and Sodium Chloride, with a pH of 7."
1634149|NCT01976585|Drug|Poly-ICLC|Poly-ICLC is supplied by Oncovir in single-dose vials containing 1 mL of 2 mg/mL opalescent white suspension. Each milliliter of Poly-ICLC for injection contains 2 mg/mL poly-IC, 1.5 mg/mL poly-L-lysine, and 5 mg/mL sodium carboxymethylcellulose in 0.9% sodium chloride solution and adjusted to pH 7.6-7.8 with sodium hydroxide.
1634150|NCT01976572|Drug|colestilan|
1634151|NCT01976572|Drug|candesartan|
1634152|NCT01976559|Device|Tympanic Membrane Displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.
For each ICP level during the CSF infusion testing, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration."
1634153|NCT01976559|Device|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
1634154|NCT01976546|Device|Intubation with mcgrath videolaryngoscope and Boedeker intubation foreceps|Patients will be intubated with the Mcgrath videolaryngoscope and a tracheal tube placed by Boedeker intubation foreceps
1634241|NCT01975753|Drug|Morphine|
1634242|NCT01975753|Drug|Fentanyl|
1634155|NCT01976520|Biological|Oncoquest-CLL vaccine|Comparison of 4 different dose levels of Oncoquest-CLL vaccine: 100 micrograms (mcg)/0.2 milliliters (mL), 200 mcg/0.4 mL, 375 mcg/0.75 mL, and 500 mcg/mL. Patients will receive a total of 5 doses of vaccines; the first 2 doses separated by 2 week intervals and the last 3 doses by 1 month intervals. Vaccine will be given by sc injections in 2 sites in upper arms or legs.
1634156|NCT01976507|Drug|dabigatran etexilate mesylate|Immediately following the ablation procedure (4-6 hours after sheath pull and vascular hemostasis), dabigatran etexilate 150mg bid, or 75mg twice daily based on creatinine clearance in the Use in Specified Populations (USPI), will be administered for a minimum of 3 months post RF ablation.
1634157|NCT01976494|Device|The domestic PCA equipment 'Accufuser Omnibus®'|"Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.
Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.
Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.
After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.
After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
1634158|NCT01976494|Device|Imported PCA equipment 'Infusor SV®, Baxter, USA'|"Subject patient selection: the purpose and method of this research will be explained to the patients who satisfy the exclusion criteria before surgery, and written consent regarding research participation will be obtained.
Use of PCA equipment by patients is determined by randomization. Regardless of the PCA equipment type, the basal rate and bolus dose are equally set to 2 mL/hr and 2 mL for the entire research period.
Epidural PCA regime: normal saline added to 0.75% ropivacaine 40 mL and fentanyl 15-20 mcg/kg for a total volume of 100 ml.
After pretreatment, the chest epidural catheter is mounted in the pretreatment room or operating room. The catheter tip is adjusted to be fixed between T6-7 or T7-8.
After mounting the catheter, a test dose of 1% lidocaine 3 ml and epinephrine 1:200.000 is injected. Ten minutes later, sensory loss and skin dermatome will be checked using an alcohol swab."
1634159|NCT01976481|Device|sunbed exposure|exposure to sunbed ultraviolet radiation
1634160|NCT01976468|Other|SCC metastasis|occurrence of SCC metastasis
1634161|NCT01976455|Other|20% fewer calories|
1634162|NCT01976455|Other|40% fewer calories|
1634163|NCT01976429|Other|flight/diving simulation|measurement of ET function during simulated flight/diving in pressure chamber
1634164|NCT01976429|Other|ET function testing at ambient pressure|ET function testing at ambient pressure using sonometry, tubomonometry, 9-step test, maneuver sequence
1634165|NCT01976429|Other|nasal video-endoscopy|examination of nose, nasopharynx,and Eustachian tube orifice
1634166|NCT01976416|Drug|Hydroxyurea|
1634167|NCT01976416|Drug|Placebo|
1634168|NCT01976403|Behavioral|Pain Booklet|The Pain Relief After Cardiac Surgery is originally a Canadian booklet. The booklet is further developed and modified for Norwegian patients
1634169|NCT01976390|Drug|Everolimus|0.75mg twice a day, Orally, starting on day of transplant
1634170|NCT01976390|Drug|Sirolimus|5mg, Orally, starting on day of transplant; decreasing to 3mg
1634171|NCT01976364|Drug|Tofacitinib|Tofacitinib 5 mg tablet twice daily
1634172|NCT01976364|Drug|Tofacitinib|Tofactinib 10 mg tablet twice daily
1634173|NCT01976364|Drug|Methotrexate|Methotrexate 7.5-20 mg weekly
1634174|NCT01976364|Drug|Placebo Methotrexate|Placebo to match active methotrexate orally once a week
1634175|NCT01976338|Drug|Ranibizumab 0.5 mg|intravitreal injection of 0.05 ml
1634176|NCT01976338|Other|Sham injection|Sham intravitreal injection
1634177|NCT01976325|Other|Ottawa Malaria Decision Aid|The Ottawa Malaria Decision Aid is a tool that helps patients become involved in decision making about which malaria prophylaxis pill is right for them to take. The decision aid provides information about the options for malaria chemoprophylaxis, information about the financial costs and time required to adhere to the course of preventative medication, and clarifies personal values. The decision aid is designed to complement counseling from a health practitioner.
1634178|NCT01976312|Other|Sham injection|Sham injections referred to the imitation of an intravitreal injection using an injection syringe without needle.
1634179|NCT01976312|Drug|Ranibizumab 0.5 mg|Ranibizumab solution for injection was supplied in vials. Each vial contained ranibizumab concentration of 10mg/mL labeled as 0.5 mg/0.5 mL, corresponding to a 0.5 mg dose level. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial for single use only
1634180|NCT01976299|Device|AVERT|
1634183|NCT01976273|Device|1064nm Q-switch Laser|
1634184|NCT01976273|Other|Glycolic Acid Peels|
1634185|NCT01976260|Device|Fractional Radiofrequency|
1634186|NCT01976260|Device|1550-nm Fractional Photothermolysis|
1634187|NCT01976247|Device|High Intensity Focused Ultrasound Device|
1634188|NCT01976247|Device|Noninvasive Cryolipolysis Device|
1634189|NCT01976234|Other|Fresh RBC|Patients will receive fresh blood only
1634190|NCT01976234|Other|Old RBC|
1634191|NCT01976221|Behavioral|Prioritization|team-based multifaceted case-based interactive training program in priority setting and waiting time decision
1634192|NCT01976208|Drug|Omalizumab|The recommended dose is 0.016mg/kg/IgE(IU/ml) every 4 weeks. It is administered by subcutaneous injection.If the total dose per 4 weeks is 150~300mg, the dosing interval will be every 4 weeks; if the total dose per 4 weeks is 450mg~750mg，then dosing interval is every 2 weeks.
1634193|NCT01976208|Drug|placebo|
1634194|NCT01976195|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
1634195|NCT01976195|Drug|Thalidomide|Thalidomide 150mg per day, 15 consecutive days
1634196|NCT01976182|Drug|Methotrexate|methotrexate 10mg / m² orally once a week, (at split doses of 5 mg/m2 in the morning and 5 mg/m2 at night), that is to say 2 tablets of 2.5 mg at each take, during 4 months.
1634197|NCT01976182|Drug|Cyclophosphamide|cyclophosphamide 100 mg orally once daily, that is to say 2 tablets of 50 mg at each take, during 4 months.
1634198|NCT01976169|Drug|PD-0332991 and T-DM1|"The subjects will be administered T-DM1 by intravenous infusion at 3.6 mg/kg for 90 minutes on day 1 of each 21 day cycle. Infusion timing may vary from 30-90 minutes depending on how well the subject tolerates the treatment.
A standard 3+3 trial design will be used for PD-0332991 dose escalation cohorts.The dosing of PD-0332991 will be divided into 3 cohorts, the subjects will receive PD-0332991 on days 5-18 of each 21 day cycle.
Cohort 1 : PD-0332991 - 100 mg daily (oral) Cohort 2 : PD-0332991 - 150 mg daily (oral) Cohort 3 : PD-0332991 - 200 mg daily (oral)"
1634199|NCT01976156|Dietary Supplement|PhosphoLean|PhosphoLean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
1634200|NCT01976156|Dietary Supplement|Placebo|Placebo consists of rice flour
1634201|NCT01976143|Drug|NKTR-102|
1634202|NCT01976130|Procedure|Bronchoscopy|
1634203|NCT01976117|Device|enose|
1634204|NCT01976104|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
1634205|NCT01976104|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
1634206|NCT01976104|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
1634207|NCT01976104|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
1634208|NCT01976091|Drug|scAAVrh74.tMCK.hSGCA|
1634209|NCT01976078|Drug|Midazolam/Ranitidine/Esomeprazole|Each of the three drugs will be given at 10% of their usual doses for age/weight.
1634212|NCT01976039|Other|rhinopharyngeal retrograde clearance (RRC)|The rhinopharyngeal retrograde clearance is a respiratory physical therapy technique that uses a forced inspiratory maneuver to clear the nasopharynx
1634213|NCT01976026|Device|Flow Diversion|
1634214|NCT01976026|Device|Best Standard Therapy|
1634215|NCT01976013|Device|Coaguchek|The investigators plan to draw 10μL blood (i.e. approximately 1/5000 of the blood volume of an ELBW infant) within the scope of routine blood sampling. Thus, the number of blood samples will be variable. A cumulative sample volume for the whole study period will not exceed 300μL.
1634216|NCT01976000|Procedure|multi-slice Computed Tomography angiography and three-dimensional reconstruction software|
1634217|NCT01975987|Device|Bonfils fiberscope|
1634218|NCT01975974|Device|Ultrasound|Using ultrasound as a guide for peripheral venous cannulation in obese patients
1634219|NCT01975961|Drug|Crestor 20mg(Rosuvastatin 20mg), Micardis 80mg(Telmisartan 80mg) , FDC|For co-administration, Crestor 1 tablet and Micardis 1 tablet. For FDC administration, FDC 1 tablet.
1634220|NCT01975948|Other|Mental Health Practice Support Program|"training and (2) practice support.
Three half day workshop sessions over a 24 week period.
Practice support:
3 evidence based Supported Self Management tools (Cognitive Behavioral Interpersonal Skills Manual,Bounceback program, Antidepressant Skills Workbook), and Practice support coordinator provides guidance to incorporate newly acquired tools, skills, and processes"
1634221|NCT01975948|Other|Treatment as Usual|Physicians manage patients with depression as usual
1634222|NCT01975935|Drug|Amlexanox|25 mg amlexanox tablets blinded by encapsulation
1634223|NCT01975935|Drug|Placebo|placebo sham blinded by encapsulation in the same capsules as the study drug arm
1992016|NCT00038727|Behavioral|DPPOS Boost Lifestyle|In addition to quarterly group, 2 additional classes per year and an annual 15 minute check-up.
1634225|NCT01975909|Device|Transcranial Magnetic Stimulation|0.2 Hz (5 pulses every six seconds in a counter-clockwise current, followed by the same five pulses in a clockwise current); 10 pulses per region, 30 pulses per session; 5 days a week for 4 weeks.
1634226|NCT01975896|Behavioral|Meditation|The intervention's curriculum will include: 1) the body scan; 2) training in the awareness of the sensations of breathing; 3) training in directing the attention to simple activities of daily life; 4) practice of 'open awareness' in which students will be instructed to just notice which events (physical sensation, sound, visual object, thought) their attention is spontaneously drawn to from moment to moment; 5) mindful movement (standing and walking exercises); and 6) mindful eating. In addition to the weekly training session, students will practice mindfulness techniques for 15 minutes daily in class with the health education teacher and for an additional 15 minutes daily on their own
1634227|NCT01975870|Other|Application on smartphone|innovative application on smartphone which helps to increase the awareness of sedentary behavior of the user by messages, scoring system, ...
1634228|NCT01975857|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
1634229|NCT01975857|Behavioral|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
1634230|NCT01975844|Other|Individualized Anemia Mangement Protocol|"Phase 1 (1-3 months): Develop individualized patient models and Anemia Management Protocols (AMP) while patients are receiving standard medical care.
Phase 2 (9 months): Individualized AMP study period. Phase 3 (9 months): Follow up period: return to standard-care AMP ."
1634231|NCT01975831|Drug|MEDI4736|Anti-PD-L1
1634232|NCT01975831|Drug|Tremelimumab|Anti-CTLA-4
1634233|NCT01975818|Drug|Molidustat (BAY 85-3934)|Oral doses of BAY85-3934 will be available in multiples of 25,50,75 and 150 mg tablets
1634234|NCT01975818|Biological|Epoetin alfa/beta|
1634235|NCT01975805|Other|Chlorhexidine Gluconate|
1634236|NCT01975805|Other|Povidone Iodine|
1634237|NCT01975779|Drug|Cohort A1: Lu AE58054 or placebo|One single oral dose 60 mg (one 60 mg tablet) followed by 60 mg once daily for 7 days, or matching placebo.
1634238|NCT01975779|Drug|Cohort A2: Lu AE58054 or placebo|One single oral dose 120 mg (two 60 mg tablets) followed by 120 mg once daily for 7 days, or matching placebo.
1634239|NCT01975779|Drug|Cohort B1: Lu AE58054|Two single oral doses 60 mg with >=7 days washout.
1992017|NCT00038727|Behavioral|Intensive Lifestyle Group Session|16 session curriculum in group format. In DPP delivered to ILS as individual sessions
1634243|NCT01975740|Other|Sham manual diaphragm release technique|
1634244|NCT01975740|Other|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
1634245|NCT01975727|Drug|Placebo|Injection of placebo (saline 0.9%)
1634246|NCT01975727|Drug|Dexamethasone 3 mg|10 ml Seringue with Dexamethasone
1634247|NCT01975727|Drug|Dexamethasone 6 mg|10 ml Seringue with Dexamethasone
1634248|NCT01975727|Drug|Dexamethasone 12 mg|10 ml Seringue with Dexamethasone
1634249|NCT01975714|Drug|Preservative-free latanoprost|
1634250|NCT01975714|Drug|Preservative-free bimatoprost|
1634251|NCT01975701|Drug|BGJ398|Capsule for oral use.
1634252|NCT01975688|Drug|Sativex|"Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring.
Each vial contains 10 mL; each 100 uL actuation delivers 2.7 mg THC and 2.5 mg CBD."
1634253|NCT01975675|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
1634254|NCT01975675|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (≤ 60 kg = 600 mg, > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
1634255|NCT01975662|Drug|Daptomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
1634256|NCT01975662|Drug|Vancomycin|Duration of treatment will be determined based on the type of bacteremia. Patients with uncomplicated bacteremia will receive a minimum of 14 days antibiotics and those with complicated bacteremia or infective endocarditis will receive a minimum of 28 to 42 days antibiotics from the date that microbiological clearance is achieved.
1634257|NCT01975649|Drug|Tribulus Terrestris|patients will use 750 mg/day during 120 days
1634258|NCT01975649|Other|Placebo|patients will use placebo pills with the same shape of the drug
1634259|NCT01975636|Drug|E2609|Single oral 100 mg +/- 10 mg E2609 with a level of radioactive exposure consistent with the Radioactive Drug Research Committee allowance
1634260|NCT01975623|Device|HARMONIC ACE®+ Shears (HS)|We plan to evaluate the efficacy of the HS for the sealing of PAs in an ex-vivo human model. Efficacy will be measured and compared using the bursting pressure point following vascular energy sealing. Energy sealing may be superior to stapling devices as it eliminates the need for excessive tissue dissection around the pulmonary vessels, which in turn decrease the incidence of vascular injuries during VATS anatomical lung resection. All vessels will be sealed ex-vivo using the HARMONIC ACE®+ Shears (Ethicon, Cincinnati, Ohio, USA).
1634261|NCT01975610|Drug|CC-292|375 mg PO daily (250 mg in the AM and 125 mg in the PM for 28 days)
1634262|NCT01975610|Drug|Placebo|Twice daily for 28 days
1634263|NCT01975597|Procedure|Bone marrow aspirates and biopsy|
1634264|NCT01975584|Behavioral|Trier Social Stress Test|Participants will participate in a standardized role play (Trier Social Stress Test ). A role play is pretending to be in a certain situation. A research staff member will describe the role play, during which teh participant will act out a scene. Participants will be asked to imagine that they are in a certain role with several other research team members who will also participate in the role play. Participants will also be asked to do some math problems without using paper or pencil.
1634265|NCT01975571|Device|Cochlear® Nucleus™ Hybrid L24|The Nucleus Hybrid L24 cochlear implant incorporates an electrode array designed to preserve residual hearing. This has been accomplished by employing a thin, straight, intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The Nucleus Hybrid L24 array has 22 electrodes spread over 16 mm and an anticipated insertion depth of 16 mm. It is slim, with its dimensions ranging from 0.35 x 0.25 mm (at the tip) to 0.55 x 0.4 mm, and designed to minimize lateral wall forces with a stiffened basal section to prevent buckling. The resultant insertion angle is about 280-300° in the scala tympani for the Hybrid L24, as confirmed in temporal bone trials at the Medical University Hannover and the University of Melbourne.
1634266|NCT01975571|Device|Cochlear® Nucleus™ Hybrid S12|The Nucleus Hybrid S12 cochlear implant incorporates an electrode array designed to stimulate the high-frequency, basal region of the cochlea while maintaining useful acoustic hearing in the low-frequency, apical region. This has been accomplished by employing a short, thin, straight intracochlear electrode array attached to a Nucleus cochlear implant receiver/stimulator. The electrode array incorporates a collar to prevent over-insertion, or further migration, into the cochlea beyond the point where the basal turn curves into the ascending segment. Thus, the electrode array is placed within the straight segment of the basal turn of the scala tympani via a cochleostomy.
1634267|NCT01975558|Biological|Sampling (blood, urine, sebum, saliva)|sampling at baseline, during radiation therapy and after
1634270|NCT01975519|Drug|TRC105 and Pazopanib|Weekly TRC105 in combination with standard dose Pazopanib.
1634272|NCT01975480|Drug|Desvenlafaxine|
1634273|NCT01975467|Device|CRx|The CRx is used to treat mid-shaft, with or without comminution clavicle fractures.
1634274|NCT01975454|Drug|Chemotherapy|Oxaliplatin (130 mg/m2) was given intravenously (iv) for at least 2 h on day 1; Capecitabine (1000 mg/m2) was given orally, twice daily on days 1-14. Each cycle was 21 days. Cycles were repeated until disease progression or unacceptable toxicity.
1634708|NCT01972165|Procedure|Endoscopic carpal tunnel release|
1634275|NCT01975454|Drug|Herbal therapy|TLBZT based herbal decoction administered orally twice a day
1634276|NCT01975441|Drug|Diethylcarbamazine|Diethylcarbamazine 6mg/kg
1634277|NCT01975441|Drug|Albendazole|Albendazole 400mg
1634278|NCT01975441|Drug|Ivermectin|Ivermectin 200 mcg/kg
2011866|NCT02365324|Behavioral|Peer-Education Family Fitness Program (PE-FFP)|The proposed integrated project will be implemented by peers and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
2011867|NCT02365324|Behavioral|Family Fitness Program (FFP)|The proposed integrated project will be implemented by adults and will evaluate the effects of an evidence-based extension education program, grounded in Stages of Change Learning Theory and guided by Social Cognitive Theory (SCT), having 2 arms for the study (with and without a peer-education mode of delivery) on balancing calories to manage body weight (BW), reducing certain foods and food components, increasing selected foods and nutrients, building healthy eating patterns [i.e., fundamental principles of the Dietary Guidelines for Americans (DGAs), 2010] and SCT variables.
2011868|NCT02363946|Drug|ARC-AAT Injection|RNA interference (RNAi)-based, liver-targeted therapeutic
2011869|NCT02363946|Other|Placebo|0.9 % normal saline
2011870|NCT02363751|Drug|Bevacizumab|"Patients will be treated for a maximum of 6 (21days) chemotherapy cycles (Gemcitabine+platinium salt+bevacizumab).
In case of disease control (complete, partial or stable disease) treatment with bevacizumab 15mg/Kg monotherapy every 21 days will be continued until disease progression or until the end of the 24 months of follow-up."
2011871|NCT02362802|Device|Implantable Cardioverter Defibrillator|
2011872|NCT02362503|Drug|BMS-663068|BMS-663068
2011873|NCT02362503|Other|Placebo|Placebo
1634287|NCT01975363|Dietary Supplement|curcumin|Participants will be randomized to either 50 mg BID or 100 mg BID NEC for a 3 month treatment period.
1634288|NCT01975363|Other|Biomarker analysis|Breast adipose tissue and plasma samples will be obtained at baseline and 3 months for biomarker analyses. Breast adipose tissue samples will be obtained via fine needle aspiration. Plasma samples from the baseline blood draw will be assessed for curcumin/COG and also stored at -80°C for biomarker analyses.
1634289|NCT01975363|Other|Assessment of Dietary Intake|Food frequency questionnaires will be obtained at 0 months and 24-hour dietary recalls will be obtained at 1, 2 and 3 months of the study.
1634290|NCT01975363|Other|Daily Log|All participants will complete a daily log on the date and time of NEC administration, potential adverse events, and medications.
1634291|NCT01975337|Drug|Alisporivir|Alisporivir supplied as 200 mg oral capsules in blister packs (7 units per blister pack)
1634294|NCT01975311|Other|Lumbopelvic Manipulation|High-velocity low-amplitude non-specific lumbopelvic thrust manipulation
1634295|NCT01975311|Other|Passive lumbar spine flexion and extension|Passive lumbar spine flexion and extension without reaching the physiological end feel for 1 min from a side lying position.
1634296|NCT01975298|Drug|Laquinimod|Oral Administration
1634297|NCT01975298|Drug|Avonex®|Interferon β1A 30 μg/0.5mL administered Intra Muscular
1634298|NCT01975285|Drug|Dexamethasone|0.5% Bupivacaine with 1:200,000 epinephrine + Dexamethasone 4mg per 20cc
1634299|NCT01975285|Drug|Saline|0.5% Bupivacaine with 1:200,000epinephrine + Saline 1 ml per 20cc
1634300|NCT01975272|Drug|Ferinject|
1634301|NCT01975272|Drug|Ferrous fumarate|
1634302|NCT01975272|Drug|Placebo for ferrous fumarate|
1634303|NCT01975272|Drug|Placebo for ferinject|
1634304|NCT01975259|Drug|Oral Glucose Tolerance test (75g 2-hour)|A standard 2-hour oral glucose tolerance test where fasted patients (10hours overnight) consume a 75g glucose solution & have glucose levels recorded up to every 30 mins for 2hours
1634305|NCT01975259|Drug|Modified Oral Glucose Tolerance Test (50g 4-hours)|A 4-hour version of the oral glucose tolerance test where fasted patients (10hours overnight) consume a 50g of glucose solution & have glucose levels recorded up to every 5mins as well pancreatic and incretin responses at 10 fixed time points.
1634306|NCT01975259|Drug|Matched isoglycemic clamp|A glucose drip will be infused at a variable rate that recreates the individual subjects blood glucose values obtained during their 4-hour modified oral glucose tolerance test. This test will therefore last 4-hours and again subjects will be fasted (10hours overnight) at the time of the test. The same blood tests will be performed at the same time points as the modified glucose tolerance test
1634307|NCT01975259|Drug|Hyperglycemic clamp with concurrent GLP-1 infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GLP-1 will be commenced at a rate of 0.25pmol/kg/min for 60mins and then continued at a rate of 1.2pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
1634308|NCT01975259|Drug|Hyperglycemic Clamp with concurrent GIP infusion|An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp). After 60mins an infusion of GIP will be commenced at a rate of 1pmol/kg/min for 60mins and then continued at a rate of 4pmol/kg/min for a further 60mins. Subjects will be blinded to what infusion they are receiving.
1634309|NCT01975259|Drug|Hyperglycemic clamp with placebo infusion|"An intravenous glucose infusion will be infused at a rate that maintains blood glucose at a level of 180-216mg/dL (10-12 mmol/l) (hyperglycemic clamp).
After 60mins an infusion of normal saline will be commenced as a placebo infusion. It will be infused at a rate so that the total volume of fluid is similar to that infused during the other two hyperglycemic clamp interventions. Subjects will be blinded to what infusion they are receiving."
1634310|NCT01975259|Other|Liquid Meal Test (Carbohydrate-rich)|A standardised liquid meal (carbohydrate-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
1634348|NCT01974986|Other|High-Na low-CHO beverage|A volume of fluid (high-Na, low-CHO) was given after exercise to return each subject's body mass (to euhydration).
1634311|NCT01975259|Other|Liquid Meal Test (Fat-rich)|A standardised liquid meal (fat-rich) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
1634312|NCT01975259|Other|Liquid Meal Test (Mixed)|A standardised liquid meal (mixed) containing approximately 500kcal would be administered to patients who had fasted overnight (10hrs). Over the next 4hours bloods would be sampled at 10 fixed time points to measure features of the incretin response to this type of meal.
1634313|NCT01975259|Device|Continuous Glucose Monitoring|Continuous glucose monitoring entails wearing a small portable device, usually on the upper arm, for a period of three days. The device uses a small plastic tube to record the glucose level from interstitial fluid & every minute wirelessly transmits this information to a base unit to enable a very accurate estimate of average blood sugar control to be defined.
1634314|NCT01975246|Drug|Telmisartan + amlodipine|FDC tablet
1634315|NCT01975246|Drug|hydrochlorothiazide|tablet
1634316|NCT01975246|Drug|Telmisartan + amlodipine|FDC tablet
1634317|NCT01975246|Drug|Placebo|placebo matching hydrochlorothiazide tablet
1634318|NCT01975233|Device|WEB Aneurysm Embolization System|WEB Aneurysm Embolization System
1634319|NCT01975220|Drug|Empagliflozin/Metformin XR, FDC|Experimental: high dose empagliflozin/metformin XR, FDC tablet
1634320|NCT01975220|Drug|Empagliflozin/Metformin XR FDC|Experimental: low dose empagliflozin/metformin XR, FDC tablet
1634321|NCT01975220|Drug|25 mg Empagliflozin/1000 mg Metformin XR, FDC|Experimental, high dose Empagliflozin/Metformin XR,FDC Tablet
1634322|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
1634323|NCT01975220|Drug|1 tablet Empagliflozin/3 tablets Metformin XR|Active Comparator: 1x empagliflozin/3x metformin XR tablets
1634324|NCT01975220|Drug|1 tablet Empagliflozin/2 tablets Metformin XR|Active Comparator: 1x empagliflozin/2x metformin XR tablets
1634325|NCT01975207|Behavioral|Treatment as usual|Participants will be treated as per clinic's standard treatment for depression.
1634326|NCT01975207|Behavioral|Internet Intervention|"One of the major treatments for mild-moderate depressive disorders is cognitive behavioural therapy (CBT). It has been possible to operationalize some of this treatment and internet-based approaches to this have been developed. The most widely examined was developed in Australia and is termed MoodGYM (https://moodgym.anu.edu.au/welcome). This program has been widely studied, and these studies have shown it is very effective for many individuals in family practice"
1634327|NCT01975207|Behavioral|Depression Treatment Pathway|"There has been a growing awareness in health care circles that certain high frequency, high cost addiction and mental health disorders may be best addressed via the systemic adoption of clinical pathways. A clinical pathway is defined as a multidisciplinary outline of anticipated care, placed in an appropriate timeframe, to help a patient with a specific condition or set of symptoms move progressively through a clinical experience to positive outcomes. A clinical pathway incorporates guidelines, protocols and evidence informed best practice into everyday use for the patient and family."
1634328|NCT01975194|Drug|Rosuvastatin|Patients will be started at 20 mg per day and then increased to 40 mg per day if not at target by six weeks
1634329|NCT01975181|Behavioral|Diet|In receiving recommendations for a Mediterranean-style diet, subjects are encouraged to get protein predominantly from fish and legumes, fat from olive oil or other sources high in omega-3 oils, to eat whole grains and complex carbohydrates while avoiding highly processed foods. Subjects are also coached on portion control, stress-eating and snacking, aiming for adequate water intake, and eating meals including breakfast with regularity.
1634330|NCT01975181|Behavioral|Exercise|After assessing safety of exercise with a supervised, graded exercise tolerance test, subjects are given a prescription for exercise with activities tailored to their preferences and physical limitations aiming for at least 150 minutes of continuous aerobic exercise per week.
1634331|NCT01975181|Behavioral|Stress Management|"In supervised coaching sessions and with assigned homework behaviors, subjects learn to use a tension tamer with visualized imagery, deep breathing, and progressive muscle relaxation to live with lower levels of stress."
1634332|NCT01975181|Behavioral|Sleep Improvement|"After evaluation of treatment of sleep pathologies such as obstructive sleep apnea and periodic limb movement disorder, subjects are taught to employ tension tamer techniques and pursue daily exercise to improve sleep latency and sleep continuity."
1634333|NCT01975168|Device|Handylaser Trion laser acupuncture|intervention interval is 3 times per week for 12 weeks
1634334|NCT01975155|Other|food questionnaire|
1634335|NCT01975155|Other|Urinary mycotoxin test|
1634336|NCT01975142|Drug|Trastuzumab - Emtansine|
1634337|NCT01975129|Drug|Vagitocin|
1634338|NCT01975116|Drug|azurin-derived cell-penetrating peptide p28|Given IV
1634339|NCT01975103|Procedure|Topcon Endpoint Management|
1634341|NCT01975077|Drug|fruquintinib|Fruquintinib is a capsule in the form of 1mg and 5mg, orally, daily
1634342|NCT01975064|Drug|Propofol|Propofol will be infused individually for a sufficient level of anesthesia during the entire surgical procedure.
1634343|NCT01975064|Drug|Sevoflurane|Sevoflurane will be administered by vaporizer individually for a sufficient level of anesthesia during the entire surgical procedure.
1634344|NCT01975051|Drug|Mitefosine|Tablet Miltefosine 100 mg in two devided doses for 12 weeks
1634345|NCT01975025|Procedure|Short daily dialysis for 2 weeks|
1634346|NCT01975012|Drug|Rilpivirine|"For Cohort 1, Stage 1: RPV will be given orally as a 25-mg film-coated tablet (or for dosing in younger children, as granules [2.5 mg/g]) each day with a meal.
For Cohort 1, Stage 2: The dose of RPV will be determined once Cohort 1, Stage 1 data are available.
For Cohort 2: The dose of RPV will be determined once Cohort 1 data are available."
1634347|NCT01974986|Other|Water with flavoring and non-nutritive sweetener.|A volume of fluid (water) was given after exercise to return each subject's body mass (to euhydration).
1634709|NCT01972152|Drug|G-Pen(TM) 1 mg|
1634710|NCT01972152|Drug|Lilly Glucagon(TM) 1 mg|
1634349|NCT01974986|Other|Low-Na high-CHO beverage|A volume of fluid (low-Na, high-CHO) was given after exercise to return each subject's body mass (to euhydration).
1634350|NCT01974973|Procedure|Autologous bone marrow mononuclear cell transplantation|Intrathecal autologous bone marrow mononuclear cell transplantation
1634351|NCT01974947|Other|Blood sample, sperm sample and clinical examens|Blood sample, sperm sample and clinical examens will be done at the day of the inclusion
1634352|NCT01974934|Drug|Desvenlafaxine Succinate|
1634353|NCT01974921|Device|ALAIR Catheter. Radiofrequency system.|Radiofrequency with Alair Catheter trhough flexible bronchoscopy in three different sessions (right lower lobe, left lower lobe, both upper lobes).
1634354|NCT01974908|Procedure|Fibrillatory Factor calculation (FF)|During sinus rhythm these patients will undergo a simple pacing protocol to allow us to calculate FF, which is an area we would predict is mod likely to be the origin of their VT.
1634355|NCT01974895|Biological|FluLaval® Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
1634356|NCT01974895|Biological|Fluzone®|1 or 2 doses administered IM in deltoid region of non-dominant arm (for subjects ≥12 months of age) or anterolateral region of left thigh (for subjects <12 months of age) on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects), respectively.
1634357|NCT01974882|Other|Ice pack|Cryotherapy was applied via reusable ice bags filled with ice. Ice packs were immediately applied after the dressing was placed on the wound. The ice pack maintained in place for a continuous 24 hours adn was refilled as needed. After twenty-four hours, patients had the option of using ice packs for as long as they wished. The duration of ice pack usage was noted.
1634358|NCT01974869|Drug|Anti-tumor necrosis factor alpha agents|Treatment with biologics
1634359|NCT01974843|Drug|Levobupivacaine|in the levobupivacaine-tramadol (LT) group received a caudal injection of levobupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg levobupivacaine plus 35 mg tramadol), resulting in a total volume of 1 ml/kg at maximum volume of 15 ml
1634360|NCT01974843|Drug|Bupivacaine|in the bupivacaine-tramadol (BT) group received a caudal injection of bupivacaine 0.25% plus tramadol 2 mg/kg (maximum doses; 35 mg bupivacaine plus 35 mg tramadol)
1634361|NCT01974817|Biological|13-valent conjugate pneumococcal vaccine|0.5ml IM for one dose
1634362|NCT01974804|Procedure|MRI|
1634363|NCT01974791|Behavioral|GET Living|GET Living is an exposure based treatment jointly delivered by a cognitive-behavioral therapist and physical therapy to help children and adolescents suffering with chronic pain and headache progressively return to valued life activities.
1634364|NCT01974778|Dietary Supplement|Meal|Meal
1634366|NCT01974752|Drug|75mg selumetinib|selumetinib tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
1634367|NCT01974752|Drug|placebo|placebo tablets p.o. twice daily taken in combination with dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle.
1634368|NCT01974752|Drug|Dacarbazine|dacarbazine 1000mg/m2 iv on day 1 of every 21-day cycle taken in combination with either selumetinib or placebo tablets p.o. twice daily.
1634369|NCT01974739|Drug|Hydrochloorthiazide|
1634370|NCT01974739|Drug|placebo|
1634371|NCT01974726|Other|ET Stress test|Performed in pressure chamber. For subjects with intact tympanic membranes, chamber pressure increased from ambient to +2500 daPa (+2000 daPa for children). At that pressure and then at down-stepped pressures of 250 daPa/steps to a chamber pressure of -1500 daPa (or a passive ET opening), the subject will swallow to attempt to open the ET as detected by sonotubometry and/or a change in ear canal pressure. ET passive opening and closing pressures will then be determined. In ears with a non-intact tympanic membrane, a small volume probe connected to a pressure transducer will be placed in the ear canals and the procedure repeated with continuous recording of ME pressure. ET opening is recorded as a change in ME pressure toward local ambient.
1634372|NCT01974726|Other|Sonotubometry|Microphones are placed in the ear canals and covered with ear protectors. A nasal probe placed in one nostril introduces a white noise to the nasopharynx and the subject is asked to swallow. The test system identifies the sound frequency best transmitted through an open ET (if the test is positive, i.e. ET opens) and the procedure is repeated with the nasal sound pressure delivered at that frequency. The probe is then placed in the contralateral nostril and the procedure repeated. The microphone signals from both ear canals are continuously outputted and recorded. A positive ET opening is defined as a 5 dB increase above baseline during any of the 4 swallows and can be semi-quantified as the area under the baseline-adjusted ear canal sound pressure-time curve. The test is designed to measure the presence or absence of muscle-assisted ET openings during swallowing at local ambient pressure.
1634373|NCT01974726|Other|Forced Response Test (FRT)|The FRT requires a non-intact tympanic membrane and uses an instrument consisting of an ear canal probe coupled serially to a differential pressure transducer, via a valve to a flow sensor and via a second valve to a variable-speed constant-flow pump. The probe is sealed in the ear canal and both valves are opened. The pump is set to deliver a constant flow of 11 ml/min which increases ME pressure to passively open the ET. This is followed by a decrease in ME pressure to steady state pressure and flow conditions. The subject is asked to swallow which either transiently increases (further ET dilation) or decreases (ET constriction) the transET flow. The pump is turned off causing the ET to close at a residual ME pressure. This procedure is repeated at flow rates of 23 and then 46 ml/min.
1634374|NCT01974726|Other|Inflation Deflation Test (IDT)|The IDT requires a non-intact tympanic membrane and uses the FRT instrument. ME pressure is increased to 250 daPa (ref ambient), the valves to the flow sensor and pump closed and the subject is asked to swallow repeatedly at a natural interval while monitoring ME pressure until further swallowing fails to change ME pressure. The procedure is repeated with an applied under-pressure of -250 daPa. The outcome variable is the percent pressure change (%reduction) at test end. The test measures the muscle-assisted tubal openings under minor stress (ME under-pressure) and facilitative (ME over-pressure) conditions, and can detect a patulous/semi-patulous ET by an inability to maintain applied ME over and/or under-pressures between swallows.
1634663|NCT01972529|Drug|placebo (lower baseline platelet count)|60 mg placebo (3 x 20 mg matching placebo tablets)
1634375|NCT01974726|Other|Maneuver Sequence|The sequence consists of the Toynbee, Valsalva, Sniffing and Continuous Pressure Test (CPT). The test system consists of ear canal and nasal pressure probes. For the Toynbee test the subject pinches both nostrils (without constricting the nasal probe) and swallows; for the Sniffing test, the subject performs a series of forcible sniffs that must achieve a nasopharyngeal pressure of at least -400 daPa; for the Valsalva test the subject pinches both nostrils and forcibly blows against the closed nose to achieve a nasopharyngeal pressure of at least 400 daPa, and for the CPT the subject breathes through his/her mouth in a relaxed manner for 2 minutes.
1634376|NCT01974726|Other|9-Step Test|This test requires an intact tympanic membrane. Middle ear (ME) pressure is recorded by tympanometry before and after application of a 300 daPa over-pressure to the ear canal and then before and after application of a 300 daPa under-pressure to the ear canal. Between steps, the subject is asked to swallow in an attempt to open the ET and change ME pressure. A positive test is indicated by a minimum 10 daPa change in ME pressure after a given swallow and excellent muscle-assisted ET opening is indicated by an initial change to a more negative ME pressure after a swallow, followed by a return to 0 daPa, a positive ME pressure and a return to 0 daPa for sequential swallows. The test is designed to measure the presence/absence of active ET openings during swallowing at ambient pressures.
1634377|NCT01974726|Other|Tubomanometry|The test system is commercially available and can test ears with and without an intact tympanic membrane. Pressure sensors are inserted bilaterally into the ear canals and sealed. A controlled air-flow is introduced into the nose and nasopharynx and the subject swallows. ET openings are detected as a change in ME pressure measured directly as a pressure pulse in the ear canal for ears with a non-intact tympanic membrane or indirectly as a change in ear canal pressure caused by tympanic membrane displacement in ears with intact tympanic membranes. The outcome is the detection of a pressure change in the ear canal during swallowing which is indicative of a muscle-assisted tubal opening.
1634378|NCT01974726|Other|Videoendoscopic assessment of ETF|The subject's nose is topically anesthetized and decongested with 4% lidocaine and 0.05% oxymetazoline. If ventilation tubes are present, probes are sealed in the ear canal(s)and a pressure of 200 daPa is applied to the ME(s) to assess ET opening. If tympanic membranes are intact, microphones for sonotubometry are placed in the ear canals. Then, an endoscope attached to a video camera is introduced into the ipsilateral nasal cavity and focused on the ET orifice. For sonotubometry, the sound source probe is placed in the contralateral nostril. The subject is asked to swallow, vocalize and perform a series of mandibular movements. Signals from the video camera and pressure transducer or sonotubometry microphones are continuously recorded. The data are studied to document dilation of the nasopharyngeal ET orifice during swallowing and to rule in or out an anatomical or functional nasopharyngeal abnormality as the cause of a diagnosed ET dysfunction.
1634379|NCT01974726|Other|Pressure chamber ET test|Performed in pressure chamber. Pressure increased to create middle-ear underpressure, then subject is asked to swallow several times. Middle-ear pressures are then measured by tympanometry. This is repeated with decreased chamber pressure, creating a middle-ear overpressure.
1634380|NCT01974700|Drug|Levetiracetam|500 mg intravenous dose during the operative case then 500 mg orally twice a day for a total of seven days
1634381|NCT01974687|Drug|Uprifosbuvir|Uprifosbuvir 5 mg, 25 mg, or 50 mg capsule, or 150 mg tablet, administered by mouth.
1634382|NCT01974687|Drug|Placebo|Matching placebo to uprifosbuvir capsule administered by mouth.
1634383|NCT01974687|Drug|Itraconazole|Itraconazole is supplied as 10 mg/mL oral solution or 100 mg capsules administered by mouth.
1634384|NCT01974674|Procedure|Allogeneic transplantation of intrahepatic islet|
1634385|NCT01974661|Biological|COMBIG-DC (ilixadencel)|Allogenic dendrite-cell based therapeutic vaccine
1634386|NCT01974648|Drug|propofol|
1634387|NCT01974648|Drug|propofol and remifentanil|
1634388|NCT01974635|Device|AMES Therapy|During the therapy session, the AMES device rotates the hand into flexion and extension, while the patient assists with this motion, as possible. At the same time, the AMES device provides sensory stimulation by vibrating the tendons of muscles stretched by the movement. The vibratory stimulus switches from one side of the limb to the other when the rotation reverses direction so that the sensory stimulation remains functionally related to the movement. The subject will receive visual bio-feedback of their contribution to the motor movement.
1634389|NCT01974622|Drug|Visudyne|Half fluence verteporfin
1634390|NCT01974609|Drug|Narcotic|Hydrocodone 5mg + acetaminophen 325 mg
1634391|NCT01974609|Drug|non-narcotic|ibuprofen 600mg + acetaminophen 325 mg
1634392|NCT01974596|Dietary Supplement|Probiotic tablets of Lactobacillus reuteri|
1634393|NCT01974596|Dietary Supplement|Placebo tablets|
1634394|NCT01974583|Procedure|regrafted with thin split-thickness skin graft|Group A (the treatment group) were regrafted with thin split-thickness skin graft
1634395|NCT01974583|Procedure|covered with the occlusive hydrocellular dressing|group B covered with the occlusive hydrocellular dressing (Allevyn Adhesive, Smith & Nephew)
1634396|NCT01974583|Procedure|covered with paraffin gauze|Group C covered with paraffin gauze
1634397|NCT01974570|Dietary Supplement|Marealis refined peptide concentrate|2 tablets, once per day before noon
1634398|NCT01974570|Dietary Supplement|Placebo|2 tablets, once per day before noon
1634399|NCT01974557|Other|Exercise|
1634400|NCT01974544|Drug|Best medical treatment|If patients are unable to maintain their haemoglobin A1c (HbA1c) values below 6.5% on diet alone, treatment with metformin 1g twice daily will be started. If HbA1c remains above 7.0% then liraglutide 0.6 mg once daily (with a subsequent increases to 1.2 mg and 1.8 mg once daily). If liraglutide is not tolerated then a Dipeptidyl peptidase IV inhibitor (sitagliptin, saxagliptin, linagliptin) or pioglitazone will be considered. If HbA1c remains above 7.5% long acting insulin analogues such as detemir o glargine will be added. If insulin is started liraglutide can be stopped. The insulin dose will be adjusted according to the morning fasting blood glucose concentration. Finally, Fast-acting meal time insulin (lispro, aspart or glulisine) will be added if glycemic goal is not achieved. Repaglinide can be considered in patients with significant renal impairment and in patients who refused insulin treatment.
1634401|NCT01974544|Procedure|gastric bypass|For the gastric bypass, the gastric pouch will be adjusted to a volume of 15-20 ml. The alimentary limb will be a standard 150 cm and the biliopancreatic limb 50 cm. A hand-sewn gastro-jejunal anastomosis will be performed over a 34 French bougie
1634664|NCT01972529|Drug|avatrombopag (higher baseline platelet count)|40 mg avatrombopag (2 x 20 mg tablets)
1634402|NCT01974544|Procedure|sleeve gastrectomy|The sleeve gastrectomy will be done using laparoscopic staplers over a 34 French bougie.The greater curvature will be dissected 4 cm proximal to the pylorus leaving the antrum. Short gastric vessels will be dissected using the harmonic scalpel up to the gastro-esophageal junction. The stapler will be reinforced. The resected stomach will be removed in a plastic bag through the left flank trocar
1634403|NCT01974544|Drug|General interventions for all groups: blood presure|Patients will receive an angiotensin-converting-enzyme (ACE) inhibitor or angiotensin II receptor antagonists (ARA II) to meet strict blood pressure targets of the ADA / European Association for Study of Diabetes (EASD) or in the presence of micro or macroalbuminuria. In addition to ACE inhibitors (or if there were side-effects, an angiotensin-II receptor antagonist), calcium antagonist, diuretics or Beta blockers can be added as needed. Aspirin 100 mg daily will be used for secondary prevention in patients with a history of ischaemic cardiovascular disease.
1634404|NCT01974544|Drug|General interventions for all groups: dysilipidemia|Raised fasting serum cholesterol concentrations (greater than 4.5 mmol/L) or combined dyslipidaemias will be treated with atorvastatin 10-80mg once daily. Gemfibrozilo or fenofibrate once daily can be used for isolated hypertriglyceridaemia (fasting serum triglyceride concentration >4.0 mmol/L), or fenofibrate can be added to statin treatment if the fasting serum triglyceride concentration was also raised (>4.0 mmol/L).
1634405|NCT01974544|Behavioral|General interventions for all groups: lifestyle|Exercise is an important part of the diabetes management plan. The ADA recommendations for the adults with diabetes is at least 150 min/week of moderate-intensity aerobic physical activity (50-70% of maximum heart rate), with no more than two consecutive days without exercise. A kinesiologist will design an individual plan of physical training for each patient. Also, a nutritionist will be design an individual dietitian plan, this plan should be formulated as a collaborative therapeutic alliance among the patient and family, physician, and other members of the health care team.
1634406|NCT01974518|Drug|Rituximab and Cyclophosphamide IV|
1634407|NCT01974505|Device|intubation using optiscope|Optiscope (Clarus Medical, Minneapolis, MN, USA) is a semi-rigid fiberscope designed for endotracheal intubation. Anesthetic providers who are novice on optiscope will perform intubation using optiscope.
1634408|NCT01974492|Procedure|Upper leg vein harvesting|Patients whose saphenous veins are harvested from upper legs.
1634409|NCT01974492|Procedure|Lower leg vein harvesting|Patients whose saphenous veins are harvested from lower legs.
1634410|NCT01974479|Biological|anti-CD19 redirected NK cells|Haploidentical donor NK cells will be expanded and electroporated over 10 days and infused. NK cells will be infused at single dose on day 0. The patient will receive cyclophosphamide 60mg/kg on day - 7 , and Fludarabine 25 mg/m2/day will be given on day -6 to day -2 prior to the NK cell infusion. IL- 2 will be given subcutaneously for 6 doses every alternate day starting on day -1, for NK cell survival.
1634411|NCT01974466|Other|Goal A|controled fluid therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of two or more of four criteria:1. HR <120 beats/min, 2.MAP 65-85 mm Hg, 3. urine output ≥1 ml/kg /h 4. HCT ≤35%.
1634412|NCT01974466|Other|Goal B|"controled fluid therapy：10~5ml/kg/h，crystalloid vs colloid 2:1 resuscitation target： fulfillment of all of the following criteria:
1 CVP 8-12 mmHg , 2.MAP 65-85 mm Hg, 3. urine output ≥0.5 ml/kg/h 4. ScvO2 ≤70%"
1634413|NCT01974453|Radiation|Radiation dose|Radiation dose adsorbed by operators
1634414|NCT01974440|Drug|Bendamustine|90 milligram per meter square (mg/m^2) administered intravenously on Days 1 to 2 of Cycles 1 to 6.
1634415|NCT01974440|Drug|Rituximab|375 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
1634416|NCT01974440|Drug|Cyclophosphamide|750 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
1634417|NCT01974440|Drug|Doxorubicin|50 mg/m^2 administered intravenously on Day 1 of Cycles 1 to 6.
1634418|NCT01974440|Drug|Vincristine|1.4 mg/m^2 (maximum total 2 mg) administered intravenously on Day 1 of Cycles 1 to 6.
1634419|NCT01974440|Drug|Prednisone|100 mg administered orally on Days 1 to 5 of Cycles 1 to 6.
1634420|NCT01974440|Drug|PCI-32765 (Ibrutinib)|560 mg (4*140 mg) capsules administered orally once daily, continuously starting on Cycle 1, Day 1.
1634421|NCT01974440|Drug|Placebo|Placebo (4 capsules) matched to ibrutinib administered orally once daily, continuously starting on Cycle 1, Day 1.
1634422|NCT01974414|Drug|orally administered cedar honey|
1634423|NCT01974401|Device|supragingival irrigators containing chlorhexidine|patients received irrigation by oxyjet supra gingival irrigators containing chlorhexidine for at least 3 minutes for all dentulous regions of jaws which was performed by researchers once daily.
1634424|NCT01974388|Procedure|LSG started 2 cm from the pylorus|Laparoscopic sleeve gastrectomy started 2 cm from pylorus
1634425|NCT01974388|Procedure|LSG started 6 cm from pylorus|LSG started 6 cm from pylorus
1634426|NCT01974375|Drug|micafungin|Micafungin 100 mg/day intravenous (2.0 mg/kg/day in subjects weighing <40 kg)
1634427|NCT01974375|Drug|Fluconazole|Fluconazole 100~200mg/day, IV care until oral medication becomes possible
1634428|NCT01974362|Device|Dental Implant|Place dental implants in both jaws (maxilla and mandible) according to manufacturer specifications
1634429|NCT01974362|Device|Monolithic Zirconia|rehabilitation with monolithic zirconia implant-prosthesis
1634430|NCT01974362|Device|Zirconia-Feldspathic|restore dental implants with a zirconia suprastructure and feldspathic veneers
1634431|NCT01974349|Drug|selumetinib (oral)|Volunteers will receive: 75 mg selumetinib oral dose in a fasted state (Treatment A) followed by a second 75 mg selumetinib oral dose in the fed state (Treatment B) with a washout period of at least 7 days between doses, or: 75 mg selumetinib oral dose in the fed state (Treatment B) followed by a second 75 mg selumetinib oral dose in the fasted state (Treatment A) with a washout period of at least 7 days between doses.
1634432|NCT01974336|Drug|ursodeoxycholic acid|
1634433|NCT01974323|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
1634434|NCT01974323|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
1634435|NCT01974310|Procedure|Vitrectomy & Intraocular gas fill|
1634436|NCT01974310|Procedure|Postoperative face-down positioning|
1634437|NCT01974297|Drug|Atorvastatin 10mg, fenofibric acid 135mg|Atorvastatin 10mg, fenofibric acid 135mg/day PO for 12 weeks
1634438|NCT01974297|Drug|atorvastatin 20mg|Atorvastatin 20mg/day PO for 12weeks
1634439|NCT01974284|Drug|percutaneous ethanol ablation|The volume of 99% ethanol to be injected is calculated using a standardized formula. Ethanol is instilled with a needle under ultrasound guidance after administration of local anesthesia.
1634440|NCT01974258|Drug|Cobimetinib|Escalating dose
1634441|NCT01974258|Drug|Cobimetinib|Orally administered once daily for 21 consecutive days, followed by 7 days off.
1634442|NCT01974258|Drug|Onartuzumab|Administered by IV infusion every 2 weeks
1634443|NCT01974258|Drug|Vemurafenib|Orally administered twice daily
1634444|NCT01974245|Drug|Cholecalciferol|100,000 IU/week for 12 weeks
1634445|NCT01974245|Drug|Placebo|100 drops/ week for 12 weeks
1634446|NCT01974206|Biological|ASP0113|intramuscular injection
1634447|NCT01974206|Drug|Placebo|intramuscular injection
1634448|NCT01974193|Drug|Floseal|application of floseal on intervention arm
1634449|NCT01974167|Drug|Eldecalcitol|Eldecalcitol 0.75 microgram once daily orally
1634450|NCT01974167|Drug|Alfacalcidol|Alfacalcidol 1 microgram once daily orally
1634451|NCT01974154|Other|Cohort I|We will evaluate serum and lung ELF obtained by bronchoalveolar lavage, under previous protocols, from 159 individuals at baseline and at 0, 3, 6 and 12 months.
1634452|NCT01974154|Other|Cohort II|Quantify the cilia length on prepared slides from 67 cohort II samples of airway epithelium from biological samples were already obtained from subjects who were consented to participate in prior WCMC IRB approved protocols.
1634453|NCT01974141|Drug|Dapsone Gel|Dapsone gel applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
1634454|NCT01974141|Drug|Dapsone Gel Vehicle|Dapsone gel vehicle applied topically to the face and to affected areas of the trunk once daily for 12 weeks.
1634455|NCT01974128|Procedure|ASC isolation and implantation|This trial will study ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The injection catheter will be used for delivery of the ASCs therapy
1634456|NCT01974115|Device|Radial extracorporeal shock wave therapy|All patients were treated with radial extracorporeal shock waves using the Swiss Dolorclast (Electro Medical Systems S.A., Nyon, Switzerland) and the Power+ handpiece with the 36-mm applicator. Patients were treated unilaterally with two weekly treatments for four weeks on a randomly selected leg (left or right), totaling eight treatments on the selected side. After the application of coupling gel, treatment was performed at 3.5 to 4 bar, with 15,000 impulses per session, and applied at 15 Hz. Impulses were applied homogeneously over the posterior thigh and buttock area. One patient was treated on both legs, with each leg considered an independent treatment.
1634457|NCT01974102|Behavioral|Lifestyle counseling|Active and control participants will receive nutritional and physical activity counseling.
1634458|NCT01974102|Behavioral|Mindfulness Based Stress Reduction|Active participants will receive 8 weeks of Mindfulness Based Stress Reduction therapy.
1634459|NCT01974089|Other|Modified diet|
1634460|NCT01974076|Device|Active tDCS + CBT|
1634461|NCT01974076|Device|Sham tDCS + CBT|
1634463|NCT01974037|Dietary Supplement|Capsaicin|Capsaicin in the concentration of 0.5 µmol/L was mixed in the test solutions in Capsaicin_effect subgroups
1634464|NCT01974037|Dietary Supplement|NaCl|NaCl in various concentrations was desorved in the test solutions in Salt_effect subgroups
1634465|NCT01974024|Drug|methylprednisolone|Adult patients who experienced DIH within 3 days after the administration of dexamethasone as an antiemetic were screened. Eligible patients were randomly assigned to receive dexamethasone or methylprednisolone as an antiemetic (randomization phase). In the next cycle of chemotherapy, the dexamethasone group received methylprednisolone and vice versa in the methylprednisolone group (crossover phase).
1634466|NCT01974011|Procedure|Performing dorsal penile nerve block (DPNB)|
1634469|NCT01973985|Other|Pleural Manometry|Intrapleural pressure will be monitored with the use of an electronic pleural manometer (Mirador Biomedical CompassTM Thoracentesis Assist Device).
1634470|NCT01973985|Other|Thoracic ultrasonography|"Thoracic ultrasound scan will be done before drainage of pleural effusion - all participants.
Thoracic ultrasound scans will also be done during drainage of pleural effusion and the results will be recorded after every 100mL of pleural fluid drained - all participants.
Thoracic ultrasound scan will be done after drainage of pleural effusion - all participants.
Thoracic ultrasound scan will also be be done during clinic follow-up as part of routine clinical care - all participants."
1634471|NCT01973985|Procedure|Pleural aspiration catheter OR chest drain (standard care)|Insertion of pleural aspiration catheter OR intercostal chest drain under ultrasound guidance - all participants (standard care).
1634472|NCT01973985|Procedure|Talc slurry pleurodesis via chest drain (standard care)|Talc slurry pleurodesis via intercostal chest drain where/when clinically indicated as part of routine clinical care participants with intercostal chest drain only (standard care).
1634473|NCT01973972|Behavioral|Weight management|Weight management group visits using low-carbohydrate diet followed for weight management.
1634474|NCT01973972|Behavioral|Shared medical appointments (SMA)|Diabetes management group visits for diabetes management.
1634475|NCT01973946|Other|Symptom Alert and Coaching|Patients heard self-care messages when they reported a symptom was present. The Symptom Alert and Coaching intervention alerted study nurse practitioners of unresolved symptoms daily. The NPs responded to all alerts generated by patients and using evidence based guidelines, called patients to further assess and to intensify symptom treatment.
1634476|NCT01973933|Drug|Metformin and Pyrimethamine|
1634477|NCT01973920|Drug|Oshadi Icp|
1634517|NCT01973608|Drug|MSB0010445 (1.8 mg/kg)|MSB0010445 will be administered at a single dose of 1.8 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
1634665|NCT01972529|Drug|placebo (higher baseline platelet count)|40 mg placebo (2 x 20 mg matching placebo tablets)
1634666|NCT01972516|Drug|Tivozanib|
1634478|NCT01973907|Other|Fluid Sparing Resuscitation Strategy|"Tier 1: Initiate IV/IO vasoactive medication infusion support immediately. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Clinically unacceptable delay in ability to initiate vasoactive medication infusion(s) and/or 2. Documented intravascular hypovolemia.
Tier 2: Vasoactive medication(s) should be preferentially titrated/escalated to achieve recommended ACCM hemodynamic goals. Further IV/IO isotonic fluid bolus therapy [crystalloid (0.9% Normal Saline or Ringers Lactate) or colloid (5% Albumin)] should be avoided; small volume isotonic fluid boluses [5-10 mL/kg (250-500 mL for participants ≥ 50 kg)] may be provided if required due to A. Documented intravascular hypovolemia.
Intervention end: Patient is free from vasoactive medication support and shock is reversed."
1634479|NCT01973894|Procedure|Blood and urine sampling|"Blood and urine sampling will follow this schedule:
24h: blood (3ml)
48h: blood (3ml) and urine
End of infusion: blood (3ml)
6h after end of infusion: blood (3ml) and urine. Blood samples will be centrifuged for 10 minutes at 3300rpm, then supernatant will be placed into test tubes and stored at -20°C; urine samples will be freeze at -20°C as well.
Then all frozen samples will be analyzed to get Midazolam concentrations."
1634480|NCT01973881|Procedure|T1 Weighted MRI (magnetic resonance imaging)|"Enrolled subjects will have an MRI scan performed at baseline (within 1 month before beginning therapy), at the time of a scheduled bone marrow biopsy or end of treatment cycle (6 months), and after 12 months.
Please note: Patients in this study will be treated with chemotherapy as determined by the hematologist or the treatment protocol for an independent clinical trial for therapy of myelofibrosis. Treatment and monitoring will be performed under the usual standard of care that includes physical examinations, laboratory testing, and other indicated imaging examinations."
1634481|NCT01973868|Drug|Regorafenib (Stivarga, BAY73-4506)|
1634482|NCT01973868|Drug|Cetuximab (ERBITUX)|
1634483|NCT01973855|Drug|Western Medicine|Physical cooling,Hydrocortisone
1634484|NCT01973855|Drug|TCM and Western Medicine|Third Infectious diseases soup recipe
1634485|NCT01973842|Drug|0.1 mg triptorelin|
1634486|NCT01973842|Drug|0.2 mg triptorelin|
1634487|NCT01973842|Drug|0.4 mg triptorelin|
1634488|NCT01973829|Other|Checklist for Early Recognition and Treatment of Acute Illness (CERTAIN)|This study is about training and implementation of best critical care practices in the international ICUs with variable resources facilitated by access to a specifically designed electronic checklist
1634489|NCT01973816|Drug|Triptoreline 11.25 i.v.; Estradiol 0.5% percutaneous gel;|Triptoreline 11.25 administered for 3 months, two consecutive cures Estradiol administered daily for 6 months
1634490|NCT01973816|Procedure|rectal shaving; rectal disc excision; colorectal resection|
1634491|NCT01973816|Drug|Cyproterone acetate 50 mg; estradiol 0.5% percutaneous|Daily intake for 18 months
1634492|NCT01973816|Drug|Estradiol 0.5% percutaneous gel; Cyproterone acetate 50 mg oral|Daily intake during 24 months
1634493|NCT01973790|Drug|Z-338|100mg TID
1634494|NCT01973777|Device|IUB|intrauterine contraceptive device
1634495|NCT01973764|Procedure|Ultrasound guided ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed under ultrasound guidance.
1634496|NCT01973764|Procedure|landmark-based ventricular drain insertion|Ventricular puncture and insertion of the intraventricular catheter is performed without any guiding devices and is based on anatomical landmarks.
1634498|NCT01973725|Drug|Icotinib Hydrochloride|Patients will receive Icotinib Hydrochloride at 125mg/times,oral three times daily for 21 days.
1634499|NCT01973712|Procedure|Locked Compression Plating|
1634500|NCT01973712|Procedure|Retrograde Intramedullary Nailing (RIMN)|
1634501|NCT01973699|Other|visualization in shoulder arthroscopy|Evaluating the effect of performing shoulder arthroscopy with and without epinephrine on visualization
1634502|NCT01973686|Behavioral|Physical activity|
1634503|NCT01973673|Behavioral|Bone health educational materials|
1634504|NCT01973660|Drug|Lapatinib|
1634505|NCT01973660|Drug|Trastuzumab|
1634506|NCT01973660|Drug|Endocrine Therapy|Letrozole or tamoxifen will be prescribed according to patient's menopausal status
1634507|NCT01973660|Drug|Paclitaxel|Only administrated if tumor progression is observed by US on week 6
1634508|NCT01973647|Behavioral|Cognitive Behavioral Therapy for Insomnia|Six weekly sessions of cognitive behavioral therapy for insomnia
1634509|NCT01973647|Behavioral|COPD Education|Six weekly sessions of COPD education
1634510|NCT01973647|Behavioral|Attention Control|Six weekly sessions of non-sleep, non-COPD health education
1634511|NCT01973634|Radiation|sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)|Minimal surgical margin of 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 4 x 2.5 Gy boost)
1634512|NCT01973634|Radiation|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)|Minimal surgical margin of 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.12 Gy)
1634513|NCT01973634|Radiation|sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)|Minimal surgical margin < 1 mm, conventional arm with sequential boost (15 x 2.67 Gy WBI + 6 x 2.48 Gy boost)
1634514|NCT01973634|Radiation|SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)|Minimal surgical margin < 1 mm, experimental arm with SIB (15 x 2.67 Gy WBI and SIB 15 x 2.67-3.33 Gy)
1634515|NCT01973608|Drug|MSB0010445 (0.3 milligram per kilogram [mg/kg])|MSB0010445 will be administered at a single dose of 0.3 mg/kg as intravenous (IV) infusion over approximately 1 hour every 3 weeks (q3w) for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of Stereotactic Body Radiation Therapy (SBRT) to the targeted reference lesion.
1634516|NCT01973608|Drug|MSB0010445 (1.0 mg/kg)|MSB0010445 will be administered at a single dose of 1.0 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
1634518|NCT01973608|Drug|MSB0010445 (2.4 mg/kg)|MSB0010445 will be administered at a single dose of 2.4 mg/kg as IV infusion over approximately 1 hour q3w for the first 12 Weeks as a part of induction phase followed by maintenance dose of 0.3 mg/kg drug every three weeks until significant clinical progression, occurrence of unacceptable toxicity, or withdrawal of consent. The first administration of MSB0010445 will be performed 3 days after the last dose of SBRT to the targeted reference lesion.
1634519|NCT01973608|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT will be administered using a dose and schedule recommended based upon the data showing the best abscopal effect using multiple fractions if one site will be targeted subject received 3 fractions (1 per day) of 8 Gray (Gy) each (total: 24 Gy). If the target lesion will be located in the thorax, the maximum total dose administered will be 18 Gy (3 x 6 Gy).
1634520|NCT01973595|Dietary Supplement|Almonds, Then no almonds|Whole, raw almonds with skin, or whole, raw almonds with skin that have been ground into a paste.
1634521|NCT01973595|Other|No Almonds, Then almonds|No almonds will be consumed by participants for 3 weeks.
1634524|NCT01973556|Other|Pharmacist-Physician Collaborative Medication Therapy Management|
1634525|NCT01973543|Biological|VY-AADC01|Neurosurgical delivery of VY-AADC01 to the brain.
1634526|NCT01973530|Procedure|adductor canal block|Continuous adductor canal block and single shot posterior tibial nerve block under ultrasound guidance and using nerve stimulating needle (bolus: 0.5% Ropivacaine 10-15ml with dexamethasone 4mg ;with single shot posterior tibial nerve block (8-10ml 0.5% ropivacaine)
1634527|NCT01973530|Procedure|femoral nerve block|Femoral nerve catheter inserted under ultrasound guidance using nerve stimulating needle administering ropivacaine bolus 10-15ml and infusing 0.2% ropivacaine at 4-6ml/h; plus a single shot posterior tibial nerve block under ultrasound guidance and use of nerve stimulating needle
1634528|NCT01973517|Drug|Feraheme|Patients with relapsing remitting multiple sclerosis will be administered Feraheme 5mg/kg IV via slow push once and imaged under high-field MRI at least 24 hours following administration, to allow for adequate clearance of intravascular pharmaceutical.
1634529|NCT01973517|Drug|Gadolinium-based contrast|Patients with relapsing remitting multiple sclerosis will be administered gadolinium-based contrast at a dose of 0.1 mmol/kg IV once and imaged under high-field MRI immediately following administration.
1634530|NCT01973504|Drug|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
1634531|NCT01973504|Drug|Control|Crystalloid solution IV infusion drip to keep vein open
1634532|NCT01973491|Drug|ATX-MS-1467|Subjects will receive ATX-MS-1467 50 microgram (mcg), 200 mcg and 800 mcg on Day 1, Day 15 and Day 29 respectively during the titration period followed by biweekly dose of ATX-MS-1467 800 mcg for 16 weeks during the treatment period.
1634533|NCT01973478|Device|DBS|
1634534|NCT01973478|Device|SHAM|
1634535|NCT01973465|Biological|Stool|Implanting fecal matter via colonscope
1634536|NCT01973452|Drug|Dexmedetomidine|
1634537|NCT01973452|Drug|Placebo|
1634538|NCT01973439|Other|Intervention 1: PK assessment while on Twice Daily Abacavir|Week 0
1634539|NCT01973439|Other|Intervention 2: PK assessment while on Once Daily Abacavir|Week 4
1634540|NCT01973426|Device|Isolated Orthosis for Thumb Actuation (IOTA)|In this pilot study, we plan to investigate whether the IOTA can effectively facilitate the ability of participants to perform a specific set of clinically relevant tasks conducted in a clinic setting. The IOTA is a device developed at the Wyss Institute at Harvard University, in collaboration with Children's Hospital Boston, for assisting opposable thumb grasping tasks. The IOTA contains an adjustable brace fitted to the thumb and dorsum of the hand that is easy to put on and facilitates grasping motions through flexible cable-driven actuators that assist with joint abduction and extension.
1634541|NCT01973413|Device|Diabetes Assistant (DiAs)|The Control-to-Range (CTR) algorithm that will be used in DiAs will automatically adjusts insulin delivery in response to CGM values that have exceeded or are predicted to exceed the bounds of a pre-specified blood glucose range.
1634542|NCT01973413|Device|Tandem t:slim Insulin Pump|FDA, market-approved insulin pump.
1634543|NCT01973413|Device|Dexcom G4 Platinum sensor|FDA, market-approved continuous glucose monitor (CGM)
1634544|NCT01973400|Dietary Supplement|Tocotrienol|Palm-Oil derived Vitamin E, tocotrienol
1634545|NCT01973400|Dietary Supplement|Placebo|Placebo
1634546|NCT01973387|Drug|Rituximab|Up to 6 cycles (total of 8 doses administered by intravenous infusion): 375 mg/m2 on Day 1 of Cycle 1, 500 mg/m2 on Day 15 of Cycle 1 (Weeks 1-4); 500 mg/m2 on Day 1 and Day 15 of Cycle 2 (Weeks 5-8); and 500 mg/m2 on Day 1 of Cycles 3-6 (Weeks 9-24).
1634547|NCT01973387|Drug|Ibrutinib|420 mg capsules administered by mouth daily until disease progression or unacceptable toxicity, whichever occurs first.
1634548|NCT01973374|Behavioral|Text Message Intervention|
1634551|NCT01973348|Device|4-hour AmblyZ glasses|4-hour AmblyZ glasses for moderate amblyopia
1634552|NCT01973348|Device|12-hour AmblyZ glasses|12-hour AmblyZ glasses for severe amblyopia
1634553|NCT01973348|Device|2-hour patching|2-hour patching for moderate amblyopia
1634554|NCT01973348|Device|6-hour patching|6-hour patching for severe amblyopia
1634580|NCT01973153|Behavioral|Brief Motivational Counseling (BMC)|3-5 minute BMC delivered by clinicians and nurses at well, sick, and WIC visits with the goal of reducing obesogenic behaviors. During BMC, the medical team facilitates the selection of a specific goal (i.e., reduce sugar sweetened beverage consumption) that is meaningful to the mother and teaches the mother simple behavioral strategies.
1634581|NCT01973153|Behavioral|Brief Motivational Counseling Plus Phone Calls (BMC + Phone)|BMC as described above that is supplemented by monthly telephone contacts with community health workers designed to identify and overcome barriers to goal progress.
1634706|NCT01972178|Drug|Statins|Any statin allowed (i.e. rosuvastatin, simvastatin, pravastatin, atorvastatin etc)
1634707|NCT01972165|Procedure|Mini-incision carpal tunnel release|
2011874|NCT02361684|Behavioral|Blended CBT treatment|Internet based blended CBT depression treatment combines individual face-to-face cognitive behavioural therapy (CBT) with CBT delivered through an Internet based treatment platform with mobile phone components (either integrated in the treatment platform or as a separate system). The core components of the CBT treatment are: (1) psycho-education, (2) cognitive restructuring, (3) behavioural activation, (4) positive psychology, and (5) relapse prevention. These will be delivered over 10 sessions. For this study, the ratio between the number of face-to-face sessions and the number of online module will be 1/3 face-to-face and 2/3 online.
2011875|NCT02361684|Other|Treatment as usual|Treatment as usual (TAU) is defined as the routine care that subjects receive when they are diagnosed with depression in the primary care system. In practice, this means that treatment as usual may vary between patients. We will not interfere with treatment as usual but we will monitor carefully which health care services are utilized by usual care patients using patient records and through self-report
2011876|NCT02360579|Biological|LN-144|A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are reinfused with the autologous TIL (LN-144) followed by IL-2.
1634558|NCT01973322|Other|arm 1: DC Vaccine + RT|three daily doses of 8 Gy up to 12 Gy delivered to one non-index metastatic field between vaccine doses 1 and 2 (optional to one additional field between vaccine doses 7 and 8) utilizing IMRT-IMAT techniques
1634559|NCT01973322|Other|arm 2: DC Vaccine + IFN-alfa|daily 3 MU subcutaneous IFN-alfa for 7 days before leukapheresis (day -15 to -9, and for 7 days before any other additional leukapheresis)
1634560|NCT01973322|Other|arm 3: both arm 1 and 2 + RT|both 1 and 2 external immunostimulant conditions (Intradermal Autologous Dendritic Cell Vaccine + 3 single boosts of RT + IFN-alfa, 3 MU daily for 7 days before leukapheresis)
1634561|NCT01973322|Biological|arm 4: DC Vaccine|neither 1 or 2 external immunostimulant conditions (only Intradermal Autologous Dendritic Cell Vaccine)
1634562|NCT01973309|Drug|Vantictumab combined with paclitaxel|Vantictumab combined with paclitaxel will be administered IV.
1634563|NCT01973296|Behavioral|ED to home care transition|The CTI coach's role is to build self-management capabilities for the patient and caregiver. During each contact, the coach reviews the four components of the CTI: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The coach assists the patient use the PHR to document and maintain vital information and to communicate with providers.
1634564|NCT01973296|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
1634565|NCT01973283|Drug|Antidepressant Medication|If patient has a history of non-response or cannot tolerate escitalopram and/or duloxetine, then they will be treated openly with an approved antidepressant.
1634566|NCT01973270|Behavioral|Neuroadaptive cognitive training|TCT exercises consist of three modules: an Auditory Processing Module (40-50 hours of training); a Visual Processing Module (30 hours); a Cognitive Control Module prototype (20 hours). [Based on the results of our current RCT, Posit Science has revised aspects of the training modules in order to further optimize its effectiveness for treatment of schizophrenia. In this study, we will use updated versions of the training software: an Auditory Module (20 hours), and a Social Module (10 hours). Features from the Cognitive Control module prototype have been expanded and incorporated into these new modules.
1634567|NCT01973257|Procedure|imaging diagnostics|
1634568|NCT01973244|Drug|NNC0195-0092|"A single dose administered subcutaneously (s.c., under the skin) of 4 different doses of NNC0195-0092 in an escalating order.
Each subject will be allocated to one dose level only. After completion of each dose cohort, a safety evaluation will be conducted prior to dose escalation."
1634569|NCT01973244|Drug|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 7 days. The daily dose is 0.03 mg/kg/day.
1634570|NCT01973231|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial metformin (equal to or above 1000 mg/day and up to 3000 mg/day).
1634571|NCT01973231|Drug|lixisenatide|Starting dose of 10 microg to be administered s.c. once daily, within the hour prior to the first meal of the day or the evening meal in addition to subject's stable pre-trial metformin (equal to or above 1000mg/day and up to 3000mg/day). Dose escalation to 20 microg s.c. once daily from day 15 after randomization.
1634572|NCT01973218|Biological|Meningococcal B Recombinant vaccine rMenB+OMV NZ|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) vaccination with two doses of rMenV+OMV NZ vaccine (0.5 mL) in the non-dominant arm, one month apart. Subjects were followed for two months.
1634573|NCT01973218|Biological|Placebo|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
1634574|NCT01973218|Biological|Meningococcal ACWY-CRM conjugate vaccine|Subjects were randomized to one of two treatment groups to receive intramuscular (IM) injection of saline solution followed by one dose of MenACWY-CRM vaccine (0.5 mL), one month apart. Subjects were followed for two months.
1634575|NCT01973205|Drug|Acetaminophen 250 mg and Aspirin 250 mg|2 tablets each containing Acetaminophen 250 mg and Aspirin 250 mg
1634576|NCT01973205|Drug|Placebo|2 placebo tablets matching acetaminophen 250 mg and aspirin 250 mg tablets
1634577|NCT01973179|Radiation|Radiation therapy|Radiation therapy with protons
1634578|NCT01973166|Device|Picosecond Q-switched Laser Treatment|
1634579|NCT01973166|Device|Nanosecond Q-switched Laser Treatment|
1634662|NCT01972529|Drug|avatrombopag (lower baseline platelet count)|60 mg avatrombopag (3 x 20 mg tablets)
2011877|NCT02359994|Device|PerClot Polysaccharide Hemostatic System|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot or the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
1634582|NCT01973153|Behavioral|Brief Motivational Counseling Plus Home Visits (BMC + Home)|BMC as described above that is supplemented by monthly home visits with community health workers designed to identify and overcome barriers to goal progress.
1634583|NCT01973140|Drug|Tolvaptan|Adult male volunteers will be given a given a 60mg or a 30 mg dose of tolvaptan. Blood and urine samples will be collected at specified time points for the next 24 hours.
1634584|NCT01973140|Drug|Hypertonic saline infusion|A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
1634585|NCT01973127|Other|Verum rTMS|rTMS on the right dorsolateral prefrontal cortex. TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). TMS will be conducted in the form of 'conventional rTMS', whereby 30 trains of 10 Hz pulses with a duration of 5 seconds and an inter-train interval of 25 seconds are applied to the righ dorsolateral prefrontal cortex (50 pulses per train, 6000 pulses per session). Used equipment: Magstim Rapid 2 device.
1634586|NCT01973127|Other|Sham rTMS|TMS procedure: The resting motor threshold (RMT) will be defined in each subject as the minimal stimulation intensity evoking an MEP of ≥ 0.05 mV in 50% of the trials in the muscle of the right thumb (M. abductor pollicis brevis). Like in verum TMS coil will be placed on the skull, but no magnetic field will be pulsed. Used equipment: Magstim Rapid 2 device.
1634587|NCT01973114|Drug|Latanoprost|
1634588|NCT01973114|Other|Placebo|
1634589|NCT01973101|Drug|Cisplatin|50 mg/m2 - Day 1
1634590|NCT01973101|Drug|Gemcitabine|Gemcitabine 1000mg/m2 on day 1 and day 8.
1634591|NCT01973101|Drug|cisplatin|Cisplatin 40 mg/m2 on day 1, day8, day15, day22, day 36 of radiotherapy period.
1634592|NCT01973101|Radiation|Radiotherapy|45 Gy
1634593|NCT01973101|Radiation|Brachytherapy|80 Gy
1634594|NCT01973062|Biological|rituximab|Given IV
1634595|NCT01973062|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
1634596|NCT01973049|Drug|Daclatasvir|
1634597|NCT01973049|Drug|Asunaprevir|
1634598|NCT01973049|Drug|BMS-791325|
1634599|NCT01973049|Drug|Ribavirin|
1634600|NCT01973049|Drug|Placebo matching Ribavirin|
1634601|NCT01973036|Device|Foley Catheter|The balloon will be inflated with 30 cc of sterile saline. The catheter will be taped to the patient's leg so that traction is maintained. The catheter will be assessed hourly for expulsion by a health care provider by applying gentle traction on the catheter or a vaginal examination if it is unclear by traction. Once the Foley catheter is expelled or 12 hours reached, the induction will be continued with oxytocin per this protocol.
1634602|NCT01973036|Drug|Oxytocin|Each arm will receive oxytocin at a rate of 2 milliunits/milliliter. If the fetal status is reassuring, this can be increased by 2 milliunits/milliliter every 30 minutes to achieve an adequate contraction pattern as per the institution's definition to a maximum of 30 milliunits/milliliter. This infusion may be continued until delivery.
1634603|NCT01973023|Other|Motion analysis|Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
1634604|NCT01973010|Other|Massage|Massage therapy is an intervention that can be used to relax muscle and regulate displaced joints by manual manipulation.
1634605|NCT01973010|Drug|Ibuprofen|Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
1634606|NCT01972997|Device|SENSIMED Triggerfish|
1634607|NCT01972984|Drug|Anastrozole|Participants will be instructed to take one tablet of anastrozole orally per day with fluids. This tablet will be taken at the same time every day. Participants will be given a drug diary to record drug administration and aid in drug compliance. Should the participant miss a dose they will be asked to record it in their diary and resume the normal dose schedule the next day.
1634608|NCT01972971|Other|patient education|one by one patient education
1634609|NCT01972958|Other|comprehensive care|comprehensice assessment,physical activity training, community resources referral, health education.
1634610|NCT01972945|Procedure|Vaginoscopy|Vaginoscopy, otherwise known as the 'no touch' technique, describes a technique where the hysteroscope is guided into the uterus without the need for potentially painful vaginal instrumentation i.e. passage of a vaginal speculum to separate the vaginal walls, cleansing of the cervix and sometimes application of traumatic forceps to the ectocervix in order to stabilise it.
1634611|NCT01972945|Procedure|Standard Hysteroscopy|Traditional hysteroscopy consists of introducing speculum and grasping of the cervix to provide counter traction to allow instrumentation of the uterus. Introducing a speculum also allows the cervix to be cleaned with sterilising fluid.
1634612|NCT01972932|Dietary Supplement|Bio K+® 2 capsules orally (or via nasogastric tube)|Bio-K+® 2 capsules orally (or via nasogastric tube) once per day starting at randomization until five days after the discontinuation of the antibiotic.
1634613|NCT01972932|Dietary Supplement|Placebo|Placebo Comparator: 2 capsules orally (or via nasogastric tube) once per day starting randomization until five days after the discontinuation of the antibiotic.
1634614|NCT01972919|Radiation|Radiation Therapy|Radiation therapy dose escalation to an MR-defined GTV of up to 69.75 Gy at 2.25 Gy per fraction.
1634615|NCT01972919|Drug|Concurrent chemotherapy (Gemcitabine, Capecitabine)|Gemcitabine 400mg 1m2 IV weekly x 6 doses. Capecitabine 825 mg/mm2 po bid Monday-Friday on days of radiation use 500mg tablets.
1634616|NCT01972906|Device|moxibustion|apply moxibustion according to traditional Chinese medicine
1634617|NCT01972906|Drug|Ibuprofen Sustained Release Capsules|apply Ibuprofen (H20013062), 0.3g， Bid, lasting 3 days before menstrual cycle
1634618|NCT01972893|Drug|ZYD1|"Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.
Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.
Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
1634619|NCT01972893|Drug|Placebo|"Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.
Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.
Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I."
1634620|NCT01972880|Drug|ASP1941|Oral
1634711|NCT01972152|Drug|G-Pen(TM) 0.5 mg|
1634621|NCT01972867|Device|NanoKnife Procedure|Under general anesthesia and with paralytic on board, patients will have monopolar probes inserted bracketing the tumor. A total of 90 electrical pulses will be delivered to irreversibly electroporate the tissue.
1634622|NCT01972854|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
1634623|NCT01972854|Drug|placebo solution|0.0% riboflavin ophthalmic solution
1634624|NCT01972854|Device|KXL System|30mW/cm2
1634625|NCT01972841|Drug|Solifenacin succinate|Oral tablet
1634626|NCT01972841|Drug|Mirabegron|Oral tablet
1634627|NCT01972841|Drug|Placebo|Oral tablet
1634628|NCT01972828|Drug|FLUID MANAGEMENT GUIDED WITH PRELOAD-DEPENDENCE PARAMETERS (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using preload dependence indexes. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
1634629|NCT01972828|Drug|STANDARD-GUIDED FLUID MANAGEMENT (VOLUVEN ®)|in this arm, fluid loading is administered with an algorithm using central venous pressure. This algorithm is used every hour during the first 6 hours after inclusion, then every 4 hours until vasopressor weaning, and whenever mean arterial pressure fell below 65 mm Hg. Fluid loading is performed with cristalloids or colloids at the discretion of the attending physician.
1634630|NCT01972789|Drug|Ranibizumab|Ranibizumab solution for injection is commercially supplied in vials with each vial containing ranibizumab in the concentration of 10 mg/ml (0.5 mg/0.05 ml, corresponding to a 0.5 mg dose level). It will be prescribed and administered by the investigator or designee.
1634631|NCT01972776|Drug|QBM076|Supplied in 25 mg and 75 mg capsules
1634632|NCT01972776|Drug|Placebo|Matching placebo capsules
1634633|NCT01972763|Drug|Ranibizumab|Ranibizumab is formulated as a sterile solution and will be used in the case of an intervention.
1634634|NCT01972750|Drug|Dovitinib|daily oral intake of capsule
1634635|NCT01972737|Biological|Ad5-hGCC-PADRE vaccine|A single intramuscular dose (100 billion virus particles) of Ad5-hGCC-PADRE vaccine.
2011878|NCT02359994|Device|Arista AH|During the intraoperative period, the subject will be evaluated for bleeding; only those who meet the intraoperative inclusion criterion will be enrolled into the study. After confirmation of the intraoperative eligibility criteria, the subject will be randomized to receive an adjunct application of PerClot or the control device. The prescribed hemostatic agent will be applied according to its Instructions for Use.
1634637|NCT01972711|Drug|SEP-363856|SEP-36385625 as a single oral dose of 50 mg
1634638|NCT01972711|Drug|Amisulpride|Amisulpride as a single oral dose of 400 mg
1634639|NCT01972711|Drug|Placebo|single oral dose placebo
1634640|NCT01972698|Other|Self-directed and simulation-assisted training|"All participants will attend an ultrasound introductory course (lectures and illustrative interactive cases).
Participants randomized to the intervention group will undergo a completely self-directed lung and focused cardiac ultrasound curriculum.
A set of video-lectures on how to perform US on a critically ill patient (video-tutorials on image acquisition, troubleshooting, and pitfalls) will be provided.
Participant will have access to an ultrasound simulator.
Finally, participants in the intervention group will be asked to perform self-directed lung and focused cardiac ultrasound examinations on critically ill patients.
An investigator will supervise the sessions but will not interfere with the self-learning process.
- To support their learning, trainees will have access to on-line virtual FCU and LUS modules created by the Toronto General Hospital Department of Anesthesia Perioperative Interactive Education (http://pie.med.utoronto.ca/TTE/index.htm)."
1634641|NCT01972698|Other|Traditional apprenticeship training|"All participants will attend an half-day ultrasound introductory course.
Participants randomized to the conventional group will initially attend 2-hour hands-on session on healthy volunteers, fully supervised by an expert critical care ultrasonographer (acquisition of basic knowledge with US machine settings and probe positioning and orientation, normal view acquisition, and identification of normal anatomical structures and landmarks).
Subsequently, participants will attend a 3-hours hands-on session on critically ill patients, fully supervised by an expert critical care ultrasonographer."
1634645|NCT01972672|Drug|Icaritin|Icaritin 600 mg orally, twice daily for a total daily dose of 1200 mg
1634646|NCT01972659|Drug|placebo|Active comparator 50 mg/kg iv bolus plus 15 mg/kg continuous infusion
1634647|NCT01972659|Drug|Magnesium Sulphate|"Experimental :
50 mg/kg bolus plus 15 mg/kg continuous infusion"
1634648|NCT01972659|Drug|sugammadex|4 mg/kg iv bolus at the end of the surgery
1634649|NCT01972633|Procedure|Laser|Endovenous Laser (1470nm) ablation of great or small saphenous vein
1634650|NCT01972633|Procedure|Radiofrequency|Endovenous Radiofrequency (VNUS Closure Fast) of great or small saphenous vein
1634651|NCT01972620|Drug|Bupivacaine|A 50:50 mixture of normal saline (8 ml) and 0.5% Bupivacaine was prepared within a 20 ml syringe (Total volume 16 ml; Final concentration = 0.25%). Following delivery of the gallbladder specimen in the Multi-modal analgesia group, 8 ml of 0.25% bupivacaine solution was sprayed onto the cystic plate (gallbladder fossa) with a spinal needle advanced under direct laparoscopic vision via a 5mm right subcostal laparoscopic port. The anesthetic solution was sprayed at an operating distance from the cystic plate of ~ 2 cm. Following evacuation of the pneumoperitoneum, again within the Multi-modal analgesia group, the remaining 8 ml of 0.25% Bupivacaine was infiltrated subcutaneously at each of the four laparoscopic port sites (2 ml per port site) prior to standard sutured closure of each incision
1634652|NCT01972607|Other|Exercise Training|12 weeks of aerobic exercise training performed 3x/week at moderate intensity with sessions of 40 min.
1634653|NCT01972594|Procedure|Targetted protocol with pedometer|12 week protocol based on targetted steps are given to the patient along with a pedometer.
1634654|NCT01972594|Device|Accelerometer(ActivPAL)|
1634655|NCT01972581|Other|Reaction Time Training|
2011879|NCT02360592|Drug|Entecavir|In arm 1, Entecavir is used for 48 weeks and the follow up 24 weeks as conventional control, In arm 2 and 3, Entecavir is used for 8 weeks.
2011880|NCT02360592|Drug|Interferon alfa-2b|In arm 2 and 3, interferon alfa-2b is used for 48 weeks
1634659|NCT01972555|Procedure|Minimally invasive aortic valve replacement|
1634660|NCT01972555|Procedure|Conventional aortic valve replacement|
1634661|NCT01972542|Dietary Supplement|Oral fat tolerance test|
1712103|NCT01370694|Drug|vincristine|
1634667|NCT01972503|Drug|5-FU and oxaliplatin|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. In arm A, patients accepted intraoperative intraportal infusion of 5-FU 1g and oxaliplatin 100mg+ curative resection + mFOLFOX6.
1634668|NCT01972503|Procedure|colorectal cancer resection+ adjuvant chemotherapy (mFOLFOX6)|Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to two arms. All patients in both arms accept curative resection of colorectal cancer,and accept standard adjuvant chemotherapy (mFOLFOX6).
1634669|NCT01972490|Drug|avastin+chemotherapy of mFOLFOX6 or FOLFIRI|Drug: avastin On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of avastin (180 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
1634670|NCT01972490|Drug|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
1634671|NCT01972477|Drug|DLBS1449|Study treatment will be DLBS1449 softcapsules at a dose of 1x75 mg daily or DLBS1449 at a dose of 1x150 mg daily. DLBS1449 will be given every day for 8 weeks.
1634672|NCT01972477|Other|Placebo|Placebo will be given every day for 8 weeks.
2011881|NCT02360592|Drug|Interleukin 2|In arm 3, Interleukin 2 is used for 12 weeks
2011882|NCT02360592|Drug|Hepatitis B Vaccine|In arm 3, Hepatitis B Vaccine is used for 48 weeks
1634675|NCT01972451|Procedure|Colonoscopy with enhanced dye|
1634676|NCT01972438|Drug|ASEDs|Experimental Intervention
1634677|NCT01972438|Drug|Saline|Control Intervention
1634678|NCT01972425|Other|Biomarker-based diagnostic|The intervention will be a biomarker-based diagnostic test for the exclusion of VAP
2011883|NCT02358330|Other|EHR Enhanced Clinic Intervention|The clinics assigned to the experimental condition will have EHR enhancements introduced.
1634680|NCT01972399|Procedure|Laser|This is a surgery that the patient will undergo and the laser will be used to clean the surface of the implant.
1634681|NCT01972399|Procedure|Mechanical debridement|This is a surgery that the patient will undergo to have the surface of the implant cleaned using hand instruments.
1634682|NCT01972386|Device|Spectrum Image Analysis using a Linear Array Ultrasound Bronchoscope|
1634683|NCT01972373|Drug|Bevacizumab-IRDye800CW|Intravenous administration of a microdose (4.5mg, subtherapeutic) of Bevacizumab-IRDye800CW prior to the endoscopic procedure
1634684|NCT01972373|Device|NIR fluorescence endoscopy|48-72 hours administration of Bevacizumab-IRDye800CW a flexible NIR fluorescence endoscopy will be performed via the rectum
1634685|NCT01972347|Drug|Dabrafenib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintenance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
1634686|NCT01972347|Drug|Trametinib|Patients will receive neoadjuvant treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 12 weeks. Patients will then have complete lymph node dissection and will continue on maintainance treatment with dabrafenib 150mg twice a day and trametinib 2mg once a day for 40 weeks.
1634687|NCT01972334|Biological|FMT|as explained in study arm
1634688|NCT01972334|Biological|placebo|salt water or saline will be given as placebo
1634689|NCT01972321|Other|Technology supported supervision|"CHWs will be provided with mobile phones and solar chargers to carry out the following:
Establish closed user groups (CUGs) to enable two-way communication between CHWs and their supervisors free of charge to the users.
Data submission through mobile phones 2.1. receive motivational performance related feedback provided in response. 2.2. Automated messages to supervisors which 2.2.1. Flags problems and strengths/successes identified in CHWs data 2.2.2. Alerting supervisors as to which CHWs require targeted supervision. 2.3. CHWs data summarised in a user friendly format and made accessible to district statisticians
Monthly motivational short message service (SMS) messages provided to CHWs that are locally relevant to CHW work and that are designed to impact positively on CHW performance."
1634690|NCT01972321|Behavioral|Community supported supervision|CHWs will facilitate the clubs using a learning, planning and action cycle. Club members will rank child health challenges faced by their community using picture cards and decide which one to focus on for each cycle. They will discuss solutions, which include supporting CHWs services, and take actions to meet challenges. They will also promote group decision-making and ownership and through this process gain tangible results. Solutions to health challenges developed by club members are a key focus of the village health club approach. Village Health Clubs are based on 5 guiding principles: clubs are open to all, village owned, intended to support CHW work, strength based, and fun and focused.
1634691|NCT01972321|Other|Integrated community case management|Implementation of integrated community case management, with provision of training and equipment to CHWs for diagnosis and treatment of malaria, pneumonia and diarrhoea in children less than 5 years of age. Supportive supervision of CHWs will be provided by assigned health facility supervisors.
1634692|NCT01972308|Behavioral|Patient Advocate|Subject works with a Patient Advocate who coaches, models, and assists with preparations for a visit with the asthma doctor; attends the visit with permission of participant and provider; and confirms understanding. The PA facilitates scheduling, obtaining insurance coverage, overcoming patients' unique social and administrative barriers to carrying out medical advice, and transfer of information between providers and patients
1634693|NCT01972269|Drug|Bupivacaine-fentanyl|0.125% bupivacaine-fentanyl 5mcg/mL
1634694|NCT01972269|Drug|Lidocaine|2% lidocaine
1634695|NCT01972243|Other|no intervention|
1634696|NCT01972230|Drug|Sevoflurane|
1634697|NCT01972230|Drug|Diprivan + Remifentanil TCI|
2011884|NCT02356276|Procedure|D2 lymphadenectomy|
1634702|NCT01972204|Behavioral|Intensive adherence instruction|Instruction with educational brochure
1634703|NCT01972204|Behavioral|Control|Instruction as per usual practice
1634704|NCT01972178|Drug|PRC-4016|
1634705|NCT01972178|Drug|Placebo|
1634712|NCT01972139|Device|Renal Denervation using the Symplicity Renal Denervation System|Subjects randomized to the renal denervation group underwent angiography and renal denervation.
1634713|NCT01972139|Other|Sham Renal Denervation|Prior to enrollment closure, subjects were treated with sham renal denervation. After enrollment closure, subjects previously enrolled were no longer eligible to cross-over.
1634714|NCT01972139|Device|Renal Angiography|Subjects who met all criteria after the screening period did undergo a renal artery angiogram to evaluate renal artery anatomy. Only subjects with eligible renal artery anatomy were randomized.
1634715|NCT01972113|Dietary Supplement|Placebo-Control|one placebo softgel capsules per day (for 8 weeks) containing no vitamin K2 (menaquinone-7)
1634716|NCT01972113|Dietary Supplement|Low-Dose Vitamin K2 (menaquinone-7; 45 mcg/d)|one 45-mcg vitamin K2 (menaquinone-7) softgel capsule per day and one placebo softgel per day (containing no menaquinone-7) for 8 weeks
1634717|NCT01972113|Dietary Supplement|High-Dose Vitamin K2 (menaquinone-7; 90 mcg/d)|one 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
1634718|NCT01972100|Device|Low-level laser therapy (808nm)|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on quadriceps femoris muscles between sets of isokinetic knee flexion-extension exercise
1634719|NCT01972100|Other|isokinetic exercise|
1634720|NCT01972100|Device|Placebo low-level laser therapy|
1634721|NCT01972087|Behavioral|Telephone simulation training|The intervention consists of four 20-minute telephone simulation training sessions over a 4 month period (one session each month). Each 20-minute training session will include 3 simulated 9-1-1 calls, performed by a standardized caller (trained actor) and feedback will be provided right away by a trained observer who takes notes during the simulation calls and discusses the teaching points after the session. In total, the 9-1-1 dispatchers will receive 12 different simulated calls.
1634722|NCT01972074|Drug|Memantine|Tablet
1634723|NCT01972074|Drug|Placebo|
1634724|NCT01972061|Device|Foot stimulation|Foot stimulation electrically activates the somatic afferent nerves in the foot using FDA-approved, commercially available transcutaneous electrical nerve stimulator (TENS) and skin surface electrodes attached to the foot.
1634725|NCT01972048|Behavioral|mMammogram|Text messages delivered via mobile app to participants designed to inform them about breast cancer screening and encourage them to schedule a mammogram.
1634726|NCT01972048|Other|Print brochure|Mailed print brochure about breast cancer screening and community resources.
1634727|NCT01972035|Drug|Valacyclovir|Experimental Arm
1634728|NCT01972035|Drug|Valganciclovir|Standard of care
1634729|NCT01972022|Device|EES SYNERGY™|percutaneous coronary intervention with implantation of Bioabsorbable Polymer EES
1634730|NCT01972022|Device|ZES, RESOLUTE Integrity™|percutaneous coronary intervention using ZES, RESOLUTE Integrity™ coronary stent
1634731|NCT01972009|Procedure|Cardiac catheterisation|Simultaneous measurement of pressure and flow velocity in the pulmonary artery is achieved during right heart catheterisation by passing a catheter as per usual practice into the pulmonary artery, a purpose-designed wire (Combiwire) will then be advanced approximately 1 cm beyond the end of the catheter. The data obtained will be used for wave intensity analysis.
1634732|NCT01971983|Other|High-velocity, low-amplitude (HVLA)|With the subject lying on his/her side, the therapist will rotate the patient's trunk, flex his/her hip and knee of the upper leg. The therapist positions his caudad forearm over the hip, while the cephalad forearm lies over the patient's shoulder. The therapist's hands will be positioned over the lumbar spine's spinous process to be manipulated.
1634733|NCT01971983|Other|Muscle energy (ME)|This technique involves the active movement of the patient to activate a specific musculature in order to move a bony segment of a given joint in a specific direction in relation to the adjacent bone. This technique aims to restore the restricted movement of the joint in question.
1634734|NCT01971983|Other|Sham|Individuals in this group received a sham intervention type, in order to simulate an intervention.
1634735|NCT01971970|Biological|Infliximab|Remission induction in anti-TNF naïve patients will be achieved by administration of 5 mg/kg IFX infusions at week 0, 2 and 6.
1634736|NCT01971970|Biological|Adalimumab|ADA is administered as subcutaneous injections every other week.In children (age below 18 years), remission induction in anti-TNF naïve patients will be achieved by an initial loading dose of 80 mg, followed by 40 mg 2 weeks later. In adults, remission is induced by 160 mg at week 0, followed by 80 mg at week 2
1634737|NCT01971918|Biological|anti drug antibodies dosage|anti drug antibodies dosage
1634738|NCT01971892|Other|Non Invasive ventilation (facial mask and NIV ventilator)|Non invasive ventilation (NIV) which associated pressure support ventilation (PSV: 5 to 15 cmH2O) and positive end expiratory pressure (PEEP: 5 to 10 cmH2O). NIW will be delivered through a facial mask with either NIV ventilator or ICU ventilator with NIV option
1634739|NCT01971892|Other|Standard oxygen therapy with facial mask|facial Venturi mask
1634740|NCT01971879|Procedure|Remote ischemic preconditioning|"A blood pressure cuff is placed on one arm and is inflated to 200mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.
The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
1634741|NCT01971879|Procedure|Control|"A blood pressure cuff is placed on one arm and is inflated to 10mmHg during 5 minutes. During the following 5 minutes, the cuff is inflated at the same pressure on the contralateral arm. This sequence is repeated 3 times, that is to say 3 sequences of cuff inflation for 5 minutes on each arm followed by 5 minutes without inflation.
The treadmill test starts 5 minutes after the end of the last deflation of the cuff."
1634742|NCT01971853|Drug|oral placebo|Ibuprofen placebo and Acetaminophen placebo will be added to a Demerol-Vistaril regimen
1634743|NCT01971853|Drug|Oral Analgesics|Ibuprofen at 5.0 mg/kg and Acetaminophen at 15.0 mg/kg will be added to a Demerol-Vistaril regimen
1634744|NCT01971840|Behavioral|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
1712104|NCT01370694|Drug|prednisolone|
1634745|NCT01971827|Behavioral|MOVI-KIDS|MOVI-KIDS is a multidimensional intervention that consist of: a) for children, 4.5 h/week of a standardized recreative, non-competitive physical activity extracurricular program; b) informative sessions to parents and teachers about how schoolchildren can became more active, and c) interventions in the playground (environmental changes: equipment, facilities, painting, etc.) aimed to promote physical activity during recess (MOVI-Playground).
1634746|NCT01971814|Drug|Infliximab|All patients meeting inclusion criteria will receive the infliximab 10mg/kg IV as part of standard care of the hospitalized patient with severe ulcerative colitis at UCSF Medical Center.
1634747|NCT01971801|Dietary Supplement|Vitamin D3 50,000 IU|Capsule given by mouth once a week
1634748|NCT01971801|Other|Placebo|One capsule given by mouth weekly
1634749|NCT01971788|Device|Optical Coherence Tomography of the infarct related artery|
1634750|NCT01971775|Device|Ultrasonically activated Shears|Dissection and lymphovascular sealing with Ultrasonically Activated Shears
1634751|NCT01971775|Device|Conventional Monopolar Electrocautery|Dissection and lymphovascular sealing with Conventional Monopolar Electrocautery
1634752|NCT01971762|Behavioral|Follow recommendations based on scientific evidence to S. aureus bacteremia management|
1634753|NCT01971762|Behavioral|Not to follow recommendations based on scientific evidence to S. aureus bacteremia management|
1634754|NCT01971749|Procedure|Coronary stent procedure (CSP)|
1634755|NCT01971749|Procedure|Coronary-artery bypass grafting (CABG)|
1634756|NCT01971723|Other|T+ Supplement|Randomized, placebo-controlled, double blind protocol with two treatment groups (matched by lean body mass). Group 1 will receive the recommended serving of one scoop (11g) of T+ supplement. This serving will be taken 45 minutes before the beginning of working out on an empty stomach (>1 hour after meal). On non-training days, the participants will also take a serving at the same time as on training days. This will continue for four weeks (28 days).
1634757|NCT01971723|Other|Placebo|The placebo group will consume a calorie-match placebo in the same manner as the supplement group (one serving 45 minutes prior to work outs on an empty stomach). The placebo group will also follow the same supplementation patterns and workout as their counterparts in the supplement group.
1634758|NCT01971710|Behavioral|Community leader engagement|Community leaders conducting advocacy, community dialogue and community action plans on PMTCT/MCH
1634759|NCT01971710|Behavioral|Community days|The provision of facilitated dialogues, advocacy and education, and selected health services, to a community on a specific day
1634760|NCT01971710|Behavioral|Community Peer Groups|Pregnant women in community peer groups receiving information and education on PMTCT/MCH through 4 weekly peer-led classes . Men in community peer groups receiving information and education on their role in supporting women and families through 4 peer-led education sessions.
1634761|NCT01971684|Drug|Second Line ITP agents|The treating physicians will select the second line agent and clinical data will be collected.
1634762|NCT01971671|Other|no intervention.|
1634763|NCT01971658|Drug|Thalidomide®|
1634764|NCT01971658|Drug|Cyclophosphamide|
1634765|NCT01971658|Drug|Velcade®|
1634766|NCT01971658|Drug|Dexaméthasone|
1634767|NCT01971645|Drug|Dexamethasone|Patients may receive 0.1 mg/kg preservative-free dexamethasone (max. dose 4 mg) either perineurally or intramuscularly.
1634768|NCT01971645|Drug|Ropivacaine|Patients will receive 2 mg/kg of 0.5% ropivacaine (max. dose 100 mg) perineurally.
1634769|NCT01971632|Drug|Oxycodone & naloxone combination, prolonged release|
1634770|NCT01971632|Drug|placebo oxycodone / naloxone|
1634771|NCT01971606|Drug|Rosuvastatin|"Patients will be randomized in a ratio of 1:1 to A) High-dose rosuvastatin vs. B) Placebo.
A) Rosuvastatin group : Administration of 40mg of rosuvastatin PO 12 hours before surgery and 20mg of rosuvastatin PO 2hours before surgery and 10mg of rosuvastatin PO daily at postoperative period.
B) Placebo group : Administration of placebo at 12 hours and 2 hours before surgery and 10mg of rosuvastatin PO daily at postoperative period."
1634772|NCT01971593|Drug|Eplerenone|
1634773|NCT01971580|Drug|Ambrisentan|
1634774|NCT01971567|Device|HIRREM|
1634775|NCT01971554|Drug|MK-8666|MK-8666, capsules, oral, QD, Days 1 to 14
1634776|NCT01971554|Drug|Placebo|Placebo, capsules, oral, QD, Days 1 to 14
1634777|NCT01971541|Behavioral|Mindfulness-Based Stress Reduction|A validated 8-week group program that teaches mindfulness meditation
1634778|NCT01971541|Behavioral|Cognitive Processing Therapy|A validated group program of PTSD treatment, which focuses on cognitive processing.
1634779|NCT01971528|Device|Electronic muscle stimulator|Participants will perform 8 weeks of electrical stimulation for Quadriceps muscle belly(30 minutes/time, 3 times/week).
1634780|NCT01971528|Other|Muscle strength training|Participants will perform 8 weeks of isotonic contraction muscle strength training for lower extremities.
2011885|NCT02356276|Procedure|Hyperthermic Intraperitoneal Chemotherapy|The first HIPEC is conducted within 48 h after surgery: Normal saline 3000 -4000ml, Paclitaxel 75mg/m^2, 43°C, 60min. The second HIPEC is performed after 24 hours of the first HIPEC. The regimens are Paclitaxel 100 mg/m^2, 43°C, 60min.
2011886|NCT02356276|Drug|Systemic chemotherapy (XELOX or SOX regimens)|"XELOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; Capecitabine: 1 g/m^2 bid, days 1-14, every 3 weeks for a total of 6-8 cycles.
SOX regimen: Oxaliplatin: 130 mg/m^2, IV, d1; S-1, 40 mg/m^2 bid, po, day 1-14 (S-1: BSA <1.25m^2, 40mg bid, 1.25m^2≤ BSA ≤1.5m^2, 50mg bid, BSA>1.5m^2, 60 mg bid) bid, d1-14, po, every 3 weeks for a total of 6-8 cycles."
2011887|NCT02354950|Drug|GSK1265744 30mg|GSK1265744 30mg tablets are white to almost white coated oval tablets. All subjects will receive GSK1265744 30mg as a single oral dose in the fasted state followed by PK sampling.
2011888|NCT02350777|Procedure|Donor peripheral blood progenitor cells: stimulation, harvesting, isolation and T-cell depletion|For related donors, beginning 5-6 days before the day of HPC(A) or HPC (M) TCD boost infusion, the normal donor will receive GCSF per institutional guidelines. On the fifth and sixth days of this course of G-CSF, the donor will undergo daily leukapheresis designed to provide a minimum of 5x10^6 CD34+ cells/kg of the transplant recipient's weight. For unrelated donors, the G-CSF will be administered and the leukapheresis obtained according to the National Marrow Donor Program protocol IND, and institutional guidelines. Mononuclear cell fractions (i.e., CD34+ cells) collected on the fourth and fifth days will be pooled.
2011889|NCT02350777|Device|CliniMACS Cell Selection System|
2011890|NCT02349815|Drug|Levonorgestrel (Jaydess, Skyla, BAY86-5028)|Women use Levonorgestrel (Jaydess, BAY86-5028) .
1634784|NCT01971502|Drug|Placebo to BI 1060469|single rising doses
1634785|NCT01971502|Drug|BI 1060469|food effect
1634786|NCT01971502|Drug|BI 1060469|single rising doses
1634787|NCT01971489|Drug|Buparlisib|Given PO
1634788|NCT01971489|Drug|Cisplatin|Given IV
1634789|NCT01971489|Drug|Gemcitabine Hydrochloride|Given IV
1634790|NCT01971489|Other|Laboratory Biomarker Analysis|Correlative studies
1634791|NCT01971489|Other|Pharmacological Study|Correlative studies
1634792|NCT01971489|Other|Questionnaire Administration|Ancillary studies
2011891|NCT02349633|Drug|PF-06747775|
1634794|NCT01971463|Other|Normal saline|intravenous administration of 500cc of 0.9% NaCl over 30 minutes
1634795|NCT01971450|Drug|Iloprost (Ventavis, BAYQ6256)|
1634796|NCT01971437|Procedure|Cystodistension & Cystoscopy|Women with refractory OAB receiving Cystoscopy and cystodistension
1634797|NCT01971424|Dietary Supplement|Mg oxide|
1634798|NCT01971424|Other|healthy diet|
1634799|NCT01971411|Drug|Calcium 500mg with 200 IU Vitamin D - 2 tablets daily|
1634800|NCT01971411|Procedure|Blood levels of Vitamin D, Serum CTX, Mg, Ca++ and iPTH|
1634801|NCT01971411|Behavioral|Usual sun exposure documentation|
1634802|NCT01971411|Behavioral|Dietary intake of calcium, vitamin D, magnesium|
1634803|NCT01971398|Behavioral|Positive FASD education brochure|Exposure to a positive FASD education brochure
1634804|NCT01971398|Behavioral|Negative FASD education brochure|Exposure to a negative FASD education brochure
1634805|NCT01971398|Behavioral|Active comparator (a general women's health brochure)|Exposure to a general women's health brochure
1634806|NCT01971385|Drug|Squaric Acid solution|
1634807|NCT01971385|Drug|Placebo solution|
1634808|NCT01971346|Drug|etanercept|100 mg Etanercept injections per week (2 separate single-use pre-filled 50 mg subcutaneous injections taken on two separate days) for 3 months
1634809|NCT01971320|Device|Urostim I stimulation|Urostim I stimulation will be done during meals for 6 weeks
1634810|NCT01971307|Other|SGE-PsyScan|
1634811|NCT01971281|Device|NovoTTF-100L|Patients will be treated continuously with the NovoTTF-100L. TTFields treatment will consist of wearing four electrically insulated electrode arrays on the torso. The treatment enables the patient to maintain regular daily routine.
1634812|NCT01971281|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 over 30 minute infusion will be administered once weekly for up to 7 weeks (or until toxicity necessitates reducing or holding a dose), followed by a week rest from treatment. Subsequent cycles will consist of once weekly infusions days 1, 8, 15 every 28 days.
1634813|NCT01971281|Drug|nab-Paclitaxel|nab-paclitaxel 125 mg/m^2 administered as an intravenous infusion over 30-40 minutes on days 1, 8 and 15 of each 28-day cycle.
1634814|NCT01971268|Device|Dental Implant|place dental implants according to manufacturer guidelines
1634815|NCT01971268|Device|Platform-Switch Dental Implant|Place Dental Implant with an abutment narrower than the implant platform
1634816|NCT01971268|Device|Platform-Matched dental implant|Place Dental Implant with abutment with same size as the platform
1634817|NCT01971255|Biological|Ca/04/2009/H1N1r Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
1634818|NCT01971242|Drug|Exenatide|2mg, SC (subcutaneous) once weekly. Number of weeks: 48 weeks. Exenatide is a 39-amino-acid peptide
1634819|NCT01971242|Other|Placebo|Placebo, 2mg, SC (subcutaneous), once weekly for 48 weeks.
1634820|NCT01971229|Other|Carbohydrate based drink|After consumption of the test drink to record the insulin response and gastric emptying.
1634821|NCT01971229|Other|Whey protein based drink|After consumption of the test drink to record the insulin response and gastric emptying.
1634822|NCT01971216|Behavioral|Relaxation|
2011892|NCT02349633|Drug|Palbociclib|
2011893|NCT02349633|Drug|Avelumab|
1634825|NCT01971190|Drug|Intravitreal Aflibercept injection|"2mg intravitreal Aflibercept(Eylea) injection at baseline, at 1 month, and at 2 month.
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
Central subfield thickness is thicker than the previous exam
BCVA letter score is worse than the previous exam (because of the persistent CSC)"
1634826|NCT01971190|Drug|Sham injection|"Sham injection at baseline, at 1 month, and at 2 month.
At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
Central subfield thickness is thicker than the previous exam
BCVA letter score is worse than the previous exam (because of the persistent CSC)"
2011894|NCT02344797|Procedure|Remote ischemic preconditioning|The remote ischemic preconditioning procedure is carried out immediately after the induction of regional or general anesthesia. The blood pressure cuff is placed on the upper limb. The cuff is inflated to 200 mmHg resulting in a total occlusion of the blood flow to the limb. After 5 minutes of ischemia the cuff is deflated and the limb is reperfused for 5 minutes. The procedure is carried out 4 times in a row. For patients with systolic blood pressures >185 mmHg, the cuff will be inflated to at least 15 mmHg above the patient's systolic blood pressure.
2011895|NCT02340611|Drug|Olaparib|Polyadenosine 5'diphosphoribose polymerase (PARP) Inhibitor
2011896|NCT02340611|Drug|Cediranib|Vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor that is a potent inhibitor of all three VEGF receptors (VEGFR-1, -2 and -3)
2011897|NCT02339571|Biological|Ipilimumab|Given IV
2011898|NCT02339571|Other|Laboratory Biomarker Analysis|Correlative studies
1634827|NCT01971190|Procedure|Half-fluence photodynamic therapy|"At 3 month, 4 month, 5 month, and 6 month, PRN treatment of aflibercept injection or half-fluence photodynamic therapy may be done, if one of following conditions is fulfilled.
The PRN treatment method was decided by investigator's discretion.
Of patient who had persistent intra- or subretina fluid on SD-OCT
Central subfield thickness is not decreased to more than 50 micrometer compared with baseline central subfield thickness
Best-corrected ETDRS letter score dose not increased more than 5 letters than baseline (because of the persistent CSC).
Central subfield thickness is thicker than the previous exam
BCVA letter score is worse than the previous exam (because of the persistent CSC)"
1634828|NCT01971177|Device|Femtosecond laser cataract surgery|"The VICTUS lens fragmentation procedure is part of the femtosecond laser assisted cataract procedure, which generates precise cuts inside the cataractous lens, leading to a softening and fragmentation of the lens.
The correct positioning of the cuts inside the lens can be verified by means of an optical coherence tomograph (OCT) before starting the laser assisted fragmentation process.
Various surgical patterns will be used within this study. For each pattern different geometry/laser parameters can be adjusted individually according to each patient's cataract status.
All the patients who are enrolled in the laser groups (all cataract grades) will be treated with femtosecond laser assisted capsulotomy before the femtosecond laser assisted lens fragmentation by VICTUS femtosecond laser platform."
1634829|NCT01971177|Procedure|Manual cataract surgery|"Manual: manual group acts as a control group where the lens fragmentation are per-formed manually without femtosecond laser assisted lens fragmentation"
1634830|NCT01971164|Drug|JTZ-951|Subjects will receive JTZ-951 or Placebo
1634831|NCT01971164|Drug|Placebo|
1634832|NCT01971151|Behavioral|Exposure therapy|"Treatment protocol:
1) preparation consisting of intake and identification of feared movements, activities and situations and their underlying catastrophic beliefs. 2) education, 3)exposure sessions: patients confront threatening situations and behavioral experiments are performed that are targeted at correcting erroneous catastrophic beliefs. 4) homework assignments."
1634833|NCT01971138|Other|this is a survey|
1634834|NCT01971112|Dietary Supplement|Multivitamins and minerals|Dietary supplement Arm X: Vitamins B6, B12,folic acid, A, D, E, and Iron, and copper at one US-RDA. Plus vitamin C 500 mg, and zinc 14 mg will be given orally daily during 52 weeks.
1634835|NCT01971099|Drug|tribulus terrestris|patients will use 750mg/day of tribulus terrestris
1634836|NCT01971099|Other|Placebo|patients will take one pill a day (the same shape of the drug)
1634837|NCT01971073|Device|transcranial direct current stimulation|"arm Participants will receive bilateral anodal-left cathodal-right tDCS or anodal-right cathodal-left tDCS over the DLPFC.
The following parameters will be used: stimulation intensity of 2 milliAmps for 20 minutes (6 consecutive sessions )."
1634838|NCT01971073|Device|sham tDCS|the sham tDCS group. Neuropsychological testing and symptom ratings will be conducted at baseline and 4 weeks after the end of treatment
1634839|NCT01971060|Device|surgery utilizing V-Loc suture|V-Loc suture will be utilized in the repair of the uterus following removal of fibroid tumors. a second look laparoscopy will be done on all subjects to evaluate scar tissue formation.
1634840|NCT01971047|Drug|Regular Insulin|"Group 1 Treatment Arm,Follow dosing for BG >180 per the following formula:
Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin
Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin
Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin
Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose"
1634841|NCT01971047|Drug|Humalog|"Group 2 treatment arm. Follow dosing for Blood glucose > 180, per the following formula:
Patients with Type 2 Diabetes to receive dosage based on the formula: (BG-120)/30= # units of insulin
Patients with Type 1 Diabetes to receive dosage based on the formula: (BG-120)/40=# units of insulin
Patients with Type 1 Diabetes and Type 2 Diabetes over the age of 70 or with chronic kidney disease to receive dosage based on the formula: (BG-120)/50=# units of insulin
Consider repeating dose if BG>240 mg/dl after 2 hours of initial dose"
1634842|NCT01971034|Drug|Paclitaxel|80 mg/m2, IV, Day 1, Day 8 and Day 15.
1634843|NCT01971034|Drug|Metformin|850mg, PO, every 8 hours, daily.
1634844|NCT01971021|Device|Randomization between two well established clinical routine vascular access devices|
1634845|NCT01971008|Device|Elastic abdominal binder|
1634846|NCT01971008|Device|Placebo binder|
1634847|NCT01970995|Other|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
1634848|NCT01970995|Other|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 85 days in an ambulatory setting
1634849|NCT01970995|Other|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 85 days in an ambulatory setting
1634850|NCT01970982|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
1634851|NCT01970982|Other|Smoking abstinence (SA)|SA for 5 days in confinement
1634852|NCT01970982|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
2011899|NCT02339571|Biological|Nivolumab|Given IV
1634854|NCT01970930|Procedure|Blood specimen|4 green top tube 40 cc of blood draw
1634855|NCT01970917|Device|Olixia pure eye drops|
1634856|NCT01970917|Device|Placebo|0.9% physiological saline solution
1634857|NCT01970904|Drug|Alisporivir|Alisporivir 100 mg or 200 mg soft gel capsules (SGC) in blister packs for oral administration
1634858|NCT01970904|Drug|Ribavirin|Ribavirin tablets of various strengths for oral administration
1634859|NCT01970904|Drug|Peg-IFNα2a|Peg-IFNα2a solution for subcutaneous injection
1634860|NCT01970891|Device|neuromuscular stimulation device|effect of neuromuscular stimulation device at specific muscle sites will be examined for freezing of gait relief
1634861|NCT01970878|Drug|GFF MDI (PT 003)|GFF MDI administered as two puffs BID
1634862|NCT01970878|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
1634863|NCT01970878|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
1634864|NCT01970878|Drug|Open-label tiotropium bromide inhalation (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 μg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
1634867|NCT01970852|Other|Standard tablet computer|No special enhancements or links to personal health information.
1634868|NCT01970852|Other|Enhanced tablet computer|Tablet computer with personalized access to data from the patient's electronic health record.
1634869|NCT01970839|Device|tourniquet, sensory nerve conduction abnormality|
1634870|NCT01970826|Procedure|Single Dental Implants|place single unit dental implants, 2 mm below crestal bone and follow manufacturer guidelines.
1634871|NCT01970826|Procedure|Sterilized Aseptic|Operatory room will be prepared totally aseptic
1634872|NCT01970826|Procedure|Sterilized Clean|Operatory room will be prepared clean but not aseptic
1634873|NCT01970826|Procedure|Full-Mouth Dental Implants|dental implants for full-mouth implant rehabilitation.
1634874|NCT01970826|Procedure|Partial Rehabilitation|two or more implants to support partial rehabilitation
1634875|NCT01970826|Procedure|Duration of Surgery|it will be measure the amount of time to perform the dental implant surgery. It will be measured from the time that the surgeon does the first incision until the last suture is made.
1634876|NCT01970813|Device|acupuncture and bee venom acupuncture point injection|acupuncture and bee venom acupuncture point injection at 10 acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
1634877|NCT01970813|Device|sham acupuncture and normal saline injections|sham acupuncture and normal saline injections at 10 sham acupuncture points twice a week for 12 weeks. This intervention is added on to the conventional antiparkinsonian drugs.
1634878|NCT01970800|Drug|Growth Hormone|Will obtain daily injections and will evaluate the IGF-1 and IGFBP3 every 3 months
1634879|NCT01970787|Device|Radiofrequency Ablation (RFA) using the HALO Ablation System|
1634880|NCT01970774|Other|MTM with PGx|Patients will attend MTM sessions and receive PGx testing
1634881|NCT01970748|Drug|Propranolol|Propranolol 10mg BID initially and titrate dosage every week to achieve 25% drop of heart rate (keep heart rate>55 or systemic blood pressure>90mmHg)
1634882|NCT01970748|Procedure|Esophageal variceal ligation|Esophageal variceal ligation every 3-4 weeks to achieve variceal eradication under endoscopy
1634883|NCT01970735|Biological|Blood test|
2011900|NCT02339571|Other|Questionnaire Administration|Ancillary studies
2011901|NCT02339571|Biological|Sargramostim|Given SC
2011902|NCT02339207|Drug|AL-335 matching placebo|=
2011903|NCT02339207|Drug|AL-335|
2011904|NCT02336113|Behavioral|multidisciplinary treatment|The pharmacist will conduct medication reconciliation at admission, perform medication reviews during the hospital stay and provide drug information (written and oral) to the patient before discharge
2011905|NCT02335346|Drug|Duloxetine|Administered orally
1634892|NCT01970683|Dietary Supplement|VSL #3 BID|
1634893|NCT01970657|Biological|No treatment specified|No intervention
1634894|NCT01970657|Biological|No treatment|None specified
1634895|NCT01970644|Radiation|Gamma knife radiosurgery|Depending on maximum tumour diameter, patients will receive a single dose of 15-20 Gy to the isodose surface which encompasses the entire metastasis.
1634896|NCT01970631|Behavioral|Motivational Interviewing (MI)|The motivational interviewing arms of SPARKS will consist of Health Educators trained in Motivational Interviewing (MI) techniques contacting participants at regular intervals over the course of the nine months following participants' total knee replacement (TKR).
1634897|NCT01970631|Other|Financial Incentives|The financial intervention arms of SPARKS will provide compensation to participants for completing physical activity logs weekly/bi-weekly and reaching pre-specified physical activity goals.
1634898|NCT01970618|Drug|RV1162 single dose|Safety and tolerability of single escalating doses
1634899|NCT01970618|Drug|RV1162 matching placebo single dose|Safety and tolerability of single escalating doses
1634900|NCT01970618|Drug|RV1162: 7 day repeat dose|Safety and tolerability of a repeat dose
1634901|NCT01970618|Drug|RV1162 matching placebo: 7 day repeat dose|Safety and tolerability of a repeat dose
1634902|NCT01970618|Drug|RV1162: 14 day repeat dose|Safety and tolerability of repeat escalating doses
1634903|NCT01970618|Drug|RV1162 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
1634904|NCT01970605|Procedure|Surgical reconstruction|"In contrast to silver acetate impregnated vascular graft, Silver Graft can be immersed in an antibiotic containing solution prior to implantation. This practice should always be followed according to each participant's hospital guidelines and experience. The long term efficacy of the metallic silver coating will not be reduced.
Common practice antibiotic co-medication before, during and after surgery needs to be documented but is at the discretion of each participating institution.
Due to the registry character of this assessment, i.e. routine use of the investigational product, local antibiotics, e.g. dipping of the vascular graft into a rifampin solution is permissible."
1634905|NCT01970592|Behavioral|POWER training|Individuals with chronic post-stroke hemiparesis will undergo training to improve muscle power generation for 24 sessions (3 times/week) that includes both resistive and task-specific elements. Session duration will be ~90 minutes/day (inclusive of rest intervals). Training will include five distinct resistance activities aimed at improving muscle power-- each previously reported to contribute to improved walking
1634906|NCT01970579|Device|Paclitaxel coated balloon|"Treatment of target lesion with study balloon (coated). Diameter of treatment balloon = RVD
Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)
Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)
If two treatment balloons are necessary overlap between the balloon must be 10 mm
Inflation pressure 7-10 atm
Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting"
1634907|NCT01970579|Device|uncoated PTA catheter|"Treatment of target lesion with study balloon (uncoated). Diameter of treatment balloon = RVD
Each study balloon must only be used once (except postdilatation is necessary which may be done with the same balloon used for the initial dilatation)
Treatment balloon must be 20 mm longer than lesion length (to assure balloon overlap of 10 mm proximal and distal to lesion)
If two treatment balloons are necessary overlap between the balloon must be 10 mm
Inflation pressure 7-10 atm
Intraluminal defects or haziness should be treated with additional inflations and/or aggressive anti-platelet agents or bailout stenting."
1634908|NCT01970566|Other|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
1634909|NCT01970566|Other|Behavioral|Intense Exercise/Moderate Calorie Restriction
1634910|NCT01970566|Other|Behavioral and Drug|Topiramate-Phentermine plus cognitive behavioral therapy
1634911|NCT01970566|Other|Behavioral|Intense Exercise/Moderate Calorie Restriction
1634912|NCT01970553|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials
1634913|NCT01970553|Drug|Gemcitabine|1000 mg vial, powder for injectable solution
1634914|NCT01970540|Drug|lurbinectedin (PM01183)|lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.
1634915|NCT01970540|Drug|Doxorubicin|Commercially available presentations of vials containing doxorubicin will be provided as appropriate.
1634916|NCT01970527|Biological|Ipilimumab|Given IV
1634917|NCT01970527|Other|Laboratory Biomarker Analysis|Correlative studies
1634918|NCT01970527|Other|Pharmacological Study|Correlative studies
1634919|NCT01970527|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1634920|NCT01970514|Device|ARO Spinal System|The device provides an internal axial rotation orthosis (ARO) for patients being surgically treated for herniated nucleus pulposus (HNP).
1634921|NCT01970501|Drug|bucindolol hydrochloride|
1634922|NCT01970501|Drug|metoprolol succinate|
1634923|NCT01970488|Biological|Adalimumab|Administered by subcutaneous injection
1634924|NCT01970488|Biological|ABP 501|Administered by subcutaneous injection
1634925|NCT01970475|Biological|ABP 501|Solution for subcutaneous injection in pre-filled syringe
1634926|NCT01970475|Biological|Adalimumab|Solution for subcutaneous injection in pre-filled syringe
1634927|NCT01970462|Drug|Sitagliptin|Sitagliptin prior to hospital discharge and 6 weeks following discharge.
1634928|NCT01970462|Drug|Placebo|Patients are reandomized to Sitagliptin or placebo for 6 weeks post-operatively
1634929|NCT01970449|Biological|DNA Nat-B env vaccine|The DNA Nat-B env vaccine will be administered as a 4-mg dose injection intramuscularly (IM) by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
1634930|NCT01970449|Biological|NYVAC Nat-B env vaccine|NVYAC Nat-B env vaccine will be administered as a 3 × 10^7 plaque forming units (pfu) dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
1634931|NCT01970449|Biological|DNA CON-S env vaccine|The DNA CON-S env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
1634932|NCT01970449|Biological|NYVAC CON-S env vaccine|NVYAC CON-S env vaccine will be administered as a 3 × 10^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
1634933|NCT01970449|Biological|DNA Mosaic env vaccine|The DNA Mosaic env vaccine will be administered as a 4-mg dose injection IM by Biojector 2000 ® in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
1634934|NCT01970449|Biological|NYVAC Mosaic env vaccine|NVYAC Mosaic env vaccine will be administered as a 3 × 10^7 pfu dose IM by needle and syringe in the deltoid muscle of the non-dominant arm (unless medically contraindicated).
1634935|NCT01970449|Biological|Placebo|Placebo for both DNA and NYVAC vaccines will be administered in the deltoid muscle of the non-dominant arm (unless medically contraindicated) as sodium chloride for injection, 0.9%.
1634936|NCT01970449|Device|Biojector 2000® Needle-Free Injection Management System™ (Biojector 2000®)|All three DNA env vaccines will be administered IM in the deltoid muscle of the non-dominant arm (unless medically contraindicated) using the Biojector 2000® device.
1634937|NCT01970436|Other|Remote Prenatal Care|Remote Prenatal Care using a combination of in-person and telemedicine prenatal care visits.
1634938|NCT01970423|Device|CRT|The new device is the first CRT-P that relies on a physiological parameter, respiration, to allow the pacemaker to follow the patient's breath and help create an appropriate pacing rate.
1634939|NCT01970423|Device|conventional right ventricular stimulation|
1634940|NCT01970410|Drug|teriflunomide|14 mg oral teriflunomide daily
1634941|NCT01970397|Device|JUVEDERM® Ultra XC|Up to 3.0 mLs JUVEDERM® Ultra XC injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
1634942|NCT01970397|Device|Belotero Balance®|Up to 3.0 mLs Belotero Balance® injected into the mid to deep dermis (2.0 mLs for initial treatment and 1.0 mL for touch-up treatment).
1634943|NCT01970384|Device|Transcranial direct current stimulation|20 Minutes of transcranial direct current stimulation (20 min, 1 mA) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke stimulation will be applied over the cortical swallow motor area of the right hemisphere.
1634944|NCT01970384|Device|Sham stimulation|20 Minutes of sham transcranial direct current stimulation (20 min, no current applied) administered over the contralesional cortical swallow motor area once daily over 4 consecutive days. In case of a brainstem stroke sham stimulation will be applied over the cortical swallow motor area of the right hemisphere.
1634945|NCT01970371|Drug|plazomicin|intravenous repeating doses
1634946|NCT01970371|Drug|colistin|intravenous repeating doses
1634947|NCT01970371|Drug|meropenem|intravenous repeating doses
1634948|NCT01970371|Drug|tigecycline|intravenous repeating doses
1634949|NCT01970371|Drug|antibiotic of Investigator's choice|repeating doses
1634950|NCT01970358|Biological|Poly-ICLC|
1634951|NCT01970358|Biological|Peptides|
1634952|NCT01970345|Drug|IGF-1|IGF-1 is an FDA-approved (IND exemption #113450), commercially available compound that crosses the blood-brain barrier and has beneficial effects on synaptic development by promoting neuronal cell survival, synaptic maturation, and synaptic plasticity.
1634953|NCT01970345|Drug|Placebo/saline|Placebo
1634954|NCT01970332|Procedure|Revascularization Surgery|
1634955|NCT01970332|Other|Supervised exercise therapy|
1634956|NCT01970306|Device|MatriStem PSM|All esophageal anastomoses will be reinforced circumferentially with ACell MatriStem PSM.
1635010|NCT01969942|Drug|Melphalan|
1635011|NCT01969929|Procedure|20G Vitrectomy|
1634957|NCT01970293|Other|Introduction to AA volunteer|In-person, in jail introduction to an AA volunteer, who will offer assistance in attending 2 AA meetings.
1634958|NCT01970280|Drug|Enoxaparin|
1634959|NCT01970267|Procedure|Laser Ablation of Floaters|
1634960|NCT01970267|Procedure|Sham Laser Treatment|Laser will be set at 0.3 millijoules (mJ). There will be a 100% absorptive filter (black spot) of about 1cm placed centrally on the lens. All laser aiming beams will be placed within the 1cm filter. Laser will be applied at 0.3 mJ at the absorptive black spot (100% density filter) in order to create a realistic treatment therapy procedure.
1634961|NCT01970254|Other|HBV screening tests|Three (3) hepatitis B virus (HBV) infection tests: HBsAg, anti-HBc, and anti-HBs
1634962|NCT01970254|Behavioral|HBV risk assessment survey|Estimated time to complete the HBV risk assessment tool is 5 minutes.
2011906|NCT02328027|Drug|99mTc-rhAnnexin V-128|1 single intravenous bolus administration of 250 MBq, at Day 1 and at Day 42.
2011907|NCT02329405|Drug|Rifampicin|
1634965|NCT01970228|Diagnostic Test|68Ga-citrate and 18F-FDG PET/CT imaging|Single-day study of the two PET tracers
1634966|NCT01970215|Drug|TA-8995|
1634967|NCT01970215|Drug|Atorvastatin|
1634968|NCT01970215|Drug|Rosuvastatin|
1634969|NCT01970215|Drug|TA-8995 0mg (placebo)|
1634970|NCT01970215|Drug|Placebo Statin|
1634971|NCT01970202|Drug|40mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 40mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
1634972|NCT01970202|Drug|60mg Enoxaparin|Patients with obesity undergoing laparoscopic sleeve gastrectomy, will receive 60mg Enoxaparin per day for 3 days after surgery by subcutaneous administration.
1634973|NCT01970202|Other|Control|no treatment
1634974|NCT01970176|Drug|Tadalafil|
1634975|NCT01970176|Drug|Placebo|
1634976|NCT01970163|Other|DermACELL|Acellular dermal matrix is applied at Baseline visit. The study product may be reapplied an additional time (between Weeks 2 and 12 for venous stasis ulcers and between Weeks 3 and 12 for diabetic foot ulcers).
1634977|NCT01970163|Other|GraftJacket|Acellular dermal matrix applied at Baseline visit. May be reapplied one additional time during study (between Week 2 and 12 for venous stasis ulcers and Week 3 and 12 for diabetic foot ulcers).
1634978|NCT01970163|Other|Conventional Care Dressings|"Depending on the state of the wound (dry or moist), different types of nonadherent dressings would be utilized as the primary dressing:
If the wound is dry, a nonadherent dressing, such an oil emulsion dressing, may be appropriate, as these dressings tend to donate moisture to the wound.
Hydrogels can also be used if the wound is in need of moisture.
For a wound that is more moist, a more absorptive dressing may be more appropriate to help reduce potential for maceration.
A secondary dressing may be desired to add either loft or cushion."
1634979|NCT01970150|Device|rTMS real|
1634980|NCT01970137|Drug|KPS-0373, High dose|
1634981|NCT01970137|Drug|KPS-0373, Low dose|
1634982|NCT01970124|Drug|KPS-0373, High dose|
1634983|NCT01970124|Drug|KPS-0373, Low dose|
1634984|NCT01970111|Drug|KPS-0373, High dose|
1634985|NCT01970111|Drug|KPS-0373, Low dose|
1634986|NCT01970098|Drug|KPS-0373, High dose|
1634987|NCT01970098|Drug|KPS-0373, Low dose|
1634988|NCT01970098|Drug|Placebo|
1634989|NCT01970072|Drug|Remimazolam Tosylate|
1634990|NCT01970072|Drug|Midazolam|
1634991|NCT01970059|Drug|Extended-Release Carvedilol Sulfate|
1634992|NCT01970059|Drug|Sustained-release Metoprolol Succinate|
1634993|NCT01970046|Drug|Placebo/Metformin|"Run in period ：placebo and metformin 500 mg t.i.d for 6 weeks
Phase A : Placebo and metformin 500 mg t.i.d for 24 weeks
Phase B : SP2086 50 mg b.i.d and metformin 500 mg t.i.d for 28 weeks"
1634994|NCT01970046|Drug|SP2086 50 mg b.i.d/Metformin|"Run-in period: placebo and Metformin 500 mg t.i.d for 6weeks
Phase A:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 24 weeks
Phase B:SP2086 50 mg b.i.d and Metformin 500 mg t.i.d for 28 weeks"
1634995|NCT01970046|Drug|SP2086 50 mg q.d./Metformin|"Run-in period: placebo and Metformin 500 mg t.i.d for 6 weeks
Phase A:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 24 weeks
Phase B:SP2086 50 mg q.d and Metformin 500 mg t.i.d for 28 weeks"
1634996|NCT01970033|Drug|Placebo|"Run in period ：oral tablets of Placebo twice daily for 2 weeks
Phase A : oral tablets of Placebo twice daily for 24 weeks
Phase B : SP2086 50 mg b.i.d or SP2086 100 mg q.d. for 28 weeks"
1634997|NCT01970033|Drug|SP2086 50 mg b.i.d.|"Run-in period: placebo twice daily for 2 weeks
Phase A:SP2086 50 mg b.i.d for 24 weeks
Phase B:SP2086 50 mg b.i.d for 28 weeks"
1634998|NCT01970033|Drug|SP2086 100 mg q.d.|"Run-in period:placebo twice daily for 2 weeks
Phase A: SP2086 100 mg q.d. for 24 weeks
Phase B: SP2086 100 mg q.d. for 28 weeks"
1634999|NCT01970020|Drug|JNJ-38518168|Following an at least 10-hour overnight fast, participants will receive a single dose containing 30 mg of 14C JNJ-38518168 given as an oral solution on Day 1
1635000|NCT01970007|Device|Zilver Vena Venous Stent|stenting
1635001|NCT01969994|Other|Controlled dietary background|Controlled dietary flavanol-/procyanidin- background, consisting of daily intake for 14 days (day -17 to -4) of a commercially available flavanol-/procyanidin-containing cocoa-based drink (250 mg cocoa flavanols; 40 mg of (−)-epicatechin) followed by a 4-day period (day -4 to 0) of a low-flavanol diet.
1635002|NCT01969994|Other|(−)-[2-14C]epicatechin intake|Single oral intake of an aqueous solution of a mixture of non-radiolabeled (−)-epicatechin and a single-carbon-14 radiolabeled (−)-[2-14C]epicatechin. The target amount of EC delivered with test drink will be 60 mg, 58.5 mg of which consist of non-radiolabled EC and 1.54 mg (300 µCi) consist of (−)-[2-14C]epicatechin.
1635003|NCT01969981|Procedure|PICC placement with Sherlock 3CG|
1635004|NCT01969968|Other|Lipophilic Organic Polluants dosage|Urinary, blood and fat dosage of Lipophilic Organic Polluants
1635005|NCT01969955|Drug|nanoparticle albumin-bound paclitaxel|Nanoparticle albumin-bound paclitaxel is given at 130 mg/m2 intravenously on day 1 and 8, every 21 days.
1635006|NCT01969942|Biological|allogeneic stem cell transplantation|
1635007|NCT01969942|Drug|Clyclophosphamide|
1635008|NCT01969942|Drug|Fludarabina|
1635009|NCT01969942|Drug|Busulfan|
2011908|NCT02329405|Drug|Placebo|
2011909|NCT02327143|Drug|LY2835219|Administered orally
1635012|NCT01969929|Procedure|23G vitrectomy|
2011910|NCT02327143|Drug|^13C-LY2835219|Administered IV
1635014|NCT01969903|Drug|Precedex injection|
1635015|NCT01969890|Drug|G-CSF administration|Zarzio - 5 microg/kg bis in die for 6 days
1635016|NCT01969877|Drug|cetuximab|
1635017|NCT01969877|Drug|cisplatin|
1635018|NCT01969864|Behavioral|HRSA Video Intervention|
1635019|NCT01969864|Behavioral|PI Video Intervention|
1635020|NCT01969864|Behavioral|CDC Health Website Intervention|
2011911|NCT02327013|Drug|vortioxetine 10 mg tablet|Oral tablets, once daily
1635022|NCT01969838|Drug|Momelotinib|Momelotinib tablet administered orally once daily
1635023|NCT01969838|Drug|Ruxolitinib|Ruxolitinib tablets administered orally twice daily
1635024|NCT01969838|Drug|Placebo to match momelotinib|Placebo to match momelotinib tablets administered orally once daily
1635025|NCT01969838|Drug|Placebo to match ruxolitinib|Placebo to match ruxolitinib tablets administered orally twice daily
1635026|NCT01969825|Behavioral|Massage|
1635027|NCT01969812|Device|Evie Slow-release Insemination Device|
1635028|NCT01969812|Other|Traditional Intrauterine Insemination|
1635029|NCT01969799|Drug|Amikacin fosfomycin inhalation solution|300 mg of amikacin and 120 mg of fosfomycin twice daily for 10 days to be administered by aerosol via the eFlow Inline System
1635030|NCT01969799|Drug|Aerosolized placebo|Placebo twice daily for 10 days to be administered by aerosol the eFlow Inline System
1635031|NCT01969786|Other|Corneal ulcer prevention program|The corneal ulcer prevention intervention consists of training female community health volunteers to diagnose corneal abrasions and to treat the abrasions with 1% itraconazole and 1% chloramphenicol ointments 3 times a day for 3 days.
1635032|NCT01969773|Drug|Botulinum toxin A|Patients will be randomly assigned to receive intravesical injection of 100U of BoNT-A (BOTOX, Allergan, Irvine, CA, USA)
1635033|NCT01969773|Drug|Normal saline instillation|Patients will be randomly assigned to receive intravesical injection of injection with normal saline.
1635034|NCT01969760|Behavioral|Healthy Families DC Program|A tailored family-based intervention for health promotion goal setting, substance use prevention, and promotion of physical activity
1635035|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
1635036|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
1635037|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
1635038|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
1635039|NCT01969747|Drug|Empagliflozin medium|Empagliflozin medium
1635040|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
1635041|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
1635042|NCT01969747|Drug|Empagliflozin high placebo|Empagliflozin high placebo
1635043|NCT01969747|Drug|Empagliflozin medium placebo|Empagliflozin medium placebo
1635044|NCT01969747|Drug|Empagliflozin low placebo|Empagliflozin low placebo
1635045|NCT01969747|Drug|Empagliflozin low|Empagliflozin low
1635046|NCT01969747|Drug|Empagliflozin high|Empagliflozin high
1635047|NCT01969734|Device|Zephyr endobronchial valve placement|
1635048|NCT01969721|Drug|fluticasone propionate|low dose
1635049|NCT01969721|Drug|salmeterol|
1635050|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
1635051|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
1635052|NCT01969721|Drug|tiotropium|tiotropium high dose
1635053|NCT01969721|Drug|olodaterol|
1635054|NCT01969721|Drug|olodaterol|
1635055|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
1635056|NCT01969721|Drug|placebo|placebo/dummy for blinding purposes
1635057|NCT01969721|Drug|tiotropium|tiotropium low dose
1635058|NCT01969721|Drug|fluticasone propionate|low dose
1635059|NCT01969721|Drug|salmeterol|
1635060|NCT01969708|Drug|aflibercept|
1635061|NCT01969708|Drug|bevacizumab|
2011912|NCT02327013|Drug|vortioxetine 20 mg tablet|Oral tablets, once daily
1635063|NCT01969682|Drug|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
1635064|NCT01969682|Drug|Rifampin|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin
1635065|NCT01969669|Drug|ABT-199|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
1635066|NCT01969669|Drug|Ketoconazole|Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with ketoconazole
1635067|NCT01969656|Drug|2MD|
1635068|NCT01969656|Drug|Calcitriol|
1635069|NCT01969656|Drug|Placebo|
1635072|NCT01969630|Device|PEB|Paclitaxel eluting balloon angioplasty plus provisional nitinol stent implantation
1635073|NCT01969630|Device|PES|Systematic Paclitaxel eluting stent angioplasty
1635074|NCT01969617|Drug|Nalmefene 18 mg, then placebo|One single oral dose Nalmefene on Day 1 and Placebo on Day 8
1635075|NCT01969617|Drug|Placebo, then Nalmefene 18 mg|One single oral dose Placebo on Day 1 and Nalmefene on Day 8
1635119|NCT01969318|Drug|SP2086 (100 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 100 mg q.d. and 500 mg t.i.d for 12 weeks
1635161|NCT01968954|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
1635162|NCT01968954|Other|Placebo|subcutaneous injection, every 2 weeks for 12 months
1635163|NCT01968941|Radiation|Stereotactic Body Radiotherapy (SBRT)|
2011913|NCT02327013|Other|Placebo tablet|Oral tablets, once daily
2011914|NCT02325401|Drug|Metformin|Escalating doses of 2000mg, 2550 mg and 3000mg. Starting 1 week prior to the initiation of chemoradiation and ending the final day of chemo or radiation.
2011915|NCT02325401|Drug|Cisplatin|Dosed at 100mg/m2 on days 1, 22, and 43
1635076|NCT01969604|Behavioral|Motivational Lifestyle Counselling|"The intervention will focus on individual goal setting and self-efficacy, where participants describe their everyday life in terms of sitting time and set goals how to reduce their daily sitting time. Project staff will introduce the patients to the possible benefits of reducing their daily sitting time.
The intervention focuses on 4 key messages or themes, which are written in booklets that will be handed to the patients: 1) Reduce daily TV-viewing, 2) Substitute sitting with standing when possible, 3) Break up prolonged sitting and 4) Maximum 30 minutes of sitting.
Based on the patients' own individually goals the patients decide how many weekly SMS reminders they want to receive during the 16-week intervention period.Example:
• Hello X. Raise from your table stand-up and allow gravity to assist your lunch to digest. Bonus: You burn more energy when you stand."
2011916|NCT02325401|Radiation|Radiation Therapy|70 Gy in 2 Gy once daily fractions of 35 fractions
2011917|NCT02321150|Procedure|Cautery|"Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.
Conjunctiva undermined at the recipient site.
Relaxing incisions placed at the corners of the recipient site.
Graft is slid into place
Graft / host interface is gently dried with a Qtip
Bipolar cautery is applied after grasping the graft and host conjunctiva gently between cautery forceps.
Power setting: 25.
Duration of cautery: 4 -5 seconds; the tissue should whiten and contract as desiccation and coagulation take place. Some charring may occur.
Counter traction is applied to the conjunctiva as the cautery forceps are gently teased off
Cautery is applied at the 4 apices of the graft then in between these points."
1635079|NCT01969578|Drug|bicalutamide + triptorelin|
1635080|NCT01969578|Drug|Cisplatin + Doxorubicin|
1635081|NCT01969578|Drug|Carboplatin + Paclitaxel|
1635082|NCT01969565|Drug|Carfilzomib|
1635083|NCT01969565|Drug|Dexamethasone|
1635084|NCT01969539|Drug|Combivent Respimat via tee adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via tee adapter
1635085|NCT01969539|Drug|Combivent Respimat via ventilator adapter|Patients (all); previously intubated and ventilated; in need of bronchodilation w/CVT-R via ventilator adapter
1635086|NCT01969526|Other|Multifactorial intervention|Intervention consists in three different actions on frailty dimensions, applied to each subject in the intervention group, in groups of 15 participants: rehabilitative therapy and physical exercise plus intake of hyperproteic shakes, memory workshop and review of the medication.
1635087|NCT01969513|Procedure|PROCEDURE: EPLEY MANOEUVRE|The procedure involves a series of four movements of the head and body from sitting to lying, rolling over and back to sitting.
1635088|NCT01969513|Procedure|PROCEDURE: SHAM MANOEUVRE|Placebo manoeuvre is performed with the patient lying down over the affected side for 5 minutes as it is described in similar studies.
1635089|NCT01969500|Behavioral|Mobile Application|
1635090|NCT01969500|Behavioral|Treatment as Usual|
1635091|NCT01969487|Other|Preoperative warm-up on simulator|
1635092|NCT01969474|Drug|Cannabis|Cannabis capsules given once daily for a month
1635093|NCT01969474|Drug|Placebo|Placebo
1635094|NCT01969461|Behavioral|Motivational Enhancement Therapy (MET)|The 4-session MET intervention will address alcohol use and HIV medication (ART) adherence. Sessions will be delivered in the clinic or the home by a CHW (outreach worker, etc) already providing services in the clinic. In sessions 1 and 2 (each behavior will get its own session), CHW will elicit the client's view of the problem using MI techniques, building motivation for change by eliciting and reinforcing change talk. The CHW will deliver feedback and discuss the consideration of a behavior change plan option, and the client sets the change plan goal and consolidates commitment. In the last two sessions, the CHW will review the change plan, continue to elicit and reinforce change talk, problem-solve barriers, consolidate commitment, and consider strategies to maintain behavior change.
1635095|NCT01969448|Procedure|Inframammary Fold Incision or Lateral Radial Incision|
1635096|NCT01969448|Procedure|Lateral Radial Incision|
1635097|NCT01969448|Procedure|Inframammary Fold Incision|
1635098|NCT01969448|Device|Laser-assisted fluorescence angiography|All study arms will utilize this device to evaluate breast perfusion just prior to mastectomy, at the conclusion of the mastectomy procedure, and following conclusion of reconstruction and immediate implant.
1635099|NCT01969435|Drug|Carmustine|
1635100|NCT01969435|Drug|Etoposide phosphate|
1635101|NCT01969435|Drug|Cytarabine|
1635102|NCT01969435|Drug|Melphalan HCl (propylene glycol-free)|
1635103|NCT01969422|Procedure|observation|intervention is the contact with online question answering serice ad subseudd
1635106|NCT01969396|Device|SonoBiopsy Catheter|Catheter utilized in dual role: sonohysterography and endometrial biopsy
1635107|NCT01969396|Device|Endometrial biopsy catheter|Endometrial sample obtained without the assistance of sonohysterography
1635108|NCT01969383|Other|Heated pool training|
1635109|NCT01969370|Behavioral|Experimental|Option to request non-medically actionable incidental information (after receiving education about them)
1635110|NCT01969357|Drug|Placebo|Tablets(n=4),once daily for 84 days
1635111|NCT01969357|Drug|50 mg SP2086|Tablets(n=1),50mg strength+tablets(n=3) 0 mg once daily for 84 days
1635112|NCT01969357|Drug|100 mg SP2086|Tablets(n=1),100 mg strength+tablets(n=3) once 0 mg daily for 84 days
1635113|NCT01969357|Drug|200 mg SP2086|Tablets(n=2),100 mg strength+tablets(n=2) 0mg once daily for 84 days
1635114|NCT01969357|Drug|100 mg Sitagliptin|Tablets(n=1),100 mg strength+tablets(n=3),0 mg strength once daily for 84 days
1635115|NCT01969331|Dietary Supplement|Normia|One capsule twice a day/14 days
1635116|NCT01969331|Dietary Supplement|Placebo|maltodextrin, microcrystalline cellulose; hypromellose, silicium dioxide (E551), magnesium stearate, colouring agent: titanium dioxide ( E171)
1635117|NCT01969318|Drug|Placebo /Metformin|Patients are administered oral tablets of placebo once daily and metformin 500 mg t.i.d for 2 weeks at run-in period.After randomized,patients will be administered the drugs too
1635118|NCT01969318|Drug|SP2086(50 mg q.d.)/Metformin|patients are administered oral placebo once daily and metformin 500 mg t.i.d for 2 weeks at the run-in period .After randomized ,patients will be administered SP2086 50 mg q.d. and 500 mg t.i.d for 12 weeks
1635164|NCT01968941|Radiation|Conventional Radiotherapy (CRT)|
1635120|NCT01969305|Behavioral|Kazakhstani Family Together|Adolescent-caregiver pairs will receive three 45-minute interactive multi-media sessions with avatars customized to participants' gender that will focus on risk reduction self-efficacy, resistance to peer pressure, decision-making skills and caregiver-adolescent communication, support and monitoring to strengthen youth's relationships with caregivers and reduce youth's risks of drug use and sexual risk behaviors. Through the multimedia tool, participants will confront a series of sexual risks and substance use related situations and will practice their listening, empathy, assertiveness, refusal, and other interpersonal skills. Each caregiver-youth pair will work jointly and engage in discussions, exercises, and behavioral rehearsal as directed by the program.
1635121|NCT01969305|Behavioral|Usual Care Alone|"Adolescents from both study arms will receive the usual care, a health education program about how to prevent drug use and HIV/STIs (sexually transmitted infections). The health education curriculum is delivered in a group format by trained peer educators and outreach workers. The curriculum consists of three 45-minute sessions that include lectures and interactive quizzes about drugs and HIV. These three sessions include information on the following topics:
Facts and Myth about HIV. HIV/STIs modes of transmission;
Prevention of HIV. Abstinence and Safe Sex. Attitudes and values about sexuality, sexual risk behaviors, and condom use;
Knowledge, attitudes and beliefs about drinking and drug use. Risks and consequences of drug use."
1635122|NCT01969292|Other|Colometer|Real time software based image analysis tool.
1635123|NCT01969292|Other|Sham Software|Software that displays constant positive feedback that is unrelated to the quality measures of the actual colonoscopy.
1635124|NCT01969266|Drug|Treatment A: PCI-32765|840 mg capsule formulation administered by mouth on Day 1
1635125|NCT01969266|Drug|Treatment B: PCI-32765|840 mg solution formulation administered by mouth on Day 1
2011918|NCT02321150|Procedure|Sutures|"Pterygium dissected off, corneal bed burred smooth and autograft harvested as per usual technique.
Conjunctiva undermined at the recipient site.
Graft is slid into place The graft is secured to host conjunctiva using 7 interrupted sutures"
1635127|NCT01969227|Drug|subanesthetic ketamine|
2011919|NCT02319655|Procedure|Air tamponade|Air tamponade
1635129|NCT01969201|Drug|Urofollitrophin|
1635130|NCT01969201|Drug|Follitrophin alpha|
1635131|NCT01969175|Other|Low-glycemic-load and milk-free diet|
1635132|NCT01969162|Procedure|Tear Sample Collection|Tear sample collection as per protocol. No investigational drug is administered in this study.
1635133|NCT01969149|Drug|Exenatide|
1635134|NCT01969149|Drug|Insulin|
1635135|NCT01969136|Drug|Drug: EVP-6124|
1635136|NCT01969136|Drug|Placebo|
1635137|NCT01969123|Drug|Drug: EVP-6124|
1635138|NCT01969123|Drug|Placebo|
1635139|NCT01969110|Dietary Supplement|Oral IMPACT|Oral IMPACT enriched with arginine, omega-3 fatty acids, and RNA by enteral feeding after surgery
1635140|NCT01969097|Device|tDCS|transcranial direct current stimulation (tDCS)
1635141|NCT01969097|Behavioral|Motor training|Motor training of the affected upper extremity (5 days, 25 min/day).
1635142|NCT01969084|Drug|Linagliptin|
1635143|NCT01969084|Drug|Placebo|
1635144|NCT01969084|Other|Microcirculation testing|The endothelial function of the micro-circulation will be assessed by measuring the hyperemic response of the vessels in the superficial skin of the forearm after the iontophoresis of acetylcholine. The endothelium independent vasodilation will be assessed by the iontophoresis of sodium nitroprusside. Laser Doppler perfusion imaging will be used to measure relative changes in flow velocity.Visible and NIR Medical Hyperspectral Imaging (MHSI) data will be collected with a HyperMed OxyView MHSI System (HyperMed, Inc., Watertown, MA). MHSI images will be obtained from same forearm area where the iontophoresis of acetylcholine and sodium nitroprusside will be performed, before and after the iontophoresis test.
1635145|NCT01969084|Other|Macrocirculation testing|Use ultrasound to measure brachial artery flow mediated vasodilation (FMD, endothelium-dependent vasodilation) and nitroglycerin induced dilation (NID, endothelium-independent vasodilation).
1635146|NCT01969084|Other|MRI Scans|Phosphorus-31 MRI data will be obtained during an exercise protocol. Muscle oxygenation will be measured using the blood oxygenation level-dependent magnetic resonance imaging (BOLD MRI) technique after induced hyperemia.
1635147|NCT01969071|Drug|Levosimendan|The effects of levosimendan on renal function
1635148|NCT01969071|Drug|Dobutamine|Standard Inotropic agent
1635149|NCT01969058|Drug|Isotretinoin|Isotretinoin is a drug that is approved for use in the treatment of severe acne. The aim of this study is to evaluate the role of Isotretinoin on immune activation and inflammation.
1635150|NCT01969045|Device|Enk Fiberoptic Atomizer|Nebulization of local anesthetics with the Enk Fiberoptic Atomizer by Cook Medical during the felxible bronchoscopy
1635151|NCT01969045|Device|bronchoscope|Standard procedure: Administration of local anesthetics via the working channel of the bronchoscope during the felxible bronchoscopy
1635152|NCT01969032|Drug|Paclitaxel, Carboplatinum, Doxorubicin, Endoxan, Capecitabine|Paclitaxel 60 mg/m2 IV weekly plus Carboplatinum AUC2 IV weekly for 9 weeks, then Doxorubicin 25 mg/m2 IV weekly plus Endoxan 50 mg per os q.i.d. plus Capecitabine 500 mg t.i.d for 9 weeks
1635153|NCT01969019|Drug|methylprednisolone, prednisone|
1635154|NCT01969006|Drug|Marcaine ½%|
1635155|NCT01969006|Procedure|Needle prick|
2011920|NCT02319655|Procedure|Balanced salt solution filling|BSS filling
1635157|NCT01968980|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
1635158|NCT01968980|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
1635159|NCT01968967|Drug|Bococizumab (PF-04950615; RN316)|150 mg every 2 weeks, subcutaneous injection, 12 months
1635160|NCT01968967|Other|Placebo|subcutaneous injection every 2 weeks for 12 months
1635605|NCT01965561|Device|SJT|Use of SAM Junctional Tourniquet (SJT)
2011921|NCT02319837|Drug|Enzalutamide|
2011922|NCT02319837|Drug|Placebo|Sugar pill to mimic enzalutamide
2011923|NCT02319837|Drug|Leuprolide|
2011924|NCT02317887|Biological|RS1 AAV Vector|Gene transfer by intravitreal injection of the RS1 AAV vector (AAV8-scRS/IRBPhRS)
2011925|NCT02317250|Procedure|Amyloid imaging|Amyloid imaging brain scans are administered once to all arms.
2011926|NCT02317250|Procedure|FDG-PET|[F-18] FDG-PET brain scans are administered once to all arms.
1635165|NCT01968915|Drug|LCL161|Patients will receive oral LCL161 once a week until unacceptable toxicity, disease progression and/or withdrawal of consent.
1635166|NCT01968915|Drug|Paclitaxel|Patients will receive weekly paclitaxel as intravenous infusion over 1 hour in combination with LCL161, from cycle 2 in dose escalation part or from the first cycle in dose expansion part, and will continue it until unacceptable toxicity, disease progression and/or withdrawal of consent.
1635167|NCT01968902|Biological|incabotulinumtoxinA|A dose of 200 units to 400 units of Xeomin will be injected by EMG-guided technique into the appropriate muscles in the effected leg at injection visit
1635168|NCT01968902|Biological|Placebo|Saline injection on the day of injection visit
1635169|NCT01968889|Other|Non invasive phrenic nerve stimulation|Non invasive phrenic nerve stimulation allowing to measure the twitch airway pressure during airway occlusion
1635170|NCT01968876|Other|Medication Adherence Smartphone App|MyMedSchedule is a consumer-grade smartphone application currently available on various marketplaces of the Android and iOS platforms that acts as a portal to the free service MyMedSchedule.com website. It can interface with the MedActionPlan discharge planning tool for providers by automatically populating fields, allowing medication lists to be pushed to a subject's MyMedSchedule account, allowing the input of complex medication regimens, and aiding in medication reconciliation. A MyMedSchedule account can be setup with the patient's name, date of birth, allergies, emergency contact, healthcare providers, insurance plan information, and complete medication list. Medication dose and refill reminders can be set and sent through short message service (SMS) text message or e-mail. SMS text message reminders will be used for this study.
1635171|NCT01968850|Drug|alendronate/vitamin D|once weekly 70mg oral dose of alendronate co-formulated with 5600IU vitamin D3 (cholecalciferol) for 24 weeks.
1635172|NCT01968837|Other|Cervical cancer screening|
1635173|NCT01968824|Procedure|Brachial Plexus Nerve Block|The brachial plexus will be visualized under ultrasound and a 22 gauge, 3.5 inch needle will be used. 20 cc of bupivicaine will be injected around the brachial plexus after confirming negative aspiration every 5 cc
1635174|NCT01968811|Device|Avance Foam dressing kit|
1635175|NCT01968798|Drug|Aspirin|100mg enteric-coated aspirin, taken daily
1635176|NCT01968798|Drug|Placebo|100mg enteric-coated placebo, taken daily
1635177|NCT01968785|Radiation|Radiation Dose 25 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 25 Gy to the renal artery.
1635178|NCT01968785|Radiation|Radiation Dose 50 Gy|Renal Denervation is performed using the Beta-Cath 3.5F to a deliver radiation dose 50 Gy to the renal artery.
1635179|NCT01968772|Other|Transdermal Magnesium Chloride|Each participant will be provided with a spray bottle containing a transdermal magnesium chloride solution and asked to apply 4 sprays per each arm and each leg 2 times a day as follows: pump 4 sprays into the palm of your hand and apply to each arm and each leg 2 times a day for a total of 32 sprays daily. Rub the contents of 4 sprays on one limb and repeat for each limb coating evenly.
1635180|NCT01968759|Drug|Sevelamer|
1635181|NCT01968759|Drug|Ramipril and Irbesartan|
1635182|NCT01968733|Drug|Solithromycin|
1635183|NCT01968733|Drug|Moxifloxacin|
1635184|NCT01968720|Drug|CAT-2003|
1635185|NCT01968720|Drug|Placebo|
1635186|NCT01968707|Drug|ChloraPrep CHG/IPA Hi-Lite Orange Tint|Apply topically.
1635187|NCT01968707|Other|Normal Saline|Apply topically.
1635188|NCT01968707|Drug|3M CHG/IPA Prep Tint 10.5-mL|Apply topically.
1635189|NCT01968707|Drug|3M CHG/IPA Prep Tint 26-mL|Apply topically
1635190|NCT01968694|Drug|IV Lidocaine|
1635191|NCT01968694|Drug|IV diphenhydramine|
1635192|NCT01968681|Procedure|Alexandrite laser|3 different alexandrite laser settings are used in respectively 3 different treatment areas and compared with a non-treated control area.
1635193|NCT01968668|Drug|BAY94-8862|1.25 mg BAY94-8862 tablet once daily in the morning
1635194|NCT01968668|Drug|BAY94-8862|2.5 mg BAY94-8862 tablet once daily in the morning
1635195|NCT01968668|Drug|BAY94-8862|5 mg BAY94-8862 tablet once daily in the morning
1635196|NCT01968668|Drug|BAY94-8862|7.5 mg BAY94-8862 tablet once daily in the morning
1635197|NCT01968668|Drug|BAY94-8862|10 mg BAY94-8862 tablet once daily in the morning
1635198|NCT01968668|Drug|Placebo|Placebo tablet once daily in the morning
1635199|NCT01968668|Drug|BAY 94-8862|15 mg BAY 94-8862 tablet once daily in the morning
1635200|NCT01968668|Drug|BAY 94-8862|20 mg BAY 94-8862 tablet once daily in the morning
1635202|NCT01968642|Behavioral|Educational Intervention|
1635203|NCT01968629|Drug|Eovist|
1635204|NCT01968616|Drug|Ranibizumab, 0.5mg, Intravitreal|
1635205|NCT01968590|Drug|Cholecalciferol|A pharmacist employed by DDrops(trademark) prepares two sets of bottles, one set has 600IU per metered dose and the other set has 4,000IU per metered dose. Participants are randomized to one or the other dose, and they take one measured drop orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
1635207|NCT01968564|Drug|Placebo pill|sugar and other inert substances
1635208|NCT01968564|Drug|High-dose curcumin pill|2000mg curcumin pill/day
1635209|NCT01968564|Drug|Low-dose curcumin pill|500mg curcumin pill/day
1635210|NCT01968551|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
1635211|NCT01968551|Drug|DRV|800 mg tablet administered orally once daily
1635212|NCT01968551|Drug|Baseline DRV- containing ARV regimen|Participants will take their baseline DRV- containing ARV regimen as prescribed.
1635214|NCT01968525|Biological|pre-oxygen|3 min of preoxygenation before anesthesia induction.
1635215|NCT01968512|Device|Transcranial Direct Current Stimulation|This technique consists in the use of low voltage electric current to increase or reduce neuronal excitability in the area stimulated. This is a non-invasive and safe intervention having infrequent and insignificant side effects characterized by mild local discomfort, itching, tingling and/or headache of short term.
1635216|NCT01968512|Device|Sham|Same character of Transcranial Direct Current Stimulation but without current
1635217|NCT01968486|Drug|PDT standard fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT standard fluence (wavelength, 689 nm; dose, 50 J/cm2; light intensity, 600 mW/cm2 for 83 s). Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
1635218|NCT01968486|Drug|PDT reduced fluence, ranibizumab|In the verteporfin PDT combination therapy arm patients were treated on day one with 0.5 mg (10 mg/ml) IVR injection and after seven days with PDT reduced fluence ( wavelength, 689 nm; dose, 25 J/cm2 ; light intensity, 300 mW/cm2 for 83 s).Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
1635219|NCT01968486|Drug|ranibizumab|In the ranibizumab monotherapy arm patients were treated with a loading phase of three consecutive 0.5 mg (10 mg/ml) IVR injections every six weeks. Ranibizumab pro re nata (PRN) could be administered with a 30-day interval if re-treatment criterion were met. Re-treatment was based on increase of intraretinal or subretinal fluid > 50 μm on OCT; loss of 5 letters or more on BCVA Early Treatment Diabetic Retinopathy Study (ETDRS) chart; fluorescein leakage from the CNV on FA images.
1635220|NCT01968473|Device|NMES Device comfort|NMES device, establishing Sensory, Motor and Pain thresholds and Pain tolerance.
1635225|NCT01968434|Device|protective cough syrup|The mucoadhesive and radical scavenging properties of the components create a protective film on the pharynx which protects irritated mucosa from cough generating stimuli such as post nasal drip, irritating elements, dehydration.
1635226|NCT01968434|Drug|carbocisteine cough syrup|Mucolytic
1635227|NCT01968421|Drug|OM-85|two courses of 7mg of OM-85 or matching placebo to take one oral capsule per day for 10 days a month for 3 consecutive months at the beginning of the study, then 3 months later with the same schedule for 1 year.
1635228|NCT01968408|Dietary Supplement|Lactobacillus reuteri DSM 17938|10(9) CFU/daily
1635229|NCT01968408|Dietary Supplement|Placebo|
1635230|NCT01968395|Drug|Caspofungin 70 mg|Intravenous use
1635231|NCT01968382|Drug|IMM 124-E (Hyperimmune Bovine Colostrum)|Hyper-immune bovine colostrum enriched with anti-LPS antibodies and which has been designated by Immuron as IMM-124E.
1635232|NCT01968382|Drug|Placebo (High protein milk powder)|Subjects will receive a total of 4 sachets (2 in the morning and 2 in the evening) daily
1635233|NCT01968369|Dietary Supplement|tomato sauce|We are randomising healthy men (N=14-28) to consume a high fat meal either with or without tomato sauce (80 gr) in a cross-over design with a 7 days wash-out period. During the week before the study, all the subjects will be maintained in a low fibers diet and only subjects randomized to tomatoes will receive a daily dose of 80 mg of tomato sauce (80 gr for 7 days= total load 560 mg).
1635234|NCT01968356|Drug|3M CHG/IPA Prep Colorless|Apply topically.
1635235|NCT01968356|Drug|3M CHG/IPA Prep Tint|CHG 2%/IPA 70%
1635236|NCT01968356|Drug|ChloraPrep CHG/IPA Hi-Lite Orange Tint|Apply topically.
1635237|NCT01968356|Other|Normal Saline|Apply topically.
1635238|NCT01968343|Behavioral|Cognitive-behavioral therapy.|Subjects receive 22 sessions of cognitive-behavioral therapy.
1635239|NCT01968343|Other|Supportive therapy.|Subjects receive 22 sessions of supportive therapy.
1635240|NCT01968330|Behavioral|Go!®to sleep|
1635243|NCT01968304|Other|Iron status follow up|
1635244|NCT01968291|Behavioral|Teach-back|Patients are asked to repeat back in their own words their understanding of the discharge information that was provided to them.
1635245|NCT01968278|Other|Baked milk|
1635246|NCT01968265|Drug|ISIS-GCCRRx|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
1635247|NCT01968265|Drug|Placebo|3 doses on alternate days during the first week and then once weekly for 5 weeks + daily metformin
1635248|NCT01968252|Other|Concurrent TTE and TEE|All subjects will undergo both transthoracic echocardiography and transesophageal echocardiography to compare the results of measurements obtained from both imaging locations.
1635249|NCT01968239|Drug|Ranibizumab|comparison of different re-treatment criteria for intravitreal injection of ranibizumab
1635250|NCT01968226|Drug|[F-18] RDG-K5|Up to fifteen (15) subjects with carotid stenosis >50% who are undergoing planned carotid endarterectomy will be imaged under PET with [F-18] RDG-K5
1635251|NCT01968213|Drug|Rucaparib|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
1635252|NCT01968213|Drug|Placebo|Oral tablets administered twice daily with 8 oz (240 mL) of water on an empty stomach or with food; 28-day cycles of treatment. Doses should be taken as close to 12 hours apart as possible, preferably at the same times every day. Tablets should be swallowed whole.
1635253|NCT01968200|Drug|Enalapril|Naprilene 5 mg tablets; Dosage: 2.5 to 10 mg/12h Duration of treatment: up to end of follow up
1635254|NCT01968187|Drug|FE 992097|
1635255|NCT01968187|Drug|Placebo|
1635256|NCT01968161|Drug|Asenapine|
1635257|NCT01968135|Drug|Combined Oral Contraceptive Pill|150 mcg levonorgestrel and 30 mcg ethinyl estradiol combined oral contraceptive pill
1635258|NCT01968135|Drug|Placebo Sugar Pill|Placebo Sugar Pill
1635313|NCT01967810|Drug|ANG1005|ANG1005 at a starting dose of 650 mg/m2 by intravenous infusion once every 3 weeks
1635390|NCT01967199|Device|Everolimus-eluting balloon expandable stent|Everolimus-eluting balloon expandable stent (Xience Prime or Xience Xpedition or Xience Alpine)
1635259|NCT01968122|Device|intravascular stent therapy|Device selection depended on arterial access and lesion morphology. For patients with smooth arterial access and Mori A lesion or the mid-basilar artery and distal M1 segment lesions, the Apollo balloon-mounted stent was selected. For patients with tortuous arterial access and Mori B or C lesion, or lesion with a significant mismatch in the diameter between proximal and distal segment, angioplasty plus self-expanding stent (Gateway balloon plus Wingspan stent system) is preferred . For patients with tortuous arterial access with a Mori A lesion, or small target vessel diameter (<2.5 mm), direct dilation with Gateway balloon was selected. If severe dissection or elastic recoil occurred after angioplasty, a balloon-mounted stent (for patients with less tortuous access) or Wingspan (for patients with severe tortuous access or small target vessel) stent were allowed to be implanted.
2011927|NCT02315690|Drug|dihydroartemisinin-piperaquine (DHAp)|In the fMDA arm, all individuals in the target area will receive dihydroartemisinin-piperaquine (DHAp) once daily for 3 days with the first dose taken no later than 5 weeks from the index case presentation (goal within one week).
2011928|NCT02315690|Procedure|reactive case detection|Individuals in RACD target areas will be tested by RDT and if positive will be taken to the nearest health facility for treatment as per program operating procedures.
1635262|NCT01968096|Device|home-based ankle continuous passive motion machine.|A rehabilitation program of machine driven passive stretch.
1635263|NCT01968083|Biological|RSV cps2 Vaccine|10^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
1635264|NCT01968083|Biological|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
2011929|NCT02315430|Drug|Cabozantinib S-malate|Given PO
2011930|NCT02315430|Other|Laboratory Biomarker Analysis|Optional correlative studies
2011931|NCT02315443|Drug|NA-1|
1635268|NCT01968057|Drug|Baricitinib|Administered orally
1635269|NCT01968057|Drug|Ciclosporin|Administered orally
1635270|NCT01968044|Drug|Gemigliptin|
1635271|NCT01968044|Drug|Placebo to Linagliptin|
1635272|NCT01968031|Drug|Istradefylline 40 mg|Istradefylline 40 mg and placebo
1635273|NCT01968031|Drug|Istradefylline 20 mg|Istradefylline 20 mg and placebo
1635274|NCT01968031|Drug|Placebo|Placebo
1635275|NCT01968018|Drug|Tramadol HCI/acetaminophen|Participants will receive tablet of tramadol HCI (37.5 mg)/acetaminophen (325 mg) on Day 1. Participants may increase their daily dosage of study medication is 1 to 2 tablets every 4 to 6 hours as needed for pain relief up to maximum of 8 tablets per day.
1635276|NCT01968005|Drug|Etoreat®(Etodolac-Lidocaine Topical Patch)|
1635277|NCT01968005|Drug|Placebo|
1635278|NCT01967992|Behavioral|Behavioral: Low Carbohydrate, Ketogenic Diet|
1635279|NCT01967992|Behavioral|American Diabetes Association Diet|
1635280|NCT01967992|Behavioral|Mindfulness and Positive Affect Skills|
1635281|NCT01967979|Drug|RO5285119|Single dose, alone and after repeated administration of itraconazole or fluoxetine
1635282|NCT01967979|Drug|fluoxetine|Multiple doses
1635283|NCT01967979|Drug|itraconazole|Multiple doses
1635284|NCT01967966|Drug|GDC-0032|Single oral dose
1635285|NCT01967966|Drug|GDC-0032|Single IV dose
1635286|NCT01967953|Procedure|EVLP Group|"EVLP technique: Steen solution; normothermia; low flow, open atrium, low hematocrit.
Endpoints of EVLP assessment of lungs suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy"
1635287|NCT01967940|Drug|TAF|25 mg tablet administered orally once daily with food
1635288|NCT01967940|Drug|Placebo|Tablets to match TAF administered orally once daily with food
1635289|NCT01967940|Drug|E/C/F/TAF|150/150/200/10 mg STR administered orally once daily with food
1635290|NCT01967940|Drug|Current failing ARV regimen|Participants will continue taking their current ARV regimen as prescribed in Part 1.
1635291|NCT01967940|Drug|ATV|300 mg tablet administered orally once daily.
1635292|NCT01967927|Drug|18F-MISO|A radiolabeled imaging agent that has been used for investigating tumor hypoxia with positron emission tomography (PET).
1635293|NCT01967914|Other|PVI|Measurement of PVI (plethysmography variability index)
1635294|NCT01967901|Behavioral|Self-care management program|The self-care management consists of the usual care with an additional multidisciplinary self-management program that includes additional home and clinic visits and telephone follow-ups made by the self-care management nurse and clinic visits to the dietician.
1635295|NCT01967888|Drug|Reparixin|Solution for iv infusion
1635296|NCT01967888|Drug|Placebo|Physiologic solution
1635297|NCT01967875|Drug|Capecitabine+Cisplatin|Cisplatin 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles.Capecitabine is to be continued until disease progression or intolerable toxicity.
1635298|NCT01967875|Drug|Docetaxel+Capecitabine|Docetaxel 75mg/m2, d1; Capecitabine 1700-2000mg/m2/day on days1-14 every 21 days, 6 cycles. Capecitabine is to be continued until disease progression or intolerable toxicity.
1635299|NCT01967862|Procedure|computed tomography|Undergo CT
1635300|NCT01967862|Procedure|bone scan|Undergo bone scan
1635301|NCT01967862|Procedure|3-Tesla magnetic resonance imaging|Undergo axial MRI
1635302|NCT01967862|Procedure|diffusion-weighted magnetic resonance imaging|Undergo WB MRI
1635303|NCT01967862|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT
1635304|NCT01967862|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT
1635305|NCT01967862|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT
1635306|NCT01967862|Other|laboratory biomarker analysis|Correlative studies
1635307|NCT01967849|Diagnostic Test|Oral Glucose tolerance test|
1635308|NCT01967836|Device|Glad Press 'n Seal|Application of Glad Press n' Seal product as an IV site dressing protection during subject showering
2011932|NCT02315443|Drug|Placebo|
2011933|NCT02313753|Behavioral|CLASP|
2011934|NCT02313753|Behavioral|SAFE|
2011935|NCT02312102|Drug|Lenalidomide|Chemotherapy
2011936|NCT02312102|Drug|Velcade|Chemotherapy
1635314|NCT01967810|Drug|Bevacizumab|For patients enrolled in the bevacizumab-refractory in recurrent GBM (Arm 2), treatments with bevacizumab may be continued and administered every 2 or 3 weeks at the Investigator's discretion.
1635315|NCT01967797|Behavioral|5As Team Intervention|The intervention group will participate in an additional 6 month intensive learning collaborative model designed around the 5As of obesity management, but which addresses areas identified as barriers (i.e. weight bias, clinical environment, clinic processes & team based care, mental health, counseling around emotional eating, caregiver fatigue, designing appropriate patient follow-up, and additional topics identified by the professionals). A clinical Champion identified by our partner SSPCN will be available to provide 1:1 support and coaching of the practitioners & teams as needed. The practitioners will work collaboratively to do their own needs assessment, and will identify additional resources or tools that they need to overcome the barriers to weight management in their setting. The research team will use a Practice Facilitation model to provide additional resource and support to the change process for the practitioners.
1635316|NCT01967784|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
1635317|NCT01967771|Drug|DTG|DTG will be supplied as 50 mg tablet to be administered orally
1635318|NCT01967771|Drug|CBZ|CBZ will be supplied as 100 mg and 200 mg extended release tablet to be administered orally
1635319|NCT01967758|Biological|Cohort 1|Four doses of IV ADU-623 at a dose of 3 x 10^7cfu
1635320|NCT01967758|Biological|Cohort 2|Four doses of IV ADU-623 at a dose of 3 x 10^8cfu
1635321|NCT01967758|Biological|Cohort 3|Four doses of IV ADU-623 at a dose of 3 x 10^9cfu
1635322|NCT01967758|Drug|Antibiotics|A 3-day course of oral amoxicillin (500 mg three times per day) or trimethoprim/sulfamethoxazole in penicillin-allergic patients (160 mg trimethoprim / 800mg sulfamethoxazole at 12 hour intervals) will be initiated for each patient 3 days following each dose of ADU-623. Patients will receive a 7-day course of antibiotics starting at the end of treatment visit.
1635323|NCT01967745|Procedure|laparoscopic appendectomy|The laparoscopic appendectomy was performed with three trocars. Pneumoperitoneum was created using an open Hasson technique. The mesoappendix was divided using a harmonic scalpel or endoscopic tissue fusion device. The appendix was divided by placing one endoscopic loop and cut with harmonic scalpel. The specimen was removed through the umbilical port.
1635324|NCT01967745|Procedure|open appendectomy|The open appendectomy was carried out in the standard way with McBurney muscle splitting incision (in supine position).
1635325|NCT01967732|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
1635326|NCT01967732|Other|CC|Single use of subject's own conventional cigarette (CC)
1635327|NCT01967732|Other|NNS|Single administration of 1 mg of nicotine
1635328|NCT01967719|Other|mTHS 2.2|Single use of mTHS 2.2
1635329|NCT01967719|Other|mCC|Single use of subject's own mCC
1635330|NCT01967719|Other|NNS|Single administration of 1 mg of nicotine
1635331|NCT01967706|Other|mTHS|Single use of Tobacco Heating System 2.2 Menthol (mTHS)
1635332|NCT01967706|Other|mCC|Single use of subject's own menthol cigarette (mCC)
1635333|NCT01967706|Other|NRT|Single administration of 2 mg gum (Nicorette® 2mg)
1635334|NCT01967693|Procedure|Retrospective analysis of data|Retrospective data analysis
2011937|NCT02312037|Biological|Antibody Drug Conjugate Chemotherapeutic|"Three Treatment Regimens:
Mylotarg <=9 mg/m2 as a single agent on Day 1 & 14 of a 28-day cycle for a total of two cycles
Mylotarg in combination with a recognized anthracycline and/or nucleoside-antagonist containing regimen
Mylotarg as monotherapy or in tested combinations with ATRA and/or arsenic trioxide for APL"
2011938|NCT02311933|Other|Laboratory Biomarker Analysis|Correlative studies
1635337|NCT01967667|Dietary Supplement|Liposomal glutathione|Escalating dose steps
1635338|NCT01967667|Dietary Supplement|Placebo|escalating dose steps
1635339|NCT01967654|Other|Technical Assistance, training and clinical reminders|
1635340|NCT01967654|Other|Referral to Community Health Worker|
2011939|NCT02311933|Other|Pharmacological Study|Correlative studies
1635344|NCT01967589|Drug|NNC0113-0987|Once-daily doses for oral administration. Multiple doses with sequential dose increments over 10 weeks. Progression to next dose increment is based on a safety evaluation
1635345|NCT01967589|Drug|placebo|Once-daily doses for oral administration
2011940|NCT02311933|Drug|Tamoxifen Citrate|Given PO
1635347|NCT01967550|Drug|diclofenac diethylamine, DDEA 2.32% gel|
1635348|NCT01967550|Drug|Placebo|
2011941|NCT02311933|Drug|Z-Endoxifen Hydrochloride|Given PO
2011942|NCT02311153|Device|Mallinckrodt Endotracheal Tube (ETT)|Patient is intubated for airway protection and ventilation with the Mallinckrodt ETT.
1635351|NCT01967524|Drug|botulinum toxin A + ropivacaïne|"D0 :
Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)
QDSA (Saint-Antoine pain questionnaire)
QCD (Pain questionnaire)
MPI (Multidimensional Pain Inventory)
Beck scale
HAD (Hospital Anxiety and Depression scale)
SF36 (Short Form 36)
injection of botulinum toxin A associated with ropivacaïne
D30, D90, D120 and D150 (phone call): Calcul of the average of EN
D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
2011943|NCT02311153|Device|Laryseal Laryngeal mask airway (LMA)|Laryseal Laryngeal mask airway is used to provide airway protection and ventilation.
2011944|NCT02308111|Drug|Obeticholic Acid (OCA)|"Non-cirrhotic and classified as Child-Pugh Class A: 5 mg tablet of OCA once daily titrating up to a maximum of 10 mg OCA once daily based on tolerability at 3 months for the duration of the study (majority of patients).
Cirrhotic and classified as Child-Pugh Class B and C: 5 mg tablet of OCA once weekly titrating up to 5 mg OCA twice weekly based on tolerability at 3 months, subsequently titrating up to 10 mg OCA twice weekly based on tolerability (maximum for Child-Pugh C) and subsequently titrating up to 5 mg daily based on tolerability (maximum for Child-Pugh B) for the duration of the study."
2011945|NCT02308111|Drug|Placebo|One tablet daily (or a lower frequency depending on Child Pugh score) for the remainder of the study
2011946|NCT02306291|Drug|GMI-1271|Dose escalation
2011947|NCT02306291|Drug|GMI-1271|Dose expansion
2011948|NCT02306291|Drug|GMI-1271|Safety run-in then dose expansion
1635352|NCT01967524|Drug|Ropivacaïne|"D0 :
Calcul of the average of EN (digital scale) (EN completed from D-8 to D-1)
QDSA (Saint-Antoine pain questionnaire)
QCD (Pain Questionnaire)
MPI (Multidimensional Pain Inventory)
Beck scale
HAD (Hospital Anxiety and Depression scale)
SF36 (Short Form 36)
injection of ropivacaïne alone
D30, D90, D120 and D150 (phone call): Calcul of the average of EN
D60 and D180 (on site visits): adverse events reporting, calcul of the average of EN, PGI-I (Patient Global Impression of Improvement), questionnaires (QDSA, QCD, MPI, treatment satisfaction, Beck scale, HAD and SF36)."
1635353|NCT01967498|Drug|Montelukast|
1635354|NCT01967485|Other|Text- Messaging|Text messages will be sent to the parents of children enrolled in the study.
1635355|NCT01967485|Other|Treatment as usual|Children will receive stimulant treatment for ADHD.
1635356|NCT01967472|Drug|amodiaquine-artesunate (AQAS) co-formulated|
1635357|NCT01967472|Drug|Artemether-lumefantrine combination (AL)|
1635358|NCT01967459|Drug|Cholecalciferol|Single dose D-cura cholecalciferol drink 100 000 IU/ml, in total 300 000 IU (=3ml)
1635359|NCT01967459|Drug|Cholecalciferol|Single dose D-cura cholecalciferol drink 250 000 IU/ml, in total 75 000 IU (=3ml)
1635360|NCT01967433|Drug|Diphenhydramine|
1635361|NCT01967433|Drug|Placebo|
1635362|NCT01967420|Behavioral|Cognitive remediation|CIRCuiTS is a computerised cognitive remediation program which consists of tasks to improve cognition, the use of strategy training and the teaching of generalisable community functioning skills.
1635363|NCT01967420|Behavioral|Social cognition training|The social cognition training is a computerised program which aims to improve emotion recognition through a variety of lessons and games.
1635364|NCT01967407|Procedure|Irreversible Electroporation (IRE)|Percutaneous CT-fluoroscopic-guided Irreversible Electroporation.
1635365|NCT01967394|Other|Use of internet based social marketing intervention|"Eleven counties in Kentucky will be targeted with ads on Google and Facebook that direct adolescent mothers to an Internet-based social marketing intervention. The ads will be implemented using Facebook's and Google's ad network. The ads are setup, configured, and adjusted online. Facebook has identified key words that are recommended for adolescent mothers: 16 and pregnant, teen mom,' and names of television shows with subject matter specific to adolescent mothers. We will target the ads to correspond to a geographical area that specifies a distance from the largest city in each county, and we will specify county lines. Ads will only appear on the Internet in the counties that are targeted for the intervention."
1635366|NCT01967394|Other|No use of social media|No social media ads will be available in these counties.
1635367|NCT01967381|Drug|Methamphetamine (Desoxyn®)|The pharmacodynamic effects of methamphetamine (Desoxyn®) will be determined during placebo, oxazepam (Serax®), naltrexone (Revia®) and combined oxazepam and naltrexone maintenance.
1635368|NCT01967368|Drug|Intanza|Principal Investigator would be responsible for injecting the intradermal vaccine in a sterile technique.
1635369|NCT01967368|Drug|Vaxigrip|Principal Investigator would be responsible for injecting the intrmuscular vaccine in a sterile technique.
1635370|NCT01967355|Other|lipid apheresis|
1635371|NCT01967342|Behavioral|Pain Ed|A 10-week psychosocial group treatment for chronic pain that focuses on providing information about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to take ownership of their chronic pain care through building deeper knowledge about their pain condition and their interactions with the health care system.
1635372|NCT01967342|Behavioral|CBT for Pain|A 10-week psychosocial group treatment for chronic pain that focuses on providing information and skills about the development, course, and treatment of chronic pain, as well as information about factors associated with reduced pain (e.g., sleep). In particular, it seeks to empower patients to self-manage their chronic pain through building deeper knowledge about and better skills for improving their pain condition and their interactions with the health care system.
1635373|NCT01967342|Other|Usual Care|A comparison condition in which patients receive standard individualized medical care from the federally qualified health center partnering on this study. Care can include basic biological interventions, such as medication or surgery, as well as supplementary care such as chiropractic or physical therapy. However, cost has a pragmatic influence on the amount of services provided, sought, and received.
1635374|NCT01967329|Drug|Standard Triple|Oral twice-daily doses of rabeprazole (20 mg), amoxicillin (1 g) and clarithromycin (500 mg)
1635375|NCT01967329|Drug|Sequential|Oral twice-daily doses of rabeprazole (20 mg) and amoxicillin (1 g) on days 1-5, and on days 6-10, rabeprazole (20 mg), metronidazole (500 mg) and clarithromycin (500 mg)
1635376|NCT01967329|Drug|Quadruple|Oral doses of rabeprazole (20 mg) twice daily, metronidazole (500 mg) three times daily, bismuth subsalicylate (Pepto-Bismol) (2 tablets) four times daily and tetracycline (500 mg) four times daily
1635377|NCT01967290|Device|Vibratory feedback and 3D movement analysis|Hand-to-mouth task performed under vibratory feedback combined with 3D continuous movement analysis.
1635378|NCT01967290|Device|Only 3D movement analysis|Hand-to-mouth task performed under 3D continuous movement analysis only
1635379|NCT01967277|Device|Handi-Dome Laser|One, 30 minute treatment, every other day for 16 weeks.
1635380|NCT01967277|Device|Incandescent red light source.|One, 30 minute treatment, every other day for 16 weeks.
1635381|NCT01967264|Drug|Udenafil|Udenafil tablets
1635382|NCT01967264|Drug|Placebo|Placebo tablets
1635383|NCT01967251|Drug|Udenafil|Udenafil tablets
1635384|NCT01967251|Drug|Placebo|Udenafil placebo-matching tablets
1635385|NCT01967238|Biological|IM Pneumococcal, meningococcal, or flu vaccine|Volunteers given one of the 3 vaccines
2011949|NCT02306161|Drug|Cyclophosphamide|Given IV
2011950|NCT02306161|Drug|Doxorubicin Hydrochloride|Given IV
1635388|NCT01967212|Device|Game-based swallow biofeedback|"The intervention are divided into two parts：
Traditional swallowing training 30 min by speech therapist.
Game-based biofeedback combined with Mendelsohn's maneuver and effortful swallow 30 min by investigator."
1635389|NCT01967212|Behavioral|Swallow training without biofeedback|"The intervention are divided into two parts：
Traditional swallowing training 30 min by speech therapist.
Mendelsohn's maneuver and effortful swallow without biofeedback 30 min."
2011951|NCT02306161|Drug|Etoposide|Given IV
2011952|NCT02306161|Radiation|External Beam Radiation Therapy|Undergo EBRT
1635391|NCT01967199|Device|paclitaxel eluting balloon|paclitaxel eluting balloon (SeQuent Please)
1635392|NCT01967186|Procedure|Intraportal islet transplantation|
1635393|NCT01967186|Procedure|Intramuscular islet transplantation|
1635394|NCT01967186|Procedure|Intramuscular transpl with stemcells|
1635395|NCT01967186|Procedure|Kidney transplantation|All patients will undergo kidney transplantation regardless of arm
1635396|NCT01967173|Drug|Flovent Diskus® 100 mcg|Flovent is an ICS
1635397|NCT01967173|Drug|Flovent Diskus® 250 mcg|Flovent is an ICS
1635398|NCT01967173|Drug|Flovent Diskus® 500 mcg|Flovent is an ICS
1635399|NCT01967173|Drug|Advair Diskus® 100/50 mcg|Advair is an ICS/LABA combination
1635400|NCT01967173|Drug|Advair Diskus® 250/50 mcg|Advair is an ICS/LABA combination
1635401|NCT01967147|Drug|Propylene Glycol, 0.6% eye drops|Commercially available eye drops used during Treatment Phase
1635402|NCT01967147|Drug|Preservative-free 0.9% Saline solution|Commercially available solution used as Run-in (1 drop in each eye 4 times a day for 15 days) and during Treatment Phase
1635403|NCT01967134|Biological|Aeras-456|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
1635404|NCT01967121|Device|Compex unit's Active Recovery® program|Compex unit's Active Recovery® program will be performed for 15 minutes once per day.
1635405|NCT01967121|Other|Ice application|Participants will apply ice on their hamstring for 15 minutes three times per day until muscle soreness is no longer present
1635406|NCT01967108|Other|chest physiotherapy|chest physiotherapy, up to one hour from extubation, in ICU patients
1635407|NCT01967095|Drug|erlotinib|Cycle 1, week 1 (D1-D7) will consist of pulse dose erlotinib on D1 & D2 without daily low dose erlotinib on D3-7. For all subsequent weeks, patients will take high dose erlotinib on D1 & D2, & will receive erlotinib 50 mg oral daily x 5 days on days 3-7. On days 1 & 2, patients will take one of the following doses of erlotinib, depending on the dose cohort they are enrolled in: Dose level 1 600 mg oral daily on D1, D2 Dose level 2 750 mg oral daily on D1, D2 Dose level 3 900 mg oral daily on D1, D2 Dose level 4 1050 mg oral daily on D1, D2. An additional Dose -1 (pulse dose erlotinib on D1, D2 with 25 mg oral daily x 5 days in D3-D7) will be reserved, in the unlikely situation that Dose 1 is proved too toxic. If Dose -1 is tolerated well (600mg oral daily D1, D2 & 25mg oral daily D3-D7), pulse dose escalation can continue as described above, with erlotinib at the daily low dose of 25 mg oral on D3-D7.
1635408|NCT01967082|Behavioral|Survey|Survey asking about health-related attitudes and behaviors completed at first visit.
1635409|NCT01967082|Other|Smart Phone Application|Smoking cessation and prevention smart phone application provided to participants at first visit
1635410|NCT01967082|Behavioral|Telephone Survey|Telephone survey performed at 1 and 4 months after participant receives smart phone application.
1635411|NCT01967069|Drug|DFD01 Spray|
1635412|NCT01967069|Drug|Vehicle Spray|
1635413|NCT01967043|Drug|Oraxol|Oraxol (Paclitaxel + HM30181AK). Paclitaxel will be supplied as 30 mg capsules and HM30181AK-US will be supplied as 15 mg tablets.
1635414|NCT01967017|Drug|Lidocaine|
1635415|NCT01967017|Drug|Placebo|
1635416|NCT01967004|Device|Morph|Morph is a small electric controller that is retrofit into existing myoelectric prostheses to equip them with wireless identification capabilities. Specifically, Morph allows the prosthesis to react to RFID tags in the environment.
1635417|NCT01966978|Drug|Metformin|Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day)
1635418|NCT01966978|Drug|Detemir|Insulin detemir will be started in both groups at 0.3 units/kg or conversion 1:1 from dose of basal insulin prior to randomization. The titration will be primarily patient-driven, based on our study protocol table. Additional physician driven titration will be allowed in both groups if patient fails to intensify basal insulin dose as directed.
1635419|NCT01966978|Drug|Liraglutide|Initial dose of 0.6 mg/day with weekly increments of 0.6 mg until dose of 1.8 mg/day or maximal tolerated dose (at least 1.2 mg/day)is reached
1635420|NCT01966978|Drug|Insulin Aspart|Insulin aspart will be initiated at a dose of 0.3 units/kg/day divided among the number of meals taken daily and titrated based on physician clinical judgment with the goal of pre-prandial BG 70-130 mg/dL and post-prandial BG <180
1635421|NCT01966965|Drug|PIOLIN®|PIOLIN® SHAMPOO 5 DAYS CONTINUOUSLY STOP A WEEK AND APPLY AGAIN
1635422|NCT01966965|Drug|NEDAX|AS SPECIFIED AT THE LEAFLET
1635423|NCT01966926|Behavioral|weighing frequency instructions and tips|Weekly emails with nutrition, physical activity, and weight tracking tips sent for 24 weeks
1635424|NCT01966913|Drug|Bevacizumab|
1635425|NCT01966913|Drug|ICE chemotherapy regimen|Etoposide, 300 mg/m²/d in two daily injections at 12-h intervals, Carboplatin, AUC 4/d by injections adjusted daily to the creatinine clearance, Ifosfamide, 2400 mg/m²/d, For 5 consecutive days followed by HSC reinjection and G-CSF (filgrastim- Neupogen) on D11 of each intensive cycle
1635426|NCT01966900|Biological|CN54gp140 mixed with GLA-AF|Each vaccination an intramuscular injection of 100 micrograms CN54gp140 mixed with 5 micrograms GLA-AF
1635427|NCT01966887|Genetic|MYDICAR-single intracoronary infusion|AAV1/Serca2a
1635428|NCT01966887|Genetic|Placebo; single intracoronary infusion|single intracoronary infusion
1635429|NCT01966861|Other|weaning guided by LUS (lung ultrasound)|Predictive early signs of respiratory distress are assessed by lung ultrasound (LUS score >14) and if present will trigger protocolised intervention (eg- fluid balance,diuretics, thoracocentesis, antibiotics when required [CPIS>6], hemglobin>8g/dl triggers transfusion)
1635430|NCT01966848|Device|Wich prosthesis is used|
1635465|NCT01966627|Other|abdominal and liver magnetic resonance imaging|magnetic resonance imaging scan of abdomen and liver - abdominal and liver mri
1635466|NCT01966627|Other|stool sample|stool sample taken to investigate metabolites
1635467|NCT01966627|Other|liver biopsy|liver biopsy to examine for cellular change and steatosis
1635468|NCT01966614|Drug|PRX302|Single intraprostatic bilateral injection at a dose of 0.6 µg/g
1635469|NCT01966614|Other|Placebo|Single intraprostatic bilateral injection of vehicle only
1635470|NCT01966601|Drug|TRV027 Dose #1|TRV027 continuous intravenous infusion Dose #1
1635431|NCT01966835|Behavioral|High intensity aerobic interval training|The intervention consists of a total of 18 moderate-to-high intensity aerobic interval training sessions (20-30 minutes/session) spread over a maximum of eight weeks (2-3 times/week) as shown in Table 1. The training sessions are performed on bicycle ergometers (Kettler) and supervised by physiotherapists. Each session is built up by brief periods of high-intensity aerobic exercise (70-80 %) separated by recovery periods of lower-intensity (40-50%). Each session is introduced by a 5-minute warm-up and ends with a 5-minute cool-down (equivalent to 40-50% watt max). The absolute exercise intensity/workload (watt) is determined individually for each participant based on the watt max test performed at baseline.
1635432|NCT01966822|Drug|Dolutegravir, 50mg every 24 hours|Dolutegravir, 50mg every 24 hours
1635433|NCT01966822|Drug|Protease Inhibitor/ritonavir|Protease Inhibitor/ritonavir
2011953|NCT02306161|Biological|Ganitumab|Given IV
1635435|NCT01966783|Drug|Budesonide 2 mg suppository|per day
1635436|NCT01966783|Drug|Budesonide 4 mg suppository|per day
1635437|NCT01966783|Drug|Mesalazine 1 g suppository|per day
1635438|NCT01966783|Drug|Budesonide 2 mg suppository/Mesalazine 1 g suppository|per day
1635439|NCT01966770|Device|Pair 1 (ocufilcon D / ocufilcon D)|Randomized to contra lateral lens pair 1 (ocufilcon D hydrogel / ocufilcon D hydrogel)
1635440|NCT01966770|Device|Pair 2 (ocufilcon D / enfilcon A)|Randomized to contra lateral lens pair 2 (ocufilcon D hydrogel / enfilcon A silicone)
1635441|NCT01966770|Device|Pair 3 (ocufilcon D / comfilcon A)|Randomized to contra lateral lens pair 3 (ocufilcon D hydrogel / comfilcon A silicone)
1635442|NCT01966770|Device|Pair 4 (methafilcon A / methafilcon A)|Randomized to contra lateral lens pair 4 (methafilcon A hydrogel sphere / methafilcon A hydrogel asphere)
1635443|NCT01966770|Device|Pair 5 (methafilcon A / comfilcon A)|Randomized to contra lateral lens pair 5 (methafilcon A hydrogel / comfilcon A silicone)
1635444|NCT01966770|Device|Pair 6 (omafilcon A / comfilcon A)|Randomized to contra lateral lens pair 6 (omafilcon A hydrogel / comfilcon A silicone)
1635445|NCT01966731|Drug|Hydroxyurea|Hydroxyurea will begin at 15-20 mg/kg PO daily. Six months of treatment will be given at the fixed dose, followed by another six months with dose escalation (2.5-5.0 mg/kg increments every 8 weeks) as tolerated to 20-30 mg/kg/day or MTD. The dose escalation phase will continue through the 12-month evaluation, after which hydroxyurea will continue in maintenance phase until the common treatment termination date. The daily dose will be calculated using available capsule sizes and a goal of 15-20 (17.5 ± 2.5) mg/kg/day based on weight. After 6 months of treatment, hydroxyurea will be titrated according to myelosuppression, and will be increased to 20-30 mg/kg/day or the maximum tolerated dose (MTD). Hydroxyurea dose escalation will occur in 5.0 ± 2.5 mg/kg/day increments.
1635446|NCT01966718|Drug|Repository corticotropin injection|An adrenocorticotropic hormone (ACTH) analogue that stimulates the adrenal cortex to secrete cortisol, corticosterone, aldosterone, and a number of weakly androgenic substances
1635447|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Internet, guided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.
Participants are guided by a therapist. Treatment is delivered via the Internet."
1635448|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Internet, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.
Participants are not guided by a therapist. Treatment is delivered via the Internet."
1635449|NCT01966705|Behavioral|Cognitive Behavior Therapy, exposure and response prevention (Book, unguided)|"This intervention entails different exercises aimed at exposure to health anxiety stimuli.
Participants are not guided by a therapist. Treatment is delivered in book form."
1635450|NCT01966692|Drug|Fluticasone Propionate Formulation 1|Fluticasone Propionate dry powder inhaler Formulation 1
1635451|NCT01966692|Drug|Fluticasone Propionate Formulation 2|Fluticasone Propionate dry powder inhaler Formulation 2
1635452|NCT01966692|Drug|Fluticasone Propionate Formulation 3|Fluticasone Propionate dry powder inhaler Formulation 3
1635453|NCT01966692|Drug|Fluticasone Propionate Formulation 3*|"Fluticasone Propionate dry powder inhaler Formulation 3*
*(The asterisk) A different batch of the formulation 3 is given to the patient to ensure that the study is sufficiently powered to show bioequivalence between two batches of the same formulation."
1635454|NCT01966679|Drug|AZD7325|
1635455|NCT01966679|Drug|Placebo|
1635456|NCT01966666|Drug|TPI-287 2 mg/m2|2 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
1635457|NCT01966666|Drug|TPI-287 6.3 mg/m2|6.3 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
1635458|NCT01966666|Drug|TPI-287 20 mg/m2|20 mg/m2 of TPI-287 diluted with 500mL 0.9% sodium chloride. TPI-287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class.
1635459|NCT01966666|Drug|Placebo|500mL 0.9% sodium chloride.
1635460|NCT01966653|Drug|nitrofurantoin|nitrofurantoin 100 mg po tid for 5 days
1635461|NCT01966653|Drug|fosfomycin|fosfomycin 3g po single dose
1635462|NCT01966640|Biological|Basophil Activation Test|blood sample for Basophil Activation Test
1635463|NCT01966627|Other|ogtt|oral glucose tolerance test
1635464|NCT01966627|Other|genotyping|genotyping to look for risk alleles
1635471|NCT01966601|Drug|TRV027 Dose #2|TRV027 continuous intravenous infusion Dose #2
2011954|NCT02306161|Drug|Ifosfamide|Given IV
2011955|NCT02306161|Other|Laboratory Biomarker Analysis|Correlative studies
2011956|NCT02306161|Other|Pharmacological Study|Correlative studies
2011957|NCT02306161|Radiation|Stereotactic Radiosurgery|Undergo SBRT
2011958|NCT02306161|Procedure|Therapeutic Surgical Procedure|Undergo surgery
2011959|NCT02306161|Drug|Vincristine Sulfate|Given IV
2011960|NCT02304276|Radiation|18F-Fluoride PET-CT|Injection of 18F-Fluoride with target activity 125MBq giving an anticipated radiation exposure of 3mSv CT scanning protocol giving an anticipated radiation exposure of 13mSv
2011961|NCT02304276|Radiation|CT calcium score of aortic valve|CT associated with an anticipated radiation exposure of 3mSv (Cohorts 2 and 3 only)
1635472|NCT01966601|Drug|TRV027 Dose #3|TRV027 continuous intravenous infusion Dose #3
1635473|NCT01966601|Drug|Placebo|Placebo continuous intravenous infusion
1635474|NCT01966588|Other|Blood samples for whole genomic/transcriptomic sequencing|Participants in the Metabolic Arm will receive one blood draw, while participants in the Neutropenia Arm will receive a total of three blood draws: one at baseline, another 3 months later, and one 1 year later, with the possibility of further follow-up.
1635475|NCT01966588|Other|UKU Side Effect Rating Scale|Clinician-rated scale of psychic, neurological, autonomic, and other side effects related to psychotropic drugs; ratings are based on a 10-30 minute interview with each participant.
1635476|NCT01966575|Drug|Progestin|The experimental group will have no progestin prior to ovulation induction with clomiphene citrate, while the comparison group will have progestin medication prior to ovulation induction with clomiphene citrate, as per usual care.
1635477|NCT01966562|Behavioral|WHOLE-BODY VIBRATION TRAINING|The vibration stimulus consisted of uniform vertical oscillations Power Plate® Next Generation (Power Plate North America, Northbrook, IL, USA). Subjects stood on the platform holding an quarter squat positions with the feet shoulder-width apart. Then, they perform ankle extensions with the following work sequence (establishing a rhythm of 100 b.p.m.: 1 b.p.m for the concentric phase; and 5 b.p.m. for the eccentric phase). After the familiarization 2-weeks, subjects trained 3 days per week for 6-months (72 sessions) using a vibrating training program that began with 5 sets and a frequency of 35 Hz per session and increasing by 11 sets and 40 Hz frequency the last month maintaining a series of parameters: vibration amplitude (4 mm) working time (60 s) and recovery time (60 s).
1635478|NCT01966562|Behavioral|MULTICOMPONENT TRAINING|This training combined vertical jumps and high intensity walking. During the first month, small reactive vertical jumps (without knee and ankle flexion) were performed. After the first month, subjects performed drop jumps progressively starting at a height of 5 cm and finishing at 25 cm at the end of the programme (increases of 5 cm each month). Additionally, the sets were increased from 4x10 jumps to 6x10 each week, finishing the last week with 4x10. In this sense, the drop jumps were the same each month but the total load (imposed by height) increased progressively. Regarding the aerobic exercise, the load increased progressively along the 6 months. The intensity ranged between 50-75% of reserve heart rate, the volume ranged between 30-60 min.
1635479|NCT01966549|Drug|CNTO 6785|CNTO 6785 (6 mg/kg) will be administered by intravenous (into a vein) infusion on Weeks 0, 2, 4, 8 and 12. Participants who weigh more than 100 kg will receive a dose of 600 mg of CNTO 6785.
1635480|NCT01966549|Drug|Placebo|Sterile, 5 percent dextrose will be used as the placebo in this study. Placebo will be administered by intravenous infusion on Weeks 0, 2, 4, 8 and 12.
1635481|NCT01966536|Procedure|CD133+ cells transplantation into ovarian artery of one ovary|
1635482|NCT01966523|Behavioral|Intervention|Provider Training: i. on-line education course and ii. algorithms and checklists. The course consists of 4 cases: 2 for urinary tract infection and 2 for lower respiratory tract infections with multiple choice questions and evidence-based feedback. To reinforce provider learning, posters displaying algorithms guiding appropriate antimicrobial initiation for infections will be placed in all nursing home units. Laminated pocket cards with the algorithms will be given to providers. Providers will complete simple checklists for each suspected infection throughout the study. B. Proxy Information: The printed material explains, in a lay fashion: i. the nature of infection in advanced dementia, ii. treatment options, iii. concerns about antimicrobial overuse, and iv. features of appropriate antimicrobial use.
1635483|NCT01966523|Other|Control|
1635484|NCT01966510|Other|Cord Blood Transplantation|
1635485|NCT01966484|Drug|Succinylcholine|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
1635486|NCT01966484|Drug|Mivacurium|Anaesthesia was induced and maintained with propofol(1-2mg/kg and 5mg/kg/h) and remifentanil (1µg/kg and 0,2µ/kg/min). The study arm is immobilized and a dual electrode for peripheral nerve stimulation is placed over the ulnar nerve near the wrist. Neuromuscular monitoring is performed with accelerometry. the patients receive the muscle relaxant according to the study group.
1635487|NCT01966471|Drug|Trastuzumab Emtansine|Trastuzumab emtansine IV infusion (duration 90 minutes) will be administered at 3.6 mg/kg q3w for up to 18 cycles (1 cycle = 21 days).
1635488|NCT01966471|Drug|Trastuzumab|Trastuzumab IV infusion (duration 90 minutes) will be administered at 8 mg/kg loading dose followed by 6 mg/kg IV q3w for up to 18 cycles (1 cycle = 21 days).
1635489|NCT01966471|Drug|Pertuzumab|Pertuzumab infusion (duration 60 minutes) will be administered at 840 mg loading dose followed by 420 mg IV q3w for up to 18 cycles (1 cycle = 21 days).
1635490|NCT01966471|Drug|Paclitaxel|IV infusion of paclitaxel 80 mg/m^2 once weekly may be administered concurrently with trastuzumab in combination with pertuzumab for 12 weeks.
1635491|NCT01966471|Drug|Epirubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using epirubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
1635492|NCT01966471|Drug|Doxorubicin|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using doxorubicin may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
1635493|NCT01966471|Drug|Docetaxel|IV infusion either docetaxel every 3 weeks (q3w) (at 100 milligram per square meter [mg/m^2] for 3 cycles (1 cycle = 21 days); at 75 mg/m2 for 4 cycles; or start at 75 mg/m^2 in the first cycle and escalate to 100 mg/m^2 if no dose limiting toxicity occurs, for a total of 3 cycles at minimum) may be administered concurrently with trastuzumab in combination with pertuzumab.
1635494|NCT01966471|Drug|Cyclophosphamide|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using cyclophosphamide (FEC) may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
1635495|NCT01966471|Drug|5-Fluorouracil|3 to 4 cycles (1 cycle = 21 days) of standard of care anthracycline-based chemotherapy using 5-fluorouracil, may be administered in both Arms 1 and 2 as per discretion of the investigator and local prescribing information/institutional guidelines.
1635601|NCT01965574|Procedure|Trendelenburg position|
1712644|NCT01366573|Other|Placebo|Placebo
1635496|NCT01966458|Device|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
1635497|NCT01966458|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
2011962|NCT02303431|Drug|Edoxaban low dose|Edoxaban low dose
1635499|NCT01966432|Behavioral|Referral to Treatment|Patients receive a referral to treatment for substance abuse, with up to 2 follow-up phone calls. Patients are re-screened at followup visits.
1635500|NCT01966432|Behavioral|Brief Intervention|Patients receive a brief intervention aimed at reducing substance use, and are re-screened at followup visits.
1635501|NCT01966419|Drug|ornithine phenylacetate|dose levels predicated on level of hepatic decompensation
1635502|NCT01966419|Drug|placebo intravenous infusion|visually identical to active experimental
1635503|NCT01966406|Device|Nasogastric tube|
1635504|NCT01966406|Other|No nasogastric tube|
1635505|NCT01966393|Other|60-hours intervention|Interventions will be conducted at the research centre (RC) or at the patient's home based on the patient's preference. If the study takes place at the RC, patients will be admitted at 7:00. If the study takes place at the patient's home, a research team member will be at the patient's home at 7:00. Closed-loop strategy will start at 8:00 on day 1 and end at 20:00 on day 3. During the interventions conducted at the RC, patients will have access to entertainment activities such as movies, video games, board games, foosball, etc. During the interventions conducted at the patient's home, patients will do their usual activities. For interventions conducted at the RC, patients will freely choose their meals from a large choice of prepared frozen meals. For interventions conducted at the patient's home, patients will freely choose their meals. Participants will be encouraged to conduct their usual physical activities whether they conduct the study at the RC or at the patient's home.
1635506|NCT01966380|Device|Leia|
1635507|NCT01966367|Biological|CD34 Stem Cell Selection Therapy|The CliniMacs (PLUS) Reagent System (Miltenyi CliniMacs CD34+ Cell Selection Device) will be used to remove T-cells from the peripheral blood stem cell transplant in order to decrease the risk of acute and chronic graft versus host disease (GVHD).
1635508|NCT01966354|Procedure|Ultrasound-guided Internal jugular venous approach|"The physician will use an ultrasound machine to perform an ultrasound-guided internal jugular venous cannulation: the needle and the vein will be visualized in real time in the ultrasound image to make the cannulation process easier and safer.
In each one of three study arms, however, the ultrasound approach will be different depending on the axis on wich the vein is visualized (longitudinal, transversal or oblique) and the way the needle enters the ultrasound plane (in-plane or out of plane)."
1635509|NCT01966341|Behavioral|CBT/ Hypnotherapy|The CBT program will consist of 7 sessions that will encompass the following skills of Symptom monitoring, Stress Management, Coping Skills, Relaxation training, Problem solving, and Cognitive Restructuring.The hypnotherapy program will be modeled after the North Carolina Standardized Hypnosis Treatment for Irritable Bowel Syndrome
1635510|NCT01966341|Drug|Routine Management|Treatment with use of antispasmodics,laxatives, and/or bulking agents (fiber) +/- antibiotics.
1635511|NCT01966328|Drug|36% Resolvine Intravitreal Injection|36% Resolvine Intravitreal Injection
1635512|NCT01966328|Drug|9% Resolvine Intravitreal Injection|9% Resolvine Intravitreal Injection
1635513|NCT01966302|Drug|BPS-314d-MR|15-150 mcg po BID,
1635514|NCT01966289|Drug|CY|CY is administered intravenously at 200 mg/m2
1635515|NCT01966289|Biological|GVAX|GVAX is administered intradermally at 5E8 colon cancer cells + 5E7 GM-CSF secreting cells
1635516|NCT01966289|Drug|SGI-110|SGI-110 is administered subcutaneously at 60 mg/m2
2011963|NCT02303431|Drug|Edoxaban high dose|Edoxaban high dose
2011964|NCT02301975|Drug|Fluticasone Furoate/Vilanterol 100/25 mcg via ELLIPTA inhaler|FF/Vilanterol 100/25 mcg inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device and 100/25 mcg per actuation.
1635519|NCT01966263|Procedure|LIA of the posterior capsule of the knee|the surgeon infiltrates the posterior capsule of the knee using 100 mL ropivacaine 0.2% with 0.5 mg epinephrine.
1635520|NCT01966263|Procedure|LIA of the anterior capsule of the knee|the surgeon infiltrates the anterior capsule of the knee using 50 mL ropivacaine 0.2% with 0.25 mg epinephrine.
1635521|NCT01966263|Procedure|LIA of the subcutaneous tissue of the knee|the surgeon infiltrates the subcutaneous tissue of the knee using 50 mL ropivacaine 0.2% before wound closure.
1635522|NCT01966263|Procedure|FNB with catheter|pre-operatively the anesthesiologist will ultrasound guided place a catheter close to the femoral nerve using sodium chloride (NaCl 0.9%) (no local anesthetic). During surgery, when the LIA of the posterior capsule is performed, 20 mL ropivacaine 0.2% will be administered through the catheter to create a femoral nerve block (FNB). Postoperatively patients will receive 20 mL ropivacaine 0.2% through the catheter 6 times daily for 24 hours
1635523|NCT01966250|Device|electroacupuncture and usual care|"Electroacupuncture: Using 0.25 mm (diameter) X 0.40 mm (length) sized disposable stainless steel needles, electric stimulation will be applied with an electronic stimulator (ES-160, ITO co. LTD, Japan) 2 times/week × 4 weeks. Stimulation will be applied with the current in biphasic wave form. Acupuncture points are Jia-ji (Ex-B2, L3-L5; bilateral) as necessary points and reasonable points (according to decision of practitioner) as accessory points. Each session lasts 15 minutes.
Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated."
1635524|NCT01966250|Device|Usual care|Usual care: Physical therapy and patient education will be performed 2 times per week for 4 weeks. ICT lasts 15 minutes and Hot or Ice pack lasts 10minutes. Doctors will educate patient physiology, pathology, and epidemiology of low back pain. And also suitable postures and exercises for low back pain will be educated.
1635602|NCT01965561|Device|CRoC|Use of Combat Ready Clamp (CRoC)
1635603|NCT01965561|Device|AAJT|Use of Abdominal Aortic and Junctional Tourniquet (AAJT)
2011965|NCT02301975|Drug|Placebo inhalation powders via ELLIPTA inhaler|Placebo inhalation powders administered once daily via ELLIPTA inhaler. 30 doses per device.
2011966|NCT02301975|Drug|Fluticasone Propionate/Salmeterol 250/50 mcg via ACCUHALER/DISKUS inhaler|FP/Salmeterol 250/50 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250/50 mcg per actuation.
1635525|NCT01966224|Biological|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.
Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for the groups will be to receive one re-vaccination dose."
1635526|NCT01966198|Other|Tilt test|The experiment protocol consists of a sequence of passive postural changes gained with a tilt table, each of them lasting 10 minutes. The sequence consists of: (i) baseline recording in supine position; (ii) tilt at 45 degrees angle; (iii) recovery period in supine position; (iv) tilt at 90 degrees angle and (v) recovery in supine position.
1635527|NCT01966185|Other|Tutor function on|The simulator-integrated tutor function with volumetric green lighting of the intended volume to be drilled.
1635528|NCT01966172|Drug|Ibuprofen|oral ibuprofen 400mg 4 times daily
1635529|NCT01966172|Drug|Gabapentin|Oral Gabapentin 300mg twice daily
1635530|NCT01966172|Drug|Morphine|10 mg morphine orally 4 times daily
1635531|NCT01966172|Drug|Paracetamol|oral paracetamol 1000mg four times daily
1635532|NCT01966159|Device|SYNERGY Investigational Device|percutaneous coronary intervention
1635533|NCT01966159|Device|PE Plus Investigational Device|percutaneous coronary intervention
1635534|NCT01966146|Device|Echography GE Healthcare Vivid E9|Echography GE Healthcare Vivid E9
1635535|NCT01966133|Drug|Ethiodized Oil + Doxorubicin|TACE using doxorubicin-lipiodol mixture
1635536|NCT01966120|Drug|BF-200 ALA gel|BF-200 ALA was applied over 1-2 fields of approximately 20 cm² in total, allowed to dry for approximately 10 minutes, and covered with occlusive tape material for 3 h.
1635537|NCT01966120|Drug|Placebo to BF-200 ALA gel|The reference product was a placebo (a nanoemulsion gel formulation similar to the Investigational Medicinal Product (IMP), but without the active ingredient). The placebo was packaged, assigned to each patient, and administered in the same way as the IMP.
1635538|NCT01966120|Procedure|Photodynamic therapy with BF-RhodoLED|After cleaning the lesions, the entire treatment field(s) were illuminated using the novel narrow spectrum BF-RhodoLED lamp, a red light illumination source (approximately 635 nm) developed by Biofrontera, until a total light dose of 37 J/cm² (per treated field) was achieved.
1635539|NCT01966107|Drug|Aclidinium Bromide|400 μg, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
1635540|NCT01966107|Drug|Placebo|Dose matched placebo, twice per day, oral administration via a multi-dose dry-powder inhaler (DPI)
1635541|NCT01966081|Other|Blood sample|
1635542|NCT01966081|Other|tissue samples from abdominal subcutaneous adipose|
1635543|NCT01966068|Other|MyAsthma Web Portal|Parents will log on to the MyAsthma Web Portal up to three different times over a 6 month period. During each portal visit, parents will be asked to complete a survey which will include questions regarding their views on treatment preferences, goals, asthma control, and medications for their child with asthma.
1635544|NCT01966055|Drug|Solithromycin|
1635545|NCT01966042|Procedure|Local sedation|All subjects enrolled in the study underwent local sedation for bone marrow aspiration.
1635546|NCT01966042|Procedure|Bone Marrow Aspiration|All subjects enrolled in the study underwent bone marrow aspiration after they had been anesthetized from the posterior iliac crest. The sample was aspirated into a series of sterile syringes and brought to the cell processing room/laboratory. The processing was in accordance to the Standard Operating Procedure developed observing Good Practice Guidelines.
1635547|NCT01966042|Procedure|Minithoracotomy|The surgical procedure used as cardiac access route was the left anterolateral thoracotomy or left anterior minithoracotomy, depending on the segment of the left ventricle to be treated, allowing the good access to the viable myocardial areas.
1635548|NCT01966042|Biological|Autologous bone marrow mononuclear cells infusion|Once the subject had his or her chest opened and the coronary anatomy reviewed by examination of the pre-operatory nuclear scan to define the area of ischemia, the surgeon drew up the cells into a series of syringes and injected the entire contents of the cell preparation in a series of injections directly into the myocardium.
1635549|NCT01966029|Drug|BMN 110|All pateints receive treatment with BMN 110
1635550|NCT01966016|Procedure|Pacing|"In this study we intend to include patients that have indication to and are intended to undergo CRT implantation with an additional electrode on LV, that have inclusion criteria and have signed an informed consent.
In this study we will include 20 patients for each study arm (overall 100)- each patient will have both treatment configurations and these two will be compared"
2011967|NCT02301975|Drug|Placebo inhalation powder via ACCUHALER/DISKUS inhaler|Placebo inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device.
1635555|NCT01965990|Other|NEP|A homemade very low-calorie protein-based formula by enteral route (8-French nasogastric tube) for 14 days. The administration was continuous (h-24) by a feeding pump. The formula was made up of a fixed amount of aminoacids and a variable amount of high-quality proteins: 1.2 g/kg (ideal body weight). Other components were: pro-lipolytic substances (coenzyme Q10 and L-carnitine), linseed oil, policosanol, fructo-oligo saccharides, potassium, sodium and magnesium chloride. The intervention included also the daily oral administration of a multivitamin-multimineral supplement, alkalizing substances (calcium carbonate, 1500 mg; magnesium carbonate, 850 mg; potassium bicarbonate, 500 mg; sodium bicarbonate, 1500 mg; potassium citrate, 500 mg) and herbal remedies. All patients were also prescribed treatment with a proton pump inhibitor and ursodeoxycholic acid. A minimum intake of 2 liters/day of unsweetened fluids was recommended (3 litres in case of a history of kidney stones).
1635556|NCT01965977|Drug|Bortezomib|Bortezomib 1.3mg/m2, on day 1 and 15 SC Repeat every month for 12months
1635557|NCT01965964|Procedure|Questionnaire|
1635558|NCT01965951|Other|Computerized Plasticity-based Adaptive Cognitive Training|Computerized Plasticity-based Adaptive Cognitive Training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, one hour each session.
1635559|NCT01965951|Other|Commercially available computerized training|Commercially available computerized training requiring a total maximum of 39 treatment sessions, 4-5 times weekly, one hour each session.
1635604|NCT01965561|Device|JETT|Use of Junctional Emergency Treatment Tool (JETT)
1715229|NCT00000293|Drug|Nefazodone|
1635560|NCT01965938|Device|RIFL (Rigid and Flexing Laryngoscope)|Patients in the RIFL group will undergo bronchoscopy using the Rigid and Flexing Laryngoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
1635561|NCT01965938|Device|Fiberoptic Bronchoscope|Patients in the control group will undergo bronchoscopy using the flexible fiberoptic bronchoscope. Once the carina is visualized with the bronchoscope, the endotracheal tube will be advanced, and the bronchoscope removed.
1635562|NCT01965925|Drug|Modafinil|Ratio of 2:1 subjects will be in the experimental arm receiving modafinil for 8 weeks.
1635563|NCT01965925|Drug|Placebo|For every randomly assigned 2 subjects receiving active drug, 1 will be randomly assigned to receive placebo for 8 weeks.
1635564|NCT01965912|Drug|Kuvan®|Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
1635565|NCT01965899|Device|Insertable Cardiac Monitor Implant|The Reveal LINQ is a leadless device that is recommended to be implanted in the region of the thorax. Two electrodes on the body of the device continuously monitor the patient's subcutaneous ECG. The device stores ECG recordings from the patient-activated episodes and ECG recordings from automatically detected arrhythmias. Documentation of episode occurrence will be retained.
1635566|NCT01965886|Procedure|Medial approach|Total knee replacement performed through a longitudinal incision medial to the patella
1635567|NCT01965886|Procedure|Keblish approach|Total knee replacement performed through a longitudinal incision lateral to the patella
1635568|NCT01965873|Dietary Supplement|Enteral nutrition|Same as arm description
1635569|NCT01965860|Other|additional curriculum|
1635570|NCT01965847|Behavioral|Medication therapy management|
1635571|NCT01965834|Drug|Fenofibrate|Upon screening, registration and enrollment, all subjects will receive Fenofibrate 160 mg orally daily for at least 2 months and may continue receiving study medication for as long as in the opinion of the investigator there is clinical benefit in doing so. Patients with calculated creatinine clearance < 50 mL/min will receive a reduced dose of 54 mg orally daily.
1635572|NCT01965821|Device|Continuous control of Pcuff followed by manual control|continuous control of tracheal cuff pressure using an electronic device for 24 h followed by manual control of cuff pressure using a manometer
1635573|NCT01965821|Device|Manual control of Pcuff followed by continuous control|24 h of manual control using a manometer followed by 24 h of continuous control using an electronic device
1635574|NCT01965808|Drug|LY2157299|Administered orally
1635575|NCT01965795|Dietary Supplement|Whole Coffee Fruit Concentrate (WCFC)|Neurfactor is a powder dietary supplement patented by Futureceuticals, in which the active ingredient is WCFC. It is hypothesized that the whole fruit of the coffee plant, Coffea arabica, has very unique, important benefits for healthy aging not available from regular coffee, other coffee extracts, green coffee bean extracts, caffeine, or other leading botanicals. NeuroFactor is thought to increase Brain‐Derived Neurotrophic Factor, a protein vital for neuron development, repair and protection and essential for learning, memory, alertness, controlling body weight, and energy metabolism.
1635576|NCT01965795|Dietary Supplement|Nutrim|Nutrim is an oat bran powder Nutrim is hypothesized to bestow a number of benefits such as cardiovascular health, glucose management and healthy digestion. However, improved cognition is not one of the hypothesized benefits. This product is free of caffeine and stimulants.
1635578|NCT01965769|Other|No gastric residual evaluation|Infants will not receive routine gastric residual evaluation prior to feeding.
1635579|NCT01965756|Drug|Metformin|
1635580|NCT01965756|Drug|Placebos|
1635581|NCT01965743|Behavioral|Contraception Information Packet|The intervention will consist of brief education about IUC and development of interpersonal skills, including how to initiate conversations about reproductive health issues in social settings and debunking common IUC myths
1635582|NCT01965730|Drug|epsilon-aminocaproic acid (EACA)|
1635585|NCT01965691|Dietary Supplement|Protein intake|"Oral consumption of eight hourly experimental meals-
4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavored liquid, protein free cookies and corn oil
4 isotopically labeled experimental meals."
1635586|NCT01965678|Other|Osteopathic Manipulative Treatment|
1635587|NCT01965665|Device|MediHoney HCS dressing|
1635588|NCT01965652|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
1635589|NCT01965652|Drug|Placebo|Placebo tablet taken orally once a day
1635590|NCT01965639|Other|Extension of Care|Clinical care will be delivered by a multidisciplinary team including (but not limited to) a physician, nurse practitioner, dietitian, pharmacist, licensed clinical social worker (LCSW), case manager, health educator and a community health worker in community settings including home visits and community based clinics.
1635591|NCT01965626|Drug|Oseltamivir|Oseltamivir 150 mg twice per day, 7 consecutive days
1635592|NCT01965626|Drug|Dexamethasone|Dexamethasone 40 mg per day, 4 consecutive days
1635593|NCT01965613|Biological|Xilonix|IV
1635594|NCT01965600|Drug|PF-06282999|Tablet, 125 mg, TID, 3 days, 1 of 2 periods
1635595|NCT01965600|Drug|Placebo|Tablet, 0 mg, TID, 3 days, 1 of 2 periods
1635596|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
1635597|NCT01965600|Drug|PF-06282999|Tablet, 500 mg, BID, 3 days, 1 of 2 periods
1635598|NCT01965600|Drug|Placebo|Tablet, 0 mg, BID, 3 days, 1 of 2 periods
1635599|NCT01965600|Other|LPS|IV bolus, 4 ng/kg, 1 day, QD, 2 of 2 periods
1635600|NCT01965587|Procedure|novasure mirena IUS combined|novasure mirena IUS combined
1635606|NCT01965548|Procedure|Treatment of splenic injury|"There are four possible treatments of splenic injury in this study:
splenectomy
splenic artery embolisation
non-operative management
any combination of the three treatments mentioned"
1635607|NCT01965535|Drug|LDV/SOF|LDV/SOF (90/400 mg) FDC tablet administered orally once daily
1635608|NCT01965535|Drug|RBV|RBV (200 mg tablets) administered orally in a divided daily dose based on weight (1000 mg per day for participants weighing < 75 kg; 1200 mg per day for participants weighing ≥ 75 kg)
1635609|NCT01965535|Drug|Placebo to match LDV/SOF|Placebo to match LDV/SOF administered orally once daily
1635610|NCT01965535|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
1635611|NCT01965522|Drug|Melatonin|Melatonin 20mg taken orally once daily. This is in the form of one capsule which contains two pills of melatonin, 10 mg each.
1635612|NCT01965522|Drug|Vitamin D|Vitamin D 2000 IU taken orally once daily. This is in the form of one capsule which contains two pills of vitamin D, 1000 IU each.
1635613|NCT01965522|Drug|Placebo (melatonin)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains melatonin tablets.
1635614|NCT01965522|Drug|Placebo (vitamin D)|Overencapsulated placebo capsule which contains an inert substance. The capsule appears identical to the capsule which contains vitamin D tablets.
1635615|NCT01965509|Drug|PEX168 or placebo|injection has to administered subcutaneously weekly
1635616|NCT01965496|Drug|PEX168|A injection administered subcutaneously
1635617|NCT01965483|Radiation|once-weekly breast irradiation|
1635618|NCT01965470|Other|Combination Prevention|
1635619|NCT01965470|Other|Enhanced Care|
1635620|NCT01965431|Drug|BI 207127|Medium dose oral administration
1635621|NCT01965431|Drug|BI 207127 placebo|
1635622|NCT01965431|Drug|Faldaprevir placebo|
1635623|NCT01965431|Drug|Faldaprevir|Medium dose oral administration
1635624|NCT01965431|Drug|Moxifloxacin (Avalox®)|
1635625|NCT01965418|Drug|Fufang Biejia Ruangan Tablet|
1635626|NCT01965418|Drug|Placebo|
2011968|NCT02301975|Drug|Fluticasone Propionate 250 mcg via ACCUHALER/DISKUS inhaler|FP 250 mcg inhalation powder administered twice daily via ACCUHALER/DISKUS inhaler. 60 doses per device and 250 mcg per actuation.
2011969|NCT02299414|Drug|Anti-hypertensive therapy|1st line anti-hypertensive (Labetalol or Nifedipine ER) started; escalate to maximum dose and a preferred 2nd line medication if needed (nifedipine ER or Labetalol)
2011970|NCT02299414|Other|No anti-hypertensive therapy (unless BP is severe)|Treatment will not be started if blood pressure remains <160/105; for blood pressure ≥160/105, treatment with labetalol or Nifedipine ER will be initiated and maintained at lowest dose needed to keep blood pressure under 160/105.
2011971|NCT02299440|Other|Baseline evaluation|Before perfusions begin, each patient will have a baseline evaluation including the following: the Columbia Suicide Severity Rating Scale (CSSRS), the Beck Scale for Suicide Ideation (BSSI), a physical pain VAS (visual analog scale), a mental pain VAS, the Clinical Global Impressions Scale (CGI-S), Beck's Hopeless scale (BHS), the Inventory of Depressive Symptomatology for the Clinician (IDS-C30), the Patient Rated Inventory of Side Effects (PRISE), the Young Mania Rating Scale (YMRS) and the Brief Psychiatric Rating Scale (BPRS).
2011972|NCT02299440|Drug|1st perfusion of ketamine|A 1st perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 0)
1635634|NCT01965392|Other|Health education intervention|'Health education intervention'
1635635|NCT01965379|Other|Restriction on food containing phosphorus additives|The substitution of foods containing phosphorus additives for others with the same nutritional value for each individual of the study.
1635636|NCT01965379|Other|Standard care|The control group mantained the usual renal diet oriented prior to the study with a booklet.
1635637|NCT01965366|Behavioral|Virtual reality exposure therapy|Virtual reality exposure (VRE) therapy is a form of exposure therapy in which participants are helped to confront their traumatic memories in a therapeutic manner. They describe the events out loud and their therapist attempts to match what they are describing in the virtual reality. This is done repeatedly, allowing distress associated with these memories to decrease. Material that emerges during the VRE exposure is processed, or discussed, after the exposure, allowing participants to think about themselves and the event differently.
1635638|NCT01965366|Drug|0.5 mg DEX|A dose of DEX will be given the night before (approximately 10 hours before) each of 5 to 11 individual virtual reality exposure (VRE) therapy sessions.
1635639|NCT01965353|Drug|Panobinostat|- Panobinostat - single oral dose on days 1, 3, 5, 8, 10 and 12 and followed by a 9-day rest period.
1635640|NCT01965353|Drug|Dexamethasone|Dexamethasone - oral dose on Days 1, 2, 4, 5, 8, 9, 11 and 12 followed by a 9-day rest period
1635641|NCT01965353|Drug|Lenalidomide|Lenalidomide - daily oral dose on Days 1-14 followed by 7-day rest period
1635642|NCT01965353|Drug|Bortezomib|Bortezomib - subcutaneous injection, on Days 1, 4, 8, and 11 followed by a 10-day rest period. At least 72 hours should elapse between bortezomib doses, but if needed an interval of 70 hours is permitted
1635643|NCT01965340|Other|Systematic Therapeutic Drug Monitoring for the intervention group|
1635644|NCT01965327|Drug|Interferon Gamma-1b|"Subjects will begin by taking 10 mcg/m2 of IFN-g-1b for the first two weeks of the study. Dose will be escalated to 25 mcg/m2 of IFN-g-1b for weeks three and four of the study. Finally, the dose will be escalated to 50 mcg/m2 of IFN-g-1b for the last eight weeks of the study, which is the current dose approved by the FDA for children.
All doses will be administered via subcutaneous injection."
1635688|NCT01964963|Drug|Alogliptin|Alogliptin tablets
1635689|NCT01964937|Biological|DNA-HIV-PT123|The DNA-HIV-PT123 (containing clade C ZM96 gag and gp140 along with CN54 pol-nef) will be administered at a dose of 4 mg IM.
1635690|NCT01964937|Biological|NYVAC-HIV-PT1|The NYVAC-HIV-PT1 vaccine (containing clade C ZM96 gp140) will be administered at a dose of greater than or equal to 5×10^6 plaque-forming units (PFU)IM, for a planned maximum dose of 1.2×10^8 PFU.
1635733|NCT01964755|Drug|Methotrexate|Methotrexate administered starting on Day 2, per study protocol.
1715230|NCT00000294|Drug|Carvedilol|
1635645|NCT01965314|Other|Simulation based training|In addition to traditional training (as delivered to participants in the Traditional Training Group), participants in the Simulation Training Group will receive the following:- Following initial familiarization with the simulator SG participants will identify relevant structures and follow their course in the virtual arm. They will insert a virtual needle into the virtual environment and advance it using an in-plane technique towards various target structures. They will be given immediate directed computer generated feedback and offered the opportunity for repetitive, deliberate practice. The simulator, which SG participants will use, will comprise of a PHANTOM Desktop (http://www.sensable.com/), an haptic immersive workbench and the H3D API (http://www.sensegraphics.se/). The SG subject will scan and perform procedure specific tasks on a virtual arm. Training will continue until they reach proficiency levels set by experts using the same device
1635646|NCT01965314|Other|Traditional training|Subjects will be offered standardized multimodal training. This will be comprised of demonstration by suitably trained individuals of relevant anatomy using pre-existing cadaveric samples, performing ultrasound scans of the relevant areas on volunteers under expert supervision, and the practice of needle insertion under ultrasound-guidance using commonly used tissue phantoms (turkey breasts).
1635647|NCT01965301|Drug|BP1.5375 suspension|single oral dose
1635648|NCT01965301|Drug|Diphenhydramine|single oral dose of Diphenhydramine 50mg
1635649|NCT01965301|Drug|Placebo|Single oral dose
1635650|NCT01965288|Device|comfilcon A|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
1635651|NCT01965288|Device|lotrafilcon B|test lens Pair(comfilcon A) or the control lens Pair(lotrafilcon B)
1635652|NCT01965275|Drug|Erlotinib or Gefitinib|Patients received the treatment with high-dose, pulsatile Erlotinib(600 mg every 4 days) or Gefitinib (1000 mg every 4 days) until disease progression or unacceptable toxicity occurred. The overall study period takes about 12 months
1635653|NCT01965262|Device|Hema-copolymer Lens|contact lens
1635654|NCT01965262|Device|etafilcon A Lens|contact lens
1635655|NCT01965249|Device|Long stitch|AWC with the long stitch technique using MonoMax USP 1, 150 cm loop, HRT48mm
1635656|NCT01965249|Device|Short Stitch|Short stitch suture technique using MonoMax USP 2/0, 150 cm, HR26 mm
1635657|NCT01965236|Dietary Supplement|sodium chloride|Patients are given 5 pills (1 g per pill) of sodium chloride per day for 6 weeks. After a one-week wash out period, a second period of 6 weeks is started with 5 placebo (microcrystalline cellulose) pills per day.
1635658|NCT01965236|Dietary Supplement|Placebo|
1635659|NCT01965223|Radiation|Multi-fraction SABR|Multi-fraction SABR; 48Gy delivered in 4 fractions, delivered over 2 weeks, with each fraction delivered 48 hours apart.
1635660|NCT01965223|Radiation|Single Fraction SABR|Single fraction SABR; 28Gy delivered in 1 fraction
1635661|NCT01965210|Other|Rye + high dose inulin + low dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
1635662|NCT01965210|Other|Rye + equal doses of inulin & gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
1635663|NCT01965210|Other|Rye + low dose inulin + high dose gluten|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
1635664|NCT01965210|Other|Large non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
1635665|NCT01965210|Other|Small non-supplemented rye|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
1635666|NCT01965210|Other|Refined wheat bread|In a randomized cross-over design each subject receive one of six iso-caloric breakfasts on six different occasions, separated by 1 w wash-out.
2011973|NCT02299440|Drug|1st perfusion of saline|A 1st perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 0)
2011974|NCT02299440|Other|Follow-up between perfusions|Patients will be re-evaluated with a selection of questionnaires at 40 minutes, 120 minutes, 4 hours, and 24 hours after the end of the first perfusion, and then again at 48 hours after the end of the first perfusion and right before the second perfusion and then again Day 3, Day 4, Week 2, Week 4 and Week 6.
1635669|NCT01965158|Drug|Naldemedine|Naldemedine 0.2 mg tablet taken orally once a day
1635670|NCT01965158|Drug|Placebo|Placebo tablet taken orally once a day
1635673|NCT01965132|Drug|Biologic DMARD|
1635675|NCT01965106|Drug|QPI-1007 Injection|1.5 mg QPI-1007 Injection
1635676|NCT01965106|Drug|(including placebo)|Sham injection procedure
1635677|NCT01965093|Procedure|perioperative desaturation|children aged 0-5 years old who receive general anesthesia and developed perioperative desaturation
1635678|NCT01965093|Procedure|no perioperative desaturation|children aged 0-5 years who did not developed perioperative desaturation under general anesthesia
1635679|NCT01965080|Drug|Exemestane|One tablet Exemestane 25 mg daily
1635680|NCT01965067|Drug|sugammadex|"sugammadex 4.0 mg/kg is administered in deep block state(1 - 2 PTCs) in different temperature state
Reversal effect of sugammadex in temperature state"
1635681|NCT01965054|Dietary Supplement|Fish Oil Supplement Group|1 liquid gel pill (440mg omega-3 fatty acids from fish oil) taken daily, enrollment to delivery
1635682|NCT01965041|Drug|aflibercept|2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
1635683|NCT01965028|Device|Transcranial random noise stimulation (tRNS)|High frequency tRNS (Neuroconn, Eldith DC-Stimulator Plus): 100-650Hz, 2mA, 20min, 10s ramp time, left and right auditory cortex, 5x7cm electrode with the inferior middle part over T3/T4 Arms: tRNS
1635684|NCT01965015|Device|Implantation of the V-Wave inter-atrial shunt|Percutaneous implantation of the V-Wave shunt by right heart catheterization (RHC) approach
1635685|NCT01965002|Device|ExAblate Magnetic Resonance Imaging Guided High Intensity Focused Ultrasound (MRgHIFU)|
1715472|NCT00000456|Drug|naltrexone (Revia)|
1635691|NCT01964937|Biological|NYVAC-HIV-PT4|The NYVAC-HIV-PT4 vaccine (containing ZM96 gag-CN54 pol-nef) will be administered at a dose of greater than or equal to 5×10^6 PFU IM, for a planned maximum dose of 1.1×10^7 PFU.
1635692|NCT01964937|Biological|AIDSVAX B/E®|The AIDSVAX B/E ® vaccine will be administered as a 1 mL/600 mcg dose IM.
1635693|NCT01964937|Biological|Placebo vaccine|The placebo vaccine contains sodium chloride for injection USP, 0.9% and will be administered as a 1 mL injection IM.
1635694|NCT01964924|Drug|Akt Inhibitor GSK2141795|Given PO
1635695|NCT01964924|Other|Laboratory Biomarker Analysis|Correlative studies
1635696|NCT01964924|Drug|Trametinib|Given PO
1635697|NCT01964911|Drug|Ropivacaïne|"The first 3 days, analgesic treatments will be provided, as usual, depending on pain intensity (EN <3/10 : non opioids, EN 3-5/10 : weak opioids, EN>5/10 : strong opioids).
If NRS is still over 5/10, continuous nerve block will be proposed. Patients will receive ropivacaïne, 5 mL/h during 7 days, with possibility of one bolus before wound care, through a stimulating catheter stimulong sono®.
In association, analgesic treatments will be provided, as usual, depending on pain intensity (as during the first 3 days)."
1635698|NCT01964898|Behavioral|Behavioral Activation (BA)|5 to 9 Behavioral Activation (BA) counseling sessions focused on cessation and mood management. BA sessions will occur over the 12 weeks after hospital discharge.
1635699|NCT01964898|Behavioral|Standard Smoking Cessation Counseling|1 hour of in hospital counseling based on clinical guidelines
1635700|NCT01964898|Drug|Nicotine patch|An 8 week supply of the nicotine patch will be provided if the patient is cleared by their MD.
1635701|NCT01964898|Other|Printed Self-help materials for Smoking Cessation|
1635702|NCT01964885|Dietary Supplement|IQP-AS-105|
1635703|NCT01964885|Dietary Supplement|Placebo|
1635704|NCT01964872|Drug|JNJ-38877618: Part 1a|Single ascending dose administered orally in liquid formulation (Formulation A). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
1635705|NCT01964872|Drug|JNJ-38877618: Part 1b|Single dose administered orally in capsule formulation (Formulation B). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
1635706|NCT01964872|Drug|JNJ-38877618: Part 1c (optional)|Single dose administered orally in an alternative capsule formulation (Formulation C). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
1635707|NCT01964872|Drug|JNJ-38877618: Part 2|Single ascending dose administered orally in the formulation selected based on Parts 1a, 1b, and 1c (if applicable). The planned dose range for Parts 1 and 2 will be 6 to 1200 mg.
1635708|NCT01964872|Drug|JNJ-38877618: Part 3|Multiple ascending dose and formulation determined in Part 2 (not to exceed 600 mg) administered orally.
1635709|NCT01964872|Drug|JNJ-38877618: Part 4 (optional)|Single dose and formulation as determined in Part 3 administered orally in older healthy male participant cohort.
1635710|NCT01964872|Drug|Placebo: Parts 1a, 2, 3, and 4 (optional)|Administered orally matched to study drug
1635711|NCT01964859|Biological|autologous skin fibroblasts|
1635712|NCT01964846|Dietary Supplement|Resveratrol, curcumin|
1635713|NCT01964846|Dietary Supplement|Placebo|
1635714|NCT01964833|Procedure|Periodontal treatment|"Periodontal treatment will consist of oral hygiene instructions, with the monitored orientation of brushing technique and recommendation of the daily use of dental floss. Calculus deposits will also be removed using ultrasound equipment with the appropriate tips for periodontics as well as scaling and planing with dental instruments, as recommended by the AAP (2001). Treatment will be carried out in two to four one-hour sessions.
Patient will receive sham PDT."
1635715|NCT01964833|Procedure|Periodontal treatment and PDT|Patients will receive periodontal treatment as previously described and PDT. PDT will be administered at the end of the periodontal treatment session at sites with pocket depths equal to or greater than 4 mm. A diode laser will be used at the 660 nm wavelength, P= 100 mW, 9 J/point, D = 22 J/cm2 (per point). The photosensitizer (BlueMet 0.005 % DMC)will be deposited at the fundus of the periodontal pocket using a syringe. The laser will be applied to the mucosa over the oral epithelium that lines the periodontal pocket using an optical fiber.
1635716|NCT01964820|Behavioral|Positive Affect Skills Training|"Our intervention teaches 8 skills that research suggests lead to increased positive emotions, beginning with basic skills (recognizing and savoring positive events), and progressing to more complex ones such as goal- setting and acts of kindness. Established skills such as reappraising negative thoughts are also taught, in the context of cultivating positive emotions and coping with stress.
The skills are taught over 5 weeks, with one or more new skills introduced each week. A week consists of 1-2 days of didactic material and 5-6 days of real-life skills practice and reporting.
For a full description, see A positive affect intervention for people experiencing health-related stress: development and non-randomized pilot test (Moskowitz et al., 2012)."
1635717|NCT01964807|Other|Cigarette, NIDA test type with 16.6 mg nicotine|Smoke a single cigarette for up to 10 minutes
1635718|NCT01964807|Other|Cigarette, NIDA test type with <0.45 mg nicotine|Smoke a single low-nicotine cigarette for up to 10 minutes
1635719|NCT01964807|Other|Electronic cigarette with 18 mg/ml nicotine|Use electronic cigarette with 18 mg/ml nicotine for 30 minutes
1635720|NCT01964807|Other|Electronic Cigarette with no nicotine|Use electronic cigarette with no nicotine for 30 minutes
1635721|NCT01964807|Other|Moist snuff|Use moist snuff for 30 minutes
1635722|NCT01964807|Other|sham smoking|Sham smoking or e-cigarette use consists of puffing on a drinking straw for 10 minutes
1635723|NCT01964807|Other|Secondhand cigarette smoke (SHS)|180-minute exposure to SHS generated by controlled dilution of smoke from machine-smoked cigarettes
1635724|NCT01964807|Other|Conditioned, filtered air|Exposure to conditioned, filtered air for 180 minutes
1635725|NCT01964807|Other|sham moist snuff|Chew gum for 30 minutes
1635726|NCT01964781|Drug|Tranexamic Acid|Topical administration - does it reduce surgical bleeding?
1635727|NCT01964781|Drug|Bupivacaine|Topical Bupivacaine- does it reduce surgical pain?
1635728|NCT01964781|Drug|Adrenaline|Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
1635729|NCT01964781|Drug|tranexamic acid plus saline|
1635730|NCT01964781|Drug|saline|
1635731|NCT01964768|Other|Skin prick-test|
1635732|NCT01964755|Drug|Doxorubicin|Doxorubicin 20 mg/m2 intravenously will be administered on Day 1 in patients with systemic (non-primary CNS) lymphoma as per institutional guidelines
1635734|NCT01964755|Drug|Leucovorin|Leucovorin administered first intravenously 24 hours after start of Methotrexate infusion, then orally every 6 hours for at least 10 doses, per study protocol.
1635735|NCT01964755|Biological|Hydroxyurea|Hydroxyurea administered orally twice daily starting on Day 2, and continuing for a total of 10 doses, per study protocol
1635736|NCT01964755|Drug|Zidovudine|Zidovudine administered first intravenously on Day 2, and then orally twice daily for 10 doses, per study protocol.
1635737|NCT01964755|Drug|Rituximab|Rituximab is optional and will be administered to study participants, per study protocol.
1635738|NCT01964742|Genetic|blood samples|
1635739|NCT01964729|Device|rTMS|The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.
1635740|NCT01964729|Device|Sham rTMS|Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
1635741|NCT01964716|Biological|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (multidose vial formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
1635742|NCT01964716|Biological|13-valent pneumococcal conjugate vaccine|Subjects will receive three doses (0.5 mL each) of 13-valent pneumococcal conjugate vaccine (single-dose syringe formulation) in the anterolateral thigh muscle of the left leg. Dose 1 is administered between 42 and 70 days of age, dose 2 is administered 28 to 42 days after dose 1, dose 3 is administered 28 to 42 days after dose 2.
1635743|NCT01964703|Drug|Rubus occidentalis extract|
1635744|NCT01964677|Device|Magnetic Resonance Image-guided High Intensity Focused Ultrasound (MR-HIFU)|
1635745|NCT01964664|Behavioral|Mindfulness Meditation Training|6-week, one-on-one meditation training. 90-minute home study visit once per week with research assistant. Learn Mindfulness-Based Cognitive Therapy curriculum and mindfulness techniques, and are asked to practice guided meditations 30-45 minutes each day.
1635746|NCT01964664|Behavioral|Audio Group|Listen to 30-minute podcasts on a daily basis, and discuss podcasts with research assistant at 90-minute weekly home visits. 6 weeks total.
1635747|NCT01964651|Drug|JNJ-42165279 50 mg|JNJ-42165279 50 mg orally administered once daily for 10 days.
1635748|NCT01964651|Drug|JNJ-42165279 100 mg|JNJ-42165279 100 mg orally administered once daily for 10 days.
1635749|NCT01964651|Drug|JNJ-42165279 30 mg|JNJ-42165279 30 mg orally administered once daily for 10 days.
1635750|NCT01964651|Drug|Placebo|Matching placebo orally administered once daily for 10 days.
1635751|NCT01964638|Procedure|Targeted Biopsy|
1635752|NCT01964625|Other|PET-CT Scan|PET-CT scan will be done at baseline (per standard of care), at onset and confirmation of chronic GvHD and after initiation of therapy to assess response.
1635753|NCT01964599|Dietary Supplement|PF-RS|n=20 will consume PF-RS containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
1635754|NCT01964599|Dietary Supplement|PF-RO1|n=20 will consume PF-RO1 containing 30 g potato fiber for 14 days and will consume a control containing no fiber for 14 days.
1635755|NCT01964599|Dietary Supplement|PF-RO2|n=20 will consume PF-RO2 containing 30 g potato fiber for 14 days and then will consume a control containing no fiber for 14 days.
1635756|NCT01964599|Dietary Supplement|Control|
1635757|NCT01964586|Drug|Dexmedetomidine|2 mcg/kg dexmedetomidine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
1635758|NCT01964586|Drug|Lidocaine|10 ml 2% lidocaine was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
1635759|NCT01964586|Drug|Adrenaline|12.5 mcg/ml 10 ml adrenaline was administered 10 minutes before the surgery by infiltration to the both side of the nasal septum.
1635760|NCT01964573|Drug|Rotigotine|"Day 1-3: 2 mg patch once daily
Day 4-6: 4 mg patch once daily"
1635761|NCT01964573|Other|Placebo|"Placebo patches matching with Rotigotine 2 mg patches and 4 mg patches.
Frequency:
Day 1-3: 2 mg patch once daily
Day 4-6: 4 mg patch once daily"
2011975|NCT02299440|Drug|2nd perfusion of ketamine|A 2nd perfusion of ketamine is performed: 0.5 mg/kg diluted in saline, administered over 40 minutes by intravenous (IV) pump and cardiorespiratory monitoring. (Day 2)
1635764|NCT01964547|Drug|Sativex|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
1635765|NCT01964547|Drug|Placebo|Patients self-administered their allocated randomized treatment on an outpatient basis, up to a maximum of 12 sprays to the oral mucosa per day (following an initial titration period).
1635766|NCT01964534|Drug|ABI-007|ABI-007 : 125 mg/m² IV /30min (day 1, day 8, day 15)
1635767|NCT01964534|Drug|Gemcitabine|1000 mg/m² IV /30min (day 1, day 8, day 15)
1635768|NCT01964534|Drug|simplified LV5FU2|Folinic acid: 400 mg/m² IV /2h (day 1, day 15) Bolus 5-FU: 400 mg/m² IV /15min (day 1, day 15) 5-FU infusion: 2400 mg/m² IV /46h (day 1-2, day 15-16)
1635770|NCT01964508|Other|Fine needle aspiration|
1635771|NCT01964495|Drug|Discontinuation of treatment according to CRP levels|The cutoff point is a CRP below 100 mg/L and a reduction to 50% of the initial value.
1635772|NCT01964495|Drug|Discontinuation of treatment according to PCT levels|The cutoff point is a PCT below 0.25 mcg/L or a reduction to 10% of the initial value.
1635773|NCT01964495|Drug|Treatment according to current guidelines|Often a 7 days course of antibiotics, treatment may be extended if the attending physician deems it necessary.
1635774|NCT01964482|Other|Strength training|Strength training followed by intake of a protein drink
1635775|NCT01964469|Behavioral|mobile & web-based action plan|Evidence-based best practice primary care asthma program including asthma self-management education replacing the written self-management action plan with the Breathe mobile health and web-based application
1635776|NCT01964456|Other|Joint perception task|
1635777|NCT01964456|Behavioral|Body Shape Questionnaire|
1635778|NCT01964456|Other|Measure of the heart rate|
1715717|NCT00000727|Drug|Pyrimethamine|
2011976|NCT02299440|Drug|2nd perfusion of saline|A 2nd perfusion of saline is performed: the same volume of saline as in the ketamine arm, administered over 40 minutes by IV pump and cardiorespiratory monitoring. (Day 2)
2011977|NCT02297438|Drug|Palbociclib|Palbociclib, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
2011978|NCT02297438|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
1635782|NCT01964417|Drug|Colonoscopy after bowel cleansing|
1635783|NCT01964404|Drug|Marijuana|
1635784|NCT01964404|Drug|Dronabinol|
1635785|NCT01964404|Drug|Placebo|
1635786|NCT01964391|Drug|Trastuzumab|Trastuzumab will be administered subcutaneously at a fixed dose of 600 mg (irrespective of body weight) every 3 weeks for 1 year (adjuvant or neo-adjuvant plus adjuvant therapy).
1635787|NCT01964391|Drug|Doxorubicin|Doxorubicin will be administered in combination with trastuzumab and cyclophosphamide in the adjuvant setting as per local Product Information and the investigator's discretion.
1635788|NCT01964391|Drug|Cyclophosphamide|Cyclophosphamide will be administered in combination with trastuzumab and doxorubicin in the adjuvant setting as per local Product Information and the investigator's discretion.
1635789|NCT01964391|Drug|Paclitaxel|Paclitaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
1635790|NCT01964391|Drug|Docetaxel|Docetaxel will be administered in combination with trastuzumab in the adjuvant setting as per local Product Information and the investigator's discretion.
1635791|NCT01964391|Drug|Carboplatin|Carboplatin will be administered in combination with trastuzumab and docetaxel in the adjuvant setting as per local Product Information and the investigator's discretion.
1635792|NCT01964391|Drug|Neo-adjuvant chemotherapy|Neo-adjuvant chemotherapy will be administered according to local guidelines in combination with trastuzumab in the neo-adjuvant setting. The study protocol does not mention any specific neo-adjuvant chemotherapy drug names.
1635793|NCT01964378|Drug|Cebranopadol|Participant will take one or two tablet(s) of cebranopadol in the morning and one or two placebo double-dummy morphine-like capsule(s) in the morning and the evening.
1635794|NCT01964378|Drug|Morphine Prolonged Release|Participant will take one or two morphine capsule(s) in the morning and in the evening and one or two placebo double-dummy cebranopadol-like tablet(s) in the morning.
1635795|NCT01964365|Drug|Cresto 20mg|tablet, rosuvastatin 20mg
1635796|NCT01964365|Drug|Fenofibric acid 135mg|capsule, fenofibric acid 135mg
1635797|NCT01964365|Drug|Cresto 20mg, Fenofibric acid 135mg|rosuvastatin 20mg, Fenofibric acid 135mg
1635798|NCT01964352|Drug|tiotropium|fixed dose combination
1635799|NCT01964352|Drug|placebo|
1635800|NCT01964352|Drug|olodaterol|fixed dose combination
1635801|NCT01964352|Drug|tiotropium|fixed dose combination
1635802|NCT01964352|Drug|tiotropium|
1635803|NCT01964352|Drug|olodaterol|fixed dose combination
1635804|NCT01964339|Other|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (venous blood gas and metabolic panel) and data collection from PSG study.|Venous blood gas, basic metabolic panel, PSG variable data collection.
1635805|NCT01964339|Other|BMI greater than or equal to 30kg/m2 scheduled for PSG. Undergo blood draw (arterial blood gas and metabolic panel) and data collection from PSG study.|Arterial blood gas, basic metabolic panel, PSG variable data collection
1635806|NCT01964326|Drug|Atorvastatin calcium 10 mg|Atorvastatin calcium 10 mg tablet to be administered orally every day
1635807|NCT01964300|Biological|peginterferon alfa-2b|Given SC
1635808|NCT01964300|Other|laboratory biomarker analysis|Correlative studies
1635809|NCT01964287|Drug|GEMBRAX|
1635810|NCT01964287|Drug|FOLFIRINOX|
1635811|NCT01964261|Device|Neural Prosthetic System 2 (NPS2)|The NPS2 comprises 2 NeuroPort Arrays (Pt) and 1 NeuroPort Array (SIROF). Each Pt array is comprised of 100 1.5 mm microelectrodes organized on a 4mm x 4mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Of the 100 electrodes, 96 are wire bonded using 25m gold alloy insulated wires sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface. The SIROF Array is similar to the Pt Array, the only difference is a change in the tip of the electrodes from platinum to sputtered iridium oxide film (SIROF).
1635812|NCT01964248|Drug|Placebo|Placebo cream applied 2 hours before blood sample
1635813|NCT01964248|Drug|lidocaïne/prilocaïne 5%|Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
1635814|NCT01964235|Drug|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
1635815|NCT01964235|Drug|Placebo|Placebo will be administered orally and continuously on a twice a day dosing schedule.
1635816|NCT01964222|Behavioral|Decision Aid (DA)|Participants will be shown (on a computer) a targeted, web-based decision aid focused on the topic of clinical trials in addition to usual care.
1635817|NCT01964196|Drug|ASP1517|Oral administration
1635818|NCT01964196|Drug|Placebo|Oral
1635819|NCT01964183|Drug|tolterodine|Oral
1635820|NCT01964183|Drug|mirabegron|Oral
1635821|NCT01964170|Drug|ASP3550|subcutaneous
1635822|NCT01964170|Drug|Goserelin|subcutaneous
1635823|NCT01964157|Drug|LDK378|LDK378 750mg oral administration and continuously (28-day treatment schedule as one treatment cycle)
1635824|NCT01964144|Drug|Dovitinib|Dovitinib 500mg (5 capsules x 100 mg/day) for 5 consecutive days and 2 days rest
1635825|NCT01964131|Drug|D961H sachet 20 mg|"Each subject will be randomised evenly to one of Treatment: A-->B (Sequence 1) or Treatment: B-->A (Sequence 2).
Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
1635909|NCT01963494|Behavioral|Individual planning intervention|Target persons form action plans on their own.
1636320|NCT01960205|Drug|metformin|500mg three times a day for 6 months
2011979|NCT02297438|Drug|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
1635826|NCT01964131|Drug|D961H HPMC capsule 20 mg|"Each subject will be randomised evenly to one of Treatment: A-->B (Sequence 1) or Treatment: B-->A (Sequence 2). Treatment A: D961H sachet 20 mg Treatment B: D961H HPMC capsule 20 mg"
1635827|NCT01964118|Other|Intermittent Fasting group|Intermittent fasting for 12 months
1635828|NCT01964118|Other|control group|usual diet for 6 months and intermittent fasting for other 6 months
1635830|NCT01964092|Behavioral|Individual Placement and Support|
1635831|NCT01964092|Behavioral|Ordinary employment schemes|
1635832|NCT01964079|Drug|Amlodipine|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 5 mg amlodipine, the dose will be titrated up to 10 mg amlodipine. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
1635833|NCT01964079|Drug|Losartan|Eligible subjects will be randomized 1:1 to either an amlodipine or a losartan group by a computer-generated random number table. For patients who fail to respond to 50 mg losartan, the dose will be titrated up to 100 mg losartan. At subsequent visits, additional antihypertensive therapy (hydrochlorothiazide) will be added if systolic (>140 mmHg) or diastolic (>90 mmHg) BP is inadequate. Study drugs are administered once a day for 24 weeks. The dose will be titrated up if SBP is over 90 mmHg or there are no symptoms of hypotension (syncope, loss of consciousness, or orthostatic hypotension). If up-titration is not tolerable, because of side effects or hypotension, the previous dose will be administered as the final tolerable dose.
1635834|NCT01964066|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography balloon dilatation
1635835|NCT01964066|Procedure|Thoracic epidural analgesia|Thoracic epidural analgesia between thoracic vertebrae VII-VIII (Ropivacaine 0.5%-10ml)
1635836|NCT01964066|Procedure|Premedication|For premedication used trimeperidine 2%-1ml intravenously.
1635837|NCT01964053|Behavioral|PATCH intervention|The intervention group will receive usual care and the PATCH intervention. The intervention is comprised of two phases in which the in-hospital discharge education session is followed by 12 weeks of post-discharge education sessions delivered by telephone. The focus of this study is to test the mechanism of the proposed patient activation intervention on HF self-management adherence and associated health outcomes.
1635838|NCT01964053|Behavioral|Usual care|Usual care refers to the standardized discharge written information and scheduled doctor appointments. Standardized discharge instruction, as recommended by CMS and the Joint Commission, includes: activity level, diet, discharge medications, follow-up doctor appointment, weight monitoring, and what to do if symptoms worsen.113 No further follow-ups are routinely done by the hospital and patients are told to see their primary care provider if problems occur.
1635839|NCT01964040|Drug|peri-neural dexmedetomidine as adjuvant to bupivacaine in femoral nerve block|"ultrasound quided femoral nerve block with injection of 15 ml bupivacaine 0.5% perineurally with 0.5 ml dexmedetomidine (50 microgram) either perineurally or subcutaneously.
After adequate assessment of femoral nerve block, patients will be transferred to the operating room to receive a standard general anesthesia"
1635840|NCT01964027|Drug|second line chemoregime for advanced gastric cancer|Irinotecan(Camptosar)150mg /m2 d1,（intravenous infusion of 30-90 minutes) + epirubicin(Pharmorubicin) 50mg/m2 (total dose does not exceed 700mg/m2) every 21days for 1 treatment * 6 cycles as the second line chemoregime for advanced gastric cancer
1635841|NCT01964014|Drug|advagrf|"All enrolled subjects will discontinue the existing Tacrolimus preparations for 6 months from enrollment and be converted to Extended Release Tacrolimus at a biologically equivalent dose. They will also discontinue enteric-coated mycophenolate sdium or mycophenolate sodium and be treated with Sirolimus and observed.
advagrf+sirolimus one time to eat."
1635842|NCT01964001|Dietary Supplement|Vitamin B-6|Vitamin B-6 50 mg/d
1635843|NCT01964001|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 300 mg
1635844|NCT01964001|Dietary Supplement|Vitamin B-6+Coenzyme Q10|Vitamin B-6 (50 mg/d) and Coenzyme Q10 (300 mg/d)
1635845|NCT01964001|Other|Placebo|starch
1635846|NCT01963988|Procedure|Transurethral Coagulation (TUC)|
1635847|NCT01963988|Procedure|Transurethral Resection(TUR)|
1635848|NCT01963962|Drug|Copper IUD|
1635849|NCT01963962|Drug|Levonorgestrel IUD|
1635850|NCT01963936|Device|Supreme LMA|
1635851|NCT01963936|Device|Facial mask|
1635852|NCT01963923|Behavioral|Pulmonary Rehabilitation Program|The pulmonary rehabilitation program includes an endurance training with a cycloergometer, a strength training with elastic bands and two dairy sessions of incentive spirometry with a volume-oriented device.
1635853|NCT01963910|Drug|30% Mannitol in vehicle cream|applied to one half of the upper lip following removal of capsaicin cream.
1635854|NCT01963910|Drug|vehicle cream|application to the other half of the upper lip following capsaicin cream removal
1635855|NCT01963884|Procedure|Tooth Extraction|Tooth from the maxillary anterior area extracted and alveolar socket remains intact
1635856|NCT01963884|Radiation|Cone-Beam technology evaluation|Patient is submitted to a localized cone-beam image before tooth extraction and 6 month later, prior to implant installation.
1635857|NCT01963884|Other|Measure Alveolar Socket Remodeling|In a computer, cone-beam images are superimposed to measure total the amount of ridge dimension
1635858|NCT01963871|Other|Yoga|Twice weekly one hour sessions of Hatha Yoga for 12 weeks
1635859|NCT01963858|Procedure|Functional relaxation|Functional relaxation during colonoscopy
1635860|NCT01963858|Procedure|No relaxation|No relaxation during colonoscopy
1635861|NCT01963845|Drug|Sitagliptin|
1635862|NCT01963845|Drug|Placebo|
1635863|NCT01963832|Drug|Fluoxetine|
1635864|NCT01963832|Drug|Placebo|
1635865|NCT01963832|Procedure|eCMIT|
1635866|NCT01963832|Procedure|Usual Care|
1635867|NCT01963819|Other|Endometrial biopsy|The endometrial biopsy will be done in the luteal phase (cycle day 18-22) prior to the treatment cycle (antagonist)
1636089|NCT01962181|Drug|Ritalin|Patients with ADHD and healthy subjects will be examined under Ritalin or placebo
1635868|NCT01963806|Behavioral|Smartphone-supplemented iCBT|"The Internet-administered cognitive behavioural self-help program (iCBT) will be divided into 10 weekly, progressively available modules covering CBT and Acceptance and Commitment Therapy (ACT) conceptualisations of anxiety disorders, as well as more specific therapeutic techniques such as cognitive restructuring, exposure training, attention and breathing exercises and relapse prevention . Each module also includes writing exercises.
Also included is a tailored smartphone application. Briefly, the application allows the user to access, create and modify a personal database of behaviours and check-off these behaviours immediately when completed. Frequency of carried-out behaviours are recorded and displayed as statistics. The application also allows users to browse and search a database of behaviours uploaded by other study participants, providing both inspiration and a sense of social support."
1635869|NCT01963806|Behavioral|Therapist support|The role of the therapists will be to provide feedback on the written exercises of each treatment module, as well as to provide support and encouragement. As a rule of thumb, the therapists will devote 15 minutes per participant and week.
1635870|NCT01963806|Other|Active waiting list|Completes measurements at day 24 and 48 and at the end of the initial treatment period, otherwise no activity until crossover.
1635871|NCT01963793|Drug|Aprepitant|Aprepitant gel (10 mg/g)
1635872|NCT01963793|Drug|Placebo|gel without active component
1635873|NCT01963780|Device|OCS Lung Preservation|
1635874|NCT01963767|Drug|NT-020|"Recommended intake of NT-020 (NutraStem®) is two (2) capsules daily. This comprises Vitamin D3 (2000 IU), BioVin® (40 mg) and the proprietary blend (900mg). This recommended intake was calculated from doses analyzed in scientific research and based on the dose within the submitted patent.
Scientific description of the ingredients of the product per a 2 capsule dose Vitamin D3 (as cholecalciferol) - 2000 IU BioVin® Grape Extract - 40 mg Proprietary Blend - 900mg Green Tea Extract (Camellia sinensis) Wild Blueberries* (whole fruit) Carnosine VitaBlue® Wild Blueberry Extract*
Vaccinium angustifolium
Other Ingredients:
Magnesium stearate, Cellulose (vegetarian capsules) Contains no yeast, wheat, corn, milk, egg, soy, glutens, artificial colors or flavors, added sugar, starch or preservatives."
1635875|NCT01963767|Dietary Supplement|Placebo|
1635876|NCT01963754|Device|Dental Implants in Posterior Mandible|Place dental implants in posterior mandible, distal from canine, according to manufacturer recommendations
1635877|NCT01963754|Drug|Subperiosteal 1:100.000 Articaine 4% epinephrine|Administration of subperiosteal anesthesia for implant placement
1635878|NCT01963754|Drug|Loco-regional 1:100.000 Articaine 4% epinephrine|Administer loco-regional anesthesia for implant placement in posterior mandible
1635879|NCT01963741|Drug|leukotriene D4|Nasal challenge using 16% ethanol diluent, the concentration of which corresponded to the highest concentration of LTD4, was undertaken for exclusion of subjects hypersensitive to ethanol or saline. The LTD4 challenge could be initiated provided that NAR increase was <30%. Ranges of 4 to 16 mcg.mL-1 LTD4 diluents were applied for a double-fold increment approach at intervals of 6 minutes.
1635880|NCT01963741|Drug|histamine|Nasal challenge using 0.9% saline, was undertaken for exclusion of subjects hypersensitive to saline. The histamine nasal challenge could be initiated provided that NAR increase was <30%. Ranges of 0.4 to 3.2 mg.mL-1 histamine diluents were applied for a double-fold increment approach at intervals of 3 minutes.
2011980|NCT02297438|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
1635883|NCT01963715|Drug|IMGN289|
1635884|NCT01963702|Drug|Docetaxol|
1635885|NCT01963702|Drug|Oxaliplatin|
1635886|NCT01963702|Drug|Capecitabine|
1635887|NCT01963689|Other|Intervention Group 2|Massage with Ylang Ylang Essence was applied for 30 seconds on the handle and the sternum area
1635888|NCT01963689|Other|Intervention Group 1|Massage with Ylang Ylang essential oil in the wrist and in the region of the sternum
1635889|NCT01963689|Other|Intervention Group 3|Put a drop of essential oil of ylang ylang in cotton located within the freshener and inhale throughout their work shift
1635890|NCT01963676|Device|tDCS|
1635891|NCT01963676|Device|Sham stimulation|
1635892|NCT01963663|Drug|Metformin|metformin 1000 mg daily in two divided doses of 500 mg tablets
1635893|NCT01963663|Drug|Pioglitazone|pioglitazone 30 mg daily in two divided doses of 15 mg tablets
1635894|NCT01963637|Device|gastric tomodensitometry with gas at 3 months and 12 months|
1635895|NCT01963624|Device|Ultrasonography|Comparison of B-mode US alone and combined use of elasto-doppler US along with B-mode US.
1635896|NCT01963611|Drug|Plovamer acetate 0.5 milligram (mg)|Plovamer acetate was administered at a dose of 0.5 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
1635897|NCT01963611|Drug|Copaxone 20 mg|Plovamer acetate was administered at a dose of 3 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
1635898|NCT01963611|Drug|Plovamer acetate 3 mg|Plovamer acetate was administered at a dose of 10 mg as weekly subcutaneous injection for 40 weeks up to a maximum of 14 months.
1635899|NCT01963611|Drug|Plovamer acetate 10 mg|Plovamer acetate was administered as two subcutaneous injection of 10 mg weekly for 40 weeks up to a maximum of 14 months.
1635900|NCT01963611|Drug|Plovamer acetate 20 mg|Copaxone was administered at a dose of 20 mg as subcutaneous injection once daily for 40 weeks up to a maximum of 14 months.
1635901|NCT01963598|Drug|REGN1033 (SAR391786)|
1635902|NCT01963598|Drug|placebo|
1635903|NCT01963572|Other|SG will be screened every time when they visit the clinics.|
1635904|NCT01963559|Drug|Lidocaine/prilocaine 1g (topical administration)|Cutaneous blood flow measurement using laser Doppler
1635905|NCT01963546|Other|different types of anesthesia|
1635906|NCT01963546|Drug|Dexmedetomidine|After selecting the appropriate anesthesia method, assess the effect of dexmedetomidine on controlling stress response from diabetics undergoing laparoscopic gastric-bypass surgical.The stress indicators are the same as described above.
1635907|NCT01963507|Behavioral|Resistance training|Resistance training performed three times at week for 16 weeks, in 8 exercises for the main muscles, the protocol of 3 sets of 10 repetitions with intensity of 50% of 1 maximum repetition (MR).
1635908|NCT01963494|Behavioral|Dyadic planning intervention|Dyadic planning refers to creating together with a partner if-then plans on when, where, and how the individual target person will implement a new behaviour.
1635910|NCT01963494|Behavioral|General motivational treatment|Both partners are asked to read a brochure that aims at enhancing their motivation to increase levels of moderate physical activity. They respond to a quiz afterwards.
2011981|NCT02297698|Biological|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5 mg/mL) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. Patients randomized to this arm will receive vaccinations of nelipepimut-S/GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first vaccination will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
1635913|NCT01963468|Behavioral|Early language intervention|Parents will practice the specific set of strategies (visual, interactive, tactile, responsive) during sessions that occur weekly and last 1 hour for a total of 26 sessions, over 6 months. Each session will include four segments: (a) the therapist will review the intervention strategies taught in the workshop (10 min), (b) the therapist will model the intervention strategy with the child (10 min), (c) the parent will practice the strategy with her child with coaching from the therapist across four different routines and activities of the parent's choice (30 min), and (d) the therapist will provide feedback to the parent, summarize the session, and answer the parent's questions (10 min).
1635914|NCT01963455|Biological|paraurethral injection of MDCs|MDCs transplantation by paraurethral injection .
1635915|NCT01963442|Radiation|Chest X-ray|at Day 0, Day 30 and relapse
1635916|NCT01963442|Biological|blood sampling /Cell Counts/ C reactive protein (CRP)/Biochemistry|
1635917|NCT01963442|Drug|Augmentin|2 tablets 3 times a day for 5 days from Day 3
1635918|NCT01963442|Drug|Placebo (for Augmentin)|2 tablets 3 times a day for 5 days from Day 3
1635919|NCT01963442|Drug|Beta-Lactams|administered from Day 0 to Day 3
1635920|NCT01963429|Radiation|Proton beam therapy|
1635921|NCT01963416|Dietary Supplement|macro- and micro-nutrient matched control (240 ml)|
1635922|NCT01963416|Dietary Supplement|Orange juice|
1635923|NCT01963416|Dietary Supplement|whole orange fruit|
1635924|NCT01963416|Dietary Supplement|Processed whole orange|
1635925|NCT01963403|Drug|EE 30mcg/LNG 150mcg|1 pill per day; daily during study participation (up to 84 days)
1635926|NCT01963403|Drug|Placebo|1 pill per day; daily during study participation (up to 84 days)
1635927|NCT01963390|Drug|Testosterone Therapy|In this observational study we will be enrolling testosterone deficient men who intend to undergo testosterone therapy.
1635928|NCT01963377|Device|O2 through nasal cannulae|supplementation of O2 through nasal cannulae during bronchoscopy
1635929|NCT01963377|Device|O2-channel|supplementation of O2 through aspiration channel of bronchoscope during bronchoscopy
1635930|NCT01963364|Dietary Supplement|Inulin challenge|On two study days one week apart, fasted participants will consume 500ml of water, flavoured with lime juice, containing 40g inulin.
1635931|NCT01963364|Dietary Supplement|oligofructose supplement|Starting at the end of study day 1, consumption of 5 grams oligofructose coloured with carmine red food dye(<5%), dissolved in a hot drink, twice daily for 6 1/2 days/ 13 doses. The 14th dose of the week is the inulin challenge consumed as part of study day 1.
1635932|NCT01963338|Device|Intradermal injection in the forearm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device.
1635933|NCT01963338|Device|Intradermal injection in the upper arm (0,1cc NaCl 0,9%)|This injection is conducted by the newly developed device in the upper arm (deltoid region).
1635934|NCT01963338|Drug|Intramuscular injection in the upper arm (0,5cc NaCl 0,9%)|This injection is conducted by needle and syringe in the upper arm (deltoid region).
1635935|NCT01963325|Drug|S-1 plus Abraxane|Patients will receive Abraxane at 100 mg/m2 X 3 doses on Days 1, 8. S-1 chemotherapy was given based on the body surface area, <1.25 m2: 80mg/day, 1.25~1.5 m2: 100mg/day, ≧1.5 m2: 120mg/day. Given orally twice daily for 14 days, followed by 7 days without treatment.
1635936|NCT01963312|Procedure|Transarterial Supraselective Embolization of the prostate|
1635937|NCT01963312|Procedure|Transurethral Resection of the prostate|
1635938|NCT01963299|Drug|5 ml Ropivacaine 10% + physiological saline|
1635939|NCT01963299|Drug|5 ml Ropivacaine 10% + Clonidine 1 µg/kg|
1635940|NCT01963286|Device|ICD with enhanced SVT discriminators|ICD will be programmed to uniform device settings with enhanced SVT discrimintators enabled.
1635941|NCT01963273|Procedure|Video Assisted Ablation of Pilonidal Sinus|
1635942|NCT01963260|Drug|MK-8723|MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
1635943|NCT01963260|Drug|Matching Placebo|Matching placebo to MK-8723 administered as a single IV infusion over approximately 4 hours on Day 1.
1635944|NCT01963221|Radiation|fludeoxyglucose(18f)|
1635945|NCT01963221|Other|blood sample|
1635946|NCT01963221|Other|cardiac and aortic magnetic resonance imaging|
1635947|NCT01963221|Other|carotid femoral pulse wave velocity|
1635948|NCT01963221|Radiation|positron emission tomography|
1635949|NCT01963221|Radiation|computed tomography|
1635952|NCT01963195|Drug|Icotinib|Patients can accept the treatment with Icotinib (250/375/500mg tid) until disease progression or unacceptable toxicities occurred. The overall study period takes about 24 months
1635953|NCT01963182|Drug|Irinotecan|
1636039|NCT01962532|Drug|Part 1: JNJ-42756493|JNJ-42756493 dose escalation starting at dose of 2 mg orally daily for 21-day cycles and 28 day cycles Intermitting dosing regimen (7 days on and 7 days off) up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
1636040|NCT01962532|Drug|Part 2: JNJ-42756493|Recommended Phase 2 JNJ-42756493 dose determined in Part 1 administered orally for 28-days cycles (Intermitting dosing regimen).
1636090|NCT01962181|Drug|Placebo|
1636432|NCT01959490|Other|pharmacogenomic studies|Correlative studies
1635956|NCT01963156|Behavioral|Prescription synchronization|"Each patient's medication that has the greatest quantity of pills on hand after randomization will be defined as the index medication and partial supplies will be provided for all other eligible medications in order to synchronize all of a patient's medication. Prescribers will be contacted for a new prescription to ensure all eligible medications are on the same renewal schedule.
Randomization will occur within strata of whether patients are enrolled in the ReadyFill@Mail program. Once synchronized, patients who are not enrolled in the ReadyFill@Mail program will initiate their own refills. Patients who are enrolled in the ReadyFill@Mail program will have their refills automatically filled, however patients may disenroll from ReadyFill@Mail at any time, in which case they will initiate their own refills. Patients may disenroll in whole or in part from the program at any point."
1635957|NCT01963143|Biological|Gammaplex (5%)|
1635958|NCT01963143|Biological|Gammaplex 10|
1635959|NCT01963117|Radiation|Combined hyperthermia and radiation therapy|
1635960|NCT01963104|Procedure|Automated hearing test|Subjects will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
1635961|NCT01963104|Procedure|Pure-tone Screener test|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
1635962|NCT01963104|Procedure|Digits-in-noise test|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
1635963|NCT01963104|Procedure|No screening test|This group of subjects will not receive a screening test. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
1635964|NCT01963104|Procedure|Automated hearing test/Motivation video|Subjects will take an automated hearing test that presents tones at different pitches and volumes.Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
1635965|NCT01963104|Procedure|Pure-tone Screener/Motivation video|During the test different tones are going to be presented at one volume level. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
1635966|NCT01963104|Procedure|Digits-in-noise test/Motivational video|During the test subjects will hear a pattern of 3 numbers with variable noise in the background and identify the pattern they hear, and receive printed recommendations for hearing healthcare follow-up. They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
1635967|NCT01963104|Procedure|No screening test/Motivational video|This group of subjects will not receive a screening test. They will watch a brief video that shows how hearing works and learn about the different types of hearing loss. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this group will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
1635968|NCT01963104|Procedure|Home Hearing Screening Test|Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care.
1636041|NCT01962519|Dietary Supplement|Early oral feeding|Oral fluids starting on POD 1, followed by a soft diet (thin purée six times a day) on day 2, and regular solid diet thereafter
1636042|NCT01962493|Other|Sodium bicarbonate/ Sodium Fluoride|Toothpaste containing sodium bicarbonate and sodium fluoride as cosmetic
1636043|NCT01962493|Other|Sodium fluoride|Toothpaste containing sodium fluoride as cosmetic
1636044|NCT01962493|Drug|Chlorhexidine digluconate|Mouthwash containing chlorhexidine digluconate
1636091|NCT01962168|Device|Evolution® Biliary Stent - Uncovered|Commercially available device
1636092|NCT01962142|Other|Assessment of activity capacities|
1635969|NCT01963104|Procedure|Home Hearing Screening Test/Brief video|"Subjects will be taught the set-up for a home hearing screening test and will take an automated hearing test that presents tones at different pitches and volumes. Participants will identify whether or not they heard the tone and receive printed recommendations for hearing healthcare follow-up. All subjects will complete the Hearing Handicap Inventory (HHI) questionnaire and the Hearing Beliefs Questionnaire (HBQ). They will also watch a brief video that shows how hearing works and learn about the different types of hearing loss.
Approximately 6-8 months after their initial appointment, subjects in this groups will receive a telephone call and will be asked questions related to their actions and attitudes related to hearing and hearing health care."
1635970|NCT01963091|Drug|oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
1635971|NCT01963091|Drug|saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo at 1:15pm. This dose and timing of administration was selected based on previous studies that have used similar doses of oxytocin (Ditzen, et al., 2009; Heinrichs, et al., 2003). Intranasal oxytocin and matching placebo will be compounded by Pitt Street Pharmacy Custom Compounding (Mt. Pleasant, South Carolina). Randomization will be done by a licensed pharmacist who will keep a record of the blind and be available should unblinding be necessary.
1635972|NCT01963078|Drug|Oxytocin|
1635973|NCT01963078|Drug|Saline|
1635974|NCT01963052|Drug|AGS15E|intravenous (IV) infusion
1635975|NCT01963039|Device|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
1635976|NCT01963039|Procedure|Sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer (PMMA) is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
1635977|NCT01963026|Other|ToCUEST featuring a 'variable practice' approach.|Intervention Variable practice: The ToCUEST (Task-Oriented Client-centred Upper Extremity Skill Training) module [17] will be given to the participants, in which individual goals will be extracted using the COPM (Canadian Occupational Performance Measure). The training program will start with a task analysis and is based on principles of training physiology and motor learning, including variability practice, random practice, distribution based practice, feedback, whole learning. A detailed description of the ToCUEST module is given in Spooren et al. [17]. Intervention B will be called 'ToCUEST variability' in the present project.
1635978|NCT01963026|Other|ToCUEST featuring a 'constant practice' approach.|Intervention Constant practice: In order to evaluate the contribution of the component 'variability practice' in contrast with 'constant practice' the participants will be offered the modified ToCUEST ('ToCUEST constant') module in which the component 'variability practice' is replaced by 'constant practice'.
1635979|NCT01963013|Device|Non-returning catheter valve|
1635980|NCT01963013|Device|Conventional urine bag|
1635981|NCT01962987|Drug|Diclofenac sodium|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
1635982|NCT01962987|Other|Placebo|Topical administration of approximately 0.5g twice daily to the 25 sq cm treatment area for 60 days.
1635983|NCT01962974|Biological|Golimumab 2 mg/kg IV|Study drug (golimumab 2 mg/kg IV) will be administered as an intravenous (IV) infusion at Weeks 0, 4, 12, 20 and 28.
1635984|NCT01962961|Dietary Supplement|PharmaNAC (N-acetylcysteine)|"PharmaNAC is considered a nutritional supplement and can be obtained without a prescription. All participants will be asked to ingest two tablets twice per day during this trial. For those randomized to PharmaNAC 1800 mg twice daily, this will be two active tablets twice per day. For those randomized to PharmaNAC 900 mg twice daily, this will be one active tablet twice per day and one matching placebo tablet twice per day. For those randomized to placebo, this will be two matching placebo tablets twice per day.
PharmaNAC can be taken with or without food. The effervescent tablets should be dissolved in 8 oz. of water or juice prior to oral intake. Each participant will take study drug and/or matching placebo for 8 weeks (up to 60 days)."
1635985|NCT01962961|Dietary Supplement|Matching placebo|Inactive pill that matches PharmaNAC on taste, color, and appearance.
1635986|NCT01962948|Drug|paclitaxel|Given IV
1635987|NCT01962948|Drug|ganetespib|Given IV
1635988|NCT01962948|Other|laboratory biomarker analysis|Correlative studies
1635989|NCT01962935|Drug|AZD4721|Part A - multiple ascending dose, daily; Part B - one dose decided after part A, daily
1635990|NCT01962935|Drug|Placebo|Part A - multiple ascending dose daily
1635991|NCT01962935|Drug|AZD5069|Part B - one dose decided after part A, twice a day
1635992|NCT01962922|Drug|LCP-Tacro|once-daily extended release tablet
1635993|NCT01962922|Drug|Tacrolimus -IR|twice daily capsules
1635994|NCT01962909|Drug|PTP-01|Dose level 1 is 10mCi (50ug of peptide)
1635995|NCT01962896|Drug|Erlotinib|
1635996|NCT01962896|Drug|Sirolimus|
1636045|NCT01962480|Procedure|The hernia gap is sutured intracorporally|The hernia gab is closed with non-absorbable suture (Ethibond Excel 2-0, Ethicon, Johnson & Johnson©) performed by an intracorporally interrupted sutured technique using an Auto Suture© Endo-Slide knot-tying instrument. The stitches are placed with a distance of 0.5 - 1 cm from the fascial edges and with a distance of 0.5-1 cm. between the stitches, performed under a 6-8 mmHg intrabdominal pressure.
1636093|NCT01962129|Biological|Sampling of blood|
1636094|NCT01962116|Drug|Citrate 4%|
1635997|NCT01962883|Other|Osteopathic treatment|"The following treatment protocol is an outline only; structures will be treated only if the dysfunction was present during the evaluation.
Week 1: Venous Sinuses, diaphragms, major cranial compactions, sphenobasilar symphysis normalization and dural release
Week 2 Non-Physiological without respect of axis dysfunction in cranium, spine, pelvis, ankle. Non-physiological with respect of axis dysfunctions in the cranium. Temporal and orbital sutures.
Week 3 Non-Physiological with respect of axis dysfunction lesions within the spine, pelvis and ankle. Visceral tissues: kidneys, liver, spleen, heart. Cerebral hemisphere and lateral ventricles.
Week 4 Physiological dysfunctions within the cranium, spine, pelvis, and ankle. Myofascial restrictions and muscles of the jaw and eye."
1635998|NCT01962870|Drug|Vasopressin|Participants aged 6 to 9.5 years of age will receive the maximum dose of 24 IU (12 IU twice daily). Participants aged 9.6 to 12 years of age will receive the maximum dose of 32 IU (16 IU twice daily).
1635999|NCT01962870|Drug|Placebo|
1636000|NCT01962857|Behavioral|Exercise|4-week supervised high intensity shuttle running intervention, 3 sessions per week (12 sessions in total)
1636001|NCT01962844|Dietary Supplement|Coconut Oil|Patients were followed for 6 months with dietary treatment. Beginning supplementation with coconut oil extra virgin from the third month of intervention nutrition. Coconut oil was consumed neat or added to fruit.
1636002|NCT01962844|Behavioral|Diet|Patients were instructed to follow the dietary treatment for 6 months
1636003|NCT01962831|Drug|Dinoprostone|
1636004|NCT01962831|Device|Single balloon foley catheter|
1636005|NCT01962818|Other|HFOV combined with sigh breaths|"It is planned only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).
All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.
Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
1636006|NCT01962805|Drug|Proellex Formulation A|
1636007|NCT01962805|Drug|Proellex Formulation B|
1636008|NCT01962792|Drug|Ibrutinib|
1636009|NCT01962792|Drug|Carfilzomib|
1636010|NCT01962792|Drug|Dexamethasone|
1636011|NCT01962779|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP). CPAP typically is used for people who have breathing problems, such as sleep apnea.
1636012|NCT01962766|Behavioral|Myofunctionnal therapy|
1636013|NCT01962766|Behavioral|instructions|
1636014|NCT01962753|Drug|18FAV45|Admnistration of 18FAV45 if patient is compliant with one of those treatment: Seroplex, Zoloft, Deroxat, Venlafaxine, Mirtazapine, Moclamine,
1636015|NCT01962740|Device|Drug-eluting stent implantation|
1636016|NCT01962714|Behavioral|Loving-Kindness Meditation|12-week loving-kindness meditation course
1636017|NCT01962714|Behavioral|Cognitive Processing Therapy|12-week CPT course
2011982|NCT02297698|Drug|Trastuzumab|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first trastuzumab infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Trastuzumab will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
1636020|NCT01962675|Device|Transcranial direct current stimulation + step training|Direct current stimulation of motor cortex with low stimulation intensity
1636021|NCT01962675|Behavioral|Sham transcranial direct current stimulation + step training|Stepping over specified soft foam obstacles
1636022|NCT01962662|Other|EMG biofeedback training|EMG biofeedback assisted tibialis anterial force level control
1636023|NCT01962662|Other|U/E exercise|strengthening and stretching
1636024|NCT01962636|Drug|Fludarabine|25 mg/m^2 IV of Fludarabine will be given over 1 hour on days -8, -7, and -6 pre-UCB transplant.
1636025|NCT01962636|Drug|Cyclophosphamide|60 mg/kg IV of Cyclophosphamide will be given over 2 hours on days -7 and -6 pre-UCB transplant.
1636026|NCT01962636|Radiation|Total Body Irradiation|165 cGy of total body irradiation will be given twice a day on days -4, -3, -2, and -1.
1636027|NCT01962636|Drug|Cyclosporine A|Cyclosporine A (CSA) will start day -3 and will be administered PO/IV maintaining a trough level between 200 and 400 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
1636028|NCT01962636|Drug|Mycophenylate mofetil|Mycophenylate mofetil (MMF) 3 gram/day IV/PO for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours beginning day -3.
1636029|NCT01962636|Biological|Umbilical cord blood|Pre-medications and UCB infusion will be per current institutional policies/guidelines. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. If 2 units are used, both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending or designee.
1636030|NCT01962623|Other|IPT-MBD|IPT-MBD is a modified form of Interpersonal Psychotherapy for Depressed Adolescents (IPT-A), which emphasizes building skills in managing relationships, helping with problem solving, and strengthening communication skills.
1636031|NCT01962610|Other|ePCA and Pain keycept intervention|Study designed ePCA and pain keycept interventions are embedded in electronic medical record during patient ED visit.
1636032|NCT01962597|Other|aerobic exercise|
1636033|NCT01962597|Other|resistance training|
1636038|NCT01962545|Drug|OAC alone|Single APT with either aspirin or clopidogrel is discontinued in this arm.
1636095|NCT01962116|Drug|unfractionated heparin|
1636433|NCT01959490|Drug|Bevacizumab|
1636046|NCT01962467|Drug|FF/LEV FDC|Intranasal aqueous microsuspension containing 25.0 microgram (µg) of FF and 50 µg of LEV as a fixed dose combination. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
1636047|NCT01962467|Drug|FF|Intranasal aqueous microsuspension containing 27.5µg of FF. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
1636048|NCT01962467|Drug|LEV|Intranasal aqueous microsuspension containing 50 µg of LEV. It will be administered as two 50 µL sprays per nostril in the morning in a fasted state
1636049|NCT01962454|Drug|Deuterated Water|D2O 70% will be supplied as clear liquid, provided in 50 millilitre (mL) unit dose vials; administered per orally.
1636050|NCT01962454|Drug|Testosterone enanthate|Testosterone enanthate 125mg injection will be supplied as colorless to pale yellow liquid; administered intramuscular (IM).
1636051|NCT01962454|Drug|Placebo to match testosterone enanthate|Placebo to match testosterone enanthate 0.625 mL injection will be supplied as greenish yellow, bright and clear oily liquid; administered intramuscular (IM).
1636052|NCT01962441|Drug|SOF|400 mg tablet administered orally once daily
1636053|NCT01962441|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1636054|NCT01962441|Drug|Peg-IFN|180 µg administered via subcutaneous injection once weekly
1636055|NCT01962428|Drug|ticagrelor|Patients will receive ticagrelor 360mg loading dose or 180mg loading dose , then 90mg bid maintenance dose starting 12 hours after loading dose.
2011983|NCT02297698|Drug|GM-CSF|For patients randomized to the GM-CSF alone arm, they will receive inoculations of GM-CSF (250mcg) administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of trastuzumab infusion. The first injection will be given with the third dose of maintenance trastuzumab administered as monotherapy optimally, but may be given with later maintenance doses of trastuzumab, provided there are at least six remaining doses of trastuzumab to overlap with the primary vaccine series.
2011984|NCT02293954|Procedure|radionuclide imaging|Given copper Cu 64 anti-CEA monoclonal antibody M5A IV
2011985|NCT02293954|Procedure|positron emission tomography|Undergo PET
2011986|NCT02293954|Other|laboratory biomarker analysis|Correlative studies
2011987|NCT02293954|Other|pharmacological study|Correlative studies
1636061|NCT01962402|Drug|lorcaserin|Patients will receive lorcaserin 10mg tablet, 1 tablet twice daily for 12 weeks.
1636062|NCT01962402|Behavioral|Intensive dietary counseling|All patients in the study will receive intensive dietary counseling, encouraging eating minimal carbohydrates and sugars.
1636063|NCT01962389|Device|Winsor Laser Catheter|
1636064|NCT01962376|Drug|Oxaliplatin;Capecitabine|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk.Evaluation for every two cycles.
1636065|NCT01962376|Drug|Oxaliplatin;Capecitabine;Bevacizumab|A cycle:Capecitabine 2000mg/m2 D1-D14 q3wk、Oxaliplatin 130 mg/m2 D1 q3wk add and subtract. Bevacizumab 7.5mg/kg D1 q3wk.Evaluation for every two cycles.
1636066|NCT01962363|Drug|EPI-743|EPI-743 (alpha-tocotrienol quinone) is a small molecule therapeutic that was rationally designed to replete reduced glutathione through NQO1-catalyzed electron transfer from NADPH.
1636067|NCT01962350|Device|Deep Brain Transcranial Magnetic Stimulation|H1-Coil deep brain rTMS at cortex prefrontal.
1636068|NCT01962337|Drug|FPA008|Infusion
1636069|NCT01962337|Drug|Placebo|Infusion
1636070|NCT01962324|Radiation|SIB Dose-Escalation Radiotherapy|
1636071|NCT01962311|Procedure|lumbar puncture|lumbar puncture at enrollment in study
1636072|NCT01962298|Drug|sugammadex 2mg/kg|
1636073|NCT01962298|Drug|neostigmine|
1636074|NCT01962298|Drug|sugammadex 4mg/kg|
1636075|NCT01962298|Drug|placebo|
1636076|NCT01962298|Drug|Single rocuronium dose|
1636077|NCT01962298|Drug|Repeated rocuronium dose|
1636078|NCT01962298|Drug|Continuous rocuronium infusion|
2011988|NCT02293954|Drug|Cu 64 anti-CEA monoclonal antibody M5A IV|Cu 64 anti-CEA monoclonal antibody M5A IV
1636080|NCT01962272|Behavioral|Weekly nutritional counseling|The counseling included assessment of food intake, advice about improvement, motivation and specific food plans, as well as motivation to comply to the recommended dose of Forticare®.
1636081|NCT01962272|Dietary Supplement|Forticare®.|
1636082|NCT01962259|Behavioral|Physical activity|
1636083|NCT01962246|Drug|Oxaliplatin; Capecitabine|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for eight cycles postoperation
1636084|NCT01962246|Other|Oxaliplatin; Capecitabine; concurrent radiotherapy|Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for two cycles preoperation , Capecitabine 2000mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation Radiation: radiotherapy 50 Gy in 25 fractions (2Gy /day, 5 days/week,Monday through Friday, ) Other Name: XRT
1636085|NCT01962233|Biological|mesenchymal stem cells|"Procedure: On the basis of conventional therapy, at the same time, selected patients were given by intravenous infusion of umbilical cord blood stem cells 100-800 million. All patients before treatment, after treatment for 15days, 90days and 180 days were evaluated respectively the curative effect.
Intravenous infusion of umbilical cord derived mesenchymal stem cells"
1636086|NCT01962220|Behavioral|Study Intervention for Retention (APFU)|"Each newly identified HIV-infected pregnant woman randomized to the experimental arm will be assigned an outreach worker/counselor (Mama Mshauri).
Mama Mshauri tasks will include:
Immediately engaging the newly identified pregnant woman, providing individualized adherence and disclosure support, management of ART side effects, and helping the client navigate the health system.
Providing tailored individualized health education during home visits.
Additional intervention components include:
Appointments and Reminders: SMS or telephone reminders 1 week and 3 days before appointments. Reinforcement of importance of follow-up during home visits and every contact.
Patient Tracking and Defaulter Tracing: Monthly visits and immediate calls/home visit if she misses an appointment."
1636088|NCT01962194|Device|Deep Brain Stimulation|"In this study we will use implantable Deep Brain Stimulation (DBS) system with local field potential sensing capability. The Device is the Medtronic, Inc DBS Implantable System, Activa PC+S, which has therapy equivalent to Activa PC, and has a new sensing programmer."
1636097|NCT01962090|Other|Thoracic Spine Thrust in Seated Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
1636098|NCT01962090|Other|Thoracic Spine Thrust in Supine Position|The thoracic spine manipulation used here is a manipulation technique that involves positioning the patient so that a small amplitude quick stretch can be applied to the least mobile area of the thoracic spine as identified by the licensed physical therapist during spinal segmental mobility testing.
1636099|NCT01962077|Procedure|MedCem MTA pulpotomies in primary teeth.|
1636100|NCT01962064|Behavioral|Cognitive assessment|
1636101|NCT01962064|Other|Brain imaging examination MRI|
1636102|NCT01962051|Device|Amplatzer Cardiac Plug|
1636103|NCT01962038|Behavioral|Combined Aerobic and Resistance Exercise|Gym and home based aerobic and resistance exercises
1636104|NCT01962038|Behavioral|Stretching Exercises|Gym and home based stretching exercises
1636105|NCT01962038|Behavioral|Cognitive Training|Group-based cognitive training
1636106|NCT01962025|Procedure|Buttonhole needling technique|the intervention is the type of needling used for home hemodialysis patients. They will be randomized to either buttonhole cannulation or stepladder cannulation
1636107|NCT01962012|Device|AcceleDent Aura|
1636108|NCT01962012|Device|Sham Device|
1636109|NCT01961999|Procedure|Early RRT|"In the early arm renal replacement therapy was started on the basis of refractory oliguria: urine output <0,5ml/Kg/h for > 6 hours"
1636110|NCT01961999|Procedure|Late RRT|"In the late arm at least one the following criteria must be fulfilled prior to initiation of renal replacement therapy:
persistent and refractory oliguria (<0,5ml/Kg/h >12h), despite therapy refractory extravascular fluid overload azotemia >40mmol/L or 240mg/dL metabolic acidosis (pH<7,2) hyperkaliemia (k+>6mmol/L)"
1636111|NCT01961986|Procedure|TSR - traditional subscapularis release|Total Shoulder Replacement surgery performed using the traditional subscapularis release approach.
1636112|NCT01961986|Procedure|TSR - rotator cuff sparing|Total Shoulder Replacement surgery performed using the rotator cuff sparing approach.
1636113|NCT01961973|Procedure|Cultured Chondrocytes|This method has two stages. In the first stage, a knee arthroscopy is done to harvest viable cartilage cells which are then sent to a lab to be cultured for 6 weeks. In the second stage, an arthrotomy is performed. The area of cartilage deficiency is prepared and the cultured cells are transplanted onto it. After discharge from the hospital, the patient is advised partial weight bearing on the operated leg for 6 weeks after the surgery.
1636114|NCT01961973|Procedure|Cultured BMAC|This method also has two major stages. The first stage involves harvesting BMAC from the patient's iliac crest (hip bone), which are then sent to the laboratory for culture for 3 weeks. Simultaneously, an arthroscopy is performed on the affected knee and the area of cartilage deficiency is debrided and microfractured. In the second stage, the cultured BMAC are injected into the affected knee and cells attach themselves to the microfractured area. The patient is then recalled at 4, 5 and 6 weeks from the first stage for an injection of Hyaluronic Acid into the operated knee.
1636115|NCT01961960|Biological|ASP7374|intramuscular
1636116|NCT01961947|Biological|ASP7374|subcutaneous
1636117|NCT01961947|Biological|approved egg-derived TIV|subcutaneous
1636118|NCT01961934|Drug|Sodium Acetate C11 PET/CT Imaging|
1636119|NCT01961921|Drug|ALN-TTR02 (patisiran) administered by intravenous (IV) infusion|
1636120|NCT01961908|Drug|Proellex|
1636121|NCT01961895|Procedure|Continuous lumbar plexus (LP) block analgesia|
1636122|NCT01961895|Drug|Intravenous patient-controlled analgesia|
1636123|NCT01961882|Drug|OCV-501|
1636124|NCT01961882|Drug|Placebo|
1636125|NCT01961869|Other|Fast release BRB confection|Fast release BRB confection includes lyophilized black raspberry powder, corn syrup, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients
1636126|NCT01961869|Other|Intermed release BRBconfect|Intermediate release BRB confection includes lyophilized black raspberry powder, corn syrup, sugar, and pectin. All ingredients are generally regarded as safe (GRAS) food ingredients
1636127|NCT01961869|Other|Prolong release BRB confect|Prolonged release BRB confection includes lyophilized black raspberry powder, corn syrup, corn starch, and sugar. All ingredients are generally regarded as safe (GRAS) food ingredients.
1636128|NCT01961856|Drug|Clopidogrel and Ticagrelor|Clopidogrel 600mg loading dose followed by Ticagrelor 180mg loading dose
1636129|NCT01961856|Drug|Ticagrelor|Ticagrelor 180mg loading dose
1636132|NCT01961830|Drug|ME1100 inhalation solution|
1636133|NCT01961817|Other|Retromolar Vocal Cord Visualisation|For easier insertion of the laryngoscope the head of the patient will be turned to the left site. Thereafter the blade (Miller) will be inserted into the mouth and pushed carefully as far as possible laterally to receive a direct view of the vocal cords. Then the performing anesthesiologist determine the Cormack & Lehane score without and thereafter with a BURP (backward upward rightward pressure) maneuver.
1636134|NCT01961817|Other|Conventional Vocal Cord Visualisation|The head of the patient will be positioned as usual. After 2 minutes oxygen insufflation the laryngoscope will be inserted laterally to push the tongue to the left side in order to release the sight to the vocal cords. Thereafter the anesthesiologist determines the Cormack & Lehane score without and thereafter with performance of the BURP (backward upward rightward pressure) maneuver.
1636135|NCT01961804|Procedure|Reversion|
1636136|NCT01961791|Procedure|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
1636137|NCT01961778|Device|Radio-Frequency Ablation|
1636138|NCT01961778|Device|Cryotherapy|
1636139|NCT01961765|Drug|cabozantinib|
1636285|NCT01960530|Other|Dexamethasone|Challenge agent
1636140|NCT01961752|Drug|Saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using 15 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
1636141|NCT01961752|Drug|Bupivacaine + saline|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10 ml bupivacaine (total 50 mg) and 5 ml saline just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
1636142|NCT01961752|Drug|Bupivacaine + triamcinolone acetonide|All patients undergo endoscopic submucosal dissection. The local injection was performed using a mixture of 10ml bupivacaine (total 50 mg) and 5 ml triamcinolone acetonide (total 50 mg) just before the ESD was finished. It was delivered through the endoscopy suite and injected into the cautery ulcer base in aliquots of 1 mL at equal intervals (1 cm apart). The number of injections per patient was dependent on the size of resection.
1636143|NCT01961739|Drug|2% lidocaine|Topical application, twice per day for 15 consecutive days
1636144|NCT01961739|Drug|placebo|topical application, twice per day for 15 consecutive days
1636145|NCT01961726|Biological|Placebo|Coronary Sinus Delivery
1636146|NCT01961726|Biological|30 mg dose of JVS-100|Coronary Sinus Delivery
1636147|NCT01961726|Biological|45 mg dose of JVS-100|Coronary Sinus Delivery
1636148|NCT01961700|Other|Physiotherapy|Physiotherapy treatment
1636149|NCT01961687|Device|Resorbable Mesh|Phasix Mesh
1636150|NCT01961674|Dietary Supplement|Capsinoid/placebo and rice|The subject will ingest six capsinoid/placebo capsules and a standardized amount of white rice (equivalent to 50g carbohydrates). Each capsule consists 1.5mg of capsinoids, making a total dose of 9mg capsinoids.
1636151|NCT01961661|Dietary Supplement|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)
1 capsule/die for 1 month"
1636152|NCT01961661|Dietary Supplement|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)
1 cps/die for 12 months"
1636153|NCT01961648|Device|Rebreathing bag|
1636154|NCT01961648|Device|Sham rebreathing|
1636155|NCT01961648|Device|Mask|
1636156|NCT01961635|Device|dental implants|place implant according fabricant guidelines, 2mm sub-crestally
1636157|NCT01961635|Device|Zirconia abutments|place zirconia abutment on the day of implant placement
1636158|NCT01961635|Device|Titanium Abutments|place titanium abutment on the day of implant placement
1636159|NCT01961635|Device|cad-cam acrylic abutments|place cad-cam acrylic abutment on the day of implant placement
1636160|NCT01961635|Procedure|Subcrestal|place implant 2mm below crestal bone
1636161|NCT01961635|Device|platform-switch|abutment platform is narrow than implant diameter
1636162|NCT01961635|Procedure|one-time one-abutment|place the final abutment on the day of surgery and not remove it
1636163|NCT01961635|Procedure|Torque 20 n/cm2|the amount of torque applied to the abutment
1636164|NCT01961622|Device|Florence D2A or similar closed loop glucose control system|Subject's glucose level will be controlled by the Florence D2A or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator 2 ® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a smartphone
1636165|NCT01961622|Device|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
1636166|NCT01961609|Biological|Secukinumab 150 mg|Patients will self-administer secukinumab loading dosing with 150 mg secukinumab administered subcutaneously at Day 0 (initiation of study drug), weeks 1, 2, 3 & 4 and then 4-weekly. Following the Primary Endpoint at 16 weeks, patients meeting the NICE criteria of adequate response will be eligible to continue on study treatment for a further 32 weeks at the 150mg dose. Patients not achieving the NICE criteria at the Primary Endpoint at 16 weeks on the 150mg dose should be up titrated to 300mg. Following assessment at week 48 patients meeting the NICE criteria of adequate response will be eligible to continue on study treatment for a further 24 weeks at the 150mg dose. Patients not achieving the NICE criteria at 48 weeks on the 150mg dose should be up titrated to 300mg.
1636167|NCT01961609|Biological|Secukinumab 300 mg|Patients will self-administer 300 mg secukinumab administered subcutaneously at Day 0 (initiation of study drug) and at weeks 1, 2, 3 & 4. And then 300mg secukinumab administered 4-weekly. Following the Primary Endpoint at 16 weeks, patients meeting the NICE criteria of adequate response will be eligible to continue on study treatment for a further 32 weeks. Patients not meeting this NICE criterion will return to routine treatment under the care of their usual Clinical Team. Following assessment at week 48, patients meeting the NICE criteria of adequate response will be eligible to continue on study treatment for a further 24 weeks. Patients not meeting this NICE criterion will return to routine treatment under the care of their usual Clinical Team.
1636168|NCT01961596|Other|Cooling Ice Spray|"A bursts of the Cooling Ice Spray over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test."
1636169|NCT01961596|Other|water|A bursts of the water spray (room temperature over a period of 10 seconds (15 cm distance) will be applied at the dominant foot in before each test.
1636170|NCT01961583|Drug|18F-Fluciclatide|"Baseline 18F-Fluciclatide PET imaging will be obtained before starting of Pazopanib therapy(within 7 days).
Subsequent 18F-Fluciclatide PET should be performed on 7 days after Pazopanib therapy"
1636171|NCT01961544|Drug|Eribulin mesylate|1.4 mg/m2 (as eribulin 1.23 mg/m2) day by 2-5 minutes IV on Day 1 and 8 every 21 days
1636172|NCT01961531|Device|Accuboost APBI|28Gy delivered in 5 daily fractions
2011989|NCT02293681|Drug|Infliximab|This is an observational study. Participants receiving intravenous infusion of infliximab will be observed.
2011990|NCT02293681|Drug|NSAIDs|This is an observational study. Participants receiving aspirin, ibuprofen and naproxen as NSAIDs will be observed.
1636286|NCT01960517|Device|ACS Catheter|
1636434|NCT01959477|Drug|busulfan|Given IV
1636175|NCT01961492|Other|Fecal microbiota transplantation|A single fecal microbiota transplantation through colonoscope
1636176|NCT01961479|Behavioral|Internet-based CBT for patients with PMS|Internet-based cognitive-behavioural self-help treatment
1636177|NCT01961479|Other|Waiting list|During the waiting period, participants receive no treatment.
1636178|NCT01961466|Other|psychological and social self-administered questionnaires|
1636179|NCT01961453|Drug|Isosorbide Mononitrate, sustained release|60 mg if Titration Stage 1 OR 120 mg if Titration Stage 2
1636180|NCT01961453|Drug|Placebo capsule|One capsule of placebo administered once daily at 8 am.
1636181|NCT01961427|Dietary Supplement|sodium nitrate|Ingestion of 3mmol, 6mmol and 12mmol sodium nitrate
1636182|NCT01961427|Dietary Supplement|Beetroot juice|concentrated beetroot juice (dosage 3mmol, 6mmol and 12mmol)
1636183|NCT01961414|Drug|Aflibercept|Patients will receive Aflibercept 2.0mg intravitreal injection at all scheduled study visits
1636184|NCT01961401|Behavioral|exercise|
1636185|NCT01961388|Drug|Bay G5421 Glucobay|Oral, dosage of Acarbose as per the directions of treating physician
1636186|NCT01961388|Drug|Metformin|Oral, dosage of Metformin as per the directions of treating physician
2011991|NCT02293681|Drug|DMARDs|This is an observational study. Participants receiving methotrexate (MTX), sulfasalazine, and thalidomide as DMRADs will be observed.
1636188|NCT01961349|Drug|Intralipid|Treated by Anaesthesiologist. (Intralipid is being used as a placebo for Diprivan.)
1636189|NCT01961349|Drug|ICI35,868 (Diprivan)|Treated by Anaesthesiologist
1636190|NCT01961349|Drug|ICI35,868 (Diprivan) + EES0000645/A (SDS)|Treated by Endoscopist with EES0000645/A(SDS)
1636191|NCT01961336|Drug|Testosterone|10 mg of testosterone gel applied on the external side of the thigh for 21 days starting from the first day of menstruation prior to initiation of ovarian stimulation with rFSH for IVF/ICSI
2011992|NCT02290691|Biological|Influenza Vaccine|Influenza Vaccine
1636193|NCT01961310|Biological|Plasma analysis for bacterial translocation|1 ml of plasma will be obtained (blood sample). DNA will be extracted and amplified, and real-time quantitative PCR (polymerase chain reaction) performed.
1636194|NCT01961310|Biological|Stool analysis|DNA from stool samples will be extracted, amplified, and used to identify the bacteria species present.
2011993|NCT02290340|Drug|MEDI8897|Anti-RSV monoclonal antibody with an extended half-life.
1636196|NCT01961284|Device|Zygomatic implant placement|
1636197|NCT01961284|Device|conventional implants and augmentation of maxilla|
1636198|NCT01961271|Drug|Buprenorphine transdermal patch|Please see Arm Description.
1636199|NCT01961258|Other|Computerized data base analysis and sampling of patients for outpatient clinic evaluation|
1636200|NCT01961245|Device|nocturnal non-invasive ventilation|patients will undergo a non-invasive ventilation during the night
1636201|NCT01961219|Procedure|Manipulation Under Anesthesia|Closed manipulation under anesthesia.
1636202|NCT01961219|Procedure|Arthroscopic capsular release|Arthroscopic capsular release
1636203|NCT01961206|Other|bacteremia caused by ESBL producing E.coli or K.pneumoniae|community-onset bacteremia caused by ESBL producing E.coli or K.pneumoniae
1636204|NCT01961193|Device|contact lens|A bandage contact lens will be inserted by a physician from the ophthalmology department within the first 24 hours of admission of the patient to the ICU. The position of the lens will be confirmed. The lens will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit.
1636205|NCT01961193|Device|punctal plug|A punctal plug will be inserted into each eye. Lubricant drops ethylcellulose) will be instilled four times daily into each eye. The punctal plug will remain in-situ as long as the patient is considered to require artificial lubrication or until discharge from the intensive care unit at which time it will be removed by a physician from the ophthalmology department.
1636206|NCT01961180|Drug|Cipralex|the dosage is crescendo for one week and descending for two weeks with half dosage, to avoid side effects.
1636207|NCT01961180|Drug|Placebo|Placebo
2011994|NCT02290340|Drug|Placebo|Solution containing no active ingredients.
1636209|NCT01961154|Drug|Asthma medication reduction|The asthma medications will be reduced in three steps up to total cessation of asthma drugs or up to asthma exacerbation. First step: Long-acting beta-agonist will be discontinued. The use of inhaled corticosteroids is continued, using the same dosage, preparation, and inhaler as before, for six weeks. Second step: medium to high daily inhaled corticosteroids dose is reduced to low daily dose, for six weeks. Third step: low inhaled corticosteroids dose will be stopped, for six weeks. Before each reduction, saline challenge will be performed.
1636210|NCT01961128|Behavioral|Exercise Intervention|
1636214|NCT01961102|Procedure|hysteroscopy/curettage in case of suspicious aspect will be done a rapid section|
2011995|NCT02288182|Device|Straumann VivOss|Patients will receive Straumann VivOss for sinus augmentation.
1636216|NCT01961076|Other|overnight nutrition regime|Patients receive the specified overnight nutrition regimen
1636217|NCT01961063|Drug|busulfan|Given IV
1636218|NCT01961063|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Given IV
1636219|NCT01961063|Other|pharmacological study|Correlative studies
1636220|NCT01961063|Other|laboratory biomarker analysis|Correlative studies
1636221|NCT01961050|Behavioral|Dual-Focused Brief Physician Intervention (DFBPI)|The DFBPI is incorporated in OB/GYN clinic visit. The intervention consists of two brief (5 to 10 minutes) manualized counseling segments delivered face-to-face by an OB/GYN in the context of two clinic visits.
1636222|NCT01961050|Other|Services as usual|Active Comparator: Standard OB/GYN clinic visits that include OB/GYN services as usual.
1636223|NCT01961037|Other|Tai Chi: Moving for Better Balance|Participants will attend one-hour Tai Chi classes twice weekly for 16 weeks.
2011996|NCT02288182|Device|Geistlich Bio-Oss|Patients will receive Geistlich Bio-Oss for sinus augmentation.
2011997|NCT02288897|Drug|PV-10 (10% rose bengal disodium)|
2011998|NCT02288897|Drug|Dacarbazine, temozolomide or talimogene laherparepvec|
1636224|NCT01960998|Behavioral|Pelvic Floor Muscle Training|Evidence-based pelvic floor muscle training program that has been adapted to telehealth format. Training is begun 2-4 weeks before surgery and continued 2 months after surgery. Content is accessed in daily 10-minute sessions on a secure website
1636225|NCT01960998|Behavioral|Perioperative Care and Wetness Management|Telehealth program that includes include general perioperative care; wetness, odor and skin care management; and outcome measures. The program is begun 1-4 weeks before surgery and continued 2 months after surgery. Content is accessed in 10-minute sessions on a secure website - daily preoperatively and for the first 2 months post-operatively, then weekly until 6 months post-operatively.
1636226|NCT01960985|Other|Physicaltherapy|
1636227|NCT01960972|Other|Salt substitute|A salt substitute using 25% of potassium chloride and 75% of sodium chloride will be implemented in each of the villages.
1636228|NCT01960946|Dietary Supplement|Modified Citrus Pectin (MCP) vs placebo|5 grams by mouth three times a day
1636229|NCT01960933|Procedure|Percutaneous coronary intervention|
1636230|NCT01960933|Procedure|FFR|
1636231|NCT01960920|Other|Filtered diesel exhaust|Mask-filtered exposure to diesel exhaust
1636232|NCT01960920|Other|Unfiltered diesel exhaust|Diesel Exhaust Inhalation
1636233|NCT01960920|Other|Clean air|No pollution and no filter mask
1636234|NCT01960907|Device|CHROMED monitoring system|Optimization of patient's treatment according to the data collected by the home monitoring devices
1636235|NCT01960868|Other|standard physiotherapy|
1636236|NCT01960868|Other|experimental physical therapy|
1636237|NCT01960855|Drug|ABT-494|
1636238|NCT01960855|Drug|Placebo|
1636239|NCT01960842|Drug|Levodopa-carbidopa intestinal gel|Dose levels will be individually optimized. Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
1636240|NCT01960842|Device|CADD-Legacy® 1400 ambulatory infusion pump|
1636241|NCT01960842|Device|PEG tube|percutaneous endoscopic gastrostomy tube
1636242|NCT01960842|Device|J-tube|jejunal tube
1636243|NCT01960829|Drug|Everolimus|
1636244|NCT01960816|Device|Procedure: thermal coagulation of tissue in the nasal airway|The Vivaer Stylus is used to deliver low-power, temperature-controlled, radiofrequency energy to tissues of the nasal airway to cause coagulation of soft tissues and submucosal tissue shrinkage.
1636245|NCT01960803|Radiation|Intraoperative Electron Radiotherapy|Intraoperative Electron Radiotherapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure.
1636246|NCT01960777|Procedure|Onstep|
1636247|NCT01960777|Procedure|Laparoscopic repair|
1636248|NCT01960764|Drug|Pre-Treatment with Dial liquid antibacterial soap|This arm will be pre-treated with Dial liquid antibacterial soap and alcohol prior to the autologous microbiome transplant.
1636249|NCT01960764|Other|Control|
1636250|NCT01960751|Other|neurocognitive tests battery|The two groups (exposed: 0.05 to 1 Gy; unexposed: less than 0.05 Gy) will receive the same neurocognitive tests battery.
1636251|NCT01960738|Other|A pre-dive checklist|The pre-dive checklist included a checklist of tasks to be undertaken before the dive, a dive-plan that asked the diver to plan the depth, and amount of gas kept at different levels of diving, and 4 dive tips.
1636252|NCT01960725|Biological|RV5 (Pentavalent Rotavirus Vaccine)|
1636253|NCT01960712|Device|Transpapillary plastic stent (7-10 Fr)|Duodenoscopy plus transpapillary bile cannulation plus stent insertion.
1636254|NCT01960686|Biological|Low dose RSV F Antigen|
1636255|NCT01960686|Biological|High dose RSV F Antigen|
1636256|NCT01960686|Biological|Dose 1 of Aluminum Adjuvant|
1636257|NCT01960686|Biological|Dose 2 of Aluminum Adjuvant|
1636258|NCT01960686|Biological|Dose 3 of Aluminum Adjuvant|
1636259|NCT01960686|Biological|Dose 4 of Aluminum Adjuvant|
1636260|NCT01960686|Biological|Placebo|
1636261|NCT01960673|Device|LMA proseal|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
1636262|NCT01960673|Device|igel LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region.
1636263|NCT01960673|Device|air Q LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
1636264|NCT01960673|Device|ambu LMA|It would be used to observe the leak pressure at 30,45,60 degree of the head and neck position and the condition between the vocal cord and peri-laryngeal region. The cuff pressure would be kept at 30 cm H20.
1636265|NCT01960660|Dietary Supplement|Omega-3 Fatty Acids|
1636266|NCT01960647|Device|Percutaneous transluminal angioplasty with uncoated balloon|
1636267|NCT01960647|Device|Percutaneous transluminal angioplasty with Paclitaxel balloon|
1636268|NCT01960621|Drug|cyclodextrin|intravenous
1636269|NCT01960608|Other|24_hours_urine_sodium|
1636270|NCT01960595|Procedure|IV fentanyl PCA|
1636271|NCT01960595|Procedure|local bupivacaine infiltration and post-OP IV fentanyl PCA|
1636272|NCT01960595|Procedure|Nerve Blocks and post-OP IV fentanyl PCA|
1636273|NCT01960582|Behavioral|New Practice Strategy|Application of a structured case management strategy on housing adaptation cases
2011999|NCT02286999|Drug|B. infantis|Infants in the intervention group will receive two doses of B. infantis on Day 7 and Day 14 of life, while infants in the placebo group will be dosed with placebo on Day 7 and Day 14
1636276|NCT01960556|Other|Simulation Training|Simulation training provided to one group
1636277|NCT01960543|Drug|fentanyl 15 microg|
1636278|NCT01960543|Drug|Bupivacaine 7 mg|
1636279|NCT01960543|Drug|Bupivacaine 9 mg|
1636280|NCT01960543|Drug|Levobupivacaine 7 mg|
1636281|NCT01960543|Drug|Levobupivacaine 9 mg|
1636282|NCT01960530|Drug|Hydrocortisone granules|Multi-particulate granules
1636283|NCT01960530|Drug|Hydrocortisone Tablet|Standard hydrocortisone tablets
1636284|NCT01960530|Drug|i.v. Hydrocortisone Injection|Standard hydrocortisone solution for intravenous injection
1636287|NCT01960504|Device|Percutaneous Coronary Intervention (DREAMS) stenting|
1636288|NCT01960491|Device|Device Closure of Atrial Septal Defect|"Device Closure of Atrial Septal Defect by Carag Bioresorbable Septal Occluder"
1636289|NCT01960478|Biological|(for each intervention)|
1636290|NCT01960478|Other|Blood test|
1636291|NCT01960465|Device|Continuous positive airway pressure|A portable ventilatory assist device, which is the standard first line treatment of sleep apnea.
1636292|NCT01960452|Behavioral|Serial awakenings|The first study night will be a baseline sleep recording. The second night will consist of a series of awakenings (using auditory tones) and subsequent periods of falling back asleep in order to examine the cortical dynamics of hyperarousal or other dysfunction during these two critical sleep processes in insomnia.
1636293|NCT01960426|Other|Measurement of drug (Adalimumab/Infliximab)|Measurement of drug (adalimumab/infliximab) and ADAs in the presence of drug.
1636294|NCT01960426|Other|Intensify treatment with the existing drug|Intensify treatment with the existing drug and if this fails empirically switch to another TNF antagonist
1636295|NCT01960413|Drug|Montelukast added to Hydroxyurea|
1636296|NCT01960413|Drug|Placebo added to Hydroxyurea|
1636297|NCT01960400|Device|transcranial direct current stimulation (tDCS) (active or placebo)|TDCS was delivered according to the method described by Fregni et al. (2006) and the safety parameters related to tDCS application were respected (DaSilva et al., 2011). Direct current was delivered using a battery-driven constant current stimulator coupled to saline-soaked (0.9% NaCl) sponge electrodes (5 X 7 cm). Anodal stimulation was delivered over the M1; the anode was placed over C3 or C4 position in the 10/20 system for the EEG electrode position, contralateral to the affected limb, and the cathode over the opposite supraorbital area (i.e. ipsilateral to the affected limb). In the laboratory, a constant current of an intensity of 2 mA was applied for 20 min/day X 5 consecutive days during the first and the second weeks of GMI. To help maintain the potential effects of the neurostimulation, the tDCS was also applied simultaneously with GMI once a week during the 2 other phases until the end of the six weeks GMI program, for a total of 14 treatment sessions.
1636298|NCT01960400|Device|Graded motor imagery (GMI)|The treatment was performed using a software (Recognise™ online) provided by NOI group (http://www.noigroup.com/recognise). As an alternative to the software (for patients without an internet access), the patient could do the exercises with a Recognise™ Flash Cards set consists of 25 left and 25 right matching images (upper limb or lower limb). Using standardized procedures, inspired from the randomized controlled trial conducted by Moseley (2004, 2006), the participants performed the therapy at home, 10 minutes per session, 3x/day, 6 days/week, using the computer software and a mirror box (Lagueux et al., 2012).
1636299|NCT01960387|Drug|Clofarabine|Clofarabine will be administered as a 1-hour (range: 1 hour minimum to 2 hours maximum) intravenous infusion at a dose of 40mg/m2 daily on days 1 through 5.
1636300|NCT01960387|Drug|Cytarabine|Cytarabine at a dose of 1g/m2 daily will be given as a 2-hour intravenous infusion, starting 3 hours after the completion of clofarabine administration on days 1 through 5.
1636301|NCT01960374|Drug|Selumetinib|1, 2 or 3 x 25 mg selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) capsule administered orally as a single dose on Day 1 of the study (total dose 25 mg, 50 mg and 75 mg respectively) with 240 ml of water at room temperature.
1636302|NCT01960361|Device|ICE dental implant|ICE- Implant Classical Esthetic implant
1636303|NCT01960348|Drug|patisiran (ALN-TTR02)|administered by intravenous (IV) infusion
1636304|NCT01960348|Drug|Sterile Normal Saline (0.9% NaCl)|administered by intravenous (IV) infusion
1636305|NCT01960335|Dietary Supplement|Whey Protein|Whey protein provided in 20 gram servings administered three times per day. once in the morning upon waking; a second serving in the mid-afternoon; and a third serving within 2 hours of going to sleep at night.
1636306|NCT01960335|Dietary Supplement|Whey Protein and Resistance Exericse|Subjects will receive 20 grams of whey protein three times per day along with 4 days per week of resistance exercise training throughout the 16 week intervention.
1636307|NCT01960335|Other|Whey Protein and RISE exercise routine|Subjects will consume 20 grams of whey protein three times per day (total of 60 grams) and perform a combination of exercise involving functional resistance exercise (R); sprint intervals (I); stretching/pilates/yoga (S); and endurance exercise (E); RISE four days per week.
1636308|NCT01960322|Behavioral|Telemetric|A manualized behavioral management approach focusing on avoidance and addressing barriers to adherence, delivered via telephone or internet chat applications.
1636309|NCT01960309|Other|Minimal invasive cardiac imaging|"Coronary CT angiography (CCTA)
Coronary magnetic resonance imaging (CMR)
Echocardiography"
1636310|NCT01960296|Drug|Clopidogrel|Continue home dose of clopidogrel into surgery
1636311|NCT01960296|Drug|Discontinue Clopidogrel|Discontinue home dose of clopidogrel one week before surgery. Resume after surgery.
1636312|NCT01960283|Drug|Methotrexate (Novatrex ®) + anti-H1|"Methotrexate (Novatrex ®) tablets 2.5 mg methotrexate 0.2 mg/kg/week as a single dose, orally for 8 weeks.
After 8 weeks, if the treatment is still not efficient, the dose will be increased to 0.25 mg/kg/week and continued until W18.
For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and methotrexate will be added in this group."
1636313|NCT01960283|Drug|Placebo + anti-H1|"Placebo: 0.2 mg / kg / week as a single dose, orally for 8 weeks. After eight weeks, if the patient is still very embarrassed, the dose is increased to 0.25 mg / kg / week in a weekly dose.
For anti-H1 treatment, the same molecules with the same dosage than before the recruitment will be continued, and the placebo of methotrexate will be added in this group."
1636314|NCT01960270|Device|Device: INTERSTIM II|A second stimulator is implanted on controlateral site
1636315|NCT01960257|Device|Digital Health Feedback System|This intervention uses an ingestion sensor and a wearable sensor (worn as a patch on the skin), which are new technologies approved by the FDA, to collect information about patients taking their TB medications. The wearable sensor records information, which is uploaded wirelessly to a mobile device and then to a secure computer. Together the sensors and the mobile device transmitting the information to the study computer are called a digital health feedback system (DHFS), which provides information about when patients have taken their TB medications.
1636316|NCT01960257|Other|SOC DOT|
1636317|NCT01960231|Other|OGTT|
1636318|NCT01960205|Drug|Saxagliptin|5mg a day for 6 months
1636319|NCT01960205|Drug|saxagliptin|2.5 mg a day for 6 months
1636321|NCT01960205|Other|lifestyle intervention|lifestyle intervention for 6 months
1636322|NCT01960192|Drug|HD-MTX-Ara-C regimen|high-does metrotrexate 3.5g/m2 d1 ivgtt 6h,cytarabine 1g/m2 bid d2-3.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
1636323|NCT01960192|Drug|FVD regimen|FVD regimen(fotemustine, teniposide and dexamethasone),fotemustine 100mg/m2 d1 ivgtt,teniposide 60mg/m2 d2-4 ivgtt,dexamethasone 40mg d1-5 ivgtt.Continued use to the end of chemotherapy .Every 21 days for one cycle and four cycles are required. Efficacy was evaluated every two cycles
1636324|NCT01960179|Drug|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
1636325|NCT01960166|Behavioral|Active Distraction|iPad will be used as active distraction
1636326|NCT01960166|Behavioral|Passive Distraction|child will watch TV as passive distraction
1636327|NCT01960153|Drug|Tadalafil|Tadalafil tablets, 20 mg to 40 mg per day x 48 weeks
1636328|NCT01960153|Drug|Placebo|Placebo of tadalafil. Subjects will take one tablet once per day and will be titrated to two tablets once per day after one week. Subjects are on study drug for the duration of the trial.
1636329|NCT01960140|Drug|Baricitinib|Administered orally
1636330|NCT01960140|Drug|Simvastatin|Administered orally
1636331|NCT01960127|Behavioral|Aerobic exercise|
1636332|NCT01960114|Drug|Acetaminophen ER|Single dose (2 tablets) Acetaminophen ER 750 mg
1636333|NCT01960114|Drug|Placebo|Single dose (2 tablets) Acetaminophen ER 750 mg matching placebo
1636334|NCT01960101|Other|LactoXeros|
1636335|NCT01960101|Device|Aequasyal|
1636336|NCT01960088|Drug|HPV vaccine|
1636337|NCT01960075|Drug|Fosphenytoin|
1636338|NCT01960075|Drug|Levetiracetam|
1636339|NCT01960075|Drug|Valproic acid|
1636340|NCT01960062|Device|Diabetes software and device|USB cord, CD-rom, and application to allow communication with provider
1636341|NCT01960049|Procedure|ropivacaine + iv PCA|
1636342|NCT01960049|Procedure|saline and IV PCA|
2012000|NCT02286999|Drug|Placebo|
1636345|NCT01960023|Drug|Cetuximab|400 mg/m2 IV loading dose followed by weekly cetuximab 250 mg/m2 IV until disease progression
1636346|NCT01960023|Drug|Neratinib|"Phase I portion of the study:
Dose level 1: 120 mg/day; Dose level 2: 160 mg/day; Dose level 3: 200 mg/day; Dose level 4: 240 mg/day
Phase II portion of the study: The recommended dose determined in the Phase I portion of the study."
1636347|NCT01960010|Drug|MIM-D3 Ophthalmic Solution|1% MIM-D3 dosed BID
1636348|NCT01960010|Drug|Vehicle|Vehicle dosed BID
1636349|NCT01959997|Procedure|Redo PVI|
1636350|NCT01959997|Procedure|PVI + RDN|
1636351|NCT01959984|Other|100g Standard Noodles|Subjects are required to take 100g standard noodles,and then blood samples are collected at 0min,30min,60min,120min,180min.
1636352|NCT01959984|Other|75g Oral Glucose|Subjects are required to take 75g glucose solution,and then blood samples are collected at 0min,30min,60min,120min,180min.
1636353|NCT01959971|Drug|alirocumab|"Pharmaceutical form:Solution for injection
Route of administration: Subcutaneous"
1636354|NCT01959971|Drug|Placebo|"Pharmaceutical form:Solution for injection
Route of administration: Subcutaneous"
1636355|NCT01959958|Other|Questionnaire/Interview|Participants will each complete an interview with questionnaires assessing nocturnal enuresis, health-related quality of life, emotional and behavioral functioning, family functioning, and stressful life events. Participants who report nocturnal enuresis will also be asked to identify interventions they have used in the past, along with barriers to intervention implementation.
1636356|NCT01959945|Biological|Flublok® Quadrivalent Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
1636357|NCT01959945|Biological|Fluarix Quadrivalent® Influenza Virus Vaccine|Intramuscular (Relevant year formulation)
1636358|NCT01959932|Other|Tobacco Heating System (THS 2.2)|THS 2.2 ad libitum for 5 days in confinement
1636359|NCT01959932|Other|Smoking abstinence (SA)|SA for 5 days in confinement
1636360|NCT01959932|Other|Conventional cigarette (CC)|Subject's own preferred brand of CC ad libitum for 5 days in confinement
1636361|NCT01959919|Device|Refacto FusENGO|Dosage will be chosen by PI based on patient condition.
1636362|NCT01959880|Device|The Contour Profile Gel (CPG) breast implants|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement.
The Contour Profile Gel is available in sizes 125cc - 690cc and 4 styles with various projection and height options in this study."
1636363|NCT01959867|Device|SurgiMend® PRS|Subjects enrolled in to this cohort will receive SurgiMend® PRS (ADM) product during the first stage of the reconstruction (expander insertion).
1636364|NCT01959867|Other|No Intervention|Subjects enrolled in to this cohort will not receive an acellular dermal matrix (ADM) product during the first stage of the reconstruction (expander insertion).
1636365|NCT01959854|Device|carboxymethylcellulose|0.25% carboxymethylcellulose preservative free
1636366|NCT01959854|Device|xanthan gum|0.2% xanthan gum preservative free
1636367|NCT01959841|Drug|ASP2151|200 mg once daily or 400 mg once daily
1636368|NCT01959841|Drug|valaciclovir|1000 mg three times daily
1636369|NCT01959828|Drug|IK-3001|
1636370|NCT01959802|Procedure|Vitrectomy|
1636371|NCT01959776|Procedure|Vitrectomy|
1636372|NCT01959763|Behavioral|Weight loss counseling program|Randomized study persons are given either one of the two different methods of weight loss counseling program without ICT or with ICT-based counseling. As a control for the study groups one group is receiving only ICT-based counseling and one group does not receive any of the counseling methods.
1636435|NCT01959477|Drug|etoposide|Given IV
1636373|NCT01959750|Behavioral|problem-based sessions|weekly sessions for small groups of caregivers, led by two psychologists acting as moderators and using a systemic approach, as suggested in other peer-support groups using a problem-based method
1636374|NCT01959737|Procedure|skin-to.skin-contact|Immediately after initial stabilization/ assessment of the VLBW infant, skin-to-skin contact of mother and infant is initiated and kept up for 60 minutes.
1636375|NCT01959724|Other|Vitrectomy|
1636376|NCT01959711|Procedure|Posterior RA|Posterior retroperitoneoscopic adrenalectomy
1636377|NCT01959711|Procedure|Lateral transperitoneal LA|Lateral transperitoneal laparoscopic adrenalectomy
1636378|NCT01959698|Drug|Carboplatin|Given IV
1636379|NCT01959698|Drug|Carfilzomib|Given IV
1636380|NCT01959698|Drug|Etoposide|Given IV
1636381|NCT01959698|Drug|Ifosfamide|Given IV
1636382|NCT01959698|Other|Laboratory Biomarker Analysis|Correlative studies
1636383|NCT01959698|Other|Pharmacological Study|Correlative studies
1636384|NCT01959698|Biological|Rituximab|Given IV
1636385|NCT01959685|Drug|Androxal|125 mg Androxal, 250 mg Androxal separated by at least 7 days
1636386|NCT01959685|Drug|Placebo|Placebo, single dose
1636387|NCT01959672|Procedure|4-Dimensional Computed Tomography|Correlative studies
1636388|NCT01959672|Drug|Fluorouracil|Given IV
1636389|NCT01959672|Drug|Gemcitabine Hydrochloride|Given IV
1636390|NCT01959672|Other|Laboratory Biomarker Analysis|Correlative studies
1636391|NCT01959672|Drug|Leucovorin Calcium|Given IV
1636392|NCT01959672|Drug|Nelfinavir Mesylate|Given PO
1636393|NCT01959672|Biological|Oregovomab|Given IV
1636394|NCT01959672|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1636395|NCT01959672|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
1636396|NCT01959646|Dietary Supplement|Aged Garlic Extract Supplementation Group|Subjects will be asked to consume three (3) capsules of 600 mg aged garlic extract (AGE) with food twice a day, for a total of 3.6 grams per day.
1636397|NCT01959646|Other|Standard for Groups|To assess for eligible study participants, the research team will use the Cholestech LDX® System (Alere™ Inc, Waltham, MA) to analyze finger-prick blood samples. This is an efficient and economical point of care testing for c-Reactive Protein (CRP), cholesterol and related lipids, and blood glucose, as diagnostic tools which provide information for immediate risk assessment and therapeutic monitoring of heart disease, inflammatory disorders and diabetes. Each finger prick will be treated individually.
1636398|NCT01959646|Dietary Supplement|Placebo|Participants will be asked to consume three (3) placebo capsules with food twice a day.
1636399|NCT01959633|Drug|Vemurafenib|Vemurafenib 960 mg b.i.d. for each course of treatment lasting 28 days
1636400|NCT01959633|Drug|Peg-interferon|"In the Phase I are included 3 cohorts. Cohort 1) Peg-interferon 1 µg/Kg one time per week s.c. Cohort 2) Peg-interferon 2 µg/Kg one time per week s.c. Cohort 3) Peg-interferon 3 µg/Kg one time per week s.c. Interferon treatment should start after 15 days of Vemurafenib only
In the Phase II is included the cohort selected by phase I due to MTD and expanded at RD."
1636401|NCT01959620|Behavioral|1-Session Exposure Therapy|One exposure therapy session lasting one hour
1636402|NCT01959620|Behavioral|3-Session Exposure Therapy|Three exposure therapy sessions lasting one hour each, delivered one week apart
1636403|NCT01959607|Other|THS 2.2|Single use of the Tobacco Heating System 2.2 (THS 2.2)
1636404|NCT01959607|Other|CC|Single use of subject's own cigarette (CC)
1636405|NCT01959607|Other|NRT Gum|Single administration of the nicotine replacement therapy (NRT) 2 mg gum (Nicorette® 2mg)
1636406|NCT01959594|Drug|3 mg PF-06412562|oral dosing of 3 mg PF-06412562 tablets three times a day for 14 days
1636407|NCT01959594|Drug|10 mg PF-06412562|oral dosing of 10 mg PF-06412562 tablets three times a day for 14 days
1636408|NCT01959594|Drug|25 mg PF-06412562|oral dosing of 25 mg PF-06412562 tablets three times a day for 14 days
1636409|NCT01959594|Drug|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
1636410|NCT01959594|Drug|PF-06412562 TBD mg|oral dosing of PF-06412562 tablets three times a day for 14 days. Dosage and frequency to-be-determined based on previous cohorts
1636411|NCT01959581|Device|Movement Enhancing Device|Naturalistic play activities using the hands while wearing the movement enhancing device.
1636412|NCT01959568|Procedure|Vitrectomy and tamponade|"In the double tamponade arm the result of surgery is vitreous cavity filled in a half with perfluorodecalin and in another half - with silicone oil.
In the silicone oil tamponade arm the result of surgery is vitreous cavity filled with conventional or heavy silicone oil, depending on predominant retinal breaks location."
1636413|NCT01959555|Other|No treatment given|Patients will not be treated with any specific product. Data collection only.
1636414|NCT01959542|Device|MRI|
1636415|NCT01959542|Other|PSA Blood Test|Serum PSA will also be subsequently checked on the same day as each follow-up MR is performed, i.e. TP 1, 2 and 3, and right after finishing EBRT. 1-2 mls of blood will be sampled per blood test.
2012001|NCT02286713|Behavioral|Patient Decision Aid|Participants will receive study materials including a video to watch about lung cancer screening
1636418|NCT01959516|Drug|Glycopyrronium|Glycopyrronium capsule for inhalation once per day via SDDPI
1636419|NCT01959516|Drug|Tiotropium|Tiotropium capsule for inhalation once per day via HandiHaler® device
1636420|NCT01959516|Drug|Placebo to glycopyrronium|Placebo to glycopyrronium capsule for inhalation once per day via SDDPI
1636421|NCT01959516|Drug|Placebo to tiotropium|Placebo to tiotropium capsule for inhalation once per day via HandiHaler® device
1636422|NCT01959503|Device|Progel Vascular Sealant|
1636423|NCT01959503|Device|Gelfoam Plus|
1636424|NCT01959490|Biological|trastuzumab|Given IV
1636425|NCT01959490|Biological|Pertuzumab|Given IV
1636426|NCT01959490|Drug|docetaxel|Given IV
1636427|NCT01959490|Drug|carboplatin|Given IV
1636428|NCT01959490|Drug|doxorubicin|Given IV
1636429|NCT01959490|Drug|cyclophosphamide|Given IV
1636430|NCT01959490|Drug|paclitaxel|Given IV
1636431|NCT01959490|Other|laboratory biomarker analysis|Correlative studies
1636436|NCT01959477|Drug|cyclophosphamide|Given IV
1636437|NCT01959477|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
1636438|NCT01959477|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
2012002|NCT02286713|Behavioral|Standard Educational Information|Participants will receive study materials including a booklet to read about lung cancer screening.
1636441|NCT01959451|Drug|Prasugrel|see Arm description
1636442|NCT01959451|Drug|Clopidogrel|see arm description
1636443|NCT01959438|Drug|Sodium selenite (Introselen)|Intravenous infusion daily for each week day during 2 weeks (10 infusions). After that chemotherapy during 6 weeks. Chemotherapy for each patients is the first line treatment, so chemotherapy differs among patients, with respect to which treatment a patient got as first line.
1636444|NCT01959438|Drug|Sodium selenite|Intravenous treatment as described above. Cohorts of 3 patient are given a fixed dose for daily treatment (started with 0.5 mg/m2) and if no grade 3 or 4 toxicity, a new cohort is started on a higher dose. The dose for next cohort is 50% higher than for the former cohort. If grade 3 or 4 toxicity is found in 1 patient, 3 more patients are included on the same dose and if one more patient has serious toxicity it is considered to high a dose and a dose in between the toxic dose and the one before is tested. Thus if 2 patients in 3-6 tested patients has serious toxicity by a certain dose, this dose is to high and the highest dose is considered the earlier tested dose.
1636445|NCT01959425|Other|Off OAT Group (Test)|Discontinuation of OAT Therapy
1636446|NCT01959425|Other|On OAT Group (Control)|Continuation of OAT Therapy
1636447|NCT01959412|Drug|Indacaterol 27.5 mcg|indacaterol 27.5 mcg twice daily inhaled once via inhaler
1636448|NCT01959412|Drug|Indacaterol 37.5|Indacaterol 37.5 mcg once daily, inhaled once via inhaler
1636449|NCT01959412|Drug|Indacaterol 55 mcg|Indacaterol 55 mcg once daily, inhaled once via inhaler
1636450|NCT01959412|Drug|Indacaterol 75 mcg|Indacaterol 75 mcg once daily, inhaled once via inhaler
1636451|NCT01959412|Drug|Indacaterol 150 mcg|Indacaterol 150 mcg once daily, inhaled once via inhaler
1636452|NCT01959412|Drug|Placebo|Placebo to indacaterol once or twice daily (depending on assigned sequence) via inlaher
1636453|NCT01959399|Drug|ASP015K|oral tablet
1636454|NCT01959399|Drug|Rosuvastatin|oral tablet
1636455|NCT01959386|Drug|Trastuzumab|Participants will be receiving trastuzumab as part of their treatment for breast cancer according to the judgement of physician and according to the actual summary of product characteristics. The study protocol does not influence the physician's decision regarding diagnostics, therapy or frequency of medical examination during or after the treatment.
1636456|NCT01959373|Procedure|electroencephalograms (EEG)|
1636457|NCT01959373|Procedure|electro-myography (EMG)|
1636458|NCT01959360|Procedure|Direct lateral|Total hip replacement; direct lateral approach
1636459|NCT01959360|Procedure|minimal invasive|Total hip replacement; minimal invasive approach
1636460|NCT01959360|Procedure|modified minimal invasive|Total hip replacement; modified minimal invasive approach
1636461|NCT01959347|Procedure|Miduretheral Sling|MUS can include the TVT™ (mechanical cut mesh only, Gynecare, ETHICON Women's Health & Urology, Somerville, NJ), TVT-O™ (mechanical cut mesh only, Gynecare), or Monarc™ (American Medical Systems, Minnetonka, MN).
1636462|NCT01959347|Other|Miduretheral Sling with behavioral/pelvic floor therapy|MUS is combined with components of behavioral therapy (designed to change behaviors to encourage continence), and pelvic floor muscle therapy (designed to strengthen the pelvic floor muscles, enhance the physiological closure of the bladder neck, and improve coordination). This is done prior to MUS (1 visit) and after MUS for 5 visits at 2, 4, 6, 8 weeks and 6 months.
1636463|NCT01959334|Drug|Glucagon IN|3 mg of glucagon in 30 mg of AMG504-1 dry powder intranasal 3 doses, separated by at least 7 days
1636464|NCT01959334|Drug|Glucagon IM|1 mg of glucagon solution intramuscularly 3 doses separated by at least 7 days
1636465|NCT01959308|Other|N.A.|
1636466|NCT01959295|Drug|ASP2151|200 mg once daily
1636467|NCT01959295|Drug|ASP2151 placebo|once daily
1636468|NCT01959282|Drug|Placebo|Participants will receive placebo once daily
1636469|NCT01959282|Drug|JNJ-54781532 25 mg once daily|Participants will receive 25 mg of JNJ-54781532 once daily
1636470|NCT01959282|Drug|JNJ-54781532 75 mg once daily|Participants will receive 75 mg of JNJ-54781532 once daily
1636471|NCT01959282|Drug|JNJ-54781532 150 mg once daily|Participants will receive 150 mg of JNJ-54781532 once daily
1636472|NCT01959282|Drug|JNJ-54781532 75 mg twice daily|Participants will receive 75 mg of JNJ-54781532 twice daily
1636473|NCT01959269|Drug|Regorafenib (Stivarga, BAY 73-4506)|As determined by the treating physician
1636474|NCT01959256|Behavioral|Visual perceptual learning|24 times of training for visual perceptual learning
1636475|NCT01959243|Drug|Brimonidine Tartrate|
1636476|NCT01959243|Drug|Vehicle|
1636477|NCT01959230|Drug|Brimonidine Tartrate|
1636478|NCT01959230|Drug|Vehicle|
1636479|NCT01959217|Behavioral|PM Component Text Reminders|The number of PM components (strategic encoding, monitoring, and cue salience) that will comprise the tailored text reminders will be determined by Phase 1.
1636480|NCT01959217|Behavioral|Traditional Text Reminders|"Traditional text reminders include: Take your medication."
1636481|NCT01959204|Drug|Oxycodone|Pain
1636482|NCT01959191|Drug|Dual antiplatelet therapy including aspirin and clopidogrel after off-pump coronary bypass surgery|aspirin 100mg/day and clopidogrel 75mg/day, PO, from the day of surgery for 1 year
1636483|NCT01959165|Drug|MEDI7183 low dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
1636484|NCT01959165|Drug|MEDI7183 medium dose|MEDI7183 will be administered by SC on Day 1, Week 2, 4, and 8
1636485|NCT01959165|Drug|MEDI7183 high dose|MEDI7183 will be administered by SC on Day 1, and placebo for MEDI7183 at Week 2, 4, and 8
1636486|NCT01959165|Drug|Matching Placebo|Placebo will be administered by SC on Day 1, Week 2,4, and 8
1636487|NCT01959152|Device|HiRes™ 90K Advantage implant with HiFocus™ Mid-Scala electrode|
1636488|NCT01959139|Drug|PEGPH20|3 ug/kg on Day 1, IV over 15 minutes
1636489|NCT01959139|Drug|Oxaliplatin|85 mg/m^2, on Day 2, IV over 2 hours
1636490|NCT01959139|Drug|Leucovorin|400 mg/m^2, on Day 2, IV over 2 hours
1636491|NCT01959139|Drug|Irinotecan|180 mg/m^2, on Day 2, IV over 1.5 hours
1636492|NCT01959139|Drug|5-fluorouracil|2,400 mg/m^2, Days 2-4, IV over 46 hours
1636493|NCT01959126|Behavioral|Stress-reduction class|Study participants enrolled in a 12-week stress reduction course based on the principles of mindfulness. They attended four six-hour workshops and participated in 12 weekly hour-long web video conferencing calls to reinforce what was taught in the workshops. We have two groups: chronically-stressed maternal caregivers of children on the autism spectrum and control mothers whose children have no significant psychiatric or physical impairment. Both groups received similar instruction.
1636494|NCT01959113|Biological|Autologous Microbiome Transplant|
1636495|NCT01959113|Other|Placebo Arm|
1636496|NCT01959100|Drug|Azithromycin|250 mg x 3/week per os during a meal for a period of 2 years
1636497|NCT01959100|Drug|Placebo|250 mg x 3/week during a meal for a period of 2 years
1636498|NCT01959087|Procedure|single port surgery|Single port surgery can be converted in multiport surgery if necessary
1636499|NCT01959087|Procedure|Multiport surgery|
1636500|NCT01959074|Drug|Naftopidil|Naftopidil 75mg 1T qd hs
1636501|NCT01959074|Drug|Placebo for Naftopidil|Placebo 1T qd hs
1636502|NCT01959074|Drug|Standard treatment|aceclofenac 100mg on demand
1636503|NCT01959061|Drug|Raltitrexed|4mg, every 4 weeks,transhepatic arterial infusion
1636504|NCT01959061|Drug|Oxaliplatin|100~150mg, every 4 weeks, transhepatic arterial infusion
1636505|NCT01959061|Drug|lipiodol|5-20ml, every 4 weeks, hepatic artery embolization
1636506|NCT01959048|Drug|fecal microbiota transplantation|
1636507|NCT01959035|Drug|Aripiprazole once-monthly|400 or 300 mg/month; 6 intramuscular (IM) injections starting at baseline
1636508|NCT01959022|Drug|Doxazosin XL|Subjects will participate in a 2 week flexible-dose titration of doxazosin based on clinical response and adverse effects followed by 6 weeks of steady dose treatment.
1636509|NCT01959009|Other|HFOV combined with sigh breaths|"We plan only to investigate infants already ventilated on the HFOV-modus on high frequency oscillators, where the HFOV modus can be superimposed on conventional modes of ventilation. This gives the opportunity to combine HFOV with intermittent sigh breaths with a pre-set frequency and pre-set peak inspiratory pressure (PIP) and thus comparing HFOV combined with sigh breaths (HFOV-sigh) with conventional HFOV (HFOV-only).
All included participants will be exposed to the two different ventilator strategies tested in this trial, albeit in alternating and different order.
Each patient will serve, as it's own control. The trial will involve four alternating 1-hours periods allowing a sufficient wash-out period, as it has been shown that alveolar recruitment and derecruitment may take up to 25 min after changes to ventilator pressures At study start the patients will randomly be assigned to either starting with HFOV-only or HFOV-sigh"
1636511|NCT01958983|Behavioral|Music Therapy Group Session|
1636512|NCT01958970|Drug|PINTA 745|"PINTA 745 will be administered once weekly by IV infusion.
Cohort dose schedules:
3mg/kg weekly for 12 weeks
3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks
6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
1636513|NCT01958970|Drug|Placebo|"Placebo will be administered once weekly by IV infusion.
Cohort dose schedules:
3mg/kg weekly for 12 weeks
3mg/kg for 3 weeks, followed by 1mg/kg for 9 weeks
6mg/kg for 3 weeks, followed by 2mg/kg for 9 weeks"
1636514|NCT01958957|Drug|Ginkgolides Meglumine Injection|25mg, intravenous drip, once a day. Number of Cycles: 14 days.
1636515|NCT01958944|Drug|Nitric oxide|
1636518|NCT01958905|Drug|Artemether-lumefantrine fixed combination|
1636519|NCT01958892|Procedure|TURP, TUERP|
1636520|NCT01958879|Drug|ringer with corticosteroid|200 mL Ringer solution+1mg dexamethasone after finishing the irrigation
1636521|NCT01958879|Drug|ringer without corticosteroid|200 mL Ringer solution
1636522|NCT01958866|Drug|Tinospora Crispa-extract Product|
1636523|NCT01958866|Drug|Acetaminophen|
1636524|NCT01958866|Other|Placebo|
1636525|NCT01958853|Device|RINCE|The NeuroPoint device is used to deliver repeat applications of RINCE therapy
1636526|NCT01958840|Behavioral|Behavioral Activation for Depression Treatment|
1636527|NCT01958840|Behavioral|Supportive Counseling|
1636528|NCT01958827|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection.
1636529|NCT01958814|Drug|Salbutamol|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
1636530|NCT01958814|Drug|Placebo|First administration of salbutamol or placebo at M0 and 2nd salbutamol or placebo at M60 (or M0 + 60 minutes)
1636531|NCT01958801|Other|Supraclavicular block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
1636532|NCT01958801|Other|Interscalene block|Redirection of the needle is allowed when spread of local anesthetics does not surround the brachial plexus appropriately and involuntary movement of the forearm or hand is not necessary to confirm the correct placement of the needle.
1636533|NCT01958788|Behavioral|Cognitive-Behavioural Treatment|12 weekly sessions of individual cognitive-behavioural treatment (CBT) targeting intolerance of uncertainty.
1636534|NCT01958775|Drug|GLP-2|single subcutaneous dose of 1500mcg
1636535|NCT01958775|Drug|Placebo|
1636536|NCT01958762|Other|Invitation for oral cavity cancer screening|
1636537|NCT01958749|Procedure|Fat graft with Platelet Rich Plasma|
1636538|NCT01958736|Other|Ballistic Strength Training|The experimental group will complete jump squats on the leg sled, single leg toe push offs (or bilateral where unable to complete single), alternating legs (i.e. bounding), mini tramp jumping, progressing to jogging, quick hip flexion and bounding on land.
1715827|NCT00000781|Drug|Didanosine|
1636539|NCT01958736|Other|Usual Care Physiotherapy|This group will complete a suite of exercises based upon existing rehabilitation practices that aim to improve mobility after stroke. The supervising physiotherapist will select and progress the exercises, recording the performance of exercises in an exercise log and detailing incidence of adverse events. Exercise selection will include: gait retraining, cardiovascular fitness, lower limb strengthening, static and dynamic balance.
1636540|NCT01958723|Other|Hospitalists|Introduction of Problem Specific Templates
1636541|NCT01958684|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|LNG-IUS once inserted will be effective for 5 years.
1636542|NCT01958684|Device|Copper-IUD|Copper-IUD once inserted will be effective for more than 10 years.
1636543|NCT01958671|Drug|Ertugliflozin 5 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
1636544|NCT01958671|Drug|Ertugliflozin 10 mg|One tablet taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
1636545|NCT01958671|Drug|Placebo to Ertugliflozin|One placebo tablet matching the ertugliflozin 5 mg tablet and/or 1 placebo tablet matching the ertugliflozin 10 mg tablet per day taken orally the same time in the morning from Day 1 through Week 52 (Phase A and Phase B).
1636546|NCT01958671|Drug|Metformin|500 mg (1 tablet) in the morning and 500 mg (1 tablet) in the evening for 2 weeks, 1000 mg (2 tablets 500 mg) in the morning and 500 mg (1 tablet) in the evening for 2 weeks and 1000 mg (2 tablets 500 mg) in the morning and 1000 mg (2 tablets 500 mg) in the evening, thereafter.
1636547|NCT01958671|Drug|Placebo to Metformin|1 tablet in the morning and 1 tablet in the evening for 2 weeks, 2 tablets in the morning and 1 tablet in the evening for 2 weeks and 2 tablets in the morning and 2 tablets in the evening, thereafter.
1636548|NCT01958671|Drug|Glimepiride|Dosing and titration of glimepiride as rescue therapy was determined by the investigator.
1636549|NCT01958645|Drug|MEDI8111|MEDI8111 lyophilisate for solution for infusion
1636550|NCT01958645|Other|Placebo|Placebo for MEDI8111 saline solution for infusion
1636551|NCT01958632|Procedure|Nerve reconstruction|
1636552|NCT01958619|Drug|1440mg PQP tablets|Piperaquine phosphate tablets (1440mg)
1636553|NCT01958619|Drug|960mg PQP tablets|Piperaquine phosphate tablets (960mg)
1636554|NCT01958619|Drug|800mg OZ439 + TPGS|OZ439 (800mg) + TPGS granules for oral suspension
1636555|NCT01958619|Drug|960mg PQP granules|Piperaquine phosphate granules for oral solution (960mg)
1636556|NCT01958606|Other|High-intensity interval training (HIT)|Treadmill exercise using bursts of concentrated effort alternated with recovery periods
1636557|NCT01958606|Other|Traditional Aerobic Training|Moderate intensity continuous aerobic exercise on a treadmill
1636558|NCT01958593|Drug|Comparator|Comparator administered in two experimental sessions; may take part in Stage 2 upon learning condition assignment
1636559|NCT01958593|Drug|Full-dose MDMA|Participants receive full-dose MDMA during two experimental sessions; after learning their condition assignment, participants will receive a third full-dose session.
1636560|NCT01958593|Behavioral|Psychotherapy|Psychotherapy before and after experimental sessions
1636561|NCT01958580|Drug|Gemcitabine Hydrochloride|Given IV
1636562|NCT01958580|Drug|Docetaxel|Given IV
1636563|NCT01958580|Radiation|Internal Radiation Therapy|Undergo brachytherapy
1636564|NCT01958580|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1636565|NCT01958580|Radiation|External Beam Radiation Therapy|Undergo EBRT
1636566|NCT01958580|Other|Laboratory Biomarker Analysis|Correlative studies
1636567|NCT01958567|Other|Optical Coherence Tomography|
1636568|NCT01958554|Behavioral|Intervention Group|
1636569|NCT01958541|Behavioral|Sleep Intervention I|Insomnia-focused behavioral treatment (4 sessions).
1636570|NCT01958541|Behavioral|Sleep Intervention II|Insomnia-focused behavioral treatment (4 sessions).
1636571|NCT01958515|Other|research blood draw and tissue biopsy|
1636572|NCT01958502|Genetic|surgical treatment of non union with mesenchymal stem cells with BMP2 within a 3-D tissue engineered scaffold|
1636573|NCT01958489|Drug|Evacetrapib|Administered orally
1636574|NCT01958489|Drug|Pravastatin|Administered orally
1636575|NCT01958476|Drug|Neonatal Morphine Solution|"Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose."
1636576|NCT01958476|Drug|Methadone|"Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose."
1636615|NCT01958164|Drug|Actilyse|Actilyse 2mg/2ml will be given if the CVAD has not been restored at time 120min.
1636616|NCT01958164|Drug|Saline solution|Instil Saline solution 2 ml into the disfunctional CVAD once at time O only for patients enrolled in Group II
1636617|NCT01958164|Drug|Actilyse|Instil Actilyse 2 mg/ 2 ml into the dysfunctional CVAD at time O.
1636618|NCT01958164|Drug|Actilyse|Second dose of Actilyse 2mg/2ml will be given if CVAD has not been restored at time 120min.
1636924|NCT01955707|Drug|natalizumab|Administered as described in the treatment arm
1636577|NCT01958476|Drug|Phenobarbital|"A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally >8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.
Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores <8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period."
1636578|NCT01958463|Procedure|Fecal Microbiota transplantation.|Fecal Microbiota transplantation during colonoscopy.
1636579|NCT01958450|Procedure|Er:YAG laser|acne scar treatment using Er:YAG laser
1636580|NCT01958450|Procedure|Bipolar radiofrequency with diode laser|acne scar treatment with bipolar radiofrequency combined with diode laser
1636581|NCT01958437|Device|Transcranial direct current stimulation (tDCS)|Active and/or sham; All participants receive both stimulation condition. Groups will be counterbalanced (half receiving active tDCS in the first session and sham in the second session; the other half receiving the opposite).
1636582|NCT01958398|Behavioral|Promillekoll|Smartphone app monitoring alcohol use with feedback.
1636583|NCT01958398|Behavioral|PartyPlanner|Smartphone-adapted web based app for simulating an event with alcohol consumption in advance, real time monitoring alcohol use with feedback during the event and the possibility to compare these two.
1636584|NCT01958385|Device|placement of g-Cath EZ suture anchors|
1636585|NCT01958385|Procedure|Sham procedure|
1636586|NCT01958385|Behavioral|Diet and Exercise|A structured diet and exercise plan
1636587|NCT01958372|Dietary Supplement|soy isoflavones|Given PO
1636588|NCT01958372|Drug|cisplatin|Given IV
1636589|NCT01958372|Drug|etoposide|Given IV
1636590|NCT01958372|Drug|pemetrexed disodium|Given IV
1636591|NCT01958372|Radiation|radiation therapy|Undergo RT
1636592|NCT01958359|Behavioral|Short IVR|IVR-based alcohol diary with feedback
1636593|NCT01958359|Behavioral|Therapeutic IVR|IVR-based conversation offering a menu of exercises and vignettes.
1636594|NCT01958346|Other|Lingual Traction|The tongue pulling maneuver consists of grasping the tongue with 4x4cm gauze and gently pulling the tongue out until resistance is met.
1636595|NCT01958346|Other|Sham|Standard of care fiberoptic intubation without any additional experimental maneuvers
1636596|NCT01958346|Device|Fiberoptic Intubation|
1636597|NCT01958333|Procedure|Exercise 1|Low-intensity, low-volume cardiorespiratory exercise and strength training
1636598|NCT01958333|Procedure|Exercise 2|Medium-intensity, Medium-volume cardiorespiratory exercise and strength training
1636599|NCT01958333|Procedure|Exercise 3|High-intensity, High-volume cardiorespiratory exercise and strength training
1636600|NCT01958320|Other|pharmacologic treatment of the PDA|Following randomization, infants will be treated with medications used to produce PDA closure.
1636601|NCT01958320|Other|no pharmacologic treatment of the PDA|Following randomization, infants will NOT be treated with medications used to produce PDA closure (unless they develop rescue criteria at a later point in time).
1636602|NCT01958307|Behavioral|Lifestyle intervention|The intervention program consists of four individual counseling modules focusing on diet, physical activity and weight monitoring (12th-16th, 16th-20th, 30th-34th week of gestation and 6th-8th week postpartum). The counseling sessions are given by carefully trained midwives or medical staff in combination with prenatal visits and follow a standardized curriculum. Women are provided with brochures including a list of adequate prenatal exercise programs and a pedometer. Furthermore, they receive a chart personalized according to their baseline BMI category to monitor weight development.
1636603|NCT01958294|Device|MICHI Neuroprotection System|
2012003|NCT02286713|Behavioral|Follow-Up Assessments: Questionnaires|Follow up questions administered via phone and/or mail at 1-week, 3-month, and 6-month
2012004|NCT02285777|Biological|Meningococcal ABCWY|One dose administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
2012005|NCT02285777|Biological|Placebo|One dose of placebo administered intramuscularly in the deltoid area of a non-dominant arm at Month 6 (Visit 1)
1636608|NCT01958268|Procedure|Pretest and validation of a translated questionnaire|
1636609|NCT01958255|Behavioral|planned intervention for tobacco cessation counseling|game session for rapport building followed by group discussion and tobacco cessation counseling
1636610|NCT01958242|Other|Preoperative blood harvesting|There is no true intervention, there is a protocol of preoperative blood harvesting ,and post operative administration of the same blood/
1636611|NCT01958216|Other|Intravenous injection of deuterated cholesterol diluted in intralipid 20%|At day 0, bile diverted patients will receive an intravenous injection of deuterated cholesterol diluted in intralipid 20%. The plasma, biliary and fecal content of deuterated cholesterol will be measured, by mass spectrometry, at 24, 48 and 72 hours after the initial input.
1636612|NCT01958190|Drug|Tacrolimus and Sirolimus|"Arm 1 once daily combination therapy of normal dosed extended-release tacrolimus and prednisone for 3 months and monotherapy once daily extended-release tacrolimus thereafter up to 3 years after liver transplantation.
Arm 2 once daily combination therapy of low doses sirolimus and extended-release tacrolimus and prednisone for 3 months and combination therapy of low dose sirolimus and extended-release tacrolimus thereafter for up to 3 years after liver transplantation Continue Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician Conversion to sirolimus (3-5 ng/ml) and decrease Advagraf (3-5 ng/ml); 7.5 mg prednisone and lower or discontinue steroids after day 180 at the discretion of the treating physician"
1636613|NCT01958190|Drug|Tacrolimus|Patient received standard-dose of Tracrolimus Advagraf (5-10 ng/ml) and 7.5 mg prednison; lower or discontinue steroids after day 180 at the discretion of the treating physician
1636614|NCT01958177|Biological|Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)|Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of of Bone Marrow derived Mono Nuclear Stem Cell BMMNCs)
1636925|NCT01955707|Drug|Placebo|Matched placebo
1636619|NCT01958151|Other|State-Trait Anxiety Inventory Scores|Patients are evaluated before the procedure with State-Trait Anxiety Inventory scores to determine the anxiety level.
1636620|NCT01958138|Drug|comparison of group-P (low dose propofol with isoflurane) versus group-D (alone isoflurane)|"In both groups, 5 minutes prior to LMA removal, the isoflurane concentration will be adjusted to predetermine value. In group-P, the isoflurane MAC will be 0.5 or less and in group-D, the isoflurane MAC will be 1.2 and the both groups will be ventilated with 50% oxygen and 50% nitrous oxide with a total inflow of 6 L/min and will be maintained until the exhaled end-tidal isoflurane concentration will be same as the inhaled concentration.
The LMA will be removed with cuff inflated in both groups. In group-P, the propofol 1mg/kg at isoflurane 0.5 MAC or less will be given and after 20 seconds the LMA will be removed, In group-D, the LMA will be removed once the set 1.2 MAC of isoflurane achieved and after that the isoflurane and nitrous oxide will be turned off in both group-P & group-D and throat will be suctioned and 100% oxygen will be administered until the patient regain consciousness."
1636621|NCT01958125|Device|gammaCore|Vagal stimulation
1636622|NCT01958112|Drug|GSK1120212 (trametinib)|Trametinib dose is 1.5 mg orally once per day
1636623|NCT01958112|Drug|GSK2141795|The dose of GSK2141795 is 50 mg orally once per day
1636624|NCT01958099|Behavioral|Education|
1636625|NCT01958086|Device|Neural Communication System|NeuroPort Arrays allow for the local recording of cerebral cortex. Key features include sterile, single use electrodes that provide access to a localized population of individual cells. The Neural Communication system is primarily composed of two NeuroPort Arrays. The main component of the NeuroPort Array is an array comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and has a platinum tip that is 100-200 microns in length. The Patient Pedestal is made from titanium and is 19 mm wide at the skin interface.
1636626|NCT01958073|Drug|Conjugated Estrogen Vaginal Cream|
1636627|NCT01958073|Drug|Estradiol Ring|
1636628|NCT01958073|Drug|Placebo|
1636629|NCT01958060|Drug|BI 1034020|intravenous part
1636630|NCT01958060|Drug|Placebo to BI 1034020|intravenous part
1636631|NCT01958047|Drug|ASP3652|Oral
1636632|NCT01958034|Dietary Supplement|Bilberry extract|
1636633|NCT01958021|Drug|LEE011|Ribociclib was administered orally at a dose of 600 mg once daily (three 200 mg capsules).
1636634|NCT01958021|Drug|Letrozole|Letrozole 2.5 mg tablets taken orally.
1636635|NCT01958021|Drug|LEE011 Placebo|Matching ribociclib placebo was the control drug and was administered orally once daily.
1636636|NCT01958008|Drug|Placebo to BI 113608 high dose b.i.d.|Film-coated tablet
1636637|NCT01958008|Drug|Placebo to BI 113608 low dose b.i.d.|Film-coated tablet
1636638|NCT01958008|Drug|BI 113608 high dose b.i.d.|Film-coated tablet
1636639|NCT01958008|Drug|Placebo to BI 113608 medium dose b.i.d.|Film-coated tablet
1636640|NCT01958008|Drug|BI 113608 low dose b.i.d.|Film-coated tablet
1636641|NCT01958008|Drug|BI 113608 medium dose b.i.d.|Film-coated tablet
1636642|NCT01957995|Drug|nanosomal docetaxel lipid suspension|Given IV
1636643|NCT01957995|Other|pharmacological study|Correlative studies
1636645|NCT01957956|Other|Laboratory Biomarker Analysis|Correlative studies
1636646|NCT01957956|Biological|Malignant Glioma Tumor Lysate-Pulsed Autologous Dendritic Cell Vaccine|Given ID
1636647|NCT01957956|Drug|Temozolomide|Given PO
1636648|NCT01957943|Dietary Supplement|SMOFLipid|
1636649|NCT01957943|Dietary Supplement|equivalent volume of 10% glucose solution|Patients will receive same dose of 10% glucose solution for 2 days pre operatives and 5 days post-operative
1636650|NCT01957930|Other|Intensified conventional insulin treatment|The treatment regimen of the intensified treatment group consisted of individual education and then continuous tutoring with frequent face-to-face and telephone contact.
1636651|NCT01957930|Drug|Standard treatment|Patients continuing with routine diabetes care (insulin treatment), visiting physician every four months
1636652|NCT01957917|Other|NAC (Nutritional Assessment and Counseling)|
1636653|NCT01957917|Other|Cash Transfer|
1636654|NCT01957917|Other|Food Assistance|
1636655|NCT01957904|Device|ArterX Surgical Sealant|
1636656|NCT01957878|Biological|ProCervix|ProCervix consists of two recombinant adenylate cyclase (CyaA) proteins, CyaA-HPV 16E7 (C16-1) and CyaA-HPV 18E7 (C18-1) in a 50/50 ratio (C16C18-2 Ag mixture). ProCervix is adjuvanted by Aldara™, a cream containing 5% of imiquimod
1636657|NCT01957878|Biological|Placebo|Placebo matching ProCervix and adjuvanted by Aldara™, a cream containing 5% of imiquimod
1636658|NCT01957865|Device|Fixed SMS, real-time monitoring|SMS reminders will be sent daily for one month, then weekly for two months, then as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
1636659|NCT01957865|Device|Triggered SMS, real-time monitoring|SMS reminders will be sent as needed for missed doses to encourage adherence. The Wisepill system will automatically capture and report each time the device is opened as a proxy for the participant's adherence.
1636660|NCT01957852|Other|FloSeal|
1636661|NCT01957839|Drug|cabergoline treatment|cabergoline treatment for hyperprolactinemia group
1636662|NCT01957826|Other|bone marrow-derived MSCs injection|transendocardial injection of 30-40 million bone marrow-derived MSCs with the NOGA XPTM platform. 15 injections in the anterior wall of the left ventricle.
1636663|NCT01957826|Other|placebo intervention|placebo administration
1636664|NCT01957813|Behavioral|Lifestyle Counseling|"Peer educators will be trained using existing materials to deliver accurate messaging on FP/dual method use, during individual encounters and in group sessions.
Screening for unmet FP need in DICs Providing job aids to FP counselors Expanding FP methods with intra-uterine contraceptive devices (IUCD) and implants Time change in DIC hours of operation"
1636665|NCT01957813|Other|Standard Health Services|Peer education and health services
1636666|NCT01957800|Behavioral|Website|Website will have action planning with social interactions and support features for sharing, reusing, and recommending strategies for improving habits.
1638230|NCT01945840|Procedure|Roux en Y Gastric Bypass Surgery|
1636667|NCT01957800|Behavioral|Usual Care|Participants will record their weight and complete surveys online.
1636668|NCT01957787|Device|Cryoablation|All patients will receive cryoablation of up to 6 metastatic lung tumors.
1636669|NCT01957774|Drug|THR-18|THR-18 is an 18-mer peptide derived from the sequence of human plasminogen activator inhibitor 1 (PAI-1), having the ability to bind to a site of tissue plasminogen activator (tPA) distal to its catalytic site and uncouple the beneficial clot-dissolving properties of tPA from its deleterious non-fibrinolytic effects.
1636670|NCT01957774|Drug|Placebo|
1636671|NCT01957748|Behavioral|SoC + ALERT Intervention|Enhanced retention efforts and education modules will be implemented by the ALERT Specialist to ensure retention to care.
2012006|NCT02286167|Other|Diet modification|All patients will be participate in the intermittent, modified Atkins diet
2012007|NCT02282722|Other|Investigational informed consent for chemotherapy|Investigational informed consent materials consist of regimen-specific multimedia tools: a video plus a booklet.
1636674|NCT01957722|Procedure|microfracture|Surgical procedure which creates a marrow clot in the prepare cartilage defect.
1636675|NCT01957722|Biological|NOVOCART 3D|combination product- biologic (autologous chondrocytes) /device (scaffold) implant
1636676|NCT01957709|Other|Laboratory Biomarker Analysis|Correlative studies
1636677|NCT01957709|Biological|Recombinant Interferon Gamma|Given SC
1636678|NCT01957683|Device|eCLIPs™ Family of Products|Safety and feasibility of the eCLIPs™ Family of Products for the treatment of unruptured bifurcation intracranial aneurysms
1636679|NCT01957670|Device|Lacrima medical Prototypes|
1636680|NCT01957657|Drug|BI 207127|oral administration
1636681|NCT01957657|Drug|faldaprevir|oral administration
1636682|NCT01957657|Drug|BI 207127|oral administration
1636683|NCT01957657|Drug|BI 207127|oral administration
1636684|NCT01957657|Drug|BI 207127|oral administration
1636685|NCT01957657|Drug|faldaprevir|oral administration
1636686|NCT01957657|Drug|faldaprevir|oral administration
1636687|NCT01957657|Drug|faldaprevir|oral administration
1636688|NCT01957644|Drug|Azacitidine|
1636689|NCT01957644|Drug|Volasertib|
1636690|NCT01957631|Drug|Corticosteroid injection (Bupivacaine and Depo Medrol)|The use of corticosteroid injections to treat heel pain has been a relatively common practice. They are mainly used in conjunction with other modes of conservative therapies. With a 10cc syringe, 3 mL of 0.5% Bupivacaine and 2 mL of 80mg Depo Medrol are injected into the medial calcaneal tubercle using an aseptic technique.
1636691|NCT01957631|Biological|Platelet rich plasma injection|10-15cc of patient's blood is drawn and centrifuged in a Rotofix 32A at 1500 cycles/minute for 5 minutes to separate the platelets from the other components of blood. 4-6cc of concentrated platelets are then re-injected into the medial calcaneal tuberosity using an aseptic technique. Sterile techniques are very important in this procedure to decrease the risk of infection.
1636692|NCT01957592|Other|No treatment given|Patients will fill out a questionnaire by interview.
1636693|NCT01957579|Drug|MEDI-551|MEDI-551 will be administered by intravenous infusion at dose of 2, 4 or 8 mg/kg once per week on Days 1 and 8 in the first cycle and then once every 28 days at the start of each subsequent cycle
1636694|NCT01957566|Procedure|APS|
1636695|NCT01957553|Device|Coloplast test product|Coloplast test product is a newly developed 2-piece ostomy appliance
1636696|NCT01957553|Device|SenSura|SenSura is the commercial available CE-marked SenSura Click 2-piece ostomy appliance from Coloplast A/S
1636697|NCT01957540|Drug|Ticagrelor|
1636698|NCT01957540|Drug|Prasugrel|
1636699|NCT01957527|Device|Peripheral arterial tonometry (EndoPAT)|
2012008|NCT02282722|Other|Usual, standard-of-care informed consent for chemotherapy|The enrolling site's institutional standard-of-care informed consent materials.
1636704|NCT01957501|Other|MDDScoreTM|The child will receive a single blood draw (about 10 mL).
1636705|NCT01957488|Device|Coloplast Test Product 1|Coloplast Test product 1 is a newly developed 1-piece ostomy appliance
1636706|NCT01957488|Device|Coloplast Test Product 2|Coloplast Test product 2 is a newly developed 1-piece ostomy appliance
1636707|NCT01957488|Device|Coloplast SenSura|SenSura 1-piece is the commercial available CE-marked SenSura 1-piece from Coloplast A/S.
1636708|NCT01957475|Device|Coloplast Test product Y|Coloplast Test product Y is a newly developed 2-piece convex ostomy appliance
1636709|NCT01957475|Device|Coloplast Test product Z|Coloplast Test product Z is a newly developed 2-piece convex ostomy appliance
1636710|NCT01957462|Device|Coloplast Test V|Coloplast Test product V is a newly developed 1-piece ostomy appliance
1636711|NCT01957462|Device|Coloplast Test X|Coloplast Test X is a newly developed 1-piece ostomy appliance
1636712|NCT01957449|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization for up to 12 months
1636713|NCT01957449|Drug|Placebo|Placebo by mouth given daily throughout hospitalization for up to 12 months.
1636714|NCT01957436|Drug|abiraterone acetate|abiraterone 1000mg/day (4 tablets of 250 mg (PO) per day) + prednisone 5mg bid
1636715|NCT01957436|Radiation|radiotherapy|74 Gy in 37 fractions 3D-Conformal RT or Intensity Modulated RT (IMRT)
1636716|NCT01957436|Other|Androgen Deprivation Therapy|The ADT must consist in either LHRH agonist, LHRH antagonist or orchiectomy
1636717|NCT01957436|Drug|Docetaxel|6 cycles at 75mg/m²/cycle, one cycle every 3 weeks
1636718|NCT01957423|Dietary Supplement|Whey protein|Whey protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
1636719|NCT01957423|Dietary Supplement|Soy protein|Soy protein was provided as sachets with 15g. Patients were advised to consume two sachets per day (amounting to 22.4g of protein) mixed with food or a cold beverage, for 16 weeks. All patients remained on an unrestricted diet and did not receive nutritional advice.
1636750|NCT01957163|Drug|UMEC|Umeclidinium bromide in a powder blend with lactose and magnesium stearate was used at two different doses 62.5mcg and 125mcg.
1636751|NCT01957163|Drug|Placebo|The matching placebo DPI identical in appearance to the inhaler containing active study medication.
1715938|NCT00000838|Drug|Lamivudine|
1636720|NCT01957410|Drug|Ketamine|During Cohorts 1 and 2, a single ketamine 0.5 mg/kg dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. The predefined dose and infusion rate/duration should not be adjusted. If a patient is unable to tolerate the study medication, the infusion should be stopped. Within 1 week of completion of the open-label treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
1636721|NCT01957410|Drug|Placebo|During Cohort 2, a single placebo dose will be given as a continuous IV infusion over 40 minutes by use of an electronic syringe infusion pump. Within 1 week of completion of the double-blind treatment phase, participants can receive a single dose of ketamine 0.5 mg/kg administered as an IV infusion over 40 minutes during an optional open-label treatment phase.
1636722|NCT01957397|Device|Coloplast Test 1|Coloplast Test 1 is a newly developed 2-piece convex ostomy appliance
1636723|NCT01957397|Device|Coloplast Test 2|Coloplast Test 2 is a newly developed 2-piece convex ostomy appliance
1636724|NCT01957397|Device|Coloplast Test 3|Coloplast Test 3 is a newly developed 2-piece convex ostomy appliance
1636725|NCT01957384|Device|Coloplast Test product 1|Coloplast Test product 1 is a new ostomy appliance developed by Coloplast.
1636726|NCT01957384|Device|Coloplast Test product 2|Coloplast Test product 2 is a new ostmoy appliance developed by Coloplast A/S
1636727|NCT01957384|Device|Standard Care (Coloplast SenSura; Dansac Nova 1; Hollister Moderma FLex; Convatec Esteem; B.Braun Flexima Active)|"Standard Care was the subject usual ostomy appliance and had to be one of the following:
Coloplast: SenSura, 1-piece open bag without inspection window, size midi and maxi, custom-cut,
Dansac: Nova 1 & Nova Life, 1-piece open bag, size midi and maxi, custom-cut baseplate
Hollister: Moderma Flex, 1-piece open, size midi and maxi, custom-cut baseplate
ConvaTec: Esteem, 1-piece open bag, size midi and maxi, custom-cut baseplate
B. Braun: Flexima Active & Softima, 1-piece open bag, size midi and maxi, custom-cut baseplate"
1636728|NCT01957371|Behavioral|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, physical postures/movements, and guided rest (yoga nidra), as well as daily home practice.
1636729|NCT01957358|Behavioral|The Grief Recovery Method|The Grief Recovery Method is a structured process designed to help people with spinal cord injuries examine their knowledge of their injury, their emotional reaction to their injury, and their ability to acknowledge their grief over the injury in order to learn techniques to resolve the grief in order to achieve a more complete recovery. Participants will attend a total of 18 sessions, some one-on-one, and some in a group setting. The Grief Recovery Handbook, handouts, DVD (digital video disc) presentations and questionnaires will be used. Targeted activities to decrease isolation and assist volunteers to identify goals for recovery will be utilized.
1636730|NCT01957345|Other|Blood punction|"T1 and T2: one blood punction with signalisation test (T1 for each arm, T2 at +6 months only if an anomaly at signalisation test is detected)
signalisation test is made by flow cytometry
Stage 1: for arm bleeding disorder : flow cytometry analysis to establish reference values observed in subjects without thrombopathy for each marker after agonist stimulation and corresponding search of an effect if a center-center effect is observed on the reference values its origin will be sought and corrected.
Stage 2: for the two others arms: Several markers will be analyzed, corresponding to routes or levels of different signaling. For each of these markers, the test will evaluate quantitatively the phosphorylation activity of the protein tested."
1636731|NCT01957332|Procedure|Molecular imaging|On the day of FES-injection&scan or the day after FES-injection, 89Zr-trastuzumab (~37 MBq) will be injected. The HER2-PET will be performed 4 days after tracerinjection.
1636732|NCT01957332|Procedure|Molecular imaging|All patients receive 18F-FES (~200MBq) injection followed by a FES-PET.
1636733|NCT01957319|Drug|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg|
1636734|NCT01957319|Drug|sugar pill|
1636735|NCT01957306|Dietary Supplement|Dr. Tagliaferri's Menopause Formula|Administered as 2 grams PO BID
1636736|NCT01957293|Drug|Salbutamol|single oral administration, 4 mg
1636737|NCT01957293|Drug|Placebo|single oral administration
1636738|NCT01957280|Drug|patritumab|
1636739|NCT01957228|Procedure|bone biopsies|
1636740|NCT01957215|Drug|Indomethacin|Topical indomethacin
1636741|NCT01957215|Drug|Placebo|Placebo patch
1636742|NCT01957202|Drug|FF/levocabastine|FF/levocabastine (25mcg/50 mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
1636743|NCT01957202|Drug|FF|FF (25mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
1636744|NCT01957202|Drug|levocabastine|levocabastine (50mcg) will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
1636745|NCT01957202|Drug|Placebo|Placebo will be supplied as intranasal aqueous microsuspension in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension. Two sprays in each nostril in the morning in a fasted state will be administered.
1636746|NCT01957189|Drug|Dutasteride and Tamsulosin|0.5mg dutasteride once a day on Day 1 Period A , and Day 5 Period C,0.2mg Tamsulosin once a day on Day 1 to Day 7 in Period B and Period C
1636748|NCT01957163|Drug|FF|Dry white powder containing 100mcg of Fluticasone Furoate blended with lactose per blister was administered by DPI.
1636749|NCT01957163|Drug|VI|Dry white powder containing 25mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by DPI.
1636835|NCT01956422|Device|Continuous Positive Airway Pressure(CPAP)|
2012009|NCT02282059|Drug|sunitinib|subjects will be enrolled to receive at least one dose of sunitinib orally at 37.5 mg once a day on a continuous daily dosing regimen (CDD) or dosage modification is based on daily clinic practice
2012010|NCT02282124|Behavioral|Self-management program with monthly sessions|Patients participate in 9 sessions during the first 8th month after transplantaiton
1636754|NCT01957137|Device|InterStim® (Device Programming)|
1636755|NCT01957124|Procedure|PRF (Platelet-Rich Fibrin)|
1636756|NCT01957098|Dietary Supplement|Placebo comparator: 0% pentose|14 healthy subjects participated in a randomized double-blinded cross-over study based on four single tests. Sucrose containing drinks were supplemented with two different doses of D-xylose and in addition one dose of L-arabinose was included for comparison with earlier studies. Blood was collected fasting and for 3-h postprandially. Appetite sensations and energy intake were registered. Gastrointestinal symptoms were monitored for 24 hours
1636757|NCT01957098|Dietary Supplement|Active comparator: 4% D-xylose|
1636758|NCT01957098|Dietary Supplement|Active comparator: 8% D-xylose|
1636759|NCT01957098|Dietary Supplement|Active comparator: 8% L-arabinose|
2012011|NCT02282124|Behavioral|Usual Care, containing one session|Session takes place within the first three months after transplantation
1636761|NCT01957072|Behavioral|Behaviour change intervention|"The behaviour change intervention consists of
feedback via a web-based food diary
'coaching' with problem-solving and implementation plans
The intensive intervention phase consists of 2 home visits, 8 telephone calls and 6 reminder emails.
The maintenance phase consists of 3 telephone calls and 4 reminder emails."
1636762|NCT01957059|Drug|Regimen Selection Phase Group 2|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:
• 3 mg/kg"
1636763|NCT01957059|Drug|Regimen Selection Phase Group 3|"All doses of BMN053 will be administered as IV infusions. The proposed doses are as follows:
• 4-6 mg/kg"
1636764|NCT01957059|Drug|Treatment Phase Group 4|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3
1636765|NCT01957059|Drug|Regimen Selection Phase Group 1 (COMPLETED)|All doses of BMN053 have been administered as subcutaneous injections.
1636766|NCT01957059|Drug|Dosing Extension|All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
1636767|NCT01957046|Drug|Laxative|
1636768|NCT01957033|Behavioral|Exercise and education once/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book
1636769|NCT01957033|Behavioral|Exercise and education twice/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
1636770|NCT01957033|Behavioral|Exercise and education 3 times/week for 6 weeks|Exercises will include specific range of motion, strengthening, and motor control exercises for the neck and shoulder girdle. Education will include prognosis information, advice to stay active, and use of a book about whiplash.
1636771|NCT01957033|Other|Manual therapy once/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
1636772|NCT01957033|Other|Manual therapy twice/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
1636773|NCT01957033|Other|Manual therapy 3 times/week for 3 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
1636774|NCT01957033|Other|Manual therapy once/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
1636775|NCT01957033|Other|Manual therapy twice/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
1636776|NCT01957033|Other|Manual therapy 3 times/week for 6 weeks|Manual therapy will consist of low velocity mobilizations of the cervical and upper thoracic spine based on the findings of the treating physiotherapist.
1636777|NCT01957007|Drug|Docetaxel|Docetaxel will be administered IV.
1636778|NCT01957007|Drug|vantictumab|Vantictumab will be administered intravenously
1636779|NCT01956994|Dietary Supplement|Whey protein supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
1636780|NCT01956994|Dietary Supplement|Carbohydrate supplement|Supplements will be provided in powder form and mixed into beverages to be consumed twice per day (after breakfast and after dinner).
1636781|NCT01956981|Drug|Magnesium Sulfate|40 mg kg-1 IV magnesium sulfate (OSEL ilaç San. Ve Tic. A.Ş., Beykoz, Istanbul, Turkey) in 100 ml saline solution was applied to patients in Group M as a loading dose 10 minutes before the induction and continued during the surgery at the dose of 10-15 mg kg-1hour-1.
1636782|NCT01956981|Drug|Dexmedetomidine|1 µg kg-1 IV dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) in 100 ml saline solution was applied to patients in group D 10 minutes before the surgery and continued during the surgery at the dose of 0.5-1 µg kg-1.
1636783|NCT01956955|Drug|enoxaparin ,alteplase, unfractionated heparin|
1636784|NCT01956942|Device|Micropulse Laser Trabeculoplasty|
1636785|NCT01956942|Device|Selective Laser Trabeculoplasty|
1636786|NCT01956929|Drug|Metformin|Metformin 1000mg daily for one week, then 2000 mg daily for the second week. 4 week washout period, then crossover to placebo.
1636787|NCT01956929|Drug|Placebo|Placebo tablets for 2 weeks, then 4 weeks of washout period, then crossover to metformin.
1636788|NCT01956916|Dietary Supplement|Lactobacillus rhamnosus GG|"Capsules containing lyophilized 6x10^9 Colony Forming Units (CFU)/die LGG, (60mg) maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)
1 cps/die for 12 months"
1636836|NCT01956422|Device|Venturi Mask FiO2 40%|
2012012|NCT02281682|Drug|Imiquimod|three times a week once daily during 4 consecutive weeks. Prior to treatment: curettage
1636789|NCT01956916|Dietary Supplement|placebo|"Capsules containing maltodextrin (163 mg), gelatine capsule (75 mg), magnesium stearate (2 mg)
1 cps/die for 12 months"
1636790|NCT01956903|Genetic|Allogenic Mesenchymal Stem Cell|"Expanded in-Vitro Allogenic Mesenchymal Stem Cell (authorized by Spain, Agencia Española de Medicamentos y Productos Sanitarios with number 06-076)"
1636791|NCT01956890|Drug|PET|18F-FLT PET and MRI of the breast
1636792|NCT01956864|Drug|Vitamin D|Doses of vitamin D will be increased from a baseline dose to the maximum tolerated dose. There could therefore be up to 5 possible doses of Vitamin D. Once the maximum tolerated dose of vitamin D has been determined, patients will follow a regimen on that dose for 6 months.
1636793|NCT01956838|Dietary Supplement|umami|intraduodenal infusion of umami tastant
1636794|NCT01956838|Dietary Supplement|bitter|intraduodenal infusion of bitter tastant
1636795|NCT01956838|Dietary Supplement|sweet|intraduodenal infusion of sweet tastant
1636796|NCT01956825|Dietary Supplement|"slim water"|
1636797|NCT01956812|Drug|IMMU-107|Arm A: gemcitabine 200 mg/m2 administered weekly x 4 and IMMU-107 administered weekly x 3 for multiple cycles
1636798|NCT01956812|Drug|placebo|placebo weekly x 3 and gemcitabine 200 mg/m2 weekly x 4 for multiple cycles
1636799|NCT01956812|Drug|Gemcitabine|Gemcitabine, 200 mg/m2, given weekly x 4 in both arms
1636800|NCT01956786|Drug|Amlodipine-FA tablet,low dose group|5mg amlodipine combined with 0.4mg folic acid,once daily (Low-dose group)
1636801|NCT01956786|Drug|Amlodipine-FA tablet,high dose group|5mg amlodipine combined with 0.8mg folic acid,once daily (High-dose group)
1636802|NCT01956786|Drug|Amlodipine|5mg amlodipine,once daily
1636803|NCT01956773|Other|MeTree|Software program collecting family health history and generating clinical decision support for risk-based preventive care
1636804|NCT01956760|Other|Acupuncture and intradermal acupuncture|The acupuncture was applied at 5 acupoints(HT7 Shenmen, PC6 Neiguan, SP6 Sanyinjiao, KI6 Zhaohai, BL62 Shenmai) 3 times in a week. It was performed by a certified practitioner with sterile needles (0.25*40.0mm). The needles were inserted at least 10.0mm deep through the skin and maintained for 20 minutes The intradermal acupuncture was applied at the same acupoints, immediately after the acupuncture needles were removed. It was performed by the same practitioner with sterile needles (0.20*8.0mm).attached to skin tape (10.0*10.0mm). The needles were inserted 3.0~5.0mm deep and maintained for 48~72 hours
1636805|NCT01956747|Procedure|venapunction|
1636806|NCT01956747|Procedure|bone marrow punction|
2012013|NCT02281682|Drug|5-fluorouracil|during 4 (consecutive) weeks twice daily. Prior to treatment: curettage
1636808|NCT01956721|Procedure|Exercise training,|
1636809|NCT01956721|Procedure|Muscle biopsy|
1636810|NCT01956708|Procedure|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
1636811|NCT01956695|Drug|Lenalidomide|
1636812|NCT01956695|Drug|Rituximab|
1636813|NCT01956682|Dietary Supplement|HA formula + starch + L. reuteri|
1636814|NCT01956669|Drug|Pazopanib GW786034|Pazopanib is supplied as a series of aqueous film-coated tablets containing 200 mg (oval-shaped, white, packaged in bottles containing 34 tablets each), and 400 mg (oval-shaped, white, packaged in bottles containing 68 tablets each). Pazopanib Powder for Oral Suspension is a white to slightly colour powder supplied to the clinical sites in amber glass (United State Pharmacopeia (USP) Type III) bottles with child-resistant closures. Each bottle contains 5 g of pazopanib.
2012014|NCT02281682|Drug|Ingenol mebutate|during 3 (consecutive) days once daily. Prior to treatment: curettage
1636816|NCT01956643|Other|gum chewing|gum chewing
1636817|NCT01956643|Other|Control|Routine care during NPO
1636818|NCT01956630|Biological|Genetically modified DCs plus CIK cells|
1636819|NCT01956630|Biological|Donor leukocyte infusions (DLI)|
1636820|NCT01956617|Other|lumbar plexus block|
1636821|NCT01956604|Drug|Clonidine|
1636822|NCT01956604|Drug|Placebo|
1636823|NCT01956591|Drug|Oxybutynin|All patients are treated with oxybutynin for hyperhidrosis. Usual maintenance dose is 10mg/day, but dose may vary according to weight, efficacy and side effects. Our standard protocol starts with 2.5mg/day in the first 7 days, progresses to 5mg/day for 14 days and then reaches the usual maintenance dose of 10mg/day afterwards.
1636824|NCT01956578|Other|Breathing Exercise Cohort|All patients enrolled will be asked to wear a respiration band and perform a series of breathing exercises.
1636825|NCT01956565|Other|Inspiratory Muscle training|Participants will perform 8 weeks of IMT strength training using the Powerbreathe Kinetic device (Powerbreathe). Training will progress to 60% maximum inspiratory pressure (PiMax) with 30 breaths at high velocity (paced initially over a period of 15 minutes), twice a day, 5 days per week. Tidal breathing without inspiratory resistance is acceptable for recovery between each high velocity breath. Training will be titrated and supervised weekly for the first 8 weeks by a physiotherapist. After 8 weeks training the participants are advised to continue training unsupervised, twice a day, 3 times per week for a further 18 weeks.
1636826|NCT01956552|Other|biopsy or cytopuncture|
1636827|NCT01956526|Device|CORolla™ TAA device|
1636828|NCT01956513|Other|MRI (Magnetic resonance imaging)|MRI will be realised at the beginning of the study, after a cycle of chemotherapy or at changement of sequence and at the end of chemotherapy.
1636829|NCT01956500|Dietary Supplement|Instaflex|The Instaflex supplement contained the following ingredients (in 3 capsules): Glucosamine sulfate (1500 mg), methylsulfonylmethane (MSM) (500 mg), white willow bark extract (standardized to 15% salicin) (250 mg), ginger root concentrate (50 mg), boswella serrata extract (standardized to 65% boswellic acid) (125 mg), turmeric root extract (50 mg), cayenne 40m H.U. (50 mg), and hyaluronic acid (4.0 mg).
1636830|NCT01956500|Dietary Supplement|Placebo|The placebo capsules will contain magnesium stearate, an inert substance.
1636831|NCT01956487|Drug|Propafenone|Comparison of drug from 2 manufacturing sites
1636832|NCT01956474|Other|Theralight crosslinking and Riboflavin|Corneal Collagen cross linking with UV light and riboflavin
1636833|NCT01956448|Device|Drug eluting stent|Device: Percutaneous intervention with implantation of drug eluting coronary stent (Resolute Integrity)
2012015|NCT02281682|Procedure|methylaminolevulinate photodynamic therapy|methylaminolevulinate photodynamic therapy; one session. Prior to treatment: curettage
1636839|NCT01956396|Device|PrePex™ device|PrePex™ device for adult male circumcision. The non-surgical PrePex™ device with No Injected Anesthesia
1636840|NCT01956383|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
1636841|NCT01956370|Device|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
1636842|NCT01956370|Procedure|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
1636843|NCT01956357|Other|Aquatic exercise|
1636844|NCT01956357|Other|Land Exercise|
1636845|NCT01956344|Behavioral|Cognitive Behavioral Therapy|Group cognitive-behavioral therapy for hoarding disorder, 16 weeks
1636846|NCT01956318|Behavioral|Crenobalneotherapy|18 days of balneotherapy session in 3 weeks. Each day, the treatment associates 4 techniques: Kneipp Therapy, walking pool, underwater massage, bath tub and finishing with 20 minutes of rest in the Trendelendburg position. Kneipp Therapy is an alternating warm (28°C) and cold (14°C) shower on the legs during 10 minutes. Walking pool is a 60 cm deep pool at 23°C with underwater shower where patients are walking without stopping during 10 minutes. Underwater massage is realized by a senior physiotherapist. It starts at the feet and gradually rises to the thighs during 10 minutes. Bath tub is underwater shower at 30°C. It also starts at the feet and gradually rises to the thighs during 20 minutes. The interventions are standardized by timers. Adherence to each technique is supervised before each session in the usual manner for each patient treated in the spa center.
1636847|NCT01956305|Drug|DS-7309|DS-7309 powder in bottle
1636848|NCT01956305|Drug|placebo|placebo to match DS-7309 powder in bottle
1636849|NCT01956305|Drug|Metformin|Metformin 500mg tablet for Cohort F
1636850|NCT01956279|Drug|Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x 28 days
1636851|NCT01956279|Drug|Placebo|Placebo 50mg BID x 14 days, followed by Placebo 150 x 14 days, followed by Placebo 250 mg BID x 28 days
1636852|NCT01956266|Behavioral|Emotional prosodic treatment|The experimental treatment is consistent with the standard treatment in that it targets impairments in pitch/stress, loudness variability and control of speech rate, the core characteristics of prosodic insufficiency in PD (Darley, Aronson & Brown, 1969). However, the experimental treatment provides an innovative and targeted emphasis on the emotional component of the disorder. The production of emotional intonation in an utterance requires varying combinations of pitch/stress, loudness, and rate. Participants will receive clinician feedback as well as auditory and visual feedback on accuracy via the VisiPitch display.
1636853|NCT01956266|Behavioral|Standard prosodic treatment|The standard treatment includes tasks in common clinical use for treating the three main aspects of prosodic insufficiency in PD, pitch/stress, loudness, and rate. To address pitch/stress, the investigators will use contrastive stress tasks. To address rate control the investigators will use hand tapping tasks which have been shown to be effective, and to address loudness, patients will be asked to produce sentences of increasing length while maintaining an appropriate loudness level. Participants will receive clinician feedback regarding accuracy of attempts as well as auditory and visual feedback on accuracy of stress/pitch and loudness control via the VisiPitch display.
1636854|NCT01956253|Drug|Neratinib|240 mg orally once daily
1636855|NCT01956240|Procedure|Stretching-Asymptomatic subjects|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
1636856|NCT01956240|Procedure|Stretching-Subjects with shoulder pain|The stretching will be performed with the subject standing, with 90° of arm abduction and 90° of elbow flexion and palm on a flat planar surface. The subject then will place the leg opposite to the flat surface in front of the other with slight knee flexion and tilt the trunk forward like a rigid block and rotate it slightly increasing the horizontal abduction at the shoulder. This procedure will be done 4 times for 1 min and 30s interval between repetitions.
1636857|NCT01956227|Behavioral|Home-based exercise|exercise to look at balance and lower limb strength record in diary
1636858|NCT01956227|Behavioral|Education|sessions to discuss self-management ideas to modify risk of falling
1636859|NCT01956227|Behavioral|Exercise plus Education|combination of exercise sessions with education sessions to modify fall risk
1636860|NCT01956214|Other|FES Exercise|receive FES while exercising
1636861|NCT01956214|Other|Mock FES Exercise|participants will receive Mock FES
1636862|NCT01956201|Drug|Atorvastatin 20mg|[Atorvastatin Run-in Period] Take Atorvastatin 20mg 1 tablet once a day (after breakfast) [Treatment Period] Take Atrovastatin 20mg/Fenofibrate 160mg or Atorvastiatin 20mg/Placebo of Finofibrate 160mg 2 tablet once a day (after breakfast) [Extension Period] Take Atrovastatin 20mg, Fenofibrate 160mg 2 tablet once a day (after breakfast)
1636863|NCT01956201|Drug|Fenofibrate 160mg|Refer to Intervention Description of Atorvastatin 20mg
1636864|NCT01956201|Other|Placebo (Fenofibrate 160 mg)|Refer to Intervention Description of Atorvastatin 20mg
1636865|NCT01956188|Dietary Supplement|EPA and DHA supplementation|Subjects will be given 3g/d (1,2g of DHA and 1,8g of EPA) - 5 capsules per day.
1636866|NCT01956188|Dietary Supplement|Placebo|Subjects will be given 3g/d of soy oil - 5 capsules per day.
1636867|NCT01956175|Device|Electrical pharyngeal stimulation|Electrical pharyngeal stimulation via an intraluminal catheter (Phagenesis Ltd.) once daily for 10 minutes on three consecutive days. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After determining the optimal stimulation intensity, 10 minutes of stimulation are delivered.
1636868|NCT01956175|Device|Sham stimulation|The intraluminal catheter (Phagenesis Ltd.) for electrical pharyngeal stimulation is placed. The intensity of the electrical stimulation is determined following the calculation of suitable sensory threshold, tailored to the individual participants. After the optimal stimulation intensity has been determined, no electrical stimulation is delivered.
1636926|NCT01955694|Drug|BAY94-8862|2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, and 20 mg of BAY94-8862 tablets
1636869|NCT01956162|Device|Orthèse Diabète|The device ensures the discharge of the wound by the excavation of the orthopedic insole facing the wound and the load distribution in the healthy areas.
1636870|NCT01956162|Device|"Conventional Device"|Standard (e.g.: CHUT, BAROUK, Tera-Diab, Sanital, Teraheel, Aircast boots, Walker Stabil D, etc.), or customized (orthopedic insole, Ransart boot, D.T.A.C.P., etc.) removable off-loading systems
1636871|NCT01956149|Drug|Cabazitaxel|20 mg/m2 over 1 hour i.v., repeated on day 22 for maximum 6 cycles.
1636872|NCT01956136|Behavioral|Music-based Neurological Rehabilitation (MBNR)|Music-based Neurological Rehabilitation (MBNR) will involve 10 weeks of individual training (30 sessions, 1 hour per session, 3 days per week) given by a trained music therapist. The MBNR protocol utilizes structured cognitive-motor training with drums (drum set, djembe drums) and creative musical expression (music playing, song writing) with piano that are geared towards engaging and training attention, executive functions, working memory, and upper-extremity functions and for enhancing emotional self-expression, adjustment, and mood after TBI.
1636873|NCT01956136|Other|Standard Care (SC)|Standard Care (SC) consists of other types of conventional rehabilitation (physical therapy, occupational therapy, speech therapy, and/or neuropsychological rehabilitation) and medical care for TBI that the patients receive in Finnish private or public health care.
1636874|NCT01956123|Drug|FE 999049|
1636875|NCT01956123|Drug|Follitropin alfa (Gonal-F)|
1636876|NCT01956110|Drug|FE 999049|
1636877|NCT01956110|Drug|Follitropin Alfa (Gonal-F)|
1636878|NCT01956097|Dietary Supplement|HX106 590mg|
1636879|NCT01956097|Dietary Supplement|HX106 1180mg|
1636880|NCT01956097|Dietary Supplement|Placebo|
1636881|NCT01956084|Drug|LMP1/2 CTLs (Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level One:
Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2
Dose Level Two:
Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2
Dose Level Three:
Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
1636882|NCT01956084|Drug|LMP1/2 CTLs (Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level One:
Day 0: 1 x 107 cells/m2 Day 14: 1 x 107 cells/m2
Dose Level Two:
Day 0: 2 x 107 cells/m2 Day 14: 2 x 107 cells/m2
Dose Level Three:
Day 0: 5 x 107 cells/m2 Day 14: 5 x 107 cells/m2"
1636883|NCT01956058|Radiation|brachytherapy remedial|brachytherapy remedial will be performed with injection of hyaluronic acid gel to interface prostate / rectum to push the rectum back and protect it from radiation.
1636884|NCT01956045|Other|Patient's capacity|
1636885|NCT01956019|Device|MRI scanning|
1636886|NCT01956006|Drug|Milrinone|Administration of study medications, PK sampling and safety profile- add on haemodynamic invasive measurements if patient consents to.
1636887|NCT01955980|Drug|Budesonide|Inhalation
1636888|NCT01955980|Drug|Budesonide|Nasal Spray
1636889|NCT01955967|Drug|Lidocaine|
1636891|NCT01955928|Behavioral|Online Cognitive behavioral treatment for insomnia|
1636892|NCT01955889|Behavioral|Mobile Health Technology|
1636893|NCT01955889|Behavioral|Stretching & Strengthening Exercises|
1636894|NCT01955889|Behavioral|Walking with Pedometer|
1636895|NCT01955876|Drug|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Patients treated with Fosrenol in daily clinical practice.
1636896|NCT01955863|Procedure|patient discharge on postoperative day 2|The patient was discharge on postoperative day 2 (as was done routinely)
1636897|NCT01955863|Procedure|patient discharge on postoperative day 1|The patient was discharge on postoperative day 1
1636898|NCT01955863|Procedure|patient discharge in the day of surgery|The patient was discharge in the evening of the same day of surgery (average 12 hours of hospitalization)
1636899|NCT01955850|Behavioral|Cognitive behavioral treatment for insomnia|Cognitive behavioral treatment for insomnia, consisting of: psycho-education, sleep hygiene, stimulus control, sleep restriction, cognitive therapy.
1636900|NCT01955837|Drug|TAS-102|TAS-102 (35 mg/m2/dose) orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
1636901|NCT01955837|Drug|Placebo|Placebo orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
1636902|NCT01955824|Drug|1% lignocaine|
1636903|NCT01955824|Drug|2% lignocaine|
1636904|NCT01955811|Drug|Administration of platelet concentrate and taking blood samples|Patient with the need of a platelet transfusion, will have 4 intervention points. 1. directly before the start of the transfusion a blood sample will be drawn. 2. Patient receives the platelet transfusion. 3. One hour after the end of transfusion a second blood sample will be drawn. 4. 24 h after the end of the platelet transfusion a further bloos sample will be collected. The first two samples will be (beside blood cell counts) spiked in-vitro with different amounts of Human fibrinogen and blood clotting tests will be performed. The same with the 3. blood sample, but without spiking steps.
1636905|NCT01955798|Procedure|Laparoscopic direct entry Trocar|Laparoscopic direct entry with trocar
1636906|NCT01955798|Procedure|Laparoscopic entry Veress needle|Laparoscopic entry with Veress needle
1636907|NCT01955798|Device|Trocar|
1636908|NCT01955798|Device|Veress needle|
1636909|NCT01955785|Device|pressure controlled ventilator|
1636910|NCT01955785|Device|Pressure Regulated Volume Controlled Ventilator|
1636911|NCT01955772|Drug|Enteral nutrition alanyl-glutamin, Dipeptiven|Enteral nutrition versus parenteral nutrition
1636912|NCT01955759|Drug|Amiodarone tab 200 mg x 3|starting 7 days before coronary by-pass surgery per os 200 mg. x 3 tab, followed by 200 mg x 2 tab per os starting on the second postoperative day untill discharge
1636913|NCT01955759|Drug|rosuvastatin 20 mg tab x1|starting 7 days before coronary by-pass surgery
1636914|NCT01955759|Drug|beta blockers Bisoprolol in adjusted dose|starting 7 days befoe coronary by-pass surgery
1636916|NCT01955720|Drug|BI 655075|
1636917|NCT01955720|Drug|BI 655075|
1636918|NCT01955720|Drug|Placebo|
1636919|NCT01955720|Drug|BI 655075|
1636920|NCT01955720|Drug|Placebo|
1636921|NCT01955720|Drug|Placebo|
1636927|NCT01955694|Drug|Eplerenone|INSPRA 25 and 50 mg tablets (MAH: Pfizer) will be used for eplerenone 25 and 50 mg tablets
1636928|NCT01955694|Drug|Placebo|matching placebo
1636929|NCT01955668|Drug|Administration of AZD6738|An oral formulation of AZD6738 will be used. The starting dose of 20 mg BD will be escalated to reach a maximum tolerated dose in patients as defined by dose-limiting toxicity. A '3 week on, 1 week off' schedule, as deemed optimal in modelling of data from non-clinical studies, will be used initially
1636930|NCT01955655|Drug|Baclofen|Since the therapeutic window of Baclofen is narrow, the lowest dose compatible with an optimal response was used.
1636931|NCT01955655|Other|Placebo|
1636932|NCT01955642|Drug|Clopidogrel|75 mg milligrams per days of PLAVIX
1636933|NCT01955629|Drug|Aflibercept AVE0005|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
1636934|NCT01955629|Drug|Oxaliplatin|Pharmaceutical form: Concentrate for solution for infusion; Route of administration: Intravenous
1636935|NCT01955629|Drug|Capecitabine|Pharmaceutical form: Tablets; Route of administration: Oral
1636936|NCT01955616|Drug|RM-131|
1636937|NCT01955616|Drug|Placebo|
1636938|NCT01955603|Drug|NNC0215-0384|A total of seven once-weekly doses of NNC0215-0384 or placebo will be administered subcutaneously (s.c., under the skin) at one of three ascending dose levels. Each cohort will consist of eight subjects randomised to either active (6 subjects) or placebo (2 subjects) treatment. Each subject will participate in one cohort only. Dose-escalation to the next dose level will be initiated when the safety data has been evaluated and if considered safe.
1636939|NCT01955603|Drug|placebo|Placebo administered corresponding to NNC0215-0384 treatment
1636940|NCT01955590|Behavioral|Metacognitive therapy|8-12 sessions of manualized metacognitive therapy
1636941|NCT01955590|Behavioral|EMDR|8-12 sessions of manualized EMDR
1636942|NCT01955590|Behavioral|Treatment as usual|8-12 sessions of treatment of usual
1636943|NCT01955577|Drug|Placebo orally everyday|
1636944|NCT01955577|Drug|Vitamin D3 cholecalciferol|
1636945|NCT01955564|Drug|NW-3509a|single dose
1636946|NCT01955551|Behavioral|Motivational Interviewing|In the Motivational Interviewing study arm, participants will receive MI phone calls designed to evoke change talk and to prompt the participant to identify goals in regards to child behavior or parenting. The caller will engage in problem solving with the participants.
1636947|NCT01955551|Behavioral|Anticipatory Guidance on Child Development|In the Anticipatory Guidance on Child Development study arm, the participants will receive two phone calls with no MI content. The content of these phone calls is derived from an alignment of the Teaching Strategies GOLD® standards with the Head Start Development and Early Learning Framework. , This content is entirely scripted and pre-specified.
1636948|NCT01955538|Other|Control|Psychiatric treatment as usual for 6 months according to best clinical practice.
1636949|NCT01955538|Other|Basic Body Awareness Therapy|20 weeks, 1 hour/week.
1636950|NCT01955538|Other|Mixed physical activity|20 weeks, 1 hour/week.
1636951|NCT01955512|Drug|Clopidogrel|Clopidogrel 75mg daily for 7 days
1636952|NCT01955512|Drug|Placebo|Matched placebo
2012016|NCT02278796|Drug|BeEAM|chemotherapy regimen consisting of bendamustine intravenously on days −7 and −6 at 200 mg/m2; cytarabine, 400 mg/m2 intravenously daily from day −5 to day−2; etoposide, 200 mg/m2 intravenously daily from day −5 to day −2; and melphalan, 140 mg/m2 intravenously on day −1 before reinfusion of autologous stem cells
2012017|NCT02278796|Drug|BEAM|chemotherapy regimen with carmustine (BCNU) 300 mg/m2 on day -6, cytarabine, 400 mg/m2 intravenously daily from day −5 to day−2; etoposide, 200 mg/m2 intravenously daily from day −5 to day −2; and melphalan, 140 mg/m2 intravenously on day −1 before reinfusion of autologous stem cells
1636957|NCT01955486|Other|flight simulation|
1636958|NCT01955473|Drug|Sym004|Part-A (dose-escalation): Sym004 will be administered intravenously either weekly at 6 to 12 milligram per kilogram (mg/kg) or biweekly at 18 mg/kg from Week 1 until unacceptable toxicity, disease progression, or consent withdrawal. Part-B (dose-expansion): After the maximum tolerated dose (MTD) is determined in Part-A, up to 30 additional subjects will continue to receive treatment in Part-B.
1636959|NCT01955460|Drug|Cyclophosphamide|60 mg/kg/day by vein on Day -7 and -6.
1636960|NCT01955460|Drug|Mesna|60 mg/kg by vein on Day -7 and -6.
1636961|NCT01955460|Drug|Fludarabine monophosphate|25 mg/m2 by vein on Day -5 to Day -1.
1636962|NCT01955460|Biological|T-Cells|On day 0, all patients receive the assigned dose level of transduced DNRII TIL, with an equal number of transduced NGFR TIL, up to a total of 1.5 x 10^11 TIL in NS.
1636963|NCT01955460|Drug|Interleukin-2 (IL-2)|720,000 IU/kg by vein every 8-16 hours for up to 15 doses on Days 1 to 5 and 22 to 26.
1636964|NCT01955447|Dietary Supplement|no added plant-based ingredients to starchy meal|no added plant-based ingredients to starchy meal
1636965|NCT01955447|Dietary Supplement|Low level plant-based ingredients added to starchy meal|Low level plant-based ingredients added to starchy meal
1636966|NCT01955447|Dietary Supplement|Medium level plant-based ingredients added to starchy meal|Medium level plant-based ingredients added to starchy meal
1636967|NCT01955447|Dietary Supplement|High level plant-based ingredients added to starchy meal|High level plant-based ingredients added to starchy meal
1636973|NCT01955421|Drug|Erlotinib 100mg qd|
1636974|NCT01955421|Drug|Gefitinib 250mg qd|
1636975|NCT01955408|Other|Questionnaires, anticholinergic treatment, urodynamic study|
1636976|NCT01955395|Behavioral|Relaxation Response Resiliency Program (3RP)|The intervention will consist of one intake with a psychologist (approximately 60 minutes), 8 3RP sessions once a week over the course of 8 weeks (approximately 1 hour and 30 minutes each), and one exit visit (approximately 30 minutes) over the course of 3-months. During the intervention, the participant will be asked to practice what the participant has learned in the intervention by listening to a 20-minute audio CD daily. Additionally, the participant will be asked to keep track of their daily practice by filling out an online or paper log. During the 3RP session, the clinician will address any barriers or problems the participant may be having with the daily practice and help to problem solve them with the participant.
1637000|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
1638231|NCT01945840|Other|Gut hormone infusion (high dose)|
2012018|NCT02278718|Drug|NexoBrid|
2012019|NCT02278718|Procedure|Standard of Care|
2012020|NCT02277704|Drug|TNX-102 SL|
1636980|NCT01955356|Procedure|Scratching|Endometrial biopsy
1636981|NCT01955330|Procedure|Robotic Hybrid coronary artery revascularization|Lita to LAD performed by robot, Hybrid stent to other diseased coronary artery
1636982|NCT01955317|Behavioral|Hand cleansing with chlorhexidine|Pregnant women in the intervention arm will receive an intensive hand cleansing promotion delivered at 3 in-home visits between one month prenatal and 1 week post natal. The intervention will promote and discuss with mothers the benefits of hand cleansing with chlorhexidine before breastfeeding, before umbilical cord care, after contact with respiratory secretions, and the convenience of using a waterless hand sanitizer especially during the neonatal period. Each mother will receive a half-liter pump bottle with chlorhexidine lotion. The program will also educate mothers about infectious causes of morbidity and mortality in neonates and promote understanding of the risk to the neonate from these diseases.
1636983|NCT01955317|Behavioral|Mother and neonatal health counselling|This arms will receive maternal and neonatal health counselling which includes discussion and education about antenatal care, safe and clean delivery, recognition of danger signs for the mother and neonate, immediate new born care, and essential new born care. Each mother will receive a clean delivery kit and pictoral cue cards for danger sign recognition.
1636984|NCT01955304|Drug|fruquintinib|Fruquintinib 4 mg capsule, 2 discrete single doses separated by 2-weeks
1636985|NCT01955291|Device|Reinforced Feedback in Virtual Environment (RFVE)|"The patients allocated to RFVE group, will be treated using the Virtual Reality Rehabilitation System (VRRS). During the virtual therapy the subject will be seated in front of the wall screen grasping a sensorized real object with the affected hand. If the grasp is not possible the sensors will be fixed on a glove worn by the patient. The real object held by the subject, equipped with electromagnetic sensors, is matched to the virtual handling object. Thereafter, the patient moved the real object (e.g. ball) following the trajectory of the corresponding virtual object displayed on the computer screen in accordance with the requested virtual task."
1636986|NCT01955291|Other|Traditional Neuromotor Rehabilitation|The patients randomized to the Traditional Neuromotor Rehabilitation group will be asked to perform exercises for postural control, exercises for hand pre-configuration, exercises for the stimulation of manipulation and functional skills, exercises for proximal-distal coordination. All the exercises will be performed with or without the assistance of a physiotherapist. The upper limb motricity will be trained with progressive complexity. To achieve the requested goal (in a horizontal or vertical plane) patients will be asked to perform various movements, for example: shoulder flexion and extension, shoulder abduction and adduction, shoulder internal and external rotation and shoulder circumduction, elbow flexion and extension, forearm pronation and supination, hand grasping-release and clenching into a fist.
1636987|NCT01955278|Device|Definitive end colostomy with mesh|In the mesh group, a synthetic prosthetic mesh low weight type Ultrapro (15x15 cm) will be used. It will be placed in a sublay position between the rectus abdominis muscle and the posterior rectus sheath, will be sutured to the posterior rectus sheath with absorbable multifilament stitches. Once positioned and fixed the mesh the bowel will be brought out through a cross cut in the center of the mesh Finally, colon will be fixed by colocutaneous end to end absorbable multifilament sutures.
1636988|NCT01955278|Other|Conventional definitive end colostomy|
1636989|NCT01955265|Behavioral|Sports mentorship programme|1.5-hour sports mentorship session once a week, 18 weeks total.
1636990|NCT01955265|Behavioral|Health promotion|The access to a health promotion website any time during the intervention period. The website contains general health information including those related to physical activity.
1636991|NCT01955252|Drug|Azithromycin|"Investigators will do a baseline survey of every children from 5 to 15 years in the village. To detect yaws infection, investigators will collect a blood specimen for serology (qualitative and quantitative RPR testing and TPHA assay).
Investigators will identify yaws-like ulcers by means of dermatological examination. Investigators will swab papilloma and ulcers and specimens will be flown to University of Washington (Seattle). PCR methods will consist of primary screening for the presence or absence of T. p. pertenue DNA, Haemophilus ducreyi DNA and detection of the A2058G and A2059G mutations associated with azithromycin resistance.
Investigators will begin treatment with antibiotics immediately after completion of the baseline survey. Everyone in the villages will be offered azithromycin, subsequently a field team will treat all active clinical cases and their contacts 6 monthly.
For all subjects, follow-up examination will be performed at 6,12,18,24,30,36,40,and 42 months"
1636992|NCT01955239|Radiation|Intensity-modulated Radiotherapy|
1636993|NCT01955226|Other|Tegaderm CHG clear dressing|Tegaderm CHG clear dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
1636994|NCT01955226|Other|Standard clear Tegaderm dressing|Standard clear Tegaderm dressing will be used in central line care and will remain uniform as dictated by the central line maintenance bundle currently directing central line care in our children's hospital.
1636995|NCT01955213|Drug|methylnaltrexone|Patients will be treated with methylnaltrexone in a standard dosing regimen for their weight: 38-62kg:8 mg, 62-114kg:12 mg, >114 kg: 0.15 mg/kg) Methylnaltrexone will be administered subcutaneously every other day for up to 7 doses.
1636996|NCT01955200|Drug|Ticagrelor|(ASA 100mg daily + Ticagrelor 90mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
1636997|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 150mg daily) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
1636998|NCT01955200|Drug|Cilostazol|(ASA 100mg daily + Clopidogrel 75mg daily + Cilostazol 150mg Bid) x 1 month; (ASA 100mg daily + Clopidogrel 75mg daily) x 11 month.
1636999|NCT01955200|Drug|Clopidogrel|(ASA 100mg daily + Clopidogrel 75mg daily) x 12 month.
1715939|NCT00000838|Drug|Stavudine|
2012021|NCT02277704|Drug|Placebo|
2012022|NCT02276547|Device|Mitral valve replacement|Transcatheter mitral valve replacement
2012023|NCT02275338|Drug|Lanreotide Autogel|120mg administered via deep subcutaneous injection at Day 0 and Day 28.
2012024|NCT02271217|Drug|Placebo|
2012025|NCT02271217|Drug|dalfampridine-ER 7.5mg|
2012026|NCT02271217|Drug|dalfampridine-ER 10mg|
2012027|NCT02271022|Other|Non-Interventional Study|Non-Interventional Study
1637001|NCT01955187|Drug|TACROLIMUS|Initial dose: 0.05 mg/Kg/day, adjusted to achieve blood trough levels of 5-7 ng/ml) for six months. Starting at the end of month 6, tacrolimus dosage will be reduced by 25% per month, resulting in a complete withdrawal at the end of month 9.
1637002|NCT01955187|Drug|RITUXIMAB|A dose 1 g IV will be given during month 6 (at day 180), before the onset of tacrolimus dose reduction
1637003|NCT01955187|Drug|METHYLPREDNISOLONE|Month 1: 1g IV methylprednisolone daily for three doses (days 1, 2, and 3), Oral methylprednisolone (0.5mg/kg/day) for 27 days (days 4 to 30). Months 3, and 5: Repeat Month 1.
1637004|NCT01955187|Drug|CYCLOPHOSPHAMIDE|Month 2: Oral Cyclophosphamide (2.0 mg/kg/day) for 30 days. Months 4, and 6: Repeat month 2.
1637005|NCT01955174|Drug|Esophageal endoscopic injection of botulinum toxin|Endoscopic injection of botulinum toxin in the esophageal muscle : one hundred units of type A botulinum toxin (Botox®, Allergan) diluted in 10 mL of normal saline and injected at the lower third of the esophageal wall in 10 sites between 2 and 10 cm above the Z-line.
1637006|NCT01955174|Other|No injection of botulinum toxin|Upper gastro-intestinal endoscopy without any injection
1637007|NCT01955161|Drug|Placebo|Once daily, matching placebo capsules, orally
1637008|NCT01955161|Drug|Idalopirdine|Once daily, encapsulated tablets, orally
1637009|NCT01955135|Drug|Ketamine|1mg/kg bolus intravenous, 0.25mg/kg/hour intravenous for maintenance of sedation
1637010|NCT01955135|Drug|Sevoflurane|anesthesia was induced using 8% sevoflurane by inhalation with 50% nitrous oxide in oxygen; Anesthesia was maintained with sevoflurane (2%) and 50% nitrous oxide in oxygen
1637011|NCT01955135|Drug|propofol|1 mg/kg propofol as a bolus for induction. The patients then received an infusion of 100-150 mcg/kg/min propofol
1637012|NCT01955122|Device|Tandem Colonoscopy|Each patient will undergo a double procedure: standard colonoscopy using the EndoRings™ add-on device and Standard colonoscopy (without using the EndoRings™ add-on device) in a randomized order.
1637013|NCT01955109|Biological|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
2012028|NCT02271386|Behavioral|Supporting Practice for ADHD (SPA)|"The SPA intervention will last for 8 months for each study arm (first 8 months of the study for the intervention group, last 8 months for the control group). The intervention includes 3 components: 1) a series of web-based educational presentations to provide education to providers about evidence-based practice for managing ADHD and strategies for promoting effective communication with families 2) Collaborative consultation designed to address clinical issues arising in practice will be provided by members of the study team.
3) Providers will be given systematic performance feedback with regard to their use of evidence-based practices for ADHD every 2 months during the 8-month intervention period."
2012029|NCT02270502|Device|Ultrasound Philips CX50|The Philips CX50 ultrasound system is used to measure muscle size of the patients. We will measure the area and diameter of the rectus femoris muscle via ultrasound.
1637016|NCT01955083|Device|Pillar implant|Subjects receive pillar implant of the soft palate under local anesthesia as an outpatient procedure on sitting position. Using the delivery tool of the pillar implant system, the mucosa of the soft palate close to the hard palate-soft palate junction (approximate 0.5 cm) was punctured in the midline. The needle was inserted to the uvular muscle and moved parallel to the curve of the soft palate towards the tip of the uvula. After reaching the insertion point, the implant was delivered steadily after which the needle was withdrawn. This process was repeated for the second and third implants in the bilateral para-midline with a 0.2 cm horizontal distance from the first implant.
1637017|NCT01955083|Device|Radiofrequency|Subjects receive radiofrequency under local anesthesia as an outpatient procedure on sitting position. radiofrequency energy was delivered via a generator (Somnus® Model S2, Gyrus-ACMI Corporation, Maple Grove, MN, USA) with the power set to 10 watts and the maximal target temperature to 85°C. The needle electrode was inserted through the mucosa into the muscle layer at the entry points (approximately 1 cm below the hard palate-soft palate junction). The electrode was kept in place until 600 J had been delivered at the midline and 300 J at both para-midline sites (approximately 1 cm horizontal distance).
1637018|NCT01955070|Other|Multimedia Presentation for Ketamine sedation|PowerPoint presentation created with approval of section of emergency medicine for informed consent for ketamine sedation
1637019|NCT01955057|Behavioral|Research interviews|
1637020|NCT01955057|Behavioral|Tests (Fagerström, Q-MAT, H.A.D.S, SCL 90-R)|
1637021|NCT01955057|Behavioral|Projective methods (Thematic apperception Test, Rorschach)|
1637022|NCT01955057|Behavioral|Carbon monoxide test|
1637023|NCT01955044|Dietary Supplement|LCPUFA supplement|
1637024|NCT01955044|Dietary Supplement|placebo|
1637025|NCT01955031|Other|telemonitoring|A telemonitoring program with educational tools is given to people with type 2 diabetes at their home. It is composed of three softwares to improve eating habits available on touchpad, a self-monitoring blood glucose device, a balance to measure weight and fat mass, and a pedometer to evaluate physical activity. Data are securely sent and stored into a web service which delivers a synthesis to patients and health professionals.
1637026|NCT01955031|Other|Usual care|Patients are recruited during therapeutic educational sessions or appointments by general practitioners or diabetologists who take part into the Regional Health Network in Diabetes DIAMIP. If patients accept to participate to the study and sign up the protocol consent, they are given questionnaires about nutrition, physical activity and quality of life. A dietician analyses with each patient the results of a food inquiry. Patients are randomised into two groups: one arm is trained to the telemonitoring program before receiving it at home, and the other arm follows usual care. During 12 months, the telemonitoring group uses the device. The investigators (GP or diabetologists) can use the specific secured website to follow the measured parameters and to make appropriate decisions about health care of their patient. No consultation are scheduled in advance.
1637027|NCT01955018|Device|New algorithm called VeoTM (General Electric Healthcare, Milwaukee, MI, USA)|The objective of the present study is to compare Veo with the gold standard FBP for detecting pulmonary asbestos-related conditions among workers previously exposed to asbestos. Comparisons included radiation delivered and image quality.
1637028|NCT01955005|Behavioral|My HealtheVet Training|Participants will be asked to watch an on-line training video, review written materials, and print a document containing health information from their My HealtheVet account.
1637185|NCT01953952|Other|laboratory biomarker analysis|Correlative studies
1637029|NCT01955005|Other|Internet Skills Training|Participants will review written training materials to learn how to search the Internet for health information and how to decide which Internet sites have good quality information.
1637030|NCT01954992|Drug|Glufosfamide|Glufosfamide: 4500 mg/m2 IV over 6 hours (¼ dose over 30 minutes, ¾ dose over remaining 5.5 hours) on Day 1 of each 21-day cycle.
1637031|NCT01954992|Drug|Fluorouracil|Fluorouracil (5-FU): 600 mg/m2 IV over 30 minutes on Day 1 of each week
1637032|NCT01954979|Drug|Abatacept|The study will follow a standard 3+3 design with two escalating doses of abatacept to determine the maximum tolerated dose (MTD): 3 mg/kg (dose level 1) and 10 mg/kg (dose level 2). Dose-limiting toxicities (DLTs) are defined as any Grade 3 or 4 toxicities judged to be probably or definitely related to abatacept.
1637035|NCT01954940|Device|Whole Body Vibration Therapy|
1637036|NCT01954927|Drug|Gabapentin|Gabapentin is supplied as an oral suspension. Patients randomized to the gabapentin arm will receive a single dose of gabapentin as soon after enrollment as feasible. The gabapentin dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
1637037|NCT01954927|Drug|Placebo|Placebo will be prepared by the SJCRH pharmacy and will be similar in appearance, quantity and taste to the gabapentin drug. Patients randomized to the placebo arm will receive a single dose of placebo as soon after enrollment as feasible. The placebo dose will be given orally and will be approximately 15 mg/kg with a maximum dose of 900mg.
1637038|NCT01954914|Drug|Plerixafor|Administration of a single dose of Plerixafor 240 µg/kg body weight of the donor SC in the evening at 10 PM after frustraneous stem cell apheresis on day 1.
1637039|NCT01954901|Procedure|Hyperbaric oxygen therapy|
1637040|NCT01954888|Procedure|Blind technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approaches (blind and ultrasound-guided).
1637041|NCT01954888|Procedure|Ultrasound-guided technique|A mixture of 3 mL of 2% lidocaine and 7 mL of 0.5% bupivacaine is used for both approach (blind and ultrasound-guided).
1637042|NCT01954862|Other|Air Insufflation method.|Air Insufflation method.
1637043|NCT01954862|Other|CO2 insufflation|CO2 insufflation.
1637044|NCT01954862|Other|Water Immersion/CO2|Water Immersion during insertion, CO2 insufflation during withdrawal.
1637045|NCT01954862|Other|Water Exchange/CO2|Water Exchange during insertion, CO2 insufflation during withdrawal.
1637046|NCT01954862|Other|Water Immersion/AI|Water Immersion during insertion, AI insufflation during withdrawal.
1637047|NCT01954862|Other|Water Exchange/AI|Water Exchange during insertion, AI insufflation during withdrawal.
1637048|NCT01954849|Dietary Supplement|Probiotic formulation|
1637049|NCT01954836|Behavioral|initial fasting|modified fasting with daily caloric intake of <400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the first half of scheduled 4 or 6 chemotherapy cycles
1637050|NCT01954836|Behavioral|Secondary fasting|modified fasting with daily caloric intake of <400kcal by juices starting 36 to 48 h before begin of chemotherapy and lasting to 24 h after end of chemotherapy applied in the second half of scheduled 4 or 6 chemotherapy cycles
1637051|NCT01954823|Device|e-diary|"The e-diary can collect data on:
Medical data: information on diseases, treatments and attending physicians
Diary: daily report of drugs intake, symptoms and their intensity and additional relevant data
Reminders: the application can send reminders on drug intake or medical appointments to cellular phones or emails
Reports: textual and graphical reports of the data in the diary can be created"
1637052|NCT01954810|Biological|Japanese encephalitis chimeric vaccine (JECV)|Japanese encephalitis chimeric vaccine (JECV)will be administered to every children in the study for one dose and check for antibody response 4 weeks after vaccination
1637053|NCT01954784|Drug|fludarabine phosphate|
1637054|NCT01954784|Radiation|total-body irradiation|Undergo TBI
1637055|NCT01954784|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic hematopoietic SCT
1637056|NCT01954784|Drug|cyclosporine|Given PO
1637057|NCT01954784|Drug|mycophenolate mofetil|Given PO
1637058|NCT01954784|Drug|bortezomib|Given SC
1637059|NCT01954784|Drug|lenalidomide|Given PO
1637060|NCT01954784|Other|laboratory biomarker analysis|Correlative studies
1637061|NCT01954771|Behavioral|SMBG|"Control Group Patients will receive conventional care and keep on their usual SMBG methods. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
SMBG-4 Group Capillary glucose level is measured using finger stick method by 4 times (fasting plus post-meals) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively.
SMBG-7 Group Capillary glucose level is measured using finger stick method by 7 times (fasting, pre-meals, post-meals and bedtime altogether) every other day. Additionally, each patient will also wear a CGMS device for 72h in the first week and the last week, respectively."
1637062|NCT01954771|Other|CGMS|In this study, according to the protocol, all the patients will follow their prespecified SMBG methods and periodically visit doctor, but therapies will not be adjusted unless they experience severe hypoglycemia or hyperglycemia episodes. The expected duration of the trial is 12 weeks.
1637066|NCT01954745|Drug|Cabozantinib|Cabozantinib 60 mg (free base weight) per day will be administered daily and continuously for a cycle length of 28 days. Subjects will be provided with a sufficient supply of study treatment and instructions for taking the study treatment on days without scheduled clinic visits. After fasting (with exception of water) for 2 hours, subjects will take study treatment daily with a full glass of water (minimum of 8 oz/ 240 mL) and continue to fast for 1 hour after each dose of study treatment.
1637067|NCT01954732|Drug|metformin hydrochloride|Given PO
1637068|NCT01954732|Other|pharmacological study|Correlative studies
1715940|NCT00000838|Drug|Zidovudine|
1637069|NCT01954719|Procedure|cervix dilated after surgery|The surgeon inserted his or her double-gloved index digit in the cervical canal to dilate it and removed the outer gloves after digital dilatation of the cervix.
1637070|NCT01954719|Procedure|control group|surgeon not dilated cervix after surgery
1637071|NCT01954706|Other|Structured Exercise|Structured and supervised aerobic and resistance training 2 times per week
1637072|NCT01954706|Other|Usual Care|Subjects will be counseled on American Cancer Society and American College of Sports Medicine physical activity and nutritional guidelines at the initiation of the study. Study participants will be contacted by a physician or nurse on weeks 2, 6, 10, and 14 to provide support and encouragement to patients.
1637073|NCT01954693|Drug|Placebo|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily.
1637074|NCT01954693|Drug|Everolimus (RAD001)|5mg daily administered for 6 months as two oral 2.5 mg tablets once daily
1637075|NCT01954680|Behavioral|COGFLEX-skill building levels|"COGFLEX--in English-- is a computer game designed to build up a specific skill that our work has shown is impaired in children and adolescents with bipolar disorder).
In the R33, children will be randomized to receive either COGFLEX with skill-building levels or COGFLEX-control condition which is just baseline/non-probabilistic trials.
All children will play COGFLEX twice per week for 8-weeks.
This same approach has shown great success in many psychiatric disorders including schizophrenia.
This is the first such study in children/adolescents with bipolar disorder."
1637076|NCT01954680|Behavioral|COGFLEX-control condition|"In the R33, the control condition will be the same COGFLEX game--but just baseline/non-probabilistic trials. All children will play COGFLEX twice per week for 8-weeks."
1637077|NCT01954654|Device|Custom-made compression sleeve and -gauntlet|Device: Compression garments worn for a minimum of six hours per day
1637078|NCT01954654|Other|Educational information, recommendation and instruction|Educational information and recommendations about lymphedema and skin care. Instruction in physical exercises to enhance the lymph flow
1637079|NCT01954641|Other|ACCURE Navigator|"The ACCURE Real-Time Registry will automatically alert the ACCURE Navigator to follow a schedule of patient-interactions. The Navigator has been trained to employ the teachback method of patient education as appropriate per encounter. For instance: (1) initial face-to-face interaction, after the patient's first visit with the oncologist; (2) telephone call 3 business days after the initial visit; (3) contact the patient 10-21 days after the initial visit; and (4) after treatment has begun, contacting the patient every 8 weeks.It is projected that 50% of the staff will attend the Healthcare Equity Training (HET) and Booster Sessions."
1637080|NCT01954641|Other|Usual Care by Cancer Center Care Team|The Usual Care group will receive the support and care that is usually given to patients at their designated cancer center.
1637081|NCT01954628|Drug|AQX-1125|Synthetic SHIP1 activator
1637082|NCT01954628|Drug|Placebo|Placebo control
1637083|NCT01954615|Drug|5 mg ACT-281959 prodrug formulation I (Group A)|
1637084|NCT01954615|Drug|20 mg ACT-281959 prodrug formulation I (Group B)|
1637085|NCT01954615|Drug|ACT-281959 prodrug formulation I (Groups C to G doses to be defined)|
1637086|NCT01954615|Drug|ACT-281959 prodrug formulation II (Group G dose to be defined)|
1637087|NCT01954615|Drug|ACT-246475 (Group G dose to be defined)|
1637088|NCT01954615|Drug|Placebo (Groups A to F)|
1637091|NCT01954589|Drug|ACT-462206 5 mg|
1637092|NCT01954589|Drug|ACT-462206 25 mg|
1637093|NCT01954589|Drug|ACT-462206 100mg|
1637094|NCT01954589|Drug|ACT-462206 200mg|
1637095|NCT01954589|Drug|ACT-462206 400mg|
1637096|NCT01954589|Drug|ACT-462206 1000 mg|
1637097|NCT01954589|Drug|ACT-462206 1500mg|
1637098|NCT01954589|Drug|Almorexant 400mg|
1637099|NCT01954589|Drug|Placebo|
1637103|NCT01954563|Biological|MVA85A|Modified vaccinia virus Ankara (MVA) is a highly attenuated strain of vaccinia with an antigen 85A insert.
1637104|NCT01954550|Behavioral|Cycling exercise|An exercise interventionist will guide and supervise participants to participate in moderate-intensity cycling on recumbent stationary cycles for 20-50 minutes, 3 times a week for 6 months.
1637105|NCT01954550|Behavioral|Range of motion/stretching exercise|An exercise interventionist will guide and supervise participants to participate in low-intensity range of motion/stretching exercise for 20-50 minutes, 3 times a week for 6 months.
1637106|NCT01954524|Drug|IV bolus injection of Sildenafil|"Dose escalation will be performed (in different participants). The doses will be as follows:
CTP class B cirrhosis: A single 5 and 10 mg IV bolus injections of Sildenafil. CTP class C cirrhosis: A single 2.5, 5, 8 and 10 mg IV bolus injections of Sildenafil."
1637107|NCT01954511|Other|Manual therapy|The patient was supine with the cervical spine in a neutral position. The therapist brought about a contact of the occipital bone with the ﬁrst ﬁnger and medial aspect of the hand, and other hand over the frontal region of the patient's head. The mobilizing force was delivered by ﬂexing the upper cervical region using a combination of cephalic traction with the occipital hand and caudal pressure with the frontal hand. This technique was applied for 10 minutes
1637108|NCT01954511|Other|Manual therapy|The patient was prone with the cervical spine in a neutral position. The therapist placed the tips of his thumbs on the posterior surface of the C5 spinous process, while the other ﬁngers rested gently around the patients' neck. This technique was applied for 9 minutes
1637109|NCT01954511|Device|Pressure biofeedback device|Device: Stabilizer - Chattanooga Group Inc., Chattanooga, Tennessee, USA The cranio-cervical flexor stabilization exercise was done 10 times holding 10 seconds the flexing position graded through feedback from a pressure biofeedback device
1637110|NCT01954498|Dietary Supplement|Walnuts|
1637111|NCT01954498|Dietary Supplement|OTC multivitamin|
1637112|NCT01954485|Procedure|Dental implant placement with a final prosthetic abutment|
1637277|NCT01953328|Biological|Evolocumab|Administered by subcutaneous injection
1715941|NCT00000838|Drug|Didanosine|
1637113|NCT01954472|Behavioral|Enhanced portfolio plus structured exercise|"Foods on the dietary portfolio plan will contribute 9g/1000 kcal viscous fibre as β-glucan (oats, barley, oat bran breads and soups) and psyllium (cereal), 1g plant sterol/1000 kcal diet (in sterol margarine), 22.5g soy protein/1000 kcal (soy burgers, dogs, links, other soy meat analogues, soy milks, yogurts and cheese), and additional sources of plant protein from pulses (eg. Lentils, chickpeas, beans, etc) and 22.5g almonds or equivalent of other nuts/1000 kcal and increased MUFA (as olive and canola oils, avocados, nuts, margarine and salad dressings). The glycemic index will be reduced from 83 to 70 GI units (bread scale).
Exercise: The physical activity/exercise program is based on the program used at the Quebec Heart and Lung Institute."
1637114|NCT01954472|Behavioral|High fiber diet plus routine exercise|"Dietary advice will be given to encourage intake of whole grain foods (brown rice, whole wheat breads, muffins and breakfast cereals); to reduce meat consumption, choose low fat dairy products and a control margarine.
Exercise: A pamphlet (Canada's Physical Activity Guide, Health Canada) encouraging increased physical activity will be provided."
1637115|NCT01954459|Device|Insupatch|Device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous site of glucose sensor.
1637116|NCT01954459|Device|Continuous glucose sensor|Glucose sensor inserted without warming patch
1637117|NCT01954446|Device|3M|Conventional measuring of BP
1637118|NCT01954446|Device|ContiPressTM|"New way of measuring BP - ContiPressTM
Investigational device"
1637119|NCT01954446|Device|Mobil-O-Graph|2 different devices for oscillometric measurement of BP
1637120|NCT01954433|Procedure|Operated TSA Patients|Total shoulder prosthesis: Anatomic or reverse total shoulder replacement is a well-standardized procedure usually performed under general anesthesia with the patient in a beach-chair position
1637121|NCT01954433|Procedure|Operated RCR Patients|Arthroscopic rotator cuff tear reconstruction. The shoulder arthroscopy is performed according to internal and international standard procedure with patients positioned in beach-chair position under general anesthesia.
1637122|NCT01954433|Procedure|Resection interposition suspension arthroplasty (RISA)|"One of five surgical techniques can be used in this study, as routinely performed by each surgeon:
RISA with FCR-Ligament (flexor carpi radialis ligament) modified according to Epping
RISA with FCR-Ligament modified according to Weilby
RISA with APL-Ligament (abductor pollicis longus ligament)
RISA with Graftjacket modified according to Weilby
Resection arthroplasty"
1637123|NCT01954420|Behavioral|Cognitive-Behavioral Intervention|Standard care + Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player.
1637124|NCT01954420|Other|Attention Control|Standard care + Cancer education
1637125|NCT01954407|Behavioral|Smoking-Related Messages|
1637126|NCT01954394|Drug|Alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
1637127|NCT01954381|Device|transthoracic echocardiographic|
1637128|NCT01954381|Device|Doppler ultrasound.|
1637129|NCT01954381|Biological|blood samples|
1637130|NCT01954368|Drug|Placebo|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a planned weight-based volume of intranasal placebo (normal saline solution).
Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
1637131|NCT01954368|Drug|Sufentanil|"As soon as possible from ED admission, using a study drug volume schedule, triage nurse will administer to the patient a weight-based volume (corresponding to 0,4 mcg/kg) of intranasal sufentanil.
Half of the dose will be administrated in each nostril. The patient will then rapidly be brought to emergency room and after his pain being reassessed, appropriate treatment (following current recommendations) will be given by the ED nurse."
1637132|NCT01954355|Drug|LDE225|400, 600 and 800 mg OD
1637133|NCT01954355|Drug|Paclitaxel|80 mg/m2 (days 1, 8, 15)
1637134|NCT01954316|Drug|CFI-400945|Polo-like kinase 4 (PLK4) inhibitor
1637135|NCT01954303|Other|Progress of CHD|
1637136|NCT01954290|Drug|Conivaptan|Intravenous conivaptan 20 mg infused over 30 minutes as a loading dose, followed by a continuous infusion of 20 mg over 24 hours (0.83 mg/hour) for 2-4 days; may increase to a maximum dose of 40 mg over 24 hours (1.7 mg/hour) if serum sodium is not rising sufficiently; total duration of therapy not to exceed 4 days.
1637137|NCT01954290|Drug|Hypertonic saline|Hypertonic saline in the dose of 30ml/hr, with every 4 hourly measurements of serum osmolarity, serum sodium and potassium. Hypertonic saline will be increased by 30 ml to achieve target serum sodium of 150-160 and serum osmolarity 300-320
1637138|NCT01954290|Drug|Mannitol|Mannitol given at the dose of 0.5 to 1.0 gm/kg IV over 10-20 minutes. Maximum effect is seen in 20 minutes and duration of action is 4 hours. Repeat doses of 0.25 to 0.5 gm/kg Q 4-6 hours are normally frequently used.
1637139|NCT01954277|Device|Electroacupuncture|Eletroacupuncture performed using acupuncture needles.
1637140|NCT01954277|Device|Placebo Sham|Placebo Sham is performed using electrodes, without electrical stimulation. Lights and sounds were identical to active treatment.
2012030|NCT02270502|Other|Frailty Index Questionnaire|Frailty Index Questionnaire is a clinical tool to assess frailty in patients. We will ask patients to answer the questionnaire, including clarification that the questionnaire assesses the patient's pre-admission condition. The presence of a frail characteristic will be scored as 1 point. Most variables will be dichotomized (e.g. 1 point when a frail characteristic will be present and 0 points when frail characteristic will be not present).The Frailty Index will be calculated as the total number of frail characteristics of the patient divided by the total number of variables (n=50).
1637145|NCT01954238|Drug|GCC-4401C|"Orally active direct factor Xa inhibitor for use in the prevention and treatment of venous thromboembolic disease.
The dose selection for this clinical study was based on the safety, Pharmacokinetics and Pharmacodynamics results of the single dose study.
GCC-4401C was well tolerated in the single ascending dose study up to the highest single oral dose administered of 80 mg from 2.5 mg in 48 subjects.
The study consists of five cohorts (10 mg, 20 mg, 40 mg, 60 mg, and 80 mg) with eight subjects per cohort.
In the 20 mg cohort, six additional subjects will receive rivaroxaban (Xarelto®) 20 mg as an active comparator in open-label fashion."
1637278|NCT01953328|Other|Placebo to Evolocumab|Administered by subcutaneous injection
1715942|NCT00000241|Drug|Flupenthixol|
1637146|NCT01954238|Drug|Rivaroxaban|Rivaroxaban (Xarelto®) 20 mg tablets for oral administration IMP, placebo and comparator will be administered the same time points. The comparator will be administered open-label 30 minutes after a standard breakfast.
1637147|NCT01954238|Drug|Placebo|GCC-4401C matching placebo(Capsule): Strength is not applicable. GCC-4401C and placebo will be administered double-blind after a 10 hours fast.
1637148|NCT01954225|Other|Udumbara Sutra|The Udumbara sutra is a standard medicated thread smeared with latex of Udumbara (Ficus Glomerata) which has cutting and healing property.
1637149|NCT01954212|Other|Enhanced complex oral health care|"Our proposed complex oral health care (OHC) intervention (SOCLE intervention) comprises 3 levels of intervention:
Patient Level: An individualised OHC assessment on admission and individualised OHC plans for patients, which may involve staff-led OHC support, access to OHC equipment, products and specialist support services and OHC health promotion components.
Staff Level: Specialist web-based OHC educational training, including information on the oral cavity and structures; oral health problems (e.g. decay, gum disease, dry mouth); instruction on OHC techniques, equipment and products; use of the SOCLE assessment and protocol tools.
Service Level: Processes to facilitate access to specialist dental support services (e.g. dentist, hygienist, denture repair laboratory). Essential OHC equipment (toothbrushes, denture marking kits) and products (e.g. toothpaste, oral balance gel) on the ward will be available."
1637150|NCT01954199|Procedure|Neurodynamic Group|"All techniques will be executed in a pain-free way (grade III). Mild discomfort will be accepted, but it must subside as soon as the technique ends.
In the dynamic opener technique, patient will be positioned in side-lying, with the affected side upwards. The therapist will then perform grade III oscillations aiming to open the lumbar foramen;
In the side-lying slider, the patient will be in side-lying with the affected side upwards. A combination of knee and hip flexion and extension movements will produce sliding in the neural structures;
In the slump slider, the patient will be seated in slump position. Combinations between neck and knee movements will produce greater nerve excursion than the side-lying slider. Patients will perform the slump slider in a pain-free manner."
1637151|NCT01954186|Drug|intravenous & intramuscular oxytocin|intravenous or intramuscular 10 iu oxytocin
1637152|NCT01954186|Procedure|after delivery of the fetus & when anterior shoulder seen|oxytocin 10 iu after the delivery of the fetus or when the anterior shoulder was seen after the fetal head was delivered
1637153|NCT01954173|Radiation|3D conformal radiation therapy|Undergo conformal radiation therapy
1637154|NCT01954160|Device|Symplicity Renal Denervation|Renal denervation
1637155|NCT01954147|Drug|GLP-1|GLP-1 therapy
1637156|NCT01954147|Biological|SC|Stem cell infusion
1637157|NCT01954147|Other|Standard Medical Treatment|Standard Medical Treatment
1637158|NCT01954121|Drug|Levetiracetam|"Immediate release film-coated tablets at strengths of 250 mg and 500 mg.
Up-titration Period (Week 1 to Week 3): Levetiracetam (LEV) 250 mg twice daily (bid)
Stabilization Period and Evaluation Period (Week 3 to Week 30): LEV 500 mg bid
Down-titration Period (Week 30 up to Week 33)"
1637159|NCT01954121|Drug|Carbamazepine|"Immediate release tablets at a strength of 200 mg.
Up-titration Period (Week 1 to Week 3): Carbamazepine- Immediate Release (CBZ-IR) 200 mg once daily (qd)
Stabilization Period and Evaluation Period (Week 3 to Week 30): CBZ-IR 200 mg bid
Down-titration Period (Week 30 up to Week 33)"
1637160|NCT01954108|Device|hyaluronic acid sodium salt|
1637161|NCT01954108|Device|ESWT|
1637162|NCT01954082|Drug|myo-Inositol 5% Injection|"Abbott Nutrition Division, Abbott Laboratories is supplying myo-Inositol 5% Injection to the clinical centers for the duration of the trial.
Inositol: myo-Inositol 5% Injection is an isotonic, preservative-free, sterile 5% solution of myo-inositol in water containing 0.5 gm sodium chloride per liter (8.55mM), pH 6.5-7.5. It is administered via IV infusion using syringe pump over 15-30 minutes twice per day at 12-hour intervals at a dose of 80 mg inositol/kg/day (40 mg inositol/kg/dose), which is equivalent to 1.6 mL/kg/day (0.80 mL/kg/dose)."
1637163|NCT01954082|Drug|Placebo|% glucose(dextrose)
1637164|NCT01954069|Device|Semi-quantitative pregnancy test|
1637165|NCT01954056|Drug|Hydrocortisone|"• 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).
1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
1637166|NCT01954056|Drug|Placebo|"7 days of intravenous or intramuscular placebo (normal saline in equal volume)
1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose"
1637167|NCT01954043|Drug|Dabrafenib 150 mg twice a day (BID)|Dabrafenib dosed at 150mg twice a day from Day 1 to the morning of Day 29
1637168|NCT01954043|Drug|Rabeprazole 40 mg once daily (OD)|Rabeprazole dosed at 40mg each morning on Days 16 to 19
1637169|NCT01954043|Drug|Rifampin 600 mg OD|Rifampin dosed at 600mg each morning on Days 20 to 29
1637170|NCT01954030|Drug|CTO and Bevacizumab|
1637171|NCT01954030|Drug|CTO alone|
1637172|NCT01954017|Biological|STP 206|Live Biotherapeutic
1637173|NCT01954017|Biological|Sterile Water|
1637174|NCT01953991|Device|Dentures|Removable prosthesis to replace missing teeth
1637175|NCT01953978|Drug|Dexamethasone|Intravenous administration of dexamethasone 16 mg (concentration 4 mg/ml, volume 4 ml) immediately after endotracheal intubation
1637176|NCT01953978|Other|Placebo|Intravenous administration of isotonic sodium chloride (concentration 9 mg/ml, volume 4 ml) immediately after endotracheal intubation
1637177|NCT01953978|Drug|Morphine|Morphine. Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
1637178|NCT01953978|Drug|Zofran|Zofran 4 mg iv in case of moderate to severe nausea, supplemented by Zofran 1 mg iv if needed
1637179|NCT01953978|Drug|Paracetamol|Tablet Paracetamol 1 g orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
1637180|NCT01953978|Drug|Ibuprofen|Tablet Ibuprofen 400 mg orally, 1 hour preoperatively and every 6 hours after extubation time during the first 48 hours.
1637181|NCT01953952|Procedure|therapeutic conventional surgery|Undergo transoral eHNS
1637182|NCT01953952|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1637183|NCT01953952|Drug|cisplatin|Given IV
1637184|NCT01953952|Procedure|quality-of-life assessment|Ancillary studies
1715943|NCT00000242|Drug|Carbamazepine|
1637186|NCT01953939|Other|Prosthetic Limb Users|There will be a time period of 7-10 days between data collection visits in this test-retest study which is measuring reliability in the functional outcome measures regularly used in clinical practice.
1637187|NCT01953926|Drug|Neratinib|Neratinib 240 mg orally, once daily with food, continuously in 28 day cycles
1637188|NCT01953926|Drug|Paclitaxel|80mg/m^2 IV on Days 1, 8, and 15 of every 4 week cycle
1637189|NCT01953926|Drug|Fulvestrant|500 mg administered as two 5 mL injections on Days 1, 15 of the first month, then Day 1 of every 4 week cycle
2012031|NCT02270502|Other|Muscle strength tests|MRC score is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement.
1637191|NCT01953900|Genetic|GD2 T cells|"On dose levels 1 and 2 each patient receives one injection of GD2 T cells followed by VZV vaccine injection 42 days later.
Dose levels 1 and 2 are:
Dose Level 1: 1x10^6 cells/m^2
Dose Level 2: 1x10^7 cells/m^2
The next dose levels to be studied following Dose level 2 are Dose levels 7 and 8 where subjects will receive the VZV vaccine followed by a single infusion of iC9-GD2-CAR-VZV-CTLs within 48 hours after VZV vaccine:
Dose Level 7: 1 x 10^7 cells/m2
Dose Level 8: 1 x 10^8 cells/m^2
The previously planned dose levels 3-6 will not be studied."
1637192|NCT01953900|Biological|VZV vaccine|Subjects will receive a VZV vaccine with CTL infusion within 48 hours after the vaccine.
1637193|NCT01953887|Drug|EC905|Oral
1637194|NCT01953887|Drug|solifenacin|oral
1637195|NCT01953887|Drug|tamsulosin|oral
2012032|NCT02269111|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
2012033|NCT02269111|Procedure|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
1637198|NCT01953861|Drug|EC905|Oral
1637199|NCT01953848|Drug|EC905|Oral
1637200|NCT01953835|Drug|GSK2586184 standard formulation|GSK2586184 standard formulation is a white film coated round biconvex 200 mg oral tablet. For cohort A, it is to be administered at 400 mg (200 mg x 2 tablets) twice daily from Day 6 to Day 14. For cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose after standard breakfast either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day wash out period.
1637201|NCT01953835|Drug|Simvastatin|Simvastatin 10 mg oral tablet is peach-coloured, oval-shaped tablets. It is to be administered orally as a single dose of 10 mg tablet on the mornings of Day 1 and Day 10.
1637202|NCT01953835|Drug|Rosuvastatin|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
1637203|NCT01953835|Drug|GSK2586184 new formulation|GSK2586184 new formulation without poloxamer is a white film coated round biconvex 200 mg oral tablet. In cohort B, it is to be administered at 400 mg (200 mg x 2 tablets) single dose once after standard breakfast and once after overnight fasting, either on Day 1, 4 and 7 according to the treatment sequence, each separated by a 3-day washout period.
1637204|NCT01953822|Other|Data collection|Data collection from an existing electronic healthcare databases - Clinical Practice Research Datalink (CPRD) GOLD.
1637205|NCT01953809|Drug|GSK1322322|Oral tablets with unit dose strength of 500mg and dose level of 1500mg (3 x 500mg) for twice a day administration for 7 days in treatment phase
1637206|NCT01953809|Drug|EE/NE|Oral contraceptive tablet containing 0.035mg EE and 1mg NE for once daily administration for 21 days in run-in phase and 21 days in treatment phase
1637207|NCT01953809|Drug|GSK1322322 Placebo|GSK1322322 matching placebo tablets for twice a day administration (3 tablets each time) for 7 days in treatment period.
1637208|NCT01953809|Drug|EE/NE Placebo|EE/NE matching placebo tablet for once daily administration for 7 days in run-in phase.
2012034|NCT02269111|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
2012035|NCT02269111|Procedure|dynamic susceptibility contrast-enhanced magnetic resonance imaging|Undergo DSC-MRI
1637211|NCT01953770|Drug|PEG-L-asparaginase ind|1,000 U/m2 on day 3 of induction therapy, intravenously, in 200 ml of saline, during 1 hour
1637212|NCT01953770|Drug|PEG-L-asparaginase cons|1,000 U/m2 intravenously, in 200 ml of saline, during 1 hour, 24 hours after methotrexate on weeks 7, 9, and 11 - days 44, 58, and 72 (phase S1), weeks 15, 17, and 19 - days 100, 114, 128 (phase S2), weeks 23, 25, and 27 - days 156, 170, 184 (phase S3).
1637213|NCT01953770|Drug|E.coli L-asparaginase|E.coli L-asparaginase (asparaginase medac) 5,000 U/m2 intramuscularly weekly, 24 hours after methotrexate dose, from week 7 to week 12 - days 44, 51, 58. 65, 72, 79 (phase S1), from week 15 to week 20 - days 100, 107, 114, 121, 128, 135 (phase S2), from week 23 to week 28 - days 156, 163, 170, 177, 184, 191 (phase S3).
1637214|NCT01953770|Drug|High-dose Methotrexate|2,000 mg/m2 per 24 hours is given at days 43, 57, and 71 (weeks 7, 9, and 11). 1/5 of the total dose is given as slow intravenous bolus over 3-5 minutes. 4/5 of the total dose of methotrexate is injected as continuous 24 hours infusion.
1637215|NCT01953770|Drug|Low-dose Methotrexate|30 mg/м2 is given intramuscularly 1 time weekly - days 43, 50, 57, 64, 71, and 78 (weeks 7, 8, 9, 10, 11, and 12).
1637216|NCT01953770|Drug|Triple intrathecal therapy|Intrathecal injection of 3 drugs is additionally given three times during phase S-2 (weeks 15, 17, and 19 - days 99, 113, and 127), and three times during phase S-3 (weeks 23, 25, and 27 - days 155, 169, and 183).
1637217|NCT01953770|Radiation|Cranial irradiation|12 Gy cranial irradiation is conducted at weeks 31-32 of the Protocol in patients >3 years of age
1637218|NCT01953770|Drug|Daunorubicin|Daunorubicin at a dose of 45 mg/m2 i.v. for 6 hours on day 8 of induction therapy
1637219|NCT01953757|Other|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
1637220|NCT01953757|Dietary Supplement|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
1637221|NCT01953744|Drug|Fluconazole|Fluconazole is presented in 150mg capsules and will be administered by oral route at a dosage of 6-8mg/kg/day during 28 days.
1637222|NCT01953744|Drug|Meglumine Antimoniate|Meglumine Antimoniate will be administered as the standard treatment for cutaneous leishmaniasis by intravenous route at a dosage of 20mg/kg/day, during 20 days.
1638232|NCT01945840|Other|Gut hormone infusion (low dose)|
1637223|NCT01953731|Drug|Palbociclib|"In period 1, patients will receive a single 125mg oral dose of palbociclib alone. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose."
1637224|NCT01953731|Drug|Rifampin|In period 2, subjects will receive 12 daily oral doses of 600mg of rifampin and a single 125mg oral dose of palbociclib on day 8. Subjects will undergo palbociclib pharmacokinetic sampling at prespecified time points up to 120 hours post palbociclib dose.
1637225|NCT01953705|Drug|Omega 3 PUFA|fish oil concentrate standardized to long chain n-3 PUFA content
1637226|NCT01953705|Drug|Placebo|
1637227|NCT01953692|Biological|Pembrolizumab|IV infusion
1637228|NCT01953692|Drug|Lenalidomide|oral capsules
1637229|NCT01953679|Drug|Ulipristal Acetate|
1637230|NCT01953666|Other|Rehabilitation program|"Rehabilitation program with an occupational therpasit
3 training sessions (one hour) per week for a month (12 sessions)"
1637231|NCT01953666|Other|Self - Training at home|Only instructions for a self - training at home
1637232|NCT01953666|Other|No treatment|No rehabilitation program No instructions
1637233|NCT01953653|Behavioral|Structured daily diary|The intervention is a structured daily diary to describe fluctuations in key psychological and behavioral variables impacting daily risk behavior among HIV-positive young men who have sex with men (YMSM), aged 16 to 24 years old who engage in substance use and sexual risk behaviors.
1637234|NCT01953640|Other|Laboratory Biomarker Analysis|Correlative studies
1637235|NCT01953640|Other|Quality-of-Life Assessment|Ancillary studies
1637236|NCT01953627|Procedure|Surgical procedure with the system Kymerax|
1637237|NCT01953627|Device|The system Kymerax|
1637238|NCT01953614|Other|Chiropractic adjustment|
1637239|NCT01953614|Other|Sham adjustment|
1637240|NCT01953601|Drug|Verubecestat (Part I and Part II)|Verubecestat 12 mg tablet
1637241|NCT01953601|Drug|Verubecestat (Part I and Part II)|Verubecestat 40 mg tablet
1637242|NCT01953601|Other|Placebo (Part I)|Matching placebo to verubecestat tablet
1637243|NCT01953601|Other|Verubecestat (Part II)|Matching placebo to verubecestat tablet
1637244|NCT01953588|Drug|fulvestrant|Fulvestrant 500 mg IM
1637245|NCT01953588|Drug|anastrozole|Anastrozole 1 mg oral tablet
2012036|NCT02268552|Drug|branaplam|
1637247|NCT01953549|Procedure|physical fitness training|
1637248|NCT01953549|Procedure|relaxation|
1637249|NCT01953536|Drug|Vintafolide 2.5 mg|During treatment, participants receive IV vintafolide 2.5 mg.
1637250|NCT01953536|Drug|Paclitaxel 80 mg/m^2|During treatment, participants receive IV paclitaxel 80 mg/m^2.
1637251|NCT01953536|Drug|Etarfolatide|During screening and prior to screening CT scan, participants receive an IV injection of 0.1 mg etarfolatide radiolabeled with 20 to 25 milliCuries of technetium-99m.
1637252|NCT01953536|Drug|Folic acid|During screening and prior to etarfolatide injection and screening CT scan, participants receive an IV injection of 0.5 mg folic acid.
1637253|NCT01953536|Drug|Premedication for Paclitaxel|During treatment, participants receive dexamethasone 20 mg orally 12 to 6 hours prior to paclitaxel; OR promethazine 25 mg or 50 mg IV 30 to 60 minutes prior to paclitaxel; OR cimetidine 300 mg IV or ranitidine 50 mg IV 30 to 60 minutes prior to paclitaxel.
1637254|NCT01953523|Procedure|Administration of autologous adipose derived SVF|Intra-venous, intra-articular, and soft tissue injection delivery of SVF
1637255|NCT01953510|Biological|PCV10|PCV10 includes serotypes 1, 4, 5, 6B, 7F, 9V, 14, 18C, 19F and 23F and protein D is the main carrier protein
1637256|NCT01953510|Biological|PCV13|PCV13 includes serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F, individually linked to non-toxic diphtheria CRM197 carrier protein
1637257|NCT01953497|Drug|URC102|
1637258|NCT01953497|Drug|Placebo|
1637259|NCT01953484|Other|Change in extracorporeal carbon dioxide removal|
1637260|NCT01953471|Other|Allergic rhinitis|Questionnaire
1637261|NCT01953445|Drug|paclitaxel|
1637262|NCT01953445|Drug|BKM120|
1637263|NCT01953432|Drug|Doxazosin|Doxazosin is initiated at 2 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 4 weeks. Participants will be maintained on 8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
1637264|NCT01953432|Drug|Placebo|Matched placebo daily dosing
1637265|NCT01953419|Drug|Pemetrexed disodium|Patients received Pemetrexed disodium 500mg/m2 every 21 days until the presence of progressive disease or unacceptable toxicity.Patients were instructed to take oral folic acid 400 mg daily beginning 5 days before the first therapy and until the final therapy. Patients received vitamin B12 before the first cycle of Pemetrexed and every three cycles of chemotherapy.
1637266|NCT01953406|Drug|5-fluorouracil|5-fluorouracin 15mg/kg/day D1-6 civ till progression, every 4 weeks
1637267|NCT01953406|Drug|Mitomycin|Mitomycin 4mg/day iv push D1,4 till progression, every 4 weeks
1637268|NCT01953393|Other|Low-dose TNF-alpha|
1637269|NCT01953380|Behavioral|extended information|
1637270|NCT01953367|Drug|Vantobra (tobramycin)|Inhalation
1637271|NCT01953367|Drug|TOBI (tobramycin)|Inhalation
1637272|NCT01953354|Biological|Trichuris suis ova (TSO)|Six doses of TSO orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
1637273|NCT01953354|Biological|Placebo|Six doses of TSO placebo orally over a ten-week period (e.g., every 2 weeks x 10 weeks for a total of 6 total doses)
1637274|NCT01953341|Drug|AMG 333|Oral administration available in varying dose strength.
1637275|NCT01953341|Drug|Placebo|Placebo containing no active drug
1637276|NCT01953328|Drug|Atorvastatin|Administered orally once a day
2012037|NCT02268942|Device|HeartWare HVAD|
2012038|NCT02267109|Biological|Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z|IM injection of Ebola Chimpanzee Adenovirus Vector Vaccine (cAd3-EBO Z):
2012039|NCT02267109|Biological|Booster-MVA-BN® Filo or saline placebo|IM injection of Booster-MVA-BN® Filo or saline placebo
2012040|NCT02265731|Drug|venetoclax|Step-up doses of venetoclax to the designated cohort dose
1637279|NCT01953315|Biological|Autologous Muscle Progenitor Cells|Autologous MPCs, administered via a single, direct injection into the bladder neck sphincter region
1637280|NCT01953302|Procedure|"modified open mesh technique"|We positioned mesh intraperitoneally so it can provide adequate mechanical support to the weakened abdominal wall. We also preserved hernia sack to conceal the mesh.
1637281|NCT01953276|Device|Serial Electrocardiograms|All participants will have serial electrocardiograms performed.
1637282|NCT01953263|Other|Autologous Muscle Fiber Fragments|Autologous muscle fiber fragments administered via a single direct injection into the bladder neck sphincter region
1637283|NCT01953237|Behavioral|MedActive|Participants randomized to the MedActive condition will complete a 1-hour training session on MedActive, which will include ascertaining their antipsychotic administration schedule that will be pre-programmed into the application along with other personalized features. Each participate will be asked to use the medActive application over the following three months. All participants randomized to this condition will also have their antipsychotic medication adherence assessed over the 3-month period.
1637284|NCT01953237|Device|Smartphone|
1637285|NCT01953224|Behavioral|Game-based intervention|"Investigators will provide participants with a smartphone and required accessories (gift card for downloading the game application and music, headphones, armband). The game, Zombies, Run! encourages walking/jogging by playing music interspersed with a continuous narrative. Periodic zombie chases encourage brief interval training. Participants will set goals to increase their activity and receive weekly brief counseling phone calls to provide feedback."
1637286|NCT01953224|Device|Smartphone|
2012041|NCT02265731|Drug|Azacitidine|75 mg/m2 by IV infusion or subcutaneous dosing
1637288|NCT01953198|Other|Hypobaric hypoxia|Subjects are exposed to hypobaric hypoxia in the context of a high altitude expedition.
1637289|NCT01953185|Other|Sham manual diaphragm release technique|For this group, light touch at the same anatomical points was done without exerting pressure or traction. Positioning and duration were identical to the IG to perform the sham protocol (Licciardone & Russo, 2006).
1637290|NCT01953185|Other|The manual diaphragm release technique|To perform the technique the volunteer was placed in supine position with limbs relaxed. Positioned behind the head of the volunteer, the therapist performed manual contact (pisiform, ulnar edge and the last three fingers) with the underside of the costal cartilage of the 7th, 8th, 9th and 10th rib, and guiding forearms toward the shoulders of the corresponding side. In the inspiratory phase, the therapist gently pulled the points of contact with both hands, in the direction of the head, yet slightly lateral, accompanying the elevation movement of the ribs. During exhalation, the therapist deepened contact toward the inner costal, maintaining resistance throughout the inspiratory phase. In the breaths following, the therapist sought to gain traction and smooth increase in the deepening of contacts. This maneuver was performed in two sets of ten deep breaths, with a one minute interval between them.
1637291|NCT01953172|Dietary Supplement|AMP-886|AMP886 (alpha-tocotrienol) encapsulated in gelatin capsules
1637292|NCT01953172|Other|Placebo|Placebo
1637293|NCT01953159|Other|Blood Collection|
1637294|NCT01953159|Other|Patient Questionnaires|
1637295|NCT01953133|Behavioral|Couples Counselling Sessions|4 couples' counseling sessions focusing on problem solving and communication skills for the couple. Based upon the Prevention and Relationship Enhancement Program (PREP.)
1637296|NCT01953120|Drug|Belatacept|Subjects will receive intravenous belatacept at 5mg/kg every other week starting from day 1 and continuing with weeks 2, 4, 6, and 8, and then monthly at months 3, 4, 5, and 6. At month 6 patients may elect to continue for an additional six-month period of belatacept administration.
1637297|NCT01953107|Other|Oral Ferrous Fumarate|
1637298|NCT01953107|Other|Placebo|
2012042|NCT02265731|Drug|rituximab / IDEC-C2B8|375 mg/m2 on Week 6
2012043|NCT02265731|Drug|rituximab / IDEC-C2B8|500 mg/m2 Week 10 Day 1 and thereafter
1637301|NCT01953081|Drug|TD-8954|
1637302|NCT01953081|Drug|Metoclopramide|
1637303|NCT01953055|Radiation|Stereotactic ablative radiotherapy|
1637304|NCT01953042|Behavioral|Psychoeducation|4 educational sessions covering information on diagnosis, treatment, available resources and self care for OCD and OCD Spectrum Disorders
1637305|NCT01953029|Procedure|cardiac imajing|Cardiac MRI
1637306|NCT01953003|Drug|vinflunine|intraveinous administration day 1 once every 3 weeks, 280 mg/m²
1637307|NCT01953003|Drug|Capecitabine|Arm A : 1650 mg/m² Arm B : 2500 mg/m²
1637308|NCT01952990|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray device is 0.2mL (200 μL) in volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl. Subjects receiving the 100 μL dose will receive half of the contents of one device using a dose divider. Subjects receiving the 200 μL dose will first receive half of the contents of one device using a dose divider and then 4 minutes later will receive the 2nd half by removing the dose divider. Subjects receiving the 400 μL dose will first receive the entire contents of one device and then 4 minutes later will receive the contents of a 2nd device.
1637309|NCT01952977|Dietary Supplement|Test breakfast|
2012044|NCT02263547|Drug|teriflunomide|
1637311|NCT01952951|Drug|Capecitabine Oxaliplatin|after completion of chemoradiation, two cycles of capecitabine (850mg/m2 twice daily from D1 evening to D15 morning) and oxaliplatin (100mg/m2 on D1) will be administered every 3 weeks.
1637312|NCT01952951|Radiation|pelvic radiation capecitabine 5-fluorouracil|50.4Gy of pelvic radiation with capecitabine or 5-fluorouracil
1637313|NCT01952938|Procedure|LINK SL versus EnduRo|
1637314|NCT01952925|Procedure|Renal Artery denervation|RA denervation performed as part of afib ablation procedure
1637315|NCT01952912|Procedure|PkEP|
1637316|NCT01952912|Procedure|OP|
1637317|NCT01952886|Drug|Granisetron|
1637318|NCT01952886|Drug|Ondansetron|
1638233|NCT01945840|Other|Placebo infusion|
2012045|NCT02263547|Drug|Colestipol|
2012046|NCT02261883|Drug|IV Remodulin|Treprostinil is a chemically stable tricyclic analogue of prostacyclin.
2012047|NCT02261883|Drug|Placebo|matching placebo
2012048|NCT02260687|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
2012049|NCT02257528|Other|Laboratory Biomarker Analysis|Correlative studies
2012050|NCT02257528|Biological|Nivolumab|Given IV
1637319|NCT01952873|Other|Prolonged inflation|Prolonged inflation will be performed at high pressure(16 atm)and maintained for 30 sec with <0.3 atm drop during that period.
1637320|NCT01952873|Other|Rapid inflation|The rapid inflation method will consist of reaching an operator determined high-pressure (16 atm) with the stent-deployment balloon and maintaining it the duration of time determined by the operator but <30 sec if the balloon is fully inflated and longer only if the balloon requires a longer duration to become fully inflated.
1637321|NCT01952860|Other|Hatha Yoga|18 sessions of Hatha yoga over the course of radiation therapy. Each 45 to 60 minute session guided by an instructor. Participant should attend each session together with their caregiving partner. Some sessions videotaped. At first session, participant given a CD and instructions for practicing Hatha yoga at home.
1637322|NCT01952860|Behavioral|Questionnaires|Questionnaire completion at baseline, during radiation therapy, and at completion of radiation therapy.
2012051|NCT02256267|Drug|LY2835219|Administered orally
2012052|NCT02256267|Drug|Rifampin|Administered orally
2012053|NCT02255760|Drug|MEDI3902|MEDI3902
1637326|NCT01952834|Dietary Supplement|GoodBelly Probiotic|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
1637327|NCT01952834|Drug|Vancomycin|GoodBelly Probiotic 2.7 oz Daily x 6 weeks. Followed by a 4 week wash out period and then, Vancomycin, a non absorbed antibiotic administered (250 mg four times daily) orally for 10 days
1637328|NCT01952821|Other|Six-Minute Walk Test|
1637329|NCT01952821|Other|10-Meter Walk Test|
1637330|NCT01952821|Other|30-Second Chair Stand|
1637331|NCT01952821|Other|Linear Analog Scale of Function|
1637332|NCT01952821|Other|Modified Brief Fatigue Inventory|
1637333|NCT01952821|Other|FACIT-Fatigue|
1637334|NCT01952808|Behavioral|Face-to-face family mentoring and education sessions|A total of 13 home visits will be completed over a 6 month period. In addition to an introductory/orientation visit, 12 home visits will consist of family mentoring/educational sessions focused on physical activity and healthy nutrition.
1637335|NCT01952808|Behavioral|Telephone follow-up|During months 7-12, a total of up to 12 phone calls will be completed. Follow-up calls will consist of a progress report from families on physical activity and healthy diet progress/goals, along with brief content follow-up and re-enforcement points from the 12 intervention sessions.
1637336|NCT01952795|Behavioral|Diet and exercise|Total caloric intake aimed at maintaining a diet with> 50% of the caloric content in the form of carbohydrates, less than 10% in the form of saturated fats and 20% from monounsaturated / polyunsaturated (if applicable, up to 25% fat monounsaturated), less than 300 mg / day of dietary cholesterol and about 1.0 g of protein / kg ideal body weight / day.
1637337|NCT01952782|Drug|Kisspeptin 112-121|Subjects will receive up to 10 intravenous doses of kisspeptin 112-121
1637338|NCT01952782|Drug|Naloxone|Subjects will receive one intravenous dose of naloxone followed by an intravenous infusion of naloxone.
1637339|NCT01952782|Drug|Gonadotropin Releasing Hormone (GnRH)|Subjects will receive up to 10 doses of intravenous Gonadotropin Releasing Hormone (GnRH)
1637340|NCT01952769|Biological|MDV9300|"The study will be done in the following manner:
Evaluation of MDV9300 and radiation-
Cohort A-3 patients: first dose of MDV9300 3mg/m2 .If no toxicity over grade 2-second dose and on -6 mg/kg.
Cohort B -3 patiens: if no toxicity >grade 2 seen in cohort A- start dose will be 6 mg/kg If toxicity> grade 2 in 2 patients or more on a dose of 3 mg/kg the dose in cohort B will be 1 mg/kg during irradiation If toxicity> grade 2 in 2 patients or more on a dose of 1 mg/kg no further concurrent MDV9300 and radiation will be given
Evaluation of MDV9300 and cyclophosphamide
After completion of the first phase (6 patients) a cohort of 15 patients will be accrued. The treatment protocol of this cohort will be as follows:
Following radiation completion , and after recovery from treatment adverse events of grade 2 and higher, the patients will be started on concurrent biweekly MDV9300 and weekly cyclophosphamide 200mg/m2"
1637341|NCT01952756|Drug|Cilostazol|One tablet (100 mg) twice per day for 12 weeks
1637342|NCT01952756|Drug|Dummy Placebo|One tablet twice per day for 12 weeks
1637343|NCT01952743|Procedure|AF ablation with Renal Denervation|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques. Both mapping and ablation are performed under general anesthesia. The use of standard electrophysiology ablation catheter to perform renal artery ablation in hypertensive patients has been previously described. UP to 2 minutes of RF energy (10W with irrigation flow of 17 ml/min) are delivered at each location and up to 6 lesions for each artery on the longitudinal and rotational axis. Renal denervation is performed on both vascular pedicles after clinical AF ablation in patients assigned to the intervention arm.
1637344|NCT01952743|Procedure|AF ablation alone|Pulmonary vein isolation (PVI) is performed as per operator preference by previously described techniques.
1637345|NCT01952730|Biological|GVAX|
1637346|NCT01952704|Behavioral|Aerobic exercise|
1637347|NCT01952704|Behavioral|Placebo control|Non-aerobic stretching sessions will be conducted 3x/week for 30 minutes over 12 weeks.
1637348|NCT01952691|Device|kinesiotaping|correction method was used to align hallux.
1715944|NCT00000243|Drug|Buprenorphine|
2012054|NCT02255760|Drug|Placebo|Placebo
2012055|NCT02253784|Drug|Dexamethasone|
2012056|NCT02253784|Drug|Bupivacaine|
2012057|NCT02252263|Drug|Elotuzumab|
2012058|NCT02252263|Drug|Lirilumab|
2012059|NCT02252263|Drug|Urelumab|
2012060|NCT02252575|Device|Electromagnetic field|Exposure to the electromagnetic fields of electric motors
2012061|NCT02251717|Drug|LDV/SOF|Ledipasvir 90 mg /sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
2012062|NCT02249897|Drug|CHOLESTYRAMINE|CHOLESTYRAMINE CAPSULES, 6 G/DAY P.O. DURING 12 WEEKS
2012063|NCT02248844|Biological|Botulinum Toxin Type A|Botulinum toxin Type A injected into crow's feet line areas per clinical practice.
2012064|NCT02248805|Drug|MGD007|MGD007 is a gpA33 x CD3 bi-specific antibody-based molecular construct referred to as a DART molecule. MGD007 will be administered as a single agent.
2012065|NCT02247349|Biological|BMS-986012 (anti-fucosyl-GM1)|
2012066|NCT02247349|Biological|Nivolumab|
2012067|NCT02243592|Other|Laboratory Biomarker Analysis|Undergo sequencing and SNP analysis
2012068|NCT02240706|Procedure|Best Supportive Care|At Discretion of the Investigator (Transfusions)
1637350|NCT01952665|Device|comfilcon A|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
1637351|NCT01952665|Device|lotrafilcon B|Each subject randomized to wear the test lens (comfilcon A) or the control lens (lotrafilcon B) for one month of daily wear before repeating schedule for the second pair without a washout period.
1637352|NCT01952652|Drug|Group N:Naproxen sodium|drug will be given 60 minutes before surgery
1637353|NCT01952652|Drug|Group NC :naproxen sodium codeine phosphate|drug will be given 60 minutes before surgery
1637354|NCT01952639|Dietary Supplement|protein type and amount|Subjects will stay in a supine position and consume a test beverage containing different amounts ans types of protein
1637355|NCT01952626|Drug|Ondansetron|intravenous injection
1637356|NCT01952626|Drug|Palonosetron|intravenous injection
1637357|NCT01952613|Device|FES|In phase 1, five subjects (randomly chosen) will be provided the FES device and instructed to use it for ambulation for the 6 months. At the baseline visit, gait data will be collected from this group. On the 6 month follow up visit, same data collection procedure will be performed and the devices will be collected back from the subjects. After performing quality check on these devices, phase 2 of the data collection will start by providing the devices to the other five subjects and their baseline data will be collected.
1637358|NCT01952587|Biological|A peripheral blood sample|A peripheral blood sample will be collected from HIV-infected subjects and healthy control to measure TLR-7 SNP frequency by PCR. IFN-alpha production from pDCs after HIV-1 RNA sensing by TLR7 will also be assessed
1637359|NCT01952574|Drug|AMG 334|Investigational Product
1637360|NCT01952574|Drug|Placebo|Placebo Comparator
1637361|NCT01952561|Drug|dapivirine ring|
1637362|NCT01952548|Drug|K-312|
1637363|NCT01952548|Drug|Placebo|
1637364|NCT01952535|Drug|HMS5552|
1637365|NCT01952535|Drug|Placebo|
1637366|NCT01952522|Behavioral|Weighted brace|People will have to wear all the day additional weights (between 2 and 4 kilograms) at the nonparetic ankle during 3 months
1637367|NCT01952522|Behavioral|Non weighted brace|People will be given a brace with no weight they will have to wear all the day during three months.
1637368|NCT01952496|Other|Assisted Standing Treatment Program|"Assisted standing treatment program will include at least 2 hours a day, 5 days a week (a total of at least 10 hours a week) for a period of ~9 months.
Arm: Force-measuring platform"
2012069|NCT02240706|Drug|BI 836858|Monotherapy with BI 836858
2012070|NCT02241551|Drug|gemcitabine/nab-paclitaxel|three cycles of treatment in the gemcitabine/nab-paclitaxel
1637371|NCT01952457|Device|Zilver PTX|
1637372|NCT01952457|Device|prosthetic bypass|
1637373|NCT01952444|Biological|ETI-204|Intravenous (IV)
1637374|NCT01952444|Other|IV Ciprofloxacin|
1637375|NCT01952444|Other|Oral Ciprofloxacin|
1637376|NCT01952431|Device|Total Lung Capacity (TLC) testing|Comparison of TLC results
1637377|NCT01952418|Device|Monitor size|"Subjects will be randomized to perform their colonoscopy procedures while viewing a large (32) video monitor or the standard (24) video monitor."
1637378|NCT01952405|Behavioral|Dialectical behavior therapy (DBT)|Dialectical behavior therapy (DBT), developed by Marsha Linehan, has gained widespread popularity as a treatment for BPD, and its efficacy has been demonstrated in several trials.
1637379|NCT01952353|Procedure|Preoprative TACE|
1637380|NCT01952353|Procedure|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
1637381|NCT01952340|Dietary Supplement|Flaxseed|Milled flaxseed
1637382|NCT01952340|Dietary Supplement|Placebo|Wheat germ/wheat bran and mixed dietary oils
1637383|NCT01952327|Device|The pleurapump system|Implantation of the pleurapump system
1637384|NCT01952314|Drug|Naftopidil 75mg|naftopidil 75mg 1T qd hs
1637385|NCT01952314|Drug|Placebo for Naftopidil|Placebo 1T qd hs
1637386|NCT01952314|Drug|Standard treatment|Aceclofenac 100mg or tramadol37.5mg/acetaminophen 325mg on demand
1637387|NCT01952301|Device|Xenogeneic Collagen Matrix|A type I and III porcine collagen matrix, as cleared by FDA (K012423)
1637388|NCT01952301|Device|Free Gingival Graft|Autogenous, full-thickness soft tissue graft harvested from patient's palate.
1637389|NCT01952288|Drug|simvastatin|simvastatin 40 mg/day for 12 months
1637390|NCT01952288|Drug|pravastatin|pravastatin 80 mg/day for 12 months
1637391|NCT01952275|Procedure|Collection of biological samples|
1637392|NCT01952262|Other|diaphragm ultrasound|we'll perform diaphragm ultrasound in ICU critically ill patients
1637393|NCT01952249|Drug|Demcizumab|administered intravenously
1637394|NCT01952249|Drug|Taxol|administered intravenously
1637395|NCT01952236|Behavioral|Web+Mobile|We propose to evaluate the efficacy and acceptability of a Web+Mobile tobacco cessation intervention in a 2-arm Randomized Controlled Trial with 2,260 adult study participants who agree to quit smoking within a pre-specified amount of time. Participants who meet eligibility criteria will be randomly assigned to either (a) an enhanced Web Only intervention or (b) an enhanced Web+Mobile intervention.
1637396|NCT01952236|Behavioral|Web Only|A Web-based best practices smoking intervention.
1637397|NCT01952223|Drug|Cabazitaxel|Cabazitaxel administered at 25mg/m2 as a 1 hour intravenous infusion every 3 weeks (1 cycle = 21 days) for 4 cycles
1637398|NCT01952223|Radiation|Pelvic radiotherapy|"Prostate+pelvic RT (2 Gy fractions, 5 times per week):
Phase 1: pelvic radiotherapy (prostate, seminal vesicles, ilio-obturator, presacral lymph nodes) (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
1715945|NCT00000244|Drug|Dynorphin 1 - 13|
2012071|NCT02241551|Drug|mFOLFIRINOX|6 cycles in the mFOLFIRINOX
2012072|NCT02238366|Drug|triptorelin|This is an observational study. Thus, the treatment selection with triptorelin (Diphereline® or Diphereline PR®) is at investigator's discretion based on the current practice principles and guidelines/protocols, in accordance with the Summary of Product Characteristics (SmPC) approved in Romania by the National Medicines Agency.
2012073|NCT02238483|Drug|AZD7624 1.0 mg|Inhaled AZD7624 solution, 11 mg/mL
2012074|NCT02238483|Drug|Placebo|Inhaled placebo solution
1637399|NCT01952223|Radiation|prostate radiotherapy|"Prostate-only RT (2 Gy fractions, 5 times per week):
Phase 1: prostate + seminal vesicle radiotherapy (46 or 50 Gy according to the center)
Phase 2: prostate-only boost (EBRT) up to 74-78 Gy"
1637400|NCT01952210|Behavioral|nutritional consultation and exercise program|The protocol involved 20-30 minutes of individual-based nutrition consultation every week during the 8-week chemoradiation therapy. The exercise program consisted of upper extremity muscle training and walking exercise at 45%-65% of maximal heart rate reserve, 3 times per week, 20-30 minutes per session.
1637401|NCT01952210|Behavioral|usual care|pre-CCRT education included self-care during CCRT and body weight maintenance
1637402|NCT01952197|Other|Passive Leg Raise|The intervention is made on all adult patients receiving CPR by the ambulance crew. The leg raise is performed during the first minutes of CPR (limit 5 min) and will continue as long as the patients receive chest compression. In Spain the patient is immediate randomized by envelope. If the patient is randomized to PLR, the ambulance crews use a special folding stool that allows the legs to be raised about 20 degrees.
1637403|NCT01952184|Device|CBSvit HS device|closed vitrification with closed storage
1637404|NCT01952184|Device|Cryotop SC device|open vitrification with closed storage
1637405|NCT01952145|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
1637406|NCT01952145|Drug|insulin glargine|Insulin glargine is injected subcutaneously s.c. (under the skin) once daily (OD). Dose individually adjusted. Subjects should continue their pre-trial treatment with metformin.
1637407|NCT01952132|Drug|OMS643762|
1637408|NCT01952132|Drug|Placebo|
1637409|NCT01952119|Other|Secure message reminder|Single secure message reminder asking subjects to schedule an appointment with their provider or make a nurse visit to follow-up on their blood pressure
1637410|NCT01952106|Other|play computer game|
1637411|NCT01952093|Behavioral|Home-based intervention program|
1637412|NCT01952093|Behavioral|Clinical-based intervention program|
1637413|NCT01952080|Drug|teduglutide|Open label intervention. Each subject will be assigned to receive 0.0125, 0.025, or 0.05 mg/kg/day for the duration of the study
2012075|NCT02239120|Drug|optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
2012076|NCT02239120|Drug|placebo to ASA|placebo to comparator drug
2012077|NCT02239120|Drug|placebo to optional ASA as comedication|optional concomitant treatment which can be used for patients with coronary artery disease. It is not required for these pts.
1637417|NCT01952041|Behavioral|Device: Smartphone|
1637418|NCT01952041|Behavioral|Treatment as usual|
2012078|NCT02239120|Drug|placebo to dabigatran etexilate|placebo
1637420|NCT01952002|Other|Inspiratory Muscle Training|Each session The session itself consisted of the following: two sets of 15 breathe cycles without removing the breathing promoter from the mouth and with the aid of a nose clip and 1-minute interval between sets. For training, we used the breathing promoters Power Breathe® Plus Light and Medium Resistance, possessing 10 levels of load gradation ranging from 17 to 186 cm H2O, which were adjusted for each patient and allowed for the individualized prescription of IMT
1637421|NCT01951989|Drug|Imiglucérase (drug) pharmacokinetics|
1637422|NCT01951976|Other|Questionnaires|Participants will be asked to complete a set of questionnaires about their health and well-being on two occasions (baseline and follow-up). Each set of questionnaires will take about 45 minutes to complete.
1637423|NCT01951976|Other|Yoga Classes|Iyengar yoga is a traditional form of Hatha yoga that has been used previously to address quality of life issues in women with breast cancer. Iyengar yoga classes for 90 minutes twice per week for 12 weeks (total of 24 classes).
1637426|NCT01951950|Drug|Nicardipine|
1637427|NCT01951950|Drug|Esmolol|
1637428|NCT01951937|Dietary Supplement|Fish Meals|Herring and Mackerel Meals
1637429|NCT01951937|Dietary Supplement|Placebo|No fish meals
1637430|NCT01951924|Drug|Biological : I10E (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
1637431|NCT01951924|Drug|Biological: Kiovig® (Human normal Immunoglobulin for intravenous administration 100mg/mL)|
1637432|NCT01951911|Drug|Ketamine|Patients will receive either ketamine as subcutaneous infusion or placebo as subcutaneous infusion. The results will be compared with each other.
1637433|NCT01951911|Drug|Placebo|
1637434|NCT01951898|Drug|Montelukast|10mg/day, once a daily after dinner, for 28dyas
1637435|NCT01951885|Drug|tacrolimus|Tacrolimus 0.03 mg/kg/day beginning day -1. Tac will be administered IV over 24 hours and will be converted to oral administration 2 times a day when the patient has engrafted and can tolerate oral medication. Levels of Tac will be obtained to maintain a recommended target serum level of 5-12 ng/mL
1637436|NCT01951885|Drug|methotrexate|MTX 15mg/m2 IV on day +1, followed by 10mg/m2 on day +3, +6, +11. If patient < 10 kg then MTX will be given at 0.5 mg/kg IV on day +1. Then MTX will be given at 0.33 mg/kg on days +3, +6 and +11.
1637437|NCT01951885|Drug|Mycophenolate mofetil|Mycophenolate 1000mg IV twice daily will begin on day +1, and will be converted to oral administration 1000 mg twice a day once patient can tolerate oral route. Patients<40 kg will receive MMF 45 mg/kg/day (15mg/kg IV three times a day).
1637438|NCT01951885|Drug|Methotrexate (low dose)|MTX 5mg/m2 IV on day +1, +3, +6. If patient<10 kg MTX will be given at 0.17 mg/kg on day +1, +3, and +6.
1637439|NCT01951872|Behavioral|Manual-based treatment for caffeine dependence|Participants will meet with a counselor to discuss plans for caffeine reduction or cessation, and they will receive a manual-based treatment to help guide them through caffeine reduction or cessation.
1637440|NCT01951859|Other|Neuropathy/Ulcer Homeopathic topical cream|This is a GRAS topical agent containing homeopathic ingredients
1637441|NCT01951846|Drug|BIBF 1120|
1637442|NCT01951833|Device|EasyOne Pro and Ecomedics|LCI will be assessed with 2 different devices : EasyOne Pro and Ecomedics
1637443|NCT01951820|Drug|Pliaglis|Apply 0.2mg of compounded topical anesthetic (Pliaglis) to gums for 2.5 minutes before giving patient injection of local anesthetic.
1637444|NCT01951820|Drug|Benzocaine|Apply 0.2mg of topical anesthetic (benzocaine) to gums for 2.5 minutes before giving patient injection of local anesthetic.
1637445|NCT01951820|Drug|Articaine|Injection of 0.4mg of local anesthetic in gum tissue where topical anesthetic was placed
1637446|NCT01951807|Behavioral|Psychotherapy|
1637447|NCT01951781|Other|blood sample|"blood sample in newborn preterms suspected of nosocomial infection (neoCD64 arm)
When late-onset sepsis is suspected, blood samples are obtained from peripheral veins for a complete blood count, measurement of CRP and PCT concentration and one bacterial culture acording to the current recommendation of the CDC. CD64 concentration measurement require 0.2 ml aditionnal blood."
1637448|NCT01951768|Drug|Garamycin Sponge (Gentamicin-Collagen sponge)|Gentamicin Collagen Sponge: 5 × 5 cm in size containing Type I bovine collagen and 50 mg of gentamicin sulfate (equivalent to 32.5 mg of gentamicin base)
1637449|NCT01951768|Drug|Systemic Antibiotic|"Antibiotics options per protocol:
Levofloxacin PO 750 mg q.24h or 500 mg q.12h Levofloxacin IV 750 mg q.24h or 500 mg q.12h Amoxicillin/clavulanate PO 500/125 mg q.12h. or q.8h Amoxicillin/clavulanate IV 1000/200 mg q.12h or q.8h Clindamycin PO 300 mg or 450 mg q.6h Clindamycin IV 600 mg q.8h or q.6h Linezolid PO 600 mg q.12h Linezolid IV 600 mg q.12h Metronidazole PO 400 mg or 500 mg q.8h or 500 mg q.6h Metronidazole IV 500 mg q.8h or q.6h Aztreonam IV 1 g or 2 g q.12h or q.8h Piperacillin/tazobactam IV 3000/375 mg q.6h or 4000/500 mg q.8h"
1637450|NCT01951742|Biological|ANT-1401|Active
1637451|NCT01951742|Biological|Vehicle|Vehicle
1637452|NCT01951729|Drug|Control|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Starting at 0 minutes, an intravenous infusion of saline containing 1% human albumin will continue for 240 minutes."
1637453|NCT01951729|Drug|Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a constant dose of 4 pmoles/kg/min until 240 minutes."
1637454|NCT01951729|Drug|GIP without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, GIP (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes."
1637455|NCT01951729|Drug|Placebo with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
1637456|NCT01951729|Drug|Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, xenin-25 (in saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.
Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
1637457|NCT01951729|Drug|GIP with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, GIP (iin saline containing 1% human albumin) will be administered at a dose of 4 pmoles/kg/min until 240 minutes.
Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
1637458|NCT01951729|Drug|GIP plus Xenin-25 without atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes."
1637459|NCT01951729|Drug|GIP plus Xenin-25 with atropine|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes. The study is finished at 240 minutes.
Following a priming dose from 0-10 minutes, GIP and xenin-25 will each be administered at a dose of 4 pmoles/kg/min until 240 minutes.
Following a priming dose from -30 to -28 minutes, atropine will be administered at a constant dose of 0.3 mg/m2/hour until 240 minutes."
1637460|NCT01951716|Drug|Graded Glucose Infusion with Placebo|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.
Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 240 minutes.
The study is finished at 240 minutes."
1637461|NCT01951716|Drug|Graded Glucose Infusion with GIP Alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.
Starting at 0 minutes, a primed-continuous intravenous infusion of GIP in saline containing 1% human albumin will continue for 240 minutes.
The study is finished at 240 minutes."
1637462|NCT01951716|Drug|Graded Glucose Infusion with xenin-25 alone|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.
Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 240 minutes.
The study is finished at 240 minutes."
1637463|NCT01951716|Drug|Graded Glucose Infusion with GIP plus xenin-25|"Starting at 0 minutes, glucose infusion rates will be increased to 1, 2, 3, 4, 6, and 8 mg/kg/min every 40 minutes.
Starting at 0 minutes, a primed-continuous intravenous infusion of GIP plus xenin-25 in saline containing 1% human albumin will continue for 240 minutes.
The study is finished at 240 minutes."
1637464|NCT01951716|Drug|Meal Tolerance Test with Placebo|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.
Starting at 0 minutes, a primed-continuous intravenous infusion of saline containing 1% human albumin will continue for 300 minutes.
The study is finished at 300 minutes."
1637465|NCT01951716|Drug|Meal Tolerance Test with xenin-25|"At 0 minutes, a liquid mixed meal (Boost Plus) plus acetaminophen will be ingested.
Starting at 0 minutes, a primed-continuous intravenous infusion of xenin-25 in saline containing 1% human albumin will continue for 300 minutes.
The study is finished at 300 minutes."
1637466|NCT01951703|Device|senofilcon A|Control, senfilcon A
1637467|NCT01951703|Device|senofilcon A|Test, senofilcon A
1637468|NCT01951690|Drug|defactinib (VS-6063)|
1637469|NCT01951677|Drug|HBsAg|Standard hepatitis B vaccine antigen
1637470|NCT01951677|Biological|PreS HBsAg|preS hepatitis B surface antigen
1637471|NCT01951677|Biological|Advax-1(TM)|Adjuvant formulated with vaccine antigen
1637472|NCT01951677|Biological|Advax-2(TM)|Adjuvant formulated with vaccine antigen
1637473|NCT01951677|Biological|Advax-3(TM)|Adjuvant formulated with vaccine antigen
1637474|NCT01951677|Biological|Alum|Adjuvant formulated with vaccine antigen
1637475|NCT01951664|Other|Baseline Study Measures|Participants will undergo baseline objective and self-report study measures including: 1) ROM in the jaw, neck, and shoulders; 2) posture assessment; 3) pain, and 4) psychological distress. The study measures will take 30-45 minutes to administer.
1637476|NCT01951664|Behavioral|Yoga Evaluation|The evaluation includes an assessment of nine traditional Yoga components: energy, symptoms, emotions, posture, breathing patterns, gait, muscle/tissue quality, joint flexibility, and muscle strength. Emphasis will be placed on the assessment of jaw/neck/shoulder MSI requiring Yoga practice modification of those poses that are unsafe or not feasible for a patient to perform. Information from the evaluation will be used to establish the tailored Yoga program
1637477|NCT01951664|Behavioral|Yoga Program|The Yoga program has 5 components: 1) Awareness Practice to enhance self-awareness, 2)Poses - 16 core poses will be modified for each patient's specific needs, 3)Breath Work - breath awareness and proper breathing for maximum benefit, 4)Relaxation - alternating between methods of relaxation, 5)Mediation - awareness and practice of inner silence
1637478|NCT01951664|Behavioral|Yoga Practice Plan|To enhance fidelity, a standardized Yoga intervention was chosen that includes postures, meditation, relaxation, and breath work. To ensure safety, the practice plan for each patient will be reviewed prior to initiation. All MSI limitations will be discussed, and appropriate adaptive techniques will be formulated. Qualitative techniques will be used to describe and categorize the types of impairment and modifications. By developing a catalog of impairments and suitable modifications, a safe and uniform Yoga program can be further tested and widely disseminated.
1637479|NCT01951664|Other|Study Assessments|Data collection methods used to assess efficacy include physical measurement/examination, jaw range of motion (device) - scales to measure opening, cervical range of motion(Device), Shoulder Range of Motion - Goniometer, Posture - Wall Zone Grid, self-reported surveys for physical symptoms, pain, psychological symptoms, anxiety, depression and quality of life
1637480|NCT01951651|Drug|Exenatide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
1637481|NCT01951651|Drug|Glipizide|Type 2 diabetic subjects will be randomized to receive either Exenatide 10 micrograms twice daily injected subcutaneously or glipizide 5 mg twice daily orally for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma lipids, and glycosylated hemoglobin (HbA1c) as well as measurement of liver and myocardial fat content and left ventricular function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, adipocytokines, HbA1c, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
1637482|NCT01951638|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
1637483|NCT01951638|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
1637484|NCT01951638|Drug|Placebo|
1637485|NCT01951625|Drug|Vericiguat (BAY1021189) (1.25 mg)|1.25 mg BAY1021189 tablets
1637486|NCT01951625|Drug|Vericiguat (BAY1021189) (5 mg)|5 mg BAY1021189 tablets
1637487|NCT01951625|Drug|Placebo|
1637488|NCT01951612|Behavioral|Executive Function Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
1637489|NCT01951612|Behavioral|Psychoeducational Training Program|Participants will take part in ten 2-hour sessions over 5 weeks.
1637490|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule on day 1, in Part A, Period 1, in the fasted state. (Treatment A).
1637491|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a solution on day 1, in Part A, Period 2, in the fasted state. (Treatment B).
1637492|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a tablet on day 1, in Part A, Period 3, in the fasted state. (Treatment C).
1637493|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 1, in the fasted state.
1637494|NCT01951599|Drug|AZD9291|Volunteers will receive a single 20-mg dose of AZD9291 as a capsule or tablet on day 1, in Part B, Period 2, in the fed state.
1637495|NCT01951586|Drug|Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
1637496|NCT01951586|Drug|Zoledronic acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
1637497|NCT01951586|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 4 weeks (Q4W) plus one loading dose on study day 8; could be administered as often as every 3 weeks (Q3W) to participants receiving Q3W chemotherapy.
1637498|NCT01951586|Drug|Standard Chemotherapy|Standard of care chemotherapy consisting of pemetrexed or gemcitabine in combination with cisplatin or carboplatin administered according to local practice.
1637499|NCT01951586|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion in participants with bone metastasis upon investigative site request for IV bone-targeted therapy.
1637500|NCT01951573|Device|Delefilcon A multifocal contact lenses|Silicone hydrogel multifocal contact lenses for daily wear, daily disposable use
1637501|NCT01951573|Device|Lotrafilcon B multifocal contact lenses|Silicone hydrogel multifocal contact lenses with a labeled indication for daily wear and extended wear use of up to 6 days with monthly replacement
1637502|NCT01951560|Drug|Valproic Acid|By infusion over 1 hour
1637503|NCT01951560|Drug|Isotonic saline solution|By infusion over 1 hour
1638234|NCT01945840|Other|Very low calorie diet|
1637504|NCT01951547|Procedure|Nonsurgical periodontal therapy|Periodontal intervention All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique. Full mouth debridement, which consisted of scaling and root planing, was done in a single visit for all subjects using an ultrasonic scaler and gracey curettes. Additionally, all patients were given a 0.12% Chlorhexidine mouthrinse (Hexipro®). They were instructed to rinse three times a day using 15ml each time for a period of 14 days commencing immediately after completion of full mouth debridement. Thereafter at each recall visit, all participants were re-motivated and professional prophylaxis was performed.
1637505|NCT01951547|Procedure|Oral hygiene instructions|All patients were instructed in oral hygiene methods using a soft bristled toothbrush, a compact-tuft toothbrush, interdental brushes and dental floss utilizing the modified Bass technique.
1637506|NCT01951534|Behavioral|Breast Reconstruction Decisional Aid (BRDA)|
1637507|NCT01951534|Behavioral|Usual Care|
1637508|NCT01951521|Radiation|Boost|External Beam radiation delivered using intensity modulation radiation therapy (IMRT) planning, consisting of 15 Gy (in 5 sequential fractions).
1637509|NCT01951508|Drug|Methylphenidate|60mg per os, single dose
1637510|NCT01951508|Drug|Modafinil|600mg per os, single dose
1637511|NCT01951508|Drug|MDMA|125mg per os, single dose
1637512|NCT01951508|Drug|Placebo|per os
2012079|NCT02239120|Drug|ASA 100 mg|active comparator drug
2012080|NCT02239120|Drug|dabigatran etexilate|active drug
2012081|NCT02237339|Drug|Allopurinol|Uric acid lowering medication.
2012082|NCT02237339|Drug|Placebo|
1637517|NCT01951456|Behavioral|Resistance training|
1637518|NCT01951456|Behavioral|Health and Wellness|
1637519|NCT01951443|Dietary Supplement|Ginseng|400mg of encapsulated Rg3-KRG
1637520|NCT01951443|Dietary Supplement|Wheat Bran|400mg of encapsulated wheat bran
1637521|NCT01951430|Drug|Antibiotic and antifungal drugs|
1637522|NCT01951417|Drug|Adapalene/BPO Gel|Adapalene/Benzoyl Peroxide (BPO) Gel Pump (once daily)
1637523|NCT01951417|Other|Moisturizer SPF 30|Moisturizer SPF 30 (once daily)
1637524|NCT01951417|Other|Foam Wash|Foam Wash (twice daily)
1637525|NCT01951404|Drug|Allopurinol|
1637526|NCT01951404|Drug|Placebo (for allopurinol)|
1637527|NCT01951391|Other|Soap|Commercially available soap will be used to wash the subject's forearms
1637528|NCT01951378|Device|Hudson RCI® nebulizer|After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS > 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
1637529|NCT01951378|Device|NebuTech® HDN® nebulizer|All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
1637530|NCT01951378|Drug|Albuterol|Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
1637531|NCT01951352|Other|Soap|
1637532|NCT01951339|Drug|Sitagliptin|100 mg sitagliptin
1637533|NCT01951339|Drug|Glimepiride|"Active Comparator
2mg glimepiride"
1637534|NCT01951339|Drug|Placebo|2 mg placebo once daily
1637535|NCT01951339|Drug|Placebo|100 mg placebo once daily for three months
2012083|NCT02232958|Other|Hyperbaric Oxygen Treatment|Patients are placed in a special chamber in which the pressure is gradually increased up to the desired pressure with 100% Oxygen and the patient is kept at that pressure for one hour. Then the Oxygen flow is slowly reduced until the patient has been returned to one atmosphere of pressure.
1637538|NCT01951313|Other|Egg consumption|Subjects will participate in 3 testing days (randomized, crossover design). Each day, the subject will consume a carefully portioned mix-vegetable salad without eggs (C, control); 75g (about 1½ eggs) scrambled whole egg (LE, low egg), and 150g (about 3 eggs) scrambled whole egg (HE, high egg). Prior to each testing day, subjects will consume a low-carotenoid diet for 7 days to reduce blood carotenoid concentration. In the testing day, blood collected every 60 minutes for 10 hours will be processed to analyze carotenoid and vitamin E concentrations. At the 5-h time point, subjects will be fed a low fat (< 2g) and low carotenoid (< 2000µg) meal as the 2nd meal.
1637539|NCT01951300|Other|Gallium-68 citrate|Single intravenous bolus injection of 200 MBq of Gallium-68 citrate radiopharmaceutical
1637540|NCT01951287|Other|Acute beverage (water) consumption|Acute beverage consumption includes water.
1637541|NCT01951287|Other|Acute beverage (Black Coffee) consumption|Acute beverage consumption includes black coffee.
1637542|NCT01951287|Other|Acute beverage (Orange Juice) consumption|Acute beverage consumption includes Orange Juice..
1637543|NCT01951287|Other|Acute beverage (Whole Milk) consumption|Acute beverage consumption includes whole milk
1637544|NCT01951287|Other|Acute beverage (2% Milk) consumption|Acute beverage consumption includes 2% milk
1637545|NCT01951287|Other|Acute beverage (Skim Milk) consumption|Acute beverage consumption includes skim milk
1637546|NCT01951274|Drug|VPD-737|NK1 Receptor Antagonist
1637547|NCT01951274|Drug|Placebo|
1637632|NCT01950559|Other|Oral food challenge|Oral foos challenge to determine allergy to say
1637942|NCT01948011|Drug|Racecadotril suspension|Racecadotril suspension at 10, 30 and 60mg. Single oral dose.
1637548|NCT01951261|Procedure|Telemonitoring and telephone control|Early assisted discharge from hospital due to an exacerbation of chronic obstructive pulmonary disease, with telemonitoring of vitals signs (oxygen saturation, heart rate, respiratory rate, blood pressure, temperature and electrocardiogram)and telephone control dairy (morning, evening)by the pulmonologist.
1637549|NCT01951248|Device|CPAP - continuous airway pressure|3 months of treatment with CPAP treatment
1637550|NCT01951235|Drug|Imeglimin|
1637551|NCT01951235|Drug|Placebo|
1637552|NCT01951222|Drug|V0162|
1637553|NCT01951222|Other|Placebo|
1637554|NCT01951209|Drug|Rifaximin|550mg orally twice daily for 12 weeks
1637555|NCT01951209|Drug|Placebo|Matched placebo
1637556|NCT01951183|Drug|Placebo|RO681135 placebo subcutaneously daily
1637557|NCT01951183|Drug|RO6811135|Subcutaneously daily
1637558|NCT01951170|Drug|Tocilizumab|162 milligrams (mg) tocilizumab was administered subcutaneously once weekly for 24 weeks
1637559|NCT01951157|Drug|Docetaxel|Powder for solution for infusion
1637560|NCT01951157|Drug|Gemcitabine|Powder for solution for infusion
1637561|NCT01951157|Drug|Lurbinectedin (PM01183)|Powder for concentrate for solution for infusion
1637562|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
1637563|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
1637564|NCT01951144|Drug|PF-06372865 or Placebo|PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.
1637565|NCT01951144|Drug|PF-06372865 or Placebo or Lorazepam|Lorazepam 2 mg dose, PF-06372865 Dose 1, PF-06372865 Dose 2, PF-06372865 Dose 1 and Dose 2 in combination with lorazepam, placebo administered as tablet formulation
1637566|NCT01951118|Drug|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease. For patients who do not tolerate donepezil or have a history of intolerance to donepezil or cannot take donepezil for other reasons, treatment with other cholinesterase inhibitors (galantamine or rivastigmine) is permitted at any stage of the protocol. Data will be analyzed in two ways: for donepezil alone, and for any cholinesterase inhibitor (donepezil or rivastigmine or galantamine) as the intervention.
2012084|NCT02232165|Other|Hypotension avoidance|Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline. Our intervention tests whether hypotension avoidance and maintenance of MAP >= 65 mmHg is not inferior to induced hypertension.
2012085|NCT02232165|Other|Induced hypertension|Induced hypertension with MAP >= 85 mmHg for 7 days following SCI is the current recommended clinical option guideline.
2012086|NCT02231671|Drug|ALS-008176|
1637570|NCT01951092|Other|Text messaging|
1637571|NCT01951079|Drug|Intra-amniotic injection of DIGOXIN|
1637572|NCT01951066|Drug|Dexamethasone Implant|Patients will receive a single injection of a dexmethasone implant
1637573|NCT01951066|Drug|Anti-VEGF injection|Patients will receive PRN injections of an anti-VEGF agent
1637574|NCT01951053|Drug|JNJ-40411813|Participants will receive nanosuspension of JNJ-40411813 500 mg orally once daily on Day 3 in appropriate treatment periods.
1637575|NCT01951053|Drug|Placebo|Participants will receive placebo orally once daily on Days 1 to 2 or Days 1 to 3 in appropriate treatment periods.
1637576|NCT01951053|Drug|Citalopram|Participants will receive citalopram 20 mg tablet orally once daily on Day 3 in appropriate treatment periods.
1637577|NCT01951027|Drug|GX-G3 12.5 μg/kg or Placebo|Single SC injection
1637578|NCT01951027|Drug|GX-G3 25 μg/kg or Placebo|Single SC injection
1637579|NCT01951027|Drug|GX-G3 50 μg/kg or Placebo|Single SC injection
1637580|NCT01951027|Drug|GX-G3 100 μg/kg or Placebo|Single SC injection
1637581|NCT01951014|Other|Social Media Education|Health messages provided via a private Facebook group and cellular text messages will be provided across gestation.
1637582|NCT01951001|Drug|Prasugrel|For fixed-dose group, patients will receive prasugrel 10 or 5 mg/d for 1 month Irrespective of platelet function test.
1637583|NCT01950988|Device|Manual toothbrush reference|
1637584|NCT01950988|Procedure|Measure of the dental plaque|
1637585|NCT01950988|Device|Manual toothbrush Broscyl®|
1637586|NCT01950975|Biological|Peripheral blood samples in EDTA tubes|
1637587|NCT01950975|Procedure|Skin biopsies|
1637588|NCT01950962|Other|Sampling of blood|
1637589|NCT01950949|Other|300 ml Hydroxyethyl Starch 130/0.4 and Sodium Chloride Injection infusing in 15 minutes if PPV under VT 8 ml/kg was larger than 13% in the initial investigation|
1637590|NCT01950936|Other|Discontinuation of Antibiotcs|Discontinuation of Antibiotcs against lower respiratory tract infections
1637591|NCT01950923|Drug|sildenafil citrate|Given PO
1637592|NCT01950923|Other|placebo|Given PO
1637593|NCT01950923|Procedure|therapeutic conventional surgery|Undergo standard robotic partial nephrectomy
1637594|NCT01950884|Drug|Ezetimibe|Ezetimibe tablets
1637595|NCT01950884|Behavioral|Lifestyle|lifestyle
1637683|NCT01950143|Dietary Supplement|Beneforte extra broccoli soup|Volunteers will be in which they will be required to consume one portion per week of a soup containing an other variety of glucoraphanin-enriched broccoli (Beneforte extra) as part of their normal diet for one year.
2012087|NCT02231671|Drug|ALS-008112|
2012088|NCT02229383|Drug|Exenatide|2 mg weekly suspension injection
2012089|NCT02229383|Drug|Exenatide matching placebo|Once weekly Placebo injection
2012090|NCT02227472|Other|Evaluation of cognitive and pre-academic skills|Participants will complete testing to evaluate fluid reasoning, knowledge, quantitative reasoning, visual-spatial processing, verbal and non-verbal working memory, and knowledge of pre-academic skills (such as colors, letters, numbers, counting, sizes, comparisons, and shapes).
1637596|NCT01950871|Device|Prostate HistoScanning|In a single visit, subjects will first be imaged with TRUS for the purpose of generating data for prostate HS analysis. The results of HS analysis will be used later in the procedure. Subjects will then undergo two consecutive biopsy procedures. First, using TRUS, a systematic 10- to 12-core biopsy procedure will be performed. In turn, prostate HS data taken at the beginning of the procedure will be used to determine suspicious areas (displayed as red on an imaging monitor) and used to guide the biopsy procedure. Areas that are identified as suspicious (zero to a maximum of 3 areas) will then be sampled with two biopsy cores. Depending on the number of suspicious areas identified by prostate HS, the number of cores will be zero to a maximum of 6 cores.
1637597|NCT01950858|Biological|Weight reduction|
1637598|NCT01950845|Device|Closed loop automated System (LIR®: learning intravenous resuscitator)|Connection of the system to the patient under supervision of the anesthesiologist team during all the anesthesia procedure, respective of the applicability criteria for the fluid responsiveness detection.
1637599|NCT01950845|Device|manual current practice by anesthesiologist team|The anesthesiologist team will manage the fluid administration during all the anesthesia procedure.
1637600|NCT01950832|Other|Investigating clinically normal patients with optic coherence tomography|
1637601|NCT01950819|Biological|Induction therapy|All subjects will receive induction therapy with basiliximab or rabbit anti-thymocyte globulin, in the peritransplant period.
1637602|NCT01950819|Drug|Corticosteroids|All subjects are to receive maintenance therapy with corticosteroids throughout the 24 month study period. A minimum dose of 5 mg prednisone, or equivalent, per day must be maintained.
1637603|NCT01950819|Drug|EVR+rCNI|Everolimus with reduced calcineurin inhibitor- everolimus (target trough level of 3-8 ng/mL) in combination with reduced exposure to CNI (cyclosporine or tacrolimus)
1637604|NCT01950819|Drug|MPA+sCNI|Mycophenolate (mycophenolic acid sodium or mycophenolate mofetil) in combination with standard exposure to calcineurin inhibitor (cyclosporine or tacrolimus).
1637605|NCT01950806|Other|Pecan-containing diet|
1637606|NCT01950806|Other|Nut-free diet|
1637607|NCT01950793|Drug|triamcinolone acetonide|"used ultrasound-guided inject 1c.c triamcinolone acetonide 10mg/mL (Shincort®, YSP, Taiwan)into the sheath of the flexor tendons, penetrated to the A1 pulley.
One injection only Steroid"
1637608|NCT01950793|Drug|Hyaluronic Acid|"used ultrasound-guided inject 1c.c Hyaluronic acid (Artz®, Seikagaku, Japan)into the sheath of the flexor tendons, penetrated to the A1 pulley.
One injection only"
1637610|NCT01950754|Behavioral|standing with both feet|
1637611|NCT01950754|Behavioral|descent of the platform|
1637612|NCT01950754|Behavioral|standing on the platform, feet together and always with simultaneous performance of a task of mental count|
1637613|NCT01950741|Drug|aflibercept|Aflibercept is injected intravitreally though the pars plana using 30G needle-attached syringe.
1637614|NCT01950728|Device|Interferential current|Interferential current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kilohertz (kHz) and modulated frequency will be set at 50 Hz.
1637615|NCT01950728|Device|Aussie Current|Aussie current will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Carrier frequency will be set at 4 kHz and modulated frequency will be set at 50 Hz.
1637616|NCT01950728|Device|TENS|TENS will be applied during 30 minutes to volunteer's forearm at a strong but comfortable intensity. Pulse duration will be set at 125 microseconds and frequency will be set at 50 Hz.
1637617|NCT01950715|Device|sacral nerve stimulation|Sacral nerve stimulation
1637618|NCT01950702|Procedure|Laryngoscope assisted lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.
Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.
The Macintosh laryngoscope (female: 3rd blade, male: 4th blade) was inserted into the oral cavity to provide direct view of the epiglottis and then the tip of the lightwand was placed below the epiglottis."
1637619|NCT01950702|Procedure|Lightwand intubation|"After standard monitoring(EKG, pulse oximetry, NIBP), participants were induced with remifentanil and propofol continuous infusion, using targe-controlled infusion device with prexoygenation with 100% oxygen.
Manual in-line stabilization was applied with velcro during intubation to maintain neutral head position.
After 2min from administration of rocuronium, the clinician holds the wand similar to a pencil, stands directly behind the patient's head, inserts the device into the side of the mouth and sweeps the tip to the midline. After confirmation of precise location via clear light source on anterior neck, endotracheal tube was inserted and withdrawn lightwand."
1637620|NCT01950689|Drug|Nimorazole|
1637621|NCT01950689|Radiation|Radiotherapy|
1637622|NCT01950676|Device|Smart phone application|The smart phone application (Diabetes Pal), will guide patients on self-titration of insulin. Patients will be required to key in the CBG readings into the application. Up-titration of insulin dose will be carried out once every 3 days and the recommended insulin dose will be based on the mean of 3 CBG readings and a pre-specified titration algorithm. The process of using the insulin self-titration application will continue until the patient has reached the target pre-breakfast CBG.
1637623|NCT01950663|Device|RETeval|RETeval is a new handheld device intended to detect vision threatening diabetic retinopathy by measuring the response of the retina to a flash of light.
1637624|NCT01950650|Behavioral|No treatment given|Survey conducted through computer-assisted telephone interviewing.
1637625|NCT01950650|Behavioral|survey|Survey conducted via the Internet.
1637626|NCT01950637|Behavioral|No treatment given|Completion of 90-item online questionnaire.
1637627|NCT01950637|Behavioral|survey|Completion of 58-item online questionnarie.
1637628|NCT01950611|Drug|Bortezomib|Combination of arsenic trioxide with bortezomib in the treatment of relapsed acute promyelocytic leukemia
1637629|NCT01950598|Procedure|Boston KPro type I - fresh graft|Boston KPro mounted on fresh corneal carrier graft for implantation
1637630|NCT01950598|Procedure|Boston KPro type I surgery - frozen graft|Boston KPro mounted on frozen corneal carrier graft for implantation
1637631|NCT01950585|Drug|Hydroxyurea|
1637633|NCT01950546|Drug|nanosilver fluoride|The product will be applied in the volunteers in the morning, before the first class, in relative isolation, made with cotton rolls and Vaseline to protect the soft tissue. It will apply 30mg of the product with microbrush, previously standardized in a pilot study on cervical vestibular surfaces of incisors and canines healthy, on a total of 8 teeth, 4 upper and 4 lower. After a period of 7 days,the cervical dental biofilms will be collect, third on the buccal surfaces of incisors and / or canines upper and lower, with the aid of sterile spatulas.
1637634|NCT01950533|Procedure|Oral food challenge|Confirmation of allergy to egg, milk and/or peanut through an oral food challenge or documentation of a positive oral food challenge.
2012091|NCT02227472|Other|Parent questionnaires|Parents will complete questionnaires to assess behavioral manifestation of executive functions, functional independence and adaptive functioning, child and parent characteristics, situational/demographic life stress, demographics, education level, and household income.
2012092|NCT02227056|Drug|Methylphenidate|On three different days each participant will receive Methylphenidate in a dosage of 0.3 milligram/kilo rounded to the nearest full milligram dosage
2012093|NCT02226172|Drug|Glasdegib (PF-04449913)|Oral daily dose of glasdegib (PF-04449913) 100 mg tablet in a continuous regimen of 28-day cycles.
1637638|NCT01950494|Other|fiteBac Hand Sanitizer|Skin gel created for health care workers that is currently on the market. This sanitizer has an additive layer to protect the skin that is also thought to helpo hand dermatitis.
1637639|NCT01950481|Drug|LDK378|Oral LDK378 750 mg once
1637640|NCT01950468|Drug|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
1637641|NCT01950468|Drug|DaTscan|A single intravenous dose of 3 to 5 mCi
1637642|NCT01950455|Drug|NAV5001|A single intravenous dose of 8.0 ± 1.0 mCi
1637643|NCT01950442|Device|Balloon dilation|
1637644|NCT01950416|Drug|Ticagrelor 180mg loading dose and 90mg bid maintenance dose|
1637645|NCT01950416|Drug|Clopidogrel 600mg loading dose and 150mg maintenance dose|
1637646|NCT01950403|Drug|linaclotide acetate|Given PO
1637647|NCT01950403|Other|placebo|Given PO
1637648|NCT01950403|Other|pharmacological study|Correlative studies
1637649|NCT01950403|Other|laboratory biomarker analysis|Correlative studies
1637653|NCT01950364|Drug|brentuximab vedotin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg.
1637654|NCT01950364|Drug|Brentuximab vedotin and rifampicin|Brentuximab vedotin will be administered every 3 weeks at a dose of 1.8 mg/kg beginning on Cycle 1, Day 1; daily rifampicin (600 mg PO) will be administered during Cycles 0 through 3 only, beginning on Cycle 0, Day 1 (7 days before the Cycle 1, Day 1 dose of brentuximab vedotin) and continuing through Cycle 3, Day 21.
1637655|NCT01950351|Radiation|Proton Beam Therapy|55.5 Gy (RBE) delivered in 15 fractions of 3.7 Gy (RBE) to the prostate. Each fraction will be scheduled once daily allowing at least one day between treated fractions.
1637656|NCT01950351|Behavioral|Questionnaire|Symptom questionnaire completed at baseline, during the last weeks of proton therapy, 6 months, 36 months, 48 months, and 60 months after therapy.
1637657|NCT01950338|Other|Dry needling|Once the most painful spot is located within a palpable spastic taut band, the overlying skin is cleaned with alcohol. The needle will be inserted, penetrating the skin about 15-20mm, until the first local twitch response is obtained. Once the first local twitch response is obtained, the needle will be moved up and down (4 to 5 mm. vertical motions with no rotation) in the muscle at approximately 1Hz for 25-30 seconds.
1637658|NCT01950325|Biological|VRC-HIVMAB060-00-AB|VRC01 Human Monoclonal Antibody
1637659|NCT01950312|Drug|gevokizumab|
1637660|NCT01950299|Drug|Anakinra 100 mg|Anakinra 100 mg starting immediately and then every 24 hours
1637661|NCT01950299|Drug|Anakinra 100 mg|Anakinra 100 mg starting 12 hours after first dose and then every 24 hours (so that Anakinra is given every 12 hours)
1637662|NCT01950299|Drug|Placebo|Placebo 0.67 ml injections twice daily
1637663|NCT01950273|Drug|BI 695500|BI695500, once a week for 4 weeks (4 administrations in total)
1637664|NCT01950273|Drug|MabThera|MabThera, once a week for 4 weeks (4 administrations in total)
1637665|NCT01950260|Drug|Levothyroxine|Early initiation of levothyroxine after radioactive iodine (to start at 4 weeks).
1637666|NCT01950260|Other|Placebo|Placebo to start at 4 weeks after RAI
1637667|NCT01950247|Drug|Injectafer|2 doses at 15 mg/kg for a maximum single dose of 750 mg given 7 days apart for a total of up to 1500 mg.
1637668|NCT01950247|Drug|SOC|
1637669|NCT01950234|Drug|ACTH|Acthar gel
1637670|NCT01950234|Drug|Placebo|Placebo
1637671|NCT01950221|Dietary Supplement|POMx|"POMx is a 1,000 milligram capsule of natural pomegranate polyphenol extract."
1637672|NCT01950221|Other|Placebo|
1637673|NCT01950195|Procedure|Stereotactic Radiosurgery (SRS)|
1637674|NCT01950195|Biological|Ipilimumab|
1637675|NCT01950182|Drug|Endocrine therapy combined with trastuzumab|Tamoxifen or aromatase inhibitors (Anastrozole, Letrozole, or Exemestane) combined with trastuzumab
1637676|NCT01950182|Drug|Chemotherapy combined with trastuzumab|Capecitabine , Vinorelbine, or Gemcitabine combined with trastuzumab
1637677|NCT01950169|Drug|Risedronate|The bisphosphonate group (B) receive 35 mg risedronate (Optinate® Septimum) once weekly for 12 months and calcium (1000 mg) and vitamin D3 (800 IU) (Calcichew-D3®) daily for 12 months.
1637678|NCT01950169|Other|Nutritional supplement|The bisphosphonate and nutritional supplemented group (BN) receive 35 mg risedronate once weekly for 12 months plus nutritional supplement (Fresubin® protein energy drink) during the first six months following hip fracture and also calcium (1000 mg) and vitamin D3 (800 IU) daily for 12 months.
1637679|NCT01950169|Dietary Supplement|Calcium and vitamin D3|The patients in the control group (C) receive orally administered calcium 1000 mg and 800 IU vitamin D3 (Calcichew-D3®) daily for 12 months.
1637681|NCT01950143|Dietary Supplement|Standard broccoli soup|Volunteers will be required to consume one portion of broccoli soup per week as part of their normal diet for one year.
1637682|NCT01950143|Dietary Supplement|Beneforte broccoli soup|Volunteers will be required to consume one portion per week of a soup containing glucoraphanin-enriched broccoli (Beneforte®) as part of their normal diet for one year.
1637684|NCT01950130|Procedure|Preoperative IABC|IABP-Insertion upon inclusion into the trial and admission to the ICU
1637685|NCT01950117|Procedure|Endoscopic mucosal resection|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected after submucosal injection of saline solution before removal.
1637686|NCT01950117|Procedure|Conventional polypectomy|Nonpedunculated neoplastic colorectal polyps from 10 mm to 25 mm in diameter were resected using conventional polypectomy. Submucosal injection of saline solution before removal was not performed.
1637687|NCT01950104|Other|Day 3 embryo biopsy|Embryo biopsy is applied at day 3 of the embryo development.
1637688|NCT01950104|Other|Blastocyst biopsy|Embryo biopsy is applied at the blastocyst stage of the embryo development
1637689|NCT01950091|Behavioral|FitBack on-line intervention|On-line Fitback intervention: Self care for on-going pain; behaviors to lessen the chance of reoccurrence
1637690|NCT01950091|Other|Alternative Website Control|Intervention is a Menu of links to 4 popular Websites offering back pain education
1637691|NCT01950065|Device|iovera|
1637692|NCT01950052|Dietary Supplement|Diet group 800 Kcal diet|Pre-operative liver shrinking diet of 800 kcal is administered for 4 weeks
1637693|NCT01950039|Drug|Betaine|Betaine or placebo administered orally in divided doses over 3 months.
1637694|NCT01950039|Drug|Placebo|Placebo administered orally in divided doses over 3 months
1637695|NCT01950026|Procedure|cryotherapy application|"Height, weight and BMI verification
subjects in supine position after 20 minutes of resting
cryotherapy application by cold thermal bag (thermoGel brand) size P
15-20 cm above the ASIS
temperature verified before and after cryotherapy application with an infrared thermometer CA 380 CASON brand, Brazil"
1637696|NCT01950013|Behavioral|Auditory training program|Previous experiments performed under laboratory settings using a novel word-based auditory-training regimen have demonstrated substantial improvements in open-set recognition of words and sentences in noise. The current proposed study will investigate the effectiveness of the training regimen when used in a patient's home setting with their own hearing aids.
1637697|NCT01950013|Behavioral|Sham Comparator: Active Control|This is a sham intervention in which the patient listens to audio books following the same regimen as the patients receiving the auditory training.
1637698|NCT01950000|Drug|Fentanyl|
1637699|NCT01950000|Other|Placebo|
1637700|NCT01949987|Other|two hours|
1637701|NCT01949987|Other|one hour|
1637702|NCT01949974|Drug|Standard Palliative Chemotherapy|Standard Palliative Chemotherapy, depending on type cancer.
1637703|NCT01949974|Other|Integral Attention Program (PAI)|The PAI is a plan of care and treatment adapted in accordance with the evolution and needs of patients. This plan includes an initial comprehensive assessment of patients and their families during the first visit, including specialized psychological and social support when needed, voluntary art therapy and/or mindfulness. There will be outpatient monitoring, 24h phone assistance, home visits, support should hospitalization be required, and unscheduled visits by a palliative care team.
1637704|NCT01949961|Other|Ultrasound|SonoVue solution 10 ml (2 vials / 80 µl microbubbles) is given as an infusion of 0,3 ml/min for ~30 minutes, using a Bracco infusion pump.
1637705|NCT01949961|Other|Sham ultrasound|Mounting the ultrasound headframe but connecting this to a non-operative channel
1637706|NCT01949948|Drug|Tenecteplase|0.4 mg/kg single bolus intravenously
1637707|NCT01949948|Drug|Alteplase|0.9 mg/kg as 10% bolus + 90% infusion/60 minutes intravenously
1637708|NCT01949935|Drug|Mupirocin|
1637709|NCT01949922|Procedure|Injection of autologous muscle fibers into the anal sphincter.|
1637710|NCT01949922|Procedure|Pelvic floor muscle training|Pelvic floor muscle training 3 months to optimize pelvic floor muscle function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training.
1637711|NCT01949922|Behavioral|Dietary intervention|Dietary intervention 3 months to optimize defecatory function. Autologous muscle stem cell injection will only be offered to patients that still have problems after completion of pelvic floor muscle training and dietary intervention.
1637712|NCT01949922|Drug|Analgesia|Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
1637713|NCT01949909|Biological|P27A vaccine candidate|
1637714|NCT01949896|Other|NPO|Infants in this group will be made NPO for a period of time surrounding the packed red blood cell transfusion.
1637715|NCT01949896|Other|Control group: continue feedings|Feedings will be continued in this group.
1637716|NCT01949883|Drug|CPI-0610|
1637717|NCT01949870|Drug|Cisplatin|day1 and day8 at each cycle
1637718|NCT01949870|Drug|Gemcitabine|day1 and day8 at each cycle
1637719|NCT01949870|Drug|Selumetinib|25mg/day, 50mg/day and 75mg/day
1637720|NCT01949857|Biological|Attenuated HAV Vaccine, H2 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
1637721|NCT01949857|Biological|Attenuated HAV Vaccine, L-A-1 Strain|6.50 lgCCID50/Vial in babies aged 18-35 months\6.50 lgCCID50/Vial in children aged 3-15 years \6.50 lgCCID50/Vial in adults aged 16 up to 65 years old, only one dose (1Vial/dose).
1637722|NCT01949857|Biological|Inactivated HAV Vaccine, Lu8 Strain|320EU/Vial in babies aged 18-35 months\320EU/Vial in children aged 3-15 years \640EU/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose
1637723|NCT01949857|Biological|Inactivated HAV Vaccine, TZ84 Strain|250U/Vial in babies aged 18-35 months\250U/Vial in children aged 3-15 years \500U/Vial in adults aged 16 up to 65 years old\boost at month 6\two-dose.
1637724|NCT01949844|Drug|regadenoson|Lexiscan® is being used off-label. The FDA Issued IND # is 119898. For the cardiac MRI, Lexiscan® will be used at the same dosage and administration as prescribed in the package insert - 5 mL (0.4 mg regadenoson) as packaged and supplied by the manufacturer, Astellas Pharma U.S., in single-use pre-filled syringes administered by rapid intravenous injection, followed immediately by saline flush.
1637725|NCT01949844|Drug|Optimark®|For the cardiac MR, the contrast agent, Optimark® is administered as a bolus peripheral intravenous injection at a dose of 0.2 mL/kg (0.1 mmol/kg) and at a rate of 1 to 2 mL/sec delivered by manual injection.
1637726|NCT01949844|Device|Myocardial perfusion MRI|
1637727|NCT01949831|Other|Assessment of functional ability in combination with follow-up at home|
1638235|NCT01945827|Device|DeltaMaxx Microcoil System|
1637728|NCT01949818|Drug|Yangzhengxiaoji capsule combined with CHOP regimen|Yangzhengxiaoji capsule combined with CHOP regimen(Yangzhengxiaoji capsule,Cyclophosphamide,Vincristine,Doxorubicin,Prednisone)Yangzhengxiaoji capsule ,1.56g,Tid,p.o,d7-21, Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
1637729|NCT01949818|Drug|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5
1637730|NCT01949805|Drug|Peg-P-IFN-alpha-2b (AOP2014)|Pegylated interferon alpha 2b given Q2W as SC injection
1637731|NCT01949805|Drug|Hydroxyurea|Hydroyurea capsules taken daily po
1637732|NCT01949792|Drug|eptacog alfa (activated)|Subject will receive a single injection (i.v.) of 270 microg/kg rFVIIa (NovoSeven®)
1637733|NCT01949792|Drug|eptacog alfa (activated)|Subject will receive 3 injections (i.v.) of 90 microg/kg rFVIIa (NovoSeven®) over a 6 hour period (each injection will be separated by 3 hours)
1637734|NCT01949779|Device|TransForm Occlusion Balloon Catheter|
1637735|NCT01949766|Drug|Glycerol phenylbutyrate|
1637736|NCT01949753|Behavioral|Exposure therapy with pharmacological facilitation|Exposure with response prevention and pharmacological facilitation
1637737|NCT01949753|Behavioral|Exposure therapy|Exposure with response prevention without pharmacological facilitation
1637738|NCT01949740|Other|questionnaire administration|Ancillary studies
1637739|NCT01949740|Procedure|quality-of-life assessment|Ancillary studies
1637740|NCT01949727|Other|AIM 2: Pulmonary Rehabilitation|Patients exercise 2 hours per session which includes aerobic exercise (20-40 minutes per session) as well as strength training. All exercise is carefully tracked by trained Respiratory or Physical Therapists. Patients also receive education from a multi-disciplinary team aimed at patient self-management.
1637741|NCT01949714|Procedure|Removal of adrenal tumor|
1637742|NCT01949701|Biological|HLA-A*0201restricted URLC10 peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A*0201restricted URLC10 peptides with adjuvant.
1637743|NCT01949688|Biological|HLA-A*2402 or A*0201 restricted peptides|"Open Label, Non-Randomized, Safety/Efficacy study:
HLA-A*2402-positive patients will be vaccinated subcutaneously once a week with HLA-A*2402 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant.
HLA-A*0201-positive patients will be vaccinated subcutaneously once a week with HLA-A*0201 restricted peptides for VEGF-R1 and VEGF-R2 with adjuvant."
1637744|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
1637745|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
1637746|NCT01949675|Biological|Shanchol™: Oral Cholera Vaccine Killed Bivalent (O1 and O139) Whole Cell|1.5 mL, Oral administration
1637747|NCT01949662|Drug|Lorazepam|3 mg by vein one time only.
1637748|NCT01949662|Drug|Placebo|Placebo consisting of preservative free 0.9% normal saline given one time by vein.
1637749|NCT01949662|Drug|Haloperidol decanoate|8 mg/day by vein.
1637750|NCT01949662|Behavioral|Questionnaires|Questionnaire completion at baseline, and every day while participant is in the palliative care unit. These questions will take about 20 minutes to complete.
2012094|NCT02226172|Drug|Placebo|Oral daily dose of placebo 100 mg tablet in a continuous regimen of 28-day cycles.
1637756|NCT01949623|Other|Anterior Chamber (AC) tap|Aqueous Samples will be collected for measurement of biomarkers
1637757|NCT01949610|Drug|14C-JNJ26489112|Participants will receive single dose of oral suspension of 1000 mg (10 mL) of 14C-JNJ26489112 on Day 1.
1637758|NCT01949597|Procedure|laparoscopic surgery for deep endometriosis|
1637759|NCT01949584|Device|nasal continuous positive airway pressure less than or equal to 6 cm H2O|Low level continuous positive airway pressure delivered during sleep.
1637761|NCT01949558|Behavioral|Dietary Intervention|
1637762|NCT01949545|Drug|Carfilzomib|Carfilzomib was administered by IV injection over 30 minutes
1637763|NCT01949532|Drug|Carfilzomib|Carfilzomib was administered by IV injection.
1637764|NCT01949519|Drug|Lycopene and Docetaxel|During administration of standard of care Docetaxel at 75 mg/m2 on day 15 and every 21 days, study patients will also receive Lycopene at the dose specified per the dose cohort they are enrolled. There are three dose cohort levels as follows: Dose level 1 = 30 mg PO every day; Dose level 2 = 90 mg PO every day; Dose level 3 = 150 mg PO every day.Treatment will continue until disease progression or toxicity or patient withdrawal.
1637765|NCT01949506|Radiation|SBRT|Stereotactic Body Radiation Therapy
1637766|NCT01949493|Device|mechanical traction|Twelve treatments with mechanical traction using the Phystrac traction apparatus. The Phystrac provides traction to the wrist using weights between 1 and 18 kg. The weights provide a pulling force in line with the forearm. After 8 seconds the weight is lifted, and there is a rest period of 4 seconds. This cycle will be repeated 10 times. Another two sets of 10 traction movements will be applied with the wrist positioned in 30 degrees supination and 30 degrees pronation. In total, 30 traction movements will be applied during each treatment.
1637767|NCT01949493|Other|Care as usual|Usual care provided by the neurologist (e.g. corticosteroid injection, wrist splint, carpal tunnel release surgery).
1637770|NCT01949467|Drug|iron fumarate|All patients will receive a tablet of 66mg of iron, in the form of iron fumarate (Fumafer®) with 50 ml water.
1637771|NCT01949454|Drug|Fluorometholone 0.1% ophthalmic solution|
1637772|NCT01949454|Other|Artificial tears (Placebo)|Artificial tears (Placebo)
1637773|NCT01949441|Biological|ToleroMune HDM|Intradermal injection 1 x 4 administrations 4 weeks apart
1637774|NCT01949441|Biological|Placebo|Intradermal injection 1 x 4 administrations 4 weeks apart
1637775|NCT01949402|Other|Computed Tomography|"The CT scan will be performed on a 16 slice GE Discovery 670 SPECT CT scanner. A slice thickness of 0.625mm will be used. Images are acquired during an inspiratory breath hold of up to 20 seconds to minimise movement artefact. The patient will be lying supine and the scan will be a non-contrast study. Using a low dose CT chest protocol (1.7 mSv) will minimise the exposure to ionising radiation of study participants.
Participants in the haemodialysis arm of the study will have a CT done before and after haemodialysis. Participants in all other arms will have a single CT scan done during their study visit."
1637776|NCT01949402|Other|Thoracic ultrasound|The ultrasound will be performed by a single operator. The patient's position will ideally be with the patient sitting up at 45°. Ultrasound images and clips will be recorded at 10 points over each hemithorax - the 2nd, 4th and 6th intercostal spaces (ICS) in the mid-clavicular line; the 2nd, 4th and 6th ICS in the mid-axillary line; and the 2nd, 5th, 7th and 9th ICS posteriorly. Ultrasound estimation of the height of the right internal jugular vein will be undertaken. Central venous pressure will be calculated by adding 5cm. Inferior vena cava diameter will also be measured at end-inspiration and expiration. The time taken to perform each ultrasound will be recorded. Control, COPD and ILD groups will be scanned on a single occasion. Haemodialysis group will have 4 scans.
1637777|NCT01949402|Other|Spirometry|All participants in the study will undergo basic spirometry as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
1637778|NCT01949402|Other|Blood tests|All participants in the study will undergo blood tests as specified in the study assessments. This is considered a low-risk intervention and no harm is expected as a consequence of participation in the study.
1637779|NCT01949389|Behavioral|Internet-based Cognitive Behavioral Therapy for Insomnia|This is an internet-based Cognitive Behavioral treatment for insomnia. It is accessed via a computer with an internet connection and consists of 7 modules, homework, and a daily sleep log. The intervention is self administered.
1637780|NCT01949363|Drug|Cefixime|Cefixime is an FDA approved oral semi-synthetic cephalosporin antibiotic. The standard dose (400mg), high dose (800mg and 1200mg), and multiple 800mg and 1200mg doses given over a 24-hour period using a dose-frequency escalation method. Cohort A receives 400 mg orally once, Cohort B receives 800 mg orally once; Cohort C receives 1200 mg orally once; Cohort D receives 800 mg orally 3 times (every 8 hrs)
1637781|NCT01949350|Dietary Supplement|Carbohydrate|Participants will be asked to drink an isotonic carbohydrate loaded drink (preload)night before the test and also two hours prior to the CPX test.
1637782|NCT01949350|Dietary Supplement|Carbohydrate protein|Participants will be asked to drink an isotonic carbohydrate drink (Highfive energy source 4:1)the night prior to the test and also two hours prior to the CPX test.
1637783|NCT01949350|Dietary Supplement|Starved|Participants will be asked to starve as per normal clinical requirements for surgery. They are allowed to drink water upto 2 hours prior to the CPX test
1637784|NCT01949337|Drug|enzalutamide|Enzalutamide 160 mg daily, orally
1637785|NCT01949337|Drug|abiraterone|abiraterone 1000 mg daily, orally
1637786|NCT01949337|Drug|prednisone|prednisone 5 mg twice daily, orally
1637787|NCT01949324|Biological|Ciliary neurotrophic factor (CNTF)|
1637788|NCT01949324|Procedure|Surgery|Surgery to implant device for NT-501 arm and sham surgery for Sham arm
1637789|NCT01949311|Drug|Dupilumab (REGN668/SAR231893)|
1637790|NCT01949298|Procedure|dental implant placement|
1637791|NCT01949285|Device|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that non-invasively delivers electrical stimulation to the spinal cord will be used to assess and rehabilitate spared spinal cord function.
1637792|NCT01949272|Device|esophageal pressure mesurement|"EXPRESS study ventilatory setting the optimization of PEEP with esophageal pressure mesurement"
1637793|NCT01949233|Drug|Irbesartan 150-300mg capsules daily for 6 months|
1637794|NCT01949233|Drug|Doxycycline 100-200mg capsules daily for 6 months|
1637795|NCT01949233|Drug|Doxycycline placebo capsules daily for 6 months|
1637796|NCT01949233|Drug|Irbesartan placebo capsules daily for 6 months|
1637797|NCT01949207|Procedure|EVLA|Endovenous laser ablation of great saphenous vein
1637798|NCT01949207|Procedure|phlebectomies|removal of incompetent veins
1637799|NCT01949207|Procedure|TRansluminal Occlusion of Perforators (TRLOP)|TRansluminal Occlusion of Perforators (TRLOP) closure of incompetent perforators.
1637800|NCT01949194|Drug|Regorafenib|"The dose of regorafenib given will be 160 mg once a day (od) oral (po), using a 21 days on / 7 days off treatment schedule. This equates to four (4) tablets once a day for three (3) weeks. The patient should take the dose at the same time each day, with a full glass of water, and following a light meal. A light mealconsists of less than 30% fat and around 300-550 calories."
1637801|NCT01949181|Procedure|Lung surgery|
1637802|NCT01949168|Drug|Victrelis® (boceprevir) 800mg by mouth, TID (200 mg tablets)|
1637803|NCT01949168|Drug|Peg-Intron® (peginterferon-α-2b), 1.5ug/kg sc injection|
1637804|NCT01949168|Drug|Rebetol® (ribavirin), 1000/1200mg by mouth daily|
1637805|NCT01949155|Drug|OTO-201|Single, intratympanic injection
1637806|NCT01949155|Drug|Sham|Simulated single, intratympanic injection
1637807|NCT01949142|Drug|OTO-201|Single, intratympanic injection
1637808|NCT01949142|Drug|Sham|Simulated single, intratympanic injection
1637809|NCT01949129|Drug|VP16|60 mg/kg, administration: 1 day
1637810|NCT01949129|Radiation|TBI|12 Gy in 6 fractions over 3 days
1637811|NCT01949129|Drug|Thiotepa|2x5 mg/kg, 1 day
1637812|NCT01949129|Drug|Treosulfan|14g/m² BS, 3 days
1637813|NCT01949129|Drug|Fludarabine|30 mg/m² BS, 5 days
1637814|NCT01949129|Drug|Busulfan|iV, dosage according therapeutic drug monitoring, 4 days
1637815|NCT01949116|Drug|Methotrexate (MTX)|"MTX 5 mg: one 5-mg capsule by mouth once weekly
MTX 10 mg: two 5-mg capsules by mouth once weekly
MTX 15 mg: three 5-mg capsules by mouth once weekly"
1637816|NCT01949116|Drug|Placebo|"Placebo 5 mg: one 5-mg capsule by mouth once weekly
Placebo 10 mg: two 5-mg capsules by mouth once weekly
Placebo 15 mg: three 5-mg capsules by mouth once weekly"
1637817|NCT01949116|Dietary Supplement|Folic acid|1-mg tablet of folic acid by mouth once a day
1637818|NCT01949103|Drug|TD-1607|
1637819|NCT01949103|Drug|Placebo|
1638449|NCT01943825|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
1637822|NCT01949064|Device|Grindcare|
1637823|NCT01949064|Device|Michigan-type occlusal splint|
1637824|NCT01949051|Drug|Levocabastine|Intranasal aqueous 50 mcg microsuspension of levocabastine supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
1637825|NCT01949051|Drug|Placebo|Intranasal aqueous 0 mcg microsuspension supplied in an amber glass bottle fitted with a white top actuated plastic metering atomising spray pump filled with a uniform white suspension
1637826|NCT01949038|Drug|Oral alprazolam|
1637827|NCT01949038|Drug|Sublingual alprazolam|
1637828|NCT01949038|Drug|Oral placebo|
1637829|NCT01949038|Drug|Sublingual placebo|
1637830|NCT01949025|Other|ALARM intervention|The training of nursing and medical staff about the observation, detection, assessment and communication of deteriorating and critically ill patients and the introduction of a standardized observation and communication protocol on medical and surgical wards.
1637831|NCT01949012|Other|Capnography|Capnography waveform and capnometry readings
1637832|NCT01948999|Procedure|ECT|Electroconvulsive Therapy inclusive anesthesia and concomitant muscular paralysis
1637833|NCT01948999|Procedure|SHAM ECT|Anesthesia and concomitant muscular paralysis
1637834|NCT01948999|Drug|Anesthesia|Temporary induced state of analgesia
1637835|NCT01948986|Drug|Ertugliflozin|Single oral administration of tablets.
1637836|NCT01948973|Device|Subsensory|The stimulation is here set to 90% of the sensory threshold
1637837|NCT01948973|Device|OFF|The stimulation is here turned OFF
1637838|NCT01948973|Drug|Suprasensory|The stimulation is here set suprasensory
1637842|NCT01948934|Procedure|Amniotic membrane in big wounds|The wound will be washed with saline and debrided if necessary. Control microbiological cultures will be taken and applied amniotic membrane fragments sufficient to cover the wound, putting in contact the basement membrane of the AM with granulation tissue
1637843|NCT01948921|Drug|placebo|
1637844|NCT01948921|Drug|Meperidine|
1637845|NCT01948908|Drug|Intranasal midazolam|Intranasal midazolam, 0.5 mg/kg, maximum dose 10 mg, administered using mucosal atomization device (MAD).
1637846|NCT01948895|Drug|Desvenlafaxine|Patients will be initiated on 50 mg/day of Desvenlafaxine. No dose changes will be allowed for the first four weeks. If there is partial or no response after four weeks, dosage will then be increased to 100mg/day, based on tolerability and the Investigator's judgment.
1637847|NCT01948882|Device|ESS505 (BAY1454033)|
1637848|NCT01948869|Device|Phoenix II (BAY81-2996)|
1637849|NCT01948869|Device|Phoenix I (BAY81-2996)|
1637850|NCT01948856|Drug|J022X ST|"Oral administration - During 6 months and according to the approved summary of product characteristics : 1 sachet per day in the morning on an empty stomach
First month: 4 consecutive days per week during 3 consecutive weeks
5 next months: 4 consecutive days per month at monthly intervals"
1637851|NCT01948856|Drug|Placebo|"Oral administration - During 6 months : 1 sachet per day in the morning on an empty stomach
First month: 4 consecutive days per week during 3 consecutive weeks
5 next months: 4 consecutive days per month at monthly intervals"
1637852|NCT01948843|Drug|ADI-PEG 20|
1637853|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
1637854|NCT01948830|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections) prefilled syringe)
1637855|NCT01948817|Drug|Deferasirox|Deferasirox 20mg/kg taken BID
1637856|NCT01948804|Drug|GnrH Antagonist/letrozole protocol (Cetrotide; serono + Femara; Novartis Pharma AG)|
1637857|NCT01948804|Drug|microdose flare-up protocol (Lucrin; Abbott + Gonal F, Serono)|
1637858|NCT01948804|Drug|Antagonist/clomiphene protocol (Cetrotide; serono + Klomen, Kocak pharma)|
1637859|NCT01948804|Drug|GnRH antagonist protocol (Cetrotide, Serono)|
1637860|NCT01948791|Drug|ENA713|The following strengths of Rivastigmine capsules were provided: Rivastigmine capsule strengths: 1.5mg, 3mg, 4.5mg. The 6mg dose was administered as one 1.5mg capsule and one 4.5mg capsule, and when necessary, the 3mg dose could also be administered as two 1.5mg capsules. Rivastigmine was administered from 3mg/d at baseline. Then dose escalation was made in 3mg/d increments, at a minimun of 4 weeks between dose increases to a maximum dose of 12mg/d or the individual's best tolerated dose.
1637861|NCT01948778|Device|oXiris™ filter|
1637862|NCT01948778|Device|Toraymyxin Filter|
1637863|NCT01948778|Device|Standard of Care|
1637864|NCT01948765|Drug|Xenon and propofol|xenon 30% in oxygen as an adjuvant to propofol target controlled infusion (target of 0.5-1.5µg/ml)
1637865|NCT01948765|Drug|propofol|propofol target controlled infusion (target 1.5-2.5µg/ml)
1637866|NCT01948752|Other|Nutrition information on menus|
1637868|NCT01948726|Radiation|Hypofractionation with simultaneous integrated boost|
1637869|NCT01948713|Other|Strengthening of pelvic floor muscles.|Kegel exercises kinesiotherapy
1637870|NCT01948713|Other|Strengthening of hip muscles.|Kegel exercises and strengthening of hip muscles as Gluteus Maximus and Medius and adductor muscles
1637871|NCT01948700|Behavioral|Motivational Interviewing|
1637872|NCT01948700|Other|Education|
1715946|NCT00000245|Drug|Desipramine|
1637873|NCT01948674|Behavioral|Computerized tasks|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
1637874|NCT01948661|Dietary Supplement|Mirtoselect® + Meriva®|
1637875|NCT01948661|Dietary Supplement|Placebo|
1637876|NCT01948648|Drug|Colesevelam|
1637877|NCT01948648|Dietary Supplement|Fish Oil|
1637878|NCT01948648|Drug|Combination of fish oil and colesevelam|
1637879|NCT01948635|Device|tapered PVC-cuffed tracheal tubes|Patients will be intubated with tapered-shape tracheal tubes
1637880|NCT01948635|Device|Standard PVC-cuffed tracheal tube|Patients will be intubated with standard PVC cuffed tracheal tubes
1637881|NCT01948622|Drug|Mulungu|500 mg/single dose/1 hour before dental surgery
1637882|NCT01948622|Drug|Placebo|500 mg/single dose/1 hour before dental surgery
1637883|NCT01948596|Dietary Supplement|Omega-3 polyunsaturated fatty acids|
1637884|NCT01948583|Drug|Hyaluronic Acid|Arm I: new formulation applied for the first week, formulation on the marked applied for the third week (second week - wash out period) Arm II: formulation on the marked applied for the first week, new formulation applied for the third week (second week - wash out period)
1637886|NCT01948531|Drug|Gynomunal® gel|A fixed quantity of the cosmetic product will be applied on the face (including the submental area) twice a day, in the morning and in the evening (preferentially always at the same hour), with a mild massage according to the instructions received by the investigator during the basal visit (T0).
1637887|NCT01948518|Drug|Oral sildenafil 20 mg|A single dose of sildenafil will be given after recording baseline diffusion capacity and 6 minute walk. Measurements will be repeated one hour after the drug.
1637888|NCT01948505|Drug|Intravenous acetaminophen|
1637889|NCT01948505|Drug|Placebo for IV acetaminophen|
1637890|NCT01948492|Dietary Supplement|Protein intake|On the study day, the diet will be provided as free amino acids, with calories made up by a liquid diet and protein free cookies. Protein intakes will be varied as 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, 2.0 g/kg/day.
1637891|NCT01948479|Device|Optimised instant offloading insole|
1637892|NCT01948466|Behavioral|Commercials|These commercials will display child actors and try to grab the attention of the 3rd - 5th grade viewers. They will be humorous, fun, and call the viewer to action so the students will feel they should consume fruits and vegetables like the children in the commercials.
1637893|NCT01948453|Dietary Supplement|Garlic|Garlic tablet in adjunct to medical treatment
1637894|NCT01948440|Behavioral|ASI-MV Solutions|The Experimental group will complete the ASI-MV and use the ASI-MV Solutions program for eight 30-minute sessions, followed by monthly booster sessions. The Experimental group will undergo a baseline assessment and one-month post-baseline, two-month post-baseline, and six-month post-intervention.
1637895|NCT01948414|Procedure|electroencephalography|
1637896|NCT01948414|Biological|Blood sampling|
1637897|NCT01948414|Behavioral|Questionnaires regarding eating habits (TFEQ, EDI) and anxiety/depression (HAD)|
1637898|NCT01948401|Drug|LABA|long-acting beta-agonist treatment
1637899|NCT01948401|Drug|corticosteroids|chronic treatment with oral corticosteroids, high dose inhaled corticosteroids
1637900|NCT01948401|Drug|prednisolone|additional 0.5 mg/kg orally for 7 days
1637901|NCT01948388|Drug|corticotrophin 80 units|Comparison of different dosages of the drug. Ten patients will receive 80 units of corticotrophin weekly. Ten patients will receive 80 units bi-weekly of corticotrophin
1637902|NCT01948375|Device|real needle- placebo needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
1637903|NCT01948375|Device|placebo needle - real needle|All acupoints were needled through the pad but just pressed against the skin without penetration by pragmatic placebo needle, while through the pad and into the skin 15 mm by real needle. For each intervention, LI4 and RN12 are needled first in a supine position for 15 minutes; BL36 and BL25 are needled secondly in a prone position for another 15 minutes. After withdrawal of the needle, participants were asked to give answers on perception of skin penetration, needle sensation and acupuncture pain. Acupuncture was given every other day, three sessions for one kind of needle, six sessions in total for each subject. There was a two-day interval between the applications of two kinds of needles.
1637904|NCT01948362|Drug|Sulforadex|Active compound
1637905|NCT01948362|Drug|Alpha cyclodextrin|Placebo control
1637906|NCT01948349|Other|Tongue scraping|Two of four groups will use tongue scraping in conjunction with a normal oral hygiene protocol.
1637907|NCT01948349|Other|Bracket design|Two groups will be allocated to have self-ligating (Carriere) brackets. The other two groups will receive standard twin brackets.
1637908|NCT01948336|Drug|Dexmedetomidine|a loading dose of 1 µg kg-1 dexmedetomidine (Precedex Abbott Labs, North Chicago, IL) IV given over 10 minutes, followed by 0.5 µg kg-1 hour-1 IV dexmedetomidine infusion were administered. Dexmedetomidine was prepared as a 1 µg ml-1 solution using D5 0.3% NaCl solution.
1637909|NCT01948336|Drug|Ketamine|ketamine was bolused with 1 mg kg-1(IV) and followed by 1 mg kg-1 hour-1 ketamine IV infusion during the procedure.
1637910|NCT01948336|Drug|Propofol|propofol was bolused 1 mg kg-1 and 50 µg kg-1 min-1 propofol (IV) infusion during the procedure.
1637943|NCT01948011|Drug|Racecadotril granules|Racecadotril granules at 60mg. Single oral dose.
1637911|NCT01948323|Behavioral|HEDUAfrica IT package+ standard care|"The HEDUAfrica website aims to target disadvantaged pregnant women representing the core aspect of the intervention. The website is available on a touch screen panel at the two intervention clinics, (Cape Town and Soweto, South Africa). A trained healthcare worker will assist women by means of a touchscreen tablet at the follow up sessions. The website content includes a number of short videos and health messages related to a pregnancy-specific-disease outcomes.
Participants are also asked to complete 2 questionnaires (24 hour dietary recall assessment and short messaging service technology driven) in conjunction to engaging with the HEDUAfrica website. The intervention is standardized across all participants in the intervention group."
1637916|NCT01948284|Procedure|half-maximal pressure|the pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the half-maximal (-35 cm Hg).
1637917|NCT01948284|Procedure|maximal pressure|The pressure level of the suction unit (DF 601, Hanlien, Taipei, Taiwan) will be set at the maximal (-70 cm Hg).
1637918|NCT01948284|Device|Suction Unit|
1637919|NCT01948271|Drug|Trichuris Suis Ova|During the treatment phase, study drug will be provided in a liquid form and will be administered every 2 weeks, starting with the Baseline visit, through Week 14.
1637920|NCT01948245|Device|TaurolockTMHep100|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
1637921|NCT01948245|Device|Heparin 100 IE/ml|2-4 ml of the catheter lock solution will be instilled after each infusion of parenteral nutrition/intravenous fluids varying between twice weekly to once daily, depending on the individual patients HPN programme. The instilled solution is kept in the catheter until the next infusion, with a prior flushing with 10 ml of Saline both before the instillation of the catheter lock and before infusion of HPN/fluids.
1637922|NCT01948232|Drug|Perindopril|Angiotensin converting enzyme inhibitor
1637924|NCT01948193|Biological|Hexaxim™: DTaP-IPV-Hep B-PRP~T combined vaccine|0.5 mL, Intramuscular
1637925|NCT01948180|Biological|CMD-003|Autologous EBV-specific T-cells
1637926|NCT01948167|Behavioral|Interpersonal Psychotherapy- Adolescent Skills Training|A group prevention program that includes a 60-minute pre-group session, 8 weekly 90-minute group sessions, a 60-minute mid-group session, and 3 60-minute booster sessions. IPT-AST focuses on psychoeducation and interpersonal skill-building to decrease interpersonal conflict and increase interpersonal support and competence.
1637927|NCT01948167|Behavioral|Coping with Stress|A group prevention program that consists of 8 acute 90-minute group sessions, 2 parent group sessions, and 3 continuation sessions lasting 60 minutes each. Participants are taught to apply cognitive techniques to their personal thoughts, with the goal of generating effective counterarguments to unrealistic negative beliefs.
1637928|NCT01948141|Drug|nintedanib|Given PO
1637929|NCT01948128|Drug|Vitamin D3|Participants will take 4 capsules of Vitamin D which equals 40,000 IU by mouth daily during the wait time between diagnosis and surgery.
1637930|NCT01948128|Other|Placebo|Participants will take 4 capsules of placebo by mouth daily during the wait time between diagnosis and surgery.
1637931|NCT01948115|Drug|equimolar mixture of oxygen and nitrous oxide or medical air|"We need to include 150 patients for a period of 2 years. Patients will be randomized: 75 patients in each arm: 75 patients in group placebo (medical air), 75 patients in group treatment (equimolar mixture of oxygen and nitrous oxide).
Patients will be single-blind. The ECV be started at least 3 minutes after the start of administration. The maximum time of administration of the gas will be 15 minutes. Just after ECV, we compare success rate of intervention."
1637932|NCT01948089|Behavioral|Variable Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will vary weekly, and include varying auditory letters or words, or varying visual patterns or faces.
1637933|NCT01948089|Behavioral|Constant Structured Cognitive Exercise|This exercise uses the n-back paradigm in which participants are asked to keep track of one or two series of sequentially presented auditory and/or visual stimuli in order to detect targets that match those presented n-items ago in the sequence. The task begins at 1-back (i.e., watch for targets that match those just presented) and gets harder (e.g., watch for matches with items presented 2 or 3 items ago in the sequence) as performance improves. The stimuli will remain constant throughout the 10 week intervention
1637934|NCT01948076|Device|resident with GE vscan|resident with GE vscan
1637935|NCT01948063|Drug|Ubiquinol|Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.
1637936|NCT01948063|Dietary Supplement|Placebo|Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.
1637937|NCT01948050|Device|non-invasive transcranial direct current stimulation (tDCS)|
1637938|NCT01948037|Other|hydrotherapy|30-minutes/per day,for 4weeks
1637939|NCT01948037|Other|hydrotherapy|30-minutes/per day;4weeks
1637940|NCT01948024|Drug|SAPHRIS|10 mg BID sublingual tablet
1637941|NCT01948024|Drug|Asenapine|10 mg BID sublingual tablet
2012095|NCT02226055|Device|Arterial Stiffness Assessment|"The following will be measured: brachial systolic and diastolic bp, heart rate, mean arterial bp, pulse pressure, brachial augmentation index (difference between the amplitudes of the late (backward) systolic wave (P2) and the early (forward) systolic wave (P1) over the pulse pressure x 100), central augmentation, ejection duration of the left ventricle, return time (time of the pulse wave travelling from aortic root to the bifurcation and back), aortic pulse wave velocity ( velocity of the pulse wave in the aorta), central systolic bp, central pulse pressure and diastolic reflection area (provides information about the quality of diastolic filling in the coronary arteries).
We will perform an arterial age assessment. Patients are given a feedback form with their results to give to their general. Those with increased arterial stiffness will be tested for serum calcium and phosphate levels, and audited to ensure that a statin is commenced if not contraindicated."
2012096|NCT02224781|Drug|Dabrafenib|Given PO
2012097|NCT02224781|Biological|Ipilimumab|Given IV
2012098|NCT02224781|Other|Laboratory Biomarker Analysis|Correlative studies
1637948|NCT01947972|Dietary Supplement|Tailored protein fortification|4-4.5g of protein/kg/d
2012099|NCT02224781|Biological|Nivolumab|Given IV
2012100|NCT02224781|Other|Quality-of-Life Assessment|Ancillary studies
1637951|NCT01947946|Biological|Benralizumab|"Benra 30 mg q.4 Weeks is a fixed 30 mg dose of benralizumab subcutaneously on study week 0 until study week 44 inclusive.
Benra 30 mg - Placebo q.8 Weeks is a fixed 30 mg dose of benralizumab, every 4 weeks for the first 3 doses and then every 8 weeks thereafter, (placebo injections administrated at the 4 week interim visits to maintain blind). It is subcutaneously administered on study week 0 until study week 44 inclusive."
1637952|NCT01947946|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
1637953|NCT01947933|Biological|Mirikizumab- IV|Administered IV
1637954|NCT01947933|Biological|Mirikizumab - SC|Administered SC
1637955|NCT01947933|Biological|Placebo - IV|Administered IV
1637956|NCT01947920|Drug|Tramadol HCl, 50 mg|50-mg overencapsulated tablet for oral administration
1637957|NCT01947920|Drug|Placebo|Size-matching capsules containing an appropriate inactive excipient
1637958|NCT01947907|Drug|ACP-001|Once weekly subcutaneous injection
1637959|NCT01947907|Drug|Human Growth Hormone|Once daily subcutaneous injection of human Growth Hormone
2012101|NCT02224781|Drug|Trametinib|Given PO
1637961|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
1637962|NCT01947855|Drug|Empagliflozin|Empagliflozin low dose
1637963|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
1637964|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin low dose
1637965|NCT01947855|Drug|Empagliflozin|Empagliflozin high dose tablet once daily
1637966|NCT01947855|Drug|Placebo|Placebo tablet matching Empagliflozin high dose
1637967|NCT01947842|Device|Smartphone App Dosecast|The Dosecast app is configured to remind the patient to take their medication.
1637968|NCT01947803|Drug|Paliperidone Palmitate|Paliperidone Palmitate is injected with a dose of 150 mg eq. on Day 1 and 100 mg eq. on Day 8 in the deltoid muscle, followed by a monthly flexible dose range of 75 - 150 mg eq. for injection, based on patients' tolerability and/or efficacy. Monthly doses can be administered in either the deltoid or gluteal muscle alternatively. All the antipsychotics should be discontinued prior to the first dose of study drug. Other antipsychotics are prohibited across this study.
1637969|NCT01947790|Drug|pioglitazone group|
1637970|NCT01947790|Drug|Metformin group|
1637971|NCT01947777|Drug|IPI-145|25 mg oral capsule
1637972|NCT01947777|Drug|Rifampin|2x 300 mg oral capsule
1637973|NCT01947764|Behavioral|HADITHI Intervention|"The HADITHI Intervention consists of a culturally adapted, multi-component clinic-based intervention designed to support families in pediatric HIV disclosure in Kenya.
In addition to the Usual Care components, the HADITHI Intervention clinics will have the following intervention components:
Culturally modified curricula materials, including videotaped narratives, to guide counseling and group sessions.
Dedicated disclosure counselors to initiate and conduct disclosure, with one-on-one counseling for caregivers and children, as well as family-based sessions.
Post-disclosure peer support groups, facilitated by the disclosure counselors, for children who have gone through disclosure."
1637974|NCT01947751|Procedure|CVC exchange|CVC exchange when related infection is suspected
1637975|NCT01947751|Drug|CVC maintenance|CVC maintenance and adding antibiotic therapy when related infection is suspected, waiting for the cultures to take the decision of changing CVC
1637976|NCT01947738|Drug|VBY-891|Cathepsin S inhibitor
1637977|NCT01947738|Drug|Placebo|
1638008|NCT01947491|Drug|Comp01 Lotion|
1638009|NCT01947491|Drug|Vehicle Lotion|
1638010|NCT01947491|Drug|Vehicle Spray|
2012102|NCT02223338|Drug|Ciprofloxacin|Use of topical ciprofloxacin 4x daily for 3 days after intravitreal injection using standard aseptic techniques with Povidone-Iodine is a common practice intervention in the United States, and is thought by some to reduce the risk of post-injection endophthalmitis.
2012103|NCT02223338|Drug|Standard Aseptic Technique|Patients in this group will have received Povidone-Iodine Only following injections of anti-VEGF agents at least 3 times in the last 6 months.
2012104|NCT02223793|Behavioral|Information on high risk factor levels and lifestyle advice|This arm of high risk participants will be informed about their measured levels of the different cardiovascular risk factors. They will also receive information on how to lower their levels in 8 weeks
2012105|NCT02223793|Behavioral|No information on high risk factor levels but lifestyle advice|In this arm, participants will have delayed information on their risk factor levels, but they will receive general advices on how to lower levels in 8 weeks
2012106|NCT02223793|Behavioral|No information on high risk factor levels, nor lifestyle advice|In this arm, participants will have delayed information on both their risk factor levels and general information on how to lower risk factor levels.
2012107|NCT02222922|Drug|PF-06647020|Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined.
1637978|NCT01947725|Drug|Nicotine patch|Subjects in all arms will receive 12 weeks of nicotine patch. The dosage will be 4 weeks of 21 mg, 4 weeks of 14 mg, and 4 weeks of 7 mg patches as is approved by the FDA and is standard treatment at the study facility. This dosage may be adjusted based on the needs of the subject as is the standard of care.
1637979|NCT01947725|Drug|Nicotine gum or nicotine lozenge|Subjects in all arms will receive either nicotine gum or nicotine lozenge (depending on their preference). Participants who smoke less than 25 cigarettes/day will receive 2-mg gum/lozenge; participants smoking 25 or more cigarettes/day will receive 4-mg gum/lozenge. Participants will be told to try to use one piece of gum every 1-2 hours. However, participants will also be told that they may not be able to take a full, recommended dose of oral Nicotine Replacement Therapy (NRT) given their conjoint use of the patch. Participants will be urged to use at least 5 pieces/day, unless this amount of use produces negative (toxic) effects.
1637980|NCT01947725|Behavioral|Standard Smoking Cessation Therapy|Subject in both arms will receive a standard, individual smoking cessation treatment. Treatment will be delivered in eight, 20-minute individual sessions over an 8-week period.
1637981|NCT01947725|Behavioral|Health and Smoking Education|Health and Smoking Education (HSE) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. HSE treatment will focus on smoking, health, and the impact of smoking on the subject's health.
1637982|NCT01947725|Behavioral|Behavioral Activation Treatment|Behavioral Activation (BA) Treatment will be delivered in eight, 30 minute individual sessions over an 8-week period. BA treatment will focus on encouraging subjects to participate in activities that they find enjoyable and rewarding.
1637983|NCT01947712|Dietary Supplement|dark chocolate with crossover to milk chocolate|40 g/d of dark chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of milk chocolate for 4 weeks
1637984|NCT01947712|Dietary Supplement|milk chocolate with crossover to dark chocolate|40 g/d of milk chocolate for 4 weeks followed by wash-out (1 week) and by 40 g/d of dark chocolate for 4 weeks.
1637985|NCT01947699|Drug|Glyburide|
1637986|NCT01947699|Device|Continuous glucose monitor|
1637987|NCT01947686|Device|Robotically guided patellofemoral UKA isolated patellofemoral implants|A robot guided isolated patellofemoral unicompartmental knee arthroplasty procedures to replace only the patellofemoral component of the knee.
1637988|NCT01947673|Other|Mindfulness Meditation|
1637989|NCT01947673|Other|Health Education|
1637990|NCT01947660|Drug|Systemic analgesia + Continuous regional anesthesia|Systemic analgesia + Continuous regional anesthesia, peri neural for the 2 to 4 first days post-operative
1637991|NCT01947660|Drug|Systemic analgesia|Systemic analgesia as usual
1637992|NCT01947647|Behavioral|Transdiagnostic Behavior Therapy|A new transdiagnostic CBT protocol for the depressive/anxiety disorders was developed and revised through two demonstration studies and one focus group. The resulting protocol involves several primary components, including psychoeducation on the symptoms of depression and anxiety (session 1), assessment of motivation and setup of treatment plans (session 2), exposure therapy (sessions 3-15), and relapse prevention (final session). In addition to these primary components, optional modules are included to supplement exposure therapy later in treatment to address secondary symptoms (e.g., anger, sleep, hypervigilance, drinking to cope). The goal of these modules is to allow providers to tailor treatment to specific symptoms that may be present in any single or set of diagnoses that may be reducing the effects from the primary exposure approach. Session will be weekly for 45-60 minutes with homework assignments to be completed between sessions.
1637993|NCT01947647|Behavioral|Behavioral Activation Therapy|To provide an evidence-based comparison for the transdiagnostic CBT condition, a second group of participants will receive manualized BAT. In general, BAT involves teaching patients to monitor their mood and daily activities with the goal of increasing pleasant, reinforcing activities and reducing unpleasant events. In the present study, the BAT condition will be manualized, following an existing protocol in the literature. BAT will be structurally equivalent to the transdiagnostic CBT with the same session length (45-60 minutes), frequency of sessions (weekly), duration of treatment (12-16 sessions), and amount of homework.
1637994|NCT01947634|Other|ResMed Apnea Link plus|Overnight respiratory polygraphy to detect sleep-related breathing disorders is performed in Fabry patients
1637996|NCT01947595|Behavioral|intensified lifestyle intervention|"physical activity 6 hours per week, 50% guided activity
recorded by an accelerometer (Aipermotion 440)
16 sessions per year with a lifestyle advisor
nutritional advice (target weight: 5% less, if BMI > 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
1637997|NCT01947595|Behavioral|normal lifestyle intervention|"physical activity 3 hours per week
recorded by an accelerometer (Aipermotion 440)
8 sessions per year with a lifestyle advisor
nutritional advice (target weight: 5% less, if BMI > 25kg/m², less than 30% fat per caloric intake, less than 10% fatty acids per caloric intake, more than 15 g fibre per 1000 kcl)"
1637998|NCT01947595|Behavioral|Single lifestyle advice|"- Single Health care advice and lifestyle advice (30 minutes) at the beginning
recommend the individual target weight (5% less, if BMI 25> kg/m²)"
1637999|NCT01947582|Device|Ankle foot orthosis|The ankle foot orthoses (AFOs) that will be used are designed to provide assistance with anterior tibial advancement during stance and dorsi flexion assistance during swing. The device(s) are polypropylene and are custom-fabricated.
1638000|NCT01947569|Biological|Biological|
1638001|NCT01947556|Drug|insulin aspart|After hyperglycaemia (18-23 mmol/l) has been reached (by decreasing or interrupting exogenous insulin administration 12-24 hours before the experiment), aspart insulin (in a dose of 1.5 times the amount of insulin needed to reduce blood glucose to 6 mmol/l calculated by the insulin-sensitivity factor) will be administered subcutaneously by Insujet pen or conventional insulin pen, on two separate occasions, or vice versa. The injection will be given by the subject under supervision of the research staff.
1638002|NCT01947530|Procedure|Navigational Bronchoscopy|
1638003|NCT01947530|Procedure|Standard Bronchoscopy|
1638004|NCT01947517|Device|Parasol Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
1638005|NCT01947517|Device|Superflex Punctal Occluder|Patients will be randomized to receive one of these 2 punctal occluders in the management of dry eyes.
1638006|NCT01947504|Behavioral|eudcation and support intervention|
1638007|NCT01947491|Drug|DFD01 Spray|
1638011|NCT01947478|Device|MDT-2113 Drug-Eluting Balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
1638012|NCT01947478|Device|Standard angioplasty balloon|Subjects will be randomized (2:1) to the MDT-2113 Drug-Eluting Balloon Arm or to the standard non-coated PTA balloon Arm
1638013|NCT01947465|Biological|Hepatitis A vaccine and tetanus vaccine|Hepatitis A and/or tetanus vaccination will be given to participants in all group on day 0. All monovalent active hepatitis A vaccinations and all vaccines containing tetanus toxoid available in Switzerland may be used in the study
2012108|NCT02222922|Drug|PF-06647020|Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.
2012109|NCT02222922|Drug|fluconazole|combination drug used for drug-drug interaction sub-study
1638016|NCT01947439|Procedure|Percutaneous Coronary Intervention|Percutaneous Transluminal coronary angioplasty and Intervention will be performed in both of randomized groups of biolimus A9 eluting stent and zotarolimus eluting stent
1638017|NCT01947426|Dietary Supplement|DHA Supplementation|mothers consuming 400 mg of DHA/day and their neonates
1638018|NCT01947426|Dietary Supplement|Control (milk without DHA)|mothers consuming placebo product and their neonates
1638019|NCT01947413|Other|intermittent theta burst stimulation|In intermittent theta burst stimulation pattern (iTBS) will intermittently give a 2 s train of TBS every 10s for a total of 20 times (low pulse: 600 pulses in total)
1638020|NCT01947413|Other|continuous theta burst stimulation|In continuous burst stimulation pattern (cTBS) will intermittently give a cTBS treatment consists of a continuous train of TBS for 40 seconds(low pulse: 600 pulses in total).
1638021|NCT01947413|Other|sham theta burst stimulation|In sham burst stimulation pattern (sham TBS) will intermittently give a sham TBS treatment consists of a continuous train of TBS for 40 seconds(almost no pulse: 600 pulses in total).
1638022|NCT01947400|Other|Hospitalists|AIDET Training
1638023|NCT01947374|Procedure|Matrix encapsulated chondrocyte implantation|Each implant contains 6,000,000 autologous chondrocytes.
1638024|NCT01947374|Procedure|Microfracture awl|Is an awl that allow perforation of the subchondral bone.
1638025|NCT01947348|Procedure|treatment with A3 SVF|Treatment interarticular and IV with A3 SVF
1638026|NCT01947335|Device|IVUS-guided PCI|Intravascular ultrasound guided percutaneous coronary intervention
1638027|NCT01947322|Drug|Allogenic NK cells infusion|HLA Haploidentical selected NK cell infusion (one injection of 1x107/kg CD3-CD56+ cells) after chemotherapy associating fludarabine, cytosine arabinoside and cyclophosphamide.
1638028|NCT01947309|Drug|Revlimid (lenalidomide)|Revlimid (lenalidomide) as prescribed in usual clinical practice
2012110|NCT02213263|Biological|PF-05280586|PF-05280586 (rituximab-Pfizer) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
1957998|NCT02057484|Drug|Tacrolimus|oral
1638031|NCT01947270|Other|" Optimisation de la Prescription MEDicamenteuse  (Optimization of drug prescribing)"|"The multidisciplinary intervention program include:
Awareness and training of doctors by two experts (a geriatrician and a pharmacist) within participating departments.
Implementation of a checklist which aims to conduct an adapted and standardized pharmaceutical analysis"
1638032|NCT01947257|Other|the measure TRVMAX|by transthoracic echocardiography
1638033|NCT01947257|Other|the measure of the pulmonary artery|by transesophageal ultrasound
1638034|NCT01947257|Other|the direct measure of the pulmonary pressures|by right catheterization
1638035|NCT01947244|Behavioral|Doula Home Visiting|The intervention is a doula enhancement to evidence-based home visiting services. Doulas provide home visits during pregnancy and for the first six weeks postpartum, which focus on prenatal health, preparation for childbirth, bonding with the baby, and breastfeeding education. Family support workers provide longer term home visiting services. These home visits focus on sensitive and responsive parenting, early infant care, bonding with the baby, child health and development, and maternal mental health.
1638036|NCT01947244|Behavioral|Case management|Mothers are offered two prenatal and two postpartum case management meetings to assess whether mothers' basic needs (housing, nutrition, health care, mental health) are being met and make appropriate referrals.
1638037|NCT01947231|Other|Global Postural Re-education|Global Postural Re-education is a physical therapy method comprising a series of gentle active movements, implemented by the therapist using manual contacts and verbal commands, to promote postural symmetry.
1638038|NCT01947231|Other|Standard manual physical therapy|Standard manual physical therapy in this study involves a combination of exercises, pompage (gentle manual techniques of distraction and articulation of a joint), anterior-posterior mobilizations as described by Maitland, and massage that have been selected to meet the needs of each individual patient.
1638039|NCT01947218|Procedure|bronchial biopsies|
1638040|NCT01947218|Other|Determination of CO in exhaled air|
1638041|NCT01947205|Drug|paracetamol|
1638042|NCT01947205|Drug|dexketoprofen trometamol|
1638043|NCT01947205|Drug|suction curettage|
1638044|NCT01947205|Drug|suction curettage|
1638045|NCT01947205|Other|without drug|
1638046|NCT01947192|Procedure|Treatment with chlorhexidine|Application of 2% chlorhexidine digluconate (60 seconds) after the etching procedure and before the adhesive system.
1715947|NCT00000246|Drug|Flumazenil|
2012111|NCT02213263|Biological|MabThera®|MabThera® (rituximab-EU) concentrate for solution for infusion 375mg/m2 administered via IV infusion on Days 1, 8, 15, and 22
2012112|NCT02210000|Drug|Placebo|Camicinal matching placebo is available as tablet to be taken orally with 100mL of water in the morning
2012113|NCT02210000|Drug|Camicinal|Camicinal is available as 25 mg tablet to be taken orally with 100mL of water in the morning
2012114|NCT02209298|Device|CoreValve Transcatheter Valve|Patients should be accepted for TAVI by a multidisciplinary team. The procedure should use the Medtronic CoreValve SystemTM and point of enrolment is the day of the procedure. The choice of prosthesis size and access route (transfemoral, subclavian or direct aortic access) is to be left to the discretion of the operating team. Equally the intraprocedural details (anaesthetic, imaging etc.) will proceed as per usual practice.
1638047|NCT01947192|Procedure|Water pre-treatment|Treatment of acid etched dentin with sterilized water for 60 s before adhesive system application
1638048|NCT01947179|Behavioral|Anxiety Risk Reduction|Involves psychoeducation and interoceptive exposure exercises
1638049|NCT01947166|Dietary Supplement|Nestle Impact Advanced Recovery nutritional supplement|Before Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days (15 servings total) on postoperative day minus 5 through postoperative day 1 in addition to normal diet. After Surgery: Consume 1 drink box (8 ounces) three times a day for 5 days on postoperative day 2 through postoperative day 6.
1638050|NCT01947153|Drug|Metformin|Free combination
1638051|NCT01947153|Drug|Linagliptin|Fixed dose combination
1638052|NCT01947153|Drug|Metformin|Combination
1638053|NCT01947153|Drug|Linagliptin|Free combination
1638054|NCT01947140|Drug|Pralatrexate|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 10 mg/m2 to 25 mg/m2
Phase II - 25 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
1638055|NCT01947140|Drug|Romidepsin|"Phase I - Schedule A: Intravenous drug given on days 1 and 8 of each 21 day cycle Schedule B: Intravenous drug given on days 1 and 15 of each 28 day cycle Dose escalation from 12 mg/m2 to 14 mg/m2.
Phase II - 12 mg/m2 will be given intravenously once weekly on days 1 and 15 on a 28 day cycle."
1638056|NCT01947114|Drug|Propofol|
1638057|NCT01947114|Drug|Ketamine|
1638058|NCT01947114|Drug|Remifentanil|
1638059|NCT01947101|Biological|Fecal Microbiota Transplant|Fecal Microbiota Transplant will be endoscopically administered directly into the colon. Consecutive treatments will be given by rectal enema route.
1638060|NCT01947088|Behavioral|Music Therapy|Will consist of meeting with the music therapists, Certified Child Life Specialists (CCLS), or Child Life Assistants (CLA) for either music therapy for about 45 minutes, twice per week, for Weeks 1-8. The Music Therapy group will partake in interventions such as singing and playing musical instruments. All brain surgery candidates receive a neuropsychological assessment before and after surgery (9-12 months after surgery). In addition, patients who agree to participate in the study will receive cognitive screening and a music therapy evaluation prior to surgery (Baseline 1). These evaluations will also be given within 3 days of epilepsy surgery (Baseline 2), 8 weeks after surgery (Baseline 3), and 9-12 months after surgery (Baseline 4.)
1638061|NCT01947062|Drug|Intravenous Cisplatin & etoposide|Patients will receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 & 2. The dose of etoposide will be 100mg/m2 on days 1, 2 & 3.
1638062|NCT01947062|Drug|Intravenous Cisplatin & etoposide along with oral cyclophosphamide|Patients will be treated with oral cyclophosphamide at a daily dose of 50mg. Patients will also receive standard intravenous cisplatin and etoposide based chemotherapy, for a total of six cycles, delivered at three-weekly intervals. In each cycle, the dose of cisplatin will be at 50mg/m2 on days 1 & 2. The dose of etoposide will be 100mg/m2 on days 1, 2 & 3.
1638063|NCT01947049|Other|Rapid Influenza Testing with Xpert Flu|Participants with recieve rapid influenza testing with Xpert Flu
1638064|NCT01947023|Drug|Dabrafenib|Given PO
1638065|NCT01947023|Other|Laboratory Biomarker Analysis|Correlative studies
1638066|NCT01947023|Drug|Lapatinib Ditosylate|Given PO
1638067|NCT01947023|Other|Pharmacological Study|Correlative studies
1638068|NCT01947010|Biological|Prevenar 13|
1638069|NCT01947010|Biological|Pneumovax|
1638070|NCT01946997|Other|OCT Imaging both Normal and diabetic groups|Images taken to determine thickness values in the retina
1638071|NCT01946984|Procedure|ERCP|endoscopy, retrograde cholangio-pancreaticography.
1638072|NCT01946984|Drug|Diclofenac hydroxyethylpyrrolidine|
1638073|NCT01946984|Drug|Normal Saline|
1638074|NCT01946971|Drug|Lansoprazole|
1638075|NCT01946971|Drug|Placebo|
1638076|NCT01946958|Behavioral|Training in PC Triple P|PC Triple P is a brief parenting intervention combining specific advice from provider with parent rehearsal and self-evaluation.
1638077|NCT01946958|Other|Care As Usual|Pediatric residents not exposed to PC Triple P provide their standard care to parents struggling with parenting issues or child behavior concerns.
1638078|NCT01946945|Genetic|Next Generation Sequencing after Blastocyst biopsy|PGD using blastocyst biopsy and testing of the biopsy by NGS
1638079|NCT01946932|Other|Temperature treatment|
1638080|NCT01946906|Drug|Rifaximin|
1638081|NCT01946893|Behavioral|Mindfulness Meditation|A standardized and structured program based on Mindfulness Based Cognitive Therapy and Mindfulness Based Stress Reduction and has been piloted in our laboratory.Each session included 1) discussion on stress, relaxation, meditation, and mind-body interaction, 2) instruction and practice in formal and informal MM, and 3) enquiry about problem-solving techniques regarding success and difficulty in practicing mindfulness. Formal meditation instruction included a mindful Body Scan and Sitting Meditation (awareness of breath, body sensations, cognitive and emotional processes). Informal practice of mindful daily activities (e.g., washing dishes) was also taught to generalize mindfulness beyond the formal meditations. A 3-minute meditation was offered as a quick coping strategy, and it could be practiced with or without a guided recording.
1638082|NCT01946893|Behavioral|Education|The Education control was matched for session time and home practice. The internet sessions included a general health video and questions about the material. For home practice, the participants listened to podcasts about the same topic. The session topics were 1) Healthy Eating, 2) Healthy Exercise, 3) Healthy Sleep, 4) Healthy Brain, 5) Healthy Mood, and 6) Community Involvement.
1638083|NCT01946880|Drug|Mycophenolate Mofetil|Subjects will enter the trial on 1000-3000 mg/day of MMF and will be randomized to remain on MMF treatment or to be tapered off MMF within 12 weeks.
1638084|NCT01946880|Drug|Hydroxychloroquine or Chloroquine|Subjects will be on concurrent anti-malarial agents (hydroxychloroquine or chloroquine). Hydroxychloroquine is approved by the FDA for the treatment of SLE. Hydroxychloroquine has been shown to help prevent flare in SLE, and to improve skin and musculoskeletal activity in particular.Even lupus nephritis outcomes appear improved on a background of hydroxychloroquine therapy
2012115|NCT02208154|Drug|Chlorhexidine oral care (CHX-Oro)|Oromucosal gel consisting of chlorhexidine 1%, administered 4 times daily.
1638085|NCT01946880|Drug|Prednisone|Once the subject is randomized into the trial, the prednisone (or other corticosteroid) dose must be stable through Week 36 (24 weeks following protocol taper of MMF), in the absence of flares as described in Section 3.2 of the study protocol, Description of Primary Endpoint. Further taper of prednisone after that point is by the investigator's discretion based on the subject's clinical status.
1638086|NCT01946867|Device|NBTXR3|
2012116|NCT02208154|Drug|Selective oropharyngeal decontamination (SOD)|SOD consists of application of a paste containing colistin, tobramycin in a 2% concentration and nystatin 1 x 10^5 units. SOD will be applied to the mouth 4 times daily until extubation.
1638088|NCT01946841|Dietary Supplement|RealDiet®Renal|
1638089|NCT01946828|Device|FIM|Field Induced Mydriasis device
1638090|NCT01946815|Drug|Atorvastatin|Lipitor dose titration will be followed by the result of LDL lab test until it meets the target level of LDL. IVUS(optional) and FFR during follow up CAG in 12 months will be measured to evaluate the effect of lipitor.
2012117|NCT02208154|Drug|Selective Digestive Decontamination (SDD)|"SDD consists of both:
SOD (described elsewhere)
AND 10 ml of an enteric suspension containing 100 mg colistin, 80 mg tobramycin and nystatin 2 x 10^6 i.u, to be administered via the nasogastric tube.
The combination is administered 4 times daily (Unlike in previous studies, systemic antibiotics are not a part of SDD)"
1638092|NCT01946789|Biological|ALT-803|Intravenous infusion for dose level 1-5; subcutaneous injection for dose level 5a-8; two 6-week treatment cycles: ALT-803 on Day 1, 8, 15, 22; stable or benefitting patients may receive up to two additional 6-week cycles
1638093|NCT01946776|Device|implantable heart rate monitor|Implantation of Reveal XT
1638094|NCT01946763|Behavioral|pre operative education|Patients will be randomized in 2 groups (G1: educated, G2:non-educated) In the operating room and before starting anesthesia G1 will receive a pre operative education about anesthesia emergence, recovery and extubation.
1638095|NCT01946763|Behavioral|pre operative education|
1638096|NCT01946750|Biological|Serum|
1638097|NCT01946750|Biological|Stools|
1638098|NCT01946750|Biological|Saliva|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, to compare the presence of specific salivary Immune globulin type A (IgA) of C. difficile antibodies than in the serum.
1638099|NCT01946750|Biological|Whole blood|Optional sample collected for the cases and non-diarrheal control at the same time as the serum, in order to study cellular immunity and describe the determinants of the development of a protective adaptive response.
1638100|NCT01946737|Radiation|HD-CTCA with Adaptive statistical iterative reconstruction (ASIR)|
1638101|NCT01946737|Radiation|Active Comparator: Invasive coronary angiography (ICA)|
1638102|NCT01946711|Drug|Budesonide|Inhalation
1638103|NCT01946711|Drug|Budesonide|Nasal spray
1638104|NCT01946685|Drug|600 mg/day Mifepristone|
1638105|NCT01946685|Drug|Placebo|
1638106|NCT01946672|Procedure|Lower-limb drainage isotopic intraoperative detection|A radiopharmaceutical is injected into both feet on the day before surgery. Pelvic lower-limb drainage nodes (LLDNs) are identified using preoperative SPECT-CT and intraoperative isotopic probe detection, and then electively removed before complete pelvic lymphadenectomy. LLDNs and pelvic lymphadenectomy specimens undergo separate histological analysis.
1638107|NCT01946659|Behavioral|Adherence to Sleep Apnea Treatment|A health education material prepared after focus group discussion with community leaders and patients would be administered to the participants with an experienced health educator through phone. Upto 10 calls per each patient will be made to either group until 6 months or the patient has a sleep test done.
1638108|NCT01946659|Other|Standard Care Group|The standard care group gets a standard print communications about sleep apnea produced by NLHBI and American Academy of Sleep Medicine
1638109|NCT01946646|Drug|S-1-CCRT|
1638110|NCT01946633|Device|magnetic-controlled capsule endoscopy(Navicam)|
1638111|NCT01946620|Drug|Flutiform|
1638112|NCT01946620|Drug|Formoterol|
1638113|NCT01946607|Drug|Citalopram|
1638114|NCT01946607|Drug|Placebo|
1638115|NCT01946594|Other|Acetaminophen|
1638116|NCT01946594|Other|Placebo|
1638117|NCT01946581|Procedure|Cataract Surgery|
1638118|NCT01946568|Drug|Dalbavancin|Intravenous dalbavancin given at 15 mg/kg (not to exceed 1000 mg) for patients ≥5 years of age, and 25 mg/kg for patients <5 years of age.
1638119|NCT01946555|Drug|Morphine|
1638120|NCT01946555|Drug|Fentanyl|
1638121|NCT01946555|Drug|Methadone|
1638122|NCT01946555|Drug|Buprenorphine|
1638123|NCT01946555|Drug|Oxycodone|
1638124|NCT01946555|Drug|Hydromorphone|
1638125|NCT01946555|Drug|Tapentadol|
1638126|NCT01946542|Drug|beet juice concentrate|single dose of beet juice concentrate, roughly 70 mL
1638127|NCT01946542|Other|placebo|
2012118|NCT02205723|Behavioral|Asthma teaching in ER|Asthma teaching
2012119|NCT02205723|Behavioral|Smartphone Asthma Control|Smartphone Asthma Control
2012120|NCT02203903|Biological|Tumor associated antigen lymphocytes (TAA-CTL)|TAA-CTL may be generated from donors or recipients and will be tested for specificity to 4 tumor antigens commonly found in hematological malignancies (WT1, PRAME, SURVIVIN, and MAGE-A3). The goal of this cell infusion will be to initiate an immune response to residual leukemia or lymphoma that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
2012121|NCT02202980|Drug|LDV/SOF|Ledipasvir 90 mg/sofosbuvir 400 mg (LDV/SOF) FDC tablet administered orally once daily
2012122|NCT02202980|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
2012123|NCT02202980|Drug|GS-9857|GS-9857 tablets administered orally once daily with food
2012124|NCT02202980|Drug|SOF/GS-5816|Sofosbuvir (SOF) 400 mg/GS-5816 100 mg fixed-dose combination (FDC) tablets administered orally once daily
2012125|NCT02202317|Device|PET/CT Scan|Subjects will receive a PET/CT Scan in addition to SPECT imaging, from the level of the lower chest to the lower pelvis, typical of an abdominal CT, usually within 1-3 hours after Yttrium-90 treatment.
2012126|NCT02201394|Drug|Loading dose|Single loading doses of Ticagrelor (180 mg)
1638139|NCT01946477|Drug|Pomalidomide|
1638142|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
1638143|NCT01946438|Biological|Fluzone® Intradermal, Influenza Virus Vaccine (2013-2014 formulation),|0.1 mL, Intradermal
1638144|NCT01946438|Biological|Fluzone® Quadrivalent, Influenza Virus Vaccine (2013-2014 formulation),|0.5 mL, Intramuscular
1638145|NCT01946438|Biological|Fluzone® High-Dose, Influenza Virus Vaccine (2013-2014 formulation)|0.5 mL, Intramuscular
1638146|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2013-2014 formulation)
1638147|NCT01946425|Biological|Fluzone® Quadrivalent Influenza Virus Vaccine, No Preservative|0.5 mL, Intramuscular (2013-2014 formulation)
1638148|NCT01946412|Drug|Ivacaftor|
2012127|NCT02201394|Drug|Loading dose|AS 325mg
1638150|NCT01946386|Drug|LEO 90100 Aerosol, foam|The products will be applied on 6 test sites (according to random assignment to specific test sites predetermined on their anterior face of forearms) for 6 hours
1638151|NCT01946386|Drug|Betamethasone dipropionate in LEO 90100 Aerosol, foam, vehicle|
1638152|NCT01946386|Drug|LEO 90100 Aerosol, foam, vehicle|
1638153|NCT01946386|Drug|Daivobet® ointment|
1638154|NCT01946386|Drug|Dermovate® cream|
1638155|NCT01946386|Drug|Synalar® ointment|
1638156|NCT01946373|Drug|Cyclophosphamide|
1638157|NCT01946373|Drug|Fludarabine|
1638158|NCT01946373|Biological|T cells|
1638159|NCT01946373|Biological|Interleukin-2|
1638160|NCT01946373|Biological|Dendritic cell vaccine|
1638161|NCT01946360|Device|Methacetin Breath Test in ACLF and ALF patients|Methacetin Breath Test will be done on Day 0,7,14,28 in Acute on Chronic Liver Failure (ACLF)and on day 0,1,3,7 in Acute Liver failure (ALF).
1638162|NCT01946347|Other|mixed meal|"Baguette Cheese Gourmet (Crocodile:
180g, energy 452.8 Kcal, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g."
1638163|NCT01946347|Other|Acute in vivo induced hyperinsulinemia|Hyperinsulinemic (1mU/kg/min) euglycemic clamp 3 hours long
1638164|NCT01946334|Device|anorectal manometry and high-resolution three-dimensional|
1638165|NCT01946321|Other|Post-amputation functional rehabilitation (normal clinical practice)|
1638166|NCT01946308|Other|Conformational positioning system|The conformational positioning system will be compared to the standard infant crib mattress.
1638167|NCT01946295|Drug|Famotidine|100mg x 2 p.o.
1638168|NCT01946295|Drug|Placebo|
1638169|NCT01946282|Other|FIT Invitation Only|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls.
1638170|NCT01946282|Other|FIT plus Incentive|Patients meeting the inclusion / exclusion criteria are mailed invitations to complete a free colorectal cancer screening. POLYMEDCO Fecal Immunochemical Tests (FIT) are mailed to patient homes with instructions, followed up with live and TELEVOX reminder phone calls. Patients are offered a small incentive to complete their screening.
1638171|NCT01946269|Other|Goal-directed Resuscitation Therapy (GDT)|"A target value of a cardiac index (CI) greater than 2.5 L/min/m2 and a mean arterial pressure of 70 mmHg will be sought.
The first step will be fluid resuscitation with 200ml aliquots of Lactated Ringer's solution plus human albumin 20% 50 mL whenever the CI is lower than 2.5 L/min/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period or CI increases less than 10%.
When the CI is lower than or equal to 2.5L/min/m2 despite of fluid challenge, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.
The final step will be red blood transfusion to reach a hematocrit higher than 28%.
If necessary, norepinephrine infusion will be used to maintain a mean arterial pressure above 70 mmHg."
1638172|NCT01946269|Other|Standard protocol|The control group will be managed by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
1638173|NCT01946256|Drug|Amoxicillin|
1638174|NCT01946256|Drug|Erythromycin|
1638175|NCT01946243|Drug|Florbetapir F18|No Florbetapir F 18 will be administered in this study.
1638176|NCT01946217|Other|questionnaire administration|Ancillary studies
1638177|NCT01946204|Drug|Apalutamide|240 mg tablets administered by mouth on a continuous once daily dosing regimen
1638178|NCT01946204|Drug|Placebo|Matched placebo tablets administered by mouth on a continuous once daily dosing regimen
2012128|NCT02201394|Drug|Maintenance dose|Ticagrelor 90 mg BID x 3-7 days
2012129|NCT02201394|Drug|Maintenance dose|ASA 81 mg OD x 3-7 days
2012130|NCT02199041|Drug|Cyclophosphamide|Given by intravenous infusion as part of the preparative regimen.
1638182|NCT01946178|Device|Mirabilis High-Intensity Focused Ultrasound Treatment System|The intervention consists of a treatment session with the device, during which focused ultrasound energy is applied across the intact abdominal wall to ablate appropriately selected uterine fibroids under ultrasound imaging guidance.
1638183|NCT01946165|Drug|Abiraterone Acetate|1,000 mg by mouth daily for each 28 day cycle.
1638184|NCT01946165|Drug|Prednisone|5 mg by mouth once daily for each 28 day cycle.
1638185|NCT01946165|Drug|Enzalutamide|160 mg by mouth daily for each 28 day cycle.
1638186|NCT01946165|Drug|LHRHa|Patients receive a LHRHa (monthly injection or three-month injection) for a maximum of 7 months before a prostatectomy is performed. Study doctor will decide what hormone therapy patient receives.
1638187|NCT01946152|Drug|Pomalidomide|"Induction Phase Part I Starting Dose: 4 mg by mouth on Days 1-21 of each 28-day cycle for up to 6 cycles during a 6-month induction period.
Induction Phase Part II Starting Dose: Maximum tolerated dose from Part I.
Maintenance Phase: 2 mg by mouth on Days 1-21 of every 28 day cycle."
1638188|NCT01946152|Drug|Dexamethasone|Induction Phase Part I, II, and Maintenance Phase: 40 mg by mouth once weekly.
1638450|NCT01943825|Biological|CYD Dengue and Japanese Encephalitis Vaccines|0.5 mL, Subcutaneous (CYD) Intramuscular (JE)
2012131|NCT02199041|Drug|Thiotepa|Given by intravenous infusion as part of the preparative regimen.
2012132|NCT02199041|Drug|Fludarabine|Given by intravenous infusion as part of the preparative regimen.
1638189|NCT01946152|Drug|G-CSF|"Induction Phase Part I and Part II: 5 microgram/kilogram by subcutaneous injection for five days during days 22-28 of each cycle of induction therapy(cycles 1 - 6).
G-CSF not be administered during the maintenance phase dosing of pomalidomide and dexamethasone."
1638190|NCT01946152|Behavioral|Phone Calls|After end-of-study drug visit, patient called every 3 months for 1 year and every 6 months after that. These calls will take about 2-3 minutes.
1638191|NCT01946139|Procedure|comparison of screening methods|Undergo HPV screening using HC2, APTIMA and OncoHealth HPV E6/E7 assays
1638192|NCT01946139|Other|laboratory biomarker analysis|Correlative studies
1638193|NCT01946139|Other|questionnaire administration|Ancillary studies
1638194|NCT01946139|Procedure|quality-of-life assessment|Ancillary studies
1638195|NCT01946126|Other|No Intervention|There is no intervention in this study.
1638196|NCT01946100|Genetic|Multifocal Lung Adenocarcinoma|Tissue collection at the time of surgery for genetic testing and blood sample for germ line DNA.
1638197|NCT01946087|Procedure|Remote ischemic preconditioning at left upper arm|Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) & 5 min reperfusion (deflation)
1638198|NCT01946087|Procedure|Control group|keeping the cuff deflated
2012133|NCT02199041|Drug|Melphalan|Given by intravenous infusion as part of the preparative regimen.
2012134|NCT02199041|Drug|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
2012135|NCT02199041|Biological|G-CSF|Given either by intravenous infusion or subcutaneously daily until ANC >2000 for 3 consecutive days.
1638202|NCT01946061|Drug|S-1 plus oxaliplatin|Patients will receive adjuvant chemotherapy of eight 3-week cycles of oral S-1 (70 mg/m2/day on days 1 to 14 of each cycle) plus intravenous oxaliplatin (130 mg/m2 on day 1 of each cycle) for 6 months after D2 gastrectomy.
1638203|NCT01946048|Biological|mesenchymal stem cells|"Procedure: Selected patients were randomly divided into a cell therapy group and a control group.
Umbilical Cord Blood Derived Mesenchymal Stem Cells at a dose of 150-250 million."
1638204|NCT01946035|Drug|Doxazosin XL|
1638205|NCT01946035|Other|Placebo|
1638206|NCT01946022|Drug|randomization between the two GnRH analogues (agonist and antagonist)|
1638207|NCT01946009|Drug|Cidofovir 1% cream's basis, 2gr, three times per week, during 4 weeks.|
2012136|NCT02199041|Drug|Mycophenolate mofetil|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
2012137|NCT02199041|Drug|Tacrolimus|Given either orally or by intravenous infusion as part of the post-transplantation immunosuppression.
1638210|NCT01945983|Drug|Early norepinephrine|Initiation of norepinephrine, a strong vasoconstrictor, at the initiation of septic shock management, together with fluid resuscitation.
1638211|NCT01945983|Drug|Placebo|5% dextrose water intravenous drip in the same rate of calculated norepinephrine for the patient's body weight
1638212|NCT01945970|Other|Black tea extract|Black tea extract
1638213|NCT01945970|Other|Positive control|Positive control
1638214|NCT01945970|Other|Placebo|Placebo
1638215|NCT01945957|Drug|Oxytocin|"For Phase I, subjects will be randomized to receive either 24IU (6 sprays) of active oxytocin or 6 sprays of placebo (3 sprays per nostril)
For Phase II, subjects will be randomized to receive either 8 IU or 40 IU of oxytocin."
1638216|NCT01945944|Drug|Hypertonic saline (3%)|3mL of HTS given via nebulizer every 6hrs
1638217|NCT01945944|Drug|Placebo (0.9% saline)|3mL of normal saline given via nebulizer every 6hrs
1638218|NCT01945931|Other|Safe Delivery Smartphone Application|The safe delivery smartphone application is designed to train midwives and other birth attendants in developing countries in management of normal and complicated deliveries. The application is furthermore intended as a reference tool that could be used during clinical work for example for preparation before attending a birth, in a situation when a complication occurs, or for debriefing and self-evaluation after a complication. The application features four animated videos with clinical instructions of 3-8 minutes duration and written lists of essential obstetric drugs (indications, contraindications, dosage and administration and side effects) and essential equipment for a safe delivery.
1638219|NCT01945918|Behavioral|Self-management support education|Same as Arm Description
1638220|NCT01945918|Behavioral|Connection to Health Interactive Behavior Change Technology|Same as Arm Description
1638221|NCT01945918|Behavioral|Connection to Health plus Coaching (CTH+C)|Same as Arm Description
1638222|NCT01945905|Other|Intramural|Under this alternative, the patients will receive treatment with direct observation from health team. Treatment will be provided for free
1638223|NCT01945905|Other|Extramural|In this form the medication will be given by a health worker in the place chosen by patients. This option will be delivered to patients with newly diagnosed pulmonary TB without hospitalization criteria
1638224|NCT01945892|Drug|Ozurdex|"- Consent agreement - Patients should be informed that it is possible to get an active medication (Ozurdex implant) as an on label indication from the health insurance company if the diagnosis is accepted as an intraocular inflammation form of Uveitis posterior."
1638225|NCT01945879|Drug|Enoxaparine|al patients received additional low molecular heparin, if the safety cohort of three patients received at least 4 weeks of combined treatment without severe side effects, recruitment were continued until a minimum of 15 patients completed at least 3 months of treatment.
1638226|NCT01945866|Drug|intravitreal ranibizumab 0.3 mg|Intravitreal injection of 0.3mg ranibizumab performed on the day of randomization and up to every 4 weeks using defined treatment criteria
1638227|NCT01945866|Drug|dexamethasone intravitreal implant|The dexamethasone intravitreal injection will be given within 0-8 days of the ranibizumab injection. If defined criteria are met, a second dexamethasone injection in combination with intravitreal ranibizumab (within 0-8 days) will be given at the 12 week visit. If the injections are given consecutively on the same day, the ranibizumab injection must be given first.
1638228|NCT01945866|Procedure|Sham injection|No injection is given. It is a sham injection to keep the participant masked. The sham injection will be given within 0-8 days of the ranibizumab injection. If the injections are given consecutively on the same day, the sham injection must be given first.
1638236|NCT01945814|Drug|CTL for CMV seropositive donors|CTL for CMV seropositive donors-Allogeneic Multivirus Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV seropositive donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
1638237|NCT01945814|Drug|CTL for CMV naïve donors|CTL for CMV naïve donors - Allogeneic Multivirus - Directed Cytotoxic T lymphocytes (CTL) targeting CMV (IE1 and pp65), EBV (LMP2, EBNA1), and Adv (Hexon and Penton) for CMV naïve donors dose is depending on the toxicity outcome, the maximum sample size for the this phase I portion of the trial is 14. Upon the completion of mCTL safety evaluation, additional 7 patients will be accrued at the MTD level to evaluate its antiviral activity.
1638238|NCT01945801|Drug|Lasilactone|Active drug (spironolactone 100 mg plus furosemide 20 mg).
1638239|NCT01945801|Other|Sodium-Restricted Diet|The sodium-restricted diet will enforce some rules: do not use salt in cooking; do not use the salt shaker; do not ingest any industrialized food; to eat fresh salads and vegetables; do not add high-sodium seasonings, among others. The complete dietary rules will be delivered to each volunteer in a four page handout.
1638240|NCT01945801|Drug|Placebo|The placebo group will receive cellulose-based placebo pills with identical pills and flasks to active drug.
1638241|NCT01945788|Drug|Teriparatide (rDNA origin)|
1638242|NCT01945775|Drug|talazoparib|Until progression or unacceptable toxicity develops
1638243|NCT01945775|Drug|Physician's-Choice|Capecitabine, Eribulin, Gemcitabine or Vinorelbine
1638244|NCT01945762|Drug|Vandetanib 300 mg|Vandetanib commercial tablets
1638245|NCT01945749|Drug|Intraarticular steroid|1 ml methylprednisolon corticosteroid (40 mg Depo-Medrol®) mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided.
1638246|NCT01945749|Drug|Intraarticular saline|1 ml isotonic saline mixed with 4 ml Lidocain (10 mg/ml) without adrenalin. Injections are done ultrasound guided
1638247|NCT01945749|Other|Exercise therapy|"The exercise is commenced 2 weeks after injection.
The exercise includes a 10 minute warm up phase (ergometer bicycling) followed by strengthening and coordination exercises focusing on trunk, hip and knees.
In case of pain or symptom exacerbation, a rescue exercise program is administered, excluding weight bearing activities."
1638248|NCT01945736|Drug|Methadone|To determine the PK of enteral methadone in children > or = 90 days and <18 years treated for opiate withdrawal per routine medical care.
1638249|NCT01945710|Drug|E7389-LF|
1638250|NCT01945684|Drug|Botulinum toxin type A|Maximum dose 360 U
1638251|NCT01945645|Behavioral|Ready to act|The Ready to Act programme aimed to promote health-related action competence including motivation, informed decision-making, action experience and social involvement The intervention was delivered across a number of primary care settings including the GP office, health centre and pharmacy. The programme consisted of two individual counselling interviews and eight group sessions, which totalled 18 hours within a three month period.
1638252|NCT01945632|Device|conventional gracey curettes|
1638253|NCT01945632|Device|Vertically oscillating ultrasonic device|
1638254|NCT01945632|Device|piezoelectric ultrasonic scraper|
1638255|NCT01945619|Biological|Trivirus-Specific CTLs|Patients will receive up to 2 x 10^7 CHM-CTL/m2 as a single infusion and may receive up to 4 additional infusions at intervals of at least 2 weeks.
1638256|NCT01945606|Drug|Placebo (treatment 1)|Oral administration of placebo tablets
1638257|NCT01945606|Drug|BAY1067197 (treatment 2)|Oral administration of a single dose of 30 mg (3×10 mg Tablet) BAY1067197
2012138|NCT02199041|Drug|Methylprednisolone|Given either intravenously or orally, if needed to treat graft-versus-host-disease (GVHD).
1638259|NCT01945580|Procedure|Prolapse Repair|Transvaginal anterior/apical pelvic organ prolapse repair
1638260|NCT01945567|Device|Up to 3 mA, 60 us, 130 Hz deep brain stimulation|
1638261|NCT01945567|Device|Empirical unblinded deep brain stimulation programming|
1638262|NCT01945554|Procedure|Cervical nerve root infiltration|4mg Mephamesone followed by 1ml of 0.5% bupivacaine (Bupivacain®) will be administered.
1638263|NCT01945554|Procedure|Lumbar nerve root infiltration|40mg triamzinolone (Kenacort®) followed by 2ml of 0.5% bupivacaine (Bupivacain®) will be administered.
1638264|NCT01945554|Drug|Mephamesone|
1638265|NCT01945554|Drug|0.5% bupivacaine (Bupivacain®)|
1638266|NCT01945554|Drug|Kenacort®|
1638267|NCT01945541|Device|Body Composition Monitoring|Pre- and postoperative measurements of body composition (intracellular and extracellular water content)via bioimpedance spectroscopy
1638268|NCT01945528|Drug|US-guided tenotomy with PRP|"Blood will be drawn from the patient from the patient's unaffected arm. the anti-coagulated blood will be centrifuged and pure-PRP (without leukocytes) collected.
Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; PRP will be delivered in multiple depots during the procedure"
1638269|NCT01945528|Drug|US-guided tenotomy with lidocaine|Blood will be drawn from the patient from the patient's unaffected arm. Local anesthetic (lidocaine) will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a single skin portal and multiple longitudinal and transversal penetrations of the tendon will be performed; lidocaine will be delivered in multiple depots during the procedure
1638270|NCT01945515|Device|tDCS|tDCS will be applied on the primary motor cortex of the lower limb in the impared hemisphere before robotic-assisted gait training. Anodal tDCS will be applied with an intensity of 2mA for 20 min. Sham tDCS will be applied with an intensity of 2mA just for 1 min, after which the current will be slowly tapered down to 0 over a several seconds.
1638271|NCT01945515|Device|Robotic-assisted gait training|Robotic-assisted gait training with an exoskeletal type robot which simulates normal walking on a treadmill for patients with gait impairments
2012139|NCT02199041|Radiation|Total lymphoid irradiation|TLI will be administered in divided fractions given at a minimum of 6 hours apart.
1638451|NCT01943825|Biological|Japanese Encephalitis and CYD Dengue Vaccines|0.5 mL, Intramuscular (JE), Subcutaneous (CYD)
1638452|NCT01943812|Drug|Estradiol and progeterone|Estradiol and progesterone
1638795|NCT01940965|Drug|TZD|Pharmaceutical form:tablet Route of administration: oral
1638274|NCT01945476|Drug|midazolam premedication|"On the day when patients are scheduled for operation, one researcher will use a computer to randomly select and allocate patients. By randomization, patients will be divided into two groups, receiving an injection of either 0.02 mg/kg of midazolam(midazolam group) or saline (control group). The researcher who randomly allocated patients will prepare the medicines but not just medicine. Investigators must mix it with normal saline to obtain a total volume of 5 mL and label two of them all prepared medicine, never letting the doctors and subjects know which is midazolam and which is saline.
Use the QoR-40 survey form to investigate the functional recovery of the patient. This survey will be administered before the operation and on the first and second days after the operation; it will be administered three times in total."
1638275|NCT01945450|Drug|Antibiotic prophylaxis|antibiotic prophylaxis as following: 24 hours coverage with Ampicillin 2 grams*4, Gentamycin 240 mg*1, Clindamycin 600 mg*3
1638276|NCT01945450|Drug|Ampicillin|
1638277|NCT01945450|Drug|Gentamycin|
1638278|NCT01945450|Drug|Clindamycin|
1638279|NCT01945437|Drug|Magnesium Sulfate|The magnesium group receive intravenous magnesium sulfate.
1638280|NCT01945424|Biological|Quadrivalent Influenza Vaccine (QIV)|No Intervention as part of this protocol
1638281|NCT01945411|Device|the length between incisor and mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) which size is the length between incisor and mandible angle
1638282|NCT01945411|Device|the length between mouth corner-mandible angle|the use of oropharyngeal airway (Guedel-type color coded oropharyngeal airway, Hudson RCI, Teleflex Medical, Research Triangle Park, NC) of which size is the length between mouth corner and mandible angle
1638283|NCT01945398|Other|Inspiratory Muscle Training|Patients will receive IMT for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.). During training, patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Inspiratory load was set at 30% of maximal static inspiratory pressure, and weekly training loads were adjusted to maintain 30% of the PImax. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
1638284|NCT01945398|Other|SHAM|Patients will receive SHAM training for 30 min, 7 times per week, for 8 weeks using Inspiratory Muscle Trainer device (PowerBreath Inc.) without load. Patients will be instructed to maintain diaphragmatic breathing, with a breathing rate at 15 to 20 breaths/min. Each week, six training sessions were performed at home and one training session was supervised at the hospital.
1638285|NCT01945385|Behavioral|Video intervention|Brief 7 minute video of physician describing LARC methods followed by two patient testimonials about their own postabortal LARC experience.
1638286|NCT01945372|Other|EEG NeuroFeedback|
1638287|NCT01945346|Drug|PRX167700|Oral capsule
1638288|NCT01945346|Drug|Placebo|Oral capsule
2012140|NCT02199041|Biological|Lymphocyte infusions|Donors will undergo haploidentical mobilization with G-CSF. Cells will be collected by leukapheresis over two days, then processed using the investigational CliniMACS device and CD34 Microbead reagent as directed by the manufacturer.
1638290|NCT01945294|Drug|Boceprevir|800 mg three times daily orally
1638291|NCT01945294|Biological|Peg-interferon alfa-2b|1.5 mcg/kg weekly subcutaneously
1638292|NCT01945294|Drug|Ribavirin|800-1400 mg twice-daily divided orally based on body weight
1638295|NCT01945268|Drug|inactivated trivalent influenza vaccine|0.5 ml dose injected intramuscularly
1638296|NCT01945268|Other|Sterile saline|0.5 ml dose injected intramuscularly
1638297|NCT01945242|Drug|Alogliptin|Alogliptin tablets
1638299|NCT01945190|Device|Electroacupuncture|
1638300|NCT01945177|Device|narrow band imaging|narrow band imaging
1638301|NCT01945177|Device|white light endoscopy|white light endoscopy
1638302|NCT01945164|Drug|XL999|The treatment will consist of 4-week cycles in which the subject will receive XL999 administered as a 4-hour IV infusion every other week. The subject will continue to receive 4-week cycles of XL999 in the absence of progressive disease, unacceptable drug-related toxicity, and as long as the drug is available.
1638303|NCT01945151|Other|Group 2 (G2) NMES is applied in the spastic muscle (gastrocnemius).|The G2 apply NMES in the gastrocnemius motor point and the rest will be done during stretching of the gastrocnemius muscle (autogenic inhibition). Five consecutive sessions will be held in the morning and afternoon in the laboratory of Sensory Motor Rehabilitation Engineering.
1638304|NCT01945138|Device|Closed Loop Insulin|The Closed Loop Insulin system is an automated insulin delivery system based on body blood glucose. It consists of an Insulin pump, continuous glucose monitor, and a control device (laptop with algorithms).
1638305|NCT01945125|Other|rhTSH Group|Patients receiving rhTSH for RIT stimulation
1638306|NCT01945112|Device|Paper Tape|Applied to blister prone areas of the foot
1638307|NCT01945099|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
1638308|NCT01945099|Drug|hyaluronidase|
1638309|NCT01945099|Drug|Lispro-PH20|
1638310|NCT01945086|Drug|Ustekinumab|Participants will receive subcutaneous (SC) injections of either ustekinumab 45 mg or ustekinumab 90 mg at Week 0 and Week 4.
1638311|NCT01945086|Drug|Placebo|Participants will receive SC injections of placebo at Week 0 and Week 4.
1638312|NCT01945086|Other|Concomitant topical medications for atopic dermatitis|Concomitant topical medications (as defined in the protocol) can be used from 4 weeks prior to randomization and throughout the study. However, the dosage cannot be increased and new medications cannot be added until after Week 12.
1638313|NCT01945073|Behavioral|Educational Booklet (BK)|The information booklet provides age appropriate explanation about SCD: inheritance patterns for the trait and common sickle cell disorders in the Jamaican population. It includes manifestations, complications and the necessary preventive and treatment advice. In addition, issues that are common to adolescents including sexual activity, contraceptive use, drug usage, career advice and developmental changes common to persons with the disease are also discussed.
1638453|NCT01943799|Biological|GS-4774|GS-4774 2, 10, or 40 YU administered as a subcutaneous injection every 4 weeks for a total of 6 doses
1638455|NCT01943786|Drug|FOLFIRI + Cetuximab|Patients will receive study treatment (FOLFIRI + Cetuximab) according to regular clinical practice
1638314|NCT01945073|Other|Formal Counselling (CB)|The study coordinator will have a face to face counselling session, lasting about 30 minutes, with the adolescent and/or caregiver. This will include the use of the educational booklet as an education tool, as well as a thorough discussion on the disease process; its manifestations, effects, and specific concerns during the adolescent period; as well as clarification of common myths and misconceptions about the disease.
1638315|NCT01945060|Device|heart rate Control to Range System (hrCTR) using DiAs Platform|"Diabetes Assistant (DiAs) Medical Platform System
A smart-phone medical platform (DiAs);
Continuous Glucose Monitor;
Insulin pump;
Bluetooth connection;
Remote Monitoring Server."
1638316|NCT01945060|Other|DiAs Control-to-Range System not informed for heart rate|Not informing system of heart rate during exercise.
1638317|NCT01945047|Drug|Ketamine|Intravenous Bolus infusion Ketamine Hydrochloride 0.50 mg/mL over 40 minutes
1638318|NCT01945047|Drug|Midazolam|Bolus infusion of Midazolam Hydrochloride 1 mg/mL over 40 minutes
1638319|NCT01945034|Drug|Topical IBU twice daily|Topical gel administered as 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
1638320|NCT01945034|Drug|Placebo twice daily|Topical gel administered as a 4 inch strip twice daily for 7 days, and as needed for an additional 3 days
1638321|NCT01945034|Drug|Topical IBU three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
1638322|NCT01945034|Drug|Placebo three times daily|Topical gel administered as a 4 inch strip three times daily for 7 days, and as needed for additional 3 days
1638324|NCT01944995|Device|glasses broadband|
1638325|NCT01944995|Device|nasal CPAP|
1638326|NCT01944982|Biological|Expanded haploidentical natural killer cells (NKAEs)|
1638327|NCT01944969|Drug|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 0.5 mg/day (patients ≥65) or 1 mg/day (patients 18-64 years)
1638328|NCT01944943|Drug|Vismodegib|150 mg (1 capsule) of Vismodegib per day orally in continue during 12 months
1638329|NCT01944930|Device|Laparoscopic narrow band imaging|
1638330|NCT01944930|Device|Standard white-light laparoscopy|
1638331|NCT01944904|Dietary Supplement|Sugar Pill|The placebo is identical in appearance to the XOS and contains 505mg maltodextrin
1638332|NCT01944904|Dietary Supplement|XOS 2.8|2.8g XOS is white or off-white crystalline substance and contains 500mg XOS 70P and 20mg maltodextrin
1638333|NCT01944865|Other|Interval Training|The interval training group consisted of 7 to 10 repetitions of 4-6 min at the highest intensity sustainable, the active recovery was 4-6 min in intensity from 10 to 15 of scale of perceived exertion CR100.
1638334|NCT01944865|Other|Intermittent Training|The riders of intermittent training group completed 8 to 12 repetitions of 30 s all-out with 4 min of active recovery.
1638335|NCT01944852|Drug|Icodextrin|
1638336|NCT01944839|Drug|E10030|
1638337|NCT01944839|Drug|ranibizumab|
1638338|NCT01944839|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
1638339|NCT01944826|Other|Registry of patients with Tako-Tsubo cardiomyopathy|
1638340|NCT01944813|Behavioral|ACp conversation|Intervention: Advance Care Planning conersation between a healtprofessionel and a patient about end-of-life discussions.
1638341|NCT01944800|Drug|Ticagrelor|Loading dose of 180 mg, followed by maintenance dose of 180 mg per day
1638342|NCT01944800|Drug|Prasugrel|Loading dose of 60 mg, followed by maintenance dose of 10 mg/day or 5 mg/day in patients =/> 75 years or < 60 kg
1638343|NCT01944787|Other|Routine|IV Hydration at 125 cc hour
1638344|NCT01944787|Other|IV Hydration at 250cc hour|IV Hydration at 250 cc hour
1638345|NCT01944774|Drug|Nemonoxacin 500 mg|IV Infusion, once daily for 7~14 days
1638346|NCT01944774|Drug|Nemonoxacin 650 mg|IV Infusion, once daily for 7~14 days
1638347|NCT01944774|Drug|Moxifloxacin 400 mg|IV Infusion, once daily for 7~14 days
1638348|NCT01944761|Behavioral|Exercise Program|Designed to improve cardio-respiratory fitness, the exercise program will be conducted for 12 weeks at a frequency of 3 sessions per week. Each exercise session will be conducted after school for a total duration of 90 minutes. First, training in a circuit of developmentally appropriate activities (30 minutes) will occur. Second, the training circuit will be followed by participation in an organized sport (i.e. 30 minutes of floor hockey, basketball, or indoor soccer). Following the workout sessions the children will receive a healthy snack and have an opportunity for socialization (30 minutes).
1638349|NCT01944748|Behavioral|Families Able To Resolve Situations (FARS)|Family mediation is a method of resolving conflicts between parents and teens. During the mediation session, the parent and teen each meet one-on-one with a trained volunteer mediator, who is a neutral person who listens to each party's concerns without taking sides. Then the parent and teen come together and meet with this mediator to work on resolving conflicts they are having. Families participate in up to 3 mediation sessions.
1638350|NCT01944735|Drug|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to patients in 2 cohorts on days 1-15.
1638351|NCT01944735|Drug|Placebo|Repeat doses of placebo will be administered orally, once-daily, to patients in 2 cohorts on days 1-15
1638352|NCT01944722|Device|BD HPV assay on Viper LT|The BD HPV specimen will be tested with the BD HPV assay on the Viper LT instrument. The results will be compared to adjudicated histology. A portion of the specimens will be compared to a composite comparator generated by results of both Digene HPV and a polymerase chain reaction (PCR) sequencing test.
1638353|NCT01944722|Procedure|Colposcopy|Colposcopy will be performed on subjects that have abnormal cytology or HPV positive test results or random sampling of subject with normal cytology and HPV negative test results.
1638354|NCT01944709|Biological|Dendritic cell application|
1638355|NCT01944696|Other|phototherapy|Cycled versus continuous phototherapy during the first 2 wks after birth, both administered at bilirubin thresholds used in the NICHD Neonatal Network Phototherapy trial .
1638356|NCT01944683|Other|Placebo|
1638357|NCT01944683|Drug|GGF2|
1638358|NCT01944683|Drug|Midazolam|
1638359|NCT01944670|Device|Internal Joint Stabilizer - Elbow (IJS-E)|Device designed for internal stabilization of the elbow
1638796|NCT01940965|Drug|alpha-GI|Pharmaceutical form:tablet Route of administration: oral
1715948|NCT00000248|Drug|Pergolide|
1638360|NCT01944657|Device|Supplemental TMS|Supplemental TMS treatments will be administered utilizing the NeuroStar TMS Therapy® Machine. Treatment will be fixed at 120% of magnetic field intensity relative to the subject's resting motor threshold at a repetition rate of ten magnetic pulses per second, with a stimulus train duration (i.e., on time) of 4 seconds and an inter train interval (i.e., off time) of 26 seconds. The left dorsolateral prefrontal cortex will be the treatment location and this site will be determined by adjusting the TMS coil 5 cm anterior to the motor threshold location along a left superior oblique plane with a rotation point at about the tip of the patient's nose. Each treatment session will last approximately 37.5 minutes administering 3,000 magnetic pulses over the course of the treatment session.
1638361|NCT01944657|Drug|Standard Medication Monotherapy|These medications could include bupropion (Wellbutrin and others), citalopram (Celexa and others), Clomipramine (Ananfranil and others), duloxetine (Cymbalta), escitalopram (Lexapro and others), fluoxetine (Prozac and others), fluvoxamine (Luvox and others), imipramine (Tofranil and others), mirtazapine (Remeron and others), nortriptylatine (Pamelor, Aventyl, and others), paroxetine (Paxil, Pexeva, and others), phenelzine (Nardil), sertraline (Zoloft and others), tranylcypromine (Parnate and others), venlafaxine (Effexor and others).
1638362|NCT01944644|Device|Low Field Magnetic Stimulation (LFMS)|
1638363|NCT01944644|Device|Sham Low Field Magnetic Stimulation|
1638364|NCT01944631|Device|Placebo|Nasal spray saline
1638365|NCT01944631|Device|Iota-Carrageenan|Nasal spray containing 1.20 g/l Iota-Carrageenan in saline
1638366|NCT01944618|Drug|Forxiga|FORXIGA is a prescription medicine used with diet, exercise and sometimes other medicines (which may include metformin; insulin; a sulfonylurea medicine such as gliclazide, glimepiride and glibenclamide; or a dipeptidyl peptidase-4 inhibitor [DPP 4 inhibitor] such as sitagliptin or saxagliptin) to control the levels of blood sugar (glucose) in patients with type 2 diabetes mellitus.
1638367|NCT01944592|Behavioral|Gynaecology Teaching Associates (GTA's)|Two GTA's will conduct the session according to the following structure; Students will receive a short anatomy PowerPoint presentation from the GTA's followed by demonstration of a gynaecological examination on a pelvic manikin. Students will then be taken to the out-patient department where one GTA will demonstrate pelvic examination on the other. Each student will then examine one of the GTAs under supervision by the other. The three non-active students will observe each of their colleagues' examinations. The students will then undergo a role play scenario where they will examine one of the GTAs under supervision of the other and feedback will be given by both GTAs.
1638368|NCT01944592|Behavioral|Manikin (conventional) training|Clinical Lecturers in Gynaecology (equivalent to Specialist Registrar experience) will conduct the sessions as follows: Students will receive a short anatomy PowerPoint presentation (the same as used in the GTA training). The Clinical Lecturer will then demonstrate pelvic examination on the pelvic manikin. Each student will then perform the pelvic examination twice supervised by the Clinical Lecturer.
1638369|NCT01944579|Other|Blackberries|Participants will receive blackberries as part of a controlled diet.
1638370|NCT01944579|Other|Control|Participants will receive a control food (jello) as part of a controlled diet.
1638371|NCT01944566|Biological|Microbial transplant|Every subject has 2 armpits; 1 armpit is treated, the other one is not treated. There is a microbial transplant from armpit bacteria.
1638372|NCT01944553|Device|The ROSA™ robot|"The ROSA™ robot can assist in identifying the pedicle entry point and in controlling the screw trajectory through a system of continuous monitoring of patient motion. This process strengthens the accuracy of pedicle screws implantation.
Stabilisation in treatment for spine degenerative disease"
1638373|NCT01944540|Procedure|Optimized ESD with snaring|
1638374|NCT01944540|Procedure|Conventional ESD|
1638375|NCT01944501|Procedure|Transcranial Magnetic Stimulation|TMS over the left temporoparietal cortex
1638376|NCT01944501|Procedure|Transcranial Direct Current Stimulation|TDCS over the left temporoparietal cortex
1638377|NCT01944488|Drug|GnRH agonist|100 µg/m2 body surface max 100 µg i.v.
2012141|NCT02199041|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
2012142|NCT02197416|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
2012143|NCT02196181|Drug|Dabrafenib|Given PO
2012144|NCT02196181|Other|Laboratory Biomarker Analysis|Correlative studies
1638382|NCT01944436|Drug|Cholinesterase Inhibitors (Rivastigmine, Aricept, Galantamine)|
1638383|NCT01944423|Drug|d-cycloserine|d-cycloserine is a medication thought to be associated with fear extinction.
1638384|NCT01944423|Drug|Pill Placebo|
1638385|NCT01944423|Drug|Nicotine replacement therapy|All participants will receive Nicoderm CQ®, 24-hour transdermal nicotine patches and will be educated about the use of the patch at the session immediately prior to quit date. They will be instructed to apply one patch daily, beginning on quit date (week 5). Participants will use the 3-step tapering Nicoderm process (21-mg, 14-mg, and 7-mg). This regimen has been used in previous trials with a similar formulation of the patch (Fiore, 2000). A meta-analysis found no differences in outcome between 16- or 24-hour patches (Fiore et al., 1994). Participants who continue to smoke or lapse after quit day will not be instructed to discontinue the patch until their smoking level reaches 4 cigarettes/day for 4 days. Smokers who lapse during treatment will be encouraged to set a new quit date and continue their cessation attempt.
1638454|NCT01943799|Drug|OAV Regimen|Oral antiviral (OAV) regimen as administered prior to study enrollment (tenofovir disoproxil fumarate, entecavir, adefovir, lamivudine, or telbivudine either as single agents or in combination)
2012145|NCT02196181|Drug|Trametinib|Given PO
2012146|NCT02194738|Other|Cytology Specimen Collection Procedure|Undergo collection of blood and tissue
2012147|NCT02194738|Other|Laboratory Biomarker Analysis|Undergo laboratory analysis via direct sequencing and FISH
2012148|NCT02192541|Drug|Ziv-Aflibercept|Ziv-aflibercept is a soluble fusion protein with high binding affinity for VEGF-A, VEGF-B, and PIGF and thius confers anti-angiogenic activity
1638386|NCT01944423|Behavioral|Panic and Smoking Reduction Treatment|PSRT incorporates elements of standard smoking cessation treatment (i.e., counseling plus NRT) with procedures for reducing panic and enhancing tolerance to withdrawal sensations. Written therapist and patient manuals will be used and followed at all times to ensure standardized delivery of the treatment. Interventions that uniquely focus on addressing panic, fears and intolerance of anxiety, bodily-related sensations, and affect-relevant withdrawal symptoms include: (1) interoceptive exposure; (2) corrective information about anxiety and cognitive interventions designed to teach patients alternatives to catastrophic misinterpretations of the sensations and their feared consequences; and (3) situational exposure.
1638387|NCT01944410|Biological|PRP injection|injection of PRP to traumatic bone cyst defect
1638388|NCT01944384|Drug|aldactone|aldactone 25 mg for 6 months
1638389|NCT01944371|Drug|Disulfiram|This study will provide open label disulfiram. Subjects will take 1 dose of disulfiram per day for 3 days.
1638390|NCT01944332|Procedure|gamete treatment|The spermatozoa will be prepared in the standard fashion and utilized for injection after exposure to a membrane permeabilizing agent. The injected oocytes will then be exposed to activating agents for the purpose of inducing embryo development. The oocyte activating agent is calcium ionophore and for sperm membrane permeabilization to assist in sperm DNA decondensation is streptolysin O (SLO). The successfully fertilized oocytes will be further kept in culture for up to 5 days as per standard IVF/ICSI. Results in terms of fertilization and embryo cleavage will be assessed and monitored for the remainder of the culture period. Developing embryos selected according to standard criteria will be transferred to the patient or will be cryopreserved.
1638391|NCT01944319|Drug|Routine meropenem therapy|Participants in control group will accept meropenem therapy with regimen routinely decided by attending physician
1638392|NCT01944319|Drug|Meropenem therapy based on a PPK and PD model|Participants in study group will accept meropenem therapy based on a software developed from a PPK and PD model
1638393|NCT01944293|Drug|Ketamine|Single dose of 0.5 mg/kg of Ketamine given intravenously (in the vein) over 40 minutes
1638394|NCT01944293|Drug|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
1638395|NCT01944280|Other|massage|
1638396|NCT01944267|Procedure|Apically positioned flap|"Standard TUSDM Periodontology Clinic procedures will be followed. Local anesthesia will be achieved. Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
No vertical incision will be made Gingiva coronal to horizontal incision will remain intact Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.
Prepared surgical area will be measured apico-coronally and mesio-distally."
1638397|NCT01944267|Procedure|Free Gingival Graft|"Standard Clinic procedures followed. Local anesthesia achieved. Center of implant fixtures located. Crestal incision thru center of fixture will be made.
Implant fixture uncovered and healing abutment/s inserted. Horizontal incision at approx 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
No vertical incision made. Gingiva coronal to horizontal incision remains intact.
Partial thickness flap prepared and displaced apically approximately 7mm from horizontal incision; secured with sutures. Prepared recipient bed measured apico-coronally and mesio-distally. Masticatory mucosa from palate of treating side (Right or Left) harvested according to size measured from recipient bed with width of approximately 5mm at line of measurement. Harvested graft material will be transplanted on recipient bed, lined with initial horizontal incision line with sutures"
1638398|NCT01944267|Procedure|apically positioned flap with Mucograft|"Standard TUSDM Periodontology Clinic procedures followed. Local anesthesia achieved.
Center of implant fixtures will be located. Crestal incision thru the center of implant fixture will be made. Implant fixture will be uncovered and healing abutment/s will be inserted. Horizontal incision at approximately 0.5mm coronal to buccalmucogingival junction will be made 1 tooth mesial to 1 tooth distal to the treating area.
No vertical incision will be made. Gingiva coronal to horizontal incision will remain intact. Partial thickness flap will be prepared and displaced apically approximately 7mm from the horizontal incision and secured with sutures.
Prepared recipient bed will be measured apico-coronally and mesio-distally. Mucograft material will be prepared according to the manufacturer's instruction and trimmed as the size measured from the recipient and be placed and secured on the recipient bed with sutures."
1638399|NCT01944254|Procedure|Cardiac output measurement at random to respiration|Cardiac output measurement obtained by pulmonary artery catheter thermodilution technique (PAC TD)
1638400|NCT01944254|Procedure|Cardiac output measurement synchronised at start of expiration|Cardiac output measurement obtained by PAC TD
1638401|NCT01944254|Procedure|Cardiac output measurement timed to instructed exhalation|Cardiac output measurement obtained by PAC TD
1638402|NCT01944228|Device|Vagal Nerve Stimulation|30 minutes of vagal nerve stimulation using a catheter in the IJV
1638403|NCT01944228|Device|Sham Stimulation|Catheter placed in the IJV without stimulation
1638404|NCT01944215|Dietary Supplement|Meal|effect of meal
1638405|NCT01944215|Other|Exercise|effect of exercise
1638406|NCT01944215|Radiation|Sestamibi|reduce radiation dose
1638407|NCT01944215|Drug|Caffeine Tablet|effect of caffeine
1638408|NCT01944215|Other|External Heating|Heating Pad and warm blanket robe
1638409|NCT01944202|Behavioral|Educational intervention|Educational and feedback intervention, as described in the Arm Description.
1638410|NCT01944189|Dietary Supplement|Food|"Nested comparative bioavailability study: 48 out of 70 children randomized to 2 food arms under 2 dose groups of artemether lumefantrine (20mg /120 mg) treatment according to standard care weight based dose groups (> 5 to >15 kg receive 1 tablet and 15 to > 25 kg receive 2 tablets)
Food arms:
Standard arm = Milk
Experimental arm = maize porridge plus oil
Groups include Single dose group= 1 tablet of artemether lumefantrine (20/120 mg) and Double dose group= 2 tablet of artemether lumefantrine (20/120 mg)
Standard arm children receiving milk and single dose(12) Standard arm children receiving milk and double dose(12) Experimental arm children receiving maize porridge plus oil and single dose(12) Experimental arm children receiving maize porridge plus oil and double dose (12)"
1638411|NCT01944176|Drug|simvastatin, placebo|
1638797|NCT01940965|Drug|glinide|Pharmaceutical form:tablet Route of administration: oral
1638412|NCT01944163|Other|Applying a referral model|GP are randomized in clusters either to use or not to use the CaFaSpA referral model. The CaFaSpA referral models consists out of four variables, a positive ASAS IBP questionnaire, a positive family history for SpA, a good reaction to NSAIDs and back pain duration longer than 5 years. If at least two out of four variables are present a referral to the rheumatologist is advised.
1638413|NCT01944150|Behavioral|Transcutaneous electrical nerve stimulation|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse during 30 minutes lasting session
1638414|NCT01944150|Behavioral|Transcutaneous electrical nerve stimulation and hypnosis|explanations about devices and their use are given to the patient during the first session. The right place where the electrodes should be placed on, the most effective programme (optimal electric frequency provided by the machine), intensity are tested by the nurse. Following informations are collected by the second nurse: pain representation and its relief thoughts about a quiet place. TENS and hypnosis are associated in a unique 30 minutes session
1638415|NCT01944137|Other|Nursing Intervention|Participants will receive 4 planned phone calls from nurse practitioners during their first 2 cycles of chemotherapy, in order to proactively monitor and address chemotherapy-related symptoms.
1638416|NCT01944124|Behavioral|Mobile Health|Participants monitored their blood pressure 3x per week, blood glucose 1x per week, pedometer steps daily and body weight monthly. Measures from devices were transferred or inputted to a smartphone data portal. Planned exercise was logged electronically on the smartphone.
1638417|NCT01944124|Behavioral|Exercise Prescription|An exercise program was prescribed tailored to participant fitness level (using the Step Test Exercise Prescription (STEP-TM) protocol). Briefly, STEP-TM required participants to step up and down a set of 2 steps 20 times at a comfortable pace. A predictive equation including post-test heart rate, time to complete test, age, body weight and sex was used to calculate fitness. An exercise program was prescribed including aerobic exercise most days of the week for 30-60 minutes in duration at a target heart rate tailored to fitness level. Light resistance training was also prescribed 2-4 times per week.
1638418|NCT01944111|Device|Plication|Prospective clincial trial comparing adjustable gastric banding with plication versus standard adjustable gastric banding. Variables to be studied include patient age, gender, ethnicity, co-morbid disease conditions, height, weight, BMI, intra-operative data such as operative time and blood loss and post-operative outcomes including length of hosptial stay, complication rates, weight loss, and co-morbid disease resolution.
1638421|NCT01944085|Drug|Acetaminophen|Syrup
1638422|NCT01944085|Drug|Ibuprofen|Syrup
1638423|NCT01944085|Other|Vitamin C|Syrup
1638424|NCT01944072|Other|Aerobic exercise training intensity|
1638425|NCT01944059|Drug|Theramine (medical food/old drug)|Theramine® is a prescription medical food that is composed of variety of amino acids and/or their precursors.
1638426|NCT01944059|Other|Placebo (l-alanine)|Theramine like placebo comparator
1638427|NCT01944046|Drug|Placebo Nasal Spray|
1638428|NCT01944046|Drug|Oxytocin Nasal Spray|Each insufflation will deliver 8 IU or 24 IU of oxytocin. A maximum of 3 insufflations at a time will be required. Dosing will be flexible between 8 IU/day and 80 IU/day, typically in two divided doses delivered in the morning and in the afternoon. Doses will typically increase by 8 IU twice daily (BID) at week 2 and months 1 and 2 until achieving the target dose of 24 IU BID at Month 2. Subsequently doses may be increased in 8 IU BID increments ONLY at each visit until a maximum dose of 40 IU BID is achieved.
1638429|NCT01944033|Drug|association|5 mg β2-agonists + 0,5 mg Ipratropium bromide + 1ml serum saline in each nebulization which is repeated three times during 1 hour
1638430|NCT01944033|Drug|β2-agonists|0,5 mg β2-agonists + 3ml serum saline in each nebulization which is repeated three times during 1 hour
1638431|NCT01944020|Device|Active CPAP|Active CPAP will be a therapeutic dose CPAP each night for 2 months
1638432|NCT01944007|Drug|Cross-Linked Polyelectrolyte (CLP)|CLP was administered orally, in capsules, for 9 consecutive days.
1638433|NCT01943994|Drug|Psilocybin-assisted treatment|Participants will be administered 30 mg/70 kg psilocybin. Preliminary evidence from our ongoing psilocybin dose-effects study suggests that this dose is associated with mystical-type experiences.
1638434|NCT01943994|Drug|Nicotine Replacement Therapy (NRT)|
1638435|NCT01943968|Other|Blood test|
1638436|NCT01943955|Behavioral|home-based computer gaming|A computer mouse mounted to a headband and placed on the participant's head is used to interact with the game cursor. In order to interact with/play the game the participant must visually focus on the moving target and perform unpredictable head movements. Balance exercises are incorporated progressively and simultaneously during computer gaming.
1638437|NCT01943942|Drug|Montelukast 10 mg|Reference product
1638438|NCT01943942|Drug|Montelukast 10 mg|Test product
1638439|NCT01943916|Device|Imagio Scan|The Imagio Breast Imaging System is indicated for use by a qualified and trained healthcare provider for opto-acoustic (OA) evaluation of breasts in women who are referred for a diagnostic breast ultrasound work-up due to a suspicious mass (including both palpable and non-palpable) or an imaging finding (such as architectural distortion, asymmetry, or suspicious calcifications).
1638440|NCT01943890|Device|Hypertonic saline|1 mmol/ml hypertonic saline given from (small children) 1,5 ml in 3 positions twice daily increasing to (children) 2 ml in 3 positions twice daily and up to (adults) 3 ml in 3 positions twice daily
1638441|NCT01943890|Procedure|Physiotherapy|
1638442|NCT01943877|Procedure|scaling root planing|scaling root planing
1638443|NCT01943877|Drug|Propolis|experimental
1638444|NCT01943864|Drug|Trametinib (single tablet)|The drug substance is blended with inert
1638445|NCT01943864|Drug|Trametinib (Multiple tablet)|The drug substance is blended with inert
1638446|NCT01943851|Drug|GSK525762|GSK525762 1 mg, 10 mg and 30 mg will be supplied as white to off-white, amorphous free base and white to slightly colored crystalline besylate tablets, round, biconvex tablets with no markings. GSK525762 will be administered with 240 milliliter (mL) water.
1638447|NCT01943838|Drug|SAR245408|Pharmaceutical form: tablet Route of administration: oral
1638448|NCT01943825|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous
1638456|NCT01943773|Procedure|Functional Assessment|"Both arms of the study will undergo functional assessments at three points during the study progress.
BASELINE ASSESSMENT: On study entry, each participant will have a timed up-and-go, Mini Mental Status Exam, de Morton, Modified Physical Performance Test (MPPT), and a short physical performance battery performed.
ASSESSMENT OF INTERVENTION EFFECTIVENESS:
Immediately prior to the operation, all participants will undergo repeat testing. The difference in scores between the preoperative assessment and the initial assessment at enrollment will be compared in the control and intervention groups.
POST-OPERATIVE ASSESSMENT: Repeat testing will be performed 60 days following the operation."
1638457|NCT01943773|Procedure|Prehabilitation|The intervention will consist of nine 45 minute long physical therapy sessions.
1638458|NCT01943760|Drug|tramadol|The volume of the solution was adequate to maintain the concentration of 2% tramadol
1638459|NCT01943760|Drug|0.9% saline|
1638460|NCT01943734|Behavioral|Information passed on anthropometric assessment|Information passed on worker's anthropometric assessment.
1638461|NCT01943721|Drug|VISION5 Product|
1638462|NCT01943708|Device|SPAP|Novel Auto-algorithm for Auto-CPAP device
1638463|NCT01943708|Device|CPAP|Standard CPAP therapy
1638464|NCT01943695|Behavioral|Aerobic Training|
1638465|NCT01943695|Behavioral|Educational Information|Subjects will be given material regarding cancer and it's impact.
1638466|NCT01943695|Behavioral|Supervised Home Based Training|
1638467|NCT01943682|Drug|CPX-351|Comparison of Different doses of drug
1638468|NCT01943669|Device|ReWalk™ device|Twenty one-hour ReWalk™ training sessions are scheduled for each participant over a 10-week period.
1638469|NCT01943656|Device|Tobii™ Eyegaze System|Volunteers will be instructed and trained to use the Tobii™ Eyegaze System. The number of sessions required to successfully master the device depends on the learning curve of the patient. The progress will be documented accordingly. After successful completion of the training and supervised use, the inpatients will be offered the Tobii™ Eyegaze System for unsupervised use, 4 hours a week, for the following 2 months.
1638470|NCT01943643|Procedure|multislice CT angiography|Study patients will undergo MSCTA on Toshiba Aquilion CXL 128 slice CT scanner using predefined protocol. The procedure will include calcium scoring (Agatston) then CT angiography using Ultravist 370 contrast agent ((iopromide concentration 370 mg/ml, Bayer Health Care, Germany). MSCTA angiograms will be analyzed using dedicated software Vital Vitrea Advanced 6.2, Vital Images, Minnetonka, Minnesota, US. The bifurcation lesion analyses will include: the measurement of the angle between MB and SB, measurement of the lesion length, reference diameter of the vessel, degree of stenosis, atherosclerotic plaque analysis 10 mm proximal and distal in the MB, and 5 mm from the ostium of the SB, and at the level of maximum stenosis (minimal lumen diameter).
1638471|NCT01943630|Drug|15% AS101 gel|Administration of Topical 15% AS101 once a day (overnight)
1638472|NCT01943630|Drug|Vehicle|Administration of Vehicle once a day (overnight)
1638473|NCT01943617|Drug|Entecavir|anti-viral therapy
1638474|NCT01943617|Drug|Thymosin-α|anti-viral and antitherapy
1638475|NCT01943604|Other|Nutella Breakfast|Breakfast composed of bread and Nutella, milk and apple slices
1638476|NCT01943604|Other|Waffle Breakfast|Breakfast composed of waffles and syrup, milk, and apple slices
1638477|NCT01943591|Device|Endovascular coiling with standard 10-caliber platinum coils or 15-caliber platinum coils|Embolization using 15-caliber platinum coils or standard 10-caliber platinum coils.
1638478|NCT01943565|Drug|Hydromorphone 25mcg|Intrathecal Hydromorphone 25mcg
1638479|NCT01943565|Drug|Hydromorphone 50mcg|Intrathecal Hydromorphone 50mcg
1638480|NCT01943565|Drug|Hydromorphone 100mcg|Intrathecal Hydromorphone 100mcg
1638481|NCT01943565|Drug|spinal anesthesia|bupivacaine 0.75% 1.6 mL (12mg)
1638482|NCT01943552|Drug|placebo|normal saline
1638483|NCT01943552|Drug|ipratropium bromide|ipratropium bromide
2012149|NCT02192541|Drug|Ganetespib|Ganetespib is a non-geldamycin synthetic inhibitor of Hsp90 with activity against multiple cancer cell lines and tumor xenografts in preclinical models.
1638485|NCT01943526|Biological|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
1638486|NCT01943513|Biological|BIIB023|Intravenous (IV) infusions
1638487|NCT01943513|Biological|Placebo|Matched placebo
1638488|NCT01943487|Drug|EC905|Oral
1638489|NCT01943487|Drug|verapamil|Oral
1638490|NCT01943474|Device|AccuCath IV Catheter Device|Vascular access and indwelling catheter placement via study device for infusion of fluids and removal of blood samples.
1638491|NCT01943474|Device|Conventional IV Catheter Device|Vascular access and indwelling catheter placement via control device for infusion of fluids and removal of blood samples.
1638492|NCT01943461|Drug|Avelumab|Avelumab will be administered in study location using a protocol-defined dose escalation scheme until confirmed complete response (CR), confirmed progression, unacceptable toxicity, or withdrawal from the trial or investigational medicinal product (IMP) occurs.
2012150|NCT02193282|Other|Clinical Observation|Undergo observation
2012151|NCT02193282|Drug|Erlotinib Hydrochloride|Given PO
2012152|NCT02193282|Other|Laboratory Biomarker Analysis|Correlative studies
2012153|NCT02193282|Other|Placebo|Given PO
2012154|NCT02191891|Drug|BI 836845|Human monoclonal antibody. Two dose levels (high or low) depending on the dose cohort explored
1638498|NCT01943422|Drug|High-dose Interferon alfa-2b|•Vemurafenib at standard dosing with a 2 week lead-in period to identify potential effects. IFNα-2b following this (week 2 onwards) at standard induction (4 weeks) and maintenance (48 weeks) doses.
2012155|NCT02191891|Drug|afatinib|Irreversible EGFR tyrosine kinase inhibitor. Two dose levels (30 mg, 40 mg) depending on the dose cohort explored or determined dose at part A
2012156|NCT02190890|Procedure|Dry needling|
2012157|NCT02190890|Procedure|Control|
2012158|NCT02186574|Drug|Tenofovir disoproxil|
2012159|NCT02186574|Drug|Placebo Oral Tablet|
2012160|NCT02184936|Other|standard of care|
2012161|NCT02184416|Other|observational|The study is non interventional. All drugs will be prescribed
2012162|NCT02180867|Drug|Doxorubicin Hydrochloride|Given IV
2012163|NCT02180867|Drug|Ifosfamide|Given IV
1638499|NCT01943422|Drug|Vemurafenib|"Vemurafenib is a prescription medicine used to treat melanoma, that has spread to other parts of the body or cannot be removed by surgery, and that has a certain type of abnormal BRAF gene."
1638500|NCT01943409|Drug|Intralipid|soybean oil-based lipid emulsion
1638501|NCT01943409|Drug|ClinOleic|olive oil-based lipid emulsion
1638502|NCT01943396|Procedure|rheohemapheresis|Each treated patient will receive a series of 8 rheohemaphereses (cascade filtration) within 10 weeks. One plasma volume will be washed.
1638503|NCT01943383|Genetic|iPSC|Single blood draw for the production of induced pluripotent stem cells.
1638504|NCT01943370|Other|Early saline irrigation|Initiation of post-operative saline irrigation earlier during the post-operative course
1638505|NCT01943370|Other|Routine Irrigation|Routine initiation of saline irrigation
1638506|NCT01943357|Behavioral|Diabetes Self Management Program|The interventions include modeling and action-planning to enhance self-efficacy.
1638507|NCT01943344|Device|VIVASURE CLOSURE DEVICE™|implantation of VIVASURE CLOSURE DEVICE™
1638508|NCT01943318|Procedure|Liver biopsy|Histologic evaluation
1638509|NCT01943318|Device|Hepatic venous pressure gradient (HVPG) measurement|hepatic venous pressure gradient measurement (Internal jugular venous catheter)
1638510|NCT01943305|Biological|Japanese Encephalitis vaccine|IXIARO, inactivated, adsorbed vaccine. Two doses (0.5 ml each) of IXIARO one month apart
1638511|NCT01943305|Biological|Yellow Fever vaccine|STAMARIL, 1 dose (0.5 ml)
1638512|NCT01943292|Drug|Defactinib|
1638513|NCT01943279|Other|Remote Follow-up (RFU)|Women in the RFU group will be asked to return to the clinic for assessment if they have any complications.
1638514|NCT01943279|Other|Standard Follow-up (SFU)|Study Day 15 (± 3 days)requires an in-person post-abortion checkup: transvaginal ultrasound, and a bimanual exam to confirm successful pregnancy expulsion.
1638515|NCT01943266|Dietary Supplement|protein intake|on the study day, the diet will be provided as free amino acids,with calories made up by a liquid diet and protein free cookies. Protein intake will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8, and 2.0 g.kg/day
1638516|NCT01943253|Device|Conventional ESD|Conventional ESD: Conventional ESD technique using IT2-Knife, Dual-Knife, Hook-Knife (Olympus Europe, Hamburg, Germany; Olympus Japan) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Syringe
1638517|NCT01943253|Device|Hybridknife ESD|Group 2: Water-jet assisted HybridKnife® ESD technique using HybridKnife® (Erbe Elektromedizin GmbH, Tübingen, Germany) ERBE VIO 300D (V2.1.4) RF-surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany) Injection of fluid: Integrated in HybridKnife® with ERBEJet 2 water-jet surgery system (ERBE Elektromedizin GmbH, Tübingen, Germany)
1638518|NCT01943240|Drug|Paravertebral nerve block: 4 mL ropivacaine 0.5% at each of six levels|
1638519|NCT01943240|Drug|10 cc of 0.375% ropivacaine pectoral nerve block|
1638521|NCT01943201|Device|new bedsheet|sleeping 5 nights on the new bedsheet
1638522|NCT01943201|Device|conventional bedsheet|sleeping 5 nights on the conventional bedsheet
1638523|NCT01943188|Radiation|stereotactic body radiation therapy|Undergo SBRT
1638524|NCT01943188|Drug|cyclophosphamide|Given PO
1638525|NCT01943188|Biological|therapeutic autologous lymphocytes|Undergo autologous PBMC infusion
1638526|NCT01943188|Other|laboratory biomarker analysis|Correlative studies
1638527|NCT01943162|Behavioral|CPT|
1638528|NCT01943136|Drug|papaya 1% extract ointment|
1638529|NCT01943136|Drug|mupirocin 2% ointment|
1638530|NCT01943123|Dietary Supplement|probiotic drink|comparison of study group (probiotic group) with the control group regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
1638531|NCT01943123|Dietary Supplement|Placebo Comparator: plain, unsweetend, unflavored pasturised milk|comparison of control group with the study group (probiotic group) regarding the number of CFU of microbes in oral cavity and the overall oral health status measured using indices
1638532|NCT01943110|Device|ID adapter (autodisable)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin. Contains an autodisable feature to prevent reuse.
1638533|NCT01943110|Device|ID adapter (side load)|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
1638534|NCT01943084|Drug|Norditropin® FlexPro® pen|Administered as a single subcutaneous (s.c., under the skin) dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
1638535|NCT01943084|Drug|Genotropin Pen®|Administered as a single subcutaneous dose (4.0 mg) on 2 separate dosing visits (treatment periods). The 2 treatment periods will be separated by a 7-day washout period.
1638536|NCT01943071|Behavioral|Day care for patients with dementia|Day care centres designed by the local authorities for patients with dementia
1638537|NCT01943058|Drug|megestrol acetate|Given PO
1638538|NCT01943058|Device|levonorgestrel-releasing intrauterine system|Given IUD
1638539|NCT01943058|Other|laboratory biomarker analysis|Correlative studies
1638540|NCT01943058|Other|questionnaire administration|Ancillary studies
1638541|NCT01943045|Biological|NGM282|
1638542|NCT01943045|Other|Placebo|
1638543|NCT01943019|Drug|Linagliptin|
1638544|NCT01943006|Drug|Hirudoid cream 0.3 % Mucopolysaccharide polysulfate|Hirudoid cream
1638545|NCT01943006|Drug|Placebo cream without active substance|
1638546|NCT01942993|Drug|Vemurafenib|Vemurafenib will be administered at the FDA approved dose of 960 mg approximately 12 hours apart with or without a meal. Vemurafenib is provided at 240-mg film-coated tablets packed in bottles for oral administration. Vemurafenib should be swallowed whole with a glass of water and the medication should not be chewed or crushed. Management of symptomatic adverse events may require dose reductions, treatment interruptions, or treatment discontinuation. Dose reductions below 480 mg twice daily are not recommended.
1638547|NCT01942980|Radiation|Radiation therapy Brain metastasis in breast cancer|Radiation
1638548|NCT01942967|Other|Echocardiography|"Measurement of:
Left ventricular output (LVO).
Right ventricular output (RVO).
Assessment of the Mesenteric Artery Flow."
1638798|NCT01940952|Drug|Zydena (Udenafil) 50mg + Donepezil 5mg or 10mg|
1638549|NCT01942967|Other|Near Infrared Spectroscopy Monitoring|Measurement of cerebral and mesenteric regional oxygen saturation(rSO2) trends and data while the baby on CPAP or TrPA modes of noninvasive ventilation.
1638550|NCT01942954|Other|Mobile health cognitive stimulation|
1638551|NCT01942941|Device|geko™ electrical stimulation|applied to stimulate peroneal nerve and cause active muscle twitch
1638552|NCT01942928|Other|Usual NHS Care|Usual NHS care is provided by a health visitor who will diagnose excessively crying infants/infants with colic in the first instance. Parents usually will then have the opportunity to consult their health visitor when needed. The health visitor will provide support and advice on how to manage the condition within their professional remit.
1638553|NCT01942928|Other|Osteopathic Manipulative Therapy|Osteopathic treatment will be provided by experienced osteopaths once a week for up to four weeks, depending on needs. Treatment will be individualised, according to clinical findings, and involves using standard cranial osteopathic techniques. All parents will be able to ask questions.
1638554|NCT01942915|Biological|Umbilical Cord Blood Mononuclear Cells|Participants will be transplanted with umbilical cord blood mononuclear cells.
1638555|NCT01942902|Device|Continuous Glucose Monitoring System|
1638556|NCT01942889|Dietary Supplement|Antioxidant Supplementation associated to Comprehensive respiratory Rehabilitation Program|Vit E, Vit C, Selenomethionine, Zinc gluconate
1638557|NCT01942876|Behavioral|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
1638558|NCT01942876|Behavioral|Health behavior maintenance|This attention-control arm will receive a sham telephone intervention of equivalent duration on health behavior maintenance.
1638559|NCT01942863|Procedure|water exchange single balloon enteroscopy|Oral enteroscopy was performed first, followed by the anal route on the same day or later. For oral route, SBE was first advanced beyond Treitz ligation with CO2 insufflation. Then the water exchange method was used for further insertion. Briefly, residual air in the lumen was suctioned, and 37°C water was infused with a peristaltic pump through the biopsy channel to obtain lumen visualization. Turbid luminal water due to residual feces was suctioned and replaced by clean water until the small bowel lumen was clearly visualized again. Thus, infused water was removed predominantly during the insertion phase. The total volume of water was not restricted. For anal route, water exchange or CO2 insufflation method was used from the beginning of insertion respectively.
1638560|NCT01942863|Procedure|CO2 insufflation single balloon enteroscopy|Conventional enteroscopy was performed as CO2 insufflated during insertion. Oral enteroscopy was performed first, followed by the anal route on the same day or later.
1638561|NCT01942863|Other|Procedural Requirements|SBE was advanced as deeply as possible and complete small bowel visualization was attempted. When the following conditions were met, tattooing at the deepest position with India ink was performed and the endoscope was withdrawn: no further endoscopic advancement could be achieved, detection of a significant lesion and no other lesions suspected, severe stricture, obvious sedation and SBE-related adverse events happened which required termination of further intubation.
1638562|NCT01942837|Drug|Enzalutamide|"Administration: 160 mg orally once daily. Treatment will be continued until evidence of symptomatic or radiographic progression or the participant is taken off the study for another reason.
Dosing: 160 mg orally taken once daily as four 40 mg capsules."
1638563|NCT01942824|Behavioral|Text Messages|
1638564|NCT01942811|Behavioral|Quit Using Drugs Intervention Trial|The goal of the Quit Using Drugs Intervention Trial (QUIT) is to conduct a small RCT of a primary care clinic-based very brief intervention protocol for reducing the use of illegal drugs and the occurrences of drug-related harm in low-income, racially-diverse patient populations at two 'safety-net' clinics in Los Angeles. The design will emphasize screening, very brief clinician advice, and telephone drug-use health education to reduce 'at risk' drug use and thus interrupt progression from casual or episodic abuse to dependence.
1638565|NCT01942798|Device|Nintendo Wii|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
1638566|NCT01942798|Device|Wii Big Brain Academy Degree program|Subjects will receive the intervention for 40-minute sessions, 3x/week for 4 weeks. The interventions will be administered in combination of onsite group training and individualized home-based training.
1638567|NCT01942785|Drug|Brexpiprazole|2-3 mg/day, once daily dose, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgement.
1638568|NCT01942772|Device|Ankle-Foot Orthosis|
1638569|NCT01942746|Dietary Supplement|Blueberry Juice S2|Blueberry Juice S2 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that S2 juice contained 6.04 (SD=0.20) mg anthocyanins (C3G) eq/g dry mass.
1638570|NCT01942746|Dietary Supplement|Blueberry Capsules S2|Commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars was freeze dried then powdered and encapsulated in gelatin capsules. Colorimetric analysis indicated an anthocyanin concentration in the powder of 2.37(SD=0.18) mg C3G eq per capsule.
1638571|NCT01942746|Dietary Supplement|Placebo Capsule S2|Placebo Capsule S2 (containing no anthocyanins) were prepared by freeze drying red beets and grinding them to fine powder before encapsulating in gelatine capsules. Red beets do not contain anthocyanins.
1638572|NCT01942746|Dietary Supplement|Placebo Juice L1|Placebo juice was prepared from water, sugars, citric acid, sodium citrate, and artificial colors and flavours, then pasteurized. The placebo juice contains no anthocyanins.
1638614|NCT01942356|Procedure|INH - Hypotension|"Defined as: MAP < 70 % of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.
give a 200 ml fluid bolus (crystalloid).
If not successful, give ephedrine 5 mg bolus.
If not successful decrease volatile by 0.1 MAC.
Repeat from 1) if event is not resolved after step 3) for maximum of 2 iterations"
1638573|NCT01942746|Dietary Supplement|Blueberry Juice L1|Blueberry Juice L1 was commercially prepared single strength blueberry juice composed of a 50:50 blend of Rubel (Vaccinium corymbosum L.) and Tifblue (Vaccinium ashei Reade) cultivars. Colorimetric analysis showed that L1 juice contained 6.83 (SD=0.20) mg cyanidin-3-glucoside equivalents (C3GE)/g dry mass at the start of the study, declining to 5.52 (SD=0.09) mg C3GE/g dry mass after 3 months refrigerated storage.
1638574|NCT01942733|Drug|Brexpiprazole|2-3 mg/day, once daily, tablets, for oral use. The patients received 1mg/day brexpiprazole during Week 1 and 2mg/day during Week 2 (up-titration) and from Weeks 3 to 6 they received 3mg/day; depending on tolerability the dose could be reduced to 2mg/day based on the investigator's judgment.
1638575|NCT01942720|Device|Capsule endoscopy and Ileocolonoscopy tests|
1638576|NCT01942707|Procedure|abdominoplasty with Scarpa`s Fascia|During surgical detachment of the abdominal flap the Scarpa´s fascia is preserved.
1638577|NCT01942707|Procedure|Abdominoplasty without Scarpa´s Facia|During surgical detachment of the abdominal flap the Scarpa´s fascia is removed.
1638578|NCT01942694|Dietary Supplement|Vitamin D (Cholecalciferol)|Vitamin D (Cholecalciferol) 4000 IU, administered as 1 soft-gel pill daily by mouth.
1638579|NCT01942694|Other|Placebo|Administered as one soft-gel pill daily by mouth
1638580|NCT01942681|Drug|Propiverine Hydrochloride|Administrate Propiverine Hydrochloride for 12 weeks
1638584|NCT01942655|Other|Blood sample and recto-colic biopsies|
1638585|NCT01942629|Other|their will be no intervention in any of the groups, the study is retrospective|
1638586|NCT01942616|Other|Condition 1: Perpetrator Positive|Condition 1 frames the event as episodic, labels the event as domestic violence, uses a positive description of the perpetrator, and a negative description of the victim.
1638587|NCT01942616|Other|Condition 2: Perpetrator Negative|The condition 2 intervention/exposure frames the event as thematic, labels the event as assault, uses a neutral description of the perpetrator, and a negative description of the perpetrator.
1638588|NCT01942616|Other|Condition 3: Placebo|This intervention provides no details for the participant and is for comparison use in the study.
2012164|NCT02180867|Other|Laboratory Biomarker Analysis|Correlative studies
2012165|NCT02180867|Drug|Pazopanib Hydrochloride|Given PO
1638591|NCT01942577|Device|NoSting|Each participant with get both interventions. The infant's NoSting treated thigh will be sprayed with NoSting following delivery and again at 7 days of age. A quarter 1.5 x 3 inch silicon patch that is applied to the infant's thighs will be used for data sampling.
1638592|NCT01942551|Drug|Tadalafil|
1638593|NCT01942551|Drug|Dutasteride|
1638594|NCT01942538|Device|rTMS|one session : 20 runs of 10 seconds high frequency stimulation(10Hz) and 50 seconds pause - power equivalent to 90% of the motor threshold
1638595|NCT01942538|Device|sham rTMS|same session as defined with the real rTMS, but with a coil not delivering magnetic field.
1638596|NCT01942525|Other|aEEG|The amplitude integrated EEG was performed using a single-channel, biparietal aEEG (CFM 6000; Natus Medical Incorporated, San Carlos, CA)
2012166|NCT02180867|Other|Pharmacological Study|Correlative studies
1638598|NCT01942499|Other|Community-based exercise program|
1638599|NCT01942486|Device|Investigational Coating|
1638600|NCT01942473|Device|Automated FiO2 Control|Infants will be ventilated with or without automated FiO2-Control in a randomized sequence.
1638601|NCT01942460|Drug|Ferumoxytol|
1638602|NCT01942447|Biological|FMT|
1638603|NCT01942447|Drug|Vancomycin|
1638604|NCT01942421|Procedure|Cultivated mucosal epithelial transplantation|cultivated autologous mucosal epithelium, then transplant to limbal stem cell deficiency patients.
1638605|NCT01942408|Procedure|Repeat PVI|Repeat EP study 8-10 weeks post-initial PVI with re-isolation of PV reconnection
1638606|NCT01942395|Behavioral|DASH/sodium-restricted diet (DASH/SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. The target sodium content will be 1,500 mg/2,100 kcal, as per recent American Heart Association population recommendations for sodium intake. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the 21 days urinary sodium, potassium, and 8-isoprostanes will again be measured.
1638607|NCT01942395|Behavioral|Control Diet|The Control Diet will be patterned on the information we collected using Food Frequency Questionnaires during our pilot study HUM00025253 (i.e., the dietary patterns reported by previously recruited hypertensive HFPEF patients). The target sodium content will be 3,500 mg per 2,100 kcal and target potassium content for the control diet will be 2,000 mg per 2,100 kcal.
1638608|NCT01942382|Drug|Paliperidone palmitate|Participants will receive 4 injections of paliperidone palmitate of concentration ranging from 75 to 150 milligram equivalents in deltoid or gluteal muscle as randomized to treatment group A, B, or C on Days 1, 8, 36, and 64.
1638610|NCT01942356|Procedure|TIVA - Hypotension|"Defined as: MAP < 70% of baseline Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.
Give 200 mL Fluid Bolus
If not successful, give ephedrine 5 mg bolus
Repeat from 1.) if even is not resolved after 3.)"
1638611|NCT01942356|Procedure|TIVA - Hypertension|"Defined as: SBP > 130% of baseline sustained for 2 readings Change NIBP (noninvasive blood pressure) measuring interval from 3 minutes to 1 minute until resolution of the event.
1.) Labetalol 5 mg IV will be administered"
1638612|NCT01942356|Procedure|TIVA - Bradycardia|"Defined as: Heart rate < 45 beats/min
1.) Bolus of 0.2 mg glycopyrrolate"
1638613|NCT01942356|Procedure|TIVA - Tachycardia|"Defined as: Heart Rate > 90 beats/min
If associated with normal NIBP (MAP > 60 mmHg and SAP < 140): give fluid bolus of 200 mL, repeat once if required. Look for bleeding and treat if required.
If associated with hypertension (SAB > 140 mmHg): proceed with the management of the hypotention during maintenance protocol.
If associated with hypotension (MAP < 60 mmHg): proceed with the management of the hypotnetion during maintenance protocol."
2012167|NCT02180867|Radiation|Radiation Therapy|Undergo radiation therapy
2012168|NCT02180867|Procedure|Therapeutic Conventional Surgery|Undergo surgery
2012169|NCT02181296|Drug|ropivacaine|
2012170|NCT02178722|Drug|MK-3475|IV infusion
2012171|NCT02178722|Drug|INCB024360|Oral daily dosing
1638615|NCT01942356|Procedure|INH - Hypertension|"Defined as: SBP > 130% of baseline Change NIBP measuring interval from 3 minutes to 1 minute until resolution of the event.
increase Sevoflurane by 0.1 MAC
If not successful after 3 minutes (SBP >130% of baseline), increase Sevoflurane again by 0.1 MAC. Maximum of 1.2 allowed.
If still not successful (SBP >130% of baseline), Labetolol 5mg IV will be administered."
1638616|NCT01942356|Procedure|INH - Bradycardia|"Defined as: Heart Rate < 45 beats/min
1.) Bolus of 0.2 mg glycopyrrolate"
1638617|NCT01942356|Procedure|INH - Tachycardia|"Defined as: Heart rate > 90 beats/min
if associated with normal NIBP (MAP > 70% of baseline and SBP <130% of baseline) : give fluid bolus of 200 ml, repeat once if required. (look for bleeding and treat if required).
If associated with hypertension (SBP >130% of baseline) : proceed with the management of the hypertension during maintenance protocol.
If associated with hypotension (MAP < 70% of baseline) : proceed with the management of the hypotension during maintenance protocol."
1638618|NCT01942343|Drug|Droperidol 1,25 mg administration, Droperidol 0,625 mg administration, Odansetron 4 mg administration|
1638620|NCT01942317|Other|Balneotherapy|
1638621|NCT01942304|Procedure|Calcium phosphosilicate alloplastic bone putty in direct sinus augmentation|
1638622|NCT01942304|Procedure|Anorganic bovine bone mineral in direct sinus augmentation|
1638623|NCT01942291|Drug|Niacin|The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
1638624|NCT01942278|Other|BHOMA|A complex health systems, clinical care, and community intervention to improve outcomes
1638625|NCT01942265|Drug|AS03|Subjects will receive two doses of the A/H7N9 vaccine with or without AS03 delivered intramuscularly 21 days apart.
1638626|NCT01942265|Drug|MF59|Subjects will receive two doses of the A/H7N9 vaccine with or without MF59 delivered intramuscularly 21 days apart.
1638627|NCT01942265|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Subjects will receive two doses of the A/H7N9 vaccine with or without an adjuvant delivered intramuscularly approximately 21 days apart.
1638628|NCT01942239|Device|real time continuous glucose monitoring|
1638629|NCT01942187|Drug|Aripiprazole|Medication augmentation with Abilify (aripiprazole), in participants who have not responded to Selective Serotonin Reuptake Inhibitor (SSRI) treatment.
1638630|NCT01942187|Drug|Bupropion|Medication augmentation with Wellbutrin (bupropion), in participants who have not responded to SSRI treatment.
1638631|NCT01942187|Behavioral|Problem Solving Therapy|Weekly specialized psychotherapy
1638632|NCT01942174|Biological|Prevenar 13|Vaccination at the beginning of the study (day 0)
1638633|NCT01942174|Biological|Pneumo23|Vaccination 2 months later the beginning of the study
1638634|NCT01942174|Drug|Methotrexate|concerning immediate group, methotrexate is Initiated in the same time that the antipneumococcal vaccination by prevenar 13
1638635|NCT01942174|Drug|Methotrexate|"For period group, methotrexate is Initiated & month after the antipneumococcal vaccination by prevenar 13"
1638636|NCT01942161|Drug|Aripiprazole Low (2 mg/day)|administered 2 mg once daily for 6 weeks
1638637|NCT01942161|Drug|Aripiprazole Mid (6 - 12 mg/day)|administered 2 mg once daily for 2 days, followed by a maintenance dose of 6 mg for 40 days. From Day 15 onwards, the dose may be increased to 12 mg
1638638|NCT01942161|Drug|Aripiprazole High (24 - 30 mg/day)|administered 2, 6, 12, 18 mg sequentially, each dose once daily for 2 days respectively, followed by a maintenance dose of 24 mg for 34 days. From Day 15 onwards, the dose may be increased to 30 mg
1638639|NCT01942148|Drug|Aripiprazole|
1638640|NCT01942135|Drug|Palbociclib|Palbociclib 125 mg/day orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
1638641|NCT01942135|Drug|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
1638642|NCT01942135|Drug|Placebo|Placebo orally continuously dosed for 3 weeks followed by 1 week off; repeated at each subsequent cycle.
1638643|NCT01942135|Drug|Fulvestrant|Fulvestrant 500 mg intramuscularly on Days 1 and 15 of Cycle 1, and then on Day 1 of each subsequent 28 day cycle.
1638644|NCT01942122|Drug|DLBS1442 100|Study treatment will be DLBS1442 capsules at a dose of 3x100 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
1638645|NCT01942122|Drug|Mefenamic acid|Control will be mefenamic acid 500 mg tablets, administered 3 times daily for 5 days during the menstrual period, i.e. day 1st to day 5th of the menstrual period. The drug will be given within the 8 weeks of study period (2 menstrual cycles).
1638646|NCT01942122|Drug|DLBS1442 200|Study treatment will be DLBS1442 capsules at a dose of 3x200 mg daily. DLBS1442 will be taken every day for 8 weeks (2 menstrual cycles).
1638647|NCT01942109|Drug|Furosemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
1638648|NCT01942109|Drug|Torasemide|Drug will be administered per os. Dose of the agent will be adapted to clinical status of the patient. Equipotential dose for furosemide is torasemide in dose 1:4 of furosemide
1638649|NCT01942083|Drug|OPB-111077|
1638650|NCT01942070|Device|Bioresorbable vascular scaffold|
1638651|NCT01942070|Device|Durable polymer everolimus-eluting metallic stent|
1638652|NCT01942044|Device|Promus element, Xience prime, and Nobori|
1638653|NCT01942031|Behavioral|structured collegial feed back|Collegial feed back to primary care physicians at randomized primary care centers
1638654|NCT01942018|Procedure|POEM|Patients will receive Per oral endoscopic myotomy (POEM) for symptomatic gastroesophageal junction outflow obstruction (EGOO)
1638655|NCT01941992|Drug|SAMITAL®|
1638656|NCT01941992|Drug|Placebo sachets|
1638657|NCT01941979|Drug|5-FU, Capecitabine, Oxaliplatin, Leucovorin.|
1638794|NCT01940965|Drug|biguanide|Pharmaceutical form:tablet Route of administration: oral
1716063|NCT00000944|Drug|Indinavir sulfate|
1638658|NCT01941966|Drug|Capecitabine|Capecitabine, PO, 825mg/m2, on days: 1, 2, 3, 4, 5, 8, 9, 10, 11, 12, 15, 16, 17, 18, 19, 22, 23, 24, 25, 26, 29, 30, 31, 32, 33, 36, 37, 38, 39 and 40 of radiotherapy period.
1638659|NCT01941966|Drug|Mitomycins|15 mg/m2, IV, bolus, single dose on day 1 of radiotherapy
1638660|NCT01941966|Radiation|Radiotherapy|Dose: 50,4-54 Gy 28 to 30 fractions during 5 to 6 weeks
1638661|NCT01941953|Drug|Metformin and Fluorouracil|metformin 850mg PO BID plus 5FU 425mg/m2 + leucovorin 50mg IV weekly
1638662|NCT01941940|Drug|Tocilizumab|Tocilizumab at a fixed dose of 162 mg as SC injection will be administered once every week.
1638663|NCT01941940|Drug|DMARDs|Non-biologic DMARDs according to standard of care, at a stable dose that was initiated at least 4 weeks prior to baseline.
1638664|NCT01941927|Drug|Trametinib (GSK1120212)|Trametinib is a highly selective allosteric inhibitor of MEK1 andMEK2 activation and kinase activity.
1638665|NCT01941927|Drug|GSK2141795|GSK 2141795 is an ATP competitive subnanomolar pan-AKT inhibitor. In order to measure the true potency of GSK 2141795, potency (Ki*) values were determined in a filter binding assay using lower enzyme concentrations (0.1, 0.7, and 0.2 nM for human AKT1, AKT2, and AKT3, respectively). Using a sandwich ELISA, GSK 2141795 inhibited phosphorylation of GSK-3β in BT474 and LNCaP cell lines with EC50 values of 143 and 34 nM, respectively. Sincephosphorylation of GSK-3β can be modulated by other enzymes (PKA, PKC, and RSK),cellular activity of GSK 2141795 was evaluated using a phospho-PRAS40 ELISA.GSK 2141795 inhibited the phosphorylation of PRAS40 with EC50 values of 39 and 55 nM for BT474 and LNCaP cells, respectively.
1638666|NCT01941914|Drug|Calcium chloride|
1638667|NCT01941901|Drug|Calcium electroporation|Intratumoral injection, once only treatment.
1638668|NCT01941901|Drug|Electrochemotherapy with bleomycin|Intratumoral injection, once only treatment
1638669|NCT01941888|Drug|Propofol|
1638670|NCT01941888|Drug|Midazolam|
1638671|NCT01941888|Device|Target Controlled Infusion|
1638672|NCT01941875|Drug|Progesterone Effervescent Vaginal Tablets|Experimental
1638673|NCT01941862|Behavioral|Psychoeducation and Cognitive Bias Modification|
1638674|NCT01941849|Drug|Vandetanib|100 mg, 200 mg or 300 mg taken once a day during each 12-weekly cycle
1638675|NCT01941849|Radiation|131I-mIBG|Activity will be prescribed to deliver whole body absorbed dose of 0.5 Gy (+/-10%)
1638676|NCT01941836|Drug|ETC-1002|Patients receive ETC-1002
1638677|NCT01941836|Drug|Ezetimibe|Patients receive ezetimibe
1638678|NCT01941810|Dietary Supplement|bovine lactoferrin supplement|Given PO
1638679|NCT01941810|Other|questionnaire administration|Ancillary studies
1638680|NCT01941810|Procedure|quality-of-life assessment|Ancillary studies
1638681|NCT01941810|Other|laboratory biomarker analysis|Correlative studies
1638682|NCT01941797|Behavioral|interruption of oral hygiene|
1638683|NCT01941784|Other|educational intervention|Undergo health education program
1638684|NCT01941784|Other|counseling intervention|Undergo health education program
1638685|NCT01941784|Behavioral|telephone-based intervention|Receive follow-up phone calls
1638686|NCT01941784|Other|questionnaire administration|Ancillary studies
1638687|NCT01941784|Procedure|quality-of-life assessment|Ancillary studies
1638688|NCT01941771|Drug|Arm B Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Oral Vinorelbine (Navelbine oral) 50 mg 3 times weekly, monday, wednesday and friday plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1-14 in a 3 weekly schedule.
1638689|NCT01941771|Drug|Arm A Vinorelbine (Navelbine oral) Capecitabine (Xeloda)|Vinorelbine (Navelbine Oral) 60 mg/m2 day 1 and day 8 Plus Capecitabine (Xeloda) 1000 mg/m2 2 times daily day 1 to 14 in a 3 weekly schedule.
1638690|NCT01941758|Biological|trivalent influenza vaccine|
1638691|NCT01941758|Other|laboratory biomarker analysis|Correlative studies
2012172|NCT02178696|Other|Placebo, identified as placebo to participants|White tablets
1638696|NCT01941719|Behavioral|Enhanced foot care education|Personalized, computer-animated plantar pressure maps in both barefoot and in-shoe conditions were demonstrated once at baseline visit. The demonstration includes diabetic foot education on the topic of diabetic neuropathy and how barefoot walking can lead to skin breakdown and ulcer formation, which can lead to infection and eventual amputation. The education also highlights the high plantar pressures experienced by individuals while barefoot versus in-shoe and how proper footwear is necessary in conjunction with other standard self-foot care measures to prevent injury and complications.
1638697|NCT01941719|Behavioral|Standard Foot Care Education|"At baseline, a trained staff individually reviewed and dispensed the following brochures: Prevent diabetes problems: Keep your diabetes under control (NIH Publication No. 07-4349) and Prevent diabetes problems: Keep your feet and skin healthy (NIH Publication No. 07-4282) along with a 1-page summary of each brochure. Also, a 1-page supplementary diabetic shoe wear educational material was reviewed and dispensed. Keep your diabetes under control stresses sugar, blood pressure, and medication control, and nutrition and physical activity, and checking feet daily for cuts, blisters, sores, swelling, redness, or sore toenails. Keep your skin and feet healthy emphasizes the importance of checking feet daily, highlighting diabetic foot complications that can arise from neuropathy, poor circulation and dry skin, and the importance of supportive, protective, and accommodative shoewear and annual foot exams."
1638698|NCT01941706|Behavioral|Project UPLIFT|Developed for home-based treatment of depression in people with epilepsy, Project UPLIFT is based upon Mindfulness-based Cognitive Therapy for depression. It includes 8 modules, group-delivered by either telephone or Web. Trainees and people with epilepsy co-facilitate the groups, supervised by a licensed mental health professional.The co-facilitators are trained and supervised by the Principal Investigator, a Georgia-licensed clinical psychologist and Associate Professor of Behavioral Science and of Epidemiology in public health. Activities are designed to increase knowledge about depression; monitoring, challenging, and changing thoughts; coping and relaxing; attention and mindfulness; focusing on pleasure; the importance of reinforcement, and preventing relapse.
1638699|NCT01941693|Behavioral|Integrated care|Intervention for co-morbid alcohol dependence and anxiety or mood disorder. Trained therapists will deliver specific Cognitive Behavioural Therapy based upon interventions that have been supported by randomised controlled trials for alcohol use, anxiety, and depressive disorders.
1638700|NCT01941693|Behavioral|Usual care|Counselling for all subjects will continue in accord with standard practice. Currently, programs of brief individualized motivation enhancement therapy (feedback of assessment findings, reinforcement, empathy, client's own motivation) are available.
1638701|NCT01941667|Behavioral|Daily Messages, Virtual Home Visits|"Intervention includes: Measuring daily weights, 24 hour intake, heart rate, oxygen level
Daily messages requesting weight, intake, pulse ox and pulse are automated
Virtual home visits occur twice weekly where the investigators see the infant and families."
1638702|NCT01941667|Other|Usual Care|Usual care as defined by by the Cardiology Department.
1638705|NCT01941641|Drug|neoadjuvant FOLFOXIRI|
1638706|NCT01941641|Drug|Capecitabine|
1638707|NCT01941628|Drug|Rocuronium|Rocuronium 0.6 mg/kg will be used as muscle relaxant to allow intubation during induction into general anesthesia and to induce deep neuromuscular blockade for the surgery. Deep neuromuscular blockade will be maintained until the suture of fascia of musculus rectus abdominis.
1638708|NCT01941628|Drug|Succinylcholine|Standard induction into general anesthesia with succinylcholine 1 mg/kg will be performed. No other muscle relaxant will be administered during the Caesarean section until surgeon would request it. In that case, according to general standards, dose of atracurium 0.25 mg/kg will be administered.
1638709|NCT01941615|Drug|faldaprevir|oral doses for 10 days (period B)
1638710|NCT01941615|Drug|Microgynon®|oral doses for 23 days (period A+B)
1638711|NCT01941615|Drug|BI 207127|oral doses for 10 days (period B)
1638712|NCT01941602|Drug|prophylactic enoxaparin|enoxaparin had been prescribed at a dose of 40 mg (once daily) from the evening before surgery until patients were well mobilized. Also, at the time of surgery compression stockings were used, as well as a sequential compression device (SCD) until the morning after or longer if mobilization was delayed
1638713|NCT01941602|Procedure|non-prophylactic|no pharmacological prophylaxis for venous thromboembolism (VTE) had been used routinely. Occasionally, with delayed mobilization, a low-dose low molecular weight heparin (LMWH) had been prescribed. SCD had been used at increased frequency, and is today considered routine.
1638716|NCT01941576|Drug|recombinant human brain natriuretic peptide (rhBNP)|Patients are first given a loading dose of recombinant human brain natriuretic peptide (rhBNP) 1.5 mcg/kg, followed by continuous infusion recombinant human brain natriuretic peptide 0.01-0.01mcg/kg/min for 72 hours.
1638717|NCT01941576|Drug|Placebo (0.9% sodium chloride)|Patients after corrective repair of Tetralogy Of Fallot will be treat with routinely therapy, including inotropics and diuretics, combined a placebo infusion 24 hours after operation.
1638718|NCT01941563|Drug|Condoliase|1.25U, intradiscal injection, one time
1638719|NCT01941563|Drug|placebo|
1638720|NCT01941550|Drug|Cabazitaxel chemotherapy|given in 6 cycles
1638721|NCT01941537|Drug|ILV-094|IV infusion of ILV-094
1638722|NCT01941537|Drug|Placebo Comparator|Twenty patients will be enrolled in the ILV-094 placebo arm. A loading IV dose of a placebo will be given at baseline (Day 0), followed by five additional IV doses of placebo every two weeks (Weeks 2, 4, 6, 8, and 10).
1638723|NCT01941524|Drug|Poractant alfa instillation|aEEG and NIRS monitoring during poractant alfa instilation
1638724|NCT01941524|Drug|Beractant instillation|aEEG and NRs monitoring during beractant instillation
1638725|NCT01941511|Drug|Rivipansel|Subjects will receive in a randomized sequence rivipansel 4gA IV, moxifloxacin 400 mg, and placebo IV.
1638726|NCT01941498|Device|Wavelight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
1638727|NCT01941498|Procedure|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
1638728|NCT01941485|Device|WaveLight® Refractive Suite|Excimer EX500 and Femtosecond FS200 lasers (Wavelight® Refractive Suite) used during LASIK surgery for corneal flap creation and corneal ablation
1638729|NCT01941485|Procedure|LASIK surgery|Surgical procedure for treating refractive error based on corneal reshaping
1638730|NCT01941472|Other|fluid challenge|A bag of 500ml of normal saline or 4% gelatin (Gelofusine, B. Braun Medical (Suzhou) Company Limited, Suzhou, China) is infused within 15 minutes using a bag pressurized to 300 mmHg. All other treatments, including maintenance fluids, dose of vasoactive agents and ventilator settings, remain unchanged during the study period.
1638731|NCT01941446|Drug|Eravacyline and Moxifloxacin|
1638732|NCT01941433|Behavioral|Arthritis Health Journal|
1638733|NCT01941407|Drug|Eribulin|Eribulin: 1,23mg/m² d1, d8, IV Bevacizumab: 15mg/kg d1, IV
1638734|NCT01941394|Biological|Mesenchymal stem cells|Mesenchymal stem cells infusion
1638735|NCT01941381|Procedure|Tympanometry|All patients enrolled with receive a tympanogram. There will be no difference between the follow up in the groups based on the tympanometry results. The study is simply observational
1638736|NCT01941368|Dietary Supplement|Placebo|
1638737|NCT01941368|Dietary Supplement|HMB-FA|
1638738|NCT01941368|Procedure|High Intensity Interval Training|
1638739|NCT01941355|Behavioral|Exercise training component|The physical exercises consist of; deep breathing exercises and breathing exercises using incentive spirometry with expiratory positive pressure airway, cycling exercises during hospitalisation and an individualised exercise programme running from discharge to 4 weeks following surgery.
1638740|NCT01941355|Behavioral|Psycho-educative component|The psycho-educative rehabilitation programme consists of four psycho-educative consultations with a specially trained nurse. The last consultation will take place 4 weeks following surgery.
1638741|NCT01941342|Procedure|Pancreatoduodenectomy|
1638742|NCT01941342|Procedure|ENBD and Pancreatoduodenectomy|
1638743|NCT01941342|Procedure|EBD and Pancreatoduodenectomy|
1638744|NCT01941342|Procedure|PTCD and Pancreatoduodenectomy|
1638745|NCT01941329|Procedure|Panretinal Photocoagulation (PRP)|
1638746|NCT01941329|Drug|Intravitreous injection of ranibizumab|
1638799|NCT01940952|Drug|Placebo + Donepezil 5mg or 10mg|
1638747|NCT01941316|Drug|Carfilzomib|20/36 * mg/m2 stepped up dosing, IV infusion (over 30 min), on days 1, 2, 8, 9, 15 and 16 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
1638748|NCT01941316|Drug|Irinotecan|125 mg/m2, IV infusion (over 90 min), on days 1, 8, 15 of each 28 day cycle. Number of cycles: 6, or until progression, or unacceptable toxicity, or treatment delay for any reason greater than 3 weeks.
1638749|NCT01941277|Behavioral|Current Recommendations Exercise Group|
1638750|NCT01941277|Behavioral|Intensive Exercise Group|
1638751|NCT01941264|Other|community based screening and treatment|Already described in intervention arm description.
1638752|NCT01941251|Device|navigated Transcranial Magnetic Stimulation|"individualized α frequency
left DLPFC 110% motor threshold (MT)
13-15 sessions for 3 weeks"
1638753|NCT01941251|Device|navigated Transcranial Magnetic Stimulation|- placebo treatment: sham coil
1638754|NCT01941225|Drug|Inhaled iloprost 5.0 mcg|Single administration
1638755|NCT01941225|Drug|Placebo|Single administration
1638756|NCT01941212|Behavioral|Music therapy|Music therapy will be given to patients 24 hours prior and for the first 48 hours after surgery
1638757|NCT01941199|Drug|DA-1229|
1638758|NCT01941199|Drug|metformin|
1638759|NCT01941199|Drug|DA-1229 + metformin|
1638760|NCT01941186|Other|Patient Decision Aid|Short informational video on developmental delays and early intervention services aimed at helping parents make an informed decision about whether to pursue early intervention services.
1638761|NCT01941173|Biological|ziv-aflibercept|Given IV
1638762|NCT01941173|Drug|leucovorin calcium|Given IV
1638763|NCT01941173|Drug|irinotecan hydrochloride|Given IV
1638764|NCT01941173|Drug|fluorouracil|Given IV
1638765|NCT01941160|Dietary Supplement|Lacidofil® STRONG|Lacidofil® STRONG capsule twice daily
1638766|NCT01941160|Dietary Supplement|Placebo|Placebo capsule twice daily
1638767|NCT01941147|Device|pulsed ELF-MF|(75 Hz, 1,8 mT)
1638768|NCT01941134|Drug|ethinyl estradiol-levonorgestrel|Women will be asked to take a daily ethinyl estradiol-levonorgestrel combined oral contraceptive (COC) for 21 days, beginning 2-3 months pre-operatively, so as to stop at least 30 days before planned surgery date. Then, approximately 3-4 months after surgery, they will again be asked to take a daily pill for 21 days. During these pill cycles, we will collect serum samples and perform ultrasound and cervical mucus assessments on a twice-weekly basis, culminating in an inpatient stay of up to 48 hours in order to obtain more frequent sampling at the end of the pill pack.
1638769|NCT01941121|Behavioral|Linkage to PrEP or Care|Ensuring subjects complete linkage to PrEP or Care through coordinated scheduling and intensive reminders by ALERT Specialist.
1638770|NCT01941108|Behavioral|Peer Navigation Arm|Patients randomized to this arm receive regular contact with a peer navigator and a smartphone running eMOCHA software to aid in navigation.
2012173|NCT02178696|Drug|Celexa or other antidepressant as clinically indicated|Open label s-citalopram, 20 mg start up dose, increasing to 40 mg as clinically indicated; If prior non-response to this medication is noted by the patient, alternative treatments may include another first-line antidepressant:fluoxetine 20 mg; paroxetine up to 60 mg; sertraline up to 200 mg; bupropion up to 300 mg
2012174|NCT02178696|Other|"Placebo, identifed to participants as Active medication"|Blue Capsule
2012175|NCT02177630|Other|Endomyocardial Biopsy|
2012176|NCT02173470|Other|CT scan|The intervention group receives both standard care (chest x-ray) and an ultra low dose CT thorax without contrast.
2012177|NCT02169271|Drug|Aspirin|Given PO
2012178|NCT02169271|Other|Laboratory Biomarker Analysis|Correlative studies
2012179|NCT02169271|Other|Placebo|Given PO
1638778|NCT01941082|Drug|RO6867461|Single or multiple ascending dose by intravitreal injection
1638779|NCT01941069|Behavioral|Friends for Life|Friends for Life is a group CBT intervention, based on a theoretical model, which addresses cognitive, physiological and behavioral processes that are seen to interact in the development and perpetuation of excessive anxiety.
1638780|NCT01941069|Behavioral|Coping Power Program|The Coping Power Program CPP is a cognitive-behavioral, multi-component group intervention for elementary and middle school students at risk for externalizing behavior disorders. In addition to anger management, the CPP includes units on goal setting, emotional awareness, relaxation training, social skills training, problem solving, and handling peer pressure.
1638781|NCT01941056|Biological|multi-CMV epitope modified vaccinia Ankara vaccine|Given IM
1638782|NCT01941056|Other|laboratory biomarker analysis|Correlative studies
1638783|NCT01941043|Drug|CERC-301|
1638784|NCT01941043|Other|Placebo|
1638785|NCT01941030|Device|Orbital Atherectomy System|Orbital atherectomy (OA) is performed prior to adjunctive balloon angioplasty (BA)
1638786|NCT01941030|Device|Balloon Angioplasty|Type of balloon selected is driven by preference of the operator.
1638787|NCT01941004|Drug|fingolimod|Randomized to 6 month (180 days) 0.5 mg fingolimod + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
1638788|NCT01941004|Drug|Placebo (6mos) + open label fingolimod (6 mos)|Randomized to 6 month (180 days) matching placebo + 6 month (180 day) open label 0.5mg fingolimod capsules for oral administration once daily
1638789|NCT01940991|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
1638790|NCT01940991|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A, dose applied to the lateral canthal lines
1638791|NCT01940978|Drug|Methylphenidate ER|Watson generic, starting dose 18mg QD
1638792|NCT01940978|Drug|Cyproheptadine|cyproheptadine hydrochloride
1638793|NCT01940965|Drug|lixisenatide AVE0010|Pharmaceutical form:solution Route of administration: Subcutaneous injection
1716064|NCT00000944|Drug|Lamivudine|
2012180|NCT02169739|Device|Ischemic Preconditioning|Patients will undergo ischemic preconditioning once or twice daily for up to four 5-minutes cycles of bilateral upper extremity ischemia separated by 5-minute periods of reperfusion.
2012181|NCT02164916|Biological|cetuximab|Given IV
2012182|NCT02164916|Drug|irinotecan hydrochloride|Given IV
2012183|NCT02164916|Drug|vemurafenib|Given PO
1638800|NCT01940952|Drug|Zydena (Udenafil) 100mg + Donepezil 5mg or 10mg|
2012184|NCT02164513|Drug|fluticasone furoate (FF)|FF will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg and FF/VI 100 mcg/25 mcg
1638802|NCT01940926|Drug|68Ga-BNOTA-PRGD2|Single dose intravenous injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before PET/CT scanning
1638803|NCT01940913|Dietary Supplement|Probiotic capsules|
1638804|NCT01940913|Dietary Supplement|Placebo capsules|
1638805|NCT01940900|Drug|E10030|
1638806|NCT01940900|Drug|ranibizumab|
1638807|NCT01940900|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
1638808|NCT01940887|Drug|E10030|
1638809|NCT01940887|Drug|bevacizumab or aflibercept|Patients are randomized to receive either bevacizumab or aflibercept
1638810|NCT01940887|Drug|E10030 sham intravitreal injection|Pressure on the eye with a syringe with no needle
1638811|NCT01940848|Drug|STW5 (Iberogast, BAY98-7411)|Applied orally over 28 days, 20 drops STW 5 three times daily
1638812|NCT01940848|Drug|Placebo|Applied orally over 28 days, 20 drops placebo three times daily
1638813|NCT01940835|Procedure|Upper endoscopy with small bowel biopsies and brushings.|
1638814|NCT01940835|Other|Blood draw|Blood will be collected for serum, DNA, and peripheral blood mononuclear cells (PBMC).
1638815|NCT01940835|Other|Stool sample|Stool samples will be collected at baseline for future microbiome and virome studies.
1638816|NCT01940822|Other|Energy Drink|
1638817|NCT01940822|Other|Placebo Drink|
1638818|NCT01940809|Drug|Dabrafenib|Given PO
1638819|NCT01940809|Biological|Ipilimumab|Given IV
1638820|NCT01940809|Other|Laboratory Biomarker Analysis|Correlative studies
1638821|NCT01940809|Biological|Nivolumab|Given IV
1638822|NCT01940809|Drug|Trametinib|Given PO
1638823|NCT01940796|Drug|Brentuximab Vedotin|Up to five dose levels will be tested in cohorts of 3-6 participants each. Once the maximum tolerated dose (MTD) is established, 10 more participants will be treated at the MTD for analysis of efficacy.
1638824|NCT01940783|Radiation|Cone Beam Computed Tomography (CBCT)|Two postoperative CBCT scans, the first one on the day after cochlear implantation and the second after 3 months.
1638825|NCT01940783|Device|Magnetic Resonance Imaging (MRI)|One pre-operative (before cochlear implantation) MRI scan of the cochlea.
1638826|NCT01940757|Biological|Necator americanus Hookworm Larvae|Infectious larvae of the human hookworm Necator americanus
1638827|NCT01940744|Procedure|Prescriptive Mobilization|"The therapist will place the hypothenar eminence of 1 hand over the spinous process of L4. With the elbows remaining extended, the therapist will deliver a low-velocity, high amplitude oscillatory force (at approximately 2 Hz) directed at L4 for a total 60 seconds (Figure 1). Following a 30-second rest the therapist will perform a similar set of oscillations directed at L5. A second set of oscillations will then be performed in a similar manner at L4 and L5. Although not described in the original article, we'll target Grade III mobilizations. The procedure will be completed during a session after 2 sets of 60 seconds of non-thrust oscillatory manipulations will be performed over L4 and L5. Patients will be seen for 4 visits."
1638828|NCT01940744|Procedure|Pragmatic Mobilization|The techniques will of consist of passive, low velocity, oscillatory movements within the physiological range of the joint, applied to the comparable spinal level of the patient (defined as the spinal level that reproduced the patient's familiar pain). The techniques will be modified based on clinician assessment and patient feedback and consist of Grade I through Grade IV movements. Common techniques used may include unilateral posterior-anterior movements, central posterior-anterior movements, and sidelying rotations (without thrust). Since the pragmatic approach is clinician-driven, no time limit will be placed on the application and the number of mobilizations used will depend on the patient feedback (the exact definition of a pragmatic treatment). Patients will be seen for 4 visits.
1638829|NCT01940731|Drug|Colistimethate sodium|3-5mg/(kg.d)(if CLcr≥80 mL/min),The maximum dose≤300mg/d 2.5-3.8mg/(kg.d)（if CLcr=50-79mL/min），The maximum dose≤230mg/d twice a day
1638830|NCT01940718|Drug|Transdermal Androgel|T dosing will be initiated at the lowest possible level (20.25 mg testosterone = 1 pump actuation) which is expected to increase average serum T concentrations no higher than the mid-normal range (500-800 ng/dl), with respect to expected baseline measurements in our population (~300-500 ng/dl).The T dose will be adjusted two weeks after initiation of treatment based on the measurement of serum T levels. Dosing adjustments can be made at 20.25 mg testosterone increments. The medication will be taken transdermally once daily for 3.5 months.
2012185|NCT02164513|Drug|vilanterol (VI)|VI will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, FF/VI 100 mcg/25 mcg and UMEC/VI 62.5 mcg/25 mcg
2012186|NCT02164513|Drug|umeclidinium bromide (UMEC)|UMEC will be available in combination as dry powder for inhalation as FF/UMEC/VI 100 mcg/62.5 mcg/25 mcg, and UMEC/VI 62.5 mcg/25 mcg
1638835|NCT01940692|Drug|1.5g intravenous Exacyl|intravenous administration of 1.5g Exacyl preoperatively
1638836|NCT01940692|Drug|3.0g intra-articular Exacyl|3g Intra-articular Exacyl administration postoperatively
1638837|NCT01940679|Dietary Supplement|encapsulated 600 mg EPA/DHA|encapsulated 600 mg EPA/DHA
1638838|NCT01940653|Drug|Progesterone|"Procedures Transvaginal ultrasound (US) and hormone analysis for FSH, LH, E2 and P on day 2 of the cycle will be performed. The artificial preparation of the endometrium consists of 7 days oestradiol valerate (Progynova®, Bayer-Schering Pharma AG, Berlin, Germany) 2 mg bid (bi-daily), followed by 6 days oestradiol valerate 2 mg tid (thrice daily). On day 13, the endometrium is measured. If endometrial thickness is more than 7 mm, patients are randomly assigned to group A or B. All patients with an endometrium less than 7 mm on day 13 of estrogen stimulation, are excluded.
Group A receives 5 days of micronized progesterone vaginally (Utrogestan® ((Utrogestan, Besins International), 3x200mg daily), group B receives 3 days of micronized progesterone vaginally. On the 5th (group A) or 3rd (group B) day of progesterone supplementation, the cryopreserved-thawed day 3 embryo is transferred."
1638839|NCT01940640|Dietary Supplement|DHA|We will establish two groups of premature newborn children (<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).
1716065|NCT00000944|Drug|Zidovudine|
1638840|NCT01940640|Dietary Supplement|control|We will establish two groups of premature newborn children (<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
1638841|NCT01940627|Dietary Supplement|Ubiquinol|Ubiquinol 200mg/day (two capsules of 100 mg (Breakfast and lunch)) for 14 days
1638842|NCT01940627|Dietary Supplement|Control|placebo capsules (two capsules (Breakfast and lunch)) for 14 days
1638843|NCT01940614|Other|Water deprivation test|Classical water deprivation test alone
1638844|NCT01940614|Other|Water deprivationtest|classical water deprivation test plus plasma copeptin cut-off levels
1638845|NCT01940614|Other|Hypertonic saline infusion|hypertonic saline infusion test plus plasma copeptin measurement
1638846|NCT01940601|Drug|Balugrastim|Balugrastim 300 ug/kg and Balugrastim 670 ug/kg
1638847|NCT01940601|Drug|Filgrastim|Filgrastim 5 μg/kg
1638848|NCT01940588|Behavioral|Neuropsychoanalytic therapy|Psychotherapy, medication management
1638849|NCT01940575|Device|SkinPlus-Hyal®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
1638850|NCT01940575|Device|Restylane®|The Injector will administer to the eligible subject the Study Device and Comparator Device (Comparator or Study Device) respectively to the left and right nasolabial fold in a randomized manner.
1638851|NCT01940562|Drug|eltrombopag|"Children ≥= 40 kg BW:
From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d. If primary end point not reached on day +28 then from day +29 - 200 mg/d (maximal dose).
Children 20-40 kg BW:
From day +1, start eltrombopag 50 mg/d. If primary end point not reached on day +14, then from day +15 - 75 mg/d. If primary end point not reached on day +28 then from day +29 - 100 mg/d.If primary end point not reached on day +42, then from day +43 and on - 150 mg/d (maximal dose).
Children < 20 kg BW:
From day +1, start eltrombopag - 2 mg/kg/d. If primary end point not reached on day +14, then from day +15 - 3 mg/kg/d. If primary end point not reached on day +28 then from day +29 - 3.5 mg/kg (maximal dose).
If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets."
1638852|NCT01940549|Device|Trauma Focused Therapy + tDCS|
1638853|NCT01940536|Drug|Tranexamic Acid|antifibrinolytic
1638854|NCT01940536|Drug|Placebo|Placebo
1638855|NCT01940523|Drug|Topical Tranexamic Acid|3 vials of tranexamic acid (1g tranexamic acid in 10cc each) must be mixed in the operating room by the team at the start of surgery with 45cc of saline solution (for a total of 3g tranexamic acid in 75mL solution). This solution will be applied to the open joint surfaces with two 60mL syringes (one with 60mL and one with 15m). The solution will be left in contact with the tissues for five minutes. The surgeon will suction away excess solution. The site may be irrigated before or after the tranexamic acid bath as long as the solution is in contact for at least five full minutes. After that, the tourniquet will be released and the rest of the surgery will proceed according to the standard of care.
1638856|NCT01940523|Drug|Intravenous Tranexamic Acid|1 vial (1g of IV tranexamic acid in 10mL solution) will be administered prior to inflation of the tourniquet. A second 1g dose of IV tranexamic acid will be given during initiation of the closure after the tourniquet is deflated and during closure.
1638857|NCT01940510|Drug|RO5424802|Single dose without (Day 1) and with (Day 17) co-administration of rifampin
1638858|NCT01940510|Drug|rifampin|Multiple doses Days 8-16 and Days 17-20
1638859|NCT01940497|Drug|Doxorubicin|Participants will receive doxorubicin in doses according to the locally-approved regimen q3w (1 cycle), for 4 cycles prior to initiation of trastuzumab treatment.
1638860|NCT01940497|Drug|Docetaxel|Participants will receive docetaxel in doses according to the locally-approved regimen q3w for 12 weeks, in combination with trastuzumab.
1638861|NCT01940497|Drug|Paclitaxel|Participants will receive paclitaxel in doses according to the locally-approved regimen weekly for 12 weeks, in combination with trastuzumab.
1638862|NCT01940497|Drug|Trastuzumab|Participants will receive trastuzumab 600 mg SC (vial or SID) q3w for 18 cycles.
1638863|NCT01940484|Drug|Methoxy polyethylene glycol epoetin beta|
1638864|NCT01940471|Drug|TAF|25 mg tablet administered orally once daily
1638865|NCT01940471|Drug|TDF|300 mg tablet administered orally once daily
1638866|NCT01940471|Drug|TAF Placebo|Tablet administered orally once daily
1638867|NCT01940471|Drug|TDF Placebo|Tablet administered orally once daily
1638868|NCT01940445|Device|M22 ResurFX|Fractional NA treatment (ResurFX) on one side of the face
1638869|NCT01940445|Device|M22 ResurFX and QS|Fractional NA treatment followed by QS laser treatment (SST) on one side of the face
1638870|NCT01940432|Device|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhong Liao (BL33) Hui Yang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50一60mm with 30一45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50一60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with dilatational wave,50 Hz and electric current 1一5mA(milliampere).Every session lasts for 30 min per day.The participants are treated continuously for 8 weeks for 3 sessions a week, 24 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
1638871|NCT01940432|Behavioral|pelvic floor muscle training group|Procedure:first,identify anal sphincter/feel anus, and try to raise it from chair (without adding abdominal, thigh, and buttock muscles) with a position of sitting; second, identify levator ani and try to raise vagina from chair (without adding abdominal, thigh, and buttock muscles) with a position of Sitting, bent forward, elbows on knees; third, contract levator ani with a position of sitting, lying, and standing; fourth, contract anal sphincter with a position of sitting, lying, and standing. Length of Treatment and the treatment sessions are the same as treatment group.
1638872|NCT01940419|Drug|Tranexamic Acid|1g Tranexamic acid iv administered over 10 minutes just before surgery
1638873|NCT01940419|Drug|Placebo|10 ml sodium chloride iv administered over 10 minutes just before surgery
1638874|NCT01940406|Procedure|Stimulation procedure|Device
1638875|NCT01940393|Drug|Cetirizine|Drug administration
1638876|NCT01940393|Drug|Desloratadine|Drug Administration
1638877|NCT01940393|Drug|Fexofenadine|Drug administration
1638878|NCT01940393|Drug|Ebastine|Drug administration
1638879|NCT01940393|Drug|Bilastine|Drug administration
1638880|NCT01940367|Device|PTNS (Percutaneous Tibial Nerve Stimulation|PTNS therapy is performed as follows; the subject sits in a frog leg position in a chair. The area where the needle will be placed is cleaned with an alcohol swab. A 34 gauge needle (equivalent to an acupuncture needle) is inserted percutaneously approximately 5 cm cephalad to the medial malleolus of the right or left ankle (subject choice) at a 60 degree angle. A surface electrode is placed on the medial aspect of the ipsilateral calcaneous. The needle and electrode are connected to a low voltage (9 V) electrical stimulator (Urgent PC). Stimulation current with a fixed frequency of 20 Hz and a pulse width of 200 msec is increased until flexion of the big toe or fanning of all toes becomes visible, or until the subject reports a tingling sensation across the heel or bottom of the foot. The current is then set to the highest level tolerable to the subject (0-10 mA) and the subject undergoes therapy for 30 minutes.
1638881|NCT01940367|Device|TENS (Transcutaneous Electrical Nerve Stimulation)|"TENS therapy will be administered as follows:
Surface electrodes, 2 x 2 in diameter, will be placed over sacral foramen S2-4, bilaterally, using 2 channels (4 electrodes total) - Approximate locations are over posterior superior iliac spine and inferior lateral angle of sacrum. Sticker electrodes for the duration of the study will be issued to subjects. They are adhesive and can be re-used for up to 3-4 weeks with proper skin care and electrode care.
The electrodes will be connected to the TENS (Transcutaneous Electrical Nerve Stimulation) device and the following settings will be pre-set:
Mode: Burst
Cycle: 10 seconds
Frequency: 10 Hz
Pulse Width: 250 µs
Intensity: to subject comfort level"
2012187|NCT02162667|Drug|Trastuzumab|Trastuzumab 6mg/kg is ongoing to be administered for both arms after 8mg/kg loading dose.
2012188|NCT02161562|Drug|omalizumab|150mg omalizumab via sub-cutaneous injection once every 4 weeks
1638884|NCT01940341|Drug|TAF|25 mg tablet administered orally once daily
1638885|NCT01940341|Drug|TDF|300 mg tablet administered orally once daily
1638886|NCT01940341|Drug|TAF Placebo|Tablet administered orally once daily
1638887|NCT01940341|Drug|TDF Placebo|Tablet administered orally once daily
1638888|NCT01940328|Device|Transchoracic ultrasound Doppler|
1638889|NCT01940315|Biological|rBV A/B|0.5 mL dose of rBV A/B (40 µg) given at Days 0, 28 ± 5 days, and 182 ± 9 days
1638890|NCT01940315|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of Placebo will be given at Days 0, 28 ± 5 days, and 182 ± 9 days
1638891|NCT01940302|Dietary Supplement|LEHEL multi-nutrients supplement|The primary objective of this study is to evaluate the effect of a diet program including LEHEL multi-nutrients supplement as breakfast replacement on metabolic control after 12-week intervention in subjects with type 2 diabetes.
1638892|NCT01940289|Device|Algometric meter readings for perception of pain|
1638893|NCT01940276|Drug|Abiraterone acetate|
1638894|NCT01940276|Drug|Prednisone|
1638895|NCT01940263|Dietary Supplement|Anthocyanin|
1638896|NCT01940263|Dietary Supplement|Placebo|
1638897|NCT01940250|Drug|Magnesium Sulphate|MgSO4 IV infusion
1638898|NCT01940250|Drug|Sterile water|H2O IV infusion
1638899|NCT01940237|Behavioral|Psychotherapy|Interpersonal psychotherapy in the treatment of major depressive disorder.
1638900|NCT01940224|Drug|Pregabalin|Preoperative administration of pregabalin 300mg
1638901|NCT01940224|Drug|Placebo|Preoperative administration of placebo
1638902|NCT01940224|Drug|Morphine|Postoperative administration of morphine via PCA pump for 48h
2012189|NCT02161562|Drug|omalizumab|300mg omalizumab via sub-cutaneous injection once every 4 weeks
1638904|NCT01940172|Drug|Birinapant|"Dose Escalation:
Dose Level (1) - 13 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks); Dose Level (2) - 13 mg/m2 (twice weekly for 4 weeks );"
1638905|NCT01940172|Drug|Conatumumab|10 mg/kg IV on Day 1 and 15 of each cycle
1638906|NCT01940159|Drug|SEP-363856|SEP-36385625 as a single oral dose of 25, 50, 100, and 150 mcg
1638907|NCT01940159|Drug|Placebo|single oral dose placebo
1638908|NCT01940146|Drug|SPARC Placebo|Placebo
1638909|NCT01940146|Drug|SPARC1310 I|SPARC1310 I
1638910|NCT01940146|Drug|SPARC1310 II|SPARC1310 II
1638911|NCT01940146|Drug|SPARC1310 III|SPARC1310 III
1638912|NCT01940133|Drug|PQR309|Dosing will be orally, once a day for the duration of the trial.
1638913|NCT01940120|Device|Percutaneous mitral valve repair using MitraClip implant|Procedure/Surgery: Mitral valve repair or replacement surgery Repair or replacement of mitral valve
1638914|NCT01940107|Other|evaluations|Only evaluations
1638915|NCT01940107|Procedure|Protocol of physiotherapy exercises|Oriented domiciliary physiotherapeutic exercises
2012190|NCT02160015|Drug|Ibrutinib|Given PO
2012191|NCT02160015|Other|Laboratory Biomarker Analysis|Correlative studies
1638918|NCT01940081|Other|Transthoracic echocardiography|
1638919|NCT01940081|Other|Exercise test|
1638920|NCT01940081|Other|24-hour Holter electrocardiogram|
1638921|NCT01940081|Other|Contrast-enhanced magnetic resonance imaging|
1638922|NCT01940081|Other|123-iodine metaiodobenzylguanidine imaging|
1638923|NCT01940081|Other|Blood samples|
1638924|NCT01940081|Genetic|Genetic analysis|
1638925|NCT01940081|Procedure|Invasive electrophysiological study|
1638926|NCT01940081|Procedure|Endomyocardial biopsy|
1638927|NCT01940081|Procedure|Intraoperative biopsy|
1638928|NCT01940081|Procedure|Intraoperative mapping and/or ablation|
1638929|NCT01940068|Dietary Supplement|Amino acid based formula|
1638930|NCT01940055|Behavioral|Dual task treadmill walking exercise program|Participants will receive 5 minute warm up and cool down session followed by a 30 minute dual task program which includes treadmill walking while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Treadmill speed will be set so as to not exceed 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
2012192|NCT02160015|Drug|Lenalidomide|Given PO
2012193|NCT02160015|Biological|Rituximab|Given IV
1638931|NCT01940055|Behavioral|Dual task recumbent cycling exercise program|Participants will receive a 5 minute warm up and cool down session followed by a 30 minute dual task exercise program which includes recumbent cycling while playing brain fitness or cognitive games. Rest periods will be provides to the participants. Recumbent cycling speed will be set so as to achieve 60% of maximum heart rate. Heart rate and perceived excretion( per the Borg 1-10) will be measured at 5 minutes of interval.
1638932|NCT01940042|Behavioral|CO2 was removed by means of trandelenburg positions|
1638933|NCT01940016|Behavioral|communication intervention|Participants participate in a 12-week physical activity intervention (walking program)and receive health mail messages via IVR system and had the option of communicating with a health coach.
1638934|NCT01940016|Behavioral|exercise intervention|Participants participate in a 12-week physical activity intervention administered using an IVR system.
1638935|NCT01940003|Other|Aquatic exercise|The aquatic exercise program will be under the professional guidance of a physiotherapist, with water at a temperature of around 26 to 28°C. The exercise sessions will be executed following the steps: 1) Heating (stretching and flexibility, static method, during 5'); 2) Aerobic exercise (running, displacements and combined movements of arms and legs, with 1minute interval, to 1minute activity and of during 20') 3) Spot exercises (strength / endurance of the upper and lower limbs and abdomen, using the resistance of water for 15') 4) Relaxation (slow walks for 5'). During the sessions of exercises the pregnant women will have heart rate monitored by the frequency meter (Polar Electro OY) to control the intensity of the exercises that will focus on the range of moderate intensity.
1638936|NCT01939990|Drug|Placebo|The placebo looks like the study drug but it does not contain active ingredients.
1638937|NCT01939990|Drug|Nebivolol|5 to 10mg per day
2012194|NCT02158936|Drug|Eltrombopag|Eltrombopag will be round film-coated tablets containing eltrombopag equivalent to 50 mg (white to off-white), 200 mg and 300 mg (green) of eltrombopag free acid
1638940|NCT01939964|Other|Activation Mist|Activation Mist topical spray
1638941|NCT01939951|Dietary Supplement|Activation Energy Serum|7 drops or 21 drops twice daily
1638942|NCT01939938|Device|Nasal and Oronasal PAP Mask|Subjects will be imaged via MRI wearing a nasal and oronasal PAP mask at 5, 10 and 15 cm H20.
1638943|NCT01939925|Other|New plain language summary format|New plain language summary includes qualitative and quantitative description of text (absolute effects and natural frequencies provided); quantitative results provided in a table; quality of the evidence according to GRADE provided in a table; question and answer format; follows principles of linguistic frameworks (e.g. progressive movements from introduction to 'bottom line')
1638944|NCT01939925|Other|Current plain language summary format|Current plain language summary includes qualitative description of effects only; inconsistent description of the quality of the evidence; paragraph of text; inconsistent flow of information
1638945|NCT01939912|Drug|Adenosine|Antiarrhythmic agent.
1638946|NCT01939899|Drug|IXAZOMIB|Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
1638947|NCT01939886|Drug|Mefloquine - Artesunate|
1638948|NCT01939886|Drug|Artemether-lumefantrine combination|
1638949|NCT01939873|Behavioral|KRISTELLER|
1638950|NCT01939860|Other|Written and verbal patient education on hypertension and its treatment|
2012195|NCT02158936|Drug|Azacitidine|Subcutaneous Injection (IV if local standard)
1638952|NCT01939834|Device|AAA control|"AAA control is a method to determine insulin dosing to keep glucose in range. AAA control is run on the DiAs which is a medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump. The cell phone runs the AAA control and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range.
AAA control will be tested in 40 hours sessions and 5 consecutive overnight sessions."
1638953|NCT01939834|Other|CGM + insulin pump at home|The subject will be on their home insulin pump and using a CGM per their usual care.
1638954|NCT01939821|Behavioral|Educational and counselling program|"Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice."
1638955|NCT01939821|Behavioral|Educational program|"Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals."
1638956|NCT01939808|Other|Splint Neutral|
1638957|NCT01939808|Other|Splint Extended|
1638958|NCT01939795|Other|exercise training and/or CRT|Three 40-minute exercise sessions per week on a treadmill for four months
1638959|NCT01939782|Other|No Breakfast (NoB)|In both occasions the blood samples for glucose and insulin, cortisol triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and thenat 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
1639012|NCT01939379|Drug|For the 30ml ropivacaine the intervention would be the subject can request extra pain medication which would be Percocet and/or morphine PCA.|
1639013|NCT01939366|Drug|Cebranopadol 100 µg|Participants randomized to 100 μg cebranopadol will start with 100 μg per day and will remain on 100 µg per day.
2012196|NCT02158936|Drug|Placebo|Eltrombopag matching placebo tablets will be supplied
2012197|NCT02156895|Drug|Axitinib|based on Axitinib approval
2012198|NCT02151695|Procedure|panretinal photocoagulation|
2012199|NCT02151695|Drug|Aflibercept intravitreal injections|
2012200|NCT02151643|Drug|PT20|Modified ferric oxide adipate
1638960|NCT01939782|Other|Yes Breakfast (YesB)|In both occasions the blood samples for glucose and insulin, cortisol, triglycerides and intact GLP-1 will be taken after overnight fast at 8:30 and then at 8:30, 9:00, 10:30, 12:00, 12:30, 14:00 and 15:30. The samples for clock genes and for DPP4 plasma activity will be taken at 8:30, 12:00 (before lunch) and at 15:30 (3 1/2 h after lunch).
1638961|NCT01939769|Other|Exercise - Low-intensity exercise|
1638962|NCT01939769|Other|Exercise - High-intensity exercise|
1638963|NCT01939756|Device|Intravesical baobab oil|Intravesical baobab oil
1638964|NCT01939743|Drug|Diclofenac suppository plus lidocaine gel|
1638965|NCT01939743|Drug|Lidocaine gel only|
1638966|NCT01939730|Drug|Rituximab|375 mg/m^2 by vein once a week for 4 weeks on Days 1, 8, 15, 22.
1638967|NCT01939730|Drug|GM-CSF|250 mcg subcutaneously 3 times a week for 8 weeks.
1638968|NCT01939717|Other|Dance group|"Participants will attend ten weeks of set dancing classes. Each class will be one and half hours. Family members will be invited to partner each participant with Parkinson's disease during the class. Set dancing steps and sets will be thought and progressed in line with the participants abilities. Frequent rests will be taken during the classes.
Participants will be given a home exercise programme which will involve chair based exercises, mental rehearsal, listening music, watching a dance DVD and practicing dance material thought in class."
1638969|NCT01939704|Other|Pediatric Primary Care Intervention|30 minute on-site intervention with biweekly follow up phone calls to address social needs and health care status.
1638970|NCT01939704|Other|Pediatric Urgent Care Intervention|3 months of intervention protocol, including a 30 minute on-site intervention and twice monthly phone calls to address social needs and health care status.
1638971|NCT01939691|Drug|Difluprednate 0.05% ophthalmic emulsion|eyedrop
1638972|NCT01939691|Drug|Nepafenac 0.1% ophthalmic solution|eyedrop
1638973|NCT01939691|Drug|Prednisolone acetate 1% ophthalmic suspension|eye drop
1638974|NCT01939665|Device|"NanoKnife Irreversible electroporation (IRE)"|Tumor ablation with irreversible electroporation with the NanoKnife
1638975|NCT01939652|Procedure|Restrictive VS Standard Fluid Regime|
1638976|NCT01939652|Drug|Drag: Crystalloids and Colloids|
1638977|NCT01939639|Drug|Placebo|intranasal application, sodium chloride solution, 3 puffs per nostril
1638978|NCT01939639|Drug|Oxytocin|24 IU Oxytocin, intranasal application 45 min prior to the experiment
1638979|NCT01939626|Device|Single-step medium|This medium will allow in vitro culture of human embryos for 5/6 days
1638980|NCT01939613|Drug|colloids|TMMU group allows for administration of colloids early,while Parkland group infuse colloids 24 h after burn injury.
1638981|NCT01939600|Other|Starch-free breakfast|Starch-free breakfast alone
1638982|NCT01939600|Other|Hi-Maize 260|Starch-free breakfast plus 55.3g Hi-Maize 260
1638983|NCT01939600|Other|Hylon VII|Starch-free breakfast plus 56.9g Hylon VII
1638984|NCT01939600|Other|Amioca|Starch-free breakfast plus 56.4g amioca starch
1638985|NCT01939587|Drug|PBF-680 5 mg|
1638986|NCT01939587|Drug|PBF-680 20 mg|
1638987|NCT01939587|Drug|Placebo|
1638988|NCT01939574|Other|Chemoradiation Therapy|"Radiation therapy:For both intensity-modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) plans, one treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks.
Temozolomide will be administered continuously from day 1 of radiotherapy to the last day of radiation at a daily oral dose of 75 mg/m2 for a maximum of 49 days.
Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle,at the beginning of the 4th week of radiation. The dose will be 10 mg/kg of actual body weight."
1638989|NCT01939574|Other|Adjuvant Therapy|"Temozolomide will be administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events> grade 2 are noted.
Bevacizumab will be administered intravenously on days 1 and 15 of each 28-day cycle. The dose will be 10 mg/kg of actual body weight."
1638990|NCT01939561|Drug|Lamotrigine|
1638991|NCT01939561|Drug|Placebo|Placebo is tablets identically with the Lamotrigine tablets.
1638992|NCT01939548|Drug|PF-02545920|PF-02545920 2 mg BID x 7 days, then 5 mg BID until the Week 12 visit
1638993|NCT01939548|Drug|Placebo|Placebo BID until the Week 12 visit
1638994|NCT01939548|Drug|PF-02545920|PF-02545920 5 mg BID x 7 days, then 10 mg BID x 7 days, then 15 mg BID until the Week 12 visit
1638995|NCT01939535|Other|No intervention|Evaluation of an imaging technique ic MRI
1638996|NCT01939522|Biological|13-valent pneumococcal conjugate vaccine (PCV13)|
1638997|NCT01939509|Drug|Atenolol|Crossover (atenolol 25-50 mg, bisoprolol 2.5-5 mg)
1638998|NCT01939509|Drug|Bisoprolol|
1638999|NCT01939496|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
1639000|NCT01939496|Drug|Placebo|One matching placebo capsule orally in addition to the patient's anti-hyperglycemic agents (AHA) regimen used in accordance with local prescribing information.
1639001|NCT01939483|Drug|irinotecan hydrochloride|Given IV
1639002|NCT01939483|Other|laboratory biomarker analysis|Correlative studies
1639003|NCT01939457|Drug|Misoprostol|
1639004|NCT01939444|Drug|naloxone intranasal|If bioavailability is 20% or 50 %, the dose will be equivalent to the clinical range 0.4 - 1.0 mg given parenterally
1639005|NCT01939444|Drug|naloxone intravenous|The parenteral dose reflects clinically used doses for overdoses (0.4 - 1.0 mg). A washout period of at least 3 days between each intervention. IV naloxone (Naloxone B. Braun 0.4mg/ml) administered slowly over 1-2 min in the recumbent position
1639006|NCT01939418|Drug|RAD001|Afinitor 5mg qd. po.
1639007|NCT01939418|Drug|Gemcitabine|gemcitabine 800mg/m2 iv. D1 and D8 every 3 weeks
1639008|NCT01939418|Drug|Cisplatin|cisplatin 30mg/m2 iv. D1 and D8 every 3 weeks
1639009|NCT01939405|Behavioral|built environment use counseling|
1639010|NCT01939392|Device|Renal Denervation (OneShot™ Renal Denervation System)|
1639011|NCT01939379|Drug|Morphine PCA started at the end of surgery, 1 Percocet 1/325mg every 4 hours; may receive a second Percocet if needed.|
1716066|NCT00000945|Drug|Cidofovir|
1639014|NCT01939366|Drug|Cebranopadol 300 µg|Participants randomized to 300 μg cebranopadol will start with 100 μg per day and increase to 300 µg per day on day 4 and will remain on 300 µg per day.
1639015|NCT01939366|Drug|Cebranopadol 600 µg|Participants randomized to 600 μg cebranopadol will start with 200 μg per day and increase to 400 µg per day on day 4 and to 600 µg on day 7, thereafter they will remain on 600 µg per day.
1639016|NCT01939366|Drug|Pregabalin|Stepwise titration from 75 mg twice a day to 300 mg twice a day over 2 weeks.
1639017|NCT01939366|Drug|Matching Placebo|Placebo will be matched to pregabalin and cebranopadol.
1639018|NCT01939353|Drug|EB-1020 SR|100-500 mg flexible titration
1639019|NCT01939353|Drug|Matching Placebo|
2012201|NCT02151643|Drug|Placebo|Placebo matched to each drug arm
1639021|NCT01939314|Drug|Bupivacaine|Bupivavaine Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
1639022|NCT01939314|Drug|Placebo|Normal Saline Delivered by the Tx 360 Device to the Sphenopalatine Ganglion
1639023|NCT01939301|Drug|Nitric Oxide + oxygen|
1639024|NCT01939301|Drug|Nitrogen + Oxygen|
1639027|NCT01939275|Radiation|copper Cu 64-DOTA-trastuzumab|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
1639028|NCT01939275|Device|positron emission tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
1639029|NCT01939275|Other|laboratory biomarker analysis|Correlative studies
1639030|NCT01939275|Procedure|Computed Tomography|Undergo Copper Cu 64-DOTA-trastuzumab PET/CT scan
1639031|NCT01939262|Other|Limitation of Animal Fat and Protein in the Diet|Animal products were proscribed and the use of unrefined foods was encouraged. Participants were asked to limit high-fat plant foods, such as nuts, avocados, and refined oils. There was no restriction in energy intake, were encouraged to eat freely and not count calories.
1639032|NCT01939262|Other|Control|Participants assigned to the control group will be instructed to follow their usual diets.
1639033|NCT01939249|Device|Abbott Laboratories Xience|
1639034|NCT01939249|Device|Biotronik Orsiro|
1639035|NCT01939236|Drug|traditional Chinese medicine|1 bag of drug 2 times per day for 28 days according to syndrome differentiation. For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28days.
1639036|NCT01939236|Drug|Placebo (gummeline)|"Placebo of each syndrome differentiation has the same weight and smell as traditional Chinese medicine of corresponding syndrome differentiation.
1 bag of drug 2 times per day for 28 days according to syndrome differentiation.
For example, the syndrome of one patient is qi deficiency and blood stasis, he will take drugs of qi deficiency and blood stasis each bag 2 times per day for 28 days."
1639039|NCT01939210|Procedure|4-Dimensional Computed Tomography|Undergo 4D-CT
1639040|NCT01939210|Other|Educational Intervention|Participate in breathing training sessions
1639041|NCT01939210|Procedure|Meditation Therapy|Participate in breathing training sessions
1639042|NCT01939210|Other|Questionnaire Administration|Ancillary studies
1639043|NCT01939210|Radiation|Radiation Therapy|Undergo standard radiation therapy
1639044|NCT01939210|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1639048|NCT01939184|Drug|WC3055|12.5, 25, 50 or 75 mg dose
1639049|NCT01939184|Other|Placebo|Placebo
1639050|NCT01939171|Drug|Thymoglobulin|
1639051|NCT01939158|Biological|Meningococcal vaccine GSK134612|1 or 2 doses administered intramuscularly in the left anterolateral thigh or deltoid region
1639052|NCT01939158|Biological|Prevenar 13™|1 dose administered intramuscularly in the right anterolateral thigh or deltoid region
1639053|NCT01939145|Drug|Normal saline|Normal saline (0.9% NaCl) is an isotonic solution that is widely used for intravenous application but is also used as our SOC for wound irrigation. This solution has high tolerability. Normal saline has been used as the instillation solution for NPWTi. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies
1639054|NCT01939145|Device|Prontosan|Prontosan (B Braun, Bethlehem, PA) is 0.1% polyhexanide, 0.1% betaine, sodium hydroxide, and purified water. The polyhexanide is an antiseptic and betaine is a surfactant. This solution is an FDA approved device indicated for topical irrigation. This solution has high tolerability with robust antimicrobial activity. Polyhexanide has been utilized as the instillation solution for NPWTi with positive clinical results. Prontosan is currently being used as the instillation solution for NPWTi in this facility as the SOC. The dwell setting for this solution is 20 minutes. The volume of solution to be used is dependent on the size of the wound hence varies.
1639055|NCT01939132|Drug|Open label H.P. Acthar Gel|Open-label H.P. Acthar Gel 80 units given subcutaneously twice weekly for 12 weeks with 12 week extension.
1639057|NCT01939093|Drug|Diazepam|If subjects had aggressive or violent symptoms and immediate symptom control was needed, 10 mg of diazepam (intravenous injection) every 4 hours is allowed for symptom control.
1639058|NCT01939093|Dietary Supplement|Vitamin B1-6-12|All subjects will be given the Institute's medication regimen, including vitamin B1-6-12 1 tablet three times a day after meals during the whole study period.
1639059|NCT01939093|Drug|Stugeron|All subjects will be given the Institute's medication regimen, including stugeron 1 tablet three times a day after meals during the whole study period.
1639060|NCT01939080|Procedure|Exercise training with supervised sessions|
1639099|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
1639100|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
1639101|NCT01938846|Drug|paclitaxel|paclitaxel once weekly
1639102|NCT01938833|Drug|Romidepsin|
1639103|NCT01938833|Drug|Abraxane|
1639061|NCT01939067|Device|Heated Humidified High Flow Nasal Cannula|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on HHHFNC and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
1639062|NCT01939067|Device|Nasal Continuous Positive Airway Pressure|Biweekly measurement of lung mechanics (dynamic compliance, airway resistance, work of breathing) and chest wall asynchrony measures while on NCPAP and weekly when weaned off until 40 weeks post conceptional age or discharge. Recording of the level and the type of respiratory support and all cross over respiratory support devices. Recording of all growth parameters, neonatal morbidities and therapies.
1639063|NCT01939054|Drug|Nimotuzumab|
1639064|NCT01939054|Drug|docetaxel|
1639065|NCT01939054|Drug|capecitabine|
1639066|NCT01939041|Device|InMotion3 (IMT)|Participant will practice about 2-5-minute of passive, 25-30-minute of assisted-active, and 3-5-minute of active motions in wrist and forearm respectively. The wrist motions will include flexion, extension, radial deviation, and ulnar deviation. Forearm motions will include supination and pronation. During the practice, a visual display will provide online visual feedback of accuracy and coordination success.
1639067|NCT01939041|Device|Bi-Manu-Track (BMT)|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
1639068|NCT01939041|Behavioral|Control intervention (CI)|he control group's therapy will be designed to control for the duration and intensity of the robot-assisted training (90 min/day, 5 days/wk, for 4 wk). The therapeutic activities in the control group will involve passive range of motion, weight bearing, stretching, strengthening of the paretic arm, gross motor activities, coordination tasks, unilateral and bilateral fine motor tasks, transition, mobility, and posture/balance.
1639069|NCT01939028|Procedure|lymph node mapping|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
1639070|NCT01939028|Procedure|sentinel lymph node biopsy|Undergo SLN biopsy
1639071|NCT01939028|Drug|isosulfan blue|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
1639072|NCT01939028|Drug|indocyanine green solution|Undergo lymph node mapping using isosulfan blue and/or indocyanine green solution
1639073|NCT01939028|Procedure|therapeutic conventional surgery|Undergo hysterectomy, bilateral salpingo-oophorectomy and/or complete pelvic lymphadenectomy
1639074|NCT01939028|Procedure|lymphadenectomy|Undergo para-aortic lymphadenectomy
1639075|NCT01939015|Device|3D titanium miniplate|for study group by using 3D titanium miniplate under open reduction under general anesthesia with mono cortical screw, while in control group single titanium miniplate at superior border with mono cortical screw according to ideal line of osteosynthesis of champy
1639076|NCT01939015|Device|Standard titanium miniplate- single non compression miniplate|single non compression miniplate placed at superior border with monocortical screws via intraoral approach
1639077|NCT01939002|Drug|BIIB017|
1639078|NCT01939002|Drug|naproxen|
1639079|NCT01938989|Device|Clear clip-on glasses|Clip-on glasses with no light filtering properties
1639080|NCT01938989|Device|Blue light filter clip-on glasses|Clip-on glasses with blue light filtering properties equivalent to AcrySof IOLs
1639081|NCT01938976|Behavioral|TAJ Plus (Adolescent Asthma Action in Jordan) Plus the added class smoke free pledge|Its is a school-based peer-led asthma and smoking prevention program that aims at improving asthma control and lowering nicotine dependence among smokers.
1639082|NCT01938963|Behavioral|Collaborations in Health (COACH)|Primary care provider, aging worker, and Psychiatrist Consultant are trained to collaborate in their shared clients' care.
1639083|NCT01938950|Other|Aerobic Exercise|
1639084|NCT01938950|Other|Resistance Exercise|
1639085|NCT01938950|Other|Aerobic and Resistance Exercise|
1639086|NCT01938937|Device|Transcranial bright light device|
1639087|NCT01938937|Device|Transcranial sham device|
1639088|NCT01938924|Device|GekoTM|electrical neuromuscular stimulation
1639089|NCT01938911|Drug|Syntocinon-Spray|Intranasal oxytocin (24 IU)
1639090|NCT01938911|Drug|Placebo of syntocinon|Intranasal administration
1639091|NCT01938911|Behavioral|Social support|Social support from the best friend
1639092|NCT01938898|Other|Invitation letter randomisation|"There are 12 versions of the invitation letter. Three aspects of the letter will be adapted: (1) Gender of the signatory i.e. male, female or gender neutral (signed from the NICOLA team) (2) Description of NICOLA as a 'study' or 'project' and (3) Inserting a sentence guaranteeing the participants confidentially or not having this in the letter (but will still appear in the Patient Information Sheet). The twelve versions are as follows:
Male & Study & Confidentiality
Male & Study
Male & Project & Confidentiality
Male & Project
Female & Project & Confidentiality
Female & Project
Female & Study & Confidentiality
Female & Study
Neutral & Study & Confidentiality
Neutral & Study
Neutral & Project & Confidentiality
Neutral & Project"
1639093|NCT01938872|Procedure|paclitaxel eluting balloon angioplasty in below-the-knee lesions|
1639094|NCT01938859|Drug|Lithium|Lithium plasma concentration was between 0.6-1.2 mmol/L, dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
1639095|NCT01938859|Drug|Quetiapine|Quetiapine adjunctively to lithium therapy, target 400 mg/d with a minimum dose of 200 mg/d. Dose should be fixed at the end of week 4, and the maximum dosage was judged by the investigator based on the patients' tolerability.
1639096|NCT01938859|Drug|Shuganjieyu capsule|Shuganjieyu capsule adjunctively to lithium therapy, target dose 1440 mg/d.
1639097|NCT01938846|Drug|BI 860585|BI 860585 multiple dose escalation, once daily
1639098|NCT01938846|Drug|exemestane|exemestane once daily
1716067|NCT00000945|Drug|Probenecid|
1639104|NCT01938820|Drug|entecavir|anti-viral therapy
1639105|NCT01938820|Drug|Thymosin-α|antiviral and antifibrosis therapy
1639106|NCT01938807|Behavioral|CareCoach mobile application to assist in diabetes management|
1639107|NCT01938781|Drug|entecavir|antiviral therapy
1639108|NCT01938781|Drug|Peg-IFN|antiviral and antifibrosis therapy
1639109|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 60 mg dextrose
1639110|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 80 mg dextrose
1639111|NCT01938755|Drug|levobupivacaine|levobupivacaine plus 100 mg dextrose
1639112|NCT01938742|Biological|Influenza Virus Vaccine, Monovalent A/H7N9 A/Shanghai/2/2013|Monovalent influenza A/H7N9 virus vaccine for intramuscular use is a sterile, clear and slightly opalescent suspension. sanofi A/H7N9 antigen. Group 1 receives 3.75mcg A/H7N9 IM on days 1 and 21, Group 2 receives 7.5 mcg IM on days 1 and 21, Group 3, 4, 5, & 6 receives 15 mcg IM on days 1 and 21, and Group 7 receives 45 mcg IM on days 1 and 21.
1639113|NCT01938742|Drug|MF59|MF59 adjuvant is an oil-in-water emulsion composed of a small amount of squalene administered with different dosages. Group 1, 2 & 3 receives 0.7 ml of MF59 Intramuscularly (IM) on days 0 and 21. Group 4 receives MF59 on day 0, Group 5 receives MF59 on Day 21.
1639114|NCT01938729|Procedure|Liver resection and placement of hepatic artery infusion pump|
1639115|NCT01938729|Drug|FLOXURIDINE|
1639116|NCT01938729|Drug|DEXAMETHASONE|
1639117|NCT01938729|Drug|GEMCITABINE|
1639118|NCT01938716|Drug|Gemcitabine|500 mg/m2 at a fixed dose rate of 10 mg/m2/min by vein for the first 5 patients during pancreatic surgery. Next 15 subsequent patients receive 750 mg/m2 by vein at a fixed dose rate of 10 mg/m2/min.
1639119|NCT01938690|Device|Transcranial magnetic stimulation (TMS)|8 sessions of TMS followed by task specific training
1639120|NCT01938677|Radiation|Initial Gamma knife radiosurgery|
1639121|NCT01938664|Drug|Candesartan|8 mg, po (by mouth)
1639122|NCT01938664|Drug|Placebo|
1639123|NCT01938651|Procedure|high field strength magnetic resonance imaging|Undergo 7T MRI
1639124|NCT01938651|Procedure|magnetic resonance spectroscopic imaging|Undergo 31P MRS
1639125|NCT01938651|Procedure|chemical exchange saturation transfer magnetic resonance imaging|Undergo CEST-MRI
1639126|NCT01938651|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
1639127|NCT01938651|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
1639129|NCT01938625|Drug|Simeprevir|Participants will receive 150 milligram capsule of simeprevir orally (by mouth) once daily with food for 24 weeks. In Part 1, if simeprevir pre-dose plasma concentration is greater than 7,300 nanogram per milliliter (ng/mL), participants will receive simeprevir 150 milligram capsule orally every other day to complete 24 weeks of treatment.
1639130|NCT01938625|Drug|Daclatasvir|Participants will receive 60 milligram tablet of daclatasvir orally once daily for 24 weeks.
1639131|NCT01938625|Drug|Ribavirin|Participants will receive 5 or 6 tablets of 200 milligram of ribavirin orally twice a day with food for 24 weeks.
1639132|NCT01938625|Drug|Cyclosporine|Participants will receive cyclosporine as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Cyclosporine will be administered as per the manufacturer's prescribing information for 24 weeks.
1639133|NCT01938625|Drug|Tacrolimus|Participants will receive tacrolimus as one of the stable immunosuppressant therapy (no change in dose in the last month) for more than 3 months prior to the screening visit. Tacrolimus will be administered as per the manufacturer's prescribing information for 24 weeks.
1639134|NCT01938612|Drug|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21 or 28 days.
1639135|NCT01938612|Drug|tremelimumab|tremelimumab is administered by IV infusion every 4 weeks
1639136|NCT01938599|Drug|AM001 Cream, 7.5%|Cream, 2x daily for 12 weeks
1639137|NCT01938599|Drug|Placebo of AM001 Cream|Cream, 2x daily for 12 weeks
1639138|NCT01938586|Other|Steri-Strip|
1639139|NCT01938586|Other|Superficial sutures|
1639145|NCT01938560|Other|Survey Responses|Subject understanding of the risk of urinary retention and the symptoms of acute urinary retention associated with retigabine will be assessed using the survey instrument.
1639146|NCT01938547|Drug|clevidipine|
1639147|NCT01938534|Drug|Helicobacter pylori eradication|
1639148|NCT01938521|Dietary Supplement|Red Grape Cells (RGC)|Red Grape Cells (RGC) 1000 mg powder once daily by mouth for three month
1639149|NCT01938521|Dietary Supplement|Placebo (for Red Grape Cells (RGC))|Placebo (for Red Grape Cells (RGC)) powder manufactured to mimic Red Grape Cells (RGC) 1000 mg powder
1639150|NCT01938508|Drug|Minocycline|minocycline hydrochloride capsules in microgranules equivalent to 100 mg of minocycline
1639151|NCT01938495|Device|NeuRx® Diaphragm Pacing System™ (DPS)|The NeuRx® Diaphragm Pacing System™ (DPS) is a four channel, implanted percutaneous diaphragm muscle stimulation system. Pictures of the device are provided in the Clinician's Manual for the NeuRx® DPS procedure and technique guide from the manufacture Synapse Biomedical, Inc. Under general anesthesia, the intramuscular electrodes are laparoscopically implanted in the diaphragm. The ends of the implanted electrodes are tunneled subcutaneously to an exit site on the chest or abdominal wall and connected to an external stimulator.
1639152|NCT01938482|Drug|0.3% GSK1940029 gel|Will be supplied as gel for topical application
1639153|NCT01938482|Drug|1% GSK1940029 gel|Will be supplied as gel for topical application
1639154|NCT01938482|Drug|0.3%/1% vehicle gel only|Will be supplied as gel for topical application
1639155|NCT01938469|Other|Liquid Meal|
1639156|NCT01938469|Other|Solid Meal|
1639157|NCT01938456|Drug|Trametinib|Biconvex film coated oral tablets for once daily use with unit dosage strength of 0.5mg and 2.0 mg for dose level of 2.0mg, 1.5mg, 1.0mg, and 0.5mg
1639498|NCT01935947|Drug|Entinostat|Given PO
1639499|NCT01935947|Drug|Gemcitabine Hydrochloride|Given IV
1639158|NCT01938456|Drug|Docetaxel|Yellow or brownish yellow solution for injections with unit dosage strength of 20mg and 80 mg for intravenous infusion once every 3 weeks over at least one-hour infusion
1639159|NCT01938456|Drug|Filgrastim|Clear and colorless solution for once daily sub-cutaneous injection with unit dosage strength of 75 micrograms (mcg) for dose level of 50 mcg/meter^2 or 75 mcg/body
1639160|NCT01938443|Drug|GSK2256098|GSK2256098 250 mg will be supplied as white to off-white, round, biconvex tablets with no markings. GSK2256098 will be administered 30 minutes after a light meal with approximately 240 milliliter of water.
1639161|NCT01938443|Drug|Trametinib|Trametinib 0.5 mg will be supplied as capsules with no identifying markings. Trametinib will be administered orally under fasting conditions two hours after a meal.
1639162|NCT01938430|Drug|LDV/SOF|LDV/SOF FDC tablet administered orally once daily
1639163|NCT01938430|Drug|RBV|RBV tablets administered orally in a divided daily dose
1639164|NCT01938417|Drug|tobramycin|
1639165|NCT01938404|Biological|Octaplas|Octoplas infusion solution for IV administration
1639166|NCT01938404|Drug|Standard Plasma|Plasma given as replacement fluid
1639167|NCT01938391|Device|Stealth 360°® OAS|Cardiovascular Systems, Inc. Orbital Atherectomy System (OAS) is used prior to adjunctive balloon angioplasty (BA)
1639168|NCT01938378|Biological|Octaplas™|octaplas™ infusion solution for IV administration, ABO compatibile. Recommended dose for a plasma exchange is 40 to 60 ml/kg.
1639169|NCT01938352|Biological|CR8020|CR8020 15 mg/kg, administered by intravenous infusion
1639170|NCT01938352|Biological|Placebo|Placebo (hydrous dextrose in water for injection), administered by intravenous infusion
1639171|NCT01938339|Device|PET/MR|Multi-radiotracer PET/MR will be performed in patients with primary and recurrent prostate cancer
1639172|NCT01938326|Procedure|Approach Method|SIDG : 1 incision (umbilicus 2.5cm) TLDG : 5 incisions (12mm ports X 3, 5mm ports X 2, umbilicus extension up to 3cm for specimen delivery)
1639173|NCT01938313|Procedure|ERAS perioperative cares|"Patient's preoperative counseling & education before surgery
No Bowel preparation
Oral Carbohydrate Solution (OCS) loading until 2hours before surgery
Fluid restriction & Management by pulse contour analysis or transesophageal doppler
Early mobilization
Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))
Epidural patient controlled analgesics (no opioids analgesics)
Postoperative Nausea Active Control
Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)
Perioperative High content Oxygen therapy
No drain insertion
No Levin tube
Patients will be discharged at POD#4 if there's no problem."
1639174|NCT01938313|Procedure|Conventional perioperative cares|"No Patient's preoperative counseling & education before surgery
Bowel preparation
No Oral Carbohydrate Solution (OCS) loading until 2hours before surgery
Conventional Fluid Management by clinical signs (Urine output, heart rate etc.)
Conventional Mobilization
Conventional oral feeding (POD#2 SOW, #3 SFD, #4 SBD)
IV PCA
Postoperative Nausea Control if needed
No Thromboembolism prophylaxis
No or Low Content Oxygen therapy
Routine drain insertion
Levin tube insertion if needed"
1639175|NCT01938300|Drug|Magnesium Sulfate|
1639176|NCT01938300|Drug|Normal saline|
1639177|NCT01938287|Device|SENSIMED Triggerfish|
1639178|NCT01938274|Other|Educational intervention|A 30-minute discussion and slide presentation with a trained member of the research team.
1639179|NCT01938261|Drug|paracetamol|
1639180|NCT01938261|Drug|0.45 % saline solution|Placebo
1639181|NCT01938248|Drug|Apixaban|apixaban at a dose of 5 mg twice daily (2.5 mg twice daily if 2 or more of: age > 80, weight ≤ 60 kg or serum creatinine ≥ 133 mmol/L)
1639182|NCT01938248|Drug|aspirin|aspirin 81 mg once daily
1639183|NCT01938235|Drug|Exenatide|Intravenous bolus and 24-hour infusion of exenatide
1639184|NCT01938235|Drug|Placebo|Intravenous bolus and 24-hour infusion of placebo
1639185|NCT01938222|Procedure|Short Stitch|MonoMax® suture material USP (United States Pharmacopeia) 2/0, 150 cm, HR (half-round) 26 mm needle, will be applied in the short stitch technique (6:1) for abdominal wall closure.
1639186|NCT01938209|Other|seated thoracic manipulation|seated general thoracic spine manipulation
1639187|NCT01938209|Other|supine specific thoracic spine manipulation|supine specific thoracic spine manipulation
1639188|NCT01938196|Drug|KWA-0711|
1639189|NCT01938196|Drug|Placebo|
1639190|NCT01938183|Procedure|Full-mouth periodontal debridement|full-mouth periodontal debridement using an ultrasonic device in a single session for approximately 1 hour
1639191|NCT01938183|Drug|Metronidazole tablet|750 mg metronidazole tablets
1639192|NCT01938183|Drug|placebo gel|semi-solid suspension containing carbopol
1639193|NCT01938183|Drug|Metronidazole benzoate gel|15% Mtz benzoate in semi-solid suspension containing carbopol (gel)
1639194|NCT01938170|Biological|FluMist|Subjects receiving Flumist vaccine
1639195|NCT01938157|Procedure|Diffusion-weighted MR imaging|An addition 90 seconds of DWI will be added to a clinical breast MRI for all patients agreeing to participate in the study.
1639196|NCT01938144|Drug|Advil Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine tablet, 4x/day, up to 8 doses.
1639197|NCT01938144|Drug|Advil Allergy and Congestion Relief|Orally adminstered, 200 mg Ibuprofen/10 mg Phenylephrine/4 mg Chlorpheniramine tablet, 4x/day, up to 8 doses.
1639198|NCT01938144|Drug|Paracetamol|Acetaminophen 500 mg, 4x/day, up to 8 doses.
1639199|NCT01938131|Device|repeated Muscle Vibration (rMV) (Cro ® System)|The patients will be subjected to 3 daily applications of rMV of 10 minutes each, for 3 consecutive days. Between two successive applications will be observed a break of at least 15 seconds. The probe of the specific instrument (Cro ® System) will be placed near the supero-medial margin of the patella, on both quadriceps
1639200|NCT01938118|Behavioral|Obesity Prevention Group|
1639201|NCT01938118|Behavioral|Injury Prevention Group|
1639202|NCT01938105|Other|Nimotuzumab+chemoradiotherapy|Nimotuzumab 200mg per week will be administered concurrent with platinum-based chemotherapy and intensity-modulated radiation therapy. After the preoperative treatment, patients will be assessed for tumor response and operability. For those who are considered to be candidates for operation, radical surgery will be performed.
1639203|NCT01938092|Drug|Diazepam|
1639204|NCT01938092|Drug|Placebo|
1639500|NCT01935947|Drug|Irinotecan Hydrochloride|Given IV
1716421|NCT00001113|Drug|Interferon alfa-n1|
1639205|NCT01938079|Drug|Ketamine|Ketamine will be initiated as a one-time 40 mg bolus of ketamine followed by a continuous intravenous infusion of 5 micrograms/kg/min at the start of ECMO.
1639206|NCT01938079|Other|Sedative drug regimen|(Standard of Care) Fentanyl or hydromorphone and midazolam infusions will be administered to all patients and titrated at the discretion of the attending physician to maintain the desired level of sedation.
1639207|NCT01938066|Device|Procellera|bioelectric wound dressing
1639208|NCT01938066|Device|negative pressure therapy|
1639209|NCT01938053|Other|Call when test results are ready|Patients are called when the test results are ready
1639210|NCT01938053|Other|Text message when test results are ready|Patients receive a text message when results are ready
1639211|NCT01938053|Other|Call and text message when test results are ready|Patients receive both a call and a text message when test results are resay
1639212|NCT01938040|Drug|ibuprofen|single preoperative dose prior to surgery
1639213|NCT01938040|Other|sugar water/placebo|single preoperative dose prior to surgery
1639214|NCT01938027|Procedure|Transanal total mesorectal excision|Laparoscopy-assisted transanal total mesorectal excision
1639218|NCT01937988|Other|Doula Arm|
1639219|NCT01937975|Drug|Grazoprevir|100 mg oral tablet administered once a day for 10 days
1639220|NCT01937975|Drug|Elbasvir|50 mg oral tablet administered once a day for 10 days
1639221|NCT01937949|Device|Custom-made Zenith® Fenestrated AAA Endovascular Graft:|The graft will be inserted through arteries in the leg (called endovascular repair). Endovascular repair is a procedure that uses catheters that go inside your blood vessel to place a stent graft above and below the aneurysm. This procedure lines the aneurysm with a new lining (stent) so blood does not fill the artery any more.
1639222|NCT01937936|Behavioral|Cognitive Behavioral Therapy (CBT)|Family caregivers in the CBT group will receive 8 1-hour weekly Cognitive Behavioral Therapy (CBT) sessions, which will take place in their home.
1639223|NCT01937936|Behavioral|Health Education|Family caregivers in the Education group will receive 8 1-hour weekly sessions of general health education on selected topics, which will take place in their home.
1639224|NCT01937910|Behavioral|TRAIT Task|Increased paretic arm will be manipulated through the performance of a semi-immersive virtual reality-based intercept and release task called TRAIT (TRack And Intercept Task), which is performed in an interactive environment. TRAIT employs an open source Kinect sensor, which tracks 3-D joint movement. Participants are asked to control an on-screen icon using movements of their paretic arm to intercept a moving object as it emerges from the side of a computer screen. Once intercepted, they must accurately throw the object to hit a target. Participants move up through 10 levels of the game as their skill improves. Participants will complete 10 TRAIT training sessions in 4 weeks for a total of 10,000 experimental movements.
1639225|NCT01937897|Other|Bi-lateral massage|Unilateral massage on the left side of the body.
1639226|NCT01937884|Drug|Parenteral Nutrition|
1639227|NCT01937871|Drug|5 mg Tadalafil|Administered orally
1639228|NCT01937871|Drug|Placebo|Administered orally
1639229|NCT01937871|Drug|0.2 mg Tamsulosin|Administered orally
1639230|NCT01937832|Drug|Faropenem|dosage form: Injection dosage:1200 mg frequency: Three times a day
1639231|NCT01937832|Drug|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
1639232|NCT01937819|Device|SMART arm|The SMARTPHONE application for self judging bowel preparation by taking the picture of stool form.
1639233|NCT01937806|Drug|besifovir 150mg|Besifovir 150 mg q.d. + Placebo of Tenofovir Disoproxil Fumarate 300 mg q.d. + L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
1639234|NCT01937806|Drug|tenofovir 300mg|Placebo of Besifovir 150 mg q.d. + Tenofovir Disoproxil Fumarate 300 mg q.d. + Placebo of L-carnitine (L-Carn Tab. 330 mg) 660 mg q.d.
1639235|NCT01937793|Other|effortful swallowing exercise|voluntarily increases the posterior tongue base pushing effort while swallowing
1639236|NCT01937793|Other|Mendelsohn swallowing exercise|voluntarily increase the extent and duration of laryngeal elevation while swallowing
1639237|NCT01937767|Drug|Remimazolam|
1639238|NCT01937767|Drug|Propofol|
1639239|NCT01937767|Drug|Sevoflurane|
1639240|NCT01937767|Drug|Remifentanil|
1639241|NCT01937767|Drug|Fentanyl|
1639242|NCT01937767|Drug|Rocuronium|
1639243|NCT01937754|Dietary Supplement|Nitric Oxide supplement|Lozenge consisting of beetroot and 75 mg caffeine
1639244|NCT01937754|Dietary Supplement|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
1639245|NCT01937728|Drug|A: Peg-interferon alpha-2a & Ribavirin|Arm A: Patients who have low viral loads (LVL, defined as baseline HCV RNA < 400,000 IU/mL) and RVR will be treated with PEGASYS 180ug/week and Ribavirin 1000-1200 mg/day for 24 weeks with a follow-up period of 24 weeks.
1639246|NCT01937728|Drug|B: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.
Arm B: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 36 weeks with a follow-up period of 24 weeks."
1639247|NCT01937728|Drug|C: Peg-interferon alpha-2a & Ribavirin|"Patients who have HVL and an RVR will be randomized into arm B or arm C with a ratio of 1:1.
Arm C: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
1639248|NCT01937728|Drug|D: Peg-interferon alpha-2a & Ribavirin|Arm D: Patients who do not achieve a RVR but have HCV RNA PCR-seronegative at week 12 of treatment will be treated with PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks.
1639249|NCT01937728|Drug|E: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.
Arm E: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 48 weeks with a follow-up period of 24 weeks."
1639296|NCT01937364|Drug|Baclofen|Baclofen 10 mg every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
1716422|NCT00001114|Drug|Interferon alfa-2b|
1639250|NCT01937728|Drug|F: Peg-interferon alpha-2a & Ribavirin|"Patients who do not achieve a RVR and remain HCV RNA PCR-seropositive at week 12 of treatment will be randomized into arm E or arm F with a ratio of 1:1.
Arm F: PEGASYS® 180 ug/week and Ribavirin 1000-1200 mg/day for 72 weeks with a follow-up period of 24 weeks."
1639251|NCT01937715|Drug|PF-05212384|PF-05212384 at the Recommended phase 2 dose (RP2D/MTD) weekly
1639252|NCT01937715|Drug|FOLFIRI regimen|The RP2D/MTD dose of FOLFIRI regimen every 2 weeks
1639253|NCT01937715|Biological|Bevacizumab|5 mg/m^2 every 2 weeks or 7.5 mg/m^2 every 3 weeks
1639254|NCT01937715|Drug|FOLFIRI|Full dose FOLFIRI regimen every 2 weeks
1639255|NCT01937702|Other|0.9% NaCl (sodium chloride)|
1639256|NCT01937689|Drug|Pyrotinib|Pyrotinib either at 80, 160, 240, 320, 400, 480 mg ....., p.o. once daily.
1639257|NCT01937663|Drug|KWA-0711|
1639259|NCT01937637|Behavioral|Cognitive Behavioral Intervention for Breathlessness|Cognitive behavioral intervention for breathlessness, delivered by nurse practitioners during outpatient oncology appointments, in up to 8 patients with advanced lung cancer.
1639262|NCT01937611|Drug|Dexmedetomidine|Dexmedetomidine
1639263|NCT01937611|Drug|Midazolam|Midazolam
1639264|NCT01937598|Drug|Placebo|Patients administered a single dose of placebo during a mixed meal challenge.
1639265|NCT01937598|Other|Mixed meal test|Subjects will be instructed to consume the mixed meal test within 20 minutes. The exact start and stop time of the mixed meal test consumption will be recorded in the CRF. The mixed meal test procedures will be identical for all subjects randomised in the study. To detect the plasma glucose excursion after mixed meal test, plasma glucose will be closely monitored
1639266|NCT01937598|Drug|Liraglutide|Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study.
1639267|NCT01937598|Drug|Sitagliptin|Patients administered a single dose of Sitagliptin during a mixed meal challenge.
1639268|NCT01937585|Behavioral|Partner and CDC brochure condition|Receipt of a brochure designed for female partners of African American men designed to provide information about prostate cancer screening and strategies for influencing her mate to schedule a discussion with a health care provider about whether to undergo prostate cancer screening, in combination with receipt of the comparator brochure (CDC brochure for African American about prostate cancer screening).
1639269|NCT01937585|Behavioral|CDC brochure only condition|Receipt of CDC brochure by female partners of African American men designed to provide African American men information and guidance concerning whether to undergo PSA and/or DRE screening for prostate cancer
1639270|NCT01937572|Other|Visionaire system (Knee MRI)|
1639271|NCT01937572|Other|No Knee MRI|
1639272|NCT01937559|Biological|Tranexaminic Acid (TXA)|1.5g of TXA in 100ml normal saline solution
1639273|NCT01937559|Drug|Normal saline|
1639274|NCT01937546|Procedure|Primary delivery of anterior shoulder|
1639275|NCT01937546|Procedure|Primary delivery posterior shoulder|
1639276|NCT01937533|Procedure|Magnetic Resonance Imaging using an endovaginal receiver coil|
1639277|NCT01937520|Device|acupuncture|One half of subjects will receive a standardized acupuncture regiment
1639278|NCT01937520|Device|no acupuncture|placebo
1639280|NCT01937494|Drug|histamine-benzylic alcohol (magistral preparation)|passive exposure to histamine during a bronchial hyperresponsiveness challenge
1639281|NCT01937481|Behavioral|The Food Friends|The Food Friends is a research-based preschool program designed to address childhood obesity by establishing healthful eating and physical activity behaviors in preschool-aged children. The Food Friends: Fun With New Foods (12 weeks) focuses on helping children increasing children's willingness to try new foods and The Food Friends: Get Movin' With Mighty Moves (18 weeks) aims to enhance preschoolers' gross motor skill development. In effort to sustain the preschool behavior changes, the messages from The Food Friends® (Super Taster and Mighty Mover) will be extended into early elementary school through a 'booster' program. The booster program will consist of a kindergarten and 1st grade curriculum with 5 monthly units.
1639282|NCT01937468|Other|Treg-enriched infusion|Treg-enriched Cell Dose: Participants will be targeted to a defined dose of donor Treg-enriched total nucleated cells. Initial enrollment will be at target dose-level A. Subsequent cohorts will be dose escalated/de-escalated per the schema
1639283|NCT01937468|Drug|Interleukin-2|Interleukin-2: Starting the day of Treg-enriched cell infusion, each participant will receive daily subcutaneous IL-2 for self-administration for 8 weeks, followed by a 4-week hiatus. IL-2 will be administered on an outpatient basis. Expected toxicities and potential risks as well as dose modifications are described in Section 6 (Expected Toxicities and Dosing Delays/Dose Modification).
1639284|NCT01937455|Biological|rAAV1-PG9DP|4x10^12 vg administered intramuscularly
1639285|NCT01937455|Biological|rAAV1-PG9DP|4x10^13 vg administered intramuscularly
1639286|NCT01937455|Biological|rAAV1-PG9DP|8x10^13 vg administered intramuscularly
1639287|NCT01937455|Biological|rAAV1-PG9DP|1.2x10^14 vg administered intramuscularly
1639288|NCT01937442|Drug|Thalidomide Celgene™|200mg once daily and by mouth
1639289|NCT01937429|Device|Colonoscopy with blue Indigo Carmin®|
1639290|NCT01937429|Device|Standard colonoscopy with insufflation of air|
1639291|NCT01937416|Biological|autologous bone marrow mononuclear cells|Bone marrow was taken from patient oneself and mononuclear cells were isolated with deleting erythrocyte by density gradient centrifugation. Bone marrow mononuclear cells were transplanted into ischemia regions of lower limb through intramuscular injection.
1639492|NCT01935960|Other|Pharmacological Study|Correlative studies
1639297|NCT01937364|Drug|Placebo|Identical appearing placebo every 8 hours for 72 hours (9 doses) as an inpatient, or until discharge if before 72 hours.
1639298|NCT01937351|Device|Pantheris System|
1639299|NCT01937338|Drug|AZD7624|nebuliser solution; 20 mg/mL for inhalation
1639300|NCT01937338|Drug|Placebo|nebuliser solution for inhalation
1639301|NCT01937325|Drug|ivacaftor|active arm
1639302|NCT01937325|Drug|placebo|active arm
1639303|NCT01937312|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
1639304|NCT01937312|Drug|Vehicle|Inactive ingredients used as a placebo comparator
1639305|NCT01937312|Drug|Prostaglandin analogue|
1639306|NCT01937299|Drug|Brinzolamide 1%/brimonidine 0.2% ophthalmic suspension|
1639307|NCT01937299|Drug|Vehicle|Inactive ingredients used as a placebo comparator
1639308|NCT01937299|Drug|Travoprost 0.004% ophthalmic solution|
1639309|NCT01937260|Drug|Brodalumab|Group 1 consists of 20 subjects and will receive 2 oral doses of midazolam and a single SC dose of brodalumab. Group 2 consists of 10 subjects and will receive a single SC dose of brodalumab.
1639310|NCT01937247|Procedure|Putting the patient to sleep in the induction room|
1639311|NCT01937247|Procedure|Implementing parallel processing to enhance the turnover process|
1639312|NCT01937247|Procedure|Waking up the patient in the recovery room using Bridion|
1639313|NCT01937247|Procedure|STANDARD PROCESS|standard process
1639314|NCT01937234|Drug|Metoclopramide|"Intravenous injection of 10mg metoclopramide, at enrollment, then every 2 hours.
Maximum of 3 doses."
1639315|NCT01937234|Drug|Placebo|"Intravenous injection of 0.9% sodium chloride, at enrollment, then every 2 hours.
Maximum of 3 doses."
1639316|NCT01937221|Other|spectral-domain optical coherence tomography (SD-OCT)|Intervention same to all groups.
1639317|NCT01937208|Radiation|intensity modulated radiation therapy in both arms|
1639318|NCT01937208|Drug|concurrent chemotherapy with radiation|docetaxel plus cisplatin were used weekly in both arms
1639319|NCT01937195|Device|AccuCath Intravenous Catheter System|AccuCath IV Catheter System will be used for IV therapy during inpatient stay. Intervention includes vascular access, fluid infusion, and blood sample removal. Results will be compared to published literature for conventional IV catheters.
1639320|NCT01937182|Drug|Citalopram|Citalopram 10-40 mg per day administered orally
1639321|NCT01937182|Drug|Placebo|1/2-2 tablets per day with no intrinsic drug activity
1639322|NCT01937169|Behavioral|Motor Task|A motor task executed for 30 minutes after drug adminidtration
1639323|NCT01937169|Drug|Levodopa tablet|
1639324|NCT01937169|Behavioral|Sham non-motor task|A non-motor task )sham condition) will be executed for 30 minutes after drug adminidtration
1639325|NCT01937169|Drug|Placebo pill|
1639326|NCT01937156|Drug|SP-01 (Granisetron Transdermal Delivery System)|SP-01 will be applied to the upper arm 24-48 hours before the start of chemotherapy, and left in place for 7 days.
1639327|NCT01937156|Drug|Granisetron Hydrochloride Tablet|Granisetron hydrochloride 1 mg tablets will be administered 1 hour before administration of chemotherapy at the first time, then taken 12 hours after the first dose later; 2 mg/day bid, for ≥ 2 days.
1639328|NCT01937143|Behavioral|Low intensity intervention|Pamphlet with information about pain management during infant immunizations at birth of a newborn infant
1639329|NCT01937143|Behavioral|High intensity intervention|Pamphlet and video with information about pain management during immunizations at birth of a newborn infant
1639330|NCT01937143|Behavioral|Control|General information about infant immunizations at birth of a newborn infant
1639331|NCT01937130|Drug|IDN-6556|
1639332|NCT01937130|Other|Placebo|
1639333|NCT01937117|Procedure|Positron emission tomography (PET)|PET will be performed at baseline and on day 15
1639334|NCT01937117|Drug|Trastuzumab|8 mg/kg loading dose, then 6 mg/kg every 3 weeks, IV
1639335|NCT01937117|Drug|Pertuzumab|840 mg as a loading dose, then 420 mg every 3 weeks, IV
1639336|NCT01937104|Drug|Desflurane|"Anesthesia with desflurane in both Group 1 and Group 2
- adjust MAC to maintain BIS between 40-60"
1639337|NCT01937104|Drug|Remifentanil|"Adjuvant continuous administration
- adjust effect site concentration to maintain changes of vital sign below 20%"
1639338|NCT01937104|Device|Ultrasonographic measurement of ONSD|Patients were placed in the supine position with their eyes closed, and a thick gel layer was applied to the closed upper eyelid. The 7.5-MHz linear probe was placed on the gel without excessive pressure and adjusted to the proper angle for displaying the entry of the optic nerve into the globe. The intensity of the ultrasound was adjusted to display optimal contrast between the retrobulbar echogenic fat tissue and the vertical hypoechoic band. An ultrasound beam was focused on the retrobulbar area (4 cm deep) using the lowest possible acoustic power that could measure ONSD. The ONSD was measured 3 mm behind the optic disc. Measurements were performed in the transverse and sagittal planes of both eyes, and the final ONSD value was calculated by averaging 4 measured values.
1639339|NCT01937104|Procedure|Mechanical ventilation|After tracheal intubation, the lungs of the patients were then ventilated with oxygen in air (1:2) using a tidal volume of 8-10 mL/kg and a respiratory rate of 10-12/min, and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 40 mmHg and peak inspiratory pressure below 30 cmH2O.
1639340|NCT01937104|Procedure|Trendelenburg position - 30 degree|Trendelenburg position - 30 degree
1639341|NCT01937104|Procedure|Reverse Trendelenburg position - 30 degree|Reverse Trendelenburg position - 30 degree
1639342|NCT01937078|Drug|Famotidine|Each patient will receive 4 randomized treatment phases - three famotidine (one at each of the dose levels) and one placebo. Each treatment phase will last for 14 days. Doses of drug will be titrated upwards, starting at 40mg once daily on day one, 40mg twice daily on day two, and 80mg twice daily (or placebo + drug equivalent) from day three and then continue on this dose for the next 12 days. Regardless of treatment phase, subjects will take 2 tablets twice daily, with varying ratios of active famotidine to placebo. Thus famotidine 80mg/d will consist of 1 tablet of 40 mg famotidine plus 1 tablet of placebo twice a day; 120 mg /d famotidine will be 2 tablets at 40 mg morning and 1 tablet famotidine 40 mg plus 1 tablet placebo evening; famotidine 160 mg/d will be famotidine 40 mg tablets, 2 tablets twice a day. The placebo phase will consist of 2 placebo tablets twice a day.
1639343|NCT01937065|Other|No treatment|
1639493|NCT01935960|Other|Placebo|Given PO
2012202|NCT02149654|Device|Engager Transcatheter Aortic Valve Implantation System|The Engager Transcatheter Aortic Valve Implantation System is indicated for use in patients with symptomatic severe aortic valve stenosis requiring aortic valve replacement and are at high or extreme risk for operative mortality or comorbidity judged by the heart team to pose an absolute or relative contraindication for conventional aortic valve replacement. The system is intended for use in patients with a life expectancy of at least one year following TAVI. The intended performance of the system is to provide relief of aortic valve obstruction without inducing significant regurgitation, thereby restoring effective hemodynamic function of the diseased aortic valve. The intended purpose of the system in this clinical study is in line with the intended purpose in the Instructions for Use.
2012203|NCT02149043|Device|Thermography|Infrared imaging of the abdomen surface
2012204|NCT02149043|Procedure|Colonoscopy|Endoscopic examination of the colon
1639347|NCT01937026|Drug|Baricitinib|Administered orally
1639348|NCT01937026|Drug|Probenecid|Administered orally
1639349|NCT01937013|Drug|Intranasal oxytocin|Oxytocin can be given intravenously (with a needle) or intranasally (a spray into the nose). The intravenous form of drug is approved by Health Canada for use in pregnancy. The intranasal formulation is not currently approved for use by Health Canada, but is used in Europe to induce labour in pregnant women or aid lactation (breastfeeding). Participants will be randomized to receive 72 IU intranasal oxytocin on either study visit 2 or 3.
1639350|NCT01937013|Drug|Saline Nasal Mist|Participants will be randomized to receive placebo on either study visit 2 or 3.
1639351|NCT01936064|Dietary Supplement|Jobelyn + Cyclophosphamide-Epirubicin6|Jobelyn (dietary Supplement) to be used with Cyclophosphamide-Epirubicin6
1639352|NCT01936064|Drug|Placebo + Cyclophosphamide - Epirubicin 6|Routine drugs for the treatment of breast cancer to be used with Placebo
1639353|NCT01936038|Other|CPAP|CPAP
1639354|NCT01936038|Procedure|Upper Airway Toning for Improve the Compliance of CPAP|Upper Airway Toning for Improve the Compliance of CPAP
1639355|NCT01936025|Drug|Dextrometorphan|
1639356|NCT01936025|Drug|Sitagliptin|
1639357|NCT01936025|Drug|Placebo|
1639358|NCT01936012|Drug|Lisinopril 10 mg tablets of PT Dexa Medica|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
1639359|NCT01936012|Drug|Lisinopril 10 mg tablets of PT Boehringer Ingelheim Indonesia|Each tablet contains 10.89 mg of lisinopril dihydrate that equal to 10 mg lisinopril. Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
1639360|NCT01935999|Device|One piece closed pouch|A one piece closed pouch for the collection of stool from a colostomy stoma
1639361|NCT01935986|Dietary Supplement|probiotic|
1639362|NCT01935986|Dietary Supplement|placebo|
1639363|NCT01935973|Drug|Akt Inhibitor GSK2141795|Given PO
1639364|NCT01935973|Other|Laboratory Biomarker Analysis|Correlative studies
1639365|NCT01935973|Drug|Trametinib|Given PO
1639371|NCT01936961|Drug|CTLA-4 Antibody|administered intravenously over 90 minutes every 3 weeks for a total of four doses
1639372|NCT01936961|Radiation|Hypofractionated Radiotherapy|
1639373|NCT01936948|Procedure|Clip closure|Patients will be randomized to either closing the mucosal defect after polyp removal or not closing the mucosal defect using clips (main intervention and comparison). The resection margins will be approximated using clips. Complete closure is defined as approximated margins with less than 1cm gap between clips. All patients will further be randomized to two different settings of electrocautery (EndoCut or Coagulation) to standardize otherwise variable electrocautery practice, and for explorative analysis.
1639374|NCT01936935|Other|Low-fat dairy|2 servings/d of 2% non-flavored, unsweetened milk + 1 serving/d sweetened low-fat yogurt
1639375|NCT01936935|Other|Sugar-sweetened beverages|2 servings/d of non-diet soda + 1 serving/d of non-dairy pudding
1639376|NCT01936922|Device|GaitAid®|Provides visual and auditory cues for walking.
1639380|NCT01936896|Drug|Alpha 1-Antitrypsin|
1639381|NCT01936883|Radiation|HDR|High dose rate brachytherapy
1639382|NCT01936883|Radiation|LDR|Low dose rate brachytherapy boost
1639383|NCT01936870|Drug|Fesoterodine (Toviaz)|Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
1639384|NCT01936857|Drug|Buprenorphine/naloxone|Buprenorphine/naloxone induction begins with a 2-4mg test dose followed by additional doses on the day of induction to relieve withdrawal symptoms, and then titrated to a maintenance dose between 8-24 mg/day over 1 to 3 days. Doses will be directly observed and occur daily. After a minimum of 2 weeks, dosing may be changed to 3 or 4 times per week, as determined clinically appropriate by the HIV clinic study physician. Dosing will remain flexible to a maximum dose of 24mg for daily dosing and 32mg for every other day dosing, as deemed clinically appropriate by the study physician.
1639385|NCT01936857|Drug|Methadone Maintenance Therapy|Subjects randomized to methadone maintenance therapy (MMT) referral will meet with an HIV clinic case manager who will facilitate referral to MMT. Methadone dosing will be managed by MMT staff, who dispense methadone according to Ministry of Health guidelines for MMT.
1639386|NCT01936844|Drug|Anakinra (high dose)|Anakinra 100 mg daily twice daily for days 1, 2, and 3
1639387|NCT01936844|Drug|Anakinra (standard dose)|Anakinra 100 mg daily for days 4-14
1639388|NCT01936844|Drug|Placebo|Placebo twice daily for days 1, 2, and 3
1639389|NCT01936844|Drug|Placebo|Placebo daily for days 4-14
1639390|NCT01936831|Drug|Isoniazid|
1639391|NCT01936831|Dietary Supplement|Vitamin B6|
1639392|NCT01936805|Drug|Rosuvastatin|A 40 mg loading dose of rosuvastatin was administrated 24 h before the PCI.
1639393|NCT01936779|Dietary Supplement|Dietary supplement: fatty acid|Consumption of n-3 fatty acids for 8 weeks
1639394|NCT01936779|Dietary Supplement|Dietary supplement: fatty acid|Consumption of olive oil for 8 weeks.
1639494|NCT01935960|Drug|Retinoid 9cUAB30|Given PO
1639495|NCT01935947|Drug|Azacitidine|Given SC
1639496|NCT01935947|Drug|Azacitidine|Given PO
1639395|NCT01936753|Behavioral|Trained Mentor Mother and Supervisor|Trained, closely supervised Mentor Mothers guide and support the mother-infant pair to achieve timely and complete access to, and retention in PMTCT services along the entire cascade.
1639396|NCT01936740|Procedure|cataract surgery|
1639397|NCT01936727|Procedure|cataract surgery|
1639398|NCT01936714|Procedure|cataract surgery|
1639399|NCT01936701|Procedure|bilateral cataract surgery|same-day bilateral cataract surgery with implantation of intraocular lens
1639400|NCT01936688|Drug|MK-3222 200 mg|MK-3222 200 mg administered SC.
1639401|NCT01936688|Drug|MK-3222 100 mg|MK-3222 100 mg administered SC.
1639402|NCT01936688|Drug|Placebo to MK-3222|Matching placebo to MK-3222 administered SC.
1639403|NCT01936688|Drug|Placebo to Etanercept|Matching placebo to etanercept for subcutaneous injection.
1639404|NCT01936688|Drug|Etanercept 50 mg|Etanercept 50 mg for subcutaneous injection.
1639405|NCT01936675|Other|Genetic Risk Score|Patients in this arm will receive their genetic-informed risk for having a heart attack.
1639406|NCT01936662|Device|LMA|Patients randomized to the LMA group had their airways maintained with a LMA device
1639407|NCT01936662|Device|ETT|Patients assigned to this group had an ETT placed to maintain their airway, as is standard of care at this hospital
1639408|NCT01936649|Drug|AdreView (Iobenguane I 123 Injection)|AdreView 10 mCi as a single i.v administration
1639409|NCT01936636|Drug|Fentanyl|
1639410|NCT01936623|Behavioral|Computerized Brief Intervention|No additional information needed.
1639411|NCT01936610|Other|role play|In this method, researcher with two other co-researchers played 3 scenarios in 7 steps (for each scenario)including warm up, selecting participant, preparing the scene, preparing observers, play ,discussion and evaluation and generalization to education about advantages and disadvantages of normal delivery and cesarean section.
1639412|NCT01936610|Other|lecture|Describe advantages and disadvantages in one 90-min session
1639413|NCT01936597|Other|Therapeutic and preventive strategies|Single set (control Arm)
1639414|NCT01936597|Other|Therapeutic and preventive strategies|Controller
1639415|NCT01936597|Other|Therapeutic and preventive strategies|Audio
1639416|NCT01936584|Procedure|TAPP repair for inguinal hernias|
1639417|NCT01936584|Procedure|TEP repair for inguinal hernia|
1639418|NCT01936584|Other|EuraHS-QoL questionnaire|questionnaire administration
1639419|NCT01936584|Other|Carolina Comfort Scale|questionnaire administration
1639420|NCT01936571|Other|Blood samples|Blood samples, that were collected, processed and stored in the Maastro biobank in a standardized way, will be used to measure CRP, LDH, Osteopontin, CA-9 IL-6, IL-8, CEA, CYFRA 21-1, and α-2M. Clinical data will be retrieved from the electronic medical files.
1639421|NCT01936558|Other|Far infrared ray to the sole|exposure 40-minute far infrared ray to the sole for each person/amputee.
1639422|NCT01936545|Drug|propofol during liver transplantation.|The anesthesia was maintained with propofol during liver transplantation.
1639423|NCT01936545|Drug|Desflurane during liver transplantation.|The anesthesia was maintained with desflurane during liver transplantation.
1639424|NCT01936532|Drug|MLN9708|"Induction therapy Patients will receive 3 cycles of induction therapy with MLN9708 (4 mg) on Days 1, 8 and 15, plus Lenalidomide (25 mg) on Days 1 through 21 and Dexamethasone (40 mg) on Days 1, 8, 15 and 22 of a 28-day cycle.
Consolidation therapy
Early consolidation (consolidation part 1) will comprise 2 cycles of MRD identical to induction therapy.
Late consolidation (consolidation part 2) will consist in 6 additional cycles of MLN9708 (4 mg on Days 1, 8 and 15) plus lenalidomide (25 mg on Days 1 through 21) of a 28-day cycle.
Maintenance therapy MLN9708 monotherapy (4 mg/day), will be given on days 1, 8 and 15 of a 28 day cycle, during 12 months."
1639425|NCT01936532|Drug|Lenalidomide|
1639426|NCT01936532|Drug|Dexamethasone|
1639427|NCT01936519|Drug|Arm A: Everolimus|Conversion to Everolimus immunosuppression combined with mycophenolic acid (Myfortic: MPA), and complete discontinuation of Calcineurin inhibitor at 3 months post transplant.
1639428|NCT01936519|Drug|Calcineurin Inhibitor|Comparison Arm: Continuation with standard immunosuppressive therapy consisting of Calcineurin inhibitor associated with mycophenolic acid (Myfortic: MPA).
1639429|NCT01936506|Behavioral|Cognitive Training A|
1639430|NCT01936506|Behavioral|Cognitive Training B|
1639431|NCT01936493|Genetic|DNA analysis|At a future time DNA analysis will be performed
1639432|NCT01936493|Other|Hormonal analysis|Participants will provide blood samples so that hormonal factors that influence outcomes of leiomyoma treatments can be assayed.
1639433|NCT01936480|Drug|Moxifloxacin 400mg once time|
1639434|NCT01936480|Drug|Placebo|
1639435|NCT01936467|Device|Standard technique EUS-FNA|Standard suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with use of 10cc suction syringe.
1639436|NCT01936467|Device|Capillary suction technique for EUS FNA|Capillary suction Endoscopic Ultrasound- Fine Needle Aspiration (EUS-FNA) technique using the 22-gauge (Expect needle; Boston Scientific) needle: 15 to-and-fro movements within the lesion will be performed with simultaneous minimal negative pressure provided by pulling the needle stylet slowly and continuously
1639437|NCT01936441|Behavioral|Cognitive Behavioral Therapy-Insomnia (CBT-I)|See Experimental Arm Description
1639438|NCT01936441|Behavioral|Menopause Education Control (MEC)|See Experimental Arm Description
1639439|NCT01936428|Other|interview|
1639440|NCT01936415|Device|Vanguard|A prospective randomized study where the patients are randomized to receive one of two prostheses (tibial components) with different coating: Vanguard pourous coating, Biomet and Regenerex® Primary Tibial Tray, Biomet. Both prostheses are available and approved by the FDA. The main difference between the implants is the coating of the tibial tray
1639441|NCT01936415|Device|Regenerex|
1639442|NCT01936402|Behavioral|Education of chest compression depth|An American Heart Association Basic Life Support faculty educated each participant in Experimental group a standard 30-min lecture and hands- on practice for chest compression without ventilation using manikin on the floor according to 5-6cm or 6-7cm chest compression depth
1639443|NCT01936389|Drug|AR-12286|
1639497|NCT01935947|Drug|Docetaxel|Given IV
1639444|NCT01936363|Drug|Pimasertib once daily|Pimasertib will be administered as oral capsule at a dose of 60 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.
1639445|NCT01936363|Drug|Pimasertib placebo|Placebo matching Pimasertib will be administered once daily in evening until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.
1639446|NCT01936363|Drug|SAR245409 placebo|Placebo matching SAR245409 will be administered once daily in morning until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.
1639447|NCT01936363|Drug|SAR245409|SAR245409 will be administered as oral capsule at a dose of 70 milligram (mg) once daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.
1639448|NCT01936363|Drug|Pimasertib twice daily|Pimasertib will be administered as oral capsule at a dose of 60 milligram (mg) twice daily until disease progression, death, intolerable toxicity or withdrawal of informed consent, whichever comes first.
1639449|NCT01936350|Drug|Sildenafil|The intervention in this group is the use of sildenafil 50mg; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the drug.
1639450|NCT01936350|Drug|Placebo|This group will use placebo; this group will take placebo and will be evaluated by cardiac magnetic resonance before and after the oral use of the placebo pill.
1639451|NCT01936337|Drug|DLX105 Hydrogel|topical administration on psoriatic plaque
1639452|NCT01936337|Drug|Placebo|topical administration on psoriatic plaque
1639453|NCT01936324|Drug|DRM01B|Comparison of active treatment with DRM01B topical gel, 7.5% versus vehicle gel (DRM01B Vehicle gel) applied to the face for acne vulgaris
1639454|NCT01936324|Other|DRM01B Vehicle gel|
1639455|NCT01936311|Behavioral|Self-management goal elicitation|The intervention will be a form, given prior to a primary care visit, that allows patients to express a self-management goal (health goal) they would like to work on, and a preferred treatment modality.
1639456|NCT01936298|Device|A-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
1639457|NCT01936298|Device|P-ROM Continuous Passive Rehabilitation|"Half an hour of treatment during the morning with the sequential program (each finger is mobilized individually) and half an hour of treatment during the afternoon with the synchronous program (II-III-IV-V finger are mobilized simultaneously, the thumb individually)."
1639458|NCT01936285|Drug|Colchicine 2 mg loading dose; 0.5 mg bid for 5 days|
1639459|NCT01936285|Drug|Placebo|
1639460|NCT01936272|Device|Chhabra Shunt Placement|
1639461|NCT01936272|Procedure|ETV/CPC|
1639462|NCT01936246|Dietary Supplement|Increased protein|
1639463|NCT01936233|Drug|Aspirin|Aspirin 0.1 QD po
1639464|NCT01936233|Drug|Lamivudine|LAminvudine 0.1 QD po
1639465|NCT01936220|Behavioral|Continuity of specialized care|Continuity of care in treatment and professional caregiver was given during 5 year. Treatment targets included relapse prevention through recognition of prodromal symptoms, coping with negative symptoms and stress, increasing medication adherence, decrease of substance use, prevention of drop-out and stimulating and supporting participation in structural activities (work and/or education).
1639466|NCT01936220|Behavioral|Parent groups combined with Continuity of Specialized care|Approximately fifty parent group therapy sessions will be held in a flexible way over a 60 month period. Each parent group was run by two experienced family therapists.
1639467|NCT01936220|Behavioral|Discontinuity of care, non specialised care|Standard Treatment as usual (TU) was provided during 5 years by local mental health care professionals situated nearby the domicile of patients. TU had comparable treatment targets as ST but was not provided by treatment staff specialized in early intervention in schizophrenia or related disorders. However, TU was (like ST) sustained and dedicated to prevent psychotic relapse and improve social functioning.
1639468|NCT01936194|Dietary Supplement|DHA+EPA|
1639469|NCT01936194|Dietary Supplement|High Olive Oil|
1639470|NCT01936194|Dietary Supplement|DHA|
1639471|NCT01936181|Drug|Remicade (infliximab)|
1639472|NCT01936181|Drug|SB2 (proposed biosimilar to infliximab)|
1639473|NCT01936168|Device|Mechanochemical Endovenous Ablation (MOCA)|Mechanochemical Endovenous Ablation (MOCA)for treatment of great saphenous vein incompetence
1639474|NCT01936168|Procedure|Radiofrequency ablation (RFA)|Radiofrequency ablation (RFA)for treatment of great saphenous vein incompetence
1639475|NCT01936155|Device|Custom-built, two-channel stimulator|Custom-built, two-channel stimulator for stimulation of the soleus calf muscle
1639476|NCT01936142|Device|Use of RenalGuard|
1639477|NCT01936129|Drug|Copaxone|
1639478|NCT01936129|Drug|Placebo (buffered normal saline w/v)|
1639479|NCT01936116|Device|sonohysterography with inflated catheter in uterine cavity|during the procedure of sonohysterography balloon catheter is inflated in the uterine cavity
1639480|NCT01936116|Device|sonohysterography with inflated catheter in cervical cavity|During the procedure of sonohysterography balloon catheter is inflated in the cervical canal
1639481|NCT01936103|Drug|standard group|standard statin treatment:Atorvastatin statins 20mg / night .
1639482|NCT01936103|Drug|intensive group|intensive statin treatment： Admission atorvastatin statins the 80mg, after surgery，atorvastatin 40mg / night，and until 30 days after the operation
1639483|NCT01936090|Drug|Bortezomib|Given IV
1639484|NCT01936090|Radiation|Total-Body Irradiation|Undergo TBI
1639485|NCT01936090|Drug|Melphalan|Given IV
1639486|NCT01936090|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplant
1639487|NCT01936090|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
1639488|NCT01936090|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
1639489|NCT01936090|Other|Laboratory Biomarker Analysis|Correlative studies
1639490|NCT01936077|Drug|Recombinant LH (Luveris)|150 IU recombinant LH daily.
1639491|NCT01935960|Other|Laboratory Biomarker Analysis|Correlative studies
1639501|NCT01935947|Other|Laboratory Biomarker Analysis|Correlative studies
1639502|NCT01935947|Drug|Pemetrexed Disodium|Given IV
2012205|NCT02146313|Drug|DMUC4064A|Participants will receive escalated DMUC4064A dose or RP2D, as a single agent by intravenous (IV) infusion q3w on Day 1 of each cycle (21 days).
2012206|NCT02143414|Biological|Blinatumomab|Given IV
2012207|NCT02143414|Drug|Dasatinib|Given PO
1639506|NCT01935921|Biological|Cetuximab|Given IV
1639507|NCT01935921|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1639508|NCT01935921|Biological|Ipilimumab|Given IV
1639509|NCT01935921|Other|Laboratory Biomarker Analysis|Correlative studies
1639511|NCT01935895|Behavioral|Exercise on Blood Pressure Reactivity|To comparison, volunteers randomly underwent 2 experimental sessions separated by 48-72h. The exercise session consisting of 3-laps in a circuit, performing resistance and aerobic exercises: knee extension, bench press, knee flexion, rowing in the prone, squat, shoulder press and five minutes of up to down in a 15cm high step between 75-85% heart rate maximum. Resistance exercise loads used dumbbells to upper body exercises and weights attached on the legs and arms to lower body exercises. Each resistance exercise was performed in 15reps with 50% of one repetition maximum test. Two secs for repetition were performed with rhythmic control. The control session was conducted under the same conditions of the exercise session, with the exception that subjects did not perform exercises.
1639512|NCT01935882|Drug|Artemether-lumefantrine combination|
1639513|NCT01935882|Drug|Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine|
1639514|NCT01935882|Drug|Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine|
1639515|NCT01935869|Drug|LEO 90100|
1639516|NCT01935869|Drug|Vehicle|
1639517|NCT01935869|Drug|Petrolatum ointment|
1639518|NCT01935856|Drug|KHK7580|Oral administration
1639519|NCT01935843|Biological|CART-HER-2|
1639520|NCT01935830|Radiation|[11c] LAAM|intravenous administration of 15-20 mCi of [11c] LAAM.
1639521|NCT01935830|Drug|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.
1639522|NCT01935830|Drug|Efavirenz|Pretreatment with oral Efavirenz 600 mg orally every night x 14 days followed by intravenous administration of 15-20 mCI of [11c] LAAM.
1639523|NCT01935817|Drug|Silybin 94 mg + vitamin E 90 mg + phospholipids 194 mg complex|
1639524|NCT01935817|Drug|Placebo|
1639525|NCT01935804|Drug|Pioglitazone|30 mg/daily for 12 months
1639526|NCT01935804|Drug|Metformin|850 mg/daily for 12 months
1639527|NCT01935791|Drug|Glucagon|Hormone
1639528|NCT01935791|Drug|Saline|Control
1639529|NCT01935778|Drug|Docetaxel and capecitabine and oxaliplatin|Docetaxel 60 mg/m² IV Day 1 Capecitabine 800 mg/m² bid (Day 1-Day 14) Oxaliplatin 100 mg/m² IV Day 1
1639530|NCT01935778|Drug|capecitabine and oxaliplatin|Capecitabine 1,000 mg/m² bid(D1-14) Oxaliplatin 130 mg/m² IV Day 1
1639531|NCT01935765|Other|Polysomnography|Diabetes people: Examination diagnosis of the sleep apnea A night at the hospital
1639532|NCT01935765|Other|Evaluation of the autonomous nervous system|blood pressure, Heart frequence, deep breath, Orthostatism, Vasalva, Low blood pressure orthostatic
1639533|NCT01935765|Other|Clinical examination of the sleep|Functional signs, collection of medical histories and associated pathologies, Pittsburgh Sleep Quality Index PSQI, Functional Outcomes of Sleep Questionnaire FOSQ, Epworth Sleepiness Scale ESS, Hospital Anxiety and Depression scale HAD
1639534|NCT01935765|Other|Clinical examination of diabetology|history of diabet, observance, ophthalmological, renal, macroangiopathic and neuronal complications, Toronto scale, Diabetes Quality of Life (DQOL) Questionnaire
1639535|NCT01935765|Other|Biological dosages|Hematology, glycemia, lipids, CRP, creatinine, ferritin, glycosylated hemoglobin, transaminase, microalbuminuria, urine test
1639536|NCT01935765|Other|Electrocardiogram (ECG)|Electrocardiogram (ECG)
1639537|NCT01935765|Other|Carotid echography|Carotid echography
1639538|NCT01935765|Other|Blood pressure|Blood pressure
1639539|NCT01935752|Other|blood samples|blood samples
1639540|NCT01935752|Other|vascular echotracking|endothelial function study and virtual histology study
1639541|NCT01935713|Drug|Nicotine polacrilex|Participants were given the choice of 2mg or 4mg lozenges depending on how many cigarettes per day they reported to smoke.
1639542|NCT01935713|Drug|Electronic Cigarette|Participants were given an e-cigarette starter kit, charging case, and cartridges in either 12mg or 16 mg nicotine, depending on their current amount of cigarettes smoked per day.
1639543|NCT01935713|Drug|Dissolvable Tobacco Lozenge|Participants were given Ariva (light to moderate smokers) or Stonewall (heavier smokers, >2 packs per day).
1639544|NCT01935700|Drug|Colchicine|"Adjustment the dosage of colchicine during study:
The colchicine dosage will be changed when the hepatic reserved function of the participant changes from Child A to B according as following: 2 tablets after breakfast, 1 tablet after lunch and 2 tablets after dinner; continue 4 days and stop for 3 days (1 cycle); repeat this cycle until patients quit this trial. If the hepatic reserved function of the participant changes to Child C, colchicine will be stopped and participant receives regular follow-up only.If participant suffers from severe diarrhea, colchicine will be temporarily stopped. When the symptom of diarrhea subsides, colchicine will be given again but the dose will be reduced 0.5 mg/day."
1639545|NCT01935687|Device|Using of instrumented wheel|Using of instrumented wheel
1639546|NCT01935687|Device|Using of ergometer roller|Using of ergometer roller
1639547|NCT01935674|Drug|Switch ritonavir-boosted PI|Switch their existing ritonavir-boosted PI to another potent ART drug with lesser effects on serum cholesterol selected by the investigator.
1639548|NCT01935674|Drug|Continue Ritonavir-boosted PI+Rosuvastatin|Continue ritonavir-boosted PI-based ART and commence rosuvastatin 10 mg daily (5 mg daily in Asian participants).
1639550|NCT01935635|Biological|HPDCs-T immune therapy|HPDCs-T immune therapy:one time every 2 weeks during 12 weeks to 36 weeks, IV (in the vein), about 2*105-1*106 cells per time,total 12 times;
1639551|NCT01935622|Drug|Doxycycline|Doxycycline 1 tablet every 12 hours for 14 days
1639552|NCT01935622|Drug|placebo|Placebo 1 tablet every 12 hours for 14 days
1639682|NCT01934491|Behavioral|Cognitive Training B|
1716423|NCT00001114|Drug|Didanosine|
2012208|NCT02143414|Other|Laboratory Biomarker Analysis|Correlative studies
1639554|NCT01935596|Drug|ropivacaïne|spinal anesthesia.
1639555|NCT01935596|Drug|lévobupivacaïne|
1639556|NCT01935583|Behavioral|Resilience/Adjustment Counseling|Intervention to promote individual's resilience and adjustment (RAI) - The RAI is a structured approach to helping individuals after brain injury address issues related to resilience and adjustment. The RAI is implemented in seven sessions. Each session is in-person and lasts for 60 minutes.
1639557|NCT01935570|Drug|Magnesium chloride (ChronoMag Smart Tablet®)|
1639558|NCT01935570|Drug|Magnesium carbonate (Mag2® Tablet)|
1639559|NCT01935557|Drug|Continuous heparin infusion|continuous group is given an initial intravenous heparin 100u/kg and then maintain heparin infusion during procedural.
1639560|NCT01935557|Drug|Intermittent heparin infusion|Intermittent group is given an initial intravenous heparin 100u/kg. Then The ACT is tested every 30min with administration of additional heparin boluses and titration of the heparin drip based on the results and according to the judgment of the operating physician.
1639561|NCT01935544|Device|Botulinum toxin injection|
1639562|NCT01935531|Drug|3% diclofenac in 2.5% hyaluronic acid gel|
1639563|NCT01935518|Drug|Fasudil|All the patients will take the fasudil treatment for 14 days (30mg twice a day, intravenous). 3 months later they will repeat the treatment mentioned before.
1639564|NCT01935505|Behavioral|Consulting|The physicians adopted a non-directive approach, included the five 'A' (ask, advice, assess, assist and arrange), assessing the stage of readiness in quitting smoking, strengthening clients' motivation to quit smoking using the five 'R' (relevance, risks, rewards, roadblocks and repetition) approach, and providing advice to overcome psychological craving, psychological dependence and social-cultural factors associated with tobacco dependency. Each smoker takes more than 30 min to complete the intervention.
1639565|NCT01935505|Drug|Nicotine patch|According to the smokers' level of nicotine dependency, disease history, cigarette consumption, prescription of drugs were provided, Nicotine Replacement Therapy, bupropion and varenicline.
1639566|NCT01935505|Behavioral|Telephone intervention|Smokers received follow-up by a counselor at 1 week, 1, 3, 6 months and 1, 2 years using a detailed questionnaire by telephone interview. At each follow-up, we collected data, asked whether the smokers have any problem with drug use or other problems, provided problem-oriented suggestions or advice as appropriate, encouraged them to insist.
1639567|NCT01935505|Behavioral|Consulting+Telephone+Drug intervention|Include all the above interventions
1639568|NCT01935492|Drug|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"st line:
Paclitaxel and bevacizumab: 8 cycles, unless PD or unacceptable toxicity occurs earlier.
Bevacizumab until PD or unacceptable toxicity
At PD patients will go to the 2nd treatment line.
nd line:
Non-pegylated liposomal doxorubicin (Myocet®) (or capecitabine): 8 cycles, unless PD or unacceptable toxicity occurs earlier.
At PD patients will go to the 3rd treatment line. If possible, it is advised to cross-over from 2nd line non-pegylated liposomal doxorubicin to 3rd line capecitabine."
1639569|NCT01935492|Drug|Paclitaxel, Bevacizumab, liposomal doxorubicin, Capecitabine|"Arm B
st line
Paclitaxel and bevacizumab: 4 cycles, unless PD or unacceptable toxicity
Bevacizumab until PD or unacceptable toxicity
At PD < 3 months after last paclitaxel start 2nd treatment line.
At PD ≥ 3 months after last paclitaxel, start another 4 cycles
Bevacizumab until the next PD or unacceptable toxicity
At the next PD start the 2nd treatment line.
nd line:
Myocet® or capecitabine: 4 cycles, unless PD or unacceptable toxicity
At PD < 3 months start the 3rd treatment line. If possible, advised to cross-over from 2nd line Myocet® to 3rd line capecitabine.
At PD ≥ 3 months after last administration of Myocet® or capecitabine, start another 4 cycles of Myocet® or capecitabine
At the next PD start 3rd treatment line."
1639570|NCT01935479|Drug|AK159|transdermal administration of teriparatide acetate
1639571|NCT01935479|Drug|MN-10-T|subcutaneous administration of teriparatide acetate
1639572|NCT01935479|Drug|Placebo|Placebo AK159
1639573|NCT01935466|Drug|Pioglitazone|Ever users of Pioglitazone
1639574|NCT01935453|Biological|Recombinant hGM-CSF Herpes Simplex Virus Injection|
1639575|NCT01935440|Behavioral|Prevention & Testing|6 group sessions, 1 individual session, and 1 dyad session
1639576|NCT01935440|Behavioral|Prevention & Testing Control|7 group sessions
1639577|NCT01935414|Device|geko™ post-surgery for 48hrs then 4hrs/day until discharge.|
1639578|NCT01935414|Device|TEDS post-surgery for 48hrs then 4hrs/day until discharge.|
1639579|NCT01935388|Other|Common canister|Drug administration via a shared canister with a standardized cleaning protocol.
1639580|NCT01935375|Behavioral|CNM Interpersonal Psychotherapy|Eight Weekly 50 minute sessions CNM Interpersonal Psychotherapy
1639581|NCT01935375|Behavioral|Treatment as Usual|Treatment as Usual is psychotherapy provided by a mental health provider
1639582|NCT01935362|Dietary Supplement|Citrus supplement|
1639583|NCT01935362|Dietary Supplement|Placebo|
1639584|NCT01935336|Drug|Ponatinib|Ponatinib 45mg taken by mouth each day at the same time with or without food
1639585|NCT01935323|Other|High Intensity Interval Training|
1639586|NCT01935323|Other|Moderate Intensity Training|
1639587|NCT01935310|Drug|Imiquimod|"From the group of subjects who met the inclusion criteria, 22 people were selected randomly (using a random number table) since a 20-25% loss to follow up was calculated and the least amount of patients needed were 17.
During the study participants applied imiquimod cream 5% (Virosupril ® laboratories Roemmers) in the periocular area during the night, three times a week, on nonconsecutive days, for 12 weeks (3 months). If patients presented irritative dermatitis a topical 0.05% desonide cream was administered and applied for less of 5 days until symptoms improved."
1639588|NCT01935297|Behavioral|Exercise|endurance and resistance exercise 3x/week for 8 weeks
1639589|NCT01935271|Dietary Supplement|Muscle Armor Supplement|
1639590|NCT01935271|Dietary Supplement|Placebo|
2012209|NCT02143414|Drug|Mercaptopurine|Given PO
2012210|NCT02143414|Drug|Methotrexate|Given PO
2012211|NCT02143414|Drug|Prednisone|Given PO
2012212|NCT02143414|Drug|Vincristine Sulfate|Given IV
1639591|NCT01935258|Other|Psychosomatic therapy|Psychosomatic therapy delivered by a psychosomatic therapist, consists of a combination of information and education delivery, relaxation therapy and mindfulness, cognitive approaches and activating therapy. This multi-component approach is captured into a protocol in which therapists are able to modify the treatment in order to deliver a tailor-made treatment for patients with MUS.
1639592|NCT01935258|Other|care as usual|usual care of the general practitioner
1639593|NCT01935245|Device|Mini extracorporeal circulation|"Minimal-ECC versus conventional ECC circuits minimise foreign surface-blood interaction and are heparinized from tip to tip. The tubing length has been shortened to decrease crystalloid prime. Cardiotomy suction is minimised, which leads to less fibrinolysis. An active air-removal device is added to the closed circuit.
The use of minimal ECC has already shown a significant reduction of the systemic inflammatory reaction and less peroperative transfusion of blood products."
1639594|NCT01935245|Device|Conventional extracorporeal circulation|
1639595|NCT01935219|Behavioral|Goal Management Training|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
1639596|NCT01935219|Behavioral|Processing Speed Training|9 weeks, a total of 10 hours of computer-based processing speed training; 60-75 minutes/week
1639597|NCT01935219|Behavioral|Brain Health Workshop|9 weeks, 2 hour session/week, 1 hour/day homework (6 days/week), 2 x 0.5 hour sessions with trainer
1639598|NCT01935206|Drug|Naloxone (2 mg/kg)|
1639599|NCT01935206|Drug|Placebo|
2012213|NCT02142855|Behavioral|Concentric Exercise Training|8 weeks concentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
1639601|NCT01935180|Device|Colonoscopy Cap|4mm transparent cap (Olympus) mounted to the tip of a colonoscope.
1639602|NCT01935167|Drug|DW1029M 600mg|DW1029M 150mg 2 tablets b.i.d
1639603|NCT01935167|Drug|DW1029M 1200mg|DW1029M 300mg 2 tablets b.i.d
1639604|NCT01935167|Drug|Placebo|Placebo 2 tablets b.i.d.
1639605|NCT01935154|Drug|Vx-001|
1639606|NCT01935154|Drug|Placebo|
1639607|NCT01935141|Procedure|Low-Dose IV Contrast|A single intravenous dose of 30 ml of Visipaque (Iodixanol) 320 non-ionic isoosmolar contrast agent will be given for each CT scan.
1639608|NCT01935141|Device|Siemens Sensation 64-MDCT scanner.|The device will be used to perform CT Pulmonary Angiograms
1639609|NCT01935141|Drug|Visipaque 320 non-ionic isoosmolar contrast agent|Single Dose of Intravenous Iodixanol will be administered per CT scan.
1639610|NCT01935128|Drug|Arm 1 Everolimus/Reduced dose tacrolimus|Immunosuppression drug intervention
1639611|NCT01935115|Drug|Propofol|Propofol anesthesia for ECT
1639612|NCT01935115|Drug|Ketamine|Ketamine anesthesia for ECT
1639613|NCT01935089|Drug|Pegylated Interferon alpha 2b|1µg/kg/week
1639614|NCT01935076|Behavioral|Neonatal exposure to maternal obesity|
1639615|NCT01935063|Behavioral|Cognitive Behavioral Couple Therapy|CBCT includes the following: (1) re-conceptualize PVD as a multidimensional pain problem influenced by a variety of factors including thoughts, emotions, behaviors and couple interactions; (2) re-conceptualize PVD as a couple problem in which both members of the couple affect and are affected by the pain; (3) modify those factors associated with pain during intercourse with a view to increasing adaptive coping, for example, by increasing self-efficacy and decreasing catastrophizing, as well as decreasing pain intensity; (4) improve the quality of sexual functioning, reduce sexual distress and increase sexual satisfaction; (5) consolidate skills.
1639616|NCT01935063|Other|Topical Lidocaine|Nightly applications of a 5% lidocaine ointment on the vulvar vestibule, at the entry of the vagina (50mg/g, Xylocaïne®, AstraZeneca, tube of 35g) for 12 weeks, as described by Zolnoun et al. (2003). In addition, the cream will be applied to a cotton ball kept on the vestibule via the participant's underwear overnight to ensure a continued 7 to 8-hour contact between the anesthetic and the vestibule. A pamphlet with figures detailing how to apply the cream will be given to participants, in addition to a calibrated measurement tool to ensure that all participants apply the same quantity every night.
1639617|NCT01935050|Behavioral|Guided Cognitive-Behavioral Self-Help|Participants will complete the study treatment at home. Bi-weekly telephone support will be provided by study staff.
2012214|NCT02142855|Behavioral|Eccentric Exercise Training|8 weeks eccentric exercise training, 3 x per week, 60% 1-RM; 4 x 12-15 repetitions, 2 min rest between sets
1639619|NCT01935011|Other|PD, DBS|PD DBS frequency on swallowing function
1639620|NCT01934972|Other|CR + DCS (D-cycloserine)|CR + DCS
1639621|NCT01934972|Other|CR + placebo|CR + placebo
1639622|NCT01934959|Drug|Bifico|
1639623|NCT01934946|Other|comprehensive rehabilitation|received 14 days hospitalization for comprehensive rehabilitation
1639624|NCT01934946|Other|home rehabilitation|6 times home rehabilitation services within 3 months
1639625|NCT01934933|Drug|celebrex|
1639626|NCT01934933|Drug|Enbrel|
1639627|NCT01934933|Drug|Enbrel plus Celebrex|
1639629|NCT01934894|Drug|cabazitaxel|
1639630|NCT01934894|Drug|lapatinib|
1639631|NCT01934881|Device|voltage adjustment only|Only voltage will be adjusted in all programming sections.
1639632|NCT01934881|Device|Combined parameters adjustment|More than one parameter, including voltage, frequency and pulse width, will be adjusted in the programming sections.
1639633|NCT01934868|Drug|prolotherapy solution of 20% dextrose|After verifying the anatomy of the lumbosacral spine under ultrasound, a 9cm 22 gauge needle will be used to inject the prolotherapy solution to each of the points specified. In order to view the needle under ultrasound, a needle at least as thick as 22G is required. In order for the prolotherapy injections to be safe, bone must be contacted in order to avoid nerve damage. At each point a total of 1cc prolotherapy solution will be injected.
1639634|NCT01934868|Drug|Epidural Steroid Injection|Prior to the epidural injection a local anaesthetic solution of 1% lidocaine will be injected into the relevant subcutaneous and ligamentous interlaminar space. The injectant solution will be comprised of 80mg methylprednisolone combined with 10mg (2cc) 0.5% bupivicaine. The resulting 4cc will be diluted with another 4cc of normal saline giving a total volume of 8cc. A loss of resistance technique will be used and radiocontrast dye will be injected to verify the placement of the needle prior to injecting the steroid solution.
1639635|NCT01934842|Device|TAP20-C|
1639636|NCT01934842|Device|SAFE-T-FILL|
1639637|NCT01934829|Drug|urea-based cream|"urea-based cream (10% urea; Eucerin) 3 times per day plus best supportive care, starting on day 1 of sorafenib treatment, for a maximum of 12 weeks .
BSC included the ad libitum use of non-urea-based moisturizing creams, alcohol-free moisturizer and petroleum jelly. Once HFSR occurred, patients were allowed any cream, including urea based creams, as guided by the investigator."
1639638|NCT01934816|Other|Intradermal injections of GLP-1 and its analogues|native GLP-1,Exenatide (Byetta)and Liraglutide (Victoza) will be microinjected at the same visit in no particular order in all study arms
1639639|NCT01934803|Dietary Supplement|Zinc gluconate|Study participants will be randomly assigned to a zinc gluconate or placebo group and will be instructed to take one pill of study medication orally daily for 18 months.
1639640|NCT01934803|Dietary Supplement|Placebo|
1639641|NCT01934790|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Participants received intravenous (IV) injection of radium-223 dichloride 50 kBq/kg body weight every 4 weeks up to 6 injections.
1639642|NCT01934777|Drug|Docosahexaenoic Acid plus Vitamin E plus choline|DHA 250 mg plus Vitamin E (39 UI) plus Choline 201 mg
1639643|NCT01934777|Drug|placebo pearls|placebo
1639644|NCT01934751|Other|Delayed Intervention (DI)|Subjects randomized to the DI group will be given a card with the number for the usual Substance Use Service, where they will be seen within 2-4 weeks (standard practice). If they attend the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
1639645|NCT01934751|Other|Rapid Intervention (RI)|Subjects randomized to the RI group will be seen in the Substance Use Service at within 1-2 days of study enrolment. The Research Assistant will book the appointment and arrange transportation. At the Substance Use Service they will be offered supportive counseling, pharmacotherapy, and information on community treatment resources.
1639646|NCT01934738|Drug|PF-06273340|Tablets, 100 mg TID, 14 days
1639647|NCT01934738|Drug|Placebo|Tablets, TID, 14 days
1639648|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
1639649|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
1639650|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
1639651|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
1639652|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
1639653|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
1639654|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
1639655|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
1639656|NCT01934738|Drug|PF-06273340|Tablets, to be decided dose, TID or titration, 14 days
1639657|NCT01934738|Drug|Placebo|Tablets, TID or titration, 14 days
1639658|NCT01934712|Drug|Faster-acting insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
1639659|NCT01934712|Drug|insulin aspart|Single dose injected subcutaneously (s.c, under the skin)
1639660|NCT01934699|Device|Cardiac ultrasound|Patient will get echocardiographic examination during coronary angiography. 2D-Strain Analysis will be performed based on data of these echocardiographic examination. Only when vitality in the contraction impaired segments will be established based on 2D-Strain Analysis, PCI will be performed.
1639661|NCT01934699|Device|MRI scanner|Coronary angiography on patient will be canceled. Patients will get viability assessment using MRI within the next 7 days. When vitality will be established with MRI, patient will get PCI.
1639662|NCT01934686|Other|No treatment given|Patients will fill out a questionnaire by interview.
1639663|NCT01934673|Other|No treatment given|Patients will fill out a questionnaire by interview.
1639664|NCT01934647|Drug|MK-8892|Single oral capsule with up to 14 mg of MK-8892
1639665|NCT01934634|Drug|LCL161|LCL161 (tablets): 300, 600, 1200, or 1800 mg once a week (Day 1, 8, 15) for 3 weeks, every 28 days
1639666|NCT01934634|Drug|Gemcitabine|Gemcitabine IV: 1,000 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
1639667|NCT01934634|Drug|nab-Paclitaxel|nab-paclitaxel IV: 125 mg/m2 once a week (Day 1, 8, 15) for 3 weeks, every 28 days
1639668|NCT01934621|Behavioral|Strategy Training|
1639669|NCT01934621|Behavioral|Attention Control|
1639670|NCT01934608|Behavioral|Refill synch|
1639671|NCT01934595|Dietary Supplement|Beneprotein|The study will compare different protein supplementation amounts to determine if increased protein supplementation in critically ill patients improves outcomes.
1639672|NCT01934582|Drug|UT-15C SR|
1639673|NCT01934582|Drug|treprostinil diethanolamine|Open label study drug.
1639674|NCT01934569|Drug|Pravastatin, midazolam, losartan, omeprazole, caffeine and PF-05089771|PF-05089771 450mg single dose and titration from 150mg BID to 450mg BID Pravastatin 10mg dingle dose, Midazolam 7.5mg single dose, Losartan 25mg single dose, Caffeine 100mg single dose, Omeprazole 20mg single dose
1639675|NCT01934556|Drug|Ranibizumab 0.3 mg intravitreal injection|
1639676|NCT01934556|Device|Guided Laser Photocoagulation|
1639677|NCT01934543|Other|Polyunsaturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 6.0% from saturated fat; 14.4% from monounsaturated fat; 12.6% from n-6 polyunsaturated fat).
1639678|NCT01934543|Other|Saturated fatty acids diet|During 4 weeks, subjects eat a diet high in polyunsaturated fatty acids (percent of total caloric intake: 15.0% from proteins; 50.0% from carbohydrates; 35.0% from fat: 13.4% from saturated fat; 15.3% from monounsaturated fat; 4.0% from n-6 polyunsaturated fat).
1639679|NCT01934530|Procedure|Soft Tissue Grafting|"All patients were treated with infiltration of local anesthetic with vasoconstrictor if noted tolerable by the medical history. Surgeons were then notified if the patient was randomized to the test or control according to a blinded treatment assignment. In both groups, anesthesia was confirmed at the implant site and the palatal donor site if indicated. The recipient bed was then prepared.
Vertical incisions were made at the defect at line angles and horizontal incisions connected the two vertical releases intrasulcularly without involving the interdental papilla. The flap was reflected as a full thickness flap maintaining the integrity of the collagen attachment with de-epithelialization of papilla to allow for coronal advancement."
1639680|NCT01934504|Procedure|Venipuncture for blood sample collection|Analysis samples from the blood sample collection at specific time points.
1639681|NCT01934491|Behavioral|Cognitive Training A|
1639685|NCT01934439|Device|30 PAAD treatments|Subjects will don a shirt with pockets at the elbow and shoulder in each of which a muscle vibrator is located. The subject will then place the affected arm in the PAAD. The PAAD will range the affected arm, at the shoulder in the adduction-abduction direction, and at the elbow in the flexion-extension direction. The subject will assist volitionally this motion, and visual feedback of the level of their assistive torque will be provided along with a target torque level. The muscle vibrators will alternate from one side of each of the 2 joints to the other as the motion reverses, vibration always being applied to the lengthening muscles. This treatment will last 30 min in each session.
1639686|NCT01934413|Behavioral|Technology-Enhanced Transitional Palliative Care|The Transitional Care intervention will be initiated within 24 hours after enrollment, and will include initial transitional care planning, daily hospital visits, crisis prevention planning by an experienced Palliative Care nurse. The intervention will continue after the patient is discharged to home or short term skilled nursing facility, and it will involve an in-person visit between 24-48 hours post discharge, weekly virtual visits via iPad and video conference technology, and additional home visits as needed. Care plans established during initial planning will be implemented and adjusted under the guidance of the palliative care nurse delivering the intervention.
1639687|NCT01934413|Other|Usual Standard of Care|Usual care includes routine hospital discharge planning and usual physician care in primary and specialty outpatient clinics post hospital discharge. The PC consulting service provides consulting services in the inpatient setting. There are no standardized, intentional services provided to outpatients by the PC consulting team. Services provided to outpatients may occur sporadically as initiated by the patient. The majority of PC follow-up if any is a single phone call to the patient/caregiver. To account for the time spent and number of contacts made with the intervention group, the control group will be contacted by phone weekly by a non-nurse member of the study team not involved with the intervention, asked to relate what, if any, medically-related events occurred.
1639688|NCT01934374|Behavioral|Task-Oriented Lower Extremity Strengthening Training|"On the 30th day post stroke (D30), the experimental group will start to receive the TOLEST program for four weeks, one hour per session and three sessions per week. The TOLEST focuses on using task-specific circuit training combined with strengthening of bilateral lower limbs.
The control group will receive equal-dose exercises starting on D30, with the emphasis on stretching and non-functional movements of the affected lower extremity."
1639689|NCT01934361|Drug|buparlisib|Buparlisib administered orally on a continuous daily schedule. Buparlisib is manufactured as 10mg and 50mg hard gelatin capsules.
1639690|NCT01934361|Drug|carboplatin|Carboplatin intravenous infusion will be administered at a dose of AUC 5 in a 21 day cycle (every 3 weeks).
1639691|NCT01934361|Drug|lomustine|Lomustine will be administered as a single oral dose of 100 mg/m² every 6 weeks in a 42 day cycles.
1639692|NCT01934361|Drug|placebo|Placebo will be administered orally on a continuous QD dosing schedule for cycles of 42 days. Buparlisib matching placebo is manufactured as 10 mg and 50 mg hard gelatin capsules.
1639693|NCT01934348|Behavioral|Psychological First Aid|
1639694|NCT01934348|Behavioral|Usual victim advocacy Services|
1639695|NCT01934335|Drug|Vandetanib|
1639696|NCT01934335|Other|Placebo|
1639697|NCT01934322|Other|Case Management|"Furnish specific assistance and to provide referrals for the patients:
If the social determinants are not adequate, the team will lend assistance for obtaining income entitlements, health insurance coverage if eligible, stable housing, schooling for children, etc.
If there are mental disturbances, the team will refer to mental health departments inside the hospital, and if necessary, to a psychiatrist, psychologist or general practitioner (GP) out in the community.
If the patient presents risk behaviors, the team will refer to substance abuse services and links to community services in order to maintain continuity of care.
In case of somatic problems, the team will find a new GP or make contact with the previous provider, contingent on the patient's consent."
1639698|NCT01934309|Behavioral|TB reminders|The intervention to be studied involves providing clinic-based medical care providers (e.g., nurses, clinical officers, medical officers, consultants) with patient-speciﬁc clinical reminders regarding TB that are generated from a patient's electronic medical record and based on accepted clinical algorithms for TB screening and treatment.
1639699|NCT01934296|Device|Activa PC+S|Surgical implantation of Activa PC+S as one component of a therapeutic DBS system implantation
1639700|NCT01934283|Device|urine folly catheter|
1639701|NCT01934270|Other|Anaerobic Test|To evaluate the secretion of growth hormone in response to anaerobic exercise in children.
1639702|NCT01934257|Other|Marketed milk-based lactose-containing infant formula|
1639703|NCT01934257|Other|Marketed milk-based lactose-free infant formula|
1639704|NCT01934257|Other|Marketed soy-based lactose-free infant formula|
1639705|NCT01934244|Device|NovaSure Endometrial Ablation|The NovaSure Endometrial Ablation device consists of a disposable single-use, conformable bipolar electrode array mounted on an expandable frame that can create a confluent lesion on the entire interior surface area of the uterine cavity. The device is inserted transcervically into the uterine cavity, and the sheath is retracted to allow the bipolar electrode array to be deployed and conform to the uterine cavity. The disposable device works in conjunction with a dedicated NovaSure RF (radio frequency) controller to perform customized, global endometrial ablation.
1639706|NCT01934231|Drug|Amoxicillin-Potassium Clavulanate Combination|The drug is available in two sachets (CVA/AMPC Dry Syrup 0.505 g and CVA/AMPC Dry Syrup 1.01 g). CVA/AMPC Dry Syrup 1.01 g sachet contains 42.9 mg of Potassium Clavulanate and 600 mg of Amoxicillin Hydrate. It is a white to yellowish white powder and has strawberry flavor and it is white to yellowish white suspension when it is suspended before use.
1639707|NCT01934218|Device|Gel-One|
1639708|NCT01934218|Device|PBS|
1639709|NCT01934205|Drug|GSK2140944 (Single dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously as a single dose.
1639710|NCT01934205|Drug|GSK2140944 (Multiple dose)|A lyophilized formulation, pale yellow to grayish yellow cake containing 750 mg of GSK2140944 (as free base) per vial, Administered intravenously every 12 hours for 5 doses (3 days).
2012215|NCT02142049|Drug|Ibrutinib|Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
1639891|NCT01932762|Drug|Grazoprevir|100 mg every day (QD) orally
2012216|NCT02142049|Drug|Part 1: Dose Level 1|Etoposide, Prednisone, Doxorubicin, Cyclophosphamide, Vincristine, Rituximab, Pegfilgrastim
1639715|NCT01934179|Other|cytology specimen collection procedure|Undergo blood sample collection
1639716|NCT01934179|Other|laboratory biomarker analysis|Correlative studies
1639717|NCT01934179|Other|questionnaire administration|Ancillary studies
1639718|NCT01934166|Drug|Nalmefene 18 mg|One single oral dose of 18 mg
1639719|NCT01934153|Drug|[14C]Umeclidinium 18.5 mg|Umeclidinium will be supplied as clear, colorless solution, free from visible particulates, single dose, topical solution in clear glass jars. Dosage of 18.5 mg of Umeclidinium per gram is equivalent to 22 mg per gram of the bromide salt.
1639720|NCT01934140|Biological|Meningococcal vaccine GSK134612|1 dose administered intramuscularly in the non-dominant deltoid region.
1639721|NCT01934127|Biological|Investigational H7N1 vaccine GSK2789869A|One dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while second dose of GSK2789869A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
1639722|NCT01934127|Biological|Investigational H7N1 vaccine GSK2789868A|One dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of GSK2789868A H7N1 vaccine administered intramuscularly at the deltoid region of the dominant arm at Day 21
1639723|NCT01934127|Biological|Placebo|One dose of placebo administered intramuscularly at the deltoid region of the non-dominant arm at Day 0 while the second dose of placebo administered intramuscularly at the deltoid region of the dominant arm at Day 21
1639724|NCT01934101|Drug|CHR-5154|CHR-5154
1639725|NCT01934101|Drug|Placebo|Placebo
1639726|NCT01934088|Drug|Propofol|
1639727|NCT01934088|Drug|Midazolam|
1639728|NCT01934088|Drug|Fentanyl|
1639729|NCT01934075|Behavioral|Mental health treatment|6 sessions of individual mental health counseling.
1639730|NCT01934062|Procedure|Surgery|All surgeries performed at Nationwide Children's Hosp. between 1/1/2013 & 7/31/2013.
1639731|NCT01934049|Procedure|hip arthroplasty|Every patient with femoral neck fractures must undergo hip hemi-arthroplasty.
1639732|NCT01934049|Drug|Total Intravenous Anesthesia and Peripheral nerve blocks|Every patient receives Peripheral nerve blocks and Total Intravenous Anesthesia with propofol
1639733|NCT01934036|Dietary Supplement|Obex|After concluded the two months of treatment, patients will be follow-up during three months without consumption of Obex.
1639734|NCT01934036|Drug|Placebo|After concluded the two months of treatment, patients will be follow-up during three months without consumption of the placebo.
1639735|NCT01934023|Drug|Varenicline|Champix (Varenicline) is an approved smoking cessation medication
1639736|NCT01934023|Drug|Placebo|
1639737|NCT01934010|Drug|AM-101|AM-101 gel for intratympanic injection
1639738|NCT01933997|Drug|Metadoxine (MG01CI )|
1639739|NCT01933984|Drug|salmeterol/fluticasone|Each puff contains 25 mcg salmeterol /250 mcg fluticasone
1639740|NCT01933984|Drug|ipatropium/salbutamol|Each vial contains ipatropium bromide 0.5 mg and salbutamol sulfate 2.5 mg
1639741|NCT01933984|Drug|Methylprednisolone|
1639742|NCT01933984|Drug|Additional broncho-dilators inhalation|Salmeterol/fluticasone (Seretide Evohaler) 4 puffs plus fenoterol (Berotec)(0.1mg/puff) 4 puffs inhalation when target airway resistance, measured every 8 hours, not met
1639743|NCT01933984|Other|Determining personal target airway resistance|Three consecutive doses of 4, 8 and 16 puffs of fenoterol MDI (100 mcg/puff, Berotec;Boehringer Ingelheim, Ingelheim, Germany) inhalation with each dose 15 minutes apart. The airway resistance measured 15 minutes later is assigned as this patient's personal target airway resistance.
1639744|NCT01933984|Device|Ventilator support|
1639745|NCT01933971|Drug|Filgrastim test|0.3 mg/mL injectable solution in 1 mL vials Manufacturer (Drug Substance): Eurogenetec S.A., B-4102 Seraing, Belgium Manufacturer (Drug Product): Areta International S.r.l., I-21040 Gerenzano, Italy Batch release: Areta International S.r.l., I-21040 Gerenzano, Italy Route of administration: subcutaneous
1639746|NCT01933971|Drug|Filgrastim reference|"0.3 mg/mL injectable solution in 1 mL vials Licensed owner: Dompé farmaceutici S.p.A., Milan, Italy Manufacturer (Drug Product): Hoffmann - La Roche Ltd., Basel, Switzerland and Amgen Manufacturing Limited, Puertorico.
Batch release: Amgen Europe B.V., Breda, Netherlands Route of administration: subcutaneous"
2012217|NCT02137226|Drug|BI 695501|BI 695501, every two weeks for 48 weeks (25 injections in total)
1639748|NCT01933945|Procedure|TACE (transarterial chemoembolization)|First treatment for all patients included in the study
1639749|NCT01933945|Drug|Sorafenib (Nexavar, BAY43-9006)|
1639750|NCT01933932|Drug|Selumetinib|Three 25 mg selumetinib capsules (Hyd-Sulfate) be administered orally, twice daily, (total dose 75 mg dose bd) on an uninterrupted schedule.
1639751|NCT01933932|Drug|Docetaxel|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
1639752|NCT01933932|Drug|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily in combination with docetaxel 75 mg/m2 intravenously administered on day 1 of each 21 day cycle.
1639753|NCT01933932|Drug|Pegylated G-CSF|All patients will receive pegylated Granulocyte Colony Stimulating Factor (G-CSF) at least 24 hours after administration of every docetaxel dose and not within 14 days prior to the next docetaxel administration.
2012218|NCT02137226|Drug|US-licensed Humira®|one injection every 2 weeks for 48 weeks (25 injections in total)
1639756|NCT01933906|Drug|P1101|
1639757|NCT01933880|Drug|Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH)|Osmotic release oral system methylphenidate hydrochloride (OROS-MPH) starting at initial dosage of 18 milligram per day (mg/d) which can be increased to 36mg/d up to a maximum dosage of 54mg/d according to the therapeutic effect and tolerance or maintained at 36 mg or re-adjusted to 18mg due to intolerance.
1639758|NCT01933880|Other|No intervention|Participants did not receive any study drug in this group. Participants were assessed for changes in the cognitive functions and the efficacy was compared with ADHD children.
1639759|NCT01933867|Procedure|Water immersion|Water immersion means infusion of room temperature water during colonoscope insertion without air insufflation.
1639760|NCT01933867|Procedure|Air insufflation insertion|
1639761|NCT01933841|Device|TOF-Watch SX|As part of standard care, patients who undergo intraoperative neuromuscular blockade will have their TOF ratio measured and recorded during their first 10 minutes in the PACU by perioperative nursing staff.
1639762|NCT01933841|Procedure|Notify the provider|"Based on the TOF reading, the patient's PACU nurse will page the provider who administered the block and/or a designated Reversal Support team member. The page will identify the patient and notify the provider of the suboptimal TOF ratio."
1639763|NCT01933828|Procedure|OPEN lobectomy|Lobectomy and mediastinal lymph node dissection by thoracotomy with rib-spreading.
1639764|NCT01933828|Procedure|VATS lobectomy|Thoracoscopic minimally invasive lobectomy with thoracoscopic mediastinal lymph node dissection without rib-spreading.
1639765|NCT01933828|Device|ROBOT-assisted lobectomy|Robot-assisted lobectomy with mediastinal lymph node dissection (Robot group as clinical assignment in prospective Cohort).
1639766|NCT01933815|Drug|TPI 287|TPI 287 is a microtubule inhibitor belonging to the taxane diterpenoid (taxoid) family, and specifically to the abeotaxane class. TPI 287 is an Investigational Drug.
1639767|NCT01933815|Drug|Bevacizumab|Avastin (bevacizumab) is an FDA approved drug indicated for multiple cancers, including as a single agent for GBM for adult patients with progressive disease following prior therapy. Single agent effectiveness is based on improvement in objective response rate; no data is available demonstrating improvement in disease-related symptoms or survival with bevacizumab.
2012219|NCT02135029|Drug|Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
1639769|NCT01933789|Behavioral|Communication Feedback Form for Patients with Serious Illness|"The intervention, based on self-efficacy theory, identifies patients' preferences for communication about end-of-life care (EOLC) and barriers and facilitators to this communication, and collates these data into a feedback form. The feedback forms are tailored to each recipient (clinician, patient, family) to support the communication tasks which that recipient will address. Feedback forms are sent to participants prior to the target clinic visit. The primary clinician's form suggests referral to palliative care if there are potentially unmet palliative-care communication needs. All forms include tips to help the recipient respond to communication preferences appropriately."
1639770|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
1639771|NCT01933776|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap|0.5 mL, Intramuscular (IM)
1639772|NCT01933763|Drug|REGN1193|
1639773|NCT01933763|Other|Placebo|
1639774|NCT01933750|Device|PresVIEW Device Implantation|
1639775|NCT01933737|Device|Kinesio Taping|The Kinesio Taping group (KTG) (n = 31 elderly women) were submitted to the protocol of applying Kinesio Taping for gastrocnemius muscle and the muscles of the median foot. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
1639776|NCT01933737|Device|3M Micropore|The placebo tape group (PTG) (n = 31 elderly women) were submitted to the protocol of applying placebo tape (3M Micropore) for gastrocnemius muscle and the muscles of the median foot in the same way that KTG. The application of the tapes was bilateral limbs. The subjects were evaluated post-application and 48 hours after application of the tape.
1639777|NCT01933724|Drug|5 mg prednisone|Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.
1639778|NCT01933724|Drug|0 mg prednisone|Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
1639779|NCT01933711|Drug|rituximab|
1639780|NCT01933698|Drug|amoxicillin|Comparison of pharmacokinetics of both formulations
2012220|NCT02135029|Drug|Atorvastatin|Atorvastatin PO QD
2012221|NCT02135029|Other|Placebo for Bococizumab (PF-04950615;RN316)|150 mg every 2 weeks by subcutaneous injection for 24 weeks
1639783|NCT01933672|Drug|PF-04937319 once-daily|Tablets, 300 mg once-daily with breakfast, 14-days
1639784|NCT01933672|Drug|PF-04937319 split-dose|tablets, 150 mg with breakfast plus 100 mg with lunch, 14-days
1639785|NCT01933672|Drug|Sitagliptin once-daily|tablets, 100 mg once-daily with breakfast, 14-days
1639786|NCT01933659|Drug|DSW|ingesting DSW 200 cc four times a day (one hour before meal and bed time)
1639787|NCT01933633|Behavioral|Exercise|
1639788|NCT01933607|Device|TOPS System|Non-randomized study involving implantation of a TOPS via lumbar surgery to decompress and provide stability to the index level.
1639789|NCT01933594|Drug|Romidepsin|RMD will be administered over 4 hours via an intravenous (IV) catheter.
1639790|NCT01933594|Drug|Placebo for RMD: 0.9% sodium chloride for injection|Placebo for RMD will be administered over 4 hours via an IV catheter.
1639791|NCT01933568|Radiation|SABR|combined CFRT and SABR with concurrent cisplatin
1639792|NCT01933568|Drug|Cisplatin|combined CFRT and SABR with concurrent cisplatin
1639793|NCT01933555|Behavioral|Empowerment Program|
1639794|NCT01933542|Drug|Placebo|Two placebo tablets identical to the chlorzoxazone tablets.
1639795|NCT01933542|Drug|Chlorzoxazone|Two 250 mg chlorzoxazone tablets
1639796|NCT01933542|Drug|Morphine|Patient controlled intravenous morphine (PCA-pump), bolus 2.5 mg, lock-out-time 10 minutes. Concentration : Morphin 1 mg/ml.
1639797|NCT01933542|Drug|Zofran|Zofran 4 mg iv. in case of moderate to severe nausea, supplemented by Zofran 1 mg iv. if needed
1639798|NCT01933529|Drug|ARA 290|ARA 290 is injected s.c. once daily during the study period
2012222|NCT02135029|Other|Placebo for atorvastatin|PO QD
1639800|NCT01933503|Drug|OCA 5 mg|
1639801|NCT01933503|Drug|OCA 10 mg|
1639802|NCT01933503|Drug|OCA 25 mg|
1639803|NCT01933490|Other|high carbohydrate test meal|
1639804|NCT01933490|Other|high carbohydrate test meal after pre-treatment with rapid acting aspart insulin|
1639805|NCT01933490|Other|high fructose , low glucose test meal with carbohydrate and caloric content similar to the control meal|
1639806|NCT01933477|Other|MCH-focused ART services|Post-partum women who are breast feeding will be retained in the antenatal clinic to receive continued MCH-focused ART services until after the end of breastfeeding and once infants' final HIV status is determined.
1639807|NCT01933464|Drug|Cromolyn Sodium|
1639808|NCT01933464|Drug|Normal Saline|
1639809|NCT01933451|Other|Intraoperative fluid therapy|Intraoperative fluid therapy is directed by pulse pressure variation to a setting value, above 18% or below 13%.
1639810|NCT01933438|Other|Sup-ER Protocol|Early shoulder repositioning (Sup-ER Splint)
1639811|NCT01933438|Other|Control|Standard treatment
1639812|NCT01933425|Drug|rocuronium|
1639813|NCT01933425|Drug|sugammadex|
1639814|NCT01933425|Drug|placebo|
1639815|NCT01933412|Biological|Sci-B-Vac Hepatitis B Vaccine|Sci-B-Vac Hepatitis B Vaccine
1639816|NCT01933412|Biological|Engerix B Hepatitis B Vaccine|
1639817|NCT01933399|Other|Inextensible LSO (stiff back support)|Cotton/nylon canvas back support with velcro fasteners.
1639818|NCT01933399|Other|Extensible LSO, a back support that is flexible|Back support is constructed from lycra and neoprene with velcro fasteners.
1639819|NCT01933399|Other|Standard of Care|Physician visit, physician advice, medications as determined by physician, over the counter medications, and physical therapy.
1639820|NCT01933386|Device|SoundBite|Non-surgical removable bone conduction device via the teeth.
1639821|NCT01933373|Procedure|Toupet|Laparoscopic posterior partial fundoplication plus myotomy.
1639822|NCT01933373|Procedure|Dor|Anterior partial fundoplication plus myotomy.
1639823|NCT01933360|Drug|Misoprostol sublingual, 1h|Misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
1639824|NCT01933360|Drug|Placebo sublingual,1h|Placebo for misoprostol is administered sublingually 1 hour prior to surgical termination of early pregnancy
1639825|NCT01933360|Drug|Misoprostol sublingual, 3h|Misoprostol is administered sublingually, 3 hours prior to surgical termination of early pregnancy
1639826|NCT01933360|Drug|Misoprostol vaginal, 1h|Misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
1639827|NCT01933360|Drug|Misoprostol vaginal, 3h|Misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
1639828|NCT01933360|Drug|Placebo sublingual, 3h|Placebo for misoprostol is administered sublingually 3 hours prior to surgical termination of early pregnancy
1639829|NCT01933360|Drug|Placebo vaginal, 1h|Placebo for misoprostol is administered vaginally 1 hour prior to surgical termination of early pregnancy
1639830|NCT01933360|Drug|Placebo vaginal, 3h|Placebo for misoprostol is administered vaginally 3 hours prior to surgical termination of early pregnancy
1639831|NCT01933347|Drug|Gefitinib|Subjects will receive the oral administration of gefitinib 250mg/d until the tumor progression.
1639832|NCT01933334|Drug|Pirfenidone|Pirfenidone will be administered orally at a dose of 267 mg one oral capsule TID (801 mg/day) for 1 or 2 weeks followed by two 267 mg oral capsules TID (1602 mg/day) for 1 or 2 weeks (titration period) and then three 267 mg oral capsules TID (2403 mg/day) for 12 weeks (maintenance period).
1639833|NCT01933321|Biological|Intrathecal autologous stem cell|Mobilization and collection of stem cells for intravenous and intrathecal administration
1639834|NCT01933308|Other|Continuous high intensity training-CT80|Continuous exercise training at 80% of peak work rate Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
1639835|NCT01933308|Other|Training at ventilatory threshold-CTVT|Continuous exercise training at the ventilatory threshold Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
1639836|NCT01933308|Other|Interval training-IT|High intensity interval training Heart rate (HR) response observed at their target training intensity will be identified from an incremental exercise test completed at baseline. Subjects will be asked to train within ±5beats/min of this HR. Subjects will also perform upper-extremity strength training, stretching and relaxation exercises. Overall, sessions will last approximately 2hrs, including cycling (45-60min), strength training (30min), stretching (10min) and relaxation exercises (20min). Sessions will be held on Mondays, Wednesdays and Fridays. Supervision will be provided by clinical exercise physiologists trained by Dr. Pepin. Self-management training (Living Well with COPD®) will be provided by a healthcare practitioner trained by Dr. Lavoie.
1639837|NCT01933295|Behavioral|Cognitive Behavioral Therapy for Insomnia|
1639838|NCT01933295|Behavioral|Sleep Education|
1639839|NCT01933295|Behavioral|Sleep Restriction Therapy|
1639840|NCT01933282|Drug|MESA chemotherapy|Methotrexate 2g/ m2，IV d1 etoposide 100mg/ m2，VD d2，d3，d4， dexamethasone 20mg/ m2，VD d2，d3，d4, d5 Polyehylene glycol-asparaginase muscular injection 2500IU/ m2, d5
1639841|NCT01933282|Drug|MESA|Methotrexate etoposide dexamethasone Polyehylene glycol-asparaginase
1639842|NCT01933269|Drug|FACBC|
1639843|NCT01933256|Drug|HIP2B|
1639844|NCT01933256|Drug|Placebo|
1639888|NCT01932788|Drug|Vitamin D3 4000 IU in gummy form|Subjects randomized to the Vitamin D3 4000 IU gummy vitamin arm, the investigational drug, will consume 4 gummies/day beginning at 10-14 weeks of your pregnancy. All subjects will consume a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of your pregnancy.
1639889|NCT01932788|Drug|Placebo gummy vitamin|Subjects randomized to receive placebo, also in gummy form but manufactured without Vitamin D3, will consume 4 gummies/day beginning at 10-14 weeks of pregnancy. All subjects will take a prenatal vitamin (either chewable or pill form) also beginning at 10-14 weeks of pregnancy.
1639847|NCT01933230|Device|Excel Cryo Cooling System|"An Excel Cryo Cooling System collar will be place around the neck for two hours. This will cool the blood in the neck that goes to the brain causing the brain to become cool. The collar is a standard neck collar used for patients after neck surgery with a modification that allows for the placement of a cooling pack in the collar. The cooling pack is similar to the cooling packs used for sports injuries. The cooling packs will be changed every 20 minutes for the two-hour duration. During the study and for two hours after, we will collect data concerning the brain temperature, body temperature, brain oxygen level, and pressure both in the head and in the blood.
2 hour neck cooling period"
1639848|NCT01933217|Drug|Methylphenidate|
1639849|NCT01933217|Drug|Placebo|
1639850|NCT01933204|Other|Acupuncture|Acupuncture is a collection of procedures involving penetration of the skin with needles to stimulate certain points on the body. In its classical form it is a characteristic component of traditional Chinese medicine (TCM), a form of alternative medicine, and one of the oldest healing practices in the world.
1639851|NCT01933204|Drug|Climen 21 Tablets|Climen Tablets are commonly used for menopausal symptoms
1639852|NCT01933191|Behavioral|Aerobic treadmill exercise|Experimental training: Aerobic treadmill exercise (30 minutes, 70% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
1639853|NCT01933191|Behavioral|placebo exercise|placebo exercise: Aerobic treadmill exercise (30 minutes, 20% VO2max) prior to an elective minor dental procedures (e.g., extractions, endodontics, apicoectomies, dental restorations, periodontal treatment, dental implants).
1639854|NCT01933178|Device|Cirrus AS-OCT|
1639855|NCT01933165|Device|LipiView|
1639856|NCT01933152|Drug|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
1639857|NCT01933139|Other|Audio-visual presentation|
1639858|NCT01933126|Drug|HCG injection|
1639859|NCT01933126|Drug|Placebo|
1639861|NCT01933100|Other|Experimental Diet|
1639862|NCT01933087|Behavioral|Hand hygiene promotion|The intervention will adapt from the WHO Multimodal HH Improvement Strategy making use of five components: 1) system change (for example, changing systems to ensure that alcohol-based hand-rub is readily available wherever and whenever needed), 2) training and education, 3) observation and feedback, 4) reminders in the hospital, and 5) a hospital safety climate with the aim of inducing behavioural and cultural change in relation to reduce HCAI and improve HH. The intervention will be delivered to infection control ward nurses (ICWNs) of each ward at each time step by researcher and the infection control team (ICT).
1639863|NCT01933061|Drug|Abraxane|Abraxane 150- mg/m² IV on Days 1, 8, and 15 of a 28-day cycle
1639864|NCT01933061|Drug|Abraxane|Abraxane 150 mg/m^2 intravenously on Days 1, 8, and 15 of a 28-day cycle
1639865|NCT01933048|Drug|FluMist|FluMist Intranasal Vaccine
1639866|NCT01933035|Other|Immune Thrombocytopenics|Full blood count with extended platelet parameters
1639867|NCT01933035|Other|Hypo-proliferative thrombocytopenics|Full blood count with extended platelet parameters
1639868|NCT01933035|Other|Control Population|Full blood count with extended platelet parameters
1639869|NCT01933022|Drug|Eligard|Subcutaneous Injection
1639870|NCT01932996|Drug|nicotine patch plus nicotine gum/lozenge|12-week treatment with nicotine patch plus nicotine gum/lozenge
1639871|NCT01932996|Behavioral|Intensive Alcohol Intervention|Intensive alcohol abstinence counseling using CBT will include weekly individual sessions for 3 months followed by monthly booster group sessions for 3 months
1639872|NCT01932983|Device|Train of four test|TOF test includes stimulation of peripheral nerve of upper extremity, ulnar nerve in this study. Two methods of interpretation are included, visual which uses anesthesiologist TOF device, and quantitative uses intraoperative neurophysiologic monitoring device, both devices are in routine clinical practice use. Different interpretation of muscle contractions are followed, by quantitative method and visual method. Visual evaluates number of twitches and determines the degree of neuromuclular block and percent of blocked acetylcholine receptors. Quantitative method record muscle contraction by using EMG, presents each twitch as amplitude, caluculate peak to peak value, and provide numerical value and difference for each twitch.
1639873|NCT01932970|Drug|Etelcalcetide|Etelcalcetide is provided as a sterile lyophilized powder to be reconstituted with sterile water for injection.
1639874|NCT01932957|Procedure|Laparotomy arm|Laparotomy as standard treatment for ruptured ectopic pregnancy
1639875|NCT01932957|Procedure|Laparoscopy arm|Laparoscopy as treatment for ruptured ectopic pregnancy
1639876|NCT01932944|Device|No treatment|
1639877|NCT01932931|Dietary Supplement|Vitamin D supplement (50ug)|
1639878|NCT01932918|Drug|Patient controlled analgesia|"PCA with morphine in liver transplant:
Intravenous patient controlled analgesia with morphine was used for postoperative pain control in liver transplant recipients.
PCA with morphine and ketorolac:
Patient controlled analgesia with morphine and ketorolac was used for postoperative pain control in liver transplant and thoracic surgery patients.
Intravenous PCA in thoracic surgery Intravenous patient controlled analgesia was used for postoperative pain control in thoracic surgery patients.
PCEA in thoracic surgery Patient controlled epidural analgesia was used for postoperative pain control in thoracic surgery patients."
1639879|NCT01932905|Device|deep rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of central pain
1639880|NCT01932879|Other|Blackberry|Participants will be fed a higher fat, typical American diet for two 1-week periods. Participants must consume only and all food provided during the intervention periods.
1639881|NCT01932879|Other|Jello|
1639882|NCT01932866|Other|diabetic risk score|
1639883|NCT01932840|Behavioral|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock margarine packages differing only by the claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
1639884|NCT01932827|Behavioral|Mock Package Questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock cereal packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
1639885|NCT01932801|Drug|XR-NTX+HRC|
1639886|NCT01932801|Other|Placebo+HRC|
1639887|NCT01932801|Behavioral|HRC|
1639892|NCT01932762|Drug|Elbasvir|50 mg QD orally
1639893|NCT01932762|Drug|Ribavirin|Administered twice daily (BID) orally at a total daily dose of 800 mg to 1400 mg based on participant's weight on Day 1
1639894|NCT01932749|Device|Transcranial Magnetic stimulation|
1639895|NCT01932736|Other|changing ear canal pressure|ear canal pressure changes: pressure varied from +/-40 decapascals
1639896|NCT01932723|Behavioral|Lumbar stabilization exercises|The functional lumbar stabilization exercises was performed daily, 10 repetitions each, three times a day for three months consecutively.
1639897|NCT01932710|Procedure|White Blood Cell Transfusion|Patient receives white blood cells by vein from a volunteer donor. Each transfusion will take anywhere from 1 hour to several hours, depending on how treatment tolerated. Transfusion received every 3-4 days (at least 2 a week) for up to 6 weeks.
1639898|NCT01932697|Drug|Docetaxel|Given IV
1639899|NCT01932697|Radiation|Hyperfractionation|Undergo hyperfractionated IMRT
1639900|NCT01932697|Radiation|Intensity-Modulated Radiation Therapy|Undergo hyperfractionated IMRT
1639901|NCT01932697|Other|Laboratory Biomarker Analysis|Correlative studies
1639902|NCT01932697|Other|Quality-of-Life Assessment|Ancillary studies
1639903|NCT01932684|Other|Breath-Stacking|We used a silicone face mask, connected to a unidirectional valve which allowed only inspiration and is connected to a spirometer showed that the volume inspired by the individual. The face mask was attached to the appraised performed successive breaths until the researcher realized the lack of volume of air being inhaled and this time it was allowed to expire (Baker et al., 1990; Feitosa et al., 2012).
1639904|NCT01932684|Other|Incentive spirometry|We used an incentive spirometer volume (5000 Voldyne ® Sherwood Medical, USA). Subjects performed slow, deep inhalations from functional residual capacity to total lung capacity, seeking to sustain the inspiration for at least three seconds (Restrepo et al., 2011).
1639905|NCT01932684|Device|5000 Voldyne ® Sherwood Medical, USA|
1639906|NCT01932684|Device|Silicone face mask|
1639907|NCT01932658|Biological|Hematopoietic stem cell transplantation|Lymphoablation followed by hematopoietic stem cell transplantation to rescue the immune system.
1639908|NCT01932632|Other|Medication Minimization|Series of specific medication reviews done by attending MD using standardized study protocol forms and MD's clinical assessment.
1639909|NCT01932606|Drug|Nitrite|Study drug (NaNO_2 50 mcg/kg/min) will be infused for 5 minutes during the cardiac catheterization procedure.
1639910|NCT01932606|Drug|Saline Placebo for Nitrite|Normal saline placebo will be infused for 5 minutes during the cardiac catheterization procedure. Hemodynamics will then be measured at baseline after study drug infusion and again during low level exercise (20 Watts).
1639911|NCT01932593|Procedure|Infusion of autologous bone marrow|Bone marrow harvest under general anaesthetic and intravenous infusion of filtered but otherwise unselected autologous bone marrow
1639912|NCT01932580|Drug|FLOT (5-fluorouracil, oxaliplatin, docetaxel)|Administration of FLOT chemotherapy before and after surgery
1639913|NCT01932567|Other|Physiotherapy|
1639914|NCT01932567|Procedure|Electrical impedance tomography|
1639915|NCT01932554|Drug|Abciximab|Abciximab will be administered as initial bolus of dose of 0.25 mg/kg, delivered via syringe pump over 15 minutes, followed by a continuous infusion of 0.125 microgram/kg/min (max of 10 micrograms/min) infused over the next 12 hours. Infusion to start within 16 hours of admission. All patients will receive standard supportive care measures.
1639916|NCT01932554|Drug|Placebo|Inactive placebo will be administered as initial bolus followed by a continuous infusion over the next 12 hours, in syringes and volumes identical with the drug administered in the experimental arm. Infusion to begin within 16 hours of admission. All patients will also receive standard supportive care measures.
1639917|NCT01932554|Other|Intravenous hydration|intravenous hydration to provide total fluid intake of 1.25-1.5 times maintenance fluid requirements
1639918|NCT01932554|Drug|Ibuprofen|Scheduled ibuprofen,~10 mg/kg every 6-8 hours
1639919|NCT01932554|Drug|Parenteral narcotic|Parenteral morphine administered by bolus or patient-controlled analgesia to maintain pain control. Hydromorphone or fentanyl will be used in patients who do not tolerate morphine.
1639920|NCT01932554|Other|Incentive spirometry|Patients will perform incentive spirometry every 2 hours while awake
1639921|NCT01932554|Other|Supplemental oxygen|Supplemental oxygen by nasal cannula or mask will be provided if needed to maintain oxygen saturation of 92% or greater.
1639922|NCT01932541|Drug|Latuda (Lurasidone)|Latuda® (lurasidone) tablets taken by mouth once daily, between 20 mg and 120 mg a day.
1639923|NCT01932528|Drug|500 mg [14C]-LX1606|500 mg dose of LX1606 containing a target dose of 3.32 Megabecquerel (MBq) of radiation as [14C]-LX1606.
1639924|NCT01932515|Behavioral|A revised screening instrument for use in Deaf children|
1639925|NCT01932502|Drug|clobazam (Onfi)|"Subject's clonazepam will be converted to the following Onfi doses per day:
Clonazepam 0.5mg converted to Onfi 10mg first week, then titrated up to 40mg per day.
Clonazepam 1.0-2.0mg converted to Onfi 20mg first week, then titrated up to 40mg per day.
Clonazepam 2-4mg converted to Onfi 20mg first week, then titrated up to 60mg per day.
Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
The following will be the initial conversion schedule from clonazepam to Onfi:
Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg = Onfi 10mg.
Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold. Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated"
1639926|NCT01932502|Drug|Initial conversion and titration|Initial conversion will occur over two weeks followed by upward titration of up to 10mg increment per week toward the target dose. Down titration of up to 10mg will be allowed during the study.
1639927|NCT01932502|Drug|Conversion schedule - Week 1|"The following will be the initial conversion schedule from clonazepam to Onfi:
Week 1: 50% reduction of clonazepam and starting dose of Onfi, replacing the reduced clonazepam dose with the conversion rate of clonazepam 0.5mg=Onfi 10mg."
1639928|NCT01932502|Drug|Conversion schedule - Week 2|Week 2: Discontinuing clonazepam and increasing the dosage of Onfi by two-fold.
1639929|NCT01932502|Drug|Conversion schedule - Week 3|Week 3+: Titrate the dose of Onfi up to 40mg per day as tolerated.
1639930|NCT01932489|Procedure|Biopsy of a metastatic lesion.|
1639931|NCT01932476|Dietary Supplement|Gluten Challenge|Three-day gluten containing dietary challenge.
1639932|NCT01932476|Dietary Supplement|Sham Challenge|Three-day sham (gluten free) dietary challenge
1639933|NCT01932463|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
1639934|NCT01932450|Procedure|renal sympathetic denervation|One-time standard Catheter-based renal sympathetic denervation will be performed in both renal arteries by radiofrequency ablation.
1639935|NCT01932450|Drug|antihypertensive drugs|antihypertensive drugs have been used from baseline in patients, and will be modified by patient's blood pressure.
1639936|NCT01932437|Biological|ETI-204|monoclonal antibody
1639937|NCT01932437|Biological|Placebo|Placebo comparator
1639938|NCT01932424|Device|Pelorus 1500|a bedside blood propofol measurement device
1639939|NCT01932424|Drug|Propofol 2% (Diprivan 2%, Astra Zeneca UK)|
1639940|NCT01932385|Drug|Sorafenib|
1639941|NCT01932385|Other|Best Supportive Care|
2012223|NCT02132624|Biological|Autologous 3rd generation CD19-targeting CAR T cells|Autologous CD19-targeting CAR T cells with three signaling domains derived from CD3zeta, CD28 and 4-1BB.
2012224|NCT02130388|Dietary Supplement|Zinc|
1639944|NCT01932359|Other|rapidly absorbable suture (Vicryl Rapide)|
1639945|NCT01932359|Other|non-absorbable suture (Ethilon)|
1639946|NCT01932333|Drug|JNJ-40411813 50 mg|Cohort 1: Participants will receive 50 mg of JNJ-40411813 (2 capsules X 25 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
1639947|NCT01932333|Drug|JNJ-40411813 100 mg|Cohort 2: Participants will receive 100 mg of JNJ-40411813 (1 capsule X 100 mg) once a day on Day 1 in Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 in Period 2 orally (by mouth).
1639948|NCT01932333|Drug|Placebo|Cohort 1: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2; Cohort 2: Participants will receive placebo once a day on Day 1 for Period 1 and twice a day on Days 1 to 9 and once a day on Day 10 for Period 2.
1639949|NCT01932320|Drug|JNJ-40411813: Formulation A|Participants will receive JNJ-40411813 100 mg hard gelatin capsule orally (by mouth) as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
1639950|NCT01932320|Drug|JNJ-40411813: Formulation B|Participants will receive JNJ-40411813 100 mg immediate release tablet orally as a single dose for Part 1 (Period 1, Period 2, and Period 3). If selected this formulation from Part 1, participants will receive this formulation at the dose of 50 mg to 150 mg orally without food and with food in Part 2 (Period 1, Period 2); and at the dose of 50 mg to 150 mg orally without food on Day 1 and Day 10 in Part 3.
1639951|NCT01932320|Drug|JNJ-40411813: Formulation C|Participants will receive JNJ-40411813 100 mg nanosuspension orally as a single dose for Part 1 (Period 1, Period 2, and Period 3).
1639952|NCT01932320|Drug|Ketoconazole|Participants will receive ketoconazole 200 mg tablet orally twice daily with food from Day 6 to Day 14 in Part 3.
1639953|NCT01932307|Procedure|Neck strengthening exercise program|Study subjects will be introduced to a 2-minute neck strengthening exercise program and advised to follow for 10 weeks. The exercise program will include five different exercises that will strengthen the neck and stabilize the scapula. The exercises are: Chin retraction, cracking the egg, scapular clock, wall pushup and scapula retraction. Each will be completed as 3 isometric holds, 3 repetitions per set and 2 sets per exercise.
1639954|NCT01932281|Dietary Supplement|SierraSil|SierraSil is a natural, mineral supplement currently used to improve joint health and function.
1639955|NCT01932281|Dietary Supplement|Placebo|Sugar pill manufactured to mimic SierraSil 667 mg capsule
1639956|NCT01932268|Drug|Rifampicin|single arm : check a change of Colchicine concentrations from basline at 1,2,4,8,24 hours after Rifampicin administration
1639957|NCT01932255|Procedure|prophylactic spinal tap|
1639958|NCT01932255|Procedure|no prophylactic spinal tap|
1639959|NCT01932242|Biological|ETI-204|Monoclonal Antibody
1639960|NCT01932242|Biological|Placebo|Placebo comparator
1639961|NCT01932229|Drug|Afatinib treatment|
1639963|NCT01932203|Drug|aspirin|100mg once a day
1639964|NCT01932203|Drug|cilostazol|200mg once a day
1639965|NCT01932190|Procedure|Early RRT strategy|"the early strategy : RRT is started immediately when a RIFLE F status is documented"
1639966|NCT01932190|Procedure|Delayed RRT strategy|"The delayed strategy : RRT (in patients who also present RIFLE F renal failure) is started only in case of occurrence of one or more of the Alert Criteria: see summary"
1639967|NCT01932177|Drug|Everolimus and sorafenib|Everolimus will be given alone during a 2 week run-in period before starting sorafenib. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
1639968|NCT01932177|Drug|Everolimus and sorafenib|Sorafenib will be given alone during a 2 week run-in period before starting everolimus. Subsequently sorafenib will be administered twice a day while everolimus will be given once a day continuously.
1639969|NCT01932177|Drug|Everolimus and sorafenib|Bid sorafenib will be given every other week alternating with 1 week qd everolimus. Doses will be escalated.
1639970|NCT01932177|Drug|Everolimus and sorafenib|Sorafenib will be given twice a day for 3 days-on 4 days-off while everolimus will be administered continuously on a daily basis. Doses will be escalated.
1639971|NCT01932164|Procedure|maxillary alveolar graft by tissue engineering|Extraction of deciduous teeth of cleft lip and palate patients to obtain mesenchymal stem cells;
1639972|NCT01932164|Procedure|Bone tissue engineering using mesenchymal stem cells|Secondary alveolar graft in patients with cleft lip and palate using using mesenchymal stem cell obtained from dental pulp of deciduous teeth (autogenous) associated with a biomaterial composed of collagen and hydroxyapatite.
1640000|NCT01931852|Other|ACC/AHA Guideline adherent care|Participants in the invasive-based guideline-adherent care group will receive care adherent with current American College of Cardiology / American Heart Association (ACC/AHA) guideline recommendations. ( ACC/AHA Guideline adherent care )
1640001|NCT01931839|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet, oral use
1639973|NCT01932151|Drug|Terlipressin and albumin|"Single-group study (Type-1 Hepatorenal Syndrome Associated With Active Infections) Terlipressin was initially given at a dose of 1 mg/4h as an intravenous bolus for 2 days. If at day 3 serum creatinine had decreased at least 25% of the pretreatment values, the dose of terlipressin was not modified. In the remaining patients, the dose was increased up to a maximum of 2 mg/4h. Terlipressin was given until serum creatinine had decreased below 1.5 mg/dL (133 µmol/L) or for a maximum of 14 days.
In addition to terlipressin, all patients received albumin at a dose of 1g per kg body weight during the first 24 hours, followed by 40g daily,targeted to obtain a central venous pressure (CVP) between 10 and 15 cm of water."
1639974|NCT01932138|Other|Enhanced CHW intervention|"The CHW employed in this study are a health worker cadre that already exists in the Tanzanian public-sector health system, so-called home-base carers (or HBC). The HBC in this study are supervised by another existing cadre, so-called community-based health care workers (or CBHC). The CBHC are clinic-based and are charged to organize community outreach activities in the Tanzanian public-sector health systems. The CBHC (1-2 per clinic) are also active in the control arm; in this intervention arm, there role is changed: they are actively supervising a large number of CHW. Per street (or mtaa), 1-2 CHW are assigned to carry out the enhanced CHW intervention."
1639975|NCT01932138|Other|Standard of care|The standard of care in the Tanzanian health care system does not include any CHW intervention to enhance ANC and PMTCT uptake and retention. The only community-based intervention are PMTCT follow-up organized by a health worker cadre who works out of ANC and primary care clinics (so-called CBHC).
1639976|NCT01932112|Drug|Adenosine arm|After pulmonary vein isolation,20mg Intracardiac adenosine will be given to treatment group, will evaluate pulmonary vein reconnection.
1639977|NCT01932099|Device|Transcatheter aortic valve replacement|Direct Flow Medical Transcatheter Aortic Valve System is indicated for use in aortic stenosis for patients at extreme surgical risk for aortic valve replacement.
1639978|NCT01932086|Dietary Supplement|White rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
1639979|NCT01932086|Dietary Supplement|Brown rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
1639980|NCT01932086|Dietary Supplement|Black rice diet|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
1639981|NCT01932086|Dietary Supplement|Bread|All test foods contained 50 g available carbohydrate from the test food products. A glass of 250 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min
1639982|NCT01932086|Other|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.and the participants were instructed to ingest the breakfast with 10 min.
1639983|NCT01932073|Device|Low-Level Laser Therapy|Low-Level Laser Therapy will be applied, twice a week, from the moment skin reactions become painful until skin reactions are no longer painful
1639984|NCT01932060|Drug|Oxytocin Infusion|Patient will receive a blinded infusion of oxytocin after the time of delivery of the fetus which will terminate at the time of discharge from the post-anesthesia care unit.
1639985|NCT01932034|Device|BestDose Computer Software|BestDose is made by the USC Laboratory of Applied Pharmacokinetics. It uses a multiple-model, Bayesian adaptive control algorithm to find the maximally precise dose that will achieve a user-specified target concentration or concentrations.
1639986|NCT01932021|Procedure|adipose tissue grafting|
1639987|NCT01931995|Device|TMS positively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a technique that is employed to non-invasively activate or suppress targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
1639988|NCT01931995|Procedure|TMS to negatively correlated DLPFC|TMS, or transcranial magnetic stimulation, is a way of non-invasively activating or suppressing targeted regions of the cerebral cortex. One TMS system has been FDA approved to treat certain medically refractory forms of depression.
1639989|NCT01931982|Drug|Victoza|
1639990|NCT01931956|Device|MitraClip® implant|Percutaneous mitral valve repair using MitraClip implant
1639991|NCT01931943|Drug|selatinib ditosilate tablets|
1639992|NCT01931930|Dietary Supplement|Perilla extract|
1639993|NCT01931930|Dietary Supplement|Maltodextrin|
1639994|NCT01931917|Behavioral|Incredible Years Parents and Babies Program|4-5 home visits by health visitor IY parents and babies program 8 sessions Group of mothers Health visitor station Extra visits by health visitor if needed
1639995|NCT01931917|Behavioral|Usual Care|4-5 home visits by health visitor Group of mothers Health visitor station Extra visits by health visitor if needed
1639996|NCT01931878|Drug|incobotulinumtoxinA|The subject may be randomly assigned to receive incobotulinum toxinA (Xeomin) , a neurotoxin Which is approved for use by the FDA for certain conditions. This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is Xeomin, the second injections after a three month interval will be the inactive placebo. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
1639997|NCT01931878|Drug|Placebo|The subject may be randomly assigned to receive Placebo which is an inactive test substance which has no active ingredient. In this protocol we use sterile salt water as placebo.This study has a double blind cross over design. Cross over means that you will have two sets of injections. If the first set of injections is placebo, the second injections after a three month interval will be active study drug. Double blind means neither the investigators nor the subject knows which one of the two (Xeomin or placebo) is received with the first or second injections.
1639998|NCT01931865|Drug|IncobotulinumtoxinA|Subject will receive Xeomin, injected into the area of reported focal pain associated with prior cancer treatment. The total dose will depend on the extent of the area involved by pain. botulinum toxin which is marketed under the trade name of Xeomin. Xeomin is approved by FDA for certain conditions.
1639999|NCT01931852|Procedure|Cardiac MRI|Participants in the CMR-guided care group will receive a cardiac MRI.
1716424|NCT00001115|Drug|Acyclovir|
1640002|NCT01931839|Drug|Ivacaftor|Film-coated tablet, oral use
1640003|NCT01931826|Procedure|Endoscopic treatment|The presence of gastroesophageal varices was confirmed by fiberoptic esophagogastroduodenoscopy (EGD). In view of the experience of our service and local circumstances at the time of the study, the endoscopic treatment of choice was sclerotherapy, performed with a Teflon-sheathed metal needle. The sclerosing agent was 2.5% monoethanolamine oleate. Esophageal varices visible on EGD in the pre- and post-treatment period were classified as small, medium or large on the basis of criteria proposed by Paquet. All complications attributable to sclerotherapy were recorded.
1640004|NCT01931826|Procedure|Total EGDS+ endoscopy|Esophagogastric devascularization with splenectomy followed by endoscopic sclerotherapy of esophageal varices 2 months postoperatively.
1640005|NCT01931800|Biological|Sampling of blood|
1640006|NCT01931787|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
1640007|NCT01931761|Drug|[C14] selumetinib (oral)|Single oral administration [C14] 75mg
1640008|NCT01931748|Drug|MELSMON|
1640009|NCT01931748|Drug|UNCNT|
1640010|NCT01931735|Procedure|Meniscectomy|Arthroscopic meniscectomy
1640011|NCT01931735|Procedure|Arthroscopic Lavage|Arthroscopic Lavage
1640012|NCT01931722|Dietary Supplement|Branched chain amino acid|seven graded intakes of a BCAA (branched chain amino acid) mixture from 50 to 350 mg.kg-1.d-1 will be used to measure BCAA requirement
1640013|NCT01931722|Behavioral|Strength training|"Strength training will include a split-training program using all major muscle groups of the body on a three day on, one day off protocol. Muscle areas targeted on each training day will be as follows: Day1: chest, shoulder, triceps; Day2: back, biceps; Day3: legs and calfs; Day4: will be a rest day. On Day5: this cycle will begin again. A combination of free weights and machines will be used for each training day. Progressive overload protocol will be applied where the load used by every participant will be adjusted bi-weekly based on their 70% of 1 repetition maximum (maximum weight that can be lifted only one time). Instruction will be provided for all exercises and professional trainers will oversee all training sessions."
1640014|NCT01931709|Radiation|fludeoxyglucose F 18|Undergo FDG PET
1640015|NCT01931709|Device|positron emission tomography|Undergo FDG PET
1640016|NCT01931709|Device|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
1640017|NCT01931709|Other|laboratory biomarker analysis|Correlative studies
1640018|NCT01931696|Device|Verum acupuncture|100 patients receive verum acupuncture treatment once every other day,choosing Dazhui(GV14), Fengmen(BL12), Feishu(BL13), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive verum acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
1640019|NCT01931696|Device|Sham acupuncture|100 patients receive sham acupuncture treatment once every other day, choosing Jinsuo(DU08), Ganshu(BL18), Danshu(BL19), needles retention for 30 minutes and no moxibustion or electrical stimulation. Patients receive sham acupuncture once every other day with a total of 20 sessions in 6 weeks. The needle brand is Hwato®™ Sterile Acupuncture Needles for Single Use.
1640020|NCT01931683|Drug|remifentanil|The concentration of remifentanil was determined by modified Dixon's up-and-down method, starting from 1.0 ng/ml (0.2 ng/ml as a step size)
1640021|NCT01931683|Device|laryngeal mask airway (LMA)|LMA was removed when the patients opened their eyes, and spontaneous respiration and adequate tidal volume and ventilatory frequency were confirmed
1640022|NCT01931670|Drug|Elagolix|Elagolix Dose 1 for 6 month Treatment Period, Elagolix Dose 2 for the 6 month Treatment Period
1640023|NCT01931670|Other|placebo|Placebo for 6 Month Treatment Period
1640024|NCT01931657|Drug|Mifepristone prior to Mirena|
1640025|NCT01931657|Drug|Placebo prior to Mirena insertion|
1640026|NCT01931631|Behavioral|Low-fat, low-Glycemic Index, vegan diet|Low-fat, low-Glycemic Index, vegan diet
1640027|NCT01931631|Behavioral|ADA diet|Diet in accordance with the American Diabetes Association
1640028|NCT01931618|Behavioral|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
1640029|NCT01931618|Behavioral|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
1640030|NCT01931618|Behavioral|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
1640031|NCT01931605|Device|Prostatic arterial embolization using BeadBlock (Terumo)|Selective Prostatic arterial embolization using BeadBlock (Terumo)particuls
1640032|NCT01931592|Drug|ESBL eradication regimen|Fosfomycin-trometamol (3 g granules dissolved in 200 ml of water for oral administration every 72h) and colistin (2x106 IU oral solution dissolved in 50-100 ml of water given orally every 6 hours) and gentamicin (an 80 mg oral solution dissolved in 50-100 ml of water given orally every 6 hours) will be administered in a double-blind fashion for a total duration of 7 days (day 1-7). The placebo treatment will be identical in taste, consistency, colour and packaging. To include the oral cavity into the eradication regimen, all medications should be gargled for at least 10 seconds before being swallowed.
1640033|NCT01931592|Drug|Placebo ESBL eradication|Placebo preparations of fosfomycin, gentamicin and colisitin, identical in taste, texture and color will be administered at the same rate as the active comparator medication.
2012225|NCT02125240|Drug|Icotinib|125 mg three times daily (375 mg per day) by mouth
1640078|NCT01931189|Biological|NI-071|100mg/vial
1640079|NCT01931189|Biological|Infliximab|100mg/vial
1640190|NCT01930240|Drug|TRIA-662|1-MNA Chloride
1640191|NCT01930240|Drug|Placebo|Double-blind placebo
2012226|NCT02125240|Drug|Placebo|1 tablet three times daily by mouth
2012227|NCT02123823|Drug|Everolimus|10mg dose
1640034|NCT01931579|Device|confocal endo-microscopy|The intervention consists of the use of confocal endo-microscopy using the CELLVIZIO device and either the 1 mm CELLVIZIO miniprobe (ALVEOFLEX) or the 0.6 mm CELLVIZIO miniprobe (CHOLANGIOFLEX), during a navigational bronchoscopy procedure for the diagnostic of peripheral nodule. In this study, the navigational device - either radial endobronchial ultrasound (EBUS) or electromagnetic navigation (EMN) - will be moved to another location if the CELLVIZIO displays a non solid pattern, indicating that the nodule may not have been reached during the procedure. Three attempts of EBUS or EMN are allowed until the CELLVIZIO shows a solid pattern.
1640035|NCT01931566|Drug|Pioglitazone|Low-Dose Pioglitazone tablets
1640036|NCT01931566|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets
1640037|NCT01931553|Other|Standardized attending morning rounds|
1640038|NCT01931540|Behavioral|Exercise Training|Three times a week, for four months.
1640039|NCT01931527|Drug|Rasburicase|one single infusion of rasburicase (0.19 mg/kg FFM) infused over 30 min
1640040|NCT01931514|Drug|Torrent's Montelukast Sodium chewable Tablets 5mg|
1640041|NCT01931514|Drug|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
1640042|NCT01931501|Drug|Torrent's Montelukast Sodium Chewable Tablets 5mg|
1640043|NCT01931501|Drug|Singulair® (Montelukast Sodium) Chewable Tablets 5mg|
1640044|NCT01931488|Other|MIBG label with I123 or I124|PD Patients who are not allergic to Iodine will be given 8 drops of Lugol . 30 min later, patients will be injected with 123I-MIBG 6 mci (222 MBq). 3 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mci (29.6 MBq). 3 hours post-injection patients will undergo PET-CT imaging.whole-body imaging. in the evaluation of neuroendocrine tumors-Patients who are not allergic to Iodine will be given 8 drops of Lugol.30 min later, patients will be injected with 123I-MIBG 6 mCi (222 MBq).3 hours and 24 hours post-injection patients will undergo planar and SPECT imaging. at another day, patients will be injected with 124I-MIBG 0.8 mCi (29.6 MBq). 3 hours and 24 hours post-injection patients will undergo PET-CT imaging.
1640045|NCT01931488|Device|SPECT imaging|
1640046|NCT01931475|Drug|Duloxetine|Administered orally
1640047|NCT01931475|Drug|Placebo|Administered orally
2012228|NCT02123823|Drug|Everolimus|at recommended dose as per Phase I data
1640049|NCT01931449|Procedure|Modified method of digestive tract reconstruction|
1640050|NCT01931449|Procedure|Routine digestive tract reconstruction|
1640051|NCT01931436|Drug|Qing'E pill|Qing'E pill is composed of eucommia, psoralen, walnuts and garlic.
1640052|NCT01931423|Behavioral|Placental cord drainage|
2012229|NCT02123823|Drug|Everolimus|Dose escalation (24-48 patients) in Phase I. 3 dose levels depending on the dose cohort explored: 5mg, 7,5mg and 10mg
1640054|NCT01931384|Drug|Human chorionic gonadotrophin|luteal phase support using Human chorionic gonadotrophin 1500 IU intramuscular injection will be given on the day of FET and 6 days later.
1640055|NCT01931384|Drug|Placebo|Normal saline intramuscularly on the day of embryo transfer and 5 days after embryo transfer.
1640056|NCT01931371|Procedure|Anal Fistula Plug|Surgical procedure for the treatment of anal fistula with an Anal Fistula Plug
1640057|NCT01931371|Procedure|Endorectal Advancement Flap|Surgical procedure for the treatment of anal fistula by an Advancement Mucosa Flap
2012230|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
2012231|NCT02123823|Drug|BI 836845|Human monoclonal antibody at recommended dose as per Phase I data
2012232|NCT02123823|Drug|BI 836845|Human monoclonal antibody. Dose escalation (24-48 patients) in Phase I. 2 dose levels (high or low) depending on the dose cohort explored
2012233|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
1640062|NCT01931345|Behavioral|Motivational Interviewing Counseling|Counseling developed by the research team based on a motivational interviewing approach
1640063|NCT01931345|Behavioral|Standard counseling|Counseling based on Quebec guidelines for rapid HIV testing
1640064|NCT01931332|Procedure|Femoral Nerve Block with levobupivicaine|A single injection femoral nerve block (FNB) performed in the supine position with a 50mm insulated needle (NanoLine, Pajunk, Geisingen, Germany) and peripheral nerve stimulator set at 1Hz with pulse width 0.1ms. Once a quadriceps muscle twitch is identified at a stimulated current between 0.2 and 0.5mA, 20mls of 0.375% levobupivacaine (75mg) is injected in fractionated amounts after negative aspiration
1640065|NCT01931332|Procedure|Intrathecal injection of diamorphine|500mcg of intrathecal diamorphine (ID) (dissolved in 0.5mls normal saline)
2012234|NCT02123823|Drug|Exemestane|Fixed dose at 25mg
1640067|NCT01931306|Drug|Afatinib|BIBW2992 low to medium dose once daily
1640068|NCT01931293|Dietary Supplement|Supplementation of vitamin B complex, C, B12, folic acid, Iron and Zinic|Vitamin Supplement therapy
1640069|NCT01931280|Behavioral|Lifestyle Counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet based program or self-directed educational program.
1640070|NCT01931267|Behavioral|Tablet Computer Motivated Instruction|Using tablet computer to motivate patient learning breath skill and maintain practive. Research nurse will give 3 times instruction to patients during hospitalization. This arm estimated including 77 subjects
1640071|NCT01931267|Behavioral|Systematic Instruction|Research nurse give 3 times systematic instruction during hospitalization This arm estimated including 77 subjects.
1640072|NCT01931241|Drug|AHRO-001|Cohort 1: 500 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 2: 750 mg/dose, given as a single dose then as bid x7days and tid x 7days Cohort 3: 1000 mg/dose, given as a single dose then as bid x7days and tid x7days Cohort 4: 21 days dosing given at best tolerated dose determined by cohorts 1-3 Cohort 5: 12 wks dosing given at best tolerated dose determined by cohorts 1-4
1640073|NCT01931228|Procedure|MI-E plus manually assisted coughing|MI-E plus manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
1640074|NCT01931228|Procedure|manually assisted coughing|Manually assisted coughing twice a day for 48h after extubation. After this period and before discharge of the icu or day28 maximum, patients received only one daily session.
2012235|NCT02117648|Drug|LY2835219|Administered orally
2012236|NCT02117648|Drug|Clarithromycin|Administered orally
2012237|NCT02119611|Other|Deep Brain Stimulation Management|Therapy
1640080|NCT01931176|Biological|rDEN2Δ30-7169 vaccine|Administered at a dose of 10^3 plaque-forming units (PFU); delivered by subcutaneous injection in the deltoid region of the upper arm
1640081|NCT01931176|Biological|Placebo|Delivered by subcutaneous injection in the deltoid region of the upper arm
1640082|NCT01931163|Drug|Everolimus|
1640083|NCT01931150|Drug|Topical Dapsone 5% Gel|
1640084|NCT01931150|Other|Moisturizer|The moisturizer for the study will be Vanicream™ Lite Lotion.
1640085|NCT01931150|Drug|oral antibiotics|
1640086|NCT01931137|Drug|insulin 338 (GIPET I)|Dose level of 8100 nmol will be orally administered as one tablet per dose.
1640087|NCT01931124|Behavioral|High Intensity Training|
1640088|NCT01931124|Behavioral|Moderate Intensity Training|
1640089|NCT01931098|Drug|topotecan|Taken .25 mg orally, daily continuous until progression up to one year.
1640090|NCT01931098|Drug|pazopanib|600 mg orally, daily until progression, up to one year.
1640091|NCT01931085|Drug|Triclabendazole|Triclabendazole (10 mg/kg body-weight as a single dose).
1640092|NCT01931072|Behavioral|High-intensity interval training|Interval training 3 times a week for 8 weeks
1640093|NCT01931072|Behavioral|Moderate training|Moderate training 3 times a week for 8 weeks
2012238|NCT02116309|Drug|Rectal Indomethacin|
1640095|NCT01931046|Drug|Ad5-SGE-REIC/Dkk3|Ad5-SGE-REIC/Dkk-3, was designed to increase intracellular production REIC protein. The adenovirus vector is a transport mechanism to infuse the REIC protein into the cell providing a temporary transfusion of protein that induces apoptosis in target cancer cells, but does not appear to have a significant effect on normal tissues.
1640096|NCT01931033|Drug|Intranasal Oxytocin|
1640097|NCT01931020|Drug|Sucrose|The enrolled neonates will be administered 1ml of 24% sucrose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
1640098|NCT01931020|Drug|Glucose|The enrolled neonates will be administered 1ml of 25% gluose. After 2 minutes heel lancing will be performed after cleaning the heel of neonate with a sterile spirit swab, with an auto lancet. Neonate's faces and monitor screen will be filmed in real time by using two independent video cameras during the entire procedure i.e. staring 2 minutes prior to heel lance and continue 2 minutes after the procedure. The PIPP will be assessed at 30 seconds, 1 minute and 2 minute after the procedure.
1640099|NCT01931007|Drug|Autologous Bone Marrow Aspirate Concentrate|Autologous Bone marrow aspirate will be concentrated using Magellan Cell Separator and stem cell kit according to the Standard Operating Procedures is to be injected in the treatment knee. 5ml of treatment cells will be combined with 10 ml of previously separated platelet poor bone marrow plasma and used for injection under ultrasound guidance into one of the subject's painful knees.
1640100|NCT01931007|Drug|Sterile saline|Bacteriostatic 0.9% sodium chloride, preservative free manufactured by Hospira will be injected into the control knee.
1640101|NCT01930955|Drug|Amoxicillin|β-lactam antibiotics
1640102|NCT01930942|Radiation|preoperative concurrent chemoradiation|Radiation is given with 5000 cGy in 25 fractions (5 weeks). Concurrent chemotherapy consists of oxaliplatin (50 mg/m2 ) intravenously over 2 h on days 1, 8, 15, 22 and 29, and capecitabine (825 mg/m2 twice day) was given orally on each day of radiation.
1640103|NCT01930929|Procedure|Bariatric surgery|
1640104|NCT01930916|Device|INR capillary measurement with INRatio 2 device|INR capillary measurement with INRatio 2 device
1640105|NCT01930916|Other|antiphospholipid antibodies and lupus anticoagulant|Rate of antiphospholipid antibodies and lupus anticoagulant dosage A 5ml blood sample obtained by veinous punction.
1640106|NCT01930903|Device|Pantera Lux Drug Eluting Balloon|All patients are treated with the PRO-Kinetic Energy Stent and Pantera Lux drug eluting balloon for the last post dilatation.
1640107|NCT01930890|Biological|BIIB023|
1640108|NCT01930890|Drug|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
1640109|NCT01930890|Drug|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
1640110|NCT01930877|Drug|Lidocaine|Lidocaine iv bolus followed by infusion
1640111|NCT01930877|Other|Placebo (normal saline)|Normal saline bolus followed by infusion
1640112|NCT01930864|Drug|metformin|metformin up to 2500mg/d
1640113|NCT01930864|Drug|irinotecan|Irinotecan 350 mg/m² IV q21d
1640114|NCT01930851|Procedure|Gastric bypass operation|
1640115|NCT01930838|Procedure|Gastric bypass operation|
1640116|NCT01930812|Procedure|NaF PET/CT Imaging|Diagnostic imaging test that is considered investigational
1640117|NCT01930812|Procedure|99mTc-medronate whole body bone scan with SPECT|99mTc-medronate whole body bone scan with SPECT imaging. Note, that this is a standard procedure in this patient population and thus is not considered investigational.
1640118|NCT01930812|Drug|18F-Sodium Fluoride (NaF)|A single radioactive dose of 18F-NaF (185-370 MBq) is intravenously administered to subject 60 minutes prior to PET/CT imaging to evaluate whether or not subject has bone metastasis from advanced prostate or breast cancer. Entire procedure from injection to scan completion will take about 2.25 hours
1640119|NCT01930799|Behavioral|Systematic Screening and Education Regimen|Site will implement a systematic approach to screening bladder health dysfunction in multiple sclerosis patients, providing bladder health management education, and initiating appropriate urologist referrals.
2012239|NCT02116309|Drug|Epinephrine|
1640121|NCT01930773|Device|Genotyping|Patients harboring CYP2C19 *2 alleles receive 60 mg prasugrel for PCI, while non-carriers receive 600 mg clopidogrel if not pretreated with clopidogrel.
1640122|NCT01930773|Device|Phenotyping|Patients having high on-treatment platelet reactivity (HPR: greater than 208 PRU) receive 60 mg prasugrel loading dose (LD), others continue clopidogrel for PCI.
1640185|NCT01930292|Drug|Part B: Debio 1143|RD of Debio1143 oral capsules, once daily for five consecutive days starting on day 1 or 2 of each 21-day treatment cycle.
1640186|NCT01930279|Other|Blood withdrawal|Blood withdrawal
1640187|NCT01930266|Dietary Supplement|Experimental|
2012240|NCT02112916|Drug|Bortezomib|Given IV
2012241|NCT02112916|Drug|Cyclophosphamide|Given IV
1640123|NCT01930760|Behavioral|Standard Medical Training Educational|"Educational is modeled on the Theory of Planned Action, which proposes that unless people believe that their actions can have an effect on the desired outcome they have little incentive to act or persevere in the face of difficulties. Based on this theory we will be providing physicians with information on how to calculate, plot and track BMI and how this can be associated with identification of overweight children before they present with symptoms of obesity. This intervention will attempt to demonstrate that BMI calculating, plotting and tracking are useful diagnostic monitoring tools and that their actions may lead to more effective prevention and/or treatment.
The education intervention will not prescribe specific discussion initiation tools, although the participants will not be prevented from independently changing their communication behaviour."
1640124|NCT01930760|Behavioral|Motivational Interviewing behavioural|The behavioural intervention will incorporate specific Motivational Interviewing (MI) tools and information from a previously completed qualitative study with obese children (Obadia et al.). This study generated suggestions of how physicians can encourage children to think positively about making changes towards a healthier body weight. This intervention is designed to address physicians' lack of self-efficacy in communicating with children and their families about achieving a healthy body weight, and therefore would likely benefit from the input from children and the patient-centred theme of MI. It is based on the Trans-Theoretical Model and Stages of Change which postulates that people follow a step-wise progression towards change with specific constructs that need to be addressed before moving to the next step. These constructs are integral to the principles of MI
2012242|NCT02112916|Drug|Cytarabine|Given IT, IV, or SC
2012243|NCT02112916|Drug|Daunorubicin Hydrochloride|Given IV
2012244|NCT02112916|Drug|Dexamethasone|Given PO or IV
1640128|NCT01930734|Drug|Dobutamine|Dobutamine infusion up to 5mcg/Kg/min
1640129|NCT01930734|Drug|Normal Saline|Normal Saline solution 0.9% Placebo Arm
1640130|NCT01930721|Procedure|episiotomy|incision angle of episiotomy will be 60 degrees.
1640131|NCT01930721|Procedure|episiotomy|incision angle of episiotomy will be 40 degree before cutting.
1640132|NCT01930708|Drug|dimethyl fumarate|Administered as per the approved dosage in all countries where DMF has received marketing authorization.
1640133|NCT01930682|Drug|Alteplase|Alteplase is given as a intravenous bolus (8-mg) followed by 42 mg iv gtt in 90 min.
1640134|NCT01930682|Procedure|Early post-fibrinolytic catheterisation|Early post-fibrinolytic catheterisation after 3 hours but within 24 hours of the start of fibrinolytic therapy is performed, if required, PCI or, in case of insufficient ST resolution at 90 min,rescue PCI. The decision on rescue PCI will, however, be taken 90 min (or earlier if clinically indicated) after injection of alteplase according to the ST resolution (less than 50% reduction in ST-segment elevation).
1640135|NCT01930682|Procedure|Primary PCI|For STEMI Patients,primary PCI is performed within 12 hours after the onset.
1640136|NCT01930669|Other|Gravitational sympathetic stimulus|"Autonomic nervous system (ANS) activity is assessed by means of HRV, SAP variability and baroreflex control analysis daily from day 1 to discharge from ICU or day 28.
Analysis is performed (i)at rest in supine position with bed at zero degrees of inclination (ii) during modified tilt (MTILT) and (iii) recovery from MTILT in supine position at zero degrees. In a subgroup of patients motor sympathetic nervous activity (MSNA) is recorded at day 1,2 and 7.
MTILT consists in elevating head and trunk of patients at 60 degrees and lowering legs at 15 degree with a standard critical care bed. MSNA is recorded from the external peroneal nerve with microneurographic technique."
1640137|NCT01930643|Device|EMS|HELEX 573 : strength aggravation mode with middle frequency carrier(1500Hz), minimal voltage for visible muscle contraction(maximum output is 75mA) , 32 minutes per day.
1640138|NCT01930630|Device|Extraesophageal saline injection (ESI)|The patients with advanced ESCC are to undergo extraesophageal injection of 15ml saline preoperatively and subsequently detected by EUS to confirm whether saline separates esophagus from adjacent organs.
1640139|NCT01930617|Procedure|Burr hole surgery with various drainage techniques|"Surgical technique
Continuous irrigation and drainage
Passive subdural drain
Active subgaleal drain"
1640140|NCT01930604|Drug|Botox (onabotulinumtoxinA)|
1640141|NCT01930604|Drug|NeuroBloc/Myobloc (rimabotulinumtoxinB)|
1640142|NCT01930604|Drug|NaCl (placebo)|
1640143|NCT01930591|Drug|Ticagrelor|180 mg bolus followed by 90 mg BID
1640144|NCT01930591|Drug|Clopidogrel|300 mg bolus followed by 75 mg OD
1640145|NCT01930578|Other|Treatment with 0.9% normal saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.
An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
1640146|NCT01930578|Other|Treatment with D5+ 0.45 saline|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.
An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
1640147|NCT01930578|Other|Treatment with D5|"An oral dose of 0.33ml/kg of 10% Sodium Bromide solution at each of 3 study visits. Each dose of Sodium Bromide will be mixed with an equivalent volume; 1:1 of sterile water before oral intake.
An IV infusion of (1) 0.9% saline, (2) 5% Dextrose or (3) 3.3% Dextrose and 0.3% saline will be given at a rate of 1 liter over an hour in a randomized crossover design."
1640148|NCT01930565|Other|LFCO application|Application of LFCO (Lactobacillus fermented Chamaecypris obtusa ) containing creams to one randomly selected face of patients to monitor its effectiveness and safety of acne treatments.
1640149|NCT01930565|Other|TTO application|Application of TTO (Tea tree oil) containing creams to the other side of face of patients to monitor its effectiveness and safe compared with LFCO.
1640150|NCT01930552|Drug|Aflibercept AVE0005|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
1640151|NCT01930552|Drug|Leucovorin|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
1640152|NCT01930552|Drug|Irinotecan|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
1640153|NCT01930552|Drug|5-Fluorouracil|Pharmaceutical form:Solution for infusion Route of administration: Intravenous
1640188|NCT01930266|Behavioral|Active comparator|
2012245|NCT02112916|Drug|Doxorubicin Hydrochloride|Given IV
1640154|NCT01930539|Device|Ultraviolet B lamp|Ultraviolet-Fluorescent lamp (KBD, Inc, Crescent Springs, Kentucky, USA) was designed to use Ultraviolet B emitting fluorescent bulbs that have lower heat emission and allows a larger area of skin exposure. The Lamp is equipped with a timer for improved safety. This device is FDA (Food and Drug Administration) approved.
1640155|NCT01930526|Other|Pulmonary Rehabilitation|Pulmonary Rehabilitation (PR) is a short course 6-12 weeks of supervised exercise training and education for patients with COPD. This is part of their usual treatment. This study is replacing two-legged cycling with single leg training. Patients will have the usual PR outcome measures assessed but in addition will have a laboratory exercise test.
1640156|NCT01930500|Behavioral|Individual neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support to better cope with dyslexia
1640157|NCT01930500|Behavioral|Group based neuropsychological rehabilitation|Psychoeducation, teaching compensatory strategies and offering psychological support and peer support to better cope with dyslexia
1640158|NCT01930487|Dietary Supplement|dietary supplement with antioxidants|Formulation contains vitamins, a mineral, dietary antioxidants, amino acids, polyphenols and polyunsaturated fatty acids
1640159|NCT01930487|Dietary Supplement|Placebo|Placebo - Softgels manufactured to mimic the appearance of active, dietary supplement with antioxidants
1640160|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (A)|Two sublingual tablets daily for 13 months
1640161|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (B)|Two sublingual tablets daily for 13 months
1640162|NCT01930461|Biological|SLIT tablets of HDM allergen extracts, 3 different doses (C)|Two sublingual tablets daily for 13 months
1640163|NCT01930461|Biological|Placebo matching the SLIT tablets of HDM allergen extracts|Two sublingual tablets daily for 13 months
1640164|NCT01930435|Device|Sterile Humidification Device|This is a personal humidification device. It is hand held and produces sterile warm vapor.
1640165|NCT01930422|Device|tDCS procedure|The tDCS is a non-invasive neuromodulation method. A stimulator delivers a constant current of low intensity (1-2 mA) applied to the average of two bipolar electrodes placed on the scalp for 20 minutes. This constant current generates a static electric field that selectively modulates the activity of cortical neurones. A tingling sensation under the electrodes appears at the beginning and at the end of stimulation but it is transient and disappears quickly in 30 or 60 seconds.
1640166|NCT01930422|Device|Sham procedure|The tDCS placebo differs from the real tDCS by the interruption of stimulation after 30 to 60 seconds and reactivation of this stimulation 30 to 60 seconds before the end of the session, which lasted 20 minutes. The tingling felt at the beginning and the end of the session will be the same as those experienced with real stimulation. The electrodes establishment does not differ with respect to tDCS.
2012246|NCT02112916|Drug|Etoposide|Given IV
2012247|NCT02112916|Drug|Hydrocortisone Sodium Succinate|Given IT
1640169|NCT01930396|Drug|Tinzaparin|
1640170|NCT01930396|Drug|Unfractionated Heparin|
1640171|NCT01930396|Drug|Placebo (for Tinzaparin)|0.9% Normal Saline
1640172|NCT01930396|Drug|Placebo (for Unfractionated Heparin)|0.9% Normal Saline
1640173|NCT01930370|Drug|Bicarbonate hemodialysis solution (low concentration)|One-week experimental session (3 dialysis treatments) with low dialysate bicarbonate (28 mmol/L)
1640174|NCT01930370|Drug|Bicarbonate hemodialysis solution (high concentration)|One-week experimental session with high dialysate bicarbonate (38 mmol/L)
1640175|NCT01930357|Biological|Purified Vero Rabies Vaccine Serum Free (VRVg)|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
1640176|NCT01930357|Biological|Imovax® Rabies: Human Diploid Cell Vaccine (HDCV),|0.5 mL, Intramuscular (Day 0, Day 7 and Day 28).
1640177|NCT01930344|Device|3D Laparoscopic visual system|Three-dimensional endoscope used for surgery - multiple company products - and passive polarising three-dimensional laparoscopic displays;
1640178|NCT01930344|Device|2D Laparoscopic visual system|Standard 2D HD Laparoscopic Visual System
1640179|NCT01930331|Drug|artemisinin/naphthoquine|"Each tablet of ARCO (artemisinin/naphthoquine) contains 125 mg artemisinin and 50 mg of naphthoquine. The total dose for adults will be 1000mg of artemisinin and 400mg of naphthoquine in a fixed oral dose (ARCO tablet).
The regimen for children will be calculated according to the body weight (20mg artemisinin + 8mg naphthoquine per kg body weight in a fixed oral dose(ARCO tablet))."
1640180|NCT01930331|Drug|dihydroartemisinin/piperaquine phosphate|Eurartesim (dihydroartemisinin/piperaquine phosphate) is a fixed dose preparation with two dose-strengths (20 mg dihydroartemisinin and 160mg of piperaquine phosphate and 40mg dihydroartemisinin and 320mg of piperaquine phosphate. The regimen for patients with body weight of 36-75kg is three tablets of 40mg dihydroartemisinin and 320mg of piperaquine phosphate once daily for three consecutive days. Those beyond or below this range the regimen will be calculated based on the body weight.
1640181|NCT01930318|Drug|parecoxib|4 groups: PCA,Placebo,Placebo-PCA for 2 days after operation, i.v placebo in 2 days after surgery and oral placebo in the day 3 to day 5 after surgery; PCA,placebo,tramadol-PCA for 2 days after operation, i.v placebo in 2 days after surgery, and oral tramadol(0.1g t.i.d.) in the day 3 to day 5 after surgery;PCA,parecoxib,placebo-PCA for 2 days after operation, i.v parecoxib(40mg b.i.d.) in 2 days after surgery,and oral placebo in the day 3 to day 5 after surgery;PCA,parecoxib,celecoxib-PCA for 2 days after operation,i.v parecoxib(40mg b.i.d.) in 2 days after surgery and oral celecoxib(0.2g b.i.d.) in the day 3 to day 5 after surgery
1640182|NCT01930292|Drug|Part A: Debio 1143|Adaptive doses of Debio1143 oral capsules, between 50 and 400 mg until the recommended dose (RD) is determined.
1640183|NCT01930292|Drug|Paclitaxel|Paclitaxel standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle, after pre-medication to prevent severe hypersensitivity reactions.
1640184|NCT01930292|Drug|Carboplatin|Carboplatin standard of care, intravenous (IV), once on day 1 or 2 of each 21-day treatment cycle.
1640189|NCT01930253|Drug|Bortezomib|
2012248|NCT02112916|Drug|Ifosfamide|Given IV
2012249|NCT02112916|Other|Laboratory Biomarker Analysis|Correlative studies
2012250|NCT02112916|Drug|Leucovorin Calcium|Given PO or IV
2012251|NCT02112916|Drug|Mercaptopurine|Give PO
2012252|NCT02112916|Drug|Methotrexate|Given IT, IV, or PO
2012253|NCT02112916|Drug|Pegaspargase|Given IV
2012254|NCT02112916|Radiation|Radiation Therapy|Undergo radiation therapy
1640192|NCT01930227|Other|TEAS|Electric stimulation was given through electrode attached to specific acupoints
1640193|NCT01930227|Other|Non-acupoint stimulation|Electric stimulation was given through electrode attached to the shoulder
1640194|NCT01930214|Device|Percutaneous Coronary Intervention|Any Food and Drug Administration (FDA) commercially available device for treating none/mild, moderate, and severe calcified coronary lesions, with the exception of CSI's Coronary Orbital Atherectomy System (OAS).
1640195|NCT01930201|Procedure|Caudal epidural block|
1640196|NCT01930201|Other|General anesthesia|
1640197|NCT01930188|Drug|semaglutide|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
1640198|NCT01930188|Drug|sitagliptin|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
1640199|NCT01930188|Drug|placebo|Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.
1640200|NCT01930188|Drug|placebo|For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
1640201|NCT01930175|Drug|VAY736|VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner.
1640202|NCT01930175|Drug|Placebo to VAY736|Placebo to VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner. All patients that receive placebo will be offered open-label VAY736.
1640203|NCT01930175|Drug|VAY736|VAY736 will be administered to patients with mild-moderate pemphigus vulgaris in a randomized manner, following a safety review.
1640204|NCT01930162|Drug|HSC835|HSC835 is a stem cell therapy product providing a source of Hematopoietic stem cell (HSC).
1640205|NCT01930149|Behavioral|Mailed patient outreach intervention|This study's intervention is a mailed outreach letter from the health center that encourages cholesterol testing and describes the steps necessary to obtain the test at the patient's care site. Clinic staff will facilitate the ordering of tests for patients who may not have an office visit.
1640206|NCT01930136|Behavioral|Calorie restriction (25%)|
1640207|NCT01930136|Behavioral|Ad libitum health diet|
1640208|NCT01930123|Other|intravenous fructose challenge|"Patients will be admitted to our Duke Clinical Research Unit (DCRU) at least 12 hours prior to morning intravenous fructose challenge. All patients will have a standard meal in order to control for dietary composition and calorie intake prior to intravenous fructose challenge. Patients will be NPO after midnight for morning IV fructose MR biomarker measures. Patients with suspected NAFLD will have a standard of care , liver biopsy followed by , and co-localization of liver biopsy with MR."
1640209|NCT01930110|Other|60-minute exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 60-minute exercise at 60% of VO2 max. Patients will be discharged at 20:00.
1640210|NCT01930110|Other|40-minute interval exercise|Patients will be admitted at the research clinical facility at 14:30. Closed-loop strategy will start at 15:30. At 18:00, patients will performed a 40-minute interval exercise. Patients will be discharged at 20:00.
1640211|NCT01930097|Other|14 hours intervention|Subjects will be admitted at the IRCM at 6:30. Subjects will be asked to fast from midnight. At 8:00, a standardized (50g CHO for males; 30g CHO for females) meal will be served. At 12:00, a standardized (120g CHO for males; 90g CHO for females) meal will be served. At 17:00, a standardized (70g CHO for males; 50g CHO for females) meal will be served. Between meals, patients will be allowed to do sedentary activities (reading, watching television, and playing video games, etc).
1640212|NCT01930084|Other|Point of care CD4+ after HIV diagnosis|Point of care (POC) CD4+ testing immediately following HIV diagnosis
1640213|NCT01930084|Other|Accelerated ART initiation|Accelerated ART initiation for eligible participants delivered by facility personnel
1640214|NCT01930084|Behavioral|SMS appointment reminders|Cellular appointment reminders delivered by study personnel
1640215|NCT01930084|Other|Non-cash Financial Incentives|Non-cash Financial Incentives
1640216|NCT01930071|Device|PQ Bypass Guide Wire Delivery System|The PQ Bypass Guide Wire Delivery System is used to bypass lesions in the peripheral vasculature percutaneously. A guidewire is placed from the artery proximal to the lesion to the artery distal to the lesion using the vein as a conduit with the Guidewire Delivery System. Once in place, commercially available stent grafts will be placed to complete the bypass.
1640217|NCT01930058|Drug|MK-8876|MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
1640218|NCT01930045|Drug|Raltegravir (ISENTRESS™)|Raltegravir 400 mg oral tablet once every 12 hours. Participants will continue with their other prescribed antiretroviral agents throughout the study.
1640219|NCT01930045|Drug|MAALOX (MAL)|MAL (or generic equivalent) 20 mL oral single dose on Day 1
1640220|NCT01930019|Drug|Intravenous administration of the induction agent of general anesthesia (etomidate or thiopental)|
1640221|NCT01930006|Drug|MGCD265|
1640222|NCT01929993|Procedure|SWETZ|Straight wire excision of transformation zone is an electrosurgical conization method, which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
1640223|NCT01929993|Procedure|LLETZ cone|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20 mm depth. The loop is applied to the cervix outside the lateral margin of the transformation zone and brought slowly to the controlateral transformation zone margin.
1640224|NCT01929980|Drug|Bortezomib|
1640225|NCT01929954|Biological|Gintuit|One time placement of Gintuit over socket graft.
1640226|NCT01929954|Device|Bio-Gide|One time placement of Bio-Gide over socket graft.
1640227|NCT01929941|Drug|INCB047986|Initial cohort dose of INCB047986 monotherapy at the protocol-specified starting dose, with subsequent cohort escalations based on protocol-specific criteria
1640228|NCT01929941|Drug|INCB047986|INCB047986 tablets administered orally at the protocol specified dose and frequency
1640229|NCT01929941|Drug|Gemcitabine|Gemcitabine administered intravenously over 30 minutes at the protocol-specified dose and frequency
1640230|NCT01929941|Drug|nab-paclitaxel|nab-paclitaxel administered intravenously over 30 minutes at the protocol-specified dose and frequency
1641357|NCT01921699|Procedure|taking blood samples from healthy people|
1640231|NCT01929915|Procedure|Epidural patient controlled analgesia|Patient controlled epidural analgesia with marcaine(1mg/ml)+ fentanyl(1.25mcg/ml)for postoperative pain control
1640232|NCT01929915|Drug|Intravenous patient controlled analgesia|Intravenous patient controlled analgesia with morphine(1mg/ml)for post operative pain control
1640233|NCT01929889|Drug|Iloperidone|Patients in this study will be treated with Fanapt® (iloperidone). They will begin a standardized up-titration starting with a dose of 2 mg daily. Dose increases will continue until the subject has achieved clinical stability, has achieved the maximum dose of 24 mg/day, or until 8 weeks have elapsed. Once clinical stability has been achieved, the patient will continue into the treatment phase. If clinical stability is not achieved after 8 weeks, the patient will be excluded from the study.
1640234|NCT01929876|Drug|Cobimetinib|10 milligram (mg) (2* 5 mg capsules) will be administered orally on Day 1 of Period 1 and Day 4 of Period 2
1640235|NCT01929876|Drug|Itraconazole|200 mg oral solution will be administered once daily from Day 1 to Day 14 of Period 2
1640236|NCT01929863|Drug|GSK2330672|GSK2330672 will be supplied as oral solution, and will be administered BID [45 mg (2 days repeat dose) and 90 mg (5 days repeat dose) in each period]
1640237|NCT01929863|Drug|Placebo|GSK2330672 matching placebo will be supplied as oral solution, and will be administered BID (7 days of dosing in each period)
1640238|NCT01929863|Drug|Metformin|Metformin 850 mg will be administered BID from Run-in period till Day 7 of period 2
1640239|NCT01929850|Procedure|Laparscopic Sleeve Gastrectomy|The laparoscopic sleeve gastrectomy involves the placement of 5 trocars. A leak check may be performed at the same time by insufflating with a gastroscope with the remnant gastric section submerged in irrigation fluid and by infusing sterile methylene blue through a nasogastric tube. The staple line may be oversewn (3-0 Vicryl, Ethicon), only along the bleeding and leakage areas, or areas with the potential for such complications. A nasogastric decompression tube placed to monitor bleeding and an intraperitoneal drain was placed under an anastomotic stoma.
1640240|NCT01929850|Behavioral|Weight Watchers Program|Intensive medically supervised nutritional and exercise therapy
1640241|NCT01929837|Device|E-fied navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with E-field navigated rTMS (Nexstim) targeted at the tonotopic representation area of the main frequency content of tinnitus
1640242|NCT01929837|Device|non-navigated rTMS|1 hz on the superior temporal gyrus contralateral/left side with non-navigated rTMS according to external landmarks (between T3/T4 and P3/P4 EEG-electrode locations)
1640243|NCT01929837|Device|sham E-field navigated rTMS|
1640244|NCT01929837|Device|Navigated rTMS|1 hz on the left superior temporal gyrus with (MRI) navigated rTMS (Visor)
1640245|NCT01929824|Other|Oral Nitric Oxide testing|o Oral nitric oxide is measured by a breathing test where the participant will be seated in a chair and asked to breathe out into a small hand-held instrument for about 6 seconds.
1640246|NCT01929811|Drug|Metformin|Metformin: 500mg tid, orally (500mg daily in first cycle) on day 1 to day 21 of each 21 day cycle
1640247|NCT01929811|Drug|Docetaxel|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
1640248|NCT01929811|Drug|Epirubicin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
1640249|NCT01929811|Drug|cyclophosphomide|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; 6 cycles.
1640250|NCT01929798|Device|portable Artificial Pancreas|The artificial pancreas system will be allowed to employ its Model Predictive Control algorithm to make decisions about insulin delivery based on measured glucose levels.
1640251|NCT01929759|Drug|Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)|Switch from Atripla (efavirenz, emtricitabine and tenofovir) to Stribild (elvitegravir, cobicistat, emtricitabine and tenofovir)for total of 8 weeks
1640252|NCT01929746|Biological|BIIB019 subcutaneous injection|participants will be randomized to receive a single subcutaneous injection of BIIB019, 75 mg or 150 mg per dose group
1640253|NCT01929720|Behavioral|Cognitive-behavioral therapy for worry, uncertainty & insomnia|This intervention involves teaching the participant in-person strategies for managing worry, uncertainty, and insomnia and involves home practice.
2012255|NCT02112916|Drug|Thioguanine|Given PO
1640256|NCT01929694|Dietary Supplement|Berocca Boost|
1640257|NCT01929694|Dietary Supplement|Placebo|
1640258|NCT01929681|Device|Low Field Magnetic Stimulation|Low Field Magnetic Stimulation is an electromagnetic technique. It uses low strength electric fields operating at a high frequency.
1640259|NCT01929668|Drug|polyethylene glycol|
1640260|NCT01929668|Drug|Ascorbic Acid|
1640261|NCT01929655|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|BAY88-8223, 50 kBq/kg will be administered as slow bolus intravenous injection 6 times at intervals of 4 weeks between each administration
1640262|NCT01929642|Drug|Sirolimus|
1640263|NCT01929642|Drug|Everolimus|
1640264|NCT01929629|Drug|Part A|Single ascending doses
1640265|NCT01929629|Drug|Part B|Single doses food effect. Subjects to receive 2 single doses, one in fed and one in fasted.
1640266|NCT01929616|Drug|regorafenib|Patients will receive 160 mg regorafenib 1/day 3 weeks out of 4.
1640267|NCT01929603|Procedure|Pharmacokinetic sampling|Blood sampling to measure olaparib, rifampicin and 4β-hydroxycholesterol
1640268|NCT01929603|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 5 to Day 14 (Part A)
1640269|NCT01929603|Drug|Olaparib tablet dosing|Olaparib 300mg tablet taken on Days 1 and 14 (Part A). Part B dosing is 300mg olaparib bi-daily
1640270|NCT01929590|Drug|PEG-3350 group 2|split-dose (PEG-3350; 2 L the day before 17:00-19:00 h and 2 L same day of the procedure 06:00-08:00 am)
1640271|NCT01929590|Drug|PEG-3350 group 1|PEG-3350; PEG-4 L the day previous of the study, starting at 17:00 and finishing at 21:00 h
1640272|NCT01929590|Drug|PEG-3350 group 3|low-volume 2 L PEG-solution (same day of the procedure 06:00-08:00 am)
1640273|NCT01929577|Drug|ASP015K|oral tablet
1640274|NCT01929564|Other|Beneforte broccoli|Four x 100g portions of Beneforte broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
1640275|NCT01929564|Other|Parthenon Broccoli|Four x 100g portions of Parthenon broccoli will be consumed each week for twelve weeks, on top of the participants habitual diet
1640370|NCT01928914|Drug|Tafenoquine 300mg|Single dose of Tafenoquine give on Day 3 only
1640276|NCT01929551|Other|Mango puree and pear juice beverage|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
1640277|NCT01929551|Other|Commercial mango juice|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
1640278|NCT01929551|Other|Fresh natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
1640279|NCT01929551|Other|Frozen natural mango|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
1640280|NCT01929551|Other|Processed natural mango pulp|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
1640281|NCT01929551|Other|Mix of natural mango and pear|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
1640282|NCT01929551|Other|50 grams glucose load|Capillary glucose will be taken every 15 minutes for two hours (starting at time 0) to calculate the area under the curve which is the glycemic index, for each of the products.
1640283|NCT01929538|Procedure|ERCP|endoscopic retrograde cholangiopancreatography
1640284|NCT01929538|Device|covered self-expanding biliary metal stent, 12mm in diameter|
1640285|NCT01929538|Device|covered self-expanding biliary metal stent, 10mm in diameter|
1640286|NCT01929512|Drug|HCP1201 750/20mg|750mg Metformin/20mg rosuvastatin fixed dose combination tablet orally in the morning on day1 or day8.
1640287|NCT01929512|Drug|Metformin SR 750mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
1640288|NCT01929512|Drug|Rosuvastatin 20mg|Co-administration of Metformin 750mg and Rosuvastatin 20mg orally in the morning on day1 or day8.
1640289|NCT01929499|Biological|cytokine-induced killer cells|
1640290|NCT01929486|Biological|Mogamulizumab|Mogamulizumab 0.1mg/kg, 0.5mg/kg or 1.0mg/kg will be administered 8 times every week.
1640291|NCT01929460|Drug|Ciprofloxacin|ciprofloxacin oral capsule (one capsule twice a day for 3 days)
1640292|NCT01929460|Other|Placebo (for ciprofloxacin)|oral placebo capsule (one capsule twice a day for 3 days)
1640293|NCT01929434|Other|rehabilitation|Patients only receive rehabilitation of physical therapy and occupational therapy.
1640294|NCT01929434|Procedure|stem cell injection|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
1640295|NCT01929421|Drug|Gemcitabine/S-1|
1640296|NCT01929395|Device|Supine MRI|A limitation of MRI studies of the breast is that MRI exams are performed with the patient prone and the breasts in a pendant position, which is markedly different than the position of the breast when the patient is supine on the Operating Room table. The spatial information the surgeon receives from the prone MRI about the site of the tumor in the breast is hard to mentally translate into the actual site of the tumor in the breast of a supine patient prepared for surgery.
2012256|NCT02112916|Drug|Vincristine Sulfate|Given IV
1640298|NCT01929356|Procedure|Chest physiotherapy|20 minutes of chest physiotherapy by physiotherapist
1640299|NCT01929343|Drug|lidocaine following cue-induced craving|as described in Arm Description
1640300|NCT01929343|Drug|lidocaine following neutral stimulus|as described in Arm Description
1640301|NCT01929343|Drug|saline|as described in Arm Description
1640302|NCT01929330|Drug|GI198745 0.1 mg|It is available as soft gelatin capsule to be administered as 5 X 0.1 mg capsules as single oral dose with approximately 250 mL of water.
1640303|NCT01929330|Drug|GI198745 0.5 mg|It is available as soft gelatin capsule to be administered as 1 X 0.5 mg capsules as single oral dose with approximately 250 mL of water.
1640304|NCT01929317|Drug|Ropinirole CR 2mg tablet|Ropinirole CR 2mg tablets will be supplied as white oval film-coated tablets.
1640305|NCT01929317|Drug|Ropinirole CR 8mg tablet|Ropinirole CR 8mg tablets will be supplied as white oval film-coated tablets.
1640306|NCT01929317|Drug|Ropinirole CR matching Placebo tablet|Ropinirole CR matching Placebo tablet tablets (containing no active ingredients) indistinguishable in appearance from Ropinirole CR 2 mg tablets.
1640307|NCT01929304|Other|Survey|
1640308|NCT01929291|Biological|Boostrix|Single intramuscular injection
1640309|NCT01929291|Other|Safety data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form
1640310|NCT01929278|Drug|CT Gel (clindamycin 1% and tretinoin 0.025%)|Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
1640311|NCT01929278|Other|Vehicle gel patch|Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
1640365|NCT01928979|Other|no drug|Patients who suffered from hemodynamically stable nonvalvular AF or atrial flutter and had a diagnosed LA/ LAA thrombus between January 1st, 2011 and December 31st, 2012
1640366|NCT01928966|Other|Pumpkin Seeds|Participants will be asked to consume 1.5 ounces of raw, unsalted pumpkin seeds per day. The 1.5 ounces will be split in to two servings (each 0.75 ounces).
1640367|NCT01928940|Drug|dabrafenib|150 mg twice daily
1640368|NCT01928940|Drug|trametinib|2 mg once daily
1640312|NCT01929278|Other|Blank patch|Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril [approximately 2 cm x 2 cm]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
2012257|NCT02111200|Drug|Sodium Benzoate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
1640314|NCT01929252|Drug|Dexmedetomidine|2mcg.kg-1 dexmedetomidine wound infiltration
1640315|NCT01929252|Drug|Levobupivacaine|0.25% levobupivacaine (40ml) wound infiltration
1640316|NCT01929239|Drug|Anti-PSMA Designer T Cells|
1640317|NCT01929226|Biological|ETI-204|Monoclonal Antibody
1640318|NCT01929226|Biological|Placebo|Placebo comparator
1640319|NCT01929213|Drug|Udenafil|Udenafil is administered
1640320|NCT01929213|Drug|Bosentan|Bosentan is administered
1640321|NCT01929213|Drug|Udenafil/Bosentan|Udenafil and Bosentan are administered
1640322|NCT01929200|Drug|1-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 1 year.
1640323|NCT01929200|Drug|2-year treatment with icotinib|Icotinib is administered orally with a dose 125 mg 3 times daily within 4-6 weeks after operation for 2 years.
1640324|NCT01929187|Drug|Phytonail|
1640325|NCT01929187|Drug|Loceryl|
1640326|NCT01929161|Drug|Oxytocin|24 International Units
1640327|NCT01929161|Drug|Placebo (for oxytocin)|intranasal spray manufactured to mimic oxytocin nasal spray
1640328|NCT01929161|Behavioral|Lovingkindness Meditation|
1640329|NCT01929161|Behavioral|Mindfulness Meditation|
1640330|NCT01929148|Procedure|Prophylactic bilateral salpingectomy|Salpingectomy will be performed by coagulation and section of the tube, beginning from the very distal fimbrial end, carefully preserving the ovarian vascularization, and proceeding toward the uterine cornu
1640331|NCT01929148|Procedure|Laparoscopic myomectomy without PBS|Standard laparoscopic myomectomy without salpingectomy
1640332|NCT01929135|Drug|Medicated 2% atorvastatin dentifrice|Non surgical periodontal therapy accompanied by medicated 2% atorvastatin dentifrice (20 mg per ml) 2 times a day for two minutes each time, for 30
1640333|NCT01929135|Drug|Non-medicated dentifrice|Non surgical periodontal therapy accompanied by non medicated dentifrice 2 times a day for two minutes each time, for 30 days.
1640334|NCT01929122|Dietary Supplement|Placebo-Control Meals and Snacks|
1640335|NCT01929122|Dietary Supplement|Cooked Navy Bean Powder Meals and Snacks|
1640336|NCT01929122|Dietary Supplement|Rice Bran Meals and Snacks|
1640337|NCT01929109|Drug|LY2409021|Administered orally
1640338|NCT01929096|Drug|Compound Edaravone Injection|
1640339|NCT01929096|Drug|Edaravone Injection|
1640340|NCT01929083|Drug|Progesterone|Subjects will receive oral progesterone 400 mg (two x 200 mg capsules) once daily every evening for 7 days
1640341|NCT01929083|Drug|Placebo|Subjects will receive oral placebo two capsules once daily every evening for 7 days
1640342|NCT01929083|Drug|Ibutilide|Ibutilide 0.003 mg/kg administered to all subjects to moderately lengthen the QT interval
1640343|NCT01929070|Drug|HCP1007|
1640344|NCT01929070|Drug|Omarco and Crestor|
1640345|NCT01929057|Procedure|Skin biopsy|4-millimeter punch biopsies will be performed on all subjects (acne patients and healthy controls)
1640346|NCT01929057|Procedure|Blood draw|Approximately half a tube of blood will be drawn from all participants in the study
1640347|NCT01929044|Drug|654-II (anisodamine)|10mg injection
1640348|NCT01929044|Drug|Buscopan® (hyoscine butylbromide)|20mg injection
1640349|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet
1640350|NCT01929031|Drug|ibuprofen|tablet.
1640351|NCT01929031|Drug|ibuprofen|tablet
1640352|NCT01929031|Drug|caffeine|tablet
1640353|NCT01929031|Drug|ibuprofen + caffeine|Fixed Dose Combination (FDC) tablet
1640354|NCT01929031|Drug|placebo|tablet
1640355|NCT01929031|Drug|placebo|tablet
1640356|NCT01929031|Drug|caffeine|tablet
1640357|NCT01929031|Drug|ibuprofen|tablet
1640358|NCT01929031|Drug|ibuprofen + caffeine|FDC tablet
1640362|NCT01929005|Other|Comprehensive Care|Patients will receive comprehensive medical care from their CCP in clinic and the hospital. For most patients, the ambulatory care provided by the CCP will be in our onsite medicine clinic, but for some patients with subspecialty needs the CCP may be a specialist who will care for the patient in a nearby ambulatory setting (e.g., nursing home, dialysis facility). The CCPs will also supervise the nurses, pharmacists, social workers, and others who are part of the multi-disciplinary care team. Daytime inpatient care will be provided by CCPs in conjunction with our inpatient advanced practice nurses (APNs). These APNs now work with our hospitalists, so they are experienced providing hospital care.
1640363|NCT01928992|Device|3D|subjects that underwent 3D mammography
1640364|NCT01928992|Device|2D|those subjects that underwent 2D mammography
1640369|NCT01928927|Drug|Telmisartan|
2012258|NCT02111200|Drug|Sodium Phenylbutyrate|Subjects will be instructed to take the study medication with meals (08:00 breakfast; 13:00 lunch; 19:00 dinner) for 3 days.
2012259|NCT02106858|Drug|Regorafenib (Stivarga,BAY73-4506)|Patients treated by Physician with Stivarga under approved local prescriptions
2012260|NCT02106351|Drug|AbobotulinumtoxinA|Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.
2012261|NCT02105090|Drug|Anesthetics, Local|
2012262|NCT02105090|Drug|Sodium Chloride 0.9%|
2012263|NCT02104752|Drug|Curcumin|360 mg/day (divided into twice daily oral doses)
2012264|NCT02104752|Drug|Placebo|"Inactive, matched placebo (Sugar Pill)"
2012265|NCT02102490|Drug|Abemaciclib|Administered orally
2012266|NCT02101905|Other|Laboratory Biomarker Analysis|Correlative studies
2012267|NCT02101905|Drug|Lapatinib Ditosylate|Given PO
1640371|NCT01928914|Drug|Tafenoquine 600mg|Single dose of Tafenoquine given on Day 3 only
1640372|NCT01928914|Drug|Tafenoquine 1200mg|400mg Dose of Tafenoquine given on each of the three consecutive dosing days
1640373|NCT01928914|Drug|moxifloxacin|moxifloxacine given on Day 3 only
1640374|NCT01928914|Drug|Placebo for Tafenoquine|Placebo given on all three days to all groups except for group 5 on Day 3
1640375|NCT01928914|Drug|Placebo for moxifloxaxin|Placebo for moxifloxacin, given to all groups on all days except for Group 3 on Day 3
1640376|NCT01928901|Drug|administration of Sinupret|
1640377|NCT01928901|Drug|administration of Bronchipret|
1640378|NCT01928901|Drug|administration of Sinupret Placebo|
1640379|NCT01928901|Drug|administration of Bronchipret Placebo|
1640380|NCT01928888|Drug|Talcid (Hydrotalcite, BAY4516H)|2 tablets hydrotalcite (2x500mg) 1000mg and 1 capsule placebo to famotidine
1640381|NCT01928888|Drug|Famotidine|2 tablets placebo to hydrotalcite and 1 capsule famotidine 10 mg
1640382|NCT01928888|Drug|Placebo|2 tablets placebo to hydrotalcite and 1 capsule placebo to famotidine
1640383|NCT01928875|Device|AoA Monitoring|Monitoring with Entropy and SPI parameters during surgery
1640384|NCT01928875|Device|Routine (Standard) Anesthesia Monitoring|Standard of care monitoring
1640385|NCT01928862|Drug|Prepopik™ ½ sachet (9-12 years)|
1640386|NCT01928862|Drug|Prepopik™ 1 sachet (9-12 years)|
1640387|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (9-12 years)|
1640388|NCT01928862|Drug|Prepopik™ 1 sachet (13-16 years)|
1640389|NCT01928862|Drug|Oral polyethylene glycol (PEG) based preparation (13-16 years)|
2012268|NCT02101905|Other|Pharmacological Study|Correlative studies
2012269|NCT02101905|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of tumor
1640392|NCT01928823|Behavioral|CBT|12 sessions of CBT (cognitive behavioral therapy) with psychoeducation and in-vivo exposure
1640393|NCT01928823|Drug|D-Cycloserine|Administered for three times (50mg, oral) directly after exposure
1640394|NCT01928810|Behavioral|Cognitive Behavioural Therapy|12 sessions of CBT including psychoeducation, interoceptive exposure and in-vivo exposure
1640395|NCT01928797|Device|Cardiac output monitor data|The availability of cardiac output monitor provides additional hemodynamic indices that may help guide anesthesiologists to better select vasopressors
1640396|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 2000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 2000 impulses
1640397|NCT01928784|Device|Radial Extracorporeal Shock Wave Therapy 4000 impulses|Radial Extracorporeal Shock Wave Therapy, 13 Hz, 2.5 Bar, 4000 impulses
1640398|NCT01928771|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 44 inclusive.
1640399|NCT01928771|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 44 inclusive.
1640400|NCT01928758|Drug|Reduced Nicotine Content Cigarettes|Research cigarettes will have gradually reduced nicotine content
1640401|NCT01928758|Drug|Usual Nicotine Content Cigarettes|Usual Nicotine Content Cigarettes
1640402|NCT01928732|Behavioral|Cognitive Processing Therapy (CPT)|CPT consists of cognitive therapy and a written trauma narrative. Patients are taught to challenge their beliefs through Socratic questioning and the use of daily worksheets. The initial focus is on beliefs such as denial and self-blame, and then shifts to overgeneralized beliefs about self and the world. Patients process their trauma directly by writing a narrative of their traumatic event(s) that they read to themselves and to therapists. The typical protocol consists of 12 1-hr sessions. In this study, the 12-session protocol will be followed, but participants who improve more rapidly may finish in 10 sessions and those who improve more slowly may receive up to 2 additional sessions to continue working on stuck points with challenging beliefs worksheets.
1640403|NCT01928732|Behavioral|Prolonged Exposure (PE)|"PE is a manualized, 90-minute, 8-15 week treatment program based on emotional processing theory, which posits that anxiety disorders, including PTSD, reflect pathological fear structures in which emotional and cognitive associations among different elements do not accurately represent reality and renders the individual dysfunctional and distressed. PE is designed to correct erroneous connections in the targeted memory structure. PTSD sufferers typically experience two key pathological emotional response sets and related cognitions: The world is an utterly dangerous place, and I am completely incompetent and unable to cope with stress. In this study, the 12-session protocol will be followed, but participants improve more rapidly may finish in 10 sessions and those who improve more slowly may have up to 2 additional sessions to continue working on exposure."
1640404|NCT01928719|Drug|Reduced Nicotine Content Cigarettes|Cigarettes contain 8 [9 for menthol], 4, 1.7, 0.9 and 0.3 mg of nicotine
1640405|NCT01928719|Drug|Same Nicotine Content Cigarettes|about 11.4 mg nicotine per cigarette
1640406|NCT01928706|Other|Denture liner Mucopren Soft; Group 1|Complete denture wearers had their existing mandibular dentures relined with a soft silicone-based denture liner (Mucopren Soft; Group 1; n=22)
1640407|NCT01928706|Other|Denture liner Kooliner; Group 2|Complete denture wearers had their existing mandibular dentures relined with a hard acrylic resin based denture liner (Kooliner; Group 2;n=22) with chairside procedures.
1640408|NCT01928693|Drug|Besivance 0.6% Ophthalmic Suspension|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
1640409|NCT01928693|Drug|Zymaxid 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
1716636|NCT00000556|Drug|diltiazem|
2012270|NCT02101853|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HSCT
2012271|NCT02101853|Drug|Asparaginase|Given IM or IV
2012272|NCT02101853|Biological|Blinatumomab|Given IV
2012273|NCT02101853|Drug|Cyclophosphamide|Given IV
2012274|NCT02101853|Drug|Cytarabine|Given IT and IV or SC
1640410|NCT01928693|Drug|Vigamox 0.5% Ophthalmic Solution|Drop to be applied in affected eye initially every hour for the first 48 hours then doses will be reduced at each subsequent visit by 50% if patient continues to show a reduction in size of 25% from the previous visit up to every 4 hours. If subject dose has been reduced to every 4 hours at visit 3 and shows an additional reduction size of 25% at visit 4, then they will be reduced to every 6 hours.
1640411|NCT01928680|Drug|Cisplatin/Capecitabine|Cisplatin/Capecitabine: Capecitabine 1000mg/m2 orally Bid on day 1 to day 14 plus Cisplatin 75mg/m2 on day1 of each 21 day cycle, until progression or untolerable toxicity
1640412|NCT01928667|Other|Whole saliva sample|Both case and control group will be approached to consider to give permission to sample saliva. This is not obligatory. Collected samples will be stored for future DNA research.
1640413|NCT01928654|Device|Micropulse laser treatment|Device for subthreshold treatment of the retina, by decomposing a continuos wave of laser in micropulses, with 5% duty cycle, 200 milliseconds, 100 microns, and power adjusted according to patient's diopter transparency and pigmentation.
1640414|NCT01928654|Device|Laser modified ETDRS|Device for visible treatment of the retina, with direct treatment of microaneurysms or grid pattern covering the area of retinal edema.
1640415|NCT01928628|Drug|Lercanidipine 10mg|
1640416|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg|
1640417|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg|
1640418|NCT01928628|Drug|Lercanidipin 10mg Placebo|
1640419|NCT01928628|Drug|Lercanidipine10mg /Valsartan 80mg Placebo|
1640420|NCT01928628|Drug|Lercanidipine 10mg /Valsartan 160mg Placebo|
1640421|NCT01928615|Drug|Trastuzumab - intravenous solution|Trastuzumab was supplied as a powder to be reconstituted as a solution for intravenous infusion.
1640422|NCT01928615|Drug|Trastuzumab - subcutaneous solution|Trastuzumab was supplied as a solution for subcutaneous injection.
1640423|NCT01928615|Drug|Chemotherapy|Standard chemotherapy for early breast cancer.
1640424|NCT01928602|Behavioral|TherAppy Language App|Language TherAppy combines the receptive exercises of Comprehension TherAppy and Reading TherAppy with the expressive training of Naming TherAppy and Writing TherAppy. The app uses the same core functional vocabulary (nouns, verbs, & adjectives) and over 700 clear pictures. Each app tracks data, sends professional e-mailed reports, and has built-in levels, cues, and options.
1640425|NCT01928602|Behavioral|Mind-Games|A mind-game app is said to improve brain functioning at any age. The chosen app will give feedback such as score history, and progress reports. Tasks will focus on attention, memory spatial awareness and executive function.
1640426|NCT01928589|Radiation|PBI|270 cGy x15
1640427|NCT01928589|Other|PBI with chemotherapy|270 cGy x15 concurrent with chemotherapy of the treating medical oncologist's choice
1640428|NCT01928576|Drug|Azacitidine|
1640429|NCT01928576|Drug|Entinostat|
1640430|NCT01928576|Drug|Nivolumab|
1640431|NCT01928563|Drug|Dapoxetine|
1640432|NCT01928563|Drug|Udenafil|
1640433|NCT01928563|Drug|Udenafil+Dapoxetine|
1640435|NCT01928524|Drug|DOS2W|Docetaxel (30-35 mg/m2), Oxaliplatin (70 mg/m2) and S1 (30-50 mg/2) will be given every 2nd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered
1640436|NCT01928524|Drug|DOS3W|Docetaxel (25 mg/m2), Oxaliplatin (100 mg/m2) and S1 (40-60 mg/2) will be given every 3rd week. In total there is 5 dose levels and if no patients experience DLT on a given level, next dose level will be administered
1640437|NCT01928511|Drug|peg-interferon alpha 2b, 1.5mcg/kg s/c given weekly|
1640438|NCT01928511|Drug|Nucleos(t)ide analogue therapy|
1640439|NCT01928498|Device|Paclitaxel Eluting Balloon Angioplasty|
1640440|NCT01928498|Device|Percutaneous Transluminal Angioplasty (PTA)|
1640441|NCT01928485|Other|active surveillance|Undergo active surveillance
1640442|NCT01928485|Drug|Sunphenon|Given PO
1640443|NCT01928485|Other|laboratory biomarker analysis|Correlative studies
1640444|NCT01928485|Other|Questionnaire Administration|Ancillary studies
1640445|NCT01928472|Biological|H7N9c low dose with adjuvant|
1640446|NCT01928472|Biological|H7N9c medium dose with adjuvant|
1640447|NCT01928472|Biological|H7N9c high dose with adjuvant|
1640448|NCT01928472|Biological|H7N9c high dose without adjuvant|
1640449|NCT01928459|Drug|BGJ398|BGJ398 will be administered orally once daily for the first 21 days of each 28-day cycle.
1640450|NCT01928459|Drug|BYL719|BYL719 will be administered orally once daily on each day of the 28-day cycle.
1640451|NCT01928446|Drug|Lithium|Lithium in the form of extended release lithium carbonate. Subjects will be started on 600 mg/day (300mg bid) until steady state at target plasma levels between 0.6 and 0.8 meq/liter is achieved. The lowest dose will be 300 mg/day. Lithium will be prescribed for the duration of follow-up (1 year).
1640452|NCT01928446|Drug|Placebo|Oral placebo tablets will be administered for the duration of follow-up (1 year).
1640453|NCT01928433|Drug|Finafloxacin 800 mg i.v. once daily|Infused over 60 mins [i.v. pump]) for at least 3 days.
1640454|NCT01928433|Drug|Finafloxacin placebo i.v. once daily|Infused over 60 mins [i.v. pump]) for at least 3 days.
1640455|NCT01928433|Drug|Finafloxacin 800 mg tablets once daily|Administered as four 200 mg tablets
1640456|NCT01928433|Drug|Finafloxacin placebo tablets once daily|Administered as four tablets
1640457|NCT01928433|Drug|Ciprofloxacin 400 mg i.v. twice daily|Infused over approximately 60 mins [i.v. pump]) for at least 3 days
1640458|NCT01928433|Drug|Ciprofloxacin placebo i.v. twice daily|Infused over approximately 60 mins [i.v. pump]) for at least 3 days
1640459|NCT01928433|Drug|Ciprofloxacin 500 mg oral twice daily|Administered as two 250 mg capsules.
1640460|NCT01928433|Drug|Ciprofloxacin placebo oral twice daily|Administered as two capsules.
1640461|NCT01928420|Drug|Drug: NIC5-15|A natural product, found in many foods and plants with mild insulin sensitizing effects
1640462|NCT01928420|Drug|Placebo|Subjects with Alzheimer's Disease placebo comparator
1640463|NCT01928407|Drug|DARUNAVIR|The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules
1641001|NCT01924273|Drug|Talaporfin sodium|Combined Photodynamic/Pulsed Dye Laser Therapy/Talaporfin sodium
1640464|NCT01928407|Drug|ATAZANAVIR|The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
2012275|NCT02101853|Drug|Dexamethasone|Given PO or IV
2012276|NCT02101853|Drug|Etoposide|Given IV
2012277|NCT02101853|Other|Laboratory Biomarker Analysis|Correlative studies
1640468|NCT01928381|Drug|AZD5213 + pregabalin|Double blind Investigational drug AZD5213 (capsules) given in combination with pregabalin (capsules)
1640469|NCT01928381|Drug|Placebo|Double blind placebo capsules to match AZD5213 and pregabalin
1640470|NCT01928381|Drug|pregabalin capsules|Double blind pregabalin capsules to match AZD5213 and placebo
1640471|NCT01928368|Drug|AMG 282|Single dose either subcutaneously or intravenously on day 1.
1640472|NCT01928368|Drug|AMG 282 Matching Placebo|Single dose of matching AMG 282 placebo either subcutaneously or intravenously on day 1.
1640473|NCT01928342|Drug|Coenzyme A|Coenzyme A 400mg per day
1640474|NCT01928342|Drug|Placebo|Capsule without coenzyme A.
1640475|NCT01928329|Drug|Exenatide (Bydureon®)|
1640476|NCT01928329|Drug|Placebo|
1640477|NCT01928316|Drug|Mizolastine domestic (made in China)|Healthy male volunteers will receive 10 mg domestic (made in China) mizolastine tablets on Day 1 and Day 8
1640478|NCT01928316|Drug|Mizolastine (imported)|Healthy male volunteers will receive 10 mg imported mizolastine tablets on Day 1 and Day 8
1640479|NCT01928290|Drug|Irinotecan|
1640480|NCT01928290|Drug|Trastuzumab|
1640481|NCT01928290|Drug|Oxaliplatin|
1640482|NCT01928290|Drug|Leucovorin|
1640483|NCT01928290|Drug|Fluorouracil|
1640484|NCT01928264|Behavioral|Physical activity|
1640485|NCT01928251|Behavioral|Informed early monetary incentive|"Participants will be informed at 1 week after the baseline recruitment about the monetary incentive of quitting.
Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
1640486|NCT01928251|Behavioral|Uninformed early monetary incentive|"Participants will be informed at 3 months after the baseline recruitment about the monetary incentive of quitting.
Apart from the different arrangement of monetary incentives for the three RCT arms, all participants of the Quit to Win Contest will receive self-help materials on smoking cessation, including a COSH-developed self-help smoking cessation booklet, a health education card, and the quitline (i.e. 1833183). The theory-based health education card (pocket size), which guided by the HAPA, will be developed and distributed to the participants as a reminder and a 'homework assignment' to be completed at home, for the purpose of enhancing their intention and practice of the suggested behaviour (quitting smoking)."
1640487|NCT01928238|Device|Noninvasive neurally adjusted ventilatory assist (NIV-NAVA).|
1640488|NCT01928238|Device|Noninvasive pressure support ventilation (NPSV)|
1640489|NCT01928225|Biological|Human Papillomavirus vaccine|The participants receive the qHPV vaccine at entry, week 4 and week 26
1640490|NCT01928212|Device|Optical coherence tomography|
1640491|NCT01928199|Drug|Sitagliptin|
1640492|NCT01928199|Drug|Placebo|
1640493|NCT01928186|Drug|Fluorothymidine F-18|Undergo FLT PET
1640494|NCT01928186|Procedure|Positron Emission Tomography|Undergo FLT PET
1640495|NCT01928186|Other|Laboratory Biomarker Analysis|Correlative studies
1640496|NCT01928186|Drug|Run-in (short pre-surgery course) of endocrine-targeted therapy|Patients undergo run-in (short pre-surgery course) of endocrine-targeted therapy with aromatase inhibitor between the two (baseline and repeat) FLT PET scans. This is not an experimental therapy. This is a standard of care therapy that patients will continue after surgery, when the study is completed.
1640497|NCT01928173|Behavioral|Abbreviated cognitive behavioral therapy|see arm description
1640498|NCT01928173|Behavioral|Sleep education/sleep hygiene|see arm description
1640499|NCT01928160|Drug|pemetrexed disodium|Given IV
1640500|NCT01928160|Drug|carboplatin|Given IV
1640501|NCT01928160|Drug|cisplatin|Given IV
1640502|NCT01928160|Drug|erlotinib hydrochloride|Given PO
1640503|NCT01928160|Other|laboratory biomarker analysis|Correlative studies
1640504|NCT01928147|Drug|PPI-383|
1640505|NCT01928147|Drug|Placebo|
1640506|NCT01928134|Dietary Supplement|Vit K2+ Vit D3+ calcium carbonate (CaCO3)|
1640507|NCT01928134|Dietary Supplement|Vit K2+CaCO3|
1640508|NCT01928121|Other|Care provided by AF expert program|
1640509|NCT01928108|Behavioral|iPhone Application|"The iPhone application waterlogged will be used by participants using and iPhone cellular device. This application will be used to track daily fluid intake for 1 week."
1640510|NCT01928108|Behavioral|Android Application|"The Android application water my body will be used by participants using an Android cellular device. This application will be used to track daily fluid intake for 1 week."
2012278|NCT02101853|Drug|Leucovorin Calcium|Given IV or PO
1640512|NCT01928069|Drug|Torrent's Montelukast Sodium Tablets 10 mg|
1640513|NCT01928056|Drug|Torrent's Montelukast Sodium Tablets 10 mg|
1640514|NCT01928043|Drug|Curcumin|
1640515|NCT01928030|Biological|recombinant human hyaluronidase|Given SC
1640516|NCT01928004|Device|Implant placement|Participants received two Straumann Standard Implants® in the interforaminal region using the recommended surgical protocol. The implants were loaded using Locator® attachments after six to eight weeks healing time by transforming the existing lower denture to an IOD.
1640517|NCT01928004|Procedure|Conventional reline|conventional reline of the existing mandibular complete denture
1640518|NCT01927991|Behavioral|iCBT (internet-based, cognitive-behavioural therapy)|The intervention is based on cognitive-behavioural therapy (CBT) and is offered as a self-help and provided over the internet. Participants work on their own on different modules which give information about tinnitus and the associated symptoms and provide instructions for practical exercises.
1641002|NCT01924260|Drug|alisertib|Given PO
1640519|NCT01927965|Drug|Minnelide™ 001|Minnelide™ will be given as a single agent intravenously as a 30-minute infusion daily x 21 days followed by a 7-day rest period. One cycle will equal 28 days.
1640520|NCT01927952|Procedure|Kirschner wire|Surgical fixation utiliziing Kirschner wire
1640521|NCT01927952|Procedure|Integra IPP-On PIP Fusion System|surgical fixation utilizing the Integra IPP-On PIP Fusion System
1640522|NCT01927952|Procedure|Stryker Smart-Toe Implant|surgical fixation utilizing the Stryker Smart-Toe Implant
1640523|NCT01927926|Dietary Supplement|Whey-protein & polydextrose snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
1640524|NCT01927926|Dietary Supplement|Control snack|Subjects will consume one snack bar as a between-meal mid-morning snack daily for 15 days.
1640525|NCT01927913|Drug|SPD602|32, 50 or 75 mg/kg/day BID, capsule
1640526|NCT01927913|Drug|Deferasirox|Per approved country specific label
1640527|NCT01927900|Dietary Supplement|HMO|
1640528|NCT01927900|Dietary Supplement|Glucose|
1640529|NCT01927887|Drug|Ferumoxytol|Ferumoxytol will be administered as an undiluted intravenous injection dose of 6 mg/kg body weight, up to a maximum dose of 510 mg, delivered at a rate of up to 1ml/sec. Each ml of the supplied agent contains 30 mg of elemental iron and the dose will be titrated based on patients body weight in kilograms; for example at a dose of 6 mg/kg, the dose for a 50 kg person will be 50 x 6 = 300 mg. As the vial contains 30 mg/ml, 10 cc of the dose will correspond to the required 300 mg dose.
1640530|NCT01927887|Device|Nanoparticle MRI|Each subject will have one MRI scan. At the initial pre-scan visit, the subject will receive the ferumoxytol infusion. Within 48-72 hours after ferumoxytol infusion, a scan will be performed. Subjects will be imaged at Massachusetts General Hospital using commercial 3.0T imaging systems using dedicated neck coil and approved imaging protocols. The MR imaging will include conventional T1 and T2 weighted spin echo and 3 D gradient echo sequences.
1640531|NCT01927874|Procedure|Infiltration|injection of local anesthetic, associated with general anesthesia
1640532|NCT01927874|Procedure|Spinal block|injection of anesthetic
1640533|NCT01927874|Drug|Bupivacaine|10ml 0.5% bupivacaine.
1640534|NCT01927874|Drug|10 mg of hyperbaric 0.5% bupivacaine|Spinal punction and injection of local anesthetic
1640535|NCT01927861|Drug|somatropin|Administered subcutaneously (s.c., under the skin) in a daily regimen for at least 104 weeks. Subject will be offered to continue treatment for another 104 weeks.
1640536|NCT01927848|Dietary Supplement|Rosehip|Rosehip powder made from the fleshy orange walls (hypanthiums) of Rosehips with the achenes (seeds) removed, from the wild growing species Dog Rose (Rosa canina L.), in addition to vitamin C as sodium ascorbate. The active ingredient complex is Rosenoids®, Vitamin C, flavonoids, carotens, triterpene acids, and galactolipids. Rosenoids® is the registered name for the bioactive complex isolated from the rose-hip (Rosa canina) used in RH01. It is being supplied as capsules containing 750 mg of the Rosehip powder and 26.7 mg vitamin C.
1640537|NCT01927848|Dietary Supplement|Placebo|The placebo used in this study will be identical to the Rosehip capsules in both appearance and taste, except that it will not contain the active Rosehip powder ingredient Rosenoids® or vitamin C.
1640538|NCT01927835|Biological|DNA-HIV-PT123 vaccine|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered IM
1640539|NCT01927835|Biological|NYVAC-HIV-PT1 vaccine|≥ 5x10^6 PFU/ml encoding clade C ZM96 gp140 for a planned maximum dose of 1.2x10^8 PFU/ml; administered IM
1640540|NCT01927835|Biological|NYVAC-HIV-PT4 vaccine|≥ 5x10^6 PFU encoding ZM96 Gag and CN54 Pol-Nef, administered IM for a planned maximum dose of 1.1x10^7 PFU/ml; administered IM
1640541|NCT01927835|Biological|AIDSVAX B/E vaccine|300 mcg of subtype B (MN) HIV gp120 glycoprotein and 300 mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600 mcg of aluminum hydroxide gel adjuvant, administered IM
1640542|NCT01927835|Biological|Placebo for DNA/NYVAC/AIDSVAX|Sodium Chloride for injection, 0.9%; administered IM
1640543|NCT01927757|Biological|Etanercept|Administered by subcutaneous injection
1640544|NCT01927757|Drug|Methotrexate|Background methotrexate at least 15 mg weekly
1640545|NCT01927744|Drug|Docetaxel|75 mg/m2 by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
1640546|NCT01927744|Drug|Erlotinib|150 mg by mouth daily continuously until the day before surgery.
1640547|NCT01927744|Other|Placebo|150 mg by mouth daily continuously until the day before surgery.
1640548|NCT01927744|Behavioral|Questionnaires|Questionnaire completion at baseline, 14 days after treatment completion, and 8 weeks after surgery.
1640549|NCT01927744|Behavioral|Phone Call|Phone call made to patient 1 time each year after the end of treatment visit.
1640550|NCT01927744|Drug|Chemotherapy|Cisplatin 75 mg/m2 or Carboplatin AUC 6 mg.min/ml by vein on Day 1 of each 21 day cycle for a maximum of 3 cycles.
1640551|NCT01927731|Drug|Eltrombopag|300 mg orally for 60 total days. Eltrombopag started on Day -1 (the day prior to stem cell infusion in cord blood patients) and on Day +5 in patients receiving haploidentical transplant.
1640552|NCT01927718|Drug|Thalidomide|100 mg by mouth daily for 28 days in a 28 day cycle.
1640553|NCT01927718|Drug|Lenalidomide|Lenalidomide continued by mouth at the previous dose of 5 mg daily for 21 days on a 28 day cycle, 5 mg daily for 28 days on a 28 day cycle, 10 mg daily for 28 days on a 28 day cycle, or 15 mg daily for 28 days on a 28 day cycle.
1640554|NCT01927718|Behavioral|Questionnaires|Questionnaire completion at screening, once a month for the first 6 months, then every other month while on study.
1640555|NCT01927705|Biological|FURESTEM-AD Inj.|
1640556|NCT01927692|Other|Skin biopsy|An optional skin biopsy will be performed in up to 5 subjects at baseline and 2 weeks after therapeutic plasma exchange is completed.
1640557|NCT01927692|Other|Single Fiber Electromyography|An optional SFEMG study will be performed at baseline and 2 weeks after therapeutic plasma exchange is completed.
1640558|NCT01927679|Drug|Vitamin E|
1640559|NCT01927679|Drug|Eucerin|Control
1640560|NCT01927666|Dietary Supplement|100mg glucoraphanin|The extent of ITC excretion in urine from a capsule delivered dose of glucoraphanin
1640561|NCT01927640|Drug|Dexmedetomidine|During Visit 2 (Cocaine Study Day), intranasal cocaine will be administered. If randomized to this active drug arm, dexmedetomidine (0.3-0.6 mcg/kg) will then be administered followed by repeat myocardial contrast echocardiography.
1640562|NCT01927627|Drug|enzalutamide|oral therapy with enzalutamide at 160mg (4 capsules) orally once daily (QD).
1640563|NCT01927614|Radiation|Cardiac CT|"A 128-slice dual-source CT system will be used (Somatom Definition Flash, Siemens Healthcare, Germany).
The CT scan protocol will comprise 3 steps.
Prospectively gated calcium scoring.
Stress-myocardial CT perfusion.
Rest Coronary CT angiography and myocardial CT perfusion. Automated computed tomography dose index (CTDIvol) and dose- length-product (DLP) will be collected from the scanner, and effective dose will be calculated using the DLP conversion factor (0.014) for each component of the cardiac CT protocol. Based on local dose audits the predicted dose range will be 3.5 mSv to 8 mSv depending on patient body habitus."
1640564|NCT01927588|Drug|Everolimus+Tacrolimus+Prednisone|Certican, introduced at Day7 post transplant + TACreduced + Steroids.
1640565|NCT01927588|Drug|Mycophenolate+Tacrolimus+Prednisone|Myfortic + Tacrolimus full + Steroids, as control arm.
1640566|NCT01927575|Device|Standard X-Ray + CT|Standard of Care X-Ray Imaging + CT
1640567|NCT01927575|Device|Standard X-Ray + MRI|Standard of Care X-Ray Imaging + MRI
1640568|NCT01927575|Device|TOMO|Fujifilm Digital Radiographic AcSelerate CsI System with Tomosynthesis
1640569|NCT01927562|Device|Fractyl Duodenal Remodeling System|
1640570|NCT01927549|Procedure|Immediate multivessel PCI|
1640571|NCT01927549|Procedure|Culprit Lesion only PCI|
1640572|NCT01927536|Device|White LED Flashlight|white light setting
1640573|NCT01927536|Device|Red/Green Green Dominant LED Flashlight|Green LED light dominant setting
1640574|NCT01927523|Behavioral|BAM|BAM (Becoming a Man), a cognitive-behavioral group therapy intervention.
1640575|NCT01927523|Other|Match|An intensive math tutoring program.
1640576|NCT01927510|Behavioral|Early mobilisation|
2012279|NCT02101853|Drug|Mercaptopurine|Given PO
2012280|NCT02101853|Drug|Methotrexate|Given IT, IV, and PO
1640579|NCT01927484|Drug|25 mg/week oral methotrexate tablets|
1640580|NCT01927484|Drug|25mg/week oral placebo tablets|
1640581|NCT01927458|Device|Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
1640582|NCT01927445|Other|quality improvement toolkit|educational and informatics-based interventions, including brief guideline summary, decision support and audit and feedback
1640583|NCT01927419|Drug|Nivolumab|
1640584|NCT01927419|Drug|Ipilimumab|
1640585|NCT01927419|Drug|Placebo|Matching nivolumab
1640586|NCT01927406|Drug|Prostaglandin Analog|The first choice drug from group of Prostaglandin Analogues will be bimatoprost, if patient will suffer from any side effect of this drug another drug from this group will be administer. If patient turned out to cannot tolerate the prostaglandin analog therapy then the exclusion criteria will be met.
1640587|NCT01927406|Drug|Timolol|Timolol topical eye drop will be administered in Prostaglandin Analog vs Timolol arm only, in patients with elevated intraocular pressure in both eyes.
1640588|NCT01927393|Other|palliative care|Receive PCPI
1640589|NCT01927393|Behavioral|educational intervention|Receive education sessions
1640590|NCT01927393|Procedure|quality-of-life assessment|Ancillary studies
1640591|NCT01927393|Other|questionnaire administration|Ancillary studies
1640592|NCT01927393|Behavioral|telephone-based intervention|Receive telephone contacts
1640593|NCT01927380|Other|steep trendelenburg position with pneumoperitoneum|ANS activity and baroreflex modulation is assessed at (i) baseline; (ii) after induction of general anesthesia; (iii) after steep trendelenburg position (head down at 25 degrees); (iv) after induction of pneumoperitoneum and (v) after removal of trendelenburg and pneumoperitoneum
1640594|NCT01927367|Other|Clinical Decision Support System for AF|A web-based clinical decision support system, computerizing the Canadian AF clinical guidelines and best-practice approaches, to support primary care providers and patients in optimizing and standardizing AF care.
1640595|NCT01927341|Drug|MEK162|Tablet for oral use, 15 mg, BID
1640596|NCT01927341|Drug|Panitumumab|Intravenous infusion, 20mg/ml concentrate solution for infusion, Q2W (Days 1 and 15 of every cycle)
1640597|NCT01927328|Drug|Iron isomaltoside 1000|
1640598|NCT01927315|Drug|Fenofibrate 145 mg|Tablets of Fulcrosupra 145 mg to be taken at 8.00 am daily for 12 weeks.
1640599|NCT01927315|Drug|Placebo|Oral Placebo tablets once daily
1640600|NCT01927302|Behavioral|Treatment Focusing on Naming Objects|Treatment will be administered from week 0 until week 12.
1640601|NCT01927302|Behavioral|Treatment Focusing on Improving Spelling Abilities|Treatment will be administered from week 0 until week 12.
1640602|NCT01927302|Behavioral|Treatment Focusing on Improving Sentence Processing|Treatment will be administered from week 0 until week 12.
1640603|NCT01927302|Behavioral|No Treatment|No treatment will be administered.
2012281|NCT02101853|Drug|Mitoxantrone Hydrochloride|Given IV
1641003|NCT01924260|Drug|gemcitabine|Given IV
1716637|NCT00000556|Drug|digoxin|
2012282|NCT02101853|Drug|Pegaspargase|Given IV
2012283|NCT02101853|Other|Pharmacological Study|Correlative studies
2012284|NCT02101853|Drug|Therapeutic Hydrocortisone|Given IT
2012285|NCT02101853|Drug|Thioguanine|Given PO
2012286|NCT02101853|Drug|Vincristine Sulfate|Given IV
2012287|NCT02101788|Other|Laboratory Biomarker Analysis|Correlative studies
2012288|NCT02101788|Drug|Letrozole|Given PO
2012289|NCT02101788|Drug|Paclitaxel|Given IV
2012290|NCT02101788|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
2012291|NCT02101788|Other|Pharmacological Study|Correlative studies
2012292|NCT02101788|Other|Quality-of-Life Assessment|Ancillary studies
2012293|NCT02101788|Drug|Tamoxifen Citrate|Given PO
2012294|NCT02101788|Drug|Topotecan Hydrochloride|Given IV
2012295|NCT02101788|Drug|Trametinib|Given PO
2012296|NCT02100969|Drug|HIZENTRA ®|
2012297|NCT02099110|Drug|Matching Placebo to Ertugliflozin 5 mg|Placebo to ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
2012298|NCT02099110|Drug|Matching Placebo to Ertugliflozin 10 mg|Placebo to ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
1640604|NCT01927289|Procedure|Proximal Brachial Plexus vs Distal Forearm Block|"Proximal Brachial plexus block: 15 mls saline injected in distal forearm nerve block and 15 mls of 1.5% Mepivacaine injected to the brachial plexus via the supraclavicular approach.
Distal forearm block: 15 mls 1.5% Mepivacaine injected in distal forearm nerve block and 15 mls of saline injected to the brachial plexus via the supraclavicular approach"
1640605|NCT01927276|Other|Gluten Free Flour|
1640606|NCT01927276|Other|Wheat Flour|
1640607|NCT01927263|Biological|NI-071|100mg/vial
1640608|NCT01927263|Biological|Infliximab|100mg/vial
1640609|NCT01927250|Behavioral|Okada Health and Wellness program|Each participant were encouraged to practice the diet program and art therapy established by the MOA International Corporation, and to receive Okada Purifying Therapy, a domain of biofield therapy, for 3 consecutive months.
1640610|NCT01927237|Other|HLR|
1640611|NCT01927237|Other|EHR|
1640612|NCT01927224|Drug|Nifurtimox (BAYa2502) (4 x 30 mg tablet)|120 mg single dose as four 30 mg tablets after a high fat, high calorie meal
1640613|NCT01927224|Drug|Nifurtimox (BAYa2502) (slurry of 4 x 30 mg tablets in tap water)|120 mg single dose as aqueous slurry in tap water produced from four 30 mg tablets; ingestion after a high fat, high calorie meal
1640614|NCT01927224|Drug|Nifurtimox (BAYa2502) (120 mg tablet)|120 mg single dose as one 120 mg tablet after a high fat, high calorie meal
1640615|NCT01927211|Device|Silver Plated dressing|Silver plated dressing placed over Cesarean wound after skin closure, the dressing will be changed to saline-treated dressing on post-operative day 2 which will remain on the incision through post-operative day 7
1640616|NCT01927211|Device|Telfa pad dressing|Telfa pad dressing placed over Cesarean wound after skin closure, the dressing will be changed to a new Telfa pad dressing on post-operative day 2 which will remain on the incision through post-operative day 7
1640617|NCT01927198|Drug|Placebo|
1640618|NCT01927198|Drug|RDEA3170 5 mg|
1640619|NCT01927198|Drug|RDEA3170 10 mg|
1640620|NCT01927198|Drug|RDEA3170 12.5 mg|
1640621|NCT01927185|Device|Long Axis strategy|With the long-axis approach the vein appeared in the longitudinal view. With this approach only the vein was visible on the screen. The needle was held at a 30° angle, oriented in-plane with the transducer and the skin punctured at the base of the transducer. The vessel alignment was maintained during the procedure and the entire length of the needle was visible during the progression through the tissues.
1640622|NCT01927185|Device|Short Axis Strategy|With the short-axis approach the probe was positioned almost perpendicularly to the clavicle. The needle was held at an angle of 45° relative to the skin surface and sagittal to the plane of the probe (out-of-plane). During the progression to the vessel, the visualization of the needle was limited to the deformation of tissue and artefacts produced by needle advancement. When the tip abutted the vein wall, additional pressure produced transient vessel deformation, which disappeared once the wall was penetrated.
1640623|NCT01927172|Device|AirSonea|
1640624|NCT01927159|Biological|ID93 + GLA-SE|
1640625|NCT01927159|Other|Placebo|
1640626|NCT01927120|Drug|IL-2|A subcutaneous injection will be administered 3 times a week (separated by at least 1 day between injections), from day 0 to +90 (+/- 7 days).
1640627|NCT01927120|Drug|Tacrolimus|Will be administered at 0.01 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3
1640628|NCT01927120|Drug|Sirolimus|Orally on day -1. The dose for loading is 12 mg by mouth (PO)
1640629|NCT01927107|Dietary Supplement|Probiotics mixture|Comparison of probiotic mixture in addition to standard diet therapy vs. standart diet therapy
1640630|NCT01927094|Dietary Supplement|Probiotic|Comparison of probiotics vs. ORS
1640631|NCT01927094|Dietary Supplement|ORS|ORS ad libitum
1640632|NCT01927081|Behavioral|discussion group|Participants engage in discussions regarding issues related to coping with advanced cancer and pain
1640633|NCT01927081|Behavioral|gentle exercise|Patients learn gentle exercise and breathing techniques
1640634|NCT01927068|Device|CVI Paclitaxel-Coated PTA Balloon Catheter|Percutaneous Transluminal Angioplasty will be completed using a 2.0 micrograms per square millimeter. Paclitaxel-Coated Balloon. Balloon will be inflated to a size appropriate for the target vessel, as determined by the physician. Total balloon inflation time is determined by the physician, but no less than one minute.
1640635|NCT01927055|Drug|Droxidopa|Droxidopa at 100 mg, 200 mg, 300 mg
1640636|NCT01927055|Drug|Placebo|Placebo to match droxidopa capsules and strength designations
1640637|NCT01927042|Behavioral|ECHOs plus TAU|A self-help DVD that provides information for carers on eating disorders and teaches coping strategies to carers.
1640638|NCT01927042|Behavioral|Treatment as Usual|Treatment as Usual at the Eating Disorder Services includes group psychotherapy and skills training, nutritional counselling, and meal support.
1640639|NCT01927029|Drug|Progesterone|Vaginal progesterone gel 180mg/daily is given from second trimester (18 to 24 weeks) until 34 weeks.
1640640|NCT01927029|Drug|Placebo|
1640641|NCT01927016|Procedure|Esophagectomy|Esophagectomy for esophageal cancer whatever can be the surgical approach (with or without thoracotomy, minimally invasive or not)
1640642|NCT01927003|Procedure|Dorsal digito-metacarpal flap|The dorsal digito-metacarpal flap is a vascular island flap based on the dorsal digital artery and dorsal metacarpal artery. It has a longer vascular pedicle and provides tissue coverage of similar quality as that of normal glabrous skin but not sacrifice the digital artery.
1640643|NCT01926990|Procedure|perfusion computed tomography|Undergo perfusion CT
1640644|NCT01926977|Drug|Ranibizumab 0.5mg|Patient will receive intravitreal injection of Ranibizumab 0.5mg.
1640645|NCT01926977|Drug|Aflibercept 2.0mg|Patients will receive intravitreal injection of Aflibercept 2.0mg.
1640646|NCT01926951|Device|Surround Sound Externally Focused Therapeutic Ultrasound|Externally Focused Therapeutic Ultrasound using the Kona Surround Sound System
1640647|NCT01926912|Drug|No intervention|This is an observational study. Participants prescribed with paliperidone palmitate by the treating physician as per local labeling information in the hospital setting will be observed and data will be collected.
1640648|NCT01926899|Drug|Bortezomib administration|
1641719|NCT01918995|Drug|Regadenoson|Intravenous (IV)
2012299|NCT02099110|Drug|Matching Placebo to sitagliptin 100 mg|Placebo to sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
1640652|NCT01926860|Biological|Prevenar13|
1640653|NCT01926860|Biological|Hepatitis A vaccine|
1640654|NCT01926847|Drug|Riociguat (Adempas, BAY63-2521)|
1640655|NCT01926847|Drug|Placebo|
1640656|NCT01926834|Drug|Erigeron Injection|Erigeron Injection, 30ml, iv, qd, for 7days
1640657|NCT01926834|Drug|placebo|normal saline, 500ml,i.v.,qd, for 7 days
1640658|NCT01926821|Drug|Sonifilan|Sonifilan inj 20mg Intra muscular injection, twice per week for 8 weeks, total 16 times
1640659|NCT01926795|Procedure|Short leg cast|
1640660|NCT01926795|Procedure|No Immobilization|
1640661|NCT01926782|Drug|Placebo (for alirocumab)|Solution for injection, subcutaneous injections in the abdomen, thigh, or outer area of upper arm with an auto-injector.
1640662|NCT01926782|Drug|Alirocumab|Solution for injection, subcutaneous injection in the abdomen, thigh, or outer area of upper arm with an auto-injector.
1640663|NCT01926782|Drug|Statin|Atorvastatin, rosuvastatin and simvastatin at stable dose in participants with stable statin therapy
1640664|NCT01926769|Drug|Metformin|
1640665|NCT01926756|Procedure|Straight catheterization|Patient will receive the current standard practice of straight catheterization intraoperatively.
1640666|NCT01926756|Procedure|No straight catheterization|Patients will not be catheterized which is an experimental change from the current practice at our hospital.
1640667|NCT01926743|Procedure|Near infrared fluorescence imaging during laparoscopic or robotic gastrectomy|1.5mg of ICG injection around tumor each four direction by endoscopy on one or two days before surgery. NIR fluorescence imaging application during laparoscopic or robotic gastrectomy
1640668|NCT01926730|Other|Restriction diet|Selected food items will be limited in the participants diet
1640669|NCT01926678|Other|Swedish massage therapy|
1640670|NCT01926678|Other|Light touch therapy|
1640671|NCT01926665|Drug|Carfilzomib|Starting dose: 20/20 mg/m2 by vein on Days 1, 2, 15, and 16 of each 28 day cycle.
1640672|NCT01926665|Drug|Dexamethasone|4 mg by vein or mouth prior to each Carfilzomib dose in Cycle 1 and 2 to prevent infusion reactions. After dexamethasone is stopped, it should be restarted and administered prior to subsequent doses for reactions.
1640673|NCT01926652|Drug|candesartan cilexetil 32mg, amlodipine 10mg|"Part A: Treatment A (candesartan), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover.
Part B: Treatment A (Amlodipine), Treatment B (candesartan + amlodipine) 2-period, 2-treatment crossover."
1640674|NCT01926639|Biological|Radiotherapy, rituximab and DC|Lymphoma lymph nodes are irradiated with 8 Gy single treatment and injected with rituximab (5 mg) and autologous DC intratumorally. The treatment is performed 3 times targeting different lymph nodes
1640675|NCT01926626|Drug|Nicotine Patch|"Pre-Quit Period: 2 weeks of patch use (21mg/24hr)
Post Quit Period: 10 weeks of patch use (21mg/24hr for 6 weeks, 14mg/24hr for 2 weeks, and 7mg/24hr for 2 weeks)"
1640676|NCT01926626|Drug|Moclobemide|"Pre-Quit Period: 1 week of moclobemide use (400 mg/day in 2 divided doses)
Post Quit Period: 10 weeks of moclobemide use (400 mg/day in 2 divided doses)"
1640677|NCT01926613|Behavioral|Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and supported employment services.
1640678|NCT01926613|Behavioral|Supported Employment|Supported Employment is an evidence based vocational rehabilitation program
2012300|NCT02099110|Drug|Ertugliflozin 5 mg|Ertugliflozin 5 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
2012301|NCT02099110|Drug|Ertugliflozin 10 mg|Ertugliflozin 10 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
1640681|NCT01926574|Behavioral|long rehabilitation program|
1640682|NCT01926574|Behavioral|short rehabilitation program|
1640683|NCT01926574|Behavioral|Acceptance and commitment therapy (ACT)|
1640684|NCT01926561|Other|Interscalene brachial plexus block|After sterile draping around interscalene groove with povidone, a nerve stimulating needle connected to a nerve stimulator is inserted through the interscalene groove. Following involuntary contraction of shoulder, arm, forearm, or hand muscles with 0.5 milliamperes at 1 Hz using the nerve stimulator, 30 to 40 ml of mixture of 1% mepivacaine 20 ml and 0.75% ropivacaine 20 ml are injected.
1640685|NCT01926548|Drug|CJ Imatinib mesylate tablet|
1640686|NCT01926548|Drug|Gleevec film-coated tablet 2 x 100mg|
1640687|NCT01926535|Procedure|Implant of amniotic membrane grafts|Amniotic membrane grafts were implanted in the affected eyes using topical anesthesia. Each graft was sutured to the bulbar conjunctive tissue using 10-0 nylon sutures and a reinforcement stitch was applied at the cornea
1640688|NCT01926535|Device|Therapeutic contact lenses|Therapeutic contact lenses were applied in all patients included in the control group and the lenses were replaced every two months according to the pre-established gold standard for this procedure.
1640689|NCT01926522|Device|Technological Rehabilitation|"The length of stride of reference used during the exercise is personalized and depends on the height of patients. Each patient carries out the feedback for 20 minutes with the aim of generating the most symmetric and regular gait.
Patients, with the dynamometer, work on strengthening of flexor and extensor muscles with ankle speeds at 90°/sec and 120°/sec. The strengthening technique was performed twice for 10 minutes each time with a 1 minute rest between sets.
The session ends with a 20-minute feedback on dynamic balance platform by carrying out exercises in which they need to reach randomly appearing targets. Subjects begin with 12 minutes the first 4 sessions, progress to 16 minutes the next 2 sessions, then 18' (2 sessions), and finally 20', if able, during the last 4 sessions."
1640690|NCT01926522|Other|Control Rehabilitation|When needed, more than on e therapist are employed in the intervention for safety reasons.
1640691|NCT01926509|Drug|MK-8892|
1640692|NCT01926509|Drug|Placebo for MK-8892|
1640693|NCT01926496|Drug|Ingenol Mebutate Gel, 0.015%|Ingenol mebutate gel 0.015 % (Picato®) applied on the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs.
1640797|NCT01925690|Behavioral|Brief Education|Give patients a pamphlet discussing pros and cons of disease modifying therapies
1640694|NCT01926496|Drug|Imiquimod Cream, 5%|Imiquimod 5% cream applied to the selected treatment area. Retreatment if the treatment field is not completely cleared of AKs
1640695|NCT01926483|Other|Neoadjuvant Chemoradiotherapy|Surgery followed by cisplatin-based regimen and concurrent radiation (46Gy/23f), consolidate the original regimen 2 cycles.
1640696|NCT01926470|Procedure|anteroposterior approach group|anteroposterior approach group (n=104): check intravascular injection while performing S1 transforaminal epidural steroid injection in anteroposterior view under fluoroscopy
1640697|NCT01926470|Procedure|oblique approach group|oblique approach group (n=104): same as anteroposterior approach group except using oblique view
1640698|NCT01926457|Other|Treatment of Prediabetes|"Standardized treatment of prediabetes per California Diabetes and Pregnancy Program Sweet Success
diabetes education
blood glucose monitoring
medications as needed per California Diabetes and Pregnancy established protocol
growth ultrasounds
antenatal testing"
1640699|NCT01926444|Drug|GIC-1001|GIC-1001 oral tablet, white-coated, to be taken with water
1640700|NCT01926431|Other|Exercise|
1640701|NCT01926431|Other|Rest|
1640702|NCT01926418|Behavioral|Planning tasks|"Implementation intentions: Participants are asked to specify when, where and how they plan to use condoms in the future.
Executive function training aims to improve planning ability and therefore aims to increase condom use planning."
1640703|NCT01926405|Procedure|saliva collection|collection of saliva
1640704|NCT01926392|Drug|water-soluble therapy|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
1640705|NCT01926392|Drug|silver sulfadiazine|The patient acted as their own control and the experimental and comparison arms (water-soluble therapy and silver sulfadiazine) were alternated on a daily basis
1640706|NCT01926379|Behavioral|Combination intervention components|"The CIP will contain programmatic, structural, and psychosocial components, including:
use of a clinical algorithm by providers;
identification of HIV-infected family members eligible for IPT, using an ICAP-developed family care enrollment form (ICAP - International Center for AIDS Care and Treatment Programs);
review of monitoring data on IPT initiation and adherence during monthly multidisciplinary team meetings;
reimbursement of transportation costs for monthly clinic visits; and
real-time adherence support using IVR via mobile phones and trained Peer Educators."
1640707|NCT01926379|Drug|Isoniazid Prevention Therapy|Standard of care involves Isoniazid Prevention Therapy (IPT) - the administration of Isoniazid (INH) to individuals with latent infection with M. tuberculosis in order to prevent progression to active TB disease.
1640708|NCT01926366|Drug|AZD6423|Drug: AZD6423 Single or Multiple doses via infusion.
1640709|NCT01926366|Drug|Placebo|Placebo to match AZD6423 Single or Multiple doses of matching placebo delivered via infusion
1640710|NCT01926327|Biological|PRP injection|Injection of PRP in patients with knee osteoarthritis.
1640711|NCT01926327|Biological|Placebo|
1640712|NCT01926314|Device|PHENIX Neuromuscular Stimulation Therapy System device|
1640713|NCT01926314|Other|usual home care without device|
1640714|NCT01926301|Procedure|continuous veno-venous hemodialysis|
1640715|NCT01926288|Drug|Entecavir maleate tablets|
1640716|NCT01926288|Drug|blank Baraclude tablets|
1640717|NCT01926288|Drug|Blank maleate entecavir tablets|
1640718|NCT01926288|Drug|Baraclude tablets|
1640719|NCT01926275|Device|NPPV+IMT|noninvasive positive pressure ventilation and inspiratory muscle training
1640720|NCT01926275|Device|NPPV|noninvasive positive pressure ventilation
1640721|NCT01926275|Device|IMT|inspiratory muscle training
1640722|NCT01926262|Behavioral|Specific Strength Training|Specific Strength Training for the Neck and Shoulder Muscles
1640723|NCT01926236|Other|Active Symptom Control|Active Symptom Control: monthly clinical review and active symptom control as needed, including biliary drainage, antibiotics, analgesia, steroids, anti-emetics, other palliative treatment for symptom control, palliative radiotherapy, blood transfusion.
1640724|NCT01926236|Drug|L-folinic acid|L-folinic acid 175mg (or folinic acid 350mg) q14d, up to 12 cycles
1640725|NCT01926236|Drug|5 FU|5 FU 400 mg/m2 (bolus), 2400 mg/m2 (infusion), q 14d, up to 12 cycles
1640726|NCT01926236|Drug|Oxaliplatin|Oxaliplatin 85mg/m2, q 14d, up to 12 cycles
1640727|NCT01926223|Other|Home visiting|
1640728|NCT01926210|Other|mild stimulation protocol|letrozole is used from cycle day 3 to 7 and low dose recombinant FSH(no more than 150 IU/d) is used on cycle day 4,6 and 8 onwards. GnRH antagonist is only applied in case of premature LH rise might happen.
1640729|NCT01926210|Other|controlled ovarian stimulation|After fully downregulation by using short-acting GnRH agonist, 300 IU/d recombinant FSH is administrated for 5 days, then the dose is adjusted according to ovarian response.
1640730|NCT01926197|Drug|Oxaliplatin|
1640731|NCT01926197|Radiation|SBRT|
1640732|NCT01926197|Drug|Irinotecan|
1640733|NCT01926197|Drug|Leucovorin|
1640734|NCT01926197|Drug|5FU|
1640735|NCT01926184|Behavioral|Affect Regulation Treatment to Enhance Meth Intervention Success (ARTEMIS)|5-session integrative intervention to improve positive affect as well as boost and extend the effectiveness of contingency management (CM).
1640736|NCT01926184|Behavioral|Contingency Management (CM)|12-week CM protocol that provides escalating monetary reinforcement for biological evidence of methamphetamine abstinence. Delivered as the standard of care for non-treatment-seeking methamphetamine-using MSM in San Francisco. Delivered to both the intervention and attention-control arms
1640737|NCT01926171|Drug|Icotinib plus WBRT|Standard whole brain radiotherapy is given with 4000cGY/20 times, plus icotinib, which was administered orally three times per day.
1640738|NCT01926158|Drug|Denosumb|Prefilled syringe of 1 mL denosumab solution
1640739|NCT01926158|Drug|Placebo (for denosumab)|
1640740|NCT01926132|Drug|ascorbic acid 10g/20ml|ascorbic acid 10g/20cc intravenous injection for 40mins
1640741|NCT01926132|Drug|Normal Saline 150ml|Normal Saline 150ml intravenous injection for 40mins
1640742|NCT01926119|Device|Transcranial Magnetic Stimulation|
1640743|NCT01926106|Device|nIPPV|one of the twins was randomly allocated to nIPPV
1640744|NCT01926106|Device|nCPAP|another of the twins was allocated to nCPAP
1641720|NCT01918995|Drug|Placebo|Intravenous (IV)
1640745|NCT01926080|Other|DVD Intervention Arm|Half of the parents will be prospectively randomized to receive the educational bereavement DVD entitled 'Grieving in the NICU— Mending Broken Hearts When a Baby Dies Too Soon'. A specific aim of the study is to evaluate the additional benefit of the Bereavement DVD over standard bereavement care in reducing parents' grief by comparing level of grief at each time point between the intervention (DVD) and control (no DVD) group.
1640746|NCT01926054|Drug|Acthar gel|
1640747|NCT01926041|Other|Smoking cessation clinics|
1640748|NCT01926041|Behavioral|Coach-assisted lifestyle change|
1640749|NCT01926028|Biological|NDV-3A|0.5mL injection IM
1640750|NCT01926028|Biological|NDV-3|0.5mL injection IM
1640751|NCT01926028|Biological|Placebo|aluminum hydroxide and buffered saline
1640752|NCT01926015|Biological|RotaTeq™ (V260)|Live, oral, pentavalent vaccine containing 5 human-bovine reassortant rotavirus strains
1640753|NCT01926015|Biological|DTP-IPV|Diphtheria, tetanus, pertussis, inactivated polio vaccine used as part of the Japanese vaccination schedule
1640754|NCT01926002|Drug|Low-Dose MK-8351|Single administration of low-dose MK-8351.
1640755|NCT01926002|Drug|High-Dose MK-8351|High-Dose MK-8351 administered as a single inhaled dose.
1640756|NCT01926002|Drug|Placebo to MK-8351|Single-Dose Matching placebo to high-dose or low-dose MK-8351.
1640757|NCT01925989|Biological|LY2605541|Administered SC
1640758|NCT01925989|Biological|Insulin Glargine|Administered SC
1640759|NCT01925976|Behavioral|Individualized dietetic intervention-eating habits|The school-year (12 months) dietetic intervention consisted of anthropometric measurements, dietetic assessment, energy restriction tailor-made daily menus, and parental education every three weeks at each school site.
1640760|NCT01925950|Drug|orBec|
1640761|NCT01925950|Drug|Placebo|
2012302|NCT02099110|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg tablet, oral, once daily for 52 weeks during the double-blind treatment period
1640765|NCT01925924|Other|Resin-modified glass ionomer cement|This material contains fluoride
1640766|NCT01925924|Other|Composite resin|This material does not include fluoride
1640767|NCT01925911|Drug|IPI-145|25 mg BID Oral Capsule
1640768|NCT01925911|Drug|Midazolam|2 mg midazolam syrup
1640769|NCT01925898|Drug|Midazolam - active comparator|Oral midazolam - 0.7mg/kg single dose
1640770|NCT01925898|Drug|Experimental Arm: Ketamine|Oral Ketamine 5mg/kg Single dose
1640771|NCT01925885|Procedure|PVI Ablation|PVI ablation for atrial fibrillation specifically targets areas in the left atrium in the area just outside the pulmonary veins to eliminate triggers of atrial fibrillation.
1640772|NCT01925885|Procedure|FIRM Ablation|Ablation for atrial fibrillation specifically targets areas in the left or right atrium to eliminate areas that maintain atrial fibrillation without isolating the pulmonary veins
1640773|NCT01925859|Drug|EryDex (dexamethasone sodium phosphate encapsulated erythrocytes)|erythrocytes encapsulated with dexamethasone sodium phosphate (EryDex System)-corresponding to either 50 mg OR 125mg of experimental study drug
1640774|NCT01925833|Procedure|Both insertion and withdrawal|inspection and polypectomy during both insertion and withdrawal of colonoscopy
1640775|NCT01925833|Procedure|Only withdrawal|inspection and polypectomy during only withdrawal of colonoscopy
1640776|NCT01925820|Drug|Pegasys&Entecavir|180 mcg Peg-IFN alfa-2a (Pegasys) once a week for 48 weeks. Entecavir daily will also be administered concurrently for 48 weeks and then given as monotherapy for an additional 96 weeks.
1640777|NCT01925807|Behavioral|Group Intervention|The intervention will consist of 6 psycho-educational group sessions for caregivers and 6 psycho-educational group sessions for adolescents. Adolescent and caregiver sessions will be held separately and will focus on different issues. For adolescents, the group sessions will focus on coping strategies and emotional regulation. For caregivers, the group sessions will be focused on attachment, family environment, and validation.
1640779|NCT01925781|Drug|Nicotine polacrilex|2 mg and 4 mg gum will be used according to the FDA approved product labelling
1640780|NCT01925781|Other|STAM 1100mAh CE4 eGo Clearomizer|
1640781|NCT01925768|Drug|Apremilast 30 mg|30mg of Apremilast will be orally administered twice daily for 104 weeks
1640782|NCT01925768|Drug|Placebo|Identically appearing Placebo tablets will be orally administered twice daily for up to 24 weeks
1640783|NCT01925755|Other|Rivaroxaban ( Xarelto, BAY59-7939)|Patients with prior stroke or TIA history and who have never taken anticoagulation treatment regarding AF before. One film-coated tablet contains Rivaroxaban 15 mg or 20mg
1640784|NCT01925742|Other|Integrated prenatal screening for Down's syndrome|Analysis of several serum biochemical markers, and fetal nuchal translucency by ultrasound, with computation of an individual risk of fetal aneuploidy.
1640785|NCT01925742|Other|Serum QUAD Assay for aneuploidy screening|Series of biochemical markers with results integrated into a computational estimate of risk of fetal aneuploidy
1640786|NCT01925742|Other|Semiconductor MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using a targeted NIPT assay.
1640787|NCT01925742|Other|Optical-based MPSS NIPT assay using ccfDNA in maternal blood|Analysis by next-generation sequencing of ccfDNA (circulating cell-free DNA) from maternal blood, using an un-targeted NIPT assay.
1640788|NCT01925742|Other|Harmony™ Test (Ariosa Diagnostics)|Test that is commercially available (Ariosa Diagnostics). (will be used for benchmarking purposes in a subset of each arm)
1640789|NCT01925729|Biological|ragweed|ragweed arm only
1640790|NCT01925729|Biological|histamine|histamine arm only
1640791|NCT01925729|Drug|pseudoephedrine|pseudoephedrine arm only
1640792|NCT01925729|Drug|Oxymetazoline|oxymetazoline arm only
1640793|NCT01925716|Other|Corn oil|corn oil 56 g/day for 21 days
1640794|NCT01925716|Other|Olive oil|olive oil 56 g /day for 21 days
1640795|NCT01925703|Drug|Sodium ferric gluconate|Sodium ferric gluconate 250 mg administered intravenously every 12 hours until iron repletion completed (as determined by Ganzoni equation) or patient discharge, whichever comes first.
1640796|NCT01925690|Behavioral|Motivational Interviewing-Cognitive Behavioral Therapy|A telephone based talk therapy discussing pros and cons of medication use in MS.
1716842|NCT00001498|Drug|doxorubicin|
1640798|NCT01925677|Device|da Vinci® Single-Site™|Planned single-incision laparoscopic nephrectomy performed with the assistance of the Da Vinci Robotic Surgical System.
1640799|NCT01925664|Behavioral|Doula|This intervention included doulas providing weekly home visits during the last trimester of pregnancy and up to three months postpartum. Home visits focused on prenatal health, preparation for childbirth, breastfeeding education, and developing a relationship with the baby. Doulas also were present in the hospital during labor, delivery, and postpartum providing emotional support, non-medical comfort measures, and breastfeeding counseling.
1640800|NCT01925651|Radiation|No Bolus|no bolus use
1640801|NCT01925651|Radiation|Alternate Bolus|0.5cm bolus use in alternate days
1640802|NCT01925651|Radiation|Continuous Bolus|0.5 cm bolus use in continuous days
1640803|NCT01925638|Drug|BAY86-9766|
1640804|NCT01925638|Drug|Ketoconazole|
1640805|NCT01925625|Biological|Early CDT Lung blood test|The EarlyCDT-Lung Test is an early detection test designed to assist in lung cancer risk assessment and detection in the earliest stages of the disease.
1640806|NCT01925612|Drug|brentuximab vedotin|1.2 mg/kg by IV infusion every 3 weeks for up to 6 cycles
1640807|NCT01925612|Drug|brentuximab vedotin|1.8 mg/kg by IV infusion every 3 weeks for up to 6 cycles
1640808|NCT01925612|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
1640809|NCT01925612|Drug|vincristine|1.4 mg/m2 every 3 weeks by IV infusion for up to 6 cycles (dose capped at 2 mg total)
1640810|NCT01925612|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
1640811|NCT01925612|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for up to 6 cycles
1640812|NCT01925612|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for up to 6 cycles
1640813|NCT01925573|Device|Optune(NOVOTTF-100A)|
1640814|NCT01925560|Other|Agave Inulin|3x3 Latin square with 3 periods
1640815|NCT01925560|Other|Placebo|control- 0 (zero) grams/day inulin
1640816|NCT01925547|Dietary Supplement|Micellar curcumin|80 mg micellar curcumin (oral) three times a day for six weeks
1640817|NCT01925547|Dietary Supplement|Placebo|Only the excipients (without curcumin) used to prepare the curcumin micelles are given as placebo.
1640818|NCT01925534|Device|High-flow humidified nasal oxygen delivery system|During breaks from NIV oxygen will be provided through the Optiflow with FiO2 and flow-rate titrated to maintain the oxygen saturation (SpO2) above 90%.
1640819|NCT01925534|Device|Standard oxygen therapy|During breaks from NIV oxygen will be provided by standard nasal cannula or mask to maintain the SpO2 above 90%.
1640820|NCT01925521|Drug|Part1 : OPS-2071|single oral dose under fasted condition
1640821|NCT01925521|Drug|Part1 : Placebo of OPS-2071|single oral dose under fasted condition
1640822|NCT01925521|Drug|Part2 : OPS-2071|multiple twice-daily oral dosing for 5-7days
1640823|NCT01925521|Drug|Part2 : Placebo of OPS-2071|multiple twice-daily oral dosing for 5-7days
1640824|NCT01925495|Other|varied middle-ear pressure|
1640825|NCT01925495|Drug|varied middle-ear gas composition|
1640826|NCT01925495|Other|varied ear-canal pressure|
1640827|NCT01925482|Drug|6%CO2, 25%O2, balance N2|exposure of middle ear to gas
1640828|NCT01925482|Drug|6% CO2, 0%O2, balance N2|exposure of middle ear to gas
1640829|NCT01925482|Drug|20%CO2, 6%O2, balance N2|exposure of middle ear to gas
1640830|NCT01925482|Drug|0%CO2, 6%O2, balance N2|exposure of middle ear to gas
1640831|NCT01925482|Drug|6% CO2, 6%O2, balance N2|exposure of middle ear to gas
1640832|NCT01925482|Drug|6%CO2, 6%O2, 0%N2, balance argon|exposure of middle ear to gas
1640833|NCT01925469|Drug|Benzocaine|
1640834|NCT01925469|Drug|Saline spray|A saline spray will be used in the placebo group
1640835|NCT01925456|Drug|Toviaz|Means of effectiveness, adherence, and utility instruments over time will be examined to evaluate whether changes are linear from baseline to 8 weeks and 3 months. We will demonstrate the validity and responsiveness of pragmatic instruments against existing established measures (Table 3).
1640836|NCT01925443|Other|Low level laser therapy|Will be performed irradiation with low-intensity laser in quadriceps muscle
1640837|NCT01925430|Device|Screening device|Non-invasive device worn over clothes during sleep. Used to screen for sleep-disordered breathing conditions.
1640838|NCT01925430|Device|Comparative product|A non-invasive device worn on the arm or leg. It monitors body movement and sleep/wake states
1640839|NCT01925417|Biological|RBX2660 (microbiota suspension)|
1640840|NCT01925404|Behavioral|Free physical activity classes|100 hours of free activity classes will be provided
1640841|NCT01925404|Behavioral|Frequent User|Participants can become eligible for prizes by visiting the park more frequently
1640842|NCT01925391|Drug|Tono-pen XL Applanation tonometer + Ocu-film +|
1640843|NCT01925378|Drug|Nelfinavir|"All medications which a patient is taking will be reviewed at each visit, including the screening, day 1, weeks 4,12, 24.
All patients enrolled in the study will receive 1,250 mg twice PO daily for a 24 week duration."
1640844|NCT01925365|Dietary Supplement|wholegrain cereals oats (WGO)|Volunteers had to consume wholegrain cereals oats (WGO)(45g/day) for six weeks followed by a four week wash out period
1640845|NCT01925365|Dietary Supplement|Non wholegrain cereals|Volunteers had to consume non wholegrain cereals (NWG)(45g/day) for six weeks followed by a four week wash out period.
1640846|NCT01925352|Drug|Ad-HGF|5×10(9)pfu adenovirus hepatocyte growth factor was delivered by transendocardial injection into five left ventricular sites.
1640847|NCT01925339|Device|Test (immediate restoration)|Test (immediate restoration)
1640848|NCT01925339|Device|Control: delayed restoration|Control: delayed restoration
1640849|NCT01925313|Drug|CJ-30044|20.51mg a day,PO,QD
1640850|NCT01925313|Drug|TALION TAB. 10mg|10mg a day,PO,BID
1640851|NCT01925300|Drug|Concor 5mg(Bisoprolol hemifumarate 5mg) 2Tab|
1640852|NCT01925300|Drug|Crestor 20mg(Rosuvastatin calcium 20.80mg) 1Tab|
1640853|NCT01925300|Drug|Concor 5mg 2T and Crestor 20 mg 1Tab|
1640854|NCT01925287|Dietary Supplement|curcumin|500 mg curcumin were given orally either as native powder, micronized powder, or liquid micelles
1640941|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation X, single dose, under fasting conditions
1640855|NCT01925274|Drug|PF-05212384|30 minute IV infusion of PF-05212384 on days 2, 9, 16 and 23 of each cycle. Intra-patient dose escalation will commence with 110mg and will increase depending on tolerability.
1640856|NCT01925274|Drug|irinotecan|90 minutes IV infusion of irinotecan 180mg/m^2 on days 1 and 15 of each cycle
1640857|NCT01925274|Drug|Cetuximab|120 minute IV infusion of cetuximab 400mg/m^2 on cycle 1 day 1; 60 minute IV infusion of cetuximab on days 8, 15, and 22 of each cycle, and on day 1 of each cycle after cycle 1
1640858|NCT01925274|Drug|Irinotecan|90 minutes IV infusion of Irinotecan 180mg/m^2 on days 1 and 15 of each cycle
1640859|NCT01925261|Drug|TPX-100 50mg|
1640860|NCT01925261|Drug|TPX-100 100mg|
1640861|NCT01925261|Drug|TPX-100 200mg|
1640862|NCT01925261|Drug|TPX-100 20mg|
1640863|NCT01925261|Drug|Placebo|
1640864|NCT01925248|Dietary Supplement|Whey protein|Whey protein group participants will take supplement drinks that contain whey protein, daily before breakfast and before dinner for 3 months.
1640865|NCT01925248|Dietary Supplement|Placebo group|Placebo group participants will take supplement drinks that do not contain whey protein, daily before breakfast and before dinner for 3 months.
1640866|NCT01925235|Procedure|remote ischemic preconditioning|
1640867|NCT01925209|Drug|BYM338/bimagrumab|BYM338, a 150 mg/mL concentrate for solution for i.v. infusion, was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
1640868|NCT01925209|Drug|Placebo|Matching placebo to BYM338 was provided in colorless glass vials with a rubber stopper and aluminum flip-off caps.
1640869|NCT01925183|Drug|Pegylated interferon alpha-2a|180mcg once weekly; subcutaneous injection
1640870|NCT01925183|Drug|Ribavirin|600mg two times daily (BID) (e.g. 3x200mg at 6am, 3x200mg at 6pm) in patients ≥75kg body weight; 2x200mg at 6am and 3x200mg at 6pm in patients <75kg; orally
1640871|NCT01925183|Drug|Boceprevir|800mg three times daily (TID) (e.g. 4x200mg at 6am, 4x200mg at 2pm, 4x200mg at 10pm); orally
1640872|NCT01925170|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
1640873|NCT01925170|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
1640874|NCT01925170|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
1640875|NCT01925157|Biological|LY3090106 - SQ|Administered SQ.
1640876|NCT01925157|Biological|LY3090106 - IV|Administered IV.
1640877|NCT01925157|Biological|Placebo - SQ|Administered SQ.
1640878|NCT01925144|Drug|Baricitinib|Administered orally
1640879|NCT01925144|Drug|Omeprazole|Administered orally
1640880|NCT01925131|Drug|cyclophosphamide|Given IV
1640881|NCT01925131|Drug|vincristine sulfate|Given IV
1640882|NCT01925131|Drug|prednisone|Given PO
1640883|NCT01925131|Biological|inotuzumab ozogamicin|Given IV
1640884|NCT01925131|Other|laboratory biomarker analysis|Correlative studies
1640885|NCT01925118|Biological|Irradiated donor lymphocyte infusion|
1640886|NCT01925105|Other|Experimental: Optimization of treatment|Optimization of treatment of diseases and symptoms
1640887|NCT01925092|Drug|mifepristone|tablets
1640888|NCT01925079|Behavioral|Intensive Education|"Statin Treatment：The investigator will be suggested to increase the dose of atorvastatin according to guideline if a patient's LDL-C does not achieve target level.
Patient education:
Routine education at discharge.
4 education brochures will be delivered to patients.
Calendar with healthy tips will be delivered to patients before discharge.
A follow-up brochure with medical expert letter.
A total of 24 specific short messages for ACS will be developed and sent to patients (one short message per week).
Telephone follow ups will be performed according to a standard communication document.
At discharge, patients will be given a brochure for future follow up."
1640889|NCT01925079|Other|Control|"Statin Treatment：The recommended dosage of atorvastatin will be adjusted at the physician's discretion.
Patient education:
Routine education at discharge.
A follow-up brochure without medical expert letter.
At discharge, patients will be given a brochure for future follow up."
1640890|NCT01925066|Drug|Vancomycin|
1640891|NCT01925053|Other|PAL meal|The effect of consuming the PAL meal on gastric retention will be assessed
1640892|NCT01925053|Other|REF meal|The effect of consuming the REF meal on gastric retention will be assessed
1640893|NCT01925040|Device|Placement of restoration|Placement of restorations
2012303|NCT02099110|Drug|Metformin >= 1500 mg/day|Metformin >= 1500 mg/day, tablets, oral, for 52 weeks while receiving blinded investigational product during the double-blind treatment period
2012304|NCT02099110|Biological|Insulin Glargine Rescue Medication|Open-label insulin glargine, subcutaneous injection, as required as a rescue medication; dose determined per the investigator's discretion
2012305|NCT02099110|Drug|Glimepiride Rescue Medication|Open-label glimepiride tablets, oral, as required as a rescue medication, dose determined per the investigator's discretion
1640897|NCT01925001|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
1640898|NCT01925001|Drug|Sodium chloride solution|Normal saline solution (0.9% Sodium Chloride Injection USP)
1640942|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fasting conditions
1640943|NCT01924676|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, under fed conditions
1640944|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
1640945|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
1640946|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
1640947|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
1640948|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
2012306|NCT02098161|Drug|LCL-161|Starting dose of LCL-161 1500 mg by mouth on Days 1, 8, 15, and 22 of each 28 day cycle.
1640899|NCT01924988|Procedure|Prostatic Embolization|"Each patient will have a selective internal iliac arteriogram, and as necessary, an arteriogram of the anterior division of the internal iliac artery performed to identify the prostatic arterial supply. This typically arises from the inferior vesicle artery (also known as the prostatic artery), but may have supply from the superior vesicle, the internal pudental or obturator branches as well.
The prostatic arteries will be selected using standard micro-catheter technique. Embolization of the prostate will be performed with 300 to 500 um sized TAGM (Embosphere® Microspheres, Merit Medical, South Jordan, UT). The embolization endpoint will be absence of the normal blush of the prostate on post embolization angiography and stasis of flow in the prostate arteries."
1640900|NCT01924988|Drug|Embosphere® Microspheres|Embosphere® Microspheres, Merit Medical, South Jordan, UT
1640901|NCT01924975|Procedure|Saphenous vein cannulation|Intravenous cannulation to saphenous vein
1640902|NCT01924975|Device|ultrasound with a linear transducer (L15-7io)|Portable, bed-side ultrasound to detect saphenous vein
1640903|NCT01924975|Device|A 22 or 24 G intravenous catheter|
1640904|NCT01924962|Device|revascularisation|revascularisation of chronic occluded coronary artery
1640905|NCT01924949|Drug|LDV/SOF|Ledipasvir (LDV)/sofosbuvir (SOF) 90/400 mg FDC tablet administered orally once daily
1640906|NCT01924936|Behavioral|DBT Online Program|DBT online program involving three DBT skills taught across three lessons. The DBT online program will be based on a brief DBT skills intervention previously developed and pilot tested by Dr. Whiteside. This DBT online program will provide far greater clinical intensity than Intervention 1 and will be delivered with a widely-used modular software platform suitable for an R-34 project.
1640907|NCT01924910|Dietary Supplement|250,000 IU cholecalciferol as single, oral dose|250,000 IU cholecalciferol (vitamin D3) provided as a single oral dose.
1640908|NCT01924910|Dietary Supplement|Placebo|
1640909|NCT01924897|Behavioral|Exercise training|
1640910|NCT01924871|Drug|Desflurane with remifentanil|During the emergence from anesthesia,extubation was performed under 1.0 MAC desflurane with 1.0ng/ml remifentanil
1640911|NCT01924871|Drug|Desflurane|During the emergence from anesthesia,extubation was performed under 1.5 MAC desflurane
2012307|NCT02098161|Behavioral|Questionnaires|Questionnaire completion at baseline, day 1 of cycle 2 and beyond, and at end of treatment visit. The questionnaires should take about 5-10 minutes to complete.
2012308|NCT02098161|Other|Phone Calls|Study staff to call participant 1 time each month, and at 30 days after end of treatment visit.
2012309|NCT02096913|Drug|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 4 weeks (Arm I; n=6).
In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the treatment period."
1640915|NCT01924832|Drug|dimethyl fumarate|tablet
1640916|NCT01924819|Drug|Epirubicin + cisplatin + 5-fluorouracil|"Epirubicin 50 mg/m2 IV day 1, cisplatin 60 mg/m2 IV day 1, 5-fluorouracil 200 mg/m2/d IV 21 day continuous infusion (ECF chemotherapy).
If it is preferred by the clinician and patient, capecitabine (Xeloda) may be used in place of 5-fluorouracil: Capecitabine 625 mg/m2 oral tablet twice daily, days 1-21."
1640917|NCT01924819|Radiation|Preoperative chemoradiotherapy|"Chemotherapy: Continuous infusional 5-fluorouracil 200mg/m2/day, 7 days per week, throughout the entire period of radiotherapy or capecitabine 825 mg/m2, oral tablet twice daily, days 1-5 of each week of radiotherapy (without weekends).
Radiotherapy: 45 Gy of radiation in 25 fractions, five days per week for five weeks."
1640918|NCT01924819|Procedure|Gastric resection|The acceptable resections are a total gastrectomy, a subtotal gastrectomy, and an esophagogastrectomy (Ivor-Lewis esophagogastrectomy for gastroesophageal junction cancers [Siewert Type II and Siewert Type III] invading up to but no more than 2cm of the lower esophagus). The minimum extent of the operation should be a D1+ lymph node dissection but it is recommended that a D2 dissection be performed or a D1+ for gastroesophageal junction cancers requiring an esophagogastrectomy.
1640919|NCT01924806|Device|WoundWand™ Debridement Device|Group I - Electrical energy that removes necrotic, ischemic, and/or infected tissue within a wound
1640920|NCT01924806|Device|Standard of Care sharp debridement|Group II - Sharp instruments that remove necrotic, ischemic, and/or infected tissue within a wound
1640921|NCT01924793|Drug|DAS181-F02 Dry Powder in Bulk|Administered via DPI
1640922|NCT01924793|Drug|DAS181-F02 Nebulized Formulation Inhaled Dose|Administered via Nebulizer
1640923|NCT01924780|Device|Stimulation 10 minutes|NEMOS transvagal stimuli 10 minutes
1640924|NCT01924780|Device|NEMOS transvagal stimulation 60 minutes|NEMOS Device stimulation in 60 minutes
1640925|NCT01924780|Device|NEMOS Device sham stimulation 10 minutes|
1640926|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
1640927|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
1640928|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
1640929|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
1640930|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
1640931|NCT01924767|Drug|BI 10773 Placebo|po taken fasting with 240 mL water
1640932|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
1640933|NCT01924767|Drug|BI 10773|po taken fasting with 240 mL water
1640934|NCT01924741|Procedure|ALPPS|Other procedures related to ALPPS like banding of the parechyma with portal vein ligation etc.
1640935|NCT01924728|Device|Magnetic stimulation|50Hz active magnetic stimulation (coil position 100%) delivered to the pelvic floor muscles
1640936|NCT01924728|Device|Sham magnetic stimulation|50Hz sham magnetic stimulation (coil position 0%) delivered to the pelvic floor muscles
1640937|NCT01924715|Behavioral|ISTDP|An emotion focused brief psychotherapy format.
1640938|NCT01924702|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
1640939|NCT01924702|Device|transcranial direct current stimulation|1mA anodal over M1 primary motor cortex for 20min with 35cm/2 electrode, Cathode (100cm/2) contralateral
1640940|NCT01924689|Biological|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 x 10(4) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(4) spores/kg.
1640949|NCT01924650|Drug|PH-797804|Tablet, 6 mg, single dose
1640950|NCT01924637|Drug|Faster-acting insulin aspart|"A single dose will be administered subcutaneously (under the skin) in the abdomen.
Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
1640951|NCT01924637|Drug|insulin aspart|"A single dose will be administered subcutaneously (under the skin)) in the abdomen.
Each subject will be allocated to two treatment periods separated by a wash-out period of 3-12 days."
1640952|NCT01924624|Drug|Thalidomide|Patients in the Adjuvant group were given oral Thalidomide(at a dose of 100 mg per day) continuously during the follow-up period
1640953|NCT01924611|Procedure|Atraumatic Restorative Technique using cotton rolls|Atraumatic Restorative Technique using cotton rolls.
1640954|NCT01924611|Procedure|Atraumatic Restorative Technique|"Atraumatic Restorative Technique is typically used in Minimally invasive Dentistry.
This restoration technique is made using only hand instruments and is possible to be carried out in children in schools.
This particular time, the isolation of the surgical/tooth area was made using rubber dam as saliva barrier."
1640955|NCT01924598|Device|DBS to nucleus accumbens/anterior limb of internal capsule|deep brain stimulation followed by 12 month post switch on followup
1640956|NCT01924572|Procedure|cord clamping at 2 minutes|
1640957|NCT01924572|Procedure|cord clamping at 5 minutes|
1640958|NCT01924572|Procedure|cord milking|
1640959|NCT01924559|Other|standard clothing|
1640960|NCT01924559|Other|Biohazard gear|
1640961|NCT01924559|Device|Direct Laryngoscopy|
1640962|NCT01924559|Device|Glidescope|
1640963|NCT01924559|Device|Supraglottic Airway|
1640964|NCT01924546|Other|Water|1.5 L bottle of water provided in the morning of the school day, with refills provided during the course of the day.
2012310|NCT02096913|Drug|Dolormin® extra (Ibuprofen)|"Ibuprofen Tablets (as lysine-salt) 2400mg/d (400mg 2-2-2) applied orally for 12 weeks (Arm II, n=6).
In order to reduce the risk of damage to the gastrointestinal mucosa Pantoprazole is applied as concomitant medication in a dosage 40mg/d during the first 4 weeks of treatment and may be reduced to 20mg/d during the following treatment period after individual risk-benefit assessment."
2012311|NCT02093689|Drug|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5-mL solution containing 60.75 mM phenylephrine HCl (12.37 mg/mL) and 11.25 mM ketorolac trometamol (4.24 mg/mL) formulated in a 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
2012312|NCT02093689|Drug|Placebo|Placebo drug product is a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL of solution containing 20 mM sodium citrate buffer (pH 6.3 ± 0.5). For administration to patients, 4.0 mL of the drug product is added to a 500-mL bottle of commercially available irrigation solution.
1640968|NCT01924520|Drug|FK949E|Oral
1640969|NCT01924507|Device|CPAP|CPAP - continuous positive air pressure in patients with sleep apnea
1640970|NCT01924481|Dietary Supplement|High Caffeine|
1640971|NCT01924481|Dietary Supplement|Low caffeine|
1640972|NCT01924481|Dietary Supplement|High theobromine|
1640973|NCT01924481|Dietary Supplement|low theobromine|
1640974|NCT01924481|Dietary Supplement|No theobromine|
2012313|NCT02093221|Biological|180 mg/kg Alpha1-PI|
2012314|NCT02093221|Biological|90 mg/kg Alpha1-PI|
1640977|NCT01924416|Behavioral|Enhanced Care (intervention group and comparison group)|Decision aid coupled with immediate QL-PRO results
1640978|NCT01924416|Behavioral|Usual care (routine chemotherapy cycles and imaging studies)|Usual care does not receive intervention
1640979|NCT01924403|Procedure|Staple Closure|
1640980|NCT01924403|Procedure|Vertical Mattress Closure|
1640981|NCT01924403|Procedure|Running Subcuticular Closure|
1640982|NCT01924390|Device|Mineralized freeze-dried bone allograft alone|
1640983|NCT01924390|Device|Combination of Mineralized and demineralized freeze-dried bone allograft alone|
1640984|NCT01924377|Procedure|standard circumferential pulmonary vein isolation by radiofrequency ablation catheter|To perform circumferential pulmonary vein isolation left and right circumferential lines will be created with contiguous focal radiofrequency lesions at a distance >5 mm from the pulmonary vein ostia. Two additional ablation lines will be performed in the posterior left atrium (LA), and an ablation line will be placed in the mitral isthmus to prevent postablation LA flutter. Patients with a history of typical atrial flutter will also undergo cavotricuspid isthmus ablation.
1640985|NCT01924377|Procedure|CPVI + rotors' identification and ablation|In CPVI + Rotor arm, two LA sequential maps will be collected before and after CPVI, respectively. During each map creation, rotor electrograms will be identified by the physician. Rotors will be ablated after collecting the second LA sequential map.
2012315|NCT02093221|Biological|Placebo|
1640987|NCT01924351|Radiation|Stereotactic Radiosurgery plus HER-2 directed therapy in HER2-positive Breast Cancer with Brain Metastasis|
1640988|NCT01924338|Device|MRI scan|Acquisition of a high-resolution MRI scan (0.15 x 0.15 x 1.0 mm³) aligned with the AC-PC (anterior commissure-posterior commissure) line
1640989|NCT01924338|Device|Laser scan|A near-infrared laser scan of the subject's forehead is acquired
1640990|NCT01924338|Procedure|Dental cast creation|A dental cast made of PMMA (polymethyl methacrylate) of the subject's maxilla is created
1640991|NCT01924325|Drug|Apixaban|orally active direct factor Xa inhibitor
1640992|NCT01924325|Drug|Clopidogrel|an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor
1640993|NCT01924325|Drug|Aspirin|a non-steroidal anti-inflammatory drug
1640994|NCT01924325|Drug|placebo|
1640995|NCT01924312|Behavioral|Heart Health Intervention|A specialty CVD Risk Clinic will focus on education and individualized treatment programs to modify vascular risks in each subject using the methods developed, tested and shown to successfully reduce multiple CVD risk factors in the HeartHealth Program (HRSA grant, 1D1ARH1606, phase I and 2).
1640996|NCT01924299|Drug|Baricitinib|Administered orally
1640997|NCT01924299|Drug|Ketoconazole|Administered orally
1640998|NCT01924299|Drug|Fluconazole|Administered orally
1641766|NCT01918657|Drug|walnut powder|escalating doses of walnut powder
1641004|NCT01924247|Behavioral|Outpatient secondary prevention program|The comprehensive outpatient program is designed to last for 12 weeks. Participants are treated in groups of 8 or less. Every week there are two days with therapeutic and educational sessions, once with two hours of physical exercise therapy and once with 45 minutes of aerobic ergometer training and one hour of lecture and counseling. On the day with the two hours of physical therapy one of the sessions includes aerobic ergometer training or Nordic walking, and the other session focuses on improvements of fine motor skills, coordination, balance, mobilization, stretching, weight training or breathing. The lectures include three lectures on etiology, diagnosis, treatment and prevention of stroke by a neurologist, one on vascular risk factors by a cardiologist, five on nutrition counseling by nutritionists, two on active and passive smoking cessation and one lecture on psychological coping strategies given by a neuropsychologist.
1641005|NCT01924247|Behavioral|Standard treatment by family physician|Standard treatment by family physician.
1641006|NCT01924234|Drug|Morphine|
1641007|NCT01924234|Drug|Remifentanil|
1641008|NCT01924221|Other|this is an observational study. No intervention|
1641009|NCT01924208|Biological|Timothy, Phleum pretense|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) (n=30) .
1641010|NCT01924208|Biological|Live attenuated influenza virus|Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=60, 50:50 atopic:non-atopic).
1641011|NCT01924208|Procedure|Timothy + attenuated influenza virus|Allergen. Grazax® sublingual 75.000 SQ-T tablet (extracted from timothy, Phleum pretense), once daily until operation (ALK-Abelló, Hørsholm, Denmark) + Virus. Fluenz®, nasal live attenuated influenza vaccine, one 0.2 mL dose (MedImmune, Gaithersburg, USA) (n=30).
1641012|NCT01924195|Drug|Anlotinib|Anlotinib QD po.
1641013|NCT01924195|Drug|Placebo capsule|Placebo QD po.
1641014|NCT01924182|Device|SynchroMed Infusion System and Intrathecal Morphine Sulfate|Following a successful test of Intrathecal Morphine Sulfate, subjects will undergo surgery to implant the drug pump (SynchroMed Infusion System) and spinal catheter. The pump will deliver morphine directly to the spinal cord for pain control.
1641015|NCT01924182|Other|Conventional Medicine|Subjects will continue to use pain medications as prescribed by their doctor.
1641016|NCT01924169|Drug|Lenalidomide|"5 mg/day by mouth on Monday, Wednesday and Friday for 3 months. Process repeated for up to 2 years.
If IgG levels do not improve, frequency of lenalidomide increased to 5 mg/day by mouth for additional 3 months and if response is achieved, lenalidomide continued at 5mg/day 3 month on/3 month off for a total of 2 years."
1641017|NCT01924169|Biological|Influenza Vaccine|Administered as injection yearly, during the fall/winter season.
1641018|NCT01924169|Biological|Pneumovax Vaccine|Administered by injection once between month 6 and month 21. Patients, who have received the Pneumovax vaccine within last 5 years, will not receive Pneumovax vaccination.
1641019|NCT01924156|Biological|adenovirus-transfected DC + CIK|adenovirus-transfected DC vaccine plus CIK cells
1641020|NCT01924143|Drug|TD-9855|radiolabeled (100 µCi [14C]-Labeled) TD-9855 (20 mg)
1641021|NCT01924130|Other|Classroom feeding|Students are fed breakfast in the classroom at the start of the school, rather than the cafeteria before school.
1641022|NCT01924130|Behavioral|Nutrition education lessons|Students receive breakfast specific nutrition education lessons.
1641023|NCT01924130|Behavioral|Social Marketing|A social marketing campaign designed to promote consumption of one healthy breakfast a day. The marketing includes a healthy breakfast points-based reward program designed by the students and promotional campaigns.
1641024|NCT01924130|Behavioral|Parent outreach|A variety of communication methods that engage families and offer education that meets their needs, including school breakfast menus, parent newsletters, and information tables at parent-teacher meetings.
1641025|NCT01924117|Other|Linear Array HPV Genotyping assay|All samples with the suspicion of squamous intraepithelial lesion were processed with the Linnear Array methodology to identify HPV genotypes
1641026|NCT01924104|Drug|Low molecular weight heparin|2500 mIU/day, subcutaneously
1641027|NCT01924104|Drug|Low dose aspirin|75 mg/day, orally
1641028|NCT01924104|Drug|Heparin & aspirin|Aspirin (70 mg/day, orally) & heparin (40 mg/day, subcutaneously)
1641029|NCT01924104|Other|NaCl|Equivalent volume of NaCl 0.9%, subcutaneously
1641030|NCT01924091|Drug|Dapivirine gel|
1641031|NCT01924091|Drug|Dapivirine film|
1641032|NCT01924078|Drug|Capecitabine|metronomic use: capecitabine 500mg/tid
1641033|NCT01924078|Drug|aromatase Inhibitors (AIs)|Anastrozole 1mg/day p.o,Exemestane 25mg/day,Letrozole 2.5mg/day p.o.
1641036|NCT01924052|Drug|CGRP|Calcitonin-gene-related-peptide (CGRP)
1641037|NCT01924039|Behavioral|Brief Motivational Enhancement Therapy|The MET intervention consists of two 45 minute one-to-one sessions with a MET-trained therapist. The MET approach assists individuals to move through increasingly higher levels of change towards action (making change) and maintaining change. The MET approach aims to invoke rapid and internally motivated change with respect to substance use.
1641038|NCT01924039|Other|treatment as usual|Treatment as usual includes case management as well as psychiatric appointments.
1641039|NCT01924013|Dietary Supplement|Vitamin D3 (cholecalciferol)|The intervention is an oral tablet containing vitamin D3 (cholecalciferol). This vitamin D supplement will be provided in the form of small tablets (approximately 10 mm diameter) and will be custom- manufactured by Toronto Institute for Pharmaceutical Technology (TIPT) in Toronto, Ontario, Canada. Each weekly dose will consist of a single tablet. Across trial groups, the tablets will only vary with respect to the vitamin D3 dose, as described above.
1641040|NCT01924013|Dietary Supplement|Placebo|This product will be identical in appearance, taste and texture to the experimental formulation but will not include any vitamin D3.
1641041|NCT01924000|Drug|Minoxidil lotion 1%|Minoxidil lotion 1% is applied twice daily to one eyebrow.
1641042|NCT01924000|Drug|Placebo|
1641043|NCT01923987|Radiation|Short Course Radiotherapy|Radiotherapy to tumor and draining lymph node with 25 Gy in 5 fractions within 5 working days
1642412|NCT01913652|Drug|Prolonged infusional ifosfamide|
1641044|NCT01923987|Drug|Chemotherapy|"Oxaliplatin 85 mg/m2 IV over 2 hrs on Day 1
Irinotecan 180 mg/m2 IV over 30-90 mins on Day 1
Leucovorin 400 mg/m2 IV over 2 hrs on Day 1 and 2
5-fluorouracil bolus 400 mg/m2 IV push on Day 1 and 2 (or 5-fluorouracil infusion 600 mg/m2 IV continuous infusion over 22 hrs).
Bevacizumab 5 mg/kg IV over 90 mins on Day 1
Cetuximab (only for patients with K-ras wild type and positive EGFR mutation) 400 mg/m2 IV over 2 hrs on Day 1, and 250 mg/m2 IV over 1 hr on Day 8, 15, 22, 29, and 36.
FOLFOX or FOLFIRI (+-Bevacizumab ) repeats every 14 days for up to 3 courses. Cetuximab repeats every week for up to 6 courses
Postoperative FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) for up to 9 cycles (total 12 cycles)"
1641045|NCT01923987|Procedure|Delayed Surgery|If primary tumor and metastases is resectable after FOLFOX or FOLFIRI (+-Bevacizumab or Cetuximab) of 3 cycles, patients have surgical resection (and/or radiofrequency ablation to metastases).
1641046|NCT01923974|Drug|Melatonin 10 mg|
1641047|NCT01923974|Drug|Melatonin 100 mg|
1641048|NCT01923974|Drug|Placebo|
1641050|NCT01923948|Drug|Pregabalin|One 150 mg oral dose of Pregabalin given before surgery
1641051|NCT01923948|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery
1641052|NCT01923935|Drug|BUSULFEX®|BUSULFEX® 3.2 mg/kg/day iv once daily over 3 hours (day-6~day-4)
1641053|NCT01923935|Drug|Alkeran®|Alkeran® 70 mg/m2/day iv once daily over 30 minutes (day-3~day-2)
1641054|NCT01923922|Radiation|CT Perfusion|The CT perfusion scan will be performed on a multi-detector CT scanner at the time of routine preoperative neuronavigation imaging. A non-contrast CT head scan will be acquired to localize the tumour. Four 5 mm thick slices will be selected at the level of the tumour. Multiple images will be acquired at each levels starting 5 sec after the injection of 50 cc of non-ionic iodinated contrast media at a rate of 4 cc/sec. The acquisition parameters will be 80 kVp and 100 mA. The images will be acquired every second for a total of 110 sec. The post- processing will be performed and parameters will be calculated using regions of interest in the areas of tumour showing the highest perfusion values. Another region of interest will be placed in the contralateral normal looking white matter.
1641055|NCT01923909|Drug|Intra-articular platelet-rich plasma|Intra-articular platelet-rich plasma This involves withdrawal of 10-15cc of patient's blood, which is collected and centrifuged in Rotofix 32 A Centrifuge machine at 1500 cycles/minute for 5 minutes. 3-4cc of the PRP is obtained and injected into the supra patellar pouch using an aseptic technique. The procedure will be performed by the principal investigator, a qualified consultant Orthopedic surgeon. Analgesia will be administered as needed.
1641056|NCT01923909|Drug|Intra-articular corticosteroid injections|Patients receiving the IA corticosteroid will be injected 3mL of 0.5% Bupivacaine and 2mL of 80mg Depo Medrol in a 10cc syringe, using an aseptic technique into the supra patellar pouch. After an IA corticosteroid injection, patients are always advised to rest for 24 hours, and weigh bear as little as possible for the following 3 days. The procedure will be performed by a senior resident with several years of experience or a consultant Orthopedic surgeon.
1641057|NCT01923896|Behavioral|Behavioral Intervention|Behavioral intervention targeting severe feeding disorders involves the combination of escape extinction and antecedent manipulation of food presentation to lessen the aversive quality of the meal. This allows treatment to address the consequences maintaining food refusal in the least restrictive environment while ameliorating possible side effects associated with extinction procedures.
1641058|NCT01923896|Drug|d-cycloserine (DCS)|
1641059|NCT01923896|Drug|Placebo|lactose powder
1641060|NCT01923883|Procedure|EUS-FNA|EUS-guided fine needle aspiration will be performed by a single experienced endoscopist (D.H.P) using a conventional linear array echoendoscope (GF-UCT240, Olympus Optical Tokyo, Japan) under conscious sedation with midazolam and meperidine. After the optimal puncture site was determined, a puncture will be done using a 22-gauge EchoTip needle (Cook Endoscopy, Winston-Salem, NC) guided by real-time EUS imaging. Subsequently, the stylet will be slowly removed as the needle is moved to-and-fro for 15 times (capillary sampling method with stylet slow-pull technique) or negative-pressure 10 mL syringe will be applied (negative-pressure syringe suction). A total of 4 needle passes will be done for the lesion with using above two aspiration methods alternatively.
1641061|NCT01923883|Device|Echoendoscope Olympus GF-UCT240|
1641062|NCT01923870|Drug|Androxal 25 mg|
1641063|NCT01923857|Drug|Androxal 25 mg|
1641064|NCT01923844|Drug|exogenous surfactant|Preparations of poractantalfa (Curosurf, 200 mg/kg) (n = 15) or beractant (Survanta, 100 mg/kg) (n = 15) were administered in a consecutive randomized manner within the first 6 h of life. During the procedure, the tube was disconnected from the ventilator. The patient's head was held in a neutral position and surfactant preparations were given in two bolus fractions. Manual ventilation was given for 2 min after each dose. After the second dose, the endotracheal tube was reconnected and the physician (D.T.) observed the infant for 30-60 s until the oxygen saturation reached > 90% on pulse oximetry. Thereafter, the peak inspiratory pressure of the 6 ventilator was reduced by 1-2 mmH2O.
1641065|NCT01923831|Drug|Magnesium Sulfate|Magnesium sulfate 30 mg kg-1 was infused in 100mL normal saline for 10 minutes immediately before anesthesia induction. After tracheal intubation, normal saline 1.6mL ( equivalent volume as Dexamethasone 8mg) was injected, and magnesium sulfate was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
1641066|NCT01923831|Drug|dexamethasone|Normal saline 100mL was infused for 10 minutes immediately before anesthesia induction. After tracheal intubation, dexamethasone 8mg was injected, and normal saline was continuously infused at the rate of 10 mg Kg-1 h-1 until the end of surgery. (at the time of skin closure)
1641067|NCT01923818|Drug|rivaroxaban|orally active direct factor Xa inhibitor
1641068|NCT01923818|Drug|Aspirin|non-steroidal anti-inflammatory drugs
1641069|NCT01923818|Drug|placebo|
1641070|NCT01923805|Device|Vitagel|Vitagel
1641110|NCT01923454|Procedure|Peripheral iridotomy|All affected eyes underwent laser peripheral iridotomy within 24 hours after presentation. This procedure is a standard treatment for acute angle-closure. The fellow eyes will receive laser peripheral iridotomy in the same occasion or later to prevent acute angle-closure in the future.
1641111|NCT01923428|Drug|AZD1722|
1641112|NCT01923428|Drug|Placebo|
1641113|NCT01923415|Procedure|No intervention, skin biopsy|All participants will have 2 adjacent 4 mm punch biopsies collected from uninvolved and involved skin (a total of 4 biopsies).
1641071|NCT01923766|Drug|Cytotoxic T lymphocytes (CTLs).|"This Phase I dose-escalation trial is designed to evaluate the safety of donor-derived cytotoxic T lymphocytes (CTLs). Dose escalation is guided by the modified continual reassessment method (mCRM) in order to determine the maximum tolerated dose (MTD). For each group, MTD is defined as the dose at which the probability of DLT is at most 21%. Four dose levels are being evaluated namely, 5x106 cells/m2, 1.0x107 cells/m2, 1.5x107 cells/m2 and 2.5x107 cells/m2 with prior probabilities of toxicity estimated at 5%, 7.1%, 10% and 21%, respectively.
Two patients are allocated in each cohort and are followed for 30 days post IV injection for evaluation of DLTs. The trial continues until a minimum of 12 patients have been treated and stop when the maximum 18 patients have been treated."
1641072|NCT01923753|Device|Aerosure at 15 Hz|Active Aerosure HFAO device operating at lower frequency
1641073|NCT01923753|Device|Aerosure at 25 Hz|Active Aerosure HFAO device operating at higher frequency
1641074|NCT01923753|Device|Sham Aerosure|Deactivated but identical Aerosure HFAO device
1641075|NCT01923740|Device|XIENCE V EECSS|Subjects receiving XIENCE V
1641076|NCT01923740|Device|Absorb BVS System|Subjects receiving Absorb BVS System
1641077|NCT01923727|Radiation|[89Zr]Df-IAB2M|A single intravenous infusion of 5 mCi of [89Zr]Df-IAB2M in a mass dose of 10 mg, 20mg or 50mg.
1641078|NCT01923701|Behavioral|Cognitive Behavioral Therapy|GF-CBT focuses on teaching emotional self-regulation, information processing, decision making strategies,and logical thinking skills. The program is comprised of three parts: 1) Group sessions in which adolescents receive social support from peers who have had similar experiences and learn CBT skills, 2) Family group sessions in which family members learn more about adolescents' experiences and learn CBT skills so that they can encourage and reinforce these skills at home, and 3) Individual sessions in which adolescents can apply CBT skills to their own lives and work toward personal goals. Group sessions are taught with Powerpoint slides and with an accompanying workbook.
1641079|NCT01923688|Other|Informatics Alert/Nurse/physician responders|
1641080|NCT01923675|Other|Spectacles with red-blocking tint|Eyeglasses will have lenses that will correct refractive error for each subject, and will have a tint that blocks red light.
1641081|NCT01923675|Other|Spectacles with holographic diffuser and color neutral tint|Eyeglasses will correct refractive error for each subject but will have a holographic diffuser applied to the surface and will have a color neutral filter to adjust the light intensity reaching the eyes to be the same as for groups 1 and3.
1641082|NCT01923675|Other|Spectacles with holographic diffuser and red-blocking tint|Eyeglasses will correct refractive error for each subject and will be tinted to block red light, and will have a holographic diffuser to blur the image.
1641083|NCT01923675|Other|Spectacles with color neutral tint|Eyeglasses will correct refractive error for each subject and will have a color neutral tint to adjust the light intensity reaching the eyes so it is the same as for groups 1 and 3.
1641085|NCT01923649|Drug|Lanreotide 90 mg slow release formulation|Lanreotide 90 mg slow release formulation is injected deep subcutaneously, every 4 weeks, three times and compared to placebo
1641086|NCT01923649|Drug|Placebo|Placebo for somatuline slow release 90 mg
1641087|NCT01923636|Other|Standardized test report|Clinical, radiological and laboratory (virological and immunological) standardized reports
1641088|NCT01923623|Drug|Ropivacaine block|
1641089|NCT01923610|Biological|Experimental|"Biological/Vaccine: MVA-B Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)
-~ 1 x 10e8 pfu/ml 3 immunisations at week 0, 4 and 16"
1641090|NCT01923597|Drug|Green tea extract|200mg/capsule Administered orally 4 capsules per day For 3 months
1641091|NCT01923584|Drug|EPI-743 400mg|
1641092|NCT01923584|Drug|EPI-743 200mg|
1641093|NCT01923571|Other|intraoperative BGC measure|
1641094|NCT01923558|Drug|Donepezil|Donepezil Hydrochloride tablets,23 mg
1641095|NCT01923545|Drug|PEG-G-CSF|Vial, 3.6mg/day or 6mg/day, single dosing per cycle, for 1 cycle
1641096|NCT01923545|Drug|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 1 cycle
1641097|NCT01923519|Procedure|bronchofiberscopy|
1641098|NCT01923506|Radiation|stereotactic body radiation therapy|Undergo SBRT
1641099|NCT01923506|Procedure|quality-of-life assessment|Ancillary studies
1641100|NCT01923506|Other|laboratory biomarker analysis|Correlative studies
1641101|NCT01923493|Other|tuina|Patients in the tuina group will receive a tuina therapy (also known as Chinese massage). A Chinese massage lasts about 20 to 30 minutes. A series of 6 sessions with 2 treatments per week is applied.
1641102|NCT01923493|Other|no intervention|Patients in the no intervention waiting list group will not receive a study intervention. They will continue their respective pre-study therapy during the study period.
1641103|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
1641104|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
1641105|NCT01923480|Drug|15% CLINISOL - Sulfite-free (Amino Acid) Injection|
1641106|NCT01923467|Behavioral|Project Quit stop smoking program|This online stop-smoking program is individually tailored to the participant's readiness to quit, smoking triggers, and many other characteristics. It has been scientifically proven to improve quit success.
1641107|NCT01923467|Drug|Nicotine patches 21 mg|Eligible participants will receive a 2-week supply of Nicoderm CQ Step 1 patches to help them be successful in their quit attempt.
1641108|NCT01923454|Procedure|Paracentesis|At presentation, patients received immediate anterior chamber paracentesis with a 30-gauge needle. The intraocular pressure (IOP) was recorded at immediately, 15 and 30 minutes, and then 1, 24 and 48 hours after paracentesis. The IOP was compared between before paracentesis and each time-point after paracentesis. All affected eyes received antiglaucomatous medications 60 minutes after ACP and underwent peripheral iridotomy within 24 hours.
1641109|NCT01923454|Drug|Acetazolamide|All participants will receive oral acetazolamide (250 mg) 1 tablet at 1 hour after paracentesis to lower the intraocular pressure. After that, the dose of acetazolamide will be adjusted according to the level of intraocular pressure. If the eye pressure goes to normal (lower than 21 mmHg), acetazolamide will be discontinued.
1641114|NCT01923415|Procedure|No intervention, blood collection|Blood for serum analyses will be taken from all participants, blood for DNA analysis only from subjects who consent to this separately.
1641115|NCT01923415|Procedure|No intervention, urine collection|Urine will be collected from all participants.
1641116|NCT01923389|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week for 4 weeks.
1641117|NCT01923389|Drug|100 mg PF-05231023|100 mg IV infusion twice a week for 4 weeks
1641118|NCT01923376|Drug|Lactulose|If randomized to this group, subjects will receive 10 - 30 grams of lactulose per standard of care
1641119|NCT01923376|Drug|Polyethylene Glycol 3350|If subject is randomized to this group, one time dose of one gallon polyethylene glycol 3350 will be given at the time of enrollment
1641120|NCT01923363|Drug|Piperacillin/Tazobactam Standard Dose|Patients will receive a standard dose of piperacillin/tazobactam, then will have subsequent pharmacokinetic analyses on the blood concentrations drawn while on standard dose.
1641121|NCT01923363|Drug|Piperacillin/Tazobactam High Dose|Patients will be switched to higher dose after receiving the standard dose, with subsequent pharmacokinetic analyses performed on those blood concentrations while on higher dose. These pharmacokinetics of each dosing regimen will be compared.
1641122|NCT01923350|Behavioral|Weight Reduction Intervention|"The weight trial intervention components were:
Electronic feedback from the ADAPT interactive obesity treatment approach (iOTA) system, tracking participants' behavior change goals. Participants received feedback either by daily SMS (text messaging) or by weekly IVR (interactive automated calls).
Seven behavior change coaching calls, once a month for 6 months, and then one at 7.5 months halfway through the maintenance period.
Print mailings/emailings
3 Get Ready e-messages in the four weeks before the weight intervention began
Pedometers and program guides. (IVR users received printed activity logs with their program guides.)
Access to the ADAPT iOTA website for reviewing their progress and obtaining information on behavior change goals."
1641123|NCT01923350|Behavioral|Weight Reduction Control Arm|Participants received an initial brochure about managing diabetes risk, a digital scale to use in entering their weights in online questionnaires, and monthly emailed wellness messages unrelated to diabetes.
1641124|NCT01923350|Behavioral|Tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a sub-sample of those tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
1641125|NCT01923350|Behavioral|Not tested for diabetes|Due to small numbers in this group, the planned intervention was changed to a mixed-mode study, using baseline and follow-up self-administered questionnaires and semi-structured questionnaires administered to a subsample of those not tested for diabetes to identify factors differentiating the behavior of women who had and had not been tested for diabetes following a pregnancy with gestational diabetes mellitus.
1641126|NCT01923337|Drug|irinotecan hydrochloride|Given IV
1641127|NCT01923337|Drug|alisertib|Given PO
1641128|NCT01923324|Behavioral|Physician telephone consultation|Pain physician support for family physician treating patient
1641129|NCT01923324|Behavioral|Usual family physician care|Usual family physician care without telephone consultation with pain physician
1641130|NCT01923311|Drug|EVG|Elvitegravir (EVG) tablets or tablets for oral suspension (if unable to swallow) will be administered orally
1641131|NCT01923311|Drug|Background regimen|Background regimen may consist of the following RTV-boosted PIs (PI/r): lopinavir/r (Kaletra), atazanavir/r, darunavir/r, tipranavir/r, or fosamprenavir/r. For participants < 2 months old, only lopinavir/r is allowed. Use of additional antiretrovirals in background therapy may be allowed.
1641132|NCT01923298|Drug|Estradiol|
1641133|NCT01923285|Device|AXIUM Neurostimulator System|
1641134|NCT01923285|Device|Control Spinal Cord Stimulation Device|
1641135|NCT01923272|Device|AlphaCore Device|Active stimulation to the vagal nerve
1641136|NCT01923272|Device|AlphaCore|Active AlphaCore treatment
1641137|NCT01923259|Drug|Donepezil|Donepezil Hydrochloride tablets,23 mg
1641138|NCT01923246|Behavioral|Single WEB intervention|Brief WEB intervention recieved once
1641139|NCT01923246|Behavioral|Repeated WEB intervention|WEB intervention recieved twice.
1641140|NCT01923246|Behavioral|Single IVR intervention|IVR intervention recieved once
1641141|NCT01923246|Behavioral|Repeated IVR intervention|IVR intervention recieved twice
1641142|NCT01923233|Biological|AlloStim|allogeneic Th1 memory cell with CD3/CD28-coated microbeads attached.
1641143|NCT01923220|Drug|HO/02/02 20µg|Interventions involving HO/02/02 20µg VS. Aloe Vera Jel (SOC). Treatment will be applied topically once daily
1641144|NCT01923220|Other|Aloe Vera Jel|To be applied topically once daily
1641145|NCT01923207|Drug|DX-2930|
1641146|NCT01923207|Drug|Placebo|placebo, subcutaneous administration
1641147|NCT01923194|Drug|Highly Purified Urofollitropin|for Injection
1641148|NCT01923194|Drug|Recombinant Human Follitropin Alfa|for Injection
1641152|NCT01923168|Drug|BYL719|BYL719 + Letrozole
1641153|NCT01923168|Drug|BKM120|BKM120 + Letrozole
1641154|NCT01923168|Drug|Placebo|Placebo (of BYL719 or BKM120) + Letrozole
1641155|NCT01923155|Procedure|Colonoscopy|
1641156|NCT01923142|Biological|Outer-Root-Sheath Melanocytes Suspension|The treatment consists in depositing a suspension of autologous outer-root-sheath melanocytes, derived from patient's plucked hair follicles, and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
1641209|NCT01922739|Drug|Hydrocodone ER|Participants were instructed to take hydrocodone ER tablets orally with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating.
1641356|NCT01921712|Drug|Active comparator|Randomized single dose of inhaled active comparator product
1641157|NCT01923142|Biological|Placebo|The treatment consists in depositing a solution made of saline and patient's own serum on the area affected by vitiligo, after properly preparation with dermabrasion. Afterwards a targeted UVB phototherapy will be carried out by patients at home for 3 days / week from the beginning of the 5th week after transplantation till the end of the study period (12th week).
1641158|NCT01923129|Drug|Prazosin given 6 hours prior to catheter removal in the 24 hour group|Prazosin given orally (1 mg) 6 hours prior to catheter removal (hour 18 postoperatively)
1641159|NCT01923116|Drug|HPV-16 vaccine|Vaccination with SLP-HPV-01® with or without interferon-a injections.
1641160|NCT01923090|Drug|Finasteride|Finasteride 5mg once daily for 3 weeks
1641161|NCT01923090|Drug|Dutasteride|Dutasteride 0.5mg once daily for 3 weeks
1641162|NCT01923077|Drug|Simvastatin|usual care with Simvastatin
1641163|NCT01923077|Drug|Rosuvastatin|rosuvastatin 80 mg as loading dose at randomization followed by rosuvastatin 40 mg daily.
1641166|NCT01923038|Procedure|First arm: patients ventilated with zero end expiratory pressure|
1641167|NCT01923038|Procedure|Patients ventilated with Positive End Expiratory Pressure|
1641168|NCT01923038|Procedure|Patients ventilated with Positive End Expiratory Pressure plus Recruitment maneuver|
1641169|NCT01923025|Drug|RO5545965|Single dose
1641170|NCT01923012|Drug|Vitamin K2 (Menaquinone)|
1641171|NCT01922999|Drug|Melatonin|patients will receive placebo, 1mg melatonin or 3mg melatonin
1641172|NCT01922986|Device|active rTMS|10 minutes of real high-frequency (6-Hz) rTMS priming (total priming pulses = 600) plus 10 minutes of low-rate (1Hz) rTMS (total low-rate pulses = 600).
1641173|NCT01922986|Device|sham rTMS|20 minutes of sham rTMS stimulation
1641174|NCT01922986|Behavioral|conventional stroke therapy|conventional stroke therapy consisting of exercises and physical training
1641175|NCT01922973|Other|Fasting|normal volunteers fast from food on one occasion for 62.5 h; on another occasion fed 3 meals
1641176|NCT01922960|Other|micro-imaging|micro-imaging
1641177|NCT01922947|Behavioral|Motivational Interviewing w/Social Network Counseling|This is the active arm of the study.
1641178|NCT01922947|Behavioral|Active Control Condition|20-minute health counseling
1641179|NCT01922934|Behavioral|Commercial weight loss program|vouchers for Weight Watchers
1641180|NCT01922934|Behavioral|Colorado Weigh|Group behavioral weight loss program
1641181|NCT01922934|Dietary Supplement|Meal replacements|Health Management Resources meal replacement products (shakes and entrees)
1641182|NCT01922934|Drug|Obesity pharmacotherapy|Phentermine or phentermine-topiramate (Qsymia)
1641183|NCT01922934|Behavioral|Recreation center passes|1 year pass to a Denver recreation center
1641184|NCT01922921|Biological|HER-2/neu Intracellular Domain Protein|Given ID
1641185|NCT01922921|Other|Laboratory Biomarker Analysis|Correlative studies
1641186|NCT01922921|Biological|Pertuzumab|Given per standard of care
1641187|NCT01922921|Other|Placebo|Given PO
1641188|NCT01922921|Biological|Polysaccharide-K|Given PO
1641189|NCT01922921|Biological|Trastuzumab|Given per standard of care
1641190|NCT01922908|Biological|MSC Infusion|Allogeneic bone marrow derived mesenchymal stem cells given in one dose 3-10 days after stroke symptom onset
1641191|NCT01922908|Biological|Placebo Comparator|Normal saline
1641192|NCT01922895|Dietary Supplement|Lactobacillus Rhamnosus GG|Probiotic nutritional supplement; Lactobacillus Rhamnosus GG
1641193|NCT01922895|Drug|Placebo for Probiotic|Capsule manufactured without active ingredients.
1641194|NCT01922882|Behavioral|Amagugu Counseling Intervention|6-session home-based counseling intervention delivered by lay counselors at mothers' homes
1641195|NCT01922869|Dietary Supplement|Flavonoids|
1641196|NCT01922856|Biological|LTR192G with dscCfaE|Recombinant fimbrial adhesin (dscCfaE) with Modified Escherichia coli (E coli) heat labile enterotoxin (LTR192G)
1641197|NCT01922856|Other|No Intervention|Controls only receive challenge
1641198|NCT01922843|Drug|DP001 softgel capsules|
1641199|NCT01922843|Drug|Placebo|
1641200|NCT01922830|Dietary Supplement|Bio-25 (Supherb)|The Bio-25 (Supherb) is a probiotic supplement consisting of 11 different species of patented probiotic bacteria and over 25 billion active bacteria in each capsule. The bacteria in the formula are patented bacteria that have undergone drying, freezing, and double coating which ensures their survival under stomach acidity conditions and their enrooting in the intestines.
1641201|NCT01922830|Dietary Supplement|Placebo (for Bio-25, Supherb)|A pill manufactured to mimic Bio-25 (Supherb) pill
1641202|NCT01922817|Drug|Saxagliptin|5mg saxagliptin
1641203|NCT01922804|Dietary Supplement|K2 vitamin|K2 vitamin tablet
1641204|NCT01922804|Dietary Supplement|Placebo|Placebo tablets
1641205|NCT01922791|Dietary Supplement|Comparison of probiotics, fish oil and their combination to placebo|Double-blind randomized placebo controlled intervention
1641206|NCT01922778|Procedure|Endometrial Biopsy|"Recruits from the Bariatric Surgery Program will be interviewed by a study investigator prior to their bariatric surgery. During the interview, the purpose of the study will be explained as well as the surgical technique used for obtaining an endometrial sample. If the patient consents to the procedure, then this will usually be a D&C performed in one setting at the time of her bariatric surgery under general anesthesia. In the case where a patient is diagnosed with complex atypical endometrial hyperplasia or early endometrial prior to her bariatric surgery, an IUD can be inserted at the time of her bariatric surgery.
For patients not undergoing bariatric surgery, an endometrial biopsy will be performed in the clinic or office setting using an endometrial suction catheter."
1641207|NCT01922765|Drug|amoxicillin, clarithromycin, metronidazole, rabeprazole|
1641208|NCT01922752|Drug|CEP-37440|"CEP-37440 will be supplied as 25 mg and 100 mg capsules and will be orally administrated daily.
Patients will be enrolled sequentially in dose escalating cohorts to receive CEP-37440 until a maximum tolerated dose has been defined."
1641307|NCT01922011|Drug|Vancomycin (or equivalent)|IV vancomycin (or equivalent) (Infusions A,B,C,D), 10 to 15 mg/kg, infused over 60 (± 10) minutes q6h (± 1 hour)
1641210|NCT01922739|Drug|Placebo|During the double-blind titration period used in the original protocol, placebo tablets matching each dose of hydrocodone bitartrate ER tablets (active drug) were used to maintain the blind but not for purposes of comparison.
1641211|NCT01922713|Other|white maize and a corn oil capsule|~ 0 ug RAE/d
1641212|NCT01922713|Other|orange maize and a corn oil capsule|~600 ug RAE/d
1641213|NCT01922713|Other|white maize and a vitamin A capsule|600 ug RAE/d
1641214|NCT01922687|Drug|amlodipine plus atorvastatin (Caduet)|
1641215|NCT01922687|Drug|amlodipine (Norvasc)|
1641216|NCT01922674|Procedure|Standard open tension-free inguinal hernia repair with mesh|
1641217|NCT01922661|Drug|REGN1908-1909|
1641218|NCT01922661|Other|placebo|
1641219|NCT01922648|Procedure|Blood sample|An extra volume of blood is obtained, with prior consent, when phlebotomy is required for another unrelated clinical reason.
1641220|NCT01922635|Other|Valadation of the metrological properties of questionnaire of quality of life|
1641221|NCT01922596|Drug|Ropivacaine|
1641222|NCT01922596|Drug|Placebo|
1641223|NCT01922583|Drug|AUY922|AUY922 will be administered via IV over 1 hour once weekly in a 21 day cycle until disease progression
1641224|NCT01922570|Dietary Supplement|nutrition|comparion of enteral versus enteral and supplemental parenteral nutrition
1641225|NCT01922557|Device|NICOM|NICOM monitoring thoracic fluid content at baseline(T1), anhepatic phase(T2), 30 mins after reperfusion(T3) and 2 hrs after reperfusion(T4).
1641226|NCT01922518|Procedure|Septal pacing|Put RV pacing lead around the right ventricular septum and is adjusted with normal pacing axis
1641227|NCT01922518|Procedure|Apex pacing|Put RV lead around the apex
1641228|NCT01922505|Drug|PPI triple therapy|
1641229|NCT01922492|Procedure|Autologous islet transplantation|"Islet was isolated from the normal part of resected pancreas with modified Ricordi method.
After purification, the islets were infused into the liver through percutaneous transhepatic portal vein catheterization."
1641230|NCT01922492|Drug|Oral anti-diabetic drugs|"Metformin on the diagnosis of postoperative diabetes mellitus. Starting dose of 500mg per day and dose adjustment as needed to control blood glucose.
Vildagliptin added on the insufficient glycemic control with monotherapy. Starting dose of 50mg per day and dose adjustment as needed to control blood glucose."
1641231|NCT01922479|Drug|Ferric Carboxymaltose|1000mg intravenous Ferric Carboxymaltose, given as undiluted slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
1641232|NCT01922479|Drug|Placebo|20mls intravenous Normal Saline (0.9%), given as slow bolus injection over 15 minutes. Allowed to take concomitant oral iron supplements in usual clinical doses as prescribed clinically by attending physicians.
1641233|NCT01922466|Procedure|Bee Venom Acupuncture|"Bee Venom 1:20,000 under BVA Increment Protocol
- Increment Protocol as
1st week - SC 0.2cc/day, 2 days/week
2nd week - SC 0.4cc/day, 2 days/week
3nd week - SC 0.8cc/day, 2 days/week"
1641234|NCT01922466|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
1641235|NCT01922453|Other|Music and Sound|
1641236|NCT01922440|Other|None [Natural history registry]|
1641237|NCT01922427|Drug|RNS60|
1641238|NCT01922414|Device|Laser|Patients will undergo laser lithotripsy durin PNL
1641239|NCT01922414|Device|Ultrasonic|Patients will undergo ultrasonic lithotripsy during PNL
1641240|NCT01922401|Other|inverse ratio ventilation|change the I: E ratio 1:2-1:1-2:1
1641241|NCT01922388|Device|Bilateral deep brain stimulation of the subthalamic nucleus|
1641242|NCT01922388|Drug|18F-AV-133|
1641243|NCT01922375|Drug|Naftopidil|
1641244|NCT01922362|Device|Negative pressure drainage system|a close system surgical drain was placed over the graft with the length equal to the wound size. A silicon penrose drain with side holes on it covered the surgical drain to prevent direct contact of transparent film and the surgical drain, which led to poor drainage function. The penrose drains were excluded from the system during the test period due to the same function of a close system surgical drain with and without a penrose drain. A transparent film was place over the graft and drains and over a margin of the surrounding healthy skin.
1641245|NCT01922362|Device|Indirect wet dressing|The recipient site wound is covered with sulfa-tula first and then wet gauze.
1641246|NCT01922349|Drug|BI 113608|Medium dose (Multiple dosing)
1641247|NCT01922349|Drug|Placebo|Placebo (Multiple dosing)
1641248|NCT01922349|Drug|BI 113608|Low dose (Multiple dosing)
1641249|NCT01922349|Drug|Placebo|Placebo (Single dosing)
1641250|NCT01922349|Drug|BI 113608|High dose (Single dosing)
1641251|NCT01922349|Drug|BI 113608|Medium dose (Single dosing)
1641252|NCT01922349|Drug|BI 113608|Low dose (Single dosing)
1641253|NCT01922349|Drug|BI 113608|High dose (Multiple dosing)
1641254|NCT01922336|Biological|SB2|IV infusion
1641255|NCT01922336|Biological|EU Remicade|IV infusion
1641256|NCT01922336|Biological|US Remicade|IV infusion
1641257|NCT01922310|Behavioral|Communication intervention|"The intervention is a modification of current standard practice procedures for requesting consent for donation.
The intervention period commences when the possibility of organ donation is first raised with the family, and includes the time for families to make a decision. This time may last up to 72 hours."
1641258|NCT01922297|Other|Day Treatment MDFT-HIV|MDFT-HIV is a specialized intervention aimed at reducing risk factors for HIV-associated sexual behaviors. It builds protective behaviors in the adolescent's intrapersonal and interpersonal functioning, as well as those aspects of family functioning to reduce youths' high-risk sexual behavior. For instance, interventions target inadequate monitoring, parent-adolescent conflict, and parental disengagement - behaviors consistently associated with elevated HIV/STD risk. It facilitates positive and supportive family relationships, processes that can significantly reduce HIV/STD risk. Additionally, it aims to promote effective family communication about sexuality and safer sexual behaviors, among the most important protective factors against sexual risk taking behavior.
1641308|NCT01922011|Drug|Nafcillin (or equivalent)|IV nafcillin (or β-lactam equivalent) (Infusions A,B,C,D) at 100-200 mg/kg/day, in divided doses infused over 60 (± 10) min q6h (± 1 hour)
1641309|NCT01921998|Procedure|Biomarker and health economics|Biomarkers CK18 and FLT3 Ligand will be collected
1641259|NCT01922297|Other|Day Treatment SAU|Substance abuse treatment and HIV prevention services are routinely provided to youth in the day treatment programs. The day treatment programs contract to local substance abuse and mental health providers for these services that are provided both within and outside of the day treatment setting. The intervention's specific features are similar to those found in the literature on outpatient peer-based group treatment for adolescent alcohol abusers (CSAT 1998). Specifically, it is based on a cognitive-behavioral group treatment model (Kaminer et al 1998; Marshall & Marshall 1993), with a comprehensive treatment package including individual counseling and treatment planning.
1641260|NCT01922284|Biological|DNA|8mg DNA: one plasmid encoding a gag-pol-nef polypeptide derived from the 96ZM651-8 clone and one plasmid encoding gp140 env derived from clade C 97CN54
1641261|NCT01922284|Biological|MVA-C|1.108 TCID50 MVA-C (nominal titre) expressing the gag-pol-nef and gp120 env proteins derived from clade C 97CN54
1641262|NCT01922284|Biological|CN54rgp140|100ug CN54rgp140, a trimeric recombinant envelope protein derived from clade C 97CN54
1641263|NCT01922284|Biological|GLA-AF|5ug GLA-AF, an aqueous glucopyranosyl lipid A adjuvant
1641264|NCT01922271|Drug|NVA237|NVA237 44 µg inhalation capsules once daily, delivered via single-dose dry-powder inhaler (SDDPI)
1641265|NCT01922271|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via HandiHaler® device.
1641266|NCT01922271|Drug|Placebo to NVA237|Placebo to NVA237 once daily, delivered via single-dose dry-powder inhaler (SDDPI).
1641267|NCT01922271|Drug|Placebo to tiotropium|Placebo to tiotropium once daily delivered via HandiHaler® device
1641268|NCT01922271|Drug|Salbutamol|Used as resuce medication
1641269|NCT01922258|Drug|Brexpiprazole, OPC-34712|Flexible dose of 0.5 to 2 mg/day or placebo tablets for up to 12 weeks
1641270|NCT01922245|Device|Soterix 1x1 tDCS|Anodal and sham tDCS will be administered. All of the participants will also receive behavioral speech-language therapy.
1641271|NCT01922219|Behavioral|Cognitive Behavioral Therapy|14 sessions of individual psychotherapy (cognitive behavioral therapy) for depression over 12 weeks
1641272|NCT01922206|Behavioral|TRACK Intervention|"TRACK Intervention
3-session, individually administered psycho-educational intervention to promote maternal disclosure of HIV status to child"
1641273|NCT01922193|Drug|Highly Purified Urofollitropin|for injection
1641274|NCT01922193|Drug|Recombinant Human Follitropin Alfa|for injection
1641275|NCT01922180|Radiation|Chest CT scans|CT examinations were performed with a commercially available 64-detector row scanner. Images were acquired in supine position after full inspiration and full expiration, using the following parameters: slice thickness, 0.6 mm; pitch, 1.4; rotation time, 330 msec; tube voltage, 120 kiloVolts; and tube current-time product, 100 milliAmperes, with automatic exposure control (CareDose 4D, Siemens Healthcare) switched on. From raw data, 1-mm-thick section images were reconstructed at 0.7-mm intervals by using a high spatial algorithm and a soft-tissue algorithm. The inspiratory CT scan at the time of exacerbation was performed with intravenous iodinated contrast material, whereas the control scan was unenhanced.
1641276|NCT01922167|Dietary Supplement|Leucine|
1641277|NCT01922167|Dietary Supplement|Alanine|
1641278|NCT01922154|Drug|intravitreal ranibizumab|The patients received IVR (0.5 mg in 0.05 ml) injection through the pars plana in the operating room. A fornix-based conjunctival flap technique trabeculectomy with intraoperative mitomycin C was performed within 2 weeks after IVR.
1641279|NCT01922141|Drug|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg tablets will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
1641280|NCT01922141|Drug|Amlodipine|Amlodipine 5 mg/10 mg will also be blinded and supplied centrally. For Aliskiren dual therapy arm , Amlodipine is in the regimen; where as for monotherapy arms, Amlodipine is an optional add-on therapy.
1641281|NCT01922141|Drug|Ramipril|Ramipril 5 mg and ramipril 10 mg capsules will be supplied centrally. These will be blinded with matching placebos for the 2 dose strengths.
1641282|NCT01922141|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg/25 mg will be open label and supplied locally. It is an optional add-on to each arm.
1641283|NCT01922128|Drug|MC-1101, Placebo|One drop 0.5%; MC-1101; One drop 1.0% MC-1101, One drop Placebo
1641284|NCT01922115|Drug|Trospium Chloride|Subject will be administered either placebo or 60 mg dosage of Sanctura XR for treatment of overactive bladder. Subject will take Sanctura XR once every morning. Blood will be drawn for plasma extraction at each visit.
1641285|NCT01922115|Drug|Placebo|
2012316|NCT02085148|Drug|Regorafenib (BAY73-4506)|Regorafenib will be given orally once a day, across cycles of 21 days each. During each cycle regorafenib is taken for 2 weeks followed by one week off the drug. Doses of the study drug used in this study are age-dependent and the children's dose will been adjusted based on the age and the body surface area and given either as tablets or granulate.
2012317|NCT02085148|Drug|Vincristine (Cellcristin®)|Vincristine will be given at a dose of 1.5 mg/m2 (0.05 mg/kg for subjects ≤ 10 kg, maximum 2.0 mg) on Day 1 and Day 8 in 21-day cycles.
2012318|NCT02085148|Drug|Irinotecan (Irinotecan Cell pharm®)|Irinotecan will be administered at a starting dose of 50 mg/m2/day from Day 1 to Day 5, in 21 day cycles.
1641289|NCT01922089|Drug|LCZ696|LCZ696 50 mg/100 mg/200 mg bid
1641294|NCT01922063|Behavioral|Physiotherapy Intervention|20x 30 min sessions of physiotherapy
1641295|NCT01922063|Behavioral|Sham neck massage|20x 30 minutes sessions of neck massage
1641296|NCT01922050|Drug|LEO 43204 Formulation 1|
1641297|NCT01922050|Drug|LEO 43204 Formulation 2|
1641298|NCT01922050|Drug|LEO 43204 Formulation 1 Dose X|
1641299|NCT01922050|Drug|LEO 43204 Formulation 1 Dose Y|
1641300|NCT01922050|Drug|LEO 43204 Formulation 2 Dose XX|
1641301|NCT01922050|Drug|LEO 43204 Formulation 2 Dose YY|
1641302|NCT01922050|Drug|Placebo Formulation 1|
1641303|NCT01922050|Drug|Placebo Formulation 2|
1641304|NCT01922037|Drug|Omalizumab|Participants will receive omalizumab for up to 12 months per investigator standard of care and clinical practice.
1641306|NCT01922011|Drug|Daptomycin|IV daptomycin Infusion A in 12 to <18 years old (7 mg/kg); in 7 to < 12 year olds (9 mg/kg); in 24 months to <7 year olds (12 mg/kg); in 12 to <24 month olds (12 mg/kg). Infused over 60 minutes ± 10 minutes once daily followed by up to 3 dummy infusions every 6 hours (q6h) infused over 60 (± 10) min to maintain the blind.
2012319|NCT02084147|Device|positron emission tomography|Undergo PET
2012320|NCT02084147|Device|computed tomography|Undergo CT
1641312|NCT01921972|Drug|Galantamine CR|24 mg/day with dose-titration over twelve weeks
1641313|NCT01921972|Drug|Memantine|memantine 10 mg b.i.d. with a dose titration of sixteen weeks
1641314|NCT01921972|Drug|Placebo|Placebo will be similar in appearance to Memantine
1641315|NCT01921959|Behavioral|Intervention|Postpartum women are randomized to intervention or control group
1641316|NCT01921946|Drug|Fimasartan|
1641317|NCT01921946|Drug|Rosuvastatin|
1641318|NCT01921933|Device|Optiflow|The Optiflow device will be implanted in the upper extremity of Adult end-stage renal disease (ESRD) patients requiring creation of an upper extremity autogenous arteriovenous fistula for dialysis access.
1641319|NCT01921920|Drug|Omeprazole|Omeprazole 20 mg (AstraZeneca - test) Omeprazole 40 mg (AstraZeneca - test) Omeprazole 20 (Merck - reference) Omeprazole 40mg (Merck - reference)
1641320|NCT01921907|Drug|AD17137 topical treatment|
1641321|NCT01921907|Drug|Placebo|
1641322|NCT01921894|Dietary Supplement|Cholecalciferol|vitamin D supplementation with either 2,000 IU/day or 4,000 IU/day compared to vitamin D3 supplementation with 200 IU/day.
1641323|NCT01921881|Other|St John's wort|
1641324|NCT01921868|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine, 2 g/day, up to 24 months.
1641325|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 6.5 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
1641326|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 20 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
1641327|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 50 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
1641328|NCT01921855|Drug|BAY Factor VII (BAY86-6150)|BAY Factor VII (BAY86-6150), 90 µg/kg body weight, will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
1641329|NCT01921855|Drug|Placebo|Placebo will be administered as a slow intravenous (i.v.) administration over a period of 2-5 minutes (min) on Study Day 1.
1641330|NCT01921842|Behavioral|NAP-SACC Child Care Wellness Program|Nutrition And Physical activity Self-Assessment for Child Care
1641331|NCT01921829|Drug|Protocolized Diuretic Strategy|"The Protocolized Diuretic Strategy will administer diuretics according to an algorithm based on based on the stepped pharmacologic care arm used by the CARRESS-HF trial investigators. This algorithm targets a relatively aggressive goal diuresis of urine output (UO) 3-5 L/day with diuretics intensified in a stepped fashion using both loop diuretics given by intravenous (IV) bolus followed by IV continuous infusion (furosemide or alternative loop diuretic at equivalent dose), with or without concomitant thiazide diuretic (oral (PO) metolazone or IV chlorothiazide)."
1641332|NCT01921816|Device|Prismocitrate 18/0, Prism0cal|Subjects on continuous hemodiafiltration will ordinarily receive heparin as the anticoagulation. In our study, regional citrate anticoagulation with Prismacitrate is used to replace heparin. Citrate has been shown in study to be safer than heparin with reduced bleeding risk
1641333|NCT01921803|Radiation|hypofractionation|
1641334|NCT01921790|Biological|Avastin|Avastin 7.5mg/Kg, intravenous drip D1
1641335|NCT01921790|Drug|Gemcitabine|Gemcitabine 1g/m2 intravenous drip D1,D8
1641336|NCT01921790|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 intravenous drip D1
1641337|NCT01921790|Drug|Pegaspargase|Pegaspargase 2500U/m2 intramuscular injection (IM) D1
1641338|NCT01921790|Drug|Dexamethasone|Dexamethasone 20mg/d intravenous drip D1, po D2-3
1641339|NCT01921777|Drug|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
1641340|NCT01921777|Drug|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
1641341|NCT01921764|Behavioral|Workplace physical exercise|
1641342|NCT01921764|Behavioral|Home physical exercise|
2012321|NCT02084147|Device|magnetic resonance imaging|Undergo MRI
2012322|NCT02076178|Drug|744 Tablet|White to almost white oval shaped film coated 30 mg tablets for oral administration
2012323|NCT02076178|Drug|744 LA Injection|Sterile white to slightly coloured suspension containing 200 mg/mL of 744 as free acid for administration by intramuscular (IM) injection
2012324|NCT02076178|Drug|Placebo Tablet|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876
2012325|NCT02076178|Drug|Placebo Injection|Sterile saline 0.9% Sodium Chloride Injection
1641349|NCT01921738|Drug|1% Azithromycin gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placement of the in-situ gel (0.2 ml 1% Azithromycin) into the periodontal pockets in single rooted teeth; twice with an interval of 20 minutes.
1641350|NCT01921738|Drug|Azithromycin|Participants received mechanical periodontal therapy, oral hygiene instructions and antibiotic (Azithromycin 250mg x 6 capsules)
1641351|NCT01921738|Drug|placebo gel|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo (antibiotic) in situ gel.
1641352|NCT01921738|Drug|placebo capsule|Participants received mechanical periodontal therapy (Scaling and Root Planing), oral hygiene instructions and placebo (antibiotic) capsules (250mg x 6), at mouth (Po), two times a day (bid) for three days.
1641353|NCT01921725|Device|hydrophilic-based dressing (KoCarbonTM)|"BCT Hydrophilic Wound Dressing consists of PET non-woven, activated carbon fiber (ACF) cloth and PE film. The PET non-woven is vapor permeable to allow air exchange for the wound. The absorbent ACF absorbs exudate, bacteria and odor to create an effective barrier. Furthermore, far infrared ray (FIR) emitted from ACF accelerates blood circulation and metabolism to reduce healing period. The PE film helps to minimize wound trauma at dressing changes."
1641354|NCT01921712|Drug|PUR0200|Randomized single doses of 3 selected doses of PUR0200, compared to a placebo and active comparator
1641355|NCT01921712|Drug|PUR0200 Placebo|Randomized, single dose of inhaled placebo matched to PUR0200
1641358|NCT01921686|Other|Sample collection and Questionnaire|This is an observational biospecimen collection and questionnaire study. The subjects will be asked to complete a symptom questionnaire at screening visit. In addition, 3 esophageal biopsy samples will be taken to conduct laboratory analyses.
1641359|NCT01921673|Drug|Dovitinib and docetaxel|"In phase I portion of the study Docetaxel 45-75 mg/m2, intravenous, every 3 weeks Dovitinib 200-500 mg, oral, 5 days on/2 days off
In phase II portion of the study Recommended dose of docetaxel and dovitinib in phase I portion will be used."
1641360|NCT01921660|Device|Mapping with the Acutus Medical System followed by Ablation|
1641361|NCT01921647|Drug|YH4808|
1641362|NCT01921647|Drug|Nexium|
1641363|NCT01921647|Drug|Amoxicillin|
1641364|NCT01921647|Drug|clarithromycin|
1641365|NCT01921634|Other|Modified Pathologic Analysis|
1641366|NCT01921621|Behavioral|Group B - Simulation Training|Group B resident training includes the use of a dry model shoulder simulator for practicing the steps and avoiding the errors of an arthroscopic Bankart repair
1641367|NCT01921621|Behavioral|Group C - Proficiency Based Progression|Group C - Proficiency Based Progression Group C residents must test to proficiency on the cognitive material contained in the orientation video, demonstrate arthroscopic knot tying proficiency to a pre-determined benchmark, and perform an arthroscopic Bankart repair on a dry shoulder simulator model to a pre-determined benchmark in order to progress in the training exercise
1641368|NCT01921608|Device|PrePex™ device|PrePex™ device for adult male circumcision programs. The PrePex™ device is designed to enable conducting male circumcision procedure that is bloodless with no anesthesia and no sutures.
1641369|NCT01921595|Other|Valanced salt colloid|Maximum dose : 30ml/kg, IV, The infusion of valanced salt colloid is started at bleeding and continued until reach at maximum dose
1641370|NCT01921595|Other|Valanced salt crystalloid group|Maximum dose : 30ml/kg, IV, The infusion of valanced salt crystalloid is started at bleeding and continued until reach at maximum dose
1641371|NCT01921582|Drug|Methylphenidate|"Weekly appointments with study psychiatrists for the first four weeks, and then biweekly appointments for the last eight weeks.
Intervention will consist of medication as well as components of Med-Plus treatment (e.g., medication management, general support, and compliance enhancement strategies)."
1641372|NCT01921582|Behavioral|Cognitive Behavioral Therapy|"Cognitive Behavior Therapy will include three phases:
Phase 1 undertakes to eliminate binge episodes and introduce a 'regular' pattern of eating;
Phase 2 aims to reduce food intake and restructure eating-related cognitions;
Phase 3 focuses upon relapse prevention"
1641373|NCT01921569|Behavioral|Standard of Care Therapy|Rest, ice, compression, elevation (RICE), NSAID or salicylate medication for pain, Physical Therapy and stretching exercises, Reduction in impact activities, to include an arm sling.
1641374|NCT01921569|Other|dHACM Injection|Injection into affected area with micronized dHACM suspended with total volume of 1 cc normal saline.
1641375|NCT01921569|Other|Normal Saline Injection|Injection into affected area with 1.0 cc normal saline solution instead of active agent.
1641376|NCT01921556|Behavioral|active comparator, QualiCCare education|"Physicians randomized into the intervention group get a QualiCCare training workshop designed to educate professionals on the guidelines but also and particularly governing professional behavior by feedback, reminders and pathways that help to change their attitudes and care behavior. Based on behavioral and learning theory, QualiCCare intervention not only tries to increase knowledge but also internal motivation and decision making by stimuli and resources and by written instruments that guide evidence based decision support."
1641377|NCT01921543|Device|ITP Stimulation|"Model 7428 Kinetra® Neurostimulator
Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead
Model 3387 DBSTM Brain Lead
Model 7482-51 Extension
Model 7482-66 Extension
Model 7482-95 Extension
Model 7436 AccessTM Therapy Controller
Model 3628 Dual Screener TM
Model 8840 N'Vision"
1641378|NCT01921543|Device|CI/BNST stimulation|"Model 7428 Kinetra® Neurostimulator
Model 3887 DBSTM Pisces Quad Compact Model 3389 DBSTM Brain Lead
Model 3387 DBSTM Brain Lead
Model 7482-51 Extension
Model 7482-66 Extension
Model 7482-95 Extension
Model 7436 AccessTM Therapy Controller
Model 3628 Dual Screener TM
Model 8840 N'Vision"
1641379|NCT01921543|Device|No stimulation|
1641380|NCT01921530|Procedure|Interbody Fusion|The interbody fusion (IF) procedure requires exposure and removal of the disc, curetting the end plates, inserting a cage filled with bone graft, as well as stabilization with rods and screws.
1641381|NCT01921530|Procedure|Posterolateral Fusion|In posterolateral fusion stabilization is achieved using pedicle screws joined by rods. The graft used to facilitate fusion is placed between decorticated transverse processes and can be an autograft of iliac bone or local bone, allograft, or a synthetic expander.
2012326|NCT02074631|Drug|Pamidronate|Subjects randomized to pamidronate treatment will receive infusions, 1 mg/kg (to a max dose of 60mg) over 4 hours, every 3 months at approximately 100 days, 180 days, and 270 days after HCT.
1641384|NCT01921504|Device|Acupuncture|"Acupuncture treatment
Acupuncture rationale 1a) Style of acupuncture: body acupuncture (in accordance with meridian theory)
Needling details 2a) Number of needle insertions per subject per session: 9-19 2b) Acupoints: Basic points - Large Intestine(LI)4, Stomach(ST)36, Liver(LR)3, Spleen(SP)4, Conception Vessel(CV)12 Optional points - Gallbladder(GB)21, Small Intestine(SI)14, Pericardium(PC)6, External points of Hand and Neck(EX-HN)5, Stomach(ST)34 2c) Depth: 5 ~ 30mm 2d) Response sought: 'Deqi' 2e) Needle stimulation: Manipulation 2f) Retention time: 15 minutes 2g) Needle type: 25 X 30 mm, sterilized stainless steel needle, Dongbang Inc., Korea"
1641385|NCT01921491|Procedure|Dressing Application|Application of a non-adherent dressing, a moisture retentive dressing, and a multi-layer compression dressing.
1641386|NCT01921491|Device|Offloading|"Provision of offloading cast walker or similar sponsor-approved device. May convert into instant total contact cast and/or add felt/foam to supplement offloading."
1641387|NCT01921452|Device|Quantitative POC TSH Kit|A drop (approximately 30 microliter [mcL]) of blood will be taken from subject's fingertip to test TSH quantitatively by using the quantitative POC TSH test kit according to the product specification on Day 1 to Day 5.
1641388|NCT01921452|Device|Qualitative POC TSH Kit|A drop (approximately 30 mcL) of blood will be taken from subject's fingertip to test TSH qualitatively by using the qualitative POC TSH test kit according to the product specification on Day 1 to Day 5.
1642413|NCT01913639|Drug|Regorafenib|
1641389|NCT01921452|Device|Third generation TSH Kit|One milliliter (mL) of subject's venous blood will be taken to test both qualitative and quantitative TSH levels, by using the third generation TSH test kit on Day 1 to Day 5.
1641390|NCT01921439|Behavioral|Personalized Feedback|Personalized feedback reflecting the participant's current level of nicotine addiction, money spent on cigarettes, time spent smoking, and health effects of smoking.
1641391|NCT01921426|Drug|GC4419|GC4419 is a novel, highly stable manganese-containing macrocyclic ligand complex with a molecular weight of 483, whose activity mimics that of naturally occurring superoxide dismutase (SOD) enzymes. It is therefore a prototype of a new class of drugs termed selective SOD mimetics. GC4419 selectively removes superoxide anions without reacting with other reactive oxygen species, including nitric oxide, hydrogen peroxide, and peroxynitrite.
1641392|NCT01921413|Device|Urine Malaria Test|Rapid non-invasive malaria diagnostic test
1641393|NCT01921387|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
1641394|NCT01921387|Drug|Carmustine|Given IV
1641395|NCT01921387|Drug|Cytarabine|Given IV
1641396|NCT01921387|Drug|Etoposide|Given IV
1641397|NCT01921387|Other|Laboratory Biomarker Analysis|Correlative studies
1641398|NCT01921387|Drug|Melphalan|Given IV
1641399|NCT01921387|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSC transplant
1641400|NCT01921387|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
1641401|NCT01921374|Biological|sleep parameters|Since the mother-caregiver dedicates herself entirely to her son, we will performe overnight polysomnography to assess the sleep pattern.
1641402|NCT01921374|Biological|Hormonal profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters.
1641403|NCT01921374|Biological|Inflammatory profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
1641404|NCT01921374|Biological|Cardiovascular profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
1641405|NCT01921374|Biological|Metabolic profile|To assess the health profile of caregivers-mothers are analyzed some markers that may indicate an impairment or damage to the health of each of the parameters
1641406|NCT01921361|Drug|Levobupivacaine|Intrathecal 3ml (15 mg)
1641407|NCT01921361|Drug|Dexmedetomidine|Intrathecal 3 microgram (diluted 1/10, 0.3 ml)
1641408|NCT01921361|Drug|Dexmedetomidine|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion (dexmedetomidine diluted 1 microgram/ml)
1641409|NCT01921361|Drug|sodium chloride|Intravenous 1ml/kg/10 minutes and than 0.5 ml/kg/hour infusion in the control and intrathecal groups, intrathecal 0.3 ml in the control and intravenous groups.
1641410|NCT01921348|Device|acupressure pellets|The treatment group will have acupressure pellets placed in pre-determined acupressure point on the ear that relates to rhinitis.
1641411|NCT01921348|Device|acupressure pellets|The sham group will have acupressure pellets placed in a pre-determined non-specific acupressure point on the ear that is not related to rhinitis.
1641412|NCT01921335|Drug|ARRY-380 Twice Daily Dosage|ARRY-380 will be administered daily (either twice-daily along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
1641413|NCT01921335|Drug|ARRY-380 Once Daily|ARRY-380 will be administered daily once-daily) along with concurrent administration of trastuzumab on Day 1. PK sampling of ARRY-380 is planned on Day 15. Blood samples will be collected at pre-dosing, 2 hours (± 1 hour), and 6 hours (± 2 hours). The same time points will be collected for BID and QD schedules. On the PK collection day participants should fast one hour before and one hour after taking ARRY-380.
1641414|NCT01921335|Drug|Trastuzumab|6 mg/kg IV every 3 weeks
1641415|NCT01921322|Device|Pump|722 Paradigm Real-Time System
1641416|NCT01921322|Other|CGMS Gold|Device used to collect retrospective sensor data, blinded to the subjects, to compare to the treatment arm
1641417|NCT01921309|Device|Trinity CoC Total Hip System|total hip replacement with a ceramic femoral head which moves on a ceramic acetabular cup liner
1641418|NCT01921309|Device|Trinity Ceramic-on-Poly THR|total hip replacement with a ceramic femoral head which moves on a highly cross-linked ultra high molecular weight polyethylene acetabular cup liner
1641419|NCT01921296|Drug|Cyclobenzaprine|5 milligrams orally 2 hours before bedtime
1641420|NCT01921283|Device|BIS sensor attachment|For double blind method, BIS sensors were attached to all patients, but only BIS-group was measured by the value. BIS monitor was pushed back toward the anesthesiologist so that the physician could not see it. 3 L/min of oxygen was delivered by a nasal cannula to all patients throughout the procedure. Blood pressure was recorded every 5 minutes and heart rate, peripheral oxygen saturation were measured continuously. For induction of sedation, propofol 1 mg/Kg and lidocaine 30mg was administered throughout IV line and immediately followed by continuous infusion of propofol 0.04-0.06 mg/Kg/min and remifentanil 0.05 mcg/Kg/min. The evaluation of sedation depth using OAA/S was performed at 1 minute after propofol administration, endoscopy insertion, submucosal inflation by 1:100000 epinephrine with indigocarmine, initial submucosal dissection and when the patient had restlessness or coughing additively.
1641421|NCT01921283|Drug|no- BIS sensor attachment|
2012327|NCT02074631|Drug|Calcium and vitamin D|All subjects will receive a standard recommended dose of 600 IU/day of vitamin D. Subjects who do not meet the RDA will receive additional calcium supplementation.
1641423|NCT01921257|Drug|Cat-PAD|
1641424|NCT01921257|Drug|Placebo|
1641518|NCT01920659|Behavioral|High Intensity Training (HIT)|6 weeks of HIT, 3 times a week (3-5 1min on/off)
1641519|NCT01920659|Behavioral|REHIT|6 weeks 3 x week (20sec intervals)
1642414|NCT01913639|Drug|5-Fluorouracil|
2012328|NCT02074904|Drug|Topiramate|
2012329|NCT02074904|Drug|Placebo|
2012330|NCT02073279|Drug|satralizumab (SA237)|
2012331|NCT02073279|Drug|Placebo|
1641425|NCT01921244|Other|Decision Aid|"Parents will receive an intervention modified from the previously published tool called Autism: Should My Child Take Medicine for Challenging Behavior? This packet provides parents with educational information, elicits parent ratings of particular behavioral domains, describes behaviors that are and are not amenable to medication treatment, and elicits parent preferences regarding treatment. Providers will be trained on use of the intervention in practice to promote shared decision making during clinical encounters."
1641426|NCT01921231|Drug|Hyperbaric Prilocaine 1%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
1641427|NCT01921231|Drug|Hyperbaric bupivacaine 0.5%|Selective spinal anesthesia was performed on induction-block area and patient was transferred to the assigned operating room where another anesthesiologist (blinded for the arm) began to evaluate the blocking. Neither the nurse, surgeon nor the anesthesiologist involved in the patient evaluation knew the allocation group.
1641428|NCT01921218|Drug|Belatacept|Belatacept, dosing 10mg/kg- day 0, 2 weeks, 1 month, 2 months, 3 months; subsequent doses 5mg/kg monthly through duration of trial or until retransplantation, whichever is first.
1641429|NCT01921218|Drug|Calcineurin inhibitor therapy|Upon enrollment, wean calcineurin inhibitor (CNI) to target tacrolimus trough of 3-5 nanogram/milliliter (ng/ml)or equivalent cyclosporine trough. Upon initiation of hemodialysis, discontinue CNI therapy over 5 days.
1641430|NCT01921218|Drug|Mycophenolate mofetil|Continue current dose at enrollment. Upon initiation of dialysis, decrease dose by half, then discontinue 2 weeks later
1641431|NCT01921218|Drug|prednisone|Begin steroid withdrawal one month after initiation of dialysis, with monthly reduction in dose by half, with plans to discontinue prednisone by 3 months after initiation of dialysis
1641432|NCT01921205|Drug|Lacosamide|"Subjects <30 kg (LCM oral solution): 4 mg/kg - 6 mg/kg BID ( 8mg/kg/day - 12 mg/kg/day)
Subjects ≥30 kg to <50 kg (LCM oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)
Subjects ≥50 kg (LCM tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
1641433|NCT01921205|Other|Placebo|"Subjects <30 kg (placebo oral solution): 4 mg/kg - 6 mg/kg BID (8 mg/kg/day - 12 mg/kg/day)
Subjects ≥30 kg to <50 kg (placebo oral solution): 3 mg/kg - 4 mg/kg BID (6 mg/kg/day - 8 mg/kg/day)
Subjects ≥50 kg (placebo tablets): 150 mg - 200 mg BID (300 mg/day - 400 mg/day)"
1641434|NCT01921192|Drug|Folic Acid, vit B6 and B12|
1641435|NCT01921192|Drug|Placebo|
1641436|NCT01921179|Behavioral|GOALS (Goal-Oriented Attentional Regulation)|Goal-Oriented Attentional Regulation (GOALS) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). Some subjects will only receive the GOALS intervention.
1641437|NCT01921179|Behavioral|EDU (Brain Health Education)|Brain Health Education (EDU) will involve 5-weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education on brain health and functioning in a classroom format, with study materials for homework. Some subjects will start with EDU and then cross-over to the GOALS.
2012332|NCT02072668|Drug|rivaroxaban|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
1641440|NCT01921153|Other|Healthy meal plates and trays|The healthy meal plates and trays provide guidance for how to construct a meal in the military dining facility.
1641445|NCT01921114|Device|BioFlo™ Peripherally Inserted Central Catheter (PICC)|
1641446|NCT01921114|Device|Bard® Dual-Lumen PowerPICC SOLO2®|
1641447|NCT01921101|Behavioral|intensive medical nutrition|provision of participants energy and protein needs via enteral, parenteral nutrition from hospital admission to discharge
1641448|NCT01921101|Other|control|participants will receive standard care for nutrition received from hospital admission to discharge
1641449|NCT01921088|Other|real-time functional magnetic resonance imaging neurofeedback (RT-fMRI-NF)|Subjects are provided with RT-fMRI-NF.
1641450|NCT01921088|Behavioral|Ambulatory Training|Subjects are provided with an ambulatory training.
1641451|NCT01921075|Other|normal dietary behavior|normal dietary behavior during examination days
1641452|NCT01921075|Other|Magnetic resonance spectroscopy|Non-invasive diagnostic procedure
1641453|NCT01921062|Behavioral|Motor imagery|The kinesthetic motor imagery training consists of the imagination of flexion, extension, abduction, adduction, pronation and supination of their injured wrist.
1641454|NCT01921036|Procedure|traditional cardiac rehabilitation|mutifactoral cardiac rehabilitation
1641455|NCT01921036|Procedure|combined exercise|Moderate endurance and resistance exercise once a week over six months
1641456|NCT01921010|Drug|Niaspan|See Arm Description
1641457|NCT01921010|Drug|Placebo|See Arm Description
1641458|NCT01920984|Drug|intravitreal injection of 1.25 mg of bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
1641459|NCT01920971|Radiation|infrared therapy|wavelength = 890 nm, radiant power output = 6.24 W, power density = 34.7 milliWatts/cm2 for 40 min, total energy 83.2 J/cm2
1641460|NCT01920958|Other|TachoSil®|TachoSil® is a collagen sponge that is coated with the active substances human fibrinogen and human thrombin and that supports hemostasis and tissue sealing in surgery.
1641520|NCT01920646|Other|ALV|Random allocation of children of two rural farm schools per grade to receive either 300 gram cooked ALVs and school meal starch or the normal school meal as daily meal (5 days/weeks) for 3 months.
1641679|NCT01919359|Dietary Supplement|Multizyme Cellular Vitality Cyruta Plus SHEP|
1641680|NCT01919346|Drug|Eculizumab|
1641461|NCT01920945|Drug|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA, will be injected into 31 sites in the head and neck every 12 weeks for a total of 24 weeks using a sterile 30-gauge, 0.5 inch needle as 0.1 mL (5 Units) injections per each site. Injections will be divided across seven specific head/neck muscle areas (corrugator, procerus, frontalis, temporalis, suboccipital, splenius capitus and medial/lateral occipital, and trapezius).
1641462|NCT01920932|Drug|brentuximab vedotin|Given intravenously (IV).
1641463|NCT01920932|Drug|etoposide|Given IV.
1641464|NCT01920932|Drug|prednisone|Given orally (PO).
1641465|NCT01920932|Drug|doxorubicin|Given IV.
1641466|NCT01920932|Drug|cyclophosphamide|Given IV.
1641467|NCT01920932|Drug|Dacarbazine(R)|Given IV.
1641468|NCT01920932|Drug|filgrastim|Given subcutaneously (SQ) as clinically indicated.
1641469|NCT01920932|Other|quality of life assessment|Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.
1641470|NCT01920932|Radiation|radiation therapy|At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
1641471|NCT01920919|Drug|Dexamethasone|
1641472|NCT01920919|Drug|Placebo|
1641473|NCT01920906|Procedure|Skin biopsy and blood test|Analysis of histology and gene expression in affected and unaffected skin
1641474|NCT01920893|Drug|Placebo (for dupilumab)|Solution for injection; Subcutaneous injection.
1641475|NCT01920893|Drug|Dupilumab|Solution for injection; Subcutaneous injection.
1641476|NCT01920893|Drug|Mometasone furoate nasal spray|Nasal spray, 2 actuations in each nostril twice daily.
1641477|NCT01920880|Other|Quantitative Sensory Testing analysis|
1641478|NCT01920867|Procedure|RB (Retrobulbar)|Retrobulbar injection of Bone Marrow Derived Stem Cells (BMSC)
1641479|NCT01920867|Procedure|ST (Subtenon)|Subtenon injection of Bone Marrow Derived Stem Cells (BMSC)
1641480|NCT01920867|Procedure|IV (Intravenous)|Intravenous injection of Bone Marrow Derived Stem Cells (BMSC)
1641481|NCT01920867|Procedure|IVIT (Intravitreal)|Intravitreal injection of Bone Marrow Derived Stem Cells (BMSC)
1641482|NCT01920867|Procedure|IO (Intraocular)|Intraocular injection of Bone Marrow Derived Stem Cells (BMSC) with vitrectomy prior to intraocular injection. For example, may include larger amount of stem cells in the intravitreal cavity, intraneuronal injections or subretinal injections of stem cells.
1641483|NCT01920854|Drug|soluble ferric pyrophosphate|
1641484|NCT01920854|Drug|Placebo|
1641485|NCT01920841|Other|Cream A applied to left thigh and Cream B to right thigh|Half the participants will receive Cream A applied to the left thigh, and Cream B applied to the right thigh
1641486|NCT01920841|Other|Cream B applied to left thigh and Cream A to right thigh|Half the participants will receive Cream B applied to the left thigh and Cream A applied to the right thigh
1641487|NCT01920815|Other|No interventions|
1641488|NCT01920802|Drug|olanzapine|5mg BID up to 4 weeks
1641489|NCT01920802|Drug|iloperidone|6 mg BID up to 4 weeks
1641490|NCT01920802|Drug|Placebo|BID up to 4 weeks
1641491|NCT01920789|Radiation|Stereotactic radiotherapy|Margin between CTV and PTV of 5 mm in transversal direction (except for small targets (<3cm) not fixed to thoracic wall or mediastinal structures, where margin should be 10 mm) and 10 mm in longitudinal direction. Planned heterogeneous dose distribution within the PTV with about 50% higher dose to the center compared to the periphery. Hypofractionation with 22 Gy times 3 at the isocenter (15 Gy at the periphery of the PTV)during one week will be used.
1641492|NCT01920789|Radiation|Conventionally fractionated radiotherapy|Clinical target volume (CTV) comprises the Gross Tumor Volume (GTV), including its diffuse growth at the borders. Planning target volume (PTV) is defined as the CTV with a total margin of 2 cm in all directions. The patient will receive 35 fractions, with a dose of 2.0 Gy/fraction at the ICRU reference point to a total dose of 70 Gy. The treatments will be given five days a week. The total treatment time should be as close to seven weeks as possible. The aim is that the dose distribution should be as homogeneous as possible.
1641493|NCT01920776|Other|ultrasound examination|
1641494|NCT01920776|Other|Ultrasound group|Ultrasound group will receive ultrasound examination at least once a day, the results will be noted to the attending who is in charge of the treatment.
1641495|NCT01920763|Other|Clinical Measurement|No direct interventions; study is observational and clinical assessments only will be performed.
1641496|NCT01920750|Biological|MLCwA|Antigen MLSA-LAM is a pellet extracted 3x followed by removal of SDS by column chromatography. Contains many of the same proteins
1641497|NCT01920750|Biological|MLSA-LAM|Antigen MLSA-LAM is derived from M. leprae extract following sonication and centrifugation, leaving the cytosol (MLSA). Contains soluble protein antigens of M. leprae
1641498|NCT01920750|Other|Mock Antigen|Physiological saline
1641499|NCT01920737|Drug|Daunorubicin|In the event of a shortage of daunorubicin, doxorubicin may be used as a substitute.
1641500|NCT01920737|Drug|Vincristine|
1641501|NCT01920737|Drug|Prednisone|
1641502|NCT01920737|Drug|PEG-Asparaginase|
1641503|NCT01920737|Drug|Methotrexate|
1641504|NCT01920737|Drug|6-MP (6-Mercaptopurine)|
1641505|NCT01920737|Drug|Cyclophosphamide|
1641506|NCT01920737|Drug|Cytarabine|
1641507|NCT01920737|Drug|Leucovorin|
1641508|NCT01920737|Drug|Dexamethasone|
1641509|NCT01920737|Other|Blood draw|
1641510|NCT01920737|Device|CT/PET scans|PET or CT scan every 6 months for 3 years
1641513|NCT01920698|Device|Percutaneous MitraClip Device Implantation|MitraClip System includes a MitraClip device, a steerable guide catheter and a MitraClip delivery system
1641514|NCT01920698|Other|control|
1641515|NCT01920685|Other|Anxiety intervention|
1641516|NCT01920672|Behavioral|Timed Planned Activity|
1641517|NCT01920672|Behavioral|Home Safety and Education Program|
1641521|NCT01920620|Behavioral|Inpatient weight loss counseling|Weight loss counseling utilizing a 13 minute patient education video on weight loss and an 25 minute personalized health education session. Subjects set 3 specific behavior set three specific lifestyle goals prior to discharge including a calculated six month weight loss goal (10% of body weight) and specific dietary and fitness goals. Usual care group participants received no specific instruction regarding weight loss prior to discharge.
1641522|NCT01920620|Behavioral|Motivational interviewing and troubleshooting via phone|All subjects were asked to track their weights over the 6 month duration of the study. Weights were obtained by phone at weeks 1,2,3,4, 8, 12, 16, 20 and 24. Phone calls for the intervention group utilized motivational and troubleshooting techniques whereas calls in the usual care group were used only to obtain weight and assess for changes in medications or health condition.
1641523|NCT01920607|Device|magnetic anal sphincter|
1641524|NCT01920607|Device|sacral nerve stimulation|
1641527|NCT01920568|Biological|Denosumab 70 mg/mL|Denosumab will be given as a SC injection of 120 mg by administering a 1.7 mL volume in a single injection
1641528|NCT01920568|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg (or equivalent clearance-adjusted dose in subjects with baseline creatinine clearance <=60 ml/min) will be diluted in either 0.9% sodium chloride or 5% dextrose injection and administered IV.
1641529|NCT01920568|Drug|Placebo IV|The placebo will consist of 1.7 mL 0.9% w/v sodium chloride
1641530|NCT01920568|Drug|Placebo SC|The placebo will consist of either 0.9% w/v sodium chloride or 5% dextrose injection
1641531|NCT01920568|Dietary Supplement|Calcium supplement|Subjects are strongly recommended to take daily supplements of at least 500 mg calcium from the day of consent and until completion of the Week 73 follow-up visit.
1641532|NCT01920568|Dietary Supplement|Vitamin D supplement|Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
1641533|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.1 mg/kg - one single infusion
1641534|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.2 mg/kg - one single infusion
1641535|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 0.5 mg/kg - one single infusion
1641536|NCT01920555|Drug|Ketamine|Dose of Ketamine will be 1.0 mg/kg - one single infusion
1641537|NCT01920555|Drug|Placebo Midazolam|Dose of Midazolam (active placebo) will be 0.045 mg/kg - one single infusion
1641538|NCT01920542|Drug|Dexmedetomidine|administration of dexmedetomidine on dexemedetomidine group
1641539|NCT01920542|Drug|no dexmedetomidine|no administration of dexmedetomidine on control group
1641540|NCT01920529|Other|aerobic exercise|Performed aerobic exercise on a treadmill with cardiac predetermined frequency within 6 weeks and frequency of three times per week. All patients were monitored during training.
1641541|NCT01920516|Drug|Melphalan|Melphalan 1mg/kgr is rapidly infused into the isolated limb via the arterial catheter after the inflation of venous baloon catheter.
1641542|NCT01920503|Drug|Doxorubicin|Doxorubicina is loaded at the concentration of 50-75 mg/mq onto 2 ml of 70-150 µm M1 microspheres and is infused by TACE method
1641543|NCT01920490|Device|GUILT-INCREASE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
1641544|NCT01920490|Device|GUILT-STABILIZE-CORRELATION|"This uses a novel software FRIEND created at IDOR in Rio de Janeiro, Brazil. The software is used on a regular clinical fMRI scanner"
1641545|NCT01920477|Biological|Ofatumumab|Ofatumumab (human monoclonal antibody) will be provided in prefilled glass syringes containing 0.4 milliliters (mL) (20 mg) of concentration 50 mg/mL drug product
1641546|NCT01920477|Biological|Placebo|Placebo to match the active doses will consist of prefilled glass syringes containing 0.4 mL of normal saline.
1641547|NCT01920451|Behavioral|Cognitive-Behavioral Therapy for Insomnia (CBTI)|See arm description.
1641548|NCT01920438|Procedure|Percutaneous Endoscopic Gastrostomy|PEG
1641549|NCT01920438|Procedure|Radiologically-guided insertion of Gastrostomy|RIG
1641550|NCT01920425|Device|Kinesia HomeView|Motion sensor based telemedicine system for assessment of movement disorder motor symptoms in the home. Includes automated motor assessment using motion sensor and electronic dyskinesia diary.
1641551|NCT01920425|Other|Hand-written diary|Hand-written paper diary indicating state (Off, On without dyskinesias, on with non-troublesome dyskinesias, on with troublesome dyskinesias) at 30 minute intervals.
1641552|NCT01920412|Device|LAmbre Left Atrial Appendage(LAA) Occluder|Implanting the LAmbre Left Atrial Appendage Occluder to close the left atrial appendage
1641553|NCT01920399|Drug|CAZ-AVI|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
1641554|NCT01920399|Drug|0.9% Normal Saline|A single 120 minute IV infusion on Day 1, followed by three times daily (every 8 hours, q8h) as 120 minute IV infusions for 7 days (Day 2 to Day 8), and one single 120 minute IV infusion on Day 9.
1641555|NCT01920386|Drug|Tramadol hydrochloride/Acetaminophen Tab.|
1641556|NCT01920386|Drug|Tramadol hydrochloride/Acetaminophen SR Tab.|
1641557|NCT01920373|Drug|Group A (corticosteroid injection group)|
1641558|NCT01920373|Biological|Group B (platelet rich plasma injection group)|
1641559|NCT01920360|Other|SULPHUROUS WATERS IMMERSION BATHS|SULPHUROUS WATERS IMMERSION BATHS: The baths will be held in individual tubs, properly disinfected, supplied with sulphurous thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
1641560|NCT01920360|Other|NOT SULPHUROUS WATERS IMMERSION BATHS|NOT SULPHUROUS WATERS IMMERSION BATHS:The baths will be held in individual tubs, properly disinfected, supplied with not sulphur thermal water at a temperature 37-39 ° C, which encompass the optimum temperatures for therapeutic bath. The baths lasted for 20 minutes. The subjects will drink two cups of water, 300 ml before and after the baths, in order to avoid an imbalance water.
1641677|NCT01919372|Device|Telemedic assistance with a technological system|
1641561|NCT01920360|Other|CONTROL GROUP|CONTROL GROUP: This group did not receive any treatment, only received some verbal directions as to the care that should be taken to prevent and control the knee pain.
1641562|NCT01920334|Drug|Zolpidem CR 12.5mg|Patients will be given zolpidem CR 12.5mg each night for, at least, 3 consecutive nights, including the first night on the Cardiac ICU, when the undergo a full-night polysomnography
1641563|NCT01920334|Drug|Placebo|Patients will receive placebo pills at night, according to their usual sleep time, from the first night on the Cardiac ICU, until their hospital discharge
1641564|NCT01920321|Procedure|Endoscopic lung volume reduction|Prior the procedure patients undergo - high resolution chest CT , extensive phisiological assessment.
1641565|NCT01920308|Device|5 mm Bard LifeStent Vascular Stent|The LifeStent® Vascular Stent is a peripheral stent intended to improve luminal diameter in the treatment of symptomatic de-novo or restenotic lesions up to 240 mm in length in the native superficial femoral artery (SFA) and popliteal artery with reference vessel diameters ranging from 4.0 - 6.5 mm.
1641566|NCT01920295|Device|Cryoballoon ablation|
1641567|NCT01920282|Drug|Nebivolol|
1641568|NCT01920282|Other|Lifestyle Modification|
1641569|NCT01920282|Other|Nebivolol plus Lifestyle Modification|
1641570|NCT01920269|Procedure|Trans-urethral resection|Patients underwent urinary cytology of the bladder and upper urinary tract; random cold-cup biopsies of the bladder and prostatic urethra, and complete transurethral resection of all bladder tumour visible on endoscopy, ensuring muscle is included in resected samples.
1641571|NCT01920269|Drug|intravesical passive diffusion mitomycin|A dose of 40 mg mitomycin dissolved in 50 ml sterile water is infused intravesically through a Foley catheter, retained in the bladder for 60 min with catheter clamping, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations, with the same dose and methods of infusion as initial assigned treatment.
1641572|NCT01920269|Device|intravesical electromotive mitomycin|A dose of 40 mg mitomycin dissolved in 100 ml water is instilled and retained in the bladder for 30 minutes with 20 mA pulsed electric current, and then drained. Patients who have a complete response to the initial 6 weekly treatments underwent a further 10 monthly instillations with the same dose and methods of infusion as initial assigned treatment. Intravesical electromotive drug administration is given by a battery-powered generator delivering a controlled electric current that passes between the active intravesical electrode (integrated into a specific transurethral catheter) and dispersive ground electrodes (on skin of the lower abdomen). Operators set active electrode polarity and current intensity on the generator.
2012333|NCT02072668|Drug|placebo|Subject will receive rivaroxaban 20mg PO daily for 4 weeks and then matching placebo 1 PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form OR Subject will receive placebo 1 PO daily for 4 weeks, then rivaroxaban 20mg PO daily for 4 weeks, with a 2-week wash out period in between the two treatment phases. Both of the two treatments will be in capsule form.
2012334|NCT02069353|Device|QFlow 500™ Perfusion Probe (Hemedex, Cambridge, MA)|
2012335|NCT02069353|Device|Spencer Probe Depth Electrode (Ad-Tech Medical, Racine, WI)|
1641576|NCT01920230|Behavioral|Mindfulness-ACT-intervention|Half of the participants (n=109) is assigned to intervention group. The intervention is based on Mindfulness-program presented by Williams & Penman (2011) and on principles of acceptance-commitment therapy (ACT). It aims to increase mindfulness skills and psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings as well as support clarifying individual values and value-based actions. The basic principles are presented in weekly small group meetings. Participants are guided to deepen their experiences through exercises and information that is provided via specific web-site.
1641577|NCT01920230|Behavioral|No intervention|Half of the participants (n=109) don't get any special treatment. However the present study explores what kind of support they have had during the program.
1641578|NCT01920204|Drug|Midostaurin,|Midostaurin, twice daily 100 mg orally, continuously for 6 months
1641579|NCT01920191|Biological|IMA 950|
1641580|NCT01920191|Biological|Poly ICLC|
1641581|NCT01920191|Other|Immunomonitoring|Blood samples, DTH analysis
1641582|NCT01920178|Device|PinPointe Foot Laser|Active Laser Treatment Group will receive active Pinpointe Foot Laser beam. Control Placebo Sham Laser Group will receive only the localizing (aiming) non-active beam of the Pinpointe Foot Laser
1641583|NCT01920165|Other|Smoke-free legislation|The intervention under study is the smoke-free legislation in England introduced overnight on 1 July 2007. As of this date virtually all enclosed public places and workplaces are by law required to be smoke-free. More detail can be found at: http://www.smokefreeengland.co.uk
1641584|NCT01920152|Biological|PRP|Each PRP preparation requires a total of 36 ml of peripheral blood. This will be obtained via venapuncture and collected in four 9 ml extraction tubes containing 3.8% sodium citrate. The tubes are then centrifuged at 640 rpm for 8 minutes at room temperature. The 1ml plasma fraction located above the buffy coat is aspirated from each tube and dispensed into the fractioning tube. The entire PRP process takes place under laminar airflow. Immediately prior to injection, calcium chloride is is drawn up from the activator ampoule with the activation syringe and is added to the PRP fractioning tube. The activated PRP is then injected in its entirety into the hip joint under strict aseptic technique.
1641585|NCT01920152|Device|Hyaluronic Acid|Hyaluronic acid is supplied as a non-pyrogenic solution in 2.5 ml pre-filled syringes and is administered by intra-articular injection using a 22-23 gauge needle. The full 2.5 ml is injected in one joint under strict aseptic administration.
1641586|NCT01920139|Procedure|Fine needle aspiration and core biopsy of lymph node|Ultrasound guided fine needle aspiration of an abnormal lymph node followed by ultrasound guided core biopsy of the same node followed by clip placement into the node.
1641587|NCT01920139|Procedure|Axillary surgery|Patients underwent axillary node dissection or excision of setinel axillary nodes at the time of surgical treatment of their breast cancer.
1641588|NCT01920139|Other|Titanium marker|A titanium marker was deposited into the lymph node that was percutaneously biopsied , immediately after the last tissue sample obtained.
1641678|NCT01919372|Other|Standard care|
2012336|NCT02067741|Drug|CR1447|400 mg, corresponding to two 4 g stick packs applications twice daily
2012337|NCT02066181|Other|Laboratory Biomarker Analysis|Optional correlative studies
1641589|NCT01920126|Drug|sodium bicarbonate|0.5 mmol/kg for 1 hr, and then 0.15 mmol/kg/h for 23 hrs The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
1641590|NCT01920126|Drug|Saline|
1641591|NCT01920113|Drug|Dexmedetomidine - remifentanil group|
1641592|NCT01920113|Drug|Propofol - remifentanil group|
1641593|NCT01920087|Drug|ATNC05|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
1641594|NCT01920087|Drug|Placebo|Subject will take between two and four capsules of study medication per day, according to the dose titration schedule in the protocol.
1641595|NCT01920074|Drug|Nitroglycerin Ointment 0.4%|
1641600|NCT01920048|Procedure|Percutaneous Coronary Intervention|
1641601|NCT01920048|Drug|Drug Therapy for Heart Failure|The optimal combination of drugs and doses for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines
1641602|NCT01920048|Device|Device Therapy for Heart Failure|The optimal device therapy for each patient will be individualized and will be determined by his/her physician, in accordance with local and international clinical practice guidelines. In most cases the device will be an Implantable Cardioverter Defibrillator and/or Cardiac Resynchronization Therapy.
1641603|NCT01920035|Device|UroCool (Local cooling/hypothermia)|These patients will receive the UroCool device which will be inserted just prior to RARP surgery. The UroCool device will be used to effect localized cooling/hypothermia of the pelvic region prior to and during RARP surgery. It will be removed at the end of surgery.
1641604|NCT01920022|Drug|Mifepristone|Day one of medical abortion
1641605|NCT01920022|Drug|etonorgestrel|
1641606|NCT01920009|Behavioral|Pharmacist counselling session with a motivational interview|"The intervention:
The patient will be invited by the community pharmacist for two consultations the first 2 weeks after discharge and the second after 3 months.
The intervention group consultation:
Community pharmacy consultation around 2 weeks The consultation will take place in the pharmacy a face to face consultation for 20 minutes including; Motivational interview session, the pharmacists will incorporate the key motivational interview skills in their consultation Express empathy, develop discrepancy, role with resistance, support self efficacy.
The sessions will aim to develop a partnership between the pharmacist with the patient and exchange information to facilitate an informed decision. Furthermore both the pharmacist and the patient will negotiate behaviour and reach an agreement. The goal is to access motivation and elicit commitment to change behaviour in this case would be adherence to life saving medication"
1641607|NCT01919996|Drug|Azithromycin|Azithromycin oral suspension (immediate release) 12 mg/kg/day x 5 days
2012338|NCT02066181|Other|Placebo|Given PO
2012339|NCT02066181|Other|Quality-of-Life Assessment|Optional ancillary studies
1641610|NCT01919957|Other|No intervention|
1641611|NCT01919944|Drug|VLY-686|capsules containing either 10 mg or 50 mg VLY-686
1641612|NCT01919944|Drug|Placebo|Sugar capsule to mimic either VLY-686 10 mg capsule or 50 mg capsule
1641613|NCT01919918|Drug|Muscle Contraction with Metabolite Solution Administration|Participants will perform maximal elbow flexor or knee extensor contractions before and after administration of metabolite solutions of pH 7.2, pH 7.0 and pH 6.6
1641614|NCT01919905|Dietary Supplement|Vitamin D|High dose group receive 28000 IU vitamin D once a week Low dose group receive 200 IU vitamin D once a week
1641615|NCT01919892|Drug|Lithium|
1641616|NCT01919879|Drug|Cetuximab + Afatinib|Afatinib taken orally, cetuximab administered intravenously
1641617|NCT01919879|Drug|Cetuximab|Cetuximab administered intravenously
1641618|NCT01919866|Other|Transplantation of CD3/CD19 depleted stem cells|
1641619|NCT01919853|Behavioral|Mindfulness-Based Stress Reduction|
1641620|NCT01919853|Behavioral|Attention Control|
1641621|NCT01919840|Procedure|Group ROTEM|"10 min after administration of protamine, if there is a large diffuse microvascular bleeding or bleed excessively at the exit of surgery then will check an Intem, a Heptem a Extem and Fibtem.
If any of the determinations altered and the patient leaves still bleeding apply the proposed treatment algorithm for Rotem. 10 minutes after each treatment will take the test again indicated that treatment, to ensure that the defect has been corrected."
1641622|NCT01919840|Other|Group C|"10 min. after protamine administration, if there is a significant diffuse microvascular bleeding or when the patient departure from surgery if bleeds excessively will be a TCA and routed the following analytical results: prothrombin time, activated partial thromboplastin time, platelet count and fibrinogen.
If any of the determinations altered and the patient still bleeding, apply the standard protocol of the unit. 10 minutes after each treatment was performed new laboratory tests to analyze the result."
1641623|NCT01919827|Biological|Endobronchial infusion of adult mesenchymal stem cells|
1641624|NCT01919827|Biological|Autologous mesenchymal stem cells derived from bone marrow|
1641625|NCT01919814|Dietary Supplement|Appethyl™|• Four hours after breakfast you will be given a small amount of liquid to drink that will contain Appethyl™. You will not know which you are getting and it will be decided randomly, like flipping a coin. You will be presented with a pizza in a quantity more than you could reasonably be expected to eat 5 hours after the start of your lunch meal and be asked to eat to your satisfaction over 30 minutes. You are not expected to eat all of the pizza.
1641626|NCT01919814|Other|Placebo|• Four hours after breakfast you will be given a small amount of liquid to drink that will contain a placebo (inactive liquid). You will not know which you are getting and it will be decided randomly, like flipping a coin. You will be presented with a pizza in a quantity more than you could reasonably be expected to eat 5 hours after the start of your lunch meal and be asked to eat to your satisfaction over 30 minutes. You are not expected to eat all of the pizza.
2012340|NCT02066181|Drug|Sorafenib Tosylate|Given PO
2012341|NCT02065154|Drug|Cyclophosphamide|
2012342|NCT02064023|Device|insulin pump|subjects in the experimental arm will administer insulin using a pump
2012343|NCT02064023|Other|multiple daily insulin injection|Subjects will continue with usual insulin injections
2012344|NCT02062827|Biological|M032 (NSC 733972)|A single dose of HSV-1 (M032) infused through catheters into region(s) of tumor defined by MRI
2012345|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 5 mg tablet TID until study treatment discontinued or end of study
1641627|NCT01919801|Drug|Icatibant|Single dose of 30 mg icatibant administered within 12 hours of the onset of an acute attack of ACE-I-induced angioedema
1641628|NCT01919801|Drug|Placebo|
1641629|NCT01919788|Drug|Insulin (Insuman Rapid)|
1641630|NCT01919788|Drug|Glucose|
1641631|NCT01919788|Other|Saline|
1641632|NCT01919749|Other|treated recommended|Treatment will be recommended after reviewing the profiling analysis
1641633|NCT01919736|Behavioral|Gait Retraining|
1641634|NCT01919723|Drug|Ticagrelor|Ticagrelor loading dose
1641635|NCT01919723|Drug|Eptifibatide|i.v. infusion
1641636|NCT01919710|Drug|rHSA/GCSF|for treatment of neutropenia
1641637|NCT01919697|Drug|Plecanatide|
1641638|NCT01919684|Drug|LGD-6972|
1641639|NCT01919684|Drug|Placebo (Captisol®)|
1641640|NCT01919671|Drug|Tongxinluo capsule|for 90 days
1641641|NCT01919671|Drug|placebo capsule|for 90 days
1641642|NCT01919658|Procedure|nerve block|A nerve block performed as per standard of care: femoral nerve blocks, and saphenous nerve blocks performed more distally (within 10cm superior to the adductor tubercle).
1641643|NCT01919645|Other|Combined Training ( Strength + Aerobics)|Strength training performed using workout devices and aerobic training performed using stationary bicycle.
1641644|NCT01919632|Behavioral|health-behavior seminar and endurance exercise|The initial stage of the program consists of a health-behavior seminar and six weeks (twice a week for 90 minutes) of supervised endurance exercise (i.e. jogging, nordic walking, cycling or swimming) in groups. In the second phase of the program, the participants receive a recommendation to continue exercise regularly unsupervised for one year, and receive monthly supervised exercise training sessions.
1641645|NCT01919619|Drug|Lenalidomide|"If creatinine clearance greater than 60 mL/min starting dose of Lenalidomide: 10 mg by mouth daily for 21 days (followed by 7 rest days).
If creatinine clearance 30 to 60 mL/min starting dose of Lenalidomide: 5 mg by mouth daily for 21 days (followed by 7 rest days),"
1641646|NCT01919619|Drug|Ipilimumab|Ipilimumab 3 mg/kg by vein. One dose of ipilimumab (Cycle 2) given within 1-3 days from the last day of lenalidomide, then followed by 4 weeks of rest. Lenalidomide repeated daily for 21 days (Cycle 3) followed by one dose of ipilimumab (Cycle 4) within 1-3 days from the last dose of lenalidomide. Treatment repeated for a total of 8 cycles.
1641647|NCT01919606|Drug|EXPAREL|Single-dose EXPAREL diluted with 20 mL or 40 mL saline to a volume of 40 mL or 60 mL, respectively.
1641648|NCT01919593|Drug|2% chlorhexidine gluconate in 70% alcohol|skin preparation before venipuncture for blood culture in even month
1641649|NCT01919593|Drug|10%povidone iodine|skin preparation before venipuncture for blood culture in odd month
1641650|NCT01919554|Biological|SLIT tablets of HDM allergen extracts|
1641651|NCT01919541|Other|Prehabilitation|All patients will receive a prehabilitation program, which involves a personalized exercise component provided by a kinesiologist.
1641652|NCT01919541|Device|hyperinsulinemic euglycemic isoaminoacid clamp|A hyperinsulinemic euglycemic isoaminoacid clamp followed by a hyperinsulinemic euglycemic hyperaminoacid clamp performed at baseline and immediately before surgery will provide insight into insulin resistance of glucose and protein metabolism in colorectal cancer patients pre- and post-intervention. Similarly, simultaneous infusions of leucine and glucose stable isotopes will provide insight into baseline and interventional effects of the program on whole body leucine and glucose kinetics.
1641653|NCT01919541|Device|hyperinsulinemic euglycemic hyperaminoacid clamp|
1641654|NCT01919541|Dietary Supplement|whey protein supplementation|
1641655|NCT01919541|Other|Prehabilitation|All patients will receive nutrition guidance and a nutrition component with whey protein supplementation.
1641656|NCT01919528|Procedure|ultrasound|catheterization of the axillary vein under ultrasound guidance
1641657|NCT01919515|Device|ZR Crown|This is an esthetic primary molar crown.
1641658|NCT01919515|Device|Stainless Steel Crown|This is a conventional stainless steel crown.
1641659|NCT01919502|Device|Semi-quantitative urine pregnancy test|
2012346|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 20 mg tablet TID until study treatment discontinued or end of study
1641662|NCT01919476|Other|Bagel|
1641663|NCT01919476|Other|Cream Cheese|
1641664|NCT01919476|Other|Almond Butter|
1641665|NCT01919463|Behavioral|Abdominal Compression|Abdominal Compression is conducted by GI assistants during intubation process to facilitate the process. It can be conducted at different ares of the abdomen with different force.
1641666|NCT01919463|Device|Guidance of Magnetic Endoscopic Imaging (MEI) System|Live image of MEI can show the form of the colonoscope inside the body. Live image is show to colonoscopist for facilitating the intubation process.
1641667|NCT01919450|Drug|Regadenoson|Subjects will undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
1641668|NCT01919450|Radiation|Rubidium-82|Subjects undergo a rest/Lexiscan (regadenoson) stress myocardial perfusion PET study.
1641669|NCT01919437|Device|Web-Enabled Cognitive Neuropsychological Evaluation System|
1641670|NCT01919424|Drug|Methacholine Chloride|"Choline ester that acts as a non-selective muscarinic receptor agonist in the parasympathetic nervous system
Low risk - commonly used to diagnose asthma"
1641671|NCT01919424|Device|Trudell AeroEclipse*II BAN nebulizer|Generates aerosol after a certain inspiratory flow has been reached and then stops nebulization the moment the inspiratory flow falls below this value
1641672|NCT01919424|Device|The English-Wright nebulizer|"Continuous-mode nebuilzer, designed to operate continuously with tidal breathing
Roxon Medi-Tech, Montreal, PQ, Canada"
1641673|NCT01919411|Drug|Amoxicillin-Potassium Clavulanate|Patients in this arm will receive 500mg of Amoxicillin-Potassium Clavulanate Combination orally twice a day for 7 days after surgery.
1641674|NCT01919411|Drug|Placebo|Patients in this arm will receive 7 days of placebo after surgery.
1641675|NCT01919398|Drug|LY2940680|Administered orally
1641676|NCT01919385|Device|Predictive Low Glucose Minimizer|This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump. Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
1641682|NCT01919320|Device|C2 Driver System TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t
1641683|NCT01919320|Device|CSS Console TAH-t Patients|Comparison of two pneumatic drivers supporting the SynCardia TAH-t.
2012347|NCT02060487|Drug|sildenafil citrate|sildenafil citrate (PDE-5 inhibitor) 80 mg tablet TID until study treatment discontinued or end of study
1641685|NCT01919294|Drug|testosterone undecanoate|Preparation: 1 gram in 4 ml of oily base. Requires no special storage conditions. Proposed regime: 1 mg as a single intramuscular injection at 0, 6, 18, 30 and 42 weeks
1641686|NCT01919281|Behavioral|strength training|
1641687|NCT01919281|Behavioral|interval training|
1641688|NCT01919268|Device|Electrotherapy|Combination of active interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of Pilates method will be individualized to each patient's needs (pragmatic treatment).
1641689|NCT01919268|Device|Pilates|Combination of placebo interferential current with exercises of the Pilates method. Patients will receive 18 sessions of treatment over a period of 6 weeks (3 sessions/week). The exercises of the Pilates method will be individualized to each patient's needs (pragmatic treatment).
1641690|NCT01919255|Drug|Picolight + Coolprep|Picolight (1p/250cc, 5PM) + Coolprep (500cc x 2, 8PM)[Day-Prior] Picolight (1p/250cc, 7PM) + Coolprep (500cc x 2, 5AM)[Split-Dose]
1641691|NCT01919255|Drug|Picolight + Clicolon|Picolight (1p/250cc, 5PM) + Clicolon (4T x 4, 8PM) [Day-Prior] Picolight (1p/250cc, 7PM) + Clicolon (4T x 4, 5AM)[Split-Dose]
1641692|NCT01919242|Procedure|gastrectomy|gastrectomy with D1 + lymph node dissection for clinically early gastric cancer, and gastrectomy with D2 lymph node dissection for clinically advanced gastric cancer
1641693|NCT01919229|Drug|LEE011 (ribociclib)|Ribociclib was supplied in 200 mg hard gelatin capsules for oral use.
1641694|NCT01919229|Drug|letrozole|Letrozole was supplied in 2.5mg tablets for oral use.
2012348|NCT02060383|Drug|Pasireotide s.c.|To be administered to Cushing's patients
1641696|NCT01919203|Drug|Remifentanil|The starting dose of remifentanil is 0.5μg/kg and a step size is 0.05μg/kg. If LMA insertion is successful or failed in previous patient, an decrement or increment of 0.05μg/kg remifentanil is injected to next patient, respectively.
2012349|NCT02060383|Drug|Sitagliptin|Taken for 16 weeks or until the drug is found to be not effective
2012350|NCT02060383|Drug|Liraglutide|Patient will switch to liraglutide if sitagliptin is found to be inefficacious.
1641699|NCT01919177|Dietary Supplement|Nitrate rich beetroot juice|Subjects will receive 140 mL of Nitrate-rich concentrated beetroot juice.
1641700|NCT01919177|Dietary Supplement|Nitrate depleted beetroot juice|Subjects will receive 140 mL of nitrate-depleted beetroot juice.
2012351|NCT02060383|Drug|Insulin|Patient will take insulin for 16 weeks.
2012352|NCT02060383|Drug|Pasireotide LAR|To be administered to acromegaly patients
2012353|NCT02060383|Drug|Metformin|If previously normo-glycemic patients experience increases in their fasting blood glucose and meeting the criteria for diabetes while on pasireotide, they will start anti-diabetic treatment using metformin. If they continue to experience increases in their fasting blood glucose within the first 16 weeks, they will be randomized in a 1:1 ratio to receive treatment with incretin based therapy or insulin for approximately 16 weeks.
2012354|NCT02059148|Drug|LY2835219|Administered orally.
2012355|NCT02057354|Behavioral|Aerobic Exercise|The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.
2012356|NCT02057354|Behavioral|Non-Aerobic Exercise|The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
1641707|NCT01919125|Drug|IDX719|IDX719 supplied as 50 mg tablets.
1641708|NCT01919112|Device|tDCS|Anodal tDCS will be administered with swallowing exercises
1641709|NCT01919086|Drug|Bortezomib|Bortezomib SC (or IV if SC not tolerated) 1.5 mg/m^2, days 1, 8, 15 and 22
1641710|NCT01919086|Drug|Dexamethasone|Dexamethasone 40 mg PO or IV days 1, 4, 8,15 and 22 or on a split-dose regimen. (20mg BIW).
1641711|NCT01919086|Drug|Lenalidomide|Lenalidomide may be added to the patient's regimen at any time if there is evidence of hematologic disease progression
1641712|NCT01919073|Behavioral|Immediate Treatment Group|•The immediate treatment group will fill out the questions at the initial appointment and again after five treatment appointments. They will fill the questions out again at the first follow-up treatment appointment (approximately 4-5 months from the initial appointment), and then at the next (and last) follow-up appointment (approximately 7-8 months). The participants teacher will also be asked to fill out sets of questions.
1641713|NCT01919073|Behavioral|Delayed Treatment Group|•The wait list group will fill out the sets of questions again in 1-2 months. The question sets will then be completed again before beginning treatment four months from the initial completion and then again after five treatment appointments. The question sets will then be completed again at the first follow-up treatment appointment (approximately 8-9 months from the initial appointment) and at the next (and last) follow-up appointment (about 11-12 months from the initial appointment).
1641714|NCT01919047|Drug|Betanis|Oral
1641715|NCT01919021|Other|Magnetic Resonance Imaging MRI|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
1641716|NCT01919021|Other|Gamma Scintigraphy|400ml of milkshake and 12 agar beads are ingested and gamma scintigraphy scanning completed to document gastric emptying and outcome measures listed earlier.
1641717|NCT01919021|Procedure|Assessment of Gastric motor and sensory function|
2012357|NCT02056314|Other|electronic tutorial|The electronic tutorial will provide information to the participants about the nature of gambling, and how to protect themselves against the risks of problem gambling including information on coping skills, and myths associated with gambling.
2012358|NCT02056314|Other|brochure|The brochure is the current means of informing people about the risks of problem gambling. It includes information about problem gambling and help resources.
2012359|NCT02048813|Drug|Cyclophosphamide|Given IV
2012360|NCT02048813|Drug|Fludarabine Phosphate|Given IV
2012361|NCT02048813|Drug|Ibrutinib|Given PO
1641721|NCT01918956|Biological|PURETHAL Birch, 20.000 AUM/ml|comparison of different up-dosing regimes
1641722|NCT01918943|Device|PLIF and Aspen (spinous process fixation device)|Circunferential fusion with PLIF and postero-lateral fusion with the Aspen device
1641723|NCT01918930|Biological|MGA271|MGA271 anti-B7-H3 monoclonal antibody
1641724|NCT01918917|Drug|Levobupivacaine|intraarticular
1641725|NCT01918917|Drug|Dexmedetomidine|intraarticular 1 ml (100 mcg)
1641726|NCT01918917|Drug|Morphine|intravenously, patient-controlled analgesia
1641727|NCT01918904|Drug|Sodium thiosulfate|A small amount of 25% topical sodium thiosulfate cream twice daily (bid)
1641728|NCT01918904|Drug|Placebo|A small amount of topical zinc oxide and aquaphor cream twice daily (bid)
1641729|NCT01918891|Behavioral|Nurse Practitioner Only|
1641730|NCT01918891|Behavioral|Nurse Practitioner + Health Coach|
1641731|NCT01918878|Drug|Aflibercept (EYLEA)|INTARAVITREAL INJECTION OF AFLIBERCEPT
1641732|NCT01918865|Drug|ISIS-PTP1BRx|
1641733|NCT01918865|Drug|Placebo|
1641734|NCT01918865|Drug|daily OAD (metformin and/or sulfonylurea)|
1641735|NCT01918852|Drug|Capecitabine|
1641736|NCT01918852|Drug|Teysuno|
1641737|NCT01918852|Drug|Bevacizumab|
1641738|NCT01918839|Device|VINCI Plus|VINCI Plus 1ml injected into wrinkle treatment area
1641739|NCT01918839|Device|Restylane-L|Restylane-L injected into wrinkle treatment area
1641740|NCT01918826|Device|TENS|
2012362|NCT02048813|Other|Laboratory Biomarker Analysis|Correlative studies
1641742|NCT01918800|Behavioral|Fatigue: Take control|Fatigue: Take Control, is the first formal education program modeled on the MS-related fatigue guideline
1641743|NCT01918800|Behavioral|MS: Take Control|MS: Take Control includes topics of interest to people with MS other than fatigue.
1641744|NCT01918787|Device|repetitive TMS|rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control
2012363|NCT02048813|Other|Pharmacogenomic Study|Correlative studies
1641746|NCT01918761|Drug|Dacomitinib, Pemetrexed|Pemetrexed 500mg/m2 iV (q21d) Dacomitinib 45mg orally (continuous)
1641747|NCT01918748|Device|Haptic Master|The Haptic Master (HM) is a haptic device controlled according to the principles of 'admittance control'. In admittance control 'force' applied to the system (i.e. the HM arm) is measured, while 'position' (of the HM arm) is the end result.
1641748|NCT01918735|Drug|Placebo|Placebo control matched to the oral or intravenous experimental comparator drug
1641749|NCT01918735|Drug|GWP42006|"Oral administration of 25 (Group/dose level 1a and 1b), 75 (Group/dose level 2a and 2b), 200 (Group/dose level 3a and 3b) and 400 mg GWP42006 (Group/dose level 4a and 4b), provided as 50 mg/mL GWP42006 solution in sesame oil containing flavourings and sweetener, for dilution on the day of dosing, as required.
Additional intravenous administration of 5 mg GWP42006 and 10 mL Solutol HS 15 solution to Group/dose level 3a and 3b subjects."
1641750|NCT01918722|Drug|ICH-1(herbal medicine with Hirudo, Tabanus)|8herbals (with 2 herbals of Activating blood stagnation and expelling blood stasis herbs) one dose, bid, for 10 days
1641751|NCT01918722|Drug|placebo|placebo herbal medicine, one dose,bid, for 10 days
1641752|NCT01918722|Drug|ICH-2(herbal medicine without Hirudo, Tabanus)|(6herbals, without 2 herbals of promoting blood stasis) one dose, bid, for 10 days
1641753|NCT01918709|Drug|Sequence 1 : Period 1(V) Period 2(R) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
1641754|NCT01918709|Drug|Sequence 2 : Period 1(V+R) Period 2(V) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
1641755|NCT01918709|Drug|Sequence 3 : Period 1(R) Period 2(V+R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
1641756|NCT01918709|Drug|Sequence 4 : Period 1(V+R) Period 2(R) Period 3(V)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
1641757|NCT01918709|Drug|Sequence 5 : Period 1(R) Period 2(V) Period 3(V+R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
1641758|NCT01918709|Drug|Sequence 6 : Period 1(V) Period 2(V+R) Period 3(R)|Valsartan = Antihypertensive drug / Rosuvastatin = Antihyperlipidemic drug
1641759|NCT01918696|Behavioral|Anger Reduction Treatment|Eight 15-minute sessions of interpretation modification to reduce angry interpretation biases.
1641760|NCT01918696|Behavioral|Progressive Muscle Relaxation|Eight 15-minute sessions of progressive muscle relaxation (PMR) including formulation of a plan to use PMR when angry.
1641761|NCT01918696|Behavioral|Control Condition|Eight 15-minute sessions of informative videos on healthy living.
1641762|NCT01918683|Radiation|TACE transarterial chemoembolization|
1641763|NCT01918683|Radiation|stereotatic body radiotherapy (SBRT)|
1641764|NCT01918670|Procedure|catheter ablation of atrial fibrillation|electric pulmonary vein disconnection
1641765|NCT01918657|Drug|walnut powder|Subjects will be randomized in a 2:1 ratio into either an active treatment group (final dose 1500 mg walnut protein, n=20) or a placebo group (n=10). Subjects will undergo a one-day desensitization protocol designed to enable the subject to tolerate 6 mg of walnut protein or placebo (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of walnut protein or placebo, dosing build-up will occur every two weeks through dose 24 at 34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment and escalated as described to the 1500 mg target dose.
2012364|NCT02048813|Other|Quality-of-Life Assessment|Ancillary studies
2012365|NCT02048813|Biological|Rituximab|Given IV
2012366|NCT02047890|Drug|BAY1000394 (2.5mg)|BAY1000934 2.5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 1)
2012367|NCT02047890|Drug|BAY1000394 (5mg)|BAY1000934 5mg twice a day (bid) in a 3 days on and 4 days off schedule. (Cohort 2)
2012368|NCT02047708|Drug|Zibotentan|Selective endothelin-A antagonist
1641767|NCT01918644|Radiation|stereotactic body radiation therapy|Undergo SBRT
1641768|NCT01918644|Drug|capecitabine|Given PO
1641769|NCT01918644|Procedure|therapeutic conventional surgery|Undergo definitive surgery
1641770|NCT01918644|Procedure|magnetic resonance imaging|Optional correlative studies
1641771|NCT01918644|Other|laboratory biomarker analysis|Optional correlative studies
1641772|NCT01918631|Drug|tenofovir disoproxil fumarate|
1641773|NCT01918631|Drug|Entecavir|
1641776|NCT01918592|Device|MRI/acetate-PET imaging|
1641777|NCT01918579|Procedure|Patients will be tested by rapid POC CRP test|Patient will be tested with CRP test. Treatment decisions including any antibiotics prescribed will be based on test results and clinical judgement. Treatment choices are not recommended/prescribed by the study protocol.
1641778|NCT01918566|Dietary Supplement|tap water|
1641779|NCT01918566|Dietary Supplement|Single intragastric instillation of 75g Glucose in 300ml tap water via nasogastric tube|
1641780|NCT01918566|Dietary Supplement|Single intragastric instillation of 75g Glucose in 300ml tap water with 450ppm lactisole|
1641781|NCT01918566|Dietary Supplement|25g Fructose in 300ml tap water|
1641782|NCT01918566|Dietary Supplement|75g glucose in 300ml tap water with 600pmol/kg/min exendin 9-39|
1641783|NCT01918566|Dietary Supplement|300ml tap water with 450ppm lactisole|
1641784|NCT01918553|Other|clinical parameters|
1641785|NCT01918553|Other|visual acuity exams|
1641786|NCT01918553|Other|retinophotography|
1641787|NCT01918553|Other|SD-OCT|
1641788|NCT01918553|Other|Intra ocular Pressure (IOP)|
1641789|NCT01918553|Other|retinal imaging (OPTOMAP)|
1641790|NCT01918553|Other|axial length (IOL master)|
1641791|NCT01918540|Procedure|Hollow Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
1641792|NCT01918540|Procedure|Solid Centralizer|The stem used (MS30)was originally designed with a solid centralizer but has been redesigned to be used with a hollow centralizer. The patients are randomized to either solid or hollow centralizer
1641793|NCT01918540|Device|MS-30 femoral stem|This is the stem used in the study.
1641794|NCT01918527|Drug|Capecitabine|Orally on days 1-14: 2000 mg/m2/day q3w
1641795|NCT01918527|Drug|Oxaliplatin|Intravenously on day 1: 130 mg/m2 q3w
1641796|NCT01918514|Drug|Adding Magnesium Sulfate to the standard epidural and interscalene blocks for chronic pain|
1641797|NCT01918501|Procedure|Blood testing|Blood sample will be taken once from 120 volunteers. The blood will be examine in a blind fashion, including 60 MS patients diagnosed by a neurologist based on clinical and MRI findings. The control group will include 50 age and gender match healthy volunteers and 10 more patients with unrelated neurological diseases
1641800|NCT01918475|Drug|Carbetocin|Carbetocin 0.1 mg single dose is intravenously administered
1641801|NCT01918475|Drug|Placebo|1ml of NaCl 0.9% is administered intravenously
1641802|NCT01918449|Other|Clinical follow up by general practitioners in primary care|The study evaluates two different setting to follow up patients with obstructive sleep apnea on CPAP treatment
1641803|NCT01918436|Behavioral|TEAMS intervention|In the child group the children are introduced to games that are designed to enhance inhibitory control, working memory, attention, visuospatial abilities, planning, and motor skills. The parent group consists of psychoeducation and instructions in how to encourage playing these games with their children and how to support the child's development.
1641804|NCT01918436|Other|Control group|The control groups receive the standard treatment program, outlined by the clinical guidelines of Region Zealand, Denmark.
1641805|NCT01918423|Behavioral|Lifestyle intervention during pregnancy|Energy requirements for each participants´ mother were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
1641806|NCT01918410|Device|Contact Lens with alginic acid|Worn for 7 days, at least 8 hours a day
1641807|NCT01918410|Device|Contact Lens without alginic acid|Worn for 7 days, at least 8 hours a day
1641808|NCT01918397|Drug|Levofloxacin|Levofloxacin is a quinolone antibiotic used to treat lung, sinus, skin, and urinary tract infections caused by bacteria. The chemical name is (-)-(S)-9fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4benzoxazine-6-carboxylic acid hemihydrate.
1641809|NCT01918397|Drug|Optimized background regimen (OBR)|"For this study OBR will mean optimized background regimen, not including a quinolone. OBR will be selected at the discretion of the study investigator to conform with standards of care and local site guidelines. In general, the OBR regimen should include at least 3 drugs (other than levofloxacin) to which the patient's isolate is not expected to be resistant, with one of these being an injectable agent, at the usual recommended doses."
1641810|NCT01918384|Drug|NPC-14|"NPC-14 will be administrated as following steps. The dose of NPC-14 will be calculated and adjusted by a non-blinded medical doctor and/or a non-blinded pharmacist.
An initial dose of NPC-14 will be half of that calculated by distribution volume：Vd based on patient age for safety reason.
After the initial administration, the dose of NPC-14 will be adjusted and maintained by actual Vd, therapeutic drug monitoring of peak serum levels of NPC-14"
1641811|NCT01918384|Drug|Placebo|Dose will be adjusted by volume of distribution (Vd) of patients in accordance with the NPC-14 dose regimen
1641812|NCT01918371|Drug|Anti-VEGF|Patients with retinal vein occlusion or diabetic macular edema receiving anti-VEGF injection(s) in accordance with standard of care practices. This is a retrospective chart review study.
1641813|NCT01918358|Drug|Sequence 1 : Period 1 (VR 160/20 mg-1), Period 2(VR 160/20 mg-2), Period (V+R)|
1641814|NCT01918358|Drug|Sequence 2 : Period 1 (VR 160/20 mg-2), Period 2 (V+R), Period 3 (VR 160/20 mg-1)|
1641815|NCT01918358|Drug|Sequence 3 : Period 1 (V+R), Period 2 (VR 160/20 mg-2), Period 3 (VR 160/20 mg-1)|
1641816|NCT01918358|Drug|Sequence 4 : Period 1 (VR 160/20 mg-1), Period 2 (V+R), Period 3 (VR 160/20 mg-2 )|
1641817|NCT01918358|Drug|Sequence 5 : Period 1 (VR 160/20 mg-2), Period 2 (VR 160/20 mg-1), Period 3 (V+R )|
1641818|NCT01918358|Drug|Sequence 6 : Period 1 (V+R), Period 2 (VR 160/20 mg-1), Period 3 (VR 160/20 mg-2)|
1641819|NCT01918345|Behavioral|Home-based Physical Activity Program with Health Coach|This arm will receive either a trained CDE or R. Kin as a health coach and a home-based physical activity program for 6 months. Health coaches will provide one-on-one motivational interviewing (MI) and goal-setting, and will account for baseline fitness, resources, childcare, and breastfeeding, to be undertaken at participants' homes or in their communities. Prescriptions will be based on minimum recommendations for moderate-intensity exercise for postpartum women. Participants will maintain at least 150 min/week of moderate activity at a target heart rate of 30-80% with a perceived exertion of 12-15 on the Borg Scale. They will also be counseled on resistance training and pelvic floor exercises. They will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
1641820|NCT01918345|Behavioral|Home-based Low-GI Diet Program with Health Coach|This arm will receive a trained CDE health coach and a home-based low-GI diet program for 6 months. Health coaches will provide baseline education during a one-on-one visit and use MI to introduce the dietary intervention. Low GI education will be layered on top of current standard care, which asks women to consume a diet comprised of 45-65% carbohydrates (25 g of dietary fibre), 10-30% protein, and 25-35% fat. As per standard care at the DEPs, this intake will be divided into 3 meals and 2 to 4 snacks. Resources for women will include a low GI dietary food substitution list, a recipe booklet, and a tip sheet on how to lower dietary GI. Women will receive regular telephone-based coaching to advance goals. Phone-calls will be administered on a weekly basis during weeks 2-8 of the intervention, biweekly basis on weeks 10-12, and monthly basis on weeks 16-24.
1641821|NCT01918332|Drug|Valsartan 160mg|
1641822|NCT01918332|Drug|Rosuvastatin 20mg|
1641823|NCT01918332|Drug|Valsartan 160mg placebo|
1641824|NCT01918332|Drug|Rosuvastatin 20mg placebo|
1641825|NCT01918319|Behavioral|Lifestyle intervention|Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week.
1641826|NCT01918306|Drug|cisplatin|"In Arm I patients receive cisplatin IV over 1 hour on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients may crossover to Arm II upon disease progression.
In Arm II patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 orally (PO) one time a day (QD) on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity."
1641827|NCT01918306|Other|laboratory biomarker analysis|correlative studies
1641828|NCT01918306|Other|pharmacological study|correlative studies
1641829|NCT01918306|Procedure|dynamic contrast-enhanced MRI, diffusion-weighted MRI & chemical exchange saturation transfer MRI|correlative studies
1641830|NCT01918306|Drug|GDC -0941|Patients receive cisplatin as in Arm I and PI3K inhibitor GDC-0941 PO QD on days 2-6, 9-13, 16-20, and 23-27. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity
1641831|NCT01918293|Device|SMART ARM|The smartphone application for self-management of Asthma offers symptom diary, general information for asthma, the information of asthma drugs,the guideline for inhaler and the specific action plan according to daily symptom and FEV1.
1641832|NCT01918280|Procedure|Seminal analyses and testicular biopsy|Two seminal analyses spaced out 3 months followed by a testicular biopsy if the azoospermia is confirmed on semen analyses.
1641833|NCT01918254|Drug|Paclitaxel|Paclitaxel IV infusion will be administered as per schedule described in individual arm.
1641834|NCT01918254|Drug|Pertuzumab|Pertuzumab IV infusion will be administered as per schedule described in individual arm.
1641835|NCT01918254|Drug|Lumretuzumab|Lumretuzumab will be administered as per schedule described in individual arm.
1641836|NCT01918241|Drug|pegfilgrastim,30mcg/kg|Two doses SC injection of 30 mcg/kg at postchemotherapy 48hr and 120hr in cycle 2.
1641837|NCT01918241|Drug|pegfilgrastim, 60mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
1641838|NCT01918241|Drug|pegfilgrastim, 100mcg/kg|Single SC injection of the appropriate dose of drug ranging from 60 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 2.
1641839|NCT01918241|Drug|filgrastim, 5mcg/kg|At least 7 days SC injection of 5 mcg/kg at postchemotherapy 48hr in cycle 2.
1641840|NCT01918228|Behavioral|Talks about what science says about LBP|Two talks, a folder with general stretching exercises and possibility to contact health professional by telephone
1641841|NCT01918215|Device|ICD|
1641842|NCT01918215|Device|ILR|
1641843|NCT01918202|Drug|20 mg PF-02545920|Subject will receive a single dose of 20 mg PF-02545920.
1641844|NCT01918202|Drug|PF-02545920|"The dose will be selected based on the results obtained for Cohort 1. Dose options range from 30 mg to 10 mg, 5 mg, 2mg, 1 mg.
This cohort is optional."
1641845|NCT01918202|Drug|PF-02545920|The dose will be selected based on the results obtained for Cohort 1 and cohort 2.
1641846|NCT01918189|Behavioral|behavioral pain self-management intervention Pain EASE|10 modules describing behavioral and cognitive pain coping skills such as relaxation and stress reduction methods, exercise and structured physical activity, and activity pacing
1641847|NCT01918176|Drug|Palbociclib alone|Single dose of 125mg Palbociclib capsule will be administered to subjects orally and then PK samples will be collected at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
1641848|NCT01918176|Drug|Palbociclib + Rabeprazole|Two Rabeprazole 20mg tablets will be given to subjects orally once daily for 7 days. Then on the same day at least 4 hours after the last dose of Rabeprazole, single dose of 125mg Palbociclib capsule will be given to subjects orally then followed by PK samplings at 1, 2, 4, 6, 8, 12, 24, 48, 72, 96 and 120 hours.
1641849|NCT01918163|Dietary Supplement|Pomegranate pills|
1642415|NCT01913639|Drug|Leucovorin|
1641850|NCT01918150|Device|Titan 2 stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
1641851|NCT01918150|Device|Cobalt-Chromium Bare Metal Stents|The intervention is called Percutaneous Coronary Intervention (PCI); Commonly known as coronary angioplasty or simply angioplasty, it is a non-surgical procedure used to treat the stenotic (narrowed) coronary arteries of the heart found in coronary heart disease. PCI is usually performed by an interventional cardiologist.
1641852|NCT01918137|Dietary Supplement|chocolate bar|
1641853|NCT01918137|Dietary Supplement|Porridge|
1641854|NCT01918124|Radiation|radiotherapy|Pelvic radiation to 45 Gy, 1.8 Gy per day, five days per week (25 fractions) or intensive modulated pelvic radiotherapy, with brachytherapy boost to the vagina if total abdominal hysterectomy and bilateral salpingo-oophorectomy was done in surgery, or with paraaortic radiation if paraaortic lymphnode metastases were found after surgery.
1641855|NCT01918124|Drug|Cisplatin|Two courses cisplatin (50mg/m2) given on days 1 and 28 during radiotherapy.
1641856|NCT01918124|Drug|Cisplatin and Doxorubicin and Cyclophosphamide|Four courses of cisplatin (50mg/m2) and doxorubicin (60mg/m2) and cyclophosphamide (600mg/m2) chemotherapy given at 3 week intervals following completion of radiotherapy.
1641857|NCT01918124|Drug|Paclitaxel and Carboplatin|Or four courses of Paclitaxel(135mg/m2) and carboplatin (AUC=5) given at 3 week intervals following completion of radiotherapy.
1641858|NCT01918111|Procedure|Renal denervation|Renal denervation will be performed via common femoral artery with standard endovascular technique and simplicity catheter
1641859|NCT01918111|Drug|adenosine infusion treatment|Continue hypertensive medication
1641860|NCT01918098|Drug|Oxycodone/naloxone prolonged release tablets|
1641861|NCT01918085|Other|Hydrocolloid strip|An adhesive strip made of hydrocolloid adhesive
1641862|NCT01918085|Other|Strata strip|An adhesive strip made of the Strata adhesive
1641864|NCT01918059|Procedure|Tissue Adhesive skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with tissue adhesive (octyl-2-cyanoacrylate).
1641865|NCT01918059|Procedure|Absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with absorbable sutures (surgical gut).
1641866|NCT01918059|Procedure|Non-absorbable suture skin closure|The approach to repair will follow standard technique. If eyelid marginal component is present, margin repair will be performed with two 6-0 interrupted silk sutures: one at the gray line and one at the lash line. If the tarsus requires reapproximation, this will carefully be done using interrupted polyglactin vicryl sutures. The superficial skin will then be repaired with either non-absorbable sutures (6-0 polypropylene).
1641867|NCT01918033|Drug|Desloratadine 5 mg|Desloratadine 5 mg tablets
1641868|NCT01918033|Drug|Placebo|Matching placebo to desloratadine 5 mg tablets
1641869|NCT01918020|Behavioral|Go Wild with Fruits and Veggies!|Fruits and Vegetables
1641870|NCT01918020|Behavioral|Go Wild with Fruits and Veggies! delayed|Go Wild with Fruits and Veggies! delayed
1641871|NCT01918007|Procedure|Adenotonsillectomy (AT)|Standard surgical intervention for treatment of Obstructive SDB.
1641872|NCT01917994|Behavioral|Text Messages|The intervention consists of supportive, informational, and motivational text messages three times a week targeting the following domains: promoting a sense of connectedness to the clinic, fostering social support, building empowerment, ameliorating negative affect, cultivating positive affect, and promoting healthy behaviors and adherence to antiretroviral medication.
1641873|NCT01917994|Behavioral|Appointment Reminders|
1641874|NCT01917981|Device|Personal Heart Rhythm Monitor|
1641875|NCT01917968|Device|Uphold Lightweight Vaginal Support System|Pelvic organ prolapse repair via transvaginal mesh (Uphold LITE)
1641876|NCT01917968|Procedure|Traditional native tissue repair|Sarcrospinous ligament fixation or uterosacral ligament suspension and/or colporrhaphy
1641877|NCT01917942|Device|Humidification|Fisher and Paykel Healthcare MR880 humidifier + HC211 flow source. 37/44 Humidification (37oC at 100% relative humidity, 44 mg of water per litre of air, 25 litres per min initial flow rate). The patients will be instructed to use humidification from day 1 of the radiotherapy course as much as is practical; the preference is for continuous overnight humidification plus maximal use throughout the day.Humidification will continue throughout treatment until at least week 8 after the commencement of radiotherapy and will cease when the CTCAE mucositis (clinical exam) score becomes less than grade 2, or at the week 16 assessment, whichever is earliest.
1641878|NCT01917942|Other|Standard of Care|SOC: institutional standard of care for the management of mucositis. SOC will be defined by each participating institution and be kept consistent at that institution for the duration of the study. In general, SOC will consist of rinsing with 50:50 salt bicarbonate of soda mouthwash; benzydamine mouthwash; appropriate analgesic, antimicrobial and antifungal protocols etc.
1641879|NCT01917929|Device|Secur-Fit Advanced Hip Stem|Straight femoral stem intended for cementless, press-fit application.
1641880|NCT01917916|Drug|Placebo|Placebo
1641881|NCT01917916|Drug|BI 655064|
1641882|NCT01917916|Drug|BI 655064|
1641883|NCT01917916|Drug|BI 655064|
1641884|NCT01917916|Drug|Placebo|Placebo
1641885|NCT01917916|Drug|BI 655064|
1641886|NCT01917916|Drug|Placebo|
1641887|NCT01917916|Drug|Placebo|Placebo
1641888|NCT01917903|Behavioral|Gait-cognitive training|Participants will engage in a four week treadmill training program with a secondary cognitive component aimed at improving both walking and multitasking.
1642416|NCT01913639|Drug|Oxaliplatin|
1641889|NCT01917903|Behavioral|Identification of at risk variables|Participants will complete walking under three conditions: walking alone, walking while talking to an investigator in person, and walking while talking to an investigator on a cell phone. Spatiotemporal measures of gait will be collected.
1641890|NCT01917890|Dietary Supplement|Curcumin|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
Patients take 3 grams of BCM95 Curcumin (as 6 × 500 mg capsules)"
1641891|NCT01917890|Dietary Supplement|Placebo|"Patients undergo 74 Gy of intensity-modulated radiotherapy 5 times a week for 7-8 weeks.
Patients take 3 grams of roasted rice powder (as 6 × 500 mg capsules)"
1641892|NCT01917877|Drug|Bevacizumab|Bevacizumab 7mg/kg iv on day1 and 21, followed by Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
1641893|NCT01917877|Drug|Dexamethasone|Dexamethasone 10mg iv d 1-10, then 5mg iv d11-15, 2.5mg iv d16-20
1641894|NCT01917864|Behavioral|iPad Application|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
1641895|NCT01917838|Behavioral|MFG plus MyMFG|"Specific aim is to utilize mHealth to improve the Design and Do process of HW within the context of the Family Groups for Youth with Behavioral Difficulties (MFG) intervention, an EBT for DBDs in youth and their families who seek assistance at outpatient mental health clinics in urban communities.
The first component focuses on delivering HW via a highly engaging, multiplayer, interactive, cooperative, and skill-building game platform aimed at improving the Design and Do process of HW. The second component focuses on targeting factors putatively related to poor HW implementation within the Do process."
1641896|NCT01917825|Drug|MDT-15|
1641897|NCT01917812|Device|Digital Activity Tracker|
1641898|NCT01917812|Other|Smart Text Messaging|
1641899|NCT01917799|Drug|Aspirin|75mg tab of LDA once daily for 7 months
1641900|NCT01917799|Drug|Heparin|0.4 mL/day of the Enoxaparin
1641901|NCT01917786|Device|ECG|
1641902|NCT01917773|Drug|Octreotide|Average MI for all patients was calculated over 15-minutes, 30-minutes and 45- minutes before and after administration of octreotide
1641903|NCT01917773|Drug|Bisacodyl|
1641904|NCT01917747|Behavioral|Patient Navigator|The patient navigator group will involve regular phone contact with the patient navigator. The patient navigator will contact the participant by phone to conduct an interview and provide education on infant hearing and diagnostic hearing services. The timing of the subject child's appointment and the instructions of the outpatient auditory brainstem response test are discussed. In the second part of the study, further educational tools are given to parent(s) and discussion of additional follow up mechanisms, including community hearing services and types of interventions for pediatric hearing loss is imparted.
1641905|NCT01917747|Behavioral|Standard scheduling and follow-up|The subjects will have access to discuss any questions or concerns with our office or audiology staff, as is the standard of care practice. They will not be contacted by study personnel or the patient navigator after discharge from the hospital and before the initial diagnostic test or before any subsequent auditory brainstem response test. The patients may contact and be contacted by our clinic staff regarding scheduling or rescheduling of the hearing test, as is standard practice.
1641906|NCT01917734|Other|Therapeutic feeding for children with SAM|Comparison of outcomes between children with complicated SAM and children with uncomplicated SAM as well as comparisn of outcomes against national and internationally agreed upon standards of care
1641907|NCT01917721|Drug|Doxycycline|The interventional arm of the study will receive doxycycline 4.4 mg/kg/day for 14 days besides receiveing standard care: IVIG and/or Remicade.
1641908|NCT01917721|Drug|Standard care|Standard medical care will be provided to the comparative arm of the study administering IVIG and/or Remicade, but not doxycycline.
1641909|NCT01917708|Drug|Abatacept|All patients will receive 4 doses of abatacept in addition to standard GVHD prophylaxis with cyclosporine and mycophenolate mofetil.
1641910|NCT01917695|Drug|Chemotherapy|cisplatin 75 mg/m2 Paclitaxel 175 mg/m2
1641911|NCT01917695|Radiation|External Beam Radiotherapy|50 Gy/2 Gy/25 # external beam RT to cervix. four field technique. given concurrently with chemotherapy weeks 1 - 5
1641912|NCT01917695|Radiation|Brachytherapy|Ir - 192 HDR Brachytherapy - intracavitary. 7Gy x 3#. given after completion of chemoRT.
1641913|NCT01917695|Procedure|Radical Hysterectomy|Type III Radical Hysterectomy + Bilateral Pelvic Node Dissection
1641914|NCT01917682|Procedure|CorPath-assisted Percutaneous Coronary Intervention|Robotic-assisted Percutaneous Coronary Intervention
1641915|NCT01917656|Drug|liraglutide|1.8 mg administered subcutaneously (s.c., under the skin) once daily
1641916|NCT01917656|Drug|metformin|Subjects will continue on their pre-trial metformin tablet treatment, dose unchanged
1641917|NCT01917656|Drug|sulphonylurea|Subjects will continue on their pre-trial SU tablet treatment, doses unchanged
1641918|NCT01917630|Drug|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase)
1641919|NCT01917630|Drug|placebo|
2012369|NCT02047357|Other|Learning Through Play Plus|Learning Through Play (LTP) Plus is a low-literacy, sustainable program intended to provide parents with information on the healthy growth and development of their young children. The LTP research-based activities enhance children's development while simultaneously promoting attachment security through building parents' ability to read and be sensitive to their children's cues and through active involvement in their children's development. Plus the Thinking Healthy Program (THP) which adopts 'here and now' problem-solving approach. THP uses cognitive behavior therapy (CBT) techniques of active listening, changing negative thinking, and collaboration with the family.
1641922|NCT01917604|Procedure|open exposure|the open surgical methods of exposing the canine is compared with control
1641923|NCT01917604|Procedure|closed exposure|closed exposure is compared with control
1641924|NCT01917591|Device|Punch biopsies treated with MariGen Wound ECM dressing|Weekly dressing changes and review of wounds.
1641925|NCT01917591|Device|Punch biopsies treated with Oasis ECM dressing|Weekly dressing changes and wound review
1641954|NCT01917409|Device|conventional laryngoscopy|the device is to assist nasotracheal intubation
1641926|NCT01917578|Device|Ultrasound|"Evaluation of the tumor size by sonography is performed before neoadjuvant chemotherapy and prior to surgery.
Measurement of tumor size refers to WHO standards."
1641927|NCT01917578|Procedure|CNB|Typically, the pretreatment tumor specimen will be a core needle biopsy. Because 15% to 28% of patients will have no residual tumor after NAT, it is important to have an adequate pretreatment sample in which an unequivocal diagnosis of invasive carcinoma is established and evaluation of hormone receptors and HER2/ neu status is completed before treatment.
1641928|NCT01917578|Procedure|BCS, Modified Radical Mastectomy|All patients after neoadjuvant chemotherapy are performed BCS and modified radical mastectomy.
1641929|NCT01917578|Device|Pathologic Large Tissue Selected Table|"Pathologic large tissue selected table has obtained Chinese patent.Its license ID is CN101261200.
Each piece of breast tissues by cutting with the table has 3mm thickness."
1641930|NCT01917578|Device|Leica TP1020|"Procedure:
Alcohol 70 % 1h
Alcohol 80 % 1h
Alcohol 85 % 1h
Alcohol 90 % 1h
Alcohol 95 % 1h
Alcohol Ⅰ 100 % 1h
Alcohol Ⅱ 100 % 1h
Xylene Ⅰ 2h
Xylene Ⅱ 2h
Xylene Ⅲ 2h
Paraffin 6h
Paraffin 6h"
1641931|NCT01917578|Device|Pathologic Large Tissue Embedded Table|"The table is made of brass .It is applying for a chinese patent.
The table can simultaneously embed 8 piece of breast tissues."
1641932|NCT01917578|Device|Leica SM2000 R|Each of paraffin section has 4 um thickness.
1641933|NCT01917578|Procedure|HE Stain|"Procedure:
Xylene Ⅰ 60℃ 15-20 minutes
Xylene Ⅱ 60℃ 15-20 minutes
Alcohol 100% Ⅰ 3-5 minutes
Alcohol 100% Ⅱ 3-5 minutes
Alcohol 95% Ⅱ 3-5 minutes
Alcohol 90% Ⅱ 3-5 minutes
Wash in running tap water for 3 minutes
Hematoxylin 5-10 minutes
Wash in running tap water for 3 minutes
Differentiate in 1% acid alcohol for 30 seconds
Wash in running tap water for 1 minute
Bluing in 0.2% ammonia water for 30-60 seconds
Wash in running tap water for 3 minutes
Counterstain in eosin Y solution for 30-60 seconds
Wash in running tap water for 1 minute
Alcohol 90% Ⅱ 2-3 minutes
Alcohol 95% Ⅱ 2-3 minutes
Alcohol 100% Ⅱ 3-5 minutes
Alcohol 100% Ⅱ 3-5 minutes
Xylene Ⅲ 5-10 minutes
Xylene Ⅳ 5-10 minutes
Mounting with neutral resin"
1641934|NCT01917578|Device|CX22|The residual tumor areas are microscopically outlined on each slice by pathologist.
1641935|NCT01917578|Device|Epson V600|"Each slice that has been microscopically outlined is scanned by Epson V600.
Every image by scanning should be saved as JPG."
1641936|NCT01917578|Device|MRI|"Evaluation of the tumor size by MRI was performed before neoadjuvant chemotherapy and prior to surgery.
Measurement of tumor size refers to WHO standards.
The images of patients which were scanned by MRI should be burned onto disc for 3d reconstruction."
1641937|NCT01917578|Procedure|Three-Dimensional Reconstruction|"A.Pathological images three-dimensional reconstruction:
Pathological images registration is based on skin and shear mark by Photoshop 13.0 software.
Residual tumor boundary on Pathological images after registration are outlined and taken three-dimensional reconstruction by 3D-doctor 4.0 software.
Observe the shrinkage modes in three-dimensional space.
According to WHO standard,the boundaries of all residual tumor images are displayed in one plane and the longest diameter and its longest perpendicular diameter of boundaries are measured in one-dimensional space.
According to RECIST standard,the longest diameter of boundaries of residual tumor images in three-dimensional space.
B.MRI images three-dimensional reconstruction:the procedure is similar to Pathological images three-dimensional reconstruction"
1641938|NCT01917578|Device|Mammography|"Evaluation of the tumor size by mammography is performed before neoadjuvant chemotherapy and prior to surgery.
Measurement of tumor size and calcification extent refers to WHO standards.
Calcification extent is not only measured in mammography image but also under microscope."
1641939|NCT01917578|Drug|TAC,TC,TA,CAF,CEF|"TAC:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 3 cycles)
TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 2 cycles)
TA:Docetaxel 75 mg/㎡ iv day 1 + Doxorubicin 50 mg/㎡ in day 1(Cycled every 21 days for 2 cycles)
CAF:Cyclophosphamide 100 mg/㎡ po days 1-14 + Doxorubicin 30 mg/㎡ iv days 1,8 +5-fluorouracil 500 mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)
CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 3 cycles)"
1641940|NCT01917578|Drug|AC-P,TEC,AC,TC,TCH,CEF,TAC,CAF|"AC-P:Doxorubicin 60 mg/㎡ iv day 1 +Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 14 days for 4 cycles)→ Paclitaxel 175mg/㎡ by 3h iv infusion day 1(Cycled every 14 days for 4 cycles) or Paclitaxel 80mg/㎡ by 1h iv infusion weekly for 12 wks.
TEC:Docetaxel 75 mg/㎡ iv day 1 + Epirubicin 75 mg/㎡ in day 1 + Cyclophosphamide 500 mg/㎡ iv day 1(Cycled every 21 days for 6 cycles)
AC:Doxorubicin 60 mg/㎡ in day 1 + Cyclophosphamide 600 mg/㎡ iv day 1(Cycled every 21 days for 4 cycles)
TC:Docetaxel 75 mg/㎡ iv day 1 + Cyclophosphamide 600 mg/㎡in day 1(Cycled every 21 days for 4 cycles)
TCH:Docetaxel 75 mg/㎡ iv day 1 + Carboplatin AUC 6 iv day1(Cycled every 21 days for 6 cycles) + Trastuzumab 4 mg/kg iv wk 1 → Trastuzumab 2 mg/kg iv for 17 wks → Trastuzumab 6 mg/kg iv every 3 wks to complete 1 year.
CEF:Cyclophosphamide 75 mg/㎡ po day 1-14 + Epirubicin 60 mg/㎡ iv days 1,8 + 5-fluorouracil 500mg/㎡ iv days 1,8(cycled every 28 days for 6 cycles)"
1641941|NCT01917552|Drug|capecitabine|capecitabine 1250 milligram (mg) / m² po bid (D1-14)
1641942|NCT01917539|Device|Sham Treatment|Sham light treatment will consist of applying the usual eye shields used for PLT, applying the usual skin gel to the facial region, and applying the cooling probe without application of pulsed light therapy treatment.
1641943|NCT01917539|Device|Pulsed Light Therapy|Light treatment will consist of applying eye shields used for PLT, applying the skin gel to the facial region, and applying the probe with application of pulsed light therapy treatment.
1641944|NCT01917526|Device|oxygen mask|
1641945|NCT01917526|Device|oxygen cannula|
1641946|NCT01917513|Device|G-EYE™ colonoscopy|G-EYE™ colonoscopy
1641947|NCT01917513|Device|Standard Colonoscopy|Standard Colonoscopy
1641948|NCT01917474|Dietary Supplement|low lipid diet|Patients will receive a diet of about 2000 kcal daily with no more than 20 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
1641949|NCT01917474|Dietary Supplement|normal lipid diet|Patients will receive a diet of about 2000 kcal daily with 28 % of the total energy coming from lipids, mainly from the monounsaturated olive oil
1641950|NCT01917448|Drug|Morphine|spinal morphine 0.15 mg
1641951|NCT01917448|Other|control|Patient receive only local infiltration without spinal analgesia
1641952|NCT01917435|Device|video-stylet|
1641953|NCT01917435|Device|fiberoptic bronchoscope|
1716843|NCT00001499|Drug|paclitaxel|
1641955|NCT01917409|Device|video-stylet|the device is to guide the nasotracheal tube into trachea
1641956|NCT01917396|Drug|Fleet enema|
1641957|NCT01917383|Drug|Trabodenoson|Ophthalmic eye drop
1641958|NCT01917383|Drug|Latanoprost|Ophthalmic eye drop
1641959|NCT01917383|Drug|Timolol|Ophthalmic eye drop
1641960|NCT01917370|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
1641961|NCT01917357|Biological|Quinvaxem in Uniject|
1641962|NCT01917357|Biological|Quinvaxem in single dose vials|
1641963|NCT01917344|Other|MRI|
1641964|NCT01917331|Drug|Beclometasone/Formoterol/Glycopyrrolate|Active drug tested
1641965|NCT01917331|Drug|Beclometasone/Formoterol|Active comparator
2012370|NCT02046915|Drug|Imnovid (pomalidomide)|
2012371|NCT02046915|Drug|Dexamethasone|
1641968|NCT01917305|Device|platform-shifted implant|
1641969|NCT01917292|Procedure|One-Stage Full-Mouth Disinfection|"Basic oral hygiene instructions
Dental extractions will be performed (only in cases of teeth that could not be saved)
Standard cycle of supragingival ultrasonic scaling and polishing
Scaling and root planning after the administration of local anesthesia, four quadrants in one session
Minocycline Hydrochloride Ointment (Periocline, OraPharma) were delivered locally into the periodontal pockets"
1641970|NCT01917292|Procedure|Periodontal care|"Basic oral hygiene instructions
Standard cycle of supragingival ultrasonic scaling and polishing"
1641971|NCT01917279|Drug|Docetaxel plus Capecitabine|Eligible patients will receive treatment with Capecibatine (1000 mg/ m2 twice daily D1-14 Q3W) plus docetaxel(75 mg/m2, D1,Q3W) for a maximum of 6 cycles, or be treated until disease progression, unacceptable toxicity or patient request for withdrawal, whichever occurs first. Each cycle is 3 weeks in duration For the the patients with SD, PR or CR after initiate treatment phrase will enter into maintenance treatment phase.
1641972|NCT01917279|Drug|Capecitabine|Capecitabine 500 mg/m2 three times daily on days 1-21 of each 3-week cycle
1641973|NCT01917279|Drug|Capecitabine|Capecitabine 1000 mg/m2 twice daily on days 1-14 of each 3 week cycle
1641974|NCT01917253|Device|Standard Device for peripheral vein cannulation|
1641975|NCT01917253|Device|Long Catheters for peripheral vein cannulation|
1641976|NCT01917240|Other|Comprehensive Chromosome Screening|On day 5 or 6 of embryo development, all embryos will undergo a trophectoderm biopsy using the standardized technique, as according to standard laboratory protocol and without regard to study. Comprehensive Chromosome Screening (CCS) results will be available by the morning of day 6 if embryos are suitable for a fresh transfer which is the routine in our program.
1641977|NCT01917227|Behavioral|Video|
1641978|NCT01917214|Other|Sutent: Observational Study|Sutent oral therapy
1641979|NCT01917201|Procedure|IVUS-guided group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under IVUS-control: a choice of length and diameter of stent - according to IVUS data. After the completion of implantation and postdilatation of stents the control IVUS is being used. If criteria of optimal implantation were not achieved, additional impact is being made: larger balloon, higher pressure, sufficient time of impact. In case of an additional impact the repeated control IVUS is being completed and the following results are being fixed. After control IVUS the OCT procedure is carried out. During OCT possible problems corresponding to stenting are being fixed. An additional impact based on OCT data is not being used."
1641980|NCT01917201|Procedure|Non-IVUS group|"The randomization on groups was completed in accordance with stents to be implanted: Xience Prime/Xience V, Promus Element, Resolute Integrity, Biomatrix Flex, Nobori, Orsiro. In each group randomization on subgroups of IVUS-guided implantation and non-IVUS in the ratio 2:1 was completed. After randomization it is carried out coronary stenting under angiography control. After postdilatation control OCT is carried out. During OCT possible problems corresponding to stenting (malapposed struts, separate beams, a prolapse of fiber, microthrombosis) are being fixed. An additional impact based on OCT data is not being used."
2012372|NCT02046915|Drug|Endoxan (Cyclophosphamide)|
2012373|NCT02045303|Device|Contact Ultrasound Therapy|Following our protocol, the ultrasound wound therapy will start with contact ultrasound until it meets criteria to switch to noncontact ultrasound therapy.
1641983|NCT01917162|Device|Nelfilcon A contact lens|Soft contact lens CE-marked for daily disposable wear.
1641984|NCT01917162|Device|UltraFilcon B contact lens|Silicone hydrogel soft contact lens CE-marked for daily disposable wear. Private-label versions may be used.
1641985|NCT01917149|Drug|Benazepril|
1641986|NCT01917149|Drug|Valsartan|
1641987|NCT01917149|Drug|Metoprolol|
1641988|NCT01917136|Drug|11C-acetate|For each PET/CT imaging session subjects will receive a 15-25 millicurie intravenous injection of 11C-acetate
1641989|NCT01917136|Drug|[18F]Fluoro-2-deoxy-2-D-glucose|For each PET/CT imaging session subjects will receive a 10 millicurie injection of 18F-FDG
1641990|NCT01917136|Other|Cardiac MRI|Cardiac MRI is performed at 6 months to measure any change in structure and function of the treatment groups.
1641991|NCT01917123|Drug|L-Citrulline malate|L-Citrulline malate as a 1gr powder agent, twice a day, for 2 weeks and placebo as a 1gr powder agent of O.R.S, twice a day,for 2 weeks
1641992|NCT01917110|Device|omafilcon A|
1641993|NCT01917110|Device|Spectacle|
1641994|NCT01917097|Drug|Dexmedetomidine|
1641995|NCT01917084|Other|Passive range of motion (ROM) exercise|After their Norwood surgery, stable subjects will undergo passive ROM exercise therapy for up to 21 consecutive days or until hospital discharge, whichever comes first. Subjects will have completed the study after their anthropometric measurements are collected at 3 months of age
1641996|NCT01917071|Other|thoracic spine manipulation|a manual technique applied to the mid back to promote motion
1642244|NCT01915095|Device|rTMS|small magnetic pulses will be given to the brain in a non invasive manner.
2012374|NCT02045303|Device|Noncontact Ultrasound Therapy|Transition from contact to noncontact ultrasound when criteria for transition is met per our protocol.
1641997|NCT01917058|Drug|Abatacept|"This will be a randomized double blind placebo controlled study. Patients will be randomly assigned to abatacept or placebo in a 1:1 ratio based on a computer generated randomization list. The list will be generated prior to study initiation. Based on the randomization list, patients will be assigned to treatment vs. vehicle (provided by BMS) in the order in which they are enrolled. The assignment will be made by study personnel who are not involved in making clinical assessments or evaluations. The patient and the assessing physicians will remain blinded to the treatment assignment for the duration of the study.
Patients will be treated with abatacept 125mg SC self-administered each week. Treatment will be continued for 6 months to provide adequate time to assess the short-term efficacy and safety of abatacept in patients with alopecia areata. Patients will then be followed for an additional 6 months to assess the timing and incidence of relapse."
1641998|NCT01917058|Drug|placebo|
1641999|NCT01917045|Drug|Sufentanil (R30730, brand name Sufenta)|sufentanil 1ug/ml
1642000|NCT01917045|Drug|Sufentanil (R30730, brand name Sufenta) + Morphine|sufentanil 0.5ug/ml+morphine 0.25mg/ml
1642001|NCT01917045|Drug|Morphine|morphine 0. 5mg/ml
1642002|NCT01917032|Dietary Supplement|Sachets containing a blend of micronutrients in powder form (Iron, Zinc, Folic Acid, Vitamin A and C), sprinkled onto home made food|1 g orally on weekdays during 11 weeks
1642003|NCT01917032|Dietary Supplement|placebo|
1642004|NCT01917019|Drug|Placebo|matching placebo tablets
1642005|NCT01917019|Drug|BIIB041 (fampridine)|fampridine prolonged-release tablets
1642006|NCT01917006|Drug|OnabotulinumtoxinA|OnabotulinumtoxinA injected into specified muscle per protocol on Day 1.
1642007|NCT01917006|Drug|Normal Saline|Placebo (normal saline) injected into specified muscle per protocol on Day 1.
1642008|NCT01916993|Drug|NBI-98854 50 mg capsule|
2012375|NCT02043548|Drug|tocilizumab|given at a dose of 8mg/kg by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
2012376|NCT02043548|Drug|placebo|given by IV infusion every 4 weeks at 6 time points (Visits 1, 2, 3, 4, 5 and 6).
2012377|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
1642012|NCT01916954|Drug|3-day artemether-lumefantrine|
1642013|NCT01916954|Drug|5-day artemether-lumefantrine|
2012378|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
2012379|NCT02038777|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
1642016|NCT01916915|Drug|Tramadol infusion via wound catheter|
1642017|NCT01916915|Drug|Levobupivacaine|
1642018|NCT01916902|Drug|Ticagrelor- Delayed Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
1642019|NCT01916902|Drug|Ticagrelor- Immediate Administration|Subjects are randomized to receive ticagrelor immediately after enrollment versus at the time of cardiac catheterization. OCT is performed prior to and after coronary artery stenting.
1642020|NCT01916902|Procedure|Optical Coherence Tomography|
1642021|NCT01916889|Other|RACY test|
1642022|NCT01916876|Other|Integrated medical follow-up package|"At discharge, patients will receive a discharge plan by their attending caregiver.
On day 3 they will be contacted telephonically to:
i) Discuss their discharge diagnosis and medications ii) Arrange specialist clinic follow-up booking for 2 weeks iii) Reemphasise drug compliance
Reminders via SMS to attend there OPD appointment(s)
Medical out-patient review at 2-weeks and 6 weeks if required
Medical telephonic hot-line for advice"
1642023|NCT01916863|Drug|LX4211 400 mg|
1642024|NCT01916863|Drug|canagliflozin 300 mg|
1642025|NCT01916863|Drug|LX4211 Placebo|
1642026|NCT01916850|Drug|LX4211 400 mg|
1642027|NCT01916850|Drug|LX4211 800 mg|
1642028|NCT01916850|Drug|LX4211 Placebo|
1642029|NCT01916837|Other|Sampling of tumor tissue|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
1642030|NCT01916837|Other|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of breast cancer surgery
1642031|NCT01916837|Procedure|Sampling of tumor tissue after breast cancer surgery|Fresh tumor specimens were sampled prior to adding any fixative and within one hour of surgery
1642033|NCT01916798|Drug|Intralipid infusion|IV infusion of 250 ml of intralipid 20% solution at the day of Ovum pick up & another dose at the day of embryo Transfer.
1642034|NCT01916785|Drug|Dasatinib|Dasatinib is a multitargeted tyrosine kinase inhibitor with a 300-fold more potent activity on the BCR-ABL tyrosine kinase in vitro compared to imatinib mesylate
1642035|NCT01916772|Other|no interventions|no interventions
1642036|NCT01916759|Drug|Seasonal trivalent inactivated influenza vaccine (Vaxigrip®)|Administer seasonal trivalent inactivated influenza vaccine (Vaxigrip®) and collect blood specimens at 0, 1, 3, 7, 14, 28 and 100 days following vaccination.
1642037|NCT01916746|Procedure|transvaginal resection of pregnancy tissue|Patient were under general anaesthesia, placed in a dorsal lithotomy position and the bladder emptied. Expose, grasp and traction the cervix. And adrenaline (600 ug/l; 10-20 ml) was injected submucosally at the level of the cervicovaginal junction. An incision was made at the anterior cervicovaginal junction, and the bladder was dissected away until the anterior peritoneal reflection was identified. The anterior drawing hook was inserted into the vaginal incision to retract the bladder upwards. The CSP was identified as a'purple bulge' located in the anterior part of the lower uterine segment. A transverse incision was made over the most prominent area of the bulge. Ectopic pregnancy tissue inside the bulge was removed, and suction curettage through the incision on the uterus isthmus was subsequently performed. The edges of the incision were trimmed with scissors, and the myometrial and vaginal defects were closed with a continuous locking suture using 2-0 absorbable sutures.
1642077|NCT01916447|Drug|Bevacizumab|Dose (infusion of 5 mg/kg administered per site standard practice), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
1642078|NCT01916434|Other|High PUFA Salmon Fillets|High EPA/DHA levels in feed and in salmon fillets (~15% of total feed fatty acids, equal to wild salmon), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
1642583|NCT01912365|Procedure|Long Arm Splint|
1642038|NCT01916733|Drug|standard insulin protocol post-op (continuous IV insulin)|concurrent, matched cohort study of moderate postoperative glucose control in patients undergoing LEB or open AAA repair.Propensity score matching is a statistical method used to reduce the confounding effects of covariates in an observational (non-randomized) study. In practice we will select a number of variables that impact wound infection; age, gender, diabetic and non-diabetic populations, renal insufficiency (defined at creatinine ≥1.8) and indication for surgery (claudication or critical limb ischemia with rest pain or tissue loss or open AAA repair); and chose a group of patients in the Vascular Study Group matched for these variables who have not been treated with an insulin infusion). Consecutive patients undergoing elective open AAA repair or infrainguinal LEB for claudication and critical limb ischemia will be invited to enroll in the study.
1642039|NCT01916720|Drug|SB-480848 40 mg|Study Drug
1642040|NCT01916720|Drug|SB-480848 80 mg|Study Drug
1642041|NCT01916720|Drug|Placebo|Study Drug
1642042|NCT01916707|Drug|Dosing of enoxaparin for VTE prophylaxis|
1642043|NCT01916694|Device|Blue tooth enabled glucose meter with smart phone application|
1642044|NCT01916694|Behavioral|Self home blood glucose monitoring|Fingerprick testing of blood glucose levels before and 2 hours after meals
1642045|NCT01916681|Device|Cervical Foley & Misoprostol|A cervical foley combined with misoprostol will be used to induce the patient.
1642046|NCT01916681|Drug|Misoprostol Alone|Misoprostol will be used alone to induce the patient
1642047|NCT01916681|Device|Cervical Foley Alone|A cervical foley alone will be used to induce the patient
1642048|NCT01916681|Device|Cervical Foley & Pitocin|A cervical foley combined with pitocin will be used to induce the patient
1642049|NCT01916655|Behavioral|Self-Management Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy
1642050|NCT01916655|Behavioral|Self-Management Mobile Care|Provision of sleep apnea-specific self-management education and support for those who are prescribed CPAP therapy via mobile phone
1642051|NCT01916655|Behavioral|Usual Care|standard and typical CPAP educational and support protocol; is the base level education and support that is provided in the other two interventions in this study.
1642052|NCT01916642|Drug|Lidocaine 1mg/kg|The total dosage of Etomidate needed for induction of anesthesia is recorded at last.
1642053|NCT01916642|Drug|Lidocaine 1.5mg/kg|same as other
1642054|NCT01916642|Drug|Lidocaine 2mg/kg|same as other
1642055|NCT01916642|Drug|Lidocaine 2.5mg/kg|same as other
1642056|NCT01916629|Drug|Photocil for Psoriasis|Photocil for Psoriasis
1642057|NCT01916629|Other|Placebo - Sunscreen (SPF 2)|Placebo - Sunscreen (SPF 2)
1642058|NCT01916616|Behavioral|Four therapy sessions with a psychologist utilizing cognitive-behavioral therapy techniques|At the four therapy sessions, subjects will work with the psychologist to identify the triggers of their VCD episodes, learn to self-monitor symptoms and reactions, and be taught breathing retraining/relaxation techniques. The goal is to decrease patterns of subjects' thinking or behaviors that exacerbate distress from VCD symptoms.
1642059|NCT01916603|Behavioral|Normative Intervention|Diet and physical activity counselling-support and breastfeeding promotion till 12 months postpartum
1642060|NCT01916590|Drug|Bupivicaine|After surgery before the patient is discharged home their femoral catheter will then be connected to the home pain pump filled with bupivacaine 0.25% solution (without epinephrine), and the infusion will be started at 6 ml/hr. gh the catheter.
1642061|NCT01916590|Drug|placebo|
1642062|NCT01916577|Drug|Plerixafor mobilization of autologous CD117 stem cells|Peripheral mobilization of autologous CD117+ stem cells from the bone marrow in patients awaiting lung transplantation versus normal controls
1642063|NCT01916564|Other|Split-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy
Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy
1-L PEG-ELS between 8 p.m. and 8.30 p.m. on the day before and 1-L PEG-ELS between 5.30 a.m. and 6 a.m. on the day of colonoscopy"
1642064|NCT01916564|Other|Same-morning whole-dose|"2 tablets of bisacodyl 5 mg at 8 p.m. two days before colonoscopy
Low fibre diet and 2 tablets of bisacodyl 5 mg at 8 p.m. on the day before colonoscopy
2-L PEG-ELS between 5 a.m. and 6 a.m. on the day of colonoscopy"
1642065|NCT01916525|Behavioral|Exercise based cardiac rehabilitation|The cost-effectiveness between the exercise training vs. control groups
1642066|NCT01916499|Other|3 tesla magnetic resonance imaging findings; coronary artery status|
1642067|NCT01916499|Other|3 tesla magnetic resonance imaging findings; ventricular function and morphology|
1642068|NCT01916486|Behavioral|Exercise training|The EX Program will provide objective progression in the guided exercises of each participant.
1642069|NCT01916486|Behavioral|Complex mental and social activities|The Cog-Plus Program will engage participants in activities promoting cognitive function and socialization.
1642070|NCT01916486|Behavioral|Control: stretching and relaxation program|The CON Program consist of stretches, deep breathing and relaxation techniques, general posture education, and general core control exercises in the sitting position.
1642071|NCT01916473|Other|Epidural analgesia|Epidural analgesia is provided with ropvacaine 0.2% given 6 hourly
1642072|NCT01916473|Other|Continuous wound infusion|Continuous wound infusion via catheter
2012380|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
2012381|NCT02038777|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days.
1642075|NCT01916447|Drug|TAS-102|Escalating doses (20-35 mg/m2/dose, based on tolerability), orally, twice daily on days 1-5 of each 14-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
1642076|NCT01916447|Drug|CPT-11|Escalating doses (30-minute infusion of 120-180 mg/m2/dose, based on tolerability), IV (in the vein) on Day 1 of each 14-day treatment cycle. Number of cycles: until at least one of the discontinuation criteria is met.
1642245|NCT01915095|Device|Sham rTMS|sham or fake stimulation (TMS or rTMS) will be given to the brain in a non invasive manner
2012382|NCT02038777|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7.
2012383|NCT02038777|Drug|PF-04449913|PF-04449913 administered orally and continuously in 28 day cycles.
2012384|NCT02038777|Drug|Azacitidine|Azacitidine Combination Cohort; Azacitidine 75 mg/m2 for 7 days.
1642079|NCT01916434|Other|Sustainable PUFA salmon|'Sustainable' levels of EPA/DHA in feed and in salmon fillets (~6-8% of total feed fatty acids), 2 salmon fillets per week for 18 weeks, on top of habitual fish consumption.
1642080|NCT01916434|Other|No salmon|The placebo group will continue to consume their habitual diet.
1642081|NCT01916421|Procedure|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|
1642082|NCT01916408|Drug|Wobenzym plus|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
1642083|NCT01916408|Drug|PL 1|3 x 4 tablets of the study medication each day for the one week before and 3 x 2 tablets of the study medication each day for the two weeks after the marathon.
1642084|NCT01916395|Drug|sumatriptan and Treximet|sumatriptan 100mg tablet when migraine is moderate or severe in intensity. Treximet 85/500mg tablet when migraine is moderate or severe in intensity.
1642085|NCT01916382|Drug|Nitisinone|drug
1642086|NCT01916369|Biological|CTX DP|Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
1642087|NCT01916356|Other|educational video|Educational video covering topics of basic reproductive biology, infertility etiologies, risk factors, treatments and common myths.
1642088|NCT01916343|Procedure|Study Laparoscopic Curriculum|
1642089|NCT01916317|Drug|0.5% lignocaine 60mM|
1642090|NCT01916304|Drug|Levothyroxine sodium new formulation|Levothyroxine tablets
1642091|NCT01916291|Drug|Propess insertion|
1642092|NCT01916278|Device|Emervel Lips Lidocaine|
1642093|NCT01916278|Device|Juvéderma Volbella with Lidocaine|
1642094|NCT01916265|Drug|Glucagon|
1642095|NCT01916252|Drug|bortezomib (Velcade ®)|
1642096|NCT01916252|Drug|lenalidomide (Revlimid®)|
1642097|NCT01916252|Drug|busulfan (Busilvex ®)|
1642098|NCT01916252|Drug|Dexamethasone acetate|
1642099|NCT01916252|Drug|Melphalan|
1642100|NCT01916239|Dietary Supplement|Standard pomegranate extract formulation|Standard pomegranate extract formulation containing 20% punicalagin
1642101|NCT01916239|Dietary Supplement|Pomegranate extract formulation-1|New pomegranate extract formulation-1
1642102|NCT01916239|Dietary Supplement|Pomegranate extract formulation-2|New pomegranate extract formulation-2
1642103|NCT01916226|Drug|FPNS|Bottled, 16 gm net fill weight for 120 metered sprays with unit dose strength of 50 mcg per spray.
1642104|NCT01916226|Drug|FPNS Placebo|Bottled placebo nasal spray (vehicle for Fluticasone propionate aqueous nasal spray), 16 gm net fill weight for 120 metered sprays.
1642105|NCT01916226|Drug|Cetirizine|Over-encapsulated Cetirizine tablet with unit dose strength of 10 mg in High Density Poly Ethylene Bottles (20 count per bottle).
1642106|NCT01916226|Drug|Cetirizine Placebo|Over-encapsulated Cetirizine matching tablet High Density Poly Ethylene Bottles (20 count per bottle).
1642107|NCT01916213|Procedure|PICSI|If the oocytes are randomized to ICSI during the retrieval they will be ordered by the 1,4,5 8th best oocyte and PICSI to the 2,3, 6 7th best oocytes or the reverse if PICSI is selected. If one cohort is superior that cohort should be chosen by the blinded physician and the alternate cohort frozen or discarded based on their quality. This will ensure that the couple will always have the opportunity to have good quality embryo transferred regardless of how they are randomized. If there are no good quality embryos in the selected cycle we will consider it a failed transfer for that cycle and we will transfer the good quality embryos from the non- selected group as a fresh embryo transfer. For example if a couple is randomized to ICSI and all the ICSI embryos are poor quality but the PICSI embryos are good quality we will consider it a failed ICSI transfer and transfer the PICSI embryos as a fresh embryo transfer.
1642108|NCT01916200|Drug|Paroxetine CR|Paroxetine CR will be provided by GlaxoSmithKline (GSK) and be available as 12.5 mg over-encapsulated tablets with the research use only label outside the package. Paroxetine CR should be administered as a single daily dose, with or without food. The recommended initial dose is 25 mg/day. Patients were dosed in a range of 25 mg to 62.5 mg/day in the clinical trials demonstrating the effectiveness of paroxetine CR in the treatment of major depressive disorder. As with all drugs effective in the treatment of major depressive disorder, the full effect may be delayed. Some patients not responding to a 25-mg dose may benefit from dose increases, in 12.5 mg/day increments, up to a maximum of 62.5 mg/day. Dose changes should occur at intervals of at least 1 week.
1642109|NCT01916187|Drug|Imetelstat|
1642110|NCT01916174|Drug|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira B5
1642111|NCT01916174|Drug|insulin degludec/liraglutide|Subject will receive a single injection (s.c.) of IDegLira V2
1642112|NCT01916161|Other|Questionnaire|
1642113|NCT01916148|Drug|18F-DOPA|18F-DOPA is a PET scan radiotracer.
1642114|NCT01916135|Radiation|[18F]-SKI-249380|
1642115|NCT01916135|Procedure|PET/CT scan|PET scans will be performed immediately, at approximately 90 minutes, and optionally at approximately 3 hours after injection of the radiotracer. This includes an initial 30-minute PET scanning period, performed. At each subsequent time-point, a 30 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A 30-45 minute scanning time-period is typical for clinical PET studies. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point.
1642116|NCT01916135|Other|Blood draws|Blood will be drawn at the multiple time points for pharmacokinetic & metabolite analyses of 18F-SKI-249380. We anticipate these time points to be approximately 1, 5, 15, 30, and 90 minutes and 3 hours (optional), post-injection.
1642119|NCT01916109|Drug|Gemcitabine|
1642120|NCT01916109|Drug|Carboplatin|
1642121|NCT01916109|Drug|Panitumumab|
1642122|NCT01916109|Procedure|radical cystectomy|
1642123|NCT01916096|Device|Delica Device|
1642124|NCT01914991|Procedure|dynamic extension contracture orthotic|A dynamic orthosis was constructed in the experimental group using the same style of dynamic extension contracture orthotic. A mobilizing force of 250 - 300 gm/cm2 was set in each one. Patients were instructed to wear it for at least 6 hours per day and then removed it for ADL (Activity Daily Living). A static orthosis was constructed using orfitcast material to the maximum, pain-free length allowed by the tissues at night. Static and dynamic orthoses were checked once a week and adjusted as necessary.
1642125|NCT01914991|Procedure|conventional treatment Physical Therapy|Traditional treatment was applied to one control group. The treatment consisted of 10 minutes of local thermotherapy (paraffin), active exercises at the PIPJ and DIPJ (Distal interphalangeal joint), 3 sets of 15 repetitions of each exercise extending and flexing of the PIPJ with metacarpophalangeal joint from 0° to 90° respectively. Distal interphalangeal joint exercises were conducted with identical repetitions. The metacarpophalangeal joint and PIPJ exercises took place at 0 ° and involved stretching (5 sets of 3 reps, holding for 10 seconds) and Therapeutic U.S (0.8 w/cm2 / 7 minutes).
1642126|NCT01914978|Other|Food allergy handbook for parents|The food allergy handbook was designed to be a reliable resource to supplement physician management of food allergy, addressing key topics central to effective allergy management and maintenance of positive quality of life. The handbook includes evidence-based information about food allergies and their management, practical strategies for transferring allergy management skills into daily life, strategies for educating others about allergies, strategies for coping with common emotional challenges associated with food allergy, and strategies for teaching children and involving them in allergy management.
1642127|NCT01914978|Other|Food allergy treatment as usual|
1642128|NCT01914965|Drug|Bupropion|Crossover design: Oral administration of 150 mg bupropion once daily for 2 weeks, followed by 300 mg bupropion once daily for subsequent 8 weeks, tapering: 150 mg bupropion once daily for 7 days
1642129|NCT01914965|Drug|Placebo|Crossover design: Oral administration of placebo once daily for 2 weeks, followed by placebo once daily for subsequent 8 weeks, tapering: placebo once daily for 7 days
1642130|NCT01914952|Dietary Supplement|CaHMB capsule|1.0 gram of CaHMB powder in a gelatin capsule
1642131|NCT01914952|Dietary Supplement|HMB free acid gelcap|0.8 g HMB free acid is a soft gel capsule
1642132|NCT01914952|Dietary Supplement|HMB free acid mixed in water|0.8 g HMB free acid in water
1642133|NCT01914952|Dietary Supplement|CaHMB in water|1.0 g CaHMB powder mixed in water
1642134|NCT01914952|Dietary Supplement|HMB free acid|0.8 g HMB free acid
1642135|NCT01914939|Drug|Oxytocin|
1642136|NCT01914939|Behavioral|Social Skills focused CBT|
1642137|NCT01914939|Behavioral|Stress management/relaxation training|
1642138|NCT01914939|Drug|placebo drug|
1642139|NCT01914926|Drug|Metoprolol|
1642140|NCT01914926|Drug|Diltiazem|
1642141|NCT01914913|Biological|BMMNCs|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval ,transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
1642142|NCT01916057|Device|18F-FDG PET Scan|to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
1642143|NCT01916044|Other|Ultrasound|Measure of Uterine Segment by Ultrasound
1642144|NCT01916031|Behavioral|Education|
1642145|NCT01916018|Other|Clinical and radiologic exams and blood samples|
1642146|NCT01916005|Device|18F-FDG PET/CT|
1642147|NCT01915992|Other|blood samples|
1642148|NCT01915979|Biological|Plasma rich in growth factors (PRGF)|
1642149|NCT01915979|Drug|Celestone cronodose (Bethametasone)|
1642150|NCT01915966|Dietary Supplement|Cardamom, ginger and orange juice gelatin|Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation
1642151|NCT01915966|Dietary Supplement|Camomile infusion with lemon juice|Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
1642152|NCT01915940|Drug|Bimatoprost Ocular Insert|
1642153|NCT01915940|Drug|Timolol|0.5% solution
1642154|NCT01915940|Drug|Placebo drops|placebo topical eye drops
1642155|NCT01915940|Device|Placebo Ocular Insert|ocular insert without any active drug
1642156|NCT01915927|Drug|MSC-AFP|
1642157|NCT01915914|Drug|Fluticasone propionate|All subjects receive FP 0.05% cream twice daily up to 4 weeks to all affected sites and any newly occurring sites in ACUTE phase. After randomization in MAINTENANCE phase, subjects either receive emollient (Physiogel) twice daily extendedly plus FP 0.05% cream once daily twice a week to all healed sites and any newly occurring sites (Group A), or emollient (Physiogel) twice daily extendedly (Group B), up to 20 weeks. In FOLLOW-UP phase, all subjects apply emollient (Physiogel) twice daily up to 12 weeks.
1642158|NCT01915901|Drug|bismuth subsalicylate (Pepto-Bismol®)|524 mg bismuth subsalicylate twice a day (BID)
1642159|NCT01915901|Drug|matching placebo (bismuth subsalicylate)|placebo twice a day (BID)
1642160|NCT01915901|Drug|dimethyl fumarate (DMF)|dimethyl fumarate (DMF) twice a day (BID)
1642161|NCT01915888|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
1642162|NCT01915875|Other|sophrology sessions at home|The sophrology is a dynamic method of physical and psychical relaxation
1642163|NCT01915849|Drug|LIK066|LIK066 15 mg, 50 mg and 150 mg
1642164|NCT01915849|Drug|Placebo|
1642165|NCT01915836|Other|web-based video game (Quit IT)|
1642166|NCT01915836|Behavioral|Questionnaires|
1642167|NCT01915836|Behavioral|Evaluation Interview|
1642168|NCT01915823|Drug|azelastine hydrochloride and fluticasone propionate|
1642169|NCT01915823|Drug|Dymista vehicle|
2012385|NCT02039674|Biological|Pembrolizumab|intravenously (IV) every 3 weeks (Q3W) on Day 1 of each cycle prior to chemo/immunotherapy
2012386|NCT02039674|Drug|Paclitaxel|IV Q3W on Day 1 of each cycle
2012387|NCT02039674|Drug|Carboplatin|IV Q3W on Day 1 of each cycle
1642246|NCT01915095|Other|Training|at the direction of the researcher the participant will be instructed to do repetitive motor movements with their arm, hand or leg. this is called training
1642584|NCT01912352|Drug|Methylphenidate|
2012388|NCT02039674|Biological|Bevacizumab|IV Q3W on Day 1 of each cycle
2012389|NCT02039674|Drug|Pemetrexed|IV Q3W on Day 1 of each cycle
2012390|NCT02039674|Biological|Ipilimumab|IV Q3W on Day 1 of each cycle
2012391|NCT02039674|Drug|Erlotinib|Orally (po) daily (QD)
2012392|NCT02039674|Drug|Gefitinib|po QD
2012393|NCT02039505|Drug|Vedolizumab|Vedolizumab intravenous injection
1642176|NCT01915797|Other|blood and tumor samples|all tumor pathology associated with anomaly of development
1642177|NCT01915784|Device|Genuair®|Inhaler with placebo only. Once daily, for 14 days.
1642178|NCT01915784|Device|Breezhaler®|Inhaler with placebo only. Once daily, for 14 days.
2012394|NCT02039505|Drug|Vedolizumab placebo|Vedolizumab placebo
1642180|NCT01915758|Drug|clindamycin1%/tretinoin 0.025% gel|clindamycin1%/tretinoin 0.025% gel
1642181|NCT01915758|Drug|vehicle gel|vehicle gel
1642182|NCT01915745|Other|Use of SMS|Patients receive 3 SMS (at 15 days, 5 weeks and 3 months) after consulting in Emergency Department. Then they are called during 10 minutes at 6 months to check if bone densitometry will be performed and if antiosteoporotic treatment will be initiated.
1642183|NCT01915732|Drug|Duac™Once Daily Gel|1% clindamycin as clindamycin phosphate and 5% benzoyl peroxide
1642184|NCT01915732|Drug|1% clindamycin phosphate gel|1% clindamycin as clindamycin phosphate
1642185|NCT01915719|Procedure|Early non invasive ventilation|
1642186|NCT01915719|Procedure|Oxygen therapy only|
1642187|NCT01915706|Procedure|Ripcord removal|Patients randomized to intervention will have their ripcords removed in clinic at post-operative week 3. Ripcord removal will be performed by study PI at the slit lamp with standard of care sterile technique and topical/local anesthesia. Patients will be monitored 30 minutes following ripcord removal for intraocular pressure as well as complications.
1642188|NCT01915693|Radiation|Radiotherapy|External beam radiotherapy (EBRT) delivering a tumour absorbed dose of 20Gy in 5 fractions or 30Gy in 10 fractions.
1642189|NCT01915667|Drug|200 mg GLPG0634 as capsules, fasted|single oral dose of 200 mg GLPG0634 given as capsules in fasted condition
1642190|NCT01915667|Drug|200 mg GLPG0634 as tablets, fasted|single oral dose of 200 mg GLPG0634 given as tablets in fasted condition
1642191|NCT01915667|Drug|200 mg GLPG0634 as tablets, fed|single oral dose of 200 mg GLPG0634 given as tablets in fed condition
1642192|NCT01915654|Procedure|study population|Population of patients undergoing cardiac surgery between December 2008 and May 2009, with pellets transfused RBCs stored for less than 14 days
1642193|NCT01915641|Device|CPAP|Randomized those patients to group A and group B group A : CPAP treatment with optimal pressure for 1 month, repeat measurement change CPAP treatment to sham pressure 5cm H2O for 1 month, repeat measurement group B : CPAP treatment with sham pressure for 1 month, repeat measurement change CPAP treatment with optimal pressure for 1 month, repeat measurement
1642194|NCT01915628|Device|BioMatrix Flex|Percutaneous coronary intervention
1642195|NCT01915615|Other|None - this is an observational study|None - this is an observational study
1642196|NCT01915602|Drug|Refametinib (BAY86-9766)|Patients will receive refametinib 50 mg (2x20 mg + 1x10mg capsules or 50 mg tablets) bid
1642197|NCT01915602|Drug|Sorafenib (BAY43-9006)|Patients will receive sorafenib 400 mg (2 x 200 mg tablets) bid.
1642198|NCT01915589|Drug|Refametinib (BAY86-9766)|All patients who meet the entry criteria will receive refametinib 50 mg (2x20 mg + 1x10 mg capsules or 50 mg tablet) bid.
1642199|NCT01915576|Drug|BAY1125976|Oral administration once daily. Starting dose is 10 mg and will be escalated depending on any dose-limiting toxicities
1642200|NCT01915576|Drug|BAY1125976|Oral administration twice daily. Starting dose is 40mg twice daily and will be escalated depending on any dose-limiting toxicities
1642201|NCT01915576|Drug|BAY1125976|Oral administration of the defined MTD which shows optimal safety, PK profile, PD target inhibition and preliminary efficacy (once daily or twice daily) in different patient groups
1642202|NCT01915563|Procedure|REST|After a SBT patients will be extubated as usual or reconnected to mechanical ventilation for 60 min before extubation.
1642203|NCT01915550|Drug|Metformin|
1642204|NCT01915550|Drug|Humulin Insulin Mixtard|
1642205|NCT01915537|Drug|Infliximab group|Infliximab with MTX treatment: Infliximab 3mg/kg at week 0, 2, 6 and then once every 8 weeks, MTX>7.5mg per week. To observe the results at week 14, 30, 54 and 102 after 6 times IFX treatment. It recommended that continue to receiving IFX treatment after remission for a period of time in good economic condition patients while receiving MTX with HCQ or LEF in poor economic condition patients.
1642206|NCT01915537|Drug|Classic DMARDs treatment group|"Classic DMARDs treatment: combination of 2 or 3 drugs, 2-drugs combination is MTX with LEF or Thunder God Vine, 3-drugs combination is MTX with HCQ and LEF or Thunder God Vine for total 30 weeks.
Effective dose: MTX: 10-15mg per week; LEF: 20mg per day; HCQ: 200-400 mg per day; Thunder God Vine: 40-60 mg per day; It recommended that the maintain regimen is MTX with HCQ or LEF after remission for a period of time."
1642207|NCT01915524|Biological|CV9202|Intradermal injection of CV9202
1642208|NCT01915524|Radiation|local radiation|Radiotherapy will be administered in 4 daily fractions of 5 GY each to be administered within one week
1642209|NCT01915498|Drug|AG-221|AG-221 administered orally on every day of 28 day cycles until disease progression or unacceptable toxicities. Multiple doses.
1642210|NCT01915485|Radiation|Lu 177|Patients will be submitted to 4 cycles of 177-Lu with 200mCi each
1642211|NCT01915472|Drug|IMMU 130|This is a Phase II, open-label study of IMMU-130 administered every 14 days for a period of 24 weeks to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
1642212|NCT01915459|Biological|Botulinum toxin type A(Botulax®)|IM, total dose of 360 Units at wrist flexor, elbow flexor, finger flexor, and thumb flexor based on muscle tone
1642213|NCT01915459|Biological|Botulinum toxin type A(Botox®)|
1642243|NCT01915108|Drug|Remifentanil|All patients received a predetermined Ce of remifentanil by TCI according to their group assignments 10 minutes before the end of surgery (R0, remifentanil Ce of 0 ng/ml; R0.5, remifentanil Ce of 0.5 ng/ml; R1.0, remifentanil Ce of 1.0 ng/ml; R1.5, remifentanil Ce of 1.5 ng/ml).
2012395|NCT02038920|Drug|Vedolizumab|Vedolizumab intravenous injection
2012396|NCT02038920|Drug|Vedolizumab placebo|Vedolizumab placebo
2012397|NCT02038764|Drug|Placebo|Placebo
2012398|NCT02038764|Biological|PF-06342674 Dose A|Multiple SC Doses
2012399|NCT02038764|Biological|PF-06342674 Dose B|Multiple SC Doses
2012400|NCT02038764|Biological|PF-06342674 Dose C|Multiple SC Doses
1642214|NCT01915433|Other|Wahls Paleo Plus|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low in carbohydrate and high in fat but still ensure consumption of the specific micronutrients important to optimal brain function. This diet is designed to induce a low level nutritional ketosis.
1642215|NCT01915433|Other|Wahls Diet|The study diet is based upon a Paleolithic Diet, also known as a Hunter Gatherer Diet, which exceeds the recommended daily allowance of water soluble vitamins and minerals 1.5 to 8 fold and improves lipids, inflammatory biomarkers and blood pressure. The study diet is further structured to be a low glycemic diet and also ensure consumption of the specific micronutrients important to optimal brain function.
1642216|NCT01915381|Other|multimodal intervention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach, where therapist advice about benefits of PA during the exercises, to promote PA with brochure-based decalogue
1642217|NCT01915368|Behavioral|Stroke Management Program (SMP)|Participants will have usual care, and in addition, be provided with periodic information about their progress in the area of mobility using specialized activity monitors
1642218|NCT01915368|Behavioral|Stroke Monitoring Program (SMonP)|Participants will have usual care, and in addition, be progressed according to customized protocols using feedback from specialized activity monitors
1642219|NCT01915368|Behavioral|Stroke Supplementary Program (SSP)|Participants will have usual care, and in addition, will receive the same as the Stroke Monitoring Group, and also receive one additional hour of daily (5 times per week) physical exercise
1642220|NCT01915355|Device|Pulsed Dye Laser for the treatment of nail fungus|The purpose of this research is to investigate the use of the Candela V-beam Pulsed Dye Laser for the treatment of onychomycosis, a common nail fungus.
1642221|NCT01915342|Device|Focal muscular vibration|
1642222|NCT01915329|Device|RSS (repetitive sensory stimulation)|"RSS is a high frequency electrical stimulation protocol delivered to the peripheral nerves (median and ulnar nerve) of the hand. The signals are generated by a TENS-stimulator and are conveyed to each finger of the hand via a custom-made hand-shaped device with conductive contacts at each fingertip and at the palmar base.
In case of the sham-stimulation no pulses are transmitted."
1642223|NCT01915329|Device|SHAM-RSS|The same device as in the RSS intervention is used, but no electrical stimuli are transmitted.
1642224|NCT01915316|Other|prostate biopsy|Measurements of Zinc concentration along fresh Specimens taken during Trans-Perineal saturated repeat Prostate Biopsy before Specimens are sent to Pathology.
1642225|NCT01915303|Drug|Pasireotide with or without cabergoline|The trial consists of Pasireotide-untreated patients will start pasireotide 0.6mg twice a day for 8 weeks. If biochemical control is not achieved by the end of the 8 weeks, and the 0.6mg dose is well-tolerated, the dose will be increased to 0.9mg twice a day for another 8 weeks. If biochemical control is not achieved, cabergoline will be added and patients will begin combination treatment with cabergoline at the starting dose of 0.5mg once a day for 8 weeks. If biochemical control is still not achieved at the end of the third 8 week period, the dose of cabergoline wlil be increased to 1.0mg once a day. Patients can also immediately start the combination treatment by adding cabergoline 0.5mg once a day at study entry to their current maximal tolerated dose of pasireotide. Patients will continue with the combination treatment for 8 weeks. If biochemical control is not achieved by the end of the 8 week period, the dose of cabergoline will be increased to 1mg once a day.
1642226|NCT01915277|Drug|Dexmedetomidine|
1642227|NCT01915264|Drug|Acarbose/Metformin (Glucobay M, BAY81-9783)|Acarbose (25/50mg) and Metformin (500mg) in fixed dose combination.
2012401|NCT02038764|Biological|PF-06342674 Dose D|Multiple SC Doses
1642229|NCT01915199|Other|Intensive Care|Comprehensive intervention on hypertension through optimization of drug therapy, introduction of home blood pressure monitoring, and lifestyle guidance
1642230|NCT01915186|Dietary Supplement|Dihydroepiandrosterone (DHEA)|DHEA capsules are given at 25mg 3 times a day for 12 weeks
1642231|NCT01915173|Drug|Supplement|Abies nigra 4C, Carbo vegetabilis 4C, Nux vomica 4C, and Robinia pseudoacacia 4C
1642232|NCT01915173|Drug|Placebo|Lactose tablets
1642233|NCT01915173|Behavioral|Expanded Interview|
1642234|NCT01915173|Behavioral|Standard Interview|
1642235|NCT01915160|Behavioral|eTF-CBT|Standard treatment with the edition of in-treatment/session iPad activities.
1642236|NCT01915160|Behavioral|TF-CBT|Treatment as usual.
1642237|NCT01915147|Drug|OXN PR followed by OxyPR tablets|
1642238|NCT01915147|Drug|OxyPR followed by OXN PR tablets|
1642239|NCT01915134|Drug|Recombinant Human Endostatin plus gemcitabine and cisplatin|target therapy plus chemotherapy:4-6 cycles of Recombinant Human Endostatin plus gemcitabine and cisplatin:Endostatin：7.5mg/m2/d,d1-14,concomitant with chemotherapy for 4-6 cycles.Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
1642240|NCT01915134|Drug|Gemcitabine and cisplatin|only chemotherapy：Gemcitabine and cisplatin:4-6 cycles of GP chemotherapy with gemcitabine 1000mg/m2,d1,8,cisplatin80mg/m2,d1.Chemotherapy will be given once every three weeks.
1642241|NCT01915121|Behavioral|Education Intervention|1-hour educational and training sessions. In this session, participant will be provided with information about bladder cancer treatment options, and training tools directly related to Bladder Cancer. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
1642242|NCT01915121|Behavioral|Nutrition Intervention|1-hour educational and training sessions. In this session, participant will be provided with nutrition information directly related to Bladder Cancer recovery. In 4 to 5 days following the session, participants will be asked to schedule the time to talk about experience and how the intervention affects their treatment decision making and to answer some questions about the educational and training session they attended. Participants will then be called after 1-month, 3-month, and 6-month after their bladder cancer treatment to follow up.
1642636|NCT01911936|Drug|LM716|
2012402|NCT02030080|Behavioral|Financial incentives|
2012403|NCT02030080|Behavioral|Teams|
1642247|NCT01915095|Other|Motor Task|participants will be asked to perform specific motor tasks or movements with their fingers, hands, arms or legs.
1642248|NCT01915082|Drug|Azithromycin|"Zithromax® oral suspension 200 mg/ 5 mL (Pfizer, UK):
Zithromax® 1000 mg syrup per os once at recipient intake for lung transplantation (day 0); followed by Zithromax® 250 mg syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
1642249|NCT01915082|Drug|Ora-Plus|"Ora-Plus® oral suspension (Paddock Laboratories, 3940 Quebec Avenue N, Minneapolis, MN 55427, USA; NDC-number: 0574-0303-16):
Ora-Plus® 25mL syrup per os once at recipient intake for lung transplantation (day 0); followed by Ora-Plus® 6.25 mL syrup via (naso)gastric tube or per os every other day until one month after lung transplantation (days 1,3,5,7,9,11,13,15, 17,19,21,23,25,27,29 and 31)."
2012404|NCT02030080|Behavioral|Framing of feedback|
1642251|NCT01915056|Other|GA-driven Intervention|For patients assigned to the treatment arm, individuals will be offered the option of completing the GA during a visit with their primary oncologist, or attending an additional visit at the multidisciplinary geriatric oncology clinic. The intervention consists of providing results of geriatric assessment in a summary to oncologists.
1642252|NCT01915043|Other|health education for lymphedema prevention|All subjects received a multimodal intervention consist in a multimodal program with an educational approach
1642253|NCT01915030|Other|High protein diet|controlled feeding trail. Both arms are caloric restricted
1642254|NCT01915030|Other|standard protein diet|
1642255|NCT01915017|Behavioral|Cognitive Behavior Therapy for Psychosis|The CBT manual to be used for the present study was based upon the work of Kingdon and Turkington (2005) and Granholm et al., (2005) a group-delivered CBT skills training). Available manuals were modified to improve ease of training and to better accommodate the delivery of the full CBT treatment in the home environment. Supervision will be provided throughout the study by D. Turkington and S. Tai world renowned experts in CBT for psychosis. Training will be held for 1-2 weeks annually and supervision will proceed weekly via SKYPE. All therapists will be certified prior to providing treatment for the trial. Sessions are conducted weekly by master's and doctoral level therapists.
1642256|NCT01915017|Behavioral|Cognitive Adaptation Training|CAT supports are established and maintained on weekly home visits by bachelor's and master's level staff. Regular supervision will be provided by the PI who developed CAT.
1642257|NCT01915017|Behavioral|Multi-modal Cognitive Therapy|A manual driven intervention combining CBT and CAT. Weekly sessions delivered in the home focus on altering cognitive biases using CBT and bypassing cognitive deficits using environmental supports
1642258|NCT01915017|Other|Treatment as Usual|Standard medication follow up and limited case management
1642259|NCT01915004|Other|Educational Intervention|Bladder Training Video
1642260|NCT01914900|Drug|docetaxel, cisplatin, 5 fluorouracil|
1642261|NCT01914887|Drug|Allogeneic adipose tissue-derived mesenchymal stem cells|The cells will be given in different sites within the affected colonic submucosa at a total dose of 60 million cells with the use of a colonoscope.
1642262|NCT01914874|Behavioral|Mindfulness Meditation|
1642263|NCT01914848|Other|Advance Care Planning ACP|Patient of the intervention group get a decision aid video and library and up to 3 consultations with qualified Advance Care Planning Facilitators.
1642264|NCT01914848|Other|Control Group|A routine care discharge planning with the social service
1642265|NCT01914835|Behavioral|Motivational Chess|"The Motivational Chess (MC) combines Motivational Interviewing with chess game. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of chess practice and 5 hours of motivational interviewing).
The Active Control (AC) group consists of ten structured activities using cardboard, paper, crayons, among others. Volunteers are submitted to 10 sessions of 90 minutes, over three weeks (total 15 hours: 10 hours of recreational activities and 5 hours of information about basic cognitive functions)."
1642266|NCT01914822|Drug|methylphenidate hydrochloride|
1642267|NCT01914822|Drug|Sugar pill (placebo)|
1642268|NCT01914809|Other|samples blood|
1642269|NCT01914809|Other|biopsy placentaire|
1642270|NCT01914796|Drug|PF-06412562|Single doses, given by oral solution, starting at 0.5 mg up to a possible maximum of 150 mg. The subject will have been fasted for 10 hours prior to the single dose. Two doses, 120 mg and 150 mg, will be split into 3 doses such that the total dose is given over 8 hours (i.e. t = 0, 4, and 8 hours). For each dosing period, 2 subjects will be given a placebo as a comparator. One dose will be given in the fed state.
1642271|NCT01914796|Drug|PF-06412562|It is believed that for increasing doses of this compound the eye blink rate (EBR) will also increase. This arm will use EBR measurement technology to verify this hypothesis. In each dosing period, 4 subjects will be given a placebo as a comparator.
1642272|NCT01914783|Other|ultrafine particles|exposure to ultrafine particles
1642273|NCT01914783|Other|ultrafine particles and ozone|exposure to ultrafine particles and ozone
1642274|NCT01914783|Other|clean air|Exposure to clean air.
1642275|NCT01914770|Drug|Belimumab 1 mg/kg|Subjects received belimumab 1 mg/kg in addition to their ongoing stable systemic lupus erythematosus (SLE) treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, non-steroidal anti inflammatory drugs (NSAIDs), or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
1642276|NCT01914770|Drug|Belimumab 10 mg/kg|Subjects received belimumab 10 mg/kg in addition to their ongoing stable SLE treatment regimen. Belimumab was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
1642533|NCT01912703|Other|Telephone interview|Subjects with incomplete data will be asked to complete a telephone interview
1642277|NCT01914770|Drug|Placebo|Subjects received placebo in addition to their ongoing stable SLE treatment regimen. Placebo was administered intravenously at 0, 2, 4 weeks and every 4 weeks thereafter. The ongoing SLE treatment regimen was to have been stable for at least 30 days prior to Day 0, which consisted of any of the following (alone or in combination): prednisone or equivalent (from 0 to 40 mg/day when used in combination with other SLE treatment or from 7.5 to 40 mg/day alone), anti-malarials, NSAIDs, or any immunosuppressive therapy (ie, methotrexate, azathioprine, leflunomide, or mycophenolate calcineurin inhibitors, sirolimus, oral cyclophosphamide, 6-mercaptopurine, or thalidomide).
1642278|NCT01914757|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 52 inclusive.
1642279|NCT01914757|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 52 inclusive.
1642280|NCT01914744|Drug|Entecavir|entecavir 0.5 mg/day PO
1642281|NCT01914744|Drug|Lamivudine|lamivudine 100 mg/day PO
1642282|NCT01914731|Drug|Fecal Microbiota Transplant|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via frozen capsule"
1642283|NCT01914718|Drug|DA-EPOCH-R|rituximab 375mg/m2 IV day 0, etoposide 50mg/m2/d CIV days 1-4, doxorubicin 10mg/m2/d CIV days 1-4, vincristine 0.4mg/m2/d CIV days 1-4, cyclophosphamide 750mg/m2 IV day 5, prednisone 50mg PO days 1-5 twice per day
1642284|NCT01914705|Procedure|Landmark Procedure|Using Landmarks to guide SCVC placement
1642285|NCT01914705|Procedure|Ultrasound Guided Procedure|Using ultrasound to guide SCVC placement
1642286|NCT01914692|Drug|Somatostatin|Somatostatin is a kind of traditional medicines ,which is for the treatment of intestinal fistula，upper gastrointestinal hemorrhage.
1642287|NCT01914679|Device|RINCE|The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
1642288|NCT01914666|Drug|Duloxetine|Administered orally
2012405|NCT02030080|Behavioral|Daily Feedback|Participants will be given daily feedback on whether or not they walked 7000 steps or more the day before.
1642290|NCT01914627|Drug|Dimethicone|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
1642291|NCT01914627|Drug|Salicylic Acid|The treatment will be carried out once daily (in the evening) onto all scaling areas of the scalp over a period of 2 weeks, with the last application of investigational products being applied one day prior to the final visit.
1642292|NCT01914601|Device|Macintosh-King Vision|laryngoscopy will be performed with the Macintosh followed by the King Vision laryngoscope
1642293|NCT01914601|Device|King Vision-Macintosh|laryngoscopy will be performed with the King Vision followed by the Macintosh laryngoscope.
1642294|NCT01914588|Procedure|Telemonitoring|Use of wearable sensors able to record peripheral oxygen saturation, heart rate, systolic, diastolic and average blood pressure, body weight, average physical activity, with automatic transmission to the monitoring central.
1642295|NCT01914588|Other|Standard care|"Detailed instruction about medical therapy and lifestyle counseling
Telephonic support by a geriatrician, available from Monday to Friday, two hours/day
Follow-up visits"
1642296|NCT01914575|Device|Mapping with the Acutus Medical System followed by Ablation|
1642297|NCT01914562|Drug|OCA 10 mg|OCA 10 mg tablet oral
1642298|NCT01914562|Drug|OCA 25 mg|OCA 25 mg tablet oral
1642299|NCT01914549|Device|Mapping with the Acutus Medical System followed by Ablation|
1642300|NCT01914523|Device|Macintosh|Laryngeal exposure and tracheal intubation using that device
1642301|NCT01914523|Device|King Vision|Laryngeal exposure and tracheal intubation using that device
1642302|NCT01914523|Device|Glidescope|Laryngeal exposure and tracheal intubation using that device
1642303|NCT01914523|Device|AirTraq|Laryngeal exposure and tracheal intubation using that device
1642304|NCT01914510|Drug|ENMD-2076|
1642305|NCT01914484|Drug|Nilotinib|Nilotinib dose will remain fixed at 400mg bid throughout the cycles. BCR-ABL kinase inhibitor
1642306|NCT01914484|Drug|Ruxolitinib|"In the phase I part of the study, dose escalation will follow a 3+3 study design at either of 3 fixed dose levels (10 mg bid, 15 mg bid or 20 mg bid).
No intra-patient dose-escalation will occur. JAK inhibitor"
1642307|NCT01914471|Behavioral|Students for Nutrition and eXercise|These schools received the entirety of Students for Nutrition and eXercise, a middle-school-based obesity-prevention intervention combining school-wide environmental changes, multimedia, encouragement to eat healthy school cafeteria foods, and peer-led education and marketing
1642308|NCT01914458|Procedure|Low-dose computed tomography (LDCT)|Low-dose computed tomography scan
1642309|NCT01914445|Drug|Indigo Carmine|Oral administration of Indigo Carmine prior to colonoscopy
1642310|NCT01914432|Drug|YH16410|
1642311|NCT01914432|Drug|Rosuvastatin|
1642312|NCT01914432|Drug|Telmisartan|
1642313|NCT01914432|Drug|YH16410 placebo|
1642314|NCT01914432|Drug|Rosuvastatin placebo|
1642315|NCT01914432|Drug|Telmisartan placebo|
1642316|NCT01914419|Drug|Oxytocin|
1642317|NCT01914406|Other|high intense interval training|Each AIT session consisted a 10 minute warm-up period followed by 16 minutes of interval training consisting of intervals of 4-3-2 and 1 minutes duration at 85-95% of their peak capacity separated by 2-4 min active rest.
1642318|NCT01914406|Other|continuous moderate training|Continued exercise 45 min.
2012406|NCT02028884|Drug|satralizumab (SA237)|
1642320|NCT01914380|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients will be followed-up for 24 months
1642321|NCT01914367|Biological|cervarix|3 doses will be given, one on Day 0, one on Day 30 and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
1642322|NCT01914367|Biological|Gardasil|3 doses will be given, one on Day 0, one on Day 60 ± 2 days and one on Day 180 ± 7 days, intramuscular in the deltoid muscle of the non-dominant arm
1642323|NCT01914341|Other|Music|Live music played on the pentatonically tuned children's harp
1642406|NCT01913678|Other|Whole milk|The participants will be given all dietary items in their diet. In the whole milk arm, approximately 1 liter of whole milk will be included in the diet.
2012407|NCT02028884|Drug|Placebo|
2012408|NCT02026596|Procedure|Magnetic resonance imaging|
1642324|NCT01914315|Behavioral|Cardiac Rehabilitation|Patients will participate in a 6-month cardiac rehabilitation program, consisting of structured, 60-minutes, bi-weekly exercise training sessions according to a predefined protocol. Institutional activity will be complemented by 120 minutes weekly home exercise prescribed by specialist in cardiac rehabilitation. Exercise prescription will be based on a symptom limited exercise test when clinically feasible and according with the patients' functional capacity, medical history and physiological values obtained prior to exercise. Target heart rate will be set initial as 50-60% of heart rate reserve and gradually increased up to 80% of HRR. Aerobic exercise will be complemented by resistance training of low intensity.
1642325|NCT01914315|Other|Internal Medicine|Following discharge, patients will return to the IM outpatient clinics at 2-4 weeks, 3, and 6 months for consultation. These scheduled consultations will comprise of history taking, recording of any new events, physical examination and recommendations as clinically indicated. Target values for blood pressure and glucose control will be in accordance with current guidelines and special emphasis given to management of fluid retention.
1642326|NCT01914302|Device|Delica Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
1642327|NCT01914302|Device|Flash Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
1642328|NCT01914302|Device|Easy Touch Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
1642329|NCT01914302|Device|Glucoject Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
1642330|NCT01914302|Device|Microlet Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
1642331|NCT01914302|Device|Multiclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
1642332|NCT01914302|Device|Fastclix Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
1642333|NCT01914302|Device|Reli-On Lancing Device|Characterize Blood Volume and Pain under normal use circumstances
1642334|NCT01914289|Procedure|Resection|
1642335|NCT01914289|Radiation|Radiotherapy|
1642336|NCT01914263|Biological|cytokine induced killer cell|The eligible patients are infused with a single dose of 8x10^9 cord blood-derived cytokine indued killer cells.
1642337|NCT01914250|Drug|Analgesic effect of topical tetracaine 2 %|The patient will be held by the parents and comforted after local anesthesia is applied by a research investigator. Then, he will be placed on procedure's board repositioned for clipping, restrained by the parent/nurse (holding both head and arms, keeping with conventional practice). Exactly 5 minutes after the topical anesthetic was applied, the pediatric dentist will press down the chin gently straddling the frenulum while and holding it in place with visualization of tongue base. Then the frenulum will be snipped along the underside of the tongue to its base. The area will be checked to ensure complete release. Bleeding will be controlled by pressuring with a 2x2 gauze pad under the tongue. A study investigator will film the procedure using GO PRO Video Camera mounted on the forehead of the pediatric dentist
1642338|NCT01914237|Device|Castor Stent Graft|Endovascular Repair of Aortic Dissection
1642339|NCT01914224|Behavioral|dietary education of low sodium and high potassium consumption|
1642340|NCT01914224|Behavioral|dietary education of low sodium consumption only|
1642341|NCT01914211|Drug|Tranexamic Acid|100mg/kg prior to incision, 100mg/kg on CPB and 100mg/kg after reversal of heparin with protamine.
1642342|NCT01914211|Procedure|Acute Normovolemic Hemodilution|Draw 20 mL/kg (up to 5Kg) of blood from patient and replace with washed PRBCs at 10-20mL/kg. (If > 5Kg draw 20% of circulating blood volume without PRBC replacement)
1642343|NCT01914198|Other|Sleep apnea symptom survey|Parents or caregivers will complete a questionnaire regarding possible sleep apnea symptoms.
1642344|NCT01914185|Other|Comprehensive School Health (CSH)|APPLE Schools uses a CSH approach to health promotion which addresses health through four inter-related pillars 1) positive social and physical environments 2) teaching and learning 3) healthy school policy 4) partnerships and services. A key component of the APPLE Schools intervention was the placement of a full-time School Health Facilitator in each school. Their role was to facilitate the development and implementation of the project, to ensure that it met the schools' unique needs for health promotion, and that it aligned with the core principles of CSH.
1642345|NCT01914172|Other|online questionairres|see group descriptions
1642346|NCT01914159|Drug|Ranibizumab (Lucentis, Novartis Pharma GmbH, Germany)|Monthly intravitreal injections
2012409|NCT02026596|Procedure|Cerebral microdialysis catheter insertion|Is inserted only when invasive intracranial pressure monitoring is required. The same route with pressure probe is used for insertion.
2012410|NCT02025530|Other|Questionnaire|An indepth interview will be carried out and a structured questionnaire will be completed by both cases and controls
1642349|NCT01914133|Drug|Acarbose|Acarbose 50 mg given during Meal Test and Acarbose 25 mg taken with first bite of the next 3 meals.
1642350|NCT01914133|Drug|Placebo|Placebo given prior to meal the standardized meal
1642351|NCT01914107|Procedure|real-time monitoring and instruction of cancer pain|as description in arm
1642352|NCT01914107|Procedure|standard cancer pain care|as description in arm
1642353|NCT01914094|Behavioral|Prehab|
1642354|NCT01914081|Other|Resveratrol|Patients will receive one uncoated immediate-release caplets containing 500 mg resveratrol, twice daily for the 12 month intervention period
1642355|NCT01914081|Other|Placebo|
1642356|NCT01914068|Other|Supervised exercise in hospital|
1642357|NCT01914055|Device|angio-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|angio-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan)
1642358|NCT01914055|Device|OCT-guided thrombus aspiration (Eliminate catheter, Terumo, Tokyo, Japan)|FD-OCT-guided thrombus aspiration with monorail thrombus aspiration catheter (Eliminate, Terumo, Tokyo, Japan); OCT images will be acquired at the site of culprit coronary artery with a commercially available system (Lunawave System; Fastview catheter/Terumo, Tokio, Japan OR C7 System; LightLab Imaging Inc; C7 Dragonfly catheter/St Jude Medical, Westford, MA)
1642359|NCT01914042|Drug|Morphine|
1642360|NCT01914042|Drug|Milnacipran|
1642361|NCT01914016|Other|prolonged walk|Participants will be asked to walk for a duration of between 2 -6 minutes until they rate their perceived exertion as 'Hard' (RPE 16 on Borg Scale)
1642407|NCT01913665|Other|B.lactis|
1642408|NCT01913665|Other|Inulin|
1642362|NCT01913990|Drug|Dexamethasone, Ondansetron, Aprepitant|Arm B participants will be given doses of anti-emetics based on the emesis risk calculation. Doses will vary depending on the which level they fall into level 0, level 1, 2 or 3 based on the participant's diary.
1642363|NCT01913990|Other|Arm A: Standard Anti-emetic regimen|Treating physician's discretion for type of anti-emetic to be prescribed.
1642364|NCT01913977|Device|Abylcap® System: blood flow (QB): 200mL/min; gas flow (QG):7L/min|Abylcap settings
1642365|NCT01913977|Device|Abylcap® System: blood flow (QB): 300mL/min; gas flow (QG):7L/min|Abylcap settings
1642366|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):7L/min|Abylcap settings
1642367|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):1.5L/min|Abylcap settings
1642368|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):3L/min|Abylcap settings
1642369|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):6L/min|Abylcap settings
1642370|NCT01913977|Device|Abylcap® System: blood flow (QB): 400mL/min; gas flow (QG):8L/min|Abylcap settings
1642371|NCT01913964|Drug|Acetylcarnitine|
1642372|NCT01913964|Drug|Placebo|(sugar pill)
1642373|NCT01913951|Drug|vosaroxin|Given IV over 10 minutes on Day 1 and 4
1642374|NCT01913951|Drug|Azacitidine|Given SC or IV over 15 minutes on days 1-7
1642375|NCT01913925|Other|Tyrosine-Containing Food Bar|
1642376|NCT01913925|Other|Placebo Bar|
1642377|NCT01913912|Drug|LDX.|"In this study 3 different doses of LDX will be used:
30 mg capsules: 30 mg LDX, equivalent to 8.9 mg of dexamphetamine
50 mg capsules: 50 mg LDX, equivalent to 14.8 mg of dexamphetamine
70 mg capsules: 70 mg LDX, equivalent to 20.8 mg of dexamphetamine"
1642378|NCT01913912|Drug|sugar pill|Children will take once only a placebo capsule during the DBPC phase (phase 4) the morning of the testing. For blinding purpose we will blindfold the children when taking placebo.
1642379|NCT01913912|Device|computer task (Go/No-Go task)|
1642380|NCT01913912|Device|EEG|event-related potentials (ERP) and heart rate measurements
1642381|NCT01913912|Device|pupil size measurements (by using eye tracking)|
1642382|NCT01913899|Other|Occupational/ physical therapy|
1642383|NCT01913899|Other|Mirror therapy|- Intervention group: treatment sessions of 60 minutes with mirror therapy over a period of 14 days starting directly post surgical (24-48 hours)
1642384|NCT01913886|Procedure|MSCs injection|MSCs cells will be injected in two aliquots of 10 ml by catheterism
1642385|NCT01913873|Other|serum concentration changes cardiac biomarkers|Serum concentration determination for cardiac biomarkers (CK-MB and Hs-cTn) preoperatively, at induction of anesthesia (after placement of the arterial line), upon arrival at the intensive care unit (ICU), as well as every 3 hours for 12 hours, then every 6 hours the following 12 hours and a last sample is taken 48 hours after surgery.
1642386|NCT01913860|Behavioral|Improving GP antibiotics prescribing behaviour|GPs will be asked to code their UTI patients within their patient management software. Anonomysed coded patients will be electronically extracted and this information will be provided as an audit and feedback report of the GPs antibiotic prescribing practices.
1642387|NCT01913847|Drug|Sildenafil|Oral sildenafil 20 mg TID for 12 weeks
1642388|NCT01913847|Drug|Placebo|Oral placebo TID for 12 weeks
2012411|NCT02025387|Behavioral|Physical activity feedback|
2012412|NCT02025387|Behavioral|Usual care except physical activity measurement|
1642391|NCT01913808|Drug|Ferric carboxymaltose|Single intravenous dose ferric carboxymaltose
1642392|NCT01913808|Drug|ferrous glycine sulphate|Daily oral dose of 100 mg iron (ferrous glycine sulphate)
1642393|NCT01913795|Other|integrated pest management|integrated pest management and environmental strategy
1642394|NCT01913795|Other|air purifier|air purifiers
1642395|NCT01913795|Other|Sham air purifier|sham air purifiers
1642396|NCT01913769|Radiation|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
1642397|NCT01913756|Dietary Supplement|Gamalost (Norwegian traditional cheese)|
1642398|NCT01913756|Dietary Supplement|Gouda-type cheese|
1642399|NCT01913730|Drug|Bortezomib|
1642400|NCT01913730|Drug|Dexamethasone|
1642401|NCT01913717|Radiation|External beam radiotherapy|The patients will be treated with extreme hypofractionated radiotherapy with the dose delivery system that will result most fit at the in-silica study. Simultaneous Integrated Boost (SIB) technique will be applied to deliver a total dose of 36.25 Gy in 5 fractions (over 10 days) to the whole prostate (7.25 Gy/fraction) and 37.5 Gy to the dominant intraprostatic lesion DIL (7.5 Gy/fraction), profiting of the high sensibility of prostate cancer to high dose/fraction. Several strategies will be applied in order to reduce the dose to the surrounding organs at risk.
1642402|NCT01913704|Device|NatroxTM Device|"The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device.
The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks."
1642403|NCT01913691|Drug|Ipilimumab|Ipilimumab is a recombinant, human monoclonal antibody that binds to CTLA-4. It is commercially available under the brand name Yervoy . The use of ipilimumab for MCC is investigational: a study-specific supply of medication will be provided by Bristol-Myers Squibb.
1642404|NCT01913678|Other|Inulin|The participants will be given all dietary items in their diet. In the inulin arm, approximately 15 grams of inulin will be included in the diet.
1642405|NCT01913678|Other|Complete diet|The participants will be given all dietary items in their diet with no additional products.
1642409|NCT01913665|Other|B.Lactis +Inulin|
1642417|NCT01913626|Behavioral|cognitive group therapy|the cognitive group therapy is composed of eight meetings including information about memory processes, learning and practicing tools and strategies to improve cognition and memory.
1642418|NCT01913613|Device|IASD|IASD device implantation
2012413|NCT02024880|Device|Protective catheter group|The tip of this catheter is protected on insertion of the catheter.
1642420|NCT01913587|Device|Acupuncture|Acupuncture points are ST36, GB34 (bilateral), BL60 (bilateral), BL40 (bilateral), and 2 Back-su points (bilateral). Back-su points are selected as close as possible to pain region. Electroacupuncture will be performed at only 2 Back-su points (bilateral).
1642421|NCT01913587|Procedure|Nerve block|Epidural nerve block uses the mixture (10ml) of dexamethasone (10 mg) and bupivacaine (10 mg) dissolved in saline solution. Medial branch block uses mepivacaine (10 mg).
1642422|NCT01913574|Device|Acupuncture|Acupuncture is applied three times a week for 20 minutes for 2 weeks (total 6 sessions). 9 Acupuncture points, CV12, CV13, P6, SP4, ST36(bilateral),LI4 (bilateral), LR3 (bilateral), ST34 (bilateral), and GB21(bilateral) are used, and CV12, CV13, ST36, and LR3 are electro-stimulated.
1642423|NCT01913574|Procedure|Neurolytic celiac plexus block (NCPB)|An anaesthetic test is performed injecting 2ml mepivacaine. After assessing the efficacy and safety of this test, 10 ml of absolute alcohol is injected via each needle.
1642424|NCT01913561|Device|Master Caution Garment|"Master Caution Garment is embedded with 10/13 textile dry electrodes that enable 12/15-lead ECG.
The electrodes are dry, textile ECG electrodes."
1642425|NCT01913561|Device|ECG gel electrodes|Standard gel electrodes that are been in use in hospital for ECG monitoring.
1642426|NCT01913535|Drug|CERC-501|"Low dose of CERC-501 will be 10 mg/day during the first phase (3 days) and during the second phase (3 days).
High Dose of CERC-501 will be 20 mg/day during the first phase (3 days) and during the second phase (3 days).
For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.
For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
1642427|NCT01913535|Drug|Placebo|"For patients randomly assigned to the placebo/ placebo sequence, study medication will be placebo during the first phase (3 days) and during the second phase (3 days).
For patients randomly assigned to the placebo/low-dose drug sequence, the patient will receive placebo for 3 days and then 10 mg/day CERC-501 for the following 3 days.
For patients randomly assigned to the placebo/high-dose drug sequence, the patient will receive placebo for 3 days and then 20 mg/day CERC-501 for the following 3 days."
1642428|NCT01913522|Procedure|Pulmonary Vein Isolation|
1642429|NCT01913509|Device|Combined Therapy of FES and BAT|FES treatment is applied to stimulate the supraspinatus muscle and the posterior deltoid muscle of the affected shoulder. Then patients receive bilateral arm training focused on reaching, shoulder abduction, and shoulder horizontal abduction.
1642430|NCT01913509|Device|Conventional Rehabilitation|Stroke patients in CR group receive the protocol which includes (1) TENS; (2) BAT. The activities are adapted based on the level of motor impairment, and functional needs of individual patients.
1642431|NCT01913496|Other|ebalance|using the ebalance application for 14 weeks
1642432|NCT01913483|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
1642433|NCT01913483|Drug|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
1642434|NCT01913470|Drug|Losartan|Oral tablet to be taken once daily at 0.4mg/kg/day (max 25mg) for one week and then increased to 0.8mg/kg/day (max 50mg) for 7 additional weeks.
1642435|NCT01913457|Radiation|Ultrasound Doppler|Doppler Ultrasound recording on external right chest wall
1642436|NCT01913444|Drug|Recombinant Antithrombin|
1642437|NCT01913431|Drug|Baracle Tab.®|
1642438|NCT01913431|Drug|Baraclude Tab.®|
1642439|NCT01913418|Drug|Suan-Zao-Ren Tang|SZRT is composed of five herb ingredients as follows: Semen Zizyphi Spinosae (Suanzaoren), Sclerotium Poriae Cocos (Fuling), Radix Ligustici Chuanxiong (Chuanxiong), Rhizoma Anemarrhena (Zhimu), and Radix Glycyrrhizae (Gancao).The SZRT granules were packed in aluminum foil packages and administered orally at a dose of 4 g, three times per day for four weeks.
1642440|NCT01913418|Drug|Suan-Zao-Ren Tang placebo|The Suan-Zao-Ren Tang placebo granules are prepared with 4 g starch inside the same colored and sized foil packages.
2012414|NCT02024880|Device|Conventional catheter group|A standard embryo catheter
1642442|NCT01913392|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy
1642443|NCT01913379|Drug|MDV3100|Oral
1642444|NCT01913379|Drug|Gemfibrozil|Oral
1642445|NCT01913379|Drug|Itraconazole|Oral
1642446|NCT01913366|Behavioral|CM-PST|
1642447|NCT01913366|Behavioral|SG-PST|
1642448|NCT01913353|Biological|MVA BN®|0.5 ml MVA BN® with a nominal titre of 1x10E8 TCID50, administered as a subcutaneous injection
1642449|NCT01913353|Biological|ACAM2000®|0.0025 ml ACAM2000®, consisting of 2.5-12.5x10E5 plaque forming units of live vaccinia virus (VACV). Picked up with a bifurcated needle and administered by the percutaneous route (scarification) using 15 jabs of that bifurcated needle.
2012415|NCT02022826|Device|SmartPill Monitoring System|
2012416|NCT02022917|Drug|Bevacizumab|Bevacizumab 15 mg/ Kg (from post-op cycle 2) intravenous infusion for 30 minutes in a 21 days' cycle for at least three cycles (best to 6 cycles) followed by 3-weekly maintenance bevacizumab 15 mg/ Kg intravenous infusion for 17 cycles.
2012417|NCT02022423|Behavioral|Telephone counseling|4 months of weekly contact to update exercise prescription and discuss barriers and challenges to adherence
1642457|NCT01913288|Other|Biological Maternal Sounds|
1642458|NCT01913275|Procedure|Endoscopic stenting|Endoscopic stenting to decrease preopertaive jaundice
1642459|NCT01913275|Procedure|cholecystojejunostomy|surgical procedure to decrease preoperative jaundice
1642460|NCT01913262|Behavioral|Standard Behavioral treatment|Standard behavioral treatment (e.g. problem solving therapy, cognitive behavioral treatment)
1642461|NCT01913249|Procedure|LIFT|Ligation of intersphincteric fistula tract
1642534|NCT01912690|Other|aerobic training|
1642535|NCT01912690|Other|aerobic and strength training|
1642536|NCT01912677|Drug|Nifedipine|
1642462|NCT01913236|Other|Implementation intervention|Investigators will provide a comprehensive package of interventions to assist health care professionals to adhere to the recommendations. The package will include support for developing a collaborative care plan in the municipality, resources for general practitioners and other health care professionals, resources for patients, their relatives and volunteers,outreach visits to general practitioners' practices and their educational groups, educational resources and web-based resources.
1642463|NCT01913223|Device|Nestis® jet injector system with a bi-functional catheter|
1642464|NCT01913210|Dietary Supplement|Ginseng|
1642465|NCT01913197|Other|An MRI-based technique to identify prostate cancer|
1642466|NCT01913184|Device|AKITA|
1642467|NCT01913171|Other|Exercise|
1642468|NCT01913158|Drug|Anucort-HC, 25 Mg Rectal Suppository|Hydrocortisone acetate suppositories
1642469|NCT01913158|Drug|Placebo suppository|Hydrogenated palm kernel oil suppositories
1642470|NCT01913145|Device|A1c, Self-collection, Blood sample|This is a study to evaluate the safety and effectiveness of Micro-Serum/Micro-Blood (finger Stick) Specimen Collection as compared to samples obtained by standard venipuncture (blood taken from the arm vein).
1642471|NCT01913132|Device|Negative pressure wound therapy with PICO (Smith & Nephew)|Negative wound pressure therapy
1642472|NCT01913119|Drug|Romidepsin|"Day 1, 8, and 15 of a 28-day cycle Romidepsin Treatment is repeated until documented disease progression or unacceptable toxicity.
Dose and administration: 4-hour infusion of 14 mg/m2"
1642473|NCT01913106|Drug|HSV-tk +Valacyclovir in Combination with Brachytherapy|"The investigators insert a gene from a herpes simplex virus (HSV), which is a small piece of the basic structure of the virus, into the prostate gland tumor cells. The gene is called the thymidine kinase (tk) gene, which the cell uses to make a protein that can change valacyclovir, The way the tk gene will be transported into the tumor cells is by using a vector or vehicle to carry the tk gene into the cells. In this case the vector is a virus - an adenovirus. Scientists at the Department of Cell and Gene Therapy at The Methodist Hospital removed a portion of the adenovirus' genetic material that allows it to replicate so that it cannot cause infections. In place of the removed genetic material the scientists inserted the tk gene. Now the vector can carry the tk gene into tumor cells. When the vector/gene combination gets into tumor cells, it inserts itself into the cells' command center (nucleus) and tells the tumor cells to begin making thymidine kinase protein."
1642474|NCT01913080|Other|Health Log|"The Health Log consists of a permanent booklet and a refillable health log version that is filled out before each doctor's appointment. The permanent booklet has areas to record:
Personal information and emergency contact(s)
Physician names and contact information
Insurance information
Medications, vitamins and supplements
Surgeries
Health history The booklet also includes suggested questions you may want to ask your Rheumatologist about medications, lifestyle, or future/status.
The refillable health log includes questions about pain, fatigue,overall status from the Multi-Dimensional Health Assessment Questionnaire (MDHAQ), and a modified Arthritic Pain and Joint Evaluation. It also has space to write questions for the doctor's visit and prescription refills needed."
1642475|NCT01913067|Drug|Cabazitaxel|Intravenous, 25 mg/m2 every 3 weeks
1642476|NCT01913067|Procedure|Contrast-enhanced whole brain MRI|Evaluation of the volumetric reduction in the size of the brain lesion(s).
1642477|NCT01913054|Drug|Fentanyl Injection|
1642478|NCT01913054|Drug|Etomidate Fat Emulsion Injection|
1642479|NCT01913054|Drug|Propofol Injection|
1642480|NCT01913028|Drug|MEDI9929|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
1642481|NCT01913028|Drug|Placebo|1st cohort : Dose 1 MEDI9929 or placebo 2nd cohort : Dose 2 MEDI9929 or placebo 3rd cohort : Dose 3 MEDI9929 or placebo
1642482|NCT01913015|Drug|abiraterone acetate|Given PO
1642483|NCT01913015|Dietary Supplement|dietary intervention|Receive low fat breakfast
1642484|NCT01913015|Dietary Supplement|dietary intervention|Receive high fat breakfast
1642485|NCT01913015|Other|pharmacological study|Correlative studies
1642486|NCT01913015|Other|questionnaire administration|Ancillary studies
1642487|NCT01913015|Other|laboratory biomarker analysis|Correlative studies
1642488|NCT01913002|Drug|LX4211 800 mg|
1642489|NCT01913002|Drug|LX4211 2000 mg|
1642490|NCT01913002|Drug|moxifloxacin 400 mg|
1642491|NCT01913002|Drug|LX4211 Placebo|
1642492|NCT01912989|Behavioral|Lifestyle counseling|Parents will participate in one telephone and one in person session of motivational interviewing prior to their participation in an 8 week parent-exclusive treatment focusing on parenting skills to improve their child's overweight.
1642493|NCT01912976|Drug|Er:YAG AFL-PDT|Er:YAG AFL was performed with 550-600 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse. MAL cream was then applied under occlusion for 3 hrs and illuminated with a red light-emitting diode light at 37 J/cm2.
1642494|NCT01912976|Drug|MAL-PDT|a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm-2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later.
1642495|NCT01912963|Drug|Pertuzumab, Trastuzumab and Eribulin|"Each study treatment cycle lasts 21 days. The patient will receive eribulin on the first day (day 1) and on the 8th day (day 8) of the cycle. The patient will also receive trastuzumab and pertuzumab on day 1. All drugs will be given to intravenously in clinic.
In the first portion of the study, we will examine which dose of eribulin is the safest when given in combination with pertuzumab and trastuzumab. For the first 6 participants enrolled onto the study, we will be look to see if the standard dose of eribulin can be administered safely with standard doses pertuzumab and trastuzumab. If this dose of eribulin is not tolerated well, we will test the three-medication combination with a lower dose of eribulin. The highest dose that will be found to be safe will be used in the next participants. The dose you receive will depend on the number of participants who have been enrolled in the study before you and how well they have tolerated their doses."
1642496|NCT01912950|Device|Prowave LX IPL|
1642537|NCT01912677|Drug|Labetalol|
2012418|NCT02022423|Behavioral|Internet-based walking program|Four-month Internet-based walking program consisting of weekly step count goals, a personalized website with an online community, and tailored tips.
1642498|NCT01912924|Device|Spinal cord stimulator (Boston Scientific)|spinal cord stimulator trial leads and hand held battery
1642499|NCT01912898|Device|No intervention,The group with vitamin D deficient will be treated by the Endocrinology Department by loading of vitamin D|
1642500|NCT01912885|Device|TENS 1-1|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg once a week.
1642501|NCT01912885|Device|TENS 1-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on one leg twice a week.
1642502|NCT01912885|Device|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs once a week.
1642503|NCT01912885|Device|TENS 2-2|Electrical stimulation using Transcutaneous Electrical Nerve Stimulation on two legs twice a week.
1642504|NCT01912885|Device|TENS 0-1|Placebo: application os electrodes of Transcutaneous Electrical Nerve Stimulation on one leg once a week, without turning on the device.
1642505|NCT01912872|Drug|Omalizumab|Subcutaneous injection dose according to the IgE level and body weight.
1642506|NCT01912872|Drug|Budesonide|Budesonide (400 μg, 200 μg or 100 μg) tablets taken orally according to maximum daily dose.
1642507|NCT01912872|Drug|Formoterol|Formoterol 12ug tablets taken orally according to maximum daily dose.
1642508|NCT01912859|Behavioral|Nutrition/physical activity intervention|Nutrition/physical activity intervention
1642509|NCT01912846|Behavioral|Interactive advance care planning|"The facilitator will begin each course of intervention by assessing the patient's and his/her family caregiver's readiness for engagement in ACP independently.
Providing participant-centered care tailored to the specific needs of participants at each stage of readiness for engagement in ACP.
Facilitating EOL care discussions throughout the dying process.
A workbook and a video decision aid that briefly describes ACP to enhance participants' understanding of the essential elements in ACP."
1642510|NCT01912846|Behavioral|Attention usual care|a consistent master prepared nurse on the study team will provide the attention portion of the care. The initial meeting will occur before the patient discharges from hospital and the usual care nurse will give patients and family caregivers a workbook and a video with educational materials on how to manage common symptoms and a comprehensive list of resources available, including patient support organizations, support and financial assistance through the social work department..
1642511|NCT01912820|Dietary Supplement|green tea extract|Given PO
1642512|NCT01912820|Drug|quercetin|Given PO
1642513|NCT01912820|Other|placebo|Given PO
1642514|NCT01912820|Procedure|therapeutic conventional surgery|Undergo prostatectomy
1642515|NCT01912820|Other|laboratory biomarker analysis|Correlative studies
1642516|NCT01912807|Drug|Dextrose (D5NS)|Solution Dextrose 5% in Normal Saline (D5NS) was used as a second antiemetic, at an intravenous maintenace rate (4 cc per Kg for first 10 Kg, 2 cc per Kg for next 10 Kg and 1 cc per Kg for the next Kg of weight) calculated based on the patient's weight
1642517|NCT01912807|Drug|Ondansetron (Control)|Ondansetron was used at a prophylactic dose (0,05 mg per Kg) based on patient's weight.
2012419|NCT02020889|Biological|Mepolizumab|Mepolizumab will be provided as a lyophilized cake in sterile vials for individual use to be reconstituted with sterile water for Injection, just prior to use.
1642519|NCT01912781|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of gas permeable contact lenses
1642520|NCT01912781|Device|Boston Simplus multi-action solution|Commercially available solution indicated for cleaning, removing protein, rinsing, disinfecting, conditioning, storing and cushioning of fluoro silicone acrylate and silicone acrylate rigid gas permeable contact lenses
1642521|NCT01912781|Device|Gas permeable contact lenses|Commercially available gas permeable contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days).
1642522|NCT01912768|Device|FID 120947A contact lens disinfecting solution|Investigational 3% hydrogen peroxide solution intended for simultaneous cleaning, protein removal, disinfecting and storage of silicone hydrogel and soft contact lenses
1642523|NCT01912768|Device|renu fresh multi-purpose solution|Commercially available solution indicated for cleaning, removing protein deposits, rinsing, chemical disinfection, and storage of soft contact lenses
1642524|NCT01912768|Device|Soft contact lenses|Commercially available soft contact lenses worn a minimum of 8 hours each day on a daily wear basis for the duration of the study (90 days). A fresh pair will be dispensed on Day 0, Day 30, and Day 60.
1642525|NCT01912755|Drug|4% articaine with 1:100,000 epinephrine|If the primary anesthesia failed after ten minutes, an intraligamentary injection with 4% articaine with 1:100,000 epinephrine was performed and the procedure initiated. When access to the pulp chamber was available, intrapulpal anesthesia was given using 4% articaine with 1:100,000 epinephrine.
1642526|NCT01912755|Drug|2% lidocaine with 1:100,000 epinephrine|If the patient reported pain during treatment and access to the pulp chamber was not achieved, an IANB was performed with 2% lidocaine with 1:100,000 epinephrine.
1642527|NCT01912742|Behavioral|Very-low calorie diet (VLCD)|
1642528|NCT01912742|Behavioral|Low calorie diet (LCD)|
2012420|NCT02020889|Drug|Placebo|Placebo will be available as 0.9% sodium chloride
2012421|NCT02020278|Drug|Tolvaptan|"Tolvaptan 3.75-, 7.5-, 15-, and 30-mg spray-dried tablets
Dosage: Depending on age & weight:
Tablet (3.75 mg - 60 mg daily) Frequency: Once daily Duration: Subjects may be eligible to receive short-term or long-term optional tolvaptan treatment at any time during their participation in the trial, with one or more treatment cycles over a 6-month period."
2012422|NCT02017717|Biological|Nivolumab|
2012423|NCT02017717|Biological|Bevacizumab|
2012424|NCT02017717|Biological|Ipilimumab|
2012425|NCT02014649|Drug|20 mg laninamivir octanoate|
2012426|NCT02014649|Drug|Placebo|
2012427|NCT02014649|Drug|40 mg laninamivir octanoate|
2012428|NCT02008045|Device|Magnetic Resonance Imaging|Brain MRI without Contrast
2012429|NCT02008045|Behavioral|Neurodevelopmental Testing|Validated battery of neurodevelopmental and psychological tests.
1642539|NCT01912651|Drug|cephalexin|This consists of a single dose of cefazolin or, in penicillin allergic patients, clindamycin administered at the time of anesthesia administration prior to the surgical incision. In the cohort randomized to receive post-operative antibiotics, the first choice intervention will be oral cephalexin (500 mg, three times daily or four times daily, for one week). In patients who are penicillin or cephalosporin allergic, we will prescribe clindamycin (300 mg, three times daily or four times daily, for one week). Patients will be followed up within 2 to 6 weeks of surgery and outcome measures assessed. Patients will, again, be seen at 6 months and 1 year post-operatively for outcome assessment.
1642540|NCT01912638|Device|Ologen Collagen Matrix|Ologen is a porous collagen-glycosaminoglycan matrix that decrease early postoperative scarring after penetrating anti-glaucomatous surgery by randomized collagen deposition and microcyst formation. Implantation of Ologen Collagen Matrix in trabeculectomy was performed.
1642541|NCT01912638|Drug|Provisc|Provisc is an cohesive viscoelastic.
1642542|NCT01912625|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
1642543|NCT01912625|Drug|Carboplatin|Given IV
1642544|NCT01912625|Radiation|Image Guided Radiation Therapy|Undergo IGRT
1642545|NCT01912625|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1642546|NCT01912625|Other|Laboratory Biomarker Analysis|Correlative studies
1642547|NCT01912625|Drug|Paclitaxel|Given IV
1642548|NCT01912625|Other|Pharmacological Study|Correlative studies
1642549|NCT01912625|Drug|Trametinib|Given PO
1642550|NCT01912612|Drug|Duloxetine|Subjects will receive 30 mg duloxetine orally for 7 days, then 60 mg duloxetine orally for 28 days, then 30 mg duloxetine orally x 14 days.
1642551|NCT01912599|Device|Sensimed Triggerfish|IOP will be measured with the Sensimed Triggerfish, which is a disposable silicone contact lens embedded with a wireless sensor. The sensing resistive gauge in the device is circular around the center of the lens and is placed over a circumference of 11.5 mm in diameter. This corresponds to the corneoscleral junction position, where maximum corneal deformation occurs as a result of changes in IOP. A soft patch containing the receiving antenna will be applied around the eye and transmits the information via wire to the recorder that the patient will wear around the waist. The patient can continue to wear spectacles during monitoring. The device records a total of 144 measurements over a 24-hour period.
1642552|NCT01912599|Device|Blood Pressure|Patients in both groups will be fitted with a blood pressure cuff that will measure pressures for 24 hours.
1642553|NCT01912586|Other|vacuum erection device|sildenafil: 25mg/day nightly for 3 months vacuum erection device: make erections for 10-15 minutes/day for 3 months
1642554|NCT01912573|Drug|Intranasal (IN) naloxone|
1642555|NCT01912573|Drug|Intravenous (IV) naloxone|
1642556|NCT01912573|Drug|Intramuscular (IM) naloxone|
1642557|NCT01912573|Drug|Intraosseus (IO) naloxone|
1642558|NCT01912560|Drug|CAT-2003|
1642559|NCT01912560|Drug|Placebo|
1642560|NCT01912560|Drug|Statin|All patients being treated with a stable dose of a statin prior to enrollment continue on their dosing regimen.
1642561|NCT01912547|Procedure|Blood draw for TEG analysis|Blood drawn for TEG analysis
1642562|NCT01912534|Drug|Valsartan|40, 80 and 160 mg tablets of Valsartan
1642563|NCT01912534|Drug|Placebo|During Active Run-In, all patients take Valsartan. During maintenance, all patients are randomized to valsartan or placebo
1642564|NCT01912521|Behavioral|Mfangano Health Net Microclinic Program|Educational program in which HIV positive individuals are invited to recruit their social networks to form 'microclinic' groups. These groups participate in a 6-month educational curriculum composed of information on HIV biology, interpersonal communication strategies and community mobilization. At the conclusion of the program, participants are encouraged to disclose their HIV status to members of their group through a facilitated disclosure process.
1642565|NCT01912495|Drug|Boceprevir|
1642566|NCT01912482|Other|Cardiorespiratory training|The cardiorespiratory training group will undergo 18 sessions, these also periodized in a maximum six weeks, respecting the minimum weekly frequency of 3 sessions.
1642567|NCT01912482|Other|ventilatory training|The ventilatory training group will undergo 18 sessions, periodized in a maximum six weeks, respecting the minimum weekly frequency of three sessions.
1642568|NCT01912469|Drug|Traumeel|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
1642569|NCT01912469|Drug|Placebo|oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
1642570|NCT01912456|Biological|Low-volume C1-esterase inhibitor|
1642571|NCT01912456|Biological|Higher-volume C1-esterase inhibitor|
1642572|NCT01912456|Biological|Low-volume placebo|
1642573|NCT01912456|Biological|Higher-volume placebo|
1642574|NCT01912443|Drug|bevacizumab|5 mg/Kg, IV (in the vein) on day 1 and day 14 of each 28 day cycle. Number of Cycles: until progression.
1642575|NCT01912430|Behavioral|ICC (Integrated Care Coaching) Intervention Group|
1642576|NCT01912417|Other|Aerobic exercise with cycle ergometer during hemodialysis|Participants underwent hemodialysis trained on an cycle ergometer. The training is performed in the first 2 hours of hemodialysis, with a total exercise time of 60 minutes. Each exercise period of 20 minutes was separated by 10 minutes of rest. The patients are advised to work with a level of perceived exertion of 'somewhat strong' (13-14 of Borg scale). For safety, heart rate and blood pressure were monitored throughout the session. The training is terminated if the patients exceeded 80% of their maximum heart rate (MHR = 220 - age in years), blood pressure parameters are exceeded (above 200/110 or below 110/50mmHg) or the patient had chest pain, severe dyspnea, wheezing, leg cramps, confusion, visual symptoms, pallor or cyanosis.
1642577|NCT01912404|Drug|IDN-6556|25 mg BID for 28 days
1642578|NCT01912404|Drug|Placebo|Placebo controlled
1642579|NCT01912391|Drug|Selegiline|The Study Drug known as either selegiline 12 mg patch or matching placebo patch will be administered daily beginning at Visit 2 for the duration of 12 weeks.
1642580|NCT01912391|Drug|Placebo (for Selegiline)|Transdermal Placebo patch manufactured to mimic Transdermal Selegiline 12 mg. patch
1642581|NCT01912378|Drug|Oxytocin|
1642582|NCT01912365|Procedure|Above Elbow Cast|
1642585|NCT01912339|Device|Rezum System|"The Rezūm System uses sterile water vapor (steam) to treat BPH by delivering targeted, controlled doses of stored thermal energy directly to the transition zone of the prostate gland.
A narrow sheath, similar in shape and size to a cystoscope, is inserted transurethrally and positioned within the prostatic urethra between the bladder neck and the verumontanum.
A thin needle is deployed through the urethra into the transition zone, and a very short (8-10 second) treatment of water vapor is delivered directly into the hyperplastic tissue and immediately disperses through the tissue interstices.
Upon contact with the tissue, the vapor condenses, or phase shifts, into its liquid state, releasing the stored thermal energy contained within the vapor. This thermal energy is released directly against the walls of the tissue cells within the treatment zone, gently and immediately denaturing the cell membranes, thereby causing instantaneous cell death."
1642586|NCT01912339|Procedure|Rigid Cystoscopy|Endoscopy of the urinary bladder via the urethra.
1642587|NCT01912326|Device|Pacemaker Implantation|Implantation of a dual chamber pacemaker
1642588|NCT01912313|Procedure|Rectal biopsies from IBS patients or healthy subjects will be taken during proctoscopy|
1642589|NCT01912300|Behavioral|experimental condition: Passvice Video game; Avtive Video game; Exercise|
1642590|NCT01912287|Behavioral|Cognitive Behavioral Therapy|CBT focused on Generalized Anxiety Disorder (12 sessions)
1642591|NCT01912287|Behavioral|Stress Education|Active control group (12 sessions)
1642592|NCT01912287|Behavioral|Yoga|12 sessions, mindfulness components
1642593|NCT01912274|Drug|pracinostat with azacitadine|Elderly newly diagnosed patients will all receive the combination of pracinostat with azacitadine
1642594|NCT01912261|Drug|Placebo|one capsule orally daily times 84 days
1642595|NCT01912261|Drug|Polysaccharide iron complex|150 mg daily orally times 84 days
1642596|NCT01912248|Other|strength training|strength training, lower limb.
1642597|NCT01912235|Other|2-15N glutamine|Glutamine with N15 isotope tracer
1642598|NCT01912235|Other|15N2 arginine and 15N proline|Arginine and Proline isotope tracers
1642599|NCT01912235|Other|1-13C glutamine|Glutamine carbon isotope tracer
1642600|NCT01912222|Drug|IXAZOMIB|
1642601|NCT01912209|Behavioral|My Everyday Health|MyEveryday Health is a web-based nutritional and lifestyle management program. The program includes personalized diet and weight guidance, meal planners, shopping list generator, recipe finder, weight tracker and dining out and fast food guides. Based on specific algorithms, tips and suggestions on how to make changes in their diet and lifestyle will be give each time the subject logs in. The MyEverydayHealth website will also be available as an app for their smart phone to the participants. If they choose to use the app, daily reminders to log in and use their tools will be sent, along with motivating tool/tips/tricks to stay with the program.
1642602|NCT01912196|Drug|MSI-195|
1642603|NCT01912196|Drug|Placebo|
1642604|NCT01912183|Behavioral|Communication through PHR outside clinic|
1642605|NCT01912183|Behavioral|Monitoring device in PHR|
1642606|NCT01912183|Device|Physical activity and sleep monitor|
1642607|NCT01912183|Other|PHR|Access to their PHR
1642608|NCT01912170|Dietary Supplement|Fish oil|
1642609|NCT01912170|Dietary Supplement|Flaxseed oil|
1642610|NCT01912157|Behavioral|Expressive Writing|The intervention consists in 3 self-applied solitary written disclosure sessions (expressive writing)
1642611|NCT01912144|Other|Coffee|
1642612|NCT01912131|Behavioral|single pilot interview|Part 1 participants will be scheduled for their single pilot interview. There are no additional assessments.
1642613|NCT01912131|Behavioral|goals-of-care (GOC) video|Subjects will be shown the goals-of-care (GOC) video but not undergo a narrative interview process - they will be contacted as per re-assessment.
1642614|NCT01912131|Behavioral|goals-of-care (GOC) video and narrative question|subjects will watch the goals-of-care (GOC) video (described in detail in the next paragraph) and then be given the narrative question stem vetted/assessed in part 1 including any changes made to that stem in the process of Part 1 testing. Subjects in P-COCC arm will then be contacted for a telephone interview and audio-taping of their narrative. Interviews will be semi- structured and based off the narrative stem that subjects were previously given for review. Interviews will last approximately 30-45 minutes and will be conducted by staff from the MSKCC Department of Psychiatry & Behavioral Sciences,
1642615|NCT01912131|Behavioral|usual care|Subjects in the usual care arm will neither be given the narrative stem nor watch the video.
1642616|NCT01912131|Behavioral|Part 2|Will be a proof-of-concept, small scale, RCT to measure P-COCC acceptability and other quantitative and qualitative effects. Seventy five participants will be randomized to Usual Care, Video, or Video and Interview.
1642617|NCT01912118|Drug|Propofol|Propofol will be titrated via a target controlled infusion to reach a specific target BIS (as specified in treatment arm)
1642618|NCT01912118|Drug|Remifentanil|Remifentanil will be provided by a target controlled infusion to a specific effect site concentration (as specified in treatment arm)
1642619|NCT01912105|Device|Airway medix closed suction system|
1642620|NCT01912105|Device|standard closed suctioning systems|
1642621|NCT01912092|Device|Askina Calgitrol paste|
1642622|NCT01912066|Drug|Stillen|
1642623|NCT01912066|Drug|Cytotec (reference drug)|
1642624|NCT01912066|Drug|NSAID (Aceclofenac)|
1642625|NCT01912053|Radiation|Therasphere® in association with Gemcitabine and Cisplatin|Therasphere® is a radioelement
1642626|NCT01912040|Drug|Administration of 123Iodine MIBG|Patients will be administered the locally produced 123 Iodine MIBG
1642627|NCT01912027|Procedure|Open Latarjet technique|
1642628|NCT01912027|Procedure|Arthroscopic Latarjet techniques|
1642629|NCT01912014|Behavioral|Psychosocial support and counselling|
1642630|NCT01912001|Other|Telephone follow-up|
1642631|NCT01912001|Other|Sympton Assessment|
1642632|NCT01911975|Drug|Lacosamide|comparison between lacosamide 200mg twice daily and microcrystalline cellulose (placebo) 200mg twice daily.
1642633|NCT01911975|Drug|Placebo|comparison between microcrystalline cellulose (placebo) 200mg twice daily and lacosamide 200mg twice daily.
1642634|NCT01911962|Procedure|transvaginal laparoscopic surgery|
1642635|NCT01911949|Drug|Single shot femoral nerve block|Nerve block in lingual crease using ultrasound guidance
1642637|NCT01911923|Procedure|No CPAP/PEEP and 100 % oxygen|This is the control group and 100 % oxygen will be used during induction of and emergence from anesthesia, no enhanced level of CPAP/PEEP is implemented. During controlled ventilation ventilation mode is volume controlled.
1642638|NCT01911923|Procedure|CPAP/PEEP and 30 % oxygen|During all phases of anesthesia CPAP/PEEP will be used together with 100 % oxygen during induction of as well during emergence from anesthesia until after extubation when 30 % oxygen will be used.
1642639|NCT01911910|Behavioral|Electronic coaching plus standard care|The HAPPY London web-based tool will provide the participant with an individualised score for their lifestyle and 10 year CV risk score, based mainly on the modified Framingham score, and provide tailored advice and education on the suboptimal factors. Ideal targets will be set and the information will be updated at 3 and 6 months allowing the participant to view their progress. Weekly emails with brief health and lifestyle advice will be sent to encourage healthier behaviour based on clinical studies or topical issues in the media. Links to social networks, such as Facebook posting and the ability to allow chosen family and friends to view their progress will aim to further encourage healthier behaviour.
1642640|NCT01911897|Device|MobiusHD|Implant that is placed in the carotid sinus to control hypertension.
1642641|NCT01911884|Behavioral|evaluate quality of life of surgical and non surgical vaginal aplasia|protocol designed to evaluate quality of life of surgical and non surgical vaginal aplasia
1642642|NCT01911871|Biological|Blood sample|a blood sample was taken on the day of inclusion
1642643|NCT01911858|Device|Askina Calgitrol Paste|
1642644|NCT01911845|Drug|ABT-450/r/ABT-267|Tablet; ABT-450 coformulated with ritonavir and ABT-267
1642645|NCT01911845|Drug|ABT-333|Tablet
1642646|NCT01911845|Drug|Ribavirin (RBV)|Tablet
1642647|NCT01911832|Procedure|esophagojejunostomy after total gastrectomy|
1642648|NCT01911832|Procedure|Roux-en-Y gastrojejunostomy after subtotal gastrectomy|
1642649|NCT01911832|Procedure|wide tube reconstruction after subtotal gastrectomy|
1642650|NCT01911832|Procedure|narrow tube reconstruction after subtotal gastrectomy|
2012430|NCT02007512|Drug|Enzalutamide|160 mg/day administered as four 40-mg soft gelatin capsules by mouth once daily with or without food.
2012431|NCT02007512|Drug|exemestane|25 mg capsule administered as a single capsule by mouth once daily after food.
1642655|NCT01911806|Device|Back care pillow|back care pillow is specific size by age groups of standard deviation of the lumbar spinal curvature, in 20-29 years was 51.68 ± 6.94 degrees, in 30-39 years was 59.67 ± 7.02 degrees, in 40-49 years was 63.66 ± 7.62 degrees, in 50-59 years was 65.75 ± 10.85 degrees and in 60-69 years was 64.19 ± 9.69 degrees
1642656|NCT01911806|Procedure|standard physical therapy treatment|standard physical therapy treatment are ultrasound therapy and hot pack
1642657|NCT01911793|Device|Stoma Tube|Stoma tube will be inserted into stoma at the time of surgery for patients assigned to Stoma Tube group.
1642658|NCT01911780|Drug|placebo|placebo matching amlodipine capsule
1642659|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
1642660|NCT01911780|Drug|telmisartan + HCTZ|FDC tablet
1642661|NCT01911780|Drug|amlodipine|capsule
1642662|NCT01911767|Drug|dimethyl fumarate|Provided under routine clinical care
1642663|NCT01911767|Drug|Peginterferon beta-1a|Provided under routine clinical care
1642664|NCT01911767|Drug|Dalclizumab High Yield Process|Provided under routine clinical care
1642665|NCT01911754|Biological|H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)|
1642666|NCT01911741|Drug|MDV3100|Oral
1642667|NCT01911728|Drug|MDV3100|Oral
1642668|NCT01911728|Drug|Pioglitazone|Oral
1642669|NCT01911728|Drug|Warfarin|Oral
1642670|NCT01911728|Drug|Omeprazole|Oral
1642671|NCT01911728|Drug|Midazolam|Oral
1642672|NCT01911715|Drug|MDV3100|Oral
1642673|NCT01911702|Other|Standard fluidic resuscitation.|"Goals:
arterial pressure mean ≥ 65 mmHg or equal to the pre-operative
diuretic rhythm ≥ 1 ml / Kg / h
venous saturation in vena cava ≥ 70% or mixed venous saturation as Swan Ganz's catheter (SG) ≥ 65%
BE> - 3
Central Venous Pression (PVC) ≥ 8 mmHg; for patients undergoing mechanical ventilation, this limit may be raised to 12-15 mmHg."
1642674|NCT01911702|Other|Volemic small treatment|"Goals of the treatment:
arterial pressure mean ≥ 60 mmHg or ≥ 10% less than the preoperative values
diuretic rhythm ≥ 0.5 ml / kg / h
venous saturation in vena cava ≥ 60% or mixed venous saturation ≥ 55% by SG
BE> - 5
PVC goal not necessary
To achieve the therapeutic goals set out above will be executed a volemic fill up to values of PVC ≤ 5 mmHg or at maximum values of 2 mmHg more the incoming If after proper filling the targets aren't yet achieved, the patient will begin infusion of vasoactive drugs following the practice of department. If after 12 hours of admission the water balance will be > 10-15 ml / kg / h an infusion of furosemide should be initiated"
1642675|NCT01911676|Drug|PF-03463275|
1642676|NCT01911676|Drug|Placebo|
1642677|NCT01911663|Dietary Supplement|KRG|500 mg Korea red ginseng (KRG)
1642678|NCT01911663|Dietary Supplement|Placebo|500 mg placebo
1642679|NCT01911650|Other|Autologous Platelet Rich Plasma|This procedure will include a single collection of 35 mL of peripheral blood. A two-stage spinning protocol will be used: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets to yield approximately 4 mL of concentrated autologous platelet. This layer of platelet rich plasma will be placed in the syringe by the centrifuge machine.
1642680|NCT01911650|Other|Ultrasound Imaging|A conventional ultrasound in addition to AE and shear wave imaging (SWI) will be administered.
1642681|NCT01911650|Other|Quality of Life Questionnaires|This questionnaire is a self-report of pain and function associated with the Achilles tendon.
1642682|NCT01911637|Drug|VBY-036|Study drug VBY-036
1642683|NCT01911637|Drug|Placebo|Placebo
1642684|NCT01911624|Drug|direct thrombin inhibition|
1642685|NCT01911624|Drug|enoxaparin|
1642686|NCT01911611|Drug|RO6870868|Single ascending doses
1642687|NCT01911611|Drug|placebo|Single ascending doses
1642688|NCT01911598|Drug|5-FU|5-FU will be administered as per schedule specified in the respective arm.
1716844|NCT00001499|Drug|cisplatin|
1642689|NCT01911598|Drug|Carboplatin|Carboplatin will be administered as per schedule specified in the respective arm.
1642690|NCT01911598|Drug|Cisplatin|Cisplatin will be administered as per schedule specified in the respective arm.
1642691|NCT01911598|Drug|MEHD7945A|MEHD7945A will be administered as per schedule specified in the respective arms.
1642692|NCT01911598|Drug|Paclitaxel|Paclitaxel will be administered as per schedule specified in the respective arm.
1642693|NCT01911585|Behavioral|Prolonged Exposure Therapy|Prolonged exposure therapy (PE), a specific exposure therapy program for PTSD is a highly effective treatment for PTSD. The key components of PE are imaginal exposure to the traumatic event and processing it (revisiting of the traumatic memory in imagination) followed by processing of the revisiting experience, and in vivo exposure to avoided trauma-related situations and objects.
1642694|NCT01911559|Device|standing-frame|
1642696|NCT01911533|Procedure|extracorporeal removal of CO2 (ECCO2-R)|To promote a better gas-exchange, the patient with ARDS will be mechanically ventilated. This can be aggressive and harmful for the lungs. With the use of an extra-corporeal CO2-remover, CO2 can be removed so that the mechanical ventilation setting will be less aggressive and will decrease lesions in the lung. The veno-venous extracorporeal CO2-remover pumps blood from a vein via a catheter through an oxygenator (gas exchanger that adds oxygen to the blood and extracts carbon dioxide from the blood) and back into a vein.
1642697|NCT01911533|Procedure|No extracorporeal CO2-removal|Patients are their own control group.
1642698|NCT01911520|Drug|Sugammadex 2 mg/kg|Patients receive 2 mg/kg Sugammadex.
1642699|NCT01911520|Drug|Sugammadex. 4 mg/kg|Patients receive 4 mg/kg Sugammadex.
1642700|NCT01911520|Procedure|Neuromuscular monitoring.|Neuromuscular monitoring using a TOF watch SX (Organon).
1642701|NCT01911520|Procedure|Clinical evaluation of residual curarization .|Every 30 min, during the first 2 hours after the end of the surgery.
1642702|NCT01911507|Drug|INC280|Given PO
1642703|NCT01911507|Drug|erlotinib hydrochloride|Given PO
1642704|NCT01911494|Behavioral|Community Engagement|The primary objective of the community engagement activities in CLIP will be to create awareness and action around the prevention of maternal morbidity and mortality due to pre-eclampsia/eclampsia. Community engagement involves the collective action of individuals, families, religious leaders, policy makers,
1642705|NCT01911494|Device|PIERS on the Move mHealth decision aid|This mHealth application is to be used by community health workers in intervention clusters to guide collection of relevant clinical data during antenatal visits. This clinical data is used to generate a risk estimate for any women with hypertension based on the miniPIERS (Pre-eclampsia Integrated Estimate of Risk) clinical risk prediction model. This risk estimate in combination with other pre-defined treatment triggers (severe hypertension (>160mmHg systolic) or proteinuria (>3+ dipstick); absence of fetal movements for greater than 12 hours; signs of recent stroke of seizure) are collected in the app and based on this data recommendations for care of the woman are provided.
1642706|NCT01911494|Drug|Magnesium Sulfate|Women identified in intervention clusters by the community health worker during a study visit as being at high risk of- or having recently experienced- an eclamptic seizure will be given 10 g intramuscular magnesium sulfate prior to transfer to a nearby facility for further care.
1642707|NCT01911494|Drug|Methyldopa|Women identified in intervention clusters as having severe hypertension (systolic greater than 160 mmHg) by the community health worker during a study visit will be given 750 mg of oral methyldopa prior to transfer to a nearby facility for further care.
1642708|NCT01911481|Other|hydration|
1642709|NCT01911468|Drug|metformin|
1642710|NCT01911468|Drug|liraglutide|
1642711|NCT01911468|Drug|metformin and liraglutide|
1642712|NCT01911455|Drug|acamprosate|
1642713|NCT01911455|Drug|Placebo|
1642714|NCT01911442|Drug|Lurasidone 20 mg daily|Lurasidone 20 mg once daily
1642715|NCT01911442|Drug|Lurasidone|Lurasidone 60 mg once daily
1642716|NCT01911442|Drug|Placebo|Placebo
1642717|NCT01911429|Drug|Lurasidone 40 mg|Lurasidone 40 mg once daily
1642718|NCT01911429|Drug|Lurasidone 80 mg|Lurasidone 80 mg once daily
1642719|NCT01911429|Drug|Placebo 40 or 80 mg|Placebo 40 or 80 mg once daily
1642720|NCT01911416|Drug|LDE225|
1642721|NCT01911403|Procedure|Manual compression|Closure procedure by Manual compression
1642722|NCT01911403|Device|Angio-Seal|Closure procedure by angio-Seal
1642723|NCT01911390|Dietary Supplement|Bean powder|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders.
1642724|NCT01911390|Dietary Supplement|Rice bran|USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
1642725|NCT01911390|Dietary Supplement|Control arm|No bean or rice bran additive in smoothie or muffin.
1642726|NCT01911390|Dietary Supplement|Bean powder and rice bran|Archer Daniels Midland (ADM) Edible Bean Specialties, Inc. will supply cooked navy bean powders. USDA (Beaumont, TX) provided rice bran for meals that was polished from U.S. rice mills using U.S. grown rice varieties.
1642727|NCT01911377|Drug|Botulinum Toxin Type A|
1642728|NCT01911377|Drug|Normal Saline for Injection|
1642729|NCT01911364|Drug|BDP/FF/GB|Superiority over Tiotropium
1642730|NCT01911364|Drug|Tiotropium|Superiority of CHF5993 over Tiotropium
1642731|NCT01911364|Drug|BDP/FF + Tiotropium|non inferiority vs CHF5993
1642732|NCT01911351|Drug|Nitrous Oxide|Patients randomized to the intervention arm will receive nitrous oxide plus standard management for their minor procedure.
1642733|NCT01911338|Device|Real Time Feedback|Before beginning practice, one of the teachers performed the manipulation and explained the graph parameters as real-time feedback to consider when interpreting the graph, leaving the graphic as the benchmark execution
1642734|NCT01911338|Device|Traditional Learning Method|Two expert teachers in manual therapy provided indications and corrections to the group with a teacher - student ratio of 1:8.
1642735|NCT01911325|Drug|Buparlisib|
1642736|NCT01911325|Drug|Buparlisib matching placebo|
1642737|NCT01911325|Drug|Docetaxel|
1642738|NCT01911312|Device|Thermal-aided muscle stimulation|Thermal-aided muscle stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
1642739|NCT01911312|Device|Body Temperature Stimulation|Body temperature stimulation is applied to subject quadriceps (one leg) with Niveus Medical Muscle Stimulation System 110
1642740|NCT01911299|Dietary Supplement|Choline|5.25 ml of liquid glycerophosphocholine (approximately 1240 mg GPC), equivalent to 625 mg of choline
1642741|NCT01911299|Dietary Supplement|placebo supplementation consisting of vegetable glycerin (50% by volume) and deionized water|
1642742|NCT01911286|Procedure|Apnea test - Standard|
1642743|NCT01911286|Procedure|Apnea test - CPAP|
1642744|NCT01911273|Drug|PF-03446962|PF 03446962 7 mg/kg, IV, every 2 weeks, until disease progression, patient refusal or unacceptable toxicity, whichever occurs first
1642745|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life
1642746|NCT01911273|Other|Placebo|Placebo will consist of Saline (0.9% w/v Sodium Chloride Injection, USP or NS)
1642747|NCT01911273|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
1642748|NCT01911260|Dietary Supplement|Zinc amino acid chelate|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup containing zinc amino acid chelate at 3%, i.e. the equivalent to 30mg of elemental zinc per ml, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
1642749|NCT01911260|Other|Placebo|During twelve weeks, children received weekly 1ml of lemon flavor caramel syrup, disposed into an individual amber glass, containing 20ml of syrup. The supplement administration was made individually with 1ml BD Plastipak disposable syringe, directly into the child's mouth, by the principal investigator. The chosen supplementation day was Tuesday. Therefore, the following weekdays were reserved to supplement any absent student.
1642750|NCT01911247|Drug|Metformin|Metformin 850 mg once daily
1642751|NCT01911234|Biological|TNF-Kinoid|
1642752|NCT01911221|Biological|rMenB+OMV NZ|Recombinant MenB with Outer Member Vesicle (OMV) from the New Zealand strain
1642753|NCT01911208|Behavioral|RECRUIT intervention|Sites randomized to RECRUIT are taught skills to develop a tailored recruitment intervention encompassing continuous quality improvement and patient navigation.
1642754|NCT01911208|Behavioral|Control|Non-intervention control.
1642755|NCT01911195|Drug|ISOFLURANE- Experimental Arm|The experimental group will be given the anesthetic isoflurane for three hours, and will undergo cognitive tests immediately following emergence from general anesthesia while connected to an EEG machine.
1642756|NCT01911195|Other|Control Group: Cognitive Testing|The control group will undergo cognitive testing while connected to an EEG machine following a comparable rest period, but will not receive general anesthesia.
1642757|NCT01911182|Other|Inhalation of low concentration of CO2|Inhalation of 1% CO2 through nasal prongs
2012432|NCT02007512|Drug|Placebo (for enzalutamide)|Sugar pill manufactured to mimic enzalutamide administered as four soft gelatin capsules by mouth once daily with or without food.
1642759|NCT01911156|Drug|Continue NA treatment|Prescribed NA during the 72 week study period
1642760|NCT01911156|Drug|Discontinue NA Treatment|Discontinue NA Treatment
1642761|NCT01911104|Behavioral|Exercise|10 weeks of aerobic exercise
2012433|NCT02007512|Drug|exemestane|50 mg capsule administered as a single capsule by mouth once daily after food.
1642763|NCT01911078|Procedure|Renal Denervation|Renal artery ablation with the EnligHTN™ Renal Denervation System.
1642764|NCT01911078|Device|EnligHTN™ Renal Denervation System.|
1642765|NCT01911065|Biological|Zostavax™|In the Vaccination arm, healthy individuals will be vaccinated with the licensed zoster vaccine, Zostavax.
1642766|NCT01911052|Other|Telephone based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as telephone based re-education by one investigator on the day before colonoscopy.
1642767|NCT01911052|Other|Short message system based re-education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus intervention such as short message system based re-education by one investigator on the day before colonoscopy.
1642768|NCT01911039|Biological|Regulatory T Cells|
1642769|NCT01911026|Other|Reinforcement Nurse Education|The investigational, or experimental arm, will receive standard written instructions on preparing for a colonoscopy plus instructions from reinforcement educated nurse
1642770|NCT01911013|Procedure|anterior cervical discectomy and fusion|anterior cervical discectomy and fusion with anterior plating or not
1642771|NCT01911013|Device|Cage and Plate|anterior cervical discectomy and fusion is performed using cervical cage and plate
1642772|NCT01911013|Device|Cage alone|anterior cervical discectomy and fusion is performed using cage alone with plate.
1642773|NCT01911000|Radiation|RT and hyperthermia after TACE|
1642774|NCT01910987|Drug|bortezomib (optimized retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1, 4, 8 and 11, every 21 days of cycle 1 and 2; injection on Days 1, 8, 15, 22, every 35 days for cycles 3 to 6; followed by injections on Days 1, 8, 15, 22 every 35 days (Group A1) or injections every other week (Group A2). Treatment will be stopped at confirmed disease progression
1642775|NCT01910987|Drug|dexamethasone (optimized retreatment)|Type= exact number, unit = mg, number = 20, form = tablet, route = oral, intake on Days 1, 2, 4, 5, 8, 9, 11 and 12, every 21 days of cycle 1 and 2; intake on Days 1, 2, 8, 9, 15, 16, 22 and 23 every 35 days for cycles 3 to 6
1642969|NCT01909596|Device|10° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 10°
1716937|NCT00001644|Drug|Nevirapine|
2012434|NCT02007083|Procedure|Bilateral laminotomy (BL)|
2012435|NCT02007083|Procedure|Unilateral laminotomy with crossover (UL)|
2012436|NCT02007083|Procedure|Spinous Process Osteotomy (SPO)|
2012437|NCT02005497|Other|HealthLinks|
2012438|NCT02003209|Drug|Aromatase Inhibition Therapy|Given at the investigator's discretion
2012439|NCT02003209|Drug|Carboplatin|Given IV
1642776|NCT01910987|Drug|bortezomib (standard retreatment)|Type= exact number, unit = mg/m2 body surface area, number = 1.3, form = powder for solution for injection, route = subcutaneous, injection on Days 1,4,8,11, every 21 days for cycles 1 to 8 or until confirmed disease progression
1642777|NCT01910987|Drug|dexamethasone (standard retreatment)|Type = exact number, unit = mg, number = 20, form = tablet, route= oral, intake on Days 1, 2, 4, 5, 8, 9, 11, 12, every 21 days for cycles 1 to 8 or until confirmed disease progression
1642778|NCT01910974|Procedure|endoscopic sub-mucosal dissection|endoscopic sub mucosal dissection of oesophagus stomach intestine or rectum lesions
1642779|NCT01910961|Procedure|limb RIPC|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated
2012440|NCT02003209|Other|Cytology Specimen Collection Procedure|Undergo 2 core biopsies
1642781|NCT01910935|Behavioral|Physical activity prescription to develop program in group.|Overall the intervention involves a medical reference in primary care (PHC) to hypertensive patients (during routine consultation) to assist the sports facilities of the same Institute, to develop a group program of physical activity which will last 24 weeks. Led by the trained staff in physical activity to patients with chronic diseases.
1642782|NCT01910909|Radiation|Stereotactic body radiotherapy|Respiration training will be done on the day that patient decided participate this study with wearing video goggle and headphone assisted respiration by visual and voice. Four dimensional CT simulation with wearing video goggle and headphone assisted respiration by visual and voice and real time position management system (PRM) signal will be adopted. Planning MRI with diffusion image also be acquired in same condition with CT simulation. SBRT will be delivered daily 20 Gy for 3 fractions.
1642783|NCT01910896|Device|Overnight Intensive Patch|Eligible subjects will have their two scars randomized for OIP application/no treatment. OIP for overnight application (at least 6 hours) for 12 to 24 weeks.
1642784|NCT01910883|Drug|Finafloxacin i.v. solution 200 mg|
1642785|NCT01910883|Drug|Finafloxacin i.v. solution 400 mg|
1642786|NCT01910883|Drug|Finafloxacin i.v. solution 600 mg|
1642787|NCT01910883|Drug|Finafloxacin i.v. solution 800 mg|
1642788|NCT01910883|Drug|Finafloxacin i.v. solution 1000 mg|
1642789|NCT01910883|Drug|Placebo i.v. solution|
1642790|NCT01910870|Drug|Cisplatin|25 mg/m² I.V. (day 1 to day 3) Total dose : 75 mg/m² every 3 weeks
1642791|NCT01910870|Drug|Metronomic Cyclophosphamide|150 mg per os from day 1 to day 14 (total dose = 2100 mg) every 3 weeks
1642792|NCT01910857|Behavioral|Lifestyle counseling|weight reduction, low salt, physical activity, stress reduction
1642793|NCT01910844|Drug|Cisplatin|25 mg/m² I.V. from day 1 to day 3 - total dose = 75 mg/m² every 3 weeks
1642794|NCT01910844|Drug|Cyclophosphamide|Metronomic cyclophosphamide per os 150 mg from day 1 to day 14 - total dose 2100 mg every 3 weeks
1642795|NCT01910831|Drug|DerMend Moisturizing Bruise Formula|DerMend Moisturizing Bruise Formula, a skin care cream containing a proprietary blend of retinol, ceramides, arnica oil, and alpha hydroxy acids and other ingredients.
1642796|NCT01910818|Device|Fractional CO2 laser treatment|Patient will be treated with fractional laser treatment over the areas with fibrosis.
1642797|NCT01910818|Other|No treatment|Patient will also have an area that is not being treated with CO2 laser. This is the area not getting treatment.
1642798|NCT01910805|Behavioral|Lifestyle and Risk Assessment class|"Classes will be conducted by a CITI-certified Boston Public Health Commission nutritionist, who is a consultant on this project and has previously worked within the Boston African-American community to increase diabetes awareness and reduce diabetes risk. These classes will be held at a local community center to provide maximal accessibility to the women.
The intervention group will attend classes mentioned at the aforementioned centers. Each class will take 2-hours and be conducted by a CITI-certified registered nutritionist with extensive knowledge of working in the African-American community. Both classes will include a cooking demonstration. In addition, the class will include a tour of a local supermarket to aid women in identifying healthy food choices."
1642799|NCT01910792|Device|Sperti Lamp|UV light exposure 3 times per week for 12 weeks
1642800|NCT01910779|Procedure|100 joule as first biphasic shock energy|
1642801|NCT01910779|Procedure|120 joule as first biphasic shock energy|
1642802|NCT01910766|Drug|Coenzyme Q10|no more details
1642803|NCT01910766|Drug|clomiphene citrate|
1642804|NCT01910753|Procedure|APA|A 3-month program for physical activity and diet education will be followed. An exercise specialist will supervise patients twice per week, during the first six weeks. They will also follow nutrition counselling and therapeutic education by a dietician once per week. During the last six weeks, they will just follow a guide for safe and appropriate exercise regimen. The dietician will call patient weekly during this final period.
1642805|NCT01910740|Other|Enhanced Physical Activity|Individually tailored programs focused on increasing the amount of time participants spend performing mobility activities, particularly standing and walking in the late afternoons and evenings and on weekends. These participants will be provided with one or two extra sessions on weekdays and two extra sessions on weekend days for the duration of their rehabilitation stay.
1642806|NCT01910740|Other|Usual Care|Therapy provided by a multidisciplinary team which includes physiotherapy and occupational therapy on weekdays with other allied health input (eg speech pathology, social work) as indicated. Medical and nursing care is also provided seven days a week.
1642807|NCT01910740|Other|Social Interaction|To control for the extra hours of physical activity that the experimental group receives, participants in the control group shall have additional activities such as card and board games, conversation or reading as well as upper limb exercises and other physical activities that have minimal impact on ambulant mobility.
1642889|NCT01910142|Dietary Supplement|vitamin K|A calcium product will be given either with or without vitamin K. Each intervention will last for 5 weeks, each followed by a 5 week wash-out. The first intervention will start about 4 months after inclusion and the single 41Ca bolus.
1642890|NCT01910142|Dietary Supplement|calcium|
2012441|NCT02003209|Drug|Docetaxel|Given IV
2012442|NCT02003209|Drug|Goserelin Acetate|Given SC
2012443|NCT02003209|Other|Laboratory Biomarker Analysis|Correlative studies
2012444|NCT02003209|Biological|Pertuzumab|Given IV
2012445|NCT02003209|Other|Quality-of-Life Assessment|Ancillary studies
1642808|NCT01910727|Behavioral|Together on Diabetes-Hopkins|The Johns Hopkins Center for American Indian Health, with support from Bristol-Myers Squibb Foundation, Inc. is adapting a Family Health Coach model for diabetes prevention with four southwestern tribal communities. Specifically, Johns Hopkins Center for American Indian Health has designed a paraprofessional delivered pilot intervention aimed at improving the prevention and management of type 2 diabetes among American Indian youth. For Youth Participants, the pilot intervention consists of 12 sessions delivered during a 6-month intervention phase, plus 6 check-ins delivered during a 6-month follow-up phase. For Support Persons, the pilot intervention consists of 4 family skill building sessions delivered during the first 4 months of the Youth Participant's intervention phase.
1642809|NCT01910714|Behavioral|Focus On Youth|Focus on Youth is a community-based, eight session group intervention that provides youth with the skills and knowledge they need to protect themselves from HIV and other STDs. Focus on Youth uses fun, interactive activities such as games, role plays and discussions to convey prevention knowledge and skills pertaining to Protection Motivation Theoretical concepts. The intervention consists of 8 group sessions delivered daily over 8 days by two Apache facilitators to same-sex peer groups of 8-12 Apache youth. Each lesson lasts approximately 60-90 minutes. The goal of the sessions will be to teach youth about sexual and reproductive health with a specific focus on safe sex practices and sexual decision making.
1642810|NCT01910714|Behavioral|Health Education Control Condition|The health education control condition consists of team-building activities and viewing of educational videos on nutrition and fitness, environmental protection and nature. The control condition program will be delivered according to the same structure as the Focus on Youth intervention; daily for 60-90 minutes over the course of 8 days. Due to local staffing availability and the pilot nature of this research, youth in the control condition will not receive the control program in small-group peer format. Rather, youth will receive the control condition program in groups of approximately 30-50.
1642811|NCT01910701|Behavioral|Family Spirit|The Family Spirit intervention consists of 52 sessions (30-60 minutes in duration) delivered during a 39-month intervention phase and designed to positively impact a number of maternal and child behavioral and health outcomes.
1642812|NCT01910688|Device|RFA treatment|If eligible for enrollment, a focal ablation device is selected as an intervention(size according to physician preference) and mounted on the end of the endoscope and introduced via the mouth into the esophagus and gastric pouch. The gastric pouch is treated from the top of the gastric folds to and just through the stomal anastomosis.
1642813|NCT01910675|Drug|PCC|15 IU/kg Octaplex and 2 g Riastab. Additional fibrinogen if needed.
1642814|NCT01910675|Drug|FFP|4 units Octaplas. Additional fibrinogen if needed.
1642815|NCT01910662|Other|KLH 0.1 mg|KLH will be administered as single ID injection of 0.1 mg as 0.1mL of KLH (1 mg/mL)
1642816|NCT01910662|Other|KLH 5 mg|KLH will be administered as single SC injection of 5 mg
1642817|NCT01910662|Other|PBS (0.1 mL)|PBS will be administered in Part A on Day 1 as 3 ID injections and in Part C: Cohort 1 on Day 1 and Day 2 as a single ID injection
1642818|NCT01910662|Other|Tuberculin PPD|Tuberculin PPD will be administered in Part B Cohort 2 on Day 1 as single ID injection of 2TU (0.04 microg/mL) in each forearm. In Part C Cohort 2 PPD will be administered on Day 1 as a single ID injection of 2TU. On day 3, if the induration is 6 mm or more; 2 ID injections of 2 TU will be administered on Day 29 in Part B Cohort 2 and 1injection of 2TU on Day 29 in Part C Cohort 2. On day 3, if the induration is less than 6 mm, subject will be re-challenged with 10 TU (0.04 microg/mL) PPD followed by 2 ID injections of 10 TU on Day 29 in Part B Cohort 2 or 1 ID injection of 10TU on Day 29 in Part C Cohort 2.
1642819|NCT01910649|Drug|Drisapersen|Subcutaneous and Intravenous
1642820|NCT01910636|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
1642821|NCT01910636|Drug|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing according to the approved Copegus labeling in Japan (< 60 kg = 600 mg , > 60 kg to ≤ 80 kg = 800 mg, and ≥ 80 kg = 1000 mg)
1642822|NCT01910623|Other|Health Related Quality of Life (HRQOL) measures|
1642823|NCT01910610|Biological|FOLFIRI-cetuximab|
1642824|NCT01910610|Biological|mFOLFOX6-bevacizumab|
1642825|NCT01910610|Biological|OPTIMOX-bevacizumab|
1642826|NCT01910610|Biological|irinotecan-based chemo + bevacizumab|
1642827|NCT01910610|Biological|Anti-EGFR agent (cetuximab +/- irinotecan or panitumumab)|
1642828|NCT01910610|Biological|XELOX + bevacizumab|
1642829|NCT01910597|Drug|SBG|
1642830|NCT01910584|Procedure|Novasure endometrial ablation|Novasure endometrial ablation is the second generation endometrial ablation treatment aimed to cure the dysfunctional uterine bleeding(DUB),including menorrhagia.
1642831|NCT01910571|Drug|P7435|
1642832|NCT01910571|Other|Placebo|
1642833|NCT01910558|Dietary Supplement|Alpha-cyclodextrin and digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 3 gram alpha-cyclodextrin and 3 gram of starch
1642834|NCT01910558|Dietary Supplement|Alpha-cyclodextrin|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams alpha-cyclodextrin
1642835|NCT01910558|Dietary Supplement|Digestible starch|Weight maintaining diet (40% fat, 30% protein, and 30% carbohydrate) supplemented with 6 grams digestible starch
1642836|NCT01910545|Drug|OTS167IV|
1642837|NCT01910532|Drug|Clevidipine|Clevidipine for the treatment of acute hypertension defined SBP > 160 mmHg in patients who require an Intracranial Pressure Monitoring Device
2012446|NCT02003209|Procedure|Therapeutic Conventional Surgery|Undergo lumpectomy or mastectomy
2012447|NCT02003209|Biological|Trastuzumab|Given IV
1642840|NCT01910506|Drug|RDEA3170 10 mg|
1642841|NCT01910493|Behavioral|SMS reminders|Intervention participants only will be sent text messages to their phones. The content of text messages will have a maximum of 160 characters and not mention HIV and will state the dates for the forthcoming consultations, visits to the pharmacy, lab results, time to take medication and reminders for patients who miss appointments.
1642842|NCT01910480|Drug|NBI-98854 50 mg capsule once daily|
1642843|NCT01910480|Drug|Ketoconazole 400 mg (200 mg twice daily)|
1642891|NCT01910129|Device|gammaCore|vagal verve stimulation 3 times a day 8 hours apart
1643084|NCT01908868|Other|Conventional TBNA|Mediastinal and hilar lymph node aspiration using blind transbronchial needle aspiration
1642844|NCT01910467|Device|NIRS visible and predefined interventions|NIRS measurements are visible and the patients will be treated according to predefined clinical interventions: If cTOI/pTOI ratio increases >5% within a six-hours-period echocardiography will be performed and based on results of echocardiography and blood pressure a volume bolus or, if ventilated, modification of ventilation or treatment of patent ductus arteriosus will be considered.
1642845|NCT01910467|Device|NIRS not visible and treatment as usual|NIRS not visible and the patients will be treated according to routine
1642846|NCT01910454|Behavioral|Cognitive-Oriented Strategy Augmented Rehabilitation (COSTAR)|The protocol for COSTAR is based on the Cognitive-Orientation to daily Occupational Performance Intervention (CO-OP) approach which includes the following components: (1) Guided discovery - a process created by CO-OP to make certain that participants discover the strategies that will solve their own performance problems ; (2) Cognitive strategy use - participants are taught a global problem-solving strategy and are enabled to discover additional domain specific strategies that will support their skill acquisition and performance competence; and (3) Dynamic performance analysis - an observation-based process of identifying performance problems or performance breakdown. These three components from CO-OP are overlaid on the TST intervention protocol described above to address the overall hypothesis of this study: that an evidence-based stroke rehabilitation treatment protocol (task-specific training) can be enhanced when augmented with the catalyst of cognitive-oriented strategy use.
1642847|NCT01910454|Behavioral|Task Specific Training (TST)|The protocol for task-specific training is based on criteria established by Winstein and Wolf (2008) who define task-specific training (TST) as a top-down approach to rehabilitation that is based on recent integrated models of motor control, motor learning, and behavioral neuroscience and that addresses skill acquisition of performance of meaningful and relevant tasks (Winstein and Wolf, 2008). Winstein and Wolf use current theory to identify three key ingredients for a task-specific training (pg 269): (1) Challenging enough to require new learning, and engagement with attention to solve the motor problem; (2) Progressive and optimally adapted such that over practice, the task-demand is optimally adapted to the patient's capability and the environmental context. The task should not be too simple or too repetitive nor too difficult; and (3) Interesting enough to invoke active participation through engagement in meaningful activity.
1642848|NCT01910441|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
1642849|NCT01910441|Drug|Glimepiride|Glimepiride 1-6 mg once daily
1642850|NCT01910441|Drug|Metformin|Metformin (1000-1500 mg daily)
1642851|NCT01910428|Drug|L-asparaginase encapsulated in RBC|"50 IU/kg IV
100 IU/kg IV
150 IU/kg IV
200 IU/kg IV"
1642852|NCT01910415|Drug|Lumacaftor|
1642853|NCT01910415|Drug|Lumacaftor Placebo|
1642854|NCT01910415|Drug|Ivacaftor|
1642855|NCT01910415|Drug|Ivacaftor Placebo|
1642856|NCT01910415|Drug|moxifloxacin hydrochloride|
1642857|NCT01910402|Drug|Dolutegravir/abacavir/lamivudine FDC|Dolutegravir/abacavir/lamivudine FDC tablets, 50 mg/600 mg/300 mg
1642858|NCT01910402|Drug|Atazanavir|Atazanavir capsule 300 mg
1642859|NCT01910402|Drug|Ritonavir|Ritonavir tablet 100 mg
1642860|NCT01910402|Drug|Tenofovir/emtricitabine FDC|Tenofovir/emtricitabine FDC tablet 300 mg/200 mg of FTC
1642861|NCT01910389|Drug|Tadalafil|
1642862|NCT01910389|Drug|Placebo for tadalafil|
1642863|NCT01910363|Drug|A2NTX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
1642864|NCT01910363|Drug|BOTOX|Intramuscular injection of the botulinum toxin preparation in 300 units (mouse LD50) into tibialis posterior and medial gastrocnemius muscles on the affected side.
1642865|NCT01910350|Behavioral|Kin KeeperSM Cancer Prevention Intervention|
1642866|NCT01910350|Other|Standard of care|
1642867|NCT01910337|Device|Use the Polar Cardiac rate meter|
1642868|NCT01910324|Behavioral|Multidimensional Family Therapy Cross-Systems|Standard initial/engagement work in the home and detention, plus a state-of-the-art HIV education prevention module as well as standard MDFT which assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
1642869|NCT01910324|Behavioral|Enhanced Services as Usual|Standard drug treatment services in detention and state-of-the-art HIV education prevention intervention, as well as outpatient drug treatment provided by community drug treatment providers
1642870|NCT01910311|Drug|Baricitinib|Administered orally
1642871|NCT01910311|Drug|Rifampicin|Administered orally
1642872|NCT01910298|Procedure|Breast reconstruction, direct to implant with Strattice|
1642873|NCT01910298|Procedure|Two stage breast reconstruction|
1642874|NCT01910285|Drug|Remifentanyl - sufentanil placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 3 µg/kg of remifentanil and 10 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
1642875|NCT01910285|Drug|Sufentanil - remifentanyl placebo|Induction of general anesthesia with 3 mg/kg of propofol combined with 0.3 mg/kg of sufentanil and 25 ml of isotonic sodium chloride for the double blind. The trachea is then intubated after waiting the time of action of each product.
1642876|NCT01910272|Device|All subjects are wearing the non-lead attenuation cap (BLOXR)|The cap is worn by all subjects with dosimeters secured both inside and outside the cap.
1642877|NCT01910259|Drug|Amiloride|Comparison with placebo
1642878|NCT01910259|Drug|Riluzole|Comparison with placebo
1642879|NCT01910259|Drug|Fluoxetine|Comparison with placebo
1642880|NCT01910259|Drug|Placebo|Placebo comparator
1642881|NCT01910246|Drug|Metformin|
1642882|NCT01910220|Drug|REGN1033 (SAR391786)|
1642883|NCT01910220|Other|placebo|
1642884|NCT01910194|Drug|Luyxumia versus Lantus|
1642885|NCT01910181|Drug|Vemurafenib|Participants will receive vemurafenib at a dose of 960 mg twice daily orally.
1642886|NCT01910155|Drug|Ciprofloxacin/Dexamethasone|
1642887|NCT01910155|Drug|Ciprodex (R)|
1642888|NCT01910155|Drug|Placebo|
1642968|NCT01909596|Device|9° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 9°
1643173|NCT01908257|Drug|lesinurad 400 mg + ranitidine 150 mg|
1642892|NCT01910116|Drug|Shinbaro|GCSB-5 (Shinbaro) is a mixture of six purified oriental herb extracts in a fixed ratio, namely, Saposhnikovia divaricata Schischk, Glycine max Merrill, Cibotium barometz J. Smith, Eucommia ulmoides Oliver, Achyranthes japonica Nakai, and Acanthopanax sessiliflorus Seem
1642893|NCT01910116|Drug|Placebo|The study medication and placebo were identical in appearance.
1642894|NCT01910090|Drug|FLURBIPROFEN 100 mg FAMOTIDINE 20 mg MULTI-LAYER TABLET|MULTI-LAYER TABLET
1642895|NCT01910090|Drug|ANTADYS® 100 mg, PEPCID® 20 mg|ANTADYS® 100 mg, PEPCID® 20 mg two tablets, taken once
1642896|NCT01910077|Drug|Tacrobell capsule 1mg|1 capsule, oral, over the period I&II(crossover)
1642897|NCT01910077|Drug|Prograf capsule 1mg|1 capsule, oral, over the period I&II(crossover)
1642898|NCT01910064|Drug|GK530G|
1642899|NCT01910038|Drug|corticoids+ tocilizumab 8mg/Kg/month|
1642900|NCT01910025|Drug|ADI-PEG 20|
1642901|NCT01910012|Drug|ADI-PEG 20|
1642902|NCT01909999|Procedure|Osteogenic markers Evaluation|"The collection of peri-implant crevicular fluid (PICF) was performed immediately after implant insertion (Baseline) and after 7, 15, 30, 60, 90 and 120 days. The site to be collected was dried and isolated with sterile gauze. PICF was collected at four sites per implant using absorbent paper strips (Periopaper, Oralflow, Smithtown, New York). The volume of fluid was measured immediately with the aid of Periotron (Oraflow, Smithtown, New York) and conditioned at 400uL of PBS buffer + 0.05% Tween and then frozen at -80°C.
The levels of the peri-implant osteogenic markers (OPG, OCN, OPN, TGF-α, and PTH) were determined using the LUMINEX/Magpix system (HBN1A-51K and HCCBP1MAG-58K, Millipore Corporation, Billerica, MA, USA)."
1642903|NCT01909999|Procedure|Clinical parameters evaluation|"The following parameters were assessed:
Peri-implant sulcus depth (PISD): distance from the margin of the peri-implant mucosa to the bottom of the peri-implant sulcus;
Modified Bleeding on Probing Index: the presence or absence of bleeding after 10 seconds on probing around implants."
1642904|NCT01909999|Procedure|Implant instalation|The surgeries, as well as all postoperative follow-up, were performed at the dental clinic of UNIP-SP. Surgical areas were anesthetized (2% mepivacaine with 1:100,000 epinephrine) and mucoperiosteal incisions in the alveolar ridge mucosa were made. The surgical sequence follow the protocol described by the implant company supplier of implants (SIN - São Paulo, SP, BR). In all cases, for maxilla rehabilitation, 6 implants were installed, while, for mandible, 5 were used.
1642905|NCT01909999|Procedure|Prosthesis installation|The patients in the IM Group received Brånemark protocol prosthesis within 3 days after the implant. The implants were first molded and the models sent for prosthesis confection (LABDENTAL, São Paulo, SP, Brazil). All prosthesis used straight mini-abutments (SIN, São Paulo, SP), that ranged from 1mm to 4mm in height, whose were tightened with 20N of torque, followed by occlusal adjustment and clinical monitoring
1642906|NCT01909999|Procedure|Suture|Soft tissues sutures were done using absorbable polygalactin 910 suture.
1642907|NCT01909999|Drug|Post-operative care|"Postoperative care were: amoxicillin 500 mg (8-8 hours/7 days); sodic dipyrone 500mg (6-6 hours/3 days); 0.12% Chlorhexidine mouthwash"
1642908|NCT01909986|Drug|[14C]ONO-4053|Single dose [14C]ONO-4053
1642909|NCT01909973|Behavioral|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.
The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
1642910|NCT01909960|Other|Flow imaging|"Quantitative flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid and blood flows are measured with a velocity-encoding value of 5-10 cm/s and 80 cm/s respectively. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.
Clinical examination consists in Larson's score and MMSE"
1642911|NCT01909947|Other|Cardiorespiratory signal acquisition|"Cardiorespiratory signals will measure heart rate (using electrocardiography), chest and abdominal movements (using respiratory inductance plethysmography) and oxygen saturation (using pulse oximetry). Data will be acquired during 2 recording periods:
A 60-minute period while the infant receives any mode of conventional mechanical ventilation
A 5-minute period prior to extubation while the mode of ventilation is switched to endotracheal tube CPAP (Continuous Positive Airway Pressure), so that the respiratory pattern will be controlled by the infant"
1642912|NCT01909934|Drug|brentuximab vedotin|Brentuximab vedotin will be administered as a single intravenous (IV) infusion over 30 minutes on Day 1 of each 3 week cycle for up to a maximum of 16 cycles and should be administered for a minimum of 8 cycles for patients who achieve stable disease or better.
1642913|NCT01909908|Device|ECM|ECM in saline applied to wound
1642914|NCT01909908|Biological|Blood Products|Autologous blood product applied to wound, with saline cleanse on alternating weeks
1642915|NCT01909908|Device|ECM in Blood Products|Alternating treatments of ECM in saline and ECM in autologous blood products, applied to wound
1642916|NCT01909895|Other|Anger Induction|The participant is asked to recall an incident in the recent past during which they became moderately to extremely angry, or is asked to read statements out loud evoking moderate to extreme feelings of anger. The participant is asked to take a few moments to bring the details of the incident to mind and, when ready, to describe the incident in great detail to the experimenter. Participants are asked to describe key elements, such as any dialogue that transpired during the incident, along with other details of the incident, particularly regarding the feelings of that particular emotion experienced at the time. In so doing, the experimenter works to re-elicit the emotions that accompanied the original incident. The duration of the negative emotion induction task is 8 minutes.
1642917|NCT01909895|Other|Depressed Mood Induction|The participant will be asked to undergo a validated depression/sadness induction task.
1642918|NCT01909895|Other|Anxiety Induction|The participant will be asked to undergo a validated anxiety induction task.
1642919|NCT01909895|Other|Neutral emotion task|This is a neutral control task that each of the negation emotion induction tasks will be compared to.
1716938|NCT00001644|Procedure|Blood testing|
1642920|NCT01909882|Other|Massage therapy|One session of massage therapy (for 60 minutes) was done by the patient's family member. Almond oil was used for effleurage and massage facilitation. Back, shoulder deltoid muscles, front and posterior parts of legs, arms, forearms, front and back parts of thighs, palms and fingers, metatarsus, front and back of feet and toes, belly and chest, auxiliaries and neck muscles of the patients were massaged. Massage techniques used included static massage, surface tension techniques, stretching massage, superficial lymph unload, transverse friction techniques, and myofacial releasing techniques. All the massage sessions were conducted in the morning shifts. For the control group, there was no intervention and patients just received the routine care of the unit.
1642921|NCT01909869|Device|EXCEL-Ⅱ|A PILOT First-In-Man Study to evaluate safety and efficacy of the EXCEL-Ⅱ with New Cobalt ChRomium Alloys Sirolimus Eluting BioDegradable Polymer Stent In the Treatment of Patients with de novo Coronary Artery Lesions
1642922|NCT01909856|Drug|Palonosetron|Palonosetron 0.25mg d1,d3
1642923|NCT01909856|Drug|Granisetron|Granisetron 3mg d1-3
1642924|NCT01909856|Drug|Dexamethasone|Dexamethasone 10mg d1-3
1642925|NCT01909856|Drug|Cisplatin|3-day chemotherapy regimens including cisplatin, cisplatin: 25mg/m2 d1-3
1642926|NCT01909843|Biological|ALX-0171|Escalating dose of ALX-0171 during maximum 3 consecutive days: from 2.1 mg to maximum 200 mg per inhaled dose followed by daily dose of 70 mg, 140 mg or 200 mg per dose for maximum 4 consecutive days
1642927|NCT01909830|Drug|Arm A : Gemcitabine + Pemetrexed|"Gemcitabine: 1000 mg/m2 by intravenous infusion over an exact period of 30' (preferably by a pump to guarantee a constant speed of infusion) on day 3 of each cycle repeated every 14 days.
Pemetrexed: 150 mg/m2 by intravenous continuous infusion over an exact period of 8h on day 1 of each cycle repeated every 14 days."
1642928|NCT01909817|Procedure|Routine coronary angiogram|
1642929|NCT01909804|Drug|SOF|400 mg tablet administered orally once daily
1642930|NCT01909804|Drug|VEL|Tablet administered orally once daily
1642931|NCT01909804|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1642932|NCT01909791|Procedure|Prompt Laser|Focal/grid laser performed at baseline and as needed during follow-up
1642933|NCT01909791|Drug|Prompt aflibercept|Intravitreal injection of 2.0mg aflibercept performed on the day of randomization and up to every 4 weeks using defined treatment criteria
1642934|NCT01909791|Procedure|Deferred laser|Focal/grid laser is initiated while receiving anti-VEGF injections only if certain criteria are met
1642935|NCT01909791|Drug|Deferred aflibercept|Intravitreal injection of 2.0mg aflibercept performed once certain criteria for vision loss are met and then up to every 4 weeks using defined treatment criteria
1642936|NCT01909778|Drug|BI 201335|single oral doses
1642937|NCT01909765|Other|Dorsal slit|Skin and mucosa incision made together
1642938|NCT01909765|Other|Double incision|Skin and mucosa incision made separately
1642939|NCT01909752|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m2) will be administered as a single dose three days prior to beginning vaccine therapy.
1642940|NCT01909752|Biological|DRibble vaccine|DRibble vaccine will be administered at Weeks 1, 4, 7, 10, 13, 16, 19, 25, 31, 37, and 43.
1642941|NCT01909752|Drug|Imiquimod|Imiquimod cream (5%, 250 mg containing 12.5 mg imiquimod - one packet/day) will be self applied once per day starting with the second vaccine (week 4). Immediately following vaccination and for four days following each vaccine cycle (total 5 days) imiquimod will be applied to a 4 x 5-cm outlined area of healthy extremity skin that includes the vaccine site.
1642942|NCT01909752|Drug|GM-CSF|GM-CSF will be administered at 50 mcg/day starting with the second vaccine (week 4) and continuing with each subsequent vaccine. A volume of 0.2 cc will be delivered by the CADD-MSTM 3 Ambulatory infusion pump at a rate of 0.008 cc/hr. The pump will be refilled after three days for a total of six days of infusion.
1642943|NCT01909752|Biological|HPV vaccine|Immunization with HPV vaccine will consist of two 0.5-mL intramuscular injection at the time of the first and third vaccinations. The preferred site of administration is the deltoid region of the upper arm.
1642944|NCT01909739|Drug|atrovastatin|Atrovastatin 80mg was administered orally on the evening before surgery. Before anesthesia induction, atrovastatin 40mg was administered orally. And atrovastatin 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
1642945|NCT01909739|Drug|Placebo|Placebo 80mg was administered orally on the evening before surgery. Before anesthesia induction, placebo 40mg was administered orally. And placebo 40mg were administered orally in the evening of postoperative days 0, 1, and 2.
1642946|NCT01909726|Other|ScreenPlay|Interactive technology
1642947|NCT01909713|Drug|Facial Cleanser and Moisturizer SPF 30|Cetaphil® DermaControl™ Foam Wash and Moisturizer SPF 30
1642948|NCT01909700|Device|Single Incision Mesh|Single Incision Mesh is implanted for pelvic floor reconstruction
1642949|NCT01909687|Device|Blood glucose monitoring systems|
1642950|NCT01909674|Device|Switch CPAP mask type|
1642951|NCT01909661|Other|Damira/Celia peptide hydrolyzed casein|
1642952|NCT01909661|Other|Picot riz/Celia rice/Sanutri arroz|
2012448|NCT02003209|Radiation|Whole Breast Irradiation|Undergo whole breast irradiation
1642955|NCT01909635|Behavioral|Food Feelings|
1642956|NCT01909635|Behavioral|Other Feelings|
1642957|NCT01909622|Dietary Supplement|Vitamin D|
1642958|NCT01909622|Dietary Supplement|No vitamin D|
1642959|NCT01909609|Other|AAP Documents|
1642960|NCT01909609|Other|Parent Survival Guide|
1642961|NCT01909596|Other|Without orthoses|Condition control
1642962|NCT01909596|Device|6° lateral wedge insoles|Insoles with a lateral inclination set at 6°
1642963|NCT01909596|Device|10° lateral wedge insoles|Insoles with a lateral inclination set at 10°
1642964|NCT01909596|Device|Neutral customized foot orthoses|Foot orthoses with arch support and without lateral inclination
1642965|NCT01909596|Device|6° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 6°
1642966|NCT01909596|Device|7° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 7°
1642967|NCT01909596|Device|8° lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set at 8°
1642970|NCT01909596|Device|Orthotist integrated lateral customized foot orthoses|Foot orthoses with arch support and integrated lateral inclination set according to orthotist experience
1642971|NCT01909596|Device|Orthotist lateral customized foot orthoses|Foot orthoses with arch support above insoles with lateral inclination set according to orthotist experience
1642972|NCT01909583|Other|STAGES-Booklet|STAGES-booklet was designed by the investigators focussing on guiding parents through the pre-operative and operative admission period.
1642973|NCT01909570|Procedure|Elective single embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of one embryo followed by the cryotransfer of one embryo in case of no conception in the fresh cycle.
1642974|NCT01909570|Procedure|Double embryo transfer|After the FIV/ICSI procedure, the embryo transfer in this arm would be of two fresh embryos
1642975|NCT01909557|Drug|Acetyl-L-carnitine|
1642976|NCT01909557|Drug|placebo|
1642977|NCT01909544|Other|Fatiguing exercise|All participants (patients and healthy subjects) will perform the exercise both under normoxic (FiO2 = 0.21) and hyperoxic conditions (FiO2 = 100%)
1642978|NCT01909492|Procedure|Blood Draw|Patients will provide a serum sample for research.
1642979|NCT01909492|Procedure|Lumbar Puncture|Patients will have a lumbar puncture to obtain CSF.
1642980|NCT01909479|Drug|MOD-4023|Individualized once weekly dose of MOD-4023
1642981|NCT01909479|Other|Placebo|Once weekly administration of placebo
1642982|NCT01909466|Drug|Aripiprazole, OPC-14597|5 monthly applications of 400 mg of aripiprazole IM depot, where the first application is in the gluteal or deltoid muscle followed by 4 monthly administrations to the deltoid muscle
2012449|NCT02003222|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic SCT
2012450|NCT02003222|Biological|Blinatumomab|Given IV
2012451|NCT02003222|Drug|Cyclophosphamide|Given PO or IV
1642986|NCT01909440|Behavioral|exercise intervention|Receive whole body RT
1642987|NCT01909440|Dietary Supplement|nutritional supplementation|Given whey protein supplementation PO
1642988|NCT01909440|Procedure|quality-of-life assessment|Ancillary studies
1642989|NCT01909440|Other|questionnaire administration|Ancillary studies
1642990|NCT01909440|Other|pharmacological study|Correlative studies
1642991|NCT01909440|Other|laboratory biomarker analysis|Correlative studies
1642992|NCT01909427|Drug|Placebo|Placebo subcutaneous injections (SC) every 4 weeks through Week 12
1642993|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks from Week 16 through Week 28
1642994|NCT01909427|Drug|CNTO 6785 200 mg|CNTO 6785 200 mg SC every 4 weeks through Week 28
1642995|NCT01909427|Drug|CNTO 6785 100 mg|CNTO 6785 100 mg SC every 4 weeks through Week 28
1642996|NCT01909427|Drug|CNTO 6785 50 mg|CNTO 6785 50 mg SC every 4 weeks through Week 28
1642997|NCT01909427|Drug|CNTO 6785 15 mg|CNTO 6785 15 mg SC every 4 weeks through Week 28
1642998|NCT01909427|Drug|Methotrexate (MTX)|MTX at the same stable dose through Week 32, that participants were receiving prior to screening.
1642999|NCT01909414|Biological|GEO-D03 DNA Vaccine|DNA GEO-D03 vaccine will be administered as a 3 mg dose IM.
1643000|NCT01909414|Biological|MVA/HIV62B Vaccine|MVA/HIV62B vaccine will be administered as a 1 x 10^8 TCID50 dose IM.
1643001|NCT01909414|Biological|Placebo for DNA GEO-D03|Placebo for DNA GEO-D03 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
1643002|NCT01909414|Biological|Placebo for MVA/HIV62B Vaccine|Placebo for MVA/HIV62B 1 x 10^8 TCID50 (administered as 0.9 percent Sodium Chloride for Injection) will be administered IM.
1643003|NCT01909401|Drug|boceprevir|
1643004|NCT01909388|Radiation|MRI-TRUS fusion guided real time HDR|
1643005|NCT01909349|Behavioral|self-regulation|Web-based support for behavior change regarding physical activity and fruit & vegetable consumption
1643006|NCT01909336|Drug|0.3% Saline in 3.3% dextrose|Hypotonic Solutions: 0.3% Saline in 3.3% dextrose
1643007|NCT01909336|Drug|0.45% Saline in 5% dextrose|Hypotonic Solutions: 0.45% Saline in 5% dextrose
1643008|NCT01909336|Drug|0.9% Saline in 5% dextrose|Isotonic Solutions 0.9% Saline in 5% dextrose
1643009|NCT01909323|Other|maltitol 85% / FOS15%|
1643010|NCT01909323|Other|maltitol alone|
1643011|NCT01909323|Other|maltitol 68% / FOS 32%|
1643012|NCT01909323|Other|maltitol 50% / FOS 50%|
1643013|NCT01909323|Other|FOS alone|
1643014|NCT01909323|Other|Placebo|
1643015|NCT01909310|Procedure|head extension|the lungs are ventilated with the patient´s head extended
1643016|NCT01909310|Procedure|neutral position|the lungs are ventilated with the patient´s head in neutral position
1643017|NCT01909310|Procedure|anaesthesiologist´s position|the lungs are ventilated with the patient´s head positioned deemed ideal by the anaesthesiologist
1643018|NCT01909297|Device|PROSEAL LMA|Size 3,4 or 5 supraglottic device with orogastric drainage tube
1643019|NCT01909297|Device|SUPREMA LMA|Size 3,4 or 5, disposable supraglottic device with orogastric drainage tube
1643020|NCT01909297|Device|I-GEL LMA|Size 3,4,5 disposable supraglottic device with noninflatable cuff
1643021|NCT01909284|Device|Acupuncture|"BL40, BL60, ST36, GB34 : bilaterally, manual acupuncture.
Two points on 1st bladder meridian nearest location of back pain : bilaterally, electrical acupuncture."
1643022|NCT01909284|Procedure|Epidural nerve block|Lumbar nerve block will be performed by using the mixture of dexamethasone (5mg) and mepivacaine (10mg).
1643023|NCT01909271|Behavioral|Stroke Education Film Viewing|A novel, culturally tailored intervention using storytelling (narrative persuasion) in the form of two professionally produced 12-min films (in English and Spanish), in minority populations in New York City.
1643024|NCT01909271|Other|Stroke Education Pamphlet Exposure|"Usual Care: Stroke Education pamphlet and brochure distribution."
1643025|NCT01909258|Other|Goniometric measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured via goniometry.
The goniometric measurements will be taken once by an investigator on all subjects and once by a different investigator on half of the subjects (with balanced distribution of morphotypes)."
1643085|NCT01908868|Other|Endobronchial and transbronchial biopsy|Endobronchial and transbronchial lung biopsy using flexible bronchoscopy
1643174|NCT01908244|Other|Music|Pentatonic music
1643026|NCT01909258|Other|Photographic measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using photography.
Photographic measurements will be performed twice one investigator and 1 time by a different investigator (total of three measurements)."
1643027|NCT01909258|Other|EOS measure of pelvic extension reserve.|"The pelvic extension reserve (°) is measured using the imaging system EOS.
Five X-rays will be made for each volunteer on the EOS system. The first is a frontal shot in a bipedal position, reference snapshot for verifying the absence of spinal deformity or hip pathology. The second and third are profile shots, one on the left and one on the right, whole body, bipedal position; serving as a reference picture. The fourth is profile shot, whole body, with the left hip in hyperextension. For maximum left hip hyperextension, the right leg rests on a step of varying height, and the hip is maximally flexed. The fifth is a profile shot, full body, with the right hip in hyperextension. For a maximum right hip hyperextension, the left leg rests on a step of varying height, and the hip is maximally flexed."
1643028|NCT01909245|Biological|Allogenic Human Islet Cells|Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
1643029|NCT01909232|Device|Active Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the active group, magnetic power output will be delivered to the subject through the coils.
1643030|NCT01909232|Device|Inactive Cervel Neurotech Multi-Coil Transcranial Magnetic Stimulator|The Cervel Neurotech multi-coil transcranial magnetic stimulator is an investigational repetitive transcranial stimulation (rTMS) device. In the inactive group, no magnetic power output will be delivered to the subject through the coils.
1643031|NCT01909219|Drug|Sodium picosulphate/magnesium Citrate|Comparison of two different dosing regimens of sodium picosulphate/magnesium citrate
1643032|NCT01909193|Behavioral|Attention Bias Modification (ABM)|Attention training via 8 weekly repeated trials of a dot-probe task intended to direct attention away from threat stimuli.
1643033|NCT01909193|Behavioral|Cognitive Behavior Therapy|CBT will consist of 16-20 weekly individual treatment sessions aimed to reduce symptoms via cognitive and behavioral interventions
1643034|NCT01909180|Device|Revolution CT Scanner|"These scans would be considered standard of care but, because the subjects are scanned on an uncleared device they are investigational."
1643035|NCT01909167|Behavioral|Online Cognitive Behavioral Therapy (CBT)|CBT treatment: Patients randomized to the online treatment will have, in total, 10 real time individual sessions of 40min each, starting at the 20-23rd gestational week and lasting until 6 weeks postpartum. The therapy will be delivered every two weeks, with a break from the 36th gestational week until the 4th week postpartum.
1643036|NCT01909167|Other|Treatment as usual|Patients randomized to the treatment as usual arm will be advised by their GP,perinatal psychiatric team or mental health midwife concerning treatment.
2012452|NCT02003222|Drug|Cytarabine|Given IT, IV, or SC
1643038|NCT01909141|Drug|induction of ovulation using letrozole-pioglitazone-metformin|induction of ovulation will be done for arm 1 for 3 consecutive cycles unless pregnancy occured.
1643039|NCT01909141|Drug|induction of ovulation using clomiphene citrate-pioglitazone-metformin|induction of ovulation for arm 2 will be done in 3 consecutive cycles unless pregnancy occured.
1643040|NCT01909141|Radiation|transvaginal ultrasound|transvaginal ultrasound will be done starting from day 10 and every 48 hours until finding a follicle of > 18 mm or till day 20 of the cycle
1643041|NCT01909141|Other|body mass index (BMI) calculation|BMI will be calculated for all women by dividing the weight in kilograms by the height in meters squared
1643042|NCT01909141|Other|day 3: follicle stimulating hormone (FSH), luteinizing hormone (LH), thyroid stimulating hormone (TSH), total testosterone|baseline hormonal assay (day 3 FSH, LH, TSH and total testosterone) will be done for all women.
1643043|NCT01909141|Other|pretreatment blood urea and serum creatinine|blood urea and serum creatinine will be assayed before stating induction of ovulation to have baseline levels.
1643044|NCT01909141|Other|serum estradiol (E2) on day 12|serum E2 will be assayed on day 12 of the cycle for all women.
1643045|NCT01909141|Other|serum progesterone on day 21|serum progesterone will be assayed on day 21 for all women to monitor ovulation.
1643046|NCT01909141|Other|blood urea and serum creatinine every month|blood urea and serum creatinine will be assayed every month during the treatment period to find out any hazards on kidney functions
1643047|NCT01909128|Dietary Supplement|fermented milk|fermented milk with Lactobacillus CBA-L74
1643048|NCT01909128|Dietary Supplement|fermented rice|fermented rice wit Lactobacillus CBA-L74
1643049|NCT01909115|Dietary Supplement|Vitamin D3|
1643050|NCT01909102|Behavioral|ACT-based intervention|
1643051|NCT01909102|Behavioral|usual care|
1643052|NCT01909089|Drug|Spinal administration of chloroprocaine.|"In order to determine the minimum effective dose that is to be given spinally, an up-down sequential allocation will be used.
Efficacy of the analgesia will be evaluated by a 100mm visual analogue pain score (VAPS). There are two possible outcomes here:
effective: the VAPS is 10mm or lower after the 15 minutes of monitoring. An effective result will decrease the test dose of chloroprocaine with 2mg for the next patient in this study.
Ineffective: the VAPS is more than 10mm after 15 minutes of monitoring. An ineffective result will increase the test dose of chloroprocaine with 2mg for the next patient in this study. Patients who indicate an ineffective result will receive a rescue treatment by the administration of 12ml levobupivacaine epidurally."
1643053|NCT01909076|Behavioral|Electronic decision support tools|"Electronic decision support tools available to both control and intervention PCPs include patient pain assessments, (Brief Pain Inventory, Pain/Enjoyment/General Function PEG), substance abuse (DAST, AUDIT) depression (PHQ9), PTSD (PTSD ChecklistCivilian), and risk of prescription drug misuse (SOAPP and COMM). The tools calculate scores with recommendation for specific action for each tool, when appropriate."
1643054|NCT01909076|Behavioral|Enhanced patient education materials|Patient education materials will be developed and made available to both control and intervention patients. The investigators will design the materials for patients with low literacy, using pictures and simple graphics to augment written language. The research staff will make PDFs of the materials available on the study website during and after the project.
1643163|NCT01908322|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients will be followed-up from start of Nexavar therapy until death or drop out due to any reason or end of study
1643055|NCT01909076|Behavioral|Nurse care management|The nurse/care management intervention will be modeled on BMC's successful collaborative care office-based opioid treatment (OBOT) program. One fulltime nurse care manager will work with PCPs assigned to the intervention condition. The care manager will be based centrally, in the Section of General Internal Medicine, and will divide his/her time between the 3 health centers. The main focus of the nurse care manager is to assure that patients are receiving guideline-adherent care, which involves appropriate clinical assessments, opioid treatment agreements, refill management, administering monitoring tools according to risk level (urine toxicology screen, pill counts, PMP data extraction) and timely physician visits to assess pain (minimum every 6 months).
1643056|NCT01909076|Behavioral|Electronic Patient Registry|The registry will be a freestanding centralized disease management application and built using standard database technology. This system will communicate with the electronic medical record (EMR) at each community health center and with the Massachusetts State Prescription Monitoring Program (PMP) system. Data that will feed into the registry include clinical data recorded from the EMR (documentation from other clinicians and labs), data from clinical users entered into the registry via pain and opioid management forms, and the PMP. The nurse care manager will use a custom registry interface to monitor key practice activities across the entire practice at each site. The nurse care manager will use population management tools to provide aggregate measures for quality monitoring and workforce management. All quality metrics can be downloaded in aggregate form for further analysis.
1643057|NCT01909076|Behavioral|Academic detailing|All PCPs in the intervention group will receive one 30 minute individual visit 23 months after project implementation at the PCP's practice site. The visits will be conducted with at least one of the study experts in pain medication management. Visit content will combine elements of audit and feedback (e.g. review registry of individual PCP compared with that of peers and goals) as well as traditional educational outreach. Specifically, experts will review each aspect of guideline concordant care (assessment of risk and appropriateness for opioid medication, medication dosing, monitoring for harm/adherence, and pain outcomes) to solicit barriers to implementation or lack of knowledge on the underlying evidence for each aspect of care. The experts will work with the individual PCPs to address barriers identified using motivational interviewing as needed to facilitate behavioral change in applying guideline concordant care.
1643058|NCT01909063|Dietary Supplement|Vitamin D|Fortification of orange juice with 200 IU vitamin D to be drunk twice per day for 12 weeks
1643059|NCT01909063|Dietary Supplement|Vitamin D, Vitamin E, and Vitamin A|Fortification of orange juice with Vitamin D, Vitamin E, and Vitamin A to be drunk twice per day for 12 weeks
1643060|NCT01909063|Dietary Supplement|Control, 700 mg Calcium|Orange juice with 700 mg calcium to be drunk twice per day for 12 weeks
1643061|NCT01909037|Dietary Supplement|Flexofytol (bio-optimized curcumin)|2x3 caps/day (before breakfast and in the evening) for 3 months
1643062|NCT01909024|Procedure|Coil embolisation|transjugular coil embolisation of pelvic veins
1643063|NCT01909024|Procedure|endovenous treatment of leg recurrent varicose veins|endovenous treatment of leg recurrent varicose veins
1643064|NCT01909011|Device|Active CES|The active CES treatment group will receive the following dose of CES delivered over the temples bilaterally: 2mA of alternating current qt 1Hz, 5Hz, and 15,000Hz for one 20 minute session per day for 5 times per week for four weeks.
1643065|NCT01909011|Device|Sham CES|The CES sham group will receive sham CES (device off) for 20 minutes 5 times per week for two weeks.
1643066|NCT01908998|Other|Sandal|Subjectes will be scored on the Y-Balance Test wearing an Orthaheel Sandal
1643067|NCT01908985|Procedure|high intensity focused ultrasound for cyclodestruction in the eye|
1643070|NCT01908959|Behavioral|Madres para la Salud|Participants attended Madres para la Salud sessions in a group, led by a promotora at the Maricopa Medical Center and other community based sites. Sessions consisted of a 30 minute education and social support session where women learned to walk at least 150 minutes a week at a 20 minute-mile pace, and up to 30 minutes of moderate intensity walking with the group. Participants received a pedometer and learned to monitor their walking intensity. Participants set and reviewed weekly walking goals at the group sessions and recorded aerobic steps per day. After the 12 week sessions, participants met with the promotora once a week for 40 weeks of in-group walking at a moderate intensity for 30 minutes, to download and review pedometer data. Data was collected at baseline, 3, 6, 9 and 12 months.
2012453|NCT02003222|Drug|Daunorubicin Hydrochloride|Given IV
1643072|NCT01908933|Device|AeriSeal Emphysematous Lung Sealant Syst|This is a prospective, open label, single-arm, multicenter, investigational study. Patients will receive either unilateral or bilateral AeriSeal System therapy as appropriate utilizing 20 mL/subsegment dosing at 2 to 4 subsegments.
1643073|NCT01908920|Other|Osteopathic manipulative treatment|
1643074|NCT01908920|Other|SHAM|
1643075|NCT01908920|Other|CONTROL|
2012454|NCT02003222|Drug|Dexamethasone|Given PO
2012455|NCT02003222|Drug|Etoposide|Given IV
1643078|NCT01908894|Drug|BIOD-123|
1643079|NCT01908894|Drug|BIOD-125|
1643080|NCT01908894|Drug|Humalog|
1643081|NCT01908881|Behavioral|Group Workshop|The intervention consists in a group workshop (for up to 7 dyads with children aged between 6 and 12 months and two health care professional monitors) of four sessions of two hours each, held weekly. One of the sessions is characterized as including the fathers or other caregivers relevant to the upbringing of the children. Each session is structured around various activities that specifically deal with the skills associated with parental sensitivity and address relevant issues to child rearing, considering the development of the child.
1643082|NCT01908881|Behavioral|Usual Care|"According to the screening carried out various interventions are offered by Primary Health Care centers (eg. home visits) in the Chile Crece Contigo Program. During pregnancy, if the mother is screened for positive psychosocial risk she would receive different interventions consisting in (usual care at Primary Health Care Centers): home visits, evaluation by social worker and planning interventions according to a multidisciplinary team."
1643083|NCT01908868|Other|EBUS-TBNA|Mediastinal and hilar lymph node aspiration using endobronchial ultrasound
1643164|NCT01908309|Drug|Iobitridol 350|
2012456|NCT02003222|Other|Laboratory Biomarker Analysis|Correlative studies
2012457|NCT02003222|Drug|Mercaptopurine|Given PO
2012458|NCT02003222|Drug|Methotrexate|Given PO, IT or IV
2012459|NCT02003222|Drug|Pegaspargase|Given IM or IV
1643086|NCT01908855|Behavioral|Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy + emotion regulation training for patients with multiple somatoform symptoms:
20 weekly sessions individual therapy (à 50) minutes"
1643087|NCT01908855|Behavioral|Cognitive-behavioral therapy for patients with multiple somatoform symptoms|"Cognitive-behavioral therapy for patients with multiple somatoform symptoms:
20 weekly sessions individual therapy (à 50) minutes"
1643088|NCT01908842|Drug|BNX sublingual tablets|Buprenorphine/naloxone sublingual tablets
1643089|NCT01908842|Drug|BNX sublingual film|Buprenorphine/naloxone sublingual film
1643090|NCT01908842|Drug|Buprenorphine|Buprenorphine sublingual tablets
2012460|NCT02003222|Drug|Prednisone|Given PO
2012461|NCT02003222|Biological|Rituximab|Given IV
2012462|NCT02003222|Drug|Vincristine Sulfate|Given IV
2012463|NCT01999920|Drug|Vilazodone|10mg to 40mg per day for 12 weeks
2012464|NCT01999920|Drug|Placebo|One to two pills per day for 12 weeks
2012465|NCT01999322|Drug|Faster-acting insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
2012466|NCT01999322|Drug|insulin aspart|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
2012467|NCT01994239|Drug|Degarelix|First dose of 240 mg 5 Maintenance doses of 80 mg every 28 days(+/-3d)
2012468|NCT01994239|Radiation|Pelvic Radiotherapy|46 Gy in 23 fractions Prostate only-boost up to 66 Gy
1643100|NCT01908803|Drug|AL-60371/AL-817 otic suspension|
1643101|NCT01908803|Drug|Ciprofloxacin 0.3%/dexamethasone 0.1% otic suspension|CIPRODEX®
1643102|NCT01908790|Device|Mespere Venous Oximeter|The Mespere VA Oximeter System is a non-invasive medical device for measurement of venous blood oxygenation.
1643103|NCT01908790|Device|Avoximeter 4000|The portable Avoximeter 4000 provides rapid, accurate assessment of the patient's true oxygenation status at the bedside. Features: Results in less than 10 seconds; No sample preparation required; Uses whole blood sample; Easy to use.
1643104|NCT01908777|Other|High Dose Chemotherapy with Autologous Stem Cell Transplant Followed by Maintenance Therapy with Romidepsin|
1643105|NCT01908764|Drug|AL-60371 otic suspension|
1643106|NCT01908751|Procedure|Sliding Hip Screw|
1643107|NCT01908751|Procedure|Cancellous Screws|
1643108|NCT01908751|Drug|Vitamin D|
1643109|NCT01908751|Drug|Vitamin D Placebo|
1643110|NCT01908738|Drug|paracervical block with 1%lidocaine|"To determine effectiveness of paracervical block, lidocaine spray and only oral analgesic drugs for pain relief during endometrial biopsy.
Pain score(NRS) immediately after procedure and 15 minutes Group 1(1%Lidocaine) Group 2(10%Lidocaine spray) Control group(Placebo) Pain score immediately Pain score 15 minutes"
1643111|NCT01908738|Drug|10%lidocaine spray|
1643112|NCT01908725|Drug|Lamazym|ERT, i.v. infusions weekly
1643113|NCT01908712|Drug|Lamazym|ERT, i.v. infusions weekly
1643114|NCT01908699|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg tablets for oral, 1 or 2 tablets four times daily (QID) administration
1643115|NCT01908699|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR
1643116|NCT01908686|Behavioral|Pivotal Response Training|Behavioral intervention for autism
1643117|NCT01908673|Behavioral|HRV biofeedback|
1643118|NCT01908673|Behavioral|ASTM|
1643119|NCT01908660|Drug|antiretroviral drugs|zidovudine lamivudine emtricitabine abacavir tenofovir nevirapine efavirenz etravirine rilpivirine lopinavir atazanavir fosamprenavir darunavir raltegravir maraviroc ritonavir
1643120|NCT01908647|Behavioral|RT fMRI|Real-time fMRI with neurofeedback.
1643121|NCT01908647|Behavioral|Cognitive Training|Computer based attention training.
1643122|NCT01908647|Behavioral|Control RT fMRI|Control condition for real-time fMRI.
1643123|NCT01908647|Behavioral|Control Cognitive Training|Computer-based games used as a control for the computer based cognitive training intervention.
1643124|NCT01908634|Dietary Supplement|Milk-based Strawberry Beverage|
1643125|NCT01908634|Dietary Supplement|Water-Based Strawberry Beverage|
1643126|NCT01908634|Dietary Supplement|Milk-based Fruit-Mixed Beverage|
1643127|NCT01908634|Dietary Supplement|Water-Based Fruit-Mixed Beverage|
1643128|NCT01908621|Drug|G-CSF (filgrastim)|
1643129|NCT01908621|Drug|Cytosine arabinoside + G-CSF (filgrastim)|
1643130|NCT01908595|Drug|M518101|
1643131|NCT01908582|Drug|Evacetrapib|Administered orally
1643132|NCT01908582|Drug|Rifampin|Administered orally
1643133|NCT01908569|Other|MACS|The sperm will be subjected to capacitation through a density gradient together with the MACS technique in order to select the non-apoptotic spermatozoids.
1643134|NCT01908569|Other|NO MACS|The sperm capacitation will be performed through a density gradient. The MACS technique will not be applied.
1643135|NCT01908556|Drug|Letrozole|
1643136|NCT01908543|Drug|Ferrous sulphate 200mg oral tablet|Administration by mouth
1643137|NCT01908530|Device|Microprobe glucose sensor|Assessment of safety and accuracy of a novel continuous glucose monitor based on microprobe technology.
1643165|NCT01908309|Drug|Iodixanol 320|
1643166|NCT01908296|Drug|FK949E|Oral
1643167|NCT01908296|Drug|fluvoxamine|Oral
1643175|NCT01908205|Drug|Intranasal Oxytocin|
1643176|NCT01908205|Drug|Placebo|
2012469|NCT01994395|Device|The Stride Management Assist (SMA) System|Participants will participate in 18 sessions of outpatient physical therapy + 3 sessions of testing for up to 8 weeks. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait. Treatment consists of 30 minutes high intensity gait training with device, 15 minutes functional mobility with device.
2012470|NCT01994395|Other|Impairment based therapy|Participants participate in 18 weeks of outpatient physical therapy + 3 assessment sessions. Assessment (strength, flexibility, balance, sensation, endurance, transfers, gait). Treatment will be divided into: 15 min balance training, 15 minutes functional mobility (transfers, strength or flexibility training) and 15 min high intensity gait training
2012471|NCT01992952|Drug|AZD5363|Up to 480mg oral tablets twice a day, taken four days on, 3 days off treatment.
2012472|NCT01992952|Drug|Placebo|Placebo tablets taken twice a day, 4 days on treatment, 3 days off treatment
1643139|NCT01908504|Other|PET-CT|At radiation planning subjects will have a PET-CT. The CT scan — also called computerized tomography or just CT — combines a series of X-ray views taken from many different angles to produce cross-sectional images of the bones and soft tissues inside the body. A PET is a highly specialized imaging technique that uses short-lived radioactive substances (such as FDG a simple sugar labeled with a radioactive atom) to produce three-dimensional colored images of those substances functioning within the body. These images are called PET scans and the technique is termed PET scanning. PET scanning provides information about the body's chemistry not available through other procedures. Unlike CT or MRI (magnetic resonance imaging), techniques that look at anatomy or body form, PET studies metabolic activity or body function.
1643140|NCT01908491|Device|IV PCA|On arrival in the postanesthetic care unit, a patient-controlled analgesia (IV PCA) was connected to the iv catheter. The PCA regimen consisted of hydromorphone (2 mcg/kg/hr) and ketorolac (0.02 mg/kg/hr) with normal saline (total volume 100ml). PCA was programmed to deliver 1 ml/hr as background infusion and 1 ml per demand with a 10 min lockout during 48 hr period.
1643141|NCT01908491|Device|Continuous wound infusion|Patients underwent insertion of wound catheters by the surgeon just before the closure of incision site. The wound catheters, consisting of double branch and connected to elastomeric pump filled with ropivacaine (0.15~0.25%) and administered at a constant flow rate of 2 ml/hr in each branch of the catheter for 48 hr.
1643142|NCT01908478|Drug|Veliparib|
1643143|NCT01908478|Drug|Gemcitabine|
1643144|NCT01908478|Radiation|Intensity modulated radiation therapy|
1643145|NCT01908465|Drug|Ebastine|
1643146|NCT01908465|Drug|Placebo|
1643147|NCT01908452|Drug|Pyridoxine|1200 mg/d during 12 weeks
1643148|NCT01908439|Other|whole-body vibration|High amplitude whole-body vibration
2012473|NCT01992952|Drug|Fulvestrant|2 x 250mg injections, received on Days 1 and 15 of cycle 1, and on day 1 of each subsequent 28 day cycle.
2012474|NCT01988233|Behavioral|BAILAMOS© Dance Program|
1643151|NCT01908413|Drug|CUDC-427|CUDC-427 as an oral formulation administered daily on a 14 days on/7 days off schedule
1643152|NCT01908400|Biological|Intravenous transfer of BMMNC|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous Bone Marrow derived Mono Nuclear Stem Cell (BMMNCs)
1643153|NCT01908387|Drug|Oral azacitidine|100 mg to 300 mg oral azacitidine once daily for 14 days or 21 days of the initial 28-day cycle
1643154|NCT01908374|Dietary Supplement|DHA-rich fish oil versus Phospholipid-rich fish oil|This randomized, controlled crossover study will include four treatment visits (visits 2, 3, 4, and 5; days 0, 14, 42, and 56). Subjects will be randomly assigned, by sex and age, to their first treatment study product (active or control), which will be administered with a standardized low-choline, DHA-, EPA- free breakfast meal at t = 0 h. Subjects will consume placebo or phospholipid-rich fish oil for two weeks, washed out for 4 weeks, then treatments switched. Blood samples will be obtained for acute measurements on visits 2 and 4, via an indwelling venous catheter or venipuncture at t = 1, 2, 4, 6, 8, 10, and 12 h ± 5 min, to determine plasma fatty acid profile. Chronic fatty acid measurements will be determined after 2 weeks on visits 3 and 5.
1643155|NCT01908361|Behavioral|Unilateral Hybrid (InMotion3 plus CIT) Intervention|"During the 3-week InMotion3 period, participants will receive 5 minutes of muscle tone normalization preparation and passive range of motion, then 85 minutes of training using the InMotion3 robot. The participants will practice about 5 to 8 minutes of passive, 30 to 35 minutes of assisted-active, and 5 to 8 minutes of active motions in wrist and forearm, respectively.
During the 3-week CIT period, participants will receive intensive training of the affected UL in functional tasks with behavioral shaping for 1.5 hours/weekday and will be asked to wear a mitt to restrict the unaffected UL for 6 hours daily. The shaping techniques will involve individualized task selection, graded task difficulty, verbal feedback, prompting, physical assistance with movements, and modeling. Caregivers will use daily logs to document hours of mitt wearing outside the one-on-one intervention sessions."
1643156|NCT01908361|Behavioral|Bilateral Hybrid (BMT plus BAT) Intervention|"During the 3-week BMT period, patients will play a simple computer game (e.g., picking up apples) that tracks patient movements to provide instant visual feedback. The therapist will also provide verbal feedback. In each training session, the patient will practice 600 to 800 repetitions of passive-passive mode for 15 minutes, 600 to 800 repetitions of active-passive mode for 15 to 20 minutes, and 150 to 200 repetitions of active-active mode for 5 minutes, respectively, for the forearm pronation-supination and the wrist flexion-extension.
During the 3-week BAT period, participants will receive training in tasks focusing on bilateral symmetric or alternating movements of both ULs, such as lifting two cups, picking up two pegs, grasping and releasing two towels, and wiping the table with both hands."
1643157|NCT01908361|Behavioral|Conventional Rehabilitation|Participants in CR group will receive therapist-mediated functional tasks training based on neurodevelopmental techniques with emphasis on functional tasks and muscle strengthening that will involve (1) active/passive range of motions, abnormal muscle tone/reflex inhibition techniques (such as stretching and/or weight bearing), and strengthening of affected arm for 15 to 20 minutes, (2) functional tasks for training fine motor or manual dexterity for 20 minutes, and (3) activities of daily living or functional tasks involving gross motor activities, coordination tasks, transition, mobility, and posture/balance for 15 to 20 minutes. The activities will be individualized according to the level of impairment and the needs of the patients.
1643158|NCT01908348|Dietary Supplement|Erythritol|
1643159|NCT01908335|Drug|PEG-IFN-SA /RBV low dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
1643160|NCT01908335|Drug|PEG-IFN-SA /RBV middle dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
1643161|NCT01908335|Drug|PEG-IFN-SA /RBV high dose|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
1643162|NCT01908335|Drug|Pegasys /RBV|24 weeks for genotype 2,3 and 48 weeks for non-genotype2,3
1643168|NCT01908283|Biological|13-valent pneumococcal conjugated vaccine (PCV13)|Immunization with 1 dose of PCV13 (=0.5ml) intra-muscular
2012475|NCT01988233|Behavioral|Health Education Control Group|
1643177|NCT01908192|Drug|NaBen®|The Study Treatment is NaBen®, which will look, and will be packaged and maintained exactly the same way as the Control Treatment (Placebo).
1643178|NCT01908192|Drug|Placebo|The ingredients in the Control Treatment are exactly the same as in the Study Treatment, except without the primary active ingredient.
1643179|NCT01908166|Procedure|ultrasound elasticity imaging|Undergo ultrasound elastography
1643180|NCT01908140|Drug|Aclidinium Bromide / Formoterol Fumarate|
1643181|NCT01908140|Drug|Salmeterol / Fluticasone|
1643182|NCT01908127|Behavioral|tell- show- do|Children came in the operation room. Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed by the dentist for each participant to increase their familiarity with dental procedures. The duration of the appointment was about 20 minutes and constant for all children.
1643183|NCT01908127|Behavioral|film modelling|the children were directed to a quiet and comfort room to watch a film presented by a dental assistant. The film showed that the same procedure consisted of Tell-Show-Do, prophylaxis with paste and rubber cap and fluoride therapy was performed on a 5-years-old child model with a time of 20 minutes. The child in the film was cooperative and was reinforced by a reward at the end of the procedure.
1643184|NCT01908127|Drug|injection of local anesthesia solution|A topical anesthesia and injection of local anesthesia solution using mandibular alveolar nerve block technique was performed by the dentist
1643185|NCT01908127|Procedure|occlusal cavity preparation|the occlusal cavity was prepared for pulpotomy and restoration of the teeth
1643186|NCT01908114|Behavioral|Enhanced Community mobilization|
1643187|NCT01908114|Biological|Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA|
2012476|NCT01986907|Drug|ranibizumab|All patients will receive ranibizumab 0.5 mg/0.05 ml according to approved label: treatment is given monthly until maximum VA is achieved (i.e. stable VA for three consecutive monthly assessments performed while on ranibizumab treatment). Thereafter according to approved label, patients should be monitored monthly for visual acuity and treatment is to be resumed when monitoring indicates loss of visual acuity due to disease activity. Monthly injections should then be administered until stable visual acuity is reached again for three consecutive monthly assessments (implying a minimum of two injections).
1643190|NCT01908088|Biological|Cell transplantation|autologous transplantation of cultured fibroblast on amniotic membrane in patients with Epidermolysis Bullosa with mitten hands.
1643191|NCT01908075|Drug|FP/SAL|
1643192|NCT01908075|Drug|BDP/FOR|
1643195|NCT01908049|Dietary Supplement|Probiotic.|
1643196|NCT01908049|Dietary Supplement|Placebo|
1643197|NCT01908023|Behavioral|exercise|One hour, twice a week, for 5 weeks: warming-up with aerobic exercises, endurance exercises, strength exercises for large muscle groups, body awareness, range-of- motion exercises for the shoulders and stretching and relaxation
1643198|NCT01908010|Drug|ABT-354|ABT-354 Low Dose
1643199|NCT01908010|Drug|ABT-354|ABT-354 High Dose
1643200|NCT01908010|Drug|Placebo|Placebo
1643201|NCT01907997|Drug|Systemic intravenous lidocaine infusion|In group L, intravenous lidocaine infusion(0.1mg/kg) for 10minutes after induction of anesthesia. After 10 minutes, lidocaine infusion continued at rate of 3mg/kg/hr during operation, and discontinued before move the patients to PACU.
1643202|NCT01907997|Drug|normal saline infusion|In group C, the patients receive same volume of normal saline
1643203|NCT01907984|Drug|Diclofenac|
1643204|NCT01907984|Drug|Midazolam|
1643205|NCT01907945|Behavioral|Microclinic Water Program|Three session educational program is delivered to study participants and their self-selected social networks in a group setting. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
1643206|NCT01907945|Behavioral|Household education|Three session educational program is delivered to study participants at an individual household level. The three session topics are the spread of water borne illness, water treatment methods and social support for sustaining household water treatment. Sessions are taught by a trained community health worker and a study staff member.
1643207|NCT01907932|Device|VScan Ultrasound (GE Healthcare, USA)|VScan Ultrasound used to determine spleen size and the other qualities described in the arm description.
1643208|NCT01907906|Device|Mirasol System for Whole Blood|LR-pRBC units derived from WB will be treated with the Mirasol System. Treatment with the Mirasol System requires riboflavin to be mixed into the whole blood unit, which is then exposed to ultra violet (UV) light for a period of time; approximately an hour.
1643209|NCT01907893|Behavioral|Trauma Collaborative Care Plus Treatment as Usual|
1643210|NCT01907880|Drug|Pamidronate|90mg IV once every 4 weeks for 3 cycles
1643211|NCT01907880|Drug|Zoledronic acid|4mg IV every 4 weeks for 3 cycles
1643212|NCT01907880|Drug|placebo|
1643213|NCT01907867|Drug|Finafloxacin 800 mg (as 4 x 200 mg tablet) once daily for 3 days|
1643214|NCT01907854|Drug|liraglutide|Starting dose of 0.6 mg/day, with weekly dose escalations of 0.6 mg/day until the maintenance dose of 1.8 mg/day is reached. Administered subcutaneously (s.c., under the skin) once daily + metformin tablets (at least 1000 mg/day)
1643215|NCT01907854|Drug|sitagliptin|100 mg/day sitagliptin tablets once-daily + metformin (at least 1000 mg/day)
1643216|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
1643217|NCT01907854|Drug|placebo|Sitagliptin placebo tablets once-daily
1643218|NCT01907841|Other|Ischemic Preconditioning|
1643228|NCT01907789|Other|Ovarian Cancer Screening|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer will return to clinic every six months to undergo screening for ovarian cancer symptoms, physical examination, CA125, HE4, and transvaginal ultrasound.
1717165|NCT00000920|Drug|Saquinavir|
1643229|NCT01907789|Procedure|Prophylactic Salpingectomy with Delayed Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have salpingectomy performed as an outpatient procedure. After the 3-year follow up period, oophorectomy performed as an outpatient procedure.
1643230|NCT01907789|Procedure|Risk-Reducing Salpingo-Oophorectomy|Woman who have a mutation (genetic change) in one of the BRCA genes, and are at high risk for developing ovarian cancer have risk-reducing salpingo-oophorectomy (RRSO) performed as an outpatient procedure.
1643231|NCT01907789|Behavioral|Questionnaire|"Ovarian Screening Group: Quality of life (QOL) questionnaire completed at baseline, end of year 1, 2, and 3.
Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO): Quality of life (QOL) questionnaire completed at baseline, 1 month 1 year, 2 years, and 3 years after salpingectomy. Also before oophorectomy performed, 1 month and 6 months after oophorectomy.
Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Quality of life (QOL) questionnaire completed at baseline, then 1 month, 6 months, and 1 year after surgery."
1643232|NCT01907789|Procedure|Transvaginal Ultrasound|"Ovarian Cancer Screening Group: Transvaginal ultrasound performed at baseline and every 6 months for 3 years.
Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) group: Transvaginal ultrasound performed at baseline, every 6 months for 3 years after salpingectomy, then before oophorectomy.
Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Transvaginal ultrasound performed at baseline."
1643233|NCT01907789|Behavioral|Phone Call|"Ovarian Cancer Screening Group and Prophylactic Salpingectomy with Delayed Oophorectomy (PSDO) Group: Phone call made to patient one time a year after third year follow up.
Risk-Reducing Salpingo-Oophorectomy (RRSO) Group: Phone call made to patient 1 day after surgery, 1 week after surgery, then yearly."
1643234|NCT01907776|Drug|ME1100 inhalation solution|ME1100 inhalation solution (arbekacin for oral inhalation at 150mg/mL), 0.6, 2.0, 3.0, 4.0, 6.0, or 9.0mL, Single Dose
1643235|NCT01907776|Drug|ME1100 placebo inhalation solution|Vehicle placebo
1643236|NCT01907763|Drug|SOTB07 200mg|
1643237|NCT01907763|Drug|SOTB07 400mg|
1643238|NCT01907763|Drug|SOTB 200mg placebo|Placebo of SOTB07 200mg
1643239|NCT01907763|Drug|SOTB 400mg placebo|Placebo of SOTB07 400mg
1643240|NCT01907750|Device|biliary drainage tube|
1643241|NCT01907737|Other|Active tDCS and active PNS|"Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA).
Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator."
1643242|NCT01907737|Other|Active tDCS and sham PNS|Active tDCS will be applied with the anode positioned over the ipsilesional M1 and the cathode over the contralateral supraorbital region for 20 minutes (1mA). In sham PNS, the median, ulnar and radial nerves will not be actively stimulated.
1643243|NCT01907737|Other|Sham tDCS and active PNS|In sham tDCS, no current will be delivered through the tDCS device. Active PNS will be administered by 2 pairs of surface electrodes (cathode proximal). One pair will overly the median and ulnar nerves at the wrist, and the other pair will overly the radial nerve. Trains of electric stimulation will be delivered at 1 Hz by using isolation units connected to a square pulse stimulator.
1643244|NCT01907737|Other|Sham tDCS and sham PNS|No current will be delivered by the tDCS device, or to the radial, ulnar and median nerves.
1643245|NCT01907724|Drug|IDX719|IDX719 will be supplied as a 50 mg tablet for oral administration.
1643246|NCT01907724|Drug|Simeprevir|Simeprevir will be supplied as 75 mg capsules for oral administration.
1643247|NCT01907724|Drug|TMC647055|TMC647055 will be supplied as 150 mg capsules for oral administration.
1643248|NCT01907724|Drug|RTV|RTV will be supplied as 80 mg/mL solution for oral administration.
1643249|NCT01907711|Device|Acupuncture.|"Who tried the insertion and manipulation between 8 - 12 needles with guide applied at different points of the body, individually selected and customized, after the insertion, the acupoint stimulation is done through manipulation of de needle sleeve to achieve at each point the sensation known as De Qi."
1643250|NCT01907698|Behavioral|Vaginal intercourse|vaginal intercourse at least twice a week
1643251|NCT01907685|Drug|AVE8062|"Pharmaceutical form:Solution for infusion
Route of administration: Intravenous"
1643252|NCT01907685|Drug|Docetaxel|"Pharmaceutical form: solution for infusion
Route of administration: Intravenous"
1643253|NCT01907672|Procedure|Rapid Diagnostic Test|Rapid Diagnostic Test for Malaria carried out to direct antimalarial dispensing. No antimalarials for negative tests, antimalarials for positive tests
1643254|NCT01907659|Other|Release of test results|Subjects will be randomized to have viral testing and serum PCT results released or no additional testing performed other than that ordered as standard of care
1643255|NCT01907646|Device|bladder training|vescical catheter
1643256|NCT01907646|Procedure|No bladder training|
1643257|NCT01907633|Drug|No intervention|This is an observational and a retrospective study of existing data, so there will be no interventions. The exposure groups will be domperidone, proton pump inhibitors (omeprazole, lansoprazole, esomeprazole, rabeprazole, and pantoprazole), and metoclopramide.
1643258|NCT01907620|Other|blood sample|
1643259|NCT01907607|Drug|PD-0332991 will be administrated orally, formulated as gelatin capsules of 100 mg and 25 mg respectively.|"PD-0332991 dosed on a flat scale of 125 mg (1 capsule x 100 mg/day, 1 capsule x25 mg/day) will be administrated orally o.d on a 21 days on / 7 days off dosing schedule. One cycle is considered to consist of 4 weeks of PD-0332991 administration.
Patients should be instructed to administrate PD-0332991 with a sufficient amount of water at least 1 hour prior to a meal or at least 2 hours following a meal and to swallow the required number of capsules at approximately the same time on each day."
1643260|NCT01907594|Drug|D-cycloserine|
1643261|NCT01907594|Drug|Nicotine Replacement Therapy (patch)|
1643262|NCT01907594|Behavioral|Smoking Cue Exposure|
1643263|NCT01907594|Behavioral|Progressive Muscle Relaxation|
1643264|NCT01907594|Drug|Placebo|The investigators will administer Gelatin Capsule instead of D-Cycloserine in a double blind fashion to some of study subjects.
1643265|NCT01907581|Other|Quality of life questionnaires|
1643266|NCT01907542|Procedure|stapled skin closure|as above
1643267|NCT01907542|Procedure|monocryl skin suture|as above
1643268|NCT01907529|Drug|docetaxel, epirubicin and cyclophosphamide|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; totally 4 cycles
1643269|NCT01907529|Drug|docetaxel, epirubicin and cyclophosphamide plus endostar|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, cyclophosphamide 500mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostar 7.5mg/m2, IV (in the vein) from day 1 to day 14, totally 4 cycles
1643270|NCT01907516|Device|Cell phone-internet home glucose reporting system|Glucose monitoring via cell phone and internet using the Confidant Diabetes Management Application and the Confidant Connector.
1643271|NCT01907516|Behavioral|Voicemail home blood glucose reporting|Glucose monitoring via standard telephone and fax reporting.
1643272|NCT01907503|Procedure|Evaluation of the balance of force platform|
1643273|NCT01907490|Drug|Ha44 Gel|Eligible subjects will be treated at the study site on Day 0 with a single application of the maximum feasible amount of Ha44 Gel, to ensure saturation of the scalp and hair.
1643274|NCT01907477|Other|Samples taken at the clinical hematology unit|
1643275|NCT01907464|Other|clinical parameters description|description of weight, height, Bone Mass Index, dietary questionnary, amenorrhea time, pathology time for the two arms
1643276|NCT01907464|Other|para clinical parameters description|description of DMO, mass, basal metabolism, IGF-1/IGFBP-3 for the two arms
1643277|NCT01907464|Other|hormonal parameters dosing|dosing of leptine, leptine receptor, adiponectine, ghreline for the two arms
1643278|NCT01907464|Other|bone modeling markers dosing|dosing of osteocalcine, bone alkalin phosphatase, C-telopeptide of type-I collagene, osteoprotegerine/ RANKL for the two arms
1643279|NCT01907425|Other|Blood samples|
1643280|NCT01907412|Behavioral|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.
Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.
Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
1643281|NCT01907399|Other|Blood samples|
1643282|NCT01907386|Other|QSE-LSME - SSWI Ultrasound|Doppler ultrasound (DUS) and elastographic examinations will be performed using a single probe (6-1 MHz, Super Curved, Vermon, Tours, France) with the clinical Aixplorer system (Supersonic Imagine, Aix-en-Provence, France), a new generation ultrasound scanner providing an outstanding B-mode and color-Doppler image quality, allowing exportation of RF images for QSE-LSME acquisition and integrating the shear wave elastography (SSWI) mode.
1643283|NCT01907373|Drug|olmesartan medoxomil|
1643284|NCT01907373|Drug|olmesartan medoxomil+probenecid|
1643285|NCT01907360|Drug|B-HLD200 54mg capsules|
1643286|NCT01907360|Drug|C-HLD200 54mg capsules|
1643287|NCT01907334|Drug|Advair Diskus100/50 µg|Advair Diskus 100/50 µg
1643288|NCT01907334|Drug|Flovent Diskus 100 µg|Flovent Diskus 100 µg
1643289|NCT01907334|Drug|Methacholine Chloride|Methacholine Chloride in quadrupling concentrations from 0.25 to 64 mg/mL will be given based upon subject's baseline response.
1643290|NCT01907334|Drug|Albuterol|Albuterol will be administered at the end of each methacholine challenge.
1643291|NCT01907321|Behavioral|Expiratory muscle strength training|Small hand held device that provides calibrated (cmH20) resistance to expiratory pressure. Once sufficient pressure is achieved (participant blowing out into the device) a valve is released, letting air flow through.
1643292|NCT01907321|Behavioral|Placebo expiratory training|Device with the same look and feel as the active EMST, but which provides no resistance to airflow.
1643293|NCT01907321|Drug|Measures performed on all subjects|Capsaicin is a cough-inducing vapor that will be inhaled by participants to induce coughing. The airflow of the cough will be recorded and measures of compression phase duration, peak expiratory flow rate, and post-peak plateau phase will be made.
1643294|NCT01907321|Behavioral|Pulmonary function test|Measures of forced vital capacity (FVC) and Forced expiratory volume in the 1st second (FEV1), and the ratio between the two measures (FEV1/FVC). Also included is the measure of maximum expiratory pressure. Airflow from the voluntary cough will also be recorded and measured using the spirometric system. These measures will be identical to those made on the capsaicin-induced cough.
1643295|NCT01907321|Radiation|Fluoroscopic swallow study|Images from the swallow study will be used to determine the modified barium swallow impairment profile (MBSImp) score, as well as the penetration-aspiration score (PA).
1643296|NCT01907308|Drug|AMG 386|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
1643297|NCT01907308|Drug|Docetaxel|Patients will receive AMG 386 30mg/kg IV weekly plus docetaxel 75mg/m2 IV every 3 weeks.
1643298|NCT01907282|Behavioral|Family Focused Treatment|Treatment for family that focuses on skills for coping with subthreshold positive and negative symptoms and improving family communication and problem-solving
1643299|NCT01907282|Behavioral|Enhanced Care|This 3-session psychoeducational treatment assists individuals and families in coping with early warning signs of psychotic episodes.
1643300|NCT01907269|Behavioral|Video-based Intervention|Video clips delivered by DVD and Internet
1643301|NCT01907256|Procedure|inverted V incision|It is a type of incision
1643302|NCT01907256|Procedure|stair step incisions|It is a type of incision
1643303|NCT01907243|Procedure|spreader flap|producing of upper lateral cartilage flap as a spreader flap
1643304|NCT01907230|Drug|Entecavir|In the prophylactic group, participants will initiate entecavir 0.5 mg/day orally one week before biologic treatment. Entecavir treatment (adjust dosage according to renal function) will be continued normally for 12 months (6 months after stopping biologic therapy or till restart another course of biologic treatment if the clinicians' judgment is minimal risk of reactivation after the first course of biologic agent treatment).
1643930|NCT01902134|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 5 days (total 12 doses)
2012477|NCT01979471|Other|Advanced Care|"The pharmacist will complete a Comprehensive Annual Care Plan (CACP) or Standard Medication Management Assessment (SMMA), which will include:
Patient assessment
Laboratory assessment of HbA1c and lipids
Individual assessment of CVD risk and education about this risk
Calculation of cardiovascular risk will be facilitated by an online tool
Discussion of CVD risk with the patient using the interactive online tool which explains his/her individual cardiovascular risk and targets for intervention and providing the patient with education on cardiovascular risk factors and healthy lifestyle options
Treatment recommendations, Prescription adaptation(s), and/or prescribe where necessary to meet lipid, blood pressure and glycemic control targets and smoking cessation.
Regular communication with the patient's family physician after each contact with the patient
Regular follow-up with all patients a minimum of every 3-4 weeks for 3 months."
2012478|NCT01979276|Drug|Romidepsin|Romidepsin intravenously on days 1 and 15 of a 28-day cycle
2012479|NCT01979276|Drug|pomalidomide|Pomalidomide 4mg daily by mouth on days 1-21 of a 28-day cycle
1643308|NCT01907204|Drug|methylprednisolone|Oral 32mg/8d-16mg/4d-8mg/4d
1643309|NCT01907204|Drug|Budesonide|Budesonide by metered dose inhaler
1643310|NCT01907204|Drug|Budesonide|Budesonide by nebulization
1643311|NCT01907191|Drug|liposomal bupivacaine|(Ultrasound guided injection of liposomal bupivacaine)
1643312|NCT01907191|Drug|Bupivacaine|(around the anterior, lateral and medial aspect of hip joint)
1643313|NCT01907165|Drug|Temozolomide|
1643314|NCT01907165|Drug|Disulfiram|
1643315|NCT01907165|Dietary Supplement|Copper gluconate|
1643316|NCT01907152|Other|Protein enriched yoghurt drink and bread|
1643317|NCT01907139|Behavioral|Robot-assisted therapy|Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment. Vu Therapy games were developed with the goal of enabling repetitive task-specific practice including grocery shopping, cleaning a stovetop, and playing basketball. In this way, stroke patients who are unable to use their severely weakened arms in a functional way are able to practice task-specific movements in a simulated, gravity-reduced environment. Auditory and visual feedback is provided throughout game play to maintain the patient's attention and motivation. In addition, users are provided objective feedback of task performance at the end of each game to enhance motivation and awareness of progress.
1643318|NCT01907139|Behavioral|Distributed constraint-induced therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping. The shaping techniques will involve individualized task selection, graded task difficulty (e.g., practicing deficient parts of the selected activity and then performing the entire activity), verbal feedback, prompting, physical assistance with movements, and modeling. The level of challenge will be adapted based on patient ability and improvement. Participants will be also required to place their unaffected hand and wrist in a mitt for 6 hours a day during the 4-week period and document mitt compliance in daily logs.
1643319|NCT01907139|Behavioral|Dose-matched control therapy|The DMCT group mediated by the therapists will be designed to control for the duration of therapy in amount of therapy hours. This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) tasks for training fine motor or dexterous function for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected UL for 15 to 20 minutes, and (5) activities of daily living or functional tasks practice for 15 to 20 minutes. The activities will be adapted based on the level of motor impairment and individual needs of the patients.
1643320|NCT01907126|Behavioral|Nutrition Program (NP)|Nutrition Program (NP) participants will receive the same number, format, and schedule of group and individual 60-minute sessions, which will focus on low-cost strategies for improving nutrition.
1643321|NCT01907126|Behavioral|Women's Prison CoOp (WPC)|Weekly as 60-minute sessions, 3 group and two individual sessions during incarceration as close to prison discharge as possible. Session 1 focuses on understanding and reviewing HIV risks, including interpersonal violence. Session 2 addresses gender, power, violence, and affect management to counter the emotional effects of violence. Session 3 addresses IV-specific sexual safety skills, including affect management skills. Session 4 helps women begin to develop a personalized safety plan, which may include increasing social support and access to resources. Session 5 helps her finalize and practice the plan, and Session 6 problem-solves any difficulties that have arisen in executing the plan.
1643322|NCT01907113|Drug|BI 10773|oral administration
1643323|NCT01907113|Drug|BI 10773|oral administration
1643324|NCT01907113|Drug|BI 10773|oral administration
1643325|NCT01907113|Drug|BI 10773|oral administration
1643326|NCT01907113|Drug|BI 10773|oral administration
2012480|NCT01979276|Drug|Dexamethasone|Dexamethasone 40mg by mouth on days 1, 8, 15 and 22 of a 28-day cycle
2012481|NCT01972685|Procedure|Cryobiopsy biopsy|Cryobiopsy vs. Transbronchial vs. VATS biopsy
2012482|NCT01972685|Procedure|Transbronchial Biopsy|
2012483|NCT01972685|Procedure|VATS biopsy|
1643333|NCT01907087|Biological|BMN 190|30-300 mg ICV infusion administered every other week for at least 48 weeks.
1643334|NCT01907061|Drug|N-acetylcysteine|drug will be administered via IV,NG
1643335|NCT01907061|Drug|Placebo|placebo or NAC will be given
1643378|NCT01906723|Device|Walker|The Up n' Free (Easy Walking) is a gait trainer equipped with a dynamic partial weight-bearing. The trainer is designed to provide the user with independence, safety, and endurance. It allows for easy transfer from sitting to standing position and stabilizes the pelvis, allowing for free movement of the hands.
1643338|NCT01907035|Behavioral|A cognitive-behavioral intervention|Evaluate the effectiveness of a cognitive-behavioral intervention by psychologists in collaboration with MF plus routine therapy in the field of APS in anxiety-depressive patients mild to moderate, with respect to standardized usual care by physicians, improve quality of life of these people, producing at least ten-point increase in the level of overall quality of life (SF-36)
1643339|NCT01907035|Other|Usual care|
1643340|NCT01907022|Device|Left DLPFC Butterfly Coil|"High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold. Relaxation therapy during the 1Hz stimulation with external audio tape instructions.
Arms: Left DLPFC Butterfly Coil"
1643341|NCT01907009|Drug|Melphalan|Patients will receive Melphalan in three cycles In the first cycle they recieve 60mg/m2 and then 40mg/m2 in the next two cycles.
1643342|NCT01907009|Drug|Lenograstim|"Starting Lenograstim will be at 10mcg/kg/day and between cycles at 10mcg/kgs/day.
After the third cycle patient will receive 263mcg/day for 10 days."
1643343|NCT01906996|Procedure|proximal row carpectomy|excision of the scaphoid, lunate and triquetrum
1643344|NCT01906996|Procedure|four corner fusion|excision of the scaphoid and stiffening of the lunate, capitate and triquetrum by a plate
1643345|NCT01906983|Other|Doppler Ultrasound|Doppler ultrasound will be performed to patients with blunt splenic trauma, prior to discharge and again, at 3-6 months in patients with thrombosis indication.
1643346|NCT01906970|Device|ClampArt|
1643347|NCT01906957|Other|high intensity interval training (HIIT)|High-intensity interval exercise (HIIE) session This HIIE session will be based on a previous study conducted in our laboratory that compared physiological, psychological and electrocardiological tolerance of four different single bouts of HIIE in coronary patients (Guiraud et al. 2010). The selected HIIE session represented the best compromise between safety, time spent at a high level of VO2peak and psychological adherence. This HIIE session consists of a 10-min warm-up at 50% of MAP, followed by two sets of 10 min composed of repeated bouts of 15 s at 100% of MAP interspersed by 15 s of passive recovery. Four minutes of passive recovery were allowed between the two sets, as well as a 5-min cool-down after the last 15-s exercise bout. A total duration of 35 minutes will be employed for this session for coronary artery disease patients, and 22 minutes for chronic heart failure patients (Guiraut et al. 2010 b).
1643348|NCT01906957|Other|moderate intensity continuous exercise training|Moderate Intensity Continuous Exercise (MICE) session This exercise session will be based on the recommendations of the American Heart Association on exercise prescription in cardiac rehabilitation (Balady et al. 2007), suggesting that exercise intensity should lie between 50% and 80% of maximal aerobic power (MAP). We opted for an intensity of 70% of MAP. Duration will be adjusted to match total energy expenditure of the HIIE, according to the previous methodology method (Guiraud et al. 2010 b). A total duration of 28.7 minutes will be employed in healthy elderly patients, coronary artery disease patients and patients with metabolic syndrom; and 16 minutes in chronic heart failure patients.
2012484|NCT01970241|Drug|NPH|NPH given per study table based on steroid dose and patient weight in kg.
1643351|NCT01906931|Device|Portable oxygen concentrator|Respironics EverGo portable oxygen concentrator on setting 6
1643352|NCT01906931|Device|Portable oxygen cylinder|Portable oxygen cylinder at flow rate 5 Litres/min
1643353|NCT01906918|Procedure|IRPC, Remote preconditioning|The patients will be submitted to 5 minutes of upper limb compression by cuff followed by 5 minutes of reperfusion. This cycle will be repeated 4 times.
1643354|NCT01906905|Device|Transcranial Magnetic Stimulation|
1643355|NCT01906892|Other|Group drumming (participatory)|Active participation in group drumming workshops
1643356|NCT01906892|Other|Group drumming (live)|Listening to live performances of group drumming
1643357|NCT01906892|Other|Group drumming (recorded)|Listening to recorded performances of group drumming
1643358|NCT01906892|Other|Comparative activity|Taking part in a literary-based activity
1643359|NCT01906879|Drug|triple, quadruple, non-bismuth quadruple therapy|triple therapy, quadruple therapy, non-bismuth quadruple therapy
1643360|NCT01906866|Drug|Circadin 2/5/10 mg|Active arm
1643361|NCT01906866|Drug|Placebo|
1643362|NCT01906853|Biological|BCG|
1643363|NCT01906840|Drug|Turmeric|
1643364|NCT01906840|Drug|placebo|
1643365|NCT01906814|Drug|3 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first three months.
1643366|NCT01906814|Drug|6 cycles chemotherapy|Chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.monthly for the first six months.
1643367|NCT01906801|Drug|Glucosamine sulfate|
1643368|NCT01906801|Drug|Diacerein|
1643369|NCT01906801|Drug|Placebo (for Diacerein)|Sugar pill manufactured to mimic Diacerein 50 mg tablet
1643370|NCT01906788|Drug|Artemether Lumefantrine|
1643371|NCT01906788|Drug|Artemether Lumefantrine 6 dose regimen & single dose of Primaquine on day 0|
1643372|NCT01906788|Drug|Artemether Lumefantrine 6 dose regimen and single dose Primaquine on day 2|
1643373|NCT01906775|Other|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level|Programming the pacemaker output for ventricular back-up pacing to a sub-threshold level to achieve an ineffective pacing output
1643374|NCT01906762|Drug|Acetaminophen|This protocol prepared by a nurse and labeled as Drug A. Since the rapid injection of Acetaminophen can result in hypotension, therefore based on the Apotel Injection Instruction, it must be infused slowly within 15 minutes.
1643375|NCT01906762|Drug|Morphine|This protocol was prepared by a nurse and labeled as Drug B. Since the rapid injection of Morphine can result in histamine release, therefore it must be infused slowly within 15 minutes. The nurse, who was in charge of infusing pain reliever, was unaware of the type of injected drug.
1643376|NCT01906749|Drug|Colchicine|0.5mg once daily orally
1643377|NCT01906749|Drug|Placebo|
1643456|NCT01905956|Dietary Supplement|IQP-AK-102|IQP-AK-102 was presented in the form of a capsule containing proprietary, patent pending combination of three soluble fibres and excipients.
1643932|NCT01902121|Drug|Technosphere® Insulin 10U + 20U|Inhaled Insulin
1643379|NCT01906710|Other|integrated medicines management|"PITH includes the following interventions:
A) MR on admission to obtain an up-to-date medication list, B) Intermediate medication review during hospitalization C) MR at discharge to maintain an up-to-date medication overview, counseling of the patient at hospital discharge and preparation of the patient to manage their medication at home., Written material is provided for oral support, which includes an overview of the current medication, a summary of potentially important side effects, advices on medication use and hospital pharmacy contact information in order to answer any possible questions, D) Information transfer to GP/community pharmacist at discharge"
1643380|NCT01906697|Procedure|middle turbinate Radio Frequency (RF) turbinoplasty|middle turbinate Radio Frequency (RF) turbinoplasty
1643381|NCT01906697|Procedure|middle turbinate resection|middle turbinate resection
1643382|NCT01906697|Procedure|middle turbinate medialization|middle turbinate medialization
1643383|NCT01906684|Drug|Acthar Gel|Patients who present with MS relapse within 72 hours of onset will be recruited for study. Upon consent they will be administered Achtar Gel for 5-14 days as clinically appropriate.
2012485|NCT01970241|Drug|Correction Factor|Given at 2 units per 50 mg/dl over 200 mg/dl and increased to 3 units/50 mg/dl over 200 if glucose rises to over 300 mg/dl. Administered qid during study duration.
2012486|NCT01969643|Drug|SGN-LIV1A|SGN-LIV1A will be given by intravenous infusion (into the vein; IV) every 3 weeks
1643386|NCT01906658|Drug|Repository corticotropin injection|Acthar given SC twice weekly (80 U or 56 U) or daily (24 U or 16 U) for 8 weeks
1643387|NCT01906645|Other|Care Transitions Innovation (C-TraIn)|Multi-component transitional care intervention including transitional nursing care, pharmacy care, and medical home linkages
1643388|NCT01906632|Biological|DC-CIK Immunotherapy|
1643389|NCT01906606|Behavioral|Parenting Program|A manualized, community-based 12 session group parenting program, facilitated by a locally recruited volunteer
1643390|NCT01906580|Drug|Peg-IFNα-2a|180ug peg-IFNα-2a, subcutaneous injection per week
1643391|NCT01906580|Drug|Entecavir|0.5mg,oral administration every day
1643392|NCT01906554|Other|Egg Dose|Different quantities of eggs
1643393|NCT01906541|Genetic|ex-vivo gene-therapy|transplantation autologous CD34+ cells, transduced with a SIN gammaretroviral vector
1643394|NCT01906528|Drug|Mivacurium|Effect of Mivacurium in males vs females
1643395|NCT01906515|Device|Continuous non-invasive hemoglobin monitoring|Anesthesiologist is provided with real-time continuous non-invasive hemoglobin monitoring to influence care provided to patient
1643396|NCT01906502|Device|Sensimed Triggerfish|
1643397|NCT01906489|Drug|AKB-6548|Oral dose administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
1643398|NCT01906489|Drug|Placebo|Oral placebo administered once daily for 20 weeks. Dose adjustment based on hemoglobin level as defined in the protocol.
1643399|NCT01906476|Behavioral|Stepped Care|Participants will receive an Internet guided cognitive behavioral treatment (iCBT) with support from a telephone coach with the possibility of being stepped up to receiving telephone cognitive behavior therapy (T-CBT) with a therapist
1643400|NCT01906476|Behavioral|Telephone Cognitive Behavior Therapy|Participants will receive telephone-administered cognitive behavioral therapy (T-CBT).
1643401|NCT01906450|Drug|Scaling and root planing plus Azithromycin|Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
1643402|NCT01906450|Drug|Scaling and root planing plus placebo|Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
1643403|NCT01906437|Device|Cardiac Magnetic Resonance Scan|Cardiac Magnetic Resonance Scan
1643404|NCT01906424|Device|Transcutaneous Electrical Spinal Cord Stimulation|A prototype device that delivers transcutaneous electrical stimulation will be used to stimulate the cervical spinal cord.
1643405|NCT01906411|Dietary Supplement|Dopamine depletion vs. Balanced aminoacid drink|
1643406|NCT01906398|Other|ketogenic diet|KD will consist of 3:1 [fat]: [protein + carbohydrate] weight ratio, with 1600 kcal restriction
2012487|NCT01969643|Drug|Trastuzumab|Trastuzumab will be given by IV every 3 weeks at a dose of 6 mg/kg (the first dose will be 8 mg/kg)
1643408|NCT01906372|Drug|Adrenocorticotropic Hormone Gel|H.P. Acthar Gel 80 units will be self-administered subcutaneously twice weekly by the subject for a period of 6 months.
1643409|NCT01906359|Other|Native palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g native palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
1643410|NCT01906359|Other|Chemically interesterified palm olein (IV56)|Test meal consists of a high fat muffin (containing 50 g chemically interesterified palm olein) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
1643411|NCT01906359|Other|High oleic sunflower oil|Test meal consists of a high fat muffin (containing 50 g high oleic sunflower oil) and a cup of milkshake, to be taken as breakfast for each postprandial study day.
1643412|NCT01906346|Drug|Cocaine|Three active doses of cocaine will be made available for self-administration during experimental sessions.
1643413|NCT01906346|Drug|Placebo|Placebo cocaine will be made available for self-administration during experimental sessions.
1643414|NCT01906333|Other|Exercise|
1643415|NCT01906333|Other|Glucose|
1643416|NCT01906333|Other|Fasted|
1643457|NCT01905956|Dietary Supplement|Placebo|The placebo contained microcrystalline cellulose and other excepients. Both active and placebo capsules had identical physical appearance in terms of size, shape, colour and opacity.
2012488|NCT01968317|Drug|Megestrol acetate and metformin|Patients will receive metformin 500 mg by mouth third daily and megestrol acetate 160 mg by mouth daily for 3 months.
1717166|NCT00000920|Drug|Lamivudine|
2012489|NCT01968317|Drug|Megestrol acetate|Patients will receive megestrol acetate 160 mg by mouth daily for 3 months.
2012490|NCT01968460|Drug|P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.6 mg and rasagiline 0.75 mg once daily
2012491|NCT01968460|Drug|Placebo|placebo
2012492|NCT01968460|Drug|P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg),|Fixed Dose Combination of pramipexole 0.3 mg and rasagiline 0.75 mg once daily
2012493|NCT01967628|Dietary Supplement|Vitamin D3 (cholecalciferol)|
2012494|NCT01967628|Dietary Supplement|Placebo Sugar Pill|
1643417|NCT01906320|Behavioral|High-Intensity Resistance training|"Intervention group performed 3 weekly sessions during 8 weeks in the intra-hospital gymnasium. Each session lasted 50-60 min, and started and ended with warm-up and cool-down periods (10-15 min).
The core session included bench press, leg press, lateral row, leg extension, lateral pull-down, abdominal crunch, low back extension, and push-ups exercises. The participants performed three sets of 8-10 repetitions with resting periods of 1-2 min on the weightlifting machines. Load was gradually increased 5-10 % as the participant strength was adapted. The load started at 70% of 6RM.
Functional exercises (abdominal crunch, low back extension, and push-ups) were performed at the end of the session to strengthen the core musculature consisting of 3 sets of 15s of isometric contractions at the beginning of the program and 30 s at the end. Dynamic contractions were added, starting with 10 repetitions at the beginning to 30 repetitions at the end of the program."
1643418|NCT01906307|Drug|LJPC-501|Patients will receive LJPC-501 at titrated doses, with a starting range from 1 to 100 ng/kg/min, by continuous infusion on Days 1 through 5. In Group 1, drug doses will be titrated to 5, 15, and 25 ng/kg/min, after which doses will be titrated in multiples of 25 ng/kg/min. In Groups 2-5, drug doses will be titrated by 25 ng/kg/min. Dose titrations will occur every 2 hours until a MAP of 110 mmHg is reached, maximum urine output is achieved, or a dose of 250 ng/kg/min is achieved. Dosing will then continue at the maximum dose achieved through Day 5.
1643419|NCT01906294|Drug|antidiabetic treatment (ATC A10B)|
1643420|NCT01906281|Other|Blood analyse, arthrocentesis, ultrasound examination|
1643421|NCT01906268|Other|Attentional Bias Modification Treatment (ABMT) - Active|"The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
1643422|NCT01906268|Other|Attentional Bias Modification Treatment - Placebo|"The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
Number of sessions: 10 ABMT sessions, 5 weeks (2 sessions once a week occurring in the same day with 40 minutes interval)"
1643423|NCT01906242|Other|water|
1643424|NCT01906242|Other|sodium hypochlorite|
1643425|NCT01906242|Other|sodium bicarbonate|
1643426|NCT01906242|Other|chlorhexidine|
1643427|NCT01906216|Drug|Sorafenib|Sorafenib will be supplied as 200 mg tablets. All subjects will take two tablets of sorafenib (200 mg tablets) twice daily (each morning and evening).
1643428|NCT01906216|Procedure|TACE|"The first treatment of TACE should be completed within 3-7 days after the administration of sorafenib started. In all cases, TACE consists of an injection containing a mixture of chemotherapeutic agents and lipiodol followed by embolization with polyvinyl alcohol (PVA) until complete stasis was achieved in the tumor-feeding vessels.Tumor-feeding vessels should be selected/superselected whenever possible. TACE will be repeated on demand depending on the radiological response."
1643429|NCT01906203|Device|body bioelectrical impedance performed by Z-Métrix (class IIa) - BIOPARHOM 12 allée des lacs de garde, Savoie Technolac BP 238, 73374 Bourget du lac, France|
1643430|NCT01906190|Biological|seasonal influenza vaccine|subjects whose antibodies less than 1:40 6 months later after primary vaccination will receive a booster dose of seasonal influenza vaccine
1643433|NCT01906151|Device|SENSIMED Triggerfish®|SENSIMED Triggerfish® (TF) is a CE-marked portable device that monitors the 24-hour intraocular pressure (IOP) pattern by a wireless contact lens sensor (CLS) placed on the eye that sends its signals wirelessly via a periorbital patched adhesive antenna to a recorder. Upon completion, the recording can be transmitted to a computer for read-out and visualization
1643434|NCT01906138|Device|SENSIMED Triggerfish®|All eligible patients will be assigned to 24-hour intraocular pressure recording using Triggerfish
1643435|NCT01906125|Drug|palbociclib capsule: phase 1 and 2 studies|125 mg dose of palbociclib. Formulation used in phase 1 and 2 studies
1643436|NCT01906125|Drug|Palbociclib capsule: phase 3 studies|125 mg dose of palbociclib. Formulation used in phase 3 studies
1643437|NCT01906125|Drug|Palbociclib capsule: ICH|125 mg dose of palbociclib. Intended final market formulation
1643438|NCT01906112|Procedure|Surgery for primary breast tumor.|Complete resection of primary breast tumor(Lumpectomy or mastectomy)
1643439|NCT01906099|Other|nutritional intervention|
1643440|NCT01906099|Other|life style modification|
1643441|NCT01906086|Other|nutritional intervention|
1643442|NCT01906086|Other|life style intervention|
1643443|NCT01906073|Drug|intranasal fentanyl spray|
1643444|NCT01906073|Drug|slow release morphine|
1643445|NCT01906060|Device|Air-Q Intubation Laryngeal Mask|Patients will be intubated using the Air-Q Laryngeal Mask.
1643446|NCT01906034|Behavioral|Exercise with supervision|
1643447|NCT01906034|Behavioral|Home-based without supervision|
1643450|NCT01906008|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.
1643451|NCT01906008|Drug|Placebo|1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.
1643452|NCT01906008|Behavioral|Questionnaires|Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.
1643453|NCT01906008|Behavioral|Sensory Test|Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.
1643454|NCT01905982|Procedure|reflectory breathing therapy|duration:2x60 minutes
1643455|NCT01905982|Procedure|conventional breathing therapy|duration:4x30 minutes
1643933|NCT01902121|Drug|Technosphere® Insulin 30U|Inhaled Insulin
2012495|NCT01966809|Drug|Photofrin photodynamic therapy.|"The subjects will receive a dose of 2.5 mg/kg of Photofrin intravenously 24 hours before planned surgical resection. Tumor resection will be carried out in the standard fashion in order to achieve the maximum tumor resection compatible with preservation of neurological function. After resection, Intralipid will be infused into the craniotomy and kept for approximately 45 min, while PDT will be performed. The illumination time will be calculated from the power density (mW) emitted by the laser and the radius (r) of the cavity to deliver a total light dose of 240 J/cm2 at a using the following formula:
Treatment Time (sec) = Light dose (J/cm2) x Cavity surface (cm2) x 1000 Power density (mW) Cavity Surface (cm2) = 4 x 3.14 x r2 The optical fiber will be placed in the center of the surgical cavity and photoillumination will commence. After PDT, the Intralipid solution will be removed and the wound will be closed. The subject will be sent to the intensive care area for recovery."
1643463|NCT01905930|Device|PCM Cervical Disc|Patients enrolled in the IDE clinical study and treated with the PCM Cervical Disc to treat degenerated cervical discs and neurological symptoms at one level from C3 to T1
1643464|NCT01905930|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Patients enrolled in the IDE clinical study and treated with an anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
1643465|NCT01905917|Other|Tele-rehabilitation|
1643466|NCT01905904|Drug|sevorane|Sevorane 4% Sevorane 7%
1643467|NCT01905891|Procedure|Superficial shave biopsy|Sample will be obtained from random dorsal forearm skin sites without evidence of keratotic lesions. The site will be selected by the investigator. Skin will first be wiped with an alcohol pad and 1% lidocaine will be superficially infiltrated per standard skin surgical procedures. 30% trichloroacetic acid (TCA, standard chemical peel) will then be applied for five minutes. TCA will be neutralized using bicarbonate. Using a cytology brush (a small brush which is used to collect cells during the course of a biopsy) cells will be collected by gentle scraping surface of the skin. Then, a superficial shave biopsy specimen, obtained by using a dermablade (a flexible, one piece blade specifically designed for shave biopsy and excision of skin lesions) will be obtained.
1643468|NCT01905878|Drug|DLBS1033|
1643469|NCT01905813|Drug|INCB040093|Escalating doses starting at 100 mg every day (QD)
1643470|NCT01905813|Drug|INCB040093|INCB040093 monotherapy - dose to be determined at completion of Phase I of the study
1643471|NCT01905813|Drug|INCB040093 + itacitinib|INCB040093 dose to be determined at completion of Part 1 of the study + itacitinib at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.
1643472|NCT01905800|Device|Biaxial rotational chair|This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
1643473|NCT01905774|Drug|Deferasirox|
1643474|NCT01905748|Other|Laboratory tests|Laboratory tests: erythrocyte sedimentation rate (ESR), Blood Count, C reactive Protein, Protein C activity, Protein S activity,Antithrombin II activity, Coagulation Factor VIII and IX,Con Willebrand Factor, prothrombin time (PT), activated partial thromboplastin time (aPTT), Fibrinogen, D Dimer and Prothrombin Fragments F1 and F2.
1643475|NCT01905735|Drug|Rhustoxicodendron 30|1/2ml Rhustoxicodendron 30 is administered orally every 7 day for 5 month.
1643476|NCT01905735|Drug|placebo|1/2 ml of dispensing alcohol is administered every 7 day for 5 month orally.
1643477|NCT01905722|Other|3 Tesla|3 Tesla scanning with intravenous infusion of tracers
1643478|NCT01905722|Other|7 Tesla|7 Tesla scanning with intravenous infusion of tracers
1643479|NCT01905709|Biological|Human fecal matter|
1643480|NCT01905696|Drug|Oral N-acetylcysteine|
1643482|NCT01905670|Device|WiCS-LV system|Wireless cardiac stimulator implant to pace the left ventricle for CRT Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
1643483|NCT01905657|Biological|Pembrolizumab|Participants who experienced disease progression on docetaxel may have been eligible to crossover to receive pembrolizumab.
1643484|NCT01905657|Drug|Docetaxel|Participants who initially receive docetaxel may be eligible to crossover to receive pembrolizumab.
1643485|NCT01905644|Procedure|Perineal ultrasound|Perineal ultrasound will be used after delivery to help detect anal sphincter ruptures.
1643486|NCT01905618|Behavioral|Web-based curriculum on tobacco dependence treatment|"The University of Massachusetts Medical School's web-based course, Basic Skills for Working with Smokers was adapted for this Randomized Controlled Trial (RCT). The goal is to provide standardized information in the following core tobacco content areas: epidemiology of tobacco use, health consequences of tobacco use, nicotine dependence and withdrawal assessment, and provision of behavioral and pharmacotherapy tobacco treatment. The course is 3 hours in length and can be completed at the student's convenience. The dean and the course director at each medical school required that the first year medical students complete the web-based curriculum prior to the next component of the study, the role play."
1643487|NCT01905618|Behavioral|Tobacco Counseling Role Play|The goal of the role play is to provide each student with the opportunity to apply what he/she learned in the web-based curriculum (the 5 As and the physician delivered intervention approach). The one hour session begins with a video of a patient-centered counseling approach which incorporates the 5A intervention presented in the web-based course. This is followed by a 30 minute role play session including various scenarios with physician/patient interaction. Students role play either as physician, patient or observer for each scenario.
1643488|NCT01905618|Behavioral|Preceptor Training and Teaching Medical Students|The goal of this intervention is to train preceptors in the use of the 5As with their patients and to teach and motivate their medical students to use the 5As. The academic detailing approach is used to provide a standardized 30 to 45 minute group training session during the third year clerkship. All preceptors and medical students are encouraged to intervene with patients who smoke. Preceptors are encouraged to model the 5As, observe and give feedback to the medical student in its use. Study-tailored handouts are available for preceptors and students. This component is implemented with the study cohort in their third year of medical school.
1717167|NCT00000920|Drug|Zidovudine|
1643489|NCT01905618|Behavioral|Booster Session|The last component of the intervention, a small group booster session, occurs during the third year of medical school. A five minute video reviews the use of the 5As and patient-centered counseling strategies. Faculty facilitate a small group discussion after viewing the video.
1643490|NCT01905605|Drug|phosphatidylcholine supplementation|phosphatidylcholine concentrate 700 mg twice per day
1643491|NCT01905605|Drug|placebo|placebo manufactured look like phosphatidylcholine concentrate dosed at 1.2 ml twice per day
1643492|NCT01905592|Drug|niraparib|Until progression or unacceptable toxicity develops
1643493|NCT01905592|Drug|Physician's choice|Choice of 4 standard of care metastatic breast cancer chemotherapies
1643494|NCT01905579|Procedure|Paracentesis of the anterior chamber|Aqueous humor parenthesis for quantitative protein analysis in patients with and without uveitis.
1643495|NCT01905566|Drug|Clopidogrel|75mg once a day
1643496|NCT01905566|Drug|Ticagrelor|90mg twice a day
1643497|NCT01905553|Drug|SSP-004184SS|Disodium salt
1643498|NCT01905540|Drug|SSP-004184AQ|Magnesium salt
1643499|NCT01905540|Drug|SSP-004184SS|Disodium salt
1643500|NCT01905527|Other|Standard Services of Group A (Group A1)|Support services provided in this group will include: Initial field nurse injection training visit; field nurse follow-up and subsequent visits; and follow-up phone calls at periodic intervals
1643501|NCT01905527|Other|Customized Services of Group A (Group A2)|In addition to the initial field nurse injection training visit and follow-up call, subjects will select from support services including field nurse follow-up visits; follow-up phone calls; email and/or text reminders; subject self-assessment and use of treatment planning tools; and mail/e-mail educational materials.
1643502|NCT01905527|Other|Group B|Support services provided in this group will include initial field nurse injection training visit and follow-up phone calls at periodic intervals.
1643503|NCT01905514|Device|internet mobile application|
1643504|NCT01905501|Drug|Balanced anesthesia|Et-Sevo maIntained 1,8-2%, remifentanyl according target-controlled infusion maintained 1-3 ng/ml
1643505|NCT01905501|Drug|Total intravenous anesthesia|Propofol 3-4 µg/ml and remifentanyl 1-3 ng/ml according target-controlled infusion
1643506|NCT01905475|Drug|POL6326|
1643507|NCT01905475|Drug|Placebo|
1643508|NCT01905462|Other|Data Collection|Analyses of data collected within the CPRD GOLD database.
1643509|NCT01905462|Biological|Cervarix|Women with last menstrual period (LMP) between 30 days before and 45 days after, or 30 days before and 90 days after any dose of Cervarix and women with LMP between 120 days and 18 months after the last Cervarix dose.
1643510|NCT01905449|Behavioral|Ultrasound visual feedback|Real-time visual displays of the tongue are used to cue participants to modify the tongue position/shape as they articulate speech sounds
1643511|NCT01905436|Drug|Annual versus Semiannual Albendazole plus Ivermectin Mass Drug Administration|Annual or semiannual Albendazole plus Ivermectin, administered by the Liberian Ministry of Health.
2012496|NCT01965704|Drug|Ondansetron|Pregnant women may receive a second dose of IV ondansetron if they have not delivered within 4 hours of receiving the IV study medication. 50% of the 90 mother/baby pairs will receive ondansetron; the baby will always get the same study medication as the mother.
1643513|NCT01905410|Drug|VVZ-149 Injection|VVZ-149 in water for injection
1643514|NCT01905410|Drug|placebo|water for injection
2012497|NCT01965704|Drug|Placebo|All doses of placebo, whether IV or oral, will mimic the same volume as the ondansetron group to maintain the blind. Pregnant women may receive a second dose of IV placebo if they have not delivered within 4 hours of being given the IV study medication. 50% of the 90 mother/baby pairs will receive placebo; the baby will always receive the same study medication as the mother.
2012498|NCT01964105|Device|3D Imaging|
1643517|NCT01905384|Device|Covered Self-expanding metal biliary stents (C-SEMS)|Used for palliation of inoperable malignant distal bile duct obstruction.
1643518|NCT01905384|Device|Uncovered Self-expanding metal biliary stents (U-SEMS)|Used for palliation of inoperable malignant distal bile duct obstructions.
1643519|NCT01905371|Drug|Dextroamphetamine|
1643520|NCT01905371|Other|Physical Therapy|One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
1643521|NCT01905371|Drug|Placebo|
1643522|NCT01905345|Procedure|Training|
1643523|NCT01905332|Other|Literacy promoting home based program|The Columbus Metropolitan Library (CML) has an early childhood literacy program, known as Ready to Read. It aims to reach parents and caregivers of children birth to five and share easy literacy-building activities that parents can use at home with their children. Ready to Read Corp members offer 5-6 home visits at no cost, educating parents on early literacy activities in the home.
1643524|NCT01905332|Other|Literacy Toolkit|Package of books, games, and multi-sensory toys to facilitate the development of emergent literacy skills.
1643525|NCT01905319|Other|Blood collecting for storage of samples|
1643526|NCT01905306|Procedure|computer guided implant planning|
1643527|NCT01905306|Procedure|free hand implants placement|
1643528|NCT01905293|Other|Feeding Study|
1643529|NCT01905280|Procedure|Non-resorbable membrane|The ridge preservation graft will be covered with a non-resorbable PTFE membrane during the surgery.
1643530|NCT01905280|Procedure|Acellular dermal matrix|The ridge preservation graft will be covered with an acellular dermal matrix allograft during the surgery.
2012499|NCT01963208|Drug|ganaxolone|200 mg and 225 mg capsules; target dose 1800 mg/day dosed 900mg 2x/day
1643532|NCT01905254|Device|Transient elastography (TE)|TE and minilaparoscopic guided liver biopsy were performed by physicians blinded to the results the other within a period of less than 3 months.
1643533|NCT01905254|Other|Liver biopsy|Minilaparoscopic guided liver biopsy was performed within a period of 3 months of Transient Elastography
1717168|NCT00000921|Drug|Prednisone|
2012500|NCT01963208|Drug|Placebo|placebo
2012501|NCT01961843|Drug|Abiraterone|Abiraterone acetate is an orally bioavailable inhibitor of steroid synthesis, specifically testosterone synthesis.
1643534|NCT01905228|Drug|CBL0137|All doses are on Days 1, 8 and 15 of every 28 day cycle. Number of Cycles: 2 or until progression or unacceptable toxicity develops
1643535|NCT01905215|Biological|RSV vaccine GSK3003892A (formulation 1)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
1643536|NCT01905215|Biological|RSV vaccine GSK3003893A (formulation 2)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
1643537|NCT01905215|Biological|RSV vaccine GSK3003895A (formulation 3)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
1643538|NCT01905215|Biological|RSV vaccine GSK3003896A (formulation 4)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
1643539|NCT01905215|Biological|RSV vaccine GSK3003898A (formulation 5)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
1643540|NCT01905215|Biological|RSV vaccine GSK3003899A (formulation 6)|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
1643541|NCT01905215|Drug|Placebo comparator|Intramuscular (IM) vaccination in the deltoid region of the non-dominant arm at Day 0 according to protocol schedule
1643542|NCT01905202|Drug|Secretrol|
1643543|NCT01905189|Procedure|Resynchronization therapy of right ventricle|Right atrio-ventricular resynchronization therapy combined with right intra-ventricular resynchronization therapy
1643544|NCT01905176|Other|In person education on heart failure topics before discharge|Individualized in-person education on HF topics aiming to promote self-care practices by using educational electronic material and booklet
1643545|NCT01905176|Other|Telephone support and education post-discharge|Individualized telephone support/education of three months duration, on HF topics, aiming to promote self-care practices while evaluating patients' current status and condition
1643546|NCT01905176|Other|Pre-discharge in person education and post-discharge telephone education and support|Patients receive both interventions of Arm 1 & 2: individualized pre-discharge counseling/education along with telephone follow-up support for three months, following the same line as mentioned in Arms 1 & 2
1643547|NCT01905163|Procedure|Tumor Debulking Surgery by laparoscopy|
1643548|NCT01905150|Drug|G-FLIP|G-FLIP is a combination of Low Doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, and Oxaliplatin
1643549|NCT01905150|Drug|G-FLIP-DM|G-FLIP-DM is low doses of Gemcitabine, Fluorouracil [5FU], Leucovorin, Irinotecan, Oxaliplatin, Docetaxel and Mitomycin C
1643550|NCT01905150|Dietary Supplement|Vitamin C|High dose of Vitamin C, used in combination with G-FLIP and then G-FLIP-DM
2012502|NCT01961843|Drug|Prednisone|Prednisone is a synthetic corticosteroid that is co-administered with abiraterone acetate to offset the hypokalemia and hypertension side effects of abiraterone acetate.
2012503|NCT01961115|Drug|Epacadostat|Given PO
1643553|NCT01905124|Drug|CF101|CF101 1 mg tablets orally every 12 hours for 24 weeks
1643554|NCT01905124|Drug|Placebo|Matching placebo tablets orally every 12 hours for 24 weeks
1643555|NCT01905111|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
1643556|NCT01905098|Other|Sauna Detoxification Protocol|"All study participants will actively undergo sauna intervention sessions.
The sauna will be pre-warmed to 160 degrees Fahrenheit and humidity set to 25% +/- 5%. Participants will have a scheduled 10-min break every 30 minutes of sauna, during which time vital signs, symptoms, and fluid intake will be assessed and recorded.
On a weekly basis, lab assessments will be performed to compare participants' baseline lab values with those during the sauna intervention, and to monitor for safety. In addition, weekly serum samples will be taken for PCB assessment."
1643557|NCT01905098|Other|Observation Sessions|All enrolled participants will undergo observation protocol consisting of one (1) hour visit weekly consistent with Sauna Visits lab assessment time points, to be completed in 3 weeks (4 total sessions within 21 days). At each Observation Visit a blood draw for CBC/D, CMP, and PCBs analysis will be performed, as well as query for symptoms and MOSES questionnaire will be assessed.
1643558|NCT01905085|Device|No intervention|
1643559|NCT01905072|Other|Education Home Visits|"Intervention will include educational home visits on:
Growth monitoring and feedback
Feeding: support exclusive breastfeeding until 6 months; delay solid feeding until 6 months; appropriate amounts of food for age; stop bottle feeding at 12 months; have nothing but breast milk/formula/4 oz juice in bottle; limit juice amount to 4 oz day; introduce cup by 10-11 months; no sweetened beverages; limited amounts of sweets.
Parenting: recognizing hunger and satiety cues; handling colic/crying; engaging baby in play.
Activity: being active with the baby; no screen time for baby and limited to 1 hour for 1-3 year olds; promote active play while maintaining safety.
Sleep: at least 10-12 hours sleep per day needed; how to promote sleeping environment for baby."
1643560|NCT01905059|Drug|monoPI - boosted lopinavir or boosted darunavir|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD) This arm was stopped by the Scientific Committee on advise of the DSMB after interim analysis showing increased risk of failure for these participants. Participants are switched to standard second line triple therapy and will be followed until the last visit at week 96.
1643561|NCT01905059|Drug|bi therapy - (boosted lopinavir or boosted darunavir) + lamivudine|boosted lopinavir (LPV/rtv 200/50 mg 2 tbs BID) with lamivudine 300 mg QD or boosted darunavir (DRV 400 mg 2 tbs plus RTV 100 mg QD)with lamivudine 300 mg QD. This arm is going on, patients will be followed on this intervention until the end of the study at week 96
1643562|NCT01905046|Drug|metformin hydrochloride|given PO
1643563|NCT01905046|Other|placebo|given PO
1643564|NCT01905020|Other|Carbohydrate-rich meal|At 19:30, patients will eat a standardized large meal (110g carbohydrate for males; 90g carbohydrate for females). Conventional insulin pump therapy or closed-loop system will be use to control glucose levels from 21:00 until 7:00 next morning.
1643565|NCT01905020|Other|Exercise|Study participants will go to a training facility around 18:00 to perform a 60min workout at 60% heart rate reserve. The workout will be on a treadmill and/or a stationary bicycle. Conventional insulin pump therapy or closed-loop system will be use to regulate glucose levels from 21:00 until 7:00 next morning.
1643566|NCT01905007|Device|Defibrillation testing|Defibrillation testing at initial ICD implantation
1643934|NCT01902108|Drug|Bupivacaine|Local infiltration before wound incision with 20 ml of Bupivacaine 0.25 % alone
1643567|NCT01904994|Procedure|POC (point-of-care) CD4+ (cluster of differentiation 4) Count|Each HIV testing and counseling (HTC) site will be equipped with POC CD4+ testing using PIMA™ Analyser (Inverness), test strips, and reagents. Study staff will obtain 25 microliters of blood via finger prick and process the POC (point-of-care) CD4+ (cluster of differentiation 4) Count' test immediately following the baseline interview. Test results will be recorded on study forms including a referral form that has multiple copies, one copy to be given to the participant, the second sent to the affiliated HIV (Human immunodeficiency virus)care clinic in the study unit, and the third kept by study staff in a locked cabinet with other confidential material. All participants, regardless of the CD4+ result, will be encouraged to enroll in HIV care as soon as they can.
1643568|NCT01904994|Procedure|Accelerated ART (antiretroviral therapy) Initiation|"Accelerated ART initiation for patients with POC CD4+ < 350 cells/uL (micro-liter) within 1 week from testing.
2 counseling sessions (one at time of HTC and other at first HIV clinic visit), and collection of blood for other baseline lab tests, but initiation prior to return of results for patients who do not meet criteria for waiting"
1643569|NCT01904994|Behavioral|Basic Care and Prevention Package|Basic care and prevention package (BCPP) provided approximately every three months that includes: condoms; soap, pill box and pictorial education about use of materials and HIV, such as family testing tools and information. Information on BCPP contents and review the educational materials will be provided. An example of educational materials is a family-testing tool to encourage the participant to have all family members tested for HIV. All BCPP items will be replenished every 3 months for all participants, regardless of ART status, beginning at linkage to HIV care.
1643570|NCT01904994|Behavioral|Cellular Appointment Reminders and Follow-Up|"SMS (short messaging service) appointment reminders for follow-up appointments.
Telephone call within 7 days of missed appointment for all patients."
1643571|NCT01904994|Other|Financial Incentive|Participants will receive a series of financial incentives to support linkage into care within 1 month and retention in care at 6 months and 12 months after testing HIV positive. The value of the financial incentive (FI) will be 80 Swaziland Rand, calculated based on the associated financial costs of traveling to clinic. These incentives will be distributed by through mobile airtime. Participants without mobile phones will be given an alternative incentive of equal value, such as a store voucher.
1643572|NCT01904981|Drug|Beta-blocker-Atenolol 50mg, PO(peroral), Once daily|
1643573|NCT01904981|Drug|Angiotensin receptor blocker-Valsartan 80mg, PO(peroral), Once daily|
1643574|NCT01904929|Other|Walk-tests|"Patients will make a 6-minute-walk-test, the 400m-walk-test and a 200m-fast walk test. These first 2 tests (TM6min and TML400m) will be made in an order determined by randomization.
This series of test will be repeated 72 hours later for the study reproducibility.
It will be followed by a phase of rest of 15 min and a test of effort on travelator, according to the protocol of  modified Bruce  in moderation of portable VO2."
1643575|NCT01904916|Procedure|Histological biopsy procedure|
1643576|NCT01904903|Drug|Trastuzumab, Pertuzumab, Ado-trastuzumab emtansine|
1643577|NCT01904890|Behavioral|CRC Prevention and Screening Education|Refer to Arm Description
1643578|NCT01904890|Behavioral|Nutrition Education|Refer to Arm Description
1643579|NCT01904877|Behavioral|Enhancing HIV testing|SMS-I intervention by cell phones, web advertisement, community outreach, and peer referral strategies to recruit MSM in Beijing City for receiving HIV testing
1643580|NCT01904864|Drug|elemental iron (NovaFerrum®)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, NovaFerrum®, for 12 weeks
1643581|NCT01904864|Drug|elemental iron (Ferrous Sulfate)|single daily dose (3mg/kg) of a 15 mg/ml elemental iron preparation, Ferrous Sulfate, for 12 weeks
1643582|NCT01904812|Other|Questionnaire about quality of life and satisfaction|
1643583|NCT01904799|Other|Cognitive Assessment test|
1643584|NCT01904786|Drug|Melatonin|
1643585|NCT01904786|Drug|placebo|
1643586|NCT01904773|Drug|AZD5213 and placebo|low dose AZD5213 capsules; high dose AZD5213 capsules; placebo capsules
1643587|NCT01904760|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day.
1643588|NCT01904760|Drug|Saline placebo|Normal saline 0.9% (guess as 4㎍/mL) : 0.5㎍/kg/hr infusion for 1 hour before operation is completed and 0.2-0.7㎍/kg/hr infusion continuously until 6:00am the next day
1643589|NCT01904747|Drug|Palbociclib administered Fasted|palbociclib given under fasting 10 hrs overnight; capsule form, 125 mg single dose
1643590|NCT01904747|Drug|Palbociclib administered Fed high calorie|palbociclib given right after a high fat high calorie meal; capsule form, 125 mg single dose
1643591|NCT01904747|Drug|Palbociclib administered Fed low calorie|palbociclib given right after a low fat low calorie meal; capsule form, 125 mg single dose
1643592|NCT01904747|Drug|Palbociclib administered Fed moderate calorie|palbociclib given between moderate calorie meal; capsule form, 125 mg single dose
1643593|NCT01904734|Drug|Clomiphene|Start with 25 mg and escalate to 50 mg in men not achieving goal for serum testosterone after 3 weeks
1643594|NCT01904721|Drug|Bimatoprost Solution 1|Bimatoprost Solution 1 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
1643595|NCT01904721|Drug|Bimatoprost Solution 2|Bimatoprost Solution 2 applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
1643596|NCT01904721|Drug|Bimatoprost Vehicle|Bimatoprost Vehicle (placebo) applied evenly onto pre-specified area on the scalp daily for 28 days, or daily for 6 months.
1643597|NCT01904708|Other|Acute Moderate Intensity Exercise|Moderate intensity exercise by walking on a treadmill at 75% of max heart rate.
1643598|NCT01904695|Drug|Herbs|Herbs 180ml by mouth every 12 hours for 8 weeks
1643599|NCT01904695|Drug|Antihypertensive drugs|Thiazide diuretics and ACE inhibitor and β-blocker in different dosage determined by the physician for 8 weeks
2012504|NCT01961115|Other|Laboratory Biomarker Analysis|Correlative studies
1643601|NCT01904656|Behavioral|"Get Behind your health"|"Participants are exposed to the Get Behind Your Health! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
1643802|NCT01903187|Device|EnligHTN Renal Denervation|Renal artery angiogram plus bilateral renal denervation with the EnligHTN renal denervation system
1643602|NCT01904656|Behavioral|Peaches|"Participants are exposed to a Healthy Eating! media campaign intervention comprising 3 phases: the media campaign, the medical chart reminder, and a combination of media campaign and chart reminder. Participants also undergo telephone interviews during years 2-4."
1643603|NCT01904643|Drug|lenalidomide|Given PO
1643604|NCT01904643|Drug|mitoxantrone hydrochloride|Given IV
1643605|NCT01904643|Drug|etoposide|Given IV
1643606|NCT01904643|Drug|cytarabine|Given IV
1643607|NCT01904630|Genetic|gene sequencing|Gene sequencing by exome capture and high throughput sequencing for identification of rare variants
1643608|NCT01904617|Other|Dextrose|
1643609|NCT01904617|Other|Normal Saline|
1643610|NCT01904604|Biological|Placebo Viaskin® Patch|Placebo (e.g., no peanut) patch in an epicutaneous application for 24 hours every 24 hours.
1643611|NCT01904604|Biological|Low-dose DBV712 Viaskin® Patch|100 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
1643612|NCT01904604|Biological|High-dose DBV712 Viaskin® Patch|250 microgram (µg) dose of peanut proteins in an epicutaneous application for 24 hours every 24 hours.
1643613|NCT01904591|Dietary Supplement|Selenium|"Selenium 50 micrograms daily per oral
1 year of treatment"
1643614|NCT01904591|Dietary Supplement|Vitamin E|"Vitamin E 400 international units daily per oral
1 year of treatment"
1643615|NCT01904578|Other|true accupressure|Four acupoints were chosen for subjects in the acupressure group. They were Shenmen on the wrist crease, Sanyinjiao point (SP6) on both feet, Fengchi on the hairline of the back neck (occipital area)and Yintang, at the top of the nose on the center line between the ends of the eyebrows.
1643616|NCT01904578|Other|sham acupressure|Non-acupoints, which were 1 to 3 traditional Chinese unit of length (CUN) away from true acupoints, were used in sham acupressure group.These points were out of the route of energy
1643617|NCT01904565|Radiation|Hyperthermia and Proton Beam|"Local hyperthermia,once a week for 5 to 7 weeks to a temperature of 41.5 to 42.5 degree Centigrade
Proton beam therapy, 5 days a week at 1.8 - 2.0 GyE per fraction to a dose of 55 - 60 GyE (preoperative) or 72 - 76 GyE (for radical. Patients who have good response at 5 weeks of treatment would be considered for preoperative treatment, while those with unsatisfactory response that could be taken up for at least R0 resection would be treated to a radical dose."
1643618|NCT01904552|Device|Electronic Root Canal Length Measurement Device|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file
1643619|NCT01904539|Drug|obeticholic acid 10 mg|Single dose OCA 10mg in each arm
1643620|NCT01904526|Drug|Guanfacine|3mg/day IR with 3-week lead-in period. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 4mg/day ER. Maintained at steady state to complete lab session. After completion of lab session, 1-week lead-in medication period to 6mg/day ER. Maintained at steady state to complete lab session. 5-day taper after lab.
1643621|NCT01904513|Dietary Supplement|Pasteurized Whole Milk|
1643622|NCT01904513|Dietary Supplement|Lactobacillus rhamnosus GR-1|
1643623|NCT01904500|Drug|Pre-operative cefazolin|
1643624|NCT01904487|Radiation|[11C]flumazenil|[11C]flumazenil is a radiotracer used to measure levels of the neurotransmitter GABA in the human brain.
1643625|NCT01904487|Drug|Tiagabine|Tiagabine raises levels of GABA in the brain. It is used in this study so that we can measure the changes in GABA levels.
1643626|NCT01904474|Other|Next.Step - e-therapeutic intervention program|
1643627|NCT01904474|Other|Standard treatment protocol|
1643628|NCT01904461|Device|Vacuum device|
1643629|NCT01904461|Procedure|Conventional surgery|
1643630|NCT01904448|Device|Auditory Brainstem Implantation in Children|
1643631|NCT01904422|Procedure|conventional periodontal treatment|
1643632|NCT01904409|Drug|Placebo|
1643633|NCT01904409|Drug|Rifaximin SSD 40 mg IR tablet|
1643634|NCT01904409|Drug|Rifaximin SSD 80 mg IR tablet|
1643635|NCT01904409|Drug|Rifaximin SSD 40 mg SER tablet|
1643636|NCT01904409|Drug|Rifaximin SSD 80 mg SER tablet|
1643637|NCT01904409|Drug|Rifaximin SSD 80 mg IR tablet + rifaximin SSD 80 mg SER tablet|
1643638|NCT01904396|Drug|Carnitine|Patients who are found to be carnitine deficient will be started on carnitine replacement and their heart function will be monitored on carnitine.
1643639|NCT01904383|Drug|Trazenta|1 tablet of 5 mg Trazenta tablets once daily
1643640|NCT01904357|Drug|Cefazolin 1 GM Injection|Subjects weighing ≥25 kg and < 50 kg will receive the 1g dose.
1643641|NCT01904357|Drug|Cefazolin 2 GM Injection|Subjects weighing ≥50 kg to ≤85 kg will receive the 2g dose.
1643642|NCT01904344|Device|Sensor testing and validation|
1643643|NCT01904318|Drug|IDP-73152 mesylate 40 mg|IDP-73152 mesylate 40 mg single dose administration
1643644|NCT01904318|Drug|IDP-73152 mesylate 80 mg|IDP-73152 mesylate 80 mg single dose administration
1643645|NCT01904318|Drug|IDP-73152 mesylate 160 mg|IDP-73152 mesylate 160 mg single dose administration
1643646|NCT01904318|Drug|IDP-73152 mesylate 320 mg|IDP-73152 mesylate 320 mg single dose administration
1643647|NCT01904318|Drug|IDP-73152 mesylate 640 mg|IDP-73152 mesylate 640 mg single dose administration
1643648|NCT01904318|Drug|IDP-73152 mesylate 1280 mg|IDP-73152 mesylate 1280 mg single dose administration
1643649|NCT01904318|Drug|Placebo|Placebo single dose administration
1643650|NCT01904292|Drug|Tocilizumab|Subcutaneous 162 mg dose QW or Q2W for 52 weeks
1643651|NCT01904279|Drug|Tocilizumab|Participants will receive 162 mg of TCZ as SC injection Q3W or Q2W for 52 weeks
1643652|NCT01904266|Procedure|GA + paravertebral block|20 cc ropivacaine 0.2% will be administered in an ultrasound-guided paravertebral block
1643653|NCT01904266|Procedure|GA + sham block|Injection of 1 cc saline subcutaneously
1643654|NCT01904253|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
1643655|NCT01904253|Drug|Amrubicin (Japan)|Patients will receive treatment administered according to the country-specific approved prescribing information
1643656|NCT01904253|Drug|Topotecan (Japan/Europe)|Patients will receive treatment administered according to the country-specific approved prescribing information
1643657|NCT01904227|Behavioral|standard outpatient DBT|Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.
1643658|NCT01904227|Behavioral|Inpatient Adaptation of DBT|"The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.
The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly."
1643659|NCT01904214|Drug|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
1643660|NCT01904188|Device|Gene Z|The Gene Z device will be used to analyze previously processed specimens for microbial organisms and compared to prior culture and sensitivity results. It is not a separate arm - all samples will be cultured in lab per standard protocol and then the Gene Z device will be used to re-analyze at a later date specimens that were previously frozen and stored and compared to culture results
1643661|NCT01904162|Drug|400 mg finafloxacin (2 x 200 mg tablets)|
1643662|NCT01904149|Drug|Placebo|Placebo single oral dose (first 8 hours)
1643663|NCT01904149|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
1643664|NCT01904149|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
1643665|NCT01904149|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol single oral dose (first 8 hours)
1643666|NCT01904149|Drug|Dexketoprofen-multiple doses|Dexketoprofen multiple oral doses t.i.d. for 3 days (total 6 doses)
1643667|NCT01904149|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
1643668|NCT01904149|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 3 days (total 6 doses)
1643669|NCT01904136|Drug|Melphalan|140 mg/m^2 by vein on Day -7.
1643670|NCT01904136|Drug|Fludarabine|40 mg/m^2 by vein daily for four doses on Days -7 to -4.
1643671|NCT01904136|Procedure|Expanded NK Cell Infusion|"Phase I: Starting dose of NK cells 1x10^5/kg by vein on Day -2. Day +7 and Day +28 second and third NK infusions.
Phase II: Maximum tolerated dose from Phase I."
1643672|NCT01904136|Procedure|Bone Marrow Transplant|Haploidentical bone marrow transplant on Day 0.
1643673|NCT01904136|Drug|Mesna|10 mg/kg by vein on Day +3 and +4.
1643674|NCT01904136|Drug|Cyclophosphamide|50 mg/kg by vein on Day +3 and +4.
1643675|NCT01904136|Drug|Tacrolimus|0.015 mg /kg by vein daily starting on Day +5 and continued by mouth for at least 4 months post transplant.
1643676|NCT01904136|Drug|Mycophenolate mofetil|15 mg/kg by mouth starting on Day +5.
1643677|NCT01904136|Drug|G-CSF|5 mcg/kg/day subcutaneously once a day daily starting on Day +7 until neutrophil recovery.
1643678|NCT01904136|Radiation|Total Body Irradiation (TBI)|All patients receive TBI 200 cGy administrated on Day -3.
1643679|NCT01904123|Drug|WP1066|"Part I starting dose: 3 mg/kg by mouth 2 times per day on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle.
Part II starting dose: Maximum tolerated dose from Part I on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle.
Part III starting dose: Maximum tolerated dose from Part II on Monday, Wednesday, and Friday of Weeks 1 and 2 of each 28-day cycle."
1643680|NCT01904123|Procedure|Advanced Brain Tumor Imaging (ABTI)|Participants imaged prior to treatment with WP1066 and within 72 hours of surgical resection, and every 8 weeks postop.
1643681|NCT01904123|Procedure|Surgical Resection|Surgery takes place within 3 working days of last WP1066 dose.
1643682|NCT01904110|Drug|Risedronate/Cholecalciferol combination(montly)|once a month
1643683|NCT01904110|Drug|Risedronate/Cholecalciferol combination(weekly)|once a week
1643684|NCT01904097|Drug|Pregabalin|Pregabalin 150 mg per oral BID (i.e. twice per day).
1643685|NCT01904097|Other|Transcranial Direct Current Stimulation|The tDCS consists of application of low intensity direct current (2 mA), with the anode placed in the dominant motor cortex (M1) and the cathode in the ipsilateral supraorbital region during 30 minutes each session, using sponge electrodes soaked with normal saline solution.
1643686|NCT01904097|Other|Sham Transcranial Direct Current Stimulation|The sham tDCS consists of the same montage of the active tDCS, but the device is turned off 30 seconds after initiating stimulation (without letting the patient notice it). Rest of the montage is kept identical as the active one during the 30 minutes that the session lasts.
1643687|NCT01904084|Device|Volar locked plating|Operative treatment of distal radius fracture with volar locking plate
1643688|NCT01904084|Device|Hoffman external fixator|Patients with distal radius fracture operated with Hoffman external fixator
1643689|NCT01904071|Procedure|UFNB (Ultrasound guided femoral nerve block)|Ultrasound Guided Femoral Nerve Block
1643690|NCT01904071|Procedure|UFIB (Ultrasound Guided Fascia Iliaca Compartment Block)|
1643691|NCT01904071|Drug|IVMS (IV Morphine)|Intravenous Morphine
1643692|NCT01904058|Drug|LUM001|
1643693|NCT01904058|Drug|Placebo|
1643694|NCT01904058|Drug|Ursodeoxycholic Acid|
1643695|NCT01904045|Other|tacrolimus Advagraf|intake of Advagraf once daily for 3 months
1643696|NCT01904045|Other|tacrolimus Prograf|intake of Prograf twice daily for 3 months
1643697|NCT01904032|Drug|Vitamin D3|50,000 international units (IUs) weekly Vitamin D3
1643698|NCT01904032|Drug|Vitamin D3 comparator|5,000 international units (IUs) of a weekly Vitamin D3 comparator
1643699|NCT01904006|Procedure|New Culture Condition|Intervention group embryos cultured grouped (5 embryos per drop) under low oxygen tension (5%) in benchtop incubators.
1643700|NCT01904006|Procedure|Standard Culture Condition|Control group embryos cultured individually (1 embryo per drop) under atmospheric oxygen tension (20%) in large-box incubators.
1643750|NCT01903577|Other|Robotic Task Performance|Subjects will perform FLS tasks on the robotic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in robotic surgery will also perform operative cases while EMG is being collected.
1643701|NCT01903993|Drug|Docetaxel|Participants received starting dose of 75 mg/m^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
1643702|NCT01903993|Drug|Atezolizumab|Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram [mg/kg]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
1643703|NCT01903980|Other|No intervention. It is a retrospective study|No intervention. It is a retrospective study
1643704|NCT01903954|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
1643705|NCT01903954|Drug|placebo|Orally b.i.d.
1643706|NCT01903954|Drug|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
1643707|NCT01903954|Drug|setrobuvir|Loading dose of 800 mg orally b.i.d on Day 1, followed by 200 mg orally b.i.d., 28 or 48 weeks
1643708|NCT01903941|Behavioral|Aerobic Exercise|
1643709|NCT01903941|Behavioral|Only Counseling|
1643710|NCT01903928|Biological|ASP0113|injection
1643711|NCT01903902|Device|SeQuent® Please Drug-eluting balloon|Balloon angioplasty using paclitaxel-eluting balloon (SeQuent® Please) will be done in native small coronary artery (vessel diameter ≥ 2.25 mm and ≤ 2.75 mm, and lesion length < 25 mm), if residual stenosis is ≤ 30% and there are no dissection of classification C and over which disturbed blood flow after plain balloon angioplasty.
1643712|NCT01903889|Other|clinic based intervention|counseling C&T clients on FP; offering condoms, pills and injectables; and referring clients for other FP methods
1643713|NCT01903889|Other|clinic and community based intervention|basic intervention is introduced along with an intervention for constructive male engagement in HIV and FP services
1643714|NCT01903876|Behavioral|Bystander & Sexual Violence Prevention|This 3-hour web-based program consists of six 30-minute modules that are interactive and range in number of segments (1-14) and types of activities. Each of the modules involves interactivity, didactic activities and two episodes of a serial drama, which allows for the modeling of positive behaviors and illustrate both positive and negative outcome expectations for intervening and for perpetrating abuse against women. Behaviors modeled include communicating with female sex partners, obtaining informed consent to have sex, and intervening to prevent abuse from taking place.
1643715|NCT01903876|Behavioral|General Health Promotion|This general health promotion web-based program is 3-hours and provides a range of activities related to reducing day-to day stress and alleviating anxiety through meditation and exercise.
1643716|NCT01903863|Biological|Fresh frozen plasma|Fresh frozen plasma is a pooled blood product containing both pro and anticoagulation factors. Patients enrolled in the intervention arm will receive scheduled fresh frozen plasma treatment every 48 hours. Patients in the control arm will receive fresh frozen plasma per current institutional standard of care. This includes supplementation for clotting/bleeding diatheses, volume replacement, or after 3 red blood cell transfusions in a 24 hour period.
1643717|NCT01903850|Device|spray cryotherapy|spray cryotherapy
1643718|NCT01903837|Drug|Samidorphan (Low Dose)|Tablets taken once daily
1643719|NCT01903837|Drug|Samidorphan (Medium Dose)|Tablets taken once daily
1643720|NCT01903837|Drug|Samidorphan (High Dose)|Tablets taken once daily
1643721|NCT01903837|Drug|Placebo|Tablets taken once daily
1643722|NCT01903837|Drug|Olanzapine|Tablets taken once daily
1643723|NCT01903824|Drug|CEP-26401|CEP-26401 as an oral solution at the assigned dose of 5, 25 and/or 125 μg.
1643724|NCT01903824|Drug|donepezil hydrochloride|Donepezil hydrochloride, two 5 mg tablets, each over-encapsulated
1643725|NCT01903824|Drug|modafinil|modafinil 200 mg tablet, over-encapsulated
1643726|NCT01903824|Drug|Placebo|Placebos formulated to match each active drug
1643727|NCT01903811|Drug|Carfilzomib|Given IV
1643728|NCT01903811|Drug|Dexamethasone|Given IV
1643729|NCT01903811|Other|Laboratory Biomarker Analysis|Correlative studies
1643730|NCT01903798|Drug|Rilonacept|Interleukin-1 blocker
1643731|NCT01903798|Drug|Mycophenolate mofetil|Immunosuppressive agent
1643732|NCT01903798|Drug|Prednisolone|Corticosteroid
1643733|NCT01903785|Drug|Salbutamol|60 minutes prior to the start of a 10km cycling time trial on a bike ergometer, subjects will inhale either 400ug of salbutamol 1600ug of salbutamol or 400ug of placebo in a randomly assigned manner in a single dose.
1643734|NCT01903785|Drug|Placebo|
1643735|NCT01903772|Other|Inspiratory Muscle Training|
1643736|NCT01903759|Other|Blood samples|
2012505|NCT01961115|Biological|MELITAC 12.1 Peptide Vaccine|Given ID/SC
1643739|NCT01903707|Other|Cognitive Remediation Therapy|Computerised training undertaken for approximately 30 minutes per day, 5 days per week for 8 weeks
1643740|NCT01903707|Other|Placebo comparator|Participant meets the therapist once per week but does not carry out the CRT intervention. (Participants are subsequently offered the chance to carry out the CRT intervention post study if they so wish).
1643741|NCT01903694|Drug|Sorafenib + Pravastatin|
1643742|NCT01903694|Drug|Sorafenib|
1643743|NCT01903681|Drug|Circadin 2 mg|First arm lower dose
1643744|NCT01903681|Drug|Circadin 10 mg|Second arm higher dose
1643745|NCT01903655|Other|telomere length|
1643746|NCT01903642|Other|proteomic analysis|
1643747|NCT01903629|Device|MCE|MCE first, followed by standard gastroscopy
1643748|NCT01903629|Device|Standard gastroscopy|
1643749|NCT01903590|Procedure|TVT surgery TOT surgery|
1643803|NCT01903187|Procedure|Sham|Renal artery angiogram
1644164|NCT01900522|Drug|ITI-214 Dose E|ITI-214 Dose E Oral Solution
2012506|NCT01958918|Drug|Ranibizumab|0.5 mg intravitreal injections of ranibizumab monthly until maximum stable BCVA with retreatment based on BCVA loss and/or SD-OCT disease activity
1643751|NCT01903577|Other|Laparoscopic Task Performance|Subjects will perform FLS tasks on the laparoscopic platform while EMG data is being collected. Task performance and NASA task load index will be assessed. Experts in laparoscopic surgery will also perform operative cases while EMG is being collected.
2012507|NCT01958918|Drug|Aflibercept|2 mg intravitreal injections of aflibercept monthly for the first 3 months, followed by 2 mg intravitreal injections once every 2 months (current EU SmPC label)
2012508|NCT01957176|Drug|ELT|Subjects will be dosed with ELT tablets or powder for oral suspension (PfOS) based on the dosage form used in the parent study. ELT tablets will be white, round film coated tablets containing ELT olamine equivalent to 12.5 mg, 25 mg, 50 mg, 75 mg and 100 mg of ELT. ELT PfOS is a reddish-brown to yellow powder contained inside an elongated sachet. Each sachet will contain ELT olamine equivalent to 20 mg of ELT per gram of powder.
2012509|NCT01954758|Other|Fresh Embryo Transfer (ET)|
1643755|NCT01903551|Device|Loco-regional catheter|it is an intra-fascial catheter for realing of the drug locally
1643756|NCT01903538|Device|Cathodal transcranial direct current stimulation (tDCS)|Cathodal transcranial direct current stimulation (tDCS) 20min, 1mA, F3 (EEG 10/20), reference right M. deltoideus
1643757|NCT01903538|Device|Sham transcranial direct current stimulation|Sham transcranial direct current stimulation (tDCS) 40s, 1mA, F3 (EEG 10/20), reference right M. deltoideus
1643758|NCT01903525|Drug|Docosahexaenoic acid (DHA)|Subjects presenting with a new concussion within 4 days of their initial injury will be identified and screened for eligibility from the investigators' regularly scheduled clinic patients. Subjects who enroll will complete 5 scheduled visits, although additional visits may be clinically indicated for symptom evaluation and treatment. All assessments done for this study are routinely done as part of the standard clinic visits for concussion at the Sports Medicine Center. Subjects will be randomized to either DHA or placebo in a 1:1 ratio, and receive enough DHA or placebo capsules to reach the target dose of 2 g of DHA per day (or placebo) until the day of their next appointment. Subjects will be instructed to take 4 capsules (2 at breakfast and 2 at dinner) for 12 weeks.
1643759|NCT01903512|Procedure|TMJ arthrocentesis|lavage of the superior TMJ space with saline and sodium hyaluronate (SH)
1643760|NCT01903499|Other|Other: Bean patty|
1643761|NCT01903499|Other|Other: Beef patty|
1643763|NCT01903473|Drug|Rapamycin|Rapamycin will be given at 6 mg loading dose for one day, followed by approximately 2 mg daily to achieve a target trough level of 5 to 10 ng/mL. Rapamycin could may be discontinued in case of resolution of chronic GVHD ≥ 3 months or in case of un-manageable side effects or progression of chronic GVHD.
1643764|NCT01903473|Other|T regulatory cells|One infusion of ≥ 0.5 x10E6 T reg cells/kg recipient at 3-4 weeks after rapamycin treatment. The infusion procedure will take one hour.
1643765|NCT01903460|Drug|LUM001|
1643766|NCT01903460|Drug|Placebo|
1643767|NCT01903447|Drug|SSRI|
1643768|NCT01903447|Behavioral|CBT|
1643769|NCT01903434|Drug|Evacetrapib|Administered orally
1643770|NCT01903421|Drug|Spinal anesthesia group: bupivacaine 10-15mg|
1643771|NCT01903421|Drug|General anesthesia group: induction propofol 1.5-2mg/kg and fentanyl 1-3g/kg, maintained with isoflurane or sevoflurane|
1643772|NCT01903421|Genetic|Blood test|DNA will be tested for the presence of ε4 allele of the apolipoprotein E gene
1643773|NCT01903421|Other|Lumbar spinal tap|1ml of cerebrospinal fluid (CSF) removed and stored for further analysis of amyloid tau protein after completion of the study
1643774|NCT01903421|Behavioral|Montreal Cognitive Assessment (MOCA) and MMSE|
1643775|NCT01903408|Radiation|Intensity-modulated radiotherapy of the pelvic lymph nodes using SIB|The intervention is the use of modern radiation techniques with simultaneous integrated boost (SIB)
1643776|NCT01903395|Behavioral|Nurse-led counselling|Nurse-led telephone counselling to double the utilization of preventive colonoscopy
1643777|NCT01903369|Device|Shear Wave Elastography|
1643778|NCT01903356|Drug|Trajenta duo|Linagliptin and Metformin
1643779|NCT01903343|Device|Shear Wave Elastography|
1643780|NCT01903330|Drug|ERC1671|Given intradermally
1643781|NCT01903330|Drug|GM-CSF|Given intradermally
1643782|NCT01903330|Drug|Cyclophosphamide|Given PO. Drug class: Alkylating Agent; Antineoplastic Agent; Nitrogen Mustard.
1643783|NCT01903330|Drug|Oral Control (Sucrose pill)|Given PO
1643784|NCT01903330|Drug|Injectable control (Sodium Chloride Injection United States Pharmacopeia (USP) (0.9%))|Given IV
1643785|NCT01903330|Drug|Bevacizumab|Given IV. Drug class: Immunological Agent; Monoclonal Antibody.
1643786|NCT01903317|Other|Topical Therapy|Subjects will continue use of topical therapy (e.g. topical corticosteroids, keratolytic agents, anthralin, coal tar, vitamin D analogs, retinoids) for their psoriasis as if they were not participating in this study.
1643787|NCT01903317|Other|Phototherapy and Systemic Therapy|Subjects will continue use of phototherapy (e.g. ultraviolet B [UVB] or ultraviolet A and psoralen [PUVA]) and systemic therapy (e.g. methotrexate, cyclosporine) for their psoriasis as if they were not participating in this study.
1643788|NCT01903317|Other|Biologic Therapy|Subjects will continue use of biologic therapy (e.g. etanercept, adalimumab, ustekinumab) for their psoriasis as if they were not participating in this study.
1643789|NCT01903304|Other|Olive Oil|3 months intervention
1643790|NCT01903291|Drug|dimethyl fumarate|As described in the treatment arm
1643791|NCT01903278|Drug|PEG-IFN-SA /RBV|
1643792|NCT01903278|Drug|Pegasys /RBV|
1643793|NCT01903265|Drug|TNX-102 SL 2.8mg|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
1643794|NCT01903265|Drug|Placebo|Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.
1643797|NCT01903239|Procedure|Low-Risk BCC Excisional Margins|After the head and neck basal cell carcinomas satisfy the National Comprehensive clinical and histopathological criteria, all tumors are excised at the 2 mm margin.
1643798|NCT01903226|Other|High intensity training|
1643799|NCT01903226|Other|Moderate intensity training|
1643800|NCT01903213|Drug|bixalomer|Oral
1643801|NCT01903200|Drug|FK949E|Oral
1643935|NCT01902108|Drug|Clonidine|Clonidine 150μg locally infiltrated with 20 ml of bupivacaine 0.25 % before wound incision
1643804|NCT01903174|Device|AeroForm Breast Tissue Expander|Breast Tissue Expander using a remote control to fill the expander with Carbon Dioxide
1643805|NCT01903161|Procedure|delayed remote ischemic preconditioning|In the delayed RIPC group, RIPC is performed 24-48 hr before surgery by 5 minutes limb ischemia and reperfusion with pneumatic cuff up to 200 mmHg repeated by four times.
1643806|NCT01903161|Procedure|control|In the control group, all the procedures were the same with delayed RIPC group, except for the fact that the three-way stopcock between the pneumatic cuff and the cuff inflator was opened and therefore the cuff pressure did not increase.
1643807|NCT01903135|Procedure|Blood test analysis in the clinical labs|for specific measurement of plasmatic bicarbonate
1643808|NCT01903135|Procedure|Pneumologist consult to establish the diagnosis of OHS|"complete respiratory check-up: Arterial blood gases analysis, spirometry, anthropometry, polygraphy or polysomnography.
Medical history, previous treatments."
1643809|NCT01903122|Drug|Cevimeline|
1643810|NCT01903109|Drug|Cevimeline|
1643811|NCT01903096|Behavioral|Cognitive Behavioral Treatment|Seven ninety-minute sessions of evidence-based psychological techniques designed to treat anxiety, depression and somatization disorders during a period of 24 weeks.
1643812|NCT01903096|Drug|Primary Care Treatment As Usual|Usual treatment offered in Primary Care Services: depending on the diagnoses, patients will be prescribed different medications until symptoms disappear.
1643813|NCT01903083|Drug|Tadalafil|One 2.5 mg tablet is self-administered orally by the study participant on a once daily basis.
1643814|NCT01903083|Drug|Gemcitabine|Three doses of gemcitabine (1000 mg / m^2)are given over a 21-day cycle. Patients may receive up to 4 cycles.
1643815|NCT01903083|Radiation|Radiation|Patients will receive 3 doses of radiation (8-10 Gy per fraction).
1643816|NCT01903083|Procedure|Pancreaticoduodenectomy|Surgical resection.
1643817|NCT01903070|Drug|Linagliptin|
1643818|NCT01903057|Drug|azithromycin|
1643819|NCT01903057|Drug|ivermectin|
1643820|NCT01903057|Drug|albendazole|
1643821|NCT01903057|Drug|placebo|
1643822|NCT01903044|Procedure|BM-MNC injection|BM-MNC cells will be injected in aliquots of 1 ml at multiple regions of the leg muscles
2012510|NCT01954758|Other|Deferred Embryo Transfer (DET)|
2012511|NCT01954758|Other|personalized Embryo Transfer (pET)|
2012512|NCT01955733|Drug|BI 695500|
1643826|NCT01903018|Drug|P276-00|
1643827|NCT01903018|Radiation|Radiation Therapy|
1643828|NCT01903018|Drug|Cisplatin|
1643829|NCT01903005|Drug|Higher bioavailability BNX sublingual tablets|Once daily, open-label treatment with higher bioavailability BNX sublingual tablets for 24 weeks
1643830|NCT01902992|Drug|Depiquick Birch (DPG103)|
1643831|NCT01902992|Drug|Placebo|
1643832|NCT01902979|Behavioral|Lifestyle intervention|
1643833|NCT01902966|Drug|Propranolol|Starting dose: 20 mg is taken by mouth twice a day (40 mg/day).
1643834|NCT01902966|Behavioral|Diary|Patients record study medication taken each day in a pill diary. Relaxation diary completed after listening to audio sessions twice a week.
1643835|NCT01902966|Behavioral|Relaxation Audio Recording|Patient given an MP3 player with an audio recording to listen to 2 times a week for up to 4 months. The recording lasts 20 minutes.
1643836|NCT01902966|Behavioral|Questionnaires|Questionnaires completed at baseline, 2 months, and 4 months.
1643837|NCT01902953|Drug|Lymphoseek and VBD Sln dissection|See detailed description of study design
1643838|NCT01902940|Other|Natural History|Assessment of natural history in IBM and CCFDN
1643839|NCT01902927|Other|Attentional distraction using IAPS protocol (standardized images)|Positive, Negative and Neutral Attentional distraction will be presented using IAPS protocol (standardized images) during exercise tests
2012513|NCT01952678|Other|Subjects dosed in a separate study|The subjects in this study were dosed with DaTscan drug product in a separate study.
1643841|NCT01902901|Genetic|Whole Genome Sequencing|Participants will receive Whole Genome Sequencing
1643842|NCT01902901|Genetic|Carrier status testing|Carrier status testing
1643843|NCT01902888|Device|GORE® VIABAHN® Endoprosthesis|
1643844|NCT01902875|Drug|Paclitaxel + Cisplatin|Paclitaxel 135mg/m2, intravenous drip, D1; Cisplatin 75 mg/m2, intravenous drip, D1; Repeat for 4 weeks interval.
1643845|NCT01902875|Biological|CIK cell therapy|Peripheral blood mononuclear cell are separated before chemotherapy, and before each CIK cell transfusion. CIK cells are transfused on D7, D14, D21(with simultaneous transfusion of IL-2 2 million units).
1643846|NCT01902862|Drug|Bortezomib|Bortezomib will be administered as intravenous infusion as 1.6 milligram per meter square (mg per m^2) on Days 1, 8, 15 and 22 of cycle 1 and Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
1643847|NCT01902862|Drug|Rituximab|Rituximab will be administered as intravenous infusion as 375 mg pert m^2 on Days 36, 43, 50, 57 of cycle 2 and (if applicable) on Days 71, 78, 85, and 92 of Cycle 3.
1643848|NCT01902849|Other|blood sampling for IL measurement|"Blood sampling to determine interleukins IL6 , IL10 plasma levels are drawn at the following moments:
T0- before the induction of anesthesia (venous cannula insertion time)
T1- after induction but before starting surgery
In the group I (TIVA -TCI) when the plasma concentration of propofol is 3-3.5 ng/ml
In group II (ISOFLURANE) when concentration of isoflurane in exhaled air (Et Isoflurane) is between 0.3-0.5%
T2, T3- at 2 and 24 hours after surgery"
1643879|NCT01902550|Drug|JNJ-54452840|JNJ-54452840 (12 ml solution containing 240 mg JNJ-54452840) will be administered intravenously over 1 minute.
1643880|NCT01902550|Drug|Placebo|Matching Placebo (normal saline) to JNJ-54452840 will be administered intravenously over 1 minute on Day 1.
1643931|NCT01902134|Drug|Dexketoprofen/Tramadol-multiple doses|Dexketoprofen/Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
2012514|NCT01948739|Device|MAHI EXO-II exoskeleton augmented with BMI system|In this longitudinal study, adult subjects with hemiparesis due to acute or chronic stroke will receive robotic-assisted training through an EEG-based BMI control of robotic exoskeleton to study the changes in upper extremity motor function, cortical plasticity (using the EEG and fMRI). The training will be provided 3x/week for 12 sessions over one-month period.
2012515|NCT01945021|Drug|Crizotinib|
2012516|NCT01942668|Drug|Estradiol|
2012517|NCT01942668|Drug|Progesterone|
1643849|NCT01902836|Biological|Conventional treatment plus DLE|"Paediatric patients with diagnosis of atopic dermatitis according to Hanifin and Rajka and evaluated with SCORAD as moderate atopic dermatitis were included. Patients were randomized and received in a double blind placebo-controlled treatment:
Group 1: Conventional treatment plus DLE Conventional Treatment: oral Cetirizine 0.25mg/kg, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; and topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; plus oral DLE (Transferon) (2mg/5mL), every day for 5 days, then every 72hrs to complete one month"
1643850|NCT01902836|Biological|Conventional treatment plus placebo|Group 2: Conventional treatment plus placebo. Conventional treatment: Cetirizine 0.25mg/kg oral, every day, for 4 weeks; chlorpheniramine 0.35 mg/Kg, daily divided in 3 doses, for 4 weeks; topical Methylprednisolone 0.1% over affected skin area, every 12h for 10 days, then every 24h for 10 days and then every 48h for 10 days and suspend; and oral placebo, every day for 5 days, then every 72hrs to complete one month.
1643851|NCT01902823|Behavioral|Services from a Nurse Navigator|Services from a Nurse Navigator
1643852|NCT01902810|Drug|Propranolol|Propranolol by mouth given daily throughout hospitalization
1643853|NCT01902810|Drug|Placebo|Placebo by mouth given daily throughout hospitalization
1643854|NCT01902797|Other|Questionnaire|Participants will be invited to complete questionnaires and those who are over 5 year of age will be asked to give blood samples.
1643855|NCT01902784|Behavioral|Storytelling Interview|
1643856|NCT01902771|Biological|Dendritic Cell Vaccine|Post-Leukapheresis. Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
1643857|NCT01902771|Biological|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
1643858|NCT01902771|Other|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
1643859|NCT01902771|Procedure|Leukapheresis|Baseline, post-surgery. Subjects will undergo leukapheresis procedure during baseline, after recovery from surgery to collect peripheral blood mononuclear cells (PBMCs) from which dendritic cells will be obtained, per study protocol.
1643860|NCT01902758|Drug|ambrisentan and theophylline|
1643861|NCT01902758|Drug|placebo|placebo for comparison group
1643862|NCT01902745|Behavioral|Social Cognitive Theory|Social Cognitive Theory of motivating participants to change their behaviors for overall health and well being.
1643863|NCT01902732|Device|Implantation of valves (IBV)|Implantation of intrabronchial valves in the most emphysematous destroyed and hyperinflated lung lobe improves the elastic recoisl of the samll airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function. This positive effect is observed particularly in patients with low interlobar collateral ventilation that can be quantified by CT fissure analysis and/or catheter-based measurement.
1643864|NCT01902719|Behavioral|Community Health Worker (CHW) Intervention|Receipt of training in use of home blood pressure machine, education about diet, exercise and physical activities to lower blood pressure, and continued support from a trained community health worker.
1643865|NCT01902719|Behavioral|Communication Skills Training|"Receipt of Do My PART (P-Prepare for Visit, A- Act at visit, R-Review doctor's recommendations, T-Take home recommendations)communication skills training."
1643866|NCT01902719|Behavioral|Problem Solving Skills Training|Receipt of a 9-week group based self-management intervention designed to help patients identify and solve self-identified barriers to hypertension control.
1643867|NCT01902693|Other|No intervention for this study|No intervention
1643868|NCT01902680|Radiation|Focal brachytherapy|Focal brachytherapy with permanent I125 localized implant.
1643869|NCT01902667|Procedure|Magnetic Resonance Imaging|
1643870|NCT01902654|Other|Cardiovascular risk factors diagnoses collection.|We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
1643871|NCT01902654|Other|History of cardiovascular disease|In all patient we collect the history of cardiovascular disease.
1643872|NCT01902654|Other|Cardiovascular risk factors association|We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
1643873|NCT01902641|Drug|Succinylcholine|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received succinycholine according to the study group.
1643874|NCT01902641|Drug|Rocuronium/Sugammadex|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium/sugammadex according to the study group.
1643875|NCT01902641|Drug|Rocuronium|Anaesthesia was induced and maintained with propofol (1-2 mg/kg) and remifentanil (0.5 µg/kg). The study arm was immobilized and a dual electrode for peripheral nerve stimulation was placed over the ulnar nerve near the wrist. Neuromuscular monitoring was performed with accelerometry.The patients received rocuronium according to the study group.
1643876|NCT01902589|Other|Helicobacter Pylori Culture|"Biopsy specimens for histology will be fixed in formalin, embedded in paraffin and sectioned and stained with hematoxylin and eosin.
The microbiological workup will include an imprint of the biopsy on a slide followed by a gram stain for the purpose of demonstrating H. pylori in situ. Further the biopsies will be streaked out on chocolate agar, Sheep blood agar and H. pylori selective agar supplemented with Polymixin to suppress possible contaminants.
4 days of incubation in a micro aerophilic atmosphere will follow . Susceptibility testing of H pylori will be performed with E test on Mueller Hinton agar supplemented with defibrinated sheep blood using a MacFalrland 3.0 density of a bacterial suspension. Reading the susceptibility will take place following 72 hours of incubation in a micro aerophilic atmosphere."
1643877|NCT01902563|Other|Osteopathic Manipulative Treatment|
1643878|NCT01902550|Drug|Metoprolol tartrate immediate-release (metoprolol IR)|Metoprolol IR will be administered as single oral dose of 100 mg tablet or capsule.
1717169|NCT00000922|Drug|Indinavir sulfate|
1643881|NCT01902537|Drug|Prucalopride; observational study|This is an observational study. Korean female participants with chronic constipation and having received treatment previously will be assessed for the health related QoL.
1643882|NCT01902524|Drug|Fentanyl-TTS|All of the participants will receive the study drug at least once transdermally, administration dosage starts at 12.5 microgram/hour.
1643883|NCT01902511|Drug|G-CSF+Erythropoetin|
1643884|NCT01902511|Drug|G-CSF|
1643885|NCT01902498|Drug|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
1643886|NCT01902498|Drug|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
1643887|NCT01902498|Drug|Aspirin|Aspirin 162mg po twice daily x 7days or end of hospitalization. First dose administered on post op day 1.
1643888|NCT01902485|Other|Timing of Contraceptive Initiation in Medical Abortion|
2012518|NCT01942668|Drug|Placebo|
1643891|NCT01902446|Drug|Chlorhexidine gluconate|Study solution will be applied to the oropharynx and will be distributed for 15 seconds with a swab stick. No suction will be applied for at least 30 seconds.
1643892|NCT01902433|Procedure|Astym|
1643893|NCT01902394|Other|Whole grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
1643894|NCT01902394|Other|Refined grains|Following completion of the baseline period (a 2-week run-in phase), participants in the WG group will receive a diet providing 100% of energy requirements in a diet rich in whole grains and the RG group will be provided with 100% of energy requirements in a diet rich in refined grains but otherwise similar to the WG diet for 6 weeks.
1643895|NCT01902381|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
1643896|NCT01902368|Other|gluten free diet|
1643897|NCT01902355|Procedure|modified Seldinger technique|modified Seldinger technique(guiding sheath-over-the-needle technique) use needle that is covered with guiding sheath. After desired vessel puncture, guiding sheath is instantly slid over the needle into the vessel. The needle is withdrawn, guidewire is advanced through the guiding sheath, central catheter is placed into the vessel.
1643898|NCT01902355|Procedure|Seldinger technique|The desired vessel is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and then the needle is withdrawn. Central catheter is then passed over the guidewire into the vessel.
1643899|NCT01902342|Drug|Oseltamivir 75 mg 1 cap|
1643900|NCT01902329|Drug|HMA|azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days
1643901|NCT01902329|Drug|SGN-CD33A|Given intravenously on Day 1 or Days 1 and 4 every 3 weeks (SGN-CD33A Monotherapy) or given intravenously on the final HMA dosing day every 4 weeks (SGN-CD33A+HMA)
1643902|NCT01902303|Drug|Matching Placebo|Sublingual micro dosing of placebo for 7 days
1643903|NCT01902303|Drug|BTL-TML-HSV|Sublingual micro dosing of BTL-TML-HSV for 7 days
1643904|NCT01902290|Biological|Placebo|Placebo administered SC
1643905|NCT01902290|Biological|210 mg brodalumab|210 mg brodalumab administered SC
1643906|NCT01902264|Drug|EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)|One tablet DRSP 3 mg/EE 0.02 mg/ Levomefolate calcium 0.451 mg daily for 24 days, followed by one hormone-free tablet L-5-MTHF 0.451 mg daily for 4 days over 24 weeks
1643907|NCT01902251|Drug|Enzalutamide tablet|Oral
1643908|NCT01902251|Drug|Enzalutamide capsule|Oral
1643909|NCT01902238|Procedure|EUS-guided ethanol-lipiodol mixture ablation|By using 3D-volumetric analysis, the optimal volume of ethanol/lipiodol (1:1 mixture) is calculated by computer estimation of areas on each axial image, using EUS software permitting volume calculation. After calculating optimal ethanol volume by 3D volumetric analysis, we advance the needle into the tumor and inject estimated volume of ethanol, typically 1 to 1.5 ml.
1643910|NCT01902225|Drug|Istodax|
1643911|NCT01902225|Drug|Doxil|
1643912|NCT01902212|Other|Oral Nutritional Supplement|
1643913|NCT01902199|Behavioral|TRAA intervention|The Tobacco Retraining of Automatic Approach The tobacco-RAA will be the intervention in changing approach tendencies towards tobacco. The task uses pictures of tobacco related objects (e.g, a cigarette) and pictures of non-tobacco related objects (e.g, a spoon). Patients will be presented with a joystick while pictures are presented on a computer screen. Patients will be presented with pictures, pulling pictures in a portrait format, while they push pictures in a landscape format. In the experimental condition pictures pushed will almost exclusively be smoking related pictures. In the control condition smoking pictures will be equally divided into push and pull conditions.
1643914|NCT01902186|Drug|raltegravir and atazanavir and ritonavir|switch tenofovir/emtricitabine to raltegravir
1643915|NCT01902186|Drug|tenofovir/emtricitabine and atazanavir and ritonavir|no change in antiretroviral treatment; patients will continue their regimen (tenofovir/emtricitabine and atazanavir and ritonavir)
1643916|NCT01902173|Drug|Akt Inhibitor GSK2141795|Given PO
1643917|NCT01902173|Drug|Dabrafenib|Given PO
1643918|NCT01902173|Other|Laboratory Biomarker Analysis|Correlative studies
1643919|NCT01902173|Other|Pharmacological Study|Correlative studies
1643920|NCT01902173|Drug|Trametinib|Given PO
1643921|NCT01902160|Drug|Brentuximab Vedotin|Given IV
1643922|NCT01902160|Other|Laboratory Biomarker Analysis|Correlative studies
1643923|NCT01902160|Drug|Temsirolimus|Given IV
1643924|NCT01902147|Other|Postoperative Quality Recovery Scale (PQRS)|The PQRS is completed prior to surgery to provide baseline values, and then repeated at different intervals: 15 minutes, 40 minutes, 1 and 3 days, and 4-8 weeks after the completion of surgery. Recovery is broadly defined as return to baseline or better.
1643925|NCT01902134|Drug|Placebo|Placebo single oral dose (first 8 hours)
1643926|NCT01902134|Drug|Tramadol-single dose|Tramadol single oral dose (first 8 hours)
1643927|NCT01902134|Drug|Dexketoprofen-single dose|Dexketoprofen single oral dose (first 8 hours)
1643928|NCT01902134|Drug|Dexketoprofen/Tramadol-single dose|Dexketoprofen/Tramadol oral single dose (first 8 hours)
1643929|NCT01902134|Drug|Tramadol-multiple doses|Tramadol multiple oral doses t.i.d. for 5 days (total 12 doses)
2012519|NCT01942369|Drug|Triptorelin Acetate 3.75mg intramuscular injection|"Triptorelin Acetate is a Gonadotrophin Releasing Hormone agonist (GnRHa).
Triptorelin acetate for injection 3.75mg administered as described in the patient information sheet approved in China: one intramuscular injection of the product repeated every 4 weeks."
1643938|NCT01902082|Drug|Mesenchymal stem cells|
1643939|NCT01902082|Drug|Placebo|
1643940|NCT01902069|Dietary Supplement|Phospholean|"Phospholean supplied by Cheminutra (White Bear Lake, MN). PhosphoLean® N-Oleoyl-PE + EGCG (NOPE + EGCG) is a proprietary phosphobioflavonic complex of N-oleoyl-phosphatidyl-ethanolamine (NOPE), which contains oleoyl ethanolamine (OEA) bound to phosphatidylethanolamine (PE), and epigallocatechin gallate (EGCG).
PhosphoLean® 40P is a dietary ingredient under the Dietary Supplement Health and Education Act (DSHEA) regulations of the US FDA (1994)."
1643941|NCT01902069|Dietary Supplement|Placebo|Placebo consists of rice flour
1643942|NCT01902056|Procedure|One layer allograft|The acellular dermal matrix was placed on the facial surface.
1643943|NCT01902056|Procedure|Two layer allograft|The acellular dermal matrix was placed on the facial surface.
1643944|NCT01902017|Drug|Ketotifen|5 mg PO bid
1643945|NCT01902017|Drug|Placebo|5 mg placebo PO bid
1643946|NCT01902004|Drug|Escitalopram|All subjects will receive 10 to 20mg of escitalopram open-label throughout the trial. Participants will begin taking one 10mg capsule once per day, and this dosage may be increased or decreased depending on the participant's response to the medication. Participants will continue on their assigned dosage of escitalopram until treatment completion.
1643947|NCT01902004|Drug|Memantine|Memantine dosage will be 5 to 20mg a day. Participants will initially take one 5mg capsule once a day, which will be gradually increased to a maximum of 10mg capsules twice per day.
1643948|NCT01902004|Drug|Placebo|Placebo pills will be taken in combination with the active Namenda (Memantine) pills. Participants will initially take 1 capsule per day, which will be increased to a maximum of 1 capsule twice per day.
1643949|NCT01901991|Procedure|Radioactive seed localization (RSL)|Localization of nonpalpable breast lesions with Radioactive seed localization
1643950|NCT01901991|Procedure|Wire-guided localization (WGL)|Localization of nonpalpable breast lesions with Wire-guided localization
1643951|NCT01901978|Behavioral|Caloric restrictive diet|Patients will meet weekly with a registered dietician.
1643952|NCT01901965|Behavioral|Neuromuscular electrical stimulation|
1643953|NCT01901965|Behavioral|eccentric training|
1643954|NCT01901952|Behavioral|Intensive education and lifestyle support|Group classes for 12 months (weekly for 4 months, biweekly for 4 months, monthly for 4 months), weekly peer supporter telephone calls, and diabetes education newsletters every 2 months.
1643955|NCT01901952|Behavioral|Standard of Care control group|Participants receive 2 diabetes education classes taught by a Certified Diabetes Educator. They also receive diabetes education newsletters every 2 months.
1643956|NCT01901939|Other|exercise|daily tailored low level pedaling exercise at bedside
1643957|NCT01901926|Procedure|Non Surgical Periodontal Treatment|one time intervention in the form of scaling and root planing
1643958|NCT01901913|Device|MD-bolus calculator for pre-meal bolus|
1643959|NCT01901913|Device|No MD-bolus calculator for pre-meal bolus|
1643960|NCT01901900|Biological|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
1643961|NCT01901887|Drug|Study Juice|The intervention will be 3 boxes/day for 6 months of SMARTFISH® Nutrifriend 1100, a commercially available smoothie juice box containing 1,100 mg of omega-3 HUFAs/200 ml box (approximately 550 mg EPA and 550 mg DHA/box) for a total of 3,300 mg of omega-3 HUFAs/day (approximately 1,650 mg EPA and 1,650 mg DHA/day).
1643962|NCT01901887|Drug|Placebo Juice|The placebo will be 3 boxes/day for 6 months of a placebo juice which will be identical to the study juice except that it will substitute 1,100 mg of macadamia nut oil/200 ml juice box in place of the omega-3 HUFAs for a total of 3,300 mg of macadamia nut oil/day.
1643963|NCT01901861|Drug|Sitagliptin|Sitagliptin 100mg is given before meal ingestion
1643964|NCT01901861|Drug|Placebo|Placebo is given before meal ingestion
1643965|NCT01901848|Behavioral|Cognitive Processing Therapy (CPT)|CPT is based on a social cognitive theory of PTSD that includes primary emotional responses to traumatic events such as fear, anger, and sadness, as well as secondary emotions resulting from a patient's faulty interpretations of the traumatic event. CPT addresses PTSD by facilitating affective expression so that affective components of the trauma memory can be altered. In addition, faulty beliefs about the trauma are challenged and modified using Socratic questioning.
1643966|NCT01901848|Drug|Bupropion|Bupropion is an anti-depressant medication that is commonly used in smoking cessation treatment.
1643967|NCT01901848|Drug|nicotine replacement therapy (NRT)|NRT in the form of nicotine patches and an NRT rescue method (e.g., nicotine gum, lozenge, inhaler) will be prescribed for participants for use on/after quit date.
1643968|NCT01901848|Behavioral|Integrated Care for Smoking Cessation (ICSC)|ICSC is a manualized treatment for smoking cessation involving six sessions of counseling.
1643969|NCT01901848|Behavioral|smokefreeVET|SmokefreeVET is a program that was developed by the National Institutes of Health and Department of Veterans Affairs. The program includes a text messaging protocol for reaching out to Veterans who wish to stop smoking.
1643970|NCT01901835|Procedure|mind-body intervention procedure|Participate in media diversion with humorous and non-humorous movies
1643971|NCT01901835|Other|survey administration|Ancillary studies
1643972|NCT01901835|Procedure|quality-of-life assessment|Ancillary studies
1643973|NCT01901822|Procedure|Sutured together|The soft tissue and the allograft will be sutured together using a continuous sling suture.
1643974|NCT01901822|Procedure|Sutured separately|The soft tissue and the allograft will be sutured separately using a continuous sling suture.
1643975|NCT01901809|Drug|Furosemide|
1643976|NCT01901809|Drug|Dopamine|
1643977|NCT01901796|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy- an effective, non-pharmacological treatment for depression and anxiety.
1644161|NCT01900522|Drug|ITI-214 Dose C|ITI-214 Dose C Oral Solution
1643978|NCT01901783|Procedure|With primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will be primarily closed over the membrane.
1643979|NCT01901783|Procedure|Without primary closure|A cancellous block allograft will be placed for ridge augmentation and covered with a barrier membrane. The soft tissue will not be primarily closed over the membrane.
1643980|NCT01901770|Other|educational intervention|Receive HPV vaccination educational materials
1643981|NCT01901770|Other|educational intervention|Receive influenza vaccination educational materials
1643982|NCT01901757|Drug|HCP1201, Fasted followed by fed|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fasted condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fed condition.
1643983|NCT01901757|Drug|HCP1201, Fed followed by fasted|There are 2 administration periods with 7 days of wash-out. In period 1, the subjects will receive a single oral dose of HCP1201 under fed condition. In period 2, the subjects will receive a single oral dose of HCP1201 under fasted condition.
1643984|NCT01901744|Procedure|Cataract Surgery|
1643985|NCT01901731|Procedure|transjugular coil embolisation of pelvic veins|
1643986|NCT01901731|Procedure|endovenous treatment of leg varicose veins|
1643987|NCT01901705|Drug|Indigo naturalis ointment|The Indigo naturalis ointment was composed of a 1:10 mixture of Indigo naturalis powder and a vehicle consisting of Vaseline: microcrystalline wax: olive oil (5:6:9 ratio)
1643988|NCT01901705|Drug|Placebo|The placebo was a mixture of blue dye powder (54.8% Indigo carmine aluminum lake [Blue #32] and 45.2% Allura Red AC aluminum lake [Red #40] powders), Vaseline, microcrystalline wax, and olive oil.
1643989|NCT01901692|Radiation|TACE+External beam RT|Trans-arterial chemoembolization (TACE) every 6 weeks + external beam radiation therapy starting within 3 weeks after first TACE
1643990|NCT01901692|Drug|Sorafenib|Sorafenib 800 mg/day orally
1643991|NCT01901679|Drug|Celebrex|200 mg PO BID
1643992|NCT01901666|Drug|Growth Hormone|"All GH deficient patients with bone age <14 years will be treated with GH therapy for one year.Serum IGF-1 will be measured 4weekly and GH dose will be titrated till S.IGF-1 is in mid-normal range and then after every 3 months.
Growth parameters will be assessed after every 3 months.Serum T4, TSH will be done after every 3 months. Patients will be monitored for any side effects of GH therapy"
1643993|NCT01901653|Drug|SC16LD6.5|
1643994|NCT01901640|Drug|DA-8159 (Udenafil)|
1643995|NCT01901614|Procedure|LALAK|"A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.
The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
1643996|NCT01901614|Procedure|IEK|"A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.
In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
1643997|NCT01901614|Drug|Retrobulbar Block or General Anesthesia|
1643998|NCT01901614|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections.
1643999|NCT01901614|Drug|Topical Anesthesia|
1644000|NCT01901614|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
1644001|NCT01901601|Procedure|LALAK|"A dovetail shaped cut will be made on the graft using a femtosecond laser at the eye bank. The cut depth will be proportional to the central stromal thickness of the graft. This graft will be separated from stromal bed by eye bank personnel for examination of the cut surface. High-quality graft will be replaced in preservation medium and shipped to the surgeon prior to surgery.
The host cornea will receive femtosecond laser cut consisting of a shallow lamellar cut with angled side cut to match the dovetail graft in a tongue-in-groove fashion. The femtosecond laser treatments will be performed under topical anesthesia in the laser suite. The femtosecond laser is an FDA-approved device for use in this indication (corneal transplantation including lamellar keratoplasty). A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
1644002|NCT01901601|Procedure|IEK|"A full thickness graft will be prepared at the eye bank with zigzag side cuts prepared with a femtosecond laser. The graft is separated from the rim, replaced in the preservation medium, and shipped to the surgeon prior to the surgery.
In the laser suite, the host cornea will be cut with the femtosecond laser with zigzag side cuts leaving a 70-100 micron bridge. A protective eye shield is placed over the eye. The graft will be sutured into the host bed."
1644003|NCT01901601|Drug|Retrobulbar Block or General Anesthesia|
1644004|NCT01901601|Device|optical coherence tomography (OCT)|OCT will be used to guide the depth of the graft and donor dissections. The OCT systems to be used in this study will be the RTVue (Optovue, Inc., Fremont, CA) or the Visante (Carl Zeiss Meditec, Inc., Dublin, CA). Both are FDA-approved for the mapping of corneal thickness.
1644005|NCT01901601|Drug|Topical Anesthesia|
1644006|NCT01901601|Device|femtosecond laser|The femtosecond laser system to be used in this study for host cornea preparation will be the Intralase FS system (iFS, AMO, Inc., Santa Ana, CA). The iFS is FDA-approved for corneal surgery including full thickness and lamellar keratoplasty. Eye banks use earlier versions of the Intralase system which are also FDA approved for this indication.
1644007|NCT01901588|Drug|Dexmedetomidine|intravenous dose of dexmedetomidine 0.3 mcg/kg over 5 minutes
1644008|NCT01901588|Other|Placebo|intraoperative dose of intravenous placebo
1644165|NCT01900522|Drug|ITI-214 Dose F|ITI-214 Dose F Oral Solution
1644009|NCT01901575|Drug|Remifentanil|Patients with established PVC's , sedated with remifentanil IVPCA per study protocol
1644010|NCT01901562|Device|Ductoscopic papillomectomy|Intraductal papilloma extraction through the nipple orifice by interventional ductoscopy
1644011|NCT01901549|Procedure|Renal denervation|The treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
1644012|NCT01901549|Drug|Metoprolol|Beta-blockers. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
1644013|NCT01901549|Drug|Lisinopril|ACE inhibitors. Optimal mediсal therapy will be assigned according to ACS and STE guidelines.
1644014|NCT01901536|Behavioral|Family Foundations Coparenting Program|"Family Foundations, a program for adult couples expecting their first child, is designed to help them establish positive parenting skills and adjust to the physical, social, and emotional challenges of parenthood. Program topics include coping with postpartum depression and stress, creating a caring environment, and developing the child's social and emotional competence.
Family Foundations is delivered to groups of couples through four prenatal and four postnatal classes of 2 hours each. Prenatal classes are started during the fifth or sixth month of pregnancy, and the postnatal classes end when the children are 6 months old.
Family Foundations is delivered in a community setting by childbirth educators who have received 3 days of training from Family Foundations staff."
1644015|NCT01901523|Behavioral|Reporting of discrepancy to journal|
1644016|NCT01901510|Drug|Chromoendoscopy (Indigo Carmine)|Indigo Carmine will be added to the colonic prep to attempt indirect chromoendoscopy
1644017|NCT01901510|Other|Control|The control will have minimal Indigo Carmine added to the colonic prep. This will serve to color the solution blue for blinding but not enough to provide significant staining for chromoendoscopy.
1644018|NCT01901497|Device|Nebulizer|500 mg/4 mL Amikacin nebulized using vibrating mesh nebulizer associated with a single limb bilevel ventilator. The nebulizations are considered as finished when there is no visible evidence of nebulization for a period of 30 seconds.
1644019|NCT01901484|Drug|Praziquantel|All the registered S. mansoni infected children aged 1-5 years will be randomly divided into two treatment arms: single and double dose. A second those will be administered after two weeks following the last treatment.
1644020|NCT01901471|Drug|Single bolus of Placebo of CicloMulsion® (Neurovive).|"The matching placebo of CicloMulsion® (Neurovive) is composed with refined Soya-bean oil, medium-chain triglycerides, egg lecithin, water-free glycerol, sodium oleate, sodium hydroxide, water injection. The qualitative composition of CicloMulsion® and its placebo only differ in the presence or absence of Cyclosporine A, so the final emulsions will be visually indistinguishable.
The placebo use here is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.
The placebo is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.
The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
1644021|NCT01901471|Drug|Single bolus of cyclosporine A (CicloMulsion®, Neurovive)|"The investigational medicinal product is cyclosporine A (CicloMulsion®, Neurovive).
Cyclosporine A is an immunosuppressive treatment usually used in the prevention of acute rejection after organ transplant, including cardiac transplantation. Usual dosages in organ transplantation are about 2.5 mg / kg per day in 2 doses.
CicloMulsion® is ready-to-use lipid emulsions, i.e. do not need any step of preparation or dilution.
Production blinded labelling, packaging and delivering the study drugs in every participating centre of the trial will be performed by a company following European Union's Good Manufacturing Practice.
CicloMulsion® 5mg/ml is provided in colourless glass bottles sealed with a rubber stopper, containing a nominal fill volume of 50 ml.
The study treatment will be directly taken into the vial and injected via a catheter positioned within an antecubital vein. The injection will be performed slowly over 2 to 3 minutes."
1644022|NCT01901458|Device|Spectra Optia® IDL-Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
1644023|NCT01901458|Device|Spectra Optia® Collection Set|Peripheral blood progenitor cell apheresis in G-CSF mobilized allogeneic donors using the Spectra Optia® cell separator
1644024|NCT01901445|Behavioral|Educational action with focal group|
1644025|NCT01901432|Drug|Givinostat|"In Part A patients will treated in dose levels at the following daily doses of Givinostat:
50 mg b.i.d.,
100 mg b.i.d.;
150 mg b.i.d.,
200 mg b.i.d.;
150 mg t.i.d.;
200 mg t.i.d.. Intermediate dose levels and, consequently, additionally dose levels may be used to establish the Maximum Tolerated Dose.
In Part B patients will be treated at the Maximum Tolerated Dose established in Part A. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each."
1644026|NCT01901419|Drug|Nitroglycerin infusion|Nitroglycerin infusion during rewarming
1644027|NCT01901393|Drug|IV ibuprofen|
1644028|NCT01901393|Drug|Ketorolac|
1644029|NCT01901380|Dietary Supplement|Extensively hydrolyzed casein formula + LGG|
1644030|NCT01901367|Dietary Supplement|nutritional intervention|Receive nutritional intervention
1644031|NCT01901367|Behavioral|exercise intervention|Receive exercise intervention
1644032|NCT01901367|Other|follow-up care|Receive booster follow-up sessions from the nutritionist and exercise physiologist
1644033|NCT01901367|Behavioral|counseling intervention|Receive phone counseling with a trained health coach
1644034|NCT01901367|Other|quality-of-life assessment|Ancillary studies
1644035|NCT01901367|Other|laboratory biomarker analysis|Correlative studies
1644036|NCT01901367|Other|questionnaire administration|Ancillary studies
1644037|NCT01901354|Other|Low-tidal-volume ventilation|Goal tidal volume is 6 cc/kg ideal body weight.
1644038|NCT01901354|Other|Airway Pressure Release Ventilation (APRV)|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
1644039|NCT01901341|Drug|CB-5945|
1644040|NCT01901341|Drug|Placebo|
1644041|NCT01901328|Drug|CB-5945|
1644042|NCT01901328|Drug|Placebo|
1644162|NCT01900522|Drug|ITI-214 Dose D (Elderly)|ITI-214 Dose D (Elderly) Oral Solution
1644043|NCT01901315|Procedure|Online consultation|Patients in the online consultation (intervention) group have monthly consultation with their attending psychiatrist through videoconferencing during one year. After each consultation, the medication is sent to the patient through a home delivery program. For reasons of patient safety, consultations at baseline, and after 6 and 12 months will be realized in a face-to-face form at the Institute of Psychiatry (IPq).
1644044|NCT01901315|Procedure|Face-to-face consultation|Patients in the face-to-face consultation (control) group have monthly face-to-face consultation with their attending psychiatrist during one year at the Institute of Psychiatry (IPq).
1644045|NCT01901302|Drug|CB-5945|
1644046|NCT01901302|Drug|Placebo|
1644047|NCT01901289|Device|Zilver® PTX® Drug-Eluting Peripheral Stent|Treatment of symptomatic vascular disease of the native above-the-knee femoropopliteal arteries.
1644049|NCT01901263|Behavioral|patients with alzheimer's disease|the Neuropsychiatric Inventory (NPI), is uded to assess 10 behavioral disturbances occurring in dementia patients: delusions, hallucinations, dysphoria, anxiety, agitation/aggression, euphoria, disinhibition, irritability/lability, apathy, and aberrant motor activity. The NPI uses a screening strategy to minimize administration time, examining and scoring only those behavioral domains with positive responses to screening questions.
1644050|NCT01901250|Dietary Supplement|Xylitol gummy bears|The children receive xylitol gummy bears 3 times/day within the supervised school environment.
1644051|NCT01901250|Dietary Supplement|Sugar free fiber gummy bears|The children receive sugar free fiber gummy bears 3 times/day within the supervised school environment.
1644052|NCT01901250|Behavioral|Oral health education|Oral health education, toothbrush, and fluoride toothpaste
1644053|NCT01901250|Device|Fluoride varnish|The study dentists apply the varnish on all children twice a year during the study period. The varnish is 5% sodium fluoride and contains 2.26% by weight fluoride ion in a colophony base.
1644054|NCT01901250|Device|Dental sealant|The study dentists apply the sealant on the children in the second grade when the permanent first molars are fully erupted.
1644055|NCT01901237|Behavioral|Hatha Yoga|This is a 7-week home/hospice-based instructive Hatha yoga program (available on DVD) for adolescent and young adults diagnosed with a non-curative cancer. Participants will be asked to complete a minimum of one, 75-minute yoga session per week. The DVD package includes four discs that increase in difficulty over the course of the 7-week program. The DVD focuses on postures and breathing exercises. Participants will be asked to keep track of the number and duration of yoga sessions completed over the 7-week period.
1644056|NCT01901224|Drug|Metformin 1000 mg|
1644057|NCT01901224|Drug|Placebo|
1644058|NCT01901211|Other|Exergaming Intervention|The exergaming system will be installed into the participants' homes. Players will pedal the exergame bike in order to move their game avatar. Headsets allow players to communicate with each other in real-time. Participants will play the games 3 to 5 times per week, during scheduled game times. Players will wear a heart rate (HR) monitor and will achieve game benefits for reaching their target HR. They will be asked to exercise in a target HR zone of 40-65%HR reserve. Each week, participants will receive a call from a research assistant (RA), who will provide feedback on their exercise progress and a HR goal for each week. The RA will also record physical and social activities engaged in and any difficulties like leg pain or technical issues.
1644059|NCT01901198|Biological|Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.|Recombinant Human Serum Albumin/interferon alpha2a Fusion Protein 300-1200 mcg at Day 0
1644060|NCT01901198|Biological|Peginterferon 180 mcg single dose S.C.|Pegasys 180 mcg S.C. single dose on Day 0
1644061|NCT01901185|Drug|Etanercept / Autoinjector A|Autoinjector A, a hand-held, reusable electromechanical device, and a single-use, disposable cassette preassembled with an etanercept 50-mg liquid prefilled syringe (PFS).
1644062|NCT01901172|Drug|RO5503781|Single dose on Day 1 (high fat, low fat, or fasted), Day 10 (fasted, low fat, or high fat), and Day 19 (low fat, fasted, or high fat) in a crossover design
1644063|NCT01901172|Drug|RO5503781|Daily for 5 days followed by 23 days rest per cycle
1644064|NCT01901172|Drug|RO5503781|Single doses of current formulation, optimized MBP formulation and new SDP formulation, Days 1, 8 and 15 in a crossover design
1644065|NCT01901172|Drug|RO5503781|Single doses Days 1 and 11
1644066|NCT01901172|Drug|posaconazole|Multiple doses Days 8-14
1644067|NCT01901159|Drug|RO4995819|Oral doses of RO4995819 (tablet)
1644068|NCT01901159|Drug|RO4995819|Oral doses of RO4995819 (capsule)
1644069|NCT01901146|Drug|ABP 980|
1644070|NCT01901146|Drug|trastuzumab|
1644071|NCT01901146|Drug|epirubicin|
1644072|NCT01901146|Drug|cyclophosphamide|
1644073|NCT01901146|Drug|paclitaxel|
1644074|NCT01901146|Procedure|Lumpectomy or mastectomy with sentinel node or axillary node dissection|
1644075|NCT01901133|Drug|MDV3100|Oral
1644076|NCT01901120|Drug|Betanis|oral
1644077|NCT01901107|Drug|Kiklin capsules|oral
1644078|NCT01901094|Procedure|Axillary Lymph Node Dissection (ALND)|
1644079|NCT01901094|Radiation|Nodal Radiation Therapy|
1644080|NCT01901094|Radiation|Axillary Radiation Therapy|
1644081|NCT01901081|Device|IMES|"Once subjects recover from surgical implantation of IMES (approximately two weeks), they will practice IMES control using a bench-top IMES trainer for approximately a month. As soon as the subject's custom-fit IMES Prosthesis is available, it will be fitted and programmed. Subjects will then begin six months of prosthetic training. Month 1 training entails sessions with an Occupational Therapists 4-5 times per week. Months 2-6 Training entail meeting with an Occupational Therapist twice a month. During training, subject will learn how to contract residual musculature in the amputated limb to control movements of an electromechanical wrist and hand. The therapeutic goal is to develop skills needed to perform Activities of Daily Living using the IMES prosthesis.
After completing six months of training, subjects will be given the option to continue using their IMES Prosthesis for another sixteen months."
1644082|NCT01901068|Device|MonoMax|Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
1644083|NCT01901055|Device|CPAP|CPAP is a device that has a mask worn over the nose that is attached to a device that provides positive airway pressure. CPAP is worn while sleeping, it splints open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
1644084|NCT01901055|Device|Sham-CPAP|Sham-CPAP is a device that has a mask worn over the nose that is attached to a device that looks and sounds like CPAP however it does not provide positive airway pressure. Sham-CPAP is worn while sleeping, it does not splint open the airway and prevent apneas (cessation of breathing) and hypopneas (reduced airflow while breathing).
1644085|NCT01901042|Dietary Supplement|Symbiotic|Sachets with a symbiotic product in powder form containing 4.3 g of dietary fiber and Lactobacillus reuteri in a concentration greater than 1.0 x 108 colony forming units (CFU), with five grams per sachet (Fibermais Flora Nestlé Brazil).
1644086|NCT01901042|Dietary Supplement|Maltodextrin|Control patients will receive sachets containing maltodextrin
1644087|NCT01901016|Behavioral|Jacobson progressive muscular relaxation|Jacobson progressive muscular relaxation
1644088|NCT01901016|Behavioral|Schultz's autogenic training|Schultz's autogenic training
1644089|NCT01901003|Drug|Lorazepam|
1644090|NCT01901003|Other|no premedication|
1644091|NCT01901003|Drug|Placebo (microcrystalline celluloses)|
1644092|NCT01900990|Device|Noninvasive ventilation weaning|We adopt Noninvasive Positive Pressure Ventilation in tracheotomy patients by capping the tracheotomy tube and deflating the cuff
1644093|NCT01900977|Other|Universal Testing with immediate ART|"• Combination prevention package including:
o House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with immediate eligibility for ART; Promotion of male circumcision and prevention of mother to child transmission (PMTCT) services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and prevention of mother-to-child transmission of HIV services available in the community; and Treatment of sexually transmitted infections (STIs) and provision of condoms at health units"
1644094|NCT01900977|Other|Universal Testing with ART eligibility according to National Guidelines|"Combination prevention package including:
House-to-house deployment of: Universal HIV counseling and testing; Active linkage to care for individuals diagnosed as HIV-infected, with ART eligibility according to national guidelines; Promotion of male circumcision and PMTCT services; Provision of condoms; Strengthening of HIV testing and services at health facilities and other venues; Strengthening of male circumcision and PMTCT services available in the community; and Treatment of STIs and provision of condoms at health units."
1644095|NCT01900977|Other|Standard of Care|
1644096|NCT01900964|Procedure|PTFE membrane|The non-resorbable PTFE barrier membrane will be surgically placed in conjunction with a ridge preservation procedure.
1644097|NCT01900964|Procedure|Collagen membrane|A resorbable collagen membrane is surgically placed in conjunction with a ridge preservation procedure.
1644098|NCT01900951|Drug|Temozolomide|
1644099|NCT01900938|Procedure|Continuous infusion of propofol|Propofol is continuously administered intravenously via infusion pump starting with 20 mg/kg/hr and then titrated to about 5 mg/kg/hr according to patients' sedation level.
1644100|NCT01900938|Procedure|Intermittent bolus injection of propofol|A loading dose of 2 mg of midazolam and 0.4 mg/kg of propofol is initially injected and then repeated intermittent bolus injection of 20 mg of propofol is followed according to patients' sedation level.
1644101|NCT01900938|Drug|Midazolam|
1644102|NCT01900938|Drug|Propofol|
1644103|NCT01900925|Procedure|Prescriptive Hip Exercises and Manual Therapy techniques|1) Clam Abduction exercises in sidelying, 2) Hip extension in quadruped, 3) a unilateral bridge,and; 1) anterior to posterior mobilization of the hip with distraction, 2) long axis distraction of the hip and 3) posterior-anterior mobilization of the hip in prone
1644104|NCT01900925|Procedure|Pragmatic low back pain treatment|"advise to stay active,
discourage bed rest,
appropriate medication use,
reassurance.
Short term use of manipulation/medication,
supervised exercise,
cognitive behavioral therapy,
multidisciplinary treatment,
termination of use of modalities."
1644105|NCT01900912|Other|CLTS|The goal of CLTS is to obtain Open Defecation Free (ODF) villages. CLTS aims to trigger the community's desire for change, propel them into action and encourage innovation, mutual support and appropriate local solutions, in order to foster greater ownership and sustainability. The phases are: pre-triggering (a group of trained-CLTS people visit the community and request a date to discuss sanitation-related issues for the following days), triggering (people are made to express their views on sanitation issues and their needs), monitoring (involves visits of the community twice a week for a period of 1-3 months) and certification (an external committee evaluates the village for certification as an ODF community).
1644106|NCT01900899|Procedure|Blood Sampling|At 2, 3, 4, 5, 6 years after booster vaccination.
1644107|NCT01900886|Other|Peginterferon alfa-2a|Treatment as usual clinical practice
1644108|NCT01900886|Drug|Ribavirin|Treatment as usual clinical practice
1644109|NCT01900873|Device|Inspiratory Muscle Strength Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The intervention group (strength IMT) will perform two daily sessions of 30 breaths. Measurements of Pi,max will be performed every week and training loads will be increased continuously to maintain at least 40-50% of the actual Pi,max values. Each week, one training session will be performed under supervision. Training load will be increased during this session.
1644110|NCT01900873|Device|Inspiratory Muscle Endurance Training|IMT will be performed using a variable flow resistive loading device (POWERbreathe®KH1, HaB International Ltd., Southam, UK). The device is able to store training parameters of up to 40 sessions. Most training sessions during this RCT will be performed by patients at their homes without supervision. The sham group (endurance IMT) will perform three daily sessions of 30 breaths and will train at a constant inspiratory load of no more than 10% of their initial Pi,max. Each week, one training session will be performed under supervision.
1644111|NCT01900860|Dietary Supplement|Vitamin D|Three different doses of vitamin D will be administered in a double-blinded fashion. The three doses are 400, 4000, or 10,000 IU/day
1644112|NCT01900847|Drug|Ketamine|0.3mg/kg ketamine
1644113|NCT01900847|Drug|Morphine|Dosage of morphine determined by treating physician
1644114|NCT01900847|Drug|placebo|saline of same volume as appropriate weight based dose of ketamine
1644115|NCT01900834|Other|No treatment given|The participants will not receive any treatment
1644163|NCT01900522|Drug|Placebo|ITI-214 Matching Placebo Oral Solution
1644116|NCT01900808|Device|Trained operator with M probe.|Trained operator with M probe: non-drug intervention, baseline comparator.
1644117|NCT01900808|Device|Experienced operator with M probe.|Experienced operator with M probe: non-drug intervention, longitudinal comparator.
1644118|NCT01900808|Device|Experienced operator with XL probe.|Experienced operator with XL probe: non-drug intervention, longitudinal comparator.
1644119|NCT01900795|Drug|V117957|V117957 4.5 mg suspension taken orally after surgery.
1644120|NCT01900795|Drug|Ibuprofen|Ibuprofen 400 mg tablets taken orally after surgery.
1644121|NCT01900795|Drug|Placebo|Placebo taken orally after surgery.
1644122|NCT01900782|Biological|Intervention A|Prefilled syringe.
1644123|NCT01900782|Biological|Intervention B|Prefilled syringe.
1644124|NCT01900782|Biological|Placebo|Prefilled syringe to match experimental drug and active comparator.
2012520|NCT01942330|Procedure|Laparoscopic-Assisted Natural Orifice Surgery|Surgical procedure performed using an operating endoscope that is introduced into the body through a natural orifice and is then passed into the peritoneal cavity through the lumen of an organ such as the stomach, bowel or vagina.
1644126|NCT01900756|Behavioral|THRIVES|Pre-appointment phone text In-clinic educational video Patient report card Post-clinic phone text Outpatient stroke registry
1644127|NCT01900743|Drug|Regorafenib|Regorafenib (160 mg/d) once daily for three weeks on / one week off plus Best Supportive Care (BSC)until progression (according to RECIST 1.1), intolerance or consent withdrawal.
1644128|NCT01900743|Drug|Placebo|Placebo plus BSC until progression (according to RECIST 1.1) or unacceptable toxicity. Patients who have received placebo may be offered open-label regorafenib (cross-over option) after objective tumor progression
1644129|NCT01900730|Drug|Placebo|Patient takes placebo capsule 3 times a day by mouth for 10 weeks.
1644130|NCT01900730|Drug|Valproic Acid (VPA)|Patients initially receive daily oral VPA 15 mg/kg/day divided in three doses. If patient tolerates the reduced dose for 10 consecutive days, then the VPA dose will increase to 30 mg/kg/day divided into three doses. Patients treated for 10 weeks.
1644131|NCT01900730|Behavioral|Questionnaires|Questionnaires completed at baseline, weeks 2, 6, and 10.
1644132|NCT01900730|Behavioral|Pill Diary|Patient given a pill diary to record the time each dose taken.
1644133|NCT01900730|Behavioral|Drainage Diary|Patient completes daily diary of drainage with the date and amount of fluid drained each day at home. Drained fluid from the day before brought to each clinic visit to give to the research team.
1644134|NCT01900717|Drug|LV5FU2 simplified, FOLFOX 4 simplified, FOLFIRI modified|
1644135|NCT01900717|Drug|LV5FU2 simplified,FOLFOX 4 simplified, FOLFIRI modified, Bevacizumab 5 mg/kg/ 2 weeks|
1644136|NCT01900704|Drug|SER120 750 ng|SER120 750 ng
1644137|NCT01900704|Drug|SER120 1500 ng|SER120 1500 ng
1644138|NCT01900704|Drug|Placebo|Placebo
1644139|NCT01900691|Device|Evolution® Esophageal Stent - Fully Covered|Placement of the Evolution® Esophageal Stent for benign or malignant strictures, fistulas, perforations or leaks with the intention of removal
1644140|NCT01900678|Device|VytronUS Ablation System|Pulmonary vein isolation.
1644141|NCT01900665|Drug|Solanezumab|Administered Intravenously (IV)
1644142|NCT01900665|Drug|Placebo|Administered IV
1644143|NCT01900652|Drug|LY2875358|Administered IV
1644144|NCT01900652|Drug|Erlotinib|Administered Orally
1644145|NCT01900639|Behavioral|change time of intake of aspirin|
1644146|NCT01900626|Drug|epidural catheter|epidural catheter with 0.3% ropivacaine
1644147|NCT01900613|Behavioral|Ninos Sanos Familia Sana|
1644148|NCT01900600|Other|Cardiopulmonary exercise test|All patients will undergo a first CPX prior to initiation of treatment, a second one after 3 months, and a third one after 12 months of treatment.
1644149|NCT01900600|Other|Echocardiogram|An echocardiogram (ultrasound of the heart) will be performed prior to initiation of treatment and then again 12 months later.
1644150|NCT01900587|Drug|Tapentadol ER Tamper-resistant Formulation (TRF)|Single dose of tapentadol ER 50 milligram (mg), will be administered under fasted condition.
1644151|NCT01900587|Drug|Tapentadol ER Prolonged-Release 2 (PR2)|Single dose of tapentadol ER 50 milligram (mg), prolonged release tablet will be administered under fasted condition.
1644152|NCT01900574|Drug|Golimumab|Golimumab will be administered subcutaneously. For participants weighing less than 45 kg, the dose of golimumab at Week 0 will be 90 mg/m2 (up to 200 mg) and 45 mg/m2 (up to 100 mg) at Weeks 2, 6, and 10. For participants weighing 45 kg or more, the dose of golimumab at Week 0 will be 200 mg and 100 mg at Weeks 2, 6, and 10. From Week 14, the dose of golimumab will be 45 mg/m2 and 100 mg, every 4 weeks for participants weighing less than 45 kg and 45 kg or more, respectively. From Week 18, participants weighing 45 kg or more have the option to administer golimumab at home after being properly trained. At Week 14 or at any time after, the participants have the option to decrease their dose of golimumab to 50 mg (weighing 45 kg or more) or 22.5 mg/square meter (less than 45 kg) at the discretion of the investigator. A single dose increase back to 100 mg or 45 mg/m2 is permitted based on the investigator's assessment of an increase in a participant's ulcerative colitis disease activity.
2012521|NCT01935908|Drug|levetiracetam|
2012522|NCT01934452|Drug|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
1644155|NCT01900548|Dietary Supplement|Whey protein (HPHL)|The Whey protein group are supplemented 45 gram of whey protein, high protein high leucine (HPHL), every day.
1644156|NCT01900548|Dietary Supplement|Soy protein (HPLL)|The Soy protein group are supplemented 45 gram of Soy protein, high protein low leucine (HPLL), every day.
1644157|NCT01900548|Dietary Supplement|Placebo (P)|Will not be given protein but the same energy content using maltodextrin (in a blended fashion).
1644158|NCT01900548|Other|Resistance training|For 45 minutes 3 times a week the participants will complete resistance training with elastic bands in their own homes.
1644159|NCT01900522|Drug|ITI-214 Dose A|ITI-214 Dose A Oral Solution
1644160|NCT01900522|Drug|ITI-214 Dose B|ITI-214 Oral Solution Dose B
1717170|NCT00000922|Drug|Abacavir sulfate|
2012523|NCT01934452|Drug|sunitinib|50 mg 4/2 ,oral, once a day 4 weeks on and 2 weeks off for 6 months
2012524|NCT01929018|Behavioral|Exercise|Exercise will target muscle strength and joint mobility impairments and will be delivered over a 12 week period.
1644166|NCT01900522|Drug|ITI-214 Dose G|ITI-214 Dose G Oral Solution
1644167|NCT01900522|Drug|ITI-214 Dose H|ITI-214 Dose H Oral Solution
1644168|NCT01900522|Drug|Placebo|ITI-214 Matching Placebo Oral Solution
1644169|NCT01900509|Drug|Bendamustine|Route of administration: intravenously (IV) over approximately 60 minutes, days 1-5.
1644170|NCT01900509|Drug|Clofarabine|Route of administration: IV days 1-5.
1644171|NCT01900509|Drug|Etoposide|Route of administration: IV days 1-5.
1644172|NCT01900509|Drug|Etoposide phosphate|Route of administration: Used in substitution for etoposide in participants who experience allergic reaction, Etopophos® will be administered IV.
1644173|NCT01900509|Drug|Dexamethasone|Route of administration: three times daily orally (by mouth), days 1-5.
1644174|NCT01900496|Drug|Brentuximab vedotin & Rituximab|Rituximab and brentuximab vedotin for relapsed classical Hodgkin lymphoma
1644175|NCT01900470|Behavioral|CHW Goal Support|IMPaCT CHWs will perform the following functions, depending on the needs of the participants: 1) Deconstructing Distal Goals into Proximal Goals: IMPaCT CHWs will help patients to deconstruct collaborative distal clinical goals into patient driven proximal goals and develop strategies for achieving each proximal goal.2) Creating Roadmaps: Roadmaps are individualized strategies for achieving each proximal goal identified by patients. 3) IMPaCT Partners conduct weekly follow-up with patients through either telephone or home visit in order to support the achievement of proximal goals. As part of these followup encounters, CHWs ask patients to measure their chronic disease control during their weekly followup calls/visits. 4) Group: CHWs and their Project Manager run a group session for patients in the IMPaCT arm. This group meets weekly and is a forum for patients to discuss common issues around chronic disease management and form a social support network.
1644176|NCT01900457|Other|electromyography|
1644177|NCT01900457|Other|electroencephalography|
1644178|NCT01900457|Other|approaches from psychophysics|
2012525|NCT01929018|Behavioral|Walking Program|A walking program will be established with the goal of participants walking at least five days per week. Duration of program is 12 weeks.
1644180|NCT01900431|Drug|Sarilumab|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
1644181|NCT01900431|Drug|Prednisone|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
1644182|NCT01900431|Drug|Methotrexate|Pharmaceutical form: Tablet or Capsule or Suspension; Route of administration: Orally or intravenously or intramuscular
1644183|NCT01900431|Drug|Folic/folinic acid|Pharmaceutical form: Tablet or Capsule; Route of administration: Oral
1644184|NCT01900431|Other|Placebo (for Sarilumab)|Pharmaceutical form: Prefilled syringes; Route of administration: Subcutaneous
1644185|NCT01900418|Behavioral|Walk with Ease|An evidence-based walking program
1644186|NCT01900405|Drug|Dexmedetomidine|
1644187|NCT01900392|Behavioral|Financial incentive|Participants in the direct payment and lottery arms will receive financial incentives as part of the intervention. See arm descriptions for more detail.
1644188|NCT01900379|Procedure|CPAP treatment|This device consists in a nasal continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/CPAP patients group.
1644189|NCT01900379|Other|Sham CPAP treatment|This device consists in a sham continuous positive airway pressure. It will be applied just after CABG and for 3 months for OSA/sham CPAP patients group.
1644190|NCT01900366|Procedure|Fat Biopsy|Fat biopsy
1644192|NCT01900340|Dietary Supplement|Saline|Intravenous saline infusion and intraduodenal administration of saline via feeding tube
1644193|NCT01900340|Drug|Exendin 9-39|IV exendin(9-39) infusion and intraduodenal administration of saline via feeding tube
1644194|NCT01900340|Dietary Supplement|Saline|IV saline infusion and intraduodenal administration of nutrients
1644195|NCT01900340|Drug|Exendin(9-39) plus ID nutrient|Exendin(9-39) as intravenous infusion plus intraduodenal nutrient administration
1644196|NCT01900327|Radiation|External Beam Radiation|Neoadjuvant CRT with external beam radiation (EBRT) delivering a total dose of 50.4 Gy over 28 days in 1.8 Gy fractions.
1644197|NCT01900327|Drug|Gemcitabine neoadjuvant|weekly Gemcitabine 300mg/m2 for 6 weeks neoadjuvant
1644198|NCT01900327|Procedure|Surgery|Upfront pancreato-duodenectomy
1644199|NCT01900327|Drug|Gemcitabine adjuvant|Postoperative adjuvant Chemotherapy preferentially using Gemcitabine (1000 mg/m2 6 cycles at day 1, 8, 15 of each 28-day cycle. Administered in both arms, experimental AND active comparator
1644200|NCT01900314|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|20 active sessions, within a 4 week period, where subjects receive the same repetitive Transcranial Magnetic Stimulation (rTMS) treatment parameters as the sham arm.
1644201|NCT01900301|Drug|Scopolamine|Participants will be randomized to either, .2mg/.01 mL Scopolamine, .3mg/.01 mL Scopolamine or .4mg/.01 mL Scopolamine, administered via nasal drops, prior to each session of exposure therapy
1644202|NCT01900301|Drug|intranasal placebo|Participants will be randomized to a drug placebo, administered via nasal drops, prior to each session of exposure therapy
1644203|NCT01900288|Behavioral|HPN Group Clinic Appointments using Mobile Devices (experimental)|Visual meetings with geographically distant professionals and peers using a mobile device (iPad mini).
1644204|NCT01900288|Behavioral|Mobile Device Access (placebo)|Use of iPad mini unrelated to the intervention until last contact with one connection to professionals for comparison.
1644205|NCT01900275|Other|Urine collection|Collection of 5 ml urine from urinary collection device (e.g. foley catheter).
1644206|NCT01900262|Other|Strengthening|Participants will be asked to complete 8 weeks of isolated ankle strengthening at home.
1644207|NCT01900262|Other|Balance Training|Participants will be asked to compete 8 weeks of functional balance training at home.
1644208|NCT01900262|Other|Stretching|Participants will be asked to complete a standard of practice static and dynamic stretching warm-up for 8 weeks at home.
1644209|NCT01900249|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% 1 drop per eye twice a day for 12 weeks.
1644210|NCT01900249|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5% 1 drop per eye twice a day for 12 weeks.
1644211|NCT01900249|Drug|Placebo|Placebo Ophthalmic Solution 1 drop per eye twice a day for 12 weeks.
1644293|NCT01899560|Other|non-invasive method for measuring the lung elastance|by measuring volume recruited during a change of pressure (∆PEEP/∆EELV)
1644212|NCT01900236|Behavioral|Based on behavioral motivational interviewing (MI) technique|In addition to receiving standard clinic care, the intervention will have a tailored, interactive agenda for each of the 4 sessions based on behavioral motivational interviewing (MI) technique. The goal of this intervention is for the participant to establish early behaviors that help him/her to arrive at scheduled medical appointments and learn to take medications as prescribed during the initial year of HIV care in order to in order to achieve viral suppression and improve overall health.
1644213|NCT01900210|Behavioral|WaySafe|
1644214|NCT01900197|Drug|10% Iron Isomaltoside 1000|Administered according to local routines and product labeling in doses at the doctors discretion
1644215|NCT01900184|Drug|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
1644216|NCT01900184|Drug|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
1644217|NCT01900171|Drug|QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]|
1644218|NCT01900171|Drug|Placebo|Contains magnesium stearate, silica dental type, anhydrous lactose
1644219|NCT01900158|Drug|Amphinex and Gemcitabine|Amphinex administration on day 0, followed by gemcitabine administration (1000 mg/m2) intravenously over 30 minutes and laser light application (652 nm) on day 4 followed by systemic gemcitabine (1000 mg/m2) and cisplatin (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, commencing between 7 and 21 days after the laser light application.
1644220|NCT01900158|Drug|Gemcitabine and Cisplatin|No PCI treatment (stenting only) followed by systemic gemcitabine (1000 mg/m2) intravenously over 30 minutes and cisplatin intravenously over a period of 1 hour (25 mg/m2) given on Day 1 and Day 8 of each 21-day cycle, commencing between 7 and 21 days after randomization.
1644221|NCT01900106|Drug|abacavir/lamivudine + raltegravir|abacavir/lamivudine + raltegravir
1644222|NCT01900106|Drug|abacavir/lamivudine + darunavir/ritonavir|abacavir/lamivudine + darunavir/ritonavir
1644223|NCT01900093|Drug|Acthar Gel|80 units of subcutaneous Acthar Gel therapy daily
1644224|NCT01900080|Other|Same-Day HIV testing and ART initiation|Same-day HIV testing and ART initiation
1644225|NCT01900080|Other|Standard ART Initiation|Standard ART Initiation
1644226|NCT01900080|Other|Sub-Study: Same-Day ART, CD4 Count >500|Same-day CD4 count and ART initiation for patients with CD4 count >500 cells/mm3 (CD4 count within 7 days of HIV test)
1644227|NCT01900080|Other|Sub-Study: Standard Pre-ART Care, CD4 Count >500|Standard pre-ART care for patients with CD4 count >500 cells/mm3
1644228|NCT01900067|Device|BARRIER® EasyWarm Active Self-Warming Blanket|
1644229|NCT01900054|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
1644230|NCT01900041|Drug|Pantovigar|1 capsule of Pantovigar for oral intake, given three times a day. Duration of treatment: 6 months.
1644231|NCT01900041|Drug|Minoxidil 2% only|1 ML of Minoxidil 2% solution twice a day applied to the scalp. Duration of treatment: 6 months.
1644232|NCT01900028|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with olaparib+/- itraconazole
1644233|NCT01900028|Drug|Olaparib tablet dosing|Olaparib tablets: Part A 100mg od, days 1 and 9 only. Part B 10x300mg doses over 5 days (300mg bd).
1644234|NCT01900028|Drug|Itraconazole|Itraconazole 200mg od Part A days 5 to 11 only
1644235|NCT01900015|Drug|Raltegravir|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
1644236|NCT01900015|Drug|Efavirenz|Patients on current EFV plus two nucleoside analogs will be randomly assigned to switch EFV to RAL (400mg BID), maintaining nucleoside analogs unchanged, or to continue the current regimen.
1644237|NCT01900002|Drug|Sorafenib|Starting dose 400 mg by mouth 2 times a day starting on Day 1 of Cycle 1, 4 weeks before starting TheraSphere treatment
1644238|NCT01900002|Radiation|Yttrium-90 Microspheres|After 4 weeks (+/- 1 week) of sorafenib therapy, Y-90 procedure performed. TheraSphere is administered via infusion under imaging guidance through an hepatic arterial catheter appropriately positioned in the arterial anatomy to permit selective infusion of TheraSphere into the target tissue selected for treatment.
1644239|NCT01900002|Behavioral|Follow-Up Phone Calls|After completion of End-of-Treatment visit, study staff will contact participant by phone every 3 months. Each follow-up phone call should last about 15-30 minutes.
1644240|NCT01899989|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
1644241|NCT01899989|Drug|cisplatin or carboplatin-based|Standard chemotherapy with a histology-selected cisplatin or carboplatin-based doublet will be administered intravenously as adjuvant therapy. Gemcitabine will be used for squamous cell carcinomas and pemetrexed will be used for non-squamous non-small cell lung cancer. Cisplatin or carboplatin will be used in combination with the histology-selected agent. The choice of cisplatin or carboplatin will be at the discretion of the treating medical oncologist.
1644242|NCT01899976|Device|X-Suit NIR Covered Biliary Stent|
1644243|NCT01899924|Behavioral|Event Related Potentials recording|
1644244|NCT01899911|Device|Vital Signs Patch (VSP)|Infrared and red absorbance measurement
1644245|NCT01899898|Other|Simplified Modified Atkins Diet|"Modified Atkins diet with the following modifications:
Pictorial representation of various food items and exchange lists will be provided.
Instead of weights, we will provide standardized measures
We will calculate the amount of carbohydrates of daily readily available foods in the standardized measures
We will formulate recipes and diets based on locally available and culturally acceptable foods.
We will develop a parent instruction manual.
We will also develop methods for parents with low levels of literacy to maintain seizure logs. This will be done by using bars and color codes.
We will develop methods for parents with low levels of literacy to measure and record urine ketones. This will be done by using color codes."
1644246|NCT01899898|Drug|Antiepileptic drugs alone|The anti-epileptic drugs will be continued alone for 3 months following which they will be offered Simplified Modified Atkins Diet
1644247|NCT01899885|Procedure|AHA (Acute Highrisk Abdominalsurgery): Optimized Course|"optimized course: Intervention before, during and after abdominal surgery.
Focus on fast track with multimodal standardized intervention:
standardized preparing for surgery including high dose antibiotics and epidural analgesia etc. and transfer to intermediate care before surgery (the post-anaesthesia care unit)
GDT-LiDCO fluid management pre-, per- and postoperative
Postoperative triage to 24 hour intermediate care based on ASA score and Surgical Apgar Score
Focus on early mobilization, fysiotherapy and optimal nutrition postoperatively"
1644248|NCT01899872|Behavioral|Resistance exercise session|Resistance exercise session consisting of 4 lower-limb exercises, with 4 sets, 12 repetitions per set, at an intensity of 60% of maximal strength.
1644249|NCT01899872|Behavioral|Aerobic exercise session|Aerobic exercise session consisting of 40 minutes of lower-limb bicycle.
1644250|NCT01899859|Drug|GR-MD-02|GR-MD-02; galactoarabino-rhamnogalaturonate
1644251|NCT01899859|Drug|Placebo|GR-MD-02 Placebo
1644252|NCT01899846|Drug|Hydroxyprogesterone caproate 250 mg/ml|
1644253|NCT01899833|Diagnostic Test|99mTc-Sestamibi|An injection of 99mTC-Sestamibi will be administered by IV push under medically observed conditions.
1644254|NCT01899820|Drug|Artemether lumefantrine|Artemether 20mg Lumefantrine 120mg
1644255|NCT01899820|Drug|Dihydroartemisinin piperaquine|Dihydroartemisinin 20mg Piperaquine 160mg
1644256|NCT01899807|Device|OssDsign AB|
1644257|NCT01899794|Procedure|TVT-O/Oxytrol|
1644258|NCT01899794|Device|TVT-O|
1644259|NCT01899794|Drug|Oxytrol|
1644260|NCT01899781|Drug|Antibiotic-Cefamezin|
1644261|NCT01899768|Drug|GSK2339345|Clear colorless solution in clear glass vial for oral inhalation via aqueous droplet inhaler with unit dose strength of 1000 microgram (mcg) inhaled in two actuations.
1644262|NCT01899768|Drug|Placebo|Clear colorless solution of 0.9% sodium chloride for oral inhalation via aqueous droplet inhaler inhaled in two actuations.
1644263|NCT01899755|Drug|GSK2800528, solution for injection|Drug will be administered at 3 different dose levels by subcutaneous injection.
1644264|NCT01899755|Drug|Placebo (0.9% w/v Sodium Chloride), solution for injection|Subcutaneous injection of. 0.8 mL solution will be administered
1644265|NCT01899755|Drug|Adalimumab, solution for injection|Subcutaneous injection of 0.8 mL solution will be administered (40mg)
1644266|NCT01899742|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
1644267|NCT01899742|Drug|Tiotropium 18 mcg|Inhalation Powder
2012526|NCT01929018|Behavioral|Health Self-Management Support|Health self-management support will be delivered with weekly meetings between the researcher and participant over a 12-week period.
2012527|NCT01925794|Device|COBRA PzF|
2012528|NCT01923662|Device|IST-16 (16-Channel implanted stimulator-telemeter|Surgical implantation of IST-16 stimulator and electrodes to stimulate paralyzed muscles. Subjects will receive exercise and physical therapy with the implanted device. Functional training and laboratory assessments of clinical and technical performance will be conducted.
2012529|NCT01920061|Drug|PF-05212384 (gedatolisib)|PF-05212384 weekly intravenous infusions starting at 90 mg/wk as a 3 week cycle
1644272|NCT01899716|Other|Exercise|
2012530|NCT01920061|Drug|Docetaxel|Docetaxel intravenous infusions once every 3 weeks starting at 75 mg/m^2
2012531|NCT01920061|Drug|Cisplatin|Cisplatin intravenous infusions once every 3 weeks starting at 75 mg/m^2
2012532|NCT01920061|Drug|Dacomitinib|Dacomitinib to be taken orally as a continuous once daily regimen at a starting dose of 30 mg
1644276|NCT01899690|Drug|antibiotic|Patients after breast reconstruction with implant/tissue expander reconstruction who receive the intervention will be prescribed with a 7 day course of postoperative antibiotics.
1644277|NCT01899677|Other|distilled water|0.5 cc distilled water twice daily will be added to the breast milk or formula during 30 days
1644278|NCT01899677|Drug|symbiotic|Symbiotic 1/2 sachet twice daily will be added to the breast milk or formula during 30 days
1644279|NCT01899664|Procedure|Nerve Transfer Surgery|Unilateral surgery will be performed under general non-paralytic anesthesia and no-tourniquet conditions to allow for responsive nerve simulation.
1644280|NCT01899638|Drug|UMEC/VI 125/25 mcg|Combination in high dose
1644281|NCT01899638|Drug|UMEC/VI 62.5/25 mcg|Combination in low dose
1644282|NCT01899638|Drug|UMEC 125 mcg|LAMA mono in high dose
1644283|NCT01899638|Drug|UMEC 62.5 mcg|LAMA mono in low dose
1644284|NCT01899638|Drug|VI 25 mcg|LABA mono
1644285|NCT01899625|Behavioral|Brief Behavioral Weight Loss (BWL)|12 Week treatment program consisting of 2, 90-minute individual sessions, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Treatment consistent with behavioral weight loss, low calorie, low fat diet. Increased physical activity of up to 250 minutes/week.
1644286|NCT01899625|Behavioral|Motivation Enhanced BWL|12 week treatment program consisting of 2, 90-minute individual sessions with a focus on motivation, followed by weekly PDF modules via email, and reporting of key behaviors and feedback via email. Participants will pick from one of three dietary goals and one of three physical activity goals.
1644287|NCT01899599|Drug|Gatipotuzumab|start dose 500mg at C0D1 maintenance dose 1700mg at CxD1 Number of Cycles: until progression or unacceptable toxicity develops.
1644288|NCT01899599|Drug|Placebo|start dose matching 500mg at C0D1 maintenance dose matching 1700mg at CxD1 Number of Cycles: until progression or unacceptable toxicity develops.
1644289|NCT01899586|Other|Regional Specific Training Stimulus (RSTS)|The RSTS protocol was designed to focus on specific peripheral muscle groups without imposing a significant cardiorespiratory strain. Each exercise involved contractions with moderate load but with an extended duration of up to six minutes. Eight specific exercises were performed to target all major muscle groups and enable the routine to be completed within 60 minutes including warm-up, rest periods and stretching between exercises, and cool down exercises.
1644290|NCT01899586|Other|Aerobic Exercise Regimen (AE)|Whole-body aerobic exercise at >50% of heart rate reserve (HRR) for 45 minutes, three days per week.
1644291|NCT01899573|Device|AccuCinch® Ventriculoplasty System|Percutaneous intervention for the treatment of functional mitral regurgitation
1644292|NCT01899560|Procedure|Measure lung and chest wall elastance with esophageal catheter|"Patients will be in supine position with 30-45° head of bed elevation. The cuff of the endotracheal tube will be transiently overinflated to 60 cmH2O to ensure there will be no air leaks. NMBA (cisatracurium) will be administrated [9]. The fraction of inspired oxygen (FiO2) will be adjusted for continuously monitored oxygen saturation (SpO2) between 90 to 94%. Patients will be ventilated in pressure control with 15 cmH2O of driving pressure.
A low flow pressure/volume curve from 0 to 40 cmH2O will be performed."
2012533|NCT01913314|Drug|[^14C]-LY2835219|Administered as oral solution
2012534|NCT01912716|Drug|high dose indomethacin|
2012535|NCT01912716|Other|standard dose|
1644294|NCT01899547|Procedure|laparoscopic-assisted rectal resection|Arm I: Patients undergo laparoscopic-assisted rectal resection.
1644295|NCT01899547|Procedure|conventional open rectal resection|Arm II: Patients undergo conventional open rectal resection.
1644296|NCT01899534|Other|E-screening|E-screening will be conducted on a computer tablet with wireless access. The tablet will be configured with the screening tool currently used in each clinic. The content and order of individual questions will be identical to the paper-pen version. Response options will be listed in full view under each question. Women select responses by touching the screen.
1644297|NCT01899521|Procedure|Bronchoscopy|Involves flexible fiberoptic bronchoscopy with standardized bronchoalveolar lavage (BAL) technique (isotonic saline in a sub-segment of the right middle lobe or lingula) using standard conscious sedation techniques.
1644298|NCT01899521|Dietary Supplement|Zinc sulfate 220 mg once daily|
1644299|NCT01899521|Dietary Supplement|S-adenosylmethionine 400 mg twice daily|
1644300|NCT01899508|Procedure|Virtual Reality Training Session|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
1644301|NCT01899508|Device|3D viewer with iPod Touch/iPhone (or similar smartphone)|The participant will meet with an interventionist for an hour and a half long session. During this session OA knee pain will be assessed (using self report questionnaires) prior to and post a 10 minute session using the 3D viewer and having a brief pain coping skills training.
1644302|NCT01899495|Other|High sodium diet and low sodium diet|Isocaloric diet with 60 mEq of potassium and 1gm protein/kg body weight with high sodium 300mEq; low sodium 10 mEq.
1644303|NCT01899482|Other|Manual Lymphatic Drainage|
1644304|NCT01899482|Behavioral|Education|Behavioral education.
1644305|NCT01899469|Procedure|Electromagnetic Therapy|20 sessions from Monday to Friday of 20 minutes of Electromagnetic Therapy, using the next parameters: 10 Hz of frequency and 60% of intensity, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
1644306|NCT01899469|Procedure|Transcutaneous Electrical Neurological Stimulation|"Procedure/Surgery: Transcutaneous Electrical Neurological Stimulation (TENS)
20 sessions from Monday to Friday of 20 minutes of TENS Therapy using the next parameters: 100μs of impulse width, 80 Hz of impulse frequency, and 20 sessions from Monday to Friday of 25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home."
1644307|NCT01899469|Procedure|Back School|25 minutes of Back School, the exercises were based on the re-education of breathing, self stretching trunk muscles, erector spine reinforcement, abdominal reinforcement and postural exercises. The participants had been performing 8 to 10 repetitions of each exercise and they had been recommended about making a series more at home.
1644308|NCT01899456|Device|Catheter-based renal denervation|
1644309|NCT01899443|Other|Observation|This is an observational study observing relationship between routine care and outcomes after total hip or knee arthroplasty.
1644310|NCT01899430|Drug|liraglutide|
1644311|NCT01899430|Drug|metformin|
1644312|NCT01899417|Device|ConforMIS iTotal® Knee Replacement|Patients that received a ConforMIS iTotal knee replacement versus other knee replacement devices.
1644313|NCT01899404|Biological|18-FDG PET/CT, DWI, DCE-MRI|All patients on this study will receive a Diffuse Weighted MRI and Dynamic Contrast Enhancing MRI during the routine MRI session on the day of brachytherapy (additional 10 minutes), and a FDG PET/CT scanning session on the day of brachytherapy.
1644314|NCT01899378|Dietary Supplement|Lactobacillus reuteri DSM 17938|10^8 CFU
1644315|NCT01899378|Dietary Supplement|Bifidobacterium longum infantis|10^9 CFU
1644316|NCT01899352|Procedure|Tracheostomy|Percutaneous and surgical tracheostomies will be performed with the procedure currently available in clinical practice.
1644317|NCT01899339|Other|Ultra sound energy along with tPA to treat submassive pulmonary embolism|
1644318|NCT01899326|Drug|Desipramine Hydrochloride|Given PO
1644319|NCT01899326|Biological|Filgrastim|Given PO
1644320|NCT01899326|Other|Laboratory Biomarker Analysis|Correlative studies
1644321|NCT01899313|Behavioral|CBT- based SMS text messaging intervention|
1644322|NCT01899313|Behavioral|CBT group therapy|
1644324|NCT01899287|Behavioral|group education|"The experimental intervention consists of:
A. Group education on general skin-protective behaviour. B. Group education and counselling on work-related skin-protective behaviour, which might extend to a work-place visit.
C. Social guidance related to OHE. D. Telephone hot-line for work and case-related problems, maintained by nurse."
1644325|NCT01899274|Device|bant iPhone application|
1644326|NCT01899261|Radiation|Stereotactic Radiosurgery|Undergo SBRT
1644327|NCT01899248|Drug|Sevoflurane|
1644328|NCT01899248|Drug|Desflurane|
1644329|NCT01899235|Device|drug eluting balloon|
1644330|NCT01899235|Device|drug eluting stent|
1644331|NCT01899222|Device|Handheld fundus photography|
1644332|NCT01899209|Procedure|STARR|
1644333|NCT01899209|Procedure|Laparoscopic Ventral Rectopexy|
1644334|NCT01899196|Biological|blood sampling,|
1644335|NCT01899183|Procedure|Anti-reflux Surgery|Nissen Fundoplication; Collis Gastroplasty
1644336|NCT01899170|Procedure|Deep brain stimulation|Implantation of a deep brain stimulation electrode into pain processing brain areas
1644337|NCT01899170|Device|Cervel Neurotech, Multi-coil TMS|Non-invasive selective stimulation of deep brain areas using magnetic fields.
1644338|NCT01899170|Drug|11C-Carfentanil|PET-radioligand for functional brain imaging to assess opioid binding. The compound is a potent synthetic opioid.
1644617|NCT01897142|Biological|PF-05230907|1 micrograms per kilogram of PF-05230907, IV bolus, single dose
1644339|NCT01899144|Drug|Albuterol Spiromax|Albuterol Spiromax® Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose dry powder inhaler (DPI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two DPIs filled with Albuterol Spiromax® were used.
1644340|NCT01899144|Drug|ProAir HFA|ProAir® HFA Inhalation Aerosol contains 90 mcg albuterol per actuation orally inhaled in a single dose metered dose inhaler (MDI). Participants took doses at either the 90 or 180 mcg levels. If the higher level, two MDIs filled with ProAir HFA were used.
1644341|NCT01899144|Drug|Placebo|Single dose MDIs and DPIs containing placebo taken as a single orally-inhaled actuation each.
1644342|NCT01899131|Device|platform-switch tapered internal implants|Laser-Lok permanent abutment/ new Laser Lok platform-switch implant assembly.assessment at 6,12,24 month clinicaly and radiographic
1644343|NCT01899118|Radiation|Preoperative irradiation|50.4Gy/28F/5.5w
1644344|NCT01899118|Drug|Nimotuzumab|400mg/w，0-5w
1644345|NCT01899118|Drug|Oxaliplatin|130mg/m2 d1
1644346|NCT01899118|Drug|Capecitabine|825mg/m2 bid d1-5/w,1-5w
1644347|NCT01899105|Drug|lumacaftor|
1644348|NCT01899105|Drug|ivacaftor|
1644349|NCT01899092|Drug|TT-034|The study drug will be given as a single dose IV infusion on Day 1. 5 different dose levels corresponding to the 5 cohorts of the study will be given.
1644350|NCT01899066|Drug|Lucentis, chemotherapy|"Lucentis:0.50mg/0.05ml, intravitreal injection,monthly for the first six months.
chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2."
1644351|NCT01899066|Drug|chemotherapy|chemotherapy:vincristine,1.5mg/m2;carboplatin,560mg/ m2;etoposide,150 mg/ m2.
1644352|NCT01899053|Drug|MLN0128|
1644353|NCT01899053|Drug|MLN1117|
1644354|NCT01899040|Device|neuromodulation for episodic migraine headache|
1644355|NCT01899027|Drug|Rosuvastatin|Patients will receive two overnight high doses of Rosuvastatin (40 mg 12 h before RNA and another 10 mg dose 2 h before the procedure
1644356|NCT01899027|Drug|Placebo|Patients will receive two overnight doses of Placebo 12 h before RNA and another dose 2 h before the procedure
1644357|NCT01899014|Drug|18F-choline PET-CT imaging|18F-choline PET-CT imaging
1644358|NCT01899001|Behavioral|Cognitive Behavioral Therapy|Participants will receive weekly, 30 minute sessions with a CBT-trained clinical psychologist for the first 8 weeks. Briefly, the purpose of CBT is to treat mood and associated anxiety disorders by changing dysfunctional thoughts that lead to negative mood states and maladaptive behaviors. Through the use of Socratic questioning, the therapist challenges the patient to observe the relationship between thoughts and feelings and to question the underlying beliefs that perpetuate negative affect. Ultimately, patients learns to recognize maladaptive automatic thoughts and develop a more rational and balanced way of thinking about themselves and the world around them.
1644359|NCT01899001|Behavioral|Nutrition Counseling|All women will receive nutrition/exercise counseling by a trained counselor. They will consume a self-selected diet of 1500-1800kcal/d of conventional foods based on the Food Guide Pyramid. Participants will also have an exercise goal that starts at 50 minutes per week and increases to 175 minutes per week. Sessions will teach standard weight loss skills, including self-monitoring, problem-solving, enlisting social support, and overcoming negative thoughts. Subjects will be asked to keep daily food intake and exercise logs which will be reviewed at the nutrition counseling sessions. These sessions will occur in person once weekly lasting on average 30 minutes for 16 sessions.
1644360|NCT01898975|Other|500ml fluid loading|Fluid loading to evaluate fluid responsiveness
1644361|NCT01898962|Procedure|Complete Surgical Removal|
1644362|NCT01898962|Radiation|Stereotactic Radiosurgery|
1644363|NCT01898962|Radiation|Ablative external beam radiation dose|
1644364|NCT01898962|Procedure|Subtotal surgical removal plus ablative radiation dose|Residual tumor or close/positive margins should be followed by ablative radiation doses (by either stereotactic radiosurgery or convential EBRT) to constitute definitive locoregional treatment
1644365|NCT01898962|Radiation|Radioembolization|radioembolization of the liver with Y-90 microspheres or other site-appropriate techniques
1644366|NCT01898949|Other|Cold Exposure|Participants will spend 20 minutes per day 5 times a week (workdays) in a cold room wearing light clothes (T-shirt, shorts and light shoes) for 4 weeks.
2012536|NCT01908972|Drug|Prednisolone|2mg/kg/day for 16weeks
2012537|NCT01908972|Drug|Propranolol|2mg/kg/day for 16weeks
1644369|NCT01898923|Drug|WH-1 ointment|
1644370|NCT01898923|Other|Aquacel® Hydrofiber® dressing|
1644371|NCT01898910|Procedure|PVI+renal denervation|After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done.
1644372|NCT01898910|Procedure|PVI + GP ablation|To accomplish ganglionated plexi ablation, LA target sites were identified as the anatomic locations where vagal reflexes were evoked by transcatheter high-frequency stimulation (HFS). Rectangular electrical stimuli were delivered at a frequency of 20-50 Hz, output amplitude 15 V and pulse duration of 10 ms, for 5 sec (Stimulator B-53, Biotok Inc, Russia).
1644373|NCT01898910|Drug|Optimal medial therapy (OMT)|Antiarrhythmic and antihypertensive therapy will be administered according to the guidelines
1644560|NCT01897519|Drug|ABT-719|Arm 1 lower dose, arm 2 intermediate dose, arm 3 high dose
1644561|NCT01897493|Drug|Evacetrapib|Administered orally
1644562|NCT01897493|Drug|Digoxin|Administered orally
2012538|NCT01907048|Behavioral|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure physician awareness and understanding of the key messages in the prescriber guide.
2012539|NCT01907048|Behavioral|Rivaroxaban (Xarelto, BAY59-7939)|Survey to measure patient awareness and understanding of the key messages in the patient card.
2012540|NCT01906164|Drug|ALS-008176|
2012541|NCT01906164|Drug|Placebo|
2012542|NCT01903733|Drug|bosutinib|The starting bosutinib dose is 500 mg once daily, however the dose can vary from 300 mg to 600 mg.
2012543|NCT01897896|Drug|SD-809|SD-809 tablets will be provided in dose strengths of 6, 9 and 12 mg.
1644374|NCT01898897|Procedure|epidural catheter insertion|A catheter is placed in the epidural space at thoracic level. Analgesia is realised with local anesthetics (Bupivacaine plain 0.125%), administered from the beginning of surgical intervention and 12 hours postoperative on the postoperative care unit and intensive care unit at a rate of 6-8 ml/hour.
1644375|NCT01898897|Procedure|robot assisted laparoscopic urogenital surgery|The urogenital laparoscopic surgery is assisted by DaVinci robot. The majority of interventions were prostatectomies.
1644376|NCT01898884|Drug|VP 20629|
1644377|NCT01898884|Drug|Placebo|
1644378|NCT01898871|Dietary Supplement|A daily ration of 40 kcal/kg of body weight during 56 days|On enrollment, children were examined by a pediatrician to assess their health status and they were de-wormed with one tablet of Mebendazole 500 mg.
1644379|NCT01898858|Device|Hypercapnia inhalation (Altitrainer NP 190)|Hypercapnia inhalation using an Altitrainer NP 190
1644380|NCT01898858|Device|Hypoxia and hypercapnia (Altitrainer NP 190)|Hypoxia and hypercapnia inhalation using an Altitrainer NP 190
1644381|NCT01898858|Device|Hypoxia inhalation (Altitrainer NP 190)|Hypoxia inhalation using an Altitrainer NP 190
1644382|NCT01898845|Drug|LEE011|
1644383|NCT01898819|Drug|Dexmedetomidine|
1644384|NCT01898819|Drug|saline|
1644385|NCT01898806|Drug|Intralesional Triamcinolone 2.5 mg/ml|Intralesional Triamcinolone at a strength of 2.5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
1644386|NCT01898806|Drug|Intralesional Triamcinolone 5 mg/ml|Intralesional Triamcinolone at a strength of 5 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
1644387|NCT01898806|Drug|Intralesional Triamcinolone 10 mg/ml|Intralesional Triamcinolone at a strength of 10 mg/ml. Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss up to the maximum dose of 30 mg IL TAC per month, for a total of 6 months.
1644388|NCT01898806|Drug|Intralesional Saline|Intralesional Saline (Placebo). Patients will receive intradermal injection of study medication once per month to all, or as many as possible, areas of hair loss for a total of 6 months.
2012544|NCT01898377|Drug|Imatinib mesylate, Mycophenolate mofetil|
2012545|NCT01893827|Drug|XR-NTX (Extended-Release Naltrexone)|380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.
2012546|NCT01893827|Drug|Oral Naltrexone (O-NTX)|50mg pill form of naltrexone taken 1x/day for 6 months.
2012547|NCT01892514|Procedure|core decompression|core decompression of necrotic area and graft with Platelet-Rich Fibrin (PRF) and Concentrated Bone Marrow (CBM)
2012548|NCT01892371|Drug|Quizartinib|"Phase I Starting Dose: 60 mg my mouth daily of a 28 day cycle. For the first cycle only, quizartinib administered starting on day 5 of the cycle. All subsequent cycles quizartinib will start concomitantly with AZA or cytarabine.
Phase II Starting Dose: Maximum tolerated dose from Phase I."
1644395|NCT01898780|Procedure|pancreaticojejunostomy with horizontal mattress suture|
1644396|NCT01898780|Procedure|pancreaticojejunostomy with interrupted suture|
1644397|NCT01898754|Other|Pre-ART Oligonucleotide Assay (OLA)|Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
1644398|NCT01898741|Radiation|24 Gy in 3 fractions|
1644399|NCT01898728|Drug|topical povidone-iodine after premedication with topical liquid eye drops|
1644400|NCT01898728|Drug|topical povidone-iodine after premedication with topical gel|
1644401|NCT01898715|Drug|ATR-101|
1644402|NCT01898702|Behavioral|Diabetes expert patients programme|Nine-weekly informative and educational sessions by a teaching patient who has experience on diabetes
1644403|NCT01898689|Drug|perineural infusion|"A continuous peripheral nerve block—also termed perineural local anesthetic infusion—involves the insertion of a tiny tube (a catheter) through the skin and adjacent to a peripheral nerve, followed by local anesthetic (numbing medicine) administration via the catheter, providing pain control following surgery. Continuous peripheral nerve blocks may be provided in the hospital setting, but the use of lightweight, portable pumps permits infusion at home as well."
1644404|NCT01898676|Drug|Divalproex Sodium Extended-release 250mg|Two tablets of Divalproex Sodium Extended-Release 250mg will be given to the subject in two treatment periods
1644405|NCT01898676|Drug|DEPAKOTE 250mg|Two tablets of DEPAKOTE 250mg will be given to the subject in two treatment periods.
1644406|NCT01898663|Biological|Adenovirus-transfected DC + CIK|Adenovirus-transfected autologous DC vaccine plus CIK cells
1644407|NCT01898650|Other|MR scan|
1644408|NCT01898637|Other|Augmented pulse oximetry using incentive spirometer.|Augmented pulse oximetry using incentive spirometer.
1644409|NCT01898637|Device|Incentive spirometer.|The incentive spirometer is a simple passive device that measures the amount of air a person can inhale.
1644410|NCT01898624|Drug|mirabegron|oral
1644413|NCT01898598|Drug|Placebo|Participants will receive matching placebo to vismodegib for 12 weeks.
1644414|NCT01898598|Drug|Vismodegib|Participants will receive vismodegib 150 mg oral capsule once a day for 12 weeks
1644416|NCT01898572|Other|Standard care|Newly T2DM and control individuals will be controlled by their family care physician following standard (clinical guidelines) care.
1644417|NCT01898559|Other|Switch to smoking only little cigars|Participants smoke only little cigars for 15 days.
1644418|NCT01898546|Procedure|Primary angioplasty|Primary angioplasty preceded by 300 mg aspirin plus 600 mg clopidogrel oral load doses. The radial approach and the use of thrombus aspiration catheters will be recommended. Stent will be implanted in all cases. Balloon pre-dilatation or direct stenting will be decided according to lesion characteristics.
1644419|NCT01898546|Procedure|Postconditioning|1 min after stent deployment, the angioplasty balloon will be re-inflated 4 times during 1 min at low-pressure (4 to 6 atmospheres), each separated by 1 min of reflow.
1644420|NCT01898520|Drug|Sativex|Oromucosal spray containing THC (27 mg/mL):CBD (25 mg/mL), in ethanol: propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivered THC 2.7 mg and CBD 2.5 mg. The maximum number of daily sprays was 12.
1644659|NCT01896856|Drug|regorafenib|
1644421|NCT01898520|Drug|Placebo|Oromucosal spray containing ethanol: propylene glycol(50:50) excipients, with peppermint oil (0.05%) flavouring and colourings FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%). Each 100 μL spray administered to the sub-lingual or oral mucosa delivered the colourants plus excipients. The maximum daily dose was 12 sprays per day.
1644422|NCT01898507|Other|Low nicotine cigarettes|15-day period of smoking low nicotine content cigarette level 1: 0.25 mg nicotine content, followed by a 15-day period of smoking low nicotine content cigarette level 2: 0.08 mg nicotine content.
1644423|NCT01898494|Procedure|therapeutic conventional surgery|Undergo transoral surgical resection
1644424|NCT01898494|Radiation|intensity-modulated radiation therapy|Undergo low-dose IMRT
1644425|NCT01898494|Drug|cisplatin|Given IV
1644426|NCT01898494|Drug|carboplatin|Given IV
1644427|NCT01898494|Radiation|intensity-modulated radiation therapy|Undergo standard-dose IMRT
1644428|NCT01898494|Other|laboratory biomarker analysis|Correlative studies
1644429|NCT01898494|Other|quality-of-life assessment|Ancillary studies
1644430|NCT01898468|Procedure|Pericostal Closure Technique|
1644431|NCT01898468|Procedure|Intracostal Closure Technique|
1644432|NCT01898455|Device|RhinoChill intranasal cooling|The RhinoChill device will be used to locally cool the posterior nasopharynx, surrounding tissues and vasculature using a variable cooling flow rate based on patient comfort and tolerance, for a maximum of 20 minutes. Local anaesthetic spray will be administered to patients if the nasal catheters or cooling is poorly tolerated.
1644433|NCT01898442|Drug|Ticagrelor 180mg|Rndomization to standard or high ticagrelor loading dose regimens
1644434|NCT01898442|Drug|Ticagrelor 270mg|Randomization to standard or high loading dose regimen
1644435|NCT01898442|Drug|Ticagrelor 360mg|Randomization to standrad or high loading dose regimen
1644436|NCT01898429|Device|SCC DBS|Deep Brain Stimulator
1644437|NCT01898416|Drug|5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.|"60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.
Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given."
1644438|NCT01898403|Drug|Indocyanine green solution|Administered peri-tumoral and intradermally
1644439|NCT01898403|Drug|Isosulfan blue (ISB)|Administered peri-tumoral and intradermally
1644440|NCT01898403|Diagnostic Test|Lymphoscintigraphy with 99-technetium (99Tc) sulfur colloid (TSC)|
1644441|NCT01898390|Procedure|Transplant|Bilateral Neural Allo-Transplantation with Fetal Ventral Mesencephalic Tissue
1644443|NCT01898364|Drug|GZ402666|Pharmaceutical form:lyophilized powder reconstituted for infusion Route of administration: intravenous
1644444|NCT01898351|Other|Fava bean, Lupin, Beef meat, Green pea, Hemp, Buckwheat|"The intervention visit involves a test meal to be consumed by subjects attending the Human Nutrition Unit in the morning, following an overnight fast. The meal will be consumed within 15 minutes and blood (69 mL) and urine samples will be collected during 24 hours.
The test meals are designed to contain the same amount of proteins. Alternative protein meals: a number of bread buns for each meal containing individual alternative protein flours (green pea, lupin, hemp, buckwheat, fava beans). These will deliver 30 g of protein, the remainder being provided by white flour. The control (meat) meal: a lean beef steak containing 30 g of protein and a bun containing the same amount of white flour as used for the alternative protein bread buns.
The semi structured interview guide: will take place within the Human Nutrition Unit during one of the scheduled visits, once initial screening has taken place and participants have been selected. All interviews will be digitally recorded."
1644445|NCT01898338|Drug|Fosfomycin 2gr/6h iv|
1644446|NCT01898338|Drug|Daptomycin 10mg/kg/24h iv|
1644447|NCT01898325|Device|Fibroscan|Fibroscan
1644448|NCT01898312|Drug|Mifepristone|Randomised controlled trial of Mifepristone and placebo comparator Triobe
1644449|NCT01898299|Device|transcranial Direct Current Stimulation (tDCS)|A neurostimulation technique that passes an extremely weak electric current through the brain.
1644450|NCT01898299|Device|Sham tDCS|Sham (inactive) tDCS treatment
1644451|NCT01898286|Drug|DiaPep277®|1 mg of DiaPep277® subcutaneously in the upper arm at 0, 3, 6, 9, 12, 15, 18, and 21 months, for a total of 8 administrations
1644453|NCT01898260|Device|Ultrafilcon B contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
1644454|NCT01898260|Device|Stenfilcon A contact lens|Silicone hydrogel contact lens CE-marked for daily disposable wear. Private-label versions may be used.
1644455|NCT01898247|Other|Simulation-based mastery learning|Internal Medicine residents are randomly selected to undergo simulation-based mastery learning.
1644456|NCT01898234|Device|Revaclear|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
1644457|NCT01898234|Device|Helixone high flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
1644458|NCT01898234|Device|Xevonta|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
1644459|NCT01898234|Device|Helixone low flux|Four polysulfone dialyzers of 1.8 m2, A (Revaclear, Gambro), B (Helixone high flux, Fresenius), C (Xevonta, BBraun) and D (Helixone low flux, Fresenius), were compared with each other
1644460|NCT01898221|Drug|Ethanol|We enter the CS with a sheath advanced from the right internal jugular vein. A sub-selector catheter with a ~90° angle at the tip (typically, a left internal mammary artery angioplasty guide catheter) is advanced through the CS sheath with its tip pointing superiorly and posteriorly.
1644563|NCT01897480|Biological|LY2875358|Administered IV
1644564|NCT01897480|Drug|Erlotinib|Administered Orally
1644616|NCT01897142|Drug|Placebo for PF-05230907|0.3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
1644461|NCT01898221|Procedure|Ablation|The doctor will perform only the standard procedure. Throughout the procedure, the researchers will document the following information for ALL patients: measurements such as whether the treatment was successful or unsuccessful, X-ray exposure time, procedure time, whether there were any complications, and other general procedural measurements.
1644462|NCT01898208|Device|FilmArray testing|FilmArray Blood Culture Identification (BCID) Panel is a polymerase chain reaction (PCR) panel that identifies 19 types of bacteria, 5 types of fungi, and select antimicrobial-resistance genes.
1644463|NCT01898208|Behavioral|Antimicrobial Stewardship|Real time antimicrobial stewardship: an infectious diseases pharmacist or physician will provide patient-specific recommendations to modify antimicrobial therapy.
1644464|NCT01898208|Other|Bacterial culture|This test identifies the pathogen responsible for an infection.
1644465|NCT01898208|Other|Susceptibility testing|Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics. Antibiotic susceptibility testing determines the susceptibility of a bacterial strain to a specific antibiotic or a panel of antibiotics.
1644466|NCT01898195|Drug|Varenicline|Varenicline will be provided for three months.
1644467|NCT01898195|Behavioral|Text Message|Text messages will be developed twice daily for three months
1644468|NCT01898195|Behavioral|Adherence Behavioral Therapy|Seven Adherence Behavioral Therapy sessions will given over a three month period
1644469|NCT01898182|Other|Kinetin, N6-furfuryladenine, 0.1%|
1644470|NCT01898169|Other|NJOY King 26 mg nicotine Electronic Nicotine Delivery System|NJOY® King ENDS, menthol or nonmenthol, ad libitum use for 1 week NJOY® King ENDS, menthol or nonmenthol, 2 series of puffs, with a 30-second interpuff interval in each series and 1 hour between the first puff in each series.
1644471|NCT01898156|Drug|BIW-8962|"Phase 1 -With a standard 3+3 dose escalation design, the enrollment in Phase 1 will proceed until the MTD has been defined or the highest dose level has been reached. BIW-8962 will be administered intravenously on day 1 of each 21 day cycle.
Phase 2 - RP2D of BIW-8962 determined in phase 1 portion will be administered until progression or unacceptable toxicity develops."
1644472|NCT01898143|Other|Whole body vibration|
1644473|NCT01898130|Biological|bevacizumab|Given IV
1644474|NCT01898130|Procedure|quality-of-life assessment|Ancillary studies
1644475|NCT01898117|Drug|Carbo/cyclo|
1644476|NCT01898117|Drug|Carbo/cyclo + bevacizumab|
1644477|NCT01898117|Drug|Paclitaxel|
1644478|NCT01898117|Drug|Paclitaxel + Bevacizumab|
1644479|NCT01898104|Radiation|preoperative radiation therapy|25 Gy in 5 fractions over 1 week
1644480|NCT01898104|Drug|Valproic Acid|
1644481|NCT01898104|Drug|Capecitabine|
1644482|NCT01898091|Drug|Neem Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
1644483|NCT01898091|Drug|Placebo Mouthrinse|10ml dose of assigned study mouthrinse, three times per day, for approximately 7 weeks during radiation therapy.
1644484|NCT01898078|Drug|MLN8237|Patients will be randomly assigned in a crossover fashion to receive a single 50-mg dose of alisertib (administered as 5 x 10 mg enteric-coated tablets) with or without a standard high-fat breakfast on Day 1 of Cycle 1, with the respective alternate food intake condition (fasted to fed, or fed to fasted; n = approximately 9 per sequence) on Day 1 in Cycle 2.
1644485|NCT01898065|Drug|18-F-MISO|PET scan with the 18 Fluoro Misonidazole
1644486|NCT01898052|Drug|single anaesthetic drug|inject periarticular tissue of the knee after implantation
1644487|NCT01898052|Drug|multimodal drug injection|inject periarticular tissue of the knee
1644488|NCT01898039|Biological|A2/4-1BBL melanoma vaccine|On days 14, 35, 56, 77 and 98 the appropriate dose of irradiated M20/A2B cells will be injected into three adjacent sites on the upper arm or thigh, avoiding limbs where lymph node dissection had been previously performed.
1644489|NCT01898039|Procedure|DNP sensititzation|"Include brand names, serial numbers and code names, if applicable. Other names are used to improve search results on the ClinicalTrials.gov web site.
On days 1 and 2 patients will be sensitized to DNP by topically applying 0.1 ml of 2% DNP dissolved in acetone-corn oil (Sigma) to the inner aspect of the arm."
1644490|NCT01898039|Drug|Cyclophosphamide|On day 10, intravenous low dose cyclophosphamide, 300 mg/m2, will be administered.
1644491|NCT01898026|Dietary Supplement|Bread|Samples of white bread, with or without the addition of PGX fibre blend
1644492|NCT01898026|Dietary Supplement|Mashed Potatoes|samples of mashed potatoes, with or without the addition of soluble fibre blend
1644493|NCT01898026|Dietary Supplement|Muffins|Samples of muffins, with or without the addition of PGX fibre blend
1644494|NCT01898026|Dietary Supplement|Hot Breakfast Cereal|Samples of hot breakfast cereal without the addition of soluble fibre blend
1644495|NCT01898013|Drug|Pregnenolone|
1644496|NCT01898013|Drug|Placebo|
1644497|NCT01898000|Behavioral|Triphala mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
1644498|NCT01898000|Behavioral|Chlorhexidine mouthwash|Subjects were instructed to use 15ml mouthwash twice daily and were instructed not to rinse/eat anything for 30 min after mouthwash use. Subjects were also asked to refrain from all other unassigned forms of oral hygiene aids, including dental floss and chewing gum during the study. No oral hygiene instructions like brushing and flossing were given to the subjects to exclude the influence of improved oral hygiene practices on the results.
1644499|NCT01897987|Biological|Pneumostem®|
1644500|NCT01897987|Biological|normal saline|
1644501|NCT01897974|Other|Survey|Families complete survey to measure medication compliance.
1644502|NCT01897961|Other|Anticorps anti-PLA2R1|
1644503|NCT01897948|Other|Milk-based beverage without DHA|
1644504|NCT01897948|Other|Milk-based beverage with DHA at mid level|
1644505|NCT01897948|Other|Milk-based beverage with DHA at high level|
1644506|NCT01897922|Other|An investigational infant formula containing a probiotic source|
1644507|NCT01897922|Other|Control: Marketed routine infant formula|
1644509|NCT01897870|Behavioral|HomeCoMe-program|A home visit by patients own community pharmacist within seven days after hospital discharge. The community pharmacist will perform a semi-structured interview on (1) use of the prescribed medication, (2) ADEs, (3) adherence issues, by (A) assessing patient's needs and concerns around his pharmacotherapy, (B) identifying and solving obstacles for medicines intake, (C) checking on the need for a compliance aid, (D) collecting spare medication and finally (4) knowledge on medication use, when to take which medicine and why, and medication changes made during the hospitalisation.
1644510|NCT01897857|Device|duplex Doppler ultrasonography|
1644511|NCT01897844|Drug|ITF2984 (100, 2000, 3000 mcg bid)|
1644512|NCT01897844|Drug|Placebo|
1644513|NCT01897831|Drug|xin te mie|durg:Piperacillin Sodium and Sulbactam Sodium for Injection(2:1) 1.5-3.0g,iv,bid for 7-14 days Serious infections:6.0-12.0g,iv,tid for 7-14 days
1644514|NCT01897818|Device|communication system P300 Speller|
1644515|NCT01897805|Drug|Heart-protecting Musk Pill|
1644516|NCT01897805|Drug|Placebo|
1644517|NCT01897792|Dietary Supplement|Vitamin C|
1644518|NCT01897792|Dietary Supplement|Vitamin E|
1644519|NCT01897792|Dietary Supplement|Saline (for Vitamin C)|0.9% saline administered to mimic Vitamin C
1644520|NCT01897792|Drug|Placebo (for Vitamin E)|Sugar pill administered to mimic Vitamin E
1644521|NCT01897779|Drug|RPX7009|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
1644522|NCT01897779|Drug|RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
1644523|NCT01897779|Drug|Placebo|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation for cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
1644524|NCT01897779|Drug|Combination RPX7009 and RPX2014|Two (2) groups of 15 subjects (12 active and 3 placebo) are planned for evaluation in cohort 1. Cohorts 2-5, 14 subjects (11 active and 3 placebo) are planned for evaluation in each cohort. 14 subjects (12 active and 2 placebo) are planned for evaluation in cohort 6.
1644525|NCT01897766|Drug|Somatropin|0.23 mg to 0.48 mg/kg/week
1644526|NCT01897753|Drug|growth hormone|36 months
1644527|NCT01897740|Drug|sildenafil|tablets of sildenafil 20 mg 3 times a day for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight.
1644528|NCT01897727|Drug|Spironolactone|
1644529|NCT01897727|Drug|BP medication uptitration|antihypertensive medication added or uptitrated following standard of care
1644530|NCT01897714|Drug|Melflufen|
1644531|NCT01897714|Drug|Dexamethasone|
1644532|NCT01897701|Biological|Monovalent Avian Influenza VLP (H7N9)|
1644533|NCT01897701|Biological|Adjuvant 1|
1644534|NCT01897701|Biological|Placebo|
1644535|NCT01897688|Biological|Islet Cell Transplant|
1644536|NCT01897675|Procedure|Incision and Drainage with packing (wick) placement|
1644537|NCT01897675|Procedure|Abscess drainage with loop placement|
1644538|NCT01897662|Dietary Supplement|NUTRIOSE FB06|14g/day NUTRIOSE FB06: 7g in 250 mL orange juice twice a day
1644539|NCT01897662|Dietary Supplement|GLUCIIDEX 21|7g/day GLUCIDEX 21 : 3.5g in 250 mL orange juice twice a day
1644540|NCT01897649|Dietary Supplement|NUTRIOSE FB06|15g/day NUTRIOSE FB06
1644541|NCT01897649|Dietary Supplement|GLUCIDEX 21|15g/day GLUCIDEX 21
1644542|NCT01897636|Procedure|EUS-guided fine-needle injection of DCs vaccinations|
1644543|NCT01897623|Other|ultrasound of aorta|
1644544|NCT01897610|Drug|Immuncell-LC|intravenous dripping of 200ml(10^9~2x10^10 lymphocytes/60kg adult) for 1 hour
1644545|NCT01897597|Drug|BI 144807 high dose|oral solution
1644546|NCT01897597|Drug|BI 144807 intermediate dose|tablet
1644547|NCT01897597|Drug|BI 144807 intermediate dose|tablet
1644548|NCT01897597|Drug|BI 144807 intermediate dose|tablet
1644549|NCT01897597|Drug|BI 144807 intermediate dose|tablet
1644550|NCT01897597|Drug|BI 144807 intermediate dose|oral solution
1644551|NCT01897597|Drug|BI 144807 high dose|tablet
1644552|NCT01897584|Other|inverse IE|in only one group changes of I:E ratio would be applied
1644553|NCT01897571|Drug|Tazemetostat|
1644554|NCT01897558|Device|Pacemaker implantation|
1644555|NCT01897545|Procedure|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
1644556|NCT01897545|Procedure|PV isolation+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.
After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
1644557|NCT01897532|Drug|Placebo|placebo matching tablets
1644558|NCT01897532|Drug|Linagliptin|
1644559|NCT01897519|Drug|Placebo|Placebo infusion
1644565|NCT01897467|Behavioral|Wii Fit|Exercises to be done on the Wii Fit include: warrior pose, half-moon pose, lunges, side lunges, balance bubble, ski slalom, soccer heading, and table tilt.
1644566|NCT01897467|Behavioral|Wait-List Control|Participants maintain currently physical activity and diet habits for 12 weeks. They have the option to participate in the intervention at the end of the 12-week period, but it is not mandatory.
1644567|NCT01897454|Drug|Fluorouracil|Given IV
1644568|NCT01897454|Drug|Gemcitabine Hydrochloride|Given IV
1644569|NCT01897454|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1644570|NCT01897454|Drug|Irinotecan Hydrochloride|Given IV
1644571|NCT01897454|Drug|Leucovorin Calcium|Given IV
1644572|NCT01897454|Drug|Oxaliplatin|Given IV
1644573|NCT01897441|Drug|Cyclophosphamide|Given IV
1644574|NCT01897441|Other|Cytology Specimen Collection Procedure|Correlative studies
1644575|NCT01897441|Drug|Doxorubicin Hydrochloride|Given IV
1644576|NCT01897441|Other|Laboratory Biomarker Analysis|Correlative studies
1644577|NCT01897441|Drug|Paclitaxel|Given IV
1644578|NCT01897441|Biological|Trastuzumab|Given IV
1644579|NCT01897428|Drug|Test-Bepotastine salicylate 9.64 mg|
1644580|NCT01897428|Drug|Reference-bepotastine besilate 10 mg|
1644581|NCT01897415|Biological|Autologous T cells transfected with chimeric anti-mesothelin immunoreceptor SS1|
1644582|NCT01897402|Biological|Test Vaccine|NmVac4-A/C/Y/W-135-DT™ conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each of Serogroup A, C, W-135, and Y PS conjugated to approximately 26 µg total diphtheria toxoid.
1644583|NCT01897402|Biological|US Licensed Vaccine|Meningococcal (Groups A,C,Y,W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135 and Y conjugated to approximately 48 µg total diphtheria toxoid.
1644584|NCT01897389|Drug|Treatment A|1000 mg abiraterone acetate (4 250-mg tablets - current commercial formulation, reference drug) administered as a single oral dose under fasted conditions
1644585|NCT01897389|Drug|Treatment B|1000 mg abiraterone acetate (4 250-mg tablets - new formulation) administered as a single oral dose under fasted conditions
1644586|NCT01897389|Drug|Treatment C|1000 mg abiraterone acetate (2 500-mg tablets - new formulation) administered as a single oral dose under fasted conditions
1644587|NCT01897389|Drug|Treatment D|1000 mg abiraterone acetate (4 250-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
1644588|NCT01897389|Drug|Treatment E|1000 mg abiraterone acetate (2 500-mg tablets - same composition as current commercial formulation) administered as a single oral dose under fasted conditions
1644589|NCT01897376|Procedure|Pfannenstiel incision|Pfannenstiel incision at time of cesarean section
1644590|NCT01897376|Procedure|vertical skin incision|vertical skin incision at time of cesarean section
1644591|NCT01897363|Other|Infants with Prader-Willi Syndrome|Participants will be admitted to the outpatient clinical research center for IV placement, blood draws from the IV, poking the participants finger to obtain small amounts of blood and monitored 6 hour fast.
1644592|NCT01897350|Other|Cardiac magnetic resonance imaging|
1644593|NCT01897337|Drug|Aprepitant|We administrate aprepitant with small amount of water to aprepitant group in pre treatment room. (Before patient get in the operating room)And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
1644594|NCT01897337|Drug|placebo|Patient in placebo group will be given Placebo in the PTR. And we administrate ondansetron 4mg to both group 20 minutes before the end of surgery.
1644595|NCT01897324|Drug|Growth hormone (Norditropin, Novo nordisk)|
1644596|NCT01897311|Device|transcutaneous electrical nerve stimulation|
1644597|NCT01897298|Behavioral|Urban training|Recommendation to walk a minimum of 5 days per week in urban walkable trails appropriate for the patient.
1644598|NCT01897285|Device|AQUACEL® foam adhesive dressing|
1644599|NCT01897272|Behavioral|Splinting|One group will have their wrist splinted after their carpal tunnel release surgery.
1644600|NCT01897259|Drug|Placebo Injection|Participants in the placebo group will recieve placebo injections (1cc 1% lidocaine and 1cc normal saline).
1644601|NCT01897259|Behavioral|Physical Therapy|Subjects participating in the physical therapy group will attend physical therapy and be prescribed to NSAIDS. No prolotherapy or corticosteroid injections.
1644602|NCT01897259|Drug|Corticosteroid Injections|Participants in the corticosteroid group will recieve corticosteroid injections (1 cc Kenalog 10 mg). They will also recieve anesthetic of 1 ml 1% lidocaine.
1644603|NCT01897259|Drug|Prolotherapy|Subjects participating in the prolotherapy group will recieve 1 cc 50% Dextrose and Sodium Morrhuate 1 cc injections.
1644604|NCT01897246|Procedure|Corrective osteotomy with computer-assisted pre-operative planning|The corrective osteotomy will be planned with computer-assisted pre-operative planning and virtual osteotomy.
1644605|NCT01897246|Procedure|Corrective osteotomy with conventional preoperative planning|The corrective osteotomy will be planned with conventional preoperative planning.
1644606|NCT01897233|Drug|Lumacaftor|
1644607|NCT01897233|Drug|Ivacaftor|
1644609|NCT01897181|Device|Hearing aids|Using hearing aids for 12 months
1644610|NCT01897168|Device|No intervention|
1644611|NCT01897155|Other|SBP 20-30% over baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% over the baseline. The upper limit of systolic blood pressure is 165 mmHg.
1644612|NCT01897155|Other|SBP 20-30% under baseline|Patients were assigned to receive a phenylephrine infusion in order to maintain systolic blood pressure (SBP) 20% to 30% below the baseline. The lower limit of systolic blood pressure is 75 mmHg
1644613|NCT01897142|Biological|PF-05230907|0.1 micrograms per kilogram of PF-05230907, IV bolus, single dose
1644614|NCT01897142|Drug|Placebo for PF-05230907|0.1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
1644615|NCT01897142|Biological|PF-05230907|0.3 micrograms per kilogram of PF-05230907, IV bolus, single dose
1644660|NCT01896856|Drug|TAS-102|
1644618|NCT01897142|Drug|Placebo for PF-05230907|1 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
1644619|NCT01897142|Biological|PF-05230907|2 micrograms per kilogram of PF-05230907, IV bolus, single dose
1644620|NCT01897142|Drug|Placebo for PF-05230907|2 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
1644621|NCT01897142|Biological|PF-05230907|3 micrograms per kilogram of PF-05230907, IV bolus, single dose
1644622|NCT01897142|Drug|Placebo for PF-05230907|3 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
1644623|NCT01897142|Biological|PF-05230907|5 micrograms per kilogram of PF-05230907, IV bolus, single dose
1644624|NCT01897142|Drug|Placebo for PF-05230907|5 micrograms per kilogram of placebo for PF-05230907, IV bolus, single dose
1644625|NCT01897116|Drug|Hydroxychloroquine (HCQ)|
1644626|NCT01897116|Drug|Vemurafenib (VEM)|
1644627|NCT01897090|Other|Elimination Diet|
1644628|NCT01897090|Other|Dietary Guidelines for Americans|
1644629|NCT01897077|Drug|Peanut Dissolving Film|
1644630|NCT01897064|Behavioral|Aerobic Exercise|36 sessions of aerobic exercise (12 weeks of 3 times/week, 60-minute exercise sessions) in small groups (3-5 individuals), in addition to standard psychiatric care.
1644631|NCT01897064|Other|Standard Psychiatric Treatment|Standard psychiatric treatment.
1644632|NCT01897051|Drug|Rifaximin + propranolol|"Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)
Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.
(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).
If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
1644633|NCT01897051|Drug|Propranolol + Placebo|"Placebo of Rifaximin : taking 400mg three times a day in the study period (total 1,200 mg per day)
Propranolol : taking 40mg twice a day to start. If patient is tolerable and systolic blood pressure is above 90 mmHg, the dosage can be increased by doubling to every other day upto the 360mg per day.
(Target heart rate : 25% reduction in baseline heart rate or at least 55 times per minute).
If patient is not tolerable, we can reduce the dosage step-by-step until the adverse symptoms is disappeared."
1644634|NCT01897038|Drug|Onartuzumab|Onartuzumab intravenous infusion at a starting dose of 10 or 15 milligram per kilogram body weight administered every 3 weeks (Q3W) until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
1644635|NCT01897038|Drug|Sorafenib|Sorafenib 400 milligram (mg) tablets (2 tablets of 200 mg each) orally once daily or twice daily depending on the cohort assigned until disease progression or unacceptable toxicity occurs (maximum up to 31 months).
1644636|NCT01897025|Device|real-tDCS with MI-BCI|As in Arm Description
1644637|NCT01897012|Drug|Alisertib|Given PO
1644638|NCT01897012|Other|Laboratory Biomarker Analysis|Correlative studies
1644639|NCT01897012|Drug|Romidepsin|Given IV
2012549|NCT01892371|Drug|Cytarabine|"Phase I Starting Dose: 20 mg subcutaneously twice a day for 10 days of a 28 day cycle as determined by the treating physician.
Phase II Starting Dose: Maximum tolerated dose from Phase I."
1644644|NCT01896973|Device|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment/therapy to be delivered by the surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the end of the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
1644645|NCT01896960|Drug|Bupivacaine with 15 micrograms of fentanyl|Testing 2 doses of Bupivacaine (12.5 mg and 15 mg) with 15 micrograms fentanyl
1644646|NCT01896934|Drug|Sertraline|50-200mg daily
1644647|NCT01896921|Drug|Switch to Maraviroc + Raltegravir or Dolutegravir|Change HIV-infected patients on stable, suppressed ART regimens for at least 1 year to experimental regimen of Maraviroc + Raltegravir or Dolutegravir for 48 weeks
1644648|NCT01896908|Other|Sodium restriction|"Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY __ / __ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.
The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis."
1644649|NCT01896895|Drug|IncobulinumtoxinA (Xeomin), 25 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 25 Units per eye.
1644650|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 12.5 Units|IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Main Period: 12.5 Units per eye.
1644651|NCT01896895|Drug|Placebo|Main Period: Placebo to IncobotulinumtoxinA (Xeomin), powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
1644652|NCT01896895|Drug|IncobotulinumtoxinA (Xeomin), 35 Units|"IncobotulinumtoxinA (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
Open-Label Extension: up to 35 Units per eye."
1644653|NCT01896882|Other|Sodium restriction|
1644654|NCT01896869|Drug|Ipilimumab|3 mg/kg administered IV (10mg/kg if treatment started prior to protocol v 6.3)
1644655|NCT01896869|Biological|Vaccine|5x10^8 cells administered in 6 intradermal injections
1644656|NCT01896869|Drug|FOLFIRINOX|Standard of care FOLFIRINOX may be modified according to the patient's known tolerability. Acceptable modified options could include 5-FU alone, capecitabine, FOLFOX, FOLFIRI, or FOLFIRINOX on a 21 day cycle.
1644657|NCT01896856|Drug|SGI-110|
1644658|NCT01896856|Drug|Irinotecan|
1644662|NCT01896830|Biological|Clostridium difficile Toxoid Vaccine|0.5 mL, intramuscular
1644663|NCT01896830|Biological|0.9% normal saline|0.5 mL, intramuscular
1644664|NCT01896791|Procedure|Transcranial Direct Current Stimulation|Active Transcranial Direct Current Stimulation : the anode electrode is placed in the area of the motor cortex M1 C3 or C4 position of the dominant hemisphere (International 10-20 EEG System). The cathode electrode is placed over the contralateral supraorbital region to the anode electrode. Treatment time and intensity of the stimulus: tDCS: 2 mili Ampere, 20min, 10 days.
1644665|NCT01896791|Procedure|Sham Stimulation|Sham Stimulation- appliance off during the entire period without active stimulation, with the position of the electrodes in the same sites of active stimulation
1644666|NCT01896778|Procedure|Hyperthermia Treatment|Undergo B-WARM
1644667|NCT01896778|Other|Laboratory Biomarker Analysis|Correlative studies
1644668|NCT01896765|Behavioral|Intensive Prevention Program|"Study nurse-coordinated education sessions, telephone calls, telephone hotline and telemetric care of cardiovascular risk factors (if patient internet connection available)."
1644669|NCT01896765|Other|Standard medical and interventional therapy|Medical and interventional therapy following the standard of care.
1644670|NCT01896739|Biological|Eutravac|
1644671|NCT01896726|Drug|Baricitinib|Administered orally
1644672|NCT01896726|Drug|Microgynon|Administered orally
1644673|NCT01896713|Other|MS3TMRI|Multispectral 3 Tesla MRI imaging with contrast followed by biopsy
1644676|NCT01896687|Device|Scrambler|Electrotherapy
1644677|NCT01896661|Drug|Diuretics|Chlorthalidone plus amiloride 25 and 5 mg daily, taking in the morning
1644678|NCT01896661|Drug|Calcium Channel Blockers|Amlodipine 10 mg daily, taking in the morning
1644679|NCT01896635|Biological|FMT infusions|Active FMT derived from healthy anonymous pre-screened donors
1644680|NCT01896635|Other|Placebo infusion|Placebo infusion not containing any donor microbial material
1644681|NCT01896622|Drug|Ritonavir|Impact on dabigatran PK/PD
1644682|NCT01896622|Drug|Cobicistat|Impact on dabigatran PK/PD
1644683|NCT01896609|Biological|Reiferon Retard in Arm 1|Arm 1,2,3 Reiferon Retard® 160 µg /week subcutaneous injection for 48 weeks
1644684|NCT01896609|Drug|Bon one in Arm 3|Arm 3 , Bon One ® 0.5 µg daily orally for 48 weeks
1644685|NCT01896609|Drug|Xerovirinc in Arm 2|Arm 2,3 Xerovirinc® 500mg twice daily orally for 48 weeks
1644686|NCT01896609|Drug|Ribavirin in Arm 1|Arm 1,2,3 Ribavirin in a dose of 13 mg/kg/day orally for 48 weeks
1644687|NCT01896596|Biological|Menjugate|Administered with routine vaccinations at 3 months of age
1644688|NCT01896596|Biological|Menitorix|Administered with routine vaccinations at 3 months
1644689|NCT01896596|Biological|NeisVac-C|Administered with routine vaccinations at 3 months
1644690|NCT01896583|Drug|ASP7147|300 mg, tablet, twice per day for 4 weeks oral
1644691|NCT01896583|Drug|Placebo|
1644692|NCT01896570|Procedure|Catheter ablation of subsequent atrial tachycardia|
1644693|NCT01896557|Drug|omeprazole|Influence of omeprazole on clopidogrel pharmacodynamics will be evaluated.
1644694|NCT01896557|Drug|Ranitidine|Influence of ranitidine on clopidogrel pharmacodynamics will be evaluated.
1644695|NCT01896557|Drug|Clopidogrel|Clopidogrel added to ASA therapy at the first medical visit
1644696|NCT01896544|Dietary Supplement|Cholecalciferol|7ml syringe of cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
1644697|NCT01896544|Dietary Supplement|Placebo|7ml syringe of placebo cholecalciferol suspension given through nasogastric (NG) or orogastric (OG) tube
1644698|NCT01896531|Drug|5-Fluorouracil|Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.
1644699|NCT01896531|Drug|GDC-0068|Participants will receive GDC-0068, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
1644700|NCT01896531|Drug|Leucovorin|Participants will receive leucovorin or equivalent substitute orally, on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity.
1644701|NCT01896531|Drug|Oxaliplatin|Participants will receive oxaliplatin via intravenous (IV) infusion on Day 1 of each 14-day cycle (part of mFOLFOX6 therapy). Oxaliplatin will be discontinued after completion of 8 cycles
1644702|NCT01896531|Drug|Placebo|Participants will receive matching oral placebo capsules once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
1644703|NCT01896518|Drug|Nicotine polacrilex|
1644704|NCT01896518|Drug|Tobacco lozenge|
1644705|NCT01896505|Drug|KCP-330|
1644706|NCT01896492|Drug|NAC|NAC 2gm plus cc 100mg from 3rd day of the cycle till day 8 with u/s follow up of the follicular growth.
1644707|NCT01896479|Drug|Cabozantinib (XL184) 140 mg|
1644708|NCT01896479|Drug|Cabozantinib (XL184) 60 mg|
1644709|NCT01896479|Drug|Placebo tablet|
1644710|NCT01896479|Drug|Placebo capsule|
1644711|NCT01896466|Device|Cranial Nerve Non-Invasive Neuromodulation|Portable device delivers electrical stimulation to cranial nerves V and VII via an electrode array placed on the anterior surface of the tongue. Stimulation is combined with rehabilitation exercises targeting walking and balance.
1644712|NCT01896466|Behavioral|Sham Cranial Nerve Non-Invasive Neuromodulation|Subjects participate in gait and balance rehabilitation exercises while using a device set to sub-threshold levels.
1644713|NCT01896453|Procedure|Transcranial direct current stimulation (tDCS)|Technique based on the application of weak, direct electrical current to the brain through relatively large electrodes that are placed over the scalp, in which anodal and cathodal stimulation increases and decreases cortical excitability, respectively
1644714|NCT01896453|Procedure|Transcutaneous electrical nerve stimulation (TENS)|Technique based on the application of low-voltage electrical current to the skin through relatively large electrodes that are placed over the pain area.
1717382|NCT00002072|Drug|Epoetin alfa|
1644715|NCT01896440|Drug|Ondansetron|There will be two doses investigated in each arm - standard dose (0.15 mg/kg) and high dose (0.3 mg/kg)
1644716|NCT01896427|Drug|21-benzyloxy-9alpha-fluoro-16alpha-methylpregna-1,4-dien-11beta,17alpha-diol-3,20-dione|single dose of dexamethasone (8mg) will injected
1644717|NCT01896414|Dietary Supplement|EPA (marine fatty acids)|Subjects will be randomized to receive either EPA or placebo, four 1 gram capsules daily.
1644718|NCT01896414|Dietary Supplement|Placebo|Subjects will be randomized to receive either EPA/ or placebo, four 1 gram capsules daily.
1644719|NCT01896401|Device|InSeal's Vascular Closure Device|
1644720|NCT01896388|Drug|Ifenprodil Tartrate|
1644721|NCT01896388|Drug|Placebo|
1644722|NCT01896349|Other|IPT+ antidepressant drugs|16 sessions of interpersonal psychotherapy plus antidepressant drugs.
1644723|NCT01896349|Drug|fluoxetine|Antidepressant drugs, clinician´s free choice oriented by guidelines. Monotherapy or combinations are allowed
1644724|NCT01896349|Drug|sertraline|
1644725|NCT01896349|Drug|paroxetine|
1644726|NCT01896349|Drug|Citalopram|
1644727|NCT01896349|Drug|escitalopram|
1644728|NCT01896349|Drug|fluvoxamine|
1644729|NCT01896349|Drug|Venlafaxine|
1644730|NCT01896349|Drug|Duloxetine|
1644731|NCT01896349|Drug|Bupropion|
1644732|NCT01896349|Drug|Lithium|
1644733|NCT01896349|Drug|Risperidone|
1644734|NCT01896349|Drug|tranylcypromine|
1644735|NCT01896349|Drug|Imipramine|
1644736|NCT01896349|Drug|amitriptyline|
1644737|NCT01896349|Drug|Clomipramine|
1644738|NCT01896349|Drug|nortriptyline|
1644739|NCT01896349|Drug|trazodone|
1644740|NCT01896349|Drug|Mirtazapine|
1644741|NCT01896349|Drug|sulpiride|
1644742|NCT01896336|Drug|Zolpidem Hemitartrate|"Patz - 5mg sublingual zolpidem hemitartrate
1 QD
Stilnox - 10mg oral zolpidem hemitartrate
1 QD"
1644743|NCT01896323|Drug|CC-223|CC-223 20 mg tablets
1644744|NCT01896323|Drug|Ketoconazole|Ketoconazole 400 mg tablets
1644745|NCT01896310|Device|probe-based confocal laser endomicroscopy|all patients will receive pCLE examination
1644746|NCT01896297|Drug|Pradaxa, dabigatran etexilate|75mg BID by oral
1644747|NCT01896284|Drug|0.5mg aflibercept|0.5mg aflibercept intravitreal injection will be performed every 4 weeks from baseline to week 8 (3 doses) and every 8 weeks until week 32.
1644748|NCT01896271|Drug|IL-2|HD IL-2 (brand name Proleukin), 600,000 U/kg q8h X 14 dose, IV infusion
1644749|NCT01896271|Radiation|Stereotactic Ablative Body Radiation Therapy|SABR dose varying from 8Gy-20Gy in 1-3 fractions
1644750|NCT01896245|Drug|sevoflurane 1,0|anesthesia induction with propofol, remifentanil, and sevoflurane 1,0 MAC; afterwards tracheal intubation
1644751|NCT01896245|Drug|sevoflurane 1,2|anesthesia induction with propofol, remifentanil, and sevoflurane 1,2 MAC; afterwards tracheal intubation
1644752|NCT01896245|Drug|sevoflurane 1,4|anesthesia induction with propofol, remifentanil, and sevoflurane 1,4 MAC; afterwards tracheal intubation
1644753|NCT01896232|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg, titrated up to 15 mg based on serum PTH and corrected calcium levels.
1644754|NCT01896232|Drug|Cinacalcet|Cinacalcet was administered orally once a day. The starting dose was 30 mg daily, titrated up to 180 mg daily based on serum PTH and corrected calcium levels.
1644755|NCT01896232|Drug|Oral Placebo|Administered orally once a day.
1644756|NCT01896232|Drug|Intravenous Placebo|Administered intravenously (IV) three times per week.
1644757|NCT01896219|Device|Navigation station (IMACTIS-CT®)|
1644758|NCT01896219|Device|CT|Reference method for gestures (carried out under CT) guidance
1644759|NCT01896206|Device|CNAP monitor|Patients undergoing bariatric surgery and being monitored using the CNAP monitor.
1644760|NCT01896193|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
1644761|NCT01896193|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose using weight-based dosing (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1644762|NCT01896180|Drug|ALZ-1101|ALZ-1101 Ophthalmic Solution
1644763|NCT01896180|Drug|Latanoprost|Latanoprost 0.005% Ophthalmic Solution
1644764|NCT01896167|Other|Hypoxia|Inhalation of hypoxic air (8-12% oxygen content)
1644765|NCT01896167|Other|Placebo|Inhalation of atmospheric air
1644766|NCT01896154|Dietary Supplement|NPS|Comparison of multiple dietary non-digestible polysaccharides
1644767|NCT01896128|Drug|Armodafinil|
1644768|NCT01896128|Drug|Placebo|inactive pill manufactured to mimic Armodafinil 150 mg tablet
1644769|NCT01896115|Device|Vercise DBS settings|Deep brain stimulation set at short pulse width and monopolar stimulation using current steering
2012550|NCT01892371|Drug|AZA|"Phase I Starting Dose: 75 mg/m2 subcutaneously or intravenously for 7 days of every 28 day cycle (Days 1-7), as determined by the treating physician.
Phase II Starting Dose: Maximum tolerated dose from Phase I."
1644771|NCT01896076|Other|ultrasound evaluation of caudal space|"After induction of general anesthesia, the patients were placed in the lateral position. The ultrasound evaluation include transverse and longitudinal view.
First, investigators place the transducer at the sacral cornua to obtain a transverse view.
In the transverse view, the distance between two cornua and the depth of caudal space at the sacral hiatus were measured. In the longitudinal view, the distance from the skin to the sacrococcygeal membrane and the optimal angles and the safety distance for needle insertion depending on the points of insertions were measured. From the end of dura sac to the sacral hiatus were regarded as safety distance for the needle insertion during caudal block."
1644772|NCT01896063|Procedure|Electroacupuncture|
1644773|NCT01896050|Drug|anastrozole, letrozole, exemestane|Patients were treated with one of the listed anti-hormonal medications for up to one year
1644774|NCT01896050|Drug|Tamoxifen|Patients were treated with tamoxifen for up to one year
1644775|NCT01896037|Dietary Supplement|Omega-3 supplements|Daily omega-3 supplements of 600 mg EPA (Eicosapentaenoic acid) and 300 mg DHA (Docosahexaenoic acid) for 5 months.
1644776|NCT01896024|Behavioral|Psychiatric Management|
2012551|NCT01892319|Drug|insulin detemir|Patients will be treated according to routine clinical practice at the discretion of the treating physician
1644777|NCT01896024|Behavioral|Motive-oriented therapeutic relationship/Plan Analysis|
1644778|NCT01896011|Biological|Teriparatide 20 mcg|Teriparatide 20 mcg injection pen
1644779|NCT01896011|Other|Placebo|Placebo 20 mcg injection pen
1644780|NCT01895998|Drug|Albuterol|This medication will be used as routine part of pulmonary function testing to assess for airway hyperreactivity. This is routinely done in a clinical capacity for pediatric patients with various pulmonary disease processes.
1644781|NCT01895985|Drug|Latanoprostene bunod|
1644782|NCT01895972|Drug|Latanoprostene bunod|
1644783|NCT01895959|Drug|Euflexxa|Euflexxa will be injected weekly for 3 consecutive weeks on the knee joint.
1644784|NCT01895959|Device|Magnetic Resonance Imaging (MRI)|MRI of the knee will be acquired during baseline (a week prior to the treatment), follow up visit 1 (1 week after treatment) and follow up visit 2 (3 months after treatment).
1644785|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off: tablet formulation for one week, followed by two weeks with capsule formulation.
1644786|NCT01895946|Drug|AZD5363|Oral AZD5363 twice daily, 4 days on 3 days off, tablet formulation. On day 4 AZD5363 tablet without food. On day 11 AZD5363 tablet with food.
1644787|NCT01895933|Device|5ml surgishield|"in the case of active, apply solution type adhesion barrier to merocel and pack 5ml of adhesion inhibitor Surgi Shield on the surgical site
merocel in the inflated state maintained for 36~48 hours, remove packing then solution type adhesion inhibitor is to be injected in to the surgical site"
1644788|NCT01895920|Other|Blood sample|
1644789|NCT01895894|Drug|Mycophenolate mofetil|Mycophenolate mofetil 20~30mg/kg/day PO until nephrotic syndrome relapse (max. 1 year)
1644790|NCT01895881|Drug|Estradiol|
1644791|NCT01895881|Drug|Placebo|
1644792|NCT01895868|Other|Simulation-based ultrasound training|
1644793|NCT01895855|Biological|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
1644794|NCT01895855|Biological|placebo|
1644795|NCT01895842|Drug|Ruxolitinib|"Starting dose level for Part 1: 5 mg by mouth twice a day for a 28 day cycle.
Starting dose level for Part 2: Maximum tolerated dose from Part 1."
1644796|NCT01895829|Procedure|Magnetic Resonance Imaging (MRI)|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein. Right after that, first study MRI performed. On Day 2, about 24 hours after patient receives ferumoxytol, second study MRI performed.
1644797|NCT01895829|Drug|Ferumoxytol|On Day 1, patient will have 2 standard MRIs, as part of standard of care. About an hour after these 2 scans, patient receives ferumoxytol by vein.
1644798|NCT01895816|Dietary Supplement|coated tablet|this supplement contains 700 mg of 8 natural herbals: Citrus & ZINGIBER OFFICINALE & Onion & Ocimum basilicum & Cinnamomum zelanicum & Citrullus lanatus & Citrullus vulgaris & Daucus carota
1644799|NCT01895790|Device|Pancreatic Duct Stent Placement|
2012552|NCT01892319|Drug|other injectable antidiabetic treatment regimens|Patients will be treated according to routine clinical practice at the discretion of the treating physician
2012553|NCT01887600|Drug|Roxadustat|tablet
1644802|NCT01895764|Drug|Adalimumab|adalimumab, subcutaneous injection, 40mg every 2 weeks, week 0 until week 26
1644803|NCT01895764|Drug|Methotrexate|methotrexate, subcutaneous injection, 10mg per week, week -2 until week 26
1644804|NCT01895751|Procedure|Invasive management|Invasive management includes coronary and graft angiography (diagnostic imaging test) and coronary and/or graft revascularization with percutaneous coronary intervention (PCI) and/or coronary artery bypass graft (CABG), as clinically appropriate.
1644805|NCT01895738|Behavioral|WrapAround Care|Wraparound care is an established care model that starts with linking an individual with a support￼￼￼ worker who works with them to address risk factors and enable the individual to make positive choices. It is hypothesized that by working with youth to address the risk factors in their control, the likelihood of future violence is reduced.
1644806|NCT01895699|Other|Contrast agent|
1644807|NCT01895673|Other|Gadolinium|All patients will undergo PET-MRI additional to the PET-CT they routinely undergo. All patients will be administered Gadolinium for the PET-MRI scan. This is an extra intervention than they would normally undergo.
1644808|NCT01895660|Behavioral|Variations in Pediatric Constraint-Induced Movement Therapy (P-CIMT) versus usual and customary rehabilitation|Types of constraint and dosage amounts will be varied.
2012554|NCT01887600|Drug|Placebo|tablet
1644810|NCT01895634|Device|Rev-01|Treatment arm patients have used Rev-01 at least once
1644811|NCT01895621|Procedure|Median nerve decompression at the wrist|Surgical incision of the carpal ligament at the wrist and proximal hand to decompress the median nerve.
1644812|NCT01895621|Dietary Supplement|Alpha lipoic acid post median nerve decompression|Daily supplementation of alpha lipoic acid
1644813|NCT01895608|Behavioral|Balance rehabilitation + dual-tasking|Balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands with the addition of cognitive tasks, (e.g., counting backwards or reciting lists) to be added when the participant
1644814|NCT01895608|Behavioral|Standard balance rehabilitation|Standard balance rehabilitation will involve a structured framework of balance activities that require increasing levels of complexity and multimodal stimuli and response demands.
1644815|NCT01895608|Behavioral|Cognitive training (speed of processing)|Speed of processing cognitive training involves systematically increasing the complexity of visual tasks. Task demands are increased by reducing stimulus duration, adding visual or auditory distractors, increasing number of concurrent tasks or increasing the visual field.
1644816|NCT01895608|Behavioral|Cognitive training (general cognition)|General cognitive training involves systematic training of 14 key cognitive abilities, including visual scanning, response time, eye-hand coordination, spatial perception, and working memory. Initial starting point is determined by the software using baseline evaluation.
1644817|NCT01895595|Behavioral|Guided Imagery|
1644818|NCT01895595|Behavioral|Digital Storytelling|
1644868|NCT01895205|Drug|Red blood cell transfusion|
2012555|NCT01886872|Drug|Bendamustine Hydrochloride|Given IV
2012556|NCT01886872|Drug|Ibrutinib|Given PO
2012557|NCT01886872|Other|Laboratory Biomarker Analysis|Correlative studies
1644819|NCT01895582|Other|Blood samples|"4 blood tubes of lithium heparinate (5ml) 3 blood tubes of QTF-G-IT (1ml)
1 blood dry tube (5ml)"
1644820|NCT01895569|Drug|Metformin|Metformin will be added to therapy for the first threre months.
1644821|NCT01895569|Drug|Pioglitazone|In patients not well controlled (glycated hemoglobin >6.5%) after three months of metformin, pioglitazone will be added.
1644822|NCT01895569|Drug|Sitagliptin|In patients not well controlled (glycated hemoglobin >6.5%) after three months of metformin and pioglitazone, sitagliptin will be added.
1644823|NCT01895556|Other|Information|
1644824|NCT01895556|Other|Control|
1644825|NCT01895543|Drug|Elobixibat 10 mg|10 mg Elobixibat daily, with possibility for dose adjustment to 5 mg daily.
1644826|NCT01895530|Dietary Supplement|Saccharomyces boulardii|The patients received one oral lyophilized yeast capsule, each of which contains 100 mg (0,5 x 109 cfu/g) of Saccharomyces boulardii (Merck S.A., Biocodex, Beauvais, French), once a day. The treatment started at least seven days before surgery and stopped on the operation day.
1644827|NCT01895517|Other|LBC|Cervical cancer screening by using liquid based cytology as a standard screening modality
1644828|NCT01895517|Other|LBC plus HPV DNA testing|Cervical cancer screening by using liquid based cytology plus HPV DNA testing as an experimentally screening modality
1644829|NCT01895504|Device|ColoAssist|Screening colonoscopy with the test instrument
1644830|NCT01895504|Device|MEI|Colonoscopy with Olympus colonoscopes and MEI guidance
1644831|NCT01895491|Biological|VM206DNA|
1644832|NCT01895491|Biological|VM206Ad|
1644833|NCT01895478|Behavioral|PACCI-ED use|Attending physicians were allowed to view the patient's PACCI-ED prior to completing the assessment form. Attendings were told at the time of the child's ED visit that the PACCI-ED is used to assess a child's asthma control and medication adherence, and that they could use it to complete the outcomes assessment form.
1644834|NCT01895465|Device|Slitted diaper|A diaper where a slit is made through which a urine collection bag is pulled through
1644835|NCT01895452|Drug|ALKS 9072, Low Dose|Intramuscular injection, given monthly
1644836|NCT01895452|Drug|ALKS 9072, High Dose|Intramuscular injection, given monthly
1644837|NCT01895439|Biological|Autologous Mesenchymal Stem Cells|
1644838|NCT01895413|Procedure|Bone marrow aspiration|Single intra-articular injection of autologous bone marrow-derived mesenchymal stem cells by arthroscopy
1644839|NCT01895400|Drug|Renexin (cilostazol 100mg + gingko biloba extract 80 mg)|Take Renexin 1T bid po medication for 8 weeks
1644840|NCT01895400|Drug|Placebo|Take placebo drug 1T bid po medication for 8 weeks
1644841|NCT01895387|Dietary Supplement|Dietary intervention-whole grains and legumes|Subjects in the whole-grain group consumed replacing of refined rice intake with 1/3 of legumes, 1/3 of barley, and 1/3 of wild rice three times per day as a carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake.
1644842|NCT01895387|Dietary Supplement|Dietary intervention-Refined rice|Subjects in the control group maintained their usual diet of refined rice
1644843|NCT01895374|Procedure|laser treatments|
1644844|NCT01895374|Other|amniotic membrane application|
1644845|NCT01895374|Device|hydrocolloid application|
1644846|NCT01895361|Drug|SelG1|
1644847|NCT01895361|Drug|Placebo|
1644848|NCT01895348|Drug|Propofol|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes
1644849|NCT01895348|Drug|propofol-remifentanil|Propofol TCI: effect-site concentration(Ce): Ce was titrated to 1.0 μg/ml and increased by 0.2 μg/ml every five minutes Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
1644850|NCT01895348|Drug|Dexmedetomidine-remifentanil|Dexmedetomidine infusion: After the loading dose (1 mcg/kg for 10 minutes), the continuous infusion was done (0.2 mcg/kg/hr) and the infusion rate was increased by 0.2 mcg/kg/hr every five minutes (maximum infusion rate: 1.4 mcg/kg/hr) Remifentanil TCI: effect-site concentration(Ce): Ce was titrated to 1.5 μg/ml
1644851|NCT01895335|Drug|Teriflunomide|Pharmaceutical form: film-coated tablet; Route of administration: oral
1644852|NCT01895322|Drug|OPC-41061|
1644853|NCT01895309|Drug|Enbrel (etanercept)|
1644854|NCT01895309|Drug|SB4 (proposed biosimilar to etanercept)|
1644855|NCT01895296|Drug|Pasireotide|somatostatin analogue pasireotide
1644856|NCT01895296|Drug|Placebo|placebo s.c.
1644857|NCT01895283|Behavioral|Moderate-intensity training|Training at 70% of VO2max, for 1/2 hour, three times weekly, for 10 weeks, on a bike ergometer.
1644858|NCT01895270|Drug|Isradipine|Isradipine extended release formulation
1644859|NCT01895270|Drug|Placebo|Placebo will consist of microcrystalline cellulose.
1644860|NCT01895257|Device|HAI-90Y radioembolization (SIR-spheres injection)|"Patients randomised to receive the combination of SIR-Spheres microspheres plus systemic chemotherapy LV5FU2 need to be assessed in order to determine their suitability for SIRT.
Hepatic Angiogram
Liver-Lung Break-Through Nuclear Scan"
1644861|NCT01895257|Drug|systemic chemotherapy LV5FU2|"Systemic chemotherapy with modified LV5FU2 will be administered according to the following regimen.
Cycle 1 onwards:
Day 1 Hour 0: Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion Hour + 2: 5-FU bolus 400 mg/m2, IV bolus Hour + 2: 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion Day 14 End of cycle. To be repeated every 14 days until evidence of treatment failure."
1644862|NCT01895244|Drug|Autologous stemcell transplantation with CD (cluster of differentiation) 34 selected stem cells|If no active alveolitis: mobilisation with 2x1g Cyclophosphamide If active alveolitis: mobilisation with 2x1.5g Cyclophosphamid If cardiac manifestation: Conditioning with CYC 2 x 50mg + thiotepa 2x5mg + ATG If no cardiac manifestation: Conditioning with 4 x 50mg CYC + ATG
1644863|NCT01895231|Drug|Iron isomaltoside 1000 (Monofer®)|
1644864|NCT01895231|Drug|Placebo|
1644865|NCT01895218|Drug|Iron isomaltoside 1000|A single dose of 1200 mg iron isomaltoside 1000 is given. The dose is diluted in 100 ml 0.9 % sodium chloride and given over approximately 15 min.
1644866|NCT01895218|Other|Standard medical Care|Standard medical Care is most often to recommend women with PPH to continue oral iron supplementation as recommended during pregnancy or to advise the subject to take 100 mg oral iron 1-2 times a day
1644867|NCT01895205|Drug|Iron isomaltoside 1000|
1644869|NCT01895192|Other|Assessment of sperm morphology (contrast microscopy).|Sperm head vacuoles were analyzed on 100 spermatozoa that were randomly photographed and separately analyzed using digital imaging system software. Interactive Measurement module allows measurement of sperm head areas and vacuole areas by manually depicting their outline. The area and position of each vacuole were recorded. Relative vacuole area is the ratio of the area of all the vacuoles of a spermatozoon to the area of its head.
1644870|NCT01895179|Other|Time-Restricted Feeding|Time-restricted feeding is a variant of intermittent fasting that involves eating all of one's calories within a few hours each day (typically 4-9 hours), followed by a daily fast of 15-20 hours.
1644871|NCT01895179|Other|Grazing|Grazing involves eating meals spread out over the course of the day.
1644872|NCT01895166|Procedure|EBUS-GS|EBUS is performed using an endoscope ultrasound system , which is equipped with a 20-MHz mechanical radial-type probe (UM-S20-17S;Olympus) with an external diameter of 1.4 mm and a GS (K-201; Olympus).
1644873|NCT01895166|Procedure|X-ray|The radiograph fluoroscopy are performed when the probe and GS are confirmed to reach the lesion by EBUS images ,cytologic and pathologic specimens are obtained under fluoroscopic guidance.
1644874|NCT01895140|Device|Renal denervation device|
1644875|NCT01895127|Drug|Eculizumab|
1644876|NCT01895127|Biological|Immunoglobulin|
1644877|NCT01895127|Procedure|Plasmapheresis|
1644878|NCT01895101|Drug|2 gr tranexamic acid|This group receives pericardial lavage with 2 gr tranexamic diluted in 200 ml normothermic saline solution (NaCl 0.9%).
1644879|NCT01895101|Drug|Saline|This group receives pericardial lavage with 200 ml normothermic saline solution without tranexamic acid
1644880|NCT01895088|Device|AcuFocus Corneal Inlay ACI 7000 PDT|Inlay implanted in cornea for improvement of near vision
1644881|NCT01895075|Drug|Inhaled budesonide|Inhaled budesonide 1 mg tid until 36 weeks' corrected gestational age or fully weaned from supplemental oxygen and respiratory support (CPAP or high flow nasal canula)
1644882|NCT01895075|Drug|Normal saline|2 ml normal saline by inhalation
1644883|NCT01895062|Device|Airway Management System (AMS)|"The AMS consists of a silicone collar applied under the mandible to the anterior surface of the neck.
The collar is attached to a vacuum source which delivers continuous negative external pressure to the upper airway."
1644884|NCT01895049|Drug|Induction therapy with Thymoglobulin, prednisone, everolimus and late introduction of tacrolimus|
1644885|NCT01895049|Drug|Induction therapy with Thymoglobulin, prednisone, mycophenolate sodium and late introduction of tacrolimus|
1644886|NCT01895036|Drug|Naltrexone|
1644887|NCT01895023|Drug|Dexmedetomidine|The dexmedetomidine group received intranasal dexmedetomidine 2mcg/kg premedication 45 min before induction of anaesthesia.
1644888|NCT01895023|Drug|Midazolam|The midazolam group oral midazolam 0.5 mg/kg 30 min before induction of anaesthesia.
1644889|NCT01895023|Drug|Saline|The Placebo group received intranasal saline premedication 45 min and oral saline 30 min before induction of anaesthesia
1644890|NCT01895010|Device|acupoint electric stimulation|acupoint electric stimulation combined with tropisetron 6mg before TACE
1644891|NCT01895010|Drug|tropisetron|only tropisetron 6mg before TACE
1644892|NCT01894997|Device|Neuromuscular electrical stimulator|
1644893|NCT01894997|Device|AV Impulse System Model 6000|
1644894|NCT01894984|Drug|Risperidone|This is an observational study. Risperidone will be administered as intramuscular injection at a starting dose of either 25 milligram (mg) or 37.5 mg or 50 mg (starting dose will be decided on the basis of the disease severity), every two weeks, up to Week 24, wherein after Week 8, dose may be increased or decreased at physician discretion. For first three weeks, previous oral antipsychotic drug (Benzodiazepines or Selective serotonin reuptake inhibitor [SSRI]) will be maintained and will cease at Week 3.
1644895|NCT01894984|Drug|Oral atypical anti-psychotic|This is an observational study. Oral atypical anti-psychotic for example, olanzapine, risperidone, quetiapine etc will be administered as per Investigator's discretion.
1644896|NCT01894971|Device|The Effect of Ligasure® to Destroy Cornual Portion of Fallopian Tube|
1644897|NCT01894958|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials or 3g in 30mL bottles) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
1644898|NCT01894958|Drug|Placebo|Strawberry flavored solution
1644899|NCT01894932|Behavioral|Mindfulness-based cognitive Group therapy|In this study, groups of Mindfulness-based cognitive psychotherapy, will based on Segal, Williams & Teasdale (2002)'s work to redesigned an eight-week group course which adapted the local Taiwanese culture and add the appropriate revision of the content in a more easy to understand learning materials available to patient. The group would lead by 2 clinical psychologist and each session is about 2 hours.
1644900|NCT01894932|Behavioral|psycho-physiological stress regulation group|Physical and psychological stress regulation group in eight weeks, mainly to provide understanding of physical and mental effects of stress factors, self-conceptualization of stress and psychosomatic symptoms, physiological adjustment (relaxation, diet, exercise), psychological adjustment (positive primary, secondary assessment, cognitive identification), adjust negative thoughts, learn coping by using new choice. The group would lead by 2 clinical psychologist and each session is about 2 hours.
2012558|NCT01886872|Other|Quality-of-Life Assessment|Ancillary studies
2012559|NCT01886872|Biological|Rituximab|Given IV
1644903|NCT01894906|Drug|Soluble Ferric Pyrophosphate|
1644904|NCT01894906|Other|Placebo|
1644905|NCT01894880|Procedure|early SSC|bonding straight after birth
1644906|NCT01894880|Procedure|late SSC|bonding after termination of operation
1644907|NCT01894867|Dietary Supplement|magnesium|supply magnesium oxide for 6 weeks
1644908|NCT01894867|Dietary Supplement|Placebo|
1644909|NCT01894854|Procedure|Stem collar|The stem has two versions, one with and one without a collar. The classical Furlong HAC had a collar.
1644910|NCT01894841|Behavioral|Coping Long Term with Active Suicide|an intervention to reduce suicide behavior in Veterans recently hospitalized for suicide attempt or ideation with intent.
1644911|NCT01894828|Dietary Supplement|Nutritional supplements|Patients are asked to drink two 200ml bottles of nutritional supplement daily for 14 days before surgery
1645034|NCT01893879|Drug|placebo for study drug|Given PO
2012560|NCT01885598|Drug|Apixaban|
1644912|NCT01894815|Drug|Escitalopram oxalate|The investigators will use 10mg and 20mg pills. The investigators will up-titrate escitalopram from 10 to 20mg/day according to the patient tolerability. The maximum dose (20mg/day) is sought to be achieved at week 3.
1644913|NCT01894815|Device|transcranial direct current stimulation|The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA, current density is 0.8 A/m2. Electrodes will be 5x5cm in size. The investigators will apply 15 daily, consecutive tDCS sessions (excluding weekends) and after that one session per week until the primary endpoint.
1644914|NCT01894815|Other|Sham tDCS + Placebo Pill|This group receives sham tDCS and placebo pill.
1644915|NCT01894802|Device|Implantation of CRS Arrays|Two Blackrock Microsystems CRS Arrays will be implanted in the motor cortex and sensory cortex of study participants.
1644916|NCT01894789|Drug|Ticagrelor|Blinded administration of ticagrelor for 10 days
1644917|NCT01894789|Drug|Clopidogrel|Blinded administration of clopidogrel and placebo for 10 days
1644918|NCT01894776|Drug|Rifabutin|Substance: Rifabutin Daily dose: oral, 300 mg once daily (8:00 am) for 10 days
1644919|NCT01894776|Drug|Maraviroc|Substance maraviroc daily dose 300 mg twice daily (8:00 am and 8:00 pm) for 15 days
1644920|NCT01894763|Device|Self-expandable metal stent|Placement of a self-expandable metal stent in the esophagus
1644921|NCT01894750|Behavioral|group-based skill building self-care program|
1644922|NCT01894737|Other|Placebo supplementation|Seven days of one-legged knee immobilisation with placebo supplementation
1644923|NCT01894737|Other|Creatine supplementation|Seven days of one-legged knee immobilisation with creatine supplementation.
1644924|NCT01894724|Device|NeuroSave device|
1644925|NCT01894711|Drug|Trastuzumab|Treatment with trastuzumab in HER2 positive patients
1644926|NCT01894685|Drug|Mesalazine|Mesalazine 3 grams, once daily for six months
1644927|NCT01894685|Drug|Placebo|Placebo 3 grams, once daily for six months
1644928|NCT01894672|Drug|LGX818|
1644929|NCT01894659|Other|24% oral sucrose|
1644930|NCT01894659|Other|30% oral glucose|
1644931|NCT01894646|Radiation|Positron Emission Tomagraphy (PET) Imaging|
1644932|NCT01894633|Drug|Chloroquine|The patients in the Chloroquine group received 30 Gy of total brain radiotherapy in 10 daily fractions from Monday to Friday. Furthermore, the Chloroquine plus WBI arm received a daily single dose of 150 mg CLQ po 1 hour prior to the radiation treatment, beginning during the first radiotherapy fraction and continuing for 28 days
1644933|NCT01894633|Radiation|Total brain radiotherapy|30 Gy in 10 daily fractions from Monday to Friday
2012561|NCT01886222|Other|Long-term mild hypothermia|Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
2012562|NCT01886222|Other|Normothermia|Patients assigned to the normothermia group will be kept at 36-37℃.
1644936|NCT01894607|Procedure|Contrast Enhanced Intraoperative Ultrasound|During standard of care surgery, radiologist will take images and videos with an ultrasound machine before and after patient given the contrast agent.
1644937|NCT01894607|Drug|DEFINITY|"During standard of care surgery, radiologist will take images and videos with an ultrasound machine before patient given the contrast agent.
Patient then receives the DEFINITY contrast by vein over about 1 minute. After receiving the injection of DEFINITY, radiologist will take more images and videos of the tumor and kidney(s) to compare to those recorded earlier."
1644938|NCT01894607|Behavioral|Phone Call|Follow-up phone call 30 days after standard of care surgery is complete to review any side effects patient may be having.
1644939|NCT01894594|Drug|Sodium Bicarbonate|"Oral sodium bicarbonate tablets administered at a starting dose of 0.6 mEQ/Kg body weight and will be escalated once, at 4 weeks, to 0.9 mEQ/Kg body weight.
Weekly schedule:
0-4 weeks: Serial Measurement at baseline, without therapy 4-8 weeks: *~0.6 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing 8-12 weeks: *~0.9 mEq/kg of ideal body weight of Sodium Bicarbonate tablets divided into TID dosing
* to the closest dose of 650 mg (7.74 mEq)
Ideal Body Weight is defined by the following formulas (Devine Calculation):
Ideal Body Weight (men) = 50 + 2.3 (Height (in) - 60) Ideal Body Weight (women) = 45.5 + 2.3 ( Height (in) - 60)"
1644940|NCT01894581|Dietary Supplement|LOVAZA|Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.
1644941|NCT01894581|Drug|GnRH|An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
1644942|NCT01894568|Drug|LY2605541|Administered SC using a prefilled pen.
1644943|NCT01894568|Drug|Insulin Glargine|Administered SC using a prefilled pen
1644944|NCT01894555|Drug|Aspirin|81 mg daily for 4 weeks
1644945|NCT01894542|Dietary Supplement|Water soluble cod protein|6g protein per day for 8wk
1644946|NCT01894542|Dietary Supplement|Non-water soluble cod protein|6 g protein per day for 8 wk
1644947|NCT01894542|Dietary Supplement|Intact cod protein|6 g protein per day for 8wk
1644948|NCT01894542|Dietary Supplement|Control|
1644949|NCT01894516|Drug|GLPG0634|
1644950|NCT01894516|Drug|Placebo|
1644951|NCT01894503|Drug|S8 Sinus Implant (mometasone furoate, 1350 mcg)|Bioabsorbable sinus implant with 1350 mcg of mometasone furoate released over 90 days
1644952|NCT01894477|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
1644953|NCT01894477|Drug|Fludarabine Phosphate|Given IV
1644954|NCT01894477|Other|Laboratory Biomarker Analysis|Correlative studies
1644955|NCT01894477|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
1644956|NCT01894477|Radiation|Total-Body Irradiation|Undergo TBI
1644957|NCT01894477|Drug|Treosulfan|Given IV
1644958|NCT01894464|Behavioral|Teacher led intervention|
1645026|NCT01893944|Other|virtual reality|customized applications using virtual and augmented reality to be developed.
1645027|NCT01893931|Behavioral|ED Discharge & Medication Call|Patients will receive a follow up phone call from a nurse to review discharge instructions and provide any necessary patient navigation.
2012563|NCT01881230|Drug|nab-Paclitaxel 125 mg/m2|
1644959|NCT01894451|Drug|89Zr-bevacizumab|89Zr-bevacizumab is a newly developed radiotracer. Radiotracers are compounds or drugs that are attached to small amounts of a radioactive substance. The amount of the compound or drug in a radiotracer is also very small. Radiotracers are used to make images of processes that are happening in the body, but they do not affect how the body works. 89Zr-bevacizumab is made up of the drug bevacizumab and the radioactive substance zirconium-89 (89Zr). 89Zr-bevacizumab is used for an imaging procedure called positron emission tomography/computed tomography (PET/CT). 89Zr-bevacizumab-PET/CT will be performed in this study at baseline, after 2 cycles of preoperative chemotherapy and at the completion of chemotherapy.
1644960|NCT01894451|Procedure|FDG-PET/CT|FDG-PET/CT scan: Pictures of your organs will be taken using a PET (Positron Emission Tomography) scanner. At the same time, a CT (computed tomography) scan will be performed. FDG, a radioactive substance similar to glucose (or sugar), will be injected into your vein using a needle prior to performing the PET/CT scan. After the injection, you will be asked to sit quietly for one hour to let the FDG absorb into the body. After this hour, you will be asked to lie flat on your back for up to 50 minutes while the PET and CT images are being taken. This FDG-PET/CT scan is part of regular cancer care. If you have had this test within 14 days of study enrollment, you may or may not have to have this test repeated.
1644961|NCT01894451|Procedure|MRI scan|• MRI Scan: MRI (Magnetic Resonance Imaging) scans of the breast will be taken. You will receive an injection of a dye before the MRI. You will be asked to lie flat on your back in the scanner for up to 30 minutes for pictures to be taken. This MRI scan is part of regular cancer care. If you have had this test within 14 days of study enrollment , you may or may not have to have this test repeated.
1644962|NCT01894451|Procedure|Tumor biopsies|Tumor biopsies: Prior to starting your treatment, a radiologist will use breast MRI or ultrasound imaging to localize an area of your tumor in the breast for a research biopsy. The biopsy procedure is done in an outpatient setting using a done using a needle to obtain tissue. A local anesthetic will be given to minimize any pain; however, after the procedure you can expect some discomfort and possible bruising. This biopsy is part of research.
1644963|NCT01894438|Behavioral|Mediterranean lifestyle|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean lifestyle group culinary practices, seasonality, and locality of food products, socialization during meals, rest during the day, as well as the adoption of an active living will be additionally addressed.
1644964|NCT01894438|Behavioral|Mediterranean Diet|Counseling will be based on the goal setting theory. Motivational and behavioral strategies will be also used. In the Mediterranean diet group, all food groups of the Mediterranean diet will be targeted.
1644965|NCT01894412|Biological|Etanercept (Enbrel)|
1644966|NCT01894412|Biological|HD203|
1644967|NCT01894399|Drug|HM61713|Cohort 1 : 100mg single dose in Korean Cohort 2 : 200mg single dose in Korean Cohort 3 : 300mg single dose in Korean Cohort 4 : 200mg single dose in Japanese Cohort 5 : 300mg single dose in Japanese Cohort 6 : 200mg single dose in Caucasian Cohort 7 : 300mg single dose in Caucasian
1644968|NCT01894386|Drug|FF 400 mcg|100 mcg powder for inhalation delivered by Dry Powder Inhaler (DPI)
1644969|NCT01894386|Drug|UMEC 500 mcg|125 mcg powder for inhalation delivered by DPI
1644970|NCT01894386|Drug|UMEC 250 mcg|62.5 mcg powder for inhalation delivered by DPI
1644971|NCT01894386|Drug|VI 100 mcg|25 mcg powder for inhalation delivered by DPI
1644972|NCT01894373|Drug|Adoptive Immunotherapy|Biological: in vitro expanded Cytokine Induced Killer (CIK) cells Procedure: Infusion of autologous CIK cells
1644973|NCT01894373|Biological|CIK|
1644974|NCT01894360|Drug|Belimumab 200 mg/mL|Clear to opalescent, colorless to pale yellow sterile solution sterile solution for SC injection in a single-use liquid formulation of Belimumab 200 mg/mL will be supplied in 1mL long glass prefilled syringe or autoinjector device.
1644975|NCT01894347|Other|TDM, Monitoring of Neuro-and Nephropathology|Therapeutic drug monitoring of serum levels and Monitoring of Neuro- and Nephropathology
1644976|NCT01894334|Drug|Ulinastatin|
1644977|NCT01894334|Drug|Tranexamic acid|
1644978|NCT01894334|Drug|Edaravone|
2012564|NCT01881230|Drug|Carboplatin AUC 2|
1644980|NCT01894295|Dietary Supplement|Placebo|Corn oil pearl Capsules 1 gram; were given to the intervention group once a day for 8 weeks
1644981|NCT01894295|Dietary Supplement|Vitamin D analogue|1-α hydroxyvitamin D3 dose 0.25, 0.5 and 1 microgram were given to the intervention group once a day for 8 weeks
1644982|NCT01894282|Procedure|Manual Therapy|Manual Therapy Arm
1644983|NCT01894282|Procedure|Mind Body Intervention|Combination of manual therapy and cognitive behavioral therapy for pain.
1644984|NCT01894269|Drug|Lamivudine 100mg once daily; or Entecavir 0.5mg once daily.|In experimental group, Lamivudine 100mg once daily; or Entecavir 0.5mg once daily will be commenced after TACE.
1644985|NCT01894256|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
1644986|NCT01894243|Drug|Olaparib tablet dosing|Part A - single 300mg oral dose olaparib (administered as 2x150mg tablets) Part B - 300mg oral dose olaparib (administered as 2x150mg tablets) bd
1644987|NCT01894230|Genetic|SLCO1B1*5 allele testing, results reported at randomization|Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at randomization
1644988|NCT01894230|Genetic|SLCO1B1*5 allele testing, results reported at end of study|Genetic testing for SLCO1B1*5 allele and reporting of results to patient and provider at end of study
1644989|NCT01894230|Genetic|Genetic testing for SLCO1B1*5 allele|Blood test for SLCO1B1*5 allele
1644990|NCT01894217|Genetic|Genetic testing and reporting for SLCO1B1*5 allele|Blood test for SLCO1B1*5 allele; reporting of test results to provider and participant
1645028|NCT01893931|Behavioral|Placebo Comparator|
1645029|NCT01893905|Drug|CS+SG|Chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
1645030|NCT01893905|Drug|Placebo|Placebo of chondroitin sulfate+glucosamine sulfate orally administered once a day for 24 weeks.
1645031|NCT01893892|Dietary Supplement|levocarnitine|Given PO
1645032|NCT01893892|Other|placebo|Given PO
1645033|NCT01893892|Other|questionnaire administration|Ancillary studies
2012565|NCT01881230|Drug|gemcitabine 1000 mg|
2012566|NCT01879215|Procedure|Intramedullary nailing of the tibia|Standard care surgery
1644991|NCT01894204|Other|HTPPE|No drug and no placebo were used in this study. Some exams must be performed (DLCO - evaluation of the dyspnoea and pulmonary scintigraphy), and in function of the result of the pulmonary scintigraphy, the medical care of the patient will be different : negative pulmonary scintigraphy, stop of the explorations and taken care usual of the patients; positive pulmonary scintigraphy,realisation of a cardiac echography to estimate the presence or not of a not very probable, possible or likely HTP. The indication of the right cardiac catheterization is then put on the combination of the results of the cardiac echography and the evaluation of the dyspnoea.
1644992|NCT01894191|Procedure|Air insufflation|Insufflation during colonoscopy including insertion phase
1644993|NCT01894191|Procedure|water immersion|Water will infused during insertion phase and removed during withdrawal phase of colonoscopy
1644994|NCT01894191|Procedure|Water exchange|Water will infused and removed during insertion phase of colonoscopy
1644995|NCT01894178|Device|Parker Flex-Tip® tracheal tube|
1644996|NCT01894178|Device|Portex® Tracheal Tube|
1644997|NCT01894165|Drug|ALXN1101|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
1644998|NCT01894165|Drug|Placebo|Randomized to receive a single dose of ALXN1101 or placebo as per assigned cohort dose level.
2012567|NCT01874535|Drug|Esomeprazole 40 mg|Comparison of 4-weeks and 8-weeks initial treatment duration of esomeprazole 40 mg per day on the rate of symptom relapse and sustained healing of esophagitis in patients with symptomatic erosive esophagitis
1645000|NCT01894139|Other|High-Protein/Low-GI Diet|
1645001|NCT01894139|Other|Low-protein/High-GI Diet|
1645002|NCT01894126|Behavioral|Two-way SMS Dialogue|
1645003|NCT01894126|Behavioral|One-way SMS Messaging|
1645004|NCT01894113|Procedure|transbronchial lung biopsy|
1645005|NCT01894100|Device|Shoe lift correction for leg length inequality|Lift therapy will be administered by a physical therapist. Heel lifts and full length inserts used inside participants' shoes will be constructed on-site. If an external shoe lift is required for a participant, a local shoe repair shop will construct the lifts and add them to the outside of the shoe. Participants will be required to wear the lift in their shoes when they are walking or standing while enrolled in the study; participants will keep a daily diary to record their compliance (number of hours lift worn per day, amount of lift used, type of shoes worn, general symptoms experienced, and activities performed). They will be contacted weekly to be reminded to increase their lift height and identify when they have achieved their optimal lift height.
2012568|NCT01875185|Drug|Aspirin 81 mg PO daily x 7 days|
1645008|NCT01894074|Behavioral|Intensive Dietary Intervention|Intensive dietary intervention of 800 kcal/day using liquid meal replacement for a total of 12 weeks to reduce weight to 15% from baseline weight.
1645009|NCT01894074|Behavioral|Placebo|Lifestyle counseling: standard dietary education and counseling with a goal of reducing to 1500-1800 kcal/day
1645010|NCT01894061|Biological|Bevacizumab|Bevacizumab will be administered intravenously on days 1 and 15 of each 28 day cycle. The dose of bevacizumab will be 10 mg/kg of actual body weight.
1645011|NCT01894061|Device|NovoTTF-l00A|NovoTTF-100A will be worn continuously.
1645012|NCT01894061|Other|Quality of Life Assessment|Functional Assessment of Cancer Therapy including Brain Tumor module (FACT-Br) questionnaire
1645013|NCT01894048|Drug|Qvar® (beclometasone dipropionate HFA)|Participants will be converted to Qvar (HFA-beclometasone) at an equivalent therapeutic dose to their original inhaled corticosteroids. The treatment duration will for 8 weeks after a run-in period.
1645014|NCT01894035|Drug|Ventavis (Iloprost, BAYQ6256)|Patients Diagnosed with Pulmonary Arterial Hypertension, Functional Class NYHA/WHO III, for whom was prescribed inhaled Iloprost.
1645015|NCT01894022|Drug|Ambrisentan 5 mg|Round, white, film-coated, immediate-release tablets, containing 5 mg ambrisentan. Subjects will be dosed orally once daily. Subjects may receive 5mg, or 10 mg of ambrisentan OD.
1645016|NCT01894009|Procedure|Foot manipulation|The subtalar joint was treated with gapping thrust with patient lying on the contra-lateral side. Mobilisation of the distal tibia-fibula was performed with the patient squatting and was repeated 10 times. Home training programs in order to maintain the mobility in the joints were given.
1645017|NCT01894009|Procedure|Sham foot manipulation|Sham manipulation included downsizing (a massage technique) the section underneath the heel from back forwards with four grips and palpation of the five metatarsal bones. Sham manipulations were repeated 10 times. This group was also recommended home exercises in the mornings.
1645018|NCT01893996|Drug|Adalimumab|Patients will be randomized 1:1 to receive either adalimumab or placebo for the first 26 weeks of the trial, and then after a 26 week washout period, will be crossed over into the other arm (either placebo or adalimumab) for weeks 52-78.
1645019|NCT01893996|Drug|Placebo|
1645020|NCT01893983|Behavioral|Motivational Coaching|Telephone-based Motivational Interviewing aimed at getting Veterans to engage or retain mental health treatment
1645021|NCT01893970|Behavioral|SWIFT|Participants will receive: 1) acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute) and 2) follow up telephone counseling, needs assessment and case management referral to necessary services (SWIFT).
1645022|NCT01893970|Behavioral|SWIFT-Acute|acute social work intervention for adults with mTBI, including early education, reassurance, resources and brief alcohol intervention in the ED (SWIFT-Acute)
1645023|NCT01893957|Procedure|high voltage electrical stimulation - axillary lymphadenectomy|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
1645024|NCT01893957|Procedure|High voltage electrical stimulation - ( healthy women )|Will be used high voltage electrical stimulation, Neurodyn High Volt Model (IBRAMED), twice a week, over the course of seven weeks,in 20-minute sessions on alternate days. The parameters are: high voltage pulsed current, monopolar (cathode), 100 Hz, synchronized mode, on/off relationship of 3:9 seconds, rise/decay 2:1 seconds, and motor threshold. The electrodes are positioned in the middle and distal thirds of the anterior surface of the forearm and arm.
1645025|NCT01893957|Device|Neurodyn High Volt Model (IBRAMED)|
1645035|NCT01893879|Drug|(RS)2-(3-benzoylphenyl)-propionic acid|Given PO
1645036|NCT01893879|Other|laboratory biomarker analysis|Correlative studies
1645037|NCT01893866|Drug|1 x 30 mg/mL pegvisomant|Subcutaneous injection, 30 mg, single dose.
1645038|NCT01893866|Drug|2 x 15 mg/mL pegvisomant|Subcutaneous injection, 2 injections of 15 mg, single dose.
1645039|NCT01893853|Other|Exercise Intervention|Exercise intervention trials will consist of a steady-state bout of exercise at ~70% VO2peak and a timed performance test on a cycle ergometer in a heated environment.
1645040|NCT01893840|Device|FlowOx|Boot-shaped pressure chamber generating pulsating negative pressure
1645043|NCT01893814|Dietary Supplement|Probiotics|
1645044|NCT01893814|Dietary Supplement|Control|
1645045|NCT01893801|Drug|nab-paclitaxel|25 mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
1645046|NCT01893801|Drug|Cisplatin|25mg/m2 (or 50mg/m2) given intravenously (IV) on days 1 and 8 of a 21 day cycle
1645047|NCT01893801|Drug|gemcitabine|1000mg/m2 given intravenously (IV) on days 1 and 8 of a 21 day cycle
1645048|NCT01893788|Drug|Aliskiren|Aliskiren: 150 to 300 mg daily for 48 weeks
1645049|NCT01893788|Drug|Eplerenone|50 to 100 mg daily for 48 weeks
2012569|NCT01872910|Drug|Placebo|Administered orally
1645051|NCT01893762|Biological|Aerobic exercise|Aerobic exercise: 2x30 min on an indoor rowing machine at 75% of Maximum heart rate
1645052|NCT01893762|Biological|Anaerobic exercise|Anaerobic exercise: 3x1000m maximum effort, on an indoor rowing machine
1645053|NCT01893749|Behavioral|CATCH-IT|It contains 14 modules focused on behavioral activation, cognitive behavioral therapy, interpersonal therapy and a resiliency building model, including elements such as narratives, video diaries, skill building exercises and a booster program (not yet initiated) with 6 modules that involves interaction with a live therapist. It also includes three 15-minute meetings with the primary care provider at baseline, 2 months and 12 months post intervention. These meetings are focused on the motivational interview approach where the patient and the doctor talk about the mental/physical health goals of the patient and determine the best approach for the patient by allowing the patient to have full input into the plan.
1645054|NCT01893736|Other|In-hospital professional support|In-hospital professional lactation support will consist of two 30-minute one-to-one hands-on breastfeeding counseling sessions in first 24 hours post-partum and one further 30-minute one-to-one hands-on breastfeeding counseling session on the second day of post-partum hospitalization for a total of three 30-minute sessions. The one-to-one sessions will focus on: (1) education and advice on correct breastfeeding positions and techniques, (2) education and advice on milk supply and how to avoid common breastfeeding problems, and (3) hands-on instruction and assistance with proper breastfeeding positioning and technique, latching on and newborn attachment to the breast, and manual expression of breast milk.
1645055|NCT01893736|Other|Postpartum telephone follow-up support|Postpartum telephone follow-up support will consist of telephone support 72 hours after hospital discharge and weekly for the first 4 weeks, or until weaned. Earlier telephone contacts will focus more on breastfeeding topics. Information will be solicited from the participants about problems or difficulties they are experiencing. Supportive advice will be provided regarding management of breastfeeding problems, and support and encouragement for the continuation of breastfeeding. Later contacts will focus more on advice and encouragement on breastfeeding while resuming daily activities or returning to work, nursing in public places, and expressing and storing breast milk.
1645056|NCT01893723|Procedure|ANI guided remifentanil|remifentanil administration during propofol anesthesia for laparoscopic surgery is ANI guided
1645057|NCT01893723|Procedure|ANI blind arm|remifentanil administration during propofol anesthesia for laparoscopic surgery is not ANI guided
1645058|NCT01893710|Procedure|biopsy sampling|"Two parietal peritoneal samples, each 1 cm² x 0.3 cm in depth and three omental tissue samples, each 1 cm² in size will be obtained.
Biopsy sampling will be performed in all groups. This is an observational not an interventional trial."
1645059|NCT01893697|Other|HRCT scan in a specific postural position|HRCT Scan taken in supine and lateral position
1645060|NCT01893684|Behavioral|Exercise|PRO+EX and CARB+EX groups will be prescribed an exercise program with required attendance of 3 nonconsecutive days per week. Exercise sessions will be supervised and conducted by trained graduate students in the Department of Kinesiology. Based on recommended practice, a program that combines flexibility and balance activities, weight bearing endurance exercise (walking) and resistance training to preserve lean mass will be prescribed. Each session will last ~75 min with a 35 min warm-up/aerobic exercise of mild to moderate intensity, ~30 min of resistance training, and finally, a ~10 min of balance and flexibility exercises during the cool-down period. Endurance training activities will vary but will all be weight-bearing.
1645061|NCT01893684|Behavioral|Higher Protein Diet|PRO diet recommendations will include high quality proteins with an emphasis on lean meats with protein being targeted for every meal and snack. PRO will provide dietary protein (1.6 g.kg-1.d-1; ~30% of energy intake) with a ratio of carbohydrate/protein of <1.5 and dietary lipids at ~ 30% energy intake. Energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Regarding beef intake specifically, the prescribed diet will include a minimum of one serving of beef per day, which is approximately 3 to 3.5 ounces or ~100 grams. This amount of lean cooked beef provides an average of ~25-30 grams of protein per day (www.beefnutrition.org/leanbeef.aspx). Our dietary prescription to the PRO groups that they add 3 ounces (and perhaps up to 3.5 ounces pending body size) of lean beef daily will provide an additional 25-30 grams of protein. This diet will also include 5 servings/day of vegetables and 2-3 servings/day of fruit.
1645062|NCT01893684|Behavioral|Conventional Carbohydrate Diet|For the CARB group, the diet will provide dietary protein at 0.8 g.kg-1.d-1 (~ 18% of energy intake) with a ratio of carbohydrates/protein > 3.5 and dietary lipids at ~ 30% energy intake. Through nutrition education and counseling we will ensure that the CARB group meets the RDA for protein for women of 46 grams per day from a variety of plant and animal sources. Again, energy deficit will be determined by reducing estimated daily energy needs by ~500 kcal/d. Additional recommendations will include 5 servings/day of vegetables and 2-3 servings/day of fruit. Beef intake will be discouraged in the CARB group.
1717383|NCT00002073|Drug|Epoetin alfa|
2012570|NCT01872910|Drug|LY3023703|Administered orally
2012571|NCT01872910|Drug|Celecoxib|Administered orally
2012572|NCT01871350|Dietary Supplement|Daily intake for 10 weeks (+/- 2 weeks)|
2012573|NCT01869439|Device|"gold standard LxW manual ruler measurement technique"|"Currently, the gold standard LxW manual ruler measurement technique is used for measuring the area of an external wound. The LxW is measured by measuring the longest length (head to toe) times the widest width (perpendicular to the length)."
1645066|NCT01893632|Drug|gabapentin|
1645067|NCT01893632|Drug|Placebo|
1645068|NCT01893606|Drug|N-acetyl-D-glucosamine|
1645069|NCT01893606|Drug|placebo|
1645070|NCT01893593|Other|Intervention|Guideline summary and data feedback from a baseline medical record review and a multifaceted intervention to improve clinical systems
1645071|NCT01893593|Other|Control|Guideline summary and data feedback from a baseline medical record review
1645072|NCT01893580|Behavioral|Experimental: 1. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:
Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.
Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
1645073|NCT01893580|Behavioral|Experimental: 2. Experimental|"Home-based exercise pre surgery and postoperative exercise in a team initiated six weeks after surgery. Intervention consists of:
Preoperative home-based exercise program - cardiovascular exercise of moderate-vigorous intensity for at least 30 minutes every day until surgery.
Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
1645074|NCT01893580|Behavioral|Experimental: 3. Experimental|"Early postoperative exercise in a team initiated two weeks after surgery. Intervention consists of:
Postoperative rehabilitation: A supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions and smoking cessation, nutritional counseling or patient education, this is offered too.The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks and increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
1645075|NCT01893580|Behavioral|Other: 4. Usual care|"Exercise in a team initiated six weeks after surgery consisting of a supervised 12-week rehabilitation program containing 24 group-based exercise sessions, three individual counseling sessions, and three group-based lessons in health-promoting behavior. If the participants have special needs in terms of smoking cessation, nutritional counseling or patient education, this is offered too.
The cardiorespiratory intensity is at ~50-60% of individual HRmax for the first four weeks. The next eight weeks the intensity increases to moderate-high intensity at ~70-90% of individually determined HRmax. The intensity of the strength exercise program is at ~60-80% of 1 RM."
1645076|NCT01893567|Drug|Clobex Spray|
1645077|NCT01893554|Biological|RSV ΔNS2 Δ1313 I1314L Vaccine|"For participants in Groups 1 and 3: 10^6 plaque forming units (PFU) of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
For participants in Group 2: 10^5 PFU of RSV ΔNS2 Δ1313 I1314L vaccine will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL)."
1645078|NCT01893554|Biological|Placebo (1x Leibovitz L-15 medium)|Placebo will be administered as nose drops (0.25 mL per nostril for a total of 0.5 mL).
1645079|NCT01893541|Procedure|ENDOSCOPIC BAND LIGATION|The procedures will be performed using standard technique with a multiband ligation device. Elastic bands will be placed according to physician decision, starting at esophagogastric junction. All varices will be treated during the same session. Endoscopic band ligation sessions will be repeated at intervals of 3 to 4 weeks until all varices will be obliterated.
1645080|NCT01893541|Drug|PROPRANOLOL|The initial propranolol dose will be orally BID 40 mg, irrespective of patient's weight. The objective of the administration of propranolol will be induce beta-adrenergic blockade evaluated by reduction in heart rate to 55 bpm or a 25% drop in baseline heart rate. A baseline electrocardiogram will be obtained from all patients. The doses will be adjusted during weekly visits until beta-adrenergic blockade. After the adequate dose will be reached, the visits will be scheduled monthly during the first 3 months (until EV eradication) and then at a 3-month interval until the end of follow-up.
1645081|NCT01893541|Device|a multiband ligation device|
1645082|NCT01893528|Drug|REGN2009|
1645083|NCT01893528|Other|placebo|
1645084|NCT01893515|Drug|PRC-4016|
1645085|NCT01893515|Drug|Placebo|
1645086|NCT01893502|Behavioral|Telephone counselling from Quitline|
1645087|NCT01893489|Other|68Gallium-MSA|68Gallium-MSA 2.0 mci for Positron Emission Tomogram(PET) imaging
1645088|NCT01893476|Other|Implementation educational programme|Implementation educational programme will include: brief anti-smoking counseling, mMRC scale, checklist, training patient on correct use of inhaling. Participating physicians will receive training in brief anti-smoking counselling and will be asked to record information about. Additional form containing the mMRC dyspnoea scale will be inserted into patients' medical records. We will elaborate a checklist for practitioners with information about what should be done while consulting a patient with COPD. Investigators will provide practices with training inhaler and train staff. Practitioners will be asked to teach patients in correct use of each device. Practitioners will be asked to put this information to the patient's medical records.
1645089|NCT01893463|Device|iTClamp50|
1645090|NCT01893450|Drug|Methimazole|
1645091|NCT01893450|Drug|Bromocriptine|
1645092|NCT01893450|Drug|Pentoxifylline|
1645093|NCT01893437|Drug|RO6799477|Single doses of RO6799477
1645094|NCT01893424|Drug|Sativex buccal spray|buccal spray
1645095|NCT01893424|Drug|CBD-THC-Piperine-PNL capsule|a capsule containing Cannabidiol and Tetrahydrocannabinol combination
1645138|NCT01893138|Biological|Roll-in|Placebo control is the vehicle solution used for the study product, AMDC for USR is the study product (autologous muscle derived cells for urinary sphincter repair).
1645096|NCT01893411|Drug|IncobotulinumtoxinA (16 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 400 units; Mode of administration: intramuscular injection into spastic muscles.
1645097|NCT01893411|Drug|IncobotulinumtoxinA (12 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 300 units; Mode of administration: intramuscular injection into spastic muscles.
1645098|NCT01893411|Drug|IncobotulinumtoxinA (4 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Total volume 8.0 mL; 100 units; Mode of administration: intramuscular injection into spastic muscles.
1645099|NCT01893398|Other|Multidimensional stimulation group therapy|The MST program involved three levels of treatment. The first level was focused on PWA, the second level involved the caregiver, while the third one the dyad PWA-caregiver.
1645100|NCT01893385|Drug|Vitamin D (drug)|
1645101|NCT01893372|Drug|Eltrombopag|200 mg by mouth daily in a 28 day cycle.
1645102|NCT01893372|Drug|Hypomethylating Agent (HMA)|The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.
1645103|NCT01893359|Drug|riboflavin ophthalmic solution, 0% dextran|
1645104|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 2 minutes continuous UVA)|
1645105|NCT01893359|Device|UVA Irradiation (30 mW/cm2 for 3 minutes pulsed UVA with an on/off cycle of 2 seconds UVA on/1 second UVA off)|
1645106|NCT01893359|Procedure|Laser-assisted in situ keratomileusis|
1645107|NCT01893346|Drug|CAZ-AVI|Single IV dose of Ceftazidime and Avibactam. Dosage regimen will vary depending on cohort.
1645108|NCT01893333|Procedure|Nerve sparing radical hysterectomy|"Nerve sparing radical hysterectomy
sparing hypogastric nerve
sparing pelvic splanchnic nerve ad pelvic plexus in cardinal ligament
sparing distal part of hypogastric nerve and vesical branch of pelvic splanchnic nerve"
1645109|NCT01893320|Drug|Vosaroxin|"Phase I Starting Dose: 90 mg/m2 by vein on Days 1 and 4 of each cycle.
Phase II Starting Dose: 70 mg/m2 by vein on Days 1 and 4 of each cycle, or maximum tolerated dose from Phase I."
1645110|NCT01893320|Drug|Decitabine|Phase I and II: 20 mg/m2 by vein daily for 5 consecutive days (Days 1 to 5).
1645111|NCT01893307|Radiation|Intensity-Modulated X-Ray Therapy (IMRT)|"Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).
Treating physician evaluate each patient for possible chemotherapy."
1645112|NCT01893307|Radiation|Intensity-Modulated Proton Beam Therapy (IMPT)|"Radiation therapy dosage 70 Gy (RBE) delivered 1 time each day, 5 days a week (Monday through Friday) for up to 33 treatments (about 6 ½ weeks).
Treating physician evaluate each patient for possible chemotherapy."
1645113|NCT01893307|Procedure|Modified barium swallow (MBS)|Modified barium swallow (MBS) performed at baseline, end of treatment visit, and at 6, 12, and 24 months after radiation therapy.
1645114|NCT01893307|Behavioral|Questionnaires|Questionnaires completed at baseline, each week while receiving radiation therapy, at end of treatment visit, at 10 - 12 weeks after radiation, and at 6, 12, and 24 months after radiation therapy.
1645115|NCT01893294|Drug|gemcitabine hydrochloride|Given IT
1645116|NCT01893294|Drug|fluorouracil|Given IV
1645117|NCT01893294|Radiation|radiation therapy|Undergo radiation therapy
1645118|NCT01893294|Other|laboratory biomarker analysis|Correlative studies
1645119|NCT01893281|Drug|Topical Testosterone Solution|Administered topically to axillae.
1645120|NCT01893242|Drug|Aleglitazar|Aleglitazar 150 mcg oral doses, once a day for approximately 3 years
1645121|NCT01893242|Drug|Placebo|Matching placebo to aleglitazar, once a day for approximately 3 years
1645122|NCT01893229|Drug|Lithium|Lithium is used as a mood stabiliser
1645123|NCT01893229|Drug|Valproate|Valproate is used as a mood stabiliser
1645124|NCT01893229|Drug|Oxcarbazepine|Oxcarbazepine is used as a mood stabiliser
1645125|NCT01893229|Drug|Quetiapine|Quetiapine is used as a mood stabiliser
1645126|NCT01893229|Drug|Olanzapine|Olanzapine is used as a mood stabiliser.
1645127|NCT01893229|Drug|Ziprasidone|Ziprasidone is used as a mood stabiliser
1645128|NCT01893203|Drug|BF-200 ALA cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then sun protection factor (SPF) 20 cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Ameluz cream on the area. After appropriate absorption time of 30 minutes, the patients will be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
1645129|NCT01893203|Drug|MAL cream|The symmetrical treatment areas will be randomized for treatments. First the treatment area will be wiped ethanol. Then SPF20 sun protection cream will be applied on all sun-exposed areas of the skin. Then a 0,25mm layer application of Metvix cream on the area. After appropriate absorption time of 30 minutes, the patientswill be taken to the hospital balcony for 2 hour illumination with daylight to accomplish the phototoxic reaction. Maximum dosage will be 2 grams. The treatment will be repeated after 2 weeks for thicker gr II-III lesions with the same protocol.
1645130|NCT01893190|Drug|Nimodipine|Based upon Investigator Judgement
1645131|NCT01893190|Drug|Nimodipine Microparticles|Based upon Investigator Judgement
1645132|NCT01893177|Biological|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
1645133|NCT01893164|Procedure|simple decompression|decompression of the ulnar nerve
1645134|NCT01893164|Procedure|anterior subcutaneous transposition|transposition of the ulnar nerve into subcutaneous bed
1645135|NCT01893164|Procedure|anterior intramuscular transposition|transposition of the ulnar nerve into muscular tissue
1645136|NCT01893151|Drug|Iguratimod|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),52week
1645137|NCT01893151|Drug|Iguratimod placebo|Iguratimod placebo:25 mg/tablet, taken orally, 2 tablets/day (bid),24week; Iguratimod:25 mg/tablet, taken orally, 2 tablets/day (bid),28week.
1717384|NCT00002074|Drug|Fluconazole|
1645139|NCT01893138|Other|Placebo|Placebo control is the vehicle solution used for the study product.
1645140|NCT01893138|Biological|AMDC for USR|AMDC for USR is the study product (autologous muscle derived cells for urinary sphincter repair).
1645141|NCT01893125|Drug|CNV2197944|
1645142|NCT01893125|Drug|Placebo|
1645143|NCT01893112|Behavioral|Unity Workshop|The intervention is based on other stigma reduction programs that are being used internationally (HIV Stigma Toolkit developed by the International Center for Research on Women and trigger videos developed by International Training & Education Center for health).
1645144|NCT01893112|Behavioral|Breast Cancer Screening|
1645145|NCT01893099|Drug|Sorafenib|Sorafenib will be given at the dosage of 400 mg BID. Initiation of the drug will vary dependently of the cohort and will be continued until progressive disease or intolerance.
1645146|NCT01893099|Device|Radioembolization with SIR-Spheres® (Yttrium Microspheres)|
1645147|NCT01893086|Procedure|LH alone|LH, laparoscopic hysterectomy
1645148|NCT01893086|Procedure|LH with opportunistic salpingectomy|LH, laparoscopic hysterectomy
1645149|NCT01893073|Behavioral|Mindful walking program|
1645150|NCT01893060|Drug|Povidone-Iodine|Povidone-Iodine, USP, Swabstick Singles, applied twice a day to cord stump while umbilical line(s) are in place
1645151|NCT01893060|Drug|Chlorhexidine gluconate|Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied twice a day to cord stump while umbilical line(s) are in place
1645152|NCT01893060|Drug|Pluronic Cream|Pluronic cream - (F68, Polymyxin, Nystatin, Nitrofurantoin )applied twice a day to cord stump while umbilical line(s) are in place
1645153|NCT01893060|Other|control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
1645154|NCT01893047|Behavioral|live music|live harp music
1645155|NCT01893047|Behavioral|recorded music|recorded harp music
1645156|NCT01893034|Procedure|Arthroscopic treatment of femoroacetabular impingement|
1645157|NCT01893034|Other|Physiotherapy and activity modification|
1645158|NCT01893008|Other|Inspiratory Muscle Training (IMT)|"The IMT protocol is tailored individually. Inspiratory load is set at 60% of the measured maximal inspiratory pressure (Pimax). The load is incrementally increased based on the rate of perceived exertion (RPE) scored on a scale from 0 to 10 which is scored by the patient after each training session. When patients score an RPE below 7, patients increase the inspiratory load of the threshold device with 5% to guarantee overload during each training session. Patients have to complete 30 dynamic inspiratory efforts twice daily.
Patients will be instructed to train at home 7 days a week until surgery with a minimum of 2 weeks.
Training will be started after the chemoradiation period (if applicable)."
1645159|NCT01892995|Drug|Ketamine|
1645161|NCT01892930|Radiation|stereotactic body radiation therapy|Undergo SBRT
1645162|NCT01892930|Procedure|therapeutic conventional surgery|Undergo partial or radical nephrectomy
1645163|NCT01892930|Other|laboratory biomarker analysis|Correlative studies
1645164|NCT01892904|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
1645165|NCT01892891|Drug|VBY-036|Cathepsin S inhibitor
1645166|NCT01892878|Procedure|VerteLoc|Single Arm
1645169|NCT01892852|Procedure|Acupuncture|Acupuncture treatment will be performed by licensed doctors in Traditional Korean Medicine using 0.20 mm (diameter) X 0.40 mm (length) sized disposable acupuncture 3 times per week for 3 weeks. Acupuncture points are GV20, GB20 (bilateral), LI11 (bilateral), LI10 (bilateral), EX-UE9 (bilateral), ST36 (bilateral), ST40 (bilateral), and EX-LE10 (bilateral). Each session lasts 20-30 minutes.
1645170|NCT01892839|Other|low dialysate flow, smaller dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a lower than usual dialysate flow and small dialyzer.
1645171|NCT01892839|Other|high dialysate flow, larger dialyzer|The subject will receive dialysis on the usual schedule and for the usual time but with a higher than usual dialysate flow and large dialyzer.
1645172|NCT01892826|Drug|hCG|5000IU
1645173|NCT01892813|Drug|Nicotine replacement therapy - Transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
1645174|NCT01892813|Drug|Nicotine replacement therapy - Nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
1645175|NCT01892813|Drug|Nicotine replacement therapy - Nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
1645176|NCT01892813|Drug|Bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
1645177|NCT01892813|Drug|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
1645178|NCT01892813|Drug|Combination pharmacotherapy - Transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
1645179|NCT01892813|Drug|Combination pharmacotherapy - Transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
1645180|NCT01892813|Drug|Combination pharmacotherapy - Transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
1645181|NCT01892813|Behavioral|Tobacco quitline referral|Participants assigned to this condition will receive a referral to their state tobacco quitline. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
1645242|NCT01892358|Other|Treatment as Usual|
1645243|NCT01892345|Drug|Eculizumab|"Induction Phase: 900 mg IV weekly X 4 Maintenance Phase: 1200 mg IV every two weeks
Drug: Placebo Other Names: Placebo"
1645182|NCT01892813|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
1645183|NCT01892813|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
1645184|NCT01892813|Behavioral|Behavioral activation for depressive symptoms|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
1645185|NCT01892813|Behavioral|Behavioral management of postcessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
1645186|NCT01892800|Procedure|Lung resection|
1645187|NCT01892787|Drug|Formoterol|Participants receive Atimos for 1 to 2 weeks.Partcipants then enter a washout period and after the washout period receive the alternative treatment arm.
1645188|NCT01892787|Drug|Salmeterol|Participants receive Serevent for 1 to 2 weeks. Participants then enter a washout period and after the washout period receive the alternative treatment arm.
1645190|NCT01892761|Drug|Renal transplant recipients were allocated to TCL/MMF or to CyA/MMF groups|
1645191|NCT01892748|Drug|Cholecalciferol|All patients and physicians were blinded to group assignment and treatment allocation. The first group received oral cholecalciferol of 50,000 IU/week and for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
1645192|NCT01892748|Drug|Placebo|The second group received identical placebo tablets for 6 months. All subjects were evaluated at baseline and after the end of supplementation for clinical and laboratory parameters.
1645193|NCT01892722|Drug|Interferon beta-1a i.m. injections|Administration once weekly via i.m. injections. Double-dummy masking is required to blind formulations: Patients in the interferon beta-1a i.m. arm will also take daily placebo capsules matched in appearance to the fingolimod active capsules.
1645194|NCT01892722|Drug|Fingolimod oral capsules|Administration orally once daily. Double-dummy masking is required to blind formulations: Patients in the fingolimod arm will also take weekly placebo i.m. injections (syringes matched in appearance to the active interferon beta-1a i.m. syringes).
1645195|NCT01892722|Drug|Placebo oral capsule|Placebo capsule required for double-dummy masking to blind formulations: Patients in interferon beta-1a i.m. arm will also receive daily oral placebo capsules matched in appearance to the fingolimod active capsules.
1645196|NCT01892722|Drug|Placebo i.m. injection|Placebo i.m. injection required for double-dummy masking to blind formulations: Patients in the fingolimod arm will also take weekly placebo i.m. injections (syringes matched in appearance to the active interferon beta-1a i.m. syringes).
1645197|NCT01892709|Drug|Hydromorphone|
1645198|NCT01892696|Device|varying inspiratory flow waveforms|inspiratory flow waveform was changed, in a randomized sequence using a computer ,to one of the following modalities: 1) constant inspiratory flow; 2) decelerating inspiratory flow Each inspiratory flow waveform was maintained for 30 min. During the last 5 min of this period the physiological signals were collected and measures were performed.
1645199|NCT01892683|Drug|General anesthesia with propofol|Study subjects will undergo general anesthesia with propofol according to the clinical standard protocol practiced at the hospital of the University of Munich.
1645200|NCT01892670|Other|Donation of 1 whole blood unit|Donation of 450-500 mL of whole blood according to local blood bank procedures and national guidelines.
1645201|NCT01892657|Drug|Facial Moisturizer with SPF 50+|All subjects received applications of occlusive patches dosed with Cetaphil Daily Facial Moisturizer with SPF 50+
1645202|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution, 10 mg/kg/day, once daily for 12 months
1645203|NCT01892644|Other|Venesection|Treated with venesection every 8-10 day for 12 months, or until serum-ferritin has been reduced to about 50 µg/L.
1645204|NCT01892644|Drug|Deferasirox|Deferasirox tablets ( 250 mg or 500 mg) dispersed in a drinkable solution starting with 10 mg/kg/day, once daily for 2 weeks and thereafter 20 mg/kg/day for 11,5 months.
1645205|NCT01892631|Other|Text message influenza vaccination reminder|Practices in the text messaging intervention arm will be asked to send a text message to patients under 65 at risk of influenza.
1645206|NCT01892631|Other|Standard care|Practices in the standard care arm will be asked to proceed with their seasonal influenza campaign as planned.
1645207|NCT01892618|Drug|Prevenar 13|13-valent pneumococcal conjugated vaccine
1645208|NCT01892618|Drug|Pneumovax|23-valent pneumococcal polysaccharide vaccine
1645209|NCT01892605|Behavioral|music listening|The treatment group listened to Mozart K.448 for eight minutes once daily before bedtime for at least six months.
1645210|NCT01892592|Behavioral|Diet and Lifestyle|Patients will receive up to 16 phone based coaching sessions
1645211|NCT01892579|Behavioral|Tailored Activity Program|TAP is designed to tap into spared or residual abilities and provide an environment supportive of these abilities. Activities are selected that build on preserved capabilities, long-term interests and procedural memory, but which do not tax areas of cognition that are most impaired (e.g., memory, new learning). Activities selected are simplified (1 to 2 vs multiple, complex steps), thereby minimizing errors. The activity environment is set up to provide auditory or tactile cues to facilitate recall and guide initiation and sequencing. By grading activities to match PwD capabilities, the interventionist minimizes demand that may heighten stress (e.g., high functioning individuals are introduced to more goal-directed, multi-step activities, whereas lower functioning individuals are introduced to activities involving repetitive motion (e.g., washing windows, folding towels, placing materials in a bin) and integrate multi-sensory stimulation (e.g., soft music, objects pleasant to touch).
1645345|NCT01891461|Drug|Floseal|Floseal (5 milliliters) will be applied to the exposed bone in the following order: around the margins of the tibia, the femur (anterior surface, intercondylar notch, exposed medial and lateral condyles) and around the un resurfaced portion of the patella. The other syringes (each of 5 milliliters) will then be applied to the supra-patellar synovium and into the medial and lateral gutters of the knee. No Floseal will be applied outside the knee joint capsule.
1645212|NCT01892579|Other|Home Safety and Education Program|The control group intervention is designed to control for the nonspecific elements of TAP such as social engagement with PwD and CG which may affect outcomes. It is a fully-structured, nondirective, supportive education approach that conveys empathy, respect and specific disease education elements of which have been tested in other trials. Unlike TAP, this group contains no active elements beyond its nonspecific components, has no long-lasting treatment effects, and no theoretical basis to support an effect on agitation. It is delivered by a trained research team member who uses active listening, open questioning, reflecting back, and summation with CGs.
1645213|NCT01892566|Other|mHealth Intervention|See arm description
1645214|NCT01892553|Device|tDCS|"Procedure : 3 different sessions of tDCS (listed below) presented in random order, each applied at a different study visit
Anodal tDCS: Intensity of 1.25 milliAmperes (mA) during 15 min
Cathodal tDCS: Intensity of 1.25 mA during 15 min
Sham tDCS (placebo) (1.25 mA maintained only during the first 30 sec of the 15 minutes application)"
1645215|NCT01892540|Procedure|positron emission tomography/computed tomography|Undergo PET/CT
1645216|NCT01892540|Radiation|fludeoxyglucose F 18|Undergo FDG-PET/CT
1645217|NCT01892540|Device|PET/MRI|Undergo PET/MRI positron emission tomography/magnetic resonance imaging hybrid imaging
1645218|NCT01892540|Radiation|gadopentetate dimeglumine|Undergo DTPA-PET/MRI
1645219|NCT01892540|Other|questionnaire administration|Ancillary studies
1645220|NCT01892527|Drug|Tivantinib (ARQ197)|Eligible subjects will be treated with tivantinib (ARQ 197) at a dose of 360 mg twice daily (a total daily dose of 720 mg) orally in a continuous manner and cetuximab (Erbitux) at a dose of 500 mg/mq i.v. every 2 weeks.
1645222|NCT01892501|Procedure|Guided punction of mediastinal lymphadenopathy by echoendoscopy|"EUS (by oesophageal) is performed within a maximum period of six weeks after the PET scan, under general anesthesia and endoscopic control, with a disposable 19-gauge needle (EchoTip, Cook Endoscopy) and 3 passes of the needle ganglion.
Pathological samples are taken :
3 tubes collected by node (one tube per needle pass), in most cases, only one node will be taken."
1645223|NCT01892501|Device|PET scan|The benefits of combined PET and punction EUS for the diagnosis and subsequent therapeutic management should be evaluated in these different contexts
1645224|NCT01892488|Drug|Sultamicillin|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.
Experimental intervention:
Antibiotic therapy with aminopenicillin + betalactamase inhibitor (oral Sultamicillin (2 x 750mg)) for 5 days as supplement to standard of care for patients with AE-COPD."
1645225|NCT01892488|Drug|Placebo|"Standard of care: Each patient will receive inhaled fast-acting bronchodilators (up to a maximum of 4 - 6 times daily 2 puffs (100µg) of salbutamol or other equivalent inhaled fast-acting bronchodilators), systemic corticosteroids (prednisolone 40mg/d p.o. for 7 - 10 days) and oxygen in case of hypoxemia in a standardized fashion. The pre-existing COPD medication will be continued as indicated.
Control intervention:
Placebo for 5 days as supplement to standard of care for patients with AE-COPD"
1645226|NCT01892475|Behavioral|Incentive-based physical activity program|"Drivers will be offered rewards valued at a day's rental for meeting daily step targets over the specified number of days each month from Months 1 to 4, where steps will be tracked by a step counter. They will also be offered incentives for meeting the following criteria:
Accurately predicting step target attainment the following months (SGD10)
Wearing and providing step data over the month (SGD10 and a chance to win 1 of 3 cash prizes valued at SGD500)"
1645227|NCT01892475|Behavioral|3-month follow up|After the 4-month RCT, drivers will be incentivized to wear the step counter for another 3 months (i.e. Months 5 to 7) to test if effects of the rewards are sustained once the reward is no longer in place. For wearing their step counter and providing their step data, drivers will receive a modest cash incentive (amounting to SGD10) each month as well as the chance to win 1 of 3 cash prizes valued at SGD500.
1645228|NCT01892449|Other|prolonged inspiratory to expiratory (I:E) ratio (1:1)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the prolonged I:E ratio (1:1), mechanical ventilation is maintained with during I:E ratio 1:1 during steep trendelenburg with pneumoperitoneum.
1645229|NCT01892449|Other|conventional I:E ratio (1:2)|80 patients are randomly allocated into two groups : prolonged I:E ratio (1:1) (n=40) and conventional I:E ratio (1:2) group (n=40). In the conventional I:E ratio (1:2) group (n=40), mechanical ventilation is maintained with during I:E ratio 1:2 during steep trendelenburg with pneumoperitoneum.
1645230|NCT01892436|Drug|Secukinumab|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
1645231|NCT01892423|Other|Cetaphil Moisturizing Lotion Daily Advance|
1645232|NCT01892410|Other|Cetaphil Restoraderm Skin Restoring Body Wash|Diluted (10%) 0.2ml or 0.2g of Cetaphil on semi-occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
1645233|NCT01892397|Device|Optune (NovoTTF-100A)|
1645234|NCT01892384|Drug|Placebo|matching placebo
1645235|NCT01892384|Drug|BI 409306|low dose
1645236|NCT01892384|Drug|BI 409306|medium dose
1645237|NCT01892384|Drug|BI 409306|high dose
1645241|NCT01892358|Behavioral|SKIN Intervention|
1645244|NCT01892332|Drug|epidural block with lidocaine and fentanyl|"The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting concentration of lidocaine was 1.5 % mixed with fentanyl 75 ug. All patients receive 13mL of lidocaine with fentanyl 75ug. The concentration of lidocaine for subsequent patients is determined by the outcome in the previous patient according to up and down sequential allocation in 0.1% increments. In the case of block failure, the concentration of lidocaine was increased by 0.1%.
Conversely, block success resulted in a reduction in concentration by 0.1%."
1645247|NCT01892306|Behavioral|UP CBT|The UP is an 18-session weekly cognitive behavioral intervention for anxiety and mood disorders
1645248|NCT01892306|Drug|Treatment as usual|Existing optimized pharmacotherapy as delivered by treating psychiatrist
1645250|NCT01892280|Behavioral|Teenwork intervention|Set of psychoeducational modules focused on optimizing diabetes self-care through blood glucose monitoring and insulin administration
1645251|NCT01892280|Behavioral|Text message reminders|Text message reminders to check blood glucose levels at self-selected times
1645252|NCT01892267|Device|PEG-J placement|PEG-J placement
1645253|NCT01892254|Drug|Metformin|Metformin, 2x 2 tablets a day, 500 mg tablets
1645254|NCT01892254|Drug|Placebo|Placebo (to metformin)
1645255|NCT01892241|Drug|Pegasys(Roche)|180µg of peginterferon alfa-2a (Pegasys,Roche) once weekly for 48 weeks.
1645256|NCT01892241|Drug|Entecavir|continual entecavir therapy(0.5 mg orally once daily)
1645258|NCT01892215|Procedure|Cephalad-caudad expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a cephalad-caudad direction.
1645259|NCT01892215|Procedure|Transversal expansion|Blunt expansion of the uterine incision by the physician separating the fingers in a transversal direction.
1645260|NCT01892202|Other|Cohort|
1645261|NCT01892189|Drug|Ketamine|Ketamine intravenous administration.
1645262|NCT01892189|Drug|TAK-063|TAK-063 tablets
1645263|NCT01892189|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
1645264|NCT01892176|Dietary Supplement|coenzyme q10|400mg/day, 800mg/day, 1200/day and 2400mg/day
1645265|NCT01892163|Device|Ozurdex|Dexamethasone implant (Ozurdex)
1645266|NCT01892150|Other|Sunscreen|Apply sunscreen before and after UVA and UVB irradiation
1645267|NCT01892137|Drug|Ingenol mebutate gel 0.05%|Once daily for 2 consecutive days
1645268|NCT01892124|Behavioral|Motivational Interviewing/Cognitive Behavioral-based Therapy|
1645269|NCT01892111|Other|Structured exercise program.|
1645270|NCT01892098|Dietary Supplement|Zinc Sulfate|9mg elemental zinc via 23mg zinc sulfate/day
1645271|NCT01892098|Dietary Supplement|Placebo|Cellulose pill given as placebo
1645272|NCT01892085|Behavioral|Early initiation|Initiation of breast milk expression <1 hour following delivery.
1645273|NCT01892085|Behavioral|Intermediate expression|Initiation of milk expression 1-<3 hours following delivery.
1645274|NCT01892085|Behavioral|Late initiation|Initiation of milk expression >3-6 hours following delivery.
1645275|NCT01892072|Procedure|surgical treatment|all the patients in the study must have been treated by the surgery at the first time and have been confirmed as 'complete section' by the post-surgery radiological image.
1645276|NCT01892059|Procedure|Segmental artery clamping|Laparoscopic partial nephrectomy with segmental artery clamping will be performed for patients enrolled in this group.
1645277|NCT01892059|Procedure|Main renal artery clamping|Laparoscopic partial nephrectomy with main renal artery clamping technique will be performed for patients enrolled in this group.
1645278|NCT01892046|Drug|SNX-5422|Capsule dosed every other day for 21 days out of a 28 day cycle. Dose escalation based on safety. Maintenance doses at the maximum tolerated dose.
1645279|NCT01892033|Behavioral|Aerobic Exercise|12 weeks of brisk walking
1645280|NCT01892020|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
1645281|NCT01892020|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily (BID). Dose individually adjusted. All subjects will receive metformin in combination with trial insulin.
1645282|NCT01892007|Behavioral|Cogmed RM - Online adaptive working memory training intervention|
1645283|NCT01892007|Behavioral|Cogmed RM - Online (non-adaptive, placebo) working memory training intervention|
1645285|NCT01891981|Drug|Moxetumomab Pasudotox|"Phase I Starting Dose: 30 µg/kg by vein every other day for 6 doses on Days 1, 3, 5, 7, 9, and 11 of each 21-day cycle.
Phase II Starting Dose: Maximum tolerated dose from Phase I."
1645286|NCT01891968|Drug|Bortezomib|1.3 mg/m2 subcutaneously on days 1, 4, 8 and 11 of a 28 day cycle.
1645287|NCT01891955|Behavioral|Healthy diet A|"Healthy diet A will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet B. Healthy diet A will include substantial amounts of whole grains, low-fat dairy and legumes (this is called healthy diet with grains and dairy). This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
1645522|NCT01890109|Drug|AMG 334|Single dose level administered via SC in female subjects with hot flashes associated with menopause.
1992239|NCT03322839|Behavioral|Multifaceted implementation strategies|The school-management will participate in a one-day training aimed at providing knowledge and skills related the recommendations of the guideline for the prevention of common mental disorders at the workplace.In addition every intervention school will form an implementation team that is responsible for the implementation of the guideline. The implementation team will comprise of approximately 3-5 individuals with experience in the field of social and organizational work environment, for example school-management and occupational health and safety representative. The implementation teams will participate in 4-5 workshops aimed at supporting the implementation process. Intervention schools within the same municipality will participate in the same workshop in order to promote peer-support.
1645288|NCT01891955|Behavioral|Healthy diet B|"Healthy diet B will include fruit, vegetables, fish, shellfish, lean meat, nuts, eggs and olive oil. Macro/micronutrient composition, fiber intake and glycemic load will not differ from healthy diet A. Healthy diet B will exclude grains, legumes and dairy, which will largely be replaced by root vegetables, vegetables and fruit, and slightly more lean meat, fish and nuts (this is called healthy diet without grains and dairy). Salt intake will be lower in healthy diet B. This diet is classified as very healthy using validated nutritional software. It is in accordance with official Spanish dietary recommendations for people with diabetes type 2 regarding macronutrient composition, dietary fiber, minerals and vitamins."
1645289|NCT01891942|Procedure|twitch by magstim|
1645290|NCT01891929|Behavioral|RECOS (COgnitive REmediation for Schizophrenia)|"Every RECOS patient will benefit, with his therapist, from 2 sessions of 1 hour of training per week over a 14 weeks period (M1 to M3), plus 1 hour per week of task to be realized at home. All in all, it is thus about a training period of 42 hours.
After remediation, the follow-up of the patient will be led by his therapist with monthly appointments during 6 months (M4 to M9).
In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
1645291|NCT01891929|Behavioral|TAU (Treatment As Usual)|"The treatment of the group TAU (Treatment As Usual) will consist of the usual care proposed by every service of the various inquiring centers involved. No additional session will be proposed.
In parallel, neuropsychological and clinical scores will be assessed before (M0) and after the training period (M3), as well as at the end of the study (M9). Working and relational abilities will be assessed at the beginning and at the end of the working period (M4 and M9)."
1645292|NCT01891916|Dietary Supplement|Extensively hydrolyzed casein formula + LGG|Extensively hydrolyzed formula containing Lactobacillus GG
1645293|NCT01891890|Drug|Oxcarbazepine|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
1645294|NCT01891890|Drug|Levetiracetam|Titration to target dose starting at week 3. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
1645295|NCT01891890|Drug|Lamotrigine|Titration to target dose starting at week 11. Dose increments above target may be made to a maximum of 3 increments with a minimum interval between dose escalations of 2 weeks.
1645296|NCT01891864|Drug|GP2015 Etanercept|Sandoz has developed GP2015 Etanercept (Sandoz's code for the drug product containing the active ingredient etanercept) to be biosimilar to Enbrel.
1645297|NCT01891864|Drug|Enbrel|Enbrel is used as reference product to GP2015.
1645298|NCT01891851|Drug|TMC435350 200 mg|Each patient will receive 200 mg (2 capsules) once daily orally from Day 1 to Day 7 in Session 1 and from Day 6 to Day 12 in Session 2
1645299|NCT01891851|Drug|Ritonavir 100 mg|Each patient will receive 100 mg (1 capsule) of ritonavir twice daily orally from Day 1 until Day 15 of Session 2
1645300|NCT01891838|Procedure|Volume controlled ventilation|
1645301|NCT01891838|Procedure|Pressure-controlled ventilation|
1645302|NCT01891825|Procedure|Surgical AF ablation|Minimally invasive thoracoscopic surgical ablation of atrial fibrillation
1645303|NCT01891825|Procedure|Percutaneous AF ablation|Percutaneous catheter ablation of atrial fibrillation
1645304|NCT01891812|Drug|Nitrous oxide 50%|
1645305|NCT01891799|Other|Option B+|"Using one low toxicity triple ARV regimen [(tenofovir (TDF) + lamivudine/emtricitabine (3TC/FTC) + efavirenz (EFV)] for all women, rather than adapting regimens by CD4+
Engaging all pregnant and postpartum women and their infants in the structured appointment and follow-up system currently only available to women receiving ART
Providing a simplified standardized public health approach both antenatally and postnatally, with adherence and retention support tailored to the particular health and social needs of peripartum women"
1645306|NCT01891786|Behavioral|Self-Management Intervention|The SMI will incorporate a discussion to introduce self-management and why it is important, and about problems associated with reducing CHD risk and managing type 2 diabetes. Specific topics addressed will include health behaviours to reduce CHD risk and manage diabetes including diet and exercise, as well as behaviours specific to managing diabetes, including medication adherence and self-care behaviours (e.g. footcare). Sessions are patient-directed and employ a shared decision-making approach, such that participants work with one another and the practice nurse facilitator to identify specific problems that they wish to address, and to identify solutions and approaches to managing their diabetes and CHD risk
1645307|NCT01891786|Behavioral|Risk Result|Participants will receive in-person personalised feedback about their combined genetic and lifestyle 10 year risk for developing CHD.
1645308|NCT01891773|Behavioral|Inhaled steroids in school.|Morning dose of inhaled steroids given in school by school nurse instead of at home.
1992240|NCT03322839|Behavioral|Single implementation strategy|The school-management will participate in a one-day training aimed at providing knowledge and skills related to the recommendations of the guideline for the prevention of common mental disorders at the workplace
1645311|NCT01891747|Drug|Bevacizumab|bevacizumab at 10mg/kg IV every 14 days (Phase I & phase II)
1645312|NCT01891747|Drug|Temozolomide|150 mg/m2/day for a 5-day regimen per month (Phase I & Phase II)
1645313|NCT01891747|Dietary Supplement|Vitamin C|250 mg vitamin C once a day (oral) - Phase I & Phase II
1645314|NCT01891734|Other|Problem Solving Therapy plus Moving Forward|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes. Participants in this arm will also receive the Moving Forward app for SmartPhones, which was adapted from Problem Solving Therapy to be used either as a standalone treatment or as an adjunct to other related therapies such as in-person Problem Solving Therapy or the Moving Forward website. The phone content matches Problem Solving Therapy. Benefits of the app include 24-hours accessibility of psychoeducational materials and worksheets.
1645315|NCT01891734|Other|Problem Solving Therapy|All Veterans will receive a standard 6-session administration of Problem Solving Therapy (Nezu & D'Zurilla, 1999). Session 1 will take place in-person during a scheduled appointment and will last for 1 hour. Subsequent sessions will take place over the telephone and will last for approximately 30 minutes.
1645316|NCT01891721|Behavioral|Brain Fitness Program (BFP)|"This computerized bottom-up cognitive intervention is designed to improve the speed and accuracy of auditory information processing through increasingly more difficult stimulus recognition, discrimination, sequencing, and memory tasks under conditions of close attentional control, high reward, and novelty. BFP consists of 6 exercises. Stimuli across the exercises are chosen such that they span the acoustic and organizational structure of speech, from very simple acoustic stimuli and tasks to complex manipulations of continuous speech. The exercises adaptively progress based on the subject's individual performance during a training session and become more challenging as the subject's abilities improve. Participants will work with 4 of the 6 exercises (15 min per exercise) in each session."
1645317|NCT01891721|Behavioral|Cognitive Package (Cogpack)|"This computerized top-down cognitive intervention is designed to provide training across a broad range of cognitive functions. Cogpack consists of domain-specific exercises aimed at training specific cognitive areas (attention, working memory, verbal and visual memory, executive functioning, reasoning, language) and non-domain-specific exercises that require the use of several functions at a time. Cogpack includes low-level cognitive exercises (i.e., scanning, hand-eye coordination, and psychomotor speed) that will not be included in this protocol to better separate bottom-up from top-down training interventions. There will be a total of 34 exercises and variants of the same exercises with different levels of difficulty. In each session, participants will work on a different subset of 4 to 6 exercises."
1645318|NCT01891721|Behavioral|Commercial Computer Games (Sporcle)|"Sporcle computer games will be used as a placebo treatment to control for the effects of computer exposure, contact with research personnel, time spent being cognitively active, and financial compensation for participation. The games cover trivia-type questions about geography, entertainment, science, history, literature, sports, movies, etc. Subjects will receive the same amount of attention from staff members and the same monetary reinforcements as participants in the experimental treatment groups. They will also complete 3 hours of training per week over 12 weeks, for a total of 36 hours."
1645319|NCT01891708|Other|bevacizumab, standard chemotherapy and radiation|the dose and application model of the three intervention are not specified by the sponsor who just observe the efficacy of the combination application of the three in non small cell lung cancer patients with brain metastasis once enrolled.
1645320|NCT01891695|Radiation|39.6 Gy radiation|
1645321|NCT01891682|Other|Observational|Observational, Translational non-treatment study
1645322|NCT01891669|Drug|PF-06263507|Part 1 - PF-06263507 will be administered intravenously in 21-day cycles in cohorts of 2 or more patients starting at a dose of 0.05 mg/kg. Increases in dose will continue until MTD is determined.
1645323|NCT01891669|Drug|PF-06263507|Part 2 - Patients with select tumor types will be treated at the MTD or Recommended Phase 2 dose selected in Part 1.
1645324|NCT01891656|Behavioral|Motivational Interviewing|"MI is a client centered, directive style of interacting with a person to help explore and resolve ambivalence about change (Miller & Rollnick, 2002). MI borrows from Client-Centered Counseling in its emphasis on empathy, optimism, and respect for client choice (Rogers, 1961). MI also draws from Self-Perception Theory, which says that a person becomes more or less committed to an action based on the verbal stance he or she takes (Bem, 1972). The effects of MI tend to be in the small-to-medium range when compared to no treatment, and nonsignificant when compared to more extensive treatment."
1645325|NCT01891656|Behavioral|Motivational Computer|The growing use of technology has led to the development of automated interventions for behavior change, including some that target drug and alcohol use (Elliott, et al, 2008; Lustria, et al, 2009; Revere & Dunbar, 2001; Walters, et al, 2006) and treatment interest (Lieberman & Massey, 2008). As discussed by Hester & Miller (2006), automated interventions have several potential advantages over face-to-face interventions: (I) They require little or no staff contact, which may increase cost-effectiveness; (2) they can allow for automatic data collection and follow-up; and (3) they can be disseminated with little loss of fidelity.
1645329|NCT01891617|Other|Exercise and diets|Exercise and high-fat diet Exercise and high-carbohydrate diet Sedentary and high-fat diet Sedentary and high-carbohydrate diet
1645330|NCT01891604|Dietary Supplement|breast milk with Bifidobacterium Longum subp. Infantis R0033|
1645331|NCT01891604|Dietary Supplement|breast milk|
1645332|NCT01891591|Procedure|Roux-en-Y gastric bypass (RYGP)|
1645333|NCT01891565|Behavioral|Feedback|
1645334|NCT01891526|Drug|9-cis-retinoic acid|Single dose of 9-cis-retinoic acid (Capsule 30 mg) as oral exposure
1645335|NCT01891513|Behavioral|Exercise|All participants will take part in 3 days/week of structured aerobic, stretching, and balance training for weeks 1-12. For weeks, 13-24, training will be reduced to 2 days/week and a resistance training component added. Participants will also be expected to engage in 2 bouts of 30 minutes of home-based walking per week.
1645336|NCT01891513|Drug|ACE inhibitor + exercise|In addition to exercise training, participants will receive an initial perindopril dose of 2 mg/day which will be titrated to 4 mg/day.
1645337|NCT01891513|Drug|Thiazide diuretic + exercise|In addition to exercise training, participants will receive an initial hydrochlorothiazide dose of 12.5 mg/day which will be titrated to 25 mg/day.
1645338|NCT01891513|Drug|Angiotensin receptor blocker + exercise|In addition to exercise training, participants will receive an initial losartan dose of 50 mg/day which will be titrated to 100 mg/day.
1645339|NCT01891500|Drug|Inhaled nitric oxide|Drug is initiated at 20ppm. Patients randomized to receive iNO at OI 10-15.
1645340|NCT01891500|Drug|Nitrogen Gas|Placebo gas (bioinert), Patients randomized to bioinert inhaled gas at OI 10-15.
1645341|NCT01891500|Drug|Crossover iNO|Patients who deteriorate (OI >20 on two consecutive blood gases) will be unblinded. If they are receiving placebo gas, they will be started on iNO and make up the crossover cohort.
1645344|NCT01891474|Device|U-health care|voice inception technique based U-healthcare service
1645390|NCT01891084|Drug|Backup NSAID ibuprofen|Backup NSAID ibuprofen 200mg orally every 8 hourly will also be provided to all participants, which can be taken when necessary (PRN) if the participant finds the fever intolerable.
1645581|NCT01889745|Drug|HX-1171|Anti-oxidatant, Anti-inflamation
1645346|NCT01891448|Other|WebCONSORT tool|Authors are directed to the WebCONSORT tool. The tool allows authors to obtain a customized CONSORT checklist and flow diagram specific to their trial design (e.g., non-inferiority trial, pragmatic trial, cluster trial) and type of intervention (e.g., pharmacological or non pharmacological). The checklist items and flow diagram should then be reported in the manuscript and the completed checklist submitted to the journal along with the revision.
1645347|NCT01891448|Other|Modified WebCONSORT tool|Authors are directed to a different version of the WebCONSORT tool. This tool includes the flow diagram part of the tool but not the main checklist or elements relating to CONSORT extensions.
1645348|NCT01891435|Drug|Oral paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
1645349|NCT01891435|Drug|Intravenous paracetamol|after giving medicine temperature is checked every 30 minutes for 2 hours
1645350|NCT01891435|Drug|Intramuscular diclofenac|after giving medicine temperature is checked every 30 minutes for 2 hours
1645351|NCT01891409|Device|Male circumcision using the Shang Ring device|
1645352|NCT01891396|Device|Hyaluronic Acid and TH|
1645353|NCT01891396|Device|Hyaluronic Acid|
1645354|NCT01891396|Device|Saline|Saline placebo packaged to look identical to comparator syringes.
1645355|NCT01891357|Procedure|Biopsy before and after three weeks of study treatment|Core biopsies for histological analyses, to be analysed by the central pathology
1645356|NCT01891357|Drug|Paclitaxel|
1645357|NCT01891357|Drug|lapatinib|
1645358|NCT01891357|Drug|trastuzumab|
1645359|NCT01891344|Drug|Oral rucaparib|600 mg BID
1645360|NCT01891331|Drug|VT-1161 (oral)|
1645361|NCT01891331|Drug|Fluconazole (oral)|
1645362|NCT01891318|Radiation|radiosurgery|Undergo radiosurgery
1645363|NCT01891318|Procedure|therapeutic conventional surgery|Undergo surgical resection
1645364|NCT01891318|Procedure|quality-of-life assessment|Ancillary studies
1645365|NCT01891305|Drug|VT-1161|
1645366|NCT01891305|Drug|placebo|
1645367|NCT01891292|Drug|Enalapril|0.25-0.35 mg/kg/day
1645368|NCT01891292|Drug|N-Acetylcysteine|N-Acetylcysteine 0.5 mmol/kg
1645369|NCT01891279|Other|elemental formula Elecare®|Babies will be randomized to received either elemental formula (Elecare®) or partially hydrolyzed formula (Pregestimil®) if breast milk is not available.
1645370|NCT01891279|Other|partially hydrolyzed formula|Babies will be randomized to received either partially hydrolyzed formula (Pregestimil®) or elemental formula (Elecare®)if breast milk is not available.
1645371|NCT01891266|Procedure|Non-tourniquet assisted TKA|The intervention group will undergo non-tourniquet assisted total knee arthroplasty, which means that blood flow to the lower limb is maintained throughout surgery.
1645372|NCT01891266|Procedure|Tourniquet assisted TKA|The procedure involves the use of a tourniquet around the thigh. During surgery the tourniquet will be inflated above the systolic blood pressure to ensure a complete bloodless surgical field.
1645373|NCT01891253|Device|non-invasive determination of cardiac output|
1645374|NCT01891227|Drug|Capecitabine|Capecitabine will be dosed at 1000mg/m2 twice daily for 14 days, followed by a 7-day rest period for a total cycle time of 21 days (until disease progression or unacceptable toxic effects).
1645375|NCT01891227|Drug|Bendamustine|Bendamustine 80mg/m2 will be administered on day 1 and 8 of a three week cycle (for a maximum of eight cycles).
1645376|NCT01891214|Other|Validation of the French Version of the Inflammatory Bowel Disease Questionnaire (IBDQ)|
1645377|NCT01891201|Drug|Oxytocin|Comparison of Primitive Newborn Reflexes between those exposed or not to Oxytocin
1645378|NCT01891175|Procedure|Elective caesarean section under spinal anaesthesia.|Patients with scheduled caesarean.
1645379|NCT01891175|Procedure|Elective caesarean section under spinal anaesthesia.|
1645380|NCT01891136|Drug|Peanut protein|Subjects will receive increasing amounts of peanut protein over the modified rush phase and the build-up phase of the protocol. Once the subject reaches the maintenance phase of the study, they will remain on that dose until they reach the oral food challenges at the end of the study.
1645381|NCT01891123|Device|PK guided arm|the dose of PTX or DOC will adjust based on the plasma drug concentration of previous cycle
1645382|NCT01891123|Drug|PTX 175mg/m2, DOC 75mg/m2|patients receive PTX or DOC dose based on body surface area every cycle, PTX 175mg/m2, DOC 75mg/m2
1645383|NCT01891110|Procedure|ES of the abdominal muscles|ES was applied with surface electrodes and fixed stimulation parameters with individual mA, depending on each patients´ sensibility.
1645384|NCT01891110|Procedure|ES of the limb muscles|Lower limb muscles were stimulated to produce a milking mechanism from the distal to proximal part of the limb to pump the venous blood from the peripheral to the central part of the body
1645385|NCT01891110|Procedure|ES of limbs & abdomen|The combination of the ES of the lower limb muscles and the abdominal muscles.
1645386|NCT01891097|Procedure|Acupuncture plus auricular acupuncture|"Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
Aricular acupuncture at Ear Shenmen, Heart, Kidney, Liver, Spleen, Occiput, and Subcortex.In each treatment borneol crystals will be attached to the left or right side of the ear in alternation with adhesive plaster in each acupuncture treatment visit. Subjects will be asked to press the borneol crystals lightly for five minutes in the morning, afternoon and evening everyday and reminded them to remove the plaster and borneol crystals after 48 hours."
1645387|NCT01891097|Procedure|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
1645388|NCT01891084|Drug|Paracetamol|Paracetamol 1 tablet (500mg) four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets (1gm) in each dose.
1645389|NCT01891084|Drug|Placebo|(Identical-looking) Placebo 1 tablet four times daily. For a maximum period of 5 days if the patient is still having fever. When required, participants may take up to 2 tablets in each dose.
1645582|NCT01889732|Device|ROTEM|
1717385|NCT00002074|Drug|Amphotericin B|
1645391|NCT01891071|Procedure|Lung volume recruitment|Inflation of the lungs to their maximal insufflation capacity by the consecutive delivery, by a manual resuscitator in this study, of volumes of air that are held with a closed glottis
1645392|NCT01891058|Device|drug-shock vs shock only|procainamide followed by electrocardioversion if necessary vs cardioversion only.
1645393|NCT01891045|Behavioral|OQ-45.2 no feedback|Completion of the OQ-45.2 before each session, but no feedback to therapists or patients
1645394|NCT01891045|Behavioral|OQ-45.2|Completion of the OQ-45.2 with real-time feedback to the therapist and full use of the suggested interventions every week of the treatment program
1645395|NCT01891019|Drug|Thalidomide oral|Thalidomide will be administered nightly, with each subject taking 2 capsules totaling 100 milligrams for the initial two weeks of treatment, 3 capsules totaling 150 milligrams for week 2 to week 4, and 4 capsules totaling 200 milligrams for week 4 to end of treatment. The subjects will take the medication for 12 weeks.
1645396|NCT01891006|Device|Negative Pressure Wound Therapy|The Negative Pressure Wound Therapy are changed on the 2. day and removed on the 4. day after the re-operation.
1645397|NCT01891006|Other|Standard wound dressing|The standard wound dressing is a a hydrofiber or alginate dressing used for open wounds
1645398|NCT01890993|Drug|liraglutide|Anonymised patient level data will be collected by the patients' own general practitioner and electronic case report form (eCRF) will be used to capture the data.
2012574|NCT01869439|Device|WMMS ImageReview software's LxW measurement technique|This software measurement technique is part of tthe WMMS and also measures the external wound LxW by the longest length (head to toe) times the widest width (perpendicular to the longest length).
2012575|NCT01869439|Device|WMMS ImageReview software's Visual External Wound Trace|This is a measurement technique of the ImageReview software that enables the user to trace the perimeter edge of the wound's visual image.
1645401|NCT01890967|Drug|LY3015014|Administered SC
1645402|NCT01890967|Drug|Placebo|Administered SC
1645403|NCT01890967|Drug|Statin|Administered orally
1645404|NCT01890967|Drug|Ezetimibe|Administered orally
1645405|NCT01890954|Device|Diabetes Assistant (DiAs)|Diabetes Assistance (DiAs) is a software residing in a Smartphone that contains the algorithms to regulate and control insulin deliveries (insulin bolus for: Basal rate, meal insulin and correction bolus) with inputs glucose values from a CGM and outputs insulin infusion by an insulin pump
1645406|NCT01890941|Drug|KCT-0809 ophthalmic solution|
1645407|NCT01890941|Drug|Placebo|
1645408|NCT01890915|Other|Heat Exposure|Heat exposure of 95 degrees F for up to 2 hours.
1645409|NCT01890902|Drug|Ketoprofen 10% Cream|
1645410|NCT01890902|Drug|Placebo|
1645411|NCT01890889|Dietary Supplement|Ad-Chol-Pre|
1645412|NCT01890889|Dietary Supplement|Half-dose Ad-Chol-Pre|
1645413|NCT01890889|Other|Defatted egg yolk without the active ingredient of the other two interventions|
1645414|NCT01890876|Other|Walking uphill|ascending about 500 m
1645415|NCT01890876|Other|Walking downhill|descending about 500 m
1645416|NCT01890863|Drug|Fluticasone Propionate / Salmeterol Xinafoate DISKUS|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via DISKUS (Ddpi) device.
1645417|NCT01890863|Drug|Fluticasone Propionate / Salmeterol Xinafoate ROTACAP|Fluticasone propionate and salmeterol xinafoate combination as a dry powder inhaler for oral inhalation with unit dose strength of 100/50 mcg (available in blister pack) administered via ROTAHALER (Rdpi) device.
1645418|NCT01890850|Other|Retrospective database study using administrative claims data|Data collection from OptumInsight proprietary research database which contains enrollment and claims data for individuals enrolled in commercial health plans.
1645419|NCT01890837|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
1645420|NCT01890837|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 2 weeks.
1645421|NCT01890811|Dietary Supplement|Boost High Protein|Subjects will receive stable amino acid isotopes IV and will receive Boost High Protein with added isotopes to measure anabolic response to a meal.
1645422|NCT01890798|Drug|Drisapersen|Drisapersen will be supplied as 3 millilitre (mL) vials containing 1mL sterile solution for subcutaneous injection. The strength of drisapersen solution will be 200 mg/mL.
1645423|NCT01890785|Drug|Lisdexamfetamine Dimesylate|Single dose of a 70 mg capsule on Day 1
1645424|NCT01890772|Drug|Telaprevir|
1645425|NCT01890772|Drug|Peginterferon alfa-2a|
1645426|NCT01890772|Drug|Ribavirin|
1645427|NCT01890772|Dietary Supplement|Vitamin D|
1645428|NCT01890759|Biological|Meningococcal Diphtheria Toxoid Vaccine|0.5 mL, Intramuscular
1645429|NCT01890746|Drug|Daunorubicin|For subjects between the ages of 18 and 60 years, 90 mg/m2/day by bolus IV injection through a freshly established free-flowing IV line for 10-15 minutes on days 1, 2, and 3. For subjects > 60 years: daunorubicin dose is adjusted to 60mg /m2.
1645430|NCT01890746|Drug|Cytarabine|100 mg/m2/day continuous IV infusion on Days 1 through 7.
1645468|NCT01890603|Other|Data Collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
1645469|NCT01890590|Device|CyberKnife|Stereotactic Body Radiation Therapy. 3 or 4 fractions of radiotherapy delivered by Cyberknife.
1645583|NCT01889719|Biological|MVA-CMDR|injections of MVA-CMDR vaccine
2012576|NCT01869439|Device|WMMS ImageReview software's External Wound Trace Overlay|This measurement technique is a feature of the WMMS, utilizing the visual external wound trace and overlaying it onto the thermal wound site. From the thermal overlay, variation data such as the differences in the thermal intensities (gradiency), mean, and the mode of the thermal wound bed can be measured.
2012577|NCT01867580|Device|V.A.C.Ulta with instillation|NPWT with instillation of a wound cleanser
2012578|NCT01867580|Device|V.A.C.Ulta without instillation|NPWT only
1645431|NCT01890746|Drug|Eltrombopag|200 mg orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose of IP will be increased to 300 mg if platelet counts are <100 Gi/L. IP continues until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage 100 mg orally once daily (a 50% dose reduction) will be used and after 7 days, the dose of IP will be increased to 150 mg if platelet counts are <100 Gi/L
1645432|NCT01890746|Drug|Placebo|Orally, once daily, beginning on Day 4 of the first cycle of induction. After 7 days, the dose given will be matching 300 mg Eltrombopag if platelet counts are <100 Gi/L. Placebo continues until achievement of platelet count of at least 200 Gi/L or assessment of remission of bone marrow status or a maximum of 42 days after initiation of most recent induction. In subjects of East Asian heritage placebo matching 100 mg Eltrombopag orally once daily will be used and after 7 days, the placebo matching 150 mg Eltrombopag will be given if platelet counts are <100 Gi/L.
1645433|NCT01890733|Device|Best Repair of torn Rotator Cuff|
1645434|NCT01890733|Device|InSpace™ system|
1645435|NCT01890720|Device|iNPWT|The Incisional Negative Pressure Wound Therapy (iNPWT) will be applied over the clean closed incision immediately following the operation (caesarean section). In the intervention group the therapy will be left in situ for five days.
1645436|NCT01890720|Other|Standard postoperative wound dressing|A standard wound dressing will be applied over the clean closed incision immediately following the operation (caesarean section). In the control group the dressing will be left in situ for at least 24 hours as standard procedure.
2012579|NCT01866267|Drug|Maraviroc|HIV positive patients infected with CCR5 tropic virus that have achieved an undetectable viral load on a non-Selzentry®-containing regimen [Protease Inhibitor (PI)/Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI)/Integrase Inhibitor plus 2 Nucleoside Reverse Transcriptase Inhibitor (NRTI)] are switched to once-daily Selzentry® (600mg qd) plus the same 2 NRTIs previously administered.
2012580|NCT01856478|Drug|methotrexate|intravenous bolus injection, once weekly
2012581|NCT01856478|Drug|afatinib|oral intake, once daily
2012582|NCT01856192|Drug|Cyclophosphamide|Given IV
2012583|NCT01856192|Drug|Doxorubicin Hydrochloride|Given IV
2012584|NCT01856192|Other|Laboratory Biomarker Analysis|Correlative studies
2012585|NCT01856192|Drug|Lenalidomide|Given PO
2012586|NCT01856192|Drug|Prednisone|Given PO
1645445|NCT01890694|Drug|Tolvaptan|15 mg once daily
1645446|NCT01890694|Drug|Placebo|15 mg once daily
1645447|NCT01890694|Behavioral|Hepatic Encephalopathy Assessment|The Number connection test, Digit symbol test, Constructional apraxia, Inhibitory control test, Repeatable Battery for the Assessment of Neuropsychological Status will be administered on Days 1, 2, 4, 6, and 8; discharge day; Weeks 1-4 post-discharge; and Months 2-6 post-discharge.
1645448|NCT01890694|Behavioral|Quality of Life Assessment|The SF-36 and Liver Disease Questionnaire will be administered on Day 1, Discharge day, Weeks 1-4 post-discharge, and months 2-6 post-discharge
1645449|NCT01890694|Biological|Vital signs|Vital signs (blood pressure, heart rate, respiration, temperature, weight, height) will be recorded at every visit.
1645450|NCT01890694|Biological|Blood laboratory tests|Blood laboratory tests (chemistry, hematology, liver function, urine electrolytes, renin, and copeptin) will be recorded at every visit.
1645451|NCT01890694|Procedure|Ascites Evaluation|Ascites will be assessed at every visit.
1645452|NCT01890694|Procedure|Edema|Edema will be assessed at every visit.
1645453|NCT01890681|Behavioral|Baby NAP SACC|
1645454|NCT01890681|Behavioral|Back to Sleep|
1645455|NCT01890668|Other|Osteopathic Manipulative Treatment|"Visit 1 between H60 and discharge :
Interview (pregnancy step, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam (osteopathic specific diagnosis, mobility…) Osteopathic Manipulative Treatment by sweet osteopathic mobilization Time of intervention = 30 to 45 min Visit 2 : 7 days after visit 1 (+/- 24H) with the same procedure
To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.
A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.
Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.
The follow-up for each patient is 6 months"
1645456|NCT01890668|Other|No Osteopathic manipulative Treatment|"Visit 1 between H60 and discharge :
Interview (pregnancy steps, initiation of breastfeeding, baby posture…) Osteopathic Clinical exam and Treatment will not be realized. Newborn will be undressed, lying naked (covered with polar sheet) on the exam table, dissimulated to parents by adequate screen. The osteopathic procedure will take place on a dolly to mimic from an indiscernible manner, osteopathic management.
Time of intervention = 30 to 45 min Visit 2: 7 days after visit 1 (+/- 24H) with the same procedure.
To keep the blinded procedure the interventions will be realized behind a screen, allowing interactions with parents but depriving their visibility.
A telephone contact will be perform at M1 (one month of life) to assess breastfeeding persistence and collect questionnaire data.
Two others telephone contacts will be perform at 3 months and 6 months to precise breastfeeding interruption date.
The follow-up for each patient is 6 months"
1645457|NCT01890655|Drug|MT-1303-Low|
1645458|NCT01890655|Drug|MT-1303-Middle|
1645459|NCT01890655|Drug|MT-1303-High|
1645460|NCT01890642|Device|J tip|This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
1645461|NCT01890642|Other|Pain Ease Spray|Cold Spray used to anesthetize the skin
1645462|NCT01890642|Drug|1% buffered lidocaine|Lidocaine placed using Jet Injection
1645463|NCT01890642|Other|placebo cooling spray (normal saline spray)|Normal Saline Sprayed as placebo for Pain Ease spray
1645464|NCT01890642|Other|Sucrose|Oral Sucrose used for children < 1 year
1645465|NCT01890629|Drug|Gemigliptin + Metformin / Sitagliptin + Metformin / Glimepiride + Metformin|
1645466|NCT01890616|Device|SmartPill ingestion|The participant would ingest the SmartPill and wear the data receiver for up to 5 days.
1645467|NCT01890603|Other|Data collection|Research involving materials (data, documents, records, or specimens) that have been collected, or will be collected, solely for non-research purposes (such as medical treatment or diagnosis).
1645728|NCT01888510|Procedure|computed tomography|Undergo ABC CT
2012587|NCT01856192|Biological|Rituximab|Given IV
1645470|NCT01890577|Drug|Aranesp|Observational study; minimum single dose of Aranesp required for eligibility; no protocol-specified regimen; study must not influence normal clinical practice.
1645471|NCT01890564|Other|Pressure controlled ventilation|For pressure controlled ventilation, the peak inflating pressure (PIP) is set for each tidal breath.
1645472|NCT01890564|Other|Volume controlled ventilation|For volume controlled ventilation, the tidal volume is set.
1645473|NCT01890564|Other|PRVC ventilation|Pressure-regulated, volume-controlled (PRVC) is an auto-regulated pressure-controlled mode of mechanical ventilation with a user-selected tidal volume target.
1645474|NCT01890551|Other|Dynamic kine-mri|Dynamic kinematic (KINE) magnetic resonance imaging (MRI) of the patellofemoral joint.
1645475|NCT01890538|Drug|Administration of 100 mg dimenhydrinate intravenous|
1645476|NCT01890538|Drug|2 g piracetam intravenous|
1645477|NCT01890499|Dietary Supplement|Low Residue diet arm.|Interventional arm is to provide low residue diet on postoperative day one.
1645478|NCT01890473|Drug|Abatacept|
1645479|NCT01890447|Other|Web-based survey questionnaire|Data collection will be done via web-based questionnaires generated by Sawtooth Software. Subjects will be asked for their ideal alternative (acceptance to immunisation) by selecting the factors that suit them the most. The subjects are then presented several sets of alternatives built around their ideal choice.
1645480|NCT01890434|Drug|Gadobutrol (Gadovist, BAY86-4875)|
1645481|NCT01890421|Drug|Gadobutrol (Gadovist, BAY86-4875)|
1645482|NCT01890408|Drug|wound infusion ropivacaine|"Laparotomy Hepatic surgery :
Bolu of 10 ml de ropivacaine 0,2% + infusion with elastomeric pump with ropivacaine 0,2% at a 10ml/h during 48 hours."
1645483|NCT01890395|Other|Blood draws|Blood sampling collected at 9 timepoints: pre-operative, during surgery X 3, immediately after surgery, 24 hrs post-op, 72 hrs post-op, 5 days and 7 days post
1645484|NCT01890382|Dietary Supplement|Whey protein|20 g twice a day (morning and evening)
1645485|NCT01890382|Dietary Supplement|whey plus creatine|whey protein combined with creatine (20 g and 2,5 twice a day, respectively)
1645486|NCT01890382|Dietary Supplement|leucine supplementation|7,5 g/d three times per day
1645487|NCT01890382|Dietary Supplement|soy protein|40 g twice a day
1645488|NCT01890369|Dietary Supplement|15g Mixed Essential Amino Acids|Dissolved in 250ml water.
1645489|NCT01890369|Dietary Supplement|3g Leucine|Dissolved in 250ml water.
1645490|NCT01890369|Dietary Supplement|15g Mixed Essential Amino Acid REFEED|Dissolved in 250ml water.
1645491|NCT01890356|Device|Transcranial electrical stimulation|
1645492|NCT01890343|Drug|florbetapir 18F|Subjects received a one-time intravenous (IV) bolus injection of 300 megabecquerels (MBq) florbetapir 18F.
1645493|NCT01890343|Drug|18F-FDG|FTD subjects received a one-time IV bolus injection of 185 MBq of 18F-FDG.
1645494|NCT01890330|Other|Canola Oil 25 g/d|Daily consumption of food items containing traditional canola oil (25 g/d) for 12 weeks.
1645495|NCT01890330|Other|Non-Canola Oil Mixture 25 g/d|Daily consumption of food items containing Non-Canola Oil Mixture (25 g/d) representing the typical Western diet for 12 weeks.
1645496|NCT01890317|Procedure|Mild hypothermia|Induction of mild hypothermia with invasive cooling for 24 hr in addition to primary percutaneous coronary intervention and optimal medical therapy.
1645497|NCT01890304|Other|Magnetic Resonance Imaging (MRI)|MRI will be obtained at study entry, following any TBI occuring during sanctioned practice or play, and at study exit.
1645498|NCT01890278|Radiation|Whole Brain IMRT|
1645499|NCT01890278|Radiation|Conventional Whole Brain RT|
1645500|NCT01890265|Drug|FG-3019|"Study Drug, FG-3019, 10 mg/ml, single dose vials, by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks
For the substudy, the dose will be the same but for a total of 8 infusions over 21 weeks"
1645501|NCT01890265|Drug|Placebo|"Sterile, clear aqueous solution, 10 mg/ml, single dose vials, by intravenous infusion every 3 weeks for a total of 16 infusions over 45 weeks
For the substudy, the dose will be the same but for a total of 8 infusions over 21 weeks"
1645502|NCT01890252|Device|Hyper CL|The Hyper CL is hyper osmotic contact lens that absorb fluids from the cornea and by that reduces corneal edema.
1645503|NCT01890252|Drug|saline solution|saline solution of 5% NaCl
1645504|NCT01890239|Other|Care Programme for the Last Days of Life|The Care Programme essentially aims to raise awareness among geriatric health care staff of the importance for improving end-of-life care and to prepare them for a change in end-of-life care, to train staff in delivering good end-of-life care with the support of a multi-professional document called the Care Guide for the Last Days of Life, to support dying geriatric patients with the Care Guide for the Last days of Life, to regularly evaluate the delivered end-of-life care and support and to further educate the staff in delivering optimal end-of-life care. The Care Programme consists of the following documents: (1) the Care Guide for the Last Days of Life, (2) supportive documentation and (3) an implementation guide.
1645505|NCT01890226|Behavioral|Mobile Personal Health Record App.|
1645506|NCT01890213|Biological|AVX701|
1645507|NCT01890200|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
1645508|NCT01890200|Drug|Ribavirin|conventional treatment of Hepatitis C
1645509|NCT01890200|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
1645510|NCT01890200|Drug|Placebo|Placebo, without acting ingredient.
1645511|NCT01890161|Drug|AXP1275|AXP1275 50 mg (2 × 25-mg capsules)
1645512|NCT01890161|Drug|AXP1275 matching placebo|AXP1275 matching placebo (2 capsules)
1645513|NCT01890148|Drug|AZD5069|oral BD administration of 45 mg AZD5069
1645514|NCT01890135|Drug|Zibotentan (ZD4054)|10 mg
1645515|NCT01890135|Drug|placebo|randomized double blind
1645516|NCT01890122|Drug|Alogliptin|Alogliptin tablets
1645517|NCT01890122|Drug|Metformin HCl|Metformin HCl capsules
1645518|NCT01890122|Drug|Alogliptin and Metformin Fixed-Dose Combination (FDC)|Alogliptin and metformin FDC tablets
1645519|NCT01890122|Drug|Alogliptin Placebo|Alogliptin placebo-matching tablets
1645520|NCT01890122|Drug|Metformin Placebo|Metformin placebo-matching capsules
1645521|NCT01890122|Drug|Alogliptin and Metformin FDC Placebo|Alogliptin and metformin FDC placebo-matching tablets
1645668|NCT01889004|Drug|Propofol|Escalating concentrations until loss of responsiveness
1645523|NCT01890109|Drug|AMG 334|Single dose level administered via SC in female subjects with hot flashes associated with menopause
1645524|NCT01890096|Radiation|HDR 2 Fraction|High dose-rate brachytherapy using real-time intra-operative transrectal ultrasound guidance. Patients will receive 27 Gy as a minimal Clinical Target Volume (CTV) dose delivered as two fractions of 13.5 Gy 7-13 days apart. The CTV is the ultrasound defined prostate with a 0-2 mm margin.
1645525|NCT01890096|Radiation|HDR 1 Fraction|High Dose-Rate Brachytherapy delivered in same manner as Arm 1, but to a prescribed CTV minimal dose of 19 Gy in a single fraction
1645526|NCT01890083|Behavioral|Exercise|
1645527|NCT01890083|Behavioral|Health Education|
1645528|NCT01890070|Dietary Supplement|Hazelnuts|Italian hazelnuts from Piedmont with Protected Geographical Indication Certification
1645529|NCT01890070|Dietary Supplement|Chocolate|Extra-dark Italian Chocolate (min. 70% of organic cocoa solids)
1645530|NCT01890070|Dietary Supplement|Red wine|Italian Organic Red Wine
1645531|NCT01890070|Dietary Supplement|Olive Oil|Italian Organic Olive Oil
1645532|NCT01890070|Dietary Supplement|Wild mixed greens|Italian organic wild mixed greens
1645533|NCT01890070|Dietary Supplement|Chestnut|Italian Organic Chestnut
1645534|NCT01890070|Other|No Dietary Supplement|Mediterranean Reference Diet, High Fat Diet, Low Carbohydrate or High Protein Diet without an added dietary supplement (hazelnut, chocolate, red wine, wild mixed greens, chestnuts, olive oil)
1645535|NCT01890057|Drug|Sugammadex|The dose of sugammadex
1645536|NCT01890031|Other|Interactive Cholesterol Advisory Tool|using the virtual clinician computer program for cholesterol information and education.
1645537|NCT01890031|Other|Study physician visits|In-person individual visits with a study physician to give information on cholesterol
1645538|NCT01890018|Behavioral|Electronic Pill Bottle tracking|All 4 groups will use the GlowCaps, a remote monitoring bottle, to take their statin medications
1645539|NCT01890018|Behavioral|Adherence Messaging|Some arms will receive adherence messages if they have not used the Glowcap bottles for 2 of the last 3 days.
1645540|NCT01890018|Behavioral|Social Influence|Some arms will select their own adherence feedback partner who will provide support in taking their medication as scheduled.
1645541|NCT01890005|Drug|Aspirin|Low dose aspirin (100 mg) starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
1645542|NCT01890005|Drug|Placebo|Placebo starting between 13 and 16 weeks of pregnancy until 36 weeks of pregnancy, taken at night.
1645543|NCT01889992|Radiation|Cardiac MRI|1 month post HTx, year 1 and year 2 annual post HTx eval. CMRIs completed using 1.5-Tesla Whole Body MRI system. Scout images will determine short & long-axis views of the heart. ECG-gated cine MR of 3 long axis and a contiguous short axis orientation will be obtained. T1-weighted delayed enhancement images will be obtained 10 minutes after injection of a gadolinium-based contrast agent. Measurements from each slice will be summed using the method of disks. Myocardial mass will be estimated by multiplying the myocardial wall volume at end diastole by the specific gravity of muscle (1.05gm/ml) and LV hypertrophy will be defined as LV mass indexed to height in meters 2.7 >/=35.8 g/m 2.7) (18). Delayed Gadolinium enhancement will be defined as any enhancement pattern greater than 0%.
1645544|NCT01889992|Procedure|Coronary angiography with IVUS|"Coronary angiography is a test that uses dye and special x rays to show the insides of your coronary arteries. The coronary arteries supply oxygen-rich blood to your heart.
Intravascular ultrasound is a test that uses sound waves to see inside blood vessels. This article discusses intravascular ultrasound to see inside the coronary arteries, the blood vessels that supply the heart."
1645545|NCT01889992|Other|Cardiac Allograft Remodeling|A surgical procedure in which a diseased heart is replaced with a healthy heart from a deceased person.
1645546|NCT01889992|Drug|M-TOR Immunosuppression|"Sirolimus (INN/USAN), also known as rapamycin, is an immunosuppressant drug used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. It prevents activation of T cells and B-cells by inhibiting their response to interleukin-2 (IL-2).
Sirolimus dosage based on blood levels."
1645547|NCT01889992|Procedure|Cardiac Biopsy C4D stain|A long, thin tube called a biopsy catheter is inserted through a vein in your neck or grion and guided through your blood vessels to your heart.
1645548|NCT01889992|Genetic|Genetic Mechanism of M-TOR|To identify the molecular and genetic mechanisms associated with development of early post-transplant CAR, and to evaluate the impact of mTOR-inhibitor Sirolimus on this process.
1645549|NCT01889992|Other|Cardiopulmonary Exercise Test (CPET)|The Cardiopulmonary Exercise Test is a highly sensitive, non-invasive stress test. It is considered a stress test because the exercise stresses your body's systems by making them work faster and harder. A disease or condition that affects the heart, lungs or muscles will limit how much faster and harder these systems can work. A CPET assesses how well the heart, lungs, and muscles are working individually, and how these systems are working in unison. Your heart and lungs work together to deliver oxygen to your muscles, where it is used to make energy, and to remove carbon dioxide from your body.
1645550|NCT01889979|Drug|Tramadol|100 mg of Tramadol was applied in the forearm SC (single dose).
1645551|NCT01889979|Drug|Placebo|2 ml of a sterile solution was applied in the forearm SC (single dose).
1645552|NCT01889966|Drug|Sildenafil|oral Sildenafil 3 x 20 mg for 90 days
1645553|NCT01889953|Other|EUS-guided biliary drainage|"Based on the patient`s condition, the will receive:
Rendezvous technique
Direct transluminal access transesophageal technique
Direct transluminal access transduodenal technique
or direct transluminal access using transgastric approach"
1645554|NCT01889940|Behavioral|Training for professionals (Spinal Cord Injury Unit staff).|"Prior to the training, separate focus groups for professionals, patients & families are conducted to determine each party's needs and worries.
Tailored training for professionals (customized according to focus groups contents) consists of 12 hours distributed in 2 days (1 day per week). It includes theoretical and practical exercises on early detection of PD, communication skills, management of psycho-emotional reactions, family interventions and teamwork alternatives. Standard motivational interviewing techniques for improving empathy skills and communication styles are employed.
Additionally, optional on-demand small group or individual coaching sessions (after training) will be offered (50-60 minutes per session) during a 6-months period."
1645555|NCT01889927|Other|Exercise Intervention|The exercise intervention will include aerobic, anaerobic, strength, core conditioning and stretching components.
1717386|NCT00002075|Drug|Flucytosine|
1645556|NCT01889914|Drug|2 different procedures of administration of insulin|Compare the efficiency of both types of therapeutic care in insulinoresistant type 2 diabetic patients: insulin multi injections (levemir et Apidra versus continuous infusion of insulin apidra by pump
1645557|NCT01889901|Behavioral|Enhanced walking program|The goal is to reach 12,000 steps per day by the end of the 6-month intervention period. If 12,000 steps per day are reached, participants will be encouraged to surpass this goal or to maintain this step count. Participants will be motivated by augmented behavior modification strategies such as: having access to the pedometer web page to view calculated step counts; scanning and discussing neighborhoods for available walking routes; and creating a buddy system for walking. Each will be facilitated by telephone-based physical activity behavior change counselling, occurring weekly, bi-weekly and monthly. Participants will upload their pedometer data wirelessly. At the end of the 6 months, the experimental group will be monitored for an additional 24 weeks with no further incentives.
1645558|NCT01889888|Other|Submucosal injection of ADRC|Subjects will undergo liposuction under local anesthesia. Lipoaspirate will be processed to isolate and concentrate ADRCs. Patients will undergo mechanical dilation followed by submucosal periurethral ADRC injections circle-wise into stricture site under endoscopic vision.
1645559|NCT01889875|Drug|"ALK Grazax 75,000 SQ-T Phleum pratense"|
1645560|NCT01889875|Drug|"ALK AluTard 225 Phleum pratense"|
1645561|NCT01889862|Drug|BMN165 20mg/day|Two different doses of BMN165 compared to each other and compared to placebo
1645562|NCT01889862|Drug|BMN165 40mg/day|Two different doses of BMN165 compared to each other and compared to placebo
1645563|NCT01889862|Drug|Placebo|Two different doses of BMN165 compared to each other and compared to placebo
1645564|NCT01889849|Drug|BIP 48|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
1645565|NCT01889849|Drug|Pegasys|Volunteers will be randomized into two groups, and each one will receive the two products in two stages separated by at least 4 weeks.
1645566|NCT01889836|Biological|'MenCC-Bio'|The experimental group will receive one dose of meningococcal C vaccine adsorbed produced by Bio-Manguinhos.
1645567|NCT01889836|Biological|MENJUGATE|The control group will receive one dose of meningococcal C vaccine adsorbed - MENJUGATE.
1645568|NCT01889823|Other|Hypoxia|Subjects will be breathing an individualized mix of nitrogen and room air titrated to an oxygen saturation of 80-85%.
1645569|NCT01889823|Other|Hyperoxia|Subjects will be breathing 100% oxygen
1645570|NCT01889810|Dietary Supplement|Vitamin D3 supplementation|3000IU (75µg) vitamin D3 will be given daily for a period of 26 weeks to the group who receive the active comparator. The efficacy of vitamin D3 supplementation on insulin resistance will be compared to the placebo group.
1645571|NCT01889797|Biological|Arm A: Rituximab|Rituximab 375 mg/m² IV x 4 weekly doses.
1645572|NCT01889797|Biological|Arm B: GA101|GA101 1,000 mg (flat dose) IV x 4 weekly doses.
1645573|NCT01889784|Device|Phototherapy through light emitting diode (LED) - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
1645574|NCT01889784|Device|Placebo phototherapy - 150J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 40 seconds with 3J of total energy for each diode and 150 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
1645575|NCT01889784|Device|Phototherapy through light emitting diode (LED) - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
1645576|NCT01889784|Device|Placebo phototherapy - 300J|The near-infrared radiation by light emitting diode (LED) will be performed with a cluster multi-diode arranged in an array of 34x18 cm containing 50 LEDs (GaAlAs, 850 nm). The phototherapy will be applied bilaterally on femoral quadriceps and triceps surae muscles during 80 seconds with 6J of total energy for each diode and 300 J of total energy delivery to muscle. Neither subject nor evaluators will known if LED was effective or placebo during data collection. A hidden button in the LED device is employed to ensure the double-blind procedure. This button allows selecting placebo or effective emission of near-infrared radiation while the time display is working. This button will be selected by a researcher who just participated of randomization procedure and LED application and had no access to data collection.
1645577|NCT01889771|Drug|Nicotine Patch|nicoderm patches are distributed in two different supplies through a telephone quitline
1645578|NCT01889758|Drug|Prograf|Brand: Prograf Capsules, 1.0mg Tacrolimus capsules containing white to off white powder equivalent to 1.0 mg of anhydrous tacrolimus are hard gelatin capsules with white opaque body and ivory capsules.
1645579|NCT01889758|Drug|Tacrolimus|Generic Hi: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
1645580|NCT01889758|Drug|Tacrolimus|Generic Lo: Generic tacrolimus Capsules, 1.0mg. Manufacturer to be determined (Aim 1).
1645584|NCT01889680|Drug|5-FU|400 mg/m2 IV bolus day 1 followed by 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days until disease progression
1645585|NCT01889680|Drug|LV|400 mg/m2 IV day 1 every 14 days until disease progression
1645586|NCT01889680|Drug|ziv-aflibercept|4 mg/kg IV day 1 every 14 days for 6 cycles (induction regimen); 4 mg/kg IV day 1 every 14 days until disease progression (continuation regimen)
1645587|NCT01889680|Drug|mFOLFOX6|5-FU 400 mg/m2 IV bolus plus leucovorin 400 mg/m2 IV plus oxaliplatin 85 mg/m2 IV on day 1 followed by 5-FU 2400 mg/m2 continuous IV infusion over 46 hours (days 1 and 2) every 14 days
1645588|NCT01889667|Drug|ORMD-0801 Dose # 1|Oral Insulin Formulation
1645589|NCT01889667|Drug|ORMD-0801 Dose # 2|Oral Insulin Formulation
1645590|NCT01889667|Drug|Placebo|Oil Capsules
1645591|NCT01889654|Other|Venous blood sampling|
1645592|NCT01889628|Dietary Supplement|Liquid-based Nutritional Formulae and liquid glucose|
1645593|NCT01889615|Other|PET/CT(3hours]|Low dose PET/CT 1 and 3 hours after injection of FDG, followed by a diagnostic CT with iv contrast
1645594|NCT01889602|Drug|Topiramate|Topiramate: 100 mg, 150 mg or 200 mg, po, 1x
1645595|NCT01889602|Drug|Lorazepam|Lorazepam: 2mg, po, 1x
1645596|NCT01889602|Other|Placebo|
1645597|NCT01889589|Other|Surveillance|
1645598|NCT01889576|Dietary Supplement|Magnesium Oxide|
1645599|NCT01889563|Other|Physical Exercise Training Program Exercise|Physical Exercise Training Program Exercise training was conducted in three times a week, during 12 weeks at high-intensity targets. Each session consisted of a five minute warm up (walking) at 2 km/h and 30 minutes with an intensity targets set at 70% of the peak speed rate. The increase of intensity was 0.5Km/h when the patient scored less than 4 point of Borg scale (moderate to intense effort) during each session. All evaluations were done at 6th week, in order to analyze the progression of outcomes and exactly adjust the intensity of training.
1645600|NCT01889550|Behavioral|Access to the website www.graviditetsportalen.dk|The website www.graviditetsportalen.dk contains information about the screeningtest for Downs syndrome. The website uses both text, video and animated graphics.
1645601|NCT01889550|Behavioral|Access to the website www.ouh.dk|Access to the usual information from the hospital website
1645602|NCT01889537|Behavioral|Virtual Reality|The patient will receive virtual reality during a burn care procedure
1645603|NCT01889524|Other|Mesh nebulizer|VMN (NIVO, Respironics®, Murrysville, Pennsylvania, USA) with an MMAD of 3.0 µm was placed in the elbow adapter at the mask. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL.
1645604|NCT01889524|Other|Jet nebulizer|"The JN (Misty Max, Air Life, Yorba Linda, USA) with a particle MMAD of 5 µm (according to the manufacturer information) was positioned in the circuit using a T piece placed between the circuit leak and the mask, and operated with oxygen flow at 8 L/min. Inhalation was performed using diethilene triamine penta-acetic technetium (99mTc-DTPA) with radioactivity of 25 millicuries (Nobre et al., 2007). Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and normal saline solution to complete a fill volume of 3 mL."
1645605|NCT01889524|Other|Noninvasive ventilation-NIV|Bilevel positive airway pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted to12 cmH2O peak inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure. Patients were adapted to use NIV before starting measurements, pressures were titrated before reaching the established levels and just after this period masks were fitted using the straps. They were oriented to use a breathing pattern inspiring deeply and exhaling slowing to avoid ventilator-patient asynchrony.
1645606|NCT01889511|Behavioral|Intervention group - texts|"Patients will be instructed to respond to the text message by sending a text stating if the oral agent was taken. If there is no response after 15 minutes, a second text message will be sent out, again requesting a response. Satisfaction surveys will occur in the intervention group at week 5 when the text messages end; and will take five minutes."
1645607|NCT01889498|Drug|Acetazolamide|"Acetazolamide twice a day, at 12 hour intervals:
250 mg Tablets; one tablet to be taken twice daily from three days before the day of surgery
One tablet to take two hours before surgery
500mg Intravenous Acetazolamide; to be administered upon arrival in critical care post-surgery; continuing at 12 hour intervals until last acetazolamide administration at 72 hours."
1645608|NCT01889472|Device|Nasal mask and oral appliance vs oro-nasal mask during autoCPAP therapy|
1645609|NCT01889446|Dietary Supplement|Calcium propionate|
1645610|NCT01889433|Drug|Algeron|1.5 µg/kg of body weight subcutaneously, once a week
1645611|NCT01889433|Drug|Pegasys|180 µg subcutaneously, once a week
1645612|NCT01889420|Drug|Combination therapy|"Following determination of the maximum tolerated dosages in the phase I portion of this study, all patients enrolled in the extension portion will receive the predetermined dosage combination of pomalidomide, everolimus and dexamethasone.
Cycles will span 28 days. Dosage schedules will be:
Everolimus daily for 28 days of a 28 day cycle;
Pomalidomide daily for 21 days of a 28 day cycle
Dexamethasone once weekly (on days 1,8,15,22) of a 28 day cycle."
1645613|NCT01889407|Drug|Idarubicin|8 mg/m2, iv drip on days 1-3
1645614|NCT01889394|Procedure|secondary wound healing|secondary wound healing
1645615|NCT01889394|Procedure|primary wound closure using a limberg flap|primary wound closure using a limberg flap
1645616|NCT01889381|Drug|Bone marrow cell-based therapy & 1-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human faces under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
1645669|NCT01888991|Other|Glucose Preload and Exercise Intervention|A glucose preload and exercise were administered to examine the modulate substrate oxidation
1645617|NCT01889368|Dietary Supplement|Grape Seed Extract|300 mg capsule of Grape Seed Extract; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
1645618|NCT01889368|Dietary Supplement|Placebo|300 mg capsule of maltodextrin; 1 capsule will be consumed for an acute post-prandial study day and 1 capsule will be consumed daily for 30 days.
1645619|NCT01889355|Device|AgaMatrix Blood Glucose Monitor|
1645620|NCT01889342|Behavioral|Metacognitive therapy|
1645621|NCT01889342|Behavioral|Cognitive behavioral therapy|
1645622|NCT01889329|Dietary Supplement|RUTF-1|Made from local food ingredients
1645623|NCT01889329|Dietary Supplement|RUTF-2|Made from local food ingredients
1645624|NCT01889329|Dietary Supplement|Plumpynut|Commercially made from peanut paste
1645625|NCT01889316|Device|Novii|The Novii is a modified device with similar technology to the AN24 device already being used in the USA.
1645626|NCT01889316|Device|AN24|
1645627|NCT01889303|Drug|DC|"Docetaxel plus cisplatin chemotherapy regimen was delivered as chemotherapy and concurrent chemoradiotherapy.
chemotherapy regimen: Docetaxel（Qilu Pharma. China） 75mg iv D1, Cisplatin（Qilu Pharma. China） 75mg iv D1 ,Q3W for 2 cycles, then Docetaxel 35mg iv D1, Cisplatin 25mg iv D1,QWx4 cycles(but rest in the 4th week during RT) + RT 45Gy( 5weeks) for concurrent chemoradiotherapy→ Rest for 4 weeks → Docetaxel 75mg iv D1,Cisplatin 75mg iv D1 ,Q3W for 2 cycles."
1645628|NCT01889303|Drug|concurrent chemoradiotherapy with 5-FU/CF|"FOLFOX6 regiment was delivered as adjuvant chemotherapy and 5-FU/CF as concurrent chemotherapy treatment.
Adjuvant chemotherapy: FOLFOX6 regiment : Oxaliplatin（Hengrui Medicine Co., Ltd，China） 85mg/m2 IV d1, Leucovorin （Hengrui Medicine Co., Ltd，China）400mg/m2 IV d1, 5-FU（Hengrui Medicine Co., Ltd，China） 400mg/m2 IV bolus d1, followed with 2400mg/m2 over 46h continuous infusion Q2Wx3 cycles of chemotherapy Concurrent chemotherapy : 5-FU 400mg/m2 IV and Leucovorin 20mg/m2 IV were given on the first four and the last three days in the period of radiotherapy. After radiation, patients will have a rest lasting for 4 weeks and then given Folxof6 regiment chemotherapy for 3 cycles."
1645629|NCT01889303|Radiation|adjuvant radiation|Therapy plan system was formulated by CT simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 45Gy of radiation at 1.8Gy/day, five days per week for 5 weeks, to the tumor bed, to the margins of resection, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
1645630|NCT01889290|Drug|Methylnaltrexone|Methylnaltrexone 12mg s.c. administered once daily until treatment stop of sufentanyl
1645631|NCT01889277|Drug|MT-3995-Low|
1645632|NCT01889277|Drug|MT-3995-High|
1645633|NCT01889277|Drug|Placebo|
1645634|NCT01889264|Other|Observational|Observational, Translational non-treatment study
1645635|NCT01889251|Drug|Ocriplasmin|
1645636|NCT01889251|Drug|Sham injection|
1645637|NCT01889238|Drug|Enzalutamide|160 mg administered as four soft gelatin capsules orally once daily
1645638|NCT01889212|Other|11C-erlotinib PET/CT|
1645639|NCT01889199|Drug|Flutamide|Flutamide 25 mg orally each 28 day cycle for 6 cycles
1645640|NCT01889199|Other|Placebo|Placebo orally each 28 day cycle for 6 cycles
2012588|NCT01856192|Drug|Vincristine Sulfate|Given IV
1645642|NCT01889173|Drug|TNX-102 SL Tablets at 2.8 mg|1 x TNX-102 SL Tablet (with potassium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
1645643|NCT01889173|Drug|TNX-102-B SL Tablets at 2.8 mg|1 x TNX-102-B SL Tablet (with sodium phosphate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
1645644|NCT01889173|Drug|TNX-102-C SL Tablets at 2.8 mg|1 x TNX-102-C SL Tablet (with trisodium citrate) at 2.8 mg held under the tongue until dissolution, without swallowing or chewing it.
1645645|NCT01889173|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
1645646|NCT01889160|Drug|AZD4721 Solution|1-9 mg/mL liquid solution
1645647|NCT01889160|Drug|AZD4721 Placebo|Liquid solution
1645648|NCT01889160|Drug|AZD4721 Suspension|9 mg/g liquid suspension
1645649|NCT01889147|Biological|hRESCAP|one acute bolus administration of different dosages of hRESCAP (microdose, part 1; and FIH: low dose, 414 µg; medium dose, 2480 µg; high dose, 5300 µg; part 2)
1645650|NCT01889147|Biological|Placebo|
1645651|NCT01889134|Drug|Sedron (alendronate)|
1645652|NCT01889134|Procedure|Parathyroidectomy|
1645653|NCT01889121|Behavioral|Structured psychosocial intervention|This is retrospective analysis of two groups of opiate-addicted pregnant women: 1) Pregnant women in methadone maintenance program 2) Pregnant women in methadone maintenance program AND structured psychosocial intervention
1645654|NCT01889108|Behavioral|SPEEDI|Behavior intervention combining parent education and physical therapy intervention for preterm infants
1645655|NCT01889095|Drug|BIAsp 30|patients receiving variable doses of Insulin BIAsp 30.start with 0.2 to 0.6unit per kg
1645656|NCT01889095|Drug|NPH/Reg|patients receiving Variable doses Of Insulin NPH Start with 0.2 to 0.6 unit per kg
1645657|NCT01889082|Behavioral|Behavioral Weight Loss Intervention for Young Adults|
1645658|NCT01889069|Drug|Rituximab|Rituximab will be administered at a dose of 1400 mg SC once a month for at least 4 doses during the Induction period, and at a dose of 1400 mg SC once every two months for at least 6 doses during the Maintenance period.
1645659|NCT01889069|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per standard local practice as a part of standard chemotherapy regimen.
1645660|NCT01889069|Drug|Vincristine|Vincristine will be administered as per standard local practice as a part of standard chemotherapy regimen.
1645661|NCT01889069|Drug|Doxorubicin|Doxorubicin will be administered as per standard local practice as a part of standard chemotherapy regimen.
1645662|NCT01889069|Drug|Prednisone|Prednisone will be administered as per standard local practice as a part of standard chemotherapy regimen.
1645663|NCT01889069|Drug|Bendamustine|Bendamustine will be administered as per standard local practice as a part of standard chemotherapy regimen.
1645664|NCT01889056|Drug|Erythropoietin (Epoetin beta)|
1645665|NCT01889056|Drug|Placebo|0.9% sodium chloride solution
1645666|NCT01889017|Other|patient questionnaire (tablet pc based)|
1645667|NCT01889004|Drug|Dexmedetomidine|Escalating concentrations until loss of responsiveness
1645677|NCT01888965|Drug|Dovitinib|"All patients in the study will receive Dovitinib, 500 mg orally daily for 5 days followed by 2 days off (7 day cycles) for up to 2 years.
If 500 mg is intolerable, 400 mg will be dosed. If 400 mg is intolerable, 300 mg will be dosed"
1645678|NCT01888952|Drug|Prednisone|Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.
1645679|NCT01888952|Drug|Roflumilast|Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
2012589|NCT01851174|Drug|Gemcitabine|Patients will receive Gemcitabine (1,000 mg/m^2) IV over 30 minutes after nab-paclitaxel infusion
2012590|NCT01851174|Drug|nab-Paclitaxel|Patients will receive nab-Paclitaxel (125 mg/m^2) IV over 30 minutes before Gemcitabine infusion
1645682|NCT01888900|Drug|DUAL|Asunaprevir and Daclatsvir
1645683|NCT01888900|Drug|QUAD|Asunaprevir, daclatsvir, peginterferon and ribavirin
1645684|NCT01888887|Other|Cetaphil Daily Facial Cleanser|
1645685|NCT01888874|Drug|GLPG0634|
1645686|NCT01888874|Drug|Placebo|
1645687|NCT01888861|Dietary Supplement|alpha-lipoic acid|the patients in this arm receive 900mg alpha-lipoic acid through NG tube.
1645688|NCT01888861|Drug|placebo|the patients in this arm were received 900mg placebo through NG tube.
1645689|NCT01888848|Dietary Supplement|Freeze-dried Blueberry|12g freeze-dried blueberry (powder), twice daily with water, for 90 days
1645690|NCT01888848|Dietary Supplement|Blueberry Placebo|12g blue, blueberry-flavored powder, twice daily with water, for 90 days
1645691|NCT01888835|Drug|Mirtazapine|
1645692|NCT01888835|Drug|Placebo|
1645693|NCT01888822|Drug|Ciprofloxacin|Prophylactic ciprofloxacin infusion before elective laparoscopic cholecystectomy
1645694|NCT01888822|Drug|Ampicillin-sulbactam|Prophylactic ampicillin-sulbactam infusion before elective laparoscopic cholecystectomy
1645695|NCT01888822|Drug|Placebo|Prophylactic placebo infusion before elective laparoscopic cholecystectomy
2012591|NCT01850615|Drug|Faster-acting insulin aspart|Administrated subcutaneously (s.c., under the skin) at each main meal.
1645698|NCT01888796|Drug|Linagliptin|
1645699|NCT01888796|Drug|placebo|
1645700|NCT01888783|Other|Tactile acuity measured by 2PD and the GOT|"For a detailed description of the methods see outcome measures"
1645701|NCT01888757|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
1645702|NCT01888744|Drug|GnRH agonist|
1645703|NCT01888744|Drug|GnRH antagonist|
1645704|NCT01888744|Drug|hP-hMG|
1645705|NCT01888744|Drug|Human chorionic gonadotropin|induction of final oocyte maturation
1645706|NCT01888744|Drug|Progesterone|
1645707|NCT01888731|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
1645708|NCT01888718|Drug|Fexofenadine Hydrochloride|Fexofenadine Hydrochloride Orally Disintegrating Tablets 30 mg
1645709|NCT01888679|Procedure|Head movement|Head movement in extension, flexion, right and left rotation
1645710|NCT01888653|Behavioral|Attention Bias Modification Treatment|ABMT is designed to implicitly modify patients' biased threat attendance via computerized training protocols. Recent meta analysis of 10 eligible RCTs (N=467) concluded that ABMT produced significantly greater reduction in anxiety symptoms than control training, with a medium effect size (d=.61, p<.001).11
1645711|NCT01888653|Behavioral|Attention Bias Modification Treatment|Attention Bias Modification Treatment (ABMT) is a novel 4-week, intervention designed to normalize attention bias to threat and reduce symptoms of anxiety. This neuroscience-informed treatment grew from research linking attention biases to neurocognitive perturbations in PTSD. Currently available treatments, such as cognitive behavioral therapy, may fail to address anxiety-related deficits in rapidly deployed processes instantiated in subcortical circuitries.ABMT was designed to at least partially address such rapidly-deployed processed through repetitive, computer based training methods, methods previously shown to alter implicit and dynamic neural processes.
1645712|NCT01888640|Device|TENS|"TENS Parameters: Active TENS and Placebo TENS
TENS Frequency - 10 to100 Hz
TENS Pulse Width - 200 µs
TENS Intensity - Maximal tolerable intensity
Duration: 2 hours per day. The 2 hours may be broken into smaller segments of time with a minimum of 30 minutes.
Administration - Daily
TENS Location: TENS electrode on the skin will be a 4 x 7 butterfly electrode to the cervical and lumbar region.
Placebo TENS Unit Active TENS unit Stand Care - no TENS"
1645713|NCT01888627|Other|Integrated care|The IC model was implemented into a network of the Psychosis Center of the University hospital (UKE), private psychiatrists of the UKE catchment area and other outpatient facilities. Integrated Care involves ACT treatment within this network. Patients have access to all evidence-based interventions according to need.
1645714|NCT01888588|Drug|Risk of symptomatic peptic ulcer|Current use of drugs (ASA; NSAIDs, SSRI,PPI, H2RA) versus non-use
1645715|NCT01888575|Drug|Risk of low dose aspirin discontinuation|PPI continuous use; No PPI usePPI
1645716|NCT01888562|Drug|Ponatinib|Ponatinib 45 mg daily for 4 weeks (4 weeks equal one cycle)
1645717|NCT01888549|Drug|High-dose PPI|:40mg, po(per oral) 2times.day, 8weeks
1645718|NCT01888549|Drug|standard PPI|: 40mg, po(per oral) 1times.day, 8weeks
1645719|NCT01888549|Drug|placebo|
1645720|NCT01888536|Drug|Limaprost|
1645721|NCT01888536|Drug|Pregabalin|
1645722|NCT01888536|Drug|Placebo(for Pregabalin)|mimic Pregabalin 75mg capsule
1645723|NCT01888536|Drug|Placebo(for Limaprost)|mimic Limaprost tablet
1645724|NCT01888523|Behavioral|Expressive writing|log in to an online survey and writing in the survey about your thoughts and feelings about your cancer. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
1645725|NCT01888523|Behavioral|Everyday experiences writing|log in to an online survey and writing in the survey about your thoughts and feelings about your everyday experiences. This requires 20-30 minutes of writing a day for 4 consecutive days. You will also provide saliva samples.
1645726|NCT01888510|Procedure|computed tomography|Undergo conventional free breathing CT
1645727|NCT01888510|Procedure|4-dimensional computed tomography|Undergo 4D CT
1645729|NCT01888510|Procedure|cone-beam computed tomography|Undergo ABC CBCT
1645730|NCT01888510|Procedure|cone-beam computed tomography|Undergo free breathing CBCT
1645731|NCT01888497|Drug|Gabapentin|250 mg, oral, prior to bedtime on the night before performance testing
1645732|NCT01888497|Drug|Diphenhydramine citrate|76 mg, oral, prior to bedtime on the night before performance testing
1645733|NCT01888497|Drug|Triazolam|0.5 mg, oral, prior to bedtime on the night before performance testing
1645734|NCT01888497|Drug|Placebo|Oral, prior to bedtime on the night before performance testing
1645735|NCT01888484|Biological|octanorm 16.5%|octanorm 16.5%, human normal immunoglobulin for subcutaneous (SC) administration.
1645736|NCT01888471|Procedure|Blood sample|Blood sample will be obtained from enrolled mothers at delivery(either immediately before or after delivery) Both original blood sample and cord blood sample will be obtained for serology.
1645737|NCT01888471|Other|Vaginal swab sample|Vaginal swab will be collected at delivery from a pre-defined subset of enrolled mothers for the identification of controls, for determining GBS maternal colonization status and serotype.
1645738|NCT01888458|Drug|Micafungin|All patients meeting selection criteria will receive micafungin IV. Prophylaxis will start within 48 hours of the beginning of the transplant-related conditioning regimen until 5 days after recovery from neutropenia (ANC ≥ 500/µl), or occurrence of an IFI, or up to 42 days, or withdrawal for any reason (e.g. patient's or investigator's decision, development of intolerance, death), whichever come first
1645739|NCT01888445|Drug|ASP1517|oral
1645740|NCT01888445|Drug|darbepoetin alfa|iv
1645741|NCT01888432|Drug|Everolimus + reduced tacrolimus|Everolimus will be initiated at Week 4 post transplantation. The dose will be adjusted to maintain the everolimus trough blood levels between 3-8 ng/mL for the duration of the study. Tacrolimus will be reduced to 3-5 ng/mL.
1645742|NCT01888432|Drug|Standard tacrolimus|Tacrolimus will be initiated as soon as possible after transplantation according to approved labeling recommendations. The trough level should be 5-15 ng/mL until randomization, 8-12 ng/mL from randomization until month 4 and after month 4 until end of study reduced to 6 -10 ng/mL.
1645743|NCT01888419|Other|Lipotransplantation|Lipotransplantation in general anaesthesia to the mastectomy site
1645744|NCT01888406|Behavioral|Guided Self-Help|
1645745|NCT01888406|Behavioral|Pure Self-Help|
1645746|NCT01888393|Drug|lumacaftor 200 mg q12h + ivacaftor 250 mg q12h|
1645747|NCT01888380|Procedure|Minimally invasive, virtual autopsy|Post-mortem cross-sectional imaging with CT-guided biopsy
1645748|NCT01888380|Procedure|Conventional autopsy|
1645749|NCT01888367|Drug|DFA-02 Antibiotic Gel|
1645750|NCT01888367|Drug|DFA-02 Placebo Gel|
1645751|NCT01888354|Drug|H.P. Acthar Gel (repository corticotropin injection)|Acthar Gel 80 IU
1645752|NCT01888341|Drug|Isotretinoin|Isotretinoin Capsules,20 mg
1645753|NCT01888328|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
1645754|NCT01888315|Device|Renal denervation with Symplicity Flex Medtronic/Ardian|Renal denervation using CE-marked devices will be performed according to best medical practice.
1645755|NCT01888315|Device|Renal denervation with EnligHTN St. Jude Medical|Renal denervation using CE-marked devices will be performed according to best medical practice.
1645756|NCT01888315|Device|Renal denervation with Paradise Recor|Renal denervation using CE-marked devices will be performed according to best medical practice.
1645757|NCT01888315|Device|Renal denervation with V2 Vessix|Renal denervation using CE-marked devices will be performed according to best medical practice.
1645758|NCT01888302|Drug|Cisplatin|Given IV
1645759|NCT01888302|Drug|Gemcitabine Hydrochloride|Given IV
1645760|NCT01888302|Other|Quality-of-Life Assessment|Ancillary studies
1645761|NCT01888302|Drug|Sirolimus|Given PO
1645762|NCT01888289|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
1645763|NCT01888276|Other|evaluation of word generation and of motivation|"Each subject will realize twice each test during 2 sessions with one hour in between :
During the session 1 :
The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.
The test of Stroop that assesses selective attention
During the session 2:
The test of words generation, which is to produce action verbs in response to 40 nouns, and noun in response to verbs.
The task of the casino (Iowa Gambling Test)
The task of landing
The test of Stroop"
1645764|NCT01888263|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
1645765|NCT01888250|Drug|Lamotrigine|Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
1645766|NCT01888237|Drug|Double dose of PPI|Lansoprasole (30mg) 2 tab oral BID
1645767|NCT01888237|Drug|sequence of drug use|lansoprazole 30 mg b.d. for 10 days amoxicillin 1000 mg b.d. (day 1 to day 5) metronidazole 400 mg b.d. (day 6-day 10) and clarithromycin 500 mg b.d. (day 6-day 10)
1645768|NCT01888224|Drug|Isotretinoin|Isotretinoin Capsules,40 mg
1645769|NCT01888211|Dietary Supplement|Omega 3 fatty acid supplementation|2 grams Omacor daily
1645770|NCT01888211|Dietary Supplement|Olive Oil|2 grams olive oil daily
2012592|NCT01850615|Drug|basal insulin|Administrated subcutaneously (s.c., under the skin) once daily.
2012593|NCT01846273|Drug|Ranibizumab|Intravitreal injections or 0.5 mg ranibizumab
2012594|NCT01846273|Drug|Verteporfin PDT|Infusion of 30 ml verteporfin in 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
2012595|NCT01846273|Drug|Sham PDT|Infusion of 30 ml 5% dextrose solution followed by 83 sec of laser light (50J/cm2; 600mW/cm2; 689 nm)
2012596|NCT01843842|Drug|Ergoferon|Safety and Efficiency of liquid dosage form
1645776|NCT01888159|Procedure|Bilateral Salpingectomy|
1645777|NCT01888159|Procedure|Tubal sterilization with bipolar energy|
1645778|NCT01888146|Behavioral|Interdisciplinary pain program|Interdisciplinary pain program, which includes behavioral health, nurse case management, physical therapy, and pharmacy embedded in primary care.
1645779|NCT01888133|Behavioral|Group Walk|weekly walking club session on Saturday mornings at Boston Common, lasting 30 min - 1 hour and engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
2012597|NCT01843842|Drug|Placebo|Safety and Efficiency of liquid dosage form
1645780|NCT01888133|Behavioral|Individual Walk|engage in daily physical activity (aiming for 10,000 steps/day or increase number of steps by 500 every 2 weeks)
1645781|NCT01888120|Drug|Ziconotide|
1645782|NCT01888107|Drug|Risperidone Long-acting Injectable (LAI) 25 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
1645783|NCT01888107|Drug|Risperidone LAI 37.5 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
1645784|NCT01888107|Drug|Risperidone LAI 50 mg|Risperidone LAI will be administered as a gluteal intramuscular injection given every 2 weeks for 52 weeks.
1645785|NCT01888094|Other|Ultrasound-guided cannulation and examination|
1645786|NCT01888081|Drug|A-dmDT390-bisFv(UCHT1) (Resimmune®)|
1645787|NCT01888081|Radiation|Ionizing Radiation|
1645788|NCT01888055|Device|transcranial direct current stimulation|
1645789|NCT01888055|Device|sham stimulation|
1645790|NCT01888042|Drug|Everolimus|10 mg (1 tablet of 10 mg)
1645791|NCT01888029|Device|transcranial direct current stimulation|
1645792|NCT01888029|Device|sham stimulation|
1645793|NCT01888016|Other|fascial manipulation|• 3 manual intervention on deep fascial tissues, according to fascial manipulation technique, providing a specific motor and manual assessment, and a deep manual intervention over specific fascial alteration.
1645794|NCT01888016|Other|standard physiotherapies treatment|"10 standard treatments in 2 weeks
Deltoid and infraspinatus muscles electrotherapy
Chair for passive continue mobilization at allowed range of motion (ROM). ½ h per day
Scar massage
Upper limb, cervical spine and scapula massages
Passive and assisted/active shoulder mobilization exercises
Scapula micro-mobilizations
Gleno-humeral decoaptation
Elbow, wrist and hand active mobilization
Proprioceptive exercise with and without the aid of the mirror"
1645795|NCT01888003|Drug|Iron sucrose|AMG patients will receive a standardized and well-accepted intravenous dose of 200 mg of iron sucrose (Venofer®) at −14 days and −7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females). An additional dose will be given on postoperative day 2.
1645796|NCT01888003|Drug|Epoetin Alfa|AMG patients will receive a standardized and well-accepted subcutaneous dose of 40,000 IU of epoetin alfa (PROCRIT®) plus an intravenous dose of 200 mg of iron sucrose (Venofer®) at −14 days and −7 days before their planned surgery, and if indicated, based upon laboratory testing on the day of their surgery (if patient has a Hgb < 13.0 g/dL and hematocrit between 30% and 39%, for males and females).
1645797|NCT01888003|Other|Blood Transfusion|An evidence-based, goal-directed blood transfusion protocol will be applied in AMG, CTG, and NAG patients during and after their surgical procedure to control for health provider variation in transfusion criteria and practices. This blood conservation protocol will consist primarily of the application of a restrictive transfusion trigger (Hgb < 8 g/dl) (21,22) but will also take into consideration the patient's intraoperative estimated allowable blood loss and hemodynamic stability.
1645798|NCT01887990|Drug|Ketamine|single dose IV 0.2 mg/kg ketamine
1645799|NCT01887990|Drug|placebo|saline infusion
1645800|NCT01887977|Other|MRI examination|The vocal and nasal tracts from the lips and nostrils to the beginning of the trachea are imaged with Siemens Avanto 1.5T MRI machine using carefully optimized, externally triggered imaging sequences that are synchronized with the rest of the experimental setting. A sound sample, given by the test subject, is recorded simultaneously to obtain a coupled data set: the speech sound and the precise anatomy which produces it.
1645801|NCT01887964|Other|RS4 enriched flour|Wheat flour with 30% resistant starch (type-4)
1645802|NCT01887964|Other|Control flour|Wheat flour without resistant starch (type-4)
1645803|NCT01887951|Drug|Penthrox Inhaler|
1645804|NCT01887951|Drug|Tramadol Injection|
1645805|NCT01887938|Biological|Recombinant human arylsulfatase A|Every other week (EOW) via an intrathecal drug delivery device (IDDD)
1645806|NCT01887938|Biological|Recombinant human arylsulfatase A|Every other week (EOW) via an intrathecal drug delivery device (IDDD)
1645807|NCT01887912|Biological|C. difficile Toxoid Vaccine|0.5 mL, Intramuscular
1645808|NCT01887912|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular
1645809|NCT01887899|Device|transcranial direct current stimulation|
1645810|NCT01887899|Device|sham stimulation|
1645811|NCT01887886|Drug|erlotinib|150 mg orally daily
1645812|NCT01887886|Drug|onartuzumab|15 mg/kg IV every 3 weeks
1645813|NCT01887886|Drug|placebo|IV every 3 weeks
1645814|NCT01887873|Device|Hyaluronan Thiomer i.o. implant|
1645815|NCT01887860|Other|Cetaphil Daily Facial Moisturizer SPF 50|Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
1645816|NCT01887847|Drug|Nicotine (Pharmaceutical Productions Inc.)|An investigational 2 mg sublingual nicotine tablet (Pharmaceutical Productions Inc.) will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
1645817|NCT01887847|Drug|Nicotine (Pharmaceutical Productions Inc.)|A Commit® 2 mg nicotine lozenge (GlaxoSmith Kline)will be administered in a randomized crossover design in 6 male and female otherwise healthy smokers.
1645818|NCT01887834|Dietary Supplement|Kyodophilus multi-strain probiotic capsules|
1645819|NCT01887834|Dietary Supplement|Kyodophilus Matching Placebo Capsules|
1645820|NCT01887821|Drug|Chloroquine|
1645821|NCT01887821|Drug|Dihydroartemisinin/Piperaquine|
1645822|NCT01887808|Other|Cetaphil DermaControl Oil Control Moisturizer SPF 30|
1645823|NCT01887795|Drug|Erlotinib|
1645824|NCT01887795|Drug|WBRT|
1645825|NCT01887782|Device|HFL rTMS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
1645826|NCT01887782|Device|iTBS|Magventure Cool B70 Coil with either RX100 or RX30 Stimulator
1645827|NCT01887756|Device|Tele Rehabilitation|
1645828|NCT01887743|Drug|Pantoprazole|This will be a single dose study where participants will receive 1.2mg/kg or no more than 100mg total one time dose as a liquid containing Carbon 13 labeled Pantoprazole with a final concentration of 4.0mg/mL.
1645829|NCT01887730|Behavioral|Hand washing with soap and water|Can infections be prevented by hand washing with soap and water
1645830|NCT01887730|Behavioral|Hand cleaning with alcohol-containing hand rub|Can infections be prevented by hand cleaning with alcohol-containing hand rub. Effect of intervention is assessed by following occurrence of infections
1645831|NCT01887730|Behavioral|Control|
1645832|NCT01887717|Device|TheraSphere|Treatment with TheraSphere
1645833|NCT01887717|Drug|Sorafenib|standard of care therapy for treatment of advanced hepatocellular carcinoma
1645834|NCT01887704|Device|Rotablator|Rotablator, Boston Scientific, Maple Grove, MN, USA. Rotablator will be used in the Rotablator arm.
1645835|NCT01887704|Procedure|conventional angioplasty|Conventional angioplasty was used in both arms.
1645836|NCT01887704|Procedure|stenting|Stenting was implanted in both arms.
1645837|NCT01887704|Device|Cutting balloon|Flextome cutting balloon(Boston Scientific, Natick, MA, USA) was used in both arms.
1645838|NCT01887704|Drug|Aspirin|Aspirin will be administrated in participants in both arms.
1645839|NCT01887704|Drug|Clopidogrel|Clopidogrel will be administrated to participants in both arms.
1645840|NCT01887704|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be used in both arms.
1645841|NCT01887704|Device|zotarolimus-eluting stent|Zotarolimus-eluting stent will be implanted in participants in both arms.
1645842|NCT01887704|Device|Everolimus-eluting stent|Everolimus-eluting stent will be used in both arms.
1645843|NCT01887704|Device|Sirolimus-eluting stent|Sirolimus-eluting stent will be used in both arms.
1645844|NCT01887691|Drug|eszopiclone|Eszopiclone at a dose of 1-3 mg (lowest tolerated dose, as determined using a dose escalation schedule and side effect profile)will be taken 30 minutes before bedtime for one week.
1645845|NCT01887678|Drug|Traumeel® / Zeel® Injectable Solution|Injection volume is 4.2 mL for active study medication (2.0 mL Zeel plus 2.2 mL Traumeel in one IA injection) on treatment days 1, 8 and 15.
1645846|NCT01887678|Drug|Placebo|Placebo is an injection of Saline
1645847|NCT01887665|Behavioral|incentives|A structured system of prize-based financial incentives rewards attendance at treatment visits.
1645848|NCT01887652|Other|conventional ovarian stimulation|a protocol of ovarian stimulation with recombinant FSH with dose according to age, ovarian size and previous treatment. In patients alder than 35, recombinant LH was added to ovarian stimulation.
1645849|NCT01887652|Other|individualized ovarian stimulation|After defining cut-off points of anti-mullerian hormone, using a ROC analysis, to discriminate excessive (≥20 oocytes retrieved) and poor response (≤4 oocytes retrieved), a individualized protocol was defined.Mild stimulation using daily doses (112.5 to 150 IU) of recombinant FSH or recombinant FSH combined with recombinant LH supplementation (375 IU total daily dose) were given to patients identified as at risk of excessive and poor response.
1645850|NCT01887626|Drug|Ticagrelor 90 mg whole tablet|Ticagrelor 90 mg whole tablet administered as a single oral dose
1645851|NCT01887626|Drug|Ticagrelor 90 mg tablet crushed|Ticagrelor 90 mg crushed and suspended in water
1645852|NCT01887626|Drug|Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube|Dispersed 90 mg ticagrelor 90 mg tablet suspended in water and administered through a nasogastric tube into the stomach
1645853|NCT01887613|Drug|Regnite|oral
1645856|NCT01887587|Drug|MLN9708|
1645857|NCT01887587|Drug|Vincristine|
1645858|NCT01887587|Drug|Doxorubicin|
1645859|NCT01887587|Drug|Dexamethasone|
1645860|NCT01887574|Other|questionnaire|questionnaires given to all patients to assess risk factors and quality of life
1645861|NCT01887561|Drug|dasatinib|
1645862|NCT01887548|Other|Personality Traits Questionnaires|Patients are required to fill out several personality traits questionnaires. The following personality traits scores would be collected: IBDQ, IBDQ-Emotional function score, IBDQ-Social function score, IBDQ-Bowel function score, IBDQ-Systemic symptom score, Neuroticism score, Lie (social conformity/desirability) score, Hospital anxiety score, Hospital depression score, Buss-Perry score, PA (physical aggression) score, VA (verbal aggression) score, A (anger) score, H (hostility) score.
1645863|NCT01887535|Drug|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as an oral suspension formulation.
1645864|NCT01887535|Drug|JNJ-54861911 10 mg|JNJ-54861911 10 mg will be administered as an oral suspension formulation.
1645865|NCT01887535|Drug|JNJ-54861911 30 mg|JNJ-54861911 30 mg will be administered as an oral suspension formulation.
1645866|NCT01887535|Drug|JNJ-54861911 80 mg|JNJ-54861911 80 mg will be administered as an oral suspension formulation.
1645867|NCT01887535|Drug|JNJ-54861911 25 mg|JNJ-54861911 25 mg will be administered as a solid dose formulation.
1645868|NCT01887535|Drug|Placebo|Matching placebo will be administered as an oral suspension formulation.
1645869|NCT01887522|Drug|Vinblastine + Nilotinib|"Vinblastine: administered in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
Nilotinib (Tasigna®): orally BID given continuously on Days 1- 28"
1645870|NCT01887522|Drug|Vinblastine|· Vinblastine 6 mg/m2 given in a 15-minute infusion, once weekly on Days 1, 8, 15 and 22 of each 28-day cycle.
1645871|NCT01887509|Device|Probe-based confocal laser endomicroscopy|"Patients will undergo:
Conventional rectoscopy
pCLE exam following injection of fluorescein, fluorescent contrast agent
EUS : echoendoscopy
Biopsies for histopathology : location identical to those of pCLE
Tumor resection will be performed according to standard oncologic principles.
All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.
Biopsies will be harvested in both healthy and tumor tissue as well.
After all procedures are complete, a second assessment of pCLE images by a third party will be performed."
1645872|NCT01887509|Procedure|Rectoscopy|"Patients will undergo:
Conventional rectoscopy
pCLE exam following injection of fluorescein, fluorescent contrast agent
EUS : echoendoscopy
Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.
All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.
Both healthy and tumor tissue will be examined."
1645912|NCT01887236|Behavioral|Stability Ball Program|Participants will take part in a biweekly, 8 week physical activity program that will include stability ball exercises
1645873|NCT01887509|Procedure|EUS|"Patients will undergo:
Conventional rectoscopy
pCLE exam following injection of fluorescein, fluorescent contrast agent
EUS : echoendoscopy
Biopsies for histopathology : location identical to those of pCLE - Tumor resection will be performed according to standard oncologic principles.
All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view."
1645874|NCT01887509|Procedure|Biopsy and resection|"Patients will undergo:
Conventional rectoscopy
pCLE exam following injection of fluorescein, fluorescent contrast agent
EUS : echoendoscopy
Biopsies for histopathology : location identical to those of pCLE
Tumor resection will be performed according to standard oncologic principles.
All visible lesions will be documented. Both healthy and tumor tissue will be examined. Location of sites of interest will be documented on a schema, completed with photographs of endoscopic view.
Biopsies will be harvested in both healthy and tumor tissue as well."
1645875|NCT01887483|Dietary Supplement|Vetal Laban active|Dairy product with probiotic
1645876|NCT01887483|Dietary Supplement|Placebo|Dairy product without probiotic
1645877|NCT01887470|Drug|Full dose preparation|
1645878|NCT01887470|Drug|Split dose preparation|
1645879|NCT01887457|Drug|VFEND|voriconazole will be administered in iv form
1645880|NCT01887444|Dietary Supplement|Lactobacillus reuteri DSM17938 probiotic|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to 2.108 CFU Lactobacillus reuteri living DSM17938. The probiotic is contained in a lipid emulsion.
1645881|NCT01887444|Other|Placebo|Drops suitable for infants. 2 X 5 drops / day will be issued, corresponding to the lipid emulsion without probiotics.
1645882|NCT01887431|Other|Telecare|Each patient will transmit glucometer and pump data electronically via a web site (Medtronic Carelink internet site www.carelink.minimed.com) to diabetes team and will receive feedback by telephone. Frequency of data transfer will be directly related to patients' metabolic control. In addition to data transmission Patient of the intervention group will be arriving during the intervention year for 3 clinic visit at the following time point : 0, 6 and 12 month.
1645883|NCT01887431|Other|Conventional therapy|3-month routine clinic visits
1645884|NCT01887418|Drug|QuickShot™ - 50 mg Treatment B|QuickShot™ for the delivery of testosterone
1645885|NCT01887418|Drug|QuickShot™ - 100 mg Treatment A|QuickShot™ for the delivery of testosterone
1645886|NCT01887418|Drug|Delatestryl 200 mg IM Treatment C|Standard of care
1645887|NCT01887405|Drug|Adrenaline auto-injector|"Each subject will be randomly assigned to use either the Jext or EpiPen first. The alternative auto-injector will then be used by the same subject in the second study session.
Valid for both Jext and Epipen:
Active ingredients: Adrenaline tartrate Dosage form: Prefilled auto-injector for single use, delivering one intramuscular injection Dose/strength: 150 μg Excipients: Sodium chloride, sodium metabisulphite (E223), hydrochloric acid (for pH adjustment), water"
1645888|NCT01887392|Other|Knowledge Translation Education Sessions|Two interactive sessions will be delivered to the interprofessional team at Month 1 and Month 6 and are 1 hour in length. The Clinical Consultant Pharmacist at each LTC home will lead the Knowledge Translation Sessions. Participants will watch an educational video, developed by the co-investigators with expertise in osteoporosis and geriatrics and members of the Ontario College of Family Physicians. Accompanying materials that support the topics in the video will be provided. Following the educational video, one of the experts from the video will phone the LTC home to address questions and provide the home with direct access to an expert.
1645889|NCT01887379|Drug|GRDF furosemide|The GRDF furosemide tablet contains Fe3O4, which serves as an inactive magnetic marker to allow monitoring of the tablet transit through the gastrointestinal tract, using the MMM imaging technique.
1645890|NCT01887366|Drug|TV-1380 150 mg|Subjects assigned to TV-1380 150 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. The injection volume will be the same for all treatment groups. Therefore, to accommodate the volume required for the highest dosing group (3.0 mL), subjects in this group will receive 3.0 mL IM injection of TV-1380 150 mg (1.5 mL TV-1380 and 1.5 mL placebo/diluents).
1645891|NCT01887366|Drug|TV-1380 300 mg|Subjects assigned to TV-1380 300 mg will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL TV-1380.
1645892|NCT01887366|Drug|Placebo|Subjects assigned to placebo will be administered one intra-muscular (IM) injection once weekly over 12 weeks. Subjects in this treatment group will receive 3.0 mL placebo.
1645893|NCT01887353|Drug|Ranolazine|Patients will take ranolazine 1000 mg tablets twice daily
1645894|NCT01887353|Drug|Placebo|Placebo pill manufactured to mimic ranolazine 1000 mg tablets. Patients will be instructed to take two pills a day.
1645895|NCT01887340|Drug|Carboplatin|"- carboplatine: Dose (mg) = AUC x (GFR + 25)
GFR : glomérulaire filtration (ml/min)
AUC : area under curve (mg/ml x min)"
1645896|NCT01887340|Drug|Etoposide|100 mg/m2 D1 to D5
1645897|NCT01887340|Drug|Cisplatin|20 mg/m2 de D1 to D5
1645898|NCT01887327|Drug|stannsoporfin|
1645899|NCT01887327|Drug|Placebo|
1645900|NCT01887314|Dietary Supplement|Standardized Ginger extract|
1645901|NCT01887301|Drug|Sativex|Patients receive four sprays (each 100 uL) of Sativex to the oral mucosa, which contain 10.8 mg THC and 10 mg CBD in total.
1645904|NCT01887275|Device|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment. First month: ozone concentration: 20µg ~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
1645905|NCT01887275|Drug|conventional interferon-α|Patients in the conventional interferon-α treatment group received subcutaneouslly injection of 5 million units of conventional interferon-α in three times per week for at least 24 weeks.
1645906|NCT01887262|Device|BCM-guided fluid management|
1645907|NCT01887262|Procedure|Fluid management based on the clinical information alone|
1645908|NCT01887249|Drug|Clarithromycin|
1645909|NCT01887249|Drug|metronidazole|
1645910|NCT01887249|Drug|esomeprazole|
1645911|NCT01887236|Behavioral|Step physical activity program|Participants will take part in a biweekly, 8 week physical activity program that will include step exercises
1645913|NCT01887223|Procedure|Transconjunctival needling revision|Surgical revision. A 25 Gauge needle was inserted under the subconjunctival space and perforate the encapsulated bled. The encapsulated bleb was ruptured with sweeping movement up and down, back and forth.
1645914|NCT01887223|Drug|Medical treatment|Hypotensive eye drops are initialized one by one regarding intraocular pressure control. Nonspecific beta blocker and/or prostaglandin, followed by carbonic anhydrase inhibitors and/or selective alpha agonist.
1645915|NCT01887210|Behavioral|IMB Gaming Adherence Intervention|Combination of smart pill bottle cap with mobile gaming application tailored for those living with HIV
1645916|NCT01887210|Behavioral|Enhanced treatment as usual|Smart pill bottle cap and mobile phone but no game
1645917|NCT01887197|Other|Absorptive clearance scan|Subjects inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m sulfur colloid.
1645918|NCT01887197|Drug|inhaled hypertonic saline (7%)|nebulized hypertonic saline (7%)
1645919|NCT01887197|Drug|mannitol inhalation powder|mannitol inhalation powder
1645920|NCT01887184|Drug|Dexmedetomidine|Dexmedetomidine 1.5mcg/kg was given intranassaly
1645921|NCT01887171|Drug|Tacrolimus|1000 ml of HTK solution (Custodiol, Dr. Franz Köhler Chemie GmBH) cooled to 2-4˚C containing 20 ng/ml Tacrolimus would be given through intraportal (under gravity pressure of 40 cm H2O) and intraarterial infusion (under pressure of 40-50 mm Hg) followed by intraportal infusion of 200 ml 5% solution of Albumin containing 20 ng/ml Tacrolimus under gravity pressure of 40 cm H2O.
1645922|NCT01887158|Drug|Polyethylene glycol|
1645923|NCT01887158|Drug|Bisacodyl|
1645924|NCT01887145|Procedure|Endoscopic surgery|Surgery dwas done under local anesthesia injected at the portal sites only. Tourniquet was used. Each of the two skin incisions in the endoscopic procedure was 1 cm long. With the endoscope inserted from the distal portal and a hook knife inserted from the proximal portal, the transverse carpal ligament was divided from its distal edge to its proximal edge. Incisions were closed with non-absorbables sutures and a soft dressing was applied. Sutures were removed 10 days postoperatively.
1645925|NCT01887145|Procedure|Open surgery|Open carpal tunnel release using conventional open technique under local anesthesia and tourniquet. The incision in the open procedure extended from about 1 cm proximal to 3 cm distal to the wrist crease. The transverse carpal ligament was divided; no additional procedures were performed. a soft dressing was applied. Dressing and sutures were removed 10 days postoperatively.
1645926|NCT01887132|Drug|Donepezil|
1645927|NCT01887132|Drug|Placebo|
1645928|NCT01887119|Drug|Eplerenone|
1645929|NCT01887119|Other|Placebo|Eplerenone-matched placebo
1645930|NCT01887106|Drug|GLPG1205 single ascending doses, oral suspension|Single dose, oral suspension at 10 mg/mL or 50 mg/mL, starting dose of 10mg escalating up to 800mg
1645931|NCT01887106|Drug|Placebo single ascending doses, oral suspension|Single dose, oral suspension matching placebo
1645932|NCT01887106|Drug|GLPG1205, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension at 10 mg/mL or 50 mg/mL, anticipated doses: 100mg to 400mg
1645933|NCT01887106|Drug|Placebo, multiple ascending doses, oral suspension|Multiple doses, daily for 14 days, oral suspension matching placebo
1645934|NCT01887093|Behavioral|walking|Participants in both walking groups were requested to walk at the speed of 2.5 miles/h for 30 min/day or more on at least 5 days/week for a period of 12 weeks.One group was asked to walk in the morning and the other group was asked to walk in the evening.
1645935|NCT01887080|Other|Exercise|"This group had the exercise program, thrice a week for eight weeks.
The exercise protocol consists of 10 exercises: aerobic and resistance exercises. It was used a moderate intensity (60% of maximum heart rate of stress test with progression until 80%). Subjects were taught to monitor exercise intensity by measuring the manual heart rate, by using the scale of perceived exertion Borg (11-13), and by observation of signs.
The exercise protocol was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
1645936|NCT01887080|Device|Microcurrent|"This group had the exercise program after electrolipolysis, thrice a week for eight weeks.
The electrolipolysis consisted of 30-minute sessions: the first 15 minutes with a frequency of 30 Hz and the final 15 minutes with a frequency of 10 Hz; with a pulse time of 10 ms; and an intensity below the threshold of sensitivity (with a maximum of 750 μA). There were used 4 transcutaneous electrodes in the abdominal region (parallel position).
Microcurrent was done with supervision from a distance, using information technologies (SMS, phone, email ...), and when necessary it was resorted to routine meetings."
1645937|NCT01887080|Other|Cardiovascular Risk Factors|It was handed flyers on major cardiovascular risk factors: cholesterol, obesity, diabetes, smoking and hypertension.
1645938|NCT01887067|Procedure|Renal denervation therapy|
1645939|NCT01887054|Device|Tower of Hanoi|
1645940|NCT01887054|Other|Placebo group - non use of Tower of Hanoi|
1645941|NCT01887041|Procedure|Stent|Endoscopically inserted biliary tract drainage
1645942|NCT01887041|Procedure|Biliodigestive anastomosis|Biliodigestive anastomosis
1645943|NCT01887028|Device|Fisher and Paykel Humidifier (MR860AEU)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation
1645944|NCT01887015|Device|Nasal high flow cannula (OptiflowTM, MR850 heated humidified, Fisher & Paykel Healthcare, Auckland, New Zealand)|
1645945|NCT01887002|Drug|ONO-2952|ONO-2952 Active tablets, every day for 2 weeks
1645946|NCT01887002|Drug|Placebo comparator|ONO-2952 Matching Placebo every day for 2 weeks
1645947|NCT01886989|Dietary Supplement|Cocoa polyphenols|Cocoa polyphenols (960mg) reconstituted in water
1645948|NCT01886976|Biological|CART-138 cells|
1645949|NCT01886963|Procedure|SPY - Unblinded use of SPY Elite|Surgeon plans tissue advancement flaps with the aid of Spy Elite System imaging
1645950|NCT01886963|Procedure|Control - Blinded use of SPY Elite|Surgeon is blinded to Spy Elite imaging and plans tissue advancement flaps according to clinical judgment alone
1645951|NCT01886937|Drug|Phentermine|After 7 days of phentermine 37.5 mg administration, food intake should be less than after 14 days of placebo.
1645952|NCT01886937|Drug|placebo|Food intake as measured by a laboratory study should be greater after 7 days of placebo administration compared to seven days of phentermine administration.
1646160|NCT01885403|Device|non-invasive respiratory parameter measurements|
1645953|NCT01886924|Behavioral|Brief Computer MI for Smoking Cessation|Brief computer MI intervention to motivate tobacco quitline use
1645954|NCT01886924|Behavioral|Nutrition Control|Computer delivered nutrition education control condition
1645955|NCT01886911|Other|Attention Training Intervention Game|
1645956|NCT01886911|Other|Prosocial Training Intervention Game|
1645957|NCT01886911|Other|Control for Attention Intervention|
1645958|NCT01886911|Other|Control for Prosocial Intervention|
1645959|NCT01886898|Other|Infant formula|infant formula
1645960|NCT01886898|Other|Breastfeeding|
1645961|NCT01886885|Behavioral|Mindfulness Based Chronic Pain Management Intervention|Mindfulness-Based Chronic Pain Management (MBCPM) is an intervention developed by Jackie Gardner-Nix, MD for individuals suffering from chronic pain. The focus of MBCPM is to teach clients skills that will facilitate the development of detached observation and reduce the experience of suffering through cognitive re-appraisal. The activities used within MBCPM include mindfulness meditation, gentle stretching/mindful movement, guided imagery, art techniques, psychoeducation, and discussion. There are daily homework assignments of just 5-30 minutes a day in MBCPM. Each class is two hours long with a break in the middle.
2012598|NCT01843543|Other|Mindfulness Based Stress Reduction Course|The MBSR course developed by Jon Kabat-Zinn is a mind-body intervention that incorporates mindfulness techniques. This is an eight week MBSR course at OHSU. Class instruction will be augmented by daily home practices of listening to audiotapes, diary reflections, and reading preloaded on itouch devices provided to participants. Adherence will be assessed through in-house iMINDr tracking program loaded on the itouch.
2012599|NCT01838434|Drug|lenalidomide|given PO
2012600|NCT01838434|Drug|idelalisib|given PO
1645971|NCT01886820|Drug|[18F]NAV4694|
1645972|NCT01886807|Device|TrueView PCD Video Laryngoscope|
1645973|NCT01886794|Drug|Topical Vaginal Estrogen Cream/placebo|Topical vaginal estrogen cream is commonly but not universally used to improve the health of vaginal tissue prior to surgery. This study will provide data regarding estrogen effects for post-menopausal women undergoing pelvic organ prolapse.
1645974|NCT01886781|Drug|Lactobacillus plantarum 299v|two capsules of 5 X 10 ^9 c.f.u each
1645975|NCT01886781|Drug|Placebo comparator|Micro-crystalline cellulose powder, identical taste, texture and appearance
1645976|NCT01886781|Other|Run in period|Run -in period of one to two weeks. No treatment. Treatment started at baseline following randomization to either L.plantarum 299v or placebo
1645977|NCT01886781|Other|Wash - out period|Wash - out period following treatment phase of eight weeks
1645978|NCT01886768|Device|Double pledget nasal anesthesia (DPNA)|By using a transnasal endoscope as a guide and a biopsy forceps, two gauze strips soaked with decongestant and anesthesia will be delivered to the middle meatus followed by the inferior meatus under real-time transnasal endoscopic guidance.
1645979|NCT01886768|Device|Single pledget nasal anesthesia (SPNA)|Another randomized group of patients will also receive endoscopic-guided gauze pledgetting using a transnasal endoscope as a guide and a biopsy forceps. One gauze strip soaked with decongestant and anesthesia will be delivered to either the middle meatus or inferior meatus determined by anterior rhinoscopy.
1645980|NCT01886755|Dietary Supplement|ORS rehydration solution|
1645981|NCT01886755|Dietary Supplement|placebo|
1645982|NCT01886742|Drug|Standard Dose Group|The standard dose of Cefazolin will be administered intravenously.
1645983|NCT01886742|Drug|Weight Based Group|The weight-based dose group will receive 30 mg/kg cefazolin dose intravenously.
1645984|NCT01886729|Other|transcranial direct current stimulation (tDCS)|
1645985|NCT01886716|Behavioral|Anxiety Attention Training|Anxiety Attention Training will preferentially direct participants' attention away from reminders of anxiety.
1645986|NCT01886716|Behavioral|Alcohol Attention Training|Alcohol Attention Training will preferentially direct participants' attention away from reminders of alcohol.
1645987|NCT01886716|Behavioral|Control Training|Placebo Anxiety Training and Placebo Alcohol Training will not preferentially direct participants' attention away from reminders of anxiety or alcohol.
1645988|NCT01886703|Behavioral|Pedometer Walking Program|All subjects will be prescribed a low-intensity walking program based on their current activity level and an daily assigned step count goal (with the current physical activity recommendations of 30 minutes of moderate-to-vigorous activity per day or 150 minutes per week as the ideal goal). Participants will be provided with face-to-face counseling and written material describing their specific individualized walking program. Participants will also be instructed to maintain their normal activities as much as possible during the intervention period. Participants will be given a pedometer and instructed to wear it at least 5 days per week for the duration of the study.
1645989|NCT01886690|Drug|carboxymethylcellulose sodium based new eye drop formulation|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation in each eye as per protocol for 90 days.
1645990|NCT01886690|Drug|carboxymethylcellulose sodium based eye drops|1 to 2 drops carboxymethylcellulose sodium based (REFRESH PLUS®) eye drops in each eye as per protocol for 90 days.
1645991|NCT01886677|Behavioral|Immediate diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
1645992|NCT01886677|Behavioral|Delayed diet and exercise intervention|Both arms will receive the same intervention: a healthful diet plus exercise intervention to promote a weight loss of up to 2 pounds/week. The only difference is the timing of the delivery of the intervention (immediate vs. delayed).
1645993|NCT01886664|Drug|sevoflurane|
1645994|NCT01886664|Drug|Desflurane|
1645995|NCT01886638|Drug|Abacavir|
1645996|NCT01886625|Procedure|unilateral single-port VATS sympathicotomy|
1645997|NCT01886612|Device|Duo-STIM neuromuscular electrical stimulator|
1645998|NCT01886612|Device|AV Impulse System Model 6000|
1645999|NCT01886599|Drug|Asunaprevir|
1646000|NCT01886586|Behavioral|Problem Solving Therapy|6-12 sessions of Problem Solving Therapy (both members of dyad)
1646001|NCT01886586|Behavioral|Problem Solving Therapy + Exercise|6-12 sessions of Problem Solving Therapy + Exercise (both members of dyad)
1717387|NCT00002075|Drug|Fluconazole|
1646002|NCT01886586|Other|Enhanced Usual Care|Staff will document and monitor all mental health treatment (e.g., medications that participant may be taking) and psychotherapy (e.g. counseling or social services).
1646003|NCT01886573|Drug|Azacitidine|Given SC
1646004|NCT01886573|Drug|Entinostat|Given PO
1646005|NCT01886573|Other|Laboratory Biomarker Analysis|Correlative studies
1646006|NCT01886573|Other|Pharmacological Study|Correlative studies
1646007|NCT01886573|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1646008|NCT01886560|Drug|Doxycycline|Tablets Doxycycline 50mg bid for 2 weeks,50mg qd for 10 weeks.
1646009|NCT01886560|Drug|Placebo|Tablets placebo one PO per day for 12 weeks
1646010|NCT01886547|Other|Prostate health screening|
1646011|NCT01886534|Other|Standardized Heart Failure Discharge Summary to Primary Care Physicians©|At hospital discharge, in addition to usual care, the Study Nurse will fax an introduction letter and a 1-page comprehensive Standardized Heart Failure Discharge Summary to Primary Care Physicians© integrating Canadian Cardiovascular Society HF guideline recommendations to the patient's family physician.
1646012|NCT01886534|Behavioral|Standardized education sessions|Following baseline data collection, and prior to hospital discharge or within 72 hours of discharge, all patient/caregiver dyads in the intervention group will receive a 45-60-minute standardized education session with the study nurse according to individualized patient learning needs, aimed to ensure similar baseline level of heart failure self-care knowledge. Verbal (teach-back) and written information from the Trial of Education And Compliance in Heart dysfunction (TEACH) RCT will be provided to all patient/caregiver dyads. Information regarding self-care such as dietary restrictions, exercise guidelines, weight and symptom monitoring (shortness of breath, swelling of the ankles) included in the education package will be reviewed. The teaching sessions will occur at 1 week, 2 weeks, 1 month and 2 months post-discharge.
1646013|NCT01886534|Other|Heart Failure Diuretic Decision Support Tool for Patient Self Management©|Each patient/caregiver dyad will be provided a paper-based Heart Failure Diuretic Decision Support Tool for Patient Self Management© at hospital discharge assisting in the titration of their oral furosemide. The purpose of this tool will be to assist the patient/caregiver in keeping track of signs and symptoms of worsening heart failure. The family physician will also be provided an access to similar decision support tool for management of clinical deterioration.
1646014|NCT01886534|Other|Digital talking scale|Prior to hospital discharge, the patient/caregiver dyad will be provided a digital, talking scale to measure their weight in their home setting.
1646015|NCT01886534|Other|Usual care|Patients allocated to the usual care group will receive the hospital-approved heart failure management booklet which meets evidence-based requirements for outpatient heart failure management. Patients will meet with the hospital HF nurse-clinician (standard at this institution) to review heart failure symptoms and signs, diet and exercise recommendations. They will also meet with the ward pharmacist prior to hospital discharge to review medications and side effects. Referral to the HF clinic and any HF initiative will be left to the discretion of the most responsible physician.
1646016|NCT01886521|Procedure|Lumbar drain|
1646017|NCT01886521|Procedure|Ventricular drain|
1646018|NCT01886508|Procedure|Nerve-spring radical hysterectomy|Nerve-spring radical hysterectomy that is reserve some pelvic autonomic nerves during radical hysterectomy. Reserve hypogastric nerve trunk during dissecting cardinal ligament. Reserve pelvic splanchnic nerve trunk during exsecting uterosacral ligament. Reserve bladder nerve of pelvic plexus during dissecting vesicouterine ligament.
1646019|NCT01886508|Procedure|radical hysterectomy|Radical hysterectomy is Piver III hysterectomy and Q-M classification Type C1 hysterectomy.
1646020|NCT01886495|Other|nutrition intervention|
1646021|NCT01886482|Other|nutrition intervention|high protein diet
1646022|NCT01886469|Drug|HLD100-B|d-amphetamine sulfate capsules, 30 mg, CII (25% SR, 30% pH coat, slow release; formulation B)
1646023|NCT01886469|Drug|HLD100-C|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, fast release; formulation E) - this intervention may be deemed unnecessary based on results from Intervention 1.
1646024|NCT01886469|Drug|HLD100-E|d-amphetamine sulfate capsules, 30 mg, CII (20% SR, 20% pH coat, medium release; formulation E) - this intervention may be deemed unnecessary based on results from Interventions 1 and 2.
1646025|NCT01886456|Device|Laser trabeculoplasty|
1646026|NCT01886443|Drug|Antithrombin-III|
1646027|NCT01886443|Drug|Infliximab|
1646028|NCT01886443|Drug|Apotransferrin|
1646029|NCT01886443|Drug|Human recombinant erythropoietin|
1646030|NCT01886443|Drug|C1-Inhibitor|
1646031|NCT01886443|Drug|Glutathione|
1646032|NCT01886443|Drug|Alfa-tocopherol|
1646033|NCT01886443|Drug|Melatonin|
1646034|NCT01886443|Drug|Epoprostenol|
1646035|NCT01886430|Other|Functional electrical stimulation|Functional electrical stimulation for 10 days
1646036|NCT01886430|Other|Placebo electrical stimulation|Placebo electrical stimulation for 10 days
1646037|NCT01886404|Drug|Efavirenz|"HIV-infected subjects currently receiving efavirenz (EFV) containing antiretroviral therapy (ART) will be asked to provide plasma samples. In addition to blood samples for determination of EFV concentrations, we will collect whole blood samples for functional Single Nucleotide Polymorphism (SNP) discovery within known candidate genes of interest in drug metabolism and transport.
Subjects will be at steady state for efavirenz when blood samples are collected. EFV is usually taken during the evening hours. The study consists of 2 blood draws at 12 and 18 hours post EFV dose. At the first blood draw, venous blood will be obtained by venous puncture for plasma concentrations of EFV and pharmacogenetics. At 18 hours post EFV dose , a second blood draw by venous puncture will be obtained for EFV plasma concentrations.
Demographics and clinical parameters will be collected at the time of the first visit, Neuropsychological tests and questionnaires completed as well."
1646110|NCT01885858|Behavioral|Mestizo profile|Clinics receive simulated patients (SPs) enacting the mestizo profile, and interpreting a standardized script with a biographical and clinical background. The mestizo SP does not wear a lliclla (a traditional woven cloth that covers the back and shoulders) or long braids, but a pony tail or loose hair; she wears make-up and, a vest made of polar fleece, tight pants and culturally salient accessories; her patterns of speech are faster and her posture and movement less rigid than the indigenous SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
1717388|NCT00002075|Drug|Amphotericin B|
1646038|NCT01886391|Behavioral|Diaphragmatic Breathing Retraining|Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 [5-min DBR], 1 for week 2 [10-min DBR], 1 for weeks 3-8 [15-min DBR]), developed by the PI, to use to practice their deep breathing.
1646039|NCT01886378|Drug|UX007|
1646040|NCT01886365|Device|Space GlucoseControl System, B. Braun, Melsungen, Germany|Computerized algorithmic application of insulin
1646041|NCT01886365|Other|Conventional therapy with a fixed insulin dosing scheme|Routine care
1646042|NCT01886352|Drug|Standard Injection of Levobupivacaine in portal sites.|All port sites will be injected with 0.1ml/kg levobupivacaine at the end of surgery, after trocar removal.
1646043|NCT01886352|Drug|Additional injection of 0,5% levobupivacaine.|Immediately following insufflation 0.15ml/kg levobupivacaine will be injected in the peritoneal cavity via a trocar. At the end of the surgery, this process will be repeated with the same dose at 0.15ml/kg.
1646044|NCT01886352|Drug|Intraperitoneal atomization of levobupivacaine.|"Immediately following insufflation the Optispray® surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:
Each subdiaphragmatic area 0.05 ml/kg
Dome of abdomen then settling onto bowel 0.05 ml/kg
Surgical dissection site 0.05 ml/kg
At the end of the surgery - this process will be repeated with the same doses at 0.15 ml/kg."
1646045|NCT01886339|Other|SNIF test (Sniff Nasal Inspiratory Force)|
1646046|NCT01886326|Other|Consumption of 42 grams of peanuts daily|Consumption of the given 42 grams of peanuts daily without instructions for use (i.e. with/without meals, etc.)
1646047|NCT01886313|Drug|Civamide Nasal Spray|
1646048|NCT01886313|Drug|Placebo|
1646049|NCT01886287|Drug|Octreotide LAR|Octreotide LAR as outlined in Treatment Arm.
1646050|NCT01886274|Device|Transcranial direct current stimulation|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
1646051|NCT01886248|Drug|Freeze-dried Concentrated Human Antithrombin Ⅲ 500 IU|
1646052|NCT01886235|Procedure|Diagnostic Microscopy|Undergo intravital microscopy
1646053|NCT01886235|Drug|Fluorescein Sodium Injection|Given IV
1646054|NCT01886235|Other|Laboratory Biomarker Analysis|Correlative studies
1646055|NCT01886235|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1646058|NCT01886209|Drug|Prednisone|
1646059|NCT01886209|Drug|VX-509|
1646060|NCT01886209|Drug|Methylprednisolone|
1646061|NCT01886196|Drug|Non-steroidal anti-inflammatory drug (Ibuprofen)|400mg of ibuprofen administered after exercise training session 3 days per week
1646062|NCT01886196|Other|placebo|placebo designed to mimic experimental drug (ibuprofen)
1646063|NCT01886196|Behavioral|Resistance exercise|3 sets of 8-12 repetitions of resistance exercise (full body with a focus on the distal radius) completed 3 days/week under supervision in the research gym
1646064|NCT01886196|Behavioral|Flexibility training|3 days of full body stretching program (approximately 1 hour) to be performed at participants home unsupervised
1646065|NCT01886183|Other|Virtual Reality Training|The participants of the study will be trained 10 balance games during 14 sessions
1646066|NCT01886183|Other|Physical Therapy|Patients of the control group will be trained with balance exercises.
1646067|NCT01886170|Other|Phase II of the Study: Information regarding Current Diabetes Control|Participants will receive information regarding their current diabetes control in different ways depending on their assigned study arm.
1646068|NCT01886157|Procedure|Corticosteroid injection + Trigger Splint+ Education and Home exercises|Standard corticosteroid injection. Hand based, single digit trigger splint will be applied. Education and instructions about home exercises.
1646069|NCT01886157|Procedure|Corticosteroid injection|Standard trigger finger corticosteroid injection.
1646070|NCT01886144|Device|Knee OA Brace|
1646071|NCT01886131|Other|Synchronised video-polysomnography|"We will record the electrical activity of the STN (local field potentials) during the 2 consecutive nights following the implantation of the electrodes in the STN for DBS. In this period, the deep brain stimulator will not yet be connected to the intracranial electrodes.
The intracranial EEG signal from the STN will be synchronised with the scalp EEG and other video-polysomnographic parameters.
The STN recordings during the phasic movements of RBD will be compared to the recordings obtained at the same level during a motor task."
1646072|NCT01886118|Procedure|Endometrial biopsy|A luteal phase endometrial biopsy will be performed in the cycle prior to the patient's In Vitro Fertilization stimulation cycle using a standard Pipelle Endometrial Suction curette in all participants between days ovulation+5 and ovulation+7 of the cycle preceding the stimulation cycle
1646073|NCT01886118|Other|Autologous Endometrial Co-Culture|embryos will be transferred to Endocell co-culture media for Autologous Endometrial Co-Culture between day 2 and day 5
1646074|NCT01886118|Other|Conventional media culture|embryos are cultured in conventional media
1646111|NCT01885845|Device|Excellent BRASSS-V Drape™.|Immediately after delivery and cord clamping, blood measurement will begin. The calibrated delivery drape should be placed under the buttocks of the woman and tied around the woman's waist with the funnel portion hanging down between her legs. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
1717389|NCT00002076|Drug|Fluconazole|
1646075|NCT01886105|Drug|Sm-EDTMP|"Subjects receive a tracer infusion of Samarium-153 EDTMP at 1 mCi/kg. 3D dosimetry using SPECT images are obtained post tracer infusion to determine the distribution of dose delivered to the tumor and surrounding normal tissues. Tracer activity will be applied to development of the external beam radiation planning. Second treatment infusion of Samarium will then be implemented. Maximum activity administered will be 30 mCi/kg. After the treatment infusion, SPECT scans will again be performed to confirm the total dose delivered and subsequently adjust the external beam portion of the treatment plan, as necessary. Autologous stem cell infusion is administered 14 days after Treatment infusion of Samarium-153 EDTMP."
1646076|NCT01886105|Other|Autologous Stem Cell Infusion|"Approximately 14 days after administration of treatment dose of Samarium, patients will receive Autologous Stem Cell Infusion."
1646077|NCT01886105|Radiation|External Beam Radiotherapy|The radiotherapy portion of the combined plan will be delivered according to the judgement of the treating radiation oncologist. The total dose to be used will be modified based on surrounding tissue tolerances as evidenced by Samarium infusion and SPECT image planning.
1646078|NCT01886092|Device|Active rTMS 1|repetitive transcranial magnetic stimulation (Figured 8-Coil Cool-B65): 1000 stimuli of 1Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left primary auditory cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects).
1646079|NCT01886092|Device|Active rTMS 2|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. (20 subjects)
1646080|NCT01886092|Device|Active rTMS 3|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left dorsolateral prefrontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment. (20 subjects)
1646081|NCT01886092|Device|sham condition|Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session. (20 subjects)
1646082|NCT01886079|Drug|dexmedetomidine|0.4 mcg/kg/h, IV, The infusion of study drug is started after anesthesia induction and continued until 24 hours after surgery
1646083|NCT01886079|Drug|Saline|0.4 mcg/kg/h, IV
1646084|NCT01886066|Biological|Indocyanine Green (ICG)|ICG (Indocyanine Green) will be used as a fluorescent agent to identify sentinel lymph nodes intraoperatively. The ICG will be administered in solution (1.25mg/ml) as four 1ml injections into the cervix (superficial and deep) at 3 and 9 o'clock.
1646085|NCT01886053|Drug|Faropenem（high dose group）|dosage form: Injection dosage:2400 mg frequency: Three times a day
1646086|NCT01886053|Drug|Faropenem（low-dose group)|dosage form: Injection dosage:2400 mg frequency: twice a day
1646087|NCT01886053|Drug|Ertapenem|dosage form: Injection dosage:1000 mg frequency: once a day
1646088|NCT01886027|Behavioral|Emotional Awareness and Expression Training|An emotional processing intervention, which aims to reduce stress by helping patients become aware of, and express emotions related to stressful life experiences, as well as teaching patients how to relate to others differently.
1646089|NCT01886027|Behavioral|Relaxation Training|Teaches patients different relaxation training skills to reduce their distress and discomfort (i.e., progressive muscle relaxation, applied relaxation, or guided imagery.
1646090|NCT01886014|Drug|Oxytocin|
1646091|NCT01886014|Other|placebo|
1646092|NCT01886001|Drug|Povidone-Iodine|Umbilical stump care. Povidone-Iodine, USP, Swabstick Singles, applied once a day to cord stump while umbilical line(s) are in place
1646093|NCT01886001|Drug|Chlorhexidine|Umbilical stump care. Chlorhexidine Gluconate 2% w/v; 70% Isopropyl Alcohol v/v Swabstick Single, applied once a day to cord stump while umbilical line(s) are in place
1646094|NCT01886001|Drug|Pluronic|Umbilical stump care. Pluronic gel - (F68, Polymyxin, Nystatin, Nitrofurantoin)applied once a day to cord stump while umbilical line(s) are in place
1646095|NCT01886001|Other|Control|No product is applied to cord stump while umbilical line(s) are in place. This is the current standard of care at UVA.
1646096|NCT01885988|Drug|Nebivolol|Nebivolol 5, 10 or 20 mg tablet, oral, daily for 3 months. Nebivolol dosage will be titrated per blood pressure results.
1646097|NCT01885988|Drug|Sugar Pill|Sugar pill 5, 10 or 20mg taken by mouth, daily. Sugar pill dosage will be titrated per blood pressure results.
1646098|NCT01885962|Behavioral|iSHIFTup|Internet-delivered program to support behaviors to prevent pressure ulcers and promote healthy skin in adults with spinal cord injury.
1646099|NCT01885949|Drug|Tivozanib|Oral
1646100|NCT01885949|Drug|Enzalutamide|oral
1646101|NCT01885936|Drug|Albuterol|Initially 4 mg daily for one week, 4 mg BID per oral daily for the next 5 weeks. If the 4 mg BID per oral is well tolerated, the dose will be increased to 8 mg each morning/4 mg each evening for one week, followed by 8 mg BID per oral for the remainder of the study.
1646102|NCT01885936|Drug|Placebo|
2012601|NCT01838161|Behavioral|Part II|Parents will be exposed to an educational video intervention if they are enrolled in this intervention condition.
1646104|NCT01885910|Drug|Doxycycline 100mg|Doxycycline 100mg by mouth once daily
1646105|NCT01885910|Drug|Aczone 5% gel|Aczone 5% gel twice daily
2012602|NCT01838161|Behavioral|Part III|•video educational
1646107|NCT01885884|Behavioral|Embedded Supportive Care|
1646108|NCT01885871|Device|Picosecond QS Nd:YAG Laser|Up to 2 laser treatments delivered 6 weeks apart
1646109|NCT01885858|Behavioral|Indigenous profile|Clinics receive simulated patients (SPs) enacting the indigenous profile, and interpreting a standardized script with a biographical and clinical background. The indigenous SP wears a lliclla (a traditional woven cloth that covers the back and shoulders), long braids, a woven cardigan and loose pants; she uses no make-up and, her patterns of speech are slower and her posture and movement more rigid than the mestizo SP. The script indicates that SPs do not want to have any more children and that her choice of method is the pill.
1646155|NCT01885429|Dietary Supplement|Low Protein High Leucine Spike|Subject consumes 6.25g of whey protein plus 5g of leucine following unilateral exercise
1646156|NCT01885429|Dietary Supplement|Low Protein + High Leucine + BCAA Spike|Subject consumes 6.25g of whey protein plus 5g of leucine plus valine and isoleucine (BCAA) following unilateral exercise
1646157|NCT01885416|Other|consumption of test meal based on dairy products|
1646158|NCT01885416|Other|consumption of high fat test meal without dairy products|
1646112|NCT01885845|Other|Indirect weight assesment of blood loss|"Just after delivery and cord clamping, a sheet with plastic backing will be placed under the buttocks of the woman. A basin will be placed directly under her on a small shelf on the delivery table. Blood loss will be measured for at least one hour or, if bleeding continues after one hour, until active bleeding has stopped.
After bleeding has stopped, all gauze pieces and mops will be counted and then placed in the collection basin. The basin will be placed on the scale and weighed. The weight of the blood will be assessed by subtracting the weight of the basin, gauzes and mops from the total weight of the soaked materials assuming that one gram is equivalent to 1 ml."
1646113|NCT01885832|Biological|Autologous adipose tissue stromal vascular fraction|
1646114|NCT01885819|Biological|Autologous stromal vascular fraction cells|
1646115|NCT01885806|Device|Magnetic Stimulator Magstim Rapid 2|All procedures will use the Magnetic Stimulator Magstim Rapid 2. Total of session: 10 rTMS protocol: Freqüency: 10 Hz Intensity: 90% limiar motor Session duration: 16 minutes (20 TMS sequences of 6 second with intervals of 30 seconds between each sequence) Location: Left dorsolateral pre-frontal cortex
1646116|NCT01885806|Device|Sham Magnetic Stimulator|"This intervention will follow the same protocol of the rTMS except that subjects will not receive magnetic stimulation of the brain.
Total of session: 10"
1646117|NCT01885793|Device|Cuffed endotracheal tube|Intubation with a cuffed endotracheal tube (ETT).
1646118|NCT01885780|Device|Laser-assisted Astigmatic keratotomy|Laser-assisted Astigmatic keratotomy are performed by the VICTUS™ Femtosecond Laser Platform.
1646119|NCT01885741|Device|IPBS|
1646120|NCT01885728|Dietary Supplement|An arginine rich nutritional supplement|Impact is a nutritional supplement formulated with 18 grams of protein per serving and 24 essential nutrients including arginine.
1646121|NCT01885715|Drug|Injection of neostigmine|"At induction, we will inject rocuronium 0.6 mg/kg for rocuronium arms and cisatracurium 0.15 mg/kg for cisatracurium arms.
During surgical procedure, we will monitor train of four(TOF)using nerve stimulator. When TOF ratio recover to 0.5, normal saline 5 ml will be injected in placebo arms. And neostigmine 10, 20, or 40 ㎍/kg will injected in each arms."
1646122|NCT01885702|Biological|DC vaccination|DC vaccination
1646123|NCT01885689|Drug|clofarabine|Given IV
1646124|NCT01885689|Drug|melphalan|Given IV
1646125|NCT01885689|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
1646126|NCT01885689|Drug|tacrolimus|Given IV or PO
1646127|NCT01885689|Drug|sirolimus|Given PO
1646128|NCT01885689|Other|Pharmacological Study|Correlative studies
1646129|NCT01885676|Device|PRGF-Endoret|PRGF-Endoret mesotherapy micro injection.
1646130|NCT01885676|Other|Saline Solution|Saline Solution mesotherapy micro injection
1646132|NCT01885650|Other|Airway Clearance Techniques|
1646133|NCT01885637|Other|Transition program|Accelerated transition program from oncological treatment to continuous specialized palliative care and psychological intervention at home for incurable cancer patients
1646134|NCT01885624|Biological|TAB08|monoclonal antibody
1646135|NCT01885611|Other|Multi-Drug Therapy (Novartis Ⓡ)|The MDT is provided by the World Health Organization (WHO) and NovartisⓇ. The MB pack consists of Rifampicin (300mg/tab x 2 tablets), Clofazimine (100mg/tab x 3 tabs and 50mg/tab x 28 tabs), Dapsone (100mg/tab x 29 tabs) and the PB pack consists of Rifampicin (300mg/tab x 2 tablets) and Dapsone (100mg/tab x 29 tabs).
1646136|NCT01885611|Dietary Supplement|Virgin Coconut Oil|cold-processed VCO
1646138|NCT01885585|Drug|Apixaban|
1646139|NCT01885572|Device|TiLOOP Bra|Titaniferously coated polypropylene mesh
1646140|NCT01885559|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
1646141|NCT01885559|Drug|Telmisartan|Telmisartan titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
1646142|NCT01885559|Drug|Placebo|Placebo titrated to 40mg and 80mg, as tolerated by participants, to achieve standard blood pressure control of 110-130/80 mm Hg.
1646143|NCT01885546|Device|AgaMatrix Blood Glucose Monitor|
1646144|NCT01885520|Dietary Supplement|fasting condition|eperisone SR tablet 75mg administrated under fasting
1646145|NCT01885520|Dietary Supplement|fed condition|eperisone SR tablet 75mg administrated fed condition
1646146|NCT01885507|Other|Pass recommendations on ventilation factors and extubation|"the use of tidal volume < 7 ml/kg and of a positive expiratory pressure = 6 to 8 cmH20 (centimeter of water)
extubation as soon as ventilatory weaning is associated with a glasgow coma scale equal or above 10 and cough"
1646147|NCT01885481|Drug|Dexamethasone|epidural steroid injection using dexamethasone
1646148|NCT01885481|Drug|Betamethasone|epidural steroid injection using betamethasone
1646149|NCT01885455|Other|Usual Care|Usual care includes: complete staging work-up (CT/PET scan and possible mediastinoscopy), surgical consultation with a general or cardiothoracic surgeon, cardiac clearance and/or pulmonary function testing (if deemed necessary by the evaluating surgeon), surgical resection (wedge resection, lobectomy, pneumonectomy, or radiosurgery, as indicated by the size and location of the tumor), and adjuvant therapy (radiotherapy and/or chemotherapy, as determined by the intraoperative findings and pathology results).
1646150|NCT01885455|Other|Intervention Arm|The proposed Intervention (EPDPN) will be administered by the PNs at the intervention sites on an outpatient basis. Several defining, fundamental characteristics of the PNs will ensure consistency of the intervention delivery across the various study sites.
1646151|NCT01885442|Device|In-bed leg cycle ergometry|Patients will receive 30 minutes of in-bed leg cycling in addition to routine physiotherapy, 6 days per week, for the duration of their ICU stay (to a maximum of 28 days).
1646152|NCT01885429|Dietary Supplement|Positive Control|Subject consumes 25g of whey protein following unilateral exercise
1646153|NCT01885429|Dietary Supplement|Negative Control|Subject consumes 6.25g of whey protein following unilateral exercise
1646154|NCT01885429|Dietary Supplement|Low Protein Low Leucine Spike|Subject consumes 6.25g of whey protein plus 3g of leucine following unilateral exercise
1646159|NCT01885416|Other|consumption of high fat test meal with dairy products|
1646161|NCT01885390|Device|ROX COUPLER|The COUPLER will be used to create an anastomosis in the iliac region (between the iliac artery and vein).
1646162|NCT01885377|Other|Specific exercise group|A program where exercise load is individually adjusted and the exercises progressed during a 3 month period. The 'pain monitoring model' were used to find the individual resistance. Several exercises are performed eccentrically in order to load more. Initially the exercises were PT-tutored every week and then every other week.
1646163|NCT01885377|Other|Control exercise group|A program with movements to maintain flexibility in the neck and shoulder muscles. Initially PT-tutored every week and then every other week.
1646164|NCT01885364|Drug|Normal saline|intravenous injection with normal saline before injection of propofol
1646165|NCT01885364|Drug|Esmolol|intravenous injection with remifentanil 0.5 mg/kg before injection of propofol
1646166|NCT01885364|Drug|Remifentanil|intravenous injection with remifentanil 0.35 ug/kg before injection of propofol
1646167|NCT01885364|Drug|propofol|intravenous injection after pretreatment
1646168|NCT01885351|Behavioral|MyCRCS+Prefs|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies.
Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+ arm in its entirety will be 5-7 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
1646169|NCT01885351|Behavioral|MyCRCS+Prefs+Barriers|"Patients who are identified by the IPHR as study participants will see an attractive link. In the Prefs+Barriers arm, via question prompt lists, patients will first identify their CRCS preference using previously developed elicitation strategies, and subsequently based on their test preference determine their top 3-5 test-specific barriers/concerns in real time.
Tailoring will be used to increase salience of information, motivation, communication, and action plans. We envision the Prefs+Barriers arm in its entirety will be 15-25 minutes, but will depend on Phase I formative work. If the patient remains non-adherent, they will receive an e-mail reminder generated by the IPHR (specific text and frequency determined in Phase I). The Prefs content is identical to the preference portion of the Prefs+Barriers arm, which will allow us to assess the incremental benefit of addressing preferences only and the incremental benefit of addressing preferences and barriers."
1646170|NCT01885338|Drug|N-acetylcysteine (NAC)|
1646171|NCT01885338|Drug|Inactive placebo capsule|
1646172|NCT01885325|Other|Physical Activity Preschool Intervention|Preschools randomized to the multi-component physical activity preschool intervention received four major components:Move IN (physical education and other indoor activity programming), Move OUT (recess and structured outdoor activity), Move to Learn (Physical activity in classroom, academic lessons), and enhancing the social environment to promote PA.The focus in the physical education classes, recess, daily lessons, and reduction of sedentary time will be on providing activities that 3-to 5-year-old children enjoy.
1646173|NCT01885312|Behavioral|Adaptive Tailored Intervention|Adaptive
1646174|NCT01885312|Behavioral|Consequence-based Intervention|Loss Framed
1646175|NCT01885312|Behavioral|Tailored, not adaptive, based Intervention|Baseline tailored not adaptive
1646176|NCT01885312|Other|Assessment only|EMA only
1646177|NCT01885299|Radiation|SRS/SBRT|Intervention varies by condition being treated.
1646178|NCT01885286|Procedure|circumcision with simple circumcision device|Circumcision performed with the device in the operating room using local anesthesia
1646179|NCT01885273|Procedure|Pressurized irrigation method|The pressurized irrigation device is modified from using a special Syringe, connected to Gomco's Vacuum/Pressure Pump Model 309 that generate steady irrigation stream at pressure between 4 to 15 psi that is recommended to be safe and effective pressure for wound cleansing.
1646180|NCT01885273|Procedure|Swabbing wound cleansing method|All patients in control group had wounds cleansed with swabbing technique using forceps and cotton wool (in sterile dressing pack)
1646181|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 1|3 doses on alternate days during the first week and then once weekly for 12 weeks
1646182|NCT01885260|Drug|ISIS-GCGRRx - Dose Level 2|3 doses on alternate days during the first week and then once weekly for 12 weeks
1646183|NCT01885260|Drug|Placebo|3 doses on alternate days during the first week and then once weekly for 12 weeks
1646184|NCT01885234|Other|Aerobic exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of aerobic exercise in a bicycle, 3 times a week
1646185|NCT01885234|Other|Stretch exercise|Pregnant women with Gestational Diabetes and pregnant women with chronic hypertension will perform 50 minutes of stretch exercise, once a week
1646187|NCT01885208|Drug|semaglutide|One dose of 1.0 mg semaglutide administered subcutaneously (s.c., under the skin) once-weekly
1646188|NCT01885208|Drug|exenatide|One dose of 2.0 mg exenatide ER administered subcutaneously (s.c., under the skin) once-weekly
1646189|NCT01885195|Drug|MEK162|MEK162 will be dosed on a flat scale of 45 mg twice daily on a continuous dosing schedule.
1646190|NCT01885182|Drug|Oxycodone/Naloxone|
1646191|NCT01885182|Drug|Oxycodone|
1646192|NCT01885169|Biological|Flumist®|The three cohorts will receive Flumist® and will be swabbed for inflammatory markers and viral shedding.
1646193|NCT01885156|Drug|Naftin 1% Cream|Topically applied once a day
1646194|NCT01885156|Drug|Placebo Cream|Topically applied once a day
1646195|NCT01885143|Radiation|Digital Breast Tomosynthesis|
1646196|NCT01885130|Other|Cetaphil Daily Advance Ultra Hydrating Lotion|0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
1646197|NCT01885117|Biological|TIVf|Trivalent Influenza Virus Vaccine (purified surface antigen, inactivated, egg-derived)
1646198|NCT01885104|Drug|Polyethylene Glycol (PEG 3350)|Oral 17 g dose of PEG 3350 solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
1646241|NCT01884701|Device|ENABLER-P Catheter System|
1646199|NCT01885104|Drug|Placebo|Oral 17 g dose of Placebo solution concentrate in a volume of approximately 30 mL, once a day, for 14 days.
1646200|NCT01885104|Drug|Bisacodyl laxative tablets (rescue medication)|5.0 mg tablets, 1 to 3 tablets in a single daily dose, to be provided for use as rescue medication if participant has not had bowel movement for 72 hours after start of treatment.
1646201|NCT01885091|Other|Kinerase|
1646202|NCT01885078|Drug|Baricitinib|Administered orally
1646203|NCT01885078|Drug|Placebo|Administered orally
1646204|NCT01885065|Other|Gel-based artificial saliva|"Gel-based artificial saliva is an edible non-nutritious gel intended to relieve dry mouth.
Taking orally 1-2 teaspoon each time, 5 times / day (30-50 ml/ day) for four weeks."
1646205|NCT01885052|Behavioral|QuitTXT Study|Assess the efficacy of a 6-8 week text message program to help young adults quit smoking.
1646206|NCT01885052|Behavioral|Low Contact|
1646207|NCT01885026|Behavioral|eScreen|
1646208|NCT01885026|Other|Assessment only of alcohol and drug use.|
1646209|NCT01885013|Drug|Metformin + Myocet + Cyclophosphamide|"Metformin + Myocet + Cyclophosphamide:
Metformin 1000 mg, 2 times daily per os*. Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles Cyclophosphamide 600 mg/m2, intravenous infusion, at day 1 every 21 days.
* During cycle 1, patients will assume only metformin from day 1 to day 13 and will begin chemotherapy from day 14. From day 1 to day 3, patients will assume Metformin 1000 mg once a day. Starting from day 4 patients will assume Metformin 1000 mg 2 times a day."
1646210|NCT01885013|Drug|Myocet + Cyclophosphamide|"Myocet + Cyclophosphamide:
Myocet 60 mg/m2, intravenous infusion, on day 1, every 21 days Cyclophosphamide 600 mg/m2, intravenous infusion, on day 1, every 21 days Chemotherapy will be performed for 8 cycles"
1646211|NCT01885000|Drug|once-daily brimonidine tartrate 0.5% gel|
1646212|NCT01885000|Drug|once-daily brimonidine tartrate vehicle gel|
1646213|NCT01884987|Drug|GM1|This group will be treated with GM1 80mg daily for 14 days, and then followed with GM1 40mg daily for 46 days.
1646214|NCT01884974|Other|myeloproliferative disease|Echocardiogram, demographic data, St George respiratory questioner
1646215|NCT01884961|Other|Boost of radiotherapy + high dose IL-2 treatment|Boost of radiotherapy + high dose IL-2 treatment
1646216|NCT01884948|Drug|Omegaven™|
1646217|NCT01884935|Biological|Natalizumab|As specified in the treatment arm
1646218|NCT01884922|Drug|Nilotinib|Tasigna®(nilotinib):: 50 mg, 150 mg and 200 mg capsules. Tasigna® capsules contain lactose monohydrate, crospovidone, poloxamer, colloidal silicon dioxide and magnesium. Orally; the capsules should be swallowed as a whole with water. No food should be consumed for 2 hours before the dose is taken and for at least one hour thereafter. For patients who are unable to swallow capsules, the content of each capsule may be dispersed in one teaspoon of apple sauce or compote or nonfat plain yogurt and should be taken immediately. Not more than one teaspoon of apple sauce / yogourt, and no food other than apple sauce or nonfat plain yogurt must be used.
1646219|NCT01884922|Drug|Vinblastine|"Vinblastine: 3 to 6 mg/m2 once weekly in a 15-minute infusion, on Days 1, 8, 15 and 22 of each cycle.
Each 28-day cycle is repeated on Day 29/Day 1. No intra-patient doseescalation is permitted. Dose allocation will be centrally defined, based on toxicity observed in patients previously evaluated. Every new patient will be treated at the best current recommended dose, i.e. the dose associated with an estimated level of toxicity that is judged acceptable (20% DLT). At least two patients fully observed with no DLT are requested at a given dose level before dose escalation."
1646220|NCT01884909|Drug|Metoprolol Succinate ER Tablet 200 mg|1 * 200 mg tablet per day
1646221|NCT01884909|Drug|'TOPROL-XL®' ER Tablets 200 mg|1 * 200 mg tablet per day
1646222|NCT01884896|Drug|Metoprolol Succinate ER Tablet 200 mg|1 * 200 mg tablet per day
1646223|NCT01884896|Drug|'TOPROL-XL®' ER Tablets 200 mg|1 * 200 mg tablet per day
1646224|NCT01884883|Device|PROTEOR Internal unicompartmental knee brace|
1646225|NCT01884870|Procedure|Surgical Treatment|Surgical Treatment - open, endoscopic or laparoscopic
1646226|NCT01884857|Drug|Metoprolol Succinate ER Tablets 50 mg|1* 50 mg tablet once a day
1646227|NCT01884857|Drug|'TOPROL-XL®' ER Tablets 50 mg|1 * 50 mg tablet per day
1646228|NCT01884844|Drug|Vitamin D3, Cholecalciferol|
1646229|NCT01884844|Drug|Placebo|
1646230|NCT01884831|Biological|study of the efficacy of skin equivalent comprising living cells and skin biodegradable substrate for the treatment of skin lesions|
1646231|NCT01884818|Other|Manipulation vs. TNS thoracic pain|
1646232|NCT01884805|Device|Monocular Adaptive Optics Visual Simulator (AOVIS-I)|The procedure is guided by the custom made software and its graphical user interface. The interface has been designed to be user-friendly, being very similar to the software usually managed by the clinicians in their daily professional practice. The complete procedure in one patient takes less than 5 minutes and is completely non-invasive. The optical measurements only involve the use of low power infrared laser and the visual testing is as simple for the patients as watching television and making responses.
1646233|NCT01884792|Other|Sitting OGTT|
1646234|NCT01884792|Other|Standing OGTT|
1646235|NCT01884792|Other|Sitting CGM|
1646236|NCT01884792|Other|Standing CGM|
1646237|NCT01884740|Drug|SIACI of Erbitux and Bevacizumab|Subjects will receive a single intra-arterial dose of Cetuximab (200 m/m2) and Bevacizumab (15 mg/kg) via Superselective Intraarterial Cerebral Infusion (SIACI).
1646238|NCT01884727|Dietary Supplement|Salt Water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of salt water or breakfast, and at 11 am after consumption of salt water and breakfast. Subjects will receive a second portion of salt water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
1646239|NCT01884727|Dietary Supplement|ASEA water|Subjects to arrive fasted and will spend two 24-h periods inside the metabolic chamber (ASEA or salt water) with a one week interval between visits. Blood will be drawn at 9 am prior to consumption of ASEA water or breakfast, and at 11 am after consumption of ASEA water and breakfast. Subjects will receive a second portion of ASEA water at 10:15 pm just prior to bedtime. The energy content of meals will be identical at each visit.
1646240|NCT01884714|Other|High fat/high calorie meal|All subjects are provided a high calorie (~1300kcal) and high fat (~60g fat) breakfast meal.
1646242|NCT01884688|Drug|ENK Cell Infusion|Day 0(1 dose) ENK Cell Infusion Day 0 to + 12 (13 doses) Aldesleukin (IL2), 3x10 IU
1646243|NCT01884675|Drug|Ambrisentan 5 mg|White, film-coated, immediate-release tablets, containing 5 mg ambrisentan for single dose oral.
1646244|NCT01884675|Drug|Placebo|White, film-coated, ambrisentan-matching placebo tablet for single oral dose
1646245|NCT01884662|Behavioral|Virtual walking|"As in mirror therapy for amputee phantom pain, there is evidence that neuropathic SCI pain responds to images of the person with SCI's legs walking; we achieve this via a virtual reality approach where the subject perceives it is his/her legs walking."
1646246|NCT01884662|Behavioral|Wheeling tape|This control condition mirrors the experimental condition in all respects except it shows still legs in a wheelchair traversing the same path as the virtual walking condition
1646247|NCT01884636|Drug|isavuconazole|oral
1646248|NCT01884636|Drug|methotrexate|oral
1646249|NCT01884623|Drug|Cetuximab|
1646250|NCT01884623|Drug|Methotrexate|
1646253|NCT01884584|Drug|Indocyanine green (ICG)|Initial dose of 0.22 mg/kg, which has proven successful in identifying tumor tissue in canine experiments, will be used. The dose will be based on actual body weight. This dose is approximately 40% of the standard human dose for determining cardiac output.
1646254|NCT01884571|Drug|Basiliximab|20 mg, IV (in the vein) on day 1 and 4.
1646255|NCT01884571|Drug|Methylprednisolone|125 mg, IV (in the vein) on day 1.
1646256|NCT01884571|Drug|Prednisone|60 mg PO (by mouth) on days 2-7, 40 mg PO days 8-14, 20 mg PO days 15-21, and 10mg PO days 22-28.
1646257|NCT01884571|Drug|Tacrolimus|1-5 mg PO, BID (twice a day) days 2-180.
1646258|NCT01884571|Drug|Mycophenolate mofetil|500 mg PO, BID days 2-7, 500 mg PO each morning and 1000 mg each night, days 8-14, 1000 mg PO BID days 15-180.
1646259|NCT01884558|Drug|isavuconazole|oral
1646260|NCT01884558|Drug|metformin|oral
1646261|NCT01884545|Behavioral|Health coaching|Telephonic health coaching sessions with a trained certified health coach for a period of 6 months (total of 10 biweekly calls).
1646262|NCT01884545|Genetic|Genetic risk counseling|In addition to the SRA subjects will receive genetic risk counseling at the risk counseling visit with a clinic provider. Genetic test results for CHD (rs10757274) and T2D (rs7903146, rs1801282, rs5219) risk variants will be incorporated into the risk profile reviewed with subjects.
1646263|NCT01884545|Behavioral|Standard risk assessment|Standard risk assessment for coronary heart disease (CHD) and type 2 diabetes (T2D). Standard risk factors are reviewed by a provider at a risk counseling visit with the subject.
1646264|NCT01884532|Device|ASR-XL Metal-on-Metal|All patients that are post-operative will have undergone total hip arthroplasty with the ASR-XL Metal-on-Metal device.
1646265|NCT01884519|Biological|Fluarix/Influsplit SSW® (2013-2014 season)|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
1646266|NCT01884506|Dietary Supplement|labeled iron solution|labeled iron as ferrous sulfate (6mg/test meal)
1646267|NCT01884506|Dietary Supplement|labeled iron solution and ascorbic acid|labeled iron as ferrous sulfate plus ascorbic acid (6mg:30mg /test meal)
1646268|NCT01884493|Device|real iTBS|Theta-burst magnetic stimulation (TBS) is a repetitive transcranial magnetic stimulation (rTMS) technique that elicits long-lasting changes in the excitability of human primary motor cortex (M1).
1646269|NCT01884493|Device|sham iTBS|The sham test will be done by transferring the double cone coil 90 degrees anteriorly and putting the lower edge of the coil of the vertex.
1646270|NCT01884467|Drug|Gentamicin|Comparison of Gentamicin versus placebo
1646271|NCT01884467|Drug|Placebo|
1646272|NCT01884454|Behavioral|Sleep deprivation|Volunteers will be submitted to total sleep deprivation (SD) or selective REM sleep deprivation for 48 hours. After SD, these volunteers will be allowed to sleep for 48 hours (period rebound).
1646273|NCT01884441|Drug|Bendamustine|"Schedule:
Day 2: Bendamustine 90mg/mq Day 3: Bendamustine 90mg/mq for a maximum of 4 cycles"
1646274|NCT01884441|Drug|Gemcitabine|Day 1: Gemcitabine 800mg/mq, Day 4: Gemcitabine 800mg/mq for a maximum of 4 cycles
1646275|NCT01884441|Drug|Vinorelbine|Day 1 Vinorelbine 20mg/mq for a maximum of 4 cycles
1646276|NCT01884428|Drug|panobinostat|Dose excalation oral panobinostat 3 days a week for a maximum of 4 cycles of three weeks duration
1646277|NCT01884428|Drug|Ifosfamide|Ifosfamide 2000 mg/m2 on days 1 to 4 as a 2-hour infusion for a maximum of 4 cycles of three weeks duration
1646278|NCT01884428|Drug|Gemcitabine|Gemcitabine 800 mg/m2 on days 1 and 4 for a maximum of 4 cycles of three weeks duration
1646279|NCT01884428|Drug|Vinorelbine|Vinorelbine 20 mg/m2 on day 1 for a maximum of 4 cycles of three weeks duration
1646280|NCT01884428|Drug|Prednisolone|Prednisolone 100 mg on days 1 to 4 for a maximum of 4 cycles of three weeks duration
1646281|NCT01884415|Biological|HBV vaccine|Patients receive a second cycle of vaccination
1646282|NCT01884415|Biological|HBV vaccine|Patients receive vaccination according to the guidelines.
1646283|NCT01884402|Drug|Peginterferon alfa-2a|Treatment as usual clinical practice
1646284|NCT01884402|Drug|Ribavirin|Treatment as usual clinical practice
1646285|NCT01884389|Other|Patient Navigation|Home-based medical and social support services, as an extension of and collaboration with primary care services provided. Phone calls and visits scheduled based on patient's level of need. Communication with primary care team via navigation plan faxed / emailed as needed. Volunteers will also be matched with intervention patients to provide additional support services by phone / in-person visits.
1646286|NCT01884376|Device|Neuromaix|
1646287|NCT01884363|Other|Once ounce per day of walnuts|
1646289|NCT01884337|Drug|Apixaban|
1646290|NCT01884324|Other|Early Delivery|"This will be a randomized clinical investigation. The subjects will be allocated into early and late delivery groups using concealed allocation envelopes, which will be created prior to the start of the study using a random allocation sequence. The trial will be conducted in an intent-to-treat fashion."
1646364|NCT01883726|Device|Figueroa's presurgical nasoalveolar molding|Figueroa NAM
1646291|NCT01884311|Biological|Subgam|Subgam-VF dose will be given as 1.37 of the established IGIV dose (expressed in mg/kg/week) for 26 weeks (26 infusions) beginning one week after the last IGIV infusion. Dose of Subgam-VF will then be adjusted based on the ratio of the Immunoglobulin G (IgG) average concentration achieved with Subgam-VF compared to IGIV.
1646292|NCT01884298|Drug|remifentanil(Ultiva)|remifentanil (TCI, Ce 3 ng /ml)for intra-operative analgesia
1646293|NCT01884298|Drug|epidural infusing 2% lidocaine|epidural infusing 2% lidocaine 4ml bolus followed by 6-18ml/hr for intra-operative analgesia
1646294|NCT01884285|Drug|Part A: AZD8186 monotherapy|The initial schedule will use intermittent dosing of AZD8186. Dose, frequency and schedule in subsequent cohorts may be modified in response to safety, tolerability, pharmacokinetic and preclinical data.
1646295|NCT01884285|Drug|Part B: AZD8186 monotherapy|Part B will be at a dose(s) and schedule(s) at or below from Part A
1646296|NCT01884285|Drug|Part C1: Abiraterone acetate combination with AZD8186|Dose and schedule finding of AZD8186 added to approved labelled dose of abiraterone acetate (with prednisone).
1646297|NCT01884285|Drug|Part D1: AZD2014 combination with AZD8186|Dose & schedule finding of AZD8186 in combination with AZD2014
1646298|NCT01884285|Drug|Part D2 AZD2014 combination with AZD8186|Combination AZD8186/ AZD2014 dose expansion at dose determined in Part D1
1646299|NCT01884285|Drug|Part C2: Abiraterone acetate combination with AZD8186|Dose expansion of AZD8186 at dose determined in Part C1 added to approved dose of abiraterone acetate (with prednisone)
1646300|NCT01884272|Drug|lesinurad 400 mg|
1646301|NCT01884272|Drug|naproxen 250 mg|
1646302|NCT01884272|Drug|indomethacin 25 mg|
1646303|NCT01884259|Drug|Docetaxel|75 mg/m² on day 1 of 21-days cycle
1646304|NCT01884259|Drug|Cisplatin|75 mg/m² on day 1 of 21-days cycle
1646305|NCT01884259|Drug|5-fluorouracil|750 mg/m² day 1 to 5 during 24 hours of 21-days cycle
1646306|NCT01884259|Biological|Cetuximab Induction|weekly, starting with 400 mg/m² during 120 min.(saturation) then continuing with 250 mg/m²; duration 3 cycles with 21 days
1646307|NCT01884259|Biological|Cetuximab Radioimmunotherapy|weekly, starting with 400 mg/m² during 120 min.(saturation only arm A) then continuing with 250 mg/m²; duration 7 weeks
1646308|NCT01884259|Radiation|Boost irradiation|First 18 irradiations once daily with single dose of 1,8 Gy for 5 days per week. In addition by day 19 a second irradiation boost will be applied for further 12 days(1,5 Gy per day with at least 5 hours interval to 1,8 Gy dose. This results in total clinical target dose of 72 Gy and total subclinical target dose of 54 Gy. Duration of irradiation: 6 weeks
1646309|NCT01884246|Behavioral|Self-care CVD risk reduction|A patient-centered, culturally appropriate lifestyle approach to promoting self-care in high risk patients.
1646310|NCT01884246|Other|Referral to primary care provider for CVD risk management|The study team provides a primary care provider for the patient, makes the referral and sends appropriate CVD risk reduction guidelines to the provider.
1646311|NCT01884233|Behavioral|Standard Care|Standard care will include usual treatment for HIV and a pamphlet that will be provided to the participants with information about ART adherence and relapse prevention.
1646312|NCT01884233|Behavioral|Text Messaging CBT (TXT-CBT)|Those assigned to TXT-CBT will be given a treatment manual (developed in Phase I) containing descriptions of core therapeutic content/topics for each week. HIV-infected participants will have initial meeting with a CBT clinician to review the core CBT concepts for promoting ART adherence. The 3 most applicable medication adherence skills will be identified for emphasis in tailored messages. A research coordinator will meet with the participants weekly at data collection visits throughout the intervention phase to answer any technical questions and ensure that the intervention program is working properly.
1646313|NCT01884220|Other|There are no interventions in this study.|
1646314|NCT01884207|Other|MRI|
1646315|NCT01884168|Biological|Dc-CIK immunotherapy|The patients with malignant cavity effusion are treated with dendritic cells (DC) plus cytokine induced killer cells (CIK) locally.
2012603|NCT01833936|Device|Compex® muscle stimulator|The Compex® muscle stimulator is a commercially available muscle stimulator that is approved by the Food and Drug Administration (FDA), a governmental body. It is not investigational. The investigational part of this study aims to evaluate if the use of muscle simulation after Achilles tendon surgery will reduce calf atrophy.
1646317|NCT01884142|Other|Aerobic Exercise Training|
1646318|NCT01884116|Drug|NSAID patch|
1646319|NCT01884116|Drug|NSAID patch + transcutaneous electric nerve stimulation|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
1646320|NCT01884116|Drug|NSAID patch + heating pad|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
1646321|NCT01884116|Drug|NSAID patch + topical capsaicin|The patients of the experimental groups will be divided in to three groups according to what they are administered: NSAID patch plus transcutaneous electric nerve stimulation, NSAID patch plus heating pad, and NSAID patch plus topical capsaicin. All the groups will be observed for two weeks.
2012604|NCT01833936|Device|(inactive) muscle stimulator|A placebo (inactive) muscle stimulator, which will be placed immediately following surgery. Eight electrodes will be placed on the lower leg: four electrodes on the gastrocnemius (calf muscle), and two electrodes each on the lateral gastrocnemius (side) and anterior tibialis muscle (front). Subjects will be instructed to use the stimulator for three 20 minute sessions per day.
2012605|NCT01832467|Drug|cetuximab-containing chemotherapy|
2012606|NCT01819662|Other|Enhanced standard management|Echocardiogram followed by letter to GP about results.
1646325|NCT01884064|Device|rTMS|rTMS
1646326|NCT01884064|Device|Sham rTMS|Sham rTMS
1646365|NCT01883713|Device|Brain Oximetry|Non invasive brain oximeter will be applied on the patient's forehead to monitor the brain oxygen saturation throughout the surgery.
2012607|NCT01819662|Other|Optimised heart failure management|Echocardiogram followed by referral to comprehensive heart failure service for those with left ventricular dysfunction
2012608|NCT01819662|Other|Standard management|Usual care
1646327|NCT01884038|Drug|treprostinil sodium|"A single dose strength of treprostinil sodium (1.0 mg/mL) and matching placebo will be provided in 20-mL multi-dose vials.
The study drug will be started after induction of anesthesia and increased incrementally to a target dose of 10 ng/kg/min during surgery and 48 hours post-operative"
1646328|NCT01884038|Drug|Placebo|
1646331|NCT01884012|Procedure|long term oxygen therapy|
1646332|NCT01883999|Device|GORE® EXCLUDER® Iliac Branch Endoprosthesis|
1646333|NCT01883986|Behavioral|Palliative Care|Care delivered by a nurse including symptom assessment and management, patient education on lung cancer and treatment options , discussion and communication about preferences for care, psychosocial assessment including referrals to ancillary services such as social services and spiritual care as requested by the patient.
1646334|NCT01883947|Procedure|Touch massage|Touch massage is a gentle massage with strokes on hands, arms, feet and legs with at pressure of 2.5 N which is more gentle than Swedish massage but harder than strokes performed with a brush. The speed of the strokes is about 1-5 cm/sec. During the massage, the subjects will lie on a bed. Intervention group will receive touch massage on hands and feet and the intervention will start one week after the onset of stroke and last for 30 minutes each time, five days a week for two weeks
1646335|NCT01883947|Other|non-TENS|Subjects in the control group will have sham treatment which is a non-active transcutaneous electrical nerve stimulation (non-TENS), while they lie in bed with electrodes attached to the skin of the affected arm. The device will be manipulated in a way so that no electrical impulses will reach the electrodes. During treatment, the masseur will remain in the room without initiating any conversation.
1646336|NCT01883934|Other|Enhanced clinic-based support/counseling|Additional enhanced support services and educational services provided by embryologists, nurses and physicians in the Frozen Embryo Donation Service will be offered.
1646337|NCT01883934|Other|Control|
1646338|NCT01883921|Other|Immunoglobulin Therapy|
1646339|NCT01883908|Device|Acupuncture with Seirin® needles|Participants will be randomized to receive either usual medical care or acupuncture treatment plus usual medical care once a week for 8 weeks coinciding with their chemoradiation treatments. The length of the study will be 16 weeks: 8 weeks of treatment and two follow up visits at 4 weeks and 8 weeks after radiation (weeks 12 and 16).
1646340|NCT01883908|Other|Usual medical care|usual medical care such as viscous Lidocaine for relief of pain
1646341|NCT01883895|Device|Forgionei-Barber pressure-pain stimulator|Pain testing will be conducted using a Forgioni-Barber pressure-pain stimulator to deliver 3000-gm force to the middle digit of the non-dominant middle finger for up to 120 seconds. During stimulation, subjects will press a button attached to a timer when the pressure stimulus first becomes painful (pain threshold) and will also rate their perceived pain intensity using a 0-100 numeric pain rating scale at 20 second intervals during the 2 minute exposure to the pressure stimulus. This validated protocol has been used in previous research by investigators in this study. This will be used for both exercise sessions and the control session. Forgionei-Barber pressure-pain stimulator will be used.
1646342|NCT01883895|Other|Concentric Exercise|Concentric testing will utilize a dumbbell with elbow flexion exercise. Subjects will perform 5 sets of 20 reps at 30% MVC. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
1646343|NCT01883895|Other|isometric exercise|When undergoing isometric exercise, subjects will perform 5 sets of sustained muscle contraction for 65 seconds using a hand-grip dynamometer. Pain testing will be conducted using a Forgionei-Barber pressure-pain stimulator immediately before and after the exercise.
1646344|NCT01883882|Behavioral|opioid taper support|Weekly visits with physician's assistant (supervised by pain physician/psychiatrist and pain psychologist) who provides pharmacological and psychological support for opioid taper at 10% per week
1646345|NCT01883869|Drug|ticagrelor|
1646346|NCT01883869|Drug|placebo|placebo
1646347|NCT01883856|Device|Silicone plate Ahmed Glaucoma Valve (Model FP7)|This intervention is conducted as a surgical intervention.
1646348|NCT01883856|Device|Porous Plate Ahmed Glaucoma Valve (Model M4)|This intervention is conducted as a surgical intervention.
1646349|NCT01883843|Device|sham tDCS + TOCT|Every day will be given a continuous low-intensity stimulation of 0.5mA (for a current density of 60μA/cm2) only for 10 seconds at the beginning and at the end of the stimulation for 10 consecutive days after any rehabilitative treatment. The mounting of electrodes for sham stimulation is the same used for the experimental group.
1646350|NCT01883843|Device|real tDCS + TOCT|Every day will be given continuous stimulation duration of 15 minutes with intensity of 0.5 mA (for a current density of 60μA/cm2), generated by a constant current stimulator rechargeable batteries for 10 consecutive days after any rehabilitation treatment in the gym. Two sponge electrodes are placed, soaked in saline solution, fixed by an elastic band, the anode consists of an electrode oblong 8cm2 positioned at M1 area on the lower limb affection (following the medial sagittal axis, with the center of the electrode positioned at one centimeter laterally to the vertex) while the cathode (48cm2) is placed in the contralateral supraorbitale area as reference electrode. The current reaches 0.5mA and decreases with a ramp of 10 seconds.
1646351|NCT01883830|Device|gaming therapy (Xbox)|
1646352|NCT01883830|Device|Dynamic balance platform (Biodex)|
1646353|NCT01883817|Drug|DHA Omega-3|Patients will receive a fixed dose of DHA (1,200 mg/day, 600 mg twice daily) or placebo (corn/soy oil) over 10 weeks
1646354|NCT01883817|Drug|Placebo|corn/soy oil capsule with similar color, taste, and shape as experimental drug (DHA)
1646355|NCT01883804|Drug|Methyldopa|6 weeks of Methyldopa administration; where the dose will be increased according to safety of efficacy.
1646356|NCT01883791|Behavioral|SBIRT|See above Arm description.
1646357|NCT01883791|Behavioral|Health Education|See Arm Description.
1646358|NCT01883765|Behavioral|Neurofeedback active|
1646359|NCT01883765|Behavioral|Neurofeedback sham|
1646360|NCT01883765|Behavioral|Metacognitive Training|
1646361|NCT01883752|Procedure|Goal-directed Therapy group|Fluid administration is based on the respiratory variation in the pulse oximeter waveform
1646362|NCT01883739|Other|Parental Presence at Handover Rounds|
1646363|NCT01883726|Device|Grayson's presurgical nasoalveolar molding|Grayson NAM
1646367|NCT01883700|Other|Boiled Chickpeas with Oil|
1646368|NCT01883700|Other|Instant Mashed Potatoes|
1646369|NCT01883700|Other|Instant Mashed Potatoes with Egg Whites|
1646370|NCT01883687|Procedure|Septoplasty|
1646371|NCT01883674|Other|Resistance training|All group will exercise 3x/week. Each session of resistance training will last 60min. and will target main muscular groups.
1646372|NCT01883661|Biological|BMMNC|Bone Marrow derived Mono Nuclear Stem Cell (MNCs) by intravenously route total 3 doses in one month period .
1646373|NCT01883648|Drug|Coconut Oil Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
1646374|NCT01883648|Other|Placebo Beverage|There are 2 treatment arms: Fuel for Thought™ and placebo, with a treatment allocation of 1:1. After 3 months of treatment in one group, subjects will have a 3-5 day wash-out period before receiving the alternate (opposite) treatment for 3 months.
1646375|NCT01883635|Behavioral|Survivor-only progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor only
1646376|NCT01883635|Behavioral|Dyadic progressive walking and resistance exercise|Daily, home-based, tailored exercise program delivered over the course of 6 weeks to the survivor and caregiver as a dyad
1646377|NCT01883609|Biological|RTS,S/AS01B|Each RTS,S/AS01B dose will be given intramuscularly, and will contain 50mcg of RTS,S and standard adult dose of AS01
1646378|NCT01883609|Biological|ChAd63 ME-TRAP|ChAd63 ME-TRAP will be given intramuscularly at a dose of 5 x 1010 vp
1646379|NCT01883609|Biological|MVA ME-TRAP|MVA ME-TRAP will be given intramuscularly at a dose of 2 x 108 pfu
1646380|NCT01883596|Drug|0.12% chlorhexidine solution|Bexident® (0.12% chlorhexidine solution)
1646381|NCT01883596|Drug|Placebo|7.4% alcohol, glycerine, normal saline solution, applied topically, every 8 hrs.
1646382|NCT01883583|Device|Contrast-enhanced Ultrasound And Sonoelastography|Before ultrasound guided biopsy of transplanted kidney, we will perform conventional, Sonoelastography and real-time contrast-enhanced ultrasound using Sonovue for acquisition of parameters and data, respectively.
1646383|NCT01883570|Other|training in visual search strategy|
1646384|NCT01883570|Other|access to a library of chest x-rays without search strategy|
1646385|NCT01883544|Drug|ALXN1007|
1646386|NCT01883531|Drug|Inhaled Mannitol|Active treatment is inhaled mannitol with a particle size of 3-4 microns
1646387|NCT01883531|Drug|Inhaled Placebo|The PLacebo is non respirable mannitol due to the big size particle
1646388|NCT01883518|Biological|Autologous dendritic cell vaccine|Autologous dendritic cell vaccine loaded with allogeneic tumor lysate expression of cancer testis antigens
1646389|NCT01883505|Drug|Levodopa and carbidopa|Subcutaneous continuous administration
1646390|NCT01883505|Drug|Placebo|Subcutaneous continuous administration
1646391|NCT01883492|Device|Femoral Stem|JMDN classification/Class III device
1646392|NCT01883492|Device|Acetabular Cup|JMDN classification: Class III device
1646393|NCT01883492|Device|Acetabular Liner|JMDN classification: Class III device
1646394|NCT01883479|Behavioral|Exercise|Telephone-based intervention designed to increase exercise among postpartum women.
1646395|NCT01883479|Behavioral|Wellness/Support|Telephone-based intervention designed to provide support to postpartum women.
1646396|NCT01883466|Other|Forearm venous occlusion plethysmography study|Measurement of forearm blood flow during unilateral intrabrachial infusion of four vasodilator drugs in incremental doses separated with 20-min washout periods. Bradykinin (endothelial-dependent vasodilator that releases t-PA) was infused at 100, 300 and 1000 pmol/min; acetylcholine (endothelial independent vasodilator that does not release t-PA) was infused at 5, 10 and 20 mcg/min; sodium nitroprusside (endothelial independent vasodilator that does not release t-PA) was infused at 2, 4 and 8 mcg/min and verapamil (endothelial independent and NO independent vasodilator that does not release t-PA) was infused at 10, 30 and 100 mcg/min. Bradykinin, acetylcholine and sodium nitroprusside were given in random order and verapamil was administered last due to its long acting effects.
1646397|NCT01883453|Device|Glucose oxidase+5%glucose|A hydrogen peroxide producing enzyme
1646398|NCT01883453|Device|Saline+5%glucose|Isotonic saline + 5% glucose in a bag-on-valve nasal spray device
1646399|NCT01883440|Drug|Glucose oxidase + glucose|Isotone saline + 200U/ml of glucose oxidase + 5% of glucose in a bag on valve nasal spray device
1646400|NCT01883440|Drug|Saline+glucose|Placebo arm
1646401|NCT01883427|Drug|Placebo|placebo containing saline+glucose
1646402|NCT01883427|Drug|Glucose oxidase|a hydrogen peroxide producing enzyme that creates an acidous environment to which rhinoviruses are sensitive.
1646403|NCT01883414|Device|Ultherapy™|All subjects will receive an Ultherapy™ treatment at triple depth using the 4-4.5mm, 7- 3.0mm, 10-1.5mm transducers on one half of the scar and no treatment on the other half of the scar. Treatments will be provided to the defined scar area, treating with a density of lines that is equivalent to 30 lines per transducer per 2.5cm in scar length for a total of 90 lines in a 2.5cm X 2.5cm square area.
1646404|NCT01883401|Dietary Supplement|Freeze-dried strawberries|25g or 50g freeze-dried strawberries reconstituted in water
1646405|NCT01883401|Dietary Supplement|Dietary fiber|4g or 8g dietary fiber blended in water
1646406|NCT01883375|Behavioral|Dignity Talk|Patient and family member participants will be given the Dignity Talk framework questions and asked to use them in conversation with each other. Research nurse will return at day 4-6 to confirm both participants have covered all items they wish to discuss. 4-6 months after the death of patient, family members will be contacted in order to collect data pertaining to their bereavement experiences and distress. Will also be asked to complete evaluative feedback on Dignity Talk.
1646407|NCT01883375|Behavioral|The Dignity Talk Communication Topics|There have not been any non-completers - this arm not being used currently
1646408|NCT01883362|Drug|Midostaurin (PKC412)|Midostaurin (PKC412) 50mg twice a day for 28 days of each cycle. Patients will be treated for 12 cycles.
1646409|NCT01883362|Other|Standard of Care|Standard of Care is not defined per protocol. The investigator will prescribe based on the commonly used medications given in the post SCT setting.
1646410|NCT01883349|Procedure|Kidney Transplant|Kidney Transplant Surgery
1717390|NCT00002077|Drug|Fluconazole|
1646411|NCT01883323|Drug|Cyclophosphamide|i.v., 60mg/kg per day for 2 days
1646412|NCT01883323|Drug|Fludarabine|i.v., 25mg/m2 per day for 5 days
1646413|NCT01883323|Biological|Tumor-Infiltrating Lymphocytes|i.v., 1x10^10 - 1.6x10^11 cells
1646414|NCT01883323|Biological|Low-Dose Interleukin|i.v., 125,000 IU/kg subcut per day, for 2 weeks (2 days rest between each week)
1646415|NCT01883310|Device|sham tDCS + TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The sham transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 30 s over the right cerebellar position.
1646416|NCT01883310|Device|real tDCS +TOCT|Anodal transcranial direct current stimulation will be delivered through 2 sponge electrodes (surface area: 25 cm2) soaked in a saline solution. For the cerebellar transcranial direct current stimulation, the anodal electrode will be centered on the right cerebellar cortex, 3 cm lateral to the inion, and the cathodal electrode will be positioned on the right buccinator muscle. Anodal stimulation intensity will be set at 2 mili Ampere and delivered using a rechargeable batteries direct current stimulator.The real transcranial direct current stimulation group will consist of anodal transcranial direct current stimulation applied for a total duration of 15 minutes over the right cerebellar position.
1646417|NCT01883297|Biological|Re-stimulated tumor-infiltrating lymphocytes (TILs)|Intravenous infusions: Dose level 1 (3 patients): 3x10^7 TILs (with maximum 3x10^6 autologous dendritic cells); Dose level 2 (3 patients): 1x10^8 TILs (with maximum 1x10^7 autologous dendritic cells); Dose level 3 (3 patients): 3x10^8 TILs (with maximum 3x10^8 autologous dendritic cells)
1646418|NCT01883297|Biological|Interleukin-2|Subcutaneous injections of IL-2 x 4 days during the first week and x 5 days the second week with 2 days of rest in between each week of dosing
1646419|NCT01883297|Drug|Cyclophosphamide|Intravenous infusion: 30 mg/kg/day for 2 days (Day -3 and -2 prior to infusion of TILs)
1646420|NCT01883284|Other|Tests in vitro after sampling nasal cells of CF patients or controls|Nasal cells of CF patients or controls were collected by scratching of intermediate turbinate and cultured in vitro. Epigenetic modifiers treatment was applied to these ex vivo nasal epithelia. Then, mRNA, protein and secretions were quantified.
1646421|NCT01883271|Other|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
1646422|NCT01883271|Other|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
1646423|NCT01883258|Other|High intensity aerobic interval training|Supervised aerobic interval training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 40 minutes and will consist of 10-minute warm up at 70% of maximal heart rate (HRmax), four 4-minute intervals at 90% of HRmax with 3-min active recovery at 70% of HRmax and 5-minute cool down at 70% of HRmax.
1646424|NCT01883258|Other|Continuous moderate intensity exercise|Supervised exercise training will be performed on bicycles 4 times per week for 8 weeks. Each training session will last 47 minutes and will consist of continuous moderate intensity cycling at 70% of HRmax.
1646425|NCT01883245|Device|real tDCS|2 milliampere real direct current stimulation for 20 minutes daily for 5 days.
1646426|NCT01883245|Device|sham tDCS|2 milliampere sham direct current stimulation for 20 minutes daily for 5 days.
1646427|NCT01883232|Device|Onset Mixing Pen by Onpharma|Sodium Bicarbonate 8.4%
1646428|NCT01883232|Device|2% lidocaine with 1:100,000 epinephrine|2% lidocaine with 1:100,000 epinephrine administered with a syringe prior to the procedure
1646429|NCT01883219|Drug|TKI|Imatinib will be given for patients without BCR/ABL mutations with a dose of 400mg/d or 600mg/d. The second-generation TKI will be given for those with mutations(except for mutation of T315I). The therapy will be suspended if patient peripheral blood absolute neutrophil counts (ANC) is <0.5×10^9/L and or platelet count is <2.0×10^9/L. Donor Lymphocyte Infusion(1.0×10^8/kg) will be given for patients with mutation of T315I.
1646430|NCT01883193|Dietary Supplement|Comprehensive Maternal Nutrition Intervention|The nutrition intervention will be delivered before conception or at 12 weeks gestation and continued through delivery and compared with a control group. The supplement to be used is a multi-micronutrient (MMN) fortified lipid-based supplement composed of dried skimmed milk, soybean and peanut extract, sugar, maltodextrin stabilizers, and emulsifiers.
1646431|NCT01883180|Drug|ATG|ATG will be intravenously infused via a central venous catheter in 3 or 4 days, from day -4 or -3 until day 0. The other conditioning drugs administered before transplantation include cytosine arabinoside (Ara-C), busulfan (Bu),cyclophosphamide (Cy), Semustine(Me-CCNU), and ATG. All transplant recipients will receive cyclosporine A (CsA), mycophenolate mofetil(MMF), and short-term methotrexate for aGVHD prevention.
1646432|NCT01883167|Drug|RDEA3170 10 mg|RDEA3170 10 mg once daily (qd)
1646433|NCT01883167|Drug|Febuxostat 40 mg|Febuxostat 40 mg qd
1646434|NCT01883167|Drug|placebo|placebo qd
1646438|NCT01883128|Device|Whole Body MRI|Full parametric MRI using T1W, T2W, Diffusion-weighted and dynamic-contrast-enhanced images at 3Tesla
1646439|NCT01883128|Procedure|Focal Salvage Therapy|Cryotherapy and HIFU will be used to targeted the areas of tumor only with a margin of normal tissue.
1646440|NCT01883128|Procedure|MRI Targeted biopsies|Image registration will be used to target biopsies followed by full mapping biopsies of the prostate. All biopsies will be carried out transperineally
1646441|NCT01883102|Drug|Capsaicin 0.1%|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
1646442|NCT01883102|Drug|Placebo|Cream will be cleansed from sites A and B with soap and water each morning before reapplying.
1646443|NCT01883089|Behavioral|Motivational Enhancement Therapy|
1646444|NCT01883076|Biological|autologous cell-based delivery|"autologous cells (derived from self)"
1958017|NCT02044653|Drug|GX-E2|Each Group of Peritoneal dialysis patients (n=10) will be administered GX-E2 3ug/kg to 8ug/kg
1958018|NCT02044653|Drug|GX-E2|Each Group of Peritoneal dialysis patients (n=24) will be administered GX-E2 5ug/kg to 8ug/kg
1646447|NCT01883050|Device|Self Monitoring Software Application|Computer Software application to track health progress after interventional surgery
1646448|NCT01883037|Other|Blood glucose results|The glucose value from the HemoCue Glucose 201 RT will be compared with the Trust Laboratory value.
1646449|NCT01883024|Other|A decision support software|
1646450|NCT01883024|Other|Insulin Pump|
1646451|NCT01883024|Other|Continuous glucose monitoring|
1646452|NCT01883011|Drug|Piracetam|
1646453|NCT01883011|Other|Placebo|
1646454|NCT01882998|Behavioral|Extended repeat HIV testing and enhanced counseling|Pregnant/breastfeeding women in the intervention arm and their male partners if present will receive extended repeat HIV testing and enhanced counseling around the time of labor and delivery and throughout the breastfeeding period.
1646455|NCT01882985|Drug|Docetaxel|Given IV
1646456|NCT01882985|Dietary Supplement|Lycopene|Given PO
1646457|NCT01882972|Behavioral|Exercise|
1646458|NCT01882972|Behavioral|Meditation|
1646459|NCT01882959|Other|Radiofrequncy Denervation|
1646460|NCT01882946|Biological|DCVax-Direct|Autologous, activated dendritic cells for intratumoral injection
1646461|NCT01882933|Drug|HIPEC (Hyperthermic Intraperitoneal Chemoperfusion) with oxaliplatin|After the D2 resection is complete HIPEC can start. A roller pump forces the chemotherapy solution (oxaliplatin 250 mg/m² with 2 Liters of G5%/m²) into the abdomen through the inflow catheter and pulls it out through the drains. A heat exchanger keeps the intraperitoneal fluid at 42°-43°C.
1646462|NCT01882933|Procedure|Curative gastrectomy|All the patients will undergo a D1-D2 gastrectomy carried out according to Japanese guidelines and to the European recommendations for the preservation of spleen and pancreas
1646463|NCT01882920|Drug|Goal Directed Intravenous Restrictive Fluid Therapy|Basal infusion of crystalloids (normal saline,Ringer's lactate,Ringer's solution) at 4 ml/kg/h and boluses of colloids (HES 130/0.4 ) for values of cardiac index (CI) <2.5 l/min/m2, stroke volume index (SVI) < 35 SVI ml/m2 and stroke volume variation (SVV)> 15%. In the case of CI <2.5 l/min/m2 and SVI <35 ml/m2 with SVV < 15%, an infusion with dopamine was initiated.
1646464|NCT01882920|Drug|Conventional Intravenous Fluid therapy|Basal infusion of crystalloid (normal saline,Ringer's lactate,Ringer's solution)variable from 4 to 12 ml/kg/hour.
1646465|NCT01882907|Drug|vildagliptin|vildagliptin 50mg bid for 16 weeks
1646466|NCT01882907|Drug|Pioglitazone|Pioglitazone 15mg bid for 16 weeks
1958019|NCT02044653|Drug|GX-E2|Each Group of Hemodialysis patients (n=30) will be administered GX-E2 5ug/kg to 8ug/kg
1958020|NCT02044653|Drug|NESP|Each Group of Hemodialysis (n=30) will be administered NESP 30ug
1646469|NCT01882881|Other|Healthy American Control Diet|The Control Diet will be comprised of the same foods as the test diets except for the isocaloric substitution of almonds and/or dark chocolate and cocoa for sources of saturated fat; an approximate 250 kcal substitution. In an effort to keep all the diets consistent (except for the specific foods to be tested), the Control Diet will be slightly higher in fiber (20-25g) and lower in cholesterol (~250 mg) than the typical consumption practices (15g and 278 mg, respectively).
1646470|NCT01882881|Other|Dark Chocolate/Cocoa Diet|The Dark Chocolate/Cocoa Diet will include a daily hot cocoa beverage containing 11g of natural cocoa powder and 6 pieces of Hershey's Bliss Dark Chocolate (43g of dark chocolate). This amount of dark chocolate and cocoa will allow for the isocaloric substitution with 1.5oz almonds. The total diet will provide ~33% of calories from fat. The SFA (~12%) in the Dark Chocolate/Cocoa Diet will match that of the Control Diet and be slightly higher than the Almond Diet, however the saturated fat will be comprised largely of stearic acid from the dark chocolate; cholesterol will be ≤200 mg/day. The fiber in the Dark Chocolate/Cocoa Diet will be higher than both the Control and Almond Diets due to the fiber content of the dark chocolate (~9g).
1646471|NCT01882881|Other|Almond Diet|The Almond Diet will include 1.5 oz of almonds daily and provide ~34% of calories from fat. The Almond Diet will be lower in SFA than the Control and Dark Chocolate/Cocoa Diets, containing ~ 8-9% calories from SFA. In addition, both almond containing diets will be slightly higher in MUFA and PUFA than the Control and Dark Chocolate/Cocoa Diets, as a result of the nutrient profile of the almonds. Cholesterol will be ≤200 mg/day; fiber will be increased compared to the Control Diet due to the inclusion of almonds.
1646472|NCT01882881|Other|Dark Chocolate/Cocoa + Almond Diet|This diet is designed to test the additive effects of combining consumption of dark chocolate and cocoa with almonds. The diet will include the same hot cocoa beverage (11g) and dark chocolate pieces (43g) plus 1.5 oz of almonds. Additional high saturated fat foods are removed from the Control Diet to account for both the dark chocolate and almonds. As a result, the total fat will be similar to the other three test diets at ~34-35% and the SFA will match that of the Almond Diet at ~8-9%. The fiber content of this diet will be highest (~35g); cholesterol will remain ≤200 mg/day.
1646473|NCT01882868|Drug|Aflibercept|Pharmaceutical form: Concentrated solution (100 mg/4 mL [25 mg/mL], 200 mg/8 mL [25 mg/mL]) for infusion; Route of administration: Intravenous
1646474|NCT01882868|Drug|Levofolinate|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
1646475|NCT01882868|Drug|Irinotecan|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
1646476|NCT01882868|Drug|5-FU|Pharmaceutical form: Solution for infusion (marketed formulation); Route of administration: Intravenous
1646477|NCT01882842|Procedure|Endometrial biopsy|Endometrial biopsy will be performed in the study group and timed according to a positive urinary LH (ovulation) kit at LH+7 to +9 days.
1646478|NCT01882842|Device|Transvaginal ultrasound|A detailed assessment of the endometrium will be performed including two- and three- dimensional ultrasound, as well as power Doppler acquisitions.
1717391|NCT00002078|Drug|Interferon alfa-n3|
1958021|NCT02044653|Drug|MIRCERA|Each Group of Peritoneal dialysis (n=24) will be administered MIRCERA 0.6ug/kg
1646480|NCT01882816|Radiation|IMRT|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions (Monday through Friday, excluding holidays). A total dose of 70Gy is planned. Patients will be seen weekly during radiation as per standard procedure at MSKCC
1646481|NCT01882816|Device|DWI MRI|The DW and multiparametric MRI will be recommended for 3 months, 6 months, and then every 6 months (all +/- 4 weeks) until 2 years post-RT unless contraindicated for main campus patients only. This schedule may be altered, as clinically indicated.
1646482|NCT01882816|Drug|Doxorubicin|Low dose radiosensitizing doxorubicin at 10 mg/m2 will be administered weekly.
1646483|NCT01882816|Other|Modified Barium Swallow Impairment Profile (MBSImP)|The MBSImP is a standardized tool which assesses swallowing impairment as it relates to oral, pharyngeal, and esophageal impairments.
1646484|NCT01882803|Drug|IPI-145 (duvelisib)|PI3K Inhibitor
1646485|NCT01882777|Behavioral|Household drinking water filters and cookstoves|The intervention consists of providing households with a household-based drinking water filter (Lifestraw® Family version 2.0) and high efficiency cook stoves (Eco Zoom) as well as instructions on how to use them. The intervention is delivered at community level through community health workers (CHWs). Following initial distribution of the products, CHWs visit households fortnightly to reinforce messages about correct and consistent use.
1646486|NCT01882764|Drug|HMPL-004 tablet|HMPL-004 tablet given at a strength of 1800 mg/day, (600 mg t.i.d.)
1646487|NCT01882764|Drug|Placebo Tablet|
1646488|NCT01882751|Device|Conformis CR Total Knee Replacement|iTotal CR by Conformis
1646489|NCT01882751|Device|Off the Shelf|A standard knee replacement not using ConforMIS' iFit technology
1646490|NCT01882725|Device|Erchonia HP Scanner (HPS)|The Erchonia HP Scanner (HPS) Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
1646491|NCT01882712|Drug|CD07805/47 Gel 0.5%|
1646492|NCT01882712|Drug|CD07805/47 Gel Placebo|
1646493|NCT01882699|Device|Cereve Sleep System|cerebral hypothermia
1646494|NCT01882686|Other|Classification Based Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation. This subclassification is the base for matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
1646495|NCT01882673|Behavioral|Brief Computer Motivational Interviewing for Smoking Cessation|Brief computer motivational interviewing intervention to motivated tobacco quitline use
1646496|NCT01882673|Behavioral|Nutrition Control|Computer delivered nutrition education control condition
1646497|NCT01882660|Drug|Decitabine|
1646498|NCT01882647|Drug|000-0551 Lotion|
1646499|NCT01882647|Drug|Vehicle Lotion|
1646500|NCT01882634|Device|Ultrasound (Trademark:VScan; Manufacturer:General Electric)|Standardized measurements were made and aorta will be visualized in a minimum of three hard copy images: upper transverse projection abdominal aorta at the level of epigastrium (celiac trunk) lower transverse section for distal view of aorta (pre-bifurcation), and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm)
1646501|NCT01882621|Drug|Monosialoganglioside(GM1)|80mg,ivdrip (in the vein) on day 0 - day 3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
1646502|NCT01882621|Drug|normal saline|80mg,ivdrip(in the vein) on day 0-3 of each 21 day cycle. Number of Cycles: 4-6 cycles.
1646503|NCT01882608|Other|Mental Health Telemetry (MHT)|Ecological momentary assessment (EMA) focuses on using data collected from subjects living their daily lives in their natural environments using minimally invasive techniques to improve the quality of the data collected. MHT is an evolution of EMA. MHT was developed at Sunnybrook in partnership with the University of Toronto; it uses cell phones to collect self-report data on symptoms of illness and then transmit it in real-time to a central database. Principal advantages of MHT over EMA include the ability to time- and date-stamp data, thus eliminating retrospective record completion, and the ability to observe and monitor data flow in real-time, without having to wait for participants to upload or deliver the data (e.g., at their next doctors' appointment).
1646504|NCT01882595|Other|Nebulization through the tracheostomy|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The first session was performed prior to tracheostomy removal. During the first nebulization, subjects inhaled the aerosol through the tracheostomy, cuff inflated and inner cannula removed.
1646505|NCT01882595|Other|Nebulization through the mouth|Each subject received two nebulization sessions under spontaneous breathing in a sitting position. The second nebulization was performed when the tracheostome was totally scarred. During the second nebulization, subjects inhaled the aerosol a mouth piece and wore a nose clip.
1646506|NCT01882556|Drug|onabotulinumtoxinA|
1646507|NCT01882556|Drug|Placebo|
1646508|NCT01882543|Drug|AQX-1125|Synthetic SHIP1 activator
1646509|NCT01882543|Drug|Placebo|Double blind placebo capsule
1646510|NCT01882530|Drug|Paracetamol|
1646511|NCT01882530|Drug|Nefopam|
1646512|NCT01882530|Drug|Ketoprofen|
1646513|NCT01882530|Drug|Morphine|
1646514|NCT01882517|Dietary Supplement|Yogurt that contains plant stanol esters|
1646515|NCT01882517|Dietary Supplement|Placebo yogurt|
1646516|NCT01882504|Drug|gevokizumab|
1646517|NCT01882491|Drug|Placebo|Solution for subcutaneous injection
1646518|NCT01882491|Drug|gevokizumab|Solution for subcutaneous injection
1646519|NCT01882465|Device|etafilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
1646520|NCT01882465|Device|2-HEMA, EGDMA Non-ionic|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
1646521|NCT01882465|Device|hefilcon A|Lenses to be worn in a daily wear modality, and disposed of at the end of each follow-up visit.
1646644|NCT01881581|Biological|D-GPEi|D-GPEi is used in Arm A,B,C,G and H.
1646522|NCT01882452|Behavioral|Memory Specificity Training|This intervention is a manualised, structured treatment delivered over 5 x 60 minute sessions to groups of 5-8 individuals. This treatment involves repeated practice of retrieving specific autobiographical memories in response to positive, negative and neutral cue words. There is a single psychoeducation component in the first session about memory difficulties common in depression which provides the rationale for this treatment. The training is supplemented by weekly homework practice.
1646523|NCT01882452|Behavioral|Education and Support|The education-and-support comparison condition is matched with the experimental arm for length and format (ie., 5 x 60 minute weekly sessions in groups of 5-8 individuals). Groups receive a single psychoeducation component where information about depression is provided. This is followed by non-directive support where participants are encouraged to raise different kinds of events that occur each week for discussion in the group. The sessions are supplemented by a homework diary where participants will be invited to note down an event that occurs each day, which may be positive, negative, or benign and non-emotional in nature. This material will provide the basis for discussion in the weekly group meetings.
1646524|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 6 months
1646525|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 6 months
1646526|NCT01882439|Other|Placebo|tablets, to match tofacitinib 5 mg BID x 3 months
1646527|NCT01882439|Drug|Tofacitinib|tablets, 5 mg BID x 3 months
1646528|NCT01882439|Other|Placebo|tablets, to match tofacitinib 10 mg BID x 3 months
1646529|NCT01882439|Drug|Tofacitinib|tablets, 10 mg BID x 3 months
1646530|NCT01882426|Other|Enhanced treatment algorithm|Practitioners assigned to the intervention arm will be educated on the use of the Enhanced Algorithm.
1646531|NCT01882426|Other|Usual Care|usual step care practice
1646532|NCT01882413|Other|No intervention|No intervention
1646533|NCT01882400|Drug|Bisphosphonate treatment|Treatment with Calcium, vitamin D and a weekly bisphosphonate. Comparison of bone mass, fracture rate, pain intensity and scoliosis progression before and after treatment
1646534|NCT01882387|Drug|TXA127|Injection, 300mcg/kg/day for 28 days
1646535|NCT01882374|Drug|TXA127|Injection, 300mcg/kg/day for 28 days
1646536|NCT01882361|Drug|injectable naltrexone|Vivitrol is an extended-release, microsphere formulation of naltrexone designed to be administered by intramuscular (IM) gluteal injection every 4 weeks or once a month. After IM injection, the naltrexone plasma concentration time profile is characterized by a transient initial peak, which occurs approximately 2 hours after injection, followed by a second peak observed approximately 2 - 3 days later. Beginning approximately 14 days after dosing, concentrations slowly decline, with measurable levels for greater than 1 month.
1646537|NCT01882361|Drug|placebo comparator|this placebo has no specific pharmacological activity
1646538|NCT01882348|Behavioral|CEASE Intervention|The CEASE intervention works within existing systems of care to address parental smoking. Elements include (1) Identification of smokers and self-assessment of quitting preferences; (2) Counseling (brief motivational messaging elements include collaborative goal setting, set quit date, personal barriers to quitting, problem-solving strategies, implementing smoke-free homes and cars, and social support, strategies shown to increase satisfaction with the pediatric visit. (3) Medication (NRT prescription and free 1 week supply (while supplies last)—including for those cutting down to quit as recommended in latest guidelines); (4) Quitline enrollment; and (5) Review of CEASE action sheets at each visit until the family is smoke-free.
1646539|NCT01882335|Behavioral|Peer support for exclusive breastfeeding|Pregnant women were identified and randomized to peer support for exclusive breastfeeding in clusters. They were followed up for 6 months post delivery.
1646540|NCT01882322|Drug|Prograf|oral
1646541|NCT01882322|Drug|Advagraf|oral
1646542|NCT01882296|Drug|AGSPT_10|AGSPT 10mg for 7days administration
1646543|NCT01882296|Drug|AGSPT_20|AGSPT 20mg for 7days administration
1646544|NCT01882296|Drug|AGSPT_40|AGSPT 20mg x 2tablet for 7days administration
1646545|NCT01882296|Drug|Pantoprazole_20|Pantoprazole 20mg for 7days administration
1646546|NCT01882296|Drug|Pantoprazole_40|Pantoprazole 40mg for 7days administration
1958023|NCT02043691|Device|Cook Custom Aortic Endograft|The Cook Custom Aortic Endograft has a variable design such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
1646548|NCT01882257|Device|BiPAP|BiPAP-auto (Phillips Respironics)is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is used to treat obstructive sleep apnea.
1646549|NCT01882257|Device|BiPAP/AVAPS (Phillips Respironics)|BiPAP/AVAPS (Phillips Respironics) is a noninvasive positive pressure ventilation device worn with a mask interface of the subject's choice. It is specifically designed to treat nocturnal hypoventilation due to an underlying neuromuscular disorder.
1646550|NCT01882244|Behavioral|Neural Pathfinder Training|Neural Pathfinder Training consists of game-based computerized training tools that target goal-directed attention regulation. Training will involve 6-8 weeks of 1-2 hour in-person or remote sessions with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of short attentional regulation practice and computer-assisted cognitive training game play.
1646551|NCT01882244|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 6-8 weeks of 1-2 hour in-person or remote sessions covering brain anatomy and health with a trainer involving an average of one session per week; about 15 minutes a week of telephone contacts with the trainer; and approximately 20 hours of homework (35 minutes/5 days a week), consisting of computer game play involving decision-making and motor skills.
1646552|NCT01882231|Other|DCE-MRI, DW-MRI, MT-MRI, and CEST-MRI|Imaging techniques using high-field MRI to make quantitative assessments in patients with osteosarcoma or Ewing sarcoma
1646553|NCT01882218|Drug|Galactose|After surgery, galactose will be dripped into the belly for up to 24 hours after surgery
1646554|NCT01882218|Drug|Standard Treatment|Standard liver surgery.
1646555|NCT01882205|Device|Virtual chromoendoscopy|
1646556|NCT01882205|Procedure|Chromoendoscopy|Panchromocolonoscopy with methyleen blue 0.1%
1646645|NCT01881581|Biological|M-GPE|M-GPE is used in Arm D,E,F,G and H
1646683|NCT01881295|Dietary Supplement|High dose potato|
1646558|NCT01882179|Drug|Mineralocorticoid receptor antagonist potassium-canrenoate|
1646559|NCT01882179|Drug|placebo|
1646560|NCT01882166|Drug|fostimon|
1646561|NCT01882166|Drug|puregon|
1646562|NCT01882153|Behavioral|Pivotal Response Training (PRT)|The behaviorally-based intervention is a treatment model that uses the principles of Applied Behavior Analysis (Koegel, Openden, Fredeen, & Koegel, 2006) to increase children's adaptive behaviors and decrease maladaptive behaviors.
1646563|NCT01882153|Behavioral|PACE Therapy|The developmentally based intervention is grounded in a development theory, that focuses on child-directed interactions with warm and caring individuals that aid in acquiring missed developmental and functional milestones.
1646564|NCT01882153|Behavioral|PACE and PRT Hybrid|The hybrid based treatment has an eclectic approach that incorporates both systematic (behaviorally-based) and affect-based learning (developmentally-based)that focuses on increasing children's skill development (http://www.pacificautism.org).
1646565|NCT01882140|Other|Electrical Stimulation by Capacitive Field|
1646566|NCT01882140|Other|Electrical Stimulation by Capacitive Field Placebo Sham|
1646567|NCT01882127|Drug|All-Trans Retinoid Acid(ATRA)|patients in ATRA&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
1646568|NCT01882127|Drug|Dexamethasone|Patients in High dose-DEX treatment group take dexamethasone( orally , 40mg daily for 4 days),patients in ATRA&High dose-DEX group take All-Trans Retinoic Acid(orally,10mg every 8 hours a day for 12 consecutive weeks) in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days).
1646569|NCT01882101|Procedure|Posterior tibial nerve stimulation|34G needle is introduced percutaneously three finger-breadths superior to the medial malleolus and an electrode is attached to the ipsilateral foot. Electrical stimulation is applied monitoring motor and sensory response. The treatment lasts for 30 minutes, and will be repeated twice a week for 6 weeks.
1646570|NCT01882101|Procedure|Biofeedback|Electrodes are attached to the lower abdomen and acryl plug is inserted into the anal canal. The patients perform pelvic muscle exercise watching EMG activity of themselves. The treatment lasts over 30 minutes, and will be repeated twice a week for 6 weeks.
1646571|NCT01882088|Drug|Mucofalk|Mucofalk 15 g/day i.e. 5 g TID per os, 15-20 min before meal
1646572|NCT01882075|Drug|Open loop|
1646573|NCT01882075|Device|Closed-loop|
1646574|NCT01882062|Drug|Triheptanoin 1g/kg/day|
1646575|NCT01882049|Device|REALIZE Gastric band (ETHICON)|Placement of gastric band around upper stomach
1646576|NCT01882036|Procedure|Gastric Bypass w/ matched hypocaloric diet|Roux en Y Gastric Bypass with Hypocaloric liquid diet for 10 days
1646577|NCT01882036|Other|Hypocaloric diet|Hypocaloric liquid diet for 10 days
1646578|NCT01882010|Procedure|blood draw|week -8
1646579|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week -8
1646580|NCT01882010|Procedure|blood draw|week -4
1646581|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week -4
1646582|NCT01882010|Procedure|blood draw|week 0
1646583|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week 0
1646584|NCT01882010|Procedure|MEG|week 0
1646585|NCT01882010|Drug|sargramostim|"lyophilized 250 micrograms/vial
6 micrograms/kg daily subcutaneous injection
56 days"
1646586|NCT01882010|Drug|placebo|saline solution daily subcutaneous injection 56 days
1646587|NCT01882010|Procedure|blood draw|week +2
1646588|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +2
1646589|NCT01882010|Procedure|blood draw|week +4
1646590|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +4
1646591|NCT01882010|Procedure|blood draw|week +6
1646592|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +6
1646593|NCT01882010|Procedure|blood draw|week +8
1646594|NCT01882010|Procedure|physical exam and UPDRS part III assessment|week +8
1646595|NCT01882010|Procedure|MEG|week +12
1646596|NCT01882010|Procedure|blood draw|week +12
1646597|NCT01882010|Behavioral|physical exam and UPDRS part III assessment|week +12
1646598|NCT01882010|Procedure|Motion Analysis|Week -4
1646599|NCT01882010|Procedure|Motion Analysis|Week +8
1646600|NCT01882010|Procedure|Motion Analysis|Week +12
1646601|NCT01881997|Drug|Fentanyl|Fentanyl Intramuscular (IM), 1ugm/kg, x1
1646602|NCT01881997|Drug|Normal Saline|IM normal saline
1646603|NCT01881984|Drug|Ravicti|Open-label design comparing Ravicti at doses of 2, 4, and 6 grams/m2/day
1992243|NCT03322813|Device|ExAblate 4000 - Type 2|Using ExAblate Model 4000 Type-2 to temporarily disrupt the blood brain barrier in non-enhancing glioblastomas undergoing resection
1646606|NCT01881958|Drug|DiaPep277®|
1646607|NCT01881945|Other|Non-invasive physiological signal recording on healthy volunteer|
1646608|NCT01881932|Device|Acupuncture using Seirin® needles|"Participants will receive acupuncture weekly until the end of chemotherapy.
Subjects will receive acupuncture at documented acupoints. To improve blinding effect, the acupuncturist will also tap 2 guiding tubes at 2 sham points , and immediately affix a pair of needles to the surface of the same points with adhesive tape, without needle insertion."
1646648|NCT01881555|Procedure|invasive coronary angiography|
1646649|NCT01881555|Procedure|Functional testing by fractional flow reserve measurement|Functional testing by fractional flow reserve measurement
1646684|NCT01881295|Dietary Supplement|High dose French fries|
1646609|NCT01881932|Device|Sham Acupuncture using Park Sham placebo acupuncture device|"Participants will receive sham acupuncture until the end of chemotherapy.
Acupuncturist will insert Park Sham Devices, non-penetrating sham acupuncture device consisting of a retractable needle and an adhesive tube into the sham points, and then immediately apply 2 pieces of adhesive tape next to the needles. In addition, she will tap a mock plastic needle guiding tube on the surface of each of the 8 true points in the arm and leg to produce some discernible sensation and then immediately apply a needle with a piece of adhesive tape to the dermal surface, without needle insertion."
1646610|NCT01881919|Dietary Supplement|Treatment|Address: Nature's Best, Century Place, Tunbridge Wells, Kent, TN2 3BE Phone:+44(0)1892 552030 Email:info@naturesbest.co.uk
1646611|NCT01881919|Dietary Supplement|Control|Address: Fagron GmbH&Co. KG, 22885 Barsbuttel, Germany Phone: +49(0)4067067680
1646612|NCT01881906|Other|Usual care|
1646613|NCT01881906|Other|Exercise|
1646614|NCT01881893|Behavioral|ACHD-CARE Program|The ACHD-CARE program will be provided in eight 90-minute weekly sessions. The intervention includes information about living with congenital heart disease, cognitive behavioral therapy (CBT) and coping techniques, and opportunities for peer interaction.
1646615|NCT01881880|Device|Bilateral mammography with Tomosynthesis|no intervention pre specified to be administered to participants
1646616|NCT01881867|Biological|Glycosylated Recombinant Human Interleukin-7|Given SC
1646617|NCT01881867|Other|Laboratory Biomarker Analysis|Correlative studies
1646618|NCT01881841|Behavioral|cMET|Those in cMET complete the 2-session self-administered computerized intervention which includes 8 exercises designed to encourage adolescents to evaluate the impact of alcohol and other substance use on their health and well-being and consider changing their use.
2012609|NCT01819597|Procedure|Encephaloduroarteriosynangiosis (EDAS)|The operation is a form of indirect revascularization or EC-IC bypass, performed under general endotracheal anesthesia, with intraoperative electroencephalographic monitoring. The surgery consists in the dissection and relocation of the superficial temporal artery (STA) and middle meningeal artery (MMA) branches, which are separated from their surrounding tissues under microscopic visualization and re-routed through a craniotomy to be placed intracranially in close proximity to the branches of the middle cerebral artery (MCA). The MCA branches are dissected in the arachnoid space and the STA and MMA are kept in position with microsutures to the arachnoid or MMA dural cuffs, maintaining close contact between the EC and MCA branches.
1646621|NCT01881815|Other|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
1646622|NCT01881789|Drug|Oprozomib|Subjects will receive Oprozomib extended release (ER) Tablets (hereafter referred to as oprozomib) administered orally, once daily on 1, 2, 8, 9, 15,16, 22 and 23 of 28-day cycles
1646623|NCT01881789|Drug|Lenalidomide|Subjects will receive lenalidomide 25 mg on Days 1-21 of 28 day cycles
1646624|NCT01881789|Drug|Dexamethasone|Subjects will receive dexamethasone 20 mg on Days 1, 2, 8, 9, 15, 16, 22, and 23 of 28 day cycles
1646625|NCT01881789|Drug|Cyclophosphamide|Subjects will receive cyclophophamide 300 mg/m2 on Days 1, 8 and 15 of 28 day cycles
1646626|NCT01881776|Procedure|ISB|"In SISB group; a 5 cm block needle (Stimuplex®A, B Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). 20 mL 0.5% ropivacaine was injected through the needle.
For CISB, a 5cm stimulating needle (Contiplex® Tuohy, B. Braun Medical, Bethlehem, PA) was inserted in-plane in order to place the needle tip between the upper and middle trunks of the brachial plexus (C5-C6). A nonstimulating catheter was inserted approximately 3 cm beyond the tip of the needle. 20 mL 0.5% ropivacaine was injected through the catheter."
1646627|NCT01881763|Drug|Ketamine|Ketamine 1-2 mgr/ kg IV
1646628|NCT01881763|Drug|Methohexital|Methohexital 0.5-1mg/kg IV
1646631|NCT01881737|Drug|Pregnenolone|"With Baseline serving as approximately day 1, twice daily intake of orally administered pregnenolone will occur on a schedule consisting of an up-titration followed by a down-titration as described below.
Week 1 and 2: 100 mg
Week 3 and 4: 200 mg
Week 5 and 6: 300 mg
Week 7 and 8: 400 mg
Week 9 -12: 500 mg
At the end of Week 12, pregnenolone was decreased by 50 mg twice a day every 3 days until it was discontinued.
If the participant is unable to tolerate a specific dose then he/she will be maintained at the highest tolerated dose until down titration occurs."
1646632|NCT01881724|Behavioral|Sleep education|
1646633|NCT01881711|Device|ShuntCheck-Micro-Pumper (SCMP)|"ShuntCheck uses thermal dilution to detect flow in CSF shunts. CSF is cooled transcutaneously with an ice pack and ShuntCheck's thermosensor detects a temperature drop due to CSF flow downstream of the ice. Micro-Pumper is a handheld device which vibrates the shunt valve to generate a temporary increase in CSF flow in patent but temporarily non-flowing shunts. This flow increase can be detected by ShuntCheck."
1646634|NCT01881711|Device|Imaging|Imaging of ventricle size
1646635|NCT01881698|Other|Platelet function during pregnancy Multiple Electrode Aggregometry (Multiplate@) device|Observation of platelet function in pregnancy
1646636|NCT01881659|Other|HPV screening|Women who signed informed consent will be screened with HPV testing.
1646637|NCT01881646|Radiation|Positron emission tomography (PET) using [11C]PBR28|
1646638|NCT01881633|Drug|ISU302|
1646639|NCT01881633|Drug|Placebo|
1646640|NCT01881620|Device|COMBI TEP : PET / enhanced CT scan|diagnostic imaging exam
1646641|NCT01881607|Behavioral|RESPIRNET Program|"The intervention at the classroom consisted of six sessions with the pupils of one hour each that were conducted by the teacher/tutor. We provided the teachers with a training session and a teachers' guide, and we gave each pupil a workbook with the activities. At the school level, the intervention consisted of four types of posters with specific messages directed to students, teachers, and parents, and the fourth poster type advertised the new smoking laws. we gave teachers and school managers the guide Towards a Smoke-Free School to facilitate the prevention and control of smoking (active and passive) in the school environment. Family level activities: Parents were required to complete the My risk thermometer activity at home with their children. Parents received a brochure with information on the risks of SHS exposure and recommendations to prevent SHS exposure, and a refrigerator magnet with the logo of the program."
1646642|NCT01881594|Procedure|Procedure/Surgery|daily stimulation of efferent loop prior to surgery (ileostomy closure)
1646643|NCT01881581|Biological|Saline Solution|Saline Solution is used as control in all arms.
1646650|NCT01881516|Device|acupuncture|once per week for 6 weeks，30 mins for each treatment and for seven main acupoints
1646651|NCT01881516|Device|sham acupuncture|the same acupoints and time as in acupuncture arm, but use a Park Sham Device
1646652|NCT01881503|Biological|HBOC-201|HBOC-201 is purified, cross-linked, acellular bovine hemoglobin (Hb) in a modified lactated Ringer's solution.
1646653|NCT01881490|Device|MRE|Developing the Pediatric Crohn's Disease Intestinal Damage Score (pMEDIC score) and the Pediatric MRE-Based Activity Index (PICMI)
2012610|NCT01817712|Behavioral|Individual Placement & Support|"IPS uses an integrated place-train approach to help people obtain and maintain community-based competitive employment in their chosen occupation."
1646655|NCT01881464|Device|Endopath from Itamar medical - FDA approved device.|endothelial function assessment by Endopath device
1646656|NCT01881464|Drug|Anti TNF Alfa.|This study will assessed the presence of endothelial dysfunction in patients with Crohn's disease before and after 12 weeks treatment of anti TNF α.
1646657|NCT01881451|Drug|18F-EF5 PET/CT scan|Patients will undergo an investigations 18F-EF5 PET/CT scan.
1646658|NCT01881451|Procedure|Optional biopsy|Patients who choose to participate, will undergo a tissue biopsy.
1646659|NCT01881425|Procedure|Glaucoma Surgery|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. A partial thickness scleral flap with its base at the corneoscleral junction after cauterization of the flap area, and a window opening is created under the flap with a Kelly-punch to remove a portion of the sclera, Schlemm's canal and the trabecular meshwork to enter the anterior chamber. An iridectomy is done in many cases to prevent future blockage of the sclerostomy. The scleral flap is then sutured loosely back in place with several sutures. The conjunctiva is closed in a watertight fashion at the end of the procedure."
1646660|NCT01881425|Device|InnFocus MicroShunt|"An initial pocket is created under the conjunctiva and Tenon's capsule and the wound bed is treated for two minutes with mitomycin C (MMC, 0.2 mg/ml)soaked sponges. This is done using a fornix-based conjunctival incision at the corneoscleral junction. After cauterization of the flap area, a knife is used to create a shallow pocket at the scleral surface and an opening into the AC. The device is then threaded through the track until the proximal end is in the anterior chamber and the fin of the device is pushed into the shallow scleral pocket. The device is checked to observe aqueous flow and the distal end placed under the Tenons/conjunctiva. The conjunctiva is closed in a watertight fashion at the end of the procedure."
1646661|NCT01881412|Drug|fluticasone|During discharge, the study MD/nurse informs the family that the child has been randomized to the inhaled corticosteroid (ICS) group, and will be prescribed fluticasone to help control the asthma. The families preferred pharmacy is determined and a prescription for a fluticasone multi-dose inhaler (MDI) provided. Dosing follows the NHLBI asthma guidelines for low dose ICS in this age group (88 mcg administered twice per day, dispense one inhaler, 3 refills). In addition to standard asthma discharge instructions, the family receives specific instructions for ICS administration, possible side effects of medication use, and distinction between controller and quick-relief rescue medications. Parents are instructed to discuss with their primary care provider the length of ICS use.
1646662|NCT01881412|Other|Standard Asthma Discharge Instructions|Study MD or nurse provides asthma discharge instructions using a standardized checklist. The topics covered include 1) description of asthma manifestations related to current visit, 2) signs of respiratory distress family should be looking for, 3) instructions to follow up with the child's primary care provider within one week, 4) provision and review of an asthma action plan, 5) provision of a spacer device to be used with inhalers (if family does not already possess), and 6) smoking cessation advice. (if indicated)
1646663|NCT01881399|Device|Fluorescence cholangiography (da Vinci surgical system)|Patients will received IV injection of ICG intra-operatively, allowing surgeons to view bile ducts under fluorescence imaging using the da Vinci surgical system with fluorescence Imaging system.
1646664|NCT01881399|Other|Virtual cholangiography|Images from virtual cholangiography will be superimposed in real time on images obtained with fluorescence.
1646665|NCT01881399|Procedure|Conventional IOC|Patients will undergo conventional intraoperative cholangiography (with use of radio-opaque dye), allowing surgeons to view bile ducts under Rx imaging.
1646666|NCT01881386|Device|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Spectroscopy
1646667|NCT01881373|Other|CHL program|Multiple component environmentally focused program designed with community engagement.
1646668|NCT01881360|Other|Gluten-free diet|A diet that is free of the gluten component
1646669|NCT01881360|Other|Hypocaloric diet|A standard hypocaloric diet with a daily 1500 caloric intake.
1646670|NCT01881347|Dietary Supplement|Resveratrol|Resveratrol 100 mg daily for 2 weeks followed by resveratrol 300 mg daily for 2 weeks.
1646671|NCT01881347|Dietary Supplement|Placebo|Placebo 100 mg daily for 2 weeks followed by placebo 300 mg daily for 2 weeks.
1646672|NCT01881334|Biological|CliniMACS CD34 Reagent System|The CliniMACS CD34 Reagent System is a medical device that is used in vitro to select and enrich CD34+ cells from heterogeneous hematologic cell populations for transplantation in cases where this is clinically indicated.
1646673|NCT01881321|Behavioral|Counseling Intervention|20-40 minute contraceptive counseling session based on the principles of motivational interviewing
1646674|NCT01881308|Drug|TNF inhibitors|
1646675|NCT01881308|Drug|Synthetic DMARD(s)|
1646676|NCT01881308|Drug|Co-medication: Synthetic DMARDs|Synthetic DMARDs given as co-medication for TNF inhibitors as appropriate.
1646677|NCT01881295|Dietary Supplement|Placebo control|
1646678|NCT01881295|Dietary Supplement|Low dose potassium gluconate|
1646679|NCT01881295|Dietary Supplement|Medium dose potassium gluconate|
1646680|NCT01881295|Dietary Supplement|High dose potassium gluconate|
1646681|NCT01881295|Dietary Supplement|Low dose potato|
1646682|NCT01881295|Dietary Supplement|Medium dose potato|
1717614|NCT00002190|Drug|Zidovudine|
2012611|NCT01817712|Behavioral|VA Transitional Work Program|"The long-standing approach to vocational rehabilitation in VHA and state programs is the train-place or stepwise model that is founded on the assumption that the patient or client benefits from some form of pre-vocational training, instruction, or practice in a protected, but artificial, work setting prior to entering or being placed in a competitive work role."
1646685|NCT01881295|Dietary Supplement|Basal diet control|
1646686|NCT01881282|Drug|Carraghenates Cream|Carraghenates cream will be administered 3-4 gram (g) each time (one sixth of a piece) through anal canal, twice a day (once in the morning and once in the evening); for consecutive 6 days.
1646687|NCT01881282|Drug|Mayinglong Musk Hemorrhoid Ointment|Mayinglong musk hemorrhoid ointment will be administered 2 g each time through anal canal, twice a day (once in the morning and once in the evening) for consecutive 6 days.
1646691|NCT01881217|Drug|BAY1179470|BAY1179470 will be administered as a 1-hour intravenous infusion.
1646692|NCT01881204|Dietary Supplement|Hesperidin and Calcilock|Hesperidin (552mg) and Calcilock® (amount per day: Calcium: 684 mg; Phosphorus: 282mg; Magnesium: 102mg; Zinc: 2.86mg; Vitamin C: 20 mg; Vitamin K1: 28µg; Vitamin D: 1.86µg) will be administered in the form of cookies (biscuit).
1646693|NCT01881204|Dietary Supplement|Hesperidin|Hesperidin (552mg) will be administered in the form of cookies (biscuit).
1646694|NCT01881204|Dietary Supplement|Control|Cookies without Hesperidin or Calcilock added.
1646695|NCT01881191|Other|MRI|
1646696|NCT01881178|Dietary Supplement|NOPALEA|
1646697|NCT01881165|Drug|Cranberry|
1646698|NCT01881165|Drug|Placebo|
1646699|NCT01881152|Other|Educational campaign|Multilevel educational campaign on stroke sympton recognition and the need for calling the Emergency Services
1646700|NCT01881152|Other|Usual care|Information on stroke usually delivered at the community level.
1646701|NCT01881139|Behavioral|exercise training|
1646702|NCT01881126|Drug|bimatoprost 0.01%|Bimatoprost 0.01% administered to both eyes once daily for 12 weeks.
1646703|NCT01881126|Drug|travatan 0.004%|Travatan 0.004% administered to both eyes once daily for 12 weeks.
1646704|NCT01881126|Drug|timolol 0.5%|Timolol 0.5% administered to both eyes once daily for 12 weeks.
1646705|NCT01881126|Drug|hypromellose 0.3%|Hypromellose 0.3% lubricant eye drops (for masking purposes) administered to both eyes once daily for 12 weeks.
2012612|NCT01816061|Behavioral|Experimental - COMPASS|Controlled randomized clinical trial. Fifty-five participants in the intervention group will receive eight goal self-management sessions over a period of approximately ten weeks.
2012613|NCT01816061|Behavioral|Control - COMPASS|Increased hours of patient-provider interactions Group.
1646708|NCT01881100|Other|resin infiltration|The test group (41 children) had caries lesions treated with the resin infiltration technique using Icon by the following procedure: rubber dam applying; etching with 15% hydrochloric acid for 120 s; surface rinsing and drying; dehydrating with ethanol for 30 s and air-drying; infiltrant resin infiltration with a syringe for 180 s; resin polymerization (polymerized by blue light - wavelength of 450 nm and intensity of 800mW/cm2; resin reapplication for 60 s and polymerization; rubber dam removal, and working on the infiltrated lesion with polishing rubbers. After the procedure fluoride varnish was applied.
1646709|NCT01881100|Other|fluoride varnish|All tooth surfaces including WSL treated with fluoride varnish (2,26% F, Duraphat ® Colgate Palmolive, Hamburg, Germany).
1646710|NCT01881087|Drug|Hyperbaric Levobupivacaine 0.75%|Each 4 ml of the administred solution contains: Chlorhydrate Levogyre Bupivacaine 30 mg, Glucose 290.8 mg and water for injection c.s.
1646711|NCT01881074|Drug|Triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the triclosan containing toothpaste provided to them. Additional tubes of triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
1646712|NCT01881074|Drug|Non-triclosan containing toothpaste|Type II diabetic patients will be instructed to brush their teeth at the same time day and with the same frequency as usual for them using only the non-triclosan containing toothpaste (i.e. placebo) provided to them. Additional tubes of non-triclosan containing toothpaste will be provided to the participants for the duration of the study as needed. Following their baseline appointment, patients will be asked to return at 6 weeks, 3, 6, 9 and 12 months for an oral exam and dental cleaning. Samples will be collected at baseline, 3, 6 and 12 months. Samples collected may include venous blood, gingival crevicular fluid, plaque and saliva. Female study participants may be asked to perform a pregnancy test.
1646713|NCT01881048|Dietary Supplement|Omega-3 fatty acid|Given PO
1646714|NCT01881048|Drug|Celecoxib|Given PO
1646715|NCT01881035|Procedure|Renal nerve denervation|Renal nerve denervation is performed by catheter ablation of renal arteries influencing the sympathetic nerves.
1646716|NCT01881022|Behavioral|Psychosexual Intervention|Couples will complete six weekly psychosexual counselling sessions. Each session will focus on areas relevant to sex therapy and sexual dysfunction in couples facing breast cancer (e.g. education, communication, body imagery, sensate focusing, and problem solving). Sessions will be one hour in length (Note: Session 1 will be 1.5 hours), during which couples will meet with a facilitator via videoconferencing.
2012614|NCT01816009|Other|duration of antibiotic treatment|Used antibiotics already have the AMM in this indication
1646718|NCT01880996|Other|Tai-chi/Qi-gong|Tai-chi/Qi-gong employs a series of positions and movements that are performed in a slow, flowing manner to help a person concentrate on breathing and motion. The treatments will take place once a week at the Dept. of the Gyneco-oncology and the patients will be instructed to practice tai-chi at home on a daily basis
1646719|NCT01880970|Other|starter infant formula with pro and prebiotics|
1646720|NCT01880970|Other|Placebo comparator|
1646721|NCT01880957|Drug|Lithium|
1646722|NCT01880957|Drug|Lamotrigine|
1646723|NCT01880944|Other|NC-MRI, CE-MRI|non-contrast spine MRI(NC-MRI) contrast-enhanced spine MRI(CE-MRI)
1646724|NCT01880931|Drug|Remifentanil|The effect site concentration of remifentanil
1646725|NCT01880905|Procedure|Measure of uteroovarian ligament length during gynecological surgery|
1646910|NCT01879371|Drug|Ibuprofen (Brufen®)|oral dose
1646911|NCT01879358|Device|Drug-eluting stent|
2012615|NCT01814813|Biological|HSPPC-96|intradermal infusion
2012616|NCT01814813|Drug|bevacizumab|intravenous
1646726|NCT01880892|Procedure|Cricopharyngeal myotomy|Endoscopic laser cricopharyngeal myotomy is one of the standard treatments for Zenker's Diverticulum. It takes about 30 minutes and at our institution requires a one night of observation in the hospital.
1646727|NCT01880892|Device|Restech's Dx-pH Probe|This is not an intervention, but a newer device that measure the pH of the nasopharynx and detects laryngopharyngeal reflux. We will perform 24 hour tests with this device to see if there is an increase in laryngopharyngeal reflux follow cricopharyngeal myotomy.
1646728|NCT01880879|Device|helios stent|the group with helios stent implanted
1646729|NCT01880866|Drug|(-)-Epicatechin|A single dose of purified (-)-epicatechin will be administered orally to subjects after a regularly scheduled right heart catheterization. The subjects will be monitored for 5 hours and released.
1646730|NCT01880853|Other|mammography|participants were screened by mammography alone every year
1646731|NCT01880853|Other|ultrasound|participants were screened by ultrasound alone every year
1646732|NCT01880853|Other|mammography and ultrasound|Participants were screened by both mammography and ultrasound every year
1646733|NCT01880840|Drug|205.5 mcg of azelastine hydrochloride|nasal spray
1646734|NCT01880840|Drug|137 mcg of azelastine hydrochloride|nasal spray
1646735|NCT01880827|Procedure|Roux-en-Y|"Subjects in the intervention group will be divided into two consecutive surgical groups, and operated at the Department of Surgery at Turku University Hospital (Kiinamyllynkatu 4-8, Turku). During surgery, Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG) is performed using standard laparoscopic techniques. In RYGB procedure large part of the ventricle, duodenum, and proximal jejunum (ad 1.5 meters from pylorus) is bypassed. New stomach pouch is anastomosed into the new proximal jejunum, and remaining larger portion of the stomach, duodenum, and jejunum are reattached to the distal part of the jejunum for the secretion of pancreatic, gastrointestinal, and biliary juice. In SG a notable amount of ventricle is removed to create a stomach pouch which effectively restricts the amount of food feasible to ingest. After the surgery, subjects are controlled in hospital ward for approximately three days."
1646736|NCT01880827|Drug|GIP-infusion|Blood flow and volume during infusion
1646737|NCT01880827|Drug|GLP-1|Blood flow and volume during infusion
1646738|NCT01880827|Drug|MMS|Blood flow and volume after meal solution
1646739|NCT01880827|Procedure|Sleeve gastrectomy|
2012617|NCT01815047|Dietary Supplement|Vitamin D3 Supplementation|
2012618|NCT01807182|Biological|Aldesleukin|Given IV
1646742|NCT01880775|Drug|Prilocaine|experimental
1646743|NCT01880775|Drug|Bupivacaine|marcaine heavy 0.5% 7.5 mg intrathecal
1646744|NCT01880749|Drug|RAD001|
1646745|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD with the option to vary time of administration within a window of plus/minus 8 hours. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
1646746|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered under the skin OD at the same time each day. A maximum of 3 pre-trial OADs are allowed during the trial at an unchanged, stable dose level and dosing frequency.
1646747|NCT01880736|Drug|insulin degludec|Individual dose adjusted once weekly. IDeg (100 U/mL, 3 mL FlexTouch® pen PDS290) to be administered subcutaneously (under the skin) OD at the same time each day. A maximum of 3 pre-trial oral anti-diabetic drugs (OADs) are allowed during the trial at an unchanged, stable dose level and dosing frequency.
1646748|NCT01880723|Drug|Albuterol|2.5 mg diluted in 3mL normal saline nebulized using a Power Neb2 nebulizer
1646749|NCT01880723|Drug|Placebo saline|nebulized 3mL normal saline) using a Power Neb2 nebulizer
1646750|NCT01880710|Procedure|Subtotal hysterectomy|Subtotal abdominal hysterectomy where the body of the uterus is removed but the cervix is spared.
1646751|NCT01880710|Procedure|Total Hysterectomy|total abdominal hysterectomy where the body as well as the cervix of the uterus are removed.
1646752|NCT01880697|Biological|TIVc|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, cell-based)
1646753|NCT01880671|Device|Inactive Migraine Medical Device|
1646754|NCT01880671|Device|Migraine Medical Device|
1646755|NCT01880658|Drug|Capecitabine|Capecitabine 1000mg/m2,po(orally) on day 1-14 of 21 day cycle. Number of cycles: 16 cycles (1 year)
1646756|NCT01880645|Procedure|Fine Needle Aspiration (FNA)|If patient received chemotherapy before surgery, fine needle aspiration (FNA) performed of any abnormal lymph nodes either right before or during standard breast and underarm surgery. To perform FNA, area is numbed with anesthetic and a needle is inserted into the affected area so that cells can be collected.
1646757|NCT01880645|Procedure|Ultrasound|Patient receives an ultrasound of lymph nodes at diagnosis and on the day of surgery. Marker clip(s) placed using a needle in the abnormal lymph node(s).
1646758|NCT01880645|Procedure|Breast Surgery + Lymph Node Removal|Patient receives standard breast and underarm surgery (underarm lymph node removal and either a partial mastectomy or total mastectomy with or without reconstruction).
1646841|NCT01879943|Device|PillCam Colon 2|PillCam® COLON 2 capsule endoscopy is a minimally invasive tool for direct visualization of the colon, including identifying the occurrence of polyps.
1646842|NCT01879943|Procedure|Colonoscopy|Standard colonoscopy is the standard against which capsule endoscopy is compared.
2012619|NCT01807182|Drug|Cyclophosphamide|Given IV
2012620|NCT01807182|Drug|Fludarabine Phosphate|Given IV
2012621|NCT01807182|Other|Laboratory Biomarker Analysis|Correlative studies
2012622|NCT01807182|Biological|Therapeutic Tumor Infiltrating Lymphocytes|Undergo TIL infusion
2012623|NCT01807728|Other|Group 1 Training Program|Up to four group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
2012624|NCT01807728|Other|Group 2 Training Program|Two group classes which will involve peer interaction, hands on training activities, and interaction with group leader(s).
1646759|NCT01880632|Drug|XELOX|"Patients will be given the perioperative chemotherapy as below once recruited:
Capecitabine ：500 mg tablets（Roche） Oxaliplatin：50mg/10ml（according to daily practice in each center）
Schedule of Oxaliplatin plus capecitabine (XELOX) will be as follow:
Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3 weeks(treatment for 2 weeks and rest 1 week) Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks"
1646760|NCT01880619|Drug|Tamsulosin|Patients in this arm will receive Tamsulosin 0.4 mg daily
1646761|NCT01880619|Drug|Solifenacin|Patients in the arm will receive Solifenacin
1646762|NCT01880619|Drug|Control|Patients in this are will receive placebo
1646763|NCT01880606|Procedure|colonoscopy with endomicroscopy|Examination will be performed in two steps. On the way from rectum to caecum, mucosa will be evaluated with white light endoscopy and random biopsies will be taken according to the routine standard with minimum of 2 biopsies from each 10 cm of colon. On the way back (from caecum to rectum) mucosa will be stained with indigo carmine and after intravenous fluorescein injection all macroscopically abnormal lesions will be examined by endomicroscopy and biopsied. Additionally, all places where random biopsies were taken will be also examined with endomicrosopy.
1646764|NCT01880593|Drug|Ketamine and Lithium|Subjects in this arm take 600-1200mg of Lithium pills at night for duration of the study.
1646765|NCT01880593|Drug|Ketamine and Placebo|Subjects in this arm take placebo pills at night for duration of the study.
1646766|NCT01880567|Drug|Ibrutinib|560 mg by mouth daily for each 28 day cycle.
1646767|NCT01880567|Drug|Rituximab|375 mg/m2 by vein given cycle 1 day 1, 8, 15 and 22 +/- 1 day (Cycle 1), followed by rituximab on day one of every cycle starting in cycles 3 - 8. Following cycle 8 rituximab given on day 1 of every other cycle for up to 2 years.
1646768|NCT01880554|Device|Contrast-enhanced intraoperative ultrasound|"Once the patient is included in the study, a staging procedure is performed in three stages before hepatic metastases treatment:
Step # 1 preoperative (maximum 8 weeks before surgery Steps # 2 and # 3 intraoperative performed by the same surgeon in 2 stages"
1646769|NCT01880541|Other|hypnosedation|hypnosedation
1646770|NCT01880541|Other|general anesthésia|general anesthesia
1646771|NCT01880528|Drug|lisinopril|Given PO
1646772|NCT01880528|Drug|placebo|Given PO
1646773|NCT01880515|Drug|Tetracycline|The experimental group will receive tetracycline 250mg every 12 hours for 1 month the same day at initiation of BIBW2992 whereas the non-intervention group will recieve general dermatological recomendations while on treatment with BIBW2992.
1646774|NCT01880502|Drug|Belviq 10mg|Belviq 10mg single dose administration
1646775|NCT01880502|Drug|Belviq 20mg|Belviq 20mg single dose administration
1646776|NCT01880502|Drug|Placebo|Placebo single dose administration
1646777|NCT01880489|Behavioral|MI + CBST Intervention|The intervention focuses on exploring health goals, creating an action plan, learning about the impact stress, stigma, and substance use can have on health, improving personal growth and social support, and connecting with resources. The first two sessions will be primarily Motivational Interviewing and will explore participants' feelings about their sexual risk, substance use, non-medically monitored hormone and silicone use, and any other issues. Group sessions (Sessions 3-6) will incorporate Cognitive Behavioral Skills Training focusing barriers to physical and mental health. The last session will focus on reviewing progress toward health goals, identifying barriers to change, and generating a plan for connection to ongoing care to reach target health goals.
1646778|NCT01880476|Other|Home visits and group program|Participants will receive up to three home visits by a Registered Nurse and two home visits by a Registered Dietitian over the 6-month intervention period. Participants will also be invited to attend a monthly Diabetes Wellness Day group program which will include diabetes education, interaction with peer volunteers, group exercise, and a meal. The Registered Nurse will coordinate care to help participants access necessary community supports and services and lead monthly interprofessional case conferences to develop a client-centred plan of care for each study participant.
1646779|NCT01880463|Drug|Omega-3 fatty acids (fish oil)|
1646780|NCT01880463|Dietary Supplement|Vitamin D3|
1646781|NCT01880463|Dietary Supplement|Vitamin D3 placebo|
1646782|NCT01880463|Drug|Fish oil placebo|
1646783|NCT01880450|Behavioral|Project Prepared|Behavioral intervention to reduce sexual risk and promote healthy relationships
1646784|NCT01880450|Behavioral|TEEN|Control condition the promote communication, decision-making skills etc.
1646785|NCT01880437|Drug|cytarabine|Cohort 2: 20 mg sc daily for 10 days starting Day 1, with a possible further cycle of 20 mg sc daily for 5 days starting no earlier than Day 29
1646786|NCT01880437|Drug|vismodegib|Cohorts 1 and 2: 150 mg orally daily
1646787|NCT01880424|Drug|Placebo|matching Placebo Capsules, Oral, once daily
1646788|NCT01880424|Drug|Linaclotide|Linaclotide 290 ug Capsules, Oral, once daily
1646789|NCT01880411|Biological|PEK Fusion Protein Vaccine|PEK (PE-E7-K3), a recombinant protein combined with GPI-0100 adjuvant
1646790|NCT01880398|Other|Kshar Sutra|The Kshar Sutra was a standard medicated thread smeared with Kshar of Apamarga (Achyranthus aspera), Shnuhi (Eforbia Nerrifolia) which has quality of cutting and Haridra(Curcuma Longa) which is used as a antiseptic. The ph value of the thread thus prepared was determined and its sterilization effected by ultraviolet radiation. The alkalinity of Kshar Sutra was 9.2ph.
1646791|NCT01880385|Biological|Bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 4 cycles
1646792|NCT01880385|Drug|Cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
1646793|NCT01880385|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
1646794|NCT01880385|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
1646795|NCT01880385|Drug|Docetaxel|Adjuvant: 100 mg/m2 q3w, 4 cycles
1646796|NCT01880385|Biological|Trastuzumab|Adjuvant: 8 mg/kg d1 in the 1st cycle then 6 mg/kg for d1 q3w, 17 cycles if tumor overexpress HER2
1646797|NCT01880372|Dietary Supplement|Alpha Lipoic Acid|Same as Arm description
1646798|NCT01880359|Drug|Cisplatin|
1646799|NCT01880359|Radiation|Radiotherapy|
1646800|NCT01880359|Drug|Placebo|
1646801|NCT01880359|Drug|Nimorazole|
1646905|NCT01879410|Drug|Placebo NDPI|Placebo is administered via NDPI as one inhalation once daily in the morning. The inhaler contains 2 strips with 30 blisters of placebo per strip in the form of dry white powder.
1646802|NCT01880346|Dietary Supplement|Vitamin D Powder|Patients will be randomly assigned to a powder supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
1646803|NCT01880346|Dietary Supplement|Vitamin D Oil|Patients will be randomly assigned to an oil based supplement of 100,000 IU vitamin D3. Randomization will be in blocks of 4 (meaning for every 4 subjects there will be 2 vitamin D and 2 placebo treated patients). Blood will be drawn by IV catheter at baseline, 2, 4, 8, 12, 24, 48, and 72 hours after vitamin D3 dosing
1646804|NCT01880333|Other|Modified Atkin Diet|Eligible children will be started on Modified Atkins diet with help of trained dietician. Carbohydrates intake will be restricted to 5 grams/ day in children<18 mo and 10grams/day in children 18mo- 3 years.Carbohydrate values of various food items will be explained in detail. Fats (e.g. cream, butter, oils, and ghee) will be encouraged. Proteins (cheese, fish, eggs, chicken, and soya products) will be unrestricted. Calcium and multivitamin supplementation will be done. Syrups will be restricted. Clear carbohydrates free fluids- will not be restricted. Medications will be changed to carbohydrate free preparations, wherever available. Diary of events will be recorded including seizure frequency and any adverse or positive effect. Urine ketones chart will be maintained.
1646805|NCT01880320|Drug|CD0271 0.3% / CD1579 2.5%|
1646806|NCT01880320|Drug|CD0271 0.1% / CD1579 2.5%|
1646807|NCT01880320|Drug|Topical Gel Vehicle|
1646808|NCT01880307|Drug|Azathioprine|
1646809|NCT01880307|Drug|Infliximab|
1646810|NCT01880307|Drug|Prednisolon|
1646811|NCT01880294|Drug|No intervention|Asian participants diagnosed with chronic constipation using ANMA diagnostic questionnaire will be observed.
1646812|NCT01880281|Other|Meat and vegetable diet|After having a diet of 3 days and the investigational's day, the volunteers will have the other diet
1646813|NCT01880268|Device|BCI-controlled neurorehabilitation device|"Brain computer interface (BCI) -controlled neurorehabilitation device uses a participant's EEG to control with movements of an ordinary rehabilitation device (an upper limb ergometry, arm bike)"
1646814|NCT01880268|Behavioral|Standard rehabilitation therapy|Standard rehabilitation therapy for patient with stroke includes 1 hour of physical therapy and 1 hour of occupational therapy
1646815|NCT01880255|Device|Repetitive Transcranial Magnetic Stimulation|rTMS is a non-invasive procedure involving the use of magnetic fields to stimulate nerve cells.
1646816|NCT01880216|Drug|Bemiparin sodium|subcutaneous application daily for 7±2 days
1646817|NCT01880216|Drug|Enoxaparin sodium|subcutaneous for 7±2 days
1646818|NCT01880203|Procedure|aspiration in thyroid node for Molecular Cytogenetic Analysis.|
1646819|NCT01880190|Other|Ringer's Lactate|
1646820|NCT01880190|Other|HES 130/0.4 and Ringer's Lactate|
1646821|NCT01880151|Device|EEG|EEG recorded during a resting condition and during an episodic memory task condition
1646822|NCT01880138|Other|watching animated cartoon before general anesthesia|
1646823|NCT01880138|Other|not watching animated cartoon beofre general anaesthesia|
1646824|NCT01880125|Drug|Tramadol HCI/Acetaminophen|Test drug: Tramadol HCI/Acetaminophen 75/650mg, two times daily. Reference drug: Tramadol HCI/Acetaminophen 37.5/325 mg, four times daily.
1646825|NCT01880112|Drug|Cefazolin|Cefazolin will be administered as pre-operative prophylaxis in normal weight patients undergoing Cesarean delivery. Tissue and serum levels will be measured at the time of the incision and when the incision is closed.
1646826|NCT01880099|Drug|placebo|placebo compared to 8mg of galatamine
1646827|NCT01880099|Drug|Galantamine 8mg|8mg of galatamine compared to placebo
1646828|NCT01880099|Drug|Galantamine 16mg|16mg of galatamine compared to placebo
1646829|NCT01880086|Drug|Clomiphene citrate|
1646830|NCT01880086|Drug|Placebo|Placebo pill that will have appearance identical to the treatment pill but will not contain active medication.
1646831|NCT01880073|Device|FemVue device|The device will be used in conjunction with what is now considered the standard of care to determine if it's as effective.
1646832|NCT01880060|Behavioral|INCENT weight loss program|Tangible incentives seem to be effective in enhancing short term, but not long-term weight loss. The monetary rewards are based on participant quarterly weigh-ins and the monetary amount of incentive will be identical to the percentage of body weight lost. Participants who lose 1, 2, 3, 4, or 5% of their body weight will then be compensated with 1, 2, 3, 4, or 5 dollars per month. Dollar amounts for participants that lose more than 5% of initial body weight then increase by increments of 5 (e.g., 5-9% weight loss = $5; 10-14%=$10; 15-19%=$15; >20%=$20). These incentives will be based on quarterly weight and all percentage weight loss is calculated based on a participant's initial weight. commencement). Participants receive monthly checks that reflect the percent weight loss.
1646833|NCT01880060|Behavioral|Livin My Weigh|Livin My Weigh is an internet-delivered weight loss program without daily support or financial incentives. Participants receive quarterly newsletters with tips on weight loss, increasing physical activity, and menu suggestions, and optional quarterly educational sessions. Weight is measured in the same manner as the INCENT participants.
1646834|NCT01880047|Drug|Eltrombopag|Eltrombopag will be administered for 8 weeks or until the platelet count exceeds 150,000; at this point dosing will stop, subject will be considered a responder and the subject will eligible for entering Part 2 (the long term treatment part of the study. The dose at which the subject achieved the primary endpoint (> 50,000 and increase by > 20,000) will be considered the dose of response. Dose escalation will continue, despite satisfaction of the primary endpoint of study (> 50,000 and > 20,000 above baseline), unless the platelet count reaches the lower limit of normal range 150,000. Subjects will stop study medication if the platelet count is within the normal range, thereby minimizing any safety risk associated with elevated platelet count.
1646835|NCT01880047|Drug|Placebo|
1646836|NCT01880034|Other|Lipid Emulsion Survey|
1646837|NCT01879969|Procedure|classic procedure of planning|analysis of pictures, 2D radiographs and aesthetics; model surgery and acrylic splint
1646838|NCT01879969|Procedure|computer assisted orthognathic planning and surgery of asymmetric patients|
1646839|NCT01879956|Other|Craft Activities|There is no intervention method used to perform the task.
1646840|NCT01879956|Behavioral|OGI Method|metacognitive approach to assess executive functions.
1717615|NCT00002191|Drug|Albendazole|
1646843|NCT01879930|Drug|doxycycline|"Zadorin-100® (doxycycline), licence number Swissmedic: 43051 Legal holder: Mepha Pharma AG, Aesch/BL
Oral intake during study period (4 weeks) once in the morning and once in the evening
The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit Zadorin® 100"
1646844|NCT01879930|Drug|placebo|"Placebo Galepharm Composition: lactose monohydrate, ceolus PH 102, croscarmellose sodium, magnesiumstearat, manufacturer: Pharmacy Hotz, 8700 Küsnacht, Switzerland
Oral intake during study period (4 weeks) once in the morning and once in the evening
The masking of the agents is conducted using bordeaux-coloured, opaque hard-gelatine capsules (size 00) of the French company LGA. The hard-gelatine capsules are each filled with 1 unit placebo 100mg in the sham-group"
1646845|NCT01879917|Drug|Liraglutide|
1646846|NCT01879904|Procedure|Endoscopic submucosal dissection (ESD)|This study is suggest to patients with superficial medium or distal rectal tumors. The lesion was identified and demarcated using white-light endoscopy, magnifying endoscopy, and chromoendoscopy. Then, marking around the lesions was performed. Local injection was made using injection needle, and then mucosal incision was performed around the lesion using endo-knives. Submucosal dissection was performed using endo-knives. Hemostasis and vessel coagulation were practiced using primary hemostatic forceps during the procedure.
1646847|NCT01879891|Other|Aerobic|Exercise training will consist of bicycle ergometer riding starting at 67% of heart rate max for 20 minutes. Exercise Intensity will be progressively increased every week until 80% of heart rate max for 40 minute sessions is reached.
1646848|NCT01879878|Dietary Supplement|Verum, broccoli sprout grain|Patients will be randomly classified into two groups - verum and placebo. The patients in the experimental arm will receive capsules with broccoli sprout grain containing a total of 90mg sulforaphane active substance per day over one year as nutrition supplement whereas patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution.
1646849|NCT01879878|Dietary Supplement|placebo|Patients assigned to the placebo group will receive inactive substance (methylcellulose) with identical capsule and portion distribution as the experimental arm.
1646850|NCT01879865|Other|Non-stimulation|The volunteers will be wearing noise-cancelling headphones (silent) and will be stimulated as little as possible. The volunteer will be instructed to keep his/her eyes closed.
1646851|NCT01879865|Other|Stimulation|The volunteers will be wearing noise-cancelling headphones, through which they will hear a continuous loop of recorded operating room noise (monitor beeps, talking), to simulate operating room conditions. The volunteer will be instructed to keep his/her eyes closed.
1646852|NCT01879852|Behavioral|Quadriceps intensive strengthening|Quadriceps intensive strengthening includes high-intensity neuromuscular electrical stimulation to the quadriceps muscle for 10 minutes and overload to the the eccentric phase of quadriceps strengthening exercises.
1646853|NCT01879852|Behavioral|Standard rehabilitation|Standard rehabilitation will include interventions for typical knee impairments (effusion, knee motion deficits, lower extremity muscle weakness, and gait deviations) as well as advanced rehabilitation interventions as indicated (jump and agility exercises)
1646854|NCT01879839|Dietary Supplement|Diet|Patients receive special diet 4 days prior to contrast-agent administration.
2012625|NCT01806597|Biological|secukinumab 150 mg|Study treatment will be provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consists of one secukinumab 150 mg s.c. injection plus one placebo secukinumab s.c. injection and will take place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients will also receive two placebo injections at Weeks 17, 18 and 19. Patients will self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
1646857|NCT01879813|Dietary Supplement|Phospholipid drink|Participant in an intervention parallel group will consume a drink with added phospholipids
1646858|NCT01879813|Dietary Supplement|Placebo milk drink|Participant in an intervention parallel group will consume a drink without added phospholipids
1646859|NCT01879800|Behavioral|Acceptance and Commitment Therapy plus Illness Management|
1646860|NCT01879787|Other|tDCS|tDCS involves application of very low-amplitude direct currents(2 mA or less) via surface scalp electrodes.This produces a sub-sensory level of electrical stimulation which remains imperceptible by most people during its application. In a small percentage of patients it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease corticomotor excitability. Cathodal tDCS decrease and anodal tDCS increase the motor cortex excitability.
1646861|NCT01879774|Other|Neuropsychological and motoric tests|"Evaluation before and after therapy of hyponatremia
Neuropsychological tests
Mini Mental Status Test
Dem-Tect
Rey-Osterrieth Complex Figure Test
Trailmaking Test
Beck Depression Inventory
d2-R (optional)
Motoric tests
modified UPDRS (Unified Parkinson Disease Rating Scale) Part III
Timed-up-and-go Test
Halstead Fingertapping Test
AIMS (Abnormal involuntary movement scale)
EEG"
1646862|NCT01879748|Drug|Rasagiline|"Each subject will be enrolled into 1 of 4 cohorts:
cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
Each subject will then be randomly assigned to 1 of the following groups:
rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)
rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)
rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)
placebo (8 Japanese and 8 Caucasian subjects)"
1646906|NCT01879397|Device|Research Ultrasound Exam|"Collection of backscattered ultrasound data during non-invasive ultrasound exam
ARFI based images of the carotid artery and plaque
Ultrasound signals received by the ultrasound imaging system are recorded. These signals are discarded during the image formation process for a standard duplex ultrasound exam."
1646907|NCT01879384|Device|CMA 70 catheter directly positioned in bone tissue|At the end of the surgery the CMA microdialysis catheter is placed inside the bone
1646908|NCT01879371|Drug|Ibuprofen+caffeine FDC|oral dose
1646863|NCT01879748|Drug|Placebo|"Each subject will be enrolled into 1 of 4 cohorts:
cohort 1 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 2 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 3 (16 Japanese subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
cohort 4 (16 Caucasian subjects): 4 subjects each for 0.5, 1, and 2 mg of rasagiline and placebo
Each subject will then be randomly assigned to 1 of the following groups:
rasagiline at 0.5 mg (8 Japanese and 8 Caucasian subjects)
rasagiline at 1 mg (8 Japanese and 8 Caucasian subjects)
rasagiline at 2 mg (8 Japanese and 8 Caucasian subjects)
placebo (8 Japanese and 8 Caucasian subjects)"
1646864|NCT01879735|Drug|11C-CSar|PET/CT recording with bile acid tracer 11C-cholylsarcosine used to evaluate the transport of bile acids.
1646865|NCT01879735|Drug|ICG|Infusion of indocyanine green prior and during the PET/CT scanning with the bile tracer 11C-CSar.
1646866|NCT01879722|Drug|TAK-063|TAK-063 tablets
1646867|NCT01879722|Drug|TAK-063 Placebo|TAK-063 placebo-matching tablets
1646868|NCT01879709|Behavioral|Yoga Training|Participants will be imparted yoga training for twenty-one days, for one hour a day. This will include postures or Asanas (exercises) and Pranayam (Breathing protocols). The training starts with 'Om' chanting followed by warm up exercises and then breathing exercises. The Breathing exercises (Pranayama) are practiced before practice of Asana.
1646869|NCT01879709|Behavioral|Physical Exercise|This group will take part in a general physical exercise program incorporating simple physical exercises for one hour daily, including Saturdays. The schedule will include fifteen minutes of brisk walking followed by light exercises adapted from the National Fitness Corps - Handbook for Middle High and Higher Secondary Schools as used by Duraiswamy et al. (2007).
1646870|NCT01879709|Other|Treatment as Usual|"Placebo Comparator: Treatment as Usual Group
Participants who will continue in the department with clinical treatment as usual. No supplementation will be provided"
1646871|NCT01879696|Device|ECSPRESS catheter with active vacuum|
1646872|NCT01879683|Drug|LiRIS® 400 mg|LiRIS® 400 mg is a drug-device combination product which is placed in the bladder during cystoscopy, remains in the bladder for up to 14 days gradually releasing lidocaine, and removed from the bladder via cystoscopy.
1646873|NCT01879670|Device|CircuLite Synergy left ventricular assist device|
1646874|NCT01879657|Drug|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
1646875|NCT01879644|Behavioral|NF|
1646876|NCT01879644|Behavioral|SM|
1646877|NCT01879644|Behavioral|PE|
1646878|NCT01879644|Behavioral|SU|
1646879|NCT01879631|Procedure|radial keratotomy|
1646880|NCT01879618|Drug|Fragmin|variable dosing regimen
1646881|NCT01879605|Drug|Docusate natrium and sorbitol|
1646882|NCT01879605|Drug|Bisacodyl|
1646883|NCT01879579|Other|Mobile Insulin Titration Intervention|Patients send their fasting blood glucose levels to the clinic diabetes nurses via text message each weekday. The diabetes nurses call each patient once a week to give insulin titration instructions to replace in-person clinic visits for insulin titration.
1646885|NCT01879553|Biological|TIV|Trivalent Influenza Virus Vaccine (surface antigen, inactivated, egg-derived)
1646886|NCT01879540|Biological|aTIV|Adjuvanted Trivalent Influenza Virus Vaccine (surface antigen, inactivated, adjuvanted with MF59C.1, egg-derived)
1646887|NCT01879527|Drug|Amiloride hydrochlorothiazide|Blinding will be done by over-encapsulating amiloride HCT tablets and providing corresponding placebo capsules.Patients will be provided with capsules (size 00) containing one tablet of study medication (Amilostad HCT 5/50mg tablet or placebo) and instructed to take these capsules once daily in the morning together with breakfast. Visit 2 will be scheduled one week after baseline and at visit 2 patients will be provided with capsules containing two tablets of study medication. This maintenance dose will not be changed throughout the remaining study period. Placebo will be administered in the exact same manner.
1646888|NCT01879527|Drug|Sugar pill|containing placebo
1646889|NCT01879514|Drug|Chinese Herb Prescription Granule plus prednisone|Chinese Herb Prescription Granule includes ZiBuGanShen Granule and BuShenTongLuo Granule
1646890|NCT01879514|Drug|Placebo|Placebo includes placebo of ZiBuGanShen Granule and placebo of BuShenTongLuo Granule
1646891|NCT01879501|Behavioral|Low Vision Self-Management Program|The program has been describe above.
1646892|NCT01879488|Drug|technetium-99m - Diethylenetriaminepentaacetic acid|
1646893|NCT01879488|Device|Vibrating-mesh nebulizer|
1646894|NCT01879488|Other|Gamma scintigraphy|
1646895|NCT01879488|Other|Preoperative spirometry|
1646896|NCT01879475|Device|032-11|Topical haemostat
1646897|NCT01879475|Device|Floseal (R)|Topical haemostat
1646898|NCT01879462|Drug|GSK2878175|Round tablets (5.0mg) given once daily single and repeated (to 7 days), Oral dose.
1646899|NCT01879462|Drug|Placebo|Visually matching GSK2878175
1646900|NCT01879423|Drug|Lamotrigine Dispersible/Chewable tablets 5mg*5|Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day1 and Single dose of Lamotrigine Compressed 25mg*1 tablet at Day15
1646901|NCT01879423|Drug|Lamotrigine Compressed tablet 25mg|Single dose of lamotrigine compressed 25mg*1 tablet at Day1 and Single dose of lamotrigine dispersible/chewable 5mg*5 tablets at Day15
1646902|NCT01879410|Drug|UMEC/VI Inhalation Powder 62.5/25 mcg via NDPI|The drug is administered via NDPI as one inhalation once daily in the morning. NDPI has two strips, each containing 30 blisters of medication. The first strip has UMEC blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 62.5 mcg per blister and the second strip has VI blended with lactose and magnesium stearate in the form of dry white powder with a dosage of 25 mcg per blister.
1646903|NCT01879410|Drug|FSC Inhalation Powder 250/50 mcg via ACCUHALER/DISKUS|The drug is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains a single strip with 60 blisters of medication. The strip has 250 mcg of fluticasone propionate and 50 mcg of salmeterol per blister in the form of dry white powder.
1646904|NCT01879410|Drug|Placebo DISKUS|Placebo is administered via ACCUHALER/DISKUS inhaler as one inhalation each morning and evening. The inhaler contains 1 strip with 60 blisters of placebo in the form of dry white powder.
1646909|NCT01879371|Drug|Ibuprofen (Nurofen Immedia®)|oral dose
1646912|NCT01879345|Drug|BIA 2-093 - 1800 mg (Group 1)|3 tablets of BIA 2-093
1646913|NCT01879345|Drug|BIA 2-093 - 2400 mg (Group 2)|4 tablets of BIA 2-093 600 mg
1646914|NCT01879345|Drug|Placebo|placebo tablets
1646915|NCT01879332|Drug|Placebo|Matching placebo tablets for oral administration
1646916|NCT01879332|Drug|BIA 2-093 3000 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
1646917|NCT01879332|Drug|BIA 2-093 3600 mg once daily|Eslicarbazepine acetate 600 mg tablets for oral administration
1646918|NCT01879319|Biological|Evolocumab AMD|Evolocumab subcutaneous injection using a single use, disposable AMD containing 3.5 mL deliverable volume.
1646919|NCT01879319|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection using a handheld mechanical (spring-based) prefilled AI/Pen, each containing 1.0 mL deliverable volume.
1646920|NCT01879293|Drug|Metformin|
1646921|NCT01879293|Drug|placebo|
1646922|NCT01879280|Procedure|Traditional pterional craniotomy|In the standard pterional craniotomy group, the attachment of the temporalis will be cut and the temporalis will be mobilized prior to exposure of the underlying bony calvarium. This maneuver is currently accepted for use by the majority of neurosurgeons nationwide.
1646923|NCT01879280|Procedure|Osteoplastic craniotomy|"In the osteoplastic group, the temporalis will be left attached to the bony calvarium prior to exposure of the tumor. There are ways to turn a bone flap with the temporalis still attached (i.e., an osteoplastic craniotomy). However, this method is thought to be slightly more time-consuming and is used less often in many centers. Aside from the extra time involved, we do not feel that leaving the temporalis attached to the bony calvarium disadvantages the patient in any fashion and may--in fact--result in less post-operative morbidity."
1646924|NCT01879267|Behavioral|Exercise training|6 months of exercise training (2 times 30 min per week) starting one week after a 6-months natural course observation period
1646925|NCT01879254|Device|Deep Brain Stimulation|
1646926|NCT01879241|Drug|Rasagiline|
1646927|NCT01879241|Drug|Placebo|a sugar pill manufactured to mimic Rasagiline 1 mg tablet
1646928|NCT01879228|Drug|Sitagliptin|The GPA test as described in the primary outcome section will be performed at baseline and after 6 months of therapy in the Sitagliptin and placebo arms. Furthermore, evaluation of endogenous GLP-1 levels will be assessed by a mixed meal tolerance test compared at baseline and 6 months.
1646930|NCT01879202|Drug|Methylphenidate modified release|Ritalin 20mg once daily within the first week, Ritalin 30mg once daily within the second week and afterwards Ritalin 40mg will be taken once daily throughout the remaining active treatment phase.
1646931|NCT01879202|Drug|Maltodextrin|Study medication will be taken once daily. Patients will take 20mg of study medication within the first week, 30mg within the second week and afterwards 40mg of study medication throughout the remaining active study period.
1646932|NCT01879189|Behavioral|Breast Cancer Screening Decision Aid|The intervention will include access to the personal decision aid tool for patients in the intervention arm of the study, determined by the randomized physician schedule and the patient's appointment time.
1646933|NCT01879176|Device|CytoSorb|
1646934|NCT01879163|Biological|MVA85A-IMX313|Intradermal injection of MVA85A-IMX313 (MVA85A-IMX313 combines the candidate TB vaccine MVA85A with the carrier protein IMX313)
1646935|NCT01879163|Biological|MVA85A|Intradermal injection of MVA85A (recombinant Modified Vaccinia virus Ankara expressing the M. tb antigen 85A)
1646936|NCT01879150|Device|Cyclaplex bone anchor|Device implantation
1646937|NCT01879111|Other|patient-targeted feedback|Using a randomised-controlled study design half of the patients will receive a patient-targeted written screening feedback. This feedback contains information about depression in general, depression-severity adapted treatment guidelines and contact-information for treatment.
1646938|NCT01879098|Dietary Supplement|Probiotic: Bacillus subtilis|Bacillus subtilis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
1646939|NCT01879098|Dietary Supplement|Lactobacillus plantarum|Lactobacillus plantarum will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
1646940|NCT01879098|Dietary Supplement|Bifidobacterium animalis|Bifidobacterium animalis will be taken as a capsule once daily for 6 weeks by subjects in the group receiving this supplement (group is unknown, double-blinded).
1646941|NCT01879098|Dietary Supplement|Placebo|Placebo will be taken once daily for 6 weeks by every subject at some point in the study (crossover design).
1646942|NCT01879085|Drug|Docetaxel|75 mg/m2 IV over 60 minutes on day 8 every 21 days (1 cycle).
1646943|NCT01879085|Drug|Gemcitabine|given on days 1 and 8 at 900 mg/m2 IV over 90 minutes (fixed dose infusion rate at 10 mg/m2/min) every 21 days (1 cycle). For dose level -2, Gem will be given over 67.5 minutes at 10 mg/m2/min.
1646944|NCT01879085|Drug|Vorinostat|will be given orally at the specified dose levels (Table 2) on days -1 to +2 and days +7-9 every 21 days (treatment for 3 days starting one day prior to chemotherapy on every cycle).
1646945|NCT01879085|Drug|Pegfilgrastim|Administered on day 9 subcutaneously at 6 mg.
1646946|NCT01879059|Behavioral|Exercise|short period of inactivity (5 days) followed by a return to physical activity (1 day)
1646947|NCT01879046|Procedure|arthroplasty|Blood, bone marrow, synovial fluid and Hoffa's fat pad samplings
1646948|NCT01879033|Device|Reactive hyperemia peripheral artery tonometry (Rh-PAT)|Pulse volume is measured by a finger plethysmographic device which are sensed by a pressure transducer and transferred to a computer where the signal is amplified, displayed and stored (EndoPAT, Itamar Medical). Fingertip probes are placed on the index finger of both hands and 5 minutes of baseline recording are obtained. Blood flow is then occluded in one arm for 5 minutes, using a standard blood pressure cuff. Recording continues in both fingers during occlusion and for 5 minutes after release of the cuff. The RH-PAT index is calculated as the ratio of the average pulse amplitude in the post-hyperemic phase divided by the average baseline amplitude, with normalization to the signal in the control arm to compensate for any systemic changes.
1646992|NCT01878643|Drug|Placebo|normal saline administered to patient via nebulization
1647121|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 1 tablet of 5 mg and placebo po 1 tablet BID x 9 months Placebo injections every 2 weeks x 12 months
1646949|NCT01879033|Other|Blood levels for glucose, insulin, lipids and adipocytokines|A fasting laboratory evaluation will include chemistry panel (basic metabolic, liver function tests), CBC, lipid profile, urinalysis and HbA1c. All obese recruited subjects after a 12 hour fast will undergo an OGTT using a glucose load of 1.75 g/kg body weight with a maximum of 75 g. Blood samples will be collected for insulin, glucose, leptin, adiponectin, hsCRP and FFA. Serum and urine will be stored at -70 degrees Centigrade for measuring markers of oxidative stress and adipocytokines (including TNF-α, PAI-1)
1646950|NCT01879020|Drug|TA-8995|Drug: TA-8995 1mg
1646951|NCT01879020|Drug|TA-8995|Drug: TA-8995 2.5mg
1646952|NCT01879020|Drug|TA-8995|Drug: TA-8995 5mg
1646953|NCT01879020|Drug|TA-8995|Drug: TA-8995 10mg
1646954|NCT01879020|Drug|TA-8995|Drug: TA-8995 25mg
1646955|NCT01879020|Drug|Placebo|Placebo (TA-8995 1mg)
1646956|NCT01879020|Drug|Placebo|Placebo (TA-8995 2.5mg)
1646957|NCT01879020|Drug|Placebo|Placebo (TA-8995 5mg)
1646958|NCT01879020|Drug|Placebo|Placebo (TA-8995 10mg)
1646959|NCT01879020|Drug|Placebo|Placebo (TA-8995 25mg)
1646960|NCT01879007|Drug|Factive® Tab / Factive IV|
1646961|NCT01878994|Behavioral|Counselling group|
1646962|NCT01878994|Behavioral|Nereu group|
1646963|NCT01878968|Other|Script and CPR/Mechanical ventilation video.|Patients will be randomized to receive the script (see addendum) plus video. Video was produced by and is the property of the study investigators.
1646964|NCT01878955|Genetic|AMH level difference between patient with PCOS and multicystic ovaries.|
1646965|NCT01878942|Drug|Placebo|"Capsules containing mannitol looking identical to LSD
per os"
1646966|NCT01878942|Drug|LSD|200µg per os, single dose
1646968|NCT01878903|Other|Electronic VAS|Post-opearive pain patients will be assessed using electional VAS and verbal NRS
1646969|NCT01878890|Drug|Efavirenz|
1646970|NCT01878864|Drug|Bupivacaine lozenge|
1646971|NCT01878864|Drug|Lidocaine-adrenalin injection|
1646972|NCT01878838|Procedure|Femtosecond Laser Assisted Cataract Surgery w/ Catalys Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
1646973|NCT01878838|Procedure|Femtosecond Laser Assisted Cataract Surgery w/ LenSx Laser|Cohort subjects will undergo Femtosecond Laser Assisted Cataract Surgery in both eyes, with the Optimedica Catalys laser on one eye, and the Alcon LensX laser on the other. First eyes will be randomized.
1646974|NCT01878825|Biological|Fluviral™|1 dose administered intramuscularly in deltoid region of non-dominant arm.
1646975|NCT01878812|Biological|Fluarix/Influsplit Tetra® (2013-2014 season)|1 dose administered intramuscularly in the deltoid region of non-dominant arm
1646976|NCT01878799|Drug|GS-7977/GS- 5885 FDC|The GS-7977/GS-5885 FDC product combines a potent HCV nucleotide inhibitor and a potent HCV NS5A inhibitor and will be given for 12 weeks.
1646977|NCT01878786|Drug|Everolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus .
1646978|NCT01878786|Drug|Tacrolimus|One of the immunosuppressants currently being evaluated to replace CNIs in patients with CNI nephropathy is the mammalian Target of Rapamycin (mTOR) inhibitor, Sirolimus. Everolimus is a derivative of Sirolimus and belongs to this class of immunosuppressants, therefore, both drugs have similar side effect profile. The half-life of Everolimus is almost half of Sirolimus (Everolimus 30 hours vs Sirolimus 62 hours), which makes its dose adjustment easier although it would require more frequent dosing. In clinical trials, Everolimus has demonstrated its potential role as a safe alternative in minimizing and/or eliminating CNI such as Cyclosporin A and Tacrolimus.
1646979|NCT01878786|Drug|Mycophenolate mofetil (MMF/MPA)|Control Drug
1646980|NCT01878773|Other|High Quality Volume CT Scan; MRI Scan|Patients will have the High Quality volume CT scan immediately after their CT scan followed by MRI scan.
1646981|NCT01878747|Behavioral|Provider Tailored Intervention for Perioperative Stress|Provider Tailored Intervention for Perioperative Stress (P-TIPS) is developed based on the proximal-distal theory that suggested that in acute procedural settings specific adult behaviors directly affect children's distress and coping behaviors. P-TIPS aims at reducing preoperative anxiety in children via modifying adults' behavior.
1646982|NCT01878734|Dietary Supplement|Micronutrient Powders|Mothers will receive a one box containing 30 sachets of Micronutrient Powders (MNP) every other month. MNP will be procured offshore with support from UNICEF Supply Division in Copenhagen, which maintains a list of approved MNP suppliers and ensures compliance with standard requirements and product specifications. For this study MNP will be purchased from Piramal Healthcare Ltd, India.
1646983|NCT01878721|Radiation|PET/CT|positron emission tomography/computed tomography
1646984|NCT01878708|Drug|PEG-L-asparaginase|
1646985|NCT01878708|Drug|Dexamethasone acetate|-dexamethasone 40mg daily for 4 days with every cycle.
1646986|NCT01878695|Drug|IV/oral n-acetylcysteine|
1646989|NCT01878656|Drug|Sevoflurane|The investigators decrease to 1 minimal alveolar concentration(MAC) of anesthetic combination of sevoflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, sevoflurane and nitrous oxide are discontinued.
1646990|NCT01878656|Drug|Desflurane|The investigators decrease to 1 MAC of anesthetic combination of desflurane and nitrous oxide, and maintain end-tidal concentration of anesthetic combination at 1 MAC until the end of surgery. At the end of surgery, desflurane and nitrous oxide are discontinued.
1646991|NCT01878643|Drug|vancomycin or gentamicin|Choice of antibiotic is determined by Gram stain of sputum.The antibiotic is administered via nebulization through the ventilator circuit every 8 hours
1646993|NCT01878630|Device|Remote Patient Management|"Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist) plus devices for Remote Patient Management at patient site for daily monitoring of ECG, weight, blood pressure, self-report of health status:
weighing scale (Seca 861 with bluetooth, seca gmbh & co. kg.)
blood pressure device (UA767PBT with bluetooth, A&D Ltd.)
ECG-eventrecorder (PhysioMem® PM 1000, getemed Medizin- und Informationstechnik AG)
patient-communication platform (Physio-Gate® PG 1000, getemed Medizin- und Informationstechnik AG)
help call device (DORO Easy 510/ Doro HandlePlus 334gsm, doro AB)
at center site:
- electronic patient record (eHealth connect 2.0, T-Systems International)"
1646994|NCT01878630|Other|Usual Care|Guideline-based care in heart failure including at least 5 scheduled doctor's visits within 12 months (GP and specialist)
1646995|NCT01878617|Radiation|Craniospinal Irradiation with boost to the primary tumor site|All participants will undergo craniospinal irradiation (CSI) with boost to the primary tumor site. The dose given is based on the molecular and risk group as noted in the arm descriptions. The type of radiation used includes conformal radiation therapy (photons) or intensity modulated radiation therapy (IMRT) or proton beam therapy.
1646996|NCT01878617|Drug|Cyclophosphamide|Route of Administration (ROA): Intravenously (IV)
1646997|NCT01878617|Drug|Cisplatin|ROA: IV
1646998|NCT01878617|Drug|Vincristine|ROA: IV
1646999|NCT01878617|Drug|Vismodegib|ROA: Orally (PO)
1647000|NCT01878617|Drug|Pemetrexed|ROA: IV
1647001|NCT01878617|Drug|Gemcitabine|ROA: IV
1647002|NCT01878617|Other|Aerobic Training|
1647003|NCT01878617|Other|Neurocognitive Remediation|
1647004|NCT01878604|Genetic|Gene analysis|Gene analysis
1647005|NCT01878604|Other|Historical data of lipid-lowering drug administration|Collecting historical data of lipid-lowering drug administration
1647006|NCT01878604|Other|Historical data of plasma lipids, xanthoma changes|Collecting historical data of plasma lipids and xanthoma changes
1647007|NCT01878578|Drug|Eslicarbazepine acetate|Tablets containing ESL 600 mg
1647008|NCT01878578|Drug|phenytoin|Hidantina® tablets containing 100 mg of phenytoin
1647009|NCT01878578|Drug|Placebo|Tablets containing matching placebo
1647010|NCT01878565|Drug|Drug|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with 800 unit of HBIG intramuscularly at day 0, 1, 2, 3 and 4, then were treated with 75 μg of GM-CSF subcutaneously at day 2, 3, 4, 5 and 6, and finally were injected 20 μg of HBV vaccine subcutaneously at day 6.
1647011|NCT01878565|Drug|GM-CSF control|Given four times in week 0, 4, 12 and 24. At each time of treatment, the patients will be hospitalized and treated with saline placebo intramuscularly or subcutaneously at day 2, 3, 4, 5, 6.
1647012|NCT01878539|Device|coagulometer|
1647013|NCT01878539|Behavioral|training programme|
1647014|NCT01878526|Drug|Alginic acid|Algycon 1 tab chew tid after meal
1647015|NCT01878526|Drug|placebo (for domperidone)|placebo (for domperidone) 1 tab oral tid before meal
1647016|NCT01878526|Drug|Domperidone|domperidone (10 mg) 1 tab oral tid before meal
1647017|NCT01878526|Drug|placebo (of alginic acid)|placebo (for alginic acid) 1 tab chew tid after meal
1647018|NCT01878513|Drug|risperidone|3 levels of dosing dependent on which condition a patient is assigned to.
1647019|NCT01878500|Device|Intraoperative stereotactic imaging with VectorVision|Surgeon will use intraoperative stereotactic imaging with VectorVision® Cranial Guided Image System by Brainlab Inc. to assist in bladder exstrophy closure. Prior to the operation a team consisting of pediatric urologist, pediatric radiologists, and a VectorVision rep will use pre-operative MRI to map out specific bony and muscular structures of the pelvic floor. Doing so will allow the pediatric urologist to use these markers intraoperatively to help guide his closure and also allow for future surgeons who use this technology to understand the correct planes to develop for the same surgery.
1647020|NCT01878487|Device|Thrombus aspiration (Intravascular Ultrasound catheter (Boston))|"There is a single arm in the study where all patients are undergoing primary percutaneous coronary intervention for an acute myocardial infarction.
All patients will have an Intravascular Ultrasound three times:
At baseline
After thrombus aspiration with a thrombus extraction catheter
After stent deployment
We are however assessing the physiological response of patients having an acute myocardial infarction and this is not a test of the devices as such."
1647021|NCT01878474|Drug|TA-8995|TA-8905 5, 10, 25, 50 (fasted and fed), 100 and 150 mg
1647022|NCT01878474|Drug|TA-8995|Drug: TA-8995 25 mg
1647023|NCT01878474|Drug|TA-8995|Drug: TA-8995 25 mg
1647024|NCT01878474|Drug|TA-8995|Drug: TA-8995 25, 50, 100 and 150 mg
1647025|NCT01878474|Drug|Placebo|Single ascending dose in Caucasian men
1647026|NCT01878474|Drug|Placebo|Age-effect in Caucasian men
1647027|NCT01878474|Drug|Placebo|Gender-effect in Caucasian women
1647028|NCT01878474|Drug|Placebo|Single ascending dose in Japanese men
1647029|NCT01878461|Drug|Vehicle|
1647030|NCT01878461|Drug|M518101|
1647031|NCT01878448|Drug|Anlotinib|
1647032|NCT01878435|Other|SMS reminder|
1647033|NCT01878435|Other|Travel subsidy|
1647034|NCT01878435|Other|Travel subsidy 2|
1647035|NCT01878422|Drug|Arm A: FOLFIRI or FOLFOX + Bevacizumab|Arm A: FOLFIRI or FOLFOX + Bevacizumab or Arm E: FOLFIRI or FOLFOX plus BEVACIZUMAB
1647036|NCT01878422|Drug|Arm B: FOLFIRI or FOLFOX|Arm B: FOLFIRI or FOLFOX or Arm C: FOLFIRI or FOLFOX
1647037|NCT01878422|Drug|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB|Arm D: FOLFIRI or FOLFOX plus CETUXIMAB
1647038|NCT01878422|Drug|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB|Arm F: FOLFIRI or FOLFOX plus BEVACIZUMAB and CETUXIMAB
1647039|NCT01878396|Drug|Anti-B-RAF|
1647040|NCT01878383|Device|Genexpert assay|
1647041|NCT01878370|Other|High risk|"Aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting criteria for high-risk sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to a list of chart numbers identifying those patients at highest risk.
Family physicians in Arm 2 are asked to complete a worksheet that also includes goal setting and action planning, but focuses on reducing the number of patients with high-risk criteria and offers some suggested practice-based approaches."
1647042|NCT01878370|Other|Best Practice|"Standard, aggregate-level feedback reports focusing on the proportion of patients with hypertension and/or diabetes and/or ischemic heart disease meeting targets sent via courier every six months and available on a password protected website. Family physicians in this arm will also have access through this website to patient-level data to identify patients not achieving optimal quality of care targets.
Family physicians in Arm 1 are asked to complete a worksheet that follows continuous quality improvement principles, including setting an aim statement, engagement with team members in the clinic, testing change concepts at first on a small scale, and then scaling up in a effort to spread best practices."
1647043|NCT01878357|Drug|dihydroartemisinin-piperaquine|Treatment will be given to all malaria-positive individuals on microscopic examination. The dosage will be calculated based on body weight. The drug that will be given is 3-day dihydroartemisinin-piperaquine (DHP) treatment. The drug will be given by health care personnel at their houses assisted by health care volunteers of the integrated health post (Posyandu cadre).
1647044|NCT01878357|Drug|primaquine|One day primaquine (PQ) treatment will be given for P. falciparum infected subjects. For patients who are infected by P. vivax and P. ovale,PQ will be given for 14 days
1647045|NCT01878344|Drug|NAC|
1647046|NCT01878344|Drug|Saline|
1647047|NCT01878318|Drug|methotrexate|stable dose
1647048|NCT01878318|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks, 24 weeks
1647049|NCT01878305|Device|Molecular Adsorbent Recirculating System (MARS)|MARS is an extracorporeal albumin dialysis device, used in the treatment of liver failure patients to stabilize the patient and halt the progression of HE, giving the liver time to recover in some cases and allowing additional time before liver transplantation in others.
1647050|NCT01878292|Drug|Placebo|Dose matched placebo tablets, once per day, oral administration.
1647051|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 15 mg per day, oral administration
1647052|NCT01878292|Drug|Vilazodone|Vilazodone tablets, 30 mg once per day, oral administration
1647053|NCT01878279|Other|Underlying medical illness|
1647054|NCT01878266|Radiation|Hypofractionated Arm (1)|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
1647055|NCT01878266|Radiation|Hypofractionated Arm (2)|The total dose to 4500 cGy in 15 fractions in 3 weeks
1647056|NCT01878266|Radiation|Conventional Arm (3)|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.Conventional arm
1647057|NCT01878240|Procedure|EVAR without coils embolization/ Coils embolization during EVAR|
1647058|NCT01878227|Drug|Coenzyme A|Coenzyme A 400mg per day
1647059|NCT01878227|Drug|Fenofibrate 200mg|Fenofibrate 200mg per day
1647060|NCT01878214|Behavioral|Targeted messaging|6 targeted mailed messages and 6 booster text messages
1647061|NCT01878214|Behavioral|Standard messaging|1 informational letter
1647062|NCT01878201|Drug|Fimasartan|Fimasartan 30 mg
1647063|NCT01878201|Drug|Valsartan|Valsartan 80 mg
1647064|NCT01878188|Drug|BC-819/PEI|Intravesical instillation
1647065|NCT01878188|Drug|BCG Vaccine|intravesical instillations
1647066|NCT01878175|Behavioral|Functional Movement Retraining|15-week rehabilitation / exercise intervention, including visits at the Durham VA medical center, in-home with clinical personnel, and via telephone. The intervention is tailored to participants' post-operative functional status, particularly unilateral balance asymmetries. The exercise program will focus on three areas: lower extremity mobility (ankle, knee and hip), muscle stability (quadriceps and gluteal muscle strength) and functional movement patterns (lower extremity focus). Participants will be instructed to perform their prescribed stretching exercises daily and strengthening exercises three times per week (on non-consecutive days).
1647067|NCT01878162|Other|Exercise|
1647068|NCT01878136|Drug|Tissue Plasminogen Activator|Dose: 1mg Q8 x 12 doses, or until clearance of blood from ventricles and cisterns Administration: intraventricular administration (through external ventricular drain)
1647069|NCT01878123|Biological|AMP-110|Dose levels 1 through 7: Single intravenous infusion on Day 0
1647070|NCT01878123|Other|Placebo|Dose levels 4 through 7: Single intravenous infusion on Day 0
1647071|NCT01878110|Behavioral|COMB|
1647072|NCT01878097|Behavioral|Green Dot Bystander Intevention|Intervention allocated at the school level
1647073|NCT01878097|Behavioral|Control|Awareness Education
1647076|NCT01878058|Other|MRI Scan|Patient will receive an additional MRI scan in addition to their standard of care imaging
1647081|NCT01877967|Dietary Supplement|VSL#3|The intervention group will be asked to ingest two sachets (2x4.4g) of the food supplement (VSL#3) each day for 12 weeks, either both at the same time, or one in the morning and one in the evening. This food supplement is in powder form and can be ingested with either cold food or any non-carbonated cold drink. The control group will be given a placebo, although as it is a double-blind intervention, will not know it is a placebo. They will similarly to the intervention group be asked to take two sachets (2x4.4g) of a powder rach day for 12 weeks, either both at the same time, or one in the morning and one in the evening.
1647082|NCT01877967|Dietary Supplement|placebo|
1647083|NCT01877954|Drug|Extra-fine hydrofluoroalkane beclometasone dipropionate|
1647084|NCT01877954|Drug|Fluticasone propionate|
1647085|NCT01877941|Device|Pulmonary Artery Catheter (PAC)|A catheter is inserted into the pulmonary artery, through the internal jugular vein; cardiac output is indicated by the speed that a temperature gradient dissipates.
1647086|NCT01877941|Device|Endotracheal Cardiac Output Monitor (ECOM)|An FDA-approved medical device is inserted into the patient's throat; cardiac output is calculated by measuring how electricity moves through the chest.
1647087|NCT01877941|Device|Estimated Continuous Cardiac Output (esCCO)|Sensors are placed on the arm, finger and leg to calculate Pulse Wave Transit Time (PWTT); the time it takes for the pulse of the heartbeat to travel through the body.
1647120|NCT01877668|Drug|Adalimumab|Placebo po 2 tablets BIDx 12 months Adalimumab 40 mg subcu injections every 2 weeks x 12 months
1647088|NCT01877928|Device|Boussignac CPAP device|Is a continuous positive airway pressure (CPAP) system marketed in Canada and the US for the treatment of Obstructive Sleep Apnea. The main difference is that this system is portable wheres the standard hospital CPAP is not. This allows for the application immediately post-extubation.
1647089|NCT01877928|Device|standard CPAP|Standard of care postoperative treatment for OSA.
2012626|NCT01806597|Biological|secukinumab 300 mg|Study treatment will be provided in pre-filled syringes of secukinumab 150 mg in 1 mL. Each dosing consists of two secukinumab 150 mg s.c. injections and will take place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients will also receive two placebo injections at Weeks 17, 18 and 19. Patients will self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
1647093|NCT01877889|Drug|Canagliflozin|One 300 mg over-encapsulated tablet taken orally (by mouth) once daily for 4 days during Part 1 and Part 2 (Sequence 1 [treatment period 2] or Sequence 2 [treatment period 1]).
1647094|NCT01877889|Drug|Dapagliflozin|One 10 mg over-encapsulated tablet taken orally once daily for 4 days during Part 2 (Sequence 1 [treatment period 1] or Sequence 2 [treatment period 2]).
1647095|NCT01877863|Other|exercise|12 weeks of intradialytic biking at Borg intensity 3 - 4 for 15 to 60 minutes on each dialysis run
1647096|NCT01877850|Procedure|weaning protocol|"Reduction of pressure support ventilation (PSV) by 2cmH2O at a time to a maximum of 4cmH2O per day.
When a patient was able to tolerate PSV less than 8 cmH2O for at least 120 minutes, the nurses started to reduce End Expiratory Positive Pressure (PEEP) by 2cmH2O at a time to a maximum of 4cmH2O per day.
When a patient was able to tolerate PSV less than 8 cmH2O with PEEP less than 6 cmH2O, the nurses started SBT trial: Continuos Positive Pressure Airways of 6cmH2O for at least 120 minutes and following discontinuation from ventilator."
1647097|NCT01877837|Drug|Alemtuzumab|"Adjusted Ideal Body Weight Formula: AIBW = IBW + [(0.4) x (ABW - IBW)]
b) Medications
i.) Alemtuzumab I. Hb S% must be < or = 45% within 7 days prior to initiation of Alemtuzumab II. Iron chelation and hydroxyurea must be discontinued >48 hours before initiating therapy III. Alemtuzumab will be diluted in 100mL of 0.9% NS and infused at a rate as below"
1647098|NCT01877837|Drug|Fludarabine|I. Fludarabine should be diluted in 100 ml 0.9%NS and given over 30 minutes. II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Fludarabine
1647099|NCT01877837|Drug|Melphalan|"I. Melphalan should be diluted in 0.9%NS to a concentration of 0.1 -0.45 mg/mL and given over 45 minutes. *Entire dose must be infused within 60 minutes of reconstitution in Pharmacy.
II. A daily dose of an antiemetic should be given 30 minutes prior to administration of the Melphalan III. Patients should be encouraged to suck on a popsicle or something similar during the Melphalan infusion."
1647100|NCT01877837|Procedure|Stem Cells|Infusion of Hematopoietic Stem Cells
1647101|NCT01877824|Other|Fast-track training|
1647102|NCT01877811|Drug|RXDX-105|"During Phase 1/1b, subjects will receive daily oral doses of RXDX-105 in 28-day cycles (except for Day 2 of Cycle 1). To determine the recommended Phase 2 dose (RP2D), doses will be administered in an escalated fashion starting at 20 mg/day.
During Phase 1b, subjects will be administered the RP2D in 28-day treatment cycles until documented radiographic progression, unacceptable toxicity, withdrawal of consent, or protocol specified parameters to stop treatment."
1647103|NCT01877798|Procedure|volume resuscitation, vasoactive drug|
1647104|NCT01877785|Drug|MHAA4549A|Single-ascending dose of MHAA4549A
1647105|NCT01877785|Drug|Placebo|Placebo to MHAA4549A
1647106|NCT01877772|Procedure|Bone Trephination|For the bone trephination, the wire will be advanced into the insertion site through the cortex and into the metaphyseal bone of proximal humerus.
1647107|NCT01877759|Biological|Mesenchymal stem cell|Intravenous dose of Mesenchymal stem cell derived from human Bone Marrow & umbilical cord , IN 6 divided doses , at interval of 1 week .
1647108|NCT01877746|Drug|Combination of prednisone and azathioprine|"Prednisone for a total of 90 days, with initial dose 1mg/kg/day p.o., given for 12 days and then tapered every 5 days for 5mg/day to the maintenance dose of 0.2mg/kg/day. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.
Azathioprine for 100 days in total, with dose 1 mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
1647109|NCT01877746|Drug|Combination of prednisone and azathioprine|"Prednisone for a total of 6 months, with initial dose 1mg/kg/day p.o. given for 4 weeks with a subsequent maintenance dose of 0,33 mg/kg/den. The daily dose of Prednisone will be rounded to the nearest value divisible by 5.
Azathioprine for 6 months in total, with dose 2mg/kg/day. The daily dose of Azathioprine will be rounded to the nearest value divisible by 25."
1647110|NCT01877746|Other|No intervention|No intervention, only standard medical therapy
1647111|NCT01877733|Other|Maximal strength training|
1647112|NCT01877720|Device|noninvasive respiratory support with NAVA mode and PSV|
1647113|NCT01877707|Other|home monitoring|Record daily - peak flow measurements, pulse rate, oxygen saturation levels, weight,activity and daily sputum samples.
1647114|NCT01877694|Drug|Auriclosene Solution 0.3%|Ophthalmic solution dispensed as drops onto the eye
1647115|NCT01877694|Drug|Auriclosene Vehicle|Ophthalmic Vehicle solution dispensed as drops onto the eye
1647116|NCT01877681|Procedure|Tele-assistance|Assisted care (Tele-assistance) provided by an expert nurse through a informatic online application
1647117|NCT01877681|Procedure|Active comparator|Usual care as specified in the PU practice guideline
1647118|NCT01877668|Drug|Tofacitinib 5 mg BID|Tofacitinib orally (po) 1 tablet of 5 mg and placebo po 1 tablet BID x 12 months Placebo injections subcu every 2 weeks x 12 months
1647119|NCT01877668|Drug|Tofacitinib 10 mg BID|Tofacitinib po 2 tablets of 5 mg BID x 12 months Placebo injections subcu every 2 weeks x 12 months
1647261|NCT01876576|Other|Low residue breakfast and lunch|Low residue
1647122|NCT01877668|Drug|Placebo|Placebo po 2 tablets BIDx 3 months followed by tofacitinib po 2 tablets (5 mg) BID x 9 months Placebo injections every 2 weeks x 12 months
2012627|NCT01806597|Biological|Placebo|Placebo will be provided in 1 mL pre-filled syringes. Each dosing consists of two s.c. injections and will take place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Week 8 and at Week 12. At Week 16, ppIGA responders will continue on placebo with dosing at Weeks 16, 17, 18, 19 and 20, then once every four weeks from Week 24 until Week 76 inclusive. At Week 80, ppIGA responders will end their participation in the study while ppIGA non-responders will be re-randomized, to receive 150 mg or 300 mg secukinumab once every four weeks starting at Week 80 until Week 128 inclusive. Patients will self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
1647129|NCT01877629|Drug|ACT-129968 500 mg Tablet|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
1647130|NCT01877629|Drug|ACT-129968 250 mg Capsule|ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist
1647131|NCT01877616|Other|diagnostic test|Polysomnography
1647132|NCT01877616|Other|Diagnostic test|overnight polysomnography
1647133|NCT01877590|Drug|alpha-lipoic acid|
1647134|NCT01877577|Dietary Supplement|Vitamin D3|Study patients who took 2,000 IU daily of vitamin D3 will be compared to those who took 4,000 IU daily to determine the different effects of vitamin D3 dose on quality of life, disease activity, and the laboratory tests in this study.
1647136|NCT01877551|Drug|Tauroursodeoxycholic acid|The intervention group will receive 1.75 grams of tauroursodeoxycholic acid daily for 30 days.
1647137|NCT01877551|Other|Placebo tablet|The placebo group will receive a placebo tablet that is identical to the treatment group except that it does not contain tauroursodeoxycholic acid. The pills will be taken once daily for 30 days.
1647138|NCT01877538|Other|[11C]donepezil PET|Positron Emission Tomography (PET) imaging of acetylcholinesterase with the ligand [11C]donepezil
1647139|NCT01877525|Procedure|Colonoscopy|The location, size, and morphology of all lesions detected during colonoscopy were recorded. The size of each identified polyp was visually estimated . All diminutive polyps (defined as ≤5 mm) were endoscopically imaged and histology predictions (adenoma vs. non-adenomatous polyp) were made using HDWL with/without NBI at the discretion of the endoscopist.
1647140|NCT01877512|Drug|Change in daily dosage of Growth Hormone|
1647141|NCT01877499|Other|Optimization of HDF key parameters|"First, patients actually receiving standard dialysis will be switched to post-dilution HDF.
Then, a stepwise increase in 3 key parameters of the HDF prescription will be applied in a standardized way, in order to obtain the highest achievable convection volume.
Precisely, the following 3 parameters will successively be increased towards a maximal target:
Treatment time (up to 4 hours per session);
Blood flow rate (up to 400 mL/min;
Filtration fraction, defined as the ratio between extracted plasma water flow rate and blood flow rate (up to 33%).
Maximal values for these parameters will be those achieved within pre-specified safety limits."
1647142|NCT01877486|Procedure|Ablation|Pulmonary vein isolation following dofetilide
1647143|NCT01877473|Procedure|Ablation|
1647144|NCT01877460|Other|Dietary intervention|All arms were given to all participants, in a randomized order, to be consumed within 10 min after 12-h overnight fasting.
1647145|NCT01877447|Device|Transcranial Direct Current Stimulation|Current Stimulation with cathodal stimulation over right dorsolateral prefrontal cortex. Anodal stimulation over left deltoid region
1647146|NCT01877434|Procedure|Reversed shoulder arthroplasty|
1647147|NCT01877421|Drug|2 mg KSL-W|
1647148|NCT01877421|Drug|4 mg KSL-W|
1647149|NCT01877421|Drug|6 mg KSL-W|
1647150|NCT01877421|Drug|10 mg KSL-W|
1647151|NCT01877421|Drug|20 mg KSL-W|
1647152|NCT01877421|Drug|30 mg KSL-W|
1647153|NCT01877421|Drug|50 mg KSL-W|
1647154|NCT01877421|Drug|75 mg KSL-W|
1647155|NCT01877421|Drug|100 mg KSL-W|
1647156|NCT01877421|Other|Placebo|Cetylpyridinium chloride (CPC) as an additive, isomalt as a bulk sweetener, peppermint powder for flavoring, sucralose as an intense sweetener, colloidal silicon dioxide is a flow enhancer, magnesium stearate as a process aid, and the proprietary gum base formulation.
1647157|NCT01877408|Procedure|Open surgical circumcision|Open surgical circumcision using a technique approved by the WHO (dorsal slit)
1647158|NCT01877408|Device|Unicirc device with tissue adhesive|Removal of foreskin with Unicirc disposal device and wound sealing with tissue adhesive.
1647159|NCT01877395|Biological|Purified Vero Rabies Vaccine (VRVg)|0.5 mL, Intramuscular
1647160|NCT01877395|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
1647162|NCT01876264|Procedure|Extended resection|
1647163|NCT01876264|Procedure|Conventional resection|
1647169|NCT01876238|Other|T-PAT|
1647170|NCT01876238|Other|Surveys|Pre-test and posttest surveys and questionnaires
1647171|NCT01876225|Behavioral|Forced coughing during cervical punch biopsy|
1647172|NCT01877356|Procedure|bilateral spinal anesthesia|prilocaine plain 2% 50 mg
1647173|NCT01877356|Procedure|unilateral spinal anesthesia|prilocaine 2% hyperbaric 30 mg
1647174|NCT01877343|Device|CVInsight(TM)|Patient will be placed on a tilt table and pulse oximetry (Nonin Medical) and blood pressure will be measured at different table positions (different angles). Four positions will be explored. A hemodynamic monitor called CVInsight(TM) will be used to monitor the pulse oximeter readings.
1647175|NCT01877330|Procedure|Interscalene block for shoulder arthroscopy|
1647223|NCT01876901|Procedure|ACAI Group (coloanal anastomosis Immediate)|"After the surgical resection, coloanal anastomosis is performed usually after completion of a reservoir J when it is possible. Preventive ostomy is performed most often.
In the absence of fistula, the patient will reoperation for stoma closure of its branch"
1647176|NCT01877317|Device|SelfFit adjusted hearing device|Comparison of threshold measurements through in-situ audiometry with full diagnostic audiometry; Comparison of First-Fit based on SelfFit-formula with conventional fitting formula NAL-NL1 (IG-measurements; Speech intelligibility with First fit of SelfFit; Speech intelligibility with Final fit of SelfFit; Comparison of fine tuning through SelfFit (Final fit) with First fit; Comparison of Final fit with Traditional fit (conventional fitted hearing aid of the test person)
1647177|NCT01877304|Device|AKITA|
1647178|NCT01877278|Device|Wearable pulsed electromagnetic fields|
1647179|NCT01877265|Drug|LY2605541|
1647180|NCT01877252|Procedure|Surgical revascularization|
1647181|NCT01877252|Procedure|Endovascular revascularization|
1647182|NCT01877252|Other|No vascular intervention|
1647183|NCT01877239|Other|non-intervention|observation of Etanercept treatment in moderately active RA patients in Austria. Etanercept treatment according to Austrian SmPC
1647184|NCT01877226|Drug|Tapentadol|Tapentadol tamper resistant prolonged-release formulation (TRF) will be administered as 250 milligram oral tablet once (in the morning, 30 minutes after breakfast) on Day 1 and 6, and twice daily (in the morning, 30 minutes after breakfast and in the evening) on Day 4 and 5.
1647185|NCT01877213|Behavioral|Coaching with coordinate care|The coordinator nurse will manage ambulatory care with the patient's GP and participate to patient's education.
1647186|NCT01877200|Other|No treatment given|Patients will fill out a questionnaire by interview.
1647187|NCT01877187|Drug|Lipiodol|Lipiodol is used as a carrier for chemotherapy agents and also as an occlusion agent. In TACE procedures, Lipiodol is mixed with the chemotherapy agent(s) and delivered to the tumor via the hepatic artery, causing necrosis of the targeted tumor(s).
1647188|NCT01877174|Device|MICHI(TM) NPS+f|Transcarotid delivery system for carotid stents with flow reversal
1647189|NCT01877174|Procedure|transcarotid stenting|
1647190|NCT01877161|Device|Repetitive magnetic stimulation to superior temporal gyrus|Repetitive magnetic stimulation to superior temporal gyrus
1647191|NCT01877161|Device|Repetitive magnetic stimulation to middle temporal gyrus|Repetitive magnetic stimulation to middle temporal gyrus
1647192|NCT01877161|Device|Repetitive magnetic stimulation (Sham)|Repetitive magnetic stimulation (Sham)
1647193|NCT01877148|Device|tDCS|tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The anodal tDCS increase the excitability.
1647194|NCT01877148|Behavioral|Physiotherapy|Physiotherapy protocol followed the guidelines outlined in clinical practice guideline for physical therapy in Parkinson disease of the Royal Dutch society for physical therapy (Keus, 2007). This guideline proposes some objectives for motor rehabilitation in patients with PD, such as: flexibility, strength, coordination, balance, posture and gait. The difficulty of exercises ranged according with Hoehn and Yahr (HY) staging scale. In this way, each stage of HY had a specific physical therapy protocol following the guideline.
1647195|NCT01877122|Device|Proflex® Mesh Mesh implantation|Implantation of mesh in the incision of inguinal area
1647196|NCT01877122|Device|Marlex® Mesh Implant|
1647197|NCT01877096|Behavioral|Motivational Interviewing|A brief motivational interviewing session
1647198|NCT01877096|Behavioral|Attention Control|Participants will be asked to discuss the sources (e.g., the Internet) in which they receive information about their health. This group is designed to control for potential beneficial effects of meeting with an interventionist.
1647199|NCT01877083|Drug|Lenvatinib|Starting dose of 24 mg orally, once per day
1647200|NCT01877070|Behavioral|assessments|
1647201|NCT01877057|Dietary Supplement|Saturn|
1647202|NCT01877044|Dietary Supplement|NAXUS|
1647203|NCT01877044|Dietary Supplement|Placebo|
1647204|NCT01877031|Device|Virtual Reality|A magnetically tracked needle with an associated virtual image will be superimposed on the ultrasound image to give the user a better idea of the position of the needle.
1647205|NCT01877031|Device|Ultrasound|Standard of Care - Ultrasound guided intervention
1647206|NCT01877018|Behavioral|electronic reminder|Electronic reminder introduced into primary care medical health record, identifying invited people to the population-based colorectal cancer screening program, to promote their participation.
1647207|NCT01877005|Drug|Ruxolitinib|
1647208|NCT01876992|Drug|Metformin|
1647209|NCT01876979|Device|IMF Screws|stainless steel screws placed in bone
1647210|NCT01876979|Device|Erich Arch Bars|Surgical braces wired around teeth
1647211|NCT01876966|Drug|Etravirine|200 mg ETR b.i.d. from Day 1 to Day 21 with a single 200 mg dose of ETR in the morning on Day 22
1647212|NCT01876966|Drug|Darunavir/ritonavir|DRV/rtv 600/100 mg b.i.d. from Day 1 to Day 21 with a single dose of DRV/rtv in the morning on Day 22
1647213|NCT01876966|Drug|artemether/lumefantrine|3 days of treatment with artemether/lumefantrine 80/480 mg (6 doses of 4 tablets [20/120 mg] at 0, 8, 24, 36, 48, and 60 hours)
1647214|NCT01876953|Drug|cytarabine|Given IV
1647215|NCT01876953|Drug|idarubicin|Given IV
1647216|NCT01876953|Drug|dasatinib|Given PO
1647217|NCT01876953|Other|laboratory biomarker analysis|Correlative studies
1647218|NCT01876940|Device|air-Q, followed by fiberoptic intubation|
1647219|NCT01876940|Device|Free-hand Fiberoptic Intubation|Fiberoptic tracheal intubation will be performed without use of the air-Q and timed. Laryngeal grade of view will also be assessed
1647220|NCT01876927|Other|DOX 4 cycles - Surgery|DOX 4 cycles - Surgery
1647221|NCT01876927|Other|DOX 2 cycles - Surgery - DOX 2 cycles|DOX 2 cycles - Surgery - DOX 2 cycles
1647222|NCT01876901|Procedure|Delayed coloanal anastomosis (ACAD)|"Delayed coloanal anastomosis ACAD Whatever the mode of continuity restoration used, resection is the same in the two groups. It consists of total excision of the rectum and its mesorectum, that intervention should be performed by laparotomy or laparoscopy.
After surgical resection, the colon is exteriorized through the anus and attached to the buttock.
By day 6, exteriorized colon is resected and coloanal anastomosis is performed without preventive stoma derivation"
1647259|NCT01876589|Device|Xience Prime|Drug eluting metallic stent
1647260|NCT01876576|Other|Clear liquids|Clear liquids
1647224|NCT01876875|Dietary Supplement|Energy-restricted, n-3 polysaturated fatty acids-rich diet|The active diet aimed to reduce body weight, to enhance the total intake of n-3 PUFA and to decrease the total intake of n-6 PUFAs. The diet plan was designed to supply an energy intake of 20 kcal/kg/day to maintain an ideal body weight, and followed the guidelines of the American Heart Association (AHA) 'Step-One' Diet: Carbohydrates (mainly complex carbohydrates) and protein constituted of 50-60% and 10-20% of total calories, respectively, and total fat did not exceed 30% of calories. Food values for energy and nutrients were taken from the tables of the Italian National Institute of Nutrition, Souci's Food Composition and Nutrition Tables and the European Institute of Oncology. For long-term and practical daily eating habits, it was important to easily incorporate and consume a variety of selected foods.
1647225|NCT01876875|Dietary Supplement|Usual diet|The patients of this group were randomized to continue their usual diet
1647226|NCT01876862|Other|Antiretroviral treatment interruption|pilot study in chronically HIV-infected patients with an ultralow HIV reservoir undergoing treatment-interruption.
1647227|NCT01876849|Drug|exenatide|subcutaneous injection, 5mcg or 10 mcg, twice daily
1647228|NCT01876836|Device|i-gel|i-gel placed after induction
1647229|NCT01876836|Device|C-LMA|placed after induction
1647230|NCT01876823|Drug|es-citalopram|es-citalopram 10mg/day will be given for the first week, and 20mg/day starting at week 2.
1647231|NCT01876823|Drug|Memantine|After two weeks on Lexapro, Memantine 5mg will be added. The dose will increase to 10mg for the second week and will be increased at a rate of 5mg per week. Memantine dosage will not exceed 20mg.
1647232|NCT01876810|Drug|Gemfibrozil|600 mg of gemfibrozil (one capsule) twice daily for two weeks.
1647233|NCT01876810|Drug|Placebo|One lactose pill twice a day for two weeks.
1647234|NCT01876797|Drug|ticagrelor/prasugrel|
1647235|NCT01876784|Drug|Vandetanib (SAR390530)|"Pharmaceutical form: tablet
Route of administration: oral"
1647236|NCT01876784|Drug|Placebo|"Pharmaceutical form: tablet
Route of administration: oral"
1647237|NCT01876771|Other|Lu-DOTA-TATE radiopharmaceutical|
1647238|NCT01876758|Behavioral|Cognitive Intervention: Memory Training|Paper-and-pencil and computerized exercises pre- and post-ECT which may be helpful in recovering episodic memories and allow for the retention of learned strategies
1647239|NCT01876758|Behavioral|Comparable general mental stimulation|Active control will work on commercially available puzzle games at the same time prior and after ECT to determine if the developed memory training program is more effective than mere mental stimulation.
1647240|NCT01876745|Drug|eptacog alfa (activated)|Patients will be treated according to routine clinical practice at the direction of the treating physician. Data will be collected once a year after patient is registered with baseline visit until end of the study.
1647241|NCT01876732|Drug|Vitamin B12|Consented subjects are screened for Vitamin B12 deficiency with measurements of serum vitamin B12 concentrations and plasma levels of MMA, drawn prior to the first hemodialysis (HD) session of the week. Those with an MMA over 800nmol/L are given 1000mcg of IM vitamin B12 weekly for the first month and then monthly for 3 consecutive months. Following therapy, serum B12, MMA levels, percent iron saturation, parathyroid levels and peripheral blood smear are to be repeated and compared to previous levels. Subjects also complete a Kidney Disease Quality of Life- 36 (KDQOL-36) prior to therapy and again post treatment.
1647242|NCT01876719|Drug|AR08|
1647243|NCT01876719|Drug|Placebo|
1647244|NCT01876706|Device|UroLift® System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, and Canada. The UroLift® System is indicated for the treatment of symptoms due to urinary outflow obstruction secondary to benign prostatic hyperplasia (BPH) in men 50 years of age or older. During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
1647245|NCT01876693|Procedure|prophylactic percutaneous gastrostomy|prophylactic percutaneous gastrostomy with nutrition counselling
1647246|NCT01876680|Other|Stretching and aerobic exercise|"Stretching programme for neck/shoulder muscles three times weekly and aerobic exercise för 30 minutes three times weekly.
Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
1647247|NCT01876680|Other|Strength training|"Stretching programme for neck/shoulder muscles three times weekly, aerobic exercise för 30 minutes three times weekly and weight training using dumbbells for the neck/shoulder area and exercises to strengthen core and leg muscles for 45 minutes three times weekly.
Participants kept exercise diaries and physiotherapist provided support over the phone or through e-mail. The intervention lasted one year."
1647248|NCT01876667|Other|Intervention (CPCRS) Group|CPCRS staff will order evidence-based lipid-lowering and/or antihypertensive medications, adjust doses, and order follow-up laboratory parameters, as necessary under pre-approved regional treatment protocols. Patients will be monitored for medication adherence and adverse effects. Patients receive dietary, exercise, and smoking cessation counseling verbally and through mailing of pre-printed Kaiser Permanente approved, patient education pamphlets, as necessary per the discretion of the clinical pharmacy specialist. Patients requiring more dietary counseling will be referred to dieticians, education classes, or other appropriate resources offered at KPCO. Primary care providers will be informed of all medication initiations or dosage adjustments.
1647249|NCT01876667|Other|Placebo|Usual Care
1647250|NCT01876654|Device|TruMatch® patient specific cutting guide|
1647251|NCT01876641|Drug|Vemurafenib + Cobimetinib, Decitabine|
1647254|NCT01876615|Drug|YH4808|experimental drug
1647255|NCT01876615|Drug|Diclofenac|Depain tablet 25mg
1647256|NCT01876615|Drug|YH4808+Diclofenac|
1647257|NCT01876602|Behavioral|feeling states exercise intervention|exercise prescription based on intensity of exercise that feels good.
1647258|NCT01876589|Device|Bioresorbable vascular scaffold|Drug eluting coronary stent, resorbable in 2-3 years
1647262|NCT01876563|Dietary Supplement|vitamin D|one tab 4000 IU/day vitamin D
1647263|NCT01876563|Dietary Supplement|placebo|one tab per day placebo
1647264|NCT01876550|Drug|Mupirocin Calcium Cream, 2%|Mupirocin Calcium Cream, 2% (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
1647265|NCT01876550|Drug|Bactroban® Cream|Bactroban® Cream (mupirocin calcium cream, 2%) (GlaxoSmithKline) applied topically 3 times per day for 10 consecutive days.
1647266|NCT01876550|Drug|Cream vehicle of test product|Cream vehicle of test product (Taro Pharmaceuticals Inc.) applied topically 3 times per day for 10 consecutive days.
1647267|NCT01876537|Device|Hardware wound healing|
1647268|NCT01876537|Device|Usual Surgery|
1647269|NCT01876524|Device|Transcranial Random Noise Stimulation|Random Noise Stimulation between 100 and 500 Hz and 400-500 microAmperes are applied over head in particular areas
1647270|NCT01876511|Drug|MK-3475|MK-3475 10 mg/kg every 14 days
1647271|NCT01876511|Drug|MK-3475|MK-3475 200mg flat dose every 21 days
1647272|NCT01876498|Procedure|Xiaflex surgery|Xiaflex surgery
1647273|NCT01876485|Behavioral|Empowering Patients in Chronic Care (EPIC)|EPIC group training sessions consisting of 6 one-hour group sessions occurring over a 6-month period. Group sessions will consist of behavioral coaching focused on diabetes management. Following each group-session, patients enrolled in the intervention arm will meet with a designated member of their primary care team to personalize diabetes goals and action plans.
1647274|NCT01876485|Behavioral|Enhanced Usual Care (EUC)|Patients randomized to EUC will be referred to the PACT RN Care Manager for diabetes management, and will also receive a packet of educational materials regarding diabetes management, including a letter delineating the diabetes management resources available at their facility.
1647275|NCT01876472|Behavioral|Assessment of music perception skills|A sequence of tones is presented to participants. Then the same sequence is presented again, with the 4th tone being one to six half tones different from the first sequence. Participants are asked to indicate when they hear a difference betweent the first and the second sequence.
1647276|NCT01876459|Other|MRI|
1647277|NCT01876459|Procedure|lumbar puncture|
1647278|NCT01876459|Behavioral|neuropsychological tests|
1647282|NCT01876433|Drug|Mirabegron|
1647283|NCT01876433|Drug|Placebo|
1647285|NCT01876407|Device|Low intensity laser for oral mucositis|
1647286|NCT01876407|Device|Low intensity laser for oral mucositis switch off|Low intensity laser for oral mucositis switch off
1647287|NCT01876394|Other|Coconut Oil|Shake with 50 g Coconut oil
1647288|NCT01876394|Other|Canola Oil|Shake with 50 g Canola oil
1647289|NCT01876394|Other|Grapeseed Oil|Shake with 50 g Grapeseed oil
1647290|NCT01876394|Other|Chia Oil|Shake with 50 g Chia oil
1647291|NCT01876394|Other|Butter|Shake with 50 g Butter
1647292|NCT01876381|Drug|OPC-41061|The maximum number of days of administration will be 8 days (8 doses) in total 4 days each in the dose-escalation period and intermittant administration period. The investigational medicinal product (IMP) will be administered once daily after breakfast
1647293|NCT01876368|Drug|LCZ696|
1647294|NCT01876368|Drug|Olmesartan|
1647295|NCT01876368|Drug|Placebo of LCZ696|
1647296|NCT01876368|Drug|Placebo of Olmesartan|
1647297|NCT01876355|Drug|Clonidine|o The concentration of clonidine in the solution is 12.5 µg/ml. Continuous iv infusion of 0.02 ml/kg/h results in a dosage of 0.25 µg/kg/h. The maximum dosage achieved is 25 µg/h. The total amount of clonidine given to a person with a body weight 100 kg or more will be 600 µg a day. Since the doses chosen are in the low range, there will be no dosage adjustment for renal- or liver failure.
1647298|NCT01876355|Drug|SodiumChloride|Placebo. Pharmaceutical form: Injection. Route of administration: Intravenous use.
1647299|NCT01876342|Procedure|open repair|2-0 sutures
1647300|NCT01876342|Procedure|endoscopic TEP repair|mesh
1647301|NCT01876316|Drug|Moxifloxacin|single oral administration of 400mg of moxifloxacin
1647302|NCT01876316|Drug|Placebo|single oral administration of 400mg of placebo
1647303|NCT01876303|Other|laboratory biomarker analysis|Correlative studies
1647304|NCT01876303|Other|questionnaire administration|Ancillary studies
1647305|NCT01876290|Drug|Dexamethasone and Ondansetron|Comparison between Dexamethasone and Ondansetron and placebo in the prevention of postoperative Nausea and Vomiting
1647306|NCT01876290|Drug|Placebo|Placebo
1647309|NCT01876199|Behavioral|intense follow up|
1647310|NCT01876186|Drug|Solifenacin for 12 weeks|Solifenacin 5 mg one a day for 12 weeks
1647311|NCT01876186|Drug|Solifenacin for 24 weeks|Solifenacin 5 mg once a day for 24 weeks
1647312|NCT01876173|Behavioral|Patient Decision Aid for an ICD (primary prevention, non-CRT)|The intervention group will receive the PtDA, which provides a lay summary that outlines the facts, risks, benefits (including probabilities), specific to the option of an implantable defibrillator or the option of medical management to prepare them for consultation with the physician. Values are assessed to reveal which features of each option are important to patients.
1647313|NCT01876160|Other|Transcutaneous electrical nerve stimulation|
1647314|NCT01876121|Drug|Celecoxib|oral
1647315|NCT01876108|Drug|H.pylori eradication (Omeprazole, Amoxicillin, Bismuth subcitrate, Azithromycin)|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks.
1647356|NCT01875731|Behavioral|BPS|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
1647357|NCT01875731|Behavioral|Guideline|Strategy based on enforced guideline guided antibiotic use
1647358|NCT01875718|Drug|UC1010|
1647316|NCT01876095|Procedure|Multidisciplinary medication review|"Consists of the following steps:
1. Elderly care physician and nursing staff evaluate with the patient the experience of taking medicines, adverse drug reactions and patient's preferences.
2. Pharmacist reviews medication to identify drug related problems using START/STOPP en Beers criteria.
3/4. Meeting of elderly care physician, pharmacist. Possibilities to discontinue prescribed medication will be examined resulting in pharmaceutical care plan that optimizes the patient's medication i.e. which inappropriate medication should be discontinued following a prioritization and time schedule.
5. Execution of pharmaceutical care plan according to agreed schedule."
1647317|NCT01876082|Drug|PAZOPANIB treatment|"Pazopanib
800 mg per day
oral administration
at least 1 hour before or 2 hours after a meal,
until disease progression or for 12 months maximum"
1647318|NCT01876082|Drug|Active Comparator: Vinblastine and Methotrexate|Active Comparator: Vinblastine and Methotrexate vinblastine 5 mg / m², methotrexate 30 mg / m (J1, J8, J15, J21, 6 months and then J1, J15) 28 days per cycle until disease progression or for 12 months.
1647319|NCT01876069|Device|22 gauge ProCore needle aspiration|Pancreatic mass evaluation through the 22 gauge ProCore needle aspiration
1647320|NCT01876069|Device|22 gauge Fine needle aspiration|Pancreatic mass evaluation through the 22 gauge Fine needle aspiration
1647321|NCT01876056|Behavioral|Brief CaCBTp|Brief CBT for psychosis is comonly used in the West and had an established evidence base. Recently this therapy has been culturally adapted for use with clients from Pakistan.
1958024|NCT02043691|Device|Zenith t-Branch Endovascular Graft|The Zenith t-Branch Endovascular Graft is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for proximal fixation of the device. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents.
1647323|NCT01876030|Device|FES|
1647324|NCT01876017|Biological|Intravenous transfer of Autologous (BMMNCs)|Intervention therapy , Total 3 doses ,in 30 days ,in 7days interval Intravenous transfer of Autologous (BMMNCs)
1647325|NCT01876004|Drug|Methotrexate|50 mg/m2, IM (intramuscularly), single dose
1647326|NCT01876004|Drug|Placebo|Prescribed Placebo IM (intramuscularly), single dose
1647327|NCT01875991|Drug|Etanercept via Autoinjector A|Autoinjector A is a hand-held, reusable, electromechanical device used with a single-use disposable cassette preassembled with an etanercept 50-mg prefilled syringe.
1647328|NCT01875991|Drug|Etanercept via Autoinjector B|Autoinjector B is a single-use, spring-loaded, self-contained autoinjector preassembled with an etanercept 50-mg prefilled syringe.
1647329|NCT01875978|Dietary Supplement|Phytosterols & placebo|Group A:Phytosterols 1.8g/day with one meal for 4 weeks first;group B:placebo first
1647330|NCT01875952|Drug|Isoniazid|Isoniazid, 10 mg/Kg/day, no more than 300 mg/day, for six months
1647331|NCT01875939|Drug|Oral WCK2349|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
1647332|NCT01875939|Drug|IV WCK771|The subjects will be randomly assigned to receive WCK 2349 1000 mg as an oral dose in fed or fasting state (1:1) in the food effect study as per the randomization schedule. The subjects completing the food effect study (i.e., Period 1 and Period 2) will be administered WCK 771 800 mg as an intravenous infusion in fasting state in Period 3 of the study.
1647333|NCT01875926|Biological|ALX-0171|single dose of 200 mg ALX-0171 via oral inhalation
1647334|NCT01875926|Biological|ALX-0171|repeated doses of 200 mg ALX-0171 via oral inhalation once daily for 5 consecutive days
1647335|NCT01875926|Biological|ALX-0171|Single dose of 0.3 mg/kg body weight ALX-0171 via intravenous administration
1647336|NCT01875913|Behavioral|Curiosity Message|Participants will receive email messages that contain one of 8 curiosity-inducing questions. The message will tell participants that they will receive a message with the answer after they complete their VHR (health review that can be completed online).
1647337|NCT01875913|Behavioral|Standard Message|"Participants will receive email messages that contain standard language encouraging them to complete their VHRs (health review that can be completed online)."
1647338|NCT01875900|Other|Video-assisted learning and self-directed training|The Neonatal Resuscitation Program (NRP) DVD will be provided for video study and a low-fidelity newborn manikin for self-directed resuscitation training (90 minutes training time, six students per group).
1647339|NCT01875900|Other|Simulation-based neonatal resuscitation training|Students will learn initial assessment of newborns and basic resuscitation skills and actively apply these skills during simulated clinical scenarios both with a low- and high-fidelity manikin (90 minutes training time, six students per group).
1647340|NCT01875887|Procedure|rapid prototyping technology|Rapid prototyping technology was applied in treatment of bilateral maxillofacial post-traumatic deformities
1647341|NCT01875874|Biological|ELAD|Continuous treatment with the ELAD System for a minimum of 3 days to a maximum of 10 days. The subject's ultrafiltrated blood is circulated through 4 cartridges, each containing approximately 110 grams of C3A cells (approximately 440 grams total).
1647343|NCT01875848|Drug|buprenorphine/naloxone|partial opioid agonist
1647344|NCT01875848|Drug|opioid dose escalation|up to 25% increase in patient's current opioid dose
1647345|NCT01875835|Device|Xience™ V stent (Abbott Vascular, Santa Clara, California, USA)|
1647346|NCT01875835|Device|Multilink-Vision stent(Abbott Vascular, Santa Clara, California, USA)|
1647347|NCT01875822|Dietary Supplement|Super-Curcumin|The investigators are comparing the effects of the two dosages of Super-Curcumin@ capsules in the sample of subjects diagnosed as DSM IV-R schizophrenia
1647348|NCT01875796|Behavioral|Cognitive-Behavioral Therapy|
1647349|NCT01875796|Behavioral|Motivation Enhancement Therapy|
1647350|NCT01875796|Behavioral|Integrated Cannabis and Anxiety Reduction Treatment|
1647351|NCT01875796|Behavioral|False Safety Behavior Elimination Therapy|
1647352|NCT01875783|Device|OCT imaging|Optical coherence tomography (OCT) imaging is a noninvasive, rapid, and readily performed method for evaluating the anatomy of the central retina.
1647353|NCT01875757|Drug|Vitamin D3|
1647354|NCT01875757|Drug|Placebo|
1647355|NCT01875744|Drug|Polyethylene glycol 4000|
1647360|NCT01875705|Drug|GDC-0994|Escalating doses of GDC-0994 until maximum tolerated dose is reached
1647361|NCT01875705|Drug|GDC-0994|Recommended dose determined in Stage I-Dose Escalation phase, until disease progression
1647362|NCT01875679|Other|Comprehensive Surgical Coaching|
1647363|NCT01875679|Other|Conventional Surgical Training|Surgical training as per participant's residency program
1647364|NCT01875666|Drug|Trastuzumab|8 mg/kg IV, single dose
1647365|NCT01875666|Drug|pertuzumab|840 mg IV single dose
1647366|NCT01875666|Drug|lapatinib|1000 mg daily for 7 days
1647367|NCT01875653|Biological|Autologous Dendritic Cell-Tumor Cell Immunotherapy (DC-TC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
1647368|NCT01875653|Biological|Autologous PBMCs in GM-CSF (MC)|Comparison of a cancer treatment containing patient specific irradiated tumor cells mixed with antigen presenting immune cells suspended in an immune system stimulant vs. a cancer treatment containing patient specific immune cells suspended in an immune system stimulant
1647369|NCT01875627|Dietary Supplement|Konjac noodles|Replacement of carbohydrate noodles with non-caloric Konjac noodles (viscous gel meal)
1647370|NCT01875627|Dietary Supplement|Carbohydrate and Konjac Noodles|
1647371|NCT01875627|Dietary Supplement|Carbohydrate noodles|
1647372|NCT01875614|Device|Mapping with the Acutus Medical System followed by Ablation|
1647375|NCT01875575|Dietary Supplement|Placebo|
1647376|NCT01875575|Dietary Supplement|Glucose 25g|
1647377|NCT01875575|Dietary Supplement|Glucose 10g|
1647378|NCT01875562|Drug|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
1647379|NCT01875549|Device|stent insertion|to use a LCD stent at an unilateral or bilateral stent insertion
1647380|NCT01875549|Procedure|Endoscopic retrograde cholangiopancreatoscopy(ERCP)|to use ERCP for a stent insertion in an obstructive biliary tract
1647381|NCT01875536|Device|rTMS|The subjects were seated in a comfortable chair with head and arm rests. Focal TMS of the motor cortex was performed with a 70-mm figure-8 coil attached to magnetic stimulator stimulation parameters : frequency of 1Hz on the uninjured hemisphere by stroke; 1500 pulses with an intensity of 90% of MT 10 sessions of rTMS, one per day, always before conventional physical therapy
1647382|NCT01875536|Behavioral|conventional physical therapy|The physical therapy program was composed of the activities of flexibility, transfer and posture, strength, coordination, balance, and sensory stimulation. The physical therapy was applied for about 30 minutes, three days per week.
1647383|NCT01875523|Drug|Serelaxin|
1647384|NCT01875510|Dietary Supplement|Fish-oil emulsions|"Fish -oil emulsions:
Preterm infants will receive a fish-oil emulsion administered from the first day of life 1gr/kg, second day 2gr/kg and third day and after 3 gr/kg."
1647385|NCT01875510|Dietary Supplement|soybean-oil emulsion|soybean-oil emulsion
1647386|NCT01875497|Dietary Supplement|grape fruit (vitis vinifera) extract in capsule with 205 mg|Before the exercise the indivuduals intake only one capsule of the grape fruit extract with 205 mg. This dosage is free of contraindications according to others studies.
1647387|NCT01875471|Device|delefilcon A|Daily disposable soft contact lens to be worn at least 8 hours daily
1647388|NCT01875471|Device|narafilcon A|Daily disposable contact lens to be worn at least 8 hours daily
1647389|NCT01875445|Drug|Inositol|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
1647390|NCT01875445|Drug|Placebo|Taken as 2g of powder TID for 2 weeks, then 4g of powder TID for 2 weeks and then 6g of powder TID for the remainder of the study.
1647391|NCT01875419|Device|Transcranial direct current stimulation (tDCS)|"Patients - tDCS arm: 1 mA current delivered for 20 minutes once a week for 8 weeks, immediately prior to CBT.
Patients - Sham arm: brief current change at the beginning (0 min) and end of each stimulation session (20 min) in order to mimic the effect of an actual stimulation, but no current delivered in between."
1647392|NCT01875419|Behavioral|Cognitive Behavioural Therapy|8 sessions of one hour (once weekly) immediately after tDCS or sham stimulation
1647393|NCT01875406|Other|diagnostic exercises|
1647394|NCT01875393|Drug|TOOKAD® Soluble|The VTP procedure will consist of a single, 10 minute infusion of 4mg/kg TOOKAD® Soluble. The drug will be activated by laser light at 753nm, with a fixed energy of 200Joules/cm, and a fixed power of 150mWatts/cm, delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance.
1647395|NCT01875380|Drug|Regorafenib|
1647396|NCT01875367|Drug|Trastuzumab subcutaneous inyection vial|Subcutaneous injection vial with a fixed dose of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) identical to that provided by the device. 3 weeks x 2 cycles.
1647397|NCT01875367|Device|Trastuzumab subcutaneous device administration|Single injection device is provided and loaded with the mixture of trastuzumab (600mg) and recombinant human hyaluronidase (10.000U) and is ready for use. 3 weeks x 2 cycles
1647398|NCT01875354|Dietary Supplement|Dietary Supplements and TR90 Eating Plan|Supplements to maintain muscle, assist in utilization of body fat, curb appetite, support positive willpower along with TR90 Eating plan. TR90 Eating Plan will consist of approximately 30 g high quality protein along with fruit, vegetables and complex carbohydrates
1647399|NCT01875354|Dietary Supplement|Placebo and Low Fat Eating Plan|
1958025|NCT02043691|Device|Surgeon-Modified Endograft|The Surgeon-Modified Endografts are created in the operating room by modifying a commercially-available Cook Zenith or Cook TX2 device such that seal and fixation may be obtained proximal and distal to pathology in the juxtarenal aorta, suprarenal or thoracoabdominal aorta. Grafts may include a combination of up to 5 fenestrations and branches.
1647444|NCT01875042|Device|TENS|Transcutaneous electrical nerve stimulation
1717616|NCT00002192|Drug|Rifapentine|
1958027|NCT02041702|Procedure|Cardiac MRI scan|Patients who are randomized into the Cardiac MRI Scan group will undergo a Cardiac MRI scan
1647402|NCT01875328|Other|Telemedicine|Post stroke follow up in home using telemedicine.
1647403|NCT01875328|Other|Clinic|Post stroke clinic group follow up
1647404|NCT01875315|Other|Diagnostic Cardiac Imaging|
1647405|NCT01875289|Procedure|obturator nerve block|
1647406|NCT01875263|Drug|Cloxacilin|2g/4 hours i.v., 5 days
1647407|NCT01875263|Drug|Cloxacillin|2g/4h 14 days Standard therapy
1647408|NCT01875263|Drug|Levofloxacin|500 mg v.o./24h, 9 days
2012628|NCT01804790|Drug|mFolfirinox|Investigational arm: Neoadjuvant chemotherapy mFolfirinox, 4 cycles:oxaliplatin: 85 mg/m2 in 2 hours at D1 irinotecan: 180 mg/m² in 90 min at D1 folinic acid: 400 mg/m2 simultaneously in 2 hours at D1 during the irinotecan infusion 5FU : 2400 mg/m2 continuous infusion during 48 hours (1200 mg/m2 at D1 and D2), every 14 days during 2 months (4 cycles), then CRT (50 Gy (2 Gy/session, 25 fractions) + capecitabine 800mg/m2 bid 5 days/7), then surgery with TME 6-8 weeks after chemoradiation, and 4 months of adjuvant CT depending on ypTNM and center choice.
1647412|NCT01875237|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
1647413|NCT01875237|Drug|Melphalan|140 mg/m2 by vein on Day -2.
1647414|NCT01875237|Drug|Alemtuzumab|50 mg by vein on Day -1.
1647415|NCT01875237|Procedure|Stem Cell infusion|Stem cell infusion on Day 0. Goal is to administer more than 3 x 10^6 CD34+ cells/kg of peripheral blood progenitor cells (PBPC).
1647416|NCT01875237|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml) between Day +1 and Day +45. Tacrolimus is changed to oral dosing when tolerated. Tacrolimus tapering should start on approximately Day +35 with the intention for the patient to be completely off the drug by approximately Day +45.
1647417|NCT01875237|Drug|Mini Methotrexate|5 mg/m2 by vein on Days +1, +3, +6.
1647418|NCT01875237|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
1647419|NCT01875237|Procedure|Donor Lymphocyte Infusion (DLI)|iCasp9 (BPZ-1001)-Modified T-cells) of 3 X 10^6/kg in 100 ml infused over approximately a one hour period between Day + 56 to Day +64.
1647420|NCT01875237|Drug|AP1903|0.4 mg/kg as a 2 hour infusion for patients that present with a clinical diagnosis of grade I GvHD. For patients with a clinical diagnosis of grade > 2 GvHD, a single dose of AP1903 0.4 mg/kg as a 2 hour infusion will be administered. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Patients who experience a partial response within 72 hours may receive a second dose of AP1903. Patients whose GvHD is progressing after 7 days, have no response by 14 days, or are not in a complete response at day 28 can receive secondary therapy.
1647421|NCT01875237|Drug|Methylprednisolone|1.6 mg/kg per day by vein divided in 2 to 3 daily doses. Patients whose GvHD resolves as defined by a complete response within 72 hours, would have steroids stopped immediately. Patients who fail to achieve a complete response within 72 hours of an initial dose of AP1903, or within 48 hours of a second dose of AP1903, will be maintained on this dose for no less than 7 days. Steroids can then be tapered as tolerated to no less than 0.6 mg/kg per day at day 28.
1647422|NCT01875237|Behavioral|Questionnaire|Completion of a quality of life questionnaire that will take 10-15 minutes between Days + 28 and + 56, about twice a week until about 2 months after the T-cell infusion, and then 6 and 12 months after the stem cell transplant.
1647423|NCT01875224|Drug|Belatacept|
1647424|NCT01875224|Drug|Tacrolimus|Standard administration of tacrolimus
1647425|NCT01875198|Procedure|Radical Antegrade Modular Pancreatectomy with Splenectomy|
1647426|NCT01875198|Procedure|Radical Antegrade Modular Pancreatectomy without splenectomy|distal pancreatectomy without pancreatectomy
1958028|NCT02041702|Device|SJM MRI conditional pacing system implant|Patients in both arms of this study should receive SJM MRI conditional pacing system implant before randomization
1647428|NCT01875172|Drug|Bupropion SR|Comparison of bupropion SR or placebo + smoking cessation counseling
1647429|NCT01875172|Drug|placebo|
1647430|NCT01875172|Behavioral|smoking cessation counseling|
1647431|NCT01875159|Drug|Caffeine citrate 6 mg/kg/day|Comparison of caffeine citrate 6 mg/kg/day versus no caffeine (usual care) on extent of intermittent hypoxia at 35, 36, 37, 38, 39, and 40 weeks postmenstrual age.
1647432|NCT01875146|Other|4x4 min HIT|Conventional 4x4 min high-intensity interval training
1647433|NCT01875146|Other|4x4 min HIT + WBV (18 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 18 Hz during the active rest
1647434|NCT01875146|Other|4x4 min HIT + (30 Hz)|4x4 min high-intensity interval training in combination with whole-body vibration at 30 Hz during the active rest
1647435|NCT01875146|Other|whole-body vibration at 30 Hz|4x3 min whole-body vibration at 30 Hz
1647436|NCT01875133|Other|altitude exposure|stay at different altitudes: 490, 1630, 2590 m
1647437|NCT01875107|Drug|insulin pre-treatment|insulin pre-treatment of pregnant diabetic patients who receive betamethasone
1647438|NCT01875094|Other|Self-Management / MTM using Health IT|
1647439|NCT01875081|Biological|Livercellgram|"Livercellgram
Dosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip ② Component: Autologous bone marrow-derived mesenchymal stem cell ③ Amount: 5X107 cells, 1-time or 2-time injection ④ Storage Method: Stored in airtight container at 20~25℃
Injection Method: Directly inject into liver through hepatic artery"
1647440|NCT01875068|Behavioral|Consultations between NPs and PAs and their supervising physicians|Required discussion with physician prior to referral by a nurse practitioner or physician assistant
1647441|NCT01875068|Behavioral|versus NPs and PAs who are not required to discuss patient referrals (control group).|
1647442|NCT01875055|Device|NIRS and Algorithm|NIRS cerebral oximetry will be used to guide the use of an algorithm based on the modification of previously defined important physiologic variables will be initiated to reverse the desaturation (beginning when the saturation drops at least 10% from the baseline) that occur in the ICU
1647443|NCT01875055|Device|NIRS derived cerebral oximetry|NIRS sensors will be placed the forehead of the patient but NIRS derived data will be blinded to the ICU caregivers
1647445|NCT01875042|Device|Sham TENS|Sham Transcutaneous electrical nerve stimulation
1647446|NCT01875029|Device|sham-tDCS + back school|sham tDCS + back school
1647447|NCT01875029|Device|real-tDCS + back school|real tDCS + back school
1647448|NCT01875016|Procedure|CRyo-Ablation to Treat HOCM.|CRyo-Ablation to Treat Patients With HOCM.
1647449|NCT01875003|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at high or low dose Q4W.
1647450|NCT01875003|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection Q4W.
1647451|NCT01875003|Drug|Standard of Care|Participants will continue to receive ICS therapy (total daily dose of 500-2000 mcg fluticasone propionate DPI or equivalent) along with at least one second controller medications (e.g. long-acting beta agonists [LABAs], leukotriene receptor antagonists (LTRAs), long-acting muscarinic antagonists (LAMAs), or theophylline) as standard of care.
1647452|NCT01874990|Dietary Supplement|high sodium diet|The high-sodium diet was obtained by adding 6g of sodium chloride to the individual's regular diet
1647453|NCT01874990|Dietary Supplement|low-salt diet|
1647454|NCT01874977|Behavioral|Pedometer|Will receive the educational booklet and discussion, plus a pedometer and a diary to record their daily step counts from the pedometer.
1647455|NCT01874977|Behavioral|Educational materials|"Will receive the educational booklet (Be Active Your Way: A guide for Adults; http://www.health.gov/paguidelines/adultguide/default.aspx).and a discussion of simple ways to increase physical activity in daily life based on the booklet, following the baseline assessment."
1647456|NCT01874977|Behavioral|Step count goals|Will receive the educational booklet and discussion, and the pedometer and step diary, plus will be given individualized daily step targets.
1647457|NCT01874964|Behavioral|Methadone Maintenance|Individuals who are enrolled in methadone maintenance treatment at the time of incarceration are maintained on pre-incarceration dosage levels of methadone during short-term (6 months or less)incarceration. They will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
1647458|NCT01874964|Behavioral|Linkage to methadone maintenance|Individuals in the comparison arm will undergo methadone detoxification during short term incarceration, however, they will be actively assisted to return to their home clinic upon release and receive 10 financial assistance with treatment payments.
1647459|NCT01874951|Drug|Naltrexone|1 mg of naltrexone will be given twice daily to all patients assigned to active drug.
1647460|NCT01874951|Drug|Placebo|Placebo identical in appearance to naltrexone will be given twice daily to all patients assigned to placebo.
1647461|NCT01874938|Biological|LY2875358|Administered IV
1647462|NCT01874899|Device|RestoreSensor Neurostimulation|
1647463|NCT01874873|Drug|Anlotinib|
1647464|NCT01874860|Drug|Doxycycline|Doxycycline capsule, 100 mg, taken twice daily
1647465|NCT01874860|Drug|Hydrocortisone 1% cream|Applied to the face, hands, feet, neck, back, and chest each evening (Topical cream)
1647466|NCT01874860|Other|Sunscreen|Applied to exposed skin areas at least 30 minutes before going outdoors each morning.
1647467|NCT01874860|Other|Moisturizer|Applied to the face, hands, feet, neck, back, and chest each morning after sunscreen
1647468|NCT01874860|Drug|Clindamycin|Recommended for daily use if rash returns (Topical cream)
1647469|NCT01874860|Drug|Medrol-dose pack (Steroid)|Patients will receive a Medrol dose-pack while continuing the extensive treatment regimen.
1647470|NCT01874847|Dietary Supplement|Melatonin|Melatonin 10mg or 3mg capsule, one will be given at night, for 28 days
1647471|NCT01874847|Dietary Supplement|Sugar pill|Sugar pill will be given, one capsule, once at night, for 28 days
1647472|NCT01874834|Other|ozone|Exposure to 300 ppb ozone with intermittent exercise about 20 hr after exposure to each arm (ie, either air, ozone, diesel exhaust, or ozone combined with diesel exhaust)
1647473|NCT01874821|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
1647474|NCT01874821|Other|Standard of Care|The current Standard of Care for treating this condition includes corticosteroid injections and physical therapy.
1647475|NCT01874795|Device|TENS|Adhesive electrodes (MultiStick®, USA) were placed on each side, about 3 cm to the right and left of midline vertebral process, at C7 (Channel 1) and T4 (Channel 2).
1647476|NCT01874795|Device|Placebo|The frequency of stimulation was 80 Hz and the pulse duration was 150 μs, equipment did not provide stimulation current.
1647477|NCT01874782|Device|transcranial electrical stimulation|TES: medical device TRANSAIR: electrodes placed on the forehead and over the mastoid processes using Velcro straps. Treatment protocol: six 30-minute sessions over a two-week period and stimulation variables (bipolar current; 1.0-3.0 milliamp (mA) amplitude, 3.5 ms duration and 77.5 Hz frequency).
1647478|NCT01874769|Other|Blood collection|"5 ml of blood on dry tube: Verification of the absence of auto-antibodies to type VII collagen.
10 ml of blood sample on heparin: Verification of the absence of circulating reactive T-Lymphocytes clones to type VII collagen
5 ml of Blood samples on ethylenediaminetetraacetic acid (EDTA): HLA genotyping of patient selected on the clinical and molecular criteria."
1647479|NCT01874769|Other|Skin biopsies|"A 5-mm punch skin biopsy in the groin region performed under local anaesthesic will be undertaken during visit 1.
During the second visit, two additional 5-mm punch skin biopsies will be taken to assess stem cells proliferative capacity in 10 shortlisted patients"
2012629|NCT01804790|Radiation|Radiotherapy 50Gy|5 radiations per week of 2 Gy for 5 weeks
2012630|NCT01804790|Drug|Capecitabine|1600mg/m2 (800mg/m2 twice daily) for 5 weeks
2012631|NCT01804790|Procedure|TME surgery|
1647483|NCT01874743|Drug|Rosuvastatin 20 mg/day|All patients must take 20mg/day of rosavastatin during 3 months
1647484|NCT01874730|Other|Combined epidural-general anesthesia (CEGA)|Combined epidural-general anesthesia (CEGA) will be used intraoperatively and patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
1647535|NCT01874379|Other|'M'-Technique®|'M'-Technique is a series of gentle stroking movements performed in a set sequence, with a set pressure of 3 on a scale of 0-10.
1647536|NCT01874379|Other|Guided Imagery|Diane L. Tusek's Guided Imagery for Pre-Procedure/Surgery™ will be used.
1647485|NCT01874730|Drug|Volulyte® (6% HES 130/0.4 in balanced solution)|"For the SOC Group: Intraoperative fluid management includes Volulyte® (6% HES 130/0.4 in balanced solution) as the only colloid solution to be used, the daily dosage of Volulyte® is restricted to 50 ml/kg.
For the ERS Group:
GDFT regimen will be utilized using Volulyte® (6% HES 130/0.4 in balanced solution) during surgery. The daily dosage of Volulyte® is restricted to 50 ml/kg."
1647486|NCT01874730|Other|Patient-Controlled Epidural Analgesia (PCEA)|For the ERS Group, patient-controlled epidural analgesia (PCEA) will be used postoperatively in a multimodal analgesic regimen.
1647487|NCT01874717|Other|Conscious sedation for dental care|
1647488|NCT01874717|Drug|midazolam|
1647489|NCT01874704|Behavioral|Comparison of biomarkers of stress|
1647490|NCT01874678|Drug|TS-1/Cisplatin|
1647491|NCT01874665|Drug|ponatinib|45 mg taken orally once-daily
1647492|NCT01874652|Device|Light Weight Breast Implants|Light Weight Breast Implants
1647493|NCT01874639|Device|standard bipolar coagulation|
1647494|NCT01874639|Device|Aquamantys® probe for liver hemostasis|
1647495|NCT01874626|Drug|Placebo|Placebo cream
1647496|NCT01874626|Drug|SST-0225 Topical Ibuprofen Cream|SST-0225 Topical Ibuprofen Cream
1647497|NCT01874613|Device|FRC implant reconstruction|A cranioplasty with the FRC implant is performed.
1647498|NCT01874613|Device|FRC implant reconstruction|The orbital floor fracture is reconstructed with the FRC implant.
2012632|NCT01804790|Drug|mFolfox6 or capecitabine|oxaliplatine 85mg/m2 (day 1 of cycle; perfusion in 2h), folinic acid 400mg/m2 (day 1 of cycle perfusion in 2h), 5-fluorouracil (bolus 4OOmg/m2 in 10min and 2400mg/m2 perfusion continuous 46h). Arm A - 12 cycles ; Arm B - 6 cycles OR Capecitabine 2500mg/m2/day (Each cycle consists of 1250mg/m2 twice daily for D1-14 then pause therapeutic from D15-21). Arm A - 8 cycles; Arm B 4 cycles.
1647500|NCT01874587|Radiation|adaptative radiotherapy|weekly replanning
1647501|NCT01874574|Drug|Hylan G-F 20|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
1647502|NCT01874574|Drug|Corticosteroid|After full aseptic preparation, Single shot intra-articular injection either 6 mL of Hylan G-F 20 or 1 mL of 40 mg triamcinolone acetonide plus 5 mL of 1% xylocaine with adrenaline were injected into the joint cavity using the infero-lateral approach via a 21-gauge needle.
1647503|NCT01874561|Drug|Custirsen|Custirsen will be administered iv using an infusion pump over a 2-hour period.
1647504|NCT01874561|Drug|Placebo|Placebo (commercially available normal saline) will be administered iv using an infusion pump over a 2-hour period.
1647505|NCT01874561|Drug|Moxifloxacin|Moxifloxacin (400 mg) will be administered orally with 240 mL of room temperature still water.
2012633|NCT01804686|Drug|PCI-32765 (Ibrutinib)|PCI-32765 (Ibrutinib) will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent PCI-32765 clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at approximately the same time each day.
1647507|NCT01874522|Drug|TAS-102 tablets|"Crossover bioavailability part: 60 mg/dose, orally, up to 2 single doses separated by 1-week washout.
Extension part: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met."
1647508|NCT01874522|Drug|TAS-102 oral solution|60 mg/dose, orally, up to 2 single doses separated by 1-week washout
1647509|NCT01874509|Behavioral|Check Your Drinking|
1647510|NCT01874509|Behavioral|Alcohol Help Centre|
1647511|NCT01874496|Dietary Supplement|GDS, no meal|GDS, no meal
1647512|NCT01874496|Dietary Supplement|GDS, meal|GDS, meal
1647513|NCT01874496|Dietary Supplement|control, no meal|control, no meal
1647514|NCT01874496|Dietary Supplement|control, meal|control, meal
1647515|NCT01874483|Drug|Placebo|placebo
1647516|NCT01874483|Drug|BI 187004|BI 187004, dose 2
1647517|NCT01874483|Drug|BI 187004|BI 187004, dose 4
1647518|NCT01874483|Drug|BI 187004|BI 187004, dose 5
1647519|NCT01874483|Drug|BI 187004|BI 187004, dose 6
1647520|NCT01874483|Drug|BI 187004|BI 187004, dose 7
1647521|NCT01874483|Drug|BI 187004|BI 187004, dose 1
1647522|NCT01874483|Drug|BI 187004|BI 187004, dose 3
1647523|NCT01874470|Device|renal denervation|
1647524|NCT01874470|Other|standard medication|
1647525|NCT01874457|Biological|MMR (Mumps, Measles and Rubella)|MMR (Mumps, Measles and Rubella)
2012634|NCT01802333|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplant
2012635|NCT01802333|Drug|Cytarabine|Given IV
2012636|NCT01802333|Drug|Daunorubicin Hydrochloride|Given IV
2012637|NCT01802333|Drug|Idarubicin|Given IV
1647530|NCT01874431|Drug|Finerenone (BAY 94-8862)|
1647531|NCT01874431|Drug|Placebo|
2012638|NCT01802333|Other|Laboratory Biomarker Analysis|Correlative studies
1647533|NCT01874392|Drug|Investigational inhaled insulin (Technosphere)|by MannKind Corp. IND 61,729
1647534|NCT01874392|Device|Artificial Pancreas (AP) device (APS©)|"Device includes:
OneTouch® Ping® Glucose Management System with modified Meter-Remote from Animas® Corp or the OmniPod® Insulin Management System from Insulet Corp.
Dexcom® G4® CGM System (CGM) from Dexcom® Corp
Control algorithm: zone-Model Predictive Control (zone-MPC) with safety Health Monitoring System (HMS)"
2012639|NCT01802333|Drug|Vorinostat|Given PO
2012640|NCT01800773|Behavioral|Written Exposure Therapy|Written exposure therapy is a 5 session, weekly treatment in which individuals write about their trauma event in a specified manner.
2012641|NCT01800773|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is an evidence-based treatment for PTSD. CPT consists of 12, weekly sessions.
2012642|NCT01799278|Drug|MLN8237|MLN8237 will be administered orally. The study drug will be administered on an empty stomach with the patient remaining nothing by mouth (NPO), except for water and prescribed medications, for 2 hours before and 1 hour after each dose. Patients will be instructed to take each oral dose of MLN8237 with 8 ounces (1 cup, 240 mL) of water.
1647537|NCT01874379|Other|Standard of Care|Normal Procedures, no complementary medicine intervention.
1647538|NCT01874366|Drug|P11187|"Part I: Step wise dose escalation(10 to 1500 mg, qd, Oral)
Part II: Step wise dose escalation in multiple dosing (≤ 1500 mg, qd, Oral) for 14 consecutive days.
Part III: Study drug administered (≤ 1500 mg, qd, Oral) under fasted or fed conditions in two different periods separated by a wash-out interval."
1647539|NCT01874366|Drug|Placebo|"Placebo capsules will be matching in appearance with the active drug capsules of P11187.
In Part I, there will be up to 6 cohorts of 8 subjects each in single dose assessment. Two subjects from each cohort will be dosed with placebo
In Part II, there will be 3 cohorts of 12 subjects each and three subjects from each cohort will be dosed with placebo"
2012643|NCT01796314|Behavioral|Therapeutic Educational Program|"The intervention is a therapeutic educational programme as recommended in the care of Alzheimer's disease. It includes two consultations for the dyad AD patient/caregiver and four group sessions, one a week, for caregivers only. The intervention length is 2 months.
These collective sessions focus on :
Knowledge of the disease
Pharmacological and non pharmacological treatments. Behavioural and psychological symptoms of dementia
Crisis situations. Prevention of caregiver's exhaustion
Assistive devices and care pathways.
Monitoring will consist of a two consultations to 6 and 12 months including assessment of secondary outcome measures."
2012644|NCT01794104|Drug|LMP400|Top1 inhibitors such as LMP400 are potent anticancer agents because stabilizing cleavage complex formation induces replication-and transcription-mediated DNA damage and delays DNA repair, leading to apoptosis. Preclinical and clinical data indicate that baseline tumor levels of Top1 correlate strongly with ability to respond to Top1 inhibitor therapy.
1647542|NCT01874340|Drug|Placebo|Placebo will be administered at predefined visits over the 6-month treatment phase.
1647543|NCT01874340|Drug|AIN457|AIN457 will be administered at predefined visits over the 6-month treatment phase.
1647546|NCT01874314|Drug|SQ109|300mg or 450mg of SQ109 administered orally, once daily for 7 days.
1647547|NCT01874314|Other|SQ109 Placebo|Placebo is a round, coated, yellow, unscored tablet. SQ109 Placebo administered orally, once daily for 7 days.
1647548|NCT01874314|Drug|Moxifloxacin|400mg of moxifloxacin (positive control) administered orally, once daily for 7 days.
1647549|NCT01874301|Other|High quantity probiotic|The intervention type is food product
1647550|NCT01874301|Other|Low quantity probiotic|The intervention type is food product
1647551|NCT01874301|Other|placebo|
1647552|NCT01874288|Drug|0.5 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
1647553|NCT01874288|Drug|1.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
1647554|NCT01874288|Drug|2.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
1647555|NCT01874288|Drug|4.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
1647556|NCT01874288|Drug|6.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
1647557|NCT01874288|Drug|8.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
1647558|NCT01874288|Drug|10.0 mg/m2 DI-Leu16-IL2|If dose limiting toxicities are observed in one of the initial three patients enrolled in a dose level, then, another three patients must be enrolled at the same level before dose escalation can proceed. Each patient will receive the same dose level assigned at the time of enrollment. No intra- patient dose escalation will be permitted.
1647559|NCT01874275|Device|VECTTOR|"The VT-200, or VECTTOR system, delivers electrical stimulation via electrodes on the acupuncture points of a patient's feet/legs and hands/arms to provide symptomatic relief of chronic intractable pain and/or management of post-surgical pain.
Once these electrodes are placed, the machine determines the appropriate choice of stimulation by automatically measuring body temperatures through the use of thermistors placed on the fingers during a testing sequence."
1647560|NCT01874262|Device|Mobile-phone based patient support|The mobile-phone based patient support (investigational medical device) is a stand-alone software product used on the patients' own smart phone and used in addition to medical treatment.
1647561|NCT01874262|Device|e-diary|All patients (active and control group) participating in the study will report their daily use of ticagrelor in an e-diary which will be initiated on all study patients' smart phones.
1647562|NCT01874249|Other|Electronic detailed information|Electronic detailed information about non alcoholic fatty liver disease.
1647563|NCT01874249|Other|NAFLD Score|diagnosis of advanced fibrosis by NAFLD score, calculated according to Hepatology 2007;45(4):846-854
1647564|NCT01874249|Other|Transient elastography|Transient elastography values greater than 8 kPa
1647565|NCT01874236|Drug|0.75% bupivacaine|Week 1: SI joint injection with .75% bupivacaine Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint sham block
1647844|NCT01872000|Procedure|Cataract surgery|
1647845|NCT01871987|Drug|FK949E|oral
1647566|NCT01874236|Drug|.75% bupivacaine|Week 1: SI join sham block Week 2: SI joint injection with .75% bupivacaine Week 3: SI joint injection with .75% bupivacaine
1647567|NCT01874236|Drug|.75% bupivacaine|Week 1: SI join injection with .75% bupivacaine Week 2: SI join sham block Week 3: SI joint injection with .75% bupivacaine
1647568|NCT01874197|Device|B-TEVAR device|Creation and implantation of the Branched Thorcoabdominal aortic anerysm device
1647569|NCT01874184|Other|counseling intervention|Take part in weekly group counseling sessions
1647570|NCT01874184|Behavioral|behavioral dietary intervention|Set goals for changing dietary habits
1647571|NCT01874184|Behavioral|exercise intervention|Attend group exercise activities
1647572|NCT01874184|Other|questionnaire administration|Ancillary studies
1647573|NCT01874184|Other|laboratory biomarker analysis|Correlative studies
1647574|NCT01874171|Drug|Cisplatin|
1647575|NCT01874171|Drug|Cetuximab|
1647576|NCT01874145|Drug|GA 20 mg/mL|Glatiramer acetate (GA) 20 mg/mL subcutaneous (SC) injection, the commercial product, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
1647577|NCT01874145|Drug|GA 40 mg/mL|Glatiramer acetate (GA) 40 mg/mL subcutaneous (SC) injection, is a single-use pre-filled syringe (PFS) containing 1.0 ml of a clear, colorless to slightly yellow, sterile, non-pyrogenic solution.
1647578|NCT01874132|Behavioral|Exercise training|Both training programs were of moderate-to-vigorous intensity, three days per week for nine months.
1647579|NCT01874119|Drug|Fosaprepitant|During treatment admission, intravenous fosaprepitant 150 mg every 48 hours during 6-day hospital admission
1647580|NCT01874106|Other|Diet Therapy|The patients in this arm were educated to follow a especial type of diet (anti-inflammatory diet)in addition to nutrition counseling for 10 weeks.
1647581|NCT01874106|Other|Control Group|The patients in this arm received nutrition counseling and education in general based on their needs as a control group for 10 weeks.
1647582|NCT01874093|Device|The Ischemic Stroke System|SPG stimulation and standard of care
1647583|NCT01874093|Device|Sham control|Sham stimulation and standard of care
1647584|NCT01874080|Drug|Saxagliptin/Metformin|
1647585|NCT01874067|Device|Arthritis glove|Isotoner three-quarter finger arthritis glove
1647586|NCT01874054|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
1647587|NCT01874054|Drug|bendamustine|90 mg/m2 on Days 1 and 2 of 3-week cycles
1647588|NCT01874041|Other|Massage|
1647589|NCT01874041|Other|Occlusal splint|
1647590|NCT01874028|Drug|trientine dihydrochloride|Patients will take their normal prescribed dose (x1) of trientine dihydrochloride 300mg
1647591|NCT01874015|Biological|mesenchymal cell transplantation|Mesenchymal cell transplantation in patients with Crohn's disease.
1647592|NCT01874015|Biological|mesenchymal cell and fibroblast injection|Transplantation of mesenchymal cell and fibroblast in patients with crohn's disease.
1647593|NCT01874002|Device|Combo stent|Percutaneous coronary intervention of patients with an indication for stent treatment with the COMBO stent, a stent with an endothelial progenitor cell attracting coating and abluminal sirolimus matrix. All consecutive patients treated with, or attempted treatment with, a COMBO stent are followed by telephone contact for 5 years.
1647594|NCT01873989|Drug|Testosterone replacement|
1647595|NCT01873989|Other|Waitlist control|
1647596|NCT01873950|Drug|Ranolazine|
1647597|NCT01873950|Drug|Dofetilide|
1647598|NCT01873950|Drug|Verapamil|
1647599|NCT01873950|Drug|Quinidine sulfate|
1647600|NCT01873950|Drug|Placebo|
1647601|NCT01873937|Radiation|Red LED|Phototherapy with red LED on temporomandibular area
1647602|NCT01873937|Radiation|INFRARED LED|Phototherapy with infrared LED on temporomandibular area
1647603|NCT01873937|Radiation|LASER|Phototherapy with LASER INFRARED on temporomandibular area
1647604|NCT01873898|Device|Rex Medical Closer™ Vascular Closure System|The Rex Medical CloserTM Vascular Closure System is currently being investigated for use in closing and reducing time to hemostasis at the femoral arterial puncture site in subjects who have undergone diagnostic angiography procedures or interventional procedures using up to a 7 French procedural sheath. This study will evaluate the safety and efficacy of the Rex Medical CloserTM Vascular Closure System to close the femoral artery access site of subjects who have undergone diagnostic angiography procedures with early ambulation and discharge as soon as possible after sheath removal and device placement.
1647605|NCT01873885|Drug|Placebo Single IV (Intravenous) Infusion|0.9% Sodium Chloride - 30 minute IV infusion
1647606|NCT01873885|Drug|Experimental: Single IV Infusion Vasomera (PB1046)|
1647607|NCT01873872|Dietary Supplement|Theralac probiotic|
1647608|NCT01873872|Dietary Supplement|Culturelle probiotic|
1647609|NCT01873872|Other|placebo|
1647610|NCT01873859|Drug|Metformin|Incidence of lactic acidosis in diabetic patients receiving contrast media in the presence of metformin.
1647611|NCT01872741|Procedure|Minipterional craniotomy|Minipterional craniotomy approach for ruptured and unruptured aneurysms
1647612|NCT01872741|Procedure|Pterional craniotomy|Pterional craniotomy approach for ruptured and unruptured aneurysm
1647613|NCT01873833|Drug|capecitabine|Given PO
1647614|NCT01873833|Drug|cyclophosphamide|Given PO
1647615|NCT01873833|Drug|lapatinib ditosylate|Given PO
1647616|NCT01873833|Biological|trastuzumab|Given IV
1647617|NCT01873833|Other|laboratory biomarker analysis|Correlative studies
1647618|NCT01873820|Dietary Supplement|Calcium ascorbate|
1647619|NCT01873820|Dietary Supplement|Ascorbic acid|
1647620|NCT01873807|Drug|IDA|Idarubicin: 15mg/m2/d: -8->-6d
1647621|NCT01873807|Radiation|TBI|TBI: 4.5 Gy/d, -5d, -4d
1647622|NCT01873807|Drug|CTX|CY:60mg/kg/d, -3d, -2d
1647623|NCT01873807|Drug|VP-16|VP-16: 15mg/kg, -2d, -1d
1647624|NCT01873794|Device|Bright white light|
1647625|NCT01873794|Device|Dim red light|
1647626|NCT01873781|Drug|Cyclopentolatehydrochloride|Cyclopentolatehydrochloride 0.5% (Thilo, Alcon, Vienna), dose: 1 drop for study eye
1647846|NCT01871974|Drug|FK949E|oral
1647847|NCT01871961|Drug|Methotrexate (Metoject® prefilled pen)|
1717741|NCT00002251|Drug|Ganciclovir|
1647627|NCT01873768|Drug|Tranexamic Acid (TXA)|1g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 1g in 250cc of saline will be infused over 30 minutes beginning at the time of wound closure.
1647628|NCT01873768|Drug|ε-Aminocaproic Acid (EACA)|7g in 250cc of saline given over 30 minutes just prior to raising the tourniquet and making the initial incision. A second 7g of EACA in 250cc saline will be infused over 30 minutes beginning at the time of wound closure.
1647629|NCT01873755|Behavioral|asthma physical activity intervention|School- and community-based intervention includes several components: a classroom-based physical activity program, asthma awareness week at the school, asthma education for parents and students enrolled in the study, collaboration with child's physician to ensure proper medical treatment of child's asthma asthma education for school personnel
1647630|NCT01873742|Other|STIC feedback system|This condition includes the use of the STIC feedback system.
1647631|NCT01873729|Drug|Naltrexone|Adults with ADHD
1647632|NCT01873716|Drug|Indocyanine green|Indocyanine green (ICG) for injection, 0.25mg/kg intravenously. A maximum of 25mg is given, approximately 30-60 minutes before carotid endarterectomy
1647633|NCT01873703|Drug|pracinostat|Histone deacetylase inhibitor (HDACi)
1647634|NCT01873703|Drug|Placebo|Placebo
1647635|NCT01873703|Drug|Azacitidine|Active comparator 75 mg/m2 Azacitidine for 7 days of each 28 day cycle, via subcutaneous (SC) injection or intravenous infusion if SC injections are intolerable
1647636|NCT01873690|Drug|Ciprofloxacin|Once, 400 mg IV
1647637|NCT01873690|Drug|Placebo|5% Dextrose in water
1647638|NCT01873677|Drug|M518101|
1647639|NCT01873677|Drug|Vehicle|
1647640|NCT01873664|Behavioral|Jaw-tapping|to tap their jaws vertically at 1.6 Hz at home twice a day for 30 seconds every day during four weeks.
1647641|NCT01873651|Device|Implantation of a Delta III Prosthesis|Implantation of a Delta III Prosthesis
1647642|NCT01873638|Procedure|Cholecystectomy|
1647643|NCT01873625|Biological|mesenchymal cell transplantation|Mesenchymal stem cell transplantation in patients with rheumatoid arthritis for resurfacing of articular cartilage of knee due to osteoarthritis.
1647644|NCT01873625|Biological|placebo|
1647645|NCT01873612|Procedure|Hypoxic ventilatory response|
1647646|NCT01873612|Procedure|Hypercapnic ventilatory response|
1647647|NCT01873599|Behavioral|Positive Affect Journaling|
1647648|NCT01873586|Device|OsteoStrux Collagen Ceramic Scaffold|OsteoStrux Collagen Ceramic Scaffold
2012645|NCT01792375|Procedure|Concurrent membrane sweeping with Dinoprostone|"Women assigned to Sweep had their cervix swept by inserting the examining finger as high as possible past the internal cervical os, immediately followed by the placement of a 10mg Dinoprostone vaginal insert in the posterior fornix."
2012646|NCT01792375|Drug|10mg Dinoprostone vaginal insert|"For women assigned to No sweep: The only 10mg Dinoprostone vaginal insert were placed in the posterior fornix for cervical ripening"
2012647|NCT01790113|Device|Univers™|Control
1647652|NCT01873547|Procedure|cell therapy|Mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture.
1647653|NCT01873547|Other|rehabilitation|Patients only receive rehabilitation of limb function.
1647654|NCT01873534|Drug|FMX-8|FMX-8 is a fusion protein of the human hemojuvelin (HJV) protein.
1647655|NCT01873521|Procedure|Non invasive ventilation|
1647656|NCT01873508|Drug|RO4917523|Fast release MR capsule, single dose
1647657|NCT01873508|Drug|RO4917523|Target release MR capsule, single dose
1647658|NCT01873508|Drug|RO4917523|Slow release MR capsule, single dose
1647659|NCT01873508|Drug|RO4917523|[13C]-labeled tracer dose i.v.
1647660|NCT01873495|Drug|Omacetaxine|"Omacetaxine 1.25 mg/m² sub-cutaneously twice daily for 5 consecutive days every 28 (± 8) days for 3 cycles.
Patients in continuous remission after 3 cycles of consolidation will receive maintenance omacetaxine 1.25 mg/m² twice daily for 3 days, every 28 days for up to 6 cycles"
1647661|NCT01873482|Behavioral|Movement to rhythm|Movement to rhythm
1647662|NCT01873469|Radiation|Radiochemotherapy|postoperative radiochemotherapy 60 Gy/ Temozolomide
1647663|NCT01873456|Other|multifactorial nutritional intervention|
1647664|NCT01873443|Drug|Rituximab, MTX, folic acid|Rituximab IV 1000mg MTX 10~25mg/week Folic acid at least 5mg/week
1647665|NCT01873430|Drug|Melatonin|
1647666|NCT01873417|Drug|BG00012 (DMF)|
1647667|NCT01873404|Drug|BG00010|As specified in the treatment arm
1647668|NCT01873404|Drug|Placebo|As specified in the treatment arm
1647669|NCT01873391|Procedure|Diagnostic hysteroscopy|
1647670|NCT01873378|Drug|Triptorelin 3.75 mg|
1647671|NCT01873365|Other|Data collection|Case report forms (CRFs), logbooks and booklets.
1647672|NCT01873352|Procedure|catheter ablation|Patient anesthesia will be administered according to standard EP lab protocol. Arterial and venous access will be achieved through cannulation of the right and/or left femoral arteries and veins as per the usual practice of the EP lab. Full systemic anticoagulation will be instituted as per standard hospital procedures to a target ACT of approximately 300 seconds or greater. Intravascular ultrasound may be used to assist in the positioning of study catheters during the procedure. The AF ablation procedure will be performed using a cryoballoon ablation catheter. Complete pulmonary vein isolation will be the goal of the ablation procedure and PV isolation must be confirmed by a multielectrode mapping catheter within each PV. Pulmonary vein isolation is the only intervention. A cavo-tricuspid isthmus line may be placed in patients with either a history of ECG-determined typical flutter or induced typical flutter during the procedure.
1647712|NCT01873066|Device|Closed-loop system|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
1647713|NCT01873066|Device|real-time CGM|Subject's glucose level is controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
2012648|NCT01790113|Device|Eclipse™ Total Shoulder Replacement|Investigational
2012649|NCT01790100|Drug|VX-135|12 weeks of VX-135
2012650|NCT01790100|Drug|Ribavirin|12 weeks of ribavirin
2012651|NCT01790152|Other|Assessment of Therapy Complications|Ancillary studies
1647673|NCT01873352|Procedure|renal sympathetic denervation|Right or left femoral artery access. Real-time 3D aorta-renal artery maps constructed with the use of a navigation system and ablation catheter. Mapping and ablation performed after PVI and under identical sedation protocol used for AF ablation. RF delivery of 6 watts to be applied discretely from the first distal main renal artery bifurcation all the way back to the ostium; RF duration of each delivery 1.5 mins; lesions delivered at multiple sites based on multipolar catheter position within renal artery. Use of specifically designed RF delivery system for renal artery denervation is mandatory (RDN). To confirm renal denervation, high-frequency stimulation (HFS) will be applied before the initial and after each RF delivery within the renal artery. Rectangular electrical stimuli will be delivered at the ostium of the targeted renal artery at a frequency of 20 Hz, with an amplitude 15 V and pulse duration of 10 ms for 10 secs.
1647674|NCT01873339|Drug|Darapladib|The subjects will receive darapladib 160 mg once daily on Days 3-14. It is provided as Enteric coated, free base (micronized) 160 mg tablet.
1647675|NCT01873339|Drug|Midazolam|The subjects will receive a single oral dose of midazolam 5 mg on Day 1, 3 and14. It is provided as syrup. Each mL of syrup contains midazolam hydrochloride equivalent to 2 mg midazolam
1647676|NCT01873326|Drug|Paclitaxel|
1647677|NCT01873326|Drug|Ifosfamide|
1647678|NCT01873326|Drug|Cisplatin|
1647679|NCT01873326|Drug|Mesna|
1647680|NCT01873326|Drug|Bleomycin|
1647681|NCT01873326|Drug|Etoposide|
1647682|NCT01873313|Drug|Ropivacaine|
1647683|NCT01873300|Procedure|Endoscopic Esophageal Myotomy|Endoscopic mucosotomy, with submucosal tunneling and circular muscular fiber myotomy and mucosa closure.
1647684|NCT01873274|Dietary Supplement|MK-7 containing capsule|
1647685|NCT01873274|Dietary Supplement|basic yogurt enriched with MK-7|
1647686|NCT01873274|Dietary Supplement|nutrient-enriched yogurt with MK-7|
1647687|NCT01873248|Drug|68Ga-DOTATATE|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image Neuroendocrine tumors by Positron Emission Tomography.
1647688|NCT01873222|Device|OFDI-guided PCI & IVUS|"Assessment by IVUS at post-PCI
Assessment by OFDI at a 8-month follow-up"
1647689|NCT01873222|Device|IVUS-guided PCI & OFDI|"Assessment by OFDI at post-PCI
Assessment by OFDI at a 8-month follow-up"
1647690|NCT01873196|Behavioral|Receive extra oil|
1647691|NCT01873196|Behavioral|Receives behavior changed messages on CSB package|
1647692|NCT01873183|Other|Goal directed fluid therapy|
1647693|NCT01873170|Drug|levonorgestrel exposure|
1647694|NCT01873170|Drug|DMPA exposure|
1647695|NCT01873170|Drug|etonogestrel exposure|
1647696|NCT01873170|Device|IUD insertion|
1647697|NCT01873170|Device|subdermal contraceptive implant insertion|
1647698|NCT01873157|Drug|Bortezomib|"Patients will receive two cycles of Bortezomib (Velcade®) at an interval of three months.
Each cycle will consist of intravenously administered (within 3-5 seconds) Bortezomib 1.3 mg/m2 twice weekly on days 1, 4, 8 and 11."
1647699|NCT01873157|Drug|Placebo|"Patients will receive two cycles of Placebo (NaCl solution) at an interval of three months.
Each cycle will consist of intravenously administered (within 3-5 seconds) Placebo twice weekly on days 1, 4, 8 and 11."
1647700|NCT01873144|Drug|Epinephrine 1/1000|Nebulization of 0.5 mL/kg (maximum 3 mL) of epinephrine 1/1000 every 4h for three times and afterwards at physician in charge criteria
1647701|NCT01873144|Drug|HSS 3%|Nebulization 2 mL of HSS (3%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
1647702|NCT01873144|Device|HHHFNC|Precision Flow (Vapotherm Inc. Stevensville, Maryland, US ) and RT329 (Fisher and Paykel Healthcare, Auckland, New Zealand) were the dispositive used depending on the availability. Fisher and Paykel nasal cannula was used in both devices, depending on age
1647703|NCT01873144|Drug|NS (0.9%)|Nebulization of 2 mL of NS (0.9%)+ epinephrine every 4h for three times and afterwards at physician in charge criteria
1647704|NCT01873131|Drug|topical timolol maleate|Timolol maleate 0.5% ophthalmic solution will be used. The dose will be 1 drop per square centimeter of hemangioma, rubbed into the area by the parent/guardian twice daily. The intent is to cover the entire lesion without excess of medication. Therefore, the dose can be lowered from 1 drop/cm2 at the discretion of the investigators, but not increased. This dose should not have significant systemic side effects given that the normal systemic intravenous dose for propanolol is 2mg/kg/day and there would be much less systemic absorption if the solution is applied topically. It is well established that the stratum corneum greatly slows the transport of timolol.
1647705|NCT01873131|Device|Pulsed dye laser|A 595-nm PDL (V-beam Perfecta, Candela Corp, Wayland, MA, USA) with a dynamic cooling device (DCD) will be utilized for all treatments. This device is cleared by the FDA for clinical treatment of vascular lesions. Protective eyewear for patient and all participants in the treatment room will be provided. A spot size of 7 or 10 mm will be used with an average fluence (energy delivered per unit area, in J/cm2) of 9 J/cm2 (range 8-10.0 J/cm2). Fluence will vary according to patient and hemangioma characteristics, including age, skin type, location, lesion thickness and response to treatment. A 30-50 ms cryogen spray cooling (CSC) duration will precede the laser pulse duration of 0.4 ms.
1647706|NCT01873118|Other|RN-RHDS protocol|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)
1647707|NCT01873118|Other|RN-RHDS+PT-RHDS protocol|The discharging nurse obtains and reviews patient self-report of discharge readiness using the Readiness for Hospital Discharge Scale - Patient version and then completes the Readiness for Hospital Discharge Scale (RN version)
1647708|NCT01873118|Other|RN-RHDS + PT-RHDS + NIAF|The discharging nurse assesses each patient being discharged home using the Readiness for Hospital Discharge Scale (RN version)after reviewing the patients self-perception of discharge readiness (PT-RHDS) and then records any actions taken in response to the discharge readiness assessment on the Nurse Initiated Action form (NIAF). When any item on the RN-RHDS is less than 7, an action is required.
1647709|NCT01873105|Other|Health Team Educational Intervention|AHRQ TeamStepps processes will be used to redesign health team discharge communication processes and an educational intervention for health care team members
1647710|NCT01873079|Drug|Esomeprazole|
1647711|NCT01873079|Other|Standard care|No PPI or other study medication given
1647714|NCT01873053|Drug|WIN-34B|Patients assigned to Experimental group(1st or 2nd group) take WIN-34B 450mg or WIN-34B 900mg BID for 12weeks
2012652|NCT01790152|Other|Laboratory Biomarker Analysis|Correlative studies
2012653|NCT01790152|Other|Quality-of-Life Assessment|Ancillary studies
1647718|NCT01873027|Device|OFDI|"OFDI-guided PCI and assessment by OFDI at pre-PCI and post-PCI
Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
1647719|NCT01873027|Device|IVUS|"IVUS-guided PCI and assessment by IVUS at pre-PCI and post-PCI
Follow-up contact at the time of hospital discharge, 8 months and 12months after PCI"
1647720|NCT01873014|Drug|chinese herbs-I|two agent per day, twice a day
1647721|NCT01873014|Drug|chinese herbs-II|two agent per day, twice a day
1647722|NCT01873001|Drug|Pioglitazone HCl|15 mg tablet administered by mouth on Day 1, and Day 8 1 hour after study drug administration
1647723|NCT01873001|Drug|Abiraterone acetate|1000 mg tablets administered by mouth on Day 8
1647724|NCT01872988|Drug|Tenofovir|Administer Tenofovir to HCC patients who are indicated for TACE after randomization
1647725|NCT01872988|Drug|Placebo|Administer Placebo to HCC patients who are indicated for TACE after randomization
1647726|NCT01872975|Radiation|regional nodal XRT|
1647727|NCT01872975|Radiation|chestwall XRT|
1647728|NCT01872975|Radiation|WBI|
1647729|NCT01872962|Drug|gemcitabine and cisplatin (Induction chemotherapy)|Patients receive gemcitabine (1000 mg/m² d1,8) and cisplatin (80mg/m² d1) every 3 weeks for 3 cycles before concurrent chemoradiotherapy.
1647730|NCT01872962|Radiation|IMRT and concurrent cisplatin|Intensity modulated-radiotherapy (IMRT) is given as 2.0-2.30 Gy per fraction with five daily fractions per week for 6-7 weeks to a total dose of 66 Gy or greater to the primary tumor, concurrently with cisplatin 100 mg/m² every 3 weeks for 3 cycles.
1647731|NCT01872936|Drug|Miravirsen|
1647732|NCT01872936|Drug|Telaprevir|
1647733|NCT01872936|Drug|Ribavirin|
1647734|NCT01872923|Drug|Amphinex|Photosensitiser
1647735|NCT01872923|Drug|Bleomycin|Anticancer agent
1647736|NCT01872923|Device|Laser|Laser that emits red light at 652 nm.
2012654|NCT01790152|Other|Questionnaire Administration|Ancillary studies
2012655|NCT01789567|Device|Engager™ aortic valve|Implantation of the Medtronic Engager™ bioprosthesis via direct aortic approach
2012656|NCT01789645|Other|Conservative group|The conservative group will received 3 treatment sessions of physical therapy based on neuromodulation of nociceptive processing of 30 minutes of duration, once per week.
1647740|NCT01872897|Drug|Sodium Alginate Double Action Tablets|Four tablets as a single dose
1647741|NCT01872897|Drug|Placebo|4 tablets as a single dose
2012657|NCT01789645|Procedure|Surgical group|The surgical group will receive the surgical procedure consisting of the decompression and release of the median nerve at the carpal tunnel performed by an experienced surgeon according to standardized protocols.
2012658|NCT01788410|Procedure|Cryoablation under image guidance|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
1647746|NCT01872858|Drug|Aspirin|Aspirin, 100mg, Q.D, p.o, 2yr
1647747|NCT01872858|Drug|Cilostazol|cilostazol, 100mg, B.I.D, p.o, 2yr
1647748|NCT01872845|Drug|Pravastatin 40mg|Pravastatin 40mg PO daily for 1year from the day of BES implantation
1647749|NCT01872845|Drug|Rosuvastatin|Rosuvastatin 20mg PO daily for 1year from the day of BES implantation
1647750|NCT01872832|Drug|RDEA3170 and Placebo|
1647751|NCT01872819|Other|antitumor drug screening assay|Undergo high throughput drug sensitivity assay
1647752|NCT01872819|Drug|chemotherapy|Patients receive 1 of 160 possible interventions
1647753|NCT01872819|Biological|biological therapy|Patients receive 1 of 160 possible interventions
1647754|NCT01872806|Radiation|a dialing smartphone will be placed on the chest and the ear|
1647755|NCT01872780|Drug|Rosiglitazone|single oral administration of 4mg of rosiglitazone
1647756|NCT01872780|Genetic|CYP2C8 genotype|CYP2C8*11.
1647757|NCT01872754|Drug|1: Remifentanil|1: Remifentanil group The infusion of Remifentanil by TCI begins at distance from the introduction of fiberoptic. The effect site target is 4 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 1 ng / ml effect site concentration) separated by 1 minute intervals until an OAAS score of 4 and respiratory frequency range between 10 and 20 cycles per minute.
1647758|NCT01872754|Drug|2: Propofol|2: Propofol group- The infusion of Propofol by TCI begins at distance from the introduction of fiberoptic. The effect site target is 2,5 ng / ml.- A titration in increments or decrements (respectively increase or decrease of 0.5 mg / ml concentration effect site) separated by 1 minute intervals until an OAAS score of 4 and included respiratory rate between 10 and 20 cycles per minute.
1647759|NCT01872728|Drug|Bilateral facial block after general anesthesia before surgery|Bilateral facial block (infraorbital and infratrochlear) after general anesthesia before surgery with intravenous placebo or bilateral block with placebo and intravenous morphine
1647760|NCT01872715|Drug|Oracea|
1647761|NCT01872702|Drug|malaria elimination using DP and low-dose primaquine|Treatment of all persons resident in the intervention villages including those who do not have malaria parasites as detected by rapid diagnostic test. This is to interrupt p.f malaria transmission by removing the reservoir of all potentially infectious people from the area.
1647765|NCT01872676|Other|Spine manipulation|
1647766|NCT01872676|Other|Manipulation sham|
1647767|NCT01872663|Procedure|Continuous positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
1647768|NCT01872663|Procedure|Incentive spirometry|The volume of incentive spirometry (Voldyne ®) is able to provide increased transpulmonary pressure gradient, which can prevent or reverse atelectasis.
1647769|NCT01872663|Procedure|Breath Stacking|The method allowed to obtain a maximum lung expansion with minimal patient compliance.
1647805|NCT01872403|Drug|nanoparticle albumin-bound paclitaxel/carboplatin|Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
1647770|NCT01872663|Procedure|Expiratory Positive Airway Pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
1647771|NCT01872663|Procedure|Intermittent positive pressure breathing|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
1647772|NCT01872663|Procedure|Bi-level positive airway pressure|The use of positive pressure airway seeking the prevention or treatment of hypoxic respiratory failure, improved arterial oxygenation, restoration or maintenance of lung volume reduction and atelectasis, decrease the work of breathing, decreased dyspnea index and increased residual volume.
1647773|NCT01872650|Device|C-Qur|In subjects assigned to the treatment arm, the C-Qur™ Film must be applied beneath the incision. The C-Qur™ film can also be applied to other areas considered to be adhesiogenic (e.g. the dissection site and ostomy site but not around the anastomosis). The number of C-Qur™ Film sheets placed is limited to a maximum area of coverage of 774cm2.
1647774|NCT01872637|Behavioral|Progressive Multi-Component Intervention|
1647775|NCT01872637|Behavioral|Usual Care|
1647776|NCT01872624|Procedure|Bronchoscopy|Bronchoscopic delivery of one-way valves and bone-marrow derived mesenchymal stromal cells.
1647777|NCT01872611|Drug|Nepafenac Ophthalmic Suspension, 0.3%|
1647778|NCT01872611|Other|Vehicle|Inactive ingredients used as placebo comparator
1647779|NCT01872611|Drug|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
1647780|NCT01872598|Drug|Group 1|
1647781|NCT01872598|Drug|Group 2|
1647782|NCT01872598|Drug|Group 3|
1647783|NCT01872585|Behavioral|Mentalization based therapy|12-24 weekly 1 hour individual therapy sessions with Masters level therapists who are trained and supervised by Dr. Suchman (the Principal Investigator) in the Parenting from the Inside Out approach. The broad goals of the program are to help prevent the onset of substance abuse and psychiatric disorders, promote adaptive interpersonal relationships and social-emotional functioning in caregivers and their children, and help prevent the transmission of psychiatric illness across generations
1647784|NCT01872572|Drug|Subcutaneous RB006 0.5 mg/kg|Subcutaneous RB006 0.5 mg/kg
1647785|NCT01872572|Drug|Subcutaneous RB006 1.0 mg/kg|Subcutaneous RB006 1.0 mg/kg
1647786|NCT01872572|Drug|Subcutaneous RB006 3.0 mg/kg|Subcutaneous RB006 3.0 mg/kg
1647787|NCT01872572|Drug|Subcutaneous RB006 2.0 mg|"Arm 1: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 72 hours post-RB006 administration
Arm 2: 4 subjects received an IV bolus injection of 1 mg/kg RB007 at 24, 72, and 120 hours post-RB006 administration."
1647788|NCT01872572|Drug|Placebo|Placebo
1647789|NCT01872559|Other|3D Sonography analysis|Those patients who are scheduled to have an ultrasound as part of their infertility treatment will be offered the opportunity to have additional measurements done at the time of their ultrasound; these additional measurements will take less than 2 minutes and do not require any additional sonograms, tests, or interventions.
1647790|NCT01872546|Drug|HUMIRA 40mg|
1647791|NCT01872533|Other|Hypoxia Exposure|Participants spent 10 consecutive nights (approximately 100 hours of exposure) in a hypoxic tent at ~ 15% O2 (ca. 2400 m elevation).
1647792|NCT01872507|Other|Biofeedback training|usual treatment +12 biofeedback training
1647793|NCT01872494|Other|local|This group uses local analgesia infusion pump of 0.33% ropivacaine 250ml through the wound for postoperative analgesia.
1647794|NCT01872494|Other|intravenous|This group is treated with intravenous analgesia pump infusion of flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.
1647795|NCT01872494|Drug|0.33% ropivacaine 250ml|
1647796|NCT01872494|Drug|flurbiprofen axetil 150mg,palonosetron 0.5mg,pentazocine 240mg.|
1647797|NCT01872481|Device|rTMS|rTMS in series of 20 trains of 6 s in duration (54-s intertrain interval) at a stimulation rate of 10 Hz (1200 pulses) at an intensity of 90% rest motor threshold. Sessions will be administered 5 days a week (Monday to Friday) during two consecutive weeks.
1647798|NCT01872481|Device|Sham rTMS|A coil with similar appearance to the active coil in shape and weight, producing a similar sound artifact but without emission of a magnetic pulse is used for the control group.
1647799|NCT01872468|Behavioral|Structured intervention|Initial training session based on patient personal experiences and reflexion (30 minutes). CKD learning session (30 minutes). Personal plan of actions to cope with own disease (30 minutes. Discussion of doubts (30 minutes). Follow up visits every four months at physicians and nurses´ offices over a two-year period
1647800|NCT01872455|Dietary Supplement|n-3 rich diet|This dietary plan included seafood (salmon, sardines, herrings, and bluefish) and specific fruits and vegetables (oranges, strawberries, cherries, bananas, courgettes, artichokes, mushrooms, cauliflowers and pumpkins). Olive oil, rich in monounsaturated fats, was also included in the dietary plan. Patients were encouraged to use n-3 rich margarine as additional source of fatty acids. According to the data of the manufacturer, the fatty acid composition of this margarine was 3.4 mg of n-3 and 7.8 mg of n-6 per 100 g of weight. To keep n-6 PUFA intake low, patients were also requested to eat less eggs, meat, whole grains and cereals. All the components of the diet were fresh foods, with the exception of salmon and herrings that could also be preserved. Because no change in body weight was requested, patients maintained the same energy and protein intake of the diet that they assumed before entering the study.
1647801|NCT01872455|Dietary Supplement|Usual diet|Usual diet of the patients
1647802|NCT01872442|Drug|Dasatinib|"Dasatinib 100mg daily starting at inclusion
If ANC ≤ 1.5.109/L, platelets ≤ 100.0.109/L or lymphocytes > 4.0.109/L at 3 months, dasatinib will be continued alone, and patients will be still followed in the study"
1647803|NCT01872442|Drug|Peg-Interferon alpha2b|30 µg weekly starting month 4- month 21
1647804|NCT01872416|Device|Liposomal Doxorubicin Combined With ifosfamide|Liposomal Doxorubicin Combined With ifosfamide Second-line Treatment in Small Cell Lung Cancer
1647841|NCT01872026|Drug|ASP7991|oral
1647842|NCT01872013|Drug|ASP7991|oral
1647843|NCT01872013|Drug|Placebo|oral
1647806|NCT01872390|Other|Combination Intervention Package|CIP will contain programmatic, structural and psychosocial components including: 1) nurse training and mentorship in TB/HIV cotreatment using a clinical algorithm; 2) reimbursement of transportation costs to monthly clinic visits for patients and treatment supporters; 3) health education using a TB and HIV treatment literacy curriculum for patients and treatment supporters; and 4) real-time adherence support using short message service (SMS) text messaging and trained village health workers (VHW). These components were selected for their promise, practicality, and feasibility of implementation and scale-up in HIV programs in diverse settings - in addition to SOC.
1647807|NCT01872390|Other|Standard of Care|Usual procedures for management of HIV-infected TB patients will be followed: Three I's training, ART provision to TB patients in integrated clinics, and treatment supporter for TB treatment.
1647808|NCT01872377|Radiation|CyberKnife® Stereotactic Body Radiotherapy(SBRT)Boost|Stereotactic body radiotherapy (SBRT) is a minimally invasive treatment technique that allows for ultra-high doses of radiation to be delivered to small areas with precision. In this study all participants will receive one of 5 dose levels that will be assigned according to Time-to-Event Continual Reassessment Method (TITE-CRM). Three fractions of various dose levels would be delivered over 5 to 10 days (typically Monday, Wednesday and Friday) with at least 36 hours between two sessions. In case of technical or medical problem, the authorized total treatment time is 12 days.
1647809|NCT01872351|Drug|Nutraceuticals|
1647810|NCT01872338|Behavioral|Mindfulness-Based Cognitive Therapy for Suicide|Psychotherapeutic intervention that integrates mindfulness meditation with Safety Planning, with a specific focus on reducing suicide risk.
1647811|NCT01872338|Behavioral|Treatment as usual|VA standard care for suicide prevention
1647812|NCT01872325|Behavioral|Education|An education program will be developed using behaviour change techniques specifically mapped to address modifiable factors identified in a previous study. These techniques will include: information about the significance of agonal breathing, modeling/demonstration of desired behavioural skills, rehearsal of desired skills, and monitoring/reinforcement and feedback.
1647813|NCT01872312|Device|treatment with valves (The Spiration® IBV Valve System)|treat BPF
1647814|NCT01872286|Device|AKE-1|
1647815|NCT01872286|Device|Pillcam SB2|
1647816|NCT01872273|Other|Moderate Physical Exercise|This intervention is comprised of two separate visits at least one week apart. The purpose of visit 1 is to determine the cycle ergometer workload that produces a moderate exercise intensity of 60% heart rate reserve to be used on visit 2. The purpose of visit 2 is to determine changes in platelet reactivity in response to moderate exercise.
2012659|NCT01788410|Device|MRI Seednet Cryotherapy System (Galil Medical)|Observing efficacy of cryoablation to nerves and facet joints for the treatment of radicular pain and pain resulting from facet joint disease.
2012660|NCT01783925|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients in daily life clinical practice treatment receiving EYLEA according to indication on the label.
1647820|NCT01872234|Device|Two-lead CRT-P|The two lead CRT-P will consist of a dual chamber pacemaker, a right atrial lead and a left ventricular lead.
1647822|NCT01872208|Device|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) as an above-knee femoro-popliteal bypass graft using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration.
1647823|NCT01872195|Other|The comprehensive patient safety checklist system|The comprehensive patient safety checklist system follows each patient from admission to discharge with separate short checklists at each point of care: On admission to the hospital and ward (operating theatre nurse, ward doctor, surgeon, anaesthesiologist, ward nurse - 5 lists), in the operating theatre (here covered by the WHO-Safe Surgery checklist), at the recovery/ICU unit (nurse- 1 list), at discharge from the hospital (ward doctor, ward nurse - 2 lists).
1647824|NCT01872182|Drug|ALS-L1023|daily twice for 12 weeks
1647825|NCT01872182|Drug|placebo|daily twice for 12 weeks
1647826|NCT01872169|Other|Disordered eating screening questionnaire|
1647827|NCT01872156|Other|Intervention GESTABAC|"Intervention based on the Clinician`s Guide to helping Pregnant Women Quit Smoking on the rates of abstinence of the patients in whom it has been controlled in this period of time, at the end of the pregnancy and after the childbirth."
1647828|NCT01872156|Other|Control Group|The group control will act according to usual management.
1647829|NCT01872143|Device|transcranial Direct Current Stimulation|daily or twice-a-day administration of transcranial Direct Current Stimulation from a minimum of 10 session to a maximum of 20
1647830|NCT01872117|Other|Shortwave therapy|Will be conducted in four stages, on different days: i) lower limb in extension and application of 180° for 20 min, ii) Lower limb knee flexion of 90° and application for 20 min; iii) lower limb extension in 180° without application iv) lower limb knee flexion of 90° without application.
1647831|NCT01872117|Other|Microwave therapy|Will be held in two stages, on different days: i) lower limb in extension with angle of 180° and application for 20 min, ii) lower limb in extension of 180° without application.
1647832|NCT01872104|Procedure|Photodynamic therapy|Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
1647833|NCT01872091|Other|cryotherapy by immersion|
1647834|NCT01872091|Other|Control group|
1647835|NCT01872078|Drug|AZD4901 (oral)|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
1647836|NCT01872078|Drug|Placebo to match AZD4901|Patients randomized to 1 of 4 treatment groups: AZD4901 20 mg once a day, AZD4901 20 mg twice a day, AZD4901 40 mg twice a day or placebo
1647837|NCT01872065|Drug|ARC-520|
1647838|NCT01872065|Drug|Placebo|
1647839|NCT01872052|Device|Acutus Medical System Mapping|Mapping with the Acutus Medical System followed by intracardiac ablation of typical atrial flutter
1647840|NCT01872039|Drug|Perdipine injection|IV
1647848|NCT01871948|Other|"We Want to Know campaign, Patient survey at 2 time points"|Randomly assigned patients attending cancer clinics at Washington or Georgia sites during February 2013 to August 2013 will be presented with or mailed a survey about cancer communication approximately 2 weeks later and a follow-up survey approximately 3 months later. Additionally, this group will also receive a follow-up phone call approximately 4 weeks after baseline survey.
1647849|NCT01871935|Drug|Remifentanil|Anaesthesia with remifentanil/propofol.
1647850|NCT01871935|Drug|Sufentanil|Anaesthesia with sufentanil/propofol
1647851|NCT01871922|Drug|Placebo|Saline
1647852|NCT01871922|Drug|Atropine|Atropine
1647853|NCT01871896|Device|Endoscopic Suturing to Create Early Satiety|Evaluating the efficacy of endoscopic suturing for weight loss.
1647854|NCT01871883|Procedure|Skin biopsy|Two skin biopsies will be taken with a 3 mm punch in the retroauricular area. The procedure will be done by an investigator, under aseptic and antiseptic conditions and under local anesthesia with lidocaine and epinephrine. The incision will be sutured with 6-0 Nylon, and the stitches will be removed after 5 days. One biopsy will be processed for immunohistochemistry, the other for RNA extraction and analysis.
1647855|NCT01871883|Procedure|Oral mucosa specimen|The sample for keratinocytes from oral mucosa will be taken with a Foam knife, which is a non-invasive procedure. It does not need anesthesia, and it does not leave scars. The procedure consists in gently brush the oral mucosa with the knife five times, and the material that will be obtained will be fixed in a PBS solution for RNA analysis.
1647856|NCT01871870|Device|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an outpatient automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm programmed into a smart phone.
2012661|NCT01781832|Device|ARFI-Derived Shear Wave Velocities|An ultrasound based scan using acoustic radiation force impulse-derived shear wave velocities to obtain images of the urinary bladder. The research ultrasound scan will take approximately 10 to 15 minutes to complete.
2012662|NCT01777997|Drug|Emtricitabine/rilpivirine/tenofovir disoproxil fumarate|
1647859|NCT01871844|Drug|ITF2984 (500, 1000, 2000 mcg bid for 7 days)|
1647860|NCT01871844|Drug|octreotide 50 mcg tid|
1647861|NCT01871844|Drug|Placebo|
1647862|NCT01871831|Device|6 blood glucose monitoring systems for self-testing|
1647863|NCT01871818|Behavioral|Combined program|Combined program with physiotherapy, endurance training and resistance training
1647864|NCT01871818|Behavioral|Physiotherapy in private practice|Physiotherapy in private practice
1647867|NCT01871792|Drug|Pitavastatin|
1647868|NCT01871792|Drug|Placebo|Sugar pill manufactured to mimic Pitavastatin 4 mg tablet
1647869|NCT01871779|Other|Standard Treadmill Exercise|Standard treadmill exercise to the point of pain twice weekly for 35-45 minutes for 12 weeks
1647870|NCT01871779|Other|Intermittent treadmill & resistance training|Combination of standard treadmill training and resistance training with weights twice weekly for 12 weeks
1647871|NCT01871766|Drug|Vincristine|"Dosage and route of administration:
< 1 year of age=0.025 mg/kg intravenously (IV)
> 1 year and < 3 years= 0.05 mg/kg IV
≥ 3 years=1.5 mg/m^2 IV. Maximum dose 2 mg in all participants."
1647872|NCT01871766|Drug|Dactinomycin|"Dosage and route of administration:
< 1 year=0.025 mg/kg IV push
≥ 1 year=0.045 mg/kg IV push over 1 to 5 minutes."
1647873|NCT01871766|Drug|Cyclophosphamide|"Dosage and route of administration:
During VAC chemotherapy:
< 3 years of age = 40 mg/kg IV
≥ 3 years of age = 1200 mg/m^2 IV, with MESNA.
During maintenance for intermediate-risk participants:
oral cyclophosphamide 50 mg/m^2/dose/day (liquid or tablet)"
1647874|NCT01871766|Procedure|Surgical Resection|Surgery will be performed for the primary site tumor with the goal of removing tumor cells while maintaining function in the organ or adjacent organs involved.
1647875|NCT01871766|Procedure|Radiation|Radiation therapy will be delivered at approximately week 13 (intermediate risk) or week 19 (high risk) after initiation of chemotherapy. Certain patients will receive radiation at week 4.
1647876|NCT01871766|Drug|Bevacizumab|Dosage and route of administration: 15 mg/kg/dose/day IV.
1647877|NCT01871766|Drug|Sorafenib|Dosage and route of administration: 90 mg/m^2/dose twice daily.
1647878|NCT01871766|Drug|Myeloid Growth Factor|"If a participant's chemotherapy has been delayed or modified for hematologic toxicity, or if participant experiences a significant life-threatening toxicity due to bone marrow suppression, myeloid growth factor (either filgrastim or peg-filgrastim) will be given per institutional practice.
High Risk participants receive filgrastim 5 micrograms/kg/day (maximum 300 micrograms) subcutaneously beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/µL whichever comes last. Sargramostim or peg-filgrastim may not be used."
1647879|NCT01871766|Procedure|Lymph Node Sampling|"Clinical and/or imaging evaluation of regional lymph nodes will be conducted pretreatment and preoperatively as part of staging. This will aid in determining the efficacy of this procedure in defining involved lymphatics in at risk patients."
1647880|NCT01871766|Drug|Irinotecan|Dosage and Route Administration: During interval compressed therapy - irinotecan 50mg/m^2 IV (maximum dose 100 mg/day) daily x 5.
1647881|NCT01871766|Drug|Ifosfamide|Dosage and Route of Administration: During interval compressed therapy - Age > 1 year: 1800 mg/m^2/day IV x 5 Age <1 year: treat with 50% doses calculated on a m^2 basis.
1647882|NCT01871766|Drug|Etoposide|"Dosage and Route of Administration:
Age >1 year 100 mg/m^2/day IV x 5 Age < 1 year treat with 50% doses calculated on a m^2 basis"
1647883|NCT01871766|Drug|Etoposide Phosphate|Dosage and Route of Administration: Used in substitution for etoposide in participants who experience allergic reaction. It will be administered 100 mg/m^2/day IV.
1647884|NCT01871766|Drug|Doxorubicin|"Dosage and route of Administration:
Age ≥1 year, 37.5 mg/m^2 IV over 1 hour x 2 days Age <1 year, 18.75 mg/m^2 (i.e., a 50% dose reduction) IV over 1 hour x 2 days."
1647885|NCT01871766|Drug|Dexrazoxane|"Dosage and Route of Administration: Dexrazoxane dose should be 10x that of doxorubicin.
Age ≥1 year, 375 mg/m^2 IV over 15-30 minutes Age <1 year, 187l.5 mg/m^2 (i.e., a 50% dose reduction) IV over 15-30 minutes."
1648026|NCT01870687|Drug|20mg VAC BNO 1095 FCT|
1648027|NCT01870687|Drug|Placebo|
1647886|NCT01871766|Drug|^1^1C-methionine|Participants receive ^1^1C-methionine to relate the distribution, intensity and change in ^1^1C-methionine CTPET imaging of the primary site to tumor control and patient outcome.
1647887|NCT01871753|Other|Anti-Infective Agents|10 days of antibiotics, started and selected according to the antibiogram results. In case of reinfection or relapse, re-administration of antimicrobial agents will be performed according to the antibiogram results (for a maximum of 3 cycles of ten days of antibiotics during the 12 months of the follow-up)
1647888|NCT01871740|Drug|Enalapril maleate and folic acid tablets|Enalapril maleate and folic acid tablets, (10mg/0.8mg)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
1647889|NCT01871740|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
1647890|NCT01871727|Drug|E7777|administered by intravenous (i.v.) infusion over 60 minutes (+/-10 minutes) on 5 consecutive days during every cycle of 21 days
1647891|NCT01871701|Drug|Escitalopram|Escitalopram
1647892|NCT01871701|Drug|Quetiapine|Quetiapine
1647893|NCT01871701|Drug|Moxifloxacin|Moxifloxacin
1647894|NCT01871701|Other|Placebo|Placebo
1647895|NCT01871688|Behavioral|pelvic floor rehabilitation program with neuromodulation|pelvic floor rehabilitation program with neuromodulation
1647896|NCT01871675|Drug|IPI-145|
1647897|NCT01871675|Drug|Rituximab|
1647898|NCT01871675|Drug|Bendamustine|
1647899|NCT01871662|Drug|Legalon® SIL (Silibinin)|Silibinin 20 mg/Kg/day
1647900|NCT01871662|Drug|Pegylated interferon alfa2b|1.5 µg/kg once-weekly
1647901|NCT01871662|Drug|Ribavirin|At weight-based dose 800-1400 mg/day (BID, OS)
1647902|NCT01871649|Drug|golimumab|golimumab 50mg subcutaneous injections (in combination with methotrexate), once a month, for a period of 22 weeks
1647903|NCT01871649|Drug|methotrexate|Methotrexate will be started at a dosage of 15 mg/week orally and, if well tolerated, increased to 20mg/week at week 4 and 25mg/week at week 8 of the trial. If well tolerated, the maximum dose of 25 mg/week will be sustained until end of study (week 50). Folic acid 5 mg/week will be administered orally one day after the MTX intake.
1647904|NCT01871636|Procedure|Endoscopic mucosal resection|Endoscopic mucosal resection removes tissue in a piece meal technique or by snare limited to the mucosa.
1647905|NCT01871636|Procedure|Waterjet-assisted ESD|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
1647906|NCT01871636|Device|HybridKnife|The waterjet-assisted endoscopic submucosal dissection (WESD) technology allows pressure controlled injection of fluids through the tip of a recently developed HybridKnife®. Submucosal injection, circumferential cutting and dissection of lesions.
1647907|NCT01871623|Procedure|Segmental Le Fort I osteotomy|comparison the stability of segmental Le Fort I osteotomy with conventional approach of one-piece Le Fort I osteotomy
1647908|NCT01871623|Procedure|One-piece Le Fort I Osteotomy|conventional approach
1647909|NCT01871610|Drug|[18F]AV-45 PET amyloid binding imaging|
1647910|NCT01871597|Device|Pulmonary Artery Energy Seal|Pulmonary artery energy seal devices such as: Ligasure, Harmonic scalpel, Enseal, Thunderbeat, Unipolar and Conventional bipolar Cautery, metal clip or Hem-o-lok clip will be used to seal the artery(ies)
1647911|NCT01871584|Device|Colon cleansing by hydrotherapy|The Angel of Water™ system will be used for hydrotherapy of the colon in adult subjects scheduled for elective colonoscopy.
1647912|NCT01871571|Biological|bevacizumab|Given IV
1647913|NCT01871571|Drug|oxaliplatin|Given IV
1647914|NCT01871571|Drug|leucovorin calcium|Given IV
1647915|NCT01871571|Drug|fluorouracil|Given IV
1647916|NCT01871571|Other|laboratory biomarker analysis|Correlative studies
1647917|NCT01871558|Drug|Vildagliptin|50 mg b.i.d
1647918|NCT01871558|Drug|Metformin|metformin is to be kept unchanged
1647919|NCT01871558|Drug|sulfonylurea (SU)|
1647920|NCT01871558|Drug|Basal Insulin|
2012663|NCT01769469|Drug|FTC/TDF (Truvada®)|There are no interventions for this study except that subjects will be administered FTC/TDF (Truvada®) will be administered as part of ATN 110 and ATN 113.
1647922|NCT01871532|Drug|Gonal-f®|
1647923|NCT01871519|Device|Balloon kyphoplasty|The devices to be used in this study are intended for percutaneous balloon kyphoplasty (BKP) and consist of the Kyphon® bone access needles and cannulae, inflatable bone tamps, curettes, polymethyl methacrylate bone cement (PMMA) bone cements, and bone filler devices.
1647924|NCT01871506|Behavioral|Standard Care (SC)|"Initial counseling session: The initial counseling session will last approximately 45 minutes and will be conducted in-person or by phone by a tobacco treatment counselor. The session will be structured in a 5 As format and utilize Motivational Interviewing (MI) techniques.
3 Weekly Follow-up Counseling Sessions: SC Patients will be offered 3 weekly proactive follow-up sessions, concentrated on quitting and staying quit throughout cancer treatment.
Medication advice: The tobacco counselor will advise SC subjects to use smoking cessation medication to assist with their quit. Smoking cessation medication will not be provided by the study free of cost for SC subjects."
1647925|NCT01871506|Behavioral|Intensive Counseling (IC)|"The IC model includes all components of the SC as well as extended counseling support and up to 90 days of free FDA approved smoking cessation medication.
Extended counseling support: Participants in the IC group will be offered the same initial 4 counseling sessions as the SC group as well as 4 additional proactive biweekly sessions and 3 monthly booster sessions.
Smoking cessation medication: IC participants will be offered a 4-week supply of FDA-approved smoking cessation medication (varenicline, bupropion or nicotine replacement therapy) of their choice, with the option to renew the medication twice for up to 90 days of free medication. Participants are not required to take smoking cessation medication."
1647926|NCT01871493|Drug|LY2605541|Administered subcutaneous (SQ)
1647927|NCT01871493|Drug|Insulin Lispro|Administered SQ
1648028|NCT01870674|Drug|YH12852|
1648029|NCT01870674|Drug|Prucalopride|
1648030|NCT01870674|Drug|Placebo|
1648596|NCT01866410|Other|Laboratory Biomarker Analysis|Correlative studies
1647928|NCT01871480|Drug|Group A:cytokine-induced killer cell +gefitinib|CIK cells: intravenous infusions; D14-16; one cycle every month,at least 6 cycles;Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity.
1647929|NCT01871480|Drug|Group B:Gefitinib|Gefitinib treated with 250mg for daily oral administration in the absence of disease progression or unacceptable toxicity
1647930|NCT01871467|Drug|Sargramostim|
1647931|NCT01871454|Radiation|stereotactic ablative radiotherapy (SABR)|standard of care radiation therapy
1647932|NCT01871454|Drug|Pentoxifylline|pentoxifylline
2012664|NCT01752712|Drug|CBSST + Oxytocin|The oxytocin dose of 80 IU/day, will be administered in two divided doses: 40 IU in the morning and 40 IU in the evening. Oxytocin will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
1647939|NCT01871428|Drug|aleglitazar|150 mcg orally daily
1647940|NCT01871428|Drug|placebo|matching aleglitazar placebo orally daily
1647941|NCT01871415|Drug|aleglitazar|150 mcg orally daily
1647942|NCT01871415|Drug|metformin|pre-existing background regimen and dose
1647943|NCT01871415|Drug|placebo|matching aleglitazar placebo orally daily
1647944|NCT01871402|Drug|000-0551 Lotion|
1647945|NCT01871402|Drug|Vehicle Lotion|
1647946|NCT01871376|Drug|Intravitreal aflibercept injection 2.0mg|Monthly 2.0mg intravitreal aflibercept injection, followed by Q8W dosing with 2.0mg intravitreal aflibercept injection or as often as monthly if needed for 1 year for both treatment naive and prior treatment arms.
1647947|NCT01871363|Radiation|chemoradiation|"radiotherapy: 50 Gy to the pelvis (25x 2 Gy on days 1-35, excluding weekends) .IMRT planing and technique with high energy photons will be used. All fields will be treated daily. Multileaf collimators will be used to shape individual radiation fields. Patients will be irradiated in a prone position with a full bladder and by using belly board to minimize exposure of the small bowel.
capecitabine 825 mg/m² p.o. twice daily on days 1-35 (including weekends),
bevacizumab: at dose 5 mg/kg on days -1, 15, 31.
Radical surgery (TME): to be undertaken ideally 6-8 weeks following completion of chemoradiation."
1647949|NCT01871337|Behavioral|Paula method|The Paula method will be taught to the participants by several registered Paula instructors. Subjects allocated to this intervention will receive one 45-minute group session per week for 12 weeks (with up to 30 minutes for personal questions regarding the exercises). This length of time is crucial because it has been demonstrated that it take three months for women to adequately learn the exercises in order for them to practice independently at home. Participants will be encouraged to practice daily for 15 minutes and report their at- home training.
1647950|NCT01871324|Behavioral|Lifestyle counseling|group therapy
1647951|NCT01871311|Drug|Nilotinib + Cetuximab|"Nilotinib BID for a 28-day cycle + Cetuximab 400 mg/m2 on day 1 dose then 250 mg/m2 weekly
Three dose levels for nilotinib:
Dose level -1 200-mg daily Dose level 1 200-mg BID Dose level 2 300-mg BID
Cycle duration will be 4 weeks, with weekly evaluation of toxicity. Assessment of tumor progression will occur every 2 cycles. Subjects will be treated until disease progression or cessation due to intolerable toxicity."
1647952|NCT01871298|Other|Pilot Website Evaluation Component|The pilot health website will contain educational health information such as: health-related videos, searchable map of HIV prevention and other needed health and social services, and the option to register for automatic text message updates on relevant health information.
1647953|NCT01871285|Drug|Buprenorphine|
1647954|NCT01871285|Drug|Placebo film|Matching placebo buccal film
1647955|NCT01871285|Drug|Oxycodone|Oxycodone extended-release (ER) or immediate-release (IR) 5, 10, 15, 20, and 30 mg over-encapsulated oral tablets
1647956|NCT01871285|Drug|Morphine sulfate|Morphine sulfate 15, 30, and 60 mg ER or 15 and 30 mg IR over-encapsulated oral tablets
1647957|NCT01871285|Drug|Placebo capsule|Oral placebo capsules matching the over-encapsulated morphine sulfate and oxycodone tablets
1647958|NCT01871272|Procedure|Arthroscopic Meniscus Surgery|Surgery to the meniscus - resection or repair.
1647959|NCT01871233|Drug|Perampanel|Patients will enter this program on the same dose of perampanel that they were receiving at the end of their participation in Studies 207, 307, or 235. Doses of perampanel and of concomitant anti-epileptic drugs (AEDs) can be adjusted based on clinical judgment. A minimum daily dose permitted will be 12 mg per day. Treatment will be prescribed as long as clinically appropriate according to the judgment of the treating physician and the approved summary of Product Characteristics (SmPC). Tablets will be available in strengths of 2 mg, 4 mg, 6 mg, 8 mg, 10 mg, and 12 mg. Patients will be instructed to take their perampanel tablets once daily, by mouth, before bedtime, and with food.
1647960|NCT01871220|Device|Concave Transition Profile|An Atlantis abutment is delivered with a concave transition profile.
1647961|NCT01871220|Device|Divergent Transition Profile|An Atlantis abutment is delivered with a linear transition profile
1647962|NCT01871181|Procedure|Ilioinguinal block|0.25% bupivacaine will be administered on a mg/kg basis
1647963|NCT01871181|Procedure|Local infiltration|Surgeon will infiltrate incision area with local anesthetic before closure.
1647964|NCT01871168|Procedure|TAP block|Infusion of 0.5-1% lidocaine
1647965|NCT01871168|Procedure|Sham TAP block|Infusion of saline
1647966|NCT01871155|Dietary Supplement|Nutri-jelly|"an edible nutritious gel for chewing and swallowing difficulties 1 box contains 250 ml with 250 kcal
1 serving is considered as food supplement"
1647967|NCT01871142|Drug|Placebo|100 mL
1647968|NCT01871142|Drug|Aes-103|Single dose of 1000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
1647969|NCT01871142|Drug|Aes-103|Single dose of 3000mg Aes-103 dissolved in 100 mL of Tropicana Pure Premium Orange Juice
1648031|NCT01870661|Device|Long axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the long axis.
1648032|NCT01870661|Device|Short axis IV placement with ultrasound|Peripheral IV placement with the ultrasound probe viewing the vessel in the short axis.
1648231|NCT01869192|Radiation|Radiation Therapy|Standard dosing, fields depending on clinical findings
1717742|NCT00002252|Drug|Octreotide|
1647970|NCT01871129|Drug|Dexmedetomidine|Dexmedetomidine will be diluted into a saline solution to a recommended concentration of 4 micrograms per millilitre. The saline will then be initially administered at the rate of 0.5 micrograms/kg/h and from that point the amount will be reduced to the point where the patient breathes well and is calm (compare dexmedetomidine recommendation at 0.2-1.4 ug/kg/h). The infusion rate will then be approximately 1-10 ml/h for a patient of 80 kgs weight. The exact dosage cannot be predetermined because it differs in each individual. In the control group the infusion speed is matching.
1647971|NCT01871129|Other|Saline (placebo)|Saline placebo infusion will be adjusted the same fashion as the active comparator drug.
1647972|NCT01871116|Behavioral|POWER-remote|Web-based weight loss program.
1647973|NCT01871116|Behavioral|Self-directed|"Pamphlet entitled Aim for a Healthy Weight will be given."
1647974|NCT01871103|Procedure|The dorsal homodigital island flap|The dorsal homodigital island flap is used for tissue reconstruction in different regions of the finger.
1647975|NCT01871090|Device|Unpaired remote monitoring transmitter|Unpaired remote monitoring transmitter
1647976|NCT01871077|Drug|PRO-156|Drug: PRO-156 ophthalmic solution One drop of PRO-156 ophthalmic solution administered to each eye, four times a day for 10 days.
1647977|NCT01871064|Device|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
1647978|NCT01871025|Other|Hospital and home exercise training|Hospital exercise training (aerobic and strength) followed by exercise training
1647979|NCT01871025|Other|Usual care|Usual care includes respiratory physiotherapy techniques during hospitalization and adequate physical activity recommendations, but not exercise training
1647980|NCT01870999|Drug|aripiprazole IM depot|Aripiprazole IM depot supplied as 200 mg or 400 mg vials of lyophilized aripiprazole powder to prepare for IM injection.
1647981|NCT01870999|Drug|aripiprazole tablets|Aripiprazole tablets 10 mg once daily in the morning for 14 days.
1647982|NCT01870986|Biological|PF-06410293|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
1647983|NCT01870986|Biological|Humira (adalimumab-EU)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
1647984|NCT01870986|Biological|Humira (adalimumab-US)|40 mg/0.8 mL administered by sub-cutaneous injection with a single-use prefilled syringe.
1647985|NCT01870973|Procedure|root canal treatment, anesthesia, pain medications, and antibiotic|Root canal treatment is the intervention (no initial treatment versus initial treatment). We are not studying a drug or device.
1647986|NCT01870973|Procedure|no root canal treatment, anesthesia, pain medications, and antibiotic|
1647987|NCT01870960|Other|7 patients will be recuting to received EMDOGAIM in left side|
1647988|NCT01870960|Other|7 patients will be recuting to received EMDOGAIM in right side|
1647989|NCT01870947|Behavioral|Exercise on stationary recumbent exercise cycle|
1647990|NCT01870947|Behavioral|Health Education|"Informational brochure (Better Health and You, Weight Control Information Network, June, 2004)"
1647991|NCT01870947|Behavioral|Questionnaires|
1647992|NCT01870947|Procedure|Neuroimaging|Imaging data will be acquired on a Siemens 3.0T Wide-Bore Verio MRI scanner.
1647993|NCT01870947|Procedure|Genetic and Biomarkers|Patients will be asked to fast for approximately 12 hours and will have approximately 2 Tbs. of blood drawn at baseline and the end of treatment (EOT).
1647994|NCT01870934|Device|Camera|No real intervention, but a comparison of different methods including the new medical device 3D camera.
1647995|NCT01870921|Drug|Ticagrelor|90mg/tablet, 1 tablet bid
1647996|NCT01870908|Drug|tacrolimus|
1647997|NCT01870908|Drug|biological agents|
1647998|NCT01870895|Drug|YM060|oral
1647999|NCT01870895|Drug|Placebo|oral
1648000|NCT01870882|Behavioral|Attentional retraining|
1648001|NCT01870882|Behavioral|Control condition|
1648002|NCT01870856|Device|Spectacles|Per participant's habitual prescription
1648003|NCT01870856|Device|Delefilcon A contact lenses|Silicone hydrogel single vision contact lenses
1648004|NCT01870856|Device|Etafilcon A contact lenses|Hydrogel single vision contact lenses
1648005|NCT01870843|Drug|Escitalopram|Escitalopram will be administered as oral tablets 10 mg per day and then the dose of escitalopram will be flexibly adjusted up to maximum of 20 mg per day for the next 7 weeks, based on the investigator's clinical judgment.
1648006|NCT01870830|Other|Altitude exposure|Stay at different altitudes: 490, 1650, 2590 m
1648007|NCT01870817|Dietary Supplement|Home jejunostomy feeding|
1648008|NCT01870804|Drug|Rosuvastatin|
1648009|NCT01870804|Drug|Atorvastatin|
1648010|NCT01870791|Drug|Omegaven|Weekly omegaven infusion in combination with EOX chemotherapy
1648013|NCT01870765|Device|non-invasive ventilation|non-invasive ventilation via face mask
1648014|NCT01870765|Device|high-flow oxygen|high-flow oxygen via nasal cannula
1648015|NCT01870765|Procedure|fiberoptic bronchoscopy|fiberoptic bronchoscopy including broncho-alveolar lavage
1648016|NCT01870752|Radiation|Chemotherapy|
1648017|NCT01870739|Drug|sacubitril/valsartan (LCZ696)|200 mg tablets
1648018|NCT01870739|Drug|olmesartan|
1648019|NCT01870739|Other|placebo to sacubitril/valsartan (LCZ696)|placebo
1648020|NCT01870739|Other|placebo to olmesartan|placebo
1648021|NCT01870739|Drug|Amlodipine (Optional)|If required, open label amlodipine (2.5 mg, 5 mg, or 10 mg qd) was added to treatment regimen
1648022|NCT01870726|Drug|INC280|Phase Ib: INC280 will be given at the starting dose of 200mg twice daily. Phase II: INC280 will be given at the dose of 400mg (tablets) twice daily.
1648023|NCT01870726|Drug|Buparlisib|Buparlisib will be given at the starting dose of 50mg once daily.
1648024|NCT01870700|Drug|lactobacillus reuteri|Lactobacillus reuteri (DSM 17938) was administered in the dose of 108 colony-forming units (CFU) in tablets of a commercially available preparation (Reuflor, Italchimici, Pomezia; BioGaia AB, Stockholm, Sweden), 30 minutes after feeding, twice per day for 4 weeks
1648025|NCT01870700|Drug|placebo|a supplementation with placebo was administered in tablets of a commercially available preparation 30 minutes after feeding, twice per day for 4 weeks
1648033|NCT01870648|Drug|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
1648034|NCT01870648|Drug|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
1648035|NCT01870635|Drug|Ondansetron|Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
1648036|NCT01870635|Drug|Placebo|Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
1648037|NCT01870622|Procedure|Flow waves|Flow waves will be used to confirm correct tube placement in newborn infants.
1648038|NCT01870622|Procedure|ECO2|ECO2 will be used to confirm correct tube placement in newborn infants.
1648039|NCT01870609|Drug|defactinib (VS-6063)|
1648040|NCT01870609|Drug|Placebo|Sugar pill manufactured to mimic defactinib tablet
1648041|NCT01870596|Drug|Cytarabine|Given IV
1648042|NCT01870596|Drug|CHK1 Inhibitor SCH 900776|Given IV
1648043|NCT01870596|Other|Laboratory Biomarker Analysis|Correlative studies
1648044|NCT01870583|Drug|Iodine povidone|Iodine skin preparation solution prior to cesarean delivery
1648045|NCT01870583|Drug|Chlorhexidine|Chlorhexidine skin preparation solution prior to cesarean delivery
1648046|NCT01870583|Drug|Combination iodine and chlorhexidine|Combination iodine povidone and chlorhexidine skin preparation solution prior to cesarean delivery
1648047|NCT01870570|Other|Reference Glucose|
1648048|NCT01870570|Other|Food Product A: Corn Flakes|
1648049|NCT01870570|Other|Food Product B: Ginger Bread|
1648050|NCT01870570|Other|Food Product C:Sandwiched Breakfast Biscuit|
1648051|NCT01870570|Other|Food Product D: Crackers Nature|
1648052|NCT01870570|Other|Food Product E: Breakfast Biscuit|
1648053|NCT01870570|Other|Food Product F: White Bread|
1648054|NCT01870544|Dietary Supplement|Lactobacillus Rhamnosus GG|LGG will be administered orally for 44 days
1648055|NCT01870544|Dietary Supplement|Placebo|placebo will be administered daily for 44 days
2012665|NCT01752712|Drug|CBSST + Placebo|Matching placebo spray will be administered intranasally (10 puffs of the spray, 5 in each nostril at each administration). CBSST groups will occur for an hour twice/week. Nasal spray will be administered an hour prior to the CBSST group.
1648058|NCT01870505|Drug|BYL719|
1648059|NCT01870505|Drug|Letrozole|
1648060|NCT01870505|Drug|Exemestane|
1648061|NCT01870492|Drug|Activase|Patients treated with Activase
1648062|NCT01870492|Device|Endovascular therapy|Patients treated with endovascular therapy, such as IA-tPA, mechanical thrombectomy, etc for acute ischemic stroke or transient ischemic attack.
1648063|NCT01870479|Other|Live music|
1648064|NCT01870479|Other|Taped music|
1648065|NCT01870466|Drug|Cilostazol|cilostazol bid for 7 days
1648066|NCT01870466|Drug|Simvastatin|simvastatin qd for 7 days
1648067|NCT01870466|Drug|Rosuvastatin|rosuvastatin qd for 7 days
1648068|NCT01870440|Drug|Ozurdex Intravitreal Injection (0.7 mg)|Intravitreal Injection
1648069|NCT01870427|Drug|Aflibercept (2.0 mg)|Intravitreal Aflibercept (2.0 mg)
1648070|NCT01870414|Other|cryotherapy by immersion|the dominant leg was immersed in cold water for 20 minutes [2, 17], temperature of 4º C [22, 24], water level at 20 cm
1648073|NCT01870388|Drug|Baricitinib|Administered orally
1648074|NCT01870362|Drug|Probiotic (Inersan)|
1648075|NCT01870362|Drug|Placebo|
1648076|NCT01870349|Procedure|Gingival Crevicular Fluid Sampling|Gingival crevicular fluids will be sampled from single implant restorations that have been in function for at least 6 months
1648077|NCT01870336|Device|Combined treatment of medial knee osteoarthritis|
1648078|NCT01870323|Behavioral|SMART Behavioral Group|Test the efficacy of using social media to deliver a physical activity intervention based on social cognitive principles to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, as well as receipt of weekly video-based behavioral modules).
1648079|NCT01870323|Behavioral|SMART Informational Group|Test the efficacy of using social media to deliver a physical activity intervention to increase lifestyle physical activity in low-active adolescents (i.e., access to regularly posted physical activity content on a study-specific, restricted access Facebook Group, but does not receive the weekly video-based behavioral modules).
1648080|NCT01870310|Procedure|Catheterised renal denervation|
1648084|NCT01870284|Drug|Ixekizumab|Administered SC
1648085|NCT01870284|Drug|Placebo|Administered SC
1648086|NCT01870284|Drug|Adalimumab|Administered SC
1648087|NCT01870271|Behavioral|Developmentally adapted cognitive processing therapy|
1648088|NCT01870258|Other|ANN prediction of myocardial infarction|
1648089|NCT01870245|Drug|ACHN-975|Intravenous multiple dose
1648090|NCT01870245|Drug|placebo|Intravenous multiple dose
1648091|NCT01870232|Procedure|US guided block|Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
1648092|NCT01870219|Drug|Sevoflurane|sevoflurane was initiated at %8 sevoflurane for anesthesia induction and maintained at 2% to %4 until the electrical stimulus was delivered
1648093|NCT01870219|Drug|Ketamine|ketamine was given to 1mg/kg ıv bolus
1648094|NCT01870206|Biological|Trivalent OPV Birmex|Newborns who receive OPV vaccine produced in Vero cells by Birmex one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
1648188|NCT01869491|Drug|Compound Sodium Alginate Double Action Chewable Tablets|2 tablets four times daily
1717743|NCT00002253|Drug|Octreotide|
1648095|NCT01870206|Biological|Trivalent OPV Sanofi Pasteur|Newborns who receive OPV vaccine produced in Vero cells by Sanofi Pasteur one dose of vaccine immediately after random allocation (at birth). A second dose is given four weeks after the first application.
1648096|NCT01870193|Dietary Supplement|Glycine, cysteine (as n-acetylcysteine), alanine|"Young controls will receive cysteine plus glycine for 2 weeks
The elderly subjects will be randomized in a double-blinded design to receive either cysteine plus glycine OR alanine for a period of 4 months"
1648097|NCT01870180|Device|EyeBag|fabric bag of beads which can be heated in a microwave
1648098|NCT01870180|Other|Placebo|
1648099|NCT01870167|Drug|co-amoxiclav|a single iv dose of co-amoxiclav (50/mg/Kg) at the time of PEG insertion.
1648100|NCT01870167|Dietary Supplement|Placebo|Placebo
1648101|NCT01870154|Behavioral|Training|The objective of the intervention is learning from the work experience of professionals attending the workshop to know and recognize the risk and process of the burnout syndrome and the characteristics specific to the health setting, as well as promoting prevention lines by transmitting strategies to manage and control the elements and consequences of the syndrome process (physical, psychological, and social).
1648102|NCT01870141|Behavioral|Cognitive-Behavioral Intervention|"1 weekly individual 45 min-session for 24 weeks. The program comprises the following cognitive-behavioral strategies:
self-monitoring
problem solving
goal definition
cognitive restructuring
activation of personal and social resources"
1648103|NCT01870128|Drug|Combination Steroid|Methylprednisolone 1000 mg intravenous for 3 days Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg twice daily Sulfasalazine 2000 to 3000 mg per day
1648104|NCT01870128|Drug|Methotrexate|Methotrexate 15 to 25 mg PO per week
1648105|NCT01870128|Drug|Combination|Methotrexate 15 to 25 mg PO per week Hydroxychloroquine 200 mg Twice daily Sulfasalazine 2000 to 3000 mg per day
1648106|NCT01870115|Dietary Supplement|Fiber Pill|This fiber pill has been manufactured to mimic the pill that contains the dietary supplements melatonin (M), strontium citrate (S), vitamin D3 (D) and vitamin K2 (K) in appearance but does not contain the supplements
1648107|NCT01870115|Dietary Supplement|Melatonin, Strontium citrate, Vitamins D3 and K2|Each pill has been manufactured to contain the dietary supplements 2.5mg melatonin (M), 225mg strontium citrate (S), 1000IU vitamin D3 (D) and 30mcg vitamin K2 (K)
1648108|NCT01870102|Drug|Pelubiprofen IR (Pelubiprofen 30mg) TID|
1648109|NCT01870102|Drug|Pelubiprofen SR (Pelubiprofen 45 mg) BID|
1648110|NCT01870089|Device|SmartCare/PS-NIV Drägerwerk Lübeck Germany|
1648114|NCT01870050|Drug|Dapsone gel - verum|
1648115|NCT01870037|Drug|Placebo (PBS-20% sucrose)|
1648116|NCT01870037|Drug|hMaxi-K|Single Treatment/ 2 escalating dose levels (16000 µg and 24000 µg by IM injection)
1648117|NCT01870024|Drug|Clonazepam|clonazepam 0,015 mg/kg
1648118|NCT01870024|Drug|Fosphenytoin|fosphenytoin 20 mg/kg Equivalent Phenytoin (EP) by intravenous infusion over a period of 15 minutes
1648119|NCT01870024|Drug|Placebo|placebo 20 mg/kg by intravenous infusion over a period of 15 minutes
1648120|NCT01870024|Drug|Lorazepam|lorazepam 0,1mg/kg by intravenous injection over a period of 2 to 3 minutes)
1648121|NCT01870011|Drug|Desflurane balanced anesthesia|Desflurane balanced anesthesia induced with thiopental sodium, remifentanil and atracurium and maintained with remifentanil target controlled infusion and desflurane inhalation
1648122|NCT01870011|Drug|Propofol total intravenous anesthesia|Propofol total intravenous anesthesia induced with propofol, remifentanil and atracurium and maintained with remifentanil and propofol target controlled infusion
1648123|NCT01869985|Drug|HCP1104 / Mulex Tab. and Airtal Tab.|HCP1104 / Eperisone plus Aceclofenac
1648124|NCT01869959|Drug|LY2405319|Administered SC
1648125|NCT01869959|Drug|Placebo|Administered SC
1648126|NCT01869946|Drug|Ropivacaine|
1648127|NCT01869933|Drug|OC-10X|
1648128|NCT01869920|Behavioral|Intervention group|Education on breastfeeding
1648129|NCT01869920|Behavioral|Usual care|Usual care
1648130|NCT01869907|Drug|Minocycline|100 mg once daily by mouth during 14 days
1648131|NCT01869907|Drug|placebo|once daily by mouth during 14 days
1648132|NCT01869907|Drug|Amitriptyline|25mg once daily by mouth during 14 days
1648133|NCT01869894|Procedure|metallic biliary stent insertion (double bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
1648134|NCT01869894|Procedure|metallic biliary stent insertion (single bare - S&G Biotech.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
1648189|NCT01869491|Drug|Matching placebo tablets|2 tablets four times daily
1648190|NCT01869478|Drug|Intravenous Thrombolysis|
1648191|NCT01869478|Device|Endovascular Arterial Reperfusion|
1648232|NCT01869179|Behavioral|Choir program|Attend weekly choir sessions for 12 months at the Senior Center. Choir sessions will last about 90 minutes each with a 20 minute break. Take part in 3 informal choir concerts.
1648233|NCT01869166|Biological|CART-EGFR|
1648234|NCT01869140|Device|spinal manual therapy|spinal manipulation either manual or instrumental (activator)
1717744|NCT00002254|Drug|Alovudine|
1648135|NCT01869894|Procedure|metallic biliary stent insertion (single bare - Taewoong Medical.)|The patients who had malignant biliary obstruction will be enrolled our study. Enrolled patient will be randomized to three group (uncovered double bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (S&G Biotech.) vs. uncovered single bare metallic stent (Taewoong Medical.)). After metallic biliary stent insertion, enrolled patients will be followed at least one time per one month. Blood test (including total bilirubin, gamma-GT) will be done for follow-up study. During follow-up period, if biliary obstruction is suspected, imaging study (CT or MRCP) will be done. With such follow-up tools, we compare 6-month patency rate and median patency duration among three groups.
1648136|NCT01869881|Drug|Anplag(Sarpogrelate)|Sarpogrelate 100mg 2 tablets, bid, 400mg/day
1648137|NCT01869881|Drug|Placebo|Placebo 100mg 2 tablets, bid, 400mg/day
1648138|NCT01869855|Procedure|Subdural Drainage|
1648139|NCT01869855|Procedure|Subperiosteal Drainage|
1648140|NCT01869842|Procedure|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
1648141|NCT01869842|Procedure|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
1648142|NCT01869842|Procedure|percutaneous coronary intervention|the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion
1648143|NCT01869842|Procedure|OCT-guided percutaneous coronary intervention|the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
1648144|NCT01869829|Drug|Observational antifungal therapy|"Observational study of primary antifungal therapy utilized and outcomes, including:
fluconazole, voriconazole, amphotericin B, caspofungin, and micafungin
All agents are given as standard of care."
1648145|NCT01869803|Drug|gemtuzumab ozogamicin|Given IV
1648146|NCT01869803|Other|laboratory biomarker analysis|Correlative studies
1648147|NCT01869790|Other|Different fat types|Saturated, monounsaturated fats
1648148|NCT01869777|Procedure|bioelectric impedance analysis|Undergo bioelectric impedance analysis
1648149|NCT01869764|Dietary Supplement|omega-3 fatty acid|Given PO
1648150|NCT01869764|Other|placebo|Given PO
1648151|NCT01869764|Other|laboratory biomarker analysis|Correlative studies
1648152|NCT01869751|Drug|Prucalopride|Treatment with prucalopride for slow-transit constipation
1648153|NCT01869738|Device|MGuard Prime|
1648154|NCT01869738|Device|(BMS/DES)|
1648155|NCT01869725|Radiation|gallium Ga 68-edotreotide|Given IV
1648156|NCT01869725|Procedure|positron emission tomography/computed tomography|Undergo gallium Ga 68-edotreotide PET/CT scan
1648157|NCT01869725|Radiation|indium In 111 pentetreotide|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
1648158|NCT01869725|Procedure|computed tomography|Undergo indium In 111 pentetreotide contrast-enhanced CT scan
1648159|NCT01869725|Procedure|contrast-enhanced magnetic resonance imaging|Undergo indium In 111 pentetreotide contrast-enhanced CT or MRI scan
1648160|NCT01869712|Other|Cupping therapy|
1648161|NCT01869712|Other|Acupuncture|
1648162|NCT01869699|Drug|Acetaminophen|acetaminophen 1 gram/100mLs intravenously administered over 15 minutes
1648163|NCT01869699|Drug|Placebo|Normal saline placebo Normal saline 100 mLs intravenous, administered over 15 minutes
1648164|NCT01869686|Biological|Denosumab|60 mg
1648165|NCT01869673|Device|Face Mask|Patients will be ventilated trough a face mask first and trough a oral mask thereafter
1648166|NCT01869673|Device|Oral Mask|Patients will be ventilated trough an oral mask first and trough a face mask thereafter
1648167|NCT01869660|Behavioral|Shared Decision Making|The focus of the SDM is to empower patients to discuss their attitudes and preferences toward treatments.
1648168|NCT01869647|Radiation|Ultra low dose CT scan|Ultra low dose CT scan
1648169|NCT01869647|Radiation|Regular CT or Low Dose CT scan|Regular CT or Low Dose CT scan
1648170|NCT01869647|Radiation|No imaging|No imaging
1648171|NCT01869634|Drug|darunavir with ritonavir and fixed-dose viread+emtricitabine daily|
1648172|NCT01869621|Drug|Metformin|6 days treatment with metformin to steady-state
1648173|NCT01869608|Procedure|oral glucose tolerance test 2 days post-partum|Screening for type 2 diabetes after gestational diabetes mellitus.
1648174|NCT01869582|Device|Fetoscope, Fetal heart rate|
1648175|NCT01869582|Device|Upright Resuscitator, Resuscitation|
1648176|NCT01869582|Device|Doppler, Fetal heart rate|
1648177|NCT01869582|Device|Standard Resuscitator, Resuscitation|
1648178|NCT01869569|Drug|Pregabalin|At the 4-week dose-titration phase, will receive one capsule of pregabalin (75 mg) twice daily from Day 1 to Day 7, and two capsules of pregabalin (150 mg) twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of pregabalin.
1648179|NCT01869569|Drug|Placebo|At the 4-week dose-titration phase, will receive one capsule of placebo twice daily from Day 1 to Day 7, and two capsules of placebo twice daily from Day 8 to Day 14. From Day 15 to Day 28, patients will perform dosage adjustments based on the pain relief and tolerability. At maintenance phase, patients will take the optimized dosage of placebo.
1648180|NCT01869556|Drug|Oxytocin|Oxytocin 5IU IV bolus, followed by an infusion of oxytocin 20IU/L, running at at rate of 40mIU/min for 8 hours
1648181|NCT01869556|Drug|Ergot|Ergot 0.25mg IV
1648182|NCT01869556|Drug|Carboprost|Carboprost 0.25mg IM
1648183|NCT01869543|Other|Stand Alone Air Cleaner|This is an environmental intervention using a stand alone air cleaner designed to reduce the air pollution levels in the home.
1648184|NCT01869543|Other|HVAC Modification|This is an environmental intervention that modifies the home HVAC system to include high efficiency air filtration designed to reduce the air pollution levels in the home.
1648185|NCT01869517|Other|intrastromal corneal ring segments (Keraring) implantation|
1648186|NCT01869517|Other|Intrastromal corneal continuous ring (Myoring) implantation|
1648187|NCT01869504|Device|Balloon-tipped intercostal drain|Ballooned intercostal drain for pleural effusion, inserted using local anaesthetic and ultrasound guidance.
1717745|NCT00002255|Drug|Filgrastim|
1648192|NCT01869465|Other|Pre-treatment snack|The snack will consist of a 300 ml Safi mango juice and a doughnut. Ingredients of the Safi mango juice include vitamin C, fruit flavors from concentrate, sugar, water, citric acid, color E 110 and preservative E 221. The doughnuts will be made of wheat flour, baking powder, sugar and cooking oil. A local manufacturer (House of Eden (U) Limited) will be contracted to make, pre-pack and distribute the snack to the research team at the schools during Mass Drug Administration (MDA). All children in the schools randomized to the snack arm will receive the snack shortly before swallowing the drug. The snack will be distributed by the class teachers who will also distribute record the treatment and snack in separate registers.
1648193|NCT01869465|Behavioral|Education arm|In the education arm, children will receive specific messages for schistosomiasis transmission and control 1 month prior to Mass Drug Administration (MDA). A synopsis of the messages will include the following:What schistosomiasis is and its public health significance among school age children, Schistosomiasis transmission methods, signs and symptoms and its complications, Control methods including the importance of taking preventive treatment annually, Side effects of preventive treatment, why some people suffer serious side-effects and others do not and what to do in order to mitigate the side effects.From each school, the head teacher and the school teacher in-charge of health and sanitation will be trained in the above aspects of schistosomiasis transmission and control, in basic principles of health education and in communication skills through a 2 days training workshop.
1648194|NCT01869452|Behavioral|therapeutic education|knowledge of disease, risk factors, diet, medication, alert symptoms
2012666|NCT01751230|Behavioral|WIC E-Moms|Participants enrolled in the E-Moms group will receive a personalized dietary prescription to promote weight loss and arrive at pregravid weight by 6 months postpartum. Our weight loss intervention will incorporate standard WIC nutritional advice and will encouraged 150 minutes/week of moderate intensity activity, which is about 3,000 - 4,000 steps/day above baseline, as recommended for maintenance of healthy weight. Each participant will be assigned a trained weight management counselor who will provide frequent recommendations and advice and support at least once per week.
2012667|NCT01747915|Drug|Pregabalin Dose Level 1|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 300 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum dose of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
1648199|NCT01869426|Dietary Supplement|VSL#3 drops|
1648200|NCT01869426|Dietary Supplement|VSL#3 drops placebo|
1648201|NCT01869413|Drug|Tranexamic Acid|Tranexamic acid will be administered as an intravenous infusion of 10 mg/kg over 10 minutes (loading dose) prior to surgical incision, followed by 5 mg/kg/hour continuous maintenance infusion for the length of surgery (typically 4 to 8 hours).
1648202|NCT01869413|Drug|Placebo|As there is no standard of care concerning administration of anti-fibrinolytic agents in cystectomy procedures, controls will follow the same dosing and schedule as above (loading dose followed by maintenance infusion), but with 0.9% sodium chloride.
1648203|NCT01869387|Device|Non-invasive ventilation|
1648204|NCT01869374|Device|MagVenture MagPro MST|Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.
1648205|NCT01869374|Device|RUL ECT|RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.
1648206|NCT01869361|Drug|Indomethacin|Study drug
1648207|NCT01869361|Drug|Placebo|Control drug
1648208|NCT01869348|Behavioral|Monitor intervention|"Investigators will lend each participant 1 Jawbone Up activity monitor and 1 mini tablet device. Participants will receive weekly brief phone calls with counseling related to self-efficacy and self-regulation. The monitors will be programmed to provide idle alerts that vibrate when participants have reached a cut point for a bout of sedentary behavior (e.g., 30 minutes). Participants will monitor their progress using an app on the tablet that provides graphical feedback on physical activity and sedentary behavior."
1648209|NCT01869335|Device|radiography|
1648210|NCT01869335|Device|MRI (magnetic resonance imaging)|
1648211|NCT01869322|Device|Sling and Swathe|Sling and Swathe immobilization of humeral shaft fracture.
1648212|NCT01869322|Device|Coaptation Splint|Coaptation splint immobilization of humeral shaft fractures.
1648213|NCT01869309|Drug|Prasugrel|Patients will discontinue ticagrelor treatment and start 10 mg prasugrel daily while continuing 81 mg of aspirin daily.
1648214|NCT01869309|Drug|Ticagrelor|Patients will be given 180 mg of Ticagrelor followed by 90 mg twice a day while continuing 81 mg of aspirin daily).
1648215|NCT01869296|Procedure|higher flow rates|higher flow rates endoscope pump water immersion colonoscopy : 10.4 ml/sec
1648216|NCT01869296|Procedure|lower flow rates|lower flow rates endoscope pump water immersion colonoscopy : 1.7 ml/sec
1648217|NCT01869283|Other|Kinesiotherapy|
1648218|NCT01869283|Other|Ultrasound|
1648219|NCT01869283|Other|Diadynamic currents|
1648220|NCT01869257|Device|Triclosan coated suture|The patients in the treated arm will have the abdominal wound sutured with triclosan-coated suture
1648221|NCT01869257|Device|regular suture|The control arm will have the abdominal wound sutured with a regular non-coated suture
1648222|NCT01869231|Dietary Supplement|olive oil|
1648223|NCT01869231|Dietary Supplement|olive oil and chewing gum|
1648224|NCT01869231|Dietary Supplement|chewing gum|
1648225|NCT01869231|Dietary Supplement|water|
1648226|NCT01869205|Device|Endobronchial valve|One-way endobronchial valves are placed in segmental bronchi of the most hyperinflated and least perfused lobe of the emphysematous lungs on computed tomography (CT). Before the procedure, we confirm that the target lobe has no collateral ventilation with other lobes using Chartis® System (Pulmonx, Inc. Redwood City, CA, USA).
1648227|NCT01869192|Drug|Epirubicin|Epirubicin 90 mg/m2 d1 q3w
1648228|NCT01869192|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 d1 q3w
1648229|NCT01869192|Drug|Docetaxel|Docetaxel 75 mg/m2 d1 q3w
1648230|NCT01869192|Drug|Capecitabine|Capecitabine 1000 mg/m2/dose bid x 14d q3w
1648901|NCT01864018|Other|Laboratory Biomarker Analysis|Correlative studies
1648235|NCT01869127|Device|Shoes|A unisex canvas slip-on with a sturdy sole.
1648236|NCT01869114|Drug|Sirolimus|Given PO
1648237|NCT01869114|Drug|Azacitidine|Given IV
1648238|NCT01869088|Drug|Recombinant Human Adenovirus Type 5 Injection|After identifying the target artery of HCC, Recombinant Human Adenovirus Type 5 Injection（15.0*1011vp：0.5ml*3） will be first infused through the target artery
1648239|NCT01869088|Procedure|Transartery Chemoembolization|Transartery chemoembolization with chemothrapy drugs (E-ADM 50mg, Lobaplatin 50 mg, MMC 6mg)and followed with embolization with lipiodol or/and polyvinyl alcohol particles.
1648240|NCT01869075|Other|Knowledge Translation (KT) toolkit|KT toolkit consists of: use of pre-printed orders, use of pharmacist as project lead and human reminder for prescribing, audit and feedback, education for staff
1648241|NCT01869062|Device|SonR CRT Optimization 'On'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'on'.
1648242|NCT01869062|Device|SonR CRT Optimization 'Off'|Intervention: Implanted CRT-D device with the SonR optimization algorithm programmed being 'off' (Standard of Care).
1648243|NCT01869036|Drug|caudal anesthesia|Standard caudal anesthesia (Marcaine 2mg/kg)
1648244|NCT01869036|Drug|caudal anesthesia supplemented with morphine|Caudal anesthesia supplemented with Morphine (10 µg/kg in children less than 10 kg and 20 µg/kg in children more than 10 kg)
1648245|NCT01869023|Drug|Gemcitabine|Combination of Gemcitabine 250 mg/m2 in six hour infusion with cisplatin 35 mg/m2 administered day 1 and 8, for six cycles.
1648246|NCT01869023|Drug|Cisplatin|Cisplatin 35 mg/m2SC applied on day 1 of 3 weeks cycles
1648247|NCT01869010|Other|Low sodium water overload in HIV tenofovir, HIV no tenofovir and seronegative controls|This test is based on the exploration of the tubular response to an acute fluid load. After overnight fast, all participants received twenty cc/Kg of mineralized water per os and two liters of intravenous hypotonic solution (0.66%) infused in two hours. Three blood samples are drawn (at 0, 60 and 120 minutes) and also urine samples are collected from each person at baseline and at 30 (±5) minutes intervals during the whole test. From the obtained blood and urine samples creatinine and osmolarity are measured, and then from the data corresponding to the most hypotonic urine sample (maximum dilution) and its corresponding blood sample three renal physiological parameters (proximal sodium clearance, free water clearance, sodium TALH reabsorption) are analyzed. Since patient inclusion follow up period is one month
1648248|NCT01868997|Drug|teprotumumab|
1648249|NCT01868997|Drug|normal saline|
1648250|NCT01868984|Drug|Paclitaxel|Paclitaxel solution treatment of each lesion encountered will be attempted until the 20 mg Paclitaxel dose limit is met. The volume administered will depend on the diameter and length of the venous outflow segment.
1648251|NCT01868984|Procedure|Standard Therapy|Standard treatment of all stenotic lesions will be carried out in the usual fashion. Intravenous heparin will be administered in a standard dose of 70 units/kg. Lesions that respond poorly to angioplasty (>30% residual stenosis after angioplasty treatment with 2 inflations) will be stented. Stent selection will be based on clinical setting. Initial stent treatment will utilize an uncovered nitinol stent. Treatment of in-stent restenosis will include initial balloon angioplasty, and use of a covered stent (Viabahn, GORE, or Fluency, Bard).
1648252|NCT01868971|Device|EndoRings|Colonoscopy procedure, standard endo-therapy interventions will be performed in accordance with physician`s evaluation
1648253|NCT01868945|Dietary Supplement|5 µg/day Hy.D Calcifediol|5 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
1648254|NCT01868945|Dietary Supplement|10 µg/day Hy.D Calcifediol|10 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
1648255|NCT01868945|Dietary Supplement|15 µg/day Hy.D Calcifediol|15 µg/day Hy.D Calcifediol taken together with breakfast for a total period of 24 weeks
1648256|NCT01868945|Dietary Supplement|20 µg/day vitamin D3|20 µg/day vitamin D3 taken together with breakfast for a total period of 24 weeks
1648257|NCT01868932|Other|hypertonic saline|inhaled nebulized 3%NaCl
1648258|NCT01868932|Other|saline|inhaled nebulized 0.9% NaCl
1648259|NCT01868919|Behavioral|Positive Parenting Program|Level 3 or 4 of Triple P
2012668|NCT01747915|Drug|Pregabalin Dose Level 2|Pregabalin, either liquid or capsule, dosed twice daily, escalated up to a maximum of 600 mg/day beginning at Randomization to Taper Phase, then tapered down to a maximum of 150 mg/day during 1 week Taper Phase to End of Study/Early Termination.
2012669|NCT01747915|Drug|Placebo|Placebo, either liquid or capsule, dosed twice daily beginning at Randomization to End of Study/Early Termination.
2012670|NCT01748162|Drug|Fluticasone|Daily inhaled steroids. Fluticasone 2 puffs inhaled orally twice daily for six months.
1648266|NCT01868893|Drug|Obinutuzumab|
1648267|NCT01868893|Drug|Chlorambucil|
1648268|NCT01868880|Drug|Ivabradine plus beta-blocker (bisoprolol)|Ivabradine will be administered at a dose of 5 mg twice daily in addition to a low dose of beta-blocker (bisoprolol 1,25 or 2,5 mg). After four weeks of treatment ivabradine will be eventually lowered up to 2,5 mg twice daily in the presence of side effects (phosphenes, diplopia, headache or dizziness).
1648269|NCT01868880|Drug|betablocker titration|Beta blocker Bisoprolol will be up-titrated biweekly starting from the initial dose of 1,25-2,5 mg daily up to the max dose of 10 mg daily or to the maximum tolerated dose.
1648270|NCT01868867|Behavioral|Intervention|On line tutorial followed by text messaging during treatment and iPad for patient education
1648271|NCT01868841|Radiation|AdreView|10 millicurie of AdreView (123I-mIBG)
1648272|NCT01868841|Other|Single Photon Emission Computed Tomography|
1648273|NCT01868828|Drug|PAD|Induction Therapy of PAD for 4 cycles.
1648274|NCT01868828|Drug|VCD|Induction Therapy of VCD for 4 cycles.
1648275|NCT01868828|Other|ASCT|Not suitable for transplant patients will continue accept treatment for 8 cycles.
1648276|NCT01868802|Drug|Ketamine|A single dose of 0.5mg/kg intravenous ketamine infusion will be administered over 40 minutes.
1648277|NCT01868802|Drug|Placebo|Saline at 0.9% intravenous infusion will be administered over 40 minutes.
1648279|NCT01868776|Drug|buffered lidocaine|
1648280|NCT01868776|Drug|nonbuffered lidocaine|
1717746|NCT00002255|Drug|Epoetin alfa|
1648281|NCT01868763|Device|telemedical devices (weighing machine and step counter)|
1648282|NCT01868763|Behavioral|care calls once per week for 12 weeks|
1648283|NCT01868750|Dietary Supplement|Calcitriol|1.0ug twice daily for 7 days before surgery
1648284|NCT01868750|Dietary Supplement|Control Pill|placebo pill taken twice daily for 7 days before surgery
1648285|NCT01868737|Dietary Supplement|Probiotic|Lactobacillus rhamnosus GG and Bifidobacterium infantis'
1648286|NCT01868737|Dietary Supplement|Placebo|MCT oil
1648287|NCT01868711|Behavioral|Cognitive Behavior Therapy|"Fourteen sessions of cognitive behavior therapy for depression. The patient will be psycho educated about symptoms of depression. The patient will learn to use the following basic cognitive-behavioral techniques for the treatment of depression:
Constructing an 'Action Schedule', setting goals, doing 'Behavioral Experiments', and constructing a thought record, checking accuracy of thoughts, re framing thoughts when necessary and learn to engage in problem solving for particular situations."
1648288|NCT01868698|Other|high-voltage electrical stimulation|
1648289|NCT01868698|Other|Kinesiotherapy|
1648290|NCT01868698|Other|shortwave diathermy|
1648291|NCT01868685|Drug|BYM338|BYM338
1648292|NCT01868685|Drug|Placebo|Placebo
1648293|NCT01868672|Behavioral|Educational print materials and coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
1648294|NCT01868659|Behavioral|Diagnostic checklist|Diagnostic checklist used before patient discharged
1648295|NCT01868659|Behavioral|Usual care with no diagnostic checklist|Patient receives usual care with no research intervention
1648296|NCT01868646|Drug|Subetta|Efficiency and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus
1648297|NCT01868646|Drug|Placebo|
1648298|NCT01868633|Drug|Dexamethasone|
1648299|NCT01868633|Drug|Placebo|
1648300|NCT01868620|Device|Iontophoretic CXL|
1648301|NCT01868620|Device|Standard CXL|
1648302|NCT01868594|Drug|Subetta|Efficiency and Safety of Subetta in the combined treatment of patients with type I diabetes mellitus
1648303|NCT01868594|Drug|Placebo|
1648304|NCT01868581|Drug|insulin degludec|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
1648305|NCT01868581|Drug|insulin degludec/insulin aspart|Each subject will be allocated to 2 single injections of trial product on 2 separate dosing visits, administered subcutaneously (s.c., under the skin).
1648306|NCT01868568|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin).
1648307|NCT01868568|Drug|insulin degludec/insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
1648308|NCT01868568|Drug|insulin degludec/insulin aspart 40|A single dose administered subcutaneously (s.c., under the skin).
1648309|NCT01868568|Drug|insulin degludec/insulin aspart 45|A single dose administered subcutaneously (s.c., under the skin).
1648310|NCT01868568|Drug|insulin degludec/insulin aspart 55|A single dose administered subcutaneously (s.c., under the skin).
1648311|NCT01868568|Drug|insulin aspart|A single dose administered subcutaneously (s.c., under the skin).
1648312|NCT01868568|Drug|biphasic insulin aspart 30|A single dose administered subcutaneously (s.c., under the skin).
1648313|NCT01868568|Drug|placebo|A single dose administered subcutaneously (s.c., under the skin).
1648314|NCT01868555|Drug|insulin degludec|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
1648315|NCT01868555|Drug|insulin degludec/insulin aspart 30|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
1648316|NCT01868555|Drug|insulin degludec/insulin aspart 45|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
1648317|NCT01868555|Drug|placebo|Administered as once daily subcutaneous (s.c., under the skin) dose per 0.6 nmol/kg body weight for 6 days
1648318|NCT01868542|Drug|insulin detemir|Insulin detemir was administered once daily to the subjects. The dose was titrated based on the previous breakfast SMPG values.
1648319|NCT01868529|Drug|insulin degludec|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
1648320|NCT01868529|Drug|insulin glargine|Once daily dosing administered subcutaneously (s.c., under the skin) followed by a clamp visit. The two treatment periods will be separated by a wash-out period where the subjects will resume their normal insulin treatment.
1648321|NCT01868516|Drug|dexmecamylamine|
1648322|NCT01868516|Drug|Placebo|
1648323|NCT01868503|Drug|lapatinib ditosylate|Given PO
1648324|NCT01868503|Radiation|radiation therapy|Undergo radiation therapy
1648325|NCT01868503|Other|laboratory biomarker analysis|Correlative studies
1648326|NCT01868490|Drug|cytokine induced killer cells|at least 10*9 CIK cells, IV on day 0, 14, 28
1648327|NCT01868477|Drug|Erythropoietin alpha|
1648328|NCT01868477|Drug|Erythropoietin alpha|
1648329|NCT01868477|Drug|Deferasirox|
1648330|NCT01868464|Biological|BCG TICE strain|All doses: Tice Bacillus Calmette-Guerin (BCG) will be administered as a single 0.1 ml ID injection over the deltoid muscle of the preferred arm. Groups 1 - 4 will receive one dose of Tice BCG intradermally at 2x10^6 cfu, 4x10^6 cfu, 8x10^6 cfu and 16x10^6 cfu, respectively.
1648331|NCT01868451|Drug|Brentuximab vedotin (SGN-35)|
1648332|NCT01868451|Drug|Doxorubicin HCL|
1648333|NCT01868451|Drug|Vinblastine Sulfate|
1648334|NCT01868451|Drug|Dacarbazine|
1648335|NCT01868451|Radiation|Involved-Site Radiation Therapy (ISRT)|
1648336|NCT01868451|Procedure|Interim PET|
1648337|NCT01868451|Radiation|consolidation volume RT (CVRT)|
1648338|NCT01868438|Drug|pyronaridine-artesunate granules|
1648339|NCT01868438|Drug|Pyronaridine-artesunate tablets|
1648404|NCT01867918|Procedure|Radiofrequency ablation, microwave, radiation therapy|Radiofrequency ablation Microwave ablation Radiation therapy
1648405|NCT01867918|Drug|Standard Chemotherapy|
1648340|NCT01868425|Drug|multimodal:acetaminophen, gabapentin, ketamine, bupivacaine|acetaminophen, gabapentin, ketamine, bupivacaine and standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane
1648341|NCT01868425|Drug|placebo pills and injectables|receives standard care which includes ketorolac, bupivacaine, fentanyl, ondansetron, dexamethasone, sevoflourane plus placebos of intervention arm meds
1648342|NCT01868412|Device|Abilar 10% resin salve|The resin salve may be spread directly onto the wound, after which the area is covered with a bandage suitable for local wound care. The bandage prohibits salve from moving away from the wound area. If the skin condition is more widespread or contains cavities or fistulae, the salve may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the degree of infection and amount of wound secretion.
1648343|NCT01868412|Device|Activon Tube 25 g|Wound care with the medical honey is carried out in the same manner than the resin salve treatment: honey may be spread directly onto the wound and the wound area is covered with a bandage suitable for local wound care. Similarly, if the skin condition is more widespread or wound contains cavities or fistulae, the medical honey may be spread as a film with a thickness of at least 1 mm onto a gauze or gauze ribbon that is then used to fill the cavity or fistulae channel. Bandages are changed every 1-3 days, depending on the severity of infection and amount of wound secretion.
2012671|NCT01746979|Drug|TH-302|TH-302 will be administered at a dose of 340 milligrams per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
1648345|NCT01868373|Biological|Microbiota Transplantation (FMT)|Active therapy
1648346|NCT01868360|Drug|Subconjunctival aflibercept|subconjunctival aflibercept injection
1648347|NCT01868360|Other|Placebo: Standard of care only|Patients will receive standard of care (steroids and cyclosporine) treatment only.
1648348|NCT01868347|Other|treatment|preemptive PEEP before pneumoperitoneum and trendelenburg
1648349|NCT01868347|Other|control|PEEP after pneumoperitoneum and trendelenburg
1648350|NCT01868334|Behavioral|Pillar 1: Convenient Vaccination Services|"Extend Vaccination Season: Begin vaccinating for influenza as soon as vaccine arrives; use every visit as opportunity to vaccinate; extend the season for influenza by vaccinating in January and beyond.
Use Express Vaccination services such as influenza vaccination clinics, Open access vaccine scheduling (for all vaccines), or dedicated vaccination station. When giving influenza vaccination, screen for need for PPSV/Tdap."
1648351|NCT01868334|Behavioral|Pillar 2: Patient notification|"Patient Education: notifying patients of doctor recommendations for vaccination; providing information on express vaccination services via email, autodialer, on-hold messages, clinic websites, and/or social media"
1648352|NCT01868334|Behavioral|Pillar 3: Enhanced Office Systems|Routine assessment for office systems flow to ensure staff consistently promoting vaccination: utilization of EMR prompts, review of Immunization tabs within EMR, and/or checking vaccination status as part of vital signs when rooming. Empower staff to vaccinate by use of a standing orders program (SOP). Order a sufficient supply of vaccination to cover increased rates
1648353|NCT01868334|Behavioral|Pillar 4: Motivation|Utilization of an Office Immunization Champion who will track overall progress towards their goal - setting a goal of increased rates of 20 to 25% for influenza vaccine; monitoring and sharing progress with staff regularly; and changing office systems flow as needed to increased vaccination rates.
1648354|NCT01868295|Behavioral|Sleeping with denture|Sleeping with denture at night
1648355|NCT01868282|Procedure|Hamstrings block|patients enrolled in the study will receive subsartorial saphenous nerve block in all the three groups. Patients in group 1 will receive perimuscular injections around the gracilis and semi-tendinosus muscles. The needle is redirected to the fascial plane between Sartorius and gracilis muscle after the sub-sartorial canal block where 7.5 ml of 0.5% ropivacaine is injected around the muscle. The needle is further advanced to the fascial planes between semimembranosus and semitendinosus and an additional 7.5 ml of 0.5% ropivacaine will be injected around the semitendinosus muscle. Following this a sham injection of 10mL of saline for the anterior division of obturator nerve will also be performed as in group 2 to ensure blinding.
1648356|NCT01868282|Procedure|Obturator block|Patients in group 2 will receive anterior division of obturator nerve block along with subsartorial canal block. After ensuring aseptic precautions, the saphenous nerve block is performed similar to that as in group 1. The anterior branch of obturator nerve will be visualised in the proximal thigh medial to femoral vessels between adductor longus and adductor brevis. A 22 gauge 90 mm PNS block needle will be inserted under ultrasound guidance to reach the anterior division of obturator nerve confirmed with neurostimulation followed by injection of 10 ml of 0.5% ropivacaine around the nerve. This group will receive sham injection of 15mL of saline around semitendinosus and semimembranosus as in group 1
1648357|NCT01868282|Procedure|Control group|The patients in group 3 will form the control group. After performance of the subsartorial saphenous nerve block, patients in group 3 will receive sham injections of saline for the obturator nerve block and the hamstrings block (perimuscular injections).
2012672|NCT01746979|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 1000 (mg/m^2) as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
1648361|NCT01868256|Other|early discharge (<72 h)|
1648362|NCT01868256|Other|Conventional discharge|
1648363|NCT01868243|Drug|Dabigatran|Group 1 - Dabigatran 110 mg (50 patients)
1648364|NCT01868243|Drug|Warfarin|Warfarin adjusted-dose
1648365|NCT01868230|Behavioral|Lifestyle Intervention|
1648366|NCT01868191|Drug|Benfotiamine|Treatment with 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
1648367|NCT01868191|Drug|Placebo for benfotiamine|Treatment with placebo for benfotiamine 600 mg/day for the first 3 months followed by 300 mg/day for 9 months
1648368|NCT01868178|Device|BIS and Spectral Entropy|The aim of the study was investigated the effectiveness of Spectral Entropy and BIS in avoiding awareness
1648402|NCT01867944|Behavioral|Perineal Self-Acupressure|The core of the technique is to have subjects repeatedly press on and massage their perineum before defecation to fragment and soften the stool before it passes the lower rectum and anus.
1648592|NCT01866423|Drug|orteronel|Given PO
1648369|NCT01868139|Device|Liquid nitrogen spray cryotherapy with the truFreeze device|Low-pressure liquid nitrogen is sprayed through an upper endoscope on the diseased esophageal tissue to freeze and destroy it. The upper endoscope enables direct visualization of mucosal freeze during spray of the liquid nitrogen onto the mucosa and avoids the need for direct contact with the tissues. The target area is frozen and thawed for several consecutive cycles. The treated tissue becomes necrotic and sloughs, with new, healthy tissue regenerating in its place.
1648370|NCT01868126|Drug|DE-117 ophthalmic solution|
1648371|NCT01868126|Drug|latanoprost ophthalmic solution|
1648372|NCT01868126|Other|Placebo|
1648373|NCT01868113|Drug|Inhaled corticosteroid|Inhaled fluticasone 500mcg 12 hourly up to discharge or a maximum of 5 days
1648374|NCT01868113|Other|Placebo|Placebo to be administered 12hourly
1648375|NCT01868100|Other|self-completion questionnaire|
1648376|NCT01868087|Dietary Supplement|Boost Plus®|
1648377|NCT01868087|Dietary Supplement|Impact Advanced Recovery®|
1648378|NCT01868074|Device|Insole|Custom-molded arch-supporting insole
1648379|NCT01868061|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
1648380|NCT01868061|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
1648381|NCT01868048|Drug|Sativex|"Contains delta -9 tetrahydrocannabinol (THC), 27 mg/mL:cannabidiol (CBD), 25 mg/mL, in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring.
Subjects receive study medication delivered in 100 microlitre actuations by a pump action oromucosal spray. Maximum permitted dose is 10 actuations per day. Each actuation delivers THC 2.7 mg and CBD 2.5 mg."
1648382|NCT01868048|Drug|Placebo|Oromucosal spray, containing no active drug but ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring and colorants. Maximum permitted dose is 10 actuations per day.
1648383|NCT01868035|Drug|tositumomab and iodine I-131 tositumomab|"Subjects received the following treatments of TST/I-131 TST by intravenous (IV) infusion:
Dosimetric Dose: 450 mg of TST infused over 1 hour immediately followed by 35 mg of TST labeled with 5 milliCuries (mCi) of I 131 infused over 30 minutes.
Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 60 minutes, immediately followed by 35 mg of TST labeled with the subject-specific mCi activity of I 131 needed to deliver a total body dose of 75 centiGrays (cGy), infused over 30 minutes for subjects with a platelet count of 150,000/mm3. Subjects with platelet counts of 100,000 to 149,999/mm3 received 65 cGy, and obese subjects were dosed based upon 137% of their calculated lean body mass."
2012673|NCT01746979|Drug|Placebo (5 percent dextrose - D5W)|TH-302 placebo (5 percent dextrose - D5W) will be administered as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle. Doses will be administered until evidence of progressive disease, intolerable toxicity or subject withdrawal.
2012674|NCT01740427|Drug|PD-0332991|PD-0332991, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
2012675|NCT01740427|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
1648390|NCT01868009|Device|ELLIPTA|Novel dry powder inhaler (placebo) with 30 doses (2 strips with 30 blisters per strip)
1648391|NCT01868009|Device|DISKUS|Multidose dry powder inhaler (placebo) containing a foil strip worth 60 blisters (1 strip with 60 blisters per strip)
1648392|NCT01867996|Drug|Retosiban|Retosiban will be supplied as clear colorless solution for infusion (300 mg in 20 mL via). Subject will receive loading dose of 6 mg over 5 min infusion followed by 6 mg/hour infusion for 12 hrs on Day 1 and Day 18.
1648393|NCT01867996|Drug|EFZ 600 mg|EZF 600 mg will be supplied as a yellow, capsular-shaped, film-coated tablet. Subjects will receive EFZ 600mg OD in the evening from Day 3 till Day 18.
1648394|NCT01867983|Behavioral|Weight gain prevention and smoking cessation|"The two intervention groups will receive weight gain prevention either:
Simultaneous: weight control treatment simultaneous with cessation treatment (5 proactive calls with a quit coach combined with weight coach/nutritionist followed by 5 'contact control calls'), or Sequential: weight control treatment added after cessation treatment (5 proactive calls with a quit coach followed by 5 weight coach/nutritionist calls). All three study arms will include a total of 10 phone counseling calls, interactive web, mailed support materials, access to nicotine replacement therapy (NRT) and unlimited participant initiated calls."
1648395|NCT01867983|Behavioral|Smoking cessation|The control group will receive cessation treatment calls (5 proactive calls with a quit coach followed by 5 contact control calls.
1648396|NCT01867970|Device|Tool|"The It's LiFe! tool consists of three different elements:
the 3D accelerometer (Figure 7-8);
the application (app) on a Samsung Smartphone (Figure 6);
a web application and server called It's LiFe! online (powered by Sananet). The transmission of data from the accelerometer towards the app is via a Bluetooth connection. Every 15 minutes, or when the users press the refresh button, the Smartphone will connect to the accelerometer. The accelerometer should be within a 5 meter distance from the Smartphone. The transmission of data from the Smartphone towards the It's LiFe! server is via an internet connection. Therefore the Smartphone needs a SIM card with a data subscription."
1648397|NCT01867970|Behavioral|Self-management Support Program|Consultations 1)The PN will increase awareness of the PA pattern, she will inform the patient about the health risks related to a sedentary lifestyle. Assessment of the PA level is done by completing the SQUASH questionnaire. The patient gets a leaflet with information about being active. 2)A day goal will be set in minutes a day, based on the results of the measurements of the first two weeks. The pre-measurement in condition 1 is an objective measurement by the tool and they are visible for the PN on the monitor portal of the It's LiFe! Server. The PN will encourage the patient to focus on goals that fit to the patient's preferences and to set up a SMART plan to reach personal goal. 3)The PN will discuss the results and barriers and facilitators related to physical activities. 4)The PN will discuss the results, behavior change and habits, with the patient.
1648398|NCT01867957|Biological|Low-dose GC1109|50ug/dose
1648399|NCT01867957|Biological|High-dose GC1109|100ug/dose
1648400|NCT01867957|Biological|Low-dose Placebo|0.9% Saline 0.5 mL
1648401|NCT01867957|Biological|High-dose Placebo|0.9% Saline 1.0 mL
1648403|NCT01867944|Behavioral|Educational Control|Education on conventional treatment options for chronic constipation.
1648593|NCT01866423|Other|laboratory biomarker analysis|Correlative studies
1648406|NCT01867892|Drug|ICT of oxapliplatin, irinotecan, leucovorin, and fluorouracil and CCRT|oxapliplatin ,irinotecan ,5FU +leucovorin ,RT 5,040cGy in 28 fractions/5.5 wks and 5FU 450mg/m2 iv 30min weekly
1648407|NCT01867892|Drug|ICT of Gemcitabine,oxapliplatin, leucovorin, and fluorouracil + CCRT|Gem ,Oxa ,5FU +LV ,RT 5,040cGy in 28 fractions/5.5 wks and Gem 400mg/m2 iv 40min weekly
1648408|NCT01867879|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
1648409|NCT01867879|Drug|Placebo|Placebo tablets, orally, single dose.
1648410|NCT01867866|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
1648411|NCT01867866|Drug|Trifluridine|35 mg/m2, orally, single dose
1648412|NCT01867853|Device|PLR|passive leg raising test was done before and at the end of SBT
1648413|NCT01867827|Other|Neurofeedback and Physical Exercise|
1648414|NCT01867827|Other|Physical Exercise|
1648415|NCT01867814|Procedure|Pneumoperitoneum|Pneumoperitoneum 15 mmHg and 10 mmHg
1648416|NCT01867775|Drug|Mirtazapine|Mirtazapine 15 mg, at night, once a day for 14 days
1648417|NCT01867762|Drug|JNJ 49095397|JNJ 49095397 400 microgram will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
1648418|NCT01867762|Drug|Placebo|Placebo will be inhaled by participants once daily by using a dry powder inhaler for 12 weeks.
1648419|NCT01867749|Behavioral|Group Interpersonal Psychotherapy (IPT-G)|
1648420|NCT01867749|Behavioral|Coping with Depression (CWD)|
1648421|NCT01867736|Device|Passeo-18 Lux DRB|
1648422|NCT01867736|Device|Standard PTA (POBA)|
1648423|NCT01867723|Other|Internet communication application|Intervention 1 Effect of internet support program will be tested on cancer patients and their family caregivers No intervention
2012676|NCT01740427|Drug|Placebo|Placebo, 125mg, orally once daily on Day 1 to Day 21 of every 28-day cycle followed by 7 days off treatment
2012677|NCT01740427|Drug|Letrozole|Letrozole, 2.5mg, orally once daily (continuously)
2012678|NCT01739309|Drug|LY2835219|Administered orally
2012679|NCT01737268|Drug|FK949E|Oral tablet
2012680|NCT01736124|Other|computerized cognitive training|A variety of computer games tailored to address their personal cognitive deficits.
1648429|NCT01867697|Drug|Cetuximab|
1648430|NCT01867697|Drug|Irinotecan|
1648431|NCT01867697|Drug|Oxaliplatin|
1648432|NCT01867697|Drug|Folinic Acid|
1648433|NCT01867697|Drug|Calcium Carbonate|
1648434|NCT01867684|Other|Psychotherapy|
1648435|NCT01867671|Biological|Peanut Oral Immunotherapy - Liquid Extract|Used during initial dose escalation for doses 0.1 to 0.8 mg.
1648436|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Liquid Extract form|Similar in appearance, texture, and taste to peanut liquid extract.
1648437|NCT01867671|Biological|Peanut Oral Immunotherapy - Peanut Flour|This will be used for the remainder of dose escalation, build-up, and maintenance.
1648438|NCT01867671|Biological|Placebo for Peanut Oral Immunotherapy - Peanut Flour|Similar in appearance, texture, and taste to peanut flour.
1648439|NCT01867658|Device|Progel® Pleural Air Leak Sealant|Video-assisted or robotic-assisted surgical lung procedures plus Progel® Pleural Air Leak Sealant
1648440|NCT01867645|Drug|IgM-enriched Intravenous Immunoglobulins|IgM-enriched IVIG (Pentaglobin, Biotest Pharma GmbH, Dreieich, Germany) at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days.
1648441|NCT01867645|Drug|Human Albumin|Human albumin 1% (Biotest Pharma GmbH, Dreieich, Germany) as placebo at a dose of 0.25g/kg body weight/day as a continuous intravenous infusion at a rate of 2g/h over a period of 3 days
1648442|NCT01867632|Device|Acellular Dermal Matrix|
1648443|NCT01867619|Drug|Lomustine|Starting dose 30 mg/m^2 by mouth daily on Day 1 and 29.
1648444|NCT01867619|Drug|Temozolomide|75 mg/m^2 by mouth daily on Days 1 to 42.
1648445|NCT01867619|Drug|Thalidomide|200 mg/m^2 by mouth daily.
1648446|NCT01867606|Biological|serum-derived bovine immunoglobulin protein isolate|Given PO
1648447|NCT01867606|Other|placebo|Given PO
1648448|NCT01867606|Other|laboratory biomarker analysis|Correlative studies
1648449|NCT01867606|Other|quality-of-life assessment|Ancillary studies
1648450|NCT01867606|Other|questionnaire administration|Ancillary studies
2012681|NCT01736124|Other|control games|A variety of computer games that are engaging but not designed to enhance cognitive skills
1648454|NCT01867567|Procedure|abdominal bandage|
1648455|NCT01867554|Genetic|gene analysis|gene analysis
1648456|NCT01867528|Procedure|Laparoscopic adhesiolysis|
1648457|NCT01867528|Procedure|Open adhesiolysis|
1648458|NCT01867502|Drug|MET + Vildagliptin Group|"Vidagliptin group will receive 50mg of this drug twice a day during 12 weeks added to usual metformin.
For the glicemic control evaluation will be used the capilar glycemia at home. The adjustments will be done by the researcher coordinator."
1648459|NCT01867502|Drug|MET + Glibenclamide Group|"The initial dose of glibenclamide group will be 5mg / day during the first week of study, later it will increase to 10 mg / day (2 x 5mg). With the control the dose may be adjusted, reaching the maximum dose allowed, which is 20 mg / day.
For the glycemic control evaluation will be used the capillar glycemia at home. The adjustments will be done by the researcher coordinator."
1648460|NCT01867489|Other|No intervention|
1648461|NCT01867476|Other|Automated Adherence Monitoring System|
2012682|NCT01732822|Drug|Ticagrelor|Ticagrelor 90 mg bd (and Clopidogrel placebo od) taken orally as tablets
2012683|NCT01732822|Drug|Clopidogrel|Clopidogrel 75 mg od (and Ticagrelor placebo bd) taken orally as tablets
2012684|NCT01731600|Drug|turoctocog alfa pegol|Fixed dose of turoctocog alfa pegol for intravenous injections (i.v.) twice weekly for prophylaxis. In addition, turoctocog alfa pegol will be administered to treat bleeding episodes during the trial period. Bleeding episodes will be treated with doses of 20-75 U/kg body weight.
1648462|NCT01867463|Biological|Pfs25-EPA/Alhydrogel|The Pfs25-EPA conjugate was produced by reaction between thiolated PpPfs25 and maleimideactivated EcEPA, followed by purification using size-exclusion chromatography. The cGMP Pfs25-EPA conjugate Lot# WRAIR1634 was manufactured at Walter Reed Bioproduction facility in cGMP compliance in May 2010. Alhydrogel (Brenntag, Denmark) is an aluminum hydroxide gel and has been extensively used as an adjuvant in licensed human vaccines. Alhydrogel is supplied as a sterile product in water without preservatives. Pfs25- EPA/Alhydrogel WRAIR Lot #1668 was manufactured and filled as single-use vials at Walter Reed Bioproduction facility in cGMP compliance in October 2010. Each vial contains 78 g/mL conjugated Pfs25, 93 g/mL conjugated EPA and 1600 g/mL Alhydrogel in a volume of 0.8 mL. The vial label reads: 78 g/mL Conjugated Pfs25 on Alhydrogel .
1648463|NCT01867463|Biological|Euvax B|Euvax B consists of highly purified, noninfectious particles of HBsAg absorbed onto aluminum salts as an adjuvant and preserved with thimerosal.
1648464|NCT01867463|Biological|Menactra|Menactra , Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine, is a sterile, intramuscularly administered vaccine that contains Neisseria meningitidis serogroup A, C, Y and W-135 capsular polysaccharide antigens individually conjugated to diphtheria toxoid protein. N meningitidis A, C, Y and W-135 strains are cultured on Mueller Hinton agar (3) and grown in Watson Scherp (4) media. The polysaccharides are extracted from the N meningitidis cells and purified by centrifugation, detergent precipitation, alcohol precipitation, solvent extraction and diafiltration.
1648465|NCT01867437|Drug|Placebo|Sterile solution (vehicle) for subcutaneous infusion
1648466|NCT01867437|Drug|RM-493|Sterile solution (2mg/ml) for subcutaneous infusion
2012685|NCT01728805|Biological|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
2012686|NCT01728805|Drug|Vorinostat|
2012687|NCT01722929|Device|Sensor on surgery side|
2012688|NCT01722929|Device|Sensor on non-surgery side|
2012689|NCT01720524|Drug|placebo|IV placebo or 0.9% sodium chloride or 10% dextrose. Infusion rate based on weight.
2012690|NCT01720524|Drug|iv sildenafil|loading dose of 0.1 mg/kg over 30 minutes followed by maintenance dose of 0.03 mg/kg/h. To infuse minimum 48 hours and maximum of 14 days.
2012691|NCT01720342|Procedure|Aortic Valve Replacement surgery|Aortic Valve Replacement surgery of the native aortic valve with the Enable® aortic bioprosthesis.
2012692|NCT01719744|Drug|ENMD-2076|
2012693|NCT01719224|Procedure|elevated body position|
1648476|NCT01867294|Drug|spironolactone|Given topically
1648477|NCT01867294|Other|placebo|Given topically
1648478|NCT01867294|Other|questionnaire administration|Ancillary studies
1648479|NCT01867294|Drug|sunscreen|Given topically
1648480|NCT01867294|Procedure|management of therapy complications|Moisturizer given topically
1648481|NCT01867294|Drug|doxycycline|Given PO
1648482|NCT01867294|Drug|therapeutic hydrocortisone|Given topically
1648483|NCT01867281|Drug|aspirin|
1648484|NCT01867268|Drug|Acetazolamide|Acetazolamide administration for 10 days adjust dosage with weight of the patient
1648485|NCT01867268|Other|prone positioning|prone positioning the patient for 10 days following the surgery
1648486|NCT01867268|Other|Acetazolamide+ prone positioning|administration of acetazolamide and position the patient for 10 days following the surgery
1648487|NCT01867255|Drug|venlafaxine ER (extended-release) 75 mg|A single dose of venlafaxine ER 75 mg is to be administered once at each of two study visits, pre- and post-gastric bypass surgery.
1648488|NCT01867242|Other|Cigarettes|Smoke their usual brand of cigarettes and follow their normal patterns of use.
1648489|NCT01867242|Other|Snus|Winterchill or Robust flavors
1648490|NCT01867229|Other|observational|standard of care fore patients with non metastatic breast cancer
2012694|NCT01719224|Procedure|supine body position|
1648493|NCT01867203|Other|Genotyping|
1648494|NCT01867190|Biological|ASCT01 (Autologous Stem Cell Transplantation)|Single Administration of the entire ASCT01 preparation at rate if 10million CD45+ cells per milliliter at 5 ml per minute via the intra- via intra-arterial infusion route and 6 or more injections of approximately 0.2 ml each intramuscular route
1648495|NCT01867177|Other|HIV testing|"HIV testing. Enhanced testing protocol is used: RESPECT, an evidence-based HIV prevention counseling intervention helping people increase condom use, decrease risky behaviors (resulting in a decrease in STIs) compared to those who did not receive the intervention. RESPECT includes: one-on-one counseling using a structured protocol; teachable moments during counseling to motivate clients to change risk-taking behaviors; to explore the contexts in which risk behaviors occur to increase awareness of susceptibility; and negotiate achievable next steps with the client that support the larger risk reduction goal. Implemented using a structured protocol with monitoring to ensure the fidelity of the testing intervention."
1648496|NCT01867177|Other|standard of HIV care|Standard linkage and referral to HIV care includes HIV counseling, testing, and referrals. Both intervention and comparison groups will receive these.
1648497|NCT01867177|Behavioral|HIV care utilization|Sites will use a peer-based, client navigation model of an Integrated HIV/AIDS Early Intervention Services (ARTAS), Community Health Worker (CHW) Program, case management/support services linking people to continuous, coordinated care after HIV dx. Another site will do Motivational Enhancement Intervention (MEI) sessions with quality of ife workshops and support groups. Health Educators recruit clients, make appointments, escort to test sites, intake, review. Additional components can include food security support, social and group support, drop in centers, text messaging and social media, depending on sites. All sites focus on approaches to reach community members and facilitate their supportive linkage to care with behavioral and structural supports.
1648498|NCT01867164|Drug|Gynoclin V|One ovule containing 80 milligram (mg) terconazole, 100 mg clindamycin and 0.5 mg fluocinolone acetonide will be administered vaginally, every 24 hours at night, for 3 days.
1648499|NCT01867164|Drug|Vagitrol V|One ovule containing 500 mg metronidazole, 0.5 mg fluocinolone acetonide and 100,000.00 microgram/milliliter nystatin will be administered vaginally, every 24 hours at night, for 10 days.
1648500|NCT01867151|Dietary Supplement|Gluten Free Diet|
1648501|NCT01867151|Dietary Supplement|Normal Diet|
1648502|NCT01867138|Drug|Cefazolin|
1648503|NCT01867138|Drug|Vancomycin|
1648504|NCT01867138|Drug|Amikacin|
1717747|NCT00002255|Drug|Zidovudine|
1648505|NCT01867125|Drug|Lebrikizumab|Lebrikizumab will be administered as SC injection at 125 or 37.5 mg every 4 weeks, for 104 weeks.
1648506|NCT01867125|Drug|Placebo|Lebrikizumab matching placebo will be administered as SC injection every 4 weeks for 52 weeks.
1648507|NCT01867112|Behavioral|Physical Activity|Physical activity either by individualized program or general guidelines
1648508|NCT01867086|Biological|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Vigil™ 1.0 x 10e7 cells/intradermal injection once every 3 weeks.
1648509|NCT01867086|Drug|Carboplatinum|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion) one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
1648510|NCT01867086|Drug|Carboplatinum and Taxol|Patients meeting eligibility criteria will receive either carboplatinum alone (AUC 6/30 minute infusion) or carboplatinum (AUC 5/30 minute infusion) and taxol (175 mg/m2 3-hour infusion one day prior to Vigil™ 1.0 x 10e7 cells/ intradermal injection, once every three weeks. At recurrence, patients allergic to carboplatinum will receive docetaxel 75 mg/m2/1 hour infusion, one day prior to Vigil™ 1.0 x 10e7 cells/intradermal injection every 3 weeks. Patients with stable disease (SD) or better and unable to tolerate continued chemotherapy will be allowed to continue Vigil™ alone for up to 12 cycles or as long as vaccine is available; conversely, patients with SD or better who exhaust Vigil™ supply may continue on chemotherapy alone.
1648511|NCT01867073|Other|Biomarker|
1648512|NCT01867060|Device|Automated Cardiac Event Recorder|Automated Cardiac Event Recorder to be worn continuously for one week.
1648513|NCT01867060|Device|Personal Heart Rhythm Monitor|Personal Heart Rhythm Monitor to be used twice-daily for three months.
2012695|NCT01716806|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
2012696|NCT01716806|Drug|bendamustine|70 mg/m2 by IV infusion on Days 1 and 2 of 3-week cycle
1648516|NCT01867034|Other|Drug Eluting Stent|Comparison of two stents to see which results in best outcome.
1648517|NCT01867034|Other|Bare Metal Stent|
1648518|NCT01867021|Biological|Fluvirin(TIVf)|
1648519|NCT01867021|Biological|Agriflu (TIV)|
1648520|NCT01866995|Drug|"Raylis"|"Raylis (1 kapsule contains: ginseng root powder 50 mg, false ginseng root powder 50 mg, codonopsis root powder 50 mg, astragalus membranaceus root powder 50 mg, epimedium alpinum herbal extract 100 mg)"
1648521|NCT01866995|Other|standard prostatostasis therapy|
1648522|NCT01866982|Procedure|Umbilical Cord Milking|Umbilical cord milked toward the neonate four times at a speed of 20cm/2seconds, prior to clamping and cutting umbilical cord. Procedure takes about 10-20 seconds.
1648523|NCT01866982|Procedure|Delayed Cord Clamping|Performed by positioning the baby 20 cm below the placenta for 45-60 seconds prior to umbilical cord clamping and cutting.
1648524|NCT01866969|Other|questionnaire administration|Ancillary studies
1648525|NCT01866969|Procedure|quality-of-life assessment|Ancillary studies
1648526|NCT01866943|Drug|Tranexamic Acid|Tranexamic Acid 1.5 g (100 mg/mL)in 100cc normal saline is applied topically to the wound for 5 minutes time then suctioned and the skin closed. The control group receives just normal saline and no drug.
1648527|NCT01866943|Drug|Normal Saline Solution|
1648528|NCT01866930|Biological|Pegylated Interferon Lambda-1a|
1648529|NCT01866930|Drug|Daclatasvir (DCV)|
1648530|NCT01866930|Drug|Ribasphere (RBV)|
1648531|NCT01866917|Drug|Ropivacaine 0.5% 20cc injectate bilaterally|
1648532|NCT01866891|Other|Three months of regular perdialytic physical activity (cycling)|Cycling, in lying position, at a rate of thirty minutes per dialysis session (three a week), regardless of performance
1648533|NCT01866878|Device|equipment rehabilitation stereognosis|
1648534|NCT01866878|Device|TENS|
2012697|NCT01716806|Drug|dacarbazine|375 mg/m2 every 3 weeks by IV infusion
1648536|NCT01866826|Drug|Rifaximin/ Placebo|subject will receive either three capsules of rifaximin (183.3 mg each) by mouth twice daily (total 1100 mg Daily) or will receive three capsules of placebo by mouth twice daily.
1648537|NCT01866813|Behavioral|Cognitive training intervention group|The intervention group will be asked to participate in an internet-delivered cognitive training pro-gram using the Danish edition of Scientific Brain Training Pro on their home personal computer. The software is provided through the Internet, and no software installation is needed onto the participant personal computer. Reminders to train will be provided by e-mail. The training involves working with the program for 40-60 minutes a day, five days a week, for six weeks.
1648538|NCT01866800|Device|Renal Guard|Renal Guard
1648539|NCT01866800|Drug|Conventional Treatment|Saline and N-acetylcysteine
1648540|NCT01866774|Other|Fecal calprotectin level|
1648541|NCT01866761|Procedure|Periodontal treatment|
1648542|NCT01866748|Drug|semaglutide|A maximum of six single-dose cohorts of oral semaglutide administered according to an ascending dose design. Starting dose 2 mg, max. dose 60 mg. Progression to next dose will be based on safety evaluation. Sequential cohorts.
1648543|NCT01866748|Drug|semaglutide|Oral semaglutide administered as five multiple dose cohorts, where one of the cohorts will test a different dosing condition compared to the others. End doses from 10 mg/day to 60 mg/day. Progression to next dose will be based on safety evaluation. Semi-parallel cohorts.
1648544|NCT01866748|Drug|placebo|In each cohort of 10, eight subjects will randomised to active treatment and two to placebo.
1648594|NCT01866410|Drug|Cabozantinib S-malate|Given PO
1648595|NCT01866410|Drug|Erlotinib Hydrochloride|Given PO
2012698|NCT01716806|Drug|nivolumab|3 mg/kg every 3 weeks by IV infusion
2012699|NCT01715597|Drug|ascorbic acid|ascorbic acid 2g in normal saline 500ml IV start 30min before the operation and infusion for 2 hour
2012700|NCT01715597|Drug|Normal saline|normal saline 500ml IV
2012701|NCT01707264|Drug|NEOD001|Monoclonal antibody administered by intravenous infusion every 28 days.
2012702|NCT01702909|Drug|Interleukin-2|Interleukin-2
1648545|NCT01866748|Drug|placebo|In each cohort of 24, 16 subjects will be randomised to active treatment, four to placebo and four to a enhancer-containing placebo (placebo C).
1648546|NCT01866735|Other|Standardized Rehabilitation Therapy|
1648547|NCT01866722|Behavioral|Usual care|Participants will get a brief (<5 min) telephone counseling session about quitting. After that, printed materials with resources to help quitting will be mailed to the participants.
1648548|NCT01866722|Behavioral|Reduction|Participants will have 3 telephone counseling sessions that focus on ways to reduce tobacco cigarette smoking. After the final session printed materials with resources to help quitting will be mailed to the participants.
1648549|NCT01866722|Behavioral|5Rs|Participants will have 3 telephone counseling sessions that focus on the 5Rs for quitting tobacco cigarette smoking (Relevance, Risks, Rewards, Roadblocks, Repeat). After the final session printed materials with resources to help quitting will be mailed to the participants.
1648550|NCT01866709|Drug|Sodium polystyrene sulfonate|Oral suspension in water of 15g sodium polystyrene sulfonate administered three times (tid) daily for 48 hours without co-administration of Sorbitol.
1648551|NCT01866709|Drug|Silicified microcrystalline cellulose|Oral suspension in water of placebo administered three times (tid) daily for 48 hours.
1648552|NCT01866696|Device|oral implants|"For all cases, the following surgical and prosthetic protocol was followed.:
Clinical examination
Radiological examination
Guided oral implants insertion
Immediate Prosthetic loading
Follow-up"
1648553|NCT01866683|Behavioral|1 month respiratory training|Bhastrika yoga respiratory training: 30 kapalabhati and 1 surya bedhana form 1 bhastrika
1648554|NCT01866683|Behavioral|1 month waiting period|waiting or detraining period
1648555|NCT01866670|Behavioral|spiritual support|-Spiritual Support: deep breathing + guided image + meditation
1648556|NCT01866670|Behavioral|relaxation therapy|Relaxation Therapy: deep breathing
1648557|NCT01866657|Drug|Vasoconstrictor Agents|cerebral desaturations may be treated with IV vasoactives to increase blood pressure or cardiac output at attending physician's descretion.
1648558|NCT01866657|Other|Head/neck repositioning|Assure that arterial and venous neck blood flow is not obstructed related to patient positioning
1648559|NCT01866657|Other|Increase ETCO2|Allow normalization or slight increase in end tidal CO2 to cause selective cerebral vasodilation and increased tissue blood flow/O2 delivery
1648560|NCT01866657|Other|IV fluid bolus|Administer IV fluids to increase preload and cardiac output
1648561|NCT01866657|Drug|Additional anesthesia|By deepening anesthetic there will be a decrease in cerebral metabolic oxygen consumption.
1648562|NCT01866657|Biological|RBC transfusion|By administering RBCs there will be a increase in intravascular volume and cardiac preload and an increase in oxygen carrying capacity
1648563|NCT01866657|Drug|Increase FiO2|Increase FiO2 to improve oxygen delivery to tissue
1648564|NCT01866644|Drug|N-acetylcysteine|Bath transplanted liver with N-acetylcysteine
1648565|NCT01866644|Drug|Saline|Bath saline transplanted liver
1648566|NCT01866618|Procedure|Uterine Aspiration and Endometrial Biopsy/Embryo Biopsy|Patients will undergo two uterine aspirations and one endometrial biopsy. Any embryos obtained will undergo embryo biopsy for Comprehensive Chromosome Screening (CCS). All embryos will be cryopreserved for subsequent use in a thaw cycle.
1648567|NCT01866618|Drug|Leuprolide Acetate|
1648568|NCT01866618|Drug|Human Chorionic Gonadotropin (hCG)|
1648569|NCT01866605|Drug|Midazolam|Intravenous midazolam 0.3 mg/kg
1648570|NCT01866605|Drug|Normal Saline|Normal saline injection will be given to groups not receiving midazolam
1648571|NCT01866605|Device|Bair Hugger|Forced air warming
2012703|NCT01702844|Drug|Nab-Paclitaxel|Administer 2 cycles of Nab-Paclitaxel 100 mg/m2 IV on days 1 8 and 15
1648573|NCT01866566|Biological|HBV-3|Give a single 0.5 mL HBV and get blood samples at 0,1.5,4.5 month
1648574|NCT01866566|Biological|HBV-6|Give a single 0.5 mL HBV and get blood samples at 0,1.5,7.5 month
1648575|NCT01866566|Biological|varicella-3|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,4.5 month
1648576|NCT01866566|Biological|varicella-6|Give 2 doses varicella vaccine (a single 0.5 mL) and get blood samples at 0,1.5,7.5 month
1648577|NCT01866553|Drug|Nilotinib|300 mg capsule BID oral use
1648578|NCT01866553|Drug|Pegylated interferon α-2b|25 - 40 microgram per week for subcutaneous use
1648579|NCT01866540|Drug|FLUENZ|live attenuated influenza vaccine
1648580|NCT01866514|Procedure|proximal humerus intraosseous vascular access|The arm receiving the IO needle is positioned with the arm abducted to shoulder level (in position required for surgery), with the arm rotated inward, into the optimal position, with the palms faced down. Deeply palpate the humerus until the junction of the humeral shaft and the humeral head, the surgical neck is identified; the insertion site is in the surgical neck. With the 45mm IO needle placed perpendicular to the plane of the skin, the IO needle is inserted into the surgical neck using a slightly superior angle of insertion and the needle is inserted to the hub. The stylet will be removed and an EZ-Connect primed with 2% preservative-free lidocaine will be attached to the catheter hub. Aspirate return will be attempted to confirm needle placement within the medullary cavity.
1648581|NCT01866514|Drug|2% preservative-free lidocaine|
1648582|NCT01866514|Device|EZ-IO|
1648583|NCT01866501|Procedure|Proximal Humerus Intraosseous Vascular Access|Using the blended technique, device operators will establish proximal humerus intraosseous vascular access by inserting an IO needle.
1648584|NCT01866501|Device|EZ-IO|
1648585|NCT01866488|Drug|Misoprostol|
1648586|NCT01866488|Other|Placebo|
1648587|NCT01866475|Device|EZ-IO|To have an EZ-IO placed up to 48 hours
1648588|NCT01866462|Other|NM504|NM504 is a medical food designed to shift the dysbiota reported in type 2 diabetes. The placebo is carboxymethylcellulose prepared to look, taste and mix like NM504.
1648590|NCT01866436|Other|Multimedia group|Participants are provided with unrestricted access to the online multimedia educational tools for self-directed study (during the study period)
1648591|NCT01866436|Other|Study Day Group|"Participants in the control arm of the study attend a conventional teaching Study Day involving a series of lectures on Open and Laparoscopic Anterior Resection"
1648597|NCT01866397|Other|Cidofovir pharmacokinetics|Blood samples were drawn before and 15, 30, 60, 120, 240, 360, 720 and 1440 minutes after the start of the cidofovir infusion. Plasma and ultrafiltration samples were collected from the outlet of the ultrafiltrate compartment of the hemofilter.
1648598|NCT01866384|Procedure|mild induced hypothermia|Patients with intraparancymal hemorrhage within 6 hours of onset will be randomized to either the mild induced hypothermia group or the normal temperature group (control). In this arm, the patient will have 72 hours of Targeted Temperature Managment to mild induced hypothermia (32-34 degrees Celcius).
1648599|NCT01866384|Other|Normal Temperature|In this arm, the patient will have standard of care intraparenchymal hemorrhage management per institutional policy, with normal body temperature management (36-37 degrees Celcius).
1648600|NCT01866371|Procedure|Retinal imaging|Retinal imaging procedures include adaptive optics imaging, optical coherence tomography and fundus photography.
1648601|NCT01866358|Procedure|Intraosseous infusion|Using intraosseous infusion for resustation in this group
1648602|NCT01866345|Procedure|Surgically facilitated Orthodontic treatment|Surgically facilitated Orthodontic treatment in the mandibular anterior region
1648603|NCT01866345|Procedure|Conventional orthodontic treatment|Conventional orthodontic Procedure
1648604|NCT01866332|Other|Conventional Physical Therapy|Combination of manual therapy techniques, general exercises and specific exercises for spinal segmental stabilization. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). The treatment will be tailored to the patient presentation (i.e. pragmatic treatment).
1648605|NCT01866332|Device|Kinesio Tex Gold ( Kinesiotaping )|Kinesiotaping intervention is based upon the use of specific elastic tapes (known as Kinesio Tex Gold) that are applied with a certain amount of tension fixed to the skin of patients with the target muscles in a stretched position. The tapes will be placed over the superficial back muscles (erector spinae muscles).
1648606|NCT01866319|Biological|Pembrolizumab|With Amendment 05, all Second Course participants will be treated with a fixed dose of pembrolizumab 200 mg Q3W.
1648607|NCT01866319|Biological|Ipilimumab|No change with Amendment 05.
1648608|NCT01866306|Biological|RV16UB|RV16UB is administered by spraying an atomized viral suspension into a single nostril. Planned doses of RV16UB in Part 1 are 10 Tissue Culture Infective Dose 50 (TCID50), 100 TCID50, 1000 TCID50 and 10,000 TCID50.
1648609|NCT01866306|Drug|LABA|Asthmatic participants were treated with LABA as part of their standard of care
1648610|NCT01866293|Drug|Cabozantinib (XL184)|
1648611|NCT01866280|Behavioral|Normal sleep|Normal sleep= sleep 2300-0700
1648612|NCT01866280|Behavioral|Normal meals|Normal meal times=approximately 1.5, 5, and 11 h after wake up for breakfast, lunch, and dinner, and snack at 13 h after wake up time
1648613|NCT01866280|Behavioral|Late sleep|Late sleep=sleep at 0230-1030 hours
1648614|NCT01866280|Behavioral|Late meals|Late meal times= approximately 4.5, 7, and 13 h after wake up time for breakfast, lunch and dinner, and snack at 15 h.
2012704|NCT01701492|Other|Questionnaire|A one-time assessment using both performance-based measures as well as both self- and parent-report questionnaires.
1648616|NCT01866254|Drug|Hydromorphone|Injection of 100 mcg hydromorphone into the intrathecal space
1648617|NCT01866254|Drug|Morphine|Injection of 200 mcg of intrathecal morphine
1648618|NCT01866241|Drug|Misoprostol|Is a prostaglandin
1648619|NCT01866228|Other|Consultation Recording|
1648620|NCT01866215|Other|exercise|cycling at 100W during 60 min
1648621|NCT01866215|Dietary Supplement|fructose|isocaloric nutrition with fructose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
1648622|NCT01866215|Dietary Supplement|glucose|isocaloric nutrition with glucose, cream and whey protein during the 24 hour following a glycogen/intramyocellular lipid depleting exercise
1648623|NCT01866189|Other|PET and MRI|F-MISO PET followed by brain MRI (MRI-1)(diffusion, FLAIR, perfusion, TOF)
1648624|NCT01866176|Device|Stabilizing Knee Brace|Brace with no valgus action
1648625|NCT01866176|Device|Valgus Knee Brace|Valgus brace with traditional three point bending system
1648626|NCT01866176|Device|New Knee Brace|Brace with new mechanism to decrease the knee loading.
1648627|NCT01866163|Drug|LEO 90100|
1648628|NCT01866163|Drug|Vehicle|
1648629|NCT01866124|Other|Cash transfer|Recipient of transfers Mothers are the primary recipient of the CT. Cash is transferred using mobile phone credits that can be cashed at specific cash points provided by a telecom company.
1648630|NCT01866111|Drug|YKP3089|
1648631|NCT01866111|Drug|Placebo|
1648632|NCT01866098|Drug|Naltrexone|25 or 50mg (randomized) oral capsule taken once daily for 52 weeks to establish optimal dose for weight loss over the course of the study.
1648633|NCT01866098|Drug|Placebo|
1648634|NCT01866085|Procedure|AdVance® sling procedure|
1648635|NCT01866085|Procedure|ARGUS Sling procedure|
1648636|NCT01866059|Device|Calcium silicate cement|Calcium silicate cement
1648637|NCT01866059|Device|Glass Ionomer Cement|Glass Ionomer Cement
1648638|NCT01866059|Device|Resin Modified Glass Ionomer Cement|Resin Modified Glass Ionomer Cement
1648639|NCT01866046|Behavioral|RESPECT-IPV|rapid HIV testing intervention and behavioral counseling session where identify risks and develop a risk reduction plan
1648640|NCT01866033|Drug|PCI-32765 (Treatment A)|560 mg capsules administered by mouth on Day 1, Period 1
1648641|NCT01866033|Drug|PCI-32765 (Treatment B)|560 mg capsules administered by mouth (without grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
1648642|NCT01866033|Drug|PCI-32765 (Treatment C)|140 mg capsule administered by mouth (with grapefruit juice) on Day 1 during Period 2 or 3 according to randomization schedule
1648643|NCT01866033|Drug|13C6 PCI-32765 (reference)|100 mcg administered intravenously 2 h after study drug
1648644|NCT01866007|Drug|Guselkumab (lyophilized formulation)|Participants will receive a single SC injection of 100 mg guselkumab prepared from lyophilized formulation.
1648902|NCT01864018|Other|Pharmacological Study|Correlative studies
2012705|NCT01701492|Other|Neurocognitive Evaluation|A one-time neurocognitive evaluation conducted in the Psychology Clinic
2012706|NCT01696734|Drug|Domperidone|Starting Dose: 10 mg by mouth 3 times a day.
1648645|NCT01866007|Drug|Guselkumab (liquid formulation with PFS-U)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS-U.
1648646|NCT01866007|Drug|Guselkumab (liquid formulation with PFS FID)|Participants will receive a single SC injection of 100 mg guselkumab, liquid formulation with PFS FID.
1648647|NCT01866007|Drug|Guselkumab (liquid formulation)|Participants will receive a single IV infusion of 100 mg guselkumab prepared from liquid formulation.
1648648|NCT01865968|Biological|Inactivated HAV vaccine|Hepatitis A vaccine (Healive), 500 u per dose per 0.5 millilitre. Vaccines will be administered with one-dose or two-dose regimen of the arm 6 months apart in the deltoid muscle.
1648649|NCT01865968|Biological|Live attenuated HAV vaccine|Live attenuated hepatitis A vaccine, 6.50 lgCCID50 per dose per 0.5 millilitre. Vaccines will be administered with one-dose regimen in the deltoid muscle.
1648650|NCT01865955|Procedure|Ultrasound|Ultrasound applied to the lumbar region to determine spinal needle placement.
1648651|NCT01865955|Device|The spinal needle|
1648652|NCT01865942|Procedure|open surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
1648653|NCT01865942|Procedure|Minimal access surgery|The to surgical procedures are individually well know, but the outcome of the procedures in respect to perioperative bleeding and change in quality of life has to our knowledge not been compared.
1648654|NCT01865929|Device|Robotic hysterectomy|Minimally invasive hysterectomy for benign disorders. Comparing robotic hysterectomy with vaginal hysterectomy and traditional laparoscopic hysterectomy
1648655|NCT01865929|Procedure|Vaginal or laparoscopic hysterectomy|Benign hysterectomy performed by traditional minimal invasive procedures.
1648656|NCT01865916|Drug|Polyethylene Glycol (PEG) and 15 mg Bisacodyl|Subjects will be asked to take split dose of 2L PEG and 3 tablets of 5 mg Bisacodyl
1648657|NCT01865916|Drug|Polyethylene Glycol (PEG) + ascorbic acid|Subjects will be asked to take split dose of 2L PEG and vitamin C
1648658|NCT01865851|Device|Classic Face Mask and NuMask|
1648659|NCT01865838|Device|Seprafilm (Sanofi, USA)|Studies have unequivocally shown that Seprafilm is effective in reducing internal adhesion formation after abdominal surgery. In a large scaled randomized controlled trial involving about 1700 patients, Fazio et al. found that the use or Seprafilm reduces the risk of small bowel intestinal obstruction which required operative intervention. The safety profile of Seprafilm has also been nicely demonstrated in a randomized controlled trial by Beck et al. in this study, the authors concluded that within the context of abdomino-pelvic surgery, Seprafilm does not increase the incidence of abdominal/pelvic abscesses in patients after abdomino-pelvic surgery; if anything, the anti-adhesive properties of Seprafilm are such that the authors noted an increased risk of anastomotic complications in patients whose bowel anastomoses were in close contact with Seprafilm.
1648660|NCT01865825|Radiation|Esophageal Barium Xray|"•Fast for 4 hours prior to the Esophagram (upper GI x-ray). You will drink a liquid that has barium or another contrast agent in it. The radiologist will use the X-ray machine to look at your upper GI tract while you drink the contrast liquid. The x-ray exam should take between 10-15 minutes.
We will have patients complete the Mayo Dysphasia Questionnaire-30 day."
1648661|NCT01865812|Drug|obeticholic acid (OCA)|All subjects will be treated with OCA (oral administration, 10 mg, once daily) for 8 weeks and should continue their prestudy dose of ursodeoxycholic acid (UDCA). After completion of the 8 week Primary Treatment Phase of the study and the 4 week follow up period, during which time subjects do not take OCA, all eligible subjects will be offered the opportunity to enter an open label long term safety extension phase, during which they will receive 10 mg OCA daily for up to 2 years.
2012707|NCT01696734|Behavioral|Questionnaires|Questionnaire completion at baseline, 8 weeks after drug, 6 months, then every 6 months.
1648663|NCT01865760|Dietary Supplement|Oral Glucose tolerance test (OGGT)|At baseline subjects will consume 50 g glucose dissolved in water in 10 minutes
1648664|NCT01865760|Other|Isoglycemic intravenous glucose infusion (IIGI)|The IIGI will be performed using a sterile 20 % wt/vol glucose infusion. The infusion rate will be adjusted, aiming at a duplication of the plasma glucose profile determined in the corresponding OGGT.
1648665|NCT01865760|Dietary Supplement|Liquid mixed meal|At baseline subject will consume the liquid mixed meal in 10 minutes
1648666|NCT01865760|Drug|Octreotide|At baseline subjects will receive Octreotid 100 µg subcutaneous
1648667|NCT01865760|Drug|Synthetic Exendin 9-39|At baseline subjects will receive a liquid mixed meal and iv bolus infusion of Exendin(9-39) 43.000 pmol/kg followed by a continuous infusion of 900 pmol/kg/min in the next 5 hours
1648668|NCT01865747|Drug|Cabozantinib tablets|
1648669|NCT01865747|Drug|Everolimus (Afinitor) tablets|
1648670|NCT01865734|Other|Physical therapy after initial podiatry visit|Individuals in the early physical therapy group will receive physical therapy in accordance with the American Physical Therapy Association plantar heel pain practice guidelines and recent evidence in support of manual therapy intervention. Treatment provided will be based on identified impairments and may include manual therapy (joint and soft tissue mobilization/thrust manipulation to the lower half of the body), lower leg and plantar foot specific stretching/self mobilization, foot and lower leg muscle performance training, night splints, taping, over the counter orthotics/heel cup/heel cushion, and iontophoresis. Specific intervention will be selected at the discretion of the treating physical therapist.
1648671|NCT01865734|Other|Usual care provided by podiatry|Individuals in the usual podiatric care group will receive care typical of podiatry management of plantar heel pain. According to practice guidelines, the first 6 weeks of treatment includes foot taping/padding, home stretching exercises, arch support/heel cup, shoe recommendations, oral anti-inflammatories, and corticosteroid injection. The next 6 months may include corticosteroid injection, custom orthotics, night splint, immobilization, and physical therapy. If unresponsive after 6 months of treatment, extracorporal shock wave therapy or a fasciotomy surgery is considered. Additionally, the podiatrist may order radiographs or ultrasound imaging within their scope of practice. Specific intervention will be selected at the discretion of the treating podiatrist.
1648672|NCT01865721|Drug|Entonox|Entonox will be used according to the allocated method
1648837|NCT01864395|Procedure|Online MUF|Hemofilter is used online while the heart-lung machine is connected to the patient.
2012708|NCT01696734|Other|Phone Calls|At 2 weeks and 4 weeks(± 3 days) of treatment, the physician will contact the patient via telephone to assess whether or not a dosage increase is warranted.
1648674|NCT01865695|Drug|Creon|Creon is a licensed product, manufactured by Abbott Laboratories, Inc. used for the therapeutic indication of pancreatic exocrine insufficiency. The route of administration is oral, with capsules being taken with main meals without chewing. The most commonly reported adverse reactions to Creon are gastrointestinal disorders of mild or moderate severity (up to 10% of patients). These include nausea, vomiting, constipation, diarrhoea and abdominal distension. An uncommon reaction (<0.01%) of patients may develop skin reactions such as a rash or itching. No additional adverse drug reactions have been identified.
1648675|NCT01865695|Other|Placebo|
1648676|NCT01865669|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L
1648677|NCT01865656|Other|Skills training|Refresher training on Basic Emergency Obstetric and Newborn care
1648678|NCT01865656|Other|Emergency obstetric drills|Emergency obstetric drills to practice timely and appropriate management of postpartum hemorrhage and preeclampsia/eclampsia
1648679|NCT01865656|Other|Revised Case Sheets|Revised case sheets will be introduced to capture the timing and appropriate medical treatment of women in labor and newborns
1648680|NCT01865656|Other|Supportive supervision|Quarterly supportive supervision visits each of the intervention first referral units.
1648681|NCT01865656|Other|Referral strengthening|To support referral systems that ensure timely and appropriate treatment for obstetric emergencies
1648682|NCT01865643|Device|GlideScope|The GlideScope is used to assist with difficult tracheal intubation.
2012709|NCT01692418|Drug|Ferric carboxymaltose|1000mg of ferric carboxymaltose will be administered as an i.v. infusion (100ml normal saline)
2012710|NCT01692418|Drug|Normal saline|Normal saline will be administered as an i.v. infusion (100ml normal saline)
2012711|NCT01688921|Biological|AFLURIA vaccine (2012-2013 formulation)|Patients will receive a single 0.5 mL injection of AFLURIA vaccine in the deltoid region.
1648686|NCT01865604|Device|Anodal tDCS|
1648687|NCT01865604|Device|Cathodal tDCS|
1648688|NCT01865604|Device|sham tDCS|
1648689|NCT01865591|Device|Ultrasound-based Renal Denervation|
1648690|NCT01865578|Device|tDCS|Transcranial direct current stimulation involves the application of weak electric currents to the brain.
1648691|NCT01865578|Device|Sham Stimulation|no electrical stimulation
1648692|NCT01865552|Biological|SB4|SC administration
1648693|NCT01865552|Biological|EU sourced Enbrel|SC administration
1648694|NCT01865552|Biological|US sourced Enbrel|SC administration
2012712|NCT01688921|Device|Needle-Syringe|
2012713|NCT01688921|Device|Stratis needle-free injection device|
1648697|NCT01865526|Dietary Supplement|Six point diet|"The 6-point diet is a list of six items indicating how to modify their dietary habits:
Do not add salt at table and for cooking;
Food to avoid: any kind of salami, sausages, cheese and dairy products or canned food;
Replace noodle or bread with special no-protein food;
The second course (meat, fish and eggs) are allowed once a day in the usual quantity;
4-5 servings/day of fruits or vegetables are suggested;
Once or twice a week the main course may be of normal noodle with legumes instead of the second course, with fruit and vegetables."
1648698|NCT01865526|Dietary Supplement|Low protein diet|Classical low-protein diet prescribed according to the patients' desired body weight (DBW), obtained by multiplying the squared value of the height times a reference BMI value of 23. These diets contained at least 30 kcal/kg/day (25 in overweight patients), with a dietary sodium intake restricted to 2.5 g/day.
1648699|NCT01865500|Drug|Budesonide 4 mg|It will be evaluated at baseline, 24 h, 48 h and before discharge
1648700|NCT01865500|Drug|Budesonide 8 mg|Baseline FEV1 and before discharge FEV1 were evaluated
1648701|NCT01865500|Drug|Metil prednisolone|
1648702|NCT01865487|Biological|AERAS-456|H56:IC31 (designated as AERAS-456 for Aeras-sponsored clinical development) contains a fusion protein (referred to as H56 antigen, or H56) of 3 mycobacterial antigens (the early secreted antigens Ag85B and ESAT-6, and the latency antigen Rv2660c) formulated in the Th1-stimulating IC31 adjuvant.
1648703|NCT01865487|Biological|Placebo|0.8 mL sterile buffer consisting of 10mM Tris and 169mM NaCl at pH 7.4
1648704|NCT01865474|Drug|DLBS1033|1 DLBS1033 tablet 490 mg thrice daily for 2 months
1648705|NCT01865474|Drug|placebo tablet of DLBS1033|1 placebo tablet of DLBS1033 thrice daily for 2 months
2012714|NCT01686594|Drug|8-methoxypsoralen|8-methoxypsoralen 10mg per 20 kg body weight 1 hour before UVA exposure
1648707|NCT01865435|Genetic|cord blood sample|
1648708|NCT01865422|Other|parent-proxy QoL chronic cough specific questionnaire (PC-QOL)|
1648709|NCT01865409|Behavioral|Kangaroo Care|Kangaroo care is a technique practiced on newborn, usually preterm, infants wherein the infant is held, skin-to-skin, with an adult.
1648710|NCT01865396|Behavioral|Interventional palliative care|Palliative support team will meet the patient soon after diagnosis of incurable disease and will meet the patient at least once a month. The patient will also receive the standard oncologic care.
1648711|NCT01865396|Behavioral|Standard oncologic care|Patients will receive standard oncologic care.
1648712|NCT01865383|Behavioral|Microfinance and Health Leadership|Microfinance and Health Leadership: Participants will be eligible to receive small loans and business training as part of the microfinance component. Nominated leaders in camps will receive health leadership training on prevention of HIV risk behaviors and gender based violence perpetration, and then pass on knowledge to camp members.
1648713|NCT01865370|Dietary Supplement|Kochujang Pills|Kochujang Pills (34.5g/day)
1648714|NCT01865370|Dietary Supplement|Placebo|Placebo (34.5g/day)
1648715|NCT01865357|Other|Brain MRI - Clinical and cognitive evaluation|"Clinical evaluation (EDSS, MSFC)
Cognitive evaluation with tests of information processing speed, attention, working memory, episodic memory and executive functions, assessment of confounding factors (depression (BDI) and anxiety (HAD), mood (EHD), fatigue (M-FIS) and assessment of quality of life (SEP-59)
Brain MRI (3 Tesla): FLAIR, 3D MPRAGE T1 and DTI"
2012715|NCT01684215|Drug|PD-0332991|PD-0332991 (100 mg or 125 mg) will be orally administered once a day for 3 weeks followed by 1 week off treatment, in the morning on an empty stomach. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
1648716|NCT01865357|Other|Eye movement|Assessment of eye Movements (EyeBrain software) for only the group of 15 healthy subjects at baseline and at 12 months
1648717|NCT01865331|Drug|insulin degludec|Single dose administered subcutaneously (s.c., under the skin).
1648718|NCT01865331|Drug|placebo|Administered subcutaneously (s.c., under the skin)
1648719|NCT01865331|Drug|insulin degludec/insulin aspart 50|Single dose of IDegAsp 50 administered subcutaneously (s.c., under the skin)
1648720|NCT01865318|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin)
1648721|NCT01865305|Drug|insulin degludec/insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
1648722|NCT01865305|Drug|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
1648723|NCT01865305|Drug|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
1648724|NCT01865305|Drug|insulin degludec|Single dose administrated subcutaneously (s.c., under the skin).
1648725|NCT01865305|Drug|insulin aspart|Single dose administrated subcutaneously (s.c., under the skin).
1648726|NCT01865305|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin) as comparator.
1648727|NCT01865305|Drug|insulin degludec/insulin aspart 40|Single dose administrated subcutaneously (s.c., under the skin).
1648728|NCT01865305|Drug|insulin degludec/insulin aspart 50|Single dose administrated subcutaneously (s.c., under the skin).
1648729|NCT01865305|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin).
1648730|NCT01865292|Drug|insulin degludec|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
1648731|NCT01865292|Drug|insulin glargine|Three single doses administrated subcutaneously (s.c., under the skin) on three separate dosing visits. Dose will vary when administered to subjects with type 1 and type 2 diabetes, respectively.
1648732|NCT01865279|Drug|insulin degludec|Ascending single doses - 5 dose levels. Escalation to next dose level will be performed following evaluation of safety data.
1648733|NCT01865279|Drug|placebo|Ascending single doses - 5 dose levels
1648734|NCT01865279|Drug|insulin degludec|A single dose corresponding to that of isophane human insulin
1648735|NCT01865279|Drug|isophane human insulin|A single dose of 0.4 IU/kg is administered to subjects with type 1 diabetes while a single dose of 0.6 IU/kg is administered to subjects with type 2 diabetes
1648736|NCT01865266|Drug|Ulinaststin for injection|
1648737|NCT01865266|Drug|placebo|
1648738|NCT01865253|Device|Renal Denervation|Renal Denervation
1648739|NCT01865240|Device|Renal Denervation|Renal Denervation Catheter
1648740|NCT01865227|Behavioral|Group Counseling|
1648741|NCT01865201|Drug|Edaravone|Be used at a dose of 30mg, intravenously, twice per day, for 14 days.
1648742|NCT01865201|Other|Common fundamental management|common fundamental management, which was as follows: ①Methylprednisolone, administered by intravenous infusion at a 500mg daily for 3 consecutive days and then gradually tailed off in 30 days with administration of oral prednisolone. ②Dehydration drugs.
1648743|NCT01865188|Drug|LCZ696|Experimental monotherapy doses
1648744|NCT01865188|Drug|Amlodipine|Active comparator monotherapy doses
1648745|NCT01865188|Drug|LCZ696 and amlodipine combination|Experimental combination doses
1648746|NCT01865188|Drug|Placebo|Placebo comparator dose
1648747|NCT01865175|Drug|ionic iron|Subjects will take ionic iron daily for 7 days followed by 7 days of no medicine followed by 7 days of heme iron.
1648748|NCT01865175|Drug|heme iron polypeptide|Subject will take heme iron daily for 7 days followed by 7 days of no medicine followed by 7 days of ionic iron.
1648749|NCT01865162|Other|ketogenic diet|Treatment will consist of ketogenic diet. KD will consist of 4:1 [fat] : [protein+carbohydrate] weight ratio with 1600 kcal restriction. The diet will be supplemented with vitamins, calcium, phosphorus, zinc and selenium supplements to meet the requirements of US Dietary Reference Intakes (DRI) standard.
1648750|NCT01865149|Procedure|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
1648751|NCT01865136|Other|Medical Post Abortion Care|Women with incomplete abortion is diagnosed and treated with misoprostol
1648752|NCT01865123|Behavioral|Transcendental Meditation|A standard 7 step course will be offered including an introductory and preparatory lectures, personal one-on-one instruction with a certified TM teacher followed by 3 consecutive days of classes on how to meditate correctly and effortlessly, how to understand mechanisms of stress release and sequential development to higher levels of human consciousness and enjoying ones full potential. Followup meetings will provide checking of TM practice, sharing of group experiences with the TM practice and knowledge to motivate and inspire continued regularity with the practice. The certified TM instructor will have experience with PTSD in this veteran population.
1648753|NCT01865123|Behavioral|Prolonged Exposure|Prolonged exposure therapy, a specific form of cognitive behavioral therapy, is considered the standard psychotherapy treatment for PTSD . The delivery of PE will be by a trained study therapist. There will be 16 individual sessions provided to each participant. Homework will include relaxation and breathing exercises and anxiety diaries.
1648754|NCT01865123|Behavioral|Educational control|This group will receive group-administered didactic health education specific to the PTSD veterans population. It will include emphasis on healthy lifestyle changes to promote more positive mental and physical health. The classes will be matched with the TM and PE interventions to control for time, instructor attention and other non-specific factors.
1648755|NCT01865110|Drug|R-CHOP|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 8 cycles
1648756|NCT01865110|Drug|R-CHOP / R-HAD|R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) administered in 3 week cycles for 3 cycles R-HAD (rituximab, cytarabine, dexamethasone) administered in 3 week cycles for 4 cycles alternating
1648757|NCT01865110|Drug|Rituximab|Rituximab SC 1400 mg every 8 weeks for 24 months
1648758|NCT01865110|Drug|Lenalidomide|Lenalidomide 15 mg 3 weeks every 4 weeks for 24 months
1648838|NCT01864395|Procedure|Offline MUF|Hemofilter is used offline when the heart-lung machine is not connected to the patient.
1717748|NCT00002256|Drug|Zalcitabine|
1648759|NCT01865097|Behavioral|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the relaxation guided imagery and asked to listen to it at home.
1648760|NCT01865097|Behavioral|Relaxing music|An individualized session of listening to relaxing music will be conducted. After the session patients will be given a CD with the relaxing music and asked to listen to it at home.
1648761|NCT01865084|Drug|Tadalafil|Administered orally
1648762|NCT01865084|Drug|Placebo|
1648763|NCT01865071|Procedure|loop ileostomi|
1648764|NCT01865019|Device|mechanical ventilation|
1648765|NCT01864993|Dietary Supplement|gluten|The enrolled patients will be invited to follow a gluten free diet. Patients responsive to the diet will be invited to assume gluten or placebo following a double blind with cross over scheme
1648766|NCT01864993|Dietary Supplement|Placebo|Patients responsive to the diet will be invited to blindly assume gluten or placebo following a double blind with cross over scheme
1648767|NCT01864980|Procedure|blood transfusion, intermittent Hbsatlab measurement|In the Hbsatlab group, RBC administration and its timing will be based on intermittent Hbsatlab measurement (routine care)
1648768|NCT01864980|Procedure|blood transfusion, based on continuous SpHb readings|RBC administration and its timing will be based on continuous SpHb readings while Hbsatlab values, measured every 30 min. by an objective observer, will not be visible to the attending anaesthetist.
1648769|NCT01864954|Behavioral|Web+phone|We propose to evaluate the feasibility, acceptability, and efficacy of a Web+phone treatment program in a small, randomized, controlled pilot study. Women who have quit smoking during pregnancy will be randomly assigned to either (a) an Enhanced Web+phone intervention or (b) a Basic Web Information-Only control condition.
1648770|NCT01864941|Procedure|Catheter venography with balloon venoplasty|All eligible patients will undergo catheter venography with balloon venoplasty and/or sham at baseline and at week 48 (i.e. Cross over design) followed by clinical and radiologic observation for a minimum of 48 weeks after each procedure.
1648771|NCT01864941|Device|Catheter venography with balloon venoplasty and balloon|
1648772|NCT01864915|Drug|Prucalopride|Prucalopride 2mg daily starting three days before the colon capsule study (total of 4 doses with the last at 0800hrs on day of colon capsule study)
1648773|NCT01864915|Procedure|Colon Capsule|Colon capsule procedure performed day prior to colonoscopy, at 0800 hrs on day 4.
1648774|NCT01864902|Biological|CART33 cells|genetically modified lymphocyte therapy
1648775|NCT01864902|Biological|anti-CD33 CART|
1648776|NCT01864902|Biological|anti-CD33 CAR T cells|
1648777|NCT01864889|Biological|anti-CD19-CAR vector-transduced T cells|genetically engineered lymphocyte therapy
1648778|NCT01864876|Biological|GLA-AF|Glucopyranosyl Lipid A (GLA) in an aqueous formulation (AF).
1648779|NCT01864876|Biological|GLA-SE|Glucopyranosyl Lipid A (GLA) in a stable oil-in-water emulsion (SE).
1648780|NCT01864876|Biological|EM060G (SE)|The same stable oil-in-water emulsion (SE), but without GLA.
1648781|NCT01864863|Drug|HGP1206|One Bosentan 125 mg tablet
1648782|NCT01864863|Drug|Traclear|Two Bosentan 62.5 mg tablets
1648783|NCT01864850|Radiation|Standard RT|70 Gy / 7 weeks / 2 Gy per fraction
1648784|NCT01864850|Radiation|Hypofractionated RT|55 Gy / 7 weeks with 2 weeks interruption / 3 Gy per fraction until 30 Gy, after interruption 2.5 Gy per fraction until 55 Gy
1648785|NCT01864824|Drug|methyl donor|The design will include a 2 week placebo run-in followed by a baseline blank study (2-hrs exposure to medical air) to provide benchmarks for all assessed variables. Participants will then receive a 4-week placebo treatment before the first PM2.5 exposure study. A 4-week methyl-donor treatment (Dose: 2.5 mg of folic acid, 50 mg of vitamin B6, and 1 mg of vitamin B12 once a day) will precede the 2nd PM2.5 exposure.
1648786|NCT01864824|Drug|Placebo|Placebo
1648787|NCT01864811|Behavioral|Baby-CIMT|Baby-CIMT is a very much modified model of constraint induced movement therapy for infants. It is developed to suit small children and their needs of stimulation. The infant should wear a comfortable glove on the less affected hand, while stimulating the use of the affected hand 30 minutes per day during 2 periods of 6-weeks training before 12 month. The hand training provides the baby with amusing and easily handled toys.
1648788|NCT01864811|Behavioral|Baby-Massage|For baby massage, there will be a special instructional course by a health professional certified for baby massage. Massage should be given every day during 2 periods of 6 weeks. Families will be responsible for the massage.
1648789|NCT01864798|Drug|Denosumab|
1648790|NCT01864785|Procedure|Fixation Combined With Fusion|Articular process fusion with bone graft was carried out after screw fixation
1648791|NCT01864785|Procedure|Fixation Alone|Use the Posterior approach to achieve the reduction and stabilization by pedicle screw and rod alone
1648792|NCT01864772|Drug|Carbo, 5FU, Cetuximab|"6 cycles (1 cycle = 21 days) of: carboplatin AUC 5, 5FU D1-4 1000mg/m²/d, every 21 days cetuximab weekly (400 mg/m² the first week of treatment and then 250 mg/m²/w)
Maintenance by cetuximab 500 mg/m² every 2 weeks until progression or toxicity"
1648793|NCT01864759|Biological|ICOVIR-5|
1648794|NCT01864746|Drug|Palbociclib PD-0332991|palbociclib at a dose of 125 mg once daily, day 1 to day 21 followed by 7 days off treatment in a 28-day cycle
1648795|NCT01864746|Drug|Placebo|Arm B: Placebo of palbociclib once daily day 1 to day 21 followed by 7 days off treatment in a 28-day cycle for thirteen cycles
1648796|NCT01864733|Other|Physical rehabilitation (exercise).|
1648797|NCT01864720|Behavioral|Professionally-administered cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. This multimodal approach combines behavioural (i.e., stimulus control therapy, sleep restriction), cognitive (i.e., cognitive restructuring), and educational (i.e., sleep hygiene) strategies that are administered over a 6-week period.
1648839|NCT01864382|Other|Core stability|Core stability 5 days a week during 5 weeks
1648840|NCT01864382|Other|Standard Physiotherapy Exercises|Standard Physiotherapy Exercises is a conventional treatment program 5 days a week during 5 weeks
1648903|NCT01864018|Other|Quality-of-Life Assessment|Ancillary studies
1648904|NCT01864018|Other|Questionnaire Administration|Ancillary studies
1649207|NCT01861613|Biological|HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)|
1648798|NCT01864720|Behavioral|Web-based cognitive-behavioral therapy for insomnia (CBT-I)|The treatment content will be the same whether it is administered by a professional or self-administered. Each week, the patients will first have to read written information on the website, and then watch a video capsule (duration between 5 and 20 min each). The treatment material will be identical to the video (DVD)-based CBT-I that we previously developed. Patients will complete their daily sleep diary electronically on the website and the content will be interactive. It will include the sending of automated emails to remind participants to complete the treatment tasks and encourage adherence, provision of tailored feedback (e.g., texts, charts) based on the information that they provide in their sleep diary, as well as quizzes with automated correction to reinforce patients' understanding of the content.
1648799|NCT01864707|Other|Usual care + acupuncture|Patients of this group receive a standardized acupuncture treatment over 12 weeks in addition to usual care
1648800|NCT01864707|Other|usual care+mbsr|Patients of this group receive mindfulness based stress reduction in addition to usual care
1648801|NCT01864707|Other|usual care|Patients in this group will follow the same treatment for fatigue they received at study entry
1648802|NCT01864694|Behavioral|TLC-Diet|Participants receive diet intervention through an automated telephone system
1648803|NCT01864694|Behavioral|WEB-Diet|Participants receive diet intervention through a web-based system
1648804|NCT01864694|Other|Assessment-only control|Assessment-only control
1648805|NCT01864681|Drug|Gefitinib and Metformin|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
1648806|NCT01864681|Drug|Gefitinib and placebo|Gefitinib will be administered once every day. If subject has complete response, partial response, stable disease, or unacceptable toxicity.
1648807|NCT01864655|Drug|saracatinib|oral drug given to experimental group
1648808|NCT01864655|Drug|Placebo|Placebo given to placebo group
1648809|NCT01864642|Procedure|osteopathic manipulative treatment (OMT)|
1648810|NCT01864642|Procedure|osteopathic manipulative treatment (OMT)|OMT is a form of manual medicine performed by osteopathic physicians
2012716|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
1648812|NCT01864616|Dietary Supplement|Vitamin D3|
1648813|NCT01864603|Other|Universal ART in a streamlined care model|immediate ART start for all HIV+ in community with streamlined care
1648814|NCT01864603|Other|Annual Community Health Campaigns|HIV and multi-disease testing for all community members
1648815|NCT01864603|Other|Targeted PrEP, Targeted testing, and Targeted care interventions|
1648816|NCT01864603|Other|Baseline community-based HIV and multi-disease testing|HIV and multi-disease testing for all community members at baseline only
1648817|NCT01864590|Device|Vacuum Pack|Vacuum Pack Technique described by Barker et al.
1648818|NCT01864590|Device|Double Sylo Bag - Mesh Protocol|"double sylo bag, one underneath the fascia and the other sutured to the skin, at the initial operation.
At subsequent surgeries once the abdomen is clean the investigators leave the same subfascial sylo bag and use a prolene mesh attached to the fascia. This mesh is resutured every day until the abdominal fascia is approximated enough to permit closure"
1648819|NCT01864577|Other|Negative Pleural Suction at -20 cm H2O|
1648820|NCT01864577|Other|Water seal|
2012717|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
1648822|NCT01864551|Drug|Lamotrigine|
1648823|NCT01864551|Drug|Olanzapine|
1648824|NCT01864538|Drug|TH-302|480 mg/m2 by iv infusion over 30 - 60 min on Days 1, 8, and 15 of a 28-day cycle.
1648825|NCT01864525|Drug|Octanoic acid|
1648826|NCT01864525|Drug|Placebo pill|
1648827|NCT01864499|Procedure|ultrasound measurement of variations in the diameter of the sheath of the optic nerve|pre-and postoperative optic nerve and J2 and J5 for all patients
2012718|NCT01684215|Drug|PD-0332991|PD-0332991, 125 mg, will be orally administered with food once a day for 3 weeks followed by 1 week off treatment. PD-0332991 will be administered once a day together with letrozole. Dose reduction of PD-0332991 by one (100 mg) or two (75 mg) dose level is permitted depending on treatment related toxicity.
2012719|NCT01684215|Drug|letrozole|Letrozole, 2.5 mg, will be orally administered once a day in continuous daily dosing together with PD-0332991. Dose reduction of letrozole is not permitted, but dosing interruptions for letrozole-related toxicity are allowed as per investigator's medical judgement.
1648830|NCT01864460|Behavioral|lifestyle modification|Structured weight loss or weight maintenance and aerobic exercise intervention for 12 months or standard of care weight and exercise management
1648831|NCT01864447|Behavioral|VTE REHABILITATION: High-Caloric Expenditure Exercise Training (HCE) and The Dietary Behavioral Weight Loss Intervention (BWL)|
1648832|NCT01864434|Device|Stryker posterior cruciat retaining (PCR) total knee arthroplasty (TKA)|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
1648833|NCT01864434|Device|Zimmer PCR TKA|The fluoroscopy procedure itself is used as a means of data collection and is not the intervention under investigation; therefore, the study is observational and not interventional.
1648834|NCT01864408|Other|"Usual practice counseling"|
1648835|NCT01864408|Other|"Standard usual practice clinical counseling with the pelvic organ prolapse web-based tool (iPad)."|"After a new patient history and physical exam, with POP-Q exam, the subjects specific exam findings are entered into the Interactive Pelvic Organ Prolapse Quantification (POP-Q) Program. The program then constructs a cartoon of the subjects physical exam findings. This image is then used in counseling in addition to standard usual practice counseling."
1648836|NCT01864395|Procedure|Centrifugation Method|Currently used to separate whole blood into red blood cells (RBCs) and plasma components. The RBCs are washed with normal saline and re-infused into the patient, while the plasma portion is discarded.
1648900|NCT01864018|Drug|Ixazomib Citrate|Given PO
2012720|NCT01682447|Other|Extensive Pulmonary Rehabilitation Program|Fulltime pulmonary rehabilitation program. Duration: 12 weeks
1648842|NCT01864356|Drug|NT100|
1648843|NCT01864356|Drug|Placebo|
1648844|NCT01864343|Device|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Innercool RTx)
1648845|NCT01864330|Device|Thealoz Duo®|Eye Drops
1648846|NCT01864330|Device|Hyabak®|Eye Drops
1648847|NCT01864330|Device|Hydrabak®|Eye Drops
1648848|NCT01864317|Device|7-Tesla MRI|High resolution functional and structural imaging of the visual pathway
1648849|NCT01864317|Other|Optical Coherence Tomography|Measurement of retinal nerve fiber thickness
1648850|NCT01864317|Other|Heidelberg Retina Tomography|Measurement of retinal nerve fiber thickness
1648851|NCT01864317|Other|Scanning Laser Polarimetry|Measurement of retinal nerve fiber thickness
1648852|NCT01864317|Other|Humphrey Perimetry|Visual Field Testing
1648853|NCT01864317|Other|Applanation Tonometry|Measurement of Intraocular Pressure
1648854|NCT01864291|Device|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
1648855|NCT01864278|Device|Lutonix Drug Coated Balloon|Subject will receive treatment with the Lutonix Drug Coated Balloon
1648856|NCT01864265|Drug|Certolizumab Pegol|Certolizumab Pegol (Cimzia®) is an engineered, humanized antibody-Fab'-fragment with specificity for human TNF-α, that is conjugated to polyethylene glycol (PEG). Certolizumab Pegol (Cimzia®) is a humanized antibody-Fab'-fragment that is produced in Escherichia coli and subsequently PEGylated to prolong its circulating half-time to be similar to that of an intact mAB. Certolizumab Pegol has a high affinity for TNF α with a Kd90pM and is an effective TNF α inhibitor. Certolizumab pegol does not neutralize TNFß (lymphotoxin), a related cytokine, and does not activate complement or kill cells via antibody-dependent cellular toxicity.
1648857|NCT01864265|Drug|Placebo|Placebo will be administered according to the label of the biological
1648858|NCT01864252|Other|Remote ischaemic preconditioning|3 cycles of 5 minutes to arm and legs
1648859|NCT01864252|Drug|IV Normal saline|Normal saline IV started prior to knife to skin at a rate of 2-5 mls/h and stopped just after weaning off bypass.
1648860|NCT01864252|Drug|IV Glyceryl trinitrate 2-5ml/h|IV GTN given during surgery started prior to knife to skin and stopped after weaning off cardiopulmonary bypass.
1648861|NCT01864239|Other|Medicines Advice Service|"The intervention consists of:
Telephone consultations with a pharmacist
Follow-up tailored written information
A medicine reminder chart"
1648862|NCT01864226|Drug|RO5545965|Multiple ascending doses
1648863|NCT01864226|Drug|placebo|Multiple ascending doses
2012721|NCT01681225|Other|Esophageal-pressure guided mechanical ventilation|
2012722|NCT01681225|Other|High PEEP mechanical ventilation|
2012723|NCT01676350|Procedure|IO access using EZ-IO®|IO line placed using an FDA-approved device called an EZ-IO®.
1648867|NCT01864187|Drug|Dexmedetomidine|The volunteers would receive a dosage of dexmedetomidine by 1μg/kg.
1648868|NCT01864174|Drug|Metformin XR|
1648869|NCT01864174|Drug|Metformin IR|
1648870|NCT01864174|Drug|Placebo matching with Metformin XR|
1648871|NCT01864174|Drug|Placebo matching with Metformin IR|
1648872|NCT01864161|Drug|gluconate iron|FERLIXIT fl 15mg/kg divided into weekly administrations of 125mg up to a maximum of 1000mg
1648873|NCT01864161|Drug|Liposomal iron|Sideral forte 30 mg/die
1648874|NCT01864148|Drug|BIIB033|
1648875|NCT01864148|Other|Placebo|
1648876|NCT01864148|Drug|Avonex|
1648877|NCT01864135|Device|3T MRI (Magnetom Verio 3T, Erlangen, Germany)|
1648878|NCT01864135|Device|Transrectal ultrasound (Bk Medical Pro Focus Ultraview 2202 system)|
1648879|NCT01864109|Drug|Cyclophosphamide|
1648880|NCT01864109|Device|Doxorubicin|
1648881|NCT01864109|Drug|Vincristine|
1648882|NCT01864109|Device|Ifosfamide|
1648883|NCT01864109|Drug|Etoposide|
1648884|NCT01864109|Procedure|Surgery|
1648885|NCT01864109|Radiation|Radiation Therapy*|If local control includes RT, RT should be given concurrently with chemotherapy cycles
1648886|NCT01864109|Drug|Temozolomide|
1648887|NCT01864109|Drug|Irinotecan|
2012724|NCT01676051|Other|Skin culture|Culture swab used to culture skin adjacent to incision
2012725|NCT01672892|Radiation|3-dimensional conformal radiation therapy|Undergo radiation therapy
1648890|NCT01864083|Procedure|Positron Emission Tomography (PET)|
1648891|NCT01864083|Drug|Fluorine-18 labeled 1-amino-3-fluorocyclobutane-1-carboxylic acid (FACBC)|
1648892|NCT01864083|Procedure|Positron emission mammography (PEM) When available|
1648893|NCT01864083|Procedure|MR|
1648894|NCT01864070|Other|TheraSphere|TheraSphere glass microspheres containing Y-90 injected into catheter, and will deliver 120 Gy to entire tumor bearing portion of the liver given at a single session on Cycle 1 Day 15.
1648895|NCT01864070|Drug|Everolimus|"Starting dose: is 5 mg by mouth daily for cycles 1 and 2. Patients will receive standard dose of Everolimus at 10 mg by mouth daily starting cycle 3 day 1.
Dose Expansion Cohort Starting Dose: Maximum tolerated dose from dose escalation cohort."
1648896|NCT01864070|Other|Phone Call|At least 1 time a week by phone or at the clinic for up to 30 days after last everolimus dose, study staff will follow up. Patient asked about any side effects they may have had. The call should last about 10-15 minutes.
1648897|NCT01864057|Drug|thiamine hydrochloride 100 mg|
1648898|NCT01864018|Drug|Cyclophosphamide|Given PO
1648899|NCT01864018|Drug|Dexamethasone|Given PO
2012726|NCT01672892|Radiation|intensity-modulated radiation therapy|Undergo radiation therapy
2012727|NCT01670578|Biological|PRP|
2012728|NCT01670578|Device|Hyaluronic acid|
2012729|NCT01669798|Drug|BIBF 1120|PO 200mg BID
2012730|NCT01668784|Biological|Nivolumab|
2012731|NCT01668784|Drug|Everolimus|
2012732|NCT01666600|Drug|BIBF 1120|BIBF 1120 is given as 2 x minimal tolerated dose per day as long as as a clinical benefit is considered by the treating physician.
1648905|NCT01864005|Drug|Ticagrelor|90mg tablets. loading dose of 180mg ticagrelor tablets (two 90mg tablets) taken orally, followed by 90mg of ticagrelor 12 hours after the first dose. Duration of treatment: 6 weeks.
1648906|NCT01864005|Drug|Clopidogrel|75mg capsule. loading dose of 600mg clopidogrel capsules (eight 75mg capsules) taken orally, follow by 75mg of clopidogrel capsules orally od. Duration of treatment: 6 weeks.
1648907|NCT01863966|Other|hot water drinking therapy|Drink 200ml hot water 3min before and after a meal. Swallow food with hot water and drink 200ml hot water before sleep
1648908|NCT01863966|Procedure|Pneumatic dilation|Patients who are unsatisfied with hot water drinking therapy are to receive standard pneumatic dilation under endoscope
1648909|NCT01863953|Drug|Fixed-Combination Bimatoprost/Brimonidine|One drop fixed-combination bimatoprost/brimonidine in each eye twice daily for 6 weeks.
1648910|NCT01863953|Drug|Bimatoprost Ophthalmic Solution 0.01%|One drop bimatoprost ophthalmic solution 0.01% in each eye in the evening for 6 weeks.
1648911|NCT01863953|Drug|Vehicle Ophthalmic Solution|One drop vehicle ophthalmic solution in each eye in the morning daily for 6 weeks.
1648912|NCT01863953|Drug|Brimonidine Tartrate Ophthalmic Solution 0.2%|One drop brimonidine tartrate ophthalmic solution 0.2% in each eye twice daily for 6 weeks.
1648913|NCT01863940|Device|Wound Catheter|Wound catheter placement in split thickness skin graft donor site on the thigh with continuous infusion of procaine 0.5% at 4-5cc/hr for 48 hours.
1648914|NCT01863927|Other|Research intervention|After heat acclimation the participant will be randomly exposed to 4 conditions during four separate consecutive days: 1) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest (control group); 2) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest (control group); 3) walking on a treadmill for two hours in hot-wet conditions (30OC, 70% RH) while wearing military uniforms and a vest with a ventilator (experimental group); 4) walking on a treadmill for two hours in hot-dry conditions (40OC, 30% RH) while wearing military uniforms and a vest with a ventilator (experimental group)
2012733|NCT01666600|Radiation|radiotherapy|36 Gy, 2 Gy / fraction, 18 fractions
1648916|NCT01863901|Device|Treatment with Cryo-Touch III device|
1648917|NCT01863888|Drug|teriflunomide HMR1726|Pharmaceutical form:tablet Route of administration: oral
1648918|NCT01863888|Drug|cholestyramine|Pharmaceutical form:powder Route of administration: oral
1648919|NCT01863888|Drug|charcoal|Pharmaceutical form:granule Route of administration: oral
1648920|NCT01863862|Radiation|Radiochemotherapy or radiotherapy|"50 Gy, 2 Gy per fraction with simultaneous 5-Fu and leucovorin or 5 x 5 Gy for patients unfit for chemotherapy.
Patients with complete clinical response 8-10 weeks after radiotherapy will be closely observed and rescue surgery will be performed in a case of local recurrence.
Patients with persistent tumour 8-10 weeks after radiotherapy will undergo transanal endoscopic microsurgery or total mesorectal excision. After transanal endosciopic microsurgery, patients with ypT0-1 disease and negative surgical margins will be closely observed and rescue total mesorectal excision will be performed in a case of local recurrence; those with ypT2-3 disease or with positive margin will undergo immediate conversion to total mesorectal excision."
1648921|NCT01863849|Biological|Fluval AB suspension for injection|Single intramuscular injection of Fluval AB and collect serum samples for immunogenicity
1648922|NCT01863836|Procedure|Fluoroscopy|
1648923|NCT01863836|Procedure|Radial EBUS-guided biopsy|
1648924|NCT01863823|Drug|Amoxicillin and Tetracyclines|202 symptomatic and 148 asymptomatic individuals were recruited and tested using Saliva H. pylori antigen tests (HPS), H. pylori flagellin (HPF), the urea breathe test (UBT) and the polymerase chain reaction (PCR) test. Test subjects also received various treatments.
1648925|NCT01863823|Drug|Mouth washing|Two time washing mouth per day
1648926|NCT01863810|Drug|KW21052|1 Tablet contains 300mg of pregabalin. Oral, once a day, for 8 weeks.
1648927|NCT01863810|Drug|Lyrica|1 Capsule contains 150mg of pregabalin. Oral, twice a day, for 8 weeks.
1648928|NCT01863810|Drug|Lyrica (low dose)|1 Capsule contains 75mg of pregabalin. Oral, twice a day, for 1 week.
1648929|NCT01863810|Drug|Placebo of KW21052|Oral,once a day, for 8 weeks
1648930|NCT01863810|Drug|Placebo of Lyrica|Oral, twice a day, for 8 weeks.
1648931|NCT01863797|Other|Early induction|
1648932|NCT01863797|Other|Expectant mamagement|
1648933|NCT01863784|Drug|JNJ-38518168|All participants will receive JNJ-38518168 30 mg tablet once daily from Day 1 to Day 14.
1648934|NCT01863771|Drug|Golimumab|Participants will receive 200 mg golimumab at Week 0 and 100 mg golimumab at Week 2 as a subcutaneous (SC) (under the skin) injection in the induction phase. Participants who have a clinical response in the induction phase and are randomly allocated to golimumab in the maintenance phase will receive 100 mg SC every 4 weeks through Week 52. Participants who do not have a clinical response in the induction phase will receive 100 mg of golimumab SC at Week 4 and will continue with 100 mg of golimumab SC every 4 weeks through Week 52 only if a response is obtained by Week 8.
1648935|NCT01863771|Other|Placebo|Participants who have a clinical response to golimumab in the induction phase and are randomly allocated to placebo in the maintenance phase will receive SC placebo every 4 weeks through Week 52. However, participants receiving placebo and who will lose clinical response any time during the study will be eligible to receive 100 mg golimumab SC every 4 weeks through Week 52.
2012734|NCT01664910|Drug|CMC-544|0.6, 1.2 or 1.8 mg/m2 (dose is based on actual body weight) by vein on Day -13.
2012735|NCT01664910|Drug|Fludarabine|30 mg/m2 by vein on Days -5, -4 and -3.
1648938|NCT01863732|Biological|Secukinumab|Eligible patients having completed the core study continue in the extension study under the same blinded dosage regimen (1 PFS); because of the double dummy design, placebo containing PFS is administered simultaneously, for a total of two injections. As of week 156, the same dosage regimen is administered open label, thus a single injection takes place.
1649037|NCT01863069|Drug|(IM) AVONEX®|
1649204|NCT01861639|Device|Effective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an effective stimulation.
2012736|NCT01664910|Drug|Bendamustine|130 mg/m2 by vein on Days -5, -4 and -3.
2012737|NCT01664910|Drug|Rituximab|375 mg/m2 by vein (based on actual body weight) on Day -6, Day +1 and +8 for patients with CD20+ disease.
1648939|NCT01863732|Biological|Secukinumab|Eligible patients having completed the core study continue in the extension study under the same blinded dosage regimen (1 PFS); because of the double dummy design, placebo containing PFS is administered simultaneously, for a total of two injections. As of week 156, the same dosage regimen is administered open label, thus a single injection takes place.
1648940|NCT01863719|Drug|Colistin|Aerosol: In Dosing period 2 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses, followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 75mg colistin base activity via aerosol every 6 hours x 4 doses in combination with 3.3mg/kg colistin base activity IV every 8 hours x 3 doses.
1648941|NCT01863719|Drug|Colistin|Intravenous: In Dosing period 1 subjects receive 3.3mg/kg colistin base activity every 8 hours x 3 doses (total exposure 10mg/kg) intravenously (IV) followed by a washout period of at least 3 days. In Dosing period 3 subjects receive 3.3mg/kg colistin base activity IV every 8 hours x 3 doses in combination with 75mg colistin base activity via aerosol every 6 hours x 4 doses.
1648942|NCT01863706|Drug|Misoprostol|400µg oral misoprostol
1648943|NCT01863706|Drug|Oxytocin|20 IU Oxytocin
1648944|NCT01863680|Drug|COL-1620|The subjects will be administered with COL-1620 vaginal progesterone gel (1.125 grams of progesterone gel containing 90 milligram that is 8 percent [%] gel) vaginally once daily, from the day of ovum pick-up (OPU) until Week 12.
1648945|NCT01863680|Drug|Gonadotropin-releasing hormone (GnRH) analogue|Subjects will undergo conventional controlled ovarian stimulation (COS) therapy for in-vitro Fertilization and Embryo Transfer (IVF/ET) according to the Investigator's discretion using GnRH analogue (agonist or antagonist) preparation.
1648946|NCT01863680|Drug|Follicle-stimulating hormone (FSH)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using FSH containing preparation.
1648947|NCT01863680|Drug|Human Chorionic Gonadotropin (hCG)|Subjects will undergo conventional COS therapy for IVF/ET according to the Investigator's discretion using hCG preparation.
1648948|NCT01863667|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
1648949|NCT01863667|Drug|Glimepiride|Glimepiride tablet 1 mg and/or 2 mg (uptitrated to a maximum dose 6 mg/day) administered orally once daily with breakfast or the first main meal
1648950|NCT01863667|Drug|Omarigliptin Placebo|Matching placebo to omarigliptin capsule administered orally once weekly
1648951|NCT01863667|Drug|Glimepiride Placebo|Matching placebo to glimepiride tablet administered orally once daily with breakfast or the first main meal
1648952|NCT01863654|Drug|Montelukast 5 mg chewable tablets|Reference product
1648953|NCT01863654|Drug|Montelukast 5 mg chewable tablets|Test product
1648954|NCT01863641|Drug|calcitriol|Patients will receive calcitriol at a fixed dose of 0.25 µg (one oral pearl) daily.
1648955|NCT01863641|Drug|placebo|Patients will receive placebo similar to intervention (shape, color and design) 1 oral unit daily.
1648956|NCT01863628|Other|aerobic exercise|
1648957|NCT01863628|Other|psychoeducation|
1648958|NCT01863615|Drug|Isotretinoin 40 mg|Roaccutan 2 capsules of 20 mg; reference drug
1648959|NCT01863615|Drug|Isotretinoin 40 mg|Oratane 2 capsules of 20 mg; test drug
1648960|NCT01863602|Drug|Lamotrigine tablets|Administered for long-term according to the prescribing information in the locally approved label by the authorities.
1648961|NCT01863589|Drug|Adefovir tablets|Administered according to the prescribing information in the locally approved label by the authorities.
1648962|NCT01863576|Dietary Supplement|Omega-3|The group omega-3 receives 5 capsules / day, each capsule containing 1100mg of lipids, and 600 mg of omega-3, 3g of omega-3 per day (1.8 g EPA and 1.2 g DHA) for a period of 8 weeks.
1648963|NCT01863576|Dietary Supplement|Placebo Comparator|The group placebo receives 5 capsules / day of corn oil containing 1100mg each, for a period of 8 weeks.
2012738|NCT01664910|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation on Day 0.
2012739|NCT01664910|Drug|Thymoglobulin|1 mg/kg (based on actual body weight) by vein patients receiving a matched unrelated donor (MUD) on Days -2 and -1.
2012740|NCT01664910|Drug|Tacrolimus|0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion on Day -2, daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after Day +90 if no graft versus host disease (GVHD) is present.
2012741|NCT01664910|Drug|Methotrexate|5 mg/m2 by vein on Days +1, +3, and +6 for all patients. Patients receiving an unrelated graft will also be given Methotrexate on Day +11 after the transplant.
1648971|NCT01863537|Behavioral|Multimedia Connect|
1648972|NCT01863537|Behavioral|Traditional Connect|
1648973|NCT01863511|Drug|loop diuretic|
1648974|NCT01863511|Drug|tolvaptan|
1648975|NCT01863511|Procedure|ultrafiltration|
1648976|NCT01863498|Other|Epidural|Patients will have an epidural for pain control
1648977|NCT01863498|Other|PCA|Patients will have PCA for pain control
1648978|NCT01863485|Drug|CM082 Tablet|CM082 tablets taken orally once a day on 28-day cycles
1648979|NCT01863472|Device|HeartLight(TM) Laser Balloon|With the HeartLight(TM) Laser Balloon pulmonary vein isolation is done endoscopically guided
1648980|NCT01863472|Device|irrigated radiofrequency current ablation|The irrigated radiofrequency current ablation is used for pulmonary vein isolation
1648981|NCT01863459|Drug|Lisdexamfetamine Dimesylate|
1648982|NCT01863459|Drug|placebo|
1648983|NCT01863446|Device|Lighting1|Ocular light exposure to a red wavelength light for one or two nights
1648984|NCT01863446|Device|Lighting2|Ocular light exposure to a blue/green wavelength light for one night
1648985|NCT01863446|Other|Lighting3|Ocular light exposure to a red wavelength light (Device 1) on night 1 and to a blue/green wavelength light (Device 2) for on night 2
1648986|NCT01863433|Biological|Trivalent Influenza Vaccine|
1648988|NCT01863407|Drug|DAM|composed of dexamethasone, allantoin and metronidazole
1648989|NCT01863407|Drug|Normal Saline|Normal Saline 250ml
1648990|NCT01863394|Other|Screening by mothers|
1648991|NCT01863394|Other|Active comparator: Screening by community health workers|
1649205|NCT01861626|Drug|V0057 - A mg|Single oral administration
1717749|NCT00002257|Drug|Ganciclovir|
1648992|NCT01863381|Device|Tympanic membrane displacement (TMD)|"The CCFP Analyser has a passive mode and an active mode. When used in active mode, the device generates a tone burst that is transmitted to the ear to elicit contraction of the stapedius muscle. The passive mode requires no stimulus or sound burst.
For the lying, sitting, standing, and 10-degree head-down tilt conditions, the active mode will be used. Each condition comprises 13 stimuli of 0.3s duration.
Overnight recording of non-invasive ICP will be done using the passive mode of the CCFP device."
1648993|NCT01863381|Device|DPOAE|DPOAE measurement uses a clinical acoustic probe to record the ear's response to two simultaneous tones. DPOAE measurements will be made for 13 tones. The total measurement time for each condition is 2-4 minutes.
1648994|NCT01863368|Other|Preservative-free saline solution eyedrops|1 drop in each eye, 4 times a day, for up to two weeks as washout prior to Phase I and Phase II.
1648995|NCT01863368|Other|Systane® ULTRA lubricant eyedrops|
1648996|NCT01863368|Other|OPTIVE® lubricating eyedrops|
1648997|NCT01863355|Drug|B0 group: bolus 0.6mcg/kg without background infusion|
1648998|NCT01863355|Drug|BL group: bolus 0.4mcg/kg with background infusion rate 0.2mcg/kg/hr|
1648999|NCT01863355|Drug|BH group: bolus 0.2mcg/kg with background infusion rate 0.4mcg/kg/hr|
1649000|NCT01863342|Procedure|CSI score < 40|
1649001|NCT01863342|Procedure|CSI score ≥ 40|
1649002|NCT01863329|Procedure|retrobulbar ultrasound|both optic nerve sheath diameter (the posterior 3mm of the papilla), 5 individual measurement
1649003|NCT01863316|Device|I gel|
1649004|NCT01863316|Device|LMA Supreme|
2012742|NCT01664910|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7 for patients receiving related and MUD. G-CSF will continue until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
1649006|NCT01863277|Drug|Melatonin|
1649007|NCT01863277|Drug|placebo|
1649008|NCT01863264|Other|Cold Thin Liquid Barium|Cold thin liquid barium will be fed to the participant from a standard bottle (60ml Similac® Volu-Feeder® with an attached Similac® Infant Nipple and Ring (standard flow)). For this study the refrigerated (cold) thin liquid barium will be measured for an exact temperature of 4-9°C prior to administration to control for any temperature variation. A total of 5 swallows will be visualized and saved electronically on the hospital's electronic storage system.
1649009|NCT01863251|Drug|Atomoxetine|
1649010|NCT01863238|Other|Ophthalmologic examinations|Subjects will undergo an ophthalmologic examination at study entry (Day 1) and every 6 months thereafter for 2 years (Months 6, 12, 18, and 24). Subjects who discontinue treatment with commercially-available ivacaftor for any reason and are willing to continue participation in the study will complete the study.
1649011|NCT01863238|Drug|Ivacaftor Exposed|
1649012|NCT01863225|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 14-days
1649013|NCT01863225|Drug|Rosuvastatin|20 mg daily, 28-42 days
1649014|NCT01863225|Drug|Atorvastatin|40 mg daily, 28-42 days
1649015|NCT01863225|Drug|Rosuvastatin|40 mg daily, 28-42 days
1649016|NCT01863225|Drug|Atorvastatin|80 mg daily, 28-42 days
1649017|NCT01863212|Procedure|Blood sampling for genetic analyse|Blood sampling are performed at the initiation visit in order to screen for allele variants
1649018|NCT01863212|Behavioral|Stroop test|Selective attention test where subjects, in one minute, names the ink color of several words without naming the word itself.
1649019|NCT01863212|Other|fMRI|Functional Magnetic Resonance Imaging, performed to view brain activity
1649020|NCT01863199|Drug|Lucentis (Treat and extend)|Lucentis 0.5mg will be administered on an as needed basis after a loading dose using a treatment extending protocol and home monitoring.
1649021|NCT01863199|Drug|Lucentis every 4 weeks|Lucentis 0.5mg administered intravitreally every four weeks for 12 months
1649022|NCT01863199|Drug|Lucentis every 12 weeks|Lucentis 0.5mg administered intravitreally every twelve weeks for 12 months
2012743|NCT01662934|Device|I RUNE|
2012744|NCT01662934|Device|sham|
2012745|NCT01659437|Drug|Clarithromycin Extended Release|oral administration of Clarithromycin extended release
1649026|NCT01863173|Drug|metoprolol|using B blocker in patient group
1649027|NCT01863173|Drug|placebo|placebo to control group
1649028|NCT01863160|Drug|0.1% ZEP-3 cream|"Topical application of 250mg ZEP-3 cream (0.1%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).
The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.
Right arm, single treatment area - ZEP-3 (0.1%)
Left arm, single treatment area - Placebo cream"
1649029|NCT01863160|Drug|placebo|"Topical application of 250mg ZEP-3 cream (1.0%) vs. placebo 4 times daily The IP is applied to in advanced demarcated sites in a dose escalating mode to 3 different treatment area sizes: small area of 2x1 cm (2 cm2), medium area of 2x5 cm (10 cm2), and large area of 4x5 cm (20 cm2).
The IP ZEP-3 cream will be applied on both ventral forearms (one application site per forearm) in a non-occlusive mode, spread and rubbed over the demarcated area.
Right arm, single treatment area - ZEP-3 (1.0%)
Left arm, single treatment area - Placebo cream"
1649030|NCT01863147|Drug|Sitagliptin and acarbose|Sitagliptin group: The intervention drug is sitagliptin. Acarbose group: The intervention drug is acarbose.
1649031|NCT01863134|Drug|Eptifibatide|
1649032|NCT01863134|Drug|Placebo|
1649033|NCT01863108|Biological|GeniusVac-Mel4|Multiple sub-cutaneous injections (1 injection weekly during 3 weeks) of GeniusVac-Mel4 (3 increasing dose groups) in patients with melanoma
1649034|NCT01863095|Behavioral|Personalized Feedback and Exercise|
1649035|NCT01863082|Other|exercise|practice of physical exercise
1649036|NCT01863069|Drug|Interferon beta 1a|
2012746|NCT01659437|Drug|Streptomycin intramuscular injection|daily intramuscular drug injection
2012747|NCT01654445|Drug|Tenecteplase|Tenecteplase will be given to the patient as an intravenous bolus over 1- 2 minutes within 90 minutes of the first slice of the CTA. This is an open-label trial, all patients will receive tenecteplase, either tier 1 or tier 2 dosage.
2012748|NCT01652508|Other|Control|Participants in the control group are provided a self-help leaflet on smoking cessation only
2012749|NCT01652508|Behavioral|Acceptance and Commitment Therapy|All participants are given an initial smoking cessation session via face to face by Acceptance and Commitment Therapy. Two other sessions using the same therapy will be provided by telephone. The total contact time by ACT will be 45 mins (15 mins per session).
1649039|NCT01863043|Procedure|No aspiration of gastric contents|Infants will not have routine aspiration of gastric contents prior to every feeding to assess residual gastric contents.
1649040|NCT01863043|Procedure|Routine aspiration of gastric contents|Infants will have routine aspiration of gastric contents prior to each feeding to monitor the amount of residual gastric contents remaining in the stomach.
2012750|NCT01652027|Drug|FVIII concentrate|usual treatment as directed by treating physician
1649042|NCT01863017|Device|tDCS|
1649043|NCT01863004|Drug|Bortezomib|
1649044|NCT01862991|Other|Hygroscopic cervical dilators|Dilapan-S osmotic cervical dilators inserted through the internal os.
1649045|NCT01862991|Drug|Misoprostol|400 mcg buccal misoprostol 90 pre-op
1649046|NCT01862991|Drug|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically ~24 hours pre-op in patients that are greater than 22 weeks gestation
1649047|NCT01862991|Drug|Mifepristone|200 mcg Mifepristone orally
1649048|NCT01862978|Drug|Heparin|
1649049|NCT01862978|Drug|Nadroparin|
1649050|NCT01862978|Drug|Placebo|
1649051|NCT01862965|Drug|PredEver|Firstline treatment with prednisone and Everolimus
2012751|NCT01642251|Drug|Cisplatin|Given IV
1649053|NCT01862939|Drug|DS-7309|1, 2.5, 5, 10, 20 mg DS-7309 powder in bottle.
1649054|NCT01862939|Drug|placebo|placebo to match part 2 DS-7309
1649055|NCT01862926|Drug|Rituximab|
1649056|NCT01862926|Drug|Cyclophosphamide|
1649057|NCT01862913|Other|Computer-assisted cognitive-behavioral therapy|The intervention arm will receive eight sessions of computer-assisted CBT plus usual medical treatment, as described in the AUGE Clinical Guidelines for Depression. Computer-assisted CBT sessions will be delivered on a weekly basis and assisted by trained psychologists in face-to-face meetings. The program is called 'Yo pienso, siento y actúo mejor' (YPSA-M); in English, 'I think, feel, and behave better'. Topics covered in the program will include information on symptoms and causes of depression, treatment options, problem-solving techniques and other cognitive-orientated strategies to challenge negative thoughts.
1649058|NCT01862913|Other|Usual care treatment|The control arm will receive treatment as usual from the primary care clinics. The professionals in the primary care centers will be instructed to follow the AUGE Clinical Guidelines for Depression.
1649059|NCT01862900|Biological|MEDI6469|Patients receive 3 doses of MEDI6469; one on Days 1, 3, and 5
1649060|NCT01862887|Drug|PH-797804|Tablet, 24 mg, single dose
1649061|NCT01862887|Drug|Moxifloxacin|Tablet, 400 mg, single dose
1649062|NCT01862887|Drug|Placebo|Tablet, PH-797804 matched placebo, single dose
1649063|NCT01862874|Biological|V501|
1649064|NCT01862874|Biological|Placebo|
1649065|NCT01862835|Drug|Degarelix|
1649066|NCT01862835|Drug|Testosterone|
1649067|NCT01862835|Drug|Anastrozole|
1649068|NCT01862835|Drug|Estrogen patch|
1649069|NCT01862822|Other|upright position|
2012752|NCT01642251|Drug|Etoposide|Given IV
2012753|NCT01642251|Other|Laboratory Biomarker Analysis|Correlative studies
2012754|NCT01642251|Other|Placebo|Given PO
2012755|NCT01642251|Other|Quality-of-Life Assessment|Ancillary studies
2012756|NCT01642251|Other|Questionnaire Administration|Ancillary studies
1649075|NCT01862705|Other|Thoracic spine manipulation|TSM thrust or non-thrust
1649076|NCT01862692|Behavioral|Baby-Net|Parents randomized to the intervention condition will receive a computerized adaptation of the empirically supported PALS parenting program as well as a laptop and wireless Internet connection. In this study, we adapted original 10-session PALS program for computer administration and included a session on reading (Read to Me, Inc.; http://www.readtomeprogram.org/index.html), developed to be incorporated within the PALS program. Each session includes the following: (a) a presentation of concepts, behaviors, and examples, (b) check-in questions recorded to the data base for review by both parent and coach, (c) the creation of a 5 minute computer-collected video of mother-infant interactions for later review by coach and parent, (d) a summary of topics, (e) daily activities (homework), (f) feedback about the program recorded to the database and (g) a weekly telephone coach call to review mother-infant computer-administered video and session topics and skills.
1649077|NCT01862692|Behavioral|Developmental Awareness Skills|Mothers in this condition will receive weekly phone contact with a coach as well as a laptop and wireless Internet connection. The laptop will contain a computer-based infant intervention program that is structurally similar to the Infant Program in terms of components (e.g., information pages, mother-infant video recording pages; coach contact pages), however weekly information will focus on their infants' development, with no direct maternal skills instruction. Mothers in this condition will receive the same number of contacts with the computer and coach as mothers in the InfantNet condition and will participate in weekly phone calls with a coach. During phone calls, parents will co-view weekly mother-infant video with their coach, with mothers having been instructed to play with their infant (with no prescribed tasks to perform) and the discussion will focus on general infant development.
1649078|NCT01862679|Other|High-flux haemodialysis|High-flux haemodialysis is the standard dialysis modality currently in use in the UK
1649079|NCT01862679|Procedure|Haemodiafiltration|"During Haemodiafiltration, the dialysis machine removes more water from the blood than during normal hemodialysis. The additional liquid is continually replaced with an ultra-pure solution. Thus, the machine exchanges a high volume of fluid during treatment and removes the liquid together with toxins from the blood."
1649206|NCT01861626|Drug|Isotretinoin|Single oral administration
1649256|NCT01861210|Behavioral|Individual Counseling and Testing|
2012757|NCT01642251|Drug|Veliparib|Given PO
2012758|NCT01641471|Device|EMPI Select TENS|The unit is capable of 0-60 milliamps of output current.
2012759|NCT01641471|Device|Placebo EMPI Select TENS|The sham unit appears identical to the Active TENS unit, yet is created to deliver low-level, non-therapeutic electrical stimulation.
1649080|NCT01862653|Device|Auricular Acupuncture|Subjects receiving the auricular acupuncture intervention will be treated in a quiet private room sitting in a comfortable chair. The external ear cartilage of both ears will be cleaned with isopropyl alcohol swabs. A clean insertion technique will be used with stainless steel SEIRIN D type acupuncture needles (0.20mm diameter, 15mm length) on each of the identified acupuncture points (Shen men, Point zero, brain, thalamus, Pineal, Master cerebral, Insomnia 1, Kidney, Heart, Insomnia 2, Occiput, Forehead) to bilateral ears for a total of 30 minutes. Acupuncture will be administered by a board certified Psychiatrist with supplemental privileges to perform acupuncture.
1649081|NCT01862640|Drug|Brexpiprazole, OPC-34712|Once-daily, tablets
1649082|NCT01862627|Procedure|Optical coherence tomography|
1649083|NCT01862601|Device|JetTouch Needle-free injection system|Needle-free injection system believed to provide consistent and reliable delivery of material to the bladder wall.
1649084|NCT01862562|Procedure|Open surgery|Conventional technique
1649085|NCT01862562|Procedure|Laparoscopic surgery|New minimum invasive technique
1649086|NCT01862549|Behavioral|Dialectical Behavior Therapy for children|
1649087|NCT01862549|Behavioral|Treatment as Usual|
1649088|NCT01862536|Drug|Tadalafil|Daily use of study drug to treat pulmonary hypertension.
1649089|NCT01862536|Drug|placebo|Daily use in double blind study.
1649090|NCT01862523|Biological|Capsaicin|Thirty-three* well-characterized IR patients will be recruited and screened for participation in this study with nasal capsaicin spray (0,1 mmol/l ) using the treatment regimen described by van Rijswijk et al. (1 x 5 applications in one day, with 1 hour between each application)
1649091|NCT01862523|Biological|diluent|diluent
1649092|NCT01862497|Drug|Carvedilol vs. Prazosin|
1649093|NCT01862484|Dietary Supplement|Restricted Diet|Child is on an additive, gluten free diet. Child receives daily snacks which conform to the restrictive diet.
1649094|NCT01862484|Dietary Supplement|Ruse Diet|Child is on an additive, gluten free diet. Child receives daily snacks which violate the restrictive diet
1649095|NCT01862471|Device|Neuromuscular Electrical Stimulation|Frequency of 36Hz, a balanced biphasic waveform with a pulse width of 350μs, a ramp up time of 500ms, a contraction time of 1s and a ramp down time of 500ms.
1649096|NCT01862471|Device|Intermittent Pneumatic Compression|Programmed to deliver compression every 20 seconds at a pressure of 130mmHg for a 1 second duration over a period of 5 minutes.
1649097|NCT01862458|Biological|tPA alone|
1649098|NCT01862458|Biological|tPA plus dornase|
1649099|NCT01862432|Other|Immediate skin-to-skin|The newborn is place on his mother's chest, immediately (in the first minute of life), in order to allow complete skin-to-skin contact.
1649100|NCT01862419|Other|Alert|
1649101|NCT01862406|Other|Label|Participants were presented with either a generic label or a brand-name label
1649102|NCT01862393|Device|400 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 400 microseconds
1649103|NCT01862393|Device|700 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 700 microseconds
1649104|NCT01862393|Device|1000 microseconds|Neuromuscular electrical stimulation with stimulus phase duration of 1000 microseconds
1649105|NCT01862380|Other|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
1649106|NCT01862380|Other|Functional explorations|Functional explorations of cortisol and aldosterone production during stimulation by ITT and sodium depletion respectively
1649107|NCT01862367|Drug|catridecacog|No treatment given. All patients enrolled in this observational study will receive their medication through usual commercial channels.
1649108|NCT01862354|Procedure|Transverse abdominal plan block|Transverse abdominal plan block was performed after induction of anaesthesia and before surgery. 3 mg/kg of Ropivacaine 5mg/ml (maximum 200 mg) plus 150 microg of Clonidine were injected at the good place. The was realised with the aid of ultrasound
1649109|NCT01862354|Procedure|Continuous wound infusion|In this group, a multihole catheter was surgically inserted vertically before skin closure. The catheter was primed with Ropivacaine 2 mg/ml 10 ml plus clonidine 150 microg before the end of anaesthesia. Continuous wound infusion was started at a rate of 10 ml per hour of Ropivacaine 2 mg/ml during the first 9 hours after the surgery.
1649110|NCT01862341|Dietary Supplement|ANMUM In-Shape Nutritional Milk Powder for Active Mothers|
1649111|NCT01862328|Drug|MLN4924 and Docetaxel|"MLN4924 (IV) and Docetaxel (IV) in patients to determine maximum tolerated dose (MTD) on a 21-day cycle:
MLN4924 on Days 1,3,5 of each cycle
Docetaxel on Day 1 of each cycle
On Day 1 of each cycle, patients receive both agents"
1649112|NCT01862328|Drug|MLN4924 + Paclitaxel + Carboplatin (Arm 2)|"MLN4924 (IV) Paclitaxel (IV), and Carboplatin (IV) in patients to determine maximum tolerated dose (MTD) on a 21-day cycle:
MLN4924 on Days 1,3,5 of each cycle
Paclitaxel on Day 1 of each cycle
Carboplatin on Day 1 of each cycle
On Day 1 of each cycle, patients receive all 3 agents"
1649113|NCT01862328|Drug|MLN4924 + Gemcitabine (Arm 3)|"MLN4924 (IV) and Gemcitabine (IV) in patients to determine maximum tolerated dose (MTD) on a 28-day cycle:
•MLN4924 and Gemcitabine on Days 1,8,15 of each cycle"
1649114|NCT01862315|Drug|Floxuridine (FUDR)|
1649115|NCT01862315|Drug|dexamethasone|
1649116|NCT01862315|Drug|Gemcitabine|
1649117|NCT01862315|Drug|Oxaliplatin|
1649118|NCT01862315|Other|MRI|
1649119|NCT01862315|Other|Research blood draws|These are optional
1649120|NCT01862302|Drug|Haloperidol|1mg the night before and 1mg the morning of surgery; OR Haloperidol 2mg the morning of surgery
1649121|NCT01862302|Drug|Placebo|1 dose the night before and 1 dose the morning of surgery; OR 2 doses the morning of surgery
1649122|NCT01862289|Other|Diagnostic of chronic hyperventilation syndrome|Nijmegen questionnaire, Hyperventilation challenge and blood gases
1649123|NCT01862263|Drug|Vildagliptin|Orally active and highly selective inhibitor of DPP-4
1649124|NCT01862263|Drug|Insulin|Long- acting human insulin analog indicated to improve glycemic control
1649125|NCT01862263|Drug|Placebo|Matching placebo of vildagliptin
1649202|NCT01861639|Device|fMRI|Functional MRI data will be acquired during the performance of the memory task. Functional data will be acquired with a blood oxygenation level dependant (BOLD) contrast sensitive gradient echo, T2*-weighted echo-planar imaging sequence
2012760|NCT01632787|Other|Questionnaires and Optometrist Prism Challenge/Treatment|A Vertical Heterophoria Symptom Questionnaire (VHSQ) as well as Headache Disability Index (HDI) survey is used on all Emergency Department (ED) headache patients to assess medical history and symptom burden. Prism testing (or Prism Challenge) is performed by the study optometrist to identify those who have Vertical Heterophoria (VH). Prism Challenge is similar to prescription eyeglass testing, but with unique lenses that are meant to reduce strain on eyes that are misaligned. Follow-up questionnaires are then administered to assess any improvement in symptom burden.
1649127|NCT01862237|Other|Intervention|"blood collection
Completion of a pre-operative cardiac MRI.
Completion of a coronary angiography examination
Completion during the surgery d'une myocardial biopsy,
Aortic echocardiographic follow-up (including post-operative ultrasound and ultrasound at 1 year
Completion of a cardiac MRI 1 year after surgery."
1649128|NCT01862224|Drug|JNJ-38518168|JNJ-38518168 30 mg once daily, Week 0 to Week 52.
1649129|NCT01862224|Drug|Placebo|Matching placebo once daily (Week 0 to Week 12).
1649130|NCT01862224|Drug|Methotrexate|All participants will continue receiving methotrexate up to Week 12. After Week 12, the dose of methotrexate may be adjusted as per Investigator's discretion.
1649131|NCT01862211|Other|blood sampling|A blood sampling will be performed for the genetic analysis and the measurement of serum IL-8.
1649132|NCT01862198|Device|EUS-guided biliary drainage with a hybrid metallic stent|EUS-guided biliary drainage with a newly designed hybrid metallic stent
1649133|NCT01862185|Other|semi-quantitative procalcitonin|
1649134|NCT01862172|Other|Additional MRI|
1649135|NCT01862159|Procedure|laparoscopic gastric bypass surgery|laparoscopic gastric bypass surgery
1649136|NCT01862146|Procedure|smoke expose|
1649137|NCT01862133|Other|Patient preferences|Software for recording patients' preferences for which providers see which parts of their EMRs, and EMR software for restricting access to data based on patients' preferences.
1649138|NCT01862120|Drug|Dose D1 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
1649139|NCT01862120|Drug|placebo|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
1649140|NCT01862120|Drug|Dose D2 of Interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
1649141|NCT01862120|Drug|Dose D3 of interleukin-2|subcutaneous injection of Interleukin-2 during 5 days, once daily repeated administration(Induction period). At day 15 single administration of Interleukin-2 every two weeks during one year (maintenance period).
1649142|NCT01862081|Drug|Docetaxel|Participants will receive docetaxel 75 milligrams per meter-squared (mg/m^2) intravenous (IV) dose on Day 1 of each 21-day cycle.
1649143|NCT01862081|Drug|GDC-0032|Participants will receive escalated dose of GDC-0032. The initial dose will be 3 mg capsules or 2 mg tablets.
1649144|NCT01862081|Drug|Paclitaxel|Participants will receive paclitaxel 80 mg/m^2 IV dose on Day 1, 8, 15 and 22 of each 28-day cycle.
1649145|NCT01862068|Other|Blood samples and clinical data|Blood samples will be performed at inclusion and at 12 months from all patients (4 groups GPA, MPA, EGPA and Atherosclerotic patients)
1649146|NCT01862068|Other|Blood sample|Blood sample will be performed at inclusion from all healthy patients
1649147|NCT01862042|Other|Follow-up diary and questionnaire|A follow-up diary will be completed by the families and the different practitioners working with the patient. One year after the death of the patient, a questionnaire will be proposed to the parents of the child by a psychologist.
2012761|NCT01630083|Drug|Epirubicin|50 mg/m2; d 1 q3w for max. 8 cycles
2012762|NCT01630083|Drug|Oxaliplatin|130 mg/m2; d 1 q3w for max. 8 cycles
1649151|NCT01862003|Drug|AZD8931|160 mg AZD8931 tablets, twice daily on days 1 - 4 of each 2-weekly cycle
1649152|NCT01862003|Drug|Irinotecan|180 mg/m2 (IV infusion) of Irinotecan on day 1 of each 2-weekly cycle - can be given simultaneously with Folinic acid.
1649153|NCT01862003|Drug|Folinic Acid|350 mg (IV infusion) of Folinic acid on day 1 of each 2-weekly cycle - can be given simultaneously with Irinotecan.
1649154|NCT01862003|Drug|Fluorouracil|400 mg/m2 (IV bolus) of Fluorouracil on day 1 of each 2-weekly cycle, to be given after completion of Irinotecan and Folinic acid.
1649155|NCT01862003|Drug|Fluorouracil|2400 mg/m2 (IV) continuous infusion of Fluorouracil given over 46 hours - infusion to start after 5FU bolus.
1649156|NCT01861990|Drug|Valproic Acid|All participants enrolled on valproic acid arm.
1649157|NCT01861977|Behavioral|Cognitive Behavioral Therapy|Participants in this arm will be invited to attend 8 weekly group meetings and 3 monthly follow-up meetings. In each meeting a coordinator will explore the experiences of the participants and encourage them to look for strategies to solve problems associated with changing habits. In the meetings we will use a therapeutic education approach with motivational interviewing techniques and problem solving in order to increase self-efficacy and motivation to adopt healthy habits. There will be periodic reminders and telephone contacts with patients before the meetings to assess the achievement of objectives.
1649158|NCT01861977|Behavioral|Informational Workshop|Participants will be invited to participate in 4 weekly group meetings and an additional reinforcing meeting in the 5th month. In each meeting, workshop techniques will be used, together with educational materials as brochures, pictures, etc. The informational material will focus on the benefits of lifestyle changes in diet and physical activity.
1649159|NCT01861964|Dietary Supplement|Placebo (Maltodextrin)|Maltodextrin 505mg/capsule 8 capsules/day (4 with breakfast and 4 with dinner meal)
1649160|NCT01861964|Dietary Supplement|Xylooligosarcharide 1.4g|8 capsules (512 mg/capsule) 4 with breakfast and 4 with dinner meal
1649161|NCT01861964|Dietary Supplement|Xylooligosarcharide 2.8g|8 capsules (520 mg/capsule) to be taken in the morning and in the evening
1649162|NCT01861951|Drug|Pazopanib|
1649163|NCT01861951|Drug|Doxorubicin|
1649164|NCT01861938|Biological|Melanoma vaccine modified to express HLA A2/4-1BB ligand|
1649203|NCT01861639|Device|EEG|EEG will be coupled with task performance in an event-related manner to be able to isolate brain activity of each type of stimuli presented. EEG imaging data will be acquired during the memory task.
1649165|NCT01861912|Device|Arsenic trioxide TACE|Arsenic trioxide powder 20mg dissolved in lipiodol(the dosage of lipiodol is decided according to the volume of the target lesion)is used for transcatheter arterial chemoembolization(TACE). TACE will be repeated after 4~6 weeks if it is necessary according to the assessment from imaging modalities
1649166|NCT01861912|Drug|Arsenic trioxide intravenous infusion|Arsenic trioxide intravenous infusion: arsenic trioxide powder 0.15mg/Kg/d(maxim 10mg/d) dissolved in 250ml 0.9%NaCl solution is used for intravenous infusion.Every course will last for 3 weeks and the next course will be continued after 1 week suspension.Intravenous infusion will be suspended 3 days before and 7~14 days after TACE.
1649167|NCT01861912|Drug|lipiodol|Lipiodol is used to dissolve arsenic trioxide for TACE,with the dosage decided according to the volume of the target lesion.
1649168|NCT01861912|Drug|NaCl solution|250ml NaCl solution is used to dissolve the arsenic trioxide for intravenous infusion.
1649169|NCT01861899|Device|SI-LOK|Sacro-iliac joint fusion
1649170|NCT01861886|Device|ESS505 (BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 in the proximal portion of the fallopian tubes using a transvaginal approach. Subsequent transvaginal ultrasound (TVU) or hysterosalpingogram (HSG) was performed approximately ≤ 3 hours and 90 days following insert placement.
1649171|NCT01861873|Other|measuring liver function by 18-FDGal PET/CT|
1649172|NCT01861860|Device|TAXUS™ Element long stent|Segments are selected using bifurcation branch take-off. The reference is selected or estimated on both sides of the bifurcation and is applied to the concerned segment. The objective is to attain > 80% of the reference cross-sectional areas (CSA) per segment. The balloon diameter is adapted to the endoluminal diameter of the reference.
1649173|NCT01861847|Drug|7-Keto Dehydroepiandrosterone|7-Keto Dehydroepiandrosterone, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
1649174|NCT01861847|Drug|Placebo|Placebo, 100 mg capsules given orally twice daily for 4 weeks in one of the two intervention phases, dependent on randomization assignment.
1649175|NCT01861834|Drug|Omegaven 10%|"Patients with a sustained TPN requirement due to short bowel syndrome and TPN-associated liver disease that threatens progression to liver failure and death, for which the only available means of prevention at present is timely liver and/or intestinal transplant.
Omegaven 10%, 1 gram/kg, IV, every 12 hours until transplantation, or stopping TPN"
1649176|NCT01861821|Device|Multiport flexible catheter|Multiport flexible catheter has three ports for the delivery of epidural medication
1649177|NCT01861821|Device|Uniport flexible catheter|Uniport flexible catheter has one port for the delivery of epidural medication
2012763|NCT01630083|Drug|Capecitabine|625 mg/m2; p.o. d 1 - d 21 q3w twice daily for max. 8 cycles
1649179|NCT01861795|Other|Preterm Neonates|Preterm Neonates
1649180|NCT01861782|Other|Dead Sea Solar and Water Treatment|
1649181|NCT01861782|Other|Sulfur Pool & Medicinal Mud|
1649182|NCT01861769|Other|Technology-enhanced Teleconsultation|Technology-enhanced Group Tele-consultation. This consultation method requires that participants be prepared to review and receive feedback on audiorecorded CPT sessions in a group format. The CPT expert randomly selects two clinician sessions each week that have been audiorecorded to use for feedback and discussion in group teleconference based on procedures used in previous training initiatives (Stirman, Bhar, et al., 2010). Five- to twenty-minute segments of the two sessions will be shared within the group consultation. The CPT expert will provide feedback on the sessions with an emphasis on review of key learning points. These consultation group sessions will be facilitated with collaborative meeting software that includes audio file uploading.
1649183|NCT01861769|Other|Standard Teleconsultation|Standard Tele-consultation Group. The CPT expert will randomly select clinicians for case presentation each week. Each clinician will be responsible for verbally presenting on their CPT cases throughout the 6-month period of consultation course. No audiorecorded content will be reviewed within the calls. All other procedures used in the above condition will be used here.
1649184|NCT01861756|Other|Diabetes Medication Choice decision aid|The Diabetes Medication Choice decision aid cards provide information about medications commonly used to treat type 2 diabetes mellitus. The tool was originally developed and successfully evaluated by Mayo Clinic researchers.
1649185|NCT01861743|Other|Multimodal Analgesia|Subjects are given medications preop, intraop and postop that implement a multi-modal approach to managing pain.
1649186|NCT01861743|Other|Patient controlled analgesia|Subjects will be treated with patient controlled narcotic analgesia for pain management.
1649187|NCT01861730|Biological|AERAS-404|AERAS-404 has two components: the H4 antigen and the IC31 adjuvant. The reconstitution of the vaccine components, H4 antigen (manufactured at SP) and IC31 adjuvant (supplied by SSI), will take place at the clinical research site (CRS) prior to injection.
1649188|NCT01861730|Biological|Placebo|Tris buffered saline (10mM Tris, pH 7.4, 150nm sodium chloride).
1649189|NCT01861717|Drug|lanreotide|Somatuline Depot 90 mg deep subcutaneous injecton every 4 weeks X 3 doses
1649190|NCT01861704|Device|Lyric|Extended wear hearing instrument
1649191|NCT01861704|Device|Lyric2|Extended wear hearing instrument
1649192|NCT01861691|Procedure|Open surgery|Conventional technique
1649193|NCT01861691|Procedure|Laparoscopic surgery|New minimum invasive technique
1649194|NCT01861678|Procedure|High tie of IMA|Conventional technique
1649195|NCT01861678|Procedure|Low tie of IMA|Technique for preserving left colic arterial perfusion
2012764|NCT01630083|Drug|IMAB362 800/600 mg/m2|"800 mg/m2 loading dose on cycle 1.
600 mg/m2 every 3 weeks."
2012765|NCT01630083|Drug|IMAB362 1000 mg/m2|1000 mg/m2 every 3 weeks.
1649198|NCT01861652|Device|Venous Health Systems Vasculaire Leg Compression Device|Leg (calf) compression device used to alleviate symptoms of restless legs
1649199|NCT01861639|Device|ineffective rTMS|A 20Hz repetitive transcranial magnetic stimulation (rTMS) will be applied for 900 ms with an intensity of 90% of motor threshold. Active stimulation will be applied on the L-DLPFC compared to an ineffective stimulation.
1649200|NCT01861639|Device|active TBS|A continuous Theta-Burst Stimulation (cTBS) protocol will be applied over the L-DLPFC. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec
1649201|NCT01861639|Device|Sham TBS|A Sham stimulation will be applied over the L-DLPFC. a placebo coil will be used.
1649312|NCT01860729|Drug|Anacetrapib|
1649208|NCT01861600|Other|S-26 Gold|(13.4 g/L protein) with 100% Fat Blend A
1649209|NCT01861600|Other|S-26 Gold EF1|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend
1649210|NCT01861600|Other|S-26 Gold EF2|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 3.0 g/L oligofructose
1649211|NCT01861600|Other|S-26 Gold EF3|(13.4 g/L protein) with 60% Fat Blend A and 40% Betapol fat blend, and supplemented with 5.0 g/L oligofructose
1649212|NCT01861600|Other|Human Milk|Human Milk
2012766|NCT01628432|Procedure|conservative hysterectomy I|conservative hysterectomy for benign disease
1649214|NCT01861574|Device|Real TMS: Active Comparator|2 ( 20 minute) sessions of TMS
1649215|NCT01861574|Device|Sham TMS: Sham Comparator|102 seconds of sham or active tms.
1649216|NCT01861574|Device|Transcranial Magnetic Stimulation|1-2 seconds of TMS either of Sham or Active.
1649217|NCT01861561|Drug|Low-dose intravenous cyclophosphamide|Intravenous cyclophosphamide 500 mg/m2/dose every 4 weeks/months, total 7 doses
1649218|NCT01861561|Drug|High-dose intravenous cyclophosphamide|"Intravenous cyclophosphamide every 4 weeks/months, total in 7 doses:
the 1st dose-500 mg/m2/dose,the 2nd dose-750 mg/m2/dose, the 3rd-7th doses- 1,000 mg/m2/dose with the maximum dose at 1,500 mg/dose"
1649219|NCT01861535|Drug|Imiquimod|
1649220|NCT01861535|Procedure|Surgery|
1649221|NCT01861522|Drug|Bepotastine besilate|Two TAU-284 5mg tablets will be taken orally twice a day
1649222|NCT01861522|Drug|Placebo|Two Placebo tablets will be taken orally twice a day
1649223|NCT01861509|Drug|BP-C1|BP-C1, 0.05% solution for injections; doses: 0.035 mg/kg body weight (0.7 ml/kg) intramuscularly once daily for 32 consecutive days
1649224|NCT01861496|Drug|LiPlaCis|LiPlaCis IV every 3 weeks on day 1, day 8
1649225|NCT01861457|Other|Nozin® Nasal Sanitizer®|The treatment agent tested was the alcohol and natural oil preparation that comprises the commercially available over-the-counter (OTC) product, NOZIN® Nasal Sanitizer® antiseptic, by Global Life Technologies Corp, with the addition of benzalkonium chloride (0.13%), as described for the patented and safety-tested formulation.
1649226|NCT01861457|Other|Placebo|The placebo preparation, utilized to account for the potential mechanical effects of the application process, was phosphate buffered saline (PBS).
1649227|NCT01861431|Behavioral|HIV Sexual Risk reduction|4 sessions of HIV sexual risk reduction
1649228|NCT01861431|Behavioral|HIV Sexual Risk reduction plus Microfinance|4 sessions of sexual risk reduction plus 12 sessions of financial literacy, 12 sessions of business development training, 10 sessions of business mentorship; matched savings throughout course of intervention
2012767|NCT01628432|Procedure|Conservative hysterectomy II|bilateral salpingectomy during hysterectomy without conservation of the ovaries
2012768|NCT01625182|Drug|Fingolimod|Fingolimod 0.5 mg capsules
1649231|NCT01861405|Behavioral|neuropsychological testing and quality of life assessments|
1649232|NCT01861405|Radiation|Standard of Care WBRT or SRS|
1649233|NCT01861405|Device|Functional magnetic resonance imaging|
1649234|NCT01861392|Procedure|sensorio-motor training|
1649235|NCT01861379|Procedure|Ghost Ileostomy|At the end of Laparoscopic Anterior Rectal Resection, once the colorectal anastomosis was performed, the terminal ileum was identified and a window in the mesentery was created to pass a rubber tube (we usually use an urinary catheter) around the intestinal loop. The tube was subsequently exteriorized trough the trocar incision in the right flank.
1649236|NCT01861366|Other|A one year multifaceted implementation strategy|
1649237|NCT01861366|Other|A three hour lecture about the guidelines|
1649238|NCT01861353|Other|Cranberry-lingonberry juice|
1649239|NCT01861353|Other|Placebo juice|Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
1649240|NCT01861340|Drug|Lenalidomide, Dexamethasone, and MEDI-551|Patients will receive Lenalidomide and dexamethasone as per standard of care. Patients with a clinical response after 2 cycles will get 2 cycles of MEDI-551.
1649241|NCT01861327|Drug|CO2|carbon dioxide (CO2) as arterial contrast media
1649242|NCT01861327|Drug|Iodine contrast media|Iodine as arterial contrast media
1649243|NCT01861314|Drug|Bortezomib|Given SC
1649244|NCT01861314|Drug|Decitabine|Given IV
1649245|NCT01861314|Other|Laboratory Biomarker Analysis|Correlative studies
1649246|NCT01861314|Other|Pharmacological Study|Correlative studies
1649247|NCT01861314|Drug|Sorafenib Tosylate|Given PO
1649248|NCT01861301|Other|Laboratory Biomarker Analysis|Correlative studies
1649249|NCT01861301|Drug|Tivantinib|Given PO
1649250|NCT01861275|Device|Nasal CPAP|Nasal CPAP treatment for obstructive sleep apnoea
1649251|NCT01861262|Device|Measurement of StO2|The procedure is a measurement and non-invasive monitoring system of percentage of oxygen saturation of haemoglobin in tissues using infrared technology. The system used in the study is the tissue oxygenation monitor InSpectraTM StO2 Spot Check, Model 300 consisting of a clamp applied to the base of the thumb of the patient.
1649252|NCT01861249|Drug|SAR339658|"Pharmaceutical form: Solution for infusion
Route of administration: Intravenous"
2012769|NCT01625182|Drug|Placebo Comparator|Matching placebo capsules
1649254|NCT01861223|Drug|afatinib (30 or 40mg) + nimotuzumab (100 or 200mg)|
1649255|NCT01861210|Behavioral|Couples Voluntary HIV Counseling and Testing|
2012770|NCT01622868|Other|Laboratory Biomarker Analysis|Correlative studies
2012771|NCT01622868|Drug|Lapatinib Ditosylate|Given PO
2012772|NCT01622868|Radiation|Stereotactic Radiosurgery|Undergo SRS
2012773|NCT01622868|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
2012774|NCT01615731|Drug|Mifepristone|200mg Mifepristone orally
2012775|NCT01615731|Other|Hygroscopic cervical dilators|Dilapan-S osmostic cervical dilators inserted through the internal os
2012776|NCT01615731|Drug|Misoprostol|400mcg buccal misoprostol 90 minutes pre-op
2012777|NCT01615731|Drug|Intra-amniotic digoxin|1mg digoxin administered intra-amniotically ~24 hours pre-op
2012778|NCT01615055|Drug|Fluoxetine|20-40 mg fluoxetine po qd for 6 months
2012779|NCT01615055|Other|Placebo|20-40 mg pharmacologically inactive tablets for 6 months
1649257|NCT01861197|Drug|Dovitinib|Dovitinib 500mg daily for 5 days on/ 2 day off until progression
1649258|NCT01861171|Dietary Supplement|Green Tea|Twenty women with obesity and pre-hypertension, aged 28-59 years, with stable body weight were randomized to receive a daily supplement of 3 capsules that contained either 500mg of green tea extract (GTE) or a matching placebo for 4 weeks, with a washout period of 2 weeks between the treatments.
1649259|NCT01861158|Behavioral|Parenting Wisely|Computer-based, online, interactive parenting intervention
1649260|NCT01861145|Device|Bed Alarm|The bed alarm is a device that is worn at night with a sensor in the child's underwear. The alarm will activate when the child urinates, helping the brain to link the sensation of a full bladder with wakening.
1649261|NCT01861145|Drug|Nasonex|Intranasal steroids are used by otolaryngologists as first line treatment for adenotonsillar hypertrophy in children with suspected sleep-disordered breathing and obstructive sleep apnea. The spray helps to shrink the size of the adenoids and tonsils, diminishing the amount of tissue obstructing the child's airway.
1649262|NCT01861119|Drug|Silicone gel Kelo-cort™;|
1649263|NCT01861119|Drug|Onion extract gel Contractubex™|
2012780|NCT01613183|Drug|Chinese herbal Medicine|The intervention of Chinese Medicine group is not fixed. The clinicians provide the prescription to patient base their own Chinese Medicine theory. Chinese clinicians can adjust the medicinal in prescription based on the condition of patient during the treatment procedure. The prescription of Chinese clinicians' are pure Chinese herb.
2012781|NCT01613183|Other|the dummy of a Chinese Medicine prescription|Patients in placebo group will receive the dummy of the core drug patterns screened in previous retrospective study. The previous core drug patterns include Fried semen Ziziphi Spinosae, Tuckahoe, Preparation of Polygala, Chinese Angelica root, Lotus heart, White peony root, dried tangerine peel, acorus calamus, Coptis chinensis, and Licorice health.
2012782|NCT01613300|Drug|Ofatumumab|Ofatumumab as part of the reduced intensity conditioning regimen (RIC)
2012783|NCT01608464|Drug|irinotecan and docetaxel|combination of irinotecan and docetaxel regimen for 2 cycles, recycling every 21 days Irinotecan 100 mg/m2 by intra venous infusion over 2 hours in day1 and docetaxel 40 mg/m2 over one hour will be given on day 1 Assessment by PET scan and CT chest and abdomen will be done 2-3 weeks after end of 2nd cycle of irinotecan and docetaxel
2012784|NCT01608464|Drug|Cisplatin, fluorouracil and concurrent radiation therapy|Cisplatin, fluorouracil and concurrent radiation therapy 50 Gy in 25 fractions over 5 weeks with cisplatin 75 mg/m2 on first day of week 1 and week 5 and fluorouracil 750 mg/m2 daily by continuous intra venous infusion at Day 1 and Day 29 of Radiation therapy for 4 days.
1649272|NCT01861067|Procedure|LESS-TLH|
1649273|NCT01861067|Procedure|LESS-LAVH|
1649275|NCT01861041|Drug|Heavy Bupivacaine|7,5 mg intrathecal hyperbaric bupivacain,
1649276|NCT01861041|Drug|Isobaric Bupivacaine|7.5 mg intratecal isobaric bupivacain
1649277|NCT01861015|Drug|Epinephrine|
1649278|NCT01861015|Drug|Vasopressin|
1649279|NCT01861002|Drug|Azacytidine|Dose assigned at study entry. Azacytidine will be given subcutaneously, once daily on days 1 to 5, for a total of 5 doses.
1649280|NCT01861002|Drug|Fludarabine|30 mg/m2/dose, intravenous infusion over 30 minutes, once daily, on days 6 to 10, total 5 doses
1649281|NCT01861002|Drug|Cytarabine|2000 mg/m2/dose intravenous infusion over 3 hours, starting 4 hours after the beginning of fludarabine, once daily, on days 6 to 10, total 5 doses.
1649282|NCT01860989|Drug|KAE609|KAE609 75mg single dose
1649283|NCT01860989|Drug|KAE609|KAE609 150mg single dose
1649284|NCT01860989|Drug|KAE609|KAE609 225mg single dose
1649285|NCT01860989|Drug|KAE609|KAE609 300mg single dose
1649286|NCT01860976|Drug|Abatacept|
1649287|NCT01860976|Drug|Placebo|
1649288|NCT01860963|Procedure|Anal Pap smear and HPV DNA testing|Anal Pap smear is a standard diagnostic test used for early detection of pre-cancerous cells and anal HPV.
1649289|NCT01860950|Device|Transcranial Direct Current Stimulation|20 milliamps of current for 20 minutes
1649290|NCT01860950|Device|Transcranial Direct current Stimulation|20 milliamps of current for 20 minutes
1649291|NCT01860937|Procedure|leukapheresis or collection of PBMCs|
1649292|NCT01860937|Drug|cyclophosphamide based chemotherapy regimens|
1649293|NCT01860937|Biological|modified T cells|
1649294|NCT01860924|Behavioral|exercise|vigorous intensity exercise
1649295|NCT01860924|Behavioral|health education|education
1649296|NCT01860911|Drug|Insulin|
1649297|NCT01860911|Drug|NG-monomethyl-L-arginine|
1649298|NCT01860898|Other|Skin Biopsy|Biopsy samples will be taken as a 2mm x 2cm excision of a wedge of skin at the edge of the incision during your surgery at the Mayo Clinic Rochester. Such excisions are frequently done as part of routine skin closure for optimal skin cosmesis following the surgical procedure.
1649299|NCT01860859|Procedure|Closure of the hysterotomy at the time of primary cesarean|
1649300|NCT01860833|Drug|Ibuprofen|time of treatment 14 days
1649301|NCT01860833|Drug|Celecoxib|time of treatment 14 days
1649302|NCT01860833|Drug|Diclofenac|time of treatment 14 days
1649303|NCT01860820|Device|Geko device|
1649304|NCT01860807|Drug|Ibudilast|
1649305|NCT01860807|Drug|Placebo|
1649307|NCT01860781|Drug|paliperidone palmitate|paliperidone palmitate 150mgeq(1 day), 100mgeq(8days), 75mg(monthly)
1649308|NCT01860755|Other|Control postural education, general range of motion and strengthening in addition to the standard of care|Control: postural education, general range of motion and strengthening in addition to the standard of care rest followed by graded exertion. Individuals were seen once weekly for eight weeks or until time of medical clearance to return to sport.
1649309|NCT01860755|Other|Physiotherapy|Physiotherapy: including vestibular rehabilitation and multimodal treatment for the cervical spine, once weekly with the study physiotherapist for 8 weeks or until time of medical clearance to return to sport.
1649310|NCT01860742|Drug|Interferon alpha-2b|Interferon α-2b in a dose of 5000000 Units administered subcutaneously every second day
1649311|NCT01860742|Drug|177Lu-DOTATATE|177Lu-octreotate infusions in fixed activities of 7,4 GigaBecqurel each, given 8-11 weeks apart, injected intravenously with simultaneous infusion of an amino acid solution
1649314|NCT01860716|Drug|Melatonin|Melatonin 2 mg prolonged-release tablet, administration via nasogastric tube.
1649315|NCT01860716|Drug|Placebo|
1649316|NCT01860703|Drug|Deferiprone|Ferriprox 500 mg tablets
1649317|NCT01860703|Drug|deferiprone matching placebo tablets|deferiprone matching placebo tablets
1649318|NCT01860703|Drug|moxifloxacin|Active control
1649319|NCT01860703|Drug|placebo|moxifloxacin-matching placebo
1649320|NCT01860690|Drug|Methotrexate|50 mg / meter squer Intramuscular (IM) MTX.
1649321|NCT01860677|Device|Fisher Wallace Cranial Stimulator|The Fisher Wallace Cranial Stimulator device generates micro currents of electricity using a patented series of radio frequencies.
1649322|NCT01860664|Drug|hydrocortisone ophthalmic ointment 0.5%|"Patients will be instructed to apply Hydrocortisone Ophthalmic Ointment 0.5% or placebo in the lower cul de sac or lid margin BID
Patients will be instructed to not use the study medications at least 2 hours prior to their appointment.
Study medication dosing details:
0.05 grams hydrocortisone per gram of combination product
each application equal to 1/20th of a gram
total amount of active ingredient applied to each eye per application = 0.0025 grams hydrocortisone
total amount hydrocortisone applied per eye per day = 0.005 grams hydrocortisone
Total amount of active ingredient applied per eye throughout duration of the two week study = 0.07 grams hydrocortisone"
1649323|NCT01860664|Drug|placebo|Mineral oil and white petrolatum
1649325|NCT01860638|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) intravenous (IV) every 2 weeks (Q2W) throughout the study, with the exception of bevacizumab monotherapy prior to PD1, which will be given as 15 mg/kg IV every 3 weeks (Q3W).
1649326|NCT01860638|Drug|Lomustine|Lomustine will be administered at a dose of 90 milligrams per square meter (mg/m^2) orally (PO) every 6 weeks (Q6W), with a cap of 160 milligrams (mg) per dose. In the absence of hematologic toxicity following the first dose, the second and subsequent doses may be increased to 110 mg/m^2 PO Q6W, with a cap of 200 mg per dose.
1649327|NCT01860638|Drug|Placebo|Placebo will be administered IV, in a formulation matched to bevacizumab, Q2W.
1649328|NCT01860638|Radiation|Radiotherapy|Radiotherapy will be administered for a total dose of 60 Gray (Gy), administered in 2-Gy fractions, 5 days per week for 6 weeks during first-line treatment.
1649329|NCT01860638|Drug|Temozolomide|Temozolomide will be administered orally (PO) as 75 mg/m^2 per day for the first 6 weeks of first-line treatment (concurrent treatment), followed by 6 cycles (28 days each) as follows: 150 mg/m^2 per day for the first 5 days of Cycle 1, then 200 mg/m^2 per day (if permitted by the participant's hematological and non-hematological toxicity profile) for the first 5 days of Cycles 2-6.
1649330|NCT01860638|Drug|SOC Agent|The choice of SOC agent will be at the discretion of investigator. The SOC agent will be administered during third-line treatment and subsequent lines, as per standard practice.
1649331|NCT01860625|Drug|Donepezil patch|
1649332|NCT01860625|Drug|placebo|
1649333|NCT01860612|Device|Artificial Iris (CustomFlex)|
1649334|NCT01860599|Behavioral|Exercise|150 minutes of moderate exercise per week
1649335|NCT01860599|Behavioral|Without exercise|Pre-study activity level (i.e. no exercise)
1649336|NCT01860586|Drug|Bevacizumab|Bevacizumab (1.25mg/0.05mL) will be injected into the study eye, at the end of the surgical repair of the retinal detachment and at Month 1, 2 and 3.
1649337|NCT01860573|Drug|Amino acids|
1649338|NCT01860560|Device|High-Flow Therapy|Blower-based High Flow Therapy delivered by nasal cannula
1649339|NCT01860560|Device|Continuous Positive Airway Pressure|CPAP Therapy delivered by laboratory Positive Airway Pressure titration device.
1649340|NCT01860547|Dietary Supplement|Bilberries|Frozen bilberries, 100 g/d
1649341|NCT01860547|Dietary Supplement|Sea buckthorn berry|Dried sea buckthorn berries, 20 g/d
1649342|NCT01860547|Dietary Supplement|Sea buckthorn phenolic extract|Ethanol-water extract from sea buckthorn berries, combined with maltodextrin, 14.6 g/d (7.3 g sea buckthorn extract + 7.3 g maltodextrin)
1649343|NCT01860547|Dietary Supplement|Sea buckthorn oil|Sea buckthorn oil, 4 g (8 capsules)/d
1649344|NCT01860534|Behavioral|eye covers|The infants were randomly assigned by alternating enrolled patients between one of two groups prior to their first ROP screening. Group A was patched for their first ROP exam and then unpatched for their second exam while group B was unpatched for their first ROP exam and unpatched for their second exam. The patched subjects had eye covers after their eyes were dilated, and the unpatched subjects had comfort measures similar to the patched subjects but their eyes were not covered. The patching of the eyes was done in the same way that it is done for eye protection during phototherapy, with the same model of eye patches (Natus biliband) and with the same nursing care.
1649345|NCT01860521|Procedure|Programmed Intermittent Epidural Bolus|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL, 10 mL every hour, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.
1649346|NCT01860521|Procedure|Continuous Epidural Infusion|An initial epidural loading dose consisting of 0.0625% levobupivacaine 20 mL (Chirocaine®, Abbott, Chicago, USA) plus sufentanil 10 µg (Fentatienil®, Angelini, Rome, Italy) was followed by 0.0625% levobupivacaine with sufentanil 0.5 µg/mL at a rate of 10 mL/h, starting 60 minutes after the administration of the initial epidural loading dose until expulsion of the fetus. If the patient still felt pain (VAPS score ≥ 30mm), despite the analgesia, additional manual incremental boluses of 5-mL levobupivacaine 0.125% until the VAPS score was < 30 mm were administered.
1649385|NCT01860235|Drug|Injectable anesthesia|Injectable anesthesia 2% lidocaine with epinephrine 1:100.000
1649386|NCT01860235|Drug|2% Benzocaine|Topical anesthetic - 200mg/g of 2% benzocaine
1649387|NCT01860235|Drug|Placebo|Manipulated with the same appearance and viscosity of topical anesthetics mentioned above
1649388|NCT01860222|Procedure|SR|
1649389|NCT01860222|Procedure|PLAT|
1649702|NCT01857934|Drug|cyclophosphamide|Given intravenously (IV)
1649347|NCT01860521|Procedure|Procedure of interruption of pregnancy|Patients were administered 1 mg of gemeprost pessaries (Cervidil®, Merck Serono SPA, Roma, Italy) in the posterior fornix of the vagina every 3 hours up to 5 doses. If the expulsion of the fetus did not occur, the therapeutic regimen was repeated after 24 hours from the initiation of the treatment. Induction-to-abortion time (hours) was considered the period of time comprised between the first gemeprost pessary administration and fetal expulsion. Failure of induction of abortion was defined as women undelivered after two completed cycles (48h).The evacuation of the uterus under general anesthesia was performed if ultrasonography showed retained productions of conception.
1649348|NCT01860521|Drug|Drug used for analgesia procedures|Levobupivacaine (Chirocaine®, Abbott, Chicago, IL, USA) and sufentanil(Fentatienil®, Angelini, Rome, Italy) were administered in both study groups according to the regimen of each intervention arm (Programmed Intermittent Epidural Bolus Versus Continuous Epidural Infusion).
1649349|NCT01860521|Device|Pump for programmed intermittent bolus.|Pump administering programmed intermittent epidural bolus for the maintenance of analgesia was used.
1649350|NCT01860521|Device|Pump for continuous epidural infusion.|Pump administering continuous epidural infusion for the maintenance of analgesia was used.
1649351|NCT01860521|Drug|Drug used for termination of pregnancy procedure.|Gemeprost pessaries.
1649352|NCT01860508|Drug|pemetrexed /carboplatin|
1649353|NCT01860495|Procedure|perforated membrane|perforated membrane that could give a chance for posetive contributionn of periosteal and gingival mesenchymal stem cells in periodontal regeneration
1649354|NCT01860495|Procedure|G2|tradetional occlusive collagen membrane
1649355|NCT01860482|Drug|Newrabell® Tablet 10mg|
1649356|NCT01860469|Procedure|vancomycin-soaked mesh|
1649357|NCT01860469|Procedure|plain mesh|
1649358|NCT01860456|Drug|Imatinib/Nilotinib|Imatinib: 400 mg/day oral - Nilotinib: 600-800 mg/day oral
1649359|NCT01860443|Other|Telepsychiatry collaborative program|"The intervention includes:
Online training for the health staff
Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression
Online supervision in a web platform by specialists
Telephone monitoring"
1649360|NCT01860443|Other|Usual care|"Online training for the health staff
Medical and psychological treatment, as described in the AUGE Clinical Guidelines for Depression"
1649361|NCT01860430|Drug|Cetuximab/IMRT Plus Ipilimumab|Cetuximab/IMRT Plus Ipilimumab (14 Week Regimen) IMRT, Weeks 2-8: 70-74.0 Gy with 2.0 Gy daily fractions delivered in 7-7.5 weeks Cetuximab, Weeks 1-8 Week 1: 400 mg/m2 Weeks 2-8 (concurrent with IMRT): 250 mg/m2/week Ipilimumab, Weeks 5, 8, 11, 14 Ipilimumab dose will be determined by cohort (1, 3, 6, or 10 mg/kg)
1649362|NCT01860417|Biological|Allogenic Mesenchymal Stromal Cells|
1649363|NCT01860417|Drug|Mepivacaine|
1649364|NCT01860404|Drug|Branched Chain Amino Acids|The three BCAA's will be combined together and dissolved in a flavored solution.
1649365|NCT01860404|Drug|Placebo solution|The placebo solution will have similar taste, texture, consistency and appearance as the BCAA solution.
1649367|NCT01860378|Other|Full price|Participants will receive a voucher for the full price of a Tdap vaccine ($63.99) + a baby care product voucher or gift card
1649368|NCT01860378|Other|$5 off|Participants will receive a voucher for $5 off a Tdap vaccine + a baby care product voucher or gift card.
1649369|NCT01860365|Other|Complementary medicine consultation and treatment|Patients receiving chemotherapy will be referred by their oncology provider to complementary medicine (CM) consultation and treatment provided in addition to conventional supportive care.CM consultation will include assessment of patients' concerns and well-being, current CM use (including herbal and nutritional supplements), and construction of CM treatment based on efficacy and safety considerations.
1649370|NCT01860365|Other|Patients receiving conventional supportive care|Patients receiving chemotherapy will be offered assessment of their concerns and well-being as well as their current complementary medicine (CM) use (including herbal and nutritional supplements). Patients in this arm study will receive conventional supportive care with no added CM consultation or treatment.
1649371|NCT01860352|Dietary Supplement|Fish OIl|
1649372|NCT01860326|Drug|Alisporivir|Capsules supplied as open labeled bulk medication in 10-unit blister packages
1649373|NCT01860313|Behavioral|Web-based interactive education|An educational program for training teachers and educators to better recognize mental health problems in adolescents and children
1649374|NCT01860313|Behavioral|Text and Video-based education|This group received the material that composed the web-based education environment without any kind of interactivity. This material was composed by some videos about children mental health and a support text.
1649375|NCT01860300|Drug|Amoxicillin-Potassium Clavulanate Combination|Amoxicillin-Potassium Clavulanate Combination will be prescribed at the dose of 25/3.6 mg/kg/day for 10 days, 2 times/day, as oral suspension.
1649376|NCT01860300|Drug|placebo|
1649377|NCT01860287|Drug|Buprenorphine|This is a within-subjects, double-blind, placebo-controlled experiment during which each participant will receive sublingual buprenorphine (0.2, .4 mg) and placebo across 2 sessions.
1649378|NCT01860287|Drug|Placebo|
1649379|NCT01860274|Device|Mesh|
1649380|NCT01860274|Procedure|Control|
1649381|NCT01860261|Behavioral|Aerobic and Strength Training Intervention|The exercise intervention has three components: (1) aerobic exercise with a metabolic equivalent of task (MET) energy expenditure of at least 900 MET-minutes per week; (2) strength training consisting of 2 sets of 4 upper body exercises (bench press, seated row, shoulder press, and pull down), 3 sets of 3 leg exercises (leg press, extension, and flexion) and 2 sets each of abdominal crunches and back extensions. Weights for each exercise will be gradually increased as participants can complete 12 repetitions for each set on 2 consecutive sessions, with participants performing strength training twice per week total. Three workshops on using ChiWalking or ChiRunning technique for achievement of aerobic activity goals will be provided to participants in the experimental arm.
1649382|NCT01860248|Drug|Vapocoolant spray|The Vapocoolant spray containing alkane is applied for 20 seconds.
1649383|NCT01860248|Drug|Water spray|This spray is covered so the patient and the investigator can not find the spray type out.
1649384|NCT01860235|Drug|EMLA|% eutectic mixture of 25mg/g lidocaine and 25 mg/g of prilocaine
1649390|NCT01860209|Procedure|Hemodialysis|Intermittent ambulatory hemodialysis session, according to the patient usual protocol (defined by the treating nephrologist independently of the study)
1649391|NCT01860196|Drug|Meditoxin|
1649392|NCT01860196|Drug|Normal saline|
1649393|NCT01860183|Drug|Mycophenolate mofetil|Mycophenolate will be administered to all study patients at dose of 3 g daily for the first seven days posttransplant. Afterwards, study patients will continue, as randomized, on either 3 g, or 2 g MMF daily.
1649394|NCT01860170|Drug|Cohort 1-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.
Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.
Bortezomib 0.7 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
1649395|NCT01860170|Drug|Cohort 2-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.
Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.
Bortezomib 1 mg/ m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
1649396|NCT01860170|Drug|Cohort 3-Bortezomib (Velcade ®)|"Conditioning Regimen: Fludarabine 30 mg/m2 on days -7, -6, -5, -4, -3 and -2; Busulfan 0.8 mg/kg, every 6 hours on days -3 and -2; Patients with matched unrelated donor also receive rATG (Thymoglobulin ®) 2 mg/kg on days -4, -3, -2 and -1.
Cyclophosphamide 50 mg/kg, in 500 mL NS over 2 hours on days +3 and +4. Concomitant hydration with NS with 20 mEq/L at 250 mL/hr starting 4 hours before and continuing until 24 hours after the second dose is given. Furosemide on as needed basis to maintain fluid balance is also given. It is important to avoid administration of any immunosuppressive drugs include steroids after day 0.
Bortezomib 1.3 mg/m2 rapid IV push on days 0 (at least 6 hours after transplant) and +3."
1649397|NCT01860157|Device|Brainsway H1-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
1649398|NCT01860157|Device|Brainsway H1-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
1649399|NCT01860144|Drug|Bevacizumab|
1649400|NCT01860131|Behavioral|Weight Wise Community Modules|Program designed to educate patients regarding proper diet, exercise,and behavioural modification techniques with emphasis on increasing self-management, enhancing self-efficacy and identifying/overcoming barriers to success.
1649401|NCT01860105|Drug|MDCO-157|intravenous administration
1649402|NCT01860105|Drug|PLAVIX|oral administration
1649403|NCT01860079|Procedure|early discharge|In the early discharge group, patients are actively targeted for hospital discharge within 48-56 hours.
1649404|NCT01860066|Drug|QVA149|QVA149 via inhaler twice a day
1649405|NCT01860066|Drug|fluticasone/salmeterol|fluticasone/salmeterol via inhaler twice a day
1649406|NCT01860053|Behavioral|behavioral intervention|This intervention targets eating behavior to reduce vomiting and associated complications in post-operative LAGB patients.
2012785|NCT01607346|Drug|ezogabine/retigabine|Starting dose of 300mg/day, titrate up to a targeted maximum dose of 1200 mg/day. Dose can be reduced to a minimum of 600 mg/day if unable to tolerate higher doses
2012786|NCT01605227|Drug|cabozantinib|Tablets taken orally once-daily
1649412|NCT01859988|Drug|Dupilumab|
1649413|NCT01859988|Drug|Placebo|
1649414|NCT01859962|Drug|PPI-668|
1649415|NCT01859962|Drug|BI 207127 Dose 1|
1649416|NCT01859962|Drug|BI 207127 Dose 2|
1649417|NCT01859962|Drug|Faldaprevir|
1649418|NCT01859962|Drug|Ribavirin|
1649419|NCT01859962|Drug|BI 207127 Placebo|
1649420|NCT01859949|Drug|Genotropin (somatropin)|Genotropin(somatoropin) 12 mg, Genotropin(somatropin) will be given at a dose of 0.067 mg/kg/day or 0.033 mg/kg/day to all participating patients
1649421|NCT01859936|Device|MRI|The intervention is that preoperative MRI breast will be performed in 220 women under 56 years with newly diagnosed breast cancer. Aims are to analyze if the intervention will affect primary management, decrease the number of reoperations and to analyze if the intervention leads to an increasing number of unnecessary mastectomies compared to the non intervention arm.
1649422|NCT01859923|Drug|100 mg Delamanid|100 mg Delamanid BID for 6 months
1649423|NCT01859923|Drug|50 mg Delamanid|50 mg Delamanid BID for 6 months
1649424|NCT01859923|Drug|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 6 months
1649425|NCT01859923|Drug|10 mg Delamanid Pediatric Formulation|Patients > 10 kg will receive DPF 10 mg BID for 6 months
1649426|NCT01859923|Drug|5 mg Delamanid Pediatric Formulation|"Patients > 8 kg or ≤ 10 kg will receive DPF 5 mg BID for 6 months
Patients ≤ 8 kg will receive DPF 5 mg QD for 6 months"
1649427|NCT01859923|Drug|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
1649428|NCT01859910|Procedure|compression and scrub of lid margin|compression and scrub of lid margin for 5 circles before cataract surgery
1649429|NCT01859910|Procedure|routine preparation for cataract|
1649469|NCT01859546|Behavioral|Short message service|Short message service reminders on cell phones in improving the compliance of subsequent visits for routine immunization for children
1649703|NCT01857934|Drug|topotecan|Given IV
1649430|NCT01859884|Behavioral|Inform Me: web-based education tool|The purpose of Inform Me is to help kidney transplant candidates understand what kidneys from increased risk donors are and describes the risks and benefits of accepting and refusing a kidney from an increased risk donor. Increased risk donors are donors who engaged in behaviors that increase their chances of having: Human Immunodeficiency Virus, Hepatitis B Virus , Hepatitis C Virus. Inform Me focuses only on increased risk donor kidneys. Inform Me aims to prepare patients to make a decision with their transplant team to accept or to refuse a kidney from an increased risk donor. Inform Me does not try to convince patients to accept or refuse a kidney from increased risk donors.
1649431|NCT01859871|Behavioral|Website Intervention|Study participants will take the self-administered pre-test in the intervention arm and will be introduced to the website to inform the public of various topics concerning end-stage kidney disease and kidney transplantation. Few websites about transplantation are tailored to potential Hispanic kidney transplant candidates or the Hispanic community. This website is designed to fill the void and be an effective bilingual web-based educational resource targeted to Hispanic patients and public which can serve as a culturally competent tool to enhance knowledge and attitudes about living kidney donation.
1649432|NCT01859858|Dietary Supplement|curcumin|
1649433|NCT01859858|Drug|Irinotecan|
1649434|NCT01859845|Other|Smartphone|"Our team of dermatologists and biomechanical engineers led by the PI developed a simulation skills training prototype device using a smartphone. Software was developed to teach dermoscopic evaluation of pigmented lesions using the three-poin checklist of dermoscopy. The software used in the smartphone presentation of the educational intervention also provides a decision tree of clinical management options and best-practices feedback. No patients are involved in this research."
1649435|NCT01859832|Other|Cylex ImmuKnow Assay|This is not an interventional study. However the assay being tested on the samples of all enrolled participants in the Cylex ImmuKnow Assay
1649436|NCT01859819|Drug|Rituximab|
1649437|NCT01859819|Drug|IT Cytarabine|
1649438|NCT01859806|Procedure|Pancreaticogastrostomy group|Standard PD with regional lymphadenectomy was performed. PG was done between pancreatic stump and posterior surface of the stomach with 2 layer interrupted anastomosis,and duct to mucosa.
1649439|NCT01859806|Procedure|Isolated Roux PJ group|Isolated Roux PJ group, reconstruction was begun using the transected jejunum and ,which was anastomosed in end to side fashion. A separate Roux loop was performed for HJ, by dividing the jejunum about 40 cm beyond the pancreatic anastomosis and GJ was done in this loop (30 cm caudally from HJ). The PJ loop was anastomosed to the main loop (20 cm caudal to GJ).
1649440|NCT01859793|Drug|sitagliptin|100 mg pill, administered once/day orally
1649441|NCT01859793|Drug|Placebo|Matching placebo in appearance given once/day orally
1649442|NCT01859780|Other|Visual distractor|
1649443|NCT01859767|Drug|[123I]MNI-672 SPECT|Subjects will be dosed by intravenous injection to a target dose of 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) I-123 MNI-672 prior to the SPECT scan.
1649444|NCT01859754|Biological|Octagam 5%|Intravenous immunoglobulin 5%
1649445|NCT01859754|Biological|Other marketed IVIG product|Any intravenous immunoglobulin marketed product approved for the treatment of PID
2012787|NCT01605227|Drug|prednisone|Taken twice a day orally. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
1649450|NCT01859728|Drug|Irinotecan|"Irinotecan 65mg/m² D1 and D8 q21 days, until disease progression or unacceptable toxicity.
Given in association with standard hydration and anti-emetics."
1649451|NCT01859728|Drug|Cisplatin|"Cisplatin 60mg/m² D1 q 21 days, until disease progression or unacceptable toxicity.
Given in association with standard hydration and anti-emetics."
1649452|NCT01859728|Drug|Cisplatin|"Cisplatin 25mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity. , with standard hydration and antiemetics.
Given in association with standard hydration and anti-emetics."
1649453|NCT01859728|Drug|Gemcitabine|"Gemcitabine 1000mg/m² D1 and D8 every 21 days, until disease progression or unacceptable toxicity.
Given in association with standard hydration and anti-emetics."
1649454|NCT01859715|Drug|Oxycodone|Subjects given oxycodone 5mg by ED provider decision or by triage nurse randomization.
1649455|NCT01859715|Drug|Hydrocodone|Subjects given hydrocodone/acetaminophen 5mg/500mg by ED provider decision or by triage nurse randomization.
1649456|NCT01859715|Drug|Ondansetron|Subjects given ondansetron 4mg for reported nausea or vomiting. Treatment determined either by triage nursing protocol or by provider discretion. Observational intervention only.
1649457|NCT01859702|Drug|Moxifloxacin 0.5%/Dexamethasone 0.1% ophthalmic solution|
1649458|NCT01859689|Radiation|brachytherapy|Undergo image-guided HDR brachytherapy
1649459|NCT01859689|Radiation|image-guided radiation therapy|Undergo image-guided HDR brachytherapy
1649460|NCT01859689|Other|laboratory biomarker analysis|Correlative studies
1649461|NCT01859650|Other|MR and CT imaging|
1649462|NCT01859637|Biological|Filgrastim|Zarzio®/Filgrastim HEXAL® solution for injection was provided in prefilled syringes with two strengths at 300 μg/0.5 ml (30 MU) and 480 μg/0.5 ml (48 MU). Dosage and duration for each patient is as per the recommendations in the SmPC.
1649463|NCT01859624|Drug|Albuterol|Albuterol 4 mg
1649464|NCT01859611|Device|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
1649465|NCT01859585|Drug|Parecoxib|Parecoxib 40 mg intravenous
1649466|NCT01859585|Drug|Ketorolac|Ketorolac 30 mg intravenous
1649467|NCT01859559|Procedure|Ultrasound-guided peripheral intravenous access line placement|The ED technician will use an ultrasound machine with a vascular probe to visualize the vein and guide the PIV line using a one-operator dynamic technique.
1649468|NCT01859559|Procedure|Landmark Approach to peripheral intravenous access line placement|ED technician will use standard anatomical landmarks and palpation to puncture the skin and insert the peripheral intravenous access line in the upper extremity.
1649547|NCT01858961|Drug|Pegylated Interferon|Once a week
1649548|NCT01858948|Drug|Omega|Omega-3 supplements
1649470|NCT01859533|Device|Neopuff|"Group I neonates (Experimental group) includes 30 newborns showing signs of TTN who will receive administration of CPAP (5 cm of H2O) via T- piece (Neopuff; Fisher and Paykel Healthcare, Auckland, New Zealand).
Group II neonates (Control group) includes 30 newborns who will receive nasal prong oxygen treatment; standard care according to Siva Subramanian et al. (2010)."
1649471|NCT01859520|Procedure|swim-up, density gradient sperm preparation techniques|Sperms are prepared by sperm washing techniques before used in assisted reproductive technologies. Most commonly used sperm preparation methods are the swim up and the density gradient. Recent studies shows that the DNA integrity status of the spermatozoa is related to the success in assisted reproduction techniques. Sperm preparation methods may theoretically cause damage sperm DNA. Therefore it is important to select the optimum method of sperm preparation causing least sperm DNA damage. Aim of our study is to investigate and compare the effect two different sperm preparation techniques on DNA fragmentation.
1649472|NCT01859507|Drug|Botox|In the first session, proper history taking and proper counseling of the couple including the description of the new modality (BOTOX injection) of treatment and subsequent dilatation sessions. During examination, all our maneuvers are gentle to gain trust of the patient. Following sterilization, we used surface (Xylocaine gel 2% ASTRA ZENECA) anesthesia before the injection. In addition we used finger like ice packs pre-prepared in a surgical latex glove, on the perineum. We made sure to check that the tip of the needle is not in a vessel by aspirating before proceeding with the injection of each bolus of BOTOX.
1649473|NCT01859494|Device|NINJA 3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes self-tested capillary fingerstick and palm blood using the NINJA 3 Investigational Blood Glucose Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to reference method results obtained from subject capillary plasma.
1649474|NCT01859481|Drug|Placebo|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
1649475|NCT01859481|Drug|Eletriptan HBr 40 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
1649476|NCT01859481|Drug|Eletriptan HBr 80 mg|All subjects will receive open label eletriptan 40 mg per attack for the first three attacks in the phase 1 of the study. For the next 4 attacks subjects will be assigned to either eletriptan 40 mg or 80 mg group based on the response in the phase 1 portion of the study. In phase II, in each group subjects will receive eletriptan 40 mg or 80 mg for 3 attacks and placebo for 1 attack. In each group double-blind placebo will be inserted at random.
1649477|NCT01859468|Dietary Supplement|Amorphous calcium carbonate|
1649478|NCT01859468|Other|Placebo|
1649479|NCT01859455|Drug|LGT209 50 mg|Active experimental drug
1649480|NCT01859455|Drug|LGT209 300 mg|Active experimental drug
1649481|NCT01859455|Drug|Placebo|Placebo comparator
1649482|NCT01859455|Drug|Statins (atorvastatin or simvastatin)|Stable doses of atorvastatin or simvastatin
1649483|NCT01859442|Procedure|Structured responsive interval exercise training programme|
1649484|NCT01859442|Other|Sham group|NO intervention in this group, only standard care (no exercise programme)
1649485|NCT01859429|Other|Stepped Care|Step 1: Screening for psychosocial distress Step 2: If a patient is moderately or highly distressed according to step 1, the physician performs a brief structured interview and arranges, if necessary, appropriate psychosocial care Step 3: psychosocial care as indicated by step 2
1649486|NCT01859416|Dietary Supplement|Oral nutritional supplement|
1649487|NCT01859403|Genetic|Personalized Genomics|A set of single nucleotide polymorphisms in genes important for obesity, eating behaviors and exercise
1649488|NCT01859390|Drug|AquADEKs-2|AquADEKs-2 contains standard amounts of fat-soluble vitamins (A, D, E, K) that are contained in typical CF multivitamin supplements plus several antioxidants including beta-carotene, mixed tocopherols (different forms of vitamin E), coenzyme Q10 (CoQ10), mixed carotenoids (lutein, lycopene and zeaxanthin), and the minerals zinc and selenium.
1649489|NCT01859390|Dietary Supplement|control multivitamin|The control multivitamin contains standard (standard for CF multivitamin supplements) amounts of vitamins A, B, D, E, and K without added antioxidants.
1649490|NCT01859377|Drug|V0498 - A mg|Single oromucosal administration
1649491|NCT01859377|Drug|Ibuprofen|Single oral administration
1649492|NCT01859351|Drug|WX-037|
1649493|NCT01859351|Drug|WX-554|
1649494|NCT01859338|Procedure|cone-beam computed tomography|Undergo CBCT
1649495|NCT01859338|Procedure|magnetic resonance imaging|Undergo MRI
1649496|NCT01859338|Procedure|computed tomography|Undergo fan beam computed tomography
1649497|NCT01859325|Biological|rVSV|Attenuated recombinant vesicular stomatitis virus containing HIV-1 gag gene
1649498|NCT01859325|Biological|IL-12 pDNA adjuvant|plasmid DNA containing human IL-12 gene
1649499|NCT01859325|Biological|HIV-Mag pDNA|plasmid DNA vaccine containing genes encoding multiple HIV-1 proteins
1649500|NCT01859325|Drug|Placebo|
1649549|NCT01858948|Drug|Placebo|Similar in shape and color to Omega supplements
1649550|NCT01858948|Drug|Quetiapine fumarate|Patients will be started on 100 mg BID of quetiapine, and the dose adjusted based on tolerability and response. The quetiapine target dose is 400-600 mg.
1649551|NCT01858935|Drug|ND-L02-s0201 Injection|Single IV infusion.
1649552|NCT01858935|Drug|Placebo|Single IV infusion.
1649600|NCT01858662|Drug|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, 1.30-hour IV infusion every 2 weeks
1649601|NCT01858662|Drug|Cetuximab|Cetuximab 400 mg/m² in 100 ml NaCl 0.9% 2-hour IV infusion for 1rst cycle and after the 1rst cycle 250 mg/m² in 100 ml NaCl 0.9% 1-hour IV infusion
1649704|NCT01857934|Biological|hu14.18K322A|Given IV
1649503|NCT01859286|Other|standardized sign out process|The intervention phase included was the introduction of a standardized TOC (transfer of care) process, which occurred during April and May of 2012. TOC was done at a predefined location in each section of the emergency department (Medicine and Trauma). All participating residents were given a diagram detailing the central location and seating arrangement. The outgoing attending was designated to handle all distractions or disturbances that occurred during sign out. The most senior resident coming on to shift was designated the data resident. The data resident's role was to operate a centralized computer with the ED tracking board and EMR and review pending orders, vital signs and resulted labs and radiology reports after each patient was signed out. A brief pause was implemented to allow the oncoming team to ask any questions regarding that patient's care or course. The post TOC data form and protocol were identical to that of the control phase.
1649504|NCT01859273|Behavioral|mHealth|mHealth prototype system consisting of electronic medication tray, blood pressure cuff and smart phone
1649505|NCT01859260|Device|CPAP/autopap|
1649506|NCT01859247|Device|rTMS|
1649507|NCT01859234|Drug|89Zr-bevacizumab|89Zr-bevacizumab will only be given once, prior for the PET scan. 5 mg will be given iv.
1649508|NCT01859221|Radiation|Stereotactic radiation|Stereotactic radiation
1649509|NCT01859182|Drug|selumetinib|Given PO
1649510|NCT01859182|Drug|Akt inhibitor MK2206|Given PO
1649511|NCT01859182|Other|laboratory biomarker analysis|Correlative studies
1649512|NCT01859182|Other|pharmacogenomic studies|Correlative studies
1649513|NCT01859182|Procedure|quality-of-life assessment|Ancillary studies
1649514|NCT01859169|Procedure|Photodynamic therapy|﻿Each patient to whom PDT was offered underwent a specific, detailed educational process by a dedicated team member(P.B., P.J., or K.E.), after which informed consent was obtained.Porfimer sodium (Photofrin; Axcan Pharma Inc, Quebec, Canada)was used as a photo sensitizing agent, administered intravenously at a dose of 2 mg/kg body weight 48 hours before illumination.A diode laser system (InGaAIP Laser Diode; Diomed Inc, An-dover, MA) with a maximum power output of 2000 mW and a wavelength of 633+-3 nm was used as a light source, delivered through a 3.0-m length fiber having a 2.5-cm-long cylindrical diffuser at its distal end (Pioneer Optics, Windsor Locks, CT).
1649515|NCT01859143|Biological|Trivalent Influenza Vaccine|A single dose of 10^(7.0 ± 0.5) FFU of trivalent influenza vaccine will be administered as intranasal spray on Day 1.
1649516|NCT01859143|Other|Placebo|A single dose of placebo matched to trivalent influenza vaccine will be administered as intranasal spray on Day 1.
1649517|NCT01859130|Device|Zimmer Persona Total Knee System|
1649518|NCT01859117|Biological|3 x 10^6 cells|3 x 10^6 cells administered on Study Days 1 and 8
1649519|NCT01859117|Biological|10 x 10^6 cells|10 x 10^6 cells administered on Study Days 1 and 8
1649520|NCT01859117|Biological|30 x 10^6 cells|30 x 10^6 Human Placenta Derived cells (PDA-002) administered intramuscularly on Study Days 1 and 8
1649521|NCT01859117|Biological|100 x 10^6 cells|100 x 10^6 cells administered on Study Days 1 and 8
1649522|NCT01859104|Behavioral|Use of smartphone app|
2012788|NCT01602770|Drug|EV/DNG (Qlaira, BAY86-5027)|Qlaira is taken daily continously with no pause between cycles in a four-phasic dose regimen, making up a treatment of up to 28 days. The first two tablets contain 3 mg Estradiol Valerate (E2V). The next five tablets include 2 mg E2V and 2 mg Dienogest (DNG) followed by 17 tablets with 2 mg E2V and 3 mg DNG. Finally, there are two tablets with 1 mg E2V and two placebo tablets.
1649524|NCT01859078|Drug|Baricitinib|Administered orally
1649525|NCT01859078|Drug|Digoxin|Administered orally
1649526|NCT01859065|Behavioral|Intensified anticipatory guidance|Mothers receive video-based and handout-based anticipatory guidance regarding non-urgent problems in addition to the routine anticipatory guidance
1649527|NCT01859065|Behavioral|Routine|Routine anticipatory guidance (control)
1649528|NCT01859052|Other|Low carbohydrate diet|Subjects will follow the Atkins for Life diet. They will be given the book and a study dietitian will guide them through the induction, ongoing weight loss, pre-maintenance, and lifetime maintenance phases.
1649529|NCT01859052|Other|Low calorie low fat diet|The diet will be a nutritionally balanced, hypocaloric diet with a deficit of 750 kcal/day as guided by TEE. The goal is to match the calorie deficit to the low-CHO diet
1649530|NCT01859052|Other|AHA diet recommendations|given information in accordance with the diet and lifestyle recommendations of the American Heart Association.
1649531|NCT01859039|Biological|Administration of Live attenuated influenza vaccine|
1649532|NCT01859026|Drug|MEK162|Treatment as outlined in study arms.
1649533|NCT01859026|Drug|Erlotinib|Treatment as outlined in study arms.
1649534|NCT01859013|Drug|Topiramate|Topiramate will be initiated at a dose of 25 mg (taken orally once daily in the evening), escalated to 50 mg (taken orally once daily in the evening) after 1 week, and escalated to 75 mg (taken orally 25 mg in the morning and 50 mg in the evening) after 2 weeks. Patients who do not tolerate dose escalation will be reduced to the highest tolerated dose for the remainder of the trial.
1649535|NCT01859013|Other|Placebo|Placebo will be taken orally once daily in the evening for the first two weeks, and orally twice daily (AM and PM) for the remainder of the study.
1649536|NCT01859000|Other|Multidimensional Family Therapy|MDFT assesses and intervenes in four domains to address comorbid substance abuse and trauma symptoms: 1) adolescent, 2) parent, 3) family, and 4) external systems. MDFT therapists will address trauma symptoms among both teens and parents, aiming to improve coping and reduce the impact of stress on the family. Consistent with a multidimensional approach, MDFT trauma-focused interventions address the needs of both youth and their parents, and MDFT therapists seek collaboration and advocacy from school and court personnel.
1649537|NCT01859000|Other|Group CBT|Trauma symptoms will be addressed using techniques designed to reduce cognitions that maintain anxiety and depressive symptoms and improve coping, such as cognitive restructuring, gradual exposure, and helping teens to understand and accept reminders of the event and ongoing stressors (Pynoos et al, 1998).
1649542|NCT01858961|Drug|BI 201335|Once a day
1649543|NCT01858961|Drug|ribavirin|Twice a day
1649544|NCT01858961|Drug|BI 207127|Twice a day
1649545|NCT01858961|Drug|Telaprevir|Three times a day
1649546|NCT01858961|Drug|ribavirin|Twice a day
1649697|NCT01857999|Drug|Placebo|
1649553|NCT01858922|Drug|ABVE-PC|"Doxorubicin (A) 25mg/m2/day IV over 10min on Day 1 & Day 2
Bleomycin (B) 5units/m2/day IV over 10min on Day 1 10units/m2/day IV over 10min on Day 8
Vincristine (V) 1.4mg/m2/day IV push with extravasation precautions on Day 1 & 8 (Max dose 2.8mg)
Etoposide (E) 125mg/m2/day IV over 1hr at a concentration of </=0.4mg/ml in NS on Day 1, 2 & 3
Prednisone (P) 40mg/m2/day PO divided in 2 doses every day on Day 1-7 IV equivalent of methylprednisolone is acceptable
Cyclophosphamide (C) 800 mg/m2 IV over 1 hr in 200 ml/m2 NS on Day 1"
1649554|NCT01858922|Drug|DECA|"Dexamethasone (D):
10 mg/m2 IV over 15 minutes on Day 1 and Day 2, prior to Etoposide/Cytarabine.
Etoposide (E):
100 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with cytarabine*
Cytarabine (A):
3000 mg/m2 IV over 3 hours on Day 1 and Day 2 as continuous infusion mixed with etoposide*
*Mix together in NS at an etoposide concentration of </=0.4 mg/ml
Dexamethasone eyedrops:
2 drops in each eye 4 times a day on Day 1, Day 2, and Day 3.
Cisplatin (C):
90 mg/m2 over 6 hours in 1000 ml/m2 NS + 10 gram/m2 mannitol on Day 1 as continuous infusion."
1649555|NCT01858909|Drug|Melatonin|Administration via oral or via a nasogastric tube followed by 20mL saline
1649556|NCT01858896|Drug|Glucagon-Like Peptide- 1 (GLP-1) infusion|GLP-1 infusion during experimental period
1649557|NCT01858896|Other|Placebo Comparator: Saline Infusion|Saline infusion (placebo) during experimental period
1649558|NCT01858883|Drug|itacitinib|
1649559|NCT01858883|Drug|Gemcitabine|
1649560|NCT01858883|Drug|nab-paclitaxel|
1649561|NCT01858883|Drug|filgrastim|
1649562|NCT01858870|Drug|lacosamide|routine clinical practice
1649563|NCT01858844|Other|CHEST COMPRESSION TECHNIQUE (CCT)|The CCT was held with the placement of one of the hands were not engaged in. The following has been applied a symmetric oblique direction, pressure from top to bottom on the half thorax rib cage so that it went according to the complacency of the ribcage. This pressure was applied in the expiratory phase and held for 10 seconds, totaling 6 repetitions of the maneuver during 60 seconds. The other hand held on the contralateral iliac crest to stabilize the patient. The technique was held during 5 consecutive minutes with range of a respiratory incursion every 60 seconds. Immediately after and 10 minutes after the end of the application of the technique, the data was measured again.
1649564|NCT01858831|Drug|Atovaquone/proguanil HCL|Atovaquone/proguanil HCL
1649565|NCT01858831|Drug|Atovaquone|Atovaquone
1649566|NCT01858805|Procedure|esophagectomy|
1649567|NCT01858792|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
1649568|NCT01858792|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
1649569|NCT01858792|Other|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
1649570|NCT01858779|Behavioral|Measurement of peripheral pulse|All patients will be introduced and trained for the measurement of peripheral pulse. Patients will keep a pulse-diary tro detect atrial fibrillation.
1649571|NCT01858779|Device|72h holter ECG|All petients will receive regular 72h Holter ECG at 3 and 6 months after inclusion in the study.
1649572|NCT01858766|Drug|SOF|400 mg tablet administered orally once daily
1649573|NCT01858766|Drug|VEL|Tablet administered orally once daily
1649574|NCT01858766|Drug|RBV|200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1649575|NCT01858753|Biological|Autologous fibroblasts|
1649576|NCT01858753|Biological|placebo sterile saline|
1649577|NCT01858740|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
1649578|NCT01858740|Drug|Fludarabine Phosphate|Given IV
1649579|NCT01858740|Other|Laboratory Biomarker Analysis|Correlative studies
1649580|NCT01858740|Drug|Methotrexate|Given IV
1649581|NCT01858740|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
1649582|NCT01858740|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Undergo CD45RA+ T cell-depleted allogeneic peripheral blood stem cell transplant
1649583|NCT01858740|Drug|Tacrolimus|Given IV or PO
1649584|NCT01858740|Drug|Thiotepa|Given IV
1649585|NCT01858740|Radiation|Total-Body Irradiation|Undergo TBI
1649586|NCT01858727|Other|forced air warming group|30 minutes before the preoperative will use forced air warming
1649587|NCT01858727|Other|control group resistive heating|do not heating group
1649588|NCT01858714|Behavioral|Behavior Therapy for Weight Loss|Standard behavioral treatment for weight loss and weight loss maintenance.
1649589|NCT01858714|Behavioral|Behavior Therapy + Environment|Standard behavioral therapy with an emphasis on environmental strategies.
1649590|NCT01858714|Behavioral|Acceptance-based Behavior Therapy + Environment|Behavioral therapy with acceptance-based and environmental strategies.
1649591|NCT01858701|Device|Lotrafilcon B toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
1649592|NCT01858701|Device|Comfilcon A toric contact lens|Commercially available, silicone hydrogel contact lens for correction of astigmatism
1649593|NCT01858688|Device|Multiparametric MRI|an MRI of the prostate will be performed
1649594|NCT01858688|Procedure|Prostate biopsy|a biopsy of the prostate will be performed according to standard procedures for men on active surveillance
1649595|NCT01858675|Other|Biomarkers, red blood cells and plasma assessment|
1649596|NCT01858662|Procedure|Metastases Resection ( multiple steep surgery possible)|Metastases resection will be process by surgery, after a randomized chemotherapy (FOLFOX or FOLFIRI) + Target therapy (Cetuximab). The surgery will allow to compare the pathological response on the resected metastases by the chemotherapy + target therapy type.
1649597|NCT01858662|Drug|5-Fluorouracile|5-FU bolus 400 mg/m2, IV bolus every 2 weeks 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion every 2 weeks
1649598|NCT01858662|Drug|leucovorin L|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, 2-hour IV infusion
1649599|NCT01858662|Drug|Oxaliplatin|Oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, 2-hour IV infusion every 2 weeks
1649698|NCT01857986|Device|AnapnoGuard 100 control unit|
1649602|NCT01858649|Procedure|Metastases resection|Surgery of colorectal cancer metastases will be proceeded after 3 to 6 cycles of chemotherapy ( folfox or folfiri) + bevacizumab .
1649603|NCT01858649|Drug|Bevacizumab|Bevacizumab 5 mg/kg in 100 ml NaCl 0.9% IV infusion 3 to 5 cycles. No bevacizumab for ultimate cycle .
1649604|NCT01858649|Drug|5 FU|Leucovorin L (levoleucovorin) 200 mg/m2 (or folinic acid 400 mg/m²) in 250 ml glucose 5%, IV infusion 3 to 6 cycles 5-FU bolus 400 mg/m2, IV bolus 3 to 6 cycles 5-FU continuous infusion 2400 mg/m2, 46-hour cont. IV infusion 3 to 6 cycles
1649605|NCT01858649|Drug|Oxaliplatin|oxaliplatin 85 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
1649606|NCT01858649|Drug|Irinotecan|Irinotecan 180 mg/m² in 150 ml NaCl 0.9%, IV infusion 3 to 6 cycles
1649607|NCT01858636|Device|Angio-Seal VIP 6 French (6F) and 8 French (8F) devices|These devices are used for the vascular closure procedure
1649608|NCT01858623|Drug|Losartan/hydrochlorothiazide|
1649609|NCT01858623|Drug|Losartan|
1649610|NCT01858623|Drug|Hydrochlorothiazide|
1649611|NCT01858610|Drug|Irbeasartan/hydrochlorothiazide|
1649612|NCT01858610|Drug|Irbesartan|
1649613|NCT01858610|Drug|Hydrochlorothiazide|
1649614|NCT01858584|Drug|Gastrotuss|"Gastrotuss baby: syrup based on alginate consisting of: magnesium alginate, simethicone, fructose, xanthan gum, honey, D-panthenol, fluid extracts of Althaea officinalis, Papaver rhoeas, zinc oxide, sodium bicarbonate, sodium hydroxide, p-hydroxybenzoate of methyl-sodium, sodium propyl p-hydroxybenzoate, natural flavors, erythrosine (E127), purified water.
dosage:
Infants weighing <5 kg in 2.5 ml 5-10 min after feeding. In case of regurgitation after administration, 1 ml additional
Infants weighing> 5 kg per 5 ml dose after the meal and the evening before putting the baby to sleep The administration should be maximum 3 times per day"
1649615|NCT01858584|Dietary Supplement|thickened milk|Milk thickened (formulat AR): contains a special thickener derived from corn starch waxy, that maintains its fluidity into the bottle and thickens just inside the stomach of the child, and this makes it easy to use in breastfeeding , as it is usable with a common teat.
1649616|NCT01858571|Drug|Low dose chemotherapy|"Metronomic chemotherapy schedule : Alternating cycles of Cycle A and B (Each cycle includes 3 weeks of drug administration) with each drug rounded off to the nearest tablet/capsule size.
Cycle A
Daily oral Thalidomide (at 3mg/kg)
Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)
Daily oral Etoposide (50 mg/m2/d)
Cycle B
Daily oral Thalidomide (at 3mg/kg)
Daily oral Celecoxib (100 mg BID for patients < 20 kg, 200 mg BID for patients 20-50 kg, and 400 mg BID for patients > 50 kg)
Daily oral Cyclophosphamide (2.5 mg/kg/d to a maximum of 100 mg/d) every 21 days"
1649617|NCT01858558|Biological|aMIL|Patients will receive Prevnar vaccine followed by aMIL harvest. On day 0, patients will receive auto transplant followed by Tadalafil and aMIL. At day 60, patients will receive Lenalidomide.
1649618|NCT01858558|Drug|No aMIL|Patients will receive Prevnar vaccine followed by aMIL harvest. On day 0, patients will receive auto transplant followed by Tadalafil. At day 60, patients will receive Lenalidomide.
1649619|NCT01858545|Device|MatriStem|MatriStem MicroMatrix and MatriStem Wound Matrix
1649620|NCT01858545|Device|Cellular Dermal Replacement Tissue|Cellular Dermal Replacement Tissue
2012789|NCT01597193|Drug|enzalutamide|80 mg (2 capsules) or 160 mg (4 capsules) taken orally daily.
2012790|NCT01597193|Drug|anastrozole|1 mg/day
1649623|NCT01858506|Procedure|I-ACE intervention|lifestyle counselling using the interactive assessment, counselling and education (I-ACE)-based method.
1649624|NCT01858506|Procedure|Standard Lifestyle Advice|lifestyle counselling using the standard lifestyle advice (SLA) program currently provided to Clalit Health Services patients.
1649625|NCT01858493|Behavioral|Continence promotion group education workshop|Interactive group education workshop promoting continence
1649626|NCT01858493|Behavioral|Sham health lecture|Interactive group education workshop about general health
1649627|NCT01858480|Drug|D-ribose|D-ribose powder for oral solution and D-ribose for injection.
1649628|NCT01858480|Other|Placebo|Placebo dosage form designed to mock active.
1649629|NCT01858467|Device|Endotracheal intubation|Portex endotracheal tube 6.5mm or 7.0mm internal diameter
1649630|NCT01858467|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway Size 3 or Size 4 with gastric tube insertion.
1649631|NCT01858454|Procedure|HALS|In HALS, a trocar of 5-mm calipers was inserted through the umbilicus. Next, suprapubic transverse skin incision of 3-4cm in length was made and a wound retractor (Alexis; Applied Medical, Rancho Santa Margarita, CA) was inserted through the suprapubic opening.
1649632|NCT01858454|Procedure|Open surgery|In open surgery, the patient was placed in the supine position and the operation was carried out in a standard manner as described elsewhere [Luciano AA. Myomectomy. Clin Obstet Gynecol 2009;52:362-71.].
1649633|NCT01858441|Drug|Abiraterone Acetate|
2012791|NCT01597193|Drug|exemestane|The exemestane dose is 25mg daily.
2012792|NCT01597193|Drug|fulvestrant|500 mg every 28 days
2012793|NCT01597193|Drug|enzalutamide|160 mg (4 capsules) taken orally daily.
2012794|NCT01597193|Drug|exemestane|The exemestane dose is 50 mg daily.
2012795|NCT01596296|Device|Transcervical foley catheter|16 French foley catheter insertion
1649639|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter. The dose of dacomitinib for patients in Cohort A may be further escalated in increments of 15 mg.
1649640|NCT01858389|Drug|Dacomitinib|Dacomitinib 45 mg every 12 hours Days 1-4 of the first week, and then 60 mg every 12 hours Days 1-4 of each 2-week cycle thereafter.
1649699|NCT01857973|Device|Hybrid Closed Loop|The Hybrid Closed Loop System is an investigational device intended for closed loop control of blood glucose.
1649700|NCT01857960|Behavioral|Survey|A survey is directly applied to subjects who meet the inclusion and exclusion criteria
1649701|NCT01857947|Other|AECOPD Mr proADM|
2012796|NCT01596296|Drug|Dinoprostone 10mg|Dinoprostone vaginal insertion
2012797|NCT01592240|Drug|PBO|Placebo Q28d
2012798|NCT01592240|Drug|200mg PF-04950615 (RN316)|PF-04950615 200 mg, Q28d
2012799|NCT01592240|Drug|300mg PF-04950615 (RN316)|PF-04950615 300 mg, Q28d
2012800|NCT01592240|Drug|PBO|Placebo, Q14d
2012801|NCT01592240|Drug|PF-04950615|PF-04950615 50mg, Q14d
1649641|NCT01858376|Dietary Supplement|Capros dietary supplement|Study participants will have 2 to 3 baseline blood draws, 3 blood draws while taking Capros supplements and 2 wash out blood draws after finishing 12 weeks of Capros supplementation. Participants will attend 7 to 8 study visits (depending on number of baseline visits needed) and at each visit participants will have their blood drawn as well as height, weight, blood pressure, and pulse measured.
2012802|NCT01592240|Drug|PF-04950615|PF-04950615 100 mg, Q14d
2012803|NCT01592240|Drug|PF-04950615|PF-04950615 150mg, Q14d
1649644|NCT01858350|Other|Active Music Therapy|
1649645|NCT01858350|Other|Passive Music Therapy|
1649646|NCT01858350|Other|Distraction Therapy|
1649647|NCT01858337|Other|green beans group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With green beans every other day.
1649648|NCT01858337|Other|Artichoke group|Infants were weaned with vegetable purees for the first 18 days of weaning. One vegetable type per day. With artichoke every other day.
1649649|NCT01858337|Other|Apple group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With apple every other day.
1649650|NCT01858337|Other|Plums group|Infants were weaned with fruit purees for the first 18 days of weaning. One fruit type per day. With Plums every other day.
1649651|NCT01858324|Other|Educational tools|Subjects will receive the educational tools. They will then receive one month after a questionnaire about knowledge, anxiety and satisfaction.
1649652|NCT01858311|Dietary Supplement|Tocotrienol Capsules|Vitamin E TCT capsules- 400mg to 800mg per day (2 in the morning and 2 in the evening)
1649653|NCT01858311|Other|Placebo Vehicle|Placebo capsules per day (2 in the morning and 2 in the evening)
1649654|NCT01858298|Other|Conservative treatment: pulpectomy and composite resin crown|
1649655|NCT01858298|Other|Non-conservative treatment: Tooth extraction|
1649656|NCT01858272|Drug|H5.020CMV.PDGF-b and limb compression bandage|
1649657|NCT01858246|Device|Bonebridge|
1649658|NCT01858246|Device|Bone Anchored Hearing Aid|
1649659|NCT01858233|Behavioral|Intensive Behavioral Modification|Intensive dietary counseling, increased physical activity, lactation counseling
2012804|NCT01590407|Drug|ALS-002200|ALS-002200
2012805|NCT01590407|Drug|Placebo|Placebo
2012806|NCT01590160|Drug|Ganetespib|IV, Using dose from Phase I
2012807|NCT01588470|Drug|pioglitazone|45 mg per day for 6 months
2012808|NCT01583166|Drug|Bupivicaine + epinephrine|10ml 0.5% bupivicaine plus 1:200,000 epinephrine
1649665|NCT01858181|Biological|ocaratuzumab|
1649666|NCT01858168|Drug|Olaparib|Tablets to be taken on an empty stomach twice a day.
1649667|NCT01858168|Drug|Temozolomide|Tablets to be taken on an empty stomach before bedtime.
1649668|NCT01858168|Drug|Irinotecan|Administered via IV
1649669|NCT01858155|Drug|Melatonin|
1649670|NCT01858142|Behavioral|Parental presence decision tool|
1649671|NCT01858142|Behavioral|Standard preparation|
1649672|NCT01858129|Drug|Experimental group: Budicort by Inhalation|Inhaled Budicort twice daily
1649673|NCT01858129|Drug|placebo|
1649674|NCT01858116|Drug|[68Ga]ABY-025|Intravenous injection followed by PET imaging
1649675|NCT01858103|Drug|BMN 110|
1649676|NCT01858090|Drug|Control Group Chirocaine|Control group: Spinal anesthesia with levobupivacaine+Serum Physiologic %0.9 (Total volume 3 mL)
1649677|NCT01858090|Drug|Group Fentanyl|
1649678|NCT01858090|Drug|Group sufentanil|
1649679|NCT01858090|Drug|Ephedrine|If systolic blood pressure values decreased more than 20% with respect to the baseline values, or decreased to <100 mmHg, fluid loading and ephedrine (5 mg) were administered.
1649680|NCT01858090|Drug|Atropine sulfate|A decrease in heart rate to less than 55 beats/min was considered as bradycardia, and atropine (0.5 mg) was administered
1649681|NCT01858090|Drug|Propofol|Intravenous propofol (up to 0.5 mg/kg) was administered if patients had discomfort
1649682|NCT01858090|Drug|Metoclopramide|Metoclopramide (10 mg IV) was administered for nausea
1649683|NCT01858090|Drug|Diphenhydramine|for severe pruritus
1649684|NCT01858090|Drug|pethidine hydrochloride|pethidine hydrochloride (50 mg IM) was administered as the first analgesic postoperatively
1649685|NCT01858090|Drug|Diclofenac sodium|as additional analgesic among cases in which VAS>3(Postoperatively)
1649686|NCT01858077|Device|ABSORB BVS™|Bioresorbable scaffold
1649687|NCT01858077|Device|XIENCE™|Drug eluting metallic stent
1649688|NCT01858064|Drug|OROS-MPH|Capsule administered daily, beginning at 36 mg/day and titrated on a weekly basis for 3 weeks in increments of 18-36 mg/day to a maximum daily dose of 90 mg/day.
1649689|NCT01858051|Dietary Supplement|Cholecalciferol|
1649690|NCT01858051|Dietary Supplement|Placebo|
1649691|NCT01858038|Device|Fraxel Repair - Fractional Laser treatment|An FDA-approved Fractional 10,600 nm laser source will be used for laser exposures performed 2 months prior to biopsies of treated sites
1649692|NCT01858025|Radiation|Pencil Beam scanning Radiation|
1649693|NCT01858025|Drug|5-fluorouracil|
1649694|NCT01858025|Drug|Mitomycin-C|
1649695|NCT01858012|Behavioral|Moderate alcohol cessation|patients will have moderate alcohol use discontinued for 6 weeks
1649696|NCT01857999|Drug|Losartan|
2012809|NCT01583166|Drug|Sodium chloride + epinephrine|10ml 0.9% sodium chloride plus 1:200,000 epinephrine
2012810|NCT01581333|Drug|Empirical antimicrobial treatment discontinuation|Empirical antimicrobial treatment discontinuation will occur when the patient is: Afebrile, with resolution of signs, symptoms and test abnormalities secondary to complementary source of infection and with normalization of vital signs for ≥ 72 h.
2012811|NCT01581333|Drug|Standard empirical antimicrobial treatment discontinuation|"The empirical antimicrobial treatment discontinuation will occur when the patient is:
The neutrophil count is above 500 million per mm3."
2012812|NCT01576016|Device|Accent MRI system|Patients implanted with an Accent MRI system will receive 30 minutes of magnetic scan imaging
2012813|NCT01576016|Device|Accent MRI system|Patients implanted with an Accent MRI system will wait for one hour without receiving an MRI scan
2012814|NCT01575548|Drug|Pazopanib Hydrochloride|Given PO
1649705|NCT01857934|Procedure|peripheral blood stem cell harvest|Following evaluation and approval by a member of the transplant staff and completion of the consent form by the participant, collection of peripheral blood stem cells (PBSC) may take place.
1649706|NCT01857934|Procedure|surgical resection|The primary tumor will be resected surgically following two initial courses of chemotherapy, if feasible. Patients who are unable to have their primary tumor resected after the initial two courses of induction chemotherapy will undergo surgery for resection of the primary tumor mass and careful lymph node staging.
1649707|NCT01857934|Drug|cisplatin|Given IV
1649708|NCT01857934|Drug|etoposide|Given IV
1649709|NCT01857934|Drug|doxorubicin|Given IV
1649710|NCT01857934|Drug|vincristine|Given IV
1649711|NCT01857934|Drug|busulfan|Given IV
1649712|NCT01857934|Drug|melphalan|Given IV
1649713|NCT01857934|Biological|peripheral blood stem cell transplantation|Transplantation of previously harvested peripheral blood stem cells.
1649714|NCT01857934|Biological|natural killer cell infusion|Natural killer (NK) cells obtained from a suitable donor will be given together with hu14.18K322A prior to early hematopoietic cell recovery. In the event there is not a suitable parental donor, consenting participants will receive an additional course of hu14.18K322A.
1649715|NCT01857934|Radiation|radiation therapy|Radiation therapy to the primary and metastatic disease sites will follow peripheral blood stem cell transplant with the exception of any patient requiring emergent radiotherapy. External beam radiotherapy will be delivered to the primary site and select metastatic and bulky nodal sites.
1649716|NCT01857934|Biological|GM-CSF|Given subcutaneously (SQ)
1649717|NCT01857934|Biological|G-CSF|Given subcutaneously (SQ)
1649718|NCT01857934|Drug|mesna|Given IV
1649719|NCT01857934|Drug|levetiracetam|Given IV
1649720|NCT01857934|Biological|interleukin-2|Given by continuous infusion during MRD maintenance, and SQ during induction.
1649721|NCT01857934|Drug|Isotretinoin|Given orally (PO)
1649722|NCT01857934|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
1649723|NCT01857921|Drug|Pravastatin 20mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:
Test group:
Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization
Control group:
Pravastatin 20mg daily for 12 months after randomization"
1649724|NCT01857921|Drug|Atorvastatin 40 mg and trimetazidine MR 70 mg/day for 12 months after randomization|"Patients with mono antiplatelet therapy with aspirin who had had received CABG previously fulfilling all enrollment criteria will be randomly assigned to the type of two groups. Randomization of statin therapy will be done 1:1 to one of two different groups on the web-based program:
Test group:
Atorvastatin 40 mg and trimetazidine MR 70 mg daily for 12 months after randomization
Control group:
Pravastatin 20mg daily for 12 months after randomization"
2012815|NCT01575548|Other|Pharmacological Study|Correlative studies
1649726|NCT01857882|Other|Decision Support Workshop|"Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.
Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities
Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system
Social worker (30 mins): values clarification exercise
Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience"
2012816|NCT01575548|Other|Placebo|Given PO
2012817|NCT01575548|Other|Quality-of-Life Assessment|Ancillary studies
2012818|NCT01575548|Other|Questionnaire Administration|Ancillary studies
1649730|NCT01857856|Drug|Eplerenone|eplerenone (inspra; pfizer) one tablet (50mg standard dosis; 25mg reduced dosis) per day
1649731|NCT01857843|Device|Zotalolimus Eluting Stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or Resolute-integrity) or EES (Xience®) in a ratio of 1:1."
1649732|NCT01857843|Device|Everolimus eluting stent|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients with native coronary arteries who fulfill all enrollment criteria for OCT study will be randomized to receive either ZES (Endeavor®-Sprint or resolute-integrity) or EES (Xience®) in a ratio of 1:1."
1717750|NCT00002258|Drug|Interleukin-3|
2012819|NCT01572389|Behavioral|Healthy Outcomes through Patient Empowerment (HOPE)|HOPE participants will receive 6 behavioral coaching telephone sessions and 3 booster sessions over a six month period followed by usual primary care during the subsequent 6 months maintenance period.
2012820|NCT01572389|Behavioral|Enhanced Usual Care|All participants receive usual VA primary care plus a dedicated screening for diabetes control and clinically significant depressive symptoms. Patients and primary care providers are notified of these results and given recommendations for usual care.
2012821|NCT01570387|Drug|Pomalidomide|Cohort 1 = 2 mg/day, Cohort 2 = 3 mg/day, Cohort 3 = 4 mg/day: Days 1-28
2012822|NCT01570387|Drug|Dexamethasone|10-20 mg on days 1, 8, 15, and 22
2012823|NCT01570036|Drug|Herceptin|Herceptin will be administered to patients every three weeks as monotherapy for one year, to be given upon completion of standard of care chemotherapy/radiotherapy. The first Herceptin infusion will be given no sooner than three weeks and no later than 12 weeks after completion of chemotherapy/radiotherapy. Herceptin will be dosed at the recommended initial loading dose of 8 mg/kg and at recommended maintenance doses of 6 mg/kg q3wk.
1649733|NCT01857843|Drug|Ezetimibe 10mg & Simvastatin 40mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.
Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)
Pravastatin 20mg (mevalotin®, BMS)"
1649734|NCT01857843|Drug|Pravastatin 20mg|"Permuted block randomization into 4 groups according to the type of drug and stent will be carried out in a ratio of 1:1:1:1(i.e.,Vytorin-ZES, Vytorin-EES, mevalotin-ZES, or mevalotin-EES) for balanced randomization.
Patients will be randomized in a ratio of 1:1 according to the two different types of lipid lowering treatment.
Ezetimibe 10mg/Simvastatin 40mg (Vytorin®, MSD)
Pravastatin 20mg (mevalotin®, BMS)"
1649735|NCT01857830|Behavioral|Meditation Retreat|The intervention is a one week meditation and yoga retreat hosted at the La Costa Resort and Spa in Carlsbad, CA.
1649736|NCT01857830|Behavioral|Active Comparator Relaxation Group|Participants are randomized to stay at La Costa Resort and Spa for 6 days. Participants will receive daily meals similar to the meals for those in the retreat group. Participants will also receive a daily one hour lecture on topics related to longevity and health.
1649737|NCT01857817|Drug|VT-122|The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.
1649738|NCT01857817|Drug|Placebo|The placebo capsules will be prepared to match the active drug.
1649739|NCT01857804|Drug|Amoxicillin|In the test group a systemic antibiotic regimen will be initiated at 3 days before surgery and continued for 10 days. (2 x 750mg amoxicillin/day or 2 x 1g amoxicillin/day depending on the weight of the patient)
1649740|NCT01857804|Drug|Chlorhexidine gluconate|The exposed implant surfaces will be cleaned 3 minutes with antiseptics (chlorhexidine gluconate 0,2%) during the surgical treatment
1649741|NCT01857804|Drug|Saline|The exposed implant surfaces will be cleaned 3 minutes with saline during the surgical treatment
1649742|NCT01857791|Behavioral|multidisciplinary, behavior modification|
1649743|NCT01857765|Behavioral|Rehabilitation|Range of motion stretching exercises
1649744|NCT01857765|Behavioral|Follow-up|Follow-up with surgeon's clinic
1649745|NCT01857752|Drug|Temozolomide|
1649746|NCT01857726|Drug|Doxorubicin|Transarterial chemoembolization (TACE) with adriamycin
1649747|NCT01857726|Drug|Cisplatin|transarterial chemoinfusion with cisplatin 50-100 mg
1649748|NCT01857713|Device|Reza Band UES Assist Device|Device is worn by patient to reduce or eliminate laryngopharyngeal reflux
1649749|NCT01857700|Other|Compensation for transport cost|
1649750|NCT01857700|Other|Compensation for lost wages|
1649751|NCT01857700|Other|Compensation for transport cost and lost wages|
1649752|NCT01857700|Other|Standard of Care|Consistent with standard of care, participants in this group will be offered a refreshment during their office visit.
1649755|NCT01857648|Other|Physical activity counseling|Home visits including physical activity promotion by the trained Community Health Workers.
1649756|NCT01857622|Drug|DU-176b 15mg|oral DU-176b 15mg once daily
1649757|NCT01857622|Drug|DU-176b 30mg|oral DU-176b 30mg once daily
1649758|NCT01857622|Drug|DU-176b 60mg|oral DU-176b 60mg once daily
1649759|NCT01857609|Drug|Metformin|
1649760|NCT01857609|Drug|Metformin and Pantoprazole|
1649761|NCT01857609|Drug|Metformin and Rabeprazole|
1649762|NCT01857596|Drug|bupropion, Lorexys low-dose, Lorexys moderate-dose|Lorexys is a proprietary fixed-dose combination of two agents
1649763|NCT01857583|Drug|15mg DU-176b|
1649764|NCT01857583|Drug|30mg DU-176b|
1649765|NCT01857583|Drug|Fondaparinux|
1649766|NCT01857570|Radiation|Volume Computed Tomography of the wrist and carpus|
1649767|NCT01857557|Other|Aerobic exercise|Patients receiving exercise program in addition to usual headache care
1649768|NCT01857544|Drug|Aflibercept|Monthly 2.0mg Aflibercept Intravitreal Injection
1649769|NCT01857531|Drug|Ganaxolone|"Pre-Quit Period:
Beginning at Session P1, subjects will receive ganaxolone at a dose of 400mg total daily (200mg bid) for the first three days, 800mg total daily (400mg bid) for the next three days and 1200mg total daily (600mg bid) for the remainder of the first four weeks.
Post-Quit Period:
Following the quit-day, subjects will receive ganaxolone at a dose of (1200mg total daily) for the next week. Down-titration of ganaxolone will begin at post-quit week two. Subjects will receive ganaxolone at a dose of 800mg total daily (400mg bid) to take for three days and 400mg total daily (200mg bid) to take for three."
1649770|NCT01857531|Drug|Nicotine Patch|"Pre-Quit Period:
Beginning at Session P2, subjects will receive active 21mg/24h nicotine patches to apply daily for the next two weeks.
Post-Quit Period:
Following the quit-day, subjects will continue to apply active nicotine patches daily for the remainder of the study (21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week)."
1649772|NCT01857492|Device|tDCS|
1649773|NCT01857492|Behavioral|Meditation|Both Active and SHAM groups will receive Meditation.
1649774|NCT01857479|Drug|Inhaled budesonide|The control group will receive only nebulized budesonide 1 mg b.i.d. thrice a week for four months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day]. The first dose will be administered under direct supervision. If the first dose is tolerated, therapy would be continued for the total duration of the study (4 months). The patient will be advised to clean the nebulizer chamber with soap and water after each administration to avoid contamination.
1649826|NCT01857076|Procedure|Gastric bypass surgery|Gastric bypass surgery performed laparoscopically
1649827|NCT01857076|Procedure|Surgical ileal transposition with sleeve|Surgical Treatment with Ileal Transposition in the duodenum and Vertical Sleeve Gastrectomy through laparoscopic surgery.
1649869|NCT01856725|Procedure|Hemodynamic measurements for CRT device programming|
1649870|NCT01856725|Device|CRT device implant with MultiPoint Pacing|
1649775|NCT01857479|Drug|Inhaled amphotericin|"Amphotericin B deoxycholate (50 mg) will be dissolved in 10 mL sterile water for injection (5 mg/mL). The solution remains stable for at least 7 days at 2°C to 8°C. Ten milligrams of the drug (2 mL) will be nebulized over 10-15 minutes twice in a day for three times a week (Effective dose: 10 mg b.i.d. thrice a week) using a jet nebulizer. Nebulized budesonide will be administered at a dose of 1 mg b.i.d. thrice a week after nebulization with amphotericin B. The total duration of therapy would last 4 months. Patients will also receive a metered dose inhaler of formoterol/budesonide (6/200) at a dose of 2 puffs b.i.d. and as and when required [max 10 puff/day].
The first dose will be administered under direct supervision."
1649776|NCT01857466|Procedure|Floseal|
1649777|NCT01857466|Procedure|Bipolar coagulation|
1649778|NCT01857453|Drug|carboplatine|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
1649779|NCT01857453|Drug|Etoposide|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
1649780|NCT01857453|Radiation|radiation therapy|carboplatine + etoposide based chemotherapy followed by radiation therapy with 24 Gy on the in toto neuro axis and 54 Gy on the post operative bed
2012824|NCT01570036|Drug|NeuVax vaccine|At the time of vaccine administration, a frozen solution of E75 acetate (1.5mg/ml) is thawed and 1000mcg E75 peptide mixed thoroughly with 250mcg GM-CSF. This constitutes the NeuVax vaccine. For patients randomized to the Herceptin + NeuVax vaccine arm, they will commence Herceptin monotherapy and then will begin the NeuVax vaccine series immediately after completion of the third Herceptin infusion. The vaccine series consists of NeuVax vaccine administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
1649782|NCT01857401|Other|No intervention, observational study only|No intervention. We are collecting blood for an ex vivo study
1649783|NCT01857388|Behavioral|ParentCorps|
1649784|NCT01857375|Device|Insulin Pen Device|Insulin pen was compared to administration of insulin using standard syringes.
1649785|NCT01857362|Drug|Nitisinone 20 mg|Nitisinone 20 mg capsules
1649786|NCT01857362|Drug|Nitisinone 10 mg|Nitisinone 10 mg capsules
1649789|NCT01857336|Other|infusion of G-CSF mobilized peripheral harvest|
1649790|NCT01857323|Drug|Albuterol Spiromax®|Albuterol Spiromax delivers 90 mcg of albuterol base from the mouthpiece per triggered dose. Participants took doses of 2 inhalations each twice a day (morning and evening) for a total daily dose of 360 mcg. The first 45 enrolled participants constituted a subgroup who were dosed for 35 days, while most participants were dosed for 50 days.
1649791|NCT01857310|Dietary Supplement|5 mg folic acid and 30 mg elemental zinc|
1649792|NCT01857310|Drug|Placebo Comparator: Placebo|
1649793|NCT01857297|Biological|Enzira® vaccine|
1649794|NCT01857284|Drug|Tauroursodeoxycholic Acid Capsules|250mg.tid.po
1649795|NCT01857284|Drug|Ursodeoxycholic Acid Capsules|250mg.tid.po
1649796|NCT01857271|Drug|Erlotinib Hydrochloride|Given PO
1649797|NCT01857271|Procedure|Therapeutic Conventional Surgery|Undergo thoracotomy
1649798|NCT01857271|Other|Laboratory Biomarker Analysis|Correlative studies
1649799|NCT01857258|Dietary Supplement|Green Tea Concentrate|Green tea concentrate is being examined as a dietary supplement that can regulate postprandial excursions in blood glucose
1649800|NCT01857245|Other|Intensive Models (mDOT and CGT) of HCV Care|Modified Directly Observed therapy (mDOT) and concurrent group treatment (CGT) are on-site HCV treatment models.
1649801|NCT01857232|Drug|Ondansetron, dexamethasone, fosaprepitant|
1649802|NCT01857232|Drug|Placebo|
1649803|NCT01857219|Behavioral|Tai chi|
1649804|NCT01857206|Biological|Mammalian cell based flu vaccine|
1649805|NCT01857206|Biological|Egg based flu vaccine|
1649806|NCT01857193|Drug|LEE011|LEE011 is taken orally once per day for 21 days of each 28 day cycle. LEE011 comes in 50 mg and 200 mg capsules.
1649807|NCT01857193|Drug|Exemestane|Exemestane is taken orally once per day. Exemestane comes in 25 mg tablets.
1649808|NCT01857193|Drug|Everolimus|Everolimus is taken orally once per day. Everolimus comes in 1 mg, 2.5 mg, 5mg, and 7.5 mg tablets
1649809|NCT01857180|Other|Curriculum|
1649810|NCT01857167|Dietary Supplement|Fish Oil Supplementation|
1649811|NCT01857167|Dietary Supplement|Flaxseed Oil Supplementation|
1649812|NCT01857167|Dietary Supplement|placebo|
1649813|NCT01857154|Dietary Supplement|Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate.
Subjects not currently being treated with bisphosphonates will be administered 500 mg micronized calcium carbonate."
1649814|NCT01857154|Dietary Supplement|Non-Micronized Calcium Carbonate|"Subjects currently being treated with bisphosphonates will be administered 1000 mg non-micronized calcium carbonate.
Subjects not currently being treated with bisphosphonates will be administered 1000 mg non- micronized calcium carbonate."
1649815|NCT01857154|Dietary Supplement|Vitamin D3|All subjects in the study cohort will be administered 800 IU Vitamin D3.
1649816|NCT01857141|Drug|preemptive dexmedetomidine epidural bolus injection(1.5 mcg/kg)|Patients in the pre-emptive groups recived a dose of 1.5㎍/kg dexmedetomidine dissolved into normal saline 10cc before the induction of
1649817|NCT01857141|Drug|normal saline|patients in the control groups received the equivalent volume of normal saline.
1649818|NCT01857128|Device|Drawtex dressing|
1649819|NCT01857128|Device|Negative Pressure Wound Therapy|
1649820|NCT01857115|Drug|Carfilzomib|
1649821|NCT01857115|Drug|Cyclophosphamide|
1649822|NCT01857115|Drug|Dexamethasone|
1649823|NCT01857102|Device|etafilcon A|Soft contact lens to be worn in a daily wear, daily disposable modality for one week
1649824|NCT01857102|Device|etafilcon A for Astigmatism|Soft contact lens to be worn by participants in a daily wear, daily disposable modality for one week.
1649825|NCT01857089|Device|Orthotest CE|"Orthotest CE is a rigid base mapping system composed by 1024 pressure transducers uniformly distributed in a 35x35 cm surface.
Orthotest CE is a product manufactured by Vista-Medical. The patient sit on the rigid base during 2 hours to record the pressure and all the data needed for the pilot study.
Pressure measurement"
1649828|NCT01857076|Other|Clinical|The study subjects allocated for clinical treatment will have these treatment divided into three phases. The first one based on glycemic control through weight loss, the second one based on anti-hyperglycemic medications and the last one based on medical monitoring for a further twelve months for the maintenance of the results.
1649829|NCT01857063|Drug|Montelukast|Montelukast 5 mg chewable tablets, taken orally once daily at bedtime for 7 days
1649830|NCT01857063|Drug|Placebo|Matching placebo chewable tablets, taken orally once daily at bedtime for 7 days
1649831|NCT01857037|Other|Histoscanning™ and multiparametric MRI|Detection and localization of prostate cancer local recurrences after radiation therapy using Histoscanning™ and multiparametric MRI
1649832|NCT01857024|Drug|sevelamer carbonate (Renvela®)|800 mg tablets or 2.4 g powder for oral suspension should be administered as instructed in the Renvela® SmPC.
1649833|NCT01857011|Drug|Intravenous Iron sucrose|Intravenous Iron Sucrose 200 mg in the immediate postoperative period and first day postop.
1649834|NCT01857011|Drug|Oral Iron|Oral iron(III)-hydroxide polymaltose complex 100 mg twice daily in the fist 8 postoperative weeks.
1649835|NCT01856998|Drug|Propofol|
1649836|NCT01856998|Drug|Diprivan|
1649837|NCT01856985|Drug|Misoprostol|
1649838|NCT01856985|Drug|Mifepristone|
1649839|NCT01856972|Procedure|Instrument Assisted Soft Tissue Mobilization|IASTM treatment: will be performed with the sound assisted soft tissue mobilization tool #5. Patient will be placed in the prone position with the ankle in a relaxed position. The treating therapist will perform 10 scanning strokes in the caudal, cephalic, medial, lateral directions for a total of 40 strokes over the Gastrocnemius/Soleus complex. The therapist can then perform more concentrated strokes in areas noted by the therapist as tight, with a maximum treatment time of 5 minutes.
1649840|NCT01856972|Procedure|Rearfoot joint mobilization|A high velocity-low amplitude distractive thrust is directed at the talocrural joint. The procedure is performed with the patient in the supine position. The therapist interlaces hands over the dorsum of the foot with 5th digit placed on talus. The therapist slightly pronates and dorsiflexes the foot. Tension is taken up in a caudal direction until the soft tissue barrier is engaged. A distractive thrust is then applied. This is performed up to 2 times. If the therapist notes a cavitation, the patient is progressed to ROM exercises. If there is no cavitation is noted by the therapist the thrust mobilization is reapplied.
1649841|NCT01856972|Other|Static stretching/ROM exercises|Gastrocnemius stretch at wall 3 sets of 30 second holds. Soleus stretch at wall 3 sets of 30 second holds. Standing bilateral dorsiflexion on step x30 with full ROM. Standing bilateral plantar flexion on step x30 with full ROM.
1649842|NCT01856959|Drug|Magnesium Sulfate|2ml of 7.5% solution of isotonic magnesium heptahydrate, 150 mg
1649843|NCT01856959|Drug|magnesium sulfate & albuterol|0.5ml of albuterol mixed with 2ml of isotonic magnesium sulfate,150mg+2.5mg
1649844|NCT01856959|Drug|Albuterol|0.5ml of albuterol mixed with 1.5cc of normal saline, 2.5 mg
1649845|NCT01856946|Dietary Supplement|4,000 IU vitamin D3|two 2,000 IU vitamin D3 pills (total 4,000 IU) daily for six months.
1649846|NCT01856933|Drug|PSMA ADC|2.5 mg/kg, IV, over 60 minutes every 3 weeks
2012825|NCT01570036|Drug|GM-CSF|For patients randomized to the Herceptin + GM-CSF only arm, they will commence Herceptin monotherapy and then will begin the GM-CSF inoculation series immediately after completion of the third Herceptin infusion. The GM-CSF inoculation series consists of 250mcg GM-CSF administered intradermally every three weeks for six total vaccinations, 30-120 minutes after completion of Herceptin infusion.
2012826|NCT01569607|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Training sessions for 5 days in a row
2012827|NCT01569607|Device|Sham stimulation|Sham stimulation
2012828|NCT01562977|Drug|Rituximab, Gemcitabine, Oxaliplatin, Dexametasone|until progression or unacceptable toxicity develops, 8 cicles max Rituximab: 375 mg/m2, IV, day 1. Gemcitabine: 1000 mg/m2, IV, day 2. Oxaliplatin: 100 mg/m2, IV, day 2. Dexametasone: 20 mg/day, days 1-3, oral.
1649851|NCT01856881|Drug|AMG 876|Ascending multiple doses of study drug administered SC
1649852|NCT01856868|Drug|(-)-epicatechin|purified nutritional extract (-)-epicatechin 100mg/day orally for 8 weeks.
1649853|NCT01856855|Radiation|Stereotactic Body Radiation Therapy with Integrated Boost|SBRT with Integrated boost at 7.25 Gy and 8.00 Gy per fraction for five fractions
1649854|NCT01856842|Procedure|Angiography and embolotherapy|
1649855|NCT01856829|Dietary Supplement|Omega-3|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
1649856|NCT01856829|Other|Placebo|The capsule will be take daily for 4 weeks before and for the duration of the tests of the perceptual-cognitive training protocol. The testing period will held at intervals of 3 to 7 days for 5 sessions (maximum of 5 weeks testing). Taking products will be made more specifically 30 minutes before the start of the sessions.
1649857|NCT01856816|Other|Meal Pattern Treatment A|"In treatment A, subjects consumed 100% of salad vegetables and canola oil in the first meal and 0% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
1649858|NCT01856816|Other|Meal Pattern Treatment B|"In treatment B, subjects consumed 50% of salad vegetables and canola oil in the first meal and 50% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
1649859|NCT01856816|Other|Meal Pattern Treatment C|"In treatment C, subjects consumed 75% of vegetables and oil in the first meal and 25% in the second. Additional protein-rich chef's salad ingredients were distributed equally between meals."
1649860|NCT01856803|Drug|anti thymoglobulin|
2012829|NCT01557166|Drug|liraglutide|3.0 mg liraglutide administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
1649863|NCT01856777|Device|Semi-quantitative panel test|
1649864|NCT01856777|Device|High sensitivity urine pregnancy test|
1649865|NCT01856764|Drug|0.5% Roflumilast Cream|Roflumilast 0.5% cream
1649866|NCT01856764|Drug|Vehicle Cream|Roflumilast formulation vehicle
1649867|NCT01856738|Drug|Rivastigmine|Capsule. Dose 3,0 - 6,0 mg BID
1649868|NCT01856738|Drug|Placebo (for rivastigmine)|Capsule. Dose 3,0 - 6,0 mg BID
1649871|NCT01856712|Drug|Naltrexone|Naltexone was chosen for this study because naltrexone is the only medication available in both oral daily and injectable monthly formulations, which will allow the study to examine issues around medication adherence.
2012830|NCT01557166|Drug|placebo|Placebo administered subcutaneously (s.c., under the skin) once daily for 32 weeks + diet and exercise
2012831|NCT01556841|Biological|TroVax®|"Pre-amendment 10:
Patients will be randomised to receive either TroVax® 1 x 10↑9 TCID50/mL in 1mL (experimental arm) or matched placebo (control arm) on a 1:1 basis. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19, 25, 31, 37, 43 and 49. No further treatment will be given beyond week 49.Treatment will be stopped early if confirmed progression or unacceptable toxicity.
Post-amendment 10:
Patients will be registered to receive TroVax 1 x 10↑9 TCID50/mL in 1mL only. A single dose will be given by intramuscular injection during the following weeks: 2, 4, 7, 10, 13, 19 and 25. No further treatment will be given beyond week 25.Treatment will be stopped early if confirmed progression or unacceptable toxicity."
1649874|NCT01856673|Behavioral|Common Elements Treatment Approach|It was developed for treating symptoms related to violent trauma, i.e. symptoms of depression, anxiety and distress, among a population victimized by violence and torture in Colombia. The most relevant components for treatment of these 3 problematic issues were identified from literature review and a panel of experts. Descriptions and schemes have been developed in order to guarantee facility of use by community counselors who have little background in mental health skills. These counselors, who will be called Lay Psychosocial Community Workers (LPCW), will receive training in this technique before beginning of interventions. Application of this technique will be supervised constantly by mental health professionals (psychologist or social worker) from the project team.
1649875|NCT01856673|Behavioral|Narrative Community Group Therapy|It consists on teaching skills to people in the community to provide mental health therapy. Therapy will be performed by LPCW under constant supervision of mental health professionals (psychologists or social workers). Sessions will begin with a series of introductory activities that motivates participants to propose different problems that they would like to solve in the group. A participant proposed a problem and he/she will be asked to talk about it. LPCW and/or psychologist will support individuals if anyone needs help to solve a psychological crisis. At the end of this narration, participants will be asked about who has had a similar situation, and how they solved it. In this way, proposed solutions will be collected by the LPCW. Finally, session closes with a motivating activity.
1649876|NCT01856673|Other|Standby group|Standby group: they will be assessed at baseline with the initial survey and they will wait between 10 and 12 weeks; an exit assessment will be performed with the study instrument. After the exit survey, control group participants will have an appointment with a professional psychologist to determine whether they require a mental health treatment. Those with such necessity will receive treatment in the ACOPLE center by professional psychologists or they will be referred to other health care level according to the type of psychopathology (e.g., psychosis) or its severity. Also, participants in the control group will be monitoring monthly by phone calls and if they have any psychological problem, they will be assessed in the ACOPLE center.
1649877|NCT01856660|Behavioral|Low-Carbohydrate Diet|Participants are provided with a 6-month standard lifestyle intervention where carbohydrate intake is limited to 50 g/day. There is no calorie restriction for participants following the Low-Carbohydrate diet. Gradual increase in physical activity across the trial to > 40 min per day, 5 times/week.
1649878|NCT01856660|Behavioral|Low-fat Diet|Participants are provided with a 6-month standard lifestyle intervention. They will follow an energy restricted, low-fat diet where the daily energy consumption target is 1,200- 1,500 kilocalories/d. The fat intake target is 28% or less of daily kilocalories. Gradual increase in physical activity until participants are active at least 40 min per day, 5 times/week.
1649879|NCT01856647|Procedure|Adipose tissue biopsy (fat biopsy)|An adipose tissue biopsy will be performed after a 10-12 hour overnight fast. A small sample of fat tissue will be removed from the subject for gene expression analysis. A subcutaneous fat biopsy (~3 ml) will be obtained from the lower abdomen following local anesthesia.
1649880|NCT01856634|Drug|100 mg Delamanid|100 mg Delamanid BID for 10 days
1649881|NCT01856634|Drug|50 mg Delamanid|50 mg Delamanid BID for 10 days
1649882|NCT01856634|Drug|25 mg Pediatric Formulation Delamanid|25 mg Pediatric Formulation Delamanid BID for 10 days
1649883|NCT01856634|Drug|10 mg Delamanid Pediatric Formulation|Patients > 10 kg will receive DPF 10 mg BID for 10 days
1649884|NCT01856634|Drug|5 mg Delamanid Pediatric Formulation|"Patients > 8 kg and ≤ 10 kg will receive DPF 5 mg BID for 10 days
Patients ≤ 8 kg will receive DPF 5 mg QD for 10 days"
1649885|NCT01856634|Drug|Optimized Background Regimen|Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country
1649886|NCT01856621|Drug|Seretide Diskus and charcoal|2 inhalations as a single dose
1649887|NCT01856621|Drug|Seretide Diskus|2 inhalations as a single dose
1649888|NCT01856621|Drug|SF Easyhaler and charcoal|2 inhalations as a single dose
1649889|NCT01856621|Drug|SF Easyhaler|2 inhalations as a single dose
2012832|NCT01556841|Biological|Placebo|"Pre-amendment 10:
Matched placebo will be administered as above.
Post-amendment 10:
TRI-70 onwards received TroVax only."
2012833|NCT01554085|Drug|ALS-002158|ALS-002158
1649892|NCT01856582|Biological|CD34+|CD34+ cells are selected using the CliniMACS System; without preparative regimen
1649893|NCT01856569|Other|no intervention|in real life of drug,dosage,frequency and duration
1649894|NCT01856556|Drug|NRX-1074|Single IV or PO administration
1649895|NCT01856556|Drug|Placebo|Single IV or PO placebo administration
1649896|NCT01856543|Other|Eucerin|
1649897|NCT01856543|Other|Mometasone Furoate 0.1%|
1649898|NCT01856530|Drug|Oxytocin|Liquid metered-dose nasal spray, 24 IU, administered once
1649899|NCT01856530|Drug|Placebo|Matched placebo nasal spray
1649900|NCT01856517|Drug|Clonidine|
1649901|NCT01856517|Drug|Placebo|
2012834|NCT01554085|Drug|Placebo|placebo
1649905|NCT01856452|Device|the mixture including indocyanine green|Sentinel lymph node biopsy using near-infrared imaging system and gamma probe detector for the mixture of indocyanine green, blue dye, and radioisotope during operation
1650109|NCT01854996|Drug|PF-05089771|450mg
1649906|NCT01856452|Device|radioisotope|Sentinel lymph node biopsy using gamma probe detector for radioisotope during operation
1649907|NCT01856439|Drug|ProSavin|Long term follow up of patients who received ProSavin in a previous study
1649908|NCT01856426|Drug|EDP239|
1649909|NCT01856426|Drug|Placebo|
1649910|NCT01856413|Drug|Zutectra|Subcutaneous injections of Zutectra up to 1,000 IU (2 ml) per week.
1649911|NCT01856387|Biological|high neutrophil to lymphocyte ratio|
1649912|NCT01856387|Other|normal neutrophil-to Lymphocyte ratio|
1649913|NCT01856374|Device|Sirolimus-eluting stent (Cypher SelectTM, Cordis, Miami, FL)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
1649914|NCT01856374|Device|Everolimus-eluting stent(Xience Prime®, Abbott Vascular, Santa Claea, CA)|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; Xience Prime® vs. Cypher SelectTM and pravastatin 20mg vs. atorvastatin 40mg.
1649915|NCT01856374|Drug|Pravastatin 20mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
1649916|NCT01856374|Drug|Atorvastatin 40mg|2x2 randomization by the treatment of dyslipidemia (In patients of dyslipidemia: pravastatin 20mg/day vs. atorvastatin 40mg and the types of the implanted cypher vs xience.
1649917|NCT01856361|Drug|Ramipril|Angiotensin Converting Enzyme Inhibitor
1649918|NCT01856361|Drug|Placebo|Placebo pill that will match the treatment pill
1649919|NCT01856348|Drug|Vitamin D|
2012835|NCT01553084|Drug|Varenicline|Participants will receive 12 weeks of pharmacotherapy during the post-quit period plus an additional 7 day pre-quit run-in. Participants will be asked to take a 0.5 mg pill once a day for the first 3 days and then increase to a 0.5 mg pill twice a day (8 hours apart) for 4 days. On the 8th day, their target quit date, they will increase to their target maintenance dose of a 1 mg pill twice daily. If participants report significant adverse events such as nausea, a dose reduction to two 0.5 mg doses per day will be advised.
2012836|NCT01553084|Drug|Nicotine lozenge|Participants will receive 12 weeks NRT. Participants will be given 2 mg or 4 mg lozenges based on morning smoking latency, and will be given package insert use instructions. Medication use will start on the morning of their assigned quit day. They will be urged to use at least 5 pieces/day, unless this amount produces adverse effects.
1649922|NCT01856322|Drug|Sulindac|one tablet 150mg twice daily
1649923|NCT01856322|Drug|Placebo|One tablet twice daily
1649924|NCT01856322|Other|Validate assays and shipping methods|
1649925|NCT01856309|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneously (SC) at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 2, and every 2 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
1649926|NCT01856309|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0 (administered as the last dose in CNTO136ARA3002 or CNTO136ARA3003), 4, and every 4 weeks through Week 156 for participants who completed CNTO136ARA3002 and through Week 208 for participants who completed CNTO136ARA3003.
1649927|NCT01856309|Drug|Placebo|Between sirukumab 50 mg injections, placebo SC injections will be administered at Weeks 2, 6, and every 4 weeks until the study becomes open-label, and placebo injections are discontinued.
1649928|NCT01856296|Procedure|Biopsy|
1649929|NCT01856283|Drug|Nilotinib 300mg BID|Nilotinib
2012837|NCT01553084|Drug|Nicotine Patch|Participants will receive 12 weeks NRT. Patch dosing will be 8 weeks of 21 mg, then 2 weeks of 14 mg, then 2 weeks of 7 mg (those smoking 5-10 cigs/day will receive reduced patch dosing). Medication use will start on the morning of their assigned quit day. They will be urged to use 1 patch/day, unless it produces adverse effects.
1649931|NCT01856257|Biological|Anti-thymocyte Globulin (Rabbit)|The target dosage is 6mg/kg total over 3 to 4 days. The recommended route of administration is intravenous infusion using a high-flow vein.
1649932|NCT01856257|Biological|belatacept|Participants will receive belatacept at a dose of 10mg/kg up on day 1, 5, 14, 28, 56 and 84. After 84 days, subjects will receive a maintenance dose of 5 mg/kg every 4 weeks until completion of the trial.
1649933|NCT01856257|Drug|methylprednisolone|Methylprednisolone will be administered at a target dose of 500 mg beginning on the day of transplant, and tapered to 250 mg day 1 post-transplant, 125 mg day 2 post-transplant, 60 mg day 3 post-transplant, 30 mg day 4 post-transplant and day 5 post-transplant 0 mg if therapeutic tacrolimus level achieved for groups 1 and 3.
1649934|NCT01856257|Biological|basiliximab|Basiliximab will be administered in two doses of 20 mg each.
1649935|NCT01856257|Drug|mycophenolate mofetil|Mycophenolate Mofetil will be administered at a target dose of 1000 mg orally twice a day. Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
1649936|NCT01856257|Drug|tacrolimus|The site investigator will identify a starting tacrolimus dose at their discretion, in order to achieve the target trough levels, no later than 5 days post-transplantation. The dose will be adjusted to 5-8ng/ml for the active comparator arm (thymoglobulin + tacrolimus + MMF arm) or tapered off in the experimental arm (basiliximab + 20 weeks of tacrolimus + MMF + belatacept).
1649937|NCT01856244|Behavioral|treadmill walking|
1649938|NCT01856244|Device|Treadmill|
1649939|NCT01856231|Behavioral|Lifestyle physical activity - self-efficacy|Subjects will come into an exercise lab 2 days per week and perform 10-20 minutes of walking, 13 strength training exercises, stretching and a behavioral intervention including goal setting, etc.
1649940|NCT01856218|Drug|UX003|
1649941|NCT01856205|Drug|Intravenous immunoglobulin [ImmunoRel™ (batch 20081217)]|"IVIG group received 400mg/kg/day intravenous at the rate of 0.01 to 0.02 ml/kg body weight/minute for 5 days or appearance of side effect or adverse events.
Placebo group received 0.9% saline intravenous at similar rate."
1649949|NCT01856179|Dietary Supplement|Echium oil|Oil of Echium platagineum (natural plant oil) ca. 15-18 g/d (Croda)
1649950|NCT01856166|Device|Release analgesia by CADD SMITHS PCEA pump|Analgesia will be release by continuous manner with an automatic pump
1649951|NCT01856166|Device|Release analgesia by CADD SMITHS PIEB pump|Analgesia will be release by bolus with an automatic pump
1649952|NCT01856166|Drug|Levobupivacaine|
1649953|NCT01856166|Drug|Sufentanil|
1649954|NCT01856153|Dietary Supplement|Before meal|
1649955|NCT01856153|Dietary Supplement|With Meal|
1649956|NCT01856153|Dietary Supplement|After meal|
1649957|NCT01856140|Biological|ALLO-ASC(allogeneic adipose derived mesenchymal stem cell) injection|
1649958|NCT01856127|Drug|Vilazodone|Vilazodone is a newly introduced antidepressant which, in contrast to the selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) appears to have a minimal adverse effect on sexual functioning
1649959|NCT01856127|Drug|Sertraline|Sertraline hydrochloride (trade names Zoloft, Lustral) is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class.
1649960|NCT01856114|Drug|Fentanyl Buccal Tablet|Fentanyl buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
1649961|NCT01856114|Other|Placebo Buccal Tablet|Placebo buccal tablet given to put in between upper gum and cheek one hour after a six minute walk test.
1649962|NCT01856114|Behavioral|Questionnaires|Completion of two questionnaires at beginning of study visit. It should take about 10 minutes to complete. At the end of study visit, completion of last questionnaire. It should take about 5 minutes to complete the questionnaire.
1649963|NCT01856101|Drug|BEZ235|The investigational study drug used in this trial is BEZ235, supplied as 200 mg, 300 mg and 400 mg sachets. BEZ235 is administered continuously twice-daily; complete cycle is 28 days. Starting dose is 300mg PO bid. At cycle 1 day 15, based on a clinical assessment, dose is adjusted for the rest of the study:• If no adverse event (AE) or only mild AE (G1) : the dose will be increase to 400 mg bid• If AE = G2 : the patient will continue at 300 mg bid • If G3 AE or higher : BEZ235 will be interrupt until resolved to ≤ G1 then reduce dose to 200 mg bid
1649964|NCT01856088|Device|Inspiron Stent|stent implantation
1649965|NCT01856088|Device|Biomatrix Flex Stent|stent implantation
1649966|NCT01856062|Drug|Placebo|A placebo with similar appearance to dexamethasone will be given with a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
1649967|NCT01856062|Drug|Dexamethasone|Oral dexamethasone will be added to a standard regimen of clomiphene citrate (100mg/day oral for 5 days) for ovulation induction
1649969|NCT01856036|Procedure|Cryoablation|Cryoablation of breast cancer will be performed using a freeze-thaw technique and an IceCure probe. Cryoablation cycles will be determined by IceCure software programmed by the treating surgeon.
1649970|NCT01856023|Drug|High Dose Interleukin-2|
1649971|NCT01856023|Drug|Ipilimumab|
1649972|NCT01856010|Other|ECT treatment|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide to do ECT treatment, they are in the ECT group.
1649973|NCT01856010|Other|Standard Care (Non-ECT group)|The decision to administer ECT treatment will have already been made before the subject is approached about study participation. Only individuals who were referred for ECT due to behavior refractory to standard care will be eligible to participate. If they decide not to do ECT treatment and continue with standard care, they are in the Standard Care (Non-ECT) Group.
1649974|NCT01855997|Drug|Peg-IFN alfa-2a|Participants received Peg-IFN alfa-2a prior to enrollment for at least 24 weeks. Dosing was chosen according to standard of care or at the discretion of the treating physician.
1649975|NCT01855984|Dietary Supplement|Oral mixed tocotrienols|200mg per day
1649976|NCT01855984|Dietary Supplement|Placebo|Capsules containing soya bean oil that has similar appearance with the mixed tocotrienol capsules
1649977|NCT01855971|Dietary Supplement|EGCG|Life Extension, Mega Green Tea Extract Decaffeinated is a dietary supplement containing EGCG extract (45% EGCG). This extract contains 98% total polyphenols and 45% epigallocatechin-3-gallate (EGCG). EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.
1649978|NCT01855971|Dietary Supplement|Placebo|Same capsules containing rice flour. No active treatment is given.
1649979|NCT01855971|Other|cognitive training|Feskits program 3 times per week (1 hour/session) Patients in this arm of the trial carried out computerized online training drawn from the Feskits program (www.feskits.com), chosen to have attention, memory and executive function components. Specifically the sessions included the following exercises: sustained attention, attention/perception, working memory, auditory and visual memory, executive function and language.
1649980|NCT01855958|Procedure|DIMST|The investigators used electro acupuncture of 2 Hz during 30 minutes.
1649981|NCT01855958|Procedure|Placebo-sham|Electro acupuncture with rubber electrodes, without current passing.
1649982|NCT01855945|Biological|Swine Influenza|Comparison of different dosages of vaccines
1649983|NCT01855932|Behavioral|Technology Supported|All participants will complete 8 weeks of recording of dietary intake, weight, and physical activity on a smartphone application. Time-stamped data from the smartphone will upload automatically to the application server, where it will be visible to the lifestyle coach. The participant's real-time diet, activity and weight data relative to their goals will be visually depicted on the participant's smartphone. The coach will monitor participant adherence and send supportive text messages. Response to the application will be assessed 3 weeks after enrollment into the study; measured by number of food items recorded between weeks 1-3 of the intervention; an indicator of use and adherence. Based on adherence, some participants may receive 4 telephone coaching sessions between weeks 5 and 8. Telephone coaching sessions will include feedback on self-monitoring and goal attainment, problem solving, and motivational interviewing.
1649984|NCT01855919|Drug|Duloxetine|Administered orally
1649985|NCT01855919|Drug|Placebo|Administered orally
1649986|NCT01855906|Procedure|Gap balanced surgical technique|Gap balanced surgical technique
1649987|NCT01855906|Procedure|Measured resection|Measured resection surgical technique
1649988|NCT01855893|Other|Auto-acupressure|Patients will receive instructions about how to apply auto-acupressure once in a day during one week by their health care professionals.This technique will be complementary to the conventional treatment.
1650237|NCT01854034|Drug|AUY922|AUY922 administered intravenously once a week at 70mg/m2
1649989|NCT01855893|Other|Conventional treatment|Conventional treatment consist of: 7 days with paracetamol 1g /8 hours and/ or ibuprofen 400mg/ 8 hours, and tetrazepam 50 mg/ 12 hours
1649990|NCT01855880|Biological|AbGn-168H|
1649991|NCT01855880|Biological|placebo|
2012838|NCT01552473|Behavioral|Brain Training Program 1|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide information on brain injury and its recovery process. Activities involved in the sessions include discussion of study material. Participants will be encouraged to apply the information to their daily lives. The program includes additional outside practice of the activities.
1649993|NCT01855854|Drug|Icotinib|Icotinib: 250 mg is administered orally three times per day, until disease progression or untolerable toxicity.
1649994|NCT01855841|Drug|Hemin|A single perfusion of 4mg/kg hemin diluted in 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
1649995|NCT01855841|Drug|placebo|A single perfusion of 100mL of NaCl 0.9% administered as soon as possible after the end of the ERCP followed by 100mL of NaCL 0.9% to flush the vein
1649996|NCT01855828|Drug|Pertuzumab|First dose is 840mg, maintenance dose is 420mg. Pertuzumab will be administered once every 3 weeks for 24 weeks (8 doses total)
1649997|NCT01855828|Drug|Trastuzumab|"For weeks 1-12, first dose is 4 mg/kg, maintenance dose is 2 mg/kg administered every week (12 doses total).
For weeks 13-24, dose is 6mg/kg administered every 3 weeks (4 doses total)."
1649998|NCT01855828|Drug|Paclitaxel|Administered at 80mg/m2 every week from week 1 to 12 (12 doses total).
1649999|NCT01855828|Drug|5-fluorouracil|Administered at 500 mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
1650000|NCT01855828|Drug|Epirubicin|Administered at 75mg/m2 every 3 weeks during weeks 13-24 (4 doses total).
1650001|NCT01855828|Drug|Cyclophosphamide|Administered at 500mg/m2 for every 3 weeks during weeks 13-24 (4 doses total).
1650005|NCT01855776|Device|Fitbit|Fitbit Zip is a wireless pedometer that tracks steps of participants, and will be offered in conjunction with a tailored website with customized information for participants, employers, and/or charities.
1650006|NCT01855776|Behavioral|Cash Incentives|Incentives will be awarded to participants for meeting specified weekly step goals as measured by a pedometer.
1650007|NCT01855776|Behavioral|Charitable Incentives|Incentives will be awarded to charities selected by participants should the latter meet specified weekly step goals measured by a pedometer.
1650008|NCT01855776|Other|Usual Care|"The usual care programme consists of educational materials designed by the Singapore Health Promotion Board. It includes material on how to stay active, walking programmes, and healthy eating."
1650009|NCT01855763|Drug|Metformin|
1650010|NCT01855763|Drug|Insulin|
1650011|NCT01855750|Drug|Ibrutinib|560 mg capsules administered by mouth once daily (21-day cycles)
1650012|NCT01855750|Drug|Placebo|4 matched capsules administered by mouth once daily (21-day cycles)
1650013|NCT01855750|Drug|Rituximab|375 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
1650014|NCT01855750|Drug|Cyclophosphamide|750 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
1650015|NCT01855750|Drug|Doxorubicin|50 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
1650016|NCT01855750|Drug|Vincristine|1.4 mg/m2 administered intravenously once on Day 1 of each cycle (21-day cycles)
1650017|NCT01855750|Drug|Prednisone (or equivalent)|100 mg capsules administered by mouth once daily on Day 1 to Day 5 of each cycle
1650018|NCT01855737|Drug|Warfarin|Prescribe warfarin to the patients who are needed.
1650019|NCT01855724|Drug|Gemcitabine-Pazopanib|
1650020|NCT01855711|Drug|GR68755 (Alosetron hydrochloride) 1 mg tablet|1 tablet (1 mg) once a day
1650022|NCT01855685|Genetic|X vivo gene therapy|Transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing GP91PHOX gene
1650023|NCT01855672|Device|Stimulation of the Occipital Nerves|Electrical stimulation of the occipital nerves.
1650024|NCT01855646|Other|Structured Sign Out Form|
1650025|NCT01855633|Device|Traditional Theta burst stimulation (TBS)|
1650026|NCT01855633|Device|Modified TBS rTMS|
1650027|NCT01855633|Device|Sham rTMS|
1650028|NCT01855607|Other|topical menthol|7.5% Methylsalicylate / 2% Menthol Lotion
1650029|NCT01855607|Other|placebo cream|The control (placebo) product has same amount of Methylsalicylate (7.5%) and no menthol.
1650030|NCT01855594|Drug|Lithium Carbonate|250 mg/tablet, 6 weeks course of oral administration
1650031|NCT01855594|Drug|Placebo|placebo tablet, 6 week course of oral administration
1650032|NCT01855581|Drug|pediatric sedation (propofol, ketamine, etc)|"Presedation assessment was performed by hospitalists and pediatric sedation was performed by protocol in the sedation unit.
Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events were collected retrospectively."
1650033|NCT01855568|Procedure|Single-dose Methotrexate|"Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell <15% between day 11 and 14."
1650034|NCT01855568|Procedure|Two-dose methotrexate protocol|"Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell <15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment."
1650238|NCT01854021|Procedure|intravenous anesthesia|intravenous anesthesia
1650035|NCT01855555|Drug|sedation with propofol|"When a patient is admitted to the Pediatric Sedation Center, a presedation assessment is performed by hospitalists. Then Pediatric sedation is performed by protocol in the sedation unit.
Data on demographics, primary illness, ASA, snoring history, URI symptom, medications used, procedure and recovery times, medication doses, outcomes of anesthesia, airway interventions and adverse events will be reported."
1650036|NCT01855542|Other|0.9% normal saline|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
1650037|NCT01855542|Other|plasmalyte|In each group, patients received either 0.9% normal saline or plasmalyte solution until end of surgery.
1650038|NCT01855529|Drug|Ropivacaine in one arm and placebo (NaCl) in the other arm|
1650039|NCT01855516|Drug|Heparin|
1650040|NCT01855503|Procedure|Core Biopsy|
1650041|NCT01855490|Drug|Exenatide|
1650042|NCT01855477|Procedure|Histological biopsy procedure|
1650043|NCT01855464|Procedure|wedge resection|Complementary to parietal pleurectomy lung tissue is resected.
1650044|NCT01855464|Procedure|parietal pleurectomy|The parietal pleura is resected for treating primary pneumothorax.
1650045|NCT01855451|Drug|Cetuximab|
1650046|NCT01855451|Radiation|RT (70 Gy in 35 fractions)|
1650047|NCT01855451|Drug|Cisplatin|
1650048|NCT01855438|Behavioral|Living Donor Transplant Education|The Living Donor Transplant Education informs kidney transplant candidates about living donor transplants and provides guidance in broaching and maintaining discussion about the topic.
1650049|NCT01855412|Other|PAD endovascular treatments|All FDA-cleared endovascular PAD treatments
1650050|NCT01855399|Behavioral|Peer Coaching|All participants will be assigned to one of 87 peer coaches, who also are Detroit VA diabetes patients who previously had poor glycemic control but are currently in good control. After their baseline assessment, participants in both arms will receive information on their lab and blood pressure values and will be randomized to one of the two study arms. Participants randomized to both groups will be scheduled for an initial visit with their coach. The coach will then help them list questions and concerns they wish to discuss with their health care provider, practice raising their questions and concerns and develop an action plan to address barriers to self-management they have identified. During the next six months coaches will call their assigned peers once a week to provide support for their action steps.
1650051|NCT01855399|Behavioral|Computer Decision Aid and Self-Management Support Tool|The iDecide tool is designed to present key tailored, evidence-based information on diabetes and diabetes treatments. Importantly for a peer support intervention, all content information will be provided through the tool, with the role of the peer mentor being to assist the participant to go through the program and participate in helping the patient formulate questions and concerns to discuss with their health care provider, to set their own behavioral goals and action steps, and to help the participant practice raising the issues they plan to discuss with their health care provider.
1650052|NCT01855399|Behavioral|Coach Training|All coaches will receive training in behavioral coaching, with an emphasis on Motivational Interviewing. All coaches will have the opportunity to attend monthly coaching group meeting with other coaches. These meetings will offer additional training and the opportunity for support and sharing of coaching strategies.
1650053|NCT01855386|Other|Subjects with Gestational Diabetes|Subjects with a history of Gestational Diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
1650054|NCT01855386|Other|Controls without Gestational Diabetes|Matched control subjects without gestational diabetes will provide blood samples, blood pressure measured with a blood pressure cuff, pulse, height, weight, and ultrasound of the liver at the 6 week postpartum and 6 month postpartum visits.
1650055|NCT01855373|Dietary Supplement|PEAK ATP® with GlycoCarn®|PEAK ATP® with GlycoCarn® {Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule) and Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule)}: 2 capsules twice daily on an empty stomach
1650056|NCT01855373|Dietary Supplement|PEAK ATP®|PEAK ATP® (Adenosine 5'-Triphosphate Disodium Salt (100mg/capsule): 2 capsules twice daily on an empty stomach
1650057|NCT01855373|Dietary Supplement|GlycoCarn®|GlycoCarn® (Glycine Propionyl-L-Carnitine Hydrochloride, USP (500mg/capsule): 2 capsules twice daily on an empty stomach
1650058|NCT01855373|Other|Placebo|Placebo: 2 capsules twice daily on an empty stomach
1650060|NCT01855347|Device|Near Infrared Spectroscopy|NIRS Monitoring with four channels regional areas of the preterm infant, such as: Submandibular, Periumbilical, Abdominal (Spleen region) and infant thigh.
1650061|NCT01855334|Drug|Spironolactone|
1650062|NCT01855334|Dietary Supplement|L-arginine|
1650063|NCT01855334|Drug|Placebo|
1650064|NCT01855321|Drug|Vitamin D|The cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
1650065|NCT01855321|Drug|Placebo|The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
1650066|NCT01855308|Procedure|Single site robotic chole|Cholecystectomy
1650067|NCT01855308|Device|da Vinci Si Surgical System|minimally invasive robotic surgical system designed to facilitate complex procedures
1650068|NCT01855295|Dietary Supplement|Protein Supplement|During the treatment phase, study subjects are advised to increase protein intake to 1.2 g/kg/day for 12 weeks. In addition to any protein supplementation the participant is on, supervised supplementation on each dialysis session is provided. Each participant receives 45 grams of liquid protein supplement (Provide Sugar Free produced by Provide Nutrition LC) at each dialysis treatment for additional 12 weeks for total study duration of 24 weeks.
1650110|NCT01854970|Drug|esomeprazole|Patients with pharyngolaryngeal symptoms will have a clinical evaluation, laryngoscopy, and pharyngoesophageal pH-impedance. Then a treatment by esomeprazole during 8 weeks in the term of which the second clinical evaluation and pH-impedance will be made.
1650111|NCT01854957|Biological|Autologous Mesenchymal Stem Cells|Single dose of 1-2 x 1000000 cells/Kg body weight
1650112|NCT01854944|Drug|Brexpiprazole 1mg to 4mg|
1650069|NCT01855282|Behavioral|Behavioral Intervention|Intervention participants attended up to 10 educational sessions teaching them about diabetes, and modifiable lifestyle factors (behaviors) to reduce the risk of diabetes by controlling weight. Sessions were conducted by Promotoras using culturally sensitive and appropriate materials and themes. Group activities and support were also emphasized. The control participants like the intervention were measured and interviewed before and again after the intervention sessions, but received no educational instruction or materials.
1650070|NCT01855269|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri (BioGaia, Stockholm, Sweden):at a dose of 100 million colony forming unit in 5 drops, 30 minutes after feeding, once per day for 3 weeks
1650071|NCT01855269|Dietary Supplement|Herbal drop|Herbal drop containing sodium bicarbonate, Pimpinella anisum oil,foeniculum vulgare oil, Mentha piperita (Babs, Berko, Istanbul, Turkey):5 drops 30 minutes after feeding, once per day for 3 weeks
1650072|NCT01855269|Dietary Supplement|placebo sterile water|
1650073|NCT01855256|Drug|Oxybutynin|Oxybutynin is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
1650074|NCT01855256|Drug|Placebo|Placebo is started at a dose of 2.5 mg / day and increased gradually until an effective dose without exceed 7.5 mg / day up to 6 weeks.
1650079|NCT01855230|Drug|ASM-024|ASM-024 b.i.d for 14 days
1650080|NCT01855230|Drug|Placebo|Placebo b.i.d. for 14 days
1650081|NCT01855217|Drug|Sugammadex|1 mg/kg total BW based sugammadex reversal of deep block
1650082|NCT01855217|Drug|Sugammadex|1 mg/kg ideal BW based sugammadex reversal of deep block
1650083|NCT01855217|Drug|Placebo|0,9% NaCl
1650084|NCT01855204|Radiation|Computed tomographic urography|Computed tomographic (CT) urography was done with the protocols of low voltage and low iodine concentration.
1650085|NCT01855178|Device|Emfit Movement Monitor|Factory settings
1650086|NCT01855165|Behavioral|Advice on DDIs|
1650087|NCT01855152|Other|Optimised WHELD intervention|Experimental: Optimised WHELD intervention
1650088|NCT01855152|Other|Treatment as usual|Treatment delivered as usual in the care home
1650089|NCT01855139|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg OD or 20 mg OD
1650090|NCT01855126|Other|Blue light|On week 6, half of the subjects will be given light masks that deliver blue light before the estimated CBTmin and the other half will be exposed to red light under identical conditions - placebo control. On week 9, the ones who experienced blue light on week 6 will experience the red light, while the ones who experienced the red light on week 6 will experience the blue light on week 9. If subjects awaken while the mask is on, they will be instructed to try to fall asleep again or to stay in bed with their eyes closed. The light mask will always be turned on 120 min before estimated core body temperature minimum (CBTmin); it is expected that blue light exposure will delay the timing of the CBTmin.
1650091|NCT01855126|Other|Red light|On week 6, half of the subjects will be given light masks that deliver blue light before the estimated CBTmin and the other half will be exposed to red light under identical conditions - placebo control. On week 9, the ones who experienced blue light on week 6 will experience the red light, while the ones who experienced the red light on week 6 will experience the blue light on week 9. If subjects awaken while the mask is on, they will be instructed to try to fall asleep again or to stay in bed with their eyes closed. The light mask will always be turned on 120 min before estimated CBTmin; it is expected that blue light exposure will delay the timing of the CBTmin.
1650092|NCT01855100|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Starting dose (3 weeks): 15 mg BID, then 15 mg OD or 20 mg OD.
1650093|NCT01855074|Drug|Risperidone|Risperidone 25 milligram (mg) will be given as intramuscular injection for every 2 weeks up to 6 months. Participants with persistent symptoms and/or requiring higher doses of antipsychotics will be administered higher doses of risperidone. Doses will be adjusted as per Investigator's discretion.
1650094|NCT01855061|Procedure|Biopsy|"Histological biopsy of the index lesion (a radiological measurable lesion on which biopsy is performed) at baseline, as well as when showing progressive disease. Histological biopsies will be subjected to DNA sequencing to assess the mutational profile, as well as to analysis of carboxylesterase activity."
1650095|NCT01855061|Procedure|Blood samples|Blood samples will be taken at baseline to determine patient's genetic background variation (germline DNA).
1650096|NCT01855061|Procedure|Pharmacokinetics|Blood samples will be taken for pharmacokinetic analysis of the active irinotecan metabolite (SN-38).
1650097|NCT01855061|Procedure|Midazolam clearance test|Patients who are being treated in Rotterdam will be subjected to blood draws for validation of the earlier developed midazolam phenotyping test (midazolam clearance test), which may be an indicator for pharmacokinetics of irinotecan.
1650098|NCT01855048|Biological|N-Rephasin® SAL200|continuous intravenous infusion over 60 minutes
1650099|NCT01855048|Other|INT200-Placebo|Formulation buffer for continuous intravenous infusion over 60 minutes
1650100|NCT01855035|Other|prolonged ECG monitoring|10-day Holter ECG measurement
1650101|NCT01855035|Other|standard care|Usual care according to current guidelines (minimum of 24 hours of cardiac monitoring).
1650102|NCT01855022|Behavioral|MI + IVR|Participants in the intervention group received motivational interviewing from a registered nurse who is trained and proficient in this behavioral change modality. In addition, participants were instructed to make a daily toll-free call to an automated interactive voice response (IVR) system provided by Pharos Innovations® (Chicago, IL) for 30 days after discharge from the index admission. On each call patients heard a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the IVR system was automatically downloaded to a secure Internet site for review by the nurse at each hospital location.
1650103|NCT01855009|Dietary Supplement|MannaBears|Subjects will be administered 4 MannaBears daily
1650104|NCT01855009|Dietary Supplement|AlgaeCal Calcium|Subjects will be administered 750 mg AlgaeCal Calcium
1650105|NCT01855009|Dietary Supplement|Calcium carbonate|Subjects will be administered 1000 mg calcium carbonate
1650106|NCT01855009|Dietary Supplement|Vitamin D3|Subjects will be administered 800 IU vitamin D3
1650107|NCT01854996|Drug|PF-05089771|450mg
1650108|NCT01854996|Drug|PF-05089771|450mg
1650114|NCT01854918|Biological|evolocumab (AMG 145) and standard of care|evolocumab (AMG 145) is a fully human monoclonal antibody against PCSK9. Standard of care therapy is per local practice; this could include prescribed therapies and/or dietary/exercise regimes
1650115|NCT01854918|Other|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
1650116|NCT01854905|Other|No Treatment|Patients attending consultation for LASIK on Day 1. No intervention or treatment is administered during the study.
1650117|NCT01854892|Other|Manipulation|High velocity short amplitude thrust spinal manipulation applied to the lumbar spine.
1650118|NCT01854892|Other|Mobilization|Static isometric contractions of the lumbar spine to induce spinal mobilization
1650119|NCT01854892|Other|Laser Therapy|Cold laser applied to the paravertebral muscles in the lumbar region
1650120|NCT01854866|Other|Drug-packaging microparticles|Drug-packaging microparticles are perfused to the pleural or peritoneal cavity of patients with four times per week.
1650121|NCT01854853|Behavioral|STYLE Brazil|Multifamily group HIV/STI Prevention Intervention
1650122|NCT01854853|Behavioral|Health Promotion|Health promotion intervention
1650123|NCT01854827|Drug|Intravenous immunoglobulin (IVIG)|All participants will receive the same dose of IVIG at the same intervals in an open-label fashion as long as the subject does not have any increased risk for toxicity for any IVIG infusion. IVIG will be initiated on day 3 (up to day 5) after HPE surgery (HPE is day 0) at a dose of 1 gm/kg body weight by slow intravenous infusion over at least 4 hours. The same dose (1 gm/kg) and duration of infusion will be repeated on day 30 and day 60 after HPE.
1650124|NCT01854814|Drug|Mycophenolate mofetil|Mycophenolate mofetil 1.5g/day plus maximum tolerated labeled dose losartan
1650125|NCT01854814|Drug|Losartan|Maximum tolerated labeled dose of Losartan
1650126|NCT01854801|Other|Individual medical Care|Individual medical care in occupational and environmental diseases centers
1650127|NCT01854801|Other|Individual electromagnetic exposures|During 7 days, patient hold a dosimeter measuring their electromagnetic exposures for FM, TV, GSM, DECT, WIFI, TETRA and relay antenna emissions. During this week, patients notify intensity and time of their symptoms on a self-questionary
1650128|NCT01854788|Other|Autogenic drainage|It was performed following J. Chevallier recommendations.In this trial it was considered a self-administrated technique because physiotherapist only gave oral advice in order to ensure a correct performance of the technique.
1650129|NCT01854788|Other|Slow expiration with glottis opened in lateral posture|It was performed following Postiaux´s recommendations. In this trial the technique was considered active-assisted because the physiotherapy played a role important in their execution.
1650130|NCT01854788|Other|Temporary-positive expiratory pressure|The diaphragmatic breathing was required for this technique whereas patients remain seated in front of the device with a nose clip. The inspiratory /expiratory ratio was 1:2.It was taken into account as a device-administrated technique for this trial.
1650131|NCT01854775|Drug|E/C/F/TAF|E/C/F/TAF tablets contain 150 mg of elvitegravir (EVG), 150 mg of cobicistat (COBI), 200 mg of emtricitabine (FTC), and 10 mg of tenofovir alafenamide (TAF; as 11.2 mg of TAF fumarate)
2012839|NCT01552473|Behavioral|Brain Training Program 2|The training program includes 12 sessions conducted over 8 weeks. The goal of these treatment sessions is to provide strategies to improve brain injury and its recovery process. Activities involved in the sessions include strategies and discussion of study material. Participants will be encouraged to apply the strategies and information to their daily lives. The program includes additional outside practice of the activities.
2012840|NCT01550861|Procedure|in vitro maturation|Maturation of immature oocytes in the laboratory following oocyte retrieval
1650134|NCT01854749|Drug|S1 combined with cisplatin|
1650135|NCT01854736|Drug|Grazax|GRAZAX
1650136|NCT01854736|Other|Placebo|Placebo
1650137|NCT01854723|Drug|Switching to NPH insulin|Patients in this arm will be transitioned from insulin glargine to NPH insulin with subsequent titration according to algorithm within protocol. If needed, meal-time insulin will be added during study period.
1650138|NCT01854723|Drug|Continuation of insulin glargine|Patients in this group will serve as a control group, and information will be collected regarding the safety, effectiveness, and cost of treatment for use in this study.
2012841|NCT01550861|Procedure|Polar Body Biopsy with preimplantation genetic screening|Polar body biopsy is performed on the day that the oocyte is retrieved. Microarray analysis will will be performed and compared with FISH and microarray analysis of day 3 or day 5 biopsy.
1650143|NCT01854697|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
1650144|NCT01854697|Drug|Ribavirin|Tablet
1650145|NCT01854697|Drug|Telaprevir|Film-coated tablet
1650146|NCT01854697|Drug|Pegylated Interferon alpha 2-a (PegIFN)|Pre-filled syringe
1650147|NCT01854684|Drug|Temoporfin|Given IV
1650148|NCT01854684|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
1650149|NCT01854684|Drug|Photodynamic Therapy|Undergo intraoperative PDT
1650150|NCT01854684|Other|Laboratory Biomarker Analysis|Correlative studies
1650151|NCT01854684|Other|Pharmacological Study|Correlative studies
1650152|NCT01854671|Other|family planning counseling let by community health workers|The family planning counseling sessions led by community health workers will present advantages of birth spacing, available methods of postpartum contraception, contraindications (if any) for the method, when each method can be safely started postpartum, where each method can be obtained, and importance of 6 week postpartum clinic follow-up. There will also be a take-home contraceptive method brochure given at conclusion of information session -primarily pictorial and in Arabic, to facilitate discussion at home with husbands and family members.
1650153|NCT01854658|Drug|GFF MDI (PT003)|GFF MDI administered as two puffs BID
1650154|NCT01854658|Drug|GP MDI (PT001)|GP MDI administered as two puffs BID
1650155|NCT01854658|Drug|FF MDI (PT005)|FF MDI administered as two puffs BID
1650156|NCT01854658|Drug|Placebo|
1650157|NCT01854645|Drug|GFF MDI|GFF MDI administered as two puffs Bis in Di.e. Twice Daily (BID)
1650158|NCT01854645|Drug|GP MDI|GP MDI administered as two puffs BID
1650159|NCT01854645|Drug|FF MDI|FF MDI administered as two puffs BID
1717874|NCT00002343|Drug|Rifabutin|
1650160|NCT01854645|Drug|Open-label tiotropium bromide inhalation powder (Spiriva® Handihaler®)|Taken as 1 capsule daily containing 18 µg of open-label tiotropium via the Handihaler dry powder inhaler (DPI)
1650161|NCT01854645|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID
1650162|NCT01854632|Biological|SIIL Live Attenuated Influenza Vaccine|Trivalent live-attenuated influenza vaccine 2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
1650163|NCT01854632|Biological|Matched placebo|Matched placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
1650164|NCT01854619|Device|Photodisinfection (antimicrobial photodynamic therapy, aPDT)|A 0.03% solution of methylene blue is irrigated into the involved paranasal sinus followed by placement of a saline filled balloon with a center light diffusing fiber optic. This is illuminated at 150 mW/cm2 power density for 8 minutes. This is repeated for each involved sinus.
1650165|NCT01854619|Device|Saline irrigation|The active comparator arm will receive saline irrigation via syringe that is administered using a sinus irrigation catheter under endoscopic control.
1650166|NCT01854606|Drug|AEB071|a Protein Kinase C Inhibitor
1650167|NCT01854606|Drug|Everolimus|mTOR inhibitor
1650168|NCT01854593|Drug|Bevacizumab|0.16 mg/0.05 ml bevacizumab (single injection on 1 day before operation)
1650169|NCT01854593|Procedure|Vitrectomy|vitrectomy of 25 gauge system.
1650170|NCT01854593|Device|Sham injection|Sham injection one day before vitrectomy
1650171|NCT01854567|Biological|Infusion of one MPC expanded cord unit and one unexpanded cord unit|Infusion of one MPC expanded cord unit and one unexpanded cord unit.
1650172|NCT01854567|Biological|Infusion of two unexpanded cord blood units.|Umbilical Cord Blood.
1650173|NCT01854554|Radiation|IMPT|IMPT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
1650174|NCT01854554|Radiation|IMRT|IMRT treatments delivered as once daily fractions, 5 days per week Monday - Friday for 30 treatments.
1650175|NCT01854554|Behavioral|Cognitive Tests|Cognitive tests given at baseline, 4 months, then every 2 months for 2 years.
1650176|NCT01854554|Behavioral|Questionnaires|Questionnaires about quality of life and symptoms given at baseline, 4 months, then every 2 months for 2 years.
1650177|NCT01854528|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
1650178|NCT01854528|Drug|Ribavirin|Tablet
1650179|NCT01854528|Drug|Pegylated Interferon a-2a (PegINF)|Pre-filled syringe
1650180|NCT01854528|Drug|Telaprevir|Film-coated tablet
1650181|NCT01854515|Drug|Budesonide|
1650182|NCT01854515|Drug|Dexamethasone acetate|
1650183|NCT01854502|Behavioral|Oral hygiene and fluoride use|Parents were given instructions how to brush and clean between teeth and to use fluoride toothpaste two times a day.
1650184|NCT01854502|Behavioral|Diet and use of xylitol|Parents were asked to fill in one-day diaries of their own diet in the waiting room. The dental professional pointed out the frequency of meals and snacks, as well as suggested the timing of xylitol products.
1650185|NCT01854489|Drug|Placebo|The volunteers will be given Oral placebo at 20.00 for 7 days [Phase 1 ]
1650186|NCT01854489|Drug|Rifampicin|The volunteers will be given oral rifampicin (Rimapen, Orion, Finland) 600 mg as a single daily dose at 20.00 for 7 days
1650187|NCT01854489|Drug|Buprenorphine|The volunteers will be given single dose of 0,4 mg intra venous buprenorphine or 0,6 mg sublingual buprenorphine on day 5.
2012842|NCT01536717|Drug|Articaine hydrochloride 2% solution|"4 ml/h periosteal wound infusion
duration of 72 h"
1650189|NCT01854463|Drug|Vitamin D3|2000IU per day
1650190|NCT01854463|Drug|placebo|elemental calcium 200mg per day per 24 weeks
1650191|NCT01854450|Other|Asymmetrical Lateral Decubitus|"After randomization, women are postured in pronounced lateral decubitus (side opposite to the back of the fetus), with the inferior leg in extension, and the superior leg in hyperflexion, during 1 hour (minimum 30 minutes).
Then, women are encouraged to take this posture during labor as frequently as possible if the fetus remains in occipitoposterior position"
1650192|NCT01854450|Other|control|usual obstetrical care
1650193|NCT01854437|Drug|Mg Oxide|250 mg orally for 4 weeks
1650194|NCT01854424|Other|Bronchoalveolar lavage (BAL) before day 2 , between days 5-7 and days 10-14 of evolution.|All the samples will be obtained during current care in the first week of evolution, and the last set of samples (BAL and blood sample between day 10-14) only in patients still under ventilation at this time point.
1650195|NCT01854411|Other|analgesic measure|ibuprofen and ketoprofen measured into breast milk
1650196|NCT01854398|Device|CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months.
1650197|NCT01854398|Device|sham-CPAP group|Enrolled patients are randomized to CPAP group or sham-CPAP group by 1:1 ratio. The patients in each group will undergo CPAP or sham-CPAP for 3 months. Sham CPAP consists of a CPAP machine that is modified to include a large hidden leak in the exhaust port of the mask to disperse the therapeutic pressure.
1650198|NCT01854385|Drug|Sumatriptan 100 mg|This is a single-arm, unblinded study of treatment for post-traumatic headache with the open label medication sumatriptan and is being undertaken to test necessary study instruments and procedures, establish feasibility and determine side effects in a population with complicated mild, moderate and severe TBI.
1650199|NCT01854372|Drug|R-HCVAD and R-MC|
2012843|NCT01536717|Drug|Sodium Chloride|Placebo Sodium chloride 0,9%
1650239|NCT01854021|Procedure|combined intravenous-inhalational anesthesia|combined intravenous-inhalational anesthesia
1650240|NCT01854021|Procedure|inhalational anesthesia|inhalational anesthesia
1650241|NCT01854008|Other|rehabilitation more the urban circuit|"included in a standard rehabilitation program + the urban circuit. A total of 32 urban walking circuits were developed jointly with the town hall of Mataró(124,000 in habitants)and were included in a triptych called A PEU, FEM SALUT! Itineraris urbans per Mataró http://www.mataro.cat/web/portal/ca/salut/salut_publica/itineraris/index"
1650242|NCT01854008|Other|rehabilitation program but not given urbane circuits|Only rehabilitation program and general recommendations on physical activity and lifestyle . No urbans circuits.
1717875|NCT00002344|Drug|Azithromycin|
1650201|NCT01854346|Behavioral|Social skills group training, KONTAKT|KONTAKT is a manual-based social skills group training for children with high functioning autism spectrum disorder (ASD). The program is based on cognitive behavioral therapy (CBT) principles and knowledge of social cognition. The group treatment includes exercises in social skills as well as discussions of social cognition, social interaction, self-reflection and description of themselves and others. The children are training to make contact, to understand and follow social rules, to become aware of themselves and others, to perceive verbal and nonverbal signals in a communication, to develop problem solving skills and coping strategies to manage conflict and to enhance their self-confidence. Intervention includes 12 (brief intervention) and 24 (long intervention) sessions. Each group consists of 4-8 children/adolescents ant two group leaders. The treatment are conducted in cooperation with both parents and teachers.
1650202|NCT01854333|Other|ADOS module 1-4 or ADI-R|
1650203|NCT01854320|Behavioral|Acceptance-based treatment|
1650204|NCT01854320|Behavioral|Standard behavioral treatment|
1650205|NCT01854307|Procedure|Pneumoperitoneum and SVV/PPV|
1650206|NCT01854294|Drug|GM604|GM604 treated group subject will receive a slow IV bolus injection (~1min) of 6.4 mL (320mg @50 mg/mL=6.4 mL) for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
1650207|NCT01854294|Drug|Placebo comparator|Placebo comparator group subject will receive a slow IV bolus injection (~1min) of 6.4 mL bacteriostatic saline for each dose. A total of 6 doses will be administered over two weeks (on Mondays, Wednesdays and Fridays for the first 2 weeks).
1650208|NCT01854268|Drug|Healthy adults who receive capsaicin|Participants will be seated in a comfortable chair and fitted with cotton elastic bands designed to measure changes in chest wall and abdominal movement during cough. The participant will hold a facemask attached to a pneumotachograph, nebulized, and dosimeter. The participant will receive 3 nebulized doses of 200 microMolar capsaicin through the facemask. The participants will have a minute in between each presentation and water will be available at all times.
1650209|NCT01854255|Drug|doxorubicin and cisplatin|doxorubicin and cisplatin as intraperitoneal chemotherapy
1650210|NCT01854242|Other|Glycogen Storage Disease type Ia patients|The participants will have one blood draw for this study. The test will be performed on the blood.
1650211|NCT01854229|Device|Prometra Programmable Intrathecal Infusion Pump|There are two enrollment groups (arms). One is for new patients who are going to have a Prometra Pump implanted. The other arm is for patients who were part of the IDE-study prior to FDA approval of the pump, and are willing to continue to be followed as part of a study.
1650212|NCT01854216|Drug|Rotigotine transdermal patch 1mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 1 mg / 24 hours
1650213|NCT01854216|Drug|Rotigotine transdermal patch 2 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 2 mg / 24 hours
1650214|NCT01854216|Drug|Rotigotine transdermal patch 4 mg / 24 hours|Rotigotine transdermal patch, repeated dose application over 24 hours; 4 mg / 24 hours
1650215|NCT01854203|Drug|Inductive chemotherapy + concurrent cisplatin and IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (30mg/m2，on day 1) repeated every week for 6 cycles during radiotherapy.
1650216|NCT01854203|Drug|Inductive chemotherapy + IMRT|Patients receive Gemcitabine (800mg/m2 on day 1,8) and cisplatin (80mg/m2 on day 1)of a 21 day cycle, patients received four cycles chemotherapy before the radiotherapy, then receive radical radiotherapy with IMRT.
1650217|NCT01854190|Device|WatchPAT|BP was measured by oscillometric method on automatic device. Endothelial function was assessed by peripheral arterial tonometry (PAT) by EndoPAT2000® and the OSA diagnosis also through PAT, using the portable device WatchPAT200®. Anthropometric evaluation was performed through measurements of waist, hip and neck circumference, body mass index, waist to height ratio (WHtR), and body composition assessed by bioelectrical impedance.
1650218|NCT01854177|Drug|Aprepitant|
1650219|NCT01854177|Drug|placebo|
1650220|NCT01854164|Dietary Supplement|HGE (hydrolyzed ginseng extract)|
1650221|NCT01854164|Dietary Supplement|Placebo|
1650222|NCT01854151|Other|New Labeling/Dosing Strategy|Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
1650223|NCT01854138|Device|Prevena Incision Management System|"Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Knee Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days.
Prevena Incision Management system will be applied to clean surgical wounds of patients undergoing Total Hip Arthroplasty, immediately post-operatively. The unit will remain in place and functional for 7-8 days."
2012844|NCT01535014|Drug|Dietressa|Comparison of different dosages (frequency) of drug
2012845|NCT01535014|Device|Placebo|"Placebo either (2 tablets 3 times daily) or
(1 tablet 6 times daily)"
1650226|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 6-8 of each monthly TMZ cycle (standard 200 mg/m^2 x 5 days) with group 1.
1650227|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (standard 200 mg/m^2 x 5 days) with group 2.
1650228|NCT01854099|Biological|PEP-CMV|500 µg of PEP-CMV vaccine given intradermally on day 22-24 of each monthly TMZ cycle (dose-intensified 100 mg/m^2 x 21 days) with group 3.
1650229|NCT01854086|Other|Questionnaires about compliance and persistence with bisphosphonates treatment|
1650230|NCT01854073|Drug|Hyoscine butyl bromide|
1650231|NCT01854073|Drug|Normal saline|
1650232|NCT01854047|Drug|Dupilumab|Solution for injection, Subcutaneous injection
1650233|NCT01854047|Drug|placebo|Solution for injection, Subcutaneous injection
1650234|NCT01854047|Drug|ICS/LABA therapy|Oral inhalation, Prior therapy with Mometasone furoate /formoterol, budesonide / formoterol, or fluticasone propionate / salmeterol continued at stable dose
1650235|NCT01854047|Drug|Salbutamol/albuterol|Oral inhalation as needed
1650236|NCT01854047|Drug|Levosalbutamol/levalbuterol|Oral inhalation as needed
2012846|NCT01524289|Drug|Anacetrapib|one 100 mg tablet, orally once daily for 52 weeks
2012847|NCT01524289|Drug|Placebo for Anacetrapib|one tablet, orally, once daily for 52 weeks
1650243|NCT01853995|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|New Class II Corrector
1650244|NCT01853982|Drug|Ceftolozane/Tazobactam|
1650245|NCT01853982|Drug|Piperacillin/Tazobactam|
1650246|NCT01853969|Other|Typing assessment|
1650247|NCT01853956|Drug|Alprazolam 0.25 mg|Reference product
1650248|NCT01853956|Drug|Alprazolam 0.25 mg|Test product
2012848|NCT01515774|Drug|Mirapex ER|Change Requip or Mirapex to Mirapex ER
1650250|NCT01853917|Other|questionaires and structured interviews|We will do questionaires on pregnant women before they have their baby and after they have their baby. We will do structured interviews after they have their baby
1650251|NCT01853904|Procedure|Bronchoscopy/ BAL with Channel Suction|The wall suction used for the channel suction will be set at 80 mm Hg. This arm is for patients who will receive channel suction first to obtain the specimen then syringe suction to obtain the specimen.
1650252|NCT01853904|Procedure|Bronchoscopy/BAL with Syringe Suction|Syringe based suctioning will be performed with 20mL syringe.
1650253|NCT01853891|Other|dim light at night|
2012849|NCT01511081|Radiation|SBRT (stereotactic body radiotherapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body radiotherapy (SBRT). Each treatment taking about 30-45 minutes per day.
2012850|NCT01511081|Radiation|SBPT (stereotactic body proton therapy)|50 Gy (RBE) in 4 daily treatments of stereotactic body proton therapy (SBPT). Each treatment taking about 30-45 minutes per day.
1650256|NCT01853865|Other|Instruction in self-referral|
1650257|NCT01853852|Drug|GR181413A/AT1001 solution|Powder for reconstitution
1650258|NCT01853852|Drug|GR181413A/AT1001 capsule|Size 2, hard gelatin capsule, white opaque / blue opaque
1650259|NCT01853852|Other|Potable water|Matched, Size 2, hard gelatin capsule, white opaque/blue opaque
1650260|NCT01853852|Drug|Placebo capsule|Solution matched
1650261|NCT01853826|Drug|afatinib|Patients will receive afatinib once daily
1650262|NCT01853813|Drug|Bevacizumab and FOLFIRI|"The CENTRAL trial is a biologically enriched prospective phase II clinical trial in which patients treated with first-line modified FOLFIRI and bevacizumab will be prospectively stratified according to LDH serum levels.
After written informed consent patients will be enrolled. Patients will be considered evaluable for study aim if response rate was radiologically evaluated at least once during treatment course.
Treatment will be administered until progression, patients' withdrawal of consent, unacceptable toxicity"
1650263|NCT01853800|Drug|Rivaroxaban (Xarelto, BAY59-7939)|
1650264|NCT01853787|Drug|Formoterol Fumarate|Formoterol Fumarate, one inhalation of 12 mcg via MDI (Metered Dose Inhaler) Modulite will be taken in double blind randomized way immediately after T0 evaluation.
1650265|NCT01853787|Drug|Salmeterol|Salmeterol 50 mcg via MDI (Metered Dose Inhaler), one inhalation only, immediately after T0 evaluation
1650266|NCT01853774|Behavioral|Tailored navigation|
1650267|NCT01853761|Device|Exercise after|"Aerobic exercise just after microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.
30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
1650268|NCT01853761|Device|Exercise at same time|"Aerobic exercise at the same time microcurrent in the abdominal region, intensity below the sensivity threshold and a maximum of 1 mA.
30 minutes of aerobic moderate-intensity exercise (50%VO2 max) using Karvonen´s formula, performed on a cycloergometer. Were used Borg scale (12-13) and Polar® heart monitors to control heart rate."
1650269|NCT01853761|Device|Transcutaneos|Microcurrent device in the abdominal region with four transcutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
1650270|NCT01853761|Device|percutaneous microcurrent|Microcurrent device in the abdominal region with four percutaneous electrodes in a parallel position, intensity below the sensivity threshold and a maximum of 1 mA.
1650271|NCT01853761|Device|25-10Hz|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 10 Hz.
1650272|NCT01853761|Device|25-50Hz microcurrent|microcurrent device in the abdominal whith intensity below the sensivity threshold and a maximum of 1 mA. Every 15 minutes changed from 25Hz to 50 Hz.
2012851|NCT01504672|Other|Medication review|"In the intervention, the pharmacist will evaluate:
Is there an indication for the drug?
Has the drug desired effect?
Is the dose correct and dosing scheme correct?
Side effects, contraindications, inappropriate drugs
Interactions
Treatment time
Cost effectiveness
Adherence to recommendation list
Problems with handling the drugs (for example crushing of the tablets)
Untreated indication
Double medications
Administration of drugs"
1650276|NCT01853722|Drug|DCN01|Three serial applications per periocular region.
1650277|NCT01853722|Drug|Unisol|Three serial applications per periocular region.
1650278|NCT01853709|Behavioral|Education|
1650279|NCT01853709|Other|Fiber free diet|
1650280|NCT01853709|Dietary Supplement|Adjuvants|
1650281|NCT01853709|Drug|Polyethylene glycol (PEG)|
1650282|NCT01853709|Drug|Bisacodyl|
1650283|NCT01853696|Drug|loteprednol etabonate|
1650284|NCT01853696|Drug|prednisolone acetate 1%|
1650285|NCT01853683|Procedure|Conservative Management|
1650286|NCT01853683|Procedure|Operative Management|
1650287|NCT01853670|Radiation|concurrent chemo + IGRT|
1650288|NCT01853670|Radiation|neoadjuvant chemo + IGRT|
1650289|NCT01853657|Other|Virological monitoring|
1650290|NCT01853644|Drug|Tivozanib|1.5 mg Given PO (orally)days 1-21 or every 28 day cycle
1650291|NCT01853631|Biological|CD19 CAR T Cells|"Group 1: CD19.CAR/28137ζ at 1×10^6 cells/m^2 and CD19.CAR/28ζ at 1×10^6 cells/m^2
Group 2: CD19.CAR/28137ζ at 5×10^6 cells/m^2 and CD19.CAR/28ζ at 5×10^6 cells/m^2
Group 3: CD19.CAR/28137ζ at 2×10^7 cells/m^2 and CD19.CAR/28ζ at 2×10^7 cells/m^2"
1650292|NCT01853631|Drug|Fludarabine|3 daily doses of fludarabine (30 mg/m2) will be administered finishing at least 24 hours before T cell infusion.
1650293|NCT01853631|Drug|Cyclophosphamide|3 daily doses of cyclophosphamide (500 mg/m2/day) will be administered finishing at least 24 hours before T cell infusion.
2012852|NCT01504204|Drug|Adapalene + benzoyl peroxide samples|A sample size tube of the study medication, combination adapalene 0.1% plus benzoyl peroxide 2.5% gel, will be provided with instruction on proper application, including demonstration, at the first visit.
2012853|NCT01504204|Drug|Adapalene + benzoyl peroxide from standard tube|Subjects are instructed to apply the combination adapalene 0.1% plus benzoyl peroxide 2.5% gel once daily to all affected areas.
2012854|NCT01502956|Device|InterStim® device|Eligible subjects will complete baseline assessments, be randomized and scheduled for first stage lead placement (FSLP) InterStim®. The criterion for an initial clinical response to InterStim® therapy will be defined as a ≥50% improvement in the mean number of UUIE/day on a minimum 3 day bladder diary, completed during the 7-14 days following the first stage lead placement (FSLP). Subjects with a ≥ 50% improvement mean number of UUIE/day will be eligible to proceed with implantation of the implantable pulse generator (IPG). Subjects will then be followed monthly to determine the response to therapy.
2012855|NCT01502956|Drug|Botox® injection|Eligible subjects will complete baseline assessments, be randomized and scheduled for Botox A® injection visit. Subjects who received a Botox A® injection will be assessed for a clinical response, at 1 month from injection, using the same clinical criterion (≥50% improvement in the mean number of UUIE/day on a 3 day bladder diary completed prior to the 1 month visit). Those subjects that experience a clinical response, at one month, will be eligible for a repeat Botox A® injection after 6 months, if they experience degradation of clinical effect, using the PGSC.
1650299|NCT01853605|Device|Anatomically shaped silicone gel-filled breast implants|Surgical implant
1650300|NCT01853579|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg (after 4 increments of 25μg at 3 months, 1, 2 and 3 years; from the starting dose of 50μg).
1650301|NCT01853579|Drug|Placebo|"Control patients will obtain a placebo pill of the same characteristics as the intervention drug, and mock titration will be carried out identically to the intervention drug.
Pharmaceutical composition of placebo (100 mg): Lactose monohydrate 66 mg, Maize starch 25 mg, Gelatin 5 mg, Croscarmellose sodium 3.5 mg, Magnesium stearate (vegetable source) 0.5 mg."
1650302|NCT01853566|Drug|growth hormone|GH group intervention: use of GH - initial dose of 0.5 UI/day (0.2 mg/day), with readjustments to 1.0 UI/day (0.4 mg/day) and 1.5 UI/day (0.6 mg/day) after 1 and 2 months of treatment, respectively. The last GH dose will be maintained until the end of the study. These GH dosages were based on the dose used for adults of the same age with GHD. Subjects will be re-evaluated after 6 months of GH therapy or placebo according to muscle strength and body composition .The other group received placebo using the same scheme as the GH group.
1650303|NCT01853553|Drug|Spironolactone|
1650304|NCT01853553|Drug|Sugar pill|
2012856|NCT01498445|Drug|Dasatinib|Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
1650307|NCT01853488|Radiation|DXA|Osteodensitometry
1650308|NCT01853488|Radiation|pQCT|Osteodensitometry
1650309|NCT01853475|Drug|PQP tablets 960mg|Piperaquine phosphate tablets 960mg
1650310|NCT01853475|Drug|PQP tablets 1440mg|Piperaquine phosphate tablets 1440mg
1650311|NCT01853475|Drug|OZ439+TPGS 800mg|OZ439+TPGS prototype formulation 800mg
1650312|NCT01853475|Drug|OZ439 PIB 800mg|OZ439 Powder in Bottle Aqueous Solution 800mg
1650315|NCT01853449|Drug|Fentanyl Citrate|
1650316|NCT01853449|Other|CWS|Chest wall strapping to reduce vital capacity by 20% of its baseline value
1650317|NCT01853449|Drug|Placebo|0.9% saline
1650318|NCT01853436|Device|Strattice™ Reconstructive Tissue Matrix|Experimental arm: Device: Strattice Reconstructive Tissue Matrix Unilateral or bilateral mastectomy. Immediate breast reconstruction with sub-pectoralis muscle placement of a breast implant with ADM, single stage reconstruction technique. Control arm: Device: no device. Immediate breast tissue expander/implant based reconstruction with a two-stage reconstruction technique.
1650319|NCT01853423|Drug|Rapamune|Small amount of 0.1% rapamune ointment applied topically to affected facial areas twice daily for the first two weeks, then once daily.
1650320|NCT01853410|Device|gekoTM|
1650321|NCT01853397|Device|Liposonix System (Model 2)|
1650322|NCT01853384|Biological|HP802-247|Study Dosage / Usage: 260 µL (130 µL, one spray, of each solution) containing 0.5 X 10(6th) cells per mL every 14 days.
1650323|NCT01853384|Other|HP802-247 Vehicle|HP802-247 Vehicle consists of two separate components, a fibrinogen solution (Component 1) and a cell free thrombin solution which is identical to Component 2 except that no keratinocytes and no fibroblasts are present. A single dose is created when combined on the wound surface.
1650324|NCT01853371|Procedure|Wet cupping|Wet cupping is the process of using a vacuum at different points on the body in order to gather the blood in that area. Then apply few superficial incisions (small, light scratches using a razor) on those areas, followed by repeating the vacuum on the same areas in order to remove 'harmful' blood which lies just beneath the surface of the skin. In this study, the wet cupping procedure was not done on certain days of the lunar month.
1650325|NCT01853371|Other|Conventional treatment|According to Saudi Hypertension management guidelines, hypertension patients may require life style modification alone , especially for newly diagnosed cases, or my require life style modification and drug treatment. This will be decided by the treating team in the hospital.
1650326|NCT01853358|Biological|NK Cell infusion|"level 1: 1 x 10e6 NK cells /kg;
level 2: 5 x 10e6 NK cells /kg;
level 3: > 5.10e6 and ≤ 5.10e7 cellules NK/kg"
1650328|NCT01853306|Drug|Veliparib|veliparib
1650329|NCT01853293|Drug|Kudzu extract|
1650330|NCT01853293|Drug|Placebo|
1650397|NCT01852747|Procedure|Multilevel Spinal fusion with Actifuse ABX®|Multilevel spinal fusion as treatment for adult spinal deformity with Actifuse ABX®. Actifuse ABX® is a silicate substituted calcium phosphate bone void filler intended for orthopedic applications such as a filler for gaps and voids that are not intrinsic to the stability of the bony structure.
1650627|NCT01850862|Other|Orientation (without exercise)|Orientation about osteoarthritis disease but without any exercise program
1650331|NCT01853293|Behavioral|Medical Management|Medical Management is a manualized treatment deriving from a number of empirically tested manualized therapies designed to approximate a primary care approach to alcohol dependence. The treatment, delivered by a medical professional (i.e., nurse or physician), monitors medication side effects, provides strategies to increase medication adherence and supports abstinence through psychoeducation and referral to groups such as Alcoholics Anonymous. The visits allow for assessments of drinking, overall functioning, medication adherence, and side effects. Also at one of these weekly visits, a blood sample will be taken for liver function tests (GGT, ALT, AST). Samples will be further analyzed for two measures of heavy drinking: carbohydrate deficient transferrin (CDT) and phosphatidylethanol (PEth).
2012857|NCT01498445|Drug|Decitabine|Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
2012858|NCT01498445|Drug|Decitabine|Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
1650334|NCT01853267|Procedure|Intervention Group (Non-Packing)|The haemostatic pack placed in the perianal abscess cavity will be removed on discharge and the wound will be left to heal without packing in situ
1650335|NCT01853267|Procedure|Control group (Packing)|After the procedure the abscess cavity will be packed with a non-adherent dressing as per standard treatment and the packing changed at regular intervals in the community until healing by secondary intention is complete.
1650336|NCT01853254|Drug|Peginterferon alfa-2a|Both combination and monotherapy for both genotype 2/3 and genotype non-2/3: 180 μg subcutaneously once weekly.
1650337|NCT01853254|Drug|Ribavirin|For genotype 2/3, 800 mg orally daily, in 2 split doses for 24 weeks. For genotype non-2/3, 1000 mg orally daily for participants weighing < 75 kg or 1200 mg orally daily for participants weighing ≥ 75 kg, in 2 split doses, for 48 weeks.
1650338|NCT01853241|Procedure|Single Balloon|All patients in this group will undergo single balloon enteroscopy
1650339|NCT01853241|Procedure|Spirus|All patients in this group will undergo Spirus Enteroscopy
1650340|NCT01853228|Drug|Phase1 and Phase 2: decitabine|20 mg/m2 administered by intravenous infusion over 1 hour once daily for 5 consecutive days (Day 1 to Day 5 of 28-day cycle)
1650341|NCT01853228|Drug|Phase 1: cytarabine|1 g/m2, 2 g/m2, and 1.5 g/m2 dose levels administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle) for the determination of the maximum tolerated dose
1650342|NCT01853228|Drug|Phase 2: cytarabine|Phase 1 maximum tolerated dose administered by intravenous infusion over 4 hours daily for 5 consecutive days (Day 8 to Day 12 of 28-day cycle)
1650343|NCT01853215|Device|T.A.L.O.N. Intraosseous System|intraosseous catheter for use in the sternum
1650344|NCT01853202|Behavioral|Supervised aerobic exercise training|
1650345|NCT01853189|Other|OMT + Usual Care|patients from this group received 6 sessions of OMT
1650346|NCT01853189|Other|Usual Care|patients from control group received standard care + osteopathic evaluation only, according to the same schedule of the study group
1650347|NCT01853176|Drug|Liposomal Injection Bupivacaine (Exparel)|
1650348|NCT01853176|Drug|Standard bupivicaine|
1650349|NCT01853163|Procedure|Gadolinium analysis in bone and tissue samples|Gadolinium analysis in bone and tissue samples from patients undergoing an orthopaedic surgical procedure who had received Gadolinium-containing contrast agents in the past.
1650350|NCT01853150|Device|rTMS Motor cortex|
1650351|NCT01853150|Device|rTMS Supplementary motor area|
2012859|NCT01496846|Drug|IANB Articaine|IANB anesthesia given with 1.7cc of 4% articaine, 1:100,000 epinephrine.
1650353|NCT01853124|Drug|Placebo|All patients in this arm of the study will take 1 sachet containing inactive ingredients (maltodextrin, magnesium stearate, and ascorbic acid) twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total of 2 sachets per day for 5 days.
1650354|NCT01853124|Drug|Lacidofil|All patients in this arm of the study will take 1 sachet twice daily for 5 days. Each sachet will contain a minimum of 4 billion colony-forming units (CFU) of Lactobacillus rhamnosus Rosell-11 (95%) and L. helveticus Rosell-52 (5%). The total weight of all ingredients is 1 gm. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Total daily dose = 8 billion CFU x 5 days.
1650356|NCT01853098|Behavioral|Positive Affect Training (PAT)|During the PAT sessions, the participants will be taught the basics of mindfulness and how to concentrate their thoughts and feelings on the present moment in a non-judgmental fashion. As the therapy sessions continue, participants will be introduced to basic loving-kindness meditation (LKM). They will be taught to identify and focus the positive feelings they have when they are around someone or something they care about, and transfer these feelings first to themselves, then to a close friend, to a neutral individual, to people whom they dislike, and finally to all living beings.
1650357|NCT01853085|Drug|Bimatoprost Ophthalmic Solution|Patients with primary open angle glaucoma (POAG) or ocular hypertension (OHT) treated with Lumigan® UD (bimatoprost ophthalmic solution) administered in accordance with physician standard practice for up to 12 weeks.
1650358|NCT01853072|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Test intervention
1650359|NCT01853072|Other|Nepafenac vehicle|Inactive ingredients used as placebo comparator
1650360|NCT01853072|Drug|Prednisolone acetate|1 drop instilled in the operative eye 4 times daily beginning post-operatively on the day of surgery for the first 2 weeks, followed by 2 times daily for the next 2 weeks
1650361|NCT01853046|Drug|Regorafenib (Stivarga, BAY73-4506)|Regorafenib 160 mg o.d. will be administered as a single dose on Day 1 of Stage 1 followed by multiple dosing in an intermittent administration schedule (3 week-on/1 week-off) over 2 cycles in Stage 2 (56 days, cycle defined as 28 days)
1650362|NCT01853033|Biological|ABT-122|Injection
1650363|NCT01853033|Biological|Placebo|Placebo Injection
1650398|NCT01852734|Procedure|embolizations ,uterine fibroid|"26 patients will be treat with Bead-block microspheres, 500-700 and 700-900µm until flow stop (  cut the tree appearance)
26 patients will be treat with Embosphere, 500-700µm and /or 700-900 until near stasis  flow stop"
1650399|NCT01852734|Procedure|embolizations|comparison between the two microspheres
1650628|NCT01850849|Drug|LEO 39652 cream|
1650364|NCT01853020|Drug|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70 kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.
Low Dose (0.015 mg/kg = 1.05 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ¼ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.
Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately ½ of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
1650365|NCT01853020|Drug|Placebo|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes.
1650366|NCT01853007|Behavioral|COACH Program|
1650367|NCT01852994|Drug|Testosterone replacement|Application quarterly of Testosterone Undecylate
1650368|NCT01852994|Other|Exercise training|Aerobic and strength exercise training
1650369|NCT01852981|Behavioral|Lifestyle counseling|Strategies consisted of group discussion, some physical activities, phone support, and printed materials. The content and strategies were elaborated by a team formed by a doctor, nutritionists, a psychologist, and physical education professionals and the main aim was to promote the engagement in physical activity, working not only on behavioral change but also on the environment attributes available for physical activity practice. The main strategy was the group discussion, which sessions lasted 120 minutes each and its frequency changed as follow: in the first month they were weekly; in the second occurred twice per month; and in the third month onwards sessions were monthly. All sessions occurred in the Primary Health Unit or inside a community association building.
1650370|NCT01852981|Behavioral|Supervised exercise|Supervised exercise program in groups. Individuals in this program participated in three weekly structured and supervised sessions of aerobic, strength, and stretching exercises, drawn up in accordance to the American College of Sports Medicine recommendations. Load, intensity, and exercise adjustments were made during the program. All sessions lasted 60 minutes each and occurred in a gymnasium nearby the Primary Health Unit.
1650371|NCT01852955|Drug|IV acetaminophen|Administration of IV acetaminophen 1000 mg over 15 minutes at the start of surgical closure
1650372|NCT01852955|Drug|Placebo|Administration of placebo (sterile normal saline)group-same volume of saline solution administered in the same fashion as the acetaminophen
1650373|NCT01852942|Drug|Losartan|We will start with 50 mg of losartan by mouth daily. We will increase the dosage to 100 mg by mouth daily after 14 days. The maximal tolerable dosage (up to 100mg by mouth daily) will be continued for a total of 30 months.
1650374|NCT01852942|Drug|Placebo|one tablet by mouth daily
1650375|NCT01852929|Other|Subject using usual positive airway pressure therapy while sleeping for one night|Participants use their usual positive airway pressure therapy while sleeping overnight
1650376|NCT01852916|Device|CPAP|Nasal Continuous Positive Airway Pressure Ventilation using Infant Flow CPAP machine
1650377|NCT01852916|Device|NHFOV|Nasal High Frequency Oscillatory Ventilation
1650378|NCT01852903|Dietary Supplement|calcium ascorbate|
1650379|NCT01852903|Dietary Supplement|ascorbic acid|
1650380|NCT01852903|Other|placebo|
1650381|NCT01852890|Drug|Ascorbate|Intravenous infusion of high-dose ascorbate
1650382|NCT01852890|Drug|Gemcitabine|Intravenous chemotherapeutic
1650383|NCT01852890|Radiation|Radiation therapy|
1650384|NCT01852877|Behavioral|Corrections case management|Corrections case management is a long-term (18-24 months) program that seeks to improve the linkage of HIV-positive persons recently released from jail or prison to community-based HIV care, retain them in care, and reduce recidivism. Compared to the long-standing Ryan White case management program, corrections case management has greater access to housing and a greater emphasis on employment. Clients completing the program are then linked to the Ryan White case management program.
1650385|NCT01852864|Drug|240mg degarelix s.c. injection|7 days prior to radical prostatectomy the patient will have a subcutaneous injection of 240mg degarelix.
1650386|NCT01852851|Behavioral|Employment and Arthritis: Making it Work|A ten week on-line eLearning program designed to help people with inflammatory arthritis stay employed. The program consists of 1) 5 interactive web-based eLearning modules that participants will complete individually in between the weekly group sessions, 2) 5 weekly group sessions conducted as virtual real-time web-based group meetings led by a trained facilitator, 3) asynchronous communications such as a message board to facilitate additional interactions among participants, 4) consultations with an occupational therapist (in-person)for an ergonomic assessment, and a vocational rehabilitation counsellor (on-line consultation using web technology) for job retention vocational counselling.
1650387|NCT01852825|Biological|MK-8237|A single tablet of MK-8237 with 12 DU, administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
1650388|NCT01852825|Other|Placebo|A single placebo tablet administered sublingually, at approximately the same time each day for 84 days (+/- 5 days)
1650389|NCT01852825|Biological|NAC|0.1 mL fixed volume of 10,000 BU/mL of HDM extract is delivered with a Pfeiffer Bidose Nasal Delivery System (or equivalent) to each nostril for a total dose of 1800 BU at the start of Part 1; and in Part 2 on Days -14, 56 and 84
1650390|NCT01852812|Drug|Montelukast Oral Granules (OG)|Montelukast 4 mg in one sachet
1650391|NCT01852812|Drug|Montelukast Chewable Tablets (CT)|Montelukast 5 mg in one tablet
2012860|NCT01496846|Drug|SUP Articaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 4% articaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
1650393|NCT01852786|Other|Contraceptives, Oral, Combined|• The women, presenting for hormonal contraception use and with no contraindications for hormonal therapy, one of the two medicines registered in Lithuania will be administered׃ Daylette (20 micrograms of Ethinylestradiol and 3 mg of Drospirenone) or Lindynette (20 micrograms of Ethinylestradiol and 75 micrograms of Gestoden).
1650394|NCT01852786|Other|Controls|The women, The women presenting for non-hormonal contraception use, will be recommended BCM or NFPM.
1650395|NCT01852773|Procedure|Open repair of thoracic aorta injury|open surgical management of aortic injury
1650396|NCT01852773|Procedure|TEVAR|Use of endovascular (minimally invasive) techniques for repair of aortic injury
2012861|NCT01496846|Drug|SUP Lidocaine|After unsuccessful IANB with articaine, proceed to give 1.7cc of 2% lidocaine with 1:100,000 epinephrine in buccal mucosa as a supplemental infiltration injection (SUP).
1650400|NCT01852721|Behavioral|Experimental: Men and Mediterranean diet|The 12-week nutritional education program will include 3 group sessions with 8-12 participants per group. During the 1st group session, the registered dietitian (RD) will explain the major principles of the Mediterranean diet (MedDiet) and related heath benefits. At week 4, subjects will be invited to a Mediterranean cooking lesson. At week 8, the group session will address barriers and difficulties in adhering to the recommendations. Individual sessions will take place at weeks 1, 5 and 10 in order to evaluate the dietary changes and to select further individualized objectives for increasing the adherence to the MedDiet. The RD will encourage participants to make their own decision about changes while promoting their autonomy and competence. Qualitative 24-h recalls will be performed by telephone at weeks 3, 6, 9 and 12 to reinforce key principles of the MedDiet. No further contact with the RD will be offered during the follow-up period.
1650401|NCT01852721|Behavioral|Experimental: Women and Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women adherence to the Mediterranean diet.
1650402|NCT01852695|Behavioral|Family Integrated Care|Parents are integrated into the care of their infants in the NICU. Parents consent to spending up to eight hours a day with their infant, attend special education sessions, participate in daily medical rounds, and do basic infant charting. This will enable parents to provide care for infants with nursing supervision in the areas of feeding, bathing, dressing and holding skin to skin.
1650403|NCT01852682|Drug|PA21|
1650404|NCT01852669|Procedure|Inversion|Patients inverted 30 degree head down in Trendelenburg position
1650405|NCT01852669|Procedure|Shock Wave Lithotripsy|Shock wave lithotripsy
1650406|NCT01852669|Drug|Hydration|Hydration of patient with 0.5L NaCl and 20mg frusemide IV
1650407|NCT01852656|Behavioral|Postcard and IVR Reminder Group|"IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012."
1650408|NCT01852656|Behavioral|Postcard Only Reminder Group|Postcard: The postcard will be sent as a single postcard to each individual on the list. The postcard will be sent to the home address of the member. If the postcard is returned, due to an inaccurate address, the postcard will not be re-sent. The postcard does not identify that the member has a chronic health condition such as asthma or COPD. The postcard will be mailed during the last two weeks of September, 2012.
1650409|NCT01852656|Behavioral|IVR Only Reminder Group|IVR: Subjects in this reminder group will receive an automated telephone call to their primary telephone number. A total of 2 call attempts per member will be made. The IVR system will provide a message about the importance of annual influenza vaccination. The member can also request additional information about influenza vaccination and influenza vaccination locations and times.
1650410|NCT01852643|Procedure|Spreader graft|Spreader graft technique is performed by a group of expert surgeons.
1650411|NCT01852643|Procedure|Lateral crural overlay|Lateral crural overlay technique is performed by a group of expert surgeons.
1650412|NCT01852630|Drug|cefepime + Albumin|cefepime + Albumin will be given for 2 days
1650413|NCT01852630|Drug|Imipenem + Albumin|Imipenem + Albumin will be given for 2 days.
1650414|NCT01852617|Behavioral|Training in smoking cessation counseling|"Midwife facilitators in the intervention clinics will be identified and trained to deliver the 5 A's to pregnant women and will then disseminate and implement the program. The 5 A's (Ask, Advise, Assess, Assist, Arrange) is a strategy consisting of a brief cessation counseling session of 5-15 minutes delivered by a trained provider, which is considered the standard of care worldwide"
1650415|NCT01852604|Drug|Samatasvir|Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.
1650416|NCT01852604|Drug|Simeprevir|Simeprevir will be supplied as 75 and 150 mg oral capsules.
1650417|NCT01852604|Drug|Ribavirin (RBV)|Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.
1650418|NCT01852604|Drug|TMC647055|TMC647055 will be supplied as 150 mg oral capsules.
1650419|NCT01852604|Drug|Ritonavir (RTV)|Ritonavir will be supplied as 80 mg/mL oral solution.
1650420|NCT01852604|Biological|Pegylated interferon (Peg-IFN)|Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.
1650421|NCT01852604|Other|Samatasvir matching placebo|Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.
1650422|NCT01852591|Biological|PCV 13|
1650423|NCT01852578|Drug|Cabazitaxel|Cabazitaxel: 25 mg/m² i.v over 1 h on day 1. Cycles repeated ever 3 weeks
1650424|NCT01852565|Drug|Darapladib|Enteric coated, free base (micronized) white round tablet, 160mg, Oral/repeat dose/10 days (Treatment Period 1), 14 days (Treatment Period 2)
1650425|NCT01852565|Drug|Diltiazem|Extended release, Blue capsule imprinted with cardizem CD and 240mg on one end, 240 mg, Oral/repeat dose/17 days
1650426|NCT01852552|Device|transcatheter aortic valve implantation|Patients undergoing TAVI with transfemoral, transapical, or any other vascular access
1650427|NCT01852552|Procedure|Aortic Valve Replacement|Surgical AVR, with all kind of commercially available prosthesis (stented, stentless, mechanical)
1650428|NCT01852539|Drug|dexmedetomidine|The dose of dexmedetomidine was determined by modified Dixon's up-and-down method, starting from 0.5 μg/kg (0.1 μg/kg as a step size).
1650429|NCT01852539|Drug|propofol|Propofol 2.0 mg/kg was administrated
1650430|NCT01852539|Device|laryngeal mask airway (LMA)|The insertion of laryngeal mask airway (LMA) was attempted, after confirming the loss of eyelash reflex,the bispectral index (BIS) score decreased below 60.
1650542|NCT01851590|Drug|Terbinafine|250 mg of Terbinafine is taken orally once daily for 3 months (Generics) in toenail onychomycosis.
1650629|NCT01850849|Drug|cream vehicle|
1650431|NCT01852526|Device|Experimental: hybrid system|The intervention group will receive a hybrid system with PLIF and a flexible pedicle screw system above the fusion. Surgery will be performed using the following devices (Dynamic Rod® Hersteller: AESCULAP AG, Tuttlingen
1650432|NCT01852526|Device|Active Comparator: Plif|monosegmental PLIF
2012862|NCT01492192|Drug|18F-RGD-PET-CT and perfusion CT scans on 3 occasions|"Fluciclatide (GE Healthcare) (AH111585) is a small cyclic peptide containing the RGD tripeptide (figure 1), which preferentially binds with high affinity to α¬vβ3 integrins that are up-regulated in angiogenesis.
The IMP is supplied as a solution for injection, 400 MBq at the reference date and time. Participants will receive one injection of the imaging agent at this dose on 3 occasions"
2012863|NCT01483066|Device|ShapeMatch Technology|ShapeMatch Technology places a plastic cutting guide on the end of the femur and tibia, so that cuts that do not automatically default to the mechanical axis, but rather attempt to recreate the patient's anatomic alignment.
1650435|NCT01852500|Other|Sham Osteopathic Manipulative Treatment|Patients from this group received sham osteopathic treatments twice a week for the entire length of stay in the unit.
1650436|NCT01852500|Other|Standard care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
1650437|NCT01852487|Dietary Supplement|400mg /day during 6 months|
1650438|NCT01852474|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will receive tDCS stimulation 1x per day for 5 days (over the period of 1 week). Each session will be 20 minutes long. The subject will receive active stimulation for the entire 20 minutes.
1650439|NCT01852461|Drug|Beractant|Beractant;both initial and subsequent dosing is 100 mg/kg (4 mL/kg), which may be given every 6 hours up to four total doses
1650440|NCT01852461|Drug|Poractant alfa|porcine lung extract, initial dosing is 200 mg/kg (2.5 mL/kg) and repeated dosing is given at 100 mg/kg (1.25 mL/kg) every 12 hours, up to maximum of two additional doses when indicated
1650441|NCT01852448|Genetic|Blood or Saliva Sample Collection|A blood or saliva sample will be obtained for genotyping of TCF7L2 and approximately ten other genes implicated in type 2 diabetes.
1650442|NCT01852448|Other|Glucose -potentiated arginine (GPA) stimulation tests|Glucose -potentiated arginine (GPA) stimulation tests and mixed meal tolerance tests (MMTT) will be performed on two separate days in the outpatient setting.
1650443|NCT01852435|Drug|R-CEOP-70|
1650444|NCT01852435|Drug|R-CEOP-90|
1650445|NCT01852435|Drug|R-CHOP-50|
1650446|NCT01852409|Drug|bevacizumab|
1650447|NCT01852396|Procedure|Retroclavicular block|Retroclavicular approach ultrasound guided regional anesthesia
1650448|NCT01852383|Drug|Duloxetine|"Patients were evaluated weekly for the first 6 weeks and every two weeks for the next 6 weeks. At 0, 1, 4, 8, and 12 weeks, the study psychiatrist completed the Cornell Dysthymia Rating Scale , Clinical Global Impression (CGI) scale, and side effect ratings using the Treatment Emergent Symptom Scale. The research rater completed a SCID-P at baseline and the 24-item HAM-D at each visit, and the patient completed the Beck Depression Inventory-II at each visit.
Adverse events: All adverse events and serious adverse events were documented.
The maximum duration of delay before active treatment (medication or psychotherapy) was 1 week.
Dropout: Patients who had a CGI score of 6 or 7 for two weeks during the second half of the study were dropped by the investigator from the trial."
2012864|NCT01477489|Drug|Veliparib|Starting dose of veliparib will be 50 mg taken twice daily and will escalate up to a possible 200 mg twice daily.
1650450|NCT01852357|Other|Neurofeedback|The intervention will be 24 sessions of beta/sensorimotor rhythm (SMR) neurofeedback.
1650451|NCT01852357|Other|Sham Neurofeedback|Feedback generated by data not associated with the current participant.
1650452|NCT01852344|Drug|Methylphenidate|20 mgs of methylphenidate or placebo to be administered one hour before task performance
1650453|NCT01852344|Drug|Placebo|20 mgs of methylphenidate or a placebo to be administered one hour before task performance
1650454|NCT01852331|Drug|PGD granules|The preparation of Peony-Glycyrrhiza Decoction (PGD) granules is in compliance with Pharmacopoeia of the People's Republic of China and Good Manufacturing Practice (GMP). Briefly, sliced, broiled Paeoniae Alba Radix and Glycyrrhizae Radix in a ratio of 1:1 in weight will be immersed and boiled in an 8-fold volume of distilled water for 2.5 hours. This process will be repeated twice. The extract solution will be pooled and concentrated into granule form. Weight of the resulting granules contained in two 9g-sachet packs (to be taken in one day) is equivalent to 45 g raw herbal materials which are supplied for one day.
1650455|NCT01852331|Drug|Placebo|The placebo granules are prepared to be identical to PGD granules in smell, taste and color.
1650456|NCT01852318|Drug|pregabalin 75mg daily for 12 weeks|oral pregabalin 75mg daily for 12 weeks
1650457|NCT01852318|Drug|fexofenadine 60 mg daily for 12 weeks|fexofenadine 60 mg daily for 12 weeks
1650458|NCT01852318|Drug|placebo|
2012865|NCT01477489|Radiation|Standard radiation treatment|Limited to 60 Gy.
2012866|NCT01463644|Drug|Mepolizumab|This is an anti IL-5 which is given once a month intravenously at the dose of 750 mg.
1650461|NCT01852292|Drug|Paclitaxel|
1650462|NCT01852292|Drug|Buparlisib|
1650463|NCT01852292|Drug|Buparlisib Placebo|
1650464|NCT01852279|Device|BCI-FES|Brain computer Interface delivered Function Electrical Stimulation
1650465|NCT01852279|Device|Passive muscle stimulation|Functional Electrical stimulation delivered by therapist
1650466|NCT01852266|Biological|RSV cps2 Vaccine|10^5.3 plaque forming units (PFUs) of RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
1650467|NCT01852266|Biological|Placebo Vaccine|Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).
1650468|NCT01852253|Procedure|2% chlorhexidine|
1650469|NCT01852253|Procedure|0.12% chlorhexidine|
1650470|NCT01852214|Drug|Prasugrel|Patients receiving prasugrel will be treated with 60mg loading dose and 10mg maintenance dose
1650471|NCT01852214|Drug|Ticagrelor|Patients receiving ticagrelor will be treated with a 180mg loading dose and 90mg bid maintenance dose
1650626|NCT01850862|Other|Collective group exercise program in patients with KOA|
1650630|NCT01850836|Procedure|repetitive transcranial magnetic stimulation|
2012867|NCT01463644|Drug|placebo|The placebo will consist of 100 mL normal saline solution (0.9%, 154 mmol/L sodium chloride).
1650472|NCT01852201|Device|Endovascular Mechanical Thrombectomy|Endovascular intervention can be performed under either general anesthesia or conscious sedation based on best practices as determined by treating physician. Attempt should be made to expedite the transition from imaging to treatment in as rapid a fashion as possible. The subject should be prepared for the planned interventional procedure according to standard hospital procedures. Mechanical revascularization should be performed with the operators standard thrombectomy technique using aspiration or a stent retriever, separately or in combination.
1650473|NCT01852188|Other|Type of glove used for intrapartum vaginal exams|Patients will be randomized to either sterile or clean gloves during intrapartum vaginal exams.
1650474|NCT01852175|Drug|Prasugrel|Prasugrel 60mg loading dose and 10mg maintenance dose
1650475|NCT01852175|Drug|Ticagrelor|Ticagrelor 180mg loading dose and 90mg bid maintenance dose
1650476|NCT01852162|Drug|Dabigatran|Dabigatran 150mg
1650477|NCT01852162|Drug|Placebo|Matching placebo tablets
1650478|NCT01852149|Device|MPAS Implant|The Mitralign System consists of a set of catheters that enable the physician to position and place sutures and anchors through the posterior (back) annulus of the mitral valve under the guidance of echocardiography and fluoroscopy. Once the anchored sutures are in place, the sutures are pulled together. When the valve leaflets are close together, the sutures are locked with at least one stainless steel lock. The Bident Translation Catheter allows implantation of two pairs of pledgets. Each pair of pledgets plicates the annulus and then the pledgets are locked together from the ventricular side with a lock.
1650479|NCT01852136|Device|BD NEXT 31G x 5 mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
1650480|NCT01852136|Device|BD NEXT 31G x 8mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
1650481|NCT01852136|Device|BD NEXT 32G x 4mm pen needle|Each pen needle type will be used for approximately one week. Subjects will use their current pen injector device.
1650482|NCT01852123|Device|High-sensitivity troponin I assay|
1650483|NCT01852110|Drug|MK-7622|MK-7622 capsule
1650484|NCT01852110|Drug|Placebo|Matching placebo to MK-7622 capsule
1650485|NCT01852110|Drug|AChEI|One of the following AChEIs, as prescribed by the participant's primary care physician: donepezil, 10 mg total daily dose administered orally; rivastigmine, 9.5 or 13.3 mg/24 hours administered by transdermal patch or 6-12 mg total daily dose administered orally; galantamine, 16-24 mg total daily dose administered orally
1650486|NCT01852097|Behavioral|CBT based online intervention to elicit and address perceptual and practical barriers to taking medication.|"The general approach to the intervention is the following:
Assess and profile individual perceptual and practical barriers to medication for IBD using validated questionnaires.
Give feedback to individuals on their questionnaire responses.
Provide individualised advice to address doubts, misconceptions and concerns for currently prescribed medications.
Provide advice on overcoming practical barriers.
Send motivational messages (and reminders if applicable) by email or text based on the unique profile of each participant.
Provide information about how to raise concerns with medical practitioners and how to get the most from a medical consultation."
1650487|NCT01852071|Genetic|EFS-ADA transduced CD34+ cells from the bone marrow|Eligible subjects will undergo bone marrow harvest under general anesthesia. The marrow will be processed to isolate CD34+ cells and transduced with the EFS-ADA lentiviral vector. If sufficient cells are obtained, the subjects will undergo marrow cytoreduction with busulfan (4 mg/kg). If the transduced CD34+ final cell product meets all release criteria, the cells will be infused intravenously. PEG-ADA enzyme replacement therapy will be discontinued at day +30. After discharge from the hospital, the subject will be seen for interval history and examination by either their home physician, the principal investigator or a clinical investigator and have blood drawn at months 1, 2, 3, 4, 5, 6, 8, 10, 12, 15, 18, 21, and 24.
1650488|NCT01852058|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injected into the detrusor wall on Day 1. Treatments are readministered as needed with a minimum 12 week interval between doses.
1650490|NCT01852032|Radiation|Computed Tomography and Mammography and Tomosynthesis|Computed Tomography and Mammography and Tomosynthesis
1650491|NCT01852019|Drug|Cangrelor|Cangrelor IV administered as a 30 µg/kg bolus, followed by 4 µg/kg/min infusion for two hours on study Days 1 and 8
1650492|NCT01852019|Drug|Prasugrel|"Day 1: Subjects received prasugrel (60 mg) either during the initial cangrelor infusion (at 1.0 hours or 1.5 hours after infusion start) or within 5 minutes of discontinuing the cangrelor infusion.
Subjects will be given either 5 or 6 additional 10-mg doses to be taken every 24 hours between Day 1 and Day 8."
1650493|NCT01852006|Device|Abdominal Binder|Abdominal Binding to increase end-expiratory gastric pressure by 5-8 centimetres of water at rest.
1650494|NCT01851993|Drug|Ondansetron|
1650495|NCT01851993|Drug|Placebo|0.9% saline
1650496|NCT01851980|Other|CWS|Chest wall strapping to reduced vital capacity by 20% of its baseline value
1650497|NCT01851980|Drug|Furosemide|40 mg and 120 mg
1650498|NCT01851980|Drug|Placebo|0.9% saline
1650499|NCT01851967|Other|MoodGYM|MoodGYM, a publicly-available online CBT program developed by the Centre for Mental Health Research at The Australian National University has been shown by multiple studies to be effective in reducing symptoms of depression. MoodGYM consists of five interactive modules. Participants will be asked to complete one module each week and progress through the program sequentially.
1650500|NCT01851954|Drug|Clarithromycin|IV clarithromycin infusion
1650501|NCT01851941|Drug|mFOLFOX6 (folinic acid, 5-fluorouracil, and oxaliplatin )|Modified FOLFOX6 regimen consists of oxaliplatin 100 mg/m2 and FA 100 mg/m2 given as a 2 hour intravenous infusion, followed by 5-FU 2.4 g/m2 given as a continuous infusion over 46 hour, which is repeated every 2 weeks. Patients receive 4 cycles of neoadjuvant modified FOLFOX6 followed by curative radical surgery with D2 dissection and 4 cycles of adjuvant modified FOLFOX6.
1650502|NCT01851915|Behavioral|Cognitive Behavioral Therapy|14 sessions psychological treatment for depression
1650503|NCT01851915|Behavioral|Interpersonal Psychotherapy (IPT)|14 sessions psychological treatment for depression
1650504|NCT01851876|Device|Endometrial injury|Endometrial injury with Endometrial Suction Curette (pipelle) will be performed.
1650505|NCT01851863|Drug|Omeprazole|Prescribe Omeprazole(20mg, po, qd, 30min before breakfast).
1650506|NCT01851863|Drug|Flupentixol-Melitracen(psychological and GI) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast).The patients were told that: GI symptoms in FD are attributable to both psychological and GI mechanisms. Flupentixol-Melitracen relieves FD symptoms through both psychological and GI mechanisms.
1650507|NCT01851863|Drug|Flupentixol-Melitracen(psychological) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told that: GI symptoms were attributable to somatization of their psychological problems; and Flupentixol-Melitracen is an antipsychotic drug and primarily acts centrally to alleviate FD symptoms by regulating the psychological condition.
1650508|NCT01851863|Drug|Flupentixol-Melitracen(without explanation) + Omeprazole|Prescribe Flupentixol and Melitracen Tablets(one tablet, po, qd, 1 hour after breakfast) and Omeprazole (20mg, po, qd, 30min before breakfast). The patients were told only that Flupentixol-Melitrace has been proven to be effective in FD treatment and were not provided additional explanations of the relationships between their GI symptoms and their psychological condition and the reasons for the prescription of Flupentixol-Melitrace.
1650509|NCT01851850|Drug|Opicapone|25mg or 50mg once per day
1650510|NCT01851837|Other|Exercise time|Continuous training, Interval training
1650511|NCT01851824|Drug|acenocoumarol|4 mg single oral doses on Days 1 and 23
1650512|NCT01851824|Drug|vemurafenib|960 mg orally bid, 20 days (Days 4-23)
1650513|NCT01851798|Other|Home sleep test administered to all enrolled subjects|
1650514|NCT01851785|Behavioral|Decision Aid (DA) Intervention|"Patients randomized to the DA Intervention will watch a Knee OA Decision Aid (DA) developed by the Foundation for Informed Medical Decision Making and then receive a brief counseling session called AskMe3. The DA is a video that provides viewers with information about OA, treatment choices such as lifestyle changes, non-drug treatments, medication, injections, complementary therapies, and surgery, as well as the pros and cons of each type of treatment. The AskMe3 is a communication, skill-building intervention, which instructs patients to ask 3 questions to the doctor: 1) What is my main problem? 2) What do I need to do? 3) Why is it important for me to do this?"
1650515|NCT01851772|Device|Treatment with Electronic Brachytherapy|
1650516|NCT01851759|Drug|cinepazide|"2 branches of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
1 branch of simulation agent of Methanesulfonic acid cinepazide injection was matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
1650517|NCT01851759|Drug|placebo|"2 branches of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day.
1 branch of simulation agent of Methanesulfonic acid cinepazide injection were matched into 250 ml 0.9% sodium chloride injection, iv gtt, speed is 100ml/h, once per day."
1650518|NCT01851733|Device|MRI-guided Laser Heat Ablation (MLA)|
1650519|NCT01851733|Drug|Doxorubicin|
1650520|NCT01851733|Other|Blood draw - dendritic cells|"The second 10 patients enrolled to Arm B:
before MLA (up to 3 days before)
2 weeks after MLA
4 weeks after MLA
every 2 weeks thereafter for up to 3 months after biopsy (provided there is no significant chemotherapy induced cytopenia)"
1650521|NCT01851733|Device|Dynamic Susceptibility Contrast Magnetic Resonance Imaging|
1650522|NCT01851720|Drug|Low dose fentanyl PCA|
1650523|NCT01851720|Drug|Standard IV fentanyl bolus|
1650524|NCT01851707|Drug|IPI-145|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
1650525|NCT01851707|Drug|Placebo|2 blinded capsules will be administered twice a day (morning and night) for 12 weeks.
1650526|NCT01851694|Drug|GLP-1|Each subject in this arm will receive GLP-1 infusion and a placebo infusion during a GPA test.
1650527|NCT01851694|Drug|GIP|Each subject in this arm will receive GIP infusion and placebo during a GPA test.
1650528|NCT01851681|Drug|Amoxicillin|
1650529|NCT01851655|Behavioral|Plyometric Exercise|Treatment sessions include a combination of running, jumping and agility activities (plyometric exercise). Each rehabilitation session will also include an abbreviated, standardized program of lower extremity strengthening (leg press, machine squats, knee extensions; 3 sets x 10 repetitions each), flexibility (standing gastrocnemius and quadriceps stretch, hamstrings stretch in long-sitting; 2 x 30 seconds each) and proprioception (standing on foam and a tilt board; 3 x 30 seconds each).
2012868|NCT01463306|Drug|Pregabalin|Pregabalin administered as either capsule or liquid oral formulations. Subjects <4 years of age at Visit 1 will receive study medication 3 times daily (TID) in equally divided doses. Subjects who are ≥4 years of age at Visit 1 will receive study medication twice daily (BID) in equally divided doses. Children less than 17 years of age will receive from 2.5 mg/kg/day to 10.0 mg/kg/day (maximum 600 mg/day. Adults 17 and older will receive from 150 mg/day to 600 mg/day.
2012869|NCT01458132|Drug|GSK2248761|Treatment with GSK2248761
2012870|NCT01454076|Drug|Ixazomib 2.5 mg|Ixazomib 2.5 mg Capsule B (Cycle 1 only)
2012871|NCT01454076|Drug|Ixazomib 4 mg Capsule A|Ixazomib 4 mg Capsule A (Cycle 1 only)
1650534|NCT01851629|Behavioral|Locomotor Training|Individuals are provided manual assistance for intense, task-specific stepping practice on a treadmill and overground.
1650535|NCT01851629|Other|Cross-Sectional Testing (No Intervention)|Individuals with and without spinal cord injury will be evaluated to develop protocols within our laboratory to assess reflexes (spinal tract integrity), walking ability, and whether mirror images during walking enhance or disrupt motor responses during walking.
1650536|NCT01851616|Dietary Supplement|25g of glucose in 200ml tap water, given orally (plus 50 mg 13C-sodium acetate)|
1650537|NCT01851616|Dietary Supplement|10g Glucose in 200ml tap water given orally (plus 50 mg 13C-sodium acetate)|
1650538|NCT01851603|Device|AVL-3288|Drug
1650539|NCT01851603|Drug|Placebo|Identical diluent to that used for AVL-3288
1650540|NCT01851590|Device|Resin Lacquer|30% Resin Lacquer is applied once daily for 9 months (Abicin®) in toenail onychomycosis.
1650541|NCT01851590|Drug|Amorolfine|5% Amorolfine Lacquer is applied once weekly for 9 months (Loceryl®) in toenail onychomycosis.
1650631|NCT01850823|Drug|placebo|
2012872|NCT01454076|Drug|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 2 and beyond )
2012873|NCT01454076|Drug|Ketoconazole|Ketoconazole 400 mg tablets (Cycle 1 only)
1650543|NCT01851577|Behavioral|Family Foundations coparenting program|Family Foundations is a coparenting program for new mothers and fathers designed to teach them skills needed to parent together effectively and facilitate healthy child development. Family Foundations will be administered concurrently with home visiting.
1650544|NCT01851577|Behavioral|Home visiting|Home visiting is a child abuse prevention approach for new mothers designed to strengthen protective factors and mitigate risk factors in order to promote optimal child development.
1650545|NCT01851564|Device|Self-expanding mesh-metal oesophageal stent (SEMS)|A removable stent designed for the treatment of bleeding oesophageal varices.
1650546|NCT01851564|Other|Standard Therapy|Standard Medical and Endoscopic Therapy
1650547|NCT01851551|Drug|Vincristine Sulfate Liposome Injection plus rituximab|
1650548|NCT01851538|Other|Observational study; no intervention.|
1650549|NCT01851525|Device|ThermoCoolSmartTouch ablation catheter, Biosense Webster|
1650550|NCT01851512|Drug|T-R (Test-Reference drug)|
1650551|NCT01851512|Drug|R-T (Reference-Test drug)|
1650552|NCT01851499|Dietary Supplement|Ultramicronized PEA (Normast)|600 mg
1650553|NCT01851486|Drug|Clonidine|Clonidine 0.15 mg
1650554|NCT01851486|Drug|Naloxone|naloxone 0.15 mg/kg
1650555|NCT01851486|Drug|placebo|
1650556|NCT01851486|Other|saline|
1650557|NCT01851473|Drug|cocaine|25 mg IV on days 1, 5, and 10
1650558|NCT01851473|Drug|quinine|80 mg orally on days 7-10
1650559|NCT01851473|Drug|acetazolamide|15 mg orally on days 2-5
2012874|NCT01454076|Drug|Rifampin|Rifampin 600 mg capsule (Cycle 1 only)
1650561|NCT01851408|Drug|sorafenib tosylate|Given orally
1650562|NCT01851408|Drug|temsirolimus|Given IV
2012875|NCT01454076|Drug|Clarithromycin|Clarithromycin 500 mg tablets (Cycle 1 only)
1650564|NCT01851343|Other|Bone Marrow Stromal Cell (BMSC) Infusion|Subjects will receive 4 weekly BMSC infusions and be monitored for AEs as well as for clinical improvement and mucosal healing.
1650565|NCT01851330|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
1650566|NCT01851330|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1650567|NCT01851304|Dietary Supplement|Satiety of breads|One separate breakfast session to consume each bread along with 125 mL skim milk. The session will start after an overnight fast followed by 5 separate blood draws over a 3 hour period before a provided lunch.
1650568|NCT01851304|Dietary Supplement|Satiety of puddings|One separate breakfast session will be used to evaluate satiating efficacy of puddings after an overnight fast. After pudding consumption, five separate blood draws will be taken over a 3 hour period before a provided lunch.
1650569|NCT01851278|Drug|Triamcinolone hexacetonide|High dose means 40mg or 2ml of triamcinolone hexacetonide
1650570|NCT01851278|Drug|Triamcinolone hexacetonide|Low dose means 20mg or 1 ml of triamcinolone hexacetonide
1650571|NCT01851265|Drug|Olaparib|400mg olaparib capsule formulation taken 30 minutes after allocated meal. 5-14 days between arms.
1650572|NCT01851265|Other|Dietary Fasted|Allocated breakfast prior to dosing with 400mg olaparib capsules
1650573|NCT01851265|Other|Dietary standard|Allocated breakfast prior to dosing with 400mg olaparib capsules
1650574|NCT01851265|Other|Dietary High Fat|Allocated breakfast prior to dosing with 400mg olaparib capsules
1650575|NCT01851252|Device|Methacetin (with Breath testing device)|The methacetin is enriched with carbon 13, a stable non- radioactive isotope, and has been found to be safe in hundreds of studies. The material is very similar to acetominophen. 75 milligrams (mm) of this material pre- dissolved in water are used. This material undergoes rapid metabolism by the liver.
1650576|NCT01851226|Procedure|Hands-on ERCP training.|The standard cannulation technique was used with a sphincterotome preloaded with a guidewire, positioned in the ampullary orifice, and targeting the presumed entry of common bile duct (CBD) or pancreatic duct (PD). During the whole procedure of cannulation by trainees, the senior endoscopist would actively communicate with trainees through verbal and/or hands-on assistance to help them to make the performance more correctly. If the trainees failed to enter the targeted duct within the designated length of time, the senior endoscopist would take over the duodenoscope and continue the following procedure of cannulation. The whole procedure of cannulation was recorded by video. Rectal indomethacin and/or pancreatic stent was used in high-risky patients.
1650577|NCT01851200|Drug|Brentuximab Vedotin|Intravenous Brentuximab Vedotin at the dose of 1.8 mg/Kg every 3 weeks until disease progression or onset of unacceptable toxicity
1650578|NCT01851187|Behavioral|antenatal psychological intervention|"emotion management included:
(1) Establish relationship between the health care workers and the pregnant women, (2) Determine training objectives, (3) Guide to practice relaxation training, including imagination and abdominal breathing. (4) Make cognitive adjustment, (5) Relieve anxiety and tension by scene simulation and stimulus exposure. (6) Learn emotional self-regulation, (7) Improve self-efficacy by group interaction. (8) Teach prenatal knowledge ,(9) Guide interactive trainings between pregnant women and their couples; (10) Visit delivery rooms."
1650579|NCT01851187|Behavioral|routine prenatal care|Prenatal routine inspection included blood pressure, weight, uterine fundal height, abdominal circumference, fetal presentation, fetal position, fetal heart rate and so on.
2012876|NCT01454076|Drug|Ixazomib 4 mg Capsule B|Ixazomib 4 mg Capsule B (Cycle 1 and beyond)
2012877|NCT01442649|Drug|Oxaliplatin|85mg/m² over 120 mn on D1 every 2 weeks up to progression or toxicity
1650582|NCT01851161|Procedure|computed tomography|Undergo conventional CT scan in both supine and prone positioning
1650583|NCT01851161|Procedure|4-dimensional computed tomography|Undergo 4D CT scan in both supine and prone positioning
1650584|NCT01851161|Radiation|radiation therapy|Undergo radiation therapy
1650585|NCT01851148|Other|osteopathic manipulative treatment|It consists of 8 sessions in 6 months. Each osteopathic session is based on a structural evaluation and an indirect technique treatment.
2012878|NCT01442649|Drug|Folinic Acid|400 mg/m² (racemic) (or 200 mg/m² if L-folinic acid) over 2 h IV on D1 (in the same time that oxaliplatin or irinotecan) every 2 weeks up to progression or toxicity
2012879|NCT01442649|Drug|5-fluoro-uracil|400mg/m² in bolus on D1, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
1650586|NCT01851148|Other|sham treatment|"Sham therapy was administered with subjects lying supine on the treatment table while the operator used light manual contact to treat the subject. The practitioner's attention was distracted by subtracting serial seven calculation in silence"
1650587|NCT01851148|Drug|triptans|administration of triptans drug treatment according to international guidelines
1650588|NCT01851135|Other|Neuropsychological examination and quality of life measures|
1650589|NCT01851122|Dietary Supplement|L-theanine capsule|L-theanine 250mg capsule
1650590|NCT01851109|Behavioral|genetic counseling|"The genetic counseling sessions are conducted by a licensed genetic counselor, certified by the American Board of Genetic Counseling and the American Board of Medical Genetics. This clinical counseling session may include, but is not limited to the following:
A review of medical and family history information to determine which genetic test (BRCA, HNPCC, p53, etc.), if any, is appropriate;
Discuss how the results - positive or negative - affect cancer risk
Discuss how cancer risk might be managed (surveillance, prophylactic surgery, oral contraceptives, etc.);
Discuss how the test is conducted and what the results might be (positive, negative, uncertain);
Discuss the disadvantages of genetic testing (cost, insurance coverage, worry about insurance discrimination, uncertain results, etc.) and the psychological and emotional issues surrounding testing, etc."
1650591|NCT01851096|Drug|SNX-5422|Capsules dosed every other day in the morning starting at a dose of 50 mg/m2. Dose escalation based on safety. Subjects will also receive 150 mg erlotinib daily (in the afternoon).
1650592|NCT01851083|Biological|autologous bone marrow mononuclear cells|BMMNC infusion of either 6x10^6 cells/kg or 10x10^6 cells/kg weight.
1650593|NCT01851083|Other|Placebo Infusion|Placebo infusion of 0.9% Sodium Chloride
1650594|NCT01851070|Drug|Allogeneic Mesenchymal Precursor Cells|
1650595|NCT01851070|Drug|Normal Saline|
1650596|NCT01851057|Behavioral|STAR|Problem-solving and education intervention (8 total sessions)
1650597|NCT01851057|Behavioral|Education Only|Education around epilepsy (8 total sessions)
1650598|NCT01851044|Procedure|Platelet Rich Plasma|
1650599|NCT01851044|Procedure|Whole Blood Injection|
1650600|NCT01851044|Procedure|Saline Injection|
1650601|NCT01851031|Procedure|the minor approach|Thirty-six patients (the minor approach group) were treated with minor parotid anterior approach
1650602|NCT01851018|Radiation|Hypofraction|Patient reported toxicities related to Hypofraction radiation treatment (3 Gy daily, 5 fractions per week) up to a total of 36 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant firmagon (240 mg given as two subcutaneous injections of 120 mg at a concentration of 40 mg/mL as a starting dose with a maintenance dose of 80 mg given as one subcutaneous injection at a concentration of 20 mg/mL administered every 28 days).
1650603|NCT01851018|Radiation|Standard|Patient reported toxicities related to the Standard radiation treatment (2 Gy daily, 5 fractions per week) up to a total of 44 Gy to the prostate (+/- seminal vesicles) plus brachytherapy boost (15 Gy in a single fraction) with 4 months neo-adjuvant LHRH agonists
1650604|NCT01851005|Drug|Dexmedetomidine|Infusion of dexmedetomidine (0.4 ug/kg/hr)
1650605|NCT01851005|Drug|Sevoflurane|Control Vol% to maintain BIS 40~45
1650606|NCT01851005|Drug|Propofol and Remifentanil|Control effect site concentration for maintain BIS 40~45 and changes of vital signs within 20%.
1650607|NCT01851005|Drug|Normal saline|Use as placebo
1650608|NCT01851005|Drug|Rocuronium|0.8 mg/kg for induction
1650609|NCT01850992|Device|Active CPAP|Effective CPAP will be administered
1650610|NCT01850992|Device|Sham CPAP|This is placebo CPAP
1650611|NCT01850979|Drug|Tacrolimus|tacrolimus 0,03% eyedrops (olive oil vehicle) every 12 hours for 3 months placebo : olive oil eyedrops every 12 hours for 3 months
1650612|NCT01850979|Drug|Olive Oil|All patients in this groups receive eye drops containing olive oil (vehicle of tacrolimus eye drops) twice a day (every 12 hours) for 90 days.
1650613|NCT01850966|Drug|Iguratimod|The usual adult dosage for oral use of 25 mg tablet of iguratimod once daily for 4 weeks or more, after which the dosage should be increased to one 25 mg tablet taken twice daily.
1650614|NCT01850953|Drug|Varenicline|This is an approved smoking cessation medication.
1650615|NCT01850953|Drug|Placebo|
1650616|NCT01850940|Drug|Tolvaptan|Tolvaptan (OPC-41061) is a benzazepine derivative synthesized by Otsuka Pharmaceutical Company, Ltd. Tolvaptan was approved for the treatment of specific forms of hyponatremia by the United States (US) Food and Drug Administration (FDA) in May 2009, the European Medicines Agency on Aug 2009, Japan (Oct 2010), China (Sep 2011) and Korea (Sep 2011). Tolvaptan was approved for the adjunct treatment of volume overload in heart failure by the Japanese Ministry of Health, Labour, and Welfare (MHLW) in Oct 2010. It is also being developed for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and for the treatment of hepatic edema.
1650617|NCT01850940|Other|conventional thearpy|conventional therapy with salt limitation ,et al
1650618|NCT01850927|Procedure|Remote ischaemic preconditioning|
1650619|NCT01850927|Procedure|Control|
1650620|NCT01850901|Procedure|Renal sympathetic denervation|
1650621|NCT01850888|Drug|131 I-Metaiodobenzylguanidine (131I-MIBG)|Minimum dose of 10 mCi/kg and up to 18 mCi/kg maximum will be diluted in 25 ml of normal saline, and will be infused intravenously over 90-120 minutes.
1650622|NCT01850888|Drug|Potassium iodide solution|For the therapeutic MIBG administration, potassium iodide solution will be administered in a loading dose of 6mg/kg orally at least 8 hours prior to the MIBG injection, and then will be given at 1mg/kg/dose every 4 hours on days 0-6, then 1 mg/kg/day through day 45 post injection. The minimum dose of potassium iodide to be given is one drop, which equals 50 mg.
1650623|NCT01850888|Drug|G-CSF|It is recommended that patients with ANC less than 750 after MIBG infusion begin G-CSF 5 mcg/kg/day subcutaneously (or receive equivalent single dose of Neulasta every 14 days while neutropenic) until neutrophil recovery (generally >5000).
1650624|NCT01850888|Procedure|hematopoietic stem cell infusion|The majority of patients on this protocol will have autologous PBSCs available. Allogeneic stem cells may be utilized in patients who has received a prior allogeneic transplant. The minimum quantity for peripheral blood stem cells is 1.5 x 106 CD34+ cells/kg (optimum > 2 x 106 CD34+ cells/kg). The minimum dose for bone marrow is 1.0 x 108 mononuclear cells/kg (optimum >2.0 x 108 mononuclear cells/kg). Infusion will be performed according to institutional guidelines.
1650625|NCT01850875|Behavioral|Eye-Movement-Desensitization-Reprocessing|
1650632|NCT01850823|Drug|Mometasone Nasal Spray|
1650633|NCT01850823|Drug|Mometasone nasal spray|
1650634|NCT01850810|Other|Experimental Study Product|
1650635|NCT01850810|Other|Control Study Product|
1650636|NCT01850784|Dietary Supplement|High energy formula|The infants with CHD will be fed with high energy formula (Similac; 1kcal/ml)
1650637|NCT01850784|Dietary Supplement|Standard formula|The infants with CHD will be fed with standard formula (0.6-0.7 kcal/ml)
1650638|NCT01850771|Procedure|Regenexx PL-Disc|Injection into the epidural space under image guidance of autologous, concentrated peripheral blood based platelet mix combined with a nanogram dose of corticosteroid.
1650639|NCT01850771|Procedure|Steroid Epidural|Injection into the epidural space under image guidance of 3 mg of betamethasone.
1650640|NCT01850758|Procedure|Regenexx SD|stem cell treatment
1650641|NCT01850758|Other|Exercise Therapy|exercise therapy control
2012880|NCT01442649|Drug|Irinotecan|180 mg/m2 over 90 mn IV on D1 every 2 weeks up to progression or toxicity
1650643|NCT01850732|Other|Ultrasound of aorta|
1650644|NCT01850719|Procedure|Arthroscopic Partial Meniscectomy|Arthroscopic partial APM is performed within 4 weeks in day-care. No standard physical therapy is prescribed after surgery, as advised by the Dutch Orthopaedic Association Guidelines.
1650645|NCT01850719|Other|Physical Therapy|"Conservative treatment consist of 16 sessions PT and a home exercise program. These programs are developed for our population, 45-70 years, with a focus on closed-chain strength exercises and cardiovascular exercises.
In case conservative treatment has failed, patients can cross-over and delayed APM is then performed. This can be done, from completion of the PT program, during the entire study."
1650646|NCT01850680|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form:solution Route of administration: subcutaneous
1650647|NCT01850680|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
1650648|NCT01850680|Drug|methotrexate|Pharmaceutical form:capsule Route of administration: oral
1650649|NCT01850680|Drug|folic acid|Pharmaceutical form:tablet Route of administration: oral
1650650|NCT01850667|Radiation|Stereotactic body radiotherapy|"Total stereotactic Body radiotherapy (SBRT) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours.
At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. In patients without gastroduodenal ulcer on Esophagogastroduodenoscopy (EGD) before SBRT, D2ml of gastrointestinal tract should not exceed 35 Gy. In patients with gastroduodenal ulcer on EGD before SBRT, D2ml of gastrointestinal tract should exceed 28 Gy. (D2ml: minimum dose to 2 ml of gastrointestinal tract)"
2012881|NCT01442649|Drug|Bevacizumab|5 mg/kg IV over 90 mn on D1 every 2 weeks up to progression or toxicity
2012882|NCT01442649|Drug|Cetuximab|500mg/m² on D1 every 2 weeks up to progression or toxicity
2012883|NCT01442714|Drug|Azacitidine|75 mg/m2 SC/IV on d 1-7, IV
2012884|NCT01442714|Drug|Lenalidomide|50mg PO given on d 8-28, oral
2012885|NCT01440751|Device|Use of ologen Collagen Matrix in trabeculectomy (ologen)|Place ologen CM on the top of the loosely-sutured scleral flap under conjunctiva before suturing. It is recommended to suture the scleral flap with 1 or 2 stiches loosely for the convenience of future suture lysis and to coordinate with the tamponading effect of ologen CM to create a fluctuating scleral flap that prevents bleb wound adhesion and modulates aqueous humor outflow for ideal IOP control without leakage.
1650656|NCT01850641|Drug|PA21|
1650657|NCT01850628|Drug|Paclitaxel|
1650658|NCT01850628|Biological|trastuzumab|
1650659|NCT01850628|Biological|pertuzumab|
2012886|NCT01440751|Drug|Use of Mitomycin-C (MMC) in trabeculectomy|After outlining and creating a superficial scleral flap, a cellulose sponge soaked with MMC(0.4mg/mL) is applied for up to 3 mins according to physician's routine method of application. The area treated is copiously irrigated with balanced isotonic solution. Alternatively, 15mcg of MMC may be injected intra-Tenon's at the end of the procedure. Patients receiving mitomycin will be billed as per operating room practice.
2012887|NCT01440088|Drug|TH-302 in Combination with Doxorubicin|"300 mg/m2 of TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.
Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.
Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.
Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle.
Doxorubicin administration will start between 2 to 4 hours after completion of the TH-302 infusion when used in combination with TH-302."
1650662|NCT01850602|Drug|PA21|
1650663|NCT01850602|Drug|Sevelamer hydrochloride|
1650664|NCT01850589|Other|Aggressive Therapy|"Pharmacotherapy adjuncts offered at no cost are as follows:
Chantix (varenicline) GlaxoSmithKline,
Zyban (bupropion) Pfizer,and Nicoderm/Nicorette (nicotine nasal spray, inhaler, transdermal patches and gum) GlaxoSmithKline."
1650665|NCT01850576|Behavioral|Risk Reduction Intervention|STEP is based on social learning theory and provides age-appropriate and culturally acceptable HIV prevention information in a format that encourages information growth and skills enhancement. The program is delivered by 'Instructors,' undergraduate college students aged 18-24, one hour per week for 10 weeks.
1650666|NCT01850563|Other|Hyperbaric oxygen given at 2.4 ATA for 30 minutes immediately prior to SRS - HBOT for 30 minutes - SRS without prior HBO|
1650667|NCT01850550|Behavioral|Weight loss Groups|The intervention will consist of 12 weekly one-hour weight loss sessions led by successful volunteer peers. Participants are provided with a modified version of the Diabetes Prevention Program manual and are mentored by peer leaders at weight loss sessions.
1650668|NCT01850537|Device|treatment of degenerative disc disease using the PROW LIF|TLIF procedure for the treatment of degenerative disc disease using the PROW LIF procedure (system)
1650669|NCT01850524|Drug|IXAZOMIB + Lenalidomide + Dexamethasone|"Patients will receive single oral dose of IXAZOMIB (4.0mg) on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days for the first 18 cycles or until progressive disease or unacceptable toxicity, whichever comes first.
After cycle 18 IXAZOMIB and Lenalidomide will be reduced and Dexamethasone will be discontinued."
1650670|NCT01850524|Drug|Placebo + Lenalidomide + Dexamethasone|"Patients will receive single oral dose of Placebo on days 1,8,15 and single oral dose of Lenalidomide (25mg) on days 1-21 and single oral dose of Dexamethasone (40mg) on days 1,8, 15 and 22 every 28 days for the first 18 cycles or until progressive disease or unacceptable toxicity, whichever comes first.
After cycle 18 IXAZOMIB and Lenalidomide will be reduced and Dexamethasone will be discontinued."
1650671|NCT01850511|Procedure|Vibrissae trimming|Patients will have oxymetazoline administered prior to assessment of outcome measures to ensure minimal impact of erectile mucosal tissue on measurement.
1650672|NCT01850511|Drug|Application of oxymetazoline|Afrin will be administered to minimize the impact of erectile mucosal tissue on obstruction.
1650673|NCT01850485|Device|microcirculation by SDF and NIRS, in 33 and 36 degrees|at baseline, after 12 and 24 hours in both arms
1650674|NCT01850446|Drug|Ergoferon|Safety and Efficiency
1650675|NCT01850446|Drug|Oseltamivir|Safety and Efficiency
1650676|NCT01850433|Behavioral|Internet based CBT for body dysmorphic disorder|
1650677|NCT01850420|Drug|IMC-1|
1650678|NCT01850407|Behavioral|Education Counseling|
1650679|NCT01850394|Drug|Tranexamic Acid|Inject tranexamic acid solution intra-articularly after fascia closure
1650680|NCT01850394|Drug|Physiologic saline|Use physiologic saline for mixing with tranexamic acid or use alone in placebo group
1650681|NCT01850381|Drug|GM608|For GM608: 320 mg/dose reconstituted with 6.4 mL bateriostatic saline. Administer 6.4 mL GM608 dosing solution by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
1650682|NCT01850381|Drug|Placebo Comparator|For Placebo: Administer 6.4 mL Bacteriostatic saline by intravenous (IV) bolus over 1 min, on Monday, Wednesday, Friday for two consecutive weeks.
1650683|NCT01850368|Radiation|Stereotactic ablative radiotherapy|"The HCC patients with major portal vein tumor thrombosis (tumor thrombosis in the main portal vein or 1st branch of portal vein) will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 40 Gy in 4 fractionations. Patients receive 4 fractionations separated by >48 hours.
At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 19.2 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 19.2 Gy. Dose of spinal cord do not exceed 26 Gy. Dose of esophagus, stomach and intestine do not exceed 35 Gy."
1650684|NCT01850355|Drug|Buspirone|Children with autism spectrum disorders will receive buspirone treatment for eight weeks. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards, subjects will be maintained on maximum achieved dose until the end of the trial (dose maintenance pahe). During the titration phase, total dose will be increased by 10mg at each visit and by 5mg on the 4th day after each visit.
1650685|NCT01850342|Procedure|Periurethral injection of fat micrograft enriched with ADRC|Subjects will undergo liposuction under local anesthesia. One part of lipoaspirate will be processed to isolate and concentrate ADRCs. Another part of lipoaspirate will be washed and homogenized to prepare fat tissue micrograft. After that fat tissue micrograft will be mixed with ADRC. Autologous fat micrograft enriched with ADRC will be injected at the bulbomembranous region of urethra circle-wise under endoscopic vision.
1650686|NCT01850329|Other|computed-assisted information program|
1650687|NCT01850316|Radiation|Stereotactic Ablative Radiotherapy|Preferred target coverage of 40 Gy: coverage and total dose determined by irradiated liver volume NTCP (normal tissue complication probability) nomogram and OAR dose limits
1650688|NCT01850303|Drug|Pemetrexed|
1650689|NCT01850303|Drug|Gemcitabine|
1650690|NCT01850303|Drug|Induction chemotherapy|4 cycles of carboplatin-paclitaxel
1650691|NCT01850277|Drug|Amiodarone|The pharmacological treatment in the rhythm control strategy consist of amiodarone given orally including the loading dose up to 600mg daily - for the first 4 weeks. Then, a maintenance dose of 200mg/daily is prescribed. The use of other anti-arrhythmic agents is possible unless they are contraindicated. The introduction of amiodarone must not be performed unless the patient is treated effectively with oral anticoagulants for 3 weeks at least. Discontinuation of amiodarone results neither in withdrawal from the study nor in change of the treatment arm.
1650692|NCT01850277|Procedure|External electrical cardioversion (EEC)|"The first EEC is performed after the loading dose of amiodarone has been administered. A maximal number of shocks during one cardioversion is 3. The amount of the energy delivered during shocks is left at discretion of a physician performing the EEC. The EEC must be performed in accordance with the present guidelines on EEC and post-procedural care and the state of art.
If atrial fibrillation reoccur, the patient should undergo a next EEC as soon as possible but preserving the safety time margins (i.e. effective anticoagulation period). The maximal no. of EEC procedures is 3. If sinus rhythm resumption or its maintenance is impossible or AF reoccur after the 3rd EEC, a strategy of rhythm control is discontinued and a rate control strategy is implemented."
1650693|NCT01850277|Drug|Pharmacotherapy to slow and control ventricular rate|The pharmacotherapy should be consistent with current guidelines. It should include negative chronotropic and negative dromotropic agents such as beta-blockers, digitalis and amiodarone (the use of other, less popular agents, is also possible). The choice of the agents as well as their dosages are left at discretion of the treating physician. The goal of the therapy is to obtain BiVp% >95%
1650694|NCT01850277|Procedure|Atrioventricular junction ablation (AVJA)|The procedure of atrioventricular junction ablation is dedicated to the patients in the rate control group in who the rate control is unsatisfactory. An AVJA procedure is not obligatory. The decision to perform an AVJA should be discussed with the patient and should be made collectively by the therapeutic team.
1650695|NCT01850264|Device|Application of quadripolar / bipolar LV electrodes|
1650696|NCT01850251|Dietary Supplement|Supplement with HMB and vitamin D|High protein, high calorie nutritional supplement enriched with hydroxymethylbutyrate and vitamin D.
1650697|NCT01850251|Dietary Supplement|Standard nutritional supplement|High protein, high calorie nutritional supplement.
1650698|NCT01850238|Biological|AADvac1|AADvac1 is intended as an active vaccination for disease-modifying treatment of Alzheimer's disease.
1650699|NCT01850238|Other|Placebo|The placebo contains the same buffer and adjuvant as AADvac1, but lacks the API.
1650700|NCT01850225|Device|Auditory brainstem implant|
1650701|NCT01850199|Other|Smart telemedicine remote monitoring for gestational diabetes|Intervention consists of a telemedicine platform which includes artificial intelligence tools to analyse glucose values and guarantee an optimal glucose control from the diagnosis of gestational diabetes to delivery.
1650702|NCT01850199|Other|Usual management|Usual care will be provided, including face-to-face visits
1650703|NCT01850186|Device|Dual yellow Laser|Patients will receive treatment by stabilized kilnman trio for four weeks (one application per day). Patient will receive 4 treatments by Dual yellow Laser on the hemi-face (side determinated by randomisation, split body study) at weeks 4, 6, 9 and 12.
1650704|NCT01850186|Drug|Stabilized kilnman trio|The stabilized kilnman trio will be prescribed for one month at inclusion (all over the face, one application per day), and on the half of the face not treated by laser at weeks 4, 8 and 12 (one application per day).
1650705|NCT01850173|Device|A vertical vibration platform Fitybe|They performed 6 series, and each series consisted of four 30-second repetitions with a frequency of 35 Hz and 2 millimeters of amplitude, with 60 seconds of rest between each series.
1650706|NCT01850160|Drug|GROUP A: Valsartan plus Chlorthalidone|Combination therapy of Valsartan plus Chlorthalidone: Valsartan 80 mg / Chlorthalidone 12,5 mg. Once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg / Chlorthalidone 25 mg once daily.
1650707|NCT01850160|Drug|GROUP B: Valsartan|GROUP B: Treatment monotherapy: Valsartan 80 mg once daily during 12 weeks. If the goals of blood Pressure are uncontrolled at week 6, the dose will be increase to Valsartan 160 mg once daily.
1650708|NCT01850160|Drug|GROUP C: Chlorthalidone|GROUP C: Treatment monotherapy: Chlorthalidone 12,5 mg once daily during 12 weeks. If the goals of blood pressure are uncontrolled at week 6, the dose will be increase to Chlorthalidone 25 mg once daily.
1650709|NCT01850147|Drug|Sunitinib, chemotherapy|sunitinib, 12.5mg/day, for 7 days before each cycle of chemotherapy; chemotherapy, single agent including docetaxel, albumin-bound paclitaxel, vinorelbine, gemcitabine, pemetrexed, or paclitaxel, as determined by the investigator
1650710|NCT01850134|Other|Experimental Study Product|
1650711|NCT01850134|Other|Control Study Product|
1650712|NCT01850121|Drug|Infliximab|5 mg/kg every 6 weeks during the first year and 3 mg/kg every 8 weeks during the second year. Concomitant treatment with methotrexate 7.5 mg/week.
1650713|NCT01850108|Drug|Thymoglobulin|"Day 9 - 0.5 mg/kg IV before BMT
Days 8 & 7 - 2mg/kg IV before BMT"
1650714|NCT01850108|Drug|Fludarabine|On Days -6 to -2 before BMT, 30 mg/m2/day IV
1650715|NCT01850108|Drug|Cyclophosphamide (CTX)|Days 6 & 5 before BMT, 14.5 mg/kg IV; 50 mg/kg each day on 3rd & 4th day after BMT
1650716|NCT01850108|Drug|Mesna|Days 3 & 4 after BMT: 40 mg/kg IV
1650717|NCT01850108|Drug|Sirolimus|Adjusted to maintain a serum trough level of 3-12 ng/mL, taken orally beginning on 5 days after BMT and taken to 1 year after BMT.
1650718|NCT01850108|Drug|Mycophenolate mofetil (MMF)|15 mg/kg orally with maximum dose 3 mg/day beginning 5 days after BMT and taken to day 35 after BMT
1650719|NCT01850108|Procedure|Bone marrow transplantation|Day 0 - Transplantation of hematopoietic cells derived from bone marrow of a donor to a recipient as treatment for hematologic disorders
1650720|NCT01850108|Radiation|Total body irradiation|200 cGy on the day before BMT. Radiation delivered to the entire body of the recipient to eradicate bone marrow cells in the recipient to prepare the recipient to receive the transplanted
1650721|NCT01850095|Drug|treatment azelaic acid (azelan)|treatment for 6 months
1650722|NCT01850095|Drug|dorspirenone/ethynil estradiol|
2012888|NCT01440088|Drug|Doxorubicin|"Doxorubicin may be delivered as a bolus administration or as a continuous infusion administration; administration schedule must be specified prior to enrollment.
Doxorubicin bolus administration: 75 mg/m2 administered by bolus injection starting on Day 1 of a 21-day cycle.
Doxorubicin continuous administration: 75 mg/m2 administered by continuous IV infusion over 48-96 hours starting on Day 1 of a 21-day cycle."
1650724|NCT01850056|Device|drug eluting balloon catheter (trade name: Orchid)|
1650725|NCT01850056|Device|common percutaneous transluminal angioplasty balloon catheter (trade name: Admiral)|
2012889|NCT01439503|Behavioral|Intervention|"The intervention will consist of an education program. The education program includes providing the ability to enjoy condom use through improved skills related to finding the right fit and feel of condoms, using lubricants that are compatible with latex, negotiating condom use, negotiating sex, and talking with new and existing sex partners about ways to sexualize condoms."
2012890|NCT01428635|Drug|Eltrombopag|Starting dose 50 mg by mouth daily. Dose escalation allowed every 2 weeks to 100 mg, 150 mg, 200 mg and 300 mg according to platelet response (except for patients of East Asian ancestry who receive starting dose of 25 mg daily with dose escalation allowed every two weeks to 50 mg). Treatment cycle defined as daily continuous dosing.
2012891|NCT01421329|Behavioral|Intervention|Receive weekly emails, information about the benefits of exercise, and compensation.
1650730|NCT01850017|Drug|Dexmedetomidine|In the intervention arm dexmedetomidine at a dose of 1 mcg/kg over 20 mins followed by an infusion of 0.5 mcg/kg/h for the duration of the surgery.
1650732|NCT01849991|Biological|Lactobacillus reuteri|"Lactobacillus reuteri oil drops are a natural product containing Lactobacillus reuteri (LR), which has traditionally been used for the establishment of a well-functioning gastrointestinal (GI) microbiota and prevention and treatment of mild diarrhea associated with GI-tract infections, travel or antibiotic treatment.
The drug is a clear liquid when suspended in sunflower oil. The drug will be administered orally, 0.2cc once daily."
1650733|NCT01849991|Biological|Placebo|Placebo is sunflower oil (vehicle for LR). The placebo will be administered the same way as drug listed above.
1650734|NCT01849978|Behavioral|Newsletter about physical activity and breast cancer survivors|Both groups will receive a newsletter that covers: 1) the recommendation to pursue at least 150 mins/week of moderate to strenuous intensity PA, 2) the benefits of PA specific to breast cancer survivors (e.g., reducing in death and breast cancer recurrence), and 3) their total minutes of moderate to strenuous intensity PA and how this compares to the recommendation.
1650735|NCT01849978|Behavioral|Changing your habits brochure|"Both groups will receive the brochure titled Changing Your Habits: Steps to Better Health, developed by the NIH, that describes, based a person's stage of change, the benefits of PA, how to overcome common barriers to PA, and if ready, how to plan for PA."
1650736|NCT01849978|Behavioral|Tips for making exercise enjoyable and personally-valued|Participants will get a list of potentially enjoyable activities and a space to list other activities after they consider aspects that can make events fun/interesting.13 Aspects to consider include: location (indoors vs. outdoors, the latter which may appeal to some), hobbies that can involve PA (e.g., sports, dancing), whether the activity is made more enjoyable by having it performed by oneself or with others (e.g., team activities vs. individual activities); what valued outcomes may be achieved (e.g., sense of competence, pride, better health, body image), accompanying activities that are pleasant (e.g., listening to music), etc.
1650737|NCT01849978|Behavioral|Testimonials from breast cancer survivors|Participants will get two to three testimonials of actual breast cancer survivors. These testimonials will include story-like details of what these survivors find enjoyable about exercising and what they have done to make exercise enjoyable.
1650738|NCT01849965|Drug|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever occurs sooner.
1650739|NCT01849965|Drug|placebo vehicle gel|
1650740|NCT01849965|Drug|Standard of Care gel, Aquasite|
1650741|NCT01849939|Drug|Fludarabin (post-allograft immunosuppressive therapy modulation and DLI Mononuclear cells from allogenic blood)|
1650742|NCT01849926|Drug|Ibuprofen|
1650743|NCT01849926|Drug|Mecillinam|
1650744|NCT01849913|Other|Laser|The laser will be used 830 nm, 30 milliwatts twice a week: the initial dosage will be 5.9 J per point. The irradiation will be performed bilaterally on the belly of the trapezius muscle as well as 2 cm to the right and left and 2 and 4 cm below the belly of the muscle.
1650745|NCT01849913|Other|Placebo|"To provide the blinding: the laser equipment has two identical application points furnished by the manufacturer - one active and the other a placebo (does not emit energy)."
1650746|NCT01849900|Other|Knowing your body|"Women will receive the Knowing your body kit. The kit contains: 6 ovulation test strips, a 12 month menstrual log sheet/calendar, and a thermometer to help women determine their body temperature; and educational materials that contain information on female body parts involved in pregnancy, hormones and the menstrual cycle, how birth control works, body temperature changes, characteristics of cervical fluid, and adapting to pregnancy during the first trimester. Participants will receive a total of 10 visits. During the first visit, the nursing student/community health workers team will review the intervention kit and continue to discuss topics related to women's health during subsequent visits."
1650747|NCT01849900|Behavioral|Healthy Lifestyle|Women will receive educational materials on healthy lifestyle such as maintaining good nutrition and the importance of folic acid for women of childbearing age during the first visit. Participants will receive a total of 10 visits. The nursing student/community health workers team will continue to discuss topics related to promoting healthy lifestyle during subsequent visits.
1650748|NCT01849887|Biological|bone marrow-derived mesenchymal stem cells|bone marrow-derived mesenchymal stem cells
1650749|NCT01849887|Drug|Placebo|Placebo
1650750|NCT01849874|Drug|MEK162, MEK inhibitor; oral|multiple dose, single schedule
1650751|NCT01849874|Drug|Physician's choice chemotherapy|"Patients will receive one of the following chemotherapies as determined by the physician:
Liposomal doxorubicin, anthracycline antibiotic; intravenous (multiple dose, single schedule)
Paclitaxel, mitotic inhibitor; intravenous (multiple dose, single schedule)
Topotecan, topoisomerase 1 inhibitor; intravenous (multiple dose, single schedule)"
1650752|NCT01849861|Drug|Methimazole|"Patients with serum TSH initially on the 1st. Quartile (TSH: 0.4 to 1.0 mIU / ml) will receive treatment with Methimazole (initial dose of 5mg/day) with the goal of raising the TSH values to range between 2.0 and 4.0 mIU / ml (the half upper range of normal).
After six months with TSH in the target range (2.0 and 4.0 mIU / ml), these patients will be subjected to the same examination protocol performed at baseline and assessed to the effects of treatment on outcome variables.
Variables considered in this study:
TSH and FT4
Questionnaire of Quality of life for older adults (WHOQOL-OLD)
Mini-Mental State Examination
Geriatric Depression Scale
Cardiopulmonary exercise testing - cardiopulmonary capacity"
1650753|NCT01849848|Drug|SyB L-0501|The administration of SyB L-0501 at 90 mg/m^2/day by 60-minute intravenous infusion for 2 consecutive days followed by 26 days of monitoring. This is considered to be one cycle and may be repeated up to 6 times. Dose reduction or discontinuation is permitted from the second cycle as necessary according to adverse events and the results of monitoring during the previous cycle.
1650754|NCT01849835|Procedure|trans-rectal to perform the prostate biopsy|the puncture points are at the rectal
1650755|NCT01849835|Procedure|trans-perineal to perform the prostate biopsy|the puncture points are at the perineal
1650756|NCT01849822|Device|Neural Prosthetic System|The Neural Prosthetic System is primarily composed of two NeuroPort Arrays. Each array is comprised of 100 microelectrodes (1.5 mm in length) uniformly organized on a 4 mm x 4 mm silicon base that is 0.25 mm thick. Each microelectrode is insulated with Parylene-C polymer and is electrically isolated from neighboring electrodes by non-conducting glass. Each microelectrode has a platinum tip that is 100-200 microns in length and offers impedance values from 100-800 kilo-ohms. Of the 100 electrodes, 96 are wire bonded using 25 micron gold alloy insulated wires collectively sealed with a silicone elastomer. The wire bundle is potted to a printed circuit board with epoxy, the printed circuit board is inserted into the Patient Pedestal (percutaneous connector), and then the Patient Pedestal is filled with silicone elastomer. Two fine platinum reference wires are also attached to the Patient Pedestal. The Patient Pedestal is 19 mm wide at the skin interface.
1650757|NCT01849809|Procedure|Gamma Ventral Capsulotomy|
1650758|NCT01849796|Device|tDCS|TDCS/sham will be delivered using the battery-operated device Phoresor II Auto with two saline-soaked sponge electrodes. To deliver excitatory (anodal) tDCS over the motor cortex, the main electrode will be placed over the motor cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. To deliver inhibitory (cathodal) tDCS, the main electrode will be placed over the somatosensory cortex on the hemisphere contralateral to the major source of pain. The second electrode will be placed on the skin overlying the supraorbital region ipsilateral to the affected area. The current will be delivered at the intensity of 2mA for 20 minutes. To deliver sham, the current will be delivered for 30 sec only to elicit tingling skin sensation but no cortical excitability changes.
2012892|NCT01420627|Biological|EZN-2279|weekly administration of EZN-2279 via IM injection
2012893|NCT01420627|Biological|Adagen|
1650770|NCT01849757|Other|prime crystalloid|used for priming the CPB circuit
1650771|NCT01849757|Other|Human Albumin|Used as a constituent for priming the CPB circuit
1650772|NCT01849757|Other|Voluven|Used as a constituent for priming the CPB circuit
1650773|NCT01849744|Drug|VS-4718|
1650774|NCT01849731|Other|Face-to-face|is carried out by the GPs during the clinic visit and consists of seven visits, one every three months. Each session consists of completing a diabetes care record sheet (DCRS) together with the patient. The DCRS consists of two parts: Five questions on self-care activities in the last three months and a graph with previously measured HbA1c levels. This information is completed at each session, resulting in a graph showing the evolution of glycaemic control related to self-care activities. The DCRS is explained patients, emphasising the relationship between self-care and glycemic control. At the end of the session, patients are given a copy of the DCRS and suggested to show it and discuss it with their relatives.
1650775|NCT01849731|Other|Face-to-face intervention plus telephone reinforcement|In this group patients receive the above described intervention A plus a telephone reinforcement It consists on five telephone calls lasting about 10 minutes each, to provide advice on carrying out physical exercise and eating a balanced diet and to encourage the use of health services related to diabetes control. Any problems or doubts that patients have stemming from any aspect of diabetes care are also discussed. Telephone reinforcement is carried out by a professional who has previously been trained in promoting T2DM self-management and in motivational interviewing techniques.
1650776|NCT01849705|Other|No intervention|
1650777|NCT01849692|Drug|ESBA1008 solution|Intravitreal injection or infusion
1650778|NCT01849692|Drug|Ranibizumab|Intravitreal injection
1650779|NCT01849679|Other|Evaluation of Swallowing|Evaluating for pharyngeal delay, pharyngeal stasis, and penetration/aspiration
1650780|NCT01849666|Drug|phenprocoumon|6 mg oral single dose
1650781|NCT01849666|Drug|vemurafenib|960 mg bid orally
1650782|NCT01849640|Drug|DHA-piperaquine and Primaquine|Subject will be enrolled in open label fashion to a 3-day treatment course of DHA-piperaquine (DP) by directly observed therapy (DOT, all patients will receive a total of 9 tablets containing 40mg DHA and 320mg of piperaquine in divided doses at 0, 24 and 48 hours (3 tablets once per day) for the 3 day course. At completion of DP treatment volunteers will be randomized in an open label fashion to receive a single 45 mg dose of primaquine or no therapy.
1650783|NCT01849627|Behavioral|Low-ED|This condition will be instructed to make food consumption decisions based solely upon the ED of a food. The goal of the ED condition will be to consume at least 10 foods ≤ 1.0 kcal/g (i.e., fruits and vegetables, broth based soups, non-fat yogurts, some legumes, egg substitutes, some white fish, etc.) and no more than 2 foods ≥ 3.0 kcal/g (i.e., crackers, chips, cookies, hard cheeses, hot dogs, salad dressings, etc.) per day.
1650784|NCT01849627|Behavioral|Energy Balance|Energy Balance will receive an individualized daily energy goal which will be their measured resting metabolic rate multiplied by a physical activity level (PAL) of 1.12 (men) or 1.14 (women) (low active).
1650785|NCT01849614|Other|Cardiac SPECT perfusion scan|A SPECT cardiac perfusion scan provides a three-dimensional map of blood flow to the heart tissue. The scan will be taken at rest only.
1650786|NCT01849601|Device|percutaneous transluminal angioplasty balloon catheter|
1650787|NCT01849588|Drug|Sorafenib|
1650788|NCT01849575|Behavioral|Intervention|"Information about carotid ultrasound results to the participant and his/her primary care physician in the form of atherosclerosis highlighted graphically in color against normal vascular age patterns and as plaque formation. General information about atherosclerosis as a dynamic modifiable process and recommendation to follow clinical guidelines for risk factor control. After 2─4 weeks a follow─up call by a research nurse, to give additional information and reassurance, if needed. Identical information to the study participant is sent by post after 6 months.
CVD risk factors are managed according to clinical guidelines within primary health care during the entire study period."
1650789|NCT01849562|Drug|Sovaprevir|NS3/4A protease inhibitor
1650790|NCT01849562|Drug|ACH-3102|NS5A inhibitor
1650791|NCT01849562|Drug|RBV|
1650792|NCT01849562|Drug|Placebo|
1650793|NCT01849549|Behavioral|Neuropsychological testing|Experimental test about cognitive deficit of interest and standard neuropsychological tests.
1650794|NCT01849549|Other|MRI|Anatomical, diffusion, and/or functional MRI
1650795|NCT01849536|Device|SENSIMED Triggerfish®|
1650796|NCT01849523|Behavioral|Web-based information and support|
1650797|NCT01849510|Radiation|hypofractionated 12x3 Gy + integrated boost 12x4 Gy|hypofractionated, homogeneous radiation (12x3 Gy) with simultaneously administrated, integrated boost (12x4 Gy) mediated by IGRT & hfSRT
1650798|NCT01849510|Radiation|hypofractionated 10x3 Gy|hypofractionated, homogeneous radiation (10x3 Gy)
1650799|NCT01849497|Biological|Evolocumab Pre-filled Syringe|Evolocumab subcutaneous injection via a single use, disposable pre-filled syringe.
1650800|NCT01849497|Biological|Evolocumab AI/pen|Evolocumab subcutaneous injection via a handheld mechanical (spring-based) autoinjector/pen.
1650801|NCT01849484|Radiation|Radiation according to indication with hippocampal sparing|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
1650802|NCT01849484|Radiation|Radiation according to indication without hippocampal protection|Performed with hippocampal sparing Meningioma-total dose up to 50.4 Gy (+ additional boost up to 59.4 Gy) Hypophyseal adenoma - total dose up to 50.4 Gy (+additional boost up to 54 Gy) SCLC (prophylactic cranial irradiation) - total dose up to 36.0 Gy
1650803|NCT01849471|Other|questionnaires|patients receive questionnaires regarding socioeconomic aspects before, during and after therapy
1650804|NCT01849458|Device|BioFiber|Subjects implanted with BioFiber or BioFiber-CM Scaffold
1650805|NCT01849445|Procedure|Intensive physiotherapy|Participants will visit hospital for physiotherapy sessions once a week for 6 weeks in addition to completing prescribed exercises twice a week at home on their own.
1650806|NCT01849445|Other|Home physiotherapy exercises|Patients will be asked to complete prescribed exercises at home on their own 3 times a week for 6 weeks.
1650850|NCT01849094|Drug|milrinone 10mg ER|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
1717876|NCT00002345|Drug|Megestrol acetate|
1650807|NCT01849419|Drug|Within-subjects (MDMA)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received a single dose of MDMA (0.75, 1.5 mg/kg) on two session, oxytocin (20 IU) as an active control on one session (see second Intervention), and placebo one session (see third intervention).
1650808|NCT01849419|Drug|Within-subjects (oxytocin)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received oxytocin (20 IU) on one session, MDMA on two sessions (see first Intervention), and placebo on one session (see third Intervention).
1650809|NCT01849419|Drug|Within-subjects (placebo)|This was a within-subjects, double-blind, double-dummy, placebo-controlled experiment during which each participant received placebo on one session, MDMA on two sessions (see first Intervention), and oxytocin (20 IU) on one session (see second Intervention).
1650810|NCT01849406|Drug|nasal spray Budesonide|one week therapy of nasal budesonide twice per day
1650811|NCT01849406|Drug|Nasal spray Normal Saline|one week therapy of nasal normal saline twice per day
1650812|NCT01849393|Other|Questionnaire|Participants who consent to participate in this study will complete a short questionnaire. The survey will be completely anonymous (not matched with the participant's name). Estimated time to complete the survey is 10-20 minutes.
1650813|NCT01849380|Drug|S-1|S-1(SuLi, QILU Pharmaceutical co.ltd ) was given at a standard dose of 40 mg/m2 twice daily in cycles of 14-day consecutive administration
1650814|NCT01849380|Drug|5-FU|5-FU was given at a standard dose of 500mg/m2 (infusion, d1, d8 respectively),
1650815|NCT01849367|Device|Eldith Neuroconn tDCS device|
1650816|NCT01849341|Drug|Roflumilast alternated days|500 mcg per day on alternate days (roflumilast 500μg eod) for 2 weeks
1650817|NCT01849341|Drug|Roflumilast 500 mcg per day|
1650818|NCT01849315|Behavioral|AKIDS II|Physically active intervention
1650819|NCT01849302|Dietary Supplement|Beverages varying in macronutrient content on appetite|In this randomized, within-subject study, subjects are asked to consume 7 iso-energetic and iso-volumetric beverages as breakfast (20% of estimated energy requirements) with varying distribution of macronutrients. The objective is to identify the optimal protein quantity or macronutrient distribution on suppressing appetite.
1650820|NCT01849289|Drug|Insulin Degludec|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
1650821|NCT01849289|Drug|Insulin Glargine|Administered subcutaneously (under the skin), dose individually adjusted, once daily in combination with metformin at the unchanged, stable, pre-randomisation dose level and dosing frequency.
1650822|NCT01849276|Drug|metformin hydrochloride|Given orally
1650823|NCT01849276|Drug|cytarabine|Given IV
1650824|NCT01849276|Other|laboratory biomarker analysis|Correlative studies
2012894|NCT01416584|Behavioral|methadone contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace.
2012895|NCT01416584|Behavioral|Methadone & Abstinence Contingency|Participants had to enroll in methadone treatment and take daily doses of methadone to gain access to the workplace and they had to provide opiate and cocaine negative urine samples to maintain the maximum pay.
1650827|NCT01849250|Drug|Docosahexaenoic Acid|Given PO
1650828|NCT01849250|Other|Laboratory Biomarker Analysis|Correlative studies
1650829|NCT01849250|Other|Placebo|Given PO
1650830|NCT01849237|Genetic|Mesenchymal stromal cells|MSCs intravenous infusion of 1-2 millions/kg/day will be performed not more than 10 hs after onset of septic shock in patients with severe neutropenia(≤ 1x10^9/l).
1650831|NCT01849237|Drug|Standard therapy of septic shock|Antibiotic therapy Fluid therapy Vasopressors Inotropic therapy Steroids
1650832|NCT01849224|Other|Pelvic and lower extremity exercise|
1650833|NCT01849211|Drug|rocuronium|
1650834|NCT01849198|Device|accelerometry m. trapezius and m. adductor pollicis|
1650835|NCT01849185|Other|Food supplement|
1650836|NCT01849172|Other|acupuncture|Stick adhesive tapes to all points. For ST25, EX-CA1 and RN4, insert the needle vertically through the pads and the skin, and then slowly and vertically penetrate through the layer of fatty tissue, up into the muscles of the abdominal wall .For RN4, manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times. Insert the needle vertically at SP6 to a depth of 1 cm. Manipulate the needle with an even lifting, thrusting and twisting method slightly for 3 times to reach de-qi. Put the electric stimulator on the pair of EX-CA1 and ST25 points with a dilatational wave, 10/50 Hz, 0.5-1.0mA. To turn on the current intensity till the abdomen shivers. The same manipulation methods for RN4 and SP6 will be given every 10 minutes (3 times in all).
1650837|NCT01849172|Other|sham acupuncture|"Non-points proximate to RN4 (P1), EX-CA1(P2)，ST25 (P3) and SP6 (P4) (double sides) are used.P1 and P3 are at the sites 1 cm (outward in horizontal direction) proximate to RN4 and ST25 respectively. P2 is 2 cm (outward in horizontal direction) proximate to EX-CA1. P4 is at the middle site of the spleen meridian and the kidney meridian (backward in horizontal direction proximate to SP6).
Stick adhesive tapes to all points. Blunt needles will be used to be inserted to but not piercing the skin. Even lifting, thrusting and twisting manipulation methods will be given for each non-point for 3 times. Put the sham electric stimulator on the pair of P2 and P3 with the same parameters as the acupuncture group. But there is no current intensity actually."
1650838|NCT01849159|Biological|Mesenchymal stem cells|Intravenous infusion of MSC suspension, pre-conditioned under 1% oxygen, in the amount of 200 mln. cells per 400 mL of sodium chloride physiological solution
1650839|NCT01849159|Other|Reference therapy: 400 mL of 0.9% NaCl solution|
2012896|NCT01416389|Drug|LY2523355|Administered intravenously
1650845|NCT01849133|Radiation|external fractionated radiotherapy|conventional external beam radiotherapy
1650846|NCT01849133|Radiation|intraoperative radiotherapy|Intraoperative radiotherapy (IORT). Total delivered dose 21Gy (Gray), 90% isodose
1650847|NCT01849120|Device|EQUANOX Advance 8004CB sensor|The EQUANOX Advance 8004CB sensors placed in peripheral sites of neonates and infants will be used to detect peripheral perfusion and oxygen delivery.
1650848|NCT01849107|Biological|Plasma citrulline|
1650849|NCT01849094|Drug|Milrinone 6mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
1650904|NCT01848743|Drug|Tenofovir|
1650851|NCT01849094|Drug|milrinone 14mg|Administration of study medications, PK sampling If Part B - add on 6 hour haemodynamic invasive measurements
1650852|NCT01849081|Device|CPAP|Subjects in the intervention arm will be treated with continuous positive airway pressure (CPAP) device at night.
1650853|NCT01849081|Behavioral|LIfestyle|Subjects will undergo 12 weeks of dietary counseling.
1650854|NCT01849068|Drug|Ezetimibe|Ezetimibe 10 mg/d for 12 weeks
1650855|NCT01849068|Drug|Placebo|Placebo for 12 weeks
2012897|NCT01416389|Drug|Ixabepilone|Administered intravenously
2012898|NCT01416389|Drug|pegfilgrastim|Administered intravenously
2012899|NCT01416389|Drug|filgrastim|Administered intravenously
1650859|NCT01849042|Drug|Ebixa|add-on of Ebixa oral pump already receiving donepezil with stable dosage
1650860|NCT01849042|Drug|donepezil|
1650861|NCT01849029|Behavioral|Cognitive Processing Therapy-Cognitive|Cognitive Processing Therapy-Cognitive (CPT-C) uses education about trauma reactions, emotional processing, and cognitive strategies to reduce trauma-related cognitive distortions. CPT is a manualised 12 session cognitive behavioral treatment for PTSD which offers an alternative to purely exposure based interventions. CPT has a smaller exposure component than imaginal exposure therapy and is therefore potentially more acceptable to clients or practitioners seeking alternatives to purely exposure focused treatments. CPT-C omits the written trauma account, and includes more practice of cognitive techniques during the sessions. The treatment was developed for twice weekly sessions over 6 weeks. It also directly targets associated problems such as depression, guilt and anger.
1650862|NCT01849016|Drug|N-Acetylcysteine|
1650863|NCT01849016|Drug|Placebo|
1650864|NCT01849003|Drug|GS-6615|GS-6615 tablet(s) administered orally
1650865|NCT01848990|Drug|Commercial Hylenex® recombinant (hyaluronidase human injection)|
1650866|NCT01848990|Drug|Precommercial Hylenex recombinant (hyaluronidase human injection)|
1650867|NCT01848990|Drug|Insulin lispro|
1650868|NCT01848990|Drug|Insulin aspart|
1650869|NCT01848990|Drug|Insulin glulisine|
1650870|NCT01848977|Device|vascular occlusion test|Using Invos® probe attacted to one thenar muscle, tissue oxgyenation is measured by VOT.
1650871|NCT01848977|Device|vascular occlusion test|Using Inspectra™ probe attacted to another thenar muscle, tissue oxgyenation is measured by VOT.
1650872|NCT01848964|Device|Clinical and instrumented measurements|"Clinical examination will include stump pain, wound, scar and unusual shape.
Questionnaire will include satisfaction scale (SatPro), comfort scale (SCE), and functional scale (PPA-LCI)
After installing the sensors on the stump, the patient will put his prosthesis on and will perform the following tasks: gait, sitting and standing posture and gait initiation.
Pressure repartition at the stump-socket interface will be assessed with the 14 flat sensors.
Gait parameters will be assessed with the OptoGait device. Standing posture and gait initiation parameters will be assessed with a force-plate."
1650873|NCT01848951|Drug|Epidural|
1650874|NCT01848951|Drug|TAP Block|
1650875|NCT01848938|Behavioral|Smartphone treatment with PFMT|A smartphone application with information on SUI, life style information, different programmes of PFMT with increasing severity, possibility to save statistics on training. The treatment period is three months
1650876|NCT01848925|Biological|SANGUINATE™|40 mg/mL intravenous infusion.
1650877|NCT01848925|Drug|Hydroxyurea|Standard of care for Sickle Cell treatment, 15 mg/kg.
1650878|NCT01848912|Device|Zephyr Biopatch Device|
1650879|NCT01848899|Drug|Iodixanol|contrast media used during coronary angiography
1650880|NCT01848899|Drug|Ioxaglate|contrast media used during coronary angiography
1650881|NCT01848899|Drug|Bivalirudin|A direct thrombin inhibitor
1650882|NCT01848886|Procedure|Endoscopic radial artery harvest|Radial artery harvest is performed as an endoscopic procedure.
1650883|NCT01848886|Procedure|Open radial artery harvest|Radial artery harvest is performed as an open procedure.
1650884|NCT01848886|Procedure|Mammarioradial graft (Y-graft)|The radial artery is used as an composite graft positioned on the internal mammarian artery.
1650885|NCT01848886|Procedure|Aortoradial graft (Free RA)|The radial artery is used as an free graft positioned on the aorta.
1650886|NCT01848873|Drug|Amlodipine|amlodipine 5mg daily
1650887|NCT01848873|Drug|amlodipine-FA tablet, low dose group|5mg amlodipine combined with 0.4 mg of folic acid, daily.
1650888|NCT01848873|Drug|amlodipine-FA tablet ,high dose group|amlodipine 5mg and folic acid 0.8mg daily
1650889|NCT01848860|Procedure|Thoracoscopic bullectomy and pleural abrasion|Thoracoscopic bullectomy and pleural abrasion will be performed in a standard fashion under general anesthesia using intubated one-lung ventilation. When blebs are identified, they will be grasped with the ring forceps and excised with an endoscopic stapler. Blind apical stapling was done at the most suspicious area if no bleb could be identified. Thoracoscopic pleural abrasion will be performed at the parietal pleura above the 5th intercostal space by inserting the dissector with a strip of diathermy scratch pad through the port sites in all patients.
1650890|NCT01848860|Biological|Mesh coverage of the staple line|Absorbable mesh coverage of the staple line will be performed in the mesh group after thoracoscopic bullectomy in the mesh group
1650891|NCT01848847|Procedure|Hysteroscopy|
1650892|NCT01848834|Biological|Pembrolizumab|IV infusion
2012900|NCT01415232|Device|Sonosite S-Nerve® US system (SonoSite, Bothell,WA)|Ultrasound to measure depth to the epidural space in morbidly obese parturients
1650895|NCT01848808|Dietary Supplement|Wobenzym PS|
1650896|NCT01848808|Dietary Supplement|Placebo|
1650897|NCT01848795|Device|EndoBarrier Gastrointestinal Liner|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
1650898|NCT01848795|Device|Easy life balloon|Endoscopy placement of EndoBarrier, and clinical and biochemical follow up
1650899|NCT01848782|Behavioral|interpretation of the abstract of the systematic review|
1650900|NCT01848769|Drug|CHF1535 pMDI + AC Plus|Four inhalations for a total dose of BDP/FF 200/24 mcg
1650901|NCT01848769|Drug|BDP + AC Plus|Four inhalations for a total dose of BDP 200 mcg
1650902|NCT01848769|Drug|Formoterol + AC Plus|Four inhalations for a total dose of Formoterol 24 mcg
1650903|NCT01848756|Drug|SNX-5422|Capsule(s) dosed every other day for 21 days (total = 11 doses), out of a 28-day treatment cycle.
1650909|NCT01848704|Behavioral|interpretation of the abstract|
1650910|NCT01848691|Other|Measurement of carbon monoxide level in exhaled breath|Measurement of end-tidal carbon monoxide concentration
1650911|NCT01848665|Drug|Indomethacin|
1650912|NCT01848665|Drug|Placebo|
1650913|NCT01848652|Drug|infusion of MYOCET|
1650914|NCT01848639|Drug|Spironolactone|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to spironolactone. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
1650915|NCT01848639|Drug|Placebo|After a month in run-in period under 25 mg per 2 days of spironolactone administered per os in practice after dialysis session three times a week, patients will be randomized to placebo. The dose should be increased to 25 mg once daily and could be adjusted in using an algorithm used in the EPHESUS and EMPHASIS-HF trials.
1650916|NCT01848613|Drug|Vinorelbine|
1650917|NCT01848600|Behavioral|interpretation of the abstract|the intervention consist to interpret the results of the meta-analysis after reading the abstract.
1650918|NCT01848587|Other|acupuncture|
1650919|NCT01848587|Other|usual care|
1650920|NCT01848574|Other|standardized multifaceted information procedure to improve patients' comprehension|
2012901|NCT01410812|Behavioral|Control|Receive weekly emails asking participants about their exercise and receive cash.
1650922|NCT01848535|Dietary Supplement|GOS addition|GOS (2.5g 3x per day) supplemented during 12 days
1650923|NCT01848535|Dietary Supplement|Placebo|Maltodextrine(2.5g 3x per day) supplemented during 12 days
1650924|NCT01848509|Device|With teletransmission|Teletransmission of alerts
1650925|NCT01848496|Procedure|Gingival displacement|Gingival displacement is a dental procedure that allows exposure of the finishing line of a dental cavity in order to produce a well-adapted restoration.
1650926|NCT01848483|Behavioral|AIDS EPC Package plus MI|"Motivational Interviewing: In MI session #1, the nurse will set the agenda & ask the participant to discuss any adjustments to the AIDS diagnosis. In sessions #2 - 4, the participant will be asked to set the agenda related to current concerns. In sessions #3 & 4, the nurse will also introduce advance care planning.
EPC Package: Participants will be seen by palliative care providers, for approximately 30 minutes each, in the following order: 1) Chaplain: introduces the concept of EPC clinic & conducts a spiritual evaluation/intervention as needed. 2) Social worker: conducts an evaluation/intervention as needed. 3) Psychologist: conducts an evaluation/intervention as needed. 4) Palliative Care Physician: conducts symptom management, medication reconciliation & coordination of care."
1650927|NCT01848483|Other|Standard of Care (SOC)|The routine standard of care provider visit occurs in the following order. The vital signs are taken and the participant sees the nurse to review medications. The provider visits are scheduled for approximately 30 minutes, except for a new patient or patient with complex medical needs. The provider conducts a history to elicit symptoms, health problems, concerns, and a physical exam, then orders labs or immunizations; and referrals to subspecialty clinics. Medications are prescribed or renewed. The patient then receives a follow-up appointment, typically every 3 months for a stable patient. If the patient starts ART, an appointment to the nurse educator is required. Typically, the patient will have 1- 2 visits to the nurse educator to begin medications and follow-up for side-effects.
1650928|NCT01848470|Drug|CG400549 640mg|multiple oral doses of 640 mg CG400549 (n=6) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
1650929|NCT01848470|Drug|CG400549 320 mg|multiple oral doses of 320 mg CG400549 (n=6) QD for 5 days in the fed state
1650930|NCT01848470|Drug|CG400549 640 mg|multiple oral doses of 640 mg CG400549 (n=6) QD for 5 days in the fed state
1650931|NCT01848470|Drug|CG400549 960 mg|multiple oral doses of 960 mg CG400549 (n=6) QD for 5 days in the fed state
1650932|NCT01848470|Drug|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) BID for 5 days (Days 1-5) and a final dose on Day 6 in the fed state
1650933|NCT01848470|Drug|Placebo 320mg|multiple oral doses of 320 mg placebo (n=2) QD for 5 days in the fed state
1650934|NCT01848470|Drug|placebo 960 mg|multiple oral doses of 960 mg placebo (n=2) QD for 5 days in the fed state
1650935|NCT01848470|Drug|Placebo 640mg|multiple oral doses of 640 mg placebo (n=2) QD for 5 days in the fed state
1650936|NCT01848457|Drug|Pantoprazole|0.3 mg/kg IV over 15 min immediately prior to cisplatin as a loading dose on days 1 & 2 followed by 1.3 mg/kg IV infused over 4 h concurrent with the 4 h cisplatin infusion on days 1 & 2 of treatment Cycles 1 & 2 (Treatment Arms 1, 3) OR Cycles 3 & 4 (Treatment Arms 2, 4)
1650937|NCT01848457|Drug|High-dose methotrexate infusion duration|High-dose methotrexate (12 g/sq m, maximum dose 20 g) will be infused over 4 hours or 12 hours
1650938|NCT01848444|Other|Breastmilk|to measure levels of contaminants in human breastmilk samples
1650939|NCT01848379|Procedure|ADT+FD|
1650940|NCT01848379|Procedure|FD|
1650941|NCT01848366|Device|Biowave Treatment|Twelve weekly treatments
1650942|NCT01848353|Behavioral|Exercise training|All participants will perform exercise training at the wellness center. Exercise duration and intensity will be recorded with heart rate monitors.
1650943|NCT01848340|Drug|GSK1265744B (sodium salt) containing 14C-GSK1265744B|A white to slightly colored nonsterile crystalline powder for oral solution
1650944|NCT01848340|Drug|150 mg GSK1265744B|This is GSK1265744B (sodium salt of GSK1265744), lactose monohydrate, Microcrystalline cellulose, hypromellose, sodium lauryl sulfate, croscarmellose sodium, magnesium stearate, Opadry film-coating, white OY-S-28876 tablet
1650945|NCT01848340|Drug|Placebo|Microcrystalline cellulose, Opadry film-coating, white OY-S-28876 tablet
1650946|NCT01848327|Dietary Supplement|Caprylic Triglyceride|Caprylic Triglyceride is a medical food that is used for the dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
1650947|NCT01848327|Dietary Supplement|Placebo|Placebo (40 gram packet orally once a day for 90 days)
1650948|NCT01848314|Procedure|Renal Denervation|Flowmeasurements will be performed before and after renal denervation
1650949|NCT01848301|Device|Optical Coherence Tomography|OCT imaging of the LAD coronary artery
1717877|NCT00002346|Drug|Adefovir dipivoxil|
2012902|NCT01410812|Behavioral|Suggested Tying Intervention|Participants receive 4 iTunes audio novels for their own iPods to listen to only at the gym
1650950|NCT01848301|Drug|Acetylcholine|Infusion in the coronary artery to study endothelial function
1650951|NCT01848301|Procedure|Brachial Artery Flow Mediated Dilation|Assess peripheral brachial artery endothelial function
1650952|NCT01848288|Device|CENTURION® Vision System (CVS)|Phacoemulsification aspiration platform, with configuration consisting of Centurion® Vision System Phaco Emulsifier Aspirator, 45° Balanced ultrasonic tip, and INTREPID Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
1650953|NCT01848288|Device|INFINITI® Vision System (IVS)|Phacoemulsification aspiration platform, with configuration consisting of Infiniti® Vision System Phaco Emulsifier Aspirator, 45° Mini Flared Kelman tip, and Ultra Infusion Sleeve, for use during routine cataract extraction by phacoemulsification with intraocular lens implantation.
1650954|NCT01848275|Device|Thermocool®Rcatheter|The full length RDN was performed discretely from distal to proximal by point to point using Thermocool®Rcatheter
1650955|NCT01848275|Device|Thermocool®Rcatheter|The proximity renal denervation was performed discretely at 10-15 mm of proximal renal artery, using Thermocool®Rcatheter
1650956|NCT01848262|Procedure|ECALMIST|Surfactant administration via 17 (5 French) gauge, 133 mm length vascular catheter. 5 ml/kg will be drawn up in a 5 or 10 ml syringe. The vascular catheter will be inserted through the vocal cords under direct vision using a standard laryngoscope with the appropriate blade for gestational age. The procedure will be done without removing the NCPAP. A bolus of surfactant of 0.25-0.5 ml will be administered, after observing the surfactant moving up and down as indication of accurate intubation of the trachea. The surfactant will be slowly injected by small pulses of 0.25-0.5 ml over 20-30 seconds, each bolus with 10 seconds apart. At the end of the procedure, the operator will flush the catheter with 0.5 ml of air before removing the catheter.
1650957|NCT01848262|Procedure|InSure|Patients who will receive surfactant via this technique will have their NCPAP removed and then they will be orally intubated with a standard endotracheal tube (ETT) using standard endotracheal intubation procedures using appropriate size ETT according to the birth weight. Bovine surfactant will be administered through the ETT using the same technique described above for arm 1. Manual lung inflation using a Jackson -Rees anesthesia bag at 20/5-cm H2O pressure will be performed during the surfactant instillation after which the patient will be extubated promptly as per the discretion of the neonatal team. Immediately following extubation, nCPAP support will be recommenced. No premedication, such as sedation or atropine, will be used during either procedure.
1650958|NCT01848236|Dietary Supplement|Vitamin D2|Ergocalciferol vitamin D2
1650959|NCT01848236|Dietary Supplement|Vitamin D3|Cholecalciferol vitamin D2
1650960|NCT01848210|Drug|Coumarin/troxerutin|Coumarin + troxerutin fixed-dose combination tablets
1650961|NCT01848210|Drug|Placebo|Coumarin + troxerutin placebo-matching tablets
1650962|NCT01848197|Drug|paclitaxel|
1650964|NCT01848171|Drug|L-thyroxine|
1650965|NCT01848158|Device|acupuncture|Patients randomized to active treatment will receive acupuncture treatment with press needles (small acupuncture needles manufactured with attached bandage that makes the needle flush with skin) at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a seed magnet at ear shen men position for 4 hours on treatment days.
1650966|NCT01848158|Device|sham acupuncture|Patients randomized to sham treatment will receive sham acupuncture with similarly appearing bandages placed without press needles attached at sites GV 24.5 or GV20, Ht 7 or Ht 3, Ki 3, Lr 3, LI 4 or LI 11, Lu 7 or Lu 5, Sp6, ST 36, using up to 15 points per patient three days per week for the duration of mechanical ventilation (maximum of 14 calendar days from the time of the first acupuncture treatment). We will also apply a similarly appearing bandage without seed magnet underneath at ear shen men position for 4 hours on treatment days.
1650967|NCT01848145|Drug|Ofatumumab|The first dose of ofatumumab administered on Day 1 will be 300 mg to minimize infusion reactions. If the initial 300 mg dose of ofatumumab is well-tolerated, without occurrence of any infusion-associated AEs of >= grade 3, on Day 3 ofatumumab will increase to 1000 mg IV. If the Day 3 dose was well-tolerated (i.e., no infusion-associated AE >= grade 3), on Day 8 the ofatumumab dose will escalate to 2000 mg IV. To achieve the primary endpoint for this study, 20% of the 2000 mg ofatumumab dose only will be administered over the first 30 minutes and if tolerated the remaining 80% of the dose will be infused over the remaining 1.5/hours of each treatment. Ofatumumab doses, weeks 3-8, will remain at 2000 mg IV with no further dose escalations. If the Day 8 (Week 2) dose is tolerated all subsequent doses may be infused in the same manner.
1650968|NCT01848132|Drug|Bortezomib|Bortezomib: subcutaneous, 1,3 mg/m2, day 1, 8, 15.
1650969|NCT01848132|Drug|Rituximab|Rituximab: intravenous, 375 mg/m2, day 1
1650970|NCT01848132|Drug|Cyclophosphamide|Cyclophosphamide: intravenous, 750 mg/m2, day 1
1650971|NCT01848132|Drug|Doxorubicin|Adriamycin:intravenous, 50 mg/m2, day 1
1650972|NCT01848132|Drug|Prednisone|Prednisone: oral, 100 mg, days 1-5
1650973|NCT01848132|Drug|Vincristine|Vincristine: intravenous, 1,4 mg/m2, day 1
1650974|NCT01848119|Drug|Gabapentin|
1650975|NCT01848119|Drug|lactose|
1650976|NCT01848106|Drug|pegnivacogin/anivamersen|
1650977|NCT01848106|Drug|Bivalirudin|
1650978|NCT01848093|Other|sputum collection|collecting of spontaneous sputum from the patient
1650979|NCT01848080|Behavioral|Tai Chi based exercise program|A Tai Chi based exercise program that uses movement repetition favoring directional adjustments in space, supervised by a physiotherapist, has been shown to be effective in improving balance in individuals with physical impairments, including those presenting with sequelae following a stroke.
1650980|NCT01848067|Drug|Alisertib|Given PO
1650981|NCT01848067|Drug|Abiraterone acetate|Given PO
1650982|NCT01848067|Drug|Prednisone|Given PO
1650983|NCT01848054|Drug|Buprenorphine/naloxone sublingual tablets|Advanced-formulation buprenorphine/naloxone sublingual tablets
1650984|NCT01848054|Drug|Buprenorphine|Buprenorphine sublingual tablets
1650985|NCT01848041|Drug|RVL-1201|RVL-1201 0.1% Ophthalmic Solution
1650986|NCT01848041|Drug|RVL-1201 Vehicle Placebo|RVL-1201 Vehicle Placebo
1650987|NCT01848015|Other|detection of CTCs|
1717878|NCT00002347|Drug|Saquinavir|
1650988|NCT01848002|Drug|catridecacog|For 5 consecutive days, one daily dose of rFXIII was administered intravenously (IV) to eight subjects in each dose group (10 or 25 U/kg).
1650989|NCT01848002|Drug|placebo|For 5 consecutive days, one daily dose of placebo was administered intravenously (IV) to two subjects in each dose group (10 or 25 U/kg).
1650990|NCT01847989|Drug|catridecacog|Single doses of rFXIII administered intravenously (IV) to eight subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
1650991|NCT01847989|Drug|placebo|Single doses of placebo administered intravenously (IV) to two subjects in each of the five dose groups (2, 5, 10, 25 and 50 U/kg).
1650992|NCT01847976|Drug|Doxycycline|Participants will be asked to take 100 mg of Doxycycline by mouth twice a day for 12 weeks.
1650993|NCT01847963|Drug|Sindhuvallathy mezhugu ( SVM)|500 mg capsules per oral twice daily for 45 days a Siddha classical literature preparation
1650994|NCT01847963|Drug|Kalladaippu Kudineer (KK) -|130 ml decoction twice daily-per oral for 45 days, a Siddha classical literature preparation
1650995|NCT01847950|Dietary Supplement|Short-chain fructo-oligosaccharides|Short-chain fructo-oligosaccharides are consummed at 5g/day for 6 weeks
1650996|NCT01847950|Dietary Supplement|Maltodextrin|
1650997|NCT01847924|Drug|MLC901|24 weeks intervention with orally MLC901. 2 capsules 3 times a day
1650998|NCT01847924|Drug|Placebo|24 weeks intervention with orally placebo. 2 capsules 3 times a day
1650999|NCT01847911|Other|Self instructed video learning|A complete video lesson of neonatal resuscitation including initial resuscitative maneuvers and administration of ventilation with a SIB and a T-piece resuscitator presented in the primary language of the participating center or university (Spanish or English). A portable kit with a newborn mannequin will be provided for independent video guided practice during the session.
1651000|NCT01847911|Other|instructor training|a pre-validated OSCE neonatal resuscitation program
1651001|NCT01847898|Procedure|Vertebral Body Stenting (VBS)|Vertebral Augmentation with a Stent
1651002|NCT01847898|Procedure|Balloon Kyphoplasty|Vertebral Augmentation with a Balloon (device not specified)
2012903|NCT01410812|Behavioral|Forced Tying Intervention|Participants receive cash and also 4 iTunes audio novels for a loaned iPod accessible only at the gym to listen to only at the gym.
1651004|NCT01847872|Drug|IPV IM Needle|
1651005|NCT01847872|Drug|IPV ID Needle|
1651006|NCT01847872|Drug|IPV IM Device|
1651007|NCT01847872|Drug|IPV ID Device|
1651008|NCT01847859|Procedure|Ultrasound examination by nurses|Focused examination of the pleural space and inferior vena cava.Reference method: Cardiologists performed ultrasound examinations.
1651009|NCT01847833|Other|MRI scan|
1651010|NCT01847820|Device|AmniSure ROM test|Comparison of AmniSure ROM test to clinical diagnosis of ROM.
1651011|NCT01847807|Drug|low dose Astragalus|
1651012|NCT01847807|Drug|high dose astagalus|
1651013|NCT01847794|Device|Cell Search® CTC epithelial kit|"Collect peripheral blood sample of 50 gastric cancer patients pre-chemotherapy and post two cycles of chemotherapy(response evaluation).
Blood samples will be transferred to central lab to detect HER2 positive CTCs by Cellsearch epithelial kit.
Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
1651014|NCT01847781|Biological|Prevenar13|
1651015|NCT01847768|Biological|GMP-grade HRV-39|Experimental rhinovirus infection: an FDA approved, GMP-grade HRV-39 stock (gift from Dr. Ronald B. Turner, University of Virginia), which has now been approved by Health Canada for human experimental use, will be used in this study.
1651016|NCT01847768|Procedure|Bronchoalveolar Lavage|
1651017|NCT01847768|Drug|Methacholine Inhalation Challenge|The purpose of this test is to determine if lung airways narrow by more than 20%, which confirms an asthma diagnosis.
1651018|NCT01847768|Procedure|Nasal Lavage|
1651019|NCT01847768|Procedure|Nasal Scrapings|This process uses a rhinoprobe to gently scrape the mucosal lining of the nose
1651020|NCT01847768|Procedure|Bronchial Brushings|
1651021|NCT01847768|Procedure|Lung Mucosal Biopsy|
1651022|NCT01847768|Procedure|Allergen Skin Prick Testing|For the purposes of this study, allergy skin testing will be done with the following aero-allergens: cat epidermis, dog epidermis, horse, grass mix, tree mix, weed mix, ragweed and house dust mite, along with a histamine positive control and a buffer & glycerol negative control.
1651023|NCT01847768|Procedure|Venipuncture|Peripheral blood for assessment of neutralizing antibodies to HRV-39
1651024|NCT01847768|Procedure|Bronchoscopy|A small flexible tube the size of a pencil, with a video-camera built into the tip (called a bronchoscope), will be inserted through the nose or mouth and down into the lungs.
1651025|NCT01847768|Procedure|Spirometry|
1651026|NCT01847755|Drug|Oxygen at 1.5 ATA (atmospheres absolute).|Each patient will undergo 5 times-a-week Hyperbaric treatments to 1.5 ATA (atmospheres absolute) for up to 120 treatments. Treatment in hyperbaric chamber will be approximately 60 minutes. At specified intervals 40,80,120, patient will be assessed by Spect scan and cognitive assessments to provide outcome measure data. Pt will have a 3 month post treatment follow up assessment.
1651027|NCT01847742|Behavioral|Eye Movement Desensitization and Reprocessing Therapy|
1651028|NCT01847703|Procedure|Robotic surgery|Minimal invasive surgery performed with daVinci robotic system
1651029|NCT01847703|Procedure|Abdominal surgery|Current gold standard
2012904|NCT01395004|Drug|GSK2110183|GSK2110183 was orally administered at 125 mg once daily.
1651031|NCT01847677|Drug|Bevacizumab|
1651032|NCT01847677|Drug|Paclitaxel|
1651033|NCT01847677|Drug|Carboplatin|
1651034|NCT01847664|Drug|Rifamycin SV-MMX® 400 mg b.i.d.|
1651035|NCT01847664|Drug|Rifamycin SV-MMX® 600 mg t.i.d.|
1651036|NCT01847664|Drug|Rifamycin SV-MMX® Placebo|
1651037|NCT01847651|Procedure|Vastus Muscle Biopsy|Both Arms, all 3 visits at 0, 4 and 12 weeks
1651188|NCT01846520|Procedure|quality-of-life assessment|Ancillary studies
2012905|NCT01385527|Behavioral|Weekly Internet survey|Parents will complete a weekly online survey about medication use.
2012906|NCT01385527|Drug|Topical Triamcinolone|Topical triamcinolone to all affected areas once daily
1651038|NCT01847651|Drug|LOLA or placebo|Hepa-Merz Granulat 3000 Hepa-Merz granules 3g (Each 5g sachet contains 3g of L-ornithine L-aspartate) L-ornithine L-aspartate LOLA Randomised to a daily dose 18g per day, two sachets of Hepa-Merz granules three times a day (or placebo)for 12 weeks
1651039|NCT01847651|Other|Cognitive assessment (PHES)|Both Arms, all 3 visits at 0, 4 and 12 weeks
1651040|NCT01847651|Other|Cognitive Assessement (Cogstate)|Both Arms, all 3 visits at 0, 4 and 12 weeks
1651041|NCT01847651|Other|blood and urine sampling|Both Arms, all 3 visits at 0, 4 and 12 weeks
1651042|NCT01847651|Other|Nutritional assessment|Both Arms, all 3 visits at 0, 4 and 12 weeks
1651043|NCT01847651|Other|MRI brain and spectroscopy|Both Arms, all 3 visits at 0, 4 and 12 weeks
1651044|NCT01847651|Other|MRI leg cross section|Both Arms, all 3 visits at 0, 4 and 12 weeks
1651045|NCT01847651|Other|Functional MRI (working memory and attention tasks)|Both Arms, all 3 visits at 0, 4 and 12 weeks
1651046|NCT01847638|Drug|Prolensa (bromfenac 0.07%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
1651047|NCT01847638|Drug|Ilevro (nepafenac 0.3%)|Comparison of Prolensa (bromfenac ophthalmic solution) 0.07% QD vs. Ilevro (nepafenac ophthalmic suspension) 0.3% QD for Treatment of Ocular Inflammation Associated with Cataract Surgery
1651048|NCT01847625|Other|simulator|
1651049|NCT01847612|Procedure|indocyanine green fluorescent cholangiography|
1651050|NCT01847612|Drug|methylene blue|
1651051|NCT01847599|Other|Educational Intervention to enhance the adherence of Patient treated by capecitabine +/- Lapatinib|
1651052|NCT01847586|Procedure|Paired Associative Stimulation|PAS simulates in humans the induction of long-term potentiation (LTP), a prototype of synaptic neuroplasticity. PAS involves the repetitive pairing of electrical stimulation of the median nerve with - 25 ms later - transcranial magnetic stimulation (TMS) of the contralateral DLPFC. As such, these two stimulations arrive simultaneously in the DLPFC and result in potentiation of TMS induced cortical evoked potential, analogous to in vitro LTP.
1651053|NCT01847586|Procedure|Paired Associative Stimulation-Control|PAS-C is a control PAS paradigm in which TMS to the left DLPFC follows the electrical stimulation of the right median nerve by 100 ms, and, thus, does not result in contemporaneous occurrence of the two stimulations in the cortex and consequently no LTP.
1651054|NCT01847573|Drug|HT-100|May be administered in either fed or fasted state
1651055|NCT01847534|Other|Supplemental PN|
1651056|NCT01847534|Other|Standard Care|
1651057|NCT01847521|Dietary Supplement|Luteolin, Quercetin and Rutin combined in a capsule|
1651058|NCT01847508|Device|PHILOS+|Proximal Humerus Internal Locking System with screw tip augmentation (PHILOS+) with high viscous polymethylmethacrylate (PMMA) cement (Traumacem V+).
1651059|NCT01847508|Device|PHILOS|Proximal Humerus Internal Locking System (PHILOS).
1651060|NCT01847495|Drug|Irinotecan|40mg/m2 x 3-5 days
1651061|NCT01847495|Radiation|CyberKnife|45-60 Gy for 3-5 days CyberKnife SBRT to liver metastasis within 10 elapsed days. Irinotecan will be administered on the same day, prior to SBRT.
1651062|NCT01847482|Device|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest
1651063|NCT01847469|Behavioral|Enhanced-Cognitive Processing Therapy-C (E-CPT-C)|
1651064|NCT01847469|Drug|Zonisamide|
1651065|NCT01847469|Drug|Placebo|
1651066|NCT01847456|Drug|human insulin as nasal spray|
1651067|NCT01847456|Drug|Placebo|
1651068|NCT01847443|Drug|Nicotine (2 mg)|2 mg nicotine gum in two formulations
1651069|NCT01847443|Drug|Nicotine (4 mg)|4 mg nicotine gum in two formulations
1651070|NCT01847430|Biological|Engerix™-B Kinder|Single dose administered intramuscularly in the deltoid region of non-dominant arm at Day 0.
1651071|NCT01847417|Drug|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
1651072|NCT01847417|Drug|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
1651073|NCT01847417|Drug|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
1651074|NCT01847417|Drug|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
1651075|NCT01847404|Drug|Test 1= ASA 100 mg and pantoprazole 20 mg capsule formulation one|Formulation Test 1 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
1651076|NCT01847404|Drug|Test 2= ASA 100 mg and pantoprazole 20 mg capsule formulation two|Formulation Test 2 of a fixed dose combination capsule of ASA and pantoprazole (Each capsule contains ASA 100 mg and pantoprazole 20 mg) manufactured by Piramal Healthcare Limited, India for GSK
1651077|NCT01847404|Drug|ASA 100 mg tablet|Aspirin® Protect 100 mg tablets (Each tablet contains ASA 100 mg) manufactured by Bayer vital GmbH, 51368 Leverkusen, Germany
1651078|NCT01847404|Drug|Pantoprazole 20 mg gastro-resistant tablet|Protium® 20 mg gastro-resistant tablets (Each gastro-resistant tablet contains 20 mg of pantoprazole (as sodium sesquihydrate)) marketing authorisation holder Nycomed GmbH, Byk-Gulden-Straβe 2, D-78467, Konstanz, Germany
1651079|NCT01847391|Drug|GS-6615|GS-6615 tablet(s) administered orally once daily
1651080|NCT01847391|Drug|Placebo|Placebo tablet(s) to match GS-6615 administered orally once daily
1651081|NCT01847378|Procedure|Catheter ablation|During mapping and ablation tissue voltage and impedance will be stored and analyzed thereafter. The same procedure will be done in regard to activating maps.
1651082|NCT01847365|Device|Transcorneal electrical stimulation|Transcorneal electrical stimulation will be delivered by the CE-marked Okustim device.
1651083|NCT01847352|Drug|Intravenous administration of ferric carboxymaltose|Intravenous administration of ferric carboxymaltose 15mg/kg up to a maximum dose of 1000mg
1651084|NCT01847352|Other|Subacute hypoxic exposures|Exposure to six hours of isocapnic hypoxia with end-tidal partial pressure of oxygen clamped at 55 Torr, with and without prior iron infusion
1651085|NCT01847339|Drug|bupivacaine|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the bupivacaine solution %0.25 and then will be placed by the surgeon in the epidural space before final closure.
1651086|NCT01847339|Other|saline solution|In study group a 1 square centimeter piece of absorbable gelatin sponge will be soaked in the saline solution and then will be placed by the surgeon in the epidural space before final closure
1651087|NCT01847326|Drug|carboplatin|Given IV
1651088|NCT01847326|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1651089|NCT01847326|Drug|fluorouracil|Given IV
1651090|NCT01847326|Drug|hydroxyurea|Given PO
1651091|NCT01847326|Procedure|therapeutic conventional surgery|Undergo surgical resection
1651092|NCT01847326|Radiation|radiation therapy|Undergo radiation therapy
1651093|NCT01847326|Radiation|hyperfractionated radiation therapy|Undergo hyperfractionated radiation therapy
1651094|NCT01847326|Other|laboratory biomarker analysis|Correlative studies
1651095|NCT01847313|Drug|Liraglutide|Daily administration of liraglutide for 6 months
1651096|NCT01847300|Behavioral|cSBI-M|In cSBI-M participants complete a computerized screen for alcohol and tobacco use and then view 10 pages describing the health effects of substance use and true life stories of those affected by substance use.
1651097|NCT01847274|Drug|Active comparator: Niraparib|Niraparib vs placebo 2:1 ratio
1651098|NCT01847274|Drug|placebo|
1651099|NCT01847261|Dietary Supplement|Soy Dairy Protein Blend|
1651100|NCT01847261|Dietary Supplement|Positive Control (Dairy Whey Protein)|
1651101|NCT01847235|Drug|Temozolomide|Temozolomide 200 mg/m2/d in a fasting state for 5 consecutive days (1,000 mg/m2 per 28-day cycle).
1651102|NCT01847222|Biological|SANGUINATE™|PEG-bHb-CO
1651103|NCT01847222|Drug|Normal Saline Solution|Placebo
1651105|NCT01847196|Device|Angel® Catheter|The Angel® Catheter combines the functions of an inferior vena cava (IVC) filter and a multi-lumen central venous catheter (CVC). The device is designed to be placed in the inferior vena cava, via the femoral vein, for the prevention of Pulmonary Embolism (PE), and for access to the central venous system. The device is intended for short-term use (less than 30 days) and must be removed before hospital discharge.
1651106|NCT01847183|Behavioral|Click City®: Alcohol|A school based program, Click City®: Alcohol consists of 12 effective components delivered in 7th grade and a booster of 5 effective components delivered in 8th grade.
1651107|NCT01847170|Biological|Fecal Microbial Transplantation|
1651108|NCT01847157|Device|tDCS|"Intelect mobile combination (Intelect, USA) is utilized as a direct current stimulator. The 25 cm2 electrodes on a sponge slice immersed in physiological salt solution are fixed on the left and right positions C3/ C4 of subject head (according to the international 10-20 system of electroencephalogram).
During the treatment, 1.5 mA electric current is applied to stimulate the subjects in the experimental group for totally 30 minutes. At the start and the end of stimulation, the electric current will gradually increase from zero, or reduce to zero in 1 minute in order to avoid the possible appearance of slight flash effect of subject eyesight, which is caused by instantly turning on or turning off the electric current."
1651109|NCT01847157|Drug|Epidermis anesthesia|"15 g of Emla 5% Cream(anesthetic) is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.
Furthermore, 10 g Emla 5% Cream(anesthetic) is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
1651110|NCT01847157|Drug|sham anesthesia|"15 g of 5% body Cream is applied to the ventral surface of the forearm of unaffected side with a distance of 10 mm from the wrist, and an area of 150 mm long x 50 mm wide.
10 g body Cream is applied to the ventral surface of the upper arm of affected side with a distance of 10 mm from the wrist, and an area of 100 mm long x 50 mm wide."
1651111|NCT01847157|Other|Repeated passive movement|"Repeated passive wrist extension training: Patients' wrist joint are passively moved by a trained occupational therapist (joint moving angle = 0- 60 degree), frequency 1 Hz, maintain for 20 minutes.
Finger passive flexion and extension training: Patients' fingers joint are passively moved by a trained occupational therapist, frequency 1 Hz, maintain for 10 minutes."
1651112|NCT01847157|Device|sham tDCS|The equipment of sham stimulation in the control group is exactly the same as the equipment in the experiment group. However, the only difference is that 30 seconds after the start of electric current, the experimenter turns off the powder under subject ignorance situation. The stimulation just gives patients weak sense of electric current, in order to blind them for which group they are in.
1651113|NCT01847144|Drug|Gliclazide 80mg OD|Gliclazide 80mg OD (DPP-IV inhibitor) - for 4 weeks duration followed by a 2 week wash-out period.
1651114|NCT01847144|Drug|Sitagliptin 100mg OD|Sitagliptin 100mg OD (sulphonylurea)- for 4 weeks duration followed by a 2 week wash-out period.
1651115|NCT01847131|Drug|oxymetazoline|0.05% Oxymetazoline nasal sprays were commercially available.
1651116|NCT01847131|Drug|Placebo nasal spray|Placebo nasal spray has made by the local pharmaceutical company in thailand who commercially manufacture and sell 0.05% oxymetazoline nasal spray. The placebo contains the same ingredients as the drug except the active ingredient.
1651117|NCT01847118|Drug|Sevacizumab|
1651118|NCT01847105|Other|RevitaLens|Multi-purpose disinfecting solution
1651119|NCT01847105|Other|OptiFree PureMoist|Multi-purpose disinfecting solution
1651120|NCT01847092|Drug|AZD1722|
1651121|NCT01847092|Drug|Placebo|Placebo for AZD1722
1651122|NCT01847079|Other|Procalcitonin|Procalcitonin to guide obtaining bloodcultures
1651123|NCT01847066|Device|Erbium 2940 plus cosmetics plus Impact|Laser used in all arms
1651124|NCT01847066|Device|Erbium 2940 plus cosmetics|laser
1651125|NCT01847053|Other|cinnamon|Intervention will be both ground cinnamon and cinnamon extract.
1651189|NCT01846520|Other|questionnaire administration|Ancillary studies
1651281|NCT01845753|Other|Observation|Observation
1651316|NCT01845493|Dietary Supplement|Sulforaphane Homogenate|Active
1651126|NCT01847027|Drug|NutraStem|"Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress."
1651127|NCT01847027|Drug|Placebo|Determine whether NutraStem® in combination with an exercise stimulus will cause increased human peripheral blood sample levels of CD34+ and CD133+ adult stem cells and whether these stem cells display more protection against oxidative stress.
1651129|NCT01847001|Drug|Propranolol|Propranolol starting dose is 20mg b.i.d.; propranolol dose is up-titrated to 40mg b.i.d. to 80 mg daily with chemotherapy depending on tolerability. Tolerability is assessed every 2 weeks.
1651130|NCT01847001|Other|DOT imaging|(Non-experimental) During the baseline visit, you will undergo DOT evaluation of your tumor for determination of blood, fat, and water content in the affected and unaffected breast. DOT readings will be obtained at 4 additional time points: after paclitaxel week #3, before AC week #1, before AC week #3, and prior to surgery.
1651131|NCT01847001|Drug|Paclitaxel|(Non-experimental) given as a one-hour intravenous infusion (IV) every week for a total of 12 weeks; the first dose of paclitaxel may be given over 90 minutes, per the discretion of your treating doctor. The dose will be given in 80 mg/m2 based on individual body surface area (BSA). This drug is given through a vein in the arm or a catheter (eg. Infusaport, Portacath).
1651132|NCT01847001|Drug|Nab-paclitaxel|(Non-experimental) In the event paclitaxel is not available due to manufacturing and supply shortages, nab-paclitaxel will be substituted for paclitaxel. The dose is 100 mg/m2 IV infusion over 30 minutes weekly (or institutional standard). No premedications are given with nab-paclitaxel.
1651133|NCT01847001|Drug|Trastuzumab|(Non-experimental) (only if HER2-positive): Trastuzumab is given as an IV infusion initially over 90 minutes for the first dose, then 30-60 minutes every 3 weeks in subsequent doses if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
1651134|NCT01847001|Drug|Pertuzumab|(Non-experimental) (only if HER2-positive): Pertuzumab is given as an IV infusion over 60 minutes on the first dose, then 30-60 minutes every 3 weeks if well tolerated. To be given every 3 weeks with paclitaxel/propranolol.
1651135|NCT01847001|Drug|Doxorubicin|(Non-experimental) Doxorubicin will be given as a 510 minute intravenous infusion (IV) in a dose of 60 mg/m2; cyclophosphamide will be given as a 3060 minutes intravenous infusion (IV) in a dose of 600 mg/m2 based on BSA. This chemotherapy regimen will be given every 2 weeks for total of 8 weeks or 2 months.
1651136|NCT01847001|Drug|Cyclophosphamide|(Non-experimental) Doxorubicin 60 mg/m2 IV over 5-10 minutes, Cyclophosphamide 600 mg/m2 IV infusion over 30-60 minutes. The first cycle should be initiated with 3 weeks after the last paclitaxel and/or trastuzumab/pertuzumab dose.
1651137|NCT01847001|Procedure|Surgery|After you complete all chemotherapy plus propranolol treatment, you will then have surgery to remove the breast tumor if your doctor feels that it is medically appropriate (if you have had a good response to the treatment) - lumpectomy/mastectomy.
1651138|NCT01847001|Drug|Premedication|As premedication to prevent some of the side effects associated with paclitaxel, you will also receive dexamethasone (Decadron) in a dose of 10 mg, diphenhydramine (Benadryl) in doses of 2550 mg, and an H2 blocker (eg. ranitidine 50 mg or equivalent) 3060 minutes before each paclitaxel infusion. If no hypersensitivity reactions are experienced, dexamethasone may be reduced in increments of 2 mg per week per dose (until a minimum of 2 mg has been reached).
1651139|NCT01847001|Drug|Anti-nausea therapy|In addition to doxorubicin, you will receive an anti-nausea therapy and dexamethasone about 3060 minutes before AC chemotherapy.
1651140|NCT01847001|Drug|Pegfilgrastim|When you receive the AC chemotherapy, you will also receive treatment with a drug called pegfilgrastim (Neulasta). Neulasta is a commercially available drug. It stimulates the production of white blood cells and reduces the likelihood of developing a low white blood cell count and fever after chemotherapy. It will be given as an injection under the skin on the day after each chemotherapy treatment (day 2).
1651141|NCT01846988|Device|crossover treatment (REMstar Auto A-Flex)|All subjects will use same device with 4 week crossover of settings of APAP and CPAP
1651142|NCT01846975|Drug|IV Abatacept|Transition from weekly SC- to a single IV-Abatacept but also the return to weekly SC treatments after a 4 week break.
1651143|NCT01846962|Drug|Budesonide|The administered dose of topical steroid was 0.5 mg/2 mL. Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
1651144|NCT01846962|Drug|Fluticasone|The administered dose of topical steroid was 0.5 mg/2 mL. Patients were trained to swallow puffs and to non eat or drink fo 30 minutes after ingestion. Patients noncompliant with therapy, monthly assessed by Pediatric Allergologists, were withdrawn from the study.
1651145|NCT01846962|Behavioral|six-foods elimination diet|six-foods elimination diet. The standard panel of foods tested included the 6 most common allergenic foods in childhood (cow's milk, egg, soy, wheat, peanuts, fish), plus foods that were suspiciously implicated in triggering an allergic reaction referred by patients or their parents. Both perennial (dust mite, Parietaria, Alternaria, cat and dog dander) and seasonal (grass pollen including Graminaceae, Olea europea, Platanus) aeroallergens have been tested.
1651146|NCT01846936|Procedure|DLT with conventional technique|The double lumen tube is introduced into the glottis under direct laryngoscopy. After the bronchial cuff had passes the vocal cords, the tube is rotated counterclockwise 90° and advanced until a slight resistance was encountered.
1651147|NCT01846936|Procedure|BB with conventional technique|"The brochial blocker (BB) is introduced through the endotracheal tube to the desired bronchus under FOB vision by turning the device's steering wheel.
The BB cuff is inflated with air under FOB vision with the volume necessary to seal the bronchus and initiate one lung ventilation."
1651148|NCT01846936|Procedure|Disconnection technique|Disconnection technique 1) deflate of the blocker cuff, 2) turn-off the ventilator and opened the APL valve allowing both lungs to collapse, 3) after loss of carbon dioxide trace in the capnograph, reinflate blocker cuff with the same volume of air as during the initial insertion, 4) reconnect the tube to the ventilator allowing only dependent-lung reventilation with a 5 cmH2O positive end-expiratory pressure preceded by a single recruitment maneuver performed by elevating the airway pressure to 40 cmH2O for 7 seconds.
1651150|NCT01846910|Behavioral|Tooth Whitening|1. A dental check-up will ensure the absence of contraindications to tooth whitening (cavities, soft tissue pathology, severe periodontitis) 2. Removal of calculus, plaque, or stains with a dental polishing 3. Treatment time is approximately 1 hour total4. Lips are retracted, tongue protector is placed and protective eyewear used 5. Saliva is suctioned and teeth are air dried 6. A liquid rubber dam material is applied to protect gums and cured by visible light. 7. The bleaching material is placed on the enamel surface of the involved teeth and is replaced if drying occurs 8. After 15 minutes, the bleach is suctioned, mouth rinsed and process repeated 9. Three to four applications are typically used
1651151|NCT01846910|Behavioral|Motivational Counseling|Normally three counseling sessions. Session #1: Introductions; discuss habits, feelings, pros and cons of smoking; degree of addiction; previous quit attempts and relapse; reinforce patient confidence; open-ended questions to illicit self-efficacy; homework includes Pack-Track and Why Test. Session #2: Discuss smoking patterns, triggers, and risk situations; discuss methods to resist triggers, need for medications; prepare environment and back-up plan; discuss quit date; homework to review self-help workbook. Session #3: Reinforce previous concepts; review resistance plan; discuss and arrange pharmaceutical cessation aids; set quit date; homework to finalize all self/home preparations; offer tooth polishing on quit date; follow-up by telephone or appointment.
1651152|NCT01846871|Drug|Tivozanib|
1651153|NCT01846845|Device|Conventional Prosthetic Transfemoral Socket System|Conventional transfemoral may include an ischial containment socket, a pin suspension socket, and/or suction suspension socket
1651154|NCT01846845|Device|Novel Prosthetic transfemoral socket system|Prosthetic socket that incorporates lower socket trim-lines and transfemoral vacuum suspension
1651155|NCT01846832|Drug|TMC435|150 mg taken orally (by mouth) as a capsule with food once daily for 12 weeks.
1651156|NCT01846832|Drug|Pegylated interferon alfa-2a (PegIFNα-2a)|180 mcg administered according to the manufacturer's prescribing information as a 0.5 mL subcutaneous (under the skin) (SC) injection once a week in the morning or evening for up to 24 weeks.
1651157|NCT01846832|Drug|Ribavirin (RBV)|1000 mg or 1200 mg administered according to the manufacturer's prescribing information for up to 24 weeks. If the participant's baseline body weight is < 75 kg, the total daily dose of RBV will be 1000 mg, administered orally (by mouth) as 400 mg (2 tablets of 200 mg, intake with food) in the morning and 600 mg (3 tablets of 200 mg, intake with food) in the evening. If the baseline body weight is > or = 75 kg, the total daily dose will be 1200 mg, administered as 600 mg in the morning and evening (3 tablets of 200 mg per intake, with food).
1651158|NCT01846806|Other|Rifaximin|Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 days.
1651159|NCT01846793|Drug|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
1651160|NCT01846780|Procedure|PTA & stenting|PTA & stenting of the iliac veins and/or common femoral vein. Patients who need to undergo endophlebectomy of the common femoral vein with AV-fistula creation are also included.
1651161|NCT01846767|Other|Oral glucose breath test|Simultaneous oral glucose tolerance test and exogenous 13C-glucose breath test following a 12hr overnight fast. Fasting samples were obtained for plasma glucose, insulin, c-peptide, leptin, adiponectin, resistin, HbA1c and two breath 13CO2 abundance values (at t = -15 and -5min). At t = 0min, each subject drank a 75g glucose solution (Thornton & Ross, UK) containing 0.15g of 1-13C glucose. Further breath samples (every 15 min over a 240min interval) and further plasma blood glucose, insulin and c-peptide samples (90,120,180min) were also taken.
1651162|NCT01846741|Device|M106 VNS Therapy System|
1651163|NCT01846728|Drug|Estrogen suppression|Estrogen production will be suppressed for 3 months by administering a drug, lupron, that suppresses ovarian function
1651164|NCT01846715|Biological|Implantation of SRC|
2012907|NCT01377922|Drug|Amifampridine Phosphate|30-80 mg given 3-4 times per day with a maximum single dose of 20 mg (2 x 10 mg tablets).
2012908|NCT01377922|Drug|Placebo|Matching number of tablets to the individual patient's tablet count of active at baseline.
1651167|NCT01846689|Drug|ESS (medical food/drug)|Prescription medical food erythropoietin stimulating system
1651168|NCT01846676|Behavioral|Active Communication Education Program|The program called Active Communication Education (ACE), that is a semistructured rehabilitation program for people with hearing loss, which aims to improve rehabilitation of hearing aids users by a strategy based on problem solution.
1651169|NCT01846676|Other|Control|Participants in this arm will not receive intervention during the study protocol time. After the completion of the protocol, they will receive the same intervention that the intervention group, meaning the ACE program intervention.
1651170|NCT01846663|Drug|Placebo|Placebo, oral, 0 mg BID, 6 months of treatment
1651171|NCT01846663|Drug|Rifaximin|Rifaximin, oral, 550 mg BID, 6 months treatment
1651172|NCT01846650|Drug|Capecitabine tablets|Single oral Capecitabine tablets 2000mg qd
1651173|NCT01846650|Drug|XELODA|Single oral XELODA 2000mg qd
1651174|NCT01846637|Procedure|laparoscopic sleeve gastrectomy|
1651175|NCT01846624|Drug|Decitabine|Given IV
1651176|NCT01846624|Drug|Midostaurin|Given PO
2012909|NCT01376167|Drug|Chloroquine 600mg|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial
2012910|NCT01376167|Drug|Chloroquine 300mg|300mg Chloroquine given to each subject on Day 3 of the trial
2012911|NCT01376167|Drug|Tafenoquine 50mg|single dose 50mg Tafenoquine given to subject on treatment arm 1 on Days 1 or 2
2012912|NCT01376167|Drug|Tafenoquine 100mg|single dose 100mg Tafenoquine given to subject on treatment arm 2 on Days 1 or 2
1651181|NCT01846585|Behavioral|Arousal Based Therapy for Insomnia|Intervention includes education about sleep and a desensitization technique to reduce sleep interfering arousal
1651182|NCT01846585|Behavioral|Cognitive Behavioral Therapy for Insomnia|Intervention includes education about sleep and behavioral and cognitive strategies to improve sleep
1651183|NCT01846559|Biological|Endotoxin|E.coli Endotoxin Day 7 - 2 ng/kg
1651184|NCT01846559|Drug|Clopidogrel|Clopidogrel (tablet) over 8 days Day 1: 300 mg loading dose Day 2-7: 75 mg orally once daily
1651185|NCT01846559|Drug|Ticagrelor|Ticagrelor over 8 days (tablet) Day 1: 180 mg loading dose Day 2-7: 90 mg orally twice daily
1651186|NCT01846520|Other|educational intervention|Receive FCPCI home education sessions
1651187|NCT01846520|Behavioral|telephone-based intervention|Receive FCPCI telephone support sessions and 24 hour telephone support
1717879|NCT00002347|Drug|Nevirapine|
1651190|NCT01846507|Drug|Tranexamic Acid|Subjects will be instructed to take 2 tablets (1300) mg of Lysteda three times daily (3900 mg/daily) for five days during monthly menstruation.
1651191|NCT01846481|Drug|RBP-8000 100 mg|RBP-8000 100 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
1651192|NCT01846481|Drug|Placebo|IV infusion of Placebo administered 1 minute after cocaine infusion on either day 3 or 6.
1651193|NCT01846481|Drug|Cocaine|50 mg intravenous (IV) dose of cocaine administered over 10 minutes on Days 1, 3 and 6.
1651194|NCT01846481|Drug|RBP-8000 200 mg|RBP-8000 200 mg administered in the vein on either study day 3 or 6. There is a 72-hour washout between Days 3 and 6
1651195|NCT01846468|Drug|LHW090|1 mg, 12.5 mg, 100 mg capsules
1651196|NCT01846468|Drug|Placebo|Matching placebo capsules
1651197|NCT01846455|Drug|2.0mg Buprenorphine/0.5mg Naloxone|Each participant received a single sublingual dose of Suboxone® on Day 1 following a fast of at least 8 hours prior to dosing and 2 hours after dosing.
1651198|NCT01846455|Drug|Promethazine|Each participant received a 25-mg or 50-mg promethazine oral dose 30 minutes before Suboxone® administration and then 25-mg promethazine orally or by rectal suppositories every 4 hours as needed for nausea and vomiting during the first 48 hours after Suboxone® administration.
1651199|NCT01846442|Drug|Placebo|Placebo vaginal suppository containing 0.0% (0 mg) DHEA; daily dosing with one suppository for 12 weeks.
1651200|NCT01846442|Drug|DHEA (0.25%)|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
1651201|NCT01846442|Drug|DHEA (0.5%)|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
1651202|NCT01846442|Drug|DHEA (1.0%)|Vaginal suppository containing 1.0% (13 mg) DHEA; daily dosing with one suppository for 12 weeks.
1651203|NCT01846429|Drug|Sodium Bicarbonate|Cohort 1 patients will take 10 capsules/day; cohort 2 patients will take 20 capsules/day; cohort 3 patients will take 30 capsules/day and cohort 4 patients will take 40 capsules/day. Cohort 2 - 4 patients will begin at the cohort 1 dose and dose escalate to their respective cohort doses in order to prevent any side effects associated with alkalosis. Dose escalation will occur at a rate of 10 capsules/week.
1651204|NCT01846416|Drug|Atezolizumab (MPDL3280A) [TECENTRIQ], an engineered anti-PDL1 antibody|Atezolizumab 1200 mg IV on Day 1 of each 21-day cycle until disease progression.
1651205|NCT01846403|Device|Semi-quantitative urine pregnancy test|
1651206|NCT01846390|Drug|Gemcitabine|Group 1 = 1000 mg/m2 D1, D8. Subsequent dose levels according to toxicity = 600-1000 mg/m2 D1, D15.
1651207|NCT01846390|Drug|Dexamethasone|40 mg D1 - D4
1651208|NCT01846390|Drug|Cisplatin|75 mg/m2 D1
1651209|NCT01846390|Drug|Romidepsin|Dose Level 0 - 6 mg/m2 D1, D8. Subsequent dose levels according to toxicity 6-14 mg/m2 D1, D15.
1651210|NCT01846377|Behavioral|G4H-Diab-Nano|The Diab and Nanoswarm games present fun, challenging: knowledge mini-games enabling children to learn desired behavior changes; goal-setting tailored to child's current behaviors and preferences to make lifestyle changes; problem solving to enable children to find strategies to overcome behavior change barriers; motivational statements tailored to child's values to enhance their desire to make the goal related lifestyle changes; and energy balance games to enable them to balance food portions with physical activities. Each game has 9 sessions each with approximately 45-60 min of game-play. At the end of each session, goals are set. The child is allowed to re-play non-behavior change mini-games, and view video segments, but not redo their goal setting or behavior change mini-games.
1651211|NCT01846364|Dietary Supplement|Diindolylmethane (DIM)|300 mg of Bioresponse DIM (100mg/day of active DIM) a day for 30 days
1651212|NCT01846338|Dietary Supplement|green tea extract EGCG|EGCG, 500mg, tid, 4 weeks
1651213|NCT01846325|Dietary Supplement|vitamin E|
1651214|NCT01846325|Dietary Supplement|DHA|
1651215|NCT01846325|Other|placebo|
1651216|NCT01846312|Other|No treatment given|The participants will not receive any treatment.
1651217|NCT01846299|Other|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
1651218|NCT01846299|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
1651219|NCT01846286|Behavioral|Questionnaires|Five questionnaires about pain and symptoms, each taking approximately 25 - 50 minutes to complete
1651220|NCT01846286|Other|Quantitative Sensory Testing|Tests measure sensitivity to touch, coolness, warmth, hot/cold feeling, and pin pricks. The sensory tests will take about 30 minutes to 1 hour to complete.
1651224|NCT01846247|Other|Standard Care + VEM|Patient will receive standard stroke unit care with earlier and additional physiotherapy and nursing sessions as per an intervention protocol.
1651225|NCT01846247|Other|Standard care|
1651226|NCT01846221|Drug|Clonidine|Subjects randomized to clonidine will receive a mixture of 100 micrograms clonidine and 12.5 mg bupivacaine 10 ml of volume.
1651227|NCT01846221|Drug|Fentanyl|Subjects randomized to fentanyl will receive 100 mcg fentanyl and 12.5 mg bupivacaine in 10 ml of volume.
1651228|NCT01846208|Drug|Egg Oral Immunotherapy|Commercially available egg white solid dispensed by the central manufacturer. Study product will be dispensed in vials for low doses, capsules for mid-range doses, and bulk powder with dosing scoops for the higher doses.
1651229|NCT01846208|Drug|Baked Egg|Predetermined food substances with known amounts of Baked Egg (egg protein) with standardized dosing/consumption instructions.
1651230|NCT01846195|Device|CM 1500|
1651231|NCT01846182|Drug|Duloxetine|serotonin norepinephrine reuptake inhibitor
1651232|NCT01846182|Drug|Pregabalin|alpha-2-alpha subunit calcium channel ligand
1651233|NCT01846182|Drug|Placebo|Placebo
1651277|NCT01845792|Drug|Cabazitaxel with Abiraterone Acetate|Cabazitaxel intravenously every 3 weeks, in combination with abiraterone acetate and prednisone orally daily.
1651278|NCT01845792|Drug|Cabazitaxel|Cabazitaxel intravenously every 3 weeks
1651279|NCT01845779|Drug|DCF regimen|
1651234|NCT01846169|Behavioral|Food deliveries|Frequency of food deliveries is based on level of food insecurity at baseline (i.e., more food insecurity receives more frequent food deliveries). Deliveries are tailored to the diet of the client (e.g., consist of soft foods if participant has trouble chewing; has more fruits and vegetables if that was a food category the participant at less of at baseline). The brief nutrition education is a review of basic nutrition concepts and healthy eating ideas.
1651235|NCT01846156|Drug|MgSO4|A randomized controlled study that compare three regimens for administration of MgSO4 used for the cases of severe pre-eclampsia that will be performed in the Obstetrics & Gynecology Department, Kasr Al-Ainy Hospital, Cairo University
1651236|NCT01846143|Biological|pBCAR3-phosphopeptide|
1651237|NCT01846143|Biological|pIRS2-phosphopeptide|
1651238|NCT01846143|Biological|2-MpP (pBCAR3-phosphopeptide + pIRS2-phosphopeptide)|
1651239|NCT01846130|Dietary Supplement|Leucine|
1651240|NCT01846130|Behavioral|Exercise|
1651241|NCT01846130|Dietary Supplement|Whey protein|
1651242|NCT01846117|Dietary Supplement|secoisolariciresinol diglucoside, vitamin D, whey powder|SDG supplementation as a packet of 1.6g/day of BeneFlax containing 600 mg SDG for 24 weeks Vitamin D Natural Product Number (NPN) 80003663 WN Pharmaceuticals Natural Factors Whey Factors
1651243|NCT01846104|Biological|50-μg booster dose RVEc|Subjects will be recruited from the 10 subjects who received three 50-μg doses of RVEc during the Phase 1 trial. Subjects will receive a single booster dose only and will be followed for 6 months after vaccination.
1651244|NCT01846091|Other|Laboratory Biomarker Analysis|Correlative studies
1651245|NCT01846091|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IT
1651246|NCT01846078|Device|optical biometric measurement (IOLMaster)|IOLMaster version 5.4 was used to measure the patients' optical biometry by non contact technique.
1651247|NCT01846039|Device|Crosslinked hyaluronic acid gel|Up to 3 mL administered by intradermal injection
1651248|NCT01846026|Drug|Vitamin D|compare how vitamin D influences the course of ulcerative colitis versus placebo
1651249|NCT01846026|Drug|placebo|
1651250|NCT01846013|Behavioral|Stand|Stand at least half of the workday at work.
1651251|NCT01846013|Behavioral|Move|Increase movement time at work. Move more by making small changes (walking meetings, take stairs, etc).
1651252|NCT01846013|Behavioral|Stand and Move|Increase standing time to half of workday (4h) and increase movement time at work.
1651253|NCT01846000|Procedure|low-level laser treatment|A gallium-aluminum-arsenide laser will be employed for the LLLT and placebo treatment. The device will be calibrated with a wavelength of 780 nm, energy density of 25 J/cm2, power of 50 mW and power density of 1.25 W/cm2. Exposure time will be 20 seconds per point, resulting in a total energy of 1 J per point. The spot application method will be used in contact with the skin and with a conventional tip, covering an area of 0.04 cm2.
1651254|NCT01845987|Drug|Placebo|Placebo, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
1651255|NCT01845987|Drug|CNTO 1959|CNTO 1959 200 mg, as two 1-ml subcutaneous (SC) injections, at Week 0 and Week 4
2012913|NCT01376167|Drug|Tafenoquine 300mg|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2
2012914|NCT01376167|Drug|Tafenoquine 600mg|single dose 600mg Tafenoquine given to subject on treatment arm 4 on Days 1 or 2
1651258|NCT01845961|Drug|Galantamine Hydrobromide-ER|8mg and 16 mg
1651259|NCT01845948|Behavioral|parental training programme|In the experimental group, parents participated in the parental training programme approximately one month before the start of the academic year in primary school. Two social workers, who have minimum five- year experience in giving family counselling,implemented the interventions.
1651260|NCT01845948|Behavioral|Placebo Control|Parents had no intervention except that an information leaflet for parents on helping children to adapt the new primary school life published by Education Bureau was given to each parent in the control group at the end of data collection.
1651261|NCT01845935|Device|Percutaneous Image-guided Cryoablation (FPRPR3508 IceRod® PLUS Needles)|Treatment consists of a percutaneous cryoablation performed under anesthesia and imaging control.
1651262|NCT01845922|Dietary Supplement|Low sodium diet|Low sodium diet
1651263|NCT01845909|Other|ECG and survey screening|
1651264|NCT01845896|Behavioral|Training|
1651265|NCT01845883|Procedure|Deep Brain Stimulation (DBS)|Patients with DBS will participate to the study both when the stimulation is off and on.
1651266|NCT01845857|Behavioral|Chronic Disease Self-Management Workshop|6 week, small group self-management workshop
1651267|NCT01845844|Drug|Ranibizumab 0.3mg/0.05cc|"Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.
Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria."
1651268|NCT01845831|Drug|Sitagliptin|Sitagliptin will be taken orally at 100 mg or 50 mg once a day per renal function.
1651269|NCT01845831|Drug|Basal Bolus|Basal bolus regimen with glargine once daily and rapid-acting insulin (lispro or aspart) before meals + + correction doses of rapid acting insulin if needed
1651270|NCT01845831|Drug|Metformin and Sitagliptin|Janumet is a combination of metformin and sitagliptin. Patients with HbA1c ≤ 7% will be discharged on the combination of metformin and sitagliptin (Janumet ® 500/50 mg) twice daily for 6 months.
1651271|NCT01845831|Drug|Glargine|"Patients with blood glucose between 140-200 mg/dL during hospitalization will receive 0.2 units per kg weight per day.
Patients with blood glucose between 201-400 mg/dL during hospitalization will receive 0.25 units per kg weight per day."
1651272|NCT01845831|Drug|Glargine 50%|Glargine will be prescribed at 50% of daily hospital dose.
1651273|NCT01845831|Drug|Glargine 80%|Glargine will be prescribed at 80% of daily hospital dose.
2012915|NCT01376167|Drug|Primaquine 15mg|15mg Primaquine given once daily to subject on treatment arm 5 on Days 2 to 15.
2012916|NCT01376167|Drug|Chloroquine 600mg (Part 2 )|600mg Chloroquine given to each subject on Day 1 and Day2 of the trial.
2012917|NCT01376167|Drug|Chloroquine 300mg (Part 2 )|300mg Chloroquine given to each subject on Day 3 of the trial.
1651280|NCT01845766|Other|exercise rehabilitation|
2012918|NCT01376167|Drug|Tafenoquine 300mg (Part 2)|single dose 300mg Tafenoquine given to subject on treatment arm 3 on Days 1 or 2.
1651282|NCT01845740|Drug|milatuzumab|Milatuzumab has been used in clinical trials for multiple myeloma, non-Hodgkin's lymphoma and leukemia in the intravenous dosing form. In this study, milatuzumab is being given subcutaneously in patients with lupus.
1651283|NCT01845740|Drug|Placebo|Placebo will be administered subcutaneously once weekly for 4 weeks.
1651284|NCT01845727|Drug|Topical Amphotericin B at 3%|
1651285|NCT01845714|Procedure|Corneal Cross Linking|
1651286|NCT01845714|Procedure|Corneal Cross Linking combined with topoguided PRK|
1651287|NCT01845701|Drug|Artesunate-Amodiaquine|"Pharmacology: Amodiaquine is effective against the erythrocytic stages of all four species of P. falciparum. Amodiaquine accumulates in the parasite's lysosomes and prevents breakdown of haemoglobin on which the parasite depends for its survival.
Artesunate is a water-soluble hemisuccinate derivative of artemisinin. Artesunate and its active metabolite dihydroartemisinin are potent blood schizonticides, active against the ring stage of the parasite.
The fixed-dose combination dihydroartemisinin-piperaquine has a cost advantage over other ACTs that brings it within reach of many, making it a potential best candidate for deployment in Africa and other poor countries. The drug is currently produced in China (Duo-cotecxin®)."
1651288|NCT01845701|Drug|Dihydroartemisinine-Piperaquine|It is a bisquinoline antimalarial drug (1,3-bis[1-(7-chloro-4 quinolyl)-4- piperazinyl]-propane) that was first synthesised in the 1960s, and used extensively in China and Indochina as prophylaxis and treatment during the next 20 years. A number of Chinese research groups documented that it was at least as effective as, and better tolerated than, chloroquine against falciparum and vivax malaria. With the development of piperaquine-resistant strains of P. falciparum and the emergence of the artemisinin derivatives, its use declined during the 1980s. However, during the next decade, piperaquine was rediscovered by Chinese scientists as one of a number of compounds suitable for combination with an artemisinin derivative.
1651289|NCT01845701|Drug|Artemether-lumefantrine combination|CoArtem® is an oral, fixed combination of artemether- a derivative of artemisinin and lumefantrine- a novel molecule developed by the Academy of Military Medical Sciences (AMMS) in Beijing. It is the only co-formulated ACT approved by WHO and is currently available through WHO at a negotiated public sector price. Both compounds are effective as single agents. However, recrudescence is common with artemether and lumefantrine has a slow onset of action. A fixed combination tablet (20 mg artemether/120 mg lumefantrine) has therefore been developed. Fixed combination therapy improves compliance and has the advantage of carrying a lower risk of selecting drug resistant strains. No resistance to either component has been observed to date.
1651290|NCT01845688|Drug|Losartan Tablets & QingReMoShen Granule|
1651291|NCT01845688|Drug|Losartan Tablets & Placebo Granule|
1651292|NCT01845675|Drug|temozolomide or dacarbazine-based chemotherapy, endostatin|
1651293|NCT01845662|Other|Surgical or non-surgical management|Retrospective surgical (splenectomy) or non-surgical management (embolization or conservative management)
1651294|NCT01845649|Drug|Estradiol Vaginal Gel|Daily for 14 days followed by 3 times per week for 10 weeks
1651295|NCT01845649|Drug|Vehicle|Daily for 14 days followed by 3 times per week for 10 weeks
2012919|NCT01376167|Drug|Primaquine 15mg (Part2 )|15mg Primaquine given once daily to subject on treatment arm 3 on Days 2 to 15.
2012920|NCT01376752|Procedure|maximal cytoreductive surgery|maximal cytoreductive surgery with or without HIPEC For HIPEC : the cisplatin will be used at 75mg/m2
1651298|NCT01845623|Drug|QAB149 75 mg Concept 1|QAB149 delivered via the concept 1 device.
1651299|NCT01845623|Drug|QAB149 75 mg Epic Test Fixture|QAB149 delivered via the EPIC test fixture
1651300|NCT01845623|Other|Placebo Concept 1|Placebo administered via the Concept 1 device.
1651301|NCT01845623|Other|Placebo EPIC Test Fixture|Placebo administered via the EPIC Test Fixture.
1651302|NCT01845610|Dietary Supplement|Fortified fat-based paste with essential fatty acids, DHA, ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese|Complementary food supplement providing micronutrients, essential fatty acids, DHA and ARA, phytase, L-lysine, potassium, phosphorous, magnesium and manganese
1651303|NCT01845610|Dietary Supplement|Fortified fat-based paste with essential fatty acids|Complementary food supplement fortified with micronutrients and essential fatty acids
1651304|NCT01845597|Procedure|MAKOplasty® medial UKA|A robot guided medical Unicompartmental knee arthroplasty (UKA) is a procedure to replace only the medial tibiofemoral compartment of the knee.
1651305|NCT01845584|Drug|NPB-01|
1651306|NCT01845558|Drug|Wobenzym® plus|
1651307|NCT01845558|Other|Placebo|
1651308|NCT01845545|Other|Early provision of microfinance|The CPSL staff will support the formation of the self-help groups from the start of the study. The women in this group will have access to microfinance from the first 18 months of the study and will be eligible for emergency loans (up to Rs3000) and general purpose loans, (Rs50-3000) after 3-6 months of starting the self-help group.
1651309|NCT01845532|Drug|TPI|Trigger point injection with 25G needle on the shoulder before surgery(0.5% procaine, 0.25~0.5% lidocaine, 0.125% bupivacaine)
1651310|NCT01845532|Drug|EMLA cream|EMLA cream with occluding dressing on the shoulder before surgery(5% of eutectic mixture with 2.5% lidocaine and 2.5% prilocaine)
1651311|NCT01845519|Behavioral|Tailored Email|Participants will receive tailored emails.
1651312|NCT01845519|Behavioral|Targeted Email|Participants will receive targeted emails.
1651313|NCT01845506|Device|Cardiorespiratory monitor|Subjects will also be fitted with conventional monitoring devices as per the standard of care (3 or 5 lead ECG, pulse oximeter, blood pressure cuff) and will have vital statistics obtained by a trained research assistant at regular 5-minute intervals including blood pressure, heart rate, temperature, and respiratory rate using the standard cardiorespiratory bedside monitor's cycling protocol. The same parameters will be obtained from the wireless sensor at identical time points for a duration of 2 hours. Data obtained from both conventional and study sources will be entered into an encrypted USB device for later analysis.
1651314|NCT01845506|Device|Wireless pressure sensor|Following informed consent, each subject will be fitted with a wireless sensor attached to a conventional laptop computer. The sensors fit around the participant's chest and work as transducers.
1651315|NCT01845493|Dietary Supplement|Alpha Sprout Homogenate|Alpha Sprout Homogenate
2012921|NCT01376115|Drug|Nelarabine|
1651317|NCT01845480|Behavioral|Wellness coaching|Wellness coaching that includes modeling, goal setting, self-monitoring, social support, and health behavior education
1651318|NCT01845454|Device|trūFreeze™ Spray Cryotherapy|The trūFreeze™ System consists of a console containing a holding tank for medical grade liquid nitrogen and a spray tip CSATM Catheter. The physician uses the console to initiate and control the flow and duration of the cryogen spray. The liquid nitrogen is propelled through a spray CSATM Catheter to the selected site by pressure in the holding tank and freezing techniques are monitored by direct visualization with an endoscope. Once the freezing is completed, the cryogen flow is terminated and the thawing system may be engaged to allow accessory removal. If multiple cycles are used, thawing is initiated at the end of the procedure.
1651319|NCT01845441|Drug|Dexmedetomidine|Precedex will be given to randomized subjects in thi study to evaluate its efficacy in maintaining optimal sedation and preserving neurological exam.
1651320|NCT01845441|Drug|Fentanyl|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
1651321|NCT01845441|Drug|Midazolam|Patients in the control arm will receive no medication or standard sedative drug for the interventional procedure.
1651322|NCT01845428|Drug|Pravastatin|After collecting baseline plasma samples, participants will receive pravastatin 20mg daily. After 6 weeks, we will collect samples and safety data. Subsequent statin therapy will be at the discretion of the treating physician.
1651323|NCT01845415|Behavioral|Social Marketing Campaign|The campaign will involve distribution of posters throughout the communities promoting awareness of the consequences of fall injuries and encouraging people to go to an website that provides safety information and injury stories.
1651324|NCT01845415|Behavioral|Intervention components|Doctors and nurses in these communities will perform health education to parents of 1 through 4 year olds around the risks of falls in the home when these parents visit the doctor for regular visits. Also, several parenting classes in these communities will be modified to include educational videos and discussion of these issues
1651325|NCT01845402|Biological|blood and urine samples|A blood sample and urine sample will be collected for purpose of the study. CKD (Chronic kidney injury) will be diagnosed according to the KDIGO criteria in children.
1651326|NCT01845389|Device|Epidural (B. Braun)|20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
1651327|NCT01845389|Device|Spinal (Wiley Spinal Catheter)|The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
1651328|NCT01845376|Procedure|local anesthesia group|Patients will receive local anesthesia similar to that described by Amid et al. except that 1% lidocaine with adrenaline (1:200,000) will be used instead of a mixture of lidocaine and bupivacaine.
1651329|NCT01845376|Procedure|spinal anesthesia group|Patients will be positioned in the lateral position and a Whitacre 25 G needle will be inserted at L3-4 intervertebral space and then heavy bupivacaine 0.5% 15 mg will be injected.
1651330|NCT01845376|Procedure|general anesthesia group|Patients will be induced with propofol 2 mg/kg and fentanyl 1.5 µg /kg. They are then allowed to breathe spontaneously with sevoflurane 2% to 2.5% in a mixture of 60% oxygen through a laryngeal mask. End-tidal concentration of sevoflurane will be adjusted to keep end-tidal sevoflurane 1MAC. Supplemental doses of 25 µg of fentanyl will be administered if intraoperative heart rate and blood pressure are greater than 20% of baseline.
2012922|NCT01371110|Drug|Ketamine|Ketamine hydrochloride is a nonbarbiturate anesthetic. It is formulated as a slight acid (pH 3.5 to 5.5) sterile solution for intravenous or intramuscular injection in concentrations containing the equivalent of either 50 or 100mg ketamine base per milliliter.
1651332|NCT01845350|Other|M2 macrophage introduction|"Generation of autologous M2 macrophages from peripheral blood of non-acute stroke patients
Intrathecal introduction of autologous M2 macrophages"
1651333|NCT01845337|Drug|Teysuno|
1651334|NCT01845337|Drug|Capecitabine|
1651335|NCT01845311|Device|ReZolve2 Scaffold|
2012923|NCT01371110|Drug|Midazolam|Midazolam is a short-acting benzodiazepine central nervous (CNS) depressant.
1651337|NCT01845285|Device|Aortic Valve Replacement|Transthoracic Echo (TTE),CT Scan (ECG triggered, contrast enhanced),Aorto-Iliac Angiogram,Peripheral Evaluation,Coronary Evaluation,12 lead ECG,Arrhythmia Assessment, New York Heart Association (NYHA) functional status, Modified Rankin Score Assessment (mRS) if symptomatic for stroke, Current Cardiac Medications, Transthoracic echo (TTE)
1651338|NCT01845272|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (candesartan 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
1651339|NCT01845272|Drug|candesartan cilexetil 32mg, amlodipine 10mg|Treatment A (amlodipine 10 days), at least 4 days wash-out, Treatment B (candesartan + amlodipine 10 days, 2-period, 2-treatment crossover
1651340|NCT01845259|Drug|Liraglutide|Once a day 1,8 mg subcutaneous injection for 16 weeks
1651341|NCT01845259|Drug|Liraglutide Placebo|Once a day 1,8 mg subcutaneous injection for 16 weeks
1651342|NCT01845246|Device|Prospective TDM Arm of colistin|
1651343|NCT01845220|Drug|Broccoli Sprout Extract|150 nanomol of sulforaphane/cm2 of skin in 80% acetone for 3 applications on 3 successive days prior to alcohol challenge
1651344|NCT01845220|Drug|Placebo|80% acetone
1651345|NCT01845194|Drug|Codeine|"Treatment period 2:
5 mg Codeine once"
1651346|NCT01845194|Drug|Midazolam|"Treatment period 1:
0.2 mg Midazolam 3x
Treatment period 2:
1 mg Midazolam once"
1651347|NCT01845194|Drug|Pravastatin|"Treatment period 2:
5 mg Pravastatin once"
1651348|NCT01845194|Drug|Torsemide|"Treatment period 1:
2.5 mg Torsemide 3x
Treatment period 2:
0.25 mg Torsemide once"
1651349|NCT01845194|Drug|Talinolol|"Treatment period 1:
50 mg Talinolol 3x
Treatment period 2:
2.5 mg Talinolol once"
1651350|NCT01845194|Drug|Caffeine|"Treatment period 1:
50 mg Caffeine 3x"
1651351|NCT01845194|Drug|Metoprolol|"Treatment period 1:
5 mg Metoprolol 3x"
1651352|NCT01845181|Drug|PBF-680|Dose: 10, 20, 40 ,60 mg/day (making combination of 5 y 20 mg forms).
1651353|NCT01845181|Drug|Placebo|1 or 2 or 3 capsules of placebo.
1717880|NCT00002347|Drug|Zidovudine|
2012924|NCT01365793|Drug|0.45% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.45% saline used as the replacement fluid
1651354|NCT01845168|Other|Computer-alert|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in kombination, Adenosine-diphosphate-inhibitor (ADP-inhibitor), blood-thinning medicine, Selective serotonin reuptake-inhibitor (SSRI) and steroids
1651355|NCT01845168|Device|A computer alerts which pops up when the GP presribes NSAID/ASA to a patient with risk-factors|A computer-alert which is activated when the physician is making a prescription for ASA or NSAID. Only for patients with riskfactors such as: Age over 60, males-gender, NSAID and ASA in combination, ADP-inhibitor, bloodthinning medicine, SSRI, and steroids
1651356|NCT01845168|Device|Computer-alert|
1651357|NCT01845155|Behavioral|Neuro-Music-Therapy according to the Heidelberg Model|"The neuro-music therapy according to the Heidelberg Model for tinnitus is a manualized short term music therapeutic treatment lasting for nine consecutive 50-minutes sessions of individualized therapy. Therapy takes place on five consecutive days (from Monday to Friday) with two therapy sessions per day. It comprises both active and receptive forms of music therapy. The interventions are structured into the following modules Directive Counseling, Resonance Training, Neuroauditive Cortex Training, Tinnitus Reconditioning.
For more details on the music therapy see Argstatter et al. 2012"
1651358|NCT01845155|Behavioral|Counselling|Duration: single session of 50 min Tinnitus specific procedures: The counseling group receives the identical counselling procedure as the music therapy group.
1651359|NCT01845142|Drug|single administration of 100.000 I.U. vitamin D|
1651360|NCT01845142|Drug|Placebo|
1651361|NCT01845129|Device|atDCS|atDCS will be delivered with a constant current of 1 mA during simultaneous resting-state (RS) and task-related (picture naming) functional magnetic resonance imaging (fMRI). The current will be turned on prior to the RS-fMRI scan and continues for 20 minutes.
1651362|NCT01845129|Device|sham tDCS|During sham the current will be increeased and decreased in a ramp-like fashion (10 sec)
1651363|NCT01845116|Drug|Omegaven®|10% Omegaven® initiated at a starting dose of 0.5g/kg/day for two days and then advancing to the goal dose of 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
1651364|NCT01845090|Drug|Lanthanum carbonate|the effect on serum FGF23
1651365|NCT01845090|Drug|Calcium Carbonate|Calcium carbonate 500mg~1000 mg tid for 6 months
1651366|NCT01845077|Drug|2x500 mg Metformin (Glumetza)|2 tablets
1651367|NCT01845077|Drug|5 mg Linagliptin/1000 mg Metformin FDC|FDC tablet
1651368|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
1651369|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
1651370|NCT01845077|Drug|3x500 mg Metformin (Glumetza)|3 tablets
1651371|NCT01845077|Drug|5 mg Linagliptin (Tradjenta)|1 tablet
1651372|NCT01845077|Drug|2 x 500 mg Metformin (Glumetza)|2 tablets
1651373|NCT01845077|Drug|5 mg Linagliptin/1000mg Metformin FDC|FDC Tablet
1651374|NCT01845077|Drug|2 x 2.5 mg Linagliptin/750 mg Metformin FDC|2 FDC tablets
1651375|NCT01845064|Drug|DM199|
1651376|NCT01845064|Drug|Placebo|
1651377|NCT01845038|Drug|OTX-TPa ~4µg/day over 2 mos. with natural tears drops|OTX-TPa is a hydrogel punctum plug eluting travoprost in a sustained release of ~4µg/day over 2 months. Subjects in this arm will also receive natural tears drops.
1651378|NCT01845038|Drug|OTX-TPb ~3µg/day over 3 months with natural tears drops|OTX-TPb is a hydrogel punctum plug eluting travoprost in a sustained release of ~3µg/day over 3 months. Subjects in this arm will also receive natural tears drops.
1651379|NCT01845038|Drug|Timolol Maleate (0.5%) dosed twice daily with punctum plug without drug|Timolol Maleate (0.5%) ophthalmic solution dosed twice daily. Subjects in this arm will also have a hydrogel punctum plug without drug placed.
1651380|NCT01845025|Drug|Formoterol 12 mcg|Formoterol 12 mcg one inhalation twice daily, via dry powder inhaler
1651381|NCT01845025|Drug|Fluticasone propionate 100 mcg|Fluticasone propionate 100 mcg one inhalation twice daily via dry powder inhaler
1651382|NCT01845025|Drug|Fluticasone propionate 250 mcg|Fluticasone propionate 250 mcg one inhalation twice daily via dry powder inhaler
1651383|NCT01845025|Drug|Fluticasone propionate 500 mcg|Fluticasone propionate 500 mcg, one inhalation twice daily via dry powder inhaler
1651384|NCT01845025|Drug|Placebo|Placebo to match formoterol one inhalation twice daily via dry powder inhaler
1651385|NCT01845012|Other|Daily hemodialysis at low dialysate flow|Daily hemodialysis at low dialysate flow during 3 months: 6 times 2h to 2h30 per week at a dialysate flow rate of 200 ml/min in order that the total duration of weekly dialysis is equivalent to the duration of weekly dialysis during the last 3 months of conventional hemodialysis. Other parameters of dialysis (dialysate, dialysis machine, generator, blood flow, anticoagulation) are the same as the reference period of conventional hemodialysis.
1651386|NCT01844999|Behavioral|Personal Patient Profile - Prostate (P3P)|Website supporting informed patient decision making about prostate cancer care through tailored education and coaching
1651387|NCT01844999|Behavioral|Standard prostate cancer information websites|Standard prostate cancer information websites (e.g., NCI, ASCO) presented to patients in addition to patient education that is usual in their clinics
1651388|NCT01844986|Drug|Olaparib 300mg tablets|Olaparib/placebo tablets p.o 300mg twice daily for up to 2 years or until objective radiological disease progression as per RECIST as assessed by the Investigator. Patients with evidence of stable disease (or those who have progressed), may continue on treatment beyond 2 years, if in the patient's best interest. Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
1651389|NCT01844973|Drug|M518101|Proper quantity twice a day
1651390|NCT01844973|Drug|Vehicle|Proper quantity twice a day
1651391|NCT01844960|Procedure|Single Incision Gastric Band Insertion|Insertion of gastric band though single abdominal incision
1651392|NCT01844960|Procedure|Multiple Incision Gastric Band Insertion|Insertion of gastric band though multiple abdominal incisions
1651435|NCT01844609|Behavioral|Self Study Journal Club|This Self Study Journal Club will read articles and prepare written answers to the study questions on their own time. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
1651393|NCT01844947|Drug|Vinflunine|"Vinflunine (Javlor®, Pierre Fabre Pharma): 320 mg/m2 I.V., day 1, repeated every 21 days for patients with PS 0, adequate renal (creatinine clearance >60 ml/min) and hepatic function (as described in the inclusion criteria). PLEASE NOTE THAT THE 320 mg/m2 ARM IS CLOSED FOR RECRUITMENT.
For patients with PS 1, or age 75 to 80 years, or exposed to radiation of the lower pelvis region, or with impaired renal function (creatinine clearance 40-60 ml/min) but adequate hepatic function (as described in the inclusion criteria), the dose of vinflunine is 280 mg/m2 I.V. day 1, repeated every 21 days."
1651394|NCT01844947|Drug|Sorafenib|"Sorafenib (Nexavar®, Bayer HealthCare) daily dosage from day 2 through day 21 (repeated every 21 days):
Step 1: 400 mg P.O. (i.e. one (1) tablet 200 mg morning and evening, 1+0+1) Step 2: 600 P.O. (i.e. one (1) tablet 200 mg morning and two tablets evening, 1+0+2) Step 3: 800 mg P.O. (i.e. two (2) tablets 200 mg morning and evening, 2+0+2) Doses of sorafenib higher than 400 mg P.O. b.i.d. are not allowed."
1651395|NCT01844934|Other|Prehabilitation|The three week, 3 days / week prehabilitation exercise program will consist of resistance training, step training and stretching(flexibility) as well as cardiovascular endurance training. Intensity of training will increase over the three weeks. Classes will be delivered over a four week period with a gap during the third week allowing additional time for participants to practice their exercises. The home exercise program will be designed to account for the additional week.
1651396|NCT01844908|Procedure|Electroacupuncture|
1651397|NCT01844895|Drug|Abatacept|
1651398|NCT01844869|Drug|omacetaxine mepesuccinate|
1651399|NCT01844856|Drug|Eravacycline|
1651400|NCT01844856|Drug|Ertapenem|
1651401|NCT01844856|Drug|Placebo|Administered IV to maintain the blind.
1651402|NCT01844843|Device|TCD-10023 drug eluting stent|Implantation of new drug eluting stent in coronary artery lesions
1651403|NCT01844830|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Intranasally administered regional anesthetic
1651404|NCT01844830|Drug|Placebo|Inactive ingredients supplied in identical nasal sprayer
1651405|NCT01844817|Drug|OGX-427|Three separate administrations of OGX-427 will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive 600mg OGX-427 prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. OGX-427 will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
1651406|NCT01844817|Drug|Placebo|Three separate administrations of Placebo will be given during the 9-day Loading Dose Period. Following the Loading Dose Period, patients will receive placebo prior to the administration of nab-paclitaxel (125mg/m2 IV)and gemcitabine (1000mg/m2 IV)administration on Day 1, 8, and 15 of each cycle. Placebo will also be administered on Day 22 during each cycle (i.e., weekly). Patients will continue 28 day treatment cycles until disease progression or until other reasons for discontinuation from treatment.
1651407|NCT01844804|Biological|PF-06438179|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
1651408|NCT01844804|Biological|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
1651409|NCT01844804|Biological|Remicade|Single-dose of 10 mg/kg administered as an intravenous infusion in not less than 2 hours on Day 1
1651410|NCT01844791|Drug|OCZ103-OS|OCZ103-OS is given in combination with chemotherapy each cycle
1651411|NCT01844791|Drug|Platinum|Platinum is given as standard chemotherapy each cycle
1651412|NCT01844791|Drug|Gemcitabine|Gemcitabine is given as standard chemotherapy each cycle
1651413|NCT01844778|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder was administered via TOBI® Podhaler (T-326 inhaler).
1651414|NCT01844778|Drug|Tobramycin inhalation solution|Tobramycin inhalation solution was administered via nebuliser
1651415|NCT01844778|Drug|Colistimethate|Colistimethate was administered via nebuliser.
1651416|NCT01844765|Drug|nilotinib|Nilotinib will be administered at 230mg/m2 ,twice daily for up to 66 cycles (1 cycle = 28 days). Drug will be supplied in 50mg, 150mg,and 200mg capsules. Dose administration will be rounded to the nearest 50mg dose (to a maximum dose of 400mg).
1651417|NCT01844752|Drug|NVN1000 1% Gel|Twice daily NVN1000 1% Gel for 12 weeks
1651418|NCT01844752|Drug|NVN1000 4% Gel|Twice daily NVN1000 4% Gel for 12 weeks
1651419|NCT01844752|Drug|Vehicle Gel|Twice daily Vehicle Gel for 12 weeks
1651420|NCT01844739|Drug|NVN1000 4% Gel|
1651421|NCT01844739|Drug|Vehicle Gel|
1651422|NCT01844726|Drug|GLYX-13|Single injection (5 mg/kg) of GLYX-13, an NMDAR partial agonist
1651423|NCT01844726|Drug|Placebo|Single injection of placebo (saline)
1651424|NCT01844713|Behavioral|Workbook|Subjects will read a workbook about sun protection
1651425|NCT01844700|Drug|Ziprasidone|random assignment to ZIP (20-160mg/d, bid dosing)
1651426|NCT01844700|Drug|aripiprazole, quetiapine, or risperidone|random assignement to Usual Care antipsychotic UC antipsychotic (aripiprazole 2-30mg/d, quetiapine 25-800mg/d or risperidone 0.1-8mg/d)
1651427|NCT01844687|Drug|CBD|Each subject in the study was tested on eight days, each day receiving a different combination of active/inactive cannabis cigarettes plus 0, 200, 400 or 800 mg of CBD in random order. Cigarettes contained either 0.01 or 5.30% THC. At each visit, participants were given four gelatin capsules containing lactose and 0 or 200 mg of CBD in combinations to achieve scheduled dose level.
1651428|NCT01844674|Drug|Tizanidine|Participants will receive tizanidine as single oral doses, 2 milligrams (mg) on Day 1 and repeated on Day 22, each following an overnight fast >/= 10 hours.
1651429|NCT01844674|Drug|Vemurafenib|Participants will receive vemurafenib as multiple oral doses, 960 mg twice daily on Days 2 to 22.
1651430|NCT01844661|Biological|CELYVIR|
1651431|NCT01844648|Drug|NH004 tropicamide|Intra-oral slow dissolving muco-adhesive thin film containing 1 mg tropicamide
1651432|NCT01844648|Drug|NH004 Placebo|Intra-oral slow dissolving muco-adhesive thin film
1651433|NCT01844635|Drug|Thymoglobulin|
1651434|NCT01844622|Other|Domperidone|Domperidone dosage may be increased depending on how well the patient responds. However before increasing the dosage, patients will have follow-up EKG to evaluate any possible side effects including irregular heartbeats.
1651591|NCT01843452|Biological|PANITUMUMAB|6 mg/kg IV administered over 60 min infusion on days 1,15 and 29.
1651436|NCT01844609|Behavioral|Intensive Journal Club|This Intensive Journal Club will read articles and prepare written answers to the study questions along with a fluent English speaker. The participants will read 24 articles; 12 gynecology and 12 obstetrics, based on monthly journal clubs available online at the Obstetrics and Gynecology website. Participants will prepare oral presentations of the studies and answers to the study questions. They will have interactive sessions with this fluent English speaking monitor 3 times a week, one hour sessions for 8 weeks. The first and last article will serve as a basis for the oral and written exam in which they will be tested on comprehension, verbal and written Medical English.
2012925|NCT01365793|Drug|0.9% saline replacement fluid|10cc/Kg bolus of 0.9% saline followed by 0.9% saline used as the replacement fluid.
2012926|NCT01365793|Drug|0.45% saline intravenous fluid|0.45% saline fluid
1651439|NCT01844583|Drug|alisertib|
1651440|NCT01844583|Drug|esomeprazole|
1651441|NCT01844583|Drug|rifampin|
1651442|NCT01844557|Other|Swallowing Exercises|Participants perform 3 swallowing exercises.
1651443|NCT01844557|Behavioral|Symptom Inventory|Participants complete an M.D. Anderson Symptom Inventory for Head and Neck Cancer Patients before swallowing exercise procedure.
1651444|NCT01844557|Behavioral|Questionnaires|Participants fill out 3 questionnaires after swallowing exercises. The questionnaires will take about 10 minutes to complete.
1651445|NCT01844544|Other|inspection of medical records|
1651446|NCT01844531|Drug|empagliflozin|single tablet empagliflozin
1651447|NCT01844531|Drug|metformin (Glucophage®)|single tablet metformin
1651448|NCT01844531|Drug|metformin (Glucophage®)|single tablet metformin
1651449|NCT01844531|Drug|empagliflozin|single tablet empagliflozin
1651450|NCT01844531|Drug|empagliflozin and metformin|FDC tablet empagliflozin and metformin
1651451|NCT01844531|Drug|empagliflozin and metformin|FDC tablet empagliflozin and metformin
1651452|NCT01844518|Biological|Abatacept|
1651453|NCT01844505|Biological|Nivolumab|
1651454|NCT01844505|Biological|Ipilimumab|
1651455|NCT01844505|Biological|Placebo for Nivolumab|
1651456|NCT01844505|Biological|Placebo for Ipilimumab|
1651457|NCT01844492|Behavioral|The PARTNER Intervention|"In general terms, the PARTNER intervention gives 1) new leadership responsibilities and advanced communication training to the local nurse leaders and social work members of the ICU team and 2) makes systems-level changes to reliably achieve desired care practices. One PARTNER interventionist is assigned as the main support for each family, and, through detailed hand-offs and introductions, the ICU's other interventionists fill in when needed. The interdisciplinary intervention 1) gives new responsibilities and advanced communication skills training to existing ICU staff (local nurse leaders and social work members of the ICU team); 2) changes care defaults to ensure frequent clinician-family meetings; 3) adds protocolized, nurse-administered coaching and emotional support of surrogates before and during clinician-family meetings, and 4) increases use of palliative care services for patients with a poor prognosis."
1651458|NCT01844492|Other|ICU Usual Care Control|The control group will receive usual care, in which the frequency and content of clinician-family communication is determined by the clinical team according to their usual practice. No study ICU has a protocolized approach to family communication and instead clinicians determine the timing and frequency of communication with families. All sites have palliative care services.
1651459|NCT01844479|Device|diabetic foot orthotic|The Dynamic Foot Orthosis (DFO) is designed with a rolling link mechanism at the distal 3rd to reduce sliding friction at the metatarsal heads in addition to decreasing compressive forces. The relative sliding motion of two compliant surfaces over each other allows some deformation horizontally and lowers frictional resistance. The DFO addresses the friction element by accommodating the normal sliding and rolling motion at the distal 3rd of the foot during gait. Additionally, the DFO has a silicone layer at the metatarsal head and the remainder of the anterior section made of 2 separated orthotic layers that slide over each other. This provides an articulating surface to provide a relative motion between the orthotic segments while transmitting load.
1651460|NCT01844479|Other|Standard innersole|
1651461|NCT01844466|Procedure|Physiotherapy and speech therapy|
1651462|NCT01844453|Procedure|Endometrial Biopsy|The Local Endometrial Injury will be performed using the standard technique using a Pipelle sampling catheter in the outpatient department. After a speculum examination is performed and the cervix is well visualized, the Pipelle will be inserted gently through the cervical canal into the uterine cavity and advanced slowly until resistance is noted. At this point the internal piston is withdrawn to create negative suction and the Pipelle is gently maneuvered up and down alongside the uterine cavity wall. The Pipelle catheter is then withdrawn gently and any obtained specimen (uterine lining) will be sent for histopathological examination.
1651463|NCT01844440|Procedure|High resolution manometry|Subjects will undergo impedance / manometry recording with solid-state catheter systems, during a 30-min fasting and a 2-hour postprandial periods.
1651464|NCT01844427|Drug|Memantine|Memantine HCl is an NMDA antagonist currently FDA approved for the treatment of moderate to severe Alzheimer's-type dementia.
1651465|NCT01844427|Drug|Placebo|
1651466|NCT01844414|Behavioral|Parolee Comprehensive Care + Phone Coach|A nurse case managed and specialized hepatitis education program with the hepatitis A/B (HAV/HBV) vaccination series (to all eligible) and coach-facilitated mentoring (mostly by cell-phone).
1651467|NCT01844414|Behavioral|Parolee Brief HBV Program + Phone Coach|A brief hepatitis/HIV education program with the Hepatitis A/B vaccine series and coach-facilitated mentoring.
1651468|NCT01844414|Behavioral|Usual Care Group|Control Group: A brief general health information program with one-on-one coaching and the Hepatitis A/B vaccine
1651469|NCT01844401|Drug|Albuterol Spiromax®|Albuterol Spiromax® 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
1651470|NCT01844401|Drug|ProAir® HFA|ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
1651471|NCT01844388|Drug|carboxymethylcellulose based eye drop formula|1-2 drops of carboxymethylcellulose based eye drop formula in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
2012927|NCT01365793|Drug|0.9% saline Intravenous fluid|0.9% saline fluid
1651472|NCT01844388|Drug|carboxymethylcellulose sodium based eye drop solution|1-2 drops carboxymethylcellulose sodium based eye drop solution (REFRESH CONTACTS®) in each eye, a minimum of 4 times a day for 90 days. One of the 4 times a day may be to prepare the contact lens for insertion.
1651473|NCT01844375|Dietary Supplement|Carbohydrate group|The patients will be given 12.5% carbohydrates drink 800 mL the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
1651474|NCT01844375|Other|Control group|The patients will be given water 800 mL to drink the night before surgery, between 1900 and 2400 h, and another 400 ml in the morning.
1651475|NCT01844362|Procedure|uterine transplantation|Transplantation of the uterus from live donor and IVF treatment.
1651476|NCT01844336|Device|PBASE system 1.1 + CT100 (active treatment)|
1651477|NCT01844336|Device|PBASE system 1.1 + CT100 (placebo treatment)|
1651478|NCT01844323|Other|Palbociclib Formulation Reference|Single 45 mg dose; Dosage form is capsule taken orally.
1651479|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
1651480|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
1651481|NCT01844323|Other|Palbociclib Formulation Test|Single 45 mg dose; Dosage form is capsule taken orally.
1651482|NCT01844310|Drug|RAL+TDF+LPV/r|Group A will be assigned with RAL-based regimen (RAL+TDF+LPV/r).
1651483|NCT01844310|Drug|3TC+TDF+LPV/r|Group B will be assigned with 3TC+TDF+LPV/r
1651484|NCT01844297|Drug|TDF+3TC+EFV|
2012928|NCT01363258|Behavioral|Managing Oral Hygiene Using Threat Reduction (MOUTh )|The intervention combines best mouth care practices with a constellation of behavioral techniques that reduce threat perception and thereby prevent or de-escalate care-resistant behavior.
2012929|NCT01363258|Procedure|Evidence-based mouth care|Mouth care tailored to the needs of older adults, including care of dentures.
1651487|NCT01844271|Device|Low Level Laser (LLL)|"Comparison of different dosages of a Low Level Laser applied in six different locations of the knee extensor muscles of the lower limb non-dominant before a strenuous exercise.
We performed stretching and warming up of the muscles involved, assessment of muscle pain, withdrawal of blood sample, test muscle function (MVC), application of dose of low level laser designated for each volunteer (0, 2, 6 or 10), performing eccentric contractions protocol in isokinetic dynamometer . After the protocol we evaluated muscle function, the DOMS, and blood analyzes in 1 minute, 1 hour, 24 hours, 48 hours 72 hours and 96 hours.
In a second stage, the optimal dose defined by the first part of the study will be tested in two different powers, 100 and 400mW. The study was repeated in two experimental groups using the optimal dose established and the powers of 100 and 400mW that was randomly distributed in groups."
1651488|NCT01844258|Procedure|Modified technique|Peripheral 1-1.5 mm curvilinear capsulorhexis of anterior capsule
1651489|NCT01844258|Procedure|Traditional technique|Central 5-6 mm curvilinear capsulorhexis of anterior capsule
1651490|NCT01844245|Procedure|Radiofrequency ablation (RFA)|The RFA probe is introduced into bile duct. Bipolar electronic coagulation is performed to the tumorous segment.
1651491|NCT01844232|Drug|arbaclofen|Arbaclofen ER tablets, 20 mg, 30 mg and 40 mg
1651492|NCT01844219|Procedure|elective or emergency aortic surgery (including ascending, arch, descending thoracic aorta)|
1651493|NCT01844206|Drug|Epidural Morphine|Patients will be given 3mg epidural morphine, 24 hours after the initial dose.
1651494|NCT01844206|Drug|Epidural Saline|Patients will be given epidural saline 6ml, 24 hours after receiving epidural morphine 3 mg.
1651495|NCT01844193|Device|Compex Rehab|"Participants in this arm will use a Compex® Rehab unit for neuromuscular electrical stimulation starting with postoperative at-home day 1 and continue using the unit twice a day, every day, until a 10-week follow-up is reached. The unit produces a 380 microsecond biphasic curve and utilizes a four phase process for the treatment (Warm-up, Work, Relaxation, and Recovery) for a total treatment time of 20 minutes and 5 seconds per session. All frequencies are delivered at the maximum subjective tolerable intensity. Participants will control this intensity and be asked to select a level that is tolerable although mildly uncomfortable; they will be instructed to increase this intensity as tolerated."
1651496|NCT01844180|Drug|ONO-2952|
1651497|NCT01844180|Drug|ONO-2952 Matching Placebo|
1651498|NCT01844167|Procedure|Noxipoint Therapy (NT)|"• For severe chronic neck pain patients, cervical braces are recommended within the first 2-3 days of each treatment session. The patient has to avoid using the treated tissues/muscles during the Rest Period: Similar to all other cells, the muscle cell healing or regeneration takes time. Patients are instructed not to use the newly recovered muscle/tissue during the Rest Period, which is about three days if they are forty or younger, plus about one extra day for every 10 additional years of age. If the patient has extensive injured muscles, take two more days of rest. Ice packs may be used during or soon after the session to prevent Delayed Onset of Muscle Soreness (DOMS) from the TENS stimulation."
1651499|NCT01844167|Procedure|Physical therapy(PT)|•Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded. Placebo effect consideration: TENS is included in both arms to obfuscate the process. Using TENS in the PT arm serves both as a sham-therapy-equivalent to what is used in the NT arm to neutralize placebo bias, and as a meaningful therapeutic remedy. The subject is thus blinded.
2012930|NCT01363102|Procedure|SOMS|Apply a number to mobilization goal for patient
2012931|NCT01352494|Drug|docetaxel|docetaxel - 75 mg/m2, IV (in the vein), every 3 weeks, 4 cycles
1651502|NCT01844128|Dietary Supplement|weight loss|
1651503|NCT01844115|Drug|Placebo|
1651504|NCT01844115|Drug|Vilazodone|Viibryd
1651505|NCT01844102|Device|PrePex|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
1651592|NCT01843452|Drug|MITOMYCIN|10 mg/m2 IV administered over 15 min infusion on days 1 and 29.
1651506|NCT01844076|Drug|Phase I (Quinacrine)|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
1651507|NCT01844076|Drug|Capecitabine|The Phase I portion of the study will aim to determine the tolerability of both agents in combinations when used at established clinical doses. This portion of the study will more closely resemble a pilot study or feasibility study rather than a dose escalation.
1651508|NCT01844063|Genetic|Conventional plus BM-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times).
1651509|NCT01844063|Genetic|Conventional plus UC-MSC treatment|Received conventional treatment and bone marrow mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×10e5/Kg,1×10e6/Kg,or 1×10e7/Kg, once a week, 8 times)
1651510|NCT01844063|Drug|Conventional treatment|"Received conventional treatment including:
A.antiviral drugs(Entecavir,Lamivudine,Adefovir dipivoxil,et al); B.Hepatoprotective drugs(Ademetionine1,4-butanethiosulfonate for Injection, Reduced Glutathione for Injection,Polyene Phosphatidylcholine, et al); C.Plasma."
1651511|NCT01844050|Drug|Chinese herbal medicine|According to the traditional Chinese medicine syndrome of subject to make up a prescription within the 35 kinds of chosen Chinese herbal medicine, and the dosage without limitation.
1651512|NCT01844050|Drug|Placebo|
1651513|NCT01844037|Device|OneShot Ablation System|Renal denervation
1651514|NCT01844024|Other|misoprostol by midwife|Women with incomplete abortion is diagnosed and treated with misoprostol by midwife
1651515|NCT01844011|Other|Daily electronic reminders|Women in the intervention arm will be sent either daily text messages on the weekdays on their cell phone or emails on the weekdays reminding them to track kick counts on the chart
1651516|NCT01843998|Drug|Sirolimus 0.1% Ointment|Sirolimus 0.1% ointment will be applied topically to all affected areas of the skin twice daily for 6 months or until progression or unacceptable toxicity.
1651517|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 6
1651518|NCT01843972|Drug|BI 691751|oral solution
1651519|NCT01843972|Drug|Placebo|placebo solution
1651520|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 2
1651521|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 5
1651522|NCT01843972|Drug|BI 691751|1 tablet
1651523|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 3
1651524|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 4
1651525|NCT01843972|Drug|BI 691751|oral solution BI 691751, dose 7
1651526|NCT01843972|Drug|BI 691751|oral solution BI 69175, dose 1
1651527|NCT01843933|Device|Capnography|Capnostream 20 Portable Capnography Monitor with Internal Printer by Oridion
1651528|NCT01843920|Drug|Timolol-dorzolamide (Glaucoma drops)|Patients will receive the standard post-operative drops regardless of what group you are in. The glaucoma drops will only be given to the experimental group.
1651529|NCT01843920|Drug|standard post-operative topical drops|Patients will receive the standard post-operative drops regardless of what group ther are in. The standard post-operative drops are Prednisolone acetate,Polymyxin B and Trimethoprim
1651530|NCT01843907|Behavioral|Empowerment|To give patients the necessary resources to take care of their own health
1651531|NCT01843907|Other|Conversation with nurse|To find out, if the nurse, using her ....
1651532|NCT01843894|Biological|RU-101|Recombinant human serum albumin
1651533|NCT01843881|Drug|Exendin 9, 39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
1651534|NCT01843881|Drug|Placebo|A saline infusion will be given to match the study drug infusion.
1651535|NCT01843868|Drug|Standard anti-emetics in conjunction with R-CHOP|
1651536|NCT01843855|Drug|Exendin 9,39|Exendin 9,39 is a competitive antagonist of endogenous GLP-1.
1651537|NCT01843855|Drug|Placebo|A saline infusion will be given to match the study drug infusion.
2012932|NCT01352494|Drug|gemcitabine|gemcitabine - 100 mg/m2, IV (in the vein) on day 1 and 8 day of each 28 day cycle, 4 cycles
2012933|NCT01350882|Drug|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
1651540|NCT01843829|Drug|Oxaliplatin|
1651541|NCT01843829|Drug|Capecitabine|
1651542|NCT01843829|Drug|Carboplatin|
1651543|NCT01843829|Drug|Paclitaxel|
1651544|NCT01843829|Radiation|Radiotherapy|
1651545|NCT01843829|Procedure|Surgery|Patients will have their tumour surgically removed by two-phase oesophagectomy and two-field lymphadenectomy.
2012934|NCT01350882|Drug|Physiological serum : sodium chloride, sodium citrate|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
2012935|NCT01350700|Other|Scars assessment & QOL|Scar assessment and quality of life questionnaires
1651548|NCT01843790|Drug|GCS-100|The amount (in mg) of GCS-100 to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The study drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
1651549|NCT01843790|Drug|Placebo, Saline|The amount (in mg) of drug to be administered will be determined based on body surface area, which will be calculated based on body weight and height. The drug dose should be calculated on Day 1. Drug should be added to an infusion bag or syringe containing 0.9% Sodium Chloride Injection, USP. Drug be infused into a large vein via a large bore catheter to avoid local irritation and administered at no more than 2 mg/mL in no less than 60 mL.
1651550|NCT01843777|Behavioral|Standard-of-Care|the standard of care in audiologic practice
1651551|NCT01843777|Behavioral|Treatment|motivational interviewing
1651552|NCT01843764|Device|HRP2 and LDH based rapid diagnostic tests for P.falciparum|
1651593|NCT01843452|Drug|CAPECITABINE|825mg/m2 orally twice daily on study days 1 through 45.
1651594|NCT01843439|Dietary Supplement|Magnesium|
1651595|NCT01843439|Behavioral|Education for asthma action plan|
1651596|NCT01843439|Behavioral|hot-lines for acute exacerbation of asthma|
1651553|NCT01843751|Drug|buprenorphine/naloxone|Buprenorphine/naloxone (Suboxone) is considered a well-investigated, highly effective medication-assisted treatment for opiate dependence, but it may only be supervised through the few specialist treatment facilities in the state, or by physicians who have historically been less likely to offer this service. The effectiveness of community physician treatment supervision has not been tested for those in the criminal justice system.
1651554|NCT01843738|Radiation|Radiation therapy|Per standard of care
1651555|NCT01843738|Drug|Vemurafenib|The starting dose of vemurafenib will be the patient's baseline tolerating dose, between 720 - and 960 mg PO bid.
1651556|NCT01843725|Drug|capecitabine|escalation dose of capecitabine continuously
1651557|NCT01843725|Drug|aflibercept|Intravenous 6mg/kg every 3 weeks
1651558|NCT01843725|Drug|Capecitabine|dose escalation, from 1700 to 2500mg/m2/day 2 weeks out of 3
1651559|NCT01843699|Drug|Topiramate flexible dosage|
1651560|NCT01843699|Drug|Placebo matching tablets|
1651561|NCT01843699|Behavioral|4-session gambling cognitive restructuring|
1651562|NCT01843686|Device|Magellan®|Autologous Platelet Rich Plasma Prepared Using the Magellan System
1651563|NCT01843686|Other|Placebo Saline Gel and Usual and Customary Standard of Care|
1651564|NCT01843673|Procedure|computed tomography|Undergo FBCT
1651565|NCT01843673|Procedure|cone-beam computed tomography|Undergo dual CBCT
1651566|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Varian kV OBI
1651567|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Brain Lab ExacTrac
1651568|NCT01843673|Procedure|radiography|Undergo 2-D x-ray with Varian MV OBI
1651569|NCT01843673|Procedure|electronic portal imaging|Undergo EPID imaging
1651570|NCT01843673|Radiation|image-guided adaptive radiation therapy|Undergo IGART
1651571|NCT01843660|Drug|Tramadol HCl-Paracetamol|Participants will receive 1 to 2 tablets of tramadol HCl-paracetamol orally once daily (each tablet containing tramadol 37.5 milligram [mg] and paracetamol 325mg) for up to a total duration of 6 hours. Additional dose may be given based upon the clinical requirement.
1651572|NCT01843647|Drug|Icotinib|Patients receive 8-week icotinib induction treatment before surgery and 1-year icotinib adjuvant therapy after surgery.Icotinib is administered orally with a dose 125 mg 3 times daily.
1651573|NCT01843647|Drug|Chemotherapy|"After surgery patients receive 4-cycle adjuvant chemotherapy with vinorelbine
/cisplatin regimen, until untolerable toxicity or disease progression."
1651574|NCT01843634|Drug|ODSH|
2012936|NCT01348438|Device|Medtronic Engager Transcatheter Aortic Valve Implantation System|Transapical implantation of the Medtronic Engager Transcatheter Aortic Valve Implantation System
2012937|NCT01346189|Behavioral|Behavioral Economic Intervention|Various combinations of financial incentives to patients and providers.
1651577|NCT01843595|Behavioral|REFIT Intervention|The intervention will include 2 face-to-face group meetings, weekly check-in sessions, weekly tailored feedback, and weekly lessons focused on specific weight loss behaviors. All participants will be encouraged increase their physical activity to approximately 250 minutes of moderate to vigorous physical activity per week.
1651578|NCT01843569|Biological|In Vitro maturation|
1651579|NCT01843556|Drug|E2022 Tape Formulation|E2022 tape formulation applied to different application sites and at different intervals in Japanese healthy elderly males
1651581|NCT01843530|Drug|Berinert|
1651582|NCT01843530|Drug|Clemastin|
1651583|NCT01843530|Drug|Cortisone acetate|
1651584|NCT01843530|Drug|NaCl|
1651585|NCT01843504|Biological|platelet rich plasma|A blood draw of 15 mL of the subject's own blood will be performed. The study coordinator will then place the sample in the Platelet Separator System (a centrifuge) and spin the blood sample in using a two-stage spinning: the 1st separates red blood cells from platelets, and the 2nd concentrates the platelets. This will be spun by centrifuge to yield 6 mL of concentrated autologous platelet. Under continuous ultrasound evaluation, 1.0-2.0 mL of the prepared PRP will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
1651586|NCT01843504|Other|saline|A blood draw of 15 mL of the subject's own blood will be performed to maintain blinding. Under continuous ultrasound evaluation, 1.0-2.0 mL of the saline solution will be injected onto the origin of the patella tendon itself will be peppered along a short segment of the tendon into the areas of palpated tenderness and US-documented pathology.
1651587|NCT01843491|Biological|Ad-PfCA|Vaccine
1651588|NCT01843478|Other|Self-Collected HPV Test|The HPV self-collected test is followed by results counseling by phone when the result is available (usually 2-3 weeks). Women are encouraged to have Pap testing.
1651589|NCT01843465|Other|Maneuvers for documenting the disconnection|
1651590|NCT01843452|Radiation|RADIOTHERAPY|"External beam radiotherapy (daily fraction dose 1.8Gy) on Monday through Friday starting on study day 1.
Days 1-28, dose of 36 Gy in 1.8 Gy/fraction (20 fractions) to the clinical target volume 1 (CTV1) including the primary tumor and involved lymph nodes and areas at risk for metastatic spread (which includes gross tumour volumes (GTV) and a 1-cm expansion, mesorectal space, inguinal, femoral, external iliac, internal iliac, and common iliac vessels).
Days 29-45, a boost dose of 23.4 Gy in 1.8 Gy/fraction (13 fractions) to the GTV."
2012938|NCT01344824|Biological|bevacizumab|15 mg/kg once per 21 day cycle (up to 4 cycles).
2012939|NCT01344824|Drug|carboplatin|Area Under the Curve (AUC)=6, once every 21 day cycle (up to 4 cycles)
2012940|NCT01344824|Drug|erlotinib hydrochloride|150mg, daily for 21 day cycle (up to 4 cycles)
2012941|NCT01344824|Drug|pemetrexed disodium|500 mg/m2 on day 1 of a 21 day cycle (up to 4 cycles)
2012942|NCT01340911|Drug|SRT3025|SRT3025 will be supplied as hard gelatin capsules containing either 27.4 mg (25 mg SRT3025 free base equivalent) or 274 mg (250 mg SRT3025 free base equivalent) of SRT3025 HCl monohydrate drug substance.
1651597|NCT01843439|Behavioral|Inhaler technique training|
1651598|NCT01843426|Drug|Low-volume, low-concentration contrast (iodixanol - Visipaque 270) CT scan|An ECG-synchronized, contrast-medium enhanced CT study of the heart for the evaluation of the aortic root complex and general cardiac morphology will be obtained. This is immediately followed by a CT angiographic study of the chest, abdomen, and pelvis (beyond the femoral heads), which utilizes the same contrast bolus that is injected for evaluating the heart. This latter vascular study serves to evaluate the TAVR deployment catheter access route through the femoral, iliac, and aortic vascular stations. In clinical routine, we have been performing this type of study with total contrast media volumes ranging from 40-120 mL of iodinated contrast material.
1651599|NCT01843413|Radiation|stereotactic radiosurgery|Undergo SRS
1651600|NCT01843413|Procedure|quality-of-life assessment|Ancillary studies
1651601|NCT01843413|Procedure|cognitive assessment|Ancillary studies
2012943|NCT01340911|Drug|Placebo|For placebo product, the SRT3025 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 105) to match the SRT3025 investigational product.
1651603|NCT01843387|Biological|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 1 or Placebo
1651604|NCT01843387|Biological|Mesenchymal Precursor Cells (MPCs)|Single Intravenous Infusion of MPCs Dose 2 or Placebo
1651605|NCT01843374|Drug|Tremelimumab|Tremelimumab is to be administered as an IV solution, followed by observation.
1651606|NCT01843374|Drug|Placebo|Placebo is to be administered as an IV solution, followed by observation.
1651607|NCT01843348|Drug|Everolimus|
1651608|NCT01843348|Drug|Tacrolimus|Capsules: 0.5 mg, 1 mg or 5 mg. Dosing schedule: transplant to month 2: 4-8ng/ml, month 3 to month 12 3-5 ng/ml according to standard blood levels
1651609|NCT01843348|Drug|Cyclosporin A|Capsules: 10 mg, 25 mg, 50 mg or 100 mg. Transplantation to month 2: 75 - 125 ng/ml, month 3 to month 12: 50 - 100 ng/ml
1651610|NCT01843348|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Tablets: 180 mg or 360 mg. Dosing: duration of study 360 mg bid and no less than 360 mg daily dose
1651611|NCT01843348|Drug|Mycophenolate mofetil (MMF)|Capsules: 250 or 500 mg. Dosing: duration of study 500 mg bid and no less than 500 mg total daily dose
1651612|NCT01843348|Drug|Corticosteroids|A minimum dose of 5 mg prednisolon or equivalent
1651613|NCT01843348|Drug|Simulect|Lyophilisate in vials with ampoules of sterile water for injection (5 mL), one vial containing 20 mg lyophilisate given intravenously on the day of transplantation and on day four post-transplantation.
1651614|NCT01843322|Procedure|endoleak repair procedure (navigation technology )|
1651615|NCT01843309|Drug|Spironolactone 100mg|
1651616|NCT01843309|Drug|Spironolactone 200mg|
1651617|NCT01843309|Drug|Placebo|
1651618|NCT01843296|Drug|Magnesium Sulfate|Injection of 50 mg of magnesium sulfate 50% (0.1 ml),intrathecally.
1651619|NCT01843296|Procedure|Spinal Anesthesia|Lumbar puncture was performed in sitting position,at the one level above iliac crest. Using a median approach, a 25-G Quincke needle was introduced with the needle aperture directed laterally.
1651620|NCT01843296|Drug|Bupivacaine|
1651621|NCT01843296|Drug|Fentanyl|
1651622|NCT01843283|Behavioral|Daily Enhancement Meaningful Activity (DEMA)|
1651623|NCT01843283|Behavioral|Information Support (IS)|
1651624|NCT01843270|Device|actual body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
1651625|NCT01843270|Device|ideal body weight based size|According randomized allocated group, the laryngeal mask airway is inserted based on actual or ideal body weight-based sizes before the surgery.
1651626|NCT01843257|Other|Alcohol challenge test Alcohol visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 alcohol, visit 2 placebo).
1651627|NCT01843257|Other|Alcohol challenge test Placebo visit first|Subjects will be assessed in two testing sessions about 1 week apart, in which their response to alcohol or nonalcoholic (placebo) beverage will be evaluated in a randomized cross-over fashion (visit 1 placebo, visit 2 alcohol).
2012944|NCT01333241|Behavioral|Lifestyle behavior intervention|6 months of group education and individual teaching and coaching.
1651630|NCT01843218|Other|Evaluation of erectile dysfunction|Register R / P and self-administered questionnaire IIEF-5
1651631|NCT01843205|Drug|Methamphetamine|The pharmacodynamic effects of methamphetamine will be determined during placebo and buspirone maintenance.
1651632|NCT01843192|Device|Endocutter|
1651633|NCT01843179|Drug|Cytarabine|Up to two cycles. Administered via IV infusion on Days 1-5 of each 28 day cycle
1651634|NCT01843179|Drug|Sulindac|Taken orally twice per day at home for 12 months
1651635|NCT01843166|Drug|Premarin vaginal cream|2g at bedtime twice weekly
1651636|NCT01843166|Drug|Placebo cream|2g at bedtime twice weekly
1651637|NCT01843153|Drug|Ropivacaine|
1651638|NCT01843127|Drug|Ranolazine|
1651639|NCT01843127|Drug|Placebo|
1651640|NCT01843127|Drug|Exenatide|
1651641|NCT01843114|Device|FDOCT|Measurement of retinal blood velocities
1651642|NCT01843114|Other|Dynamic Vessel Analyzer|Measurement of retinal vessel diameters
1651643|NCT01843101|Device|Optical Coherence Tomography|Imaging of the cornea using ultrahigh resolution Spectral Domain OCT
1651644|NCT01843088|Drug|Mannitol cream|25% mannitol in PENcream (See above) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
1651645|NCT01843088|Drug|Placebo Cream|This is the vehicle only cream (PENcream) (See above) This will be applied as needed to one side of the body (blinded assignment) over painful painful areas of legs following a 10 km run, on the day of the run and for five days afterwards.
1651646|NCT01843075|Drug|Liraglutide|Daily subcutaneous injection
1651647|NCT01843075|Drug|Placebo|Daily subcutaneous injection
1717881|NCT00002347|Drug|Zalcitabine|
1651648|NCT01843062|Drug|Selumetinib|3 capsules of 25 mg strength orally twice a day for approximately 5 weeks treatment period
1651649|NCT01843062|Drug|Placebo|3 capsules ( to match Selumetinib capsules) orally twice a day for approximately 5 weeks treatment period
1651650|NCT01843062|Drug|Radioactive Iodine Therapy|A single oral radioactive iodine dose of 100 mCI(3.7 GBq) 131I (+/-10% at the time of administration)to be administered 30 days after randomization. Additionaly, Thyrogen (Recombinant human TSH) will be used to stimulate iodine uptake according to the manufacturer's recommendation(0.9 mg intramuscular injection once a day for the 2 days prior to the dose of radioactive iodine)
1651651|NCT01843049|Radiation|Radiotherapy|Patients will receive from 5 to 6 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
1651652|NCT01843049|Drug|Chemotherapy (5-FU+DDP)|Patients will receive 2 cycles of concurrent chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 and 29-31 plus 5-FU 500mg/m2 IV continuous infusion over 24h daily on Days 1-4 and 29-32) during radiotherapy period. Consolidation chemotherapy (cisplatin 25mg/m2 IV daily on Days 1-3 plus 5-FU 600mg/m2 IV daily on Days 1-5, cycled every 4 weeks) will be given for 2 cycles one month after the end of radiochemotherapy.
1651653|NCT01843036|Other|Durham Connects|Durham Connects begins with a visit during the birthing hospital stay, followed by 1-3 nurse home visits between 4-12 weeks of infant age, and then a follow-up contact one month later. During the visits, the nurse engages with the mother and completes a health and psychosocial assessment, during which she systematically assesses risk and family needs in 12 important empirically-derived areas of family functioning across 4 domains (i.e. - healthcare, parenting/childcare, family violence/safety, and maternal well-being). For each domain found to be at risk, the nurse intervenes directly to support the mother (mild risk) or connects the mother with matched community resources as needed to address individualized long-term family needs (moderate or severe risk).
1651654|NCT01843023|Drug|Extended Release Naltrexone|naltrexone for extended release injectable suspension
1651655|NCT01843023|Behavioral|Psychosocial Treatment|Psychosocial treatment will consist of group and individual drug abuse counseling at MMTC and in the community.
1651656|NCT01843023|Drug|Buprenorphine|Participants assigned to TAU will receive buprenorphine for opioid withdrawal and will either be tapered off the medication or will remain on it for individualized lengths of time during the six month study.
1651657|NCT01843010|Drug|Parecoxib|Parecoxib 40mg will be intravenously infused.
1651658|NCT01843010|Drug|Placebo|Normal saline 5ml will be intravenously infused.
1651659|NCT01842997|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|122 participants (19 at 5-9 weeks pregnant,36 at 10-19 weeks pregnant,13 at 20-29 weeks pregnant,54 at more than 30 weeks pregnant) received split-virion, non-adjuvanted H1N1 vaccine of 15 μg.
1651660|NCT01842984|Behavioral|I-SOCIAL intervention|The I-SOCIAL intervention is based on findings from Cohen-Mansfield and Parpura-Gill (2007), which highlighted the important role of barriers in contributing to loneliness in older persons. These barriers include a perceived lack of opportunities for social contacts, low social self-efficacy, and health and mobility difficulties. The intervention includes: (1) identifying the barriers for the specific person; (2) up to 10 meetings with an activities counselor. The meetings include discussions concerning options for social contacts and use of techniques and resources to tackle the barriers; and (3) group meetings of participants and the activities counselors in order to provide a concrete social event and as a venue to discuss barriers and ways to address them.
1651661|NCT01842971|Procedure|two stage hepatectomy|
2012945|NCT01315873|Drug|Bendamustine|"On days 1 and 4 of each cycle, bendamustine is given at 90 mg/m^2 after bortezomib . Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.
Patients will be treated until disease progression after at least one cycle of treatment."
2012946|NCT01315873|Drug|Bortezomib|"On days 1 and 4 of each cycle, bortezomib is given first at 1.3 mg/m^2 followed by bendamustine given at 90 mg/m^2. Patients will be dose reduced to 75 mg/m^2, and then to 60 mg/m^2 bendamustine on days 1 and 4 if ANC is not >1 x 10^9/L and platelets are not >50 x 10^9/L on day 1 of each cycle.
Patients will be treated until disease progression after at least one cycle of treatment."
1651664|NCT01842945|Behavioral|Internet-based cognitive behavioural therapy (iCBT) without therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and does not include a therapist contact.
1651665|NCT01842945|Behavioral|Internet-based cognitive behavioural therapy (iCBT) with therapist contact.|The iCBT consists of our structured self-help program lasting a total of eight active treatment weeks and includes a therapist contact.
1651666|NCT01842932|Drug|Phloroglucin|Premedication of colonoscopy
1651667|NCT01842932|Drug|Cimetropium bromide|Premedication of colonoscopy
1651668|NCT01842932|Procedure|Colonoscopy|Diagnostic examination of colon
1651669|NCT01842932|Drug|Placebo|Placebo for double-blind study These are harmless to the human body, and are composed of saline solution without drug efficacy.
1651670|NCT01842919|Other|Kinesthetics tests|
1651671|NCT01842919|Other|Psychological questionnaires|
1651672|NCT01842919|Other|structural Magnetic ResonanceImaging (MRI)|
1651673|NCT01842906|Device|Theravent|nasal EPAP device
1651674|NCT01842906|Device|Control|Sham device without EPAP
1651675|NCT01842893|Drug|Fentanyl Ethypharm|After an open-label titration to identify an optimal dose, patients were randomized to 1 of 13 prespecified sequences of 9 tablets (6 fentanyl and 3 placebo)
1651676|NCT01842841|Drug|velaglucerase alfa|15-60 U/kg, EOW
1651677|NCT01842828|Other|Standard care plus electronic cigarettes|
1651678|NCT01842828|Behavioral|Standard care|
1651679|NCT01842815|Device|755 nm alexandrite laser|755 nm alexandrite laser for the treatment of unwante, non cosmetic, tattoos.
1651680|NCT01842802|Device|Diode Laser|Diode Laser for treatment of subcutaneous fat
1651681|NCT01842802|Device|YAG laser|YAG laser for treatment of subcutaneous fat
1651682|NCT01842789|Device|Acessa Procedure|Acessa Procedure
1651683|NCT01842750|Device|Endorectal Balloon insertion|
2012947|NCT01313676|Drug|fluticasone furoate/vilanterol|100/25mcg given once daily via novel dry powder inhaler
1651734|NCT01842295|Other|Blood and sperm samples|Blood and sperm samples will be done in each visit
1651684|NCT01842737|Procedure|Spinal treatment|This treatment will be applied to the low back region only. During a HVLA treatment, the study doctor will ask the participant to lie on their side on a treatment table. After carefully helping the participant into the proper position, the doctor will make a quick and controlled push with their hand to slightly move joints in the low back. During this procedure, the participant may feel and/or hear a popping sound. After treatment, the doctor may ask the participant to rest on the table for a few moments. During palpation procedure, the doctor will touch several areas in the low back while asking questions about pain, tenderness and other sensations felt during this procedure. The participant will watch the doctor perform the palpation procedure in real time with a tablet computer.
1651685|NCT01842737|Procedure|Massage|The study doctor will perform a massage of each foot while the participant lies face up in a relaxed position on a treatment table. The procedure will last approximately 10-20 minutes including massage to the toes, heel, sole, and top of each foot.
1651686|NCT01842724|Procedure|Motec total wrist arthroplasty|
1651687|NCT01842724|Procedure|Remotion total wrist arthroplasty|
1651688|NCT01842698|Device|ultrasoundguided paravertebral catheter|
1651689|NCT01842685|Procedure|Bladder Thermal Distention|Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.
1651690|NCT01842672|Drug|Clofarabine|Dose Escalation of Clofarabine
1651691|NCT01842672|Drug|Mitoxantrone|
1651692|NCT01842659|Genetic|Methylation Index|To calculate the methylation index (MI) of imprinted regions.
1651693|NCT01842646|Drug|PF-04449913|Patients will be enrolled according to a two-step study design. Twenty patients will be enrolled in the first stage. All patients will be given a daily oral dose of PF-0444913 100 mg for up to 4 cycles, with an optional continuation phase. Dose escalation to 200 mg will be provided for patients who do not have at least hematologic improvement following 2 cycles, and dose reduction to 50 mg will be permitted for patients with significant toxicity. If at least 2 patients respond in the initial stage, and additional 15 patients will be enrolled in the second stage.
1651694|NCT01842633|Drug|Paracetamol and Caffeine|Caplets containing 500 milligrams (mg) of paracetamol and 65 mg of caffeine
1651695|NCT01842633|Drug|Ibuprofen|Caplets containing 200 mg of ibuprofen
1651696|NCT01842633|Other|Placebo|Matching placebo caplets
2012948|NCT01313676|Drug|fluticasone furoate|100mcg given once daily via novel dry powder inhaler
1651698|NCT01842607|Biological|Mepolizumab|Mepolizumab (a fully humanised IgG antibody) 100 mg injected SC once every 4 weeks for 12 months. Mepolizumab will be provided as a lyophilised cake in sterile vials
1651699|NCT01842594|Drug|Sirolimus and hydroxychloroquine|"Both hydroxychloroquine 200 mg/tab and sirolimus 1 mg/tab are pills each are taken 2 tablet orally QD for 2 cycles .
Each treatment cycle is 28 days."
1651700|NCT01842581|Drug|Rifaximin|
1651701|NCT01842581|Drug|Rifaximin and Lactulose|
1651702|NCT01842555|Other|Registry|Registry
1651703|NCT01842542|Device|NeuroStar Transcranial Magnetic Stimulation (TMS)|"Acute phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, five times weekly for up to 8 weeks.
3 week taper phase: 120% of observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/session, 3 times during the first week, 2 times during the second week and one time during the third week. In addition to treatments, patients may receive treatment as usual at the direction of their treating physician."
1651704|NCT01842529|Biological|botulinum toxin injection|
1651705|NCT01842529|Biological|0.9% normal saline injection|
1651706|NCT01842529|Device|Implantable loop recorder|
1651707|NCT01842516|Drug|LCB01-0371 800mg|LCB0-0371 800mg
1651708|NCT01842516|Drug|LCB01-0371 1200mg|LCB01-0371 1200mg
1651709|NCT01842516|Drug|Placebo|Placebo
1651710|NCT01842503|Drug|GET 73|300 mg tid on 3 days cycle
1651711|NCT01842503|Drug|inactive ingredients capsule|3 capsules tid on 3 days cycle
1651712|NCT01842477|Procedure|Implantation of bone substitute plus autologous cultured mesenchymal cells|Implantation surgery of a synthetic bone substitute associated with autologous bone marrow cells expanded
1651713|NCT01842464|Procedure|Anterior Sacro-Spinous|Anterior Sacro-Spinous
1651714|NCT01842451|Drug|VX-135|
1651715|NCT01842451|Drug|Daclatasvir|
1651716|NCT01842438|Behavioral|Behavioral: psychosexual intervention|6 session manualised intervention, This manual-based family-relational-psychosexual support was based on systemic principles combined with techniques from sex therapy, i.e. sensate focus. The manual offered an intermediate level of specificity, enabling practitioners to use their own therapeutic style and take some lead from the couple while meeting the objectives of the intervention. Specialist training in delivery of the intervention was provided to practitioners holding accredited counselling or psychotherapy qualifications. Practitioners engaged in routine clinical supervision with one additional team supervision session offered by one of the practitioners
1651717|NCT01842412|Behavioral|exercise|one bout of exercise training
1651718|NCT01842399|Dietary Supplement|Resveratrol|Dietary Supplement
1651719|NCT01842399|Drug|Placebo|2x/day orally
2012949|NCT01313676|Drug|vilanterol|25mcg given once daily via novel dry powder inhaler
1651721|NCT01842373|Drug|LMX4|
1651722|NCT01842373|Drug|BLT|
1651723|NCT01842360|Biological|Placebo|The subjects will receive daily dose of placebo during 12 months
1651724|NCT01842360|Biological|MV130|The subjects will receive daily dose of MV130 during 12 months
1651725|NCT01842347|Other|Fecal microbiota|
1651726|NCT01842334|Behavioral|Cognitive Behavioral Therapy|CBT administered to to both DCS and placebo group.
1651727|NCT01842334|Drug|Nicotine Replacement Therapy|NRT administered to both DCS and placebo group.
1651728|NCT01842321|Drug|Abiraterone Acetate|Patients will receive abiraterone acetate at 1,000 mg (four 250 mg tablets daily in the morning after an overnight fast) concurrently with prednisone(1) at 10 mg once daily.
1651735|NCT01842282|Drug|Amlexanox|
2012950|NCT01313676|Other|Placebo|placebo comparator once daily via novel dry powder inhaler
2012951|NCT01307267|Drug|PF-05082566|Intravenous, Dose escalation, once per month
1651736|NCT01842269|Drug|Mycophenolate Mofetil 500mg|
1651737|NCT01842269|Drug|Mycophenolate Mofetil 250mg|
1651738|NCT01842256|Drug|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"3 Tablets (telmisartan 80mg, amlodipine 5mg, atorvastatin 40mg each one),
oral intake, once in a period
over the period Ⅰ&Ⅱ(crossover)"
1651739|NCT01842256|Drug|atorvastatin 40mg|"1 Tablet (atorvastatin 40mg),
oral intake, once in a period
over the period Ⅰ&Ⅱ(crossover)"
1651740|NCT01842243|Procedure|Apical pacing|Pacemaker set to pace at right ventricular apex initially.
1651741|NCT01842243|Procedure|Septal pacing|Pacemaker set to pace at right ventricular septum initially.
1651742|NCT01842243|Device|Pacemaker|MR conditional Pacemaker implanted in all study patients
1651743|NCT01842230|Drug|Telmisartan 80mg, S-amlodipine 5mg and Atorvastatin 40mg|"Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day
Atorvastatin 40mg: 1 tablet, oral, once daily, 2days
over the period I & II(cross-over)"
1651744|NCT01842230|Drug|Telmisartan 80mg and S-amlodipine 5mg|"Telmisartan 80mg, S-amlodipine 5mg: 1 tablet, oral, once daily, 1day
over the period I & II(cross-over)"
1651745|NCT01842217|Procedure|FES-PET|
1651746|NCT01842204|Device|Magnetic field therapy device|Therapy device for 1 week.
1651747|NCT01842204|Device|Non magnetic field therapy device.|Non-active device for 1 week.
1651748|NCT01842191|Dietary Supplement|Fish Oil|Patients received 4g/day Omega Rx capsules (Dr. Sears zone diet) containing 0.8 g EPA and 1.6 g DHA and excipient (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
1651749|NCT01842191|Dietary Supplement|Placebo|Orally, 4 Capsules per day, (glycerin, water purified, tocopherol, sunflower oil and titanium dioxide), during 12 months.
1651750|NCT01842178|Procedure|scratching|"Endometrial Injury
Done between 18-24 days prior to embryo transfer cycle.
Using transfer catheter.
Introduction of the same to the uterine fundus.
Systematic scrapping of the four uterine walls, lengthwise.
Performed by a skilled doctor.
Subsequent ultrasound control."
1651751|NCT01842165|Drug|Intravenous injection of 177Lu-octreotate|Treatment will consist of 177Lu-octreotate injections in fixed activities of 7,4 GBq (200 mCi) (±5%) each, given 12 weeks (±1 week) apart, injected intravenously simultaneously with nephroprotective perfusion of an amino acid solution.
1651752|NCT01842139|Biological|basiliximab|Given IV
1651753|NCT01842139|Biological|WT1 126-134 peptide vaccine|Given SC
1651754|NCT01842139|Drug|Montanide ISA 51 VG|Given SC
1651755|NCT01842139|Drug|poly ICLC|Given SC
1651756|NCT01842139|Other|laboratory biomarker analysis|Correlative studies
1651757|NCT01842126|Biological|BG00010 IV|Ascending Doses intravenous (IV) of BG00010
1651758|NCT01842126|Biological|BG00010 SC|Ascending Doses subcutaneous (SC) of BG00010
1651759|NCT01842126|Drug|Placebo IV|Ascending Doses intravenous (IV) of Placebo
1651760|NCT01842126|Drug|Placebo SC|Ascending Doses subcutaneous (SC) of placebo
1651761|NCT01842113|Drug|Rifaximin|Rifaximin 550mg by mouth twice a day
1651762|NCT01842113|Drug|Lactulose|Lactulose 30ml by mouth three times a day
1651763|NCT01842113|Drug|Lactulose Placebo|Lactulose Placebo 30ml three times a day
1651764|NCT01842113|Drug|Rifaximin Placebo|Rifaximin Placebo twice a day
1651765|NCT01842100|Drug|Universal antibiotic prophylaxis|100 mg twice daily for 7 days starting on the day of induced abortion
1651766|NCT01842100|Other|Screen-and-treat|Specific antibiotic treatment was only given if the women was found to have sexually transmitted infection(s) on screening.
1651767|NCT01842087|Other|Control Food|For a period of 2 weeks, participants will consume control foods in addition to their usual diets.
1651768|NCT01842087|Other|Fiber Fortified Food|For a period of 4 weeks, participants will consume food fortified with fiber in addition to their usual diets.
1651769|NCT01842074|Drug|Bortezomib|Pilot study on the efficacy and safety of bortezomib during desensitization before a living kidney donation
1651770|NCT01842061|Behavioral|Active Living Program|
1651771|NCT01842061|Behavioral|Education|
2012952|NCT01307267|Drug|rituximab|Intravenous, 375 mg/m2, once per week for 4 weeks
2012953|NCT01307267|Drug|PF-05082566|IV, Dose escalation, once per month
1651774|NCT01842035|Drug|regadenoson|Prior to the implantation of a clinically indicated ICD, the heart rate response to regadenoson will be assessed. Regadenoson will be administered intravenously as a fixed intravenous bolus dose of 400 μg followed by a 5 mL saline flush. Medications (including beta-blockers) will be withheld on the morning of the test. The heart rate and blood pressure will be measured at baseline and every minute after regadenoson bolus for at least 5 minutes and until the heart rate and blood pressure are clearly returning towards baseline.
1651775|NCT01842022|Dietary Supplement|Isomaltulose|Isomaltulose sweetened meal will be given to each of four groups who differ in their glucose tolerance
1651776|NCT01842022|Dietary Supplement|Sucrose|Sucrose sweetened meal will be given to each of four groups who differ in their glucose tolerance
1651777|NCT01842022|Dietary Supplement|Glucose|Glucose sweetened meal will be given to each of four groups who differ in their glucose tolerance
1651778|NCT01842009|Device|High Definition transcranial Direct Current Stimulation|
1651779|NCT01841996|Drug|ME1111 solution|Once a day for 28 days
1651780|NCT01841996|Drug|Vehicle Solution|Once a day for 28 days
1651781|NCT01841983|Other|Be Well Work Well|"The intervention follows principles for integrated approaches to promoting and protecting worker health. It will occur on 4 inpatient units at Massachusetts General Hospital beginning in January 2013, and will continue for 1 year.
Overall intervention objectives:
Motivate individual staff members to engage in targeted health and safety behavior changes;
build awareness of ergonomic and safety hazards and of opportunities for healthy dietary choices and physical activity;
facilitate unit-level norms supportive of breaks, safe patient handling, and targeted health and safety behaviors; and
promote co-worker and supervisor support for targeted health and safety behaviors."
1651782|NCT01841970|Device|HET Bipolar System|The HET Bipolar System is used to treat hemorrhoids by bipolar ligation of the superior hemorrhoidal blood supply.
1651783|NCT01841957|Procedure|ISBCS|same-day cataract surgery
1651784|NCT01841957|Procedure|DSBCS|bilateral surgery delayed by 1-3 weeks amongst eyes
1651785|NCT01841944|Drug|Pikasol|Pikasol®, 3 capsules (1.8 g EPA+DHA)/day
1651786|NCT01841944|Other|Corn oil|Corn oil (56% linoleic acid, 32% oleic acid, 10% palmitic acid), unchanged and according to the manufacturer
1651787|NCT01841931|Drug|Buprenorphine/Naloxone|Sublingual buprenorphine/naloxone taken in a 3 day induction, with a final daily dose (up to 32 mg depending on the subject) taken daily, as prescribed by the study psychiatrist. Subjects will continue buprenorphine for study duration (6 months).
1651788|NCT01841918|Biological|Avian Flu Vaccine|
1651789|NCT01841905|Other|Observational Study|Observational Study
1651790|NCT01841892|Behavioral|Community Therapeutic Workplace|Participants will be enrolled in Phase 1 training for 4 months, and will then be offered to apply for employment with collaborating community employers.
1651791|NCT01841879|Behavioral|Intervention Program|"Receives an integrated tobacco control and occupational health (OH) intervention (The Healthy, Safe, and Tobacco-Free Worksites program) aimed at promoting tobacco cessation among workers and supporting the adoption, implementation, and enforcement of tobacco control policies.
Through six health education events at the worksites, blue-collar workers (who face dual health risks through their exposures to occupational hazards and their high rates of tobacco use) will gain the knowledge, skills, and social support needed to quit tobacco use.
Simultaneously, management will receive OH and tobacco policy consultations to help build a healthy and safe work environment, where workers' hazardous exposures are reduced."
1651792|NCT01841879|Behavioral|Delayed Intervention|Receives abbreviated 2-month delayed intervention designed to provide employees with knowledge and skills to quit tobacco after final data collection time point, as well as one non-tobacco event in between data collection points.
2012954|NCT01301053|Other|Current UVA intensive care insulin protocol|Current UVA intensive care insulin protocol used for insulin management for 12 hours
1651794|NCT01841853|Behavioral|Senior meetings|The intervention will be led by professionals such as a registered occupational therapist, a nurse, a physical therapist, and a social worker. The intervention will comprise four weekly meetings in small groups (4-6 participants) in addition to an individual follow-up home visit two to three weeks after the last senior meeting. To use groups involve the possibility of peer education where participants in a person-centeredness perspective are seen as experts on their own situation and learn from each other. The relationship between the personnel and the participants in the senior meetings can be described as a partnership. Respect for the participant and his/her values, and that the participant gets an opportunity to maintain and develop their own power over their own everyday activities will be essential in the meeting.
1651795|NCT01841840|Other|Low-Frequency Passive Vibration|10 minute session of passive vibration set to a frequency of 25Hz and a high amplitude exposed to the legs
1651796|NCT01841840|Other|High-Frequency Pasive Vibration|10 minute session of passive vibration set to a frequency of 40Hz and a low amplitude exposed to the legs
1651797|NCT01841827|Drug|Cilostazol|
1651798|NCT01841827|Drug|Placebo|
1651799|NCT01841814|Radiation|Bone densitometry.|
1651800|NCT01841801|Device|Thermal Adhesive Patch|
1651801|NCT01841801|Device|Marketed Thermal Adhesive Patch|
1651802|NCT01841801|Device|Placebo Patch|
1651803|NCT01841788|Device|Thermal Adhesion Patch|
1651804|NCT01841788|Device|Marketed Thermal Adhesion Patch|
1651805|NCT01841788|Device|Placebo Patch|
1651806|NCT01841775|Drug|interferon α 2b + ribavirin|"interferon α 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks
ribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks"
2012955|NCT01301053|Other|"Current UVA intensive care insulin protocol with brakes"|"Current UVA intensive care insulin protocol for insulin management with the addition of brakes which reduces insulin administration based on continuous glucose monitoring data between hourly reference glucose data to reduce episodes of hypoglycemia (blood glucose <70 mg/dl)and severe hypoglycemia (blood glucose<50 mg/dl)."
1651808|NCT01841749|Procedure|sentinel node biopsy and mastectomy|sentinel node biopsy and mastectomy
1651813|NCT01841723|Drug|Ibrutinib|Given PO
1651814|NCT01841723|Other|Laboratory Biomarker Analysis|Correlative studies
1651815|NCT01841723|Other|Pharmacological Study|Correlative studies
1651816|NCT01841697|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg oral capsule once a week for 24 weeks
1651817|NCT01841697|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once a day for 24 weeks
1651818|NCT01841697|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg oral capsule once a week for 24 weeks
1651819|NCT01841697|Drug|Placebo to Sitagliptin|Placebo to sitagliptin 100 mg oral tablet once a day for 24 weeks
1651820|NCT01841697|Drug|Open-label Metformin|Metformin oral tablet(s) - total daily dose of ≥1500 mg, once or twice a day
1651821|NCT01841697|Drug|Open-label Glimepiride|Glimepiride oral tablet(s) - total daily dose of 1 to 6 mg once a day as rescue therapy
1651822|NCT01841684|Drug|Anacetrapib|100 mg tablet orally, once daily for 12 weeks
1651823|NCT01841684|Drug|Placebo|Placebo for anacetrapib orally, once daily for 12 weeks
1651824|NCT01841671|Biological|IPV|Blood samples for poliovirus neutralizing antibodies to be obtained as follows: Group 1 at weeks 8, 16, 28 and 29; Group 2 and 3 at 8, 24, 28 and 29. Stool samples for poliovirus cuantification, for all groups, to be obtained at weeks 28, 29, 30, 31, 32.
1651825|NCT01841671|Biological|bOPV|As indicated
1651826|NCT01841671|Biological|mOPV type 2|Administered at 28 weeks of age to all study participants
1651827|NCT01841671|Biological|Rotarix|Administered at 8 and 16 weeks to all study participants accepting to recive this vaccine
1651828|NCT01841658|Dietary Supplement|Folic acid|Participants will be instructed to consume 2 tablets per day, a total of 800 micrograms folic acid. To facilitate compliance, participants will be instructed in the use of a compliance calendar and will receive frequent telephone and 'text' reminders from project staff. Additionally, compliance will be determined by return pill count.
1651829|NCT01841645|Dietary Supplement|CLA depletion-repletion|
1651830|NCT01841632|Drug|MultiStem|
1651862|NCT01841411|Drug|Metronidazole + N-Acetyl cysteine|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement, It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has antibacterial and antibiofilm activities
1717882|NCT00002348|Drug|Mitoguazone|
1651831|NCT01841619|Drug|IVIg|All enrolled subjects will receive IVIg treatment following the protocol that proved to be efficacious in the treatment of patients with autoimmune blistering diseases as well as some patients with CLE. The drug will be administered at 500 mg/kg/day on consecutive days up to a total of 2 g/kg/month for 3 months in the Institute for Clinical and Translational Science (ICTS) at University of California, Irvine. After 3 months of treatment, IVIg will be discontinued and the subjects will be monitored for additional 6 months for a possible relapse. In the case of relapse, which is expected to occur in <25% subjects, the subjects will be re-treated by the standard protocol.
1651833|NCT01841593|Drug|Raltegravir|Isentress 400mg tablet taken twice daily
1651834|NCT01841593|Drug|Amlodipine|generic amlodipine 5mg tablets (Accord healthcare Limited, UK)
1651835|NCT01841567|Device|Mepilex border post. op|
1651836|NCT01841567|Device|Mepilex border post op|
1651837|NCT01841554|Device|Cardioband|
1651838|NCT01841541|Behavioral|Referral of presumptive of TB cases by informal providers|Training of informal providers to effectively refer TB suspects in the community to the primary health care system
1651839|NCT01841528|Other|fresh embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. Two fresh embryos will be transferred at Day 3. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
1651840|NCT01841528|Other|frozen-thawed embryo transfer|rFSH/GnRH antagonist will be administered for ovarian stimulation. Oocyte pick-up will be performed when at least two follicles ≥18mm. All embryos will be vitrified in fresh cycle, and at least 2 embryos should be frozen at Day 3. Two months later, two thawed Day 3 embryos will be transferred with HRT (hormone replacement therapy) prepared endometrium. Luteal phase support will last 2 weeks for all subjects in this group. Two weeks after embryo transfer, serum HCG will be measured to determine pregnant or not. If biochemical pregnancy is achieved, luteal phase support will be continued to 10 weeks gestation. Pregnancy complications and final outcome will be followed up till 6 weeks after delivery.
1651841|NCT01841515|Drug|Desmopressin administration|
1651842|NCT01841502|Drug|Paroxetine|paroxetine 20 mg once daily
1651843|NCT01841502|Drug|telaprevir|telaprevir 1125 mg twice daily
1651844|NCT01841489|Drug|Treatment A|1600 mg GS-9973 (Formulation 1)
1651845|NCT01841489|Drug|Treatment B|1600 mg GS-9973 (Formulation 1) plus 20 mg omeprazole
1651846|NCT01841489|Drug|Treatment C|1600 mg GS-9973 (Formulation 1) plus 40 mg famotidine
1651847|NCT01841489|Drug|Treatment D|1600 mg GS-9973 (Formulation 2)
1651848|NCT01841489|Drug|Treatment E|1600 mg GS-9973 (Formulation 2) plus 20 mg omeprazole
1651849|NCT01841489|Drug|Treatment F|1600 mg GS-9973 (Formulation 2) plus 40 mg famotidine
1651850|NCT01841489|Drug|Treatment G|1600 mg GS-9973 (Reference formulation)
1651851|NCT01841489|Drug|Treatment H|1600 mg GS-9973 (Formulation 1 or Formulation 2, based on results from Part A)
1651852|NCT01841489|Drug|Treatment I|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
1651853|NCT01841489|Drug|Treatment J|An alternate dose of the chosen formulation from Part A up to 1200 mg administered twice-daily
1651854|NCT01841476|Drug|POL6326|
1651855|NCT01841463|Drug|P1446A-05|- In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) & vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. The next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The max tolerated dose (MTD) of P1446A-05 & vemurafenib co-administered will be determined. In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, & 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity to determine efficacy of the co-administration. Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples & undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration.
1651856|NCT01841463|Drug|Vemurafenib (Zelboraf®)|"In the 'Dose escalation' phase patients will be co-administered P1446A-05 (150, 250, 350 mg qd) and vemurafenib (720, 960 mg bid) in a cohort of 3 to 6 patients on a 28-day cycle, until the occurrence of disease progression or unacceptable toxicity. Escalation to the next higher dose during the dose escalation phase will depend upon demonstrated safety in the previous dose group. The maximum tolerated dose (MTD) of P1446A-05 and vemurafenib co-administered will be determined.
In the 'Extension' phase, 60 patients with BRAF V600E/K mutations (40 patients naïve to selective BRAF inhibitor therapy, and 20 progressing on selective BRAF inhibitor therapy) will be treated at the MTD on a 28-day cycle
Additionally, there will be a cohort of 10 patients who consent for mandatory serial tumor biopsy samples and undergo 'Monotherapy' for 14 days with P1446A-05 at the MTD of the co-administration."
1651857|NCT01841450|Device|iStent|Implantation of one iStent in conjunction with cataract surgery
1651858|NCT01841450|Procedure|Cataract surgery|Cataract surgery alone
1651859|NCT01841437|Device|iStent|
1651860|NCT01841424|Behavioral|Dietary counseling. Maintain a food diary.|The dietary intervention will be conducted by a registered dietician once. The dietary guidelines for study participants will be similar to those for gestational diabetes including 18 to 24 kcal/kg diet with 40% carbohydrates, 30% protein, 30% fat. No participant will be given a diet that is less than 2,000 kcal per day. Study subjects will record a food diary and to bring it to prenatal visits. Study subjects will limit intake of high calorie dense and acellular processed foods to 1-2 times per week if at all and to increase total percentage of fruits and vegetables to 5-9 items per day.
1651861|NCT01841411|Drug|N-Acetyl cysteine|N-Acetyl cysteine is a pharmaceutical drug and nutritional supplement,it is a derivative of the natural amino acid cysteine, from which it differs by virtue of the introduction of an acetyl group on the nitrogen atom of the amino terminal.It is used mainly as a mucolytic and in management of paracetamol overdose. It has been observed that N-acetyl cysteine has shown good properties in terms of combating bacterial infections. In particular, it has been observed that NAC presents good activity in terms of inhibiting bacterial adhesion and in dissolving the biofilm matrix.
1651863|NCT01841411|Drug|metronidazole|Metronidazole is an antibiotic effective against anaerobic bacteria and certain parasites.It can be used in treatment of vaginal infections such as trichomoniasis and bacterial vaginosis in treatment of bacterial vaginosis, it can be used in treatment of bacterial vaginosis either in a dose of 500 mg twice daily or 250 mg three times daily for seven days
1651864|NCT01841398|Behavioral|Multimedia Lifestyle Improvement|"Goal setting to improve diet, physical activity or smoking behaviours
Regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference."
1651865|NCT01841398|Behavioral|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
1651866|NCT01841385|Other|Pilates method|Therapeutic intervention in the Pilates method has two regular weekly sessions for 12 weeks, totaling 24 sessions. For the protocol of Pilates exercises, exercises on soil and equipment, with gradual progression of the load.
1651867|NCT01841372|Other|Second Life|Second Life is an online virtual reality environment.
1651868|NCT01841372|Behavioral|Group Phone Conference Call|
1651869|NCT01841359|Drug|Pramlintide|See description above (arm description).
1651870|NCT01841346|Procedure|Procedure: PCI|
1651871|NCT01841333|Drug|PF-04449913|100mg given orally
1651872|NCT01841320|Other|Integrated methadone and antiretroviral therapy (iMART) clinic|
1651873|NCT01841307|Drug|Cromolyn Sodium|
1651874|NCT01841294|Drug|Intravenous Lidocaine|Lidocaine infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
1651875|NCT01841294|Drug|Normal saline infusion|Normal saline infusion: 1.5 mg/kg bolus on 10 minutes (maximum 150 mg) followed by 1.5 mg/kg/h
2012956|NCT01297114|Drug|Florbetaben|This is a purely observational study. Results of the Florbetaben PET scan will be correlated with other observations.
1651878|NCT01841255|Device|Mouthpiece (Umox)|Device used to perform preoxygenation in the operating room context
1651879|NCT01841255|Device|facemask|
1651880|NCT01841242|Drug|alcoholic povidone iodine|
1651881|NCT01841242|Drug|alcoholic chlorhexidine|
1651882|NCT01841216|Device|Lower Body Exercises with and without resistance|lower body exercises with and without resistance designed to activate the gluteal/hip musculature
1651883|NCT01841177|Drug|Milrinone|Milrinone is a potent selective phosphodiesterase (PDE) type III inhibitor which stimulates myocardial function (inotropy), causes peripheral vasodilatation (afterload reduction) and improves myocardial relaxation (lusitropy).
1651884|NCT01841164|Drug|Montelukast|
1651885|NCT01841164|Drug|Placebo for montelukast|Sugar pills manufactured to mimic Singulair
1651886|NCT01841164|Other|Inhaled leukotriene E4|Inhalation challenge with aerosolized GMP-grade LTE4 (Cayman Chemical Company 1180 East Ellsworth Road, Ann Arbor, Michigan 48108,USA)
1651887|NCT01841151|Behavioral|SCP training|
1651888|NCT01841151|Behavioral|Live Z-score training|
1651889|NCT01841151|Behavioral|WM training|
1651890|NCT01841125|Drug|escitalopram|escitalopram 15mg, QD(once a day), Oral medication, 24weeks
1651891|NCT01841125|Drug|Placebo|placebo 15mg, QD(once a day), Oral medication
1651892|NCT01841112|Drug|BI 409306|tablet
1651893|NCT01841112|Drug|BI 409306|tablet
1651894|NCT01841112|Drug|BI 409306|tablet
1651895|NCT01841112|Drug|BI 409306|tablet
1651896|NCT01841112|Drug|placebo|placebo tablet
1651897|NCT01841112|Drug|placebo|placebo tablet
1651898|NCT01841112|Drug|BI 409306|tablet
1651899|NCT01841099|Drug|Mesalamine|Mesalamine granules
1651900|NCT01841099|Drug|Placebo granules|Provided by Ferring Pharma
1651901|NCT01841086|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
1651902|NCT01841086|Drug|UI03SPG300CT|Sarpogrelate HCl 300mg once a day or 100mg three times a day
1651903|NCT01841073|Dietary Supplement|Inulin|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
1651904|NCT01841073|Dietary Supplement|Cellulose|Subjects will have 4 dietary counselling sessions in the first 9 weeks of the study with a goal to lose 5% of their body weight by week 9. They will be asked to maintain their weight loss until week 18.
1651905|NCT01841073|Dietary Supplement|Inulin|Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
1651906|NCT01841073|Dietary Supplement|Cellulose|Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
1651907|NCT01841073|Dietary Supplement|Inulin|"Subject will take inulin for 6 weeks in total with no other change to their diet or lifestyle.
Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
1651908|NCT01841073|Dietary Supplement|Cellulose|"Subject will take cellulose for 6 weeks in total with no other change to their diet or lifestyle.
Subject will wear a Continuous Glucose Monitor for 4 x 5 days during the study."
1651909|NCT01841060|Procedure|Radiofrequency|Radiofrequency
1651910|NCT01841047|Radiation|Radiotherapy|Evaluation of the efficacy of the combination with radio-surgery helical tomotherapy irradiation to a dose of radiation of 54 Gy in patients with retroperitoneal liposarcoma of operable
1651911|NCT01841034|Drug|Conceptio EA|The patients are included during a consultation whether it is with a clinician or a biologist of the Center. It is suggested in routine in the service, to all the patients consulting for a problem of infertility and presenting pathological spermatic data, taking the food complement Conceptio. At the patients wishing to take this complement it will be suggested participating in this study. This complement is usually bought by the patient, within the framework of this study this one will be gracefully supplied. The follow-up of the patient will contain no examination and no anybody visit besides the usually realized follow-up.
1651912|NCT01841021|Drug|Brentuximab vedotin|Brentuximab vedotin will be given by intravenous infusion (into a vein) on Day 1 of every 21 day cycle.
1651913|NCT01841008|Drug|Protopic|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
1651914|NCT01841008|Drug|Placebo : Diprobase|Topical treatment (tacrolimus or placebo) will be delivered to the patient by the hospital pharmacy and should be applied twice per week (3 or 4 days apart) for 24 weeks.
1651915|NCT01840995|Procedure|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
1651916|NCT01840982|Dietary Supplement|Mixed grain 1|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
1651917|NCT01840982|Dietary Supplement|Mixed grain 2|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
1651918|NCT01840982|Dietary Supplement|White rice|All test foods contained 50 g available carbohydrate from the test food products. A glass of 200 ml water was served together with the clinical trial food, and the participants were instructed to ingest the breakfast with 15 min.
1651919|NCT01840982|Other|Glucose solution|All test foods contained 50 g available carbohydrate from the test food products.
1651920|NCT01840956|Biological|HAVG|HAVG is implanted into patients' arm.
1651921|NCT01840943|Drug|CAELYX|CAELYX 50 mg per square meter will be administered intravenously on Day 1 of each cycle as: 60 to 90-minute infusion to the participants not undergoing pharmacokinetic (PK) evaluation and 90-minute infusion to the participants undergoing for PK evaluation.
1651922|NCT01840943|Drug|Topotecan HCl|Topotecan 1.25 mg per square meter per day will be administered, intravenously for 30-minutes duration, on Day 1 to Day 5 of each cycle.
1651923|NCT01840891|Behavioral|Lactose H2 breath test (LH2BT)|Prevalence of lactose intolerance stated with a positive LH2BT and/or a positive LTT in RTRs with chronic norovirus infection.
1651924|NCT01840865|Device|brain stimulation|oscillating direct current brain stimulation
1651925|NCT01840865|Device|no stimulation|sham Stimulation
1651926|NCT01840839|Device|brain stimulation|
1651927|NCT01840839|Device|Sham Stimulation|
1651928|NCT01840826|Other|RED-D Care Management|The Case Management intervention will continue for 12 weeks post-discharge (from the index admission).
1651929|NCT01840813|Drug|Misoprostol|It is a synthetic prostaglandin (PgE1 analogue)used as a uterotonic substance.
1651930|NCT01840813|Drug|Normal saline|It is a placebo group
1651931|NCT01840800|Drug|Ropivacaine|
1651932|NCT01840800|Drug|placebo|
1651933|NCT01840787|Device|balafilcon A (8.6)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
1651934|NCT01840787|Device|balafilcon A (8.3)|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
1651935|NCT01840787|Device|senofilcon A|To be worn for 8 hours in one eye, and its comfort compared to another lens on another eye.
1651936|NCT01840774|Drug|Low-dose pain medication (Ketalar) and saline placebo|
1651937|NCT01840761|Drug|herbal drug|
1651938|NCT01840761|Drug|placebo|
1651939|NCT01840735|Drug|GS-5737|
1651940|NCT01840735|Drug|Placebo|
1651941|NCT01840722|Other|MI-based HIV Risk Reduction|As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
1651942|NCT01840709|Behavioral|Psychotherapy|Psychoanalytic brief group psychotherapy once a week for 20 consecutive weeks
1651943|NCT01840696|Drug|Regadenoson|Vasodilator stress testing
1651944|NCT01840683|Device|H.E.L.P. therapy (H.E.L.P. Plasmat Futura System)|
1651945|NCT01840670|Drug|Rapid fluid load test|The test will be performed by infusing 250-300 mL/m2 Body Surface Area of 6% hydroxyethyl starch 6% 130/0.4 (VoluvenR) in 30 minutes
1651946|NCT01840644|Other|Walking on treadmill, different velocities and incline|Walking on treadmill twice, with one week interval in each session the child will walk in different velocities and incline
1651947|NCT01840631|Behavioral|Nutritional Counseling|Participants enrolled will be randomized into group nutrition counseling or individual nutrition counseling classes, for a total of 6 classes. Classes will meet one time a month. Classes will cover topics including nutrition, exercise, and behavior to promote healthy eating.
1651948|NCT01840618|Device|Nasal Continuous positive airway pressure (CPAP)|We will initiate treatment of OSA with CPAP for 3 months in PCOS adolescents with moderate to severe OSA. Compliance will be defined as the average number of hours for which CPAP was used per night over the 12-wk treatment period. Adherence with CPAP will be defined as CPAP use ≥4 hours daily. The primary outcome variable will be insulin sensitivity measured as change in GIR. Changes in cardio metabolic variables after CPAP treatment will be expressed as a percentage of the corresponding baseline values.
1651949|NCT01840605|Drug|Bepotastine besilate|Two TAU-284 5mg tablets and one ketotifen fumarate dry syrup 1g placebo will be taken orally twice a day
1651950|NCT01840605|Drug|ketotifen fumarate|Two TAU-284 5 mg placebo tablets and one ketotifen fumarate dry syrup 1g will be taken orally twice a day
1651951|NCT01840592|Drug|Sorafenib|
1651952|NCT01840592|Drug|Doxorubicin|
2012957|NCT01289275|Drug|Nicotine Patches|Subjects randomized into the patch condition will receive 8 weeks of nicotine patches at discharge. The kit will contain 4 weeks of 21mg patches, 2 weeks of 14mg, and 2 weeks of 7mg.
1651964|NCT01840566|Drug|Carmustine|
1651965|NCT01840566|Drug|Etoposide|
1651966|NCT01840566|Drug|Cytarabine|
1651967|NCT01840566|Drug|Melphalan|
1651968|NCT01840566|Biological|Pegfilgrastim|
1651969|NCT01840566|Biological|19-28z T CELLS|
1651970|NCT01840566|Procedure|Autologous Stem Cell Transplantation|
1651971|NCT01840553|Drug|oral sodium phosphate tablets|
1651972|NCT01840553|Drug|polyethylene glycol|
1651973|NCT01840540|Drug|Arterial infusion of autologous mesenchymal stem cells|
1651974|NCT01840501|Drug|JNJ-42721458 (single dose)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) as single doses, starting from 0.1 mg.
1651975|NCT01840501|Drug|JNJ-42721458 (multiple doses)|JNJ-42721458 will be administered subcutaneously (an injection under the skin) once daily, starting with a dose of 5.0 mg.
1651976|NCT01840501|Drug|Placebo (single dose)|Matching placebo will be administered subcutaneously (an injection under the skin) as a single dose in Part 1.
1651977|NCT01840501|Drug|Placebo (multiple doses)|Matching placebo will be administered subcutaneously (an injection under the skin) once daily for 10 days in Part 2.
1651978|NCT01840488|Drug|Irosustat (BN83495)|"Three parts (A, B & C) open label, multiple cohort, dose escalation study with once daily administration of irosustat at 1, 5, 20, 40 and 80 mg. Patients treated in any cohort were not allowed to escalate to higher doses or be enrolled in another dosing cohort.
Part A - Single oral daily dose for 7 days, Part B - Repeated oral daily dose for 28 days and Part C - Repeated oral daily administration until disease progression."
1651979|NCT01840449|Drug|Somatuline Autogel® 60, 90 or 120 mg|
1651980|NCT01840436|Device|MUCIPLIQ|MUCIPLIQ is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
1651981|NCT01840436|Device|Placebo|Placebo is applied by mouthwash, for 2 to 3 minutes before being spat out, twice a day.
1651982|NCT01840423|Drug|ODM-104|ODM-104
1651983|NCT01840423|Drug|Placebo|Placebo
1651984|NCT01840423|Drug|Entacapone|entacapone + levodopa/carbidopa
1651985|NCT01840423|Drug|levodopa/carbidopa|entacapone + levodopa/carbidopa
1651986|NCT01840410|Drug|Ranibizumab|Ranibizumab 0.5mg/0.5mL was administered intravitreally to the participant.
1651987|NCT01840410|Other|Sham control|The sham vial did not contain active drug (empty sterile vial). The sham injection was an imitation of an intravitreal injection using an injection syringe without a needle touching the eye.
1651988|NCT01840384|Dietary Supplement|Multi-micronutrients|
1651989|NCT01840384|Dietary Supplement|Maltodextrin and Lactose|
1651990|NCT01840371|Drug|Conventional sedation|"Propofol Meperidine : 25 mg IV just before procedure
IV bolus of 1 mg/kg for sedation induction,
Infusion of 60 mcg/min/kg for maintenance of sedation
Additional bolus dose of 10mg as needed for adequate sedation"
1651991|NCT01840371|Drug|Experimental sedation|"Fentanyl
IV bolus of 1 µg/kg for sedation induction
Additional bolus dose of 0.5 µg/kg as needed for adequate pain control Propofol
IV bolus of 0.4 mg/kg for sedation induction
Infusion of 30 µg/min/kg for maintenance of sedation
Additional bolus dose of 10mg as needed for adequate depth of sedation"
1651992|NCT01840358|Other|Observation of hypoglycemias frequency 3 days before and after pump initiation|
1651994|NCT01840332|Drug|L-thyroxin|Low dose of L-thyroxin (50 microg/day) will be used during 4 weeks. If TSH is < 30 after 4 weeks the study continues up to 6 weeks.
1651995|NCT01840306|Other|Biomarker Analysis|
1651996|NCT01840267|Device|ultrasonographic measurement of optic nerve sheath diameter|A thick layer of gel is applied on the upper closed eyelid. The linear 13- to 6-MHz ultrasound probe is then placed in the gel, without exerting pressure on the eye. Two measurements are taken for each optic nerve: one in the transverse plane, with the probe being horizontal, and one in the sagittal plane, with the probe being vertical. The final ONSD is the mean of these measurements.
1651997|NCT01840254|Drug|dexmedetomidine|
1651998|NCT01840254|Drug|normal saline|
1652001|NCT01840228|Drug|Micronized progesterone suppository|
1652002|NCT01840189|Other|Cortef|Treatment A is oral hydrocortisone replacement ( Cortef 5 mg) administered according to weight-adjusted doses for 2 months
1652003|NCT01840189|Other|Solu-cortef|"Treatment B is continuous subcutaneous hydrocortisone infusion with the initial standard dose of 10mg/m2/24hrs. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
This part of the study will take 2 months."
1652004|NCT01840176|Procedure|McCall culdoplasty|The modified McCall Culdoplasty procedure is a relatively simple procedure that is performed after removal of the uterus and cervix from the apex of the vagina wherein the angles of the vagina are attached to their respective uterosacral ligament and the cul-de-sac is surgically obliterated for support postoperatively. This is done with a single 0-vicryl suture. There will be no additional interventions applied during the hysterectomy aside from the McCall culdoplasty.
1652007|NCT01840150|Procedure|breath test|Undergo NA-NOSE breath test
1652008|NCT01840150|Other|laboratory biomarker analysis|Correlative studies
1652009|NCT01840137|Other|Baseline Strength Test|A symptom limited submaximal cardiopulmonary exercise test to estimate the subject's exercise capacity.
1652010|NCT01840137|Other|Exercise|Treadmill and muscle exercises.
1652011|NCT01840124|Device|Radiofrequency ablation of fibroids|The Acessa device delivers radiofrequency energy to uterine fibroids to destroy fibroid tissue. The patient undergoes a standard laparoscopy of the pelvis. A laparoscopic ultrasound is performed to identify the precise size and location of the fibroids. The Acessa radiofrequency probe is then placed into the fibroid and the radiofrequency energy is delivered. The fibroid tissue is destroyed and the fibroid shrinks down in size to decrease fibroid-related symptoms.
1652012|NCT01840111|Behavioral|Quit Smoking 6 hours|participants will quit smoking 6 hours prior to the cue-exposure sessions
1652013|NCT01840111|Behavioral|Quit Smoking 24 hours|participants will quit smoking 24 hours prior to the fMRI scan
1652014|NCT01840098|Dietary Supplement|low leucine content drink|
1652015|NCT01840098|Dietary Supplement|high leucine content drink|
1652016|NCT01840098|Dietary Supplement|low leucine + HMB drink|
1652017|NCT01840098|Dietary Supplement|Control/carbohydrate|
1652018|NCT01840098|Behavioral|36 hour fasting|
1652019|NCT01840085|Drug|0.03% DSC127 topical gel|
1652020|NCT01840072|Other|Active antihypertensive treatment|Initial antihypertensive treatment with angiotensin-converting enzyme inhibitors (Enalapril) and/or calcium channel blockers as second line medication; and/or diuretics as third line medications. Based on patients' baseline BP level, the first-line medication (intravenous Enalapril) can be used alone, or in combination with second-line medication (calcium channel blocker), and third-line medication (diuretics) to achieve the target systolic BP lowering by 10% to 25% within the first 24 hours after randomization and to achieve systolic BP below 140 mm Hg and diastolic BP below 90 mm Hg and maintain this BP level afterwards during the hospitalization.
1652021|NCT01840059|Device|Renal sympathetic denervation|A fit for purpose radiofrequency catheter is guided to the renal artery using fluoroscopy. This is connected to an external RF generator. RF energy is applied through the catheter to the renal artery wall with the goal of disrupting the sympathetic nerves which run in the adventitia
1652022|NCT01840046|Drug|Interleukin-2|"The patient will receive 4 cycles of recombinant interleukin 2 (aldesleukin, Proleukin ®) subcutaneously according to the following dosing schedule:
5 to 7 days (Monday to Friday) in weeks 1, 3, 6 and 9.
The dosage is as follows:
S1: 1.5 mille-International unit / day (D1 to D5), S3, S6 and S9: 3 mille-International unit /Jour (D1 to D5)."
1652023|NCT01840033|Device|group Piccnut|Vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
1652024|NCT01840033|Device|Tunnelled nutritional central catheter|After consent, patients will be randomised to PICC Line (group A) or tunnelled nutritional central catheter with cuff (group B). Duration of inclusion will be 24 months. After randomisation, patients will have catheter inserted by a competent radiologist following an echography. Radiologist will have to answer a questionnaire and doctors will note any catheter-related complications. After that, vessels echography will be systematically repeated at 3 months and 12 months for thrombosis research. Follow-up visit will be held at 1,3,6,9 and 12 months. At every step, major and minor complications will be noted by the investigators.
1652027|NCT01840007|Drug|Metformin Group|"The chosen posology is 2540 mg/day of metformin-base so 3 tablets/day of Glucophage ® 1000.
Patients should take 3 tablets/day at the rate of 1tablet in morning, noon and evening to favor the absorbtion and reduce the risk of gastrointestinal intolerance. In case of missed dose, patients will be allowed to take 2 tablets on the next grip. The drug will be presented in its officinale form of Glucophage ® 1000 with specifications indicated in the Vidal dictionary. It will be provided each month, to patient, 3 boxes of 30 tablets of Glucophage ® 1000. The patient will be asked to rate each day, on a calendar, the number of tablets of Glucophage ® 1000 effectively taken. It will also ask to the patient to bring back used boxes of Glucophage ® 1000 to count any tablets not taken."
1652028|NCT01839994|Radiation|CF-CRT combined with BT or SBRT boost.|CF-CRT to the prostate and SV (IM risk group) or to the prostate, SV and LN (high risk group) to the TD of 50 Gy, 2.0 Gy d fx, 5 days a week over the period of 5 weeks AND A. Two 10 Gy fractions of HDR BT 1-7 d. before external beam radiotherapy and one 1-7 d. after external beam radiotherapy OR B. Two stereotactic body radiotherapy (SBRT) fractions of 10 Gy to the prostate (CTV boost) delivered with dynamic SBRT technique (IMRT or Rapid Arc). First and second fraction of SBRT boost is scheduled 1-7 d. before and 1-7 d. after the start of conventionally fractionated radiotherapy, respectively.
1652029|NCT01839994|Radiation|CF-CRT alone|Conventionally fractionated EB-CRT (IMRT or Rapid Arc) to the TD of 50 Gy, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).of 50 Gy in 2.0 Gy per fraction, 5 days a week over the period of 5 weeks, followed by a boost to the prostate (26 or 28 Gy in 2.0 Gy per fraction 5 days a week over the period of 2.5 weeks) to the total dose of 76 or 78 Gy (intermediate or high risk group of patients, respectively).
1652030|NCT01839994|Drug|Hormonal treatment (neoadjuvant androgen deprivation)|Hormonal treatment: three months of neoadjuvant androgen deprivation (MAB -maximal androgen blockade) in all patients. Long-term (3 years) of adjuvant hormonotherapy (LHRH agonists only) in high risk patients.
1652031|NCT01839981|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
1652032|NCT01839968|Other|Ex vivo addition of normal platelet rich plasma to prasugrel-treated platelet rich plasma|
1652033|NCT01839955|Drug|erlotinib hydrochloride|"Dose Escalation Group:
Begins day 1: given 150mg daily, orally
Extension Group:
Begins Day 1: 150mg daily, orally"
1652034|NCT01839955|Drug|quinacrine dihydrochloride - Escalation dose|Begins Day 8: Loading dose (first cycle only) 50mg three times daily for 7 days followed by 21 days of 50mg maintenance dose. Level -1: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg every other day for three weeks). Level 1 [starting dose]: Loading dose (50mg three times daily for 7 days), maintenance dose (50mg daily for three weeks). Level 2: Loading dose (100mg three times daily for 7 days), maintenance dose (100mg every other day for three weeks). Level 3: Loading dose (150mg three times daily for 7 days), maintenance dose (200mg every other day for three weeks). Level 4: Loading dose (200mg three times daily for 7 days), maintenance dose (400mg every other day for three weeks). Subsequent patient cohort(s) will be enrolled depending on the safety and tolerability of subjects
1652035|NCT01839955|Other|laboratory biomarker analysis|Correlative studies
1652036|NCT01839955|Other|pharmacological study|Correlative studies
1652037|NCT01839955|Drug|quinacrine dihydrochloride - Extension dose|Participants will be treated at recommended dose from expansion group to confirm tolerability and evaluate early response
1652038|NCT01839942|Procedure|hernia gap closure|type of gap closure during laparoscopic repair of a ventral hernia: none, extracorporal, intracorporal
1652039|NCT01839942|Procedure|extracorporal suturing of gap|ventral hernia gap is sutured extracorporally
1652040|NCT01839929|Drug|Prograf|oral
1652041|NCT01839929|Drug|Advagraf|oral
1652042|NCT01839916|Biological|therapeutic allogeneic lymphocytes|Given IV
1652043|NCT01839916|Other|laboratory biomarker analysis|Correlative studies
1652044|NCT01839903|Other|EDIS|Changes made to EDIS system to improve tracking and treatment of smoking in the ED
1652045|NCT01839903|Other|Care as usual|Care as usual in the ED will be tracked
1652046|NCT01839890|Device|Bare metal Stent plus Paclitaxel Balloon|After the permeabilization of the clinical event responsible artery with conventional therapy (including the insertion of a conventional metal stent and once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
1652047|NCT01839890|Device|Bare metal Stent|After the permeabilization of the clinical event responsible artery with conventional therapy a conventional metal stent will be inserted. Once by the interventional cardiologist gives good final result), patients will be randomized in a 1:1 ratio
1652048|NCT01839877|Drug|HIA DEBIRI + systemic FOLFOX|
1652049|NCT01839864|Behavioral|Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count|Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only
1652050|NCT01839851|Drug|Treatment with any inhaled corticosteroid|Use of any inhaled corticosteroid (daily frequency and dose will be registered)
1652051|NCT01839851|Drug|Treatment with any intranasal glucocorticoid|Use of any inhaled intranasal glucocorticoid (daily dose and frequency will be registered)
1652052|NCT01839838|Radiation|Proton Therapy|
1652053|NCT01839825|Device|QuietCare|
1652054|NCT01839812|Drug|Cosyntropin|A cosyntropin stimulation test is administered to each patient at 3 time points during the study to evaluate adrenal response.
1652055|NCT01839799|Drug|Gemcitabine|1000mg/m2 IV over 30 to 100 minutes, day 1, 8, 15
1652056|NCT01839799|Drug|Abraxane|125 mg/m2 IV over 30 minutes, day 1, 8, 15
1652057|NCT01839799|Drug|FOLFIRINOX|Irinotecan 180 mg/m2 Day 1 Oxaliplatin 85 mg/m2 Day 1 5-FU 400 mg/m2 bolus with Leucovorin 200 mg/m2 over 2h, Day 1, then 5-FU 2400 mg/m2 over 46h. Four cycles, if tolerated
1652058|NCT01839799|Radiation|Chemoradiation|
1652059|NCT01839773|Drug|Paclitaxel|Oral administration on day 1,8,15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
1652060|NCT01839773|Drug|Paclitaxel|Premedication, IV infusion on day 1 of 3-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
1652061|NCT01839747|Procedure|PET-MRI|Imaging
1652062|NCT01839747|Procedure|PET-CT|Imaging
1652063|NCT01839734|Drug|Lubiprostone|Lubiprostone 24 mcg by mouth (PO) once-daily
1652064|NCT01839721|Drug|Bifilact®|placebo, standard dose 1.3 billion twice a day, high dose 10 billion three time a day
1652065|NCT01839721|Other|placebo|
1652066|NCT01839708|Behavioral|Lifestyle Counseling|The intervention will determine the differential outcomes of reading generic materials versus viewing custom DVDs containing targeted health information and discussions with MI-trained moderators on weight gain prevention.
1652067|NCT01839695|Device|Valiant Mona LSA Stent Graft System|All subjects will be implanted with this device
1652071|NCT01839656|Drug|nusinersen|Administered by intrathecal (IT) injection
1652072|NCT01839643|Drug|Meloxicam vaginal ring|
1652073|NCT01839630|Drug|Sorafenib (Nexavar, BAY43-9006)|sorafenib treatment (including dose, duration, modification) and TACE procedure are decided by the investigator
1652074|NCT01839617|Dietary Supplement|Early parenteral nutrition|
1652075|NCT01839617|Dietary Supplement|Late parenteral nutrition|
1652076|NCT01839604|Drug|AZD9150|Intravenous infusion over 3 hours.
1652077|NCT01839591|Device|catheter ALAIR|Catheter ALAIR Radiofrequency 65°
1652078|NCT01839578|Drug|Anticoagulation to prevent clotting of the extracorporeal circuit. (regional citrate anticoagulation)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.
Ci-Ca protocole for MultiFiltrate® CRRT machine :
4% trisodium citrate solution
Calcium chloride solution (100 mmol/L)
Dialysate flow rate: 35 ml/kg/h
Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of 3
Citrate infusion titrated to maintain postfilter ionized calcium between 0.25 and 0.35 mmol/L.
Calcium chloride infusion titrated to maintain systemic ionized calcium between 1.12 and 1.2 mmol/L.
Blood flow adapted to the acid-base status"
1652079|NCT01839578|Drug|Anticoagulation to prevent clotting of the extracorporeal circuit (Unfractionated heparin)|"Anticoagulation to prevent clotting of the extracorporeal circuit. Unfractionated heparin and regional citrate anticoagulation will be compared.
Continuous infusion of unfractionated heparin: starting infusion rate at 600 IU/h then adjusted to maintain partial thromboplastin time at 1-1.4 times the normal value.
Standard dialysate for CRRT : Prismasol® K2 solution
Dialysate flow rate: 35 ml/kg/h
Blood flow rate: adjusted to maintain a ratio blood flow rate / dialysate flow rate of"
1652080|NCT01839565|Device|Quadrilateral Surface Plate|Patients with acetabular fracture surgically treated using the Quadrilateral Surface Plate
1652081|NCT01839552|Drug|Fentanyl Citrate Nasal Spray (FCNS)|
1652082|NCT01839539|Biological|dendritic and cytokine-induced killer cells|
1652129|NCT01839188|Biological|RotaTeq|Human-bovine rotavirus reassortants (live) vaccine 2mL oral administration at 2, 4 and 6 month
1652649|NCT01835132|Device|Gevokizumab|Subcutaneous injection of 60 mg gevokizumab
1652083|NCT01839526|Drug|Iohexol|Evaluations of renal and cardiac function are standard-of-care in young patients with Fabry disease. This study uses the more precise iGFR measurement of renal function. No investigational drug will be administered in this study for the treatment of Fabry disease.
1652085|NCT01839487|Drug|PEGPH20+nab-paclitaxel+gemcitabine|PEGPH20 3ug/kg + nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2. PEGPH20 given IV x2/week for Cycle 1 and weekly for Cycle 2 and beyond. Nab-paclitaxel and gemcitabine given IV x1/week for 3 weeks for all cycles.
1652086|NCT01839487|Drug|nab-paclitaxel + gemcitabine|nab-paclitaxel 125 mg/m2 + gemcitabine 1000 mg/m2 given IV x1/week 3/4 weeks per cycle
1652087|NCT01839474|Device|CPAP|Appropriately sized nasal prongs will be selected for the patient, gently applied ensuring a tight seal, and securely fastened. The CPAP machine will be turned on to deliver a pressure of 5 cm H2O in the inspiratory limb of the system. Patients will be allowed to be in the position of most comfort, preferably with mouth closed to maintain pressure in the circuit.
1652088|NCT01839448|Biological|Post-partum oral glucose tolerance test|All patients will have an oral glucose tolerance test at 4 to 12 weeks after the end of pregnancy. Study representatives will contact patients by phone to remind them of the necessity of this test, and its importance for their health.
1652089|NCT01839435|Procedure|outpatient surgery|
1652090|NCT01839422|Behavioral|Memory assessment|Cognitive assessment : Neuropsycological tests, learning sessions of new stimuli.
1652091|NCT01839422|Other|Brain imaging examination MRI|Brain imaging examination : Structural and functional MRI to compare differences between each sample.
1652092|NCT01839409|Behavioral|vestibular stimulation|Physical activity and vestibular stimulation will be used in order to improve circadian rhythms
1652093|NCT01839396|Device|Deep Brain Stimulation|The Vercise™ DBS system will be implanted in subjects in both study arms. Stimulation parameters will vary depending on the study arm assignment. All subjects will receive therapeutic settings at the end of the blinded period.
1652094|NCT01839383|Other|different dialysate calcium concentration|
1652095|NCT01839370|Device|Closed Loop with Pramlintide|A closed-loop automated insulin management system (Adaptive Insulin Meal Supervisor- AIMS) for meals utilizing continuous glucose monitoring (CGM)and subcutaneous insulin pump and a standard pramlintide therapy will be compared to a standard pramlintide therapy alone to control glucose levels in individuals with type 1 diabetes. DiAs is controlled by the subject, with assistance from the study personnel as needed.
1652096|NCT01839357|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily for 6 weeks; subjects with severe to moderate renal impairment (ie, CrCl of 15 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily for 6 weeks in the study.
1652097|NCT01839344|Dietary Supplement|Quercetin|Quercetin 250 mg capsules; oral single dose of 2000 mg
1652098|NCT01839344|Drug|Acarbose|Acarbose 100 mg tablet; oral single dose of 100 mg
1652099|NCT01839344|Drug|placebo|An oral single dose of a solid, colored empty capsule.
1652100|NCT01839331|Drug|Low Dose Ampion|4 mL Ampion
1652101|NCT01839331|Drug|High Dose Ampion|10 mL Ampion 10mL
1652102|NCT01839331|Drug|Placebo Low Dose 4 mL|4 mL Placebo
1652103|NCT01839331|Drug|Placebo 10 mL|Placebo 10 mL
1652104|NCT01839318|Device|Nelfilcon A contact lenses|
1652105|NCT01839318|Device|Omafilcon A contact lenses|
1652106|NCT01839318|Device|Etafilcon A contact lenses|
1652107|NCT01839305|Other|Hydrotherapy|Hydrotherapy, monitored by physical therapists, performed in groups of up to 10 volunteers, for 45 min per session, twice a week, for 16 weeks
1652108|NCT01839292|Device|uncovered D-type stent insertion|
1652109|NCT01839292|Device|double-layered ComVi stent insertion|
1652110|NCT01839279|Drug|Tizanidine|
1652111|NCT01839279|Drug|Placebo|
1652112|NCT01839279|Drug|Moxifloxacin|
1652113|NCT01839253|Drug|b-blocker(Atenolol)|
1652114|NCT01839253|Drug|ACE inhibitor(Enapril)|
1652115|NCT01839253|Other|control|
1652116|NCT01839240|Drug|azacitidine|Given IV or SC
1652117|NCT01839240|Drug|cytarabine|Given IV
1652118|NCT01839240|Drug|mitoxantrone hydrochloride|Given IV
1652119|NCT01839240|Other|laboratory biomarker analysis|Correlative studies
1652120|NCT01839227|Other|Neurologic and neuropsychologic tests|"Cognitive functioning was assessed with the following test: Korean Mini-Mental State Examination (K-MMSE) and visuomotor test of D-LOTCA battery.
Regional cerebral oxygen saturation was continuously monitored using the INVOS 5100 (somatics,Troy, MI) with bifrontal placement of two sensors before the induction of the anesthesia until the end of operation.
Baseline rSO2 was defined as the average saturation value over a 1 min period before induction of general anesthesia, beginning approximately 3 min after the sensors were applied in supine position. After the induction, baseline prone rSO2 was defined over a 5min period after the change of position.
There is no intervention were made according to rSO2 values. Physiologic variables including BIS, PaCO2,PaO2, glucose, electrolyte, hematocrit, HR, MAP, and nasopharyngeal temperature were measured every 1 hours during the surgery."
1652121|NCT01839214|Drug|VB-201 160mg|
1652122|NCT01839214|Drug|Placebo|
1652123|NCT01839201|Other|control|No psychological intervention
1652124|NCT01839201|Other|suggestion|In the suggestion group patients received suggestions evoking their images of favourite place at the time of narcosis induction.
1652125|NCT01839201|Other|dreamfilm|In the dreamfilm group patients worked out the dreamfilm plan using a favourite place technique one day prior to surgery. At the induction of anesthesia the series of images prepared by suggestions was evoked.
1652126|NCT01839188|Biological|PR5I (V419)|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b conjugate [Meningococcal Outer Membrane Protein Complex], and hepatitis B [Recombinant] Vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
1652127|NCT01839188|Biological|Pediacel|Adsorbed diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliomyelitis and Haemophilus influenzae type b conjugate vaccine 0.5 mL intramuscular injection at 4 months of age
1652128|NCT01839188|Biological|NeisVac-C|Meningococcal group C polysaccharide conjugate vaccine adsorbed 0.5 mL intramuscular injection at 2 and 4 months of age
1652650|NCT01835119|Drug|gum|gum
1652130|NCT01839188|Biological|Prevenar 13|Pneumococcal conjugate vaccine (13-valent, adsorbed) 0.5 mL intramuscular injection at 2 and 4 months of age
1652131|NCT01839175|Biological|Hexavalent vaccine|0.5 mL intramuscular injection at 2, 3 and 4 months of age (primary series) 0.5 mL intramuscular injection at 12 or 13 months of age (booster)
1652132|NCT01839175|Biological|NeisVac-C|0.5 mL intramuscular injection at 2 and 4 months of age
1652133|NCT01839175|Biological|Prevenar 13|0.5 mL intramuscular injection at 2 and 4 months of age (primary series) 0.5 mL intramuscular injection at 13 months of age (booster)
1652134|NCT01839175|Biological|RotaTeq|2 mL oral administration at 2, 3 and 4 months
1652135|NCT01839175|Biological|Nimenrix|0.5 mL intramuscular injection at 12 months
1652136|NCT01839175|Biological|M-M-RVAXPRO|0.5 mL intramuscular or subcutaneous injection at 13 months of age
1652137|NCT01839162|Procedure|Coronary angiography|Diagnostic coronary angiography
1652138|NCT01839162|Procedure|PCI|Percutaneous coronary intervention
1652139|NCT01839162|Procedure|Right approach|Right transradial access
1652140|NCT01839162|Procedure|Left approach|Left transradial access
1652141|NCT01839149|Drug|TI-001|TI-001 is intranasal oxytocin
1652142|NCT01839149|Drug|Placebo|
1652143|NCT01839136|Procedure|Intrauterine transfer of gametes|
1652144|NCT01839136|Procedure|Intrauterine transfer of embryos|
1652145|NCT01839123|Device|Prosthetic Suction or Pin Socket|Conventional prosthetic socket utilizing non-vacuum suspension to secure the residual limb to the prosthesis. Non-vacuum suspension includes pin/lock suspension and suction suspension.
1652146|NCT01839123|Device|Prosthetic LimbLogic Vacuum Socket|Prosthetic socket that incorporates conventional vacuum suspension using the commercially available LimbLogic vacuum pump
1652147|NCT01839110|Drug|Ranolazine|Ranolazine at 500mg by mouth twice per day and after two weeks will increase to 1000mg by mouth twice per day and continue for a total of 26 weeks.
1652148|NCT01839110|Drug|Placebo|Placebo by mouth twice per day for a total of 26 weeks.
1652149|NCT01839097|Drug|Belinostat|"Belinostat will be administered by intravenous infusion once daily for up to 5 days depending on the dose cohort as follows:
Cohort 1: belinostat 1000 mg/m2 IV on Day 1
Cohort 2: belinostat 1000 mg/m2 IV on Day 1-2
Cohort 3: belinostat 1000 mg/m2 IV on Day 1-3
Cohort 4: belinostat 1000 mg/m2 IV on Day 1-4
Cohort 5: belinostat 1000 mg/m2 IV on Day 1-5"
1652150|NCT01839097|Drug|CHOP|"Cyclophosphamide - 750 mg/m2 - IV - Day 1
Vincristine - 1.4 mg/m2 - IV - Day 1
Doxorubicin - 50mg/m2 - IV - Day 1
Prednisone 100mg PO - On Day 1 Prednisone will be administered after chemotherapy part of CHOP, and on Day 2-5 after belinostat."
1652151|NCT01839084|Drug|Xenon|general anaesthesia with xenon 60% in oxygen (FiO2=0.4)
1652152|NCT01839084|Drug|Isoflurane|general anesthesia with isoflurane 1.2% in 40% oxygen/medical air
1652153|NCT01839071|Procedure|biopsy|
1652154|NCT01839058|Other|Esophageal Manometry|Both cohorts will undergo standard high resolution esophageal manometry testing. This entails a catheter passed through the nose into the esophagus and measures pressure changes with a series of wet swallows. As part of the study, we will also be instilling both weak acid and saline into the esophagus.
1652155|NCT01839032|Drug|Vinorelbine cisplatin radiotherapy|"During the induction period, patients received chemotherapy for two 3-week cycles. Bolus intravenous vinorelbine 25 mg/m², was administered on day 1, then cisplatin 80 mg/m² was administered over 1-hour infusion. Vinorelbine 60 mg/m² was also administered on day 8.
Patients with objective response (OR) or no change (NC) continued the concomitant period (CP) including two additional 3-week cycles of radio chemotherapy (vinorelvine 20 mg D1 D3 D5 Cisplatin 80 mg/m² 66 Gy)."
1652156|NCT01839019|Drug|ODM-102|Single dose escalation
1652157|NCT01839019|Drug|Placebo for ODM-102|Single dose escalation
1652158|NCT01839006|Procedure|dismembered pyeloplasty|Using a flank approach, as the patient was placed in the lateral decubitus position, and an anterior subcostal incision was made. The narrow segment of UPJ was identified and resected, and then the proximal edge of the ureter was spatulated to allow a wide anastomosis between the ureter and the most dependent part of the renal pelvis. The extent of renal pelvis reduction was decided by the surgeon.
1652159|NCT01838993|Drug|Lidocaine inhalation|Lidocaine inhalation before intubation
1652160|NCT01838993|Drug|Placebo|
1652161|NCT01838980|Device|Motus GI Clean-Up Device|
1652162|NCT01838967|Drug|C - V - C+V|Drug will be administered to according to C - V - C+V sequence for 3 period.
1652163|NCT01838967|Drug|C - C+V - V|Drug will be administered to according to C - C+V - V sequence for 3 period.
1652164|NCT01838967|Drug|V - C - C+V|Drug will be administered to according to V - C - C+V sequence for 3 period.
1652165|NCT01838967|Drug|V - C+V - C|Drug will be administered to according to V - C+V - C sequence for 3 period.
1652166|NCT01838967|Drug|C+V - C - V|Drug will be administered to according to C+V - C - V sequence for 3 period.
1652167|NCT01838967|Drug|C+V - V - C|Drug will be administered to according to C+V - V - C sequence for 3 period.
1652168|NCT01838954|Device|Short-wave diathermy|Device operating at a frequency of 27.12 MHz in continuous mode with an effective nominal output of 400 W in the patient circuit.
1652169|NCT01838941|Drug|Betaine|"Betaine will be given orally (mixed with food or dissolved in water, juice, milk, or formula) or through gastrostomy tube as follows:
6 g/day in children < 30 kg, in 3 divided doses (2 g at meal time)
12 g/day in children > 30 kg, in 4 divided doses (3 g at meal time and bed time)."
1652170|NCT01838928|Drug|Bupivacaine|
1652171|NCT01838915|Dietary Supplement|Prebiotics+Glutamine|"Prebiotics are nondigestible food ingredients, generally oligosaccharides, that modify intestinal microbiota balance by stimulating the growth of beneficial bacteria.
Glutamine is a non-essential amino acid that can be metabolized by epithelial cells, enhancing barrier function."
1652172|NCT01838915|Dietary Supplement|Placebo|Maltodextrin, 20 g.
1652173|NCT01838902|Drug|DHA-PPQ|Participants will receive a 3 day course of DHA-PPQ
1652174|NCT01838902|Drug|PQ (0.75)|Participants will receive a single dose of PQ at 0.75mg base/kg body weight
1652175|NCT01838902|Drug|PQ (0.4)|Participants will receive a single dose of PQ at 0.4mg base/kg body weight
1652176|NCT01838902|Drug|PQ (0.2)|Participants will receive a single dose of PQ at 0.2mg base/kg body weight
1652651|NCT01835106|Procedure|Epidural catheter is used postoperatively|
1652177|NCT01838889|Behavioral|Culturally adapted psychological intervention (Positive Health Programme)|This study will evaluate the efficacy of a group psychological intervention (PHP) based on the principles of Cognitive Behaviour Therapy in treating depression in postpartum women.
1652178|NCT01838876|Drug|Cariprazine|Cariprazine capsules 0.5 mg, 1.0 mg, and 1.5 mg; Cariprazine doses 1.5, 3.0, or 4.5 mg/d; patients will be titrated to a starting dose of 3.0 mg/d. Patients can stay on 3.0 mg/d or the dose can be adjusted to 1.5 mg or 4.5 mg based on investigator's judgment of response and tolerability. Oral administration.
1652179|NCT01838863|Biological|Type AB plasma|The plasma is thawed and administered to subjects in the experimental (plasma) arm.
1652180|NCT01838863|Drug|Crystalloid fluid (standard of care for resuscitation)|Normal saline will be give to subjects in the standard arm as the current standard of care for an initial resuscitation fluid
1652181|NCT01838850|Drug|CS8635 20/5/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.
Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine (AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, oral placebo tablet. All tablets are given once a day.
Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 40-5-12.5mg, given once a day."
1652182|NCT01838850|Drug|Olmetec® Plus 20/12.5mg and placebo|"Run-in period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, given once a day.
Double-blind period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Hydrochlorothiazide(HCTZ) 20-12.5mg, oral placebo tablet. All tablets are given once a day.
Open-label period: Coated, Oral tablet containing Olmesartan medoxomil(OM)-Amlodipine(AML)-Hydrochlorothiazide(HCTZ) 20-5-12.5mg, given once a day."
1652183|NCT01838824|Behavioral|Speed of Processing Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself.
1652184|NCT01838811|Behavioral|Speed of Process Training|SPT involves trainer-guided practice of computer-based exercises, including Target Detection (indicating presence or absence of targets, identifying targets, etc.) and Discrimination and Localization (performing same/ different discriminations of targets presented very quickly and followed by a masking pattern) 10, 19, 84. Display speed, ranging from 17 to 500 ms, is the primary manipulation during training, which increases task demands and thus demands on PS itself. These training tasks are tailored to each individual's ability by the trainer.
1652185|NCT01838798|Other|Baseline activities|Initial consent procedures and baseline data collection.
1652186|NCT01838798|Other|Clinical interview with a psychologist|"Clinical interview with a psychologist.
This interview with a psychologist will take place after patient consent procedures, and at least 2 days after discontinuation of sedation, and before leaving the ICU. This interview will include:
An inventory of peritraumatic distress symptoms
A questionnaire on peritraumatic dissociative experiences
An assessment of related, potential impacts
The HADS questionnaire"
1652187|NCT01838798|Other|Telephone interview 2 months after ICU discharge|"At 2 months after leaving the ICU, a psychologist will contact the patient with questions regarding his/her representation of hospitalization. This implies the following:
Questionnaires assessing memories and stressors (Questionnaires ICUMT, and ICU-SEQ
An assessment of psychological trauma
An assessment of potential impacts"
1652188|NCT01838798|Other|Clinical interview with a psychologist|"At 4 months after ICU discharge, the patient has a clinical interview during which a psychologist will:
assess cognitive functions
evaluate clinical symptoms of depression
assess quality of life
assess symptoms of post traumatic stress"
1652189|NCT01838785|Drug|18F-DTBZ AV-133|
1652190|NCT01838772|Drug|Pegylated-Interferon and Ribavirin|This is an open-label, single arm demonstration study. Intervention consists in treatment with Pegylated-interferon (Peg-Intron®, 1.5 microgr/kg/week, as subcutaneous injection) and ribavirin (Rebetol®, weight-based dosing, 2-daily doses) for 48 weeks, or 24 weeks for patients with genotype 2 and 3, moderate liver fibrosis, and rapid virological response.
1652191|NCT01838733|Other|Observational study|
1652192|NCT01838720|Procedure|zero ischemia laparoscopic RFA assisted TE|
1652193|NCT01838720|Procedure|ischemia|conventional laparoscopic partial nephrectomy
1652194|NCT01838707|Drug|0.125% Bupivacaine HCL @ 4-5 ml/h|
1652195|NCT01838707|Drug|0.125% Bupivacaine HCL , Morphine sulphate @ 3 mg 3-5 ml/h|
1652196|NCT01838707|Drug|0.125% Bupivacaine, Fentanyl 100 mic @ 3-5 ml/h|
1652197|NCT01838694|Biological|Ala-Cpn10|
1652198|NCT01838694|Drug|Placebo|
1652199|NCT01838681|Drug|Placebo|Once daily, tablets, orally
1652200|NCT01838681|Drug|Brexpiprazole|1, 2, or 3 mg/day, once daily dose, tablets, orally. Uptitration in weekly steps from 1 mg/day
1652201|NCT01838681|Drug|ADT|Duloxetine, escitalopram, fluoxetine, paroxetine IR, sertraline, venlafaxine XR; dosing according to label
1652202|NCT01838668|Drug|Placebo|Two placebo capsules orally BID
1652203|NCT01838668|Drug|dimethyl fumarate|Two dimethyl fumarate 120mg capsules orally BID
1652205|NCT01838642|Drug|Ponatinib|Ponatinib tablets will be administered orally, continually, once daily at a dose of 30 mg. A cycle of ponatinib is defined as 28 consecutive days starting with the first day of the treatment cycle. Treatment will be administered primarily in an outpatient setting.
1652206|NCT01838616|Drug|Tapentadol Prolonged Release|All participants started with 50 mg tapentadol hydrochloride prolonged release (twice daily). The dose of tapentadol hydrochloride prolonged release will be adjusted in increments of 50 mg to a level that provided adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants are permitted a maximum dose of 250 mg twice a day (500 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
1652207|NCT01838616|Drug|Oxycodone/Naloxone Prolonged Release|All participants start with 10 mg/5 mg oxycodone/naloxone (twice daily). The dose of oxycodone/naloxone may be adjusted in increments of 10mg/ 5 mg oxycodone/naloxone to a level that provide adequate analgesia. Titration will be after a minimum of 3 days on a dose. Participants will be permitted a maximum dose of 50 mg/ 20 mg oxycodone/naloxone twice daily a day (100 mg/40 mg total daily dose). After titration participants will remain on the stable dose for 9 weeks.
1652208|NCT01838603|Other|Qualitative interview|Qualitative interview to sample the patients feelings, experiences and thoughts risen by the treatments in the program
1652209|NCT01838590|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
1652210|NCT01838590|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1652211|NCT01838564|Other|Routine Data collection|"Patients assigned to the control arm answered PediQUEST (PQ) surveys at most once a week and at least once a month. PQ-surveys were administered through a tablet computer if patient was at the clinic or ward or over the phone if patient was primarily at home. PQ-survey had 9 age- and respondent- adapted versions.
Control arm participants reported their satisfaction with the PediQUEST technology twice 4th and 8th PediQUEST administration. These surveys were embedded in PediQUEST."
1652212|NCT01838564|Other|Feedback of patient-reported outcomes|Patients, parents and primary providers received printed reports summarizing patient/parent reported outcomes for last five visits. When child reported moderate-severe distress an email was automatically sent to primary providers (oncologist, nurses and psychosocial clinicians), as well as to the pain and palliative care services.
1652213|NCT01838551|Drug|COR-003|
1652214|NCT01838538|Drug|Bevacizumab|
1652215|NCT01838538|Drug|TC:paclitaxel + carboplatin|
1652216|NCT01838499|Biological|MEDI8968|SC injection at baseline, Week 4 and Week 8
1652217|NCT01838499|Biological|Saline|SC injection at baseline, Week 4 and Week 8
1652218|NCT01838486|Procedure|Bladder Thermal Distention|Bladder Thermal Distention (BTD) is an approved procedure in Europe and Israel. Continuous irrigation of the bladder with warm saline with the PelvixTT system. The procedure will be performed on an outpatients basis. The procedure lasts 1 hour.
1652219|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
1652220|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
1652221|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
1652222|NCT01838473|Procedure|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
1652223|NCT01838460|Drug|sublingual nicotine tablets|6 mg = 3 tablets
1652224|NCT01838460|Other|Smokeless tobacco|Swedish type moist snuff
1652225|NCT01838447|Dietary Supplement|Cholecalciferol|The High Dose group is based on the age-specific UL. These doses were chosen to elevate 25OHD well above 50 nmol/L, while minimizing the risk of vitamin D toxicity (e.g. hypercalcemia, hypercalciuria)
1652228|NCT01838408|Other|Ez2go Complete|EZ2Go Complete
1652229|NCT01838408|Other|LoSo Prep|LoSo Prep ™ Magnesium Citrate plus Bisacodyl Kit Study Arm
1652232|NCT01838382|Device|classic LMA insertion|Classic LMA (cLMA) will be inserted when no response is obtained in the train-of-four stimulation. The fiberoptic view through the LMA, intraoperative complications of the cLMA, any complication during anesthesia emergence will be recorded. The device is examined and noted for the presence of visible blood.
1652233|NCT01838369|Drug|BI-505|
1652234|NCT01838343|Other|Ultrasound|Goal-directed ultrasound using a GE Vscan performed by a critical care fellow trained in ultrasonography.
1652235|NCT01838330|Dietary Supplement|psyllium|15 grams/day for 1 week, followed by 30 grams/day for 4 months
1652236|NCT01838317|Drug|Pioglitazone|
1652239|NCT01838278|Behavioral|Vojta Physiotherapy Method|Children in the experimental group or Vojta Group, received two weekly sessions of sensory-motor stimulation and two weekly sessions of Vojta Physiotherapy. Sensory motor stimulation and Vojta physiotherapy sessions lasted 50 minutes each. A guidance programme was also given to parents to carry out at home to promote the overall development of the child and teach the necessary Vojta method exercises, these were to be performed four times a day for 20 minutes.
1652240|NCT01838265|Procedure|Transrectal Ultrasound-Guided Biopsy|Active Surveillance Alone (AS). Transrectal Ultrasound-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies).
1652241|NCT01838265|Procedure|MRI Ultrasound Biopsy|MRI-Managed Active Surveillance (MRI-AS). MRI Ultrasound or MRI-guided biopsies within 6 months of enrollment and at 1 year intervals thereafter (maximum four biopsies)
1652242|NCT01838265|Behavioral|Expanded Prostate Cancer index Composite Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
1652243|NCT01838265|Behavioral|Short-Form 12 of Health Related Quality of Life Questionnaire|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
1652244|NCT01838265|Behavioral|Memorial Anxiety Scale for Prostate Cancer|Quality of life questionnaire obtained at Baseline, and at 12, 24 and 36 months after initial biopsy
1652245|NCT01838265|Procedure|Plasma/Serum Sample for biomarkers|Plasma/Serum Sample for biomarkers obtained at Baseline, and at 12, 24 and 36 months after initial biopsy for correlative studies (CTC, fcDNA, SNPs)
1652246|NCT01838265|Procedure|Urine Sample for Biomarkers|Urine Sample for biomarkers obtained at Baseline, and at 12, 24, and 36 months for correlative studies (hypermethylated DNA)
1652247|NCT01838265|Procedure|Blood Tests for Blood Urea Nitrogen and Creatinine|Blood Tests for Blood Urea Nitrogen (BUN) and Creatinine obtained at 0 - 6 months, and at 12, 24, and 36 months from initial biopsy. This is optional, subject may refuse
1652248|NCT01838265|Procedure|Blood Test for Serum PSA|Blood test for Serum PSA obtained at Baseline, at every 6 months up to 36 months from initial biopsy.
1652249|NCT01838252|Procedure|Hyaluronic acid|Hyaluronic acid filler will be injected in to the lower lid, elevating it to a more anatomic position
1652250|NCT01838252|Procedure|Saline|Saline will be injected in to the lower lid, elevating it to a more anatomic position
1652251|NCT01838239|Dietary Supplement|Fish Oil|Ocean Nutrition Fish Oil Capsules containing 1.9 g eicosapentaenoic acid (EPA) and 1.5 g docosahexaenoic acid (DHA)
1652252|NCT01838226|Behavioral|Problem Solving|A group problem-solving intervention, with interval phone calls delivered to check in on goal progress and reinforce group learning. Groups will meet monthly for 6 months, and each patient will be called once between each group session. Each group will consist of 10 patients. Problem-solving teaches patients to overcome internal barriers to healthful behaviors. Problem solving will be combined, at all group sessions, with self-efficacy training, so that patients will be taught simultaneously to overcome both internal and external barriers. Participants will be asked to develop personal goals related to CVD-related behaviors (e.g., smoking and weight reduction).
1652253|NCT01838200|Biological|Bacillus Calmette-Guérin (BCG) vaccine|Bacillus Calmette-Guérin (BCG) is a living attenuated strain of Mycobacterium bovis that stimulates cell-mediated immunity by producing a localized and self-limiting infection. BCG is used worldwide for vaccination against tuberculosis. BCG is an immunostimulating agent that has been also shown to have anti-tumour activity in several clinical studies. The exact mechanism of action is not well known, but study data suggest that active non-specific immune responses are induced. It is probable that BCG invokes a local inflammatory response involving a variety of immune cells, such as macrophages, natural killer cells and T cells
1652254|NCT01838200|Drug|Ipilimumab|Ipilimumab is a human CTLA-4-blocking antibody, designed to suppress the CTLA-4 inhibition of T cells. Ipilimumab is marketed by Bristol-Myers-Squibb under the name Yervoy® and was first approved by the FDA and TGA in 2011 for the treatment of unresectable or metastatic melanoma
1652255|NCT01838187|Radiation|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
1652256|NCT01838174|Drug|ACTHAR Gel (ACTH)|15 days of daily injections
1652257|NCT01838174|Drug|IV steroids with oral taper|3 days of intravenous methylprednisolone followed by 11 days of oral taper
1652260|NCT01838135|Device|WheelSeeU Training Program|WheelSeeU sessions will be administered by a peer-trainer (older adult wheelchair user), who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSeeU session will be tailored to the individual goals of participants, which will be identified during the start of each session.
1652261|NCT01838109|Dietary Supplement|oral nutritional supplement|
1652262|NCT01838096|Device|THA using 4th generation CoC|
1652263|NCT01838083|Drug|Insulin glargine new formulation HOE901|Pharmaceutical form: solution Route of administration: subcutaneous
1652264|NCT01838057|Device|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
1652265|NCT01838057|Other|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
1652266|NCT01838044|Drug|pregabalin and celecoxib|"During the first study period subjects in Arm A will be administered a daily fixed dose of celecoxib 200 mg once daily and pregabalin 150 mg (75 mg BID) for one week (during Week 0) followed by pregabalin 300 mg (150 mg BID) daily for the remaining 4 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.
All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
1652267|NCT01838044|Drug|Placebo and celecoxib|"Subjects in Arm B will be administered a daily fixed dose celecoxib 200 mg and placebo of pregabalin for 5 weeks. During the second study period all subjects will be administered concomitant treatment of a daily fixed dose of celecoxib 200 mg once daily and pregabalin 300 mg (150 mg BID). Subjects in Arm B will be initiated on pregabalin 150 mg (75 mg BID) daily for one week, before pregabalin will up titrated to 300 mg (150 mg BID) daily.
All subjects will complete a treatment taper (a) after completing the second study period or (b) after premature study discontinuation. During treatment taper, the pregabalin dose will be decreased to 150 mg (75 mg BID) daily and subjects will participate in a follow up visit for a final safety assessment."
1652269|NCT01838005|Behavioral|Conditional cash transfer|Eligible women randomized to the intervention group will receive the standard of care plus small and increasing cash payments, on the condition that they attend scheduled clinic visits on time (+/-5days), accept HIV services, deliver in a health facility, and at six weeks postpartum adhere to prescribed infant prophylactic drugs (cotrimoxazole, extended NVP) and provide blood sample for DNA PCR infant early HIV diagnosis.
1652270|NCT01837992|Drug|Primaquine|
1652271|NCT01837992|Drug|delayed primaquine|
1652272|NCT01837979|Procedure|cell-free fetal DNA|cell-free fetal DNA for DBS and maternal serum screening high risk pregnant women. Comparison of multiple Down's syndrome screening tests.
1652273|NCT01837966|Other|Lavender oil|2 drops for aromatherapy
1652274|NCT01837966|Other|Placebo|2 drops unscented mineral oil for aromatherapy
1652275|NCT01837953|Behavioral|Group Psychodynamic Interpersonal Psychotherapy|For those participants randomized to the USH + Group Psychodynamic Interpersonal Psychotherapy (GPIP) condition, this intervention will consist of 16 weekly 90 minute sessions of GPIP. GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment. Examples of the patient's cyclical relational patterns (CRPs) that may underlie their symptoms are discussed and the patient will be encouraged to work on these in the groups. Therapists will be given a written summary of each patient's CRP.
1652299|NCT01837797|Drug|Brexpiprazole 1 mg|once daily dose, tablets, orally
1652300|NCT01837797|Drug|Brexpiprazole 3 mg|once daily dose, tablets, orally
1717883|NCT00002349|Drug|Stavudine|
1652276|NCT01837953|Behavioral|Unguided Self-Help|All participants will first receive 10 weeks of Unguided Self-help. The USH will be based on Dr. Christopher Fairburn's CBT-oriented and evidence based self-help treatment plan for binge eating explained in his book, Overcoming Binge Eating. The USH program follows six steps: (1) Getting Started: Self-monitoring, weekly weighing; (2) Regular Eating: Establishing a pattern of regular eating; (3) Alternatives to Binge Eating: Substituting alternative activities; (4) Problem Solving and Taking Stock: Practicing problem solving and reviewing progress; (5) Dieting and Related Forms of Avoidance: Tackling the three forms of dieting and other forms of avoidance eating; and (6) What Next? Preventing relapse and dealing with other problems.
1652277|NCT01837940|Dietary Supplement|Placebo|Galactooligosaccharide (GOS) and rhamnose in a powder formulation
1652278|NCT01837940|Dietary Supplement|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri DSM17938, Galactooligosaccharide (GOS), rhamnose in a powder formulation
1652279|NCT01837927|Drug|NVA237|Once daily for 52 weeks
1652280|NCT01837927|Drug|Tiotropium Respimat®|Once daily for 52 weeks
1652281|NCT01837914|Procedure|Maxillary expansion|
1652282|NCT01837914|Procedure|Adenotonsillectomy|
1652283|NCT01837901|Device|transcorneal electrostimulation|OkuStim is used to determine the phosphene threshold, and then to administer electrostimulation
1652284|NCT01837888|Device|WheelSee Training Program|WheelSee sessions will be administered by a peer-trainer, who will be trained in a 2-day workshop to use social cognitive approaches (i.e. facilitating successful performance of wheelchair skills, learning through observation of peers, positive verbal reinforcement from peers and family members, and re-interpretation of physiological symptoms) to foster the improvement of self-efficacy for wheelchair use. Each WheelSee session will be tailored to the individual goals of participants, which will be identified during the start of each WheelSee session.
1652285|NCT01837875|Behavioral|Chronic Disease Self-Management Program (CDSMP)|The Chronic Disease Self-Management Program (CDSMP) is a 2.5 hour workshop given weekly for six weeks. People with different chronic health problems attend together and support one another in making positive changes in their health. Workshops are facilitated by two trained leaders, one or both of whom are non-health professionals with a chronic disease themselves. It is the process in which the program is taught that makes it effective. Classes are highly participative, and mutual support builds the participants' confidence in their ability to manage their health and maintain active and fulfilling lives.
1652286|NCT01837875|Behavioral|Mail-delivered arthritis kit|"The Arthritis Self-Management Tool Kit contains 1) a Self Test to help participants determine how arthritis affects their lives and self-tailor the use of the Tool Kit, including items related to pain, fatigue, physical limitations, and health worries; 2) information sheets: Working with Your Doctor and the Health Care System; Exercise; Medications; Healthy Eating; Fatigue and Pain Management; Finding Community Resources; and Dealing with One's Emotions; 3) information sheets on key process components of the ASMP: Action Planning, Problem Solving, Deciding What to Try, and Individualizing an Exercise Program; 4) The Arthritis Helpbook; 5) audio relaxation and exercise compact discs (CDs); and 6) an audio CD of all material printed on the information sheets."
1652287|NCT01837875|Behavioral|Support group|"Interested participants will be referred to the Lupus: Listening and Learning Group, a Charleston-based support group affiliated with the Lupus Foundation of America (LFA). One to two LFA-trained facilitators implement the group. The meeting format generally includes a specific discussion topic or an informative presentation such as by a medical or counseling professional, pharmacist, or lupus researcher. This program is followed by time within the group for further interaction and support among the attendees who wish to participate. The Lupus: Listening and Learning Group is open to all lupus patients, family members, friends and supporters, and there is no pre-registration or fee involved."
1652288|NCT01837875|Behavioral|Listserv|A project listserv will be established to link all intervention participants to facilitate exchange of coping strategies, pose questions, and share preferred educational resources or any other information relative to their everyday and disease-specific experiences and/or participation in the project. Participants will be provided with a URL, from which they will be able to subscribe to the listserv. Once subscribed, they will be able to post and receive messages, managed by a listserv moderator, who will be responsible for distribution to listserv members as appropriate. Participants will have the option to unsubscribe at any time.
1652289|NCT01837862|Drug|Mebendazole|Mebendazole will be given orally twice daily for over the course of treatment (70 weeks for low-grade glioma patients, 48 weeks for high-grade glioma/pontine glioma patients). Mebendazole will be prescribed according to the particular dose cohort for each patient (50 mg/kg/day, 100 mg/kg/day, or 200 mg/kg/day).
1652290|NCT01837862|Drug|Vincristine|Low-grade glioma patients only. Vincristine will be dosed as per the following: For patients < 12kg: 0.05 mg/kg; for patient > 12kg: 1.5mg/m2 (maximal dose 2.0 mg). Vincristine will be administered intravenously on Day 1 of weeks 0,1,2,3,4,5 during the 10-week induction cycle and on Day 1 of Weeks 0,1,2 of the six 10-week maintenance cycles.
1652291|NCT01837862|Drug|Carboplatin|Low-grade glioma patients only. Carboplatin will be dosed at 175 mg/m2. Carboplatin will be administered intravenously on Day 1 of Weeks 0,1,2,3 of the 10-week Induction cycle, and on Day 1 of Weeks 0,1,2,3 during the six 10-week maintenance cycles.
1652292|NCT01837862|Drug|Temozolomide|Low-grade glioma patients only. Temozolomide will be dosed at 200 mg/m2/day. Temozolomide will be given orally for 5 days during Week 6 of the 10-week induction cycle and for 5 days during Week 6 of the six 10-week maintenance cycles.
1652293|NCT01837862|Drug|Bevacizumab|High-grade glioma/pontine glioma patients only. Bevacizumab will be dosed at 10mg/kg/dose. Bevacizumab will be administered intravenously on Days 1 and 15 of each maintenance cycle.
1652294|NCT01837862|Drug|Irinotecan|High-grade glioma/pontine glioma patients only. Irinotecan will be administered at doses 125 mg/m2, 150 mg/m2, 250 mg/m2, or 300 mg/m2, depending on patient tolerance and concomitant enzyme-inducing anti-epileptic medication use. Irinotecan will be administered intravenously on Days 1 and 15 of each maintenance cycle.
1652295|NCT01837836|Behavioral|Health education|Health education will include 1. Importance and demonstration of hygienic practices for safe drinking water 2. Promotion of water purification 3. Capacity building of community for safe water availability.
1652297|NCT01837810|Drug|Ibuprofen|800mg every 8 hours as needed for pain
1652298|NCT01837797|Drug|Placebo|Once daily, tablets, orally
1652653|NCT01835093|Drug|Tipepidine Hibenzate|
1652301|NCT01837784|Other|Optimization of blood pressure according to guidelines|There is no specific recommendation for the intervention. The goal of the intervention is an optimization of blood pressure control. The intervention is at the discretion of the physician, but should adhere to guidelines. The intervention may therefore embrace measures such as drug prescriptions or lifestyle interventions.
1652302|NCT01837771|Device|Diaphragmatic stimulation|
1652303|NCT01837745|Drug|rhTSH stimulation|Intramuscular injections of rhTSH (0.9 mg) on two consecutive days on LT4 treatment
1652304|NCT01837745|Drug|I131|An activity of 1.1 GBq of I131 is given orally 24 hours after the second injection of rhTSH.
1652305|NCT01837745|Other|Follow up|"10 (+/- 2 months) after randomization: a neck ultrasound and a serum Tg measurement after rhTSH or LT4 stimulation
2 years (+/- 2 months) after randomization: a serum Tg measurement under LT4 treatment (Tg/LT4)
3 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4
4 years (+/- 2 months) after randomization: a serum Tg/LT4
5 years (+/- 2 months) after randomization: a neck ultrasound and a serum Tg/LT4"
1652306|NCT01837732|Other|Relational Touch|"Relational touch 15 mn  relational touch, hand touch (neck, face and head)"
1652307|NCT01837732|Other|Relational:|Relational: 10 mn verbal patient's centered exchanges
1652308|NCT01837719|Drug|Atazanavir|300-mg capsule
1652309|NCT01837719|Drug|Cobicistat|150-mg tablet
1652310|NCT01837719|Drug|Atazanavir/Cobicistat FDC|Atazanavir 300-mg/cobicistat 150-mg FDC tablet
1652311|NCT01837693|Procedure|Experimental: immediate colposcopy|A immediate colposcopy in this arm may detect potentially spontaneous regressive cervical lesions, so may determine an over diagnosis and over treatment, which the study want to estimate
1652312|NCT01837680|Drug|Insulin|
1652313|NCT01837667|Drug|LB-100 for Injection|Part 1 and Part 2: LB-100 for Injection infusion on Days 1,2,3 of each 21 day cycle.
1652314|NCT01837667|Drug|Docetaxel|Part 2: Docetaxel infusion on Day 2 of each 21 day cycle.
1652316|NCT01837641|Biological|LY3002813-IV|Administered IV
1652317|NCT01837641|Biological|LY3002183-SC|Administered SC
1652318|NCT01837641|Drug|Placebo-IV|Administered IV
1652319|NCT01837628|Drug|Lidocaine Gel|
1652320|NCT01837628|Drug|Paraffin Oil|
1652321|NCT01837615|Device|Photopill treatment|
1652322|NCT01837602|Biological|cMet RNA CAR T cells|
1652323|NCT01837589|Other|QCT|
1652324|NCT01837589|Other|DXA|
1652325|NCT01837576|Drug|Calcipotriol plus BDP gel in different doses|Topical , Once daily, 3 weeks
1652326|NCT01837550|Behavioral|Intervention group|The intervention group followed a five-week program that consisted of reading material, home training assignments, online and telephone interaction with an audiologist, and participation in a discussion forum.
1652327|NCT01837550|Behavioral|Control group|The control group only had access to reading material.
1652328|NCT01837524|Behavioral|KP Personal Shopper Visits|Testing co-shopping visits conducted in the grocery store (1:1 visits with dietitian while grocery shopping) versus in-office visits which are the current standard of care.
1652329|NCT01837524|Behavioral|In-Office Dietitian Visits|Participants will have 3, 1 hour in-office sessions with the dietitian during which targeted curriculum on nutritional knowledge, weight management, healthier eating, menu and label reading, will be delivered. These visits will take place monthly over a three month period.
1652330|NCT01837511|Other|Data acquisition and analysis|Tumor tissue samples submitted with a Patient and Tumor-Sample Characteristics. Form containing previously collected specific clinical data of patients with pathologically proven stage I, II and III NSCLC.
1652331|NCT01837498|Drug|Neostigmine|At the conclusion of the surgical procedure, neuromuscular block will be reversed with neostigmine
1652332|NCT01837498|Drug|Sugammadex|At the conclusion of the surgical procedure, neuromuscular block will be reversed with sugammadex
1652333|NCT01837485|Drug|Lactol|The Symbiotic Lactol® (Bioplus Life Sciences Pvt.) was applied 3 times a day for 3 months. Lactol is composed of the followings; Lactobacillus Sporogenes (15 × 107 Spores), Fructo-Oligosaccharides, Microcrystalline Cellulose, Sodium starch Glycolate, Povidone, Hypermellose Stearate, Sillicon Dioxide, and Propylene Glycol.
1652334|NCT01837485|Drug|Placebo|Placebo pill was applied 3 times a day for 3 months
1652335|NCT01837472|Drug|Probiotic|Patients in the probiotic group received the probiotic compound Balance® (Protexin Co., Somerset, UK) or similar placebo, twice daily after meal for 14 consecutive days. Balance® capsules contains seven bacteria species including Lactobacillus strains (L. casei, L. rhamnosus, L. acidophilus, and L. bulgaricus), Bifidobacterium strains (B. breve and B. longum), and Streptococcus thermophiles. Total viable count (TVC) is 1 x 108 CFU/per capsule. Other Ingredients are Fructo-oligosaccharide as prebiotic, magnesium stearate, and hydroxypropyl methyl cellulose.
1652336|NCT01837472|Drug|Placebo|Patients in the placebo group received the placebo capsule twice daily after meal for 14 consecutive days.
1652337|NCT01837446|Drug|2% morphine solution|
1652338|NCT01837446|Drug|Magnesium aluminum hydroxide|
1652339|NCT01837446|Drug|2% viscous lidocaine|
1652340|NCT01837446|Drug|Diphenhydramine|
1652341|NCT01837433|Drug|Prednisone 1 week|Prednisone 1 week 30mg/day and Celecoxib 400mg in first day, and then 200mg bid in the remaining next week, total 2 weeks.
1652342|NCT01837433|Drug|Prednisone 6 weeks|Guidelines recommend
1652343|NCT01837420|Drug|VB-201 80mg|
1652344|NCT01837420|Drug|VB-201 160mg|
1652345|NCT01837420|Drug|Placebo|
1652346|NCT01837407|Procedure|Composite Flap|nerve transfer with the dorsal branch of the digital nerve
1652347|NCT01837394|Procedure|Block of the SN and ONP|7.5 ml of Ropivacaine 7.5 mg/ml injected at each site
1652348|NCT01837394|Procedure|Placebo block|7.5 ml of isotonic saline solution 154 mmol/l injected at each site
1652349|NCT01837394|Drug|Paracetamol|
1652350|NCT01837394|Drug|Morphine|5 mg as needed
1652351|NCT01837394|Drug|Ondansetron|4 mg i.v. as needed in the PACU
1652352|NCT01837394|Drug|Metoclopramide|10 mg tablet as needed in the postoperative period after discharge from the PACU
1652399|NCT01837017|Behavioral|Home-based Exercise|This is a control group with no intervention
1652652|NCT01835106|Procedure|Fascia iliaca compartment catheter is used postoperatively|
1652353|NCT01837381|Procedure|TEA|Arterial feeders to tumors were identified and catheterized with a microcatheter to a branch supplying a Couinaud segment or subsegmental level for delivery of the therapeutic agent, which was Lipiodol-ethanol mixture at 2:1 ratio by volume for TEA (Lipiodol Ultrafluide, Guerbet, France; Dehydrated alcohol [absolute alcohol], Martindale Pharmaceuticals, United Kingdom). The agents were delivered under fluoroscopic control to completely fill up the vasculature of all tumors. The maximum total volume of Lipiodol-ethanol mixture or cisplatin emulsion to be delivered in one treatment session was 60 mL.
1652354|NCT01837368|Other|observational research|It is a observational research, no intervention are performed
1652355|NCT01837355|Dietary Supplement|Lactobacillus rhamnosus|
1652356|NCT01837355|Dietary Supplement|Placebo|
1652357|NCT01837342|Procedure|Surgical reserction|
1652358|NCT01837342|Other|Radiological percutaneous drainage and washing drainage|
1652360|NCT01837316|Drug|FF/VI 100/25 mcg|First strip: Fluticasone furoate inhalation powder blended with lactose, 100 mcg per blister
1652361|NCT01837316|Drug|Placebo|First strip: Inhalation powder of lactose
1652362|NCT01837303|Procedure|Pap smear|"A pap smear/cervical cytology is performed using a spatula and brush to obtain cells from the ectocervical and endocervical region of the cervix. The specimen will be collected twice to put in the standard clinical pap medium and another to put in the study pap medium.
These slides will be processed so that they may be reviewed by a single board certified pathologist.
There are no other interventions or follow up. All participants will undergo the above described procedures. There is no placebo."
1652363|NCT01837290|Drug|dexmedetomidine infusion for premedication|Group Dexmedetomidine (Group D): Midazolam 0.02 mg/kg + 0.5 μg/kg/10 min dexmedetomidine infusion for premedication; Spinal block (Hyperbaric bupivacaine 0.5% 12.5 mg) (n=30)
1652364|NCT01837290|Drug|Midazolam|intravenous Midazolam 0.02 mg/kg for premedication
1652365|NCT01837290|Drug|saline infusion|Saline infusion to facilitate blinding
1652366|NCT01837290|Drug|Spinal block with hyperbaric bupivacaine 0.5% 12.5 mg|Hyperbaric bupivacaine injection for spinal block
1652367|NCT01837277|Drug|Use of Raltegravir-based regimens|Use of Raltegravir-based regimens: patients will receive a Raltegravir-based ART regimen (RAL 400 mg BID + TDF 300 mg QD + 3TC 150 mg BID)
1652368|NCT01837277|Drug|Efavirenz-based regimens|Efavirenz-based regimens: patients will receive an EFV-based regimen (EFV 600 mg QD + TDGF 300 mg QD + 3TC 300 mg QD)
1652369|NCT01837264|Device|Magellan®|
1652370|NCT01837251|Drug|Carboplatin|
1652371|NCT01837251|Drug|PLD|
1652372|NCT01837251|Biological|Bevacizumab|
1652373|NCT01837238|Dietary Supplement|HMB|Following this initial round of testing,participant will be assigned to daily HMB supplementation for 6 months. You will be asked to consume a 1000mg HMB capsule 3 times per day, 7 days per week, for 6 months.
1652374|NCT01837238|Dietary Supplement|placebo|The placebo group will consume non-nutritive placebo pills daily for 6 months.
1652375|NCT01837199|Drug|Metronidazole plus Amoxicillin|All subjects will receive scaling and root planing combined with systemic metronidazole (400 mg) and amoxicillin (500 mg). Both antibiotics were administered T.I.D. for 14 days.
1652376|NCT01837160|Procedure|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
1652377|NCT01837160|Radiation|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
1652378|NCT01837160|Procedure|Echocardiogram|Echocardiography.
1652379|NCT01837160|Radiation|CT-coronary angiogram scan|CT-coronary angiogram following CT-PET scan. Standard protocol.
1652380|NCT01837160|Procedure|Aortic Valve Replacement|For AVR (already scheduled prior to enrollment)
1652381|NCT01837147|Behavioral|Technology-Based Physical Activity Promotion|Participants assigned to this group will use a web-integrated physical activity monitor, and accompanying website, to improve their physical activity levels.
1652382|NCT01837147|Behavioral|Pedometer Intervention|Participants assigned to this group will receive a pedometer and be trained in its use.
1652383|NCT01837134|Device|telemedical (TM) group|telemedical devices (weighing machine and step counter)
1652384|NCT01837134|Behavioral|telemedical coaching (TMC) group|care calls once per week for 12 weeks
1652385|NCT01837121|Other|the SMS reminder message|the SMS reminder message will sent to the SMS group patients 1 week and 3 day before there appointment,to remind them the exact time and address of the revisit appointment.
1652386|NCT01837108|Drug|Eplerenone|2 tabs of eplerenone 25 mg will be over-encapsulated and a fully mimicking placebo will be provided by the department of clinical pharmacy of the Radboud University Medical Centre Nijmegen
1652387|NCT01837108|Drug|Placebo|
1652388|NCT01837095|Drug|POL6326|POL6326 will be given by i.v. infusion over 2 hours. Treatment will occur on days prior to, on the day of and on days after treatment with eribulin
1652389|NCT01837082|Drug|ferric carboxymaltose|
1652390|NCT01837082|Drug|Placebo|
1652391|NCT01837069|Drug|Metoprolol|25mg PO BID if the HR is elevated at preadmission testing
1652392|NCT01837069|Drug|Lisinopril|2.5mg PO QD if the HR is elevated at preadmission testing
1652393|NCT01837069|Drug|Atorvastatin|80mg PO QD at preadmission testing
1652394|NCT01837069|Behavioral|Lifestyle counseling|Diet, exercise, medication adherance and smoking counseling
1652395|NCT01837043|Drug|Belatacept|
1652396|NCT01837043|Drug|Calcineurin Inhibitor|
1652397|NCT01837030|Drug|Ferrous sulfate|Ferrous sulfate 325mg by mouth twice daily for the duration of the 12 month follow up period
1652398|NCT01837030|Procedure|Capsule Endoscopy|GIVEN capsule
1717884|NCT00002350|Biological|APL 400-003|
1652400|NCT01837004|Behavioral|CORTEX|2-hour sessions for a period of four weeks prior to the initial exercise program start. One hour will be devoted to computerized training (stationary dual-task & cognitive control training, self-priming, certainty training) whereas the other hour will be devoted to exergaming involving non-stationary, dual-task training.
1652401|NCT01836991|Procedure|surgery|
1652402|NCT01836978|Other|Prehabilitation|Patients in this group will follow the multimodal protocol consisting of nutritional counseling with Immunocal® whey protein supplementation, an individualized physical exercise program and stress reduction strategies.
1652403|NCT01836965|Behavioral|Social Skills Intervention|Twelve week manual based social skills curriculum targeting social fluency and responsiveness.
1652404|NCT01836939|Drug|TSO 2500|TSO 2500: 2500 embryonated, viable TSO/15 mL/day every 2 weeks X 10 weeks
1652405|NCT01836939|Drug|TSO 7500|12 weeks of treatment with TSO 2500 ova or TSO 7500 ova given every 2 weeks (a total of 6 doses).
1652406|NCT01836926|Procedure|Open intersphincteric resection|"laparotomy arm: surgical Instruments for open approach operation: Abdominal anterior resection combined with peranal intersphincteric resection of the rectum
Abdominal step a high ligation of the inferior mesenteric artery is performed together with a full mobilization of the left colon. A circular incision of the anal canal is performed 1 cm below the tumour. Both the mucosa and the muscular layer are incised to transect the internal anal sphincter. A coloanal anastomosis, transverse coloplasty or colonic J-pouch and a diverting loop ileostomy are associated with the hand-sewn coloanal anastomosis.
laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description
intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach"
1652407|NCT01836926|Device|laparoscopic intersphincteric resection|laparoscopic approach group: instruments used: laparoscopic instruments mentioned at the arm description instruments: laparoscopic instruments mentioned in the laparoscopic rectal resection arm intervention: laparoscopic mobilization of the rectum and colon combined with the peranal intersphincteric resection as in the laparotomy approach
1652408|NCT01836900|Device|Endoscopic hemostasis|Hemostasis with Standard Therapy (standard clip or thermal therapy + injection of adrenaline solution) or by application of the Over The Scope Clip and injection of adrenaline solution
1652409|NCT01836887|Dietary Supplement|Very low polyphenol fruit based drink (control)|
1652410|NCT01836887|Dietary Supplement|Polyphenol-enriched fruit-based drink - low|
1652411|NCT01836887|Dietary Supplement|Polyphenol-enriched fruit-based drink - high|
1652412|NCT01836874|Drug|No intervention|This is an observational study. Participants receiving topiramate 25 mg once-a-day for 1 week and later on, receiving increase dose up to 200 mg, twice-a-day, orally will be observed for 3 months.
1652413|NCT01836861|Drug|IPI-145|Intravenous infusion: approximately 2.8 μg IPI-145 containing 14.8 kBq of radioactivity; Oral suspension: 25 mg IPI-145 containing approximately 3.15 MBq of radioactivity; Oral capsule: 25 mg IPI-145
1652414|NCT01836848|Procedure|measuring cerebral perfusion by NIRS with ICG|application of a bolus of 5mg indocyanine green (ICG) in 3ml saline 0,9% i.v. in 1 second and measuring the ICG turnover with the near-infrared-spectroscopy (NIRS)
1652415|NCT01836835|Other|Pregnancy Unique Questionnaire of Emesis (PUQE)|For hyperemesis gravidarum patients the Pregnancy Unique Questionnaire of Emesis (PUQE) (3 questions regarding the amount of nausea and vomiting during 24 hours) will be answered both at hospital admittance and discharge. For control patients the questionnaire will be answered at inclusion.
1652416|NCT01836835|Other|24 hours self-reported nutritional intake form|A nutritional intake form where relevant food and liquid items can be checked prospectively after consummation during 24 hours. This form will be filled in starting the morning following inclusion.
1652417|NCT01836822|Procedure|EBUS guided transbronchial forceps biopsy (EBUS-TBFB)|
1652418|NCT01836822|Procedure|EBUS guided transbronchial needle aspiration (EBUS-TBNA)|
1652419|NCT01836822|Procedure|large bore (19G) histologic needle biopsy of the mediastinal lymph nodes|
1652420|NCT01836822|Procedure|Bronchoalveolar lavage (BAL)|
1652421|NCT01836822|Procedure|Endobronchial forceps biopsy|
1652422|NCT01836809|Drug|nesiritide|nesiritide at 0.005 mcg/kg/min without a bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
1652423|NCT01836809|Drug|placebo|placebo bolus starting 6 hours after the subject has come off of cardiopulmonary bypass and will continue for 48 hours.
1652424|NCT01836796|Dietary Supplement|Lactobacillus Reuteri|100 million Lactobacillus Reuteri once daily or 10 billion Lactobacillus Reuteri once daily for 12 weeks.
1652425|NCT01836796|Dietary Supplement|Lactobacillus Reuteri DSM17938|Powder corresponding to 100 million or 10 billion Lactobacillus Reuteri is added to water once daily for 12 weeks.
2012958|NCT01289275|Behavioral|Telephone Counseling|Telephone counseling is conducted in the appropriate language (Spanish and English) by veteran counselors at the California Smokers' Helpline. The counseling protocol is similar to that used by the Helpline in previous efficacy studies. Counseling is proactive so after the smoker calls in subsequent calls are made by the counselor, a process that reduces attrition. The counseling group will receive proactive sessions initiated by quitline staff within 2 days of discharge, and a total of 6 individualized telephone counseling session that extend to two months post discharge. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) that are scheduled according to the probability of relapse. Counselors will use a structured protocol so that there will be a record for each counseling call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.
1652428|NCT01836757|Drug|MethylSulfonylMethane (MSM)|Intervention is MSM 3 gr twice a day for 26 weeks (6 gr/day total)
1652429|NCT01836757|Drug|Placebo|
1652430|NCT01836744|Device|Survival rate dental implant (OsseoSpeed™)|
1652431|NCT01836731|Behavioral|Classic Intervention|"The standard classic approach will implement a total of 20 community health club sessions delivered through weekly education programs in the target communities as per the training manual. Community health workers (CHW) will receive careful training in the delivery of the CBEHPP instruction. High quality instructional materials (in color) will be used. Club members will each receive a membership card to be used to track attendance and compliance. Finally model home competitions and a graduation ceremony will be held. Monitoring of the clubs will be conducted by community health workers using mobile phones."
1652432|NCT01836731|Behavioral|Minimum Intervention|"The lite trial arm will only implement 8 sessions covering all the WASH topics. It will be facilitated by CHWs receiving minimal training and using black/white photocopies of instructional materials. Members will not be issued with membership cards and will not have a graduation ceremony or home garden competitions. Minimal monitoring of this arm will be carried out by environmental health officers."
1652433|NCT01836705|Drug|SAR302503 (TG101348)|"Pharmaceutical form:capsule
Route of administration: oral"
1652434|NCT01836705|Drug|Placebo SAR302503|"Pharmaceutical form:capsule
Route of administration: oral"
1652435|NCT01836705|Drug|Panolosetron|"Pharmaceutical form:solution
Route of administration: intravenous"
1652436|NCT01836692|Radiation|Intensity Modulated Radiotherapy treatment|Intensity Modulated Radiotherapy treatment
1652437|NCT01836679|Drug|Chidamide|Given orally
1652438|NCT01836679|Drug|Paclitaxel|Given IV
1652439|NCT01836679|Drug|Carboplatin|Given IV
1652440|NCT01836679|Drug|Placebo|Given orally
1652441|NCT01836653|Drug|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1652442|NCT01836653|Drug|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1652443|NCT01836653|Drug|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1652444|NCT01836653|Drug|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1652445|NCT01836653|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1652446|NCT01836653|Drug|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1652447|NCT01836627|Other|Hyperinsufflation therapy|15 minutes twice a day of hyperinsufflation with Cough Assist® device
1652448|NCT01836614|Drug|Lidocaine|The treatment group will receive a 1.5mg/kg intravenous lidocaine bolus over 10 minutes after induction by means of an infusion pump. This bolus will be followed by an intravenous lidocaine infusion of 1 mg/kg/hr. The infusion will be stopped after extubation prior to leaving the operative room or after 5 hours from the start of the infusion, which ever comes first.
1652449|NCT01836601|Behavioral|Family-centered nighttime communication bundle|
1652450|NCT01836588|Procedure|conventional cervix biopsy|"Object of this study is the evaluation of two different methods of gaining cervical tissue in order to determine whether, and if so in what extent, a CIN is existent. The first method is a cervical biopsy, the second method is a gentle tissue saving curettage of the cervix uteri. Also is to be investigated that the latter method shows a reduction of pain and morbidity after the procedure.
For this reason the pathological outcome of the two methods will be compared to the result of a conisation, which will be received by the patient to cure their cervical lesions."
1652451|NCT01836575|Drug|Pemetrexed|Pemetrexed, 500 mg/m2 + Pretreatment [dexamethasone + vitamin B12 + folic acid, as per pemetrexed label] + Antiemetic therapy at investigator's discretion.
1652452|NCT01836575|Drug|Carboplatin|Carboplatin [Target AUC 5 IV infusion,based on Calvert formula,GFR estimated using estimated creatinine clearance per Cockcroft and Gault formula, obtained prior to each cycle].
1652453|NCT01836562|Biological|STEM CELL THERAPY|Intra thecal injection of autologous MNC ,Intra thecal inj.of 100 millions MNC in 3 doses at 10 days interval.
1652455|NCT01836536|Drug|Bevacizumab standard of care|Standard treatment associated with circulating leucocytes (blood samplings)
1652456|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
1652457|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
1652458|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
1652459|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
1652460|NCT01836523|Drug|liraglutide|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
1652461|NCT01836523|Drug|placebo|Subjects randomised to 0.6 mg liraglutide treatment or liraglutide placebo as an add-on to their pre-trial insulin treatment will remain on this dose throughout the study (52 weeks). Administered subcutaneously (s.c., under the skin) once daily.
1652462|NCT01836497|Device|SD01 ICD lead|
1652463|NCT01836484|Diagnostic Test|Diffusion-weighted MRI|
1652464|NCT01836484|Diagnostic Test|Fluorodeoxyglucose-18-PET/CT|
1652465|NCT01836484|Diagnostic Test|Fluoro-ethyl-coline-PET/CT|
1652466|NCT01836471|Drug|QAW039|QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)
1652467|NCT01836471|Drug|Placebo QAW039|Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
1652535|NCT01835951|Other|Grouped Debriefing|Debriefing consists in an analysis by the investigator of the management of the anaesthesia crisis simulated in the presence of all the subjects included in the Groupe Debriefing group.
1652468|NCT01836471|Drug|Fluticasone 250 mcg|Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).
1652469|NCT01836471|Drug|Fluticasone 100 mcg|Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
1652470|NCT01836458|Drug|KAE609|Patients will receive KAE609 single dose at a different dose level in each cohort.
1652471|NCT01836445|Behavioral|Keep It Up!|
1652472|NCT01836445|Behavioral|HIV Knowledge Control|
1652473|NCT01836432|Drug|FOLFIRINOX|"FOLFIRINOX consisting of Oxaliplatin 85 mg/m^2 IV over 2 hours; Irinotecan 180 mg/m^2 IV over 90 minutes; Leucovorin 400 mg/m^2 IV over 2 hours; Fluorouracil 2.4 g/m^2 IV over 46 hours - given on days 22, 36, 50, and 64 for Arm 1A. FOLFIRINOX given on days 1, 15, 29, 43 and 57 for Arm 2A.
For arms 1B and 2B patients with disease progression at day 71-80 evaluation will receive FOLFIRINOX as noted above on a biweekly basis.
For arms 1A and 2A patients with stable disease after surgical resection will continue to receive FOLFIRINOX as noted above on a biweekly basis.
For arms 1B and 2B patients deemed ineligible for surgical resection with noted disease progression will be given FOLFIRINOX as noted above on a biweekly basis."
1652474|NCT01836432|Biological|Algenpantucel-L Immunotherapy|"HAPa1 and HAPa2 immunotherapy components Arm 1 (1A and 1B) only: Algenpantucel-L Immunotherapy (HAPa) consisting of 300 Million HAPa cells given by intradermal injection on days 1, 8, 15, 29, 43 and 57.
Patients receiving chemoradiation with HAPa will receive HAPa on days 1 and 15 of the 5.5 week 5-FU chemoradiation cycle.
Patients receiving continuation or salvage FOLFIRINOX with HAPa will receive HAPa biweekly, 7 days offset from the administration of FOLFIRNOX for up to 18 doses total.
Patients receiving adjuvant gemcitabine therapy with HAPa will receive HAPa on days 1 and 15 of each cycle for 5 cycles for up to 18 doses total.
Patients receiving continuation or salvage gemcitabine/nab-paclitaxel with HAPa will receive HAPa on days 8 and 22 (of each cycle) for up to 18 doses total."
1652475|NCT01836432|Radiation|5-FU Chemoradiation|All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive 5-FU Chemoradiation consisting of 5-FU continuous IV infusion of 200-250 mg/m^2/day given 5-7 days each week over 5.5 weeks concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
1652476|NCT01836432|Drug|Gemcitabine|"Gemcitabine 1000 mg/m^2 given intravenously over 30 minutes for 3 weeks (days 1, 8 and 15) with 1 week rest.
All Arms: Given as adjuvant treatment (days 1, 8 and 15) with 1 week rest for 6 cycles for all arms after surgical resection.
Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.
Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.
Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.
Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles."
1652477|NCT01836432|Drug|Capecitabine|All Arms; subjects that do not have distant disease at evaluation (day 71-80) are eligible to receive capecitabine in place of 5-FU during radiation. Capecitabine consisting of 825 mg/m^2 PO BID M-F concurrently with external beam radiation given at 1.8 Gy per fraction for 28 fractions for a total dose of 50.4 Gy.
1652478|NCT01836432|Drug|Nab-Paclitaxel|"Nab-Paclitaxel 125 mg/m^2 given intravenously over 30-40 minutes (followed by Gemcitabine)
Arm 1B Gemcitabine/Nab-Paclitaxel on days 22, 29, 36, 50, 57 and 64. Arm 2B Gemcitabine/Nab-Paclitaxel on days 1, 8, 15, 29, 36, 43, 57, 64, and 71.
Arms 1A and 2A: Patients with distant disease at first disease evaluation (days 71-80) - Gemcitabine/Nab-Paclitaxel given as salvage therapy (days 1, 8 and 15) with 1 week rest for 6 cycles.
Arms 1B and 2B: Patients with stable disease after surgical resection will continue to receive Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles.
Arms 1A and 2A: Patients deemed ineligible for surgical resection with noted disease progression will be given salvage Gemcitabine/Nab-Paclitaxel (days 1, 8 and 15) with 1 week rest for 6 cycles."
1652479|NCT01836419|Procedure|classic LMA insertion|
1652480|NCT01836406|Drug|Ketorolac tromethamine and remote ischemic preconditioning|Ketorolac tromethamine/ single / 1mg/kg/ intravenous administration 30 min before renal artery clamping, remote ischemic preconditioning / 200 mmHg / 5 min inflation and 10 min deflation / 3 cycles / after anesthetic induction
1652481|NCT01836393|Drug|Plavina cream|The essential plai cream has anti-inflammatory and antimicrobial effects (Wasuwat1989, Giwanon 2000, Pithayanukul 2007, and Tripathi 2008). Active chemicals of plai cream are composed of sabinene, alpha and gamma tepinenes, terpinen 4-ol and (E)-1-(3,4-dimethoxyphenyl butadiene (DMPBD). The DMPBD has a property of anti-inflammatory activity(Ozaki 1991, Jeenapongsa 2003). Plavina® 40 mg in 100 gm (contains DMPBD of …%). This product was supplied in lacquered aluminum collapsible tube containing 100 gram cream packing.
1652482|NCT01836380|Behavioral|Exercise Training|
1652483|NCT01836367|Drug|Ingenol Mebutate 0.015%|Picato
1652484|NCT01836354|Behavioral|DESERVE education|Those patients assigned to education will receive stroke comprehensive intervention which focuses on three main areas, Risk perception, Medication Adherence, and Patient-Physician Communication. We will test whether phone calls and visits with a health worker after discharge, videos and a workbook are linked to better control of blood pressure and other risk factors
1652485|NCT01836341|Drug|Afatinib|
1652486|NCT01836341|Drug|Cisplatin|
1652487|NCT01836341|Drug|Carboplatin|
1652488|NCT01836341|Drug|Pemetrexed|
1652489|NCT01836341|Radiation|Radiation therapy|
1652490|NCT01836328|Drug|Parenteral /oral methadone ratio 1:2|"See arm/group descriptions"
1652491|NCT01836328|Drug|Parenteral /oral methadone ratio 1:1.2|"See arm/group descriptions"
1652492|NCT01836315|Other|Observational Study|
1652493|NCT01836302|Other|Observation|
1652494|NCT01836289|Drug|High-dose Cyclophosphamide|
1652495|NCT01836276|Drug|Varenicline|1 mg of varenicline twice daily after titration to full strength in the first week following standard dosing guidelines
1652640|NCT01835184|Other|laboratory biomarker analysis|Correlative studies
1652497|NCT01836224|Drug|Terlipressin|Terlipressin (1.3mcg/min i.e 2mg over 24 hr to max of terlipressin 5.2mcg/min i.e. up to 8mg over 24hr) .The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure) >65 .Terlipressin 2mg in 48ml,1ml=42mcg=0.67mg/min, max dose 8mg/day- 8ml/hr of infusion.
1652498|NCT01836224|Drug|Noradrenaline|Noradrenaline 2amp (4000mcg in 50ml) at 6ml/hr = 7.5mcg/min and dose maximum 60mcg/min 24ml/hr double strength. The dose to be increased every 15min from start dose by 1ml and to decrease by 0.5ml every 15min keeping MAP (Mean Arterial Pressure)>65
1652499|NCT01836211|Other|Fast strategy|High sensitivity troponin T followed by computed coronary tomography angiography
1652500|NCT01836211|Other|Standard of care strategy|Standard of care strategy: serial electrocardiograms and cardiac biomarkers followed by stress/rest cardiac imaging study
1652501|NCT01836198|Drug|LY2409021|Administered orally
1652502|NCT01836198|Drug|Gemfibrozil|Administered orally
1652503|NCT01836198|Drug|Ketoconazole|Administered orally
1652504|NCT01836198|Drug|Clarithromycin|Administered orally
1652505|NCT01836185|Drug|Evacetrapib|
1652506|NCT01836172|Drug|YJP-14|An 50% ethanolic extract of Lindera obtusiloba stems
1652507|NCT01836159|Other|iPad Intervention|"Patients are to self-administer 20 minutes of gaming sessions, in any configuration that is preferred. Patients will be instructed to play the iPad game with the more affected arm/hand. Start and stop times of the iPad intervention will be downloaded from the iPad, which will allow calculation of the total dose received. Patients may receive outpatient rehabilitation as required as part of usual care.
The 'Stroke Rehab' software for the iPad was specifically designed for patients with either fine motor weakness and/or neglect. It contains 6 stages:
Popping a stationary balloon
Popping a moving balloon
Popping a pair of stationary balloons
Popping a pair of moving balloons
Stretching a balloon to pop
Balloon/Text distraction test"
1652508|NCT01836159|Other|Standard/ Usual Care|Patients may receive outpatient rehabilitation as required as part of usual care. Patients will be instructed not to play with an iPad during the 2 week intervention period (in case they have one).
1652509|NCT01836146|Device|EnligHTN™ Renal Artery Ablation Catheter|
1652510|NCT01836133|Drug|Erlotinib 150 mg|
1652511|NCT01836120|Drug|Raltitrexed plus Docetaxel|"Raltitrexed plus Docetaxel (Raltitrexed 3mg/m2 d
1; Docetaxel 75mg/m2 d1, every 3 weeks, 4-6 cycles)"
1652512|NCT01836120|Drug|Docetaxel|Docetaxel (Docetaxel 75mg/m2 d1, every 3weeks,4-6 cycles)
1652513|NCT01836094|Drug|Methylene Blue (USP grade, 280mg oral)|
1652514|NCT01836094|Drug|Placebo|oral, one time
1652515|NCT01836081|Other|Volume expansion|
1652516|NCT01836068|Drug|Enfuvirtide|Enfuvirtide 90 mg subcutaneously twice daily will be administered to all patients on day 3 and 4 post-transplant and during any periods when oral medications are not expected to be tolerated for ≥ 24 hours, or during periods when ART is held due to interactions
1652517|NCT01836029|Drug|VTX-2337|TLR8 Agonist
1652518|NCT01836029|Drug|Carboplatin|
1652519|NCT01836029|Drug|Cisplatin|
1652520|NCT01836029|Drug|5-fluorouracil|
1652521|NCT01836029|Drug|Placebo|
1652522|NCT01836016|Drug|Salbutamol (Ventolin®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
1652523|NCT01836016|Drug|Formoterol (Oxis Turbuhaler®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
1652524|NCT01836016|Drug|Salmeterol / fluticasone (Seretide®)|According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
1652525|NCT01836016|Drug|Bufei granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
1652526|NCT01836016|Drug|Bufeijianpi granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
1652527|NCT01836016|Drug|Bufeiyishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
1652528|NCT01836016|Drug|Yiqizishen granule|According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
1652529|NCT01836016|Drug|conventional medicine + TCM|Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
1652530|NCT01836003|Other|Tokafatso programmatic intervention|"Tokafatso programmatic intervention:
SMS-based platform for delivery of CD4 test results
Participatory educational session for clinic staff
Loan program for HIV and CD4 testing supplies
Facilitation of tracing of HAART-eligible pregnant women"
1958035|NCT02023866|Drug|Cysteamine Bitartrate|Cysteamine Bitartrate Delayed-release Capsules
2012959|NCT01289275|Behavioral|Brief Hospital Counseling|All subjects receive bedside counseling either from Respiratory Therapists or nurses according to the hospital's particular practices.
1652533|NCT01835977|Device|Irreversible Electroporation (Nanoknife)|
1652534|NCT01835964|Procedure|Glucose Variability Observation|On the morning of ~Day 17 for a metabolic challenge involving a standardized liquid mixed meal intended to raise the blood glucose approximately 150 mg/dl, followed four hours later by the induction of hypoglycemia with intravenous insulin administration with goal glucose of 55 mg/dl. After carbohydrate rescue, the subject will receive a meal and will be monitored until glucose is stable above 80 mg/dl.
2012960|NCT01284504|Drug|Celecoxib|200 mg tablet oral
1652536|NCT01835951|Other|Individual Debriefing|Individual debriefing consists in a individual meeting between each subject of the study and the investigator to analyze the management of the anaesthesia crisis simulated.
1652537|NCT01835938|Drug|1- Erlotinib|"Erlotinib 50 mg tablet by mouth every day for 14 days,
Erlotinib 100 mg tablet by mouth every day for 14 days,
Erlotinib 150 mg tablet by mouth every day for 14 days,"
1652538|NCT01835938|Drug|placebo|"Placebo 50 mg tablet by mouth every day for 14 days,
Placebo 100 mg tablet by mouth every day for 14 days,
Placebo 150 mg tablet by mouth every day for 14 days,"
1652539|NCT01835925|Genetic|Tissue specimen|
1652540|NCT01835912|Other|Sodium Citrate Dihydrate|Dose sodium citrate dihydrate through 2 dosing protocols (Acute and Chronic)
1652541|NCT01835899|Drug|Placebo|Placebo to BI 1015550
1652542|NCT01835899|Drug|BI 1015550|medium dose 1 powder for oral solution
1652543|NCT01835899|Drug|BI 1015550|medium dose 2 powder for oral solution
1652544|NCT01835899|Drug|BI1015550|low dose 2 powder for oral solution
1652545|NCT01835899|Drug|BI 1015550|low dose 1 powder for oral solution
1652546|NCT01835886|Other|Patients will ascend and descend a flight of 10 steps|Patients referred to pulmonary rehabilitation with documented lung disease will ascend and descend a flight of 10 steps for a period of 30 seconds
1652547|NCT01835873|Other|Lactated Ringer's|
1652548|NCT01835873|Other|HES 130/0.42|Balanced colloid solution
1652549|NCT01835860|Procedure|Prostate artery embolization|
1652550|NCT01835847|Drug|Tipepidine Hibenzate|
1652551|NCT01835834|Procedure|zirconia bridge restoration|
1652552|NCT01835821|Device|prosthetic crowns|prosthetic crowns
1652553|NCT01835808|Device|Fractional flow reserve (St. Jude Medical pressure-wire)|CAD patients submitted to coronary angiography and in which coronary lesions are to be evaluated with pressure-wire (FFR functional evaluation)
1652554|NCT01835795|Device|Radial Extracorporeal Shock Wave|Radial Extracorporeal Shock Wave applicator use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 10 to 15 hertz frequency, 2 to 4 bar pressure
1652555|NCT01835795|Device|Placebo|Placebo applicator, use in 6 sessions with 1 week of interval, 1000 impulses per myofascial trigger point, 10 to 15 hertz frequency, 2 to 4 bar pressure
2012961|NCT01284504|Other|placebo|Placebo, tab
1652557|NCT01834820|Drug|Epinephrine and Dexamethasone|
1652558|NCT01834820|Drug|Hypertonic Saline|
1652559|NCT01834820|Drug|Normal Saline|
1652560|NCT01834794|Behavioral|MET/CBT/CM plus NRT|Behavioral Treatment for Cannabis plus Behavioral Treatment for Tobacco: both primarily delivered by computer. Additional NRT.
1652561|NCT01834781|Device|Pulsed electromagnetic fields|
1652562|NCT01834781|Device|w/o pulsed electromagnetic fields|
1652563|NCT01835756|Device|Erchonia MLS|The Erchonia® MLS contains 10 independent diodes, each emitting 17 milliwatts (mW), 635 nanometers (nm) of red laser light. The Erchonia MLS is applied to the lower back and hips area for 15 minutes per treatment administration, 6 times across 3 weeks, 2 times per week.
1652564|NCT01835756|Device|Placebo Laser|The Placebo Laser has the same appearance and administration application as the Erchonia MLS but does not emit any therapeutic light.
1652565|NCT01835743|Device|Erchonia HPS Laser|The Erchonia HPS Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
1652566|NCT01835743|Device|Placebo Laser|The Placebo Laser is administered to the subject's heel 6 times across 3 consecutive weeks, 2 times each week, for 10 minutes of treatment time per administration.
1652567|NCT01835730|Drug|PE0139 Injection|
1652568|NCT01835730|Drug|Placebo|
1652569|NCT01835704|Other|Radio-frequency dennervation of facet joint|
1652570|NCT01835704|Other|Diagnostic nerve-blocks performed under direct x-ray vision|
2012962|NCT01284283|Device|Scandinavian Total Ankle Replacement System (STAR Ankle)|For total ankle replacement
2012963|NCT01274338|Biological|Ipilimumab|Given IV
1652573|NCT01835678|Drug|Linagliptin|orally 5 mg/d for 4 weeks
1652574|NCT01835678|Drug|Placebo|orally once a day for 4 weeks
1652575|NCT01835665|Drug|Nimodipine|Nimodipine is an FDA-approved drug for subarachnoid hemorrhage indication
1652576|NCT01835652|Other|Active Exercise|
1652577|NCT01835652|Other|Passive Exercise|
1652578|NCT01835639|Dietary Supplement|Cholecalciferol, 2000 or 4000 IUs by mouth daily for 12 weeks|Supplements will be provided as oral capsules.
1652579|NCT01835626|Drug|Vismodegib|Vismodegib will be taken daily for 12 weeks. It should be taken at approximately the same time each day. Patients will be given a supply of vismodegib on Week 1, Day 1 to last until their next study visit. They will be asked to keep a record of each dose of vismodegib you take. After 12 weeks, they will be evaluated again to make sure they are still eligible to participate in the study. If they are eligible to continue, they will continue taking vismodeib daily as before for another 7 weeks while they receive radiation therapy.
1652580|NCT01835626|Radiation|Radiation therapy|Radiation therapy will be started after the patient has finished taking vismodegib for 12 weeks. They will receive radiation once a day, Monday through Friday, for 7 weeks. Each radiation treatment may take up to 30 minutes.
1652581|NCT01835613|Other|Biomarkers Measures|At the routine visits (0, 3, 6, 12 and 18 months), a clinical evaluation will be made and samples collected for assaying the biomarkers.
1652582|NCT01835600|Other|PEEP|PEEP means that when mechanical ventilation is suspended, the value of expiratory valve in the anesthesia machine is set at 10 cmH2O with 1 L/min 100% oxygen.
1652583|NCT01835587|Drug|Oral Azacitidine|Cohorts of 3 to 6 subjects will be treated at escalating or de-escalating sequential dose levels until a preliminary MTD is identified.
1652641|NCT01835184|Other|pharmacological study|Correlative studies
1652642|NCT01835158|Drug|Cabozantinib S-malate|Given PO
1652643|NCT01835158|Other|Laboratory Biomarker Analysis|Correlative studies
1652644|NCT01835158|Drug|Sunitinib Malate|Given PO
1652645|NCT01835145|Drug|Cabozantinib S-malate|Given PO
1652646|NCT01835145|Drug|Dacarbazine|Given IV
1652647|NCT01835145|Other|Laboratory Biomarker Analysis|Correlative studies
1652648|NCT01835145|Drug|Temozolomide|Given PO
1717885|NCT00002351|Drug|Indinavir sulfate|
1652584|NCT01835574|Behavioral|Conditional cash transfer and cognitive-behavioral aftercare|The intervention combines a 12-week conditional cash transfer (CCT) intervention with 4-weeks of cognitive-behavioral group aftercare (AC) among women who use ATS. CCT includes thrice weekly urine screening for 12 weeks; participants receive $ for ATS-negative screens. Those with 3 negative screens in a week participants receive a cash bonus, which increase per month to mitigate habituation to the CCT reward schedule. Women who complete >=50% of ATS negative screening visits may participate in a 4-week, cognitive-behavioral AC group delivered immediately after CCT, which includes: 1) experiential group exercises; 2) didactic recovery skills training; 3) meditation and relaxation training; and 4) a ''lucky draw'' which is a form of CCT that provides positive reinforcement for group attendance.
1652585|NCT01835561|Drug|Pomalidomide|Single oral dose of 4‐mg capsule
1652586|NCT01835561|Drug|Pomalidomide|4-mg capsule
1652587|NCT01835548|Drug|NT0102|One or two tablets once daily
1652588|NCT01835548|Drug|Placebo|One or two tablets once daily
1652589|NCT01835535|Device|TIVUS|
1652590|NCT01835509|Behavioral|Intervention, Camp plus reunions|
1652591|NCT01835496|Drug|single 1500 mg dose of Ferriprox|A single dose of 1500mg of Ferriprox (three 500mg tablets) administered under fasting conditions
1652592|NCT01835470|Drug|Abatacept|
1652593|NCT01835457|Drug|Lipopolysaccharide|LPS is used to elicit an inflammatory response in all subjects.
1652594|NCT01835457|Behavioral|Concentration/meditation|A self-taught concentration/meditation technique that Mr Wim Hof developed himself, characterized by cycles consisting of a few minutes of hyperventilation followed by breath holding for up to 1-2 minutes and deep concentration (mindset).
1652595|NCT01835444|Other|PA/MD model|Intervention wards are hospital wards at which ward care is provided by both Physician Assistants (PAs) and Medical Doctors (MDs)
1652596|NCT01835431|Drug|insulin degludec/insulin aspart|Administered subcutaneously (s.c., under the skin) once daily with a main meal. Dose individually adjusted.
1652597|NCT01835431|Drug|insulin aspart|Administered s.c. with the remaining meals. Dose individually adjusted.
1652598|NCT01835431|Drug|insulin detemir|Administered s.c. once or twice daily. Dose individually adjusted. Subjects will continue with their pre-trial dosing scheme (once (OD) or twice daily (BID)) and will be allowed to switch from OD to BID dosing.
1652599|NCT01835431|Drug|insulin aspart|Administered s.c. at meal-times. Dose individually adjusted.
2012964|NCT01274338|Other|Quality-of-Life Assessment|Ancillary studies
1652601|NCT01835405|Device|LiquiBand Flex|
1652602|NCT01835405|Device|Dermabond Advanced|
1652603|NCT01835405|Device|Sutures (Prolene)|
1652604|NCT01835392|Procedure|Remote Ischemic Preconditioning|Lower limb ischemia/reperfusion cycles
1652605|NCT01835392|Other|Control|Sham placement of blood pressure cuff without inflation
1652606|NCT01835379|Device|Oasis|Oasis Ultra will be applied once per week for up to 12 weeks.
1652607|NCT01835379|Other|Standard|
1652608|NCT01835353|Drug|Prasugrel 100mg loading dose|
1652609|NCT01835353|Drug|Prasugrel 60mg loading dose|Prasugrel 60mg loading dose
1652610|NCT01835340|Device|Drug: Propofol Anesthesia Patients will undergo propofol anesthesia.|
1652611|NCT01835314|Drug|Stiripentol|Stiripentol 5-50mg/kg/d divided twice or three times a day by mouth
1652612|NCT01835288|Drug|arsenic trioxide|Given IV
1652613|NCT01835288|Other|laboratory biomarker analysis|Correlative studies
1652614|NCT01835275|Behavioral|Enhanced Audio|
1652615|NCT01835275|Behavioral|Audio|
1652616|NCT01835262|Drug|Morphine|Morphine: 0.1 mg /kg given as IVP
1652617|NCT01835262|Drug|Ketamine|Ketamine:0.3 mg/given as IVP
1652618|NCT01835249|Other|Intensive BP Arm|Participants in the Intensive arm have a goal of SBP <120 mmHg.
1652619|NCT01835249|Other|Standard BP arm|Participants in the Standard BP arm have a goal of SBP <140 mmHg.
1652620|NCT01835236|Drug|Trastuzumab|"First administration (loading dose) 8 mg/kg i.v. infusion over 90 min.
- then every 3 weeks until progression 6 mg/kg i.v. infusion over 30 to 90 min."
1652621|NCT01835236|Drug|Pertuzumab|"First administration (loading dose) 840 mg i.v. infusion over 60 min.
- then every 3 weeks until progression 420 mg i.v. infusion over 30 to 60 min."
1652622|NCT01835236|Drug|Paclitaxel|Day 1, 8 and 15; every 4 weeks for ≥4 months 90 mg/m2 i.v. infusion
1652623|NCT01835236|Drug|Vinorelbine|"First administration: Day 1 and 8 25 mg/m2 i.v. infusion
then day 1 and 8, every 3 weeks for ≥4 months 30 mg/m2 i.v. infusion"
1652624|NCT01835236|Drug|T-DM1|Every 3 weeks until unacceptable toxicity or progressive disease is observed 3.6 mg/kg i.v. infusion First dose: over 90 min (± 10 min.) Subsequent doses: over 30 min. (± 10 min.)
1652625|NCT01835223|Other|Laboratory Biomarker Analysis|Correlative studies
1652626|NCT01835223|Other|Pharmacological Study|Correlative studies
1652627|NCT01835223|Drug|Tivozanib|Given PO
1652628|NCT01835197|Drug|PF-04965842|Subjects will receive single doses of 3, 10, 30, 100, 200, 400, or 800 mg of PF-04695842 (solution or suspension) in a dose escalation format.
1652629|NCT01835197|Drug|Placebo|Subjects will receive single doses of PF-04695842 matching placebo (solution or suspension) in a dose escalation format.
1652630|NCT01835197|Drug|PF-04965842|Subjects will receive doses of 30, 100 or 200 mg (solution or suspension) once daily for 10 days.
1652631|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo (solution or suspension) once daily for 10 days.
1652632|NCT01835197|Drug|PF-04965842|Subjects will receive doses of 100 or 200 mg (suspension or solution) twice daily for 10 days.
1652633|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo doses (suspension or solution) twice daily for 10 days.
1652634|NCT01835197|Drug|PF-04965842|Subjects will receive 200 mg dose (suspension or solution) twice daily for 10 days.
1652635|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) twice daily for 10 days.
1652636|NCT01835197|Drug|PF-04965842|Subjects will receive 400 mg dose (suspension or solution) once daily for 10 days.
1652637|NCT01835197|Drug|Placebo|Subjects will receive PF-04965842 matching placebo dose (suspension or solution) once daily for 10 days.
1652638|NCT01835184|Drug|cabozantinib-s-malate|Given PO
1652639|NCT01835184|Drug|vemurafenib|Given PO
1652654|NCT01835067|Drug|Ranibizumab|Single intravitreal injection of 500 micrograms ranibizumab in 0.05mls
1652655|NCT01835067|Drug|C3F8 Gas|Single intravitreal injection of 0.3 mls C3F8
1652656|NCT01835067|Drug|tPA|Single intravitreal injection of 50 micrograms tPA in 0.05 mls
1652657|NCT01835054|Other|Blood biomarkers|Observational Study using Imaging and Biomarkers
1652658|NCT01835054|Genetic|DNA collection|Observational Study using Imaging and Biomarkers
1652659|NCT01835054|Other|Echocardiography|Observational Study using Imaging and Biomarkers
1652660|NCT01835054|Other|Cardiopulmonary exercise testing|Observational Study using Imaging and Biomarkers
1652661|NCT01835054|Other|Magnetic resonance imaging (MRI)|Observational Study using Imaging and Biomarkers
1652662|NCT01835054|Other|Exercise stress doppler echocardiography|Observational Study using Imaging and Biomarkers
1652663|NCT01835054|Other|Holter ECG|Observational Study using Imaging and Biomarkers
1652664|NCT01835041|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
1652665|NCT01835041|Drug|oxaliplatin|Given IV
1652666|NCT01835041|Drug|leucovorin calcium|Given IV
1652667|NCT01835041|Drug|irinotecan hydrochloride|Given IV
1652668|NCT01835041|Drug|fluorouracil|Given IV
1652669|NCT01835041|Other|laboratory biomarker analysis|Correlative studies
1652670|NCT01835028|Other|Echocardiography|Observational Study using Imaging and Biomarkers
1652671|NCT01835028|Other|Computed tomography|Observational Study using Imaging and Biomarkers
1652672|NCT01835028|Other|Magnetic resonance imaging|Observational Study using Imaging and Biomarkers
1652673|NCT01835028|Other|Blood biomarkers|Observational Study using Imaging and Biomarkers
1652674|NCT01835028|Other|Stress echocardiography|Observational Study using Imaging and Biomarkers
1652675|NCT01835015|Drug|CLG561|Administered by intravitreal injection, Day 1
1652676|NCT01835002|Device|Electrostimulation|
1652677|NCT01834989|Drug|Insulin-like growth factor I|
1652678|NCT01834989|Drug|Placebo|
2012965|NCT01274338|Biological|Recombinant Interferon Alfa-2b|Given IV and SC
2012966|NCT01272830|Drug|Placebo|Two capsules taken twice daily with meals
1652681|NCT01834950|Other|Blood test|
1652682|NCT01834937|Device|ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery)|Focused Ultrasound Surgery - FUS delivered by ExAblate for the palliation of pain due to bone metastases.
1652683|NCT01834924|Other|HELPix|Low literacy, bilingual (English/Spanish) medication instruction sheets used as a framework for provider medication counseling, plus provider dose demonstration, parent teachback/showback, provider medication log review, provision of oral dosing syringe to parent
1652684|NCT01834911|Drug|Tetrabenazine withdrawal|Tetrabenazine will be withdrawn for at least 3 days in Huntington disease patients currently on the drug. Patients will be examined via Stroop test in the OFF state. Two doses of 12.5 mg tetrabenazine will be introduced, spaced 3 hours apart. Stroop test will be performed 6 hours after initial OFF Stroop test.
1652685|NCT01834898|Drug|Controlled-release oxycodone|Controlled-release oxycodone. First day postoperatively, 40 mg / day divided into 20 mg of 12 in 12 hours and in the second postoperative day, 20 mg / day divided into 10 mg of 12 in 12 hours
1652686|NCT01834885|Drug|QVA149|QVA149 via inhaler twice a day
1652687|NCT01834885|Drug|fluticasone/salmeterol|fluticasone/slameterol via inhaler twice a day
2012967|NCT01272830|Drug|Apatone®B|Two capsules taken twice daily with meals
2012968|NCT01272232|Drug|liraglutide|Liraglutide 3.0 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
1652690|NCT01834859|Behavioral|Multidisciplinary outpatient program|Diet (phase 1) and multidisciplinary lifestyle intervention (phase 2)
1652691|NCT01834859|Behavioral|Inpatient lifestyle program|Diet (phase 1) and lifestyle intervention (phase 2)
2012969|NCT01272232|Drug|liraglutide|Liraglutide 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
2012970|NCT01272232|Drug|placebo|Liraglutide placebo of either 3.0 mg or 1.8 mg for subcutaneous (under the skin) injection once daily for 56 weeks.
1652694|NCT01834833|Other|Follow-up|Evaluation by a cardiologist using echocardiography, completed by education of the patient if necessary
1652695|NCT01834768|Drug|Eplerenone|
1652696|NCT01834755|Other|Evaluation of psychological phenotype|
1652697|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
1652698|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 100g PEG3350 plus 9g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
1652699|NCT01834742|Drug|NER1006|Single evening dose of 750mL solution containing 75g PEG3350 plus 5.6g sodium sulphate. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate, 20.1g ascorbic acid.
1652700|NCT01834742|Drug|Moviprep|Reconstituted and administered in accordance with recommended split dose intake: one litre in the evening, one litre the following morning.
1652701|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350 and 56.6g sodium ascorbate.
1652702|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 33.9g sodium ascorbate and 21.4g magnesium ascorbate.
1652703|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 40g PEG3350, 6g sodium sulphate and 33.9g sodium ascorbate.
1652704|NCT01834742|Drug|NER1006|Single evening dose containing formulation selected from Part A of study. Single morning dose containing 29g PEG3350 and 4.8g sulphate and 23.3g ascorbic acid.
2012971|NCT01272219|Drug|liraglutide|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide 3.0 mg for 12 weeks (until week 68).
2012972|NCT01272219|Drug|placebo|Subject with no pre-diabetes at screening, receiving liraglutide 3.0 mg subcutaneous (under the skin) injection once daily for 56 weeks. Subjects completing 56 weeks are re-randomised to receive liraglutide placebo for 12 weeks (until week 68).
1652705|NCT01834729|Drug|Alfuzosin|oral alfuzosin immediate release (IR) 2.5 mg (Part A) or oral alfuzosin extended release (ER) 10 mg (Part B)
1652706|NCT01834729|Other|Placebo|placebo capsule identical to the study drug
1652707|NCT01834716|Behavioral|Aerobic vs. Non-Aerobic exercise|
1652708|NCT01834703|Procedure|UAE|The patient will be admitted into hospital for UAE. UAE was performed with patients under local anesthesia. Embosphere particles (BioSphere Medical) with a size of 500 - 700µm were used in all procedures. Embospheres were mixed with contrast material and saline and injected into each uterine artery until either parenchyma filling of the fibroids had stopped (target embolization) or the main uterine artery was blocked with stasis of contrast material (selective embolization). After the procedure, women were admitted to the gynecology ward for postprocedural care. All patients were advised to stay in the hospital for at least 1 night.
1652709|NCT01834703|Procedure|HIFU|Treatment will be given to the patient in one or more sessions on an outpatient basis. The uterine fibroid will be identified and located with ultrasonography and ablated with HIFU. For lesion beyond 6 cm distance from skin, HIFU is given at a power of 1200-1500 watt for 1500 - 2000 times at each spot, for 50 milli-second each time, at an interval of 100 milli-second, at a spot distance of 1.5cm, a line distance of 1.5cm, and a plane distance of 1.0 -1.5cm; for lesion within 6 cm distance from skin, HIFU is given at a power of 1300±15% Watt for 40 times at each spot, for120 milli-second each time, at an interval of 100 milli-second, at a spot distance of 0.3cm, a line distance of 0.3cm, and a plane distance of 0.8cm.
1652710|NCT01834664|Biological|stem cell (MNCs )|Intra thecal transplantation of autologous stem cell [MNCs ]Per dose at the interval
1652711|NCT01834651|Drug|Cabozantinib|Cabozantinib 60 mg daily (oral). Subjects may continue to receive study treatment until they experience unacceptable drug-related toxicity or disease progression.
1652712|NCT01834638|Drug|ABT-126|capsule(s)
1652713|NCT01834625|Procedure|Shunt surgery|
1652714|NCT01834612|Device|CM1500|blood volume monitor
1652715|NCT01834599|Device|cerebral oximetry|tissue saturation measurement in pregnant women
1652716|NCT01834586|Drug|Anesthetic Topical Adhesive Synera|"For subjects taking interferon beta subcutaneous (Betaseron, Extavia or Rebif) apply one patch 60 minutes prior to each injection (every-other day or three times per week) for two weeks, then 30 minutes prior for two weeks.
For subjects taking glatiramer acetate subcutaneous (Copaxone) apply one patch 60 minutes prior to each injection (daily) for one week and then 30 minutes prior for one week"
1652717|NCT01834573|Behavioral|physical exercise|10 weeks physical exercise; three times a week
1652718|NCT01834547|Drug|Drugs use: methylphenidate|40 mg tablets
1652719|NCT01834547|Drug|Drug use: modafinil|40 mg tablets
1652720|NCT01834547|Drug|caffeine|400 mg
1652721|NCT01834547|Drug|placebo|placebo
1652722|NCT01834534|Behavioral|CarePartners for depression|Automated telephone calls for depression monitoring and self-management support.
1652723|NCT01834521|Other|Web-based screening and tailored support|
1652724|NCT01834508|Drug|oral entecavir 0.5mg daily and adefovir 10mg daily for 144 weeks|
1652725|NCT01834495|Device|Balloon expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
1652726|NCT01834495|Device|Self expandable stent|provisional stenting should be performed; the case that optimal ballooning response in not obtained should be enrolled. Optimal balloon response is defined as a residual pressure gradient of > 15mmHg, residual stenosis of >30% and flow limiting dissection
1652727|NCT01834482|Dietary Supplement|Modified Atkins diet|Patients will receive the modified Atkins diet with a 20 gram per day carbohydrate limit and encouragement to consume plenty of fat and eat to satiety.
1652728|NCT01834482|Dietary Supplement|KetoCal|Patients will receive a KetoCal 4:1 ratio (fat: carbohydrates and protein) liquid daily for the first month (if randomized to this arm of the study). They will also be started on the modified Atkins diet.
1652729|NCT01834469|Drug|iv injection of ICG|An iv injection will be performed for the ovarian cancer patient before the operation.
1652730|NCT01834456|Other|Med Complex Children Intervention|Comprehensive Care, including creating a care plan, offering and integrating developmental and behavioral care, with added care coordination in a Medical Home/Primary Care Practice
1652731|NCT01834443|Device|Direct current galvanic vestibular stimulation|
1652732|NCT01834430|Dietary Supplement|enteral nutrition|
1652733|NCT01834417|Device|TexiMat|
1652734|NCT01834404|Drug|Phentermine-Topiramate ER|The dosing of the study drug was phentermine 3.75 mg / topiramate 23 mg days 1-5. The dosing of the study drug was increased to phentermine 7.5 mg / topiramate 46 mg days 6-14.
1652735|NCT01834404|Drug|Placebo|Placebo pills matched the study drug in appearance for the 2 dose levels.
1652736|NCT01834378|Behavioral|Low intensity intervention|We administer, a pedometer and the participants receive a prescription on physical exercise.
1652737|NCT01834378|Behavioral|High intensity intervention.|We schedule group sessions for changes in behavior e.g. type of physical activity to prefer, barriers for change of life style etc.
1652738|NCT01834365|Other|Structured education|Formatted education about hypertension
1652739|NCT01834365|Other|Checklist|
1652740|NCT01834365|Other|Without structure education with checklist|
1652741|NCT01834352|Drug|Walnut Protein Flour|Daily ingestion of gradually increasing amounts of walnut protein flour in order to induce desensitization to walnut and an unrelated tree nut.
1652742|NCT01834352|Drug|Oat flour|Oat flour that is administered as a placebo in identical increasing doses as the active walnut flour treatment.
1652743|NCT01834339|Biological|AlloDerm|
1652744|NCT01834339|Biological|EVPOME|
1652745|NCT01834326|Biological|EVPOME (autogenous ex vivo produced oral mucosa equivalent)|EVPOME is manufactured from the subjects own oral cells and is implanted back in the subjects mouth after an approximately 30 day manufacturing process.
1652746|NCT01834326|Biological|POM (Palatal oral mucosa)|POM is a tissue graft harvested from the palate and surgically placed into the defect area
1652788|NCT01834014|Drug|5-FU|2400 mg/m2 continuous infusion over 46 hours on day 1 and 2 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1653093|NCT01831323|Dietary Supplement|VSL#3|VSL#3
1652747|NCT01834300|Behavioral|Unsupervised exercise training|The patients will be given lecture on lifestyle changes and its benefitial effects on health at the begining of the study by the exercise trainer. There will be no conatct with the exercise trainer for the period of intervention for 4 months.
1652748|NCT01834300|Behavioral|Supervised exercise training|Patients will be encouraged to exercise four times per week for 30-45 min at 60-80 % of maximal heart rate, with a 5 min warm-up and warm-down. Participants will be given free access to a variety of affiliated sports centres and will use the Wellness Key system, a software program that enables researchers to remotely track the exercise activity of participants very accurately. To ensure compliance with rest or exercise, all participants of both groups will have their mean physical activity level in 2 non-consecutive weeks evaluated with an ambulatory accelerometer.
1652749|NCT01834287|Behavioral|Physical Activity Intervention|Participants in the Physical Activity intervention arm of the study receive a Spanish language, motivationally-tailored, Internet-based Physical Activity intervention that specifically addresses the Physical Activity barriers and intervention needs/preferences of Latinas.
1652750|NCT01834287|Behavioral|Wellness Control|Participants will receive a Spanish language, Internet-based Wellness Contact control intervention addressing relevant health topics other than physical activity.
1652751|NCT01834274|Drug|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
1652752|NCT01834274|Drug|Fasiglifam (TAK-875) Placebo|Fasiglifam (TAK-875) placebo-matching tablets
1652753|NCT01834274|Drug|Sitagliptin|Sitagliptin tablets
1652754|NCT01834274|Drug|Sitagliptin Placebo|Sitagliptin placebo-matching tablets
1652755|NCT01834274|Drug|Metformin|Metformin tablets
1652756|NCT01834261|Drug|Syntocinon Nasal Spray, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
1652757|NCT01834261|Drug|Syntocinon Placebo Formulation, 40IU|Subjects will be scanned twice. Prior to first brain scanning session, they will be randomly assigned to receive either Syntocinon or Placebo. Prior to second scanning session, they will receive what they have not received in the first session; i.e., same subjects will be receiving both Syntocinon and placebo on two different days.
1652758|NCT01834248|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC and ID
1652759|NCT01834248|Drug|Decitabine|Given IV
1652760|NCT01834248|Other|Laboratory Biomarker Analysis|Correlative studies
1652761|NCT01834248|Drug|Poly ICLC|Given SC
1652762|NCT01834235|Drug|Gemcitabine|Gemcitabine IV at a dose of 1000mg/m2 on days 1, 8, and 15 of a 4 week cycle.
1652763|NCT01834235|Drug|nab-paclitaxel|Nab-paclitaxel will be administered at a dose of 125 mg/m2 as a 30 minute infusion (maximum infusion time not to exceed 40 minutes) on Days 1, 7 and 15 for a 28 day cycle
1652764|NCT01834235|Drug|NPC-1C|NPC-1C(NEO-102) infusion at a dose of 1.5mg/kg IV on days 1 and 15 of a 28 day cycle. This will be administered 30 minutes after completion of the gemcitabine infusion.
1652765|NCT01834222|Biological|Non-intervention|Non-intervention
1652766|NCT01834209|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily for 28-day cycles
1652767|NCT01834209|Drug|Prednisone or prednisolone|5 mg tablet taken orally once daily
1652768|NCT01834196|Device|Swept-Source Optical Coherence Tomography|Noninvasive imaging of the retinal vasculature in patient with existing microvascular disease.
1652769|NCT01834183|Drug|Tivozanib|
1652770|NCT01834183|Drug|Gemcitabine|
1652771|NCT01834170|Drug|Gemcitabine|"Two intratumoral injections of gemcitabine under endoscopic ultrasound (EUS)-guidance at month 0 and month 3.
The patients will receive systemic chemotherapy with or without radiotherapy at the discretion of oncologist"
1652772|NCT01834144|Other|Exercise Training|
1652773|NCT01834131|Behavioral|Comprehensive Intervention|The comprehensive intervention includes physician education, a community health worker home intervention and a mobile health intervention. Please see Arm Description for details.
1652774|NCT01834118|Procedure|Renal Denervation|Sympathetic nerve ablation via transcatheter renal denervation
1652775|NCT01834105|Drug|Liuwei Dihuang Pills|
1652776|NCT01834092|Other|Plasma|2 Units of plasma transfused equvilant to 2 times 275ml
1652777|NCT01834079|Biological|STEM CELL THERAPY|Autologous stem cells(MNCs ) intra thecal .Intra thecal transplantation of single arm autologous MNCs 100 millions per dose in 3 divided doses at interval of 7 days,Intrathecal/Intravenous .Follow up will be taken to three Months or as required
1652778|NCT01834066|Biological|Stem Cell|Intralesional transfer of Autologous Stem cell (MNCs) per dose. 6 doses in 3 months
1652779|NCT01834053|Biological|autologous Stem Cell|Intrathecal transplantation of autologous 100 millions Stem cells{MNCs } per dose'
1652780|NCT01834040|Other|Intralesional/ Intravenous of Autologous Stem cells.|Intralesional/ Intravenous of Autologous MNCs per dose
1652781|NCT01834027|Behavioral|Jazz music|Jazz music from artists including Miles Davis, Ella Fitzgerald, Nat King Cole, Dave Brubeck, etc. will be played through headphones for post-surgical hysterectomy patients while they are in the post anesthesia care unit.
1652782|NCT01834027|Behavioral|No music|In this group no music will be played in PACU
1652783|NCT01834014|Drug|Bevacizumab|5 mg/kg intravenously administered over 90 minutes (can be reduced to 30 minutes at the minimum) on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1652784|NCT01834014|Drug|Cetuximab|250 mg/m2 intravenously administered over 60 minutes (400 mg/m2 over 120 minutes as the initial dose) on day 1 and day 8 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1652785|NCT01834014|Drug|L-OHP|85 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1652786|NCT01834014|Drug|l-LV|200 mg/m2 intravenously administered over 120 minutes on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1652787|NCT01834014|Drug|5-FU|400 mg/m2 intravenous bolus on day 1 of a 2-week cycle. Liver resection if resectable after 8 cycles or continue until progression of disease.
1653043|NCT01831661|Drug|GLUCOPHAGE®XR|GLUCOPHAGE®XR 750 mg once a day
1652789|NCT01833988|Device|Bi-hormonal Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
1652790|NCT01833988|Other|Usual Care|Comparator week to closed-loop control, utilizing usual camp care and the subject's own insulin pump.
1652791|NCT01833975|Biological|Transplantation of Autologous stem cell [MNCs] .|Intra thecal transplantation of Autologous stem cell [MNCs],100millions per dose in 3 divided doses at interval of 10 days.
1652792|NCT01833949|Procedure|Unilateral laparoscopic drilling|Unilateral laparoscopic drilling with diathermy adjusted to ovarian volume
1652793|NCT01833949|Procedure|Bilateral laparoscopic drilling|Bilateral laparoscopic drilling with fixed doses energy
1652796|NCT01833923|Drug|anlotinib|oral medicine.
1652797|NCT01833910|Other|AHA CPR Anytime Video Self-Instruction Kit|CPR Training utilizing a video self-instruction kit including training video and inflatable manikin.
1652798|NCT01833910|Other|AHA CPR Anytime DVD|A CPR Training Video, originally developed as part of a kit, administered without the accompanying manikin.
1652799|NCT01833897|Drug|Standard of Care|Quetiapine, olanzapine-fluoxetine, and lurasidone are approved treatments for bipolar depression. Quetiapine dosing will follow the product label(Anon), and will be titrated over the first 4 days to the target dose of 300 mg. Olanzapine-fluoxetine dosing will also follow standard guidelines. Lurasidone will be started at 20 mg, and titrated up to 60 mg daily as clinically indicated. Study physicians will use clinical judgment to choose between standard-of care treatments, and have the option to titrate standard-of-care within approved ranges, and to prescribe adjunctive benztropine and benzodiazepines if clinically indicated.
1652800|NCT01833897|Drug|Ketamine|Ketamine administration will be carried out according to the methods as described by previous studies. Subjects will receive ketamine hydrochloride (0.5 mg/kg) intravenously during 40 minutes. This dosage was selected based on previous trials of ketamine for the treatment of refractory depression and bipolar depression. Vital signs (blood pressure, heart rate) will be closely monitored throughout the time of infusion. Subjects will be evaluated for 2 consecutive days during this phase; i.e. treatment days (day 1) and rating days (day 2). Non-responders to ketamine will not proceed into the DCS phase. Response will be a 25% improvement on the Hamilton Depression Rating Scale (HDRS).
1652801|NCT01833897|Drug|D-cycloserine|Immediately after the ketamine infusion, subjects will begin an eight-week treatment of DCS adjunctive to standard of care. DCS dosing will begin at 250 mg for three days→500mg (2 capsules)/day for 1 week → 750 mg (3 capsules)/day for 1 week → and 1000 mg (4 capsules)/day for the remainder of the study.
1652802|NCT01833884|Other|Collection of blood specimen|Collection of blood specimen for Cytokines dosing scheduled before , during and after treatment of Hodgkin's lymphoma (last collection date about 90 days after the end of treatment)
2012973|NCT01272219|Drug|liraglutide|Liraglutide 3.0 mg, subcutaneous (under the skin) injection once daily for 160 weeks.
2012974|NCT01272219|Drug|placebo|Liraglutide placebo, subcutaneous (under the skin) injection once daily for 160 weeks.
2012975|NCT01272037|Drug|Anastrozole|Given PO
2012976|NCT01272037|Drug|Exemestane|Given PO
1652807|NCT01833845|Drug|Ribavirin|weight-based doses (1000 mg/day administered BID [twice daily] for subjects ≤ 75 kg and 1200 mg/day administered BID for subjects > 75 kg). Those subjects receiving 1000 mg/day RBV will take 2 tablets of 200 mg/tablet in the morning and 3 tablets in the evening, and those subjects receiving 1200 mg/day RBV will take 3 tablets morning and evening.
1652808|NCT01833845|Drug|Hydroxychloroquine|subjects will receive HCQ 575 mg administered as a single tablet once daily (QD)
2012977|NCT01272037|Other|Laboratory Biomarker Analysis|Correlative studies
2012978|NCT01272037|Drug|Letrozole|Given PO
2012979|NCT01272037|Other|Quality-of-Life Assessment|Ancillary studies (closed as of 12/1/12)
1652812|NCT01833819|Drug|Dexmedetomidine and lidocaine|
1652813|NCT01833819|Drug|Remifentanil|
1652814|NCT01833806|Device|ExAblate MRgFUS|Focused Ultrasound Ablation
1652815|NCT01833793|Drug|Levonorgestrel IUD (Mirena, BAY86-5028)|Women who have been prescribed Mirena in contraception; followed up for 12 months
1652816|NCT01833767|Drug|Cyclophosphamide and Interleukin 2|Cytoxan IV day 1, IL2 IV days 1-5
1652817|NCT01833754|Drug|Romosozumab|Administered as three 70 mg/mL prefilled syringe injections
1652818|NCT01833741|Drug|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® RC) administered as one drop in the study eye(s) each evening for 12 weeks.
1652819|NCT01833728|Drug|nefopam-propacetamol combination|"Patients in both groups will receive intravenous patient-controlled analgesia (PCA) using fentanyl.
In nefopam-propacetamol combination group, patients will receive nefopam(20mg mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours."
1653044|NCT01831648|Other|Blood sample|
1653094|NCT01831323|Drug|Rifaximin|Rifaximin
2012980|NCT01272037|Drug|Systemic Chemotherapy|Given IV
2012981|NCT01272037|Drug|Tamoxifen Citrate|Given PO
1958040|NCT02021656|Drug|LDV/SOF|90/400 mg FDC tablet administered orally once daily
2012982|NCT01263717|Drug|tesamorelin|Tesamorelin (growth hormone releasing hormone) 2mg daily given by subcutaneous injection x 6 months during randomized phase, followed by 6 months of open-label tesamorelin at same dose
2012983|NCT01263717|Drug|placebo|Placebo 2mg daily given by subcutaneous injection for the first 6 months of the study, followed by an open-label phase of 6 months of tesamorelin (growth hormone releasing hormone) treatment, 2mg daily given by subcutaneous injection
2012984|NCT01253642|Procedure|Biopsy of Prostate|Undergo TRUS-guided prostate biopsy OR image-guided (CT or ultrasound) core bone or soft tissue biopsy
2012985|NCT01253642|Drug|Docetaxel|Given IV
1652820|NCT01833728|Drug|propacetamol alone|In propacetamol alone group, patients will receive placebo (normal saline 2 ml mixed to normal saline 100mL) and propacetamol(2g mixed to normal saline 100mL), 30 minutes before the end of operation, every 6 hours for up to 48 hours.
1652821|NCT01833715|Drug|Morphine|Morphine group,receive morphine 0.08 mg / kg at the start of surgery
1652822|NCT01833715|Drug|Methadone|Methadone group,receive methadone 0.08 mg / kg at the start of surgery
1652823|NCT01833715|Drug|TIVA|TIVA: General anesthesia will be based on Remifentanil and Propofol (TIVA-TCI), titrated to achieve bispectral index (BIS) between 40 and 60.
1652824|NCT01833689|Dietary Supplement|food consumption|"Reference food The reference food is 50 g glucose powder dissolved in 250ml water
Test foods The test foods are prepared according to manufacturer's instructions, representing the food as normally consumed. The test foods are consumed once only on separate occasions as a portion providing 50g of available carbohydrate.
Breakfast cereals should be consumed with 150 ml milk which is additional to the 50 g available carbohydrate in the cereal. In testing breakfast cereals, the reference food must also be consumed with an additional 150 ml milk."
1652825|NCT01833676|Drug|Sevoflurane|
1652826|NCT01833676|Drug|Desflurane|
1652827|NCT01833663|Drug|Solifenacin Succinate Tablets|
1652828|NCT01833663|Drug|Estrogen|
1652829|NCT01833650|Dietary Supplement|thymus honey mouthwash|
1652830|NCT01833637|Other|APN Intervention|Patients randomized to this group will be asked to fill out a patient symptom assessment using an iPad at the time of registration and then every day until released from the hospital. It should take about 10 minutes to complete this questionnaire each time. Based on the patients' answers and in cooperation with their health care provider, an Advanced Practice Nurse (APN) will provide information about symptom management and options for services that are available after the patient leaves the hospital. The survey responses will be shared with the patients' healthcare team so that they better understand how they are feeling. The APN will work closely with the healthcare team. Patients will be asked to fill out a Patient Satisfaction Questionnaire at the time of discharge.
1652831|NCT01833624|Dietary Supplement|Peptamen® AF|Comparison of two types of enteral nutrition feeding: Peptamen® AF and Sondalis® HP
1652832|NCT01833624|Dietary Supplement|Sondalis® HP|
1652833|NCT01833611|Drug|Entecavir|entecavir 0.5mg qd
1652834|NCT01833611|Drug|placebo|placebo qd
1652835|NCT01833598|Procedure|PNT + PRP|The PNT + PRP group will undergo needle tenotomy under direct and continuous ultrasound guidance with even distribution of PRP into the peritendinous area(s) of PNT around the affected tendon.
1652836|NCT01833598|Procedure|PNT alone|The PNT group will undergo needle tenotomy under direct and continuous ultrasound guidance local anesthesia into the affected tendon. 10 minutes after the injection, the ultrasound machine probe will be passed over the areas treated both to evaluate for any structural changes and for any complications.
1652837|NCT01833585|Biological|Peripheral blood mononuclear cell|Peripheral blood mononuclear cell solution 59 cc will be injected to the gastrocnemius muscle of ischemic limb of patients with critical limb ischemia
1652838|NCT01833572|Drug|Gefitinib|Eligible participants will be given orally gefitinib 250mg daily before surgery for 42 days or until disease progression or unacceptable toxicity. Best supportive care is allowed in this period.
1652839|NCT01833559|Dietary Supplement|Dietary control|
1652840|NCT01833559|Drug|Insulin|If feast blood glucose is over 7.0 mmol/L, the patient will be hospitalized and insulin will be used. The kind of insulin used depends on the need of patients.
1652841|NCT01833546|Drug|TH-302 monotherapy|TH-302 will be administered weekly at a dose ranging from 240-480 milligram per square meter (mg/m^2) as intravenous infusion over 30 or 60 minutes on Day 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
1652842|NCT01833546|Drug|TH-302|TH-302 will be administered weekly at a dose of either 240 or 340 mg/m^2 as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle, until evidence of progressive disease, intolerable toxicity or subject withdrawal.
1652843|NCT01833546|Drug|Gemcitabine|Gemcitabine will be administered weekly at a dose of 1000 mg/m^2 as intravenous infusion over 30 minutes on Day 1, 8 and 15 of every 28-day cycle, until evidence of progressive disease, intolerable toxicity or subject withdrawal.
1652844|NCT01833533|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
1652845|NCT01833533|Drug|Ribavirin|Capsule
1652846|NCT01833533|Drug|Placebo for Ribavirin|Capsule
2012986|NCT01253642|Other|Laboratory Biomarker Analysis|Correlative studies
1652848|NCT01833507|Behavioral|Self-Exercise|Behavioral Goal Setting
1652849|NCT01833507|Behavioral|Usual Care|Participants will have full access to all of the educational materials which are available to all Mayo Clinic patients in literature racks in the individual clinics. Participants will subsequently be given entry into the active intervention at the 2-month check.
1652850|NCT01833494|Drug|PA21|
1652851|NCT01833481|Radiation|Fluoroscopy surveillance of patients while walking|While each subject performs a gait activity (normal walking) under fluoroscopic surveillance on a level treadmill, a data acquisition (DAQ) system will be used to determine the vibrations/sounds occurring during walking.
1652852|NCT01833455|Drug|PVC Suppression using Flecainide|Flecainide will be administered to result in a reduction in PVC burden.
1652853|NCT01833455|Drug|No PVC Suppression using Placebo|Placebo (sugar pills) will be given to result in no alteration in PVC burden.
2012987|NCT01253642|Drug|Phenelzine Sulfate|Given PO
2012988|NCT01251575|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
1652856|NCT01833403|Other|Hyperinsulinemic-euglycemic clamp|Subject will received 6,6 2H2 Glucose prior and during a 4 hr hyperinsulinemic-euglycemic clamp to characterize hepatic insulin resistance prior to bariatric surgery
1717886|NCT00002352|Drug|Lobucavir|
2012989|NCT01251575|Drug|Cyclosporine|Given PO or IV
2012990|NCT01251575|Drug|Fludarabine Phosphate|Given IV
2012991|NCT01251575|Other|Laboratory Biomarker Analysis|Correlative studies
2012992|NCT01251575|Drug|Mycophenolate Mofetil|Given PO
2012993|NCT01251575|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
2012994|NCT01251575|Drug|Sirolimus|Given PO
1652857|NCT01833390|Drug|HXe MRI lung ventilation|MagniXene (HXe) is an Investigational New Drug made of xenon noble gas. Through a physical process using alkali vapors and powerful lasers, xenon atoms have their nuclear spin preferentially aligned (hyperpolarized), thus offering a highly enhanced signal inside an MRI scanner. High-resolution images of the lung spaces are acquired within a short breath-hold after inhalation of HXe.
1652858|NCT01833377|Dietary Supplement|caraway sample|
1652859|NCT01833377|Dietary Supplement|placebo|
1652860|NCT01833364|Procedure|Implantation of the Peripheral Nerve Graft|"The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.
The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility."
1652861|NCT01833351|Drug|IV Vitamin C|"We will begin by enrolling 3 people at each dose level and if there are any problems seen, we will enroll 3 more people to that dose to see if that problem happens again and this may total a maximum of 6 people. Therefore a maximum of 6 people may be enrolled at each of these Vitamin C dose levels, 1 gram, 5 grams, 10 grams, 25 grams, 50 grams, 75 grams, and 100 grams.
If you are eligible for the study and decide to participate, the total time involved could be approximately 4 weeks."
1652862|NCT01833351|Drug|IV Vitamin C|"There will be 4 dose levels of intravenous vitamin C selected for this part of the study. The first dose level will be 25% of the top dose level found to be safe in Part 1, followed by 50% of the top dose level, followed by 75% of the top dose level, and finally 100% of the top dose. For example, if 100 grams of vitamin C given by vein is found to be safe in Part 1, then the first dose level we will choose will be 25 grams, followed by 50 grams, then 75 grams, and finally 100 grams.
Three to 6 people will be invited to participate in each of the dose levels and you will be asked to get a total of 4 doses at that level spread out over 4 weeks. In addition, you will have an initial visit and a follow-up visit both lasting 30 minutes. This will total 6 visits."
1652863|NCT01833338|Device|Imaging|All patients undergo non-invasive (MSCT) and invasive (IVUS, OCT) imaging
1652864|NCT01833325|Radiation|Proton radiation|Proton radiation given to a total dose of 24 cobalt gray equivalent (CGE) in 2 treatments
1652865|NCT01833312|Device|Hypothermia|In patients randomised to therapeutic hypothermia, induction of cooling will be started by infusion of 4°C isotone saline or Ringer's lactate administered over a period of 30 to 60 minutes. A body temperature between 34.0 and 35.0°C will be targeted. Body temperature will be monitored through bladder or rectal thermal probes, and cooling procedures will be adapted to keep body temperature as close as possible to the target. Maintenance of body temperature in the target range will be performed with a surface or endovascular cooling device. After a cooling period of 24h, controlled rewarming to 36°C with a rate of 0.2°C/h will be started. After 36°C have been reached, the device will be disconnected.
1652866|NCT01833312|Drug|Buspirone|anti-shivering treatment
1652867|NCT01833312|Drug|Pethidine|anti-shivering treatment
1652868|NCT01833299|Procedure|TACE-Sorafenib group|"Transcatheter arterial chemoembolization drugs and dosage:TACE with chemothrapy drugs (E-ADM 50mg, carboplatin 300 mg, MMC 8mg)and followed with embolization with lipiodol and absorbable gelatin sponge particles or polyvinyl alcohol particles.
Oral sorafenib (400 mg BID) will be start the 2-4 weeks after the first TACE treatment and will continue until the patient shows disease progression, until unacceptable toxicity occurs, or until study termination."
1652869|NCT01833299|Procedure|TACE|
1652870|NCT01833286|Procedure|TACE+RFA|TACE first, followed by RFA within 2 months
1652871|NCT01833286|Procedure|re-resection|repeat hepatectomy for recurrent small HCC
1652872|NCT01833273|Drug|PolyMVA|Subjects will take 8 tsp/day of PolyMVA over a 26 week period while receiving standard of care from his/her neuro-oncologist. Subjects will begin taking the study compound after maximal surgical resection of the tumor and receiving an initial treatment of radiation therapy. Subjects will not take study compound on days when they receive chemotherapy.
1652873|NCT01833260|Behavioral|Music|
1652874|NCT01833234|Other|Interviews and questionnaires|
1652875|NCT01833221|Drug|injection of 1% lidocaine, 2mL for facial nerve block|injection with a fine needle of 2mL lidocaine in close contact of the facial nerve trunk
1652876|NCT01833208|Other|Laboratory Biomarker Analysis|Correlative studies
1652877|NCT01833208|Radiation|Radiation Therapy|Undergo single-fraction radiation therapy
1652878|NCT01833182|Other|Tailored home intervention|The occupational therapist (OT) interventionist will develop a set of environmental modification choices to improve performance in problematic activities identified during the clinical evaluation. A plan for resolving the barriers identified during clinical assessment will be developed. The participant will review the barrier removal options and will make an informed choice resulting in a final treatment plan. Modification installation which will be provided, at no cost to the participant, by a contractor trained by the study PI. The tailored intervention includes training in the use of the new equipment or architectural changes. Photographs of identified barriers, study measures, and intervention plans will be reviewed by the principal investigator during team meetings to ensure treatment fidelity.
1652879|NCT01833182|Other|Sham intervention|We have developed a kit containing 12 standard adaptive equipment (AD) items (e.g., jar opener). The AD kit has been specifically designed to address fine motor function and will not influence fall outcomes. Two pieces of AD will be provided during each session, and the individual will be instructed to use each AD by the OT interventionist
2012995|NCT01251575|Radiation|Total-Body Irradiation|Undergo total-body irradiation
1652881|NCT01833156|Device|MoistureMeterD|measuring erythema size and the dielectric constant values
1652882|NCT01833143|Drug|Bortezomib|
1652883|NCT01833143|Drug|Acyclovir|
1652884|NCT01833130|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 155 U total dose per treatment injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
2012996|NCT01248416|Drug|Aromatase Inhibitor|
2012997|NCT01248416|Drug|Growth Hormone|
2012998|NCT01248416|Drug|Aromatase Inhibitor and Growth Hormone|
1652885|NCT01833130|Drug|Normal saline (placebo)|Placebo (Normal saline) injected into specified head and neck muscles on Day 1 followed by a second treatment at Week 12.
1652886|NCT01833117|Other|FID 119515A|topical ocular drops
1652887|NCT01833117|Other|Blink® Tears|topical ocular drops
1652888|NCT01833104|Behavioral|Presence - Perspective - Affect|"PRESENCE: Cultivate attentional skills & interoceptive body awareness. 2 exercises: Breathing Meditation & Body Scan.
PERSPECTIVE: Focus on cognitive aspects of compassion; take perspectives on thoughts, the self, & other people; observe more macroscopic dynamics within oneself, your inner parts; do not fully identify with them / be aware of their transiency; strengthen the ability to detach from one's own perspective, take the perspectives of others, trying to understand their thoughts, motives, feelings. 2 exercises: Observing-thoughts Meditation & Perspective Dyad.
AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation & Affect Dyad."
1652889|NCT01833104|Behavioral|Presence - Affect - Perspective.|As specified above however the order is interchanged between the cohorts TC1 and TC2.
1652890|NCT01833104|Behavioral|Affect|"AFFECT: Cultivate emotional/motivational aspects of compassion; cultivate a sense of benevolence, love, care, opening the heart for oneself and others; work with obstacles, e.g. fear, anger or sadness (emotion acceptance); pro-social motivations as an alley towards loving / benevolent feelings and as a consequence of them. 2 exercises: Loving-kindness Meditation & Affect Dyad."
1652891|NCT01833091|Other|artificial night|Infants in the intervention group received light cyclic with pattern 12 hours. Light period was from 7 to 19 during which the infants were put in the normal environmental light and dark period was from 19 to 7 during which was the infants' incubator was covered with linen cloth. The vital signsand & arterial oxygen saturation of the infants in the intervention group were controlled before covering the incubator i.e. at 19. Also, the infant's vital signs were again monitored at 7 am.The infant weighed in every day at 7 am during the 10 days of study. Feeding tolerance was daily determined at 8 am, using nasogastric tube or orogastric tube to control residue as well as to review the presence or absence of abdominal distention, vomiting.
1652892|NCT01833078|Drug|ghrelin|ghrelin administration subcutaneously for 7 days
1652893|NCT01833065|Drug|Elobixibat 10 mg/day|Elobixibat 10 mg/day
1652894|NCT01833065|Drug|Elobixibat 5 mg/day|Elobixibat 5 mg/day
1652895|NCT01833065|Drug|Placebo|Placebo
1652896|NCT01833052|Device|TAVI (Medtronic CoreValve)|
1652897|NCT01833052|Device|Claret-Filter|
1652898|NCT01833039|Drug|Ibrutinib|Ibrutinib
1652899|NCT01833026|Device|Spirometry test|For the initial visit for the intervention group, an initial demographics form and a health questionnaire will given to the subject to complete. To evaluate the breathing and quality of living, a spirometry test will be performed that will evaluate how well and how fast the subject can breath and blow out air.
1652900|NCT01833026|Drug|Levalbuterol|The spirometry test will be performed with a breathing medication called Levalbuterol (Xopenex®). Levalbuterol is used in standard practice for COPD and is commonly used during spirometry.
1652901|NCT01833013|Other|live birth date and quality of life assessment|
1652902|NCT01833000|Device|Cerebral and splanchnic ear infrared spectroscopy (NIRS) and mesenteric Doppler|
1652903|NCT01832987|Drug|co-trimoxazole|On 4, 5 or 6 consecutive days, co-trimoxazole 960 mg will be added to the normal treatment regimen
1652904|NCT01832974|Drug|IL-13-PE|IL-13-PE intravenous infusion
1652905|NCT01832961|Device|flutter valve exercises|30 minutes of flutter exercises
1652906|NCT01832961|Device|flutter-sham exercises|30 minutes of flutter-sham exercises
1652907|NCT01832948|Drug|Endostar|
1652908|NCT01832948|Drug|Oxaliplatin|
1652909|NCT01832948|Drug|Folinic acid|
1652910|NCT01832948|Drug|5-FU|
1652911|NCT01832935|Drug|insulin glargine|The starting dose of insulin Glargine was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
1652912|NCT01832935|Drug|Insulin NPH|The starting dose of insulin NPH was 24 units per day (0.2-0.6 unit/kg) in 2 divided doses
1652913|NCT01832922|Drug|Bendamustine|
1652914|NCT01832922|Drug|Rituximab|
1652915|NCT01832909|Other|Walnut Diet|Controlled diet with 1.5 oz/d of walnuts.
1652916|NCT01832909|Other|Control Diet|Controlled diet without walnuts.
1652917|NCT01832896|Drug|Ecallantide subcutaneous dosing|For acute attacks of Hereditary Angioedema in children and adolescents, Ecallantide will be administered.
1652918|NCT01832883|Device|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
1652919|NCT01832870|Drug|sipuleucel-T|
1652920|NCT01832870|Drug|ipilimumab|
1652921|NCT01832857|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is the maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
1652922|NCT01832844|Procedure|"Group  with scan prior to infiltration "|Scan will be conducted by the operator performing the gesture. He will examine the lumbar spine from L3 to S1, in longitudinal and cross sections and determine the best surgical approach. This will be defined by the largest interspinous space or better visibility of the epidural space. The depth of the epidural space will be noted. The selected stage will be marked with a skin pen to facilitate its location thereafter
1652923|NCT01832844|Procedure|"Group  without scan "|
1652924|NCT01832818|Device|NuNec Cervical Disc|Patients will be enrolled and implanted with the NuNec device at a single level C3 to C7.
1652925|NCT01832805|Other|Theta burst stimulation.|In each session, subjects will receive 54 Theta burst trains of 2 seconds duration, separated by an intertrain interval of 18 seconds, delivered on the left dorsolateral prefrontal cortex (DLPFC). The treatment protocol of in total 20 Theta burst sessions will be spread over 4 days, yielding a total of 32400 stimuli. On each stimulation day, a given patient shall receive 5 sessions with a between session delay of 10 to 15 minutes.
1718081|NCT00002398|Drug|Levocarnitine|
1652926|NCT01832792|Other|Face-to-face self-help|Participants in this arm will receive face-to-face self-help; that is, self-help with the support of a therapist, attending the clinic in person.
1652927|NCT01832792|Other|E-mail self-help|Participants in this arm will receive e-mail self-help; that is, self-help with the support of a therapist, provided via e-mail.
1652928|NCT01832792|Other|Waiting List|Waiting list condition - participants assigned to a waiting list (no intervention) condition
1652929|NCT01832779|Other|Achalasia subjects|Information about the subject's medical history, leading up to the need for an Achalasia treatment, the procedure itself and how the subject does after the procedure, including after the subject's gets home, will be collected. This will be done by gathering relevant information from the subject's medical chart and/or by talking with the subject prior to and after your medical procedures. There are no specific study procedures or tests. All information collected is part of the subject's medical care and will be collected even if the subject is not in the study.
1652930|NCT01832766|Drug|Dronabinol|dronabinol 10 mg one capsule by mouth at 8:00 a.m.
1652931|NCT01832766|Other|Placebo Comparator|one capsule given by mouth at 8:00 a.m.
1652932|NCT01832753|Drug|Levothyroxine|
1652933|NCT01832740|Device|brain stimulation|oscillating direct current brain stimulation
1652934|NCT01832740|Device|SHAM|no stimulation
1652935|NCT01832727|Drug|Oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 or on Days 1, 2, 8, and 9 of the 14-day treatment cycle.
1652936|NCT01832727|Drug|Dexamethasone|Dexamethasone 20 mg will be taken on Days 1, 2, 8, and 9
1652937|NCT01832701|Other|Coffee|coffee versus placebo
1652938|NCT01832701|Other|Placebo comparator|maltodextrine with caffeine
1652939|NCT01832688|Other|Programmatic prenatal care optimization|To further integrate and improve nutrition-related services and messages in the prenatal care package.
1652940|NCT01832675|Drug|Xylocain, cutaneous spray, solution|10 mg lidocaine/spray. The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
1652941|NCT01832675|Drug|Bupivacaine lozenge|25 mg bupivacaine/lozenge. The patient will get one lozenge 10-15 minutes before the examination.
1652942|NCT01832662|Other|coffee|coffee, placebo enriched with polyphenols and placebo with caffeine
1652943|NCT01832662|Other|coffee polyphenols mixed with placebo|coffee polyphenols mixed with placebo
1652944|NCT01832662|Other|maltodextrin enriched with caffeine|maltodextrin enriched with caffeine
1652945|NCT01832649|Behavioral|Exercise|Supervised moderate-vigorous exercise in group, based on strength and calisthenics exercises, 2 times per week during 8 weeks.
1652946|NCT01832649|Behavioral|Health education|Supervised groups 2 times per week during 8 weeks.
1652947|NCT01832636|Dietary Supplement|Alanyl-Glutamine|Alanyl-Glutamine and Glycine doses will be prepared immediately prior to administration by dissolving in formula, milk, or fruit juice. Administration of each dose will be directly observed by a study nurse or health agent.
1652948|NCT01832623|Other|Exploration of Vitamin D roles|"Visit 1: questioning, physical examination, blood sampling (including plasma collection for future genetic analyses), carotid ultrasound
Visit 2 (same day as visit 1 or maxi 3 months later): HR-pQCT, dual energy x-ray absorptiometry (DXA), iontophoresis of acetylcholine and sodium nitroprusside"
1652950|NCT01832584|Dietary Supplement|RGC|
1652951|NCT01832584|Dietary Supplement|Placebo|
1652952|NCT01832571|Drug|Once daily Truvada®|At the enrollment visit, participant's eligibility is assessed per protocol and she is provided with a 30 day supply of Truvada and instructed to take one tablet orally once daily with or without food. Each tablet contains 200 mg emtricitabine (FTC) and 300 mg tenofovir disoproxil fumarate (TDF). Participants will receive Truvada at each clinic visit after it is confirmed that she is HIV negative. There will be a 1 month follow-up visit after enrollment. Thereafter, participants will have quarterly visits until April 2014.
1652953|NCT01832558|Drug|Eplerenone|
1652954|NCT01832558|Drug|Placebo|
1652955|NCT01832545|Other|Aquatic Exercise|
1652956|NCT01832545|Behavioral|Educational Program|Control Group
1652957|NCT01832532|Drug|liraglutide|daily use of drug. Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose
1652958|NCT01832506|Drug|MSC2156119J|Subjects will be administered with MSC2156119J 215 mg, 300 mg and 500 mg orally once daily for repeated 21-day cycles until disease progression or unacceptable toxicity.
1652959|NCT01832493|Device|Cardiac Resynchronization Therapy|All study patients were evaluated for the optimal atrial-ventricular (AV) programmed interval using various methods.
1652960|NCT01832480|Drug|MTZ 500 mg BID x 7 days|MTZ 500 mg BID x 7days
1652961|NCT01832480|Drug|MTZ 2 g|MTZ 2 g
1652963|NCT01832454|Other|Intra thecal inj of autologous MNC|Intra thecal inj of autologous MNC
1652964|NCT01832441|Other|Intra thecal transplantation of autologous MNC|Intra thecal inj.of 100 millions MNC in 3 doses at 7 days interval
1652965|NCT01832428|Other|Intra thecal transplantation of Autologous Stem Cells|Intra thecal transplantation of Autologous Stem Cells
1652966|NCT01832415|Drug|Bevacizumab|Observation of bevacizumab administration in first line ovarian cancer treatment
1652967|NCT01832402|Drug|Fentanyl Pectin Nasal Spray|Fentanyl pectin nasal (FPNS) dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
1652968|NCT01832402|Drug|Placebo Nasal Spray|Placebo nasal spray administered intranasally 20 minutes before the second 6-minute walk test. Same dose repeated at least 30 minutes after the first dose and 20 minutes prior to the third and final 6 minute walk test.
1652969|NCT01832402|Other|Walk Test|Walk test administered before first dose of drug/placebo nasal spray. Participant will rest for 30 minutes after walk test. Drug/placebo nasal spray administered, then participant will wait 20 minutes before repeating second 6 minute walk test. After second walk test, participant will rest for 30 minutes. Drug/placebo nasal spray administered for second time, then participant will wait for 20 minutes. Walk test administered again for 6 minutes.
1652970|NCT01832402|Behavioral|Questionnaires|Questionnaires completed at baseline, before each walk test, and at end of final walk test.
1652971|NCT01832402|Behavioral|Mental Ability Tests|Four mental ability tests administered after each walk test to include finger tapping, simple mathematics questions, recall of numbers, and recall of objects.
1652972|NCT01832389|Device|PiCCO|
1652973|NCT01832376|Procedure|Ultrasound guided needle lavage|A 18-gauge needle connected to a 5 ml syringe with 4 ml of saline solution will be used to puncture the calcification with freehand technique and under constant sonographic monitoring. With the tip of the needle placed in the center of the deposit, the calcification will be flushed. If backflow of calcific material can be identified in the syringe, lavage of the deposit will be performed by successive propulsion and aspiration with the syringe plunger. In cases where no material can be extracted, repeated perforation of the deposit will be performed to possibly initiate or accelerate spontaneous resorption.
1652974|NCT01832363|Drug|HXe MRI guided treatment sequence for BT|HXe MRI consists in imaging the inhaled xenon gas inside the human lungs during a short breath-hold. High resolution 3D maps of the HXe distribution inside the lungs provide information regarding ventilation of the lungs, as the signal is proportional to the local concentration of HXe. A high MRI signal translates in unobstructed ventilation, while ventilation defects appear as dark regions on the map. HXe MRI will be performed pre and post bronchodilator in order to determine the airways which potentially are the most responsive to BT treatment. All HXe MRI images will be repeated within the same day for consistency check and after three weeks to study temporal variability. The reactivity of the airways will establish the treatment order, with the most problematic airways to be treated in the first BT session (not to exceed six).
1652975|NCT01832363|Other|Standard treatment sequence for BT (control)|Patients undergoing standard BT procedure will have HXe MRI performed at time intervals similar to HXe MRI guided BT patients. While HXe images will not be used for guiding the sequence for airways to receive the BT treatment, metrics extracted from HXe images will be compared with clinically accepted asthma severity metrics (spirometry and asthma questionnaires) to assess HXe MRI as a biomarker for asthma severity.
1652976|NCT01832350|Drug|Nuedexta (20/10)|Drug: Nuedexta (20/10) administered orally, two times a day, every 12 hours, during a 26-week period.
1652977|NCT01832337|Procedure|Limb remote ischemic preconditioning (LRIP)|Limb remote ischemic preconditioning (LRIP) consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
1652978|NCT01832311|Drug|Ketorolac|Patients (both non-diabetic and diabetic) were randomized into subgroups receiving topical nonsteroidal anti-inflammatory drug (NSAID) ketorolac 0.5%, dosed 4 times a day, starting 3-7 days before surgery and ending 4-5 weeks after surgery respectively, and into subgroups not receiving NSAID.
1652979|NCT01832298|Drug|Simmitecan Hydrochloride for Injection|Either at 12.5 mg, 25 mg、50 mg、80 mg、120 mg、160 mg、200 mg
1652980|NCT01832285|Drug|fluvoxamine|100mg/day, PO(in the mouth) each day during 6 weeks
1652981|NCT01832272|Procedure|Reinflation after early tourniquet deflation|The tourniquet is released after cement implant fixation, and then reinflated, once arterial bleeding was controlled
1652982|NCT01832259|Drug|Pazopanib|Pazopanib, 800 mg, orally daily for 28 days prior to radical prostatectomy.
1652983|NCT01832259|Other|Placebo|Placebo tablet orally, daily for 28 days prior to radical prostatectomy.
2012999|NCT01246102|Drug|AT13387|Treatment will be administered as a 1-hour IV infusion on 2 consecutive days of every week for 3 weeks, followed by a 1-week period without drug administration.
2013000|NCT01246336|Other|collection of exhaled breath|no intervention
2013001|NCT01243762|Drug|dalotuzumab|Administered intravenously (IV) once weekly in 28-day cycles for a maximum of 6 months of study therapy
1652987|NCT01832194|Drug|Botox|
1652988|NCT01832168|Procedure|Robotic Assisted Laparoscopic Prostatectomy|Robotic Assisted Laparoscopic Prostatectomy with nerve-sparing technique
1652989|NCT01832168|Other|Application of Absorbable Hemostat|Application of Surgicel® SNoW Absorbable Hemostat by Johnson and Johnson on the neurovascular bundle after removal of the cancerous prostate.
1652990|NCT01832168|Other|Application of dehydrated human amniotic membrane|Application of dehydrated human amniotic membrane (DHAM) on the neurovascular bundle after removal of the cancerous prostate.
1652991|NCT01832155|Behavioral|Hatha yoga|Hatha yoga poses that were specifically designed by a group of yoga experts for older adults with knee osteoarthritis. Program included physical poses and sequence that focus on strengthening the lower extremities, and relaxation techniques.
1652992|NCT01832155|Behavioral|Hatha Yoga|The same intervention was provided to the wait-list control group at the end of 8 weeks when the intervention completed their intervention classes.
1652993|NCT01832129|Drug|Oral administration of vitamin B12|Daily high dose oral vitamin B12 (1mg) will be administered over 4 weeks. The patients adherence to this regimen will be monitored with an electronic punch card.
1652994|NCT01832129|Drug|i.m. injection of vitamin B12|Intramuscular injections of 1 mg vitamin B12 will be performed at days 7, 14, and 21.
1652995|NCT01832116|Drug|89Zr-MMOT0530A|Injection of 89Zr-MMOT0530A followed by 2 or 3 PET scans at different time points
1652996|NCT01832103|Drug|MK-7145|
1652997|NCT01832077|Device|90 D|rural doctors exam eye fundus by 90 D
1652998|NCT01832077|Device|fundus camera and grader|taking fundus pictures and graded by graders in ZOC
1652999|NCT01832064|Behavioral|Mailed Chronic Disease Self-Management Program|materials are mailed to participants
1653000|NCT01832051|Drug|89Zr-trastuzumab injection|
1653001|NCT01832038|Drug|Lacosamide|"Strength: Lacosamide (LCM) 50 mg, LCM 100 mg
Formulation: Tablet
Frequency: twice daily during the study period (until the date of approval)
At the completion of EP0008 [NCT01710657], all subjects who choose to enroll in EP0009 will be taking a dose of Lacosamide 200 mg/day. At the beginning of EP0009, the investigator may maintain the LCM dose or increase or decrease the dose. During the Treatment Period, the investigator will be allowed to increase or decrease the dose of LCM to optimize tolerability and seizure reduction. The LCM dose may be decreased to 100 mg/day or increased, no faster than 100 mg/day per week, up to 400 mg/day."
2013002|NCT01243762|Drug|MK-0752|Administered orally (PO) weekly in 28-day cycles for a maximum of 6 months of study therapy
2013003|NCT01243762|Drug|ridaforolimus|Administered PO daily for 5 consecutive days per week in 28-day cycles for a maximum of 6 months of study therapy
2013004|NCT01243762|Drug|MK-2206|Administered PO weekly in 28-day cycles for a maximum of 6 months of study therapy
1653002|NCT01832025|Procedure|internal maxillary sinus floor elevation technique|The internal lift procedure uses a drilling instrument (a drill that cuts through bone) to break through the bone for where the implant will later go. This creates an opening in the necessary area to allow more bone material to be added, which will move the sinus up and allow for the implant to be securely placed.
1653003|NCT01832025|Procedure|external maxillary sinus floor elevation technique|The external lift procedure involves cutting through the upper-most part of the gums to then cut through the bone to create an opening in the necessary area. The sinus will be manually lifted and the bone material will be added, which will allow for the implant to be securely placed.
1653004|NCT01832012|Other|Multimedia|AHA specific BLS refresher video, 7 minutes in length.
1653005|NCT01832012|Other|Hands-on practice|Hands-on BLS CPR practice on a Laerdal BLS manikin.
1653006|NCT01831999|Behavioral|RecoveryTrack - Extended Care (RT-E)|Counselors in this condition will be trained on the RecoveryTrack-Extended Care (RT-E) web-based monitoring system so that they are able to navigate the computer application, and implement the clinical content and procedures of the intervention. Counselors will conduct monitoring and feedback sessions using RT-E for clients newly admitted to IOP over a course of eight months. If the client is not attending treatment, counselors will attempt contact over the phone and via other methods. When contacted, the counselor will conduct the RT-E assessment and, as the situation warrants, provide support to reengage the client in treatment or support recovery in other ways mentioned. HIV risk will be assessed as well, with encouragement of testing and referral to HIV specialists as needed.
1653007|NCT01831986|Dietary Supplement|Pregnenolone and L-Theanine|Pregnenolone (50 mg/day) with L-theanine (400 mg/day)
1653008|NCT01831986|Other|Placebo|Caps
1653009|NCT01831973|Drug|Lipotecan|
1653010|NCT01831960|Drug|cortexolone 17α-propionate|
1653011|NCT01831947|Biological|Ranibizumab|
1653012|NCT01831934|Biological|Fluzone®|This vaccine is given intramuscularly, either the 2010-2011 or 2011-2012 vaccination was given as appropriate
1653013|NCT01831921|Behavioral|Lifestyle Weight Loss|Changing diet, physical activity, and self-regulatory behaviors to promote weight loss.
1653014|NCT01831921|Behavioral|Counseling|Individual nutrition counseling will be delivered by a registered dietitian.
1653015|NCT01831908|Other|Lifestyle counseling|People attending the community center will be provided with information on their health problems and will receive advise on how to improve blood pressure, glucose and cholesterol levels.
1653016|NCT01831895|Device|MobiusHD™|Implant that is placed in the carotid sinus to control hypertension.
1653017|NCT01831869|Drug|L-thyroxine|
1653018|NCT01831856|Drug|1g of F373280|Oral administration, one capsule each evening with dinner.
1653019|NCT01831856|Drug|Placebo|Oral administration, one capsule each evening with dinner.
2013005|NCT01243385|Drug|Metformin|Metformin Lifelong follow-up at a target dose of 2 x 1000 mg daily Until progression, unacceptable toxicity or refusal
2013006|NCT01235689|Biological|adalimumab|Subject will be assigned to this intervention during the study upon Success Criteria evaluations.
2013007|NCT01235689|Drug|prednisone|All subjects will start this intervention upon enrollment into the study except those that Early Randomize and meet protocol specific criteria. Depending on the evaluation criteria subjects may continue this therapy or stop it during the study.
1653023|NCT01831830|Behavioral|The Veterans' In-home Program|VIP realigns environmental demands to match Veterans' abilities through the modification of home environments, development of meaningful activities tailored to Veterans' strengths, training in the use of emotion-regulation strategies to address behavioral/interpersonal difficulties, and training in the use of cognitive strategies to compensate for cognitive impairments. In its family focus, VIP provides family members with education and training to understand and manage the Veterans' limitations.
1653024|NCT01831817|Drug|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Calcium sodium phosphosilicate dentifrice (5% w/w) and 1500 ppm F as sodium monofluorophosphate
1653025|NCT01831817|Drug|0% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|No calcium sodium phosphosilicate and 1500 ppm F as sodium monofluorophosphate
1653026|NCT01831817|Drug|Sodium monofluorophosphate dentifrice|Sodium monofluorophospate dentifrice (1000 ppm F)
1653027|NCT01831817|Drug|Sodium Fluoride dentifrice|Dentifrice containing 1100ppm F as sodium fluoride
1653028|NCT01831804|Drug|GSK1278863|White to off-white smooth ointment with unit dose strength of 0.05%w/w, 0.1%w/w, 0.5%w/w, 1.0%w/w for topical application as single or repeat doses.
1653029|NCT01831804|Drug|Placebo|White to off-white smooth ointment for topical application as single or repeat doses.
1653030|NCT01831791|Drug|Dutasteride 0.5 mg|Dutasteride will be supplied as soft gelatin capsules, containing 0.5 mg of Dutasteride and it will be packaged in high-density polyethylene (HDPE) bottles with plastic child-resistant closures.
2013008|NCT01235689|Drug|azathioprine|Subjects will start this therapy after moving through all other therapeutic options. This will be used in conjunction with adalimumab and once assigned to this intervention, the subject will continue taking it until they complete the study or discontinue.
2013009|NCT01234831|Device|nucleic acid amplification of nasal swab; nasal swab culture|Nasal swab is performed and analyzed using nucleic acid amplification to determine the presence or absence of MRSA DNA. One nasal swab is performed each day for three consecutive days during hospitalization.
1653035|NCT01831726|Drug|Dovitinib (TKI258)|Dovitinib (TKI) will be dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule.
1653036|NCT01831700|Drug|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
1653037|NCT01831700|Drug|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
1653038|NCT01831687|Drug|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
1653039|NCT01831687|Drug|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
1653040|NCT01831674|Drug|Metformin Hydrochloride Extended-Release Tablets USP 750|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
1653041|NCT01831674|Drug|GLUCOPHAGE®XR tablet 750 mg|GLUCOPHAGE®XR 750 mg once a day
1653042|NCT01831661|Drug|Metformin Hydrochloride Extended-Release Tablets USP 750 mg|Metformin Hydrochloride Extended-Release Tablets 750 mg once a day
2013010|NCT01234831|Other|Nasal swab culture|Nasal swabs are obtained if the clinician caring for the patient identifies the patient as eligible to be screened for colonization. An algorithm for screening eligible patients is available electronically as part of the patient's standard medical record to the clinicians providing care.
2013011|NCT01224925|Procedure|direct pulp capping over carious exposure|Dycal: covered with Fuji IX
1653048|NCT01831622|Drug|Ritalin|On one of the two test-dates the patient participant is administered methylphenidate, in the dose prescribed by the patients doctor.
1653049|NCT01831622|Drug|Placebo|On one of the test-dates the patient participants are administered a sugar pill, matching their prescribes medical dose.
1653050|NCT01831596|Device|ciSNaP|
1653051|NCT01831583|Device|Measurement of PPG waveforms|The ViSi Vital Signs Monitor will measure PPG waveforms for 4 hours.
1653052|NCT01831583|Device|Measurement of Pulse Arrival Time (PAT)|The ViSi Vital Signs Monitor will measure PAT waveforms for 4 hours.
1653053|NCT01831570|Other|GENETIC and radiographs|GENETIC : Blood sample for genetic analysis will be performed at inclusion in order to built a DNA collection OTHER: Serum samples will be performed at inclusion M0, M36 and M72 for serum biomarkers assessment OTHER : These radiographs will be performed at M0, M36 and M72
1653054|NCT01831557|Other|Blood samples will be taken for gene sequencing|
2013012|NCT01224925|Procedure|Direct pulp capping|WMTA capping over exposed pulp, wet pellet, FujiIX
1653056|NCT01831531|Drug|S-1|S-1 40 mg (BSA ≤ 1.6 m2) or 50 mg (BSA >1.6 m2) p.o bid d1-28
1653057|NCT01831531|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
1653058|NCT01831518|Device|CRT Implant|
1653059|NCT01831518|Device|Body Surface ECG Mapping|
1653060|NCT01831505|Drug|Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them|
1653061|NCT01831492|Device|zeolite + dolomite|Given for 12 weeks, after a 4 weeks wash- out of all supplements/drugs
1653062|NCT01831492|Device|cellulose|given for 14 weeks
1653063|NCT01831479|Drug|Rosuvastatin|Single administration of rosuvastatin 20mg tablet QD for 7 consecutive days
1653064|NCT01831479|Drug|Olmesartan|Single administration of olmesartan 40mg tablet QD for 7 consecutive days
1653065|NCT01831479|Drug|Rosuvastatin and olmesartan|Co-administration of rosuvastatin 20mg tablet and and olmesartan 40mg tablet QD for 7 consecutive days
1653066|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g BID (twice daily) for 12 weeks
1653067|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g BID (twice daily) for 12 weeks
1653068|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) BID (twice daily) for 12 weeks
1653069|NCT01831466|Drug|tofacitinib ointment 20 mg/g|tofacitinib ointment 20 mg/g QD (once daily) for 12 weeks
1653070|NCT01831466|Drug|tofacitinib ointment 10 mg/g|tofacitinib ointment 10 mg/g QD (once daily) for 12 weeks
1653071|NCT01831466|Drug|placebo ointment (vehicle)|placebo ointment (vehicle) QD (once daily) for 12 weeks
1653072|NCT01831453|Drug|omega-3|polyunsaturated fatty acids(PUFAs) 1 gram three times per day for 6 months
1653073|NCT01831453|Drug|placebo|soft gelatinous capsules filled with isopropylmyristate oil
1653074|NCT01831440|Behavioral|medicine combined CBT|medicine：Clinical routine antidepressant treatment CBT：During the treatment period，weekly for 8 weeks，and monthly for the maintenance phase.Therapists receive group supervision monthly.
1653075|NCT01831440|Drug|medicine|Participants receive only clinical routine antidepressant treatment,Which include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
1653076|NCT01831427|Drug|GS-5745|GS-5745 administered by intravenous infusion or subcutaneous injection
1653077|NCT01831427|Drug|Placebo to match GS-5745|Placebo to match GS-5745 administered by intravenous infusion
1653078|NCT01831414|Other|Water immersion at cervical level|balneotherapy session of spinal cord patients with a Water immersion at cervical level
1653079|NCT01831414|Other|Water immersion at xyphoid level|balneotherapy session of spinal cord patients with a Water immersion at xyphoid level
1653080|NCT01831401|Procedure|Operating table position 0° head down (Horizontal)|
1653081|NCT01831401|Procedure|Operating table position 7° head down.|
1653082|NCT01831401|Procedure|Operating table position Y° head down|Operating table position Y° head down (angle required to obtain vertical Transverse Pelvis Lines).
1653083|NCT01831401|Device|Standard straight acetabular component introducer without alignment guide.|
1653084|NCT01831401|Device|Modified 35° acetabular component introducer.|
1653085|NCT01831401|Device|Inclinometer-assisted acetabular component introducer.|
1653086|NCT01831388|Other|breathing techniques|"During all practice sessions, patients are seated in a chair, where they are guided through a set routine of various breathing techniques (detailed in Appendix A). No yoga poses are involved. There is no demand on the patient's physical condition and no risk of injury. The breath training program, with patients seated throughout, includes:
- an initial teaching session (approximately 30-minute) at main campus by an MSKCC Integrative Medicine Service yoga-breathing instructor; - twice daily,breathing exercises (each approximately 15-minute) for 6 weeks practiced by patients at home with supplied recorded audio instructions; - and weekly follow-up phone calls by research staff (+/- 3 days from day 7 of each week) to identify and manage problems and to determine compliance."
1653087|NCT01831388|Behavioral|Self-Administered Baseline and Transition Dyspnea Indexes|Patients are asked to complete baseline SAC-BDI/TDI questionnaires at the pulmonary clinic. Patients will return to the pulmonary clinic at about week 6 for SAC-BDI/TDI and tests, and to return the diary recording their home exercises. Resting and post-6MWT pulse oximetry, and Hospital Anxiety and Depression Scale (HADS) will be evaluated as well.
1653088|NCT01831375|Behavioral|Speak Up|Intervention group_treatment group
1653089|NCT01831375|Behavioral|Get connected|Participants will learn to be connected with social resources in the community.
1653090|NCT01831362|Behavioral|Mindfulness-Based Cognitive Therapy|
1653091|NCT01831362|Behavioral|Focused Awareness (FA)|
1653092|NCT01831362|Behavioral|Open- Monitoring|
1653095|NCT01831323|Drug|Mesalazine|Mesalazine
1653096|NCT01831323|Dietary Supplement|Psyllium|psyllium
1653097|NCT01831310|Dietary Supplement|Standard (Kabiven)|Parenteral nutrition provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
1653098|NCT01831310|Dietary Supplement|Standard-Glutamine|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. it was 0.3-0.4 g/kg/day for glutamine dipeptide (Dipeptiven) supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
1653099|NCT01831310|Dietary Supplement|Standard-Omega 3 fatty acid|Parenteral nutrition (Kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven)supplementation was 0.1-0.2 g/kg /day. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
1653100|NCT01831310|Dietary Supplement|Standard-glutamine-omega 3|Parenteral nutrition (kabiven) provided 25-30 kcal/kg/day energy and 0.15-0.20 g/kg/day nitrogen. The dose of omega 3 fatty acid (omegaven) supplementation was 0.1-0.2 g/kg /day and it was 0.3-0.4 g/kg/day for glutamine dipeptide (dipeptiven)supplementation. All nutrient substrates were mixed in 3 litre bags and infused in 24 h through a dedicated central venous line
1653101|NCT01831297|Device|measurement of blood pressure|measurement of pulse wave velocity
1653102|NCT01831284|Procedure|Sigmoidoscopy with biopsy|Sigmoidoscopy with biopsy
1653103|NCT01831271|Other|Prescribed physical activity|Prescribed physical activity is a tailored physical activity programme with monitoring of progress and a follow-up. Also includes interview: exploratory talk, commitment/decision, life style change, health promotion, evaluation of readiness for change, reflection, assessment of motivation, patient specific goal assessment, conclusion and plan for follow-up at 14 weeks. Patients are guided by the physiotherapist to increase their overall activity and strength with i.e. walking and other self-mediated activities and exercise.
1653104|NCT01831271|Other|Neck specific training|The active physiotherapy rehabilitation program consists of a standardised and structured physiotherapy program (twice a week) with medical exercise therapy and if needed vestibular rehabilitation. At the start of the intervention motivational interviewing will be included. Additionally once a week during the first 14 weeks of the program the physiotherapist informs the patient about physiology of pain, stress, exercise, breathing, relaxation, coping, pacing and ergonomics. All through the treatment program a cognitive approach from the physiotherapist according to theoretical behaviour change models will be used.
1653105|NCT01831258|Device|SensAwake On|
1653106|NCT01831258|Device|SensAwake Off|
2013013|NCT01223404|Drug|Nicotine|Nicotine patch, 7 mg / 24 hrs, one single administration
2013014|NCT01223404|Drug|Mecamylamine|Mecamylamine HCl, 7.5 mg p.o., one single administration
2013015|NCT01223404|Drug|Placebo|Placebo patch and placebo capsule (filler: methylcellulose)
2013016|NCT01217034|Drug|TACE with sorafenib|Sorafenib will be administrated at a dose of 400mg o.d. before the first TACE. After 2days drug rest, TACE will be conducted. Sorafenib will be resumed at a dose of 400mg o.d. from 3 days after TACE(the resumption day can be postponed until 21 days after TACE). When tolerability is confirmed at 1 week after resumption, the dose of sorafenib will be increased to 400mg b.i.d. When tumor increases, TACE will be repeated.
1653111|NCT01831206|Procedure|Collagen cross-linking|"Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.
Standard treatment arm will receive only standard medication."
1653112|NCT01831193|Drug|Curcumin|
1653113|NCT01831167|Other|dynamic light|
1653114|NCT01831154|Drug|Tight Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
1653115|NCT01831154|Drug|Conventional Glycemic|The insulin infusion consisted of 100 units of regular insulin in 100 ml of normal saline.
1653116|NCT01831154|Drug|Standard Glycemic|Insulin was Regular Insulin administered intravenous bolus.
1653117|NCT01831128|Device|ASV Treatment|
1653118|NCT01831102|Other|none- observational study|
2013017|NCT01217034|Procedure|TACE alone|TACE will be conducted at scheduled day. When tumor increases, TACE will be repeated.
1653120|NCT01831076|Drug|Exemestane|Given PO
1653121|NCT01831063|Behavioral|Simulation|The experimental group received a simulation based seizure teaching session in addition to the traditional seizure teaching
2013018|NCT01213758|Other|Measuring liver function by PET/CT|Measuring liver function by use of FDGal and PET/CT before, 1 month and 3 months after stereotactic radiotherapy for liver tumors
2013019|NCT01212900|Drug|Statin Drugs|LDL. Cholesterol
2013020|NCT01212900|Other|HMG-CoA Reductase Inhibitors|Reduction
2013021|NCT01212822|Biological|bevacizumab|Given IV
2013022|NCT01212822|Drug|oxaliplatin|Given IV
2013023|NCT01212822|Drug|leucovorin calcium|Given IV
2013024|NCT01212822|Drug|fluorouracil|Given IV
2013025|NCT01212822|Procedure|therapeutic conventional surgery|Undergo surgical resection
1653998|NCT01824472|Device|sham CPAP|Placebo for sleep apnea
2013026|NCT01212822|Other|laboratory biomarker analysis|Correlative studies
2013027|NCT01212679|Drug|nerve growth factor|The experimental group patients will receive NGF 20ug/d intranasally for 2 weeks.
2013028|NCT01212679|Drug|nomral saline|The Placebo Comparator group patients will receive nomral saline 20ug/d intranasally for 2 weeks.
2013029|NCT01210222|Biological|Trebananib|Given IV
2013030|NCT01209416|Drug|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
2013031|NCT01209416|Drug|Ghrelin|Ghrelin infusion 4.2 ng/kg/min throughout the investigation day
2013032|NCT01209416|Other|Placebo|placebo tablets or saline infusion
2013033|NCT01207310|Behavioral|smoking cessation counseling|two 60-minute face-to-face treatment sessions and three 20-minute follow-up contacts at weeks 2, 3, and 9
2013034|NCT01207310|Drug|Nicotine patch|8 weeks' worth of nicotine patches
2013035|NCT01207310|Device|alphanumeric pager|therapeutic messages to be delivered for three months
2013036|NCT01201070|Drug|antithrombin III|3000 IU bolus at the time of randomization vs the study group 1000 IU after 8 h (24 h G0) 1000 IU after 16 h (8 h G1) TOTAL 5000/UI 24h
1653128|NCT01831037|Other|Regression of fibrosis|Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (>50% of cases).
1653129|NCT01831037|Other|Specific risk factors related to hepatocellular carcinoma|Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.
1653130|NCT01831024|Device|Dignicap System|The DigniCap™ System consists of the digitized system for controlled scalp cooling (Digni C3) in conjunction with the soft, tight-fitting silicon cap (DigniCap™), the neoprene outer cap (DigniTherm™), and the liquid coolant (DigniCool). DIGNISTICK™ is prepared to log data from a treatment when inserted in the slot. DIGNICARD™ is a key card which has to be inserted in order to start a treatment.
1653131|NCT01831011|Drug|mildronate injection|
1653132|NCT01831011|Drug|cinepazide maleate injection|
1653133|NCT01831011|Drug|aspirin|
1653134|NCT01830985|Drug|VX-509|VX-509 dose may be increased every 8 weeks in a stepwise fashion from 100 to 150 mg and from 150 to 200 mg, as needed (determined by ongoing disease activity by CDAI)
1653135|NCT01830972|Drug|6g/day SA-ER tablets|
1653136|NCT01830972|Drug|6g/day SA-ER tablets and 6g/day SA-IR capsules|
1653137|NCT01830972|Drug|12g/day SA-ER|
1653138|NCT01830959|Drug|Roflumilast|Roflumilast
1653139|NCT01830959|Drug|Placebo|Placebo one a day
1653140|NCT01830946|Other|Whey Protein|Whey protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
1653141|NCT01830946|Other|Combined Resistance and High-Intensity Interval training|Completed 3 d/wk for 4 wks (2 d of Resistance Training (RT) and 1 d of High-Intensity Interval Training (HITT)). RT exercises were chest press, seated row,leg press, shoulder press, leg extension, and leg curl (3 total sets: 2 sets of 10 repetitions and a 3rd set to muscular exhaustion with a load equaling 75-85% of 1-Repetition Maximum(RM)). All exercises and sets were separated by 90-120 sec of rest. HIIT training was completed on commerical cardiovascular equipment and requires subjects to rate their perceived exertion on a scale from 1 to 10 (1= resting quietly, 5= a warm-up level, 10= an all-out exertion). Subjects warmed-up for 2 min at level 5 and increased their exertion each min for 3 min until level 9 is perceived and then recover at level 6 for 1 min. This pattern was repeated 4 times, where the 4th cycle subjects increased their last min of exertion to level 10, followed by 1-min recovery at the initial warm-up level 5.
1653142|NCT01830946|Other|Casein Protein|Casein protein will be consumed every night of the week as the last food or caloric beverage prior to sleep in the evening at least two hours after dinner but no more than 30 minutes before bed.
1653143|NCT01830933|Other|BreastCARE|Physician Report. At the time of an individual participant's visit to her primary care physician and her completion of the assessment tool, her physician will receive a physician report. The physician report is designed to facilitate communication about breast cancer risk during the primary care visit and to provide tailored risk reduction recommendations.
1653144|NCT01830920|Drug|THR-184|THR-184 is a synthetic oligopeptide administered intravenously.
1653145|NCT01830920|Drug|Placebo|A normal saline solution identical in appearance to the active drug solution
1653146|NCT01830907|Dietary Supplement|carbohydrates|
1653147|NCT01830907|Dietary Supplement|vitamins|
1653148|NCT01830894|Device|MRI|3 MRI on different times during the study for each arm.
1653149|NCT01830881|Drug|Midazolam|5 mL oral midazolam oral syrup (2 mg/mL) 30-60 minutes prior to procedure
1653150|NCT01830881|Drug|Ibuprofen|800 mg oral ibuprofen 30-60 minutes prior to procedure
1653151|NCT01830881|Other|Placebo-Cherry syrup|5 mL oral placebo-cherry syrup 30-60 minutes prior to procedure
1653152|NCT01830881|Drug|Lidocaine|injection of 20 mL 1% lidocaine without epinephrine
1653153|NCT01830868|Drug|Zonisamide tablets|The recommended initial daily dose is 50 mg in two divided doses. After one week the dose may be increased to 100 mg daily and thereafter the dose may be increased at weekly intervals, in increments of up to 100 mg. Doses of 300 mg to 500 mg per day have been shown to be effective, though some patients, especially those not taking CYP3A4 (cytochrome P450)-inducing agents, may respond to lower doses.
1653154|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 1)
1653155|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 2)
1653156|NCT01830855|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months (lot 3)
1653157|NCT01830855|Biological|Havrix (HAV)|0.5 mL dose or 1.0 mL dose dependent on age given at month 0 and 6.
1653158|NCT01830855|Biological|Saline|0.5 mL dose of sterile normal saline for injection.
2013037|NCT01200355|Drug|micafungin|Micafungin 100 mg intravenously once daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
2013038|NCT01200355|Drug|posaconazole|Posaconazole 400 mg orally twice daily. Randomized treatment will be initiated 24-48 h after completion of the last dose of chemotherapy.
2013039|NCT01198158|Biological|Bevacizumab|Given IV
1653163|NCT01830829|Drug|Jalyn|study drug
1653164|NCT01830829|Drug|Placebo|Placebo
1653165|NCT01830816|Drug|ixazomib (MLN9708)|
1653166|NCT01830790|Drug|Sildenafil citrate|Single dose of 100mg Sildenafil citrate
1653167|NCT01830777|Drug|Brentuximab Vedotin|Intravenously on Day 1 during re-induction therapy. Intravenously every 21 days during maintenance therapy
1653168|NCT01830777|Drug|Mitoxantrone|Intravenously on Days 3-7 of re-induction therapy.
1653169|NCT01830777|Drug|Etoposide|Intravenously on Days 3-7 of re-induction therapy.
1653170|NCT01830777|Drug|Cytarabine|Intravenously on Days 3-7 of re-induction therapy.
1653171|NCT01830764|Drug|Red Light (PDT)|LTS, 0.3% applied topically followed by red light dose (75 J/cm2 or 150 J/cm2)
1653264|NCT01829997|Device|nanOss Bioactive 3D BVF|nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
1653172|NCT01830751|Other|Restrained Sitting Treatment|Training in avoidance of trunk flexion, with the use of a tall backrest with lumbar support to which the participant straps themselves. Participants are taught to strap into the backrest while while seated in a chair, and with hips and knees bent at right angles, for one hour at the appointed time of day.
1653173|NCT01830738|Procedure|Single-port, peri-umbilical hysterectomy|Patients in this arm have a hysterectomy via a single-port peri-umbilical laparoscopic surgical technique.
1653174|NCT01830738|Procedure|Multi-port hysterectomy|Patients in this arm have a hysterectomy via a conventional multi-port laparoscopic surgical technique.
1653175|NCT01830712|Drug|eptacog alfa (activated)|A review of retrospectively longitudinal data gathered in the routine follow-up from a subset of patients who underwent EOS in studies F7HAEM/USA/3/USA and F7HAEM/USA/4/USA (NCT01561391). Data will be compiled, analysed, and reported in aggregate form.
1653176|NCT01830699|Drug|Rilonacept|160 mg intra-bursal once
1653177|NCT01830699|Drug|Corticosteroid|2 cc (40 mg/mL) triamcinolone intra-bursal once
1653178|NCT01830686|Other|Sugarcane bagasse|One brownie containing 10 g of sugarcane bagasse and 2 cookies containing 3 g of sugarcane bagasse (total of 13 g of sugarcane bagasse per day)
1653179|NCT01830686|Other|Non-caloric, non-fermentable fiber|One brownie containing 10 g of fiber and 2 cookies containing 3 g of fiber (total of 13 g of non-caloric, non-fermentable fiber per day)
1653180|NCT01830686|Other|Minimal fiber|One brownie containing 3g of fiber and two cookies containing 1g of fiber (total of 4 g of dietary fiber per day)
1653181|NCT01830660|Drug|Hetrombopag Olamine Tablets|
1653182|NCT01830660|Drug|placebo|
1653183|NCT01830634|Behavioral|Theraband with strengthening and stretching exercise|
1653184|NCT01830621|Drug|BBI608|
1653185|NCT01830621|Drug|Placebo|
1653186|NCT01830621|Other|Best Supportive Care|
1653187|NCT01830595|Drug|Recombinant Lactoferrin|
1653188|NCT01830595|Drug|Placebo|
1653189|NCT01830582|Procedure|Advanced MR Imaging|
1653190|NCT01830569|Behavioral|The EBMeDS system|"The EBMeDS system receives structured patient data from the electronic medical records in HealthOne and returns reminders, therapeutic suggestions and diagnosis-specific links to guidelines. Electronic forms and calculators (e.g. a calculator for glomerular filtration) are integrated in the system.
The original EBMeDS system was developed by Duodecim in Finland and covers a full spectrum of all clinical areas. Relevant reminders in all clinical areas are shown to the physicians in the intervention group."
1653191|NCT01830569|Other|Evidence Linker|The Evidence Linker is already integrated in Belgian routine practice since 2012 and could be considered as part of the usual care process. When entering a diagnosis coded in ICPC, relevant clinical practice guidelines are retrieved by the Evidence Linker and could by consulted on the initiative of the family physician.
1653192|NCT01830556|Drug|Cetuximab|Group A:Day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes Day 1 Cisplatin 100mg/m2 or Carboplatin AUC 5 day 1-4 5-Fluorouracil 1000 mg/m2 iv 24 h Group B day 1 Cetuximab 400 mg/m2 iv 120 minutes Day 8 and 15 Cetuximab 250 mg/m2 iv 60 minutes day 1 Paclitaxel 175 mg/m2 day 1 Carboplatin AUC 5 treatment for 6 cycles thereafter day 1 Cetuximab 500 mg/m2 every second week treatment until progress or unacceptable toxicity
1653193|NCT01830543|Drug|rivaroxaban 2.5 mg|One 2.5 mg tablet twice daily for up to twelve months
1653194|NCT01830543|Drug|rivaroxaban 15 mg|One 15 mg tablet once daily for up to twelve months
1653195|NCT01830543|Drug|rivaroxaban 10 mg|One 10 mg tablet once daily for up to twelve months
1653196|NCT01830543|Drug|aspirin (ASA)|Low-dose aspirin tablet once daily for twelve months
1653197|NCT01830543|Drug|vitamin K antagonist (VKA)|Dose-adjusted VKA tablet (target International Normalized Ratio (INR) 2.0 to 3.0) once daily for twelve months
1653198|NCT01830543|Drug|clopidogrel|One 75 mg tablet once daily for up to twelve months
1653199|NCT01830543|Drug|prasugrel|One 10 mg tablet once daily for up to twelve months
1653200|NCT01830543|Drug|ticagrelor|One 90 mg tablet twice daily for up to twelve months
1653201|NCT01830530|Drug|Telmisartan|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
1653202|NCT01830530|Drug|Nifedipine|Subjects treated with telmisartan 80 mg (1 capsule daily in the morning) plus nifedipine slow release 30 mg (1 capsule daily in the morning) combination
1653203|NCT01830530|Drug|placebo|two tablets daily in the morning
1653204|NCT01830517|Drug|Amlodipine, Losartan|
1653205|NCT01830504|Drug|BKM120|"BKM 120, 100 mg/day continuously. For patients who do not tolerate the protocol-specified dosing schedule, dose adjustments are permitted in order to allow the patient to continue the study treatment. Dose level -1 : 80 mg/day continuously, Dose level -2 : 80 mg/day 5 days out of 7. All dose modifications, interruptions or discontinuations must be based on the worst preceding toxicity as graded by the NCI Clinical Toxicity Criteria (NCI-CTCAE version 4.03.
A change from continuous schedule to intermittent (5 days out of 7) must be preceded by 2 days without treatment."
1653206|NCT01830491|Drug|Clopidogrel|
1653207|NCT01830491|Drug|aspirin 100mg|
2013040|NCT01198158|Drug|Everolimus|Given PO
2013041|NCT01198158|Other|Laboratory Biomarker Analysis|Correlative studies
1653210|NCT01830465|Drug|Bortezomib (VELCADE)|1,3 mg/m2, intravenous bolus (over 3-5 seconds) on days 1, 4, 8, 11 of each 21 day cycle. Number of Cycles: 6.
1653211|NCT01830465|Drug|Rituximab|375 mg/m2 as intravenous infusion on day 1 of cycle III, IV, V, VI. Two additional doses will be administered at week + 3 and week + 6 after cycle VI.
1653212|NCT01830452|Procedure|Self-fixating Parietex Progrip Mesh|Lichtenstein hernioplasty using a self fixating Parietex Progrip mesh not needing any fixating devices
1653213|NCT01830439|Drug|PA-824 200mg|Two single administrations of 200mg PA-824 each administered by four 50mg tablets, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
1653214|NCT01830439|Drug|PA-824 50mg|Two single administrations of 50mg PA-824 each administered by one 50mg tablet, one administered in the fed state and one administered in the fasted state. The two administrations were separated by 8 days.
1653426|NCT01828684|Other|Therapeutic Lens Coating|Subjects will wear a therapeutic lens coating for 2 weeks.
2013042|NCT01198158|Other|Pharmacological Study|Correlative studies
2013043|NCT01196390|Drug|Carboplatin|Given IV
1653216|NCT01830387|Device|Polymetric clips|The study team will prospectively enroll subjects with a diagnosis of appendicitis who are scheduled for laparoscopic appendectomy to have Hem-o-Lok® clips used for closure of the appendiceal stump.
1653217|NCT01830387|Other|Endoscopic Staplers|The study team will retrospectively identify patients who have undergone laparoscopic appendectomy by performing a database search. The operative notes will be reviewed for these patients to select patients who underwent ligation of the appendix with an endoscopic stapler.
1653218|NCT01830361|Drug|midostaurin (PKC412)|Midostaurin 50 mg (2 capsules) twice daily days 8-21 in induction II + consolidation I-III; maintenance treatment twice daily continuously for 12 months
1653219|NCT01830348|Drug|DSC127|DSC127 0.03%, daily topical application to diabetic foot ulcer for a period of up to 28 days or until ulcer closure, whichever is sooner
1653220|NCT01830348|Drug|placebo vehicle gel|
1653221|NCT01830335|Drug|Indomethacin|
1653222|NCT01830335|Drug|Placebo|
1653223|NCT01830322|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. CPI-613 will be given 2x weekly, administered on Days 1 and 4 of each of the 3 treatment weeks, followed by a week of rest. The dose of CPI-613 will be 3,000 mg/m2 infused IV over 2 hours (this is approximate maximum tolerated dosing [MTD]), via a central venous catheter with D5W running at a rate of about 125-150 mL/hr.
1653224|NCT01830322|Drug|Gemcitabine|
1653225|NCT01830322|Drug|Any non-gemcitabine chemotherapies or best supportive care|
1653226|NCT01830309|Drug|CJ-12420 200mg|"Period1: CJ-12420 200mg fed condition Period2: CJ-12420 200mg fasting condition
Period1: CJ-12420 200mg fasting condition Period2: CJ-12420 200mg fed condition"
1653227|NCT01830296|Drug|Remifentanil+morphine|Morphine, Remifentanil+Morphine
1653228|NCT01830283|Biological|varicella vaccine|The providers would get varicella vaccine
1653229|NCT01830270|Drug|Epirubicin|8 weekly cycles of chemotherapy with epirubicin (50 mg/m2)associated with cisplatin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
1653230|NCT01830270|Drug|Cisplatin|8 weekly cycles of chemotherapy with cisplatin (30 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
1653231|NCT01830270|Drug|Paclitaxel|8 weekly cycles of chemotherapy with paclitaxel (90 mg/m2) associated with epirubicin and paclitaxel with a break of one week without chemotherapy between cycle 4 and 5.
1653232|NCT01830270|Procedure|gastric surgery|surgery will be scheduled within 4-6 weeks after the end of the last cycle of chemotherapy.
1653233|NCT01830257|Other|sending message|Sending the suggestive short message
1653234|NCT01830244|Drug|Nab-Paclitaxel|Nab-Paclitaxel- 125 mg/m2 days 1,8, 15 for 12 weeks
1653235|NCT01830231|Drug|Cabazitaxel|Cabazitaxel, to be given intravenously once every 21 days, starting at a dose of 25 mg/m2 as a 1-hour intravenous infusion.
1653236|NCT01830231|Drug|Vinflunine|"Vinflunine, to be given intravenously once every 21 days, as a 20 minute intravenous infusion, starting at a dose of:
320 mg/m2 in patients aged ≤75 years with PS 0 and no prior pelvic radiation, and of
280 mg/m2 in patients aged >75 - ≤80 years or with PS 1 or prior pelvic radiation,
250 mg/m2 in patients aged >80 years."
1653237|NCT01830218|Procedure|Obstetric anesthesia and analgesia|All anesthesia procedures during labor: labor analgesia, anesthesia for Cesarean section, anesthesia for procedures in third stage of labor
1653238|NCT01830205|Drug|Daclatasvir|
1653239|NCT01830192|Other|Training set|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
1653240|NCT01830192|Other|VERIFICATION SET|We evaluate the clinical, ultrasound and laboratory features to predict endometrial cancer disease preoperative
1653241|NCT01830166|Radiation|Low Dose Radiation Focal Brachytherapy|Low Dose Radiation Focal Brachytherapy
1653242|NCT01830153|Drug|RAD001|
1653243|NCT01830140|Drug|Bimatoprost 0.01%|Bimatoprost 0.01% (LUMIGAN® 0.01%) administered each evening in both eyes for 6 weeks.
1653244|NCT01830140|Drug|Bimatoprost 0.03%|Bimatoprost 0.03% (LUMIGAN® 0.03%) administered each evening in both eyes for 6 weeks.
1653245|NCT01830127|Drug|Ribavirin|24 Weeks
1653246|NCT01830127|Drug|BI 207127 high dose|24 Weeks
1653247|NCT01830127|Drug|Faldaprevir|24 Weeks
1653248|NCT01830127|Drug|Ribavirin|24 Weeks
1653249|NCT01830127|Drug|BI 207127 low dose|24 Weeks
1653250|NCT01830127|Drug|Faldaprevir|24 Weeks
1653251|NCT01830114|Behavioral|Web app|The Checkup and Choices web application
1653252|NCT01830101|Drug|TMZ plus concurrent re-irradiation|
1653253|NCT01830101|Drug|Temozolomide|low-dose temozolomide daily for one year
1653254|NCT01830088|Behavioral|Attachment Based Family Therapy|Attachment-Based Family Therapy (ABFT) is is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors
1653255|NCT01830088|Behavioral|Enhanced Usual Care|No attempt is made to control any aspect of the enhanced usual care except for pre-scheduled assessment plan
1653256|NCT01830075|Behavioral|Consultations|The patients receive two consultations with a spiritual counsellor. In these consultations life evens and life goals are discussed.
1653257|NCT01830062|Other|NIRS|Near infrared spectroscopy of at least 2 major epicardial vessels
1653258|NCT01830062|Other|CACS|Coronary artery calcium score assessed by multi-slice computed tomography
1653259|NCT01830049|Other|Take blood|
1653260|NCT01830023|Device|cardiac ultrasound examination|cardiac ultrasound examination to examine the vitality
1653261|NCT01830010|Drug|Study Part 1: KRP203|All subjects will receive KRP203 for 111 days
1653262|NCT01830010|Drug|Study Part 2: KRP203 lower dose|
1653263|NCT01830010|Drug|Study Part 2: KRP203 higher dose|
2013044|NCT01196390|Other|Laboratory Biomarker Analysis|Correlative studies
2013045|NCT01196390|Drug|Paclitaxel|Given IV
2013046|NCT01196390|Other|Quality-of-Life Assessment|Ancillary studies
2013047|NCT01196390|Radiation|Radiation Therapy|Undergo radiation therapy
1653265|NCT01829984|Other|Verbal and Written Instruction|"Pre-teaching Evaluation: Patient
Pre-teaching Evaluation: Caregiver
o To be completed immediately before the teaching. Administered by the nurse who will provide the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection.
Post-teaching Evaluation: Patient Post-teaching Evaluation: Caregiver To be completed immediately after the teaching. Administered by the nurse who provided the teaching. The form utilized will depend on if the patient or caregiver will be administering the injection."
1653266|NCT01829984|Other|Verbal and Written Plus Simulation|"Post-injection Evaluation: Patient
Post-injection Evaluation: Caregiver
o To be completed after the injection is administered (outside of MSKCC) by the patient or caregiver. The form utilized will depend on if the patient or caregiver has administered the injection. They will return this evaluation at the patient's next visit (2 weeks later).
Nurse Evaluation: Control
Nurse Evaluation: Model o To be completed immediately following the completion of the teaching by the nurse. The form utilized will depend on if the teaching was part of the control or intervention phase of the study."
1653267|NCT01829971|Drug|MRX34|micro RNA therapy
1653268|NCT01829958|Drug|rituximab|
1653269|NCT01829958|Drug|prednisone|
1653270|NCT01829958|Behavioral|Geriatric Assessment|
1653271|NCT01829932|Dietary Supplement|Factor Altered Diet|
1653272|NCT01829919|Drug|Brisdelle (paroxetine mesylate)|All subjects will receive Brisdelle (paroxetine mesylate) Capsules 7.5 mg, first as a single dose and then, following a five-day wash-out period, once per day for 14 days.
1653273|NCT01829906|Behavioral|Multidisciplinary outpatient programme|
1653274|NCT01829906|Behavioral|Inpatient lifestyle programme|
1653275|NCT01829893|Drug|In combination of 0.2mg finasteride and 5mg tamsulosin|oral medication with 240 mL water
1653276|NCT01829893|Drug|GL2701 capsule|oral medication with 240 mL water
1653277|NCT01829867|Drug|sNN0031|
1653278|NCT01829841|Drug|Famitinib|Famitinib 25 mg p.o. qd
1653279|NCT01829841|Drug|Sunitinib|Sunitinib 50 mg p.o. qd
1653280|NCT01829828|Behavioral|No intervention|This is an observational study with no investigational drug administered.
1653281|NCT01829815|Behavioral|Parents Make the Difference|"The intervention, entitled Parents Make the Difference, will include 10 sessions. Parents will attend in a group, and sessions will include didactic information, guided discussion, and modeling and practice of new skills. All sessions focus on positive parenting skills, with specific skills across three domains that have strong links to child outcomes: (a) positive, non-physical behavior management strategies, (b) strategies for promoting children's early learning, and (c) strategies, primarily use of bed nets, for preventing malaria in children."
1653282|NCT01829802|Drug|Ritonavir boosted Atazanavir|Ritonavir boosted Atazanavir 300/100 mg QD in combination with other drugs
1653283|NCT01829802|Drug|Raltegravir|Raltegravir 400 BID in combination with Ritonavir boosted Atazanavir 300/100 mg QD during 48 weeks
1653284|NCT01829802|Drug|TDF/FTC (or 3TC)|Fixed dose combination of Tenofovir 300 mg/Emtricitabine 200 mg or Tenofovir 300 mg/Lamivudine 300 mg plus Ritonavir Boosted Atazanavir 300/100mg given once a day
1653285|NCT01829789|Behavioral|Group Community Reinforcement Training for Parents|
1653286|NCT01829789|Behavioral|Individual Community Reinforcement Training for Parents|
1653287|NCT01829776|Behavioral|Educational intervention|This is an 8-week comprehensive fall prevention exercise and education program, with one 2-hour session each week, for people with MS, adapted from a similar program for older adults.
1653288|NCT01829763|Drug|injection botox|
1653289|NCT01829750|Genetic|Cardiac progenitor cell infusion|"(Stage 1) Cardiac progenitor cell infusion in patients who assigned as active comparator group
(Stage 2) Rescuing transplantation is applicable in patients, along with their written consent, 4 months after palliations who were allocated as control group in stage 1."
1653290|NCT01829711|Drug|moxetumomab pasudotox|
1653291|NCT01829711|Drug|IV Bag Protectant for Moxetumomab pasudotox|
1653292|NCT01829698|Drug|tauroursodeoxycholic|Testing arm: tauroursodeoxycholic acid, 750mg , divided into three times, each time 250mg, oral administration, after meal
1653293|NCT01829698|Drug|ursodeoxycholic acid|ursodeoxycholic acid, 750mg ,divided into three times, each time 250mg, oral administration, after meal
1653294|NCT01829685|Drug|Entecavir, Adefovir|
1653295|NCT01829672|Radiation|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s, i.v.
1x 40ml Ultravist (370mg J/ml)3-5ml/s i.v. Contrast agent administration"
1653296|NCT01829659|Drug|Ticagrelor|
1653297|NCT01829646|Other|functional MRI|Functional MRI on day 22 of the chemoradiotherapy treatment. Parameters of these images will be later on correlated with outcome.
1653298|NCT01829646|Other|Hypoxia gene expression profile.|Tumour biopsies will be obtained as part of the staging procedure (standard). On this biopsies we will conduct a hypoxia gene expression profile (15 genes on PCR that can be analyzed individually or as a group through one binary variable). Hypoxia will be a parameter in our prognostic/predictive model.
1653299|NCT01829646|Other|Functional MRI before start of treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with outcome.
1653300|NCT01829633|Procedure|Physiotherapy|Shoulder physiotherapy with exercises
1653301|NCT01829620|Behavioral|TAU|This is standard outpatient mental health care that is routinely provided in study site outpatient clinics.
1653302|NCT01829620|Behavioral|CCVT+TAU|"Participants in the CCVT + TAU condition will receive caring texts at 1 day, 1 week, 1, 2, 3, 4, 6, 8, 10, & 12 months, and on their birthday. Text messages will indicate a general concern for the individual and a link to a website with general resources including behavioral health and crisis services.
Participants in both conditions will continue to receive usual behavioral health care according to standard operating procedures."
1653303|NCT01829607|Other|Functional electrical stimulation of peripheral muscles|
1653343|NCT01829334|Other|Sodium fluoride varnish|Topical application of 5% sodium fluoride varnish onto pits and fissures of permanent first molars, repeated every 6 months
1653344|NCT01829334|Other|Silver fluoride solution|Topical application of 38% silver fluoride solution onto pits and fissures of permanent first molars, repeated every 12 months
1653345|NCT01829321|Drug|GLPG0974|1 capsule in the morning and 1 capsule in the evening with food during 28 days
1653304|NCT01829594|Other|Case management|Nurses and a physiotherapist (PT) worked as case managers (CM). The intervention lasted 12 months and comprised 4 dimensions. The first was traditional CM tasks: assessment, planning, monitoring, care coordination and evaluation. Home visits were made at least once a month. The second and third was general and specific information related to the participants' situation. The fourth part included aspects of continuity and safety. The PT also paid home visits and made an assessment regarding physical function and balance. The intervention consisted of multidimensional prevention of falls and/or consequences of falls, and supporting and motivating the participant to increased physical activity. When those in the control group had participated for 12 months they were offered the intervention.
1653305|NCT01829581|Other|no intervention, only descriptive data analysis|
1653306|NCT01829568|Drug|Ibrutinib|Given PO
1653307|NCT01829568|Other|Laboratory Biomarker Analysis|Correlative studies
1653308|NCT01829568|Drug|Lenalidomide|Given PO
1653309|NCT01829568|Other|Pharmacological Study|Correlative studies
1653310|NCT01829568|Biological|Rituximab|Given IV
1653311|NCT01829555|Behavioral|contingency management|Participants will receive a voucher for each self-monitored blood glucose test completed during the target testing window, and a bonus amount for each day that 4 tests fall within the testing windows and are separated by more than 2 hours.
1653312|NCT01829542|Dietary Supplement|Freeze-dried blueberry powder dissolved in water|Wild blueberry freeze-dried powder dissolved in water
1653313|NCT01829542|Dietary Supplement|Control|Macro- and micro-nutrient matched control in water
1653314|NCT01829529|Drug|Amoxicillin|Amoxicillin
1653315|NCT01829516|Drug|Oxytocin|Intranasal oxytocin
1653316|NCT01829516|Drug|Placebo|Intranasal placebo
1653317|NCT01829503|Drug|decitabine and cytarabine|
1653318|NCT01829503|Other|Supportive Care|blood product transfusions, antiemetic medications, antiviral and antifungal medications, empiric antibiotics
1653319|NCT01829490|Biological|ChAdOx1 85A|Intramuscular injection
1653320|NCT01829490|Biological|MVA85A|Intramuscular injection
1653321|NCT01829477|Drug|TAK-875|TAK-875 50 mg tablets
1653322|NCT01829477|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
1653323|NCT01829477|Drug|Glimepiride|Glimepiride tablet.
1653324|NCT01829464|Drug|Placebo|TAK-875 placebo-matching tablets
1653325|NCT01829464|Drug|TAK-875|TAK-875 tablets
1653326|NCT01829464|Drug|TAK-875|TAK-875 tablets
1653327|NCT01829451|Other|Hyaluronic acid gel|Hyaluronic acid gel is placed into the uterus after endometrial ablation
1653328|NCT01829438|Behavioral|Listening to fast music|
1653329|NCT01829438|Behavioral|Listening to preferred music|
1653330|NCT01829438|Behavioral|Listening to slow music|
1653331|NCT01829425|Drug|Anticholinergic medications|The study will use either of two standard, long acting anti-cholinergic medications and dosages. Pharmacotherapy counseling sessions will also be administered over 8 weeks by trained research personnel. Pharmacotherapy counseling sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the medication counselor administers the sessions in a standardized fashion. Pill counts will be performed at the conclusion of the 8 weeks of pharmacotherapy counseling. Subjects will be provided the medication for 1 year.
1653332|NCT01829425|Behavioral|Hypnotherapy|Hypnotherapy will be administered approximately weekly over 8 weeks by certified, trained clinical hypnotherapists. Sessions will be audio-recorded and one or more sessions will be reviewed by study personnel to ensure that the hypnotherapist administers the hypnotherapy session in a standardized fashion.Subjects will receive or download a digital recording specially prepared for them to for home practice of hypnotherapy sessions.Following the 8 weeks of therapy, subjects will be encouraged to continue to practice self-hypnosis and/or listen to their home practice digital recording and this practice will be tracked for the 1 year duration of the study.
1653333|NCT01829412|Other|DW-MRI|MRI imaging with diffusion weighted sequences of the whole body
1653334|NCT01829399|Drug|Bupivacaine with Epinephrine|10-15 mL 0.25% Bupivicaine with epinephrine 1:200,000 subcutaneous axillary ring
1653335|NCT01829399|Drug|Normal Saline|
1653336|NCT01829386|Other|Non heme iron levels on MRI|"MRI scans of the head will be performed to determine the amount of Non heme iron in areas of the brain of hemorrhagic stroke patients and hopefully predict the amount of brain damage.
Each MRI will take up to 1 hour to complete and will be done on day 3, day 7, day 10, day 14 and day 30. Some of the (MRIs) Magnetic Resonance Imaging will be clinically indicated and sequences will be added to the clinical scan with each sequence adding 10 minutes to the scan. Some sequences will be done only for research."
1653337|NCT01829373|Biological|vaccine 1650-G|
1653338|NCT01829360|Behavioral|Treatment (interactive book reading, dialogic reading, shared book reading)|In Study 1, children are randomized to one of four treatment conditions, determining whether they will hear the treated words either 12, 24, 36, or 48 times during treatment. In Study 2, one of the intensities from Study 1 will be tested more extensively by examining how best to achieve the adequate intensity. Specifically, is it better to hear the word more often in the book or to read the book more times? In the treatment condition, words are randomized to more repetitions in the book or to more repetitions of reading the same book to address this question.
1653339|NCT01829347|Biological|ELAD|ELAD is an extracorporeal system that draws blood from the subject via a dual-lumen catheter placed in a large vein, and then separates the plasma fluid (ultrafiltrate) from cellular components using a specifically-designed ultrafiltrate generator cartridge. While the cellular components are returned to the subject via the venous access, the ultrafiltrate is circulated at a high flow rate through the four metabolically-active ELAD cartridges which contain cloned, immortalized human hepatoblastoma cells (VTL C3A cells) derived from a subclone of the human hepatoblastoma cell line HepG2.
1653340|NCT01829347|Other|Standard of Care treatment|Standard of care is predefined treatment for sAAH complications (ascites, hepatic encephalopathy, varices, etc.)
1653341|NCT01829334|Other|ART dental sealant|ART dental sealant placed with glass ionomer material using the ART technique on permanent first molar, single-time placement and no replacement
1653342|NCT01829334|Other|Resin dental sealant|Resin dental sealant placed on pits and fissures of first permanent molars, single-time placement and no replacement
1653346|NCT01829321|Drug|Placebo|1 capsule in the morning and 1 capsule in the evening with food during 28 days
1653347|NCT01829308|Behavioral|The brief interventions are delivered by behavioral health counselors (Specialist)|Behavioral Health Specialists perform the brief intervention. The screening and referral to treatment processes remain the same as with the Generalist condition.
1653348|NCT01829308|Behavioral|The brief interventions are delivered by the primary care provider (Generalist)|Primary care providers perform the brief intervention. The screening and referral to treatment processes remain the same as with the Specialist condition.
1653349|NCT01829295|Drug|Mycophenolate mofetil|For the first two weeks, an introductory dose of 500 mg BID orally. After two weeks, the dose will be increased to 1.5 g BID.
1653350|NCT01829295|Drug|Methotrexate|For the first two weeks, an introductory dose of 15 mg/week (7.5mg BID once a week) orally. After two weeks, the dose will be increased to 25 mg/week (12.5mg BID once a week)
1653351|NCT01829295|Drug|Prednisone|All patients enrolled in the study will be initially taking concomitant oral corticosteroids at 1 mg/kg or 60 mg daily, whichever is less. Initial corticosteroid dose will be continued for 2 to 4 weeks at which point prednisone will be gradually tapered. Prednisone will be tapered to and held at 7.5 mg/day for the first 6 months of the study.
1653352|NCT01829282|Behavioral|Risk Reduction|
1653353|NCT01829256|Behavioral|Pharmacist telehealth intervention|A tailored intervention with medication management and behavioral components. The behavioral modules may include, diet, exercise, weight, tobacco use, medication management, side effects, diabetes education, DKD/ HTN/ CVD risk and knowledge.Based on the patient's responses to a series of questions, there will be a provision of tailored feedback to reinforce evidence-based behavior for disease and lifestyle management.
1653354|NCT01829243|Drug|Milnacipran|
1653355|NCT01829243|Drug|Placebo|
1653356|NCT01829230|Device|1 Day Acuvue Moist|Lenses will be worn in a daily wear modality
1653357|NCT01829217|Drug|Sunitinib|
1653358|NCT01829191|Device|Soft Contact Test Lens A|FDA-approved, non-marketed daily disposable soft contact lens, conventional design
1653359|NCT01829191|Device|Soft Contact Test Lens C|Daily disposable soft contact lens with new optical design
1653360|NCT01829178|Drug|Silymarin|Silymarin 420 mg in 3 divided dose plus standard chemotherapy
1653361|NCT01829178|Drug|Placebo|placebo tablets: 420 mg in 3 divided dose
1653362|NCT01829178|Drug|chemotherapy|All patients will receive standard chemotherapy: cisplatin 50-60mg/m2 + fluorouracil 750 mg/m2 + docetaxel 60-80 mg/m2
1653363|NCT01829165|Device|rTMS Treatment|MRI-compatible TMS stimulator
1653364|NCT01829152|Device|CHM|
1653365|NCT01829113|Drug|OGX-427|"Three loading doses of OGX-427 at 600mg IV will be administered Days -9 to -1.
Following the loading dose period, OGX-427 will be administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. OGX-427 will be given prior to the administration of pemetrexed (500mg/m2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle. A maximum of four treatment cycles will be administered.
Patients with objective response or stable disease after four cycles of therapy will move on to a Maintenance Phase of OGX-427 administered at 600mg IV weekly Days 1, 8 and 15 of each 21 day cycle plus pemetrexed (500mg/m2 IV on Day 1). Patients may remain on maintenance as long as they are benefiting and have no evidence of disease progression."
1653366|NCT01829113|Drug|Placebo|"Three loading doses of placebo will be administered IV Days -9 to -1.
Following the loading dose period, placebo will be administered IV weekly Days 1, 8 and 15 of each 21 day cycle during the Treatment Phase. Placebo will be given prior to the administration of pemetrexed (500mg/m2 IV) and carboplatin (AUC 6 IV) on Day 1 of each cycle. A maximum of four treatment cycles will be administered.
Patients with objective response or stable disease after four cycles of therapy will move on to a Maintenance Phase of placebo administered IV weekly Days 1, 8 and 15 of each 21 day cycle plus pemetrexed (500mg/m2 IV on Day 1). Patients may remain on maintenance as long as they are benefiting and have no evidence of disease progression."
2013048|NCT01196390|Procedure|Therapeutic Conventional Surgery|Undergo surgery
2013049|NCT01196390|Biological|Trastuzumab|Given IV
2013050|NCT01195610|Behavioral|Dietary intervention|Instruction to diet for 6 month
1653370|NCT01829048|Drug|PF-02545920|15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
1653371|NCT01829048|Drug|PF-02545920|15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
1653372|NCT01829048|Drug|PF-02545920|15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
1653373|NCT01829048|Drug|Placebo|Placebo Q12h
1653374|NCT01829035|Other|Conventional Transarterial Chemoembolization (cTACE)|"Concurrent use of the following material/drug is defined as cTACE in this trial.
Embolization material (e.g., gelatin sponges, porous gelatin particles, Ivalon, etc.) other than ethiodized oil
Anti-tumor drug:
Unapproved drug/embolization material from each regulatory agency should not be used.
To chemo-embolize all arteries feeding viable lesions via super selective cTACE, which is more effective and can be recommended as it rarely causes impairment of non-cancerous liver tissues. After assessing the disappearance of tumor stain as much as possible by angiography, the cTACE procedure should be completed"
1653375|NCT01829022|Procedure|E-NOTES|Embryonic-Natural Orifice Transumbilical Endoscopic Surgery for Myomectomy with Traction of Multidirectional Sutures
1653376|NCT01829009|Other|Resistance Exercise Group|"An individualized resistance exercise program wil be applied twice a week by an expert physiotherapist. Every 2 weeks, intensity will be reassessed by the same physiotherapist. Weekly, participants will be asked about incidents such as the occurrence of falls or hospitalizations during this study period.
Physical performance and functional status will be assessed by the blind investigator at weeks 6,12 and 24"
1653377|NCT01828996|Device|Shock wave therapy|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region.
1653378|NCT01828996|Device|Placebo|A total of 3000 pulses will be applied, moving the shock head every 500 pulses to cover the entire prostate and pelvic floor region
2013051|NCT01191983|Drug|Methoxy polyethylene glycol-epoetin beta [Mircera]|Starting dose of 1.2 mcg/kg, adjusted according to Hb values, administered by subcutaneous injection Q4W
2013052|NCT01176916|Drug|Aromasin (exemestane)|This is a NIS, the dosage, frequency and duration base on the LPD approved by SFDA.
2013053|NCT01176266|Drug|asfotase alfa|
2013054|NCT01173640|Drug|Midazolam|2 mg oral dose
2013055|NCT01173640|Dietary Supplement|resveratrol (single dose)|1 g oral dose
2013056|NCT01173640|Dietary Supplement|resveratrol (multiple dose)|1 g oral dose for 8 days
1653381|NCT01828970|Drug|Basal-bolus detemir-aspart insulin regimen|After the first CGM was completed during the conventional anti-diabetic treatment, patients received a rapid-acting insulin analogue before each meal (i.e., aspart) and a basal long-acting insulin analogue (i.e., detemir) once or twice daily. The analogues were titrated for optimal glycemic control. After one month of the aspart and detemir regimen, a physician adapted the insulin doses according to the glucose values observed from the second CGM.
1653382|NCT01828957|Biological|Pneumostem®|
1653383|NCT01828957|Other|Normal Saline|
1653384|NCT01828944|Dietary Supplement|olive oil|
1653385|NCT01828931|Behavioral|Lifestyle Intervention|A lifestyle intervention (LI) aimed at reducing caloric intake and increasing physical activity
1653386|NCT01828931|Other|Usual Care|Care as usual
1653387|NCT01828918|Genetic|microRNAs|
1653388|NCT01828905|Device|"CERAMENT™|BONE VOID FILLER"|ceramic bone void filler
1653389|NCT01828905|Procedure|Autologous cancellous bone graft|autologous cancellous bone graft
1653390|NCT01828892|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device.
1653391|NCT01828892|Procedure|Endoscopy exploration|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization.
1653392|NCT01828892|Drug|Antibiotics (ceftazidime, cefotaxime, or meropenem, with or without vancomycin)|Antibacterial therapy in patients with signs of systemic sepsis or local inflammation with pain
1653393|NCT01828892|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition
1653394|NCT01828879|Drug|Tacrolimus|Tacrolimus ointment, 0.1 percent will be applied twice daily, in adult population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
1653395|NCT01828866|Behavioral|EMDR|EMDR is a protocolized, evidence-based treatment for PTSD. Here we use it to target addiction memory representations that elicit craving and may influence drinking behavior. The EMDR study protocol is based on the standard EMDR protocol and other EMDR approaches used in addiction.
1653396|NCT01828866|Behavioral|Community Reinforcement Approach|"CRA is based on behavioural therapy principles:
Functional analysis
Communication skills
Problem-solving skills
Sobriety sampling
Social networking
Refusal of substances
Reinforcing activities
Relapse management
Medication monitoring"
1653397|NCT01828840|Drug|epidural morphine via PCEA|
1653398|NCT01828840|Drug|epidural fentanyl via PCEA|
1653399|NCT01828840|Drug|epidural methadone via PCEA|
1653400|NCT01828840|Drug|intravenous morphine via PCA|
1653401|NCT01828827|Drug|PA-824 1000 mg|Two single administrations of 1000mg each administered by 5 tablets of 200mg, one administered in the fed state and one administered in the fasted state.
1653402|NCT01828801|Device|Pinnacle Metal-on Metal|All patients that are post-operative will have undergone total hip arthroplasty with the Pinnacle Metal-on-Metal device
1653403|NCT01828788|Drug|Ropivacaine|
1653404|NCT01828788|Drug|placebo|
1653405|NCT01828775|Other|palliative care|Receive early PCI
1653406|NCT01828775|Other|palliative care|Receive delayed PCI
1653407|NCT01828775|Procedure|quality-of-life assessment|Ancillary studies
1653408|NCT01828775|Other|survey administration|Ancillary studies
1653409|NCT01828762|Biological|DC-TC+GM-CSF|
1653410|NCT01828736|Biological|Trastuzumab|Bottles of 150 mg; Charging dose: 8mg/kg then 6mg/kg every 21 days given IV
1653411|NCT01828736|Drug|Gemcitabine|Given IV, 1000 mg/m² BSA on Day 1 and Day 8 every 21 days
1653412|NCT01828736|Drug|Carboplatin|Given IV: AUC 5 on Day 1 every 21 days
1653413|NCT01828736|Drug|Cisplatin|Given IV, 70 mg/m² BSA on day 1 every 21 days
1653414|NCT01828723|Biological|SVF|
1653415|NCT01828710|Dietary Supplement|Myo-inositol normospermic|4000mg/die of myo-inositol and 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months.
1653416|NCT01828710|Dietary Supplement|Myo-inositol OAT|B 13 OAT patients treated with 4000mg/die of myo-inositol associated to 400 µg of folic acid (Inofolic® Lo.Li. pharma s.r.l., Roma) for three months
1653417|NCT01828710|Dietary Supplement|Folic Acid normospermic|Group C 20 normospermic patients treated with 400 µg of folic acid (kindly provided by Lo.Li. pharma s.r.l., Roma) for three months.
1653418|NCT01828697|Drug|Low dose nadroparin|"Fixed low dose nadroparin:
< 100 kg: 2850 IU subcutaneously once-daily
100 kg and above: 3800 IU subcutaneously once-daily"
1653419|NCT01828697|Drug|Intermediate dose nadroparin|"Intermediate weight-adjusted dose nadroparin:
< 50 kg: 3800 IU subcutaneously once-daily;
50 to < 70 kg: 5700 IU subcutaneously once-daily;
70 to < 100 kg: 7600 IU subcutaneously once-daily;
100 kg or above: 9500 IU subcutaneously once-daily."
1653420|NCT01828697|Drug|Low dose enoxaparin|"Fixed low dose enoxaparin:
< 100 kg: 40 mg subcutaneously once-daily
100 kg and above: 60 mg subcutaneously once-daily"
1653421|NCT01828697|Drug|Intermediate dose enoxaparin|"Intermediate weight-adjusted dose enoxaparin:
< 50 kg: 60 mg subcutaneously once-daily, or;
50 kg to < 70 kg: 80 mg subcutaneously once-daily, or;
70 kg to < 100 kg: 100 mg subcutaneously once-daily, or;
100 kg or above: 120 mg subcutaneously once-daily."
1653422|NCT01828697|Drug|Low dose dalteparin|"Fixed low dose dalteparin:
< 100 kg: 5000 IU subcutaneously once-daily
100 kg and above: 7500 IU subcutaneously once-daily"
1653423|NCT01828697|Drug|Intermediate dose dalteparin|"Intermediate weight-adjusted dose dalteparin:
< 50 kg: 7500 IU subcutaneously once-daily, or;
50 kg to < 70 kg: 10000 IU subcutaneously once-daily, or;
70 kg to < 100 kg: 12500 IU subcutaneously once-daily, or;
100 kg or above: 15000 IU subcutaneously once-daily."
1653424|NCT01828697|Drug|Fixed low dose tinzaparin|"Fixed low dose tinzaparin:
< 100 kg: 3500 IU subcutaneously once-daily
100 kg and above: 4500 IU subcutaneously once-daily"
1653425|NCT01828697|Drug|Intermediate dose tinzaparin|"Intermediate weight-adjusted dose tinzaparin:
< 50 kg: 4500 IU subcutaneously once-daily, or;
50 kg to < 70 kg: 7000 IU subcutaneously once-daily, or;
70 kg to < 100 kg: 10000 IU subcutaneously once-daily, or;
100 kg or above: 12000 IU subcutaneously once-daily."
1653427|NCT01828684|Other|Sham Lens Coating|Each subject will wear a sham lens coating for 2 weeks.
1653428|NCT01828671|Other|Oral Glucose Solution 296 mls|Should the participant be eligible to participate, they will be scheduled for two separate study visits to assess the glycemic response of the oral glucose solution.
1653429|NCT01828671|Other|Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a study visit to assess the glycemic response of the corn tortillas.
1653430|NCT01828671|Other|Low Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a low amount of soy flour.
1653431|NCT01828671|Other|Moderate Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a moderate amount of soy flour.
1653432|NCT01828671|Other|High Soy Flour Corn Tortilla|Should the participant be eligible to participate, they will be scheduled for a single study visit to assess the glycemic response of corn tortillas with a high amount of soy flour.
1653433|NCT01828658|Other|Strict bioimpedance guided dry weight prescription|Post dialysis patient dry weight was exclusively prescribed using the ideal weight measured by the BCM device (+/- 1.1 Kg).
1653434|NCT01828645|Dietary Supplement|Carbohydrate plus whey protein enriched drink|The patients will drink 200 mL of the nutritional supplement (Jucy, Fresenius Kabi, Brazil) 2h before upper digestive endoscopy under sedation with propofol.
1653435|NCT01828632|Procedure|Respiratory Physical Therapy|Patients were randomly assigned to receive either a preoperative respiratory physiotherapy program (Intervention group, RPT) which included lung re-expansion (Incentive Spirometer, Voldyne5000, Teleflex medical USA) and respiratory muscle training (Threshold IMT, Respironics Inc. Pittsburgh, PA, USA) or usual care (Control group). Immediately after randomization the RPT group patients received detailed instructions about the training program and how correctly use the IMT and incentive spirometer devices. The patients trained daily, for 30 consecutive days. Each session consisted in 20 minutes of IMT and incentive spirometer. The patients adherence to the program was evaluated weekly by the physical therapist. Postoperative physical therapy was the same for both groups and consisted in lung re-expansion exercise with the aid of the incentive spirometer. Besides, patients were placed in sitting position rather than lying and early mobilization was stimulated.
1653436|NCT01828619|Procedure|modified BuFlu conditioning|The regimen consisted of hydroxyurea 80 mg/kg on d -10; cytorabine 2 g/m2 on d -9; busulfan 3.2mg/kg/day iv. ×3days( on d -8 to -6); Flu30mg/m^2 i.v.×5days(on d-6 to-2) and semustine 250 mg/m2 on d -3.
1653437|NCT01828606|Device|coban 2 system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment
According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
1653438|NCT01828606|Device|coban lite system|"All centres will perform the pressure measurements with Picopress, Microlab Elettronica, Italy For mobility measurements all centres will be supplied with pedometers. For perometry the centres will use their own equipment
According to protocol the materials are applied to the whole leg and the measuring devices are put in place"
1653439|NCT01828593|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|SBI is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. SBI does not contain any milk products such as lactose, casein, or whey. SBI is gluten-free, dye-free, and soy-free. SBI is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
1653440|NCT01828593|Other|Placebo|Matching placebo
1653441|NCT01828580|Device|active laparoscope positioner (AutoLap)|
1653442|NCT01828567|Behavioral|Shared decision making with a Prevention Coach|A series of two phone sessions with a prevention coach. The first to engage the veteran to choose a preferred prevention program and link them to PACT, and a follow-up call one month later to assess the progress of the prevention plan.
1653443|NCT01828554|Drug|Xeloda|"Cycle 1: Days 1-7 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Ideal Body Weight to calculate dosage. Cycle 1, Day 8-No drug.
Cycle 1: Days 9-15 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage. Days 16-21-No drug.
Cycle 2 and greater: Days 1-14 (21 day cycle): 1250 mg/m2 Xeloda orally twice a day using Actual Body Weight to calculate dosage."
1653444|NCT01828541|Behavioral|Hypnosis|Patients in this group will receive standard care plus 4 sessions of hypnosis.
1653445|NCT01828541|Other|Standard of Care|
1653446|NCT01828528|Procedure|Sleeve gastrectomy|An intra-operative liver biopsy was performed in 20 patients
1653447|NCT01828515|Drug|Vilazodone|Participants will be randomized to either vilazodone or placebo titrated as follows: 10 mg x 7 days, 20 mg x 7 days and 40 mg x 5 days.
1653448|NCT01828515|Drug|Placebo|
1653449|NCT01828502|Behavioral|Education|Participants in both groups will receive education by the EPA on the danger of exposure to secondhand smoke and how exposure can be prevented.
1653450|NCT01828502|Behavioral|Cotinine Education|Those randomized to the active intervention will also be provided with education utilizing the cotinine test strip in conjunction with the education from the EPA.
1653451|NCT01828489|Drug|Randomisation course 1 mitoxantrone versus DaunoXome|In course one with cytarabine and etoposide either mitoxantrone (standard) or DaunoXome (experimental) is given as anthracycline.
1653452|NCT01828489|Drug|Randomisation course 2 ADxE versus FLADx|The second course is randomised to either ADxE (standard arm) or FLADx
1653453|NCT01828476|Drug|Abiraterone|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
1653454|NCT01828476|Drug|ABT-263|ARM A(Abiraterone with ABT-263) and ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
1653455|NCT01828476|Drug|Hydroxychloroquine|ARM B(Abiraterone with both ABT-263 and Hydroxychloroquine)
1653456|NCT01828463|Drug|Nitisinone|doses 1, 2, 4 & 8 mg plus no treatment arm
1653457|NCT01828437|Drug|Pyridoxine plus prednisolone|
1653458|NCT01828437|Drug|Prednisolone|
1653459|NCT01828411|Device|Transpharyngeal ultrasonography|Transpharyngeal Dopplerultrasonography (Device: iE33 xMatrix Philips). Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid arteries.
1653999|NCT01824472|Behavioral|CC|Placebo (sham) for insomnia
1653460|NCT01828411|Device|Duplex sonography|Assessment of cerebral blood flow by detection of blood flow velocities in the extracranial carotid and middle cerebral arteries during coronary artery bypass grafting.
1653461|NCT01828398|Device|real-tDCS + UE robot-assisted therapy|
1653462|NCT01828398|Device|sham-tDCS + UE robot-assisted therapy|
1653463|NCT01828385|Drug|Magnesium Sulfate|Magnesium sulfate + rocuronium + sugammadex
1653464|NCT01828385|Drug|Saline|Saline + rocuronium + sugammadex
1653465|NCT01828372|Other|additional blood withdrawals|Blood withdrawals by either venous puncture or placement of permanent venous catheter.
1653466|NCT01828359|Drug|Amosartan® tab|comparison of different combination of anti-hypertension drug
1653467|NCT01828359|Drug|Cozaar® plus pro tab|comparison of different combination of anti-hypertension drug
1653468|NCT01828346|Drug|Birinapant|"Dose escalation part: (Drug escalation dose levels)
Dose Level (1) - 13mg/m2 (twice a week for 3 of 4 weeks)
Dose Level (-1) - 11 mg/m2 (twice a week for 3 of 4 weeks)
Dose Level (2) - 13mg/m2 (twice weekly x 4 weeks)
Dose Level (3a) - 17mg/m2 (twice weekly × 4 weeks)OR
Dose Level (3b) - 17mg/m2 (twice a week for 3 of 4 weeks)"
1653469|NCT01828346|Drug|5-Azacitidine|Dose Level (0) - 75mg/m2 daily
1653470|NCT01828333|Other|No intervention|No intervention
1653471|NCT01828320|Behavioral|Cognitive Behavior Therapy for Insomnia, Interpersonal and Social Rhythms Therapy, Chronotherapy|
1653472|NCT01828320|Behavioral|Psychoeducation|
1653473|NCT01828307|Behavioral|Motivational enhancement therapy (MET)|MET is a client-centered, directive method of enhancing intrinsic motivation for change by exploring and resolving ambivalence. In this intervention MET will focus on exercise.
1653474|NCT01828307|Behavioral|Contingency management|Contingency management is a behavioral treatment that utilizes extrinsic motivation by offering individuals tangible rewards such as prizes for completion of specific target behaviors. The target behavior in this study is exercise.
1653475|NCT01828307|Behavioral|Standard Aftercare Treatment|Aftercare includes the following topics: substance use, high-risk situations, coping and life skills training, focus groups for depression and anxiety, and AIDS education.
1653476|NCT01828294|Drug|Subcutaneous immunoglobulins|Immunoglobulins used subcutaneously for maintenance of other immune mediated disorders.
1653477|NCT01828281|Device|CPAP|All subjects will undergo ultrasound examination of the abdomen the day after overnight polysomnography (PSG) and then at 3 months after completion of therapeutic or subtherapeutic CPAP treatment of 4 cm water.
1653479|NCT01828242|Behavioral|Empowerment model to improve dietary intake|Empowerment model using specific guidelines to improve dietary intake
1653480|NCT01828242|Other|Control group following conventional approach|Control group following conventional approach
1653481|NCT01828229|Behavioral|female inactivity and hypercaloric diet|female inactivity and hypercaloric diet for 2 weeks
1653482|NCT01828229|Behavioral|inactivity|inactivity for 2 weeks
1653483|NCT01828229|Behavioral|inactivity and hypercaloric diet|inactivity and hypercaloric diet for 2 weeks
1653484|NCT01828229|Behavioral|normal activity and hypercaloric diet|normal activity and hypercaloric diet for 2 weeks
1653485|NCT01828229|Behavioral|inactivity and iso-caloric diet|inactivity and iso-caloric diet for 2 weeks
1653486|NCT01828216|Device|Home sleep study|The home sleep study is a pocket-sized digital recording device. It is a multi-channel screening tool that measures airflow through a nasal cannula connected to a pressure transducer, providing an apnea-hypopnea index (AHI) based on recording time. It also detects both respiratory and abdominal efforts through the effort sensor and can differentiate between obstructive and central events
1653487|NCT01828216|Device|conventional polysomnography|conventional type I sleep study according to international guidelines
1653488|NCT01828203|Drug|Minocycline|
1653489|NCT01828203|Drug|Placebo|
1653490|NCT01828203|Procedure|Surgical spinal cord decompression|Surgical decompression by means at the discretion of the clinical management team will occur within 24 hours of injury in all subjects. Stabilization will occur at that time but may also include further interventions at a later time.
1653491|NCT01828203|Procedure|Maintenance of minimum mean arterial pressure (MAP)|Standardized hemodynamic management protocol aimed at maintaining MAP ≥ 85 mm Hg for 7 days using volume augmentation with isotonic crystalloid followed by inotropic support if needed will be applied to all subjects.
1653492|NCT01828190|Other|Hyperbaric oxygen|HBOT will be given for 40 sessions of 2 atmospheres for 90 minutes each session, 5 times a week (2 months). TNF alpha blocker therapy will remain the treatment received before recruitment.
1653493|NCT01828177|Drug|PDI-320|
1653494|NCT01828177|Drug|PDI-320 Monad #1|
1653495|NCT01828177|Drug|PDI-320 Monad #2|
1653496|NCT01828177|Drug|Vehicle|
1653497|NCT01828164|Device|Ultrasound|The Aevo System™ is an ultrasound emitting dental device.
1653498|NCT01828164|Device|Sham comparator|Ultrasound not activated in the comparator side of the device.20 minutes per day of ultrasound treatment on the active side of the device. The device consists of a mouth guard type device with transducers embedded in the mouth guard. In the split mouth design, the treatment arm consist of the side of the mouth with the transducers activated while the comparator arm has the transducers deactivated.
1653499|NCT01828151|Device|Noninvasive ventilation mask|
1653500|NCT01828138|Dietary Supplement|Sodium|supplemental sodium tablets 150-200 mmol/day in 5 days
1653501|NCT01828138|Dietary Supplement|Placebo|Placebo are given in 5 days
1653544|NCT01827865|Drug|Etodolac Extended Release Tablets 600mg|Etodolac Extended Release Tablets 600mg once a day
1653545|NCT01827839|Biological|Herpes Zoster vaccine (GSK1437173A)|2 doses administered intramuscularly in deltoid region of non-dominant arm.
1653571|NCT01827644|Drug|Afuresertib HPMC capsule - Fasted State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fasted state
1653572|NCT01827644|Drug|Afuresertib ECT - Fasted State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fasted state
1653573|NCT01827644|Drug|Afuresertib GC - Fed State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fed state
1653502|NCT01828125|Procedure|Hypoglycaemic hyperinsulinemic clamp|A first catheter will be inserted for infusion of D-[6,6-2H2] glucose and insulin. A second catheter will be inserted for infusion of dextrose. Dextrose infusion will be enriched with D-[6,6-2H2] glucose. A third catheter will be inserted for sampling. D-[6,6-2H2] glucose will be administered as a priming dose followed by a constant infusion throughout the experiment. Insulin will be administered as a primed continuous infusion. The first two hours will serve as an equilibration period for the tracer while glucose infusion will be adjusted to achieve a plasma glucose concentration of 5 mmol/L. The third hour is considered the baseline period. Following this, dextrose infusion rate will be decreased over a period of 1 hour to attain hypoglycaemia with a target blood glucose level at 2.8 mmol/L. At the end of the fourth hour, a subcutaneous glucagon dose will be given and plasma samples will be drawn for the determination of labelled and unlabelled glucose, plasma insulin and glucagon.
1653503|NCT01828125|Drug|Glucagon|
1653504|NCT01828112|Drug|Ceritinib|Ceritinib is the investigational treatment and is referred to as the investigational study drug and was provided as 150 mg hard gelatin capsules for oral use. The dose was 750 mg once daily.
1653505|NCT01828112|Drug|pemetrexed|Pemetrexed was one of the chemotherapy treatments. Pemetrexed, a reconstituted solution, was intravenously administered over 10 minutes at 500 mg/m2 every 21 days.
1653506|NCT01828112|Drug|docetaxel|Docetaxel was one of the chemotherapy treatments. Docetaxel, a reconstituted solution, was intravenously administered over 1 hour, at 75 mg/m2 every 21 days.
1653507|NCT01828099|Drug|Ceritinib|Ceritinib was administered orally once-daily fasted at a dose of 750 mg capsules on a continuous dosing schedule. Ceritinib (LDK378) was the investigational treatment and is referred to as the investigational study treatment/drug.
1653508|NCT01828099|Drug|Pemetrexed|Pemetrexed was administered at a dose of 500 mg/m2 as an iv infusion on Day 1 of each 21-day cycle to patients randomized to the chemotherapy arm.
1653509|NCT01828099|Drug|Cisplatin|Cisplatin was administered by IV at a dose of 75 mg/m2 every 21 days for up to 4 cycles.
1653510|NCT01828099|Drug|Carboplatin|Carboplatin was administered as iv infusion (AUC 5-6) every 21 days up to 4 cycles
1653511|NCT01828086|Biological|CJM112|Monoclonal antibody
1653512|NCT01828086|Biological|Secukinumab|Monoclonal antibody
1653513|NCT01828086|Other|Placebo|Liquid for subcutaneous injection without active drug.
1653514|NCT01828073|Drug|Raltegravir|No study-specific drugs will be given to women or infants during this study. Women will be receiving RAL for clinical indications outside of the study.
1653515|NCT01828060|Dietary Supplement|Jobelyn™|Sorghum bicolor leaf sheath extract
1653516|NCT01828060|Dietary Supplement|Placebo|Placebo capsules
1653517|NCT01828047|Device|orthogonal polarization spectral (OPS) imaging|orthogonal polarization spectral (OPS) imaging allows noninvasive observation of human microcirculation in all accessible tissue surfaces
1653521|NCT01828021|Biological|Margetuximab|Anti-HER2 monoclonal antibody
1653522|NCT01827995|Other|Self assessment|Intervention group: Simplified followup Mifepristone at outpatient clinic, followed by the administration of misoprostol 24-48 hours later (in the clinic or at home). The women will not return to the clinic for routine follow up visit, but are given instructions on how to use a checklist and a low sensitivity pregnancy test around day 10-14. They are asked only to return if they have any health problems or screen positively. The low sensitivity urinary-hCG (with HCG of 1000 IU/ml) test will be used. Women will be provided the pregnancy test free of cost along with a pictorial checklist. A research assistant or a nurse will explain in detail how to use the pregnancy test as well as the checklist, and provide phone numbers in case of any questions or doubts. Follow-up interviews will be conducted through home visits or phone (if woman has one) during the next 1-2 days to screen for on-going pregnancies and assess acceptability the self-assessment.
1653523|NCT01827995|Other|Routine assessment|Follow up in the clinic
1653524|NCT01827982|Drug|JNJ-54861911 1mg|JNJ-54861911 1 mg will be administered as a single oral dose after an overnight fast of at least 10 hours.
1653525|NCT01827982|Drug|JNJ-54861911 3 mg|JNJ-54861911 3 mg will be administered as a single oral dose.
1653526|NCT01827982|Drug|JNJ-54861911 9 mg|JNJ-54861911 9 mg will be administered as a single oral dose.
1653527|NCT01827982|Drug|JNJ-54861911 27 mg|JNJ-54861911 27 mg will be administered as a single oral dose.
1653528|NCT01827982|Drug|JNJ-54861911 81 mg|JNJ-54861911 81 mg will be administered as a single oral dose.
1653529|NCT01827982|Drug|JNJ-54861911 160 mg|JNJ-54861911 160 mg will be administered as a single oral dose.
1653530|NCT01827982|Drug|JNJ-54861911 tbd|The dose of JNJ-54861911 will be derived from the results obtained in Parts 1 and 2.
1653531|NCT01827982|Drug|JNJ-54861911 9 mg|Study drug will be administered after an overnight fast of at least 10 hours and within 120 minutes after placement of the spinal catheter.
1653532|NCT01827982|Drug|Placebo|Matching placebo will be given as a single oral dose.
1653533|NCT01827969|Procedure|ablathermy focused ultrasound|ablathermy focused ultrasound
1653534|NCT01827956|Other|Blood sample for identifying the polymorphism|Blood sample for identifying the polymorphism
1653535|NCT01827943|Drug|TORISEL|Temsirolimus
1653536|NCT01827930|Drug|Imatinib Mesylate|Imatinib Mesylate LMC
1653537|NCT01827917|Biological|rabies vaccine|Injection on day 0、7、21
1653538|NCT01827904|Device|Transcranial ExAblate|
1653539|NCT01827904|Device|Sham Transcranial ExAblate|
1653540|NCT01827891|Procedure|remote ischemic preconditioning (RIPC)|Those randomized to RIPC group had a pneumatic medical tourniquet cuff (width , 5 cm ; length , 40 cm) placed around their upper arm at < 2 hours before the PCI procedure. The pneumatic medical cuff was inflated to a pressure of 200 mm Hg for 5 minutes , followed by 5 minutes of deflation to allow reperfusion. This procedure was repeated for 3 times.
1653541|NCT01827878|Drug|Lisinopril and Hydrochlorothiazide Tablets (20+25) mg|Lisinopril and Hydrochlorothiazide (20+25) mg Tablets once a day
1653542|NCT01827878|Drug|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets|Zestoretic® 20/25 lisinopril/hydrochlorothiazide Tablets once a day
1653543|NCT01827865|Drug|Etodolac Extended Release Tablets USP 600mg|Etodolac Extended Release Tablets USP 600mg once a day
1654000|NCT01824459|Drug|S-1|S-1：40~60mg bid，d1~14 q3W
2013057|NCT01173432|Device|continuous positive airway pressure|an device to be used during sleep, which was a nasal mask connected to a device with pressure applied to upper airway
1653547|NCT01827813|Procedure|Transrectal prostate biopsy with ultrasonography.|Transrectal prostate biopsy was performed in left lateral decubitus position with sedo-analgesia in saturation biopsy group and without sedoanalgesia in 10-12 core biopsy group on outpatient basis. After preparation of the rectal ultrasound probe and assuming an appropriate position, ultrasonographic examination of the prostate was performed on axial and sagittal plane. Periprostatic block was performed with the injection of 3 cc of prilocaine to each of the right and left lobes in the right and left periprostatic region in both groups before biopsy. Biopsy procedure was performed with an 18 G, 20 cm tru-cut biopsy needle and an automatic biopsy gun. After passing beyond the rectal mucosa, the needle was advanced until 0.5 cm proximal to the area of interest by tracking the image of the needle on the screen.
1653548|NCT01827813|Procedure|Periprostatic block|Periprostatic block was used for local anesthesia. 3 cc 2% prilocaine was injected to both periprostatic region in both saturation biopsy and 10-12 core biopsy group with transrectal ultrasonography.
1653549|NCT01827813|Procedure|Sedoanalgesia|Sedoanalgesia was used in saturation biopsy group. It was given by an anesthesiologist. Patients were given adequate counselling regarding sedoanesthesia as well as the biopsy procedure. They were advised to fast the night before the procedure.Before induction of sedoanalgesia all patients were monitorized for peripheric oxygen saturation and electrocardiography (ECG).Additionally nasal oxygen with 3ml/min was given to all patients by nasal canula.Sedoanalgesia was induced with 0.05mg/kg of midazolam, 1mg/kg of propofol and 1mg/kg of fentanyl. additional propofol was given with dose of 0.3mg/kg as patients needed.
1653550|NCT01827800|Behavioral|eHealth weight loss intervention|This trial involves a multi-level, systems-change weight loss intervention. At the provider level, we make it easier for PCPs to deliver weight loss counseling by embedding patient progress data and counseling recommendations in the electronic health record. At the patient level, we provide engaging self-monitoring interfaces, immediate tailored feedback, skills training, and evidence-based lifestyle counseling from trusted care providers.
1653551|NCT01827787|Drug|Eribulin|Intravenously on Day 1 and 8 of each cycle
1653552|NCT01827774|Device|Surgisis® Soft Tissue Graft|Surgisis® Soft Tissue Graft for pelvic organ prolapse repair
1653553|NCT01827761|Behavioral|Questionnaire|After informed consent for this study is obtained, patients will be given questionnaire #1 that includes rating their knowledge of the side effects of treatment, their understanding of the treatment schedule, what do in the event of complication, how to reach the medical team and an assessment of the level of anxiety. The questionnaire will be repeated at day 1 of the first chemotherapy treatment to assess the effectiveness of the teaching session. In addition, questionnaire #3 will be administered at day 1 of cycle 2 of their first chemotherapy.
1653554|NCT01827748|Device|Intraoperative Autorefractor IAR-1|This is an auto-refractor mounted on an operating microscope and used with the subject in a supine position
1653555|NCT01827748|Device|Hartmann-Shack Auto Refractor|Standard auto-refractor used with subject sitting upright in front of the instrument.
2013058|NCT01171339|Other|Optimization strategy (complex intervention)|"Healthcare assistant (HCA) and computer assisted optimization of multi-medication (complex intervention) in accordance with recommended standard#
#Recommended standard: clinical practice guideline Geriatrie of the guideline group of Hesse (part 1 and 2)"
1653557|NCT01827722|Drug|Ozurdex|Intravitreal injection of Ozurdex
1653558|NCT01827722|Drug|Ranibizumab|Intravitreal Injection of Ranibizumab
1653559|NCT01827722|Drug|Combination Ozurdex with Ranibizumab PRN|Intravitreal Injection of combination medication Ozurdex and Ranibizumab
1653560|NCT01827709|Other|A polymerase chain reaction -based hypoxia classifier|"Recently, a polymerase chain reaction (PCR) -based hypoxia classifier gene signature was published that can be easily applied. Using this classifier, patients will be divided in hypoxic or non-hypoxic subgroups.
These subgroups will be correlated to locoregional control. The hypoxic signature will also be related to parameters on DCE-MRI, DWI and FDG-PET."
1653561|NCT01827709|Other|Functional imaging before treatment.|As part of the standard staging procedure all patients will undergo an MRI of the neck. We will however also take DWI and DCE images at this time point. Parameters of these images will be later on correlated with pathology.
1653562|NCT01827709|Other|Immunohistochemical staining|At 3 levels of the tumour, chosen by the radiologist on the functional imaging modalities, 4µm thick slices will me taken. On each level an immunohistochemical staining will be carried out (GLUT-1, CA-IX, HIF-1alpha, VEGF, KI 67). The result of this staining will be correlated with parameters derived from the functional imaging modalities.
1653563|NCT01827709|Other|MRI of the resection specimen|To account for the shrinkage of the tumour due to fixation, the resection specimen will be placed in a box and scanned with an MRI. From this a shrinkage factor will be calculated using the original pre-treatment MRI.
1653564|NCT01827709|Other|Tumour volume delineation and comparison|On the imaging modalities the tumor volume will be delineated. This will also be done on the resection specimen. Later on the different tumour volumes will be correlated.
1653565|NCT01827696|Dietary Supplement|Ginseng|Effect of four weeks of daily Ginseng intake (2gm/day) on muscle soreness following downhill running exercise
1653566|NCT01827683|Other|Hyperbaric oxygen|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
1653567|NCT01827670|Drug|Stannous fluoride|Test dentifrice containing 0.454% SnF
1653568|NCT01827670|Drug|Sodium monofluorophosphate|Control dentifrice containing 0.76% w/w Sodium Monofluorophosphate [1000 parts per million (ppm) fluoride]
1653569|NCT01827657|Drug|GSK2336805|Two 30 mg GSK2336805 tablets for a 60 mg single dose will be administered in this study
1653570|NCT01827644|Drug|Afuresertib GC - Fasted State|White opaque hard gelatin capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib GC administered in fasted state
1653613|NCT01827462|Biological|Trivalent, inactivated influenza vaccine (TIV)|Licensed Seasonal Influenza Vaccine TIV
2013059|NCT01169974|Other|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest before and following tourniquet ischemias of 1 , 2 & 3 minutes
2013060|NCT01169337|Other|Clinical Observation|Undergo observation
2013061|NCT01169337|Other|Laboratory Biomarker Analysis|Correlative studies
2013062|NCT01169337|Drug|Lenalidomide|Given PO
2013063|NCT01169337|Other|Quality-of-Life Assessment|Ancillary studies
1653574|NCT01827644|Drug|Afuresertib HPMC capsule - Fed State|White opaque HPMC capsule containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib HPMC capsule administered in fed state
1653575|NCT01827644|Drug|Afuresertib ECT - Fed State|White to off white, round, biconvex coated tablet containing afuresertib 25 mg. Subjects will receive single oral dose of afuresertib ECT administered in fed state
1653576|NCT01827631|Drug|GSK1605786 capsule|Swedish Orange, size 0, hard gelatine capsules
1653577|NCT01827618|Drug|Rapamycin|
1653578|NCT01827605|Other|ZEVALIN|Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).
1653579|NCT01827605|Drug|BEAM|"BEAM REGIMEN day -6 Carmustine* 300 mg/ m2 i.v. in 250ml dextrose 5% solution
from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr
day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr
day 0
UReinfusion of autologous stem cells following this rules:
Patient collecting ≥6x106 CD34+ cells/kg use >4x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;
Patient collecting 4-6x106 CD34+ cells/kg use >2x106 CD34+ cells/kg for ASCT and keep >2x106 CD34+ cells/kg for back up;
Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.
day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC > 1500/mmc"
1653580|NCT01827592|Drug|Elobixibat 10 mg|Elobixibat 10 mg/day
1653581|NCT01827592|Drug|Elobixibat 5 mg|Elobixibat 5 mg/day
1653582|NCT01827592|Drug|Placebo|Placebo
1653583|NCT01827579|Biological|CD25/71 allodepleted donor T-cells|CD25/71 allodepleted donor T-cells will be administered at a dose of 10^5 /kg at day 30 post-SCT, 3 x 10^5 /kg at day 60 and 10^6 /kg at day 90 post transplant
1653584|NCT01827566|Other|gluten|
1653585|NCT01827566|Other|gluten free flour|
1653586|NCT01827553|Drug|Induction chemotherapy with gemcitabine or FOLFIRINOX|According to medical recommendation, induction chemotherapy is performed with gemcitabine (3 cycles a 3 administrations, 1000 mg/m^2/d)or FOLFIRINOX (6 cycles; 1 cycle: oxaliplatin 85 mg/m^2 2 h infusion, folinic acid 400 mg/ m^2 2h infusion completed after 30 min with irinotecan infusion 180 mg/m^2 for 90 minutes, bolus application 5-FU 400 mg/m^2 followed by 46h infusion of 5-FU 2400 mg/m^2)
1653587|NCT01827553|Radiation|Radiotherapy, 28 x 1.8 Gy|Radiotherapy combined with chemotherapy starts on day 1 of chemotherapy. Radiation volume is restricted to macroscopic visual tumor region. Radiation is performed in 28 fractions with 1.8 Gy resulting in a total dose of 50.4 Gy.
1653588|NCT01827553|Drug|Chemotherapy, gemcitabine|5 cycles of 300 mg/m^2/d gemcitabine infusions and than 3 administrations of 1000 mg/m^2/d
1653589|NCT01827553|Drug|Chemotherapy with gemcitabine or FOLFIRINOX according to induction chemotherapy|Chemotherapeutic administration started with during induction chemotherapy is continued; Gemcitabine: 3 cycles a 3 administrations of 1000 mg/m^2/d gemcitabine infusions FOLFIRINOX: 6 cycles
1653590|NCT01827540|Drug|Cenicriviroc|
1653591|NCT01827540|Drug|Dolutegravir|
1653592|NCT01827540|Drug|Midazolam|
1653593|NCT01827501|Device|PulsioflexTM Monitoring|Fluid and catecholamine management according to PulsioflexTM measurements
1653594|NCT01826383|Behavioral|Active-Video|This group will watch an active-video with pain management strategies for parents
1653595|NCT01826383|Behavioral|Placebo Video|This group will watch a placebo-video describing immunization generally.
1653596|NCT01826370|Drug|Linagliptin|tablet
1653597|NCT01826331|Behavioral|Incentives for Participation|Participants will receive three smoking cessation programs
1653598|NCT01826331|Behavioral|Incentives for Cessation|Participants will have access to a smoking cessation program
1653599|NCT01826318|Behavioral|Stress coping|"Students in the intervention group received a 10 minute instruction to cope with stress. They were informed that an emergency situation is a stressful experience for health care workers and that perceived stress may interfere with their decision-making abilities and performance. Particularly, feeling overwhelmed by stress may cause cognitive impairment potentially leading to loss of concept how to deal with an emergency situation, which in turn further increases stress (vicious cycle). However, it is possible to overcome this situation by focusing on the basic conditions of the situation and the immediate actions that are needed. They were instructed that they should ask two task-focusing questions aloud (what is the patient's condition?, what immediate action is needed?) to overcome the negative consequences of feeling overwhelmed by stress."
1653600|NCT01826305|Procedure|Formal Rehabilitation Therapy|Patients that will be randomized to the formal rehabilitation therapy cohort will be prescribed formal therapy for twelve weeks with supervised exercises to regain knee strength and range of motion. Therapists will not be involved in the study design and therapists will not be informed that patients are participating in this study. The content, frequency, and duration of the rehabilitation program will be at the discretion of the treating therapist, consistent with usual practice.
1653601|NCT01826305|Procedure|Independent Exercise Cohort|The patients who will be in the independent exercises cohort will be registered on www.careforpatients.com, an online rehabilitation resource that provides computer aided rehabilitative exercises. Patients will follow a prepared 12-week protocol of exercises to perform post-operatively to gradually regain their knee strength, flexion, extension, abduction, and adduction.
1653602|NCT01826279|Dietary Supplement|Resveratrol|500mg 3 times daily for 1 month
1653603|NCT01826279|Other|Placebo|1 placebo tablet 3 times daily for 1 month
1653604|NCT01826266|Drug|PER977, Placebo|
1653605|NCT01826253|Drug|hydroxyethylstarch 130/0.4|Bolus of 100ml of HES 130/0.4 repeated until maximization of cardiac output
1653606|NCT01826240|Behavioral|MBCT+SPI|Safety Planning Intervention (SPI), a very brief intervention focused on identifying personalized coping strategies to manage acute suicidality, is combined with Mindfulness-Based Cognitive Therapy (MBCT), a group intervention comprised of mindfulness training and cognitive therapy techniques. Treatment lasts 9 weeks.
1958051|NCT02010567|Drug|CRLX101|CRLX101 is an experimental nanoparticle formulation of the anticancer agent camptothecin manufactured by Cerulean Pharma Inc..
1653610|NCT01827475|Drug|Ibuprofen|single dose
1653611|NCT01827475|Drug|Acetaminophen|single dose
1653612|NCT01827475|Drug|Ibuprofen-acetaminophen combination|single dose
1653614|NCT01827462|Biological|Quadrivalent, inactivated influenza vaccine (IIV4)|Licensed Seasonal Influenza Vaccine IIV4
1653615|NCT01827462|Biological|High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)|Licensed Seasonal High-Dose Influenza Vaccine TIV
1653616|NCT01827449|Device|Fluidotherapy warming device|Device uses airborne heated cellulose particles which are blown against the skin to provide convective warming.
1653617|NCT01827436|Behavioral|Conventional physical therapy|
1653618|NCT01827436|Behavioral|Asymmetrical gait training|
1653619|NCT01827423|Device|Surgical removal of sinonasal papiloma|An endoscopic endonasal surgical device is used to remove the sinonasal papilomas in the study subjects.
1653620|NCT01827410|Procedure|Ventral hernia repair|
1653621|NCT01827397|Biological|EN41-UGR7C HIV vaccine|
1653622|NCT01827397|Biological|NaCl|
2013064|NCT01152008|Other|tourniquet ischemia|Recording of cutaneous blood flow on the forearm at rest and during cycle exercise 50W before and following tourniquet ischemia
2013065|NCT01144377|Drug|LY2541546|Administered subcutaneously
2013066|NCT01144377|Drug|Placebo|Administered subcutaneously
2013067|NCT01143779|Drug|FLT-PET|FLT-PET scan uses the FLT solution (dosage of FLT in range between 1 and 10 mCi) with imaging performed 60-90 minutes after FLT intravenous injection.
1653630|NCT01827371|Biological|MVA Smallpox Vaccine|Subjects receive two dose regimen of IMVAMUNE® (1x10^8 TCID50/0.5 mL per dose) via the SC route using either a syringe and needle or the Stratis™ system. Arm A receives doses via syringe and needle on days 1 and 29; Arm B receives doses via syringe and needle on days 1 and 15, Arm C receives doses via syringe and needle on days 1 and 22, Arm D receives doses via Stratis on days 1 and 29.
1653631|NCT01827358|Drug|Mupirocin calcium|Mupirocin calcium cream 2% applied topically to umbilicus and perianal area every 8 hours for 5 days, for a total of 15 applications
1653632|NCT01827358|Drug|Mupirocin calcium|Mupirocin calcium ointment 2% will be applied intranasally every 8 hours for 5 days, for a total of 15 applications
1653633|NCT01827345|Dietary Supplement|Vitamin D|Participants will take the Institute of Medicine's recommended daily dose of vitamin D (800 IU/day) for six months.
1653634|NCT01827332|Drug|Oxytocin|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
1653635|NCT01827332|Drug|Saline|Subjects will be administered 40 IUs of oxytocin nasal spray or matching placebo prior to two individual sessions of MET.
1653636|NCT01827306|Drug|Biofreeze|
1653637|NCT01827293|Drug|Promethazine|
1653638|NCT01827293|Drug|Lorazepam|
1653639|NCT01827280|Drug|Vildagliptin|Vildagliptin 50mg/pill will be administered at 10 AM and at 6 PM also for 30 days.
1653640|NCT01827267|Drug|neratinib|
1653641|NCT01827267|Drug|temsirolimus|
1653642|NCT01827254|Other|sunitinib: observational study|Observational study evaluating patients who were treated with sunitinib in 1st line and in 3rd line
1653644|NCT01827228|Other|Assays|May vary across sites
1653645|NCT01827228|Other|HIV medical care|This will be expedited and assisted via community outreach for Recents and Acutes
1653646|NCT01827228|Other|Social network and venue tracing|This is described in Arms 1 and 2
1653647|NCT01827228|Other|Community alerts|When we find recently or acutely infected participants, we will issue community alerts as described in Arm descriptions
1653648|NCT01827228|Other|Community education|Throughout the study we will educate affected communities about recent and acute HIV infection and about the importance of avoiding stigma
1653649|NCT01827228|Behavioral|HIV counseling|As part of HIV testing, we will provide participants with standard counseling
1653650|NCT01827215|Behavioral|Intervention (VPA)|Intervention participants will have access to the Virtual Patient Advocate system for a period of 12 months. They will be encouraged to log on at least once a month, but frequency and duration of conversations with the VPA is at the discretion of the participant.
1653651|NCT01827202|Other|RAS blockade discontinuation|In the initial two weeks of the study, all RAS blockade will be eliminated from the subjects' antihypertensive regimen
1653652|NCT01827202|Drug|Aliskiren|
1653653|NCT01827202|Drug|Candesartan|
1653654|NCT01827189|Other|Comprehensive primary care|Practices participating in the comprehensive primary care initiative receive a monthly amount from Centers for Medicare and Medicaid Services for each attributed Medicare patient, plus technical support of a learning collaborative, and can share in any net savings generated.
1653655|NCT01827176|Other|Recurrent Acute Rhinosinusitis|Clinical Characteristic of Recurrent Acute Rhinosinusitis
1653656|NCT01827163|Drug|Paclitaxel|
1653657|NCT01827163|Drug|Trastuzumab|The q 3 week trastuzumab may be started at the last dose of paclitaxel infusion or from 1-3 weeks after the last dose of paclitaxel. Trastuzumab may also be administered at a dose of 6mg/kg during the last dose of paclitaxel in the THL phase.
1653658|NCT01827163|Drug|Lapatinib|
1653659|NCT01827163|Drug|Pegfilgrastim|Pegfilgrastim SQ is given on day # 2 of each paclitaxel cycle and may be dropped at the last paclitaxel infusion. Filgrastim may be used in lieu of pegfilgrastim at the physician's discretion.
1653660|NCT01827150|Drug|Redbull, energy drink|A can of 250 mL of the energy drink Redbull will be administered randomly to the subjects
1653661|NCT01827137|Biological|WT1 Analog Peptide Vaccine|
1653662|NCT01827137|Biological|Sargramostim (GM-CSF)|
1653663|NCT01827137|Drug|lenalidomide|Optional lenalidomide maintenance starting 3-months post auto SCT
1653664|NCT01827124|Drug|Carbetocin|
1653665|NCT01827124|Drug|oxytocin|
1653666|NCT01827111|Drug|ABI-007|Starting dose of ABI-007 is 150 mg/m2 administered by vein on days 1, 8, 15 every 28 days. The cycle length for ABI-007 is 28 days.
1653667|NCT01827111|Drug|Ipilimumab|3 mg/kg by vein over 90 minutes on day 1. Ipilimumab dose repeated every 21 days for a total of 4 doses.
1653668|NCT01827111|Behavioral|Phone Call|Every 2 months for 6 months, then every 3 months for up to 2 years, participant contacted by telephone. Each call should last about 5 minutes.
1653848|NCT01825551|Drug|Granulocyte Colony Stimulating Factor|
1653849|NCT01825551|Drug|Placebo|
1654534|NCT01820611|Device|Arcos Revision Stem System|Revision Hip System
1653669|NCT01827098|Procedure|Endodontic Regeneration|Blood clot formation is induced in the root canal after disinfection. Collagen material is placed over the clot. The canal access is sealed with white MTA and glass ionomer restoration. Permanent restoration is placed 3 months later on top of the MTA.
1653670|NCT01827085|Device|Conventional Macintosh laryngoscope|
1653671|NCT01827085|Device|Stortz videolaryngoscope|
1653672|NCT01827072|Drug|NPB-01|
1653673|NCT01827059|Drug|Bosentan|125-mg orange-white, round, biconvex, film-coated tablets
1653674|NCT01827059|Drug|Placebo|
1653675|NCT01827046|Drug|rt-PA|Up to 9 doses of 1.0 mg of rt-PA will be administered through the catheter that was placed directly into the intracerebral hemorrhage using minimally invasive surgery.
1653676|NCT01827033|Behavioral|meditation training|
1653677|NCT01827020|Drug|Lidocaine 2 %|12 mL lidocaine 2% 1mg/kg
1653678|NCT01827020|Drug|Ketamine plus Lidocaine|ketamine 0.5 mg/kg + Lidocaine 2% 1 mg/kg in total volume of 12 mL
1653679|NCT01827020|Drug|Saline|12 mL saline (0.9% isotonic solution)
1653680|NCT01827007|Other|Volume expansion with gelofusine|
1653681|NCT01826994|Device|heart type fatty acid binding protein testing|
1653682|NCT01826981|Drug|LDV/SOF|Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
1653683|NCT01826981|Drug|SOF|SOF 400 mg tablet administered orally once daily
1653684|NCT01826981|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1653685|NCT01826981|Drug|Peg-IFN|pegylated interferon (Peg-IFN) 180 µg administered subcutaneously once weekly
1653686|NCT01826981|Drug|GS-9669|GS-9669 500 mg (2 × 250 mg tablet) administered orally once daily
1653687|NCT01826981|Drug|VEL|Velpatasvir (VEL) tablet(s) administered orally once daily
1653688|NCT01826968|Procedure|Alveolar Recruitment maneuver|In this group and during recruitment maneuver the investigators used pressure control ventilation and increased inspiratory time to 50%. The investigators used alveolar recruitment maneuver by increasing inspiratory pressure to 20 cmH20 and progressively increasing Positive Expiratory Pressure (PEEP) up to 45 cmH2O maximal (Ppeak) inspiratory pressure. The recruitment maneuver lasted 2 minutes. After the maneuver PEEP was set to 8 cmH2O and was left until the end of the operation. After the end of the recruitment maneuver volume control ventilation was used until the end of the operation too.
1653689|NCT01826942|Device|Lumenis UltraPulse single fractional CO2 laser treatment thin skin|
1653690|NCT01826942|Device|Single fractional CO2 treatment at surgical area closure procedure on thick skin|
1653691|NCT01826929|Other|Therapeutic education|
1653692|NCT01826916|Drug|DX-88 (ecallantide)|solution for injection 10 mg/mL
1653693|NCT01826890|Other|NAVA Technology|Use of NAVA technology: Diaphragmatic monitoring and NAVA ventilation mode
1653694|NCT01826877|Biological|AdGMCAIX-transduced autologous dendritic cells|Given ID
1653695|NCT01826877|Biological|therapeutic autologous dendritic cells|Given ID
1653696|NCT01826877|Other|laboratory biomarker analysis|Correlative studies
1653697|NCT01826864|Biological|sargramostim|Given SC
1653698|NCT01826864|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
1653699|NCT01826864|Other|laboratory biomarker analysis|Correlative studies
1653700|NCT01826864|Other|hypertonic saline|Given SC
1653701|NCT01826851|Drug|Exparel|"Patients in this group will receive 266 mg Exparel diluted with 0.9% normal saline to a total volume of 50 mL and administered via parasternal intercostal nerve block prior to sternal closure.
Post-operatively, patients will receive IV fentanyl as needed in the ICU while still intubated. A fentanyl PCA pump will be set up post-extubation as soon as possible and prior to the patient leaving the ICU."
1653702|NCT01826851|Drug|Placebo|"Patients in this group will receive 50 mL of 0.9% normal saline as a parasternal intercostal nerve block prior to sternal closure.
Post-surgical pain management will be the same as for the Exparel group."
1653703|NCT01826838|Drug|Dasatinib|
1653704|NCT01826825|Behavioral|Cognitive Screen|Cognitive Screen
1653705|NCT01826825|Behavioral|Mini-Cog|Cognitive Screen
1653706|NCT01826812|Other|30 minutes sustained reading|The participants will be given a text to read silently in 30 minutes.
1653707|NCT01826812|Other|Dry eye exam|Tear break-up time, tear collection, osmolarity, Schirmer test, corneal and conjunctival staining.
1653708|NCT01826786|Drug|JNJ-42165279 (100 mg)|JNJ-42165279 (100 mg/day) will be orally administered once daily for 4 consecutive days.
1653709|NCT01826786|Drug|Placebo|Matching placebo to JNJ-42165279 will be orally administered once daily for 4 consecutive days.
1653710|NCT01826773|Drug|CardioPET™|CardioPET™ will be intravenously injected to each subject as a single radio-labeled dose of up to 8 mCi (296 MBq).
1653711|NCT01826760|Other|Using training and testing groups to construct ANN based on laboratory tests|
1653712|NCT01826747|Drug|crinone (progesterone 8%, vaginal application)|
1653713|NCT01826721|Other|Transplant Medication Information Teaching Tool|Online e-learning tool for post-transplant medication education.
1653714|NCT01826708|Biological|Identification of breakpoints|Identification of breakpoints in Molecular Biology : demonstration of a chimeric sequence corresponding to a junction region between the two chromosomes
1653715|NCT01826695|Other|Neurodynamic technique group|"Neurodynamic techniques are used in order to move most of the nerves between the neck and hand, including the median nerve, radial and ulnar, brachial plexus, spinal nerves and cervical nerve roots.
The patient is placed supine position. The treatment will be carry out 3 times per week during 8 weeks."
1653716|NCT01826695|Other|Placebo group|Women in this group realized standard treatment in the Fibromyalgia Association without neurodynamic techniques.
1653717|NCT01826682|Other|Physiotherapy program+medical treatment|Patients included in this group are going to receive physiotherapy during their hospital stay 45 minutes every day. The physical training is based on respiratory exercises, the use of a flutter (positive expiratory pressure), pedaling and theraband exercises.
1653718|NCT01826682|Other|Medical treatment|Standard medical treatment without physiotherapy.
1653850|NCT01825525|Device|Exposure to ScopeGuide|The 2 minute protocol exposure to the electromagnetic field of the ScopeGuide device.
1718082|NCT00002398|Drug|Adefovir dipivoxil|
1653719|NCT01826669|Procedure|Stretching|Patients submitted to respiratory muscle stretching related to the increase thoracic mobility. Stretching were performed in the upper trapezius, scalenes, sternocleidomastoids, major pectoral and intercostals. The muscle stretching were performed passively by a single therapist trained and experienced. The subjects were positioned supine or lateral, knees flexed in order to correct the lumbar curve. Stretching occurred during the expiratory phase, leading to muscle maximum length, with two series of ten consecutive incursions for each muscle, with an interval of one minute between series. The patients were properly informed to perform slow exhalations and pursed-lip during stretching.
2013068|NCT01142297|Device|dental implant and modified dental implant|standard SLA surface and chemically modified surface
2013069|NCT01115283|Behavioral|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
2013070|NCT01115283|Behavioral|Video Games|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
2013071|NCT01115283|Behavioral|Occlusion therapy|Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
1653724|NCT01826630|Other|CLn BodyWash|Comparing two washes to determine change in bacterial load.
1653725|NCT01826630|Other|Cetaphil Daily Facial Cleanser|Comparing two washes to determine change in bacterial load.
1653726|NCT01826604|Device|Alexis O C-Section Retractor|The Alexis O C-section retractor will be used.
1653727|NCT01826604|Other|Control- Conventional retractors|Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.
1653728|NCT01826591|Behavioral|Low-Carbohydrate Diet|Counseling/instruction on how to follow a low-carbohydrate diet.
1653729|NCT01826591|Behavioral|Low-Fat Diet|Counseling/instruction on how to follow a low-fat diet.
1653730|NCT01826591|Behavioral|Mobile App|Mobile app to increase vegetable consumption. Participants with iPhones will be re-randomized to receive a mobile app beginning at either months 4-5 or months 7-8. The first phase during months 4-7 will be used to compare the effect of a mobile app (intervention) vs. no mobile app (waiting-list control). The a priori hypothesis is that vegetable consumption will increase among those who receive the app in both diet groups.
1653731|NCT01826578|Procedure|using only one port for laparoscopic surgery|using only one port for laparoscopic surgery
2013072|NCT01113554|Other|questionnaire administration|
1653733|NCT01826552|Device|Osiro Hybrid Drug-Eluting Stent|Osiro Hybrid Drug-Eluting Stent (Biotronik AG, Bulach, Switzeland)
1653734|NCT01826552|Device|Resolute Integrity|Resolute Integrity zotarolimus-eluting stent (Medtronic Cardiovascular, CA, Minnesota, USA)
1653735|NCT01826539|Procedure|flap includes a donor nerve|the donor nerve is attached with the flap for sensory reconstruction of the finger
1653736|NCT01826526|Device|TauroSept®|"5 ml of TauroSept® will be instilled into the catheter (CVAD) each time after total parenteral nutrition (TPN) has been completed. The frequency of administration depends on the schedule of HPN. It varies between twice per week and once daily.
The duration of TauroSept® administration in this trial will be 12 months."
1653737|NCT01826513|Device|Standard AutoSet algorithm|An AutoSet device with a standard algorithm developed for sleep breathing parameters that are specific to a particular gender.
1653738|NCT01826513|Device|Modified AutoSet algorithm|An AutoSet device with an algorithm developed for sleep breathing parameters specific to females.
1653739|NCT01826500|Other|blood test|blood test
1653740|NCT01826487|Drug|Ataluren|Ataluren PO 10-,10-,20-mg/kg for 48 weeks.
1653741|NCT01826487|Drug|Placebo|Placebo PO 10-,10-,20-,mg/kg for 48 weeks.
1653742|NCT01826474|Drug|PRO045, 0.15 mg/kg/week|Subcutaneous injection
1653743|NCT01826474|Drug|PRO045, 1.0 mg/kg/week|Subcutaneous injection
1653744|NCT01826474|Drug|PRO045, 3.0 mg/kg/week|Subcutaneous injection
1653745|NCT01826474|Drug|PRO045, 6.0 mg/kg/week|Subcutaneous injection
1653746|NCT01826474|Drug|PRO045, 9.0 mg/kg/week|Subcutaneous injection
1653747|NCT01826474|Drug|PRO045, selected dose|Subcutaneous injection
1653748|NCT01826461|Drug|PDI-192|
1653749|NCT01826461|Drug|Vehicle|
1653750|NCT01826448|Drug|PLX3397|
1653751|NCT01826448|Drug|vemurafenib|
1653752|NCT01826435|Behavioral|Electronic Intervention|Patients will be able to receive the intervention notifications over the electronic/multimedia mode they prefer; selecting either text messaging/mobile web and/or email/online web. Text message or email alerts with an included uniform resource locator (URL) link to the specified mobile or online web site will be utilized to notify patients of a pending encounter available on mobile. Topics that will be addressed in the intervention include medication and side effects, social support, hypertension knowledge, memory and smoking. All intervention encounters that are designed to collect responses from the patient will require the patient to supply credentials before responding to the encounter; thus, ensuring privacy of the patient session, as well as patient-specific tracking of responses.
2013073|NCT01113554|Behavioral|exercise intervention|
2013074|NCT01113554|Procedure|quality-of-life assessment|
1653755|NCT01826409|Dietary Supplement|Fermented Red Ginseng|Fermented red ginseng 2.7g/day for 4 weeks
1653756|NCT01826409|Dietary Supplement|Placebo|Placebo 2.7g/day for 4 weeks
1653757|NCT01826396|Drug|Irinotecan|Comparison of standard and high dose irinotecan
1653758|NCT01826214|Drug|LDE225|LDE225 will be supplied as 200 mg capsules by Novartis. Patients will receive study treatment on an outpatient basis. LDE225 will be dispensed every two weeks for the first four weeks and at the start of every four weeks thereafter, as needed.
1653759|NCT01826201|Drug|MOL4239|10% MOL4239 ointment to one target lesion twice a day for 28.5 consecutive days
1653760|NCT01826201|Drug|Placebo|placebo ointment to the contralateral target lesion twice a day for 28.5 consecutive days
1653761|NCT01826188|Drug|THC 5 mg/ml and CBD 50 mg/ml.|
2013075|NCT01113554|Other|survey administration|
2013076|NCT01113554|Procedure|management of therapy complications|
2013077|NCT01113554|Procedure|psychosocial assessment and care|
1653762|NCT01826175|Drug|Ticagrelor|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
1653763|NCT01826175|Drug|Clopidogrel|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
1653764|NCT01826175|Device|Optical Coherence Tomography|Subjects are randomized to receive a loading dose of ticagrelor or clopidogrel, and all subjects have Optical Coherence Tomography (OCT) imaging performed at the end of their stenting procedures.
1653765|NCT01826162|Other|acetate or placebo infusion|
1958052|NCT02010567|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine pro-drug, metabolically converted to 5-fluorouracil after administration. It is indicated as adjuvant treatment in patients with stage III colorectal cancer (Dukes' C colon cancer), and as first-line treatment of metastatic colorectal cancer.
2013078|NCT01108445|Drug|Everolimus|Subjects in this treatment arm will receive everolimusRAD001 10 mg orally once daily by mouth on days 1 through 42 for each 42 day cycle.
2013079|NCT01108445|Drug|Sunitinib|50 mg daily by mouth on days 1 through 28 of each 42 day cycle.
1653769|NCT01826136|Device|Acapella device|
1653770|NCT01826123|Device|Conventional laboratory testing (Central laboratory)|aPTT, INR, fibrinogen concentration, platelet count
1653771|NCT01826123|Device|POC testing|ROTEM: Clotting time (CT) in the EXTEM- and INTEM-test, Maximal clot firmness in the FIBTEM-test, Clot Lysis Index (CLI) multiplate: Area under the aggregation curve following stimulation with arachidonic acid (ASA) and Adenosine diphosphate (ADP)
1653772|NCT01826110|Drug|[11C]PIB|Approximately 15 mCI [11C]PIB IV x1
1653773|NCT01826097|Device|La-Z-Boy Massage Chair Vibration Effect on Bladder Cancer Cell Concentration|
1653774|NCT01826071|Other|Static Stretch|
1653775|NCT01826071|Other|Active Elongation|
1653776|NCT01826058|Radiation|Stereotactic body radiation therapy|
1653777|NCT01826045|Drug|Poly-gamma Glutamic Acid|
1653778|NCT01826045|Drug|Placebo|
1653779|NCT01826032|Device|CPAP|CPAP treatment every night plus standard care for OSA: lifestyle, and sleep hygiene counselling
1653780|NCT01826032|Other|Standard care for OSA|sleep higiene and dietary counseling
1653781|NCT01826019|Other|Intervention|In intervention communities, management plans will be developed by the NPHW for all enrolled participants. The NPHWs will educate participants about CVD, HT treatment, lifestyle modifications and initiate therapy according to the modified WHO CVD risk-management algorithm, including referral of high-risk patients to physicians and safety monitoring where appropriate. Participants in intervention communities will have support from family or friends (treatment supporters) and will receive educational materials and treatment reminders using text-messaging, email, and printed materials, as appropriate for the participant and the community setting. Evidence-based CV medications will be made available to the NPHWs and supervising physicians for participant treatment.
1653782|NCT01826019|Other|Usual Care|At initial screening, eligible participants will be provided with a brief information booklet/leaflet (customized to the community or region) regarding lifestyle modification and be advised to see their usual physician for care that is considered appropriate. No structured interventions will be employed.
1653783|NCT01826006|Device|Excimer laser|
1653784|NCT01826006|Device|Manual Thrombus Aspiration|
1653785|NCT01825993|Drug|L-BUPIVACAINE ; MORPHINE|
1653786|NCT01825993|Drug|MORPHINE|
1653787|NCT01825980|Drug|BZF961|There will be 2 parts to the study: Part 1: BZF monotherapy. Part 2: Cohort IIa: BZF961 monotherapy at 3 TBD doses; Cohort IIb: BZF961 in combination with ritonavir at TBD doses.
1653788|NCT01825980|Drug|Ritonavir|Ritonavir will be given as a boosting agent in Part 2, Cohort IIb in combination with BZF961
1653789|NCT01825980|Drug|Placebo|Placebo
1653790|NCT01825967|Other|C-reactive protein|measured C-reactive protein in all patients with acute diverticulitis
1653791|NCT01825954|Device|RINCE|The intervention uses the NeuroPoint device to deliver repeat applications of RINCE therapy stimulation. The sham uses the NeuroPoint device, but the RINCE therapy stimulation is not turned on.
1653792|NCT01825941|Drug|metoclopramide|10 milligrams, administered intravenously over 15 minutes
1653793|NCT01825941|Drug|diphenhydramine|50 milligrams, administered intravenously over 15 minutes
1653794|NCT01825941|Drug|placebo|
1653795|NCT01825928|Drug|Paliperidone|Paliperidone group,3mg/pill,3mg/day forced titration method,last 84 days
1653796|NCT01825928|Drug|placebo|placebo group,3mg/pill,3mg/day forced titration method,last 84 days
1653797|NCT01825915|Procedure|Laparoscopic Hysterectomy|
1653798|NCT01825915|Procedure|Laparoscopic Supracervical Hysterectomy|
1653799|NCT01825902|Other|fluorine F 18 fluorothymidine|Undergo 18F-FLT PET
1653800|NCT01825902|Radiation|fludeoxyglucose F 18|Undergo 18F-FDG PET
1653801|NCT01825902|Procedure|positron emission tomography|Undergo 18F-FLT PET and 18F-FDG PET
1653802|NCT01825902|Procedure|diffusion-weighted magnetic resonance imaging|Undergo DW-MRI
1653803|NCT01825902|Other|laboratory biomarker analysis|Correlative studies
1653804|NCT01825889|Drug|Evacetrapib|Administered orally
1653805|NCT01825876|Drug|Evacetrapib|Oral administration
1653806|NCT01825876|Drug|Warfarin|Oral administration
1653807|NCT01825863|Drug|Ropivacaine|
1653808|NCT01825863|Drug|Saline 9%|
1653809|NCT01825850|Drug|Gemigliptin|
1653810|NCT01825850|Drug|Irbesartan|
1653811|NCT01825837|Drug|BIA 2-093 1800 mg once daily [Group 1 (Part II)]|BIA 2-093 1800 mg taken orally in the evening, for 2 weeks
1653812|NCT01825837|Drug|BIA 2-093 900 mg once daily [Group 2 (Part II)]|BIA 2-093 900 mg taken orally in the evening, for 2 weeks
1653813|NCT01825837|Drug|BIA 2-093 300 mg once daily [Group 3 (Part II)]|BIA 2-093 300 mg taken orally in the evening, for 2 weeks.
1653814|NCT01825837|Drug|BIA 2-093 900 mg (Part I)|In Part I, patients received one 900 mg BIA 2-093 tablet once daily, taken orally in the evening, for 2 weeks.
1653853|NCT01825499|Other|Registry|
1653854|NCT01825486|Behavioral|accidental falls|
1653855|NCT01825473|Drug|Erythromycin|
1653815|NCT01825824|Radiation|Stereotactic ablative radiotherapy|The HCC patients with size ≤5 cm and 3 cm apart from gastrointestinal tract will be included in this study. Total stereotactic ablative radiotherapy (SABR) doses will be 60 Gy in 3 fractionations. Patients receive 3 fractionations separated by >48 hours. At least 700 ml of normal liver (entire liver minus cumulative GTV) should not receive a total dose of > 17 Gy in three fractions. If volume of normal liver does not exceed 700 ml, at least 70% of normal liver should not receive a total dose of > 17 Gy. Dose of esophagus, stomach and intestine do not exceed 30 Gy.
1653816|NCT01825811|Biological|TissueGene-C (Low dose)|TissueGene-C at 1.0 x 10^6 cells mixed with fibrin-glue
1653817|NCT01825811|Biological|TissueGene-C (High dose)|TissueGene-C at 3.0 x 10^6 cells mixed with fibrin-glue
2013080|NCT01107639|Biological|cetuximab|Loading dose 400 mg/m2 2h infusion Weekly: 250 mg/m2 1h infusion
2013081|NCT01107639|Drug|cisplatin|"Cisplatin 75 mg/m2 1h infusion d1, 22
Cisplatin 25 mg/m2 1h infusion weekly x5"
1653820|NCT01825785|Drug|Treatment Interval 1|Dose every 2 weeks
1653821|NCT01825785|Drug|Treatment Interval 2|Dose every 4 weeks
1653822|NCT01825759|Drug|danshen dripping pill|
1653823|NCT01825746|Other|Implementation of the MOHR assessment in primary care workflow|The MOHR assessment includes (1) asking patients to complete the MOHR assessment on the web prior to encounters (available at www.MyOwnHealthReport.org it addresses10 distinct health behaviors and psychosocial issues including physical activity, diet, alcohol consumption, tobacco use, drug use, sleep, stress, depression and anxiety), (2) provision, via the tool, immediate patient feedback that includes identification of unhealthy issues, assessment of readiness to change, prioritization of issues to change, and preparation for goal-setting and action planning, (3) feedback to the primary care team on the patient status and priorities for change, (4) provision of counseling, goal setting, and referrals to local resources by clinicians during the subsequent office visit, and (5) follow-up with the clinicians and local resources as agreed upon by the patient and clinician.
1653824|NCT01825733|Drug|ramosetron|Ramosetron 0.3 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
1653825|NCT01825733|Drug|palonosetron|palonosetrno 0.075 mg was mixed to the PCA. Same dose of drug was administered 10 minutes before the end of surgery according to the allocated group.
1653826|NCT01825720|Drug|(Glucose-Insulin-Potassium)GIK group|infusion of 0.1 IU/kg/hr of insulin and mixture of 30% dextrose water with 80 mmol/l of potassium in the rate of 0.5 ml/kg/hr through out the surgery
1653827|NCT01825720|Drug|normal saline group|same rate of normal saline
1653828|NCT01825707|Drug|[14C]-YH4808 200 mg|[14C]-YH4808 200 mg (oral) on day1
1653829|NCT01825694|Behavioral|Trauma-focused Substance Abuse Intervention|An integrated treatment approach to reduce substance use and PTSD symptoms. The intervention program includes: 1) 1-2 individual sessions during which youth talk about the trauma, during the course of the intervention program; 2) 16 group sessions for youth; 3) 2 conjoint sessions with parents to improve communication and problem-solving skills; and 4) 2 parent-education group sessions.
1653830|NCT01825681|Behavioral|Positive Affect|Six-session skill-building program designed to raise levels of positive emotion when skills are practiced over the duration of the program.
1653831|NCT01825668|Other|Plant Sterols|
1653832|NCT01825668|Other|High cholesterol|
1653833|NCT01825668|Other|Placebo|
1653834|NCT01825655|Drug|Cetirizine|
1653835|NCT01825655|Drug|Placebo or sugar pill|
1653836|NCT01825642|Procedure|nerve-sparing radical prostatectomy|
1653837|NCT01825642|Procedure|seminal vesicle-sparing radical prostatectomy|
1653838|NCT01825629|Other|Multidisciplinary therapy|"Physical Therapy: Cervical traction, Cranium fore flexion 15 °, Open-close mouth dental contactless (10 mm), Opening movement with a small resistor (one finger on chin), Flexion of the head, without actually lifting, resisting in the front, Occipital extension, Cranium fore flexion 15 °, Cervical traction.
Myofascial Therapy: Induction suboccipital, compression - decompression of the temporomandibular joint, horizontal induction of the temporomandibular joint, deep fascia induction in the temporal region, deep induction of the masseter fascia, deep induction of the external pterygoid, and induction of intraoral pterygoid.
Deontology therapy: the patient are going to port a deprogramming occlusal splint every night, an average of 8 hours per day, for 15 weeks."
1653839|NCT01825629|Other|Placebo|
1653840|NCT01825616|Dietary Supplement|Vitamin D2 mushroom powder|Subjects will be given Portobello mushroom powder with or without vitamin D mixed in soymilk powder in six plastic containers (one for each week of the study). Subjects will ingest one level teaspoon of the product each day (with or without 4,000 IU vitamin D2) and consume during breakfast in one of the following ways: mixed in water, juice, yogurt, or milk.
1653841|NCT01825616|Other|Placebo|Mushroom powder without vitamin D2
1653842|NCT01825603|Drug|ADH-1|Given IV
1653843|NCT01825603|Drug|cisplatin|Given IV
1653844|NCT01825603|Drug|gemcitabine hydrochloride|Given IV
1653845|NCT01825603|Other|laboratory biomarker analysis|Correlative studies
1653846|NCT01825590|Other|Dialysate and serum sodium concentration aligned|
1653847|NCT01825577|Drug|Transdermal Methylphenidate|2 Weeks of once daily 10mg Transdermal Methylphenidate followed by 2 weeks of once daily 15mg Transdermal Methylphenidate. Patch will be worn for approximately 7-10hrs each day.
2013082|NCT01107639|Drug|docetaxel|"Docetaxel 75 mg/m2 1h infusion d1, 22
Docetaxel 20 mg/m2 1/2h infusion weekly x5"
2013083|NCT01107639|Procedure|adjuvant therapy|During the adjuvant phase, all infusions, given every two weeks, will be at a dose of 500mg/m².
2013084|NCT01107639|Procedure|neoadjuvant therapy|During the neoadjuvant phase, the first infusion of cetuximab should be at a dose of 400 mg/m² administered over a period of 2 hours and all subsequent infusions, given weekly, should be of 250 mg/m² over a period of 1 hour, unless any infusion related reaction was observed at a previous infusion. (The maximum infusion rate is 10 mg/min, corresponding to 2 mL/min ready-to-use solution.
2013085|NCT01088737|Drug|Imiquimod|Imiquimod 5% cream is applied once daily. Each patient will begin with the application 3x/week. After two weeks of treatment the inflammation response to imiquimod will be assessed. If no or only minor inflammation is detectable in the treatment area, the dosing schedule will be increased to 5x/week. After four weeks of treatment the inflammation response will be assessed again. If still no or only minor inflammation is detectable, application will be extended to daily use.
1653856|NCT01825473|Device|Multi-channel intra-luminal impedance (MII) pH monitoring|
1653857|NCT01825473|Drug|Placebo (D5W)|
1653858|NCT01825460|Other|Manual Therapy Protocol|The manual therapy protocol consists in the application of the following techniques: stretching diaphragm, Inhibition for phrenic center, Neuromuscular technique, technique jones and balance technique functional.
1653859|NCT01825460|Other|Two manual techniques|The two manual techniques applied to control group are: inhibition for phrenic center and neuromuscular technique.
1653860|NCT01825447|Drug|Placebo|0.9% sodium chloride for injection x 1 dose administered intravenously (IV) push over 4 min.
1653861|NCT01825447|Drug|Oxycodone + Naltrexone|Oxycodone hydrochloride (HCl) 20 mg IV and naltrexone HCl 2.4 mg IV administered simultaneously x 1 dose IV push over 4 min.
1653862|NCT01825447|Drug|Oxycodone|Oxycodone HCl 20 mg for injection x 1 dose IV push over 4 min.
1653863|NCT01825434|Dietary Supplement|yogurt containing: polydextrose L. acidophilus NCFM® B. lactis HN019|NCFM Group
1653864|NCT01825421|Other|Intervention is to stop antibiotics at 24h .|Stoppage of antibiotics at 24h in the intervention arm, randomization based on neutrophil CD64 values.
1653865|NCT01825408|Drug|Doxycycline|Subjects with CRSwNP who are not allergic to doxycycline will receive Doxycycline 100mg BID for either 3 or 6 weeks duration.
1653866|NCT01825408|Drug|Azithromycin|Subjects with CRS without Nasal Polyposis (CRSwNP)who are not allergic to azithromycin will be given Azithromycin 250mg daily for either 3 or 6 weeks duration.
1653867|NCT01825408|Drug|Augmentin|If a subject in any of the study arms is allergic to the medication he/she is supposed to receive, he/she will be given Augmentin 875mg BID for either 3 or 6 weeks duration
1653868|NCT01825395|Drug|3, 4-Diaminopyridine|
1653869|NCT01825382|Device|iBGStar meter|Subjects will receive iBGStar meter and iPhone to use as meter during the study.
1653870|NCT01825369|Drug|IV L-carnitine|See arm description
1653871|NCT01825356|Procedure|Dorsal Cheilectomy without Amniotic Membrane Tissue Implantation|
1653872|NCT01825356|Procedure|Dorsal Cheilectomy with Amniotic Membrane Tissue Implantation|
1653873|NCT01825330|Device|TMS and cognitive stimulation|Synchronized TMS and cognitive stimulation to 6 brain areas.
1653874|NCT01825330|Device|sham|
1653875|NCT01825317|Device|NeuroAD|synchronized TMS+COGNITIVE TRAINING
1653876|NCT01825317|Device|Sham device|Sham TMS+cog, has the same sound and appearance as the real device, delivers no energy.
1653877|NCT01825304|Device|titrated setting peep|titrated setting peep according to esophageal pressure in experimental group; setting peep on the patient's PaO2 and FiO2 in control group.
1653878|NCT01825291|Procedure|CPAP treatment|
1653879|NCT01825278|Device|ExSpiron Respiratory Volume Monitor (RVM, ExSpiron™, Respiratory Motion, Inc.; Waltham, MA|Monitoring sensors will be applied to patient's right chest and the monitoring device will collect breathing parameters such as breathing rate and volumes before, during and after the procedure until patient is ready to leave the recovery room. At the beginning and at the end of the study investigator will perform a one-time measurement of patient's respiratory parameters using a standard handheld spirometer. This is a non-invasive device that is commonly used in clinical care not related to research.
1653880|NCT01825265|Drug|Docetaxel|40 mg/m^2 IV over 1 hour on Day 1.
1653881|NCT01825265|Drug|RAD001|30 mg orally on Days 1 and 8.
1653882|NCT01825265|Drug|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
1653883|NCT01825252|Behavioral|Social Network Intervention|Approximately 20% of people are trained to have discussions endorsing less risky behaviors with members of their social network.
1653884|NCT01825252|Behavioral|Counsel, Test, and Treat|People receive standard-of-care HIV/STD counseling, testing, and treatment
1653885|NCT01825239|Other|Collection of measurements during LV pacing during electrophysiology study|During the electrophysiology study, measurements will be obtained while pacing from different left ventricular regions in context to scar as determined by SPECT-CT testing.
1653886|NCT01825226|Other|Enhanced-Homestead Food Production Program|Participation in an enhanced-homestead food production program including home gardening and nutrition and health behavior change communication
1653887|NCT01825213|Device|Multispectral CT of the liver|Analysis of the background liver and liver lesions will be performed on Multi Spectral CT images and compared to histology.
1653888|NCT01825200|Biological|Flublok|A Biologics Licensing Application (BLA) for Flublok was approved by the FDA for influenza immunization of adults 18-49 years of age. Flublok is produced using recombinant technology under serum-free conditions.
1653889|NCT01825200|Biological|Afluria|Afluria is approved for use in persons 5 years of age and older and is produced by inactivation and disruption of live influenza virus grown in embryonated chicken eggs.
1653890|NCT01825187|Device|ULTRAPRO Mesh|Patients who are randomized to this group will received ULTRAPRO Mesh for their hernia repair
1653891|NCT01825187|Device|3DMAX|Patients who are randomized to this group will receive 3DMAX mesh for their hernia repair
1653892|NCT01825187|Other|Evaluation|To evaluate the ease of use and time it takes residents to place and perform the surgery using these two different meshes.
1653893|NCT01825174|Behavioral|Ball games program|twice a week different ball games 90min
1653894|NCT01825174|Behavioral|Nutrition counseling|9 units of 90min each of nutrition counseling
1653895|NCT01825148|Other|radiolabeled Exendin|
1653896|NCT01825135|Device|Neuromuscular electrical stimulation|
1653897|NCT01825135|Device|sham stimulation|sham stimulation will be applied to the quadriceps
1653898|NCT01825122|Drug|Nadolol|
1653899|NCT01825122|Drug|Placebo|
1653900|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus vaccine with no intervention in normal breastfeeding practices before and after receiving vaccine.
1653901|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 6 and 10 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
1653902|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus, with no intervention in normal breastfeeding practices before and after receiving vaccine.
1653903|NCT01825109|Biological|Rotavirus Vaccine & Breastfeeding|Administration of Rotarix at 14 and 18 weeks co-administered with oral polio virus. Breastfeeding will not be permitted 45 minutes prior to vaccine administration and 45 minutes after each vaccine administration.
1653904|NCT01825083|Drug|Ketamine|Ketamine group receives 0.5mg/kg followed by an infusion of 1.5mcg/kg/min.
1653905|NCT01825083|Drug|Placebo|0.9 % normal saline group receives same volume as the ketamine dose
1653906|NCT01825070|Dietary Supplement|Montmorency cherry concentrate|Tart Montmorency cherry juice concentrate
1653907|NCT01825057|Behavioral|See One|
1653908|NCT01825057|Behavioral|Do One|
1653909|NCT01825057|Behavioral|Order One|
1653910|NCT01825044|Drug|NeuroSTAT 5 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 5 mg/kg bodyweight/day continuous infusion
1653911|NCT01825044|Drug|NeuroSTAT 10 mg/kg/day|Intravenous bolus of NeuroSTAT (Ciclosporin) 2.5 mg/kg bodyweight followed by 5 days of 10 mg/kg bodyweight/day continuous infusion
1653912|NCT01825031|Drug|Raltegravir|400mg twice daily for the first 12 weeks only in addition to 3 standard ARVs
1653913|NCT01825031|Drug|Fluconazole|100mg once daily for 12 weeks
1653914|NCT01825031|Drug|Azithromycin|500mg once daily for 5 days
1653915|NCT01825031|Drug|Albendazole|a single dose 400mg
1653916|NCT01825031|Drug|Isoniazid|300mg taken immediately in combination with cotrimoxazole
1653917|NCT01825031|Dietary Supplement|Ready to Use Supplementary Food|2x92g packets daily of high energy, low protein lipid-based paste for 12 weeks
2013086|NCT01078909|Biological|Eicosapentaenoic Acid and Docosahexaenoic Acid (EPA + DHA)|Comparison of 4 doses of EPA+DHA on in vivo and ex vivo (monocytes) response to an inflammatory stimulus (endotoxin) following a 6 month supplementation period
2013087|NCT01077518|Drug|Ofatumumab and Bendamustine infusions (Arm A)|Up to 8 cycles of Bendamustine (90 mg/m2 Days 1 and 2, every 21 days) given in combination with 12 doses of ofatumumab (1000 mg). Ofatumumab will be given on day 1 of each cycle of bendamustine as long as patients in Arm A receive bendamustine. Once patients in Arm A complete bendamustine therapy, the remaining doses of ofatumumab will be given monthly until all 12 doses are completed.
1653920|NCT01824992|Drug|Yallaferon®|
2013088|NCT01077518|Drug|Bendamustine infusion (Arm B)|Bendamustine (120 mg/m2 Days 1 and 2, every 21 days, up to 8 cycles).
2013089|NCT01061151|Drug|Zidovudine (ZDV)|Antepartum Arm A: 300 mg orally twice daily beginning at greater than or equal to 14 weeks gestation (at study entry) through delivery
1653923|NCT01824940|Behavioral|Standard care|"Standard Care:
Exclusive breastfeeding promotion for all infants, birth to 6 months
Strengthened PMTCT (prevention of mother to child transmission of HIV) services
Strengthened Village Health Worker system"
1653924|NCT01824940|Other|WASH|"WASH:
Standard care interventions
Provide household ventilated pit latrine, water treatment solution, and monthly liquid soap, two hand-washing facilities and protected infant play space
Provide interpersonal communication interventions promoting feces disposal in a latrine, HWWS (hand washing with soap), drinking water treatment, hygienic weaning food preparation, and preventing babies from putting dirt and animal feces in their mouths."
1653925|NCT01824940|Dietary Supplement|Nutrition|"IYCF:
Standard care interventions
Provide 20 g/d Nutributter from 6-18 months
Provide interpersonal communication interventions promoting optimal use of locally available foods for complementary feeding after 6 months, continued breastfeeding and feeding during illness."
1653926|NCT01824940|Other|WASH and Nutrition|"Sanitation/Hygiene AND Nutrition:
Standard care interventions
All WASH interventions
All IYCF interventions"
1653927|NCT01824927|Procedure|First eye (FE)|Phacoemulsification cataract extraction surgery
1653928|NCT01824927|Procedure|Second eye (SE)|Phacoemulsification cataract extraction surgery
1653929|NCT01824927|Drug|Steroids eye drops|Use steroids eye drops to decrease the pain.
1653930|NCT01824914|Device|McGrath Videolaryngoscope|A kind of portable videolaryngoscopes, produced by Aircraft Medical. It has been used for difficult airway.
1653931|NCT01824901|Drug|docetaxel|Given IV
1653932|NCT01824901|Drug|AZD4547|Given PO
1653933|NCT01824888|Drug|JUC solution|1.5 ml JUC solution rubbing on hands for 30 seconds, repeated twice
1653934|NCT01824888|Drug|propan-2-ol|1.5 ml propan-2-ol rubbing on hands for 30 seconds, repeated twice
1653935|NCT01824875|Drug|temozolomide|Given PO
1653936|NCT01824875|Drug|capecitabine|Given PO
1653937|NCT01824875|Other|laboratory biomarker analysis|Correlative studies
1653938|NCT01824849|Procedure|Total arytenoidectomy|Endoscopic total arytenoidectomy was performed on patients with bilateral vocal fold paralysis
1653939|NCT01824849|Procedure|Partial arytenoidectomy|Endoscopic partial arytenoidectomy was performed on patients with bilateral vocal fold paralysis
1653940|NCT01824836|Drug|anastrozole|Given PO
1653941|NCT01824836|Other|questionnaire administration|Ancillary studies
1653942|NCT01824836|Other|laboratory biomarker analysis|Correlative studies
1653943|NCT01824836|Other|pharmacogenomic studies|Correlative studies
1653944|NCT01824823|Drug|afatinib|Given PO
1653945|NCT01824823|Other|placebo|Given PO
1653946|NCT01824810|Procedure|Intramuscular Stimulation|"Intramuscular Stimulation is the insertion of fine, flexible needles into shortened muscle tissue. No substance is injected. In shortened or supersensitive muscles, stimulation of stretch receptors in the muscle causes a lengthening response in the affected tissue. This reflex response is felt by the patient as a cramping sensation which releases as the muscle returns to a normal length. Needles may be inserted and removed immediately or inserted and left in the tissue for several minutes. Practitioners may also use the approach of twirling the needles to enhance the grasping response in the muscle."
1653947|NCT01824810|Procedure|myoActivation|In myoActivation treatments, a fine needle is used to administer a micro-injection (less than .2 mL) of saline (0.9%) targeted to muscle, fascia, connective tissue, and scar tissue. The needle is inserted into shortened muscle tissue to elicit a reflex response that lengthens the tissue and promotes a healing response. One session includes between 10 and 80 needle insertions, and is a combination of deep and shallow needling techniques. Additionally, the practitioner treats superficial fascia and scar tissue by using multiple shallow needle insertions to a scarred area and/or areas of abnormal elevation and depression in the skin.
1653948|NCT01824810|Procedure|Neural Prolotherapy|Participants in the neural prolotherapy group will receive micro-injections of a dextrose or mannitol solution directly under the skin using a very fine needle. This treatment targets the superficial cutaneous nerves. It is suggested that these injections quickly reduce cutaneous nerve edema, allowing these nerves to freely cross the fascia to reach the skin. Treatments may include up to 200 micro-injections with a fine needle. Injections follow major nerve routes associated with neck and upper back pain.
1653949|NCT01824810|Procedure|Sham Needling Control|The sham needling control group will receive up to 5 needle insertions in areas unrelated directly to whiplash pain. No injection will be given though participants in this group will not be aware of the presence or absence of a substance injection. Sham treatments will take anywhere from 15 to 60 minutes, to preserve blindness.
1653950|NCT01824771|Other|Plasma lactate were measured|Three different doses (20 ml/kg/h, 35 ml/kg/h and 45 ml/kg/h) of CVVH were applied to critically ill patients who experiencing CVVH. Each dose of CVVH was sequentially gave to each patient and lasted for 30 minutes separately
1653951|NCT01824758|Drug|Lidocaine|Group L lidocaine (1.5 mg/kg), (rocuronium) (0.05mg/kg).
1653952|NCT01824758|Drug|Esmolol|Group E: esmolol (1 mg/kg), (rocuronium) (0.05mg/kg)
1653953|NCT01824758|Drug|rocuronium|0.05 mg/kg rocuronium
1653954|NCT01824758|Drug|Placebo|Group C: Placebo (NaCl 0.9%, 5 ml), (rocuronium) (0.05mg/kg)
1653955|NCT01824745|Other|educational intervention|Receive the SCP-BCS template booklet
1653956|NCT01824745|Other|counseling intervention|Receive counseling sessions with a patient navigator
1653957|NCT01824745|Procedure|standard follow-up care|Receive standard follow-up care
1653958|NCT01824745|Procedure|quality-of-life assessment|Ancillary studies
1653959|NCT01824745|Other|questionnaire administration|Ancillary studies
1653960|NCT01824706|Procedure|craniectomy|craniectomy
1653961|NCT01824693|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic HCT
1653962|NCT01824693|Drug|Busulfan|Given IV
1653963|NCT01824693|Drug|Cyclophosphamide|Given IV
1653964|NCT01824693|Drug|Fludarabine Phosphate|Given IV
1653965|NCT01824693|Other|Laboratory Biomarker Analysis|Correlative studies
1653966|NCT01824693|Drug|Melphalan|Given IV
1653967|NCT01824693|Drug|Mycophenolate Mofetil|Given IV or PO
1653968|NCT01824693|Other|Pharmacological Study|Correlative studies
1653969|NCT01824693|Drug|Tacrolimus|Given IV or PO
1653970|NCT01824680|Behavioral|Physical activity|"There is two sequences, one before and one after the physical activity program. Each sequence contains one rest session and one exercise session"
1653971|NCT01824667|Dietary Supplement|B-GOS|
1653972|NCT01824667|Dietary Supplement|Maltodextrin|
1653973|NCT01824654|Other|Validation of the new rigid registration software|Several new features of this beta software such as an improved correction system by automatic capture of DSA, an automated 3D/3D rigid registration, recognition of the origin of internal iliac arteries will be implemented. This new beta version will be tested in 20 cases of EVAR/FEVAR at CHUM Research center and Dalhousie University-QEII Health Sciences Centre.
1653974|NCT01824654|Other|Validation of the new elastic registration software|This software integrating deformation of vasculature induced by insertion of endovascular devices will be tested in real time in 20 patients requiring SG procedures at CHUM Research center and Dalhousie University-QEII Health Sciences Centre and compared to the prior cohort having EVAR/FEVAR procedures with rigid registration.
1653975|NCT01824641|Device|Eliminate aspiration catheter|Eliminate aspiration catheter
1653976|NCT01824641|Procedure|Conventional primary angioplasty|Primary angioplasty without thrombus aspiration
1653977|NCT01824615|Drug|Sunitinib|37.5mg everyday from D1-D28
1653978|NCT01824602|Drug|Eslicarbazepine acetate 1800 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
1653979|NCT01824602|Drug|Eslicarbazepine acetate 1200 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
1653980|NCT01824602|Drug|Eslicarbazepine acetate 600 mg|Eslicarbazepine acetate to be taken orally, was available as 600 mg tablets.
1653981|NCT01824602|Drug|Placebo|Placebo sugar pills
1653982|NCT01824589|Device|-7 cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -7 cmH2O between periods of positive pressure ventilations.
1653983|NCT01824589|Device|-12cm H2O ITPR|Single use disposable non-invasive device that is connected to a vacuum source and a means to deliver a positive pressure breath and generates negative3 pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure of -12 cmH2O between periods of positive pressure ventilations.
1653984|NCT01824576|Device|ITPR|Single use noninvasive device that is connected to a vacuum source and a means to deliver a positive pressure breath. The device generates negative pressure during the expiratory phase, thus creating subatmospheric intrathoracic pressure between the periods of positive pressure ventilations.
1653985|NCT01824563|Other|Observational study|
1653986|NCT01824550|Other|home-based exercise training condition|Home based endurance exercise training
1653987|NCT01824537|Biological|HPV vaccine, Gardasil 9|Once recruited, both individuals in a couple will be randomized independently to Gardasil 9 or placebo (Havrix).
1653988|NCT01824537|Biological|Hepatitis A vaccine|Provided by GSK.
1653989|NCT01824524|Drug|Hydromorphone|Participants will be administered a single dose of Osmotic Release Oral System (OROS) hydromorphone tablet of 8 milligram (mg) orally on Day 1 under fasting conditions.
1653990|NCT01824511|Behavioral|Smokers cease smoking|Smokers are paid to be abstinent for four weeks, and stop-smoking medications may not be used.
1653991|NCT01824498|Other|Low Fat diet|Low fat diet = 20% fat
1653992|NCT01824498|Other|Low Fat high n3 diet|Low Fat high n3 diet = 20% fat + 3% n3
1653993|NCT01824498|Other|High Fat Diet|High Fat Diet = 40% fat
1653994|NCT01824485|Drug|viscosupplementation 1+1+1|intra-articular injection with 1 ampoule per week for 3 weeks
1653995|NCT01824485|Drug|viscosupplementation 3 at once|single intra-articular injection with 3 ampoules
1653996|NCT01824472|Device|CPAP|Treatment for sleep apnea
1653997|NCT01824472|Behavioral|CBT|Treatment for insomnia
1654001|NCT01824459|Drug|Oxaliplatin|oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W
1654002|NCT01824459|Drug|Cisplatin|cisplatin：60mg/m2，iv drip ，d1,q3W
1654003|NCT01824446|Drug|Radiolabeled SPD602 (FBS0701, SSP-004184)|A single oral dose of 3g of radio-labelled SSP-004184 on Day 1
1654004|NCT01824433|Drug|venlafaxine|venlafaxine 75-225mg qd
1654005|NCT01824433|Drug|fluoxetine|fluoxetine 20-60mg qd
1654006|NCT01824420|Drug|Detrusitol 4mg QD and Oxybutynin ER 5mg QD|Study group
1654007|NCT01824420|Drug|Detrusitol 4mg QD|Control group
1654008|NCT01824407|Device|Electrohydraulic-generated shock wave|
1654009|NCT01824407|Device|Sham device plus standard of care|
1654012|NCT01824381|Procedure|Place amniotic membrane in large wounds|"After the process of obtaining the amniotic membrane, it must be processed, frozen and thawed.
The wound is washed with saline and, if necessary it will be debrided. We will take microbiological control cultures. Then apply the amniotic membrane fragments sufficient to cover the wound by contacting the basal membrane of the amniotic membrane with granulation tissue.
We will place a new membrane weekly to a maximum of 6 times."
1654013|NCT01824381|Procedure|Obtaining and Cryopreservation of amniotic membrane|
1654014|NCT01824381|Drug|amniotic membrane|
1654015|NCT01824368|Procedure|Extracorporeal Photopheresis Procedure (FEC)|"The FEC will be held in the Cellex (Therakos), and authorized device in routine use in our unit for performing FEC in the treatment of graft-versus-host and cutaneous T-cell lymphoma. After performing a blood count, will connect the patient to Cellex through a central or peripheral.
1500 mL typically be processed peripheral blood mononuclear fraction obtained by apheresis process. Then be added Uvadex (8-metoxipsolareno, 0.017 mL / mL) to the mononuclear fraction bag and proceed to photoactivation with UVA radiation.
Finally the photoactivated product is again infuse the patient. It will monitor the final blood count to assess hemoglobin and platelets. The entire procedure is performed in a single step and closed mode, with Cellex."
1654016|NCT01824355|Device|Ninja 3 PLUS Investigational BG Monitoring System|Untrained subjects with diabetes performed self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the Ninja 3 PLUS Investigational BG Monitoring System. Study staff tested subject fingerstick blood. All BG results were compared to a reference laboratory glucose method.
1654017|NCT01824342|Biological|Denosumab|Administered by subcutaneous injection
1654018|NCT01824329|Procedure|Prostate capsule sparing cystectomy|Removes the adenoma and prostatic urethra along with the urinary bladder, but leaves in situ the prostatic capsule and subsequently the surrounding neurovascular bundle.
1654019|NCT01824329|Procedure|Nerve sparing cystectomy|Attempts to spare the cavernosal nerves that travel immediately adjacent to the lateral prostate and are routinely divided during a standard RCP.
1654020|NCT01824303|Drug|LiRIS 400 mg|LiRIS 400 mg contains lidocaine which is gradually released into the bladder over 14 days.
1654021|NCT01824303|Other|LiRIS Placebo|LiRIS Placebo contains lactose, inactive substance.
1654022|NCT01824290|Drug|Tadalafil|Administered orally by tablet form for heavy and middle weight participants. Administered orally by suspension for light weight participants.
1654023|NCT01824290|Drug|Placebo|Administered orally by tablet for heavy and middle weight participants. Administered orally by suspension for light weight participants.
1654024|NCT01824277|Other|Structured Pre-operative Diabetes Optimization|Patients will receive structured pre-operative diabetes optimization while they wait for surgery. Patients will be referred to the Youville Diabetes Center where they will undergo preoperative optimization of their diabetes management. This will include in-depth diabetes education and instruction pertaining to lifestyle modification (blood glucose monitoring, nutrition, and physical activity) to improve glycemic control. Pharmacologic therapy will be reviewed by the Youville Diabetes Center certified diabetes nurse educators.
1654025|NCT01824264|Drug|LIK066|Experimental treatment doses
1654026|NCT01824264|Drug|Sitagliptin|Active comparator treatment dose
1654027|NCT01824264|Drug|Placebo|Placebo comparator dose
1654028|NCT01824251|Drug|NPB-01|
1654029|NCT01824238|Drug|Anacetrapib|
1654030|NCT01824238|Drug|Placebo for anacetrapib|
1654031|NCT01824225|Drug|Aflibercept|
1654033|NCT01824186|Procedure|SILC|Underwent single-incision laparoscopic cholecystectomy
1654034|NCT01824186|Procedure|LC|Underwent conventional 4-port laparoscopic cholecystectomy
1654035|NCT01824173|Other|Increase in the levels of plasma amino acids|Aminosyn 15%; 160 mg/kg FFM/h for 4 hours
1654036|NCT01824173|Other|Aerobic exercise|Moderate intensity for 45 minutes
1654037|NCT01824160|Device|Repair of RV-PA Conduit Disruption|Repair of RV-PA Conduit Disruption
1654038|NCT01824134|Other|Klean & Klear The Dandy Day Corp|
1654039|NCT01824134|Other|The Skin Gel Herbal Answers, Inc|
1654040|NCT01824121|Biological|stem cell therapy|Bone marrow will be collected from the iliac crest under local anesthesia. Mesenchymal Stem Cells (MSCs) will be isolated and cultivated in vitro. Patients will be catheterized and the MSCs will then be administered by intra-arterial route via the internal carotid artery and the vertebral artery that is largest in caliber, injecting small boluses manually through a microcatheter.
1654041|NCT01824108|Procedure|Lumbar discectomy|All the patients were in prone positions on the operation table and received general anesthesia. A midline incision was made and paravertebral muscles were dissected unilaterally. Disc excision and nerve root decompression were initially accomplished through a unilateral transflaval approach. Then the wound was closed with a suction drain.
1654069|NCT01823848|Drug|Normal saline enema|Rectally administered medication to treat constipation
1654070|NCT01823848|Drug|Mineral oil enema|Mineral oil enema administered to treat constipation. 66ml per rectum
1654042|NCT01824108|Procedure|Lumbar discectomy combined with Wallis interspinous dynamic stability system|The Wallis interspinous implant is placed after a lumbar discectomy. Interspinal ligaments of operated segment were removed and supraspinal ligament were retained. And then the proper size of Wallis implant was mounted underneath the supraspinous ligament and secured to the spine with the attached Dacron bands,above and below the corresponding spinous processes.
1654043|NCT01824095|Dietary Supplement|Dietary supplement|
1654044|NCT01824082|Drug|Perineural infusion [continuous peripheral nerve block(s)]|Electronic, programmable, portable infusion pumps will be used to administer perineural study solution at fixed rates for over 6 days. Subjects will receive a total of 1,100 mL of study fluid from either one (upper extremity) or two (lower extremity) pump and external reservoir combinations. The continuous basal infusion rate will be determined by catheter location: femoral 2.5 mL/h; popliteal-sciatic 5 mL/h; and infraclavicular 7.5 mL/h (37.5 mg/h for both upper and lower extremity subjects). No patient-controlled bolus dose will be included. Subjects will have the option of returning 4-16 weeks later for a second infusion of the alternate treatment solution.
1654045|NCT01824069|Other|Intramuscular injection of a suspension of adult mesenchymal stem cells derived|Intramuscular injection of a suspension of adult mesenchymal stem cells derived from adipose tissue at doses of 1 million per kilo of weight. Only one dosis by patients
1654046|NCT01824056|Drug|18F-FDG|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.
The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
1654047|NCT01824043|Drug|intravitreal ranibizumab injections|Patients will be treated monthly: intravitreal ranibizumab (0.5 mg) will be administered in an open-label fashion, using 3 monthly injections (at day 0, day 30 and day 60) followed by an additional post treatment visit, a month after the last injection, for posterior reports
1654048|NCT01824030|Device|FFR guided PCI|FFR to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
1654049|NCT01824030|Device|OCT guided PCI|OCT to assess coronary artery stenosis severity and indication to perform and eventually optimize percutaneous coronary intervention
1654050|NCT01824017|Other|Blood Draw|
1654051|NCT01824004|Drug|S-1|
1654052|NCT01823991|Drug|VitaBlue™|"Self administration of nutritional supplement COGNUTRIN for 3 months.
The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
1654053|NCT01823991|Other|Placebo|"Self administration of placebo for 3 months.
Investigators use a placebo to make sure that it really is the study medicine that is making a difference in the participant's condition. It does not have anything in it that would normally help or harm most people."
1654054|NCT01823991|Drug|Lovaza®|"Self administration of nutritional supplement COGNUTRIN for 3 months.
The supplement to be used will be a combination of the following: (1) VitaBlue (40% polyphenolics, 12.5% anthocyanins from blueberries (BB) and (2) n-3 fatty acids - Lovaza."
2013090|NCT01061151|Drug|Nevirapine (NVP)|"For women, 200 mg orally (one single dose) at onset of labor; for infants, oral suspension (dosing according to birth weight) once a day beginning as soon as possible after birth until there is no longer any risk of MTCT or until the end of follow-up (104 weeks), whichever comes first.
Postpartum Arm B infants: NVP age-based daily dosing starting from Week 1 postpartum visit (day 6-14) and continuing for up to 2 weeks after complete breastfeeding cessation or completion of follow up, whichever comes first."
1654056|NCT01823965|Drug|ranibizumab|
1654057|NCT01823939|Drug|iOWH032|"Part A: Participants will be randomized at a 3:1 ratio to receive treatment with iOWH032 or placebo. A randomisation code will be generated. Each participant will be assigned the next participant number available and thereby will be assigned randomly. Active treatment will consist of an oral tablet containing 300 mg of iOWH032. The placebo will consist of identical looking tablets.
Part B: There will be no randomization during this trial. All eligible patients will receive 300 mg of iOWH032."
1654058|NCT01823926|Other|Noninvasive ventilation|Bilevel positive pressure (BiPAP Synchrony, Respironics®, Murrysville, Pennsylvania, USA) was applied through face mask (Comfort Full 2, Respironics®, Murrysville, Pennsylvania, USA) attached with straps and pressure adjusted were 12 cmH2O of inspiratory pressure and 5 cmH2O of expiratory pressure at the beginning of the procedure (França et al., 2006).
1654059|NCT01823926|Device|Jet nebulizer|"Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. JN (Mist yMax, Air Life, Yorba Linda, USA) was positioned in the circuit using a T piece, particle size generation in a 5 µm range (according to the manufacturer information) and flow oxygen tritated at 8 L/min."
1654060|NCT01823926|Device|The vibrating mesh nebulizer (VMN)|Both nebulizers were charged with 2.5 mg of salbutamol and 0.25 mg of ipratropium bromide and 3 mL of saline solution was added to complete 3 Ml. VMN (Aeroneb Solo, Galway, Ireland) was positioned in the mask using an elbow (Elbow Kit, Respironics®, Murrysville, Pennsylvania, USA), particle size generation in a 1 µm and connected to electrical energy.
1654061|NCT01823913|Drug|Test formulation|A single oral dose of a combination tablet of amlodipine orotate 10mg and valsartan 160mg
1654062|NCT01823913|Drug|Reference formulation|A single oral dose of a combination tablet of amlodipine besylate 10mg and valsartan 160mg
1654063|NCT01823900|Drug|Test formulation|Single administration of a combination tablet of Rosuvastatin 20mg and Olmesartan 40mg
1654064|NCT01823900|Drug|Reference formulation|Co-administration of Rosuvastatin 20mg tablet and Olmesartan 40mg tablet
1654065|NCT01823887|Device|Vagus Nerve Stimulation (VNS)|Electrical Stimulation of the Vagus Nerve
1654066|NCT01823874|Procedure|virtual reality distraction|Pain distraction will be measured with both the HMD virtual reality method and the ID virtual reality method.
1654067|NCT01823861|Behavioral|Mobile phone-based intervention|Automated voice message to support post-abortion contraception use every two weeks for total of three months. Direct follow up phone call by family planning counsellor depending on response to voice message.
1654068|NCT01823848|Drug|Sodium phosphate enema|Rectally administered medication to treat constipation
1654535|NCT01820598|Device|Multisite NMES training during 6 weeks|
1654071|NCT01823835|Drug|GDC-0810|GDC-0810 will be administered orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent (up to 3 years).
1654072|NCT01823835|Drug|LHRH Agonist|LHRH agonist will be administered once monthly until disease progression, unacceptable toxicity, or withdrawal of consent (up to 3 years). Choice of LHRH agonist will be an institutional choice approved for use in breast cancer.
1654073|NCT01823835|Drug|Palbociclib|Palbociclib will be administered orally once daily until disease progression, unacceptable toxicity, or withdrawal of consent (up to 3 years).
1654074|NCT01823822|Dietary Supplement|Oral protein supplement (Tested product)|Test product: oral protein supplement, sweetened flavoured dairy product, type fresh cheese rich in milk protein (15 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
1654075|NCT01823822|Dietary Supplement|Iso-caloric supplement (Control product)|Control product: sweetened flavoured fresh cheese, with low milk protein content (3 g/150 grams). Dosage is 2 pots daily, at least 5 days/week for 4 consecutive weeks.
1654076|NCT01823809|Device|adenosine stress Cardiac Magnetic Resonance Imaging|
1654077|NCT01823796|Other|Fibromyalgia women group|Assessment of this group at baseline in order to be compared with a control group.
1654078|NCT01823796|Other|Healthy women|These women are assessed in order to be compared with fibromyalgia women group.
1654079|NCT01823783|Other|Muscle biopsy|Muscle biopsy
1654080|NCT01823770|Drug|Rotigotine|Subjects randomized to rotigotine will start treatment with a rotigotine dose of 1mg/24h for 1 week. The dose can be increased weekly until either the optimal or the maximal dose of 3mg/24h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1mg/24h every other day until complete withdrawal (Taper period).
1654081|NCT01823770|Drug|Placebo patchs|Subject randomized on the placebo group will be treated with placebo patchs, following the same modalities and study periods that the rotigotine arm
1654082|NCT01823757|Other|Pharmaceutical care|pharmacists provide pharmaceutical care to the intervention group, comparing to ordinary care in control group
1654083|NCT01823744|Dietary Supplement|micronutrient supplementation|
1654084|NCT01823718|Biological|Injection of allogenic CTL EBV specific|
1654085|NCT01823705|Device|Exilis Implantable Gastric Electrical Stimulation (GES)|
1654086|NCT01823692|Other|ultrasonography|after manipulation and reduction were performed by single emergency medicine specialist under Bier block regional anesthesia or procedural sedation-analgesia, The ultrasonography was performed by the single emergency department physician in a long axis both in a anterioposterior and lateral views in determining whether the distal and proximal distal to a fracture was in a straight line (less than 3 mm difference) or not?
1654087|NCT01823679|Drug|Capecitabine|Given orally
1654088|NCT01823653|Device|Liposonix System (Model 2)|Treatment of Subcutaneous Adipose Tissue in the thighs using High Intensity Focused Ultrasound
1654089|NCT01823640|Other|placebo|
1654090|NCT01823640|Other|Human Rhinovirus strain 16 (HRV-16)|100 TCID50 dosis of HRV-16 will be inoculated on day 7 and / or day 0
1654091|NCT01823627|Procedure|Spirometry with reversibility test|Spirometry with reversibility test and CATest questionaire. following will be measured FEV1 L/s FVC L/s FEV1/FVC ration
1654092|NCT01823601|Behavioral|Behavioral Management Program|Consists in 10 Sessions of 120 minutes of duration, to train diaphragmatic breathing; autogenic training of muscle relaxation; progressive self-focus meditation and cognitive-behavioral training.
1654093|NCT01823601|Behavioral|Seminars in Health|Volunteers that participate in 10 weekly sessions of seminars in health
1654094|NCT01823588|Behavioral|Nurse-led reminder through email.|"Both groups will receive an educational program and usual care. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form.
Educational program and usual cardiovascular prevention. The educational program will consist of 1-hour sessions, during which the NCM emphasize the importance of blood pressure control and correct measurement, give advice for a correct blood pressure self-measurement; report non-pharmacological strategies for a healthy lifestyle, and instruction on how to fill the daily self-assessment form."
1654095|NCT01823575|Device|Silicone-covered metallic stent|deployment of silicone-covered metallic stent for malignant ureteral obstruction as a new therapy as compared with placement of double-J stent as a conventional therapy
1654096|NCT01823575|Device|Double-J stent|Placement of double-J stent as a conventional treatment to be compared with a new experimental treatment - deployment of silicone-covered metallic stent
1654097|NCT01823562|Drug|lyophilized black raspberry confection|Given PO
1654098|NCT01823562|Other|laboratory biomarker analysis|Correlative studies
1654099|NCT01823562|Dietary Supplement|dietary intervention|Follow a low polyphenol diet
1654100|NCT01823562|Dietary Supplement|dietary intervention|Follow a low ellagitannin diet
1654101|NCT01823562|Procedure|quality-of-life assessment|Ancillary studies
1654102|NCT01823562|Other|questionnaire administration|Ancillary studies
1654103|NCT01823549|Other|questionnaire administration|Ancillary studies
1654104|NCT01823536|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|Subjects received at day 1 a single dose of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
1654105|NCT01823523|Drug|Cefazolin, Cephalexin, Clindamycin|
1654106|NCT01823510|Drug|Ticagrelor + Aspirin|Single loading doses of Ticagrelor (180 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (ticagrelor 90 mg twice daily + ASA 81 mg once daily).
1654107|NCT01823510|Drug|Clopidogrel + Aspirin|Single loading doses of Clopidogrel (600 mg) and ASA (325 mg), followed by daily dosing for 5-7 days (clopidogrel 75 mg + ASA 81 mg once daily).
1654108|NCT01823497|Drug|Morphine|Morphine will be used to control pain post-surgery.
1654109|NCT01823484|Device|AN 69 ST hemofilter|
1654110|NCT01823484|Device|AN 69 hemofilter|
1654228|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 600 mg per day and up-titrated in 600 mg steps until 1800 mg (maximum dose) according to clinical response.
1654111|NCT01823471|Other|The use of I-scan in the detection of polyps in HNPCC|Prior the colonoscopy patients will be randomized to white light first or i-scan first. After the caecum is reached patients will be first examined according to the randomization. Each colonic segment will be investigated in a back to back fashion, during the second pass the other modality will be used.
1654112|NCT01823458|Behavioral|Lottery Insurance|
1654113|NCT01823458|Behavioral|Standard Lottery|
1654114|NCT01823445|Other|Xylitol disk|
1654115|NCT01823406|Procedure|Euglycemic clamp (normal blood sugar clamp) for 4 hours|
1654116|NCT01823406|Procedure|hyperglycemic clamp (elevated blood sugar to 300) for 4 hours|
1654117|NCT01823393|Drug|Heparin|Valvuloplasty is performed in a conventional manner, ie with an injection of unfractionated heparin (50 IU / kg) at the start of procedure
1654118|NCT01823393|Drug|NaCl|valvuloplasty is performed without heparin (placebo injection)
1654119|NCT01823380|Procedure|Blood test|Blood test
1654120|NCT01823367|Behavioral|Diabetes Prevention Program (DPP)|Diabetes Prevention Program (DPP): This is an evidence-based curriculum that has shown that it is possible to prevent or delay Type 2 Diabetes (T2D) in individuals if they keep a healthy weight, eat a nutritious diet, and stay physically active.
1654121|NCT01823354|Other|Polysomnography|Polysomnography involves the collection of the electroencephalogram, electromyogram of, and electro-oculogram to differentiate the various stages of sleep. Determination of different stages and cycles of sleep will be manually by reading the EEG, EMG, EOG over periods of 30 seconds after the standardized criteria of AASM (American Academy of Sleep Medicine). Registration will take place between sleep and 23h 7am.
1654122|NCT01823354|Other|Clinical Scales|Index of Restless Legs Syndrome Severity, Index of insomnia Severity, Beck's Inventory of Depression, Anxiety Inventory: State-Trait, form Y.
1654123|NCT01823354|Other|Assessment of executive functions|"Verbal fluencies Test GREFEX (Assessment of the spontaneous flexibility), Stroop Test GREFEX (Inhibition of the automatic response Capacity ), Trail Making Test GREFEX (Assessment of flexibility reactive), Wisconsin Card Sorting Test(Overall assessment of executive functions), Working memory TAP, Flexibility TAP, Go/no go TAP, Phasic alertness (Assessment of speed information processing)."
1654124|NCT01823354|Other|Medical consultation|open questions
1654125|NCT01823341|Device|Pump suspension algorithm|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia.
1654126|NCT01823328|Drug|Ketamine|Subjects will receive ketamine for sedation prior to rapid sequence intubation.
1654127|NCT01823328|Drug|Etomidate|Subjects will receive etomidate for sedation prior to rapid sequence intubation.
1654131|NCT01823302|Dietary Supplement|nutrition counseling plus oral milk-based nutritional supplement|Study group subjects were instructed to consume at least 2 servings (230 mL per serving) of an oral milk-based nutritional supplement daily, in addition to their regular diet, for a total of 120 (±3) days.
1654132|NCT01823302|Other|nutritional counseling|nutritional counseling
1654133|NCT01823289|Drug|Itraconazole|Itraconazole 200 milligram (mg) intravenous injection will be given twice daily for first 2 days, 200 mg once daily for the subsequent 12 days, then sequential itraconazole oral solution 200 mg twice daily will be given for 2 to 4 weeks.
1654134|NCT01823276|Other|Tyrosine-Containing Bar|
1654135|NCT01823276|Other|Placebo Bar|
1654136|NCT01823263|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
1654137|NCT01823263|Procedure|Blood sample|In the morning following partial sleep deprivation or normal sleep, a blood sample will be taken to assess the level of metabolism-linked and neurodegenerative-linked molecules, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as ghrelin
1654138|NCT01823263|Procedure|Interference task|30-minute interference task
1654139|NCT01823263|Behavioral|Memory tasks|Participants will be allowed to learn a procedural memory task before going to bed. Participants will be retested in the morning to assess their change in performance. Other memory tests will also be given to assess the working memory performance in the morning following the intervention.
1654140|NCT01823263|Behavioral|Intake task|After a normal night of sleep or partial sleep deprivation, participants are presented with an ad libitum meal choice and can select the amount to ingest during a limited time window. Amount and selection will be recorded
1654141|NCT01823263|Behavioral|Working memory function task|Participants will be evaluated on their working memory performance in the morning following either nighttime intervention (NS or PSD)
1654142|NCT01823250|Behavioral|Family Therapy based on Structural Family Therapy|Once per week family therapy based on Structural Family Therapy. Sees to improve parenting practices, communication, and problem solving skills. It also seeks to increase the attachment/bond between parents and adolescents.
1654143|NCT01823250|Behavioral|Group Therapy|Group Therapy is provided once per week and is designed to share information on HIV and STI risk and protection. There are typically 8-10 adolescents in a group.
1654144|NCT01823250|Behavioral|Psychoeducational Sessions|Psycho-educational sessions are used to provide didactic in formation to parents alone, adolescents alone, or both together. Content may focus on parenting, drug use risks, depression, HIV/STI risk or other major issues that adolescents and families confront. There are also modules that focus on culture-related stressors and processes that can be provided to families for whom this is a prominent issue.
1654145|NCT01823250|Behavioral|Individual Adolescent Therapy Sessions|Individual sessions with the adolescent focus on Motivational Interviewing, coaching for family sessions, and monitoring of unhealthy behaviors.
1654226|NCT01822691|Drug|INCB024360|INCB024360 is an inhibitor of the enzyme indoleamine 2,3-dioxygenase (IDO) that is proposed for development for the treatment of malignant diseases. Participants were to receive the study drug in 28 day (4 week) cycles of treatment.
1654229|NCT01822678|Drug|Placebo|Placebo
1654230|NCT01822665|Drug|Ibuprofen|Liquid gelation capsules or tablets of 400 mg strength
1654147|NCT01823224|Drug|"2 capsules Oral Tylenol 2000 mg and IV salt water"|"The participants randomized to receive the '2 capsules Oral Acetaminophen 500 mg and IV salt water repeated 4 hours after that dose to equal 2000mg. A pre-op pain score was obtained and pain scores every 15 min x 1 hour then per recovery routine and they did a 24 hour home diary to record pain scores for 24 hours post surgery. Their opioid morphine equivalent was recorded intraoperatively, recovery and at home. This was compared to the other group receiving IV acetaminophen.and the pain scores and morphine equivalents were collected the same as in the comparative group. Each group received a placebo version oral or iv accordingly."
1654148|NCT01823224|Drug|"IV tylenol 1000mg and 2 oral capsule sugar pills"|"IV acetaminophen 1000mg and 2 oral capsule sugar pills were given to participants that were randomized to receive the IV acetaminophen. The same collection of pain scores and morphine equivalents was completed the same as the other group."
1654149|NCT01823198|Drug|Busulfan|"32 mg/m2 test dose based on actual body weight given by vein within 2 weeks of the preparative regimen.
Busulfan adjusted dose determined to achieve a systemic exposure represented by an average daily AUC of 6000 µMol-min ± 5% on Day -13 to Day -10. Patients over age 60 and/or with performance status =2 receive and AUC of 4000 microM x min for each dose. If it is not feasible to perform the pharmacokinetic studies, Busulfan dose of 130 mg/m2 administered (100 mg/m2 for age over 60 or PS=2).
PK-guided daily high-dose Busulfan dose(s) started immediately upon completion of the daily fludarabine doses."
1654150|NCT01823198|Drug|Fludarabine|40 mg/m2 by vein dosed per actual body weight/actual body surface area on Day -13 to Day -10.
1654151|NCT01823198|Procedure|Alloreactive NK infusion|Alloreactive NK cell infusion given by vein on Day -8 at one of 4 dose levels based on the number of NK cells (CD3-,CD 56+ cells)/kg recipient body weight. Dose levels are: 10^6, 10^7, 3 x 10^7, 10^8.
1654152|NCT01823198|Drug|Interleukin-2|0.5 million units subcutaneously on Day -8 to Day -4.
1654153|NCT01823198|Procedure|Stem Cell Infusion|Peripheral blood progenitor cells infused on Day 0 or on arrival of the unrelated donor cells.
1654154|NCT01823198|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
1654155|NCT01823198|Drug|Tacrolimus|Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted with a goal to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after Day +90 if no GvHD is present.
1654156|NCT01823198|Drug|Methotrexate|5 mg/m2 administered intravenously on Days 1, 3, 6 and 11 post transplant.
1654157|NCT01823185|Drug|clopidogrel|Genotyping will be carried out using Spartan genotyping System on all intervention group and those patients who do not carry the CYP2C19 allele 2 or 3 will be given clopidogrel (75 mg per day) while all patients who carry the CYP2C19 allele 2 or 3 will be prescribed Ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
1654158|NCT01823185|Drug|Ticagrelor or prasugrel|ticagrelor (90 mg twice daily) or prasugrel ( 10mg once daily or 5mg once daily if the patient older than 75 years or a body weight < 60kg) according to local protocol.
1654159|NCT01823172|Procedure|Methylene blue dye injection of sentinel lymph node|Single arm study. Methylene blue will be injected into the 1st SLN and traced via the efferent lymphatic to the 2nd echelon lymph node.
1654160|NCT01823159|Drug|retigabine|Single oral administration of a 400 mg tablet.
1654161|NCT01823159|Drug|placebo|Single oral administration of a tablet
1654162|NCT01823146|Drug|Oxytocin spray|single dose of 24 IU oxytocin, self-administered intranasally (IN)
1654163|NCT01823146|Drug|Placebo spray|single dose of 24 IU placebo (same solution as oxytocin spray but without oxytocin), self-administered intranasally (IN)
1654164|NCT01823133|Drug|gemigliptin only|gemigliptin 50mg qd on day 1~7
1654165|NCT01823133|Drug|rosuvastatin only|rosuvastatin 20mg qd on day 1~7
1654166|NCT01823133|Drug|gemigliptin and rosuvastatin|gemigliptin 50mg, rosuvastatin 20mg qd on day 1~7
1654167|NCT01823120|Other|Supportive and interactive text messages|
1654168|NCT01823107|Device|Meso BioMatrix Device|
1654169|NCT01823081|Drug|Intravitreal injection of bevacizumab (Avastin)|
1654170|NCT01823081|Drug|Intravitreal injection of fasudil and bevacizumab (Avastin)|intravitreal injections of bevacizumab and fasudil are performed at two different sites (superior temporal and inferior temporal quadrants respectively)
1654171|NCT01823068|Drug|Vandetanib|Patients will begin on once daily vandetanib at 300 mg with one cycle of 4 weeks.
1654172|NCT01823055|Procedure|Transvaginal suture capturing mesh device|The Uphold™ LITE vaginal support system is an intra-vaginal approach to apical and anterior vaginal wall prolapse repair that utilizes a suture capturing device to place the mesh. After primary dissection the suturing device is used to pull the mesh through the sacrospinous ligament, medial to the ischial spine. An anterior colporraphy was allowed following the Uphold™ LITE procedure at the discretion of the surgeon if deemed necessary.
1654173|NCT01823042|Drug|azathioprine+enteral nutrition|
1654174|NCT01823042|Drug|Azathioprine|
1654175|NCT01823029|Drug|erythropoietin|
1654176|NCT01823029|Drug|enteral nutrition.|
1654177|NCT01823029|Drug|injection of iron|
1654178|NCT01823016|Drug|Placebo|Placebo tablet, taken once daily
1654179|NCT01823016|Drug|JNJ-38518168|JNJ-38518168, 30 mg tablet, taken once daily
1654180|NCT01823003|Radiation|34 Gy in a single fraction|34 Gy in a single fraction in case of Distance to chest wall > 1 cm, tumour size < 2 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
1654181|NCT01823003|Radiation|54Gy 18Gy/fr. x 3 fractions|54Gy administered in 3 fractions of 18Gy in case of distance to chest wall > 1 cm, tumour size between 2 and 5 cm and distance to the main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
1654227|NCT01822678|Drug|Eslicarbazepine Acetate|Eslicarbazepine Acetate, starting with 800 mg per day and up-titrated in 800 mg steps until 2400 mg (maximum dose) according to clinical response.
1654536|NCT01820585|Drug|Placebo|Tablets
1654182|NCT01823003|Radiation|60Gy (12 x 5 fr.s)|50Gy administered in 5 fractions of 12 Gy for Peripheral Nodes in case of distance to chest wall < 1 cm, tumour size < 5 cm and distance to main bronchus > 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR) will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
1654183|NCT01823003|Radiation|60Gy (7.5Gy x 8fr.)|60 Gy administered in 8 fractions of 7.5 Gy for mediastinal nodes in case of tumour size < 5 cm and distance to the main bronchus < 2 cm. STEREOTACTIC ABLATIVE RADIOTHERAPY (SABR)will be administered with volumetric modulated arcs, with photon beam energy of 6-10 MV. The number of arcs and their ballistic is left undefined in order to allow for optimization of the dose distribution. Bolus is not allowed.
1654184|NCT01822977|Drug|omeprazole|
1654185|NCT01822964|Device|targeted brain cooling (33°C) by RhinoChill device|targeted brain cooling by Rhinochill device to 33°C tympanic temperature during TAVI procedure. After valve implantation, slow rewarming until 35.5°C
1654186|NCT01822964|Device|Placebo - current clinical practice, no cooling|
1654187|NCT01822951|Drug|Cerebrolysin|"Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20.
Placebo for donepezil:1 tablet per day from TC 1 Day 1 on and 2 tablets per day from Visit 3 - Visit 5, p.o."
1654188|NCT01822951|Drug|Donepezil|"5-10 mg donepezil: 1x5 mg donepezil as 1 tablet per day from TC 1 Day 1 on and 2x5 mg donepezil as 2 tablets from Visit 3- Visit 5, p.o.
Intravenous medication is given in three treatment courses (TC). Each treatment course lasts for two weeks and consists of 10 infusions (5 infusions weekly). The first treatment course (TC 1) will be in Week 1 and 2, second treatment course (TC 2) will be repeated during Week 9 and 10 and third treatment course (TC 3) during Week 19 and 20."
1654189|NCT01822938|Other|incentive program for physical activity|
1654190|NCT01822925|Drug|DA-9801 300mg|300 mg of DA-9801 in tablet form, to be taken 3 times daily for 12 weeks.
1654191|NCT01822925|Drug|DA-9801 600mg|600 mg of DA-9801 in tablet form, to be taken 3 times daily for 12 weeks.
1654192|NCT01822925|Drug|DA-9801 900mg|900 mg of DA-9801 in tablet form, to be taken 3 times daily for 12 weeks.
1654193|NCT01822925|Drug|Placebo|Placebo, in tablet form, to be taken 3 times daily for 12 weeks. The placebo is the same formulation as DA-9801 except that it does not contain the active pharmaceutical ingredient.
1654196|NCT01822899|Drug|Umeclidinium bromide/Vilanterol|Dry white powder of UMEC 62.5 mcg per blister and VI 25 mcg per blister as NDPI with 30 doses (2 strips with 30 blisters per strip).
1654197|NCT01822899|Drug|Placebo ACCUHALER/DISKUS|Dry white powder of matching placebo as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
1654198|NCT01822899|Drug|Fluticasone propionate/Salmeterol|Dry white powder of fluticasone propionate 500 mcg per blister 50 mcg salmeterol per blister as multidose dry powder inhaler containing a foil strip with 60 blisters (1 strip with 60 blisters per strip).
1654199|NCT01822899|Drug|Placebo NDPI|Dry white powder of matching placebo as NDPI with 30 doses (2 strips with 30 blisters per strip).
1654200|NCT01822886|Drug|Romidepsin, Gemcitabine|Romidepsin 12 mg/m2 d.1,8, 15 for 6 cycles + Gemcitabine 800 mg/m2 d.1, 15 for 6 cycles by 28 days followed by Romidepsin 14 mg/m2 d. 1, 15 to PD.
1654201|NCT01822860|Drug|Chlorthalidone 12.5 mg|
1654202|NCT01822860|Drug|Hydrochlorothiazide 25 mg|
1654203|NCT01822860|Drug|Placebo|
1654204|NCT01822821|Drug|IV Acetaminophen|Patients will receive up to four doses of IV Acetaminophen (1000mg)every six hours after surgery along with standard PCA (patient controlled) opioids.
1654205|NCT01822821|Drug|Placebo|Patients will receive up to four doses placebo every six hours after surgery along with standard PCA (patient controlled) opioids.
1654206|NCT01822808|Drug|Hydralazine|Hydralazine and placebo will be supplied as 25mg identical tablets and given at a dosage of 75mg/day up to week 4, thereafter 150mg/day up to week 24.
1654207|NCT01822808|Drug|Isosorbide Dinitrate|Isosorbide dinitrate and placebo will be supplied as 10mg identical tablets and given at a dosage of 30mg/day up to week 4, thereafter 60mg/day up to week 24.
1654208|NCT01822795|Procedure|Lung volume reduction coïl treatment|
1654209|NCT01822795|Other|Regular medical treatment|
1654210|NCT01822782|Biological|Bacteriological analysis of vaginal sample|Bacteriological analysis of vaginal sample
1654211|NCT01822769|Other|Cardiopulmonary rehabilitation|See Arm Description
1654212|NCT01822769|Other|Standard of care|See Arm Description
1654213|NCT01822756|Drug|ruxolitinib|
1654214|NCT01822756|Drug|gemcitabine|Other names: Gemzar®
1654215|NCT01822756|Drug|nab-paclitaxel|Other names: Abraxane®
1654216|NCT01822756|Drug|filgrastim|Prophylactic GCSF support was filgrastim and was given in Cycle 1 on Days 2 to 5, 9 to 12, and 16 to 19, unless chemotherapy was held for toxicity, then prophylactic GCSF support was also held.
1654217|NCT01822743|Procedure|Osteopathic manipulative treatment|Osteopathic compression of pterygopalatine node
1654218|NCT01822743|Procedure|sham comparator|
1654219|NCT01822730|Drug|paliperidone|Paliperidone group,6mg/pill,6mg-12mg/day non-forced titration method,last 2-4weeks
1654220|NCT01822730|Drug|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
1654221|NCT01822717|Behavioral|Nonvisual foot inspection|Teaching use of nonvisual senses (tactile and olfactory) to empower people with diabetes and visual impairment to perform a systematic self-examination of their own feet
1654222|NCT01822717|Behavioral|Usual Care|Standard instructions for foot care for people with visual impairment include advice to have a sighted family member or friend check the person's feet regularly
1654223|NCT01822704|Device|Low intensity whole body vibration|
1654224|NCT01822704|Device|High intensity whole body vibration|
1654225|NCT01822704|Behavioral|Leg exercises|
1654537|NCT01820585|Drug|ESL 400 mg|tablets
1654231|NCT01822665|Drug|Paracetamol|Paracetamol fast dissolving tablets of 500 mg strength
1654232|NCT01822665|Other|Placebo|Placebo tablets
1654233|NCT01822652|Genetic|iC9-GD2 T Cell Lymphocytes-frozen cells|"Subjects will receive the iC9-GD2 T cells through an IV over 5 to 10 minutes.
Subjects will receive one of the following dose levels (cells/m2):
Dose Level 1 = 1 x 10^7
Dose Level 2 = 1 x 10^8
Dose Level 3 = 2 x 10^8
Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
1654234|NCT01822652|Genetic|iC9-GD2 T Cell Lymphocytes-fresh cells|"For subjects who will receive a fresh T cell product:
Dose Level 1 = 1 x 10^8
Dose Level 2 = 1.5 x 10^8
Dose Level 3 = 2 x 10^8
Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
1654235|NCT01822652|Drug|Cyclophosphamide|Cyclophosphamide (500 mg/m2/day x 2 days, for patients <12 kg = 16.7 mg/kg/day x 2 days)
1654236|NCT01822652|Drug|Fludarabine|Fludarabine (30 mg/m2/day x 3 days, for patients <12 kg = 1 mg/kg/day x 3 days)
1654237|NCT01822652|Drug|pembrolizumab|pembrolizumab (2 mg/kg on Day -1 and on Day 21).
1654238|NCT01822652|Genetic|iC9-GD2 T Cell Lymphocytes-fresh cells|"subjects who will receive a fresh T cell product:
Dose Level 1 = 1.5 x 10^8
Dose Level 2 = 2 x 10^8
Six weeks after the infusion, patients will have a disease re-evaluation. If the disease has not gotten worse AND they have not had a severe side effect caused by the infusion of the iC9-GD2 T cells, the subject may be eligible to receive up to 2 additional doses of T cells. Each dose will be at the same dose level as the first infusion, if available, and separated by at least 6 weeks."
1654239|NCT01822639|Drug|GSK2944404 FDC|Uncoated, round, yellow white bilayer fixed dose combination tablet containing 5 mg amlodipine and 20 mg enalapril for single dose oral administration in each period.
1654240|NCT01822639|Drug|Amlodipine 5 mg|Emerald-shaped white 5 mg amlodipine table for single dose oral co-administration with enalapril maleate tablet in each period.
1654241|NCT01822639|Drug|Enalapril Maleate 20 mg|Peach triangle shaped 20 mg enalapril maleate tablet for single dose oral co-administration with amlodipine in each period.
1654242|NCT01822626|Behavioral|motivational counseling|A family pediatrician-lead counselling was offered to children assigned to the intervention group. The counselling program consisted of 5 motivational interviews based on Stages of Change Theory. Child and family always had to leave the meeting having agreed two objectives, one concerning food and one physical activity improvements, clearly defined and achievable. During each subsequent interview was assessed the degree of achievement of the objectives of the previous meeting. Based on the assessment the objective could be reinforced or redefined. After each change the objectives were recorded.
1654243|NCT01822613|Drug|LJM716|LJM716 (10-40 mg/kg) will be given as a once weekly infusion beginning on cycle 1 day 1. The doses of LJM716 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
1654244|NCT01822613|Drug|BYL719|BYL719 (200-400 mg) will be administered orally on a once daily schedule starting cycle 1 day 1. The doses of BYL719 will be increased as dose escalation proceeds until a maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) is established.
1654245|NCT01822613|Drug|Paclitaxel|In the Phase II portion of the study Paclitaxel is one of the 3 physician's choice drug which allows single-agent paclitaxel to be used per manufacturer's label.
1654246|NCT01822613|Drug|Docetaxel|In the Phase II portion of the study Docetaxel is one of the 3 physician's choice drug which allows single-agent docetaxel to be used per manufacturer's label.
1654247|NCT01822613|Drug|Irinotecan|In the Phase II portion of the study Irinotecan is one of the 3 physician's choice drug which allows single-agent irinotecan to be used per manufacturer's label
1654248|NCT01822600|Drug|Human albumin|Each patient in the intervention group received Human Albumin 20%® (ZLB Behring GmbH, Marburg, Germany), immediately. The dosage of albumin infusion was 10 g q8h for 1 day in patients with albumin levels ranging from 25 g/L to 29 g/L or 2 days in those with albumin levels < 25 g/L.
1654249|NCT01822600|Drug|Omeprazole|"After endoscopic hemostasis, each enrolled patient received an 80 mg loading dose of intravenous omeprazole (Losec®, AstraZeneca AB, Södertälje, Sweden) immediately. Patients then received a 3-day continuous omeprazole infusion in dosage of 80 mg per day.
After omeprazole infusion, oral esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) 40 mg per day was given in the normal albumin group and the intervention group until the end of follow-up.
After omeprazole infusion, oral omeprazole (Losec®) 20 mg per day was given in the cohort control group until the end of follow-up."
1654250|NCT01822587|Drug|Propranolol, 40 mg|
1654251|NCT01822587|Drug|Propranolol, 80 mg|
1654252|NCT01822587|Drug|Placebo|
1654253|NCT01822574|Procedure|Cutting Guide Technique|The guide is clamped onto the patella and tightened so that it remains stable. The guide has a slot that allows insertion of a standard sagittal saw blade, and this slot guides the blade as it is advanced across the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
1654254|NCT01822574|Procedure|Haptic Feedback Technique|It consists of a free hand cut (no guide used) with a standard sagittal saw that is oriented based on osteo-cartilaginous landmarks and haptic palpation of the patella by the surgeon. The resection thickness/obliquity can be altered based on haptic feedback (use of the sense of touch) of the patella. The thickness is then measured in the center of the patella to ensure that the resection goal is achieved. Additional resection may be performed as needed.
1654255|NCT01822574|Procedure|Four Quadrant Technique|Resection is performed in a free handed fashion, but after resection, the thickness of the patella is measured separately in all four quadrants (superolateral, superomedial, inferomedial, and inferolateral). Additional resection is performed as needed based on the quadrant measurements and the measurements are repeated after each resection until satisfactory resection thickness and symmetry are obtained.
1654256|NCT01822561|Drug|Eplerenone 50mg|All patients will receive the same dose of eplerenone.
1654257|NCT01822548|Drug|Vildagliptin|100 mg daily
1654538|NCT01820585|Drug|ESL 800 mg|tablets
1654258|NCT01822548|Drug|Glibenclamide|2.5 mg (total daily), progressively increased up to a maximum dose of 5 mg x 2/ day.
1654259|NCT01822548|Drug|Metformin|concomitant therapy with metformin is present in each arm (MAX dose: 2500 mg/die)
1654260|NCT01822535|Drug|Midodrine hydrochloride|Midodrine hydrochloride is an approved medication used to treat low blood pressure. We are using a standard dose of 10 mg (tablet) only one time to determine if the effects of this drug improve the ability to maintain body core temperature in a cool environment (off-label use). A physician will administer the drug once before the cool thermal challenge in subjects with tetraplegia only(Visit 2)
1654261|NCT01822522|Drug|Cabozantinib S-malate|Given PO
1654262|NCT01822522|Other|Laboratory Biomarker Analysis|Correlative studies
1654263|NCT01822522|Other|Pharmacological Study|Correlative studies
1654264|NCT01822509|Biological|Ipilimumab|Given IV
1654265|NCT01822509|Other|Laboratory Biomarker Analysis|Correlative studies
1654266|NCT01822509|Biological|Nivolumab|Given IV
2013091|NCT01061151|Drug|Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])|"Antepartum Arm A: 200 mg/300 mg x 2 tablets for a total dose of 400 mg/600 mg orally once ideally at onset of labor or as soon as possible thereafter; 200 mg/300 mg (1 tablet) orally each day after delivery for 7 days or the date of the Week 1 visit (up to 14 days), whichever is later.
Antepartum Arm C: 200 mg/300 mg orally once daily beginning at greater than or equal to 14 weeks gestation (at study entry) until Week 1 postpartum visit (up to 14 days)
Postpartum Arm A: 200 mg/300 mg orally once daily from Week 1 postpartum visit until completion of followup."
2013092|NCT01061151|Drug|Lamivudine-Zidovudine (3TC-ZDV)|Antepartum Arm B: 150 mg/300 mg orally twice daily beginning at greater than or equal to 14 weeks gestation (at study entry) through delivery and until 1 week postpartum visit (up to 14 days)
1654276|NCT01822483|Drug|Mycophenolate sodium|The conversion will be performed abruptly for all patients. Mycophenolate mofetil will be discontinued one day before the day of conversion (Day 1). Mycophenolate sodium will be introduced on day 1 with equivalent doses.
1654277|NCT01822483|Drug|Mycophenolate mofetil|Mycophenolate mofetil dose will be maintained or adjusted to keep 30 to 60 mg*h ml-1.
1654278|NCT01822457|Device|Nike FuelBand (NFB)|The Nike Fuel Band (NFB) is a wrist-worn sensor with a built-in accelerometer for motion quantification. It is programmed to estimate the number of steps taken per day, and also predict energy expenditure in units known as Nike Fuel. Accompanying software allows the user to set daily targets and monitor their activity through a graphical user interface.
1654279|NCT01822444|Other|Biomarker analysis|
1654280|NCT01822431|Radiation|metaiodobenzylguanidine scintigraphy|
1654281|NCT01822418|Drug|agomelatine|n.a.
1654284|NCT01822392|Behavioral|Online Parent Management Training (Interactive)|
1654285|NCT01822392|Behavioral|Online Parent Management Training (Recorded)|
1654286|NCT01822379|Procedure|Melanocyte Keratinocyte transplantation|Transplantation of cells prepared with dispase
1654287|NCT01822366|Behavioral|Trauma-focused Cognitive Behavioral Therapy|
1654288|NCT01822353|Dietary Supplement|Dietary supplement|Milk, egg or nut oral immunotherapy
1654289|NCT01822340|Drug|HM10560A|Once weekly HM10560A
1654290|NCT01822340|Drug|Genotropin|Once daily Genotropin
1654291|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers contingent on drug abstinence with values the same across all patients
1654292|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers contingent on cocaine abstinence with more severe patients receiving greater value vouchers
1654293|NCT01822327|Behavioral|Contingency Management|CRA plus Vouchers earned independent of cocaine use
1654294|NCT01822314|Drug|Abraxane|Abraxane at the dosage of 125 mg/m2 will be delivered over 30 minutes on week 1, 2 and 3 followed by 1 week rest. week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
1654295|NCT01822314|Drug|Paclitaxel|Paclitaxel at the dosage of 90 mg/m2 diluted in 250 mL of water for injection (WFI) over 1 hour given week 1, 2 and 3 followed by 1 week rest and will be repeated for 4 cycles followed by AC or EC (adriamycin or epirubicin and cyclophosphamide) on day 1 every 3 weeks for 4 cycles or FEC (fluorouracil, epirubicin, and cyclophosphamide) on day 1 every three weeks for 4 cycles
1654296|NCT01822301|Procedure|Repeat Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat grafting is considered a standard of care procedure in plastic surgery. In brief, fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the facial deformity using specialized injection cannulas. In this study, we will treat 5 subjects from protocol (IRB # PRO09060101) with an additional fat graft treatment to assess whether this will increase fat graft retention over time. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) with be used for comparison.
1654297|NCT01822288|Drug|Tibolone|Tibolone 2.5 mg once a day for patients with menopausal syndrome (self-paid)
1654298|NCT01822288|Drug|Estradiol & medroxyprogesterone acetate|Estradiol & medroxyprogesterone acetate once a day for patients with menopausal syndromes, for patients without the need for self-paid drug
1654299|NCT01822275|Drug|Chemotherapy with Temodar.|Once the patient has had surgery, patients will receive 6 weeks of radiation therapy with concurrent chemotherapy on protcol. This will be followed by a maximum of 12 cycles of adjuvent chemotherapy with Temodar.
1654300|NCT01822275|Radiation|Radiation therapy|
1654301|NCT01822262|Procedure|minimally invasive cholecystolithotomy with gallbladder reservation|
1654302|NCT01822262|Procedure|laparoscopic cholecystectomy|
1654303|NCT01822249|Drug|EPI-743|
1654539|NCT01820585|Drug|ESL 1200 mg|tablets
1654304|NCT01822236|Other|Craniosacral Therapy Program|The ten techniques of craniosacral therapy program are: Still Point (CV-4, Sacred Feet), diaphragms(pelvic, respiratory, thoracic inlet, hyoid, Occipital Cranial Base), Decompression L5-S1, Dural Tube Glide, Lift Front, Parietal Lift, Compression / decompression of the joint sphenobasilar, Temporary Technique, Compression / decompression of the temporomandibular joints, and Still Point CV-4.
1654305|NCT01822236|Other|One technique of craniosacral therapy|Decompression L5-S1: lumbosacral decompression
1654306|NCT01822223|Device|Dental implant-abutments|"At week-8, abutments will be removed and replaced with new Laser-Lok® abutments. An inter-arm randomization will assign subjects to one of two sub-groups per treatment arm. Sub-groups 1-a & 2-a: will receive a new Laser-Lok® abutment and a soft-tissue biopsy at week-8; a force-probe clinical attachment assessment of the same site will be delayed until week-16.
Sub-groups 1-b & 2-b: will receive a new Laser-Lok® abutment and a force-probe clinical attachment assessment at week-8; a biopsy harvested from the same study site will be delayed until week-16.
The implants will be restored following standard technique and a final visit will occur 6 months following permanent restoration."
1654307|NCT01822210|Drug|Botox|injection by gastroscopy (100 Allergen units)
1654308|NCT01822197|Device|Phototherapy|light will be administered at a minimum distance of 12 inches away to provide 10,000 lux
1654309|NCT01822171|Other|Discharge medication counseling from a pharmacist|Patient will be educated about proper dosing instructions, potential side effects, and when to recontact the treating physician office.
1654310|NCT01822171|Other|Home medication if needed|Patient will be provided with medication to take home, when needed.
1654311|NCT01822171|Other|Follow-up visit at Medication Therapy Management clinic|This comprehensive Medication Therapy Management clinic follow-up visit is scheduled for 7 days post hospital discharge. The approximately 1 hour visit is scheduled with a pharmacist to review current drug therapy and make recommendations, if needed, to improve medication utilization.
1654312|NCT01822158|Other|Vaginal Delivery Debrief Checklist|Participating team members will utilize Vaginal Delivery Debrief checklist
1654313|NCT01822145|Device|ICD|
1654316|NCT01822119|Device|Baha Attract System|
1654317|NCT01822106|Other|Placebo|
1654318|NCT01822093|Biological|Cytovir-ADV|"A single dose 1x10e4 CD3+ T cells/kg patient weight of Cytovir ADV is prescribed to patients on exhibiting two consecutive PCR positive Adenovirus viraemia results > 1000 copies/ml. Patients are followed up by continued monitoring of Adenovirus viraemia results. If patients exhibit uncontrolled ADV viraemia at ≥ 4 weeks following the first cell dose, they will be prescribed a second cell dose of 10e5 CD3+ T cell/kg. Patients will be monitored for 6 months following infusion of Cytovir ADV.
This is a feasibility/pilot study and has no control group"
1654319|NCT01822080|Drug|Dienogest (Visanne, BAY86-5258)|2 mg dienogest (DNG) once daily by mouth
1654320|NCT01822080|Drug|Placebo|Matching placebo once daily by mouth
1654321|NCT01822041|Drug|ARN-509|Single oral dose of 240 mg ARN-509
1654322|NCT01822028|Drug|Treatment A|Florastor® placebo. Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day).
1654323|NCT01822028|Drug|Treatment B|"Florastor® capsules dosed at 1000 mg daily (two 250 mg capsules two times per day).
Zavesca® capsules dosed at 300 mg daily (one 100 mg capsule three times per day)."
1654324|NCT01822015|Drug|Sirolimus|Given PO
1654325|NCT01822015|Drug|Idarubicin|Given IV
1654326|NCT01822015|Drug|Cytarabine|Given IV
1654327|NCT01822002|Procedure|Canalith repositioning maneuver|
1654328|NCT01821989|Dietary Supplement|Lactoferrin|dose of 100 mg/day
1654329|NCT01821989|Dietary Supplement|Lactoferrin|dose of 150 mg/kg/ twice daily
1654330|NCT01821989|Dietary Supplement|Placebo|in form of distilled water
1654331|NCT01821976|Procedure|Ertl Procedure|
1654332|NCT01821976|Procedure|Burgess Procedure|
1654333|NCT01821963|Drug|Pegylated Interferon Alfa 2a|Starting dose: 180 mcg subcutaneously once weekly.
1654334|NCT01821963|Drug|Ribavirin|Starting dose: 1,000 mg by mouth daily.
1654335|NCT01821963|Drug|Telaprevir|Starting dose: 750 mg by mouth 3 times a day.
1654336|NCT01821950|Behavioral|Yoga during physical education|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
1654337|NCT01821937|Drug|faldaprevir(high dose)|faldaprevir(high dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to high dose treatment in random order
1654338|NCT01821937|Drug|Faldaprevir(low dose)|faldaprevir(low dose) will be taken by 1 day single use and 10 days multiple use. the subjects will be assigned to low dose treatment in random order
1654339|NCT01821911|Biological|Zagreb2-1-1|Injection on day 0、7、21
1654340|NCT01821911|Biological|Essen|Injection on day 0、3、7、14、28
1654341|NCT01821898|Drug|Oral Budesonide|This group will receive oral viscous budesonide at a dose of 1 or 2 mg depending on the height divided twice a day
1654342|NCT01821898|Other|Elimination diet|This group will receive an elimination diet
1654343|NCT01821885|Behavioral|Spirometry and a brief advice to quit smoking|During a year, recruitment for active smoker patients was done by doctors in primary care medical offices. In the intervention group, after been randomized, one trained nurse completed the questionnaires and did the spirometry with bronchodilator test and set a date with its family doctor who did a minimal smoking cessation counselling intervention and informed the patients about the spirometry results according to established protocol.
1654344|NCT01821885|Behavioral|Brief advice to quit smoking|During a year, recruitment for active smokers patients occurred through doctors in primary care medical offices. After be randomized, in de control group, a nurse complete the questionnaires. Below, patients go to the family doctor who will do a minimal smoking cessation counselling intervention.
1654345|NCT01821872|Drug|Administration of paracetamol|Administration of 1g intravenous paracetamol
1654346|NCT01821859|Drug|Abraxane|Abraxane will be infused at a dose of 220 mg/m² in 20 mL normal saline per 100 mg vial over 30 minutes. This will follow the Bevacizumab infusion.
1654347|NCT01821859|Drug|Bevacizumab|Bevacizumab will be infused at a dose of 10 mg/kg in 100 mL normal saline over 30 minutes ± 10 minutes. It is given first, prior to the Abraxane infusion.
1654348|NCT01821846|Drug|liraglutide|Administered either alone or in combination therapy according to the package insert (PI). Self-administered once daily, at any time subcutaneously (s.c., under the skin) in the abdomen, thigh or upper arm).
1654349|NCT01821833|Dietary Supplement|Omega-3 fatty acid|"Patients receive omega-3 fatty acid capsules orally beginning 1 week prior to paclitaxel treatment.
Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first).
Each 1-gram capsule contains approximately 465 mg eicosapentaenoic acid (EPA) and 375 mg docosahexaenoic acid (DHA)."
1654350|NCT01821833|Dietary Supplement|Placebo|"Patients receive placebo capsules orally beginning 1 week prior to paclitaxel treatment.
Capsule administration continues until paclitaxel is discontinued or for 12 weeks maximum (whichever comes first)"
1654351|NCT01821833|Drug|Paclitaxel|Patients will receive, as part of their standard of care, weekly paclitaxel at 70 to 90 mg/m2 intravenously for a minimum of 2 months. Treatment 3 out of 4 weeks is allowed.
1654352|NCT01821820|Other|Pistachios|
1654353|NCT01821781|Drug|Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan|Between days -23 and -15: alemtuzumab test dose, 3mg IV or SQ Day -14: alemtuzumab, 10mg IV or SQ Day -13: alemtuzumab, 15mg IV or SQ Day -12: alemtuzumab, 20mg IV or SQ Days -8 to -4: fludarabine, 30mg/m2 IV Day -4: thiotepa 4mg/kg IV q 12 hours Day -3: melphalan, 140mg/m2 IV Day 0: stem cell infusion Day +7: G-CSF
1654354|NCT01821768|Procedure|Sentinel Lymph Node Biopsy|
1654355|NCT01821755|Behavioral|Foster parent intervention|parent management training for foster parents, consisting of 10 individual home visits and 3 group sessions. Duration is four months
1654356|NCT01821742|Other|Ultrasound cardiac output measurement|
1654357|NCT01821729|Drug|FOLFIRINOX|Oxaliplatin via IV on Day 1 over 2 hours; Irinotecan via IV on Day 1 over 90 minutes, 5FU via IV on Day 1 over 2-4 minutes
1654358|NCT01821729|Drug|Losartan|Taken orally every day during Phase I for all 8 cycles
1654359|NCT01821729|Radiation|Proton Beam Radiation|30-45 minutes per day, daily Monday-Friday
1654360|NCT01821716|Biological|Prick test Dermatophagoides pteronyssinus allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.
Three concentrations of Dermatophagoides pteronyssinus allergen extract, together with a positive and negative control, using 10 mg/ml histamine dichloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
1654361|NCT01821703|Drug|LY3045697|Administered as oral solution
1654362|NCT01821703|Drug|Placebo|Administered as oral solution
1654363|NCT01821703|Drug|Spironolactone|Administered as capsule
1654364|NCT01821703|Drug|Placebo|Administered as capsule
1654365|NCT01821690|Drug|Buspirone|Buspirone/placebo will be given in increasing increments of 15 mg as needed. Subjects will start with 15 mg on day one and end with 60 mg on day 91 or placebo equivalent. Dose is titrated based on treatment response.
1654366|NCT01821690|Drug|Placebo|The placebo tablets taste and look identical to buspirone.
1654367|NCT01821677|Drug|Low Dose Danazol|
1654368|NCT01821677|Drug|Placebo|
1654369|NCT01821664|Device|Prosthetic vascular graft|Implantation of a prosthetic vascular graft
1654370|NCT01821651|Device|HeartNavigator|Procedure with software
1654371|NCT01821651|Device|EchoNav|Procedure with software
1654372|NCT01821651|Other|Control-Group EN|Procedure without software
1654373|NCT01821651|Other|Control-group HN|Procedure without software
1654374|NCT01821625|Drug|Eltrombopag|Study patients will be provided eltrombopag to raise platelet levels before anti-hepatitis C drugs are initiated, and will continue eltrombopag throughout the study.
1654375|NCT01821612|Drug|oxaliplatin|IV
1654376|NCT01821612|Drug|irinotecan|IV
1654377|NCT01821612|Drug|leucovorin|IV
1654378|NCT01821612|Drug|5-fluorouracil|IV
1654379|NCT01821612|Drug|capecitabine|PO
1654380|NCT01821612|Radiation|radiation|
1654381|NCT01821612|Procedure|surgery|
1654382|NCT01821612|Drug|gemcitabine|IV
1654383|NCT01821599|Other|Nonaccelerated Rehabilitation|Nonaccelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 6 months of recovery.
1654384|NCT01821599|Other|Accelerated Rehabilitation|Accelerated Rehabilitation After Anterior Cruciate Ligament Reconstruction in 4 months of recovery.
1654385|NCT01821586|Other|Modified ORS-1|
1654386|NCT01821586|Other|Modified ORS-2 (ReSoMal)|
1654387|NCT01821586|Other|Modified ORS-3 (Benefibre)|
1654390|NCT01821560|Drug|Baclofen|
1654391|NCT01821560|Drug|placebo|
1654392|NCT01821547|Drug|Hepatitis B vaccine|Immunisation with HepB vaccine (HBvaxPRO, 10μg/ml, Sanofi Pastuer) via intramuscular injection into the non-dominant deltoid (part 1 only).
1654393|NCT01821534|Other|No Intervention|No treatment (intervention) was administered.
1654394|NCT01821521|Drug|AGSPT_L20|
1654395|NCT01821521|Drug|Pantoloc 40mg|
1654396|NCT01821508|Other|Clinical Treatment|metabolic surgery for diabetes and weight control
1654397|NCT01821508|Procedure|Roux-En-Y gastric bypass surgery|laparoscopic surgical procedure with Endoscopic Surgical Stapler
1654398|NCT01821495|Biological|DC-CIK|
1654399|NCT01821495|Biological|Dendritic and Cytokine-induced Killer Cells|Concurrent of radiotherapy and chemotherapy plus 3 cycles of Dendritic and Cytokine-induced Killer Cells(DC-CIK) treatment
1654400|NCT01821482|Biological|Dendritic and Cytokine-induced Killer Cells|
1654543|NCT01820559|Drug|Placebo|Tablets
1654401|NCT01821469|Behavioral|psychoeducation|Bipolar disorders are educated to learn about their pathology
1654402|NCT01821456|Drug|Antiinfectives|To analyze to efficacy of (novel) drug therapies
1654403|NCT01821443|Other|Stereotactic radiosurgery (SRS)|"Dose & prescription The dose will be prescribed to the isodose surface, which encompasses the margin of the metastasis (50-90% [maximum=100%]), as defined by target delineation on the imaging studies.
The prescribed dose is dependent on the prescription isodose volume (IDV). The prescription IDV is defined as the volume (cm3) that is encompassed by the prescription isodose line (IDL)."
1654404|NCT01821430|Drug|Pregabalin|Titration of intervention will begin with 50mg PO BID x 2 days, then 100mg PO BID x 2 days, then 150mg PO BID X 2 days, then on day 7 full dose of Pregabalin 400mg PO QD for six weeks
1654405|NCT01821430|Drug|Placebo|Placebo group will follow the same titration as the pregabalin group
1654406|NCT01821417|Device|Microtextured dental implant treatment|Microtextured dental implant treatment will include a surgically inserted device implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
1654407|NCT01821417|Device|Dental implant treatment|Treatment with dental implants; implants with a machined collar will be surgically implanted into edentulous areas of the jaw where natural teeth have been lost and adequate bone exists.
1654408|NCT01821404|Drug|Atorvastatin|Capsules including 80 mg of atorvastatin
1654409|NCT01821404|Drug|Placebo|Similar capsules as in the atorvastatin arm, but without the active ingredient
1654410|NCT01821391|Drug|NDL-PDT|Metvix natural daylight photodynamic therapy
1654411|NCT01821391|Drug|c-PDT|Metvix conventional photodynamic therapy
1654412|NCT01821391|Drug|placebo c-PDT|Metvix placebo conventional photodynamic therapy
1654413|NCT01821378|Drug|Lurasidone|Lurasidone 20 mg once daily
1654414|NCT01821378|Drug|Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2|Lurasidone 80 mg once daily
1654415|NCT01821378|Drug|Placebo|Once Daily
1654416|NCT01821352|Device|Erchonia Obesity Laser|10 independent 17 milliwatts 532 nm green diode lasers
1654417|NCT01821352|Device|Placebo Laser|Emits light that has no therapeutic effect
1654418|NCT01821313|Other|Moderate exercise|
1654419|NCT01821313|Other|High Intensity Interval Exercise|
1654420|NCT01821287|Other|CHD|The study is not providing an intervention but rather is observational/studying factors that could contribute to nutritional failure in single ventricle CHD infants
1654425|NCT01820325|Drug|Buparlisib|
1654426|NCT01820325|Drug|Buparlisib placebo|Placebo + Carboplatin + Paclitaxel
1654427|NCT01820325|Drug|Carboplatin|
1654428|NCT01820325|Drug|Paclitaxel|
1654429|NCT01820312|Radiation|Low-Dose Fractionated Radiation Therapy/Paclitaxel|
1654430|NCT01820299|Drug|Grape Seed Extract|All patients enrolled to the study will take Grape Seed Extract alone for 21 days.
1654431|NCT01820299|Drug|Vitamin D|From Day 22 until Day 64 of the study, patients will take Grape Seed Extract and Vitamin D together. Patients will take Vitamin D once at a day at 4000 IU.
1654432|NCT01820286|Behavioral|Positive psychology intervention|
1654433|NCT01820286|Behavioral|Recollection intervention|
1654434|NCT01820260|Drug|Ingenol mebutate gel|
1654435|NCT01820260|Drug|placebo|
1654436|NCT01820247|Drug|enteral nutrition|
1654437|NCT01820247|Drug|Tripterygium glycosides|
1654438|NCT01820234|Other|In-person dermatology evaluation|Every patient will be evaluated by an in person dermatologist present at the screening.
1654439|NCT01820234|Other|Store-and-forward teledermatology evaluation|Every patient will be evaluated online via a store and forward teledermatology modality.
1654440|NCT01820221|Procedure|Suture vs. staples closure method after c-section in obese women.|Random card draw to either suture skin closure or staple skin closure arm of study.
1654442|NCT01821235|Drug|Neurontin® (gabapentin) batch A|Neurontin® 800 mg tablets (gabapentin) batch A, given 2 times
1654443|NCT01821235|Drug|Neurontin® (gabapentin) batch B|Neurontin® 800 mg tablets (gabapentin) batch B, given 1 time
1654444|NCT01821235|Drug|Gabasandoz® (gabapentin) batch A|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 2 times
1654445|NCT01821235|Drug|Gabasandoz® (gabapentin) batch B|Gabasandoz® 800 mg tablets (gabapentin) batch A, given 1 time
1654446|NCT01821222|Device|Wired mothers|"The wired mothers SMS component provided health education and appointment reminders to encourage attendance at routine antenatal care, skilled delivery attendance and postnatal care. A specially-designed software automatically generated and sent text messages throughout the pregnancy until six weeks after delivery. The frequency and content of the messages varied according to the women's gestational age.
Mobile phone vouchers allowed all wired mothers to communicate directly with primary health care providers. Primary health care facilities randomised for intervention and hospitals were provided with a mobile phone with sufficient credit, while wired mothers were given a phone voucher with modest credit and a card with the phone number of her local primary health care provider."
1654489|NCT01820936|Drug|Sequence 5: PCI-32765|After completion of the 4-way crossover, an additional separate cohort of 8 subjects were enrolled. These subjects participated in 1 treatment period to document safety and PK
1654490|NCT01820923|Device|Transcranial direct current stimulation (tDCS)|2 mA of intensity, 20 minutes of stimulation over the left fronto-temporal prefrontal cortex.
1654491|NCT01820923|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Frequency of stimulation: 10Hz. Interstimulus interval: 1 min. Number of stimuli per session: 300. Number of sessions per week: 4 Total number of stimuli: 1.200
1654638|NCT01819701|Dietary Supplement|LC-1000|L-carnitine 1000 mg /d
1654447|NCT01821209|Procedure|Placement of sling|Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
1654448|NCT01821196|Procedure|biopsy|biopsies will be evaluated with immunohistochemistry and gene expression studies
1654449|NCT01821170|Drug|Methylphenidate|Patient will take treatment during two months
1654450|NCT01821170|Device|cognitive remediation|Patient will have 12 sessions during 6 to 8 weeks
1654451|NCT01821170|Behavioral|supportive psychotherapy|Patients will have 12 sessions during 6 to 8 weeks
1654452|NCT01821170|Other|neuropsychological tests|neuropsychological tests will assess attentional and executive performance
1654453|NCT01821157|Procedure|Open-flap|Open-flap(control group; n=28 sides/105 teeth): An internal beveled incision was performed at the buccal aspect of the involved teeth. Afterwards, a sulcular incision was completed to allow gingival tissue removal. A full-thickness mucoperiosteal flap was reflected to remove and remodel bone tissue by means of surgical chisels, as necessary, until a 3mm distance was achieved between the bone crest and the cement-enamel junction (CEJ). The exposed root surfaces were carefully planed with curettes. Interrupted sutures were performed at the papilla to allow GM stabilization in the CEJ position.
1654454|NCT01821157|Procedure|Flapless|FL (test group; n=28 sides/105 teeth): Internal beveled and sulcular incisions and gingival tissue removal were performed as above described for the control group, replacing the GM in the CEJ position. However, the alveolar bone was removed and remodeled, as necessary, using micro chisels, via incisions, without flap elevation. The root surfaces were also carefully planed via incisions. The required distance of 3mm between the bone crest and the CEJ was checked by inserting a periodontal probe into the incision. Sutures were not performed.
1654455|NCT01821144|Behavioral|Salt reduction|Salt reduction
1654456|NCT01821144|Other|Control|No salt awareness education
1654457|NCT01821131|Other|muffin|
1654458|NCT01821118|Biological|Ponezumab|Infusion of Ponezumab (Day 1=10mg/kg; Day 30 and Day 60 dose = 7.5mg/kg) or placebo (saline); administered via infusion for a total infusion time of 20 minutes.
1654459|NCT01821118|Other|placebo|placebo (saline)- given via infusion total infusion time of 20 minutes
1654460|NCT01821105|Procedure|PET Scan|All patients will receive whole body PET scans (chest-abdomen-pelvis).
1654461|NCT01821105|Procedure|CT Scan|All patients will receive CT scans of the abdomen and pelvis with contrast.
1654462|NCT01821105|Radiation|fludeoxyglucose F 18|Given IV
1654463|NCT01821105|Procedure|computer-aided detection/diagnosis|Undergo computer-aided detection/diagnosis during surgery
1654464|NCT01821092|Procedure|implant insertion and abutment connection|After implant insertion, immediate or in healed ridge, the titanium abutment with switching platform will be connected
1654465|NCT01821092|Device|osseointegrated implant|Osseointegrated Implant Insertion
1654466|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as powder in capsule (2x100 mg)
1654467|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
1654468|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
1654469|NCT01821079|Drug|PF-05175157|Single 200 mg dose of PF-05175157 administered as tablet formulation (2x100 mg)
1654470|NCT01821066|Drug|PD-0332991 alone|PD-0332991 is administered alone as a single oral 125 mg dose on Day 1 of Period 1.
1654471|NCT01821066|Drug|Tamoxifen 60 mg|On Days 1-4 of Period 2, tamoxifen is administered daily as 60 mg oral doses (using three 20mg tablets).
1654472|NCT01821066|Drug|Tamoxifen 20 mg|On Days 5-27 of Period 2, tamoxifen is administered daily as 20 mg oral doses.
1654473|NCT01821066|Drug|PD-0332991 combination|PD-0332991 is administered in combination with tamoxifen on Day 22 of Period 2 as a single 125 mg oral dose.
1654474|NCT01821040|Drug|Lodotra®|Lodotra, starting dose of 15mg administered in the evening
1654475|NCT01821040|Drug|Prednisone IR (immediate release)|Prednisone IR 15mg daily start dose (immediate release) administered in the morning,
1654476|NCT01821027|Drug|Simvastatin|One 40 mg tablet taken orally (by mouth) on Day 1 and Day 7.
1654477|NCT01821027|Drug|Canagliflozin (JNJ-28431754)|One 300 mg dose (ie, one 100 mg and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Days 2 through Day 7.
1654478|NCT01821014|Other|Telemedicine|Patients undergo a detailed history and examination to the degree that is possible using the videoconference program, skype, a digital camera for high-resolution images, and an electronic stethoscope. A clinic volunteer aids with examination, translation and documentation.
1654479|NCT01821014|Other|In-person physician interaction|Patients undergo a detailed history and examination by an in-person physician. A clinic volunteer aids with examination, translation and documentation, as needed.
1654480|NCT01821001|Drug|Vaginal Bromocriptine|Patients will receive 2.5 mg of vaginal bromocriptine tablet twice a day for the intervention. This will be administered for 6 months.
1654481|NCT01820975|Dietary Supplement|High protein intake|
1654482|NCT01820975|Other|Placebo comparator|No protein intake
1654483|NCT01820962|Procedure|heparin|when not in use CVCs are locked with heparin
1654484|NCT01820962|Procedure|concentrated citrate|when not in use the CVC is locked with concentrated citrate
1654485|NCT01820936|Drug|Sequence 1: PCI-32765|Period 1 = Treatment D, Period 2 = Treatment C, Period 3 = Treatment A, Period 4 = Treatment B
1654486|NCT01820936|Drug|Sequence 2: PCI-32765|Period 1 = Treatment A, Period 2 = Treatment D, Period 3 = Treatment B, Period 4 = Treatment C
1654487|NCT01820936|Drug|Sequence 3: PCI-32765|Period 1 = Treatment B, Period 2 = Treatment A, Period 3 = Treatment C, Period 4 = Treatment D
1654488|NCT01820936|Drug|Sequence 4: PCI-32765|Period 1 = Treatment C, Period 2 = Treatment B, Period 3 = Treatment D, Period 4 = Treatment A
1718083|NCT00002399|Drug|Posaconazole|
1654492|NCT01820923|Device|Transcranial Direct Current Stimulation (SHAM)|The electrodes of stimulation will be applied in the left fronto-temporal prefrontal cortex, but the device will be turned off.
1654493|NCT01820923|Device|Repetitive Transcranial Magnetic Stimulation (SHAM)|The coil will be applied on the left fronto-temporal prefrontal cortex, but the device will be turned off.
1654494|NCT01820910|Drug|Doxycycline|All enrolled patients will be treated with doxycycline 100 mg bid daily, orally, for four weeks followed by four weeks rest, repeated for three cycles. Response will be assessed by MRI (magnetic resonance imaging) and ophthalmologic examination at the end of the planned treatment. Patients who will achieve complete response, partial response or have a stable disease at 3 months from upfront doxycycline will be monitored for infection re-occurrence and assessed for response with MRI and ophthalmologist evaluation every six months for the first five years.
1654495|NCT01820897|Drug|Fosfomycin-Trometamol|
1654496|NCT01820897|Drug|Sulfamethoxazole trimethoprim|
1654500|NCT01820871|Other|Self-Management Using Smartphone Application for Type2 DM|
1654501|NCT01820871|Other|self-management using booklet for management type 2 DM|
1654507|NCT01820832|Drug|Calcitriol|Calcitriol 0.5 ug/BIW for 24 weeks.
1654508|NCT01820806|Drug|100 mg dose of [14C] GLPG0634|Subjects will be dosed with a single oral 100 mg dose of [14C] GLPG0634 on one occasion
1654509|NCT01820793|Drug|Cefoxitin|proof of concept study to evaluate the efficacy of cefoxitin (2 grams every 6 hours for 10 days) in 40 women presenting acute ESBL-producing E.coli pyelonephritis without severity symptoms and to perform on half of the participants repeated measurements of cefoxitin serum levels (6 blood samples within 6 hours following an injection).
1654510|NCT01820780|Other|Natriuretic peptides levels to J7 and J14|
1654511|NCT01820780|Other|Consultations specialized to J7 and J14|Optimization of treatments Education on the signs of alert of the disease and on the medicines Reduction of the rate of BNP or NTproBNP = 30 % between the exit of the hospitalization and the second consultation Planning of an adapted coverage
1654512|NCT01820780|Other|Phone calls in 6 months and 12 months|
1654513|NCT01820780|Other|Natriuretic peptides levels at 6 months|
1654514|NCT01820780|Other|Consultation with the general doctor or the cardiologist to J30 with blood results|
1654515|NCT01820767|Drug|Paricalcitol|Oral Paricalcitol. parathyroid hormone i mcg/100. 3 days per week, the same day as haemodialysis is done, during 12 weeks.
1654516|NCT01820767|Drug|Paricalcitol, atorvastatin|"Oral Paricalcitol. parathyroid hormone i mgc/100. 3 days a week, the same day as haemodialysis, during 12 weeks.
Atorvastatin: 20 mg/day oral (1 take) during 12 weeks."
1654517|NCT01820767|Drug|Atorvastatin|Atorvastatin: 20 mg/day oral (1 take) during 12 weeks
1654518|NCT01820754|Drug|Ipilimumab|"Neoadjuvant (Pre-Surgery): Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes
Adjuvant (Post-Surgery): Ipilimumab 10 mg/kg IV every 3 weeks times 2 doses beginning 4 weeks postoperative ( up to 10 weeks if needed for recovery)
Maintenance: Ipilimumab 10 mg/kg/IV every 12 weeks times 2 doses"
1654519|NCT01820754|Drug|Paclitaxel, Cisplatin, Carboplatin|"Neoadjuvant (Pre-Surgery) Cycle 1: Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 1 cycle)
Cycles 2 and 3: Ipilimumab 10 mg/kg IV over 90 minutes, Paclitaxel 175 mg/m2 IV over 3 hours , followed by Cisplatin 75 mg/m2 IV over 60 minutes or carboplatin AUC 6 IV over 30-60 minutes on day 1(Every 21 days x 2 cycles)"
1654520|NCT01820728|Drug|DA-3801 Injection|
1654521|NCT01820728|Drug|Gonal-F®|
1654522|NCT01820715|Drug|600㎍ of DA-3030 Injection|
1654523|NCT01820715|Drug|Placebo|
1654524|NCT01820702|Other|Defined Training Programme|A Smith Machine with fixed rails was used to guide the heel raise and squat exercises in the vertical axis. A metronome was used to direct the subjects during the performance of the exercises. Squats and heel raises were performed against body weight plus the additional weight of the barbell (15 kg). The heel raises were performed with straight knees and without ankle dorsiflexion. The shallow squats were performed continuously for 3 minutes. The hopping and the cross-hopping exercises were performed without Smith Machine. The bilateral hops were performed at ~ 3 repetitions per second with 15-s rest insertions between each set. Cross-hopping was performed continuously for 3 minutes against ~ 1.3 repetitions per second. Except for the duration of the static squat, with progressed from 45 s at HDT1 to 70 s at HDT5, none of the exercises were progressed during the study. Including the scheduled rest pauses, the LRT sessions were completed in 24 minutes.
1654525|NCT01820689|Other|Tympanometry measurement|The tympanometry measurement will be verify and compared with the time of palatoplasty.
1654526|NCT01820676|Device|iUni G2+|The iUni G2+ Unicompartmental Resurfacing Device (iUni) is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation (Fitz).
1654527|NCT01820663|Other|Modified Atkins Diet|A high fat, high protein, low- carbohydrate diet
1654528|NCT01820663|Other|Control diet|The control diet is a diet determined by the attending physician caring for the patient and may consist of either a low sodium diet, a low sodium/ low cholesterol diet, a regular diet or a diabetic diet.
1654529|NCT01820650|Device|iTotal G2 CR Knee Replacement System|Total Knee replacement
1654530|NCT01820637|Device|The Boston Scientific DES SFA Paclitaxel-Eluting Self-Expanding Stent System (DES SFA)|Drug-eluting SFA self-expanding stent
1654531|NCT01820624|Drug|tretinoin|Given PO
1654532|NCT01820624|Drug|lithium carbonate|Given PO
1654533|NCT01820624|Other|laboratory biomarker analysis|Correlative studies
1654544|NCT01820559|Drug|ESL 1200 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
1654545|NCT01820559|Drug|ESL 800 mg|Eslicarbazepine acetate was supplied in 400-mg and 600-mg tablets and was administered with a dose of 800 or 1200 mg QD in the evening by the oral route.
1654546|NCT01820533|Other|Cell Phone Survey|Eight item survey for smokers being treated in the YNHH Emergency Dept. The survey asks about the type of cell phone(s) subjects have, how much they pay for cell service monthly, housing status, and if they receive any benefit that would qualify them for the Lifeline program.
1654547|NCT01820520|Drug|brilliant blue G|Double staining with brilliant blue G 0.025% for macular surgery
1654548|NCT01820507|Device|Optiflow (Fisher&Paykel)|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
1654549|NCT01820507|Device|Nasal cannulae or controlled oxygen concentration mask|The described method of oxygen supply will be maintained continuously for the first 24 hours after extubation.
1654550|NCT01820494|Other|Experimental Infant Formula|Infant formula to be fed ad libitum
1654551|NCT01820481|Drug|WIN-901X dose level 1|100mg Bid, PO, 12weeks
1654552|NCT01820481|Drug|WIN-901X dose level 2|200mg Bid, PO, 12weeks
1654553|NCT01820481|Drug|WIN-901X dose level 3|300mg Bid, PO, 12weeks
1654554|NCT01820481|Drug|Placebo|Bid, PO, 12weeks
1654555|NCT01820468|Behavioral|Adapted critical time intervention team|
2013093|NCT01061151|Drug|Lopinavir-ritonavir (LPV-RTV)|"Antepartum Arm B: A daily dose of 400 mg/100 mg orally twice daily beginning at >/= 14 weeks gestation (at study entry) through 28 weeks gestation (through second trimester); daily dose of 600 mg/150 mg orally twice daily beginning at >/= 28 weeks gestation or at next visit (during third trimester) through delivery; daily dose of 400 mg/100 mg orally twice daily after delivery until Week 1 postpartum visit (up to 14 days).
Antepartum Arm C: dailly dose of 400 mg/100 mg orally twice daily beginning at > 14 weeks gestation (at study entry) through 28 weeks gestation (through second trimester); daily dose of 600 mg/150 mg orally twice daily beginning > 28 weeks gestation, or at the next visit (during third trimester) through delivery; daily dose of 400 mg/100 mg orally twice daily after delivery until week 1 postpartum visit (up to 14 days).
Postpartum Arm A: a total daily dose of 800 mg/200 mg orally twice daily from Week 1 postpartum visit until completion of followup."
1654560|NCT01820416|Radiation|Low-level Laser Therapy|Portable unit containing two laser diodes producing 532 and 635 nm wavelengths. Both diodes produced energy levels of 7.5 mw (class IIIb). Beams from both diodes were dispersed through lenses to create parallel line-generated beams, rather than spots. The 532 nm light was constant, and the 635 nm light was pulsed, with frequencies of 15 and 33 Hz. The pulsing alternated between frequencies every 30 seconds.
1654561|NCT01820416|Other|Placebo Comparator: Disabled Laser|Portable unit containing two DISABLED laser diodes. Same protocol was followed as for the Experimental (radiation) group, except that the disabled diodes produced no radiation.
1654562|NCT01820403|Other|portion size kcal of box lunch|
1654563|NCT01820377|Behavioral|Aboriginal Youth Mentorship Program|High school students volunteer as mentors, and develop an after-school program that they then deliver to children in grade 4. The mentors meet twice a week. The first day, they develop an activity plan and decide roles and responsibilities to ensure successful delivery of each activity. The second day, they deliver the program to the grade 4s, which incorporates a healthy snack, 45-minutes of physical activity, and educational games/activities. Grade 4s are our intervention group
1654564|NCT01820364|Drug|LGX818|BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
1654566|NCT01820338|Behavioral|Behavioral Child Tx Contacts|Each parent and child dyad will participate in group meetings. Children and parents will meet in simultaneous, but separate, groups at each meeting. The intervention will include 12 sessions over 16 weeks. Families will also participate in a maintenance intervention for the next eight months. The primary treatment objectives will be to decrease caloric intake in a nutritionally sound manner and to increase moderate intensity exercise. Changes in dietary habits will be addressed via a modified version of the Stoplight System. Children and adults will be encouraged to eat a well-balanced diet based on the food guide pyramid. Parents and children will also be given pedometers and they will be asked to keep track of the number of steps they take each day. Each week parents and children will set goals to gradually increase physical activity. Parent and their children will be asked to record what they eat and drink, as well as their physical activity on daily food logs.
1654567|NCT01820338|Behavioral|Behavioral Parent-Tx Contacts|Only the participating parent(s) will attend group meetings. The intervention will include weekly sessions for the first 8 weeks and biweekly sessions for the next 8 weeks. They will also participate in a maintenance intervention for eight months. Each session will last 90 minutes. The sessions for parents in the parent-only program will be structured the same as the parents sessions for the family-based intervention and will also cover the same topics. As with the family-based intervention, the parent and their children assigned to the parent-only intervention will be asked to record what they eat and drink, as well as their physical activity, on a daily basis. Each week group interventionists will model the goal setting process with parents and suggest a general range of age-appropriate dietary and physical activity targets that might be appropriate for each child and parent.
1654568|NCT01820338|Other|Dietary and Physical Activity Information|Both the child and parent will attend the treatment sessions in this program. The condition will include a series of meetings addressing key aspects of nutrition, physical activity, and health promotion such as national guidelines regarding proper nutrition, guidelines for physical activity, strategies to cope with stress, healthy sources and guidelines for intake of fiber, calcium, protein, grains & carbohydrates. Topics will also include use of vitamin & mineral supplements, dental and sleep hygiene, self-esteem, family communication, and assertiveness training in dealing with peer victimization. The families in the Health Education group will not receive training in behavioral self-regulation strategies, such as goal setting and self-monitoring. Children will participate in a group physical activity during each session such as frisbee, jump rope, stoplight tag. They will also sample healthy snacks such as pretzels or fruits and vegetables.
1654569|NCT01820208|Drug|G-CSF|G-CSF would be given at a dose of 5 microgram/kg daily for 5 days followed by once in 3 days for a total of 12 doses.
1654570|NCT01820208|Drug|Placebo|Placebo would be given s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses)
1654571|NCT01820195|Drug|Oral N-Acetyl Cystein|Oral N-Acetyl Cystein 600 mg bid started the day before contrast administration and continue the day after exposure to contrast
1654572|NCT01820195|Drug|IV N-Acetyl Cystein|Bolus IV administration of 1200 mg N- Acetyl Cystein half an hour before contrast media administration
1654573|NCT01820195|Drug|Placebo group|The patients in this group will be received both oral placebo and IV placebo
1654574|NCT01820182|Device|capsule endoscopies|Patients inclusion following inclusion criterias Randomization of capsule ingestion order Videocapsule recording by the two capsules Reading of the two capsules films in randomized order by two different readers in each center Reviewing of discordant capsule films by an expert panel
1654575|NCT01820169|Device|;Accu-Chek Compact Plus LCM bulk Japan|HbA1c would be changed by more careful control in blood glucose with SMBG.
1654576|NCT01820156|Device|Home Respiratory Polygraphy|
1654577|NCT01820156|Device|Standard Polysomnography|
1654578|NCT01820143|Drug|Ilaprazole|
1654579|NCT01820143|Drug|Esomeprazole|
1654580|NCT01820130|Device|St Jude Medical EON mini rechargeable system|implantation of Eon Mini Neurostimulation System (IPG Model 3788)
1654581|NCT01820117|Other|Neurocognitive Evaluation|The neurocognitive evaluation will include measures of academic achievement, intelligence, sustained attention, memory, processing speed, executive functions, functional behavior, and emotional functioning.
1654582|NCT01820117|Other|Quantitative Brain Imaging|Imaging will include raw images to both quantify white matter hyperintensities and hemosiderin deposits, as well as cortical thickness and tissue segmentation. Brain imaging will be repeated on participants who are concurrently enrolled on BRIGHT and MIND protocols at St. Jude and who completed prior brain imaging during the BRIGHT clinic visit. The repeat MRI will be done at their 6 month MIND clinic visit.
1654583|NCT01820117|Other|Neurologic Evaluation|Evaluation includes a complete review of neurologic symptoms, and interview and examination by the neurologist, assessment of neurologic symptoms and determination of their impact on day-to-day living, and quantified neurologic examination by the neurologist.
1654584|NCT01820117|Other|Health Questionnaire|Participants will be asked to complete an approximately 450-item survey to assess health history and status, social and demographic factors, health behaviors, and psychosocial constructs.
1654585|NCT01820117|Other|Vascular Testing|Digital assessment of endothelial function will be studied, and central blood and pulse pressure and carotid-femoral pulse wave velocity will be non-invasively measured.
1654586|NCT01820117|Other|Cardiopulmonary Exercise Testing|Study participants will undergo cardiopulmonary exercise testing by treadmill. Those participants whose physical performance does not permit walking safely on the treadmill (extreme deconditioning, lower extremity paralysis, balance disorder, acute lower extremity injury) will perform cardiopulmonary exercise testing on a bicycle or upper extremity ergometer using a comparable testing protocol.
1654587|NCT01820117|Other|Echocardiography|A complete 3D as well as 2D echocardiogram with Doppler and M-mode will be performed.
1654588|NCT01820117|Other|Pulmonary Function Testing|Pulmonary function testing will include spirometry, lung volume measurements by body plethysmography, and single-breath carbon monoxide-diffusion capacity (DLCO).
1654589|NCT01820117|Procedure|Serum Biomarkers|Blood for serum biomarkers associated with cardiovascular morbidity will be drawn, including high-sensitivity C-reactive protein, serum homocysteine.
1654590|NCT01820117|Other|Ophthalmology Examination|Ophthalmology examination will include a review of symptoms, examination, and fundus imaging. The examination will consist of visual acuity testing, refraction testing, retinoscopy, ocular pressure, and examination under mydriasis. Fundus photography will be used to capture an image of the retina for examination of potential hypertensive retinopathy.
1654591|NCT01820104|Drug|lansoprazole, 30 mg per day for 6 days|
1654592|NCT01820091|Drug|Folotyn|A cycle of Folotyn treatment is 28 days, with treatment on Days 1 and 15 in each cycle.
1654593|NCT01820091|Drug|Fusilev|Fusilev will be administered either four times a day (QID) (6 hours apart, ±10 minutes), twice a day (BID) (8 hours apart, ±10 minutes) or once a day (QD) by IV push (3-5 minutes) at a dose of 5 mg/m2 according to the cohort to which patients are assigned.
1654594|NCT01820078|Drug|Experimental arm|Oral paricalcitol, 1 ug/day, plus daily treatment. 6 months (all study)
1654595|NCT01820078|Other|Comparator Arm|Daily treatment is not define by protocol, because daily treatment in CKD is highly variable and includes salt and/or blood pressure regulation, angiotensine system stoppers, controlled diet, etc.
1654596|NCT01820065|Procedure|Cataract surgery with IOL implantation|Phacoemulsification with implantation of single piece Acrysof IOL
1654597|NCT01820052|Drug|Oral Iron|230 mg of elemental oral iron tablets will be administered daily for 3 months
1654598|NCT01820052|Drug|Oral Placebo|Oral tablets matching oral iron will be administered daily for 3 months
1654599|NCT01820039|Other|FertiScreen|FertiScreen is an online application to assess whether referral is necessary or expectant management is indicated.
2013094|NCT01059643|Drug|LY2523355|Dose determined by patient body surface area: 5 mg/m2, administered intravenously on days 1, 2, 3 of a 21 day cycle; for up to 2 cycles (4 cycles for prostate cancer patients). Additional cycles administered based on patient response assessment.
1654605|NCT01820013|Device|Customised Dynamic Elastomeric fabric Orthoses|Eligible participants will be measured and fitted with a customised Dynamic Elastomeric Fabric Orthoses. The participant may require a re-fitting of the garment as they progress through their pregnancy. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
1654606|NCT01820013|Device|Serola Sacroiliac Belt|Eligible participants will be measured and fitted with a Serola sacroiliac belt. Participants will also be issued with standardised advice on PGP management via an information leaflet from Association of Chartered Physiotherapists in Women's health website.
1654637|NCT01819714|Other|Multi-sensory supportive care|"The Serre-Cavalier center will implement Snoezelen-type multisensory care sessions for included patients; these care sessions correspond with the patients' daily hygiene/toilette care.
The impact of this multisensory strategy will be evaluated using a before-after design."
1718084|NCT00002399|Drug|Fluconazole|
1654607|NCT01820000|Procedure|Diffusion Weighted Imaging with MRI scans|Subjects will have an MRI(magnetic resonance imaging)performed. This sequence will take no longer than 10 to 15 minutes to complete. Only DWI (diffusion weighted imaging) will be added to the standard cardiac MR protocol for viability which requires contrast injection. DWI(diffusion weighted imaging) sequence does not require contrast injection.
1654608|NCT01819987|Behavioral|Tablet computer|Participants in the intervention group will receive eight weekly online sessions and interactive activities delivered through tablet computers. Intervention participants will receive instructions for accessing the program via the tablet at an in-person session. Automated weekly emails will be sent to participating mothers for the intervention duration to encourage study engagement.
1654609|NCT01819987|Behavioral|Mailing information|Participants in the control group will receive general health promotion topics relevant to preschool-age children (such as immunization, injury prevention and school readiness) via mailing materials that are bilingual weekly for eight weeks. These materials will be obtained from CDC and AAP.
1654610|NCT01819974|Other|Stratified medication review|A mediciation review will be performed in patients with high medication error rik. Patients in the highest risk will receive the medication review from a clinical pharmacologist whereas patients assessed in lesser risk will receive the medication review from a clinical pharmacist.
1654611|NCT01819961|Drug|MCT/LCT and fish oil|
1654612|NCT01819961|Drug|MCT/LCT|
1654613|NCT01819948|Dietary Supplement|PhytoMed™|
1654614|NCT01819935|Drug|linezolid (Zyvox)|As prescribed-this is retrospective cohort of existing clinical data.
1654615|NCT01819935|Drug|vancomycin|As prescribed-this is retrospective cohort of existing clinical data.
1654616|NCT01819922|Drug|PF-05175157|600 mg as powder in capsule, one dose within 5 minutes prior to AM meal
1654617|NCT01819922|Drug|Placebo|Placebo powder in capsule, one dose within 5 minutes prior to AM meal
1654618|NCT01819909|Procedure|Postoperative Jackins Exercise Protocol|Jackin's exercises were initially designed for patients with difficulty performing forward elevation. The patient initially is positioned supine to perform shoulder flexion. When the patient can actively elevate in the supine position, one to two pounds of weight is placed in the patients hand and the patient is asked to repeat the maneuver of supine active elevation. When the patient can do this with little difficulty, the head of the bed is elevated approximately 20 degrees from the supine position and the sequence is repeated. Once the patient is able to perform flexion in this elevated head position, the inclination of the patient is increased in 20 degree increments until the patient is able to perform upright sitting shoulder flexion.
1654619|NCT01819909|Procedure|Postoperative Pulleys Exercise Protocol|Pulleys have been used in postoperative shoulder rehabilitation to improve passive as well as active range of motion and develop strength.
1654620|NCT01819896|Drug|Pacemaker and defibrillator|
1654621|NCT01819870|Drug|Dilatrend SR capsule 32mg|"1 capsule, oral, once daily, 7days
over the period I&II(crossover)"
1654622|NCT01819870|Drug|Dilatrend IR tablet 25mg|"1 tablet, oral, once daily, 7days
over the period I&II(crossover)"
1654623|NCT01819857|Drug|Xomolix 0.625 mg intravenously|intravenous administration of 0.625 mg droperidol
1654624|NCT01819857|Drug|Xomolix 1.25 mg|intravenous administration of 1.25 mg droperidol
1654625|NCT01819857|Drug|Zofran 8 mg|intravenous administration of 8 mg ondansetron
1654626|NCT01819844|Device|Closed-loop blood glucose control|The InPatient Closed Loop Device is made up of the three components; the Abbott FreeStyle Navigator subcutaneous continuous glucose monitor, the Symbiq insulin-dextrose infusion system, and the control algorithm. In this feasibility trial we will study 6 insulin-sensitive subjects with type 1 diabetes and 6 subjects with type 2 diabetes and a high insulin requirement (3 with total daily dose from 1-1.9 u/kg and 3 with total daily dose > 2 u/kg).
2013095|NCT01059643|Drug|pegfilgrastim|6 mg, administered subcutaneously 24 hours after third dose of LY2523355 on day 4 of each 21-day cycle, for up to 2 cycles of LY2523355 administration (4 cycles for prostate cancer patients). Additional cycles of LY2523355 administered based on patient response assessment.
2013096|NCT01052974|Drug|ropivacaine|"A widespread collectively practice for the analgesia in prehospital or preoperative period is the single injection of local anesthetic with the technique of the femoral or iliofascial block.
Intervention: Analgesic treatment using a femoral perineural catheter (inserted from the hospital admission) with continuous infusion of ropivacaïne controlled by placebo."
1654629|NCT01819818|Drug|No intervention|This is an observational study. Korean schizophrenic participants receiving paliperidone palmitate as an intramuscular injections will be observed.
1654630|NCT01819805|Drug|No intervention|This is an observational study. Patients taking extended release tramadol hydrochloride 75 mg and acetaminophen 650 mg orally twice daily will be observed.
1654631|NCT01819792|Other|Multiplex respiratory viral PCR|
1654632|NCT01819779|Drug|Exforge tab. 10/160mg|
1654633|NCT01819779|Drug|Lodivixx tab. 5/160mg|
1654634|NCT01819753|Procedure|Percutaneous nephrolithotomy|The procedure is done under general anesthesia in the supine position. A Retrograde pyelogram is done to locate the stone in the kidney. With a small incision in the flank, the percutaneous nephrolithotomy (PCN) needle is passed into the pelvis of the kidney. The position of the needle is confirmed by fluoroscopy. A guide wire is passed through the needle into the pelvis. The needle is then withdrawn with the guide wire still inside the pelvis. Over the guide wire the dilators are passed and a working sheath is introduced. A nephroscope is then passed inside and stones are taken out.
1654635|NCT01819740|Other|"determine the levels of the HEM substance in seminal plasma"|
1654636|NCT01819727|Drug|BMN 165|"After informed consent, eligible subjects will be randomized (1:1) to titrate up to one of two dose regimens: 20 mg/day or 40 mg/day. All subjects will initiate IP at a fixed-dose of 2.5 mg/week for 4 weeks (Induction).
After the Induction Period, subjects will enter the Titration Period (Week 5 up to Week 32) where they will increase their weekly BMN 165 dose to a daily dose regimen of 20 mg/day or 40 mg/day. The Titration Period will be individualized to each subject based on a minimum of 6 weeks (the time it takes to reach a dose regimen of 20 mg/day with no dose interruptions) and up to 28 weeks (accounts for dose interruptions due to AEs). Subjects will stop titration once they have achieved either the 20 mg/day or 40 mg/day dose. A maintenance dose will be administered for 4 weeks."
2013097|NCT01051310|Device|Medtronic CoreValve System|Transcatheter Aortic Valve
2013098|NCT01051518|Device|Medtronic CoreValve System|Transcatheter Aortic Valve
1654639|NCT01819701|Dietary Supplement|LC-2000|L-carnitine: 2000 mg/d
1654640|NCT01819701|Dietary Supplement|Q10-150|Coenzyme Q10: 150 mg/d
1654641|NCT01819701|Dietary Supplement|Q10-300|Coenzyme Q10: 300 mg/d
1654642|NCT01819701|Other|Placebo|
1654643|NCT01819688|Procedure|laparoscopic liver resection|
1654644|NCT01819675|Device|Low frequency rTMS|
1654645|NCT01819675|Device|High frequency rTMS|
1654646|NCT01819675|Device|Sham rTMS|
1654650|NCT01819649|Dietary Supplement|SelenoPRECISE selenium-enriched yeast tablet, Pharma Nord Denmark A/S|
1654651|NCT01819636|Other|sparkling highly mineral bicarbonated sodium water|1,25 liter a day at the mealtimes
1654652|NCT01819623|Other|Non-pharmacological therapy|It consists of a weekly two-hour session. During the first hour yoga classes will taught by teacher, during second hour supervised cognitive training by a psychologist based on Memory Program designed by Memory Unit of Madrid
2013099|NCT01038856|Drug|Erlotinib|Erlotinib supplied as tablets; oral dose of erlotinib of 150 mg daily to be continued for 16 weeks. Responders will continue for up to 12 months, non-responders will cease taking erlotinib
1654655|NCT01819571|Drug|Fluid loading (Voluven)|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 8ml / kg loading during 15 minutes after induction of anesthesia on both groups
1654656|NCT01819558|Biological|recwt1-A10+AS01B|
1654657|NCT01819532|Procedure|Milking group|"The umbilical cord will be milked toward the neonate four times prior to clamping the umbilical cord."
1654658|NCT01819532|Procedure|Immediate cord clamping|The umbilical cord will be clamped and cut immediately after delivery of the neonate.
1654659|NCT01819519|Behavioral|Educational Intervention|The patient will told if previously infected or seronegative and what is the risk of the becoming infected. The research assistant will deliver a 5-10 minutes educational intervention, which will consist of a CMV video and some Q&A.
1654660|NCT01819506|Behavioral|Task Practice Physical Rehabilitation Therapy|Similar to stroke rehabilitation occupational therapy.
1654661|NCT01819493|Behavioral|Lifestyle Intervention|Family-based group lifestyle intervention
1654662|NCT01819493|Behavioral|Standard Family-Based intervention|Comparison intervention
1654663|NCT01819480|Procedure|Transoral robotic surgery|Transoral robotic surgery using the daVinci robot to remove primary tumor
1654664|NCT01819467|Device|Seprafilm|Seprafilm will be placed onto the uterine incision and the anterior midline of the uterus following the primary cesarean section
1654665|NCT01819454|Device|pH monitoring (Restech)|"see in detail description of the study part of the protocol"
1654666|NCT01819441|Drug|Azelnidipine|8mg or 16mg
1654667|NCT01819441|Drug|Perindopril|4mg or 8mg
1654668|NCT01819441|Drug|hydrochlorothiazide|12.5mg or 25mg
1654669|NCT01819428|Drug|NOV120101 (Poziotinib)|NOV120101 (Poziotinib)12 mg PO once daily until disease progression or unacceptable toxicity development
1654670|NCT01819415|Dietary Supplement|Anti-VEGF plus AREDS-2|Omega-3 metabolites supplementation
1654671|NCT01819415|Dietary Supplement|Anti-VEGF plus AREDS-1|Patients receiving intravitreal anti-VEGF and AREDS-1 supplementation plus Lutein, without Omega-3.
1654672|NCT01819402|Drug|Pioglitazone vs Glimepiride|
1654673|NCT01819389|Drug|Imatinib and Nilotinib|
1654674|NCT01819376|Other|Facebook Status Update|
1654675|NCT01819363|Procedure|Pleural elastance|The pleural pressure level will be zero at the time of the insertion site of the drain on the skin. The pleural pressure is set to the value measured at end-expiration. The pleural pressure is measured at baseline, after withdrawal of 10 ml of liquid and thereafter every 400 ml of pleural effusion evacuated to the pressure to be negative, from that moment the measurement will occur every 200 ml of pleural effusion drained to obtain 800 ml of liquid. Patients that are removed less than 800 ml of liquid will be excluded from the protocol. The pleural elastance is then calculated in cm H2O / L and the data placed in a pressure curve by volume.
1654676|NCT01819350|Other|G1, G2 and G3|Nutritional, respiratory and endocrine group applicated 12 subjects
1654677|NCT01819350|Other|G4 and G5|Application of trhree pediadic medidines of antibiotic group on dental biofilm 12 subjects
1654678|NCT01819324|Behavioral|Targeting the Teachable Moment|TTMI material (every other week for 4 months)
1654679|NCT01819324|Behavioral|Standardized Lifestyle Management|SLM material (every other week for 4 months)
2013100|NCT01036321|Drug|Purified isoflavones|Soy-based isoflavone concentrate with methyl cellulose blend filler - Take 2 capsules daily
2013101|NCT01036321|Drug|Methyl cellulose blend|Placebo - Take 2 capsules daily
1654682|NCT01819285|Procedure|Immediate Orchiectomy or depot LHRH|
1654683|NCT01819285|Procedure|Delayed Orchiectomy or depot LHRH|
1654684|NCT01819272|Drug|Met DR|metformin delayed-release tablets
1654685|NCT01819272|Drug|Met XR|metformin extended-release tablets
1654686|NCT01819272|Drug|Placebo|placebo delayed-release tablets
2013102|NCT01025752|Behavioral|Face to face cognitive behavior therapy|Ten session face to face cognitive behavior therapy for chronic low back pain
2013103|NCT01025752|Behavioral|IVR based cognitive behavioral therapy|Ten session cognitive behavior therapy for chronic low back pain using interactive voice response therapy
2013104|NCT01025284|Drug|LY2523355|Administered intravenously
1654687|NCT01819259|Drug|Nicotine nasal spray|This study will use nicotine nasal spray to safely and effectively model the effects of initial smoking experiences in nonsmokers. Neither the safety nor the effectiveness of this drug will be assessed. The overall goal of the proposed research is to evaluate the behavioral and genetic mechanisms of smoking risk in non-smoking young adults (aged 18-25 years of age) with and without ADHD using a novel laboratory-based model of intranasal nicotine administration. The effects of two doses of intranasally administered nicotine versus placebo will be assessed. In addition, nicotine self-administration will be evaluated under conditions that are likely to be more cognitively challenging among individuals with ADHD.
1654688|NCT01819259|Drug|Placebo|
1654689|NCT01819246|Procedure|Aphersis Treatment Arm|
1654690|NCT01819246|Other|Control Arm|
1654691|NCT01819233|Behavioral|Behavioral dietary intervention|Receive caloric restricted dietary intervention
1654692|NCT01819233|Procedure|Therapeutic conventional surgery|Undergo definitive lumpectomy
1654693|NCT01819233|Radiation|Radiation therapy|Undergo radiation therapy
1654694|NCT01819233|Other|Counseling intervention|Receive dietary counseling
1654695|NCT01819233|Procedure|Quality-of-life assessment|Ancillary studies
1654696|NCT01819220|Drug|amlodipine/valsartan|"This is a phase IV clinical study. The study is a 24 week, prospective, randomized open labeled multicenter study to compare the efficacy of amlodipine/valsartan combination vs telmisartan/hydrochlorothiazide combination in reducing post prandial sugar. The study will be performed in hypertensive patients with metabolic syndrome.
Active group: Starting dose of amlodipine 5mg/ valsartan 80mg comparator group: Telmisartan 40mg/hydrochlorothiazide 12.5mg When the blood pressure is above the target goal of 140/90mmHg, up titration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.
When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
1654697|NCT01819220|Drug|hydrochlorothiazide/telmisartan|"When the blood pressure is above the target goal of 140/90mmHg, uptitration to amlodipine 5/valsartan 160 and/or telmisartan 80/hydrochlorothiazide 12.5mg is allowed.
When the blood pressure is above 140/90mmhg at the 12th week, addition of doxazosin 4mg is allowed."
1654698|NCT01819207|Other|blood test by thromboelastography|
1654699|NCT01819194|Device|senofilcon A|
1654700|NCT01819155|Biological|Adjuvanted seasonal trivalent inactivated influenza vaccine|
1654701|NCT01819155|Biological|Seasonal trivalent inactivated influenza vaccine|
1654702|NCT01819155|Biological|Saline (bacteriostatic 0.9% sodium chloride for injection)|
1654703|NCT01819142|Device|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly.
2013105|NCT01018823|Drug|Ertugliflozin|Ertugliflozin oral dosing 1 mg, 5 mg, 25 mg, or 100 mg solutions/suspensions administered once daily for 14 days immediately after breakfast
2013106|NCT01018823|Drug|Placebo to Ertugliflozin|Placebo oral dosing solutions/suspensions administered once daily for 14 days immediately after breakfast
2013107|NCT01016730|Drug|Bortezomib|Given IV
1654707|NCT01819090|Device|Elysee 150 ventilator|
1654708|NCT01819090|Device|Elysee 150 ventilator with a ventilation switch control|
1654709|NCT01819077|Procedure|TMMR|Radical hysterectomy by Total Mesometrial Resection (TMMR) and therapeutic lymphadenectomy (tLNE)
2013108|NCT01016730|Other|Laboratory Biomarker Analysis|Correlative studies
2013109|NCT01016730|Other|Questionnaire Administration|Ancillary studies
1654712|NCT01819051|Device|MOE Antimicrobial Plasma Treatment System|Plasma applied to great toenail 1X/week for three weeks
1654713|NCT01819038|Procedure|continuous renal replacement therapy|
1654714|NCT01819025|Behavioral|4 face-to-face therapy session and a smartphone-app|An 8 week blended therapy with both face-to-face therapy sessions and support through a smartphone application.
1654715|NCT01819025|Behavioral|CBT, treatment as usual|10 sessions of face-to-face therapy, full behavioral activation
1654716|NCT01819012|Drug|Isoflurane 1.0 MAC|10 min-inhalation of each concentration of isoflurane, 1.0 MAC
1654717|NCT01819012|Drug|Isoflurane 1.5 MAC|10 min-inhalation of each concentration of isoflurane, 1.5 MAC
1654718|NCT01819012|Drug|Isoflurane 2.0 MAC|10 min-inhalation of each concentration of isoflurane, 2.0 MAC
1654719|NCT01818999|Drug|IXABEPILONE|injection
1654720|NCT01818999|Radiation|STEREOTACTIC BODY RADIATION THERAPY|SBRT will begin between 1 and 5 weeks after the initiation of Ixabepilone. Patients will receive one, three, or five fractions.
1654721|NCT01818986|Drug|Sipuleucel-T|
1654722|NCT01818986|Radiation|Stereotactic Ablative Body Radiation|
1654723|NCT01818973|Drug|Xeloda|po, 1000mg/m2/12h daily, day 1 in the afternoon until day 15 in the morning, 8 cycles
1654724|NCT01818973|Drug|Oxaliplatin|iv, 130mg/m2, day 1, 1 cycle during neoadjuvant chemotherapy and 3 cycles in adjuvant chemotherapy 100mg/m2, day 1, 2 cycles during concurrent chemoradiotherapy
1654725|NCT01818973|Drug|Bevacizumab|iv, 7.5 mg/kg, day 1, 3 cycles during neoadjuvant chemotherapy and concurrent chemoradiotherapy
1654726|NCT01818973|Radiation|Radiation|Intensity-modulated radiation therapy, 50 Gy/25 fractions during 5 weeks
1654727|NCT01818973|Procedure|surgery|Total Mesorectal Excision (TME)
1654728|NCT01818960|Procedure|IRA-PCI|IRA only PCI at the time of Primary PCI
1654729|NCT01818960|Procedure|SS-PCI|Same sitting multivessel PCI as an adjunct to primary PCI
1654730|NCT01818934|Procedure|hip ultrasound|Standardized single-examiner Hip ultrasound was offered to all babies in the universal group, babies at increased risk in the selective group, and to no babies in the clinical exam only group
1654731|NCT01818921|Drug|ZGN-440 sterile diluent|ZGN-440 sterile diluent/placebo
1654732|NCT01818921|Drug|1.2 mg ZGN-440 for injectable suspension|1.2 mg beloranib
1654733|NCT01818921|Drug|1.8 mg ZGN-440 for injectable suspension|1.8 mg beloranib
1654734|NCT01818908|Drug|DA-EPOCH|DA-EPOCH regimen
1654735|NCT01818882|Other|Standard care|Standard care for dyspneic patients including contextual analysis, conventional clinical exam and a chest X-Ray.
1654767|NCT01818661|Drug|FDG Fluorodeoxyglucose 18|
1654807|NCT01818297|Device|PrimeAdvanced® neurostimulator system|Neurostimulator and associated components
1654736|NCT01818882|Device|Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI)|Standard care (as described for the other intervention) + pleuropulmonary ultrasound using the Vscan portable ultrasound device (GE Healthcare, Wauwatosa, WI).
1654737|NCT01818869|Drug|AZD8848|Multiple doses inhaled IMP via a nebulizer
1654738|NCT01818869|Drug|Placebo to match AZD8848|Multiple doses inhaled matching placebo via a nebulizer
1654739|NCT01818856|Drug|Ritonavir withdrawal, atazanavir 200 mg/12h|
1654740|NCT01818856|Drug|Telaprevir interactions|
1654741|NCT01818843|Other|Inhaled Carbon Monoxide|Inhaled Carbon Monoxide in newborn
1654742|NCT01818804|Dietary Supplement|n-3PUFA|
1654743|NCT01818804|Dietary Supplement|olive oil|
1654744|NCT01818791|Behavioral|Making Proud Choices|Making Proud Choices (MPC) is a well-established pregnancy and HIV/STI risk-reduction EBP with multiple trials demonstrating its effectiveness. Using Social Cognitive Theory, the Theories of Reasoned Action, and Planned Behavior, MPC aims to influence adolescents' knowledge and beliefs about risk, efficacy, and control to change behavior. MPC stresses the role of sexual responsibility, community, and pride in making safer sexual choices. The program promotes abstinence first, but also provides information and skills needed for safer-sex decision-making and practices (e.g., condom use).
1654745|NCT01818791|Behavioral|Making Proud Choices AND Getting To Outcomes|"In addition to MPC, these sites receive the Getting To Outcomes(GTO) intervention, which builds capacity for EBPs by strengthening the knowledge, attitudes, and skills needed to choose, plan, implement, evaluate, and sustain those EBPs. GTO poses ten steps that must be addressed and provides practitioners with the guidance necessary to address those steps with quality—i.e., as close to the ideal as possible. Implementation of these ten steps is facilitated by three types of assistance: the GTO manual of text and tools originally published by the RAND Corporation and then applied to teen pregnancy (PSBA-GTO), face-to-face training, and onsite TA. Consistent with social cognitive theories of behavioral change exposure to GTO training and TA leads to more knowledge about performing GTO-related activities, which leads to more positive attitudes towards these activities, which in turn leads to the execution of more GTO-related behaviors."
1654746|NCT01818778|Other|Cognitive stimulation program|The stimulation program was composed of therapy- and education-based exercises which were specifically designed to stimulate reasoning, memory, and attention skills in adults.
1654747|NCT01818778|Other|Standard Friendly Visit|"Volunteers provided standard friendly visits to residents which included a friendly greeting and casual conversation about issues which interest the resident."
1654748|NCT01818765|Procedure|Trans-ventricular-septal placement of LV pacing lead|
1654749|NCT01818765|Other|Pre-procedure speckle-tracking echocardiography|Assessment of site of latest mechanical activation
1654750|NCT01818765|Other|Acute response assessment|Cardiac output monitoring
1654751|NCT01818752|Drug|Carfilzomib|Carfilzomib was administered over 30 minutes on days 1, 2, 8, 9, 22, 23, 29, and 30 for nine 42-day cycles. Carfilzomib 20 mg/m² IV was administered on days 1 and 2 of cycle 1, followed by escalation to 36 mg/m² IV starting on day 8 of cycle 1.
1654752|NCT01818752|Drug|Bortezomib|Bortezomib 1.3 mg/m² was administered as a bolus IV injection or as a subcutaneous injection (per investigator's choice, dose modification, or regulatory approval) on days 1, 4, 8, 11, 22, 25, 29, and 32 of cycles 1 to 4, and on days 1, 8, 22, and 29 of cycles 5 to 9.
1654753|NCT01818752|Drug|Melphalan|Melphalan 9 mg/m² was taken orally on days 1 to 4 of all cycles.
1654754|NCT01818752|Drug|Prednisone|Prednisone 60 mg/m² was taken orally on days 1 to 4 of all cycles.
1654755|NCT01818739|Procedure|sentinel lymph node detection|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
1654756|NCT01818739|Drug|indocyanine green solution|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
1654757|NCT01818739|Drug|isosulfan blue|Undergo sentinel lymph node detection using fluorescence imaging with indocyanine green solution and isosulfan blue
1654758|NCT01818739|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
1654759|NCT01818726|Drug|ICL670A and standard immunosupressive therapy (Cyclosporine A)|In the investigational arm all patients recieve a standard immunosuppressant (Cyclosporine A). The starting dose of Exjade will be 20 mg/kg/day with up- and down-titration steps of 5-10 mg/kg/day if necessary, depending on serum ferritin, tolerability and comorbidities. Doses above 30 mg/kg are discouraged as such experience is limited in aplastic anemia. Patients are to take Exjade once daily at least 30 minutes before meals, on the same time each day. A combination of 250 mg and 500 mg tablets may be used to provide a specific dose level. The duration of treatment in this study is 12 months. The investigator muct emphasize complaince and will instruct the patients to take the Exjade exactly as prescribe.
1654760|NCT01818726|Drug|Immunosupressive therapy (Cyclosporine A)|Comparative group of patients with aplastic anemia and transfusion-dependent iron overload is undergoing treatment programs of standard immunosuppressive treatment ( immunosupressant -Cyclosporine A)
1654761|NCT01818713|Drug|2B3-101|50 mg/m2 2B3-101 intravenous 3-weekly administration
1654762|NCT01818700|Drug|Buprenorphine|8weeks treatment with Norspan®(Buprenorphine)
1654763|NCT01818687|Drug|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
1654764|NCT01818674|Behavioral|Microclinic Social Network Behavioral Health Program (full program with education curriculum in classroom setting)|An approximately 7-month participatory program (sessions and educational materials) that will increase knowledge and skills in diabetes self-management and peer support and monitoring. The curriculum include causes of diabetes, prevention of complications, symptoms, self-management strategies, diet, exercise, peer monitoring and support by trained Project nurses from MoH health centers, local physicians, and university professors. Each class will provide 2-3 hours of discussion to foster active class participation and engagement for ~28 participants.
1654765|NCT01818674|Behavioral|Modified Microclinic Behavioral Health Program with limited social network (education curriculum in classroom setting)|This program will be provided to Group B and will increase participants knowledge about diabetes self-management. For the education program in group B there are no group-based or team-building activities, group goal setting, and classroom is lecture style with more limited class participation and interaction.
1654766|NCT01818674|Other|Risk Factor Monitoring Control|Measurement of metabolic risk factors for obesity and diabetes as described by the primary and secondary outcomes
1654768|NCT01818648|Drug|Exenatide|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
1654769|NCT01818648|Drug|Placebo|Qualifying participants will be assigned to 2 different treatment arms consisting of placebo or exenatide 5 mcg administered subcutaneously twice: the first dose during fasting and the second four hours later. Subsequently, participants will switch over to the alternate treatment arm. In both arms participants will undergo a series of measurements including 24 hour GI transit, permeability measurements by using mannitol and lactulose, and 24 hour urine and stool collections.
1654770|NCT01818622|Device|Blue-blocking goggles/screens|Goggles with amber tinted lenses, all model's transmittance spectra are identical. Goggles and screens are tested at Department of Physics and Technology, University of Bergen. Patients and non-bipolar controls choose model for best comfort.
1654771|NCT01818622|Device|Clear-lensed goggles|Clear lensed safety eyewear. Patients may choose model for best comfort.
1654772|NCT01818609|Behavioral|Step reduction|taking less than 1500 steps/d
1654773|NCT01818596|Drug|E/C/F/TAF|E/C/F/TAF FDC tablet administered orally once daily with food
1654774|NCT01818583|Drug|Potassium chloride|
1654775|NCT01818583|Drug|Glucose 50 MG/ML|
1654776|NCT01818570|Drug|PPC-5650|A dose of 2.5 mg PPC-5650 in a 100 ml solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
1654777|NCT01818570|Drug|Placebo|A 100 ml placebo solution will be administered to the esophagus with an infusion rate of 7ml/min in one out of three visit days.
1654778|NCT01818557|Behavioral|Blood glucose testing|Patients will be assigned either to blood glucose monitoring done every day (during a fasting state and 2 hours after breakfast, lunch and dinner) continued throughout gestation or to blood glucose monitoring done every other day with the same timeframes outlined above.
1654779|NCT01818544|Drug|BAY85-8501|BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
1654780|NCT01818544|Drug|Placebo|Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
1654781|NCT01818531|Procedure|Adductor canal block|
1654782|NCT01818531|Procedure|Lumbar plexus block|
1654783|NCT01818492|Biological|NI-0501|
1654786|NCT01818453|Behavioral|Computerized self-help program for depression|For 8 weeks, participants will engage in a computerized self-help program for depression, called deprexis. This program consists of 10 content modules representing different psychotherapeutic approaches broadly consistent with a cognitive-behavioral perspective. Modules are organized as simulated dialogues in which the program explains and illustrates concepts and techniques, engages the user in exercises, and continuously asks users to respond by selecting from response options. Subsequent content is then tailored to the users' responses, resulting in a simulated conversational flow. Participants can access the self-help program as often as they would like and since it is self-guided, they will determine how often they access the material. Each module can be completed in 10 to 60 minutes, depending on the user's reading speed, interest, motivation, and individual path through the program.
1654789|NCT01818427|Biological|infusion of 2 units of plasma|infusion of 2 units of plasma
1654790|NCT01818414|Drug|Misoprostol|400 mcg of buccal misoprostol, 3 hours prior to planned D&E
1654791|NCT01818414|Drug|Folic Acid|4 mg of buccal folic acid, 3 hours prior to planned D&E
1654794|NCT01818388|Device|ZOLL Intravascular Temperature Management System (IVTM)|Induced therapeutic hypothermia post cardiac arrest.
1654795|NCT01818375|Procedure|Goal Directed Fluid Therapy (GDFT)-Esophageal doppler guided|
1654796|NCT01818375|Other|Standard fluid therapy|
1654797|NCT01818362|Biological|MVA NP+M1|MVA NP+M1 1.5 x 10⁸pfu intramuscularly.
1654798|NCT01818362|Biological|ChAdOx1 NP+M1|ChAdOx1 NP+M1 2.5 x 10¹⁰vp intramuscularly.
1654799|NCT01818349|Other|isokinetic lower-limb training|concentric training of the affected plantarflexors, hip flexors and hip extensors
1654800|NCT01818349|Other|isokinetic upper-limb training|concentric training of the affected wrist extensors, elbow flexors and shoulder flexors
1654801|NCT01818336|Drug|Penicillin skin test kit|Allergy skin testing is done by puncture and intradermal. If all tests negative, subjects receive an oral amoxicillin challenge.
1654802|NCT01818323|Other|Intra-tumoral T4 immunotherapy|Intra-tumoral administration of T4-positive patient-derived T-cells contained within 1 mL.
1654803|NCT01818310|Biological|Group A: Intramuscular|"Intramuscular BMAC application The study subjects in the Group A will receive a treatment of 35ml BMAC administered intramuscularly into the affected limb, in individual punctures of 1 ml.
The punctures will be applied into the crural muscle around the defect, the procedure takes approx. 60 minutes."
1654804|NCT01818310|Biological|Group B: Intraarterial|Intraarterial BMAC application The study subjects in the Group B will receive a treatment of 35ml BMAC administered intraarterially into the affected limb.
1654805|NCT01818310|Biological|Group C: Intravenous|Group C: Intravenous The study subjects in the Group C will receive a treatment of 35ml BMAC administered intravenously into the affected limb.
1654806|NCT01818310|Procedure|Group D: Surgical endovascular treatment with maximum medicamentous treatment|Group D: Control Group Control Group - no experimental intervention, standard endovascular treatment or bypass surgery or maximum medicamentous treatment
1654938|NCT01817452|Drug|Trastuzumab|
2013110|NCT01014533|Drug|Placebo dispensed to subject.|Placebo for 11 days, (one pill at bedtime on nights 1 and 2, 2 pills at bedtime on nights 3-10, and 1 pill at bedtime on night 11, then D/C). They return to the Sleep Lab for polysomnography on nights 8 - 10 of medication so their sleep data can be compared.
1654811|NCT01818271|Behavioral|conventional physical therapy|will receive a conventional out-patient program which will include: lower extremity stretching and strengthening exercise; fitness using cycle ergometer; balance exercises in standing; over ground walking and stair exercises
1654812|NCT01818271|Behavioral|community-based group rehabilitation|"Group training will include different workstations to target dynamic standing balance and walking. The key features includes facilitate repetition of task-related movements, tailored to the patient and patient's goals, in a meaningful context. Specifically:
Advanced dynamic tasks, including stepping and other transitional tasks to treadmill & over ground walking) with use of various inexpensive exercise assistive equipment such as mini-exercise stepper or elliptical machines.
Treadmill walking exercise program."
1654813|NCT01818258|Drug|ZDV+3TC+LPV/r|
1654814|NCT01818245|Drug|LY2605541|Administered SC.
1654815|NCT01818232|Drug|[14C]-LX4211|
1654816|NCT01818219|Procedure|Records of EADI derived parameters|
1654817|NCT01818206|Other|Collection of induced sputum in order to evaluate the efficacy of a cocktail of 10 bacteriophages.|Collection of induced sputum on cystic fibrosis patients in order to evaluate the efficacy of a cocktail of 10 bacteriophages.
1654818|NCT01818180|Dietary Supplement|URELL|
1654819|NCT01818180|Other|Placebo|
1654820|NCT01818167|Drug|10% Benzoyl Peroxide Topical Body Wash|
1654821|NCT01818167|Drug|Provodine Topical Cream|
1654822|NCT01818154|Other|LED phototherapy|
1654823|NCT01818154|Other|narrowband UVB phototherapy|
1654824|NCT01818141|Drug|Vancomycin|Vancomycin 125mg by mouth every 6 hours for 10 days
1654825|NCT01818141|Drug|Fidaxomicin|Fidaxomicin 200mg by mouth every 12 hours for 10 days
1654826|NCT01818128|Device|Neutral shape of bronchial tip|Intubation is performed without transforming the shape of the bonchial tipof a double lumen tube.
1654827|NCT01818128|Device|Bent shape of bronchial tip|Intubation is performed with the double lumen tube, which bronchial tip has been bent 45 degrees and maintained for 5 min.
1654828|NCT01818115|Device|Hydrus Implant|
1654829|NCT01818115|Procedure|IOL placement|
1654830|NCT01818102|Device|Width 1000 HU/Level -450 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 1000 HU and level -450 HU.
1654831|NCT01818102|Device|Width 400 HU/Level 25 HU|Double-lumen tube size is selected according to the internal diameter of the left mainstem bronchus measured in the chest computed tomography with width 400 HU and level 25 HU.
1654832|NCT01818089|Device|Lung sound analyzer|Patients will be aucultated with lung sound analyzer. The auscultation will be done three times daily during the duration of the complete hospital stay.
1654833|NCT01818076|Drug|Botulinum Toxin Type A|Botulinum toxin type A, Dose A applied to the lateral canthal area
1654834|NCT01818063|Drug|Paclitaxel|Given IV
1654835|NCT01818063|Drug|Carboplatin|Given IV
1654836|NCT01818063|Drug|Doxorubicin|Given IV
1654837|NCT01818063|Drug|Cyclophosphamide|Given IV
1654838|NCT01818063|Drug|Veliparib|Given PO
1654839|NCT01818050|Other|Liver Function Tests|LFTs will be checked periodically after Wing stent placement to evaluate stent patency
1654840|NCT01818037|Procedure|Cataract surgery|
1654841|NCT01818024|Drug|Single IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
1654842|NCT01818024|Drug|Matching placebo single dose IV infusion|Matching placebo solution available for IV administration.
1654843|NCT01818024|Drug|Single IH dose of GSK2862277|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
1654844|NCT01818024|Drug|Matching placebo single dose IH|Matching placebo nebulised solution available for IH administration.
1654845|NCT01818024|Drug|Repeat IV dose of GSK2862277|GSK2862277 solution available in a 40 mg vial for IV administration.
1654846|NCT01818024|Drug|Matching placebo repeat dose IV infusion|Matching placebo solution available for IV administration.
1654847|NCT01818024|Drug|Repeat IH dose selected of GSK2862277 from Part 2|GSK2862277 nebulised solution available in a 40 mg vial for IH administration.
1654848|NCT01818024|Drug|Matching placebo repeat dose IH|Matching placebo nebulised solution available for IH administration.
1654849|NCT01818011|Drug|GSK1322322 Initial fit for purpose tablets|Beige, capsule shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
1654850|NCT01818011|Drug|GSK1322322 over granulated tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1500 mg (3 x 500 mg) for single dose oral administration in Part A
1654851|NCT01818011|Drug|GSK1322322 intended commercial tablets|Light beige, oval shaped, film-coated tablet with unit dose strength of 500 mg/tablet and dose level of 1000 mg (2 x 500),1500 mg (3 x 500 mg) and 2000 mg (4 x 500mg) for single dose oral administration in Part A and B and repeat dose administration twice daily in Part C
1654852|NCT01818011|Drug|Placebo tablets|Light beige, oval-shaped, film-coated tablet for repeat dose oral administration (BID for 6 days) in Part C
1654853|NCT01818011|Drug|13C-GSK1322322 stable isotope powder|White to slightly colored non-sterile crystalline powder for oral suspension with dose level of 50 mg as a single dose with GSK1322322 tablets in Part A
1654854|NCT01818011|Drug|GSK1322322 for injection|White to slightly colored lyophilized powder cake in clear glass vials with unit dose strength of 400 mg/vial and dose levels of 600 mg (1.5 x 400 mg/vial), 900 mg (2.25x400mg/vial), 1200 mg (3x400mg/vial and 1200 mg (3 x 400 mg) for IV administration either as single dose in Part B or as a repeat dose (BID for 4 days) in Part C
1654855|NCT01818011|Drug|Placebo injection|A clear and colorless 0.9% Sodium Chloride solution for intravenous administration twice daily for 4 days in Part C
1654939|NCT01817452|Drug|Pertuzumab|
1654940|NCT01817452|Drug|Paclitaxel|
1654856|NCT01817998|Other|Physical Exercise|Comparison of high versus low intensity physical exercise in patients with atrial fibrillation.
1654857|NCT01817985|Drug|GS-5816|
1654858|NCT01817972|Biological|Certolizumab pegol|Subcutaneous injection
1654859|NCT01817972|Drug|Azathioprine|50mg tablets
1654860|NCT01817959|Drug|Reparixin|Continuous i.v. infusion into a central vein for 7 days, starting approximately 12 hrs (6-18 hrs) before each pancreatic islet infusion.
1654861|NCT01817959|Drug|Placebo|Continuous infusion at a volume/rate matching active treatment.
1654862|NCT01817946|Other|Genetic Testing|Genetic testing services will be provided by the University of Chicago under the guidance of Dr. Soma Das, PhD. Services will be coordinated by Rachel Alvarez, CMDIR Associate Director. Genetic testing will include standard sequencing of the MTM1 gene followed by CGH array for deletion/duplication in cases where no pathologic variant is identified by standard sequencing.
1654863|NCT01817933|Behavioral|physical therapy|
1654864|NCT01817920|Behavioral|integrated multidisciplinary fall prevention program|
1654865|NCT01817907|Drug|Placebo pill|Subjects will receive a sugar pill during the placebo arm
1654866|NCT01817907|Drug|Trazodone|Subjects will receive trazodone during one of their treatment arm studies
1654867|NCT01817894|Drug|Eflornithine cream 11.5 w/w %|Split face intervention with application of Eflornithine cream 11.5 w/w % versus no treatment for six months
1654868|NCT01817868|Other|Recombinant Factor VIII (Kogenate, BAY14-2222)|All dosage, frequency and duration for drugs will be under the decision of the treating physician.
1654869|NCT01817855|Drug|AZD7624|Multiple ascending doses (starting from 300 µg lung deposited dose up to 1200 µg) inhaled IMP via a nebulizer
1654870|NCT01817855|Drug|Placebo to match|Multiple doses inhaled placebo via a nebulizer
1654871|NCT01817842|Behavioral|Mobile EX cessation support|Mobile EX cessation support is designed to enhance the Washington D.C. Quitline (DCQL) by giving participants the ability track their cessation attempt on a phone-based app and thus create a profile documenting their progress and set-backs over the days or weeks in between QL contacts. Participants receive summary information and graphics that help them understand what is working best for them. Participants also receive 24-hr, momentary access to a set of interactive cessation tools on their phone.
1654872|NCT01817842|Behavioral|DC Quitline Support|Participants assigned to standard DC Quitline programming receive 6 proactive QL counseling sessions and optional, free nicotine replacement therapy (NRT).
1654873|NCT01817842|Behavioral|Device Control|Mobile phone for use during cessation attempt but with no mEX support components
1654874|NCT01817829|Drug|paracetamol|500 mg oral tablet
1654875|NCT01817829|Drug|placebo|
1654876|NCT01817816|Procedure|Botox_A|
1654877|NCT01817816|Procedure|Botox_B|
1654878|NCT01817803|Drug|furosemide/no spironolactone|furosemide (doubling previous furosemide dose)
1654879|NCT01817803|Drug|metolazone/no spironolactone|metolazone (add 2.5mg qod)
1654880|NCT01817803|Drug|furosemid/spironolactone|furosemide (doubling previous furosemide dose)+spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
1654881|NCT01817803|Drug|metolazone/spironolactone|metolazone (add 2.5mg qod)+ spironolactone (doubling previous spironolactone dose or add 12.5mg BID if previous non-user)
1654882|NCT01817790|Drug|Fluticasone propionate|Nasal spray formulation (200 mcg/day)
1654883|NCT01817790|Drug|Placebo|Vehicle for Fluticasone propionate aqueous nasal spray
1654884|NCT01817777|Drug|Metformin Small Pack|A single small pack of metformin will consist of a blister package containing 10 pills with a patient information leaflet in local language. The small packs will be available at each site in the following doses: 500 mg, 850 mg, and 1000 mg. The small pack size of metformin is not yet marketed. Small pack metformin will be provided by GSK as GSK brand metformin.
1654885|NCT01817777|Drug|Metformin Large Pack|The large pack will consist of 1 month's supply of metformin.
1654886|NCT01817764|Drug|Umeclidinium/vilanterol|Dry white powder delivered via NDPI (2 strips with 30 blisters each, first containing UMEC 62.5 mcg per blister and second containing VI 25 mcg per blister), administered as one inhalation of UMEC/VI 62.5/25 mcg once-daily in the morning
1654887|NCT01817764|Drug|Fluticasone propionate/salmeterol|Dry white powder delivered via ACCUHALER/DISKUS (1 strip with 60 blisters, containing 250 mcg fluticasone propionate and 50 mcg salmeterol per blister), administered as one inhalation of FSC 250/50 mcg each morning and evening
1654888|NCT01817764|Drug|Placebo|Placebo will be administered via ACCUHALER/DISKUS or NDPI. Dry white powder administered as one inhalation each morning and evening via ACCUHALER/DISKUS (1 strip with 60 blisters containing placebo) OR once-daily in the morning via NDPI (2 strips with 30 blisters each, containing placebo)
1654889|NCT01817751|Drug|sorafenib tosylate|Given PO
1654890|NCT01817751|Drug|valproic acid|Given PO
1654891|NCT01817751|Drug|sildenafil citrate|Given PO
1654892|NCT01817738|Biological|CV9104|Intradermal injection of CV9104
1654893|NCT01817738|Biological|Placebo|Intradermal injection of placebo
1654894|NCT01817725|Biological|HBV vaccine (Engerix B)|Engerix-B (20μg/ml, GlaxoSmithKline Biologicals) is administered intramuscularly at 0, 2, 4, 6, 8, 10, 12 months. The dosage will be 20μg in those <= 20 years old and 40μg in those > 20 years old.
1654897|NCT01817699|Other|High Hb target|"25 to 250 μg of methoxy polyethylene glycol epoetin beta (Mircera®, Chugai pharmaceutical Co. Ltd.) will be administered subcutaneously at 2- to 6-week interval.
Dose and interval will be adjusted according to hemoglobin level and its target."
1654898|NCT01817699|Dietary Supplement|cholecalciferol|1,000 IU (1 tablet)/day, orally. Tablets are repacked into blister package.
1654941|NCT01817439|Drug|Amiodarone|patients will be randomly assigned to oral OR IV Amiodarone
1654942|NCT01817426|Drug|Infliximab|
1654899|NCT01817686|Other|Comfort Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
1654900|NCT01817686|Other|Life Extension Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
1654901|NCT01817686|Other|Standard Default AD forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, the patients will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
1654902|NCT01817673|Dietary Supplement|creatine|20 g/d for 5 d followed by 5 g/d throughout the trial
1654903|NCT01817673|Dietary Supplement|placebo|
1654904|NCT01817660|Procedure|Open repair of popliteal artery|
1654905|NCT01817660|Procedure|Endovascular repair of popliteal artery|
1654906|NCT01817647|Procedure|Colorectal surgery|
1654907|NCT01817634|Dietary Supplement|Fish powder corn-soy blend'+ Fish oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
1654908|NCT01817634|Dietary Supplement|Fish powder corn-soy blend + corn oil capsule.|Omega 3 food supplement: 500 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
1654909|NCT01817634|Dietary Supplement|Corn-soy blend + fish oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Omega 3 capsule: 500 mg DHA + EPA, daily for 12 months.
1654910|NCT01817634|Dietary Supplement|Corn-soy blend + corn oil capsule.|control food supplement: 0 mg DHA + EPA, daily for 12 months. Control capsule: 0 mg DHA + EPA, daily for 12 months.
1654911|NCT01817621|Behavioral|Experimental Intervention|The experimental intervention arm will include the same measures as the TAU comparison study arm. In addition, participants will attend several sessions addressing body dissatisfaction, including psychoeducation on the antecedents and consequences of body dissatisfaction, the common comorbidity of depressed mood, and how these factors can affect HIV self-care behaviors.
1654912|NCT01817621|Behavioral|TAU|Participants assigned to the TAU condition will receive appropriate services and referrals as needed, as would be typical of patients at Fenway Health or MGH, and will attend bi-weekly appointments with a study research assistant (RA) to complete study questionnaires and assess pocketed adherence, including HAART doses that participants may have taken outside of Wisepill.
1654913|NCT01817595|Other|BG Star Meter (Conventional) Internet Blood Glucose Reporting|Patients in BG Star Meter Group will report using BG software through uploading information onto a computer and sending readings to their endocrinologist via email
1654914|NCT01817595|Other|iBG Star (iphone) Internet Blood Glucose Method|25 patients will be randomized to the iBGstar system will upload their readings to their iPhone and send in their readings using the iPhone.
1654915|NCT01817582|Drug|Lotemax Gel + Restasis|
1654916|NCT01817582|Drug|Lotemax Gel|
1654917|NCT01817582|Drug|Restasis|
1654918|NCT01817556|Drug|Stillen Tab.|
1654919|NCT01817556|Drug|Mucosta Tab.|
1654920|NCT01817543|Device|AutoloGel|Autologel is a platelet-rich plasma gel used in the treatment of non-healing wounds
1654921|NCT01817530|Other|Placebo|Placebo for 6 Month Treatment Period
1654922|NCT01817530|Drug|Elagolix|Elagolix Dose 1 for 6 Month treatment Period
1654923|NCT01817530|Drug|Estradiol/norethindrone acetate, E2/NETA|E2/NETA Dose 1
1654924|NCT01817530|Drug|Estradiol/norethindrone acetate, E2/NETA Dose 2|E2/NETA Dose 2
1654925|NCT01817530|Other|Placebo|Placebo for 6 Month Treatment Period
1654926|NCT01817530|Drug|Elagolix|Elagolix Dose 2 for 6 Month Treatment Period
1654927|NCT01817530|Drug|Estradiol/norethindrone acetate, E2/NETA|E2/NETA Dose 1
1654928|NCT01817530|Drug|Estradiol/norethindrone acetate|E2/NETA Dose 2
1654929|NCT01817517|Device|Medtronic Activa Deep Brain Stimulation System|
1654930|NCT01817504|Procedure|Systematic transplantectomy|Transplantectomy within two months after return to dialyse. Antiproliferatives stop at the start of dialysis. Maintenance basic immunosuppressive treatment without dose reduction up to two weeks after transplantectomy. Abrupt discontinuation of the basic immunosuppressive treatment ttwo weeks after transplantectomy. Maintenance corticosteroids at 5mg per day until one month after transplantectomy then stop corticosteroids within one month.
1654931|NCT01817504|Procedure|Progressive reduction of immunosuppression|"Progressive reduction of immunosuppression. Transplantectomy for cause only. Antiproliferatives withdrawn at the start of dialysis. Maintenance of anticalcineurin or mTOR inhibitors half dose for 3 months, ¼ dose for 3 months and then stop. Maintenance corticosteroids for 6 months up to 5 mg per day, and then soft stop in 3 months.
In case of transplantectomy by reason in the control group, basic immunosuppression will be continued at the maintenance dose during the current surgical procedure, and withdrawn two weeks later, similary to the strategy used in the study group."
1654934|NCT01817478|Other|microbiologic sample|
1654935|NCT01817465|Drug|Motilitone ®|
1654936|NCT01817465|Drug|Pantoline®|
1654937|NCT01817465|Drug|Motilitone® and Pantoline®|
1654944|NCT01817413|Procedure|Mineral trioxide aggregate|An apical barrier of mineral trioxide aggregate (MTA cement) will be placed in the tooth root at the open apex in order to achieve root end closure via an apexification technique
1654945|NCT01817413|Procedure|Revascularisation|Pulp revascularisation will be induced by instrumentation through the open apex so that a blood clot forms within the root canal in order to achieve root end closure via apexogenesis
1654946|NCT01817400|Other|Microdialysis|"Microdialysis probes will be inserted into the abdominal and femoral subcutaneous adipose tissue. Two control probes at each site will be perfused at 2.0 µL/min with Ringer's solution to measure basal interstitial testosterone and estradiol levels. One experimental probe at each site will be perfused with the 'compound' 20ug/dl at 2.0 µL/min to assess the interstitial conversion of androstenedione to estrone and estradiol. The 'compound' will be infused. Either one or the other hormone (androstenedione OR testosterone) will be used per experiment. The second control probe will be positioned at each site to ensure acquisition of data in the event that one of the other probes becomes dysfunctional. We will then collect microdialysis samples every 60 min over the next 120 min."
1654947|NCT01817400|Dietary Supplement|Vascepa - Fish Oil|We will perform a control cycle of daily, first-morning voided urine, as previously reported by our group to assess the hormonal features of the menstrual cycle of each of the five participants in this arm. Upon completion of the control cycle, the participant will initiate therapy with aspirin 81mg per day, plus Vascepa 30mg daily. Participants will collect urine for a second menstrual cycle while on treatment, using methods that we have previously employed. At the completion of the second cycle of urine collection, the medications will be stopped and the study will be completed.
1654948|NCT01817400|Drug|Aspirin|
1654949|NCT01817400|Drug|Pioglitazone|e will perform a control cycle of daily, first morning voided urine as previously reported by our group, to assess the hormonal features of the menstrual cycle of each of the five participants. Upon completion of the control cycle, the participant will initiate therapy with pioglitazone, 45 mg daily, a dose that has previously been shown to result in a 30% reduction in fasting insulin. She will take the pioglitazone without any monitoring for a second menstrual cycle and then collect urinary hormones for the third menstrual cycle, continuing the pioglitazone until the third menstrual cycle is completed.
1654950|NCT01817387|Behavioral|PRIME|Mobile application designed to improve psychosocial functioning and motivational deficits
1654951|NCT01817387|Behavioral|Cognitive Training|Auditory processing, verbal learning, memory, processing speed, and social cognition
1654953|NCT01817348|Procedure|Lidocaine group|"Patient position: prone position with arm under the abdomen and the elbow flexed to a right angle
Injection with a 25-gauge, 1.5-inch long needle fitted with 3ml syringe filled with 3ml 1% lidocaine."
1654954|NCT01817348|Other|Physiotherapy (PT)|- Include electric therapy, hot pack, followed by stretch exercise and joint mobilization
1654955|NCT01817335|Procedure|psychosocial assessment and care|Participate in psycho-educational program
1654956|NCT01817335|Other|educational intervention|Participate in psycho-educational program
1654957|NCT01817335|Other|communication skills training|Participate in psycho-educational program
1654958|NCT01817335|Other|questionnaire administration|Ancillary studies
1654959|NCT01817322|Drug|Standard Dose of Myfortic and Reduced Dose of Myfortic|Low Dose of Neoral (Cyclosporine) and Standard Dose of Myfortic (Enteric-Coated Mycophenolate Sodium) vs. with Conventional Dose of Neoral (Cyclosporine) and Reduced Dose of Myfortic (Enteric-Coated Mycophenolate Sodium)
1654960|NCT01817322|Drug|Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group|500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
1654961|NCT01817322|Drug|Basiliximab injected both control group and experimental group|The subject must be injected 20 mg of Simulect in Kidney transplantation day and just before the OP. After 4 days(96hour ± 12hr), the subject must be injected 20mg of Simulect, again.
1654962|NCT01817309|Other|endotoxin assay in peritoneal dialysis effluent|endotoxin level by Limulus Amebocyte Lysate (LAL) assay
1654963|NCT01817296|Procedure|Testicular Biopsy|Micro-dissection testicular sperm extraction for sperm retrieval
1654964|NCT01817283|Drug|Triptolide|Triptolide Wilfordii is a Chinese old herb which is widely used as a remedy for rheumatic diseases and nephropathy in China. It is approved that it can play a role as an immune modular.
1654965|NCT01817283|Drug|cART|Participants who will be enrolled in this trial would keep their previous combined antiretroviral therapy, such as zidovudine or stavudine plus lamivudine plus nevirapine or efavirenz.
1654966|NCT01817283|Drug|placebo|Placebo pills produced the same as Triptolide wilfordii.
1654968|NCT01817257|Drug|Low Molecular Weight Heparin (LMWH)|Participants randomised to Arm A will have already received LMWH (Fragmin®), tinzaparin (Innohep®) or enoxaparin (Clexane®) at treatment dose for six months off trial, and should continue the same drug at the same dose for a further six months on trial. No dose alterations are required unless clinically indicated.
1654969|NCT01817244|Other|care management|6-month care management
1654970|NCT01817218|Drug|Platelet Rich Plasma|
1654971|NCT01817218|Device|Osakidetza protocol|"Patients in the control group will be treated following the recommendations of the Ezkerraldea-Enkarterri Health Region, that is, using a moist healing environment (as described in Uso racional de los productos de cura en ambiente húmedo. Plan de formación continuada de Osakidetza, 2011).
The type of material used to treat and dress the wound will be chosen after the assessment of the wound and surrounding skin, type and quantity of exudate and whether there are signs of infection. Wound care will be carried out every 48-72 hours, as is the current usual practice."
1655025|NCT01816841|Procedure|biopsy|Undergo scalpel biopsy
1655026|NCT01816841|Procedure|examination|Undergo COE
1655027|NCT01816841|Procedure|Comparison of surgical margins by COE vs. DVFE|Surgical margin determination using DVFE
1654972|NCT01817205|Procedure|TACE with Hyperthermia Treatment|"Transcatheter arterial chemoembolization (TACE) is performed under local anesthesia with right femoral puncture. The feeding lobar hepatic artery is selectively catheterized for drug delivery.
Systemic hyperthermia is induced with an external energy source using microwave electromagnetic energy, with the patient lying supine on the treatment bed of the hyperthermia equipment, exposing the abdomen to the microwave transmitter."
1654973|NCT01817192|Drug|Adjuvant Chemotherapy|
1654974|NCT01817192|Other|Radiographic surveillance|Serial radiographic surveillance is a current standard of care for stage I lung cancer
1654975|NCT01817192|Other|Pervenio™ Lung RS Assay|This CLIA-approved assay is a standard tool that is now available to all clinicians to improve the prognostic evaluation of patients after resection of early stage non-squamous NSCLC. It will be performed on tumor specimens for patients who are potentially eligible for this study. Patients identified through the assay as high-risk will be randomized to either adjuvant chemotherapy or observation.
1654976|NCT01817179|Other|FES neuroprosthesis to dorsiflexors on affected leg|
1654977|NCT01817166|Drug|Vitamin D|Patients will receive 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
1654978|NCT01817166|Drug|Placebo|Patients will receive a placebo treatment mimicking 100.000 UI of cholecalciferol every 14 days for a maximum of 24 months or until conversion to full multiple sclerosis has occurred.
1654979|NCT01817166|Other|Imaging|All patients are scheduled for MRI scans at baseline, 3 months, 12 months, 24 months, as well as upon conversion to full MS.
1654980|NCT01817166|Biological|Lumbar puncture|A baseline collection of cerebral spinal fluid may be required for certain patients (doctor's decision.)
1654981|NCT01817166|Biological|Blood sampling|Blood sampling is required of all patients at baseline, 3 months, 6 months, 12 months, 18 months and 24 months, as well as upon conversion to MS.
1654982|NCT01817166|Biological|Urine samples|Urine samples are required of all patients at baseline, 3 months, 6 months, 12 months, 18 months, 24 months, and upon conversion to MS.
1654983|NCT01817153|Drug|hydrocortison hemisuccinate|
1654984|NCT01817153|Drug|placebo followed by hydrocortisone hemisuccinate|
1654985|NCT01817114|Device|Auto Remote Ischemic Conditioning (AutoRIC) device|
1654986|NCT01817101|Dietary Supplement|Omega-3 fatty acid supplementation|Gelatine capsule, 1 at each meals (3 per day) during one year
1654987|NCT01817088|Procedure|New targeting procedure without electrophysiology|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.
1654988|NCT01817088|Procedure|Classical neurosurgical procedure|It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
1654989|NCT01817075|Drug|Chlorhexidine Gluconate|Given CGH cleansing
1654990|NCT01817075|Procedure|Wound Care Management|Given control cleansing
1654991|NCT01817075|Other|Questionnaire Administration|Ancillary studies
1654992|NCT01817075|Other|Laboratory Biomarker Analysis|Correlative studies
1654993|NCT01817049|Behavioral|HAPA-based coach education workshop|A 3.5 hour workshop will target HAPA constructs by providing injury risk information (risk perceptions), FIFA 11+ effectiveness evidence (outcome expectancies), and hands-on experience administering the 11+ program to a soccer team (task self-efficacy). Action planning and coping planning exercises will also be conducted.
1654994|NCT01817049|Behavioral|placebo attention control|
1654995|NCT01817036|Dietary Supplement|Placebo|placebo
1654996|NCT01817036|Dietary Supplement|Vitamin D|400 IU vitamin D per pill
1654997|NCT01817023|Radiation|SIB-IMRT|SIB-IMRT was given to the patients with regimen of 69.96Gy-73.92Gy to the gross target volume, 60Gy to the high risk clinical target volume, 50Gy to the low risk clinical target volume
1654998|NCT01817023|Drug|Cisplatin|Cisplatin 100mg/m2 was delivered at d1,d22 and d43 to the CCRT group patients during radiotherapy.
1654999|NCT01817010|Behavioral|Multi-Component Rehabilitation (CMC)|
1655000|NCT01817010|Behavioral|Control (CON)|
1655001|NCT01816997|Drug|Pravastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
1655002|NCT01816997|Drug|Rosuvastatin|"The impaired fasting glucose (IFG) subjects with total cholesterol 200-280 mg/dL were randomized into two groups: pravastatin 40 mg or rosuvastatin 10 mg.
IFG subjects with total cholesterol less than 200 mg/dL will be served as controls."
1655003|NCT01816997|Drug|Control|placebo
1655004|NCT01816984|Drug|PI3K inhibitor BKM120|Given PO
1655005|NCT01816984|Biological|cetuximab|Given IV
1655006|NCT01816984|Other|laboratory biomarker analysis|Correlative studies
1655007|NCT01816984|Other|questionnaire administration|Ancillary studies
1655008|NCT01816971|Drug|dexamethasone|Given IV or PO
1655009|NCT01816971|Drug|carfilzomib|Given IV
1655010|NCT01816971|Drug|lenalidomide|Given PO
1655011|NCT01816971|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
1655012|NCT01816971|Other|laboratory biomarker analysis|Correlative studies
1655013|NCT01816958|Other|co-administration of TMS and infused ketamine|co-administration of TMS and infused ketamine
1655014|NCT01816945|Behavioral|MOMBA web-based application|Web-based, interactive, social network application.
1655015|NCT01816932|Procedure|Home Visit|The intervention is the location of the insertion visit.
1655016|NCT01816919|Other|collecting breath samples|
1655017|NCT01816906|Device|Footwear :PU|"One group of patients will receive Footwear with PU insoles"
1655018|NCT01816906|Device|Footwear: MCP|One group of patients will receive footwear with MCP insoles
1655019|NCT01816893|Drug|Spironolactone and hypoglycemia|
1655020|NCT01816893|Drug|Placebo and hypoglycemia|
1655021|NCT01816893|Drug|Placebo and euglycemia|
1655022|NCT01816867|Device|Intramesh T1 implantation|
1655023|NCT01816854|Device|Stenting|
1655024|NCT01816841|Procedure|fluorescence imaging|Undergo DVFE
1655028|NCT01816828|Behavioral|Gay Poz Sex|Gay Poz Sex is a community-driven, peer-facilitated program for HIV+ gay and bisexual men. This eight week program is offered to small groups of 5-8 men and provides information about sexual health, the legal context of HIV non-disclosure and uses motivational interviewing to support each individual in setting and achieving a personal goal.
1655029|NCT01816828|Other|Wait List/Standard of Care|Participants are given referrals to existing resources in the community. Referrals and uptake will be tracked.
1655030|NCT01816815|Drug|BAY1002670|
1655031|NCT01816815|Drug|Placebo|
1655032|NCT01816802|Device|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
1655033|NCT01816789|Drug|rFSH|
1655034|NCT01816789|Drug|buserelin|
1655035|NCT01816776|Device|Treatment Group (transvenous stimulation of the phrenic nerve)|device implant, optimal medical therapy and device initiation 1 month post implant.
1655036|NCT01816776|Device|Control Group (Optimal Medical Therapy)|device implant, optimal medical therapy and delayed device initiation (7 months post device implant)
2013111|NCT01014533|Drug|Gabapentin dispensed to subject.|After spending 3 baseline nights in the UM Sleep Lab, alcohol dependent subjects are randomized to receive either gabapentin or placebo for 11 days. (1 pill (600 mg) at bedtime on nights 1 and 2, 2 pills (totalling 1200 mg) at bedtime on nights 3-10, and 1 pill (600 mg) at bedtime on night 11, then D/C). On nights 8 - 10 of medication, subjects return to the lab and sleep 3 more nights with the same procedures.
2013112|NCT01013714|Procedure|Cardiac Sympathetic Denervation (CSD)|Cardiac sympathetic denervation is performed using an endoscopic procedure called VATS (video-assisted thoracoscopic sympathectomy). The surgeon removes the lower half of the stellate ganglia in addition to the thoracic ganglia of T2 - T4 on both the right and left side. The VATS procedure provides a minimally invasive endoscopic approach that is safe and effective. The procedure can be completed in less than 45 minutes on each side.
1655039|NCT01816750|Device|Cardiac GSI|A novel method of computed tomography scanning (Cardiac Gemstone Spectral Imaging - Cardiac GSI) and image reconstruction (Adaptive Statistical Iterative Reconstruction- ASIR.
1655040|NCT01816698|Drug|Taurine granule|1 package(1.6g taurine granule) once a day after meals, 12 weeks
1655041|NCT01816698|Drug|Placebo|Placebo: 1 package once a day after meals, 12 weeks
1655042|NCT01816685|Device|CPAP|
1655043|NCT01816672|Device|AutoloGel|Treatment with Autologel and standard of care twice a week for the first two weeks and once a week thereafter
1655044|NCT01816672|Other|Usual and Customary Care|Standard of care treatment twice weekly for 2 weeks then weekly
1655045|NCT01816659|Drug|Metformin ER|500 mg by mouth once daily, beginning the day after colonoscopy for one week, and then escalation to 1000 mg/day. The duration of the trial will be from the preoperative endoscopy till the surgery, and should be not less than 10 days and not more than 30 days.
1655046|NCT01816646|Drug|Cidofovir|2.5 mg/kg of cidofovir administered in 100 ml of normal saline solution through a transurethral catheter inside the bladder. The urinary catheter will be clamped for 2 hours.
1655047|NCT01816646|Drug|Probenecid|2 grams by mouth given approximately 3 hours prior to the bladder instillation of cidofovir.
1655048|NCT01816633|Device|AutoloGel|AutoloGel is a platelet-rich plasma (PRP) gel used in the treatment of non-healing chronic wounds. It will be administered twice weekly for 2 weeks then weekly
2013113|NCT01013714|Drug|Routine Care|Anti-arrhythmic medications are continued for the duration of the study unless discontinued or adjusted to due to drug toxicity, intolerance, or ICD shock. All anti-arrhythmic medications (whether in the routine care or surgical arm) can be adjusted at the discretion of the treating physician.
1655050|NCT01816607|Procedure|new functional magnetic resonance imaging (MRI) protocols|diffusion-weighted MRI, dynamic-contrast enhanced MRI, MR spectroscopy, blood-level oxygen dependent (BOLD) MRI
2013114|NCT01013649|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-dimensional conformal radiation therapy
2013115|NCT01013649|Drug|Capecitabine|Given PO
2013116|NCT01013649|Drug|Chemotherapy|Given combination chemotherapy
2013117|NCT01013649|Drug|Erlotinib Hydrochloride|Given PO
1655055|NCT01816581|Drug|Targin|
1655056|NCT01816581|Drug|Oxynorm|
1655057|NCT01816581|Drug|Morphine|
1655058|NCT01816568|Procedure|SILS appendectomy|Single incision laparoscopic appendectomy will be performed
1655059|NCT01816568|Procedure|Three port laparoscopic appendectomy|Three port laparoscopic appendectomy will be performed
1655060|NCT01816555|Dietary Supplement|Vitamin D|Subjects will be assigned to a dosage level between 600IU daily and 10,000IU daily depending on their age, weight and current vitamin D level
1655061|NCT01816542|Other|patch tests on healthy skin|Patches will be placed on healthy skin.
2013118|NCT01013649|Drug|Fluorouracil|Given IV
2013119|NCT01013649|Drug|Gemcitabine Hydrochloride|Given IV
2013120|NCT01013649|Radiation|Intensity-Modulated Radiation Therapy|Undergo intensity-modulated radiation therapy
2013121|NCT01013649|Other|Laboratory Biomarker Analysis|Correlative studies
1655066|NCT01816516|Behavioral|Healthy Babies|"Each lesson is designed to promote the development of healthy infant eating, and incorporates research-based information, opportunities for mothers to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques. During lessons, mothers engage in activities in support of lesson goals. Intervention strategies focusing on feeding practices will include modification of the feeding environment (e.g., television off during feeding).
The telephone contacts, 10 minutes in length, made at 6, 8, and 10 months, reinforce key concepts in the lessons after conclusion of the intervention to maintain effects."
1655100|NCT01816204|Behavioral|Therapist assisted online treatment|7 weekly interactive online modules with 10-15 minute counselor consultation via video conference.
1655101|NCT01816204|Behavioral|face-to-face individual therapy|weekly individual counseling as usual.
2013122|NCT01013649|Other|Quality-of-Life Assessment|Ancillary studies
2013123|NCT01004978|Drug|Cisplatin|Undergo TACE
2013124|NCT01004978|Drug|Doxorubicin Hydrochloride|Undergo TACE
2013125|NCT01004978|Drug|Doxorubicin-Eluting Beads|Undergo TACE
2013126|NCT01004978|Other|Laboratory Biomarker Analysis|Correlative studies
1655067|NCT01816516|Behavioral|Expanded Food and Nutrition Education Program|Core EFNEP concepts are United States Department of Agriculture (USDA) My Pyramid, fruits, vegetables, meats, whole grains, food safety, and food resource management. Educators for the EFNEP group will use the EFNEP lessons which address basic knowledge customized for families with infants. Mothers in the EFNEP group will receive a series of six lessons from the nutrition education program offered in each state; they provide a series of lessons focused on nutrition education for families and do not include extensive content on feeding infants.
1655068|NCT01816503|Drug|No intervention|This is an observational study. The minimum initial dose will be fentanyl matrix 75 micrograms/h and the investigator can adjust the dosage according to the degree of the patients' pain control during the 9 days of the study period. Fentanyl matrix is a transdermal patch that is applied on the patient's skin.
1655069|NCT01816490|Drug|Intravenous Silibinin (iSIL)|
1655070|NCT01816477|Device|ON-Q soaker catheter system|"ON-Q soaker catheter system with Ropivicaine at 7 cc per hour placed by a single surgeon in the operating room. 7.5 catheters will be tunneled subcutaneously in the anterior axilla bilateral and secured with steri-strips and dressing. ON-Q systems will be primed with 750 cc and refilled accordingly to provide for 6 days of analgesia. Catheters will be removed by the surgeon in the hospital or clinic on the 6th post operative day. Patients may request removal of the catheter prior to the 6th day and this will not be considered a withdrawal from the study or complication and will be included in overall analysis, but noted accordingly."
1655071|NCT01816477|Drug|Epidural (ropivicaine 0.25%)|Thoracic epidural with Ropivicaine 0.25% placed pre-operatively by the anesthesiologist. Epidurals will remain in place for 72 hours and discontinued by the anesthesia pain management team.
1655072|NCT01816464|Biological|Trivalent Influenza Vaccine|"The formulation based on the WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus.
The vaccine to be used in the study in 2013 is Vaxigrip (Sanofi Pasteur), or other equivalent licensed vaccine should the latter not be available, which will be procured commercially in pre-filled syringes. Using aseptic technique, participants will be injected with 0.5 mL of TIV from pre-filled syringe."
1655073|NCT01816451|Other|running training|The present study was designed to compare the physiological effects between the two training regimes and the control group.The subjects from interval and continuous group performed others activities as resistance training, swimming or soccer. Those activities wasn't controlled by our study, but the individual didn't do physical activities at least 3 hours before started our running sessions. The control group simply performed their normal physical activities (resistance training, swimming or soccer). But, each 3 weeks we had a contact with control group to check about any injury or illness that could affect the final results. None were found.
1655074|NCT01816425|Device|Thermoplastic partial denture|
1655075|NCT01816425|Device|CoCr partial denture|
1655076|NCT01816412|Device|MD02-LDCB Paclitaxel coated balloon catheter|
1655077|NCT01816412|Procedure|Standard Uncoated Balloon Angioplasty Catheter|
1655078|NCT01816399|Procedure|Routine coronary angiography|
1655079|NCT01816386|Other|Acupuncture Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press needles (with a sharp tip) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
1655080|NCT01816386|Other|Acupressure Regimen|Patients in the acupuncture and the acupressure group will receive a standardised treatment comprising 12 SEIRIN® press plasters (with a blunt knob instead a sharp needle) at 7 acupuncture points (Du 26, He 9, Ren 17, bilateral LI 4, He 9, LV 3, Ma 36 and Pe 6). The point regimen is based on consensus process of national and international experts. All needling will be documented by the acupuncturist. Application time is supposed to be 84-96 hours. Modification, especially less points according to the patients reaction during treatment is allowed.
1655081|NCT01816373|Device|Vacuum Bell|Patients with pectus excavatum will be submitted to a negative pressure treatment with the Vacuum Bell device
1655082|NCT01816360|Other|Olfactory aromatherapy|Inhalation of essential oils.
1655083|NCT01816360|Other|Yogatherapy|Yogatherapy respiratory exercises.
1655084|NCT01816347|Procedure|Routine PCI|
1655085|NCT01816334|Drug|methylprednisolone|
1655086|NCT01816334|Drug|Ketoprofen|
1655087|NCT01816334|Drug|Sodium Chloride|
1655088|NCT01816321|Drug|Corifollitropin alfa|Corifollitropin alfa 150μg on day 2 of the menstrual cycle (stimulation day 1)
1655089|NCT01816321|Drug|recombinant FSH|recombinant FSH 300IU/daily from day 2 of the cycle (stimulation day 8)until day of ovulation triggering
1655090|NCT01816321|Drug|Ganirelix|Ganirelix 0.25mg/daily from day 7 of the cycle(stimulation day 6) until day of ovulation triggering
1655091|NCT01816321|Drug|hp HMG|hp HMG 300IU/daily from day 9 of the cycle (stimulation day 8)until day of ovulation triggering
1655092|NCT01816295|Drug|Testosterone Solution|Administered topically to axillae.
1655093|NCT01816295|Drug|Placebo Solution|Administered topically to axillae.
1655094|NCT01816282|Drug|Evicel|Evicel (5ml) is sprayed over the soft tissue after the implant of prosthetic components and before wounding closure
1655095|NCT01816256|Procedure|Upper gastrointestinal endoscopy and Doppler ultrasound|This is a one arm study. All patients will receive two screening tests (Doppler ultrasound, upper gastrointestinal endoscopy).
1655096|NCT01816243|Drug|TTS-Fentanyl|Transdermal Therapeutic System (TTS)-fentanyl patches releasing fentanyl in the range of 12.5 to 100 microgram per hour (mcg/hr) rate. The initial dose of fentanyl TTS will be calculated based on each participant's opioid requirement. Patches will be usually replaced every 72 hours. Doses will be escalated in steps of 25 mcg/hr, if pain cannot be controlled. The study duration will be 30 days after first patch application.
1655097|NCT01816243|Drug|Morphine|Participants will be allowed the use of oral morphine syrup for the duration of TTS-fentanyl treatment to enable appropriate dose titration. It is expected that most of the participants will be titrated to an appropriate dose of TTS-fentanyl within 1 week.
1655098|NCT01816230|Drug|NiCord®|
1655099|NCT01816217|Device|Intubation with The McGrath Mac videolaryngoscope|
2013127|NCT01004978|Drug|Mitomycin|Undergo TACE
1655103|NCT01816178|Behavioral|communication training|Participants were instructed in the use of a voices output communication aid.
1655104|NCT01816165|Drug|Acipimox|Subjects will take acipimox 250mg by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day.
1655105|NCT01816165|Drug|Placebo|Subjects will take placebo by mouth four times a day for a total of seven days plus one dose the morning of the final study visit day
1655106|NCT01816152|Other|Tailored Active intervention|Subjects experience a baseline for 1 week and an active intervention for 4 weeks. The active intervention is a bluish white light source delivering at least 300 lux at the eye of the patient during at least 2 hours daily.
1655107|NCT01816152|Other|Inactive intervention|Subjects experience a baseline for 1 week and an inactive intervention for 4 weeks. The inactive intervention is a yellowish white light source delivering at most 50 lux at the eye of the patient during at least 2 hours daily.
1655108|NCT01816139|Drug|WC3011|
1655109|NCT01816139|Drug|Vehicle|
1655110|NCT01816113|Biological|ChAd63 PvDBP 5 x 10^9|1 dose of ChAd63 PvDBP 5 x 10^9 vp intramuscularly
1655111|NCT01816113|Biological|ChAd63 PvDBP 5 x 10^10|1 dose of ChAd63 PvDBP 5 x 10^10 vp intramuscularly
1655112|NCT01816113|Biological|MVA PvDBP 1 x 10^8|1 dose MVA PvDBP 1 x 108 pfu 8 weeks later intramuscularly
1655113|NCT01816113|Biological|MVA PvDBP 2 x 10^8|1 dose MVA PvDBP 2 x 108 pfu 8 weeks later intramuscularly
1655114|NCT01816100|Other|specifically design 6 month resistance training program|Data will be kept on the number of repetitions and amount of weight per exercise session See intervention description
1655115|NCT01816100|Behavioral|6 months weight resistance and balance program|3 phases first phase-strength improvement using stationary machines second phase-time is divided between stationary machines, balance, dexterity third phase-free weight movements
1655116|NCT01816087|Other|brief geriatric assessment|All participants will be screened for geriatric syndromes using the brief assessment tool. Mix a simple questions and simple tests
1655117|NCT01816074|Drug|Vyvanse (lisdexamphetamine)|Active ADHD drug, Vyvanse, is administered to mother.
1655118|NCT01816074|Behavioral|Behavior Parent Training|Mother is given 8 weeks of individual sessions of behavioral parent training
2013128|NCT01004978|Other|Pharmacological Study|Correlative studies
2013129|NCT01004978|Other|Placebo|Given PO
2013130|NCT01004978|Drug|Sorafenib Tosylate|Given PO
2013131|NCT01000506|Biological|Mepolizumab 750|Mepolizumab 750mg every four weeks by i.v.
1655125|NCT01816035|Other|Laboratory Biomarker Analysis|Correlative studies
1655126|NCT01816035|Other|Pharmacological Study|Correlative studies
1655127|NCT01816035|Biological|Trastuzumab Emtansine|Given IV
1655129|NCT01815996|Other|One time blood draw to look at patient's DNA|One time blood draw to look at patient's DNA
1655130|NCT01815983|Other|Videolaryngoscopy review.|Review of video recordings.
1655131|NCT01815970|Behavioral|Pulmonary Rehabilitation|8 weeks of Pulmonary Rehabilitation including exercise and COPD related education.
1655132|NCT01815957|Drug|Rnalozine|. After enrollment in the study, participants will initiate Ranolazine for 4 weeks. The participant's usual anti-anginal medication regimen will be continued unchanged throughout study duration. Patients will receive Ranolazine 500 mg orally twice daily for 1 week, and the dose will be increased to 1,000 mg twice daily for an additional 3 weeks if tolerated.
1655133|NCT01815944|Drug|0.75% Ropivacaine|
1655134|NCT01815944|Drug|Normal saline|
1655135|NCT01815944|Drug|Dextrose 5%|
1655136|NCT01815918|Drug|Hydrocortisone|Patients randomized to treatment arm will three doses of 100 mg of hydrocortisone at the following times: prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
1655137|NCT01815918|Drug|Placebo|Patients receive placebo prior to surgery, 8 hours after the first dose and 16 hours after the first dose.
1655138|NCT01815905|Other|Mobile program for occupational and speech therapy|
1655139|NCT01815905|Other|Traditional rehabilitation therapy|
1655140|NCT01815892|Drug|Withdrawal of furosemide|The patient (previously on furosemide) will have the furosemide stopped for 2 weeks. The interdialytic weight gain, BP and 24 hour urine volume and sodium excretion will be measured
1655141|NCT01815892|Drug|furosemide administration|The patient will receive 120 mgm furosemide daily for 2 weeks and the interdialytic weight gain, BP and 24 hr urine volume and sodium excretion will be measured.
1655142|NCT01815866|Procedure|CF with culturable NTM|CF patients who produce culturable aerosols of NTM will receive the following test: pulmonary function test, collecting a sputum culture if possible, coughing for 5 minutes into a tube connected to a canister, hypertonic saline and albuterol will be given after the 5 minutes of coughing and then they would repeat with another 5 minutes of coughing. There can be a break inbetween the coughing if needed.
1655143|NCT01815853|Radiation|Pre-operative chemoradiotherapy|"Pre-operative chemoradiotherapy arm:
Radiotherapy (45Grey/25F) + chemotherapy(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles)"
1655144|NCT01815853|Drug|Capecitabine,Oxaliplatin|chemotherapy:(Capecitabine 1000mg/m2,d1-d14+Oxaliplatin 130mg/m2 D1, 2 cycles)
1655145|NCT01815840|Drug|Vismodegib|Vismodegib 150 mg hard gelatin capsule orally once daily
1655146|NCT01815840|Drug|Placebo|Vismodegib placebo orally once daily
1655147|NCT01815827|Drug|inclacumab|single intravenous doses
1655148|NCT01815814|Other|Rolfing / Myofascial Structural Integration|"Rolfing is similar to deep massage. It is also known as myofascial structural integration."
1655149|NCT01815801|Other|Lungs were not mechanically ventilated during subclavian vein catheterization|Control group
1655150|NCT01815801|Other|Lungs were mechanically ventilated during subclavian vein catheterization|Ventilated group
2013132|NCT01000506|Biological|Mepolizumab 250|Mepolizumab 250mg every four weeks by i.v.
2013133|NCT01000506|Biological|Mepolizumab 75|Mepolizumab 75mg every four weeks by i.v.
2013134|NCT01000506|Drug|Placebo saline|Placebo saline every four weeks by i.v.
2013135|NCT00991471|Behavioral|Interaction with MDRN STAT|Interaction with MDRNSTAT at triage to obtain orders for investigations and/or treatment
1655151|NCT01815788|Device|Use of a personal sound amplifying device = TeoFirst|
1655152|NCT01815775|Other|clinical and imaging examinations|"Quantitative CSF flow study was performed by 2D phase-contrast velocity-encoded cine MRI (repetition/echo time, 15/7 ms; field of view = 140 x 140 mm²; matrix size = 256 x 128, flip angle = 25 degrees,one excitation, slice thickness = 5 mm). Cerebrospinal fluid flow was measured with a velocity-encoding value of 10-20 cm/s. Peripheral gating was used to cover the entire cardiac cycle with retrospective cardiac synchronization of 32 quantitative flow-encoded images per cycle.
Clinical examination consists in neuropsychological assessment (including mini mental state examination test and Bradley's scale) as well as Hakim's triad evaluation"
1655153|NCT01815762|Other|Active arm|"In the active arm of the study, the number of ultrasound lung comets (ULC) will directly adjust the prescribed post-hemodialysis dry weight. See study flowchart on page 1.
If the patient does not tolerate the intervention (as described above), he will continue the study in the medication arm, where the actual intervention in stopped, and extra cardio-protective drugs are added to the medication."
1655154|NCT01815749|Biological|autologous CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T cells|Given IV
1655155|NCT01815749|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation
1655156|NCT01815749|Other|laboratory biomarker analysis|Correlative studies
1655157|NCT01815736|Drug|E/C/F/TAF|Elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) (150/150/200/10 mg) FDC tablet administered orally once daily
1655158|NCT01815736|Drug|E/C/F/TDF|Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate (E/C/F/TDF) (150/150/200/300 mg) FDC tablet administered orally once daily
1655159|NCT01815736|Drug|EFV/FTC/TDF|Efavirenz (EFV)/FTC/TDF (600/200/300 mg) FDC tablet administered orally once daily
1655160|NCT01815736|Drug|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
1655161|NCT01815736|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
1655162|NCT01815736|Drug|FTC/TDF|Emtricitabine (FTC)/TDF (200/300 mg) tablet administered orally once daily
1655163|NCT01815736|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
1655164|NCT01815723|Drug|FP187|500 mg FP187 daily, two tablets of 125 mg twice daily, from 125 mg daily up-titrated to full dose over a 4-week phase, total treatment phase of 20 weeks
1655165|NCT01815723|Drug|Dimethyl fumarate|720 mg Fumaderm® daily, two tablets of 120 mg three times daily, from 30 mg daily up-titrated to full dose over a 9-week phase, total treatment phase of 20 weeks
1655166|NCT01815723|Drug|FP187 placebo|FP187 matching placebo tablets in the same regimen as for FP187 arm
1655167|NCT01815723|Drug|Fumaderm® placebo|Fumaderm® matching placebo tablets in the same regimen as for Fumaderm® arm
1655168|NCT01815710|Other|Pediatric Asthma Clinical Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with asthma. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
1655169|NCT01815710|Other|Vomiting & Diarrhea Pathway|Implementation of a clinical pathway outlining standardized, evidence-based care for pediatric patients with vomiting and diarrhea. These clinical pathways use organized, time-sequenced interventions to achieve optimal patient outcomes.
1655170|NCT01815697|Device|Enhanced External Counterpulsation|Enhanced external counterpulsation (EECP) is mainly used in cardiovascular and cerebrovascular diseases, which has been proven to be able to improve microcirculation and endothelial function. EECP therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients will receive 35-36 hours EECP intervention, 1-hour session every day over a 7-week period.
1655171|NCT01815684|Drug|ASP3652|Oral
1655172|NCT01815684|Drug|Placebo|Oral
1655173|NCT01815671|Procedure|colonoscopy in the lateral horizontal position|colonoscopy in the lateral horizontal position with tilt down
1655174|NCT01815658|Device|Carbon fiber intramedullary nail (PEEK-CF)|Carbon fiber polyether-ether-ketone (PEEK-CF) PICCOLE Nail - produced by Carbofix, Herzlyia, Israel.
1655175|NCT01815645|Behavioral|ST+CM|12 weeks of the standard treatment offered by a open treatment service for drug addiction of the city of Sao Paulo (AME) plus Contingency Management
1655176|NCT01815645|Behavioral|standard treatment|12 weeks of standard treatment offered by AME (a open treatment service for drug addiction of the city of Sao Paulo)
1655177|NCT01815632|Other|Early infusion of autologous marrow|Intravenous infusion of autologous bone marrow without prior myeloablation on the day of bone marrow harvest and infusion of autologous blood at one year post-bone marrow harvest
1655178|NCT01815632|Other|Late infusion of autologous marrow|Infusion of blood on day of bone marrow harvest with intravenous infusion of autologous bone marrow without prior myeloablation one year post-bone marrow harvest.
1655179|NCT01815619|Other|on-site pathologist|on-site pathologist will read the slide during the procedure to render a diagnosis
1655180|NCT01815619|Other|off-site pathologist|Cell block will be sent to an off-site pathologist for evaluation
1655181|NCT01815606|Procedure|biopsy with 19 gauge needle|biopsy with 19 gauge needle
1655182|NCT01815606|Procedure|biopsy with 25 gauge needle|biopsy with 25 gauge needle
1655183|NCT01815593|Device|Enhanced external counterpulsation|Enhanced external counterpulsation therapy is done by sequential inflation of 3 sets of cuffs wrapped around the lower extremities during diastole and deflation of the cuffs during systole. The systolic deflation/ Diastolic inflation sequence of EECP leads to systolic unloading and diastolic augmentation, resulting in increased blood flow in a pulsatile manner. The patients receive 35-36 hours EECP intervention, 1 -hour session every day over a 7-week period.
1655184|NCT01815580|Drug|Atripla or Stribild|Antiretroviral therapy
1655185|NCT01815541|Drug|teicoplanin|
1655186|NCT01815528|Drug|Catumaxomab|"Catumaxomab dosing comprises the following four intraperitoneal (i.p.) infusions via an i.p.-port or an indwelling catheter:
10 µg on day 0
20 µg on day 3
50 µg on day 7
150 µg on day 10"
1655187|NCT01815515|Drug|18F-DCFBC|
1655188|NCT01815502|Drug|Dobutamine|Patients will receive a dobutamine infusion during catheterization.
1655369|NCT01814124|Other|Advice and home exercise|
1718085|NCT00002400|Drug|Indinavir sulfate|
2013136|NCT00991471|Behavioral|No MDRNSTAT|Standard management of nurse-only triage for assignment of CTAS
1655190|NCT01815450|Drug|BLI1100|BLI1100 topical cream
1655191|NCT01815450|Drug|BLI1100 - modified formulation|BLI1100 topical cream
1655192|NCT01815450|Drug|Placebo|Placebo topical cream
1655193|NCT01815437|Dietary Supplement|Mushroom Vitamin D2|2000 IU vitamin D2 in a mushroom extract, once/day for 12 weeks
1655194|NCT01815437|Dietary Supplement|Cholecalciferol|2000 IU crystalline cholecalciferol once/day for 12 weeks
1655195|NCT01815437|Dietary Supplement|Vitamin D2 - Ergocalciferol|2000 IU vitamin D2, ergocalciferol once/day for 12 weeks
1655196|NCT01815437|Dietary Supplement|Mushroom Extract|Same quantity of mushroom extract in a capsule
2013137|NCT00981149|Drug|duloxetine|Evaluate the analgesic effect of 30 mg duloxetine twice daily in comparison to matching placebo at baseline (BL) and follow up over a six week period
2013138|NCT00981149|Drug|Placebo|Placebo match duloxetine for 6 week period.
2013139|NCT00980460|Drug|Cisplatin|Given IV
1655200|NCT01815411|Dietary Supplement|Mushroom extract|The mushroom extract (Andosan) is given orally in doses 30 m x 2 daily for 21 days
1655201|NCT01815398|Behavioral|Cognitive Remediation|Neuropsychological Educational Approach to Remediation (NEAR) is an evidence based, manualized cognitive remediation program that targets cognitive deficits (eg memory, processing speed, executive functioning, working memory and attention) with the intent of improving daily functioning.NEAR is conducted in a small group setting, allowing for supportive social interaction while participants work at their own computer station on engaging computerized activities that are selected to address their unique profile of cognitive deficits. Then, as a group they discuss how their respective cognitive activities will help them achieve their vocational goals.
1655202|NCT01815398|Behavioral|Computer Skills Training|Participants utilize an interactive software program that delivers tutorials, lessons, and practice sessions to develop computer skills for office based employment. During the learning activities, the clinician offers coaching and assistance in setting up computerized training exercises as needed.
1655203|NCT01815372|Procedure|Single penetration dual injection (SPEDI) block technique to block the sciatic and the saphenous nerve with one needle penetration of the skin|
1655204|NCT01815372|Procedure|The classical popliteal sciatic nerve block combined with the mid-femoral saphenous nerve block|
1655205|NCT01815359|Procedure|Cytoreductive Surgery|Optimal Surgical Debulking
1655206|NCT01815359|Drug|HIPEC with Mitomycin-C|
1655207|NCT01815359|Drug|EPIC with FUDR and Leucovorin|
1655208|NCT01815346|Procedure|Acupuncture|"One group receives acupuncture 2 times a week for 6 weeks.
One group receives acupuncture 3 times a week for 4 weeks.
Participants receive acupuncture to the arms, legs, and abdomen. The acupuncture needles will be left in place for about 20 minutes."
1655209|NCT01815346|Behavioral|Questionnaires|Three questionnaires completed at baseline, midpoint, and four weeks after completion of acupuncture treatment.
1655210|NCT01815346|Other|Hand Function and Balance Tests|Tests completed at baseline, midpoint, and four weeks after completion of acupuncture treatment. These tests should take about 20 minutes to complete.
1655211|NCT01815333|Drug|Feraheme|6 mg of iron/kg (maximum 510 mg/dose) injected at a rate of 1 ml/sec (30 mg/sec) or slower after initial MRI.
1655212|NCT01815333|Procedure|Magnetic Resonance Imaging (MRI)|MRI scan performed before Feraheme injection. After Feraheme injection, MRI scan performed 2 days later, and then again the following day.
1655213|NCT01815320|Procedure|Contrast-enhanced ultrasound (CE-US)|
1655214|NCT01815320|Device|SonoVue|
1655215|NCT01815307|Drug|Gemcitabine|1000mg/m2, day 1 every 2 weeks
1655216|NCT01815307|Drug|S-1|80mg/m2/day, day 1-28, every 6 weeks
1655217|NCT01815294|Drug|DOXIL/CAELYX (doxorubicin) Treatment Sequence AB|Cycle 1 = Treatment A, Cycle 2 = Treatment B
1655218|NCT01815294|Drug|DOXIL/CAELYX (doxorubicin) Treatment Sequence BA|Cycle 1 = Treatment B, Cycle 2 = Treatment A
1655219|NCT01815281|Device|Foot Mechanical Stimulation (GONDOLA)|
1655220|NCT01815268|Biological|HD Vaccine|Nursing home residents over 65 years are allocated to receive high-dose vaccine. Residents under 65 years are provided standard-dose vaccine.
1655221|NCT01815268|Biological|SD Vaccine|Nursing home residents are allocated to receive standard-dose vaccine.
1655222|NCT01815268|Biological|Free Vaccine|Nursing home facilities are provided free standard-dose vaccine for their staff.
1655223|NCT01815268|Biological|Usual Care|Nursing home staff will have access to influenza vaccine, per standard of care. No free vaccine provided as part of study.
1655224|NCT01815255|Drug|tenofovir (TDF)|
1655225|NCT01815242|Drug|nab-Paclitaxel|
1655226|NCT01815242|Drug|Gemcitabine|
1655227|NCT01815242|Drug|Carboplatin|
1655228|NCT01815229|Procedure|tracheal lavages|tracheal lavages obtained during endotracheal intubation.
1655229|NCT01815216|Procedure|Bariatric surgery|Gastric bypass surgery
1655230|NCT01815216|Behavioral|Brain activity in resting state|Measure of activity in brain networks during resting state
1655231|NCT01815216|Behavioral|Memory performance|"Assess concentration in 2D-location task (i.e. memory game)"
1655232|NCT01815203|Drug|Caffeine|Administration of one gelatin capsule containing 200-300 mg of caffeine with subsequent cognitive tasks and food test.
1655233|NCT01815203|Drug|Placebo|Administration of placebo with subsequent cognitive tasks and food test.
1655234|NCT01815177|Device|Arthroscopic transosseous fixation|
1655235|NCT01815177|Device|Suture anchors|
1655236|NCT01815164|Behavioral|Hypnotherapy|Gut-directed hypnotherapy administered by an experienced hypnotherapist.
1655534|NCT01812889|Drug|TOL-463 Vaginal ovule|TOL-463 Vaginal Ovule
2013140|NCT00980460|Drug|Doxorubicin Hydrochloride|Given IV
2013141|NCT00980460|Drug|Fluorouracil|Given IV
2013142|NCT00980460|Drug|Irinotecan Hydrochloride|Given IV
2013143|NCT00980460|Other|Laboratory Biomarker Analysis|Correlative studies
2013144|NCT00980460|Procedure|Liver Transplantation|Undergo liver transplant
2013145|NCT00980460|Drug|Temsirolimus|Given IV
2013146|NCT00980460|Procedure|Therapeutic Conventional Surgery|Undergo surgery
2013147|NCT00980460|Drug|Vincristine Sulfate|Given IV
1655237|NCT01815164|Behavioral|Educational intervention|Educational intervention vith education regarding Irritabel bowel Syndrome.
1655238|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,000 IU administered at the time of GnRH agonist trigger
1655239|NCT01815138|Drug|hCG|Adjuvant low dose hCG 1,500 IU administered 35 hours after GnRH agonist trigger
1655240|NCT01815125|Drug|Ondansetron|The intervention of interest will be the administration of one dose of oral ondansetron in the emergency department. The dosage will be 8 mg.
1655241|NCT01815125|Drug|PLacebo|placebo
1655242|NCT01815112|Other|Magnetic resonance imaging|CSF flow measurement at Sylvius' aqueduct and cervical levels. Apparent diffusion coefficient and fractional anisotropy determination in corpus callosum, cingulum and hippocampus.
1655243|NCT01815112|Other|Positron emission tomography|Tissue-time activity curves in hippocampus, cingulum, medio-temporal cortex and choroid plexus.
1655244|NCT01815099|Device|rTMS Treatment|Either 10 or 15 rTMS sessions (2 or 3 times/week for 5 weeks, respectively)
1655245|NCT01815086|Biological|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)|Single infusion of 124I-labeled anti-amyloid mAb 11-1F4: 2 mCi (1 mg)
2013148|NCT00972517|Biological|GSK investigational vaccine GSK2340272A|Three intramuscular injections
2013149|NCT00950300|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil, 500 milligrams per meter-squared (mg/m^2) via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
1655250|NCT01815021|Dietary Supplement|amorphous calcium carbonate|
1655251|NCT01815021|Dietary Supplement|crystalline calcium supplements|
1655252|NCT01815008|Drug|Clopidogrel|Clopidogrel 75 mg daily
1655253|NCT01815008|Drug|Aspirin|Aspirin 81 mg daily
1655254|NCT01814995|Behavioral|Nutrition/Physical Activity Intervention|Please see Arm description.
1655255|NCT01814982|Drug|JNJ-17299425|JNJ-17299425 will be administered at a starting dose of 1 milligram (10 milliliter of a 0.1 mg/ml solution) as intravenous bolus injection over 2 minutes in central vein.
1655256|NCT01814969|Radiation|Hyperfractionated Radiochemotherapy|28 x 1.5Gy 2 times a day; gap between the fractions min. 6-8h - duration of treatment 2.5 weeks + simultaneous bolus 5-Fluorouracil (the each cycle consisted of 5-fluorouracil 325 mg/m2 per day) on 1-3 and 16-18 (last 3 days of radiotherapy).
1655257|NCT01814969|Radiation|Hyperfractionated Radiotherapy|28 x 1.5Gy 2 times a day; gap between the factions min. 6-8h - duration of treatment 2.5 weeks
1655258|NCT01814956|Drug|Lipoplus 20%|Lipoplus 20% (MCT/LCT/FO) i.v. lipid emulsion for parenteral nutrition
1655259|NCT01814956|Drug|Lipofundin N 20%|Lipofundin N 20% (LCT, soy bean oil) i.v. lipid emulsion for parenteral nutrition
1655260|NCT01814930|Behavioral|Brief standardized contraceptive counseling intervention|The intervention employed an in-person counseling strategy that included empowerment messaging and an instrument to clarify the participants' preferences for contraception in the context of their goals for future childbearing.
1655261|NCT01814917|Drug|colestilan|body surface area equivalent (BSAeq) 3 g/day, 6 g/day, 9 g/day, 12 g/day or 15 g/day
1655262|NCT01814917|Drug|CBPB|
1655263|NCT01814904|Drug|colestilan-L|body surface area equivalent (BSAeq) 3 g/day
1655264|NCT01814904|Drug|colestilan-M|BSAeq 6 g/day
1655265|NCT01814904|Drug|colestilan-H|BSAeq 9 g/day
1655266|NCT01814904|Drug|CBPB|
1655267|NCT01814891|Other|Orange maize feeding|This group was fed orange maize.
1655268|NCT01814891|Other|Vitamin A supplement|This group received a dose of vitamin A at the estimated average requirement each feeding day of the intervention.
1655269|NCT01814891|Other|Oil only|This group received a small amount of plain oil without vitamin A.
1655270|NCT01814878|Drug|Tramadol HCl/Acetaminophen ER|2 tablets of ER (tramadol HCl [75 mg]/acetaminophen [650 mg]) will be administered at 0, 12, 24 and 36 hours
1655271|NCT01814878|Drug|Tramadol HCl/Acetaminophen IR|2 tablets of IR (tramadol HCl [37.5 mg]/acetaminophen [325 mg]) at 0, 6, 12, 18, 24, 30, 36 and 42 hours
1655272|NCT01814865|Drug|Abiraterone Acetate|1000 mg PO OD x 2 weeks
1655273|NCT01814865|Drug|Prednisone|5 mg PO OD x 2 weeks
1655274|NCT01814865|Drug|Aromatase Inhibitor|1 mg PO OD x 2 weeks
1655275|NCT01814852|Device|Shockwave system|
1655276|NCT01814852|Device|Sham treatment|Sham treatment that looks, sounds and feels like real LI-ESWT treatment by Renova.
1655277|NCT01814839|Drug|ALN-TTRSC (revusiran)|Ascending doses of ALN-TTRSC (revusiran) by subcutaneous (SC) injection
1655278|NCT01814839|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
1655279|NCT01814826|Drug|MLN4924 and azacitidine|"MLN4924 (IV) and azacitidine (IV) in AML patients to determine maximum tolerated dose (MTD) on a 28-day cycle:
Azacitidine Days 1, 2, 3, 4, 5, 8, 9 in Cycle 1 and for all subsequent cycles
MLN4924 on Days 1, 3, and 5 for Cycle 1 and all subsequent cycles
Both agents given on Days 1, 3, and 5 of Cycle 1 and all subsequent cycles"
1655282|NCT01814800|Biological|RI-002|Immune Globulin Intravenous (IGIV)
1655283|NCT01814787|Other|CHICA Type 2 Diabetes Module|Information with regard to family history of type 2 diabetes, race/ethnicity, and maternal history of gestational diabetes will be gathered for every patient. This data will then be utilized by the CHICA system when a child is age 10 or older and presents to the clinic. Data regarding the child's BMI at that time will be analyzed by the CHICA system. If the child's BMI > 85th percentile, a prompt will appear on the provider worksheet asking the clinician whether the child might have insulin resistance. All information will then be analyzed to determine whether the child has 2 or more risk factors for the development of type 2 diabetes. If at least 2 risk factors are present, then the CHICA system goes on to coordinate the diagnosis and long-term management of type 2 diabetes.
1655284|NCT01814774|Other|No Intervention|No treatment (intervention) was administered.
1655285|NCT01814761|Drug|Bimatoprost 0.01%|One drop of bimatoprost 0.01% (Lumigan® 0.01%) in the affected eye(s) every evening for 12 weeks.
1655286|NCT01814748|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly
1655287|NCT01814748|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly
1655535|NCT01812889|Drug|TOL-463 Vaginal gel|TOL-463 Vaginal Gel
1655288|NCT01814748|Drug|Metformin|Open-label metformin (dosed daily according to the country-specific product label) was to be initiated for participants meeting protocol-specified glycemic criteria, but was otherwise prohibited.
1655289|NCT01814735|Other|Brown rice|
1655290|NCT01814735|Other|White rice|
1655291|NCT01814709|Drug|GDC-0032|Oral doses of GDC-0032
1655292|NCT01814709|Drug|Itraconazole|Oral doses of Itraconazole
1655293|NCT01814709|Drug|Rifampin|Oral doses of Rifampin
1655294|NCT01814696|Device|MedSentry System|Subjects will use the MedSentry System and electronic pillbox, to manage their medications.
1655295|NCT01814683|Drug|Primaquine|14 days of supervised primaquine (7mg/kg total dose) administered once per day (0.5 mg/kg).
1655296|NCT01814683|Drug|Primaquine|7 days of supervised primaquine (7mg/kg total dose) administered once per day (1.0 mg/kg OD) followed by 7 days of placebo.
1655297|NCT01814683|Drug|Placebo|14 days placebo.
1655298|NCT01814670|Biological|botulinum toxin Type A|20 units botulinum toxin Type A (total dose) injected into frown lines on Day 1.
1655299|NCT01814657|Drug|Lidocaine hydrochloride (HCl) 1% solution|Comparison of paracervical block using Lidocaine versus Normal Saline placebo in patients undergoing oocyte retrieval during IVF.
1655300|NCT01814657|Drug|Sterile Normal Saline%|Sterile normal saline used as placebo for lidocaine hydrochloride (HCl)1% solution
1655301|NCT01814644|Behavioral|TRIMM Intervention|Individuals in the TRIMM arm receive daily, individualized text-messages promoting positive lifestyle changes to support weight loss/management.
1655302|NCT01814644|Behavioral|Standard Care|Individual assessment, lifestyle counseling
1655303|NCT01814631|Other|image quality and resolution|Image quality and resolution will be viewed using Aloka processor
1655304|NCT01814631|Other|image quality and resolution|image quality and resolution will be viewed on the EU-me2
1655305|NCT01814618|Drug|Budesonide Respules|Subjects irrigate their noses with budesonide respules. They will use one respule per nostril twice daily for three months.
1655306|NCT01814605|Procedure|Infragluteal space group|"Sciatic Nerve Block Infragluteal group: Ultrasound scanning will be used to identify and mark the greater trochanter laterally and the ischial tuberosity medially. The midpoint between these two structures is a rough non-binding estimate of the approximate location of the sciatic nerve. The sciatic nerve is usually found anterior (deep) to the gluteus maximus muscle and lateral to the origin of the biceps femoris muscle at the ischial tuberosity as well as medial to the greater trochanter.
The end point of nerve block in this group is obtaining a circumferential local anesthetic spread around the sciatic nerve."
1655307|NCT01814605|Procedure|Subgluteal space group|Subgluteal space group: The operator will identify the gluteus maximus and biceps femoris muscles at the level of the greater trochanter and ischial tuberosity and the infragluteal space.
1655308|NCT01814592|Procedure|coronally partial thickness flap plus connective tissue|The design of the flap will be performed according to the technique described by de Sanctis and Zucchelli 2007.
1655309|NCT01814592|Procedure|coronally mucosal thickness flap|The design of the flap will be performed according to the technique described by Greenwell H, Vance G, Munninger B and Johnston H.
1655310|NCT01814579|Device|Unidirectional Barbed Suture (V-Loc)|Patients enrolled in the Unidirectional Barbed Suture arm will have their vaginal cuff closed using this device during their robotic hysterectomy.
1655311|NCT01814579|Device|polyglactin 910 (Vicryl)|Patients in the Smooth Suture arm will have their vaginal cuff closed with this device during their robotic hysterectomy.
1655312|NCT01814553|Drug|afatinib|Daily treatment starting 40 mg per day
1655313|NCT01814553|Drug|loperamide|Follow cohort assignment and diarrhea management guidelines
1655314|NCT01814540|Dietary Supplement|Bovine Milk Oligosaccharide|The BMO powder will be isolated from whey streams by Hilmar Ingredients (Hilmar, California 95324). Hilmar Ingredients employs the same membrane filtration, and centrifugation processes used to purify whey protein in their commercial practice to extract and purify BMO from whey permeate. Furthermore, the same sterilization processes used on the equipment to purify whey products will be used to purify BMO. This method uses a novel high-throughput food-grade isolation protocol that leads to purification of specific BMOs with bifidogenic activity as prebiotic oligosaccharides that mimic the activities observed for Human Milk Oligosaccharides (HMO). This strategy of developing methods for their large scale fractionation allows us to obtain a final product that mimics the naturally beneficial oligosaccharides present in human milk.
1655315|NCT01814540|Dietary Supplement|Placebo Glucose Polymer|
1655316|NCT01814527|Dietary Supplement|Docosahexaenoic acid|5 capsules containing 440mg of Docosahexaenoic acid (DHA)for total daily dosing of 2200mg of DHA daily
1655317|NCT01814527|Drug|Placebo|5 capsules that are identical to the treatment.
1655318|NCT01814514|Drug|Timolol-trusopt|
1655319|NCT01814514|Drug|placebo|
1655320|NCT01814501|Biological|panitumumab|Given IV
1655321|NCT01814501|Drug|irinotecan hydrochloride|Given IV
1655322|NCT01814501|Drug|fluorouracil|Given IV
1655323|NCT01814501|Drug|leucovorin calcium|Given IV
1655324|NCT01814488|Procedure|allogeneic transplant|"Allogenic transplant using either a Marrow Unrelated Donor or a Cord Blood unit or a family Haploidentical donor.
The conditioning regimen in standard use is:
Thiotepa (Tepadina) i.v. 5 mg/kg/daily (total dose 10 mg/kg) day -7 and -6;
Busulfan (Busilvex) i.v. 3,2 mg/kg/day (total dose 9,6 mg/kg) as a single daily dose day -5, -4, -3;
Fludarabine i.v. 50 mg/m2 (total dose150 mg/m2) day -5, -4, -3.
Primary antifungal prophylaxis is Micafungin 50 mg/die i.v. (1 mg/kg if <40 kg) day 0 to engraftment. After engraftment continue antifungal prophylaxis according to local practice."
1655325|NCT01814475|Drug|A: Fludarabine + Busulphan|Fludarabine 30 mg/m2/d, day -8 to day-3 and Busulphan (Busilvex) 0,8 mg/Kg/i.v. dose x 4 doses on days -5,-4 and x 2 doses on day -3, total dose 8 mg/Kg) prior allogenic transplant (day zero)
1655326|NCT01814475|Drug|B: Fludarabine + Thiotepa|Fludarabine 30 mg/m2/d day -8 to day -3 Thiotepa 6 mg/Kg for 2 doses ( days -4, -3) prior allogeneic transplant (day zero)
1655327|NCT01814462|Device|6 months CPAP|
1655328|NCT01814449|Other|18FMISO PET/CT scan|The baseline 18F-FMISO PET/CT scans were scheduled before initiation of endocrine therapy. All patients were injected intravenously with 370 MBq of 18F-FMISO and PET/CT static emission scans were conducted at 4 hours after injection.
1655621|NCT01812174|Device|23mm mitral valve (On-X)|Heart mitral valve replacement surgery: 23mm Mitral
1655329|NCT01814449|Drug|Letrozole|Patients were assigned to primary endocrine therapy with letrozole 2.5mg daily for at least 4 months.
1655330|NCT01814436|Device|scaffold-free SHED-derived pellet|The purpose of this clinical trial is to both clarify the efficiency of autologous SHED to regenerate pulp and periodontal tissue in the patients with avulsed immature permanent teeth and pulp necrosis to confirm the safety of using autologous stem cells in clinical endodontic regenerative medicine.
1655331|NCT01814423|Drug|Chloroquine-base 50 mg|
1655332|NCT01814423|Drug|Chloroquine-base 70 mg|
1655333|NCT01814410|Drug|Intravenous ethanol placebo plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
1655334|NCT01814410|Drug|intravenous ethanol 40mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
1655335|NCT01814410|Drug|intravenous ethanol 100mg% plus nicotine infusions|nicotine infusions: 1) placebo; 2) nicotine 0.5 mg/70 kg; 3) nicotine 1.0 mg/70 kg
1655336|NCT01814397|Drug|Anastrozole|1 mg orally daily
1655337|NCT01814397|Drug|exemestane|25 mg orally daily
1655338|NCT01814397|Drug|letrozole|2.5 mg orally daily
1655339|NCT01814384|Device|prosthesis GMK ® without the ancillary MyKnee ® LBS|
1655340|NCT01814384|Device|Matched patient cutting blocks MyKnee ® LBS|
1655341|NCT01814371|Drug|2% mupirocin ointment|Participants over 1 month of age, apply ointment to the anterior nares twice daily for 5 days.
1655342|NCT01814371|Other|Bleach Bath (dilute)|Participants over 1 month of age, pour 1/4 cup of bleach into a bath tub filled 1/4 full of water. Soak in bath for 15 minutes daily for 5 days.
1655343|NCT01814371|Behavioral|Hygiene Protocol|"Follow key hygiene tips:
Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.
Use liquid(pour or pump) soaps instead of bar soaps.
Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.
Do not share personal care items such as razors, brushes, or deodorant.
Wash all sheets and towels in hot water. Wash sheets every week.
Use towels and wash cloths only once before washing and do not share."
1655344|NCT01814358|Dietary Supplement|Whey protein powder|Subjects on this arm will consume 20g whey protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
1655345|NCT01814358|Dietary Supplement|Control protein|Subjects on this arm will consume 20g gelatin protein powder mixed with water 15 minutes prior to breakfast, lunch, and dinner for two days
1655346|NCT01814332|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
1655347|NCT01814332|Drug|Placebo|Placebo compound treatment for comparison with IP
1655348|NCT01814319|Drug|Probenecid 1 gr oral twice daily|Probenecid 1 gram oral twice daily
1655349|NCT01814319|Drug|Placebo|Matching placebo oral twice daily
1655350|NCT01814306|Device|Supreme LMA|Use Supreme LMA to compare efficay with Proseal LMA in prone position insertion
1655351|NCT01814306|Device|Proseal LMA|Use Proseal LMA to compare efficay with Supreme LMA in prone position insertion
1655352|NCT01814293|Device|Handheld humidifier|Subjects will be randomized into 2 groups: handheld humidifier group (FDA cleared medical device that uses distilled water) & control group. Both groups may use any supportive modalities desired such as over-the-counter cold medications (OTCs), room air humidifier etc. Follow up surveys will be obtained on days 1 and 2 following the ED visit to assess whether then intervention (use of handheld humidifier) improved symptom scores or reduced the use of OTC medications or room humidifier.
1655353|NCT01814280|Other|Medication review|Medication review performed by either a clinical pharmacist or a clinical pharmacologist
1655354|NCT01814267|Other|telemedicine|"Intervention group: care and follow-up through telemedicine (e-consultations)
1 hospital consultation at inclusion time, week 0
then every 15 days, after the transmission of medical data and photos via internet by the nurse, telemedicine e-consultations until the wound has healed (week 2,week 4, week 6, week 8, week 10, week 12, week 14, week 16, week 18, week 20, week 22, week 24 : end point study), i.e. 12 e-consultations over a 6-month period.
1 hospital consultation to validate that the wound is well-healed"
1655355|NCT01814267|Other|conventional|"conventional group: iterative diabetes physicians consultations at hospital
1 consultation at inclusion time, week 0
1 consultation 2 weeks after inclusion, week 2
1 consultation per month until the wound has healed (week 4, week 8, week 12, week 16, week 20, week 24: end-point study), i.e. 6 consultations over a 6-month period
1 consultation to validate that the wound is well-healed"
1655356|NCT01814241|Drug|Open label peanut OIT|Subject will take increasing amounts of peanut protein up to a maximum maintenace dose of 1450mg.
1655357|NCT01814228|Procedure|transcatheter ablation of ganglionated plexi in right atrium|
1655358|NCT01814215|Behavioral|Keys to Healthy Family Child Care Homes|The Keys to Healthy Family Child Care Homes intervention will be delivered to providers via a health behavior coach using a consistent structure and sequence of coaching contacts, including an introductory self-assessment, hands-on workshops, on-site home visits with goal setting and action planning, follow-up coaching phone calls using Motivational Interviewing-inspired techniques, and supportive print toolkit materials.
1655359|NCT01814202|Other|PTM202|
1655360|NCT01814202|Other|Placebo|
1655361|NCT01814189|Drug|Sumatriptan+Promethazine (SPr)|
1655362|NCT01814176|Device|Intubation with GlideScope Video Laryngoscope or Macintosh Direct Laryngoscope|
1655363|NCT01814163|Drug|paclitaxel, carboplatin and bevacizumab|Paclitaxel 200 mg/m2, carboplatin area under curve (AUC) 6 mg/ml/min plus bevacizumab 15 mg/kg on day 1, every 21 days. Total number of cycles: 6. After 6 cycles bevacizumab on monotherapy until progression
1655364|NCT01814137|Drug|insulin degludec/insulin aspart|For subcutaneous (s.c., under the skin) administration twice daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
1655365|NCT01814137|Drug|insulin degludec|For subcutaneous (s.c., under the skin) administration once daily in combination with up to 2 oral antidiabetic drugs (OADs- dose and dosing frequency of OAD should remain unchanged).
1655366|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration once daily. Dose of IDegAsp and IAsp are individually adjusted.
1655367|NCT01814137|Drug|insulin aspart|For subcutaneous (s.c., under the skin) administration three times a day. Dose of IDeg and IAsp are individually adjusted.
1655368|NCT01814124|Other|Manual therapy plus exercise|
1655370|NCT01814111|Procedure|renal sympathetic denervation|The ablation catheter was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis.
1655371|NCT01814098|Drug|Escitalopram|Escitalopram tablets will be administered orally at 10 milligram per day (mg/day). The dose may be increased to maximum of 20 mg/day depending on Investigators discretion for 24 weeks
1655372|NCT01814085|Drug|Escitalopram|Escitalopram tablets will be administered orally in the dose range of 10 to 20 milligram per day (mg/day) for 8 weeks. Dose can be adjusted as per Investigator's discretion depending on participant's response.
1655373|NCT01814072|Behavioral|12 Telephone Coaching Sessions|Participants will receive 12 telephone coaching sessions
1655374|NCT01814072|Behavioral|24 Telephone Coaching Sessions|Participants will receive 24 telephone coaching sessions
1655375|NCT01814072|Behavioral|Report to Primary Care Physician|Participants will have a report detailing their weight loss progress sent to their primary care physician
1655376|NCT01814072|Behavioral|Text Messages|Participants will receive regular text messages
1655377|NCT01814072|Behavioral|Recommendations to use meal replacements|Participants will receive recommendations from their coach to use meal replacements
1655378|NCT01814072|Behavioral|Buddy Training|Participants will have a buddy that will be trained via webinars to be a supportive buddy
1655379|NCT01814059|Drug|sirolimus|
1655380|NCT01814046|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses) (only for cohort A).
1655381|NCT01814046|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
1655382|NCT01814046|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
1655383|NCT01814046|Biological|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL and high dose aldesleukin (Cohort A) or no aldesleukin (Cohort B). On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
1655384|NCT01814033|Other|Experimental: LRU Pillow|Foam wedge with a trough for positioning of the lower leg in an elevated position.
1655385|NCT01814033|Other|Control Group|Standard bed pillows placed under the lower leg to facilitate elevation
1655386|NCT01814020|Drug|MOB015B|
1655387|NCT01814007|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1655388|NCT01813994|Drug|Arm1: Statin|"Study1 (only H. pylori infected patients) Arm1: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take statins for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.
Study2 (only H. pylori non-infected patients) Arm1: In this arm2, all patients start taking statins after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
1655389|NCT01813994|Drug|Arm2: Placebo|"Study1 (only H. pylori infected patients) Arm2: All patients undergo H. pylori eradication therapy after 2 weeks from the endoscopic submucosal dissection. In this arm2, all patients take placebos for 6 months. Then, follow-up endoscopy for gastric biopsy and CLO test will be performed after 6.5 months from the endoscopic submucosal dissection.
Study2 (only H. pylori non-infected patients) Arm2: In this arm2, all patients start taking placebos after 2 weeks from the endoscopic submucosal dissection. Follow-up endoscopy for gastric biopsy will be performed after 6.5 months from the endoscopic submucosal dissection."
1655390|NCT01813981|Dietary Supplement|Low roast coffee|Instant coffee
1655391|NCT01813981|Dietary Supplement|High roast coffee|Instant coffee
1655392|NCT01813981|Dietary Supplement|Control (Caffeine dissolved in water)|Caffeine dissolved in water
1655393|NCT01813968|Procedure|Ischemic postconditioning|
1655394|NCT01813955|Drug|Papaverine or placebo|Papaverine delayed release (depot capsule, 300 mg, orally, one single dosage per subject) or placebo
1655395|NCT01813929|Drug|Metformin|Six week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, 500/1000 for one week, and then 1000mg twice daily for the remainder of the 6 week intervention. If uptitration is not tolerated, max dose will be max tolerated dose of at least 500 mg twice daily.
1655396|NCT01813929|Drug|Placebo|Six-week intervention: Study drug/placebo will be given in a forced uptitration with 500 mg once daily for one week, 500 mg twice daily for one week, and then the higher dose (850 mg) for the remainder of the 6 week intervention.
1655397|NCT01813916|Other|proteomic analysis|
1655398|NCT01813903|Behavioral|Intensified dietary counseling|The intervention is completed by public health nurses who will be trained to provide family-centered empowering and motivational lifestyle counseling at the normal health check visit. Parents expecting child will use web application developed for nutritional counseling. Web application consists of dietary questionnaire from which the parents will receive immediately automatic feedback. Feedback concerns the quality of diet in relation to the Finnish nutrition recommendations. Feedback will be given in an encouraging format. Own targets of food changes can also be recorded in the application, and the application can be used to monitor how they are achieved.
1655399|NCT01813903|Behavioral|Mobile application|Mothers expecting child will use mobile application. Mobile application consists of text, audio and video exercises, which are aimed to increase the psychological flexibility and thus mental and physical well-being.
1655400|NCT01813890|Drug|Tapentadol IR 50 mg|Tapentadol IR 50 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
1655401|NCT01813890|Drug|Tapentadol IR 75 mg|Tapentadol IR 75 mg will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
1655402|NCT01813890|Drug|Placebo|Placebo will be administered as a single oral dose once every 4 to 6 hours, during the double blind treatment period.
1655700|NCT01811680|Device|Variable Speed and Sensing Treadmill|open label study on variable speed and sending treadmill training for hemiplegic gait training.
1655701|NCT01811667|Drug|Sirolimus|
1655403|NCT01813877|Radiation|FDOPA PET/CT|Positron emission tomography (PET) is an established imaging technique that utilizes small amounts of radioactivity attached to very minimal amounts of substances (tracers) that are injected via a hand or arm vein. These substances can track certain features of cancers that can be visualized by using the PET/CT scanner, in this instance the amino acid 18F-DOPA.
1655404|NCT01813864|Behavioral|CASPAR/Treatment Planning|All counselors in the study will receive additional training in treatment planning and the CASPAR Resource Guide software to easily identify and link patients to services not available at substance abuse treatment centers such as General Educational Development (GED) training, dental clinics, job training, etc.
1655405|NCT01813851|Device|Exercise training in addition to nutritional support|
1655406|NCT01813838|Drug|ACADESINE 140mg/kg/d|"3 patients will be included at the initial dose of 140mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.
In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 140mg/kg/d.
In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 85mg/kg/d"
1655407|NCT01813838|Drug|ACADESINE 210mg/kg/d|"3 patients will be included at the dose of 210mg/kg/d. In absence of toxicity, 3 additional patients will be included at the higher dosage.
In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 210mg/kg/d.
In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 140mg/kg/d"
1655408|NCT01813838|Drug|ACADESINE 315mg/kg/d|"3 patients will be included at the dose of 315mg/kg/d.
In case of 1/3 toxicity, 3 additionnal patients will be included at the same dose level, currently 315mg/kg/d.
In case of toxicity in 2 or more patients, the dose of acadesine will be reduced at the the dose of 210mg/kg/d"
1655409|NCT01813825|Other|Registry|
1655410|NCT01813812|Drug|DA-6034|
1655411|NCT01813812|Drug|Rebamipide 300mg|
1655412|NCT01813799|Drug|DA-9801|
1655413|NCT01813799|Drug|Placebo|
1655414|NCT01813786|Device|755nm Alexandrite Laser with handpiece 2|Focusing energy on skin
1655415|NCT01813786|Device|755nm Alexandrite Laser with handpiece 1|focusing energy at skin surface
1655416|NCT01813786|Device|755nm Alexandrite Laser with handpiece 3|Focusing energy on skin
1655417|NCT01813773|Drug|Intravitreal Aflibercept Injection (IAI)|EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
1655418|NCT01813760|Device|Illuiminage ® Diode Laser|Diode laser for treatment of peri-orbital and peri-oral wrinkles
1655419|NCT01813747|Device|1440 nm wavelength laser with handpiece (Cynosure)|To assess the effectiveness of device in skin tightening and laser lipolysis in the mandibular and sub-mandibular areas.
1655420|NCT01813734|Drug|Ponatinib|28 day cycle
1655421|NCT01813708|Behavioral|Intensive Life-Style|16 weekly sessions conducted by certified nutritionists certified in behavioural modification, and self-care techniques, including self-monitoring, healthy nutrition, physical activity, problem solving, relapse prevention, self-reinforcement, long-term motivation, and stress management
1655422|NCT01813708|Behavioral|Collaborative Education|16 weekly sessions conducted by certified diabetes educators including: diabetes knowledge, nutrition, exercise, goal establishment in diabetes, problem solving, relapse prevention, self-monitoring, family and sexuality in diabetes, emotional management in diabetes, and stress management. Patients established their own goals
1655423|NCT01813695|Procedure|Preemptive genotyping in medical record|
1655424|NCT01813695|Procedure|Genotyping not included in electronic medical record|
1655425|NCT01813682|Other|treatment group1|fe-1 group with TPN of iron supplementation of 200μg/kg/d.
1655426|NCT01813682|Other|treatment group2|fe-2 group with TPN of iron supplementation of 400μg/BW (BW=birth weight)
1655427|NCT01813669|Behavioral|Integrative Coping Group|"The proposed 12-week intervention will integrate yoga-based skills with cognitive-behavioral principles. The development of this program was based on existing and empirically-validated cognitive-behavioral interventions for youth (i.e., Coping Cat and Cat Project; Kendall et al.) and therapeutic yoga interventions (e.g., Galantino et al., 2008 for review). The intervention will be broken down into four three-week modules, which address the following:
Module 1: Introduction to group and awareness of body Module 2: Awareness of emotion and developing an understanding of the mind-body connection Module 3: Focus on cognitive process Module 4: Experiential practice and therapeutic discussions"
1655428|NCT01813656|Drug|Aripiprazole|Aripiprazole group,5mg/pill,10mg/day non-forced titration method,last 12weeks
1655429|NCT01813656|Drug|placebo|placebo group,5mg/pill,10mg/day non-forced titration method,last 12 weeks
1655430|NCT01813643|Drug|Risperidone|Risperidone group,1mg/pill,2mg-6mg/day non-forced titration method,last 2-4weeks
1655431|NCT01813643|Drug|Aripiprazole|Aripiprazole group,5mg/pill,20mg-30mg/day non-forced titration method,last 2-4weeks
1655432|NCT01813630|Drug|DA-3002|
1655433|NCT01813630|Drug|Genotropin®|
1655434|NCT01813617|Drug|Immunosuppressive Agents|Patients in the cohort received medical treatment according to standard care.
1655435|NCT01813604|Biological|Group A: Trivalent Oral Polio Vaccine|Group A will receive 3 doses of trivalent oral polio vaccine (tOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
1655436|NCT01813604|Biological|Group B: Bivalent Oral Polio Vaccine|Group B will receive 3 doses of bivalent oral polio vaccine (bOPV) at 6, 10 and 14 weeks of age. A challenge dose of tOPV will be administered at 18 weeks of age.
1655437|NCT01813604|Biological|Group C: Inactivated Polio Vaccine|Group C will receive 2 doses of inactivated polio vaccine (IPV) at 6 and 14 weeks of age. IPV will be administered intramuscularly using standard needle and syringe. A challenge dose of tOPV will be administered at 18 weeks of age.
1655438|NCT01813604|Biological|Group D: fractional IPV (f-IPV)|Group D will receive 2 doses of fractional inactivated polio vaccine (f-IPV) at 6 and 14 weeks of age. f-IPV (one-fifth dose of IPV) will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
1655439|NCT01813604|Biological|Arm E: f-IPV and bOPV|Group E will receive 2 doses of f-IPV at 6 and 14 weeks of age with bOPV at 10 weeks of age. f-IPV will be administered intradermally using MicroJet 600 microneedle hub by NanoPass Technologies. A challenge dose of tOPV will be administered at 18 weeks of age.
1655440|NCT01813591|Drug|H.P. Acthar Gel|Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
1655441|NCT01813578|Other|Exercise|Intensive aerobic and muscle endurance exercise
1655442|NCT01813565|Drug|Hyaluronic acid/chondroitin sulfate|Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
1655443|NCT01813552|Drug|Samatasvir|Samatasvir 150 mg oral tablets (50mg x 3), single dose
1655444|NCT01813552|Drug|Omeprazole|40 mg delayed-release oral capsules, once daily
1655445|NCT01813552|Drug|Ritonavir|100 mg oral tablets, once daily
1655446|NCT01813539|Drug|ARGX-110|Outpatient intravenous infusion, in step-wise increments, every 3 weeks.
1655447|NCT01813526|Other|Experimental Infant Formula|Nutritionally complete free amino acid-based medical food.
1655448|NCT01813513|Drug|IDX719|50 mg tablet for oral administration
1655449|NCT01813513|Drug|Simeprevir|150 mg capsule for oral administration
1655450|NCT01813500|Other|Blood and stool sample|Subjects are asked to provide a blood sample (6 to 10cc) and a stool sample. An additional blood sample will be requested if the subject has a flare.
1655451|NCT01813487|Drug|HBsAg vaccine with Entecavir|
1655453|NCT01813461|Drug|14C-labeled prodrug isavuconazonium sulfate|oral
1655454|NCT01813448|Drug|Fidaxomicin|oral
1655455|NCT01813448|Drug|Placebo|oral
1655456|NCT01813435|Drug|Ticagrelor|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy.
1655457|NCT01813435|Drug|Acetylsalicylic Acid|Comparison of 1 month of ticagrelor and aspirin followed by 23 months of ticagrelor monotherapy versus 12 months of standard dual anti platelet therapy (DAPT) followed by aspirin monotherapy
1655458|NCT01813435|Drug|Clopidogrel|"Active Comparator: Reference treatment strategy Acute Coronary Syndrome (ACS) patients incl. unstable angina (UA) patients: ASA and Brilique(ticagrelor) for 12 months followed by 12 months of ASA monotherapy.
Stable Coronary Artery Disease (CAD) patients: ASA and clopidogrel for 12 months followed by 12 months of ASA monotherapy"
1655459|NCT01813422|Biological|Evolocumab|Administered by subcutaneous injection
1655460|NCT01813422|Drug|Placebo|Administered by subcutaneous injection
1655461|NCT01813396|Other|joint mobilization plus massage|
1655462|NCT01813396|Other|joint mobilization/shoulder physical activity guide|
1655463|NCT01813383|Other|There is not any intervention|
1655464|NCT01813370|Other|No intervention|No intervention is planned as part of this protocol. Historical data will be transferred to MSK via electronic data transfer. Patient's PSA, testosterone, and vital status data will be transferred to MSK via electronic data transfer.
1655465|NCT01813357|Drug|Rosuvastatin|encapsulated tablet 20mg daily
1655466|NCT01813357|Other|Placebo|Placebo arm included to maintain blinding
1655467|NCT01813318|Drug|Acamprosate|The maximum dose of acamprosate to be used in this study is 1998 mg per day for those subjects weighing greater than 50kg and 1332 mg per day for those less weighing less than 50kg.
1655468|NCT01813318|Drug|Placebo|Subjects receiving placebo will be dosed similarly to the acamprosate group.
1655469|NCT01813305|Drug|CSTC1|vapor fraction from seeds of Glycine max (L.) Merr. and composition thereof
1655470|NCT01813305|Drug|CSTC1 Matched vehicle|
1655471|NCT01813279|Other|the cell therapy|the reinjection of autologous stromal vascular fraction of adipose tissue issue on the fingers of patients with scleroderma.
1655472|NCT01813253|Drug|Irinotecan|150 mg/m2 IV once every 2 weeks until progression or unacceptable toxicity develops
1655473|NCT01813253|Drug|Nimotuzumab|400mg IV once weekly until progression or unacceptable toxicity develops
1655474|NCT01813240|Drug|Minocycline|
1655475|NCT01813240|Drug|placebo|
1655476|NCT01813227|Drug|Carfilzomib|If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
1655477|NCT01813227|Drug|Rituximab|"If you decide to participate in the study, in addition to the carfilzomib and possible dexamethasone administration, If less than a partial remission (PR) after 4 cycles is achieved, rituximab 375 mg/m2 on day 16 of each subsequent cycle will be added to the treatment. Subjects who meet the criteria for progression prior to 4 cycles of therapy will have rituximab 375 mg/m2 weekly for 4 consecutive weeks every 3 cycles added to the treatment. Subjects will be treated to maximal response plus 2 additional cycles to a maximum of 12 cycles.
At the beginning of every cycle, your study doctor will see if your general health is satisfactory. You will be asked to report any side effects or problems you have had since the start of the last treatment cycle as well as any medication change(s)."
1655478|NCT01813227|Drug|Dexamethasone|"If you decide to participate in the study, you will receive carfilzomib on Days 1, 2, 8, 9, 15, and 16 every 28 days for a minimum of 2 cycles (approximately 2 months). You may receive additional cycles for as long as your disease remains stable or improved or until your study doctor determines that you should stop receiving the study drug or you decide to stop participating in the study.
You will also receive dexamethasone weekly on Days 1, 2, 8, 9, 15 and 16 starting with cycle 1 and continuing every cycle thereafter."
1655479|NCT01813214|Drug|Vemurafenib|
1655480|NCT01813201|Drug|Testosterone undecanoate|Testosterone undecanoate intramuscular long-acting, 1000 mg/dose, administered at inclusion and every 12 weeks for 9 months (4 dose) (testosterone group) against the administration of placebo (saline isotonic solution).
1655481|NCT01813201|Drug|Saline isotonic solution|Saline isotonic solution (placebo)intramuscular,administered at inclusion and every 12 weeks for 9 months (4 dose)
1655811|NCT01810887|Drug|Darunavir|Darunavir ethanolate will be administered as single oral dosing of two tablets of 300 milligram (mg) on Day 3.
1655949|NCT01809821|Behavioral|Online Sleep Education|
1655482|NCT01813188|Procedure|ABM seeded onto a porous TCP and DBM|"cells collection under sedation . 114 mL are obtained and processed through a ficoll gradient.
Autologous bone marrow (ABM) cells seeded onto a porous tricalcium phosphate ceramic (TCP) and demineralized bone matrix (DBM)"
1655483|NCT01813188|Procedure|autologous bone graft|autologous bone graft
1655484|NCT01813175|Other|Regular non-hydrolysed cow's milk I|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture I
1655485|NCT01813175|Other|Regular non-hydrolysed cow's milk II|Regular non-hydrolysed cow's milk based infant formula with synbiotics mixture II
1655486|NCT01813175|Other|Regular non-hydrolysed cow's milk - control|Regular non-hydrolysed cow's milk based infant formula without synbiotics mixture
1655487|NCT01813162|Drug|Tenofovir 1% gel|
1655488|NCT01813162|Drug|Vaginal product|
1655489|NCT01813149|Drug|phenylephrine and clonidine|Subjects will be injected with phenylephrine and clonidine at both affected and unaffected sites.
1655490|NCT01813149|Other|punch biopsy|
1655491|NCT01813136|Drug|Continuous pazopanib (Arm A)|Daily oral administration of pazopanib 800mg (28 days cycles) from randomization until progression (according to RECIST 1.1) under treatment, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization
1655492|NCT01813136|Drug|Intermittent pazopanib (Arm B)|"Temporary discontinuation of pazopanib at randomization, after an initial period of 6 cycles (28 days) of daily administration of pazopanib 800mg from inclusion until randomization. Pazopanib will be reintroduced for 6 cycles of 28 days, with daily administration of pazopanib 800mg, as soon as the patient relapses (progressive disease according to RECIST 1.1). At the end of this additional 6 cycles, study drug will be stopped a second time.
This sequential scheme will be maintained until the patient experiences on-treatment progression"
1655493|NCT01813123|Behavioral|RealTeen|A web-based, gender-specific program intended improve girls' cognitive and behavioral skills. Each of the 9 sessions requires approximately 20 minutes. After initial intervention, girls will receive two annual booster sessions (i.e., a 20-minute review of previously learned material indexed to new age).
1655494|NCT01813110|Drug|4 g prescription omega-3 concentrate|4 g/d prescription omega-3 fatty acid concentrate taken orally for 8-12 weeks
1655495|NCT01813110|Drug|Placebo|
1655496|NCT01813084|Drug|RV1729 single dose|Safety and tolerability of single escalating doses
1655497|NCT01813084|Drug|RV1729 matching placebo single dose|Safety and tolerability of single escalating doses
1655498|NCT01813084|Drug|RV1729: 14 day repeat dose|Safety and tolerability of repeat escalating doses
1655499|NCT01813084|Drug|RV1729 matching placebo: 14 day repeat dose|Safety and tolerability of repeat escalating doses
1655500|NCT01813071|Biological|WRSS1|
1655501|NCT01813058|Drug|Tranexamic Acid|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to either:
placebo i.e. saline 0.9% (intravenous injection)
intravenous TXA given as a loading dose over 15 minutes of 50 mg/kg bolus ( within an hour prior to surgical incision) and 10 mg/kg/hr infusion for the duration of the surgery."
1655502|NCT01813058|Drug|Placebo|"Following a standardized general anesthetic protocol, patients coming with idiopathic scoliosis will be randomized to:
Placebo ( 0.9% Normal saline) intravenously given as a 0.5 ml/kg loading dose over 15 minutes followed by a 0.1 ml/kg/hr continuous infusion throughout the surgery or
TXA as previously described."
1655503|NCT01813045|Procedure|Cardiac MRI scan|Cardiac MRI scan with assessment of late gadolinium enhancement and T1 mapping.
1655504|NCT01813045|Radiation|CT-PET scan|Computed Tomography / Positron Emission Tomography scan with 18F-fluciclatide tracer.
1655505|NCT01813045|Radiation|CT-coronary angiogram|CT-coronary angiogram following CT-PET scan. Standard protocol.
1655506|NCT01813032|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
1655507|NCT01813032|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
1655508|NCT01813019|Drug|AFQ056|mGluR5 antagonist
1655509|NCT01813019|Drug|Placebo|Matched placebo
1655510|NCT01813006|Drug|Omega-3|
1655511|NCT01813006|Drug|placebo|
1655512|NCT01812993|Device|Non-invasive ventilatory treatment with auto-BPAP|
1655513|NCT01812980|Biological|Trivalent Inactivated Influenza Vaccine|"WHO recommendation for influenza vaccines for 2013 for the Southern-hemisphere included the following vaccine strains:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Victoria/361/2011 (H3N2)-like virus; - a B/Wisconsin/1/2010-like virus."
1655514|NCT01812967|Dietary Supplement|Milk Fat|
1655515|NCT01812967|Dietary Supplement|Milk Protein|
1655516|NCT01812967|Dietary Supplement|Lactose|
1655517|NCT01812967|Other|Whole milk (3.25% M.F.(|Commercially available milk from the grocery store
1655518|NCT01812967|Dietary Supplement|Simulated Milk Beverage|Added lactose + fat + protein together to form a mixture
1655519|NCT01812954|Drug|Methotrexate|
1655520|NCT01812954|Drug|Cyclosporins|
1655521|NCT01812954|Drug|fumaric acid|
1655522|NCT01812954|Drug|Acitretin|
1655523|NCT01812954|Drug|Infliximab|
1655524|NCT01812954|Drug|etanercept|
1655525|NCT01812954|Drug|Adalimumab|
1655526|NCT01812954|Drug|Ustekinumab|
1655527|NCT01812941|Other|trauma: blood collection|Blood samples collected at certain timepoints. Time points for burn/trauma subjects: Day0,Day1,Day2,and Day6 and Day7.
1655528|NCT01812941|Other|healthy volunteers: blood collection|blood collected at designated time intervals
1655529|NCT01812941|Other|Burn: blood collection|blood collected at designated time intervals
1655530|NCT01812928|Drug|Diclofenac|
1655531|NCT01812915|Device|Cylindrical-shape cuff ETT (Group C)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt Hi-Lo(TM) endotracheal tube.
1655532|NCT01812915|Device|Tapered-shape cuff ETT (Group T)|Randomized allocation of the endotracheal cuffs for general anesthesia, mechanical ventilation will be maintained with Mallinckrodt TaperGuard(TM) endotracheal tube.
1655533|NCT01812902|Procedure|Radical Prostatectomy|
1655536|NCT01812863|Procedure|Supraclavicular nerve block|"Following injection of morphine, an ultrasound-guided supraclavicular nerve catheter (Angiocath) will be placed in Group 2. All catheters will be placed by one of the anesthesiologist trained in regional pain control using a 25 mm linear US probe in a sterile fashion.
If the examination is unchanged from preoperative assessment, an injection block using 5 ml of 0.25% bupivacaine with 1:200,000 epinephrine will be administered. Bupivacaine is a long acting local anesthetic that prevents nerve conduction and action potential initiation by decreasing the permeability of the neuronal membrane to sodium. We use a maximum dose of 5 mL of 0.25% bupivacaine, and we usually base the dose on a ml/kg (0.2 ml/kg) with a maximum dose not to exceed 2.5 mg/kg. This will be well below toxic levels."
1655537|NCT01812837|Device|Microneedle|The study device (Microchannel Skin System by 3M Company)is fabricated from medicalgrade polymer consisting of a rectangular array of 351 pyramidal, 700-μm-long, solid microneedles.
1655538|NCT01812837|Drug|Aminolevulinic Acid|Levulan® Kerastick® DUSA Pharmaceuticals, Inc., Wilmington, MA
1655539|NCT01812837|Radiation|Blue light|Blu-U unit (DUSA Pharmaceuticals, Inc., Wilmington, MA)
1655540|NCT01812824|Behavioral|Intervention (Virtual Patient Advocate)|"Intervention (Virtual Patient Advocate) participants will have access to the Gabby system for 6 months. There is no required dose or frequency that they have to log on to the system, but the investigators will suggest that they log on once a week."
1655541|NCT01812798|Other|Double Blind Placebo Controlled Food Challenge|"All participants will undergo Double Blind Placebo Controlled Food Challenge. Participants will be randomized to receive either Peanut on Day 1, Placebo on Day 2, or vice versa.
For 'Peanut' arm, participants will be fed increasing doses of peanut until mild objective allergic reaction is observed.
Doses will be increased every 20-30 minutes. All doses are listed in g peanut flour
0.1 0.25 0.5 0.75
1 2.5 5 10 25 50 100 250 500 750 1000 2500 5000
For Placebo arm, participants will be fed increasing amounts of food matrix without peanut flour."
1655542|NCT01812772|Device|Double J-stent with a long tether|Patients will receive a double-J stent placement with a long tether following ureteroscopy.
1655543|NCT01812772|Device|Double J-stent without a long tether|Patients will receive a double-J stent placement without a long tether following ureteroscopy.
1655544|NCT01812759|Drug|Fentanyl Nasal Spray|100 mcg nasal spray administered in each nostril.
1655545|NCT01812759|Drug|Hydromorphone PCA|Initial loading dose 0.2 mg with demand doses of 0.2 mg and lockout interval of 15 minutes. There will be no basal dose and the 8-hour dose limit will be 6.4 mg.
1655546|NCT01812759|Other|Placebo Nasal Spray|1 placebo nasal spray administered in each nostril.
1655547|NCT01812746|Drug|BIND-014|
1655548|NCT01812720|Drug|carfilzomib|Given IV
1655549|NCT01812720|Drug|dexamethasone|Given PO
1655550|NCT01812720|Other|laboratory biomarker analysis|Correlative studies
1655551|NCT01812707|Drug|Alirocumab|Two SC injections in the abdomen only
1655552|NCT01812707|Drug|Placebo (for alirocumab)|"Two subcutaneous (SC) injections in the abdomen only
Route of administration: subcutaneous injection (1 mL) in the abdomen"
1655553|NCT01812707|Drug|Atorvastatin|"Orally once daily at a stable dose of 5 to 20 mg as background therapy
Route of administration: oral administration in the evening"
1655555|NCT01812668|Drug|cabozantinib-s-malate|Given PO
1655556|NCT01812668|Radiation|fluorine F 18 d-FMAU|Undergo 18F PET/FMAU PET scan
1655557|NCT01812668|Procedure|positron emission tomography|Undergo 18F PET/FMAU PET scan
1655558|NCT01812668|Other|pharmacological study|Correlative studies
1655559|NCT01812668|Other|laboratory biomarker analysis|Correlative studies
1655560|NCT01812655|Device|Virtual Reality|
1655561|NCT01812655|Other|Passive Distraction|
1655562|NCT01812642|Drug|JNJ-37822681|JNJ-37822681 oral capsule will be administered at a starting dose of either 20 mg (once daily) or 10 milligram (twice daily) for 14 days.
1655563|NCT01812642|Other|Placebo|Matching Placebo will be administered orally, once daily in the evening (12 hour after JNJ-37822681 20 mg administration) for 14 days.
1655564|NCT01812629|Other|Experimental Infant Formula|Infant formula to be fed ad libitum
1655565|NCT01812616|Drug|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
1655566|NCT01812616|Drug|Placebo|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and Food, Drugs & Cosmetics (FD&C)certified color additives; FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
1655567|NCT01812603|Drug|Sativex|Administered orally as a spray to the cheek according to a standard dose titration regimen, until patients reach a maximum tolerated dose (maximum 12 sprays per day). Each spray delivers 100 μl (Δ9tetrahydrocannabinol (THC), 27 mg/ml: Cannabidiol (CBD), 25 mg/ml).
1655568|NCT01812590|Behavioral|Exercise|
1655569|NCT01812564|Biological|Platelet Poor Plasma (PPP)|
1655570|NCT01812564|Biological|Platelet Rich Plasma (PRP)|
1655571|NCT01812551|Drug|Alendronate|As active drug, we used Alendros (Abiogen Pharma, Pisa, Italy), distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
1655572|NCT01812551|Drug|Placebo|Placebo was distributed to the patients in plain bottles and boxes (bearing only the center and patient codes).
1655573|NCT01812538|Drug|DIC075V|"Four single dose treatments:
Placebo (normal saline)
Moxifloxacin (positive control)
DIC075V 37.5 mg
DIC075V 75 mg
All subjects receive each of the 4 treatments."
1655574|NCT01812525|Drug|NaCl 3%|NaCl 3%: 4ml QID
1655575|NCT01812525|Other|Standard therapy|Standard therapy includes suctioning nasal secretions, water-electrolyte balance maintenance and oxygen supplementation when needed
1655757|NCT01811277|Drug|SOX sequential S-1|"4-6 cycles SOX followed by S-1 monotherapy until disease progression
S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1"
1655576|NCT01812512|Behavioral|Teaching for Interactive Patient Self-Management (TIPS) for Heart Failure (HF|The curriculum plan adapts components from the Rochester Participatory Decision-Making Scale (RPAD) and recent advances in communication skills training for chronic disease to develop a valid and reliable intervention specific to Home Telehealth (HT) shared decision making, effective telehealth communication, and patient self-management for heart failure (HF), using established best-practices and Veteran input. Veteran volunteers will participate in video recorded simulations to promote nurse care coordinator (NCC) active participation and problem-solving during the course. Scenarios are taken from transcribed actual HT interactions from the first exploratory RRP study of HT. The course is set up as one live session, one online module, and a final live session for more difficult conversations.
1655577|NCT01812486|Radiation|dose de escalation|
1655578|NCT01812486|Radiation|standard dose|
1655579|NCT01812473|Other|Blood sampling|During the treatment of voriconazole, at steady plasma concentrations of voriconazole, one plasma sample and one serum sample are taken.
1655580|NCT01812460|Other|Intervention-training-group|As descriped in Arm Description
1655581|NCT01812447|Device|Spiration Valve System|Subjects assigned to the treatment group will undergo a bronchoscopic procedure to have valves placed in the most diseased lobe of the lung to occlude all segments of the lobe.
1655582|NCT01812447|Other|Medical Management|Stable management is based on the ACP/ACCP/ATS/ERS Guidelines for Management of Stable COPD. Medical management will include management of COPD medications, oxygen use, and pulmonary rehabilitation.
1655583|NCT01812434|Drug|Sildenafil|20mg three time daily for 28 days
1655584|NCT01812434|Drug|Placebo|20 mg three times daily for 28 days
1655585|NCT01812421|Other|Hypertension Health Education Protocol (HHEP)|
1655586|NCT01812395|Device|Thyroidectomy using harmonic focus (r)|Harmonic focus(r) device is used to seal and cut the vessels during thyroidectomy.
1655587|NCT01812395|Procedure|Conventional thyroidectomy|Vessels are ligated with sutures then cut using classic scalpel or scissors.
1655588|NCT01812382|Drug|Retapamulin Microdialysis|After a 30 minutes equilibration period of the microdialysis procedure/infusion with normal saline solution, 50nanogram (ng)/mL Retapamulin injectable solution will be infused at a flow rate of 1.5 microliter/minute over a period of 90 minutes. The total dose perfused for each of the 3 microdialysis tubes will be 6.75ng.
1655589|NCT01812369|Drug|GEMCITABINE CISPLATINE|
1655590|NCT01812369|Drug|METHOTRXATE VINBLASTINE DOXORUBICINE CISPLATINE G-CSF|
1655591|NCT01812356|Device|Cryomaze procedure using Nitrous oxide|Cryomaze procedure using Nitrous oxide
1655592|NCT01812356|Device|Cryomaze procedure using Argon|Cryomaze procedure using Argon
1655593|NCT01812343|Other|Exercise test|
1655594|NCT01812330|Drug|Clopidogrel|After 600mg loading dose, 75mg or 150mg Qd
1655595|NCT01812330|Drug|Ticagrelor|90mg Bid
1655596|NCT01812317|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
1655597|NCT01812317|Procedure|Badimon Chamber Study|Ex-vivo assessment of thrombus formation using the Badimon Chamber
1655598|NCT01812304|Other|hands-on training|the intervention consists of a predefined hands-on training program including 25 technical steps to manage a vaginal breech
1655599|NCT01812304|Other|frontal teaching|one teacher demonstrates all 25 items listed in the OSATS checklist. Probands listen and watch.
1655600|NCT01812291|Behavioral|Step 1: Diabetes-Specific CBT (5 group sessions)|"Diabetes-Specific CBT (5 group sessions) focusing on diabetes-related problems and distress ('DIAMOS - Strengthening Diabetes Motivation').
Includes:
Diabetes problem analysis/ definition
Diabetes problem solving intervention
Cognitive restructuring of diabetes problems
Activation of personal and social resources
Goal definition and agreement"
1655601|NCT01812291|Behavioral|Step 2: Depression-Specific CBT (6 single sessions)|"Depression-Specific CBT (6 single sessions) focusing on depressive cognitions and affective problems (manualised).
Includes:
Functional explanatory model of depression
Cognitive restructuring of negative thoughts
Practice of alternative beneficial thoughts
Specific cognitive interventions regarding self-criticism, guilt, low self-esteem, fear, and inactivity."
1655602|NCT01812291|Behavioral|Step 3: Referral to Psychotherapist and/or Psychiatrist|Non-responders to previous treatment steps will be referred to an psychotherapist and/or psychiatrist for intensified treatment. Treatments procedures will be monitored and interventions will be scored to enable the evaluation of treatment effects.
1655603|NCT01812291|Behavioral|Standard Diabetes Education|"Standard diabetes education and professional care.
Includes:
Health care and specific topics (e. g. blood pressure)
Diabetes complications
Healthy and unhealthy foods, cooking recommendations and recipes
Foot care: exercises, care and control, injuries, and diabetic neuropathy
Sports, activities and exercise
Social aspects of living with diabetes"
1655606|NCT01812265|Drug|PF-06305591|single Dose
1655607|NCT01812265|Drug|PF-06305591|single Dose
1655608|NCT01812265|Drug|Placebo|Single Dose
1655609|NCT01812252|Drug|Azacitidine|Given IV or SC
1655610|NCT01812252|Drug|Decitabine|Given IV or SC
1655611|NCT01812252|Other|Quality-of-Life Assessment|Ancillary studies
1655612|NCT01812239|Drug|Vaginal Progesterone gel.|Daily administration of Vaginal Progesterone gel in pregnant women with twins between the 20th week of pregnancy and the 34th week of pregnancy.
1655613|NCT01812239|Procedure|fetal fibronectin swab.|Collection of quantatative fetal fibronectin swab one week after randomization into the trial for both arms. Randomziation occurs between 20 weeks - 24 weeks of gestation.
1655614|NCT01812239|Drug|Placebo gel|weekly vaginal administration of the placebo gel from randomization until 34 weeks of gestation.
1655615|NCT01812213|Drug|[18F]NAV4694|
1655616|NCT01812200|Drug|Dabigatran, Ticagrelor, ASA|
1655617|NCT01812200|Drug|Rivaroxaban, Ticagrelor, ASA|
1655618|NCT01812200|Drug|Phenprocoumon, Ticagrelor, ASA|
1655619|NCT01812187|Behavioral|SHIFT Cognitive Behavioral Therapy|Manualized, evidence-based, cognitive behavioral therapy for the treatment of substance abuse disorders
1655620|NCT01812174|Device|17mm aortic valve (On-X )|Heart aortic valve replacement surgery: 17mm Aortic
1655622|NCT01812161|Other|acupuncture protocol 1|Disposable, single-use, sterilized needles made of stainless steel, 0.25 x 30 mm and 0.30 x 40/50mm (Wuxi Jiajian Medical Instrument. 251226 Wuxi, China) will be inserted to a depth of 15-35 mm in some acupoints. After getting the needle sensation (de qi), some acupoints will receive electrical stimulation and the others will receive manual stimulation. All participants will receive treatment twice a week; each treatment session can be separated by an interval of 2-4 days, with a maximum of 32 treatment sessions during 16 weeks. Each treatment session lasts for 30 minutes.
1655623|NCT01812161|Other|Acupuncture protocol 2|Disposable, single-use, sterilized needles (0.20 x 20mm) made of stainless steel will be inserted to a depth of <5 mm at non-acupoints without evoking the needle sensation (Deqi). Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture protocol 1 group. No manual stimulation of the needles will be performed.
1655624|NCT01812148|Procedure|Cytoreductive surgery and HIPEC|Cytoreductive surgery and hyperthermic intra-peritoneal chemotherapy (HIPEC) with Oxaliplatin as chemotherapeutic agent
1655625|NCT01812135|Biological|400 U EV71 vaccine with adjuvant|400 U EV71 vaccine contain 0.4 mg AL/0.5 ml aluminum hydroxide adjuvant
1655626|NCT01812122|Drug|Glimepiride|
1655627|NCT01812122|Drug|Vildagliptin|
1655628|NCT01812109|Device|Hutchison Technologies Inspectra StO2 SpotCheck Near-Infrared Spectroscopy|Device: Near-Infrared Spectroscopy Transscrotal NIRS is a series of 6 transcutaneous scrotal measurements, 3 on both left/right. Each measurement is completely non-invasive, painless and takes ~15 seconds each. Thus, no sedation or supplemental analgesia is needed for NIRS. The NIRS probe will be placed on the anterior, lateral and posterior scrotum on the left/right sides, immediately overlying and parallel to the long axis of the testis but on the skin to obtain the 6 total measurements. The unaffected testis will serve as the patient's own control. Study coordinators will be performing the ER transscrotal NIRS testing. For uniformity, all will be trained for testicular probe placement methods. NIRS will not delay the gray scale/color Doppler testicular US or surgery.
1655629|NCT01812096|Other|Subcutaneous bortezomib|
1655630|NCT01812096|Other|Intravenous bortezomib|
1655631|NCT01812070|Behavioral|ACT|
1655632|NCT01812070|Behavioral|CBT|
1655633|NCT01812057|Drug|Dexamethasone|Dexamethasone 8 mg IV (as a one time dose)
1655634|NCT01812057|Drug|Placebo|Sodium Chloride 0.9% -5 ml
1655635|NCT01812044|Drug|subtenons anesthetic - preservative-free bupivacaine 0.75%|
1655636|NCT01812044|Drug|topical anesthetic - 0.5 cc of lidocaine 3.5% ophthalmic gel|
1655637|NCT01812044|Drug|topical control - 0.5 cc of Hypromellose 0.3% gel|
1655638|NCT01812044|Drug|subtenons control - 0.5 cc of Normal Saline|
1655639|NCT01812031|Other|medical imaging|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.
Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.
Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
1655640|NCT01812018|Drug|Endostar|Endostar administered at 7.5 mg/m2, intravenously (IV), on Day 1-14 every 21 days for up to 4-6 consecutive cycles
1655641|NCT01812018|Drug|Gemcitabine|Gemcitabine administered at 1000 mg/m2, intravenously (IV), on Day 1 and Day 8, every 21 days for up to 4-6 consecutive cycles
1655642|NCT01812018|Drug|Docetaxel|Docetaxel administered at 75 mg/m2, intravenously (IV), on Day 2, every 21 days for up to 4-6 consecutive cycles
2013150|NCT00950300|Drug|Cyclophosphamide|Participants will receive cyclophosphamide, 500 mg/m^2 via IV bolus, on Day 1 of every 21-day cycle during Cycles 5 to 8.
2013151|NCT00950300|Drug|Docetaxel|Participants will receive docetaxel, 75 mg/m^2 via IV infusion on Day 1 of every 21-day cycle during Cycles 1 to 4.
2013152|NCT00950300|Drug|Epirubicin|Participants will receive epirubicin, 75 mg/m^2 via IV bolus or infusion, on Day 1 of every 21-day cycle during Cycles 5 to 8.
2013153|NCT00950300|Drug|Herceptin IV [trastuzumab]|Herceptin will be administered as 8 mg/kg (loading dose during Cycle 1) and 6 mg/kg (subsequent cycles) via IV infusion on Day 1 of each 21-day cycle for a total of 18 cycles.
1655647|NCT01811979|Dietary Supplement|Oral sucrose solution|Oral sucrose solution plus topical anesthetics
1655648|NCT01811979|Dietary Supplement|Steril water|steril water plus topical anesthetics
1655649|NCT01811966|Other|Volume|
1655650|NCT01811966|Other|Control|
1655651|NCT01811953|Drug|Empagliflozin|medium dose oral administration
1655652|NCT01811953|Drug|Metformin|oral administration
1655653|NCT01811953|Drug|Empagliflozin|low dose of Empagliflozin oral administration
1655654|NCT01811953|Drug|Empagliflozin/Metformin|low dose of Empagliflozin
1655655|NCT01811953|Drug|Metformin|oral administration
1655656|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
1655657|NCT01811953|Drug|Empagliflozin|medium dose oral administration
1655658|NCT01811953|Drug|Metformin|oral administration
1655659|NCT01811953|Drug|Empagliflozin/Metformin|medium dose of Empagliflozin oral administration
1655660|NCT01811940|Drug|Adderall-ER|MAS-ER 60mg/day
1655661|NCT01811940|Drug|Topiramate|Topiramate 100 mg bid.
1655662|NCT01811940|Other|Placebo|Placebo
1655663|NCT01811927|Device|PRO-Kinetic Energy Stent|Bare-metal stent
1655664|NCT01811914|Other|intraoperative TTE|
1655665|NCT01811901|Other|Reduction of DTN|15-item list of suggested interventions aiming to reduce DNT sent to SITS-WATCH centers.
1655666|NCT01811888|Behavioral|Quantitative sensory testing (QST)|
1655667|NCT01811875|Biological|Optivate 500IU|
1655808|NCT01810913|Procedure|quality-of-life assessment|Ancillary studies
1655809|NCT01810913|Radiation|intensity-modulated radiation therapy|Undergo IMRT
2013154|NCT00950300|Drug|Herceptin SC [trastuzumab]|Herceptin will be administered as fixed dose 600 mg SC on Day 1 of each 21-day cycle for a total of 18 cycles.
1655668|NCT01811862|Procedure|Acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts). Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
1655669|NCT01811862|Procedure|Sham acupuncture|Patients with multiple myeloma undergoing conditioning myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation. Patients will be randomized to acupuncture or sham acupuncture. Acupuncture treatment will be delivered once daily starting on Day -1 (Day -2 is the day chemotherapy starts)Acupuncture will continue for 5 days, or, when the patient's absolute neutrophil count drops below 200/microliter or platelet count drops below 20,000/microliter, whichever is sooner. Sham acupuncture will be delivered on the same schedule. Regardless of group assignment, every patient will receive the same usual prevention and treatment regimen for nausea, vomiting, anxiety, insomnia and fatigue that other patients who are undergoing conditioning chemotherapy in preparation for HSCT will receive in the Transplant Service.
1655670|NCT01811849|Drug|Insulin LISPRO|
1655671|NCT01811849|Drug|Insulin LISPRO|
1655672|NCT01811849|Drug|Insulin LISPRO|
1655673|NCT01811836|Dietary Supplement|Zinc|Children will have an assessment of zinc homeostasis; each child is given 2 zinc stable isotopes, one by mouth and one intravenously, followed by a stool and urine collection (4 days.) Zinc isotopes are quantified in the feces and urine, values are used to calculate the primary outcome, net zinc balance. An assessment of EE quantitatively measured using the non-invasive site specific sugar absorption test, each child drinks 100 mL of a sugar solution and a urine collection follows. The quantities of non-metabolizable sugars are measured, and the ratio of two of the sugars, lactulose and mannitol, is a measure of environmental enteropathy. Children will receive a dietary supplement, corn starch, modified to reduce its absorption, for 5 weeks, which they will add to their phala. The RS is a standard food and has been used safely in millions of people for years. After taking this RS for 4 weeks both the zinc stable isotope test and the dual sugar absorption test will be repeated.
1655674|NCT01811823|Biological|Trivalent Inactivated Influenza Vaccine|"The study vaccine will be the seasonal 2013 un-adjuvanted TIV which is provided as a 0•5 milliliter suspension of split virus mixture of 15 micrograms each of circulating H1N1- like strain, H3N2- like strain and B - like strain.
The WHO recommended vaccine formulation for Southern Hemisphere 2013 Influenza Season contains the following influenza strains:
A/California/7/2009 (H1N1)pdm-like virus
A/Victoria/361/2011 (H3N2)-like virus
B/Wisconsin/1/2010-like virus. (Yamagata lineage)"
1655675|NCT01811810|Radiation|Radiation therapy (XRT)|
1655676|NCT01811810|Other|Androgen Deprivation Therapy (ADT)|
1655677|NCT01811810|Other|Chemotherapy|
1655678|NCT01811797|Device|Low Intensity Shockwave by Renova|
1655679|NCT01811797|Device|Sham treatment|Sham treatment that looks, sounds and feels like the real LISW treatment.
1655680|NCT01811784|Behavioral|Ask people not to drink raw sap|
1655681|NCT01811784|Behavioral|Ask people not to drink sap or drink sap from skirt protected trees|Behavioural
1655682|NCT01811784|Other|No Intervention|
1655683|NCT01811784|Other|No Intervention|
1655685|NCT01811758|Behavioral|Culturally Specific CBT|
1655686|NCT01811758|Behavioral|Standard CBT|
1655687|NCT01811745|Behavioral|Jaques-Dalcroze eurhythmics training|12 months of weekly, supervised, structured, progressive, 60-min music-based multitask exercise classes (i.e., Jaques-Dalcroze eurhythmics). The music-based multitask program includes all exercises used in a previous work.
1655688|NCT01811745|Behavioral|Multicomponent exercise training|12 months of weekly, i) supervised, structured, progressive, 60-min multicomponent exercise classes, supplemented by ii) 30-min home-based exercise sessions. Briefly, the multimodal exercise program is based on core components for successful fall prevention in older adults. It contains balance, gait, coordination and strength training, with balance as a core component.
1655689|NCT01811732|Drug|Delafloxacin|Delafloxacin
1655690|NCT01811732|Drug|Vancomycin|Vancomycin
1655691|NCT01811732|Drug|Aztreonam|Aztreonam
1655692|NCT01811732|Drug|Placebo|Placebo
1655693|NCT01811719|Behavioral|Enhanced NFP (NFP+)|Women in the experimental group received three possible interventions. First they received regular and periodic structured intimate partner violence (IPV) assessments from their nurse. Those who indicted any IPV - whether physical violence or emotional abuse or controlling behavior - were then given the Parker-McFarlane Brochure Intervention. Finally, all women were provided the Markman and Stanley Within My Reach curriculum according to their needs and interests.
1655694|NCT01811719|Behavioral|NFP as usual|The Nurse Family Partnership is a well-known and widely used nurse home visit program developed by David Olds. It has been rigorously tested and replicated and is now considered a best practice.
1655695|NCT01811706|Drug|Dalfampridine|Dalfampridine will be provided at an oral dose of 10mg every 12 hours, for 4 weeks period
1655696|NCT01811706|Drug|Placebo|Placebo will be administered orally every 12 hours, for a 4 week period.
1655697|NCT01811693|Drug|Glycerly Trinitrate|5mg/24hour (0.2mg/hour) transdermal
1655698|NCT01811693|Drug|Glycerly Trinitrate|10mg/24hour (0.4mg/hour) transdermal
1655699|NCT01811693|Drug|Glycerly Trinitrate|0.4 mg sublingual single metered spray
1655810|NCT01810900|Device|Protescal|
1655702|NCT01811654|Device|Intra-Articular Hyaluronic Acid-Euflexxa|IAHA was approved by the FDA in 1997 as a synovial fluid replacement device to help relieve the pain associated with knee osteoarthritis (OA) in patients who fail to respond adequately to conservative treatment and simple analgesics. In this study, IAHA, specifically Euflexxa, will be used off-label to determine whether patients afflicted with PFPS will experience similar analgesic effects as seen in those with OA.
1655703|NCT01811641|Other|season, dietary intake|
1655704|NCT01811628|Behavioral|Questionnaire|Questionnaire completion taking about 10-15 minutes.
1655705|NCT01811628|Behavioral|Interview|Audio-recorded interview that will last about 1 hour.
1655706|NCT01811615|Other|alcohol-free experimental mouth rinse|
1655707|NCT01811615|Other|alcohol-containing mouth rinsing|
1655708|NCT01811602|Other|Training|The participants randomized to the pelvic floor muscle training intervention will receive pelvic floor muscle training (0-12 weeks) delivered by a physiotherapist with clinical expertise and training in treating pelvic floor dysfunction. The intervention is 9 individual, one-on-one, 45-minute sessions; weekly for weeks 0-6 and bi-weekly for weeks 7-12 (first session will be 60 minutes). The sessions will provide pelvic floor muscle training based on the latest evidence, including biofeedback, to teach the correct technique for pelvic floor contractions, and participants will be asked to complete daily pelvic floor exercises at home.
1655709|NCT01811602|Other|Usual Care|The participants randomized to the educational pamphlet intervention (usual care control) will receive a 1-page sheet on pelvic floor muscle training, specifically Kegel exercises, which is equivalent to current standard care. Individuals randomized to this group will be placed on the clinic waiting list and be eligible for treatment following completion of the 12 week (end of study) measures.
1655710|NCT01811589|Device|Thomale-Guide|Ventricular catheter placement with the Thomale-Guide instrument
1655711|NCT01811589|Other|Free-hand|Ventricular catheter placement without a guidance (free-hand)
1655712|NCT01811576|Drug|TV-1106|
1655713|NCT01811576|Drug|Recombinant human growth hormone|Subcutaneous once daily
1655714|NCT01811563|Device|Zimmer|
1655715|NCT01811563|Device|Stryker|
1655716|NCT01811550|Other|Glycemic Control|
1655717|NCT01811537|Device|Artificial Chordae|
1655718|NCT01811511|Dietary Supplement|Chungkookjang|
1655719|NCT01811511|Dietary Supplement|Placebo|
1655720|NCT01811498|Drug|Bevacizumab|
1655721|NCT01811485|Drug|LMF237 50/250 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 250 mg twice daily
1655722|NCT01811485|Drug|LMF237 50/500 mg|Corresponds to vildagliptin 50 mg twice daily and metformin 500 mg twice daily
1655723|NCT01811485|Drug|Placebo|Matching placebo of LMF237 (contained vildagliptin 50 mg as active ingredient) twice daily
1655724|NCT01811472|Drug|LCQ908|LCQ908 5 mg, 10 mg, 20 mg tablets
1655725|NCT01811472|Drug|placebo|Matching placebo of LCQ908 5 mg, 10 mg, 20 mg tablets.
1655726|NCT01811459|Drug|Quetiapine|PO
1655727|NCT01811459|Drug|Haloperidol|IV
1655728|NCT01811459|Drug|Placebo|PO or IV
1655729|NCT01811446|Device|Muscle Activation with Niveus and Intelect Devices|Subjects will receive muscle activation technology from the Niveus device on one leg and from the Intelect (commercially-available third-party) device on the other. The order of use and the leg applied to will be randomized.
1655730|NCT01811420|Procedure|Chemomechanical Caries Removal|Chemomechanical Caries Removal Using A Papain-Based Gel
1655731|NCT01811420|Procedure|Conventional method|Dental caries removal using rotatory instrument
1655732|NCT01811407|Behavioral|Precommitment announcement|
1655733|NCT01811407|Behavioral|Results announcement|
1655734|NCT01811407|Behavioral|Walking program|
1655735|NCT01811394|Radiation|protons|Treatment is performed using 16 x 4 GyE protons
1655736|NCT01811394|Radiation|carbon ions|Treatment is performed using 16 x 4 GyE carbon ions
1655737|NCT01811381|Drug|Curcumin|Subjects will take 800 mg of curcumin in 4 capsules BID per day prior to meals
1655738|NCT01811381|Behavioral|aerobic yoga|Each week, subjects will attend two one hour aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute aerobic yoga practice sessions at home. If proficient, subjects will take a live-video conference remote class, HIPAA approved SecureVideo classes. Modification of consent has been approved.
1655739|NCT01811381|Behavioral|non aerobic yoga|"Subjects will take two non-aerobic (stretching) classes weekly as well as practice two 30 minutes yoga routines at home weekly.
Each week, subjects will attend two one hour non-aerobic yoga classes under the supervision of certified yoga instructors and complete two 30 minute non-aerobic yoga practice sessions at home."
1655740|NCT01811381|Dietary Supplement|Placebo|Subjects will take 4 capsules x BID of placebo
1655741|NCT01811368|Biological|rituximab|Given IV
1655742|NCT01811368|Biological|ibritumomab tiuxetan|Given IV
1655743|NCT01811368|Biological|anti-thymocyte globulin|Given IV
1655744|NCT01811368|Radiation|total nodal irradiation|Undergo TLI
1655745|NCT01811368|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
1655746|NCT01811368|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
1655747|NCT01811368|Drug|cyclosporine|Given PO or IV
1655748|NCT01811368|Drug|mycophenolate mofetil|Given PO or IV
1655749|NCT01811355|Drug|Mexiletine|Sodium channel blocker
1655750|NCT01811355|Drug|Placebo|Placebo
1655751|NCT01811329|Dietary Supplement|Dairy fat|
1655752|NCT01811329|Dietary Supplement|Dairy fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
1655753|NCT01811329|Dietary Supplement|Palm fat|
1655754|NCT01811329|Dietary Supplement|Palm fat + MFGM|BPC50, a dairy fraction rich in milk fat globule membrane proteins and phospholipids manufactured by Fonterra, will make up 50% of the shake's total fat.
1655756|NCT01811303|Other|D-fagomine|Measure the changes produced on the postprandial Glycaemic response to 50 g of sucrose in 200 ml water if added 40 mg D-fagomine
1655950|NCT01809808|Procedure|Surgery for acromegaly|(non-experimental) standard procedure
1655758|NCT01811264|Behavioral|Patient-Participation Aid|The PPA consists of a folder that addresses the three behaviors we hope to influence: agenda setting, asking questions, and making preferences known. The information inside contains sample questions for each section, with room for the patient to write her own questions. Each section models behavior by giving context for the items and specific example questions. It also addresses barriers to understanding by indicating that it is acceptable to ask questions when something is not clear or terms are unfamiliar.
1655760|NCT01811238|Drug|Oxycodone/naloxone|Targin 5mg, 10mg, 20mg up to 40mg b.i.d
1655761|NCT01811225|Drug|Low dose progesterone|"The low dose progesterone is seven days of placebo Tri-sprintec + placebo generic Prometrium twice a day (7AM and 7PM)."
1655762|NCT01811225|Drug|High dose progesterone|"The high progesterone dose is seven days of placebo Tri-Sprintec + 200mg of generic Prometrium twice a day (7AM and 7PM)."
1655763|NCT01811212|Drug|Cabozantinib S-malate|Given PO
1655764|NCT01811212|Other|Laboratory Biomarker Analysis|Correlative studies
1655765|NCT01811186|Drug|Oxycodone/naloxone|Oxycodone/naloxone titration
1655766|NCT01811173|Other|Nurse-physician comprehensive care|"Components of the intervention include:
Complete assessment of the patient's and family's needs conducted by the nurse.
Comprehensive treatment program developed by the nurse and in consultation with the primary care physician.
Multimorbid care plan integrating all care aspects.
Action Plan for patients, supporting self management
Proactive monitoring according to the plan."
1655767|NCT01811160|Drug|Melatonin|A capsule of melatonin was administered nightly (20:00hrs).
1655768|NCT01811160|Drug|Placebo|Placebo capsules were administered at 20:00hrs for eight weeks
1655769|NCT01811147|Drug|Selective Serotonin Reuptake Inhibitor (SSRI)|Subjects with depression will be treated with a Selective Serotonin Reuptake Inhibitor (SSRI) or a Serotonin-norepinephrine reuptake inhibitor (SNRI) for 24 months.
1655770|NCT01811134|Device|PIPELINE flow diverter stent|endovascular procedure using the medical device PIPELINE
1655771|NCT01811134|Device|Coils, with or without expendable stent|endovascular embolization procedure using microspires, with the possibility of using a balloon temporary and / or implantation of a stent complementary intracranial before implementation of microspires
1655772|NCT01811121|Drug|5-aminolévulinique acid (5-ALA)|oral administration of 20mg/kg of 5-ALA 3-5 hours before the surgical incision
1655773|NCT01811121|Drug|Placebo|Oral administration of 1g of ascorbic acid LAROSCORBINE in 50ml of water 3 hours before surgery
1655774|NCT01811095|Other|Training|"Training with the da Vinci® Skills Simulator to complete a proficiency-based curriculum in 6 simulator exercises relevant to robotic suturing over a 5-week period. We will ask participants in the training group to aim to complete the exercises Camera targeting 1, Camera targeting 2, Suture sponge 1, Suture sponge 2,and Suture sponge 3 to the target score (overall score green checkmark and all component scores to the level of yellow triangle or green checkmark, equivalent to a completed score) on two non-consecutive attempts. For the Suturing skills (SymbionixTM): Horizontal suturing defect task, the scoring is different. For this task, we have elected to ask participants to aim to complete the task ten times,rather than to achieve a certain target score."
1655775|NCT01811082|Drug|Coenzyme A|Coenzyme A 400mg per day.
1655776|NCT01811082|Drug|Pantethine|Pantethine 600mg per day.
1655777|NCT01811069|Procedure|Head up|30˚ reverse trendelenburg body position
1655778|NCT01811056|Drug|Mifepristone|Mifepristone use outside of the center
1655779|NCT01811043|Behavioral|Guided Meditation|
1655780|NCT01811043|Behavioral|Music|
1655781|NCT01811043|Behavioral|Supportive Dialogue|
1655782|NCT01811030|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
1655783|NCT01811017|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
1655784|NCT01811004|Device|miraDry|miraDry
1655785|NCT01811004|Device|Nd:YAG Laser|Nd:YAG 1440 nm Laser
1655786|NCT01811004|Device|Botox®|Botox®
1655787|NCT01810991|Device|Nd:YAG Laser|Nd:YAG 1440nm Laser
1655790|NCT01810965|Procedure|First evaluation phase : no intervention / Second evaluation phase: bloodletting of 7 ml/kg (with a maximum of 500ml)|
1655791|NCT01810952|Drug|Glargine insulin|In both protocols glargine dose was increased by 10% if the FSG value was 141-200 mg/dL and by 20% if the FSG value was more than 200 mg/dL, and decreased by 10% if the FSG was 70-89 mg/dL and by 20% if the FSG was less than 70 mg/dL.
1655792|NCT01810952|Drug|Lispro insulin|In both protocols lispro insulin was given to cover meals. Additional lispro insulin was Lispro insulin was administered before meals to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro Insulin Arm.
1655793|NCT01810952|Drug|NPH Insulin|NPH insulin was given once or twice a day to cover the prednisone or glucocorticoid equivalent in the Glargine/Lispro/NPH Insulin Arm
1655794|NCT01810939|Drug|Patiromer|
1655795|NCT01810939|Drug|Placebo|
1655796|NCT01810926|Biological|polyclonal antibody|iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)
1655797|NCT01810926|Drug|Rituximab|single infusion of200 mg/m2 on day -1
1655798|NCT01810926|Drug|Treosulfan|iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)
1655799|NCT01810926|Drug|Fludarabine|iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan
1655800|NCT01810926|Drug|Thiotepa|iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals
1655801|NCT01810926|Drug|Cyclosporine A|iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL
1655802|NCT01810926|Drug|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6
1655803|NCT01810926|Drug|Methotrexate|iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11
1655804|NCT01810913|Drug|cisplatin|Given IV
1655805|NCT01810913|Drug|docetaxel|Given IV
1655806|NCT01810913|Biological|cetuximab|Given IV
1655807|NCT01810913|Other|laboratory biomarker analysis|Correlative studies
1655812|NCT01810887|Drug|Ritonavir|Ritonavir capsule will be administered orally twice daily at a dose of 100 mg for 5 days.
1655813|NCT01810874|Procedure|Transperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by transperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
1655814|NCT01810874|Procedure|Extraperitoneal laparoscopic aortic lymphadenectomy|Aortic/para-aortic lymph nodes dissection and retrieval by extraperitoneal laparoscopy; the intervention may be completed by robotic-assisted or traditional laparoscopy.
1655816|NCT01810848|Device|Hylan G-F 20|"Synvisc is an elastoviscous high molecular weight fluid which is injected into the knee joint (intra-articular) for relief of pain from osteoarthritis in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics."
1655817|NCT01810848|Other|Control|Control is puncture of the skin at the site of the knee.
1655818|NCT01810809|Procedure|articular lavage with saline injection|Patients will receive articular lavage with saline injection
1655819|NCT01810809|Drug|1 ampoule of Hylan GF-20|Patients will receive viscosupplementation with 2ml (1 ampoule) of Hylan GF-20
1655820|NCT01810809|Drug|2 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 4ml (2 ampoules) of Hylan GF-20
1655821|NCT01810809|Drug|3 ampoules of Hylan GF-20|Patients will receive viscosupplementation with 6ml (3 ampoules) of Hylan GF-20
1655822|NCT01810796|Drug|Ranolazine|Ranolazine versus placebo
1655823|NCT01810783|Drug|Brexpiprazole|1 to 4 mg/day, once daily, tablets, orally. The patients received 2 mg/day brexpiprazole on Day 1. If a patient could not tolerate the 2 mg dose on Day 1, the dose was decreased to 1 mg/day at Day 2. The patients received 1 or 2 mg/day from Days 2 to 7, 1, 2, or 3 mg/day from Days 8 to 14, and 1, 2, 3, or 4 mg/day from Day 15 to completion of the Treatment Period (up-titration).
1655824|NCT01810770|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride, 55 kBq/kg body weight, will be administered as a slow bolus IV injection at 4 week intervals for up to 6 doses.
1655825|NCT01810757|Radiation|Standard planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, using one plan per patient.
1655826|NCT01810757|Radiation|Adaptive planning radiotherapy|36 Gray dose given in 6 fractions of 6 Grays over 6 weeks, selecting the best fit from three plans per patient.
1655827|NCT01810744|Other|capillaroscopy|
1655828|NCT01810744|Other|blood pressure measurement|
1655829|NCT01810731|Biological|Quadrivalent Inactivated Influenza Vaccine (QIV)|
1655830|NCT01810731|Biological|Inactivated Polio Vaccine|
1655831|NCT01810731|Biological|Double Dose QIV|
1655832|NCT01810718|Drug|nilotinib|Maximum tolerated dosage (MTD) will be defined in Phase I. First 3 patients (pts) will receive Nilotinib 200mg daily dose. If no dose limiting toxicities after at least 1month the next 3 pts will be treated with 300mg. If are>=2 dose limiting toxicities the Phase I will end and MTD will be defined as the next lower dosage. If they will observe 1dose limiting toxicities, they will treat other 3 pts (same dosage); if there isn't dose limiting toxicity, they will increase the dosage in the next cohort; but if they will observe another dose limiting toxicity (tot limiting toxicities 2/6 pts), the study will continue using the previous dose. MTD will be considered the maximum dosage used to treat 6 pts achieving at most 1 dose limiting toxicities, or the previous dosage if with this dosage they we will achieve 2 dose limiting toxicities. Doses will not be escalated beyond >600 or <200mg/die The MTD will be used for phase II
1655833|NCT01810705|Drug|GRASPA|Patients receiving Intervention (experimental group) will be treated with one injection of graspa per cycle of treatment, each cycle during 28 days, for a duration up to 24 cycles maximum
1655834|NCT01810692|Device|Group1:Spiriva® Respimat®|COPD patients using Respimat®
1655835|NCT01810692|Device|Group2:Hirobriz®/Oslif®/Onbrez® Breezhaler®|COPD patients using Breezhaler®®
1655836|NCT01810679|Device|Perceval S Aortic Heart Valve|Perceval S Sutureless Aortic Heart Valve
1655837|NCT01810666|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Participants received Recombinant Factor VIII (Rec. factor VIII) on-demand treatment for 12 weeks followed by a 12 weeks prophylaxis treatment phase. The dose and mode of prophylaxis treatment was 25 IU/Kg, 3 times/per week. The dose in on-demand treatment was decided by physician according to the package insert or the current standard of care.
1655838|NCT01810653|Drug|Macrogol (Transipeg, BAY81-8430)|Up to 4 sachets per day based on individual titration
1655839|NCT01810653|Drug|Macrogol (Forlax)|Up to 4 sachets per day based on individual titration
1655840|NCT01810640|Procedure|Percutaneous Liver Biopsy|Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
1655841|NCT01810627|Radiation|MVCT|Patients will receive an additional MVCT scan at their one month follow up visit.
1655842|NCT01810614|Other|ADPKD Diet|Diet specifically designed for people with ADPKD
1655843|NCT01810601|Drug|GnRh, HMG, HCG, Progesterone|GnRh analogue (0.05 mg/day), HMG (150-300 iu/day), HCG (5000 iu/day), Progesterone (100 mg/day)
1655844|NCT01810588|Device|CliniMACS® CD34 Reagent System|The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
1655845|NCT01810588|Drug|Fludarabine|Administer 30 mg/m2 /day intravenously x 5 days (Day -7 to Day -3) of a total dose of 150 mg/m2. Fludarabine will be dosed according to actual body weight.
1655846|NCT01810588|Drug|Melphalan|Administer 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis
1655951|NCT01809808|Drug|Medications for acromegaly|(non-experimental) standard procedure
1655952|NCT01809795|Other|Blueberry Smoothie|
1655953|NCT01809795|Other|Sham Smoothie|
1718209|NCT00002461|Drug|cyclophosphamide|
1655847|NCT01810588|Drug|Rabbit ATG (rATG)|Administer 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
1655848|NCT01810575|Drug|WC3036-11F/Alprostadil in Vehicle 2.5%|330 mcg alprostadil in 2.5% vehicle
1655849|NCT01810575|Drug|WC3036-12F/Alprostadil in Vehicle 0.5%|330 mcg alprostadil in 0.5% vehicle
1655850|NCT01810575|Drug|WC3036-13P/Vehicle Only 0.5%|100 mg cream vehicle 0.5%.
1655851|NCT01810562|Other|Specific treatment in addition to standard stroke care|"Stimulation of both the affected side and not affected side. Treatment twice per day for three months. Unperturbed side always stimulated first.
Isstimulering achieved by an ice cube melted on each of the affected ektremitetene evenly distributed.
Brushing on thin clothing or directly on the skin, 10 times rapidly for each location. On the back of m. deltoideus from right to left side of the body, laterally along the humerus, frontally, along the radius / ulna laterally, frontal and dorsal palm, along the femur first laterally and frontally, along the tibia / fibula laterally, frontally and the footplate dorsal side.
Scrolling with spiked ball over the same area as brushing for two minutes evenly.
Firm pressure for two minutes evenly in the same area."
1655852|NCT01810549|Drug|Anakinra|Each subject will receive one single subcutaneous injection of 100mg Anakinra during the study, a total of one injection.
1655853|NCT01810549|Drug|Placebo|Every subject will receive one single subcutaneous injection of Placebo during the study, a total of one injection.
1655854|NCT01810536|Device|Hi-flow nasal cannula|Different ways of providing supplemental oxygen will be compared: hi-flow nasal cannulas versus Venturi masks
1655855|NCT01810536|Device|Venturi mask|
1655856|NCT01810523|Behavioral|Narrative|Narrative form as described above.
1655857|NCT01810523|Behavioral|Control|Blank piece of paper
1655858|NCT01810510|Procedure|PAV Ventilation|PAV is a mode of ventilation in which the only set parameter is the proportion of work/effort that is provided regardless of the ventilatory pattern the patient chooses- the patient has full control over pressure, volume, flow and time of inspiration as well as respiratory rate. In this mode, the ventilator measures patient respiratory mechanics every 10-15 breaths and delivers a level of pressure proportional to patient effort, thereby maintaining a set proportion of patient effort regardless of the patient's ventilatory pattern. The patients will be on this mode of ventilation for 60 minutes.
1655859|NCT01810510|Procedure|NAVA Ventilation|With NAVA, delivery from the ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi), which is measured by a specially designed nasogastric or orogastric catheter (NGT or OGT) containing EMG electrodes that cross the diaphragm. In this mode, the ventilator measures the Edi with each breath and instantaneously delivers a level of pressure proportional to Edi magnitude, thereby providing a set proportion of effort on a breath-to-breath basis. The patients will be on this mode of ventilation for 60 minutes.
1655860|NCT01810497|Procedure|Use of ear bandage|Elastic bandage to be used on the postoperative period of otoplasty, starting immediately after the procedure. To be used 24hours/day for the specified period.
1655861|NCT01810484|Device|Ultherapy® treatment only|Focused ultrasound energy delivered below the surface of the skin
1655862|NCT01810484|Device|Ultherapy® treatment and CO2 laser treatment|"Ultherapy® treatment: Focused ultrasound energy delivered below the surface of the skin;
CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin."
1655863|NCT01810484|Device|CO2 Laser treatment only|CO2 Laser: Fractionated energy delivered to the surface of the skin for ablative and thermal injury to the skin layers for resurfacing the skin.
1655864|NCT01810471|Device|Applying ankle support device (white non-elastic tape, kinesiotape (TM), soft brace (Malleotrain TM)|
1655865|NCT01810458|Device|Abdominal ultrasound|Abdominal ultrasound will be done at the liver biopsy visits. The purpose of the ultrasound is to evaluate for the presence of liver fibrosis and identify the biopsy site.
1655866|NCT01810458|Procedure|History and physical|Every study participant will be asked about their medical history and will have a physical exam done at the screening, year 1, year 2, and year 3 visits.
1655867|NCT01810458|Procedure|Intravenous catheter|Every study participant will have and intravenous catheter (IV) placed at every study visit. The IV will be used for the collection of blood at the screening, year 2, year 2, and year 3 visits. It will also be used for the administration of medication at the first liver biopsy, as well as the year 3 visit if the biopsy is repeated.
1655868|NCT01810458|Procedure|Blood draw|At the screening, year 1, year 2, and year 3 visits, every participant will have blood collected from the IV that is placed in one of their veins.
1655869|NCT01810458|Other|Liver questionnaire|At the screening and year 3 visits, every subject will complete a questionnaire which involves questions regarding liver health.
1655870|NCT01810458|Procedure|Liver Biopsy|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine (a numbing medicine) injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. Once the relaxation medication and numbing medicine have been given, a sample of liver tissue will be collected using a needle biopsy device.
1655871|NCT01810458|Drug|Midazolam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
1655954|NCT01809769|Biological|Mesenchymal stem cells low-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
1655955|NCT01809769|Biological|Mesenchymal stem cells mid-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
1656002|NCT01809353|Other|Placebo|Single matching intravenous dose
1655872|NCT01810458|Drug|Fentanyl|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
1655873|NCT01810458|Drug|Lidocaine|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
1655874|NCT01810458|Drug|Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
1655875|NCT01810458|Drug|Lorazepam|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
1655876|NCT01810458|Drug|Oxycodone/Acetaminophen|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
1655877|NCT01810458|Drug|Ondansetron|Every participating subject who passes the screening visit, will have a liver biopsy done with the use of lidocaine injected into skin where the biopsy will be collected. At the time of the biopsy, either lorazepam (a medicine used to treat anxiety and cause relaxation) or midazolam (a medicine used to cause sleepiness and amnesia) and fentanyl (a medicine used to relieve pain) will be used. After the biopsy is done, participants who continue to have pain may receive either oxycodone/acetaminophen or acetaminophen (medicines used to relieve pain). Any participant who experiences nausea may receive ondansetron (a medicine used to relieve nausea).
1655878|NCT01810432|Drug|Evacetrapib|Administered orally
1655879|NCT01810432|Other|High-fat Meal|Administered orally, at breakfast.
1655880|NCT01810419|Device|Vscan Ultrasound (GE Healthcare, USA)|Vscan Ultrasound used to determine spleen size and the other qualities described in the arm description.
1655881|NCT01810419|Device|Conventional Ultrasound|Conventional Ultrasound used to determine spleen size and the other qualities described in the arm description.
1655882|NCT01810406|Procedure|CSE with 10 ml EVE|Combined Spinal-Epidural (CSE) with 10 ml Epidural Volume Extension (EVE)
1655883|NCT01810406|Procedure|CSE without EVE|Combined Spinal-Epidural (CSE) without Epidural Volume Extension (EVE)
1655884|NCT01810393|Drug|Trastuzumab|Trastuzumab will be administered at a dose of 6 milligrams per kilogram (mg/kg) IV or 600 milligrams per 5 milliliter (mg/5mL) SC in 21-day cycles as per schedule described in respective arm.
1655885|NCT01810380|Drug|Placebo|Once daily as tablets and capsules, orally
1655886|NCT01810380|Drug|Brexpiprazole|2-4 mg/day, once daily, tablets, orally
1655887|NCT01810380|Drug|Quetiapine extended release|400-800 mg/day, once daily, encapsulated tablets, orally
1655888|NCT01810367|Drug|ABX Combined With Cisplatin|
1655889|NCT01810367|Drug|Gemcitabine Combined With Cisplatin|
1655890|NCT01810354|Drug|Cefazolin|
1655893|NCT01810315|Drug|TFV 1% gel|
1655894|NCT01810315|Drug|Estradiol vaginal cream|
1655895|NCT01810302|Drug|Nicardipine hydrochloride|Nicardipine hydrochloride 4mg by intrathecal administration twice a day until post-hemorrhage day 10.
1655896|NCT01810302|Drug|Preservative-free normal saline|Preservative-free normal saline 1.6 mL by intrathecal administration twice a day until post-hemorrhage day 10.
1655946|NCT01809847|Drug|Ofatumumab|"Study treatment comprises eight weeks of induction therapy with ofatumumab in combination with high-dose dexamethasone. The first dose of ofatumumab is 300 mg followed by seven infusions of 2000 mg ofatumumab. Dexamethasone will be given orally at doses of 40 mg on days 1-4 in weeks 1, 3, 5, and 7. Patients who achieved a CR, PR shall proceed to maintenance therapy. Maintenance therapy consists of 6 monthly infusions of 1000 mg ofatumumab.
An HLA-matched sibling donor or HLA-matched unrelated donor can be identified for approximately 70% of patients. Donor search will be completed within six weeks for 95% of the patients. Patients with a donor will proceed to allogeneic HCT as soon as possible prior to, or during maintenance therapy."
1655897|NCT01810289|Behavioral|START|"INTERVENTION: START is clinic-level (not individual-patient) intervention to catalyze the process of ART initiation among HIV-infected adults who meet CD4-based criteria for combination ART (e.g., adults with a CD4 T cell level < 350/ul). The three START components are: (1) real-time point-of-care CD4 testing using the Alere PIMA platform to ascertain treatment eligibility in real time at first presentation to care, (2)targeted knowledge transfer(i.e., dissemination) of recent scientific evidence regarding effects rapid ART initiation on survival to front line health care workers; and 3)feedback and reporting to clinic and providers. There three components represent empirically validated steps in the PRECEED implementation model.
This intervention will be implemented at all Makerere Joint AIDS Program (MJAP) clinics in Kampala and Mbarara districts in a step-wedge design."
1655898|NCT01810276|Other|Saline|400 mL of Saline will be given intravenously over 2 hours once
1655899|NCT01810276|Other|Platelets|2 apheresis units of platelets (approximately 200 ml) will be given intravenously over 2 hours.
1655900|NCT01810263|Dietary Supplement|high protein supplement|Dietary Supplement: high protein supplement
1655901|NCT01810250|Device|Endurant Stent Graft|
1655902|NCT01810237|Drug|Dabigatran.|Dabigatran will be used instead of LMWH for anticoagulation bridging.
1655903|NCT01810224|Procedure|Surgical revascularization|The final intervention (surgical revascularization) will be the same for both arms.
1655904|NCT01810211|Other|Horizontal Adduction Stretch and Pendulums|
1655905|NCT01810211|Other|Modified Sleeper Stretch and Pendulum|
1655906|NCT01810198|Procedure|Cardiac CT|Perform a non-invasive Cardiac CT Angiogram
1655907|NCT01810198|Procedure|Invasive Coronary Angiography|Patient undergoes Invasive Coronary Angiography
1655908|NCT01810185|Drug|Low dose naltrexone|4.5 mg daily for 12 weeeks
1655909|NCT01810185|Drug|Placebo|
1655910|NCT01810172|Device|Digital pleural drainage system|Reusable device with disposable collection system for digital monitoring of air leak.
1655911|NCT01810172|Device|Dry suction pleura drainage device|Disposable dry suction operating system. Collects pleural fluid and monitors for air leak.
1655912|NCT01810159|Other|Integrated collaborative care|
1655913|NCT01810159|Other|Education and Resources|
1655914|NCT01810146|Other|Digestive functions investigations|
1655915|NCT01810120|Biological|TCR alfa beta T cell depletion|total nucleated cells from the leukapheresis product will undergo TCR alfa beta negative selection and the product of the depletion will be infused to the patient
1655916|NCT01810107|Procedure|Children Examined with the OCT Probe|The child undergoing therapy will have the Optical Coherence Tomography (OCT) probe to examine the vocal fold.
1655917|NCT01810094|Device|Fracture Fixation|Thoracolumbar Fracture Fixation
1655918|NCT01810068|Procedure|Holmium laser enucleation of the prostate|Laser assisted enucleation of the prostatic adenoma
1655919|NCT01810068|Procedure|Monopolar transurethral resection of the prostate|using the monopolar electrocautery to resect the prostate adenoma
1655920|NCT01810068|Procedure|Bipolar transurethral resection of the prostate|using the bipolar electrocautery to resect the prostate adenoma
1655921|NCT01810068|Procedure|Diagnostic cystoscopy|Cysto-urethroscopy
1655922|NCT01810042|Drug|ranibizumab|0.5mg of ranibizumab is injected into the vitreous cavity through pars plana.
1655923|NCT01810029|Behavioral|Cardiac Rehabilitation plus Transcendental Meditation|The stress reduction intervention, Transcendental Meditation program is added on to the standard cardiac rehabilitation programs for patients with documented coronary artery disease
1655924|NCT01810016|Biological|Ipilimumab|
1655925|NCT01810016|Biological|NY-ESO-1 Protein Vaccine|
1655926|NCT01810016|Biological|NY-ESO-1 OLP4 Vaccine|
1655927|NCT01810003|Dietary Supplement|High DHA|10 week supplementation period
1655928|NCT01810003|Dietary Supplement|High EPA|10 week supplementation period
1655929|NCT01810003|Dietary Supplement|Placebo|10 week supplementation period
1655930|NCT01809990|Behavioral|Internet-delivered Cognitive Behavior Therapy|
1655931|NCT01809977|Procedure|collagen cross-linking procedure (total removal)|patients underwent Corneal collagen cross-linking procedure with totally corneal epithelium removing. Total removal was performed by mechanical debridement of the corneal epithelium over the central 9 mm.
1655932|NCT01809977|Procedure|collagen cross-linking procedure (partial removal)|patients underwent Corneal collagen cross-linking procedure with partially corneal epithelium removing. Partial removal was performed by removing a 3-mm width ring and leaving the central 3 mm of the cornea intact.
1655933|NCT01809964|Biological|ANT-1401|
1655934|NCT01809964|Biological|Vehicle|
1655935|NCT01809938|Other|Black tea|300ml of tea without milk
1655936|NCT01809938|Other|Tea with milk|250ml of black tea with 50ml of full fat milk
1655937|NCT01809925|Dietary Supplement|psyllium fiber 6.8g|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
1655938|NCT01809925|Dietary Supplement|placebo|Subjects will drink their assigned test product as quickly as possible immediately before eating breakfast at each visit.
1655939|NCT01809912|Drug|Recombinant human apolipoprotein(a) Kringle V|
1655941|NCT01809886|Drug|Sugammadex|50 patients, aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with sugammadex 4 mg/kg when surgery is over, maintaining a profound block level until that point in time (no response to TOF and PTC<2).
1655942|NCT01809886|Drug|Neostigmine|50 patients aged between 2 and 11 years scheduled for surgery and requiring muscle relaxation. The reversal will be made with neostigmine 0. 05 mg/kg and atropine 0.025 mg/kg (conventional reverser treatment) when surgery is over, maintaining a profound block level unit that point in time (no response to TOF and PTC<2).
1655943|NCT01809873|Behavioral|Performance based incentives|Facilities enrolled in the intervention arm will receive a financial incentive that is based on their diagnosis and prescription practices for malaria over that quarter. The intervention will last 12 months.
1655944|NCT01809860|Drug|isavuconazole|Oral
1655945|NCT01809860|Drug|sirolimus|Oral
1655947|NCT01809834|Device|Etafilcon A|
1655948|NCT01809834|Device|Stenfilcon A|
1655956|NCT01809769|Biological|Mesenchymal stem cells high-dose group|Biological: Adipose tissue derived mesenchymal stem cells administrated for intra-articular use
1655957|NCT01809756|Other|Caphosol|Caphosol 4 times a day
1655958|NCT01809743|Drug|Regadenoson central -central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
1655959|NCT01809743|Drug|Regadenoson peripheral - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
1655960|NCT01809743|Drug|Regadenoson central - peripheral|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
1655961|NCT01809743|Drug|Regadenoson peripheral - central|To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).
1655962|NCT01809743|Drug|Adenosine|Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.
1655963|NCT01809717|Other|Weight Lifting Exercises|
1655964|NCT01809691|Drug|TAK-700|300 mg, PO, twice daily
1655965|NCT01809691|Drug|Bicalutamide|50 mg, PO, q daily
1655966|NCT01809678|Behavioral|Smoking Cessation|Once weekly program of cognitive-behavioral therapy for smoking cessation
1655967|NCT01809678|Behavioral|Yoga|Twice weekly program of 1-hour Iyengar yoga classes
1655968|NCT01809678|Other|Wellness|Twice weekly program of 1-hour wellness classes on a variety of health topics.
1655969|NCT01809665|Device|ICD/CRT-P therapy|
1655970|NCT01809665|Other|MRI|
1655971|NCT01809652|Other|Remote Implant Support Capability|Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
1655972|NCT01809639|Drug|Progesterone|
1655973|NCT01809639|Drug|Placebo|Standard placebo
1655974|NCT01809626|Drug|Zolpidem|
1655975|NCT01809626|Other|Placebo|
1655976|NCT01809613|Procedure|Functional Magnetic Resonance Imaging (fMRI)|During the deep brain stimulation (DBS) surgery of the subthalamic nucleus within the thalamocortical basal ganglion, an additional lead extendor will be connected to the DBS electrode to allow externalization of the lead. Following confirmation of electrode location with MRI, a series of fMRI scans will be run. Total scanning time will be limited to 35 minutes.
1655977|NCT01809600|Other|No intervention (observational study)|
1655978|NCT01809587|Device|IQP-PO-101|
1655979|NCT01809561|Procedure|tissue biopsy during surgical treatment|The samples collected will test for histological diagnosis of endometriosis and verification tests will be done to characterize the telomeres array and telomerase levels and other characteristics for genomic instability such as spontaneous aneuploidy.
1655980|NCT01809548|Other|Early intervention group|solid food will be introduced between week 10 and 12
1655981|NCT01809548|Other|Late intervention group|solid food is introduced between 16-18th week of gestation corrected for prematurity
1655982|NCT01809535|Device|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Monthly group were received EVL at 28-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
1655983|NCT01809535|Device|Wilson-Cook four shooter saeed multi-band ligator|Patients in the Biweekly group were received EVL at 14-day treatment intervals.Orally 20 mg of rabeprazole (Pariet®) once a day for 2 weeks was given to hasten post-EVL ulcer healing in each treatment session. Once esophageal varices were obliterated, surveillance endoscopy was done every 3 months for one year, then every 6 months to check for recurrent varices.
1655984|NCT01809522|Procedure|Posterior reconstruction of the rhabdosphincter|
1655985|NCT01809509|Procedure|Endometrial biopsy|
1655986|NCT01809496|Behavioral|Informational Counseling|
1655987|NCT01809496|Behavioral|Patient Centered Counseling|
1655993|NCT01809457|Other|educational poster|educational poster for dental trauma
1655994|NCT01809444|Drug|Prednisone+placebo of Doxycycline|Prednisone: 50 mg/d for 14 day, tailed by 40 mg/d for 14 day, 30 mg/d for 28 day, 20 mg/d for 28 day, 15 mg/d for 14 day, 10 mg/d for 14 day, in total 16 weeks; Placebo of doxycycline: administered for 16 weeks
1655995|NCT01809444|Drug|Doxycycline+placebo of Prednisone|Doxycycline: 50 mg PO per day for 12 weeks, and placebo for another 4 weeks; Placebo of prednisone: administered for 16 weeks.
1655996|NCT01809431|Behavioral|Intervention|Using a two-group, repeated measures experimental design, this proposed study will test a 14-week intensive intervention on the benefits of breastfeeding, understanding gestational diabetes and risk of progression to prediabetes and type 2 diabetes, nutrition and exercise education, coping skills training, and physical activity (Phase I) and 3 months of continued monthly contact (Phase II) to help overweight women diagnosed with gestational diabetes improve metabolic, clinical, weight, adiposity, health behaviors and self-efficacy.
1655997|NCT01809418|Device|keePAP|
1655998|NCT01809392|Drug|decitabine|36 mg/m2 on day 42 after transplantation and administered daily for 5 consecutive days every 28 days for up to a total of 10 cycles
1655999|NCT01809379|Drug|chemotherapy with doxorubicin and cisplatin|intraperitoneal chemotherapy applied as an aerosol and under pressure
1656000|NCT01809366|Procedure|seminal plasma insemination|
1656001|NCT01809353|Drug|JNJ-54452840|Single intravenous (medication is injected into a vein) doses of 20 mg, 80 mg, and 240 mg
1656003|NCT01809340|Drug|Minocycline|In the 12-day open-label treatment phase, patients will self administer oral minocycline 200 mg on Day 1, 100 mg twice daily on Days 2 to 11, and 100 mg on the morning of Day 12. In the 6-week blinded treatment phase, responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first. In the 6-week open-label treatment phase, non-responders may self administer oral minocycline 100 mg twice daily from the evening of Day 12 for up to 6 weeks (Day 54).
1656004|NCT01809340|Drug|Placebo|Patients in the 6-week blinded treatment phase, may self administer placebo twice daily from the evening of Day 12 for up to 6 weeks (Day 54), or until relapse, whichever comes first.
1656005|NCT01809340|Drug|Ketamine|In the 12-day open-label treatment phase, all patients will receive 1 IV infusion of 0.5 mg/kg ketamine over 40 minutes on Days 1, 3, 5, 8, 10 and 12.
1656006|NCT01809327|Drug|Canagliflozin 100 mg|One 100 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 100 mg arm) or with the evening meal (for the Canagliflozin 100 mg + Metformin XR arm).
1656007|NCT01809327|Drug|Canagliflozin 300 mg|One 300 mg capsule taken orally (by mouth) once daily either before the morning meal (for the Canagliflozin 300 mg arm) or with the evening meal (for the Canagliflozin 300 mg + Metformin XR arm).
1656008|NCT01809327|Drug|Metformin XR|One 500 mg tablet (Day 1 up to week 1); two 500 mg tablets (Week 1 up to Week 3); three 500 mg tablets (Week 3 to Week 6); four 500 mg tablets (Week 6 to Week 9). Tablets will be administered with the evening meal.
1656009|NCT01809314|Drug|Epoetin beta|Treatment will be given according to standard of care and the Summary of Product Characteristics during the study.
1656010|NCT01809301|Drug|Niaspan|
1656011|NCT01809301|Drug|TRIA-662|
1656012|NCT01809275|Drug|QBECO|
1656013|NCT01809275|Drug|Placebo|
1656014|NCT01809262|Drug|single dose of 5 mcg|solution for inhalation
1656015|NCT01809262|Drug|single dose of placebo|solution for inhalation
1656016|NCT01809262|Drug|single dose of 40 mcg|solution for inhalation
1656017|NCT01809262|Drug|single dose of 20 mcg|solution for inhalation
1656018|NCT01809262|Drug|single dose of 2 mcg|solution for inhalation
1656019|NCT01809262|Drug|single dose of 10 mcg|solution for inhalation
1656020|NCT01809236|Biological|Conbercept|intravitreal injection of 0.5 mg Conbercept
1656021|NCT01809223|Drug|conbercept, Fixed|intravitreal injection of 0.5 mg conbercept per month, fixed injection
1656022|NCT01809223|Drug|conbercept, PRN|intravitreal injection of 0.5 mg conbercept as need, PRN
1656023|NCT01809223|Other|sham injection|sham intravitreal injection per month, fixed injection
2013155|NCT00949234|Drug|tenofovir + emtricitabine, lopinavir/ritonavir|"The preferred regimen will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a creatinine clearance 30-49 mL/min, dosing of Truvada is 1 tablet by mouth every other day. For patients with creatinine clearance <30 mL/min or on hemodialysis, Truvada should not be used. For intolerance to Truvada, Combivir (zidovudine 300mg/lamivudine 150mg)will be available to be taken as 1 PO BID. For highest-risk category exposures (receptive anal intercourse with a known or suspected HIV-positive source patient or in cases of suspected source drug resistance, see Schema, below) one of the following should be added to the above standard treatment, creating an expanded regimen:
Preferred: Lopinavir/ritonavir (200mg/50mg), 2 tablets orally twice daily or 4 tablets once daily"
2013156|NCT00942331|Biological|Bevacizumab|Given IV
2013157|NCT00942331|Drug|Cisplatin|Given IV
2013158|NCT00942331|Drug|Gemcitabine Hydrochloride|Given IV
2013159|NCT00942331|Other|Laboratory Biomarker Analysis|Correlative studies
1656029|NCT01809197|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
1656030|NCT01809197|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses for near/far-sightedness, astigmatism, and/or presbyopia, replaced per manufacturer's instructions
1656031|NCT01809197|Device|OPTI-FREE PureMoist Multi-Purpose Disinfecting Solution (MPDS)|Multi-purpose disinfecting solution for contact lens care, used per manufacturer's instructions
1656032|NCT01809197|Device|Habitual Multi-Purpose Solution (MPS)|Multi-purpose solution for contact lens care according to subject's habitual brand, used per manufacturer's instructions
1656033|NCT01809184|Drug|insulin 287|Orally administered insulin 287. The subjects will be dosed in the fasting state and receive one single dose followed by a 24-hour euglycaemic glucose clamp.
1656034|NCT01809184|Drug|insulin glargine|Insulin glargine administered subcutaneously (s.c., under the skin) at fixed dose levels.
1656035|NCT01809184|Drug|placebo|Oral placebo adminstered corresponding to insulin 287 treatment
1656036|NCT01809171|Drug|Vitamin D3|ampoule
1656037|NCT01809171|Drug|Placebo|ampoule
1656038|NCT01809158|Drug|minocycline|
1656039|NCT01809158|Drug|placebo|
1656040|NCT01809145|Other|MELISA test|MELISA test for hypersensitivity to metals in sarcoidosis
1656041|NCT01809132|Drug|Anakinra|Anakinra, interleukin-1 receptor antagonist; 100 mg/0.67 mL solution for subcutaneous injection.
1656042|NCT01809132|Drug|Pentoxifylline|Pentoxifylline, generic
1656043|NCT01809132|Drug|Zinc Sulfate|Zinc Sulfate, nutritional supplement
1656044|NCT01809132|Drug|Methylprednisolone|Methylprednisolone, corticosteroid
1656045|NCT01809119|Procedure|Partial nephrectomy|
1656046|NCT01809106|Drug|Morphine|60 mg /24 ore
1656047|NCT01809106|Drug|Fentanyl|25 microg/h
1656048|NCT01809106|Drug|Buprenorphine|35 microg/h
1656049|NCT01809106|Drug|Oxycodone|40 mg /24 ore
1656050|NCT01809093|Biological|Blood draw|3-4 tablespoons of blood will be drawn, one time.
1656051|NCT01809067|Other|Lavender aromatherapy inhalers|Patients will self-administer lavender aromatherapy from hand held inhalers containing lavender essential oil.
1656052|NCT01809054|Drug|Arixtra|
1656053|NCT01809054|Device|Pneumatic compression stockings|Pneumatic compression stockings (MCS, Active Care, medical compression systems Inc., Israel)
1656054|NCT01809054|Drug|Aspirin|
1656055|NCT01809041|Drug|Sevoflurane|
1656056|NCT01809041|Drug|propofol|
1656057|NCT01809041|Drug|remifentanil|
1656058|NCT01809028|Procedure|EUS FNA with 2 passes|biopsy with 2 passes
1656059|NCT01809028|Procedure|EUS FNA with 4 passes|biopsy with 4 passes
1656060|NCT01809002|Biological|Processed Nerve Allograft (human)|
1656061|NCT01809002|Device|Collagen Nerve Cuff|Bovine collagen based nerve cuff
1656062|NCT01808989|Other|Exercise oxymetry|
1656063|NCT01808976|Other|Problem Solving Therapy|this is a mobile app that participants use to solve problems. It will guide participants through a stepwise process for identifying a means for creating action plans.
1656064|NCT01808976|Behavioral|Evolution|This is a therapeutic video game that targets the cognitive control network, associated with depression. Participants are expected to play the game daily for 20 minutes over 4 weeks.
1656065|NCT01808976|Behavioral|Basic health push app|This is an app that send daily tips for improving your mood.
1656066|NCT01808950|Drug|0.06% Resiquimod Gel - A|single 60mg dose
1656067|NCT01808950|Drug|0.06% Resiquimod Gel - B|single 100mg dose
1656068|NCT01808950|Drug|0.06% Resiquimod Gel - C|shave biopsy of BCC followed by single 100mg dose
1656069|NCT01808937|Other|Morphea|
1656070|NCT01808911|Drug|Steroid + cyclophosphamide|
1656071|NCT01808911|Drug|Steroid + rituximab|
1656072|NCT01808898|Procedure|Local Anaesthetic|On the day of the procedure and before the patients are treated, a designated clinician will draw up the local anaesthetic (2mls consisting of 1ml of 3% mepivacaine (short / medium acting) and 1ml of 0.5% bupivacaine (long acting)
1656073|NCT01808885|Drug|olesoxime (TRO19622)|"olesoxime (3 caps: 495 mg, od) will be administered orally as 165 mg soft capsules for 6 months.
Investigational products will be allocated in a 1:1 ratio from Baseline/Visit 0 to Week 24 (Visit 3/Final Visit)."
1656074|NCT01808885|Drug|placebo|placebo capsule shells with identical appearance as the active compound TRO19622
1656075|NCT01808859|Device|Tourniquet|hyperbaric bupivacaine 12.5-15 mg Celecoxib 400 mg and paracetamol 1 g will be given preoperatively. Postoperatively celecoxib 200 mg x 2 and paracetamol 1 g/6 h is given is given for 2 weeks.
1656076|NCT01808820|Biological|Dendritic Cell Vaccine|Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
1656077|NCT01808820|Biological|Tumor Lysate|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
1656078|NCT01808820|Other|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
1656079|NCT01808820|Procedure|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
1656080|NCT01808794|Device|Mucograft|Mucograft Collagen Matrix
1656081|NCT01808794|Device|Dynamatrix|Dynamatrix
2013160|NCT00942331|Other|Placebo|Given IV
2013161|NCT00932854|Procedure|EBUS|Endobronchial ultrasound guided transbronchial needle aspiration will be performed under conscious sedation and as an outpatient procedure. Additional bronchoscopy, transbronchial biopsies and bronchoalveolar lavage will be performed at the investigator's discretion.
2013162|NCT00924027|Radiation|Brachytherapy|Brachytherapy, the placement of a radioactive source close to a tumor, is a well-established part of the treatment of many malignancies, both for palliative and definitive applications. High dose brachytherapy is useful in many malignancies in order to deliver a high dose of radiation therapy to tumor in a conformal fashion with a rapid dose fall-off with the objective of sparing normal surrounding tissue.
1656085|NCT01808755|Dietary Supplement|D Mannose|1 gr. every 8 hours
1656086|NCT01808755|Drug|trimethoprim/sulfamethoxazole|one cp b.i.d. for 5 days. Then one week of antibiotic every 4 weeks for the following 23 weeks
1656087|NCT01808742|Device|Treatment with CryoTouch III Device|Bilateral forehead treatment with CryoTouch III device on the temporal branch of the facial nerve. Subject will be treated once and may be retreated up to 7 days after initial treatment.
1656088|NCT01808716|Device|Low-level laser therapy (808nm) and exercise|Use of low-level laser therapy(LLLT)or placebo-LLLT applied on biceps brachii for muscle damage recovery
1656089|NCT01808703|Device|PeriZone PerioPatch|The PeriZone PerioPatch is an approved barrier or device product intended for the management of all types of oral wounds, injuries and ulcerations of the gingival and oral mucosa (510K number K103054). PerioPatch devices will be applied adjunctively following scaling and root planing).
1656090|NCT01808703|Procedure|Scaling and root planing alone|Following completion of the Baseline examination, all randomized patients will receive full mouth scaling and root planing at a maximum of two visits within a 14-day time period (Weeks -2 to 0). Use of hand curettes and/or ultrasonic instruments will be permitted. Local or topical anesthesia may be used for patient comfort at the discretion of the clinician performing the scaling and root planing.
1656091|NCT01808690|Drug|Metformin|
1656092|NCT01808690|Drug|Placebo|
1656093|NCT01808677|Other|Thoracic Reirradiation Registry|Data collected in the registry includes patient characteristics/demographics, disease characteristics, treatment details (radiation, chemotherapy, surgery, etc.), toxicity rates, and survival outcomes.
1656094|NCT01808664|Behavioral|Standardized Patient Instructor Intervention|"In each case, patients will harbor underlying concerns about a serious underlying condition (e.g., either disc herniation or osteoporosis) and will request inappropriate tests. Standardized patient instructors (SPIs) will portray new patients visiting the clinic for the first time, and electronic medical records will be identical to that of actual new patients.
During the initial part of intervention visits, SPIs will assess the extent to which PCPs engage in patient-centered techniques specified in the final intervention model. SPIs will then break of their role and either teach or reinforce PCP use of the techniques, presenting techniques in a logical sequence while emphasizing flexibility in their use. SPIs will use scripts to deliver the interventions, providing opportunities for PCPs to ask questions, discuss concepts, and practice (by role playing) patient-centered techniques."
2013163|NCT00921388|Other|Varenicline and smoking cessation counseling|All subjects receive smoking cessation counseling and varenicline 0.5mg daily for three days then twice a day for the next four days; then 1 mg twice a day for 11 weeks. Counseling is integrated within the exercise or relaxation treatment program.
1656095|NCT01808664|Behavioral|Control|"In the latter half of visits with control PCPs, standardized patient instructors will share information with physicians regarding the acute low back pain self-care and bone health, but will not discuss patient-centered techniques or conduct training. The total duration of the control information sharing will be about one-third the SPI intervention to enhance patient-centeredness."
1656096|NCT01808651|Drug|Fluoxetine|Administered orally
1656097|NCT01808638|Drug|Atu027 & gemcitabine in lead in safety period|Subjects will be treated in a 28-day cycle with Atu027 twice weekly for 4 weeks and gemcitabine once weekly for the first three weeks.
1656098|NCT01808638|Drug|Atu027 & gemcitabine in treatment arm 1|"Subjects will be treated in a 28-day cycle with Atu027 and gemcitabine once weekly for three consecutive weeks (on days 1, 8, and 15). During week four no treatment is administered.
Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
1656099|NCT01808638|Drug|Atu027 & gemcitabine in treatment arm 2|"Subjects will be treated in a 28-day cycle with gemcitabine once weekly (on days 4, 11, and 18) and Atu027 twice weekly (on days 1, 4, 8, 11, 15, 18, 22, and 25). The 28-day combination cycle is followed by a 28-day gemcitabine monotherapy cycle.
Treatment will be continued in consecutive 28-day cycles until unacceptable toxicity or disease progression occurs."
1656100|NCT01808625|Other|HYPERBARIC OXYGEN STIMULATION|30 daily sessions, 6 days a week of 90 min exposure to 100% oxygen at 2 ATA.
1656101|NCT01808612|Drug|Fluoxetine|
1656102|NCT01808612|Drug|Placebo|
1656103|NCT01808599|Drug|Chlorambucil|
1656104|NCT01808599|Drug|Rituximab i.v.|
1656105|NCT01808599|Drug|Rituximab s.c.|
1656106|NCT01808586|Procedure|Betamethasone|6 mg/mL injected into the facet joint as dictated by modified dual-comparative medial branch block diagnostic protocol
1656107|NCT01808586|Procedure|Dexamethasone|4mg/mL
1656108|NCT01808586|Procedure|Intramuscular Lidocaine|2%
1656109|NCT01808586|Behavioral|Home Exercise|Standardized home exercise program
1656114|NCT01808560|Device|LipiFlow Pre-Treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
1656115|NCT01808560|Device|LipiFlow Post-treatment|The LipiFlow Thermal Pulsation System is intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
1656116|NCT01808547|Drug|ISV-303|0.075% bromfenac in DuraSite dosed BID
1656117|NCT01808547|Other|DuraSite Vehicle|DuraSite vehicle dosed BID
1656118|NCT01808534|Drug|palifosfamide|Given IV
1656119|NCT01808521|Drug|N-Acetylcysteine|IV administration of N-Acetylcysteine at 150mg/kg over 60 min first, then if well tolerated, 150mb/kg over 17 hours
1656120|NCT01808508|Device|Continuous positive airway pressure|Continuous positive airway pressure is a machine used with sleep which compresses air delivered via a nasal mask and thus helps stent the airway open.
1656121|NCT01808508|Device|Sham or placebo continuous positive airway pressure|Sham or placebo CPAP is a machine used instead of therapeutic CPAP. This machine is similar to a therapeutic CPAP machine but has built in leaks and does not deliver pressure. It is not effective in treating OSAS.
1656122|NCT01808495|Drug|Mitomycin C|
1656123|NCT01808482|Drug|Part A: 100 mg/mL GSK2618960|100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
1656124|NCT01808482|Drug|Part A: matching placebo|Matching placebo
1656125|NCT01808482|Drug|Part B: Dose of GSK2618960 decided from Part A|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
1656126|NCT01808482|Drug|Part B: matching placebo|Matching placebo
1656127|NCT01808482|Drug|Part C: Dose of GSK2618960 decided from Part A and B|100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
1656128|NCT01808469|Biological|Monoclonal antibody|
1656129|NCT01808456|Biological|influenza trivalent inactive vaccine|one time IM injection of standard influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
1656130|NCT01808456|Biological|influenza trivalent inactive vaccine high dose|one time IM injection of high dose influenza vaccine to measure immunogenicity, safety, and efficacy in organ transplant recipients
1656131|NCT01808443|Other|Cryotherapy|up to a maximum of four treatments every 21-28 days
1656132|NCT01808443|Other|laser|up to a maximum of four treatments every 21-28 days
1656133|NCT01808430|Procedure|VATS for confirmed non-small cell lung cancer (NSCLC)|Video-Assisted Thoracoscopic Surgery for NSCLC patients
1656134|NCT01808417|Drug|Near Infrared Imaging|The intervention to be administered is the drug indocyanine green.
1656135|NCT01808404|Behavioral|Web-Based Guided Self-Help|"The intervention will involve counselors using the web-based guided self-help program with their student clients. Counselors will complete a web-based training followed by a period of time in which they will monitor and guide students in completing the program. Students will access a series of three web-based lessons in which they will receive an intervention based on Acceptance and Commitment Therapy (ACT) focused on personal values, acceptance of difficult emotions, and mindfulness."
1656136|NCT01808378|Drug|Expanded adipose-derived stem cells|Local injection of autologousadipose derived stem cells
1656427|NCT01805999|Dietary Supplement|7 g Ispaghula|
1656139|NCT01808352|Drug|FTC/TDF|All participants will be offered once daily oral emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (FTC/TDF) combined with C4.
1656140|NCT01808339|Drug|Fluticasone Furoate (FF)|Inhalation powder 100 microgram per blister strip to be administered via dry powder inhaler either in the morning (AM dose with FF and PM dose with +/-2 days).
1656141|NCT01808339|Drug|Placebo|Placebo in single strip to be administered via dry powder inhaler in the morning and evening for 14 days (+/- 2 days).
1656142|NCT01808326|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
1656143|NCT01808313|Drug|ambrisentan|Ambrisentan 5 mg will be administered to eligible subjects for 12 weeks
1656144|NCT01808300|Drug|Pregabalin 300mg, Thioctic acid 600mg|"A: Pregabalin - Pregabalin 300mg will be administered orally twice a day for 3 days
B: Thioctic acid - Thioctic acid 600mg will be administered orally once a day for 3 days
C: Pregabalin plus Thioctic acid - Pregabalin plus Thioctic acid same way as A and B"
1656145|NCT01808287|Device|Edwards SAPIEN 3 Transcatheter Heart Valve|The Edwards SAPIEN 3 Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (intermediate or higher operable risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
1656146|NCT01808274|Device|Edwards CENTERA Self-Expanding Transcatheter Heart Valve|The Edwards CENTERA Transcatheter Heart Valve (THV) System is indicated for use in symptomatic patients (high surgical risk) with severe aortic stenosis requiring aortic valve replacement (AVR).
1656147|NCT01808261|Drug|GSK249320 100/mg|Clear to opalescent, colorless to pale yellow or pale brown, and is supplied as a sterile, concentrated solution (1000mg/vial). GSK249320 is for IV use only.
1656148|NCT01808261|Drug|Placebo|Placebo is a clear, colorless solution (50mM acetate buffer, pH 5.5 containing 0.02% (w/v) polysorbate-80 and made isotonic with 111.2 mM sodium chloride). Placebo is for intravenous (IV) use only.
1656149|NCT01808248|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
1656150|NCT01808248|Drug|PEG|Peginterferon alfa 2a (PEG) 180 μg administered once weekly by subcutaneous injection
1656151|NCT01808248|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1656152|NCT01808235|Behavioral|Oral Health Intervention|The dental hygienist will assess the IMD's tooth brushing technique and will provide specific feedback on the tooth brushing technique, including areas of the dentition missed in brushing. The IMDs will be given a powered toothbrush that records time, date and duration of toothbrushing activity, along with the direction and extent of motion of the toothbrushing activity. In addition, use of interdental cleaning aids will be recommended. The dental hygienist will review the findings from the oral health evaluation with the IMDs and caregivers, and provide detailed feedback on treatment and prevention of the oral health conditions and symptoms. The dental hygienist or study coordinator will call subjects by telephone biweekly to monitor oral hygiene practices and to provide coaching, if needed. Oral hygiene technique assessments will be conducted again three months after the first visit, and once more three months later, at the end of the intervention.
1656153|NCT01808222|Drug|FACBC|
1656154|NCT01808209|Device|stenfilcon A|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
1656155|NCT01808209|Device|filcon II 3|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
1656156|NCT01808196|Drug|Losartan Potassium|The medication dosage for Losartan will change throughout this study slowly increasing to a larger amount. You will start the study drug at a low dose. It will be increased at Visit 3/Week 4, unless you have certain side effects. The dose of study drug will be increased depending on your weight and how well you tolerate each dose and will not exceed 100mg of study drug. It may be increased or decreased during the study if there are any side effects.
1656157|NCT01808183|Device|Near Infrared Spectroscopy Pads|NIRS pads are commonly used as a noninvasive method of assessing deep tissue perfusion, originally designed to assess cerebral perfusion during anesthesia.
1656158|NCT01808170|Procedure|Laparoscopic ovarian cystectomy|will be performed using video control under general anesthesia, pneumoperitoneum is induced by carbon dioxide, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection.after a cleavage plane between the cyst wall and ovarian cortex is identified, the ovaries are pulled slowly and gently in opposite directions by means of two a traumatic grasping forceps. After removing the pseudo capsule from the abdominal cavity, selective minimal (15 watt) bipolar coagulation of bleeding is performed, without excessive coagulation of the surgical defect to avoid damaging the ovary.
1656159|NCT01808170|Procedure|laparoscopic cyst deroofing|will be performed using video control under general anesthesia, pneumoperitoneum is induced by CO2, with three 5-mm trocars in the lower abdomen and a 10-mm intraumbilical main trocar, and we will use 5-mm scissors and graspers, and Ringer's lactate solution for irrigation. Before initiating ovarian surgery, the ovaries are completely freed with obtuse and sharp dissection. after mobilizing the ovary, the contents of the cyst is removed with the suction-irrigator probe and the cavity is irrigated. The inside of the cyst is evaluated and the portion of ovarian cortex involved with endometriosis is removed. Small blood vessels from the ovarian bed and bleeding from the ovarian hilum can be controlled with bipolar electro coagulation (15 watt). Low-power bipolar coagulation applied to the inside wall of the redundant ovarian capsule
1656160|NCT01808157|Drug|CT327 ointment|
1656161|NCT01808157|Drug|placebo|
1656166|NCT01808118|Biological|adalimumab|40 mg every other week
1656167|NCT01808118|Biological|Placebo|every other week
1656168|NCT01808105|Other|Control Formula|Feeding ad libitum
1656169|NCT01808105|Other|Experimental Formula 1|Feeding ad libitum
1656170|NCT01808105|Other|Experimental Formula 2|Feeding ad libitum
1656171|NCT01808105|Other|Human Milk|Feeding ad libitum
1718210|NCT00002461|Drug|etoposide|
1656172|NCT01808092|Drug|ceftazidim-avibactam (CAZ-AVI, experimental product)|2000mg ceftazidime plus 500mg avibactam
1656173|NCT01808092|Drug|meropenem (active comparator)|1000mg of Meropenem
1656174|NCT01808079|Other|Laboratory Biomarker Analysis|Correlative studies
1656175|NCT01808066|Device|Groundskeeper|Groundskeeper is a product developed for helping players develop skills to increase focus and attention. The game is played on small Sifteo Cubes that have sensors that react to you and each other. There are new games that might help children with ADHD and Autism learn to better focus and keep attention on a task.
1656176|NCT01808053|Device|BodyGuardian remote health monitoring system|The remote health management system connects personal health sensors with secure mobile communication devices. It is also able to give immediate feedback to the user. The solution is a multi-tiered mobile health platform. The front-end includes an adhesive snap-strip body sensor (BodyGuardian) that can measure HR, ECG, respiration rate (RR), and activity which is FDA approved for detection of non-lethal cardiac arrhythmias. It can wirelessly communicate with off-body sensors such as a BP cuff and scale to incorporate BP and weight data based on automated algorithms and can solicit symptoms from the user. It can also be used as an event recorder inputting symptoms and recording simultaneous physiologic data.
1656177|NCT01808040|Drug|TAK700|dose is dependant on dose escalation timepoint and dose expansion cohort dose will be the RP2D determined based on the dose escalation cohort final dose recommendation
1656178|NCT01808014|Drug|nefopam|The chief investigator prepared the medications according to the selected randomized table, and investigators who were not involved in medication preparation recorded the pain and prevalence of complications in study subjects. The double-blind restriction was lifted if the patient withdrew from the study, and the next patient was classified into a group while blinded by using the randomized table.Intramuscular midazolam 0.05 mg/kg was administered as a premedication, and then a blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room.
1656179|NCT01807988|Behavioral|iCBT|Internetbased cognitive behavior therapy (iCBT) contains interventions that will help the participant to change her behavior to experience more positive reinforcement in daily life and also to challenge her negative patterns of thought. There are also information and exercices to improve sleep, increase physical activity, train mindfulness, handle anxiety and to learn about depression.
1656180|NCT01807975|Other|Forced oscillation|
1656181|NCT01807962|Drug|rapidocain and bethametsaone|"lidocaine (Rapidocain(R)): 4ml of 1% Lidocaine
bethametasone (Diprophos): 1ml ampoule (containing 5mg/ml dipropionate de betamethasone and 2mg/ml phosphate disodique de betamethasone)"
1656182|NCT01807962|Drug|sterile saline|Placebo = 5ml of sterile saline solution
1656183|NCT01807949|Drug|Placebo|Matching placebo tablet
1656184|NCT01807949|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
1656185|NCT01807949|Drug|Ivacaftor|Film-coated tablet
1656186|NCT01807936|Procedure|Lymphadenectomy|
1656187|NCT01807923|Drug|Lumacaftor Plus Ivacaftor Combination|Fixed dose combination tablet
1656188|NCT01807923|Drug|Ivacaftor|Film-coated tablet
1656189|NCT01807923|Drug|Placebo|Matching placebo tablet
1656190|NCT01807910|Drug|methyl-D9-choline|Subjects in both arms will be infused with methyl-D9-choline in order to assess the biosynthesis and kinetics of secretory lipoprotein phospholipids.
1656191|NCT01807897|Device|Continuous positive airway pressure|Nocturnal continuous positive airway pressure, titrated to minimize apnea-hypopnea index
1656192|NCT01807897|Device|Nocturnal supplemental oxygen|Nocturnal supplemental oxygen, titrated to 2-4 liters/minute with target of eliminating nocturnal hypoxemia
1656193|NCT01807897|Behavioral|Healthy Lifestyle and Sleep Education|A 60-minute educational intervention with slide show and printed materials, educating the patient in healthy sleep habits and heart-healthy lifestyle
1656194|NCT01807884|Procedure|Optimized oral care|An optimization of the oropharyngeal suction procedure will include use of a subglottic drainage in a specified order: 1. subglottic suction, 1.oral suction followed by mouth care 3. subglottic suction 4. tracheal suction
1656195|NCT01807884|Other|Routine oral care|Oral suction followed by mouth care and tracheal suction without any subglottic suction
2013164|NCT00921388|Behavioral|Exercise or relaxation treatment|One hour exercise sessions twice a week for 8 weeks, then once a week for 8 weeks, then once every other week for 4 weeks. Subjects in the control group receive a relaxation program that controls for contact time.
2013165|NCT00918645|Drug|41 Ca|single oral 1.2 microgram dose of 41Ca; the first two recruited study subjects will also receive an oral dose of stable calcium isotope (46Ca) to compare initial kinetics with prior work.
2013166|NCT00918723|Drug|Fludarabine Phosphate|Given IV
2013167|NCT00918723|Drug|Cyclophosphamide|Given IV
2013168|NCT00918723|Biological|Rituximab|Given IV
2013169|NCT00918723|Drug|Vorinostat|Given PO
1656202|NCT01807845|Dietary Supplement|enriched skimmilk with VD|enriched skimmilk with VD
1656203|NCT01807845|Dietary Supplement|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80|Skimmilk enriched with VD wherein the VD will be emulsified using Tween 80
1656204|NCT01807845|Dietary Supplement|Placebo: un-enriched skimmilk.|Placebo: un-enriched skimmilk
1656205|NCT01807832|Other|capsaicin challenge|
1656206|NCT01807819|Other|Heart Failure|Patients will undergo echocardiogram and exercise testing. Two year phone follow-up.
1656207|NCT01807806|Behavioral|Role-playing game|Eligible participants will be invited to engage with a role-playing game for 30 minutes. The role play presents situations where a service member/veteran interacts with family or friends.
1656208|NCT01807793|Behavioral|Psychoeducation|
1656209|NCT01807780|Biological|biological monitoring|
1656210|NCT01807767|Drug|Everolimus, Myfortic and Tacrolimus|"Tacrolimus discontinued (within 8 weeks of initiation of everolimus conversion).
Everolimus 1mg BID started (targeted trough 6-12ng/mL). Patients must have an everolimus concentration between 6-12ng/mL before tacrolimus is discontinued.
Myfortic 360-720 mg BID"
1656211|NCT01807767|Drug|Myfortic and Tacrolimus|Myfortic BID 360-720 mg Tacrolimus (5-12ng/mL)
1656428|NCT01805999|Dietary Supplement|7 g placebo|
2013170|NCT00915681|Drug|Silibinin|20 mg/kg/day IV
2013171|NCT00908154|Drug|Placebo|Tablets to match GSK1014802
2013172|NCT00908154|Drug|GSK1014802|Sodium channel blocker
1656212|NCT01807754|Procedure|X-ray and ultrasound imaging scanning|Digital tomosynthesis mammogram uses a low radiation dose, taking x-ray pictures of the breast from many angles to make a 3D(dimensional)image. The participant will be seated and her breast positioned as in a normal mammogram, though with reduced pressure. The x-ray tube will move quickly above the breast to take the images. Then, an ultrasound scan will be done using gel on your breast to assist in acquiring quality imaging.
1656213|NCT01807754|Procedure|Photoacoustic imaging scans for breast cancer screening|The participant will be seated in front of the laser device with the breast positioned on the laser device platform. Each subject will be given a laser protective eye mask/goggles to wear and will be instructed how to wear the mask/goggles during the scan. In addition pulse monitor leads may be placed on the participant's chest to allow the computer to record ultrasound blood flow in the breast. The low intensity laser light will be focused on the targeted area of the breast.
1656214|NCT01807741|Drug|Asenapine|Available in 5 and 10 mg.
1656215|NCT01807741|Drug|Placebo|
1656218|NCT01807715|Other|survey|Survey before procedure to obtain demographic information and contraceptive information
1656219|NCT01807702|Drug|13C-Pyruvate 13C-lactate and dichloroacetate|Subjects will receive pyruvate and have blood,CO2, and buccal cell samples collected. The second visit the subjects will receive a dose of dichloroacetate before the pyruvate is given
1656220|NCT01807676|Device|ET View Double Lumen Tube|
1656221|NCT01807676|Device|conventional Double Lumen Tube|
1656222|NCT01807663|Device|healthy volonteers|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
1656223|NCT01807663|Device|Free breath monitoring|Monitoring respiratory function of both acute and chronic neuromuscular patients during weaning or free breath period.
1656226|NCT01807637|Device|transcranial direct current stim|tDCS will be applied using a Life-Tech®, Iontophor PM Deluxe constant current stimulator with carbon rubber electrodes encased in saline (0.9% NaCl) soaked sponges that measure 5 x 5 cm (25cm2) for the anode and 5x7 for the cathode (35cm2). The anodal electrode will be placed over the lower extremity representation of primary motor cortex of the lesioned hemisphere. The cathodal electrode will be placed over the contralateral supraorbital region.
1656227|NCT01807624|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|1 spray is 0.2mL is volume and contains 6mg Tetracaine HCl 3% and 0.1mg Oxymetazoline HCl (para-butylaminobenzoic acid or PABA is active metabolite)
1656228|NCT01807611|Radiation|Total Lymphoid Irradiation|Participants receive total lymphoid irradiation over four doses.
1656229|NCT01807611|Drug|Fludarabine|Given IV.
1656230|NCT01807611|Drug|Cyclophosphamide|Given IV.
1656231|NCT01807611|Drug|Thiotepa|Given IV.
1656232|NCT01807611|Drug|Melphalan|Given IV.
1656233|NCT01807611|Biological|HPC,A Infusion|Participants received infusions of HPC,A (CD34+ selected) and HPC,A (CD45RA depleted).
1656234|NCT01807611|Biological|TC-NK Infusion|Participants receive infusions of TC-NK.
1656235|NCT01807611|Biological|G-CSF|"Participants receive G-CSF subcutaneously or intravenously.
Donors receive G-CSF subcutaneously during cell mobilization."
1656236|NCT01807611|Drug|Mesna|Mesna is generally dosed at approximately 25% of the cyclophosphamide dose. It is generally given intravenously prior to and again at 3, 6 and 9 hours following each dose of cyclophosphamide.
1656237|NCT01807611|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
1656238|NCT01807611|Drug|Mycophenolate mofetil|Given intravenously or orally.
1656239|NCT01807598|Drug|brentuximab vedotin|Brentuximab vedotin is an antibody with a covalently attached toxin. The antibody portion targets the protein CD30 on the surface of cells, and the toxin acts against those cells.
1656240|NCT01807585|Device|VenaSeal Sapheon Closure System (VSCS)|
1656241|NCT01807585|Device|ClosureFast Radiofrequency Ablation (RFA)|
1656242|NCT01807559|Device|SoundBite Hearing System|The Sonitus Medical SoundBite Hearing System prosthetic device is a bone conduction device that has been FDA cleared for the treatment of single-sided deafness (SSD) and conductive hearing loss (CHL). The Sonitus Medical SoundBite Hearing System consists of an In-the-Mouth (ITM) component, an external microphone component worn behind the ear (BTE), a calibration interface cable and PC-controlled software for subject calibration. A charger is also provided to charge the ITM and the BTE. The objective of this study is multi-site observational study is to asses the long-term patient use of the Sonitus Medical SoundBite Hearing System.
1656243|NCT01807546|Drug|rigosertib|Oral rigosertib capsules at a dose of 560 mg twice a day for 14 consecutive days of a 21-day cycle (2 weeks on, 1 week off regimen).
1656244|NCT01807533|Other|Family-centered intervention program|This program will include in-hospital intervention, after-discharge intervention and neonatal follow-up. Five sessions of in-hospital intervention will emphasize modulation of the NICU, teaching of child developmental skills, feeding support, massage, interactional activities and parent support and education. The 7-session after-discharge intervention will consist of 4 clinic visits and 3 home visits with specific care in modulation of home environment, teaching of child developmental skills, feeding support, teaching of interactional activities, and parent support and education
1656287|NCT01807169|Procedure|Colonic polypectomy or endoscopic mucosal resection (EMR).|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation
1656288|NCT01807156|Drug|Tivozanib|Oral medication given daily. No placebo.
1656289|NCT01807143|Other|laboratory biomarker analysis|Correlative studies
1656245|NCT01807520|Biological|secukinumab 150 mg|Study treatment is provided in pre-filled 1 mL syringes containing either secukinumab 150 mg or placebo secukinumab. Dosing consists of one secukinumab s.c. injection plus one placebo s.c. injection and takes place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients receive two placebo injections at Weeks 17, 18 and 19. Patients self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
1656246|NCT01807520|Biological|secukinumab 300 mg|Study treatment is provided in pre-filled 1 mL syringes containing either secukinumab 150 mg or placebo secukinumab. Dosing consists of two secukinumab s.c. injections and takes place once weekly during five weeks (at Baseline, Weeks 1, 2, 3 and 4), then once every four weeks starting at Week 8 until Week 128 inclusive. In order to maintain the blinding, patients receive two placebo injections at Weeks 17, 18 and 19. Patients self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
1656247|NCT01807520|Biological|Placebo|Study treatment is provided in pre-filled 1 mL syringes containing either secukinumab 150 mg or placebo secukinumab. Dosing consists of two placebo s.c. injections weekly for five weeks (at Baseline, Weeks 1, 2, 3 and 4), then at Weeks 8 and 12. At Week 16, placebo patients are randomly assigned to receive either secukinumab 150 mg or secukinumab 300 mg once weekly for five weeks (at Weeks 16, 17, 18, 19 and 20), then once every four weeks, starting at Week 24 until Week 128 inclusive. Patients self-administer study treatment under the supervision of site personnel when injections occur during study visits, or at home otherwise.
1656248|NCT01807507|Device|VeinViewer|VeinViewer® is designed to improve vascular access treatment standards and provide the highest possible quality in volunteer care. The device is a non-invasive handheld electronic visual aid device designed to project an image of superficial, subcutaneous vascular structures on the surface of the skin. VeinViewer's primary purpose is to assist in vascular visualization for IV starts and blood draws.
1656249|NCT01807494|Device|Total hip replacement components|All patients will receive the same implants
1656250|NCT01807481|Drug|Mircera|Once Monthly Mircera
1656251|NCT01807468|Procedure|haploidentical stem cell transplantation and NK cell therapy|
1656252|NCT01807455|Device|Restylane Vital Lidocaine|
1656253|NCT01807442|Other|Qualitative Interview and Adherence|All participants receive the same intervention. The intervention involves two qualitative interviews per participant. The first interview occurs in the hospital, and the second interview occurs at 12 weeks. Participants also receive a pill bottle that tracks when they take their aspirin. They will also receive a step counter to use for two weeks at the end of the study.
1656254|NCT01807429|Drug|Ketamine-midazolam|Ketamine 300-500mcg/kg plus midazolam 0.03 mg/kg once.
1656255|NCT01807429|Drug|Morphine|morphine 0.05 mg/kg
1656256|NCT01807416|Procedure|implant insertion and abutment connection|After implant insertion (standard platform or switching platform) the titanium abutment (standard or flat) will be connected
1656257|NCT01807403|Procedure|Deep brain stimulation|Pose of bilateral subthalamic and caudate stimulating macroelectrodes with subclavicular pacemaker.
1656258|NCT01807377|Drug|PF-05175157|200 mg tablet administered twice per day for 14 days
1656259|NCT01807377|Drug|Midazolam|2mg administered as single doses on Days 0 and 11
1656260|NCT01807377|Other|Placebo|Placebo administered twice per day for 14 days
1656261|NCT01807377|Drug|Midazolam|2mg administered as single doses on Days 0 and 11
1656262|NCT01807325|Procedure|pancreas biopsy|patients who are already having a pancreas biopsy will be invited to enroll. After obtaining enough tissue for usual medical care, we will divert some tissue for the study.
1656263|NCT01807312|Device|Endoscopic CO2 regulation unit and accessories|Olympus UCR Endoscopic CO2 Regulation Unit
1656264|NCT01807312|Device|Placebo|
1656265|NCT01807299|Dietary Supplement|Omega 3|
1656266|NCT01807299|Other|Physical Training|
1656267|NCT01807286|Drug|Pomalidomide|"Phase I: Starting dose of Pomalidomide 1 mg/day by mouth on days 1-21 of a 28 day cycle.
Phase II: Starting dose of Pomalidomide maximum tolerated dose from Phase I."
1656268|NCT01807286|Drug|Melphalan|Phase I and II: 9 mg/m2 by mouth on days 1-4 of a 28-day cycle.
1656269|NCT01807286|Drug|Dexamethasone|Phase I and II: 40 mg/day by mouth on days 1-4 of a 28 day cycle.
1656270|NCT01807286|Behavioral|Questionnaires|Questionnaires about the feeling in hands and quality of life completed at different time points during the study.
1656271|NCT01807273|Other|Walking test|
1656272|NCT01807260|Procedure|Shock wave lithotripsy|All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
1656273|NCT01807247|Procedure|Intensive lower limbs muscles strengthening|
1656274|NCT01807234|Drug|Ketorolac|Single dose of Ketorolac (Sprix) nasal spray 31.5 mg, one spray in each nostril for an acute migraine attack.
1656275|NCT01807234|Drug|Sumatriptan|Sumatriptan (Imitrex) 20 mg one single dose of nasal spray for an acute migraine attack.
1656276|NCT01807234|Drug|Placebo|Placebo one spray in each nostril and placebo one nasal spray.
1656277|NCT01807221|Drug|Finerenone (BAY94-8862)|
1656278|NCT01807221|Drug|Placebo|
1656279|NCT01807221|Drug|Inspra (eplerenone)|
1656280|NCT01807208|Other|Educational Tool|"A personalized health goal education and reminder tool, with 3 parts: report card showing the status of secondary prevention domains during hospitalization; questions to help prepare the patient for the follow-up visit; and potential questions for the physician."
1656281|NCT01807195|Other|contrast medium usage|
2013173|NCT00878995|Drug|Standard of Care Chemotherapy and/or Radiation plus Placebo (Saline) Testosterone|Standard of Care Chemotherapy and/or Radiation plus Placebo (Saline) Testosterone
2013174|NCT00878995|Drug|Arm II: Standard of Care Chemotherapy and/or Radiation plus Testosterone Enanthate|Arm II: Standard of Care Chemotherapy and/or Radiation plus Testosterone Enanthate
1656290|NCT01807130|Other|Automated HF/EP Referral|Patients in the intervention arm without compelling contraindications to HF therapies will be referred automatically to specialists in HF or electrophysiology (EP) with recommendations to consider those therapies that are not in compliance with guidelines.
1656291|NCT01807130|Other|Placebo (Registry Arm)|Patients assigned to the registry will receive referral to specialists in HF or EP as deemed necessary by the patients physicians.
1656292|NCT01807117|Procedure|positron emission tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
1656293|NCT01807117|Procedure|computed tomography|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
1656294|NCT01807117|Procedure|magnetic resonance imaging|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
1656295|NCT01807117|Radiation|fludeoxyglucose F 18|Undergo fludeoxyglucose F 18 PET-CT and PET-MRI
1656296|NCT01807104|Procedure|Anterior Approach / Posterior Approach|compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
1656297|NCT01807104|Procedure|Anterior versus Posterior Approach for total hip replacement|Compare results of total hip arthroplasty performed through either an anterior or posterior surgical approach
1656298|NCT01807091|Drug|Chemotherapy|Receive outpatient induction chemotherapy
1656299|NCT01807078|Drug|Ezetimibe|10 mg p.d. of ezetimibe
1656300|NCT01807078|Dietary Supplement|Nutraceuticals|1 capsule/day containing monacolin K 10 mg, policosanol 10 mg, and phytosterols 300 mg
1656301|NCT01807065|Biological|sipuleucel-T|Given IV
1656302|NCT01807065|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
1656303|NCT01807065|Other|laboratory biomarker analysis|Correlative studies
1656304|NCT01807052|Other|laboratory biomarker analysis|Correlative studies
1656305|NCT01807039|Procedure|hip fracture surgery|we evaluate the relationship between the monitored parameters and 30 day survival
1656306|NCT01807026|Drug|LY2886721|Administered orally
1656307|NCT01807026|Drug|Placebo|Administered orally
1656308|NCT01807013|Procedure|ultrasound, liver elastometry, minilaparoscopy|"conventional high-end ultrasound technique,
small access laparoscopy with fine laparoscopes
Acoustic radiation force impulse (ARFI): ARFI technology uses short-duration acoustic radiation forces (approximately 100 microseconds) to generate a localized tissue displacement which results in a lateral shear-wave propagation. ARFI shear wave velocity (SWV) measured in m/sec tracked with ultrasonic correlation-based methods is proportional to the square root of tissue elasticity."
1656309|NCT01807000|Drug|Radiolabeled Prucalopride Succinate|A single oral dose of 2 mg radiolabeled prucalopride succinate administered on Day 1.
1656310|NCT01806987|Behavioral|KITS Program|The KITS Program is a 4-month psychosocial intervention for children at high risk for school difficulties and their caregivers. The intervention begins in the summer before kindergarten and continues across the first two months of kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 time per week in the fall); and (b) a 12 session psychoeducational workshop to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques (once per week in summer, bi-weekly in the fall).
1656311|NCT01806974|Other|oral exam and|The study will be conducted with patient presenting a rheumatoid arthritis and for which an anti IL6 biotherapy treatment is planned. Each patient will benefit a record oral exam that will evaluate his periodontal status and on a possible periodontitis associated. Bacterial samples and cytokine will be realized (in defined periodontal pocket or in the most affected periodontal pocket depending of the periodontal status of patients) before the IL6 biotherapy and 6 month after. A periodontal charting will be realized at the same time.
1656312|NCT01806948|Drug|Ramosetron|
1656313|NCT01806935|Device|DC086|
1656314|NCT01806935|Device|Placebo|
1656315|NCT01806922|Behavioral|Yoga|
2013175|NCT00878436|Drug|Panobinostat|
2013176|NCT00878436|Drug|Bicalutamide|
2013177|NCT00878189|Drug|PF-03084014|10 mg, 50 mg or 100 mg tablets. Patients dosed from 20 mg - 500 mg, twice daily
2013178|NCT00875641|Procedure|Health Insurance Database|Review of two health insurance databases in the US to determine the safety outcomes among infants who have received Rotarix or IPV vaccination.
2013179|NCT00875654|Genetic|Autologous mesenchymal stem cells|Intravenous injection of Mesenchymal Stem Cells in a mixing of physiological salt solution/albumin 4% (volume<100ml) less than 6 weeks after stroke
1656321|NCT01806883|Behavioral|WII Rehabilitation|"30 patients will receive Wii rehabilitation of 15 minutes (tennis, boxing and golf), in comparison with 10 healthy subjects."
1656322|NCT01806883|Behavioral|Traditional rehabilitation|30 patients will receive the traditional rehabilitation.
1656323|NCT01806870|Dietary Supplement|Zinc and SAMe|If a subject has side effects their dose of Zinc will be reduced. SAMe will remain the same dose.
1656324|NCT01806857|Drug|Nuedexta|Nuedexta PO (by mouth) for 28 ± 3 days
1656325|NCT01806857|Drug|Matching Placebo|matching placebo PO (by mouth) for 28 ± 3 days
1656326|NCT01806831|Device|"Biocellulose Mask, Farhorm®"|
1656327|NCT01806818|Drug|Epirisone 50mg or placebo TID|3 times a day after meals for 1 week
1656328|NCT01806805|Drug|zonegran|
1656329|NCT01806805|Drug|placebo|
1656330|NCT01806792|Drug|risedronate combine|
1656331|NCT01806792|Drug|Risedronate|
1656332|NCT01806792|Drug|Placebo(for Risedronate)|
1656333|NCT01806792|Drug|Placebo(for risedronate combine)|
1656334|NCT01806779|Drug|Chantix|
1656335|NCT01806779|Drug|Zyban|
1656336|NCT01806779|Drug|Nicotine patches|All participants will receive 21 mg/24 h dose nicotine (nic.) patches for 1 week.
1656337|NCT01806766|Procedure|Ceramic on Ceramic bearing|cementless Total Hip Arthroplasty with Ceramic on ceramic bearing
1656338|NCT01806766|Procedure|Ceramic on Highly crosslinked polyethylene bearing|Cementless Total Hip Arthroplasty with Ceramic on Highly crosslinked polyethylene bearing
1656429|NCT01805999|Dietary Supplement|3.5g Ispaghula + 3.5 g placebo|
1656555|NCT01805011|Other|minimum 4 months of breastfeeding|
2013180|NCT00868608|Drug|Inotuzumab Ozogamicin (CMC-544)|Administered intravenously at 1.8 mg/m2 every 4 weeks for a planned 4 - 8 cycles
1656339|NCT01806753|Procedure|Intermittent midazolam/propofol injection controlled by endoscopist|"In this arm1, sedation during endoscopic submucosal dissection is controlled by endoscopists.
First, pethidine 50 mg with midazolam 0.05 mg/kg are injected in a bolus fashion.
When the patient seems to be discomfort or the patient's movements were observed, endoscopists should check the Modified Observer Assessment of Alertness/Sedation (MOAAS).
If MOAAS is 5 or 6, propofol 0.25 mg/kg will be injected. Otherwise, pethidine 12.5 mg will be injected."
1656340|NCT01806753|Procedure|Continuous propofol infusion with opioid administration|"In this arm2, sedation during endoscopic submucosal dissection is controlled by anesthesiologists.
First, remifentanil 0.5 ug/kg with propofol 0.5 mg/kg are injected in a bolus fashion.
Then, remifentanil 0.08 ug/kg/min and propofol 2 mg/kg/h are infused continuously.
When the patient seems to be discomfort or the patient's movements were observed, anesthesiologists should check the MOAAS.
If MOAAS is 5 or 6, infusion rate of propofol will be increased by 0.5 mg/kg/h. Otherwise, infusion rate of remifentanil will be increased by 0.02 ug/kg/min."
1656341|NCT01806740|Drug|Meglumine Gadoterate|DCE-MRI is a method to measure the evaluated response
1656342|NCT01806727|Behavioral|Community Lifestyle Weight Loss (LWL)|Changing dietary and physical activity behavior to promote weight loss
1656343|NCT01806727|Behavioral|Diabetes Self Management (DSM)|Changing diet, physical activity, self monitoring, and medication related behaviors to improve diabetes control
1656344|NCT01806714|Other|Text-based reminder for recommended HPV vaccine or WCC|Patients due for a well visit or HPV vaccine received a text reminder
1656345|NCT01806714|Other|Non-specific text-based reminder (general health tip)|Parents of adolescents receive preventive health tips via text messages (not specific to services for which child is due)
1656346|NCT01806701|Behavioral|Trauma-focused cognitive behavioral therapy|the 'gold-standard' behavioral treatment for children/adolescents with posttraumatic stress disorder
1656347|NCT01806688|Other|snack|
1656348|NCT01806675|Drug|fludeoxyglucose F 18|Undergo 18F FDG PET/CT
1656349|NCT01806675|Drug|2-fluoropropionyl-labeled pegylated dimeric RGD peptide|Undergo 18F FPPRGD2 PET/CT or PET/MRI
1656350|NCT01806675|Diagnostic Test|positron emission tomography|Undergo 18F FPPRGD2 PET/CT or PET/MRI
1656351|NCT01806675|Diagnostic Test|computed tomography|Undergo 18F FPPRGD2 PET/CT or PET/MRI
1656352|NCT01806675|Diagnostic Test|positron emission tomography|Undergo 18F FDG PET/CT
1656353|NCT01806675|Diagnostic Test|computed tomography|Undergo 18F FDG PET/CT
1656354|NCT01806675|Other|laboratory biomarker analysis|Correlative studies
2013181|NCT00863681|Drug|Riociguat (BAY63-2521)|BAY63-2521: 1mg tid -2.5 mg tid oral until end of study
1656357|NCT01806649|Drug|BKM120|
1656358|NCT01806636|Device|PneumRx Coil System|
1656359|NCT01806623|Drug|Fluconazole|Single oral dose of 150mg Fluconazole
1656360|NCT01806610|Drug|BPS804|Single dose BPS804 administration.
1656361|NCT01806610|Drug|Placebo|Single dose placebo administration.
1656365|NCT01806584|Biological|SRM003|One time implant (3 SRM003 pieces) on surgery day.
1656366|NCT01806584|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure
1656367|NCT01806571|Drug|Cytarabine|Given IV
1656368|NCT01806571|Drug|Daunorubicin Hydrochloride|Given IV
1656369|NCT01806571|Other|Laboratory Biomarker Analysis|Correlative studies
1656370|NCT01806571|Drug|Nilotinib|Given PO
1656371|NCT01806571|Other|Pharmacological Study|Correlative studies
1656372|NCT01806558|Procedure|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
1656373|NCT01806545|Biological|SRM003|One time implant (2 SRM003 pieces) on surgery day.
1656374|NCT01806545|Other|Participating Site's standard practice|Subjects will receive sites' standard practice treatment during the surgical procedure.
1656375|NCT01806519|Behavioral|Motor control intervention of head posture|"The tailored motor control intervention used for motor learning-procedure described by Fitts and Posner, further developed and adapted to rehabilitation of the spine by O´Sullivan.
The stages involved in the process was the Cognitive stage, Associative stage and the Autonomous stage"
1656423|NCT01806038|Other|Discharge Med Dispensing Plus Counseling - Current Practice|At hospital discharge, patients will receive standard discharge procedures and obtain discharge medications per their usual process
1656424|NCT01806025|Other|no intervention|
1656376|NCT01806506|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive bariatric procedure. LSG involves resection of a large part of the body and fundus of the stomach starting from the antrum up to the angle of His. The remaining part of the stomach (the gastric sleeve) is calibrated with a 36 French bougie.
1656377|NCT01806506|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y gastric bypass (RYGB) is an intermediate (restrictive and malabsorptive) operation. RYGB involves creation of a 15-20 mL gastric pouch that is anastomosed to a 100cm Roux limb created at 100cm from the ligament of Treitz.
1656378|NCT01806480|Behavioral|Person-centred proactive breastfeeding telephone support|Person-centred care is a model of care, which comprise components such as: building mutual trust and understanding; treating the person as an individual; respect the rights for the person, sharing decision-making, providing holistic care and developing therapeutic relationships. Furthermore, the care provider should have a sympathetic presence and show an engagement
1656379|NCT01806454|Drug|calcium|
1656380|NCT01806441|Other|3-days high fat diet|During 3 days, subjects eat a diet high in fat (percent of total caloric intake: 15.0% from proteins; 49,8% from carbohydrates; 37.0% from fat).
1656381|NCT01806441|Other|3-days low fat diet|During 3 days, subjects eat a diet low in fat (percent of caloric intake: 15.0% from proteins; 61,8% from carbohydrates; 25.0% from fats).
1656382|NCT01806415|Drug|Fenobam|Oral administration of 50, 100, or 150mg of Fenobam or placebo (lactose)
1656383|NCT01806415|Drug|Placebo|Oral administration of placebo or lactose 150 mg
1656384|NCT01806376|Drug|Subutinib Maleate capsules|Dose escalation will be dependent on any dose limiting toxicities
1656385|NCT01806363|Drug|Telmisartan 80mg|
1656386|NCT01806363|Drug|Chlorthalidone 25mg|
1656387|NCT01806350|Other|questionnaire administration|Ancillary studies
1656388|NCT01806350|Procedure|standard follow-up care|Receive usual care
1656389|NCT01806350|Other|educational intervention|Undergo PFMT
1656390|NCT01806337|Drug|Alemtuzumab|Consolidation after CHOP induction
1656391|NCT01806324|Drug|HL040XC|single dose
1656392|NCT01806324|Drug|Losartan + Atorvastatin|Single dose
1656393|NCT01806311|Drug|Candesartan32mg|
1656394|NCT01806311|Drug|Amlodipine10mg|
1656395|NCT01806298|Drug|Saizen® solution for injection (referred as Saizen®)|Saizen® solution for injection will be administered subcutaneously daily for 39 weeks according to locally approved product labeling for the currently marketed formulation of Saizen®.
1656396|NCT01806272|Drug|rhGM-CSF|The rhGM-CSF is prepared as a mouthwash solution,diluting 150μg in 100ml water(final concentration of 1.5μg/ml).Patient is instructed to use the solution five times daily.
1656397|NCT01806272|Drug|Compound Vitamin B12|Compound Vitamin B12 solution 5ml being sprayed to mouth five times daily
1656398|NCT01806259|Drug|Ketorolac 30 mg IV|
1656399|NCT01806246|Behavioral|integrative rehabilitation program|
1656400|NCT01806233|Procedure|Acupuncture|The treatment group：60 patients receive Acupuncture ，selecting acupoint on:Shenting（DU24), Baihui（DU20）, Fengchi（GB20), Hanyan（GB4）, Jianyu（LI15）, Quchi（LI11）,Waiguan（SJ5）, Zusanli（ST36）, Fenglong（ST40）, Xingjian(LV2), Yongquan（KI1）, 20minutes each time，ten times / treatment course，two treatment courses in total.
1656401|NCT01806233|Procedure|Rehabilitation|The matched group：60 patients receive rehabilitation treatment，45 minutes each once，ten time as a period of treatment，two periods of treatment in all.
1656402|NCT01806220|Procedure|Biopsy of the retrocrycoid laryngeal mucosa|Biopsies of the retrocrycoid laryngeal mucosa were performeed under sedation using a forceps introduced by the working channel of the endoscope
1656403|NCT01806220|Procedure|Biopsy of the distal esophageal mucosa|Biopsies were performeed under sedation using a forceps introduced by the working channel of the endoscope during upper digestive endoscopy
1656404|NCT01806207|Device|Durolane injection|
1656405|NCT01806207|Other|Saline injection|
1656406|NCT01806194|Behavioral|Lifestyle Counseling|Small changes behavioral counseling and social support, delivered in 16 sessions by community health workers
1656407|NCT01806194|Behavioral|Educational Control Arm|16 mailings of diabetes educational materials but no regular contact with community health workers
1656408|NCT01806181|Other|Exercise|
1656409|NCT01806168|Device|rTMS|Magstim Super Rapid-2
1656410|NCT01806142|Other|Medium-chain triglycerides|During Medium-Chain Triglycerides (MCT period), participant will asked to consume two pastries per day that will provide a total of 20 g of MCT/day for 4 weeks.
1656411|NCT01806142|Other|Corn oil|During Corn oil period (Control period), participant will asked to consume two pastries per day that will provide a total of 20 g of corn oil/day for 4 weeks.
1656412|NCT01806129|Other|educational intervention|Undergo reproductive health program
1656413|NCT01806129|Other|questionnaire administration|Ancillary studies
1656414|NCT01806129|Procedure|quality-of-life assessment|Ancillary studies
1656415|NCT01806116|Drug|decitabine|
1656416|NCT01806103|Behavioral|Antimicrobial Stewardship Bundle|Guidelines, Education, Audit and Feedback
1656417|NCT01806090|Drug|clopidogrel|continue clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
1656418|NCT01806090|Drug|Placebo|Stop clopidogrel 7 days prior to the endoscopic procedure (Colonoscopy)
1656419|NCT01806077|Drug|PZ-128|Sequential single-dose escalation; 1 to 2 hour continuous intravenous infusion
1656420|NCT01806064|Drug|TRC105 and Axitinib|
1656421|NCT01806051|Drug|Kuvan|Only PKU participants (Arm 1) will be administered Kuvan once daily either at a dose of 20 mg/kg/day (if the PKU participant is not currently taking Kuvan) or at the subject's regular dose (if the PKU participant is currently taking Kuvan). They will remain on Kuvan for 4 weeks.
1656422|NCT01806038|Other|RPh Counseling + Outpatient Med Dispensing at Discharge|On the day of discharge, a pharmacist will perform a chart review and medication reconciliation on all patients' discharge medications (for patients randomized to the intervention arm). Any medication discrepancies will be addressed with the patient's primary care team. At the time of discharge, the patient will receive his/her discharge medications dispensed from the Duke Outpatient Pharmacy, along with medication counseling by a licensed pharmacist
1656425|NCT01806012|Device|Sealing tissue with the Enseal device|
1656426|NCT01806012|Procedure|Conventional supracervical hysterectomy|
1656430|NCT01805973|Behavioral|Exercise Training|Patients will participate in a supervised exercise training programme for 18 weeks. Patients will participate in a 50 minute exercise regime three times a week.
1656431|NCT01805960|Biological|Canakinumab|
1656432|NCT01805960|Biological|Placebo|
1656433|NCT01805947|Behavioral|Lifestyle Modification|Lifestyle Modification
1656434|NCT01805934|Drug|RBLF|The patients in Group RBLF will receive a 14-day quadruple therapy,including rabeprazole(10mg bid),bismuth citrate(220mg bid),levofloxacin(200mg qm) and furazolidone(100mg bid).
1656435|NCT01805934|Drug|RA|The patients in Group RA will be sent to a penicillin skin test before treatment except they were given penicillin before. They will receive a 14-day dual therapy with high doses of rabeprazole(20mg bid) and amoxicillin(1000mg tid).
1656436|NCT01805921|Biological|PanAd3-RSV given intra-nasally (high dose)|High dose = 5x10^10 vp
1656437|NCT01805921|Biological|MVA-RSV given by intra-muscular injection (high dose)|High dose = 1x10^8 pfu
1656438|NCT01805921|Biological|PanAd3-RSV given by intra-muscular injection (high dose)|High dose = 5x10^10 vp
1656439|NCT01805921|Biological|PanAd3-RSV given intranasally (low dose)|Low dose = 5x10^9 vp
1656440|NCT01805921|Biological|MVA-RSV given by intra-muscular injection (low dose)|Low dose = 1x10^7 pfu
1656441|NCT01805921|Biological|PanAd3-RSV given by intra-muscular injection (low dose)|Low dose = 5x10^9 vp
1656442|NCT01805908|Other|111In-Pertuzumab + SPECT-CT|111In-PmAb will be provided ready for injection in a vial by Dr. Reilly's laboratory.
1656444|NCT01805882|Drug|Sofosbuvir|
1656445|NCT01805882|Drug|Ledipasvir|
1656446|NCT01805882|Drug|GS-9669|
1656447|NCT01805882|Drug|GS-9451|
1656449|NCT01805856|Drug|PIPC piperacillin sodium|
1656450|NCT01805856|Drug|CEZ, cefazolin sodium|
1656451|NCT01805843|Other|Echo, exercise echo, and if indicated, right heart catheter|routine echocardiography and special measurements of the right heart are performed at rest and during exercise
1656452|NCT01805830|Drug|MP513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
1656453|NCT01805830|Drug|Placebo|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
1656454|NCT01805817|Drug|YASMIN® (Drospirenone/Ethinyl Estradiol)|oral contraceptive pills
1656455|NCT01805817|Device|The Copper-T is an intrauterine device (IUD)|intrauterine device for contraception
1656456|NCT01805817|Device|levonorgestrel-releasing system|intrauterine device
1656457|NCT01805804|Drug|placebo/valsartan|
1656458|NCT01805791|Drug|HMPL-004 tablet|
1656459|NCT01805791|Drug|Placebo|Placebo tablets will be used in the placebo arm of the study.
1656460|NCT01805765|Drug|Qing'E pills|composed of eucommia, psoralen, walnuts and garlic
1656461|NCT01805765|Drug|Placebo|Containing 2% of Qing'E pills
1656462|NCT01805752|Other|Task-shifting to lower-cadre providers at PMTCT sites|
1656463|NCT01805752|Other|POC CD4+ cell count testing|
1656464|NCT01805752|Other|integrated mother-infant care|
1656465|NCT01805752|Other|Prominent role for influential family members (male partners) in collaboration with CHWs|
1656466|NCT01805726|Drug|xylocain|Xylocain: (C): Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum
1656467|NCT01805726|Drug|Alfentanil|(A) Local anesthesia 1% 25 ml in total (bronchoscopy) + saline serum (slow perfusion for 10 minutes) + alfentanil 10 mcg / kg (slow injection in 5 seconds)
1656468|NCT01805726|Drug|Dexmedetomidine|(D) Local anesthesia 1% 25 ml in total (bronchoscopy) + dexmedetomidine 0.5 mcg / kg (slow perfusion for 10 minutes) + 2 ml saline (slow injection for 5 seconds)
1656469|NCT01805700|Other|Caffeine enhanced energy drink|Comparison of different energy drinks
1656470|NCT01805700|Other|Glucose drink|Glucose drink (containing 84mg glucose alone)
1656471|NCT01805687|Drug|Zileuton extended release|
1656472|NCT01805674|Dietary Supplement|isoflavones combined with magnolia|1 tablet/day duration: 12 weeks
1656473|NCT01805661|Procedure|Canal Block and Capsular Injection|Continuous Adductor canal block with 15-30ml of ropivacaine 0.1% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30 ml ropivacaine 0.1% with epinephrine 1:400,000.
1656474|NCT01805661|Procedure|Femoral with Tibial Nerve Block|Continuous femoral nerve block with 15 ml of ropivacaine 0.1% followed by an infusion of ropivacaine 0.1% at 6 ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.1% up to 15 ml.
1656475|NCT01805648|Drug|rhTPO|Subcutaneously dosing of rhTPO is based on screening weight. Subjects will be given rhTPO 300 IU/Kg once daily up to 14 days in the pre-treatment period . When two consecutive platelet counts is above 50×10^9/L, the subjects will be begin to receive maintenance treatment of rhTPO 300 IU/Kg. In the period of maintenance treatment, starting dosing interval of rhTPO is every other day followed by the interval adjustments for keeping platelet counts between 30×10^9/L～100×10^9/L.
1656476|NCT01805635|Other|No intervention|No intervention
1656477|NCT01805622|Behavioral|Active Arm #1, #2, Passive Arm #1, #2|This four-arm cluster randomized trial (five community coalitions plus 1,800 African Americans, 50-74 years of age, who are not current on CRC screening per arm) compares the following implementation strategies: (1) web access to facilitator training materials and toolkits without technical assistance (TA); (2) web access, but with technical assistance (TA); (3) in-person access to facilitator training materials and toolkits without TA and (4) in-person access with TA.
1656508|NCT01805362|Other|Randomization that determine the time of treatment|
1656509|NCT01805349|Radiation|Hand X-rays|Hand X-rays to assess the digital arthrosis
1656510|NCT01805336|Other|Assessment of attentional functions by traditional tests|For assessment of attentional functions, traditional tests include : Symbol Digit Modalities Test (SDMT), Test d'Evaluation de l'Attention (TEA), Attentional Network Test (ANT).
1656659|NCT01804101|Drug|Liposomal Cytarabine-Daunorubicin CPX-351|Given IV
1656478|NCT01805609|Behavioral|Working with the Caregiving Family (WCF) training|Training curriculum will be comprised of 2 phases to be attended sequentially: (l) The Didactic Phase will consist of 6 twice a month seminars, administered over a 3 month period. Each seminar includes a 1 hour lecture & discussion followed by 1 hour of role-play exercises; Lecture segments may include short training videos which Dr. Zaider uses in the nurses' training module she teaches through the Communication Skills Laboratory. The teaching portion of the didactic sessions of the training may also be videotaped as a reference point for curriculum review. Will explain to the providers that videotapes will only be available to study staff & that the role play portion will not be recorded; (2) Consolidation Phase will consist of 6 twice a month peer-group supervision meetings for ongoing consultation on family cases, also held across a 3 month period. Length of these consolidations sessions will be up to 2 hours.
1656479|NCT01805609|Behavioral|questionnaires|
1656480|NCT01805596|Drug|clopidogrel|
1656481|NCT01805596|Drug|Ticagrelor|
1656482|NCT01805583|Other|Acceptance and Commitment Therapy (ACT)|
1656483|NCT01805583|Other|workplace intervention (WPI)|
1656484|NCT01805570|Drug|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Prasugrel before PPCI. The loading dose of Prasugrel will be 60 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
1656485|NCT01805570|Drug|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed) will be randomized to receive Ticagrelor before PPCI. The loading dose of Ticagrelor will be 360 mg. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the first hour after drug loading dose a new reduced loading dose will be administered .
1656486|NCT01805557|Drug|R-DHAP|"Rituximab 375 mg/sqm iv day 0 or 1
Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion
Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3
Dexamethasone 40 mg day 1-4
Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)
Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy"
1656487|NCT01805557|Drug|BR-DHAP|"Rituximab 375 mg/sqm iv day 0 or 1
Bortezomib SC 1.5 mg/sqm day 1, day 4
Cisplatin 100 mg/sqm iv day 1 in 6-hours infusion
Cytarabine 2000 mg/sqm in 3-hours infusion iv day 2 and day 3
Dexamethasone 40 mg day 1-4
Pegfilgrastim 6 mg sc monodose 24 hours after the end of chemotherapy or G-CSF from day 5 till stem cell harvest during mobilization's course (II o III cycle R-DHAP)
Rituximab 375 mg/sqm iv 24 hours before apheresis as purging in vivo during second courses of therapy Chemotherapy R-DHAP and BR-DHAP will be repeated every 28 days."
1656488|NCT01805544|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. SmPC recommendations are to be followed for renal impairment
1656489|NCT01805531|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg po once daily, which is also the recommended maximum dose. In subjects with moderate creatinine clearance (30-49 ml/min), the dose 15 mg once daily is recommended.
1656490|NCT01805518|Dietary Supplement|Scelectium Tortuosum|"One arm has subjects 3 weeks on Scelectium Tortuosum 25gm po/d then 3 weeks off and then 3 weeks on Placebo.
The other arm has subjects 3 weeks on placebo, then 3 weeks off and then 3 weeks on Scelectium Tortuosum 25mg po/d."
1656491|NCT01805505|Procedure|Transvaginal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Kitazato Long ET catheter (Kitazato Medical Co. Ltd., Tokyo, Japan), guided by transvaginal ultrasound
1656492|NCT01805505|Procedure|Transabdominal ultrasound-guided embryo transfer|Embryo transfer of two day-3 embryos performed with the Cook Soft-Trans ET catheter (Cook Medical Inc., Bloomington, IN, USA), guided by transabdominal ultrasound
1656493|NCT01805492|Behavioral|Dr. Dean Ornish Program for Reversing Heart Disease|Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (<10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.
1656494|NCT01805479|Other|aerobic exercise|the active arm will be asked to perform 60% of maximum heart rate
1656495|NCT01805479|Other|stretching and flexibility program|stretching and flexibility program for the Placebo Comparator Arm
1656496|NCT01805466|Device|EVADO|EVADO (Extracorporeal Vacuum-Assisted Device Optimized) device enables separation of cardiotomy suction blood, which is stored in a separate reservoir, and, if re-infusion into the CPB circuit is required, this is performed only after selective filtering and by cell saver procedures. Moreover, by using a vacuum-assisted system for blood aspiration, EVADO allows complete elimination of roller pumps, therefore reducing the extent of mechanical cellular trauma. EVADO contains a phosphorylcholine-coated oxygenator, that confers superior biocompatibility. Finally, by requiring relatively limited priming volumes, it allows reducing haemodilution.
1656497|NCT01805466|Device|Conventional CPB|conventional miniature cardiopulmonary bypass technique
1656498|NCT01805453|Drug|Losartan|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide ) + Losartan or placebo (Arm A or B) 50mg*2/day until the halting for any reason
1656499|NCT01805453|Drug|Placebo|Standard of care (Radiotherapy with concomitant temozolomide followed by monthly cures of temozolomide + Placebo 2/day until the halting for any reason
1656500|NCT01805440|Drug|Uridine|Uridine is the active treatment in this clinical trial.
1656501|NCT01805440|Drug|Placebo|Pill placebo is the inactive treatment comparator in this clinical trial.
1656502|NCT01805414|Other|Modified Carbohydrate Breakfast|
1656503|NCT01805414|Other|Control Breakfast|
1656504|NCT01805401|Device|Transcranial Direct Current Stimulation|Anode placed over the OFC or the DLPFC and cathode placed over the occipital region
1656505|NCT01805388|Drug|Experimental: Regeneration Treatment Group|Regenerative Root Canal Therapy using Triple Antibiotic Paste study drug
1656506|NCT01805388|Procedure|Control Non-Study Drug Group|Endodontic RTC with no study drug
1656507|NCT01805375|Drug|DI-B4|DI-B4 will be administered once weekly for up to a total of four weeks. The starting dose will be 0.02 mg given as an intravenous infusion. A cycle is 1 week in duration and patients should expect to receive a maximum of 4 cycles.
1656554|NCT01805024|Drug|Omigapil|
1656511|NCT01805336|Other|Assessment of attentional functions by virtual reality tests|For assessment of attentional functions, virtual reality tests include : Monotonous task of driving on motorways, Task of city driving with accident scenarios, Monotonous driving task with divided attention test ; all tests realized on a driving simulator.
1656512|NCT01805336|Other|Assessment of executive functions by traditional tests|For assessment of executive functions, traditional tests include : Wisconsin Card Sorting Test (WCST), Task verbal fluencies, Sequence Numbers Letters subtest of the Wechsler Adult Intelligence Scale (WAIS) III, Commissions.
1656513|NCT01805336|Other|Assessment of executive functions by virtual reality test|For assessment of executive functions, virtual reality test include : VAP-S.
1656514|NCT01805336|Other|Evaluation of cognitive complaint, fatigue, anxiety and depression|The following questionnaires will be completed by the participant at the inclusion visit : cognitive complaint RBN-SEP questionnaire to assess cognitive complaint, EMIF-SEP to assess fatigue, STAI (State Trait Anxiety Inventory) to assess anxiety and MADRS to assess depression.
1656515|NCT01805323|Drug|Dexamethasone Intravitreal Implant|Dexamethasone Intravitreal Implant (OZURDEX®) previously administered according to general clinical practice.
1656516|NCT01805310|Other|Bowel preparation|Subjects randomized to the mechanical bowel preparation arm will be instructed to consume 300cc of magnesium citrate no later than 3PM on preoperative day number one.
1656517|NCT01805310|Other|No bowel preparation|Subjects randomized to no bowel preparation will be instructed to continue a regular diet on preoperative day number one.
1656518|NCT01805297|Drug|Intravitreal Aflibercept Injection|One time 2.0mg aflibercept injection, following pars plana vitrectomy.
1656519|NCT01805297|Other|Standard Vitrectomy|Surgical intervention
1656520|NCT01805284|Drug|Linezolid|600 mg linezolid as a 1 hour controlled infusion (acceptable time frame is between 30 and 120 minutes), twice, at least 3 days.
1656521|NCT01805271|Drug|Everolimus|(5 or 10mg/day, i.e. 1 or 2 tablets/day)
1656522|NCT01805271|Drug|Placebo|
1656523|NCT01805258|Drug|Nevirapine|The regimen containing Nevirapine: 3TC/ZDV 150/300 mg 1 tablet BID + NEVIRAPINE 200 mg qD for 2 weeks then 200mg BID
1656524|NCT01805258|Drug|Efavirenz|The regimen containing Efavirenz: 3TC/ZDV 150/300 mg 1 tablet BID + EFAVIRENZ 600 mg qD
1656525|NCT01805245|Behavioral|Mindfulness Based Stress Reduction|Standard 8-week MBSR program; classes meet for 2.5 hours once weekly The health education control group meets at the same time and for the same amount of time
1656526|NCT01805232|Drug|artesunate|intravenous artesunate 80 mg/kg initially then after 8 hours then daily
1656527|NCT01805232|Drug|Quinine|quinine infusion 80 mg/kg every 8 hours till the patient can take orally
1656528|NCT01805219|Other|GPS and accelerometer recording (s) during exercises|
1656529|NCT01805206|Other|Assessment of urinary iFABP|
1656530|NCT01805206|Other|Administration of enteral feedings|
1656531|NCT01805193|Other|Computed tomography myocardial perfusion imaging|
1656532|NCT01805193|Other|Oxygen 15 labelled water positron emission tomography|
1656533|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (COBE Spectra System)|In Arm 1 the first PMN cell collection will be performed using the Spectra Optia System and the second PMN cell collection using the COBE Spectra System.
1656534|NCT01805180|Device|Granulocyte/Polymorphonuclear Cell Collection (Spectra Optia System)|In Arm 2 the first PMN cell collection will be performed using the COBE Spectra System and the second PMN cell collection using the Spectra Optia System.
1656535|NCT01805167|Other|Electrophysiological study of the interindividual variability of vocal performance|
1656536|NCT01805154|Device|CRT Patients|This is a group of patients who are receiving bi-ventricular pacing therapy from CRT device.
1656537|NCT01805128|Other|Facial recognition of emotions|The purpose is to consider the recognition of emotions expressed on face in patients with a schizophrenic disorder, autism and in healthy subjects.
1656538|NCT01805128|Other|understanding metaphors|Explore understanding of figurative language, including metaphor, in schizophrenic patients, autistic and healthy, and well understand how patients develop an interpretation from access to speaker's communicative intentionality (theory mind).
1656539|NCT01805128|Other|Attribution of intentionality to others in social situations depending on the type of situation|Compare the style of attribution of intentions in three populations of subjects: schizophrenic, autistic and healthy.
1656540|NCT01805115|Drug|Oral misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
1656541|NCT01805115|Drug|Sublingual misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
1656542|NCT01805115|Drug|Vaginal misoprostol|Patients were randomly allocated at the outpatient department into 4 groups with a ratio of 1:1:1:1: the oral, sublingual, vaginal, and no misoprostol group received all 400 μg of misoprostol (two tablets of Cytotec; 200 μg). All misoprostol tablets were identical and patients were blinded to group allocation
1656543|NCT01805115|Drug|Control|The control group was not given any cervical priming agents or placebo.
1656544|NCT01805089|Drug|Melatonin 3 mg|Melatonin vs. Placebo
1656545|NCT01805076|Procedure|Breast surgery|
1656546|NCT01805076|Procedure|Magnetic resonance imaging|
1656547|NCT01805076|Procedure|Mammography|
1656548|NCT01805063|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
1656549|NCT01805063|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
1656550|NCT01805050|Procedure|Arthroscopically repair of the anterior shoulder instability|Arthroscopically repair of the anterior shoulder instability
1656551|NCT01805037|Drug|brentuximab vedotin|Given IV
1656552|NCT01805037|Biological|rituximab|Given IV
1656553|NCT01805037|Other|laboratory biomarker analysis|Correlative studies
1656556|NCT01804998|Procedure|Laparoscopic Sentinel Node Biopsy|Laparoscopic Sentinel Node Biopsy or Stomach Preserving Surgery could be performed in the experimental arm.
1656557|NCT01804998|Procedure|Laparoscopy Assisted Gastrectomy|In the control arm, laparoscopy assisted gastrectomy with lymph node dissection (D1+ or more) will be performed.
1656558|NCT01804985|Drug|Imatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on imatinib, the dose should be decreased to 200mg daily;
1656559|NCT01804985|Drug|nilotinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. if on nilotinib to 200mg twice daily (which is half the standard dose for second line use, since it is anticipated that the vast majority of nilotinib entrants will be receiving 400mg twice daily because of prior imatinib intolerance);
1656560|NCT01804985|Drug|dasatinib|Imatinib, nilotinib or dasatinib; de-escalated to half the standard dose for 12 months. If on dasatinib then to 50 mg daily.
1656561|NCT01804972|Other|Verbal and written information|Patients will receive verbal information supplied by the attending doctor and also written information in the form of patient information leaflets
1656562|NCT01804972|Other|Verbal and electronic information|Patients will receive verbal information by the attending doctor and also be provided with a web address to access electronic patient information.
1656564|NCT01804946|Drug|Ergoferon|Safety and Efficiency of Ergoferon in treatment of Influenza
1656565|NCT01804946|Drug|Oseltamivir|Safety and Efficiency in treatment of Influenza
1656566|NCT01804933|Drug|profound neuromuscular blockade|Rocuronium dose will be infused to maintain a depth of NMB to PTC 1~2 intraoperatively
1656567|NCT01804920|Dietary Supplement|D-serine|
1656568|NCT01804920|Dietary Supplement|Placebo|
1656569|NCT01804907|Behavioral|Cognitive Behavioral Therapy|
1656570|NCT01804907|Behavioral|Behavioral Modification|
1656571|NCT01804881|Behavioral|Lifestyle counseling|Six week program to address problematic eating
1656572|NCT01804868|Other|case vignette tutorial|The web tutorial will be composed of 4 case vignettes. A case vignette is a clinical scenario based on clinical practice. It will ask a clinical problem the student will have to answer by reading a research article on a randomized clinical trial. Then he will have to answer questions about this article which are related to the major methodological points of a randomized trial. All these steps are available on a secured website.
1656573|NCT01804868|Other|passive web presentation on research regulation|The presentation will be a web-based voice commented video presentation on research regulation. It will allow to preserve a minimal blinding of participants, since the participants will not be informed of the intervention evaluated and will have the opportunity to follow the other intervention after the evaluation.
1656577|NCT01804829|Biological|Civacir® 10%|The active ingredient is Human Immunoglobulin G (IgG) which is a normal constituent purified from human source plasma containing a diversity of antibodies targeting the Hepatitis C Virus.
1656578|NCT01804816|Procedure|Acupuncture|Standardized acupuncture administration for 10 sessions.
1656579|NCT01804803|Procedure|Use of software-implemented glucometer for real-time collection and transmission of measured glucose values to remote server.|"Device is a smartphone-connected glucometer. The smartphone will be implemented with a software for real-time collection and transmission of measured glucose values to the remote server. Thus, the glucometer will be made hot for real-time and anywhere data transmission. In addition, at the time of blood glucose measuring, the patient will enter information on whether the measurement is being performed in the pre-prandial, post-prandial or absorptive periods, and will indicate which meals the measurement refers to (i.e., breakfast, lunch, dinner, snack). SMBG results will be immediately transmitted to the remote server, which will perform data collection and analysis, and provide feed-back to the patient and the medical staff according to pre-defined specific algorithms (Decision Supported Software, DSS)."
1656580|NCT01804803|Procedure|Use of regular glucometer|
1656586|NCT01804777|Drug|Amiloride|"Amiloride 10 mg taken every day for two weeks, along with adherence to specified diet.
On day 14 titrate dose up to Amiloride 20 mg, take every day for two weeks after completion of two week intake of Amiloride 10 mg, along with adherence to specified diet."
1656587|NCT01804777|Drug|HCTZ|"HCTZ 12.5 mg taken every day for two weeks, along with adherence to specified diet.
On day 14 titrate dose up to HCTZ 25 mg taken every day for two weeks after completion of two week intake of HCTZ 12.5 mg, along with adherence to specified diet"
1656588|NCT01804738|Other|Jasmine rice|Standardised rice:cooking liquid ratio for 50g available carbohydrate portion
1656589|NCT01804738|Other|Parboiled basmati rice|Standardised rice:cooking liquid for 50g available carbohydrate portion
1656590|NCT01804712|Drug|rituximab|Rituximab will be administered intravenously at a dose of 375 mg/m2 of body surface area once per week for 4 weeks (Days 1, 8, 15, and 22 of a 28-day cycle).
1718530|NCT00002532|Drug|ifosfamide|
1656592|NCT01804673|Drug|Fentanyl-ITS|Fentanyl Iontophoretic Transdermal (through the skin) System (ITS) will release fentanyl at the rate of 40 microgram (mcg) (1 dose) to maximum of 240 mcg per hour (6 doses) but not more than 3.2 milligram (mg) (80 doses) per 24 hours. The duration of study treatment will be 72 hours.
1656593|NCT01804660|Other|No study treatments administered|
1656594|NCT01804647|Other|No study treatments administered - blood draws only|
1656595|NCT01804634|Drug|Cyclophosphamide|preparative regimen
1656596|NCT01804634|Drug|Fludarabine|
1656597|NCT01804634|Radiation|low dose total body irradiation|
1656598|NCT01804634|Drug|Melphalan|
1656599|NCT01804634|Drug|Sirolimus|
1656600|NCT01804621|Behavioral|Health Newsletter|Participants received a health newsletter with articles about general health articles, as well as targeted health articles (differs by condition).
1656601|NCT01804608|Other|Strength|
1656602|NCT01804608|Other|Sensorimotor|
1656603|NCT01804595|Other|Sunscreen|
1656604|NCT01804595|Behavioral|Text-Message Reminders|
1656605|NCT01804595|Other|Sunscreen and Text Message Reminders|
1656606|NCT01804595|Behavioral|Education|
1958053|NCT02010567|Radiation|Radiotherapy|"This protocol allows physician discretion as to the use of Intensity Modulated Radiation Therapy (IMRT) or 3D conformal planning techniques.
Radiation begins on Day1 of neoadjuvant chemotherapy and continues for 28 (if <T4) or 30 (T4 disease) consecutive weekdays. Patient will receive 1.8 Gy daily fractions of radiotherapy without a break except for weekends and holidays.
Dose is to be prescribed to an isodose surface that encompasses the planning target volume (PTV) and that satisfies the dose uniformity guidelines below. The minimum dose to PTV1 and PTV2 shall be no less than 95% of the protocol specified dose for that volume."
1656608|NCT01804569|Other|moxibustion|modernly developed moxibustion treatment device with safe cover on top of it.
1656609|NCT01804556|Procedure|Myofascial trigger point injections on gastrocnemius muscle|On the first visit (T0), we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index using questionnaires. Then we check trigger points of gastrocnemius muscle and inject lidocaine 1 ~ 2 ml each up to four points. One week later (T1) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index again, check trigger points, and if any, inject lidocaine. If the patient do not come, we get numeric rating scale (NRS), the frequency of cramps and insomnia severity index over the telephone. Two weeks after the first visit (T2), we repeat the procedure of the first visit (T0). And four weeks after the first visit (T3) we record numeric rating scale (NRS), the frequency of cramps and insomnia severity index through face-to-face interview or by telephone.
1656610|NCT01804543|Drug|Ranolazine|ranolazine 500 mg, then 1000 mg twice a day
1656612|NCT01804504|Behavioral|Nutrition education|The intervention group will be sent out a series of education materials, be arranged to attend lectures(once a month), dietary guidance or nutrition consultation at regular intervals(once every 2 weeks).
1656613|NCT01804491|Other|Motion Analysis|3D Motion analysis with retroflective markers on the skin (Vicon camera system) of the foot and lower leg (kinematics), walking over force plate (kinetics) and pressure plates (plantar pressure distribution).
1656614|NCT01804478|Behavioral|Mild pneumatic compression|
1656615|NCT01804465|Drug|SipT Treatment|"All patients will receive standard of care SipT treatment every two weeks for a total of 3 treatments. The three treatments usually take about 30 days to complete.
SipT treatment is given in three 1 hour infusions. Each SipT treatment is generated from a standard blood cell-collection procedure (called leukapheresis) performed 2-3 days prior to the infusion."
1656616|NCT01804465|Drug|Ipilimumab|Ipilimumab will be given by IV over 90 minutes every 3 weeks. Patients will be monitored during the infusion and up to 1 hour post-infusion.
1656617|NCT01804452|Other|Observational Study|
1656618|NCT01804413|Drug|Pegvisomant|Pegvisomant 1 mg/kg injection 3 days before the glucagon test.
1656619|NCT01804413|Drug|Regular insulin|0.1-0.15 units/kg
1656620|NCT01804400|Drug|QAW039|
1656621|NCT01804400|Drug|Montelukast|
1656622|NCT01804400|Drug|Placebo|
1656623|NCT01804387|Drug|telbivudine plus adefovir|telbivudine 600 mg qd plus adefovir 10 mg qd
1656624|NCT01804387|Drug|lamivudine plus adefovir|lamivudine 100 mg qd plus adefovir 10mg qd
1656625|NCT01804374|Drug|Sorafenib|Sorafenib tablet 200 milligrams packed in bottle containing 140 tablets. Sorafenib will be administered orally twice daily at the same time every day. Two 200 mg tablets will be taken either one hour before or two hours after a meal followed by a glass of water in the morning and in the evening. In general, patient should have a low to moderate fat meal. Patients will receive Sorafenib until progression, toxicity, withdrawal of informed consent or clinical investigator decision
1656626|NCT01804374|Drug|Everolimus|Everolimus is formulated in tablets of 2.5 or 5 mg strength, blister-packed under aluminum foil in units of 10 tablets. Everolimus will be administered orally once daily at the same time every day immediately after a meal, as a single dose of 5 mg. Patients should have a low-fat breakfast. After this light meal, study medication of Everolimus is to be taken. The tablets of Everolimus should not be chewed or crushed. Patients will receive Everolimus until progression, toxicity, withdrawal of informed consent or clinical investigator decision
1656627|NCT01804361|Drug|Haporine-S|1 or 2 drops twice a day at 12 hour interval for 12 weeks
1656628|NCT01804361|Drug|Restasis (cyclosporine 0.05%)|1 or 2 drops twice a day at 12 hour interval for 12 weeks
1656629|NCT01804348|Device|AL-SENSE 1-Step|a single AL-SENSE 1-Step to use up to 12 hours or until they notice any wetness.
1656630|NCT01804335|Drug|CD5789 0.01% Cream|CD5789 0.01% cream applied on the lesions once daily for twelve weeks.
1656660|NCT01804088|Device|Formula™ 535 Iliac Balloon-Expandable Stent|Treatment of symptomatic vascular disease of the iliac arteries
1656661|NCT01804075|Drug|Methadone|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
1656662|NCT01804075|Drug|Morphine|To compare the duration of opiate medication treatment for babies on methadone versus those on morphine.
1656631|NCT01804322|Other|Standardized educational plan|"The comprehensive and standardized educational plan consists in the discussion with the patient each of the following points:
The cause and nature of the adverse event and/or drug interaction
The tolerability profile of each drug present in the schedule
The clinical manifestations associated with the current drug interactions
Any contraindication to the use of over-the-counter drugs potentially interfering with the current treatment schedule
The reasons for and the potential benefits of the suggested treatment change
An encouragement to withdraw any potentially interfering or contraindicated drug"
1656632|NCT01804322|Other|usual care|usual care according to the participating Epilepsy Centers
1656633|NCT01804309|Procedure|Sentinel lymph node biopsy (SLNB)|The intervention (SLNB) is no different in the care of patients' in the study then in those who were not included in the past or will not be included after the trial terminates. SLNB is performed according to strict professional guidelines adopted by the National Institute of Oncology, Budapest, Hungary.
2013182|NCT00860743|Drug|Antioxidant cocktail|120 mg of Coenzyme Q10 (orally), 800 mg of Superoxide Dismutase (orally), 400 IU of Vitamin E (orally) before exposure to intermittent hypoxia. Two doses of 1 g of Vitamin C in 50 cc of saline IV (in the vein) before and after exposure to intermittent hypoxia.
1656635|NCT01804283|Procedure|ischemic postconditioning|"multiple brief ischemic-reperfusion episodes immediately after sustained ischemic insult
Postconditioning was started at 30 s after aortic cross declamping, and the aorta was re-clamped for 30 s rendering global myocardial ischemia. Meanwhile aortic root suction was established during aortic re-clamping, and thereafter, the aortic clamp was released for 30 s for full myocardial reperfusion. The cycle was repeated three times after cardioplegic arrest."
1656636|NCT01804283|Procedure|double valve replacement|The double valve replacement is a procedure in which surgery is used to replace diseased aortic and mitral heart valves.
1656637|NCT01804283|Device|heart-lung machine|The heart-lung machine is commonly used in open heart surgery including double valve replacement to support the circulation during the operation.
1656638|NCT01804283|Device|Aortic cross-clamp|a surgical instrument used in cardiac surgery to clamp the aorta
2013183|NCT00858494|Drug|Hyland's Cold 'n Cough 4 Kids|Liquid homeopathic cold remedy, 5 ml by mouth every 4 hours as needed for relief of cold symptoms for up to 10 days
1656640|NCT01804257|Other|Digital Health Feedback System|The digital health offering passively collects and records medication-taking behavior and other habits of daily living
1656641|NCT01804244|Drug|TMC278|1 25-mg tablet [27.5 mg as the hydrochloride salt) taken orally (by mouth) within 10 minutes after completion of a standardized breakfast on Day 1.
1656642|NCT01804231|Other|18F-FCH PET/MRI imaging|Patients will first undergo screening to ensure eligibility. If eligible, they will undergo one scan in a Hybrid PET/MRI scanner using 18F-FCH as the radiolabeled tracer.
1656643|NCT01804218|Drug|Nadolol|
1656644|NCT01804218|Drug|Placebo|
1656645|NCT01804205|Drug|Magnesium Sulfate|MgSO4 30 mg/kg in 0.9% physiological saline (total volume 100 ml) intravenously, for 10 min, and then continuous intravenous infusion of MgSO4 at a rate of 1 g/h during the surgical procedure until the maximum of 3 h
1656646|NCT01804192|Other|Acu-TENS|Systolic and diastolic blood pressures will be taken on the left arm by a digital blood pressure monitor (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The mean arterial pressure (MAP) will be recorded from the machine. Three ECG electrodes will be applied over left and right clavicles and left upper quadrant of abdomen respectively and then connect to a digital patient monitor device (Mindray PM-8000 Express Patient Monitor, Bio-Medical Electricity, Hamburg, Germany). The heart rate (HR) will be measured. The ECG signals will be transferred to the PowerLab 16/30 (ADInstruments Pty Ltd. NSW, Australia) for data acquisition and analysis of the HRV.
1656647|NCT01804179|Other|Immunochemical Fecal Occult Blood Test (I-FOBT) Kit|Participants will receive an Immunochemical Fecal Occult Blood Test (I-FOBT) Kit (a home stool blood test) used as a first-step screening tool for colorectal cancer to take home. The research staff will provide instructions on how to use the kit.
1656648|NCT01804179|Other|Standard Intervention (SI) Educational Materials|"Screen for Life brochure"
1656649|NCT01804179|Other|CARES Intervention Educational Materials|Newly developed digital video disc (DVD) and booklet
1656650|NCT01804179|Other|Baseline Visit Survey|In both conditions, patients will participate in a Baseline Survey. Three brief items will be used to assess patient-provider discussion and recommendation: (1) Was colorectal cancer or colorectal cancer screening one of the things you discussed with the doctor or health care provider? (Yes/No). (2) If Yes, who brought the topic of colorectal cancer first? (patient/health care provider). (3) Did your doctor or health care provider recommend colorectal cancer screening? (Yes/No). These questions are necessary to evaluate the impact of interventions on patient-provider discussion of CRCS and provider recommendation of CRCS.
1656651|NCT01804179|Other|Follow-up Questionnaire|12 months after participants began to participate in the study, they will be contacted via telephone to complete a final set of questionnaires. Participants will be asked questions similar to those answered in baseline. This time they will ask about the participant's thoughts on the educational materials as well.
1656652|NCT01804166|Drug|Infliximab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive infliximab as instructed by their personal physicians.
1656653|NCT01804166|Drug|Golimumab|This study will not restrict or introduce any therapeutic interventions, including medications. Participants may continue to receive golimumab as instructed by their personal physicians.
1656654|NCT01804153|Drug|Adipose-derived expanded stem cells|Intralesional application ASC
1656655|NCT01804127|Drug|R-CHOP|rituximab 375mg/m2 day 0, cyclophosphamide 750mg/m2 IV day 1, doxorubicin 50mg/m2 IV day 1, vincristine 1.4mg/m2 IV day1 (maximum: 2mg), prednisone 50mg PO days 1-5 twice per day
1656656|NCT01804114|Procedure|Pain management following hernia repair|Continuous infusion of local anesthetic via pain pump following hernia repair
1656657|NCT01804114|Procedure|Placebo for pain management following hernia repair|Continuous infusion of placebo via pain pump following hernia repair
1656658|NCT01804101|Other|Laboratory Biomarker Analysis|Correlative studies
1656663|NCT01804049|Drug|metformin|Metformin will be given at a dose of 850 mg orally once daily for 1 month with titration up to 850 mg orally twice daily for the remainder of the study.
1656664|NCT01804049|Drug|placebo|One placebo capsule by mouth once daily for 1 month followed by one placebo capsule by mouth twice daily for the remainder of the study.
1656665|NCT01804036|Drug|Zolpidem|Week 1: 10 mg Zolpidem daily for 1 week, Week 2: 10 mg Zolpidem daily for one week, taken as needed, Week 3: 5 mg Zolpidem daily for 1 week, taken as needed.
1656666|NCT01804036|Behavioral|Mind-Body Bridging|An awareness training program. One 2 hr class per week for 3 weeks - 2 hours per session
1958054|NCT02010567|Procedure|Surgery|Surgery will take place at least 6 weeks post completion of chemoradiotherapy in patients with resectable disease; tissue from surgical resection will be preserved for correlative studies in those patients who do not achieve a pCR.
1656668|NCT01804010|Drug|Ivabradine and placebo|Single and repeated oral administrations of 3 doses of ivabradine (2.5, 5, and 10 mg). Subjects were given a single administration of ivabradine during Period 1 (P1), following a 3-day washout, they were given repeated administrations twice daily for 4.5 days during Period 2 (P2).
1656669|NCT01803997|Behavioral|Pink and Dude Chef Afterschool Cooking Program|12 educational cooking classes: two classes per week for six weeks (2 hours each)
1656670|NCT01803984|Device|MRI|
1656671|NCT01803984|Device|EndoPAT|The endothelial function will be measured with a noninvasive Peripheral Arterial Tone (PAT) signal technology using the EndoPAT device
1656672|NCT01803984|Other|Neuropsychological battery|The cognitive status in the patient cohort will be ascertained by the Repeatable Battery for the Assessment of Neuropsychological Status (RBANS).
1656673|NCT01803971|Other|Obtention of vascular access in out-of-hospital cardiac arrest patients according to the current strategy|Current strategy of obtention of a vascular access : first attempt by peripheral venous access and if failure switch to intraosseous route
1656674|NCT01803958|Radiation|partial breast irradiation|
1656675|NCT01803958|Radiation|whole breast irradiation|
1656676|NCT01803945|Drug|AVE8112|
1656677|NCT01803945|Drug|Placebo|
1656678|NCT01803932|Behavioral|Male-focused group violence prevention intervention|
1656679|NCT01803919|Device|Silver Alloy-Coated Urinary Catheters|
1656680|NCT01803919|Device|Conventional Urinary Catheter|
1656681|NCT01803880|Device|Mechanical Debridement|mechanical shaver that removes areas of damaged tissue
1656682|NCT01803880|Device|RF-Based Debridement|Electrical energy that removes areas of damaged tissue (Coblation®)
1656683|NCT01803867|Drug|rHIgM22|Administered via IV infusion
1656684|NCT01803841|Procedure|Transradial coronary angiography and intervention|
1656685|NCT01803841|Procedure|Transfemoral coronary angiography and intervention|
1656686|NCT01803828|Drug|Tadalafil|5 mg/die (1 capsule)
1656687|NCT01803828|Drug|Placebo|Placebo 5mg/die (1 capsule)
1656688|NCT01803802|Behavioral|Expressive writing|Five sessions of 30 minutes of expressive writing
1656689|NCT01803789|Device|Single Kirschner Wire|
1656690|NCT01803789|Device|Double Kirschner Wire|
1656691|NCT01803776|Behavioral|lifestyle counseling|Lifestyle intervention is based on Finnish exercise and nutrition recommendations. The children and their parents in the intervention group undergo intensive individual family-based exercise and diet intervention. They meet an exercise specialist and an authorized nutritionist, who give detailed and individualized instructions on health promoting physical activity and nutrition at months 0, 1.5, 3, 6, 12, 18, and 24 with a specific topic at each visit. After the 2-year intensive intervention period the intervention continues with yearly physical activity and dietary counseling sessions. Group-based exercise and cooking clubs are part of intervention.
1656692|NCT01803763|Drug|Omalizumab (Xolair)|Fixed dose of 300 mg omalizumab is subcutaneously administered in total 4 monthly doses
1656693|NCT01803763|Drug|Placebo|Fixed dose of placebo is subcutaneously administered in total 4 monthly doses
1656694|NCT01803750|Behavioral|in-depth, semi-structured interviews|In-depth interviews will be conducted by the Principle Investigator and will use a combination of open-ended and closed, fixed response questions. Interviews will be audio recorded if the participant agrees, and answers to fixed response questions will be marked for complete analysis. The data collection portion of the study is estimated to take approximately 8 months. Areas to be addressed in the open-ended portion of the interview include: 1) Knowledge, attitudes and beliefs toward evidence-based cancer screening and prevention approaches 2) Barriers to implementing evidence-based cancer screening practices in the individual provider's clinical setting 3) Preferences for mechanisms of information dissemination and implementation and 4) Ideas and methods to facilitate evidence-based practices to improve cancer screening in the Latino population. A community-based participatory committee (CBPC) will be formed with 5-7 key informants identified during the interview process.
1656695|NCT01803737|Behavioral|Standard Behavioral Weight Loss Intervention (SBWL)|Included changing eating behaviors, increasing physical activity, and attending regular group weight loss meetings.
1656696|NCT01803737|Behavioral|Campaign Intervention (CI)|Included changing eating behaviors and increasing physical activity, however participants will not attend regular meetings. Instead they will attend two weekly meetings at weeks 0 and 12. During the weeks they are not scheduled to attend in-person weekly meetings (weeks 1-11), they will receive education materials via e-mail. They will also have the opportunity to earn points towards prizes by reporting diet and physical activity behaviors, and body weight via e-mail.
1656700|NCT01803698|Behavioral|Training in the use of IOM charts|
1656701|NCT01803672|Behavioral|health talk and adventure-based training|To develop an integrated programme for Hong Kong Chinese childhood cancer survivors, an advisory committee was set up which included the three healthcare professionals (researchers), two school principals, two professional adventure-based trainers and one assistant professor of Sports and Recreation Management, ensuring the adequate 'dosage' of the intervention and the feasibility of implementing such programme for Hong Kong childhood cancer surviviors.
1656748|NCT01803347|Drug|◦Drug: ASCs. + fibrin glue|Experimental group
1656749|NCT01803347|Drug|fibrin glue|•Active Comparator: Fibrin glue Intervention: Drug: Fibrin adhesive
1656702|NCT01803672|Behavioral|Placebo control|They will be invited to attend leisure activities organized by a community centre in four different days during the study period. Activities will include cartoon film shows, handicraft workshops, chess games, health talks on the prevention of influenza and healthy diet, day visit to museum and theme park.
1656703|NCT01803659|Dietary Supplement|b-carotene|
1656704|NCT01803659|Dietary Supplement|retinyl palmitate|
1656705|NCT01803659|Dietary Supplement|placebo|
1656706|NCT01803646|Drug|AM-101|AM-101 gel for intratympanic injection
1656707|NCT01803646|Drug|Placebo|Placebo gel for intratympanic injection
1656708|NCT01803633|Other|Cheddar cheese|Tillamook medium cheddar cheese brand
1656709|NCT01803633|Other|Vegan cheese|Daiya brand vegan cheese
1656710|NCT01803607|Drug|odanacatib|odanacatib 50 mg oral tablet
1656711|NCT01803607|Other|placebo to odanacatib|dose-matched placebo to odanacatib, oral tablet
1656712|NCT01803594|Dietary Supplement|Krill Oil|Neptune Krill Oil Gold
1656713|NCT01803594|Dietary Supplement|Lutein|Jarrow Formulas
1656714|NCT01803594|Dietary Supplement|Nicotinic acid|Natures Way
1656715|NCT01803594|Dietary Supplement|Dairy phospholipids|PC700 manufactured by Fonterra
1656716|NCT01803594|Other|Control|Control shake without dietary supplements
1656717|NCT01803581|Other|X92001327|
1656718|NCT01803581|Other|RID shampoo|
1656719|NCT01803568|Other|Exercise|12 weeks of exercise; 4 times pr week
1656720|NCT01803555|Drug|Budesonide/Formoterol SPIROMAX®|
1656721|NCT01803555|Drug|SYMBICORT® TURBOHALER®|
1656722|NCT01803542|Radiation|Stereotactic Radiation|Participants will receive high doses of radiation treatment to tumours in the lung for 3 to 10 treatment sessions over a total of about 1 to 2 weeks.
1656723|NCT01803529|Other|heat-pack with massage|
1656724|NCT01803529|Other|heat-pack only|
1656725|NCT01803516|Behavioral|questionnaires|This study will be offered to patients who, at the time of consultation are identified as having had adjuvant breast radiation treatment following surgical treatment for breast cancer and developed radiation-induced telangiectasias. The Skindex-16 and BREAST-Q questionnaires will be used to evaluate the quality of life of The study participants. For each instrument, for each evaluation time point, QOL scores will be summed and transformed into a scale from 0-100. Descriptive statistics will be used to describe the QOL of the study participants.
1656726|NCT01803503|Drug|Docetaxel|Docetaxel 75mg/m2 day 1, every 3 weeks
1656727|NCT01803503|Drug|Sunitinib|7 days of sunitinib 12.5mg orally daily during each cycle
1656728|NCT01803477|Drug|once daily for two consecutive days (Picato)|
2013184|NCT00858130|Device|VeinOPlus|The Veinoplus® device electrically stimulates leg muscles via motor nerves, causing calf muscle contractions. The two electrodes are placed on the central part of the calf muscle on the back of the legs, and once the device is turned on, the length of treatment is 20 minutes. The device has a variable intensity setting which allows subjects to choose their own level and change the stimulations mid-cycle if desired. Subjects will use the device however they see fit for 2 months.
2013185|NCT00853944|Drug|sitagliptin|Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
2013186|NCT00849069|Biological|GSK2231395A|3 doses intramuscular injections
2013187|NCT00849069|Biological|TwinrixTM|3 doses intramuscular injections
1656733|NCT01803438|Device|cryoballoon ablation system|
1656734|NCT01803438|Drug|Antiarrhythmic Drugs|AAD therapy based on hospital clinical practice according to ESC Guidelines 2012
1656735|NCT01803425|Other|Synflorix™ data collection|Safety monitoring and evaluation: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact. Recording of SAEs throughout the study period for each subject.
1656736|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 200 mg/mL strength. Each subject will receive drisapersen 3 mg/kg administered IV once a week, continuously throughout their duration of participation
1656737|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
1656738|NCT01803412|Drug|Drisapersen|Drisapersen will be supplied as 3 mL (milliliter) vials containing 1 mL sterile solution of 220 mg/mL strength. Each subject will receive drisapersen 6 mg/kg administered SC once a week, either continuously or intermittently (for 8 weeks, followed by 4 weeks of no dosing) throughout their duration of participation
1656739|NCT01803399|Drug|GSK1322322 1200 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 1200 mg (3 vials) will be administered IV over 60 minutes
1656740|NCT01803399|Drug|GSK1322322 3000 mg|GSK1322322 will be supplied as white to slightly colored lyophilized powder 400 mg/vial for injection. Single dose of GSK1322322 3000 mg (8 vials) will be administered IV over 60 minutes
1656741|NCT01803399|Drug|Placebo|Placebo will be supplied as 0.9% sodium chloride solution. Single dose of placebo will be administered IV over 60 minutes
1656742|NCT01803399|Drug|Moxifloxacin|Moxifloxacin will be supplied as oblong, dull red film coated tablets of 400 mg strength. Single dose of moxifloxacin 400 mg will be administered orally
1656743|NCT01803386|Device|EIM Measurements|EIM measurements are taken by applying saline to the skin and placing a sensor on patients' muscles that will record electrical activity. Electrical current is generated by this machine, but patients will not be able to feel it. The electrical activity recorded is returned to the machine and analyzed by a computer.
1656744|NCT01803373|Drug|Treatment A (reference)|One tablet equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
1656745|NCT01803373|Drug|Treatment B|Five 20-mg water dispersable tablets equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
1656746|NCT01803373|Drug|Treatment C|5 grams (ie,20mg/g) equivalent to a single 100-mg dose of TMC207 taken orally (by mouth) once.
1656747|NCT01803360|Drug|Neridronate|Neridronate 100 mg solution for infusion: 4 intravenous administrations in a course of 10 days treatment
1656750|NCT01803334|Other|Marking abdomen|If the patient is randomized to the marking the abdomen group (study group) she will then have the anticipated incision needed to place the trocars during her surgery marked on her abdomen by the surgeon attending physician involved in the patient care during the preoperative counseling visit.
1656751|NCT01803321|Drug|rilonacept (IL-1 Trap)|
1656752|NCT01803321|Other|Placebo|
1656753|NCT01803308|Drug|SB9200|Part A open-label, single ascending doses of SB9200 from 100mg - 1500mg.
1656754|NCT01803308|Drug|SB9200|Part B randomised 6:2 (active:placebo) using recommended Part B starting dose, and ascending to up to 1500mg for 7-14 days of dosing.
1656755|NCT01803308|Drug|Placebo|Part B randomised 6:2 (active:placebo) using anhydrous lactose capsules identical to active comparator, minus active ingredient.
1656756|NCT01803295|Device|40 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder.
1656757|NCT01803295|Other|Standard of care MMC mixed with water|Standard of care 40mg MMC mixed with water
1656758|NCT01803295|Device|80 mg MMC gel|A reverse thermal biodegradable gel (TC-3) (low viscosity at 5°C gel appearance at body temperature)for drug retention in the urinary bladder
1656759|NCT01803282|Drug|Andecaliximab|Administered intravenously
1656760|NCT01803282|Drug|Gemcitabine|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
1656761|NCT01803282|Drug|Nab-paclitaxel|Administered intravenously on Days 1, 8, and 15 of each 28-day treatment cycle
1656762|NCT01803282|Drug|Carboplatin|Administered intravenously on Day 1 of each 21-day treatment cycle
1656763|NCT01803282|Drug|Pemetrexed|Administered intravenously on Day 1 of each 21-day treatment cycle
1656764|NCT01803282|Drug|Leucovorin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
1656765|NCT01803282|Drug|Oxaliplatin|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
1656766|NCT01803282|Drug|5-FU|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
1656767|NCT01803282|Drug|Bevacizumab|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
1656768|NCT01803282|Drug|Irinotecan|Administered intravenously on Days 1 and 15 of each 28-day treatment cycle
1656769|NCT01803282|Drug|Paclitaxel|Administered intravenously on Days 1, 8 and 15 of each 28-day treatment cycle (Breast cancer) or on Day 1 of each 21-day treatment cycle (NSCLC)
1656770|NCT01803269|Drug|topotecan hydrochloride|Given IV
1656771|NCT01803269|Drug|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
1656772|NCT01803243|Other|Ankle foot orthosis|Ankle foot orthoses are a common treatment method to control the foot position during walking and to prevent ankle plantar flexion contractures in cerebral palsy patients.
1656773|NCT01803243|Other|Shoe insole|The heel of the shorter leg of the patient is lifted by a shoe insole. This procedure is commonly applied with leg length differences of up to 20mm.
1656774|NCT01803243|Other|Modified shoe with sole lift|The heel of the shorter leg of the patient is lifted by building up the sole of the shoe (shoe sole lift). This procedure is commonly applied with leg length differences of 20mm and more.
1656775|NCT01803230|Dietary Supplement|creatine supplementation|creatine supplementation
1656776|NCT01803230|Dietary Supplement|Placebo|
1656777|NCT01803217|Other|pacemaker programming to mode switch to atrial pacing versus atrioventricular hysteresis function|
1656779|NCT01803191|Drug|Fosfomycin 3 g|Unique oral dosis of fosfomycin 1 hour before biopsy
1656780|NCT01803191|Drug|Ciprofloxacin 500 mg|Unique oral dosis of ciprofloxacin 500 mg, 1 hour before biopsy
1656781|NCT01803178|Dietary Supplement|Plant Sterols|
1656782|NCT01803178|Dietary Supplement|Placebo Product|
1656783|NCT01803165|Procedure|Single shot femoral and sciatic nerve block|Ultrasound will be performed with a linear 10- to 13-Megahertz probe while performing the nerve block. Standard American Society of Anesthesiology monitors will be applied and the patient sedated at the discretion of the anesthetic team. Complications such as vascular puncture, pain on injection, or systemic toxicity will be recorded. A perineural dosing regimen for the regional blocks will be as follows: (femoral block) 20cc of 0.5% ropivicaine and (sub-gluteal posterior sciatic block) 20cc of 0.2% ropivicaine. Epinephrine will be withheld from the local anesthetic in order to prevent the potential of further ischemic complications.
1656784|NCT01803152|Biological|Dendritic Cells Vaccine|Subjects will receive DC Vaccine administered once weekly, via intradermal injection, for 4 weeks for a total of four vaccinations, per study protocol.
1656785|NCT01803152|Biological|Lysate of Tumor|Post-DC Vaccine therapy. Up to 1.5 mg of Lysate of tumor per dose administered via intradermal injection at intervals defined by study protocol.
1656786|NCT01803152|Drug|Gemcitabine|Post-surgery, Leukapheresis and clearance of subject. Gemcitabine 1000 mg/m2 IV will be administered once weekly for 3 weeks per study protocol.
1656787|NCT01803152|Drug|Imiquimod|Subjects will self-apply Imiquimod topically to each designated vaccine site before and after scheduled administrations of DC Vaccine or Lysate, per study protocol.
1656788|NCT01803152|Procedure|Leukapheresis|Baseline, post-surgery blood draw via catheter to obtain peripheral blood mononuclear cells (PBMCs) from which Dendritic cells will be obtained.
1656789|NCT01803139|Device|Adjuvant breast radiotherapy|Adjuvant radiotherapy delivering 50 Gy in 25 treatments, with an additional boost dose of 16 Gy at the discretion of the radiation oncologist.
1656790|NCT01803113|Device|Sofia hCG FIA|Qualitative detection via immunofluorescence technology of increased level of hCG present in urine.
1656791|NCT01803100|Other|No intervention|There is no intervention in this trial
1656792|NCT01803087|Drug|Test treatments CHF 1535 100/6 pMDI (Foster®) TEST1|
1656793|NCT01803087|Drug|CHF 1535 100/6 pMDI (Foster®) using AeroChamber Plus™ (TEST 2).|
1656794|NCT01803087|Drug|BDP pMDI 100 µg (Qvar®) plus formoterol fumarate pMDI 6 µg (Atimos®) (REF)|
1656795|NCT01803087|Drug|CHF 1535 100/6 pMDI (Foster®) (CTR)|
1656796|NCT01803074|Drug|BMS-955176|BMS-955176
1656797|NCT01803074|Drug|Placebo matching with BMS-955176|Placebo matching with BMS-955176
1656798|NCT01803074|Drug|Atazanavir|Atazanavir
1656799|NCT01803074|Drug|Ritonavir|Ritonavir
1656800|NCT01803074|Drug|Tenofovir|Tenofovir
1656801|NCT01803074|Drug|Emtricitabine|Emtricitabine
1656802|NCT01803061|Behavioral|WebCan|Provide computerized PRO (Patient Reported Outcome) to treating physician at the point of care to assess late effects after head and neck cancer
1656803|NCT01803035|Drug|LTX-109 1 %|
1656804|NCT01803035|Drug|LTX-109 2 %|
1656805|NCT01803035|Drug|Placebo gel|
1656806|NCT01803009|Behavioral|Patient views NCI CRC RAT|
1656807|NCT01803009|Behavioral|View presentation regarding current chance of having an advanced adenoma|
1656808|NCT01802996|Drug|Magnesium Isoglycyrrhizinate Injection|200mg IV on day 1-5
1656809|NCT01802970|Drug|Anakinra plus Standard of Care|Patients will undergo a 2-week run-in treatment of daily anakinra alone. This will be followed by daily anakinra (100 mg SC) plus the physician's chemotherapy ( TPC) choice of standard of care (SOC) for a maximum of 6 months.TPC choice includes nab paclitaxel (100 mg/m^2 Intravenous on day 1,8 &15 of a 28 day cycle), or capecitabine (1000mg/m^2 per oral; BID choice: 14 days on, 7 days off OR 7 days on, 7 days off of a 21 day cycle), or eribulin (1.4 mg/m^2 intravenous on day 1 & 8 of a 21 day cycle), or vinorelbine (25mg/m^2 on day 1,8,15 of a 28 day cycle). After 6 months, patients may continue their SOC treatment alone until disease progression or intolerable toxicity.
1656810|NCT01802957|Other|Training of health workers in Basic Obstetric Emergency Care|Health workers at the eight health centers will be trained in maternal, newborn, and child health (MNCH) care, including all basic emergency obstetric and neonatal care (BEmONC) signal functions and other essential MNCH services. The training is a three week competency-based curriculum developed recently by the Ethiopian Federal Ministry of Health (FMoH).
1656811|NCT01802957|Other|Hospital-health center networking system|A key intervention will be the creation of an effective, formalized networking system between Saint Paul Millennium Hospital and its eight satellite health centers in Addis Ababa. The networking system will create a conducive environment for the transfer of knowledge and skills between health care providers working at the hospital and in the health centers. Monthly review meetings will bring together staff from the hospital and health centers, and dedicated cell phones will be distributed to improve communication between the networked facilities.
1656812|NCT01802957|Other|Post Basic Emergency Obstetric Training Mentorship|At Saint Paul Millennium Hospital and the health centers, providers who have undergone BEmONC training will undergo regular monthly mentorship visits for the first six months post training. The frequency of visits after six months will be adjusted based on the retention of BEmONC skills and provider performance
1656813|NCT01802957|Other|Team-Based Supportive supervision|Saint Paul Hospital will use team-based models to provide supportive supervision to health centers in its network. Representatives of the supportive supervision teams may, in addition to Saint Paul Hospital employees, include representatives from the Addis Ababa Regional Health Bureau.
1656814|NCT01802957|Other|Midwives exchange program|Saint Paul Millennium Hospital's maternity wards are often over-crowded and have to turn patients away. Health professionals incorrectly refer non-complicated deliveries, resulting in the occupation of beds that should be used for emergency deliveries. This action is attributed to inexperienced midwives at the health center level who are uncomfortable performing normal labor and delivery duties. In order to address this challenge, this project will establish an exchange program in which well-trained, experienced midwives from the hospitals will temporarily exchange places with less-experienced midwives in the health centers. This exchange would allow less-experienced midwives to work in the hospital environment, gaining the experience and confidence necessary to attend normal deliveries and identify appropriate referrals.
1656815|NCT01802957|Other|Strengthening the referral network|Mechanisms and protocols for smooth communication between the health centers and the hospital have been developed, allowing health centers to utilize the hospital's ambulance, and implementing mechanisms for back referrals and feedback. To facilitate this work, we will support the use of dedicated cell phones in each of the eight networked facilities and at Saint Paul Millennium Hospital, and institute referral log books at both the referring and receiving institutions.
1656816|NCT01802957|Other|Facility Checklists|Facility checklists will be used daily in each of the facilities to assess readiness for obstetric emergencies. Formally, the checklists will be used at the quarterly supportive supervision visits, to assess improvements over time.
1656817|NCT01802957|Other|Emergency Drills|Non-punitive obstetric drills will provide multiple measurable indicators of quality maternal care, will illustrate opportunities for improving facility capabilities and provider care, and will allow providers to assess appropriate referral mechanisms and facility readiness. Incorporating emergency drills into current training and at all levels of health facilities will also give providers hands-on experience
1656818|NCT01802944|Drug|Intranasal Insulin|
1656819|NCT01802944|Drug|Placebos|
1656820|NCT01802931|Drug|GSK239512|H3 receptor antagonist, potential victim of drug-drug interaction
1656821|NCT01802931|Drug|ketoconazole|CYP3A4 inhibitor, potential perpetrator of drug-drug interaction
1656822|NCT01802918|Drug|GSK2838232|Bottled powder with 5, 10 and 20mg unit dose strength per single dose for re-constituted oral suspension given once daily
1656823|NCT01802918|Drug|Placebo|Visually matching GSK2838232
1656824|NCT01802918|Drug|Ritonavir|100mg tablets once daily for 12 days
1656825|NCT01802905|Genetic|in depth genomic sequencing|Fresh tumour biopsies and matched normal specimens (blood and surrounding tissue) and when possible archival pretreatment specimens, will undergo in depth DNA and RNA sequencing and analysis on an oncogene panel.
1656826|NCT01802892|Drug|Ronacaleret 100 mg|Subjects in the Ronacaleret 100 mg group received one tablet orally of ronacaleret 100 mg for 5 consecutive days.
1656827|NCT01802892|Drug|Ronacaleret 400 mg|Subjects in the Ronacaleret 400 mg group received four tablets orally of ronacaleret 100 mg daily for 5 consecutive days.
1656828|NCT01802892|Drug|Plerixafor|Subjects in each group received a single dose of plerixafor (0.24mg/kg) SC on the evening of the Day 5 dosing approximately 12 hours before collection of CD34+ cells on day 6.
1656829|NCT01802879|Drug|Panobinostat|single agent panobinostat starting with last assigned dose and regimen which patient received in parent study. Additional dose modifications are at the discretion of the investigator based on guidance provided in the protocol and IB.
1656830|NCT01802866|Drug|ACU-4429|Take orally once daily for 24 months
1656831|NCT01802866|Drug|Placebo|Take orally once daily for 24 months
1656832|NCT01802853|Drug|RO6811135|Single subcutaneous dose
1656833|NCT01802853|Drug|RO6811135|Single intravenous dose
1656834|NCT01802840|Dietary Supplement|biscuits supplemented with soy fiber|Thirty nine overweight and obese college adults (19-39 y of age) were randomly assigned to consume control biscuits or biscuits supplemented with soy fiber for 12 wk (approximately 100g/d).
1656835|NCT01802814|Drug|SR-A + Epratuzumab|
1656836|NCT01802814|Drug|SR-B + Epratuzumab|
1656837|NCT01802801|Other|embryo development|intra- and inter-observator analysis
1656838|NCT01802788|Device|St Jude Medical Portico replacement aortic valve|
1656839|NCT01802788|Procedure|Transcatheter Aortic Valve Implant|
1656840|NCT01802775|Drug|edoxaban|
1656841|NCT01802775|Drug|Clopidogrel|75mg tablet
1656842|NCT01802775|Drug|Aspirin|
1656843|NCT01802762|Device|NeMo Patch and NeMo Probe|A plaster based patch (NeMo Patch) and a combined probe for ICP monitoring and near infrared spectroscopy (NIRS) are applied as sensors. Data are collected by a NIRS instrument (NeMo Control Unit)
1656844|NCT01802749|Drug|Bevacizumab|
1656845|NCT01802749|Drug|Paclitaxel|
1656846|NCT01802749|Drug|Carboplatin|
1656847|NCT01802749|Drug|pegylated liposomal doxorubicin|
1656848|NCT01802749|Drug|Gemcitabine|
1656849|NCT01802736|Behavioral|Motivational intervention counselling plus SPP|
1656850|NCT01802723|Drug|Drug: salmeterol xinafoate|
1656851|NCT01802723|Drug|Drug: Placebo|
1656854|NCT01802697|Drug|IdeS|
1656855|NCT01802697|Drug|Placebo|
1656856|NCT01802684|Biological|aflibercept|Aflibercept (VEGF Trap) Recombinant human protein, at 25 mg/ml Dose : 4 mg/Kg -Day 1, q2w Route of administration: Intravenous (60 min infusion)
1656857|NCT01802671|Other|Rehabilitation treatment and information|Patients will receive the traditional rehabilitation treatment (back school). This treatment will consist of a 4-session group therapy every week, with each session lasting 45 minutes. The content of the first session will be educational (ergonomics, pain demystification) and the other three will include physical therapy focused on stabilisation training: lower extremity stretching; finding the neutral spine position; spine stabiliser activation (transversus abdominis and multifidus); abdominal, spinal extensor and lower extremity strengthening; and proprioceptive control (stabilisation kinesitherapy)
1656858|NCT01802671|Behavioral|cognitive behavioural therapy (CBT)|"Patients will receive the same treatment in physical therapy than the control group and additionally they will receive CBT. The aim of the CBT intervention is to produce changes in the beliefs and behaviors about physical activity and avoidance of activity. The treatment's components are:
Psychoeducation to counteract the misconceptions about low back pain and to point on the relevance of maintaining an adequate level of activity.
Cognitive restructuring techniques
Behavioural therapy and activity pacing
Training on self-management pain techniques (mindfulness and relaxation). It is a 6-session group therapy, with one session per week. Each group will be composed by 6-8 participants. It will be considered as a patient who receives the treatment when the patient attends to the assessment sessions and to at least 4 out of 6 CBT sessions."
1656859|NCT01802671|Behavioral|cognitive behaviour therapy supported by ICT|The patients of this group will receive the same interventions that the CBT group but will receive a reinforcements of the sessions' content through two different ways, both based on ICTs: a web tool named TEO (Emotional Therapy Online) specially designed to practicing the therapeutic strategies at home; and SMS that will send to the patients' mobile phone with reminders and reinforcements. The content of sessions will be related to the therapeutic components including on the CBT. Patients will access TEO from their home using a personal password. Besides TEO, messages will be sent through SMS three times per week during the treatment and once a week during the follow-up. The messages will consist on reminders to do the homework along with reinforcements of the working and effort made to improve their health.
1656860|NCT01802658|Drug|Zoledronic acid|Zoledronic acid 5 mg. IV. 3 infusions. Administration 3 times inclusion M12 and M24 over two years.
1656861|NCT01802658|Drug|NA Cl|NACl 100 ml IV. 3 infusions. Administration 3 times inclusion M12, M24 over two years.
1656862|NCT01802645|Drug|Cetuximab|
1656863|NCT01802645|Drug|Bevacizumab|
1656864|NCT01802645|Drug|Irinotecan|
1656865|NCT01802645|Drug|Oxaliplatin|
1656866|NCT01802645|Drug|5-FU|
1656867|NCT01802645|Drug|Folinic Acid|
1656868|NCT01802632|Drug|AZD9291|Starting dose 20 mg, administered once daily. If tolerated subsequent cohorts will test increasing doses of AZD9291, until a maximum tolerated dose or maximum feasible dose is defined
1656869|NCT01802619|Other|inhaled nitric oxide|Nitric oxide administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled NO will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
1656870|NCT01802619|Other|inhaled Nitrogen|Standard gas including nitrogen (the vehicle of the Nitric oxide) administration will commence at the onset of CPB and last for 24 hours. At the end of 24 hours, inhaled gases will be weaned and discontinued while carefully monitoring hemodynamics for a period of 2-4 hours.
1656871|NCT01802593|Drug|AZATHIOPRINE or METHOTREXATE|Patients should continue azathioprine or 6 MP or methotrexate at their previous doses for 6 months IMM therapy 26 weeks
1656872|NCT01802593|Drug|AZATHIOPRINE or METHOTREXATE|"Patients should continue the same dose of azathioprine or 6 MP or methotrexate until the day of the second infusion (week 2)
Thiopurine therapy 2 weeks"
1656873|NCT01802580|Behavioral|Internet Survey|
1656874|NCT01802580|Drug|fluocinonide 0.05% ointment|
1656875|NCT01802567|Device|Guided Therapy- Pediatric Gene Analysis Platform|A total of 48 neuroblastoma, brain tumor, and rare tumor patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for survival, disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
1656876|NCT01802554|Behavioral|Pleasant Events Program (PEP)|Behavioral Activation Therapy
1656877|NCT01802554|Behavioral|Information Support (IS)|Information-Support (IS) condition consisted of supportive psychotherapy and informational brochures.
1656878|NCT01802541|Dietary Supplement|diacylglycerol oil|
1656879|NCT01802541|Dietary Supplement|triacylglycerol oil|
1656880|NCT01802515|Drug|Atomoxetine, low dose|The effects of 40mg low dose atomoxetine will be compared to placebo and to the 80mg atomoxetine high dose.
1656881|NCT01802515|Drug|Atomoxetine, high dose|The effects of 80mg of high dose atomoxetine will be compared to placebo and to 40mg atomoxetine low dose.
1656882|NCT01802515|Drug|Placebo|The effects of placebo will be compared to the parallel groups of Atomoxetine high (80mg) dose and Atomoxetine low (40mg) dose.
1656883|NCT01802502|Drug|Rifampicin intravenous|
1656884|NCT01802502|Drug|Oral rifampicin|
1656885|NCT01802489|Drug|Amiloride|
1656886|NCT01802489|Drug|Placebo|Placebo capsule identical in appearance to Amiloride 10mg capsule
1656887|NCT01802476|Drug|Oral Drug Formulation of PD-0332991|Treatment A consists of a single 125 mg oral dose of PD-0332991.
1656888|NCT01802476|Drug|Intravenous Formulation of PD-0332991|Treatment B consists of a 1000 mL intravenous infusion of 50 mg of PD-0332991 administered over 4 hours at a constant rate.
2013188|NCT00846742|Drug|Stanford V Chemotherapy|The Stanford V regimen is an abbreviated, multi-agent, dose-intensive regimen that utilizes many of the most active chemotherapy agents for Hodgkin lymphoma: Vinblastine, Doxorubicin, Vincristine, Bleomycin, Mechlorethamine, Etoposide, and Prednisone
1656890|NCT01802437|Drug|Fluoxetine|Adolescents who receive pharmacotherapy will be prescribed fluoxetine for 12 weeks. The dosage schedule will be 10 mg per day for the first week and 20 mg per day for the following 5 weeks. If no treatment response is observed by week 6, the dosage can be increased to 40 mg per day. Pharmacotherapy sessions will be scheduled weekly for the first 4 weeks and every other week thereafter.
1656891|NCT01802437|Behavioral|Interpersonal Psychotherapy|Adolescent randomized to an increase in therapy (4 extra therapy sessions)
1656892|NCT01802424|Behavioral|The Friends program|The Friends program is a ten weeks group interventions based on principles from Cognitive Behavioural Therapy aimed at ameliorating symptoms of anxiety and depression in children and adolescents. There are age-specific versions of the manual, one for children 8-12 years and one for adolescents 12-15 years.
1656893|NCT01802411|Drug|Liposome bupivacaine|
1656894|NCT01802411|Drug|Placebo|
1656895|NCT01802385|Drug|Sertraline|Sertraline 400mg/day for 2 weeks, then 200mg/day for 12 weeks, then tapered over 3 weeks.
1656896|NCT01802372|Behavioral|WHO CVD risk assessment package|Arm#1 (Intervention Group): Provided Ghana's National Health insurance and the WHO CVD Risk Assessment package for 12 months.
1656897|NCT01802372|Behavioral|Health Insurance only|Arm#2 (Control group): Provided Ghana's National Health Insurance for 12 months, brief behavioral counseling at baseline, and usual care.
1656898|NCT01802359|Drug|No intervention|This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
1656899|NCT01802346|Dietary Supplement|dietary intervention|Consume a low-calorie diet
1656900|NCT01802346|Procedure|nutritional support|Receive dietary advice
1656901|NCT01802346|Other|laboratory biomarker analysis|Correlative studies
2013189|NCT00846742|Radiation|Radiation Therapy|Patients who achieve less than a complete response after 8 weeks of chemotherapy will receive 25.5 Gy to individual nodal sites (tailored fields) starting 2-3 weeks following completion of all chemotherapy and recovery of ANC to at least 1000.
1656908|NCT01802320|Drug|Akt Inhibitor MK2206|Given PO
1656909|NCT01802320|Other|Laboratory Biomarker Analysis|Correlative studies
1656910|NCT01802320|Other|Pharmacological Study|Correlative studies
1656911|NCT01802307|Radiation|Brachytherapy|
1656912|NCT01802294|Behavioral|Parenting Program|"Goal of the program is reduction in child behavior problems in high-risk South African families. Program will be delivered to caregivers responsible for the wellbeing of the child.
Program activities will be delivered over 12 weekly group sessions with additional individualized in-home sessions. The groups (n = 15 participants per group) will meet weekly with community facilitators (n = 2 per group). Parenting skills will be developed during the sessions through role-plays, group-discussion, storytelling, and home practice activities.
The program is manualized in isiXhosa."
1656913|NCT01802281|Procedure|Uterosacral ligament suspension|The ULS procedure used in this protocol is a modification of the technique described by Shull.
1656914|NCT01802281|Procedure|Uphold® LITE|The Uphold® procedure used in this protocol is a modification of the technique described by Vu and Goldberg.
1656915|NCT01802268|Drug|Conversion from Tacrolimus to Sirolimus|
1656916|NCT01802268|Drug|Maintenance on tacrolimus|
1656917|NCT01802255|Drug|Sevoflurane|Sedation with inhaled anesthetic via AnaConDa.
1656918|NCT01802255|Drug|Midazolam|Intravenous sedation.
1656919|NCT01802242|Radiation|Volumetric Modulated Arc Therapy (VMAT) and High-Dose Rate (HDR) Radiotherapy|"Patients in this group will receive one of 2 treatment arms of their choice:
Arm 1: VMAT delivery with integrated VMAT boost (IB‐VMAT) GTV: 95Gy in 38fractions
Arm 2: HDR‐boost followed by VMAT GTV: 10Gy HDR + 76Gy in 38 fractions VMAT"
1656920|NCT01802242|Other|No Active Treatment - completed Prior Radiation|Already had prior radiation treatment. MRI‐guided prostate biopsy at 3 years and PSA per standard practice
1656921|NCT01802229|Procedure|Prophylactic mesh placement|Placement of a Omega 3 mesh, fixed to the border of the fascia
1656922|NCT01802229|Procedure|Fascial suture|The port-site hole is closed with simple suture of the fascia
1656923|NCT01802216|Procedure|Scaling and root planing|non-surgical periodontal disease treatment
1656924|NCT01802216|Drug|Minocycline|antibiotic microspheres
1656926|NCT01802190|Genetic|Deafness patients|SLC17A8 et POU4F3 mutations genes analysis on blood samples of deafness patients.
1656927|NCT01802177|Procedure|UVB excimer light|
1656928|NCT01802164|Device|A non-absorbable composite mesh (Ethicon Physiomesh)|To compare prophylactic mesh implantation to conventional abdominal wall closure in patients undergoing emergency laparotomy for peritonitis.
1656929|NCT01802151|Dietary Supplement|B. subtilis R0179|B. subtilis R0179 for a period of 4 weeks. One capsule per day.
1656930|NCT01802151|Dietary Supplement|Placebo|Placebo (starch, magnesium stearate, citric acid) capsules for a period of 4 weeks. One capsule per day.
1656931|NCT01802138|Biological|Activated T lymphocyte|intravenous dripping of 200 ml (10^9~2*10^10 lymphocytes) for 1 hour.
1656932|NCT01802125|Other|laboratory biomarker analysis|Correlative studies
1656933|NCT01802112|Dietary Supplement|Resistant maltodextrins|15 grams of Resistant maltodextrins per day dissolved in water during 21 days
1656934|NCT01802099|Other|Enteral nutrition|
1656935|NCT01802099|Other|Parenteral nutrition|
1656936|NCT01802086|Drug|Emla-cream|Topical anaesthetic
1656937|NCT01802086|Drug|Miniderm cream|Topical
2013190|NCT00845182|Drug|Pioglitazone|Pioglitazone 15 mg/day for 1 month and then 45 mg/day for 5 months
1656939|NCT01802047|Procedure|milk expression with electric pump|
1656940|NCT01802021|Drug|Astagalus-based Formula: Qingshu-Yiqi-Tang|"Plus astragalus-based formula: Qingshu-Yiqi-Tang 7.2gm BID during 1st line chemotherapy and 2nd line target therapy.
maximal for 6 months"
1656941|NCT01802008|Procedure|3-minute withdrawal time|"For subjects randomized to the 3-minute withdrawal time, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 1 minute, followed by a second look over each segment over 2 minutes by the same endoscopist."
1656942|NCT01802008|Procedure|6-minute withdrawal time|"For subjects randomized to the 6-minute withdrawal, advancement to the cecum will be followed by segmental withdrawal in each of 3 segments of the examined colon. Each segment will be examined over 2 minutes, followed by a second look over each segment over 2 minutes by the same endoscopist."
1656943|NCT01801982|Other|non-interventional|non-interventional
1656944|NCT01801969|Other|Rehabilitation service|"Centralized/ decentralized hospital based rehabilitation defined as hospital based rehabilitation in a single or in multiple locations, respectively.
Size of the municipality responsible for providing rehabilitation services after discharge from hospital"
2013191|NCT00845182|Drug|Exenatide|Exenatide 5mcg twice daily for 1 month, then 10mcg twice daily for 5 months
2013192|NCT00845182|Drug|Pioglitazone and Exenatide|Pioglitazone 30mg daily for 1 month and then 45mg daily for 5 months and Exenatide 5mcg twice daily for one month then 10mcg twice daily for 5 months
2013193|NCT00843882|Biological|Epoetin Alfa|Given SC
1656948|NCT01801943|Behavioral|Cognitive Remediation Therapy Group|30 min Cognitive Remediation Therapy + 60 Min Healthy Living class 3x week
1656949|NCT01801943|Behavioral|Walking Intervention (WI) Group|60 min Walking Intervention + 30 min low interface reading 3x week
1656950|NCT01801943|Behavioral|Combination Group|30 min Cognitive Remediation Therapy + 60 min Walking Intervention 3x week
1656951|NCT01801943|Behavioral|Healthy Living Group|60 Min Healthy Living class + 30 min low interface reading 3x week
1656952|NCT01801930|Drug|OCV-103 and OCV-104|0.3 mg of each
1656953|NCT01801930|Drug|OCV-103 and OCV-104|1 mg of each
1656954|NCT01801930|Drug|OCV-103 and OCV-104|3 mg of each
1656955|NCT01801930|Drug|OCV-103 and OCV-104|6 mg of each
1656958|NCT01801904|Drug|Panitumumab|6mg/kg IV given every 2 weeks until disease progression or unacceptable toxicity
1656959|NCT01801891|Device|VASGARD stimulator|The VASGARD device is a 2 channel muscle stimulator system designed for increasing venous blood flow. Controlled electrical stimuli are delivered to the patient through adhesive gel electrodes placed over the motor points of muscles on the lower leg. This elicits artificial muscular contractions which in turn increases lower limb venous haemodynamics.
1656960|NCT01801891|Other|Compression bandaging|Compression bandaging systems apply graduated external pressure to the lower limb to promote venous return to the heart reducing venous hypertension and thereby facilitate venous ulcer healing.
1656961|NCT01801878|Biological|Adipose SVF cell|adipose SVF cell transfer to the half of irradiated breast
1656962|NCT01801878|Biological|Normal saline|Normal saline inject to the half of irradiated breast
1656963|NCT01801865|Device|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan
1656964|NCT01801852|Biological|NKT cells|
1656965|NCT01801826|Device|Treatment with CryoTouch IV|Bilateral forehead treatment with the Cryo-Touch IV device on the temporal branch of the facial nerve. Subject will be treated once and may have a retreatment up to 7 days after the first treatment
1656966|NCT01801813|Other|Collecting pre-operative, per-operative data, neuro-radiological data and post-operative neuro-surgery complications|
1656967|NCT01801800|Procedure|Echocardiography|Speckle-Tracking of echocardiographic loops by a cardiologist blinded to the patient's management and outcome
1656968|NCT01801787|Device|tDCS|active vs. sham tDCS left hemisphere
1656969|NCT01801774|Drug|Subtenon 20-mg triamcinolone injection|Treatment arm will receive single subtenon 20-mg triamcinolone with gentamicin injection after uneventful phacoemulsification. 0.3% Tobramycin eye drop will be given to treatment arm for 28 days to blind the patient.
1656970|NCT01801774|Drug|Placebo|
1656971|NCT01801748|Dietary Supplement|oral wheat challenge|
1656972|NCT01801735|Drug|Meloxicam Test Capsules|
1656973|NCT01801709|Genetic|intracerebral administration of AAVrh.10cuARSA|
1656974|NCT01801696|Other|Parent massage tx group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
1656975|NCT01801696|Other|Parent massage wait-list control group|The parent-delivered massage is based on Chinese medicine. There are specific techniques for each area of difficulty, e.g. the head, fingers, and toes. After a few months, massage becomes relaxing and enjoyable, and parent touch comes back into use to effectively help the child self-regulate.
1657009|NCT01801280|Drug|Mycophenolate sodium|Daily dose: 720mg, 1080mg, 1440mg. Application alone or together with Pantozol®.
1657010|NCT01801280|Drug|Pantoprazole|Daily dose: 40mg. Application together with CellCept® or Myfortic® .
1657011|NCT01801280|Drug|Mycophenolate mofetil|Daily dose: 1000mg, 1500mg, 2000mg. Application alone or with Pantozol® .
1657063|NCT01800825|Drug|Clindamycin|Clindamycin 300 mg Orally will be administered twice daily for a total of 5 days
1718531|NCT00002532|Drug|leucovorin calcium|
1656976|NCT01801683|Other|Intervention-using PEARLS|The intervention applied in this study was the modified academic detailing method, performed by sixth-year medical students as academic detailers. The students qualified for that role because they were taught about EBM in several courses during their undergraduate curriculum. During the family medicine rotation, each GP mentored six students in total. In Split each student visited two mentors for two weeks. In the course of rotation each mentor chose two patients (cases) from real life who represented diagnostic, therapeutic or prognostic challenge. The students' task was to form an answerable question, using the Patient, Intervention, Comparison, Outcome (PICO) scheme, find the best evidence-based answer to that question and to write a brief report according to Practical Evidence about Real Life Situations (PEARLS) pattern. The mentor then reviewed the report and discussed it with the student.
1656977|NCT01801670|Procedure|Biopsy|Two 6 mm skin punch biopsies (one from pruritic skin and from involved non pruritic skin).
1656978|NCT01801670|Procedure|Blood|Peripheral blood (10 mls) to be drawn and used for cytokine analysis.
1656979|NCT01801644|Drug|gemcitabine plus cisplatin|gemcitabine 1000 mg/m2 on days 1,8,15 as a 30 minute infusion followed by cisplatin 70 mg/m2 on day 1 as an 2 hour infusion
1656980|NCT01801631|Other|Home visits|In addition to usual care the patients will receive three home visits from a trained diabetes nurse. The first visit (65 minutes) is within three weeks after discharge from the hospital; the second visit (45 minutes) is two weeks later and the third visit (45 minutes) is two months after the second home visit.
1656981|NCT01801631|Other|Consultation by telephone|In addition to usual care patients will receive a consultation by telephone within three weeks after discharge to offer them personal attention. In this consultation they will get the opportunity to discuss in ten to fifteen minutes how they feel in the period after discharge.
1656982|NCT01801605|Procedure|rTMS|Active session with stimulation and placebo session with fictive stimulation
1656983|NCT01801566|Procedure|Single implant-retained mandibular overdenture|60 patients treated with single implant retained complete mandibular denture (overdenture) opposed to a conventional maxillary denture, allocated into 2 experimental groups according to the implant loading protocol (conventional and immediate), evaluated at baseline and after 1, 3, 6 and 12 months after treatment.
1656984|NCT01801553|Other|Spinal manipulation|"-In the intervention group :
True Lumbopelvic manipulation in supine (A) or in lateral side lying (B) for subjects with LBP:
If for example, A is the best position for both patient-practitioner but after a maximum of two trials doesn't produce a pop sound then the practitioner will move to the B position for a maximum of two trials as well.
-In the control group:
Sham spinal manipulation will realize to mimic (i) the same time, (ii) interaction and (iii) action with the manual therapist but without any efficacy in the position B using the upper body of the patient to target the thoraco-lumbar hinge and not the lumbopelvic region and take the time of handling the patient like in a true SM and mimic a high velocity and short ROM action moving fast his body but with a minimal action on the patient's body."
1656985|NCT01801553|Other|sham spinal manipulation|
1656986|NCT01801553|Other|Usual medical care|
1656987|NCT01801540|Dietary Supplement|L-arabinose - effect on glucose metabolism|L-arabinose is mixed into the dough of the buns and cup cakes
2013194|NCT00843882|Other|Laboratory Biomarker Analysis|Correlative studies
1656989|NCT01801514|Device|Computed Tomography scan|Routine Computed Tomography scan
1656990|NCT01801475|Drug|Ondansetron|Pregnant & non-pregnant women will receive either 4mg or 8mg of Ondansetron (IV) once prior to surgical procedure (open-label). Women are in the study for 8 hours. Babies of pregnant women are not given Ondansetron but are in the study for 24-48 hours.
1656991|NCT01801462|Other|Simulation-based training|
2013195|NCT00843882|Drug|Lenalidomide|Given PO
1656993|NCT01801436|Drug|Bortezomib|Bortezomib 1.3 mg per (m^2) on Days 1, 4, 8, and 11 of each 3-week cycle for up to 8 cycles.
1656994|NCT01801423|Drug|Hydroxyurea|Hydroxyurea will be prescribed as an investigational therapy by the treating physician. Recommended guidelines for titration of hydroxyurea to maximal tolerated dose are below. The study intervention will include hydroxyurea to begin at ~20 mg/kg/day (range 17.5 - 26 mg/kg/day). No dose escalation will occur as this dose was shown to have some efficacy in infants with SCA and was associated with rare myelosuppression.(1)
1656995|NCT01801410|Device|Foley Catheter|Transcervical Foley catheter (silicone, size 18F with 30ml balloon)
1656996|NCT01801410|Drug|Misoprostol|25mcg every 2 hours for maximum of 12 doses
1656997|NCT01801397|Drug|osteoanabolic therapy|
1656998|NCT01801384|Behavioral|Voucher-based incentives|
1656999|NCT01801371|Drug|68Ga-BNOTA-PRGD2|Single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 at 30 minutes before brain PET/CT scanning.
1657000|NCT01801358|Drug|AEB071|Twice-daily doses of AEB071 for a cycle of 28-days, given without interruption (continuous cycles)
1657001|NCT01801358|Drug|MEK162|Twice-daily doses of MEK162 for a cycle of 28-days, given without interruption (continuous cycles)
1657002|NCT01801345|Other|Fatigued|
1657003|NCT01801345|Other|Rested|
1657004|NCT01801332|Dietary Supplement|intensive nutrition|"Patients randomized in  intensive enteral nutrition  arm will receive by feeding tube (with the use of a microsonde), and in continuous administration, 2 liters of Fresubin HP Energy (1500 kcal/liter, 75 gr prot/liter) for patients with a weight of more than 90 kgs (after ascites removal), 1.5 liters of Fresubin HP Energy for patients with a weight between 60 and 90 kgs, and 1 liter of Fresubin HP Energy for patients of less than 60 kgs. Patients with significant encephalopathy despite therapy against encephalopathy will receive Fresubin Hepa in place of Fresubin HP Energy (1300 kcal/liter, 40 gr prot/liter, 44 % branched AA). Duration of enteral nutrition by feeding tube will be 14 days. The adaptation to the targeted volume must be achieved in maximum 3 days. Enteral nutrition will be administered by nasogastric microsonde."
1657005|NCT01801332|Dietary Supplement|usual meals|"Patients randomized in  classical oral nutrition  arm (control arm) will receive usual meals (estimated at 1750 kcal/day; 70 g protein/day), and alimentary supplements between meals to achieve the ESPEN recommandations (35-40 kcal/kg/day; protein 1.2-1.5 g/kg/day) (Plauth et al, Clinical Nutrition 2006). Calories and proteins intake must be recorded daily."
1657006|NCT01801319|Device|Libra Deep Brain Stimulation System|
1657007|NCT01801306|Device|NeMo Probe|A new minimal-invasive brain tissue probe applying near infrared spectroscopy
1657008|NCT01801293|Drug|GS-5806|
1657012|NCT01801267|Procedure|Endoscopic third ventriculostomy (ETV)|Pediatric patients in need of CSF-diversion surgery will undergo an endoscopic third ventriculostomy (ETV). A neurosurgeon will make a small hole in the third ventricle (a fluid space in the brain) to allow CSF to flow out of the ventricles.
1657013|NCT01801267|Procedure|Ventricular shunt|Pediatric patients in need of CSF-diversion surgery will undergo ventricular shunt placement or revision. A neurosurgeon will insert a small tube into the ventricle (a fluid space in the brain) and connect this tube to another location in the body so that CSF can flow out of the brain and be absorbed elsewhere in the body - the belly, the top of the heart or the side of the lung. If a patient already has a shunt which is not working, a neurosurgeon will fix or replace it. This will serve as the Control arm of the study.
1657014|NCT01801254|Other|STRIDES|Self-Control TRaining for Increasing Delay of gratification through EEG operant conditioning with Source localization (STRIDES). Brain-computer interface training protocol designed to up-regulate specific types of neural activity, in regions including the left dorsolateral prefrontal cortex, the anterior cingulate cortex, and Brodmann area 6 bilaterally. Targeted neural activity types are positively associated with self-controlled behavior.
1657015|NCT01801254|Other|Sham Control|Brain-computer interface training protocol that is designed to have no effect on self-controlled behavior.
1657016|NCT01801228|Drug|Eplerenone|
2013196|NCT00835965|Drug|Dexamethasone|Dexamethasone 5 mg administered intravenously following endotracheal intubation
1657018|NCT01801189|Drug|Pregabalin|One 300 mg oral dose of Pregabalin given before surgery.
1657019|NCT01801189|Drug|Placebo (for Pregabalin)|One oral dose of placebo given before surgery.
1657020|NCT01801176|Other|MRI|MRI every 3 months during the first year and then every 6 months during the second year and then one MRI up to 36 months
1657021|NCT01801163|Drug|Sorafenib|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy and then sorafenib until disease progression.
1657022|NCT01801163|Radiation|Stereotactic radiotherapy|Sorafenib x 2 weeks followed by Stereotactic Radiotherapy then Sorafenib until disease progression.
1657023|NCT01801150|Device|CPAP nasal treatment|Treatment with titred CPAP nasal during the nighttime
1657024|NCT01801137|Drug|Everolimus (Afinitor®)|
1657025|NCT01801124|Drug|EXPAREL|single dose 266 mg of undiluted EXPAREL
1657026|NCT01801111|Drug|erlotinib [Tarceva]|Post progression: Continued treatment with RO542802 after disease progression will be in combination with Tarceva (100 mg orally daily) in patients with EGFR mutations
1657027|NCT01801111|Drug|RO5452802|multiple oral doses
1657028|NCT01801072|Drug|Levetiracetam|Details covered in Arm Descriptions.
1657029|NCT01801059|Other|educational intervention|Receive patient activation intervention by educational video and brochure
1657030|NCT01801059|Other|educational intervention|Receive patient activation intervention by educational video
1657031|NCT01801059|Other|questionnaire administration|Ancillary studies
1657032|NCT01801046|Drug|mitoxantrone hydrochloride|Given IV
1657033|NCT01801046|Drug|cytarabine|Given IV
1657034|NCT01801046|Procedure|peripheral blood stem cell transplantation|Undergo HMMACT with G-PBSC
1657035|NCT01801046|Other|laboratory biomarker analysis|Correlative studies
1657036|NCT01801020|Other|temperature measuremts|temporal artery temperature measurements will be taken from the forehead
1657037|NCT01801020|Other|temperature measuremts|different modes of temperature measuremts will be compared to one another in the same patient. if temporal measurement is higher than oral a rectal temperature will be taken
1657038|NCT01801007|Device|Flow Re-Direction Endoluminal Device|
1657039|NCT01800968|Drug|Liraglutide|Active Drug
1657040|NCT01800968|Drug|Placebo|Placebo
1657041|NCT01800955|Device|resistive capacitive diathermy treatment (resistive capacitive diathermy, Hcr 902, Unibell)|The resistive capacitive diathermy is a medical device supplying low (448 KHz) radiofrequencies with maximum output power of 200 W. It is used to reduce pain and inflammation and allowing healing processes. diathermy treatment is administered for a thirty minutes session, three times per week for a total of ten sessions.
1657042|NCT01800955|Other|sham placebo resistive capacitive diathermy treatment|"The sham treatment is administered with the diathermy device set on on but not active (not supplying energy) and the treatment session has the same modalities, frequency and duration of experimental diathermy group"
1657043|NCT01800942|Drug|Azithromycin and Placebo|A single oral dose of 2g of Azithromycin will be given to the women in labour
1657044|NCT01800929|Device|N6|Children with N5 will be upgraded to the N6 for a period of up to 2 months to evaluate.
1657045|NCT01800916|Device|Coloplast Adhesive baseplate A|Coloplast Adhesive baseplate A is a newly developed 1-piece ostomy appliance.
1657046|NCT01800916|Device|Coloplast Adhesive baseplate B|Coloplast Adhesive baseplate B is a newly developed 1-piece ostomy appliance
1657047|NCT01800916|Device|Coloplast Adhesive baseplate C|Coloplast Adhesive baseplate C is a newly developed 1-piece ostomy appliance
1657048|NCT01800916|Device|SenSura 1-Piece|SenSura 1-piece is the commercial CE-marked Coloplast 1-piece SenSura .
1657049|NCT01800903|Device|ZN-D catheter|ZN-D catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
1657050|NCT01800903|Device|ZN-C catheter|ZN-C catheter is a catheter, similar to the CE-marked SpeediCath, but with a newly developed coating.
1657051|NCT01800903|Device|SpeediCath catheter|The Speedicath cathere is CE-marked and commercially available.
1657052|NCT01800890|Device|Coloplast A|Coloplast A is a newly developed 2-piece ostomy appliance
1657053|NCT01800890|Device|Coloplast B|Coloplast B is a newly developed 2-piece ostomy appliance
1657054|NCT01800890|Device|Coloplast C|Coloplast C is a newly developed 2-piece ostomy appliance
1657055|NCT01800890|Device|SenSura Click|The comparator product is the commercial and CE-marked SenSura Click (2-piece) manufactured by Coloplast A/S.
1657056|NCT01800877|Drug|Vasopressors|
1657057|NCT01800864|Other|obesity|
1657058|NCT01800851|Other|Energy expenditure evaluation in calorimetric chamber|
2013197|NCT00835965|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
2013198|NCT00835965|Drug|Placebo Dexamethasone|
1657064|NCT01800825|Drug|Placebo|This will be an identical placebo comparator made of starch.
1657065|NCT01800812|Biological|Injections of OM-174|
1657066|NCT01800799|Drug|Baktar 800mg h.s.|Antimicrobial agent (Baktar 800mg h.s.)
1657067|NCT01800799|Drug|Celecoxib 200mg QD|Anti-inflammatory agent (Celecoxib 200mg QD)
1657068|NCT01800786|Device|CPAP|
1657071|NCT01800760|Dietary Supplement|Probiotics|Probiotics once a day for three weeks.
1657072|NCT01800747|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between three treatment strategies or arms. Patients randomized to delayed treatment arm or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
1657073|NCT01800734|Other|Clamp-Mixed Meal Arm|"Standard clinical parameters will be assessed in all patients.
Metabolic tests:
A. Euglycemic insulin clamp. A standard euglycemic insulin clamp will be carried out to assess insulin sensitivity, as previously described (1).
B. Mixed meal test. All participants will ingest a standardized mixed meal and will be monitored for 300 minutes thereafter. Right before meal ingestion, a s.c. fast insulin analogue bolus will be administered by the pump
This test will determine the time courses of:
1. plasma glucose, 2.13C/12C glucose ratio (hence, meal-derived and endogenous glucose), 3. insulin, 4. free fatty acids, 5. aminoacids, 6. glucagon, 7. incretin hormones 8. glucose control coefficients (CCs) during a mixed meal."
1657074|NCT01800721|Behavioral|SNAP|Behavioral: SNAP 7 group sessions, and 1 individual session
1657075|NCT01800721|Behavioral|SNAP Control|Behavioral: SNAP control 7 group sessions
1657076|NCT01800708|Drug|Triamcinolone acetonide|
1657077|NCT01800708|Drug|Prednisolone syrup|
1657078|NCT01800695|Drug|ABT-414|ABT-414 will be administered by intravenous infusion
1657079|NCT01800695|Drug|Temozolomide|Temozolomide will be administered per label and local prescribing regulations.
1657080|NCT01800695|Radiation|Whole Brain Radiation|Whole Brain radiation will be administered in 30 fractions.
1657081|NCT01800682|Drug|Tramodol Extended-Release (ER)|Tramodol ER, will be administered orally as either 25, 50 or 100 milligram tablet, once daily on Day 1 of each treatment period (separated with washout period of 4-14 days).
1657082|NCT01800669|Other|CHICA MLP Module|The MLP module screens families for medical-legal issues, alerts the physician to there presences and provides guidance and referral materials to help the physician resolve the issues.
1657083|NCT01800669|Other|CHICA without the MLP module|Clinics in the control group will have the CHICA system, but without the MLP module. It will screen for medical-legal issues but will not provide additional guidance and referrals to help resolve them.
1657084|NCT01800656|Procedure|"Endoloop-assisted ligate and let go colorectal polypectomy"|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps without consecutive snare polypectomy.
1657085|NCT01800656|Procedure|Endoloop-assisted snare colorectal polypectomy|The technique implies placement of endoloop snare on the base of large pedunculated colorectal polyps with consecutive snare polypectomy.
1657086|NCT01800643|Other|Analyze the pharmacokinetics of busulfan for transplantation|"Evaluate the Bu pharmacokinetics (PK) when the drug will be received by P.O or I.V and we will establish the target Area Under Curve- AUC based on a single daily dose (test dose) before HSCT. The test dose of orally Bu is 1 mg/Kg and the blood samples are collected and processed in time: 0h, 30 min, 1h, 1,5h, 2h, 3h, 4h, 5h and 6h after drug intake. After extraction of the plasma samples busulfan, quantitative analyzes of busulfan on human plasma will be performed by the liquid chromatograph. For the patients that will receive intravenously busulfan, the test dose is 32 mg/m2 and blood samples are collected in time: 0h, 30', 45', 1h, 2h, 3h, 4h, 5h, 6h and 8h after drug intake. The dose during the conditioning will depend on the test dose and the AUC target."
1657087|NCT01800630|Drug|Gemcitabine HCl Oral Formulation|
1657088|NCT01800617|Drug|Liothyronine, Sodium|
1657089|NCT01800604|Behavioral|Pain Self-Management Intervention #1|Pain Self-Management Intervention #1 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain. Participants will be encouraged to ask questions about and discuss the information presented during the treatment sessions.
1657090|NCT01800604|Behavioral|Pain Self-Management Intervention #2|Pain Self-Management Intervention #2 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #2 will emphasize cognitive restructuring skills to replace maladaptive pain-related thoughts with adaptive and reassuring ones. These skills include being able to: (1) develop awareness of one's thoughts; (2) identify and evaluate adaptive/helpful vs. unhelpful/maladaptive thoughts; and (3) develop alternative thoughts to maladaptive thoughts that are (a) realistic, (b) accurate, (c) reassuring, and (d) facilitate positive outcomes.
1657091|NCT01800604|Behavioral|Pain Self-Management Intervention #3|"Pain Self-Management Intervention #3 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). In Pain Self-Management Intervention #3, subjects will relax in a comfortable position with their eyes closed and simply listen to the clinician speak. The clinician will begin the session with a hypnotic induction focusing on being aware of sensations of relaxation, followed by suggestions for decreases in pain intensity and alterations in the sensory experience of what are sometimes uncomfortable sensations so that they are more comfortable."
1657136|NCT01800318|Device|Sham NESAP|Four electrodes will be placed on the infant's lower leg, but the TENS unit will not be turned on. The TENS unit will be covered and investigators will not know whether the TENS unit is turned on or not (sham NESAP).
1657210|NCT01799629|Drug|Glycerin suppositories|
1657211|NCT01799616|Drug|Pamidronate|
1657212|NCT01799616|Other|Placebo|
1657092|NCT01800604|Behavioral|Pain Self-Management Intervention #4|Pain Self-Management Intervention #4 will consist of four 60-minute sessions conducted in person over four weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). Pain Self-Management Intervention #4 will use hypnotic strategies and suggestions for identifying adaptive cognitions and for making adaptive changes in cognitions more integrated into a participant's belief system.
1657093|NCT01800591|Behavioral|Financial incentive|
1657094|NCT01800578|Device|monitor for depth of hypnosis|evaluation of depth of hypnosis
1657095|NCT01800565|Other|Measurement of LH in first-voided urine|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
1657096|NCT01800565|Other|collection of first-voided urine sample for LH level|participants in this study will be studied by the standard GnRH stimulation test. In addition, they will provide first voided urine sample (the experimental part)for the measurement of LH.
1657097|NCT01800552|Procedure|Intentional infiltration of a peripheral IV site|An intentional infiltration of isotonic saline solution is performed by pushing the needle through the vein wall into the subcutaneous tissue. A total volume less than or equal to 5 cc of saline is infiltrated into the tissue.
1657098|NCT01800539|Behavioral|Provider Education Model (PEM)|Providers will be trained to use evidence-based practices for early intervention service delivery in the Autism Spectrum Disorder population.
1657099|NCT01800526|Drug|N-Acetylcysteine|Oral and Intravenous administration of NAC
1657100|NCT01800513|Procedure|Endometrial Biopsy|
1657101|NCT01800513|Procedure|Sham Procedure|
1657102|NCT01800500|Behavioral|smoking cessation intervention|Purchase ST products using a fixed rate of product prices
1657103|NCT01800500|Behavioral|smoking cessation intervention|Purchase ST products using escalating product prices
1657104|NCT01800500|Other|questionnaire administration|Ancillary studies
1657105|NCT01800500|Other|quality-of-life assessment|Ancillary studies
1657106|NCT01800500|Other|laboratory biomarker analysis|Correlative studies
1657107|NCT01800500|Other|ecigarettes|Purchase ST products using escalating product prices nicotine replacement therapy
1657108|NCT01800500|Other|ecigarettes|Purchase ST products using a fixed rate of product prices nicotine replacement therapy
1657109|NCT01800487|Drug|silymarin|140 mg three times a day for 4 weeks
1657110|NCT01800487|Drug|Placebo|Placebo (silymarin) 1 tab three times a day for 4 weeks
2013199|NCT00831350|Drug|Ranibizumab|Subjects will receive study medication ranibizumab 0.5mg. Re-treatment will occur monthly through 6 injections
1657113|NCT01800435|Drug|aPCC, aPCC + TXA|Feiba 75 IU/kg i.v Feiba 75 IU/kg i.v +Cyklokapron 20 mg/kg p.o
1657114|NCT01800435|Drug|rFVIIa, rFVIIa + TXA|NovoSeven 90 µg/kg i.v NovoSeven 90 µg/kg i.v + Cyklokapron 20 mg/kg
1657115|NCT01800422|Drug|telapristone acetate|Given orally
1657116|NCT01800422|Other|placebo|Given orally
1657117|NCT01800422|Procedure|therapeutic conventional surgery|Undergo surgical resection
1657118|NCT01800422|Other|laboratory biomarker analysis|Correlative studies
1657119|NCT01800422|Other|questionnaire administration|Ancillary studies
1657120|NCT01800409|Device|AFES|During the stimulation sessions electrical stimulation will be applied for 40 minutes per day, 5 days per week for a total of 8 weeks
1657121|NCT01800396|Dietary Supplement|Milk protein|
1657122|NCT01800396|Dietary Supplement|Milk protein rich in phospholipids|
1657123|NCT01800370|Drug|Hyperglycemia|Hyperglycemia (rest controlled) will be induced by i.v. injection of 25 mL of dextrose 50% over 3 minutes with the subject supine.
1657124|NCT01800370|Drug|Saline|Saline (rest controlled) will be induced by i.v. injection of 25 mL of saline over 3 minutes with the subject supine.
1657125|NCT01800370|Other|Exercise|"Monitored exercise of 7-minute biking, 2-minute arm weights and a blood draw at the 10-minute time point will be repeated 3 times,which takes 30 minutes.
Bilateral arm curls begin at 20 pounds and decrease by 5 pounds as needed to sustain 2 minutes of exercise at a rate of 1 complete curl every 2 seconds."
1657126|NCT01800370|Procedure|Blood Draws|Blood will be sampled every 10 min from 0700 to 1300 h. Each intervention will begin at 0800 h after 1 h of baseline sampling, and be completed by 0900 h. Intervention is followed by 4 additional h of sampling to capture recovery (total sampling 6 h). Ten-min samples are for Te, LH, ACTH, cortisol, and GH. Glucose will be checked every 30 min. At 07000 h an archival serum sample will be obtained for safety-monitoring purposes.
1657127|NCT01800370|Other|Fasting procedure|Beginning at 1900 h on the evening prior to each study visit, subjects will remain fasting except for water, diet soda, and other non-caloric and non-caffeinated fluids, until 1300 h the next day.
1657128|NCT01800357|Drug|infusion of mildronate|infusion of mildronate(500mg) once a day and for 14 days
1657129|NCT01800357|Drug|placebo|infusion of plabcebo once a day and for 14 days
1657130|NCT01800357|Drug|aspirin|infusion of aspirin (100mg) once a day for days
1657131|NCT01800344|Device|LMA|
1657132|NCT01800344|Device|Ultra|Ultra
1657133|NCT01800331|Behavioral|Text2bHealthy|The intervention group uses handheld computers to keep track of their lifestyle behaviours and they will receive feedback on thier progress and tips (Text2bHealthy)
1657134|NCT01800318|Device|NESAP|Electrical stimulation will be administered via the Empi Select, a standard TENS unit. To produce analgesia, small electrodes will be placed in treatment groups on the baby's legs at specific acupuncture points: ZuSanLi (ST36), SanYinJiao (SP6), Shen Mai (Bl60), and Shui Quan (KI3)46. StimCare electrodes with a gel base will be applied to the skin ; the skin will not be punctured by these procedures. A low continuous current will be provided with minimal voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 2 minutes after the heel stick. The display will be hidden from view to prevent the rater from being able to observe whether the unit is on.
1657135|NCT01800318|Behavioral|24% oral Sucrose|One ml 24% sucrose will be given approximately two minutes before the heel stick. Sucrose will be given via oral syringe along with a pacifier.
1657208|NCT01799681|Behavioral|an 8-week blended indoor-outdoor exercise program|stretching, strength and functional training, Balance Dance, Modified Wing Chun, Square stepping exercise, and fall-prone activities practice
1657137|NCT01800318|Behavioral|Oral water|For infants in the control group, 1 ml of water will be given via oral syringe along with a pacifier 2 minutes before the heel stick. Investigators will be blinded on whether the infants are receiving water or oral sucrose.
1657138|NCT01800305|Drug|Pegylated rhEPO|
1657139|NCT01800305|Drug|EPIAO®|
1657140|NCT01800292|Drug|sildenafil|Subjects will be started on sildenafil at 20 mg PO TID at the baseline visit. Each individual will serve as his/her own control. Subjects will be evaluated at 3 months, with participation completed at that time.
1657141|NCT01800279|Other|Physiotherapy Protocol|"Kinesitherapy
Patient: supine position on the stretcher with a loop of 6 cm in the cervical area.
Tongue in the palate for all applied exercises.
Repetitions of each exercise: 8. Cervical traction. Cranium fore flexion 15 °. Open-close mouth dental contactless (10mm). Opening movement with a small resistor (one finger on chin).
Flexion of the head, without actually lifting, resisting in the front. Occipital extension. Cranium fore flexion 15 °. Cervical traction.
Myofascial Therapy. Induction suboccipital. Compression - decompression of the TMJ (Temporomandibular Joint). Horizontal Induction TMJ. Deep fascia induction in the temporal region. Deep Induction of the masseter fascia. Deep Induction of the external pterygoid. Induction of intraoral pterygoid."
1657142|NCT01800279|Other|Deontology Therapy|"For the realization of the splint, the following protocol will be developed at the Faculty of Dentistry of Granada (Spain):
Impression of the maxilla with chromatic alginate Phase plus (Zhermack ©, Rovigo, Italy).
Emptying working models in plaster-stone type IV Elite Rock (Zhermack ©, Rovigo, Italy).
Deprogramming occlusal splints were made of polyester plates with terephthalic acid of 3 mm thick Clear 120 model (Dentaflux ©, Ripoll, Madrid). We used a molding machine of thermoplastic vacuum plate The Machine Dentaflux ©, Ripoll, Madrid."
1657143|NCT01800266|Behavioral|Supervision Practices of TF-CBT|Supervisors will be trained in one of two supervision strategies: Symptom and Fidelity Monitoring (SFM) or Symptom and Fidelity Monitoring + Behavioral Rehearsal (SFM + BR)
1657144|NCT01800253|Behavioral|Inhibitory task|Participants perform a binary decision on each presented stimuli. Of the two possible outcomes, participants are instructed to make a motor response (go) for one type, and are to withhold a response (no-go) for the other type. Reaction time and accuracy are measured for each event
1657145|NCT01800253|Procedure|Blood samples|Hormone levels, neuromolecular levels and gene expression profiles will be analyzed from repeated blood samples obtained before and after the nighttime intervention
1657146|NCT01800253|Procedure|Tissue samples|Expression profiles will be analyzed from samples obtained from tissues involved in metabolism
1657147|NCT01800253|Procedure|Oral glucose tolerance test|75 g of glucose will be dissolved in 300 ml of water and given to participants, followed by blood sampling at 0, 15, 30, 60, 90, 120 and 150 minutes following the ingestion of the glucose solution.
1657148|NCT01800253|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
1657149|NCT01800240|Drug|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
1657150|NCT01800227|Drug|Torrent's Pioglitazone Hydrochloride and Metformin Hydrochloride Tablets|
1657151|NCT01800201|Behavioral|Electronic Pill Bottle, Incentives, Social Influence|The intervention group (1) will use the GlowCaps, a remote monitoring and reminder pill bottle; (2) will be assigned an engagement advisor from the study team; (3) asked to provide the study team with names and contact information of up to 3 family members or friends as support partners for medication adherence. The study team will contact these people in order listed until 1 agrees to serve in this role; (4) will select a 2-digit lucky number to be used as part of the sweepstakes-based engagement incentives in which eligibility to win will be conditional on medication adherence; and (5) will determine their preferences for Way to Health platform communication methods during the study.
1657152|NCT01800188|Procedure|Hemodialysis|A 4 hour hemodialysis with a standardized liquid meal after one hour
1657153|NCT01800188|Procedure|Hemodiafiltration|A 4 hour hemodiafiltration with a standardized liquid meal after one hour
1657154|NCT01800188|Procedure|Meal test|A 3 hour standardized liquid meal test without dialysis
1657155|NCT01800175|Device|Punctum Plug|
2013200|NCT00820157|Procedure|Cytoreductive Surgery|Cytoreductive Surgery followed by TACE for MNHCC
2013201|NCT00820157|Procedure|TACE|TACE alone or TACE followed by downstage resection for MNHCC
2013202|NCT00810810|Biological|Standard blood components|Transfusion, if ordered by physician, with unfiltered red blood cells and apheresis platelets
1657159|NCT01800149|Procedure|Ridge Augmentation|After tooth extraction, the sockets will be filled with bovine bone mineral and covered with a porcine collagen membrane
1657160|NCT01800136|Device|Repetitive Transcranial Magnetic Stimulation and Transcranial Direct Current Stimulation|Five sessions of HF-rTMS or tDCS applied daily during 5 consecutive days
1657161|NCT01800110|Dietary Supplement|pomegranate juice|
1657162|NCT01800097|Drug|modafinil|Tablet, 400 mg once daily, morning (200 mg if age 65 or above) for 3 months
1657163|NCT01800097|Drug|placebo|Tablets, 400 mg once daily ( 200 mg if age 65 or above)morning for 3 months.
1657164|NCT01800084|Device|Asir Image Acquisition|In addition to their normal image acquisition, a supplementary image acquisition lasting approximately 20 seconds (i.e. an ASIR image acquisition) will be carried out for each patient.
1657165|NCT01800071|Drug|MVA-EBNA1/LMP2 vaccine|
1657166|NCT01800045|Drug|Pitolisant|1 capsule in the morning before breakfast
1657167|NCT01800045|Drug|Placebo|1 capsule in the morning before breakfast
2013203|NCT00810810|Biological|Leukoreduced blood components|Transfusion, if ordered by a physician, of leukoreduced red blood cells and apheresis platelets
2013204|NCT00810810|Biological|Leukoreduced and irradiated|Transfusion, if ordered by physician, of gamma irradiated leukoreduced red blood cells and gamma irradiated apheresis platelets
2013205|NCT00807664|Device|Biatain Ag|Biatain Ag non adhesive ( ColoplastA/S), a polyurethane permeable backing film with an added silver complex, size 15X15. The product is CE marked
1657255|NCT01799213|Drug|Meloxicam 15 mg po QD|Eligible subjects will be take Meloxicam 15 mg po QD
2013206|NCT00807664|Device|Biatain|A standard polyurethane foam dressing Biatain non adhesive permeable backing film, size15X15 cm. the product is CE marked
1657171|NCT01800006|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed Rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
1657172|NCT01799993|Drug|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
1657173|NCT01799993|Drug|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
1657174|NCT01799954|Biological|DNA-HIV-PT123|4 mg of DNA encoding clade C ZM96 Gag and gp140, CN54 Pol-Nef, administered intramuscularly (IM)
1657175|NCT01799954|Biological|NYVAC-HIV-PT1|(along with NYVAC-HIV-PT4); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
1657176|NCT01799954|Biological|NYVAC-HIV-PT4|(along with NYVAC-HIV-PT1); ≥ 5x106 PFU encoding clade C ZM96 gp140 and ZM96 Gag and CN54 Pol-Nef, administered IM
1657177|NCT01799954|Biological|AIDSVAX® B/E|300mcg of subtype B (MN) HIV gp120 glycoprotein and 300mcg of subtype E (A244) HIV gp120 glycoprotein absorbed onto 600mcg of aluminum hydroxide gel adjuvant, administered IM.
1657178|NCT01799954|Biological|Placebo for DNA/NYVAC|Sodium Chloride for injection, 0.9% administered IM
1657179|NCT01799954|Biological|Placebo for AIDSVAX(R) B/E|600 mcg of aluminum hydroxide adjuvant, administered IM
1657180|NCT01799941|Drug|Nuedexta (DM 20 mg/Q 10 mg)|Single Arm, Open-Label Dosing with Nuedexta (DM 20 mg/Q 10 mg)
1657181|NCT01799902|Drug|Solifenacin|Oral
1657182|NCT01799889|Drug|Entospletinib|Tablet administered orally
1657183|NCT01799889|Drug|Entospletinib SDD|SDD tablet administered orally
1657184|NCT01799876|Procedure|Autologous Cell|
1657185|NCT01799876|Procedure|Standard microfracture arthroscopic surgery|
1657186|NCT01799863|Drug|Ketorolac trometamol 0.45% with carboxymethylcellulose|
1657187|NCT01799863|Drug|Preservative free artificial tear|
1657188|NCT01799850|Drug|Pioglitazone|pioglitazone 30 mg daily, pill, eight weeks, placebo randomly assigned
1657189|NCT01799850|Drug|placebo|placebo assigned randomly, double blind
1657190|NCT01799837|Drug|[C-11]MENET|PET imaging involves injecting small amounts of a radioactive material into the blood stream. The radioactive material is attached to a drug called MENET that will give information about how the brain interacts with a protein called norepinephrine (NE).
1657191|NCT01799824|Biological|ANT-1403|
1657192|NCT01799824|Biological|placebo|
1657193|NCT01799798|Drug|Denosumab|Denosumab will be given subcutaneously in a dosage of 1mg/kg body weight every 12 weeks. 4 interventions are planned until trial week 36. There is no control group planned.
1657194|NCT01799785|Behavioral|Aerobic exercise|Aerobic exercise for 8 weeks (3 times per week, 30-60 minutes each session)
1657195|NCT01799785|Other|Usual Care|
1657196|NCT01799772|Behavioral|Comprehensive Behavioral Intervention|"Evidence-based exercise program - Combination of high intensity lower extremity strengthening, endurance on the treadmill, functional task-oriented exercises, and balance techniques. During 12 sessions, subjects will be instructed to become independent in performing the exercises at home.
Physical activity promotion - Instructions to engage in moderate intensity exercise 5 days/week will be delivered along with the exercise program.
Healthy nutrition guidance - Instructions on healthy nutrition delivered by a dietitian.
Self-management - Basic self-management skills advocated by the Arthritis Foundation Self-Help Program and behavioral strategies (self-monitoring, problem solving, relapse prevention, and goal-setting) and feedback into approaches a, b and c."
1657197|NCT01799772|Other|Standard of Care Exercise Program|Typical rehabilitation after TKA surgery
1657198|NCT01799759|Behavioral|Online intervention|Child online intervention is 8 modules based on the Health Promotion/Transtheoretical Model Parent online intervention is 6 modules based on enhancing authoritative parenting,support and role models for improved nutrition, physical activity and health child body mass percentile
1657199|NCT01799759|Other|Completion of instruments only|Parent and child subejects in the waiting list control only complete surveys, body composition and fitness tests
1657200|NCT01799733|Other|LWT+AM BWL|One night of late wake therapy (LWT)(sleep 21:00-01:00 h, followed by wakefulness) plus 7 days of morning bright white light (AM BWL)(light-emitting diode-LED administered for 60 minutes, starting within 30 minutes of habitual wake time)
1657201|NCT01799733|Other|EWT+PM BWL|One night of early wake therapy (EWT) (wakefulness until 03:00 h, then sleep 03:00-07:00 h) plus 7 nights of evening bright white light (PM BWL)(light-emitting diode-LED administered 90 minutes before habitual sleep onset, for 60 minutes)
1657202|NCT01799720|Dietary Supplement|Less oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 1 took 2 capsules/day of one of the less oxidized oil (containing 300 mg EPA + DHA) and diet, . Follow-up 30 days
1657203|NCT01799720|Dietary Supplement|More oxidized oil and diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 2 took 2 capsules/day of one of the more oxidized oil (containing 300 mg EPA + DHA) and diet . Follow-up 30 days
1657204|NCT01799720|Drug|Hypercholesterolemic diet|Analyze the effect of dietary supplements Omega-3 with different levels of oxidation in the lipid profile of women who consume these supplements. For this purpose we have designed a single-blind, parallel-groups, randomized controlled trial. Finally 52 women between 25 and 75 years old randomly were distributed into three groups. Participants from group 3 only received the diet and no capsules. Follow-up 30 days
1657205|NCT01799707|Behavioral|vision restoration training|
1657206|NCT01799707|Behavioral|Discrimination Training|
1657207|NCT01799694|Drug|Inject of Autologous Adipose-derived stem cells|Inject in muscle of autologous adipose derived stem cells
1657209|NCT01799681|Behavioral|an 8-week upper limb and hand exercise program|upper limb stretching and strengthening, hand agility exercises, knot tying and Chinese calligraphy
1657213|NCT01799603|Drug|TMC435|TMC435, 100 milligram oral capsule will be administered on Day 1 of each treatment period, separated by washout period of 9 days.
1657214|NCT01799590|Drug|Topiramate|Topiramate tablets will be administered orally in the dose range of 50 to100 milligram per day (mg/day). Dose will be increased or decreased as per Investigator's discretion. Maximum daily dose limit will be 200 mg.
1657215|NCT01799577|Procedure|Laparoscopic surgery|Two methods will be compare
1657216|NCT01799564|Procedure|Micropulse|Between 1 and 3 sessions of micropulse laser will be applied in the inferior hemiretina of the randomly selected eye
1657217|NCT01799551|Behavioral|Ca CBT|Clients in intervention group will receive a CBT intervention using a manual. Intervention was developed for use in primary and secondary care using a series of qualitative studies (Naeem et al a, 2010, Naeem et al c, 2009, Naeem et al, 2009, Naeem et al, in press) during the last 5 years in Pakistan and has proven to be effective in a pilot study (Naeem et al, 2011). Intervention will consist of 6 sessions and will focus on psycho-education, symptoms management, changing negative thinking, problem solving, improving relationships and communication skills. One person from the family will be involved as a facilitator.
2013207|NCT00799383|Drug|Calcium and Vitamin D|"Calcium carbonate 625mg and vitamin D 200IU will be administered, orally, twice a day for a nine-month period.
I labelled the intervention type as drug, even though dietary supplement would be more appropriate as the system sent the following error message:
ERROR: An IND/IDE study must have at least one intervention of type: Drug, Device, Biological/Vaccine, Radiation or Genetic."
2013208|NCT00797732|Device|Acupuncture|
2013209|NCT00782275|Drug|avastin|Given intravenously on days 1 and 15
1657221|NCT01799525|Procedure|Hypercapnia by reduction of respiratory volume|By reduction of the respiratory volume, PaCO2 is raised while paO2 is kept constant by modulation of the oxygen supply through the respirator,
1657222|NCT01799512|Device|experimental: real-time continuous glucose monitoring|
1657223|NCT01799512|Device|Active comparator: blinded continuous glucose monitoring|
1657224|NCT01799499|Device|TC-3 hydrogel|
1657225|NCT01799499|Device|TC-3 hydrogel|
1657226|NCT01799499|Device|TC-3 hydrogel|
1657227|NCT01799486|Drug|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
1657228|NCT01799486|Drug|Enecavir|0.5 mg monotherapy supplied in tablets.
1657229|NCT01799486|Drug|Adefovir|10 mg monotherapy supplied in tablets.
2013210|NCT00782275|Drug|temsirolimus|Given intravenously on days 1, 8, 15, and 22
2013211|NCT00781937|Drug|liraglutide|Liraglutide 3.0 mg per day administered in a 6.0 mg/mL, 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
1657232|NCT01799447|Behavioral|Early intervention|Interventions by health visitors with 18 months training in the Marte Meo method in order to promote relations between parents and infants.
1657233|NCT01799434|Other|treadmill run|
1657234|NCT01799382|Other|Rapid on-site evaluation|Rapid on-site evaluation consists on the cytological evaluation of samples obtained during a diagnostic procedure by a pathologist present in the diagnostic suite. In the present study, cytological samples obtained with EBUS-TBNA during bronchoscopy will be evaluated.
1657235|NCT01799382|Device|EBUS-TBNA|EBUS-TBNA is a needle aspiration procedure guided by endobronchial ultrasounds performed during bronchoscopy
1657236|NCT01799369|Behavioral|Surgical Apgar Score|Post-operative care influenced by Surgical Apgar Score
1657237|NCT01799356|Drug|Moxifloxacin|daily 400 mg moksifloksasin
1657238|NCT01799356|Drug|Ofloxacin|daily 800 mg oflaksasin plus 1000 mg metronidazol treatment
1657239|NCT01799356|Drug|Metronidazole|daily 1000 mg metronidazol plus 800 mg oflaksasin treatment for uPID
1657240|NCT01799343|Other|Immersion into water|Measurements of mean arterial pressure, deepest vertical pocket of amnion fluid and Doppler flow in the umbilical and uterine arteries will be assessed before immersion, during immersion and after immersion.
1657241|NCT01799330|Procedure|Transcutaneous Electrical Muscle Stimulation (TCEMS)|
1657242|NCT01799317|Drug|Vitamin D2|These patients will receive standard of care vitamin D 1,25 therapy with intervention of vitamin D2
1657243|NCT01799304|Procedure|no distractor control group|This control condition will aim at analyzing posture and locomotion in CP children with the intent to focus attention on their equilibrium, only, without any other interference.
1657244|NCT01799304|Procedure|visual and sound attentional distractors|The distractors will be used to orient subjects' attention toward another simple and motivating task in order to avoid focalisation on postural control and locomotion and to favour a more automatic control.
1657245|NCT01799304|Procedure|sound attentional distractor alone|In addition to the previous condition, the goal of the present condition is to isolate the effects of a sound distractor, since it is known that CP children frequently exhibit visual deficits which may affect their postural and locomotion difficulties.
1657246|NCT01799304|Procedure|additional cognitive task|The additional cognitive task aimed to increase the attentional load and to analyse its impact on children's capacity to process two tasks simultaneously (the cognitive and postural or locomotor tasks)
1657247|NCT01799291|Behavioral|Decision Making Tutorial|"A web-based presentation focused on key cognitive de-biasing strategies, including helping clinician participants: consider alternative diagnoses (e.g., symptom checklists); decrease reliance on memory (e.g., mnemonics); and incorporate Bayesian reasoning (e.g., actuarial approaches)."
1657249|NCT01799265|Device|Somnetics Transcend Auto|
1657250|NCT01799265|Device|Respironics REMstar Auto with C-Flex|
1657251|NCT01799239|Device|Test product|The test product consists of an adhesive with a new top film
1657252|NCT01799239|Device|SenSura|SenSura is the CE-marked and commercially available comparator product
1657253|NCT01799226|Other|Toothpaste without triclosan|this intervention will use a toothpaste without triclosan
1657254|NCT01799226|Other|Triclosan|this intervention will use Colgate Total which contains triclosan
2013212|NCT00781937|Drug|placebo|Liraglutide placebo 3 mL FlexPen® for subcutaneous (under the skin) injection, once daily
1657256|NCT01799213|Behavioral|Cognitive Behavioral Therapy|Subjects originally assigned to placebo will receive cognitive behavioral therapy for 10 weeks
1657257|NCT01799187|Procedure|revascularization|revascularization include 3 steps: root disinfected,induction of bleeding and revascularization include 3 steps: root disinfected,induction of bleeding and sealing
1657258|NCT01799187|Procedure|apexification|apexification uses calcium hydroxide as root medication
1657259|NCT01799174|Procedure|UVA-1 Phototherapy|
1657260|NCT01799174|Procedure|Placebo|
1657261|NCT01799161|Biological|gp96-Ig Vaccine|
1657262|NCT01799161|Drug|Theophylline|300 mg capsule daily of Theophylline during 1st course, then adjusted dose
1657263|NCT01799161|Other|Oxygen|24-hr oxygen delivered via nasal cannula or oxygen mask during 1st course, then adjusted dose.
1657264|NCT01799161|Procedure|Immunologic Evaluation|Frequency of IFN-y,CD8 cells in response to vaccine in available tumor samples Blood draw to assess immunological response [frequency of CD4+, FoxP3 (Treg), et al] in treated patients.
1657265|NCT01799148|Other|Particulate air pollutants|We will determined the average concentrations of different sizes of particulate matter from 1 day or up to 7 days prior to admission in patients with acute coronary syndrome.
1657266|NCT01799135|Other|DCE-MRI scan|
1657267|NCT01799135|Radiation|Stereotactic Body Radiation Therapy|
1657268|NCT01799135|Other|4D-CT scan|
1657269|NCT01799122|Device|Mini Arc Precise Pro and Trans vaginal obturator sling (TVT-0)|
1657270|NCT01799109|Drug|Magnesium Sulfate & albuterol|
1657271|NCT01799109|Drug|albuterol|
1657272|NCT01799109|Drug|magnesium|
1657273|NCT01799096|Dietary Supplement|Sucrose|Sucrose in carbonated soft drinks (4 x250ml total1800 kJ per day)
1657274|NCT01799096|Dietary Supplement|Aspartame|Intensely sweetened soft drink (no energy content)
1657275|NCT01799083|Drug|Decitabine|A continuous 5-day lower-dose decitabine transfusion will be performed for patients during each treatment cycle, and autologous cytokine-induced killer cells may be transfused or chemotherapy may be also added.
1657276|NCT01799083|Biological|cytokine-induced killer cell|Autologous cytokine-induced killer cells may be used for patients before and after decitabine treatment.
1657277|NCT01799057|Drug|Metformin|Participants randomized to metformin will be treated at a maximum dose of 2000mg per day (i.e. 1000mg twice daily for 16-18 weeks; up-titrated from 500mg twice daily for the first 2 weeks). Participants may complete the 16-18 week treatment intervention at the lower dose of 500mg twice daily if limited by side effects.
1657278|NCT01799057|Drug|Placebo|Participants randomized to placebo will take matching oral capsules according to the same dose schedule specified for the metformin intervention.
1657279|NCT01799044|Device|Irreversible electroporation (IRE)|Tumor ablation with irreversible electroporation with the NanoKnife
1657280|NCT01799031|Other|internet-based intervention|Receive access to the WISE web-based educational intervention
1657281|NCT01799031|Procedure|management of therapy complications|Receive standard of care
1657282|NCT01799031|Other|educational intervention|Receive access to the WISE web-based educational intervention
1657283|NCT01799031|Other|questionnaire administration|Ancillary studies
1657284|NCT01799031|Procedure|quality-of-life assessment|Ancillary studies
1657285|NCT01799005|Dietary Supplement|Flavanol (410 mg)|
1657286|NCT01799005|Dietary Supplement|Control (no flavanols)|
1657287|NCT01798992|Drug|Carvedilol|
1657288|NCT01798992|Drug|Metoprolol succinate|
1657289|NCT01798992|Drug|Metoprolol succinate + doxazosin|
1657290|NCT01798979|Drug|GLPG0634|Each subject will receive multiple oral doses of GLPG0634 (200 mg daily for 7 days) from Days 2 to 8.
1657291|NCT01798979|Drug|Midazolam|Each subject will receive a single oral dose of midazolam (2 mg) on 2 occasions (Days 1 and 8)
1657292|NCT01798966|Device|SENSIMED Triggerfish|
1657293|NCT01798940|Drug|Torrent's Pioglitazone|
1657294|NCT01798927|Device|Ankle foot orthosis|Participants will receive a Tamarack ankle foot orthosis with a check strap for gait training as well as a home walking program.
1657295|NCT01798914|Drug|Technosphere Insulin Inhalation Powder|Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
1657296|NCT01798901|Drug|HDAC inhibitor AR-42|Given PO
1657297|NCT01798901|Drug|decitabine|Given IV
1657298|NCT01798901|Other|laboratory biomarker analysis|Correlative studies
1657299|NCT01798901|Other|pharmacological study|Correlative studies
1657300|NCT01798888|Procedure|Implantation of Deep Brain Stimulation|
1657301|NCT01798875|Drug|oral metformin|
1657302|NCT01798875|Drug|oral contraceptive|
1657303|NCT01798862|Procedure|Endometrial injury by hysteroscopy or pipelle sampling|
1657304|NCT01798862|Procedure|Proceed to COH directly|
1657305|NCT01798849|Drug|MK-8892|
1657306|NCT01798849|Drug|Placebo for MK-8892|
1657307|NCT01798836|Procedure|Oestradiol pre-treatment and combination of GnRH agonist/antagonist protocol|
1657308|NCT01798836|Procedure|GnRH agonist or antagonist protocol without oestradiol pre-treatment|
1657309|NCT01798823|Procedure|History, physical, LF, SPT, blood sample, FeNO, EBC.|Medical history and physical examination, (LF) lung function (spirometry, (SETC) standardized exercise treadmill challenge, (BRT) bronchial reversibility test,(MBP) metacholine bronchial provocation), (SPT) skin prick tests, blood sample, (FeNO) fractional exhaled nitric oxide measurements, (EBC) exhaled breath condensate.
1657310|NCT01798810|Procedure|Supplemental Perioperative Oxygen|Patients receiving perioperative oxygen will receive 80% FiO2 during surgery.
1657311|NCT01798784|Behavioral|Sweepstake Incentive 1|Daily sweepstake conditional on daily medication adherence
1657312|NCT01798784|Behavioral|Sweepstake Incentive 2|Daily sweepstake conditional on daily medication adherence
1657313|NCT01798784|Behavioral|Sweepstake Incentive 3|Daily sweepstake conditional on daily medication adherence
1657314|NCT01798771|Procedure|Interventional arm|5-ALA fluorescence guided surgery with the additional use of an intraoperative MRI for resection control in patients with contrast enhancing tumors.
1657315|NCT01798771|Procedure|Control arm|5-ALA fluorescence guided surgery in patients with contrast enhancing tumors.
1657350|NCT01798459|Drug|Methylphenidate|
1657316|NCT01798745|Drug|JNJ-54452840|Once daily intravenous injection(s) (medication is injected into a vein) at doses ranging from 20 mg to 240 mg, given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
1657317|NCT01798745|Other|Placebo|Once daily matching intravenous injection(s) (medication is injected into a vein) given as a single injection (Cohorts A and B); injections given once daily over 3 to 5 days (Cohorts C, D, and F); or injections given once weekly up to Day 22 (Cohorts E and F).
1657318|NCT01798732|Procedure|Selective Laser Trabeculoplasty (Tango Laser, Ellex)|One session of selective laser trabeculoplasty with the following parameters (inferior half-circumference, 50 shots, 0.8 to 1.3 mJ)
1657319|NCT01798719|Behavioral|Low Glycemic Index Mediterranean Diet|A list of foods that may be consumed frequently (green foods), sometimes (yellow foods) and never (red foods)
1657320|NCT01798719|Behavioral|General Advice|Only general advice about diet
1657321|NCT01798706|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning
Route of administration: Subcutaneous injection"
1657322|NCT01798706|Drug|Placebo|"Pharmaceutical form: Solution for injection in pre-filled pen administered 30 to 60 minutes before breakfast in the morning
Route of administration: Subcutaneous injection"
1657323|NCT01798706|Drug|Antidiabetic background therapy|Participants received a stable regimen of anti-diabetic background therapy for at least 3 months prior to screening, during the placebo run-in period and the 24 week treatment period. Allowed background antidiabetic therapy included metformin, sulfonylurea (except glibenclamide >10 mg, gliclazide >160 mg), meglitinides (except repaglinide >6 mg), pioglitazone and basal insulin. Insulin glargine, neutral protamine hagedorn (NPH) insulin, detemir, lente and ultralente were considered as basal insulin.
1657324|NCT01798693|Dietary Supplement|Placebo (maltodextrin)|
1657325|NCT01798693|Dietary Supplement|Multi-nutrient Blend|
1657326|NCT01798680|Dietary Supplement|Vitamin D3 (cholecalciferol)|Supplements containing 50,000 IU of vitamin D3 (cholecalciferol) taken orally once per week for 4 weeks (weeks 0, 1, 2, 3) followed by 2,000 IU of vitamin D3 (cholecalciferol) supplements taken orally once per day starting at 4 weeks until study discharge at 12 months
1657327|NCT01798680|Other|Placebo|Placebo pills taken once weekly for 4 weeks (weeks 0, 1, 2, 3) followed by placebo pills taken orally once per day starting at 4 weeks until study discharge at 12 months
1657328|NCT01798667|Drug|DA-8031|
1657329|NCT01798667|Drug|Placebo|Placebo of DA-8031, undistinguishable
1657330|NCT01798641|Device|MIETHKE proGAV® / MIETHKE proSA®|The programmable shunt will be adjusted through the MIETHKE proGAV® / MIETHKE proSA® valve and crossed over at 6 weeks. The open shunt will be adjusted to be closed. The closed shunt will be adjusted to open.
1657331|NCT01798628|Drug|Treatment A: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered after a high-fat meal
1657332|NCT01798628|Drug|Treatment B: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose after a low-fat meal
1657333|NCT01798628|Drug|Treatment C: abiraterone acetate|1000 mg (4 x 250 mg tablets) taken by mouth as a single dose administered in the fasted state
1657334|NCT01798602|Drug|Rosuvastatin or identical placebo|Tablet crushed for administration via feeding tube
1657335|NCT01798602|Drug|Placebo|Identical placebo for rosuvastatin
1657337|NCT01798576|Drug|Pegylated Interferon alfa-2a|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
1657338|NCT01798576|Drug|Ribavirin|Dosing was at the discretion of the investigator in accordance with local clinical practice and local labelling.
1657340|NCT01798537|Drug|Neomycin Colistin Nystatin Vancomycin|All participating study arm patients will receive SDD from admission to discharge
1657341|NCT01798511|Procedure|Nasogastric Tube Feeding|A nasogastric tube will be placed into the stomach of patients.
1657342|NCT01798511|Other|Conventional Nutritonal Management|Patients who are to have CNM will be on nil-by-mouth regimen until they either develop signs of severe AP (in which case nasojejunal tube feeding will be introduced) or the signs of AP mitigate (in which case clear liquids (as tolerated) followed by oral food (as tolerated) will be introduced)
1657343|NCT01798498|Device|Princess® VOLUME|
1657344|NCT01798485|Drug|Docetaxel|Docetaxel, 75 mg/m^2, was administered according to prevailing practice and Investigator decision, generally until disease progression, intolerability, or patient's withdrawal of consent.
1657345|NCT01798485|Drug|Ganetespib|Ganetespib, 150 mg/m^2, was administered with docetaxel. After docetaxel treatment ceased, participants whose disease has not progressed continued to receive ganetespib alone until disease progression, unacceptable toxicity, or patient's withdrawal of consent.
1657346|NCT01798472|Procedure|cemented hemiarthroplasty|Patients aged 80 years and older operated with an cemented hemiarthroplasty. Fixation of the wedge-shaped, polished ChromCobalt steel femoral stem to host bone by use of PolyMetylMetAcrylat bone cement. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel.
1657347|NCT01798472|Procedure|reverse hybrid total hip arthroplasty|Patients aged 65 to 79 years operated with an uncemented femoral component combined with cemented acetabular cup. The femoral stem is fixed to the host bone by press-fit technique. We use a tapered, proximally hydroxyapatite coated, titanium stem. The acetabular cup is fixed to the host bone with bone cement. We use an all-polyethylene design. Bone cement consists of PolyMetylMetAcrylat.
1657348|NCT01798472|Procedure|cemented total hip arthroplasty|Patients aged 65 to 79 years operated with a cemented femoral stem combined with a cemented acetabular cup. Femoral and acetabular component are fixed to the host bone by use of bone cement. The femoral stem is a polished, wedge-shaped design made of ChromCobalt steel. The acetabular cup is fixed to the host bone with bone cement.The acetabular cup an all-polyethylene design. Bone cement consists of PolyMetAcrylat.
1657349|NCT01798472|Procedure|uncemented hemiarthroplasty|"Patients aged 80 years and older are randomized to uncemented hemiarthroplasty. Fixation of the tapered, proximally hydroxyapatite coated, titanium stem to the host bone by press-fit-technique. The acetabulum is not replaced. The prosthesis articulates with the patients acetabulum with an unipolar, femoral head made of ChromCobalt steel."
1657351|NCT01798446|Drug|Axitinib|Axitinib 5mg twice will be orally administered daily with one cycle of 4 weeks. The package of axitinib must be opened right before the administration due to its photosensitivity.
1657352|NCT01798433|Device|One stent technique alone|One stent technique alone with drug-eluting stent
1657353|NCT01798433|Device|One stent technique + Elective FKB|One stent technique + Elective FKB with drug-eluting stents + balloon
1657354|NCT01798433|Procedure|Provisional approach|Provisional approach with drung-eluting stents
1657355|NCT01798433|Device|Elective 2-stent|Elective 2-stent with drug-eluting stents
1657356|NCT01798407|Device|Activa Tremor Control Sys (DBS Implant)|DBS system consists of the Activa RC 37612 System (Implantable Pulse Generator with Model 37085 Extensions (40 to 95cm), Activa Patient Programmer, and Medtronic Model 3389 DBS Lead). This system is commercially approved for the treatment of chronic, intractable Parkinson's Disease. It will be used with the Model SP-10344 Memory Mod Software which enables the physician to program the Implantable Pulse Generator to a higher frequency.
1657357|NCT01798407|Other|Randomized, staggered withdrawal phase|For responders only: double blind discontinuation will be attempted on either the 12 or 13 month visit. Stimulation intensity will be decreased by 50% and then completely discontinued two weeks later. Subjects will be seen biweekly until 15 months post activation or escape criteria are met. These escape criteria include relapse at 2 visits, hospitalization, active suicidal ideation, or withdrawing consent. If any of these criteria are met, the blind will be broken and open treatment will be resumed.
1657358|NCT01798394|Drug|Progesterone|Take micronized natural progesterone capsule by mouth, twice daily (approximately at 8 am and 8 pm) for four weeks beginning on postpartum day 4.
1657359|NCT01798394|Other|Placebo|Take placebo capsule by mouth, twice daily (approximately at 8 am and 8 pm) for 4 weeks beginning on postpartum day 4.
1657360|NCT01798381|Dietary Supplement|Essential fatty acids|
1657361|NCT01798368|Device|PBASE system 2.0|
1657362|NCT01798355|Behavioral|Cognitive Behavioral Therapy|The treatment group is offered cognitive behavior therapy(CBT) by psychologists/psychotherapists. CBT is offered according to a treatment manual and consists of 10- sessions during 12-15 weeks.
1657363|NCT01798355|Behavioral|Treatment As Usual|Treatment as usual consist of strategies such as habituation, tell-show-do, premedication with midazolam, nitrous oxide sedation and general anesthesia. All offered by dentists and dental hygienist and/or dental assistants.
1657364|NCT01798342|Dietary Supplement|Maltodextrin|The volunteers underwent MRI after the ingestion of the dietary supplement in a crossover fashion aiming at measuring the gastric residual volume
1657365|NCT01798342|Dietary Supplement|Glutamine|The volunteers ingested 400ml (4 hours before the exam was carried out) at 8:00AM and 200ml (2 hours before the exam was carried out) at 10:00AM of a beverage containing water plus 12.5% maltodextrin plus 15g of GLN before MRI
1657366|NCT01798329|Dietary Supplement|probiotic VSL#3|"VSL#3 is a probiotic that reduces:
urease faecal activity
faecal pH
inflammatory cytokine"
1657367|NCT01798316|Drug|IV Acetaminophen|Single dose, 1000g mg infusion over 15 minutes plus standard of care pain management regimen
1657368|NCT01798316|Drug|Standard of Care|Standard of care pain management regimen, no IV Acetaminophen,
1657369|NCT01798303|Drug|LY2940094|Administered orally
1657370|NCT01798303|Drug|Placebo|Administered orally
1657371|NCT01798290|Behavioral|narrative medicine: reading workshop|
1657372|NCT01798290|Behavioral|critical reading|
1657373|NCT01798277|Procedure|Catheter Ablation|Catheter ablation of ventricular tachycardia will employ three-dimensional mapping Fast Anatomical Mapping or CARTOSOUND technology (Biosense Webster Inc.), and the Thermocool Navistar catheter (Biosense Webster Inc.).
1657374|NCT01798277|Drug|Medical therapy (sotalol or amiodarone)|Patients will be tiered to one of two possible antiarrhythmic drugs (sotalol or amiodarone).
1657375|NCT01798264|Drug|ITCA 650 (exenatide in DUROS)|
1657376|NCT01798251|Drug|Oxaliplatin|Oxaliplatin 100mg/m2 d1 Intravenous infusion every 3 weeks
1657377|NCT01798251|Drug|Capecitabine|capecitabine 850mg/m2 bid, d1-14, every 3 weeks
1657378|NCT01798238|Drug|MP-513|form : Pink film-coated tablet for oral administration Dosage : 20mg/tablet frequency and duration: 1 tablet/day
1657379|NCT01798238|Drug|Placebo|Pink film-coated tablet for oral administration, frequency and duration: 1 tablet/day
1657382|NCT01798212|Procedure|endoscopic full thickness plication|
1657383|NCT01798199|Other|The training by Verve System|
1657384|NCT01798186|Drug|Cannabis|Participants will be exposed to cannabis smoke present in ambient air
1657385|NCT01798173|Biological|Serum, plasma and DNA samples|
1657386|NCT01798173|Procedure|Radiological exploration by CT scan or MRI|
1657387|NCT01798160|Procedure|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
1657388|NCT01798160|Procedure|SIRT|Selective Internal Radiation Therapy once at the beginning of the study. Follow up until endpoint.
1657389|NCT01798147|Procedure|DEB TACE|DEB TACE every 6 weeks until either no viable tumor or endpoint reached.
1657390|NCT01798147|Procedure|SIRT|Selective Internal Radiotherapy once at the beginning of the study. Follow up until endpoint.
1657391|NCT01798134|Device|TANDEM™|
1657392|NCT01798121|Biological|To compare new PPD to reference standard material|Aplisol@ will be compared to reference standard material
1657393|NCT01798121|Biological|Reference standard|Response of reference standard material compared to Aplisol@.
1657523|NCT01797237|Device|PFNA|
1657524|NCT01797237|Device|InterTAN|
1657525|NCT01797211|Dietary Supplement|Mediterranean diet|Patients underwent administration of Mediterranean diet and olive oil, or Mediterranean diet and not-fried fish, or Mediterranean diet and nuts.
1657526|NCT01797198|Drug|ASP3652|Oral
1657527|NCT01797198|Drug|Gemfibrozil|Oral
1657528|NCT01797198|Drug|Repaglinide|Oral
1657529|NCT01797185|Drug|SPARC1104|Subjects will receive SPARC1104
1657887|NCT01794416|Device|Implantable loop recorder|
1657394|NCT01798108|Radiation|Radium-223 dichloride (BAY88-8223)|- Single injection. Starting dose 46 kBq/kg b.w. Escalating doses 93, 163, 213 and 250 kBq/kg b.w. (9.8.2 Changes in addition to those described in amendments) After completion of the five dose levels above, the protocol was amended and the study extended to include patients to received multiple injections of Radium-223 - Re-treatment: Patients who had earlier been included in the study and received dose levels 46, 93 or 163 kBq/kg b.w. could be given a second injection, provided that the total dose did not exceed 250 kBq/kg b.w. - Fractionated dose (multiple dosing) Patients were given multiple injections in treatment: 5 injections of 50 kBq/kg b.w. at 3 weeks intervals. Patients were given multiple injections in treatment: 2 injections of 125 kBq/kg b.w. at 6 weeks interval
1657395|NCT01798095|Biological|Aplisol@ PPD material|Determine equivalency of materials
1657396|NCT01798095|Biological|Reference Standard|Reference standard material for comparison to newly produced materials.
1657397|NCT01798082|Other|Pelvic organ prolapse decision aid|
1657398|NCT01798069|Behavioral|reflective writing|Students allocated to the experimental arm will follow 5 sessions in Class-led instruction of reflexive writing workshops. They will be divided into 12 sub-groups of 8 students. They will write their stories about their own experiences or the experiences of their family / patient.
1657399|NCT01798069|Behavioral|reading medical publication workshops|
2013213|NCT00775684|Drug|Exenatide|Exenatide (Byetta®)—5 µg injected subcutaneously twice daily and increased after 1 month to 10 µg twice daily as tolerated by gastrointestinal effects
2013214|NCT00775684|Drug|Sitagliptin|Sitagliptin (Januvia®)100 mg by mouth every morning
1657402|NCT01798043|Other|Cardiac MRI with pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
1657403|NCT01798043|Other|Cardiac MRI with and without pacemaker stimulation|Patient is undergoing a Cardiac MRI at enrollment and 12 months later
1657404|NCT01798030|Other|Vitamin D|N/A, frozen specimen study
1657405|NCT01798017|Drug|Mifepristone and misoprostol|Women will receive 200mg mifepristone followed in 24-48h by 800mcg bucccal misoprsotol
1657406|NCT01798004|Drug|cyclophosphamide|Given IV
1657407|NCT01798004|Drug|topotecan hydrochloride|Given IV
1657408|NCT01798004|Drug|cisplatin|Given IV
1657409|NCT01798004|Drug|etoposide|Given IV
1657410|NCT01798004|Drug|vincristine sulfate|Given IV
1657411|NCT01798004|Drug|doxorubicin hydrochloride|Given IV
1657412|NCT01798004|Radiation|external beam radiation therapy|Undergo EBRT
1657413|NCT01798004|Drug|busulfan|Given IV
1657414|NCT01798004|Drug|melphalan|Given IV
1657415|NCT01798004|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
1657416|NCT01798004|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
1657417|NCT01798004|Other|pharmacological study|Correlative studies
1657418|NCT01798004|Other|laboratory biomarker analysis|Optional correlative studies
1657419|NCT01798004|Biological|filgrastim|Given SC or IV
1657420|NCT01798004|Drug|mesna|Given IV
1657421|NCT01797991|Drug|Dexamethasone per os|
1657422|NCT01797991|Drug|Matching placebo for dexamethasone IV|
1657423|NCT01797991|Drug|Dexamethasone IV|
1657424|NCT01797991|Drug|Matching placebo for dexamethasone per os|
1657425|NCT01797978|Drug|Intravenous methylene blue administration|Initial history taking and physical examination --> enrollment --> 2mg/kg IV bolus followed by 0.5mg/kg/hr slow infusion of methylene blue for 6hrs
1657426|NCT01797978|Drug|Placebo|
2013215|NCT00775684|Drug|Glimepiride|Glimepiride (Amaryl®)—0.5 mg by mouth every morning and then increased by 0.5 - 1.0 mg at each monthly visit to achieve an average fasting glucose < 110mg/dl
1657428|NCT01797952|Drug|Lactobacillus CD 2|2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
1657429|NCT01797952|Other|Placebo|The placebo is a mix of sugars and salts used as excipients in the active formulation
1657430|NCT01797926|Drug|Reference Treatment: 5 mg amlodipine + 50 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 50 mg losartan tablet administered orally in fasted state as a single dose
1657431|NCT01797926|Drug|Reference Treatment:5 mg amlodipine + 100 mg losartan|Subjects will receive 1 x 5 mg amlodipine tablet with 1 x 100 mg losartan tablet administered orally in fasted state as a single dose
1657432|NCT01797926|Drug|FDC 5/50 amlodipine/ losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 50 mg losartan in fasted state
1657433|NCT01797926|Drug|FDC 5/100 amlodipine /losartan|Subjects will receive single oral dose of 1 tablet containing 5 mg amlodipine and 100 mg losartan in fasted state
1657434|NCT01797913|Drug|gemcitabine|gemcitabine，1000mg/m2，ivgtt，DAY1&DAY8
1657435|NCT01797900|Drug|Cisplatin|induction: Cisplatin: 80mg/m2, d1 and d22 concurrent: Cisplatin: 100mg/m2, d1, 22, 43 adjuvant: cisplatin: 75mg/m2, d1, d22, d43,d64
1657436|NCT01797900|Drug|Paclitaxel|induction: paclitaxel 175mg/m2 d1,d22 adjuvant: paclitaxel 175mg/m2 d1,d22, d43,d64
1657437|NCT01797900|Radiation|IMRT|69.96Gy-73.43Gy to gross tumor volume, 60Gy to high-risk clinincal target volume, 50Gy to lower risk clincial target volume
1657438|NCT01797887|Behavioral|Diet and Lifestyle Counseling|Diet and Lifestyle Counseling
1657439|NCT01797874|Drug|Pazopanib|Experimental
1657440|NCT01797874|Drug|Placebo|placebo arm
2013216|NCT00770380|Behavioral|behavioral relapse prevention counseling|Behavioral relapse prevention counseling conducted in two one-hour sessions
1657585|NCT01796730|Drug|bambuterol|Patients will be randomized allocated to receive three treatment sequences I, II and III, every treatment period is separated by a washout period of 7 days.
1657586|NCT01796730|Drug|Placebo|
1657587|NCT01796717|Drug|C Group|Controlled group will receive piperacillin/tazobactam of 4.5g Q6h, intermittent infusion for 30 minutes
2013217|NCT00770380|Other|hypnosis for relapse prevention|Hypnosis for relapse prevention conducted in two one-hour sessions
2013218|NCT00769379|Other|Laboratory Biomarker Analysis|Correlative studies
2013219|NCT00769379|Biological|Trastuzumab|Given IV
2013220|NCT00769379|Radiation|Whole Breast Irradiation|Undergo standard whole breast irradiation
2013221|NCT00763035|Drug|Regadenoson, Dobutamine|Cross-over design in which each participant will receive regadenoson 0.4mg (5ml) one time bolus dose at one visit and dobutamine infusion (as per protocol to achieve a target heart rate of 85% of predicted for age) at another visit.
1657443|NCT01797848|Drug|Peginterferon alfa 2a|
1657444|NCT01797848|Drug|Ribavirin|
1657445|NCT01797848|Drug|Placebo matching Daclatasvir|
1657446|NCT01797848|Drug|Daclatasvir|
1657447|NCT01797835|Behavioral|CHAT brief MI intervention|CHAT is one 15-20 minute session delivered in a single PC visit and utilizes motivational interviewing with youth to target alcohol and drug use in primary care.
1657448|NCT01797835|Behavioral|usual care|Youth receive a brochure with information on AOD use.
2013222|NCT00757549|Biological|cetuximab|
2013223|NCT00757549|Drug|cisplatin|
1657451|NCT01797796|Drug|PF-06305591|150 mg PF 06305591 will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
1657452|NCT01797796|Other|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
1657453|NCT01797796|Drug|Placebo|Placebo will be administered to subjects as a 100 mL extemporaneous prepared oral solution once.
1657454|NCT01797796|Other|Capsaicin challenge|110 mg capsaicin cream (Axsain®) will be applied topically at each visit.
1657455|NCT01797783|Device|Nelfilcon A multifocal contact lens with comfort additive|
1657456|NCT01797783|Device|Nelfilcon A multifocal contact lens|
1657457|NCT01797770|Drug|polyethylene glycol|mechanical bowel preparation with polyethylene glycol one day prior to surgery
1657458|NCT01797770|Other|No Preparation|No laxatives or bowel preparation
1657459|NCT01797757|Dietary Supplement|Fish oil enriched with EPA|
1657460|NCT01797757|Dietary Supplement|MAG-EPA oil|
1657461|NCT01797757|Drug|Orlistat|
1657462|NCT01797744|Other|Vestibular rehabilitation|Usual rehabilitation and four different vestibular rehabilitation exercises, adapted to the individual patient
1657463|NCT01797731|Device|Digital hand-held surgical navigation system|Digital hand-held surgical navigation system used for tibial component placement in total knee arthroplasty
1657464|NCT01797731|Device|Conventional tibial extramedullary alignment system|This is the standard of care for total knee arthroplasty.
1657465|NCT01797718|Drug|Testosterone|1mg/kg every 4 weeks for 6 months
1657466|NCT01797718|Drug|Letrozole|2.5mg daily for 6 months. Safety criteria: if testosterone level is above 30nM at 3 months, the dosage is reduced to 2.5mg every other day
1657467|NCT01797705|Device|DeVilbiss AutoAdjust CPAP with revised algorithm|Subjects attended a one-night polysomnogram (PSG) titration study. DeVilbiss AutoAdjust CPAP with a revised algorithm was compared to hand-scored PSG to determine whether the machine results were equivalent to hand scores. Each subject acted as their own control for assessing accuracy of sleep event analysis and prescribed CPAP pressure.
1657468|NCT01797692|Other|geriatric assessment|A single geriatric assessment with a geriatrician was proposed to patients and to control population.
1657469|NCT01797679|Other|Strength Training|
1657470|NCT01797679|Other|Aerobic Exercise|
1657471|NCT01797666|Drug|Torrent's Pioglitazone Hydrochloride Tablets 45 mg|
1657472|NCT01797653|Other|CPAP therapy withdrawal|CPAP (continuous positive airway pressure) with subtherapeutic pressure during two weeks
1657473|NCT01797653|Procedure|Continue CPAP treatment|Continue treatment with therapeutic continuous positive airway pressure device
1657474|NCT01797601|Drug|Human Insulin|160 U of insulin
1657475|NCT01797601|Drug|Placebo|Insulin dilution medium without insulin
1657476|NCT01797588|Procedure|Adductor-canal block|The adductor-canal will be located via ultra sound and a total of 30mL of 0.33% ropivacaine will be injected into the area surrounding the saphenous nerve.
1657477|NCT01797588|Procedure|Periarticular infiltration|Periarticular infiltration will be performed intra-operatively and involves administering a 110 mL solution of ropivacaine 300mg, preservative free morphine 10mg, ketorolac 30mg mixed in normal saline into the knee. In each Knee: the first 20mL aliquot is injected into the posterior capsule and the medial and lateral ligaments just prior to implantation; after the implants have been cemented and curing, another 20mL is infiltrated to the quadriceps and retinacular tissues. The remaining solution (~60mL) is used to infiltrate the muscle, subcutaneous tissues.
1657478|NCT01797575|Drug|Asprin|aspirin 1000mg (2 capsules of 500mg) every morning in addition to his/her antidepressant and/or mood stabilizer medicine
1657479|NCT01797575|Dietary Supplement|N-acetyl-cysteine (NAC)|taking N-acetyl-cysteine (NAC) 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
1657480|NCT01797575|Drug|Asprin and NAC|aspirin 1000mg (2 capsules of 500mg) every morning and NAC 1000mg (2 capsules of 500mg) two times a day in addition to his/her antidepressant and/or mood stabilizer medicine
1657481|NCT01797575|Drug|Sugar Pill|research subject will be taking placebo in addition to his/her antidepressant and/or mood stabilizer medicine
1657482|NCT01797562|Drug|T.R.U.E. Test Panel 3.2|Surgical tape containing 12 polyester allergen patches.
1657483|NCT01797536|Drug|Elbasvir|
1657484|NCT01797523|Drug|Metformin|500 mg by mouth daily for 4 days on Days 1 - 4 of Cycle 0 and then 2 times a day (about 12 hours apart) every day after that. Metformin taken for 7 - 10 days in Cycle 0 before Cycle 1 begins.
1657485|NCT01797523|Drug|Letrozole|2.5 mg tablet by mouth once daily in a 28 day cycle.
1657486|NCT01797523|Drug|Everolimus|10 mg by mouth once daily in a 28 day cycle.
1657487|NCT01797510|Behavioral|Web Based Health Coaching|
1657588|NCT01796717|Drug|E Group|Therapy group will receive piperacillin/tazobactam of 4.5g Q6h, prolonged infusion for 4 hours
1657589|NCT01796678|Drug|Arginine|
1657590|NCT01796678|Drug|Placebo|Saline or Sugar pill was given as placebo
1718532|NCT00002532|Drug|methotrexate|
2013224|NCT00757549|Genetic|TdT-mediated dUTP nick end labeling assay|
2013225|NCT00757549|Other|3'-deoxy-3'-[18F]fluorothymidine|
2013226|NCT00757549|Other|immunohistochemistry staining method|
2013227|NCT00757549|Other|laboratory biomarker analysis|
2013228|NCT00757549|Radiation|fludeoxyglucose F 18|
2013229|NCT00757549|Radiation|radiation therapy|
1657488|NCT01797497|Behavioral|Care plan and coaching|In the intervention group, primary care providers and parents complete their sections of the referral care plan. Parents and referred specialists receive a copy of the form. Parents receive a 5-10 minute brief intervention by phone consisting of education and coaching. The care plan is reviewed with parents to help them practice exchanging information with the specialist and encourage parents to contact their child's primary care provider with any further questions. At the specialist visit, specialists review and complete the care plan with the parent and return the plan to the referring primary care provider. Outcome data are collected from parents before and after the specialist visit.
2013230|NCT00749606|Behavioral|Individual telephone intervention|"Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
1657490|NCT01797471|Radiation|Lattice Extreme Ablative Dose Radiation Therapy|A single fraction of LEAD RT, dose of 18 Gy will be delivered to subjects on day 1
1657491|NCT01797471|Radiation|Conventionally Fractionated Radiation|Conventionally fractionated radiation therapy will be delivered to subjects beginning on day 2 at 2 Gy per fraction for 30 fractions for a total dose of 60 Gy
1657492|NCT01797471|Drug|Platinum-based Chemotherapy Doublet|Platinum-based chemotherapy doublet administered beginning day 2 via wither weekly or every 3 week regimen. Platinum-based agent selection is at the discretion of the treating medical oncologist
2013231|NCT00749606|Behavioral|Group telephone intervention|"Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff."
2013232|NCT00743119|Drug|Oral THC|0, 10, and 20 mg
2013233|NCT00743119|Drug|Marijuana|0%, 1.98% and 3.56%
1657496|NCT01797445|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily
1657497|NCT01797445|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) FDC tablet administered orally once daily
1657498|NCT01797445|Drug|E/C/F/TDF Placebo|E/C/F/TDF placebo tablet administered orally once daily
1657499|NCT01797445|Drug|E/C/F/TAF Placebo|E/C/F/TAF placebo tablet administered orally once daily
1657500|NCT01797432|Drug|Intralesional Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Intralesional injections of 4mLs Triamcinolone Acetonide 10 mg/mL (Kenalog-10) on the whole scalp
1657501|NCT01797432|Device|Restylane|Intralesional injections of 2mLs of Restylane on one side of the scalp
1657502|NCT01797419|Drug|GS-5806|Single dose, oral liquid, .5 mL/kg
1657503|NCT01797419|Drug|Placebo|Single dose, oral liquid, .5 mL/kg
2013234|NCT00733304|Drug|Pazopanib|eyedrops
2013235|NCT00726323|Drug|foretinib (formerly GSK1363089 or XL880)|treatment with oral foretinib on one of 2 dosing regimens: 240 mg on a 5 day on / 9 day off schedule every 14 days, or 80 mg on a daily dosing schedule
1657506|NCT01797393|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
1657507|NCT01797393|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
1657508|NCT01797393|Other|" Air assisted water injection."|Cut off air inflating before examination. Water was injected through the working channel to follow the intestinal cavity until reaching the splenic flexure, small amount of air inflating could be given to help searching the cavity until reaching the cecum.
1657509|NCT01797380|Drug|Placebo|Placebo daily for duration of double-blind portion of trial
1657510|NCT01797380|Drug|Escitalopram|Escitalopram 10 mg po daily for duration of double-blind portion of trial
1657511|NCT01797354|Behavioral|Cognitive-behavioral therapy and hypnosis group|
1657512|NCT01797354|Behavioral|Support group|
1657513|NCT01797341|Drug|Tacrolimus|
1657514|NCT01797341|Drug|Tacrolimus|
1657515|NCT01797328|Procedure|cold arm|1 hour/day of cold provocation of such an extent that it is unpleasant but does not cause shivering
1657516|NCT01797328|Procedure|warm arm|To the best of ability avoid feeling cold during 6 weeks
1657517|NCT01797315|Drug|Sirolimus|
1657518|NCT01797302|Dietary Supplement|Vitamin D3|Tablet form
1657519|NCT01797289|Other|Lung CT or V/Q scanning in patients with a high pre-test clinical probability of PE and/or a positive D-dimer|
1657520|NCT01797276|Drug|Dichloroacetate|Subjects are given DCA 25mg/kg in a divided dose twice a day.
2013236|NCT00721409|Drug|PD 0332991|125 mg/d capsules orally for 3 out of 4 weeks in repeated cycles
2013237|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
2013238|NCT00721409|Drug|letrozole|2.5 mg/d tablets orally on a continuous regimen
2013239|NCT00719186|Drug|Clomiphene citrate|Clomiphene citrate 50 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
2013240|NCT00719186|Drug|Letrozole|Letrozole 2.5 mg every day for 5 days (day 3-7 of cycle), for a total of 5 cycles or 20 weeks
2013241|NCT00718666|Biological|Meningococcal vaccine GSK134612|One dose, as intramuscular injection
2013242|NCT00710034|Other|Oral tobacco|Snus
2013243|NCT00710034|Drug|Nicotine Gum|4 mg Nicotine gum
2013244|NCT00700258|Drug|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
2013245|NCT00700258|Drug|Temsirolimus|Non-interventional study. Treatment decision already made before inclusion into the registry.
2013246|NCT00700258|Drug|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
2013247|NCT00700258|Drug|Sunitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
2013248|NCT00700258|Drug|Axitinib|Non-interventional study. Treatment decision already made before inclusion into the registry.
2013249|NCT00694577|Radiation|Partial Breast Irradiation using 32 Gy / 8 fractions|32 Gy-8 Treatments, 4 Treatment Days
2013250|NCT00694577|Radiation|Partial Breast Irradiation using 36 Gy / 9 fractions|36 Gy- 9 Treatments, 4 1/2 Treatment Days
1657530|NCT01797172|Procedure|Percutaneous Cervical Nucleoplasty|Cervical nucleoplasty is a method of percutaneous disc decompression using a 19 Gauge Trocar 3 inch spine needle (ArthroCare Co., Sunnyvale, CA, USA) which is brought to the annulus fibrosis of the herniated disc. If in the correct position, the stylet is withdrawn and the Perc DC SpineWand (ArthroCare Co., Sunnyvale, CA, USA) is introduced. The procedure relies on so-called Coblation technology which involves removing a portion of the nucleus tissue by using radio frequency energy. More specific, it results in ablation of a portion of nucleus tissue, not with heat, but with a low-temperature (typically 40-70° C) plasma field of ionized particles.
1657531|NCT01797172|Procedure|Pulsed Radio Frequency|Pulsed Radio Frequency involves placement of a needle close to the to-be-treated nerve or dorsal root ganglion (DRG). The position is checked radiographically and by motor and sensory nerve stimulation. When the needle has been placed correctly an electrode is introduced, which conducts short bursts of radio frequency energy to nervous tissue. It is known as a non- or minimally neurodestructive technique, alternative to radio frequency heat lesions using so-called thermocoagulation. No nerve damage takes places as the temperature of the tip of the needle does not exceed 42°C. This is achieved by relatively long pauses between pulses which allow generated heat to dissipate and prevent the development of any thermal lesion.
1657532|NCT01797159|Radiation|Hippocampal-sparing Prophylactic Cranial Irradiation|Hippocampal-sparing Prophylactic Cranial Irradiation
1657533|NCT01797146|Procedure|Catheter Reminder and Evaluation Program|"This intervention will be implemented by ward nurses and responsible physicians. The details of intervention are shown below.
Nurse: Every morning, a ward nurse will check if any patient has a urinary catheter or a central venous catheter in place. An order sheet will be marked with a CARE-rubber stamp and the following information will be added by hand-writing.
Type and duration of urinary catheter use.
Indication of urinary catheter _________
Type and duration of central venous catheter use
Indication of urinary catheter _________
Responsible physician: During a morning round, a physician needs to fill the indication of catheter use. If a given physician does not fill the indication of urinary catheter use, the catheter will be automatically removed. If a given physician does not fill the indication of central venous catheter, the CARE team will be notified."
1657534|NCT01797133|Procedure|ID fellow-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by ID-fellows, under the supervision of ID staffs.
1657535|NCT01797133|Procedure|Pharmacist-based antibiotic pre-authorization|All prescriptions of controlled antibiotics (Piperacillin/Tazobactam, Imipenem/Cilastatin, Meropenem and Doripenem) can be freely prescribed for the first 72 hours. After that, the prescription requires approval. Antibiotic preauthorization program will be operated by general pharmacists, under the supervision of ID staffs.
1657536|NCT01797120|Drug|Fulvestrant|"Fulvestrant 500 mg Day 1 & 15 of Cycle 1, then 500 mg Day 1 of all subsequent cycles (every 28 days for 12 cycles).
If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
1657537|NCT01797120|Drug|Everolimus|"Everolimus 10 mg (2 tablets) daily x 12 cycles.
If no evidence of disease progression after 12 cycles, unblind and continue same dose and schedule until progression or unacceptable toxicity."
1657538|NCT01797120|Drug|Placebo (for Everolimus)|Placebo (2 tablets) daily x 12 cycles. Placebo manufactured to mimic everolimus tablet.
1657539|NCT01797107|Drug|Azasite|Patients will be given 1 drop twice a day for 2 days followed by 1 drop nightly for 4 weeks.
2013251|NCT00694577|Radiation|Partial Breast Irradiation using 40 Gy /10 fractions|40 Gy-10 Treatments, 5 Treatment days
2013252|NCT00690924|Drug|calcitriol|Oral
2013253|NCT00690924|Other|laboratory biomarker analysis|Correlative Study
2013254|NCT00690924|Other|pharmacological study|Correlative Study
2013255|NCT00688155|Behavioral|Physical Activity Training (PAT)|Two 1-hour center and two 15- to 45-minute home-based training sessions per week to include aerobic, strength, flexibility, and balance training for 6 months. The ultimate goal is to accumulate 150 minutes of walking per week between center and home-based sessions.
1657545|NCT01797068|Behavioral|Patient Navigator|Patients in the intervention group will be offered patient navigation and timely access to comprehensive care and services through Project Access-New Haven (PA-NH), a local non-profit organization that coordinates the provision of donated medical care and services to underserved patients through a network of participating hospitals and volunteer physicians.
1657546|NCT01797068|Other|Standard of Care|Patients in the standard of care group will experience the usual intake process in the ED setting.
1657547|NCT01797055|Drug|Human apotransferrin|intravenous infusion
1657548|NCT01797042|Behavioral|Dietary Compliance|Incorporation of sugar sweetened milk into the usual diet. Instruction on how to account for additional calories provided by sugar sweetened milk Weekly compliance checks
1657549|NCT01797029|Biological|SIIL Live Attenuated Influenza Vaccine|A single dose of SIIL Trivalent LAIV--2012/2013 Northern Hemisphere vaccine containing A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010
1657550|NCT01797029|Biological|Placebo|A single dose of inactive placebo will be identical to reconstituted SIIL LAIV in ingredients and concentrations except A/California/7/2009 (H1N1), A/Victoria/361/2011 (H3N2), B/Wisconsin/1/2010 will be replaced with egg allantoic fluid.
1657551|NCT01797003|Other|High tibial osteotomy|
1657552|NCT01796990|Behavioral|ACT|"The intervention program consists of six group sessions, about 90 minutes per session during the 9 weeks period of time. The group size is about 8-10 members per one group. All the participants get also pedometers for monitoring their physical activity during the intervention.
The program aims to enhance physically active lifestyle and well-being through important life values and build committed action based on the chosen important things. The importance is also placed to a mindful awareness and flexibility to everyday actions related to physical activity. The program don´t include psycho-educational elements or counseling of the health or the health benefits of physical activity."
1657591|NCT01796665|Drug|Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5%|
1657592|NCT01796665|Drug|Acanya Gel|
1658133|NCT01792414|Device|Sham TES|Neuroconn Eldith device
2013256|NCT00688155|Behavioral|Cognitive Training (CT)|Two 1-hour sessions per week for the first two months and then one 1-hour session per week for months 3-6.
1657553|NCT01796990|Behavioral|REF|The participants will get written feedback about their physical activity level after the baseline, and after 3, 6, 9 and 15 months of baseline compared to the current physical activity recommendations. Feedback will be created to illustrate participants´ activity level during the measurement week combining also the information from the diary. Feedback will be posted home and don´t include face to face interaction. As an incentive for participation, participants will also have opportunity to attend a body composition analyze and get short interpretation (15 min) of their own results in the research center.
1657554|NCT01796977|Device|OxyGenesys Dissolved Oxygen Dressing|
1657555|NCT01796977|Device|Standard Gauze Dressing|
1657556|NCT01796964|Drug|ESBA1008 solution|For intravitreal (IVT) injection
1657557|NCT01796964|Drug|Aflibercept|For intravitreal (IVT) injection
1657558|NCT01796951|Drug|Aspirin 325 mg daily|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
1657559|NCT01796951|Drug|Celecoxib 200 mg BID|In this single-arm trial, participants will take celecoxib 200 mg BID for 5 doses, followed by aspirin 325 mg daily for 10 days, followed by combination of celecoxib 200 mg BID for 5 doses and aspirin 325 mg daily for 3 days.
1657560|NCT01796938|Drug|Lacosamide tablet|Single dose of 100 mg Lacosamide tablet
1657561|NCT01796925|Device|aura6000 THN System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
1657562|NCT01796912|Other|Lipoprotein Apheresis|Weekly lipoprotein apheresis for 3 months
1657563|NCT01796912|Other|Sham Apheresis|Weekly sham (placebo) apheresis for 3 months
1657564|NCT01796899|Other|Brivaracetam 10 mg oral tablet|
1657565|NCT01796899|Other|Brivaracetam 50 mg oral tablet|
1657566|NCT01796899|Other|Brivaracetam 75 mg oral tablet|
1657567|NCT01796899|Other|Brivaracetam 100 mg oral tablet|
1657568|NCT01796899|Other|10 mL of Brivaracetam intravenous bolus injection (10 mg/mL)|
1657569|NCT01796886|Other|pupillometry data|
1657570|NCT01796860|Other|AFO|The purpose of this study is to investigate the impact of a specifically designed ankle foot orthosis (AFO, hinged, with tamarack joint and adjustable check strap) on the spatial and temporal gait parameters, electromyography (EMG), and walking endurance, in select individuals living with MS. Over the 13 week period, the subject will participate in 5 gait training sessions which will be at weeks 1, 2, 3, 7, and 10.
1657571|NCT01796834|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|An 8-9 week MBSR course led by an experienced instructor in a group format. Participants learn mindfulness meditation techniques and simple yoga exercises. Subjects receive four phone support calls.
1657572|NCT01796821|Drug|Vehicle gel|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.
Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.
Total application <1,500 mg gel per day."
1657573|NCT01796821|Drug|SR-T100 gel with 1.0 % SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.
Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.
Total application <1,500 mg gel per day."
1657574|NCT01796821|Drug|SR-T100 gel with 2.3% SM|"Clinical diagnosed lesion site(s): Topical application once daily with occlusive dressing.
Clinical normal skin on treated area: Topical application thrice daily without occlusive dressing.
Total application <1,500 mg gel per day."
1657575|NCT01796808|Procedure|Pedal Fat Grafting|"Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years and is considered a standard of care procedure in plastic surgery. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) with a small liposuction cannula. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then loaded into 1cc syringes and injected into the plantar fat pad using specialized injection cannulas.
Postoperatively, the foot will be bandaged for twenty-four hours and the subject will be advised to limit ambulation. Over the next three weeks, the patient will be instructed to wear a cushioned, supportive sneaker and participate in only activities of normal daily living, with no excessive aerobic activity."
1657576|NCT01796808|Drug|Local anesthetic|"To numb the foot for the fat grafting procedure, lidocaine with epinephrine will be used. This will be injected near the posterior tibial nerve to numb the bottom of the foot.
Local anesthetic of lidocaine with epinephrine will also be used to numb the fat graft harvest site (i.e. abdomen or thigh). This will allow a small incision to make so that tumescent solution can be injected into the area of fat graft harvest. Tumescent solution is a combination of injectible saline, epinephrine and lidocaine that causes numbness and vasoconstriction in the area where the fat will be harvested. This limits pain and bruising during the procedures. Only a very small amount of tumescent should be needed (i.e. <200ml). Only a few cc's of fat are needed for injection into the foot."
1657577|NCT01796795|Drug|Vehicle gel|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
1657578|NCT01796795|Drug|SR-T100 gel with 1.0% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
1657579|NCT01796795|Drug|SR-T100 gel with 2.3% of SM|Topical application on the target lesion(s)once daily with occlusive dressing; a maximum of 3 times of administration of gel without exceeding 0.2 g per administration.
1657580|NCT01796782|Drug|Xeloda|Xeloda dose is calculated according to body surface area.The recommended dose is 1000 mg/m² administered orally twice daily (morning and evening; equivalent to 2000 mg/m² total daily dose) for 2 weeks followed by a 1-week rest period given as 3-week cycles
1657581|NCT01796782|Drug|QYHJ Granules|1-4 bags bid , days 1-42, every 6 weeks
1657582|NCT01796769|Device|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|Usual CPAP treatment in sleep apnea patients
1657583|NCT01796769|Device|Continuous Positive Airway Pressure (CPAP) in sleep apnea patients|CPAP treatment with telemedicine system
1657584|NCT01796756|Other|Handover program|
1657593|NCT01796665|Drug|Placebo of Clindamycin Phosphate and Benzoyl Peroxide Topical Gel 1.2%/2.5% product|
1657594|NCT01796626|Device|M22 ResurFX module|The system delivers pulsed near Infra-Red (NIR) laser light with a nominal wavelength of 1565 nm and has a unique treatment handpiece with epidermal cooling. The clinician is able to control the settings of energy, µBeams density, scan size, and shape option from the user interface (LCD GUI) display on the main M22 console.
1657595|NCT01796613|Device|Vaginal Ring - intermittent regimen|NuvaRing® used intermittently. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck & Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
1657596|NCT01796613|Device|Vaginal Ring - continuous regimen|NuvaRing® used continuously. Nuvaring is a contraceptive vaginal ring, manufactured by N.V. Organon (a subsidiary of Merck & Co., Inc.,), Oss, the Netherlands. It contains 11.7 mg etonogestrel and 2.7 mg ethinylestradiol. It releases etonogestrel and ethinylestradiol at an average amount of 0.120 mg and 0.015 mg, respectively per 24 hours, over a period of 3 weeks. It is approved since 2001 by most countries within the European Union, and in the United Stated by the FDA.
1657597|NCT01796600|Device|The patients will have a conventional scanner, a reference examination, and a cone-beam scanner Newtom 5G just after the conventional scanner|
1657598|NCT01796587|Device|LoFric Origo|
1657599|NCT01796574|Dietary Supplement|Ketogenic diet|4:1 ratio fat: carbohydrates and protein ketogenic liquid via enteral feed
1657600|NCT01796561|Dietary Supplement|Olive leaf extract liquid|Commercially available polyphenol-rich olive leaf extract liquid
1657601|NCT01796548|Drug|Oxybutinin Extended-Release|Oxybutynin chloride 5, 10, 15 milligram (mg) per tablet 10-30 mg per day orally
1657602|NCT01796522|Drug|progesterone 200 mg / day vaginally|
1657603|NCT01796522|Drug|nifedipine (60 mg / day orally)|
1657605|NCT01796496|Other|Manipulative Therapy Techniques|"Global Technical bilateral pelvis: The technique involves inserting a small spine rotation and make a slack in three stages.
Indirect technique of lumbar roll in rotation for bilateral L3: to reduce the slack and make the body drop simultaneously, together with a high speed contraction pectoral muscles and triceps, iliac crest leading caudad which produces a rotation of the vertebra underlying joint space opening.
Dog-technic on D12: this technique reduces the slack in the abdomen toward the hand in contact with D12. Next, the therapist conducted a thrust in the direction of the reduction."
1657606|NCT01796496|Other|Functional Technique|The therapist presses the two anterior superior iliac spines to open the back of the pelvis, this maintained throughout the technique. Then patient is asked to breathe deeply and exhale, sacrum makes a flexion-extension respectively. These movements should be symmetrical and of equal duration in time.
1657607|NCT01796483|Device|Clonidine (Catapressan)|Clonidine (Catapressan) : Oral administration - Single dose (150 µg) - 90 minutes before EEG
1657608|NCT01796483|Device|Placebo 90 minutes before EEG|Placebo : Oral administration - Single dose (lactose) - 90 minutes before EEG
1657609|NCT01796470|Drug|Entospletinib|Entospletinib tablets administered orally twice daily
1657610|NCT01796470|Drug|Idelalisib|Idelalisib tablets administered orally twice daily
1657611|NCT01796444|Procedure|Sentinel Lymph Node Biopsy|Sentinel lymph nodes are identified with the combining use of intraoperative gamma detector and/or blue dye.
1657612|NCT01796444|Procedure|Intraoperative Pathological Examination|touch imprint cytology and/or frozen section and/or OSNA
1657613|NCT01796444|Procedure|Axillary Lymph Node Dissection|Axillary lymph node dissection involving removal of at least level I and II nodes.
1657614|NCT01796444|Procedure|Pathological Evaluation|H&E and IHC
1657615|NCT01796444|Drug|Adjuvant Systemic Therapy|Adjuvant systemic therapy was determined by the treating physician according to the recently NCCN.
1657616|NCT01796444|Radiation|Radiation Therapy|Whole-breast opposing tangential-field radiation therapy.
1657617|NCT01796431|Drug|Eviplera®|
1657618|NCT01796418|Drug|Beraprost sodium|
1657619|NCT01796405|Drug|Clofarabine|
1657622|NCT01796379|Behavioral|High Intensity Interval Training|9 months of high intensity interval based aerobic exercise (3 times/week)
1657623|NCT01796379|Behavioral|Moderate Training|
1657624|NCT01796366|Drug|insulin 338 (GIPET I)|Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.
1657625|NCT01796366|Drug|placebo|S.c placebo administered in combination with insulin 338
1657626|NCT01796366|Drug|insulin glargine|Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.
1657627|NCT01796366|Drug|placebo|Oral placebo administered in combination with s.c. insulin glargine
1657628|NCT01796353|Other|sexual rehabilitation|exercise plus psycho-education
1657629|NCT01796353|Other|Usual care|usual care
1657883|NCT01794429|Drug|Exenatide|Subcutaneum injection of exenatide once-weekly for 3 months
1657630|NCT01796340|Behavioral|Food cue exposure|Participants will be exposed to several kinds of their favorite food. The aim of this exposure is to increase the food cravings as much as possible.
1657631|NCT01796340|Behavioral|Psycho-education|General information about nutrients, calories, exercise and the energy balance will be provided. In addition, psychological problems that accompany overweight will be discussed.
1657632|NCT01796327|Drug|dacomitinib oral|Dacomitinib 45 mg oral tablet
1657633|NCT01796327|Drug|dacomitinib intravenous|Dacomitinib 20 mg solution will be given as 1 hour intravenous infusion
1657635|NCT01796301|Drug|Romozosumab|Administered by subcutaneous injection once a month.
1657636|NCT01796301|Drug|Teriparatide|Administered by subcutaneous injection once a day.
1657637|NCT01796288|Radiation|simultaneous radiotherapy|
1657638|NCT01796288|Drug|Erlotinib|
1657639|NCT01796275|Behavioral|Core intervention program|
1657640|NCT01796275|Behavioral|Booster session|
1657641|NCT01796275|Behavioral|Control only (Tea gathering)|
1657642|NCT01796262|Dietary Supplement|docosahexaenoic acid|Supplementation with DHA Richoil 250mg pearl b.i.d. for six months
1657643|NCT01796262|Dietary Supplement|Wheat germ oil|Wheat germ oil 250 mg pearl b.i.d. for six months
1657644|NCT01796236|Device|Minimally invasive surgery and BA400|The Cochlear Baha BA400 Abutment has been designed with a concave shape at the lower aspect of the abutment. The abutment is made of commercially pure titanium and is coated with a hydroxyapatite layer on the entire soft tissue-contacting surface of the abutment up to 3 mm below the top surface (2 mm below the top surface on 6 mm abutments).
1657645|NCT01796236|Device|Traditional surgery and BA300|The BA300 abutment is made of commercially pure titanium and is available in two different lengths (6 mm and 9 mm).
1657646|NCT01796223|Behavioral|Feedback|The Partners for Change Outcome Management System, administered at the beginning and ending of every therapy session.
1657647|NCT01796223|Behavioral|Control|
1657648|NCT01796197|Drug|Trastuzumab|
1657649|NCT01796197|Drug|Pertuzumab|
1657650|NCT01796197|Drug|Paclitaxel|
1657651|NCT01796197|Drug|Doxorubicin|
1657652|NCT01796197|Drug|Cyclophosphamide|
1657653|NCT01796197|Procedure|Mastectomy|
1657654|NCT01796197|Radiation|Radiation Therapy|
1657655|NCT01796171|Drug|Betalutin|Dose finding study, starting on 10 MBq/kg b.w. Betalutin ((177Lu)-lilotomab), single injection.
1657656|NCT01796158|Behavioral|cASBI+cMET|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit. The cMET protocol is a 2 session intervention composed of 8 exercises designed to encourage adolescents their alcohol and other substance use and develop a plan to stop or reduce their use.
1657657|NCT01796158|Behavioral|cASBI|In the cASBI protocol participants complete a computerized screen for alcohol and drug use, view their screen results on the computer, then see 10 pages of science and true life stories describing the health effects of alcohol and other substance use. The provider receives a report of the screen results and gives brief advice regarding alcohol and drug use during the office visit.
1657658|NCT01796145|Other|Fibroscan|
1657659|NCT01796132|Drug|SSRI/SNRI|Exposed group of mothers taking one of the mentioned antidepressant drugs of the class of selective serotonin reuptake inhibitors (SSRI) or serotonin/noradrenalin reuptake inhibitors (SNRI).
1657660|NCT01796119|Procedure|Ridge Splitting|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.
To measure BLI measured using PA radiographs taken immediately and 6 months post-op.
To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.
To measure implant success rate. The implants used in this study: NobelActive 3.5 - 4.3mm diameter, 10 - 13 mm in length."
1657661|NCT01796119|Procedure|Implants placed using drilling technique|"To measure the horizontal bone width before and after implant insertion and 6 months post-op.
To measure BLI measured using PA radiographs taken immediately and 6 months post-op.
To measure implant stability with the resonance frequency analyzer (Osstell,Osstell USA) at time of implant placement, 3 months and 6 months post-op.
To measure implant success rate. The implants used in this study: NobelActive 3.5-4.3mm diameter, 10 - 13 mm in length."
1657662|NCT01796106|Device|Icon|refer to instructions for use of Icon
1657663|NCT01796106|Device|fluoride varnish|The study clinician will provide oral hygiene instruction and topical fluoridation therapy (Duraphat fluoride varnish; Colgate Oral Pharmaceuticals, New York, NY, United States) to all study participants randomized to study arm 2 after the radiograph and visual exam. Topical fluoridation treatment will be provided is varnish (Duraphat) per manufacturer's instructions.
1657664|NCT01796093|Drug|Digoxin and ivabradine|No more details
1657665|NCT01796080|Other|Mueller manoeuvre|
1657666|NCT01796080|Other|Inspiratory threshold|
1657667|NCT01796080|Other|Expiratory apnoea|
1657668|NCT01796080|Other|Steady state normal breathing|
1657669|NCT01796067|Behavioral|Motivational and Family Weight Loss|This group will receive the comprehensive motivational and family weight loss intervention.
1657670|NCT01796067|Behavioral|Basic Health Education|This group will receive the comprehensive basic health education intervention.
1657671|NCT01796067|Behavioral|Online Intervention|Participants will receive the online tailored weight loss intervention program after they have either received the motivational plus family weight loss program or basic health face-to-face program.
1657884|NCT01794429|Drug|Placebo|Subcutaneum injection of placebo once-weekly for 3 months
1718533|NCT00002532|Drug|prednisolone|
1657672|NCT01796067|Behavioral|Online Control|Participants will receive the online control program after they have either received the motivational plus family weight loss program or the basic health education program.
1657673|NCT01796054|Behavioral|Stress Free Now online program|Stress Free Now is an online stress reduction program. Participants will log into online program, read and practice daily and weekly activities.
1657674|NCT01796054|Behavioral|Group support session|Participants will meet weekly for group support session to review online lessons and relaxation therapies.
1657675|NCT01796041|Drug|Indocyanine Green|
1657676|NCT01796028|Drug|METFORMIN|
1657677|NCT01796028|Drug|Placebo|
1657678|NCT01796028|Drug|TAXOTERE®|
1657679|NCT01796015|Other|ONSD ultrasound|"Description of the ONSD ultrasound: ONSD is measured 3 mm behind the globe and perpendicularly to the optic nerve axis (2 dimensions mode).
For each optic nerve, 2 measures are performed: 1 sagittal and 1 transverse. The patient is positioned in 30° dorsal elevation. Gel is applied on the eyelid and a 7,5 MHz probe is used.
At the same time and on the same side, a transcranial Doppler is performed using a 2 MHz probe placed on the temple. Are measured: systolic velocity, mean velocity, diastolic velocity, resistance index and pulsatility index.
As ONSD measures cannot be done blinded (regarding ICP monitoring), a centralised evaluation (by 2 experts) of the recorded sonograms is planned."
1657680|NCT01796002|Drug|Romidepsin + CHOP|Ro-CHOP administered in 3 week cycles for 6 cycles or until progression Romidepsin is administered at a dose of 12 mg/m² IV on day 1 and day 8 every 3 weeks.
1657681|NCT01796002|Drug|CHOP|CHOP (cyclophosphamide, doxorubicin, vincristine and prednisone) administered in 3 week cycles for 6 cycles.
1657682|NCT01795989|Device|1.5T MRI Elbow Coil|Pediatric coil for musculoskeletal imaging at 1.5 Tesla for pediatric patients and healthy participants.
1657683|NCT01795976|Genetic|NY-ESO-1 T cells|
1657684|NCT01795976|Drug|cyclophosphamide|cyclophosphamide 60mg/kg/day day -7 and day -6
1657685|NCT01795976|Drug|Fludarabine|Fludarabine given 25mg/m2 day -5 to day -1
1657686|NCT01795976|Biological|Interleukin 2|Interleukin 2 (IL2) immunotherapy given day 0 to day 6
1657687|NCT01795963|Behavioral|ePREP|The ePREP intervention teaches individuals how to recognize and combat dynamic risk factors that lead to relationship distress. Specifically, it teaches communication techniques and problem-solving skills that help couples to effectively deal with conflict. It also teaches couples how to enhance positive aspects of their relationship by fostering fun and friendship.
1657688|NCT01795963|Behavioral|Placebo Control|Participants in the control condition will view a presentation that teaches inert information about anxiety, depression, and relationships such as definitions, prevalence rates, common problems associated with these conditions and available forms of treatment. This presentation was used initially in Cuckrowicz & Joiner (2007) and has since been shown to be effective as a placebo in two previous ePREP studies (Braithwaite & Fincham, 2007; Braithwaite & Fincham, 2008). This presentation is identical to the ePREP intervention in its set up, the only difference being, there is no information included in this presentation that teaches specific skills or strategies for improving relationships, depression or anxiety.
1657689|NCT01795950|Drug|PLX-PAD|intravenous administration of a single dose of PLX-PAD cells
1657690|NCT01795937|Drug|Itraconazole|twice daily
1657691|NCT01795937|Drug|Atorvastatin|single dose
1657692|NCT01795937|Drug|Faldaprevir|once daily
1657693|NCT01795937|Drug|Rosuvastatin|single dose
1657694|NCT01795937|Drug|Faldaprevir|once daily
1657695|NCT01795924|Drug|PD-616|Patients may continue treatment through 1 year post-C1D1 or until withdrawal of consent or development of any toxicity meeting the definition of Dose-Limiting Toxicity or progressive disease, whichever occurs first.
1657696|NCT01795911|Biological|Pegylated Interferon Lambda|
1657697|NCT01795911|Drug|Ribasphere|
1657698|NCT01795911|Drug|Daclatasvir|
1657699|NCT01795898|Drug|Fentanyl|Fentanyl transdermal patches releasing 12.5 microgram of fentanyl will be applied for 3 days. The patches will be replaced every 3 days (Day 3, 7 and 10).
1657700|NCT01795885|Behavioral|16 and Pregnant|"Participants in this arm will be asked to watch an approximately 45-minute commercial-free episode of the MTV television show 16 and Pregnant once a week for 4 weeks. They will receive an email that contains a link to watch an episode of the show on the internet. The site where the videos are hosted is password protected and they are given the password in the same email. They can watch the video at any time, and can come back to it later if they need to stop watching it. The participants are asked to all watch the same episode each week. Four episodes were selected for the intervention from the first three seasons of the show."
1657701|NCT01795872|Procedure|Several diagnostic procedures|No drug will be assigned, diagnostic assessment within the study.
1657702|NCT01795859|Drug|SD-809|SD-809 tablets are available in three dose strengths: 6, 9 and 12 mg, all of which are identical in size, shape and color (white).
1657703|NCT01795859|Drug|Placebo|Placebo tablets are identical in appearance to SD-809 tablets.
1657705|NCT01795833|Other|Short text messages|In addition to structured education on healthy lifestyle provided at baseline, subjects in the arm will receive short text messages containing educational, motivational and supportive content on diet, physical activity, and smoking (if appropriate) during the study period. The content will be appropriate to the stage of the transtheoretical model of behavioural change that the subject is in. This will be assessed by questionnaire at each visit to clinic.
1657706|NCT01795820|Drug|loading with Ticagrelor|Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2
1657707|NCT01795820|Drug|no loading with Ticagrelor|"Patients allocated in the two study arms will receive the same anti platelet treatment, except for the administration of the loading dose, which will be only administered to patients allocated in Group 2.
In other words, patients randomized to this group (group 1) will not receive a loading dose of ticagrelor during the passage from clopidogrel to ticagrelor."
1657708|NCT01795794|Drug|omeprazole|
1657709|NCT01795768|Drug|AZD 4547|
1657710|NCT01795755|Behavioral|Mentalization based inpatient treatment.|1-3 month of inpatient treatment
1657885|NCT01794416|Procedure|Thoracoscopic epicardial ablation|
1657886|NCT01794416|Procedure|Endocardial catheter ablation|
1657711|NCT01795755|Behavioral|Horse assisted Therapy (HAT)|A structured program of 12 X 90 minute HAT sessions (horse care, ground and mounted work) conducted by two clinically qualified therapists who are also Level I Riding Instructors.
1657712|NCT01795742|Device|Human-Powered Nebulizer|
1657713|NCT01795729|Device|Stent|Coronary revascularization
1657714|NCT01795729|Drug|optimal medical therapy|Dual antiplatelet therapy: aspirin and a P2Y12 inhibitor as indicated
1657715|NCT01795716|Drug|mesylate imatinib capsule|Single and multiple oral mesylate imatinib capsule 400mg qd
1657716|NCT01795716|Drug|Glivec|Single and multiple oral Glivec 400mg qd
1657717|NCT01795703|Drug|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
1657718|NCT01795703|Drug|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
1657719|NCT01795677|Drug|Ruxolotinib|Ruxolotinib doses calculated with platelets count and P450 cytochrome inhibitor HSCT for patients with donor
1657720|NCT01795664|Radiation|Functional Respiratory Imaging|CT-scan of thorax, at visit 2 pre and postdose and at visit 3 pre and postdose
1657721|NCT01795664|Drug|Salmeterol xinafoate and Fluticasone propionate HFA pMDI|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg
At visit 2 or visit 3 (cross-over design)"
1657722|NCT01795664|Drug|Seretide Evohaler|"Strength: 25/250 mcg per actuation; Dose: single dose of 2 puffs; A total dose of 50/500 mcg
At visit 2 or visit 3 (cross-over design)"
1657723|NCT01795664|Drug|Placebo of Test product|"Single dose of 2 puffs
To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
1657724|NCT01795664|Drug|Placebo of Reference product|"Single dose of 2 puffs
To ensure blinding, each patient will receive two inhalers (one active and one placebo) on each dosing day."
1657725|NCT01795651|Procedure|identification of take-home message of lecture|
2013257|NCT00688155|Behavioral|Healthy Aging Education (HAE)|One 1-hour lecture each week for 3 months, then monthly.
2013258|NCT00687102|Drug|tamoxifen|oral tamoxifen plus placebo daily for 5 years
1657728|NCT01795612|Other|physical activity|
1657729|NCT01795599|Drug|Mifegyne ®|
1657730|NCT01795599|Drug|Gymiso®|
2013259|NCT00687102|Drug|raloxifene|oral raloxifene plus placebo daily for 5 years
2013260|NCT00683371|Procedure|Specimen collection|10 patients with chronic rhinosinusitis will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
1657733|NCT01795573|Biological|Cultured Treg cells|Co-culturing of recipient dendritic cells and donor Treg. Treg administration will occur 2 days before the allogeneic stem cell transplant (i.e. day -2 with reference of day 0 as stem cell infusion date).
1657734|NCT01795547|Drug|Aripiprazole and aripiprazole once-monthly|Oral aripiprazole tablets according to Summary of Product Characteristics (SmPC)/United States Prescription Information (USPI) daily for 4 weeks followed by the 1st aripiprazole intramuscular (IM) injection at the end of Week 4. Oral tablets were taken for 2 more weeks after the 1st injection. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
1657735|NCT01795547|Drug|Paliperidone and paliperidone palmitate|Oral paliperidone tablets according to SmPC/USPI daily for 3 weeks followed by 2 paliperidone palmitate IM injections at Weeks 3 and 4, respectively. Starting at the end of Week 8, additional injections were given every 4 weeks until Week 24.
1657736|NCT01795534|Dietary Supplement|Beetroot shot then placebo shot|Beetroot shot, four day wash out, then placebo shot
1657737|NCT01795534|Dietary Supplement|Placebo shot then beetroot shot|Placebo shot, four day wash out, then beetroot shot
1657738|NCT01795521|Radiation|Stereotactic Body Radiotherapy (SBRT)|A form of radiation therapy, where only the primary tumor is targeted and precise stereotactic tumor localization combined with techniques reducing breathing- induced target motion allowed small safety margins. These small volumes are treated with hypo-fractionated, escalated irradiation doses. It's now further developed in multiple clinical and technological aspects e.g. FDG-PET/CT based nodal staging, respiration correlated CT- imaging for target volume definition and image-guided treatment delivery.
1657739|NCT01795508|Behavioral|PMTO|Parent Management Training, Oregon
1657740|NCT01795508|Behavioral|TAU|Other kinds of family training
1657741|NCT01795495|Drug|Methadone hydrochloride|This drug will be used in conjunction with remifentanil as an adjunct analgesic. Remifentanil + methadone (0.1 mg/kg IV over 15 minutes) just after induction of anesthesia
1657742|NCT01795495|Drug|Magnesium Sulfate|This drug will be given with remifentanil as an adjunct analgesic. Remifentanil + magnesium (50 mg/kg bolus over 30 minutes followed by 10 mg/kg/hour).
1657743|NCT01795495|Drug|Remifentanil|
1657744|NCT01795482|Device|Forced-air warming|In the intervention groups a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the patients sitting or laying on the operating table for 15 min before start of epidural anaesthesia and afterwards till start of general anaesthesia (group 3), for 15 min before start of general anaesthesia (group 2) or only after induction of general anaesthesia (group 1, control). All patients will receive forced-air warming after induction of general anaesthesia till end of surgery.
1657745|NCT01795469|Device|Zoex compression garment|5-strap compression of abdomen, thighs and legs
1657746|NCT01795443|Other|Calibration|"Subjects will be seated on a table, feet dangling, blindfolded, arms crossed over the chest and held in place by bandages to minimize the visual and proprioceptive inputs that may contribute to the realization of the task.
The investigator uses an electronic goniometer to measure the maximal extension and flexion during a pelvic pivot. These measures will be used to determine a target position midway along the pelvic movement range."
1657810|NCT01794988|Behavioral|Pain Education|Subjects will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
1657747|NCT01795443|Other|Practice|"Propioception test: The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position.
Each subject will have three (non-measured) tries at the proprioception test without vibration, then three tries with low frequency vibration (20 Hertz), and then three tries with high frequency vibration (60 Hertz). Between each series of tries, a 2-minute rest period with walking is required."
1657748|NCT01795443|Other|Measures - no vibration|"The movements required are performed without vibration.
The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.
The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
1657749|NCT01795443|Other|Measures - low vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).
The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.
The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
1657750|NCT01795443|Other|Measures - high vibration|"The movements required are performed with low frequency vibration (20 Hertz on following device: VIBRALGIC 5; manufacturer = Electronique Conseil).
The movement required is flexion - extension of the lumbar spine without moving the shoulders; it is a pelvic rocking motion. The patients will be helped to the target position by the investigator. After keeping the target position for 5 seconds, they will be asked to completely pivot the pelvis to a forward position, then return to the target position. This test is repeated five times.
The investigator measures the lumbar angle using an electronic goniometer twice during each of the five tests: once after the patient is helped to the target angle, and once after the patient tries to remember the target angle by his/herself."
1657751|NCT01795430|Drug|etoposide|Given IV
1657752|NCT01795430|Drug|ifosfamide|Given IV
1657753|NCT01795430|Radiation|intensity-modulated radiation therapy|Undergo WB-MRI-guided IMRT
1657754|NCT01795430|Drug|topotecan hydrochloride|Given IV
1657755|NCT01795430|Drug|busulfan|Given IV
1657756|NCT01795430|Drug|melphalan|Given IV
1657757|NCT01795430|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell or bone marrow transplant
1657758|NCT01795430|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
1657759|NCT01795430|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow transplant
1657762|NCT01795404|Behavioral|Inquiry Based Stress Reduction (IBSR)|
1657763|NCT01795378|Biological|donor natural killer cell infusion|"Donor NK cells will be generated at the GCP laboratory at Asan Institute of Life Science by a team from Stem Cell Research Center, Korea Research Institute of Bioscience and Biotechnology.
The patients will receive donor NK cell infusion (DNKI) around on days 6 and 9 (generated from the first collection), and around on days 13 and 20 (generated from the second collection).
For DNKI to be given on days 6 and 9, a 3-patient cohort each will receive escalating dose of 2x10e7/kg, 5x10e7/kg, 1x10e8/kg, and 1-4 x10e8 cells.
The dose of DNKI to be given on days 13 and 20 will be 1-4 x10e8/kg."
1657764|NCT01795365|Other|Active surveillance|
1657765|NCT01795339|Drug|AZD3293|Oral solution
1657766|NCT01795339|Drug|Placebo|Oral solution
1657767|NCT01795313|Biological|HLA-A2 restricted synthetic tumor antigen|
1657768|NCT01795313|Drug|Imiquimod|
1657769|NCT01795313|Other|enzyme-linked immunosorbent assay|
1657770|NCT01795313|Other|flow cytometry|
1657771|NCT01795313|Other|immunohistochemistry staining method|
1657772|NCT01795313|Other|laboratory biomarker analysis|
1657773|NCT01795300|Radiation|Carbon Ion Radiotherapy|"Patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.
The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
1657774|NCT01795300|Radiation|Proton Therapy|"As described previously, patients will be immobilized using an individually manufactured head mask for treatment planning and RT. Contrast-enhanced CT as well as MR-imaging will be performed for target volume definition. OAR such as the brain stem, optic nerves, chiasm and spinal chord will be contoured. Dose constraints of normal tissue will be respected according to Emami et al. (33). The fractionation scheme will be taken into account for dose prescription, as well as DVH-characteristics and clinical parameters of the invidivual patient.
The Gross Tumor Volume (GTV) will be defined as the contrast-enhancing lesion on MRI on T1-weighted MR-imaging. Amino-Acid-PET or DOTATOC-PET may be used in addition to contrast-enhanced MRI for target volume definition but is not mandatory.The Clinical Target Volume (CTV) will be defined adding 1-2mm safety margin to the GTV."
1657811|NCT01794988|Behavioral|Therapeutic Interactive Voice Response|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls.
1718534|NCT00002532|Drug|vindesine|
1657775|NCT01795300|Radiation|Hypofractionated Photon Radiotherapy|"Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.
To the target volume defined for photon treatment, a total dose of 52.2 Gy E - 57.6 Gy E is applied in single fractions of 1.8Gy E. In the 3Gy E Photon arm, photon radiotherapy will be delivered to a total dose of 45 Gy E in 15 fractions."
1657776|NCT01795300|Radiation|Conventional Photon Radiotherapy|Treatment Planning for Photon Radiotherapy will be performed using the Planning Systems available at the Department of Radiation Oncology in Heidelberg, Germany (including Masterplan/Nucletron, Virtuos-Konrad/Siemens, or Precisis/STP/Stryker-Leibinger, or the Tomotherapy Software). Carbon ion and proton RT planning is performed using the treatment planning software PT-Planning (Siemens, Erlangen, Germany) including biologic plan optimization. Biologically effective dose distributions will be calculated using the a/ß ratio for meningioma as well as for the endpoint late toxicity to the brain. Patient positioning prior to radiotherapy will be evaluated by comparison of x-rays to the DRRs. Set up deviations >3mm are corrected prior to radiotherapy.
1657777|NCT01795287|Procedure|General anesthesia|GA will be inducted by fentanyl, propofol and rocuronium. GA will be maintained by sevofluran, fentanyl and rocuronium.
1657778|NCT01795287|Procedure|Spinal anesthesia|hyperbaric bupivacaine 10-15 mg i.t.
1657779|NCT01795274|Radiation|Carbon Ion Radiotherapy|Step 1 14 x 3 Gy E 42 Gy E Step 2: 15 x 3 Gy E 45 Gy E Step 3: 16 x 3 Gy E 49 Gy E Step 4: 17 x 3 Gy E 51 Gy E Step 5: 18 x 3 Gy E 54 Gy E
1657780|NCT01795248|Drug|Liraglutide|1.8 mg liraglutide
1657781|NCT01795248|Drug|Placebo|Liraglutide without the GLP-1 analogue
1657782|NCT01795235|Drug|Saline|Saline s.c.
1657783|NCT01795235|Drug|Glucagon|Glucagon s.c.
1657784|NCT01795235|Drug|Placebo|Sugar Pill
1657785|NCT01795235|Drug|Atenolol|Beta-1 receptor antagonist
1657786|NCT01795222|Drug|Midazolam|Dormire: Midazolam oral solution 2 mg/mL Sedative was administered with a syringe by the anaesthesiologist
1657787|NCT01795222|Drug|Placebo|Magistral formula prepared to match Dormire color and consistency, without active ingredients Placebo was administered the same way as midazolam
1657788|NCT01795209|Drug|Ranibizumab|"Loading dose: three monthly intravitreal injections of ranibizumab 0.5 mg
Lucentis stop criteria: V/A ≥20/20 and complete disappearance of macular edema
Retreatment: visual loss of 5 or more letter compared to previous visit"
1657789|NCT01795209|Device|Sham injection|"Three monthly sham injections followed by retreatment (sham injections) as needed
Stop criteria: V/A ≥20/20 and complete disappearance of macular edema
Retreatment: visual loss of 5 or more letter compared to previous visit"
1657790|NCT01795209|Procedure|Rescue laser|"In the Lucentis group: performed if BCVA < 20/40 or CFT ≥ 350um despite of 3 sessions of previous Lucenis injection from Month 6
In the standard of care group: performed if BCVA < 20/40 or CFT ≥ 350um from Month 3"
1657791|NCT01795183|Drug|AMISULPRIDE|Pharmaceutical form: tablet Route of administration: oral
1657792|NCT01795170|Dietary Supplement|Lysine Restricted Diet|Daily lysine intake will be managed to maintain a plasma lysine level of 50-80 µmol/L (normal range: 52-196 µmol/L). Diet prescriptions will be based on international guidelines for glutaricaciduria type I, another inborn error of lysine catabolism. In order to meet the recommended daily protein intake (DRI) [23,24], the diet may include commercially available lysine-free amino acid formulas approved for use in conditions affecting lysine metabolism, as well as commercially available low-protein products based on the participant's taste.
1657793|NCT01795170|Drug|Pyridoxine|All participants will be on 15-30 mg/kg/day of pyridoxine therapy up to a maximum of 500mg/day divided in 2-3 doses enterally
1657794|NCT01795157|Device|CCADSS|Questionnaire is transferred wireless to the physician's PC
1657795|NCT01795157|Device|pen-paper|Questionnaire completed and transferred to the physician using standard methods
1657796|NCT01795144|Drug|GLP-1|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
1657797|NCT01795144|Drug|Exendin 9-39|OGTT IGI IGI with GLP-1 infusion OGTT with Exendin 9-39 infusion
1657798|NCT01795131|Dietary Supplement|Vitamin B12|
1657799|NCT01795131|Dietary Supplement|Placebo|
1657800|NCT01795092|Other|Dermatology Consultation|A dermatology consultation will be conducted on patients randomized to this group.
1657801|NCT01795079|Device|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
1657802|NCT01795066|Device|EUS-FNB with 25-gauge (Echotip ProCore; Cook Endoscopy Inc, Limerick, Ireland)|
1657803|NCT01795053|Behavioral|Experimental: playtraining|playtraining is a play based intervention that includes techniques of behavioral management as: structuring of play situation, detailled play planning, definition of behavioral tasks, positive reinforcement, token economy. The intervention is designed to enhance play-persistence and -intensity and thereby reduce ADHD symptoms
1657804|NCT01795053|Behavioral|Placebo open play session|
1657805|NCT01795040|Dietary Supplement|omega-3/omega-6 fatty acids (PUFAs)|Equazen 500mg/day= 116 mg docosahexaenoic acid, 372 mg Eicosapentaenoic acid, 40 mg gamma-Linolenic acid
1657806|NCT01795027|Drug|S-1 plus oxaliplatin|6 courses chemotherapy with S-1 plus oxaliplatin followed by 10 courses S-1 single after d D2 resection
1657807|NCT01795027|Drug|S-1 single|16 courses S-1 single after d D2 resection
1657808|NCT01795001|Other|No intervention|
1657809|NCT01794988|Behavioral|Group Cognitive Behavioral Therapy|Each CBT session will last 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
1657812|NCT01794988|Behavioral|NO TIVR|Control - no intervention
1657813|NCT01794975|Drug|Ketamine|
1657814|NCT01794975|Drug|Atomoxetine|
1657815|NCT01794975|Other|Cold pressor test|
1657816|NCT01794975|Drug|Placebo|
1657817|NCT01794962|Other|Cognitive functional therapy|The intervention is directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder.
1657818|NCT01794962|Other|manual therapy and exercises|Patients in this group will be treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and is designed to be consistent with best current manual therapy practice.
1657819|NCT01794949|Device|Resolute Integrity stent|Drug eluting stents used to treat coronary artery blockages
1657820|NCT01794936|Device|VTI Probe|The VTI 20 MHz microvascular Laparoscopic Doppler System is a blood flow detector that compensates for the loss of tactile sensation during laparoscopic procedures by eliminating misunderstandings related to surrounding vascular anatomy. The system's sterile doppler probes fit through standard 5mm ports, making it easy to use with no special training required.
1657821|NCT01794923|Drug|IBU BID|10-cm strip of IBU 5% topical gel applied to the affected area BID (twice daily) x 3 days
1657822|NCT01794923|Drug|Placebo BID|10-cm strip of placebo topical gel applied to the affected area BID (twice daily) x 3 days
1657823|NCT01794923|Drug|IBU TID|10-cm strip of IBU 5% topical gel applied to the affected area TID (three times daily) x 3 days
1657824|NCT01794923|Drug|Placebo TID|10-cm strip of placebo topical gel applied to the affected area TID (three times daily) x 3 days
1657825|NCT01794910|Other|Pelvic floor muscle therapy|The women performed perineal contraction exercises in the dorsal decubitus, sitting, and standing positions and was applied twice per week for a total of 15 sessions
1657826|NCT01794897|Drug|Experimental: Valacyclovir treatment|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. The VAV group will receive 1.5 g Valacyclovir by mouth, twice daily for 16 weeks, after which they will be followed up without VAV for 4 weeks to monitor delayed adverse effects.
1657827|NCT01794897|Drug|Placebo comparator|Patients will have a placebo run-in for two weeks after which they will be evaluated for the variables of interest and then randomized to either VAV or placebo group in a 1:1 proportion. Subjects in the placebo arm will receive placebo for 16 weeks, after which they will be followed up without placebo for 4 weeks to monitor delayed adverse effects.
1657828|NCT01794884|Drug|Glutamine|20% N(2)-L-alanyl-L-glutamine 0.4g/kg(2ml/kg) mixed with compound amino acid (10ml/kg).Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h
1657829|NCT01794884|Drug|Ringer's solution|Ringer's solution 12ml/kg. Intravenous injection twice (24 hours、1 hour before operation). Injection rate = 6ml/kg/h.
1657830|NCT01794858|Other|Therapeutic Hypothermia|Will receive medically-necessitated ventilator support under ICU monitoring with core temperatures ≥36°C and severe acute pancreatitis defined as either a Ranson Score ≥7, a CT indicating ≥50% pancreatic necrosis, or a significant deterioration in clinical status including dysfunction of two or more organ systems. All patients will receive current standard management for severe acute pancreatitis and a standardized protocol for application of therapeutic hypothermia and rewarming. Our primary endpoints are organ-specific cardiovascular, respiratory, hematological, renal, and metabolic dysfunction as measured at 28 days. Logistic Organ Dysfunction Scores will be compared before and after therapeutic hypothermia, establishing day 4 versus day 1 changes in LOD.
1657831|NCT01794845|Drug|Erbitux|Erbitux: 400 mg/m2 as a loading dose one week prior to radiation and taxotere, and then at 250 mg/m2 given weekly on Day 1 of treatment week following Taxotere.
1657832|NCT01794845|Drug|Taxotere|Taxotere : 20 mg/m2 IV once a week on Day 1 during treatment weeks 2 to 7.
1657833|NCT01794845|Radiation|Low Dose Fractionated Radiation Therapy|Low-dose fractionated Radiation (LDFRT): 0.5 Gy per fraction twice-a-day (BID) at least 6 to 8 hours apart on Days 2 and 3 of treatment weeks 2 to 7 for a total dose of 12 Gy.
1657834|NCT01794819|Device|C-reactive protein test|Results provides within 5 minutes. This test is based on solid-phase sandwich immunometric analysis. The measurement range in whole blood samples is 8-200 mg/L.
1657835|NCT01794806|Procedure|Tooth extraction and grafting with allograft|Alveolar ridge preservation using a bone grafting material (allograft) and a synthetic dPTFE (dense Polytetrafluoroethylene) barrier membrane
1657836|NCT01794806|Procedure|Tooth extraction|Minimally traumatic single-rooted tooth extraction
1657837|NCT01794793|Drug|Pasireotide|Pasireotide subcutaneous or Long Acting Release
2013261|NCT00683371|Procedure|Specimen collection|10 patients without sinus disease will have three specimens collected from the maxillary sinus during surgery. The sinus mucosa, sinus mucus and a saline lavage will be collected. The three samples will then be analyzed with microarrays looking for bacteria, fungi, and viruses.
2013262|NCT00678444|Other|Educational video|Watching an educational video about clean intermittent self-catheterization prior to prolapse/incontinence surgery.
1657843|NCT01794767|Drug|0,9% NaCl flush|Normal Saline solution
1657844|NCT01794767|Drug|Heparin 50U/ml|Heparin solution
1657845|NCT01794754|Other|Care as usual|
1657846|NCT01794754|Other|Occupational therapy|Occupational therapy in the waiting period before surgery. Occupational therapy comprises orthoses for the CMC-joint, hand exercises, and use of alternative working methods and assistive devices. The participants are encouraged to perform hand exercises three times a week for the first 12 weeks, and to use orthosis as much as possible, both during daytime (day orthosis) and night time (night orthosis).
1657847|NCT01794741|Drug|Dymista Nasal Spray|
1657848|NCT01794741|Drug|Fluticasone propionate nasal spray|
1657849|NCT01794715|Procedure|Ultrasound examination by nurses|Ultrasound examination performed by nurses. Focused examination of the pleural space and inferior vena cava.
1657850|NCT01794702|Drug|Decitabine|Phase I and II - 20 mg/m2 by vein daily for 5 days (days 1-5)
1657851|NCT01794702|Drug|Idarubicin|Phase I and II - 10 mg/m2 by vein daily for 3 days (days 6-8)
1657852|NCT01794702|Drug|Cytarabine|Phase I and II - 1 g/m2 by vein daily for 5 days (days 6-10)
1657853|NCT01794702|Drug|Clofarabine|"Phase I Starting Dose - 15 mg/m2 by vein daily for 4 days (days 6-9)
Phase II Starting Dose - Maximum tolerated dose from Phase I (number of days selected based on Phase I portion)."
1657854|NCT01794689|Drug|Morphine|0.08mg/kg will be administered to participants randomly assigned to receive the drug via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
1657855|NCT01794689|Drug|Saline Placebo (for Morphine)|Saline Placebo will administered to participants randomly assigned to receive the placebo via IV bolus during each quantitative sensory testing session (after one night of uninterrupted sleep and after 2 nights of forced awakenings).
1657856|NCT01794676|Genetic|Blood draw|Blood draw
1657857|NCT01794663|Drug|OPN-305|Intravenous infusion for 1 hour at start of transplant procedure
1657858|NCT01794663|Drug|Placebo|Intravenous infusion for 1 hour at start of transplant procedure
1657859|NCT01794650|Dietary Supplement|Meal composition|
1657860|NCT01794624|Behavioral|Cognitive Therapy for Catastrophizing|Cognitive Therapy for Catastrophizing will involve a standardized, 6-session cognitive intervention, focusing on cognitive restructuring techniques for managing pain and reducing catastrophic thinking and includes some general coping skills training. Cognitive restructuring includes identifying patterns of dysfunctional thinking which can give rise to emotional distress, physiological arousal, or maladaptive behaviors. Patients are taught to identify and replace distorted thinking with balanced, realistic thinking. Patients learn to identify these thoughts as they occur in daily life and challenge their own negative thoughts.
1657861|NCT01794624|Behavioral|Behavioral Therapy for Sleep Continuity Disturbance|Behavioral Therapy for Sleep Continuity Disturbance (BT-SCD) will involve 6-sessions of standardized interventions on sleep restriction therapy (SRT), stimulus control therapy (SCT), and sleep hygiene education. Sleep Restriction curtails the amount of time in bed so that it matches the average baseline amount of total sleep time. Stimulus Control Therapy re-establishes the bed and bedroom as cues for sleep by insuring the patient does not spend significant time in bed awake and/or engaging in sleep-incompatible behaviors. Sleep Hygiene Education uses motivational interviewing to teach subjects about environmental and behavioral factors which may influence sleep. SRT and SCT alone or combined have demonstrated overwhelming efficacy and effectiveness.
1657862|NCT01794611|Device|laryngoscopy|
1657863|NCT01794598|Behavioral|Receiving educational material of depression care|The educational material provides patients about depression management
1657864|NCT01794585|Behavioral|Virtual Reality Based Exercise|A structured, individually tailored, protocol driven, reproducible therapeutic intervention. The study intervention will consist of individually prescribed selections from three off-the-shelf VR games that target the type and severity of balance deficits elicited during the completion of a baseline assessment. Participants randomized to receive this intervention will be assigned a home balance program that utilizes an Xbox Kinect system to provide balance activities.
1657865|NCT01794585|Behavioral|Standard Exercise|An individualized home balance exercise program that also targets identified balance system-specific deficits, however, utilizes no VR components.
1657866|NCT01794572|Drug|Melphalan|Melphalan: 140 mg/m²is infused intravenously in 30 minutes on day -2 after IV anti-emetics (5-HT3 antagonists).
1657867|NCT01794572|Biological|Autologous Hematopoietic Stem cell|"Autologous Peripheral Stem Cell Rescue : 2.5 10^6 CD-34/Kg are re-infused in the central line on day 0 after adequate premedication."
1657868|NCT01794559|Device|PEER Interactive Report|The PEER Interactive Report provides information comparing the subject's Quantitative Electroencephalography (QEEG) to a database of outcomes from patients with similar QEEG results, and how they responded to on-label treatments. This report provides a probability of how this subject will respond to treatment based upon a comparison of similar subjects in the database.
1657869|NCT01794546|Behavioral|Telehealth|Telehealth visits will alternate between a dietitian and behavioral medicine provider for either 30 minutes or 1 hour. Over a 6-month period, 12 telehealth sessions will be scheduled for each participant. The dietitian will provide dietary and physical activity recommendations, and the behavioral medicine provider will counsel on strategies for achieving specific goals. Applying a Chronic Care Model, self-management support will be augmented by linkages to community resources.
1657870|NCT01794533|Drug|Lidocaine with Epinephrine+ Normal saline|local infiltration of 1.8 mL of 2% lidocaine containing 1:200,000 epinephrine along with 0.8 mL of 0.9% sterile normal saline solution
1657871|NCT01794533|Drug|Lidocaine with Epinephrine + fentanyl|local infiltration of 1.8 mL of 2% lidocaine, containing 1:200,000 epinephrine along with 0.8 mL of fentanyl(40 µg)
1657872|NCT01794520|Drug|ABT-199|ABT-199 dosed at cohort-defined dosing schedules and dose levels for Dose Escalation Cohorts, ABT-199 dosed at defined dose and schedule for Safety Expansion Cohort, ABT-199 dosed at recommended phase two dose in combination with dexamethasone at defined schedule for Venetoclax-Dexamethasone Combination Cohort
1657873|NCT01794520|Drug|Dexamethasone|Subjects will take Dexamethasone at defined dose and schedule for Venetoclax-Dexamethasone combination cohort.
1657874|NCT01794507|Drug|ABT-199|ABT-199 at cohort-defined dosing schedules and dose levels. ABT-199 at defined dose and schedule for Safety Expansion cohort
1657875|NCT01794507|Drug|bortezomib|Bortezomib at cohort-defined dosing schedules and dose levels. Bortezomib at defined dose and schedule for Safety Expansion cohort
1657876|NCT01794507|Drug|dexamethasone|Dexamethasone at cohort-defined dosing schedules and dose levels. Dexamethasone at defined dose and schedule for Safety Expansion cohort.
1657877|NCT01794494|Procedure|Bypass surgery|Patients are treated with femoro-popliteal bypass
1657878|NCT01794494|Procedure|Endovascular recanalization|Patients are treated with PTA or subintimal angioplasty
1657879|NCT01794481|Procedure|Resistance Exercise Training (RET)|"If you are randomized to the resistance exercise training (RET) program, you will undergo up to three 1-hour training sessions per week for 7 weeks during radiation therapy.
There will be up to 3 sessions per week lasting up to one hour, and will generally include a 10- minute warm-up, rest periods and 10 minute cool-down. The goal is to perform the exercises as tolerated in week 1 and increase intensity as the weeks progress. Weights will be added each week depending on your tolerance to them. Rest periods will be incorporated into the exercises as needed. The intensity and weights used will be customized to the individual. During the home program portion, you will be asked to keep a weekly log of your exercises and the trainer will call you weekly to go over the log and provide support. At week 11 the trainer will meet with you to go over your individualized program and review your technique."
1657880|NCT01794468|Other|Dermal blood flow measurements|Dermal blood flow was measured with the Dermal Blood Flow (DBF) monitor (I.S. MedTech, Israel), which consists of a skin probe and a measuring and control feedback unit.
1657881|NCT01794455|Drug|Sertraline|50mg - 200mg daily
1657882|NCT01794455|Drug|Candesartan|4mg - 32mg daily
1718535|NCT00002533|Drug|fluconazole|
1657888|NCT01794403|Radiation|Extended Hypofractionation Radiotherapy|A total dose of 70.2 Gy will be delivered in 26 fractions, 2.7 Gy to the Planning Target Volume (PTV) by Intensity Modulated Radiotherapy (IMRT) with stationary gantry or rotating gantry technique.
1657889|NCT01794403|Radiation|Accelerated Hypofractionation Radiotherapy|A total dose of 36.25 Gy will be delivered in 5 fractions, 7.25 Gy each to the Planning Target Volume (PTV), by Stereotactic Body Radiotherapy (SBRT) techniques.
1657890|NCT01794403|Behavioral|Expanded Prostate Cancer Index Composite SF-12|The Expanded Prostate Cancer Index Composite SF-12 (EPIC-SF-12) quality of life questionnaire to be administered to study participants at protocol-defined intervals.
1657891|NCT01794403|Behavioral|International Prostate Symptom Score|International Prostate Symptom Score quality of life questionnaire to be administered to study participants at protocol-defined intervals.
1657892|NCT01794403|Behavioral|Memorial Anxiety Scale for Prostate Cancer patients|Memorial Anxiety Scale for Prostate Cancer patients quality of life questionnaire to be administered to study participants at protocol-defined intervals.
1657893|NCT01794377|Behavioral|30 minutes of high intensity training|"This group will carry out a 5-min warm-up period on bicycle ergometer at an intensity corresponding to 50% of Vo2max before performed eight times the intermittent training exercise as follows:
30 sec at 120% of Vo2max,
1 min at 50% of Vo2max,
15 sec at 30-40 revolutions per minute of strength training at 100% of the maximal anaerobic power, which will be first determined by means of a force-velocity test on a Monark ergometer,
1 min at 50% of Vo2max.
The training session will be terminated by a 3-min cool-down period at 40% of Vo2max.
Training three times per week for 5 months under supervision of an exercise physiologist.
Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).
Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
1657894|NCT01794377|Behavioral|40 of an endurance training|"The moderate-intensity continuous exercise group will carry out a 40-min session of continuous cycling at a moderate intensity (50 % of Vo2max).
Training three times per week for 5 months under supervision of an exercise physiologist.
Initial nutritional education session at the beginning of the study Questionnaires on training experience during the 5 months training period (Exercise difficulties, pain...).
Dietary Supplement: supplementation in fruits and vegetables (5 per day) during all the study."
1657895|NCT01794364|Drug|PF-06291874|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 75 mg to 500 mg.
1657896|NCT01794364|Other|placebo|Correspondingly, placebo doses will be administered as suspension.
1657897|NCT01794351|Dietary Supplement|Trans-resveratrol|In this crossoevr study, all participants also consumed 500mg trans-resveratrol (in 2 opaque vegetarian capsules), at baseline, on counterballanced days.
1657898|NCT01794351|Other|Placebo|In this crossoevr study, all participants also consumed placebo (2 opaque vegetarian capsules), at baseline, on counterballanced days.
1657899|NCT01794338|Device|Strattice Arm|Biologic mesh to be placed during hernia repair surgery
1657900|NCT01794338|Device|Bio-A Arm|Bioabsorbable mesh to be placed during hernia repair surgery
1657901|NCT01794325|Other|Trans-radial|Coronary angiography performed through trans-radial access
1657902|NCT01794325|Other|Trans-femoral|Coronary angiography performed through trans-femoral access
1657903|NCT01794312|Device|T4020|
1657904|NCT01794299|Biological|ATIR|Donor T-lymphocytes depleted ex vivo of host alloreactive T-cells using photodynamic treatment. Single intravenous infusion with 2x10E6 viable T-cells/kg.
1657905|NCT01794286|Other|Provider bulletins|
1657906|NCT01794286|Other|Trigger alerts|
1657907|NCT01794273|Drug|ephedrine and phenylephrine|
1657908|NCT01794260|Drug|Cream from Zingiber cassumunar Roxb. extract|
1657909|NCT01794260|Drug|Placebo cream|
1657910|NCT01794247|Drug|Magnesium sulfate|
1657911|NCT01794247|Drug|Fentanyl|
1657912|NCT01794247|Drug|Lidocaine|
1657913|NCT01794221|Procedure|stitches and skin adhesive|In addition to stitches, 2-octyl cyanoacrylate skin adhesive will be applied to the circumcision wound.
1657914|NCT01794221|Procedure|stitches only|standard of care
1657915|NCT01794208|Drug|FSH-GEX(TM)|
1657916|NCT01794208|Drug|Gonal-f(R)|
1657917|NCT01794195|Behavioral|Diffusion tensor imaging and fibres tracking|
1657918|NCT01794182|Drug|RP-1127 (Glyburide for Injection)|Glyburide (5-chloro-N-(4-[N-(cyclohexylcarbamoyl) sulfamoyl]phenethyl)-2- methoxybenzamide) is an anti-diabetic medication in a class of medications known as sulfonylureas. RP-1127 is a formulation of glyburide designed for intravenous administration.
1657919|NCT01794169|Drug|Azacitidine|
1657920|NCT01794169|Drug|DA|
1657921|NCT01794156|Behavioral|Cognitive behavior therapy|
1657922|NCT01794156|Behavioral|Mindfulness-based stress reduction|
1657923|NCT01794156|Behavioral|Inference-based therapy|
1958059|NCT02004236|Device|tRNS Fronto-temporal cortex|This group receive 35 sessions of tRNS over fronto-temporal cortex
1958060|NCT02004236|Device|tRNS over fusiform temporal cortex|This group receive 35 sessions of tRNS over fusiform temporal cortex
1958061|NCT02004236|Device|tRNS with sham|the subjects receive 35 session with sham
2013263|NCT00674297|Drug|Fluvastatin|Fluvastatin 40 mg daily for 3 months
2013264|NCT00664209|Drug|clartihromycin, amoxicillin, and omeprazole|clarithromycin 500mg - i PO BID x10 days; amoxicillin 1gm - i PO BID x10 days; omeprazole 10mg - i PO BID x10 days
2013265|NCT00664209|Drug|placebo|placebo therapy
1657930|NCT01794091|Drug|Eplerenone|Eplerenone 25 mg daily for 6 months
1657931|NCT01794091|Drug|Placebo|
1657932|NCT01794078|Drug|Aminophylline 400 mg|Xanthine derivative
1657933|NCT01794078|Drug|Ambrisentan 5 mg|Endothelin receptor antagonist
1657934|NCT01794078|Other|Placebo|
1658134|NCT01792414|Device|Active TES|Neuroconn Eldith device
1658135|NCT01792401|Drug|Probiotics|
1657935|NCT01794052|Other|Evidence based, DSS enabled, health care delivery model|"The study focus on preliminary work before a definitive randomised controlled trial. In this phase, we are developing an intervention for the evidence based management of hypertension and diabetes at primary care setting in India.
The components of the interventions that we are developing are:
A structured training of the health care staff for identifying people at risk of developing diabetes or hypertension
Treating patients as per a standard clinical guidelines
Giving health education to patients on lifestyle changes for better self-care
Optimizing the care pathways at the health facilities to enable better delivery of the intervention and
Development and implementation of a smartphone based decision support system (DSS) with inbuilt diagnostic and treatment algorithm"
1657936|NCT01794039|Drug|Dexamethasone|Given PO
1657937|NCT01794039|Drug|Lenalidomide|Given PO
1657938|NCT01794039|Drug|Pomalidomide|Given PO
1657939|NCT01794026|Procedure|diffusion weighted magnetic resonance imaging|for diagnostic purposes, diffusion weighted magnetic resonance imaging in all patients
1657940|NCT01794013|Behavioral|Parent training|All parents in the intervention group had to learn about DIR/ Floortime™ model approach through one on one coaching (1 hour/ session for three sessions) and through 2 hours DVD lecture.
1657941|NCT01794013|Behavioral|Routine care|routine care
1657942|NCT01794000|Drug|Prasugrel|Administered orally
1657943|NCT01794000|Drug|Placebo|Administered orally
1657944|NCT01793987|Device|Coblation polypectomy|
1657945|NCT01793961|Other|electroretinogram|
1657946|NCT01793961|Other|contrast sensitivity tests|
1657947|NCT01793948|Drug|metformin hydrochloride|Given PO
1657948|NCT01793948|Other|placebo|Given PO
1657949|NCT01793948|Other|laboratory biomarker analysis|Correlative studies
1657952|NCT01793922|Procedure|PD|pneumodilation
1657953|NCT01793922|Procedure|POEM|peroral endoscopic myotomy
1657954|NCT01793909|Other|Single Leg Exercise Training|Following the completion of baseline testing, all 3 subject groups will undergo supervised single leg, exercise training of the index (dominant) calf muscle 5 days per week for two weeks - alternating weight-bearing single leg calf raises and single leg calf extensions by endurance resistance training (weight machine apparatus).
1657955|NCT01793896|Behavioral|Control period|Analysis at recruitment and after a month without any intervention
1657956|NCT01793896|Behavioral|Diet Group|selected subjects will adopt a Mediterranean low-AGE diet. We will not include red wine in the Mediterranean diet (7 Kilocalories (KCal)/g), in order to attain more weight loss. Each subject will be instructed to reduce 500 Kcal of their estimated total daily energy requirements, so theoretically they will be able to reduce 5 - 10 % of their body weight in 3 months.
1657957|NCT01793896|Behavioral|Exercise group|The intervention will consist of 3 weekly 1 hour sessions (5 minutes of preconditioning, followed by 20 minutes cycling, brisk walking or jogging at 65-70 % maximal aerobic capacity, then 25 minutes resistance weight-lifting exercises and finally 10 minutes of stretching). Exercise intensity will be increased weekly according to the Borg Scale intensity. The exercise intervention will be supervised by physical education teachers, registering attendance at every session.
1657958|NCT01793896|Behavioral|Diet + Exercise|these patients will be incorporated to receive both Mediterranean diet plus exercise interventions
1657959|NCT01793883|Drug|40 mg Laninamivir Octanoate|
1657960|NCT01793883|Drug|80 mg Laninamivir Octanoate|
1657961|NCT01793883|Drug|Placebo|
1657962|NCT01793870|Drug|Tab carvedilol 25 mg|Carvedilol 25 mg immediate release tablet
1657963|NCT01793870|Drug|Tab carvedilol 6.25 mg|Carvedilol 6.25 mg immediate release tablet
1657964|NCT01793870|Drug|Powder carvedilol up to 2.5 mg|Carvedilol up to 2.5 mg isotopically enriched drug substance powder
1657965|NCT01793857|Other|Data collection|Paper questionnaire
1657966|NCT01793831|Procedure|FMT|Standard FMT, once
1657967|NCT01793831|Drug|5-ASA, Prednisone, Azathioprine or Remicade|
1657968|NCT01793818|Biological|Tat Oyi|Three injections in the arm
1657969|NCT01793792|Device|LVIS™ and LVIS™ Jr|
1657970|NCT01793779|Procedure|cold water immersion|
1657971|NCT01793779|Dietary Supplement|beta-hydroxy-beta-methylbutyrate free acid (HMB-FA)|
1657972|NCT01793779|Dietary Supplement|Placebo|
1657973|NCT01793766|Device|Brain modulation|Brain modulation using Eldith/Neuroconn transcranial Direct Current Stimulation device
1657974|NCT01793766|Device|Sham modulation|
1657975|NCT01793753|Drug|Propofol|
1657976|NCT01793740|Behavioral|Cogmed|Computer based program that aims to improve children's memory, attention, and processing speed.
1657977|NCT01793727|Device|Glidescope videolaryngoscope|
1657978|NCT01793701|Radiation|intensity modulated radiotherapy|"Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy).
This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial."
1658019|NCT01793272|Other|effect of pentoxifylline on ICSI outcome|semen processing with pentoxifylline prior to ICSI
1658020|NCT01793259|Drug|methotrexate prefilled pen|
1658021|NCT01793259|Drug|methotrexate prefilled syringe|
1658136|NCT01792401|Drug|Placebo|
1657979|NCT01793701|Procedure|Intracavitary brachytherapy|Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes
1657980|NCT01793701|Drug|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
1657981|NCT01793688|Drug|Sulbactam Sodium/Ampicillin Sodium|"Intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection or drip infusion. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency)).
Kit for intravenous use; The usual adult dosage is 6 g of sulbactam sodium and ampicillin sodium (potency) per day given in two divided doses via intravenous injection after dissolved in an accompanying reconstitution diluent. In the case of severe infection, the dosage may be increased if appropriate. Maximum dosage should not exceed 3 g (potency) 4 times daily (daily dose of 12 g (potency))."
1657982|NCT01793675|Procedure|transplant with haploidentical donor|patients with advanced MDS without identical sibling donor receive haploidentical transplant
1657983|NCT01793662|Procedure|Laparoscopic aortobifemoral bypass|Totally laparoscopic aortobifemoral bypass shall be performed and the patients in this intervention arm shall be compared with the control arm randomized for open aortobifemoral bypass operation.
1657984|NCT01793649|Drug|GS-5737|A single dose of GS-5737 in 2.8% saline
1657985|NCT01793636|Drug|AZD2014|AZD2014 vs Everolimus
1657986|NCT01793636|Drug|Everolimus|comparing PFS in patients treated with AZD2014 vs Everolimus
1657987|NCT01793623|Other|atrial tissue|retrieval of discarded atrial tissue
1657988|NCT01793610|Drug|Comparator-dose MDMA|Initial comparator-dose MDMA orally at the start of two separate psychotherapy sessions scheduled 3 to 5 weeks apart, with the initial dose possibly followed 1.5 to 2.5 hours later by a supplemental dose half the size of the initial dose MDMA.
1657989|NCT01793610|Drug|Active Dose 1 MDMA|An initial dose of full-dose MDMA orally given at the start of each of two psychotherapy sessions and possibly followed a dose half the size of the initial dose of MDMA 1.5 to 2.5 hours later.
1657990|NCT01793610|Drug|Active Dose 2 MDMA|
1657993|NCT01793571|Procedure|TAP block|2 groups, group A a TAP block with 20 ml of Levobupivacaine 0,5% and subcutaneous wound infiltration with 20 ml sodium chloride (to blind patient and physician) and group B, TAP block with 20 ml sodium chloride and subcutaneous wound infiltration with 20 ml Levobupivacaine 0,5% (to blind patient and physician)
1657994|NCT01793558|Procedure|Forced-air warming|In the intervention group a forced-air cover (Level 1 Snuggle Warm Upper Body Blanket, Smiths Medicals) will be positioned over the upper body of the patients laying on the operating table just beginning after the spinal block.
1657995|NCT01793519|Drug|Etanercept|Subcutaneous
1657996|NCT01793519|Drug|Infliximab|Infusion
1657997|NCT01793519|Drug|Adalimumab|Subcutaneous
1657998|NCT01793519|Drug|Placebo|Matching Placebo
1657999|NCT01793493|Other|Cognitive stimulation|"Participants are pooled in small groups (6-8 individuals). Each group participates to ten twice weekly meetings. Each CS session is run by one trained operator. One observer participates to the sessions to guarantee homogeneity between different operators. Exercises are structured with an increasing cognitive complexity and are tailored to the characteristics of the group.
Meetings (each lasting about 2 hours) have a common structure:
body awakening (10 minutes)
cognitive stimulation (1 hour and a half) scheduled as follow:
temporospatial orientation
attentional abilities
one of the following cognitive areas: language, executive functions, verbal and visual memory (encoding, consolidation, retrieval)"
1658000|NCT01793493|Other|Sanitary education|Participants attend two weekly meetings (for a total of 3 hours) focused on lifestyle education and brain functioning.
1658001|NCT01793480|Drug|Methadone|
1658002|NCT01793454|Other|Fraction of inspired oxygen 40%|
1658003|NCT01793454|Other|Fraction of inspired oxygen 80%|
1658004|NCT01793441|Drug|Placebo|Placebo will be administered in different stages of the study for 12 weeks.
1658005|NCT01793441|Drug|RG7314|RG7314 will be administered orally at a dose of 1.5 mg/day in Stage I, 4 mg/day in Stage II, 10 mg/day in Stage III and 1.5 mg/day or 10 mg/day in Stage IV for 12 weeks.
1658006|NCT01793428|Other|Capillary lactate level|Use of capillary sample to determine lactate level upon arrival at vital emergency unit and at 2 hours
1658007|NCT01793415|Drug|IodoCarb (r)|Powder, 3 grams daily for 28+-2 days
1658008|NCT01793415|Other|Placebo|Non-iodinated activated charcoal 3 g daily for 28+-2 days
1658009|NCT01793389|Procedure|Subepithelial connective tissue graft|
1658010|NCT01793389|Procedure|Platelet Rich Fibrin|
1658011|NCT01793363|Procedure|Tracheotomy|
1658012|NCT01793350|Drug|BC-DN-01 topically applied cream|Phase 1 - week 1 - total daily dose 160mg benfotiamine as 8g BC-DN-01 Phase 1 - week 2 - total daily dose 320mg benfotiamine as 16g BC-DN-01 Phase 2 - for 12 weeks - total daily dose 320mg benfotiamine as 16g BC-DN-01
1658013|NCT01793337|Other|Exposure to cold environmental temperature (-20°C)|
1658017|NCT01793298|Drug|ASM-024|Ascending doses of ASM-024
1658018|NCT01793285|Drug|ETANERCEPT|"During the LoadET study (0881A3-102090), subjects were treated with etanercept 100 mg versus 50 mg weekly. After completing this study, the subjects were allowed to continue the treatment with etanercept 50 mg weekly, etanercept 100 mg weekly, another drug, or abandoned medication at the discretion of their physician.
This is a non-interventional study in which historic data will be collected retrospectively from the patient's clinical history. During the historical period covered in the Study, patients would have received the treatment and the medical care that their treating physicians considered appropriate under the conditions of standard clinical practice."
1658022|NCT01793246|Device|probe based laser endomicroscopy (pCLE)|pCLE will be added to standard bronchoscopy for the purpose of characterizing lung cancer or for characterizing of acute rejection in transplanted lungs.
1658023|NCT01793233|Other|questionnaire administration|Ancillary studies
1658024|NCT01793233|Other|laboratory biomarker analysis|Correlative studies
1658026|NCT01793194|Other|Compression Stockings|20-30mmg Hg maternity pantyhose compression stockings
1658027|NCT01793155|Other|Inspiratory muscle training|Inspiratory muscle training, as a supplement to placebo comparator, starts the day before surgery and continues for two weeks after surgery. No sessions are performed on the surgery day. Each session consists of 2 sets of 30 inspirations with a pause between each set of 2 minutes. The target intensity before surgery is 30% of the measured MIP and starts at 15% after surgery. The intensity is incrementally increased by 2 cm H20 the first days after surgery. Patients grade their perceived exertion and register eventual adverse effects in a training diary.
1658028|NCT01793155|Other|Placebo comparator: standard physiotherapy|Standard physiotherapy - preoperative instruction and postoperative breathing exercises using positive expiratory pressure device (PEP) 3x10 breathings hourly during daytime, cough/huff for mucus clearance purpose, advice on early and active mobilization
1658029|NCT01793142|Drug|Viviant|Viviant (Bazedoxifene) 20mg once daily
1658030|NCT01793129|Device|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 72 hours
1658031|NCT01793129|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
1658032|NCT01793090|Drug|Epi-743|EPI- 743 in capsule or formulation comprised of USP/NF Sesame Oil at a potency of 100 mg EPI-743/ 1 mL total volume. Mode of Administration: Oral with meal or G-Tube infusion with food.
1658033|NCT01793090|Other|Placebo supplementation|Placebo will be administered in the same formulation as the active comparator
1658034|NCT01793077|Drug|Depo-Eligard®|Subcutaneous
1658035|NCT01793064|Behavioral|Adaptive Intervention (AI)|Adaptive Intervention Group (AI) receives adaptive step goals and feedback/incentives based on personal physical activity performance.
1658036|NCT01793064|Behavioral|Static Intervention (SI)|"Static Intervention group (SI) receives a static usual care goal of 10,000 steps/day and feedback/incentives for uploading their pedometer to the study website."
1658037|NCT01793051|Drug|Minocycline|200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for three months beginning at initiation of Lenalidomide maintenance therapy for MM.
1658038|NCT01793051|Other|Placebo|200 mg by mouth for the first day of Lenalidomide maintenance therapy for MM, then 100 mg doses every 12 hours for three months (three cycles of maintenance chemotherapy).
1658039|NCT01793051|Behavioral|Questionnaires|Completion of MD Anderson Symptom Inventory (MDASI) questionnaires at baseline, weekly during Lenalidomide therapy, and at end of treatment visit.
1658040|NCT01793038|Drug|Aromatase inhibitor (litrezole) plus uFSH arm|literozole tablets 5 mg /day for days 3-7 plus intramuscular injections of uFSH 37.5 IU/day for days 3-12
1658041|NCT01793038|Drug|clomiphene citrate-uFSH arm|clomiphene citrate 50 mg tablets twice /day for 5 days plus 37.5 IU uFSH IM injections daily for 10 days
1658042|NCT01793025|Biological|ATAC Therapy|Unselected peripheral blood mononuclear cells given 24-48 hours after induction or consolidation chemotherapy
1658043|NCT01792986|Behavioral|water-only 24-hour fasting once per week for 6 weeks|
1658044|NCT01792947|Procedure|Percutaneous electroneurostimulation of dermatome T6|The patients underwent a percutaneous electroneurostimulation of dermatome T6 during 30 minutes, every week during 12 weeks. This intervention was associated to a diet 1200 Kcal
1658045|NCT01792947|Behavioral|Diet 1200 Kcal|The patients assigned to this group must follow a 1200 Kcal diet during months
1658046|NCT01792934|Drug|XELOX regimen according to standard procedures|
1658047|NCT01792934|Drug|FOLFOX regimen according to standard procedures|
1658048|NCT01792934|Procedure|Surgery|
1658049|NCT01792934|Other|radiofrequency ablation (RFA)|
1658050|NCT01792934|Other|transarterial chemo-embolization using irinotecan drug-eluted beads ((DEBIRI-)TACE)|
1658051|NCT01792934|Radiation|stereotactic body radiation therapy (SBRT)|
1658052|NCT01792934|Drug|Bevacizumab|may be added to both regimens according to standard procedures
1658053|NCT01792934|Procedure|tumor biopsy|at baseline (diagnostic or study) biopsy and after 3 or 4 cycles an optional tumor biopsy
1658054|NCT01792921|Behavioral|COG - FUN|
1658055|NCT01792908|Device|Kinesio tape|The KT used was Kinesiology Tape® of 5 cm and it was applied according to Kase protocol (Kase K). The first layer of tape consisted of a single strip placed over the anterior talofibular ligament from insertion to origin, with a 50% tension, except the two-centimetre proximal and distal ends, applied with no tension. The same procedure was repeated for the calcaneofibular ligament and posterior talofibular ligament
1658056|NCT01792895|Procedure|Manipulation|The Cervical Spine Manipulation is a manual therapy technique directed at the hypomobile and painful vertebral level. The subject was supine with the cervical spine in a neutral position. The index finger of the therapist applies contact over the posterolateral aspect of the zygapophyseal joint of the hypomobile vertebra. The therapist performs the technique taking account the most limited movement; lateral or rotational. A maximum of 2 attempts will performed on each subject regardless audible cavitation.
1658057|NCT01792895|Procedure|Mobilization|The mobilization is a passive oscillatory technique, applied over cervical region in the hypomobile cervical level, the patient will be in prone and the therapist standing at the head of the patients with his thumbs in opposition placed at the level of the facet of the hypomobile cervical vertebra. A posteroanterior(PA) oscillatory pressure is applied, through the thumbs, over the process of the hypomobile vertebra. This oscillatory mobilization, is performed at a frequency of 2Hz (with metronome control/steps) for 2 minutes and repeated 3 times. The rest time between each mobilization was 1 minute.
1658129|NCT01792505|Biological|Dendritic Cell Vaccine in combination with Imiquimod cream|After a successful complete resection of malignant glioma, patients will receive a total of 3 vaccines, each are 2 weeks apart. Imiquimod cream will be applied prior to and after each vaccination.
1658130|NCT01792479|Drug|BIND-014|
1718829|NCT00002596|Biological|filgrastim|
1658058|NCT01792895|Procedure|Mobilization with movement|"This is a manual therapy technique that consist of applied a sustain pressure over cervical hypomobile symptomatic level and request to patient a pain free movement.
For performs it, the therapist placed his thumbs on the articular process of that level. The patient sitting. Then, the subject had to perform actively the painful motion while the therapist guides the movement of that vertebra and resists it while returning to neutral. The strength applied was parallel to the plane of the joint, and the procedure was performed in 3 sets of 10 repetitions."
1658059|NCT01792856|Other|Recovery-oriented intervention|Life coaching is defined as a collaborative, solution-focused, outcome-oriented and systematic process which aims to facilitate enhancement of life experience and goal attainment of an individual in various life domains. It is based on the theoretical framework of positive psychology and behavioural change model, and targets at building up an individual's potential via fostering hope, motivation, self-efficacy and self-regulation. The principles of life coaching thus closely align with recovery orientation that emphasizes on self-initiation and empowerment via person-centred and strength-based approach.
1658060|NCT01792856|Other|psychoeducation|Subjects will receive group-based supportive therapy provided by case managers of JCEP project. The therapy provides patients with psychoeducation about psychosis, stress management, emotional and social support. Coaching and cognitive-behavioural techniques will not be incorporated. Therapy sessions and duration will be comparable to that of recovery-oriented coaching program.
1658061|NCT01792843|Behavioral|data|"comparisons of clinical characteristics
comparisons of cognitive profiles
comparisons of grey matter density patterns
comparisons of EEG rhythms features"
1658062|NCT01792830|Drug|Metformin|"Metformin is an oral antidiabetic agent used to control high blood glucose levels and is given in divided doses with meals. During treatment initiation and dose titration, the patient's blood glucose levels will be used to determine the therapeutic response to metformin and identify the minimum effective dose for the patient.
Patients without a history of diabetes and admission HbA1c < 7% requiring SC insulin therapy in the hospital will be discharged on metformin monotherapy.
Treatment naïve patients with an HbA1c between 7% and 9% prior to admission will be discharged on metformin monotherapy or a combination of metformin and a single dose of subcutaneous insulin."
1658063|NCT01792830|Drug|Glargine insulin|"Glargine is a recombinant human insulin analog that exhibits a constant glucose-lowering profile over 24 hours and permits once-daily dosing. It is administered subcutaneously once a day at the same time every day.
Patients with an HbA1c between 7% and 9% requiring subcutaneous insulin therapy in the hospital will be discharged on oral metformin and a single dose of glargine insulin at 50% of total daily hospital dose.
Patients with an HbA1c > 9% will be discharged on oral metformin and a single dose of glargine insulin at 80% of total daily hospital dose."
1658064|NCT01792830|Drug|Glulisine|Glulisine is an injectable, recombinant insulin analog. The total daily dose varies between 0.5 to 1 unit/kg/day depending on the levels of blood glucose. Glulisine will be given within 15 minutes before a meal or within 20 minutes after starting a meal.
1658067|NCT01792804|Drug|Trimethoprim-Sulfamethoxazole|study drug 1
1658068|NCT01792804|Drug|Clindamycin|study drug 2
1658069|NCT01792804|Drug|Linezolid|study drug 3
1658070|NCT01792804|Drug|Flucloxacillin|study drug 4
1658071|NCT01792804|Drug|Cloxacillin|study drug 5
1658072|NCT01792804|Drug|Vancomycin|study drug 6
1658073|NCT01792804|Drug|Daptomycin|study drug 7
1658074|NCT01792804|Drug|Cefazolin|study drug 8
1658075|NCT01792791|Procedure|Tissue sample collection at the time of surgery|"Spanning surgery
A blood sample (32.5 ml)
joint aspirate (removal of synovial fluid) from both knees
urine sample
ORIF surgery
Joint aspirate (removal of synovial fluid) from both knees
A blood sample (32.5 ml)
Urine Sample
If patients only require one surgery, sample will be collected only once."
1658076|NCT01792778|Device|ViaValve Safety IV Catheter|Insertion of the peripheral intravenous catheters into both upper extremities of subjects
1658077|NCT01792778|Device|Insyte Autoguard BC [Blood Control] Shielded IV Catheter|
1658078|NCT01792765|Other|Ultrasound guidance|Patient will have intraoperative ultrasound .
1658079|NCT01792752|Behavioral|Enhanced HIV Care Access and Retention Intervention|Through the Enhanced HIV Care Access and Retention Intervention, the five neighborhoods will receive the 4 components of the intervention: 1) HIV Testing Campaign; 2) Treatment Re-engagement Campaign; 3) Patient Navigator Linkage to Care and Substance Abuse Treatment Team; and 4) Mobile Care Clinic. In addition to these intervention components, study participants will receive screening and access to treatment for other physical and mental co-morbidities, general primary health care, and social/psychosocial services addressing unstable housing, food insecurity, interpersonal violence, legal issues. All HIV-positive IDUs identified either through the HIV Testing Campaign or the Treatment Re-engagement Campaign will be enrolled in the HIV Care Cohort. The HIV Care Cohort will be comprised of the HIV-positive injectors who are receiving direct services in the Mobile Care Clinic. The 4 intervention components are detailed below:
1658080|NCT01792752|Behavioral|HIV Testing Campaign|When the intervention is initiated in a neighborhood, HIV rapid testing will begin and continue in a particular neighborhood from the time that the neighborhood's intervention begins until the end of the study period. Anyone testing HIV positive will be seen and counseled by a member of the Patient Navigator Team.
1658081|NCT01792752|Behavioral|Treatment Re-engagement Campaign|Simultaneously with the introduction of the HIV Testing Campaign, a patient navigator team will approach HIV-positive IDUs identified as not having seen their HIV care provider in the last 6 months. In addition, known HIV-positive IDUs within the designated neighborhoods will be approached for service enrollment and meet with a patient navigator.
1658082|NCT01792752|Behavioral|Patient Navigator Linkage to Care and Substance Abuse Treatment Team|The patient navigator team will provide informational support to the HIV-positive injectors, motivate them to attend HIV care visits and engage in substance abuse treatment, encourage their use of and adherence to antiretroviral therapies, and work with them to overcome any barriers to attendance at HIV care visits and substance abuse treatment. All clients of the patient navigator will become part of the HIV Care Cohort; they will have been identified either in the HIV Testing Campaign or the Treatment Re-Engagement Campaign.
1658131|NCT01792466|Procedure|Transpancreatic sphincterotomy|A sphinctertome will be placed into the pancreatic duct over a guidewire and the sphincter will be cut in the direction of the bile duct
1658083|NCT01792752|Behavioral|Mobile Care Clinic|Participants who choose to receive services in the study mobile HIV care clinic will receive an initial appointment and the patient navigator will ensure that the client attends it. At the initial visit, clients will have a medical history taken, be examined and have blood drawn to measure CD4 and viral load. The mobile care clinic doctor will also prescribe medications for the client at the subsequent visit which will be scheduled as soon as lab results are available and interpreted, approximately one week later. The mobile HIV care clinic van will provide health services to the general IDU population within each intervention neighborhood to avoid any stigmatization of the HIV positive clients.
1658084|NCT01792739|Drug|Lactobacillus casei variety rhamnosus granules|"Lactobacillus casei variety rhamnosus granules
: 3 gram per day (1g-1g-1g, 3 times per day)"
1658085|NCT01792739|Drug|Placebo|"Placebo granules
: 3 gram per day (1g-1g-1g, 3 times per day)"
1658086|NCT01792726|Radiation|Boost to the tumour bed|Boost to the tumour bed, with whole breast EBRT delivered according to local policy.
1658087|NCT01792713|Drug|Sertaconazole 2% cream|
1658088|NCT01792713|Drug|Placebo|
1658089|NCT01792700|Drug|esomeprazole|
1658090|NCT01792700|Drug|tripotassium dicitrate bismuthate|
1658091|NCT01792700|Drug|metronidazole|
1658092|NCT01792700|Drug|tetracycline|
1658093|NCT01792700|Drug|moxifloxacin|
1658094|NCT01792700|Drug|amoxicillin|
1658095|NCT01792687|Drug|ARN-509|Dose-escalation: 120 milligram (mg), 180 mg, 240 mg, oral, daily
1658096|NCT01792687|Drug|Abiraterone acetate|1,000 mg, oral, daily
1658097|NCT01792687|Drug|Prednisone|5 mg, oral, daily
1658098|NCT01792674|Other|In situ simulation|
1658099|NCT01792674|Other|Off site simulation|
1658100|NCT01792661|Other|Enhanced MyChart|Subjects randomized into the MyChart receive an additional site on their MyChart containing 35 extra educational links specific to CKD, targetting care for stage 3b and stage 4 patients.
1658101|NCT01792661|Other|Patient Navigator|The Patient Navigator aids subjects in education of their CKD, timely scheduling of appointments, plus determining and overcoming barriers to their CKD health care. The Patient Navigator's job is not part of routine medical care.
1658102|NCT01792661|Other|MyChart|Sign-up to MyChart is optional for Cleveland Clinic patients. Subjects enrolled into the study are signed-up for MyChart (if not already signed-up) during the consenting process.
1658103|NCT01792648|Other|Standard reference diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat
1658104|NCT01792648|Other|Almond supplemented diet|50% energy as carbohydrate, 15% energy as protein, 35% energy as total fat, 20% energy from almonds
1658105|NCT01792648|Other|Low carbohydrate reference diet|26% energy from carbohydrate, 29% energy from protein, 45% energy from total fat
1658106|NCT01792635|Drug|PF-05175157|PF-05175157 will be administered at 200 mg twice a day for 43 days.
1658107|NCT01792635|Drug|Placebo|Placebo tablets matched to PF-05175157 will be administered twice a day for 43 days.
1658108|NCT01792622|Other|Interview|Patients will be interviewed to provide descriptive information about their experience as a treated patient with pulmonary arterial hypertension. The interviews will be given one time for approximately 1 hour.
1658109|NCT01792622|Other|Questionnaire|Patients will be asked to provide subjective ratings of their experience on a questionnaire developed from the responses from Phase I. The questionnaire will be given one time for approximately 1 hour.
1658110|NCT01792609|Procedure|Maximum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
1658111|NCT01792609|Procedure|Minimum Number of Screws|The tools used for this arm of study are FDA approved with section 510 (k) K122433. These screws are regularly used in all procedures pertaining to Cobb angle correction surgeries outside of the context of this study.
1658112|NCT01792596|Other|Pasta with protein|Pasta with Protein
1658113|NCT01792596|Other|Pasta with Fiber|Pasta with Fiber
1658114|NCT01792596|Other|Pasta|Pasta
1658116|NCT01792570|Drug|RPV + DRV/r|Switch to dual HAART
1658117|NCT01792570|Drug|continue the PI/r-containing HAART.|Continue the on-going triple drug HAART.
1658118|NCT01792557|Drug|Crystallized phenol|Crystallized phenol application for pilonidal disease treatment. After sacrococcygeal region of the patient is cleaned from hairs, hairs inside the sinus are removed than crystallized phenol is applied in to the cleaned sinus. Following 2 minutes of phenol exposure, crystallized phenol is removed from the sinus. Crystallized phenol application will be repeated weekly for 4 weeks.
1658119|NCT01792557|Procedure|Limberg Flap|Limberg Flap surgery for pilonidal disease treatment
1658120|NCT01792557|Procedure|Modified Limberg Flap|Limberg flap surgery rhomboid incision is made asymmetrically 2-3 cm lateral to the midline on the side opposite to the donor area.
1658121|NCT01792557|Procedure|Karydakis Flap|Karydakis Flap surgery for pilonidal disease treatment
1658122|NCT01792544|Other|Statement|
1658123|NCT01792544|Other|No Statement|
1658124|NCT01792531|Behavioral|Parent training group|The More & Less group will focus on how to use positive parenting practices (e.g., reinforcement/encouragement, limit setting, monitoring, problem-solving, positive involvement, and emotion regulation) instead of ineffective practices (e.g., coercive behavior, negative reciprocity, escalation, and negative reinforcement). Using a parent-group approach to intervention administration, each of the twelve More & Less sessions (1.5h/wk) consist of introduction to effective parenting practices followed by a discussion and practice using role play and home practice assignments. The information and procedures will be tailored to focus on changes in the home environment, mostly related to child food habits and physical activity.
1658125|NCT01792531|Behavioral|Standard treatment with focus on lifestyle|The treatment will be provided by local pediatricians in outpatient pediatric departments and will be based on lifestyle modifications, as recommended in the action plan for Stockholm County.
1658126|NCT01792531|Behavioral|Parent training group with booster sessions|Parent training group with additional booster sessions at 8-week intervals for the following year.
1658127|NCT01792518|Drug|Placebo|
1658128|NCT01792518|Drug|Linagliptin 5mg|
1658132|NCT01792453|Other|Spring water|
1658137|NCT01792388|Dietary Supplement|Vitamin D|Capsule Form
1658138|NCT01792388|Dietary Supplement|Soya Bean oil|Capsule form
1658141|NCT01792362|Other|Weight loss diet|Control the patients diet to make them loosing weight
1658142|NCT01792349|Behavioral|STARFISH intervention|STARFISH is a behavioural intervention to encourage the user to become more physically active
1658143|NCT01792323|Drug|Insulin LISPRO|Administration of 15 IU of insulin lispro over a period of 30 seconds
1658144|NCT01792310|Drug|2-hydroxyoleic acid (2-OHOA/2OHOA)|"Patients will receive treatment cycles of 21 days, until any criterion for discontinuation (clinical or radiological progression of disease, clinically unacceptable toxicity, or another general discontinuation criterion) is met.
Patients are expected to receive between one and 6 cycles of treatment. The treatment period may be extended if clinical benefit is shown.
In the event of significant GI toxicity, the treatment schedule may be modified from continuous dosing to an intermittent regime In the case of toxicity, the dose of 2-OHOA may be reduced or delayed by up to 14 days at the discretion of the Investigator. A maximum of two dose reductions will be permitted per patient. Treatment holidays of no more than 14 days are also permitted for reasons other than toxicity. Intra-patient dose escalation may be permitted in certain specific circumstances."
1658145|NCT01792297|Dietary Supplement|Bovine colostrum|
1658146|NCT01792297|Dietary Supplement|Whey protein|
1658147|NCT01792284|Drug|LY2605541|Administered SQ
1658148|NCT01792284|Drug|Insulin Lispro|All participants will be administering insulin lispro SQ as their pre-meal insulin during the course of the trial.
1658149|NCT01792271|Other|Inhaled 7% HS (NaCl) home treatment|Administering inhaled 7% NaCl for two weeks of home treatment vs. a placebo of 0.12% NaCL during a separate home treatment period, and assessing the effects of each primarily by MCC study.
1658150|NCT01792258|Procedure|Percutaneous tracheostomy|Percutaneous tracheostomies will be performed with the kit commercially available in the current clinical practice.
1658151|NCT01792245|Device|Phototherapy|
1658152|NCT01792232|Other|Allergen|Subject specific allergen is placed in the lungs on day 1 of each triad
1658153|NCT01792232|Other|Saline|Saline will be placed in the lung on day 1 of each triad
1658154|NCT01792219|Other|Interprofessional collaboration in health care module|An educational module
1658155|NCT01792206|Drug|Zemplar|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
1658156|NCT01792206|Drug|Placebo|Zemplar 1 mcg or placebo to be taken once daily with breakfast for 3 months
1658157|NCT01792180|Behavioral|Mobility feedback device with use of instruction book|Weekly use of the mobility feedback device to measure gait speed. Two infrared sensors will be placed in the line of walking, a photo frame containing a display, symbols and lights will tell the participant when and how to perform the test. Gait speed is shown on the display and will serve as feedback to the participant. Participant can use their gait speed to decide which exercises from the instruction book he performs. Participants will be asked to keep an activity diary.
1658158|NCT01792167|Behavioral|Second Step Curriculum|social emotional learning program for 6th-8th graders. 15 50 minutes lessons in 6th grade, 13 50 minute lessons in 7th and 8th grade. covers empathy, perspective taking, anger management, impulse control, problem-solving, alcohol and drug prevention, sexual harassment, prejudice, bully prevention, bystander intervention
2013266|NCT00654615|Device|Intramedullary Radius Fixation (Micronail)|After adequate anesthesia was obtained and the patient was prepared for surgery, distraction was applied to the fracture site and preliminary reduction of the distal radius fracture was performed under fluoroscopic guidance. A pin was inserted to maintain the fracture reduction, then the Micronail was inserted inside the radius. The metaphyseal defect created by the fracture was filled using allograft or autograft bone material. Limited incisions at either the radial or ulnar columns was performed to achieve acceptable reduction of the fracture. Radiographic parameters were used to evaluate the results of the surgical management with intramedullary nailing.
1658163|NCT01792102|Drug|Carfilzomib and Dexamethasone|"Phase 1: Carfilzomib will be administered at an escalating dose by cohort as 60-minute IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle. On Cycle 1 Days 1 and 2, carfilzomib will be given at 20 mg/m^2. For all subsequent doses, carfilzomib will be administered at the dose assigned to the cohort (56, 70, or 88 mg/m^2). Dexamethasone (8 mg IV or PO) will be administered prior to carfilzomib on Days 1, 2, 8, 9, 15, and 16.
Phase 2: Carfilzomib will be administered at the MTD determined in phase 1. Maintenance: From Cycle 9 onward, carfilzomib and dexamethasone will be administered in the same fashion as during the previous treatment cycle, but only on days 1, 2, 15, and 16."
1658164|NCT01792089|Other|fat+protein meal|cream+ whey protein
1658165|NCT01792089|Other|Fat + protein + fructose meal|cream+ whey protein + fructose
1658166|NCT01792089|Other|Fat+protein+fructose+glucose meal|Cream + whey protein + glucose:fructose mixture
1658167|NCT01792063|Drug|Sevoflurane|
1658168|NCT01792063|Drug|Sevoflurane|
1658169|NCT01792050|Drug|Docetaxel|Docetaxel chemotherapy regimen given by vein over 1 hour on day 8 of each cycle.
1658170|NCT01792050|Other|Placebo|Placebo taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six pills to be taken each time for a total of 12 pills per day.
1658171|NCT01792050|Drug|Indoximod|Indoximod (1200 mg) taken orally every morning 1 hour prior to breakfast and 1 hour prior to dinner on days 1-14. Six 200 mg pills to be taken twice a day for a total of 12 pills per day.
1658172|NCT01792050|Drug|Paclitaxel|Paclitaxel chemotherapy regimen given by vein over 1 hour weekly x 3 followed by a week of rest each cycle.
1658173|NCT01792037|Drug|Etomidate|
1658174|NCT01792037|Drug|Midazolam|
1658175|NCT01792037|Drug|methylprednisolone|
1658176|NCT01792024|Device|Visualase Thermal Therapy|MR guided laser ablation of prostate cancer
1718830|NCT00002596|Drug|carboplatin|
1658177|NCT01792024|Procedure|magnetic resonance imaging|Undergo MR-guided LITT
1658178|NCT01792024|Procedure|quality-of-life assessment|Ancillary studies
1658179|NCT01792011|Device|PVI-guided fluid management|In this study of 25 adult patients undergoing OLT, we prospectively record PVIwithin 5 minutes during dissection and anhepatic phase of OLT by Masimo pulse oximeter.In this study of 25 adult patients undergoing OLT, we prospectively record study data within 5 minutes during dissection and anhepatic phase of OLT. Study data included measurements of PVI,thermodilution cardiac output, Stroke volume variation (SVV) and Pulse pressure variation (PPV).
1658180|NCT01791998|Procedure|magnetic resonance thermal imaging|Undergo MR-thermal image guided LITT
1658181|NCT01791998|Procedure|laser interstitial thermal therapy|Undergo MR-thermal image guided LITT
1658182|NCT01791985|Drug|AZD4547 / anastrozole or letrozole|"Patients will continue or restart the NSAI which they have progressed* on: either anastrozole (1mg) or letrozole (2.5mg), orally, once daily but together with twice daily AZD4547 (80mg).
AZD4547 will be given on an intermittent schedule of one week on / one week off.
*Prior to study entry, patients must have taken anastrozole or letrozole at some stage in their treatment to date for breast cancer; and shown evidence of resistance to this therapy. The NSAI does not have to be the most recent line of treatment."
1658183|NCT01791972|Drug|Albuterol Spiromax|Albuterol Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) containing a blend of albuterol sulfate with alpha-lactose monohydrate. Each actuation represents a dose of 90 mcg of albuterol sulfate. Participants received one dose of two inhalations (180 mcg).
1658184|NCT01791972|Drug|Placebo Spiromax|Placebo Spiromax is an inhalation-driven, multi-dose dry powder inhaler (DPI) delivering placebo to match the experimental drug. Participants received one dose of two inhalations.
1658185|NCT01791959|Dietary Supplement|synbiotic|2 symbiotics capsules per day for 28 weeks
1658186|NCT01791959|Other|placebo|2 Maltodexterin capsules as a placebo per day for 28 weeks
1658187|NCT01791946|Procedure|Binocular Treatment|The binocular treatment involves the completion of visual tasks via virtual reality goggles. The stimulus is presented to each eye separately, allowing for varying levels of contrast to be presented to each eye. (The visual task is therefore made more or less difficult with the variation of contrast presented to either eye.) Subjects will complete the computer-based visual tasks for approximately 36 hours total over the course of six weeks, or six hours per week for six weeks.
1658188|NCT01791946|Procedure|Sham Binocular Treatment|The sham treatment involves the same computer-based visual tasks and timeframe as the binocular treatment training but there will be no variation in contrast presentation to either eye.
1658189|NCT01791933|Drug|herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for more than 2 months
1658190|NCT01791933|Procedure|Chuna manual therapy|A type of Korean spinal manual therapy administered 5~10 minutes at physician's discretion 1-2times a week for more than 2 months Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
1658191|NCT01791933|Procedure|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40mm. Needles left for 15~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25 ) and other acupoints at physician's discretion, using a total of 10~20 acupoints 1-2times a week for more than 2 months
1658192|NCT01791933|Procedure|Bee-venom pharmacoacupuncture/pharmacoacupuncture|pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session 1-2times a week for more than 2 months
1658193|NCT01791920|Drug|Botulinum toxin type A(Botulax®)|Single administration, Day 0, 20 units
1658194|NCT01791920|Drug|Botulinum toxin type A(Botox®)|Single administration, Day 0, 20units
1658195|NCT01791907|Behavioral|Structured education in carbohydrate counting|
1658196|NCT01791907|Behavioral|Structured education in healthy food choices and low glycemic index|
1658197|NCT01791894|Drug|arsenic trioxide|Given IV
1658198|NCT01791881|Drug|Hugeltox|1.25U~2.5U/site, Maximum dosage 12.5U~60U/person
1658199|NCT01791881|Drug|Botulinum Toxin Type A(Botox®)|1.25U~2.5U/site, Maximum dosage 12.5U~60U/person
1658200|NCT01791868|Drug|Intravenous Sodium Valproate|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
1658201|NCT01791868|Drug|Placebo|According to randomization arm, patients will be treated either by intravenous sodium valproate (30 mg/kg during 15 min then 1 mg/kg/h during 12 h) or intravenous placebo. All included patients will benefit from first-line anti epileptic drugs and symptomatic medical care, in agreement with the French Experts Recommendation 2009(RFE 2009).
1658202|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with normal renal function (creatinine clearance greater than or equal to 90 ml/min)
1658203|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with mild renal impairment (creatinine clearance 60-89 ml/min)
1658204|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with moderate renal impairment (creatinine clearance 30-59 ml/min)
1658205|NCT01791855|Drug|PF-04634817|Single 50 mg dose administered to subjects with severe renal impairment (creatinine clearance 15-29 ml/min)
1658206|NCT01791842|Drug|Tocilizumab|8 mg/kg/month
1658207|NCT01791842|Drug|Placebo|
1658208|NCT01791816|Drug|Phenylephrine|"Phenylephrine dose-response comprises infusion of 0.5, 1, 2, 3, 4 micrograms/kg/min for 10 min at each dose.
If bloods pressure increases by 30% or if heart rate decreases below 40 beats per minute we will stop infusion."
1658209|NCT01791816|Drug|L-Ng-monomethyl Arginine (L-NMMA)|Systemic L-NMMA is infused as a 500μg/kg/min loading dose for 15 min followed by a 50μg/kg/min maintenance dose for the remainder of the experiment.
1658210|NCT01791803|Behavioral|hypnotherapy|One 90 minute session within 2 weeks of hospital discharge
1658211|NCT01791803|Drug|Nicotine|free one month supply after hospital discharge
1658212|NCT01791790|Device|Stimulation|
1718831|NCT00002596|Drug|cisplatin|
1658213|NCT01791790|Device|SHAM|no stimulation
1658214|NCT01791777|Behavioral|SafeCare Coaching|This study involves a comparison of different coaching models for providers who are newly trained to conduct an evidence-based parent training program (SafeCare). As part of all SafeCare trainings, all providers receive workshop training plus ongoing coaching to promote adherence to the intervention model. This research is aimed at understanding the coaching aspect of the training and dissemination processes, with the goal of implementing the most effective and efficient dissemination processes. One group of home visitors will be coached directly by NSTRC trainers, who work for NSTRC. The other group of home visitors will receive coaching that is provided by a staff member who works for the local social service agency.
1658215|NCT01791751|Drug|Clomifene Citrate|Clomiphene citrate 100 mg daily for 5 days
1658216|NCT01791738|Procedure|Acetabular positioning system|Pre-operative planning through 3D software with design and fabrication of patient specific instruments for placement of a guide pin to be used to aid in bone preparation for insertion of an acetabular cup in total hip arthroplasty
1658217|NCT01791725|Drug|ELND005|
1658218|NCT01791725|Drug|Placebo|
1658219|NCT01791712|Procedure|On-line hemodiafiltration|pre-dilution 40% of blood flow rate blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
1658220|NCT01791712|Procedure|High-flux Hemodialysis|blood flow rate 300-350 ml/min dialysate flow rate 800 ml/min
1658221|NCT01791699|Drug|Moxonidine|
1658222|NCT01791699|Drug|Placebo|
1658223|NCT01791686|Drug|CDX-1135|
1658224|NCT01791673|Device|Ultrasound glaucoma treatment|Ultrasound glaucoma treatment with EYEOP1 device
1658225|NCT01791660|Device|Zeltiq Coolsculpting System|Non-invasive device designed to cool subcutaneous fat without affecting adjacent or underlying structures.
1658226|NCT01791647|Drug|metformin 1500 mg|
1658227|NCT01791647|Drug|myoinositol 1500 mg|
1658228|NCT01791634|Procedure|proximal chevron osteotomy|
1658229|NCT01791634|Procedure|proximal open wedge osteotomy with LPS system|
1658230|NCT01791621|Other|Elimination/Challenge Diet|"An pre-specified elimination diet contains a list of food items permitted to be consumed by the study participants. These food items, selected to be consumed are whole foods of low allergenicity.
The challenge phase of the diet involves introducing 8 different foods at three days intervals. the selected challenge foods will be selected based on a review of the non-IgE mediated food allergy test results by a third-party, not directly associated with the project team."
1658231|NCT01791608|Dietary Supplement|Zinc sulfate as dietary supplementation|Zinc sulfate as dietary supplementation
1658232|NCT01791608|Dietary Supplement|Zinc amino acid chelate as dietary supplementation|Zinc amino acid chelate as dietary supplementation
1658233|NCT01791608|Dietary Supplement|Milk without fortification without zinc|Milk without fortification
1658234|NCT01791595|Drug|AZD3965|AZD3965 will be available as 5, 10, 20 and 30mg capsules and patients will take their dose orally once or twice every day of each 28 day cycle including a single dose at day-7 prior to cycle 1.Patients can have up to 12 cycles of treatment if patient is benefitting.
1658235|NCT01791556|Other|HIV-1 viral load testing|
1658236|NCT01791543|Device|Intramural Needle Ablation Catheter|
2013267|NCT00654615|Procedure|Volar Plate Fixation|After adequate anesthesia, longitudinal traction of the wrist was applied. Based on the fracture pattern, fragments were reduced and stabilized using either one 2.4mm titanium pre-contoured locking plate or a combination of locking plates. Arthrotomy was performed to verify that the fracture fragments were reduced. Plates were contoured to fit boney contours as needed. Allograft or autograft was placed in the fracture repair site as necessary. Radiographic landmarks were evaluated. Care was taken to ensure that plates were covered with periosteum or retinaculum to reduce the incidence of possible soft tissue irritation caused by the plate on the bone. The skin incision was closed; a removable splint applied.
2013268|NCT00652769|Procedure|Endobronchial or Endoscopic Ultrasound|Patients with anterior mediastinal or subcarinal disease will undergo EBUS. Patients with posterior, subcarinal or AP window disease will undergo EUS. Patients with no mediastinal disease on CT scan will undergo EBUS.
1658241|NCT01791504|Device|TissuGlu Surgical Adhesive|Standard Wound Closure Techniques Plus TissuGlu and no drains.
1658242|NCT01791491|Drug|Belatacept|Single intravenous infusion of belatacept, 7.5 mg/kg
1658247|NCT01791465|Drug|extended-release exenatide|Single arm study - 2mg Bydureon every 7 days x 16 weeks
1658248|NCT01791439|Other|lidocaine|Application of lidocaine to the glossopharyngeal nerve.
1658249|NCT01791439|Other|placebo|
1658250|NCT01791426|Device|Artelac Rebalance|Instill 1 drop of the Artelac Rebalance eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
1658251|NCT01791426|Device|Vismed|Instill 1 drop of the Vismed eye drops in each eye 3 to 5 times per day for 90(± 10) day treatment.
1658252|NCT01791413|Drug|depot medroxyprogesterone acetate|DMPA 150 mg intramuscular Before surgery 3 months (plus or minus 2 weeks)
1658253|NCT01791400|Drug|metoclopramide, injection,20mg, one time|metoclopramide, intravenous injection,20mg, one time
1658254|NCT01791400|Drug|Sumatriptan, injection, 6 mg, one time|Sumatriptan, subcutaneous injection, 6 mg, one time
1658255|NCT01791387|Drug|Dovitinib|"Patients will be treated with dovitinib (500 mg orally, once daily 5 days on/2 days off) until disease progression, intolerability, patient refusal, death or study drug discontinuation for any other reason. Dovitinib should be ingested at least 1 hour prior to a meal or at least 2 hours following a meal at approximately the same time each day.
If patients cannot tolerate the protocol-specified dosing schedule, dose reductions or treatment interruptions are permitted. When necessary, dovitinib may be reduced to 400 mg for 5 days on/2 days off. If an additional dose reduction is required, dovitinib may be reduced to 300 mg dose 5 days on/2 days off. Once dose is reduced due to an adverse event, it cannot be re-escalated. Patients are allowed only 2 dose reductions."
1658256|NCT01791374|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
1658315|NCT01789775|Drug|Drug: CD07805/47 gel|
1658316|NCT01789775|Drug|CD07805/47 gel Placebo|
1658691|NCT01787721|Procedure|Ankle manipulation|
1658257|NCT01791374|Drug|Rilotumumab|Drug: Rilotumumab Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells. Drug: Cisplatin A platinum containing chemo-therapy compound that reacts in vivo, binding to and causing crosslinking of DNA, which ultimately triggers apoptosis (programmed cell death). Drug: Capecitabine A chemo-therapy prodrug, that is enzymatically converted to 5-fluorouracil in the tumor, where it inhibits DNA synthesis and slows growth of tumor tissue.
1658258|NCT01791361|Other|Other|No intervention other than routine medical care
1658259|NCT01791348|Other|d2 test of attention|
1658260|NCT01791309|Drug|combination panitumumab and vemurafenib|Treatment will consist of panitumumab 6mg/kg IV every 14 days and vemurafenib 960mg orally twice daily. In patients who initially respond to treatment and later progress, a voluntary biopsy will be requested at the time of relapse to study mechanisms of acquired resistance. This biopsy should consist of at least one frozen core specimen. Every effort will be made to obtain this biopsy within 30 days of discontinuation of treatment and before the initiation of any new tumor-directed therapies.
1658261|NCT01791296|Drug|Dexmedetomidine|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
1658262|NCT01791296|Other|Placebo|At 21:30h, all current IV sedatives (whether continuous or intermittent) will be decreased by 50% and study drug started at 0.2 mcg/kg/hour at 21h30 to allow sleep between 22h00 and 6h00. Study infusion will be halved at 6:00am and d/c at 6:15am. The infusion rate will be increased by 0.1mcg/kg/hour every 15 minutes when the Riker-SAS is ≥ 4 up to a maximum rate of 0.7 mcg/kg/hr until the targeted sedation goal of a Riker-SAS of 3 is reached. For agitation (ie., Riker-SAS ≥ 5), 'as needed' IV midazolam (1-5 mg IV q1h prn agitation) may be administered during the upwards titration of the study medication. Administration of any dose of as needed IV midazolam will result in the increase of the study medication by 0.1 mcg/kg/hr when ≥ 15 minutes have elapsed since the last upwards titration.
1658263|NCT01791283|Procedure|Arterial waveform analysis, esofageal doppler, transthoracal cardiac ultrasound, Cardiac magnetic resonance imaging.|
1658264|NCT01791270|Device|Continuous positive airway pressure (CPAP) therapy|"Device: CPAP accordingly to the normal therapy in daily practice. In the group of 61 patients with OSA: we compared the results before and after three months of correct treatment with CPAP.
First, an automatic continuous positive airway pressure device (autoCPAP REMstar) was used to evaluate the pressure titration by night registration at patient home. AutoCPAP gets complete information about the optimum level to be set as therapeutic (CPAP pressure).
The patient has been reevaluated periodically in the outpatient Sleep Unit to verify proper adaptation and compliance of CPAP.
We considered a proper compliance when patients used CPAP ≥ 4 hours/day. This data has been extracted from the counter included in the CPAP compressor.
Procedures:
- Respiratory Polygraphy
- Ambulatory Blood Pressure Monitoring
- Endothelial dysfunction, by determining the hyperaemic response to ischemia using a Laser-Doppler flowmeter.
- ß1en subunit expression in peripheral blood leukocytes."
1658265|NCT01791244|Drug|Rebif®|
1658266|NCT01791231|Drug|Radiolabelled 14C-canagliflozin (14C-JNJ-28431754)|A single oral dose of 196 mg radiolabeled 14C-canagliflozin (14C-JNJ-28431754) liquid suspension containing approximately 40 microcurie (1480 kBq) of 14C radioactivity will be administered on Day 1.
1658267|NCT01791218|Procedure|CABG, AVR or CABG+AVR and PVI|
1658268|NCT01791218|Procedure|CABG, AVR or CABG+AVR|
1658269|NCT01791192|Drug|FTY720|Fingolimod
1658270|NCT01791192|Drug|Oral Corticosteroid|Oral Corticosteroid
1658271|NCT01791179|Behavioral|Comprehensive substance abuse services|
1658272|NCT01791166|Biological|Blood test for detecting the circulatory anti-HLA antibodies by ELISA and LUMINEX tests|
1658273|NCT01791153|Drug|Tocilizumab|Tocilizumab will be administered at a dose of 162 mg as SC injection qw or q2w for 52 weeks in Part 1 of the study and at a dose 162 mg as SC injection qw for 104 week at the discretion of the investigator in Part 2 of the study.
1658274|NCT01791153|Drug|Prednisone|Prednisone will be administered at tapering oral doses as tablets daily for 26 or 52 weeks according to the protocol-defined schedule in Part 1 of the study. Prednisone will also be administered as escape therapy to treat disease flares in an open-label manner during Part 1 at a dose and duration selected by the investigator.
1658275|NCT01791153|Drug|Tocilizumab Placebo|Tocilizumab placebo will be administered as SC injection qw or q2w for 52 weeks in Part 1 of the study.
1658276|NCT01791153|Drug|Prednisone Placebo|Prednisone placebo will be administered as tablets orally daily according to the protocol-defined schedule (from Week 26 to Week 52) in Part 1 of the study.
1658277|NCT01791153|Drug|Corticosteroids|Participants without sustained remission at Week 52 will receive corticosteroids at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
1658278|NCT01791153|Drug|Methotrexate|Participants without sustained remission at Week 52 will receive methotrexate at a dose and schedule at the discretion of the investigator for a maximum of 104 weeks.
1658279|NCT01791127|Device|market-released BIOTRONIK pacemaker system including one or two Siello S leads.|
1658280|NCT01791114|Other|Cold exposure|For the cold exposure trial, the subjects will follow an individualized cold exposure protocol maximize the elicited non-shivering thermogenesis. Subjects will be wearing liquid conditioned garments (Polar Products Inc, Stow, OH). The temperature will initially be set at 18°C, then decreased at 1 degree celsius intervals thought the air- conditioned temperature control bath until subjects report shivering. Electromyography (EMG; Delsys, Bagnoli 8, Boston, MA) will be performed continuously to verify shivering muscle activity. Upon shivering, the temperature will be increased by 1degree Celsius intervals until shivering resides. Subjects' core temperature will be measured at 10-second intervals with the use of a telemetric pill (Core Temp Inc., Palmetto, FL).
1658317|NCT01789762|Biological|Autologous plasma|Transfusions of platelet concentrates re-suspended in autologous plasma
1658281|NCT01791114|Other|Cold exposure plus propranolol|For the cold exposure plus propanol trial, temperature will be titrated as previously described. The non-selective beta-adrenergic antagonist propranolol (0.5mg/kg and up to 40) will be given orally before the beginning of the study and again after 4-6 hours. In case participant's heart rate after propranolol administration decreases below 50 beats per min or systolic blood pressure below 90 mmHg second dose of propranolol will not be administered. Heart rate and blood pressure will be monitored continuously throughout the study. Propranolol doses up to 80 mg have been shown to significantly reduce fludeoxyglucose (FDG) uptake in brown fat in clinical patients.
1658282|NCT01791114|Other|Thermoneutral Conditions|Subjects will be exposed to thermoneutral conditions (26 - 28°C)
1658283|NCT01791114|Other|Cold water consumption|Subjects will be asked to consume cold water (4 °C,10 ml/ kg body weight within 10 minutes)
1658284|NCT01791114|Other|Tepid water consumption|Subjects will be asked to consume cold water (36 C,10 ml/ kg body weight within 10 minutes)
1658285|NCT01791114|Other|Exercise|Subject will be asked to complete four bouts of exercise for 10 min- at 85% of their maximal oxygen consumption (VO2max) with 15-min breaks between each bout
1658286|NCT01791114|Other|Meal consumption|Subjects will be asked to consume a high calorie meal (12 kcal/kg, 50% carbohydrates, 30% fat, and 20% protein) within 15 minutes.
1658287|NCT01791101|Drug|Eltrombopag|
1658288|NCT01791088|Drug|sirolimus|Given PO
1658289|NCT01791088|Other|pharmacological study|Correlative studies
1658290|NCT01791088|Other|laboratory biomarker analysis|Correlative studies
1658291|NCT01791075|Device|Tan Endoglide|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
1658292|NCT01791075|Device|Endosaver|Patients assigned to this intervention will have their endothelial donor graft injected into the anterior chamber using the Tan Endoglide
1658293|NCT01791062|Device|HYTOP®|HYTOP® will be implanted once during surgery.
1658294|NCT01791049|Drug|TD-1607|
1658295|NCT01791049|Drug|Placebo|
1658296|NCT01791036|Procedure|Adductor Canal Block|Examination of the adductor canal using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin in the medial upper-thigh region. The ultrasound probe will be moved either cephalad or caudad from its initial position in order to visualize the femoral artery immediately deep to the middle of the sartorius muscle. This point will then be selected as the appropriate level for needle insertion. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
1658297|NCT01791036|Procedure|Femoral Nerve Block|Examination of the femoral nerve using ultrasound will be performed using a high frequency linear probe. Following this the ultrasound probe will be positioned perpendicular to the skin at the level of the femoral crease. The femoral artery will be identified and the femoral nerve will then be located immediately lateral to the artery, deep to the fascia iliaca and superficial to the iliopsoas muscle. The needle will be positioned next to the femoral nerve. Following this 20 ml of 0.25% bupivacaine with epinephrine will be injected incrementally over a 1 to 2 minute period. Sham blocks using subcutaneous injection of normal saline will be used in both groups to maintain patient blinding.
1658298|NCT01791023|Other|Physical exercise|30 minutes of aerobic exercise on treadmill with moderate intensity.
1658299|NCT01791010|Other|Inspiratory muscle training|
1658300|NCT01791010|Other|Training sham|Conducting fake training with the aim of blind the control group
1658301|NCT01790997|Drug|DLBS1033|1 tablet of DLBS1033 490 mg thrice daily, after meal
1658302|NCT01790997|Drug|Aspirin|1 tablet of aspirin 80 mg once daily, after meal
1658303|NCT01790997|Drug|Clopidogrel|1 tablet of clopidogrel 75 mg once daily, after meal
2013269|NCT00652769|Procedure|Bronchoscopy, CT-guided biopsy, PET scan, Mediastinoscopy|Investigations will be determined by the multi-disciplinary team responsible for the patient
2013270|NCT00641186|Drug|sodium oxybate|4.5 to 9.0 grams per night
1658306|NCT01790971|Drug|Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
1658307|NCT01790971|Drug|No Intrathecal Morphine|Depending on the randomization schedule, 100μg of morphine will or will not be added to the intrathecal mixture.
1658308|NCT01790932|Drug|BKM120|
1658309|NCT01790919|Behavioral|Cognitive therapy for depression|"Cognitive therapy (CT) for depression. There is evidence that CT for major depressive disorder (MDD) can be as effective as antidepressant medication for the initial treatment of moderate to severe MDD. Moreover, following the withdrawal of treatment, patients treated with CT are significantly less likely to relapse than patients treated with antidepressant medication and CT is at least as effective as antidepressant medication in preventing subsequent relapse. Over 14 sessions CT aims to alter the symptomatic expression of depression and reduce risk for subsequent episodes by correcting the negative beliefs and maladaptive information processing presumed to underlie the disorder and alter the systematic tendency to misperceive reality in a pessimistic fashion.
Cognitive support. An intervention to improve memory for the contents of therapy. Cognitive support involves a series of specific procedures that support the encoding and retrieval stages of an episodic memory."
1658310|NCT01790906|Procedure|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD .once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster,Diamond Bar,California)was introduced into each renal artery.then was maneuvered within the renal artery to allow energy delivery in a circumferential,longitudinally staggered manner to minimize the chance of renal artery stenosis.About six to nine ablation at 10W for 1 min each were performed in both renal arteries.during ablation, the catheter system monitored tip temperature and impedance,altering radiofrequency energy delivery in response to predetermined algorithm.
1658311|NCT01790906|Other|Conventional therapy|Optimizing drug therapy,included angiotensin-converting enzyme inhibitors,aldosterone antagonist,beta-receptor blockers,diuretic,digoxin and so on.The patients with chronic heart failure ,whos'condition need for CRT-D(cardiac resynchronization therapy )/ICD(implantable cardioverter-defibrillator),are considered to implant CRT/ICD .CRT is abbreviation for cardiac resynchronization therapy ,ICD is defined for Implantable Cardioverter defibrillator.
1658312|NCT01790893|Drug|aflibercept|
1658692|NCT01787721|Other|Sham manipulation|
1658318|NCT01789762|Biological|Additive solution|Transfusions of platelets prepared in additive solution (Intersol)
1658319|NCT01789762|Biological|Pathogen reduction process|Patients transfused with platelets treated by pathogen reduction process
1658320|NCT01789749|Other|Snare Tip Soft Coagulation|
1658321|NCT01789749|Other|No Snare Tip Soft Coagulation|
1658322|NCT01789736|Drug|PG286 Ophthalmic Solution 0.5%|PG286 Ophthalmic Solution
1658323|NCT01789736|Drug|AR-12286 Ophthalmic Solution 0.5%|AR-12286 Ophthalmic Solution 0.5%
1658324|NCT01789736|Drug|Travoprost Ophthalmic Solution 0.004%|Travoprost Ophthalmic Solution 0.004%
1658325|NCT01789723|Drug|Fusilev|Fusilev will be administered by IV push (3-5 minutes) at a dose of 5 mg/m2. Fusilev administration, QID or BID will start 24 ± 3 hours after Folotyn administration depending on the dose cohort.
1658326|NCT01789723|Drug|Folotyn|A cycle of Folotyn treatment is 7 weeks, 6 weeks of treatment followed by 1 week of rest.
1658327|NCT01790854|Drug|Prasugrel dose 5 mg/day|
1658328|NCT01790854|Drug|Prasugrel dose 10 mg/day|
1658329|NCT01790841|Device|Iforia/Ilesto ICD/CRT-D, Linox smart DF4 lead/ Protego|
1658330|NCT01790828|Drug|Xyntha : coagulation factor IIIV (recombinant)|Xyntha will be administered according to physician's discretion.
1658331|NCT01790802|Device|2RT nanosecond laser|active laser therapy
1658332|NCT01790789|Behavioral|Daily stress reduction program|Subjects will participate in activities of a daily stress reduction program.
1658333|NCT01790789|Other|Attention control|Subjects will receive periodic phone calls to review study protocol and will receive stress reduction program materials at the end of the study.
1658334|NCT01790776|Radiation|Urografin 30%|"Urografin 30% (Natrium amidotrizoas 10G, Megalumin, Amidotrizoas 65G, Natrii calcii edetas, water for injection 250 ml, with 146 mg iodium/ml).
The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (urografin 30 %) is instilled."
1658335|NCT01790776|Radiation|NaCl 0,9 % in aqua|The tip of a bladder catheter is placed at the external urethral meatus and fixed at this location. The solution (NaCl 0,9 % in aqua) is instilled. If the result is inconclusive, urografin 30 % will be instilled.
1658336|NCT01790763|Device|Keramatrix|Dressing for second degree burn
1658337|NCT01790763|Device|Mepilex|Dressing for second degree wound
1658338|NCT01790750|Device|PES first, then FFES|A 5-minute Pocket echocardiography system scan (PES) scan will be performed to detect PDA on neonates. This scan will be followed by a Full Featured Echocardiography System Scan (FFES) and scan results will be compared.
1658339|NCT01790737|Drug|Cyclophosphamide|
1658340|NCT01790737|Drug|Filgrastim|
1658341|NCT01790724|Behavioral|Walking exercise|
1658342|NCT01790711|Procedure|FMT through mid-gut|
1658343|NCT01790685|Drug|dexamethasone implant|
1658344|NCT01790672|Dietary Supplement|Ethanol|Vodka Absolut
1658345|NCT01790672|Other|Water|Lemon-flavored water
1658346|NCT01790672|Dietary Supplement|Alcoholized wine|Wine 13º or wine 8º
1658347|NCT01790672|Dietary Supplement|De-alcoholized wine|Wine 0º
2013271|NCT00638469|Radiation|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body half
2013272|NCT00638469|Other|No treatment|no UV exposure
1658350|NCT01790646|Other|intubation|intubation using Glidescope videolaryngoscope
1658351|NCT01790633|Other|ELISA|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg), anti-HBsAg antibody (anti-HBs Ab), anti-HCV antibody, and anti-HIV antibody status. Results will be given after test results are available (8-10 days).
1658352|NCT01790633|Other|Rapid Test|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®), anti-HCV antibody (HCV, using OraQuick®), and anti-HIV antibody (HIV, using VIKIA®) status. Results will be given the same day.
1658353|NCT01790620|Other|CVVHD|CVVHD will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as dialysate fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed. Isovolemic CRRT will be encouraged during this 72 hours if volume overload status is not present. After 72 hours, CVVHD will be continued and dialysate dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
1658354|NCT01790620|Other|CVVH|CVVH will be used during 72 hours with a prescribed dose of 30 ml/Kg/h Prismasol® 4 as reposition fluid. Blood flow of 200-250 ml/min, to achieve 12 - 15 L/h will be prescribed adjusting the adequate percentage of prefilter reinfusion to maintain a theorical filtration fraction between 18-22%. Isovolemic CRRT will be encouraged if volume overload status is not present. After 72 hours, CVVH will be continued and filtration dose (ml/kg/h) will be adjusted to achieve creatinine levels between 80-120 umol/L until patient recovers urine output and / or tolerates intermittent hemodialysis.
1658355|NCT01790607|Drug|ONO-2745 /CNS 7056|
2013273|NCT00628745|Other|None. Observational Study.|
2013274|NCT00625378|Drug|Sorafenib (Nexavar, BAY43-9006)|All patients are treated with sorafenib according to the dosage scheme of their previous trial.
1658361|NCT01790581|Behavioral|Balance Training|This is a 4-week supervised balance training program that has been previously validated in those with CAI by improving subjective and objective measures of function. During the 4-week program, subjects will complete three 20-25 minute sessions a week for a total of twelve supervised training sessions. The specific exercises and repetitions that will be performed per training session will include: 1) hop to stabilization (10 repetitions per direction), 2) hop to stabilization and reach (5 repetitions per direction), 3) unanticipated hop to stabilization (3 repetitions), 4) progressive single limb stance balance activities (3 repetitions), and 5) progressive single limb stance activities with eyes closed (3 repetitions).
1658362|NCT01790581|Behavioral|STARS|The STARS intervention will consist of 4 unique sensory-targeted interventions: calf stretching, ankle joint traction, anterior/posterior ankle joint mobilizations, and plantar massage. These four techniques target 3 types of sensory pathways (musculotendinous, articular, and plantar cutaneous, respectively) and will be applied in the same order for all treatment sessions: 1) 60-second calf stretch, 2) 30-second ankle traction, 3) 30-second mobilization, 4) 2-minute plantar massage, 5) 30-second ankle traction, and 6) 30-second mobilization.
1658363|NCT01790568|Drug|Vorinostat|administered at a dose of 100 mg orally, twice daily starting on day -10 in order to achieve steady-state prior to beginning the conditioning chemotherapy, and continued after transplant (day 0) until day +100.
1658364|NCT01790568|Drug|Tacrolimus|
1658365|NCT01790568|Drug|Methotrexate|
1658366|NCT01790555|Drug|Namisol|
1658367|NCT01790555|Drug|Diazepam/placebo|
1658368|NCT01790542|Other|Iron fortified cereal|Infants will be assigned to one of the three interventions: A (iron fortified cereal), B (iron fortified cereal with fruit), C (Meat)
1658369|NCT01790542|Other|Iron fortified cereal with fruit|
1658370|NCT01790542|Other|Meat|
1658371|NCT01790529|Procedure|Early administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in anesthetic room (75 to 30 minutes prior to skin incision)|
1658372|NCT01790529|Procedure|Late administration of SAP (Cefuroxime (plus metronidazole in colorectal surgery)) in the operating theatre (within 30 minutes prior to skin incision)|
1658373|NCT01790516|Drug|Cisplatin|Cisplatin 100 mg/m2 during weeks 1,4, and 7 of radiation therapy
1658374|NCT01790516|Drug|cetuximab|Cetuximab beginning at a dose of 400 mg/m2 the week before radiation commences and then 250 mg/m2 weekly during weeks 1 and 7 of radiation.
1658375|NCT01790516|Radiation|Radiation|daily radiation for 7 weeks
1658379|NCT01790490|Drug|Ketamine 0.41 mg/kg|52 minute iv infusion of ketamine 0.41 mg/kg
1658380|NCT01790490|Drug|Ketamine 0.71 mg/kg|52 minute iv infusion of ketamine 0.71 mg/kg. This dose follows K1 in all 3 orderings.
1658381|NCT01790490|Drug|Lorazepam 2 mg|52 minute infusion of lorazepam 2 mg. This serves as an active control.
1658382|NCT01790477|Procedure|Auricular Acupuncture|Application of auricular acupuncture to 5 points on the ear
1658383|NCT01790464|Drug|2% Lidocaine|2% lidocaine and peritonsillar instillation of gauze soaked with 2% lidocaine (Glossopharyngeal Group).
1658384|NCT01790464|Drug|placebo|
1658385|NCT01790451|Procedure|Irreversible Electroporation|
1658386|NCT01790438|Drug|LY2605541|Administered SQ
1658387|NCT01790438|Drug|Human Insulin NPH|Administered SQ
1658388|NCT01790425|Procedure|to infuse water into colon to open the lumen for water infusion colonoscopy|
1658389|NCT01790425|Procedure|Air colonoscopy|
1658390|NCT01790412|Behavioral|Exercise group|Combined two land aerobic sessions and one aquatic activities session
1658391|NCT01790399|Procedure|Excision of sentinel node(s)|Excision of sentinel node(s) using SENTIMAG / SIENNA + in addition to the usual method (blue and /or radioactive product)
1658392|NCT01790373|Behavioral|Suubi+Adherence|"Matched savings accounts/child development accounts (CDAs) for the adolescents held in a local bank.
Financial education and workshops on asset-building, future planning, and protection from risks
Mentorship from a young adult/near-peer
Family-based microenterprise development training
Medical Event Monitoring System
Bolstered Standard of Care: Adherence Counseling Practices
-Four to six counseling sessions to review HIV, ART, resistance, and adherence.
Medical Standard of Care:
-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda
Psychosocial Standard of Care:
-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
1658393|NCT01790373|Behavioral|Bolstered Standard of Care|"-Medical Event Monitoring System
Bolstered Standard of Care: Adherence Counseling Practices
-Four to six counseling sessions to review HIV, ART, resistance, and adherence.
Medical Standard of Care:
-Pediatric ART initiation and monitoring followed by all public clinics, and outlined in National Department of Health Guidelines for pediatric HIV care in Uganda
Psychosocial Standard of Care:
-Psychosocial support provided by lay counselors trained in standardized ART adherence counseling"
1658394|NCT01790360|Behavioral|Patient Navigation (PN) Intervention|Patient Navigation is defined as an individual relationship between a navigator and participant to promote retention in the continuum of HIV care . For this study, three experienced navigators will be hired. Their primary role will be to ensure that participants are linked to an HIV primary care provider, that they attend at least one scheduled visit within three months of receiving a confirmed HIV diagnosis, and that they are retained in care (as defined by attending three HIV visits within nine months of diagnosis). To promote linkage to HIV care, navigators will help participants identify material and other barriers to accessing care and will work with participants to overcome those barriers.
1658395|NCT01790360|Behavioral|Financial Incentives (FI) Intervention|After confirmation that they have completed their first HIV primary care visit, Financial Incentive participants will receive a gift card. Additionally, the coordinator will flip a coin and give participants a bonus gift card if the coin flip comes up heads. Participants who attend the second HIV primary care visit will receive a gift card. Patients who attend a third HIV primary care visit will receive a gift card. Study staff will be responsible for confirming participants' attendance at appointments.
1658396|NCT01790347|Behavioral|Exercise group|"The physical conditioning program included a total of three 50-55 minute sessions per week. Pregnant women started at 9 weeks and finished at 38-39 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.
Each session included 10 min of warm up and 10 min of cool down which included an specific pelvic floor muscles training. The core section of the exercise session lasted from 25 to 30 min and included moderate-intensity aerobic exercises once a week and resistance exercises twice a week."
1658397|NCT01790334|Other|Ultrasonography|
1658432|NCT01790061|Drug|Traditional treatments according to associated guidelines|Traditional treatments according to associated guidelines
1658541|NCT01789151|Device|Technetium labelled glucosamine|Nuclear medicine imaging of arthritic joints using radioactive glucosamine
1658398|NCT01790321|Device|LSF-filtering device|LifeStraw Family is a water purification device that by means of hollow fibres removes solid particles (<0.5 NTU turbidity reduction), bacteria (>Log 6 reduction), viruses (>Log 4 reduction) and cysts (>Log 3 reduction). Zinc fortification is provided by a chamber housing a zinc releasing glass-plate that is placed annexed to the hollow fibre column. It is estimated that the LSF can provide about 5 mg of zinc/l of filtered water. By consuming daily a portion of 0.6 litres of enriched water, >100% of the age-specific estimated physiologic requirement would be covered, assuming a fractional absorption of 40%.
1658399|NCT01790308|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
1658400|NCT01790308|Drug|Liraglutide|CSII for 2~4 weeks combined with Liraglutide 0.6mg/d for 1 month and 1.2mg/d for next 2 months
1658401|NCT01790295|Drug|Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)|Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
1658402|NCT01790282|Drug|estradiol plus progesterone 100 mg IM injection|estradile valaerate 2mg plus progesterone 100 mg/day support arm :E2 valerate 2mg three times /day are given to the arm cases plus P4 100 IM/day for 14 days starting on day of ovum pickup and single IM injection of 0.1 mg decapeptyl on day of ET
1658403|NCT01790282|Drug|Progesterone IM of 100 mg|Starting on day of ovum pickup ICSI cases are given prontogest 100 mg IM /day plus single dose dose of treptorline 0.1mg is given sc on day of embryo transfer
1658404|NCT01790256|Device|Cereve Sleep System at 30 degrees C|
1658405|NCT01790256|Device|Cereve Sleep System at 14-16 degrees C|
1658406|NCT01790243|Device|Lutonix Drug Coated Balloon|
1658407|NCT01790230|Device|LifeSeal™ Kit|Application of LifeSeal™ Kit for staple line reinforcement during open GI surgeries in Low Anterior Resection
1658408|NCT01790204|Dietary Supplement|Watercress Juice|The juice is prepared, by a trained member of the Chung laboratory staff, in the following manner; each serving of watercress juice will be prepared with 55gm watercress (from a local grocery store) with 220 ml purified water, for a proportion of 1:4 (w/w). The watercress and water will be placed in a 1.5 L mechanical blender and blended at low speed for approximately 15 seconds, followed by blending at a high speed for one additional minute. The resulting suspension will be filtered through two layers of cheese cloth. Remaining liquids will be manually extracted from the cheese cloth into the same container. Each serving will be measured to 200 ml. The remaining 20 ml will be used for analysis of ITC content. Each serving will be prepared and kept at 40 C until needed, no more than one hour prior to participant consumption by the subject.
1658409|NCT01790191|Behavioral|Repeated consumption of basic artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
1658410|NCT01790191|Behavioral|Repeated consumption of sweet artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
1658411|NCT01790191|Behavioral|Repeated exposure to fat artichoke purée.|In this conditioning trial, the effect of repeated consumption of different types of artichoke purée was studied. In Arm 1, participants were repeatedly exposed to basic artichoke purée. In Arm 2, participants were repeatedly exposed to sweet artichoke purée. In Arm 3, participants were repeatedly exposed to fat artichoke purée. Change in intake and liking of basic artichoke purée was evaluated at baseline and after 10 exposures to artichoke purée ; and at 3 follow-ups: after 2 weeks (FU2W), after 3 months (FU3M) and after 6 months (FU6M).
1658412|NCT01790178|Procedure|Ultrasound|The ultrasound guided group will have an ultrasound to identify the optimal site for biopsy and guide the procedure for safety purposes.
1658418|NCT01790139|Drug|Oral simethicone|10 mL of simethicone is administered as an agent to prevent colonic bubbles
1658419|NCT01790126|Drug|ARN-509|
1658420|NCT01790126|Drug|LHRH Agonist|
1658425|NCT01790087|Drug|ANX-188 Therapeutic Dose|
1658426|NCT01790087|Drug|ANX-188 Supratherapeutic dose|
1658427|NCT01790087|Drug|Saline|
1658428|NCT01790087|Drug|Moxifloxacin|
1658429|NCT01790074|Other|TrP therapy|TrP manual therapy comprises different manual approaches, e.g., compression, stretching, or transverse friction massage applied over active TrPs in the sternocleidomastoid muscle
1658430|NCT01790074|Other|TrP manual control therapy|The treatment consisted of a simulation of the same TrP therapy treatment applied to the experimental group without the application of any therapeutic pressure.
1658431|NCT01790061|Procedure|Standardized Fecal Microbiota Transplantation|Fecal microbiota transplantation by gastroscopy administration of fresh or frozen bacteria from healthy donor to the mid-gut (below the second part of duodenum).
1658688|NCT01787747|Drug|AVP-786 Dose 1/Q Dose 2|
1658433|NCT01790048|Dietary Supplement|Whey permeate RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of whey RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.
Whey RUSF contains whey permeate, WPC 80 (contains at least 80% protein), peanut paste, sugar, soy oil, a customized micronutrient premix to account for the minerals in whey permeate, and an emulsifier."
1658434|NCT01790048|Dietary Supplement|Soy Protein RUSF|"Each child will receive 75 kcal/kg/day (314 kJ/kg/day) of soy RUSF. A ration of sufficient for two weeks based on the subject's weight will be distributed at each visit. Children will be asked to return every two weeks for follow-up, where caretakers report on the child's clinical symptoms, anthropometric measurements are re-assessed, and additional supplementary food is distributed for those that remained wasted.
Soy RUSF contains extruded soy flour, peanut paste, sugar, soy oil, palm oil, a premix containing concentrated minerals and vitamins, an emulsifier and dicalcium phosphate or calcium carbonate (Roche, Mumbai, India). Soy RUSF has no protein from animal sources."
1658435|NCT01790035|Drug|LGG|
1658436|NCT01790035|Drug|Placebo|
1658437|NCT01790022|Drug|Methylprednisolone|
1658438|NCT01790009|Dietary Supplement|Flavanol rich drink|
1658439|NCT01790009|Drug|Acetaminophen|2x500 mg Acetaminophen
1658440|NCT01789996|Procedure|alternative six minute walk test|"Alternate instructions will be given Subjects will
walk as fast as they can in 6 minutes
walk as normally as they can in 6 minutes
walk leisurely as they can in 6 minutes. Pts will serve as their own controls."
1658441|NCT01789996|Procedure|Standard six minute walk test|Subjects will walk as far as they can in 6 minutes
1658442|NCT01789983|Behavioral|Walk With Ease Program|"The primary activity required of study subjects is a 6-week self-directed (non-group) WWE walking program that study participants do at a place and time that is convenient for them. To start the intervention/program, we schedule a brief baseline meeting with study participants to discuss the program, provide the WWE workbook, secure printed informed consent, and complete various questionnaires. Study participants are also asked to maintain a daily walking diary that is provided to them.
The WWE program includes a workbook with strengthening and stretching exercises, basic facts about arthritis and PA, and information on how to individualize the program."
1658443|NCT01789983|Other|Collect Blood, GA and Other Survey Tools|"Geriatric Assessment (GA) (Version 5)
Functional Assessment of Cancer Therapy-General (FACT)
Functional Assessment of Chronic Illness Therapy (FACIT)-Fatigue36
Outcome Expectations for Exercise (OEE) scale29
Self-Efficacy to Manage Arthritis or Joint Pain (ASE/Arthritis Self-Efficacy)
Perceived Self-Efficacy for Fatigue Self-Management (PSEFSM)34,35
Visual Analog Scales (VAS)
Surveys included in study are listed above. Whole Blood Sample will be collected for p16 analysis."
1658444|NCT01789970|Drug|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.
Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.
Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
1658445|NCT01789970|Drug|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.
Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
1658446|NCT01789957|Drug|AC2993|4-Week transition of AC2993 5 mcg subcutaneously injected twice daily followed by an open-ended period through study termination (up to 52 weeks) of AC2993 10 mcg subcutaneously injected twice daily
1658447|NCT01789944|Behavioral|Behavioral: Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change
1658448|NCT01789931|Device|"Lifebeam"|"The lifebeam sensor will be attached to the participant's skin during the HTT."
1658449|NCT01789918|Device|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
1658450|NCT01789905|Drug|Tigecycline (Tygacil)|Tigecycline 50 mg intravenously. Therapy conducted according to Japanese LPD of Tygacil. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
1658451|NCT01789892|Drug|methylprednisolone|Given IV
1658452|NCT01789892|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT scan
1658453|NCT01789892|Procedure|positron emission tomography|Undergo FDG PET/CT scan
1658454|NCT01789892|Procedure|computed tomography|Undergo FDG PET/CT scan
1658455|NCT01789879|Drug|Levonorgestrel|Levonorgestrel 2-rod subdermal implant (75mg/rod) placed on study day 0 after baseline evaluations and remains in place until the subject requests removal or for the duration of drug activity (currently approved for 5 years).
1658456|NCT01789879|Drug|Nevirapine|Nevirapine 200mg twice daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
1658457|NCT01789879|Drug|Efavirenz|Efavirenz 600mg once daily as part of a complete antiretroviral therapy regimen. Subjects will be on this therapy prior to entry in this study.
1658458|NCT01789853|Behavioral|Intensive Walking|8 weeks high intensity walking training over multiple stepping tasks
1658459|NCT01789853|Behavioral|Conventional Physical Therapy|Regular physical therapy for 8 weeks
1658460|NCT01789840|Device|Embosphere Microspheres|
1658461|NCT01789840|Procedure|TURP|
1658462|NCT01789827|Other|Laboratory Biomarker Analysis|Correlative studies
1658463|NCT01789827|Procedure|Radionuclide Imaging|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
1658464|NCT01789827|Biological|Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2|Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies
1658465|NCT01789814|Drug|Prasugrel|Patients will be randomized to prasugrel or clopidogrel to assess the effect of these drugs on inhibition of platelet aggregation following the cessation of bivalirudin therapy.
1658689|NCT01787747|Drug|AVP-786 Dose 2/Q Dose 2|
1658466|NCT01789814|Drug|Clopidogrel|Clopidogrel 600 mg as a loading dose immediately prior to the start of procedure and 75 mg daily thereafter
1658467|NCT01789801|Procedure|RAP palpation only|Skin disinfection by local antiseptic. Identification of the radial artery by palpation. Insertion of the needle positioned at 70 ° with regard to the artery palpated. Check the rise of arterial blood in the syringe.
1658468|NCT01789801|Procedure|RAP with ultrasound guidance|Skin disinfection by local antiseptic. Application of sterile gel. Identification of the artery via ultrasound vascular probe. Center the artery at the center of the screen. Introduction of the syringe at 70 ° with respect to the probe, in center of visualized zone. Check the rise of arterial blood in the syringe.
1658469|NCT01789788|Drug|Placebo|Matching placebo, multiple doses
1658470|NCT01789788|Drug|RO6811135|multiple ascending doses
1658471|NCT01789710|Drug|Bupropion|All participants who are medically eligible to take Bupropion will receive this study medication one week prior to their smoking quit date.
1658472|NCT01789710|Drug|Nicotine replacement therapy|All participants will receive two forms of nicotine replacement therapy - nicotine patches and a rescue method (either gum or lozenge).
1658473|NCT01789710|Behavioral|Contingency Management|All participants will be asked to provide home carbon monoxide monitoring with equipment that is loaned to them. When participants provide readings that are low enough to suggest abstinence from smoking, they are provided monetary reinforcement (i.e., money).
1658474|NCT01789697|Other|cellular device/computers|A random group of patients will receive text messages to their cellular device from the surgeon, as well as emails to their email addresses.
1658475|NCT01789684|Other|Active Provider Intervention|Participating Sites assigned to the active intervention cluster will receive a multi-faceted provider education and decision support intervention to improve appropriate referral of breast cancer patients at risk for HBOC to genetic counseling and pre-surgical referral among newly diagnosed patients.
1658476|NCT01789671|Behavioral|Family-based behavioral intervention|This behavioral treatment includes behavioral skills training and accountability, including food and activity self-monitoring, goal setting, and home environment change.
1658477|NCT01789658|Other|Cryotherapy|Cryotherapy with ice-chips, ice cream or ice water is given during conditioning treatment with chemotherapy prior to HSCT.
1658480|NCT01789632|Biological|Group A Platelet Rich Plasma Injection (PRP)|Local anesthetic (lidocaine)will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a needle will then be placed into the tendon followed by 10-12 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites. Whole blood will be drawn from the patient's unaffected arm using a butterfly needle. The blood will be centrifuged and then a dose of the platelet rich plasma will be placed into the common extensor tendon.
1658481|NCT01789632|Procedure|Group B Whole Blood Injection|Local anesthetic (lidocaine)will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a needle will then be placed into the tendon followed by 10-12 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites. Autologous whole blood will be drawn from the patient's unaffected arm using a butterfly needle and a portion of this blood will be placed into the common extensor tendon.
1658482|NCT01789632|Procedure|Group C Dry Needle tendon fenestration|Local anesthetic (lidocaine)will be infiltrated into the subcutaneous tissue of the lateral elbow. Autologous whole blood will be drawn from the patient's unaffected arm, using a butterfly needle and discarded.Local anesthetic (lidocaine)will be infiltrated into the subcutaneous tissue of the lateral elbow, after which a needle will then be placed into the tendon followed by 10-12 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.
1658483|NCT01789632|Other|Group D No injection|Local anesthetic (lidocaine)will be infiltrated into the subcutaneous tissue of the lateral elbow. Autologous whole blood will be drawn from the patient's unaffected arm using a butterfly needle. The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected.
1658484|NCT01789619|Drug|Extended release tacrolimus (Advagraf®)|
1658485|NCT01789606|Drug|Ibuprofen 600 mg Immediate Release/Extended Release Caplet|Ibuprofen 600 mg Immediate Release/Extended Release Caplet to be adminstered orally (i.e., one caplet every 12 hours, not to exceed 2 caplets per day) for pain.
1658486|NCT01789593|Other|glucose clamp|Each subject will be randomly allocated to an experimental visit sequence consisting of a hypoglycaemic glucose clamp followed by euglycaemic glucose clamp (using i.v. infusion of human soluble insulin (Actrapid®)) or vice versa separated by at least 21 days. Each visit includes an overnight stay. For each of the two conditions (euglycaemia and hypoglycaemia) cognitive performance will be assessed by a validated cognitive test
1658487|NCT01789580|Other|Gambling moderator|
1658489|NCT01789554|Other|MLS dispatch for bystander CPR|
1658490|NCT01789528|Drug|CAZ-AVI|IV infusion
1658491|NCT01789528|Drug|CXL|IV infusion
1658492|NCT01789502|Device|Fully covered metal stents|Fully covered metal stents were inserted by ERCP
1658493|NCT01789502|Device|Plastic stents|Plastic stents were inserted by ERCP
1658494|NCT01789489|Device|Medison Accuvix V20, sonde 3D5-9EK (Endovaginal 3 dimensional echography)|
1658495|NCT01789476|Drug|CR845|CR845 dosage = 0.005 mg/kg per dose, IV bolus. The initial dose was administered upon reaching a qualifying pain intensity score and followed by a supplemental dose, if requested by patient for pain. Additional doses could be administered every 8 hours up to 48 hours.
1658496|NCT01789476|Drug|Placebo|Matching placebo administered using same dosing algorithm as the active arm
1658497|NCT01789463|Other|Self rehabilitation|
1658498|NCT01789463|Other|Self rehabilitation plus physiotherapy|
1658499|NCT01789450|Procedure|Section of Periareolar Dermis in Breast Reduction.|
1658500|NCT01789437|Device|Dexamethasone Intravitreal Implant (Ozuredex)|
1658690|NCT01787747|Drug|AVP-923|
1658501|NCT01789411|Other|Drawing blood samples|Drawing blood samples from the arterial sheath prior to the standard coronary angiography procedure
1658502|NCT01789411|Device|Coronary intravascular ultrasound imaging|Coronary intravascular ultrasound imaging of a non-culprit coronary artery.
1658503|NCT01789411|Device|Coronary near-infrared spectroscopy|Near-infrared spectroscopy imaging of a non-culprit coronary artery (in patient who are included in the AtheroRemo-NIRS substudy).
1658504|NCT01789398|Drug|BF2.649|BF2.649 is provided in capsules. Patients should take 1 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast).
1658505|NCT01789385|Drug|Dexmedetomidine|Starting with a 1 mg kg-1min-1 loading dose and than continued with a0.2-0.8 mg kg-1h-1 infusion rate.
1658506|NCT01789359|Other|Blueberry Juice|Dietary intervention
1658507|NCT01789346|Device|532nm potassium titanyl phosphate (KTP) laser|
1658508|NCT01789346|Device|595nm pulsed-dye laser (PDL)|
1658509|NCT01789333|Device|UVA Light with irradiance exposure of 9 mW/cm2|"The device's light emitting diode (LED) is used to deliver a metered dose of UV-A light to a targeted treatment area for illuminating the cornea during corneal collagen cross-linking.
The aperture setting will be set at 10 mm, and the eye will be irradiated for 10 minutes for the high irradiance exposure of 9 mW/cm2. During the exposure, instillation of riboflavin will continue (1 drop every 3 minutes)."
1658510|NCT01789333|Drug|Riboflavin 0.1% ophthalmic solution|"The speculum is removed and one (1) drop of Riboflavin 0.1% ophthalmic solution will be instilled topically in the eye every 3 minutes for 30 minutes. At the end of the 30 minute riboflavin pre-treatment period, the eye will be examined to assure the presence of a yellow flare in the anterior chamber, indicating riboflavin saturation of the corneal tissue. If the yellow flare is not detected, riboflavin will continue to be instilled until the presence of the yellow flare in the anterior chamber is confirmed.
During UVA irradiation, instillation of riboflavin will be continued every 3 minutes. For a 30-minute pre-treatment and 30-minute irradiation, the total dose of riboflavin solution is approximately 32 drops, or 1.6 ml (1 drop = 0.05 ml; 1.6 mL = 1.6 mg riboflavin)."
1658511|NCT01789320|Drug|triamcinolone acetonide (Triesence®)|4 mg of TRIESENCE® (triamcinolone acetonide injectable suspension 40 mg/mL) administered as a single injection to the suprachoroidal space
1658512|NCT01789307|Dietary Supplement|corn syrup solids|oral ingestion 50 grams, 2 doses
1658513|NCT01789307|Dietary Supplement|sucrose|oral ingestion 50 grams, 2 doses
1658514|NCT01789294|Drug|Mesalamine|A standard 50 mg/kg/die daily dose of oral mesalamine was prescribed by Pediatric Gastroenterologists, which informed parents of potential side effects. Whether the drug was not well tolerated, patients were drop out. Treatment was discontinued at time 1 to look for symptom recurrence.
1658515|NCT01789294|Behavioral|DIET|Dietetic avoidance of cow's milk and egg, plus foods eventually detected by skin tests, was prescribed by Pediatric Allergologists. To ensure the correct adherence to diet with no nutritional impairment, a scheme of admitted foods and an appropriate calcium supplement dose were given to patients.
1658516|NCT01789281|Drug|Everolimus|Everolimus will be provided by the investigator in 2.5 mg, 5 mg or 10 mg tablets for daily oral administration. Everolimus can be provided as local commercial material or global supply where appropriate
1658517|NCT01789281|Drug|Sandostatin LAR Depot|Patients receiving everolimus treatment in combination with Sandostatin LAR Depot on the parent protocol will be allowed to continue Sandostatin LAR Depot treatment. Sandostatin LAR Depot will continue to be provided by Novartis or by the investigational site considering local regulations. The dose and frequency of Sandostatin LAR Intramuscular injections will be administered at the discretion of the treating physician.
1658518|NCT01789268|Device|Respiratory Inductive Plethysmography|Respiratory Inductive Plethysmography (RIP) will be used to document thoracoabdominal motion, relative minute ventilation, and apnea during the minimally invasive respiratory assessments (NIRAs). Both Full and Preterm Infants will undergo a respiratory assessment via RIP prior to and after a bronchodilator (albuterol)
1658519|NCT01789255|Drug|vorinostat|Given PO
1658520|NCT01789255|Drug|tacrolimus|Given IV or PO
1658521|NCT01789255|Drug|cyclosporine|Given IV or PO
1658522|NCT01789255|Drug|methotrexate|Given IV
1658523|NCT01789255|Other|laboratory biomarker analysis|Correlative studies
1658524|NCT01789255|Other|pharmacological study|Correlative studies
1658527|NCT01789229|Other|Tumor tissue collection|"Tissue sample is collected during therapeutic intervention by a medical doctor/surgeon.
Frozen tissue sections are first transferred to Dept.of Pathology. Pathologist samples required tissue to obtain enough evidence for analysis/diagnosis.
Rest tumor material with or without malignant cells is tranferred to the lab for Molecular Oncology of Prof.Zeillinger."
1658528|NCT01789229|Other|Sampling of ascites and pleural effusion|Samples of malignant ascites and/or malignant pleural effusion is only collected during therapeutic intervention from patients at inpatient care.
1658529|NCT01789229|Other|Collecting urine samples|Patient is asked to give a urine sample. Urine is collected in urine beaker.
1658530|NCT01789229|Other|Collecting saliva sample|Saliva sample is collected by spatula from the mouth cavity of the patient.
1658531|NCT01789229|Other|Collecting sputum|Patient is asked to produce sputum into a 50ml lab tube.
1658532|NCT01789229|Other|Collecting stool samples|Stool samples are collected prior to bowel preparation for colonoscopy. Device for sampling is provided to the patient.
1658533|NCT01789229|Other|Lavage/Irrigation|Irrigation liquid is collected during routine therapeutic or diagnostic procedure, e.g. lavage of the uterine cavity and fallopian tubes of women scheduled for surgery.
1658537|NCT01789203|Drug|Ciprofloxacin|Patients will be randomized 2:1 active comparator to placebo comparator.
1658538|NCT01789203|Drug|placebo|
1658539|NCT01789177|Device|Incentive Spirometry|Patients will be provided with plastic, disposable incentive spirometers postoperatively
1658540|NCT01789177|Other|Postoperative chest physiotherapy|Patients will be given routine postoperative chest physiotherapy instruction by nursing staff
1658542|NCT01789138|Behavioral|Situated Optimal Adherence Intervention|Situated Optimal Adherence Intervention consists of 3 individual sessions (during consecutive medication pick-up visits to the clinic) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using the Next Step Counseling approach. The intervention targets: accurate information about ART (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; promotion of perceived sense of ease and efficacy in working the ART regimen into the context of one's daily life and circumstances that may challenge drug use persistence; identification and refinement of skills that promote ease of adhering to one's ART regimen across the diverse and challenging contexts.
1658543|NCT01789125|Drug|Nicotine Patch|
1658544|NCT01789125|Behavioral|Smoking Termination and Anxiety Reduction Treatment|Integrated smoking cessation and anxiety reduction treatment
1658545|NCT01789125|Behavioral|Education-Supportive Psychotherapy|
1658546|NCT01789112|Other|Blood sample|Taking of blood sample
1658547|NCT01789099|Biological|UV1 synthetic peptide vaccine and GM-CSF|
1658548|NCT01789086|Drug|liraglutide|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
1658549|NCT01789086|Drug|placebo|Administered subcutaneously (s.c., under skin) for 5-6 weeks. Initial dose of 0.6 mg/day. The dose will be escalated by 0.6 mg/day in weekly steps to a maximum of 3.0 mg/day
1658550|NCT01789073|Dietary Supplement|Oral Impact, Nestlé Health Science|Oral Impact from Nestlé Health Science. An enteral nutritional supplement high in protein and with added immune-enhancing nutrients: arginine, fish oil and nucleotides. The intervention arm receives Oral Impact in an individually estimated dosage according to a protein requirement of 1.5 g/kg bodyweight/day (subtracted their habitual protein intake). Each patient receives this dosage orally the last 7 days prior to surgery.
1658551|NCT01789060|Other|p-AKT immunohistochemical staining|p-AKT staining on the adequate paraffin-embedded biopsy specimen or unstained slides
2013275|NCT00605566|Drug|sorafenib and cyclophosphamide|"During a run-in period, patient will start taking 50 mg QD of oral cyclophosphamide and 200 mg BID of sorafenib. On day 8 of run-in the patient will be evaluated for toxicity. In the absence of toxicity, the patient will be escalated to sorafenib 400 mg BID and continue on daily 50 mg of cyclophosphamide, or the patient will be informed to continue on sorafenib 200 mg BID and cyclophosphamide 50 mg QD. Dose escalation procedure will be repeated every 2 weeks until unable to tolerate the study drug, or a maximum of 800 mg BID is reached, or achievement of > 90% inhibition of phosphorylation of PDGFR/Raf axis in PBMC. After run-in period, patient begins cycle 1, each cycle will last 28 days. Both cyclophosphamide and sorafenib will be taken orally."
2013276|NCT00595478|Behavioral|Motivational Enhancement Therapy (MET)/CBT+CM|Behavioral Treatment
1658554|NCT01789021|Device|4 blood glucose monitoring systems|
1658555|NCT01789008|Other|Determination of Advanced Fibrosis in Alcoholic Liver Disease|
1658556|NCT01788982|Drug|Nintedanib|Nintedanib should be administered orally at a dose of 200 mg twice daily.
1658557|NCT01788982|Drug|Placebo|
1658558|NCT01788969|Drug|Lexapro|Agent + training vs Placebo + training
1658559|NCT01788969|Drug|Placebo|Agent + training vs Placebo + training
1658560|NCT01788956|Device|Mespere Venous Oximeter|Mespere Venous oximeter provides non-invasive measurement of the oxygenation of the venous blood.
1658561|NCT01788956|Device|Co-Oximeter|
2013277|NCT00595478|Behavioral|Motivational Enhancement Therapy (MET)/CBT|Behavioral Treatment
1658563|NCT01788930|Device|CPAP|
1658564|NCT01788917|Dietary Supplement|linseed oil|10 ml linseed oil per day over 10 weeks (without control oil)
1658565|NCT01788878|Behavioral|Questionnaires|"A first series of questionnaires will be given by the investigator at patients before treatment (inclusion visit) and then the questionnaires will be given at the follow-up visits planned at 6 months, 12 months and 18 months.
Medical data will be collected via the CRF."
1658566|NCT01788865|Device|cSEMS(Covered self-expandable dual-layered metal stent) implant|
1658567|NCT01788839|Behavioral|surveys|A survey including the Female Sexual Function Index (FSFI), the Modified Female Sexual Function Index (FSFI-M), the Modified Female Sexual Function Index Follow-Up (FSFI-M Follow-Up) the Sexual Activity Questionnaire (SAQ), the Female Sexual Distress Scale (FSDS-R), the Menopausal Symptom Check List (MSCL), Patient-reported Outcomes Measurement Information System Sexual Function Instrument (PROMIS-SF), Abbreviated Dyadic Adjustment Scale for Relationships (ADAS), Reproductive Health Survey-baseline (RHS-B). Reproductive Health Survey-followup and (RHS-F1)Reproductive Health Survey-followup (RHS-F2) will be conducted at the following intervals: baseline/before chemotherapy +/- 1 month, 3 months after baseline +/- 1 month, 6 months after baseline +/- 1 month, 1 year after baseline +/- 1 month, and at intervals during survivorship that include yearly for 5 years +/- 2 months.
1658568|NCT01788839|Other|Blood draw|Those patients receiving chemotherapy who consent to the optional blood draw will provide blood at baseline (before start of chemotherapy), 12 months after baseline (+/-1 month) and 24 months after baseline (+/-2 months). All patients in the subset of the premenopausal cohort receiving tamoxifen only will have required blood draws at baseline (before they begin taking tamoxifen), at 6 months post-baseline/start of tamoxifen (+/- 2 weeks), 12 months post-start of tamoxifen (+/-1 month) and 24 months post-start of tamoxifen (+/-2 months). We will ask these participants for blood draws on day 1, 2, 3 or 4 of their menses at baseline and 6 months post-baseline/start of tamoxifen and during months 1 through 5 post-baseline/start of tamoxifen.
1658569|NCT01788839|Device|Transvaginal ultrasounds|Transvaginal ultrasounds are used to determine the number of antral follicles in each ovary. They will be performed to evaluate both the number and size of antral follicles of premenopausal women on Tamoxifen as antral follicle count is a good predictor of ovarian reserve and response. All patients in the subset of the premenopausal cohort receiving tamoxifen only will also have required transvaginal ultrasounds at baseline (before they begin taking tamoxifen) and at 6 months post-start of tamoxifen (+/- 2 weeks).
1658574|NCT01788800|Behavioral|Cognitive Behavioural Therapy (CBT)|9 sessions of CBT including psychoeducation and interoceptive exposure
1958091|NCT02000908|Device|photobiomodulation|The photobiomodulation delivered by Realief Therapy involves amplitude wavelength light delivered by a class IV therapeutic laser.
1958092|NCT02000908|Other|Sham treatment|All patients in sham treatment arm cross over to laser therapy followed by physiotherapy
1658575|NCT01788787|Behavioral|Quitline-Delivered Proactive Telephone Counseling|Smokers who enroll in treatment receive standard counseling protocol offered by the Quitline. This includes up to five proactive telephone counseling calls, each designed to provide practical expert support to help smokers develop problem-solving and coping skills, secure social support, and design a plan for successful cessation and long-term abstinence.
1658576|NCT01788787|Behavioral|Follow-Up Phone Call|Six months after enrolling in treatment with the Texas Quitline, an MD Anderson research team member will contact patients to assess their smoking status via telephone.
1658577|NCT01788787|Behavioral|Smoking Cessation Training|Medical staff (i.e., medical assistants, licensed vocational nurses, registered nurse and physicians) receive initial face-to-face group training on how to ask patients about their smoking status, advise them to quit, and connect them with the Quitline. The specific content of the session will include information on quitting smoking, how to implement AAC, the effectiveness of telephone counseling for smoking cessation delivered via quitlines, and pharmacotherapies including nicotine replacement.
1658578|NCT01788787|Behavioral|Qualitative Interviews Concerning the Implementation of AAC|MD Anderson staff conduct individual in-depth interviews with administrative leadership as well as those medical staff who are authorized to enter patient information into the EMR and are trained in the Ask-Advise-Connect approach. All in-depth interviews will be recorded and transcribed.
1658579|NCT01788774|Drug|Risperidone ISM 50 mg|
1658580|NCT01788774|Drug|Risperidone ISM 75 mg|
1658581|NCT01788774|Drug|Risperidone ISM 100 mg|
1658582|NCT01788761|Dietary Supplement|Probiotic Supplemented Group|
1658583|NCT01788761|Dietary Supplement|Control Group|
1658584|NCT01788748|Device|bipolar radiofrequency and infrared|
1658585|NCT01788748|Device|fractional bipolar radiofrequency|
1658586|NCT01788722|Drug|Visanne (Dienogest, BAY86-5258)|Patients in daily life clinical practice treatment receiving Visanne (dienogest 2mg) according to indication on the label.
1658587|NCT01788709|Other|preparation cleaning solution|
1658588|NCT01788696|Radiation|Group A - Early Imaging|Total of 3 scans
1658589|NCT01788696|Radiation|Group B - Delayed Imaging|Total of 2 scans
1658590|NCT01788683|Procedure|Regenexx SD|stem cell treatment
1658591|NCT01788683|Other|Exercise Therapy|exercise therapy control
1658592|NCT01788670|Dietary Supplement|Ethanol|
1658593|NCT01788670|Other|Water|
1658594|NCT01788657|Behavioral|Standard internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
1658595|NCT01788657|Behavioral|Condensed internet-based cognitive behavior therapy|Introduction to CBT and depression, Behavioral activation, Cognitive restructuring, Improve sleep, Handeling anxiety, Relapse prevention
2013278|NCT00590122|Drug|Parcopa|at subjects current stable dose of comparator
2013279|NCT00590122|Drug|carbidopa-levodopa|at subjects current stable dose
1658598|NCT01788618|Other|Cognitive exams|"Psychopathological assessment (T0 and T3):
Scale of Spielberger
The self-administered questionnaire CES-D
Cognitive assessment(T0 and T3):
- MMS, Grober and Buschke test, memory for numbers (WAIS IV) sequence of numbers and letters (WAIS IV), arithmetic (WAIS IV), Trail Making Test, verbal Fluence, D2, Code (WAIS IV)
Quality of Life: FACT-G and FACT-An Fatigue Module (T0 and T3):
Self-assessment FACT-COG (T0,every months until T3)"
1658599|NCT01788618|Other|standardized cognitive rehabilitation|Patients will achieve 9 standardized cognitive rehabilitation sessions with the RehaCom ® software (over 3 months), and a self-assessment of their monthly experienced cognitive functioning using the self-administered questionnaire FACT-Cog
1658600|NCT01788618|Other|Standardized home exercise|These patients will take part in 9 sessions standardized home exercise (over 3 months), and a self-assessment every month felt their cognitive functioning using the self-administered questionnaire FACT Cog
1658601|NCT01788618|Other|Follow up by phone|These patients receive follow-up by phone (9 telephone calls over a period of 3 months) standardized optics to know the evolution of the disorder and felt the same way as for the other groups, a monthly self-assessment the feeling of cognitive functioning using the self-administered questionnaire FACT-Cog
1658602|NCT01788605|Drug|ramosetron|
1658603|NCT01788579|Behavioral|Multi-media WINGS|This one-hour computerized multimedia IPV prevention service tool features the same activities as the comparison condition, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance learning and provide individualized feedback. Thus, the multimedia service tool acts as a roadmap for this service session, prompting participants through the IPV screening, providing psycho-educational content on IPV and how IPV may interact with their substance misuse, providing individualized feedback on their IPV risks based on the screening e, creating a safety plan, defining relationship safety goals and identifying IPV-related service needs, and generating a personal plan for accessing services and contacting agency representative.
1658604|NCT01788579|Behavioral|Caseworker Delivered WINGS|The content for the comparison service condition incorporates the core elements of best practices for IPV screening, safety planning and referrals recommended by the American Medical Association and previous service research. It also contains brief psycho-educational content on recognizing IPV and how IPV may contribute to drug use and recidivism drawn from previous interventions and demonstrated to have promising effects in reducing rates of both IPV and drug use.
1658605|NCT01788566|Drug|Necitumumab|Administered IV
1658606|NCT01788566|Drug|Gemcitabine|Administered IV
1658607|NCT01788566|Drug|Cisplatin|Administered IV
2013280|NCT00588770|Biological|Bevacizumab|Given IV
2013281|NCT00588770|Drug|Carboplatin|Given IV
2013282|NCT00588770|Drug|Cisplatin|Given IV
1958093|NCT02000908|Other|Physiotherapy|Chiropractic massage and lymphedema treatment
2013283|NCT00588770|Drug|Docetaxel|Given IV
2013284|NCT00588770|Drug|Fluorouracil|Given IV
2013285|NCT00588770|Other|Laboratory Biomarker Analysis|Correlative studies
2013286|NCT00585195|Drug|PF-02341066|Escalating doses of PF-02341066 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg to 2000 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days (or 21 days depending on the cohort).
1658608|NCT01788540|Drug|Intralipid|IV infusion of intralipid 20% is administrated on the day of vaginal egg collection in a dose of 9 mg/ml total blood volume corresponding to intralipid 2 ml 20% diluted in 250 ml saline over 30-60 minutes.the intralipid infusion is then repeated within the 1st week of positive pregnancy test and every 2 weeks till end of first trimester
1658609|NCT01788527|Device|CGM|Real Time Continuous Glucose Monitoring
1658610|NCT01788514|Other|Videogame|Subject will play an interactive educational videogame that is designed to increase their knowledge on influenza and the influenza vaccination.
1658611|NCT01788501|Drug|Tacrolimus|D-1~D20: iv infusion, q24hr (first daily dose: 0.03mg/kg) D20~D100: po q12hr (first daily dose: the quadruple of last iv dose) Dose modification according to TDM (10-20ng/ml)
1658612|NCT01788501|Drug|Cyclosporine|D-1~D20: iv infusion, q24hr (first daily dose: 3mg/kg) D20~D100: po q12hr (first daily dose: the 3 times of last iv dose) Dose modification according to TDM (200-300ng/ml)
1658613|NCT01788501|Drug|Methotrexate|D1: 15mg/m2 iv push D3,6,(11): 10mg/m2 iv push
1658614|NCT01788488|Other|Use of procalcitonin as biomarker to guide therapy|
1658615|NCT01788475|Drug|Dexamethasone|Ozurdex 0.7mg steroid implant
1658616|NCT01788462|Drug|Tesamorelin (Egrifta)|We will observe the effects of Tesamorelin on patients with HIV and lipodystrophy.
1658617|NCT01788436|Behavioral|Cognitive Test Battery 1|The Cognitive Test Battery 1 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Pattern/Sequence Learning Task (PLT_Impl); Verbal Learning Test (VLT); Figure drawing; Mirror Drawing; Explicit Pattern Learning Task (PLT_Expl); Delayed Recall and Recognition Test; and Pursuit rotor.
1658618|NCT01788436|Behavioral|Cognitive Test Battery 2|The Cognitive Test Battery 2 comprises the following tasks: Practice with graphics tablet, pen and screen; Digit Symbol Substitution Test (DSST); Implicit Learning Retention Test; Hopkins Verbal Learning Test (HVLT); Figure drawing; Mirror Drawing; Explicit Learning Retention Test; Instrumental Learning Task; Pursuit rotor; and Sensory Motor Interception Adaptation Task.
1658619|NCT01788423|Device|hearing aid|All subjects received hearing aids, some selected by audiologist, some selected by consumer, and some programmed as placebo devices.
1658622|NCT01788397|Behavioral|Physical activity|Swimming, physiotherapy, water therapy, alpine skiing, xc-skiing, hippotherapy, climbing, cycling, rowing
1658623|NCT01788384|Drug|Clindamycin Phosphate / Benzoyl Peroxide Gel|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
1658624|NCT01788384|Drug|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
1658625|NCT01788384|Drug|Placebo (Vehicle Gel)|Dosage form: topical gel Dosage: One pea-sized amount will be applied onto six areas of the face (chin, left cheek, right cheek, nose, left forehead, right forehead), avoiding the eyes, lips and mucous membranes.
1658626|NCT01788371|Drug|Telbivudine|About 300 mothers with no treatment observedfrom 28 weeks of pregnancy to the week 4 of postpartun
1658627|NCT01788371|Drug|Lamivudine|About 300 mothers treated with lamivudine or telbivudine from 28 weeks of pregancy to the week 4 of postpartum
2013287|NCT00585195|Drug|Rifampin|600 mg QD administered from Cycle 1, Day 16 to Cycle 2, Day 1 (14 days of dosing) in combination with PF-02341066.
2013288|NCT00585195|Drug|Itraconazole|Multiple Dose Design: 200 mg QD administered from Cycle 1, Day 1 to Cycle 1, Day 16 (16 days) in combination with PF-02341066.
2013289|NCT00581529|Radiation|IMRT|Patients on protocol will be treated with accelerated radiotherapy, 3.85 Gy per fraction, bid, for 5 consecutive days for a total dose of 38.5 Gy.
2013290|NCT00581256|Radiation|IMRT|All patients treated with the optimized plan will be treated to the entire target volume to 52.2 Gy in 1.74 Gy fractions, which is biologically equivalent to 50 Gy in 2 Gy fractions. This fractionation scheme will allow the boost of 10 Gy to be incorporated into the planning directive and to be delivered simultaneously with the treatment to the remaining target volume.
1658632|NCT01788345|Other|non- invasive ventilation|non-invasive bi-level ventilation with IPAP and EPAP.
1658633|NCT01788332|Drug|Olaparib|Olaparib is a potent inhibitor of poly (ADP-ribose) polymerase enzyme (PARP), (molecular weight 434) that is being developed as a monotherapy as well as for combination with chemotherapy and other anti-cancer agents. Olaparib can lead to tumour regression in patients with DNA repair deficient NSCLC. Olaparib may also enhance the DNA damaging effects of chemotherapy.
1658634|NCT01788319|Procedure|lasertrabeculoplasty|
1658635|NCT01788306|Drug|OOPEN+BBCC|Take-home naloxone is offered as part of a behavioral prevention intervention to reduce the occurrence of future opioid overdose.
1658636|NCT01788293|Other|Intervention group|"Control group will receive per-operative fluid at the discretion of the anesthetist, whereas Intervention group will receive additional hydroxyethylstarch 6% (HES) bolus in order to minimize and maintain PVI below 14 %.
This PVI cut-off value was chosen according to previous reports [Cannesson et al., 2008; Zimmermann et al., 2010].
During the postoperative period, both groups were managed by intensivists (in the ICU) and clinicians (in the wards) not involved in the intraoperative management or in data collection. These individuals were not informed of patient allocation."
1658637|NCT01788280|Drug|Fluciclitite , PET imaging, and Bevacizumab|[18F] Fluciclatide and PET imaging in patients with glioblastoma multiforme (GBM) to be treated with Bevacizumab
1658638|NCT01788267|Other|scan examination HR-pQCT|
1658639|NCT01788254|Drug|Codeine|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
1658640|NCT01788254|Drug|Midazolam|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
1658641|NCT01788254|Drug|pravastatin|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
1658642|NCT01788254|Drug|Talinolol|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
1658643|NCT01788254|Drug|torsemide|A single oral low dose of codeine 5 mg and midazolam 1 mg administered as drop, pravastatin 5 mg, talinolol 2.5 mg, and torsemide 0.25 mg provided in capsules will be given together at the same time point (cocktail).
1658644|NCT01788228|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|2 doses administered intramuscularly (IM) in deltoid region of arm at the Day 0 and Day 21 visits.
1658645|NCT01788215|Drug|doxycycline|200mg/day in divided doses of 100mg twice daily
1658646|NCT01788215|Other|Sugar Pill|1 pill twice a day
1658647|NCT01788189|Drug|Lenalidomide|
1658648|NCT01788176|Drug|Zoledronic acid|One single dose of 5mg intravenous infusion of zoledronic acid (interventional group)
1658649|NCT01788176|Drug|Placebo|one single intravenous infusion of 100ml of saline.
1658650|NCT01788163|Genetic|EGFR mutation test|EGFR mutation being tested in tissue and blood
1658651|NCT01788150|Device|Coronary Stenting|
1658652|NCT01788137|Drug|chemotherapy (CHOP)|Treatment Arm A (CHOP): cyclophosphamide(C), 750mg/m2 for injection on day1; doxorubicin(H), 50 mg/m 2 for injection on day1; and Vincristine(O), 1.4 mg/ m2 for injection on day1, prednisone(P) 60 mg/m2 orally on days 1 to 5. The therapy was repeated every 21 days for a total of 6 cycles
1658653|NCT01788137|Drug|chemotherapy(c-ATT)|Treatment Arm B (c-ATT):Alternative 3 regimen to be used sequentially(CHOPB→IMVP-16→DHAP).The therapy was repeated every 21 days for a total of 6 cycles.
1658656|NCT01788085|Device|Bravo pH monitoring procedure|Bravo pH monitoring procedure
1658657|NCT01788072|Drug|Intranasal Oxytocin|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
1658658|NCT01788072|Drug|Placebo|24 IU taken twice daily (BID), in the morning and at noon/early afternoon
1658660|NCT01788046|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at weeks 5, 9, 13, and 17 (4-week intervals) by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
1658661|NCT01788046|Drug|Placebo|Administered intravenously (IV) three times per week.
1658662|NCT01788033|Drug|XOMA 052|0.3 mg/kg XOMA 052. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
1658663|NCT01788033|Drug|Placebo|0.3 mg/kg Placebo. Beginning on Day 0, each subject will receive one subcutaneous (SC) injection of study drug every 4 weeks for 12 weeks, a total of four injections
1658664|NCT01788020|Drug|Dexamethasone, Rituximab, Cyclophosphamide|
1658665|NCT01788020|Drug|Dexamethasone, Rituximab, Cyclophosphamide, Bortezomib|
1658666|NCT01788007|Drug|Imiquimod Topical Cream 3.75%|Imiquimod Topical Cream 3.75% (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
1658667|NCT01788007|Drug|Zyclara® (imiquimod) Topical Cream 3.75%|Zyclara® (imiquimod) Topical Cream 3.75% (Medicis Pharmaceutical Co.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
1658668|NCT01788007|Drug|Vehicle Topical Cream|Vehicle Topical Cream (Taro Pharmaceutical Industries Ltd.) applied once daily for two 14 day treatment cycles separated by a 14 day no treatment period.
1658669|NCT01787994|Genetic|Autologous CD4+ T cells genetically modified with a retroviral vector expressing the MazF endoribonuclease gene (MazF‐T), given via intravenous infusion.|
1658670|NCT01787955|Procedure|PPPD with Braun anastomosis|making communication between E-loop and A-loop (Braun anastomosis 30cm away from duodenojejunostomy, by using staple method) will be added to conventional PPPD.
1658671|NCT01787955|Procedure|conventional PPPD|
1658672|NCT01787942|Device|Tear Science LipiView|The LipiView is a non-invasive instrument that captures live, special and digital images of your tear film and measures its lipid content and quality. This is a standardized test that quantifies your lipid to help your eye doctor determine if you should undergo the LipiFlow procedure or other tear therapies that would treat your condition. In effect, the LipiView allows your eye doctor to visualize your tear films.
1658673|NCT01787929|Procedure|hemiarthroplasty for displaced femoral neck fractures|Hemiarthroplasty is a surgery for displaced femoral neck fractures
1658675|NCT01787903|Device|Real-time continuous glucose monitor|Active Comparator: MiniMed Paradigm® Veo™-system Placebo Comparator: iPro™2 Continuous Glucose Monitor (masked)
1658676|NCT01787851|Drug|Triheptanoin oil|
1658677|NCT01787838|Other|Focused Health Education|"A two-phase quality improvement study was designed to modify staff and patient behaviors. The project incorporated evidence-based strategies of staff education, feedback and incentives for performance and patient education.
The staff received monthly feedback on departmental immunization rates, and incentives for performance. A one-page patient education flyer, written at 3rd grade reading level, was added to encourage patients to inquire about it."
1658678|NCT01787825|Device|PillCam SB2 capsule|Capsule Endoscopy system
1658679|NCT01787825|Device|CapsoCam SV-1|Capsule endoscopy
1658680|NCT01787799|Device|SYNERGY|Synergy is a device/drug combination product composed of two components, a device (coronary stent system including a chromium stent platform) and a drug product (a formulation of everolimus contained in a bioabsorbable polymer coating.
1658681|NCT01787773|Device|Veniti Inferior Vena Cava Filter|
1658682|NCT01787760|Device|Test Soft Contact Lens B|Test lenses to be worn in daily wear modality
1658683|NCT01787760|Device|Test Soft Contact Lens C|Test lenses to be worn in a daily wear modality
1658684|NCT01787760|Device|Active Comparator|Control spectacle lenses to be worn in a daily wear modality
1658685|NCT01787747|Drug|AVP-786 Dose 1|
1658686|NCT01787747|Drug|AVP-786 Dose 2|
1658687|NCT01787747|Drug|AVP-786 Dose 1/Q Dose 1|
1658694|NCT01787695|Procedure|UVA1|"Patients with a vitiligo patch larger than 25cm2 will be recruited. The target patch will be divided into two halves. One half will be shielded by foil and served as control while the other half will be exposed to UVA1.
The dose of UVA1 will be 60 J/cm2, 5 times a week for 4 weeks. Patients that have no or less than 10% pigmentation change after 4 weeks will receive UVA1 130J/cm2, 5 times a week for another 4 weeks. The patients with more than 10% pigmentation change will receive UVA1 60 J/cm2, 5times a week for another 4weeks. This will be followed by assessments at 4, 8, and 12 weeks post treatment."
1658695|NCT01787682|Dietary Supplement|BOOST High Protein|
1658696|NCT01787669|Drug|Avastin (Bevacizumab)|Avastin (Bevacizumab) administered intravitreally
1658697|NCT01787669|Drug|Ozurdex (dexamethasone)|Ozurdex (dexamethasone) given intravitreally
1658698|NCT01787643|Other|Height-Adjustable Desk Intallation in Office|
1658699|NCT01787630|Device|Hyaluronic acid|Injection in connection with ultrasound
1658700|NCT01787617|Behavioral|Aerobic Plus Resistance Training Group|Participants randomized to this intervention will engage in both aerobic and resistance training in accordance with Physical Activity Guidelines for Americans, that is 150 minutes of aerobic training and 2 days of additional 20 minutes of resistance training. The aerobic training component will be completed on a treadmill and target training intensity will be self-selected at 65% to 85% of maximal aerobic capacity. Each resistance training session will consist of both upper and lower body exercises: 2 sets of 9 exercises with each set consisting of 10 repetitions.
1658701|NCT01787617|Behavioral|Control Group|Participants randomized into the control group will not be provided with memberships to any exercise facility, nor will they receive behavioral instruction on how to increase physical activity. They will receive information on living a healthy lifestyle. Such minimal interventions have not been shown to increase physical activity in participants. The participants in this group will undergo the baseline, 10 week, and 20 week testing.
1658704|NCT01787591|Other|Fat-Free Milk|Fat-free milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
1658705|NCT01787591|Other|Low-Fat Milk|Low-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
1658706|NCT01787591|Other|Full-Fat Milk|Full-fat milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
1658707|NCT01787591|Other|Soy Milk|Soy milk ingestion with 15 mg deuterium-labeled alpha-tocopherol.
1658708|NCT01787578|Drug|Sobetirome|50 mcg or 100 mcg once-daily oral
1658709|NCT01787565|Other|painPREMIER cohort|Low back pain patients prospectively recruited during the study period and managed with painPREMIER.
1658710|NCT01787565|Other|Control cohort|A matched group of low back pain patients not managed with painPREMIER.
1658711|NCT01787552|Drug|LDE225|
1658712|NCT01787552|Drug|INC424|
1658713|NCT01787539|Drug|Postoperative Chemotherapy|"Postoperative chemotherapy with EOX regimen: Epirubicin with intravenous bolus at a dose of 50 mg/m2 an on day 1; Oxaliplatin with intravenous infusion during a 2-hour period at a dose of 130 mg/m2; Capecitabine administrated orally at a twice daily dose of 625 mg /m2 during 21 days. Treatment cycles will be repeated every 3 weeks.
Postoperative chemotherapy will be administrated in patients with tumor regression grade 0, 1, 2 randomized to perioperative chemotherapy and will be initiated 6 to 12 weeks after surgery."
1658714|NCT01787526|Drug|ferric carboxymaltose|1 g intravenously per infusion
1658715|NCT01787526|Drug|oral iron|oral tablets of 100mg iron over 8 weeks, total dose 10g
1658716|NCT01787513|Other|CBM|CBM is an Internet-based intervention comprised of delivery of auditory scenarios taking place over 1 week.
1658717|NCT01787513|Other|iCBT|iCBT is a validated online CBT treatment program for depression delivered in 6 lessons over 10 weeks.
1658718|NCT01787500|Drug|Vemurafenib|"Phase I Dose Escalation: All groups treated. Starting dose of Vemurafenib 480 mg by mouth twice daily of a 14 Day cycle.
Dose Expansion Groups: . Starting dose of Vemurafenib is maximum tolerated dose from Dose Escalation Group."
1658719|NCT01787500|Drug|Cetuximab|Phase I Dose Escalation Group and Dose Expansion Groups: 500 mg/m2 by vein every 2 weeks on Day 1 of each 14 Day cycle.
1658720|NCT01787500|Drug|Irinotecan|Phase I Dose Escalation Group and Dose Expansion Groups: 180 mg/m2 by vein every 2 weeks on Day 1 of each 14 Day cycle.
1658721|NCT01787487|Drug|Ruxolitinib (RUX)|"Four weeks (28 days) on therapy is considered one standard cycle of therapy. RUX will be given orally and AZA will be administered subcutaneously (SC) in an outpatient setting
AZA will be given on days 1-5 of each 28 day cycle beginning with cycle 4. We propose to initially administer RUX alone at a dose of 5 mg orally twice daily (BID) if the baseline platelet count is 50-100 x 109/L, 15 mg twice daily if the baseline platelet count is 100 - 200 109/L, or at a dose of 20 mg twice daily if the baseline platelet count is > 200 x 109/L. Patients will receive RUX alone for cycles # 1, 2 and 3."
1658722|NCT01787487|Drug|Azacitidine (AZA)|Four weeks (28 days) on therapy is considered one standard cycle of therapy. RUX will be given orally and AZA will be administered subcutaneously (SC) in an outpatient setting AZA at 25 mg/sq.m. starting on cycle # 4. If well tolerated, the AZA dose may be further increased to 50 mg/sq.m. after 2 cycles (i.e., concomitantly with cycle # 6).
1658723|NCT01787487|Behavioral|Questionnaires|Completion of 2 questionnaires at baseline, Day 1 of Cycles 1 - 7, then every 3 cycles. It should take about 15 minutes total to complete the questionnaires.
1658724|NCT01787474|Drug|G-CSF|G-CSF daily by vein starting on Day -7 until post nadir of absolute neutrophil counts (ANC) are equal or over 1000.
1658725|NCT01787474|Drug|Fludarabine monophosphate|30 mg/m2 by vein on Days -6, -5, -4, -3, and -2.
1658726|NCT01787474|Drug|Cytarabine|2 g/m^2 by vein on Days -6, -5, -4, -3, and -2.
1658727|NCT01787474|Procedure|Natural Killer (NK) Cell Infusion|NK Cell infusion on Days 0 to 14 for 6 doses total according to dose escalation schema.
1658728|NCT01787461|Dietary Supplement|Imedeen|Two tablets per day for 6 months
1658729|NCT01787461|Dietary Supplement|Placebo|Two tablets per day for 6 months
1658730|NCT01787448|Drug|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
1658731|NCT01787448|Drug|Topical gel vehicle|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
1658732|NCT01787448|Drug|Sodium lauryl sulfate 0.1%|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
1658733|NCT01787448|Drug|Sodium chloride solution 0.9% (saline)|0.2 ml applied every 2 days (or 3 days if over the weekend) over 22 days (9 applications) followed by 10-14 day rest period and one subsequent re-application
1658734|NCT01787435|Drug|Risk of asthma in offspring|"Exposure to PPI or H2RA, respectively during pregnancy
No exposure to acid suppressing drugs during pregnancy"
1658735|NCT01787422|Other|Traditional versus Telemedicine office visit|
1658736|NCT01787409|Dietary Supplement|Cholecalciferol|Given PO
1658737|NCT01787409|Other|Laboratory Biomarker Analysis|Correlative studies
1658738|NCT01787396|Drug|Gemigliptin 50mg|
1658739|NCT01787396|Drug|Placebo(Metformin)|
1658740|NCT01787396|Drug|Metformin|
1658741|NCT01787396|Drug|Placebo(Gemigliptin)|
1658742|NCT01787383|Drug|Ingenol mebutate gel 0.05 %|Ingenol mebutate gel 0.05 % (Picato®) on trunk/extremities either applied simultaneously or sequentially
1658743|NCT01787383|Drug|Ingenol mebutate gel 0.015 %|Ingenol mebutate gel 0.015 % (Picato®) on face/scalp either applied simultaneously or sequentially
1658744|NCT01787357|Drug|Canagliflozin (JNJ-28431754)|One 300 mg dose of canagliflozin (JNJ-28431754) (comprising one 100 mg over-encapsulated tablet and one 200 mg over-encapsulated tablet) taken orally (by mouth) on Day 1 of Treatment A. One 1,200 mg dose of canagliflozin (comprising six 200 mg over-encapsulated tablets) taken orally on Day 1 of Treatment B.
1658745|NCT01787357|Drug|Placebo|Four over-encapsulated matching placebo tablets taken orally (by mouth) on Day 1 of Treatment A. Six over-encapsulated matching placebo tablets taken orally on Day 1 of Treatment C. Five encapsulated matching placebo tablets taken orally on Day 1 of Treatment D.
1658746|NCT01787357|Drug|Moxifloxacin|One 400 mg over-encapsulated tablet of moxifloxacin taken orally (by mouth) on Day 1 of Treatment D.
1658747|NCT01787344|Drug|Botulinum Toxin Type A(Botox®)|Single administration, 4units/kg body weight dose in patients with hemiplegia, 6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
1658748|NCT01787344|Drug|Botulinum toxin type A(Botulax®)|Single administration, 4units/kg body weight dose in patients with hemiplegia,6units/kg body weight dose in patients with diplegia, Maximum dosage 200units
1658749|NCT01787331|Drug|Itraconazole|Itraconazole is available as pink and blue capsules. Itraconazole should be taken with meals or within 30 minutes after a meal.
1658750|NCT01787318|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
1658751|NCT01787318|Device|InsuPatch|device which applies local heating at 40 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site
1658752|NCT01787292|Behavioral|Coordination training|finger movement coordination training using sequenced finger movements of varying pressure.
1658753|NCT01787292|Behavioral|Short Term exercise - supervised|Supervised weekly exercise. 3 bouts of 45 minutes weekly on a cycle ergometer. HR will be kept at 75% of age-related maximum.
1658754|NCT01787292|Behavioral|Long Term Exercise|6 month self-monitored training phase during which time participants will exercise according to prescribed regimen (cycling)
1658755|NCT01787279|Drug|Peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly, 48 weeks
1658756|NCT01787240|Drug|Escitalopram 10mg|
1658757|NCT01787240|Drug|Placebo|
1658758|NCT01787227|Device|xTAG RPP|
1658759|NCT01787214|Dietary Supplement|Full dose|20% of daily energy needs supplied by walnuts
1658760|NCT01787214|Dietary Supplement|Half dose|10% of daily energy needs supplied by walnuts
1658761|NCT01787214|Dietary Supplement|Control|Walnut free meals
1658762|NCT01787188|Drug|Meloxicam Test Capsules|
1658763|NCT01787188|Drug|Meloxicam Test Capsules|
1658764|NCT01787188|Drug|Placebo Capsules|
1658765|NCT01787175|Other|Integrated Medication Manager|A theory based electronic health record. Half of the provider participants were assigned the IMM to use. The other half were assigned the VA's CPRS EHR to use for the simulation. Providers were randomly assigned to a EHR to use.
1658766|NCT01787162|Other|Echocardiography, spiroergometry, cardiac catheterization|patients with CMPD will undergo echocardiography, spiroergometry, and right heart catheterization, if indicated
1658767|NCT01787149|Drug|DMARDs|
1658768|NCT01787136|Drug|Dextromethorphan|added on therapy
1658769|NCT01787123|Drug|Intravenous Cerebrolysin|14-day course of intravenous Cerebrolysin started within 4 days of ictus
1658770|NCT01787110|Drug|Oxygen|see arm description
1658772|NCT01787084|Device|Edwards SAPIEN Transcatheter Heart Valve|Non-femoral transcatheter delivery of heart valve
1658773|NCT01787071|Other|Fluid challenge|Administration of red blood cell transfusions or fresh frozen plasma is not considered as a fluid challenge.
1658774|NCT01787058|Other|Dubai Cares beneficiary|Installation or rehabilitation of school water points, latrines and hygiene kits; promotion of good WASH practices and behavior change at school and within the community; establishment of management systems to ensure sustained WASH financing, monitoring and maintenance.
1658775|NCT01787045|Other|Early and Active Physical Therapy|"Cycle-ergometer exercise will be performed in the more active manner tolerated by patient. Potency attained will be registered during 30 min of exercise.
Our physiotherapy protocol includes also others exercises like ambulation with assistance, cycle-ergometer for arms and legs, etc."
1658776|NCT01787045|Other|Passive Range of Motion|Passive mobilization will be performed in all limbs as 10 repetitions of every range of motions. Extension position will be maintained for some seconds to attaint muscular elongation in every muscular group.
1658777|NCT01787032|Drug|BI 113608|tablet
1658778|NCT01787032|Drug|BI 113608|tablet
1658779|NCT01787032|Drug|BI 113608|tablet
1658780|NCT01787032|Drug|Ketoconazole|tablet
1658781|NCT01787032|Drug|Voriconazole|tablet
1658782|NCT01787019|Other|Oral feeding|
1658819|NCT01786733|Behavioral|Supportive Therapy|
1658783|NCT01787006|Drug|Cetuximab|Initial doses 400mg/m2 (day 1), followed by weekly doses of 250mg/m2 for 14 weeks in total
1658784|NCT01787006|Drug|Cisplatin, 5-FU|"5-FU: 1000mg/m2 per day as continuous infusion on day 1-4 of cycle 1 and 2, 750mg/m2/day as continuous infusion on day 1-4 of cycle 3 and 4
Cisplatin 20mg/m2/day as intravenous bolus over 60 min on day 1-4 of every cycle"
1658785|NCT01787006|Radiation|Radiotherapy|59.4 Gy (33 fractions of 1.8 Gy) over 6.5-7 weeks (5 x 1.8 Gy per week)on primary tumor. 50.4 Gy on locoregional lymphnodes. If resectability is reached after 4-4.5 weeks (36-41.4 Gy) the radiotherapy stops after 45 Gy and the patient undergoes surgery.
1658786|NCT01786993|Device|MultiPoint Pacing|Subjects are programmed to MPP between 3 and 9 months. MPP programming is stipulated by the Echocardiographic measurements (e.g. EA VTI) during an acute hemodynamic assessment at the 3-month visit in the MPP IDE study.
1658787|NCT01786993|Device|Traditional Biventricular Pacing|Subjects are programmed to Quadripolar BiV pacing between 3 and 9 months using any of the 10 vectors available.
1658788|NCT01786967|Drug|Fesoterodine Fumarate|FDA approved anticholinergic medication used for treatment of urge urinary incontinence
1658789|NCT01786954|Device|Icare rebound tonometry|
1658790|NCT01786954|Device|Tonopen applanation|
1658791|NCT01786954|Device|Goldmann applanation|
1658792|NCT01786941|Other|Pre-Diabetes Group - 6-mo Aerobic and Resistance combined exercise training|
1658793|NCT01786941|Other|GBP Group - Non-diabetics intending to undergo Gastric Bypass surgery|
1658794|NCT01786928|Other|Resistance training|Resistance training group received training program for upper (shoulder flexion and abduction and biceps) and lower limbs (knee extension and flexion and hip flexion). Daily exercise for every muscle was performed with free weights at 80% of an maximal repetition test and a 4 minutes rest was allowed between each step.
1658795|NCT01786915|Drug|Bendavia 10mg|
1658796|NCT01786915|Drug|Bendavia 50mg|
1658797|NCT01786915|Drug|Placebo|
1658799|NCT01786889|Biological|blood and urine|Blood collection and urine collection after consent of the patient
1658800|NCT01786889|Behavioral|Questionnaire|The patient complete the questionnaire alone at home
1658801|NCT01786889|Behavioral|Telephone interview|The patient will be contacted by the CRA for a telephone interview of around one hour
1658802|NCT01786876|Drug|Radiolabeled SPD557|A single oral dose of 2 mg radiolabeled SPD557 administered on Day 1
1658803|NCT01786863|Procedure|Neuromuscular blockade|
1658804|NCT01786850|Procedure|Magnetic Resonance-guided High-intensity Focused Ultrasound (MRgFUS)|High intensity focused ultrasound (HIFU) is a non-invasive ablation technique under ultrasound (US) guidance for the treatment of solid tumors. Differently from other ablations, HIFU induces tissue necrosis through short (10-30s) and relatively low grade (60-80 C°) thermal stimulations. Clinical applications of HIFU include uterine fibroids, prostate, hepatic and breast cancer. Selected patients with pancreatic cancer have been treated with US-guided HIFU for both pain control and tumor debulking. The development of a MR guidance for HIFU (MRgFUS) enabled to perform real-time monitoring and precise control of beam direction, temperature changes and deposited thermal dose beyond the capability of conventional US guidance. This system has been approved for the treatment of uterine fibroids and bone metastases in the United States and European Union. As compared to conventional US-guided HIFU, MRgFUS could represent a more accurate ablation modality for unresectable pancreatic cancer.
1658805|NCT01786837|Device|Functional Magnetic Stimulation|20 minute stimulation will be applied 5 days a week for 5 weeks
1658806|NCT01786824|Drug|Hydration strategy using saline|For 12 hours preceding the coronarography, and for 12 following the coronarography, 0.9% sodium chloride at 1 ml/kg/h is administered via a slow intravenous perfusion.
1658807|NCT01786824|Drug|Hydration strategy using sodium bicarbonate|For 4-6 hours before the coronarography and for 4-6 hours after the coronarography, 500 ml of isotonic sodium bicarbonate solution (1.4%) will be administered via a slow intravenous solution.
1658808|NCT01786824|Drug|L-carnitine|"Before the coronarography (D-1), 1 gram of L-carnitine is administered via an oral solution that can be diluted in a small amount of sugar water if necessary. This administration corresponds to the beginning of a hydration protocol.
For days 0 to 7 after the coronarography, patients are administered an oral L-carnitine solution (3 grams of L-carnitine per day). The latter may be diluted in a small amount of sugar water if needed."
1658809|NCT01786824|Procedure|Coronarography|All patients included in this study are programmed for a coronarography with injection of contrast material (either iodixanol or ioxaglate). The day of coronarography = Day 0.
1658810|NCT01786811|Behavioral|Training|"Initial Training: The training program for clinicians randomized into the intervention arm will be 2.5 hours. The project will be introduced and the Serious Illness Conversation Guide shared. The training session will include a brief didactic session on Challenges in discussing advance care planning/values and goals followed by practice using the SICG.
Coaching and Feedback: We will also provide individual coaching for clinicians. Clinicians will be able to contact the study doctor to request coaching/debriefing on a challenging case; one of the investigators will respond within 24-48 hours for urgent or distressing cases (up to 72 hours on weekends). In-the-moment coaching will be by telephone or in person."
1658811|NCT01786798|Device|Transvaginal sonography|"Transvaginal sonography will be performed to:
measure the endometrial thickness
detect the endometrial pattern"
1658812|NCT01786772|Other|Cryotherapy and compression|Cryotherapy and intermittent pneumatic compression will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. Circumferential intermittent pneumatic compression to the knee joint (5 to 50 mm Hg) will be applied in conjunction with cryotherapy. The duration of intervention will be 20 minutes.
1658813|NCT01786772|Other|Cryotherapy|Cryotherapy will be applied to the knee joint using a recirculating compression unit and knee sleeve. This unit will recirculate water which is between 1-3° C. The duration of intervention will be 20 minutes.
1658814|NCT01786759|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
1658815|NCT01786759|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
1658816|NCT01786746|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy. 12 sessions.
1658817|NCT01786746|Behavioral|culturally adapted cognitive behavioral therapy|culturally adapted cognitive behavioral therapy for Chinese Americans. 12 sessions.
1658818|NCT01786733|Behavioral|Behavioral Activation|
1658820|NCT01786707|Biological|Autologous stem cells|Pancreatic artery infusion of Autologous Stem cells.
1658821|NCT01786707|Other|Hyperbaric oxygen therapy|
1658822|NCT01786707|Drug|Insulin|Insulin dose as per clinical management
1658823|NCT01786707|Drug|Metformin|Metformin dose as tolerated
1658824|NCT01786694|Device|cma microdialysis catheter placement|the microdialysis catheters are sold by CMA
1658825|NCT01786681|Procedure|Positive pressure|
1658826|NCT01786668|Drug|Tofacitinib 2 mg|4 blinded tablets (two 1 mg tablets of tofacitinib along with two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
1658827|NCT01786668|Drug|Tofacitinib 5 mg|4 blinded tablets (one 5 mg tablet of tofacitinib, one 5 mg and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
1658828|NCT01786668|Drug|Tofacitinib 10 mg|4 blinded tablets (two 5 mg tablets of tofacitinib and two 1 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
1658829|NCT01786668|Drug|Placebo|4 blinded tablets (two 1 mg and two 5 mg matching placebo tablets) will be administered orally twice a day (in the AM and PM) for 12 weeks
1658830|NCT01786655|Drug|Neosaxitoxin in saline|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% alone on one side (control). On the other side they receive NeoSTX in saline (test). Subjects receive NeoSTX in saline in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
1658831|NCT01786655|Drug|NeoSTX + bupivacaine 0.2%|NeoSTX will be administered in sequential dose cohorts. Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX with 0.2% bupivacaine. Subjects receive NeoSTX in 0.2% bupivacaine in subsequent dose escalation levels: 5 mcg, 10 mcg, 15 mcg, 20 mcg, 30 mcg, and 40 mcg of NeoSTX.
1658832|NCT01786655|Drug|NeoSTX + bupivacaine 0.2% + epinephrine 5mcg/ml|Each subject receives one injection with bupivacaine 0.2% on one side (control). On the other side they receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml. Subjects receive NeoSTX in 0.2% bupivacaine with epinephrine 5 mcg/ml in doses of 10 mcg or 30 mcg of NeoSTX.
1658833|NCT01786655|Other|Saline placebo|Each subject receives one injection with bupivacaine 0.2% alone on one side. On the other side they receive saline placebo.
1658834|NCT01786629|Drug|SUPREP Bowel Prep Kit|solution for oral administration prior to colonoscopy
1658835|NCT01786629|Drug|FDA approved bowel preparation containing electrolytes|solution for oral administration prior to colonoscopy
1658836|NCT01786616|Drug|Formoterol|
1658837|NCT01786603|Drug|Rasagiline|Rasagiline 2mg once a day for 12 months.
1658838|NCT01786603|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
1658839|NCT01786590|Procedure|EBUS-TBNA|Currently EBUS-TBNA is performed in patients with CT and/or PET positive lymph nodes in the mediastinum or hilum. In this study, all patients being considered for SBRT will undergo EBUS-TBNA for the lymph node staging prior to SBRT.
1658842|NCT01786551|Drug|Eplerenone|50 mg daily for 14 days
1658843|NCT01786538|Drug|Regorafenib/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Regorafenib will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
1658844|NCT01786538|Drug|Placebo/FOLFOX|FOLFOX consisted of oxaliplatin 85 mg/m2 on D1, leucovorin 400 mg/m2 on D1, 5-fluorouracil 400 mg/m2 intravenous bolus on D1 and 5-fluorouracil 1200 mg/m2/day continuous infusion on D1-2 (2400 mg/m2 for 46 hours). Placebo will be administered 160 mg/day given orally on D4-10 (7 days per each cycle of FOLFOX). Treatment will be repeated every 2 weeks and continued until disease progression, unacceptable toxicity or the patient's refusal.
1658845|NCT01786525|Behavioral|House Calls|60-minute home based educational intervention which will be administered by a health educator
1658846|NCT01786525|Behavioral|Web-Based Patient-Centered Decision Support Intervention|Patients will be provided with access to the study website which will allow them to learn and receive LDKT support in a way the best meets their personal values and preferences
1658847|NCT01786512|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil dose of 25-mg BID for 7 days
1658848|NCT01786512|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecardbil dose of 50-mg BID for 7 days.
1658849|NCT01786512|Drug|Placebo|Placebo
1658850|NCT01786512|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil dose of 25-mg BID for 20 weeks.
1658851|NCT01786512|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil dose of 25 mg BID for 8 weeks followed by 50-mg BID for 12 weeks
1658852|NCT01786499|Behavioral|Relaxation Response Training|
1658853|NCT01786486|Device|Amplatzer Cardiac Plug|
1658854|NCT01786473|Drug|Testogel 1%|
1658855|NCT01786473|Drug|Placebo|
1658856|NCT01786460|Other|Blood draw at Days 0, 7, 14, and 21|
1658857|NCT01786434|Drug|Routine medication arm|50 micrograms of fentanyl given before the procedure
1658858|NCT01786434|Drug|Fentanyl on-demand arm|Fentanyl 50 microgram is provided on-demand, that is, if the patient has pain during the procedure.
1658859|NCT01786408|Device|TAP20-C|
1658860|NCT01786408|Device|SAFE-T-FILL CAPILLARY BLOOD COLLECTION SYSTEM|
1658861|NCT01786395|Drug|UF-021|
1658862|NCT01786395|Drug|Placebo|
1658863|NCT01786382|Drug|PPI-668|
1658864|NCT01786382|Drug|Midazolam|
1658865|NCT01786382|Drug|Omeprazole|
1658866|NCT01786382|Drug|Telaprevir|
1658867|NCT01786356|Device|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
1658868|NCT01786356|Other|B&L MI60|same-day bilateral cataract surgery with implantation of intraocular lens B&L MI60 in one eye
1658869|NCT01786343|Drug|Decitabine|20 mg/m2 by vein daily for either 5 or 10 days.
1658870|NCT01786330|Device|Procare abdominal binder|
1658872|NCT01786317|Device|High resolution manometry|Anorectal High resoltion manometry using electronic sensors
1658873|NCT01786304|Procedure|Sacral nerve stimulation|implantation of a stimulation electrode in one of the S2-S3-S4 sacral hole then connected to a subcutaneous stimulator for permanent stimulation of the sacral nerve
1658874|NCT01786278|Radiation|Brachytherapy|Single dose of 12 Gy generated using a flexible applicator containing Iridium 192 with the range of irradiation of 1cm from the applicator axis. The extent of irradiation will cover the whole length of cancer stricture and 2cm beyond proximal and distal end of the tumor.
1658875|NCT01786278|Procedure|Endoscopic stenting|Endoscopic stenting with partially covered selfexpandable metalic stents positioned across the cancer stricture and extending 2cm proximally and 2cm distally to the proximal and distal end of the tumor, respectively
1658876|NCT01786265|Drug|Lupron|7.5 mg by injection monthly, or 30 mg every 4 months at discretion of physician.
1658877|NCT01786265|Drug|Zoladex|3.6 mg by injection monthly at discretion of physician.
1658878|NCT01786265|Drug|Degarelix|120 mg twice and then 80 mg monthly by injection at discretion of physician.
1658879|NCT01786265|Drug|Abiraterone Acetate|4 tablets (250 mg each) by mouth each day.
1658880|NCT01786265|Drug|Prednisone|5 mg by mouth daily.
1658881|NCT01786252|Drug|human chorionic gonadotropin (hCG)|"500IU of hCG diluted to a final volume of 50ul in IVF media (Global-trademark)"
1658882|NCT01786252|Drug|Placebo Comparator (for hCG)|"50ul of IVF medium (Global-trademark) to mimic hCG infusion"
1658883|NCT01786239|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day. The dose of the risperidone will be based on the participant's clinical improvement and side effects.
1658884|NCT01786239|Drug|Omega-3 capsules|The total daily dose for omega-3 subjects will be 740 mg of eicosapentanoic acid (EPA)and 400 mg of docosahexaenoic acid(DHA). This dose will start on day 1 and stay the same dose until study completion.
1658885|NCT01786239|Drug|Placebo|The total daily dose for subjects assigned to placebo will be 2000 mg. This dose will start on day 1 and stay the same dose until study completion.
1658886|NCT01786226|Drug|Oral administration of mifepristone 2.5 mg daily for three months|Experimental: 1
1658887|NCT01786226|Drug|Oral administration of mifepristone 5 mg daily for three months|Experimental: 2
1658888|NCT01786200|Drug|Aspirin|
1658889|NCT01786200|Drug|Ibuprofen|
1658890|NCT01786187|Behavioral|Light Physical Activity|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive a home-based light physical activity program to help manage a specific symptom related to cancer and cancer treatment.
1658891|NCT01786187|Other|Symptom Experience Report|Conventional treatment for cancer as prescribed by the participant's health care providers and will receive planned, structured, weekly telephone visits to report the experience of symptoms and health-related quality of life information.
1658892|NCT01786174|Drug|Gilenya|0.5mg Gilenya orally by mouth once daily for approximately 28 days
1658893|NCT01786174|Other|Placebo|0.5mg placebo (sugar pill) orally by mouth once daily for approximately 28 days
1658894|NCT01786161|Drug|Vancomycin continuous infusion|Vancomycin 24 hour intravenous continuous infusion
1658895|NCT01786161|Drug|Vancomycin intermittent dosing interval|Vancomycin intravenous infusion at rate 1000mg/hr
1658896|NCT01786148|Behavioral|mobile phone application|
1658898|NCT01786122|Other|Supervised Physical activity|Both groups received standardized usual care. The EP group will receive, in addition, a nurse supervised exercise program for 2 months in the PHC and a second phase in community facilities during the remaining 10 month
1658899|NCT01786122|Behavioral|education program on healthy habits|education program on healthy habits for 2 months in the PHC and a second phase in community facilities during the remaining 10 months
1658900|NCT01786109|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects received one dose of either 2.5 mg or 5 mg orally with water.
1658901|NCT01786109|Drug|Placebo|Placebo will match study drug; taken as one dose orally with water.
1658902|NCT01786096|Drug|SGN-CD19A|SGN-CD19A (IV) once (Day 1) or twice (Days 1 and 8) every 21 days; dose range: 0.3-6 mg/kg
1658903|NCT01786083|Behavioral|Application of Problem Solving Technique|
1658904|NCT01786070|Drug|Budesonide|
1658905|NCT01786070|Drug|placebo|
1658906|NCT01786057|Procedure|Extracorporeal shock wave therapy 1|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region and (400 shock waves/session of 0.2 mJ/mm2 per each trigger point) for gastrosoleus trigger points , 3 sessions at weekly intervals
1658907|NCT01786057|Procedure|Extracorporeal shock wave therapy 2|Extracorporeal shock wave therapy , (3000 shock waves/session of 0.2 mJ/mm2) for heel region , 3 sessions at weekly intervals
1658908|NCT01786044|Behavioral|MasterMed|An online interactive educational program
1658909|NCT01786044|Behavioral|Usual Care|
1658910|NCT01786031|Other|metastasis biopsy|
1658911|NCT01786018|Drug|Thiotepa|
1658912|NCT01786018|Drug|Busulfan|
1658913|NCT01786018|Drug|Fludarabin|
1658914|NCT01786018|Procedure|transplant (HCT)|Transplant will be PBSCs collected as per institutional standard. A portion of the PBSC product will be removed for DLI that is equivalent to 3x10^7 CD3 cells/kg recipient weight and cryopreserved.
1658915|NCT01786018|Radiation|Cytoreduction|Cytoreduction and /or radiation therapy will be given by the referring physician or the attending physician as determined on clinical grounds or to meet eligibility requirements of the protocol for patients with advanced malignancy or to reduce tumor bulk. However, no intensive chemotherapy can be given within three weeks before conditioning.
1658916|NCT01786018|Drug|Immunosuppression|Day -3. Commence cyclosporine at 5.0 mg/kg PO Q12 hours, continue to day +50 and then taper by 5% per week until day +180.
1658917|NCT01786018|Drug|Cyclosporine|"CSP is given based on adjusted body weight, at 5.0 mg/kg PO q12 hours from day -3.
If there is nausea and vomiting at anytime during CSP treatment the drug should be given intravenously at the appropriate dose that was used to obtain a therapeutic level.
See guidelines for PO to IV conversion below."
1658918|NCT01786018|Drug|Methotrexate|Day 1 15 mg Days 3, 6, 11 10 mg m2 day IV for GVHD prevention
1659694|NCT01779661|Other|Infant Massage|Infant Massage
1658919|NCT01786018|Drug|ATG|(FOR UNRELATED TRANSPLANTS ONLY) Days -3, -2: 2.5 mg /kg/day
1658920|NCT01786018|Procedure|Collection and infusions of Donor PBSC|Collection and infusions of Donor PBSC
1658921|NCT01786005|Device|Transcranial magnetic stimulation|
1658922|NCT01785992|Drug|Irosustat|Patients will receive 40mg of Irosustat once daily in addition to the aromatase inhibitor on which they progressed until disease progression or development of unacceptable toxicities.
1658923|NCT01785979|Drug|prednisone induction - chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
1658924|NCT01785979|Drug|Chloroquine|At study entry, the patients will undergo physical examination and laboratory tests, including blood cell count, malaria microscopy, immune-chromatographic test for malaria antigen, malaria serology titers, and serum protein studies with immunoglobulin M quantification, immune-fixation and immunoglobulin free light chains measurement. We will assess all participants at 1, 3, 6 and 12 months after enrollment. Clinical examination and routine laboratory tests are done every 3 months during the follow-up period. Immunoglobulin M quantification and malaria serology are done at baseline, and at month 12 visit.
1658925|NCT01785966|Behavioral|Daily checklist and clinician prompting|"Interventions are:
Checklists: The checklists are arranged in a paper notebook (one per patient) with a daily list on each page, as most ICUs do not have electronic health record systems. During the multidisciplinary visit, the checklist items are read aloud by the nurse and answered by participants of the visit. The checklist is applied at least once on all week days preferably in the mornings, although we strongly suggest applying it also on weekend days.
Daily Goals and Clinician Prompting: During the clinical discussion of each patient and the application of the checklist, the intensivists write down the daily goals in a standardized form and read them aloud to the team. Every afternoon between 3 and 5 PM, a nurse reviews the daily goals and takes note of any pending items. Subsequently, the nurse prompts the on-call physician, requesting solutions for these pending items."
1658926|NCT01785940|Procedure|Interscalene block|Interscalene catheters will be placed under aseptic precautions in each patient by one of the investigators using combined peripheral nerve stimulation and ultrasound guidance to get twitch in the C5-C6 dermatomes and documented spread of injectate near C5-6 nerve roots. Twenty mL of 0.2% ropivacaine will be injected while documenting adequate drug spread under ultrasound. After 20 min of injection, the interscalene nerve block will be evaluated and considered successful with inability to abduct the shoulder and a decrease in perceived sensation to cold of the skin over the deltoid muscle.
2013291|NCT00581256|Radiation|3D|All patients treated using the best standard technique will receive 50 Gy in 2 Gy fractions or 50.4 Gy in 1.8 Gy fractions to the entire target volume delivering one treatment per day, five fractions per week (excluding holidays). A boost of 10 Gy to the tumor bed of an intact breast will be delivered. Patients treated to the chest wall will receive a 10Gy scar boost if mastectomy margins are positive in a patient with Stage II disease or if the patient was originally diagnosed with T3 or T4 (Stage III) disease
1658928|NCT01785901|Other|without interventions|without interventions
1658929|NCT01785875|Drug|Etelcalcetide|Administered by bolus injection into the venous line of the dialysis circuit at the end of hemodialysis treatment, and prior to or during rinse-back with each hemodialysis session (ie, 3 times per week).
1658930|NCT01785862|Drug|Ibuprofen 25 mg|Lozenge, Oromucosal administration
1658931|NCT01785862|Drug|Placebo|Lozenge matching V0498 lozenge, Oromucosal administration
1658932|NCT01785849|Drug|Etelcalcetide|Administered intravenously three times per week. The starting dose was 5 mg. The dose may have been increased at 4-week intervals by 2.5 mg or 5 mg on the basis of the predialysis parathyroid hormone and corrected calcium concentrations obtained in the prior week. The minimum dose was 2.5 mg and the maximum dose was 15 mg.
1658933|NCT01785849|Drug|Placebo|Administered intravenously (IV) three times per week.
1658934|NCT01785836|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
1658935|NCT01785836|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
1658936|NCT01785836|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
1658937|NCT01785836|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face and upper chest, upper back, and shoulders (as per protocol) for 12 weeks.
1658938|NCT01785823|Other|FX2-2-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
1658939|NCT01785823|Other|D6-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
1658940|NCT01785823|Other|D8-4-2|Their background infusions of fentanyl diluent (2 ml/hr of diluent was equivalent with 0.5 μg/kg/hr of fentanyl) were maintained at the fixed-rate of 2 ml/hr until the postoperative 24 hr (FX2-2-2), or at the decremental rates of 6.0 ml/hr (D6-4-2) and 8.0 ml/hr (D8-4-2) during 1 hr, 4.0 ml/hr during 1~3 hr and 2.0 ml/hr during 3~24 hr, postoperatively. The visual analogue scores (VAS), the incidence of inadequate analgesia, the frequency of intervention of PCA, and side effects were evaluated.
2013292|NCT00578331|Drug|Olopatadine 0.6% nasal spray|2 sprays each nostril twice daily
2013293|NCT00578331|Drug|Placebo Nasal Spray|2 sprays each nostril twice daily
2013294|NCT00565851|Biological|Bevacizumab|Given IV
1658942|NCT01785797|Device|Silicon subdural drain placement after burr hole evacuation of chronic subdural hematoma|
1658943|NCT01785784|Drug|rhGM-CSF Gel|
2013295|NCT00565851|Drug|Carboplatin|Given IV
1658945|NCT01785758|Drug|Sugammadex (4 mg/Kg)|Sugammadex administered at the end of surgical procedure, once skin suture had been finished, to reverse profound neuromuscular blockade induced and maintained with rocuronium
1658946|NCT01785745|Other|Neurocognitive therapeutic exercise|Ten exercises involving specific instruments (e.g., table inclined with a board with five concentric circles, sponges of various texture). One-hour session for three times a week for five weeks.
1658947|NCT01785745|Other|Traditional therapeutic exercise|Different exercises as strengthening exercises, stretching exercises, Codman's pendulum exercises and exercises against elastic band resistance. One-hour session for three times a week for five weeks
1658948|NCT01785732|Procedure|Renal Denervation|Sympathetic renal denervation via renal arteries
1658949|NCT01785719|Behavioral|Commercial diet|Participants will be enrolled in 12 weeks of the Nutrisystem® D weight loss program; a portion-controlled, low calorie and low glycemic index meal delivery system that provides 1250-1500 calories per day. Nutrisystem® D has been proven to help overweight individuals achieve real and sustainable weight loss results. When meals and snacks are consumed as instructed, typical weight loss is 1-2 lbs per week, for an average loss of 8% body weight by the end of 3 months. Nutrisystem® D offers a balanced meal plan consistent with the nutritional recommendations of the USDA Dietary Guidelines and American Diabetes Association; individuals can still consume all of their required micro- and macronutrients, but with fewer calories.
1658950|NCT01785693|Drug|levobupivacaine, clonidine|
1658951|NCT01785680|Other|Integrated Protocol|Implement an integrated protocol in Sierra Leone for the management of MAM and non-complicated SAM that uses a single anthropometric indicator as well as the same food but in different doses to treat the continuum of malnutrition. MAM children will be given 75 g/kg/day of RUTF whereas SAM will be given 175 gr/kg/day of RUTF until MUAC>12.5 cm is reached. Then child will be given LNS, a bed net, albendazole, zinc, referral for immunizations compliant with current WHO recommendations, oral rehydration salts to give if the child has more than three loose watery stools in 24 hours, and asked to return for follow-up in 1, 3 and 6 months. Caretakers will be instructed to seek medical care sooner if the child has fever, poor appetite or signs of an acute illness.
1658952|NCT01785680|Other|Current protocol|Current protocol for treating MAM in emergencies is supplemental food distribution, often providing a fortified blended food (FBF) that requires cooking. This treatment is the standard today for treating children with MAM.
1658953|NCT01785641|Drug|ceftazidime+ciprofloxacin|2 synergistic antibiotics: ceftazidime IP + ciprofloxacin po for gram negative bacterial peritonitis
1658954|NCT01785641|Drug|ceftazidime monotherapy|ceftazidime IP for gram negative bacterial peritonitis
1658955|NCT01785641|Drug|cefazolin+gentamicin|cefazolin IP + gentamicin IP for gram positive bacterial peritonitis
1658956|NCT01785641|Drug|cefazolin monotherapy|cefazolin IP for gram positive bacterial peritonitis
1658957|NCT01785628|Dietary Supplement|Sarcosine Capsule|Sarcosine is a glycine transporter-1 (GlyT-1) inhibitor. By blocking glycine uptake, sarcosine increases synaptic glycine concentration to enhance NMDA receptor function.
1658958|NCT01785628|Dietary Supplement|Placebo Capsule|Placebo is dextrin composition.
1658959|NCT01785615|Drug|Atorvastatin|80mg
1658960|NCT01785615|Other|Placebo|80mg
1658961|NCT01785602|Drug|QAW039|Capsules
1658962|NCT01785602|Drug|Placebo|Capsules
1658963|NCT01785589|Procedure|coronary angiography|A 6 French arterial sheath was introduced into the radial artery. After administration of 5000 U heparin, the guiding catheter was advanced into the coronary ostium. Intracoronary nitroglycerin 0.2 mg was administered, and reference images were made. Significant CAD was defined as presentation of a stenosis ≥70 % in the three-epicardial vessels and ≥ 50 % in left main coronary disease. If necessary (at the discretion of the practitioner) the pressure wire was advanced across the stenosis, and Fractional flow reserve (FFR) was measured.
1658964|NCT01785576|Behavioral|Couple-Based CBT Intervention|Patients and partners will receive 4 sessions of a couple-based cognitive behavioral intervention focusing on communication and spousal support.
1658965|NCT01785563|Procedure|Nasal NIV-NAVA|Infants will be placed on nasal NIV-NAVA. Patients initial NAVA level will be set to generate a peak inspiratory pressure that is 8 cm of water greater than their current peak end expiratory pressure. If the infants are on nasal NIV-NAVA at the time of study entry their NAVA level will be increased by 50% rounded up to the nearest 0.1 cm of water per microvolt.
1658966|NCT01785550|Other|Ultrasound of nerve and muscle|Ultrasound of 6 muscles and 2 nerves will be performed.
1658967|NCT01785524|Drug|Beetroot Juice (Beet-It Stamina Shot) and Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
1658968|NCT01785524|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
1658969|NCT01785511|Radiation|UVA Radiation|UVA radiation exposure for 20 minutes
1658970|NCT01785498|Behavioral|Supplementary resources|Clinical and educational resources for patients, their families and the professionals who care for them.
1658971|NCT01785485|Other|Integrative medicine primary care model|An integrative medicine primary medical care as defined by the Arizona Center for Integrative Medicine.
1658972|NCT01785472|Drug|LCZ696|LCZ696 200 mg tablet
1658973|NCT01785472|Drug|Olmesartan|Olmesartan 20 mg capsule
1658974|NCT01785472|Drug|Placebo of LCZ696|Placebo tablet of LCZ696 200 mg once daily
1658975|NCT01785472|Drug|Placebo of Olmesartan|Placebo capsule of olmesartan 20 mg once daily
1659002|NCT01785264|Procedure|Mini-invasive surgery|"We will use the technique developed by Dr. Amlang and Professor Zwipp from Dresden, Germany. They have developed a protocol of mini-invasive surgery using specially adapted proprietary instruments.
All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none."
1658976|NCT01785459|Drug|0.5% bupivacaine|The injection site will be prepared using common sterile technique with 2% chlorhexidine. 1.5 mL of 0.5% bupivacaine will be will be injected bilaterally in the paraspinal musculature of the cervical spine. Location would be approximately 1 cm superior to spinous process of C7 and approximately 2-3 cm laterally. The needle is inserted 1 to 1.5 inches into the paraspinous musculature at this level. A 27-gauge needle would be used to minimize tissue trauma and pain to the patient. Our method of injection is followed quite closely with the technique depicted in multiple retrospective studies. We chose to follow previous reported technique secondary to good clinical efficacy and impressive documented safety profile. Additionally, before injection, aspiration would be performed to lesson chance of intravascular injection.
1658977|NCT01785459|Drug|Standard Care|10 mg Intravenous injection of Prochlorperazine
1658978|NCT01785446|Drug|Effect of dexmedetomidine on cisatracurium and sufentanil consumption|In this intervention we compared the cisatracurium consumption, recovery index and sufentanil consumption between P2 and D. The reason we are comparing patients in group D with P2 is that because they belong to the same age group.
1658979|NCT01785446|Drug|Consumption of cisatracurium and sufentanil in different age groups.|For this intervention, we compared the cisatracurium consumption, refractory index and sufentanil consumption between group P1, P2 and P3.
1658980|NCT01785433|Drug|Tiotropium HFA BAI 4.5 mcg|
1658981|NCT01785433|Drug|Tiotropium HFA BAI 9.0 mcg|
1658982|NCT01785433|Drug|SPIRIVA® HandiHaler® 18 mcg/day|
1658983|NCT01785433|Drug|Spiriva® Respimat® 5 mcg/day|
1658984|NCT01785420|Drug|Trastuzumab|A single dose of Trastuzumab (Herceptin, Hoffman La Roche) at 8 mg/Kg as a 90 minute infusion in 250 ml of normal saline, in the window period of 14 days (both days inclusive) prior to the planned date of surgery.
1658985|NCT01785420|Drug|Placebo|A 90 minute intravenous infusion of saline as placebo
1658986|NCT01785407|Dietary Supplement|Iron Supplement (Ferrous Sulfate Dried)|Iron supplements of varying concentration will be administered to the four groups in the study. Iron bioavailability from the supplements will be assessed.
1658987|NCT01785394|Drug|5 grass allergen extract|30 patients will be subjected to sublingual immunotherapy with 5 grass allergen extract Staloral, starting with 1 spurt of 10 IR/ml increasing them daily stepwise to 10 spurts, switching then to 1 spurt of 300 IR/ml, increasing daily stepwise to 10 spurts, and then maintaining this dose from February till July. 30 patients will be on placebo.
1658988|NCT01785381|Other|Added value of coordinator|Added value of coordinator
1658989|NCT01785368|Other|Implementation of guidelines|The participating ER doctors are required to request imaging exams for their patients according to a guide mutually constructed by the emergency and imaging departments of the Nîmes university hospital.
1658990|NCT01785368|Other|Baseline observation|During this period of the study, baseline data will be collected.
1658991|NCT01785355|Other|Dental treatment|"The preliminary stage deals with:
assessment of the clinical state of the patient by completing a detailed dental and periodontal chart
education of the patient regarding correct oral hygiene habits;
Phase I Therapy:
plaque control : removal of dental plaque, calculus and root planning; antimicrobial therapy (local or systemic)
evaluation of response to the treatment
Phase II Therapy - surgical phase:
extraction of hopeless teeth
evaluation of the surgical results.
Maintenance phase:
periodic reevaluation of plaque and calculus and of periodontal conditions."
1658992|NCT01785342|Other|Biosample and Imaging Collection|Collection of listed biosamples and CT imaging.
1658993|NCT01785329|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
1658994|NCT01785316|Procedure|IHP|
1658995|NCT01785303|Behavioral|CBT-I|Cognitive Behavior Therapy for Insomnia (CBT-I) consists of 4 weekly sessions delivered individually. The focus of these sessions is on modifying behaviors and cognitions related to sleep and insomnia.
1658996|NCT01785303|Procedure|CPAP|CPAP is an FDA-approved medical device used to treat obstructive sleep apnea. This device consists of a mask, hose, and machine that blows continuous air which maintains a consistent pressure of airflow preventing the upper airway from collapsing during sleep.
1658997|NCT01785290|Drug|Haloperidol 1 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:
aged ≥ 80 years
weight ≤ 50 kg
liver failure
Patients with an adjusted dosage of study drug remain allocated to their original group.
In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
1658998|NCT01785290|Drug|Haloperidol 2 mg/q8h|"Patients receive prophylactic haloperidol until discharge from the ICU or when delirium occurs. In the latter case study drug will be stopped and patients will be subsequently treated according to the delirium protocol with open-label haloperidol. To avoid unnecessary risk for side-effects the dose will be halved in patients:
aged ≥ 80 years
weight ≤ 50 kg
liver failure
Patients with an adjusted dosage of study drug remain allocated to their original group.
In case of occurrence of QTc-time prolongation the study drug will be stopped. After normalisation of QTc-time (<500msec.) the study drug will be restarted. If QTc-time becomes prolonged again, the study drug will be stopped definitively. The patient will remain allocated to the original study group."
1658999|NCT01785290|Drug|Placebo|Sodium Chloride 0.9%
1659000|NCT01785264|Procedure|Non-operative treatment|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none. Patients randomized to non-operative treatment will have a cast applied within 3 days from injury.
1659001|NCT01785264|Procedure|Open surgery|All patients included in the study will be immobilized in equinus position for the first two weeks using a below-the-knee cast. Following the first two weeks the cast is replaced with a brace that will be used for additional six weeks during which the ankle angle will be adjusted from 3 heel-lifts to none.
1659003|NCT01785251|Device|Neuromuscular Electrical Stimulation|Applied using a custom built, medically approved stimulator called the Duo-STIM. NMES to be applied to the calf muscles to elicit a muscular contraction to eject blood through the venous system.
1659004|NCT01785238|Other|renal echography|renal echography to analyse the kidney
1659005|NCT01785238|Other|Blood sampling|Blood sampling to analyse different parameters of renal function
1659006|NCT01785238|Other|collection of an urine sample|Collection of an urine sample to perform analysis of renal function parameters
1659007|NCT01785238|Other|Blood pressure measurement|
1659008|NCT01785225|Device|A product type of the modified commercial drape Tegaderm (R)|We test if a product type of the modified commercial drape Tegaderm(R) can bee used when taking blood samples under the guidance af ultrasound. The drape is used to keep the puncture area sterile and clean of ultrasound gel.
1659009|NCT01785212|Device|Stapler|stapler hepatectomy
1659010|NCT01785212|Device|CUSA (Cavitron ultrasonic aspirator; Valleylab, Boulder, CO)|CUSA is a well established device used for hepatic resection using ultrasound
1659011|NCT01785199|Procedure|Head elevation by an automatic adjustable bed|The automatic device is initiated when the patient suffers from apnea ≥ 10 seconds, which is detected by an ultra-wideband (UWB) sensor placed under the bed. The head will be slightly elevated at an angle of 10 degrees lasting 10 seconds and then be put down softly.
1659012|NCT01785186|Drug|SQ109|SQ109 300 mg
1659013|NCT01785186|Drug|Rifampicin|Rifampicin 10 to 35 mg/kg
1659014|NCT01785186|Drug|Moxifloxacin|Moxifloxacin 400mg
1659015|NCT01785186|Drug|isoniazid|isoniazid 75 mg
1659016|NCT01785186|Drug|pyrazinamide|pyrazinamide 400 mg
1659017|NCT01785186|Drug|ethambutol|ethambutol 275 mg
1659018|NCT01785186|Dietary Supplement|pyridoxine|pyridoxine 25 mg
1659019|NCT01785173|Procedure|Endoscopic-guided gauze pledgetting|By using a transnasal endoscope as a guide and a biopsy forceps, a gauze strip soaked with decongestant and anesthesia will be delivered to a selected nasal meatus chosen by anterior rhinoscopy.
1659020|NCT01785173|Procedure|Cotton-tipped applicator gauze pledgetting|In contrast to the endoscopic-guided, forceps-delivering method, a gauze strip is delivered to a selected meatus by a cotton-tipped applicator.
1659021|NCT01785160|Drug|Raltegravir|low dose oral administration
1659022|NCT01785160|Drug|Raltegravir|low dose oral administration
1659023|NCT01785160|Drug|Faldaprevir|medium dose oral administration
1659024|NCT01785147|Drug|BP1.4979|BP1.4979 at 3mg, 10mg, 15mg or placebo during 3 months.
1659025|NCT01785147|Drug|Placebo|
1659026|NCT01785134|Procedure|Omentectomy|
1659027|NCT01785134|Procedure|Gastric bypass operation|
1659028|NCT01785121|Behavioral|Structured access to a Wii game computer (Wii)|Patients who are randomized to the Wii group will be introduced to the Nintendo Wii game computer in an introduction lesson of approximately two hours and the Wii will be installed at home. During the first three months after inclusion, patients will be phoned after 2, 4, 8, 12 weeks to discuss their experiences with the Wii or to solve possible problems
1659029|NCT01785121|Behavioral|Motivational support only|The control group receives an protocolized exercise advice and telephone follow-up at 2, 4, 8 and 12 weeks
1659030|NCT01785108|Biological|GAD-Alum (Diamyd) 20 µg|
1659031|NCT01785108|Biological|GAD-Alum (Diamyd) 20 µg X 2|
1659032|NCT01785108|Drug|Vitamin D|
1659033|NCT01785108|Drug|Ibuprofen|
1659034|NCT01785095|Drug|FSH (Follicle Stimulating Hormone)|
1659035|NCT01785082|Drug|13-C-Methacetin|intravenous injection of 0.4% 13-C-Methacetin solution, once before partial liver resection, once after partial liver resection
1659036|NCT01785056|Biological|Privigen|Subjects will receive 2 g/kg/mo of Privigen® for 6 months if randomized to the treatment group.
1659037|NCT01785043|Drug|Liraglutide|Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®). One ml of solution contains 6 mg of Liraglutide (human glucagon-like peptide-1 analogue produced by recombinant DNA technology in Saccharomyces cerevisiae). One pre-filled pen contains 18 mg Liraglutide in 3 ml.
1659038|NCT01785043|Drug|Sitagliptin|Sitagliptin is available in 100 mg film-coated tablets (Januvia®). Each tablet contains sitagliptin phosphate monohydrate, equivalent to 100 mg sitagliptin.
1659039|NCT01785030|Drug|50% Nitrous oxide|
1659040|NCT01785004|Dietary Supplement|Vitamin D3 (cholecalciferol), 2000 IU per day|cholecalciferol
1659041|NCT01785004|Drug|omega-3 fatty acids (fish oil)|
1659042|NCT01784991|Drug|Hydromorphone|1mg of Hydromorphone at timepoint 0 and 1 mg of hydromorphone at 15 min timepoint.
1659043|NCT01784991|Drug|Usual care group|Patient will have pain treated at timepoint 0 as per usual care based on physician discretion. At 15 min timepoint, patients will be asked for pain level, and then subsequently treated as per physician discretion.
1659044|NCT01784978|Drug|Sunitinib|50 mg pd
1659045|NCT01784978|Drug|Everolimus|10 mg pd
1659046|NCT01784965|Drug|liraglutide|Dosing begins at 0.6 mg subcutaneous injection and increases each week, to 1.2 mg and maximum dose of 1.8 mg.
1659047|NCT01784965|Drug|Placebo|Double blinded will receive study pen with same dosing instructions starting at 0.6 mg, and each week increase to 1.2 mg and finally 1.8 mg at week three.
1659048|NCT01784952|Dietary Supplement|Dietary intervention|The intervention program consisted of replacing of refined rice intake with 1/3 of legumes, 1/3 of barleys, and 1/3 of whole grains three times per day as a high carbohydrate source and increased vegetable intake to at least 6 units (30-70 g/unit) per day for sufficient dietary fiber intake. The subjects were recommended to drink no more than one alcoholic beverage drink (15 g alcohol) per day and were assigned physical activity consisting of a regular 30-min walk after dinner each day. Participants were also instructed to record their physical activity diary for 24 h every 4 weeks.
2013296|NCT00565851|Drug|Docetaxel|Given IV
2013297|NCT00565851|Drug|Gemcitabine Hydrochloride|Given IV
1659051|NCT01784913|Biological|UV1 synthetic peptide vaccine and GM-CSF|
1659052|NCT01784900|Drug|Catumaxomab 100µg|
1659053|NCT01784900|Drug|Catumaxomab 140µg|
1659054|NCT01784887|Drug|Procellera|PROCELLERA TM is an FDA-cleared bioelectrical dressing delivered in a sterile, single layer sheet consisting of a flexible polyester fabric layer containing silver and zinc, which are held in position on the polyester with a biocompatible binder.
1659055|NCT01784874|Biological|Purified Vero Rabies Vaccine (VRVg) - Serum Free|0.5 mL, Intramuscular
1659695|NCT01779648|Device|DVT-3000|
2013298|NCT00565851|Other|Laboratory Biomarker Analysis|Correlative studies
1659056|NCT01784874|Biological|Imovax® Rabies: inactivated rabies vaccine|1.0 mL, Intramuscular
2013299|NCT00565851|Drug|Paclitaxel|Given IV
2013300|NCT00565851|Other|Quality-of-Life Assessment|Ancillary studies
2013301|NCT00564460|Drug|Finasteride|Finasteride 5 mg PO once daily for 8 weeks prior to TURP
1659060|NCT01784848|Procedure|Laparoscopic Roux-en-Y gastric bypass (LRYGB)|Laparoscopic Roux-en-Y gastric bypass (LRYGB)is the one of the techniques of bariatric surgery
1659061|NCT01784848|Other|Clinical treatment|Medical treatment aiming the control of risk factors for cardiovascular diseases (including adequate control of blood pressure), psychological assistance and dietetic advice for body weight reduction.
1659062|NCT01784835|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
1659063|NCT01784835|Other|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
1659064|NCT01784822|Device|Zenapro™ Hybrid Hernia Repair Device|Device will be placed during open or laparoscopic hernia repair.
1659065|NCT01784809|Behavioral|Multimedia WORTH|"The Multimedia WORTH intervention features the same core elements as the original version, but these core elements are translated into interactive tools and culturally tailored video vignettes designed to enhance group learning and individualized feedback. Participants will interact with Multimedia WORTH at two levels: (1) group materials will be delivered via computer projection onto a screen and (2) participants will complete individual activities and create journal logs tracking their progress on personalized goals on their personal user accounts using laptop computers. The computer multimedia support tool includes text, imagery, animations, audio and video in a format that guide the facilitator's delivery of the intervention. ***To view pilot features of the Multimedia WORTH intervention in development, please visit the following web address:
http://ccnmtl.columbia.edu/projects/worth/presentation"
1659066|NCT01784809|Behavioral|Traditional WORTH|The basic format of each WORTH session remains consistent following a sequence of 5 steps: (1) an opening (quote, song, poem) which will provide a brief culturally relevant point of inspiration to engage participants (2) Check-in to review material from the previous session, and to discuss any incidents where participants engaged in risk behaviors and to acknowledge positive ways in which women used new skills to avoid HIV risk; (3) a discussion to raise awareness of links between IPV, drug-related activities, and HIV risks; (4) a skills-building component relevant to the discussion; and (5) review and update participant needs, homework assigned for skills-building at home, and a closing ritual. The WORTH intervention consists of four 2-hour group sessions that are led by a female facilitator.
1659067|NCT01784809|Behavioral|Wellness Promotion|
1659068|NCT01784796|Behavioral|Mindfulness Based Stress Reduction|8 week Mindfulness Based Stress Reduction Program
1659069|NCT01784796|Behavioral|Health Education Program|8 week Health Education Program
1659070|NCT01784783|Behavioral|HOPE Intervention|"If the male partner chooses not to complete the study questionnaire, he may decline and participate only in the HOPE intervention component of the study. (This does not preclude the possibility of the female partner continuing to participate in the study.) Investigators anticipate that this will occur and also expect that some women and male partners randomized to the intervention arm will refuse the HOPE intervention when offered. Study staff will attempt to collect data on reasons for refusal to participate and will continue to follow these couples through 6 months postpartum to collect maternal and infant outcome data, provided the female partner does not withdraw from the study.
Key educational messages will be presented using an electronic tablet highlighting key messages and will include with relevant images as visual aids. This will help to facilitate comprehension and ensure that all relevant materials are covered during each intervention session."
1659071|NCT01784783|Behavioral|INVITE Intervention|Women will receive a clinic invitation to give to their male partners to attend the next antenatal visit for couple HIV counseling and testing.
2013302|NCT00564460|Drug|Placebo|Placebo once daily for 8 weeks
1659073|NCT01784757|Drug|ODM-201 Tablet A|Tablet A formulation of ODM-201
1659074|NCT01784757|Drug|ODM-201 Tablet B|Tablet B formulation of ODM-201
1659075|NCT01784757|Drug|ODM-201 capsule formulation|Capsule formulation of ODM-201
1659076|NCT01784744|Other|Hydroworx Pool at 98 degrees Fahrenheit|
1659077|NCT01784744|Other|Hydroworx Pool at 102 degrees Fahrenheit|
1659078|NCT01784731|Behavioral|Willingness to pay|
1659079|NCT01784718|Drug|Buphenyl|
1659080|NCT01784705|Device|Transcranial bright light therapy|The bright light treatment was given transcranially via ear canals by using bright light device. The bright light was produced using two light-emitting diodes (LEDs). The bright light was transmitted into both ear canals by an optical fibre. Daily 12 minutes TBL was taken at home during forenoon.
1659081|NCT01784705|Device|Transcranial placebo treatment|The placebo treatment was given transcranially via ear canals by placebo device. Daily 12 minutes placebo treatment was taken at home during forenoon.
1659082|NCT01784692|Dietary Supplement|Immulina|
1659083|NCT01784666|Drug|Isradipine|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to isradipine versus placebo add-on for 4 weeks, with the placebo nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the isradipine treatment effect. Subjects who respond in phase 1, and all subjects who receive isradipine in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
1659084|NCT01784666|Drug|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to isradipine vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed.
1659696|NCT01779648|Device|SCD Express|
2013303|NCT00542425|Drug|teriparatide|teriparatide 20 µg subcutaneous daily
2013304|NCT00542425|Drug|Placebo|Placebo subcutaneous daily
2013305|NCT00542425|Drug|BA058 20 µg|BA058 20 µg subcutaneous daily
2013306|NCT00542425|Drug|BA058 40 µg|BA058 40 µg subcutaneous daily
2013307|NCT00542425|Drug|BA058 80 µg|BA058 80 µg subcutaneous daily
2013308|NCT00537290|Drug|Rituximab|Rituximab 1000mg IV on Days 0 and 15
2013309|NCT00530868|Other|Letrozole (Femara)|Letrozole 2.5 mg PO a day for 24 weeks
1659085|NCT01784653|Behavioral|iMET|Self-completed, computerized motivational enhancement therapy
1659086|NCT01784653|Behavioral|MET|Clinician-delivered Motivational Enhancement Therapy
1659087|NCT01784640|Drug|Hsp90 inhibitor AUY922|Given IV
1659088|NCT01784640|Drug|pemetrexed disodium|Given IV
1659089|NCT01784640|Other|pharmacological study|Correlative studies
1659090|NCT01784640|Other|laboratory biomarker analysis|Correlative studies
1659091|NCT01784627|Behavioral|c-ASBI|Participants in the c-ASBI group will complete a computerized screen for alcohol, cannabis, tobacco and other drugs, then view their screen score and 10 pages of information about the health effects of substance use and true-life stories on the computer. Their provider will see a report of their screen results and provide advice to stop or decrease their use, or, for those at high risk, referral to complete a computerized motivational enhancement therapy intervention.
1659092|NCT01784614|Drug|LY2624803 - Solution|Administered orally as reconstituted solution
1659093|NCT01784614|Drug|LY2624803 - Capsule|Administered orally as a capsule
1659094|NCT01784614|Drug|Placebo - Solution|Administered orally as solution
1659095|NCT01784614|Drug|Placebo - Capsule|Administered orally as a capsule
1659096|NCT01784588|Device|Solyx Single Incision Sling System|Solyx Single Incision Sling System
1659097|NCT01784588|Device|Obtryx II Sling System|to compare a single incision midurethral sling to a standard outside-in transobturator sling for the treatment of female stress urinary incontinence.
1659098|NCT01784575|Other|Patient Navigator Intervention|The Patient Navigator Intervention will include 2 - 20 minute sessions with a patient navigator in which women are shown publicly available health care quality data about local pediatric practices on a non-profit quality collaborative's web site.
1659099|NCT01784562|Drug|Adempas (Riociguat, BAY63-2521)|Individual dosing of riociguat between 0.5 and 2.5 mg three times daily based on patient's well being and blood pressure. (The individual optimal dose should be determined during the initial 8-week titration phase based on patient's monitoring of systolic blood pressure and well-being.)
1659100|NCT01784549|Drug|Cisplatin Docetaxel Gefitinib Pemetrexed Vinorelbine Gemcitabine|
1659101|NCT01784536|Drug|Single-Dose IV Oritavancin Diphosphate|Oritavancin will be administered as a single IV infusion. The infusion will last approximately 3 hours.
1659102|NCT01784523|Drug|Hydroxychloroquine|
1659103|NCT01784510|Procedure|distance of dissection of gastrocolic ligament from pylorus|
1659104|NCT01784484|Other|No intervention|
1659105|NCT01784471|Device|Magic Foot™|Magic Foot™ is a shoe, providing massage together with acupressure or reflexology functions. The device is fully remotely operated and controlled.
1659106|NCT01784445|Drug|Ceftazidime|Patient undergone ERCP will receive either diclophenac sodium suppositories(100mg)plus placebo or ceftazidime (2g i.v.) plus placebo before procedure
1659107|NCT01784432|Device|Low-level laser therapy and training|
1659108|NCT01784432|Other|Training|
1659109|NCT01784419|Drug|ivacaftor|Prospective randomized double-blinded placebo controlled crossover study of the effects of ivacaftor in selected cystic fibrosis patients
1659110|NCT01784406|Behavioral|Autonomy supportive counselling|
1659111|NCT01784393|Radiation|chemoradiation|
1659112|NCT01784380|Drug|Diane-35;metformin;Clomiphene citrate; Human menopausal gonadotropin|
1659113|NCT01784367|Device|vv-ECCO2R (Novalung GmbH, Germany)|Treatment with the extracorporeal lung assist (ECLA) The ECLA is a pump driven (centrifugal pump) venovenous circuit, which removes carbon dioxide from the patients blood by means of a membrane through which the patients blood runs on the one side of the membrane and sweep gas on the other side removing the patient´s carbon dioxide. Blood flow range from 0.5 to 4.5 l/min and sweep gas flow between 1 and 10 l/min. At blood flows of 2 l/min and higher the device also oxygenates the patients blood. The diameter and length of cannulas and the sites of venous insertions are left to the decision of the treating physician. Cannulas are inserted in seldinger technique under sterile conditions. Function and patency of the extracorporeal circuit requires mild therapeutic anticoagulation.
1659114|NCT01784354|Other|Acupressure|
1659115|NCT01784354|Other|Acupressure dilatation|
1659116|NCT01784354|Behavioral|education|
1659117|NCT01784328|Device|Peristeen Bowel Irrigation System|A complete system for bowel Irrigation to manage bowel dysfunction
1659118|NCT01784315|Drug|Artemisinin combination therapies (ACT)will be used for Chloroquine resistant P.vivax|4 tablets of ACT on 0,8,24,36,48 and 60 hours will be given for Chloroquine resistant P.vivax infection.
1659119|NCT01784315|Drug|Chloroquine and Primaquine|Chloroquine:10mg/kg for day1,2 and 5mg/kg for day 3 Primaquine: 0.25mg/kg daily for 14 days.
1659120|NCT01784302|Dietary Supplement|Multivitamins|
1659121|NCT01784302|Dietary Supplement|Sodium bicarbonate|
1659122|NCT01784302|Drug|Maalox Plus extra|
1659123|NCT01784302|Drug|Raltegravir 400 mg|
1659124|NCT01784276|Behavioral|Video|"Video peer modeling: The video demonstrates various stages of the dental visit experience. Children assigned to intervention Groups B or D reviewed the video at least once, but as many times as possible before the follow up visit.
Video goggles: This is a sunglass style video eyewear that contains two computer screens that can be used to watch 2 or 3D movies. Subjects randomized to Group C or D watched a 2D movie during the return visit, using the video goggles. Subjects who refused or were unable to wear the goggles watched the movie using a hand held portable DVD player."
1659125|NCT01784263|Behavioral|Individual Cognitive Behavioral Therapy|Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).
1659126|NCT01784263|Behavioral|Standard Community Treatment|In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
1659127|NCT01784250|Drug|Clonidine|Clonidine 150 mcg tablet single dose, to receive by mouth one hour before surgery
1659128|NCT01784250|Drug|Propranolol|Propranolol 40 mg tablet single dose, to receive by mouth one hour before surgery
1659129|NCT01784250|Drug|Placebo|Sugar pill manufactured to mimic a drug
1659159|NCT01783977|Biological|NYVAC-HIV-PT1 vaccine|NYVAC-HIV-PT1 at greater than or equal to 5x10^6 plaque-forming units (PFU)/ml for a planned maximum dose of 1.2x10^8 PFU/ml; administered as 1 mL IM in participant's deltoid
1659130|NCT01784237|Procedure|anterior meatoscopy|The nasal vestibule is the most anterior part of the nasal cavity. It is lined by the same epithelium of the skin (stratified squamous epithelium) but not respiratory epithelium (pseudostratified columnar ciliated epithelium) so that an endoscope tip in this region would hardly causes trauma or bleeding. Before being inserted gently into the nasal vestibule for anterior rhinoscopy, the endoscope tip is applied with 2% lidocaine gel and then sprayed with 10% liquid lidocaine. This procedure can provide mild vestibular anesthesia which can prevent patients from sneezing when the vibrissae hair is irritated by the endoscope tip. Instead of holding the insertion tube as usual, an endoscopist holds the bending section for better control of the distal tip during anterior meatuscopy.
1659131|NCT01784237|Procedure|Nasal sniff test|All patients in the control group receive a sniff test in the left lateral decubitus (LLD) position directed and recorded by an assistant nurse. This test has been conducted for decades and is still used by many transnasal endoscopists, otolaryngologists, and pediatrics. In brief, the more patent nostril is selected by the patient inhaling through only one nostril with the other sealed by the examiner's index ﬁnger. Patients are asked to indicate which of their nostrils is most patent. If neither is more patent, the right nostril is chosen by default. The middle meatus is more difficult to examine and may be less well anesthetized than other structures. Thus, the inferior nasal meatus is selected for each case because the inferior meatus is usually the largest of the three nasal meatuses.
1659132|NCT01784224|Procedure|Blom Low Profile Voice Cannula/Passty-Muir Speaking Valves|
1659133|NCT01784211|Drug|LY2605541|Administered SQ
1659134|NCT01784211|Drug|Insulin Glargine|Administered SQ
1659135|NCT01784198|Dietary Supplement|Protein Intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
1659136|NCT01784185|Procedure|virtual bronchoscopy guided transbronchial needle aspiration|
1659137|NCT01784185|Procedure|endobronchial ultrasound guided transbronchial needle aspiration|endobronchial ultrasound guided transbronchial needle aspiration (EBUS-TBNA) of mediastinal lesions
2013310|NCT00530868|Drug|Letrozole; Avastin|Letrozole 2.5 mg PO a day and Avastin 15 mg/kg IV every 3 weeks
2013311|NCT00521885|Drug|Arixtra (Fondaparinox) 2.5 mg SC Daily|Patients will be randomized to receive Arixtra 2.5mg once a day if randomized to this arm
1659140|NCT01784159|Drug|Aspirin|Aspirin administration for 7 days
1659141|NCT01784146|Other|Oxygen|"For inhalation of oxygen, we used a noninvasive delivery system, semi - closed (Figure 3) consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the
nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a flow of 8 l / min of oxygen."
1659142|NCT01784146|Other|Heliox|"For inhalation of heliox, we used a noninvasive delivery system, semi - closed consisting of a non-toxic face mask with two unidirectional valves - inspiratory and expiratory branch - connected to the
nebulizer (Airlife Misty Neb, Baxter; Valencia, CA, USA). In the inspiratory branch, a reservoir bag (Hudson RCI, USA) with capacity of 2.5 L was connected, in order to avoid dilution of the gas. This skin was fixed to the patient's face to prevent leakage and to maintain adequate pressurization and improved patient compliance to the PEEP. The nebulizer was fed by a 11 l / min of heliox for the heliox group in accordance with a protocol of Hess et al."
1659143|NCT01784146|Other|PEEP|PEEP supplied was 10 cm H2O through valve (Vital Signs,Totowa, USA) attached to the expiratory branch.
1659144|NCT01784133|Drug|omiganan|
1659145|NCT01784133|Drug|placebo|
1659146|NCT01784120|Drug|Doxorubicin/Genexol-PM|
1659147|NCT01784107|Drug|Belotecan and Ifosfamide|
1659148|NCT01784094|Device|StromaGlide|
1659149|NCT01784081|Other|Palliative care with decision aids|Participant is followed by the palliative care team, and at each visit, patient will assess their distress and symptoms. Patients facing a treatment decision will receive a Patient Information Program link to review the diagnosis, prognosis, specific benefits and risks with the proposed chemotherapy.
1659150|NCT01784068|Drug|Nilotinib followed by treatment-free|Nilotinib will be used as commercial available capsules (except in Japan where clinical supplies is used) of 150 mg and 200 mg strength. treatment occurs during consolidation, continuation, prolonged continuation, re-initiation and re-initiation-2 phases of the study.
1659151|NCT01784042|Drug|Placebo|placebo
1659152|NCT01784042|Drug|Lovaza|
1659153|NCT01784042|Other|Dietary energy restriction|
1659154|NCT01784029|Drug|Vitamin D3|Doses are as mentioned above. Will repeat 3 month cycles of treatment if still deficient at 3 month follow up.
1659155|NCT01784016|Radiation|[11C]-PHNO|[11C]-PHNO will be administered once intravenously to conduct Positron Emission Tomography (PET) measurements of dopamine D2/D3 binding potential.
1659156|NCT01784003|Device|Powered ankle-foot prosthesis|
1659157|NCT01783990|Drug|Hydroxyurea|Active and Passive groups both are on HU.
1659158|NCT01783977|Biological|DNA-HIV-PT123 vaccine|DNA-HIV-PT123 4 mg/mL; administered as 1 mL IM in participant's deltoid
1659197|NCT01783717|Drug|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 8 weeks
1660315|NCT01774474|Drug|Triamcinolone Acetonide|
2013312|NCT00521885|Drug|Lovenox 40mg SC Daily|Patients will be randomized to receive Lovenox 40mg SC Daily if randomized to this arm
2013313|NCT00500331|Drug|GSK189075|Experimental Drug
2013314|NCT00500331|Drug|pioglitazone|Active Control
2013315|NCT00500331|Other|Placebo|Placebo Comparator
2013316|NCT00496795|Other|epirubicin/docetaxel sequential|Epirubicin 60 mg/m2, q2w 4 cycles. Followed by docetaxel 100 mg/m2 q2w 4 cycles
2013317|NCT00495469|Drug|GSK189075|GSK189075 is available as a white, capsule-shaped tablet dosage form containing 50mg, 125mg, 250mg or 500mg of GSK189075 per tablet
2013318|NCT00495469|Drug|Placebo|Available as Placebo matching tablet to GSK189075
2013319|NCT00489827|Drug|Intravenous infusion of saline|Intravenous infusion of isotonic saline at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
1659160|NCT01783977|Biological|NYVAC-HIV-PT4 vaccine|NYVAC-HIV-PT4 at greater than or equal to 5x10^6 PFU/ml for a planned maximum dose of 1.1x10^7 PFU/ml; administered as 1 mL IM in participant's deltoid
1659161|NCT01783977|Biological|Placebo for DNA-HIV-PT123 vaccine|Placebo for DNA-HIV-PT123 administered as 1 mL IM in participant's deltoid
1659162|NCT01783977|Biological|Placebo for NYVAC-HIV-PT1 vaccine|Placebo for NYVAC-HIV-PT1 vaccine administered as 1 mL IM in participant's deltoid
1659163|NCT01783977|Biological|Placebo for NYVAC-HIV-PT4 vaccine|Placebo for NYVAC-HIV-PT4 vaccine administered as 1 mL IM in the participant's deltoid
1659164|NCT01783964|Drug|[14C]-Elacytarabine|Single intravenous administration
1659165|NCT01783951|Other|S-1 plus DC-CIK|
1659166|NCT01783938|Biological|Nivolumab|
1659167|NCT01783938|Biological|Ipilimumab|
1659169|NCT01783912|Behavioral|Cognitive / Motivational Individual Sessions|Cognitive Motivational subjects will receive four evidence-based preparatory interventions (motivational interviewing, smoking reduction, practice quit attempt, and pre-quit use of nicotine replacement medication) (25 - 30 minutes each).
1659170|NCT01783912|Behavioral|Attention Control Individual Sessions|Attention control subjects will receive four placebo individual sessions (25-30 minutes each). The session content will reemphasize group discussion of the personal health risks from smoking.
1659171|NCT01783912|Drug|Nicotine Patch|Cognitive Motivational subjects will be asked to take one 21 mg patch/day for 4 weeks.
1659172|NCT01783912|Behavioral|Group Curriculum|Everyone to be put into the experimental or active comparator group will attend 2 group meetings over two weeks each of which lasts 40 minutes. Experience with the Kicking Butts program indicates that this duration is well tolerated by this population. The content of these two group meetings is based on the Kicking Butts program. The Kicking Butts program was initially developed as a cessation intervention, but consistent with the literature about the need to prepare this population to make a quit attempt, has evolved to emphasize preparation for quitting. Topics addressed include the health consequences of smoking, reasons to quit and methods of quitting.
1659173|NCT01783899|Device|Hemospray|"Patients will be resuscitated as needed to achieve hemodynamic stability in preparation for endoscopy within 24 hours of hospital admission.
once the bleeding point will be identified at endoscopy, the delivery catheter will be inserted through the endoscope and positioned toward the lesion, leaving 1-2 cm between the bleeding site and the catheter tip.
Hemospray will be then delivered in short spray bursts (for 1-2 seconds) until hemostasis was confirmed.
Once bleeding was controlled , the bleeding site will be observed for 5 minutes under endoscopy.
Oral food and fluid will be with held from the patient for 24 hours. Intravenous octreotide and esomeprazole will given for up to 24 hours. Patients will be closely monitored for signs of recurrent bleeding for 24 hours post procedure.
Recurrent bleeding will be diagnosed any patient experiencing recurrent bleeding will treated according to the institutional standard of care"
1659174|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
1659175|NCT01783886|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
1659176|NCT01783886|Procedure|Macular Laser Photocoagulation|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
1659177|NCT01783873|Other|standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™)|At Visit 1: Patients are selected and they will receive a metacholine challenge test during and outside of work. After randomization, patients undergo a standardized bronchial challenge test (SCL SCL • • GenaSOL ™ GenaSIC ™) to either an wheat flour allergen extract or didecyldimethylammonium chloride or placebo. Each bronchial challenge test is followed by blood sampling at different time points and induced sputum. The immediate bronchial response and late bronchial response will be recorded.
1659178|NCT01783860|Drug|Azithromycin|
1659179|NCT01783860|Drug|Doxycycline|
2013320|NCT00489827|Other|Intravenous glutamate infusion|Intravenous infusion of 0.125 M glutamic acid solution at a rate of 1.65 ml/hour and kg body weight beginning with institution of anesthesia and stopping 2 hours after unclamping of aorta in patients operated for unstable coronary artery disease.
1659181|NCT01783834|Drug|Gefitinib|compare progression free survivla rate and safety to both drugs
1659182|NCT01783834|Drug|Pemetrexed|compare PFS rate, safety to both drugs
1659183|NCT01783821|Drug|Budesonide|Subjects will receive the standard aerosolized dose of budesonide (0.5 mg).
1659184|NCT01783821|Drug|Placebo|Aerosolized normal saline will be prepared to mimic the intervention arm, with the quantity, appearance and timing of the doses the being the same.
1659185|NCT01783821|Drug|Formoterol|Subjects will receive the standard aerosolized dose of formoterol (20 mcg) .
1659186|NCT01783808|Other|Supplemental oxygen|"Patients are supposed to use ambulatory supplemental oxygen during physical activity. The intervention will last for six months.
In addition to supplemental oxygen the patients will be stimulated by a physiotherapist to be more physically active. A behavioural medicine intervention will be used."
1659187|NCT01783795|Genetic|Genetic Analysis|
1659188|NCT01783782|Behavioral|DIET|clear liquid diet for 12 hours on the day before CE, followed by an overnight fast
1659189|NCT01783782|Drug|polyethylene glycol 4000 solution with simethicon|patients received a high volume regime consisting of a 50 mL/Kg (up to 2 Lt/die) of PEG solution the evening before the examination, followed always by an overnight fast
1659190|NCT01783782|Drug|simethicon|Patients received 20 mL oral simethicone (Panamir, DMG, Italy, containing 40 mg simethicone in 1mL emulsion) and 200mL water 30 minutes before capsule ingestion
1659191|NCT01783769|Behavioral|"Low O.R. Traffic"|"Low OR Traffic protocol will restrict personnel movement thru the operating room to a bare minimum of personnel traffic."
1659192|NCT01783756|Drug|lapatinib ditosylate|Given PO
1659193|NCT01783756|Drug|everolimus|Given PO
1659194|NCT01783756|Drug|capecitabine|Given PO
1659195|NCT01783756|Other|laboratory biomarker analysis|Correlative studies
2013321|NCT00474864|Drug|GW856553|
2013322|NCT00466609|Drug|Clomipramine (fluoxetine plus clomipramine)|Clomipramine at maximum dosage of 75mg per day plus fluoxetine at maximum dosage of 40mg per day
1659198|NCT01783704|Dietary Supplement|Nutrition|Participants receive 2000 IU vitamin D3, 600 mg calcium, and a multivitamin daily for the duration of the study. Nutritional counseling is also provided. Participants are screened at time of randomization to assess nutritional risk using the Mini Nutritional Assessment-Short Form and contacted by a registered dietician (RD) within 7 days of randomization. Those who score ≤7 (malnourished) and participants with baseline serum albumin 2.5-3.5 g/dl receive a visit from an RD with follow-up a week later. Participants who score 8-11 (at risk of malnutrition) and have serum albumin level >3.5 g/dl receive a phone call from the RD and may receive an in-person visit if warranted. Those screening in the normal range (12-14) and have serum albumin level >3.5 g/dl receive a phone call from the RD. Weight is monitored every 4 weeks. Those who lose 2% or more body weight receive a call from the RD. Those who lose 5% or more body weight between baseline and follow-up may be referred to an RD.
1659199|NCT01783704|Behavioral|PUSH|Strength components of the muscle performance intervention are performed using a portable progressive resistive exercise device (Shuttle® MiniPress, Contemporary Design Company, P.O. Box 5089, Glacier, Washington 98244). Muscle performance focuses on bilateral hip extensors, hip abductors, knee extensors, and plantar flexors. Balance and strength are addressed with additional exercises performed while standing. The endurance intervention begins with 2-3 minutes of continuous upper and lower extremity active range of motion (AROM) with the participant sitting in order to increase the participants' heart rate (HR) or exertion closer to the target zone. The participant is then asked to walk on level surfaces and/or up and down steps to keep the HR within the training zone for 20 minutes.
1659200|NCT01783704|Behavioral|PULSE|During the AROM exercises, participants work to increase flexibility and range of motion. Exercises include the neck, shoulders, arms, trunk, hips, knees and ankles. During all AROM exercises, the participant focuses on deep breathing techniques. The second part of the session uses transcutaneous electrical nerve stimulation (TENS) on lower extremity muscle groups to decrease pain, thereby allowing greater ease of mobility. TENS uses low-level electrical current to stimulate superficial cutaneous nerve fibers through the skin. Flexible carbonized, disposable electrodes coated with a self-adhesive conductive polymer will be applied to the skin bilaterally near the motor points on muscle bellies (the gluteal complex, the quadriceps, and the gastrocnemius) for 7 minutes per muscle group.
1659201|NCT01783691|Drug|NKTT120|
1659202|NCT01783678|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
1659203|NCT01783678|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1659204|NCT01783665|Other|aerobic exercise|
1659205|NCT01783665|Other|home exercise program|
1659206|NCT01783652|Behavioral|Intervention group|Participants in the intervention group will have access to the anti-depression website modified and translated by the University of Hong Kong. 10 chapters on understanding depression, identifying depression symptoms and techniques tackling depression will be covered. Exercises and built-in questionnaires on measuring emotions will be provided in the website. Additional telephone follow-up counseling at the third, sixth and twelfth months will be conducted.
1659207|NCT01783639|Procedure|Carotid Artery Stent|Assessment of the study device (WIRION) during carotid artery stenting procedure in comparison to a performance of FDA approved filter type embolic protection devices
1659208|NCT01783626|Device|Evodial|
1659209|NCT01783626|Device|Evodial+ Condition B1|
1659210|NCT01783626|Device|Evodial+ Condition B2|
1659211|NCT01783626|Device|Evodial+ Condition C|
1659212|NCT01783613|Dietary Supplement|Docosahexaenoic acid administration: 50 mg/kg/day during 12 months|
1659213|NCT01783613|Dietary Supplement|Placebo: 50 mg/kg/day during 12 months|
1659214|NCT01783600|Device|NanoCross .014 balloon catheter|
1659215|NCT01783587|Drug|Afatinib|Taken orally once per day
1659216|NCT01783587|Drug|Docetaxel|15 mg/m2, given intravenously once per week
1659217|NCT01783587|Radiation|Radiation Therapy|Daily, Monday-Friday, for six to seven weeks
1659218|NCT01783574|Drug|Testosterone|
1659219|NCT01783574|Drug|Placebo|
1659220|NCT01783561|Drug|Caffeine|Infants will receive a blinded dose of either placebo (IV normal saline) or IV caffeine citrate 20mg/kg infused over 10 minutes within the first 2 hours of life. They will receive a blinded dose of the opposite of what they received in the DR (placebo or caffeine) at 6 hours of life. Therefore, the intervention is timing of initial caffeine dose.
1659221|NCT01783548|Drug|BDP Nasal Aerosol|
1659222|NCT01783548|Drug|Placebo|
2013323|NCT00466609|Drug|Quetiapine (fluoxetine plus quetiapine)|Quetiapine at maximum tolerated dosage of 200mg per day plus fluoxetine at maximum dosage of 40mg per day
2013324|NCT00466609|Drug|Placebo (fluoxetine plus placebo)|Placebo plus fluoxetine at maximum dosage of 80mg per day
2013325|NCT00447772|Drug|Botulinum type A toxin (Dysport®)|Active Drug: Botulinum type A toxin (Dysport®) 500 Units / 2.5 ml injected in muscles involved in cervical dystonia
2013326|NCT00442611|Drug|Abatacept|
2013327|NCT00442611|Drug|Placebo|
2013328|NCT00434512|Biological|HIV vaccine 732461|
2013329|NCT00425802|Biological|anti-thymocyte globulin|
2013330|NCT00425802|Biological|filgrastim|
2013331|NCT00425802|Biological|graft-versus-tumor induction therapy|
2013332|NCT00425802|Biological|rituximab|
2013333|NCT00425802|Drug|cyclophosphamide|
1659268|NCT01783262|Device|Device: Sham extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|
1659269|NCT01783249|Other|Stationary Exercise cycling|Stationary exercise cycling
1659270|NCT01783236|Drug|IV Acetaminophen|1000mg IV Ofirmev given every six hours for a total of four doses.
2013334|NCT00425802|Drug|cyclosporine|
2013335|NCT00425802|Drug|fludarabine phosphate|
2013336|NCT00425802|Drug|mycophenolate mofetil|
2013337|NCT00425802|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
2013338|NCT00425802|Radiation|total-body irradiation|
2013339|NCT00422058|Drug|liraglutide|Injected s.c. (under the skin) once daily
2013340|NCT00422058|Drug|orlistat|120 mg capsule. Administered thrice daily
2013341|NCT00422058|Drug|placebo|Injected s.c. (under the skin) once daily
2013342|NCT00419367|Drug|Comparator: vorinostat|Each patient will receive open-label vorinostat 400 mg q.d. capsules. Treatment will continue until disease progression, intolerable toxicity, withdrawal of consent, or physician determines it is in best interest of patient to withdrawal.
2013343|NCT00404066|Drug|Lapatinib|1250 mg, tablets, oral every day during treatment with docetaxel(every 3 weeks x 4 )
2013344|NCT00404066|Drug|Doxorubicin|60 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with cyclophosphamide.
2013345|NCT00404066|Drug|Cyclophosphamide|600 mg/m2, intravenously every 2 weeks for 4 cycles. Given as first treatment with doxorubicin.
1659238|NCT01783496|Device|Thermage CPT|Treatment with Thermage patterned, total, or framed tip
1659239|NCT01783483|Device|SternaLock Blue closure system|SternaLock Blue closure system is a primary closure system plate-based
1659240|NCT01783483|Device|Suture Wire|Closure system wire-based used to approximate the two halfs of the sternum following a median sternotomy.
1659241|NCT01783470|Drug|beta3-adrenergic receptor agonist|single dose. The subjects were randomized to receive placebo on one study day and active beta3-adrenergic receptor agonist on the other study day.
1659242|NCT01783457|Other|Control|Usual treatment: pharmacological treatment + regular sessions with their psychiatrist.
1659243|NCT01783457|Other|Individual psychoeducation|"Usual treatment + individual psychoeducational programme, consisting of 14 sessions of 60 minutes every other week for six months, focused on improving patient awareness of their condition, adherence to treatment, identification of prodromes, early intervention in potential relapses, anxiety management techniques, social skills, healthy lifestyle habits and problem solving.
Programme of sessions available upon request."
2013346|NCT00404066|Drug|Docetaxel|100 mg/m2, intravenously every 3 weeks for 4 cycles (after treatment cycles of doxorubicin and cyclophosphamide
2013347|NCT00404066|Drug|pegfilgrastim|6 mg, subcutaneously on day 2 of all cytotoxic chemotherapy treatments.
2013348|NCT00404066|Drug|filgrastim|300 or 480 mcg, subcutaneously on days 3 to 10 after cytotoxic chemotherapies.
1659247|NCT01783431|Drug|Poly ICLC|Poly-ICLC is considered an investigational drug and has not been approved by the Food and Drug Administration (FDA) for treatment of your disease. It is currently being tested in clinical trials for brain tumors, lymphoma, human immunodeficiency virus (HIV) and prostate cancer. It is thought that Poly-ICLC, when used with dendritic cells as a vaccine therapy, may work to help the immune system fight disease.
1659248|NCT01783431|Procedure|leukapheresis|Leukapheresis is a process in which white blood cells are collected from the body. These cells will be given together with Poly-ICLC therapy when subjects begin study treatment.
1659249|NCT01783418|Behavioral|Mindfulness Intervention|Mindfulness-based intervention adapted for teenagers
1659250|NCT01783392|Procedure|Transcutaneous Electrical Nerve Stimulation|
1659251|NCT01783379|Drug|micafungin|100mg/day infusion in 1 hour
1659252|NCT01783366|Device|TUBE EXCHANGER|
1659253|NCT01783353|Dietary Supplement|Zinc gluconate|
1659254|NCT01783353|Dietary Supplement|Corn starch pill|
1659255|NCT01783340|Drug|Azithromycin capsules|Azithromycin capsules will be administered at each immunization
1659256|NCT01783340|Drug|Placebo|Placebo capsules will be administered at each immunization
1659257|NCT01783340|Biological|Immunization with falciparum|three inoculations with 5 infected mosquito bites
1659258|NCT01783327|Behavioral|Teens-Connect|Teens-Connect combines Managing Diabetes and TEENCOPE. Managing Diabetes consists of 5 sessions on age-appropriate, educational content related to diabetes problem-solving and self-efficacy to improve self-management. TEENCOPE consists of 5 sessions designed to increase youth's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. The program is highly interactive and youth can talk with each other on an online moderated discussion board. Youth will be asked to use the website at least twice per week for 4 weeks.
1659259|NCT01783327|Behavioral|Planet D|Planet D provides age-appropriate diabetes education on a variety of topics and social networking discussion boards on diabetes, food and exercise, personal interests, and diabetes camp. Planet D addresses emotions and self-management through education and social networking. Youth who register can also create a profile, upload and share pictures, identify favorite news and blog feeds as well as provide comments or tags to other members. Planet D has been online since 2007 and contains numerous diabetes-related articles geared toward youth as well as a secure message board. Youth will be asked to interact with the website twice a week for 4 weeks.
1659260|NCT01783314|Procedure|MRI of liver|MRI of liver with intravenous gadoxetate disodium
1659261|NCT01783301|Drug|FSH|
1659262|NCT01783288|Other|Autonomic Function Testing|"heart rate and blood pressure will be continuously monitored while participants undergo a variety of breathing techniques (deep breathing, rapid breathing, blowing against resistance) and during sustained handgrip and cold pressor (hand in ice water). All tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the autonomic nervous system is functioning.
Also during autonomic function testing, cardiac output will be measured to analyze the shift of fluids in the body (body impedance) and / or by analyzing the air that is breathed."
1659263|NCT01783288|Other|Posture Study|Blood pressure, heart rate and blood samples (for catecholamines and hormones) will be measured & collected in the supine (lying) and upright position for each participant.
1659264|NCT01783288|Procedure|Measurement of Total Blood Volume|Total blood volume is measured by using iodinated I-131 tagged human serum albumin.
1659265|NCT01783288|Other|Exercise Capacity Test|Participants will ride on a stationary recumbent bicycle and the resistance will be gradually increased while expired air is measured.
1659266|NCT01783275|Behavioral|Aerobic exercise|12 weeks of aerobic exercise with weight maintenance
1659267|NCT01783262|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.09 mJ/mm2, 2400 pulses once a week for 4 weeks.
2013349|NCT00404066|Drug|dexamethasone|8 mg, oral taken twice a day for 3 days starting 24 hours before docetaxel
2013350|NCT00404066|Drug|trastuzumab|loading: 8 mg/kg/then 6 mg/kg, intravenous every 3 weeks for 1 year
2013351|NCT00377611|Biological|Fluarix™|
1659271|NCT01783236|Drug|Saline Placebo|Normal saline placebo given every six hours for a total of four doses if randomized to the placebo arm.
1659272|NCT01783210|Behavioral|Specific Therapeutic Lifestyle Changes program in pregnancy|"TLC Program includes diet and mild physical activity. The TLC comprises 1500 kcal/day (3 main meals and 3 snacks) composed of 55% carbohydrate, 20% protein, and 25% fat. The dietitian adds an 200 kcal/day for obese or 300 kcal/day for overweight. The exercise intervention is focused on increasing walking. All participants are advised to participate in 30 min of moderate intensity activity at least 3 days a week. Subjects wear a pedometer waist during walking session for the assessment of the adherence to the physical activity program. Women are told to consider using the talk test (being able to maintain a conversation during activity) to monitor exercise intensity, and to record the frequency and duration of the activity on a diary . Follow-up is performed at 16, 20, 28, 36 weeks."
1659273|NCT01783210|Behavioral|Dietary and behavioral counselling in pregnancy|"The Control group receives only a simple nutritional booklet about a lifestyle and healthy diet during pregnancy without explicit caloric restriction, in accordance with Italian Guidelines for a healthy diet during pregnancy, compatible with a recommended nutritional intake.
30 minutes counseling session about the appropriate gestational weight gain (GWG) at term for each different BMI category is performed. Moreover, the importance of the limited GWG for preventing unfavorable maternal-neonatal outcomes related to excessive weight gain is explained. Women are scheduled to have a follow-up at 16, 20, 28, 36 weeks."
1659279|NCT01783171|Drug|Akt Inhibitor MK2206|Given PO
1659280|NCT01783171|Drug|Dinaciclib|Given IV
1659281|NCT01783171|Other|Laboratory Biomarker Analysis|Correlative studies
1659282|NCT01783171|Other|Pharmacological Study|Correlative studies
1659283|NCT01783158|Procedure|Esophagoscopy and chromoendoscopy|"Esophagoscopy - examination of the interior of the esophagus by means of an esophagoscope.
Chromoendoscopy - a method, which involves the topical application of stains or pigments to improve tissue localization, characterization, or diagnosis during endoscopy."
1659284|NCT01783132|Device|NIOX MINO|Active group (Budesonide) will be measuring exhaled NO at least 3 times/week at home to control their Asthma treatment via a algorithm schedule. The control group (Standard of care) will be measuring exhaled NO 4 times/year at study site.
1659285|NCT01783119|Dietary Supplement|Aloe Barbadensis Miller|
1659286|NCT01783119|Dietary Supplement|placebo water|
1659287|NCT01783106|Drug|Ciprofloxacin|experimental
1659288|NCT01783106|Drug|Doxycycline|experimental
1659289|NCT01783106|Drug|Hydroxychloroquine|oral
1659290|NCT01783106|Drug|Budesonide|active comparator
1659291|NCT01783093|Other|Data Collection|Collection of data from existing medical records
1659292|NCT01783080|Behavioral|Behavioral Activation for return to work|See Arm Description
1659293|NCT01783067|Other|Pearl millet|Participants in the control arm consume pearl millet which has not been biofortified. The intervention is consumed for two days.
1659294|NCT01783067|Other|Biofortified pearl millet|Participants in the experimental arm consume pearl millet biofortified with iron and zinc. The intervention is consumed for two days.
1659295|NCT01783054|Procedure|Surgery|Subjects will then receive surgery at MUSC within 4-8 weeks following completion of chemotherapy
1659296|NCT01783054|Genetic|Genetic Expression|Subjects will have genetic expression testing done on their tissue samples.
1659297|NCT01783054|Drug|Chemotherapy|Patients will receive gemcitabine at 1000 mg/m2 and abraxane at 125 mg/m2 intravenously on days 1, 8 and 15 of a 28 day cycle for 2 cycles
1659298|NCT01783041|Drug|L-carnitine|Infants will receive L-carnitine 50 micromoles/kg/day, divided into three doses, intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent dose of enteral L-carnitine will be given to the study patients.
1659299|NCT01783041|Drug|5% Dextrose|Infants will receive 5% dextrose (placebo) three times a day (volume equivalent to the experimental drug) intravenously for a minimum of 2 weeks or until they achieve enteral feeding volume of 100 cc/kg/day. If infant is receiving 100 cc/kg/day of enteral feeds before the supplementation endpoint, an equivalent volume of enteral placebo (5% Dextrose) will be given to the study patients.
1659300|NCT01783028|Behavioral|Community Health Worker support|For the intervention group, a trained Community Health Worker (CHW) provided education, support and service coordination through home visits. The CHW first made an in home assessment visit. At the assessment visit, the participant had the opportunity to ask questions and sign written consent. During this visit, the CHW assessed the participant's knowledge of asthma, current status of asthma control, challenges with controlling asthma, self-management practices and exposure to asthma triggers. After enrollment, the participant received up to four follow-up educational visits 0.5, 1.5, 3.5 and 7 months later. In addition to scheduled visits, the CHWs worked with their participants on an as-needed basis via telephone, email, or additional home visits.
1659301|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
1659302|NCT01783015|Drug|Etanercept|Etanercept 50 mg once-weekly
1659303|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
1659304|NCT01783015|Drug|Placebo|Etanercept placebo once-weekly
1659305|NCT01783002|Radiation|11C-Methionine PET/CT scanning|PET with the radiopharmaceutical carbon-11 methionine (11C-MET) has been considered to improve diagnosis due to a superior spatial resolution and higher specificity compared to other radiotracers such as 18F-FDG. For the 11C-MET PET/CT, the patient will receive an intravenous bolus injection of 11C-MET as manufactured at the BCCA production facility at a dose of 6 (0.16 mCi) MBq per kilogram but not to exceed 555 MBq (15 mCi).
1659306|NCT01783002|Radiation|18F-FDG PET/CT scanning|For PET/CT scans, the patient will first receive an intravenous bolus injection of 18F-FDG as manufactured at the BCCA production facility in a dose determined by body weight but not to exceed 521 MBq (14.1 mCi). Our standard adult prescription (70kg adult) for 18F-FDG is 296 MBq (8.0 mCi). The target dose for body scans is increased by 59.2 MBq (1.6 mCi) for every 20 kg increase in body weight to a maximum target dose of 474 MBq (12.8 mCi).
1659490|NCT01781468|Drug|armodafinil 250 mg|given orally
1659491|NCT01781455|Drug|BBI503|
1659307|NCT01783002|Radiation|SPECT-CT scanning|For the SPECT-CT scan, each injection of intravenous 99mTc-MIBI is dosed at a maximum of 20 mCi (740MBq), as per usual standard of care. The energy window of each scan is at 140 keV, consistent with the standard of SPEC-CT imaging techniques.
1659308|NCT01782989|Drug|ORACEA®|ORACEA® (40mg doxycycline) capsule daily for 24 months
1659309|NCT01782989|Drug|Placebo|Placebo capsule daily for 24 months
1659310|NCT01782976|Drug|Cilengitide|2000 mg by vein twice weekly of each 28 day cycle.
1659311|NCT01782976|Drug|Bevacizumab|10 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
1659312|NCT01782976|Behavioral|Questionnaire|Completion of MD Anderson Symptom Inventory for Brain Tumors (MDASI-BT) at baseline, Day 1 of cycle 2, and at end of treatment visit. Questionnaire should take about 5 minutes to complete.
1659313|NCT01782963|Drug|Lenalidomide|
1659314|NCT01782963|Drug|Bortezomib|
1659315|NCT01782963|Drug|Dexamethasone|
1659316|NCT01782950|Drug|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide|Rifampicin, Isoniazid, Ethambutol, Pyrazinamide: 3, 4 or 5 tablets daily for weight below 55kg, above 55kg or above 70kg respectively for first 2 months followed by Rifampicin, Isoniazid: 3, 4 or 5 tablets daily for patients' weight below 55kg, above 55kg or above 70kg respectively for 4 months
1659317|NCT01782937|Drug|KHK4827|140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
1659318|NCT01782924|Drug|KHK4827|
1659319|NCT01782911|Dietary Supplement|Resveratrol|The patients will take 2 g of resveratrol per day for 40 days.
1659320|NCT01782911|Dietary Supplement|Placebo pills|The patients will take placebo for 40 days.
1659321|NCT01782898|Drug|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min|Esmolol administered at a rate of 0.5 mg/kg followed by an infusion of 5-15 mcg/kg/min
1659322|NCT01782898|Drug|Placebo Comparator: .9 normal saline|Placebo Comparator: Placebo .9 normal saline infused at the same rate (/mg/kg bolus followed by 5-15 mcg/kg/mn) as the Esmolol would be administered,
1659323|NCT01782885|Procedure|Intra-articular injection of PRP|Patients from this arm will receive 3 intra-articular knee injections of autologous platelet-rich plasma, one injection every two weeks (6 weeks total).
1659324|NCT01782885|Drug|Acetaminophen|Patients from this arm will receive a dosis of acetaminophen (500 mg/8 hours) while PRP treatment lasts (6 weeks total).
1659325|NCT01782872|Procedure|Interscalene Block (ISB) - 0.375% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.375% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous (IV): saline
1659326|NCT01782872|Procedure|Interscalene Block (ISB) - 0.2% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.2% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
1659327|NCT01782872|Procedure|Interscalene Block (ISB) - 0.1% Ropivacaine + additives|Ultrasound-guided single-injection ISB: ropivacaine 0.1% + (clonidine [100 mcg] + dexamethasone [4 mg] + buprenorphine [150 mcg]); Intravenous: saline
1659328|NCT01782872|Procedure|Interscalene Block (ISB) - Systemic Control|Ultrasound-guided single-injection ISB: ropivacaine 0.375%; Intravenous: clonidine (100 mcg) + dexamethasone (4 mg) + buprenorphine (150 mcg)
1659329|NCT01782859|Drug|Prednisone|
1659330|NCT01782859|Drug|Hydrocortisone|
1659331|NCT01782859|Drug|Placebo (for Prednisone)|
1659332|NCT01782846|Drug|Ixprim®|
1659333|NCT01782846|Drug|Dafalgan-Codeine®|
1659334|NCT01782833|Drug|Pletaal|
1659336|NCT01782794|Other|Data collection|Poll and questionnaire-based methodology completed by face-to-face interviews, with possible additional follow-up offered to households.
1659337|NCT01782781|Drug|ropivacaine, ketorelac and epinephrine|Active group
1659338|NCT01782781|Drug|Placebo|Placebo group
1659339|NCT01782768|Device|noninvasive positive pressure ventilation|the assisted level of the noninvasive proportional assist(PAV) and pressure support ventilation(PSV) on Neural respiratory drive(NRD) in recovering patients with acute exacerbation of chronic obstructive pulmonary disease
1659340|NCT01782755|Drug|L. rhamnosus GG - Probiotic|Twice daily, patients will receive either 1x1010 colony forming units (CFU) of L. rhamnosus GG (Culturelle, Locin Industries Ltd) in 1 capsule or an identical placebo capsule
1659341|NCT01782755|Other|Placebo - Microcrystalline Cellulose|Placebo capsule, twice daily (containing Microcrystalline Cellulose)
1659342|NCT01782742|Drug|Bexarotene|Subjects will be randomized 4:1 to receive 4 weeks of double blind treatment of either Bexarotene or Placebo
1659343|NCT01782742|Drug|Placebo|
1659345|NCT01782677|Procedure|Bilateral Surgical Resection of Carotid Bodies|
1659346|NCT01782664|Drug|100 mg GSK2586184|100 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
1659347|NCT01782664|Drug|200 mg GSK2586184|200 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
1659348|NCT01782664|Drug|400 mg GSK2586184|400 mg GSK2586184 to be taken twice daily with food (as tablets) for up to 84 days.
1659349|NCT01782664|Drug|Placebo|Placebo tablets to be taken twice daily with food for up to 84 days.
1659350|NCT01782651|Drug|Lapatinib plus capecitabine|Lapatinib plus capecitabine
1659351|NCT01782638|Behavioral|deep brain stimulation|
1659352|NCT01782625|Other|NO exercise at depth|Subjects will NOT exercise while at depth
1659353|NCT01782625|Other|exercise at depth|Subjects will exercise while at depth
1659354|NCT01782612|Procedure|Multimodal analgesic techniques|Postoperative pain was controlled for all patients routinely by intravenous sulfentanil patient-controlled analgesia (PICA) in combination with Parecoxib(40 mg, every 12 h). PICA was continued with sulfentanil (1.25 µg.h-1) and 1.25 µg sulfentanil bolus with a 8-min lockout time. Oral oxycodone 0.2 mg was administered necessarily.
1659355|NCT01782612|Procedure|Total uni-Hip Replacement|All subjects will undergo standard Total uni-Hip Replacement
1659356|NCT01782599|Other|Dual nicotine patch and electronic cigarette|
1659617|NCT01780376|Procedure|whole-body vibration (WBV)|whole-body vibration (4 mm amplitude, 25,30,35,40,45,50 Hz)
1659357|NCT01782573|Drug|Chlorhexidine gluconate|(i)a sterile washcloth was saturated with 60ml of chlorhexidine gluconate (4%) cleansing solution and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
1659358|NCT01782573|Drug|0.9% Sodium Chloride|(i)a sterile washcloth was saturated with 60ml of sodium chloride (0.9%) and generously applied to the predefined surgical site followed by vigorous scrubbing for 3 min. (ii) after being patted with a sterile towel, the standardized 3-step disinfection was performed (iii) the applied iodine-alcohol disinfectant contained 70 ml of ethyl alcohol and 10 g of povidone-iodine per 100 ml
1659359|NCT01782560|Drug|Omeprazole|Omeprazole (a proton-pump inhibitor) is the most common treatment given to infants with laryngomalacia, in the hope that this will reduce their symptoms. Although this is an effective anti-reflux medication in this population, its use is off-label, and like any medication has potential risks, particularly in very young children. Side effects that have been described include abdominal pain, diarrhea, constipation, and cough. Although omeprazole is usually a safe medication, we do not currently know if it provides any benefit in laryngomalacia.
1659360|NCT01782560|Drug|Placebo|
1659361|NCT01782547|Behavioral|Telehealth Intervention|Monthly videoconference with diabetes nurse educator; Monthly videoconference with social worker; Diabetes action plan;
1659362|NCT01782547|Other|Usual Care|Standard diabetes care- typically a visit with a diabetes health care provider every 3 months and referrals to a dietitian or mental health specialist as deemed appropriate; Study participation reminder cards twice per month
1659363|NCT01782521|Procedure|No primer|Primer not used when bonding orthodontic brackets
1659364|NCT01782508|Drug|imatinib|a selectively inhibits the KIT protein tyrosine
1659365|NCT01782508|Drug|Interferon|Interferon belongs to the large class of glycoproteins known as cytokines.
2013352|NCT00368082|Biological|TGFbeta resistant LMP-specific CTLs|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Group One:
Day 0 2 x 10^7 cells/m2 Day 14 2 x 10^7 cells/m2
Group Two:
Day 0 6 x 10^7 cells/m2 Day 14 6 x 10^7 cells/m2
Group Three:
Day 0 1.5 x 10^8 cells/m2 Day 14 1.5 x 10^8 cells/m2"
2013353|NCT00359736|Drug|sildenafil|Assessing the possible therapeutic benefit of sildenafil on exercise tolerance in IPF patients.
2013354|NCT00351611|Drug|Lyrica (pregabalin)|150 mg twice a day, oral administration
1659369|NCT01782482|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
1659370|NCT01782482|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
1659371|NCT01782456|Other|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
1659372|NCT01782443|Drug|Ziv-aflibercept|
1659373|NCT01782430|Procedure|- standard oxygenation|
1659374|NCT01782417|Behavioral|patient and provider intervention|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
1659375|NCT01782404|Device|Chlorhexidine|Bladder irrigation with chlorhexidine 0.2 mg/ml twice daily
1659376|NCT01782391|Device|Stimulation|
1659377|NCT01782391|Device|SHAM|no stimulation
1659378|NCT01782378|Device|Photomedex Helmet, with Near-Infrared Light-Emitting Diodes (LEDs), Sham Helmet is identical but has power output of 0.|The LED helmet from Photomedex, Horsham, PA will be used. 18 LED pods are in the helmet. Each LED pod: Pod size: 4.5 x 4.8 cm, 21.6 cm2 Power output: 665.3 mW Power density: 30.8 mW/cm2 20 NIR diodes, 830 nm
1659379|NCT01782378|Device|Intranasal LED device, Sham intranasal device appears identical but has power output of 0.|"Red and Near-infrared LED devices will be used.
Power output: 6.5 mW
Power density: 7.6 mW/cm2
Wavelength: 633 and 810 nm"
1659380|NCT01782365|Device|SHAM stimulation|no stimulation
1659381|NCT01782365|Device|0,75 Hz stimulation|
1659382|NCT01782352|Drug|Omega-3 fatty acids (fish oil)|
1659383|NCT01782352|Dietary Supplement|Vitamin D3|
1659384|NCT01782352|Dietary Supplement|Vitamin D3 placebo|
1659385|NCT01782352|Dietary Supplement|Fish oil placebo|
1659386|NCT01782339|Drug|Combination Chemotherapy|"4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2
*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.
NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle."
1659387|NCT01782326|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept 1 SDDPI.
1659388|NCT01782326|Drug|Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)|Salmeterol/fluticasone dry inhalation powder delivered via the Accuhaler device.
1659389|NCT01782313|Drug|tivozanib|Given PO
1659390|NCT01782313|Other|laboratory biomarker analysis|Correlative studies
1659391|NCT01782300|Biological|TV003 Vaccine|TV003 will contain an admixture of the following monovalent dengue vaccines: 10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30. TV003 vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
1659392|NCT01782300|Biological|Placebo Vaccine|Placebo vaccine will be administered by subcutaneous injection in participants' deltoid region of the upper arm.
2013355|NCT00351611|Drug|placebo|Twice a day, oral administration
1659397|NCT01782261|Drug|Liraglutide|once daily subcutaneous injection
1659398|NCT01782261|Drug|Saxagliptin|once daily tablet
1659399|NCT01782248|Other|Questionnary and IRM|
1659400|NCT01782235|Drug|Tocilizumab|
1659401|NCT01782235|Drug|Placebo|
1659952|NCT01777542|Drug|Recombinant Human Insulin Growth Factor 1 (rhIGF-1)|Subjects will receive twice daily subcutaneous injections of IGF-1.
1659402|NCT01782222|Drug|Rotigotine|"Rotigotine, transdermal patches:
10 cm^2 (2 mg / 24 hours); 20 cm^2 (4 mg / 24 hours); 30 cm^2 (6 mg / 24 hours); 40 cm^2 (8 mg / 24 hours)
The maximum Rotigotine dose allowed is 8 mg / 24 hours or 16 mg / 24 hours for patients with advanced Parkinson's Disease and 6 mg / 24 hours or 8 mg / 24 hours for those with early Parkinson's Disease Duration: up to 21 weeks (including de-escalation)"
1659403|NCT01782222|Other|Placebo|"Placebo, matching transdermal patches
Duration: up to 21 weeks (including de-escalation)"
1659404|NCT01782196|Device|Enhanced one piece drainable pouch with Type A mouldable adhesive|
1659405|NCT01782196|Device|Enhanced one piece drainable pouch with Type B mouldable adhesive|
1659406|NCT01782183|Device|Thermal camera by Flir -HM series.|The patient will be photographed twice by directing the camera externally to each tonsil from below the mandibular angle
1659407|NCT01782170|Drug|Iocide Oral Rinse|
1659408|NCT01782170|Drug|Placebo|
1659409|NCT01782144|Other|NutriSystem portion-controlled pre-packaged meals|
2013356|NCT00331344|Drug|mitoxantrone hydrochloride|Given IV
2013357|NCT00331344|Drug|ixabepilone|Given IV
1659412|NCT01782118|Dietary Supplement|Lactobacillus GG|
1659413|NCT01782105|Behavioral|Healthy lifestyle counseling|Nutritionnal and physical activity counseling and physical activity session group
1659414|NCT01782105|Behavioral|Control group|Evaluation of nutritional and physcial activity habits
1659415|NCT01782092|Other|Chiropractic Adjustment|Chiropractic adjustments will be administered using Activator Methods Basic protocol
1659416|NCT01782079|Dietary Supplement|L. brevis|
1659417|NCT01782066|Biological|MEN-ACYW135 reduced-dose intradermal administration|Modified traditional dose escalation rule (TER) in an adaptive design. The study will be performed in duplicate, with 2 vaccines.
1659418|NCT01782053|Behavioral|Picture warning|Warning contains picture proposed for each text statement by FDA
1659419|NCT01782053|Behavioral|Control|
1659420|NCT01782040|Other|Auriculotherapy group|It was used semipermanent needles (1.5mm) to stimulate points, once on a week, during 8 sessions.
1659421|NCT01782027|Drug|3H-cholesterol bound to albumin|up to 100 uCi of [3H]-cholesterol (containing approximately 0.2 mg of cholesterol) mixed with a solution containing human serum albumin will be administered as an intravenous bolus injection
1659422|NCT01782014|Procedure|colonoscopy|colonoscopy using different methods of insufflation
1659423|NCT01782001|Dietary Supplement|vitamin A|vitamin A with placebo
1659424|NCT01782001|Dietary Supplement|vitamin A and zinc|combination of vitamin A and zinc supplements
2013358|NCT00331344|Drug|prednisone|Given orally
1659426|NCT01781975|Drug|Imatinib Mesylate|
1659427|NCT01781975|Drug|Placebo (For imatinib mesylate)|
1659428|NCT01781962|Other|No Treatment|No Treatment was given in this study.
1659429|NCT01781949|Other|A: Nontargeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be offered voluntary, free, and confidential rapid HIV testing by nurses using opt-out consent during medical screening.
1659430|NCT01781949|Other|B: Enhanced targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from the Denver HIV Risk Score (DHRS). Patients will be considered at increased risk for HIV infection if they have a DHRS score of 30 or more. These increased-risk patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients identified as low risk (DHRS <30) will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
1659431|NCT01781949|Other|C: Traditional targeted rapid HIV screening|Patients who present to the ED for evaluation, who meet criteria for inclusion, and who are randomized to this arm will be asked questions from a Behavioral Risk Screening Tool (BRST). The BRST was adopted from the 2001 Centers for Disease Control and Prevention's recommendations for targeted HIV screening, and includes 6 questions. An affirmative response to 1 or more questions identifies the person as being at increased risk for HIV infection. These patients will be offered rapid HIV testing using opt-out consent by nurses during medical screening. Patients who do not respond affirmatively to any of the questions will not be offered rapid HIV testing but will eligible for diagnostic HIV testing.
1659432|NCT01781936|Drug|Fluocinolone Acetonide|
1659433|NCT01781923|Behavioral|Cognitive remediation program|Subject plays for 30 minutes, 4 times per week, for 12 weeks.
1659434|NCT01781923|Behavioral|Small group social skills training|Meet once per week for duration of 40 weeks.
1659435|NCT01781910|Dietary Supplement|Branched Chain Amino Acid drink supplement|
1659436|NCT01781910|Dietary Supplement|Placebo|
1659437|NCT01781897|Device|acupuncture|sterile, disposable needles with a length of 40 mm and a diameter of 0.25 mm (Dongbang® Acupuncture Inc, Korea)
1659438|NCT01781897|Drug|mosapride|Mosapride Citrate tablet（5mg），Dainippon Sumitomo pharmaceutical Co.Ltd,Japan
1659439|NCT01781884|Drug|Gamma Aminobutyric Acid (GABA)|two dosages will be used in this study. GABA: 50mg/kg/day and 100mg/kg/day
1659440|NCT01781884|Drug|Placebo|
1659441|NCT01781871|Biological|Prevenar13|Prevenar13 0.5ml injected intramuscularly (im.) at day 1 and at 6 months after the transplantation.
1659442|NCT01781871|Biological|Pneumovax|0.5ml Pneumovax injected intramuscularly at day 1.
1659443|NCT01781845|Procedure|AFRI-SVI Ultrasound|This research scan uses acoustic radiation force impulse (ARFI) shear wave velocity imaging (SVI)a new ultrasound technology in which unique sound waves create the images/pictures of the kidney beng examined/scanned. This ultrasound scan will take approximately 10 minutes to complete.
2013359|NCT00318669|Drug|Paroxetine hydrochloride hydrate|
1660045|NCT01776697|Drug|pelubiprofen (30mg) tablet IR|
2013360|NCT00310180|Drug|Anastrozole|Given PO
2013361|NCT00310180|Drug|Exemestane|Given PO
2013362|NCT00310180|Other|Laboratory Biomarker Analysis|Correlative studies
2013363|NCT00310180|Drug|Letrozole|Given PO
2013364|NCT00310180|Other|Quality-of-Life Assessment|Ancillary studies
2013365|NCT00310180|Radiation|Radiation Therapy|Undergo radiation therapy or partial breast irradiation
2013366|NCT00310180|Drug|Tamoxifen Citrate|Given PO
1659445|NCT01781819|Procedure|ARFI SVI Ultrasound Imaging|Following a clinical renal ultrasound scan, the research scan using the ultrasound based acoustic radiation force impulse, or shear wave velocity imaging will be performed using standard approved ultrasound machines and transducers. This imaging will take approximately 5 to 10 minutes to complete.
1659446|NCT01781806|Drug|emtricitabine 200mg/tenofovir 300mg|The intervention medication will be tenofovir + emtricitabine, provided as a fixed-dose combination tablet as Truvada®. Dosing is 1 tablet by mouth once daily. For participants with a a confirmed (i.e. two consecutive) reduction in CrCl to <50 mL/min, Truvada will be dose-reduced to 1 tablet by mouth every other day. For patients with creatinine clearance <30 mL/min, Truvada will be discontinued.
1659447|NCT01781793|Other|Room air|Humidified room air (21% oxygen) will be inspired
1659448|NCT01781793|Other|Hyperoxia|60% oxygen will be inspired
1659449|NCT01781780|Behavioral|General Nutrition Recommendations|
1659450|NCT01781780|Behavioral|Breakfast Recommendation|
1659451|NCT01781780|Behavioral|No Breakfast Recommendation|
1659452|NCT01781754|Procedure|Blood withdrawal|This is the only intervention that is part of the study. A family physician or other physician will be responsible of the diabetic treatment (common treatment, e.g Metformin).
1659453|NCT01781741|Combination Product|therapeutic lymphadenectomy (TEMLA) and Stereotactic Body radiation therapy (SBRT)|Undergo TEMLA and SBRT
1659454|NCT01781741|Other|quality-of-life assessment|Ancillary studies
1659455|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 5 Gy x 5 (over 1-2 weeks)*
1659456|NCT01781728|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT 6.6 Gy x 5 (over 1-2 weeks)*
1659457|NCT01781715|Device|Zotarolimus-eluting coronary stent|Multivessel stenting or Staged PCI with Zotarolimus-eluting coronary stent in STEMI patients
1659460|NCT01781689|Procedure|Functional Electric Stimulation|apply to the hemiplegia affected limbs, helping movement
1659461|NCT01781689|Other|Rehabilitation programs|include occupational therapy and physical therapy
1659462|NCT01781663|Device|KAM2904 Face Cream|
1659463|NCT01781663|Device|KAM3008 Body Lotion|
1659464|NCT01781663|Other|petrolatum-based moisturizer|
1659465|NCT01781650|Other|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
1659466|NCT01781650|Other|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
1659467|NCT01781650|Other|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
1659468|NCT01781637|Drug|Omalizumab|subcutaneous injection
1659469|NCT01781637|Drug|placebo|subcutaneous injection
1659470|NCT01781624|Other|Study Oral Nutritional Supplement|Supplement contains a new protein mix consisting of a blend of milk, soy, and pea protein.
1659471|NCT01781611|Drug|extended release dipyridamole 200mg/aspirin 25mg|one tablet twice daily for 24 weeks
1659472|NCT01781611|Drug|81mg aspirin|half a tablet twice daily for 24 weeks
1659473|NCT01781598|Device|Total knee arthroplasty (TKA) (Smith &Nephew®)|
1659474|NCT01781585|Procedure|hemodialysis|Patients were randomized to receive CVVH or SLED and the next day on the other.
1659475|NCT01781572|Drug|LEE011 and MEK162|MEK162 will be administered orally twice daily on a continuous dosing schedule. LEE011 will be administered orally once daily for 21 days followed by a 1 week break (28-day cycle).
1659476|NCT01781572|Drug|LEE011 and MEK162|Once the MTD(s)/RP2D have been determined for each tested dose schedule, the phase II part will begin at the RP2D on the chosen schedule in order to assess antitumor activity of the LEE011 and MEK162 combination.
1659477|NCT01781572|Drug|LEE011 and MEK162|MEK162 will be administered orally twice daily and LEE011 will be administered orally once daily for 3 weeks followed by a 1 week break (28-day cycle).
1659478|NCT01781572|Drug|LEE011 and MEK162|MEK162 will be administered orally twice daily and LEE011 will be administered once daily for 2 weeks followed by a 1 week break (21-day cycle).
1659479|NCT01781559|Dietary Supplement|phenolic acid|phenolic acid
1659480|NCT01781546|Procedure|drug-eluting balloon (DEB)|The length of the DEB is chosen so that the lesion and 2mm from both ends are covered by the DEB. If needed, several DEBs can be used to cover the whole lesion. The diameter of the DEB and the pressure used is chosen so that the balloon-artery -ratio is 0.8-1.0. In case of a flow limiting dissection, significant recoil or coronary perforation, a provisional BMS is implanted (stent-artery -ratio 1.1) and the post dilatation is performed if indicated (the lesion length is >20mm or stent malapposition is suspected).
1659481|NCT01781546|Procedure|bare-metal stent (BMS)|The BMS is implanted after predilatation (stent-artery -ratio 1.1) to cover the whole lesion and the postdilatation is performed if indicated (the lesion length >20mm or stent malapposition is suspected).
1659482|NCT01781533|Procedure|algorithm|
1659483|NCT01781520|Other|S-1 plus DC-CIK|
1659484|NCT01781507|Drug|Cetirizine|Cetirizine is an antihistamine currently indicated for allergic rhinitis
1659485|NCT01781507|Drug|Placebo|This placebo ( sugar pill) will provide the negative control for this study
1659486|NCT01781494|Procedure|Immobilization followed by protected range of motion|
1659487|NCT01781494|Procedure|Immediate range of motion|
1659488|NCT01781468|Drug|armodafinil 150 mg|given orally
1659489|NCT01781468|Other|Placebo|given orally
1659492|NCT01781442|Drug|Temsirolimus|"The recommended dose of Torisel is 25 mg infused over a 30-60 minute period once a week.
Treatment will continue until disease progression or unacceptable toxicity.
The use and dosage recommendations for Torisel will take place on the basis of the approved local product document and will be adjusted solely according to medical and therapeutic necessity."
1659493|NCT01781429|Drug|BVD-523|Oral, multiple escalating doses, twice daily, for 21 days in each treatment cycle
1659494|NCT01781403|Drug|Temozolomide|Preoperative chemoradiotherapy with fixed dose of capecitabine and temozolomide, the dose of temozolomide will be escalated for finding MTD and RD.
1659495|NCT01781390|Biological|12.5 M Mesenchymal Precursor Cells (MPC)|MPCs
1659496|NCT01781390|Other|Placebo|Placebo
1659497|NCT01781390|Biological|25M Mesenchymal Precursor Cells (MPC)|MPC
1659498|NCT01781377|Drug|PROPOFOL|PROPOFOL FOR NAUSEA AND VOMITING PROPHYLAXIS
1659499|NCT01781377|Drug|METOCLOPRAMIDE|METOCLOPRAMIDE FOR NAUSEA AND VOMITING PROPHYLAXIS
1659500|NCT01781377|Drug|PLACEBO|SALINE INFUSION
1659501|NCT01781364|Behavioral|Brain Fitness Training, Posit Science SF|Computer aided cognitive training based on principles of neuroplasticity
1659502|NCT01781351|Other|Taping the ankle|
1659503|NCT01781338|Other|Induction therapy|The intervention is dependent on the respective sub-protocol and can include either endocrine therapy, neoadjuvant chemotherapy or targeted therapy.
1659504|NCT01781325|Device|IBEHR|physical therapy device to educate patients in physical therapy exercise performance
1659505|NCT01781312|Dietary Supplement|ProTectis|
1659506|NCT01781312|Dietary Supplement|Gastrus|
1659507|NCT01781299|Device|AlloDerm RTU|
1659508|NCT01781299|Device|SurgiMend PRS|
1659511|NCT01781273|Other|Ethanol|During a 45 min period, investigators will ask participants to drink 500ml of cranberry juice, 100 ml at a time each 5 minutes. Depending of the allocation, these drinks will contain more or less alcohol. Pure ethanol will be used mixed with the beverage. The amount of alcohol to dilute in the drink will be calculated using Widmarks formula. Participants will move to the simulator room 20 minutes after having finished drinking the first 500 ml. To maintain the BAC level, investigators will use a breathalyser and provide 100 ml cranberry juice every 20 minutes with the amount of necessary alcohol. The person administrating drinks will hand over the drinks and make sure the participants breaths in before taking a sip, thereby inhaling alcohol vapour from the lid and keeping them blinded to the content.
1659512|NCT01781273|Other|Cranberry juice|100 mL cranberry juice is provided in a 250 ml container.
1659513|NCT01781247|Behavioral|Minimal behavioral intervention|The minimal behavioral intervention consists of one single counseling session of 45 minutes that targets specific MI-triggered traumatic reactions. The focus of the intervention is an educational and resource-oriented approach targeting individual patient resources and cognitive (re)structuring.
1659514|NCT01781247|Behavioral|Control intervention|"The control intervention consists of one single counseling session of 45 minutes that targets more general information about the role of psychological stress in coronary heart disease. Any terminology related to trauma will be completely avoided."
1659515|NCT01781234|Drug|Intranasal Insulin|
1659516|NCT01781234|Drug|Placebo|
1659517|NCT01781221|Device|Alpha-Bio's GRAFT Natural Bovine Bone|
1659518|NCT01781221|Device|Bio-Oss xenograft|
1659519|NCT01781208|Device|Ultrasound-Based Acoustic Radiation Force Impulse (ARFI)|Research scans using ultrasound-based acoustic radiation force impulse (ARFI) will image the liver non-invasively.
1659520|NCT01781169|Dietary Supplement|Oral supplementation of vitamin D|Weekly oral supplementation of 50,000 IU vitamin D (cholecalciferol) for eight weeks to the obese males compared with the normal-weight males. The chemical form of vitamin D is cholecalciferol capsuled as fine powder.
1659521|NCT01781143|Device|Perform Echo at home.|A group of women that follows an IVF treatment, will perform their echoes at home, instead of always make an appointment in the clinic.
1659522|NCT01781130|Procedure|Steroid injection|
1659523|NCT01781117|Procedure|Holmium Laser Enucleation of the Prostate (HoLEP)|Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.
1659524|NCT01781117|Device|Holmium laser enucleation system and morcellator|Holmium laser enucleation and morcellation
1659525|NCT01781104|Drug|RM-131|Double blind RM-131 (100 ug) will be delivered subcutaneously once daily for 14 days.
1659526|NCT01781104|Drug|Placebo|Placebo delivered subcutaneously once daily for 14 days.
1659527|NCT01781091|Device|INTELLIVENT ASV FULLY CLOSED-LOOP VENTILATION|
1659528|NCT01781091|Device|Conventionals Modes|
1659529|NCT01781078|Radiation|MRI|The study-specified MRI scan includes RF- and gradient-intensive sequences designed to test the ImageReady System in the MR environment
1659530|NCT01781078|Device|ImageReady System implant|Pacemaker and lead(s) implant
1659531|NCT01781065|Device|transcranial direct current stimulation|
1659532|NCT01781052|Drug|Ventavis (Iloprost, BAYQ6256)|Initial dose: 2.5 µg per inhalation session; 6-9 inhalations/day. Dose can be increased to up to 5.0 µg per inhalation session.
1659533|NCT01781026|Drug|Vemurafenib|Single arm trial
1659534|NCT01781013|Other|Technology-supported care|The depression care-management technology that will interact with patients is the Automated Speech Recognition (ASR) for remote monitoring data collection. The ASR will use automated telephone calls to reach out to patients to repeat depression screening using PHQ-9, triggered either by calendar date or upcoming appointments, and to remind patients of their appointments in pre-determined time. In addition, the ASR will apply a structured script to conduct automatic follow-up with patients regarding their depression treatment adherence and side effects in order to provide data to help primary medical providers promptly and optimally adapt treatment. The ASR script will also include structured relapse prevention prompts. For providers and administrators, the depression care-management technology aimed to improve their workflow regarding depression care is Enhanced Disease Registry (EDR)..
1659535|NCT01781000|Behavioral|Brain Fitness & Brain Training- Posit Science|Computer aided cognitive program designed for intensive training of auditory perception, memory and attention
1660046|NCT01776697|Drug|pelubiprofen SR (as a pelubiprofen 90 mg) tablet|
1659536|NCT01781000|Behavioral|Facial Affect Training- FAT|Computer-aided cognitive program designed for intensive training of facial affect discrimination, memory and attention
1659537|NCT01781000|Behavioral|Treatment as usual|standard treatment protocol of schizophrenia ward
1659538|NCT01780987|Drug|Apixaban|10 mg BID for 7 days followed by 5 mg BID for 23 weeks (total 24 weeks)
1659539|NCT01780987|Drug|Unfractionated Heparin (UFH)|Dosing adjustment based on APTT = 1.5-2.5 times the control value, and until INR ≥ 1.5 for 5 days or more
1659540|NCT01780987|Drug|Warfarin|Dosing for 24 weeks to target INR range between 1.5-2.5
1659541|NCT01780974|Drug|Lipoic Acid plus Omega-3 Fatty Acids|alpha lipoic acid (racemic) and fish oil concentrate
1659542|NCT01780974|Drug|Placebo|placebo capsules
1659543|NCT01780948|Drug|Atorvastatin 20 mg|Add atorvastatin 20 mg and compare 12-hour AUC of everolimus between Arm everolimus and everolimus with atorvastatin 20 mg
1659544|NCT01780948|Drug|Everolimus|Administration only everolimus, no atorvastatin. Everolimus administration with adjusted dose to target C trough (C0)level between 3-12 ng/mL.
1659545|NCT01780935|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
1659546|NCT01780922|Other|Low Calorie Cranberry Juice Cocktail|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
1659547|NCT01780922|Other|Cranberry Extract Beverage|Beverage containing cranberry at a dose of 15.2 ounces consumed within 15 minutes
1659548|NCT01780922|Other|Non-Cranberry Beverage|Beverage absent cranberry at a dose of 15.2 ounces consumed within 15 minutes
1659549|NCT01780909|Drug|Paromomycin Sulfate Fasted State|
1659550|NCT01780909|Drug|Paromomycin Sulfate Fed State|
1659551|NCT01780909|Drug|Paromomycin Sulfate w/ domperidone|
1659552|NCT01780909|Drug|Paromomycin Sulfate w/ loperamide HCl|
1659553|NCT01780883|Drug|melatonin|
1659554|NCT01780883|Drug|Placebo|Placebo tablets of Circadin®
1659555|NCT01780870|Dietary Supplement|Weight loss group (Full meal replacement products)|In the intervention arm of this non randomized, open label study to assess the effects of weight loss on insulin sensitivity and leptin tolerance subjects will use full meal replacement products (1280-1320kcal/day). Subjects will be on the full meal replacement products only, for the first 12 weeks, between 13 to 19 weeks they will be transitioned to regular food, from 19 weeks and going forward they will be on chronic maintenance phase
1659556|NCT01780844|Drug|ASKP1240|intravenous infusion
1659557|NCT01780844|Drug|Tacrolimus|intravenous or oral
1659558|NCT01780844|Drug|Mycophenolate Mofetil (MMF)|intravenous or oral
1659559|NCT01780844|Drug|Basiliximab|intravenous
1659560|NCT01780844|Drug|Methylprednisone|Intravenous
1659561|NCT01780844|Drug|Prednisone|Oral
1659562|NCT01780831|Drug|Raltegravir|RAL will be given as oral granules for suspension. Dose may be modified after ongoing PK and safety analyses.
1659563|NCT01780818|Other|Air Insufflation method.|Colonoscopy will be performed in the standard fashion, with the minimal air insufflation required to aid insertion and allowing for washing as needed. Considered to be standard procedure.
1659564|NCT01780818|Other|Water Immersion method.|Air will not be insufflated until the cecum is reached. It will be allowed only 3 times and no more than 10 seconds each time (ITT failure if >3) if the lumen cannot be seen. Infusion of water during the insertion phase of colonoscopy mainly to open the colonic lumen and progress to the cecum immersed in the water environment thus created, without attempting to clear the colon contents. Residual air in the colon will not be removed. Infused water and residual feces will be suctioned back predominantly during withdrawal.
1659565|NCT01780818|Other|Water Exchange method.|Air will not be insufflated until the cecum is reached. Infusion of a sufficient amount of water to render the lumen of the colon a slit to progress with the colonoscope. Part of the infused water will be constantly suctioned back exchanging clean for dirty or hazy water. Suction of water will also be applied when colonoscope insertion proceeds smoothly. Air pockets will be always aspirated to collapse the lumen. After cecal intubation as much residual water as possible will be aspirated before beginning the withdrawal phase. During withdrawal residual water and feces will be suctioned.
1659566|NCT01780792|Other|Dance Dance Revolution video game play|Individuals play dance dance revolution 3 times a week for 8 weeks
1659567|NCT01780779|Other|MRI|"MRI exam will be performed in all patients included in the study. The patients will be treated by chemotherapy, defined in the EURO-EWING or EURAMOS protocol.
The MR findings will not have any impact on the treatment."
1659568|NCT01780753|Drug|Primaquine|Primaquine GPO® (Government Pharmaceutical Organization, Thailand) 0.5 mg/kg will be given once daily for 14 days.
1659569|NCT01780740|Drug|Atorvastatin|Atorvastatin (80 mg od) started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
1659570|NCT01780740|Drug|Placebo|Placebo started not earlier than 6 days before surgery and continued until the 5th post-operative day included;
1659571|NCT01780727|Procedure|EGHEM|Echocardiography guided hemodynamic management. Subjects in this arm will undergo intraoperative transesophageal echocardiography as part of the study.
1659572|NCT01780714|Other|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
1659573|NCT01780714|Other|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned either A) continuing CC, or B) switching to THS 2.1
1659574|NCT01780701|Procedure|Magnetic Resonance Spectroscopy Imaging with rectal probe|
1659575|NCT01780688|Other|Conventional cigarettes (CC)|Subjects are randomized in a 1:1 fashion to be assigned to one of the 2 sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC.
1659576|NCT01780688|Other|THS 2.1|Subjects are randomized in a 1:1 fashion to be assigned in one of the sequences, either A) CC and then THS 2.1, or B) THS 2.1 and then CC
1659577|NCT01780675|Radiation|Radiation Prophylactic Cranial Irradiation|
1659578|NCT01780675|Radiation|Radiation Hippocampal Avoidance PCI|
1659647|NCT01780051|Drug|Repaglinide/Metformin combination, Repaglinide, Metformin|"Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 1.
Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 2."
1659582|NCT01780649|Procedure|IMSI|Intracytoplasmic Morphologically Selected Sperm Injection (IMSI) is a modification of IntraCytoplasmic Sperm Injection (ICSI) with a choice of the spermatozoon to be injected done at a 6000x magnification instead of 400x commonly used in ICSI
1659583|NCT01780649|Procedure|ICSI|ICSI is largely choice of the spermatozoon to be injected done at a 400x magnification
1659584|NCT01780636|Drug|botulinum toxin|
1659585|NCT01780623|Device|Bright white light|
1659586|NCT01780623|Device|Dim red light|
1659587|NCT01780610|Drug|Letrozole and human chorionic gonadotrophin|the follicular development is supported by Letrozole(LE) 2.5mg,once daily is introduced on cycle day 3 .And on cycle day 10 , a Vagina ultrasound is introduced to monitor the development of the follicular ,following by intramuscular gonadotrophin 37.5~75 IU/d until there is a Luteinizing Hormone(LH) surge or ovulation .On the day appearing Luteinizing Hormone surge，patients is always introduced intramuscular human chorionic gonadotrophin(HCG) 10000 IU.If there is sill no Luteinizing Hormone surge when the follicle is 20-24mm ,the ovulation will be induced by HCG.Then the luteum was supported by HCG 2000-2500 IU/3d.Transfer of thawed embryos will be performed 3 days after ovulation is observed.
1659588|NCT01780610|Drug|estradiol and progesterone|oral estradiol, 2 mg, once daily, was introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness was greater than 7mm, progesterone 40-60 mg in oil was administered via intramuscular injection. Transfer of thawed embryos was performed 3 days later
1659589|NCT01780584|Drug|Oral T3 Low dose|Comparison of different dosages of drug. Low dose group oral T3 is 0.5 mcg/kg q24h
1659590|NCT01780584|Drug|Placebo|Comparison of different dosages of drug. In low dose group, placebo was given alternately with oral T3 every 12h with a total 3 doses for placebo and 3 doses for oral T3
1659591|NCT01780584|Drug|Oral T3 high dose|Comparison of different dosages of drugs. Oral T3 high dose is 0.5 mcg/kg q12h
1659592|NCT01780571|Procedure|CPAP 5 cm H2O + PSV 5 cm H2O|Patients in the intervention group received Continuous Positive Airway Pressure (5 cm H2O) and Pressure Supported Ventilation (5 cm H2O)
1659593|NCT01780558|Other|natural cycles|the ovulation is monitored spontaneously or induced by HCG when the dominant follicle is larger than 18mm without LH surge. Transfer of thawed embryos will be performed 4 days after LH surge/HCG administration or 3 days after ovulation is observed.
1659594|NCT01780558|Drug|estradiol and progesterone|oral estradiol, 2 mg, once daily, is introduced on cycle day 3 with an increasing doses protocol. If the endometrial thickness is greater than 7mm, progesterone 40-60 mg in oil will be administered via intramuscular injection. Transfer of thawed embryos will be performed 3 days later.
2013367|NCT00300391|Drug|haloperidol|Aim #1. To conduct a RCT of IV haloperidol vs. placebo for the treatment of delirium in mechanically ventilated ICU patients. Patients in the cohort study that go on to develop delirium will be enrolled in a RCT comparing treatment with scheduled haloperidol vs. placebo. By comparing differences between treatment and placebo groups, we will test the hypothesis that treatment with scheduled haloperidol improves the primary outcome of 28-day and 90 day mortality and secondary outcomes of total delirium days, duration of mechanical ventilation, and ICU length of stay.
2013368|NCT00300391|Other|Saline placebo|control arem
1659597|NCT01780532|Procedure|Photoacoustic Imaging (PAI)|Standard of Care
1659598|NCT01780519|Drug|lorazepam|single dose of 1 mg lorazepam
1659599|NCT01780506|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally once daily
1659600|NCT01780506|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) FDC tablet administered orally once daily
1659601|NCT01780506|Drug|E/C/F/TDF Placebo|E/C/F/TDF placebo tablet administered orally once daily
1659602|NCT01780506|Drug|E/C/F/TAF Placebo|E/C/F/TAF placebo tablet administered orally once daily
1659603|NCT01780493|Procedure|The Direct Nipple Ureteroneocystostomy Technique|
1659604|NCT01780480|Drug|Dynamic Chinese herbal granule formula|After evaluated the style of the syndrome (Zhenghou) by an experienced integrative medicine doctor, the patients should be given a Chinese herbal granule formula twice a day for 4 weeks, which should be selected from 10 kinds of Chinese herbal granules and weekly changed according to differentiation of syndromes (Zhenghou) of patients.
1659605|NCT01780480|Drug|Placebo|The 10 kinds of matched placebo granules were of the similar appearance, taste, smell with the corresponding Chinese herbal granules respectively. The interventional process of the placebo group is similar as the Chinese herbal granule formula group
1659606|NCT01780480|Procedure|Standard medical care|Standard medical care is the basic treatment for all enrolled patients, including aspirin 75-100mg per day, standard rehabilitation training, treatment for their primary diseases, etc.
1659607|NCT01780467|Behavioral|Role of dopamine|
1659608|NCT01780454|Drug|MEDI-507|T-Cell Depleting Agent
1659609|NCT01780454|Drug|Rituximab|B-Cell Depleting Agent
1659610|NCT01780454|Radiation|Total Body Irradiation|Bone Marrow Depletion
1659611|NCT01780454|Radiation|Thymic Irradiation|
1659612|NCT01780428|Drug|CL-108 (hydrodocone 7.5 mg, acetaminophen 325 mg, promethazine 12.5 mg)|
1659613|NCT01780428|Drug|Placebo|
1659614|NCT01780415|Other|blastocoele aspiration|
1659615|NCT01780402|Behavioral|Hand feeding techniques|"Direct hand feeding technique: When the feeding assistant holds the object (e.g., fork, spoon, cup) intended to provide food or fluids to the PWD without any active involvement on the part of the PWD.
Hand-over-hand feeding technique: Occurs when the PWD is holding the object (e.g., fork, spoon, cup) in an attempt to feed/ drink for themselves. If the PWD has trouble with this activity, the feeding assistant puts his or her hand over the hand of the PWD, in an effort to guide/ support/ assist the PWD with the activity.
Hand-under-hand feeding technique: Occurs when the feeding assistant holds the object (e.g., fork, spoon, cup) and places the PWD hand over the top of their hand; therefore, the feeding assistants hand is under the hand of the PWD in a more supportive position."
1659616|NCT01780389|Drug|Open-label flexibly dosed milnacipran|
1660047|NCT01776684|Drug|EGFR TKIs (gefitinib, erlotinib, afatinib, et al)|
2013369|NCT00285337|Procedure|Laminectomy and Laminoplasty|Posterior versus anterior approach to laminectomy and laminoplasty
2013370|NCT00280800|Device|constant CPAP devices|different CPAP mode
2013371|NCT00280800|Device|automatic CPAP devices|different CPAP mode
2013372|NCT00279500|Device|Argus 16 Retinal Stimulation System|
1659618|NCT01780350|Device|ResQGARD ITD|Patients eligible for the device will receive the ResQGARD attached to a facemask or mouthpiece. The patient will use the device, provided it is tolerated, until their blood pressure is stabilized as determined by EMS personnel.
1659619|NCT01780337|Drug|Oxytocin|Intranasal dose of 20 IU oxytocin
1659620|NCT01780337|Other|Saline|Intranasal dose of saline
1659621|NCT01780324|Drug|Lidocaine|Intervention - intraurethral lidocaine
1659622|NCT01780311|Drug|antiarrhythmic drugs (Flecainide or Propafenone or Sotalol)|
1659623|NCT01780311|Procedure|Catheter Ablation|
1659624|NCT01780285|Device|Nitinol-framed lightweight PTFE mesh for hiatal repair|"The heart-shaped nitinol-framed lightweight PTFE prosthesis Rebound HRD-Hiatus hernia (Minnesota Medical Development, Inc.) of small (4,0 x 4,5 cm) to large size (5,5 х 6,0 cm) is sutured to the crura posteriorly to oesophagus with 3 or 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures, thus performing complete tension-free hiatal repair."
1659625|NCT01780285|Device|Partially absorbable lightweight mesh for hiatal repair|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro (Ethicon, Inc.) will be sutured to both crura posteriorly to oesophagus with 3 to 5 interrupted non-absorbable (Ethibond 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique).
In both arms procedure will be done in a standard fashion: placement of 30 Fr esophageal bougie, reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening, repair of hiatal hernia defect, a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure)."
1659626|NCT01780272|Other|glucose clamp|Each subject will complete one adaptation night visit followed by two experimental night visits, one normoglycaemic and one hypoglycaemic, in randomised order. While subjects are asleep, sleep patterns will be monitored online using polysomnographic recordings during a hypoglycaemic and a normoglycaemic clamp (using constant intravenous (i.v.) infusion of human soluble insulin (Actrapid®)). Plasma glucose will be monitored.
1659627|NCT01780259|Drug|Esketamine|1 spray of 14 percent of esketamine solution (14 mg of esketamine per 100 microlitre) will be administered intranasally by nasal spray pump in each nostril once (Treatment A-total dose: 28 mg), twice with 5 minutes interval (Treatment B-total dose: 56 mg), thrice with 5 minutes interval between each repeated sprays (Treatment C-total dose: 84 mg), thrice with 10 minutes interval between each repeated sprays (Treatment D-total dose: 84 mg) and 4 times with 10 minutes interval between each repeated sprays (Treatment E-total dose: 112 mg). Treatment A, B, C, D will be administered in Cohort 1; Treatment D will be administered in Cohort 2; and Treatment E will be administered in Cohort 3.
1659628|NCT01780259|Drug|Placebo|Single dose of oral placebo will be administered 5 minutes before the first intranasal spray of esketamine solution in the Treatment E of Cohort 3. Placebo solution (solution of water for injection with denatonium benzoate) will be administered intranasally solution by nasal spray pump in the Treatment F of Cohort 3.
1659629|NCT01780259|Drug|Triazolam|Single 0.25-mg oral dose of triazolam will be administered 5 minutes before the first intranasal spray of placebo solution in the Treatment F of Cohort 3.
1659630|NCT01780246|Drug|nusinersen|Administered by intrathecal (IT) injection
1659631|NCT01780233|Drug|Fentanyl 400 µg sublingual spray|
1659632|NCT01780233|Drug|Actiq® 400 µg transmucosally|Actiq® 400 µg is a solid formulation of fentanyl citrate on a plastic stick that dissolves slowly in the mouth for absorption across the buccal mucosa.
1659633|NCT01780233|Drug|Fentanyl citrate injection 100 µg intravenously|
1659634|NCT01780233|Drug|Naltrexone 50 mg|Naltrexone hydrochloride was administered approximately 12 hours and 1 hour prior to and 12 hours after each dose of fentanyl to minimize the occurrence of unacceptable adverse effects (eg, decreased respiration, nausea) often associated with administration of fentanyl.
1659635|NCT01780220|Drug|Abiraterone|Abiraterone acetate 1000mg/day + prednisone alone for one month before initiating the sequence of radiotherapy
1659636|NCT01780207|Device|PFO Closure|
1659637|NCT01780181|Drug|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
1659638|NCT01780181|Drug|Chemotherapy|treated with single-agent chemotherapy :DOC、NVB、GEM DOC 60mg/m2 d1 Q3W NVB 30mg/m2 d1，d8 Q3W GEM 1200mg/m2 d1，d8 Q3W
1659639|NCT01780129|Drug|Polydatin Injectable|Dilute two 100mg/5mL vials of HW6 into 500mL 0.9% NaCl injection and administer as i.v. infusion over 2 hours. The drug should be given as early as possible right after the IC Form is signed on Day 1, and once every 24 hours for additional 4 doses.
1659640|NCT01780116|Behavioral|Adherence therapy|Systematic and highly structured medication adherence program using the motivational interviewing (MI) technique that focuses on six principles: expressing empathy, developing discrepancy between client's beliefs and evidence, supporting self-efficacy, avoiding argumentation, and rolling with resistance to behavioral change. MI is often able (with in-depth behavioral analysis) to focus on particular consequences of problem behavior, such as medication non-adherence, that have an obvious impact on patients.
1659641|NCT01780090|Other|iPad software|A specialized iPad application, entitled SpeechPrompts, has been developed to treat prosodic difficulties commonly seen in ASDs. SpeechPrompts provides the SLPs that work with students with ASDs an additional tool to treat prosody. The SpeechPrompts software offers visual support and biofeedback to change prosody. These two tools are not typically available for school-based SLPs.
1659642|NCT01780077|Drug|RXI-109|Multiple intradermal injections of RXI-109 at incision sites
1659643|NCT01780077|Drug|Placebo|Multiple intradermal injections of placebo at incision sites
1659644|NCT01780064|Behavioral|interviews with a psychologist|interviews with a psychologist
1659645|NCT01780064|Behavioral|Questionnaires|Questionnaires
1659646|NCT01780051|Drug|Repaglinide/Metformin combination, Repaglinide, Metformin|"Co-administration of Repaglinide 2mg and Metformin HCl 500mg at once in period 1.
Administration of the Combination tablet of Repaglinide 2mg/Metformin HCl 500mg) in period 2."
1659648|NCT01780038|Behavioral|Receipt of Genetic Results|Participants will receive the results of genotyping for RS1051730
1659649|NCT01780038|Behavioral|No results given|Participants will not be offered to receive the results of genotyping for RS1051730 until all data collection has been completed.
1659650|NCT01780025|Behavioral|Auditory evoked potentials and audiometry|
1659651|NCT01780025|Behavioral|Auditory evoked potentials|Different protocols for audiometry and auditory evoked potentials
1659652|NCT01780012|Behavioral|Osteoporosis prevention program|Women will receive an oral information and advices on osteoporosis, a written leaflet on osteoporosis (risk factors, diagnosis, prevention and treatments), a letter and a leaflet on osteoporosis management to give to their family physician and phone call reminders (D15, D30, D45) to advise them to consult their family physician and, if they have a BMD prescription, to perform their BMD
1659653|NCT01779999|Other|PICC-carrying patients|Echographic monitoring of patients carrying a peripherally inserted central catheter
1659654|NCT01779973|Behavioral|Remote Observed Dosing|
1659655|NCT01779960|Other|Londrina|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
1659656|NCT01779960|Other|Leuven|Two groups of patients, one group in Londrina and another group in Leuven, will be simultaneously and objectively evaluated concerning their physical activity in daily life during one week in two different moments: in January 2013 (winter in Leuven and summer in Londrina), and then the same two groups of patients will be once again simultaneously re-evaluated during another week in July 2013 (summer in Leuven and winter in Londrina).
1659657|NCT01779947|Drug|Estradiol Vaginal Tablets 10 mcg|
1659658|NCT01779947|Drug|placebo|
1659659|NCT01779921|Drug|activated recombinant human factor VII|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
1659660|NCT01779921|Drug|Fresh frozen plasma (Source unspecified)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
1659661|NCT01779921|Drug|Plasma-derived FVII (LFB)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
1659662|NCT01779921|Drug|Prothrombin Complex conc. (PCC)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
1659663|NCT01779921|Drug|Plasma-derived FVII conc. (pdFVII Baxter)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
1659664|NCT01779921|Drug|Plasma-derived FVII conc. (pdFVII PFL)|Treatment of bleeding episodes and treatment during surgery and prophylaxis as per discretion of the investigator.
1659665|NCT01779908|Dietary Supplement|Vitamin D|
1659666|NCT01779908|Other|Placebo|
1659667|NCT01779895|Dietary Supplement|Lactobacillus paracasei probiotic strain|
1659668|NCT01779895|Dietary Supplement|Placebo|maltodextrin
1659669|NCT01779882|Drug|Busulfan-Cyclophosphamide as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
1659670|NCT01779882|Drug|Cyclophosphamide-Busulfan as Conditioning Regimen before Allogeneic Hematopoietic Stem Cell Transplantation|Test the hypothesis, that the order of application of Busulfan (BU) and Cyclophosphamide (CY) has an impact on toxicity after allogeneic Hematopoietic stem cell transplantation (HSCT) and that CY-BU reduces liver toxicity compared to BU-CY.
1659671|NCT01779869|Drug|Regadenoson|Regadenoson 400 micrograms will be administered in a single IV bolus (<10 seconds) via an antecubital cannula and followed by 5 mL of saline flush. 10-20 seconds after the regadenoson is administered, 10 mCi of 13N-ammonia as a bolus, and 0.075 mmol/Kg of gadobenate dimeglumine MR contrast agent at a rate of 5 mL/sec followed by a 15 mL normal saline flush will be administered simultaneous, each into an antecubital vein, and a 15 min list-mode PET acquisition will be acquired simultaneously with the MR perfusion imaging.
1659672|NCT01779856|Device|REVEAL Insertable Cardiac Monitor (ICM)|
1659673|NCT01779843|Drug|Cytarabine|
1659674|NCT01779843|Drug|Idarubicin|
1659675|NCT01779843|Drug|Alisertib|
1659676|NCT01779830|Drug|LY2624803 - Capsules|Administered orally as capsules.
1659677|NCT01779830|Drug|Zolpidem - Tablets|Administered orally as tablets.
1659678|NCT01779830|Drug|Placebo - Capsules|Administered orally as capsules.
1659679|NCT01779830|Drug|Placebo - Tablets|Administered orally as tablets.
1659680|NCT01779817|Behavioral|Assessment of intellectual development, capacities of attention, learning process and degree of hyperactivity of the children between 6 and 9 years.|
1659681|NCT01779804|Procedure|OFAR|OFAR
1659682|NCT01779791|Drug|PCI-32765 (Ibrutinib)|560 mg capsules administered orally once daily, continuously on a 21-day cycle until progressive disease.
1659683|NCT01779765|Dietary Supplement|PHGG|
1659684|NCT01779765|Dietary Supplement|Maltodextrin|
2013373|NCT00278512|Biological|Autologous Stem Cell Transplant|Autologous Hematopoietic Stem Cell Transplant will be performed after conditioning
1659686|NCT01779726|Radiation|CT scan before chest physician|Patients referred to department of lung medicine are randomised according to the month of birth. Patients born in even months are CT scan before a consultation with a chest physician
1659687|NCT01779726|Radiation|Usual diagnostic workup|Patients born in odd months seen in the department of lung medicine by a chest physician and maybe then CT scanned (usual workup practice according to the fast track evaluation)
1659688|NCT01779713|Genetic|Case-control transcriptomic study|No intervention
2013374|NCT00278512|Biological|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant will be performed after conditioning
1659691|NCT01779687|Drug|raltegravir|Raltegravir 400 mg BID for 7 days
1659692|NCT01779687|Drug|Atorvastatin|Atorvastatin 20 mg QD for 7 days
1659693|NCT01779661|Other|Infant Aquatics|Infant Aquatics in this study is composed of a set of pre-structured movements and techniques of relaxation, through harmonic integration of various approaches, each having a role in a specific time-window or in the infant's developmental sequence along study interventional timeline
1659697|NCT01779635|Device|oXiris as first filter|2 arms - each start off CRRT with either oXiris or M150 as first hemofilter, and then do cross-over to either hemofilters in a sequential manner when the former clots
1659698|NCT01779635|Device|M150 as first filter|start off with M150 as first hemofilter, then cross-over to oXiris when former clots, and then to M150, and then lastly to oXiris
1659699|NCT01779622|Other|Mixed meal|Ingestion of mixed meal
1659700|NCT01779609|Drug|Bosentan|
1659701|NCT01779609|Drug|Placebo|
1659702|NCT01779609|Behavioral|Exercise|Supervised exercise training program of 8 weeks, for 3x/week
1659703|NCT01779596|Drug|Bosentan|
1659704|NCT01779596|Drug|Placebo|
1659705|NCT01779570|Drug|Macrolide treatment|
1659706|NCT01779557|Drug|Huaren Peritoneal Dialysate|Huaren Peritoneal dialysate CAPD 3-5 times/d
1659707|NCT01779557|Drug|Baxter Peritoneal Dialysate|Baxter Peritoneal dialysate CAPD 3-5 times/d
1659708|NCT01779544|Other|Brief intervention, an educational model|The goal of the the brief intervention is to provide the patient knowledge to reduce uncertainty so that he or she can understand what is important after lumbar disc surgery so that belief in self-efficacy increases.
1659709|NCT01779544|Other|Exercise therapy|Patients are instructed to do prescribed exercises the first 3 months after surgery, and to log when they do these
1659710|NCT01779518|Drug|Sofosbuvir|
1659711|NCT01779518|Drug|Ribavirin|
1659712|NCT01779518|Drug|Pegylated Interferon|
1659713|NCT01779505|Biological|GS-4774|GS-4774 is a recombinant yeast-based biological product engineered to express HBV antigens. The product is a heat-killed yeast (S. cerevisiae) containing a chimera of HBV X, Score, and Core antigens.
1659714|NCT01779492|Drug|GL2907|once a day
1659715|NCT01779492|Drug|Oxycontine CR 10mg|twice a day
1659716|NCT01779479|Drug|Cabacitaxel|Cabazitaxel 25 mg/m² i.v. (Day 1) every 3 weeks (cycle) as 1-hour i.v infusion for a total of up to 4 cycles over a maximum total treatment period of 15 weeks before surgery
1659717|NCT01779479|Drug|Paclitaxel|Paclitaxel 80 mg/m² as 1-hour i.v infusion. Patients will receive weekly (Days 1, 8, 15) paclitaxel administrations for a maximum of 12 infusions for a maximum of 4 cycles over a maximum total treatment period of 15 weeks before surgery (1 cycle = 3 weeks).
1659718|NCT01779466|Drug|Desmopressin|
1659719|NCT01779466|Drug|Placebo (not active)|
1659720|NCT01779453|Drug|ETC-1002|Week 1-2, 60 mg/day; Week 3-4, 120 mg/day; Week 5-6, 180 mg/day; Week 7-8, 240 mg/day
1659721|NCT01779453|Drug|Placebo|Placebo once daily for 8 weeks
1659722|NCT01779453|Drug|Atorvastatin|Atorvastatin 10mg once daily for 8 weeks
1659723|NCT01779440|Behavioral|Electronic Decision Support System|
1659724|NCT01779427|Behavioral|AIM|An online, 12 week research study to learn if a computer-based intervention that provides direct attention and metacognitive strategy development can improve attention, memory, and executive control in adolescents with moderate-to-severe TBI who are experiencing attention difficulties post injury.
1659725|NCT01779414|Other|STAT-ED Intervention|Participants in this group will receive a motivational interview conducted by a study trained social worker, where the social worker and the family will discuss the participants issues, thoughts and feelings about receiving treatment, barriers to treatment and methods of overcoming those barriers. The study trained social worker will also make a referral for a mental health follow-up for the patient.
1659726|NCT01779401|Drug|Clopidogrel 75mg|
1659727|NCT01779401|Drug|Clopidogrel 150mg|
1659728|NCT01779401|Drug|Aspirin 100mg|
1659729|NCT01779401|Drug|Cilostazol 100mg|
1659730|NCT01779388|Procedure|Bronchoscopy|During a general anaesthesia, an evaluation will be done by conventional bronchoscopy guided by fluoroscopy and by bronchial endoscopy guided by electromagnetic navigation, the selection of order in techniques being randomly assigned.
1659731|NCT01779375|Drug|Metformin|
1659732|NCT01779375|Drug|Glargine|
1659733|NCT01779362|Drug|Metformin|Titrated to 1000 mg BID
1659734|NCT01779362|Drug|Liraglutide|Titrated to 1.8 mg/day
1659735|NCT01779362|Drug|Glargine|Titrated to target fasting glucose <90 mg/dl
1659736|NCT01779362|Drug|Placebo|Matching to metformin 1000 mg BI
1659737|NCT01779349|Device|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
1659738|NCT01779336|Drug|PL225B|"Patients will receive study drug on a daily basis for twenty-one (21) days according to the dose and schedule specified for a particular cohort of therapy.
This 21 day administration will define a treatment cycle.
Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, or withdrawal from the protocol as specified."
1659739|NCT01779323|Other|Pre and Post Sling Pelvic MRI|Pre and Post Sling Pelvic MRI
1659740|NCT01779284|Drug|Travoprost/timolol therapy|Evaluation of 24-hour pressure efficacy with travoprost/timolol therapy after 3 months of chronic dosing
1659741|NCT01779284|Drug|Latanoprost/Timolol therapy|Evaluation of 24-hour pressure efficacy for this drug after 3 months of chronic therapy
1659742|NCT01779271|Drug|Pelubiprofen|
1659743|NCT01779271|Drug|Loxoprofen|
1659744|NCT01779258|Drug|glycerol, paraffin (liquid and white soft)|1 application in the morning and in the evening
1659745|NCT01779258|Device|Atopiclair®|1 application in the morning, in the afternoon and in the evening
1659746|NCT01779258|Drug|Locatop@|"During the Run-In period:
1 application in the morning and in the evening during a maximum of 21 days"
1659747|NCT01779258|Drug|Locapred@|"During the 3 months study treatment:
1 application in the evening in case of flare "
1659748|NCT01779245|Dietary Supplement|Calcium|Milk-extracted calcium supplement will be used to modulate the calcium content of the milkshakes used.
1659749|NCT01779245|Dietary Supplement|Placebo|
1659750|NCT01779232|Drug|Danazol|100 mg day for 4 monthh in women with diagnosed endometriosis before IVF
1659751|NCT01779232|Drug|placebo|administered daily like the active comparator
1659752|NCT01779219|Device|iMRI-guided brain tumour biopsy|The PoleStar N20 iMRI system (Medtronic Navigation, Louisville, CO, USA) with a 0.15-T constant magnet was used in all procedures.
1660914|NCT01769378|Drug|Dulaglutide|Administered SQ
1659753|NCT01779219|Device|Stereotactic frameless brain tumour biopsy|The entry point, target and optimal biopsy trajectory were defined by the operator before the operation on the basis of the preoperatively obtained high-field MR images with the use of a neuronavigation workstation (Cranial 5, StealthStation Application Software, Medtronic Navigation, Louisville, CO, USA).
1659754|NCT01779206|Drug|Epirubicin|
1659755|NCT01779206|Drug|Cyclophosphamide|
1659756|NCT01779206|Drug|Docetaxel|
1659757|NCT01779206|Drug|Paclitaxel|
1659758|NCT01779193|Dietary Supplement|lactic acid bacteria|oral lactobacillus capsule (dose of 2 * 10^9 cfu per capsule), one pill daily
1659759|NCT01779193|Dietary Supplement|cranberry|oral cranberry capsule, one pill daily
1659760|NCT01779193|Dietary Supplement|placebo|placebo capsule without lactic acid bacteria and cranberry, one pill daily
1659761|NCT01779167|Drug|Thalidomide|Thalidomide 50 mg (every ODD day of a 28 day cycle: Days 1, 3, 5, 7, 9, 11, 13, 15, 17, 19, 21, 23, 25 & 27)
1659762|NCT01779167|Drug|Lenalidomide|Lenalidomide (every EVEN day of a 28 day cycle: Days 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26 & 28). Lenalidomide will be initiated at a starting dose of 5 mg.
1659763|NCT01779167|Drug|Rituximab|Rituximab 375 mg/m2 IV on Days 1, 8, 15 and 22 (+/- 2 days) and then again on the same weekly x 4 schedule every 6th cycle thereafter (Cycle 7, 13, 19, etc).
1659764|NCT01779128|Procedure|PET-CT|
1659765|NCT01779128|Procedure|MR-PET|
1659766|NCT01779102|Biological|C-Tb|C-Tb is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
1659767|NCT01779102|Biological|Tuberculin PPD RT 23 SSI|Tuberculin is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
1659768|NCT01779102|Biological|C-Tb / Tuberculin PPD RT 23 SSI|The C-Tb and Tuberculin agents are administered by the Mantoux injection technique to each volunteer in the RIGHT and LEFT forearm according to a double blind randomisation scheme
2013375|NCT00266864|Drug|Testosterone Transdermal System (Androderm 5 mg patch)|Testosterone Transdermal System (Androderm 5 mg patch)
1659771|NCT01779076|Procedure|30% oxygen|
1659772|NCT01779076|Procedure|100% oxygen|
1659773|NCT01779063|Behavioral|web based multimedia intervention|cognitive therapy based web intervention
1659774|NCT01779063|Other|educational booklet|patient education booklet
1659775|NCT01779050|Drug|Doxorubicin|
1659776|NCT01779050|Biological|Trastuzumab|
1659777|NCT01779050|Drug|Cyclophosphamide|
1659778|NCT01779050|Drug|Paclitaxel|
1659779|NCT01779050|Drug|Epirubicin|
1659780|NCT01779050|Drug|Docetaxel|
1659781|NCT01779050|Drug|Carboplatin|
1659782|NCT01779050|Drug|Fluorouracil|
1659783|NCT01779024|Drug|Ghrelin|
1659784|NCT01779024|Drug|Placebo|
1659785|NCT01779024|Procedure|fMRI|
1659786|NCT01779024|Drug|Alcohol|
1659787|NCT01778998|Procedure|MICS-group|Micro incision cataract surgery is done
1659788|NCT01778998|Procedure|SICS-group|small incision cataract surgery is done
1659789|NCT01778998|Procedure|SICS pre-cut|Small incision cataract surgery with pre-cut is done
1659790|NCT01778998|Procedure|SICS stab-incision|Small incision cataract surgery with stab-incision is done
1659791|NCT01778985|Drug|Premarin|
1659792|NCT01778985|Other|Placebo|
1659793|NCT01778972|Other|Otago home exercise programme|"Otago home exercise program was designed specifically to prevent falls. It consists of a set of leg muscle strengthening and balance retraining exercises progressing in difficulty, and a walking plan.
The exercise are individually prescribed and increase in difficulty during a series of five home visits by a physiotherapist."
1659794|NCT01778972|Other|Motivational interviewing plus Otago|This group is not only exercising at home but also getting motivational interviewing from the physiotherapist at he five home visits. The physiotherapists doing motivational interviewing are specially trained in motivational interviewing.
1659795|NCT01778959|Device|Malyugin Ring|insertion of a Malyugin Ring to stabilite the pupil during cataract surgery
1659796|NCT01778959|Device|Iris hooks|insertion of iris retractors to stabilize the pupil during cataract surgery
1659797|NCT01778959|Device|standard OVD|use of a standard cohesive OVD during cataract surgery
1659798|NCT01778959|Device|OVD|use of a highly cohesive OVD during cataract surgery
1659799|NCT01778946|Drug|Low Dose Nicotine (7mg)|
1659800|NCT01778946|Drug|Moderate Dose Nicotine (14mg)|
1659801|NCT01778933|Drug|EC17|
1659802|NCT01778920|Drug|EC17 imaging contrast agent|This is an imaging agent to locate lung adenocarcinoma cancer cells during surgery
1659803|NCT01778907|Other|Genotype information accompanied by a drug dosing advice|Dosing advices for deviating genotypes (Poor Metabolizer, Intermediate Metabolizer, Ultrarapid Metabolizer)based on the guidelines of the Royal Dutch Pharmacists Association (KNMP).
1659804|NCT01778881|Other|Massage and stretching exercises|The routine to be used in this group (stretching, massage, and diaphragmatic breathing).
1659805|NCT01778881|Other|Relaxation and imagination therapies|The routines to be adopted will focus on progressive muscle relaxation associated to imagination and diaphragmatic breathing.
1659806|NCT01778881|Other|Dental treatment|Restoring treatment will involve direct reconstruction of the anterior guides (incisive faces of the incisive and canine teeth) with resin.
1659807|NCT01778881|Other|Massage, exercises, relaxation and imagination therapies|The routine to be used in this group (stretching, massage, diaphragmatic breathing, progressive muscle relaxation and imagination therapies).
1659808|NCT01778855|Other|IV t-PA and normothermia|
1659809|NCT01778855|Device|IV-tPA and hypothermia|
1659810|NCT01778842|Drug|Clopidogrel|Patient will be randomized to this intervention will receive the standard dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
1659811|NCT01778842|Drug|Prasugrel|Patient will be randomized to this intervention will receive the low dose of prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
1659812|NCT01778829|Procedure|CPAP ventilation mode|Patients are ventilated through a nasal prong coneected to a ventilator that provides a continuous positive airway pressure
1659813|NCT01778829|Procedure|NIPPV ventilation mode|Patients are ventilated through a nasal prong connected to a ventilator that provides a non synchronized intermittent positive pressure ventilation
1659814|NCT01778803|Drug|defactinib|
1659815|NCT01778803|Drug|Paclitaxel|
1659816|NCT01778790|Device|Deep Brain Stimulation with Activa PC Multi-program Neurostimulator|"Device: DBS 130 Hertz (Hz) frequency, 90us pulsewidth, 4 Volt (V) currency Amplitude
Device: DBS - No Stimulation (Sham) 130 Hertz (Hz)frequency, 90us pulsewidth, 0 Volt (V) currency Amplitude"
1659817|NCT01778777|Device|Universe Reverse Prosthesis|Implantation of an universe reverse prosthesis
1659818|NCT01778751|Behavioral|Home Telehealth with Behavioral Education Component|The primary effectiveness outcome for this study will be hemoglobin A1c. Secondary effectiveness outcomes will include measures of diabetes self-care, self-reported medication adherence, and depressive symptoms.
1659819|NCT01778738|Procedure|Bariatric surgery, either gastric bypass surgery or sleeve gastrectomy|Vertical sleeve gastrectomy or a gastric bypass surgery in morbidly obese individuals with type 2 diabetes. Random allocation to surgical intervention
1659820|NCT01778738|Procedure|Sleeve gastrecomy|Vertical sleeve gastrectomy
1659821|NCT01778738|Procedure|Bastric bypass|Gastric bypass surgery
1659822|NCT01778712|Behavioral|Multi-level intervention|The development of a lifestyle program intended to intervene on the individual, social network and community over two years
1659823|NCT01778699|Dietary Supplement|lozenges|"The test products for the study is manufactured and provided by CD Investments srl, Italy. The placebo lozenges will look like the active lozenges with the same taste and weight of 1 gram containing only the ingredients listed above in the same proportion as the active but with no L. brevis CD2. It will not be possible to differentiate the two products.
The study center and the monitor must be informed of any deficiency in the study products (products will be kept at 4° degrees during the study)."
1659824|NCT01778686|Drug|Citalopram and Pindolol|"Citalopram: selective serotonin reuptake inhibitor
Pindolol: non-selective beta blocker and 5-HT1A receptor antagonist"
1659825|NCT01778686|Other|Placebo|On the second PET scanning day, subjects received a protein drink as well as a 50 ml saline infusion over 1 hour starting 30 min before PET scanning.
1659826|NCT01778686|Dietary Supplement|Acute tryptophan depletion|
1659827|NCT01778673|Procedure|Cast immobilization|
1659828|NCT01778660|Other|Type of Counselling (Mnemonic)|
1659829|NCT01778660|Other|Standard|
1659830|NCT01778647|Dietary Supplement|Stimulants plus Lovaza (drug)|Patients randomized to Stimulants plus Lovaza (Omega-3 fatty acids). Treated and evaluated for up to 16 weeks. COnners and CGI scales filled out by PArents, teachers and Evaluators on each visit
1659831|NCT01778647|Drug|Stimulants plus Placebo (instead of Lovaza)|Patients randomized to usual dose of stimulants plus placebo. Patients evaluated for up to 16 weeks. Conners rating scales and CGI filled out by evaluators, parents and teachers.
1659832|NCT01778634|Drug|Azithromycin|Azithromycin intravenous 20 mg/kg every 24 h x 3 days
1659833|NCT01778634|Drug|Placebo (for azithromycin)|
1659834|NCT01778621|Device|Acupuncture(Hwato®)|acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
2013376|NCT00264680|Drug|lamotrigine|
1659836|NCT01778530|Drug|TRC105|Intravenous infusion.
1659837|NCT01778517|Other|Group Psychotherapy|
1659838|NCT01778517|Other|Cognitive behavior therapy based on self help|
1659839|NCT01778465|Behavioral|Low salicylate diet|
1659840|NCT01778452|Procedure|endometrial biopsy|endometrial biopsy
1659841|NCT01778439|Drug|OMP-52M51|
1659842|NCT01778413|Drug|ATRIPLA|
1659843|NCT01778400|Procedure|radiofrequency ablation|radiofrequency ablation for the treatment as a new therapy as compared with ethanol ablation as a conventional therapy
1659844|NCT01778400|Procedure|Ethanol ablation|ethanol ablation as a conventional/control therapy to be compared with a new experimental therapy--radiofrequency ablation
1659845|NCT01778387|Procedure|Laparoscopic ventral hernia repair|Intraperitoneal ventral hernia repair with the use of Gore-tex Patch
1659846|NCT01778374|Other|No participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with no choice of counselor. This is delivered via a touchscreen tablet device.
1659847|NCT01778374|Other|Participant choice of counselor|Participants in this arm of the study are randomized to an interactive video counselor with a choice of four different counselors. These gender and ethnically diverse counselors are delivered via a touchscreen tablet device.
1659848|NCT01778348|Device|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing a model predictive control (MPC) based glucose control algorithm and communicating with the CGM device and the insulin pump.
1659849|NCT01778348|Device|Real-time CGM alone|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
1659850|NCT01778335|Procedure|Endovascular thrombectomy/thrombolysis|Endovascular mechanical thrombectomy or thrombolysis
1659851|NCT01778322|Procedure|Intracranial aneurysm embolization|Treatment of intracranial aneurysms
1659852|NCT01778309|Dietary Supplement|n-acetylcysteine supplementation|"n-acetylcysteine administration: 20 mg//kg/day, orally, daily for eight days following exercise
placebo administration: 500 mL orally, daily for eight days following exercise"
1659853|NCT01778296|Device|the neurocutaneous island flap|The neurocutaneous island flap of the dorsal branch of the digital nerve can be used for repair the defects of the proximal and middle phalanxes of adjacent fingers.
1659854|NCT01778283|Biological|Acetate-free dialysis solution|the hemodialysis solution that does not contain acetate as buffer
1659855|NCT01778270|Device|Body Bioimpedance Sensor|
1659856|NCT01778257|Dietary Supplement|Mate extract|Mate is a South American herb that is traditionally prepared as a tea and used, among others, for weight reduction.
1659857|NCT01778257|Dietary Supplement|Placebo|Amount and calorie of placebo are same with Mate extracts.
1659858|NCT01778244|Drug|metformin|1000mg/day for 24 weeks
1659859|NCT01778231|Dietary Supplement|Nutrof Total|Antioxidant and trace element supplement
1659860|NCT01778231|Dietary Supplement|Placebo|
1660915|NCT01769378|Drug|Glimepiride|Administered PO
2013377|NCT00264680|Drug|valproic acid|
1659861|NCT01778218|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose|An injection of Technetium ethylenedicysteine-deoxyglucose (99mTc-EC-DG) to yield a target activity of 25 mCi (range of 10-25 mCi) with no more than 250 micrograms of EC-DG to be administered (there must be a minimum of 24 hours between Visit 1 and 2 administrations). Investigational Product to be given by IV push.
1659862|NCT01778205|Other|Observational|
1659863|NCT01778192|Drug|Polyethylene glycol|-group 1 (same day PEG) received 4 L of PEG at 6 hours before procedure on the day of the colonoscopy
1659864|NCT01778192|Drug|Polyethylene glycol|-group 2 (split PEG, N=50) received 2 L of PEG at 6:00 p.m the evening before colonoscopy and 2 L of PEG at 4-6 hours before procedure
1659865|NCT01778192|Drug|Sodium picosulphate with magnesium citrate|-group 3 (SPMC 2) received one sachet of SPMC at 6 p.m the evening before colonoscopy and another sachet of SPMC at 4-6 hours before procedure
1659866|NCT01778192|Drug|Sodium picosulphate with magnesium citrate|-group 4 (SPMC 3) received one sachet of SPMC at 6 p.m and the other sachet at 9 p.m the evening before colonoscopy and another sachet at 4-6 hours before procedure.
1659867|NCT01778179|Drug|Tri-luma|"Pre-procedure phase (From Baseline up to Week 2)treated daily for their solar lentigines with the investigational drug (Tri-Luma® cream) for 2 weeks.
Post-procedure phase (From week 2 up to Week 13 - Visit )
- Tri-Luma® cream treatment phase (from week 5 up to week 13 - visit 3 up to visit 5):The investigational drug (Tri-Luma® cream) will be applied again (group 1) for a minimum of 4 weeks and up to 8 weeks, according to the Global Improvement of solar lentigines and absence of PIH."
1659868|NCT01778179|Procedure|Cryotherapy (CRY-AC3® device)|Procedure performed at week 2.
1659869|NCT01778166|Drug|Immuno-enhanced|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid concerning omega-3-unsaturated fatty acids 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
1659870|NCT01778166|Drug|Standard early enteral nutrition|Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C standard enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube or nasogastric tube
1659871|NCT01778153|Behavioral|Equinox Personal Coaching|Specially designed strength and aerobic exercise training program that consists of 36 sessions over 12 weeks.
1659872|NCT01778140|Other|Patient-specific computerized reminder|The intervention targets are physicians,not patients. This CDSS alerts physicians only when the patient with high risk of contrast-induced-nephropathy(CIN) is encountered. On the contrast, the CDSS will not alert when the patient without CIN risk is encountered.
1659873|NCT01778140|Other|Non-patient-specific computerized reminder|The non-patient-specific computerized reminder always pops up to remind physicians to check their patient's CIN risk no matter what CIN risk is.
1659874|NCT01778127|Behavioral|Activity Monitor|Measurement of physical activity.
1659875|NCT01778127|Behavioral|Interactive Website|Zamzee is a meter that measures activity and a website that makes moving fun. Parents of participants can set activity goals. Activity is uploaded to the website where participants track progress and earn rewards by increasing their level of activity. Participants can view leaderboards and check how other participants are doing.
1659876|NCT01778127|Behavioral|Educational Materials|All participants will receive educational handouts about physical activity. Participants will receive the educational handouts again via mail three and five months into the study to reinforce the importance of physical activity and maintain compliance.
1659877|NCT01778114|Dietary Supplement|Vitamin D2 in orange juice|1000 IU dose
1659878|NCT01778114|Dietary Supplement|Vitamin D3 in orange juice|1000 IU
1659879|NCT01778114|Dietary Supplement|Vitamin D2|capsule, 1000 IU
1659880|NCT01778114|Dietary Supplement|Vitamin D3|capsule, 1000 IU
1659881|NCT01778114|Other|Placebo|Placebo
1659882|NCT01778101|Drug|Lansoprazole|lansoprazole 1mg/kg twice a day for 14days
1659883|NCT01778088|Drug|I-131-CLR1404 Injection|
1659884|NCT01778075|Drug|Tramadol HCl 75 mg/Acetaminophen 650 mg (Newly developed ULTRACET ER)|Single oral dose of newly developed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
1659885|NCT01778075|Drug|Tramadol HCl 75 mg/Acetaminophen 650 mg (Marketed ULTRACET ER)|Single oral dose of marketed ULTRACET ER, (Tramadol HCl/Acetaminophen 75/650 mg), administered under fasted condition.
1659886|NCT01778062|Drug|Indacaterol|Indacaterol 150µg once daily oral inhalation
1659887|NCT01778062|Drug|Control|Placebo once daily oral inhalation
1659888|NCT01778049|Drug|BI 10773|Empagliflozin active
1659889|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
1659890|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 25/5 mg Dose FDC active
1659891|NCT01778049|Drug|BI 10773|Empagliflozin active
1659892|NCT01778049|Drug|BI 10773 / BI 1356|Empagliflozin / Linagliptin 10/5 mg Dose FDC active
1659893|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose placebo FDC
1659894|NCT01778049|Drug|BI 10773|Empagliflozin active
1659895|NCT01778049|Drug|BI 10773|Empagliflozin active
1659896|NCT01778049|Drug|BI 10773|Empagliflozin active
1659897|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
1659898|NCT01778049|Drug|BI 10773 Placebo|Empagliflozin placebo
1659899|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 10/5 mg Dose FDC placebo
1659900|NCT01778049|Drug|BI 10773|Empagliflozin active
1659901|NCT01778049|Drug|BI 10773 / BI 1356 Placebo|Empagliflozin / Linagliptin 25/5 mg Dose FDC placebo
1659902|NCT01778023|Drug|somatropin|A weekly dosage of 0.469 mg of somatropin per kg of body weight per week will be injected subcutaneously (under the skin) in the evening in 7 days per week.
1659906|NCT01777945|Drug|capecitabine|Participants received capecitabine according to individualized physician-prescribed regimen.
1659907|NCT01777945|Drug|docetaxel|Participants received docetaxel according to individualized physician-prescribed regimens.
1659908|NCT01777919|Drug|Temozolomide|
1659909|NCT01777919|Drug|Disulfiram|
1659910|NCT01777919|Drug|Copper|
1718832|NCT00002596|Drug|cyclophosphamide|
1659911|NCT01777893|Behavioral|High protein/ high intensity physical activity (HP-HI)|Participants follow a high protein diet and a high intensity physical activity intervention
1659912|NCT01777893|Behavioral|High protein / moderate intensity physical activity (HP-MI)|Participants follow a high protein diet and moderate intensity physical activity intervention
1659913|NCT01777893|Behavioral|Moderate protein/ high intensity physical activity (MP-HI)|Participants follow a moderate protein diet and a high intensity physical activity intervention
1659914|NCT01777893|Behavioral|Moderate protein/ moderate intensity physical activity (MP-MI)|Participants follow a moderate protein diet and moderate intensity physical activity intervention
1659915|NCT01777867|Procedure|Cough Reflex Sensitivity|Subjects inhaled increasing concentrations of citric acid, which induces coughing in a dose-dependent, reproducible matter. Following each inhalation, the number of coughs in the subsequent 15 seconds was counted and recorded. The challenge was terminated once the citric acid induced 5 or more coughs and the logarithmic (base 10) concentration provoking 5 coughs was recorded.
1659916|NCT01777867|Procedure|Methacholine Challenge|A baseline spirometry was used to assess how well the participant's lungs work by measuring how much air was inhale, how much was exhale and how quickly the participant exhaled. If this was normal, the subject inhaled slowly and deeply the methacholine test solution from a nebulizer and was told to hold their breath for 5 seconds. This was repeated until 5 inhalations were performed in no more than two minutes.
1659917|NCT01777854|Drug|Omeprazole|The principal investigator will be contacted and will work with the research pharmacist to obtain the omeprazole (20 mg PO daily for patients >20kg) and placebo. The placebo does not look like the omeprazole, however this will not be an issue because none of the subjects will have knowledge of how the medications look. The medication will be locked in the designated medication cabinet at each office. It will be prepackaged for a 28 day course. The patient will start the treatment 4 weeks prior to tonsillectomy and stop the day before surgery. The medication will be given to the patient once the consent and assent are signed. This will avoid an unnecessary office visit to improve patient compliance.
1659918|NCT01777841|Other|Electronic Care plan delivery|
1659919|NCT01777841|Other|Standard care|
1659920|NCT01777815|Device|NeoChord DS1000 Artificial Chordae Delivery System|
1659921|NCT01777802|Radiation|SBRT|
1659922|NCT01777802|Radiation|IMRT|
1659923|NCT01777802|Radiation|Brachytherapy|
1659924|NCT01777776|Drug|LEE011|LEE011 will be administered orally, once daily for 21 consecutive days followed by a 7-day planned break (28-day cycle).
1659925|NCT01777776|Drug|LGX818|LGX818 will be administered orally, once daily on a continuous dosing schedule (28-day cycle).
1659926|NCT01777763|Drug|Posaconazole 200 mg|
1659927|NCT01777763|Drug|Posaconazole 300 mg|
1659928|NCT01777750|Device|EMCOOLS flex pad; Philips Innercool RTx|Surface cooling with EMCOOLS flex pads (out-of-hospital); Infusion of 1000ml to 2000ml of cold saline (out-of-hospital); central-venous cooling (Philips Inntercool RTx)
1659929|NCT01777737|Drug|Cotrimoxazole|24 weeks of treatment
1659930|NCT01777737|Drug|Placebo|Identical capsules to cotrimoxazole
1659931|NCT01777724|Behavioral|Combination of Triple P Discussion Groups and Stress Control|The intervention consists of eight group sessions: two 120 minute Triple P Discussion Group sessions (http://www.triplep.net/), and six 90 minute Stress Control sessions (http://glasgowsteps.com/home.php).
1659932|NCT01777711|Behavioral|Mental Contrasting- Individual|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the individual. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
1659933|NCT01777711|Behavioral|Mental Contrasting- Couple|Investigators will implement the manipulation of mental contrasting/implementation intentions, focusing on the couple. This will entail 3 steps that involve: 1) contrasting of positive future outcomes associated with present conditions that hinder achievement of positive future outcomes (i.e., barriers); 2) strategies to overcome barriers and hence facilitate weight loss; and 3) construction of implementation intentions.
1659934|NCT01777685|Drug|Sulpiride|
1659935|NCT01777672|Behavioral|Dietary and oral hygiene recommendations|
1659936|NCT01777672|Dietary Supplement|oral TRPV1 agonist|Patients will receive the administration of a TRPV1 agonist (natural capsaicin) supplement before each meal, 3 meals/day, 5 days/week for 2 consecutive weeks. The TRPV1 agonist will be provided by the pharmacy of the center.
1659937|NCT01777672|Device|pharyngeal electrical stimulation|Includes neuron stimulation treatment of 1 session / day of pharyngeal electrical stimulation of 10 min duration, 3 days/week during 1 week, done at the same center.
1659938|NCT01777672|Device|transcutaneous electrical stimulation|Trans-cutaneous electrical stimuli will be applied 5 seconds every minute during 1 hour daily session, 5 days/week during 2 consecutive weeks at the same centre.
1659939|NCT01777659|Device|Transcutaneous electrical nerve stimulation|Patients will be treated with conventional TENS (ENDOMED 684 Device, ENRAF-Nonius B.V., Rotterdam, Netherlands) for 5 days (4 times/day; 30 min/session) applied on cervical region (C7-T4). TENS intervention was applied as described elsewhere.
1659940|NCT01777646|Biological|MSC_NTF cells transplantation by multiple intramuscular injections at 24 separate sites, in addition to a single intrathechal injection into the CSF|
1659941|NCT01777633|Radiation|Palliative re-irradiation for progressive DIPG in children|
1659942|NCT01777620|Biological|onabotulinumtoxinA|BOTOX® (onabotulinumtoxinA) injected into the areas of glabellar lines and crow's feet lines on Day 1.
1659943|NCT01777620|Drug|Normal Saline|Placebo (normal saline) injected into the areas of glabellar lines and crow's feet lines on Day 1.
1659944|NCT01777607|Device|IMPELLA® RP|
1659945|NCT01777594|Drug|G-202|G-202 administered by intravenous infusion (IV, in the vein) on Days 1, 2 and 3 of each 28-day cycle until progression or development of unacceptable toxicity
1659946|NCT01777581|Drug|Milnacipran|
1659947|NCT01777581|Drug|Placebo|
1659948|NCT01777568|Drug|30% oxygen|Inspired oxygen will be maintained at 30%.
1659949|NCT01777568|Drug|80% oxygen|Inspired oxygen will be maintained at 30%.
1659950|NCT01777555|Drug|CVT-301|
1659951|NCT01777555|Drug|Placebo|
1659953|NCT01777542|Drug|Placebo|Subjects will receive twice daily subcutaneous injections of a saline solution (placebo).
1659954|NCT01777529|Biological|MMR Vaccine|Administration of MMR Vaccine by Bio-Manguinhos or MMR Vaccine by GlaxoSmithKline
1659955|NCT01777503|Drug|prasugrel|prasugrel 5 mg o.d.
1659956|NCT01777503|Drug|Clopidogrel|75 mg o.d.
1659957|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences Study - Control|Usual care will be the Veteran patient care and caregiver support that are normally offered once the Geriatrics and Extended Care (GEC) referral process has occurred. This process entails the patient and caregiver work with the social worker assigned to the patient to obtain home and community based care (HCBC) services. The patients in the usual care group will be free to seek medical, psychological, social support, and social services that are available through VAMCs or any other source. In addition to this, caregivers in the usual care arm will be told about the caregiver support programs in the VHA and the caregiver will receive the national VA caregiver hotline phone number (see Appendix VI for this pamphlet). The information provided mirrors efforts to support caregivers in the VA nationally and new standards of care for VA caregivers. This will be the only contact with the usual care subjects besides the scheduled data collection assessments.
1659958|NCT01777490|Behavioral|Helping Invested Families Improve Veterans Experiences Study - HI FIVES|Caregivers in the HI-FIVES group will receive individual calls with a nurse educator to address topics he/she identified as being the highest priority learning areas. After the phone calls, caregivers will participate in evidence-based group sessions aimed to improve clinical care skills, psychological care skills, and support-seeking skills. The curriculum will be delivered by a trained nurse educator on the research team and the PI and VA Caregiver Support Staff. Three individual telephone training calls will be tailored to the individual needs of Veteran-caregiver dyad. Four group training sessions will be targeted to address common needs of Veterans and their caregivers. Given that all Veteran care recipients will have at least 2 or 3 activities of daily living (ADL) limitations. After the final group session, there will be two optional booster calls at one and three months. Four assessments in all will be collected, baseline (in person), and at 3, 9, and 15 months (by phone).
1659959|NCT01777477|Drug|Chloroquine|Addition of Chloroquine to Gemcitabine
1659960|NCT01777477|Drug|Gemcitabine|
1659961|NCT01777464|Biological|histamine|administration of histamine solution (16 mg/ml) via aerosol for 5 minutes while lying under a fMRI scan
1659962|NCT01777464|Biological|sham|sham solution
1659963|NCT01777451|Other|Additional imaging or surgery|No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)
1659964|NCT01777412|Drug|Bevacizumab|
1659965|NCT01777386|Procedure|preexpanded perforator flap surgery|
1659966|NCT01777360|Device|ALAIR, radiofrequency catheter for bronchial THERMOPLASTY|radiofrequency catheter for bronchial THERMOPLASTY
2013378|NCT00249470|Behavioral|Abstinence & Work|Participants in the Abstinence & Work group were invited to attend the workplace throughout a 26-week intervention period, but were required to provide urine samples that indicated recent cocaine abstinence to gain access to the workplace and to maintain the maximum base pay of $8.00 per hour.
2013379|NCT00249470|Behavioral|Work Only|Work Only participants were invited to attend the workplace throughout a 26-week intervention period. Participants in this group continued to provide mandatory urine samples and could earn base and performance pay. Work Only participants could work and earn base and performance pay independent of urinalysis results.
1659969|NCT01777334|Drug|Umeclidinium/Vilanterol 62.5/25 mcg|Inhalation Powder
1659970|NCT01777334|Drug|Tiotropium 18 mcg|Inhalation Powder
1659971|NCT01777321|Biological|Herpes zoster vaccine GSK1437173A|HZ/su vaccine administered either into the subcutaneous tissue of the upper arm (deltoid region) of the non-dominant arm or intramuscularly in the deltoid region of non-dominant arm on a 0,2-month schedule.
2013380|NCT00249457|Behavioral|Contingency management|Invited to attend the Therapeutic Workplace 3 hr per day, Monday through Friday. Each day when a participant reported to the workplace, she was required to provide a urine sample. If the sample tested negative for opiates and cocaine, she was allowed to work that day. Participants who gained entrance to the workplace participated in basic skills education and job skills training throughout each 3-hr work shift.
2013381|NCT00244751|Drug|GI262570|
2013382|NCT00223795|Device|Single point cane|Participants with symptomatic knee osteoarthritis will undergo gait evaluation with and without a single point cane.
2013383|NCT00217984|Other|Usual Care|Referral to smoking cessation clinic
1659976|NCT01777282|Drug|Albiglutide|Albiglutide is a fixed-dose, fully disposable pen injector system for delivery of albiglutide from a prefilled dual chamber glass cartridge that is an integral part of the pen. It is intended for single use by the subject. It is designed for manual reconstitution of the dose, priming, and insertion of the pen needle, and manual injection by the subject. The subject will inject albiglutide 30 mg weekly for 52 weeks (with optional uptitration to 50 mg weekly) subcutaneously into the abdomen, alternating between left and right sides. The pen is designed to work with standard pen needles.
1659977|NCT01777282|Drug|Sulfonylurea|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
1659978|NCT01777282|Drug|Biguanide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
1659979|NCT01777282|Drug|Glinide|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
1659980|NCT01777282|Drug|Thiazolidinedione|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
1659981|NCT01777282|Drug|Alpha-glucosidase inhibitor|Single oral antidiabetic drug as a background therapy, to be continued as previously prescribed.
1659982|NCT01777269|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
1659983|NCT01777269|Drug|Placebo|Take one capsule daily
2013384|NCT00217984|Behavioral|Extended cognitive behavior therapy|16 sessions of cognitive behavior therapy over 6 months
2013385|NCT00217737|Biological|Bevacizumab|Given IV
1659989|NCT01777243|Drug|GSK2398852|Unit dose strength: 100 mg/mL provided as 1 mL solution per vial. GSK2398852 dosage levels variable with the proposed starting dose level of GSK2398852 as 5 mg [approximately equivalent to 0.1 mg/ kg]. The next escalation dose levels are proposed as 1 mg/kg, 3 mg/kg, 10 mg/kg and 30 mg/kg.
1718833|NCT00002596|Drug|etoposide|
1659990|NCT01777243|Drug|GSK2315698|Unit dose strength: 200 mg/mL stock to be diluted. GSK2315698 will be administered at variable dosed until the concentration of the serum amyloid P component monoclonal antibody (SAP mAb) has fallen below 100 ng/mL.
1659991|NCT01777230|Procedure|SPECT-CT sentinel node mapping|sentinel node localisation using the nuclear medicine technique SPECT-CT
1659992|NCT01777230|Procedure|Magnetic Resonance Lymphangiography sentinel node mapping|Sentinel node localisation using Magnetic Resonance Lymphangiography
1659993|NCT01777230|Procedure|Intra-operative sentinel node procedure|Open or (robot-assisted) laparoscopic sentinel node detection and resection.
1659994|NCT01777217|Drug|Solifenacin succinate|IGRT with VESIcare
1659995|NCT01777217|Drug|Placebo|IGRT with placebo
1659996|NCT01777191|Drug|Ixekizumab Auto-Injector|Administered SC by auto-injector
1659997|NCT01777191|Drug|Ixekizumab Prefilled Syringe|Administered SC by prefilled syringe
1659998|NCT01777178|Other|Low bicarbonate dialysis|
1659999|NCT01777165|Drug|ABT-719|1 arm of ABT-719 higher dose, 1 arm of ABT-719 intermediate dose, and 1 arm ABT-719 lower dose
1660000|NCT01777165|Drug|Placebo|Placebo infusion
1660001|NCT01777152|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion for 6-8 cycles
1660002|NCT01777152|Drug|doxorubicin|50 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
1660003|NCT01777152|Drug|prednisone|100 mg on Days 1 to 5 of each 3-week cycle, orally for 6-8 cycles
1660004|NCT01777152|Drug|vincristine|1.4 mg/m2 (maximum 2 mg) every 3 weeks by IV infusion for 6-8 cycles
1660005|NCT01777152|Drug|cyclophosphamide|750 mg/m2 every 3 weeks by IV infusion for 6-8 cycles
2013386|NCT00217737|Drug|Fluorouracil|Given IV
1660007|NCT01777126|Other|Oral Nutrition Protocol (ONP) group|For the experimental group, an oral nutrition protocol (ONP) with restrictive instructions for parenteral nutrition is implemented. Oral intake is increased progressively with oral fluids and easily digestible food, independent of clinical bowel movements. The oral energy sips used are Fortimel Jucy® (Nutricia) 200 ml containing 300 kcal. This provides supplementary energy and essential nutrients. Supplementary fluid, approximately up to two liter, is given intravenously. Only if oral intake is still insufficient after five days, PN (Oliclinomel N7) can be initiated.
1660008|NCT01777126|Other|Control group|Subjects enrolled in this arm will undergo usual medical and pharmaceutical care. In this group, parenteral nutrition (Oliclinomel N7) is part of the routine postoperative care program.
1660009|NCT01777113|Other|High intensity aerobic training|The mode of the training will be uphill treadmill walking in 4x4 minute intervals at 85% and 95% of Heart Rate Peak (HRpeak) precede by 10-minute warm-up period on the treadmill at self-selected speed and inclination. Between the 4-minute intervals, 3-minute active breaks walking at approximately 50% of HRpeak will be applied. The training sessions will be terminated by a 3-minute cool-down period at 50% to 70% HRpeak. To compensate for increased VO2peak, the speed and/or inclination will be gradually adjusted during 3-month intervention to make sure that the target HR will be between 85% and 95% of HRpeak during the high-intensity intervals.
1660010|NCT01777113|Other|High Intensity Strength Training|Five warm-up repetitions will be completed at approximately 50% of 1 repetition maximum before the main session of four sets of four repetitions unilaterally at 85%Y95% of 1 repetition maximum for both leg press and plantarflexion. When subjects will be able to complete a fifth repetition, the weight will be increased by 1.25 to 2.5 kg, dependent on subjective feelings of capability. They will be encouraged to focus of an explosive concentric movement and a controlled eccentric movement such that the time on each phase will be in the ratio 1:2. The subjects will be regularly reminded to focus on breathing during the contraction, preventing the valsalva maneuver and high rises in blood pressure. The session will finish with a minimum 5-min warm down the treadmill device.
1660011|NCT01777113|Other|Mixed Training|Conventional training consisted of group mobility, balance and stretching exercises. Mobility training included treadmill and cycloergometer training for 10 minutes at self selected speed. Exercises at the parallel bars included weight shift from leg to leg, half-squat, turn in place, leg-trunk flexion, and extension exercises. Finally seated upper- and lower-limb stretching exercises will focus on range of motion, including trunk mobility.
1660012|NCT01777100|Drug|Sufentanil|Sufentanil 0.5 mcg.kg-1 at anesthesia induction (single dose)
1660013|NCT01777087|Other|gauze soaked with capsaicin|This is a basic science study determining the brain activation that results from painful stimulation. All subjects will have the same painful stimulations and brain images collected.
1660014|NCT01777074|Other|Data collection|Questionnaire, Vaccination book
2013387|NCT00217737|Other|Laboratory Biomarker Analysis|Correlative studies
1660016|NCT01777048|Dietary Supplement|Omega-3 Fatty Acids Supplementation|
1660017|NCT01777048|Dietary Supplement|Omega-3 Placebo|Placebo capsules manufactured to mimic Omega-3 capsules
1660018|NCT01777035|Other|early PT OT|"Passive range of motion (ROM) in pts who remain unresponsive despite sedative interruption.
active assisted ROM in supine position.
treatment is advanced to bed mobility activities
sitting balance activities followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.
progression to transfer training, and finally pre-gait training and ambulation.
progression of activities dependent on patient tolerance and stability
therapy sessions continue on a daily basis throughout hospital stay until return to prior level of function or is discharged."
1660019|NCT01777022|Other|A package of interventions|"A package of interventions consisting of strategies for increasing pregnant women's awareness of the need to report early when they perceive a reduction in fetal movements, followed with a management plan for identification and delivery of the at risk fetus in such women, will reduce rates of stillbirth"
1660020|NCT01777009|Procedure|Primary Total Knee Replacement Surgery|Patients randomized to the eversion group had patellas everted during the flexion portions of the surgery. Patients randomized to the retraction group had patellas everted only for the patellar resurfacing portions of the surgery. Both groups were mobilized with anterior tibial translation. All other aspects of surgery including postoperative care, anticoagulation, pain control, and physical therapy were done as per standard arthroplasty protocols at our institution.
1660048|NCT01776671|Drug|Gralise|Titration starting 300 mg/day up to 1800 mg/day over 2 weeks
1660049|NCT01776658|Drug|SYL1001|Ocular topical administration of SYL1001 for 10 consecutive days
2013388|NCT00217737|Drug|Leucovorin Calcium|Given IV
2013389|NCT00217737|Drug|Oxaliplatin|Given IV
1660021|NCT01776996|Drug|Continued Access Arm|All subjects will be on maraviroc 300 mg twice a day, unless a dose adjustment is required due to certain concomitant medications. For those subjects in South Africa and Argentina who were previously receiving Combivir along with maraviroc in Study A4001026, Combivir will be supplied as tablets containing 150 mg lamivudine and 300 mg zidovudine. One Combivir tablet will be taken orally twice a day.
2013390|NCT00204893|Drug|calcium formate|
1660023|NCT01776970|Drug|Cannabis Sativa extract Oromucosal spray|Comparison between active drug (Cannabis Sativa extract Oromucosal spray, containing THC (27 mg/ml):CBD (25 mg/ml) vs placebo
1660024|NCT01776957|Device|Device: Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
1660025|NCT01776931|Dietary Supplement|Lysine intake|Oral consumption of Eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
1660026|NCT01776892|Drug|Collegenase injection|"Collagenase clostridium histolyticum will be used to treat participants in this arm of the study. Affected cords will be treated with 1-3 collagenase injections at 4 week intervals, based on clinical response of the contracture. Cords will be treated until motion of the joint is within 0-5 degrees of normal, for up to 3 total injections.
Metacarpophalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.25ml of sterile diluent. Proximal interphalangeal cords will be injected with 0.58mg (10 000 units) of collagenase in 0.20ml of sterile diluent."
1660027|NCT01776892|Procedure|Needle aponeurotomy|Percutaneous needle aponeurotomy will be performed using an 18 gauge needle. The needle is inserted through the skin into the Dupuytren's cord. The needle is moved very slowly through the cord until complete rupture of the cord is obtained.
1660028|NCT01776866|Procedure|Coronary Angiography|Coronary angiography include standard coronary angiography (SA) and dual-axis rotational coronary angiography (DARCA). Patient first undergo SA of either left or right coronary system followed by DARCA.
1660029|NCT01776853|Dietary Supplement|Glucose|
1660030|NCT01776853|Dietary Supplement|Fructose|
1660031|NCT01776853|Dietary Supplement|Fructans|
1660032|NCT01776840|Drug|Bendamustine|90 mg/m2 administered intravenously on Days 1-2, Cycles 1-6
1660033|NCT01776840|Drug|Rituximab|375 mg/m2 administered intravenously on Day 1, Cycles 1-6; if complete response or partial response is achieved, 375 mg/m2 is administered on Day 1 of every second cycle for a maximum of 12 additional doses
1660034|NCT01776840|Drug|Ibrutinib|560 mg (4 x 140 mg capsules) administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or study end
1660035|NCT01776840|Drug|Placebo|4 capsules administered orally once daily continuously starting on Day 1, Cycle 1 until disease progression, or unacceptable toxicity, or the final analysis of progression-free survival
1660036|NCT01776801|Other|Infusion|Infusion studies are performed in daily clinical routine to measure cerebrospinal fluid resistance outflow. During this test ICP is slowly and securely raised. Investigators plan to analyze what are the consequences of this ICP rise in terms of autonomic system and hemodynamics.
1660037|NCT01776788|Drug|insulin lispro injection, exenatide injection|First, Patients in the exenatide group will receive short-term continuous subcutaneous insulin (CSII)therapy. The doses will be titrated every day in order to attain the glycaemic goal which is defined as a fasting capillary blood glucose of less than 6.1 mmol/L and capillary blood glucose at 2 h after each of three meals of less than 8.0 mmol/L. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then, patients will Sequential be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 8 weeks. After interventions will be stopped, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly
1660038|NCT01776788|Drug|insulin lispro injection|Patients in the control group will receive insulin with an insulin pump. The doses will be titrated every day in order to attain the glycaemic goal. Treatments will be maintained for 2 weeks after the glycaemic target will be reached. Then interventions will be stop, patients will be instructed to continue diet and physical exercise only and will be followed-up with glycaemic monitoring monthly.
1660039|NCT01776775|Device|Abdominal binder|"The abdominal binder is worn from immediately after the operation and continuously for 7 days and nights. The belts are standard abdominal binders (ostomy belts) from ETO garments© with standard height of 22 cm. and five different sizes in width (S, M, L, XL, XXL- depending on waist measure). A fitting will be done for all included patients before the operation by waist measurement according to the recommendation from the company (see below). When applied, the patients are advised to apply the belt in a lying position."
1660040|NCT01776762|Dietary Supplement|Individual nutritional therapy|Individual nutritional therapy provided by registered dietician by means of three Home-visits
1660041|NCT01776749|Device|SubQ|Spinal Cord Stimulation (SCS) and subcutaneous (SubQ) stimulation SCS trial stimulation: Implantation of the Octad lead in the epidural space. The lead implantation in the epidural space is performed under local anesthesia using a standard percutaneous technique. A key element to the technical success of an SCS procedure is the accurate placement of the lead, which results in paresthesia covering the patients' painful areas. This depends on the patients' feedback during intra-operative testing. Therefore, it is important that the patient is awake and fully cooperative during the trial stimulation.
1660042|NCT01776736|Device|Posture Correction Girdle|Posture Correction Girdle applied for 8 hours per day. Clinical, radiographic, and self-report follow-up within the girdling period (6 months).
2013391|NCT00185614|Procedure|autologous then nonmyeloablative allogeneic transplant|stem cell transplantation
1660044|NCT01776710|Behavioral|Structured education|The structured education intervention will comprise a 3-hour education workshop delivered by two trained facilitators and a follow-up telephone call 2 weeks later. The aims of the education programme are to enhance patients' understanding of peripheral arterial disease and intermittent claudication, and to support patients in increasing their daily walking activity. Key behaviour change techniques that will be incorporated will include goal setting, action planning, barrier identification/problem solving, prompt review of behavioural goals, prompt self-monitoring of behaviour, and instructions on how to perform the behaviour.
2013392|NCT00185614|Drug|cyclophosphamide|4 gm/m2, IV
2013393|NCT00185614|Drug|Melphalan|200 mg/m2; iv
2013394|NCT00185614|Drug|cyclosporin|5 mg/kg; iv or po
2013395|NCT00185614|Drug|Mycophenolate mofetil|15 mg/kg
1660050|NCT01776658|Drug|Placebo|Ocular topical administration of placebo for 10 consecutive days
1660051|NCT01776645|Behavioral|Compassion Cultivation Training Course|
1660052|NCT01776632|Behavioral|Physical activity|Promotoras provide appraisal support and negotiate behavior change goals with individual participants; provide instrumental support by organizing and leading physical activity classes within the churches and nearby church community; and advocate for church and neighborhood environmental changes that support increased moderate-to-vigorous physical activity.
1660053|NCT01776632|Behavioral|Cancer prevention|Promotoras provide workshop series on cancer prevention and control within the churches and nearby church community.
1660054|NCT01776619|Drug|PF-06305591|14 day repeated 20mg BID doses
1660055|NCT01776619|Drug|Placebo|14 day repeated BID doses
1660056|NCT01776619|Drug|PF-06305591|14 day repeated 80mg BID doses
1660057|NCT01776619|Drug|Placebo|14 day repeated BID doses
1660058|NCT01776619|Drug|PF-06305591|14 day repeated 40mg BID doses
1660059|NCT01776619|Drug|Placebo|14 day repeated BID doses
1660060|NCT01776619|Drug|PF-06305591|14 day repeated BID doses
1660061|NCT01776619|Drug|PF-06305591|relative bioavailability tablet vs. solution and food effect at 50mg dose
1660062|NCT01776606|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A, Dose A; dose applied to the lateral canthal lines
1660063|NCT01776606|Drug|Placebo|Placebo, Dose B; dose applied to the lateral canthal lines
1660064|NCT01776567|Device|Everolimus eluting stents|
1660065|NCT01776554|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
1660066|NCT01776541|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
1660067|NCT01776528|Biological|NGM282|
1660068|NCT01776528|Biological|Placebo|
1660069|NCT01776515|Drug|Tramadol hydrochloride/Acetaminophen Tab.|
1660070|NCT01776515|Drug|Tramadol hydrochloride/Acetaminophen SR Tab.|
1660071|NCT01776476|Drug|Glutamine|Glutamine dipeptide 0.5 gm/kg/day will be administered as a continuous infusion over 24 hours for up to 7 days or ICU discharge, whichever comes first.
1660072|NCT01776476|Other|Placebo|normal saline of equivalent volume to the experimental drug infusion administered as a continuous infusion over 24 hours for up to 7 days or ICU discharge, whichever comes first
1660073|NCT01776476|Procedure|Surgery|
1660074|NCT01776463|Drug|Z-360|
1660075|NCT01776463|Drug|placebo|
1660076|NCT01776450|Device|Endovascular AAA repair|
1660077|NCT01776437|Drug|BMN 673|500mcg dose of BMN 673, 2 discrete single doses separated by 21 days
1660078|NCT01776424|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 2.5 mg twice daily, tablet
1660079|NCT01776424|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5.0 mg twice daily, tablet
1660080|NCT01776424|Drug|Aspirin|Aspirin 100 mg once daily, tablet
1660081|NCT01776424|Drug|Aspirin placebo|Placebo(1), matching Aspirin tablets
1660082|NCT01776424|Drug|Rivaroxaban placebo|Placebo(2), matching Rivaroxaban tablets
1660083|NCT01776424|Drug|Pantoprazole|Subjects who are not on a PPI (proton pump inhibitor) will also be randomized to pantoprazole or pantoprazole placebo
1660084|NCT01776411|Drug|forodesine hydrochloride|
1660085|NCT01776385|Other|Blood sampling|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
1660086|NCT01776385|Other|Control Group|Biological: ISET and CellSearch Methods Sampling of blood - ISET and CellSearch Methods
1660087|NCT01776372|Device|Medela Thopaz Thoracic Drainage System|
1660088|NCT01776372|Device|Atrium Express Dry Seal Chest Drain|
1660089|NCT01776359|Dietary Supplement|High Protein|2.4g/kg of protein
1660090|NCT01776359|Dietary Supplement|Low Protein|1.2g/kg of protein
1660091|NCT01776333|Behavioral|video decision aid|
1660092|NCT01776320|Drug|Alprostadil|One unit of Vitaros(330ug of Alprostadil)once a week or once every two weeks for four or eight weeks.
1660093|NCT01776307|Drug|BBI608|BBI608 is administered at 500 mg po bid continuously.
1660094|NCT01776307|Drug|Panitumumab|Panitumumab will be administered IV on day 8 and 22 of each 28 day cycle at 6 mg/kg over 60 minutes.
1660095|NCT01776307|Drug|Capecitabine|Capecitabine will be administered orally at 1000 mg/m2 bid daily on days 8-21 every three weeks.
1660096|NCT01776307|Drug|Cetuximab|Cetuximab will be administered IV on day 5 at 400 mg/m2 intravenous infusion over 120 minutes as the initial dose, then weekly at 250mg/m2 over 60-minutes at subsequent cycles.
1660097|NCT01776281|Behavioral|Kangaroo Mother Care|
1660098|NCT01776281|Behavioral|Standard Care|
1660099|NCT01776268|Other|Oral priming|Mother's own colostrum is administered (0.1 mL to each cheek every 6 hours for 5 days) as soon as it is available from the mother regardless of when enteral feedings are initiated.
2013396|NCT00182780|Dietary Supplement|American ginseng|
2013397|NCT00182780|Other|Placebo|
1660102|NCT01776229|Behavioral|Exposure, Relaxation, & Rescripting Therapy-Child|Exposure, Relaxation, & Rescripting Therapy (ERRT) will be conducted once a week for five consecutive weeks for approximately two hours per session. Each treatment session focuses on one of the following topics/skills: psycho-education and investment in treatment, psycho-education, Progressive Muscle Relaxation, diaphragmatic breathing,child-friendly exposure to the trauma-nightmare, and rescription.
1660103|NCT01776216|Other|Dairy diet|During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy: 375 ml of reduced fat milk (1% fat), 175 g of low fat yogurt (1.5% fat) and 30g of regular cheese (34% fat) into their every day diet.
1718919|NCT00002618|Drug|methotrexate|
2013398|NCT00188045|Drug|Propranolol - Spironolactone|
2013399|NCT00187278|Device|Biventricular Pacing|Biventricular Pacemaker implant
2013400|NCT00187278|Device|RV Pacing|Standard Pacemaker implant
2013401|NCT00188071|Drug|paracetamol|
2013402|NCT00188071|Drug|ketoprofen|
2013403|NCT00188071|Drug|ketoprofen + paracetamol|
2013404|NCT00152724|Device|pressure strain system, iontophoresis|
2013405|NCT00152724|Drug|scopolamin|
2013406|NCT00152724|Drug|emla|
2013407|NCT00152724|Drug|capsaicin|
2013408|NCT00152724|Drug|aspirin|
1660104|NCT01776216|Other|Control diet|During the CONTROL diet of the study, participants will be asked to consume energy equivalent replacement products (290 ml of fruit juice, 156 ml of vegetable juice, 1 homemade cookie, 20g of cashew).
1660105|NCT01776203|Drug|Medroxyprogesterone 17-Acetate|MPA pills 20 mg (2 X 10 mg) twice daily for 3 weeks
2013409|NCT00152724|Drug|clopidogrel|
2013410|NCT00152724|Drug|celecoxib|
1660108|NCT01776125|Other|Cheek swab|Participants will be asked to give us a swab (a long Q-tip) of the inside of your cheek (inside your mouth) for genetic testing. This should take no more than 10 seconds. It will not hurt. The swab kit will be provided by Affiliated Genetics. It will include a self-addressed stamped envelope to mail the swab back to Affiliated Genetics. Participants existing x-rays will be reviewed as part of this study as well. We will review participant's medical record to look at what treatments have been executed during the course of participation. Once the individual agrees to participate in this project their private health information will be sent to Axial Biotech Inc., the company that will be doing the genetic testing.
1660109|NCT01776112|Other|Exercise|Standard treatment and participation in the sports program (cycling) including cognitive training, 3 sessions cycling (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
1660110|NCT01776112|Other|TableSoccer|Standard treatment and participation in an activity without physical improvement as placebo condition (table football in groups of 4), but including cognitive training, 3 sessions (30 min. each) per week for 3 months and 2 sessions Cogpack per week for the last 6 weeks.
1660111|NCT01776099|Dietary Supplement|Dietary supplement (4 arms, 2 active, 2 placebo)|
1660112|NCT01776086|Behavioral|Neurological testing|
1660113|NCT01776073|Behavioral|Patient Navigation|
1660114|NCT01776060|Other|generation of 'omic markers of disease progression|Aside from first in disease sampling, the serial, biannual collection of samples from PPMS patients would not only permit the identification of 'omic profiles that can be compared and contrasted to those from RRMS patients in a parallel study, but it would also allow the generation of 'omic markers of disease progression.
1660115|NCT01776047|Drug|Exforge®|
1660116|NCT01776047|Drug|G-0081|
1660117|NCT01776034|Behavioral|SystemCHANGE Group Lifestyle counseling|
1660118|NCT01776034|Behavioral|Phone Lifestyle Counseling|
1660119|NCT01776021|Other|cranberry juice|cranberry juice beverage at a dose of one 8 oz. beverage per day for six months
1660120|NCT01776021|Other|placebo beverage|placebo beverage at a dose of one 8 oz. beverage per day for six months
2013411|NCT00152724|Drug|indomethacin|
2013412|NCT00152724|Drug|acetylcholine|
2013413|NCT00152724|Drug|sodium nitroprusside|
2013414|NCT00152724|Drug|brethyllium|
2013415|NCT00152724|Device|general and local heating|
2013416|NCT00150865|Drug|ropivacaine|
2013417|NCT00111787|Drug|Lapatinib|Daily-monotherapy [1500 milligrams (mg)] for 14 days, then daily combination therapy (with weekly paclitaxel) for 12 weeks
1660128|NCT01775995|Behavioral|Meditation-CBT Intervention + Usual Care|"The intervention combines meditation and standard-of-care CBT strategies for chronic low back pain. It consists of eight weekly 2-hour group sessions guided by trained instructors. In addition to session attendance, experimental participants are asked to practice meditation at home at least 6 days/week, 30 minutes/day during the 26-week study.
Control participants will be offered the intervention after completing the study.
All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations."
1660129|NCT01775995|Other|Usual Care Alone|All participants receive usual care for opioid-treated CLBP through their regular clinicians, per their recommendations.
1660130|NCT01775982|Other|Psychiatric evaluation|"This evaluation is carried out in several stages:
Assessment of cognitive functioning;
Interview with a relative;
Interview with caregivers;
Evaluation of the presence of delirium according to DSM-IV criteria;
Evaluation of the presence of anxiety, depressive syndrome, dementia or other DSM IV;
Reports of adverse events.
A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
1660131|NCT01775982|Other|Geriatric evaluation|"This evaluation includes a brief interview with a caregiver, diverse scorings (CAM, Delirium Index, Mini Geriatric Depression Scale, Modified Early Warning Score, Clinical Global Impression sclae, Algo Plus), and adverse event reporting.
CAM scoring is carried out by a trained geriatrician and a trained nurse and/or a psychologist.
A potential intervention order effect will be taken into account by balancing in each center the number of evaluations beginning with the geriatric assessment and those starting with the psychiatric assessment."
1660132|NCT01775969|Other|Text Message|A text message with instructions is sent to the patient
1660133|NCT01775969|Other|Voicemail|A voicemail with instructions is sent to the patient
1660134|NCT01775930|Drug|Carfilzomib|20 mg/m2 over 30 minutes by vein infusion on Days 1 and 2 and a dose of 56 mg/m2 over 30 minutes by vein infusion on Days 8, 9, 15, and 16 of each 4 week cycle.
1660135|NCT01775904|Drug|LY2886721 Capsule|Administered orally.
1660136|NCT01775904|Drug|LY2886721 ODT|Administered orally.
1660137|NCT01775891|Drug|pilsicainide|The dose of pilsicainide will be 50mg tid PO. Pilsicainide will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
1660138|NCT01775891|Drug|other class IC antiarrhythmic drug|Other class IC antiarrhythmic drug that they had been taking before catheter ablation will be administrated.(flecainide 100mg bid PO or propafenone 225mg tid) Antiarrhythmic drug will be started on the night of the ablation for a duration of at least 3 months. Physicians were encouraged to stop the drugs following the 3 months treatment if possible.
2013418|NCT00111787|Drug|Paclitaxel|Weekly (80mg/m^2) combination therapy (with daily Lapatinib) for 12 weeks
1660190|NCT01775449|Behavioral|Polyamines depleted diet, associating Polydol® cans and predefined menus low in polyamines|
1660309|NCT01774526|Other|Characterise the molecular epidemiology of lung adenocarcinoma in multi-ethnic asian phenotypes|
1660310|NCT01774513|Device|Procore-Needle|
1660311|NCT01774487|Drug|Pentoxifylline|20 mg/kg/day divided in 3 doses, given orally for 90 days
1660142|NCT01775852|Behavioral|ACT-IM|1 hour discussion about migraine management (IM) and 5 hours of group therapy based on Acceptance and Commitment Therapy (ACT). IM covers symptoms and triggers for worsening of migraine symptoms, how to use migraine medications, medication overuse headache, etc. The ACT intervention includes: 1) Behavioral Change Training and; 2) Mindfulness and Acceptance Training emphasizing new ways of managing troubling thoughts, feelings, and physical sensations.
1660143|NCT01775839|Drug|Aspirin+Clopidogrel/Digoxin(oral)|oral administration of digoxin
1660144|NCT01775839|Drug|Aspirin+Clopidogrel/Digoxin(IV)|intravenous administration of digoxin
1660145|NCT01775813|Drug|Metformin|After randomization, the study drug (metformin or placebo) is gradually titrated to full dose of 1000 mg BID (or to maximum tolerated, at least 500 mg BID) over a period of 4 weeks to minimize adverse gastrointestinal effects. Participants are seen every three months to measure compliance and dispense new study drug. Every 6 months, they also have a physical examination in order to determine puberty staging. Study measurements (IVGTT, bloodwork, DXA) are performed at Tanner 4 puberty and Tanner 5 (puberty completion), at which time the study drug is stopped. Study measurements will be performed again 6 months after study drug is completed to assess if effects are persistent after study drug is stopped. During the treatment period, all participants receive standard lifestyle counseling.
1660146|NCT01775800|Other|Treatment modification|
2013419|NCT00111085|Drug|Clazosentan 1 mg/h|Subjects receive intravenous clazosentan at a rate of 1 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
2013420|NCT00111085|Drug|Clazosentan 5 mg/h|Subjects receive intravenous clazosentan at a rate of 5 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
1660149|NCT01775774|Biological|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells|Allogeneic Bone Marrow-Derived Human Mesenchymal Stem Cells will be administered intravenously.
1660150|NCT01775761|Drug|Period 1|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
1660151|NCT01775761|Drug|Period 2|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
1660152|NCT01775761|Drug|Period 3|A comparison of less than or equal to 960 mg tafamidis, 400 mg moxifloxacin and placebo on the rate corrected QT interval.
1660153|NCT01775748|Other|Active Concord Grape Juice 12 oz per day|Grape Juice 12 oz per day
1660154|NCT01775748|Other|Placebo Grape Juice 12 oz per day|Placebo Grape Juice 12 oz per day
1660155|NCT01775735|Device|Occipital nerve stimulator|Electrical stimulation of the greater occipital nerve
2013421|NCT00111085|Drug|Clazosentan 15 mg/h|Subjects receive intravenous clazosentan at a rate of 15 mg/h starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
1660157|NCT01775709|Device|PE tube with Duckbill Valve|PE tube with Duckbill Valve
1660158|NCT01775670|Device|Off-the-shelf splint|Subjects will use an off-the-shelf splint
1660159|NCT01775670|Device|OT Splint|Subjects will use a splint custom-made by Massachusetts General Hospital Occupational Therapists.
1660160|NCT01775657|Device|Thopaz (Digital drainage)|
1660161|NCT01775657|Device|Pleur Evac (Analogue drainage)|
1660162|NCT01775644|Drug|Bevacizumab|Administration of treatment will be as used in normal daily routine under local labeling.
1660163|NCT01775631|Biological|Urelumab|
1660164|NCT01775631|Biological|Rituximab|
1660165|NCT01775618|Biological|BAY94-9027|Prophylaxis treatment 25-60 IU/kg at least 1x/week.
1660166|NCT01775618|Biological|BAY94-9027|Prophylaxis treatment 25-60 IU/kg 2x/week for 12 weeks.
1660167|NCT01775605|Drug|Synera|Synera Pain Patch
1660168|NCT01775592|Drug|Arterakin (DHA-PPQ)|
1660169|NCT01775579|Drug|Glucophage SR tablet 750 mg, Crestor tablet 20 mg|
1660170|NCT01775553|Drug|Carfilzomib|During Cycle 1, patients will receive either 20 mg/m2 on days 1,2 (if the subject has not received carfilzomib as part another clinical trial within the last 4 weeks) or 56 mg/m2 (if the subject is enrolling in the present study after progression of disease on carfilzomib within the last month - for example subjects enrolled in CMAP compassionate use carfilzomib). Thereafter, all subjects will receive 56 mg/m2 for the remaining doses given Cycle 1 Day 8 onwards. Each cycle is 28 days.
1660171|NCT01775540|Drug|Systane Ultra|Artificial tear Eyedrop, 1 drop used QID for 4 weeks
1660172|NCT01775540|Drug|Saline solution|Saline solution,1 drop used QID for 4 weeks
1660173|NCT01775540|Drug|Maxidex|Eyedrop-1 drop QID for 4 weeks
1660174|NCT01775527|Other|blood test|
1660175|NCT01775501|Drug|Leucovorin|200mg/m2 administered IV on Days 1 and 15 of a 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1660176|NCT01775501|Drug|Fluorouracil|5-FU continuous infusion: 2400mg/m2 total (1200mg/m2/d on day 1 and 2) to start on Day 1 and Day 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1660177|NCT01775501|Drug|Oxaliplatin|85 mg/m2 IV on Days 1 and 15 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1660178|NCT01775501|Drug|Sorafenib|400mg po BID continuously for a 2 week lead-in phase and then Days 1-28 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1660179|NCT01775488|Device|Vortx Rx - Histotripsy BPH Device|Non-invasive histotripsy treatment / therapy to be delivered by surgeon using very low duty cycle ultrasound pulses from outside the patient's body. These pulses form a bubble cloud at the focal area within the prostate which mechanically breaks up the cellular structure of the soft tissue. During treatment, a surgeon is able to direct the bubble cloud throughout the targeted volume using controls located on the device console and using the real-time ultrasound for visualization feedback and control of the bubble cloud location.
2013422|NCT00111085|Drug|Placebo|Subjects receive intravenous placebo starting within 56 hours maximum after aneurysm rupture and continuing until Day 14 post-aneurysm rupture
2013423|NCT00070863|Behavioral|Individual Cognitive Behavioral Therapy|
2013424|NCT00064896|Procedure|MRI|
2013425|NCT00005044|Drug|Casodex|Orally at a dose of one 50 mg tablet per day started within (before or after) 14 days of the first LHRH agonist injection.
1660239|NCT01775098|Drug|allopurinol|No arms will not be change as the study as been closed.
1660191|NCT01775436|Behavioral|FAmily-CEntered Advance Care Planning|"Two-60 to 90 minute sessions scheduled one week apart.
Session 1: Respecting Choices Interview (R)to facilitate conversations and shared decision-making between the patient and surrogate about palliative care & prepare the surrogate to be able to fully represent the patient's wishes.
Session 2: Five Wishes (C). Patient selects which person the patient wants to make health care decisions for him/her; the kind of medical treatment the patient wants; how comfortable the patient wants to be; how the patient wants people to treat him/her; what patient wants loved ones to know; and any spiritual or religious concerns the patient may have."
1660192|NCT01775436|Behavioral|Healthy Living Control|"Session 1: Developmental History: Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition.
Session 2: Nutrition and Exercise: Assess nutritional status and provide advice for maintaining optimal nutrition to boost immune functioning. Administered by the RA Control and will be videotaped to control for what occurs in the FACE intervention."
1660193|NCT01775423|Drug|BBI608|
1660194|NCT01775410|Device|Wolverine System to perform atherectomy|
1660195|NCT01775397|Drug|Fidaxomicin|capsule
1660196|NCT01775397|Drug|Vancomycin|capsule
1660197|NCT01775397|Drug|Placebo|Capsule
1660198|NCT01775384|Dietary Supplement|Nutrasorb|from blueberry and green tea extracts (2,136 mg/d gallic acid equivalents)
1660199|NCT01775384|Dietary Supplement|Placebo|
1660200|NCT01775371|Procedure|Patient controlled analgesia|Loading dose 0.1 mg/kg morphine and demand dose of 1 mg morphine available every 6 minutes
1660201|NCT01775371|Procedure|Usual Care|Usual opioid analgesia determined by the provider
1660202|NCT01775358|Drug|ALRN-5281 0.015 mg/kg|
1660203|NCT01775358|Drug|ALRN-5281 0.05 mg/kg|
1660204|NCT01775358|Drug|ALRN-5281 0.15 mg/kg|
1660205|NCT01775358|Drug|Placebo 0.015 mg/kg|
1660206|NCT01775358|Drug|Placebo 0.05mg/kg|
1660207|NCT01775358|Drug|Placebo 0.15mg/kg|
1660208|NCT01775345|Procedure|Isotonic exercises|"20 sessions of muscular force work by means of isotonic exercises, that to the beginning will consist of 2 series of 10 repetitions to 60, 65 and 70 % of a MR.
Later, a gradual progression will be realized and the load will be increasing up to being able to realize, before the session 30: 2 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 2 series of 10 repetitions to 75 and 80 % of 1MR and one series of 6 repetitions to 85 and 90 % of 1MR."
1660209|NCT01775345|Procedure|Isokinetic exercises|20 sessions of muscular force work by means of isokinetic exercises, that to the beginning will consist of 2 series of 10 repetitions to 150, 180 and 210 º / seg in the first session and it will be increasing in a progressive and gradual way up to being able to realize, before the last session: 3 series of 15 repetitions to 180 º, 210 º and 240 º / seg, 2 series of 10 repetitions to 120 º and 150 º / seg and 2 series of 6 repetitions of 60 º and 90 º / seg.
1660210|NCT01775345|Procedure|Isotonic and isokinetic exercises|20 sessions of muscular force work by means of isotonic and isokinetic exercises. To the beginning it will consist of 1 series of 10 repetitions to 150, 180 and 210 º / seg and 1 series of 10 repetitions to 60, 65 and 70 % of 1 MR. A gradual progression will be realized up to reaching, before the last session, a load of: 2 series of 15 repetitions to 180, 210 and 240 º / seg, 1 series from 10 to 120 and 150 º / seg and 1 series of 6 repetitions to 60 and 90 º / seg, and 1 series of 15 repetitions to 60, 65 and 70 %, of 1MR, 1 series of 10 repetitions to 75 and 80 % of 1MR and 1 series of 3 repetitions to 85 and 90 % of 1MR.
1660211|NCT01775345|Procedure|ST|Standard therapy: The 10 first rehabilitation sessions will be common (manual therapy, electrotherapy, proprioceptive reeducation, isometric exercises, bike exercise and cryotherapy)
1660212|NCT01775332|Other|Educational Intervention|A brochure and access to a website including videos that contain detailed information about pituitary disorders will serve as the educational intervention.
1660213|NCT01775319|Dietary Supplement|Biofortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
1660214|NCT01775319|Dietary Supplement|Fortified wheat|Extrinsic label 67Zn (ZnSO4) 0.2mg 70Zn added to the IV dose
1660215|NCT01775319|Dietary Supplement|Placebo|
1660216|NCT01775293|Device|Non-absorbable polypropylene mesh|"2 step procedures
first step is insertion of Non-absorbable polypropylene mesh under the facial skin
second step is pulling of Non-absorbable polypropylene mesh after 3 weeks of 1 step"
1660217|NCT01775280|Radiation|Injection of Ytttrium-90 microspheres into the hepatic artery|INjection of Y-90 particles into the hepatic artery using endovascular access
1660218|NCT01775267|Procedure|Associating liver partition and portal vein ligation for staged hepatectomy|
1660219|NCT01775267|Procedure|Portal vein embolization or ligation|
1660220|NCT01775228|Behavioral|Peer Support|Support (informational, emotional and appraisal) in the form of like persons (i.e. age, gender) who have undergone CABG surgery with successful outcomes (post-recovery at least one year); peer support was provided by telephone for 6 weeks post cardiac surgery recovery.
1660221|NCT01775215|Radiation|Cardiac I123-MIBG Scintigraphy|
1660222|NCT01775215|Other|Cardiac MRI|
1660223|NCT01775215|Other|Stress and rest Echocardiogram|
1660224|NCT01775215|Other|High Sensitivity Troponin I|
1660225|NCT01775215|Other|Brain Natriuretic Peptide|
1660226|NCT01775189|Drug|ALO-02 weight-matched placebo|crushed sugar spheres (powder) x 1 dose
1660227|NCT01775189|Drug|crushed ALO-02 30 mg/3.6 mg|crushed ALO-02 30 mg/3.6 mg capsule x 1 dose
1660228|NCT01775189|Drug|oxycodone weight-matched placebo|crushed lactose tablets (powder) x 1 dose
1660229|NCT01775189|Drug|crushed oxycodone IR 30 mg|Three (3) crushed immediate-release (IR) oxycodone 10 mg tablets x 1 dose
1660230|NCT01775176|Drug|Metformin|
1660231|NCT01775176|Behavioral|Exercise|
1660232|NCT01775176|Behavioral|Dietary Restriction|
1660233|NCT01775150|Other|health education|Health education via text messaging
1660234|NCT01775137|Drug|TBM100|Tobramycin inhalation powder (TIP) 112mg/b.i.d
1660236|NCT01775111|Behavioral|Cognitive Training|
1660237|NCT01775111|Behavioral|Strength Training|
1660238|NCT01775111|Dietary Supplement|FortiFit|
1660312|NCT01774474|Drug|Bromfenac|
1660240|NCT01775085|Behavioral|manualized group intervention|MCG-BCS manual outlines 8 approximately, 90-minute modules: 1) Concepts & Sources of Meaning; 2) Identity, Cancer Survivorship, & Meaning; 3) Historical Sources of Meaning: Past Legacy; 4) Historical Sources of Meaning: Present & Future Legacy; 5) Attitudinal Sources of Meaning: Encountering Life's Limitations; 6) Creative Sources of Meaning: Creativity & Responsibility; 7) Experiential Sources of Meaning: Connecting with Life via Love, Beauty, & Humor; and 8) Transitions: Reflections & Hopes for the Future.
1660241|NCT01775085|Behavioral|standardized, manualized group intervention|DG is a standardized, manualized group developed by the MSKCC Psychiatry Service and utilized in a similar form in our completed and ongoing RCTs of MCGP. Based on models described by Rogers and Bloch, the essential components include reassurance, explanation, education, encouragement, and permission for expression. The process emphasizes Rogerian concepts (e.g., empathic understanding) and avoids techniques that are not exclusively supportive. The content focuses on education about here-and-now topics relevant to BCS (e.g., maintaining and eliciting social support, financial strains, return to work, physical symptom management), allowing emotional expression and discussion of difficult topics.
2013426|NCT00005044|Drug|Eulexin|Orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg (six capsules) started within (before or after) 14 days of the first LHRH agonist injection.
2013427|NCT00005044|Drug|LHRH agonist|LHRH agonist of choice. The manufacturer's instructions should be followed.
1660244|NCT01775059|Device|Integrated sensor and infusion set.|
1660245|NCT01775046|Device|DTA patients (Valiant)|Valiant Thoracic Stent Graft Implantation
1660246|NCT01775033|Other|Multicomponent intervention|Develop, implement and evaluate an organized system of regional pediatric emergency care in rural Western Pennsylvania using four pillars: education, community, protocolized triage and transport, and telemedicine.
1660247|NCT01775020|Dietary Supplement|L-arginine|
1660248|NCT01775007|Device|Brillouin Ocular Analyser|Measurement of the local viscoelastic properties (Brillouin Shift) of the Anterior Eye Segment.
1660249|NCT01774994|Other|stable isotope infusion for measurement of metabolism|
1660250|NCT01774981|Drug|Placebo|Administered IV
1660251|NCT01774981|Drug|LY3016859|Administered IV
1660252|NCT01774968|Drug|Human Regular U-500 Insulin|
2013428|NCT00005044|Radiation|radiation therapy|[Prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin receives 70.2 Gy (1.8 Gy/day x 39 fractions, five days/week)] OR [regional nodes, prostate and seminal vesicles + 1.0-1.5 cm margin will receive 46.8 Gy (1.8 Gy/day x 26 fractions, five days/week), followed by a 23.4 Gy (1.8 Gy/day x 13 fractions, five days/week) boost to the prostate and any extraprostatic tumor extension + 1.0-1.5 cm margin]
1660254|NCT01774929|Drug|TTS-fentanyl|TTS-fentanyl patches releasing at the rate of 12.5 microgram per hour for 3 days. The patches will be replaced every 3 days until 30 days.
1660255|NCT01774916|Genetic|blood samples|
1660256|NCT01774903|Drug|TTS-fentanyl|TTS-fentanyl patches releasing drug at the rate of 12.5 microgram (µg) per hour for 3 days. The patches will be replaced every 3 days until 30 days.
1660257|NCT01774877|Drug|Xinfeng capsule|Xinfeng capsule:Three each time, 3 times a day, Oral,for 3 months; placebo(for leflunomide):10mg each time, 1 time a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
1660258|NCT01774877|Drug|leflunomide|leflunomide :10mg each time, one time a day, Oral,for 3 months; placebo(for xinfeng capsule):Three each time, 3 times a day, Oral,for 3 months; Participants will continue on the stable dose of glucocorticoids and NSAIDs that they were receiving prior to study entry
1660259|NCT01774864|Drug|DA-8159 (Udenafil)|
1660260|NCT01774864|Drug|Placebo|
1660261|NCT01774851|Drug|MM-111|MM-111 (IV)
1660262|NCT01774851|Drug|Paclitaxel|Paclitaxel (IV)
1660263|NCT01774851|Drug|Trastuzumab|Trastuzumab (IV)
1660264|NCT01774838|Drug|Prasugrel|3 months treatment
1660265|NCT01774838|Drug|Clopidogrel|3 months treatment
1660266|NCT01774825|Dietary Supplement|IQP-CL-101|2 softgels twice a day
1660267|NCT01774825|Other|Placebo|2 softgels twice a day
1660268|NCT01774812|Dietary Supplement|Alfacalcidol|0.25 mcg 3x per week for 6 weeks
1660269|NCT01774812|Dietary Supplement|Ergocalciferol|50,000IU 1x per week for 6 weeks
1660270|NCT01774799|Behavioral|Advance care planning intervention|
1660271|NCT01774799|Other|Control group|
1660272|NCT01774786|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 800 milligrams per meter square (mg/m^2)/24 hour IV infusion for 120 hours (Days 1-5) q3w for 6 cycles.
1660273|NCT01774786|Drug|Capecitabine|Participants will receive capecitabine 1000 mg/m^2 orally twice daily, evening of Day 1 to morning of Day 15 (28 doses) q3w for 6 cycles.
1660274|NCT01774786|Drug|Cisplatin|Participants will receive cisplatin 80 mg/m^2 IV q3w for 6 cycles.
1660275|NCT01774786|Drug|Pertuzumab|Participants will receive pertuzumab 840 mg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
1660276|NCT01774786|Drug|Placebo|Participants will receive pertuzumab placebo IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
1660277|NCT01774786|Drug|Trastuzumab|Participants will receive 8 mg/kg IV initial dose on Day 1, followed by 6 mg/kg IV q3w until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
2013429|NCT00030576|Drug|cisplatin|
2013430|NCT00030576|Drug|erlotinib hydrochloride|
2013431|NCT00045773|Drug|Sertraline|50 - 200mg, once per day for 12 weeks.
2013432|NCT00042289|Drug|atazanavir/cobicistat|Women will receive atazanavir/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
2013433|NCT00042289|Drug|darunavir/ritonavir|Women will receive darunavir/ritonavir as prescribed by their clinicians. (Dosage will vary for each participant.)
2013434|NCT00042289|Drug|darunavir/cobicistat|Women will receive darunavir/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
2013435|NCT00042289|Drug|etravirine|Women will receive etravirine as prescribed by their clinicians. (Dosage will vary for each participant.)
2013436|NCT00042289|Drug|elvitegravir/cobicistat|Women will receive elvitegravir/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
1660278|NCT01774773|Drug|Group A: E5501 5mg, then 20mg, then 40 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days.
Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.
The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
1660279|NCT01774773|Drug|Group B: E5501 20mg, then 40mg, then 5 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): one 5 mg tablet under fed conditions on treatment morning for 28 days.
Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.
The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
1660280|NCT01774773|Drug|Group C: E5501 40mg, then 5mg, then 20 mg, then 5mg|"The post-randomization phase consists of the Treatment Period 1 (Visits 2-8): participants received 40 mg (eight 5 mg tablets) under fed conditions on treatment morning for 28 days. Treatment Period II (visits 9-15): one 5 mg tablet under fed conditions on treatment morning for 28 days. Treatment Period III (visits 16-22): 20 mg (four 5 mg tablets) under fed conditions on treatment morning for 28 days.
Treatment Period IV (visits 23-29): 5 mg tablet on treatment morning under fasted conditions for 28 days.
The washout period of 27 days or longer was set between the administration of the study drug in Treatment Periods 1, 2 and 3 and that in Treatment Periods 2, 3 and 4 respectively."
1660281|NCT01774760|Drug|18F-EF5|
1660282|NCT01774760|Procedure|Pretreatment PET/CT-scan (performed two times)|
1660283|NCT01774747|Drug|DSP-1053|DSP-1053 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
1660284|NCT01774747|Drug|Placebo|Placebo 10, 15, 20, 30, 45, 60, 90 mg once daily for 14 days
1660285|NCT01774734|Other|Physical therapy|"Physical therapy
Provided by 2 experienced physiotherapist
Applied to every patients 3 times weekly"
1660286|NCT01774734|Device|Neck Strength Exerciser (NSE)|"Neck strength exerciser use 10-20 minutes daily at home
Plus traditional physical therapy three times weekly provided by two experienced physical therapist"
1660287|NCT01774721|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) 45 mg tablets, continuous oral daily dosing.
1660288|NCT01774721|Drug|Gefitinib|Gefitinib 250 mg tablets, continuous oral daily dosing.
1660289|NCT01774708|Device|Pressure sensitive pad|"The proposed research uses an investigational device from EarlySense consisting of a pressure sensitive piezoelectric pad 350 mm x 226 mm x 12 mm or a little less than 9 by 13 inches and under a half inch thick connected to a cord resembling a phone cord to a controller 10.3 by 10.5 by 5.5 inches which in turn plugs into a standard electrical outlet. The power cord is modu¬lar, so it is possible to select a cord that is long enough without having excessive extra length. The con¬nec¬tion between the pad and the monitor has a quick release like a modular telephone.
This system is designed to very unobtrusively collect heartbeat patterns, respiratory patterns, motion in bed, and bed-exit data with no risk or inconvenience to the patient."
1660290|NCT01774695|Behavioral|Increased physical activity|"The subjects were encouraged to increase their level of physical activity for 12 weeks in the previous study.
The advice was individual but was based on the recommendations of the Swedish National Institute of health. The recommendation for increasing cardiorespiratory fitness is 20-60 minutes of moderate to vigorous intensive physical activity 3 to 5 days per week."
1660291|NCT01774682|Procedure|6-minute walk test|the test corresponds to that defined by Abdel Kafi et al in 2005
1660292|NCT01774669|Device|YouGrabber training device from YouRehab Ltd.|Patients in the experimental group (EG) will receive 16 training sessions lasting for 45 minutes each. The treatment focus is the upper extremity, in particular finder and hand function, movement coordination, and speed.
1660293|NCT01774669|Other|Therapy (PT, OT)|Patients in the control group (CG) will receive 16 therapy sessions physiotherapy or occupational therapy) lasting for 45 minutes each. The therapy focuses on upper limb movements, in particular finger and hand movements. Furthermore, movement coordination and speed shall be trained.
1660294|NCT01774656|Drug|Pharmacological Treatment|The pharmacological treatment intended to enhance reverse remodeling includes 4 drugs initiated immediately after weaning of inotropic support once achieving adequate end-organ recovery and titrated (against symptoms, potassium, and renal function) to the following maximum doses: lisinopril 40 mg daily; carvedilol 25 mg 3 times daily; spironolactone 25 mg daily; digoxin 125g daily, and losartan 150 mg daily.
1660295|NCT01774630|Drug|Nilotinib|300 mg/twice a day
1660296|NCT01774617|Procedure|Comparison of different diagnostic tests|
1660297|NCT01774604|Drug|Indomethacin|100 mg Indomethacin PR x 1
1660298|NCT01774604|Drug|Placebo|
2013437|NCT00042289|Drug|dolutegravir|Women will receive dolutegravir as prescribed by their clinicians. (Dosage will vary for each participant.)
2013438|NCT00042289|Drug|tenofovir alafenamide fumarate (TAF)|Women will receive TAF as prescribed by their clinicians. (Dosage will vary for each participant.)
1660301|NCT01774578|Drug|Docetaxel|Docetaxel given in Arm 1 prior to first progression on study. Given as an option of salvage therapy after first progression on study for Arms 2a and 2b.
1660302|NCT01774578|Biological|HyperAcute®-Lung Immunotherapy|"HAL-1, HAL-2 and HAL-3 immunotherapy components.
Up to 16 immunizations of 300 million immunotherapy cells."
1660303|NCT01774578|Drug|Gemcitabine|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
1660304|NCT01774578|Drug|Pemetrexed|Given as an option of salvage therapy after first progression on study for Arms 1, 2a and 2b.
1660305|NCT01774565|Device|Fully Automated Closed-Loop Insulin Delivery|
1660306|NCT01774565|Device|Conventional insulin therapy|
1660307|NCT01774552|Device|Photo Acoustic Microscopy and Optical Coherence tomography|Photo Acoustic Microscopy and Optical Coherence tomography
1660308|NCT01774539|Other|Diffusion MRI|Each subject will undergo one diffusion MRI scan to identify characteristics of their physes
1660313|NCT01774474|Drug|Dexamethasone|
1660316|NCT01774461|Other|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
1660317|NCT01774448|Behavioral|Mindfulness-Based Cognitive Therapy|In the experimental condition, individuals with dementia (n = 15) and their spouses (n = 15) will partake in one MBCT session per week for 8 weeks. The partners will attend separate MBCT sessions (different day of the week). In the control condition, individuals with dementia (n = 15) and their spouses (n= 15) will go through an 8-week waitlist control period.
1660318|NCT01774435|Drug|EN3342|
1660319|NCT01774422|Device|Extracorporeal CO2 removal device|
1660320|NCT01774409|Genetic|Blood and tumor samples|"Genetic: Establishment of the genetic and immunologic profile
Whole blood sampling :
1 tube for the constitutional DNA extraction;
3 tubes for ancillary studies and research.
Collection of the available archival tumor sample (frozen or FFPE). If there's no available sample, the investigator will prescribe a biopsy of a reachable lesion.
With the established profile, recommendations will be given by a multidisciplinary molecular board."
1660321|NCT01774396|Drug|Emervel® Touch|Emervel® Touch will be injected only in the intervention group.
1660322|NCT01774396|Drug|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine|Emervel® Volume Lidocaine and Emervel® Deep Lidocaine will be injected in the group #2.
1660323|NCT01774370|Drug|Pradaxa (Dabigatran etexilate mesilate)|110 mg or 150 mg b.i.d.
1660324|NCT01774344|Drug|Regorafenib (BAY73-4506)|Regorafenib, 40 mg tablets
1660325|NCT01774344|Drug|Placebo|Placebo tablets matching in appearance
1660326|NCT01774318|Other|aEEG and conventional EEG measurement|aEEG and conventional EEG measurement including video-polysomnography
1660327|NCT01774305|Drug|Dexmedetomidine|We administrate the dexmedetomidine single bolus (0.5ug/kg, intravenously) at time of muscle layer closing.
1660328|NCT01774305|Drug|Saline|We administrate the normal saline (single bolus, 0.25ml/kg) intravenously at time of muscle layer closing.
1660329|NCT01774292|Procedure|Endotracheal intubation with injection of liquid in the cuff|
1660330|NCT01774279|Other|Tissue, blood and clinical data collection|
1660331|NCT01774253|Drug|Vismodegib|
1660332|NCT01774240|Other|systematic screening and treatment of delirium|systematic screening for delirium with DOS scale and CAM ICU. In case of delirium, treatment according to guidelines.
1660333|NCT01774227|Procedure|The pops-titration group|The energy delivery is started at a low level and is increased in intervals till an audible pop is heard, following which the power is reduced downward until the pops are no longer audible, then the treatment is completed at these parameters
1660334|NCT01774227|Procedure|The slow-coagulation group|The Gaasterland's slow-coagulation energy delivery technique using the lower power for the longer duration.
1660335|NCT01774214|Procedure|Push-Pull technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Push-Pull Technique, the 7 cm catheter extension tubing will be connected to one of the three ports of a triple stopcock. A second of the 3 ports of the triple stopcock will be connected to an IV tubing set connected to a 1 L bag of NS. A 60 mL syringe will be connected to the third port of the triple stopcock. On verbal prompt, participants will pull fluid from the bag of NS by withdrawing the plunger of the 60 mL syringe, filling it with saline. They will then toggle the switch of the triple stopcock, so that it is off to the bag of NS and open to IV catheter extension tubing leading to the model. They will then depress the syringe plunger, administering the fluid to the model. These steps will be repeated until each participant believes that they have administered the requested volume of fluid to the model."
1660336|NCT01774214|Procedure|Disconnect-Reconnect Technique|"Participants will administer 900 mL (60 mL/kg) of NS to a model of a 15 kg toddler in shock. The intervention is the mode of administration of the fluid. For the Disconnect-Reconnect Technique, the proximal end of the 7 cm catheter extension tubing will be capped with a needleless adapter. The subject will be provided with 60 mL syringes filled with NS, rapidly prepared in real time by an assistant. Syringes will be prepared by withdrawing NS from a 1 L bag via a Gambro Accessory spike. The subject will administer the requested volume of NS to the model by 1. grabbing one of the fluid-filled syringes 2. connecting the fluid-filled syringe to the needleless adapter, and 3. depressing the syringe plunger resulting in administration of the NS to the model. These steps will be repeated until the subject believes they have administered the requested volume of NS to the model. Testing will begin on verbal prompt. The subject and assistant will not be permitted to switch roles."
1660337|NCT01774201|Other|Breathing exercises|Breathing exercises with positive expiratory pressure.
1660338|NCT01774162|Device|Fine needle biopsy using ProCore needle for histology.|EUS-guided biopsy of each solid lesion using the EchoTip® ProCore™ ultrasound FNB needle for histology.
1660339|NCT01774162|Device|Fine needle aspiration using conventional FNA for cytology|EUS-guided biopsy of each solid lesion using the EchoTip® Ultra™ FNA needle for cytology.
1660340|NCT01774149|Device|Few Touch Application|Users get access to the regular version of the Few Touch Application for Type 1 Diabetes.
1660341|NCT01774149|Device|Diastat|Users get the Few Touch Application with Diastat module activated.
1660342|NCT01774136|Behavioral|Enhanced HIV and MCH training for CHW|
1660343|NCT01774110|Other|Early standardized task training|Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
1660344|NCT01774097|Biological|ALD-301|Ten 1ml injections of ALD-301 in the index calf and posterior, lower thigh
1660345|NCT01774097|Biological|Placebo (vehicle)|Ten 1ml injections of placebo in the index calf and posterior, lower thigh
1660346|NCT01774084|Dietary Supplement|Experimental: PreOp, NutriciaNordica AB|
1660347|NCT01774084|Dietary Supplement|Placebo Comparator: Water|
1660348|NCT01774071|Drug|89Zr- DFO-MSTP2109A|"If you are enrolled onto Group 1:
Once you are given the diagnostic agent, the following procedures will be done:
PET scans at the approximate times:
1-4 hours after the injection
24 hours after the injection (the next day, Day 2)
48-120 hours after the injection (on either Day 3, 4, or 5)
144-168 hours after the injection (on either Day 6, 7, or 8) You will also have research bloods drawn on the following times and days,
Day 1: before the injection, approximately 5 minutes after, 30 minutes after, 1 hour after and 2-4 hours after the injection.
At each time of your scheduled PET scan."
1661123|NCT01767896|Biological|approved egg-derived TIV|subcutaneous (sc)
1660349|NCT01774071|Drug|89Zr DFO-MSTP2109A|"If you are enrolled onto Group 2:
Once you are given the study drug, the following procedures will be done:
You will have one PET scan done. The timing of the PET scan will be determined at the time of your enrollment (~ 3-7 days after injection).
No research blood work will be drawn in Group 2"
1660350|NCT01774058|Drug|Ilomedin|3000ng ilomedin in 15ml salt water will be injected intraarterial into the common femoral artery over 2 minutes for one time,then the investigators will measure the blood flow volume after 5 and then after 10 minutes on the common femoral artery. The patients will be observed by the anaesthesiologist. The patient will get ilomedin one day before the surgery and then for 6 day after surgery into the vein. (10microgramm/o,5ml in 250ml salt water)
1660351|NCT01774045|Drug|PDC-1421|
1660352|NCT01774045|Drug|Placebo|
1660353|NCT01774032|Biological|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|
2013439|NCT00042289|Drug|TAF/cobicistat|Women will receive TAF/cobicistat as prescribed by their clinicians. (Dosage will vary for each participant.)
1660355|NCT01774006|Other|individual embryo culture or group culture|Embryos cultured in a 25 microliter droplet of culture media individually in a conventional petridish or in groups of 2-10 embryos in a Well-of-the-Well petridish
1660356|NCT01773993|Drug|Pregabalin|The usual adult dosage for oral use begins at 150 mg/day of pregabalin twice daily, and should be gradually increased to 300 mg/day over 1 week or more and then maintained at 300-450 mg/day as needed. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 450 mg, and should be orally administered twice daily.
1660357|NCT01773980|Other|Clinic Intervention|The Clinic intervention consists of an educational video, an interactive meeting with clinicians and clinic staff, and a facilitated follow-up meeting with clinic staff.
1660358|NCT01773980|Other|Patient Intervention|The patient intervention consists of a single 90-minute interactive in-person session.
1660359|NCT01773967|Drug|LGG|LGG 10^10 cfu PO BID X 5 days
1660360|NCT01773967|Drug|micro-crystalline cellulose|1 capsule PO bid x 5 days
1958094|NCT02000076|Behavioral|Partial sleep deprivation allowing 3 h sleep at night|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
1660366|NCT01773902|Dietary Supplement|High Dose Protein (Individualized)|Protein supplementation according to breast milk content aiming for 4.5g/kg/d of enteral protein if <1500g b.w. or 4.0g/kg/d of enteral protein if >1500g b.w. until 1 week before discharge
1660367|NCT01773902|Dietary Supplement|High Dose Protein (Standardized)|Protein supplementation independent of individual breast milk content using a new high-dose-protein breast milk fortifier until 1 week before discharge
1660368|NCT01773902|Dietary Supplement|Standard Protein Supplementation|Protein supplementation independent of individual breast milk content using a standard-dose-protein breast milk fortifier until 1 week before discharge
1660369|NCT01773889|Drug|Denileukin Diftitox Plus Subcutaneous Pegylated IFNα-2a|
1660370|NCT01773876|Drug|Micafungin|"MYCAMINE 100 mg intravenous 100 mg of powder reconstituted in a 100 ml infusion bag of sodium chloride 0.9%
infusion over 24 hours for 14 days discontinuation of treatment if proven invasive candidiasis"
1660371|NCT01773876|Drug|PLACEBO|solution of sodium chloride 0.9% 100 ml for intravenous infusion infusion over 24 hours for 14 days discontinuation of placebo if proven invasive candidiasis
1660372|NCT01773850|Device|Stationary Carbon Nanotube X-ray Digital Breast Tomosynthesis Scanner|All patients will undergo conventional imaging and imaging with the carbon nanotube based x-ray stationary digital breast tomosynthesis scanner device.
1660373|NCT01773837|Drug|methylphenidate|methylphenidate (pill) p.o. 15 to 25 mg daily for six days
1660374|NCT01773837|Drug|placebo|placebo (pill) p.o.
1660375|NCT01773824|Behavioral|Antibiotic prescription feedback|Monthly postal and electronic feedback on antibiotic prescription rates
1660376|NCT01773824|Behavioral|No Feedback|Physicians in the control group will only be monitored for their antibiotic prescription rates (Physicians are unaware of the trial)
1660377|NCT01773811|Behavioral|Narrative Writing: Trauma-Assigned|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the assigned group will be given instructions and weekly reminders to continue to think about their most traumatic event.
1660378|NCT01773811|Behavioral|Narrative Writing: Trauma-Spontaneous|Individuals will be writing about their most traumatic life event for 3 consecutive days for 20 minutes each. Those in the spontaneous group will be given no further instructions.
1660379|NCT01773798|Drug|insulin degludec/insulin aspart 15|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
1660380|NCT01773798|Drug|insulin degludec/insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.5 U/kg Body Weight (BW).
1660381|NCT01773798|Drug|insulin degludec|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.425 U/kg Body Weight (BW).
1660382|NCT01773798|Drug|insulin aspart|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days. The dose level will be 0.075 U/kg Body Weight (BW).
1660383|NCT01773798|Drug|placebo|Each subject subject will be randomly allocated to five single doses. Administered subcutaneously (s.c, under the skin) on five dosing visits separated by 15-25 days.
1660384|NCT01773785|Drug|SPI-1620 & Docetaxel|Patients will receive 11 μg/m2 of SPI-1620 intravenously over one minute. Ten minutes after (±2 min) SPI-1620 administration, patients will receive docetaxel 75 mg/m2 intravenous. This regimen will be repeated every 3-weeks cycles until progression or intolerable toxicity.
1660464|NCT01773148|Device|Arstasis Access System (AXERA)|Placement of the AXERA device in the Femoral Artery.
1718920|NCT00002618|Drug|prednisone|
1660385|NCT01773772|Drug|Progesterone|Subjects will take 25-50 mg oral micronized progesterone at 1600 h and again at 2000 h. Progesterone dosing will be based on weight, with 25 mg administered to girls < 42kg and 50 mg given to those or = to 42 kg.
1660386|NCT01773772|Drug|Placebo|Subjects will take oral placebo suspension at 1600 h and again at 2000 h.
1660387|NCT01773759|Behavioral|Intervention child care programs|Interventions will be designed based on findings from Aims 1 and 2, will include outreach and education, and may include on-site demonstration and USIIS training or peer tutoring.
1660388|NCT01773746|Other|Neonatal Resuscitation|CPAP or Positive Pressure Ventilation will be provided.
1660389|NCT01773707|Drug|CTLA4-Ig (Abatacept)|Given as 30 minute IV infusion
1660390|NCT01773707|Drug|Placebo|Saline given as 30 minute IV infusion
1660391|NCT01773694|Behavioral|Early Water Exposure|"The Early Water Exposure (Intervention) group will receive written and verbal instructions to remove the dressing after 6 hours and wet the wound for at least 10 minutes. Wetting of the wound will include shower, tub bath, or pool exposure.
On subsequent days, all participants, regardless of group assignment, will wash the wound daily with soap and water, reapply white petrolatum and a dry dressing."
1660392|NCT01773681|Drug|Cimzia|"For the loading phase, it consists of the first 3 doses. During the loading phase, the recommended dose of Cimzia for adults with rheumatoid arthritis is 400mg initially followed by 400mg again at week 2 and week 4. A 400mg dose requires 2 subcutaneous injection of 200mg; the injections should occur at separate sites in the thigh or abdomen.
After the loading dose, will be follow with 200mg every other week. The injection should occur at either the thigh or abdomen."
1660393|NCT01773681|Device|Magnetic Resonance Imaging (MRI)|MRI of the dominant wrist, before, during and after the gadolinium contrast injection will be acquired. The dose of the gadolinium agent for this study is 0.1mmol/kg body weight. This gadolinium contrast agent will increase the image contrast in the joints in the wrist and surrounding tissues and will make the MRI pictures stand out better.
1660394|NCT01773681|Device|High-resolution peripheral quantitative computed tomography (HR-pQCT)|HR-pQCT scan of the hand and wrist will be acquired to look at the bone quality. The scan uses special x-ray equipment to make detailed pictures of bone structure.
1660395|NCT01773668|Device|Integrated sensor and infusion set.|
1660396|NCT01773655|Other|tumor specimens|"All consenting patients (Consent 1) will participate in an anonymized assessment of the prevalence of germline BAP1 mutations. Available tumor specimens from patients with MPM and metastatic uveal melanoma will be tested for BAP1 mutation. Patients whose tumors harbor BAP1 mutations and/or meet the criteria for germline mutation specified in 2.2.2 will be approached for identified germline BAP1 testing after appropriate pre-test counseling (Consent 2).
Patients who, through identified testing, are found to have germline BAP1 mutations will be asked to invite their relatives to participate in germline testing (Consent 3). First-degree relatives and any relatives with a malignancy will be prioritized. Expanding testing to family members of patients with BAP1 germline mutations is essential to delineate the penetrance and describe the various manifestations of this new cancer predisposition syndrome."
1660397|NCT01773642|Behavioral|Cognitive behavioral intervention to support pediatric HIV disclosure|
1660398|NCT01773629|Other|Intervention|Participants in the intervention arm will receive standard care plus the addition of a care manager. Care managers will function to provide culturally competent and linguistically appropriate support for the care of women identified as being at high risk for depression in pregnancy. Working with both the care providers and these study participants care managers will serve as connectors, coaches, collaborators, and negotiators working to overcome barriers to depression care delivery.
1660399|NCT01773629|Other|Control|"Standard of care: within the current care processes, a woman initiating prenatal care completes a depression risk assessment using a two-step approach. Women with high risk of depression are then scheduled for a separate visit with a member of the care team (a physician, psychologist, or other mental health provider) referred to as a perinatal depression champion for a timely formal diagnostic interview."
1660400|NCT01773616|Drug|Oral prednisolone|
1660401|NCT01773616|Drug|Rituximab|
1660402|NCT01773616|Drug|Mycophenolate mofetil|
1660403|NCT01773616|Drug|Methyl prednisolone|
1660404|NCT01773603|Device|Embryoscope|Five-day embryo culture in embryoscope which is an incubator with a built-in camera
1660405|NCT01773590|Other|Rhinovirus Infection|
1660406|NCT01773564|Device|Current hospital dressing|Patients were assigned to either arm following a randomization scheme 1:1.
1660407|NCT01773564|Device|3M™ IV Advanced Securement dressing|Patients were assigned to either arm following a randomization scheme 1:1.
1660408|NCT01773551|Other|Breast Density|Development of a Quantitative Tissue Optical Index of Breast Density
1660409|NCT01773538|Drug|Lactulose and rifaximin|3 months treatment. lactulose 25 Ml x3 per day. Rifaximin (550 mg) x 2 per day.
1660410|NCT01773538|Dietary Supplement|Branched Chain amino acids|30 grams of branched chain amino acids (Bramino) per day is given to the patients in the antiHE treatment arm along with lactulose and rifaximin.
1660411|NCT01773538|Other|Placebo|Patients in the placebo-arm receives both placebo-Bramino, placebo-lactulose and placebo-rifaximin.
1660412|NCT01773512|Drug|Rosuvastatin|All patients will be using rosuvastatin 40 mg
1660413|NCT01773486|Drug|Hesperidin|Citrus polyphenol, hesperidin
1660414|NCT01773486|Drug|Placebo|Placebo matching hesperidin
1660415|NCT01773473|Drug|Insulin Lispro Mix25|Administered SC
1660416|NCT01773473|Drug|Insulin Lispro Mix50|Administered SC
1660417|NCT01773460|Drug|Everolimus|Everolimus is given beyond progress (comparison with placebo)
1660418|NCT01773460|Drug|Everolimus-placebo|Everolimus-placebo
1660419|NCT01773447|Procedure|Set-back suture|
1660420|NCT01773447|Procedure|Vertical mattress suture|
1660421|NCT01773434|Drug|MORAb-004|"MORAb-004 5 mg/mL is administered as an intravenous infusion (IV) in an escalating dose design and will not be escalated or de-escalated in individual participants.
Part 1 (Dose escalation): 4 weekly administrations of 2, 4, 8, and 12 mg/kg in four different cohorts on Days 1, 8, 15, and 22 of a 4-week cycle (28 days).
Part 2 (Cohort expansion): 4 and 8 mg/kg on Days 1, 8, 15, and 22 of a 4-week cycle (28 days) and 12 mg/kg biweekly administration on Days 1 and 15 of a 4-week cycle in different cohorts. The dosages in Part 2 can be amended considering the results of Part 1."
1661387|NCT01765972|Device|etafilcon A with print|contact lens with print
1660422|NCT01773421|Drug|E7820|"FOOD EFFECT STUDY:
Each subject (a minimum of 12 subjects) will be assigned according to a randomization code to receive a single 50 mg dose of E7820 on Day 1, either after fasting for 10 hours, or immediately after consuming a high fat breakfast. Following a 7-day washout period, the subjects will crossover and a second 50 mg dose of E7820 will be administered on Day 8."
1660423|NCT01773421|Drug|E7820|"MTD DETERMINATION FOR BID DOSING SCHEDULE
The initial dose of E7820 will be 50 mg BID. If allowed by the rules for dose escalation,the dose escalations will be to 60 mg BID, 80 mg BID, and 100 mg BID."
1660424|NCT01773408|Drug|RO5503781 MBP|Participants will receive RO5503781 tablets daily (current formulation) containing microprecipitated bulk powder (MBP) at a starting dose of 400 milligrams (mg).
1660425|NCT01773408|Drug|RO5503781 SDP|Participants will receive RO5503781 tablets daily (new optimized formulation) containing spray-dried powder (SDP) at recommended dose(s) for development from Phase 1b to Phase 3.
1660426|NCT01773408|Drug|Idarubicin|Idarubicin will be administered as per standard clinical practice.
1660427|NCT01773408|Drug|Daunorubicin|Daunorubicin will be administered as per standard clinical practice.
1660428|NCT01773408|Drug|Cytarabine|Parts 2 and 4: Participants will receive cytarabine 1000 milligrams per meter squared (mg/m^2) intravenous (IV) infusion daily. Part 3: Participants will receive cytarabine 100-200 mg/m^2 IV infusion daily.
1660429|NCT01773395|Biological|GVAX|
1660430|NCT01773395|Biological|Placebo Vaccine|
1660431|NCT01773395|Procedure|Allogeneic Hematopoietic Stem Cell Transplant|
1660432|NCT01773395|Drug|Busulfan|
1660433|NCT01773395|Drug|Fludarabine|
1660434|NCT01773395|Drug|Tacrolimus|
1660435|NCT01773395|Drug|Methotrexate|
1660436|NCT01773382|Behavioral|weight reduction|"Set target daily energy requirement by nutritionist (25-30 Kcal/Kg/day minus 500 Kcal)
Advice and encourage patients to do aerobic exercise at least 30 minutes/day for 4-5 days/weeks.
Daily body weight measurement.
Record food diary"
1660437|NCT01773369|Behavioral|Early leg training|Children will engage in ~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by a physical therao[pist in the clinical setting.
1660438|NCT01773369|Behavioral|Delayed leg training|The training activity will be exactly the same as the Early leg training group, except that it will occur ~3 months after recruitment.
1660439|NCT01773369|Behavioral|Parent leg training|Children will engage in ~1 hour/day, 4 days/week treatment for 3 months. The treadmill will consist of supported walking on a treadmill, over ground, stair climbing, standing, kicking, splashing ... etc. leg activity. Activities will be directed by parents in their home or community environment.
1660440|NCT01773356|Dietary Supplement|Dihydrocapsiate|Kellogg's ready to eat cereal, cereal bars, and crackers will contain dihyrocapsiate or placebo. Daily consumption of dihydrocapsiate is 9mg/d or 0mg/d.
1660441|NCT01773343|Procedure|Laser|Fractionel CO2 laser: 1 versus 3 months intervals
1660442|NCT01773330|Procedure|esophageal manometry|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed.There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
1660443|NCT01773330|Dietary Supplement|Gatorade|The patient will be given Gatorade to drink at various times during the study.
1660444|NCT01773330|Other|Supine position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
1660445|NCT01773330|Other|Semi-recumbent position|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
1660446|NCT01773330|Procedure|Sitting|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
1660447|NCT01773330|Procedure|Standing|Esophageal manometry will be performed by swallowing different amounts of Gatorade depending on the protocol being followed. There will be alternate assignment of positions: supine position, semi-recumbent position,sitting position and standing up position.
2013440|NCT00042289|Drug|TAF/ritonavir|Women will receive TAF/ritonavir as prescribed by their clinicians. (Dosage will vary for each participant.)
2013441|NCT00042289|Drug|efavirenz|Women will receive efavirenz as prescribed by their clinicians. (Dosage will vary for each participant.)
1660450|NCT01773304|Other|Dietary meal intervention|Test meals with different protein types (dairy versus meat)
1660451|NCT01773291|Other|acupuncture|acupuncture on GV26 and 12 Well points
1660452|NCT01773291|Other|laser acupuncture|laser acupuncture on GV26 and 12 Well points
1660453|NCT01773291|Other|control|sham laser acupuncture
1660454|NCT01773278|Drug|Antioxidants|Patients will be prescribed the drug AquADEKS or DEKAs at a dose based on age and weight. The effects of the treatment will be monitored by serial ERG, ABR, oxysterol levels and clinical findings.
1660455|NCT01773278|Drug|Cholesterol|Patients with SLOS typically have cholesterol deficiency. They will be treated with cholesterol supplementation to keep cholesterol levels > 100 mg/dl if possible
1660456|NCT01773252|Device|Flow Detection System|
1660457|NCT01773239|Behavioral|TARA computer-based exercises|
1660458|NCT01773226|Device|"Autologous Protein Solution APS(TM)"|A therapy prepared at the point-of-care from a small sample of the patient's own blood containing high concentrations of anti-inflammatory and anabolic proteins
1660459|NCT01773213|Procedure|Ice-water-test|
1660460|NCT01773187|Drug|Pacritinib|
1660461|NCT01773187|Drug|Best Available Therapy|
1660462|NCT01773174|Drug|dabigatran etexilate|age & weight adjusted equivalent of adult dose
1660463|NCT01773161|Procedure|Cerebral palsy, post hip surgery|All subjects will undergo surgical treatment for hip subluxation or dislocation. HRQoL, radiographic, and clinical data will be measured at multiple time points.
1719033|NCT00002174|Drug|Thalidomide|
1660465|NCT01773135|Other|collection of blood sample and tocolysis adminstration|"investigators will abtain a blood sample from all patient to measure the serum level of ACTH.
all patients with threatened preterm labor will receive a fixed regimen of tocolysis in the form of nifedipine (Epilate) 10 mg orally every 15 minutes for the first hour or until cessation of uterine contractions. Then, 60 - 160 mg/day (1-2 tablets 3 times daily) of slowly releasing nifedipine (epilat retard 20 mg tablet) may be given depending on uterine activity. The patients will also receive 6 mg dexamethasone every 12 hours for 4 doses. All women will be followed up till delivery.
After delivery, investigators devide the pateints into 2 groups (full term delivery & preterm delivery) and investigators compare between these 2 groups by level of hormone."
1660466|NCT01773122|Drug|Dapsone Formulation A|Dapsone Formulation A applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
1660467|NCT01773122|Drug|Dapsone Formulation B|Dapsone Formulation B applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
1660468|NCT01773122|Drug|Dapsone Formulation C|Dapsone Formulation C applied once daily to the face, upper chest, upper back, and shoulders for 28 days.
1660469|NCT01773122|Drug|Dapsone 5% Gel|Dapsone 5% gel (ACZONE®) applied twice daily to the face, upper chest, upper back, and shoulders for 28 days.
1660470|NCT01773109|Drug|Etirinotecan pegol (NKTR-102)|
2013442|NCT00042289|Drug|lopinavir/ritonavir|Women will receive lopinavir/ritonavir as prescribed by their clinicians. (Dosage will vary for each participant.)
2013443|NCT00042289|Drug|nevirapine|Women will receive nevirapine as prescribed by their clinicians. (Dosage will vary for each participant.)
1660473|NCT01773083|Drug|unfractionated heparin|nebulized 6 times daily, daily dose 150.000 IU for the maximum duration of 14 days
1660474|NCT01773083|Drug|placebo|Placebo: Sterile saline nebulized 6 times daily for the maximum duration of 14 days
2013444|NCT00042289|Drug|rifampicin|Women will receive rifampicin as prescribed by their clinicians. (Dosage will vary for each participant.)
2013445|NCT00042289|Drug|ethambutol|Women will receive ethambutol as prescribed by their clinicians. (Dosage will vary for each participant.)
2013446|NCT00042289|Drug|isoniazid|Women will receive isoniazid as prescribed by their clinicians. (Dosage will vary for each participant.)
1660478|NCT01773057|Other|NHGDoc domain Heart Failure|Healthcare providers receive patient specific alerts in terms of diagnosing and treatment of patients with heart failure
1660479|NCT01773044|Drug|alkalinized lidocaine|recevied 0.05 mL/kg lidocaine with bicarbonate ( % 2 lidocaine 5 mL + 1 mL %8,4 NaHCO3+ 4 mL SF)
1660480|NCT01773044|Drug|Lidocaine|0.05 mL/kg lidocaine (% 2 lidocaine 5 mL + 5 mL SF),
1660481|NCT01773044|Drug|Placebo (for alcalinized lidocaine)|
1660482|NCT01773018|Drug|Volitinib|Volitinib(HMPL-504) is a tablet in the form of 25 mg ,100mgand 200 mg,oral,once daily.
2013447|NCT00042289|Drug|pyrazinamide|Women will receive pyrazinamide as prescribed by their clinicians. (Dosage will vary for each participant.)
2013448|NCT00042289|Drug|rifampicin|Women will receive rifampicin as prescribed by their clinicians. (Dosage will vary for each participant.)
1660485|NCT01772992|Behavioral|CVCTPLUS|For the intervention, couples will receive HIV testing and counseling together as a dyad, and some couples will receive ARV adherence counseling (Partner-STEPS) together as a dyad.
1660486|NCT01772979|Drug|Trabectedin|
1660487|NCT01772966|Procedure|Spinal manipulation|
1660488|NCT01772953|Drug|Treosulfan|This is a phase II, open-label, nonrandomized, prospective study of a preparative regimen consisting of treosulfan, fludarabine and low-dose total body irradiation (TBI) for children with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) undergoing allogeneic hematopoietic cell transplantation (HCT).
1660489|NCT01772940|Drug|nevirapine|Nevirapine 200 mg twice daily or 400 mg once daily per os during 96 weeks
1660490|NCT01772940|Drug|ritonavir-boosted Lopinavir|ritonavir-boosted lopinavir 800/200 mg once daily or 400/100 mg twice daily per os during 96 weeks
1660491|NCT01772940|Drug|Tenofovir/emtricitabine|tenofovir 300 mg/emtricitabine 200 mg fixed-dose combination once daily, per os for 96 weeks
1660492|NCT01772940|Drug|Zidovudine/lamivudine|zidovudine 300 mg/lamivudine 150 mg twice daily fixed-dose generic combination, per os for 96 weeks
1660493|NCT01772927|Dietary Supplement|Parenteral Nutrition|Protein and energy intakes
1660494|NCT01772901|Other|Influenza Vaccine Intervention|The intervention will include a brief 5 to 10-minute educational talk by research nurse explaining the facts of influenza and influenza vaccine and answering participant questions. The educational intervention will focus on: (1) Hong Kong government's recommendation regarding influenza vaccine during pregnancy, (2) potential complications associated with influenza during pregnancy and for young infants, (3) safety of influenza vaccine for mother and foetus, and (4) potential benefits of influenza vaccine for mother and infant, and (5) where and how to get the influenza vaccine in Hong Kong.
1660495|NCT01772875|Procedure|bladder lavage|the bladder is rinced through the urinary catheter with the lavage solution
1660496|NCT01772862|Behavioral|Intervention group|"The intervention components includes (real time sequence):
An educational session where the child is educated on his/her cancer disease. An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.
Appointment of two classmates as ambassadors. An individualized physical training program combining supervised and non-supervised training 3-5 times per week.
Continued specialized physical training when relevant. At two weeks intervals joined education, physical and social activity days at the hospital with together with one of the ambassadors"
1660528|NCT01772628|Behavioral|STI/HIV prevention education|"For this component, the project partnered with Naguru Teenage information and Health Centre a local NGO providing youth friendly Sexual Reproductive Health services. The STI/HIV prevention education was implemented once in each school on a day that had been agreed upon with the school administration."
1660740|NCT01770860|Device|6660|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
1719202|NCT00002750|Drug|melphalan|
2013449|NCT00042289|Drug|kanamycin|Women will receive kanamycin as prescribed by their clinicians. (Dosage will vary for each participant.)
2013450|NCT00042289|Drug|amikacin|Women will receive amikacin as prescribed by their clinicians. (Dosage will vary for each participant.)
2013451|NCT00042289|Drug|capreomycin|Women will receive capreomycin as prescribed by their clinicians. (Dosage will vary for each participant.)
1660497|NCT01772849|Behavioral|Intervention group|"The intervention components includes (real time sequence):
An educational session where the child is educated on his/her cancer disease An education session in the child's school where the child´s teachers, classmates and their parents are educated on the child´s cancer disease.
Appointment of two classmates as ambassadors Continued individualized education at the hospital school or at home that parallels/copies the educational curriculum in the child regular school At two weks intervals joined education, physical (separate study) and social activity days at the hospital with together with one of the ambassadors"
1660498|NCT01772836|Drug|RPX7009|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
1660499|NCT01772836|Drug|Biapenem|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
1660500|NCT01772836|Drug|Normal saline|Up to three (3) cohorts of 10 healthy adult subjects (8 active, 2 placebo)
2013452|NCT00042289|Drug|moxifloxacin|Women will receive moxifloxacin as prescribed by their clinicians. (Dosage will vary for each participant.)
2013453|NCT00042289|Drug|levofloxacin|Women will receive levofloxacin as prescribed by their clinicians. (Dosage will vary for each participant.)
2013454|NCT00042289|Drug|ofloxacin|Women will receive ofloxacin as prescribed by their clinicians. (Dosage will vary for each participant.)
1660504|NCT01772810|Drug|Human spinal cord stem cells.|Human spinal cord stem cell implantation in paralysis patients due to a spinal cord injury.
1660505|NCT01772797|Drug|LDK378|LDK378 is a capsule to be taken daily by mouth.
1660506|NCT01772797|Drug|AUY922|AUY922 is an intravenous infusion that will be administered by the investigative site to the patient on a weekly basis.
1660507|NCT01772784|Other|Phenolic acids|Phenolic acids
1660508|NCT01772758|Drug|BH4|Kuvan® or sapropterin dihydrochloride is a synthetic preparation of the dihydrochloride salt of naturally occurring tetrahydrobiopterin (BH4). Subjects will receive an oral dose of 20 mg/kg of Kuvan® (Biomarin Pharmaceuticals Inc.)
1660509|NCT01772758|Dietary Supplement|Vitamin C, 1000mg|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
1660510|NCT01772758|Dietary Supplement|Vitamin E, 600IU|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
1660511|NCT01772758|Dietary Supplement|Alpha Lipoic Acid, 600mg|Vitamin C (1000 mg) , Vitamin E (600 IU) , and alpha-lipoic acid (600 mg). all BID
1660512|NCT01772745|Procedure|SILS cholecystectomy|Single incision laparoscopic cholecystectomy will be performed
1660513|NCT01772745|Procedure|TPCL cholecystectomy|Three port laparoscopic cholecystectomy will br performed
1660514|NCT01772732|Drug|Simotinib Hydrochloride|
1660515|NCT01772719|Drug|Simvastatin and zoledronic acid|"Simvastatin 80 mg PO daily starting two days before starting chemotherapy and stopping two days after chemotherapy.
Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly."
1660516|NCT01772706|Procedure|low level laser therapy|
1660517|NCT01772706|Procedure|placebo (laser low level energy nonfunctional)|
1660518|NCT01772693|Device|ExAblate Transcranial MRgFUS|ExAblate Transcranial MR Guided Focused Ultrasound
1660519|NCT01772693|Device|Sham ExAblate Transcranial MRgFUS|Sham ExAblate Transcranial MR Guided Focused Ultrasound
1660520|NCT01772680|Dietary Supplement|Zinc Supplementation|25 mg elemental zinc taken as zinc sulfate in capsule form taken daily for 3 months
1660521|NCT01772667|Procedure|Inpatient Rehabilitation|"Rehabilitation program in Schoen Klinik Berchtesgadener Land"
1660522|NCT01772654|Device|Arterial Spin Labeled (ASL) MRI sequence|"The Arterial Spin Labeled (ASL) MRI sequence is an MRI technique in which arterial blood undergoes spatially selective inversion to label the arterial blood.
This is a magnetic technique and does not require contrast. The tagged blood is imaged and areas of hypoperfusion or hyperperfusion are revealed on the MRI sequence."
1660523|NCT01772641|Other|Scheduled Gradual Reduction + Varenicline|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
1660524|NCT01772641|Other|Scheduled Gradual Reduction + Placebo Drug|Participants will receive a four-week Scheduled Gradual Reduction (SGR) intervention in which participants cut down on the number of cigarettes smoked. This is done through a smoking schedule in which participants smoke a cigarette at given fixed and equal intervals throughout their waking day. Additionally, they will take placebo pills matching the schedule of the VN group.
1660525|NCT01772641|Other|Basic Advice + Varenicline|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take 0.5 mg of Varenicline (VN) once a day for the first three days, then 0.5 mg twice a day for the next four days, and they will continue for 13 weeks at 1.0 mg twice per day.
1660526|NCT01772641|Other|Basic Advice + Placebo Drug|Participants will receive informational pamphlets with advice about quitting smoking. Additionally, they will take placebo pills matching the schedule of the VN group.
1660527|NCT01772628|Behavioral|Classroom-based component|Selected topics about sex, communication, and relationships were integrated in 8 English classroom lessons and 8 Christian Religious Education classroom lessons. The component was implemented in a period of 14 weeks in Senior One classrooms of all the 11 intervention schools.
1719362|NCT00002785|Drug|methotrexate|
2013455|NCT00042289|Drug|ethionamide/prothionamide|Women will receive ethionamide/prothionamide as prescribed by their clinicians. (Dosage will vary for each participant.)
2013456|NCT00042289|Drug|terizidone/cycloserine|Women will receive terizidone/cycloserine as prescribed by their clinicians. (Dosage will vary for each participant.)
2013457|NCT00042289|Drug|para-aminosalicylic acid (PAS)|Women will receive PAS as prescribed by their clinicians. (Dosage will vary for each participant.)
2013458|NCT00042289|Drug|high dose isoniazid (INH)|Women will receive high dose INH as prescribed by their clinicians. (Dosage will vary for each participant.)
2013459|NCT00042289|Drug|bedaquiline|Women will receive bedaquiline as prescribed by their clinicians. (Dosage will vary for each participant.)
2013460|NCT00042289|Drug|clofazamine|Women will receive clofazamine as prescribed by their clinicians. (Dosage will vary for each participant.)
1660529|NCT01772628|Behavioral|Homework assignment component|This component was to facilitate open parent-child interactions and encourage interpersonal learning in a friendly home environment about selected Sexual Reproductive Health issues. Homework assignments were developed on the basis of the topics covered in the learners' component. Students were asked to discuss each assignment with their parents/guardians and recorded answers in 32 paged exercise books provided by the project which were eventually handed over to the researchers at the end of the intervention. Students were given 8 English homework assignments and 7 Christian Religious Education homework assignments.
1660530|NCT01772628|Behavioral|Parenting component|Three one day parenting workshops were conducted in each of the 11 schools for parents/guardians during the period in which the lessons were being implemented. First workshop was conducted at the beginning of the intervention, the second in the middle of the intervention and the third at the end of the intervention. Each workshop in a school was facilitated by one selected teacher and one selected parent in the school. In the first workshop a brochure about the intervention was distributed to all the parents/guardians in attendance.
1660531|NCT01772615|Drug|Ciprofloxacin|Antibiotic
1660532|NCT01772615|Dietary Supplement|E. coli Nissle|Probiotic
1660533|NCT01772589|Procedure|New saw blade|
1660534|NCT01772589|Procedure|Reprocessed saw blade|
1660535|NCT01772576|Device|Reliance 4-Front lead implantation|The patients selected for participation should be from the investigator's general patient population with an indication for implantation of a single or dual chamber ICD or CRT-D system.
1660536|NCT01772563|Drug|volasertib|cycle in 21 days
1660537|NCT01772563|Drug|itraconazole|over 18 days
1660538|NCT01772550|Device|20GA BD Nexiva Diffusics|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.
If the Inserter is unsuccessful in the second attempt, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
1660539|NCT01772550|Device|18GA Conventional Catheter|"The Inserter will have a single attempt on each arm (antecubital area) in which to insert the study catheter. If the catheter is not successfully inserted on the first attempt, the Inserter may make a second attempt in the contralateral arm.
If after the first attempt, there is no vein in the contralateral arm that can accommodate an 18 gauge catheter, the subject is to be discontinued from the Study, and additional (non-Study) insertion attempts may be made according to facility policies."
1660540|NCT01772537|Drug|Propofol|Intravenous anesthetic
1660541|NCT01772537|Drug|isoflurane|
1660542|NCT01772524|Biological|ALD403|
1660543|NCT01772524|Drug|Placebo|
1660544|NCT01772511|Behavioral|Questionnaire|All patients entering on this trial will have been enrolled on an oncology clinical trial and are receiving active anti-cancer treatment on that study.
1660545|NCT01772498|Behavioral|heart rate variability biofeedback|
1660546|NCT01772485|Behavioral|Cognitive Training|The training comprises a suite of 26 engaging, performance-adaptive, and rewarding training modules that provide 30 hours of rigorous neuroplasticity-based cognitive training for children with ADHD addressing deficits in core cognitive domains of alertness, selective attention and working memory of goal-relevant information, control of impulsive actions and suppression of distracting information.
1660547|NCT01772485|Behavioral|Active Control|Participants will engage in any 4 of 13 suite games (visual tiled puzzles, word games etc.) from the Hoyle Puzzle and Board games program. Suite games are randomly assigned in each session.
2013461|NCT00042289|Drug|delamanid|Women will receive delamanid as prescribed by their clinicians. (Dosage will vary for each participant.)
2013462|NCT00042289|Drug|linezolid|Women will receive linezolid as prescribed by their clinicians. (Dosage will vary for each participant.)
1660551|NCT01772433|Dietary Supplement|Olive oil|Phonophoresis with Olive oil for 10 day, daily
1660552|NCT01772433|Drug|Phonophoresis gel|Phonophoresis with base gel for 10 days, daily
1660553|NCT01772420|Drug|Eltrombopag Olamine|Given PO
1660554|NCT01772420|Other|Laboratory Biomarker Analysis|Correlative studies
1660555|NCT01772420|Drug|Lenalidomide|Given PO
1660556|NCT01772394|Behavioral|Cognitive Remediation Therapy|Cognitive remediation therapy (CRT) is an intensive training cognitive therapy that encourages people to reflect on and try to modify the way they think, with a particular focus on improving cognitive flexibility. It is a manualised therapist-led intervention consisting of multiple versions of a variety of tasks and mental exercises that address the difficulties in flexibility and holistic processing. CRT is an individual 10-sessions long program (2 sessions per week).
1660557|NCT01772394|Behavioral|Sham Therapy|The Sham therapy (ST) has been designed to match the CRT format: an individual manualised therapist-led 10-sessions long program (2 sessions per week). ST sessions have been designed so as to avoid set-shifting and central coherence training. Rather, ST is a manualised sham intervention consisting of multiple exercises on 3 domains: soft physical activity, emotional expression recognition and interpersonal functioning.
1660558|NCT01772381|Drug|Dexamethasone|Long acting corticosteroid
1660559|NCT01772368|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.
Fp at 100 mcg was an active comparator (single dose). Further, participants were instructed to administer two inhalations of Fp MDPI 50 mcg twice daily (100 mcg total dose) during the Run-in (to replace the participant's current inhaled corticosteroid) and Washout Periods between treatments."
1660560|NCT01772368|Drug|FS MDPI|FS MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate and salmeterol xinafoate dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened. The fluticasone propionate component was a fixed dose of 100 mcg. The salmeterol xinofoate dosage varied: 6.25, 12.5, 25 or 50 mcg.
1660647|NCT01771588|Dietary Supplement|Human milk fortifier|
1660648|NCT01771575|Other|Placebo device|Placebo device
1660741|NCT01770860|Device|4314|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
1719363|NCT00002785|Drug|methylprednisolone|
1660561|NCT01772368|Drug|Advair Diskus|ADVAIR DISKUS (100/50 mcg fluticasone propionate/salmeterol xinafoate) consists of a dry powder formulation of fluticasone propionate and salmeterol xinafoate in a lactose excipient. The dry powder is contained within individual blisters on a double foil strip within the device. Activation of the device opens a single blister of medication which is then dispersed into the air-stream by patient inhalation.
1660562|NCT01772368|Drug|Albuterol|Albuterol (Pro-Air) hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
1660563|NCT01772355|Device|semi automated core needle biopsy of orbital tumors|
1660564|NCT01772342|Other|HEPA filtration|Night time air purification with the PureNight air purification system with the HEPA filter in place
1660565|NCT01772342|Other|SHAM|Night time air purification with the PureNight air purification system with the HEPA filter removed
1660566|NCT01772329|Other|Cognitive Therapy|CT will be used as a preemptive treatment in an effort to minimize the effects of catastrophic thinking.
1660567|NCT01772329|Other|Routine Care|Routine Care. No Cognitive Therapy Intervention
1660568|NCT01772316|Drug|tocilizumab|162 mg subcutaneously weekly or every two weeks, 96 weeks
1660569|NCT01772303|Drug|HO/03/03 10-40 µg|HO/03/03 10-40µg once daily (Topically) for up to 24 weeks.
1660570|NCT01772290|Drug|fluconazole|Multiple oral doses
1660571|NCT01772290|Drug|itraconazole|Multiple oral doses
1660572|NCT01772290|Drug|rabeprazole|Multiple oral doses
1660573|NCT01772290|Drug|vismodegib|Multiple oral doses
1660574|NCT01772264|Drug|PF-05089771|titration from 150mg BID to 450mg BID
1660575|NCT01772264|Drug|Placebo|matched placebo
1660576|NCT01772251|Drug|Oshadi Icp|
1660577|NCT01772238|Drug|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Reference product
1660578|NCT01772238|Drug|400 mg Amoxicillin + 57 mg Clavulanic Acid/ 5 ml|Test product
1660579|NCT01772225|Other|Data collection|Medical record abstraction form and patient survey questionnaire.
1660580|NCT01772212|Drug|Terbinafine 250 mg|Test product
1660581|NCT01772212|Drug|Terbinafine 250 mg|Reference product
2013463|NCT00042289|Drug|pretomanid|Women will receive pretomanid as prescribed by their clinicians. (Dosage will vary for each participant.)
2013464|NCT00042289|Drug|atazanavir/ritonavir/tenofovir|Women will receive atazanavir/ritonavir/tenofovir as prescribed by their clinicians. (Dosage will vary for each participant.)
1660584|NCT01772186|Device|Real-time somatosensory cue|A novel sensory cue proposed in this study, which designed to facilitate weight shift during freezing-of-gait episodes. This sensory cue is controlled by the real-time analysis of gait pattern, and given only when freezing-of-gait detected.
1660585|NCT01772173|Other|Vessel measurements|Measurement of retinal vessels
1660586|NCT01772160|Other|Data collection|HZ/PHN booklet, HZ/PHN file and logbook. HZ/PHN booklet will be completed by the patient and the HZ/PHN file and logbook will be completed by the participating general practitioner.
1660587|NCT01772147|Drug|Umeclidinium bromide 62.5mcg|Inhalation powder
1660588|NCT01772147|Drug|Umeclidinium bromide 125mcg|Inhalation powder
1660589|NCT01772147|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation powder
1660590|NCT01772134|Drug|Umeclidinium bromide 62.5mcg|Inhalation Powder, LAMA 62.5mcg
1660591|NCT01772134|Drug|Umeclidinium bromide 125mcg|Inhalation Powder, LAMA 125mcg
1660592|NCT01772134|Drug|Fluticasone propionate 250mcg/Salmeterol 50mcg|Inhalation Powder, ICS/LABA
1660593|NCT01772134|Drug|Placebo|Inhalation Powder, Placebo
2013465|NCT00042289|Drug|ethinyl estradiol oral contraceptive|Women will receive ethinyl estradiol oral contraceptive as prescribed by their clinicians. (Dosage will vary for each participant.)
1660595|NCT01772082|Behavioral|Internet mediated walking program|
1660596|NCT01772056|Drug|Fluticasone, cream|Experimental Group: on treatment with twice weekly on consecutive days FP cream of 0.05% for 16 weeks or at relapse
1660597|NCT01772056|Drug|Placebo,|Control Group: on treatment with twice weekly on consecutive days vehicle cream for 16 weeks or at relapse.
1660598|NCT01772030|Other|Use of the Achieve catheter followed by ICE-guided mapping catheter|
1660599|NCT01772017|Device|Tongue Advancement Retainer Device|Tongue Advancement Retainer Device
2013466|NCT00042289|Drug|etonogestrel implant|Women will receive etonogestrel implant as prescribed by their clinicians. (Dosage will vary for each participant.)
1660601|NCT01771991|Drug|Topical Sodermix Dismutase in the form of Sodermix (SOD)|Topical Sodermix Dismutase in the form of Sodermix (SOD) will be applied twice daily, of half dollar application for 12 weeks to fibrosed area.
1660602|NCT01771991|Drug|Placebo|Placebo or cetaphil cream will be applied twice daily, of half dollar size for 12 weeks to fibrosed area.
1660603|NCT01771978|Drug|Placebo|Received 250 ml of a 5% dextrose solution as placebo
1660604|NCT01771978|Drug|Diltiazem|Received a 100 µg/kg bolus followed by a 0.3 µg/kg infusion diluted in 250 ml of 5% dextrose solution
1660605|NCT01771978|Drug|Acetylcystein|Received 150 mg/kg acetylcystein diluted in 250 ml of 5% dextrose solution
1660606|NCT01771978|Drug|diltiazem and acetylcystein|"Received a combination of drug :diltiazem and acetylcystein
bolus diltiazem 100 µg/kg followed by a 0.3 µg/kg infusion diluted in 125 ml of a 5% dextrose solution
150 mg/kg acetylcystein diluted in 125 ml of 5% dextrose solution"
1660702|NCT01771185|Drug|Best medical treatment (Metformin ; gliclazide)|Metformin 2 g/day; gliclazide 30 mg
1661388|NCT01765972|Device|Spectacles (habitual)|Spectacles
2013467|NCT00000300|Drug|LAAM|
1660607|NCT01771965|Behavioral|CB Intervention|The Cognitive Behavioral (CB) intervention is a brief, manualized, tailored one-on-one single session lasting 45-60 minutes and administered by phone. An individual format was chosen to reduce the potential discomfort of stigma of individual concerns in the presence of others. The intervention targets a change in the beliefs that influence whether or not someone enters mental health or substance use treatment. During the session, participants will be given a brief introduction to CBT and informed that CBT is based on the theory that cognitions (i.e., thoughts/beliefs), feelings and behaviors all interact with each other;101, 102 therefore, thoughts about certain situations or things influence behavior. Since thoughts are modifiable, changing thoughts about situations may change behavior.
1660608|NCT01771952|Device|Synvisc-One™|A single 6cc injection of Synvisc-One™ will be utilized in this study.
1660609|NCT01771952|Other|Sham Treatment|A single needle stick without arthrocentesis or injection.
1660610|NCT01771939|Procedure|25-G vitrectomy and phacoemulsification|25-G vitrectomy with Internal Limiting Membrane peeling and phacoemulsification (cataract intervention)
1660611|NCT01771939|Procedure|phacoemulsification (cataract surgery)|lens extraction after phacoemulsification and intra-ocular artificial lens implantation
1660612|NCT01771926|Other|potatoes|Daily intake of assigned treatment for 8 weeks
1660613|NCT01771926|Other|other carbohydrate|Daily intake of assigned treatment for 8 weeks
1660614|NCT01771913|Genetic|centrifuged fat graft|fat from the abdominal subcutaneous tissue will be taken by vacuum assisted lipectomy and immediately prepared to be grafted in the reconstructed breast that presents contour irregularities and/or volume insufficiency. No adipose derived stem cells will enrich the fat grafts in this group.
1660615|NCT01771913|Genetic|ADSCs enriched fat graft|fat from the abdominal subcutaneous tissue will be taken by suction assisted lipectomy and stromal vascular fraction will be isolated and immediately added to the fat graft that will be employed to improve contour irregularities and volume insufficiency of reconstructed breasts.
1660616|NCT01771900|Behavioral|Heart Camp Group|In Week 1, 2, and 3 subjects will attend the HEART CAMP. Subjects will set specific exercise goals. Subjects will be taught how to record exercise data on the computer at the exercise facility. Specific activities will teach subjects aerobic and resistance training exercises and build self-efficacy to exercise. During the period from month 3 to the end of study subjects will continue the training program independently and no formal sessions will be scheduled.
1660617|NCT01771900|Behavioral|Attention Control Group|Subjects will receive a 60 minute group session led by a specifically designated control group intervention nurse. Phone calls will be placed to the subject if they miss a Friday group session and attendance to meetings will be encouraged.
1660618|NCT01771887|Behavioral|education program|education program in 6 hours and monitoring phone every 15 days
1660619|NCT01771874|Drug|MDMA|125 mg per os, single dose
1660620|NCT01771874|Drug|Bupropion|Bupropion will be administered in a dose of 150mg (Wellbutrin XR) once-daily in the morning for three days followed by 300mg (2x150mg) for 4 days before the test day. On the test day, a final dose of 300mg will administered 2 hours before the administration of MDMA 125 mg or placebo.
1660621|NCT01771874|Drug|Placebo|per os
1660622|NCT01771861|Other|Trauma team activation|When admitting a potentially seriously injured patient, a trauma team is activated when prehospital information fulfills one or more prespecified criteria. The trauma team consist of a group of medical personnel including a surgeon, anesthesiologist and radiologist.
1660623|NCT01771848|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved fully infectious NF54 P. falciparum sporozoites
1660624|NCT01771822|Drug|Ibuprofen 5% topical gel|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
1660625|NCT01771822|Drug|Topical gel vehicle|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
1660626|NCT01771822|Drug|Sodium lauryl sulfate 0.2%|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
1660627|NCT01771822|Drug|Sodium chloride solution 0.9% (saline)|0.2 ml applied daily for 21 days over 3 weeks under occlusive conditions
1660628|NCT01771809|Drug|75mg PF-00547659|75 mg sterile liquid injected subcutaneously once monthly for 72 weeks in treatment period 1.
1660629|NCT01771809|Drug|225mg PF-00547659|225 mg sterile liquid injected subcutaneously once monthly for 72 weeks in treatment period 1.
1660630|NCT01771809|Drug|75mg PF-00547659|75 mg sterile liquid injected subcutaneously once monthly for 72 weeks in treatment period 2.
1660631|NCT01771796|Behavioral|Aerobic and muscle resistance training|After having been allocated randomly to one of the two groups, patients of Intervention Group are encouraged to follow a training program (aerobic and endurance muscle training) during 8 weeks.
1660632|NCT01771783|Drug|ACEI-ARB-RI|
1660633|NCT01771783|Drug|ARB-RI-ACEI|
1660634|NCT01771783|Drug|RI-ACEI-ARB|
1660635|NCT01771731|Drug|Cannabis|
1660636|NCT01771718|Device|MPTflex-multiphoton microscopy-based tomograph.|non-invasive optical biopsy
1660637|NCT01771705|Other|Dose adjust group (NFAT)|If the average residual expression of the 3 cytokines is <15%, the CNI daily dose will be reduced by 15%. If the average residual gene expression of the 3 cytokines is > 80% the CNI daily dose will be increased by 15%.
1660638|NCT01771692|Other|Extraction|Extraction of teeth in the lower arch as part of the orthodontic treatment plan
1660639|NCT01771692|Other|Non extraction|Non extraction in the lower arch as part of the orthodontic treatment plan
1660640|NCT01771679|Biological|Allogeneic Mesenchymal Bone Marrow Cells|Subjects in Part 1, Cohorts 1-3 will receive a 1550 nm Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of 0.5, 1.0, or 1.5 million mesenchymal cells per kg of body weight, not to exceed 150 million cells. Subjects in Part 2 will receive a 1550 Fraxel laser (6-8 mJ, Level 2) treatment on the face followed by a single intravenous infusion of mesenchymal cells at the Maximum Tolerated Dose, as determined by the safety results of Part 1. The dose in Part 2 is 1.5 million cells per kg, not to exceed a total of 150 million cells.
1660642|NCT01771640|Biological|intrathecal injection|Intrathecal injection of mesenchymal stem cells in patients with ALS
1660643|NCT01771627|Drug|varenicline|Given PO
1660644|NCT01771627|Drug|nicotine patch|
1660645|NCT01771614|Behavioral|Exercise|
1660646|NCT01771614|Procedure|Hyperglycemia|
1661527|NCT01764906|Device|Novosis|
1660649|NCT01771575|Device|PoNS™ device|The PoNS™ device uses electrotactile waveform in conjunction with the Cranial Nerve - Non-Invasive NeuroModulation (CN-NINM) intervention. This involves using both balance and gait training methods to stabilize symptoms, regain balance & gait, and affect the functional transfer of improved stability and mobility to activities of daily living. It is based on a body of work focused on developing the tongue-based human-machine interface and application of this technology for balance, vision, and auditory substitution and more recently as neuromodulation for brain rehabilitation after injury and disease.
1660650|NCT01771536|Other|Decision Aid|
1660651|NCT01771523|Procedure|Thyroidectomy|total thyroidectomy or lobectomy
1660652|NCT01771523|Device|use of drain|drain will be used
1660653|NCT01771497|Device|Koning Breast CT|Koning Breast CT scans will be assessed at the beginning, mid-point and end of therapy.
1660654|NCT01771484|Device|External automated abdominal binder|Participants will wear the abdominal compression binder on day 4 or 5 of the study diet. Seated and standing vitals will be collected before and during application of binder.
1660655|NCT01771471|Biological|NuQu|Allogenic juvenile chondrocytes (NuQu) in fibrin carrier.
1660656|NCT01771471|Other|Placebo|0.9% w/v Sodium Chloride for Injection, USP
1660657|NCT01771458|Drug|Targeted therapy based on molecular profiling : Imatinib|
1660658|NCT01771458|Procedure|Tumor biopsy|
1660659|NCT01771458|Drug|Standard Chemotherapy|
1660660|NCT01771458|Drug|Targeted therapy based on molecular profiling : Everolimus|
1660661|NCT01771458|Drug|Targeted therapy based on molecular profiling : Vemurafenib|
1660662|NCT01771458|Drug|Targeted therapy based on molecular profiling : Sorafenib|
1660663|NCT01771458|Drug|Targeted therapy based on molecular profiling : Erlotinib|
1660664|NCT01771458|Drug|Targeted therapy based on molecular profiling : Lapatinib + Trastuzumab|
1660665|NCT01771458|Drug|Targeted therapy based on molecular profiling : Dasatinib|
1660666|NCT01771458|Drug|Targeted therapy based on molecular profiling : Tamoxifen (or letrozole if contra-indication)|
1660667|NCT01771458|Drug|Targeted therapy based on molecular profiling : Abiraterone|
1660668|NCT01771445|Drug|IL-1Ra|100mg, s.c, once only
1660669|NCT01771445|Drug|Placebo|100mg, s.c., once only
1660670|NCT01771432|Drug|Antibiotic treatment|Kidney transplant recipients with asymptomatic bacteriuria will be treated with antibiotics
1660671|NCT01771432|Other|No treatment|Kidney transplant recipients with asymptomatic bacteriuria will be followed without antibiotic therapy
1660674|NCT01771406|Drug|Nebivolol|8 weeks of Nebivolol treatment (5mg/day)
1660675|NCT01771406|Device|Continuous positive airway pressure (CPAP)|8 weeks of CPAP treatment
1660676|NCT01771393|Device|CBCT prior to MDCT|Cone-beam scanner is performed immediately after arthrography, then multidetector scanner is performed.
1660677|NCT01771393|Device|MDCT prior to CBCT|Multidetector scanner is performed immediately after arthrography, then Cone-beam scanner is performed.
1660678|NCT01771367|Biological|Fluad|
1660679|NCT01771367|Biological|Agrippal|
1660680|NCT01771367|Biological|Placebo|
1660681|NCT01771354|Biological|Engerix B Vaccine|
1660682|NCT01771354|Biological|Placebo|
1660683|NCT01771341|Device|MAQUET SERVOi ventilator with Edi Catheter|NAVA respiratory modality
1660684|NCT01771341|Device|MAQUET SERVOi ventilator|Pressure Support
1660685|NCT01771328|Drug|Hydrocortisone|Initial standard dose of 10mg/m2/24hrs administered by pump during the treatment period, it will take 4 months. Body surface area will be calculated according to the nomogram from the formula of Du Bois and Du Bois.
1660686|NCT01771328|Drug|Cortisone acetate|Patients will take this tables two times during day according to best clinical practice of therapy of congenital adrenal hyperplasia. Usually Cortisone 25 mg 1 tbl. in the morning and Cortisone 25 1/4 tbl. in the evening. This period will take 6 months.
1660687|NCT01771315|Behavioral|Telephone follow-up|The consultation is structured by predefined themes relevant for identifying health related problems in regard to illness to give adequate education and counseling. The form of each consultation will vary according to the individual needs of the patients.
1660688|NCT01771302|Device|Bio-Oss|It is a bone substitute of bovine origin
1660689|NCT01771302|Device|calcium phosphate ceramic|It is a synthetic bone substitute ceramic that is composed of calcium and phosphate ions and prepared at high temperature
1660690|NCT01771289|Drug|docetaxel/cisplatin|weekly docetaxel/cisplatin combined with radiation
1660691|NCT01771289|Radiation|Radiation|chemoradiation
1660693|NCT01771263|Device|iControl-RP|
1660694|NCT01771250|Biological|LY2605541|Daily doses administered SQ.
1660695|NCT01771250|Biological|Insulin Glargine|Daily doses administered SQ.
1660696|NCT01771237|Behavioral|MyPeeps Manualized Group Intervention|Topics include: HIV/STI transmission, interpersonal communication, stigma management, condom use, substance use and risky sex, HIV-related harm reduction
1660697|NCT01771237|Behavioral|Standard Sexual Health Education|Topics include: HIV/STI transmission facts, myths regarding HIV transmission, information on effectiveness of condom use
1660698|NCT01771224|Dietary Supplement|Palmitoleic acid|Palmitoleic acid and 5-ASA
1660699|NCT01771211|Device|tDCS|anodal tDCS will be delivered with a constant current of 1 mA during resting-state and task-related fMRI and will continue until the end of the word-generation task. For both stimulation conditions (atDCS, sham) the current will be initially increased in a ramp-like fashion over 10 s, eliciting a tingling sensation on the scalp that fades over seconds. During sham stimulation the current will be turned off after 30 s.
1660700|NCT01771198|Drug|SIMVASTATIN|SIMVASTATIN tablet of 40mg once a day during 30 days
1660701|NCT01771185|Procedure|Duodenal jejunal bypass plus sleeve gastrectomy|Metabolic Surgery Duodenal jejunal bypass plus sleeve gastrectomy
1660907|NCT01769417|Drug|MEDI4893|Human immunoglobulin G1 kappa monoclonal antibody
1660703|NCT01771159|Device|TBC|"The anchor is capped and surgically implanted in the extra-peritoneal space of the suprapubic region of pubic hair of the lower abdomen using sutures sandwich and secure the anchor between the rectus abdominis muscle and the detrusor [bladder] muscle. Skin is closed over the implant and the bladder is drained with a Foley urethral catheter. The Phase I implant is left in place for 3+ months to allow fibroblasts and collagen from the adjacent muscles to grow into the porous PTFE and effect robust, water--tight bonding of anchor to both rectus and bladder muscles.
After a local anesthesia is injected, the remaining components of the TBC are connected forming a water-tight union of the anchor to the urinary bladder."
1660704|NCT01771146|Drug|FOLFIRINOX Regimen|6 cycles of FOLFIRINOX prior to surgical resection: Eloxatin® (Oxaliplatin) 85 mg per square meter 2-hour IV infusion Camptosar® (Irinotecan Hydrochloride) 180 mg per square meter 90-minute IV infusion via Y-connector adrucil (Fluorouracil; 5-FU)2400 mg per square meter 46-hour IV infusion
1660705|NCT01771133|Behavioral|Lifestyle intervention group|The lifestyle intervention will be delivered within an empowerment framework which promotes behavioral changes by facilitating health self-efficacy, utilizing self-praise and using active coping skills to address and manage emotions. A nutrition component primarily focuses on total calories, for which energy requirements will be individually calculated for each pregnant women and on general diet quality with an emphasis on carbohydrate quality. It will also promote an overall healthy diet, emphasizing improvement of fat quality and reducing salt intake. A physical activity component focuses on promoting regular movement and minimizes the duration of bouts of sitting or lying during waking hours as well as non-exercise activity.
1660706|NCT01771120|Other|Diagnostic tests, medical interview and questionnaires|All patients will perform these interventions.
1660707|NCT01771107|Drug|Brentuximab Vedotin|Given IV
1660708|NCT01771107|Drug|Dacarbazine|Given IV
1660709|NCT01771107|Drug|Doxorubicin Hydrochloride|Given IV
1660710|NCT01771107|Other|Laboratory Biomarker Analysis|Correlative studies
1660711|NCT01771107|Other|Pharmacological Study|Correlative studies
1660712|NCT01771107|Drug|Vinblastine|Given IV
1660713|NCT01771094|Behavioral|Effect of sweetness of the beverage in thirst sensation|"Effect of sweetness of the beverage in thirst sensation:
The participants will drink Water (control group),High Sucralose - Decarbonized Pineapple Diet Soda with a 50% increase of sucralose face to standard beverage, and Low Sucralose - Decarbonized Pineapple with a 50% decrease of sucralose face to standard beverage. The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min."
1660714|NCT01771081|Drug|Ranibizumab (or other DME treatment)|Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment
1660715|NCT01771068|Behavioral|"Triple P Positive Parenting Program Discussion Group Dealing with Disobedience"|
1660718|NCT01771042|Other|Dietary weight loss at 25% energy deficit|Dietary weight loss at 25% energy deficit. Dietary macronutrient content will comprise 25% protein, 30% fat and 45% carbohydrate.
1660719|NCT01771003|Device|CellAegis' autoRIC™ Device|Patients in the active group will have the autoRIC device (like a blood pressure cuff) inflated and deflated to a pressure of 200 mmHg in four 5 minute cycles with intervening 5 minutes of reperfusion with the cuff deflated between cycles
1660720|NCT01770990|Behavioral|Tel-PT including mail|Patients receive telephone-based psychotherapy and one letter after each telephone session.
1660721|NCT01770990|Behavioral|Tel-PT without mail|Patients receive telephone-based psychotherapy without additional letters.
1660722|NCT01770977|Device|Light-emitting diode therapy|
1660723|NCT01770977|Device|Placebo light-emitting diode therapy|
1660724|NCT01770964|Drug|Pregabalin|
1660725|NCT01770964|Drug|placebo|
1660726|NCT01770964|Behavioral|Training Type A|
1660727|NCT01770964|Behavioral|Training Type B|
1660728|NCT01770938|Device|Effective light-emitting diode therapy|
1660729|NCT01770938|Device|Placebo light-emitting diode therapy|
1660730|NCT01770925|Device|N-CPAP|"The n-CPAP group will receive at extubation a single level continuous positive airway pressure of 7 cm water for at least 48 hours before weaning is commenced. If the infant is stable for the preceding 48 hours defined by having fewer than three minor apneas and no increase in oxygen requirement, weaning will be permitted.
CPAP will be decreased from 6 cm water by 1 cm water every 24 hours if tolerated based on the above criteria. This will be done until a pressure of 4 cm water is reached.
If a pressure of 4 cm water is successfully tolerated for 48 hours then time off n-CPAP will be allowed. Thereafter, no fixed weaning regime based on number of hours in a day the infant will be allowed to come off CPAP will be prescribed."
1660731|NCT01770925|Device|n-BiPAP|"The n-BiPAP group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water). Inspiratory time of one second and respiratory rate of 30/min will always be maintained.
The infant will then receive a mean airway pressure of 5 cm water (positive end expiratory pressure of 4 cm water and peak inspiratory pressure of 6 cm of water)."
1660732|NCT01770925|Device|NIPPV|The NIPPV group will receive at extubation a mean airway pressure of 7 cm water (positive end expiratory pressure of 5 cm water and peak inspiratory pressure of 9 cm of water).
1660733|NCT01770912|Drug|Lactated Ringers|Solution used for TMJ arthrocentesis procedure. 1 cc of Lactated Ringers solution injected once after the TMJ rinsing procedure.
1660734|NCT01770912|Drug|Triamcinolone hexacetonide|1 cc of triamcinolone hexacetonide (5 mg) injected once after the TMJ rinsing procedure.
1660735|NCT01770899|Drug|Montelukast|
1660736|NCT01770899|Drug|Placebo|Gelatin capsule given every 24 hours
1660737|NCT01770886|Drug|UE2343|Oral capsule
1660738|NCT01770886|Drug|Placebo|Oral capsule
1660739|NCT01770873|Behavioral|Take Charge 2|Youth assigned to the intervention receive a Big Brothers, Big Sisters (BBBS) mentor. During the match process, BBBS staff provide 3 session on violence prevention for the youth's parents. Six months into the mentoring relationship, mentors provide 6 sessions on violence prevention for the youth.
1660908|NCT01769404|Biological|LY2605541|Daily dose administered subcutaneously
1660742|NCT01770860|Device|8336|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
1660743|NCT01770860|Device|4840|At each daily visit, designated study personnel will replace the specific test product on the assigned wound site.
1660744|NCT01770821|Other|Dietary supplement and/or physical training|
1660745|NCT01770808|Dietary Supplement|AquaCal|AquaCal is produced by Marigot Ltd. The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg). Subjects swallowed 4 capsules/day for six weeks.
1660746|NCT01770808|Dietary Supplement|AquaPT|AquaPT is produced by Marigot Ltd according to EU and FDA requirements. The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract. Subjects swallowed 4 capsules/day for six weeks.
1660747|NCT01770808|Dietary Supplement|Placebo|Subjects swallowed 4 capsules/day for six weeks.
1660748|NCT01770795|Drug|Genexol-PM/Gemcitabine|
1660751|NCT01770769|Device|Hemi - arthroplasty|cemented hemi - arthroplasty
1660752|NCT01770769|Device|internal fixation|Two cancellous parallel screws - internal fixation of the femoral neck fracture
1660753|NCT01770756|Behavioral|Self-Care Training|
1660754|NCT01770743|Biological|AV7909|Anthrax Vaccine Adsorbed plus CPG 7909 Adjuvant
1660755|NCT01770743|Biological|BioThrax|
1660756|NCT01770730|Device|Urine LAM strip test|This is a point-of-care lateral flow strip test to detect the presence of lipoarabinomannan (LAM) in patient urine samples. Only patients with a grade 2-5 visual band intensity will be considered positive and commenced on treatment
1660757|NCT01770717|Other|Spatial Frequency Domain Imaging|Assessment of Pressure Ulcer Formation using Spatial Frequency Domain Imaging
1660758|NCT01770691|Device|TIPI vaginal pessary|TIPI vaginal pessary G3 model, and TIPI SMD's
1660759|NCT01770678|Other|Constraint Induced Movement Therapy|A combination of prolonged restraint of the unaffected upper limb and massed practice of the affected upper limb.
1660760|NCT01770652|Drug|Deferiprone|Oral iron chelator
1660761|NCT01770639|Procedure|MFB|Surgical arthrodesis of the midfoot with the Midfoot Fusion Bolt (MFB)
1660762|NCT01770626|Other|Nutrition|Anthropometrics, Nutrition assessment, Bioelectrical Impedance Analysis, Blood sample, Resting Energy Expenditure. All will be done 2-3 weeks after initial study visit and will continue every 3 months study visit except the Resting Energy Expenditure which will be performed at only one visit (2-3 weeks after initial visit).
1660763|NCT01770613|Biological|Stem cells|Allogeneic mesenchymal stem cells
1660764|NCT01770600|Other|placebo|placebo pill administered daily for 5 days
1660765|NCT01770600|Drug|Riperidone|1 mg risperidone administered orally for 5 days
1660766|NCT01770587|Behavioral|Behavioral Insomnia Treatment|
1660767|NCT01770574|Device|ReproBone|Artificial bone graft is inserted as a wedge in the calcaneal lengthening osteotomy
1660768|NCT01770574|Procedure|calcaneal lengthening|Autologous bone graft is harvested from the iliac crest and inserted as a wedge in the calcaneal lengthening osteotomy
1660769|NCT01770561|Device|Integrated sensor and infusion set.|Change patients from current devices to the Integrated sensor and infusion set.
1660770|NCT01770548|Genetic|analysis of the glutamate synapse in autism|Neurophysiological, molecular and developmental analysis of the glutamate synapse in autism
1660771|NCT01770548|Genetic|DNA collection|DNA collection
1660772|NCT01770548|Other|Auditory evoked potentials|auditory evoked potentials
1660773|NCT01770509|Device|NMBM|Daily application of NMBM in addition to compression therapy
1660774|NCT01770509|Other|Compression garments|Compression garments
1660775|NCT01770496|Behavioral|Childhood vaccination reminder / recall notification|
1660776|NCT01770483|Drug|nitazoxanide|nitazoxanide 500mg twice daily
1660777|NCT01770483|Drug|conventional interferon alfa|Inj interferon 3 Million International Units thrice weekly
1660778|NCT01770483|Drug|Ribavirin|ribazole
1660779|NCT01770470|Dietary Supplement|Chitosan|The product chitosan is contained in a chewing gum formulation
1660780|NCT01770444|Other|Low-dose Cardiac CT protocol|"A cardiac CT protocol modified for reduction of radiation exposure
Prospective gating
Range: dedicated imaging (below carina to heart base)"
1660781|NCT01770444|Other|Conventional cardiac CT protocol|"Conventional CCTA protocol
Retrospective gating with tube current modulation
Range: dedicated imaging (below carina to heart base)"
1660782|NCT01770431|Drug|Huaier Granule|Huaier Granule is a traditional Chinese medicine, 20g / time, 3 times/day,Po.
1660783|NCT01770418|Radiation|Radiation Concurrent Chemotherapy|"RADIATION: Proton Radiotherapy Dose Level 1: 60 Gy (RBE) at 2.5 Gy(RBE)per fraction x 24 fractions
Dose Level 2: 60 Gy (RBE) at 3 Gy (RBE)per fraction x 20 fractions
Dose Level 3: 60.01 Gy (RBE) at 3.53 Gy (RBE)per fraction x 17 fractions
Dose Level 4: 60 Gy (RBE) at 4 Gy (RBE)per fraction x 15 fractions
CONCURRENT CHEMOTHERAPY:
Paclitaxel and Carboplatin or Cisplatin and Etoposide Paclitaxel at a dose of 45 mg/m2 and carboplatin at a dose of AUC 2 mg/min/ml(a total of 3-5 weekly doses) OR cisplatin 50mg/m2 days 1, 8, 29, and 36 and etoposide 50mg/m2 days 1-5, 29-33.
Adjuvant chemotherapy is optional ."
1660784|NCT01770405|Device|Endoscopic ultrasound fine needle aspiration|Device: nCLE needle-based Confocal Laser Endomicroscopy
1660785|NCT01770392|Drug|Nintedanib|single dose administration
1660786|NCT01770392|Drug|Rifampicin|single dose once daily for 7 days
1660787|NCT01770392|Drug|Nintedanib|single dose administration
1660909|NCT01769404|Biological|Insulin Glargine|Daily dose administered subcutaneously
1660910|NCT01769391|Drug|Necitumumab|Administered IV
1660911|NCT01769391|Drug|Paclitaxel|Administered IV
1660788|NCT01770379|Biological|Secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)"
1660789|NCT01770379|Biological|Placebo|
1660790|NCT01770366|Device|Weight and Exercise Lifestyle Support (WELS)|Intervention patients will receive a suite of devices manufactured by the FitLinxx company, including their Pebble activity monitor, ActiScale weight scale, and access to their ActiHealth.com patient portal website. Intervention participations will be able to use the features of this website, including widgets displaying their device data as well as challenge invitations to interact with other participants, as desired.
1660791|NCT01770366|Device|Usual Care|
1660792|NCT01770353|Drug|Ferumoxytol followed by MM-398|Ferumoxytol 5 mg/kg IV at 1mL/sec, given once. MM-398 80 mg/m2 IV over 90 min every 2 weeks, until progressive disease or intolerable toxicity
1660793|NCT01770340|Biological|Radical prostatectomy with implantation of allograft|Interposition of resected neurovascular bundles with allograft Avance®
1660794|NCT01770340|Procedure|Radical prostatectomy without implantation of allograft|No interposition of resected neurvascular bundles
1660795|NCT01770327|Behavioral|Effect of ingestion of different Sugary Beverages on Thirst Sensation|The participants will drink Water (control group),Non-fat Milk, Orange Juice and Iced Tea. The beverages will be presented chilled but without ice in 330 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min.
1660796|NCT01770314|Behavioral|Experimental|Participants will be given instructions via email to review eleven online lessons about opioid medication safety. Instructions will suggest that participants view one lesson per day for eleven consecutive days. Each educational lesson focuses on one or two aspects of medication safety, including how to safely store medication, and the importance of taking medication exactly as prescribed.
1660797|NCT01770301|Drug|Paclitaxel|
1660798|NCT01770301|Drug|Bevacizumab|
1660799|NCT01770288|Other|Anaerobic wingate test|
1660800|NCT01770249|Procedure|Per-oral Endoscopic Esophagomyotomy (POEM)|The surgeon is cutting only through the innermost layers of muscles in the esophagus down to the stomach, leaving the outer layer intact.
1660801|NCT01770236|Drug|IV acetaminophen|Patients randomized to the IV acetaminophen group will receive IV acetaminophen (1000 mg every 6 hours for adults and weight-based for any patient under 50 kg)instead of an On-Q pain pump catheter.
1660802|NCT01770223|Drug|boceprevir|
1660803|NCT01770223|Biological|PegIFN-2b|
1660804|NCT01770223|Drug|RBV|
1660805|NCT01770210|Drug|Patients on atorvastatin treatment|Statins Therapy
1660806|NCT01770197|Drug|IV rt-PA|IV rt-PA treatment
1660807|NCT01770184|Behavioral|Chronic Disease Self-Management Program (CDSMP)|
1660808|NCT01770171|Drug|Bevacizumab|Carboplatin AUC 5+ Paclitaxel 175 mg/mq+Bevacizumab 15 mg/kg q 21 for 6 -8 cycles + Bevacizumab 15 mg/kg
1660809|NCT01770171|Drug|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles|Carboplatin AUC 5+Paclitaxel 175 mg/mq q 21 for 6-8 cycles
1660810|NCT01770145|Drug|APOKYN|"Apokyn will be titrated to an optimum dose which reproduces 90% of the subjects' best on UPDRS score during the Initiation Period. During the APOKYN Treatment Period, subjects will inject the dose identified in the initiation period once daily at the time of their normal scheduled L-Dopa dose (L-Dopa will be delayed by 40 minutes)."
1660811|NCT01770145|Drug|L-dopa|Subjects on a stable L-Dopa regimen will be entered into the study. For the L-Dopa Baseline Period through the Initiation Period, subjects will continue their normal L-Dopa dosing regimen. During the APOKYN Treatment Period, subjects will replace their normally scheduled first morning L-Dopa dose with an APOKYN injection, and then administer their normal first morning L-Dopa dose 40 minutes later.
1660812|NCT01770145|Drug|Trimethobenzamide|Following the L-Dopa Baseline Period, subjects will initiate trimethobenzamide treatment TID for a minimum of 3 days during a Anti-Emetic Pretreatment Period. Subjects will continue trimethobenzamide therapy TID through the duratoin of the APOKYN Initiation Period and APOKYN Treatment Period.
1660813|NCT01770132|Drug|porfimer sodium|Given IV
1660814|NCT01770132|Procedure|endoscopic ultrasonography|Undergo EUS-PDT
1660815|NCT01770132|Procedure|photodynamic therapy|Undergo EUS-PDT
1660816|NCT01770132|Drug|gemcitabine hydrochloride|Given IV
1660817|NCT01770119|Biological|MMR vaccination|Unprotected children will be vaccinated with two MMR vaccines
1660818|NCT01770106|Drug|Denosumab|Subcutaneous injection of denosumab 60mg every 6 months (1 dose for study period)
1660819|NCT01770106|Drug|Alendronate|Alendronate 70mg once weekly
1660820|NCT01770093|Other|Questionnaire|
1660821|NCT01770080|Drug|Euminz®|3 to 5 time topical use of study drug.
1660822|NCT01770080|Drug|Placebo|3 to 5 time topical use of study drug.
1660823|NCT01770067|Drug|CITA-RNPT|
1660824|NCT01770054|Other|obtention of a blood sample|a blood sample will be obtained to measure glucose, HDL cholesterol, triglycerides, and for genetic testing
1660825|NCT01770041|Other|Paracetamol (observation of routine administration)|Normal administration of paracetamol as prescribed by operating surgeon
1660826|NCT01770015|Procedure|biological sampling|cutaneous, rectal, nose and mouth swabs to identify potential fungi colonization
1660827|NCT01770015|Procedure|sampling blood|HLA DR antigen, cytokines (IL 6 and 10), B-glucan
1660828|NCT01770015|Procedure|endotracheal aspiration|fungi and bacteria endotracheal aspiration
1660829|NCT01770002|Procedure|Everted suture technique|
1660830|NCT01770002|Procedure|Non-everted suture technique|
1660831|NCT01769989|Procedure|Electrodermabrasion|
1660832|NCT01769989|Procedure|Dermabrasion|
1660833|NCT01769976|Other|Periodic fasting|
1660834|NCT01769976|Other|Energy restriction|
1660835|NCT01769976|Other|Energy balance diet|
1660836|NCT01769963|Other|Research diet|Participants will be provided specially prepared meals to eat at home for three weeks. During the first week, participants will eat foods that have standard amounts of AGEs in them (this is called the control diet). During the second and third weeks, participants will eat the same foods, only they will be prepared in our kitchen in a way that limits the amount of AGEs in them (called the intervention diet).
1719364|NCT00002785|Drug|pegaspargase|
1660837|NCT01769950|Other|Choline-PET|Carbon-11 or Fluorine-18 PET-CT will be acquired with a scanner with integrated PET and CT scanning ability at the time of diagnosis. It must be however noted that Choline-PET will not be considered as an alternative to magnetic resonance imaging (MRI). In fact, all patients will undergo MRI too.
1660838|NCT01769937|Drug|H.P. Acthar Gel|Open-label H.P. Acthar Gel given subcutaneous injection once daily for 10 days with potential for additional 5 days of dosing
1660839|NCT01769924|Other|Nephrectomy|
1660840|NCT01769911|Drug|carmustine|Given IV
1660841|NCT01769911|Drug|cytarabine|Given IV
1660842|NCT01769911|Drug|melphalan|Given IV
1660843|NCT01769911|Drug|etoposide|Given IV
1660844|NCT01769911|Drug|O6-benzylguanine|Given IV
1660845|NCT01769911|Procedure|autologous hematopoietic stem cell transplantation|Undergo transduced and/or non-transduced transplant
1660846|NCT01769911|Procedure|peripheral blood stem cell transplantation|Undergo transduced and/or non-transduced transplant
1660847|NCT01769911|Other|laboratory biomarker analysis|Correlative studies
1660848|NCT01769898|Drug|Formoterol-budesonide|Formoterol-budesonide combined treatment (4.5µg/160µg Q12H)
1660849|NCT01769898|Drug|Theophylline|Theophylline 0.1 Q12H
1660850|NCT01769898|Drug|Placebo|Placebo for theophylline 0.1 Q12H
1660851|NCT01769885|Drug|tivozanib|Given PO
1660852|NCT01769885|Procedure|therapeutic conventional surgery|Undergo nephrectomy
1660853|NCT01769872|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intravenous injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e8 cells / 20mL Intrathecal injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 5x10e7 cells / 2mL Into a spinal cord injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 2x10e7 cells / 1mL
1660854|NCT01769846|Other|Early mobilization protocol|Patients in the treatment group additionally received a cycling exercise session 5 days a week, using a bedside cycle ergometer (MOTOmed Letto 2, RECK-Technik GmbH & Co. KG, Betzenweiler, Germany). The device offers the possibility to conduct passive or active cycling at six levels of increasing resistance. The aim of each session was to have the patient cycle for 20 mins at an individually adjusted intensity level. Patients were placed in a comfortable position in between the supine and the semirecumbent position. In sedated patients, cycling was performed in a passive manner for 20 consecutive minutes at a ﬁxed pedaling rate of 20 cycles/min.
1660855|NCT01769833|Drug|PEG-interferon-Alfa-2A|Pegasys ( PEG-interferon-Alfa-2A) 180mcg / subcutaneous / once-weekly
1660856|NCT01769833|Drug|Nucleosides|
1660857|NCT01769820|Drug|Dexamethasone|studies 1&2:0.75mg twice daily for 5 days, starting on day LH (Luteinising Hormone)+8 of menstrual cycle; Study 3 (adaptive) 0.2,0.4,0.5,0.75,0.8,0.9mg twice daily as above
1660858|NCT01769820|Drug|placebo|
1660859|NCT01769807|Device|CPAP|CPAP adaptation was performed by a sleep technician and the patients were instructed to use this for 1 month.
1660860|NCT01769794|Drug|Western therapy|Physical cooling paste or warm bathing, vitamin B, vitamin C. On the basis of the attending physician's judgment, participants were allowed to use Ibuprofen suspension if their body temperature was greater than 38.5℃. Likewise, the need for antibiotics was determined by the attending physicians. The use of acetaminophen or antibiotics was recorded on the case record form
1660861|NCT01769794|Drug|JET|4g/tablet, One tablet each time (Taken after dissolved in 50ml boiled water, 3 times daily if body temperature≥38.5℃)
1660862|NCT01769794|Drug|Placebo(for JET)|placebos prepared identical in color, taste and consistency to the JET (supplied by Zhongshenghaitian Pharmaceutical, Tianjin, China)
1660863|NCT01769781|Drug|anastrazole|combined treatment with aromatase inhibitor (anastrazole) plus GnRH analog (leuprolide acetate) for three months
1660864|NCT01769781|Drug|GnRH analog alone|treatment for three months with GnRH analog (leuprolide acetate) alone
1660865|NCT01769768|Drug|LDE225|LDE225 800 mg once daily dosing will begin on Cycle 1 Day 1 of a 28-day cycle.Treatment with LDE225 for both groups will continue until the patient experiences unacceptable toxicity that precludes further treatment, disease progression, withdrawal of consent and/or at the discretion of the investigator.
1660866|NCT01769768|Drug|Wafarin|15 mg single dose of warfarin (oral tablet) will be given to patients.
1660867|NCT01769768|Drug|Bupropion|75 mg single dose of bupropion(oral tablet, from an immediate release formulation) will be given to patients
1660868|NCT01769755|Biological|PDA001|"Cohort 1 Dose Level 1: ¼ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.
Cohort 2 Dose Level 2: ½ unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart.
Cohort 3 Dose Level 3: 1 unit Human Placenta-Derived Cells PDA001 infused a total of 5 times 2 weeks apart."
1660869|NCT01769755|Drug|Vehicle Controlled Placebo|"Cohort 1 Dose Level 1: ¼ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.
Cohort 2 Dose Level 2: ½ unit vehicle controlled placebo infused a total of 5 times 2 weeks apart.
Cohort 3 Dose Level 3: 1 unit vehicle controlled placebo infused a total of 5 times 2 weeks apart."
1660870|NCT01769742|Behavioral|Early mobility bundle|
1660871|NCT01769729|Behavioral|PEPP|
1660872|NCT01769729|Behavioral|Care management|
1660874|NCT01769703|Drug|Dabigatran 110/150 mg BID|Dabigatran will be taken bid for 30 days post enrolment. The dose of dabigatran will be based on patient age and renal function.
1660875|NCT01769690|Other|DBS stimulator setting alteration|"2 sleep study options Phase I: Participants will undergo 2 sleep studies, one with the stimulator on at the subject's stable, clinically effective settings and one with the stimulator off. the order of the off and on nights will be randomized. Although blinding will be attempted, because of the significant motor effects produced with the on setting, participants may be able to tell when the DBS is OFF. In the second phase, the first sleep study night will be with the stimulator OFF. The order of the HIGH, and LOW frequency nights will be randomized 1:1 and balanced across subjects and will occur on the 2nd and 3rd PSG nights.
Phase II Sleep study evaluation will include three nights of recording: 1) OFF with the stimulator off, 2) HIGH with the stimulator on at the participant's stable and clinically effective settings, and 3) LOW with the stimulator set at a low frequency that uses less energy"
1660912|NCT01769391|Drug|Carboplatin|Administered IV
1660913|NCT01769378|Drug|Placebo|Administered SQ
1719365|NCT00002785|Drug|prednisone|
1660876|NCT01769690|Other|virtual reality simulator|"This virtual pedestrian environment is a measure of real-world street-crossing behavior. This simulation is composed of an elevated platform that simulates a curb at a street-side and 3 monitors (arranged in a semi-circle) on which the subject, while wearing headtracker equipment, views the virtual environment of bidirectional traffic. When the subject deems it is safe to cross the virtual street, he/she steps off the platform/curb, which activates crossing of the street by a cartoon representation of the participant. The speed of street crossing by the cartoon is determined by each individual subject's walking speed, which is measured prior to the test."
1660877|NCT01769677|Drug|90 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 45-mg tablets (Treatment A) or one 90-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
1660878|NCT01769664|Drug|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel|Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
1660879|NCT01769664|Drug|Duac® Topical Gel|Duac® (Clindamycin 1%/Benzoyl Peroxide 5%) Topical Gel (Stiefel) applied once a day in the evening for 77 days (11 weeks)
1660880|NCT01769664|Drug|Placebo Topical Gel|Placebo (Vehicle) Topical Gel (Taro Pharmaceuticals Inc.) applied once a day in the evening for 77 days (11 weeks)
1660881|NCT01769651|Other|methadone replacement therapy|Patients are prescribed Methadone as part of their treatment plan, having been assessed as having opioid dependence syndrome and requiring pharmacological substitution therapy. A bio-psychosocial approach is taken in the treatment management of individuals.
1660882|NCT01769638|Drug|SPO1101|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 50mg), with a 7-day washout period between the formulations.
1660883|NCT01769638|Drug|SPO1101D|A single-dose of ODF and FCT formulations of sildenafil given orally in a fasted state (dose: 100mg), with a 7-day washout period between the formulations.
1660884|NCT01769625|Drug|placebo/celecoxib 400 mg and cholecalciferol 400 IU/cholecalciferol 2,000 IU|Take 1 capsule from each bottle (1 bottle containing either placebo/celecoxib and 1 bottle containing either cholecaliferol 400 IU/cholecaliferol 2,000 IU) for 30 days
1660885|NCT01769612|Other|No Intervention|
1660886|NCT01769586|Drug|Diphenhydramine|
1660887|NCT01769586|Drug|Midazolam|
1660890|NCT01769560|Behavioral|MeFirst Tailored Intervention|Participants will be lead through MeFirst, an interactive web-based tool that is tailored to their responses during the survey. This tool provides information regarding HPV Vaccination.
1660891|NCT01769547|Drug|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal.
1660892|NCT01769521|Device|Sensimed Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
1660893|NCT01769508|Drug|5-Fluorouracil|5-FU, 225 mg/m2 IVCI, during XRT.
1660894|NCT01769508|Drug|Oxaliplatin|Oxaliplatin, 85 mg/m2 IV, Days 1, 15, 29.
1660895|NCT01769508|Drug|Lapatinib|Lapatinib, Continuous PO daily dosing during XRT, dose determined during lead in portion
1660896|NCT01769508|Radiation|Radiation Therapy|Radiation therapy, 50.4 Gy (1.8 Gy/day or 28 fractions) M-F, Weeks1-6
1660897|NCT01769495|Other|2-3 day return appointment|2-3 appointment in geriatric clinic following ED discharge
1660898|NCT01769482|Drug|Udenafil|70 subjects will undergo baseline testing and then be randomized into a clinical parallel trial of udenafil 100mg po q d for 3 months.
1660899|NCT01769482|Drug|placebo|
1660904|NCT01769443|Drug|bortezomib|Bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
1660905|NCT01769443|Procedure|plasmapheresis|Plasmapheresis for 3 consecutive days (treatment days 0, 1 and 2) followed by concomitant bortezomib dosed at 1.3 mg/m^2 as a 3 to 5 second bolus administered by intravenous injection on treatment days 0, 3, 7 and 10. The first dose of bortezomib is administered between 4-8 hours after the first plasmapheresis session is completed and there must be at least 96 hours between the second and third dose of bortezomib.
1660906|NCT01769417|Drug|Placebo|Placebo
1660916|NCT01769365|Drug|7-day quadruple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1 g twice daily and metronidazole 500 mg twice daily for 7 days
1660917|NCT01769365|Drug|10-day sequential therapy|pantoprazole 40 mg twice daily and amoxicillin 1 g twice daily for 5 days, followed by pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily and metronidazole 500 mg twice daily for a further 5 days
1660918|NCT01769365|Drug|7-day standard triple therapy|pantoprazole 40 mg twice daily, clarithromycin 500 mg twice daily, and amoxicillin 1 g twice daily for 7 days
1660919|NCT01769352|Drug|PredA + Kelac|At week 12, patients will be determined to be resolved, improving/stabilized or treatment failures. Patients who have complete resolution of edema will begin treatment withdrawl. Improving/stabilizing patients will maintain current therapy. Treatment failure Group 2 patients will move to Group 3 to receive PredA q1h WA + Kelac qid starting at week 12. Treatment failure Group 1 patients will be exited from the trial so that alternative therapy can be given.
1660920|NCT01769339|Drug|Miconazole plus Hydrocortisone|Participants will apply miconazole plus hydrocortisone cream topically to the lesion twice daily up to Day 14 by rubbing gently until it has been completely penetrated into the affected vulvar (the tissues around the opening to the vagina) area and the treatment should be continued without interruption. Participants will be assessed for signs and symptoms of vulvar candidiasis at Day 14. Medication will be continued till Day 28, if signs and symptoms of vulvar candidiasis are not cured clinically on Day 14.
1660921|NCT01769326|Other|Conventional hand exercise|Conventional hand exercise consists of passive and active range of motion exercise, and simple coordination exercises with the fingers
1660922|NCT01769326|Device|MusicGlove|The MusicGlove is a glove that detects different grip types. Subjects play a musical game by completing different grips.
1660923|NCT01769326|Other|Conventional Arm Exercise|Conventional arm exercise consists of passive and active range of motion exercise, and simple weight bearing exercises
1660924|NCT01769326|Device|Resonating Arm Exerciser|The RAE is a lever that attaches to a manual wheelchair with elastic bands and can be pushed back and forth to exercise the arm.
1660925|NCT01769313|Device|Laser-assisted cataract surgery|The anterior capsulotomy and lens fragmentation will be performed by means of femtosecond laser surgery
1660926|NCT01769313|Device|Manually performed cataract surgery|The anterior capsulotomy and lens fragmentation will be performed manually.
1660927|NCT01769300|Behavioral|Clinical decision support for medication titration|Electronic health record-based clinical decision support for ADHD medication titration.
1660928|NCT01769274|Drug|PF-05089771|A single oral dose of PF-05089771 1600 mg solution to be administered on Day 1 of each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of PF-05089771 will be adminstered.
1660929|NCT01769274|Drug|Placebo|Placebo for PF-05089771 1600 mg solution administered in each treatment session. There are 2 treatment sessions, therefore 2 single oral doses of placebo will be administered.
1660930|NCT01769261|Other|eligible, Internet|Patients randomized in the internet arm. They will directly complete their health evolution after hospital discharge via the internet.
1660931|NCT01769261|Other|eligibles, telephone|Patients randomized in the telephone arm. Their health evolution after hospital discharge will be documented via a telephone interview at J45 after hospital discharge
1660932|NCT01769261|Other|non eligibles|Patients who do not have an internet access at home. Their health evolution after hospital discharge will be documented via a telephone interview at J45. after hospital discharge.
1660933|NCT01769248|Device|Fine needle aspiration|Fine needle aspiration
1660934|NCT01769248|Device|Fine needle biopsy|FNB
1660935|NCT01769235|Drug|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5%|Clindamycin Phosphate and Benzoyl Peroxide Gel, 1.2%/2.5% (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
1660936|NCT01769235|Drug|Acanya® Gel, 1.2%/2.5%|Acanya® (Clindamycin Phosphate and Benzoyl Peroxide) Gel, 1.2%/2.5% (Dow Pharmaceutical Sciences, Inc., marketed by Valeant Pharmaceuticals North America LLC)applied at approximately the same time once daily for 84 days (12 weeks).
1660937|NCT01769235|Drug|Vehicle of test product|Vehicle of test product (Taro Pharmaceuticals Inc.)applied at approximately the same time once daily for 84 days (12 weeks).
1660938|NCT01769222|Biological|Ipilimumab|Given intratumorally
1660939|NCT01769222|Radiation|Radiation therapy|Undergo local radiation therapy, 10 Gy x 3 fractions
1660947|NCT01769196|Drug|Simtuzumab|125 mg/mL single-dose vials administered subcutaneously once a week
1660948|NCT01769196|Drug|Simtuzumab placebo|Simtuzumab placebo single-dose vials administered subcutaneously once a week
1660949|NCT01769183|Drug|Squalamine Lactate ophthalmic solution 0.2%|Patients will start with Squalamine one drop twice daily to the affected eye. If at one week the neovascularization shows no sign of regression, then the dose will be doubled to four times daily with a follow up at one day and one week following the increased dose frequency, then resuming the schedule at four weeks. If neovascularization returns within the study, the dose will be doubled to four times daily. In that case, a one day and one week visit will be added after increasing the dose. Squalamine treatment will discontinue after the week 20 visit.
1660950|NCT01769170|Drug|Brincidofovir (CMX001)|
1660951|NCT01769157|Drug|L-carnitine|
1660952|NCT01769157|Drug|Placebo|
1660953|NCT01769144|Device|Acticoat Absorbent|wound dressing
1660954|NCT01769144|Device|BCT|wound dressing
1660955|NCT01769118|Drug|Caffeine|Caffeine will be given according to departmental protocol
1660956|NCT01769105|Device|Lipiflow|Patients receive a single Lipiflow-treatment
1660957|NCT01769105|Behavioral|Lid hygiene regime|Patients receive verbal and written instruction to perform lid hygiene twice daily
1660958|NCT01769092|Dietary Supplement|Fish Oil|The daily dose is divided; capsules are taken with meals for a period of 6 months.
1661528|NCT01764906|Procedure|Iliac crest bone graft|
1660959|NCT01769092|Other|Safflower Oil|Daily dose of safflower oil taken in divided doses as capsules and consumed with meals.
1660960|NCT01769079|Drug|Nitrate|Two arms: placebo and nitrate
1660961|NCT01769079|Drug|Placebo|
1660962|NCT01769066|Drug|Sequential Gefitinib With Pemetrexed/Platinum|
1660963|NCT01769066|Drug|Pemetrexed/Platinum|
1660964|NCT01769053|Other|Variable Ventilation|
1660965|NCT01769040|Drug|Rifaximin|550 mg two times daily for 28 days
1660966|NCT01769040|Drug|placebo|
1660967|NCT01769027|Drug|Sertraline+Antibiotic (penicillin/azithromycin)|"12 weeks treatment with a combination of Sertraline (to a maximum of 200 mg/day) and an antibiotic (benzathine penicillin G 1.200.000 U every 3 weeks or, in case of allergy, azithromycin 500 mg/week.
Non-responder patients will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)"
1660968|NCT01769027|Drug|Sertraline+placebo|12 weeks treatment with a combination of sertraline (to a maximum of 200 mg/day) and placebo
1660969|NCT01769027|Biological|IVIG|Patients who will not respond to SSRI+antibiotic (penicillin/azithromycin) will be treated with IVIG (2g/kg over 5 days for 5 consecutive months)
1660970|NCT01769001|Drug|PRX-102|Comparison of different doses of drug
1660971|NCT01768988|Drug|Placebo|"Conventional treatment + placebo (during 90 days).
Conventional treatment comprises a WHO step ladder approach and comprises in most cases:
Paracetamol 1g/8h
Weak opioid (tramadol at maximal doses of 400 mg/24h)
Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS < 3)."
1660972|NCT01768988|Drug|Pregabalin|"Treatment during 90 days with conventional treatment + pregabalin.
Pregabalin doses were reached until the maximal doses (300 mg/12h) depending on patient tolerability. An escalating dose scheme were desigened as follows, to avoid tolerability problems:
Week 1 75-0-75 Week 2 75-0-150 Week 3 150-0-150 Week 4 150-0-300 Week 5 300-0-300 (until the end of study)
Conventional treatment comprises a WHO step ladder approach and comprises in most cases:
Paracetamol 1g/8h
Weak opioid (tramadol at maximal doses of 400 mg/24h)
Strong opioid in substitution of weak opioid if not efficient (e. g. morphine, oxycodone, fentanyl patch, hidromorphone), at the needed doses to control pain (VAS < 3)."
1660973|NCT01768975|Drug|OLT1177 Gel|4 mL per dose, applied 3 times per day on Days 1 - 13 with only one dose administered on Day 14, assuming TID on Day 1
1660974|NCT01768975|Other|Placebo gel|Identical dose and dosing regimen as the Investigational Drug (OLT1177 Gel)
1660975|NCT01768962|Drug|Once Daily Application of TFV RG 1% Gel|Vaginal
1660976|NCT01768962|Drug|Once Daily Application of TFV RG 1% gel - Rectal|
1660977|NCT01768962|Drug|Once Daily Application of TFV RG 1% gel - Rectal|
1660978|NCT01768962|Drug|Once Daily Application of TFV RG 1% Gel - Vaginal|
1660979|NCT01768949|Device|Echocardiography|In the study RVSTAR, all the patients included will undergo an echocardiography in order to find an echocardiographic criterion predictive of the inefficacy and/or unsafeness of recruitment maneuver.
1660980|NCT01768923|Procedure|SDAI remission|SDAI remission group aims at the 2011 ACR/EILAR definition of remission (simplified disease activity score [SDAI] <3.3)
1660981|NCT01768923|Procedure|Minimal disease activity remission|Minimal disease activity group aims at minimal disease activity (DAS28<2.6) (minimal disease activity group)
1660982|NCT01768910|Other|fMRI|2 measurements using functional magnetic resonance imaging in a 3T scanner
1660983|NCT01768910|Other|bladder filling|Repetitive retrograde bladder filling via transurethral catheter with different filling volumes using body warm saline during each of the fMRI measurements.
1660984|NCT01768910|Other|bladder cooling|Retrograde bladder filling via transurethral catheter with 4-8°C saline during each of the fMRI measurements.
1660985|NCT01768910|Other|additional post-treatment fMRI scan|Should NNOAB or SCI patients receive a study independent OAB therapy by their treating physician after the 2nd fMRI scan, they will be invited for an additional third fMRI scan.
1660986|NCT01768897|Drug|CPI-613|Given IV
1660987|NCT01768897|Drug|cytarabine|Given IV
1660988|NCT01768897|Drug|mitoxantrone hydrochloride|Given IV
1660989|NCT01768897|Other|laboratory biomarker analysis|Optional correlative studies
1660990|NCT01768897|Other|pharmacological study|Correlative studies
1660991|NCT01768884|Drug|Nitric Oxide|
1660992|NCT01768884|Drug|Placebo|
1660993|NCT01768845|Genetic|umbilical cord blood (UCB)|Infusion will occur after preparative regimen in one or two UCB unit(s). If two products are used, they will be administered sequentially on the same day 1-6 hours apart. Tacrolimus and mycophenolate mofetil (MMF) will be used for GVHD prophylaxis.
1660994|NCT01768832|Behavioral|Treadmill|
1660995|NCT01768832|Behavioral|Tango|
1660996|NCT01768832|Behavioral|Stretching|
1660997|NCT01768819|Behavioral|Physical Activity|The intervention consisted of elderly-specific physical activity program for one year. During this period a total of 123 physical activity sessions were carried out. Each session lasted 50 minutes and included stretching, aerobic endurance exercises, resistance exercises, activities involving coordination, agility and flexibility, respiratory exercises and relaxation exercises. The sessions took place three times a week, according to American College of Sports Medicine (ACSM) recommendations. Workloads were adjusted for each subject bimonthly according to their capacity. The sessions were standardized and carried out by previously trained physical educators.
1661000|NCT01768793|Behavioral|Standard Parents As Teachers (PAT)|Participants will receive visits by Parent Educators, who will deliver the standard PAT curriculum. Participants will receive 28 total visits over the course of approximately 2 years.
1661173|NCT01767519|Drug|solifenacin|Beginning on Day 1, one 5 mg solifenicin capsule, with optional dose increase to 10 mg at Week 6, (both overencapsulated for blinding purposes) taken orally once daily for up to 24 weeks.
1661001|NCT01768793|Behavioral|Parents As Teachers Plus (PAT+)|Participants will receive the standard PAT curriculum, plus lifestyle intervention focusing on healthy diet and exercise, through 28 home visits over the course of approximately 2 years.
1661002|NCT01768780|Device|the anticholinergic glycopyrrolate 0.1 ㎎ + 0-15 mg hyperbaric bupivacaine|"The study subjects were patients with planned orthopedic surgery on the infrapatellar area with spinal anesthesia, and 58 patients were recruited sequentially.
A blood pressure machine, electrocardiogram, and pulse oximeter were connected to the patient in the operating room, and measurements were carried out every 5 minutes. Prior to the induction of anesthesia, the anticholinergic glycopyrrolate 0.1 ㎎ was intravenously administered after the confirmation of intravenous line opening status.
For spinal anesthesia, the patient was arranged in the lateral recumbent position, and then the L 3-4 area was disinfected. Depending on the surgical region, height, and weight of each patient, 10-15 mg hyperbaric bupivacaine was administered through a 25 G needle."
1661003|NCT01768767|Drug|Placebo|
1661004|NCT01768767|Drug|Ketamine|
1661005|NCT01768767|Drug|Ketamine/Lithium|
1661006|NCT01768754|Behavioral|Usual and Fast Walking Speeds|Stable patients with chronic obstructive pulmonary disease will demonstrate their usual and fast walking speeds over a 30 m course, with speed calculated over the middle 10 m using optical sensors. The test will be repeated after a 5 minute rest; this procedure will then be repeated on two subsequent days, at the same time of day, within one week.
1661007|NCT01768741|Procedure|Laparoscopic liver resection|participants will be performed with laparoscopic hepatectomy using laparoscopic instruments
1661008|NCT01768741|Procedure|Open liver resection|participants will be performed with open hepatectomy using laparotomic instruments
1661009|NCT01768728|Procedure|Laparoscopic left hemihepatectomy|participants will be performed with laparoscopic left hepatectomy using laparoscopic instruments
1661010|NCT01768728|Procedure|Open left hemihepatectomy|participants will be performed with traditional open left hepatectomy using laparotomic instruments
1661011|NCT01768702|Biological|Injection of C3BS-CQR-1|Injection of the C3BS-CQR-1 using the C-Cath® injection catheter.
1661012|NCT01768702|Biological|Sham, no injection|Mimic the injection procedure trough insertion of a sham catheter. No injection actually performed
1661013|NCT01768689|Behavioral|Adherence-encouraging interventions - Group meeting|One Group meeting (at the beginning of the intervention period) for all participants, focusing on issues relevant to adherence improvement
1661014|NCT01768689|Behavioral|Adherence-encouraging interventions - Individual meetings|Individual meetings focusing on adherence issues with a multidiscilinary team
1661015|NCT01768689|Behavioral|Adherence-encouraging interventions - Monthly phone calls|Monthly phone calls to detect urgent adherence-related issues
1661016|NCT01768676|Drug|avanafil|100 mg
1661017|NCT01768676|Drug|Placebo|
1661018|NCT01768663|Drug|Lumacaftor|tablet, 200mg taken every 12 hours
1661019|NCT01768663|Drug|Ivacaftor|tablet, 250mg taken every 12 hours
1661020|NCT01768663|Drug|Ciprofloxacin|750 mg taken every 12 hours
1661021|NCT01768663|Drug|Itraconazole|200mg taken once daily
1661022|NCT01768663|Drug|Rifampin|600mg taken once daily
1661023|NCT01768650|Behavioral|Self-Management #1|Self-Management #1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Sessions will include: (1) education about the role of cognitions and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Most sessions will include a brief relaxation exercise introduced over the phone.
1661024|NCT01768650|Behavioral|Self-Management #2|Self-Management #2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average). The sessions will cover a variety of topics, including: (1) the definition of chronic pain, (2) the physiological processes underlying chronic pain, (3) common pain-related conditions such as sleep and mood disturbance (including posttraumatic stress disorder, due to its prevalence among Veterans), (4) the potential effects of chronic pain on activity level, (5) communication (including communication with healthcare providers), and (6) the role of social support in managing pain.
1661025|NCT01768637|Drug|Aspirin|Aspirin 81 mg by mouth daily
1661026|NCT01768637|Drug|Clopidogrel|Clopidogrel 75 mg by mouth once daily
1661027|NCT01768624|Procedure|dialysis, kidney transplant|
1661028|NCT01768598|Other|Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
1661029|NCT01768598|Other|Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
1661030|NCT01768598|Other|Non Fracture - Boys|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
1661031|NCT01768598|Other|Non Fracture - Girls|Annual measurements of risk taking behaviour, body composition, bone microstructure, balance, diet, and physical activity over 4 years
1661032|NCT01768585|Drug|Ivabradine|Please see description of Intervention Arm
1661033|NCT01768585|Drug|Placebo|
1661034|NCT01768572|Drug|sarilumab SAR153191 (REGN88)|Pharmaceutical form: solution Route of administration: subcutaneous
1661035|NCT01768572|Drug|tocilizumab|Pharmaceutical form: solution Route of administration: intravenous
1661036|NCT01768572|Drug|hydroxychloroquine|Dispensed according to local practice.
1661037|NCT01768572|Drug|methotrexate|Dispensed according to local practice.
1661038|NCT01768572|Drug|sulfasalazine|Dispensed according to local practice.
1661039|NCT01768572|Drug|leflunomide|Dispensed according to local practice.
1661040|NCT01768572|Drug|subcutaneous placebo|Pharmaceutical form: solution Route of administration: subcutaneous
1661041|NCT01768572|Drug|intravenous placebo|Pharmaceutical form: solution Route of administration: intravenous
1661042|NCT01768559|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection 30 to 60 minutes before breakfast or dinner.
1661043|NCT01768559|Drug|Insulin glulisine QD|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before breakfast or dinner. The initial dose was 3-5 units and then individually titrated to obtain the SMPG value >5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before lunch (if administered at breakfast) or at bedtime (if administered at dinner).
1661044|NCT01768559|Drug|Insulin glulisine TID|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection within 15 minutes before each meal. The initial dose was 3-5 units for each meal and then individually titrated to obtain the SMPG value >5.6 mmol/L (100 mg/dL) and ≤7.8 mmol/L (140 mg/dL) before the next meal or at bedtime (for injection at dinner).
1661045|NCT01768559|Drug|Insulin Glargine (Mandatory background drug)|Pharmaceutical form: Solution for injection; Route of administration: Self-administered by subcutaneous injection at breakfast or dinner. Doses were adjusted to maintain a fasting self-monitored plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL).
1661046|NCT01768559|Drug|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: Oral administration. If previously taken, Metformin to be continued at stable dose (≥1.5 g/day) throughout the study.
1661047|NCT01768546|Behavioral|Virtual Diabetes Prevention Program|Participants will view 16 Video On Demand reality based TV episodes that follow 6 adults with pre-diabetes actively participating in a DPP lifestyle intervention.
1661048|NCT01768546|Behavioral|Interactive tracking and problem solving web portal|
1661049|NCT01768520|Drug|Enteron tab. 150mg(vitis vinifera extract 150mg) : twice daily for 12 weeks|"morning : 1 tab. of active Entelon 150mg plus 1 cap. of placebo Celebrex
evening : 1 tab. of active Entelon 150mg"
1661050|NCT01768520|Drug|Celebrex cap. (celecoxib 200mg) : once daily, for 12 weeks|"morning : 1 tab. of placebo Entelon 150mg + 1 cap. of active Celebrex
evening : 1 tab. of placebo Entelon 150mg"
1661051|NCT01768520|Drug|Placebo|"morning : 1 tab. of placebo Entelon 150mg + 1 cap. of placebo Celebrex
evening : 1 tab. of placebo Entelon 150mg"
1661052|NCT01768507|Dietary Supplement|Resveratrol|5 g (10 capsules) as single oral dose on day 1
1661053|NCT01768481|Drug|Atorvastatin|10 mg Atorvastatin vs placebo daily in a randomized controlled trial for one year
1661054|NCT01768481|Drug|sugar pill|placebo controlled arm receives similarly looking placebo.
1661055|NCT01768468|Drug|LAYLA tablet|1 tablet twice a day
1661056|NCT01768468|Drug|JOINS tablet|1 tablet at each time, 3 times a day
1661057|NCT01768455|Drug|Gemigliptin and Glimepiride|Gemigliptin 50mg (qd) on Day1~Day6 and Gemigliptin 50mg (qd) and Glimepiride 4mg (qd) on Day7
1661058|NCT01768455|Drug|Glimepiride|Glimepiride 4mg (qd) on Day1
1661059|NCT01768429|Behavioral|Fatty fish|
1661060|NCT01768429|Behavioral|Lean Fish|
1661061|NCT01768429|Behavioral|Alpha-linolenic acid|
1661062|NCT01768429|Behavioral|Control|
1661063|NCT01768390|Other|toothpaste containing 5,000 ppm fluoride|1 cm tootpaste twice daily during 2 minutes
1661064|NCT01768390|Other|1450 GCP|Twice gaily toothbrushing with normal adult toothpaste containing 1450 ppm F representing good clinical practice
1661065|NCT01768377|Drug|Nerve block with Lidocain|Lidocain 2% topical injection, 0.5 - 1 cc Lidocain 4% topical injection, 3 cc Lidocain 10% topical spray , total dose 50 mg
1661066|NCT01768377|Drug|Fentanyl|Fentanyl 2 microgram/Kg BW IV
1661067|NCT01768377|Drug|Midazolam|Midazolam 0.05 mg/kg BW IV infusion
1661068|NCT01768364|Drug|Trimetoprim-Sulfa (Bactrim)|
1661069|NCT01768364|Other|No antibiotics|
1661070|NCT01768351|Drug|Paricalcitol|Zemplar cp 1 mcg/day per os
1661071|NCT01768351|Drug|Calcitriol|Rocaltrol cp 0,5 mcg every other day per os
1661072|NCT01768338|Drug|Ofatumumab combined with SB-485232|Ofatumumab with escalating doses of SB-485232
1661073|NCT01768325|Device|EUS-TCB needle (QuickCore) standard of care|"The number of needle passes requiring to acquire adequate specimen were tallied.
Length of core tissue obtained
Diagnostic contribution of immunohistochemical staining
Rates of complications"
1661074|NCT01768325|Device|EUS-Guided biopsy needle (ProCore)|"The number of needle passes requiring to acquire adequate specimen were tallied.
Length of core tissue obtained
Diagnostic contribution of immunohistochemical staining
Rates of complications"
1661075|NCT01768312|Drug|Cyclosporine ophthalmic solution|1 drop twice/day for 12 weeks to both eyes
1661076|NCT01768299|Drug|Mifepristone|200 mg oral Mifepristone 24 hours before 400 mcg buccal misoprostol
1661077|NCT01768299|Drug|Misoprostol|200 mg oral Mifepristone simultaneously 400 mcg buccal misoprostol
1661078|NCT01768286|Drug|LDV/SOF|Ledipasvir (LDV) 90 mg/sofosbuvir (SOF) 400 mg fixed-dose combination (FDC) tablet administered orally once daily
1661079|NCT01768286|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1661080|NCT01768273|Drug|Midazolam|
1661081|NCT01768273|Drug|PA-824|
1661082|NCT01768260|Device|Enhanced external counterpulsation|EECP is performed for 1 hours every day, for a total of 36 hours.
1661083|NCT01768260|Drug|Aspirin|Standard drug therapy
1661084|NCT01768247|Drug|HCG (human chorionic gonadotropin)|150 international units (IU) of HCG for seven days subcutaneously concomitantly with estrogens in preparation endometrium cycles fro frozen embryos replacement
1661085|NCT01768234|Other|Supplemental water|1-2L of supplemental water provided between pre-test and post-test
1661086|NCT01768221|Behavioral|Caregiver Intervention|"Participants will speak with a chaplain for three brief, 45 minute to one hour, sessions.
The sessions will focus on topics of relationship life review, unresolved conflicts and issues of forgiveness, and future goals, lessons learned and legacy.
In the week following the third session, the chaplain will call participants for a brief check in. This call will include no new intervention content, rather it provides an opportunity for participants to mention any additional thoughts or concerns they want to discuss with the chaplain interventionist."
1661087|NCT01768208|Drug|Saxagliptin|
1661122|NCT01767896|Biological|ASP7374|subcutaneous (sc)
1661088|NCT01768195|Drug|Entecavir prophylaxis|"Entecavir 0.5mg daily from day 1 of immunochemotherapy and/or chemotherapy to 12 months after completing immunochemotherapy and/or chemotherapy.
In patients with low load of hepatitis B virus DNA(≤2000 IU/ml), rituximab will be administrated at the beginning of entecavir prophylaxis. And in patients with high load of hepatitis B virus DNA(>2000 IU/ml), rituximab will be administrated when hepatitis B virus DNA decreased to the level of 2000 IU/ml after entecavir prophylaxis."
1661089|NCT01768182|Dietary Supplement|Folinic Acid|Participants were randomly assigned to a 4-week treatment with either folinic acid (n=15) or placebo (n=15). The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
1661090|NCT01768182|Other|Placebo|The study supplementation regimens consisted of the capsules containing 5 mg of folinic acid or placebo. Participants were provided with 1 bottle, which contained 30 capsules. Subjects were instructed to take 1 capsule daily, in the morning
1661091|NCT01768169|Dietary Supplement|fish oil capsule|500 mg of natural fish oil, made up of 30% omega-3 PUFA (EPA:DHA = 3:2)
1661092|NCT01768156|Other|Experimental arm|"Serum samples are collected:
at time of diagnosis of recurrence (before 1st chemotherapy)
during each cycle of chemotherapy
after the end of chemotherapy
every 3 month until treatment failure (3-6 samples)
stop at the progression or after 18 months post chemotherapy"
1661093|NCT01768143|Behavioral|unexperienced endoscopy nurses|
1661094|NCT01768143|Behavioral|Experienced endoscopy nurses|
1661095|NCT01768117|Biological|rLP2086|0.5 ml intramuscular injection of 120 microgram bivalent rLP2085 administered at 0, 2 and 6 months
1661096|NCT01768104|Procedure|ESTD|"A 2-cm longitudinal mucosal incision was made, approximately 5cm proximal to the submucosal tumor (SMTs).
Submucosal dissection was done, creating a submucosal tunnel until the tumor was visible.
Dissection was done along the margin of the tumor.
After the tumor had been removed, the potential bleeding area in the tunnel was coagulated.
Endoclips were used to close the entry of the submucosal tunnel.
(Gong W et al. ESTD for upper gastrointestinal submucosal tumors… Endoscopy 2012; 44: 231-235)"
1661097|NCT01768104|Procedure|VATS|"General anesthesia with double lumen intubation.
Three to four cameras or working ports are placed over the chest wall.
After the lesion is visualized by thoracoscopy, the mediastinal pleura over the tumor is incised longitudinally by an endoscopic hook electrocauterizer.
The mass is exposed after the overlying muscle is split longitudinally.
The retracting suture is placed over the mass and then meticulously dissect the plane between the mass and the submucosal layer. The integrity of the mucosa must be checked.
The muscle layer is re-approximated and a chest tube is place through one of the ports.
(Luh et al. World Journal of Surgical Oncology 2012, 10:52)"
1661098|NCT01768091|Procedure|POEM|"Entry to submucosal space. After submucosal injection, a 2-cm longitudinal mucosal incision is made at approximately 13 cm proximal to the gastroesophageal junction (GEJ).
Submucosal tunnelling. A long submucosal tunnel is created to 3 cm distal to the GEJ.
Endoscopic myotomy is begun at 3 cm distal to the mucosal entry point, and is carried out in a proximal to distal direction to a total length of 10 cm.
Long endoscopic myotomy of inner circular muscle bundles is done, leaving the outer longitudinal muscle layer intact. The expected end point of myotomy is 2 cm distal to the GEJ.
Closure of mucosal entry: the mucosal incision is closed using hemostatic clips.
(Inoue H et al. POEM for esophageal achalasia… Endoscopy 2010; 42: 265-271)"
1661099|NCT01768091|Procedure|Pneumatic dilation|"A Rigiflex balloon (30 mm) was positioned at the esophagogastric junction and dilated at a pressure of 5 PSI for 1 minute, followed by 8 PSI for 1 minute.
(N Engl J Med 2011;364:1807-16.)"
1661100|NCT01768078|Procedure|Intravitreal injection of Betamethasone + antibiotics|
1661101|NCT01768078|Procedure|Intravitreal injection of antibiotics|
1661102|NCT01768065|Device|Nasal Expiratory Positive Airway Pressure Device|assigned to Nasal Expiratory Positive Airway Pressure arm
1661103|NCT01768065|Device|placebo sham|
1661104|NCT01768052|Device|functional Near Infrared Spectroscopy|fNIRS monitoring during rTMS treatment sessions.
1661105|NCT01768039|Drug|Vitamin D|
1661106|NCT01768039|Drug|Placebo|
1661107|NCT01768013|Drug|LEO 90105|Once daily for four weeks
1661108|NCT01768000|Behavioral|Family Cognitive Adaptation Training|Family CAT is a 4 month manualised intervention designed to be administered by families independent of clinician support. A self scoring checklist is provided to assess and tailor Family CAT to the individual, along with descriptions of strategies for bathing, dressing, dental hygiene, make-up, toileting, housekeeping/care of living quarters, laundry, grocery shopping, transportation, management of money and consumables, medication management, social skills, communication and telephone use, leisure skills, work skills, and orientation. Family members will watch the DVD to gain insight into how the strategies can be implemented in real world settings. Having identified the areas of need, family members will administer the interventions and evaluate their effectiveness for the individual.
1661109|NCT01767987|Drug|Ranolazine|Drug: Ranolazine 1000 mg Oral dose twice per day for 3 days leading up to PCI
1661110|NCT01767987|Drug|Placebo|Drug: Placebo Oral dose twice per day for 3 days leading up to PCI
1661111|NCT01767961|Procedure|diagnostic imaging|Undergo MBS
1661112|NCT01767961|Other|questionnaire administration|Correlative studies
1661113|NCT01767961|Procedure|quality-of-life assessment|Correlative studies
1661114|NCT01767948|Drug|PCI-32765|PCI-32765 140 mg will be administered as a single dose, orally, on Day 1.
1661115|NCT01767935|Procedure|cryosurgery|Undergo cryosurgery
1661116|NCT01767935|Radiation|radiation therapy|Undergo radiation therapy
1661117|NCT01767935|Procedure|quality-of-life assessment|Ancillary studies
1661118|NCT01767922|Dietary Supplement|Extramel 10 mg - 140 UI SOD|"Subjects took one capsule of Extramel® 140 IU, or its corresponding placebo, daily over 12 weeks.
Each volunteer was seen for the 3 visits:
visit V1, so-called inclusion visit (D0),
visit V2 at 28 days, tolerance of +/- 3 days, (D28) and
visit V3 at 84 days, tolerance of +/- 3 days, (D84)."
1661119|NCT01767922|Dietary Supplement|Placebo - Excipient only|
1719475|NCT00002805|Drug|methotrexate|
1661124|NCT01767883|Other|Facilitated Clinical Decision Support|"The primary care practices in this arm will receive:
CKD decision support algorithms added to their Clinical Decision Support
System Academic detailing concerning the rationale for the algorithms
On-going mentoring and practice facilitation
Audit and feedback during quarterly reviews of practice data with the practice facilitator by videoconference."
1661125|NCT01767883|Other|Clinical Decision Support Only|"CKD decision support algorithms added to their Clinical Decision Support
System Academic detailing concerning the rationale for the algorithms"
1661126|NCT01767870|Procedure|FIT-sigmoidoscopy|Advanced colorectal adenoma detection by fecal immunochemical test with sigmoidoscopy
1661127|NCT01767870|Procedure|Colonoscopy|Advanced colorectal adenoma detection by colonoscopy
1661128|NCT01767857|Drug|Xilonix|Xilonix is a True Human Monoclonal Antibody targeting Interleukin 1 alpha, and is administered intravenously every 2 weeks with best supportive care until clinical or radiographic progression.
1661129|NCT01767857|Drug|Placebo|Placebo plus best supportive care will be administered intravenously every 2 weeks until clinical or radiographic progression.
1661132|NCT01767831|Behavioral|iBOLUSED|The intervention will involve daily diary data upload and daily simulation-based feedback based on the collected diary data. Throughout the educational intervention, participants will record diary data every day through the use of a diary component in the internet-based system. Diary entries include data on meals, physical activity, history of the insulin basal rate and insulin boluses given that day, self-reported stress level, hypo- and hyperglycemic fear levels, and, if applicable, menstrual cycle and any physical illness. Participants will also upload data from the CGM via the Dexcom DM3 software or the Dexcom Studio Software.
1661133|NCT01767805|Procedure|Standard incubator|
1661134|NCT01767805|Procedure|Mini incubator|
1661135|NCT01767805|Procedure|5% oxygen|
1661136|NCT01767805|Procedure|20% oxygen|
1661137|NCT01767792|Drug|Bevacizumab|"Treatment will be administered on an outpatient basis. Bevacizumab is administered by IV infusion at a dose of 10 mg/kg every 2 weeks for 24 weeks (induction therapy, see Schema). One cycle lasts 28 days and includes two infusions of bevacizumab. Clinical response will be assessed by audiology and MRI at weeks 12 and 24. Subjects with hearing decline at weeks 12 and 24 will be taken off of protocol. After week 24, patients with a clinical response or stable disease (together comprising clinical benefit) will transition to maintenance therapy with bevacizumab.
During the maintenance phase, subjects will be treated with open-label bevacizumab 5 mg/kg every 3 weeks for up to 72 weeks. Subjects will be followed with audiology and MRI scans every 12 weeks. The total time of the study will be 96 weeks (24 weeks induction + 72 weeks maintenance)."
1661139|NCT01767753|Device|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
1661140|NCT01767740|Device|ULTRABRAID PLUS SUTURE|Rotator Cuff Repair with ULTRABRAID PLUS SUTURE
1661141|NCT01767740|Device|ULTRABRAID SUTURE|Rotator Cuff Repair with ULTRABRAID SUTURE
1661142|NCT01767727|Procedure|Soft tissue coverage|The dorsal homodigital island flaps are used for reconstruction of multiple finger defects
1661143|NCT01767714|Drug|Granulocyte-colony stimulating factor (G-CSF)|10 µg/kg/day G-CSF, administered by subcutaneous (SC) injection
1661144|NCT01767714|Drug|Plerixafor|0.24 mg/kg/day subcutaneous injection
1661145|NCT01767714|Drug|Placebo|0.24mg/kg/day placebo (0.9% Sodium Chloride) administered by subcutaneous injection
1661146|NCT01767701|Drug|Raltegravir|400mg twice daily for 3 months
1661147|NCT01767688|Drug|MK-3102|Single dose of 25 mg of MK-3102 (1 x 25 mg capsule) administered orally on Day 1.
1661152|NCT01767662|Procedure|manipulation|home programme
1661153|NCT01767662|Procedure|No intervention|observation
1661154|NCT01767649|Other|Caesarean|Collection of tissues and blood
1661155|NCT01767649|Other|Vaginal delivery|Collection of tissues and blood
1661156|NCT01767636|Drug|Pazopanib Hydrochloride|Given PO
1661157|NCT01767623|Drug|Vemurafenib|Vemurafenib orally BID 960 or 720 mg.
1661158|NCT01767610|Drug|micronized fenofibrate 160mg|
1661159|NCT01767610|Drug|pitavastatin Ca 2mg|
1661160|NCT01767610|Drug|micronized fenofibrate 160mg plus pitavastatin Ca 2mg|
1661161|NCT01767597|Other|ELISA testing|Enzyme-linked immuno-assay (ELISA) will be used to determine hepatitis B surface antigen (HBsAg) and anti-HBsAg antibody (anti-HBs Ab) status. Results will be given after test results are available (8-10 days).
1661162|NCT01767597|Other|Rapid testing|A rapid test will be performed to determine the subjects' hepatitis B surface antigen (HBsAg, using VIKIA®) and anti-HBs antibody status (anti-HBs Ab, using Quick ProfileTM). Results will be given the same day.
1661163|NCT01767584|Drug|Cephalexin 1g tablets|Reference product
1661164|NCT01767584|Drug|Cephalexin 1g tablets|Test product
1661165|NCT01767571|Drug|Cephalexin 125 mg/5ml|Reference product 20 ml
1661166|NCT01767571|Drug|Cephalexin 250mg/5ml|Test product 10 ml
1661167|NCT01767558|Other|Ablation / MRI|"All subjects will undergo a standard of care ablation procedure for paroxysmal AF with the CE-Marked PVAC GOLD catheter.
MRIs will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at Pre-Discharge will undergo another MRI at the 1 month follow-up visit."
1661168|NCT01767545|Drug|Dexamethasone implant|
1661169|NCT01767545|Drug|Bevacizumab|
1661170|NCT01767532|Drug|Cephalexin 125 mg/5ml|Reference product 20 ml
1661171|NCT01767532|Drug|Cephalexin 125 mg/5ml|Test product 20 ml
1661172|NCT01767519|Biological|BOTOX®|BOTOX 100U injected at Day 1 (BOTOX/solifenacin placebo arm). After a minimum of 12 weeks, all patients could request/qualify for a BOTOX injection.
1661174|NCT01767519|Drug|Botox placebo (normal saline)|Botox placebo (normal saline) intradetrusor injection at Day 1.
1661175|NCT01767519|Drug|solifenacin placebo|Beginning on Day 1, one capsule taken orally once daily for up to 24 weeks.
1958095|NCT02000076|Behavioral|Full sleep|Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
1661178|NCT01767493|Drug|[18F]Florbetapir and PET imaging|Subjects will have a baseline scan and second scan within 1 month following the baseline PET scan
1661179|NCT01767480|Device|RT|The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns in conjunction with computer games: forearm pronation-supination and wrist flexion-extension. Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually. The device has a mechanical breaking of the movement when the torques exceeded 4 Nm, emergency breaks in the reach of the patients, skin friendly materials, and minimal risk for contusions.
1661180|NCT01767480|Behavioral|Conventional rehabilitation (CR)|CR will focus on neurodevelopmental techniques with emphasis on functional tasks when possible. The functional training will be designed based on patients' motor capacity and include gross motor and fine motor dexterity training, and transitive and intransitive training. Stretching of the more affected limb, passive and active range of movements, and normalizing muscle tone by applying reflex inhibition patterns, inhibiting abnormal patterns, weight bearing with the affected limb will be applied to assist in functional task practice.
1661181|NCT01767467|Biological|Herpes zoster vaccine (GSK 1437173A)|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
1661182|NCT01767467|Drug|Placebo|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm. Dose 1 administered at Day 0. Dose 2 administered 1-2 months post Dose 1.
1661183|NCT01767454|Drug|Dabrafenib|Dabrafenib 100 mg or 150 mg BID orally will be administered. Capsules with unit dose strengths of 50 mg or 75 mg
1661184|NCT01767454|Drug|Trametinib|Trametinib 1 mg or 2 mg once daily will be administered. Tablets with unit dose strengths of 0.5 mg or 2 mg
1661185|NCT01767454|Drug|Ipilimumab|Ipilimumab 3 mg/kg intravenously over 90 minutes Q3W for a total of 4 doses will be administered. Supplied as Vials of 50 mg/10 mL (5 mg/mL) and 200 mg/40 mL (5 mg/mL)
1661186|NCT01767441|Procedure|Roux-en-Y-gastric bypass|Gastric bypass consisted of creation of a 15-20 ml gastric pouch, a 150 cm Roux limb, and a 50 cm biliopancreatic limb
1661187|NCT01767441|Procedure|laparoscopic adjustable gastric banding|Gastric banding functions by limiting food intake after the placement of an inflatable tube around the stomach just below the gastroesophageal junction, which allows for adjustment of the size of the outlet via the addition or removal of saline through a subcutaneous port.
1661188|NCT01767441|Procedure|laparoscopic sleeve gastrectomy|Sleeve gastrectomy involved a gastric reduction of 75 to 80% by resecting the stomach alongside a 30-French endoscope beginning 3 cm from pylorus and ending at the angle of His
1661189|NCT01767441|Other|diet treatment|Hypocaloric diet providing a 1000 Kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination
1661190|NCT01767428|Drug|Paracetamol|500 mg immediate release paracetamol formulations
1661191|NCT01767415|Drug|Indigo carmine|During resection, a small quantity of a special dye called indigo carmine will be infused at the margins of the tumor using computer-guided stereotactic navigation equipment. This dye will be visible during the tumor resection and it can potentially serve as an additional marker of the tumor margins. A post-operative MRI scan -which is part of the standard care- will accurately measure the extent of tumor resection.
1661192|NCT01767402|Biological|PhtD vaccine with/without adjuvant|Two doses of different formulations of PhtD vaccine administered intramuscularly in the deltoid region of the right arm at month 0 and month 2.
1661193|NCT01767402|Biological|Pneumovax 23TM|One dose of Pneumovax 23TM vaccine administered intramuscularly in the deltoid region of the right arm at month 0.
1661194|NCT01767402|Biological|NaCl|One dose administered intramuscularly in the deltoid region of the right arm at month 2.
1661195|NCT01767389|Other|The GLP-1 receptor agonist users|The GLP-1 receptor agonist users are classified based on the receipt of a GLP-1 receptor agonist at the index date. GLP-1 receptor agonists included in this study are exenatide and liraglutide
1661196|NCT01767389|Other|DPP-4 inhibitor users|DPP-4 inhibitor users are classified based on the receipt of a DPP-4 inhibitor prescription at the index date. The DPP-4 inhibitors included in this study are sitagliptin, saxagliptin, linagliptin, combination of sitagliptin and metformin (Janumet), and combination of sitagliptin and simvastatin (Juvisync)
1661197|NCT01767389|Other|Other ADA users|Classes of ADA's other than GLP-1 receptor agonists and DPP-4 inhibitors will be included in the 'other ADA' exposure group
1661198|NCT01767376|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid muscle of the arm.
1661199|NCT01767376|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the right arm (in Co-ad Group) and left arm (in TdapACWY and ACWYTdap Groups).
1661200|NCT01767363|Other|5-alpha reductase inhibitors|Use of 5-alpha reductase inhibitors over the course of the study period.
1661201|NCT01767363|Other|Alpha-blockers|Use of alpha-blockers over the study period.
1661202|NCT01767350|Procedure|Blood withdrawal for DNA|"Single withdrawal of 8 ml whole blood for DNA analysis, during a standard blood collection as part of standard clinical follow up."
1661203|NCT01767337|Device|FLUGEN 101.2 device|
1661204|NCT01767324|Device|Injection to deltoid|Deliver 0.5 milliliters of saline intradermally
1661205|NCT01767324|Device|Injection to forearm|Deliver 0.5 milliliters of saline intradermally
1661206|NCT01767324|Device|Injection to thigh|Deliver 0.5 milliliters of saline intradermally
1661207|NCT01767311|Drug|BAN2401 2.5 mg/kg|2.5 mg/kg biweekly (once every 2 weeks) administered as a 60 minute i.v. infusion
1661208|NCT01767311|Drug|BAN2401 5.0 mg/kg|5.0 mg/kg biweekly (once every 2 weeks) administered as a 60 minute i.v. infusion
1661209|NCT01767311|Drug|BAN2401 10 mg/kg|10 mg/kg biweekly (once every 2 weeks) administered as a 60 minute i.v. infusion
1661210|NCT01767311|Drug|BAN2401 5.0 mg/kg|5.0 mg/kg monthly (once every 4 weeks) administered as a 60 minute i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
1661211|NCT01767311|Drug|BAN2401 10 mg/kg|10 mg/kg monthly (once every 4 weeks) administered as a 60 minute i.v. infusion. All participants will receive biweekly infusions, participants will have placebo infusion alternating with BAN2401
1661212|NCT01767298|Drug|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
1661213|NCT01767298|Drug|Valsartan|Valsartan alone
1661214|NCT01767298|Drug|Hydrochlorothiazide|Hydrochlorothiazide alone
1661215|NCT01767285|Drug|Etonogestrel implant|This will be placed in subjects in both arms. Those in Arm 1 will receive the implant in the hospital postpartum. Those in Arm 2 will receive the implant at the 6 week postpartum visit.
1661216|NCT01767272|Drug|fexofenadine|fexofenadine brand name
1661217|NCT01767259|Drug|Valsartan/Hydrochlorothiazide|Co-administration or fixed dose combination
1661218|NCT01767259|Drug|Valsartan|Valsartan alone
1661219|NCT01767259|Drug|Hydrochlorothiazide|Hydrochlorothiazide alone
1661220|NCT01767246|Other|PFS Algorithm treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon a treatment algorithm. that addresses patients: fear avoidance beliefs, flexibility, body mechanics, and strength. The exercises and treatments are individualized to each patients with the goal of have low fear avoidance beliefs, flexibility, body mechanics, and strength.
1661221|NCT01767246|Other|Multimodal treatment|Physical Therapy treatment for Patellofemoral Syndrome based upon the Multimodal treatment (Lowry, 2008).
1661222|NCT01767233|Procedure|ERCP and pancreatic stenting|
1661223|NCT01767220|Procedure|Strategy 1 - endocardial ablation|VT substrate mapping and VT ablation are done only from endocardial. Therefore the catheters are introduced through the femoral veins/arteries. For mapping and ablation a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
1661224|NCT01767220|Procedure|Strategy 2 - endocardial and epicardial ablation|VT substrate mapping and VT ablation are done from endocardial and epicardial. Therefore the catheters are introduced through the femoral veins/arteries and into the pericardial space via a pericardial puncture. After endocardial and epicardial mapping, ablation is done from endocardial. In case of an ineffective endocardial ablation and an epicardial substrate an epicardial ablation is done. For mapping and ablation from endo- and epicardial a 3,5 mm irrigated tip catheter (Navistar Thermocool, Biosense Webster, Diamond Bar, CA, USA) will be used.
1661225|NCT01767207|Other|mental disorders|mental disorders
1661226|NCT01767207|Behavioral|screening for mental disorders|screening for mental disorders
1661233|NCT01767181|Other|Intensive light therapy|Light therapy will be applied by a Lumie Brazil fluorescent tube light box (10.000 lux) during the night shifts for 12 consecutive weeks
1661234|NCT01767181|Other|Exercise|Physical exercise will be performed in a supervised environment on the days of the night shifts, either before the start of the shift (defined as a time period beginning no earlier than 2 hours before the start of the shift) or after the end of the night shift (defined as a time period ending no longer than 2 hours after the end of the night shift)
1661235|NCT01767168|Other|comprehensive preoperative testing for risk factors of persistent postoperative pain|nociceptive reflex threshold, pain threshold, CPM-effect of hot water bath, pain sensitivity questionnaire, STAI, BDI, fear of surgical consequences
1661236|NCT01767155|Drug|AEZS-108 / zoptarelin doxorubicin|267 mg/m2 by 2-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles for a maximum of 9 cycles
1661237|NCT01767155|Drug|doxorubicin|60 mg/m2 by intravenous bolus injection or 1-hour intravenous infusion, on Day 1 of 21-day (3-week) cycles
1661238|NCT01767142|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1661239|NCT01767129|Drug|AVP-923-45|One capsule twice daily for 14 days
1661240|NCT01767129|Drug|Placebo|One capsule twice daily for 14 days
1661241|NCT01767116|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
1661242|NCT01767116|Drug|Ribavirin|Capsule
1661243|NCT01767116|Drug|Placebo for ribavirin|Capsule
1661244|NCT01767103|Drug|Ferriprox®|
1661245|NCT01767090|Drug|ASP1707|Oral
1661246|NCT01767090|Drug|Placebo|Oral
1661247|NCT01767090|Drug|Leuprorelin acetate|subcutaneous
1661248|NCT01767077|Dietary Supplement|Butter oil|Daily intake of 40 g butter oil
1661249|NCT01767077|Dietary Supplement|Cream|Daily intake of 100 g cream (40%)
1661250|NCT01767064|Other|Posted commitment letter|
1661251|NCT01767038|Procedure|OCT Spectralis|
1661252|NCT01767038|Procedure|microperimetry|
1661253|NCT01767025|Drug|Oxytocin|
1661254|NCT01767025|Drug|Sea water|
1661255|NCT01767012|Device|Polylens EC-HY10-PAL (coated)|hydrophobic acrylic IOL with modified surface properties (Heparin-coating)
1661256|NCT01767012|Device|Polylens EC-Y10-PAL (uncoated)|
1661257|NCT01766960|Other|High fat meal|A high fat breakfast will be administered to induce gall bladder emptying.
1661258|NCT01766960|Drug|Morphine|Five milligrams of intravenous morphine will be administered.
1661259|NCT01766947|Device|Sensimed Triggerfish|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
1661260|NCT01766921|Biological|Adjuvanted H5N1 pandemic influenza vaccine|Comparison of two doses of aH5N1c vaccine
1661297|NCT01766687|Dietary Supplement|Hydration|
1661261|NCT01766908|Other|Clamp cord 20, 40 or 60 seconds following vaginal or cesarean delivery|None to add
1661262|NCT01766895|Other|blood sampling|blood sampling of viral hepatitis to determined seroprevalence in uremic patients
1661263|NCT01766882|Behavioral|Lower sodium intervention|"1. Lower sodium intervention:
Dietary sodium restriction of ≤2.0 g/day or ≤85 mmol/day (approximately >180-200mmol/day in the average American diet). Sodium restriction will be implemented using intensive dietary counseling performed weekly by a registered study dietitian using the motivational interviewing technique.
Lower dialysate sodium at 137 mmol/L, if perchance a different concentration of dialysate is used for the enrolled individual, although this is unlikely in both the UM associated units, where for some time now, dialysate concentration of 137 mmol/L is currently being used as standard practice. Investigators will ensure that this sodium concentration is indeed used for all study participants."
1661264|NCT01766882|Other|Progressive Challenge to Post Dialysis Weight|The existing target post-HD weight will be progressively challenged by removing additional fluid in small increments, unless clinical evidence of volume depletion or hypotension precludes this challenge in the intervention arm. To avoid the occurrence of intradialytic hypotension, the ultrafiltration rate shall not exceed15 ml/kg/hour and post dialysis weight will not be reduced by more than 0.5 kg per dialysis session. In some patients, this may warrant prolongation of the treatment time to achieve lowering of target post dialysis weight, and this process of target weight reduction may need to continue up to and through the interim assessment phase (6-8 weeks).
1661265|NCT01766856|Other|Eustachian tube function testing|Eustachian tube function testing will consist of some or all of the following tests: Inflation/Deflation test, Forced Response test, Compliance test,Valsalva, Toynbee and Sniffing
1661266|NCT01766843|Drug|Seretide Diskus and charcoal|2 inhalations as a single dose
1661267|NCT01766843|Drug|Seretide Diskus|2 inhalations as a single dose
1661268|NCT01766843|Drug|SF Easyhaler and charcoal|2 inhalations as a single dose
1661269|NCT01766843|Drug|SF Easyhaler|2 inhalations as a single dose
1661270|NCT01766830|Device|rk28 ICT|rk28 ICT is an immunochromatographic assay intended for qualitative detection of IgG antibodies directed towards VL in human serum, plasma or whole blood. It is manufactured by EASE-Medtrend (Shanghai, China)
1661271|NCT01766830|Device|IT LEISH (rK39)|IT LEISH is an immuno-chromatographic test, using the recombinant antigen K39, to detect the presence of antibodies against Leishmania spp. It is manufactured by BioRad laboratories, USA.
1661272|NCT01766830|Device|Immunochromatographic HAT test|This is a lateral flow immunochromatographic test manufactured by Standard Diagnostics (Korea) in collaboration with FIND.
1661273|NCT01766830|Device|HAT Serostrip|The HAT Serostrip is an immunochromatographic assay developed by Coris BioConcept, France, which is designed for remote field use in individual HAT suspects.
1661274|NCT01766830|Device|Card Agglutination Trypanosoma Test (CATT)-10|The Card Agglutination Trypanosoma test (CATT) has been used for many years at large scale for mass screening of mostly asymptomatic individuals (CATT-R250). Unfortunately, its operating characteristics have only been evaluated in the context of patients with persistent fever. Although it is not strictly an RDT, the CATT is rather easily performed in remote settings, in particular since a new and more robust format (CATT-D10) allows to test a lower number of patients in peripheral health facilities. It is manufactured by the Institute of Tropical Medicine of Antwerp, Belgium.
1661275|NCT01766830|Device|Typhidot M|The Typhidot M test is a dot enzyme immunoassay that detects IgM and IgG directed against Salmonella typhi. It is manufactured by Reszon Diagnostics International, Malaysia
1661276|NCT01766830|Device|S. typhi IgM/IgG|The Salmonella typhi IgG/IgM Rapid Test is an immunochromatographic assay for the qualitative differential detection of IgG and IgM antibodies to Salmonella typhi in human serum, plasma or whole blood. It is manufactured by Standard Diagnostics (Korea)
1661277|NCT01766830|Device|Test-it Typhoid IgM|Test-it Typhoid IgM lateral flow assay is a one-step immunochromatographic assay which uses a lipopolysaccharide (LPS) antigen derived from salmonella typhi for the detection of specific IgM antibodies. It is manufactured by Life Assay, South Africa.
1661278|NCT01766830|Device|Test-it Leptospirosis IgM|The Test-it™ Leptospira lateral flow device detects IgM antibodies in humans against Leptospira in whole blood or serum. It is manufactured by Life Assay, South Africa
1661279|NCT01766830|Device|Leptospira IgG/IgM|This test enables the differential detection of IgG and IgM antibodies to Leptospira interrogans. It is manufactured by Standard Diagnostics, Korea
1661280|NCT01766817|Drug|BMS-986020|
1661281|NCT01766817|Drug|Placebo matching with BMS-986020|
1661282|NCT01766804|Dietary Supplement|Bovine Colostrum|The intervention consists of daily bovine colostrum supplementation given during the induction treatment of ALL therapy for a total of four weeks.
1661283|NCT01766804|Dietary Supplement|placebo|
1661284|NCT01766791|Other|HIT-exercise, low repetition range|High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM
1661285|NCT01766791|Other|HIT-exercise, high repetition range|High Intensity Resistance Exercise Training, high repetition range, 60 - < 75 1RM
1661286|NCT01766791|Other|HIT-exercise with protein|High Intensity Resistance Exercise Training, low repetition range, > 75% 1RM and Protein Supplementation
1661287|NCT01766791|Other|Control|control group, no intervention, maintenance of physical activity
1661288|NCT01766778|Drug|LAF237 (vildagliptin)|Vildagliptin 50mg capsule
1661289|NCT01766778|Drug|Metformin|Metformin maximum tolerance dose
1661290|NCT01766765|Procedure|Jejunostomy|Routine placement of jejunostomy tube following laparoscopic gastrectomy for gastric cancer. Immediately drip 37°C saline 20 ml/h and exchange to drip 37°C enteral nutrition fluid 20 ml/h at postoperative 6 h via jejunostomy tube
1661291|NCT01766765|Other|Early oral nutrition|Free oral nutrition as tolerance allows on POD 1.
1661292|NCT01766752|Device|GlucoTab System|Tablet based workflow and decision support system with incorporated software algorithm (GlucoTab) used for glycaemic management in non-critically ill patients with type 2 diabetes at the general ward
1661293|NCT01766739|Biological|GL-ONC1|Patients will be enrolled in groups of three and individually assessed for safety and dose limiting toxicity (DLT).
1661294|NCT01766713|Drug|Ezetimibe|
1661295|NCT01766700|Behavioral|2 no calorie beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
1661296|NCT01766700|Behavioral|2 water beverages per day|Weekly and monthly lifestyle weight loss/maintenance classes.
1661298|NCT01766674|Behavioral|Kyphosis spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis spinal exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
1661299|NCT01766661|Procedure|Hand-sewn coloanal anastomosis|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as hand-sewn coloanal anastomosis with protective loop ileostomy.
1661300|NCT01766661|Procedure|Two staged Turnbull-Cutait procedure|After low anterior rectal resection due to low rectal neoplasm patients undergo intestinal reconstructions as two staged Turnbull-Cutait procedure anastomosis without protective ileostomy.
1661301|NCT01766661|Procedure|Ultralow anterior rectal resection with total mesorectal excision|Standard ultralow anterior rectal resection with total mesorectal excision
1661302|NCT01766648|Device|Far Cortical locking screw fixation|Standard locking screw fixation
1661303|NCT01766648|Device|Standard locking screw fixation|
1661304|NCT01766622|Drug|[18F]-CP18|7mCi, IV (in the vein) at baseline
1661305|NCT01766622|Procedure|PET/ CT|At baseline, Within 3 days after the initial Birinapant dose, A third [18F]-CP18 PET/CT will be obtained within 3 days following cycle 2, day 15 Birinapant therapy
1661306|NCT01766609|Drug|Triamcinolone Acetonide|
1661307|NCT01766596|Procedure|Optical Coherence Tomography|
1661308|NCT01766583|Drug|CC-292 + lenalidomide|CC-292 + lenalidomide
1661309|NCT01766570|Other|Uncontrolled nutritional intervention with a supplemental beverage|Men and women are assigned to an uncontrolled nutritional intervention where they have to consume every day one of the beverage. Half of the subjects consume the experimental beverage containing polyphenols from berries extracts, the other half consume a placebo beverage without polyphenols. The polyphenol containing beverage daily supply 1,84 g of a strawberry and cranberry extract. This amount give the equivalent of 333 mg of polyphenols, thus corresponding to a daily consumption of one cup of berries. The placebo beverage is also a fruit taste beverage, but without polyphenols. Both beverage are isocaloric, with same appearance and taste. A 2 weeks stabilisation period precede the 6 weeks experimental period. During these two periods, subjects are advise to maintain their habitual caloric intake and their habitual activity level, and to avoid consumption of particular food with a high polyphenol content.
1661310|NCT01766570|Other|Placebo|
1661311|NCT01766557|Other|Semi-controlled nutritional intervention with fish protein diet|After a controlled NCEP-based diet for 3 months, women are assigned to a cod fillet diet. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. Then, each group receive the other diet for an additional 3 months period. The fish protein intake come from cod fillets and correspond to 50% of total protein, the remaining dietary proteins being from BPVEM (20%) and vegetable (30%). Lunches incorporating cod fillets are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. Alcohol is strictly prohibited during all periods.
1661312|NCT01766557|Other|Semi-controlled intervention with other animal proteins|Prior to experimental period, participants follow a controlled NCEP-based diet for 3 months. Then women are assigned to a diet containing beef, pork, veal, eggs, milk and milk products. At the end of this first 3 months experimental period, participants return to their NCEP-based diet for a wash-out period of 3 months. The two diets are isoenergetic. The protein intake from BPVEM correspond to 70% of total protein, other dietary proteins are from vegetable (30%) origin. Lunches incorporating animal proteins are prepared by professional dietitians, provided two time per week, and are self-consumed. Participants make their breakfasts and dinners using foods from a pre-approved list. The content in n-3 fatty acids is adjusted to provide equivalent amounts of n-3 fatty acids then in the cod protein diet. Alcohol is strictly prohibited during all periods.
1661313|NCT01766544|Other|Standard Practice Group (SPG)|The investigators planned to send a copy of the latest Canadian asthma and COPD guidelines to all PCPs in the Standard Practice (SP) Group at the start of the study period, by mail. No other intervention would be offered during the study, but upon study completion, all control participants would be offered the educational intervention received by the Targeted Intervention Strategy (TIS) Group.
1661314|NCT01766544|Other|TISG|interactive educational interventions, expert mentorship and practice-based tools. 3 interactive sessions, 2 of which would be live meetings of 3h each, and the third hour teleconference.
1661315|NCT01766531|Device|body bioelectrical impedance|
1661316|NCT01766518|Drug|Mycophenolate mofetil|MY-REPT capsule 500~1500mg/day, per oral, capsules twice a day with Tacrolimus, Corticosteroids, Basiliximab post liver transplantation
1661317|NCT01766505|Drug|Candemore tablet|"Candemore tablet 8, 16, or 32mg/tab, per oral, a tablet once a day during 16 weeks.
dosage is depends on the sitting blood pressure."
1661318|NCT01766505|Drug|Cozzar tablet|Cozzar tablet: 8mg, 16mg, 32mg/tablet, per oral, a tablet a day during 16 weeks dosage depends on sitting blood pressure
1661319|NCT01766492|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Stereotactic body radiation therapy for prostate
1661320|NCT01766479|Radiation|CT colonography|
1661321|NCT01766466|Drug|cangrelor|Open-label cangrelor IV bolus (30 µg/kg), followed by an infusion of 4 µg/kg/min for two hours.
1661322|NCT01766466|Drug|Ticagrelor|"Ticagrelor 180mg dose: administered 0.5 h or 1.5h after the initiation of cangrelor infusion
Ticagrelor 90mg: 6 or 7 doses (depending on study arm) taken every 12 hours post cangrelor infusion."
1661323|NCT01766453|Behavioral|Standard Exercise|Aerobic exercise with a progressive increase in intensity over 12 weeks.
1661324|NCT01766453|Behavioral|Bhangra dance exercise|Bhangra Dance classes taught by an instructor.
1661325|NCT01766440|Drug|Calcitriol 3 mcg/g ointment|Topical ointment; twice daily application
1661326|NCT01766414|Drug|C1-esterase inhibitor|intravenously
1661327|NCT01766414|Drug|Endotoxin|intravenously
1661328|NCT01766401|Drug|Placebo|
1661329|NCT01766401|Drug|Vilazadone|Viibryd
1661385|NCT01765972|Device|etafilcon A with Lacreon|contact lens with Lacreon
1661386|NCT01765972|Device|etafilcon A with Lacreon with print|contact lens with Lacreon and cosmetic print
1661330|NCT01766375|Drug|Cyclosporin A,mycophenolate mofetil,Methotrexate|GVHD is prevented by CSA+MMF+MTX in sibling allogeneic hematopoietic stem cell transplantation (starting from day -1, 3mg/kg of CSA was infused by continuous intravenous drip until gastrointestinal function returned normal when method of administration was changed to oral administration.
1661331|NCT01766362|Procedure|PRPC using Pascal laser|
1661332|NCT01766349|Behavioral|respiratory muscle performance|Respiratory muscle performance will include measurements of respiratory muscle strength and pulmonary function testing.
1661333|NCT01766336|Drug|Group 1 ELND005|
1661334|NCT01766336|Drug|Group 2 ELND005|
1661335|NCT01766323|Drug|Modafinil|Oral modafinil at a dose of 100mg b.i.d along with the dose of oral morphine required for pain palliation
1661336|NCT01766323|Drug|Placebo|Oral placebo b.i.d, along with the dose of oral morphine required for pain palliation
1661337|NCT01766310|Drug|Folic Acid|yellow tablet contained 5mg of folic acid, manufactured from the Government Pharmaceutical Organization, Ministry of Public Health, Thailand
1661338|NCT01766310|Drug|placebo|sugar tablet manufactured to mimic folic acid tablet
1661339|NCT01766297|Radiation|Proton Radiotherapy|
1661341|NCT01766271|Behavioral|Health Coaching|biweekly health coaching for 5 months
1661342|NCT01766271|Genetic|9p21|Genetic testing results of 9p21
1661343|NCT01766271|Other|Standard Risk Assessment|All 4 arms are assigned to receive standard assessment on coronary heart disease risk
1661344|NCT01766258|Drug|ODM-101 65mg Carbidopa|
1661345|NCT01766258|Drug|ODM-101 105mg Carbidopa|
1661346|NCT01766258|Drug|Stalevo|
1661347|NCT01766245|Drug|semaglutide|For subcutaneous (s.c., under the skin), single dose administration at two separate dosing visits.
1661348|NCT01766219|Drug|6,8-bis(benzylthio)octanoic acid|Given IV
1661350|NCT01766193|Procedure|vaginal delivery|
1661351|NCT01766193|Procedure|forceps extraction|vaginal delivery by forceps extraction
1661352|NCT01766193|Procedure|vacuum extraction|vaginal delivery by vacuum extraction
1661353|NCT01766193|Procedure|cesarean section|
1661354|NCT01766180|Drug|Fruitflow-II|150 mg/day for 3 months, orally
1661355|NCT01766180|Drug|resVida|150 mg/day for 3 months, orally
1661356|NCT01766167|Drug|MP-424|Low
1661357|NCT01766167|Drug|MP-424|Middle
1661358|NCT01766167|Drug|MP-424|High
1661359|NCT01766167|Drug|MP-424|Multiple
1661360|NCT01766154|Drug|Tirofiban|A single high-dose bolus (3 min IV infusion) of tirofiban (25 µg/kg)
1661361|NCT01766141|Other|Spinal manipulation|Spinal manipulation will consist of a single high velocity low amplitude thrust to a hypomobile vertebral segment determined by the treating clinician to contribute to the problem.
1661362|NCT01766128|Drug|Zonisamide|The first arm will be treated by zonisamide and the second one will only receive placebo
1661363|NCT01766115|Drug|Telaprevir|HCV Protease Inhibitor
1661364|NCT01766102|Procedure|Intra-operative Mammography|The patient's breast specimen will be imaged in the operating room in an intra-operative imaging device - Biovision SN #30042
1661365|NCT01766102|Procedure|Standard Mammography|There is not an added device associated with this arm.
1661366|NCT01766089|Drug|Remifentanil|Remifentanil (0.1 µg/kg/min) starting 5 min before induction of anaesthesia and continued until peritoneal closure.
1661367|NCT01766089|Drug|Dexmedetomidine|dexmedetomidine (0.4 µg/kg/h) starting 20 before induction of anaesthesia and continued until peritoneal closure
1661368|NCT01766076|Other|atorvastatin, Lipitor®|PBMC collected for immune activation assays using flowcytometry
1661369|NCT01766076|Drug|Placebo|PBMC collected for immune activation assays using flowcytometry
1661370|NCT01766063|Drug|Interferon beta-1b (Betaferon, BAY 86-5046)|Patients will be followed-up for 24 months
1661371|NCT01766050|Drug|Caffeine|
1661372|NCT01766050|Drug|Losartan|
1661373|NCT01766050|Drug|Omeprazole|
1661374|NCT01766050|Drug|Dextromethorphan|
1661375|NCT01766050|Drug|Midazolam|
1661376|NCT01766050|Biological|Belatacept|
1661377|NCT01766037|Device|Aspiration Therapy (AspireAssist)|Use of the AspireAssist device in aspiration therapy
1661378|NCT01766037|Behavioral|Lifestyle Therapy|Lifestyle therapy is a behavioral, diet and physical activity education program
1661379|NCT01766024|Drug|Interferon beta-1a|Each volunteer will receive 1 subcutaneous (sc) injection of the study drug BCD-033 (interferon beta-1a) and 1 sc injection of active comparator Rebif (interferon beta-1a) at a dose of 44 µg with an interval of at least 14 days.
1661380|NCT01766011|Other|study pre-term formula|24 kcal/fl oz pre-term formula for in-hospital use
1661381|NCT01765998|Drug|Probiotic|Clinical evaluation according to the Crohn's activity scale
1661382|NCT01765998|Drug|Placebo|
1661383|NCT01765985|Device|PSORIAMED|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.
V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.
V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
1661384|NCT01765985|Device|PLACEBO|"V0 : Selection: Information of the patient, control of inclusion and non inclusion criteria.
V1 : Control of inclusion and non inclusion criteria (treatment against psoriasis have to be discontinued for at least 3 weeks and 3 months for anti-IL12/23). Clinical scores and photographs. Explanation of the functioning of the device, then the treatment is followed at home, twice a day 5 minutes. 10% salicylic acid ointment will be applied after each session.
V2 : End of the treatment (12 weeks after V1). Clinical scores and photographs. V3 : End of the follow-up (24 weeks after V1). Clinical scores and photographs."
1958100|NCT01995071|Drug|ABT-493|Tablet
1958101|NCT01995071|Drug|ABT-530|Tablet
1661389|NCT01765959|Other|Auricular acupuncture (AA)|Auricular acupuncture (AA) group will receive treatment twice a week for four weeks. Each session will take approximately 60 minutes in which there will be active treatment time for 40 minutes. During treatment the respondents will have 5 thin sterile, disposable steel needles superficially placed in each outer ear. Before needle insertion the outer ears will be cleaned with disinfection solution. During treatment the respondents will sit down in silence; with eyes shut and focus on a normal calm breathing. The acupuncturist will not be in the room during treatment. After 40 minutes the respondents remove the needles and put them in a box suited for disposed needles. If needed, assistance to remove needles will be given from the acupuncturist.
1661390|NCT01765959|Other|cognitive behavioral therapy (CBT)|"Cognitive behavioral therapy (CBT) group will receive manual based sessions for sleeping disorders. The group meets once a week during six weeks according to following program:
Session 1 - introduction, self-help concept Session 2 - biology of sleep, sleep restriction, Session 3 - stimulus control Session 4 - visualization as relaxation, Session 5 - how to deal with negative and automatic thoughts, Session 6 - how to solve problems, planning for the future"
1661391|NCT01765946|Drug|Metformin|Metformin tablets 500 mg tris in die (tid)
1661392|NCT01765946|Drug|placebo|
1661393|NCT01765933|Dietary Supplement|DMAA|no placebo
1661394|NCT01765920|Drug|Ergoferon|Safety and Efficiency of liquid dosage form
1661395|NCT01765920|Drug|Placebo|Safety and Efficiency of liquid dosage form
1661396|NCT01765907|Device|HIFU|
1661397|NCT01765894|Other|45 minutes of moderate exercise at the fasted state. Before test day 2: 3 days of carbohydrate loading.|
1661398|NCT01765881|Drug|Misoprostol|administration of Misoprostol 25 micrograms capsule by intravaginal route every 4 hours, up to 4 capsules
1661399|NCT01765881|Drug|Dinoprostone|administration of one sustained released pessary of 10 milligrams by intravaginal route
1661400|NCT01765868|Drug|Betrixaban|Single Oral dose 80 mg betrixaban and Single IV (15 ml) carbon 14 80 micrograms Betrixaban administered over 15 minutes, 2 hours after the oral dose
1661401|NCT01765855|Drug|Betrixaban single oral dose|
1661402|NCT01765842|Biological|Rituximab|Only one cycle of rituximab will be administered in this arm.
1661403|NCT01765829|Drug|Discontinuation antipsychotic treatment|Dose reduction until withdrawal
1661404|NCT01765829|Drug|Antipsychotic treatment|Antipsychotic treatment is not modify during the study, it is administered according to common clinical practice
1661405|NCT01765816|Behavioral|high intensity interval training|
1661406|NCT01765816|Behavioral|moderate intensity training|
1661407|NCT01765803|Drug|Mellaril|Subjects will undergo a physical exam including an electrocardiogram (EKG) and have blood drawn before treatment. A single 50 gm dose of thioridazine (Mellaril) will be given to eligible subjects. A second blood draw will occur at 24 hours post-treatment.
1661410|NCT01765777|Procedure|Osteopathic Manipulative Medicine|
1661411|NCT01765777|Procedure|Phototherapy|
1661412|NCT01765764|Drug|bimatoprost solution|Bimatoprost solution once a day or twice a day applied to each eyebrow for 7 months.
1661413|NCT01765764|Drug|Vehicle to bimatoprost solution|Vehicle to bimatoprost solution once or twice a day applied to each eyebrow for 7 months.
1661415|NCT01765738|Device|PICC (Cook, Bard)|Comparison of antibiotic coated PICC vs. non-coated PICC
1661417|NCT01765712|Procedure|Anterior Cruciate ligament reconstruction bone patellar tendon bone autograft|
1661418|NCT01765712|Biological|Platelet Rich Plasma|
1661419|NCT01765699|Device|Primary knee arthroplasty|Patients undergoing primary knee arthroplasty
1661420|NCT01765686|Device|Harmonic Scalpel (Ethicon Endo-Surgery, USA)|
1661421|NCT01765686|Device|Ligasure Small Jaw (Covidien, USA)|
1661423|NCT01765660|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 mins) every two weeks, four times for a cycle.
1661424|NCT01765660|Biological|Non-mesenchymal stem cells|Other second line drugs are taken.
1661425|NCT01765647|Other|AGY|AGY is a natural health product produced in egg yolks
1661426|NCT01765634|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) each week, four times for a cycle.
1661427|NCT01765634|Biological|Non-mesenchymal stem cells|Other second line drugs are taken.
1661428|NCT01765621|Other|DDI+ System and Pharmacogenetic Data|
1661429|NCT01765608|Drug|Zonisamide|Zonisamide (Zonegran®) tablets will be administered according to a forced stepwise weekly titration scheme with weekly 100 mg escalations from 100 to 300 mg daily according to the manufacturer Eisai Inc.
1661430|NCT01765608|Drug|Placebo|
1661431|NCT01765608|Device|nCPAP|
1661432|NCT01765595|Other|DDI+|
1719644|NCT00002839|Drug|cisplatin|
1661433|NCT01765582|Drug|5-fluorouracil|Participants in Arm A will receive 3200 milligrams per square meter (mg/m^2) by 48-hour continuous intravenous (IV) infusion every 2 weeks, during the 4-6 months' induction followed by maintenance therapy including bolus dose of 400 mg/m^2, followed by a 46-hour continuous infusion (2400 mg/m^2) every 2 weeks per investigator's discretion. Participants in Arm B and C will receive a bolus dose of 400 mg/m^2, followed by a 46-hour continuous infusion (2400 mg/m^2) every 2 weeks during the 4-6 months of induction and maintenance per investigator's discretion.
1661434|NCT01765582|Drug|bevacizumab|Participants will receive 5 mg/kg IV every 2 weeks during the first 4-6 months induction phase, followed by 5 mg/kg IV every 2 weeks or 7.5 mg/kg IV every 3 weeks during maintenance therapy, and 2.5 mg/kg per week reinduction after disease progression.
1661435|NCT01765582|Drug|capecitabine|Participants will receive 1000 or 850 mg/kg orally twice daily as per investigator's discretion on Day 1 to 14, repeated every 3 weeks in maintenance phase.
1661436|NCT01765582|Drug|irinotecan|Participants will receive IV infusion of 165 mg/m^2 over 1 hour every 2 weeks (Arm A) or IV infusion of 180 mg/m^2 over 1 hour in 2 x 2 weeks cycles alternating months (in Arm B), during 4-6 months induction phase.
1661437|NCT01765582|Drug|folinic acid|Participants will receive IV infusion of 200 mg/m^² (Arm A) or 400 mg/m^2 (Arm B or C) over 2 hours every 2 weeks, during 4-6 months induction phase followed by IV infusion of 400 mg/m^2 in the maintenance therapy.
1661438|NCT01765582|Drug|oxaliplatin|Participants will receive 85 mg/m^2 over 2 hours as IV infusion every 2 weeks (Arm A, C ) or 2 x 2 week cycles alternating months (Arm B), during 4-6 months induction phase .
1661439|NCT01765569|Drug|Digoxin|Participants received single oral dose of digoxin 0.25 mg tablet on Day 1 and Day 29.
1661440|NCT01765569|Drug|Vemurafenib|Participants received vemurafenib 960 mg tablet orally BID from Day 8 to Day 35.
1661441|NCT01765556|Drug|ketoconazole|multiple doses of ketoconazole in Period B and C
1661442|NCT01765556|Drug|vemurafenib|single dose of vemurafenib in Period A and C
1661443|NCT01765543|Drug|Rifampin|Rifampin at a dose of 600 mg as capsules orally once daily will be administered from Days 8 through 23 (Periods B and C).
1661444|NCT01765543|Drug|Vemurafenib|Participants, after an overnight fast of at least 10 hours, will receive vemurafenib at a dose of 960 mg as film-coated tablets orally on Day 1 (Period A) and on Day 17 (Period C).
1661446|NCT01765517|Dietary Supplement|Probiotics|Administration of probiotics daily for 26 weeks and compared to placebo
1661447|NCT01765517|Dietary Supplement|Placebo|Administration of placebo daily for 26 weeks and compared to probiotics group
1661448|NCT01765491|Other|Split-dose polyethylene glycol|Half gallon of polyethylene glycol to be taken between 7-9 pm on the day before colonoscopy and the remaining half between 7-9 am on the day of colonoscopy
1661449|NCT01765491|Other|Morning-only polyethylene glycol|One gallon of polyethylene glycol to be taken between 5am and 9am on the day of colonoscopy
1661450|NCT01765478|Drug|HM71224 single ascending dose|
1661451|NCT01765478|Drug|HM71224 food effect|
1661452|NCT01765478|Drug|HM71224 Multiple ascending dose|
1661453|NCT01765465|Drug|Rowachol|
1661454|NCT01765465|Drug|Placebo|
1661455|NCT01765452|Drug|Closone|75mg/100mg, 8weeks, PO
1661456|NCT01765452|Drug|Plavix with Astrix|75mg, 100mg a day, 8weeks, PO
1661457|NCT01765439|Dietary Supplement|VSL#3 (Original De Simone formulation)|Study subjects will receive two sachets of VSL#3 probiotic (ie 2x900 billions of live bacteria) per day (one in the morning, one in the evening). The intervention period will be 6 weeks (plus or minus 5 days).
1661458|NCT01765426|Biological|TDV|TDV suspension for intradermal administration
1661459|NCT01765426|Drug|Placebo|Phosphate buffered saline (PBS)
1661460|NCT01765413|Biological|Varicella-zoster virus|
1661461|NCT01765413|Biological|Yellow Fever Vaccine|
1661462|NCT01765413|Biological|Placebo|
1661463|NCT01765400|Drug|Prasugrel 10 mg daily x 2 weeks|
1661464|NCT01765400|Drug|Clopidogrel 75 mg daily x 2 weeks|
1661465|NCT01765387|Behavioral|Spa session|
1661466|NCT01765374|Device|ESAOTE MyLab60|US evaluation at different time points
1661467|NCT01765374|Drug|Rituximab|
1661468|NCT01765348|Behavioral|Syntax treatment via sentence-combining method|"Sentence combining method is a discrete trial method that teaches children to form complex sentences of a same structure through drilling and modeling.
Treatments are conduced by school-speech therapist once two weeks for 8 sessions."
1661469|NCT01765348|Behavioral|Syntax treatment managed by narrative-based treatment|Target structures are embedded into narrative stories. Children are exposed to these stories and are scaffolded to form the target sentence structure through answering questions, cloze passage and story retell. Treatment are conduced by school-speech therapist once two weeks for 8 sessions.
1661470|NCT01765335|Device|NICaS system|NICaS parameters (cardiac output and total peripheral resistance) and serum BNP levels will be processed in an excel sheet including study reference number to keep confidentiality
1661471|NCT01765322|Device|ZILOS-TK IVOS Analyzer|The subjects are going to participate the treatment of assisted hatching in vitro fertilization by Zona Infrared Laser Optical System (ZILOS-TK,Hamilton Thorne Biosciences,USA)
1661472|NCT01765309|Procedure|Bilateral mastectomy with reconstruction|In each patient enrolled in the study, botulinum toxin was injected into one pectoralis muscle while saline placebo was injected on the opposite side in a randomized blinded fashion
1958102|NCT01995071|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
1958103|NCT01995071|Drug|Ribavirin (RBV)|Tablet
1661476|NCT01765283|Biological|HepaStem|
1661477|NCT01765270|Drug|Saxagliptin|one 5-mg saxagliptin tablet daily
1661478|NCT01765270|Drug|Placebo|5mg placebo tablet daily
1661479|NCT01765257|Drug|AZILECT®|
1661480|NCT01765257|Drug|Placebo|
1661481|NCT01765244|Other|Anterior lamellar nanostructured artificial human cornea.|Implantation of an anterior lamellar nanostructured artificial human cornea with allogeneic cells from dead donors and biomaterials
1661482|NCT01765231|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of antitumor therapy to at least 6 months after completing antitumor therapy
1661483|NCT01765231|Drug|Observation arm|Entecavir 0.5mg daily will be prescribed for patients with hepatitis B virus reactivation.
1661484|NCT01765218|Drug|Topiramate|Infants assigned to the topiramate group will receive 5mg/kg of topiramate daily enterally for a total of 5 doses. The first dose will be administered as soon as possible on admission.
1661485|NCT01765218|Drug|Placebo|A placebo identical in appearance to the active agent (topiramate)
1661486|NCT01765205|Device|Pulse Oximetry using the INVOS (In Vivo Optical Spectroscopy) Cerebral/Somatic Oximeter|Up to 50 healthy infants and up to 10 infants with CHD will receive the pulse oximetry using the INVOS Cerebral/Somatic Oximeter for 15 minutes to determine the effectiveness to measure somatic oxygen saturation. The pulse oximeter will be placed on the infants forehead with a hat and around the infants thigh to measure oxygen saturation.
1661487|NCT01765192|Drug|Roflumilast|Roflumilast was supplied in tablets.
1661488|NCT01765192|Drug|Roflumilast placebo|Roflumilast placebo was supplied in tablets.
1661489|NCT01765192|Drug|Montelukast|Montelukast was supplied in tablets.
1661490|NCT01765179|Drug|Oral testosterone undecanoate|Initial dose 200 mg T, BID; dose titration Days 42 and/or 84 based on serum T levels obtained 3-5 hours post AM dose on Days 30 and 72. Dosages increased or decreased in 50 mg increments.
1661491|NCT01765166|Behavioral|SSGRIN-Parent Guide|All children will receive traditional SSGRIN(Social Skills Group Intervention), but parents will vary in the level of parent treatment. Families will be randomly assigned to one of four treatment conditions(approximately 25% each): (a) Traditional SSGRIN child treatment with no parent involvement (ChO), (b) SSGRIN child treatment plus parent attention control (PAC), (c) SSGRIN child treatment plus Parent Guide-Home-study treatment (PG-HS), or (d) SSGRIN child treatment plus traditional Parent Guide treatment (PG).
1661492|NCT01765153|Behavioral|Endurance|Participants are trained daily to walk on a treadmill for as fast and as long as possible. A harness supporting part of their body weight can be used if needed. Assistance from a trainer is used if needed. A physical therapist supervises the training.
1661493|NCT01765153|Behavioral|Precision|Participants train daily to walk over ground on 15 m straight hallway with obstacles they must step over, and targets they must step onto.
1661494|NCT01765140|Drug|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with Lambert Eaton myasthenic syndrome (LEMS)
1661495|NCT01765140|Drug|3,4-diaminopyridine|Treatment use of 3,4-DAP for patients with congenital myasthenic syndrome (CMS)
1661496|NCT01765114|Drug|PEG-Formulation|
1661497|NCT01765101|Other|customized insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
1661498|NCT01765101|Other|ready made insoles|To study the immediate, short-term and intermediate-term therapeutic effects, including psychological function, physical activity , functional performance and quality of life, physical functional ability, pain and balance performance
1661499|NCT01765088|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days
1661500|NCT01765088|Drug|α-IFN|3mIU (3million) D1，3，5
1661501|NCT01765036|Drug|SonoVue®|An intravenous 4.8 ml SonoVue® bolus injection was administered to each patient during the procedure
1661502|NCT01765023|Drug|Period I : atorvastatin, Period II : atorvastatin and metformin|
1661503|NCT01765023|Drug|Period I : metformin, Period II : atorvastatin and metformin|
1661504|NCT01765010|Drug|Calcitriol|
1661505|NCT01765010|Drug|Alfacalcidol|
1661506|NCT01765010|Drug|Cholecalciferol|
1661507|NCT01765010|Drug|Placebo|
1661508|NCT01764997|Drug|Sarilumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
1661509|NCT01764997|Drug|Etanercept|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
1661510|NCT01764997|Drug|Methotrexate|Dispensed according to local practice.
1661511|NCT01764997|Drug|Placebo (for sarilumab)|
1661512|NCT01764997|Drug|Placebo (for etanercept)|
1661513|NCT01764997|Drug|Adalimumab|Pharmaceutical form: Solution for injection in pre-filled syringe; Route of administration: Subcutaneous
1661514|NCT01764984|Device|Total knee arthroplasty|Total knee arthroplasty using parapatellar approach and postero-stabilized implants.
1661515|NCT01764971|Other|IQ assessment and visual- motor assessment|Psychological examination and evaluation for both groups to diagnose those with behavioral and /or cognitive dysfunction.
1661516|NCT01764971|Other|EEG,brain imaging|For patients with cognitive or behavioral deficit, MRI brain and quantitative EEG will be done to identify any CNS abnormality.
1661517|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
1661518|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
1661519|NCT01764945|Drug|BI 201335 (Test)|oral solution 3
1661520|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
1661521|NCT01764945|Drug|BI 201335 (Reference)|soft gelatine capsule, oral administration
1661522|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
1661523|NCT01764945|Drug|BI 201335 (Test)|oral solution 1
1661524|NCT01764945|Drug|BI 201335 (Test)|oral solution 2
1661525|NCT01764932|Procedure|Fluoroscopic imaging|Contrast media (5 mL) will be injected through the catheter and fluoroscopic images will be obtained and saved in the lateral and antero-posterior projections.
1661526|NCT01764919|Radiation|[124I]FIAU|A single intravenous injection of 5 mCi[124I]FIAU in patients with diabetic foot infection who will undergo 2 PET-CT scanning.
1661532|NCT01764867|Drug|Escitalopram|Recommended dosage range of escitalopram is 10-20mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
1661533|NCT01764867|Drug|Mirtazapine|Recommended dosage range of mirtazapine is 30-45mg per day. The duration will last up to 6-12 weeks until progression or unacceptable intolerability develops.
1661534|NCT01764867|Other|modified electroconvulsive therapy|Up to 6-10 sessions of mECT will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
1661535|NCT01764867|Other|repetitive transcranial magnetic stimulation|Up to 20 sessions of rTMS will be performed for selected participants who fails to remit to initial AGT intervention during 6 to 12-week period.
1661536|NCT01764867|Drug|Fluoxetine|Fluoxetine may be prescribed for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661537|NCT01764867|Drug|Citalopram|Citalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661538|NCT01764867|Drug|Escitalopram|Escitalopram may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661539|NCT01764867|Drug|Paroxetine|Paroxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661540|NCT01764867|Drug|Sertraline|Sertraline may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661541|NCT01764867|Drug|Fluvoxamine|Fluvoxamine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661542|NCT01764867|Drug|Venlafaxine|Venlafaxine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661543|NCT01764867|Drug|Duloxetine|Duloxetine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661544|NCT01764867|Drug|Mirtazapine|Mirtazapine may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661545|NCT01764867|Drug|Bupropion|Bupropion may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661546|NCT01764867|Drug|Trazodone|Trazodone may be used for participants who are randomly assigned to the Treatment As Usual (TAU) arm based on clinician's judgement.
1661547|NCT01764854|Drug|AZD1722|doses between 5 and 90 mg may be administered based on tolerability
1661548|NCT01764841|Drug|Ciprofloxacin DPI (BAYQ3939)|Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
1661549|NCT01764841|Drug|Placebo|Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
1661550|NCT01764828|Drug|Refametinib (BAY86-9766)|
1661551|NCT01764828|Drug|Gemcitabine|
1661552|NCT01764815|Device|directSTN Acute lead connected to external neurostimulator|Test phase will be performed intra-operatively, prior to chronic lead implant
1661553|NCT01764802|Other|behavioral, psychological or informational intervention|Participate in enhanced standard care
1661554|NCT01764802|Other|behavioral, psychological or informational intervention|Participate in psychological intervention
1661555|NCT01764789|Other|questionnaire administration|Ancillary studies
1661556|NCT01764789|Procedure|quality-of-life assessment|Patients will participate in a quality life assessment.
1661557|NCT01764789|Procedure|psychosocial assessment and care|Participate in multi-component biobehavioral intervention
1661558|NCT01764789|Behavioral|behavioral intervention|Participate in multi-component biobehavioral intervention
1661559|NCT01764789|Other|cognitive intervention|A multi-component intervention based on cognitive and behavioral principles will be used. It combines effective intervention strategies selected for their relevance to patients with recurrent cancer.
1661560|NCT01764789|Other|educational intervention|Participate in multi-component biobehavioral intervention
1661561|NCT01764776|Drug|LDE225|LDE225
1661562|NCT01764750|Drug|Intrasite Vancomycin|Intrasite Vancomycin is placement of lyophilized Vancomycin powder directly into the surgical site at the completion of surgery.
1661563|NCT01764750|Drug|IV Vancomycin|IV Vancomycin is the standard route for systemic antibiotic surgical site wound infection prophylaxis.
1661564|NCT01764737|Drug|VX15/2503|single dose intravenous administration
1661565|NCT01764737|Drug|Placebo|single dose intravenous administration
1661566|NCT01764724|Behavioral|Mock package questionnaire|Within a online questionnaire we exposed participants randomly to 4 mock packages differing only by the nutrition claim it carried and asked participants to answer several questions on attitudes and understanding after each mock package.
1661567|NCT01764711|Drug|Cosyntropin administration|After 30 minutes of rest in the seated position, participants will be given cosyntropin intravenously. Blood samples will be taken 30 minutes pre-drug administration, 30 minutes post and 60 minutes post drug administration.
1661606|NCT01764347|Procedure|magnetic resonance imaging|Undergo MRI-TRUS fusion image-guided prostate biopsy
1661880|NCT01762306|Drug|Diclofenac Potassium|
1661570|NCT01764685|Drug|Topiramate|Max therapeutic dose of 150mg/day
1661571|NCT01764685|Behavioral|Medical Management|Medical Management (MM; Pettinati, 2004) will support patients' efforts to reduce their drinking. The study nurse makes direct recommendations for reducing drinking to sensible levels. The first session will use the brochure A Guide to Sensible Drinking (WHO 1996). The patient is provided with information about pharmacotherapy and the importance of adherence to topiramate/placebo. Subsequent treatment sessions (15-25 minutes) will be conducted at each study visit, during which the nurse will perform an assessment of the patient's drinking, monitor his/her medication adherence, and make recommendations to follow until the next visit. Men will be advised to consume no more than 2 drinks/day and 8 drinks/week; women will be advised to consume no more than 1 drink/day and 4 drinks/week.
1661572|NCT01764685|Drug|Placebo|Placebo
1661573|NCT01764672|Drug|Methylphenidate|Oral dose 40mg (2 x 20mg)
1661574|NCT01764672|Other|Placebo|Oral intake of 2 placebo tablets
1661575|NCT01764646|Radiation|Intensity modulated radiation therapy|Minimize radiation doses to surrounding area
1661576|NCT01764646|Radiation|Volumetric modulated arc therapy|Highly conformational dose distribution
1661577|NCT01764646|Radiation|Image guided radiation therapy|Follow target by the use of fiducial markers and ERB
1661578|NCT01764633|Biological|Evolocumab (AMG 145)|Evolocumab (AMG 145)
1661579|NCT01764633|Other|Placebo|Placebo
1661580|NCT01764633|Drug|Effective statin therapy|Effective statin therapy defined as greater than or equal to atorvastatin 20 mg or an equivalent statin
1661581|NCT01764620|Other|Elastic taping applied with tension|
1661582|NCT01764620|Other|Elastic taping applied without tension|
1661583|NCT01764620|Other|Fatigue protocol|
1661584|NCT01764607|Drug|Sirolimus|Patients randomized to this arm of the study will receive sirolimus from the time of randomization at least until 5 weeks or the removal of the skin tumor. Nephrology will determine/manage the immunosuppressant therapy.
1661585|NCT01764594|Biological|CDP7657|"CDP7657 100 mg/ ml solution
30 mg/ kg initial dose
15 mg/ kg every other week
10 weeks"
1661586|NCT01764594|Other|Placebo|Placebo comparator
1661587|NCT01764581|Procedure|Tacrolimus regulation according to ImmuKnow values|Tacrolimus dose was reduced by 25% when ImmuKnow values were below 130 ng/mL ATP and increased by 25% when ImmuKnow values exceeded 450 ng/mL. Further reductions or increases were made after serial measures until ImmuKnow values stabilized between 130 and 450 ng/mL ATP. The values of 130 and 450 ng/mL ATP were previously documented as thresholds for risks of infection and rejection, respectively with a value of 280 ng/mL corresponding with the greatest negative predictive value for either event
1661588|NCT01764568|Behavioral|Metacognitive Training (MCT)|The metacognitive group training program that will form the basis of the 16 session MCT intervention has been described in previous research (Moritz & Woodward 2007a; Moritz & Woodward 2007b; Moritz 2011) and can be obtained online at no cost (www.uke.de/mkt). This experimental intervention will consist of two 8‐module cycles occurring twice a week for 8 weeks, for a total of 16 sessions. Each module will include a 45 to 60 minute instructor-led group session using PowerPoint slides and homework assignments to facilitate learning. Groups will consist of 4-10 subjects. Subjects will be able to attend the alternate (Cognitive Remediation) group after completion of the MCT group if they wish.
1661589|NCT01764568|Behavioral|Cognitive Remediation (CR)|The CR group will use a computerized cognitive remediation program that has been used with schizophrenia patients, Scientific Brain Training Pro (SBT Pro; Vianin et al, 2010). Modules focus on attention, working memory, verbal memory, and planning and reasoning. Each session will incorporate psycho-educational group discussion of strategies, and individual work through exercises on personal tablet computers and personalized level of difficulty. The CR treatment will take place twice per week for 8 weeks, for a total of 16 sessions. Groups will consist of 4-10 subjects. Subjects will be able to attend MCT after completion of CR if they wish.
1661590|NCT01764555|Drug|acetaminophen 2 g|
1661591|NCT01764542|Procedure|Endoscopy and biopsy|Endoscopy with biopsy of the ileo-anal pouch and the ileo-anal anastomosis Blood samples
1661592|NCT01764477|Drug|PRI-724|"Gemcitabine: 1000 mg/m2 IV over 30 minutes; once weekly dosing; 3 weeks on with 1 week recovery (4 weeks per cycle)
PRI-724:
Cohort 1: 320 mg/m2/day; Cohort 2: 640 mg/m2/day; Cohort 3: 905 mg/m2/day; Continuous IV over 24 hours; daily x 7 days; 1 week on with 1 week recovery × 2 (4 weeks per cycle)"
1661593|NCT01764464|Drug|Gralise®|14 day titration (days 1-7 at 600 mg daily Gralise®; days 8-14 at 1200 mg daily Gralise®). 28 day maintenance (1800 mg daily Gralise®). 7 day taper (days 1-4 at 1200 mg daily Gralise®; days 5-7 at 600 mg daily Gralise®).
1661594|NCT01764464|Drug|Placebo|14 day titration (days 1-7 at 600 mg daily placebo; days 8-14 at 1200 mg daily placebo). 28 day maintenance (1800 mg daily placebo). 7 day taper (days 1-4 at 1200 mg daily placebo; days 5-7 at 600 mg daily placebo).
1661595|NCT01764451|Drug|Simvastatin|
1661596|NCT01764438|Procedure|Primovist-enhanced MRI|Performance of Primovist-enhanced MRI in HCC patients with very early or early stage disease, but with no suspicious intrahepatic HCC lesions by liver dynamic CT.
1661597|NCT01764425|Drug|P7435|It is oral DGATI inhibitor with potential in dyslipidemia and T2DM
1661598|NCT01764399|Behavioral|Care4U|
1661599|NCT01764386|Drug|NB|Naltrexone SR 32 mg/Bupropion SR 360 mg (NB) in combination tablets (daily dosage)
1661600|NCT01764386|Behavioral|CLI|The Comprehensive Lifestyle Intervention (CLI) program includes telephone counseling, internet education, goal setting, and online tracking tools.
1661601|NCT01764386|Behavioral|Usual Care|Usual Care is a self-directed lifestyle intervention program
1661602|NCT01764373|Other|Aerobic Exercise|Aerobic exercises in the program include cycle ergometers, treadmills, recumbent steppers and elliptical trainers.
1661603|NCT01764360|Other|KS structured clinical care training|Eight primary care sites in Zimbabwe will receive structured training for diagnosis and treatment of Kaposi sarcoma (KS)
1661604|NCT01764347|Procedure|therapeutic conventional surgery|Undergo robotic radical prostatectomy
1661605|NCT01764347|Procedure|ultrasound-guided prostate biopsy|Undergo MRI-TRUS fusion image-guided prostate biopsy
1661607|NCT01764334|Device|Fractional flow reserve|"Guidewire-based coronary pressure measurement of myocardial FFR can identify obstructive coronary lesions in patients with stable coronary disease, and potentially, medically stabilized patients with recent MI. The FFR index is measured by a conventional coronary wire (0.014) with a pressure sensor on its distal tip during coronary hyperemia induced by intravenous or intracoronary adenosine. The potential diagnostic and prognostic benefit of guidewire-based coronary pressure measurement to inform the management and treatment of patients with recent acute NSTEMI will be assessed."
1661608|NCT01764308|Dietary Supplement|Omega-3|1200mg twice a day for 24 weeks
1661609|NCT01764308|Dietary Supplement|Placebo|4 tablets twice a day for 24 weeks
1661610|NCT01764295|Drug|DWJ1276|
1661611|NCT01764295|Drug|Olmesartan|
1661612|NCT01764295|Drug|Rosuvastatin|
1661613|NCT01764295|Drug|Placebo|
1661614|NCT01764282|Behavioral|comprehensive intervention components|ART promotion, Couple testing and consulting promotion, and Condom use promotion
1661615|NCT01764269|Other|text message surveillance for fever|
1661616|NCT01764256|Biological|P2-VP8 subunit rotavirus vaccine|3 doses of P2-VP8 subunit rotavirus vaccine given 4 weeks apart
1661617|NCT01764256|Other|placebo|3 doses of IM placebo given 4 weeks apart
1661618|NCT01764243|Drug|MT-4666|low dose, high dose
1661619|NCT01764243|Drug|Placebo|
1661620|NCT01764230|Drug|triptorelin|Throughout the course of chemotherapy, patients were administered triptorelin (Diphereline SR 3 mg, Ibsen) in the form of i.m. injections, always once a month and simultaneously with the chemotherapy.
1661621|NCT01764204|Drug|Qingkailing Injection|Qingkailing Injection is a kind of natural product injection made from Chinese herbs, which has been used to treat cerebral ischemia for decades in China. The main bioactive ingredients of this injection include Baicalin, Jasminoidin, Ursodeoxycholic Acid, Concha Margaritifera,etc.
1661622|NCT01764191|Other|18F-Fluorodeoxyglucose (18F-FDG) PET/CT|All subjects suspected of cardiac sarcoidosis will receive an intravenous dose of 18F-FDG (determined by weight, but not to exceed 521 MBq). Following an uptake phase of about 60 minutes, each subject will receive a PET/CT scan to evaluate the presence of cardiac sarcoidosis.
1661623|NCT01764178|Drug|Livalo fixed combination drug|Pitavastatin 4mg / Valsartan 160mg
1661624|NCT01764178|Drug|Pitavastatin, Valsartan|Pitavastatin 4mg, Valsartan 160mg
1661625|NCT01764165|Other|Oxygen|oxygen at a rate of 2 L/min will be delivered through a small nasal cannula throughout sleep.
1661626|NCT01764165|Other|High flow of room air|Warm and humidified air at rates of 20 L/min will be delivered through a small nasal cannula throughout sleep
1661627|NCT01764152|Other|nasopharyngeal sample|The nasopharyngeal sample will be used to find the types and subtypes of influenza virus and other respiratory viruses.
1661628|NCT01764139|Procedure|Blood sampling|
1661629|NCT01764126|Drug|Pneumococcal protein vaccine|One dose of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
1661630|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 10 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
1661631|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
1661632|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 25 µg of each of three proteins without adjuvant IM
1661633|NCT01764126|Drug|Pneumococcal protein vaccine|Three doses, 4 weeks apart, of 50 µg of each of three proteins with adjuvant (aluminium hydroxide) IM
1661634|NCT01764113|Behavioral|Mindful Eating|Subjects and their parents will receive mindful eating based behavioral modification program over multiple sessions
1661635|NCT01764113|Behavioral|Standard dietary counselling|
1661636|NCT01764100|Genetic|Mesenchymal stromal cells|Mesenchymal stromal cells (MSC) intravenous infusion at least two fixed doses of mesenchymal stem cells (1 ± 0.5 x 106/kg recipient body weight for each injection) with 5 to 7 days of interval one from the other, derived from HLA unrelated donor different from the HSC donor (third party donor).
1661637|NCT01764087|Drug|KX2-391 and Paclitaxel|"A treatment cycle in phase I will consist of 28 days, according to the following schedule:
KX2-391 20 mg PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.
The trial will initially test the combination of weekly paclitaxel and KX2-391 given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort, this intervention will be terminated
A treatment cycle in phase II will consist of 28 days, according to the following schedule:
KX2-391 MTD PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle."
1661638|NCT01764074|Behavioral|Brief Sleep Intervention|Participants will meet with a therapist for three sessions to try to improve sleep problems (hypersomnia or insomnia, depending on the problems the participant has).
1661639|NCT01764048|Drug|Fix protocol|Please see arm description
1661640|NCT01764048|Drug|medications following demand protocol|Please see arm description
1661641|NCT01764035|Behavioral|Body Scan (BS) Meditation Intervention|This intervention consists of 4 individual 60-minute sessions (week 1, 2, 4, and 6) in which participants learn the body scan meditation exercise and practice it at home, daily, lying in bed at their usual bedtime after going to bed (and when waking up at night, unable to go back to sleep). The Body-Scan meditation consists of a 30-minute exercise during which participants are guided to focus their attention on certain parts of their body (e.g. toes, feet). The core skill involves gradually adopting an observant, non-judgmental, and accepting stance towards bodily sensations, including feelings and thoughts.
1661642|NCT01764035|Behavioral|Brief Supportive Psychotherapy (SP)|SP is a common form of non-specific psychotherapy available to patients with bipolar disorder in the community. It focuses on addressing a patient's current concerns, supporting a patient's adaptive coping skills, improving self-esteem, and expressing feelings and the therapeutic alliance. Using a conversational style, SP involves conveying empathy, validation, comforting and supporting patients in coping with distress about current life issues as well as providing encouragement and praise, clarification and opportunity to vent. SP will match BS in length, number of sessions and delivery schedule (four, 60-minute sessions, week 1, 2, 4, 6).
1661763|NCT01763151|Procedure|IOL combined with opposite clear corneal incision (OCCI)|aspherical, acrylic IOL with opposite clear corneal incision during cataract surgery
1661881|NCT01762306|Drug|Folic Acid|
1661643|NCT01764022|Drug|Trastuzumab|Patients will receive 6 courses of trastuzumab in combination with paclitaxel. Trastuzumab will be administered at a loading dose of 8 mg/kg (once), followed by maintenance dose of 6 mg/kg every 3 weeks (5 administrations) as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
1661644|NCT01764022|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 every 3 weeks (on Day 1 of each course) as 3 hour intravenous infusion (6 courses totally).
1661645|NCT01764009|Biological|naked DNA coding for protein AMEP|injections 28days interval of 3 increasing doses of plasmid with electrotransfer
1661646|NCT01763996|Drug|Febuxostat|Febuxostat capsules
1661647|NCT01763996|Drug|Febuxostat placebo|Febuxostat placebo-matching capsules
1661648|NCT01763983|Behavioral|Cognitive Behavioural Therapy|"CBT will be delivered individually, 1 hour per week, for 12 consecutive weeks. CBT for stress in MS is a structured, short-term, present-oriented therapy with an emphasis on problem-solving and the modification of dysfunctional thinking and behaving. Cognitive strategies include the use of dysfunctional thought records for recording and challenging negative automatic thoughts and the use of behavioural strategies to increase involvement and commitment to personal goals.
Group therapy following a similar protocol (2 hrs/week) will be offered to those in the waitlist condition after completing the study."
1661649|NCT01763983|Behavioral|Aerobic Exercise|Aerobic exercise will occur three times per week at participating gyms. Duration of the exercise periods will be 15-30 minutes for the first 4 weeks (training stage) and 30-45 minutes for the remaining 8 weeks (improvement stage). The exercise regimen will progress from light-moderate exercise (40-60% intensity) to moderate-high exercise (60-80% intensity), following the same course as the increase in duration.
1661650|NCT01763970|Radiation|SBRT|800 delivered in 5 fractions every day to total dose of 4000
1661651|NCT01763957|Behavioral|Paula Method|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list.
1661652|NCT01763957|Behavioral|Pelvic Floor Muscle Training (PFMT)|All subjects allocated to this group will receive one group lesson, 45 minute sessions once a week for twelve weeks. All will be encouraged to practice daily for 15-45 minutes at home. The teachers will be followed a set exercise list .
1661653|NCT01763944|Behavioral|Low carbohydrate diet|The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
1661654|NCT01763931|Drug|Digoxin|Digoxin once daily for 2 weeks prior to definitive breast surgery.
1661655|NCT01763918|Biological|Evolocumab|Administered by subcutaneous injection
1661656|NCT01763918|Drug|Placebo|Administered by subcutaneous injection
1661657|NCT01763905|Biological|Evolocumab|Subcutaneous injection
1661658|NCT01763905|Drug|Placebo to Evolocumab|Subcutaneous injection
1661659|NCT01763905|Drug|Ezetimibe|Tablet for oral administration
1661660|NCT01763905|Drug|Placebo to Ezetimibe|Tablet for oral administration
1661661|NCT01763879|Other|The PCV-VCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
1661662|NCT01763879|Other|The VCV-PCV group|During the PCV period, the inspiratory pressure will be adjusted to deliver a TV of 6 mL/kg (predicted body weight) to the patient's dependent lung. During the VCV period, the patient's dependent lung will be ventilated with a TV of 6 mL/kg (PBW). Whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
1661663|NCT01763866|Biological|Evolocumab|Administered by subcutaneous injection
1661664|NCT01763866|Drug|Ezetimibe|Administered orally once a day
1661665|NCT01763866|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
1661666|NCT01763866|Drug|Placebo to Ezetimibe|Administered orally once a day
1661667|NCT01763866|Drug|Atorvastatin|Administered orally once a day
1661668|NCT01763866|Drug|Rosuvastatin|Administered orally once a day
1661669|NCT01763866|Drug|Simvastatin|Administered orally once a day
1661670|NCT01763853|Drug|4% albumin|
1661671|NCT01763840|Drug|Contrast enhanced Ultrasound|Ultrasound, then contrast enhanced ultrasound.
1661672|NCT01763827|Biological|Evolocumab|Administered by subcutaneous injection
1661673|NCT01763827|Drug|Ezetimibe|Administered orally once a day
1661674|NCT01763827|Biological|Placebo to Evolocumab|Administered by subcutaneous injection
1661675|NCT01763827|Other|Placebo to Ezetimibe|Administered orally once daily
1661676|NCT01763814|Procedure|Femoral nerve block|A visible or palpable cephalad movement of the patella will confirm needle placement.
1661677|NCT01763814|Procedure|Femoral nerve block non stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered off.
1661678|NCT01763814|Procedure|Femoral nerve block stimulating catheter|A visible or palpable cephalad movement of the patella will confirm needle placement. The catheter will be placed with the nerve stimulator powered on.
1661679|NCT01763801|Device|P-Max|tip placement in correspondence to the P-Max on the ECG
1661680|NCT01763801|Device|P-Submax|tip placement in correspondence to the P-Submax on the ECG
1661681|NCT01763788|Drug|Necitumumab|Administered IV
1661682|NCT01763788|Drug|Gemcitabine|Administered IV
1661683|NCT01763788|Drug|Cisplatin|Administered IV
1661684|NCT01763775|Device|Transtek 125X|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 125X (GBF-1251-B, BF-1255-B, BF-1256-B, GBF-1257-B).
1661685|NCT01763775|Device|Transtek 950D|Measuring weight, total body water, body fat, muscle mass, and bone mass. Measure each participants by Transtek 950D (GBF-950-D).
1661882|NCT01762293|Drug|Famitinib|Famitinib 25 mg p.o. qd
1661686|NCT01763762|Behavioral|Electrical pudendal nerve stimulation|Four sacral points are selected. The two upper points are located about 1 cm bilateral to the sacrococcygeal joint. On the upper points, a needle of 0.40 Х 100 mm is inserted perpendicularly to a depth of 80 to 90 mm to produce a sensation referred to the urethra or the anus. The locations of the two lower points are about 1 cm bilateral to the tip of the coccyx. On the lower points, a needle of 0.40 Х 100 or 125 mm is inserted obliquely towards the ischiorectal fossa to a depth of 90 to 110 mm to produce a sensation referred to the urethra. After the sensation referred to the above regions is produced, each of two pairs of electrodes from a G6805-2 Multi-Purpose Health Device is connected with the two ipsilaterally inserted needles.
1661687|NCT01763762|Behavioral|PFM training|A nerve function reconstruction treatment system (AM1000B; Shenzhen Creative Industry Co.Ltd, China) is used for EMG-biofeedback assisted PFMT.
1661688|NCT01763762|Behavioral|Transvaginal ES|A neuromuscular stimulation therapy system (PHENIX USB 4，Electronic Concept Lignon Innovation, France) is used for TES
1661689|NCT01763749|Drug|Closone|Closone 75mg/100mg, 4weeks, PO
1661690|NCT01763749|Drug|Plavix with Astrix|Plavix 75mg with Astrix 100mg, 4weeks, PO
1661691|NCT01763736|Behavioral|Music|playlist per patient preference
1661692|NCT01763723|Device|IPL-home use device|A light based home use device for hair removal
1661693|NCT01763710|Drug|Paclitaxel 80 mg/m2|Paclitaxel 80 mg/m2 days 1, 8 and 15
1661694|NCT01763710|Drug|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15|Nab-paclitaxel 100 mg/m2 days 1, 8 and 15
1661695|NCT01763710|Drug|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15|Nab-paclitaxel 150 mg/m2 days 1, 8 and 15
1661696|NCT01763710|Drug|Nab-paclitaxel 150 mg/m2 days 1 and 15|Nab-paclitaxel 150 mg/m2 days 1 and 15
1661697|NCT01763697|Behavioral|taste acuity assessment|Quantitative measurement of for tasting detection and recognition thresholds, magnitude of perception and hedonic response.
1661698|NCT01763697|Behavioral|Recorded meal|
1661699|NCT01763684|Device|Signature Custom Guides|Signature Custom Guides: Signature Custom Guides are intended to be used as a surgical instrument to assist in the positioning of knee replacement components intraoperatively and in guiding the marking of bone before cutting provided that anatomic landmarks necessary for alignment and positioning of the implant are identifiable on patient imaging scans (preoperative MRI).
1661700|NCT01763684|Procedure|Conventional Instrumentation|Traditional partial knee arthroplasty without the use of Signature technology.
1661701|NCT01763671|Drug|Docetaxel|75 mg/m² IV on day one of 21 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
1661702|NCT01763671|Drug|Paclitaxel|90 mg/m² IV on day 1, 8 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
1661703|NCT01763671|Drug|Bevacizumab|10 mg/kg IV on day 1 and 15 of 28 days cycle Number of Cycles: until progression or unacceptable toxicity develops.
1661704|NCT01763658|Drug|Antox tablets(Mepaco)|effect of antioxidant on disease outcome
1661705|NCT01763658|Other|drug therapy for ITP|drugs will be selected according to ASH,2011 guidelines
1661706|NCT01763645|Drug|Bevacizumab|Patients will receive 6 courses of bevacizumab in combination with carboplatin and paclitaxel. Bevacizumab will be administered at a dose of 15 mg/kg as 90 min intravenous infusion every 3 weeks (on Day 1 of each cycle).
1661707|NCT01763645|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 mg/m2 as 3 hour intravenous infusion on Day 1 of each 3-week course (6 courses totally)
1661708|NCT01763645|Drug|Carboplatin|Carboplatin will be administered (AUC 6 mg/ml×min) as 15 - 30 min intravenous infusion just after paclitaxel on Day 1 of each 3-week course (6 courses totally).
1661709|NCT01763632|Device|Transcutaneous bilirubinometry|Device: JM-103 (Minolta, Osaka, Japan, jaundice assessment) Procedure: Transcutaneous bilirubinometry (TcB)
1661710|NCT01763619|Device|Freedom Cervical Disc|
1661711|NCT01763606|Drug|Enoxaparin|Patients will be receive 6 months of subcutaneous enoxaparin (1 mg/kg BID with a maximum starting dose of 100 mg BID. Patients who weigh more than 100 kg will start at a dose of 100 mg BID; their subsequent dosing will be guided by hematology and may change.
1661712|NCT01763606|Drug|Aspirin|Patients will receive 6 months of oral aspirin (81 mg per day unless a higher dose is preferred by study physicians although the maximum acceptable dose will be 325 mg per day).
1661713|NCT01763580|Drug|Tacrolimus|Oral
1661714|NCT01763580|Drug|Prednisolone|Oral
1661715|NCT01763554|Drug|Lu-177 DOTA-TATE|Radiopharmaceutical solution for IV injection containing DOTA-TATE labeled with Lutetium-177. Standard dose is 5.5 GBq given as a single injection once every 8 to 12 weeks for 4 doses, followed by maintenance doses of 5.5 GBq every 6 months.
1661718|NCT01763528|Other|nutrition intervention|high protein diet
1661719|NCT01763515|Procedure|Laterally wedged insoles|Patients will use laterally wedged insoles with 5o tilt toward medial side and made of ethylene vinyl acetate coated with leather. The medial thickness is 4 mm with lateral thickness of 10 mm.
1661720|NCT01763502|Other|FOOD|The food transfers consist of multiple-micronutrient-fortified corn soy blend (CSB), oil, and sugar, totaling approximately 1200 calories per day per child and including 99% of iron requirements.
1661721|NCT01763502|Other|CASH|Cash transfers equal the estimated value of the food basket if purchased in the market.
1661722|NCT01763489|Behavioral|Applicability Assessment|assess the applicability of a trial using the ASSIST tool or the synopsis
1661723|NCT01763476|Procedure|paclitaxel-coated balloon angioplasty|plain balloon angioplasty followed by paclitaxel-coated balloon angioplasty of the target lesion
1661724|NCT01763476|Procedure|atherectomy|atherectomy (TurboHawk, ev3) followed by paclitaxel-coated balloon angioplasty of the target lesion
1661725|NCT01763463|Drug|New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications|Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
1719645|NCT00002839|Drug|fluorouracil|
1661726|NCT01763463|Drug|New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))|Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
1661727|NCT01763450|Drug|bevacizumab plus chemotherapy|"Bevacizumab:
7.5mg/kg, iv, on day 1 of each 21 day cycle or 5mg/kg, iv, on day 1 of each 14 day cycle;
Oxaliplatin+capecitabine(XELOX):( The total dose not less than 70% of the recommended dose of this standard) Oxaliplatin: 130mg/m2,d1; capecitabine: 850-1,000mg/m2，d1-d14, bid，each 21 day cycle;
Oxaliplatin+5-Fluorouracil+ Levomisole（FOLFOX）:
Oxaliplatin: 85mg/m2,iv for 2 hours ,d1; Levomisole（LV）: 400mg/m2,iv for 2 hours,d1; 5-Fluorouracil（5-FU） :400mg/m2 iv,d1,then 1200mg/m2/d ×2d continuous intravenous infusion(volume dose:2400mg/m2,iv for 46-48 hours ) each 14 day cycle;"
1661728|NCT01763437|Drug|Tetracycline|Chalazia randomized to the treatment arm will be injected with 0.05 mL of 2% tetracycline solution.
1661729|NCT01763424|Drug|Calcipotriol plus Nicotinamide|Patients applied calcipotriol 0.005% and nicotinamide 4% in combination (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of one side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
1661730|NCT01763424|Drug|Calcipotriol|Patients applied calcipotriol 0.005% (By LEO Pharmaceuticals, Ballerup, Denmark) for lesions of the other side of the body. The patients uses the medications twice daily (in the morning and before sleeping) for 12 weeks; the total doses of medication used not more than 100 gram per week.
1661731|NCT01763385|Drug|Erlotinib|
1661732|NCT01763385|Radiation|concurrent brain radiotherapy|
1661733|NCT01763385|Radiation|secondary brain radiotherapy|
1661734|NCT01763346|Drug|Metformin|metformin 1000 mg bid
1661735|NCT01763346|Device|gastric banding|LAP-BAND
1661736|NCT01763333|Drug|BI 1026706 Placebo|Placebo to BI 1026706
1661737|NCT01763333|Drug|BI 1026706|different dose formulations
1661738|NCT01763333|Drug|BI 1026706|single dose (low to high dose)
1661739|NCT01763320|Procedure|Intracranial stenting group|all the participants in this group will be performed with intracranial stenting
1661740|NCT01763320|Drug|medical group|all the participants in this group will be given medical therapy including aspirin 100mg + clopidogrel 75mg per day for 90 consecutive days and clopidogrel 75mg per day thereafter
1661741|NCT01763307|Drug|RECONVAL CREAM|
1661742|NCT01763307|Drug|PLACEBO|
1661743|NCT01763294|Device|Nicolet Endeavor CR: 30min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
1661744|NCT01763294|Device|Nicolet Endeavor CR: 60min|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
1661745|NCT01763294|Device|Nicolet Endeavor CR: 30min for 3 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
1661746|NCT01763294|Device|Nicolet Endeavor CR: 30min for 5 days|Transcranial direct current stimulation (tDCS) is a safe, non-invasive method that modulates cortical excitability. In direct current polarization, the cerebral cortex is stimulated through a weak constant electric current in a noninvasive and painless manner. This weak current induces focal changes of cortical excitability increase or decrease depending on the electrode polarity- that last beyond the period of stimulation.
1661747|NCT01763294|Device|Nicolet Endeavor CR: Placebo|The same procedures just that in this case the machine produces only a 60 second stimulus at the beginning so the patient can feel the initial electric stimulus.
1661748|NCT01763281|Drug|CRH|
1661749|NCT01763281|Drug|Placebo|
1661750|NCT01763268|Biological|Trivivac vaccine|Trivalent MMR vaccine
1661751|NCT01763255|Biological|stem cell intrathecal injection|Intrathecal injection of Bone marrow derived CD133 cells
1661752|NCT01763242|Other|EMAN|See details on ESA Synchronization and Dosing in Detailed Description Above
1661753|NCT01763229|Procedure|transthoracic echocardiography|
1661754|NCT01763216|Other|Road Tour|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
1661755|NCT01763216|Other|Boatload of Crosswords|Training dosage includes 10 hours at baseline, four hours of booster training at month five, and four hours of booster training at month 11.
1661756|NCT01763203|Behavioral|Care Management+Community Health Worker|Over a period of a year subjects randomized into the Intervention arm of the study will receive support from a Care Manager. Subjects will also participate in educational group sessions on chronic disease self-management and have home visits by a Community Health Worker who will use mobile health technology.
1661757|NCT01763203|Behavioral|Usual Care|Subjects randomized into the Usual Care arm will receive educational materials about stroke distributed to the Intervention patients and will receive their post-stroke care as usual.
1661758|NCT01763190|Drug|SAR302503|"Pharmaceutical form:capsule
Route of administration: oral"
1661759|NCT01763177|Other|Oxygen|Oxygen mask 40% 8 LPM for 30 minutes
1661760|NCT01763164|Drug|MEK162|MEK162 will be administered as a fixed dose of 45 mg (3 x 15 mg tablets) BID, with a glass of water and taken with or without food.
1661761|NCT01763164|Drug|Dacarbazine|Patients randomized to dacarbazine will receive an IV infusion of dacarbazine 1000 mg/m2 over the course of 1 hour on day 1 and then every three weeks.
1661762|NCT01763151|Device|toric IOL|implantation of an aspheric, toric, acrylic IOL during cataract surgery
1661764|NCT01763138|Behavioral|oral health education|oral health education in the form of a pictorial pamphlet.
1661765|NCT01763138|Behavioral|reminder phone call|a reminder phone call on oral health instructions would be given to mothers after every one month over a period of three months.
1661766|NCT01763125|Other|Blood collection|Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.
1661767|NCT01763112|Device|Exercise Group Galileo PAH|The intervention/exercise group will do whole body vibration training on 4 days a week for 60 minutes over 4 weeks
1661768|NCT01763099|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter(at a dose of 1×10^6 cells/kg, over 15 min) in day 1 and day 15 of the cycle. If the NEU and PLT levels do not attain the completely response(CR)standards after this cycle, mesenchymal stem cells combined with cord blood will be given. If the NEU and PLT levels attain the completely response(CR)or partly response(PR) standards after this cycle, another cycle with the same strategy will be given.
1661769|NCT01763099|Biological|Mesenchymal stem cells and cord blood|Mesenchymal stem cells will be given (at a dose of 1×10^6 cells/kg,intravenously infused via a central venous catheter)on day 1.day 15, day 29 and day 43 of the cycle. Cord blood will be given intravenously infused via a central venous catheter on day 2 of the cycle.
1661770|NCT01763086|Biological|Mesenchymal stem cells|Mesenchymal stem cells will be intravenously infused via a central venous catheter,at a dose of 1×10^6 cells/kg, over 15 min. The vital signs of all patients will be closely monitored during and for 24h after MSCs administration. If the NEU and PLT levels do not attain the completely response(CR)standards within 14d, a second course of MSCs treatment will be given.
1661771|NCT01763060|Radiation|CT scan|
1661772|NCT01763060|Behavioral|Cognitive function|
1661773|NCT01763060|Radiation|MRI|
1661774|NCT01763047|Device|etafilcon A|To be worn in a daily wear modality for a minimum of 6 hours per day.
1661775|NCT01763047|Device|lotrafilcon B|Lenses will be worn in a reuseable modality; cleaned and disinfected each night.
1661776|NCT01763034|Procedure|limb ischemic preconditioning|use a simple blood pressure cuff inflate for 5 minutes and deflate for 5 minutes alternately in each arms total = 3 cycle in each arm
1661777|NCT01763021|Drug|PCI-32765|PCI-32765 will be administered as a single oral dose of PCI-32765 560 mg on Day 1 and Day 11
1661778|NCT01763021|Drug|Rifampin|Rifampin 600 mg (2 X 300 mg) daily dose will be administered orally from Day 4 to Day 13 and on Day 11 along with PCI-32765.
1661779|NCT01763008|Drug|No intervention|This is an observational study. Doripenem will be administered as per the recommended dose, ie, 500 mg, intravenously (ie, in the vein), for every 8 hours. Duration of treatment with doripenem: for nosocomial pneumonia including ventilator-associated pneumonia patients: 7 to 14 days; for complicated intra-abdominal infection patients: 5 to 14 days; for complicated urinary tract infection, including pyelonephritis (bacterial infection of the kidneys) patients: 10 days.
1661780|NCT01762995|Drug|Dolutegravir 50 mg|One tablet ( 50 mg) will be administered orally as a single dose in each period per the random code
1661781|NCT01762995|Drug|Calcium Carbonate 1200 mg|Two tablets (2 X 600 mg) will be administered orally as a single dose in three out of four periods to Cohort 1 only per the random code. Calcium carbonate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
1661782|NCT01762995|Drug|Ferrous Fumarate 324 mg|One tablet (324 mg) will be administered orally as a single dose in three out of four periods to Cohort 2 only per the random code. Ferrous fumarate will be given in fasted state, fed state and 2 hours before dolutegravir administration.
1661783|NCT01762982|Drug|0.13% Benzalkonium Chloride|Finn Chamber filled with benzalkonium chloride (0.13%) disinfectant spray water solution
1661784|NCT01762982|Drug|SLS Solution|Finn Chamber filled with SLS (0.3% w/v) water solution
1661785|NCT01762982|Drug|Normal Saline Water|Finn Chamber filled with Normal Saline water (0.9% w/v)
1661786|NCT01762982|Other|Empty Finn Chamber|Empty Finn Chamber
1661787|NCT01762969|Other|Treatment modification based on molecular response at 3 months|Patients will be treated with imatinib upon diagnosis of CML. Molecular response will be assessed at 3 months of therapy. Based on molecular response imatinib will be continued or changed to another TKI
1661788|NCT01762956|Other|Pelvic floor muscles training|The supervised muscle training will be conducted once a week with 45 minutes each session during the RT (12 weeks). In addition to the supervised sessions, patients will be instructed about the practice of home exercises and receive a guidance booklet of exercises with explanations of each exercise to be performed. These exercises must be performed daily and should be written down in the worksheet when they are performed. After this 3 month period, the patients will be encouraged to continue the exercise protocol at home without supervision. They must attend monthly to monitor adherence to home exercises.
1661793|NCT01762904|Other|Bacterial culture of the prepared skin's areas with two antiseptics and two controls|Cultures will be taken with a scrub-cup of 5 cm2 of internal area pressed over the skin previously prepared with the substances, then it added a 3 mL of culture broth (D/E Neutralizing Broth, Difco TM) containing a neutralizing agent as washing solution. The skin will scrub with a sterile rubber policeman for 1 minute and the procedure will be conducted once again. Both aliquots will gather together in a sterile tube, and a sample of 50 microliters will spread in a plate containing a neutralizing agar (D/E neutralizing Agar, Difco TM) and incubate at 35°C for 24 hrs. After incubation, the colonies will be counted.
1719733|NCT00002868|Drug|hydroxyurea|
1661794|NCT01762904|Other|Preparing skin's areas to be tested with two antiseptics and two controls|All volunteers will be provided with a neutral soap and shampoo without antiseptics for use during a period of two weeks (phase of stabilization of the skin flora). Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 1% triclosan in 70% isopropyl alcohol) and two controls (Scrub the skin without prior application of any substance and Deionized water redistilled) will be tested as skin antiseptics. The intervention consists of preparing four skin's areas with antiseptics and controls, two in each arm of the volunteer. These ones were approximately 25 cm2 on the forearm for each antiseptic or control. The substances will be applied in an outward circular motion using a sterile swab soaked with the solutions. The solution will remain on the skin for 60 seconds, 3 hours and 24 hours before the bacterial culture will be conducted. For the control where it will be does not apply any substance, the scrub starts immediately.
1661795|NCT01762891|Drug|Celecoxib|celecoxib 200mg/day by oral rout during 15 days followed by the administration of rofecoxib 25mg/day, acetaminophen 3g/day and placebo during 15 days each drug.
1661796|NCT01762891|Drug|Acetaminophen|Acetaminophen 3g/ was given during 15 days by oral rout following one of the other interventions or as the final intervention.
1661797|NCT01762891|Drug|Rofecoxib|Rofecoxib 25mg/day was given by oral rout during 15 days following one or more interventions or as the final intervention.
1661798|NCT01762891|Drug|placebo|Placebo pills were given during 15 days by oral rout as one of the four interventions.
1661799|NCT01762878|Drug|GSK2269557|Dry powder for oral inhalation (100 and 500 mcg /blister) once daily using DIKUS device. The doses of GSK2269557 planned for Part A are: 100 mcg, 500 mcg and 3000 mcg
1661800|NCT01762878|Drug|Placebo|Dry powder for oral inhalation once daily using DIKUS device
1661801|NCT01762852|Drug|Belimumab 10 mg|Belimumab is Lyophilised powder for reconstitution in 4.8 mL sterile water for injection (SWFI) and diluted in normal saline (250 mL). 400 mg per vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate). Belimumab 10 mg/kg intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
1661802|NCT01762852|Drug|Placebo|Normal saline solution (sodium chloride 154 mmol/L). Intravenous infusion (will last for 1 hr) on Day 0, Week 2, Week 4, then every 4 weeks for up to 100 weeks
1661806|NCT01762826|Dietary Supplement|Myo-inositol|Dietary control plus Myo-inositol
1661807|NCT01762826|Dietary Supplement|D-chiro-inositol|Dietary control plus D-Chiro-Inositol supplementation
1661808|NCT01762826|Dietary Supplement|D-Chiro / Myo-inositol|Dietary control Supplementation with myo and d-chiro inositol
1661809|NCT01762826|Dietary Supplement|Placebo|Dietary control plus folic acid 400 mcg daily
1661810|NCT01762813|Procedure|open and laparoscopic surgery|Curative surgery for either primary (colorectal cancer, crc) or metastatic CRC (liver surgery)
1661811|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg|Active, 50/250mcg, Twice daily (morning and evening)
1661812|NCT01762800|Drug|fluticasone propionate/salmeterol placebo|Placebo, Twice daily (morning and evening)
1661813|NCT01762800|Drug|tiotropium bromide 18mcg|Active, 18mcg, Once daily(morning)
1661814|NCT01762800|Drug|tiotropium bromide placebo|Placebo, Once daily(morning)
1661815|NCT01762800|Drug|fluticasone propionate/salmeterol 50/250mcg and tiotropium 18mcg|Active. The randomized treatment may be switched to TRIPLE therapy when COPD symptoms are uncontrolled or the subject is not satisfied with the randomized treatment at each scheduled or unscheduled visit.
1661816|NCT01762787|Drug|Cantharidin solution|5 microlitres of 0.025 to 0.5% topically on Day 1, 2 and 3
1661817|NCT01762787|Drug|Aspirin|300mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
1661818|NCT01762787|Drug|Prednisolone|30mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
1661819|NCT01762787|Drug|Placebo to aspirin|0mg three times daily orally over a course of 4 days (starting Day -3) Part 2 only
1661820|NCT01762787|Drug|Placebo to prednisolone|0mg orally once a day over a course of 4 days (starting Day -3) Part 2 only
1661821|NCT01762774|Drug|GSK2256294|GSK2256294 capsules will be administered as once daily as single dose 2 mg, 6 mg, 15 mg in Cohort 1 and 15 mg, 40 mg, 100 mg in Cohort 2. GSK2256294 capsules will be administered once or twice daily (cohorts 3 and 4) at the dose determined from the data from Cohort 1 and 2. GSK2256294 capsules will be available in 1, 5, 25 mg dose strength.
1661822|NCT01762774|Drug|Placebo|Matching placebo will be administered once daily (cohorts 1 and 2); and once or twice daily (cohorts 3 and 4).
1661823|NCT01762761|Drug|eltrombopag|TPO-R agonist
1661824|NCT01762761|Drug|placebo|placebo
1661825|NCT01762748|Drug|Saccharomyces boulardii|Oral capsule with 200 mg lyophilized S. boulardii-17 (about 4x108 cells), 6 mg sucrose and 2.4 mg magnesium stearate (Floratil®).
1661826|NCT01762735|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum.
1661827|NCT01762735|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum.
1661828|NCT01762722|Device|Reduction of inspired oxygen|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
1661829|NCT01762709|Procedure|The VT 4 ml/kg group|the dependent lung will be ventilated with a TV of 4 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
1661877|NCT01762332|Other|chronic beta-blocker treatment|Patients from the chronic beta-blocker treatment group will not be randomized, and will all be allocated to the high opioid level group.
1661830|NCT01762709|Procedure|The VT 6 ml/kg group|the dependent lung will be ventilated with a TV of 6 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
1661831|NCT01762709|Procedure|The VT 8 ml/kg group|the dependent lung will be ventilated with a TV of 8 mL/kg (predicted body weight), respectively, whereas FiO2, I: E ratio, PEEP, frequency, Ppk, and a FGF will be maintained as during two-lung ventilation (TLV) and the lumen of the nondependent lung will be left open to air. Dependent lung recruitment maneuvers will be repeated at 30-minute intervals by raising the inspiratory pressure up to 35 cmH2O for 10 seconds.
1661832|NCT01762696|Behavioral|MET|Motivational Enhancement Therapy only
1661833|NCT01762696|Behavioral|MOMENT|The full MOMENT intervention: Motivational Enhancement Therapy + momentary and daily mobile self-monitoring + motivational feedback messages prompting participants to consider their individualized coping strategies to avoid using marijuana
1661834|NCT01762683|Other|Myometrium biopsy and blood samples|"The biopsy of myometrium is specially realised for the study in surgical unit after the release of the child, in women with normal pregnancy but necessitating a caesarean.
The blood samples are realised, specially for the study, either during the medical exam before the ceasarean or specifically for the study."
1661835|NCT01762670|Drug|GoldenCare|Copper intravaginal device to treat bacterial vaginosis.
1661836|NCT01762670|Drug|Metronidazole|500 mg twice daily for 7 days
1661837|NCT01762657|Drug|Oral Cyclosporine and Oral Lansoprazole|Oral Cyclosporine A dosed at 7.5 mg/kg/day and Oral Lansoprazole dosed at 30 mg in two divided dosages to subjects ages 8-15 and 60 60 mg in divided dosages to subjects ages 16-60. The Cyclosporine A and Lansoprazole may be given as an oral tablet/capsule or oral suspension.
1661838|NCT01762657|Drug|Placebos|Two oral placebos are given at breakfast and dinner. The placebos may be given as an oral tablets/capsules or oral suspensions.
1661839|NCT01762644|Drug|Oral Cyclosporine and Oral Omeprazole|
1661840|NCT01762644|Drug|Oral Omeprazole|
1661841|NCT01762618|Behavioral|Cognitive Behavioral Therapy Group|Therapy Groups
1661842|NCT01762605|Other|Supportive Care|
1661843|NCT01762605|Procedure|Cast|
1661844|NCT01762592|Drug|Iodine (124I) Girentuximab|
1661847|NCT01762566|Dietary Supplement|wheat|wheat is administered blindly versus placebo in capsules once
1661848|NCT01762566|Dietary Supplement|xylose|placebo (xylose) will be administered blindly versus wheat in a capsule once
1661849|NCT01762553|Behavioral|The TEA intervention|TEA Gathering is a small group training session for PLH and their family members to deal with HIV-related challenges at individual level; TEA Time is home based family activities for PLHs and their family members to interact with their children after each TEA Gathering to promote family positive interaction; TEA Garden is the community events that built social integration for HIV affected families to live a healthy social life and to build sustained, supportive relationships in their communities. There will be reunions once a month for 12 months after the completion of the TEA intervention.
1661850|NCT01762540|Drug|Glucocorticoids|Prednisolone 37.5 mg x1 for 5 days
1661851|NCT01762540|Drug|Calcium Supplement|Placebo
1661852|NCT01762527|Radiation|Adaptive Radiotherapy|CTCAE scoring baseline, every 2'nd week during RT, 2 weeks, 3, 12 and 24 month after RT cineMR (time resolved MR) baseline and weekly during RT for intra fractional motion
1661853|NCT01762514|Drug|Amifostine every-other-day regimen|Amifostine 400mg/d, every-other-day regimen from Monday to Friday, every week repetition during radiotherapy
1661854|NCT01762514|Drug|Amifostine everyday regimen|Amifostine 400mg/d, everyday regimen from Monday to Friday, every week repetition during radiotherapy
1661855|NCT01762501|Drug|Azilsartan|Azilsartan 20mg/day
1661856|NCT01762501|Drug|Amlodipine|Amlodipine 5mg/day
1661857|NCT01762488|Procedure|Ablation of the renal arteries|Catheter-based renal denervation by applying low power radiofrequency to the renal artery using the EnligHTN Catheter, introduced by femoral artery access.
1661858|NCT01762488|Procedure|Renal angiography|Renal angiography by femoral access
1661859|NCT01762475|Drug|Sildenafil|
1661860|NCT01762462|Drug|SAR302503|"Pharmaceutical form:capsule
Route of administration: oral"
1661861|NCT01762449|Other|Followup survey|
1661862|NCT01762436|Drug|bisoprolol|
1661863|NCT01762436|Drug|atenolol|
1661864|NCT01762423|Device|Active Device (IVIVI SofPulse)|
1661865|NCT01762423|Device|Sham Device|
1661866|NCT01762410|Drug|P7170|Patients will receive study drug on a daily basis for twenty-one days according to the dose and schedule specified for a particular cohort of therapy. This 21 day administration will define a treatment cycle. Patients may receive consecutive treatment cycles until evidence of disease progression, intolerance of therapy, death or withdrawal from the protocol as specified.
1661867|NCT01762397|Drug|PMK-S005|
1661868|NCT01762384|Procedure|LSC|subjects of this group are submitted to surgical treatment of laparoscopic sacral colpopexy.
1661869|NCT01762384|Procedure|modified PFRS|subjects of this group are submitted to modified pelvic floor reconstructive surgery with mesh.
1661870|NCT01762384|Device|"Gynemesh"|Both surgeries will be conducted using mesh constructed from polypropylene mesh.
1661871|NCT01762371|Other|Khalifa Therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin.
1661872|NCT01762358|Other|Khalifa's therapy|One hour of Khalifa's therapy which is specially applied pressure to the skin
1661873|NCT01762358|Other|Physiotherapy|Twelve times standardized Physiotherapy
1661874|NCT01762345|Device|pessary (disposable intra-vaginal device)|pessary device(disposable intra-vaginal device)manufactured by Procter & Gamble
1661875|NCT01762332|Drug|Base level of remifentanil effect side concentration: 2ng/ml|constant remifentanil level of 2ng/ml administered using Target Control Infusion pumps.
1661876|NCT01762332|Drug|Base level of remifentanil effect side concentration: 4ng/ml|constant remifentanil level of 4ng/ml administered using Target Control Infusion pumps.
1661883|NCT01762280|Drug|Famitinib Malate Capsule|
1661884|NCT01762267|Other|nutrition intervention|DASH diet control diet
1661885|NCT01762254|Procedure|incisionless laparoscopic colectomy|Arm 1:Incisionless Laparoscopic Colectomy Laparoscopic colectomy is being performed in the same manner as conventional laparoscopic colectomy, except that at the end of procedure, the TEO device with the outer diameter of 4cm is inserted into the anus for the delivery of specimen and insertion of anvil instead of creating a small wound as in the conventional laparoscopic colectomy. Finally, intra-corporeal anastomosis is performed in the same manner with the TEO device removed.
1661886|NCT01762254|Procedure|conventional laparoscopic colectomy|Arm 2: Conventional Laparoscopic colectomy The operation is completed by laparoscopic instruments using video laparoscopy. At the end of the procedure, pneumoperitoneum is abolished and a small wound was created for the delivery of bowel and insertion of anvil of the circular stapler. Finally, pneumoperitoneum is re-created for intra-corporeal anastomosis
1661887|NCT01762241|Behavioral|Home based training using the Xbox Kinect system|Home based training 3 times a week for 12 weeks using the Xbox Kinect system
1661888|NCT01762228|Device|Transcutaneous electrical stimulation|Using a device which gives electrical stimulation, electrodes will be placed transcutaneously in oropharyngeal muscles of patients giving a sensorial stimuli during one hour for 5 days/week during 2 weeks of treatment.
1661889|NCT01762228|Dietary Supplement|TRPV1 agonist|Patient will be given a TRPV1 agonist natural product (which contains capsaicin) before every meal, during one hour for 5 days/week during 2 weeks of treatment.
1661890|NCT01762215|Behavioral|PatientsLikeMe.com|PatientsLikeMe (PLM, www.patientslikeme.com) is an established medical social networking website that encourages patients with chronic medical conditions to voluntarily share their story and seek support from a common community. Additionally, PatientsLikeMe is actively exploring opportunities to allow patients to report and track important medical data points with the hope that this will improve their longitudinal care. PatientsLikeMe has developed custom functionality for the epilepsy population including seizure tracking, peer support, and printable doctor visit support sheets.
1661891|NCT01762202|Drug|Cyclophosphamide|
1661892|NCT01762202|Drug|Fludarabine|
1661893|NCT01762202|Drug|Ofatumumab|
1661894|NCT01762189|Procedure|Phototherapy|The decision to use phototherapy conformed to the hour-specific threshold value for phototherapy presented by the American Academy of Pediatrics guidelines and was not at the discretion of the investigators.
1661895|NCT01762176|Procedure|Protocolized intensive treatment|Intensive treatment is defined as early diagnosis, frequent assessment (monthly) of disease activity that guides treatment change with the aim to achieve clinical remission based on a tight control protocol
1661896|NCT01762176|Procedure|Usual care|Usual care is defined as treatment decision at the discretion of the rheumatologists and patients reflecting daily clinical practice
1661897|NCT01762163|Drug|Qizhitongluo Capsule|
1661898|NCT01762163|Drug|Naoxintong Capsule|
1661899|NCT01762163|Drug|Aspirin Enteric-coated Tablets|
1661900|NCT01762163|Behavioral|the routine recovery training|
1661901|NCT01762163|Drug|placebo|
1661902|NCT01762150|Drug|Sorafenib|Sorafenib 400mg BID by oral until progressed;
1661903|NCT01762150|Drug|Gemcitabine|Gemcitabine: 1000mg/m2, administered by intravenous drip for 30~60min on Day 1 and 8,for 4 cycles;
1661904|NCT01762150|Drug|Cisplatin|Cisplatin: 25mg/m2, administered by intravenous drip on Day 1-3, with appropriate liquid hydration,for 4 cycles.
1661905|NCT01762137|Procedure|Flow Diversion|Endovascular flow diverter placement
1661906|NCT01762137|Procedure|Coiling|Endovascular coil placement
1661908|NCT01762085|Procedure|nerve decompression|surgical decompression involves surgical division or incision of perineural fibrous or fibro-osseous tunnel tissues which pinch, choke, compress or sharply deviate nerve trunks.
1661909|NCT01762072|Dietary Supplement|Fish oil|
1661910|NCT01762072|Dietary Supplement|vitaminB12|
1661911|NCT01762059|Device|Bi-homonal Bionic Pancreas|A computer algorithm will automatically deliver insulin lispro and glucagon based on the signal from a minimally invasive continuous glucose monitor.
1661912|NCT01762059|Other|Usual care|
1661913|NCT01762046|Drug|Glipizide|
1661914|NCT01762046|Drug|Metformin|
1661915|NCT01762046|Other|Oral Glucose Tolerance Test|
1661916|NCT01762033|Drug|ASONEP|Intravenous infusion
1661917|NCT01762020|Device|3M Cavilon No Sting Barrier Film|Half the breast will receive 3M Cavilon No Sting Barrier Film and one half will receive standard skin care
1661918|NCT01762020|Drug|Standard Preparation|standard creams
1661919|NCT01761994|Drug|Anticoagulation with nafamostat mesilate|Initial dose of nafamostat mesilate is 20mg/hr. Dosage is adjusted from 10mg to 30mg/hr according to patients' status. For priming, two vial of nafamostat mesilate was dissolved in 2mL of 5% glucose fluid, and then mixed with 1000mL of normal saline. After carefully removing air bubble from the circuit with the prepared fluid, nafamostat mesilate was dissolved with 15 mL of 5% glucose fluid and loaded in anticoagulation line with starting dose of 20mg/hr.
1661920|NCT01761968|Drug|Givinostat|"Patients will continue at their last tolerable dose and treatment schedule of Givinostat monotherapy. Givinostat is a histone-deacetylases inhibitor. The product will be supplied as hard gelatine capsules for oral administration at the strength of 50 mg, 75 mg and/or 100 mg each.
If patients previously received Givinostat in combination with other drugs during a core protocol or a compassionate use program, they will be treated at their last tolerable dose of this combination."
1661921|NCT01761955|Other|High Dairy|Consuming 4 or more servings of dairy products per day for a period of 6 months
1661923|NCT01761929|Radiation|Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance|All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
1661924|NCT01761916|Drug|CLONIDINE|Postpartum patients with very high blood pressure will be treated with oral clonidine (0,1mg)
1661925|NCT01761916|Drug|CAPTOPRIL|Postpartum patients with very high blood pressure will be treated with oral captopril (25mg)
1661926|NCT01761890|Behavioral|Dasatinib discontinuation|Treatment decision is at the discretion of the investigator and must not be made on the basis of this observational study. Patients should have their treatment initiated in accordance with the summary of product characteristics.
1661927|NCT01761877|Drug|Sulindac|
1661928|NCT01761864|Behavioral|academic detailing intervention|
1661929|NCT01761838|Other|SMT for low back pain patients|High velocity, low amplitude spinal manipulative therapy (HVLA-SMT) will be provided to the lumbopelvic region on both sides.
1661930|NCT01761838|Other|Pain induction (optional)|A randomized crossover design is used to investigate the changes in spinal stiffness and back muscle activity of asymptomatic participants following an experimental pain induction procedure. Specifically, asymptomatic participants attend two separate sessions 5 days apart. Participants will receive 0.3 ml of 5% hypertonic saline or 0.9% isotonic saline in random order into the interspinous ligaments at L3 to L5 levels. The resulting temporal changes in pain intensity, spinal stiffness and trunk muscle activity following saline injections will be monitored. During the second session, the participants will undergo the same procedures but with the previously unused saline concentration.
1661931|NCT01761838|Other|Low back pain participants without SMT|No treatment
1661932|NCT01761825|Drug|ivabradine|
1661933|NCT01761812|Other|MRI with gadofosveset and MR elastography|
1661934|NCT01761799|Behavioral|P3 Vaccine Promotion Package.|"P3 stands for Practice, Provider, and Patient level vaccine promotion package. The 5 obstetric practices randomized to the intervention arm will receive this comprehensive influenza and Tdap vaccine promotion package at the beginning of the study. Physicians and staff will be familiarized with each component, and practices will be instructed to implement each component to the best of their ability. The components include: posters, educational brochures, lapel buttons, provider-to-patient talking points, lists of nearby locations offering flu and/or Tdap vaccines (if not offered by the practice), identification of a vaccine champion within the practice, provider and staff training on vaccination during pregnancy, and use of an interactive, tablet-based educational tutorial for patients."
1661935|NCT01761786|Genetic|CYP2C19 genotyping|CYP2C19 genotyping will be performed in the intervention group. In patients with *1/*1 genotype (Extensive Metabolizer) clopidogrel will be prescribed. All patients who are carrier of a loss-to-function (*2 or *3) gene allel and all patients randomized to the control group will be prescribed prasugrel or ticagrelor, according to local protocol.
1661936|NCT01761773|Drug|cabozantinib|3 20-mg strength capsules (60 mg dose) administered as a single oral dose on Day 1 of study participation.
1661937|NCT01761760|Behavioral|Videogame-based smoking cessation intervention|Patients will enroll in a videogame that is intended to help them quit smoking. They will be given goals for quitting (based on carbon monoxide readings submitted over a secure internet server) and will earn game-based incentives either contingent or noncontingent on meeting those goals.
1661938|NCT01761747|Drug|ponatinib|
1661939|NCT01761734|Behavioral|text message|
1661940|NCT01761708|Procedure|primary ventral hernia repair with mesh|
1661941|NCT01761695|Other|Diagnosed as CML|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as chronic myeloid leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
1661942|NCT01761682|Other|Diagnosed as ALL|All patients who will be enrolled in this prospective registry are confined to those who are diagnosed as acute lymphoblastic leukemia at Asan Medical Center, Seoul, Korea, from Jan 2013 till Dec 2047
1661943|NCT01761669|Drug|Vitamin D|
1661944|NCT01761656|Drug|loading dose atorvastatin|For loading dose atorvastatin intervention, patients will be treated with 80 mg atorvastatin (lipitor) 12 hours before PCI and 40 mg atorvastatin (lipitor) 2 hours before PCI and then 20mg/d after PCI.
1661945|NCT01761656|Drug|conventional dose atorvastatin|For conventional dose atorvastatin intervention, patients will be treated with 20 mg atorvastatin (lipitor) 12 hours before PCI and then 20mg/d after PCI.
1661946|NCT01761643|Device|SoC + iTab|Text messaging reminders to improve adherence to PrEP
1661947|NCT01761617|Behavioral|Yoga class once per week|"The protocol consists of one 75-minute yoga class per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes are taught by a team of yoga instructors to ensure a low participant-to-teacher ratio."
1661948|NCT01761617|Behavioral|Yoga class twice per week|"The protocol consists of two 75-minute yoga classes per week for 12 weeks. The 12 weeks are divided into four 3-week segments, each with a theme (e.g., Listening to the Wisdom of the Body, Engaging your Power). The number of postures learned and degree of difficulty increases with each segment. The protocol provides variations and uses various aids (e.g., chair, yoga strap, yoga block) to accommodate a range of physical abilities. Classes will have eight participants at a time and are taught by a team of two yoga instructors to ensure a low yoga participant-to-teacher ratio."
1661949|NCT01761604|Device|Nasal ganglion block for TN|
1661950|NCT01761591|Device|PCI with Svelte Acrobat|Percutaneous coronary intervention with Svelte Acrobat Coronary Stent System
1661951|NCT01761591|Device|PCI with other BMS|Percutaneous coronary intervention with any other routine use CE marked bare metal stent (BMS) implantable either via direct stenting or after lesion pre-dilation
1661952|NCT01761578|Device|ART18Z Bioresorbable stent|The drug free fully bioresorbable coronary stent ART18Z is a balloon expandable poly lactic acid stent.
1661953|NCT01761565|Drug|Single dose of SUF NT 15 mcg|
1661954|NCT01761565|Drug|40 consecutive doses of SUF NT 15 mcg taken every 20 minutes|
1661955|NCT01761552|Drug|Sugammadex Reversal|
1661956|NCT01761552|Drug|Atropine/Neostigmine|
1661957|NCT01761539|Other|Aggressive Hydration|Receives 20cc/kg bolus and 3cc/kg/hr thereafter.
1661958|NCT01761539|Other|Moderate Hydration|Receives 10cc/kg bolus and 1.5cc/kg/hr thereafter.
1661959|NCT01761526|Drug|Rotigotine transdermal patch|Rotigotine transdermal patch, single-dose application over 24 hours 2 mg /24 hours (10 cm2)
1661960|NCT01761513|Drug|YH4808|"Group1
adminitration of YH4808 dose1, bid for 2weeks
wash-out period for 3weeks between period1 and period2
adminitration of YH4808 dose2, qd for 2weeks"
1661985|NCT01761279|Procedure|High definition white light endoscopy|
1661961|NCT01761513|Drug|YH4808|"Group2
adminitration of YH4808 dose2, qd for 2weeks
wash-out period for 3weeks between period1 and period2
adminitration of YH4808 dose1, bid for 2weeks"
1661962|NCT01761513|Drug|YH4808|"Group3
adminitration of YH4808 dose2, bid for 2weeks
wash-out period for 3weeks between period1 and period2
adminitration of Nexium tab 40mg, bid for 2weeks"
1661963|NCT01761513|Drug|YH4808|"Group 4
adminitration of Nexium tab 40mg, bid for 2weeks
wash-out period for 3weeks between period1 and period2
adminitration of YH4808 dose2, bid for 2weeks"
1661964|NCT01761500|Other|Modified BFM-90 protocol|Using Modified BFM-90 protocol to treat Chinese children and Adolescents with NHL
1661965|NCT01761487|Device|Gentamicin and polymyxin E|
1661966|NCT01761461|Drug|TS-1, oxaliplatin|
1661967|NCT01761448|Device|Guide Exercise (GEx-)- Training|Both intervention and control group undergo a baseline evaluation and an end evaluation including tests of the clinical routine like cardiopulmonary test (CPX), echocardiography and lactate measurement. They will also answer questionnaires referring to quality of life and the use of the system. During the training phase at home the interventional group will test the supervised training system during endurance training such as running, biking or walking and during resistance training such as performing exercise with rubber bands (at least 3x a week for about 5-6 months according to the generated prescription plan during training at the hospital). They will report their daily activity by diary. The control group will only report their physical activities by diary without using the Gex- System. At the end data are investigated to determine whether the supervised training with the GEx- System will improve the physical capacities ( VO2 peak) of patients.
1661968|NCT01761448|Device|Guided Exercise Training with an easy to wear vest with electrodes to measure ECG, respiration, activity|
1661969|NCT01761448|Device|Control group training without Guided Exercise system at home|
1661970|NCT01761435|Biological|Influenza vaccine|"Patients will be randomized at 1:1 rate and open label fashion, according to centers, and time elapsed since transplant and type of organ transplanted to one of this two interventions :
A arm (usual treatment): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline.
B arm (experimental branch): Influenza vaccine (split virion, inactivated) suspension for injection 0.5ml at the baseline and 5 weeks after the first dose.
The follow-up of both arms will be at 5, 10 and 15 weeks and one year after the baseline."
1661971|NCT01761396|Behavioral|CBT|
1661972|NCT01761396|Behavioral|UC|
1661973|NCT01761383|Other|Nintendo Wii video console and Nintendo Wii Fit Plus games|The intervention will be provision of Nintendo Wii console and Wii Fit Plus video games to use for the duration of the study with no restrictions or limitations on the games participants are allowed to play or duration of play. There will be 5 home visits over a 6-month period to evaluate Nintendo Wii use and assess patients'health, functioning and quality of life.
1661974|NCT01761370|Procedure|AHA diet plus exercise with BIB placement|AHA diet plus exercise with BIB placement for 6 months
1661975|NCT01761370|Procedure|AHA diet plus exercise with sham BIB placement|AHA diet plus exercise with sham BIB placement
1661976|NCT01761357|Other|answering to questionnaires of quality of live|
1661977|NCT01761344|Other|Intraoperative cortisol measurement.|Levels of cortisol in blood samples will be determined using a rapid cortisol assay. This is not standard procedure
1661978|NCT01761331|Other|Acupuncture|"Minimal standardized acupuncture: one needle is inserted about 3 mm in the point LI4 on the infants hands, unilaterally, for 2-10 seconds and then withdrawn.
Individualized acupuncture: maximum 5 needles are inserted, about 3 mm deep, in points chosen by the acupuncturists according to symptoms, in points recommended in a guideline produced for the trial. Needles are retained for maximum one minute."
1661979|NCT01761318|Drug|Liraglutide|"Preparation and labelling of Investigational Medicinal Product:
Liraglutide will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.
Drug accountability:
Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
1661980|NCT01761318|Drug|Liraglutide - Placebo|"Preparation and labelling of Investigational Medicinal Product:
Liraglutide - Placebo will be packed and labeled by Novo Nordisk A/S and provided in non-subject specific boxes. Labeling will be in accordance with Annex 13, local law and trial requirements. The examples of labels are not readily available, but will be supplied when received from Novo Nordisk.
Drug accountability:
Drug accountability will be cared for by the Department of Clinical Pharmacy of the LUMC. The trial product will be dispensed to each subject as required according to treatment group by the clinical pharmacist. No trial product will be dispensed to any person not enrolled in the trial."
1661981|NCT01761305|Procedure|Hypercorrective night-time brace|Hypercorrective night-time brace worn 8 hours per night. Patients are encouraged to also continue with non-specific self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
1661982|NCT01761305|Behavioral|Scoliosis specific exercises.|The intervention will be delivered in 3 x 90 minute sessions, once per month during the first 3 months. Goals are directed towards active self-correction and postural control, spinal stability, aerobic functioning and development of a positive body image. Additional postural specific exercises including self-mediated hyper-corrective exercises are to be performed with moderate intensity at least for 30 minutes at least 2-3 times per week. Other physical activities to fulfill the general recommended quota of more than 60 minutes moderate intensity physical activity per day are recommended. Reinforcement of the intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
1661983|NCT01761305|Other|Self-mediated physical activity.|Instructions for self-mediated physical activity will be delivered during a 1 hour session. Patients are encouraged to perform self-mediated physical activities of moderate intensity at least 60 minutes daily, for the entirety of the study. Reinforcement of the assigned intervention will be performed in conjunction with reassessment every 6 months. A training diary will be implemented to follow and motivate the patient's training behaviour.
1661984|NCT01761292|Drug|Givinostat|
1661986|NCT01761266|Drug|Lenvatinib|Lenvatinib: 12 mg (or 8 mg) once daily (QD) oral dosing
1661987|NCT01761266|Drug|Sorafenib|Sorafenib: 400 mg twice daily (BID) oral dosing
1661988|NCT01761240|Drug|MORAb-066|
1661989|NCT01761227|Drug|Fufangdanshen Tablets|1 tablets contains contains tanshinoneⅡA 0.67mg , salvianolic acid B 8.2mg, Panax Notoginsenosides R1 0.53mg, ginsenoside Rb1 3.03mg, ginsenoside Rg1 2.73mg, 3 tablets per time, 3 times per day for 24 weeks
1661990|NCT01761227|Drug|Placebo|Placebo for 3 tablets per time, 3 times per day for 24 weeks
1661991|NCT01761214|Drug|Fluroquinolones|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis
1661992|NCT01761214|Drug|Beta-lactamase inhibitor|All antibiotics are administered based on British Thoracic Society guideline for bronchiectasis.
1661993|NCT01761201|Drug|Levofloxacin|Levofloxacin
1661994|NCT01761201|Drug|Isoniazid|"300 mg/day for 9 months beginning after transplantation, when the liver function is stable and not before 3 months nor after 6 months."
1661995|NCT01761188|Procedure|Ablation|electrophysiology substrate mapping is the critical difference between both groups
1661996|NCT01761175|Procedure|Ultrasound-guided infraclavicular block|Ultrasound-guided single injection infraclavicular block: using an in-plane technique, 30 mL of mepivacaine 1.5% is injected at the posterior aspect of the artery.
1661997|NCT01761175|Procedure|Ultrasound-guided axillary block|Ultrasound-guided double injection axillary block: using an in-plane technique, 25 mL of mepivacaine 1.5% is injected postero-medial to the artery. During needle withdrawal, 5 mL of the same solution is injected close to the musculocutaneous nerve.
1661998|NCT01761162|Device|Patients with a ProMRI Pacemaker System|Bradycardia Slow Heart Beat
1661999|NCT01761162|Other|Magnetic Resonance Imaging (MRI) scan|MRI scan of head and lower back.
1662000|NCT01761149|Drug|Remifentanil|The present study examine two different dose of remifentanil: low dose (0.2ug/kg/min) and high dose (1.2ug/kg/min)
1662001|NCT01761136|Biological|Inoculation in upper arm deltoid|Inoculation of Hib vaccine of two brands in upper arm deltoid
1662002|NCT01761136|Biological|Inoculation in vastus lateralis muscle|Inoculation of Hib vaccine of two brands in vastus lateralis muscle
1662003|NCT01761123|Biological|VXA-A1.1|
1662004|NCT01761110|Behavioral|Community-based buprenorphine treatment (CBBT) intervention|Community-based buprenorphine treatment (CBBT) intervention consists of three components which are delivered to staff of syringe exchange programs, including: 1) providing buprenorphine education, 2) facilitating access to buprenorphine treatment, and 3) providing support to individuals who initiate buprenorphine treatment.
1662005|NCT01761097|Device|Endocuff attachment|Endocuff
1662006|NCT01761084|Behavioral|Exercise and behaviour change strategies|"cardiovascular exercise (e.g., marching, walking) for ≥10 minutes per day
postural retraining and balance exercises ≥3 days a week (will be encouraged to do these daily)
perform muscle strengthening and balance training exercises ≥ 3 days a week
the exercise intervention was developed using the Bone Fit program as a framework (http://www.bonefit.ca/). The physical therapist will tailor exercises and work with participant to integrate them into their day."
1662007|NCT01761071|Drug|topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
1662008|NCT01761071|Drug|topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland)|On operation day, the patients were randomly assigned to one of the following two groups: group KO,preoperative application of topical ketorolac 0.5% (Acular®, Allergan Inc, Irvine, CA) in one eye and topical ofloxacin 0.3% (Ocuflox®, SamilInc, Seoul, Korea)in the other eye; group DO, topical diclofenac 0.1% (Voltaren®, Novartis, Bern, Switzerland) in one eye and ofloxacin 0.3% in the other eye. Neither the surgeon nor the participants knew which ophthalmic would go to which eye. A randomly assigned ophthalmic was instilled into right eye first three times by 1 minute interval 30 minutes prior to operation and the other ophthalmic was instilled into left eye with the same manner 10 minute later.
1662009|NCT01761045|Dietary Supplement|Soup 1|Consommé soup with Monosodium L-Glutamate (MSG)
1662010|NCT01761045|Dietary Supplement|Soup 2|Consommé soup with Monosodium L-Glutamate (MSG) and Nucleic Acid (IMP)
1662011|NCT01761045|Dietary Supplement|Soup 3|Placebo soup with no Monosodium L-Glutamate (MSG) or Nucleic Acid (IMP)
1662012|NCT01761032|Device|Tanning|Participants will be placed under a tanning canopy for 4-10 minutes.
1662013|NCT01761019|Drug|Taclonex Topical Suspension|topical medication for psoriasis
1662014|NCT01761006|Device|NIOX MINO®|
1662015|NCT01760993|Drug|SPD489|Once-daily oral optimized doses of SPD489 (either 40 mg, 80 mg, 100 mg, 120 mg, 140 mg, or 160 mg) for 52 weeks
1662016|NCT01760980|Drug|Reference product (A) Aromasin (Exemestane)|Aromasin tablets will be administered under fasting conditions on two occasions
1662017|NCT01760980|Drug|Test product (B) Exemestane|Exemestane tablets will be administered under fasting conditions on one occasion
1662018|NCT01760967|Drug|Dexmedetomidine|intervention to administer dexmedetomidine or not
1662019|NCT01760954|Drug|Elagolix|Two different doses with matching placebo in 2 different arms daily over a 6 month treatment period
1662020|NCT01760954|Other|Placebo|
1662021|NCT01760941|Radiation|Radiation Therapy|Undergo standard of care radiation therapy
1662022|NCT01760941|Other|Quality-of-Life Assessment|The patient quality of life as measured by the ESAS-r; Edmonton Symptom Assessment System revised.
1662023|NCT01760941|Other|Survey Administration|The surveys consists of Radiation Therapy Worthfullness survey; BPI: brief pain inventory; NUS: narcotics usage survey.
1662069|NCT01760590|Procedure|Manual Manipulation|A grade 5 thrust to the thoracic spine
1662309|NCT01758458|Other|Laboratory Biomarker Analysis|Correlative studies
1662025|NCT01760902|Behavioral|Diet and Physical Activity|The group will convene weekly for 12 consecutive weeks and monthly thereafter for 9 consecutive months. Thus, there will be a total of 21 group-based sessions over the one-year period
1662026|NCT01760889|Drug|SPD489 low dose range (40mg, 80mg, and 100mg)|"Capsule, dose titration,
40 mg capsule once-daily for 1 week; then
80 mg capsule once-daily for 4 weeks; then,
100 mg capsule once-daily (if unable to tolerate 100 mg dose between weeks 5 to 6, then dose to be decreased to 80 mg once-daily for the remaining 21 weeks;
if able to tolerate 100 mg dose then will continue on 100 mg capsule once-daily for 21 weeks"
1662027|NCT01760889|Drug|SPD489 high dose range (120mg, 140mg and 160mg)|"Capsule, dose titration,
40 mg capsule once-daily for 1 week; then
80 mg capsule once daily for 1 week; then
120 mg capsule once-daily for 1 week, then,
140 mg capsule once-daily for 2 weeks, then
160 mg once capsule once-daily (if unable to tolerate 160 mg dose between weeks 5 to 6, then dose to be decreased to 140 mg once-daily for the remaining 21 weeks;
if able to tolerate 160 mg dose then will continue on 160 mg capsule once-daily for 21 weeks"
1662028|NCT01760889|Drug|Placebo|One capsule a day for 26 weeks
1662029|NCT01760876|Device|coronary intervention|The BioFreedom drug coated stent (DCS) Coronary Stent Delivery System is comprised of three key components
1662030|NCT01760863|Other|Oral Antibiotics|Oral Antibiotics will be prescribed for 3 months per recommendations of an infectious disease specialist.
1662031|NCT01760850|Other|educational intervention|Engage in the Esperanza y Vida educational information session for breast and cervical cancer
1662032|NCT01760850|Other|educational intervention|Engage in an educational information session for diabetes
1662033|NCT01760850|Other|questionnaire administration|Ancillary studies
1662034|NCT01760837|Other|Baked milk products to cow's milk allergic patients|
1662035|NCT01760824|Drug|Sequential therapy|Esomeprazole 20mg bid for 10 days, amoxicillin 1g bid for first 5 days, clarithromycin 500mg bid for last 5 days and metronidazole 400mg qid for last 5 days
1662036|NCT01760824|Drug|Quadruple therapy|Esomeprazole 20mg bid, metronidazole 400mg qid, bismuth sub citrate 120mg qid and tetracycline 500mg qid, all for 10 days
1662037|NCT01760811|Drug|Erbitux,merck serono|cetuximab loading dosage 400mg/m2 followed by weekly 250mg/m2 2 weeks
1662038|NCT01760798|Drug|Teriparatide|
1662039|NCT01760785|Drug|divalproex sodium|Doses will be given in 250mg increments and titrated over the first four days of study until a starting dose of 750 mg is reached. The Study Oversight Team, who is not involved in any clinical visits, will be un-blinded to study drug assignment and will have plasma concentration results and adverse event reports available to them. If a subject has no adverse events and is not at therapeutic level as indicated by the blood levels, the Study Oversight Team may inform the research pharmacy to increase the dose by 1 tablet of 250 mg to 1000 mg per day. The Study Oversight Team may also inform the research pharmacy to reduce the daily dosage back down to 750 mg per day if plasma concentrations or adverse events become intolerable. The maximum dose for the purpose of this study will be 1250 mg daily and the minimum dose will be 750 mg daily. Subjects who cannot tolerate the minimum dose will be excluded from any further study participation.
1662040|NCT01760785|Drug|Placebo|Doses will be titrated over the first four days of study in the same manner as the active study drug. After titration, the research pharmacy may increase the dose by 1 tablet per day, in the same fashion that the active drug may be adjusted, so that the participant and clinical team remain blinded to the drug assignment. The research pharmacy may also reduce the daily dosage back down by one tablet per day for the same reason.
1662041|NCT01760772|Drug|Exendin-9|Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min
1662042|NCT01760772|Drug|GLP-1|Constant infusion of GLP-1 at 0.3 pmol/kg/min
1662043|NCT01760772|Other|saline|Constant infusion
1662044|NCT01760759|Drug|antiretroviral therapy|Patients receive antiretroviral therapy.
1662045|NCT01760759|Behavioral|cell phone reminders|Patients receive reminders, scheduled to occur daily at time(s) of scheduled antiretroviral therapy dosing.
1662046|NCT01760759|Behavioral|contingency management for adherence|Patients will receive reinforcement in the form of vouchers for each video that they send in indicating adherence at the appropriate time.
1662047|NCT01760746|Other|Injection of Avastin / Lucentis, sampling aqueous humour|"Study participants will be divided into two arms. Subjects will receive Avastin or Lucentis a few days before vitrectomy surgery. The assignment will be double-masked.The first sample of aqueous humor will be obtained immediately prior to the intravitreal injection.
On the same of the intravitreal injection, a blood sample will be taken for hemoglobin A1C measurement. Approximately 1 week later when patients are having their scheduled vitrectomy surgery, an additional sample of aqueous humour will be obtained .
Intraocular cytokines levels will be measured in aqueous humor samples using multiplex cytokine assays."
1662048|NCT01760720|Behavioral|MMT CARE|
1662049|NCT01760707|Behavioral|exercise training|
1662050|NCT01760707|Behavioral|usual care|
1662051|NCT01760694|Other|Multi-Modality; IORT, Surgery, Radiation, Chemotherapy|
1662052|NCT01760681|Device|H- Coil DTMS|20 daily deep rTMS treatments
1662053|NCT01760681|Device|Sham|
1662063|NCT01760642|Drug|Midazolam|Midazolam 3 mg IV
1662064|NCT01760642|Drug|Ketoconazole|ketoconazole 400 mg PO
1662065|NCT01760642|Drug|Rifampicin|Rifampicin 600 mg PO
1662066|NCT01760629|Device|Tecotherm-HELIX|Whole body cooling using Tecotherm-HELIX
1662067|NCT01760616|Drug|Huaier Granule|Huaier Granule is a Chinese medicine, specifications: 20g / bag, manufacturer: Qidong Gaitianli Medicines Co., Ltd..
1662068|NCT01760603|Procedure|ISFF|Ischia spinous fascia fixation surgery was performed on patient with pelvic organ prolapse.
1719734|NCT00002868|Drug|idarubicin|
1662070|NCT01760590|Procedure|Mobilization|A grade 1-4 mobilization directed at thoracic spine
1662071|NCT01760577|Drug|Botulinum Toxin A (Allergan, Inc, Irvine CA)|patients received intraarticular injections by the same experienced physician using aseptic procedures.
1662072|NCT01760577|Drug|Hyalgan (Hyalgan, Fidia , Italy)|The rehabilitation program consists of 6 sessions of rehabilitation exercise for 50 miniutes/day, 3 days per week for 2 weeks and home exercise program for another 2 weeks.
1662073|NCT01760564|Drug|Miglustat|miglustat 200mg tid for adult. For children surface area correction will be made. A lower dose may be used initially to decrease side effect.
1662074|NCT01760538|Behavioral|Exercise training|exercise training
1662075|NCT01760538|Behavioral|usual care|received usual medical care after heart transplantation
1662076|NCT01760525|Drug|CGM097|Patients treated with CGM097
1662077|NCT01760512|Procedure|Gastric bypass|Gastric bypass
1662078|NCT01760499|Drug|PV-10|PV-10 administration: Within one week after completing the screening tests (or the same day as the screening tests), participants will be scheduled to have the study drug (PV-10) administered. PV-10 is given as an injection with a needle, directly into one of the participant's tumors. Participants will be given an injection of a numbing medication before the PV-10 is given.
1662079|NCT01760499|Procedure|Surgery|Surgery to remove melanoma tumors (Day 7-14): About 7-14 days after the PV-10 is given, participants will have surgery to remove their melanoma tumors. A piece of the tumor that was injected with PV-10 along with a piece of one other tumor will be sent to the laboratory for testing as part of the study.
1662080|NCT01760486|Behavioral|Shape Up Rhode Island|
1662081|NCT01760486|Behavioral|Shape Up Rhode Island + Professional Coach + Incentives|
1662082|NCT01760486|Behavioral|Shape Up Rhode Island + Peer Coach + Incentives|
1662083|NCT01760473|Drug|Intranasal challenge drug|Each of the experimental challenge drugs were administered intranasally to all participants in random order.
1662084|NCT01760460|Drug|Anacetrapib|
1662085|NCT01760460|Drug|Placebo for anacetrapib|
1662092|NCT01760434|Other|Long-term outcomes|Patients with a history of adolescent idiopathic scoliosis will return at a minimum of 20 year follow-up for new spine xrays, clinical exam, pulmonary function testing, and assessment of health related quality of life based on survey responses.
1662093|NCT01760421|Drug|Hydroxychloroquine|Hydroxychloroquine (200mg/tab) 1 tab twice daily orally for 6 months
1662094|NCT01760408|Other|all patients on Home Parenteral Nutrition|
1662095|NCT01760382|Device|Primary PCI|mechanical reopening of the STEMI-related coronary artery by PTCA, with or without coronary stent implantation
1662096|NCT01760343|Biological|Berinert|Berinert is a plasma-derived C1 esterase inhibitor (human), supplied as a freeze-dried powder for reconstitution.
1662097|NCT01760343|Biological|CSL830|CSL830 is a formulation of Berinert.
1662098|NCT01760330|Drug|IV acetaminophen|
1662099|NCT01760330|Drug|Placebo|
1662100|NCT01760317|Procedure|Midline vs Parasagittal Lumbar Epidural Steroid Injection|
1662101|NCT01760304|Drug|Budesonide / Formoterol|"Budesonide/ formoterol (B/F) 160/4.5 mcg per activation. Subject who met inclusion criteria will be have at each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of either Budesonide/formoterol (B/F) 160/4.5 mcg per activation (as per the randomization-crossover schema).
After 45 minutes , the above measurements will be repeated."
1662102|NCT01760304|Drug|Placebo|"Each visit day lung function, heart function and breathlessness measurements at baseline, then they will receive 2 puffs of placebo (as per the randomization-crossover schema).
After 45 minutes , the above measurements will be repeated."
1662103|NCT01760291|Device|WATCHMAN LAA Closure Technology|
1662104|NCT01760278|Drug|recombinant Follicle Stimulating Hormone (rFSH)|"There are two arms of the study. The Study arm and the Control arm. In each arm, subjects, after randomization, will be stimulated with rFSH 225IU/day.
On day 6, Cetrorelix 0.25mg/day to be added till the day of Ovitrell. Thereafter, ovum pick-up and embryo transfer to be done. Six weeks after transfer clinical pregnancy identified which will be the end-point of the study."
1662105|NCT01760252|Drug|Capecitabine, Oxaliplatin and Irinotecan (CAPOXIRI)|Neoadjuvant CAPOXIRI chemotherapy is an innovative strategy that builds on the advancement associated with FOLFIRINOX chemotherapy in patients with metastatic disease
1662106|NCT01760239|Behavioral|Clinical Decision Support (CDS)|The Clinical Decision Support (CDS) tool will be activated when a BP is entered in the vital sign section of the EHR. The CDS tool includes six key features: (i) prompts regarding the need for height data to classify the BP by percentile (ii) prompts to repeat any BP that is ≥90% or ≥120/80 mm Hg (iii) classification of BPs by percentile, including classification of those in pre-HT, stage 1 HT and stage 2 HT range (iv) review of previous HT diagnoses and BPs in order to classify elevated BPs as incident (first or second elevated BP) or persistent (third or greater elevated BP) (v) tailored CDS based on HT category and previous diagnoses (vi) graphical representation of current and historical BP data by age and BP percentile.
1662182|NCT01759732|Procedure|CD3-depleted hematopoietic cell transplantation|Immunogenetic depletion on CliniMACS
1662311|NCT01758458|Radiation|Radiation Therapy|Undergo radiation therapy
1662107|NCT01760226|Drug|DA-EPOCH-R for DLBCL, PTLD, AND PMBCL|"Day 1: Rituximab IV
Days 1-4: After rituximab, etoposide, vincristine, and doxorubicin will be given in a vein over 96 hours as a continuous infusion.
Day 5: cyclophosphamide will be given in a vein
Days 1-5: prednisone given by mouth twice a day
G-CSF 5mcg/kg/day will be given under the skin from day 6 until ANC has improved."
1662108|NCT01760226|Drug|Methotrexate|"CNS negative patients with high CNS risk DLBCL will receive age based, intrathecal dosing of MTX on days 1 and 5 of cycles 3 - 6 only.
CNS positive patients will receive age based, intrathecal (within the spinal fluid) MTX twice weekly for 2 weeks past the first negative cytology with a minimum of 4 weeks treatment. Then, weekly for 6 weeks and then every 4 weeks for 6 months.
DLBCL/PTLD/PMBCL CNS prophylaxis for cycles 3-6 ONLY if:
2+ extranodal sites
elevated LDH,
MYC rearrangement OR
bone or marrow disease.
ALL OTHERS receive IT MTX cycles 3-6."
1662109|NCT01760226|Drug|Etoposide|Etoposide will be given at 50mg/m2/day on days 1-4 of the first cycle of therapy (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
1662110|NCT01760226|Drug|Doxorubicin|Doxorubicin will be given at 10mg/m2/day on days 1-4 of the first cycle (dose based on patient height and weight). The doses in later cycles will be adjusted up or down based on the patient's blood test results.
1662111|NCT01760226|Drug|Vincristine|Vincristine will be given on days 1-4 of each cycle at 0.4mg/m2/day (dose based on patient height and weight).
1662112|NCT01760226|Drug|Rituximab|Rituximab (375mg/m2/dose) will only be given on Day 1 of each cycle prior to all the other chemotherapy agents. Dose is based on patient height and weight.
1662113|NCT01760226|Drug|Cyclophosphamide|Cyclophosphamide will be given on Day 5 of each cycle. In cycle 1, the dose will be 750 mg/m2 (based on patient height and weight), and the dose will be adjusted up or down for future cycles based on blood test results.
1662114|NCT01760226|Drug|Prednisone|Prednisone will be given by mouth at 60mg/m2/dose (based on height and weight) twice a day on days 1-5 of each cycle.
1662115|NCT01760226|Drug|G-CSF|G-CSF will be given at 5 mcg/kg/day during each cycle, starting on day 6, until the patient's ANC (absolute neutrophil count) is greater than 5000/mcL past nadir.
1662116|NCT01760213|Other|CBT delivered via Internet|
1662118|NCT01760174|Drug|Ropivacaine bolus in transversus abdominis plane catheter|"Ropivacaine 7,5 mg/ml, 10-25 ml in each catheter, depending on patient weight, the total dose of ropivacaine is kept less than 3 mg/kg for every bolus. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.
In the epidural catheter a bolus of 8 ml isotonic potassium chloride is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours."
1662119|NCT01760174|Drug|Bupivacain-infusion in epidural catheter|"Isotonic potassium chloride, 10-25 ml in each transversus abdominis catheter, depending on patient weight. Bolus is given every 6 hours, the first bolus is given just after induction of general anesthesia and the last bolus after 24 hours.
In the epidural catheter a bolus of 8 ml bupivacaine 2,5 mg/ml is given and an infusion of isotonic potassium chloride, 4-7 ml/t depending on patient height is started and runs for the first 24 hours"
1662120|NCT01760161|Drug|Ropivacaine|Ropicacain 3,75 mg/ml 15 ml x 4 when placing the Bilateral Dual Transverus Abdominis Plane block
1662121|NCT01760161|Drug|Isotonic potassium chloride|Isotonic potassium chloride 15 ml x 4 when placing the bilateral dual transverus abdominis plane block.
1662122|NCT01760148|Drug|interferon alpha 2b|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.
Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
1662123|NCT01760135|Dietary Supplement|high caloric nutritional supplement|high caloric nutritional supplement (25kcal/kg)
1662124|NCT01760135|Dietary Supplement|low caloric nutritional supplement|low caloric nutritional supplement(15kcal/kg)
1662125|NCT01760122|Drug|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
1662126|NCT01760122|Drug|Pegasys|sc, qw, 48 weeks.
1662127|NCT01760109|Drug|Piperacillin Sodium and Sulbactam Sodium|1.5-3.0g,iv,bid 7-14 days serious infections 6.0-12.0g,iv,tid for 7-14 days
1662128|NCT01760096|Drug|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 3-5mg/kg every other day Glucocorticoids0.25 mg/kg every day(prednisone)
1662129|NCT01760096|Drug|cyclosporin A+Glucocorticoids|cyclosporin A 3-5mg/kg every day Glucocorticoids0.25mg/kg every day(prednisone)
1662130|NCT01760096|Drug|Glucocorticoids|Glucocorticoids0.25mg/kg every day(prednisone)
1662131|NCT01760083|Device|Biolimus-eluting stent implantation|Recanalization of chronic coronary artery occlusion and subsequent implantation of one or ore Biosensor stents
1662132|NCT01760070|Device|Hybrid knife|Use Hybrid knife in ESD procedure
1662133|NCT01760070|Device|IT knife|Use IT knife in ESD procedure.
1662134|NCT01760057|Behavioral|Online HIV testing motivational videos and messages sent via mobile-phone text messaging, e-mail or instant messaging|
1662135|NCT01760057|Behavioral|Standard online message with an invitation for free HIV testing similar in content to other Peruvian websites|
1662136|NCT01760044|Device|Tissue oxygenation monitoring|The device provides continuous measures with updates based on the previous 10 seconds worth of data. Data is continuously stored.
1662137|NCT01760031|Other|Ischemic preconditioning|Subjects received ischemic preconditioning previous to cardiac catheterization
1662138|NCT01760018|Drug|desflurane group|anesthesia is maintained with desflurane and remifentanil (Desflurane group)
1662139|NCT01760018|Drug|TIVA group|anesthesia is maintained with fresofol and remifentanil (TIVA group).
1662140|NCT01760005|Drug|Gantenerumab|Subcutaneously every 4 weeks at escalating doses
1662141|NCT01760005|Drug|Solanezumab|Intravenous infusion every 4 weeks at escalating doses
1662142|NCT01760005|Drug|Matching Placebo (Gantenerumab)|Subcutaneous injection of placebo every 4 weeks
1662143|NCT01760005|Drug|Matching Placebo (Solanezumab)|Intravenous infusion of placebo every 4 weeks
1662144|NCT01760005|Drug|JNJ-54861911|25 mg daily oral tablet
1662145|NCT01760005|Drug|Matching Placebo (JNJ-54861911)|Daily oral placebo tablet
1662183|NCT01759719|Device|coronary angioplasty with PtCr stent implantation|PCI with deployment of at least 1 PtCr stent
1662310|NCT01758458|Biological|MCPyV TAg-specific Polyclonal Autologous CD8-positive T Cells|Given IV
1662146|NCT01759992|Device|Threshold® Inspiratory Muscle Trainer (treatment).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions will take place 3 times per week over a eight-week period for a total of 24 sessions. All participants were familiarized with the breathing exercises over a two-week familiarization period at the beginning of the protocol. The load will be adjusted at ≥ 50% of baseline MIP.
1662147|NCT01759979|Procedure|Laser and mechanical lithotripsy|Patients will undergo cholangioscopy guided laser treatment in addition to treatment with mechanical lithotripsy using basket and balloon techniques.
1662148|NCT01759979|Procedure|Mechanical Lithotripsy|Patients in the mechanical lithotripsy arm will undergo treatment only with basket and balloons to facilitate stone removal but not laser lithotripsy.
1662149|NCT01759953|Other|Game|InsuOnline game, on the web, in the player´s own time and rhythm
1662150|NCT01759953|Other|Traditional CME|In-classroom traditional learning session about insulin therapy for diabetes, using a presential short lecture and a group discussion of the same clinical cases presented in the InsuOnline game
1662151|NCT01759940|Drug|ropivacaine 0,375%|
1662152|NCT01759940|Drug|ropivacaine 0,75%|
1662153|NCT01759927|Behavioral|physical activity coaching|After measuring physical actity, physical fitness level, anthropometric and psychosocial variables a personalized 12 week physical activity program is made (=baseline). The intervention consisted of two face-to-face counselling sessions at the start of the intervention, short contacts by e-mail or telephone at weeks 3, 6 and 9, and two face-to-face counselling sessions at the end of the intervention. Employees exercise on their own. After 12 weeks and 6 months all measures are repeated.
1662154|NCT01759914|Drug|Potent topical steroid|
1662155|NCT01759914|Drug|Superpotent topical steroid|
1662156|NCT01759901|Procedure|Pringle|Vascular clamp is applied across hepatoduodenal ligament intermittently in 15 minutes on / 5 minutes off interval
1662157|NCT01759888|Drug|18F-DTBZ|"Subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ (10 nmole FP-(+)-DTBZ) immediately prior to each scan.
The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG."
1662158|NCT01759875|Drug|Ritonavir-boosted Atazanavir|Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1
1662159|NCT01759875|Drug|Ritonavir-boosted Atazanavir plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 (Day 4)
1662160|NCT01759875|Drug|Ritonavir-boosted Atazanavir plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Ritonavir (100mg) PO x1 and Atazanavir (300mg) PO x1 on Day 4
1662161|NCT01759862|Drug|Aminophylline|Aminophylline loading dose 5mg/kg prior to transplant and will continue to receive aminophylline 1.8mg/kg Q6h for a total of 20 doses.
1662162|NCT01759862|Other|Theophylline drug levels|Theophylline drug levels will be monitored every morning from all patients for the first 4 days post- transplant.
1662163|NCT01759862|Drug|Placebo|Patients will receive placebo infusion of normal saline, pre-transplant, followed by normal saline infusions matched by volume and frequency to treatment arm for a total of 20 doses.
1662164|NCT01759849|Other|Allergen|Allergen extract is administered by inhalation.
1662165|NCT01759836|Drug|Atorvastatin 20mg|Atorvastatin 20mg daily for 1 year
1662166|NCT01759823|Biological|mesenchymal stem cell transplantation|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will be dissolved in minimum essential medium and inoculated in culturing flask and mesenchymal will be allowed to adhere to culturing flask and mesenchymal stem cell will be injected into superior pancreatic duodenal artery . Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
1662167|NCT01759823|Other|control|5 ml of bone marrow will be aspirated and 3 mL of Vitamin B complex will be injected through transfemoral route into superior pancreatico-duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide,HYPERGLYCEMIC CLAMP TO ASSESS BETA CELL FUNCTION. Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
1662168|NCT01759823|Biological|MNC's TRANSPLANTATION|20 - 30 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - hypaque ) and stem cells will be separated. Separated mono nucleated cells will injected into superior pancreatico duodenal artery. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide HYPERGLYCEMIC CLAMP FOR ASSESSMENT OF BETA CELL FUNCTION , AND EUGLYCEMIC CLAMP TO ASSESS INSULIN SENSITIVITY .Homeostasis Model of Assessment - Insulin Resistance and Beta cell function ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
1662171|NCT01759797|Biological|intra venous injection of stem cell|Intra venous injection of mesenchymal stem cell
1662172|NCT01759784|Biological|Intraventricular injection|intraventricular injection of mesenchymal stem cell by stereo taxi in patients with ALS
1662173|NCT01759771|Drug|Vitamin D3|4,000 IU of VD3 for at least one year
1662174|NCT01759771|Drug|Placebo|Placebo for at least one year
1662175|NCT01759758|Other|Plaster Ulnar Gutter Splint|Patients are placed in a plaster ulnar gutter splint, molded in the safe position.
1662176|NCT01759758|Other|Thermoplastic Splint|Thermoplastic Splint is heat moulded to the patient's hand, stabilizing the metacarpal heads, but not immobilizing any joints. This is done by our occupational therapist.
1662177|NCT01759732|Drug|Fludarabine|40mg/M2 once daily IV on days -7 to -4
1662178|NCT01759732|Drug|Cyclophosphamide|60 mg/kg IV on day-3 and -2
1662179|NCT01759732|Biological|anti-thymocyte globulin|
1662180|NCT01759732|Biological|filgrastim|
1662181|NCT01759732|Radiation|Total body irradiation|200 cGy per day on D-5 & -4
1662184|NCT01759706|Behavioral|Enhanced recovery after surgery protocol|ERAS items implemented were: preadmission counselling, preoperative immunonutrition, no preoperative bowel preparation, epidural analgesia, no pre-anesthetic medication, intraoperative iv fluid restriction, PONV and hypothermia prophylaxis, removal of nasogastric tube (NGT) at the end of surgery, mobilization protocol, solid food diet from POD 2, early stop of iv infusions and removal of urinary catheter.
1662185|NCT01759706|Procedure|Standard perioperative care|Epidural analgesia, pre-anesthetic medication with diazepam, bowel preparation with oral assumption of sodium phosphate, removal of nasogastric tube on POD 1, solid food diet from POD 4
1662186|NCT01759706|Drug|PONV prophylaxis with Ondansetron + Dexamethasone|Postoperative nausea and vomiting prophylaxis with Ondansetron + Dexamethasone.
1662187|NCT01759706|Other|Postoperative mobilization program|Patient mobilization for 2 hours on first postoperative day Patient mobilization for 4 hours on first postoperative day + assisted deambulation in the room Patient mobilization for 6 hours on first postoperative day + assisted deambulation in the ward
1662188|NCT01759706|Drug|Epidural analgesia with naropin + sufentanil|Midthoracic epidural analgesia with naropin 0.2 % plus sufentanil 0,5 mcg/mL
1662189|NCT01759706|Drug|Pre-anesthetic medication with diazepam|Premedication before general anesthesia
1662190|NCT01759706|Behavioral|Preadmission counselling|Patient multidisciplinary preoperative counselling, including anesthesiologist, surgeon and nurse.
1662191|NCT01759706|Drug|Preoperative bowel preparation with sodium phosphate|Preoperative bowel preparation with oral assumption of sodium phosphate
1662192|NCT01759693|Procedure|Blood sampling|Blood sampling
1662193|NCT01759680|Device|Vibrosphère device|Vertical Sinusoidal vibration
1662194|NCT01759667|Other|A standard mixed Meal|All patients underwent an indirect calorimetry test, after a 12-h period of fasting from food and water, avoiding intake of alcohol or coffee, and avoiding physical exercise and cigarettes the day before the examination. To examine possible changes in the thermogenic effect of food, patients received a standard mixed meal (200 ml coconut water and a chicken salad sandwich using whole wheat bread). They then repeated the test 20 min and 60 min after eating to obtain a reading of the metabolic rate by considering DIT and the RQ in the postprandial period.
1662195|NCT01759654|Biological|AdimFlu-V|
1662196|NCT01759641|Device|Hypotension-prone patients|Hemox optical sensor equips the dialysis monitors used during this trial. It is able to measure continuously, on arterial blood line, oxygen saturation, hematocrit and blood volume reduction.
1662197|NCT01759628|Drug|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
1662198|NCT01759615|Other|Early Enteral feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
1662199|NCT01759615|Other|Late enteral feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
1662200|NCT01759602|Drug|C1-esterase inhibitor (Cinryze)|
1662201|NCT01759589|Drug|Propofol|1 mg/kg propofol IV (over 15 sec) during anesthesia induction
1662202|NCT01759589|Drug|Remifentanil and propofol|1 µg/kg IV (over 60 sec)remifentanil and 0.5 mg/kg propofol IV (over 15 sec)during anesthesia induction
1662203|NCT01759589|Drug|Sevoflurane|Sevoflurane was started at 6% for induction and continued at 1% until the electrical stimulus was delivered
1662204|NCT01759576|Drug|Canagliflozin (JNJ-28431754)|Volunteers in groups 1 through 4 will receive one 200mg tablet orally (by mouth) on Day 1. Volunteers in group 5 will receive one 200mg tablet orally on Day 1 (one hour after hemodialysis) followed, approximately 10 days later, by one 200mg tablet orally (2 hours before hemodialysis).
1662205|NCT01759563|Device|nasopharyngeal targeted brain cooling|
1662206|NCT01759537|Device|Ankylos dental endosseous implants-sub-crestal|Implants placed subcrestally
1662207|NCT01759537|Device|Ankylos dental endosseous implants-Epi-crestal|Implants placed Epi-crestally
1662208|NCT01759524|Drug|Bupivacaine|
1662209|NCT01759524|Drug|Lidocaine|
1662210|NCT01759511|Drug|Simtuzumab|200 mg/mL administered intravenously biweekly (per original protocol) or 125 mg/mL self-administered subcutaneously every 7 ± 2 days (per protocol amendment 1)
1662211|NCT01759498|Dietary Supplement|HYDRO|
1662212|NCT01759498|Dietary Supplement|ACTIVE|
1662213|NCT01759498|Dietary Supplement|HYDRO 2|
1662214|NCT01759485|Drug|Vitamin D3|once weekly oral drops preparation at a daily dose of 2000 IU X 7 = 14,000 IU per week (about 60 drops each week).
1662215|NCT01759485|Drug|placebo|
1662219|NCT01759446|Drug|Hydrocodone/Acetaminophen|
1662220|NCT01759420|Drug|Ondansetron|4mg of intravenous ondansetron
1662221|NCT01759407|Drug|Ropivicaine|
1662222|NCT01759394|Drug|Avatrombopag maleate 40 mg|"Avatrombopag maleate 40 mg (2 x 20 mg tablets- all doses are expressed as avatrombopag, the amount of free base) given with 240 mL water in three single oral doses, one during each of three treatment periods. Participants randomized to one of three treatment sequences:
Fed, Fed, Fasted; or
Fed, Fasted, Fed; or
Fasted, Fed, Fed
During the Fasted period, participants must have fasted for at least a 10-hour overnight fast and to refrain from eating for 4 hours.
During the Fed period, participants were allowed approximately 30 minutes to eat a low-fat breakfast and required to take the drug within 15 minutes of completion of breakfast.
Randomization Phase consists of three single-dose treatment periods:
Treatment Period 1 and 2 separated by a 7-day washout interval. Treatment Period 2 and 3 separated by a 28-day washout interval. Treatment period 3 and the Follow-up/ Termination Visit will be separated by a 30-day (+1 day) washout interval."
1662223|NCT01759381|Device|Negative pressure wound therapy (NPWT)|
1662306|NCT01758471|Drug|Glipizide|glipizide 5mg per pill 5mg tid p.o. for 3 month
1662307|NCT01758471|Drug|Acarbose|Acarbose 50mg per pill 100mg to 150mgtid p.o.（oral） for 3 month
1662308|NCT01758458|Biological|Aldesleukin|Given SC
1719938|NCT00002945|Drug|etoposide|IV
1662224|NCT01759368|Device|Telemonitoring assisted self-care|Telemonitoring group was given a home-care package including a weight scale, a blood pressure meter, a mobile phone and self-care instructions. The measurements taken at home to be uploaded were: diastolic and systolic blood pressure, pulse, body weight and an assessment of symptoms. The symptom assessment concerned the patient's feelings of dizziness, dyspnea, palpitation, weakness and, oedema. Patients were also asked to evaluate their overall condition- whether their condition had deteriorated, improved or remained unchanged. The patients were advised to carry out and report the measurements together with the self-assessment once a week. The responsible nurse followed patients' status and the data once a week or more frequently if needed. Based on the reported measurements, the nurse could invite the patient for a control visit. In case a patient did not make self-measurements as planned , the nurse contacted the patient and reminded him/ her to continue with monitoring
1662225|NCT01759355|Procedure|FDG PET/MR|Participants will undergo a FDG, gadolinium enhanced PET/MR scan.
1662226|NCT01759342|Behavioral|Aerobic exercise|
1662227|NCT01759342|Behavioral|Resistance exercise|
1662228|NCT01759342|Behavioral|Flexibility and postural exercise|
1662229|NCT01759342|Behavioral|Balance exercise|
1662230|NCT01759329|Dietary Supplement|test coffee|test coffee with higher alkyl pyridine content
1662231|NCT01759329|Dietary Supplement|control coffee|control coffee with regular alkyl pyridine content
1662232|NCT01759316|Other|heliox|heliox or oxygen is used in the two groups respectively
1662233|NCT01759303|Drug|pazopanib|"For subjects > 18 years of age and subjects 16-17 years of age with a BSA ≥ 1.6 Pazopanib 800mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity.
For subjects 16-17 years of age with a BSA < 1.6 m2, Pazopanib 600mg once daily will be started on Cycle 1 Day 1 and will be administered continuously for each 28-day cycle. Subjects may continue study treatment until they develop disease progression or unacceptable toxicity."
1662234|NCT01759290|Device|Absorb Bioresorbable Vascular Scaffold|Subjects receiving the Absorb Bioresorbable Vascular Scaffold
1662235|NCT01759277|Drug|Active comparator: Control: Femoral perineural local anesthetic infusion|The control group will receive a femoral nerve catheter and block under ultrasound guidance with the final position of catheter posterior to the femoral nerve and lateral to the femoral artery. Normal saline up to 10ml will be injected if necessary for hydro-dissection via the needle. The catheter will then be threaded 3-5cm past the needle tip and its location will be confirmed by a 30ml bolus of lidocaine 2% via the catheter under ultrasound visualization. The control group will receive a standardized general anesthetic with inhaled volatile anesthesia in nitrous oxide and oxygen or bupivacaine spinal anesthetic.
1662236|NCT01759277|Drug|Experimental: Adductor Canal perineural local anesthetic infusion|The experimental group will receive an adductor canal catheter and block under ultrasound guidance with the final position of catheter between the femoral artery and nerve. Normal saline up to 10ml will be injected if necessary for hydro-dissection via the needle. The catheter will then be threaded 3-5cm past the needle tip and its location will be confirmed by a 30ml bolus of lidocaine 2% via the catheter under ultrasound visualization. The control group will receive a standardized general anesthetic with inhaled volatile anesthesia in nitrous oxide and oxygen or bupivacaine spinal anesthetic.
1662237|NCT01759238|Drug|Capecitabine|825mg/m2 per os bid
1662238|NCT01759238|Drug|Bevacizumab|7.5 mg/kg
1662239|NCT01759238|Radiation|Radiotherapy|(conventional or intensity-modulated and image-guided radiotherapy)
1662240|NCT01759212|Biological|Allogeneic stem cells implantation|
1662241|NCT01759199|Procedure|Pulmonary rehabilitation assessed with six-minute walk test and six-minute stepper test|
1662242|NCT01759160|Procedure|Marsh Plasma TCI with high initial target|plasma target-controlled infusion in Marsh model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
1662243|NCT01759160|Procedure|Schnider Plasma TCI with high initial target|plasma target-controlled infusion in Schnider model(n=30) with an initial target concentration of 4 μg/ml. Target was then reset and gradually titrated to a sedation level with narcotrend index below 64.
1662244|NCT01759147|Procedure|Surgical treatment of acromioclavicular dislocation.|Coracoclavicular ligament repair using autogenous gracilis tendon implanted using an endobutton system containing fibrewires and a single transclavicular, transcoracoid bone tunnel.
1662245|NCT01759134|Other|Post discharge formula|Babies will be given either materna sensitive or similac neosure
1662248|NCT01759108|Drug|Rebamipide|Patients will be randomized 1:1 to receive either 300mg/d (100mg x3/day) of rebamipide or placebo for 12 weeks together with their usual therapy.
1662249|NCT01759095|Device|Electronic multidrug blister pack|At hospital discharge, patients will get their prescribed drugs repackaged in an electronic multidrug blister pack with 7x4 cavities. The electronic film affixed on the rear side measures the date and time when a loop is broken, i.e. when a cavity is emptied. Patients will get feedback on their adherence profiles at the community pharmacy.
1662250|NCT01759069|Procedure|Surgical treatment with microscope|
1662251|NCT01759056|Drug|AVX 470|active comparator
1662252|NCT01759056|Drug|Placebo|
1662253|NCT01759043|Procedure|guiding catheter|using a single transradial guiding catheter for coronary angiography and intervention
1662254|NCT01759043|Procedure|diagnostic catheter|diagnostic for coronary angiography and guiding catheter selection for intervention
1662255|NCT01759030|Drug|Rituximab|Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
1662256|NCT01759004|Other|volume, muscle strength, physical condition, BMI|phys. condition, muscle strength, volumetry, BMI
1662257|NCT01758991|Device|transcranial direct current stimulation (tDCS)|tDCS is a safe and painless transcranial stimulation that modulates brain activity and could improve stroke recovery. Electrodes in soaked sponges are placed over specific brain regions and held with an elastic band. Direct current is then applied through the electrodes. The patients may feel nothing or a slight tingling under the electrodes.
1662258|NCT01758978|Drug|a 60 mg dose of the hydrocodone bitartrate extended-release tablet administered as either two 30-mg tablets (Treatment A) or one 60-mg tablet (Treatment B).|Each subject will receive 1 treatment during each administration period. Subjects will receive each of the 2 treatments once. There will be a minimum 14-day washout period between the 2 administrations of study drug. Treatments will be orally administered to subjects, while they are seated, at approximately 0800 (±2 hours) on the 1st day of each administration period.
1662259|NCT01758965|Other|PPI|monotherapy of PPI
1662260|NCT01758965|Other|H2RA and surgicel|combination therapy of H2RA and surgicel
1662261|NCT01758913|Drug|Ibuprofen|To compare the efficacy, the side effects and the renal prostaglandin (PG) excretion between indomethacin and ibuprofen in extremely low birth weight (ELBW) infants.
1662262|NCT01758900|Device|CO2 insufflation regulator|The CO2 insufflation regulator is Olympus UCR(Olympus Optical Co., Ltd., Tokyo, Japan). The device connect the medical gas pipe joints and CO2 cylinders, then the CO2 gas will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
1662263|NCT01758900|Device|Air insufflation|The air will be pumped into the delivery tube which links to the water bottle until it insufflate the bowel through the SBE.
1662264|NCT01758874|Procedure|phlebotomy|repeated phlebotomy for 4 weeks
1662265|NCT01758861|Drug|EPO group|
1662266|NCT01758861|Drug|Placebo|
1662267|NCT01758835|Other|Splint 3 weeks|A removable orthosis/splint. Dynacast/Ortho-Glass AS (BSN Medical). Splint is used for 3 weeks and no additional support is used after splint removal.
1662268|NCT01758835|Other|Cast 3 weeks|A standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is removed after 3 weeks and no additional support is used after cast removal.
1662269|NCT01758835|Other|Cast 6 weeks|standard short boot cast from proximal tibia to MTP I-V joint line. Cast is made from 3M Scotchcast. Cast is changed after 3 weeks and removed after 6 weeks. No additional support is used after cast removal.
1662270|NCT01758822|Other|No endotracheal suction|Neonates in this group will be resuscitated without endotracheal suction in the initial steps of resuscitation.
1662271|NCT01758809|Procedure|Pre-emptive bupivacaine wound infiltration|Pre-emptive bupivacaine wound infiltration
1662272|NCT01758809|Procedure|intravenous patient controlled analgesia|postoperative pain control with intravenous patient controlled analgesia
1662273|NCT01758796|Procedure|Non-operative treatment|6 weeks in a cast. 4 weeks with partial weight bearing and last 2 weeks weight bearing as tolerated.
1662274|NCT01758796|Procedure|Operative treatment|Open reduction and osteosynthesis with semi-tubular plate and cortical screws.
1662275|NCT01758783|Drug|Glutamine|amino acid：1.2-2g/(kg·d) Glutamine：0.5g /(kg·d)
1662276|NCT01758757|Procedure|Vitrectomy|
1662277|NCT01758744|Drug|Inhaled Treprostinil Therapy|Treprostinil: Inhaled prostanoid therapy
1662278|NCT01758731|Drug|Olaparib|Olaparib PO (25, 50, 100 or 200 mg bid) in combination with RT and C225. BID, beginning three days prior to first C225 infusion and discontinued after RT completed.
1662279|NCT01758731|Drug|Cetuximab|Pre-RT cetuximab (C225), 400 mg/m²IV and weekly C225, 250 mg/m2 IV in during RT.
1662280|NCT01758731|Radiation|Radiation Therapy|RT to a total dose of 69.3 Gy (primary tumor and involved lymph nodes) in 33 fractions over 6 and 1/2 weeks
1662281|NCT01758718|Procedure|Eyelash line resection|Eyelash resection surgery was performed for entropion with Down's syndrome
1662282|NCT01758679|Biological|Licartin and CIK|Licartin and CIK
1662283|NCT01758666|Drug|Methotrexate,Calcium folinate|
1662284|NCT01758653|Other|No study intervention|There is no study-related intervention.
1662285|NCT01758640|Drug|Warfarin|Low dose warfarin of 5mg or less per day
1662286|NCT01758640|Drug|phenindione|Phenindione of 100mg or less per day
1662287|NCT01758627|Drug|Peritoneal dialysis (PD)|PD exchanges will be customized depending on patient fluid status. At least one daily exchange of icodextrin PD solution will be provided to PD group.
1662288|NCT01758614|Procedure|bypass surgery|all participants in this group will be performed EC-IC bypass surgery
1662289|NCT01758614|Drug|Aspirin|all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day
1662290|NCT01758614|Drug|Clopidogrel|
1662291|NCT01758601|Other|Dietary intervention with 7 servings oh white fish per week (each serve consisted of 100g of frozen Namibia hake, Pescanova S.A., Pontevedra, Spain)|
1662292|NCT01758601|Other|Previous alimentary habits, avoiding any significant nutritional imbalance, as well as any fish or seafood|
1662293|NCT01758588|Drug|Peginterferon alfa-2a|50 mcg subcutaneous injection once per week
1662294|NCT01758562|Device|Caphosol|
1662295|NCT01758549|Other|Aggressive Intravenous Hydration Group|Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.
1662296|NCT01758549|Other|Standard Fluids Arm|Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
1662297|NCT01758536|Drug|Huatuo Zaizao Pills|A tens of herbs botanical drug product 12 gram (g) in 72 mini pills formulation. It is to be used as 12 g each time, twice daily.
1662298|NCT01758523|Drug|Dutasteride|
1662299|NCT01758523|Drug|sugar pill|
1662300|NCT01758510|Genetic|HYNR-CS-Allo|The patients enrolled in the trial will be successively allocated into three cohorts for HYNR-CS-Allo inj., 0.25 X 10^6 cells/kg, 0.5 X 10^6 cells/kg, 1 X 10^6 cells/kg, according to the 3+3, up and down protocol design. The first treatment cohort will be 0.5 X 10^6 cells/kg dose cohort.
1662301|NCT01758497|Procedure|Fascia iliaca compartment block|30 ml 0.5% ropivacaine, beneath the fascia iliaca
1662302|NCT01758497|Procedure|Fascia Iliaca compartment block|30 ml 0.9% NaCl (sham block, SB), beneath the fascia iliaca
1662303|NCT01758484|Other|palliative care|Undergo supportive care intervention
1662304|NCT01758484|Other|questionnaire administration|Ancillary studies
1662305|NCT01758484|Procedure|quality-of-life assessment|Ancillary studies
1719939|NCT00002945|Drug|idarubicin|IV
1662312|NCT01758458|Biological|Recombinant Interferon Beta|Given intralesionally
1662313|NCT01758445|Radiation|Proton Radiotherapy|Radiation therapy will be given once a day. Minimum of 28 treatments and may receive 6-9 additional treatments as determined by protocol & physician.
1662314|NCT01758432|Biological|PRT064445|
1662315|NCT01758432|Biological|Placebo|
1662316|NCT01758419|Radiation|Thallium-201 Myocardial Perfusion Study|One-day Tl-201 stress/rest MPI protocol with pharmacological stress, as daily practice will be applied. CZT camera with multipinhole collimator and stationary detectors scan heart simultaneously. A 10% symmetrical energy window at 140 keV was used. Electrocardiogram-gated scans will be applied. Perfusion images were reconstructed in standard axis and polar maps of the left ventricle were obtained. Scans from CZT was analyzed in consensus by two experienced readers blinded to any information on patient identification. The software package Myovation for Alcyone, QGS and QPS were used for quantitative analysis of MPI polar maps. Automated analysis to determine ejection fraction.
1662317|NCT01758406|Biological|Intracoronary injection|stem cell transplantation
1662318|NCT01758406|Biological|Intracoronary injection of Placebo|Injection of Placebo via coronary arteries in patients with heart failure.
1662320|NCT01758380|Drug|Vildagliptin|Patients will be instructed to take Vildagliptin tablets at a fixed dose of 50 mg twice daily (double blind therapy)
1662321|NCT01758380|Drug|Gliclazide|Patients will be instructed to take Gliclazide capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
1662322|NCT01758380|Drug|Metformin|Patients in both arms will take Metformin at a dose between 1500mg-2500mg per day, in an open label fashion
1662323|NCT01758380|Drug|Placebo to Gliclazide|Patients will be instructed to take the Gliclazide matching placebo capsules at an equivalent dose to previous sulfonylurea in multiples of 80mg only (double blind therapy)
1662324|NCT01758380|Drug|Placebo to Vildagliptin|Patients will be instructed to take Vildagliptin matching placebo tablets at a fixed dose of 50 mg twice daily (double blind therapy).
1662325|NCT01758367|Drug|Deciatbine(DAC)|
1662326|NCT01758354|Other|Pompe disease newborn screening|DBS will be tested for acid alpha-glucosidase (GAA)activity. Newborns with low GAA activity will received a confirmatory blood sampling and clinical evaluation for the presence of cardiomyopathy.
1662327|NCT01758341|Procedure|Endoscopic radiofrequency ablation|Endoscopic radiofrequency ablation with the HabibTM EndoHBP catheter uses bipolar electrical energy for tissue coagulation and can be applied without any special patient preparation in the context of an endoscopic retrograde cholangiopancreatography (ERCP) examination to treat malignant biliary strictures.
1662328|NCT01758341|Procedure|Endoscopic retrograde cholangiopancreatography (ERCP)|ERCP is used to guide the RFA-catheter under radiological control to the location of the malignant stricture.
1662329|NCT01758341|Device|HabibTM EndoHPB catheter|"Used to apply radiofrequency energy to the malignant biliary stricture (see also intervention endoscopic radiofrequency ablation)"
1662330|NCT01758328|Drug|busulfan|
1662331|NCT01758328|Drug|melphalan|
1662332|NCT01758328|Drug|fludarabine|
1662333|NCT01758328|Biological|anti-thymocyte globulin (ATG)|
1662334|NCT01758328|Procedure|a T cell depleted stem cell transplant|
1662335|NCT01758315|Other|Training and in-office coaching|Participating practices will be coached to perform rapid, small-scale tests of change and to iteratively improve performance of problem-prone care systems, as well as to imbed simple measurement in routine daily work streams to guide improvement efforts. The sixteen intervention practices will serve as realistic research laboratories to help advance malpractice risk prevention and patient safety in specific areas by refining tools and strategies for smaller practices.
1662336|NCT01758302|Behavioral|Simple physical task|Participants are asked to complete a 1-time simple physical task that is not challenging nor novel (moving small objects across a room).
1662337|NCT01758302|Behavioral|Complex physical task|Participants are asked to complete a 1-time physical task that is low intensity but somewhat complex (involves a novel request to move objects in a way that is challenging and requires some coordination).
1662338|NCT01758302|Other|Cookies|Participants are asked to taste test chocolate chip cookies
1662339|NCT01758302|Other|Vegetables|Participants are asked to taste test raw celery or radishes
1662340|NCT01758302|Behavioral|No physical task|As a control, for 2 of the arms, participants are not asked to engage in a physical task
1662341|NCT01758263|Drug|Metoprolol|Metoprolol, oral administration
1662342|NCT01758263|Drug|Nebivolol|Nebivolol, oral administration
1662343|NCT01758250|Other|Acoustic Radiation Force Impulse (ARFI)|
1662344|NCT01758250|Other|Laser Doppler Flowmetry (LDF)|
1662345|NCT01758250|Other|Laser Doppler Perfusion Imaging (LDI)|
1662346|NCT01758250|Other|Optical Coherence Tomography (OCT)|
1662347|NCT01758250|Other|Orthogonal Polarization Spectral Imaging (OPSI)|
1662348|NCT01758250|Other|Nail fold video capillaroscopy (NVC)|
1662349|NCT01758237|Device|Neodymium-doped: Yttrium Aluminum Garnet (Nd:YAG) laser|This device is used to perform the peripheral iridotomy on all patients. It is a standard of care approved device.
1662350|NCT01758237|Procedure|Nd:YAG Laser Peripheral Iridotomy|After application of topical anesthetic to the eye undergoing the LPI, the patient is seated at the laser machine. Abraham iridotomy lens filled with a viscous material will be used to facilitate the procedure. The thinnest area of the iris quadrant treated will be chosen. Nd:YAG Laser will be applied until iridotomy is opened satisfactory.
1662351|NCT01758224|Other|Functional Magnetic Stimulation|The magnetic stimulation protocol (plan of study) consists of a daily expiratory (breathing out) muscle conditioning program (20 minutes). A magnetic coil will be placed on participant's back to stimulate the nerves related to the breathing function. Each stimulation will last two seconds and the time between each stimulation is about half a minute. The training session will begin with low intensity FMS for 20 minutes daily. The FMS stimulation intensity will gradually increase during the 6-week training period.
1662434|NCT01757457|Drug|Intracoronary administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
1662435|NCT01757457|Drug|Intravenous administration of an abciximab bolus during primary PCI|Intracoronary administration of an abciximab bolus (reopro 0.25mg/kg) during primary PCI
1662352|NCT01758224|Other|Resistive Expiratory Muscle Training|The REMT training will take place in the FMS lab using a standard resistive breathing device. After training, participants will perform the exercise for 20 minutes daily (5days each week for 6 weeks) in their home. Participants will wear a nose clip when performing the breathing exercise. The exercise protocol will begin with a low resistance level for 20 minutes a day. The resistance level will gradually increase during the 6-week training period.
1662353|NCT01758211|Procedure|fMRI Navigation AVM resection|intraoperative fMRI navigation guided resection in AVM patients
1662354|NCT01758211|Procedure|conventional resection|conventional resection in AVM patients
1662355|NCT01758198|Biological|Abatacept|
1662356|NCT01758198|Drug|Placebo matching with Abatacept|
1662357|NCT01758198|Drug|Methotrexate|
1662358|NCT01758185|Biological|recombinant hepatitis b vaccine|0.5ml intramuscular
1662359|NCT01758185|Biological|Aleph influenza vaccine|0.5ml intramuscular
1662360|NCT01758172|Drug|6% hydroxyethyl starch 130/0.4|
1662361|NCT01758172|Drug|Albumin|
1662362|NCT01758159|Dietary Supplement|Iron supplementation|
1662363|NCT01758159|Other|CFR|Complementary feeding with locally available foods according to optimized complementary feeding recommendation (CFR)
1662364|NCT01758146|Drug|Tamoxifen|20 mg once daily for 5 years
1662365|NCT01758146|Drug|Letrozole|Letroz, Femara, Letronat
1662366|NCT01758133|Behavioral|Exposure to medical clown activities|
1662367|NCT01758120|Drug|prednisone plus cyclophosphamide|"prednisone plus cyclophosphamide: prednisone(0.5mg/kg/day*6 months) plus cyclophosphamide(1g intravenous use,per 1 month*6months);
supportive care,including ACE-I or ARBs and blood pressure control"
1662368|NCT01758120|Drug|Prednisone alone|"prednisone alone: prednisone(0.5mg/kg/day*6 months);
supportive care,including ACE-I or ARBs and blood pressure control"
1662369|NCT01758107|Other|Withdraw cyclosporine|
1662370|NCT01758094|Drug|Sustanon 250 mg ampule (Testosterone esters)|Drug used for treatment of hypogonadism
1662371|NCT01758081|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
1662372|NCT01758081|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
1662373|NCT01758081|Dietary Supplement|Vitamin D3 placebo|
1662374|NCT01758081|Dietary Supplement|fish oil placebo|
1662375|NCT01758068|Procedure|Coconut Oil Application|Coconut oil - 4 ml
1662376|NCT01758055|Biological|Autologous MSCs transplantation|Autologous mesenchymal stem cells derived bone marrow, bronchoscopy
1662377|NCT01758042|Procedure|Haploidentical Bone Marrow/Kidney|Combined bone marrow and kidney transplantation using a haploidentical donor.
1662378|NCT01758029|Drug|testosterone undecanoate|treatment with testosterone undecanoate 1000mg intramuscular, at week 0, week 6, week 18.
1662379|NCT01757990|Dietary Supplement|Effect of Stevioside and Rebaudioside on plaque pH|After measuring baseline plaque pH, the subjects rinsed for 1 minute with the sucrose solution. Plaque pH was then measured at 5, 10, 15, 30, 45 and 60 min after the mouth rinse.
1662380|NCT01757977|Device|double lumen endotracheal tube placement and use|
1662381|NCT01757964|Biological|Bacteriotherapy|
1662382|NCT01757951|Procedure|Talocrural joint is stable after fixation of medial malleolus. Patient is then randomized|
1662383|NCT01757938|Procedure|Shang Ring Guided Circumcision|
1662384|NCT01757938|Procedure|Forceps Guided Circumcision|
1662385|NCT01757925|Behavioral|weight managment program|a comprehensive peditric weight management program consisting of 16 weekly group sessions
1662386|NCT01757925|Other|Active Gaming|partcipants will be given a gaming device and 2 games (1 at baseline and 1 at week 8)
1662387|NCT01757912|Procedure|cuff pressure|The patient will be positioned in 16 distinct body positions, immediately after correct positioning, the cuff pressure is measured during an end-expiratory ventilator hold.
1662388|NCT01757899|Drug|Methylprednisolone Arm|Day 0 - Loading dose 1 mg/kg IV bolus mixed in 5 mL NS (30 min) followed by continuous infusion Days 0 to 07 - 1 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 08 to 10 - 0.5 mg/kg/day mixed in 24cc NS and infused at 1 cc/hr Days 11 to 12 - 0.25 mg/kg/day Days 13 to 14 - 0.125 mg/kg/day
1662389|NCT01757899|Drug|Sterile Saline Arm|Patients randomized to the control arm will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 24 cc [methylprednisolone + diluting fluid], then the patient will receive 24 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm, so that investigators will remain blinded to therapy. The unblinded party will be composed of the research ARDS pharmacist. Five days after the patient is able to ingest medications, placebo is administered per os (PO) in one single daily equivalent dose. The placebo will be manipulated by the pharmacist as to resemble identical to the active drug.
1662390|NCT01757886|Other|Biomarkers to analyze both intracoronary thrombi as blood|
1662391|NCT01757873|Drug|Z160|
1662392|NCT01757873|Drug|Placebo|
1662393|NCT01757860|Drug|CARD-024|Comparison of different dosages of drug
1662394|NCT01757860|Other|Drug Carrier|Drug Carrier, 20% ethanol:80% propylene glycol oral administered solution.
1662395|NCT01757847|Behavioral|Acceptance and Commitment Therapy (ACT)|The ACT group protocol consists of four 2-hour weekly sessions focusing on a) thoughts, feelings, and bodily sensations in the context of efforts to lose weight; b) limitations of efforts to control or eliminate negative thoughts or emotions, stress, or food cravings; c) changing expectations and goals from elimination of stress or cravings to living as well as possible with such feelings; d) mindfulness exercises to increase awareness; and e) identification of personal values and goals to achieve improved quality of life.
1662432|NCT01757509|Other|Intervention group|"Participants will attend eight weeks of set dancing classes. Each class will be one and a half hours. Family members or volunteers will partner each participant with Parkinson's disease. The class will be led by a Chartered Physiotherapist who is also a set dancing teacher. Set dancing steps and sets will be thought and progressed in line with the participants' abilities. Frequent rests will be taken during the class.
Participants will be given a home exercise programme which will involve mental rehearsal, listening to music, watching dance DVD's and practicing dance material in the seated position to reduce the risk of falling."
1662433|NCT01757496|Device|Cough Assist|
1662396|NCT01757847|Behavioral|Brief MOVE-II control group intervention|The MOVE-II protocol was designed to reinforce the weight-loss principles that patients learn in MOVE! and to provide support in continued weight loss. The brief MOVE-II active control group protocol will be delivered in four 2-hour weekly group sessions. This protocol includes a psycho-educational component that reinforces the key information from the medical, nutrition, and weight loss strategies modules of the MOVE! program. After review of the psycho-educational components, patients have the opportunity to share their challenges with binge eating and weight loss. Patients will then be able to receive support and feedback from other group members and the therapist. In addition to reinforcing the strategies taught during MOVE! and to provide support in implementing those strategies, the active control group focuses on increasing self-esteem and self-efficacy by exploring patient strengths and maintaining therapeutic alliance and optimism.
1662397|NCT01757834|Device|SWUS Elastography|
1662401|NCT01757808|Drug|Ranolazine|ranolazine sustained release at a dose of 500mg for one month followed by a dose of 1000mg.
1662402|NCT01757808|Drug|Placebo|placebo at a dose of 500mg for one month followed by a dose of 1000mg.
1662403|NCT01757795|Drug|SP-8203|SP-8203 injection at single ascending doses of 10 mg, 20 mg, 40 mg, 80 mg, 160 mg and 240 mg (optional) SP-8203 injection at multiple ascending doses for 7 days at least 2 dose levels below the MTD in the single ascending portion of the trial
1662404|NCT01757795|Drug|Placebo|
1662405|NCT01757782|Drug|Oral Sildenafil|Patients were randomized into two groups. Placebo was prepared with distilled water. In group A, newborns received oral Sildenafil solution through feeding tube which was prepared by crushing a 50 mg tablet of sildenafil in distilled water to make a concentration of 5 mg/ml. In group B, newborns received placebo. The protocol for dosing was (1) first dose of 1 mg/kg/dose within 30 minutes admission or within 12 hours of delivery (whichever earlier), (2) Dosing every six hours for a maximum of 8 doses, (3) Dose was doubled if the oxygenation index (OI) or SpO2 did not improve (If OI continued to be <10% of previous value and SpO2 was not increasing >5 of previous value) and blood pressure remained stable
1662406|NCT01757782|Drug|Placebo (distilled water)|
1662407|NCT01757769|Drug|Silodosin|8 mg daily for 24 weeks
1662408|NCT01757756|Drug|Pf-05175157|200-mg administered twice daily for 14 days
1662409|NCT01757756|Drug|placebo|placebo administered twice daily for 14 days
1662410|NCT01757756|Drug|midazolam|midazolam 3-mg admistered as single doses on Day 0 and Day 11.
1662411|NCT01757717|Radiation|Ir-192 high dose rate (HDR)|Patients will be followed at 2 months (+/- 2 weeks) post-treatment and then approximately every 3 months (+/- 2 weeks) until approximately 11 months of follow up. They will be evaluated for pain referable to the treated site, clinical and radiographic evidence of local progression, and treatment related toxicity. Thereafter, patients will be followed as clinically indicated.
1662412|NCT01757704|Procedure|Open pleurae & conventional filling of heart|After completion of the left heart surgery, the heart will be actively filled with blood from the cardiopulmonary bypass circuit and lungs fully ventilated with positive end-expiratory pressure to flush out all air trapped in the lung veins and left heart. When there is no more visible air seen on Trans-esophageal echocardiography, the patient is weaned from cardiopulmonary bypass.
1662413|NCT01757704|Procedure|Intact pleurae & staged filling of heart|After the end of the left heart surgery, the heart is gradually filled with blood from the cardiopulmonary bypass circuit. Cardiac contractions fill the lungs with blood til no more air is seen in left heart on Trans-esophageal Echocardiography. Thereafter the lungs are ventilated with 50% of the estimated lung minute volume and 5 cm positive end-expiratory pressure and cardiac filling and de-airing continued. If no air is seen in the left heart full ventilation is started and the patient is weaned from cardiopulmonary bypass.
1662414|NCT01757691|Drug|Fingolimod 0.5mg/daily|
1662415|NCT01757691|Drug|Placebo|
1662417|NCT01757665|Device|Edwards Aortic and Mitral Bioprostheses Models 11000A and 11000M|Implant of an aortic valve, Model 11000A or mitral valve, Model 11000M
1662418|NCT01757639|Biological|Ipilimumab|Given IV
1662419|NCT01757639|Other|Laboratory Biomarker Analysis|Correlative studies
1662420|NCT01757626|Biological|Hu3F8 With GM-CSF|Ph I: 1 cycle consists of treatment with hu3F8 for 3 days (day 1, 3 & 5). GM-CSF starts 5 days in advance of each hu3F8 cycle at 250 mcg/m^2/day (day -4 to day 0), & at 500 mcg/m^2/day x 5 days (day 1 to day 5). Hu3F8 cycles are 5 days. Ph II pts may receive treatment on a modified schedule of 3 doses of IV hu3F8 over a maximum of 10 days, as needed. With modified schedules of hu3F8, GM-CSF will be administered at 250 mcg/m2/day x5 days before the 1st dose of hu3F8, as with the standard schedule, but then GM-CSF at 500 mcg/m2/day will be administered on day of the 1st dose of hu3F8, on the day before and on the day of the 2nd dose of hu3F8, and on the day before and on the day of the 3rd dose of hu3F8. Cycles are repeated at 2-4 week intervals between 1st days of hu3F8, through 4 cycles. Pts who complete 4 cycles of treatment w/o complications or disease progression have the option of continuing treatment for up to 24 months from their 1st dose of hu3F8.
1662421|NCT01757613|Drug|AK 3012|cutaneous use twice a day
1662422|NCT01757600|Other|Microperimetry|
1662423|NCT01757587|Drug|Vildagliptin|50 mg, 2 tablets/day on 3 months, both periods of treatment
1662424|NCT01757587|Drug|Placebo|50mg 2 tablets / day on 3 months, both periods of treatment
1662425|NCT01757574|Drug|Alemtuzumab infusion|
1662426|NCT01757561|Procedure|propofol|use total intravenous anesthesia with propofol
1662427|NCT01757561|Procedure|sevoflurane|use inhalation anesthesia with sevoflurane
1662428|NCT01757548|Procedure|open operation|high ligation of spermatic vein by open operation
1662429|NCT01757548|Procedure|microsurgery|high ligation of spermatic vein by microsurgery
1662430|NCT01757535|Drug|300 mg Oral Azacitidine|Maintenance therapy
1662431|NCT01757535|Drug|Placebo|
1662583|NCT01756339|Drug|Solithromycin|
1662436|NCT01757444|Device|BiPAP - A40|Patients receiving BiPAP AVAPS - AE ventilatory mode at home
1662437|NCT01757444|Device|BiPAP - ST|Patients receiving BiPAP- ST mode at home.
1662438|NCT01757431|Drug|Eculizumab|
1662439|NCT01757418|Drug|Immune Globulin Intravenous|A single dose of intravenous immune globulin or saline placebo administered within 24 hours of hospital presentation. The maximum dose in Phase I was 800 mg/kg. The dose for Phase II is 400mg/kg.
1662440|NCT01757418|Drug|Normal saline|A single dose of normal saline administered within 24 hours of hospital admission for uncomplicated pain crisis.
1662443|NCT01757392|Biological|Candida albicans Skin Test Antigen|0.3 ml injected intralesionally monthly. Number of injections: until wart lesion is resolved or up to 6 injections.
1662444|NCT01757379|Dietary Supplement|13C-labeled Acetate|400 mg of sodium acetate 1-13C (2 colon delivery capsules with 200 mg)
1662445|NCT01757379|Dietary Supplement|13C-labeled propionate|340 mg of sodium propionate 1-13C (2 colon delivery capsules with 170 mg)
1662446|NCT01757379|Dietary Supplement|13C-labeled butyrate|990 mg sodium butyrate 1-13C (2 colon delivery capsules with 495 mg)
1662447|NCT01757379|Dietary Supplement|Inulin|15 g of inulin dissolved in 200 ml of water
1662448|NCT01757366|Drug|Ginsenoside Rg3 plus First-line Chemotherapy|"Ginsenoside Rg3 20mg 2/day po,patients will receive Ginsenoside Rg3 until progression
XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression"
1662449|NCT01757366|Drug|First-line Chemotherapy|XELOX(oxaliplatin 130mg/m2 iv d1;capecitabine 1000mg/m2 po bid d1-14)every 3 weeks for 4 cycles followed by capecitabine until progression
1662450|NCT01757353|Behavioral|BASICS motivational interview|
1662451|NCT01757353|Behavioral|BASICS plus normative enhancement motivational interview|
1662452|NCT01757353|Behavioral|Self-directed: Information only|
1662453|NCT01757340|Behavioral|Weight loss with normal protein and leucine intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
1662454|NCT01757340|Behavioral|Weight loss with protein/leucine supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day) with the additional protein given in the form of whey protein, which has a high leucine content.
1662455|NCT01757327|Drug|Erismodegib|
1662456|NCT01757327|Drug|Placebo|
1662457|NCT01757314|Behavioral|ultrasound technique|instruction in the ultrasound technique
1662458|NCT01757314|Other|palpation technique|placement of a line via palpation technique
1662459|NCT01757301|Other|Assisted Symptom Management (ASM)|There will be 2 principal components to assisted symptom management (ASM): automated symptom monitoring, along with pain and mood self-management modules.
1662460|NCT01757301|Other|Comprehensive Symptom Management (CSM)|"This arm couples ASM with care management by a nurse-physician team, thus testing combined therapy vs. monotherapy (ASM only)."
1662461|NCT01757288|Drug|NAB-PACLITAXEL|
1662462|NCT01757288|Drug|PACLITAXEL|
1662463|NCT01757275|Drug|Esomeprazole Na|Given as 80mg bolus infusion during 30 min and then 8mg/h constant infusion during 71.5 hous
1662464|NCT01757275|Drug|Cimetidine|Given as 200mg bolus infusion during 30 min and then 60mg/h constant infusion during 71.5 hours
1662465|NCT01757275|Drug|Esomeprazole Mg|40 mg tablet once daily for 27 days
1662466|NCT01757262|Drug|90 mg Ticagrelor|Morning and Evening dose for 5 days
1662467|NCT01757262|Drug|75mg Clopidogrel|Morning dose for 5 days
1662468|NCT01757249|Drug|Combined Oral Contraceptive Pill (Microgynon 30)|Pre-IVF treatment for 8 weeks
1662469|NCT01757236|Drug|VANCOMYCIN|
1662470|NCT01757236|Drug|CEFTRIAXONE|
1662471|NCT01757236|Drug|CLINDAMYCIN|
1662472|NCT01757236|Drug|SULFAMETHOXAZOLE AND TRIMETHOPRIM (CO-TRIMOXAZOLE)|
1662473|NCT01757236|Drug|FLUOROQUINOLONE|
1662474|NCT01757236|Drug|LINEZOLID|
1662475|NCT01757236|Drug|RIFAMPIN|
1662476|NCT01757223|Biological|AdVEGF-All6A+|We will administer AdVEGF-All6A+, an adenovirus vector carrying the genetic material for human vascular endothelial growth factor to the ischemic myocardium of individuals with diffuse coronary artery disease.
1662477|NCT01757223|Biological|AdNull|AdNull is an adenovirus vector identical to AdVEGF-All6A+, except that it does not encode for a transgene.
1662478|NCT01757197|Drug|Toclizumab|8 mg/kg IV, once every 1-2 weeks. The maximum dose per infusion should not exceed 800 mg.
1662479|NCT01757184|Drug|SBC-102 [sebelipase alfa] (1 mg/kg)|
1662480|NCT01757184|Drug|Placebo|
1662481|NCT01757171|Drug|Cabazitaxel|20mg IV over 1 hour every 3 weeks
1662482|NCT01757158|Radiation|Cs-131 brachytherapy seeds|Cesium-131 is another radiation seed that may more effectively treat lung cancer patients. Cs-131 has been previously used in prostate cancer successfully. Cs-131 has similar energy to I-125 but has a much shorter half life (9days as compared to 60 days for I-125). Patients who receive Cs-131 radiation seeds are expected to be radioactive for 30 days (1 month) as compared to 180 days (6 months) with I-125.
1662483|NCT01757145|Drug|Eltrombopag|"From day +1, start eltrombopag 100 mg/d. If primary end point not reached on day +14, then from day +15 - 150 mg/d.
If primary end point not reached on day +28 then from day +29 - 200 mg/d. If primary end point not reached on day +42 then from day +43 and on - 300 mg/d maximal dose).
If present dose not tolerated, return to last tolerated dose. Eltrombopag will be discontinued after platelet count has exceeded 50,000/microliter for 14 consecutive days without administration of platelets. In case of decline of platelet count < 30,000/microliter within 15 days from eltrombopag discontinuation, it will be resumed for additional 4 weeks. After 4 weeks we will re-attempt to hold the drug (if the threshold of platelet count >50,000/microliter will be reached again)."
1662484|NCT01757132|Device|Implantable Miniature Telescope|Device - Implantable Miniature Telescope
1662485|NCT01757119|Drug|Tardyferon 80 mg|Oral administration (2 tablets)
1662486|NCT01757106|Drug|Xenon|general anaesthesia with xenon 50-60% in oxygen (FiO2=0.4-0.5)
1662487|NCT01757106|Drug|sevoflurane|general anesthesia with sevoflurane 1.4% in 50% oxygen/medical air
1662488|NCT01757093|Device|Automatic Tube Compensation plus CPAP|SPONTANEOUS BREATHING TRIAL WITH AUTOMATIC TUBE COMPENSATION plus CPAP
1662489|NCT01757093|Device|Continuous Positive Airway Pressure|SPONTANEOUS BREATHING TRIAL WITH CPAP
1662490|NCT01757080|Other|Cardiorespiratory performance assessment with ergospirometry test|
1662491|NCT01757080|Other|Biochemical analysis|
1662492|NCT01757067|Device|PVC ablation|This will compare symptoms, safety between ablation procedure vs medical therapy. Biosense Catheter used is not indicated specifically for PVC ablations and will be evaluated
1662493|NCT01757054|Dietary Supplement|ProNutrients Probiotic|Dosage is 1 individually wrapped packet (1 gram) containing probiotic powder per day for 21 days
1662494|NCT01757015|Drug|NVA237|NVA237 (50µg, o.d. via SDDPI) in the morning,
1662495|NCT01757015|Drug|Placebo to NVA237|Placebo to NVA237
1662496|NCT01757002|Behavioral|Teens randomized to the experimental arm will receive 4 sessions plus a booster of web-based, tailored asthma management.|Web-based, computer-tailored asthma management intervention delivered in 4 sessions, plus a 6 month booster.
1662497|NCT01757002|Behavioral|Teens in the control group will receive generic, web-based asthma education.|Web-based, generic asthma management intervention delivered in 4 sessions.
1662498|NCT01756989|Drug|Thalidomide, etoposide, celecoxib|"Thalidomide p.o. 1 mg/kg/day/1; the dose is gradually escalated, the maximum dose being 6 mg/kg/day. (The individual dose is set based on adverse effects.) Celecoxib p.o. 230 mg/m2/day/1-2, or in small children at 7 mg/kg/day in 1-2 doses.
Etoposide p.o. the initial dosage 20 mg/m2/day; the dose is gradually escalated, the maxi 70 mg/m2/day."
1662499|NCT01756976|Device|OrthoPat Advance|The device will be used initially in hysterectomy procedures. After a confirmation of product quality, the device will be used in routine orthopedic procedures.
1662500|NCT01756950|Biological|2 mg/kg CR8020|administered as a single 2-hour intravenous infusion
1662501|NCT01756950|Biological|5 mg/kg CR8020|administered as a single 2-hour intravenous infusion
1662502|NCT01756950|Biological|15 mg/kg CR8020|administered as a single 2-hour intravenous infusion
1662503|NCT01756950|Biological|30 mg/kg CR8020|administered as a single 2-hour intravenous infusion
1662504|NCT01756950|Biological|50 mg/kg CR8020|administered as a single 2-hour intravenous infusion
1662505|NCT01756950|Biological|Placebo|administered as a single 2-hour intravenous infusion
1662506|NCT01756937|Drug|Imotun|300.03mg/cap,orally, 1 capsule once daily for 24 weeks
1662507|NCT01756937|Drug|Placebo|1 capsule once daily for 24 weeks
1662508|NCT01756924|Drug|CEM-102|
1662509|NCT01756924|Drug|IV or Oral standard of care antibiotics|
1662510|NCT01756924|Drug|Rifampin|
1662511|NCT01756911|Device|MFM|Implantation of the MFM
1662512|NCT01756898|Drug|ASB17061|Oral administration of ASB17061 taken once daily for 28 consecutive days.
1662513|NCT01756898|Drug|Placebo|Oral administration of placebo taken once daily for 28 consecutive days.
1662514|NCT01756885|Drug|Varenicline|
1662515|NCT01756885|Drug|Placebo|
1662516|NCT01756885|Behavioral|Smoking Cessation Counseling|
1662517|NCT01756872|Procedure|Measurements of ovarian reserve|Blood test (AMH, E2, FSH) Ultrasound measurement of antral follicle count and ovarian volume
1662518|NCT01756859|Procedure|MRI Scan|
1662521|NCT01756833|Drug|Doxycycline|100 mg po bid
1662522|NCT01756833|Drug|Placebo|capsule identical to the doxycycline capsule
1662523|NCT01756820|Procedure|Single-portal Endoscopic Carpal Tunnel Release (Microaire®)|SmartRelease® ECTR endoscopic carpal tunnel release system of MicroAire (http://www.microaire.com/products/ectr-endoscopic-carpal-tunnel/smart-release-ctrs/).
1662524|NCT01756820|Procedure|Knifelight|A mini-open single portal technique using the Knifelight® device (Stryker) according to the surgical technique as described by the manufacturer (antegrade approach)
1662525|NCT01756807|Device|The COMBO Stent|The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
1662526|NCT01756794|Procedure|Liver transplantation|
1662527|NCT01756781|Drug|Midazolam|Treatment A includes a single 2 mg oral dose of midazolam alone. Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
1662528|NCT01756781|Drug|PD-0332991|Treatment B includes 8 daily 125 mg oral doses of PD-0332991.
1662529|NCT01756781|Drug|Midazolam|"Treatment B includes a single 2 mg oral midazolam dose on day 7 immediately after the day 7 PD-0332991 dose.
Treatment A includes a single 2 mg oral dose of midazolam alone."
1662584|NCT01756339|Drug|Moxifloxacin|
1662530|NCT01756781|Drug|PD-0332991|Treatment B is made up of 8 daily 125 mg oral doses of PD-0332991.
1662531|NCT01756768|Radiation|[14C]-PD-0332991|A single 125 mg oral dose of PD-0332991 containing approximately 100 microcurie of [14C]-PD-0332991.
1662532|NCT01756755|Device|PMX-20R Hemoperfusion|Polymyxin B adsorbs and remove endotoxin from the patient's circulating blood.
1662535|NCT01756729|Device|NovoTTF-100A|Multiple four-week courses of continuous NovoTTF-100A treatment.
1662536|NCT01756716|Drug|MT-3995 Low|MT-3995 Low dose for 8 weeks
1662537|NCT01756716|Drug|MT-3995 High|MT-3995 High dose for 8 weeks
1662538|NCT01756716|Drug|Placebo|Placebo for 8 weeks
1662539|NCT01756703|Drug|MT-3995 Low|MT-3995 Low dose for 8 weeks
1662540|NCT01756703|Drug|MT-3995 High|MT-3995 High dose for 8 weeks
1662541|NCT01756703|Drug|Placebo|Placebo for 8 weeks
1662544|NCT01756651|Drug|Fentanyl pectin|comparison of Intranasal fentanyl 100mcg vs 200 mcg.
1662547|NCT01756612|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered at the discretion of treating physician. Study protocol does not specify any treatment regimen.
1662548|NCT01756599|Biological|blood samples|
1662549|NCT01756586|Drug|Dexamethasone|
1662550|NCT01756586|Drug|Bupivacaine|Control
1662555|NCT01756547|Drug|Potassium Citrate|Potassium citrate, oral solution contains Tripotassium citrate monohydrate 20 grams, Citric acid monohydrate 4 grams, distilled water 40 ml, and simple syrup 100ml. The solution contained in a bottle of glass that contains 20 ml of 2 meq/ml of potassium and 2.5 meq/ml of citrate. The dose is 0,3ml/kg/day of the solution until the 38-40 weeks of corrected gestational age or unacceptable toxicity develops.
1662556|NCT01756547|Drug|Placebo|
1662557|NCT01756534|Device|SURGICEL|Surgicel® (Johnson and Johnson, New Brunswick, NJ, USA), an oxidized cellulose hemostatic agent, is indicated in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or other conventional procedures is ineffective or impractical.
1662558|NCT01756521|Drug|Moxifloxacin|
1662559|NCT01756508|Drug|eculizumab|Eculizumab 1200 mg/m2 will be administered once, 1 hour before graft reperfusion
1662560|NCT01756495|Drug|Losmapimod|Wet granulation formulation, Film coated white, 7 mm round, biconvex, plain faced Tablet of 7.5 mg or 10 mg unit dose strength. Taken orally 7.5 mg BID / 20 mg QD for 5 days in one of the 4 study periods
1662561|NCT01756495|Drug|Moxifloxacin|17.2mm x 7.1 mm capsule shaped pink biconvex tablet of 400 mg unit dose strength. Taken orally 400 mg on Day 5 in one of the 4 study periods
1662562|NCT01756495|Drug|Losmapimod matched Placebo|Direct compression formulation (visually matched to GW856553), Film coated white, 7 mm round, biconvex, plain faced Tablet. Taken orally for 5 days in one of the 4 study periods
1662563|NCT01756495|Drug|Moxifloxacin Placebo|16 mm x 8 mm capsule shaped to white film coated tablet. Taken orally for 5 days in one of the 4 study periods
1662564|NCT01756482|Drug|GS-5806|GS-5806, powder for oral solution
1662565|NCT01756482|Drug|Placebo|
1662566|NCT01756469|Behavioral|Behavioral Intervention for Alcohol Use|Behavioral Intervention for Alcohol Use
1662567|NCT01756456|Drug|rhNGF 10 µg/ml eye drops solution|rhNGF 10 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only
1662568|NCT01756456|Drug|rhNGF 20 µg/ml eye drops solution|rhNGF 20 µg/ml eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only
1662569|NCT01756456|Drug|Placebo|Placebo eye drops solution, one drop 6 times a day for 8 weeks in the affected eye only.
1662570|NCT01756443|Drug|2% lidocaine/adrenaline and 0.5% bupivacaine|
1662571|NCT01756430|Drug|Carvedilol SR 32mg, QD|"Carvedilol SR 32mg QD for 4 weeks
With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
1662572|NCT01756430|Drug|Carvedilol SR 64mg, QD|"Carvedilol SR 64mg QD for 4 weeks
With the others investigation product placebo 1 capsule QD and 1 tablet BID for 4 weeks."
1662573|NCT01756430|Drug|Carvedilol IR 25mg, QD|"Carvedilol IR 25mg QD for 4 weeks
With the others investigation product placebo 2 capsules and 1 tablet QD for 4 weeks."
1662574|NCT01756430|Drug|Carvedilol IR 25mg, BID|"Carvedilol IR 25mg BID for 4 weeks
With the others investigation product placebo 2 capsules QD for 4 weeks."
1662575|NCT01756417|Drug|Metformin|One 1,000 mg tablet of metformin taken orally (by mouth) on Day 1 and Day 8.
1662576|NCT01756417|Drug|Canagliflozin (JNJ-28431754)|Four 25 mg tablets of canagliflozin (JNJ-28431754) taken orally on Days 4 through 8.
1662577|NCT01756404|Drug|Canagliflozin (JNJ-28431754)|A 30mg/day, 100 mg/day, 300 mg/day, or 600 mg/day liquid dose administered once daily; a 300mg/day liquid dose administered in 2 divided doses (2x150 mg); or a 600 mg/day liquid dose administered in 2 divided doses (2x300 mg) using an oral (by mouth) liquid dispenser on Days 1 through 14.
1662578|NCT01756404|Drug|Placebo|Matching placebo (inactive medication) liquid dose(s) administered using an oral liquid dispenser once or twice daily on Days 1 through 14.
1662579|NCT01756378|Procedure|joint mobilization with movement|
1662580|NCT01756378|Procedure|traditional physical therapy program|I.R, stretching exercises, strengthen exercises
1662581|NCT01756365|Procedure|surgical transplantation of CECA|
1662582|NCT01756352|Drug|18F-FET|Radiotracer, surrogate marker for protein synthesis
1662585|NCT01756339|Other|Placebo to match solithromycin|
1662588|NCT01756313|Procedure|Laser+Methylaminolevulinat|It's a single arm study. Intervention as described in detailed description.
1662589|NCT01756300|Device|Celsius® ThermoCool® RD|The investigational device is designed to transmit radiofrequency (RF) current to the electrodes for ablation purposes, specifically for the treatment of resistant hypertension by renal denervation.
1662590|NCT01756287|Other|Chinese ocular exercise|A kind of massage around the acupuncture points around the eye.
1662591|NCT01756274|Device|Contour® NEXT BGMS|Lab professionals tested the BG concentration using Contour® NEXT BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
1662592|NCT01756274|Device|Contour® PLUS BGMS|Lab professionals tested the BG concentration using Contour® PLUS BGMS (Blood Glucose Monitoring System). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
1662593|NCT01756274|Device|Contour® Next EZ BGMS|Lab professionals tested the BG concentration using Contour® Next EZ BGMS (Blood Glucose Monitoring System). All meter BG results were compared with plasma results obtained with a reference laboratory glucose method, Cobas® 6000 instrument (Roche Diagnostics Corp., Indianapolis, IN).
1662594|NCT01756261|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
1662595|NCT01756248|Drug|Aflibercept(Eylea, VEGF Trap-Eye, BAY86-5321)|Patients treated with EYLEA under practical manner for AMD.
1662597|NCT01756183|Drug|S-1 + Paclitaxel Chemotherapy|"Dose of S-1: 60mg bid，Twice daily (after the breakfast and supper) for two weeks, and then suspend for one week.
Dose of Paclitaxel: 150 mg/m2, iv, 3h, at D1"
1662598|NCT01756170|Drug|paclitaxel|
1662599|NCT01756170|Drug|cisplatin|
1662600|NCT01756170|Radiation|Radiotherapy|
1662601|NCT01756157|Biological|CINRYZE with rHuPH20|
1662602|NCT01756144|Device|rhBMP-2|
1662603|NCT01756131|Drug|GSK1265744 injectable suspension|200 milligram per milliliter sterile solution for injection
1662604|NCT01756131|Other|Placebo to match injectable suspension|placebo
1662605|NCT01756118|Drug|BEZ235|A minimum of 3 dose levels
1662606|NCT01756105|Drug|Metformin|Metformin: from 500 mg 2 time per day to 2500 mg per day; with increment of 500 mg every 5 days until abstention of
1662607|NCT01756105|Drug|Rapid acting analog insulin Intermediate acting NPH Insulin|Insulin therapy:If post meal (2 hours after meal) glycaemia is > to 120 mg/dl introduce Insulin rapid acting analog (Humalog*, Novorapid*) before the meal concerned and according to the weight. If weight is < 80 kg: breakfast 5U, lunch time 3U, and dinner 4U. If weight is > 80 kg :breakast 6U, lunch time 4U, dinner 5U.If post meal glycaemia stay over 120 mg/dl but lower than130 mg/dl: do 1 U more.If post meal glycaemia stay over 140 mg/dl : do 2 UI moreIf fasting glycaemia is over 95 mg/dl : introduce NPH Insulin (Umuline NPH*, insulatard*) before sleeping : 5U if weight is < 80 kg - 6U if weight is > 80 kgIf fasting glycaemia stay over 95 mg/dl increase NPH Insulin for 1 U and for 2 U if fasting glycaemia is over 110 mg/dl.
1662608|NCT01756092|Procedure|Autologous Fat Graft|Participants will receive an autologous fat graft to correct either a benign breast deformity or a post segmental mastectomy deformity.
1662609|NCT01756079|Drug|boceprevir|
1662610|NCT01756079|Biological|PegIFN-2b|
1662611|NCT01756079|Drug|RBV|
1662612|NCT01756066|Behavioral|Different levels of cost sharing|
1662613|NCT01756053|Drug|ABT-089|Selective neuronal nicotinic receptor agonist.
1662614|NCT01756053|Drug|Placebo|Matched placebo capsules supplied by study drug supplier.
1662615|NCT01756040|Drug|Lactulose -rhamnose solution|Measurement of intestinal permeability by use of mon- digestible sugars known not to cross the intestinal barrier in normal healthy intestinal tissue
1662616|NCT01756027|Device|Ulthera System providing one treatment per cheek|Focused ultrasound energy delivered below the surface of the skin per cheek.
1662617|NCT01756027|Device|Ulthera System providing two treatments per cheek|Focused ultrasound energy delivered below the surface of the skin
1662618|NCT01756001|Device|GlowCap|The main research instrument is an electronic pill bottle called GlowCaps (by Vitality) that has the ability to transmit adherence data to the Way to Health (WTH) web portal. The investigators will measure adherence by counting the number of properly taken doses during the final four weeks of the study. Each time the pill bottle is opened, a date- and time-stamped wireless signal is sent to the Vitality server via the AT&T cellular network which will then be uploaded to the Way to Health portal for aggregation.
1662619|NCT01756001|Behavioral|Daily email, text message, or phone call reminders|
1662620|NCT01756001|Behavioral|Paid for adherence|
1662621|NCT01755988|Other|Educational website (in addition to usual care).|
1662622|NCT01755988|Other|Website and interactive platform with telemonitoring.|
1662623|NCT01755975|Drug|Romidepsin|Romidepsin will be administered intravenously on days 1, 8, and 15 of a 28-day cycle.
1662624|NCT01755975|Drug|Lenalidomide|Lenalidomide will be taken orally daily for 21 days of a 28-day cycle.
1662625|NCT01755962|Other|Glycemic Load|
1662626|NCT01755962|Other|Resistance Training|
1662627|NCT01755949|Drug|Colchicine, 0.6 mg PO BID|Colchicine tablets will be over-encapsulated by the research pharmacy to be indistinguishable from placebo
1662628|NCT01755949|Drug|Matching placebo|Matching placebo tablets will be encapsulated by the research pharmacy to be indistinguishable from active drug
1662629|NCT01755936|Other|Cardiac Magnetic Resonance Imaging|For the evaluation of left ventricular volumes, function and mass. Also for the assessment of myocardial fibrosis based on the presence of delayed enhancement. Novel application of T1 mapping techniques will be evaluated.
1662630|NCT01755936|Other|Echocardiography|Assessment of aortic stenosis severity. Also evaluate diastolic and systolic function.
1662631|NCT01755936|Other|72 hour Holter Monitor|This will enable us to detect abnormal heart rhythms which may be associated with myocardial fibrosis
1662632|NCT01755923|Drug|Gefitinib|Gefitinib 250mg once per day until the progression disease or intolerant side effects
1662633|NCT01755923|Drug|Docetaxel|Docetaxel 75mg/m2 iv, d1,every 3 weeks, at least 2-6 cycles depending on the progression disease or the patient's physical condition
1662634|NCT01755910|Other|Left thoracic paravertebral block|
1662635|NCT01755910|Other|Right thoracic paravertebral block|
1662641|NCT01755884|Dietary Supplement|Wheat oral immunotherapy|Cooked spaghetti
1662642|NCT01755871|Drug|Fingolimod|0,5mg Fingolimod once a day
1662643|NCT01755858|Drug|Bendavia|
1662644|NCT01755858|Drug|Placebo|
1662645|NCT01755845|Drug|paclitaxel|
1662646|NCT01755845|Drug|cisplatin|
1662647|NCT01755845|Radiation|radiotherapy|
1662648|NCT01755832|Procedure|Pool exercise|Group exercise in heated pool one hour per week for 12 weeks.
1662649|NCT01755819|Device|Biocomposite interference screw|
1662650|NCT01755819|Device|Extracortical ACL Tightrope fixation|
1662651|NCT01755780|Other|Left interscalene block|
1662652|NCT01755780|Other|Right interscalene block|
1662653|NCT01755767|Drug|Tivantinib|Tivantinib tablets
1662654|NCT01755767|Drug|Placebo|Matching placebo tablets
1662655|NCT01755754|Combination Product|Silicone Elastomer Vaginal Ring|Silicone Elastomer Vaginal Ring
1662656|NCT01755754|Device|Female Condom|Female condom
1662657|NCT01755741|Combination Product|Placebo Vaginal Ring|a silicone elastomer placebo vaginal ring, similar in composition to the dapivirine Ring-004 (which is currently used in IPM's ongoing Phase III program), except that it did not contain any active pharmaceutical agent, and a commercially available standard male latex condom with a silicone-based lubricant.
1662658|NCT01755741|Device|Condom|Male condom
1662659|NCT01755728|Drug|Paracetamol|Per gavage paracetamol 15 mg/kg every 6 hours, for up to 7 days.
1662660|NCT01755728|Drug|Ibuprofen|Per Gavage ibuprofen 10mg/kg x 3/d for up to 5 days Gold standard per literature
1662661|NCT01755728|Procedure|Closure of PDA|Open surgery for closure of PDA
1662662|NCT01755715|Procedure|Immediate IUD insertion|Insertion of LNG-IUD (Mirena) (at the same day to 3 days) after expulsion of placenta.
1662663|NCT01755702|Drug|Placebo|Placebo
1662664|NCT01755702|Drug|Experimental paracetamol + caffeine formulation|experimental paracetamol + caffeine formulation
1662665|NCT01755702|Drug|ibuprofen marketed formulation|ibuprofen marketed formulation
1662666|NCT01755702|Drug|Paracetamol marketed formulation|Paracetamol marketed formulation
1662670|NCT01755676|Drug|Orlistat 60 mg|1 tablet 3 times a day
1662671|NCT01755676|Other|Placebo|1 tablet 3 times a day
1662672|NCT01755663|Drug|Ivabradine and Metoprolol|
1662673|NCT01755650|Radiation|18F FPM|
1662674|NCT01755637|Drug|Albendazole|Albendazole tablets 400 mg
1662675|NCT01755624|Device|NovoTTF-100A device|
1662676|NCT01755624|Other|Best Standard of Care|
1662677|NCT01755611|Drug|Minocycline 100mg|Test product
1662678|NCT01755611|Drug|Minocycline 100mg|Reference product
1662679|NCT01755598|Biological|GSK Biologicals' investigational TB vaccine (GSK692342)|2 doses administered intramuscularly in the deltoid region of the arm.
1662680|NCT01755598|Biological|Placebo|2 doses administered intramuscularly in the deltoid region of the arm.
1662683|NCT01755559|Drug|Artesunate-amodiaquine|antimalarial ACT
1662684|NCT01755559|Drug|Dihydroartemisinin-piperaquine|antimalarial ACT
1662685|NCT01755559|Drug|Artemether-lumefantrine|antimalarial ACT
1662686|NCT01755546|Drug|EN3409|Open-Label Buprenorphine HCI Buccal Film at doses 300-900 mcg twice daily
1662687|NCT01755533|Other|Rural curriculum|Students in schools randomly assigned to this condition receive the rural version of the curriculum.
1662688|NCT01755533|Other|Classic curriculum|Students in schools randomly assigned to this condition receive the classic version of the curriculum.
1662689|NCT01755520|Drug|Ticagrelor|90mg twice daily dose
1662690|NCT01755520|Drug|Aspirin|Aspirin 100mg once daily
1662691|NCT01755520|Drug|Placebo - Ticagrelor|Placebo
1662692|NCT01755520|Drug|Placebo - Aspirin|Placebo
1662693|NCT01755507|Drug|norUDCA|Comparison of different dosages of norUDCA acid administered orally.
1662694|NCT01755507|Drug|Placebo|
1662695|NCT01755494|Drug|Saxagliptin 5 mg|Saxagliptin oral tablet 5mg, single dose
1662696|NCT01755494|Drug|Metformin XR 500 mg|Metformin XR oral tablet 500 mg, single dose
1662697|NCT01755494|Drug|Mertformin XR 2 x 500 mg|Metformin XR oral tablet 2 x 500 mg, single dose
1662698|NCT01755494|Drug|Komboglyze XR 5/500 mg|oral FDC tablet (saxagliptin 5 mg and metformin 500 mg), single dose
1662699|NCT01755494|Drug|Komboglyze XR 5/1000 mg|oral FDC tablet (saxagliptin 5 mg and metformin 1000 mg), single dose
1662700|NCT01755481|Other|Probiotic|
1662701|NCT01755481|Other|Whey protein concentrate|
1662702|NCT01755468|Drug|Intermittent insulin therapy|
1662703|NCT01755468|Drug|Continuous metformin|
1662704|NCT01755455|Drug|Ferrous sulfate 325mg|Ferrous sulfate 325mg tablet taken by mouth daily for 6 weeks
1662705|NCT01755455|Drug|Placebo|Matching placebo capsule
1662706|NCT01755442|Other|Placebo|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
1662707|NCT01755442|Drug|AMG 151|Eligible subjects will be randomly assigned (1:1) to receive AMG 151 and matching placebo in 1 of 2 sequences over 2 treatment periods.
1662708|NCT01755416|Device|Closed loop with enlite sensors, insulin, liraglutide|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. In addition to being on insulin, they would take 1.2mg of Liraglutide subcutaneoulsy before dinner on Day 1.
1662709|NCT01755416|Device|Closed loop with enlite sensors, insulin|In this study visit the subject will be on the closed loop device with enlite sensors for about 27 hours. They will not be on any study medication and will be on insulin alone.
1662710|NCT01755403|Drug|Benznidazole|
1662711|NCT01755390|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: infusion solution Route of administration: Intravenous
1662712|NCT01755377|Drug|Benznidazole|
1662713|NCT01755364|Biological|AdimFlu-V|
1662714|NCT01755338|Drug|Methylprednisolone|Methylprednisolone 15mg/kg
1662715|NCT01755338|Drug|Placebo|Placebo
1662716|NCT01755325|Drug|Compound realgar natural indigo Tablet|"Compound realgar natural indigo Tablet, 65mg/kg/d, from day1 to day14,every 4 weeks.
imatinib,0.4g,qd"
1662717|NCT01755325|Drug|placebo|
1662718|NCT01755312|Device|Medication reminder|Medication reminder
1662719|NCT01755299|Other|"Regular 5-hour Energy"|Amount equivalent to the package commercially packaged and sold (1.93 fl. oz.)
1662720|NCT01755299|Other|"Decaf 5-hour Energy"|"Commercially available 5-Hour Energy Decaf product in the amount that is packaged (1.93 fl. oz.)"
1662721|NCT01755299|Other|Compounded concentrated caffeine liquid|"Concentrated caffeine liquid has been used to compound a 135 mg/2 ounce caffeine product, which contains the same amount of caffeine as a regular 5-hour Energy"
1662722|NCT01755299|Other|Flavored bottled water|Bottled water will be flavored and colored to serve as a placebo product for this trial.
1662723|NCT01755286|Drug|OTO-201|Single intra-operative injection
1662724|NCT01755286|Drug|Placebo|Single intratympanic injection
1662725|NCT01755286|Drug|Sham|Simulated single intratympanic injection
1662726|NCT01755273|Procedure|Pancreaticoduodenectomy with more distal enteral bypass|Patients undergoing pancreaticoduodenectomy, the enteral bypass (gastrojejunostomy/duodenojejunostomy is extra 100 cm away from standard bypass )
1662728|NCT01755247|Drug|Topical Gel Vehicle|
1662729|NCT01755247|Drug|8% NVN1000 Topical Gel|
1662730|NCT01755247|Drug|8% NVN1000 Topical Gel and moisturizer|
1662731|NCT01755234|Drug|Sevoflurane|Sevfoflurane inhaled administered by laryngeal mask airway or endotracheal tube
1662732|NCT01755234|Drug|Propofol|Propofol administered via intravenous catheter at an initial rate of 1.0 -2.0 mg/kg then the Propofol infusion rate will be titrated to keep a bispectral index between 40-60
1662734|NCT01755208|Procedure|light-scattering spectroscopy|Undergo light-scattering spectroscopy
1662736|NCT01755182|Drug|approved pharmacologic therapy|
1662737|NCT01755182|Procedure|TAE|after randomization, and after 3 months
1662738|NCT01755169|Drug|Ketamine|Participants on active treatment are given ketamine orally for 2 weeks, at varying dosages (1 dosage per participant).
1662739|NCT01755169|Drug|Placebo|
1662740|NCT01755156|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once weekly (preferably on the same day of each week)
1662741|NCT01755156|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once weekly (preferably on the same day of each week)
1662742|NCT01755156|Drug|Glimepiride|Glimepiride 1 or 2 mg tablet/capsule administered orally once daily and up-titrated to a maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
1662743|NCT01755156|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet/capsule administered orally once daily and up-titrated to a mock maximum dose of 6 mg daily. Participants rescued with open-label glimepiride during Phase A will not receive glimepiride or matching placebo to glimepiride during Phase B.
1662744|NCT01755156|Drug|Insulin glargine|During Phase B of the study, participants who received a maximum up-titration of open-label glimepiride or blinded glimepiride/matching placebo to glimepiride, may be rescued with open-label insulin glargine.
1662745|NCT01755156|Drug|Metformin|Participants continue stable pre-study dose of metformin tablet(s) administered orally (>= 1500 mg daily) throughout the study.
1662746|NCT01755143|Other|Magnetic Resonance Imaging scan sequences of the head, neck, and chest|
1662747|NCT01755143|Device|Pacemaker System|
1662748|NCT01755130|Procedure|LOUIS-3D Imaging Procedure|LOUIS-3D imaging procedure either on the same day or within 10 days of a regular scheduled visit for a mammogram, ultrasound, magnetic resonance imaging (MRI) scan, or any other breast imaging procedure, between 1 and 7 days before scheduled biopsy. Results of the LOUIS-3D imaging scans compared with results of other imaging scan(s). Entire LOUIS-3D procedure should take about 30 minutes to complete.
1662749|NCT01755117|Other|Sciatic, femoral, obturator nerve blocks|
1662750|NCT01755117|Other|Sciatic nerve block, posterior lumbar plexus block|
1662751|NCT01755104|Dietary Supplement|Stablor|
1662752|NCT01755104|Dietary Supplement|Placebo|
1662755|NCT01755078|Drug|Sevelamer HCl|Non-metal phosphate binder
1954830|NCT03309748|Procedure|Dental prophylaxis|American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110
1662756|NCT01755078|Drug|Calcium-based phosphate binder|
1662757|NCT01755026|Drug|cefazolin|2 gram dose for pre-operative prophylaxis
1662758|NCT01755026|Drug|cefazolin|4 gram dose for pre-operative prophylaxis
1662759|NCT01755013|Procedure|Photodynamic Therapy|Photofrin and Photodynamic therapy using the plastic optic diffuser, conducted during Standard of care Endoscopic retrograde cholangiopancreatography (ERCP)
1662760|NCT01755000|Procedure|USCOM scan|
1662761|NCT01755000|Procedure|Fluid Bolus|
1662762|NCT01754987|Drug|Ascorbic Acid + Sorafenib|
1662763|NCT01754987|Drug|Sorafenib|
1662764|NCT01754974|Biological|Peginterferon Lambda-1a|
1662765|NCT01754974|Drug|Ribavirin|
1662766|NCT01754974|Biological|Peginterferon alfa-2a|
1662767|NCT01754961|Drug|Vitamin D|Vitamin D 500,000 IU given orally on Day 1
1662768|NCT01754961|Drug|Placebo|Placebo given orally on Day 1
1662769|NCT01754935|Drug|VX-509|50 mg oral tablet
1662770|NCT01754935|Drug|VX-509 matching placebo|0 mg oral tablet
1662771|NCT01754909|Drug|Enalapril|Enalapril once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
1662772|NCT01754909|Drug|placebo|Placebo, once a day, orally, as 2.5 , 5, or 10 mg tablets to be given in escalating doses, to subjects undergoing radiotherapy for lung cancer
1662773|NCT01754896|Other|mailing of FIT kit directly to patient|Patient receives a mailed invitation to participate in CRC screening, with a FIT screening kit included.
1662774|NCT01754896|Other|mailed invitation to pick up lab requisition and then kit|Patients receives a mailed invitation to visit their physician to discuss CRC screening. At that visit, they would receive a FIT laboratory requisition, which they will take to a local lab patient service centre to pick up a FIT kit.
1662775|NCT01754896|Other|mailing completed kits in for processing|Patients mails completed kit in for processing using postage-paid reply envelope provided.
1662776|NCT01754896|Other|dropping completed kits at lab for processing|Patient takes completed FIT in to lab patient service centre for processing.
1662777|NCT01754883|Drug|Lithium Carbonate|Oral Lithium carbonate to target serum levle of 0.6-0.8.
1662778|NCT01754870|Drug|Bendamustine and Rituximab Induction followed by Rituximab and Lenalidomide Maintenance|
1662779|NCT01754857|Drug|Bendamustine|Given IV
1662780|NCT01754857|Drug|Rituximab|Given IV
1662781|NCT01754857|Drug|Lenalidomide|Given PO
1662782|NCT01754844|Drug|AZD7624|Single dose inhaled IMP via a nebulizer
1662783|NCT01754844|Drug|Placebo to match|Single dose inhaled Placebo via a nebulizer
1662785|NCT01754818|Drug|Bendavia 10mg|
1662786|NCT01754818|Drug|Bendavia 50mg|
1662787|NCT01754818|Drug|Bendavia 100mg|
1662788|NCT01754818|Drug|Placebo|
1662789|NCT01754805|Drug|ASP015K|oral
1662790|NCT01754805|Drug|Methotrexate|oral
1662791|NCT01754792|Dietary Supplement|Pinitol|Fruit Up® (diluted with mineral water to a final volume of 250 ml) will be evaluated, and will be equivalent to an intake of 2 g of pinitol. The placebo beverage will contain equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
1662792|NCT01754779|Drug|Placebo|Matching placebo for both aims.
1662793|NCT01754779|Dietary Supplement|Citric Acid|
1662794|NCT01754779|Dietary Supplement|Potassium Citrate|
1662795|NCT01754779|Drug|Indapamide|Aim 2
1662796|NCT01754766|Drug|AGN-229666|One drop of AGN-229666 into each eye on Day 1 and Day 15.
1662797|NCT01754766|Other|vehicle of AGN-229666|One drop of vehicle of AGN-229666 into each eye on Day 1 and Day 15.
1662798|NCT01754753|Other|Telephone Friendship groups|
1662799|NCT01754740|Drug|Uréia|"The subjects were randomly divided into two groups:
1. Study Group: 19 patients received topical medication of urea 10% to be applied at the oral cavity 3-4 times per day, during three months."
1662800|NCT01754740|Drug|Placebo|Control Group: 19 patients received placebo (5% sodium carboxymethylcellulose, 0.15% methyl paraben and 10% glycerol in distilled water qsp 100g) to be applied at the oral cavity 3-4 times per day, during three months.
1662801|NCT01754714|Drug|SAMe 1000 mg|1000 mg dose group: one 500 mg capsule fasting in the morning and one 500 mg capsule before dinner
1662802|NCT01754714|Drug|SAMe 1500 mg|1500 mg dose group: two 500 mg capsules fasting in the morning and one 500 mg capsule before dinner
1662803|NCT01754714|Drug|SAMe 2000 mg|2000 mg dose group: two 500 mg capsules fasting in the morning and two 500 mg capsules before dinner
1662804|NCT01754701|Dietary Supplement|Immediate iron|Children who start 4 weeks of iron therapy on Day 0
1662805|NCT01754701|Dietary Supplement|Delayed iron|Children who start 4 weeks of iron therapy on Day 28
1662807|NCT01754675|Behavioral|Soccer|Watching the soccer match at the time that the favorite team is playing
1662808|NCT01754675|Behavioral|Movie|Watching a movie at the time that the favorite team is playing
1662809|NCT01754662|Dietary Supplement|Soy protein|2 bars daily for 8 weeks.
1662810|NCT01754662|Dietary Supplement|Isoflavones|2 bars daily for 8 weeks.
1662811|NCT01754662|Dietary Supplement|Cocoa|2 bars daily for 8 weeks.
1662812|NCT01754662|Dietary Supplement|Placebo|
1662813|NCT01754649|Drug|Misoprostol|The study group will receive two doses of misoprostol (200mcg each tablet) vaginal 12 and 4 hours prior insertion. After 24 hours of the insertion failure the women will return to the clinic and a new attempt of insertion will be done. At this time we will evaluate if the insertion was able to do or not.
1662814|NCT01754636|Other|No intervention|
1662815|NCT01754623|Drug|Capecitabine|Treatment will begin with the first round of chemotherapy. Each round of chemotherapy will take 21 days. Each round or cycle will start with participants taking capecitabine pills. Participants will take tablets of capecitabine (Xeloda®) twice per day for 14 days followed by 7 days without capecitabine.
1662888|NCT01753986|Behavioral|Brief Alcohol Intervention plus Standard Batterer Intervention|Brief Alcohol Intervention plus 40 hours or Standard Batterer Intervention
1662816|NCT01754623|Drug|Gemcitabine|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. First, this will consist of placing gemcitabine (Gemzar®) in a bag of fluid and giving it by vein over 30 minutes.
1662817|NCT01754623|Drug|Docetaxel|On the fourth day of the cycle, participants will be treated with gemcitabine and docetaxel. After the gemcitabine, participants will receive docetaxel (Taxotere®) in a bag of fluid over 1 hour.
1662818|NCT01754623|Radiation|Stereotactic body radiation therapy (SBRT)|30/40 Gy to pancreatic tumor/area of borderline resectability
1662819|NCT01754623|Other|Restaging review after radiation|After radiation, participants will be re-evaluated for surgery. Patients who have Complete Response (CR), Partial Response (PR) or stable disease (SD) will proceed with surgical exploration and resection provided they are suitable fit for surgery in the judgment of the surgical oncologist. Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT). If no surgery: then chemotherapy. If surgery: chemotherapy will be given based on response.
1662820|NCT01754623|Procedure|Surgery|Non-metastatic patients who are deemed resectable after neoadjuvant therapy will be taken to surgery. After surgery, chemotherapy will be given based on response.
1662821|NCT01754623|Drug|5-Fluorouracil|Patients who have local progression on imaging scan will be offered conventional 5-Fluorouracil based intensity-modulated radiation therapy (IMRT).
1662822|NCT01754610|Behavioral|Strengthening Family Coping Resources (SFCR)|"Trauma Version (15 weeks) and High Risk Version (10 weeks) are 2 hour sessions. Dinner will be provided at the start of group for all participants.
Activities will be conducted at each group to encourage family involvement. The treatment modules focus on family rituals and routine, strengthening families' collaborative coping, and resolution of the trauma(s) bringing the families to treatment. Activities will be both family-based and age-based."
1662823|NCT01754597|Drug|Peptide Natriurétique de type B|Peptide Natriurétique de type B
1662824|NCT01754571|Behavioral|Cognitive behavior therapy|Behavior therapy, including Relaxation, cognitive rebuilding.
1662825|NCT01754558|Procedure|Ajust system|The use of Ajust system for stress incontinence
1662826|NCT01754558|Procedure|TVT/TVT-O|sling surgery
1662827|NCT01754545|Drug|Octaplas infusion and placebo (group 1)|Intervention period is Monday-Friday in two following weeks. Active treatment with Octaplas is given 2-3 times each week and placebo is given the other 2-3 days of intervention each week. Route of administration is intravenously.
1662828|NCT01754545|Drug|Octaplas infusion and placebo (group 2)|Intervention period is Monday-Wednesday in two separate weeks (minimum of three weeks between intervention weeks). Active treatment with Octaplas is given once and placebo is given twice each week. Route of administration is intravenously.
1662829|NCT01754532|Biological|Hair Sample|Analysis of hair cortisol levels
1662830|NCT01754519|Procedure|Therapeutic Conventional Surgery|Undergo wide local excision breast surgery
1662831|NCT01754519|Radiation|Radiation Therapy|Undergo SFRT
1662832|NCT01754519|Other|Laboratory Biomarker Analysis|Correlative studies
1662833|NCT01754519|Other|Quality-of-Life Assessment|Ancillary studies
1662834|NCT01754506|Dietary Supplement|Fish Oil|EPA + DHA Group subjects (n=54) will be given n-3 fatty acid supplement softgels
1662835|NCT01754493|Drug|Duloxetine|This study is a 12-week open trial to assess the efficacy of duloxetine (Cymbalta) for the treatment of Irritable Bowel Syndrome (IBS) symptoms and comorbid Major Depressive Disorder (MDD). Participants will visit the clinic 8 times to meet with the psychiatrist. They will receive duloxetine to see if it helps their major depression and Irritable Bowel symptoms.
1662836|NCT01754480|Biological|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin, in separate syringes assembled on a syringe holder (6 mL of solution in total), applied topically to the target bleeding site.
1662837|NCT01754480|Device|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
1662838|NCT01754467|Behavioral|NEAT!|Participants will wear the accelerometer and use the NEAT! application during waking hours for 1 month. The NEAT! app will prompt participants to stand up when they have been sitting for a prolonged period.
1662839|NCT01754454|Biological|Human Umbilical Cord Derived MSC|1×10^6 UC-MSCs per kg intravenous injection the number of infusions: once a week, for four weeks in a row Time interval: estimate the condition of follow-up visit afer 28 days
1662840|NCT01754415|Device|hydraulic resistance circuit training|12 weeks (3 times per week, 40 min circuit) of hydraulic resistance circuit training that consisted of 10 types of equipments for different part of strength training.
1662841|NCT01754402|Drug|Bendamustine|Bendamustine will be administered intravenously over 1 hour (if using Treanda) or over 10 minutes (if using Bendeka) on day 1, every 28 days for 12 cycles.
1662842|NCT01754402|Drug|Pomalidomide|Pomalidomide will be administered once daily orally (PO) on days 1-21, every 28 days until disease progression or death.
1662843|NCT01754402|Drug|Dexamethasone|Dexamethasone will be administered weekly orally or intravenously on days 1, 8, 15, and 22 every 28 days until disease progression or death. After 6 cycles of treatment, the dose may be reduced to 20mg at investigator's discretion. For subjects ≥ 75 years of age, the starting dose of dexamethasone is 20 mg/day on Days 1, 8, 15 and 22 of each 28-day treatment cycle.
1662844|NCT01754389|Drug|Tacrolimus|
1662845|NCT01754389|Drug|Methotrexate|
1662846|NCT01754389|Drug|Bortezomib|
1662847|NCT01754389|Drug|Sirolimus|
1662848|NCT01754376|Drug|Aldesleukin|Intravenous therapy given every 8 hours for up to 14 doses per week.
1662849|NCT01754376|Drug|Vemurafenib|Tablets given twice daily.
1662850|NCT01754363|Device|Attune Primary Total Knee Replacement|Patients will undergo a primary total knee replacement using one of the four configurations of the Attune knee (CR FB, CR RP, PS FB, PS RP).
1662851|NCT01754350|Dietary Supplement|calorie-restricted ketogenic diet and transient fasting|"On day 1-3 and day 7-9, restriction of carbohydrates to < 60 g and of calories to 21-23 kcal/kg per day, on day 4-6 fasting. On day 1-3 and 7-9, restriction of carbohydrates can be supported by the use of drinks provided by Tavarlin."
1662852|NCT01754350|Dietary Supplement|standard nutrition|nutrition as recommended by the german society for nutrition, 30 kcal/kg per day
1662942|NCT01753596|Other|Physiological Sodium Chloride solution (0,9%)|Placebo
1719940|NCT00002945|Drug|melphalan|IV
1662853|NCT01754337|Other|Closed-loop system|Patients will be admitted at the research clinical facility at 7:00. At 8:00, a mixed meal will be served. At 9:00, patients will be asked to perform two 30-min standardized activities. At 12:00, a mixed meal will be served. At 13:00, patients will be asked to perform two 30-min activities. At 17:00, a mixed meal will be served. At 19:30, patients will perform 60 minutes of aerobic treadmill exercise at an intensity of 60% VO2max. A bedtime snack of 20g carbohydrate will be given at 21:00. Patients will be discharged at 8:00 the next morning
1662854|NCT01754324|Drug|Methadone|The starting dose of the protocol is 0.05mg/kg by mouth given every 6 hours and gradually decreased in a stepwise, standardized fashion.
1662855|NCT01754298|Procedure|Retro-articular drilling|"Drilling must be performed under AP and lateral fluoroscopic guidance, with no additional drilling in 'trans-articular', or intra-articular trans-condylar fashion.
Use a 0.045 K-wire for drilling.
Minimum of 8 wire passes per square centimeter with no maximum number of wire passes."
1662856|NCT01754298|Procedure|Trans-articular drilling|"Drilling must be performed, under arthroscopic visualization, directly through the articular cartilage, with no additional drilling in 'retro-articular', 'extra-articular', or trans-condylar (through the intercondylar notch)
Use a 0.045 K-wire for drilling
A minimum 4 wire passes per square centimeter, with a maximum of 5 wire passes per square centimeter"
1662857|NCT01754285|Drug|LF-PB and Placebo|
1662858|NCT01754285|Drug|Placebo|
1662859|NCT01754285|Drug|LF-PB|
1662860|NCT01754259|Drug|Ranolazine|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
1662861|NCT01754259|Drug|Placebo|Subject will receive labeled bottles containing tablets with ranolazine 500 mg or a matching placebo provided by the sponsor. Each patient will receive both ranolazine and placebo for 4 weeks, but both the investigator and subject are blinded to the order.
1662862|NCT01754246|Device|755nm Alexandrite Laser|755nm Alexandrite laser for treatment of epidermal pigmented lesions and skin toning in Asian skin types
1662863|NCT01754233|Device|755nm Alexandrite Laser|755nm Alexandrite Laser for epidermal and dermal pigmented lesions
1662864|NCT01754220|Drug|Montelukast|Montelukast is a leukotriene receptor antagonist
1662865|NCT01754207|Device|755nm Alexandrite Laser|755nm Alexandrite Laser
1662866|NCT01754207|Device|755nm Alexandrite Laser with CAP Array|755nm Alexandrite Laser with CAP Array
1662867|NCT01754194|Procedure|Gastric Sleeve Resection|Laparoscopic Gastric Sleeve Resection
1662868|NCT01754194|Procedure|Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
1662869|NCT01754181|Drug|Insulin|the intervention is applied only at the dose of insulin
1662870|NCT01754155|Radiation|RSA images|All subjects will have the Vitamin E polyethylene and RSA beads placed during surgery. Subjects will then have standard x-ray images and RSA images taken at specific time points up until 2 years post-operatively.
1662871|NCT01754116|Drug|GSK1265744 30 mg oral|GSK1265744B 30 mg Tablet taken orally, once a day in the morning with or without a meal
1662872|NCT01754116|Drug|Midazolam 3 mg oral + GSK1265744 30mg oral|Midazolam Syrup 3mg each mL Oral/single dose administer by oral syringe on Day -29 and Day -14
1662873|NCT01754116|Drug|GSK1265744 400 mg (200 nm)|A single dose of GSK1265744 400 mg Intra Muscular (IM) injection (Nanomilled 200 nm)
1662874|NCT01754116|Drug|GSK1265744 400 mg (1 micro m)|A single dose of GSK1265744 400 mg IM injection (Nanomilled 1 micrometer)
1662875|NCT01754116|Drug|GSK1265744 400 mg (5 micro m)|A single dose of GSK1265744 400 mg IM injection (Dry milling and homogenization 5 micrometer)
1662876|NCT01754103|Other|Tactile Training|Tactile Training to induce neuroplasticity in the visual pathway, measured with functional connectivity MRI
1662877|NCT01754090|Behavioral|Online screening and feedback|An online single session screening procedure including individualized normative feedback.
1662878|NCT01754090|Behavioral|Online booklet.|An online booklet that covers general information about alcohol, its effect on the brain and the body, potential risks and harms of drinking, and an account of the threshold values of sensible drinking
1662879|NCT01754090|Behavioral|Online multi session follow-up|"An online multi session follow-up program (i.e., Balance). The central concept of Balance is to support continued self-regulation throughout the behavior change process. There are four key aspects of the program, the first is focus on goal setting and tracking of alcohol consumption on a day-to-day basis. The second on relapse prevention - for example, when clients report drinking more than their target, they receive individualized content aimed at preventing a full blown relapse. The third is emotion regulation, where content and assignments from positive psychology and from cognitive behavioral therapy are used. Finally, intervention covers alcohol education (i.e. the same topics as in the booklet provided to the control group)."
1662880|NCT01754077|Behavioral|LENA Linguistic Feedback Reports|LENA feedback reports show hourly/daily estimates for AWC/CTC and TV/electronic media. The feedback reports will include data obtained from LENA home audio recordings that the families complete. Feedback reports are only given to parents for 8 weekly recordings. The parent does not receive a feedback report for the baseline recordings or the follow-up recordings.
1662881|NCT01754077|Behavioral|Home Visiting Educational Session|A research assistant visited the homes of the participants to discuss strategies, skills, and barriers related to enriching children's language environments. The visits included a multi-media educational module, video modeling exercise, goal setting, and linguistic feedback report review. There were 8 weekly home visits in the intervention program.
1662882|NCT01754077|Behavioral|Childhood Nutrition Education|The childhood nutrition education intervention is a brief home-visiting intervention during which parents receive information on nutrition from a research assistant. The intervention mirrored the experimental group's educational intervention and decreased the likelihood of differences between groups being the result of attentional effects. This intervention is received by the control group.
1662883|NCT01754064|Device|Cardiac Rhythm Management device|
1662884|NCT01754051|Device|PC 400 coils|
1662885|NCT01754012|Dietary Supplement|Dietary Intervention|nutrient-rich diet and 10micrograms per day of Vitamin D (cholecalciferol) supplement from MCOHealth
1662886|NCT01753999|Device|Standard CPAP|Use of the REMstar Auto A-Flex in standard CPAP therapy mode
1662887|NCT01753999|Device|CPAP - Flex|Use of Philips Respironics REMstar Auto A-Flex in C-Flex mode
1662889|NCT01753986|Behavioral|General Health Improvement Intervention plus Standard Batterer Intervention|General Health Improvement Intervention plus 40 hours of Standard Batterer Intervention
1662890|NCT01753947|Other|Deliberate Practice|
1662891|NCT01753921|Other|this is not an intervention study|Subjects will wear the headband/helmet-like device for approximately 10 minutes on four different occasions: t=0, t=1week, t=1month, t=3months. Of note, part of the device also involves electrodes that are worn to obtain an electrocardiogram or EKG.
1662892|NCT01753921|Other|this is not an intervention study|Subjects will be asked to participate in both computerized and non-computerized tests to assess subjects' cognitive (learning, language and memory) abilities, developmental level, and behavior. Tests will take place at t=0, t=1week, t=1month, t=3months.
1662893|NCT01753921|Device|MRI|MRI study of the brain will be performed at t=3months.
1662894|NCT01753908|Drug|Broccoli Sprout Extract|Given PO
1662895|NCT01753908|Other|Laboratory Biomarker Analysis|Correlative studies
1662896|NCT01753908|Other|Pharmacological Study|Urinary ITCs and metabolites measured
1662897|NCT01753908|Other|Placebo|Given PO
1662898|NCT01753882|Drug|Lexapro|Agent + training vs Placebo + training
1662899|NCT01753882|Drug|Placebo|Agent + training vs Placebo + training
1662900|NCT01753869|Procedure|Airways clearance and Hypertonic saline inhalation|
1662901|NCT01753856|Drug|Teriparatide|Administered SC
1662902|NCT01753856|Drug|Denosumab|Administered SC
1662903|NCT01753856|Drug|Demeclocycline|Administered orally
1662904|NCT01753856|Drug|Tetracycline|Administered orally
1662905|NCT01753856|Drug|Calcium Supplement|Administered orally
1662906|NCT01753856|Drug|Vitamin D|Administered orally
1662907|NCT01753843|Procedure|early cord clamping|early ( <20 seconds)
1662908|NCT01753843|Procedure|Brief Delay in cord clamping|delay in cord clamping 30 to 60 seconds
1662909|NCT01753830|Device|Durolane|
1662910|NCT01753830|Device|PBS|
1662911|NCT01753804|Other|Observational study|There is no medication or device tested in this study. This is an obversational study on the progression of the disease.
1662912|NCT01753791|Drug|80 mg PF-06473871|80 mg of PF-06473871 or placebo
1662913|NCT01753791|Drug|160 mg PF-06473871|160 mg of PF-06473871 or placebo
1662914|NCT01753791|Drug|320 mg PF-06473871|320 mg of PF-06473871 or placebo
1662915|NCT01753791|Drug|480 mg PF-06473871|480 mg of PF-06473871 or placebo
1662916|NCT01753778|Device|Cryo-Touch III Device|Treatment with Cryo-Touch III
1662917|NCT01753765|Device|Device: Cryo-Touch III Study treatment at Day 0.|Device: Cryo-Touch III Study treatment at Day 0.
1662918|NCT01753752|Drug|Chitosan- N- Acetylcysteine eye drops|
1662919|NCT01753752|Drug|Placebo|
1662920|NCT01753739|Drug|Bepotastine besilate|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
1662921|NCT01753739|Drug|Placebo|Nasal spray administered in the morning and at night approximately 12 hours apart daily for 14 days
1662922|NCT01753726|Other|Diaphragm stretching.|A manual technique of diaphragm stretching during 7 minutes. The participants were situated in a seated position.
1662923|NCT01753726|Other|Placebo.|Disconnected ultrasound was used for the 7 min as sham treatment
1662924|NCT01753713|Drug|dovitinib|Given PO
1662925|NCT01753713|Other|laboratory biomarker analysis|Correlative studies
1662926|NCT01753700|Dietary Supplement|UHT treated milk|
1662927|NCT01753687|Other|Ocular scattering of the tear film|
1662928|NCT01753687|Other|Optical Coherence Tomography (OCT)|Tear film thickness as measured with OCT
1662929|NCT01753687|Other|Measurement of tear film osmolarity|
1662930|NCT01753674|Dietary Supplement|TA-65|TA-65 will be provided to volunteers, 2 pills per day of 8 mg each
1662931|NCT01753674|Dietary Supplement|Placebo|Placebo supplement will be provided to volunteers, 2 pills per day of 8 mg each
1662932|NCT01753661|Behavioral|Linguistic Feedback Report|Throughout the study, parents will complete 16 total LENA recordings. The feedback report will include information on the parent's previous LENA recording(s), including the Adult Word Count (AWC), Conversational Turns (CTC), and TV Time (TVT). Parents in the treatment group will receive feedback reports for the baseline and 10 weekly recordings. Feedback reports will not be offered for the follow-up recordings
1662933|NCT01753661|Behavioral|Multimedia Education Sessions|Treatment group parents will receive 10 weekly home visit sessions (e.g. the ASPIRE Program) with an interventionist during which time they will review multimedia education modules. The sessions include feedback report review, module discussion, video modeling, and goal setting activities. The education modules provide parents with information on supporting the development of listening and spoken language for children with hearing loss.
1662934|NCT01753661|Behavioral|EI-As-Usual|The EI-as-usual condition will parallel the treatment condition. Families in the EI-as-usual condition will continue to receive their usual therapy. They will not participate in Project ASPIRE home visits or receive feedback on their recordings. Families in this group will complete the same assessments as the families in the treatment group.
1662935|NCT01753648|Device|Dynamic Vessel Analyzer|Retinal vessel diameter, total retinal blood flow (together with FD-OCT), retinal oxygen saturation
1662936|NCT01753648|Other|FDOCT|total retinal blood flow (together with DVA), retinal blood velocities
1662937|NCT01753648|Other|Ocular perfusion pressure|Measurement of intraocular pressure and mean arterial blood pressure for determination of ocular perfusion pressure
1662938|NCT01753635|Device|supraglottic airway placement and use|
1662939|NCT01753622|Behavioral|Exercise group|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise, 10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
1662940|NCT01753609|Device|Tulip capsule|swallowing Tulip capsule for up to 29 days
1662941|NCT01753596|Device|GENTEAL HA® Eye Drops (NOVARTIS, Switzerland)|
1720106|NCT00003028|Drug|sabarubicin|
1662943|NCT01753583|Device|Optical Coherence Tomography (OCT)|High-resolution OCT imaging of the cornea
1662944|NCT01753583|Other|Slit lamp biomicroscopy|Slit lamp biomicroscopy with fluorescein staining and slit lamp photograph
1954831|NCT03309748|Device|Dental prophylaxis + antimicrobial photodynamic therapy|Dental prophylaxis using American Dental Association, Code on Dental Procedures and Nomenclature (CDT) CDT code D1110 followed by two 8-minute irradiation cycles using GLO Brilliant home use whitening device (GLO ™ Science LLC, New York, USA).
1662948|NCT01753557|Drug|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
1662949|NCT01753557|Drug|RBV|RBV: 600 - 1000 mg/day based on body weight for 24 weeks
1662950|NCT01753557|Drug|PEG-IFN alfa-2a|PEG-IFN alfa-2a: 180mcg/week for 24 weeks
1662951|NCT01753531|Device|Flu Symptoms|
1662952|NCT01753518|Device|Subcuticular suture|subcuticular Monocryl suture closure
1662953|NCT01753518|Device|Subcuticular staple|subcuticular staple wound closure with INSORB 20 device
1662954|NCT01753505|Other|64-slice Multidetector coronary CT angiography|
1662955|NCT01753492|Device|Ologen|
1662956|NCT01753479|Other|Spectroscopy device|Spectrum data are collected using spectroscopy device via an instrumental channel of endoscope. Then spectrum data is analyzed. Numerical features (spectral slope and width of spectrum) are used for statistical analysis.
1662957|NCT01753466|Dietary Supplement|Hydration|
1662958|NCT01753453|Drug|Plerixafor|240mcg/kg, solution, subcutaneous injection
1662959|NCT01753453|Drug|Granulocyte-colony stimulating factor (G-CSF)|10 mcg/kg, solution, subcutaneous injection
1662960|NCT01753440|Procedure|Intramyocardial implantation of allogeneic mesenchymal stem cells|Intramyocardial implantation of allogeneic mesenchymal stem cells
1662961|NCT01753414|Radiation|Stereotactic Body Radiation Therapy (SBRT)|SBRT given every other day 11 Gy in 5 fractions to a total dose of 55 Gy in 10-15 days with an inter-fraction interval of 2-3 days
1662962|NCT01753414|Procedure|Surgery|Complete resection, i.e., removal of the primary tumor with at least a 2 cm margin together with nodal dissection/sampling
1662963|NCT01753401|Drug|Acthar|Acthar given SC (40 U daily or 80 U every other day) for Weeks 1-4 and tapered for Weeks 5-8
1662964|NCT01753401|Drug|Placebo for Acthar|Placebo contains the same inactive ingredients as H.P. Acthar Gel with the API. Placebo is given SC for 6 months in equal volume as the Acthar comparator.
1662965|NCT01753388|Device|Liberty Stent|
1662966|NCT01753375|Dietary Supplement|Vitamin D3|Vitamin D3 given as 50000 IU orally on weekly basis
1662967|NCT01753375|Dietary Supplement|Placebo|Placebo to be given orally on weekly basis
1662968|NCT01753362|Drug|liraglutide|
1662969|NCT01753362|Drug|placebo|
1662970|NCT01753349|Drug|BoNT-A injections, 3-4 times yearly|
1662971|NCT01753336|Drug|Dysport®|Dysport® (intramuscular injection), Up to 500 units (U)/vial using 2mL dilution, 3 treatment cycles
1662972|NCT01753323|Drug|KAF156|KAF156 was supplied as tablets for oral use.
1662973|NCT01753310|Drug|Dysport®|Intramuscular injection, between 250 and 500 units (U)/vial using 2mL dilution, 1 cycle only
1662974|NCT01753310|Drug|Placebo|Up to 2mL
1662975|NCT01753297|Drug|Triptorelin 11.25 mg|Triptorelin, one injection every 3 months. A total of 3 injections (at baseline, 3 and 6 months)
1662976|NCT01753271|Other|thoracic mobilization & shoulder mobilization & exercise|
1662977|NCT01753271|Other|shoulder mobilization & exercise|
1662978|NCT01753232|Device|DALI-adsorber|Recording of treatment data. No extra interventional treatment
1662979|NCT01753232|Device|MONET-Lipoprotein filter|Only treatment data recording. No extra interventional treatment
1662980|NCT01753219|Procedure|Onstep|
1662981|NCT01753219|Procedure|Lichtenstein|
1662982|NCT01753193|Biological|MEDI-546|MEDI-546, IV q4wks for 104 weeks
1662983|NCT01753180|Biological|collagenase|Local intra-coronary administration of MZ-004 at or into the CTO
1662984|NCT01753180|Drug|saline|Local intra-coronary administration of saline at or into the CTO
1662985|NCT01753167|Drug|MCMV3068A|Four doses of MCMV3068A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
1662986|NCT01753167|Drug|MCMV5322A|Four doses of MCMV5322A (10 mg/kg) administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
1662987|NCT01753167|Drug|Placebo|Four doses of placebo matched to MCMV5322A/MCMV3068A administered by intravenous infusion at the time of transplantation (Day 1), and at Days 8, 29, and 57.
1662988|NCT01753154|Drug|Solution B (balance PD solution)|balance 1.5% glucose, solution for peritoneal dialysis; balance 2.3% glucose, solution for peritoneal dialysis; balance 4.25% glucose, solution for peritoneal dialysis, each with 1.25 mmol/l or 1.75 mmol/l calcium
1662989|NCT01753154|Drug|Solution A (conventional PD solution)|Solutions for peritoneal dialysis: CAPD 2 (1.5% glucose, 1.75mmmol/l calcium), CAPD 3 (4.25 % glucose, 1.75mmmol/l calcium), CAPD 4 (2.3% glucose, 1.75mmmol/l calcium), CAPD 17 (1.5% glucose, 1.25mmmol/l calcium), CAPD 18 (4.25% glucose, 1.25mmmol/l calcium) and CAPD 19 (2.3% glucose, 1.25mmmol/l calcium)
1662990|NCT01753141|Behavioral|Cognitive Behavioral Therapy for smoking cessation|
1662991|NCT01753141|Behavioral|Cognitive Behavioral Therapy for smoking cessation and anxiety sensitivity reduction.|Includes anxiety sensitivity (AS) psychoeducation and interoceptive exposure exercises in addition to regular smoking cognitive behavioral therapy.
1662992|NCT01753128|Drug|imipramine|
1662993|NCT01753115|Biological|BioThrax|route of administration/schedule- 0.5 mL subcutaneous (SC) injection / 0-2-4 week schedule
1662994|NCT01753115|Drug|Ciprofloxacin|500 mg twice a day (Days 1-6, 19-21, 33-35, 40-48).
1662995|NCT01753102|Drug|Estradiol|one tablet will be inserted daily for 14 days
1662996|NCT01753089|Biological|WDVAX|
1662997|NCT01753076|Drug|Ozanezumab|Ozanezumab injection solution
1662998|NCT01753076|Drug|Placebo|Normal saline (0.9% sodium chloride) infusion
1662999|NCT01753063|Behavioral|Patient Expectations|Baseline Expectations survey (parent/guardian and adolescents 12 and older)
1663000|NCT01753063|Behavioral|Patient Expectations|3 month follow up survey (parent/guardian and adolescents 12 and older)
1663001|NCT01753050|Device|Stroke volume monitoring|Pulse contour stroke volume monitoring
1663002|NCT01753037|Dietary Supplement|Dehydroepiandrosterone (DHEA)|DHEA 130 mg administered orally for 5 days.
1663003|NCT01753037|Other|Placebo|Placebo contained in a capsule that is identical in appearance to the one used to package DHEA for 5 days.
1663004|NCT01753024|Dietary Supplement|Enteral nutrition (EN)|All patients enrolled in this study must carry out nutritional support by enteral nutrition
1663005|NCT01752998|Behavioral|Treating Opioid Patients' Pain and Sadness (TOPPS)|
1663006|NCT01752998|Behavioral|Health Education|
1663007|NCT01752985|Drug|BMS-813160|
1663008|NCT01752985|Drug|Placebo matching with BMS-813160|
1663009|NCT01752972|Dietary Supplement|Spirulina|10 g/day orally for 12 weeks
1663010|NCT01752959|Drug|Remifentanil|0.1-0.3 micg/kg/min Remifentanil iv infusion
1663011|NCT01752959|Drug|Esmolol|500 μcg/kg/dk esmolol iv lading dose after 50-500 μcg/kg/dk esmolol iv infusion
1663012|NCT01752933|Drug|SGI-110|SGI-110 will be administered by subcutaneously on Days 1 - 5 every 28 days until disease progression or unacceptable toxicity
1663014|NCT01752907|Other|General Education DVD|A general chemotherapy side effects education DVD
1663015|NCT01752907|Other|Bone Pain Education DVD|
1663016|NCT01752894|Device|Angio-guided PCI with EES or BES|Angio-guided intervention
1663017|NCT01752894|Device|OCT-guided PCI with EES or BES|OCT-guided intervention
1663018|NCT01752894|Device|PCI with BES under angio-guide or OCT guide|biolimus A9-eluting stent.
1663019|NCT01752894|Device|PCI with EES under angio-guide or OCT guide|everolimus eluting stent.
1663020|NCT01752894|Drug|Keep DAPT|maintain DAPT for 12 months according to level of uncovered strut (>6%) at 3months OCT follow up after stent implantation.
1663021|NCT01752894|Drug|Discontinue DAPT|discontinue DAPT according to level of uncovered strut (≤6%) at 3months OCT follow up after stent implantation.
1663022|NCT01752881|Biological|Influenza vaccine (split virion, inactivated)|"AdimFlu-S, Inactivated Influenza Vaccine Trivalent Types A and B (Split) Formulation 2012-2013
Dosage: 0.5mL/per syringe
Administration route: Intramuscular Injection, once"
1663023|NCT01752881|Biological|AdimFlu-S|
1663024|NCT01752868|Dietary Supplement|Supplement|Participants in this group will take the following nutritional supplements on a daily basis: curcumin, fish oil, resveratrol, sesamin, Acetyl-L-carnitine, lipoic acid, green and black teas, quercetin, pomegranate, cinnamon bark.
1663025|NCT01752855|Biological|New formulation adalimumab|New formulation adalimumab 40 mg every other week
1663026|NCT01752842|Drug|Fenofibrate|
1663027|NCT01752842|Drug|Placebo for fenofibrate|
1663028|NCT01752816|Behavioral|exercise training|
1663029|NCT01752803|Dietary Supplement|Probiotic|mix probiotic
1663030|NCT01752803|Dietary Supplement|Placebo|placebo
1663031|NCT01752790|Drug|Top-down|Patients randomized to top-down arm will receive an induction regimen of three consecutive i.v. infusions of infliximab (Remicade, 5 mg/kg) at weeks 0, 2, and 6 plus AZA (2 mg/Kg per os/day). Patients who will not respond to the induction regimen at week 8 will receive no further treatment with infliximab. Disease recurrences will be treated with infliximab (reduction of the interval between two doses). At 12 months pazients will discontinue azathioprine and continue infliximab (5mg/kg every 8 weeks). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
1663032|NCT01752790|Drug|Step-up|Patients randomized on Step-up arm will receive methylprednisolone (1 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop) plus azathioprine (2 mg/Kg/die per os/day).Disease recurrences under azathioprine will be treated with steroid courses (methylprednisolone 1-2 mg/Kg/day per os. for 2 weeks then tapering of 5 mg/week then stop). During the trial, other drugs will be not allowed, including immunosuppressive agents, other biological agents or steroids.
1663033|NCT01752777|Behavioral|Infectiousness Risk Reduction|Behavioral counseling conducted in one office session followed by 4 cell-phone-based sessions. Counseling is based on models of behavioral self-management and cognitive decision making with the primary aim to increase antiretroviral adherence, engagement in HIV care, and reduction of sexual risk behaviors for HIV transmission.
1663034|NCT01752777|Behavioral|General Health Improvement|Educational counseling to help link participants to social serves and health related strategies.
1663035|NCT01752764|Other|Test product: Salad with a high dosage fat|
1663036|NCT01752764|Other|Control product: Salad with low dosage fat|
1663037|NCT01752725|Device|BiCision®|
1663038|NCT01752725|Device|Ultracision® Har-monic Scalpel(Ethicon)|
1954834|NCT03311113|Other|Drug adherence questionnaire|Adherence to oral antibiotic therapy will be assessed by means of a questionnaire adapted from the French standardized self-assessment questionnaire of Girerd et al. This questionnaire has six questions, each question being associated with a score. Patient's drug adherence is classified into three groups based on the total score: of high, moderate and poor adherence. The questionnaire will be carried by a phone call to the patient.
1663041|NCT01752699|Drug|Methadone|patients with post-herpetic neuralgia take methadone or placebo to treat pain symptoms.
1663042|NCT01752699|Drug|Placebo|patients with post-herpetic neuralgia take placebo to treat the pain symptoms.
1663043|NCT01752686|Drug|carboplatin|carboplatin as adjuvant chemotherapy
1663044|NCT01752673|Other|Visualized pulmonary embolism computer task model|This group of participants was presented and trained to use a visual representation of diagnostic pathway for pulmonary embolism. The design of this visual representation is based on Bayes theorem and cognition enhancing visual design principles.
1663045|NCT01752673|Other|Didactic review lecture|This group of participants was presented with a didactic lecture covering the diagnostic approach of pulmonary embolism.
1663078|NCT01752348|Other|Endotoxin, US standard reference E.coli|
1954835|NCT03311100|Other|immunohistochemistry assay|biomarkers expression
1663046|NCT01752660|Behavioral|Endurance training|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center added 3 weekly sessions of endurance training for the upper extremity.
1663047|NCT01752660|Behavioral|Standard care|Standard care during a 4 week inpatient stay at a Danish multiple sclerosis rehabilitation center.
1663048|NCT01752647|Procedure|Low dose computed tomography|Low dose computed tomography scan
1663049|NCT01752634|Drug|Secukinumab (AIN457)|Secukinumab (AIN457)
1663050|NCT01752634|Drug|Placebo|Placebo PFS for s.c. administration.
1663051|NCT01752608|Behavioral|eCBT Mood|A handheld, computerized, electronic cognitive behavioral therapy (CBT) application
1663052|NCT01752595|Behavioral|Preference Based Rhythmic Auditory Stimulation Music|"Patients that have been randomized into arms 2 and 3 will be blinded to the intervention they are receiving (i.e. preference-based playlist vs. preference-based playlist that has been edited to include Rhythmic Auditory Stimulation (RAS). RAS drives synchronous neural oscillation (entrainment) and functions in two ways: (1) facilitates pace and heart-rate synchrony and (2) facilitates brain state dominance (getting into the zone). RAS will be accomplished through: (1) sequencing of subject self-selected music based on tempo, (2) accentuation of the rhythmic driving pulse with added percussive-type sounds, (3) addition of binaurally detuned pitches to follow bass lines at brain-state target frequencies (e.g., 8 Hz alpha, or 16 Hz beta), and (4) the addition of binaurally detuned background sounds (e.g., low frequency hum) at target Hz frequencies. RAS is implemented as inherent and natural to the music and may remain imperceptible to most."
1663053|NCT01752595|Other|Preference Based Music Intervention|
1663054|NCT01752582|Device|BuMA stent|About 35 patients will undergoing implantation of BuMA stent and receive 6 months dual antiplatelet therapy.
1663055|NCT01752582|Device|EXCEL stent|About 35 patients will undergoing implantation of EXCEL stent and receive 6 months dual antiplatelet therapy.
1663056|NCT01752569|Drug|Selumetinib|"The treatment schedule requires selumetinib to be taken either once daily at the same time each day or twice daily approximately 12 hours apart. Selumetinib should be taken with water at least 2 hours after a meal and 1 hour before the next meal. Selumetinib capsules will be administered in a continuous 21 day cycle (6 cycles), unless disease progression occurs.
For phase I there were 4 potential dosing levels:
Level -1 - 50mg once daily (od) (50mg daily total)
Level 1 (starting dose level for phase I) - 50mg bi-daily (bd) (100mg daily total)
Level 2 - 75mg bd (150mg daily total)
Level 3 - 100mg bd (200mg daily total)
Phase I has been completed and identified 75mg bd as the recommended phase II dose.
Phase II has begun and is utilising a dose of 75mg bd of selumetinib."
1663057|NCT01752556|Procedure|diagnosis and therapeutic decision|A conventional polysomnography will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 moths
1663058|NCT01752556|Procedure|diagnosis and therapeutic decision|A home respiratory polygraphy will be done to perform the diagnosis and therapeutic decision(CPAP or not). Treated and untreated will be followed 6 months
1663059|NCT01752543|Drug|Conivaptan|Conivaptan treatment: 20 mg bolus followed by infusion of 2 mg/hour
1663060|NCT01752543|Drug|Placebo (Dextrose)|Placebo treatment: 20 mg bolus followed by infusion of 2 mg/hour
1663061|NCT01752530|Other|Computer program C8|Experimental: Computer program C8 + treatment as usual: Playing a special computer program C8 40 min a day for 6 days a week for 8 weeks.
1663062|NCT01752530|Other|Treatment as usual|Treatment as usual at the clinic
1663063|NCT01752517|Drug|NI group|vinorelbine 25mg/m2 d1,d8; ifosfamide 1.25g/m2 d1-d3; Mesna 400mg iv 0,4,8 hours after ifosfamide administration for 3 days
1663064|NCT01752504|Behavioral|Community Mobilization|The proposed study seeks to continue C2P, a community mobilization intervention, which entails developing coalitions to plan for and bring about structural changes for purposes of reducing HIV incidence and prevalence among youth in targeted communities at five ATN sites. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action; developing coalitions that have a shared vision and mission; developing a strategic plan focused on structural changes to reduce risks associated with HIV; documenting processes; providing feedback as technical assistance to the coalitions; hosting regular working group meetings; and on-going capacity building.
1663065|NCT01752491|Drug|Ascorbate|Intravenous infusion of high-dose ascorbate
1663066|NCT01752491|Drug|Temozolomide|Oral chemotherapeutic
1663067|NCT01752491|Radiation|Radiation therapy|
1663068|NCT01752465|Behavioral|Health Coaching|Health Coaching sessions are 2 hours long. Participants individually receive a physical assessment, and recent blood work and medications are reviewed. When everyone has been assessed, the group reconvenes to watch a video about the importance of making healthy lifestyle choices, participates in a 10 min. fitness activity, and receives training on making SMART goals (SMART stands for specific, measurable, achievable, realistic, and timely). Each participant individually creates a SMART goal for him/herself, and this goal is reviewed as a group. Each participant rates the importance of this goal, and rates their level of confidence in succeeding. Progress is tracked in subsequent sessions, and metabolic health is continually monitored through routine blood work.
1663069|NCT01752465|Behavioral|Standard care|Standard clinical care will continue for all participants in the study, regardless of the study arm. This includes routine clinical visits to the attending psychiatrist, and receiving pharmacotherapy, standard patient education, and psychosocial training.
1663070|NCT01752439|Device|Anodal transcranial direct current stimulation|
1663071|NCT01752439|Device|Sham transcranial direct current stimulation|
1663072|NCT01752426|Other|Heavy Water (2H2O)|50 ml 70% 2H2O 3 times a day for the first 5 days followed by 60 ml daily for a total of 4 weeks. After the 5-day loading period, a 60 ml maintenance dose of 2H2O will be drunk at bedtime. At end of the 4th week, subjects stop drinking 2H2O (washout phase) and be followed from 6-12 weeks until beginning treatment with PCI-32765.
1663073|NCT01752426|Drug|PCI-32765|420 mg orally once daily.
1663074|NCT01752413|Dietary Supplement|Ferrous gluconate 325mg|Participants with low ferritin (<30 micrograms/L (males) or <20 micrograms/L (females)) will be asked to take two tablets of Ferrous Gluconate 325 mg (36 mg elemental iron) per day.
1663075|NCT01752413|Behavioral|Nutrition counseling|All blood donors receive current dietary counseling recommending iron rich foods
1663076|NCT01752400|Drug|AUY922|
1663077|NCT01752361|Device|Motilis-3D transit|
1663079|NCT01752335|Other|Braquial ecography|At the moment of the ecography, the clinician evaluates the endothelial responses via applying braquial ischemia and administering sublingual nitroglicerin spray to evaluate vasodilation.
1663080|NCT01752322|Drug|Lidocaine 5% medicated plaster|
1663081|NCT01752322|Drug|Placebo plaster|
1663082|NCT01752283|Procedure|video-assisted thyroidectomy|Experimental arm: video-assisted thyroidectomy under local anesthesia and hypnosis
1663083|NCT01752283|Procedure|Video-assisted thyroidectomy|video-assisted thyroidectomy under general anesthesia
1663084|NCT01752270|Drug|Diane-35 pretreatment|Diane-35 is applied from the third day of menstrual cycle for 21 days with a 7-day interval, for 3 consecutive cycles.
1663085|NCT01752270|Drug|Diane-35 pretreatment|
1663086|NCT01752257|Drug|EF5 Hypoxia|EF5 is a dye used to measure hypoxia
1663087|NCT01752244|Dietary Supplement|Placebo|corn oil Capsules 1 gram: were given to the placebo group once a day for 8 weeks
1663088|NCT01752244|Dietary Supplement|Alfacalcidol|Alfacalcidol
1663089|NCT01752231|Drug|MultiHance|
1663090|NCT01752231|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI using new pulse sequences
1663091|NCT01752218|Device|arcuate incision|
1663092|NCT01752205|Drug|Paclitaxel|45mg/m2/w,total 6 weeks
1663093|NCT01752205|Drug|Erlotinib|150mg/d,days 1-42,total 6 weeks
1663094|NCT01752205|Radiation|Radiation therapy|
1663095|NCT01752192|Device|Telerehabilitation programme|Telerehabilitation programme: Each patient in the intervention group will use a telehealth monitor. The patient will measure blood pressure, pulse and weight once or twice a week over a 3 months periode with the use of a blood pressure monitor and a weightscale connected to the monitor. The patients will also measure their steps daily by the use of a digital stepcounter. The patients will be able to see their data in a personal health record on a tablet where they can share informations with their GP, nurse and doctor at the hospital or healthcare center. The patient are also offered access to a portal called www.aktivehjerte.dk where they can find informations on rehabilitations topics in text, video and sound.
1663096|NCT01752179|Procedure|kinesio Tape : Width 5cm ,Length 35cm Y shape|"In the experimental group, Kinesio taping application of piriformis according to Kenzo Kase in 2003 is modified by using unloading technique (Macdolanld, 2004). Size and Shape of Tape is Width 5cm ,Length 35cm Y shape.
Taping method include :
stretches the piriformis muscle in side lying position ,the affected leg is upper most with hip in flexion, adduction and internal rotation.
puts the base of tape over the contralateral of sacrum with no tension.
attaches the superior tail on the buttock over the upper part of piriformis and ends at the greater trochanter of the femur.
attaches the lower tail by lifting up the soft tissue and ends at the greater trochanter of the femur.
This is an origin to insertion application."
1663097|NCT01752153|Drug|Desferrioxamine, Legalon® (Silymarin)|Desferrioxamine (Novartis Pharma AG, Switzerland) at the dose of 40 mg/Kg/day and Legalon® tablets (Madaus Pharma, Italy)
1663098|NCT01752153|Drug|Silymarin (Legalon)|
1663099|NCT01752140|Procedure|10-core prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain 10 biopsy cores.
1663100|NCT01752140|Procedure|Vienna nomogram prostate biopsy protocol|Local vascular bundle anesthesia with 2% lidocaine was performed using a 22G Chiba needle. Ultrasound guided prostate biopsy using a standard biopsy device to obtain a number of cores as defined by the Vienna nomogram.
1663101|NCT01752127|Procedure|percutaneous coronary intervention using drug eluting stent|"1. Intracoronary stenting
The procedure could be conducted via brachial, radial or femoral approaches.
There are no restrictions regarding lesion's length or diameter. For long lesions, overlapping of several stents would be allowed but only allocated type of stents should be used.
When several lesions are included in the study of a patient, each lesion may be allocated in different groups. Only if deployment of the allocated stent is not possible, crossing to other stent would be allowed.
Direct stenting or bifurcation stenting is allowed.
Predilation before stenting, IVUS examination, and administration of glycoprotein IIb/IIIa inhibitor would be determined by investigator."
1663102|NCT01752075|Drug|Revlimid|The prescribing physician should prescribe and monitor REVLIMID therapy according to the guidance and recommended schedules given in the approved Taiwan package insert (PI).
1663103|NCT01752049|Drug|Topical timolol maleate|"Topical timolol maleate 0.5% drops
Applied twice daily for 12 weeks (84 days) or until disappearance of lesions
Study drops will be applied to 4 cutaneous telangiectasias per patient (timolol drops for 3 telangiectasia per patient and placebo drops to 1 telangiectasia per patient)."
1663104|NCT01752049|Drug|placebo saline drops|Applied twice daily for 12 weeks (84 days) or until disappearance of lesions to one cutaneous telangiectasias per patient.
1663105|NCT01752036|Radiation|Stereotactic Radiotherapy (SRS)|600 cGy x 5 fractions
1663106|NCT01752023|Drug|Cisplatin + Gemcitabine with SUBATM-itraconazole|Experimental Arm
1663107|NCT01752023|Drug|Cisplatin + Gemcitabine|Active Comparator
1663108|NCT01752010|Other|Traditional Chinese Acupuncture|"Treatment will be performed by an experienced provider, and may include insertion of sterile 32-gage (0.25mm) acupuncture needles on any part of the body that can be needled while the subject is lying prone with their head in a face cradle. The needles are usually retained for 20-30 minutes along various meridian points identified by the practitioner as being blocked. Needles will be inserted to the depth typically recommended for the particular point of concern; generally 1 to 3cm. There are no constraints on the number of needles used. Acupuncture points are points of lower resistance and higher electrical conductance than the surrounding tissue. Placing the acupuncture needles into points identified as blocked is believed to help restore the flow of energy and stimulates the release of endorphins. The subject's level of pain is assessed on a 0-10 pain scale. Thirty minute acupuncture treatments will be given by the provider once a week for 6 weeks at the pain clinic."
1663130|NCT01751854|Drug|Placebo|Placebo alone or with training
1663131|NCT01751828|Drug|Sertraline|
1663132|NCT01751815|Procedure|Acu-TENS|Patients randomized to the experimental group will receive Acu-TENS on acupoints relevant to the treatment of abdominal pain and distension, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), Neiguan (pericardium meridian PC-6), Tianshu (stomach meridian ST-25), and Dachangshu (bladder meridian BL-25).
1663133|NCT01751815|Procedure|Placebo-TENS|Patients randomized to the control group will receive placebo-TENS at the same acupoints.
1663109|NCT01752010|Device|Tennant™ Biomodulator Treatment|An FDA-approved Tennant™ 650 BioModulator will be used to deliver electrical stimulation. The device will be applied directly on top of the subject's area of pain for one minute; power is adjusted until the subject feels a slight tingle. Random variations of pulse amplitude are set from zero to a chosen comfort limit. A feedback mechanism is provided by the constant monitoring of skin impedance. The device is then pressed onto the site of pain and rotated counter-clockwise. After a minute, the device is placed on the opposite side of the pain site and the procedure repeated. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
1663110|NCT01752010|Device|Transcutaneous electrical nerve stimulation (TENS) Treatment|An FDA-approved Empi™ TENS unit will be used to deliver the transcutaneous electrical nerve stimulation. The low frequency TENS unit will be applied to the subject's area of pain by the use of four integrated self-adhering 5x5 cm electrodes. The electrodes will be positioned at a distance of 3 cm and centered over the area that is most painful. The device rapidly delivers therapeutic electrical currents at various frequencies off and on 150 times a second. The subject's level of pain is assessed on a 0-10 pain scale. At no time is the level of electrical stimulation allowed to cause sustained pain. The subject will receive a weekly 15 minute visit that includes a treatment provided by the pain provider. The provider will teach the subject how to use the machine by themselves and instruct the subject to use the machine twice a day on their own during the study.
1663111|NCT01751997|Drug|Transplants from 8/8-matched Unrelated donors|"Myeloablative conditioning
Total body irradiation; 165 cGy, every 12 hours, 8 doses, days -7 to -4 (total 1320 cGy)
Cyclophosphamide; 60 mg/kg/day, IV for 30 minutes, days -3 to -2 (total 120 mg/kg)
Antithymocyte globulin (ATG); 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)
Reduced-intensity conditioning; older patients (age > 55 years) and/or patients with comorbidities
Fludarabine; 30 mg/m^2/day, IV for 1 hour, days -8 to -4 (total 150 mg/m^2)
Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -3 to -2 (total 6.4 mg/kg)
Total body irradiation; 200 cGy, every 12 hours 2 doses, days -1 (total 400 cGy)
ATG; 1.25 mg/kg/day, IV for 6 hours, days -3 to -2, (total 2.5 mg/kg)
GVHD prophylaxis
Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)
Methotrexate; 5 mg/m^2/day, IV push, days +1, +3, +6, +11"
1663112|NCT01751997|Drug|Transplants from family-mismatched/haploidentical donors|"Reduced-intensity conditioning
Total body irradiation; 200 cGy, every 12 hours, 4 doses, days -9 to -8 (total 800 cGy)
Fludarabine; 30 mg/m^2/day, IV for 1 hour, days -7 to -3 (total 150 mg/m^2)
Busulfex; 3.2 mg/kg/day, IV for 3 hours, days -6 to -5 (total 6.4 mg/kg)
ATG; 1.25 mg/kg/day, IV for 6 hours, days -4 to -1 (total 5.0 mg/kg)
GVHD prophylaxis
Tacrolimus; 0.03 mg/kg/day, IV for 24 hours from day -1 (0.12 mg/kg/day, PO, if tolerable)
Methotrexate; 5 mg/m^2/day, IV push, days +1, +3, +6, +11"
1663113|NCT01751984|Drug|ETC-1002|Weeks 1-2, 60 mg/day; Weeks 3-4, 120 mg/day; Weeks 5-6, 180 mg/day; Weeks 7-8, 240 mg/day
1663114|NCT01751984|Drug|Placebo|Placebo once daily for 8 weeks
1954836|NCT03311074|Biological|GSK2696273|GSK2696273 is a gene therapy that aims to restore ADA function in hematopoietic cell lineages and prevent the immunological manifestations. GSK2696273 is a cluster of differentiation (CD) 34+ cell enriched dispersion of human bone marrow derived hematopoietic stem cells for infusion which have been transduced with a retroviral vector containing the human ADA gene.
1954837|NCT03311061|Other|DREAMS Curriculum|Teen Pregnancy Prevention Curriculum as described in arm/group description.
1663117|NCT01751958|Radiation|Epidural steroid injection|Epidural steroid injection
1663118|NCT01751945|Behavioral|EmONC package|"The EmONC package consists of:
Maternal and neonatal health pack(clean delivery kit, emollient, chlorhexidine, sms messages) for safe motherhood and newborn wellbeing.
Enhanced trainings of community-level health care providers to provide effective maternal and neonatal health services and referral of complicated cases to health facilities and creation of linkages amongst health care providers.
Community mobilisation"
1663119|NCT01751932|Device|CGM Monitoring|All patients will be fitted with the two study CGM systems. Paradigm Veo will be configured to use the CGM part only if another pump is used.
1663120|NCT01751919|Drug|Imatinib mesylate tablet 400 mg, 1 Tablet|
1663121|NCT01751919|Drug|Glivec film-coated tablet 100 mg, 4 Tablets|
1954838|NCT03311048|Other|Nasal swab|Nasal swab was collect to upper airways inflammation evaluation.
1954839|NCT03311048|Other|Questionnaires|Clinical profile and respiratory symptoms employees' evaluation were performed using specific questionnaires (European Community Respiratory Health Survey for occupational diseases evaluation (ECRHS), (adapted by Ribeiro et al, 2007) and the International Study of Asthma and Allergies in Childhood (ISAAC) - Asthma module, previously translated and validated.
1663124|NCT01751893|Drug|Henna|
1663125|NCT01751893|Drug|Placebo|
1663126|NCT01751880|Behavioral|physical activity intervention|Exercise program is scheduled to be conducted in three phases. Phase I is in-hospital exercise program. This program will be conducted in hospital during 1 week after surgery. Phase II is home-exercise program that will be performed at home during 1 week after discharge. Phase III is main-exercise program that will be conducted the fitness center nearby hospital during 8 weeks after phase II program. Main-exercise program is focused on the functional recovery.
1663127|NCT01751867|Drug|Decitabine at 15 mg/m2|Decitabine will be given at a dose of 15 mg/m2 as a continuous intravenous infusion within a 3-hour intravenous infusion, repeated every 8 hours for 3 consecutive days.The total dose per day is 45 mg/m2; The total dose per course is 135 mg/m2. Cycles will be repeated every 6 weeks.
1663128|NCT01751867|Drug|Decitabine at 20 mg/m2|Decitabine will be given at a dose of 20 mg/m2 as 1-hour IV infusion once daily on Days 1 through 5, of a 4-week treatment cycle.
1663129|NCT01751854|Drug|SSRI|SSRI alone or with training
1958122|NCT01977222|Device|THRESHOLD(TM) INSPIRATORY MUSCLE TRAINER|Subjects will be provided with noseclips and a threshold impedance device set to 40% of their measured maximal inspiratory pressure and will be trained on using the device. Specifically, subjects will be instructed to breathe through the inspiratory muscle training device while wearing noseclips at a rate of 12 to 16 breaths per minute for 30 minutes a day, 5 days a week for 12 consecutive weeks. Each subject will be provided a customized schedule for increasing resistance by 2 cm H2O every 2 weeks to a maximum resistance of 41 cm H2O.
1663134|NCT01751802|Drug|Ecopipam|Antagonist of the dopamine D1 receptor
1663135|NCT01751802|Drug|Placebo|Placebo for Ecopipam
1663136|NCT01751789|Behavioral|Linkage|
1663137|NCT01751789|Other|Treatment as Usual|
1663138|NCT01751776|Drug|BI 655064 medium dose|Medium dose
1663139|NCT01751776|Drug|BI 655064 high dose|High dose
1663140|NCT01751776|Drug|BI 655064 high dose|High dose
1663141|NCT01751776|Drug|Placebo|Placebo
1663142|NCT01751776|Drug|BI 655064 low dose|Low dose
1663143|NCT01751776|Drug|Placebo|Placebo
1663144|NCT01751776|Drug|BI 655064 medium dose|Medium dose
1663145|NCT01751763|Drug|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator.
1663146|NCT01751750|Other|Grape|16 oz. of Concord grape juice (8 oz. consumed 2 times per day; total dose of approximately 1.2 g phenolic compounds per day), 250 mg resveratrol provided as a capsule (commercially available supplement; 125 mg consumed 2 times per day), and 1 g grape seed polyphenol extract provided as a capsule (commercially available supplement; 0.5 g consumed 2 times per day).
1663147|NCT01751737|Procedure|Prostate Cancer Imaging|After imaging is completed, subjects will be scheduled for a prostate biopsy performed as part of their clinical care. If the imaging has identified suspicious lesions in the prostate, these regions will be made visible for the Urologist to be targeted for additional biopsies. These additional biopsies will undergo histological evaluation and further metabolomic testing to better understand metabolic differences between various grades of prostate cancer lesions.
1663148|NCT01751724|Drug|Caffeine citrate|"Enrolled subjects will be randomized to receive a study drug consisting of either blinded Caffeine citrate.
Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.
After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.
Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
1663149|NCT01751724|Other|Normal saline|"Enrolled subjects will be randomized to receive a study drug consisting of blinded Placebo (equivalent volume of normal saline).
Randomization and study drug preparation will be done by the NICU pharmacy. Investigators and clinicians will be blinded to the assigned drug.
After randomization, an initial loading dose of 20 mg/Kg of study drug will be followed by a 5 mg/Kg/day maintenance dose. The assigned study drug will be administered intravenous or orally as determined by the clinical team.
Infants will continue to receive the study drug until 12 hours prior to the first elective extubation."
1663150|NCT01751698|Behavioral|JASP-EMT|JASP-EMT is a developmentally anchored behavioral intervention that assumes that communication develops from social interactions in which specific social engagement strategies, symbolic representations, and early communication forms are modeled and naturally reinforced by adult partner responses to the child. The goal of JASP-EMT is to increase (a) joint engagement, (b) initiating joint attention gestures, (c) social play involving objects and persons, and (d) verbal and nonverbal communication by facilitating meaningful social interactions. The social interaction foundation of JASP-EMT is critical. Modeling and expansions of communicative behaviors and play are used strategically within meaningful social interactions with therapists and caregivers.
1663151|NCT01751698|Behavioral|DTT|CORE-DTT is based on behavioral learning theory in which communication and related skills are taught through systematic direct instruction. The goal of CORE-DTT is to help children be successful in learning communication skills by breaking these skills down into small steps, providing systematic direct instruction on each step, and reinforcing children (e.g., with praise or access to preferred items) for demonstrating skills. Imitation and attention skills are a main focus early in intervention. DTT is the most common evidence-based approach for teaching children with ASD, and is often considered the closest to a 'standard of practice' for the field.
1663152|NCT01751685|Behavioral|Kyphosis-specific spinal strengthening exercises|Investigator developed the intervention protocol (Kyphosis-specific spinal strengthening exercises) of targeted spine exercises during our pilot study based upon the literature and clinical experience.We standardized the protocol with a written script and a video. Each exercise session will be preceded by light aerobic activity, ended with cool-down and stretching the neck, chest and all extremities. All participants will be carefully monitored to ensure that all exercises will be performed slowly, with correct body alignment and technique to minimize risk of injury.
1663153|NCT01751685|Other|Control|monthly educational lectures on various topics
1663154|NCT01751672|Behavioral|SBIRT|Screening, Brief Intervention, and Referral to Treatment. Standard, single session SBIRT.
1663155|NCT01751672|Behavioral|SBIRT+|Expanded Screening, Brief Intervention, and Referral to Treatment. One Standard SBIRT session, plus 2-6 additional Brief Intervention sessions as needed.
1663158|NCT01751633|Procedure|Surgical|
1663159|NCT01751633|Procedure|Conservative treatment|
1663160|NCT01751620|Behavioral|Project ACCEPT|The intervention, Project ACCEPT, combines weekly individual and group sessions that address a range of issues that impact engagement in care for youth living with HIV, including stigma, disclosure, health relationships, substance use, and future life plans.
1663161|NCT01751620|Behavioral|HEALTH|The comparison condition, HEALTH, matches Project ACCEPT in number of sessions and duration. The weekly sessions will cover information on alcohol, drugs, HIV and other sexually transmitted diseases (STDs) to meet the ethical responsibility to provide risk reduction information to youth assigned.
1663162|NCT01751594|Behavioral|MOVE Intervention|MOVE involves four sessions. Sessions 1 and 2 occur over a two-day time frame and are each one day long (approximately 8 hours in length). They will: lay the groundwork for the intervention; provide HIV and other sexual health-related information; introduce critical consciousness; Sessions 1 and 2 will begin the enhancement of critical consciousness and the action-reflection-action cycle. Sessions 3 and 4 are also one-day sessions each (approximately 8 hours in length) and will be administered at one month intervals following the completion of sessions 1 and 2. These sessions will be used to provide continued enhancement of critical consciousness and guided support, feedback, and social reinforcement for behavior change and self-efficacy related to increasing health-promoting behaviors and reducing HIV-related health risk behaviors.
1663163|NCT01751594|Behavioral|H4L Comparison Intervention|Health 4 Life (H4L) is a comparison intervention which will serve as the basis of comparison for Mobilizing Our Voices for Empowerment (MOVE), the treatment intervention. H4L will be a health promotion and life skills intervention to account for time and attention.
1663164|NCT01751581|Behavioral|Short Sleep|Participants will be restricted in sleep and only allowed to sleep from 1 am to 5 am.
1663165|NCT01751581|Behavioral|Habitual sleep|Participants sleep 8 h/night throughout the study phase (from 11 pm to 7 am)
1663166|NCT01751568|Drug|Raltegravir|Chewable raltegravir tablets, initially dosed at 12 mg/kg (up to a maximum of 800 mg) twice daily.
1663167|NCT01751555|Drug|Regimen:TDF+3TC+EFV|TDF+3TC+EFV for HIV/HBV co-infection
1663168|NCT01751542|Behavioral|Mindfulness + Residential Treatment|
1663169|NCT01751542|Behavioral|Residential treatment alone|
1663170|NCT01751529|Procedure|Contrast-enhanced Ultrasound|All patients will undergo a contrast-enhanced ultrasound prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
1663171|NCT01751529|Drug|Perflutren lipid|All patients will receive a contrast-enhanced ultrasound using microbubble contrast agent (perflutren lipid; Definity®) prior to planned resection or ablative therapy or as part of routine screening for kidney cancer.
1663172|NCT01751503|Procedure|Interosseous route of TPTT|Anterior transposition of Posterior tibialis tendon (PTT) is the gold standard for surgical restoration of functional dorsiflexion of a permanently paralyzed foot. Two methods of rerouting the posterior tibialis tendon have been reported, one through the interosseous membrane i.e. Interosseous route and second subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route. Both these techniques have been widely described in literature and are being extensively used in surgical management of foot drop. The selection of technique depends on surgeon choice and patient factors
1663173|NCT01751503|Procedure|Extra membranous route of TPTT|Rerouting the posterior tibialis tendon subcutaneously around the medial side of tibia i.e. Extramembranous or circumtibial route (
1663174|NCT01751490|Other|physiotherapy|physiotherapy
1663175|NCT01751490|Procedure|shoulder stabilisation surgery|arthroscopic stabilisation surgery
1663176|NCT01751464|Behavioral|WrapAround Case Management|Youth Injured by Violence will be paired with a support worker who has extensive experience working with youth affected by violence.It is important to note that the wraparound concept involves individualized care planning and management. As such, the specific care plan will be different for each participant. Through early intensive meetings, they will develop a mentoring relationship. They will work with the youth to develop a support team, which may include family, teachers, child welfare workers and truly anyone the youth has decided can help them in their path to making positive choices.
1663177|NCT01751451|Drug|Abiraterone acetate|Patients randomized to abiraterone acetate and prednisone (Group 1) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day. These patients will also be treated with prednisone 5 mg once daily with food.
1663178|NCT01751451|Drug|Abiraterone acetate plus degarelix|Patients randomized to abiraterone acetate plus degarelix and prednisone (Group 2) will be instructed to take 1000 mg (four 250 mg tablets) of abiraterone acetate orally (PO) at least 1 hour before a meal and 2 hours after a meal every day and prednisone 5 mg once daily with food. Patients will also be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1(starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (±3 days) thereafter.
1663179|NCT01751451|Drug|Degarelix|Patients randomized to degarelix alone (Group 3) will be given two subcutaneous injections of degarelix 120 mg on Cycle 1, Day 1 (starting dose) and 80 mg subcutaneous doses (maintenance doses) every 28 days (± 3 days) thereafter.
1663180|NCT01751438|Other|Best Systemic Therapy (BST)|Group 1 will continue to receive best systemic therapy (BST).
1663181|NCT01751438|Other|Best Systemic Therapy (BST) + Surgery or Radiation Therapy|Group 2 will receive best systemic therapy in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice.
1663182|NCT01751438|Behavioral|Questionnaires|Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete.
1663183|NCT01751438|Other|Phone Call/Email|Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
1663184|NCT01751425|Drug|Ruxolitinib|"Phase I Dose Escalation Group: Ruxolitinib starting dose level 5 mg orally, twice daily.
Phase II Dose Expansion Group: Ruxolitinib starting dose level MTD from Phase I."
1663185|NCT01751425|Drug|TKI|Phase I Dose Escalation Group and Phase II Dose Expansion Group: Patients continue receiving commercially available TKIs (IM, NIL or DAS) at dose they had been receiving during the last 6 months.
1663187|NCT01751399|Drug|LY2605541|Administered once as single SC dose
1663188|NCT01751386|Drug|Baclofen|
1663189|NCT01751386|Other|Placebo|
1663190|NCT01751373|Behavioral|Optimal muscle activation therapy|The proposed study uses a longitudinal, within-subject, pre/post intervention, cross-over design. All participants will complete each of 4 study phases (each 12 weeks long). These include: a) focal BTX injections in combination with either Standard Therapy or Optimal Muscle Activity Therapy; b) a three-month period where no treatment is given; c) focal BTX injections in combination either Standard Therapy or Optimal Muscle Activation Therapy; d) another three-month period where no treatment is given. The order of treatment phases will be counter-balanced across participants.
1663191|NCT01751373|Behavioral|Standard Therapy|
1663192|NCT01751360|Drug|SYR-472|
1663193|NCT01751347|Drug|Bupivacaine|Local anesthetics
1663194|NCT01751347|Drug|Lidocaine|Local anesthetics
1663195|NCT01751334|Device|total knee arthroplasty|Mobile Bearing Total knee Arthroplasty
1663196|NCT01751334|Device|total knee arthroplasty|Fixed Total Knee Arthroplasty
1663197|NCT01751321|Drug|Sitagliptin, placebo|sitagliptin 50 / metformin 1000 twice in a day and placebo 50 mg /metformin 1000 twice in a day
1663198|NCT01751308|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: Injection Route of administration: Intravenous
1663199|NCT01751295|Drug|Atorvastatin, pre-treatment 80 mg/day for 4 days before PCI|
1663200|NCT01751282|Genetic|Stem Cell|
1663201|NCT01751269|Drug|RPX7009|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
1663202|NCT01751269|Drug|Placebo|Ten (10) cohorts of 8 subjects (6 active and 2 placebo) are planned for evaluation.
1663203|NCT01751256|Device|Continuous wound infiltration|Subfascial continuous wound infiltration with Levobupivacaine: bolus 50mg and 6.25mg/h for 48 hours through a multiperforated catheter, in addition to Celecoxib 200mg twice a day, paracetamol 1g four times a day, Nefopam 20mg four times a day, and intravenous morphine for 24 hours with Patient Controlled Analgesia pump (1.2mg by bolus, 7 minutes lockout period).
1663204|NCT01751243|Other|Allo-depleted lymphocyte infusion|Doses: 1x105 CD3/Kg; 3x105 CD3/Kg; 5x105 CD3/Kg; 1x106 CD3/Kg;31x106 CD3/Kg;
1663205|NCT01751243|Other|Haploidentical transplantation of hematopoietic progenitors|Haploidentical transplantation of hematopoietic progenitors without subsequent infusion of allo-depleted lymphocytes.
1663207|NCT01751217|Behavioral|Functional Family Tx|
1663208|NCT01751217|Behavioral|Services as Usual|
1663209|NCT01751204|Dietary Supplement|Calcium tablet|
1663210|NCT01751204|Dietary Supplement|Calcium ion water (250mg)|
1663211|NCT01751204|Dietary Supplement|Calcium ion water (125mg)|
1663212|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash with Alcohol|0.2% w/v Chlorhexidine Digluconate, alcohol containing - UK Marketed Mouthwash
1663213|NCT01751178|Drug|Chlorhexidine Digluconate Mouthwash without Alcohol|0.2% w/v Chlorhexidine Digluconate, without alcohol - UK Marketed Mouthwash
1663214|NCT01751165|Biological|Herpes zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
1663215|NCT01751152|Drug|NNC0114-0006|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
1663216|NCT01751152|Drug|placebo|A single i.v. (intravenous, into the vein) dose. At week 12 the possibility to administer an additional open-label dose of NNC0114-0006 will be provided to all subjects irrespective of initial treatment allocation as long as they are not in need of rescue medication, as judged by the clinical investigator.
1663217|NCT01751139|Procedure|Blood sample collection|Blood samples will be collected at each study visit (Day 0, Month 6, Month 12, Month 24, Month 36 and Month 48) and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue infection diagnosis.
1663218|NCT01751139|Other|Data collection|Diary logs will be issued to all subjects at every visit, except Month 48 (Day 0, Month 6, Month 12, Month 24, and Month 36), as required. Any completed diary logs will be verified, as applicable. Subjects will be given a diary log in the event of the occurrence of a symptom that may be associated with suspected dengue.
1663219|NCT01751126|Drug|NOVA22007 ''Ciclosporin''|Sterile, ophthalmic cationic oil-in-water emulsion containing 1 mg/ml Ciclosporin.
1663220|NCT01751126|Drug|Placebo|Sterile, drug-free, cationic ophthalmic oil-in-water emulsion containing 0 mg/ml Ciclosporin.
1663221|NCT01751113|Drug|fluticasone propionate/salmeterol|250mcg fluticasone + 50 mcg salmeterol, twice daily 4 week treatment in each treatment sequence (crossover design)
1663222|NCT01751113|Drug|tiotropium bromide|18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
1663223|NCT01751113|Drug|fluticasone propionate/salmeterol plus tiotropium bromide|250mcg fluticasone + 50 mcg salmeterol, twice daily plus 18 mcg tiotropium bromide, once daily 4 week treatment in each treatment sequence (crossover design)
1663224|NCT01751100|Behavioral|HIV Test Offer|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test
1663225|NCT01751100|Behavioral|General Health Screen Offer|A Research Assistant (RA) will provide health education on diabetes, hypertension, and HIV. The RA will then offer free blood pressure check, blood glucose measuring, rapid Hepatitis C (HCV) test, and a free, rapid oral HIV test.
1663226|NCT01751087|Other|Mifepristone|oral mifepristone 200 mg on Day 1.
1663227|NCT01751087|Drug|misoprostol|buccal misoprostol 400 mcg on Day 2
1663228|NCT01751087|Device|Osmotic dilators|osmotic dilators on Day 1
1663229|NCT01751087|Other|placebo|placebo for mifepristone, on day 1
1663230|NCT01751087|Other|placebo|placebo for misoprostol, on day 2
1663231|NCT01751074|Drug|Rosuvastatin 10 mg|Enteric coated tablet will be administered orally as a single dose once in Treatment Period 1 (Day 1) and Treatment Period 2 (Day 15).
1663232|NCT01751074|Drug|Darapladib 160 mg|Enteric coated tablet will be administered orally as once daily for 14 days in Treatment Period 2 only (Day 5 to Day 18).
1663233|NCT01751061|Behavioral|Decision aid|A web-based decision aid to assist surrogate decision makers in prolonged mechanical ventilation decisions
1663234|NCT01751061|Other|Usual care|usual ICU care
1663235|NCT01751048|Biological|GLA-SE|Glucopyranosyl Lipid A- Stable oil-in-water emulsion (GLA-SE) is formulated in a stable oil-in-water emulsion (SE) to yield the adjuvant formulation GLA-SE. The combination of GLA-SE with a recombinant protein antigen (LEISH-F3) results in a Th1-type T cell response. GLA-SE appears as a milky- white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3 + 5 mcg GLA-SE.
1663236|NCT01751048|Biological|LEISH-F3|LEISH-F3 is a lyophilized formulation containing 50 mcg LEISH-F3 and excipients (mannitol, sucrose, and polysorbate 80). All subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3.
1663303|NCT01750476|Drug|Oral contraception|
1663304|NCT01750476|Drug|Depo-Provera|
1663306|NCT01750463|Other|Standard Laboratory Blood Draw and Hemoglobin Analysis|Patients admitted to PICU requiring hemoglobin monitoring will have a reading from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
1663237|NCT01751048|Biological|MPL-SE|Monophosphoryl Lipid A-Stable oil-in-water emulsion (MPL-SE) is an oil-in-water emulsion that contains Monophosphoryl Lipid A, an attenuated form of Lipid A from Salmonella Minnesota R595 in a emulsion (SE). The combination of MPL-SE with a recombinant protein antigen (LEISH-F3) results in a TH1-type T cell response. MPL-SE appears as a milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg of LEISH-F3+10 mcg MPL-SE.
1663238|NCT01751048|Drug|SE|Stable oil-in-water Emulsion (SE) is a squalene oil-in-water emulsion that has adjuvant properties of its own, but in a Th2-dependent manner. SE appears as milky-white liquid. 16 subjects receive vaccine on day 0, 28, and 168 of 0.5 ml of 20 mcg LEISH-F3 + SE.
1663239|NCT01751035|Behavioral|Risk Reduction through Family Therapy|RRFT is an integrative, ecologically-based approach to risk reduction and treatment. A Stage 1a feasibility trial and a Stage 1b pilot randomized controlled trial (RCT) evaluating RRFT have been completed. This Stage 1 work has resulted in a treatment manual, a clinician training protocol, and a quality assurance system. Preliminary findings from these studies are promising, indicating that RRFT can be readily learned and implemented with fidelity, and that it can lead to improvements in drug use and drug use-related risk and protective factors, PTSD symptoms, and risky sexual behaviors.
1663240|NCT01751035|Behavioral|Treatment as Usual|Participants assigned to the TAU condition will receive the standard treatment that a CSA victim would typically receive at community advocacy centers. In addition to treatment that is typically offered at the CACs, this will include a referral for substance abuse evaluation and may include referrals to other agencies in the community. TAU has been utilized as a comparison condition for several behavioral treatment evaluations involving adolescent substance abuse.
1663241|NCT01751022|Device|Device: Attain Performa Pacing Lead (along with a standard CRT-D system)|Implant and follow-up of study lead, separate analysis for each lead model
1663242|NCT01751009|Dietary Supplement|Vitamin A supplements|Sprinkles with Vitamin A
1663243|NCT01751009|Dietary Supplement|Sprinkles without Vitamin A|Active comparator
1663244|NCT01750996|Behavioral|Strongest Families|Behavioural intervention
1663245|NCT01750983|Drug|Ipilimumab|"Dose Escalation Group Starting Dose: 1.5 mg by vein over 90 minutes on Day 1 of each 28 day cycle.
Dose Expansion Group Starting Dose for Ipilimumab: Maximum tolerated dose (MTD) from Dose Escalation Group."
1663246|NCT01750983|Drug|Lenalidomide|"Dose Escalation Group Starting Dose: 10 mg by mouth on Days 1-21 of each 28 day cycle.
Dose Expansion Group Starting Dose for Lenalidomide: Maximum tolerated dose (MTD) from Dose Escalation Group."
1663247|NCT01750970|Other|Endoscopic resection under blue light (Hexvix®)|Endoscopic resection
1663248|NCT01750957|Drug|Placebo|orally daily, 12 weeks
1663249|NCT01750957|Drug|RO4917523|Dose A orally daily, 12 weeks
1663250|NCT01750957|Drug|RO4917523|Dose B orally daily, 12 weeks
1663251|NCT01750944|Procedure|Ankle first|"Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right ankles (BPA-LR).
A 15 minute walking test (WT) is performed.
BBP-LR and BPA-LR are re-measured.
2 hours of rest.
BBP-LR and the blood pressure at the left and right big toes (BPT-LR) are measured.
WT is reperformed.
BBP-LR and BPT-LR are re-measured."
1663252|NCT01750944|Procedure|Toe first|"Brachial blood pressure on both the left and right (BBP-LR) sides is measured, as well as at the left and right big toes (BPT-LR).
A 15 minute walking test (WT) is performed.
BBP-LR and BPT-LR are re-measured.
2 hours of rest.
BBP-LR and the blood pressure at the left and right ankles (BPA-LR) are measured.
WT is reperformed.
BBP-LR and BPA-LR are re-measured."
1663253|NCT01750931|Drug|Meloxicam GSK 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH &amp; Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
1663254|NCT01750931|Drug|Mobic 15mg|To demonstrate the bioequivalence of Meloxicam 15 mg tablets manufactured by Savipharm J.S.C, Vietnam and Mobic® 15 mg tablets of Boehringer Ingelheim Pharma GmbH & Co.KG Binger Str.173, 5521 Ingelheim am Rhein, Germany, in healthy adult human male subjects under fed condition
1663255|NCT01750918|Drug|Dabrafenib|Each capsule contains 50 mg or 75 mg of GSK2118436; 50 mg strength capsules are Swedish orange (dark red) opaque hypromellose size 2 capsules and 75 mg strength capsules are pink opaque hypromellose size 1 capsules. The initial dosing regimen will be twice daily (BID) continuous oral daily dosing.
1663256|NCT01750918|Drug|Trametinib|Each tablet contains 0.5mg or 2.0 mg GSK1120212; 0.5 mg is yellow modified oval biconvex film-coated tablets of size 4.8 mm X 8.9 mm and 2 mg as pink round biconvex film coated tablets;7.5 mm in diameter. The initial dosing regimen will be once daily continuous oral daily dosing.
1663257|NCT01750918|Drug|Panitumumab|Panitumumab is a sterile, colorless, translucent-to-white amorphous, proteinaceous powder available as 100 mg panitumumab in 5 mL (20 mg/mL) single-use vial; 200 mg panitumumab in 10 mL (20 mg/mL) single-use vial; 400 mg panitumumab in 20 mL (20 mg/mL) single-use vial; to be administered as an intravenous infusion over 60 minutes, every 14 days. Doses higher than 1000 mg should be administered over 90 minutes.
1663258|NCT01750918|Drug|5-fluorouracil|5-fluorouracil-based chemotherapy
1663259|NCT01750905|Drug|CD-NP|CD-NP 5 ug/kg subcutaneous injection (SQ)
1663260|NCT01750905|Drug|Placebo|Vehicle (D5W) SQ
1663261|NCT01750892|Behavioral|REACH for Independence|REACH for Independence is a transition and self-care skill-building peer support group led by a social worker. It is comprised of two 2.5-hour group sessions where participants participate in activities designed to teach self-care, self-advocacy and improve transition to adulthood skills.
1663262|NCT01750892|Behavioral|Transition Consult|The transition consult is a 1-on-1 visit with an MD and social worker. At the consults, participants will receive individualized information related to their unique medical and psychosocial needs and support related to issues relevant to their gaining healthcare independence and finding an adult doctor, such as accommodations, transportation, insurance and finances. After the consult, this group will have access to a transition coordinator who can help with any transition-related problems that may occur.
1663305|NCT01750463|Other|Masimo Pronto Rad 7 Non-Invasive hemoglobin monitor|Patients admitted to PICU requiring hemoglobin monitoring will have a total hemoglobin (SpHb) assessment from Masimo non-invasive monitor, prior to standard, required blood draw and laboratory analysis.
1663307|NCT01750437|Drug|YH1885L(Revaprazan)|
1663308|NCT01750437|Drug|Esomeprazole 20mg|
1663309|NCT01750437|Drug|placebo|
1663263|NCT01750892|Other|Study Materials|The Study Materials include a Care Binder, a Resource list, an Adult Doctor List and a Wallet Card. The Care Binder is an organizational tool to help patients with special healthcare needs manage and track important information related to their health and medical care. The Resource list has information about important community resources. The Adult Doctor List provides information about finding an adult primary care provider. The Wallet Card is a sheet for tracking important medical and personal information.
1663264|NCT01750879|Drug|Peanut Flour|Peanut Flour
1663265|NCT01750879|Drug|Oat Flour|Oat Flour
1663266|NCT01750866|Drug|Cabazitaxel|Cabazitaxel 25 mg/m2 will be administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
1663267|NCT01750866|Drug|Prednisone|Prednisone 10 mg on Day 1 of the first cycle and continue taking 10 mg po daily for the entire cycle.
1663268|NCT01750866|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony stimulating factor (Neulasta 6 mg sc) with each cycle, starting with the first cycle, to minimize the risk of complications from neutropenia.
1663269|NCT01750853|Drug|LY3045697|Administered orally
1663270|NCT01750853|Drug|Placebo|Administered orally
1663271|NCT01750840|Device|Biomet® EBI Bone Healing System|A pulsed electromagnetic fields electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 3-10 hours per day with a recommended use of 10 hours per day.
1663272|NCT01750840|Device|Biomet Orthopak® Non-Invasive Bone Growth Stimulator System|A capacitive coupling electrical stimulation device used for the treatment of fracture nonunions. Designed to be used for 24 hours per day.
1663273|NCT01750840|Device|Biomet SpinalPak® Non-Invasive Spine Fusion Stimulator|A capacitive coupling electrical stimulation device used as an adjunctive treatment to lumbar spinal fusion. Designed to be used for 24 hours per day.
1663274|NCT01750827|Drug|SB659032|single dose
1663275|NCT01750814|Biological|GC3102C|a single dose (0.5 mL) intramuscularly on the deltoid muscle
1663276|NCT01750814|Biological|GC FLU inj.|a single dose (0.5 mL) intramuscularly on the deltoid muscle
1663277|NCT01750801|Drug|Propolis|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.. The criteria for selection stated that subjects should be from 18 to 60 years old, should present good health, a minimum of 20 teeth and not be pregnant or breastfeeding.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
1663278|NCT01750801|Drug|chlorhexidine|Twenty-five subjects, both male and female, were chosen after signing the terms of agreement.The subjects went through a dental prophylaxis before starting rinse. They were then instructed to rinse twice a day for a minute, immediately after brushing (morning and night), using the 10 ml of the MGP 5%. After 45 and 90 days using the product the individuals returned for a clinical evaluation which considered changes in the soft and hard oral tissues and involved collecting plaque and gingivitis indexes. On their last appointment the subjects answered a questionnaire about their level of appreciation and acceptability of the mouthwash
1663279|NCT01750788|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
1663280|NCT01750775|Drug|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. by mouth for 8 weeks
1663281|NCT01750775|Drug|placebo Capsule|placebo Capsule 4 granules t.i.d. by mouth for 8 weeks
1663282|NCT01750762|Drug|Lenalidomide|
1663283|NCT01750749|Biological|Autologous BMDC implantation at the venous ulcer|An autologous bone marrow derived cell concentrate is obtained by bone marrow harvest (300 ml) from the iliac crest and subsequent processing using 6% hydroxyethyl starch to concentrate nucleated cells. The cells are injected using a 27 Gauge needle, in aliquots of 0.2 ml, along the venous ulcer edge. SOC treatment consisting of advanced wound management plus pressure therapy is administered simultaneously.
1663284|NCT01750736|Other|Augmented Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform the augmented exercise at home and at each data collection session.
1663285|NCT01750736|Other|General Exercise and Manual Therapy|Session 1 will include the manual therapy intervention to cervical and or thoracic regions. Subjects will perform general range of motion exercises for the neck at home and at each data collection session.
1663286|NCT01750723|Drug|Acetazolamide|1 g diluted in 10 ml saline, i.v. bolus injection.
1663287|NCT01750697|Drug|Rituximab|Participants will receive rituximab 375 mg/m^2 IV infusion on Days 1, 8, 15 and 22. Rituximab infusions will be given at a rate of 25 milligrams per hour (mg/h). This may be escalated at a rate of 25 mg/h increments every 30 minutes to a maximum of 200 mg/h.
1663288|NCT01750684|Drug|AC105|
1663289|NCT01750684|Other|Placebo|
1663290|NCT01750645|Drug|Intradetrusor Injection of Type-A Botulinum Toxin|
1663291|NCT01750645|Other|Other interventions analyzed according to protocol|"Placebo
Different dosage of Type-A Botulinum Toxin injected
Anticholinergic drugs"
1663292|NCT01750632|Procedure|Orchiectomy|The patients undergo subcapsular orchiectomy with basic surgical instruments. The patients are given local analgesia and sometimes universal anesthesia.
1663293|NCT01750593|Procedure|Radiofrequency ablation of the thyroid nodule|Under USG control, the nodule will be ablated by radiofrequency with a needle that has an active tip of 1 cm.
1663294|NCT01750580|Drug|Lirilumab|
1663295|NCT01750580|Drug|Ipilimumab|
1663296|NCT01750567|Drug|Metformin|Metformin is an antidiabetic drug which is an inexpensive and generally well tolerated medication.
1663297|NCT01750554|Other|intermediate-acting digital nerve block|non-therapeutic Bupivacaine digital nerve block to assess effect on accuracy of diagnostic readings
1663300|NCT01750515|Device|Acupuncture|
1663301|NCT01750489|Device|non-invasive ventilation (NIV)|
1663302|NCT01750476|Drug|Mirena|
1663310|NCT01750424|Procedure|Autologous Fat Grafting|
1663311|NCT01750424|Other|No intervention|Subjects in this arm will only be followed up and have no procedure performed.
1663312|NCT01750398|Drug|Testosterone cypionate|DEPO-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble of the androgenic hormone testosterone. Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. DEPO-Testosterone Injection is available in two strengths, 100 mg/mL and 200 mg/mL testosterone cypionate.
1663313|NCT01750398|Drug|Goserelin|"Goserelin is a hormone therapy, for intramuscular injectionis. It is classified as an LHRH agonist."
1663314|NCT01750398|Drug|Leuprolide|Leuprolide is a gonadotropin-releasing hormone (GnRH) agonist. For intramuscular injection.
1663315|NCT01750385|Drug|no antibiotic prophylaxis|These patients are in no antibiotic prophylaxis group will not be administered antibiotic prophylactically.
1663316|NCT01750385|Drug|second-generation cephalosporin|These patients are in antibiotic prophylaxis group will be administered second-generation cephalosporin prophylactically.
1663317|NCT01750359|Drug|curcumin|500 mg/day for 6 week
1663318|NCT01750346|Drug|Topical acetyl hexapeptide-8|
1663319|NCT01750346|Drug|Placebo|
1663320|NCT01750307|Dietary Supplement|Experimental fatty acid supplementation|4 x capsules per day. Daily dose: 1584mg EFA
1663321|NCT01750307|Dietary Supplement|Placebo comparator: MCT oil softgel|4 x capsules per day. Medium chain triglyceride pill manufactured to mimic essential fatty acid pill
1663322|NCT01750294|Drug|Chlorthalidone|
1663323|NCT01750281|Drug|Selumetinib 75 mg|Three selumetinib capsules (Hyd-Sulfate) 25 mg will be administered orally, twice daily, (75 mg dose bd) on an uninterrupted schedule.
1663324|NCT01750281|Drug|Docetaxel 75 mg/m2|Docetaxel 75 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
1663325|NCT01750281|Drug|Docetaxel 60 mg/m2|Docetaxel 60 mg/m2 will be administered intravenously on day 1 of each 21 day cycle.
1663326|NCT01750281|Drug|Placebo|Three placebo capsules will be administered orally uninterrupted twice daily.
1663327|NCT01750268|Behavioral|Medical Management Counseling|Brief alcohol and medication counseling
1663328|NCT01750268|Drug|Topiramate|Experimental medication
1663329|NCT01750268|Drug|Placebo|Placebo comparator
1663330|NCT01750255|Other|Pharmaceutical Care|Pharmaceutical care will be provided according to Dader Method for pharmaceutical care and will be carried out in collaboration with patients and physicians.The time between admission to the group and 20 days,the pharmacist will enhance the information related to treatment adherence and investigate by criteria to make an approach to the effectiveness and safety of treatment, through phone calls(weeks 1,3, 4-6) and a home visit(week 2). Pharmacist will call the patient weekly in order to increase adherence. At each appointment will assess of parameters of efficacy; Depression and Mania Rating Scale, Clinical Global Assessment Scale, Quality of life and adherence to treatment
1663331|NCT01750255|Other|Education|The control group will receive the usual care and verbal and written information and education about mental health and bipolar disorder for patients and their families. The written material is a brochure designed for this purpose, which focused on the goals and importance of adherence with pharmacological and nonpharmacological interventions to achieve treatment goals. Patients met again with the pharmacist every three months during one year. At each appointment will assess of parameters of efficacy and safety. Quality of life (Sf - 36 test), adherence to treatment, the severity of depressive symptoms in individuals, Symptoms of Mania, the psychiatrist rated patient impairment.
1663332|NCT01750242|Device|Medtronic DBS system|Advanced Parkinson's disease patients implanted with the Medtronic Deep Brain Stimulation (DBS) system.
1663337|NCT01750203|Other|Swabs|There is no intervention only swabs are being used to collect wound fluid samples
1663338|NCT01750190|Drug|FG-4592|Oral
1663339|NCT01750190|Drug|Placebo|Oral
1663340|NCT01750177|Behavioral|Television Viewing before mealtime|
1663341|NCT01750177|Behavioral|Video Game Playing|
1663342|NCT01750177|Behavioral|Computer Use|
1663343|NCT01750177|Behavioral|Sitting quietly|
1663344|NCT01750151|Dietary Supplement|Glucose Beverage|
1663345|NCT01750151|Behavioral|Video Game Playing|
1663346|NCT01750151|Dietary Supplement|Control Beverage|
1663347|NCT01750138|Drug|Glutamine|
1663348|NCT01750138|Drug|Dextrose powder|
1663349|NCT01750125|Device|measure ascending aortic blood flow with pulse wave Doppler|
1663350|NCT01750112|Device|Macrolane VRF20|Injection treatment with Macrolane VRF20
1663351|NCT01750099|Procedure|Combined Spinal-epidural|See arm description
1663352|NCT01750099|Procedure|Continuous Lumbar epidural|See arm description
1663353|NCT01750086|Drug|Teriparatide 40-mcg subcutaneous injection|
1663354|NCT01750086|Drug|Denosumab Injection|One-time Denosumab injection
1663355|NCT01750086|Drug|Alendronate Oral Tablet|weekly alendronate for 8 weeks
1663363|NCT01750060|Drug|Fentanyl|
1663364|NCT01750060|Drug|Naltrexone|
1663365|NCT01750034|Procedure|Closed method|Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
1663366|NCT01750034|Procedure|Open method|Subjects will have their burns managed by keeping the wounds exposed to the air.
1663367|NCT01750021|Dietary Supplement|High fat low carbohydrate diet|70E% fat, 20E% protein, 10E% carbohydrates
1720107|NCT00003029|Drug|cisplatin|
1663368|NCT01750021|Dietary Supplement|Low fat high carbohydrate diet|20E% fat, 20E% protein, 60E% carbohydrates
1663369|NCT01750008|Procedure|Global Fibroid Ablation|
1663370|NCT01750008|Procedure|Myomectomy|
1663371|NCT01749982|Other|Placebo|
1663372|NCT01749982|Drug|Choline bitartrate|
1663373|NCT01749982|Drug|Betaine|
1663374|NCT01749982|Drug|Choline bitartrate + Betaine|
1663375|NCT01749969|Drug|isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
1663376|NCT01749969|Drug|lenalidomide|Pharmaceutical form:capsules Route of administration: oral
1663377|NCT01749969|Drug|dexamethasone|Pharmaceutical form:solution or tablet Route of administration: intravenous or oral
1663378|NCT01749956|Radiation|Radiation|
1663379|NCT01749956|Drug|Aflibercept|
1663380|NCT01749956|Procedure|Surgery|Abdominoperineal or low anterior resection with total mesorectal excision, per standard treatment guidelines
1663381|NCT01749956|Drug|FOLFOX6|
1663382|NCT01749930|Drug|BOL-303259-X|BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning
1663383|NCT01749930|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening.
1663384|NCT01749930|Drug|BOL-303259-X|All participants will receive a topical ocular BOL-303259-X QD in the evening from 3 months (Visit 6) through 6 months (Visit7).
1663385|NCT01749917|Other|Exercise program|Exercise program An brief exercise session including proprioceptive and dexterity activities
1663386|NCT01749917|Other|Control intervention|Active upper limb range of movement exercises for 15 minutes.
1663387|NCT01749904|Drug|BOL-303259-X|Topical ocular BOL-303259-X will be administered QD in the evening and its vehicle administered QD in the morning for 3 months (visit 6).
1663388|NCT01749904|Drug|Timolol|Timolol will be administered BID once in the morning and once in the evening for 3 months (Visit 6)
1663389|NCT01749904|Drug|BOL-303259-X|All participants will receive topical ocular BOL-303259-X QD in the evening for an additional 9 months from Visit 6 through Visit 9 (1 year)
1663390|NCT01749891|Drug|ALG 1001|Patients who will receive three, monthly intravitreal injections of 1.5mg, 2.5mg ,or 4.0 /50μl of ALG-1001 in 0.05cc in isotonic saline solution.
1663391|NCT01749878|Drug|REGN1500|
1663392|NCT01749878|Drug|placebo|
1663393|NCT01749865|Biological|Cytokine-Induced Killer Cells|Cytokine-Induced Killer Cells treatment for 4 cycles
1663394|NCT01749852|Other|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 12 weeks
1663395|NCT01749852|Other|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 12 weeks
1663397|NCT01749800|Device|GVS|A small current is delivered to the vestibular system via electrodes placed over the subject's mastoid processes.
1663398|NCT01749800|Device|Sham GVS|Electrodes are placed over the subject's mastoid processes and connected to the device, but the device is not active.
1663399|NCT01749800|Device|Armeo Spring|A robotic system supports the weak arm of the subject to make it easier to perform therapeutic exercises.
1663400|NCT01749787|Drug|PRTX-100 at 1.5 mcg/kg|
1663401|NCT01749787|Drug|PRTX-100 at 3.0 mcg/kg|
1663402|NCT01749787|Drug|PRTX-100 at 6.0 mcg/kg|
1663403|NCT01749787|Drug|PRTX-100 at 12.0 mcg/kg|
1663404|NCT01749787|Drug|PRTX-100 at 240 mcg|
1663405|NCT01749787|Drug|Placebo|Placebo administered via infusion once per week for 5 weeks
1663406|NCT01749787|Drug|PRTX-100 at 420 mcg|
1663407|NCT01749774|Behavioral|Physical activity counseling|
1663408|NCT01749761|Other|BioLogic RR|Patients will be randomized to BP guided biofeedback arm which will entail regular hemodialysis with a software program turned on to allow frequent assessment of blood pressure and automated adjustments of the ultrafiltration rate based on these blood pressure measurements. The duration of this arm is 8 weeks
1663409|NCT01749761|Other|Hemodialysis without biofeedback|patients will be randomized to Standard HD (without biofeedback technology) for 8 weeks
1663410|NCT01749748|Procedure|proton magnetic resonance spectroscopy|proton magnetic resonance spectroscopy was performed for the normal breast to evaluate the chemical composition of breast
1663411|NCT01749735|Device|Transcranial Direct Current Stimulation|Continuous mild transcranial direct current stimulation will be used while the participant plays video games using the Armeo Spring Robot to support the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
1663412|NCT01749735|Device|Sham Transcranial Direct Current Stimulation|Sham transcranial direct current stimulation will be used while the participant focuses on repetitive tasks using the Armeo device that incorporate multidirectional reaching, grasp and release action of the hand of the affected arm. Intervention: 40 minute training sessions, 5 days a week for 2 weeks.
1663413|NCT01749735|Device|Armeo training|Upper extremity training with the use of a weight support device and virtual reality.
1663414|NCT01749722|Device|NaviAid™ G-Eye procedure|NaviAid™ G-Eye procedure
1663415|NCT01749709|Behavioral|Music listening|
1663416|NCT01749657|Device|Arizona|Compare custom versus off-the-shelf devices for pain and function in subjects with stage II Posterior Tibial Tendon Dysfunction (PTTD).
1663417|NCT01749618|Behavioral|Education and Feedback|Rheumatologists are rated on how systematically they assess their patients, and receive six sessions of university accredited education about systematic assessments of patients with seronegative arthritis.
1663418|NCT01749605|Drug|Nitrofurantoin monohydrate/macrocrystals 100 mg BID x 3 days|
1663419|NCT01749605|Drug|ciprofloxacin 250 mg BID x 3 days|
1663420|NCT01749592|Device|cochlear implant|Surgical implantation of a cochlear implant device
1663421|NCT01749579|Drug|Propofol|Propofol 1 mg/kg bolus then 500 microg/kg every 2 minutes until sedation level equivalent to Ramsey 3
1663422|NCT01749579|Drug|Midazolam|Midazolam 0.03 mg/Kg stat and then the same dose repeated every 2 minutes until a sedation level of Ramsey 3 is achieved.
1663709|NCT01747551|Drug|Ziv-aflibercept Placebo|
1663423|NCT01749579|Drug|Fentanyl|Fentanyl 2 microg/kg intravenous stat and every 2 minutes until the end of procedure
1663424|NCT01749566|Drug|maraviroc|Maraviroc administered at standard (300mg po bid) or reduced (300mg po daily) dosing
1663425|NCT01749553|Other|Sleeper Stretch|Posterior shoulder stretch technique
1663426|NCT01749540|Drug|ACE-536|Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
1663427|NCT01749527|Behavioral|minimal activity|Pad test with minimal activity
1663431|NCT01749488|Other|Designated dietitian for the ward|This is a randomized cluster trial. The centers randomized into this arm will designate a dietitian who will help the ward implement current recommendations for the nutrition of patients undergoing intensive care.
1663432|NCT01749475|Drug|Midazolam|The patients will be given 0.05mg/kg iv midazolam just before monitorization. During probing, in case of intolerance to the insertion of the probe, the increments of midazolam with 0.005mg/kg doses will be given.
1663433|NCT01749475|Other|hypnotherapy|A first hypnotic induction will be carried out the day before the procedure, next day, fifteen minutes before the procedure, a new induction will be performed.
1663434|NCT01749449|Other|protein and meal frequency|comparison of different levels of protein intake and meal frequency on body composition in obese adults
1663435|NCT01749436|Other|Lung ultrasound imaging examinations|Lung ultrasound examinations performed at different time-points immediately before surgery, during surgery under general anesthesia and after surgery in the recovery room to detect and monitor atelectasis related to laparoscopic procedures.
1663436|NCT01749423|Biological|OnabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
1663437|NCT01749410|Biological|onabotulinumtoxinA|Previous treatment with onabotulinumtoxinA for Chronic Migraine.
1663438|NCT01749397|Drug|Floxuridine|Given IP
1663439|NCT01749397|Other|Laboratory Biomarker Analysis|Correlative studies
1663440|NCT01749397|Other|Pharmacological Study|Correlative studies
1663441|NCT01749397|Drug|Veliparib|Given IV
1958131|NCT01967225|Drug|Tedizolid(BAY1192631)|BAY1192631 solution or tablet 200 mg,once daily,Intravenous (IV) or By Mouth (PO)for 7-21 days
1663446|NCT01749371|Drug|Vitamin E (dl-Alpha Tocopheryl)|
1663447|NCT01749358|Behavioral|Accelerated Skill Acquisition Program (ASAP)|A focused, intense, evidence-based, upper extremity rehabilitation program. The training intervention is based on the fundamental elements of skill acquisition through task-specific practice, impairment mitigation to increase capacity, and motivational enhancements to build self-confidence Dosage of therapy (number of hours of therapy) will vary based on group assignment. Frequency is 4x/week, 1 week per month for 3 months in a train-wait-train paradigm. A 2-hour orientation session precedes the first visit.
1663448|NCT01749358|Behavioral|Active Monitoring|This is an observation-only group. Any therapy received while in this group will be dosed according to usual and customary practice.
1663449|NCT01749332|Other|Perihepatic Phlebotomy|
1663450|NCT01749319|Drug|Oral baclofen|Each subject will receive one dose of oral baclofen and one dose of intravenous baclofen on different study days.
1663451|NCT01749319|Drug|Intervenous baclofen|
1663454|NCT01749293|Procedure|Haploidentical Transplant|Subjects will be dosed with pre-transplant Fludarabine (180mg/m2)and Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg. Subjects will then undergo total body irradiation 2Gy. Subjects will undergo haploidentical allogeneic bone marrow transplant, followed by Cyclophosphamide, Tacrolimus and MMF based GVHD prophylaxis.
1663455|NCT01749293|Drug|Fludarabine|Subjects in this trial will receive Fludarabine 30 mg/m2 IV QD, adjusted for CrCl from Days -8 through -3.
1663456|NCT01749293|Drug|Busulfan|Subjects in this trial will receive Busulfan total AUC 2400 μmol*min/L or 6.4mg/kg in 4 doses with seizure prophylaxis from Days -6 through -3.
1663457|NCT01749293|Radiation|Total Body Irradiation|Subjects in this trial will receive total body irradiation (2Gy fractionated) from Day -2 or -1.
1663458|NCT01749293|Drug|Cyclophosphamide|Subjects in this trial will receive Cyclophosphamide 50 mg/kg IV QD on Days 3 and 4 post-transplant.
1663459|NCT01749267|Procedure|partial caries removal only at enamel dentin junction.|Partial caries removal only at enamel dentin junction (EDJ) without carious dentin removal at the pulpal site and restoration with glass ionomer cement(SMART restoration)
1663460|NCT01749241|Drug|Loteprednol etabonate ophthalmic ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
1663461|NCT01749241|Drug|Vehicle Ophthalmic Ointment|Thin ribbon ointment to assigned eye twice daily for 14 days
1663462|NCT01749228|Drug|Etodolac Capsules USP 300 mg|300 mg capsule once a day
1663463|NCT01749228|Drug|Etodolac|500 mg tablet once a day
1663464|NCT01749215|Drug|Topiramate|
1663465|NCT01749215|Drug|placebo|
1663466|NCT01749202|Dietary Supplement|Sunflower Oil Softgels|3 x 500 mg softgel capsules/day
1663467|NCT01749202|Dietary Supplement|EPA softgels|3 x 500 mg softgel capsules/day
1663468|NCT01749202|Other|Sunflower Oil Food|3 servings/day
1663469|NCT01749202|Other|SDA soybean Oil Food|3 servings/day
1663470|NCT01749189|Dietary Supplement|Blend|22 grams of protein/day
1663471|NCT01749189|Dietary Supplement|Whey|22 grams of protein/day
1663472|NCT01749189|Dietary Supplement|Placebo|22 grams of carbohydrate/day
1663473|NCT01749176|Behavioral|SMS texting intervention|
1663474|NCT01749176|Behavioral|Control-Usual Care|
1663475|NCT01749163|Biological|Saline|
1663476|NCT01749163|Biological|GIP|
1663477|NCT01749163|Biological|GLP-1|
1663710|NCT01747538|Drug|Placebo|Solution for subcutaneous injection
1663478|NCT01749150|Drug|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 12 weeks
1663479|NCT01749150|Drug|danoprevir + ritonavir|125 mg danoprevir + 100 mg ritonvir fixed-dose combination tablet, orally b.i.d., 24 weeks
1663480|NCT01749150|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 12 weeks
1663481|NCT01749150|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
1663482|NCT01749150|Drug|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 12 weeks
1663483|NCT01749150|Drug|ribavirin [Copegus]|1000-1200 mg orally daily in divided doses, 24 weeks
1663484|NCT01749137|Drug|RM-493|
1663485|NCT01749137|Drug|Placebo|
1663486|NCT01749124|Device|My Coach Connect|Clients will call in to the system approximately twice a week for a period of four months. The study will be conducted in two phases. There will be an initial pilot phase where we will seek to enroll approximately 15-20 patients and 2-3 providers. This phase will last approximately two months and the goal will be to assess feasibility and obtain feedback on the tool and surveys to optimize them for this setting. We will begin the main phase of the study approximately one month after the end of the first phase and in that study seek to recruit approximately 150 patients and 5-10 providers from the ROADS program. Clients enrolled in this main phase of the study will enroll for a period of four months.
1663487|NCT01749111|Drug|ARM A Cyclophosphamide|Cyclophosphamide 50 mg/kg on day+3 and day+4 after bone marrow transplantation
1663488|NCT01749111|Drug|ARM B Calcineurin inhibitor and methotrexate|Graft versus host disease prophylaxis will be done with the combination of a calcineurin inhibitor (either tacrolimus or cyclosporine) and methotrexate
1663489|NCT01749098|Drug|PF-04958242|PF-04958242, 0.35 mg orally administered capsule on Day 1 and 0.25 mg orally administered capsule on Days 2 - 5
1663490|NCT01749098|Drug|Ketamine|At 60 minutes after the 0.25 mg dose of PF-04958242 on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
1663491|NCT01749098|Drug|Placebo|Placebo capsule orally administered on Days 1 - 5
1663492|NCT01749098|Drug|Ketamine|At 60 minutes after Placebo on Day 5, Ketamine (0.23 mg/kg over 1 minute, followed by a maintenance rate of 0.58 mg/kg/hr for 75 minutes) will be infused.
1663493|NCT01749085|Drug|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fasted conditions with washout, then single 200 mg oral dose of PF-04449913 under fed with washout and finally a single 200 mg dose 0f PF-04449913 following dosing to steady state with ketoconazole
1663494|NCT01749085|Drug|PF-04449913, ketoconazole|Subjects receive a 200 mg oral dose of PF-04449913 under fed conditions with washout, then single 200 mg oral dose of PF-04449913 under fasted with washout and finally a single 200 mg dose of PF-04449913 following dosing to steady state with ketoconazole
1663495|NCT01749072|Drug|Gefitinib group|Gefitinib 250mg once per day until the progression disease or intolerant side effects
1663496|NCT01749072|Drug|Vinorelbine, Ifosfamide, Mesna|Vinorelbine 25mg/m2 d1,d8; Ifosfamide 1.25g/m1 d1-d3 (Usually 2g d1-d3); Mesna 400mg 0,4,8 hours after Ifosfamide administration for uroprotection d1-d3;
1663497|NCT01749046|Drug|Remegal|Remegal 1500 mg for 12 weeks
1958132|NCT01967225|Drug|Linezolid|Linezolid solution or tablet 600 mg,twice daily,every 12 ±3 hours, Intravenous (IV) or By mouth (PO) for 7-21days
1663501|NCT01749020|Other|Polyphenol-rich Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing 500mg of polyphenols daily for a period of 4 weeks
1663502|NCT01749020|Other|Placebo Dark chocolate|Participants will be asked to consume 20g of dark chocolate containing little or no polyphenols for a period of 4 weeks
1663503|NCT01748994|Drug|Pioglitazone|30mg per day for four months
1663504|NCT01748994|Drug|Placebo|
1663505|NCT01748981|Other|Physical training|"Physical training three times a week for 20 week including endurance and strength training compare to the as usual group as controls"
1663506|NCT01748981|Other|As usual|Controls, not training
1663507|NCT01748955|Drug|Paroxetine CR for Major Depressive Episode|Dosage will be 25mg every day for 2 weeks, then 37.5mg every day for 2 weeks, and then optional increase to 50mg every day for the remainder of treatment.
1663508|NCT01748955|Drug|Bupropion XL for Major Depressive Episode|Dosage will be 150mg every day for 2 weeks, then 300mg every day for 2 weeks, and then optional increase to 450mg every day for the remainder of treatment.
1663509|NCT01748942|Drug|Dexamethasone|Given IV
1663510|NCT01748942|Drug|Dexamethasone|Given PO
1663511|NCT01748942|Other|Placebo|Given PO
1663512|NCT01748942|Procedure|Quality-of-Life Assessment|Ancillary studies
1663513|NCT01748942|Other|Questionnaire Administration|Ancillary studies
1663514|NCT01748942|Procedure|Transoral Robotic Surgery|Undergo TORS
1663515|NCT01748929|Drug|Albendazole|
1663516|NCT01748929|Drug|Placebo|
1663517|NCT01748916|Other|Papaya|Post-prandial study feeding 400-506 g papaya (1.6 mg beta-carotene, 2.1 mg beta-cryptoxanthin, 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
1663518|NCT01748916|Other|Carrot|Post-prandial study feeding 25-35 g carrot (= 1.6 mg beta-carotene), 150 g yogurt (10% fat), and 45 g of fat free bread.
1663519|NCT01748916|Other|Tomato|Post-prandial study feeding 256-396 g tomato (= 13 mg lycopene), 150 g yogurt (10% fat), and 45 g of fat free bread.
1663520|NCT01748903|Device|Target 360°, 2D Coils, Nano Coils|
1663522|NCT01748877|Drug|NXN-462|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
1663571|NCT01748604|Other|Manual Lymphatic Drainage (MLD)|MLD with Földi's technique by an expert therapist during 45 minutes
1720108|NCT00003029|Drug|fluorouracil|
1663523|NCT01748877|Drug|Placebo|Study drug is to be self-administered twice each day by the patient. Each day the first dose of study drug should be taken preferably one hour prior to, OR one hour after the first meal (breakfast) of the day. The second and final dose each day should be taken with a glass of water at least one hour after the last meal immediately before retiring to sleep.
1663524|NCT01748864|Drug|Etarfolatide (EC20)|
1663525|NCT01748851|Drug|XELOX|capecitabine 1000mg/m2 bid po D1-D14
1663526|NCT01748851|Drug|FOLFOX|5-FU 400mg/m2 iv push D1, 5-FU 1200mg/m2 over 22hr D1,D2
1663527|NCT01748838|Drug|CTX-4430|Ascending single oral doses of CTX-4430 will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross-over, fed a high fat diet and administered different single oral doses of CTX-4430
1663528|NCT01748838|Other|Mannitol|excipient blended with CTX-4430 in capsules
1663529|NCT01748838|Drug|Placebo|Single oral doses of placebo will be administered to subjects in 6 cohorts on day 1. Following a 14-day washout, subjects in two of the six cohorts will cross over, fed a high fat diet and administered single oral doses of placebo
1663530|NCT01748838|Drug|CTX-4430|Ascending repeat doses of CTX-4430 will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
1663531|NCT01748838|Drug|Placebo|Repeat doses of placebo will be administered orally, once-daily, to subjects in 4 cohorts on days 1-14.
1663532|NCT01748838|Other|Mannitol|excipient blended with CTX-4430
1663534|NCT01748812|Drug|Osteomalacia|
1663535|NCT01748799|Drug|Sativex|All participants received the same interventions (Fixed or Self-Titrated Sativex), just in different sequences.
1663536|NCT01748799|Drug|Placebo|All participants received the same interventions (Fixed or Self-Titrated Placebo), just in different sequences.
1663537|NCT01748786|Behavioral|Mindfulness Emotion Regulation|12 on-line modules provide didactic information and practice instructions re: mindfulness meditation for pain and distress
1663538|NCT01748786|Other|Health Education|12 on-line modules that provide information regarding health behaviors, but no information regarding how to put behaviors into practice
1663539|NCT01748773|Drug|Oxaliplatin|Participants will receive oxaliplatin 100 mg/m^2 IV on Day 1 of Cycles 1-3.
1663540|NCT01748773|Radiation|Radiation|Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.
1663541|NCT01748773|Drug|Capecitabine|Participants will receive capecitabine 850 mg/m^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.
1663542|NCT01748773|Drug|Trastuzumab|Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
1663543|NCT01748760|Behavioral|CLASP-A intervention|Three individual sessions with adolescent patient using acceptance based strategies and motivational interviewing techniques. Sessions focused on identifying personalized risk factors for suicidal behavior, identifying values and goals, and development of personalized safety plan.
1663544|NCT01748760|Other|Treatment as Usual|Referral to outpatient treatment as part of routine discharge planning.
1663545|NCT01748747|Drug|Montanide ISA 51 VG|Given SC
1663546|NCT01748747|Biological|MART-1 antigen|Given SC
1663547|NCT01748747|Other|laboratory biomarker analysis|Correlative studies
1663548|NCT01748747|Biological|Gag:267-274 peptide vaccine|Given SC
1663549|NCT01748747|Drug|resiquimod|Applied topically
1663550|NCT01748734|Procedure|quality-of-life assessment|Ancillary studies
1663551|NCT01748734|Other|questionnaire administration|Ancillary studies
1663552|NCT01748734|Other|counseling intervention|Undergo cognitive behavioral therapy
1663553|NCT01748734|Behavioral|behavioral intervention|Undergo cognitive behavioral therapy
1663554|NCT01748721|Biological|anti-endosialin/TEM1 monoclonal antibody MORAb-004|Given IV
1663555|NCT01748721|Other|pharmacological study|Correlative studies
1663556|NCT01748721|Other|laboratory biomarker analysis|Optional correlative studies
1663557|NCT01748708|Device|Magnetic seizure therapy|100% machine output at 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Treatments will be administered 3 times per week, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
1663558|NCT01748708|Device|Electroconvulsive therapy|ECT treatments will be administered 3 times per week using the MECTA spECTrum 5000Q. Subjects will be treated with an ultrabrief (0.3ms) pulse with a bilateral placement at 6 times the seizure threshold, up to a maximum of 15 treatments. If subjects fail to achieve the pre-defined criteria of remission at that point, they will be considered non-remitters and will exit the study.
1663559|NCT01748695|Drug|V158866|
1663560|NCT01748695|Drug|Placebo|
1663561|NCT01748682|Other|A very low calorie diet of two different consistencies|Liquid and normal consistency diet with a very low calorie diet will be given to patients pre-operatively in bariatric surgery
1663562|NCT01748669|Dietary Supplement|Garlic oil|Oral administration
1663563|NCT01748656|Device|IVAPS|IVAPS mode (RESMED Stelar 150) during 1 night
1663564|NCT01748656|Device|AVAPS|AVAPS mode (PHILIPS-RESPIRONICS-A30) during 1 night
1663565|NCT01748643|Drug|deep neuromuscular blockade with rocuronium, reversal with sugammadex|after induction of anesthesia, a rocuronium infusion (0.6mg/kg (lean body mass)/h,) is started and titrated to a post tetanic count of 1-2 twitches. At the end of surgery neuromuscular blockade will be reversed with sugammadex 4mg/kg. Patients are extubated when TOF ratio > 0.9.
1663566|NCT01748643|Drug|normal neuromuscular blockade reversal with rocuronium, reversal with neostigmine|After induction of anesthesia, top-ups of rocuronium (10mg) are given as needed to maintain a train of four count of 1-2. At the end of surgery neuromuscular blockade will be reversed with neostigmine 50μg/kg and glycopyrrolate 10μg/kg (lean body mass). Patients are extubated when the train of four ratio is > 0.9.
1663567|NCT01748630|Drug|dexmedetomidine|
1663568|NCT01748630|Drug|Midazolam|
1663569|NCT01748630|Drug|fentanyl|
1663570|NCT01748617|Other|Controlled diet|1 week of controlled diet
1663572|NCT01748604|Device|Generic intermittent pneumatic compression Device (IPC)|Generic intermittent pneumatic compression with multicompartmental pump between 50 to 80 mmHg during 30 minutes.
1663573|NCT01748604|Other|multilayer, multicomponent bandages (MB)|multilayer, multicomponent bandages (MB) until next day.
1663574|NCT01748604|Device|Lymphapress-Plus(TM) device (LPD)|Pneumatic massage with Lymphapress-Plus(TM)device that was lent during the duration of the study during 20 minutes.
1663575|NCT01748578|Drug|EBI-005-1|EBI-005-1 is an intervention to two different study arms: 5mg/ml Vs Placebo and 20 mg/ml Vs Placebo
1663576|NCT01748578|Drug|EBI-005-1 Placebo|
1663577|NCT01748552|Drug|Placebo|Administered orally as capsules
1663578|NCT01748552|Drug|LY2922083|Administered orally as capsules
1663579|NCT01748539|Drug|KHK4827|
1663580|NCT01748539|Drug|Placebo|
1663581|NCT01748526|Drug|Canagliflozin (JNJ-28431754) 200 mg|One 200 mg tablet taken orally (by mouth) on Day 1.
1663582|NCT01748526|Drug|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg tablet taken orally (by mouth) on Day 1.
1663583|NCT01748513|Other|preoperative venous return optimizing|Preoperative transthoracic echocardiography (TTE) was performed in the awake state before and after volume challenge based on 6ml colloids /kg ideal body weight.
1663584|NCT01748500|Drug|Pantoprazole|
1663585|NCT01748487|Drug|dexamethasone intravitreal implant (OZURDEX)|intravitreal implant
1663586|NCT01748474|Procedure|Supplemental oxygen via a mask|
1663587|NCT01748461|Behavioral|Structured intervention|3x/week - 10 weeks - Support by fitness instructor - Individualised exercise program (cycle ergometer)
1663588|NCT01748461|Behavioral|Coach intervention|promote autonomy - 4 visits during 10 weeks - Support by coach (encouragement) - Individualised exercise program
1663591|NCT01748435|Drug|Qutenza|Single treatment with Qutenza
1663592|NCT01748422|Drug|Qutenza|Transdermal patch
1663593|NCT01748409|Other|Biopsies of peripheral autonomic nervous system|
1663594|NCT01748409|Other|Autonomic dysfunction questionnaires|
1663595|NCT01748409|Other|Electrophysiological tests|
1663596|NCT01748396|Drug|Calcitriol|
1663597|NCT01748396|Drug|Calcium Carbonate|
1663601|NCT01748370|Drug|Vitamin D supplementation in hypogonadal men|
1663602|NCT01748370|Drug|Vitamin D supplementation in eugonadal men|
1663603|NCT01748370|Drug|Placebo hypogonadal|
1663604|NCT01748370|Drug|Placebo eugonadal|
1663605|NCT01748344|Drug|Cetirizine|10mg tablets
1663606|NCT01748344|Drug|High dose ONO-4053|Experimental
1663607|NCT01748344|Drug|Low dose ONO-4053|Experimental
1663608|NCT01748344|Drug|Placebo|None active
1663609|NCT01748331|Other|Fluid restriction|Patients will be randomized to strict fluid restriction < 1 L/day versus moderate fluid restriction < 2.5 L/day
1663610|NCT01748318|Drug|New Mexico Honey|Apply 15 ml of NM Honey to CA-MRSA Abscess compare to standard antibiotic treatment
1663611|NCT01748318|Drug|Bactrim DS|Bactrim DS
1663612|NCT01748305|Behavioral|Moderate-to-vigorous intensity exercise|Moderate-to-vigorous intensity exercise three times per day for three weeks
1663614|NCT01748279|Drug|Atorvastatin|
1663615|NCT01748279|Drug|Formoterol|12mcg of Foradil BID as maintenance COPD treatment in both treatment arms
1663616|NCT01748279|Drug|Lactose tablet|One lactose tablet taken once a day as add-on treatment to Formoterol therapy
1663617|NCT01748266|Other|microcirculatory reactivity|Microcirculation of the thenar eminence was analyzed by NIRS technology, through the StO2 and the resaturation slope after an ischemic challenge.
1663618|NCT01748253|Drug|Telmisartan-amlodipine tablet administration group (morning)|Oral-administration of one telmisartan-amlodipine tablet once a day upon morning for 12 weeks
1663619|NCT01748253|Drug|Telmisartan-amlodipine tablet administration group (bedtime)|Oral-administration of one telmisartan-amlodipine tablet once a day at bedtime for 12 weeks
1663621|NCT01748227|Behavioral|Peer-Delivered Pain Self-Management|Patients (n=20) were assigned a peer coach to meet with for 4 months to discuss pain self-management.
1663622|NCT01748201|Procedure|Joint lavage and viscosupplementation|The joint will be washed until obtaining translucent liquid and not hemorrhagic. Then it will receive an intra-articular injection of 6ml of hyaluronic acid (Synvisc One), 1ml of triamcinolone and 2 ml of ropivacaine.
1663623|NCT01748188|Procedure|Ultrasound|Ultrasound of 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
1663624|NCT01748188|Procedure|Phonophoresis|Phonophoresis with 50 mg dexketoprofen (Enangel), 1 MHz, intensity 2 W/cm2, 5 minutes, for 20 sessions.
1663625|NCT01748188|Procedure|Iontophoresis|Iontophoresis by galvanic direct current with 50 mg dexketoprofen (Enantyum), intensity 2 mA, 20 minutes, for 20 sessions.
1663699|NCT01747590|Drug|Alprazolam|
1663626|NCT01748188|Procedure|Exercises|Guideline of 7 standardized exercises to improve the muscular force and to open the subacromial space.
1663627|NCT01748188|Procedure|Cryotherapy|Cooling located by a cold air bundle to -32 Celsius degrees (ºC) for 3 minutes.
1663628|NCT01748175|Drug|Triamcinolone Acetonide|Each subject that meets inclusion/exclusion criteria will receive triamcinolone acetonide intramuscularly at the end of visit 2. Adults ≥18 years will receive 40 mg triamcinolone acetonide. Children 6-17 years will receive 1 mg/kg triamcinolone acetonide (up to 40 mg maximum). Triamcinolone acetonide will be administered as a single intramuscular dose deep in the gluteal region
1663630|NCT01748149|Drug|Vemurafenib|"Vemurafenib is supplied in 120-mg and 240-mg film-coated tablets packed in bottles for oral administration. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Dosing will not exceed the adult MTD of 960 mg BID. Patients will be provided with a Medication Diary for vemurafenib, instructed in its use, and asked to bring the diary with them to each appointment.
Treatment will be administered on an outpatient basis. Dosing is based on the BSA calculated at the beginning of each course of therapy. The dose prescribed should be rounded to the nearest deliverable dose based on the BSA adjustment and the available pill sizes. Regardless of cohort, patients will self-administer vemurafenib BID at the assigned dose level. Patients will be instructed to hold their dose of vemurafenib for PK or surgery."
1663631|NCT01748136|Device|CT Scan with Spirometry|During the screening and later during the five annual study visits the patients will be scheduled to undergo total of five CT scans. The first CT scan will take place at the beginning of the study and then each year for a period of five years.
1663632|NCT01748123|Drug|Chlorthalidone|Initial dose of 12.5mg daily Chlorthalidone (force titrated to 25mg at 4 weeks)
1663633|NCT01748123|Drug|Hydrochlorothiazide|Initial dose 25mg daily HCTZ (force titrated to 50mg at 4 weeks)
1663634|NCT01748110|Behavioral|Intensive Fitness Intervention|This intervention will involve adhering to health interventions such as behavior and diet modification, and exercise. Patients will follow-up monthly with a health counselor to verify progress.
1663635|NCT01748110|Behavioral|TRIMM|text message intervention.
1663636|NCT01748097|Drug|sodium bicarbonate 4.2%|
1663637|NCT01748084|Drug|Rituximab|Days 1 and 15, rituximab 1 gramme plus 100 mg methylprednisolone
1663638|NCT01748084|Drug|Placebo (NaCl)|Days 1 and 15, NaCl 500 ml plus 100 mg methylprednisolone
1663639|NCT01748058|Behavioral|Exercise based on active video gaming|
1663640|NCT01748045|Drug|inhaled nitric oxide|
1663641|NCT01748045|Drug|Placebo Comparator - nitrogen gas|
1663642|NCT01748032|Behavioral|Cognitive training|20 minutes/day for 5 sequential working days
1663643|NCT01748019|Drug|ST1968|ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
1663644|NCT01748006|Other|Standard of care therapy for severe decompensated heart failure|
1663645|NCT01747993|Drug|Tamsulosin (0.4 mg/j)|(1 tablet / day for 6 days)
1663646|NCT01747993|Drug|Placebo|(1 tablet / day for 6 days)
1663647|NCT01747980|Drug|PRX-112|Single dose level, four doses per cohort
1663648|NCT01747967|Other|Meal Test|Insulin secretion is stimulated by a standardized meal test. Blood and urine samples are collected in order to measure serum and urinary C peptide, glucagon and T-lymphocyte responses against selected beta-cell antigens. The meal test is performed at 0, 6, 12, 18, 24 and 30 months.
1663649|NCT01747954|Other|Bag Squeezing|To perform the BS technique, we used a Protec® manual inflation bag with a flow of 10 L / min and 100% oxygen. A Commercial Medical® manometer was adapted between the orotracheal tube and the inflation bag to monitor the inflation pressure which was recommendedat 30 cmH2O for all children of the BS group. Initially we instilled at most 0.5 ml saline solution(SS) at 0.9% followed by 10 manual hyperinflation maneuvers interspersed with 10 vibrocompression maneuvers and as a last procedure, we performed an aspiration of the orotracheal tube airways and mouth. Between the aspirations the child was re-connected to the ventilator.
1663650|NCT01747954|Other|Thoracic vibrocompression|To perform the TVC technique, we applied 10 vibrocompression maneuvers on the chest of the children during the expiratory phase of the respiratory cycle, on each of the lateral decubitus position, totaling 20 maneuvers, followed by aspiration in the dorsal decubitus position. All measurements in both study groups were performed with the child connected to the ventilator. Before starting the maneuver BS or TVC the child received an increase of 20% fraction of inspired oxygen (FiO2) from what was received previously in MV and after data collection FiO2 returned to baseline values.
1663651|NCT01747941|Drug|PF-06305591|single dose, solution
1663652|NCT01747941|Drug|Placebo|matching placebo
1663653|NCT01747941|Drug|PF-06305591|single dose, solution
1663654|NCT01747941|Drug|Placebo|matching placebo
1663655|NCT01747941|Drug|PF-06305591|single dose, solution
1663656|NCT01747941|Drug|Placebo|matching placebo
1663657|NCT01747928|Other|dual-chamber syringe|dual-chamber syringe for mock injection
1663661|NCT01747902|Procedure|Biceps Tenotomy|The biceps tenotomy group will have their bicep treated by detaching the tendon from the shoulder.
1663662|NCT01747902|Procedure|Biceps Tenodesis|The biceps tenodesis group will have their bicep detached and then re-inserted onto the shoulder.
1663700|NCT01747590|Drug|Caffeine|
1663701|NCT01747590|Other|Placebo|
1663702|NCT01747577|Drug|Solifenacin Succinate|Oral
1663703|NCT01747577|Drug|Placebo|Oral
1663704|NCT01747564|Drug|YM178 (mirabegron)|oral
1663705|NCT01747551|Drug|Oxaliplatin|
1663663|NCT01747889|Device|electronic chest drainage system|"Patients in the intervention arm are connected to Thopaz, electronic drainage system immediately after closure of the chest, patients in the control group are connected to a traditional system. Chest tubes in both groups are then connected to suction of -20 cmH2O and maintained at that level until post-operative day #1.
On the morning of post-operative day #1, presence of air leak will be recorded on suction. Then, suction will be decreased to -8 cmH2O (so-called water seal). At that time, management of chest tube drainage and decision for chest tube removal will be dictated by clinical signs, symptoms, and surgeon preference following the standard clinical algorithm for post-operative care of general thoracic patients"
1663664|NCT01747876|Drug|LEE011|LEE011 is a small molecule inhibitor of CDK4/6.
1663665|NCT01747863|Other|Neurologic examination|Neurologic examination includes: (1) neurologic examination using modify Sarnat score at </= 6 hrs of age, 24 hrs and at discharge home, (2) aEEG at 6 ± 3 hrs of age, (3) Brain MRI before discharge home to 30 days of age.
1663666|NCT01747850|Behavioral|Motivational Enhancement/Cognitive Behavioral Therapy|All participants will receive a combination of pharmacotherapy (Sativex or Placebo) associated with a weekly intervention of combined Motivational Enhancement Therapy and Cognitive Behavioral Therapy.
1663667|NCT01747850|Drug|Sativex|Study subjects will gradually increase the maximal allowed dose of Sativex starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The medication treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Spray that will be decreased by 50% to avoid abrupt withdrawal). Then exposure to medications will be stopped (so there will be a total of 12 weeks medication treatment exposure).
1663668|NCT01747850|Drug|Placebo spray|Study subjects will gradually increase the maximal allowed dose of Placebo starting at five sprays per day for the first two days and increasing of five sprays per day until reaching the max number of 42 sprays maximal per day at end of week 2 (Day 11). The target quit date will be set at Day 21 (but subjects will be allowed to stop using cannabis before if they are willing and able to). The Placebo treatment phase will then be continued for an additional 9 weeks (the last week will be a reduction phase with the use of Placebo Spray that will be decreased by 50%). Then exposure to Placebo will be stopped (so there will be a total of 12 weeks Placebo treatment exposure).
1663669|NCT01747837|Device|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.
Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
1663670|NCT01747811|Device|wavelength-1 bright light|6 weeks of daily light exposure, 30 minutes per morning
1663671|NCT01747811|Device|wavelength-2 bright light|6 weeks of daily light exposure, 30 minutes per morning
1663672|NCT01747798|Drug|auranofin|Given PO
1663673|NCT01747798|Other|laboratory biomarker analysis|Correlative studies
1663674|NCT01747785|Other|Cardiac rehabilitation|Aerobic cardiac exercise training will be provided over the 12 week study duration.
1663675|NCT01747785|Other|Myocardial deformation imaging|A 2D Doppler echocardiograph (image) of the heart will be captured during a single heart beat taken at rest and during cardiopulmonary exercise tests to measure left and right ventricular segmental systolic and diastolic strain measurements.
1663676|NCT01747785|Other|Cardiopulmonary exercise test|The cardiopulmonary exercise test consists of cycling exercise of mild and moderate intensity on an upright cycle ergometer on a tilting table (to facilitate imaging) for 6-10 minute periods within a one hour session.
1663677|NCT01747772|Device|Shear Wave Sonoelastography|Shear Wave sonoelastography (SWE) as an ultrasound technique to measure liver fibrosis was performed on patients scheduled for non-focal liver biopsy. Results were compared with pathological score from liver biopsy.
1663678|NCT01747759|Other|Kruskal-Wallis and qualitative parameters|
1663679|NCT01747746|Drug|Rivaroxaban|Rivaroxaban versus Historical controlled Anticoagulation with Warfarin and Enoxaparin
1663680|NCT01747746|Drug|Warfarin and Enoxaparin|Historical Control
1663681|NCT01747733|Device|Bispectral Index|use of BiS-monitor in the assessment of the level of sedation in patients receiving sedation in endoscopy procedures when compared to clinical sedation scales, such as the Richmond agitation-sedation score.
1663682|NCT01747720|Dietary Supplement|Vitamin D3|Given orally
1663683|NCT01747720|Dietary Supplement|Placebo|
1663684|NCT01747707|Drug|Docetaxel|
1663685|NCT01747707|Drug|Cisplatin|
1663686|NCT01747707|Drug|S-1|
1663687|NCT01747694|Behavioral|Multi-respiratory muscle training|Patients will be taught the diaphragmatic breathing technique at the same time also will be instructed a four-item (including upper-arm weighted exercise, body side-bends, modified sit-ups, body crunching) multi-respiratory muscle training motions. To practice three times/day, three days a week lasting 12 weeks at home.
1663688|NCT01747681|Procedure|Microfracture|
1663689|NCT01747668|Dietary Supplement|Similac Prenatal Vitamin soft-gel capsule|One capsule per day for Experimental Supplement A Group; Two capsules per day for Experimental Supplement B Group
1663690|NCT01747668|Dietary Supplement|Placebo (soybean oil and dl-alpha-tocopheryl acetate)|Two capsules per day for the Placebo Group; One capsule per day for the Experimental Group A
1663691|NCT01747642|Dietary Supplement|Oncoxin|Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
1663692|NCT01747642|Drug|Suranix|Tab Suranix 200 mg 2 tab bd and Syp Oncoxin 25 ml bd and Cap. Oncoxin bd for 180 days
1663693|NCT01747629|Drug|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
1663694|NCT01747629|Drug|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
1663695|NCT01747616|Device|Chitosan-N-acetylcysteine eye drops (concentration of 0.1%)|1 drop of the medical device in 1 randomly chosen eye
1663696|NCT01747616|Other|Physiological saline solution|1 drop as placebo in the other eye not receiving the medical device
1663697|NCT01747603|Other|Specialized LPTB clinic|50% of enrolled infants will be randomized to the specialized LPTB follow-up clinic.
1663698|NCT01747590|Drug|Zolpidem|
1663711|NCT01747538|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
1663712|NCT01747538|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
1663713|NCT01747525|Device|NIRS/IVUS of coronary artery|Evaluation of coronary plaque by NIRS/IVUS.
1663714|NCT01747512|Drug|C-PERT|Patients with thyroid and Head and Neck cancer
1663715|NCT01747512|Drug|G-PERT|Patients with thyroid and Head and Neck cancer
1663716|NCT01747499|Drug|Azacitidine|
1663717|NCT01747486|Biological|CART-19|CART-19 cells (autologous T cells expressing CD19 chimeric antigen receptors expressing tandem TCR zeta and 4-1BB costimulatory domains)
1663718|NCT01747447|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
1663719|NCT01747447|Dietary Supplement|Fish oil placebo|Fish oil placebo
1663720|NCT01747447|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
1663721|NCT01747447|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
1663722|NCT01747408|Drug|Human Albumin|"25% human albumin given in four escalating doses:
Group 1: .625g/kg infused over 3hrs daily X 7day
Group 2: 1.25g/kg infused over 3hrs daily X 7day
Group 3: 1.875g/kg infused over 3hrs daily X 7day
Group 4: 2.5g/kg infused over 3hrs daily X 7day"
1663723|NCT01747395|Other|Exercise training|The heart failure patients are subjected to differents protocols of physical training
1663724|NCT01747382|Procedure|Renal denervation|
1663725|NCT01747356|Device|Resolute stent treatment|A well known coronary stent system that is produced by Medtronic Company and is also recommended by FDA for treating diabetic coronary lesion.
1663726|NCT01747343|Behavioral|Underwear/Differential Reinforcement|Participants are going to be placed in underwear. Differential reinforcement will then be implemented.
1663727|NCT01747330|Drug|Pancreatin|Doses of Pancreatin <2500 lipase u/kg/feed or <4000 lipase U/g fat/intake or <10000 lipase U/kg/day given orally are used
1663728|NCT01747317|Device|FFR (PressureWire)|Fractional flow reserve measured during cardiac catheterization——A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden;ComboWire, Volcano Corporation, San Diego, California) will be advanced past the stenosis.
1663729|NCT01747304|Device|DXA Se femur scans (previously called IVA femur)|Single Energy Beam (previously called inter-vertebral assessment) by Dual energy x-ray absorptiometry of affected femur
1663730|NCT01747278|Drug|Trimethoprim/Sulfamethoxazole|Oral Trimethoprim/Sulfamethoxazole 80 mg/400mg once daily for 12 weeks.
1663731|NCT01747252|Dietary Supplement|RGC|
1663732|NCT01747252|Dietary Supplement|RGC|
1663733|NCT01747252|Dietary Supplement|Resveratrol|The equivalent of 150 mg resveratrol
1663734|NCT01747239|Drug|Cabazitaxel|25 mg/m2 IV every three weeks
1663735|NCT01747226|Other|Fluoride rinse|rinse with 15 ml for 1 minute
1663736|NCT01747226|Other|Halita|rinsing with 15 ml for 1 minute
1663737|NCT01747226|Other|Meridol Halitosis|rinsing with 15 ml for 1 minute
1663738|NCT01747226|Other|Water|rinsing with 15ml for 1 minute
1663740|NCT01747200|Procedure|Sham rTMS|
1663741|NCT01747200|Procedure|Bilateral rTMS at same frequency and in phase|
1663742|NCT01747200|Procedure|Bilateral rTMS at different frequencies|
1663743|NCT01747200|Procedure|Bilateral rTMSat same frequency and out of phase|
1663744|NCT01747200|Procedure|rTMS over TP8|
1663745|NCT01747200|Procedure|rTMS over TP7|
1663746|NCT01747174|Drug|IC Adenosine|IC Adenosine 1mg injected distally via micro-catheter in to IRA following thrombus aspiration with further dose (1mg if IRA is RCA otherwise 2mg) via guide catheter following coronary stent deployment.
1663747|NCT01747174|Drug|IC Sodium nitroprusside (SNP)|IC SNP 250mcg injected distally via micro-catheter distally in to IRA following thrombus aspiration with further 250 mcg dose delivered via guide catheter following coronary stent deployment.
1663748|NCT01747174|Procedure|Standard PCI|PCI procedure with thrombectomy (via aspiration catheter) and bivalirudin given as standard.
1663749|NCT01747161|Drug|Botulin toxin|50 I.E. Botulin toxin. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
1663750|NCT01747161|Drug|physiological water|3 mL physiological water. Injections in 6 spots of the vestibulum vaginae (3 sessions (every 6 weeks))
1663752|NCT01747135|Drug|VTS-270|
1663753|NCT01747122|Device|Wound catheter|Wound catheter, placed at end of procedure, prior to closure. To be kept in for 48 hours.
1663754|NCT01747122|Device|Epidural|
1663755|NCT01747109|Device|PREOXYFLOW|"Patients randomized in PREOXYFLOW group will received a four minutes preoxygenation period with Nasal High Flow Therapy (HFT) Optiflow ® (60 l/mn FIO2 = 1) before orotracheal intubation under laryngoscopy after crash induction"
1663756|NCT01747109|Procedure|STANDARD FACE MASK|"Patients randomized in STANDARD FACE MASK group will received a four minutes preoxygenation period with a standard face mask (15 l/mn) before orotracheal intubation under laryngoscopy after crash induction. Each hospital involved in this study will use the standard face mask as per its usual practice (no specific trademark requested by this protocol)"
1663757|NCT01747096|Drug|68-Ga-DOTANOC|
1663758|NCT01747083|Drug|FDC(gemigliptin/metformin HCl sustained release 50/1000mg(25/500mg x 2tablets))|
1663759|NCT01747070|Other|tDCS and EAC sham|The tDCS apparatus is operated on battery power, will be used rubber electrodes soaked in saline solution. The anode is placed in M1 and the cathode in the supraorbital region.
1663760|NCT01747070|Other|tDCS sham and EAC sham|For the EAC sham we will use rubber electrodes. They will be applied in the same areas of active EAC. They are connected to the same electroacupuncture device, but without current passing for the patient. All subjects receive one 30min session.
1663761|NCT01747070|Other|tDCS sham and EAC|For the sham tDCS we will use the same apparatus in the same location, but the current is stopped after 30 seconds.
1663803|NCT01746810|Radiation|Stereotactic body RT and IRGA|SABR Treatment with Dose escalation: Group 1: 40 Gy/5 fractions Group 2: 45 Gy/5 fractions Group 3: 50 Gy/5 fractions then IRGA procedure 1 week later with repeat lung biopsies, serum studies
1663762|NCT01747070|Other|tDCS and EAC|For the acupuncture we will use needles with guide tubes that are 40 mm in length and 0.25 mm in diameter. The needling will be applied using an electro acupuncture device in the dermatomes, myotome, or sclerotome corresponding to the nerve roots involved in the knee (L1, L2, L3, L4, L5, S1, and S2). All patients received one 30min session using a frequency of 2 Hz.
1663763|NCT01747057|Behavioral|Dynamic-parameters-guided fluid management|"● In preload-responsive patients defined by the following dynamic parameters: Patients fully adapted to mechanical ventilation* and with sinus rhythm.
PPV >12%. PPV: Pulse pressure variation PPV = (PPmax-PPmin)/ [(PPmax+PPmin)/2] x100 (during 5 respiratory cycles)
SVV > 12% (15). SVV: Stroke volume variation
A tidal volume (Vt) ≥ 7-10cc/kg in mechanically ventilated (in a controlled mode - control volume or control pressure) and well-adapted patients without any inspiratory effort should be guaranteed.
Fluid loading must be performed with crystalloids (1omL/Kg) or colloids (5ml/Kg) every 30 minutes until PPV-SVV < 12%, while hypoperfusion signs are present. Continue resuscitation following Surviving Sepsis Campaign rules excluding more fluid administration (as described in the standard intervention once CVP>12).
● Non-preload responsive patients (defined as PPV or SVV < 12%) will resume the same protocol as responders when fluid response parameters are negative."
1663764|NCT01747057|Behavioral|Standard-guided-fluid management|Fluid loading in patients with hypotension or elevated lactates until normalization of MAP (> 65mmHg) or CVP > 12mmHg. If CVP reaches > 12 mmHg and MAP remains < 65mmHg, norepinephrine should be started to reach MAP > 65mmHg. Once MAP is restored, if hypoperfusion signs persist (elevated lactate or urine output < 0.5mL/Kg/h), ScvO2/SvO2 must be measured. In order to reach a ScvO2 ≥70% or SVO2 ≥65%, consider giving blood transfusion if hemoglobin level (Hb) ≤ 7g/dL, and also consider dobutamine (initial dose 2,5 µg/kg/min, increased by 2,5 µg/kg/min every 30 min up to a maximum dose of 20 µg/kg/min, presence of arrhythmia, or FC>110bpm). At that point, if hypoperfusion signs remain present, consider restart protocol from the beginning.
1663765|NCT01747044|Drug|Milnacipran|100mg/day
1663766|NCT01747044|Drug|Placebo|
1663767|NCT01747031|Device|PressureWire™ Certus(St. Jude Medical Systems, Sweden)|Fractional flow reserve measured during cardiac catheterization——A pressure-monitoring guidewire(PressureWire Certus, St. Jude Medical Systems, Uppsala, Sweden) will be advanced past the stenosis.
1663768|NCT01747018|Biological|Platelet-rich Plasma|
1663769|NCT01746992|Drug|Cyclophosphamide 750mg/m2|day 1 in both arms
1663770|NCT01746992|Drug|Vincristine 1.4mg/m2|day 1
1663771|NCT01746992|Drug|Doxorubicin 50mg/m2|day 1
1663772|NCT01746992|Drug|prednisone 60mg/m2|day1-day5
1663773|NCT01746992|Drug|ifosfamide 2000mg/m2|day 22-day 24
1663774|NCT01746992|Drug|pirarubicin 50mg/m2|day 1
1663775|NCT01746992|Drug|pirarubicin 25mg/m2|day 22
1663776|NCT01746992|Drug|Etoposide phosphate 100mg/m2|day 22-day 24
1663777|NCT01746992|Drug|methotrexate 1500mg/m2|day 43
1954842|NCT03311022|Drug|Nefopam Hydrochloride 30mg Tablets|
1954843|NCT03311022|Drug|Acupan® 30mg Tablets|
1663781|NCT01746940|Drug|Cocaine HCl 4% Topical Solution|Cocaine HCl 4% Topical Solution
1663782|NCT01746940|Drug|Cocaine HCl 10% Topical Solution|Cocaine HCl 10% Topical Solution
1663783|NCT01746940|Drug|Placebo Topical Solution|Placebo Topical Solution
1663784|NCT01746927|Other|Glidescope Cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP. using in radimized method : 0 N,10 N, 20N AND 30 N
1663791|NCT01746875|Drug|Aflibercept|2.0 mg monthly x 3 doses, then as needed based on recurrence of activity on OCT. If no effect after the initial 3 doses; 2.0 mg monthly x 3 doses is repeated.
1663792|NCT01746875|Drug|Verteporfin|given if aflibercept does not have any effect. Verteporfin photodynamic therapy is given in combination with aflibercept and triamcinolone. The treatment can be repeated after 3 month.
1663793|NCT01746862|Drug|Saizen®|Subjects in the Saizen test group will receive Saizen (recombinant-human growth hormone [r-hGH]) subcutaneously 6 days per week at a weight based dose of 0.067 milligram per kilogram of body weight per day (mg/kg/day) for 12 months.
1663794|NCT01746862|Drug|Saizen®|Subjects in the Saizen control group will receive no treatment for the first 6 months and thereafter will receive Saizen (r-hGH) subcutaneously 6 days per week at a weight based dose of 0.067 mg/kg/day for the next 6 months.
1663795|NCT01746849|Biological|Palifermin|
1663796|NCT01746849|Biological|Lupron|
1663797|NCT01746849|Procedure|peripheral blood stem cell transplantation|
1663798|NCT01746849|Radiation|Total-Body Irradiation (TBI)|
1663799|NCT01746849|Drug|Thiotepa|
1663800|NCT01746849|Drug|Cyclophosphamide|
1663801|NCT01746836|Drug|Ponatinib|Starting dose of Ponatinib: 30 mg by mouth once daily.
1663802|NCT01746823|Drug|Cyclosporins|
1663804|NCT01746784|Drug|N6022|Intravenous solution of N6022 in normal saline administered by infusion pump over 1-8 minutes depending on the dose
1720468|NCT00003159|Drug|docetaxel|
1663805|NCT01746784|Drug|Normal saline|Intravenous solution of 0.9% (weight/volume) NaCl administered by infusion pump over 1-8 minutes depending on dose of active drug used in same cohort
1663806|NCT01746771|Drug|HM781-36B(Poziotinib)|QD*2weeks/3weeks
1663807|NCT01746771|Drug|Paclitaxel|175mg/m2
1663808|NCT01746771|Drug|Trastuzumab|8mg/kg
1663809|NCT01746758|Behavioral|SMS text messaging referral|The text messaging system has been designed to use codes of reproductive health conditions and their treatments. Text messages are sent by drug stores and received at the dispensaries, forwarded by a bespoke software called Snapshot, which captures data online from any computer anywhere by use of a login for confidentiality.
1663810|NCT01746745|Drug|[C14]-LY2940680|Administered as solution by mouth
1663811|NCT01746732|Drug|Ortho-Cyclen|Oral administration
1663812|NCT01746732|Drug|Evacetrapib|Oral administration
1663813|NCT01746719|Drug|Etodolac Capsules USP 300 mg|300 mg capsule once a day
1663814|NCT01746719|Drug|Etodolac|500 mg tablet once a day
1663815|NCT01746706|Device|PET amyloid tracer (Florbetapir F18 AV45 F18|
1663816|NCT01746693|Device|Dynamic Vessel Analyzer|retinal vessel diameter, retinal oxygen saturation
1663817|NCT01746693|Other|Laser Doppler Velocimetry|retinal blood flow velocity, retinal blood flow
1663818|NCT01746693|Device|7-Tesla MRI|High resolution functional and anatomical imaging of the visual pathway
1663819|NCT01746693|Other|Pattern electroretinography|inner retinal function
1663820|NCT01746693|Other|Fourier domain optical coherence tomography|Blood flow in retina.
1663821|NCT01746680|Drug|Tacrolimus with Methotrexate|Tacrolimus 1 mg for 0~week4, 2mg for week4~week8, 3mg for week8~week24 with MTX ≤20mg/week
1663822|NCT01746667|Behavioral|Exposure in vivo|
1663823|NCT01746667|Behavioral|Virtual Reality Exposure Therapy|
1663824|NCT01746654|Drug|P128-0.1 mg|P-128 at 0.1 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
1663825|NCT01746654|Drug|P128-0.3 mg|P-128 at 0.3 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; and once in Part D.
1663826|NCT01746654|Drug|P128-1.0 mg|P-128 at 1.0 mg divided evenly between the nares is administered once in Part A; multiple times in Part B and Part C; once in Part D.
1663827|NCT01746654|Drug|Placebo|Placebo was administered to both nares once in part A, multiple times in Part B and Part C, Once in part D
1663828|NCT01746641|Drug|Remifentanil|
1663829|NCT01746641|Drug|Propofol|
1663830|NCT01746628|Procedure|Hysterectomy with FloSeal|Evaluation of the effects of intrauterine FloSeal
1663831|NCT01746615|Device|Dynamic Vessel Analyzer|retinal vessel diameter & oxygen saturation
1663832|NCT01746615|Other|Bidirectional Fourier-Domain Optical Coherence Tomography (FDOCT)|retinal blood velocity
1663833|NCT01746602|Drug|Timoptic® 0.5%|Timoptic® 0.5% Eye Drops, Merck, single instillation
1663834|NCT01746602|Drug|Timophtal sine® 0.5%|Timophtal sine® 0.5%, Agepha, Eye Drops, single instillation
1663835|NCT01746602|Device|Genteal HA®|Genteal HA® Eye Drops, Novartis, single instillation
1663836|NCT01746602|Device|Hylo-Comod®|Hylo-Comod® Eye Drops, Croma-Pharma, single instillation
1663837|NCT01746602|Device|Thealoz®|Thealoz® Eye Drops, Thea, France, single instillation
1663839|NCT01746576|Other|Use of impedance threshold device during spontaneous ventilation|
1663840|NCT01746563|Drug|Ranibizumab|Intravitreal injection
1663841|NCT01746563|Procedure|Laser therapy|Laser therapy
1663842|NCT01746550|Device|MD-12-001 Stent|MD-12-001 is a self-expanding nitinol stent
1663843|NCT01746524|Device|ATTUNE Primary Total Knee Arthroplasty|Patients will undergo a primary, cemented total knee replacement using one of the four configurations of the Attune knee (CR FB, PS FB, CR RP, PS RP).
1663844|NCT01746511|Procedure|Phototherapy|Light therapy is used to treat cases of neonatal jaundice through the isomerization of the bilirubin and consequently transformation into compounds that the newborn can excrete via urine and stools.
1663845|NCT01746511|Drug|glycerin suppository|Promotes stooling through rectal stimulation and softening of stool. Given every 8 hours rectally. A pediatric glycerin suppository is 1.2 grams. All infants in this study arm will receive our standard dose of glycerin suppository which is 0.25 of the pediatric suppository or 0.3 grams.
1663846|NCT01746498|Procedure|Direct current stimulation using Anodal electrode|11 patients who received real anodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
1663847|NCT01746498|Procedure|direct current stimulation using cathodal electrode|11 patients who received real cathodal tDCS on the left DLPFC, 2 mA for 20 minute every day for 10 consecutive days
1663848|NCT01746498|Procedure|Sham direct current stimulation|11 patients who received sham anodal tDCS on the left DLPFC just for few seconds, 2 ma, every day for 10 consecutive days
1663849|NCT01746485|Drug|UT-15C|
1663850|NCT01746472|Behavioral|Facebook app - condition t|Application components hypothesized to increase the duration (t, time) that a participant spends using the application.
1663851|NCT01746472|Behavioral|Facebook app - condition z|Application components hypothesized to increase the number of friends that a user has that are eligible to install the application.
1663852|NCT01746472|Behavioral|Facebook app - condition B-active|Application components hypothesized to increase the contagiousness of the app by increasing a users ability and desire to proactively contact others.
1663853|NCT01746472|Behavioral|Facebook app - condition B-passive|Application components hypothesized to increase the contagiousness of the app by increasing the passive diffusion of information from the user to their friends.
1663854|NCT01746459|Other|Paper-Based Reminder System|Paper-based reminders include: a) affixing stickers to clients' bedroom doors, beside their beds, or in their bathrooms; b) posting signs in prominent locations; and c) placing colored flags on the documentation flowsheets.
1663855|NCT01746459|Other|Peer-Based Reminder System|Healthcare aides will provide formal and informal peer reminders about the mobility activity; the formal reminders will take place either monthly or every three months during change of shift meetings, while the informal reminders will be provided as opportunities arise during the work day.
1663857|NCT01746433|Other|Sitting up|"The patient is positioned on a Winncare type bed dressed with a pressure-sensor sheet and equipped with either a hanging triangle bar (supporting arm of the bar is adjusted to 30 degrees) or an ERGONOME device according to randomization.
The patient is first installed on the bed in a strictly supine position, the pelvis centered, and the greater trochanter over the fold of the backrest.
The investigator then gives instructions on how to use the randomized device (correct hand placement).
The patient is asked to sit up twice (two consecutive attempts). The first attempt is a learning attempt. The observations necessary for this study will be taken on the second attempt. Thus the second sitting attempt is timed, video-taped and recorded via the pressure-sensor sheet beneath the patient."
1663858|NCT01746420|Drug|rhPDGF-BB Injection|Comparison of placebo control (0 mg rhPDGF-BB) and different dosages (0.45, 0.75, 1.5, and 3.0 mg) of rhPDGF-BB Injection administered through a one-time injection
1663859|NCT01746394|Behavioral|Parents as Teachers Enhanced|Participants will receive the same monthly Parents as Teachers (PaT) lessons and materials at each home visit as the PaT arm. Additionally, these mothers will receive the enhanced nutrition and physical activity lessons and materials which will follow the family well-being format of the PaT lessons. The StartSmart lessons will focus on healthy gestational weight gain, diet, physical activity, breastfeeding, weight management, healthy eating, food shopping, meal preparation, physical activity, proper infant feeding, and infant activity time.
1663860|NCT01746394|Behavioral|Parents as Teachers|Participants will receive monthly Parents as Teachers (PaT) lessons and materials at each home visit. The Parent Educator will first connect with the mother by discussing or reviewing content from the prior visit; reflect on the mother's experience with continuing the parent-child activity from the prior visit; and agree on what will happen during the current visit. For the lesson plan, the Parent Educator will cover the following three areas using discussion, activities, and handouts: parent-child interaction, develop-centered parenting, and family well-being. In closing, the Parent Educator will review and evaluate the visit, talk about the mother's next step, and plan for the next visit.
1663861|NCT01746381|Device|Non-invasive home ventilation|A ventilator and mask will be provided to patients according to standard procedures used at the National Program of Home Ventilatory Assistance of the Montreal Chest Institute, adjusted during a daytime outpatient trial, with close follow-up as described in study protocol.
1663862|NCT01746368|Other|The Nurse-Supported Advance Care Planning Intervention|This intervention was a manualized education, support, and guidance session provided by a Registered Nurse that included information about risks, benefits, and alternatives of specific choices. It incorporated an application of the Theory for Enabling Safety.
1663863|NCT01746368|Other|Care-as-Usual|The Care-as-Usual was a session with the social worker who explained what the Advance Directive is, and guided the Veteran regarding the process of completing the Advance Directive document, without providing information about risks, benefits, and alternatives of specific choices.
1663864|NCT01746355|Procedure|rTMS|Patients undergoing of repetitive transcranial magnetic stimulation for treatment of AFP.
1663865|NCT01746342|Device|Effective continuous positive airway pressure (CPAP)|
1663866|NCT01746342|Device|Sham continuous positive airway pressure (CPAP)|
1663867|NCT01746329|Other|Tea|Oral intake of tea containing 75 grams of glucose
1663868|NCT01746329|Other|Beet root|Oral intake of beetroot juice containing 75 grams of glucose
1663869|NCT01746329|Other|Placebo|Oral intake of 75 grams of glucose in water
1663870|NCT01746303|Dietary Supplement|Omega-3 fatty acid|A fixed dose of 2.4 g/day (EPA: 1.6 g, DHA: 0.8 g; 4 capsules/d).
1663871|NCT01746303|Dietary Supplement|Blueberry powder|Whole, freeze-dried blueberry powder made of 50%:50% mixture of Tifblue and Rubel blueberries.
1663872|NCT01746303|Other|Placebo oil|Corn oil capsules that are identical in size, shape, and color to omega-3 capsules.
1663873|NCT01746303|Other|Placebo powder|Placebo powder matched for color, taste, and sugar content as closely as possible and milled similarly to the blueberry powder.
1663874|NCT01746290|Other|PulsePoint notification|When the smartphone receives the alert data, the phone alarms with auditory, tactile (vibration) and visual stimuli (Figure 1). After acknowledgement of the alert by the user, the application presents a map and text information to direct the user to the exact location of the emergency. Using local AED registry data, the application can also reveal exact AED locations in the vicinity of the emergency
1663875|NCT01746277|Drug|combined group|chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycle is 6 depending on disease evaluation and patient's physical condition combined with gefitinib 250mg once per day from the start day of chemotherapy until disease progression or intolerable side effects.
1663876|NCT01746277|Drug|Sequenced group|sequenced group chemotherapy with docetaxel 75mg/m2 d1 or pemetrexed 500mg/m2 d1, every 3 weeks,at least 2 cycles and the maximal cycles is 6 depending on disease evaluation or patient's physical condition sequenced by gefitinib 250mg once per day until disease progression or intolerable side effects.
1663877|NCT01746264|Dietary Supplement|Vitamin D3|Vitamin D 3 at 100,000 IU once a month for 3 months
1663878|NCT01746251|Drug|Afatinib|
1663879|NCT01746238|Drug|Bevacizumab|Intravenous infusion, every 2 weeks, 3 doses total
1663880|NCT01746238|Drug|Doxorubicin|Intravenous infusion, bolus infusion followed by 4 day continuous infusion, every week for 5 weeks
1663881|NCT01746238|Radiation|Radiation Therapy|Daily, Monday-Friday, for 6 weeks
1663882|NCT01746225|Drug|nab-Paclitaxel|Induction phase: 3 cycles of nab-Paclitaxel days 1, 8, 15. Maintenance phase with three maintenance schedules of nab-Paclitaxel (same total dose per cycle, different number of administrations)
1663883|NCT01746212|Procedure|One-level or two-level anterior lumbar interbody fusion|Patients electing to receive a one-level or two-level, anterior approach only (incision through the front), lumbar interbody fusion in order to treat degenerative disc disease (at one or two levels in the spine), and meeting all other inclusion criteria, are eligible for enrollment into the study.
1663884|NCT01746212|Biological|InQu Bone Graft Extender and Substitute mixed with BMAC|Surgeries utilizing InQu Bone Graft Extender and Substitute during the anterior lumbar interbody fusion surgical procedure will be elected for inclusion. InQu will be mixed with BMAC (bone marrow aspirate concentrate), which will be prepared using the SmartPRep2 centrifuge. Patients opting to use a grafting alternative will not meet inclusion criteria, and will not be eligible to enroll in this study.
1664648|NCT01740258|Radiation|Radiation Therapy|
1663885|NCT01746212|Device|Synthes Spinal Instrumentation|Synthes Spinal Instrumentation will be used during surgery as spinal stabilization.
1663886|NCT01746199|Drug|cotrimoxazole daily prophylaxis|
1663887|NCT01746199|Drug|sulphadoxine-pyrimethamine|Intermittent preventive sulphadoxine-pyrimethamine treatment
1663888|NCT01746173|Drug|Cyclophosphamide|
1663889|NCT01746173|Drug|Doxorubicin|
1663890|NCT01746173|Drug|Vincristine|
1663891|NCT01746173|Drug|Etoposide|
1663892|NCT01746173|Drug|Prednisone|
1663893|NCT01746173|Drug|Filgrastim|
1663894|NCT01746173|Drug|Plerixafor|
1663895|NCT01746173|Procedure|Stem Cell Collection|
1663896|NCT01746173|Drug|Palifermin|
1663897|NCT01746173|Drug|Gemcitabine|
1663898|NCT01746173|Drug|Busulfan|
1663899|NCT01746173|Drug|Melphalan|
1663900|NCT01746173|Procedure|Stem Cell Transplant|
1663901|NCT01746160|Drug|C1 Implant|Patients treated with dental implants.
1663902|NCT01746147|Other|No intervention and study treatment|
1663903|NCT01746121|Genetic|Salivary and blood sampling, as part of routine care. Collection of exfoliated teeth.|
1663904|NCT01746108|Biological|Synflorix™|1 or 2 doses depending on the priming status, intramuscularly in the non-dominant deltoid muscle or the thigh.
1663905|NCT01746095|Drug|Vancomycin inhalation powder|There will be two treatment cohorts in this study, each comprised of 40 randomized (1:1 active to placebo) and treated patients (adults ≥18 and children ≥12 years of age). In Cohort 1, patients will be enrolled and randomized to receive the 32 mg dose of AeroVanc bid or placebo bid. Prior to starting enrollment in Cohort 2, a safety evaluation will be carried out by the Data Monitoring Committee (DMC) based on treatment data from the first 20 patients in Cohort 1. Subject to the Sponsor's written communication of the DMC's opinion of acceptable safety, the dose for the active arm in Cohort 2 will be escalated to 64 mg bid. Optionally, the active arm for Cohort 2 may also be kept the same (32 mg bid), or reduced to 16 mg bid, depending on the outcome of the DMC's safety evaluation.
1663906|NCT01746095|Drug|Placebo inhalation powder|
1663907|NCT01746082|Biological|Influenza A/H3N2 variant Vaccine|Investigational influenza virus H3N2v vaccine, a monovalent type A inactivated vaccine (H3N2v MIV) for intramuscular use, is a sterile clear and slightly opalescent suspension prepared from influenza virus propagated in embryonated chicken eggs. The H3N2v MIV contains no preservative. Subjects will be stratified by age (approximately 100 (up to 120) subjects 18-64 years old and approximately 100 (up to 120) subjects >/=65 years old) to receive two doses of H3N2v MIV, delivered intramuscularly as 15 micrograms (mcg) of hemagglutinin (HA)/0.5 milliliter (mL) dose, 21 days apart
1663910|NCT01746056|Device|Occlusive Heat Patch|The heat patch will be applied for 2 hours every day for a period of 12 weeks.
1663911|NCT01746043|Drug|Armodafinil|150 mg by mouth once a day for 6 weeks.
1663912|NCT01746043|Other|Placebo|1 capsule by mouth 2 times a day for 6 weeks.
1663913|NCT01746043|Drug|Minocycline|100 mg by mouth 2 times a day for 6 weeks.
1663914|NCT01746043|Behavioral|Questionnaires|Completion of symptom questionnaires before chemoradiation and then 1 time a week during Weeks 1-10 of the study. Questionnaire take up to 5 minutes to complete.
1663917|NCT01746004|Drug|[^14C]-LY2157299|[^14C]-LY2157299 monohydrate administered as oral solution
1663918|NCT01745991|Device|CoSeal spray|
1663919|NCT01745978|Procedure|Precut papillotomy|
1663920|NCT01745965|Drug|T-DM1|
1663921|NCT01745965|Drug|Trastuzumab|
1663922|NCT01745952|Device|figure-of-eight active rTMS coil|navigated rTMS over epileptogenic focus using figure-of-eight active rTMS coil
1663923|NCT01745952|Device|round active rTMS coil|navigated rTMS over epileptogenic focus using round active rTMS coil
1663924|NCT01745952|Device|sham rTMS coil (figure-of-eight)|commercially available placebo coil that provides slight sensory stimulation and discharge noise without stimulating cortical tissue
1663925|NCT01745939|Other|Lumbar Manipulation|Manual therapy intervention
1663926|NCT01745939|Other|Sham manipulation|Manual therapy intervention
1663927|NCT01745926|Device|MECHANICAL CHEST COMPRESSION|
1663928|NCT01745913|Device|CliniMACS® CD34 Reagent System|If a subject is randomized to the haplo-cord transplant group, their family member will undergo a stem cell collection. The stem cells from the haplo-identical donor will be purified by a procedure called CD34 selection before they are given to the subject. A special device called the CliniMACS® CD34 Reagent System, which is not FDA approved, will be used for this purpose. The manufacturer of the device, Miltenyi Biotec, is providing the researchers access to the device for use in this research study. Because the stem cells from the haplo-identical donor are treated using the CliniMACS CD34 selection device, they cells are considered investigational.
1663929|NCT01745913|Drug|Fludarabine|Fludarabine: 30 mg/m2 /day intravenously x 5 days total dose 150 mg/m2. Fludarabine will be dosed according to actual body weight
1663930|NCT01745913|Drug|Melphalan|Melphalan: 70mg/m2/day intravenously x 2 days. Melphalan will be dosed according to actual body weight. Cryotherapy with ice chips will be administered to prevent mucositis.
1663931|NCT01745913|Drug|Rabbit ATG|Rabbit ATG (rATG): 1.5 mg/kg/day intravenously x 4 days, total 6 mg/kg. ATG will be dosed according to actual body weight. The first dose will be infused over at least six hours, and subsequent doses over at least 4 hours. Pre-medications include acetaminophen 650 mg by mouth, diphenhydramine 25-50 mg by mouth or intravenously, and methylprednisolone 2 mg/kg (1 mg/ kg at the initiation and 1 mg/kg half-way through anti-thymocyte globulin administration).
1663932|NCT01745913|Procedure|Double Umbilical Cord Blood Transplantation|All subjects will receive an UCB dose of > 3 x107/kg nucleated blood cells. It is expected that this will require co-infusion of two UCB in the large majority of cases. If two UCB are required, they will be at least 4/5 matched to the recipient.
1663985|NCT01745497|Drug|Placebo|Equivalent volume of liquid with similar color and taste.
1664107|NCT01744457|Device|Optical Quality Analysis System|Measurement of the objective scattering index (OSI)
1663933|NCT01745913|Procedure|Haplo-Identical Cord Transplantation|"If randomized to the haplo-cord group, a family member will undergo a stem cell collection. In both arms, subjects will receive a conditioning regimen prior to transplantation. The conditioning regimen utilized in this study incorporates fludarabine-Melphalan and antithymocyte globulin (ATG). This regimen has the advantage of being nearly identical to the regimen utilized for our haplo-cord regimen is based on the experience of the Dana-Farber/Mass-General regimen."
1663934|NCT01745887|Drug|EBI-005-2|The investigational drug EBI-005-2, is an intervention to three different study arms. One arm gets 5mg/ml, the other gets 20mg/ml and the last arm is Placebo.
1663935|NCT01745861|Dietary Supplement|Lipidem (Omega-3 fish oil lipid emulsion)|Lipidem 200 mg/ml daily infusion for 7 days maximum
1663936|NCT01745861|Dietary Supplement|Lipofundin® MCT/LCT 20%|Lipofundin® MCT/LCT 20% daily infusion for 7 days
1663937|NCT01745848|Drug|Roflumilast|
1663938|NCT01745835|Drug|2L Coolprep®|* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
1663939|NCT01745835|Drug|1L Coolprep® and Bisacodyl|"Coolprep® (TaeJoon Pharmaceuticals, Seoul, Korea)
* Compositions/1L : Sodium Chloride 2.691g Potassium Chloride 1.015g Anhydrous sodium sulfate 7.5g PEG 3350 100g ascorbic acid 4.7g sodium ascorbate 5.9g
Dulcolax-S® (Boehringer Ingelheim ,Seoul, Korea) * composition /1 tablet : Bisacodyl 5mg, docusate sodium 16.75mg"
1663940|NCT01745822|Drug|tenofovir disoproxil fumarate|administration: tablet 300 mg, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
1663941|NCT01745822|Drug|placebo|administration: one tablet, once a day, from enrollment at 28 weeks' gestation until 2 months postpartum
1663942|NCT01745809|Procedure|Bronchoscopy|Subjects will have a screening visit and, if they qualify to take part in the study, they will undergo a single bronchoscopy procedure. During the bronchoscopy, bronchoalveolar lavage (BAL) and bronchial brushings will be performed on each subject.
1663943|NCT01745783|Other|Bone marrow mesenchymal stem cells autologous|Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg
1663944|NCT01745783|Other|Placebo comparator|Lactated Ringer's solution, 2.5% glucose and 1% human albumin.
1663945|NCT01745770|Drug|Mesalazine - TID 1000 mg|
1663946|NCT01745770|Drug|Mesalazine - TID 2x 500 mg|
1663947|NCT01745757|Drug|Bevacizumab|Treatments received by patients in this study are prescribed in the context of standard care
1663948|NCT01745757|Drug|paclitaxel|Treatments received by patients in this study are prescribed in the context of standard care
1663949|NCT01745744|Other|Mesenchymal stem cells from adipose tissue|- Infusion of mesenchymal stem cells from adipose tissue administered intraarterially: 0.5x106 cells / kg of patient weight and 1x106 cells / kg of patient weight.
1663950|NCT01745731|Other|Cell infusion intraportal mononuclear bone marrow autologous and portal embolization of the affected segments.|Proceeds to selective application of stem cells in the portal branches of segments II and III as 10 ml aliquots of taking a time of 4 minutes between each application.
1663951|NCT01745718|Other|Cytological imprints|Each targeted biopsy is subject to cytological imprints. It causes no extra biopsies or extra discomfort for the patients
1663952|NCT01745705|Other|Cervical Spine Manipulation|
1663953|NCT01745705|Other|Manual Contact|
1663954|NCT01745692|Device|Mechanical thrombectomy|
1663955|NCT01745692|Drug|Intravenous rtPA|All patients receive IV alteplase
1663956|NCT01745679|Drug|Ceftriaxone treatment|ceftriaxone will be administered à high dose : > or equal to 75mg/kg/day or 4 gr/day
1663957|NCT01745666|Other|exercise test|Exercise test : Bruce protocol : exercise during 7 minutes, and rest during 6 minutes with registering of the electrocardiograms.
1663958|NCT01745666|Other|Epinephrine test|Epinephrine test : 1 hour after exercise test : epinephrine infusion during 20 minutes, and monitoring during 30 minutes after stop infusion with registering of electrocardiograms.
1663959|NCT01745653|Device|Low level laser therapy|
1663960|NCT01745653|Procedure|sham procedure|
1663961|NCT01745640|Drug|POMALIDOMIDE|hard capsule 4mg/day, oral route, from day 1 to 21 per 28 days cycle
1663962|NCT01745640|Drug|Dexamethasone|40mg (if patient <75 years)/20mg weekly, oral route, on day 1, 8, 15, 22 per 28 days cycle
1663963|NCT01745627|Device|755nm Alex laser|
1663964|NCT01745614|Drug|Nimesulide 100 mg tablets|Reference product
1663965|NCT01745614|Drug|Nimesulide 100 mg tablets|Test product
1663966|NCT01745601|Drug|escitalopram 10 mg|Reference product
1663967|NCT01745601|Drug|escitalopram 10 mg|Test product
1663968|NCT01745588|Drug|Pomalidomide|
1663969|NCT01745588|Procedure|stem cell|
1663970|NCT01745588|Drug|Dexamethasone|
1663971|NCT01745588|Drug|Clarithromycin|
1663972|NCT01745575|Drug|Alprazolam 2mg tablets|Reference product
1663973|NCT01745575|Drug|Alprazolam 2 mg tablets|Test product
1663974|NCT01745562|Drug|Alprazolam 0.5 mg|Reference product
1663975|NCT01745562|Drug|Alprazolam 0.5 mg|Test product
1663976|NCT01745549|Device|Needle for insulin pen, 4 mm long and with a diameter of 33 gauge|
1663977|NCT01745549|Device|Needle for insulin pen, 4 mm long and with a diameter of 32 gauge|
1663978|NCT01745536|Procedure|Oocytes are vitrified/stored using a closed device|Vitrification will be carried out using a modification of the current device (Cryotop®), thus providing air tight sealing. Closed systems are devices that are hermetically sealed before vitrification and remain sealed during storage.
1663979|NCT01745536|Procedure|Oocytes are vitrified/stored using an open device|The vitrification process takes place through direct contact with liquid nitrogen. The system has an external straw to protect the samples during storage, but the device is not hermetically sealed.
1663980|NCT01745523|Procedure|Synthetic macromolecule HPC and trehalose|Oocytes are vitrified using the synthetic macromolecule HPC and trehalose
1663981|NCT01745523|Procedure|SSS containing HSA and sucrose|• Oocytes are vitrified using the SSS containing HSA and sucrose
1663982|NCT01745510|Dietary Supplement|Docosahexaenoic acid (DHA)|Docosahexaenoic acid from algae source
1663983|NCT01745510|Dietary Supplement|Placebo|Placebo was designed to mimic the color and consistence of the oil that contains DHA
1663984|NCT01745497|Drug|Ferrous sulfate|3mg/kg liquid
1663986|NCT01745484|Other|SPECT-based treatment plan|"SPECT will be performed on all patients at baseline. Two treatment plans will be made- functional SPECT-based plan and conventional CT-based plan. Randomization will take place if both plans are satisfying established criteria for tumour coverage and normal tissue sparing. Randomization between Arm 1 and Arm 2 will be done, where the patients will be treated either by SPECT-plan or by CT-plan respectively.
The SPECT data are viewed as a multicoloured image in the spectrum colour setting to allow accurate volume contouring around a predefined colour. The threshold level is adjusted individually for each patient in order to match the size of the SPECT image within the lung volumes defined on CT. A new contour of functional lung is created from the SPECT images using a threshold of 30% of the maximum uptake for each patient. A treatment plan is generated. The principal objective for each plan is to minimize the volume of lungirradiated"
1663987|NCT01745458|Drug|SB-659032|
1663988|NCT01745458|Drug|Placebo|Matched placebo
1663989|NCT01745445|Other|concurrent chemo-radiotherapy arm|VP-16 50 mg/m2 on day 1-5 and Carboplatin AUC = 5 on day 1 will be given by intravenous infusion for 3-4 cycles. Then a total dose of 60 Gy will be given in 30 fractions of 2 Gy, 5 fractions per week; Starting the first cycle of concurrent chemotherapy at the first day of radiotherapy. The chemotherapeutic scheme is intravenous infusion of Cisplatin 25mg/m2 on day 1-3 and oral administration of Etoposide 100mg on day1-5 and 3 weeks as a cycle for 2 consecutive cycles.
1663990|NCT01745432|Device|ADBLOCK|Laparoscopic surgery
1663991|NCT01745393|Behavioral|Clinic Quality Improvement + Behavioral Counseling|
1663992|NCT01745393|Behavioral|Clinic Quality Improvement + Attention Control|
1663993|NCT01745380|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|The study drug is regional anesthetic delivered intranasally on the same side as the operative tooth
1663994|NCT01745380|Drug|Placebo|The placebo spray was identical in appearance to and was administered in the same volume and manner as the active ingredient.
1663997|NCT01745354|Drug|SD-101|SD-101 will be administered after radiation to only the largest palpable lymph node as an intratumoral injection weekly for 3 weeks at three dosing cohorts: 0.3 mg, 1 mg, and 3 mg
1663998|NCT01745354|Radiation|Local Radiation|
1663999|NCT01745328|Drug|LVX-AMX|Subjects were treated with Levofloxacin, 200mg bid, Amoxicillin, 500mg tid for 1 week, followed by 3 week of placebo.
1664000|NCT01745328|Drug|TCM|Subject is treated with TCM for 4 weeks.
1664001|NCT01745328|Drug|LVX-AMX|treatment with placebo from 2 to 4 weeks.
1664002|NCT01745315|Device|Advanced bipolar devices|
1664003|NCT01745302|Drug|TCM|TCM: In China,TCM herbs are given on the basis of the TCM syndrome differentiation as diagnosed by the TCM herbal specialist. Prescriptions formulated into granules origin from Professor Liu Jia-xiang in Longhua hospital. Package of granules is made into three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.The herbal treatment is adapted to the syndromes.
1664004|NCT01745302|Drug|EGFR-TKI|Erlotinib 150 mg oral once a day or Gefitinib 250 mg oral once a day or Icotinib 125 mg oral three times a day
1664005|NCT01745276|Device|Biphosfonate|External pins coated by biphosfonate.
1664006|NCT01745263|Drug|Vitamin D3|2000 IU/d
1664007|NCT01745263|Drug|Omega 3 fatty acids|"Ratio EPA:DHA = 1:2
1 g/d"
1664008|NCT01745263|Procedure|Strength Home Exercise|
1664009|NCT01745263|Procedure|Flexibility Home Exercise|
1664010|NCT01745250|Device|Emervel Lips|Lip treatment of both upper and lower lip
1664011|NCT01745250|Device|Juvederm Ultra Smile|Lip treatment of both upper and lower lip
1664012|NCT01745224|Device|Revlite Q switched Nd:YAG|Revlite Q switched Nd:YAG 1064nm
1664013|NCT01745224|Device|Trivantage Q switched Nd: YAG|Trivantage Q switched Nd: YAG 1064nm
1664014|NCT01745211|Device|755nm Alexandrite Laser|755nm Alexandrite laser with modified and standard handpiece
1664015|NCT01745172|Procedure|Carotid body excision|"This surgery does not involve any study drug or investigational device.
The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
1664016|NCT01745159|Drug|tacrolimus|
1664017|NCT01745146|Behavioral|ASMT|8-session, individual, psycho-educational intervention based on principles of self-monitoring and problem-solving training Significant other (friend or relative) invited to participate in 3 of 8 sessions
1664018|NCT01745146|Behavioral|PRE|8-session, individual, psycho-educational intervention based on principles of education and personal readjustment to TBI Significant other (friend or relative) invited to participate in 3 of 8 sessions
1664019|NCT01745133|Drug|vehicle foam|clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
1664020|NCT01745133|Drug|calcipotriene|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks
1664021|NCT01745133|Drug|calcipotriene + clobetasol propionate|clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
1664022|NCT01745120|Genetic|LentiGlobin® BB305 Drug Product|Transplant of autologous hematopoietic stem cells transduced with LentiGlobin® BB305 lentiviral vector.
1664024|NCT01745094|Drug|mirabegron|oral
1664025|NCT01745094|Drug|solifenacin|oral
1664026|NCT01745081|Drug|20% mannitol bolus administration|
1664027|NCT01745081|Drug|Hypertonic saline 3% bolus administration|
1664076|NCT01744678|Behavioral|blue-wavelength enriched ceiling light|Subjects will be in the experimental break room for four 20-minute periods for each Orbit 1 work shift.
1664077|NCT01744678|Behavioral|mild exercise|Subjects will be asked to achieve 65% of maximum heart rate on either a treadmill or exercise cycle for 10-minutes, three times during each Orbit 1 work shift.
1664028|NCT01745068|Other|Integrated program|Each participant's primary care physician will receive written information containing a presumed osteoporosis diagnosis, investigations to be performed, correct interpretation of any bone densitometry results in the context of a fragility fracture, and treatment options. The study coordinator will be responsible for orienting the participant to an appropriate local fall prevention program.
1664029|NCT01745055|Drug|CP-690,550 (tofacitinib)|CP-690,550 30 mg q12h for 5 days
1664030|NCT01745055|Drug|Methotrexate (MTX)|individual dose of methotrexate (stably dosed)
1664031|NCT01745042|Other|Clinical exams|Physiological and biochemical tests; quality of life questionnaire; body composition measurement
1664032|NCT01745029|Device|Motilis-3D-transit|
1664033|NCT01745016|Dietary Supplement|Placebo|
1664034|NCT01745016|Dietary Supplement|Beta-alanine|
1664035|NCT01745003|Procedure|Transcranial Direct Current Stimulation (tDCS)|tDCS is based on the application of a weak direct current to the scalp that flows between two relatively large electrodes—anode and cathode. We will be using this device to investigate fibromyalgia.
1664036|NCT01744990|Other|Oral food challenges to multiple nuts|
1664037|NCT01744977|Behavioral|packaging|Intervention provides usual statin medication dispensed in pre-prepared adherence packaging (blister packaging) rather than the previously received prescription bottles
1664038|NCT01744964|Drug|Apomorphine|1.5 mg Apomorphine
1664039|NCT01744951|Behavioral|ADAPT|"ADAPT consists of the following modules/sessions:
Module 1: Trust, positive coping strategies, and behavior management; Module 2: Developmental understanding of adoption experience; Module 3: Substance abuse prevention; Module 4: Loss and grief issues about birth family and foster care; Module 5: Attachment/joining with adoptive family; Module 6: Search for identity/self -esteem; Module 7: Adoption and the outside world; Module 8: Trauma Treatment (if appropriate)"
1664040|NCT01744938|Procedure|preoperative biliary drainage|percutaneous preoperative biliary drainage guided by CT
1664041|NCT01744925|Drug|Icotinib of routine dose|Icotinib: 125mg, oral administration, three times per day.
1664042|NCT01744925|Drug|Icotinib of high dose|Icotinib: 375mg, oral administration, three times per day.
1954848|NCT03310996|Other|Transcranial direct current stimulation|tDCS is an established research tool for non-invasive modulation of neuroplasticity. It has shown promise as a neurorehabilitation tool and demonstrated positive effects in various clinical conditions such as Alzheimer's, stroke, childhood psychosis, epilepsy and dystonias. tDCS uses low-intensity DC currents to modulate spontaneous neuronal network activity by altering the resting membrane potential.
1954849|NCT03310983|Dietary Supplement|Docosahexaenoic acid|The main study, ADORE, includes providing DHA to participants during pregnancy. No intervention is included as part of this study.
1664045|NCT01744899|Other|Sitting posture|The outcomes were measured while the participants assumed erect, slumped and slouched sitting postures.
1664046|NCT01744886|Procedure|maintain oxygenation during one lung ventilation|"All study patients will be placed on a volume controlled mode of ventilation with the following settings: tidal volume between 5 and 10 ml/kg and FIO2 at 50% and 4 cm H2O PEEP. Respiratory frequency and tidal volume will be adjusted to maintain ETCO2 between 30 and 40 mmHg. ETCO2 levels and SpO2 will be monitored continuously.
If SpO2 declines below 90% the ventilator settings will be adapted according to the following protocol: First the FIO2 is increased to 80%. If this is insufficient FIO2 is increased to 100%. If this remains insufficient 5 cm H2O of CPAP is applied to the non-ventilated lung. If this is still insufficient the surgeon will be asked to allow for temporary recruitment of the non-ventilated lung."
1664047|NCT01744873|Drug|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
1664048|NCT01744873|Drug|Bisoprolol|10 mg tablet once a day
1664049|NCT01744847|Device|Tracer Hybrid® Wire Guides, Tracer Metro® Direct™ Wire Guide|one guide wire insert to the pancreatic duct and other guide wire insert to the Common bilde duct for cannulation
1664050|NCT01744821|Dietary Supplement|Arm A: Vitamin D3 Group|
1664051|NCT01744821|Dietary Supplement|Placebo|
1664052|NCT01744808|Drug|EB-1020 IR|Immediate release
1664053|NCT01744808|Drug|EB-1020 SR1|sustained release
1664054|NCT01744808|Drug|EB-1020 SR2|Sustained release
1664055|NCT01744808|Drug|EB-1020 SR3|Sustained release
1664056|NCT01744808|Other|Placebo|Placebo formulation
1664057|NCT01744795|Other|induced changes in hemodynamics|Twenty-five patients are planned enrolled. After induction of anesthesia, insertion of the PAC and the CardioQ probe, the patient are placed in the following successive positions: a) supine, b) head-down tilt, c) head-up tilt, d) supine, e) supine with phenylephrine administration f) pace heart rate 80 bpm, g) pace heart rate 110 bpm. CO are measured simultaneously using the TEE and thermodilution technique.
1664058|NCT01744782|Drug|RP103 Q12H|
1664059|NCT01744756|Drug|Bevacizumab|One subconjunctival aplication of Bevacizumabe 0,5ml
1954850|NCT03310970|Drug|Lidocaine patch 5%|Each subject will wear three Lidocaine patches for 12 hours.
1664061|NCT01744730|Drug|Clindamycin|Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
1664062|NCT01744717|Other|Pain measurement|"Pain intensity will be measured using 2 scales based on behaviour items, the Behavioural Pain Scale (BPS) and the ESCID scale (Escala de Conductas Indicadoras de Dolor), by two independent observers , when applying two procedures registered as painful (PD) and common in clinical practice, and a non-painful procedure (PND). The measurement will be performed once per each patient and procedure.
The procedures to be studied are the following:
TURNING / POSITIONING (moving side to side or up or down in bed)
ENDOTRACHEAL SUCTIONING (insertion of suction catheter into the endotracheal tube or tracheostomy in order to aspirate secretions)
NON PAINFUL PROCEDURE (Soft friction with gauze cloth on a healthy skin tissue portion, in the outer arm, forearm or anterior tibial area)"
1954851|NCT03310970|Drug|Lidocaine Hydrochloride|Each subject will receive a dose of 0.5 mg/kg intravenously over a period of 5 minutes.
1954852|NCT03310970|Drug|Lidoderm 5 % Topical Patch|Each subject will wear three Lidoderm® patches for 12 hours.
1954853|NCT03310957|Drug|SGN-LIV1A|IV infusion every 3 weeks
1954854|NCT03310957|Drug|Pembrolizumab|IV infusion every 3 weeks
1664075|NCT01744691|Drug|Ibrutinib|All subjects will receive ibrutinib 420 mg (3 x 140-mg capsules) orally once daily.
1664078|NCT01744665|Drug|AMN107|Nilotinib will be provided by the sponsor as the study drug. Nilotinib will be provided as 150 mg capsules. Patients will take nilotinib 300mg twice daily on study and dose modifications to 450mg once daily is permitted per protocol.
1664079|NCT01744652|Drug|Crizotinib|"Arm A Crizotinib dose: 250 mg by mouth twice a day in a 28 day cycle. Crizotinib Expansion dose: 250 mg by mouth twice a day in a 28 day cycle.
Arm B Crizotinib starting dose: 250 mg by mouth every other day in a 28 day cycle. Crizotinib Expansion Dose: MTD from dose escalation group."
1664080|NCT01744652|Drug|Dasatinib|"Arm A Dasatinib starting dose: 50 mg by mouth daily in a 28 day cycle. Arm A Dasatinib Expansion Dose: MTD from dose escalation group.
Arm B Dasatinib dose: 140 mg by mouth daily in a 28 day cycle. Arm B Dasatinib Expansion Dose: 140 mg by mouth daily in a 28 day cycle."
1664081|NCT01744639|Behavioral|HCC under treatment with radioablation|The evaluation will take place over a period of 30 days.
1664082|NCT01744626|Drug|CC-292|Cohort 1: 375 mg CC-292 will be administered twice a day on Days 1-28 Cohort 2: 500 mg CC-292 will be administered twice a day on Days 1-28
1664083|NCT01744626|Drug|Rituximab|Cohort 1: Rituximab once per cycle Cohort 2: Rituximab once per cycle
1664084|NCT01744600|Behavioral|Music Therapy|The music therapy intervention will consist of individual active music therapy session each week for a period of 22 weeks. Each session will last 30 minutes.
1664085|NCT01744587|Other|Epigallocatechin Gallate (EGCG)|EGCG 600 mg per day will be provided to the test group.Four capsules will be taken daily (2# bid) by the test individuals.
1664086|NCT01744587|Dietary Supplement|Placebo|Placebo qd (2# bid) for 3 years
1664087|NCT01744574|Other|Placebo|Placebo - subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
1664088|NCT01744574|Drug|Progesterone|The progesterone will be given in the form of an active micronized natural progesterone (Prometrium). All subjects will take 200 mg twice daily orally (approximately 8am and 8pm) for twelve weeks starting seven days prior to the assigned quit date.
1664089|NCT01744574|Other|Smoking Cessation Behavioral Counseling|Subjects will receive weekly smoking cessation behavioral counseling.
1664091|NCT01744548|Behavioral|tCBT treatment|The UP comprises 4 main treatment components: 1) psychoeducation about emotions and behaviour; 2) changing misappraisals about probabilities and consequences of negative experiences; 3) preventing avoidance of negative emotion triggers; and 4) modifying emotion-driven behaviours (e.g. hypervigilance, withdrawal). The manualised tCBT intervention will be adapted in order to account for a United Kingdom (UK) audience (as the manual was developed in the United States) and older people (as the manual was developed for working-age people).
1664092|NCT01744535|Behavioral|"My Meal Mate (smartphone application)"|"A smartphone application called My Meal Mate (MMM) designed to facilitate weight loss. The app allows system users to set a goal for weight loss and self monitor diet and activity in an electronic diary. Users receive instant nutritional feedback and feedback via text message."
1664093|NCT01744535|Behavioral|Paper food diary|"The paper food diary is provided by a commerical slimming organisation called Weight Loss Resources. The diary allows the user to record daily food and drink consumed. It is accompanied by a book which provides a database of the nutritional content of 40,000 food and drinks. The diary also encourages participants to record their physical activity."
1664094|NCT01744535|Behavioral|Online food diary|"The online food diary is provided by a commerical slimming organisation called Weight Loss Resources. The electronic diary allows the user to record daily food and drink consumed. System users are also encouraged to record their physical activity."
1664095|NCT01744522|Procedure|Leech therapy|Leech therapy: Using medicinal leeches After piercing the skin and injecting anticoagulants (hirudin) and anaesthetics, they suck out blood of the incision. After 30 to 60 minutes they fall off and the wound -after a short time of after-bleeding- is bandaged up.
1664096|NCT01744509|Device|Capsule colonoscopy;|All the enrolled patients underwent all the three study procedures; the colon capsule is the intervention under evaluation; the other 2 procedures (Ct colonography and optcal colonoscopy contribute to build the composite reference standard)
1664097|NCT01744496|Drug|Rotigotine|Patches will contain 4 mg / 24 h (20 cm^2), 6 mg/ 24 h (30 cm^2), or 8 mg /24 h (40 cm^2) of Rotigotine. Application of study medication starts at the Baseline Visit. Rotigotine will be administered once daily starting at 4 mg / 24 h. Doses will then be up-titrated in weekly increments of 2 mg / 24 h until optimal or maximum dose (16 mg / 24 h) is reached and the Maintenance Period can be started. The duration of the Titration Period will vary from 1 to 7 weeks ± 3 days. The Maintenance Period will last 12 weeks ± 5 days. Thereafter, during the De-escalation Period, the dose of study medication will be decreased by 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
1664098|NCT01744496|Drug|Placebo|Placebo patches match the size of active patches 20 cm^2, 30 cm^2, or 40 cm^2 and will contain Placebo. Application of Placebo patches starts at the Baseline Visit. Placebo patches will be administered once daily starting with the equivalent of 4 mg / 24 h. Doses will then be up-titrated in weekly equivalents to 2 mg / 24 h until either optimal dose or maximum dose is reached. The maximum dose is the equivalent to 16 mg / 24 h. The duration of the Titration Period will vary from 1 to 7 weeks. The Maintenance Period will last 12 weeks ± 5 days. During the De-escalation Period, the dose of Placebo will be decreased by the equivalent to 2 mg / 24 h every other day. The De-escalation Period may last up to 12 days.
1664102|NCT01744470|Drug|Tacrolimus targeted half-dose|
1664103|NCT01744470|Drug|Tacrolimus targeted plain dose|
1664104|NCT01744457|Device|Measurement of tear film osmolarity with the TearLab® instrument|
1664105|NCT01744457|Other|Schirmer I test|
1664106|NCT01744457|Other|Tear break up time|
1664108|NCT01744457|Other|Ocular Surface Disease Index|
1664109|NCT01744444|Drug|Memantine|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
1664110|NCT01744444|Drug|Gabapentin|Patients will be randomly assigned to start on either memantine or gabapentin. For tolerance reasons, each treatment begins with a progressive increasing dose and stops with a progressive decreasing dose. The duration of the period of last dose (8 to 11 days) will be chosen according to the investigator's availability to organize post-tests.
1664111|NCT01744418|Device|HAVG graft implantation|Patients will be implanted with a Human Acellular Vascular Graft (HAVG) in the forearm or upper arm (arterial anastomosis to the radial or brachial artery, venous anastomosis to either the brachial, cephalic or very central basilica vein) using standard vascular surgical techniques. The graft will be placed in a straight or curved configuration in the first 10 patients. Loop grafts may be permitted in subsequent patients subject to acceptable graft performance at the interim safety review. Placing the graft across the elbow will be avoided.
1664112|NCT01744392|Behavioral|education intervention|Each patient will receive instructions on how to use the medication calendar to help them adhere to their medication regimen. The Meducation Calendar is developed by the clinical pharmacist participating in the research study). The clinical pharmacist will enter the medication regimen for each participant into the application for Meducation Calendar Development.
1664113|NCT01744379|Drug|Lesinurad|
1664114|NCT01744379|Drug|Placebo|
1664115|NCT01744366|Drug|Degarelix|
1664116|NCT01744366|Drug|Goserelin|
1664117|NCT01744353|Drug|Dose level 1|Abraxane 125 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
1664118|NCT01744353|Drug|Dose level 2/MTD|Abraxane 150 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
1664119|NCT01744353|Drug|Dose level 3|Abraxane 175 mg/m2 day 1, Oxaliplatin 85 mg/m2 day 1, leuocovorin 400 mg/m2 day 1, F-FU infusion 1200 mg/m2 day x 2 days IV infusion
1664120|NCT01744340|Drug|Head and neck|"Eribulin mesylate is administered by IV infusion over 2-5 minutes on day 1 and 8 of a 21 day cycle 1.4mg/m2 and Cetuximab 400 mg/m2 cycle 1 week 1, then 250 mg/m2/weekly thereafter
Dose Level 1: 0.7 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 2: 1.0 mg/m2 IV infusion days 1 and 8 of 21 day cycle Dose Level 3: 1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
1664121|NCT01744340|Drug|Colon- Closed as of May 2014|"Eribulin Mesylate:
1.4 mg/m2 IV infusion days 1 and 8 of 21 day cycle"
1664122|NCT01744314|Drug|Indomethacin and Pantoprazole|
1664123|NCT01744314|Drug|microcrystalline cellulose powder tablets|
1664124|NCT01744301|Drug|Risk of seizure|Patients newly prescribed PPI and H2RA, respectively
1664125|NCT01744288|Drug|Ticagrelor|Oral single loading dose 180ng
1664126|NCT01744288|Drug|Clopidogrel|Oral single loading dose 600mg
1664127|NCT01744288|Drug|ASA|81mg once daily from day -2 up to platelet transfusion
1664128|NCT01744275|Dietary Supplement|Omega 3 fatty acids|
1664129|NCT01744275|Dietary Supplement|corn oil|Placebo
1664130|NCT01744262|Drug|Total intravenous anesthesia|Anesthesia induction with intravenous propofol (effect site concentration 2.5 µg/mL) and remifentanil (effect site concentration 3 ng/mL) using target controlled infusion (TCI). Anesthesia maintenance with propofol effect site concentration 1.5~4 µg/mL and remifentanil effect site concentration 2~5 ng/mL.
1664131|NCT01744262|Drug|Inhalation Anesthesia|Anesthesia induction with intravenous propofol bolus of 1.5~2.5 mg/kg and remifentanil (effect site concentration 3 ng/mL)using target controlled infusion (TCI). Anesthesia maintenance with sevoflurane 1.5~2.0 % and remifentanil effect site concentration 2~5 ng/mL.
1664132|NCT01744249|Drug|Axitinib|Orally, 5mg, twice daily, until progression or until unacceptable toxicity, with or without food intake.
1664133|NCT01744249|Drug|Sandostatin LAR|Intramuscular, 30mg, single injection every 28 days, until disease progression or unacceptable toxicity
1664134|NCT01744249|Drug|Placebo|orally, twice daily, until disease progression or unacceptable toxicity, with or without food intake.
1664135|NCT01744236|Drug|Liraglutide|Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). If liraglutide is well tolerated it will be continued for 10 more weeks in a dosage of 1.8mg once daily.
1664136|NCT01744236|Drug|Sitagliptin|Sitagliptin 100mg will be given once daily for 12 weeks.
1664137|NCT01744236|Drug|Exenatide|Exenatide will be administered intravenously with a loading dose of 50ng/min for 30 minutes, followed by a maintenance dose of 25ng/min during the rest of the tests
1664138|NCT01744236|Drug|Liraglutide placebo|Liraglutide-placebo will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily). It will be continued for 10 more weeks in a dosage of 1.8mg once daily.
1664139|NCT01744236|Drug|Sitagliptin placebo|Sitagliptin-placebo be given once daily for 12 weeks.
1664140|NCT01744236|Drug|Exenatide placebo|Exenatide-placebo (saline) will be administered intravenously
1664141|NCT01744236|Drug|L-NMMA|
1664142|NCT01744223|Biological|BPX-501 and AP1903|"Patients will receive BPX-501 Donor T cells genetically modified with BPZ-1001 retroviral vector containing the iCasp suicide gene after the stem cell graft infusion is complete, but not more than 72 hours after completion of the stem cell allograft infusion.
AP1903: Dimerizer drug administered (per intravenous infusion ) in those subjects who present with severe GvHD (Grades III and IV) as well as those subjects with Grade I and II who progress or do not respond to corticosteroid therapy within 4 days."
1664143|NCT01744197|Device|Synera (lidocaine 70mg/tetracaine 70mg)|All subjects will receive 2 patch applications during this study: one Synera, one placebo. The 2 patch applications must be done on separate days. Only 1 patch will be used per application. Arm 1 subjects will receive Synera patch for the 1st application, and placebo for the second. Arm 2 patients will receive placebo patch for the 1st application, and Synera patch for the second.
1664144|NCT01744184|Drug|Entonox|Entonox arm
1664145|NCT01744184|Drug|Midazolam|up to 5mg midazolam as appropriate
1664649|NCT01740258|Drug|Temozolomide|
1664148|NCT01744158|Other|No intervention applicable|"Following consent, children will undergo a comprehensive assessment performed by a research team including rehabilitation paediatrician and therapist. Hypertonia and abnormal movements will be assessed by a pediatrician with expertise in treating children with movement disorders. The assessments will be performed at a rehabilitation clinic, or child's home, and will include:
differentiation of hypertonia by application of the Hypertonia Assessment Tool-Discriminate (HAT-D)
measurement of severity of dystonia using the Barry Albright dystonia scale, based on video recording
measurement of severity of spasticity using the modified Ashworth score
description of presence of chorea or athetosis
classification of gross motor abilities using the GMFCS and functional mobility scale (FMS)
classification of fine motor abilities using the manual ability classification system (MACS)
collection of demographic data and associated medical history"
1664149|NCT01744145|Other|Interventional 40-60|This group will receive the intervention aged 40-60
1664150|NCT01744145|Other|Interventional 60 and above|This group will receive the intervention aged 60 and above.
1664151|NCT01744132|Behavioral|Aim 3: Contract|
1664152|NCT01744119|Device|Vascutek Anaconda™ Stent Graft System|
1664153|NCT01744106|Drug|pseudoephedrine hydrochloride 30 mg tablets|
1664154|NCT01744106|Drug|Placebo tablets|
1664155|NCT01744093|Drug|Doxycycline|100 mg BID for six months
1664156|NCT01744093|Drug|Placebo (sugar pill)|100 mg BID for six months
1664157|NCT01744080|Other|Regular Wait Time|Surgery will take place no earlier than 9 months and no later than 12 months after the sport medicine physician consult.
1664158|NCT01744080|Other|Early Surgery|Patient will proceed to have rotator cuff repair surgery within 3 months of the initial consult with the sport medicine physician.
1664159|NCT01744067|Drug|Omega-3 fatty acids|2,7 g omega-3 fatty acids / day (1 capsule 3 times a day / oral administration)
1664160|NCT01744067|Drug|Placebo|Placebo capsules 3 times a day (oral administration)
1664161|NCT01744054|Device|PET/MR|
1664162|NCT01744054|Device|PET/CT|
1664163|NCT01744041|Behavioral|Dyadic Interpersonal Psychotherapy|This intervention consists of a brief psychotherapeutic intervention, Interpersonal Psychotherapy, during pregnancy. Interpersonal Psychotherapy focuses on improving social relationships and interpersonal communication to improve mood. The postpartum phase also utilizes developmentally appropriate strategies to improve the mother-infant relationship.
1664164|NCT01744041|Other|Enhanced Treatment as Usual|This intervention consists of personalized referrals to specialty mental health providers, spiritual counselors, or other needed social services. It includes some non-specific supportive techniques delivered primarily via telephone.
1664165|NCT01744028|Device|Remote Patient Monitoring|Remote patient monitoring system including exacerbations of chronic pulmonary disease Tool - Patient Reported Outcome (EXACT PRO), Lung Monitor, and Pulse Oximeter
1664166|NCT01744028|Other|Usual care|Patients in the usual care arm will continue their normally established procedures of nurse/physician contact and evaluation, as is considered standard for each individual practitioner in the study.
1664167|NCT01744015|Behavioral|Patient Decision Making tool|The experimental group will consist of typical care from the physical therapist (as with the control group) with the addition of the patient decision support tool and information dissemination. The process of information dissemination for informed decision making. Based on the literature, we have deemed three points of informational contact as necessary to improve informed decision making. We plan to inform patients through the use of a) pre-material, b) dialogue, and c) reinforcement means.
1664168|NCT01744015|Other|Standard of care|A control group will receive typical care from the physical therapist. Typical care includes physical therapist directed care of patients with low back pain, using standardized treatment algorithms (guideline oriented) for referral to physicians during cases of concern. In this model, a physician is consulted when the physical therapists feel it is necessary; or when directly requested by a patient. Physician consult is not normally provided as an option for the control group, unless evidence exists within the examination to suggest the need from a mutually agreed upon examination scheme including identification of red flags between the PT and physician. In the current model, because most of patients seen are diagnosed with non-specific LBP and do not require imaging or prescriptive medications, a majority are treated actively by the physical therapists-only during the initial visit.
1664169|NCT01744002|Other|Shoulder treatment and neck mobilization|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises; and joint mobilizations to the neck.
1664170|NCT01744002|Other|Control|This group will receive shoulder treatment with an emphasis on 1) range of motion activities, 2) joint mobilization, 3) rotator cuff strengthening and 4) a home exercise program that consists of shoulder strengthening exercises.
1664171|NCT01743989|Drug|Nilotinib|Nilotinib will be provided to patients for at least 24 or 36months. (depending if nilotinib re-initiation is necessary- nilotinib will be provided during nilotinib re-initiation phase)
1664172|NCT01743976|Drug|Donepezil|donepezil 5 mg once daily for 6 weeks
1664173|NCT01743976|Drug|Placebo|placebo or sugar pill will be taken once daily for 6 weeks
1664174|NCT01743963|Behavioral|Decision support|Clinical pharmacists mediated computerized decision support
1664175|NCT01743963|Behavioral|Usual Care|clinicians typical apporach for GID monitering
1664176|NCT01743950|Drug|Bevacizumab|10mg/kg every 2weeks.
1664177|NCT01743950|Radiation|PRDR|daily dose of 2.0gy delivered in .2gy pulses for a total of 54gy over 5.5 weeks and 27 fractions
1664178|NCT01743937|Procedure|Coronary occlusion with balloon inflation|
1664179|NCT01743924|Other|raw broccoli|To eat this plant material
1664180|NCT01743911|Other|sugar pill|Sugar pills: 20mg orally, once a day for 2 weeks
1664181|NCT01743911|Drug|Tadalafil|Tadalafil pills: 20mg orally, once a day for 2 weeks.
1664182|NCT01743898|Drug|Rivaroxaban|Patients will continue on their Rivaroxaban dose as previously prescribed by their individual physician. No dose adjustments will be made for the purpose of this study.
1664183|NCT01743898|Other|no anticoagulation|
1664184|NCT01743885|Drug|Acebutolol|10 mg/kg/jour in 2 doses during 90 days after gradual increase of doses in the first week
1664185|NCT01743885|Drug|Propanolol|3 mg/kg/jour in 3 doses during 90 days after gradual increase of doses in the first week
1664186|NCT01743872|Procedure|iOCT|"Arterial access will performed by the operating surgeon. An aortic and infrainguinal angiogram using the standard method of intravenous iodinated contrast under digital subtraction fluoroscopy will be conducted in the usual manner according to the vascular surgeon. A 54 mm section of Superficial Femoral Artery will be chosen for study imaging. An intervention sheath or injection catheter will be placed just proximal to the area of interest. An 0.014 wire will be passed distal to the area of interest. The patient will then undergo OCT of this 54mm section with each of the three mediums below using a continuous flushing method through injection catheter. All OCT imaging will be collected at a rate of 25mm/sec. In the event of a subsequent procedure, OCT imaging will again be performed."
1664187|NCT01743859|Drug|Azacitidine|Enrolled patients will receive 75 mg/m2 of azacitidine subcutaneously (SC) or intravenously (IV) on days 1-7 alone.
1664188|NCT01743859|Drug|Lenalidomide|Beginning on day 8, patients will receive 50 mg of lenalidomide PO, and will take this daily from day 8 through 28.
1664189|NCT01743859|Other|Off Therapy|2 weeks off therapy, then begin sequence again for 12 weeks.
1664190|NCT01743833|Other|Thoracic High Velocity, Low Amplitude Thrust Maneuver (HVLATM)|
1664191|NCT01743833|Other|Scapular High Velocity, Low Amplitude Thrust Maneuver|
1664192|NCT01743820|Drug|dihydroartemisinin-piperaquine|
1664193|NCT01743820|Drug|0.125 mg/kg Primaquine|
1664194|NCT01743820|Drug|0.5 mg/kg Primaquine|
1664195|NCT01743820|Drug|0.25 mg/kg Primaquine|
1664196|NCT01743820|Drug|0.0625 mg/kg Primaquine|
1664197|NCT01743807|Drug|GNKG168|GNKG168 will be given intravenously over 1 hour on days 1 through 5 followed by 9 days of rest. Dose will be assigned at study entry.
1664198|NCT01743794|Drug|Ropivacaine|wound infusion, 0.2%, bolus 10mL followed by 8 mL/h infusion
1664199|NCT01743794|Drug|Saline solution 0.9%|wound infusion, 0.9%, bolus 10mL followed by 8 mL/h
1664200|NCT01743781|Behavioral|video|view a 10-minute informational video about comprehensive eye examination
1664201|NCT01743768|Drug|SB010|Treatment group (n=19), receiving the active drug substance.
1664202|NCT01743768|Drug|Placebo|Treatment group (n=19), receiving placebo.
1664203|NCT01743755|Drug|Dexamethasone|Dexamethasone tablet 6 mg, once daily for four consecutive days
1664204|NCT01743755|Drug|Placebo|Placebo tablet, once daily for four consecutive days
1664205|NCT01743742|Drug|Vitamin E, Vitamin C|
1664206|NCT01743729|Drug|Lifitegrast|Lifitegrast Ophthalmic Solution 5.0%
1664207|NCT01743729|Drug|Placebo|Placebo for Lifitegrast Ophthalmic Solution 5.0%
1664208|NCT01743703|Other|diagnostic whole body MRI|diagnostic whole body MRI, both STIR and diffusion weighted
1664209|NCT01743690|Biological|Probiotic lactobacilli reuteri|
1664210|NCT01743690|Drug|Nystatin|
1664211|NCT01743690|Drug|fluocinolone|
1954856|NCT03310918|Other|Palliative Care|Specialized medical care for people with serious illness. This type of care is focused on providing relief from the symptoms and stress of a serious illness. The goal is to improve quality of life for both the patient and the family
1954857|NCT03310918|Other|Standard Leukemia care|Standard care per the hospital guideline
1664215|NCT01743664|Behavioral|EMDR|Patients in the experimental group will undergo 10 weekly sessions of 60 minutes each with EMDR following Shapiro's protocol for traumatic events
1664216|NCT01743664|Behavioral|Relaxation|The patients in the control group will undergo 10 weekly relaxation sessions that include diaphragmatic breathing, progressive muscle relaxation, visualization and rapid relaxation.
1664217|NCT01743651|Drug|arbaclofen|10 mg, 15 mg or 20 mg arbaclofen ER tablets administered orally 2 times per day
1664218|NCT01743651|Drug|baclofen|20 mg, 30 mg or 40 mg baclofen administered orally 4 times per day
1664219|NCT01743651|Drug|Placebo|arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
1664220|NCT01743638|Procedure|MR-Guided Laser Ablation|
1664221|NCT01743625|Drug|COV155|COV155 tablets
1664222|NCT01743625|Drug|placebo|
1664223|NCT01743612|Procedure|laser speckle contrast imaging|blood flow recording during 30 minutes after 2 post-occlusive hyperaemia of 5 minutes separated by 30 minutes.
1664224|NCT01743612|Procedure|Cooling|blood flow of the hand recording during 30 minutes in a cooling-box
1664225|NCT01743586|Other|Chest physiotherapy education intervention|breathing exercise (diaphragmatic breathing and pursed-lip breathing cough training secretion mobilization (percussion and vibration) progressive muscle relaxation pacing and energy-saving techniques
1664226|NCT01743573|Other|yoga|
1954858|NCT03310905|Drug|Isolated Abdominal Wall Transplant with Belatacept|18-months of monthly Belatacept infusions following an isolated abdominal wall transplant.
1954859|NCT03310905|Procedure|Abdominal Wall Transplant|Transplant of abdominal wall alone or in combination with another solid organ transplant.
1664229|NCT01743547|Other|Yoga|Patients will be randomized to Yoga or control group. Those in Yoga intervention will receive 8 weekly yoga sessions.
1664230|NCT01743521|Drug|TPV/PEG-IFN/RBV|"Drug Telaprevir (TPV): dosed 1125mg twice daily (given as three 375 mg film-coated tablets) orally, except in the situation where a patient is on efavirenz in which case the dose of telaprevir will be 1125mg three times daily.
Drug Ribavirin (RBV): 1000mg or 1200mg p.o daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg).
Drug PEG-IFN (other name: Pegasys): 180mcg in 0.5ml (pre-filled syringes) administered subcutaneously once weekly."
1664231|NCT01743508|Procedure|Misoprostol treatment by midwife|Misoprostol treatment by midwife
1664232|NCT01743495|Behavioral|10 home-based functional services sessions over 4 months.|The program consists of up to 10 home-based functional services sessions over 4 months.
1664233|NCT01743482|Drug|Pazopanib|
1664650|NCT01740258|Drug|Bevacizumab|
1954860|NCT03310892|Behavioral|Generic message|Generic message
1954861|NCT03310892|Behavioral|Tailored message|Tailored message
1954862|NCT03310879|Drug|Abemaciclib|Abemaciclib is a cyclin-dependent kinase (CDK) inhibitor. CDK inhibitors work to stop cell growth.
1954863|NCT03310866|Device|fiberoptic, airway|classic fiberoptic bronchoscope, fenstrated airway
1954864|NCT03310866|Device|fiberoptic, Machintosh|oral fiberoptic brochoscopic, Machintosh laryngoscope
1664235|NCT01743456|Other|Targeted intra-operative depth of anaesthesia|The intervention group receives isoflurane at a concentration that results in a BIS value between 40-60 intra-operatively.
1664236|NCT01743443|Other|Cochet-Bonnet esthesiometer central corneal sensitivity|Using the Cochet-Bonnet esthesiometer central corneal sensitivity was measured preoperatively, after 7 days, and once a month after surgery until recovery of the baseline preoperative level. Normal levels of central corneal sensitivity were considered above 40mm.
1664237|NCT01743430|Other|telerehabilitation|telerehabilitation for 4 weeks, 2 sessions per week and 30 to 50 minutes per session
1664238|NCT01743417|Behavioral|Computerised cognitive rehabilitation training|24 sessions of computerised bran training will be provided for 8 weeks (+/-2) with about 3 sessions per week to the intervention arm and active control arms. The program will be programmed to increases in difficulty for the intervention arm. In the active control arms, the difficulty level will not change.
1664239|NCT01743404|Dietary Supplement|Inflaminat|
1664240|NCT01743404|Drug|Placebo|Sugar pill manufactured to mimic Inflaminat 500 mg tablet
1664241|NCT01743391|Procedure|Office-hysteroscopy with biopsy|
1664242|NCT01743378|Procedure|TAP Block Ropivacaine 0,75 %|
1664243|NCT01743378|Procedure|TAP Block Saline 0,9 %|
1664245|NCT01743339|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy for Insomnia(4 individual therapy sessions over 5 weeks) will consist of a standard, structured, multi-component CBT intervention (sleep education, sleep hygiene, sleep restriction, stimulus control, cognitive therapy, and relapse prevention) Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions
1664246|NCT01743339|Behavioral|Control|Cognitive Processing Therapy will consist of a standard, structured 12-session protocol (PTSD education, exploring personal impact of trauma, experiencing emotions related to thoughts of trauma, cognitive therapy, and applying healthy thoughts and behaviors) delivered in individual weekly sessions.
1664247|NCT01743326|Procedure|Radio Frequency Denervation|
1664248|NCT01743326|Procedure|Local Anesthesia|
1664249|NCT01743300|Drug|Sunitinib|All patients receive once daily 50 mg sunitinib for 6 weeks in the registered schedule of 4 weeks on two weeks off treatment.
1664250|NCT01743300|Drug|Midazolam|All patients receive three times midazolam 7,5 mg on PK day 1,2, and 3 e.g. between day 14-21 of treatment, on day 28 of treatment and on day 42 of treatment.
1664251|NCT01743300|Other|Orange juice|The orange juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
1664252|NCT01743300|Other|Grapefruit juice|The grapefruit juice will be administered 3 times per day for 1 period of 3 days in the 4th week of treatment with sunitinib, just before PK day 2 on day 28 of treatment
1664253|NCT01743287|Drug|Imotun capsule|Imotun capsule: Avocado-Soya Unsaponifiables 300.03mg/Cap, per oral, a capsule once a day during for 24 weeks
1664254|NCT01743287|Drug|Imotun capsule placebo|Imotun capsule placebo: per oral, a capsule a day during 24 weeks
1664255|NCT01743274|Procedure|OCT|"Optical Coherence Tomography (OCT) is a recent imaging modality that yields cross-sectional images with a resolution 10 times greater than that of intravascular ultrasound (IVUS). OCT uses a near-infra-red light source to obtain images of the interior walls of the coronary arteries and is increasingly used to evaluate vulnerable atherosclerotic plaques and assess placement and response to stenting.
OCT images are acquired by automated pullback over 2 to 3 seconds of the light source that yields a helicoidal image of a longitudinal segment of 50 mm. Intravascular imaging is obtained by injecting contrast medium or saline solution."
1664256|NCT01743261|Other|multidisciplinary intervention|Multidisciplinary intervention Instruments of governance are the diagnostic-therapeutic rehabilitation pathways (DTRP), the Quality system and product standards; Medical care process with result-oriented autonomy Technology support of vital signs.
1664257|NCT01743261|Other|usual care|"specific pathology. access is determined by clinical stability. the instruments of governance are guidelines and consensus and the rehabilitation programme is focused on functional and cognitive areas.
the medical care process is governed by hierarchy. The technology in this model is limited to a specific specialty"
1664258|NCT01743235|Drug|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
1664259|NCT01743235|Drug|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
1664260|NCT01743235|Drug|Buspirone hydrochloride|Solid Oral Dosage. Maximum every other day (on an as needed basis)
1664261|NCT01743222|Genetic|eASC|"First cohort: Intra lymph node injection of 2.5 millions of eASCs suspended in 0.5 ml of HypoThermosol per lymph node, total dose 5 millions of cells.
Second cohort: Intra lymph node injection of 5 millions of eASCs suspended in 0.25 ml of HypoThermosol per lymph node, total dose 10 millions of cells."
1664262|NCT01743222|Drug|Placebo|"First cohort (2 volunteers): injection of 0.25 ml of HypoThermosol (HTS) per lymph node
Second cohort (2 volunteers): injection of 0.5 ml of HypoThermosol (HTS) per lymph node"
1664263|NCT01743183|Device|Threshold|The load adjustment was done weekly by a single examiner.
1664264|NCT01743170|Other|Telemonitoring of self-measured blood pressure|In the intervention group, doctors receive weekly reports via telemonitoring on the self-measured blood pressure
1954867|NCT03310827|Behavioral|Personalized Nutrition|Diet plan based on nutrition-related gene test results
1954871|NCT03310801|Procedure|ACP or Watchman|Left atrial appnedage occlusion using ACP or Watchman
1664268|NCT01743131|Drug|Abatacept|Arm B-investigational prophylaxis with abatacept, a calcineurin inhibitor and methotrexate
1664269|NCT01743131|Drug|placebo|
1664270|NCT01743118|Drug|SPS4251 Ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
1664271|NCT01743118|Drug|Placebo|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments)
1664272|NCT01743118|Drug|Daivonex® ointment|Approximately 200 µl of each TREATMENT will be topically applied per test field (1.1 cm2) once daily during a 12-day treatment period (10 treatments).
1664273|NCT01743105|Procedure|Diaphragm excursion measures 1|A first diaphragm ultrasound study will be carried out by investigator 1. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
1664274|NCT01743105|Procedure|Diaphragm excursion measures 2|A second diaphragm ultrasound study will be carried out immediately after Ultrasound 1, and by investigator 2. The results are blinded between investigators. A Vivid S6 GE Ultrasound will be used, with a phased array cardiac probe.
1664275|NCT01743092|Behavioral|Webinar|Some clients will receive a webinar as part of their treatment.
1664276|NCT01743092|Behavioral|Tutuorial workbook|A work book about their addiciton
1664277|NCT01743079|Drug|Telbivudine|LdT 600mg QD
1664278|NCT01743079|Drug|Lamivudine|LAM 100mg QD
1664279|NCT01743066|Dietary Supplement|Vitamin E|vitamin E (200 IU, caplet) daily orally for 20 weeks
1664280|NCT01743053|Device|Standard Care plus ReCell|
1664281|NCT01743053|Other|Standard Care|
1664282|NCT01743027|Drug|AL-4943A ophthalmic solution|
1664283|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
1664284|NCT01743027|Drug|Olopatadine hydrochloride ophthalmic solution, 0.1%|
1664285|NCT01743027|Drug|AL-4943A ophthalmic solution vehicle|
1664286|NCT01743014|Drug|Ramipril|Patients will receive 10 mg ramipril throughout the study. Each dose will be taken orally once daily. The duration of treatment with ramipril is 26 weeks
1664287|NCT01743014|Drug|Clopidogrel|12 weeks treatment with ramipril 10 mg and clopidogrel 75 mg once daily followed by a 2 week wash out period for clopidogrel and subsequently additional 12 weeks treatment wit both drugs after cross over.
1664288|NCT01743001|Drug|Macitentan 10 mg|Macitentan 10 mg oral tablet once daily
1664289|NCT01743001|Drug|Placebo|Macitentan-matching placebo oral tablet once daily
1664290|NCT01742988|Drug|CUDC-907|CUDC-907 administered orally with meals.
1664291|NCT01742975|Device|IFABOND (TM)|The synthetic adhesive solution Ifabond, will be applied at the end of conventional breast cancer surgery for arm A patients
1664292|NCT01742962|Procedure|Radical prostatectomy for prostate cancer|Prior treatment with open or robot assisted laparoscopic prostatectomy.
1664294|NCT01742936|Device|CoaguChek|Hand held coagulation monitor.
1664295|NCT01742936|Other|Hospital Laboratory|Coagulation testing done by hospital laboratory.
1664296|NCT01742923|Behavioral|Complex tailored intervention|
1664297|NCT01742923|Behavioral|Usual care|
1664298|NCT01742910|Procedure|intraocular lens implantation|
1664299|NCT01742897|Drug|TTS-fentanyl|
1664300|NCT01742884|Other|Thealoz|Instillation of 1 drop of Thealoz
1664301|NCT01742884|Other|Vehicle|1 drop of the vehicle will be instillated in the eye
1664302|NCT01742845|Other|Ultrasound-guided administration of ropivacaine 4.75 mg/ml|
1664303|NCT01742845|Other|landmark based superfical ropivacaine 4.75 mg/ml injection|
1664304|NCT01742832|Drug|Vilazodone|A fixed dose titration (with doses ranging from 10mg to 40mg/day) will be used. Subjects will take 10mg/day for 1 week, 20mg/day for 1 week and then 40mg/day.
1664305|NCT01742832|Drug|Citalopram|For those assigned to citalopram, the dose of citalopram will be maximized to 40mg/day. For those assigned to vilazodone, their citalopram dose will be maintained at 20mg/day for 1 week, then reduced to 10mg/day for 1 week, then switched to vilazodone 10mg/day.
1664306|NCT01742806|Device|bio-absorbable felt(NEOVEIL®)|To cover bio-absorbable felt over the lymphadenectomy area (hepatoduodenal ligament, #5 and 12/gastroduodenal artery, #6/ pancreas head /suprapancreatic area, #7,8 and 9)
1664307|NCT01742793|Drug|lenalidomide (Revlimid) and romidepsin (Istodax)|
1664309|NCT01742767|Drug|Cisplatinum|
1664310|NCT01742767|Drug|Pemetrexed|
1664311|NCT01742754|Other|Fecal Microbiota Transplantation|Fecal microbiota transplantation by colonoscopic administration of 300cc of fecal slurry from healthy donor to the right colon.
1664312|NCT01742741|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
1664313|NCT01742715|Other|PEEP by Best oxygenation|"Set PEEP at 25 cmH2O with fixed driving pressure that will result in delivery of a fixed Tidal Volume (TV) of 6ml/kg (IBW). FiO2 is set to 60%.
Then decrease PEEP in steps of 4 cmH2O every 10 min until PEEP of 5 cm H2O is reached. In each step static compliance of respiratory system and lung compliance will be measured along with ABGs, and hemodynamic parameters such as cardiac output and mixed venous O2 saturation. Best or optimal PEEP will be defined as the PEEP below which PaO2 /FIO2 falls by at least 20%. If at least 20% PaO2 /FIO2 decrement is not obtained, then PEEP that will result in the highest PaO2 will be selected."
1664314|NCT01742715|Other|PEEP by Best Compliance|"In this group assessment begins with measuring intrinsic PEEP by an expiratory hold. Thereafter, plateau pressures will be recorded after a 0.5-sec inspiratory pause.
Applied PEEP will be increased by steps of 4 cm H2O, after each incremental step the patient will be observed for 10 minutes to allow for lung unit recruitment and equilibration. Plateau pressure will be measured after each incremental step of PEEP. Applied PEEP will be increased sequentially by 4 cm H2O increments until peak inspiratory pressure of 50 cm H2O, or plateau pressure of 40 cm H2O reached, or hypotension or decrease of 20% in cardiac output is observed."
1720576|NCT00003199|Drug|melphalan|Given IV
1664315|NCT01742715|Other|PEEP by Esophageal pressure|Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiratory pressure of not more than 5 cm H2O.
1664316|NCT01742702|Drug|Nitroglycerin 0.25 mg (single dose)|From the beginning of the study until the end of year 2016 a single dose of sublingual nitroglycerin was given to examine the associated acute haemodynamic effects (recordings completed).
1664317|NCT01742702|Drug|Salbutamol 400 µg (single dose)|From the beginning of the study until the end of year 2016 a 400 µg dose of inhaled salbutamol was given to examine the associated acute haemodynamic effects (recordings completed).
1664318|NCT01742702|Drug|L-arginine (10 min infusion)|From the beginning of the study until the end of year 2016 L-arginine infusion 10 mg/kg/min could be given for 10 minutes to examine acute haemodynamic effects (recordings completed).
1664319|NCT01742702|Dietary Supplement|Liquorice (2 weeks, glycyrrhizin 290-370 mg daily)|Daily liquorice intake (daily glycyrrhizin dose 290-370 mg) for two weeks, measurements before and after intervention (recordings completed).
1664320|NCT01742702|Dietary Supplement|Small milk casein-derived polypeptides (12 weeks daily)|Daily intake of yoghurt containing small milk casein-derived polypeptides (12 weeks) and placebo yoghurt (12 weeks), measurements before and after intervention (recordings completed).
1664321|NCT01742702|Drug|Bisoprolol (5mg daily for 3 weeks)|Bisoprolol 5 mg daily for 3 weeks and placebo tablet daily for 3 weeks, double-blind, randomized, placebo-controlled cross-over protocol. Measurements before and after interventions (recordings completed).
1664322|NCT01742689|Drug|Desmopressin intranasal spray|10 microgram per puff, 40 microgram is Descript
1664323|NCT01742689|Drug|Placebo intranasal spray|Saline spray identical to desmopressin, administered as 4 sprays
1664324|NCT01742689|Drug|Indomethacin suppository|Indomethacin suppository 100 milligram single dose
1664325|NCT01742676|Drug|ADVAGRAF|oral
1664326|NCT01742676|Drug|PROGRAF|oral
1664327|NCT01742663|Drug|Diclofenac Sodium Gel 3%|Diclofenac Sodium Gel 3% (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
1664328|NCT01742663|Drug|Solaraze® (diclofenac sodium) Gel 3%|Solaraze® (diclofenac sodium) Gel 3% (Fougera Pharms)applied twice daily for 60 days.
1664329|NCT01742663|Drug|Vehicle Topical Gel|Vehicle Topical Gel (Taro Pharmaceuticals Inc.) applied twice daily for 60 days.
1664330|NCT01742650|Procedure|Screw fixation|3,5mm fully threaded cortical screw transfixation of syndesmosis
1664331|NCT01742650|Procedure|TightRope|TightRope transfixation of syndesmosis
1664332|NCT01742637|Drug|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%|Adapalene and Benzoyl Peroxide Gel 0.1%/2.5% (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
1664333|NCT01742637|Drug|Epiduo® Gel|Epiduo® (Adapalene and Benzoyl Peroxide Gel 0.1%/2.5%) (Galderma Laboratories, L.P.)applied topically once daily for 84 consecutive days.
1664334|NCT01742637|Drug|Placebo|Placebo (vehicle of test product) (Taro Pharmaceuticals Inc.)applied topically once daily for 84 consecutive days.
1664335|NCT01742624|Drug|Advagraf|oral
1664336|NCT01742624|Drug|Prograf|oral
1664337|NCT01742624|Drug|Corticosteroid|oral
1664338|NCT01742624|Drug|Mycophenolate mofetil|oral
1664339|NCT01742611|Drug|ASP1585|oral
1664340|NCT01742598|Device|Portico Transapical Aortic Valve System|
1664341|NCT01742585|Drug|ASP1585|oral
1664342|NCT01742585|Drug|placebo|oral
1664343|NCT01742572|Behavioral|Diet|Change in dietary intake
1664344|NCT01742559|Procedure|Anterior middle superior alveolar|The AMSA technique is performed according to Friedman & Hochman (1997). The needle is introduced with the bevel towards the palate tissue with a 45 ° angle and axially rotated (45° clockwise/45° counterclockwise) and 0.6 ml of the anesthetic was slowly infiltrated for 1 minute. In the control group a supraperiosteal infiltration (infiltrative) at the bottom of the vestibule is performed for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the periodontal procedure.
1664345|NCT01742559|Procedure|Supraperiosteal technique|The supraperiosteal technique is performed at the bottom of the vestibule for one minute and 1.8 ml of anesthetic solution is administrated. This amount of anesthetic is divided into doses of 0.6 ml infiltrated, respectively, in the region of the incisors, canines and premolars. After the anesthetic technique, two minutes would be expected for the beginning of the scaling and root planning procedure.
1664346|NCT01742546|Device|Therapeutic ultrasound combine TENS|"Use ultrasound treatment parameters as continuous mode, 1 MHz in frequency and 1 w/cm2 for intensity and circular stroking of sound head over affected upper trapezius muscle throughout treatment period. For simultaneous TENS parameters as pulse frequency 100-150 pps, pulse duration 50- 80 µs and adjust amplitude as produce tingling for 10 minutes. The skin electrode should be placed near the active trigger in area of trapezius muscle. And the control group received sham TENS by turn-off electrical current.
The therapeutic ultrasound machine in this study was Sonopuls 492 TM (Enraf-Nonius)."
1664347|NCT01742533|Biological|human umbilical cord mesenchymal stem cells|
1664348|NCT01742533|Biological|hUCMSCs and hCBMNCs|
1664349|NCT01742533|Biological|human cord blood mononuclear cells|
1664350|NCT01742533|Drug|Hormone Replacement Therapy|
1664351|NCT01742520|Drug|multiple doses of sucrose|unlimited number of doses par day- current status in our NICU
1664352|NCT01742520|Drug|Formula or breast milk|1-3 minutes prior to every painful procedure, breast milk or formula 0.5-1 ml will be given on the anterior part of the tongue
1664353|NCT01742507|Device|Resolute Integrity Stent|Resolute Integrity Stent
1664354|NCT01742507|Device|Biomatrix stent|Biomatrix stent
1664355|NCT01742494|Procedure|Water-jet POEM|Water-jet assisted POEM procedure was performed
1664356|NCT01742494|Procedure|Conventional POEM|POEM were performed by the use of conventional technique using injection and triangle tip knife.
1664651|NCT01740245|Device|Chlorhexidine vaginal suppositories|
1664357|NCT01742481|Behavioral|Education and empowerment|Three group sessions delivered once per week over three weeks. Education on late effects of treatment, survivorship care, how to request medical records, and role playing on how to talk to a provider about childhood cancer health risks
1664358|NCT01742468|Dietary Supplement|long-chain n-3 PUFA|Dietary supplement: n-3 LC-PUFA = Microalgae oil (Schizochytrium sp., Maris DHA oil, no. 3790, IOI, Hamburg, Germany (rich in docosahexaenoic acid (DHA)); Dosage: 8 g oil per day = 2.11 g DHA per day; Dosage form: included in 60 g sausage, 8 g tomato spread, 30 g milk powder
1664359|NCT01742468|Dietary Supplement|sunflower oil|Dietary supplement: sunflower oil Name: sunflower oil (PPM, Magdeburg, Germany); Dosage: 8 g per day; Dosage form: 8g oil was included in 60 g sausage, 8 g tomato spread, 30 g milk powder
1664360|NCT01742429|Drug|Proton pump inhibitor|
1664361|NCT01742429|Drug|Bismuth subsalicylate|
1664362|NCT01742429|Drug|Metronidazole|antibiotic
1664363|NCT01742429|Drug|Tetracycline|antibiotic
1664364|NCT01742429|Drug|Amoxicillin|antibiotic
1664365|NCT01742429|Drug|Levofloxacin|antibiotic
1664366|NCT01742416|Procedure|Ultrasound|Arterial cannulation facilitated by ultrasound.
1664367|NCT01742416|Procedure|Palpation Method|Arterial cannulation by palpation method.
1664368|NCT01742403|Radiation|R/T gating kV intrafraction monitoring|This is a Phase I Pilot study to assess the feasibility of implementing prostate radiotherapy gating using kV intrafraction monitoring.
1664369|NCT01742390|Drug|Aripiprazole|Plateau switch to aripiprazole (ARI) from risperidone (RIS) or paliperidone (PALI)
1664370|NCT01742390|Drug|risperidone or paliperidone|
1664371|NCT01742377|Procedure|Patients with GerdQ positive|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
1664372|NCT01742377|Procedure|Patients with GerdQ negative|Patients done GerdQ questionnaire, then undergone EGD. The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ). All patients had pH monitoring study within 1 week after the endoscopy.
1664373|NCT01742377|Procedure|Normal volunteers|Normal volunteers undergone EGD.The distal esophagus was examined by HD and followed by SE with a preset TE mode for esophagus ( TE-e mode ).
1664374|NCT01742364|Device|Bioject ID Pen|Participants in this arm will receive a standard dose of BCG via the Bioject ID needle-free jet injector device (investigational administration technique).
1664375|NCT01742364|Device|Needle and syringe|Participants in this arm will receive a standard dose of BCG via syringe and needle by the Mantoux technique (standard of care administration technique).
1664376|NCT01742351|Behavioral|Guided internet-based cognitive behavior therapy|
1664377|NCT01742338|Drug|Low Dose Corticosteroids|
1664378|NCT01742338|Drug|High Dose Corticosteroids|
1664379|NCT01742325|Behavioral|walking|two 20-minute sessions of walking around the nurse's station daily, five days a cycle
1664380|NCT01742312|Radiation|DEXA scan|all patients will undertake a full body DEXA scan before and after chemotherapy
1664381|NCT01742312|Procedure|Muscle biopsy|All patients will have a muscle biopsy before and after chemotherapy
1664382|NCT01742312|Other|cardio-pulmonary exercise testing (CPEX)|patients will undertake exercise in the form of an exercise bike whilst having their cardiac and ventilatory performance analysed. This will take place before and after neoadjuvant chemotherapy
1664383|NCT01742299|Drug|STI571|STI571 (imatinib mesylate)
1954872|NCT03310775|Behavioral|Parent-assisted social skills training program for young adult with ASD|The subjects will participate in the treatment program weekly for a total of 16 weeks. The final visit will be made at the point four months after the completion of treatment to see long-term effects.
1664386|NCT01742260|Procedure|Repair of cranial defects by tissue engineering|Repair of defect using mesenchymal stromal cells seeded between moulded bioceramic plates
1664387|NCT01742247|Other|Physiogel|Application of moisturizer on laser-treated area
1664388|NCT01742247|Other|Moisturizer|Application of moisturizer on laser-treated area
1664389|NCT01742234|Procedure|Organ Donation|People in this study will donate either a lung or kidney
1664390|NCT01742221|Biological|HemaMax|Placebo
1664391|NCT01742208|Drug|LX4211|Subjects will receive LX4211 once daily for 29 days
1664392|NCT01742208|Drug|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 29 days
1664393|NCT01742208|Drug|LX4211|Subjects will receive LX4211 once daily for 29 days; pioneer subjects will complete dosing prior to dosing any other study subjects.
1664394|NCT01742195|Procedure|Oral EBUS insertion|
1664395|NCT01742195|Procedure|Nasal EBUS insertion|
1664396|NCT01742182|Other|Light exposure|
1664397|NCT01742169|Behavioral|Outreach and Reminder Intervention|This intervention includes (1) phone calls and text messages to inform participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
1664398|NCT01742143|Behavioral|The Integrated Cancer Care Access Network (ICCAN)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed. Plus Initial needs assessment. Assistance with high priority social and economic needs.Monthly follow-up with ICCAN Access Facilitator to address ongoing needs in addition to as-needed assistance."
1664399|NCT01742143|Behavioral|Usual and Customary Group (U&C)|"Patients will receive written materials on social and economic resources and services. Treatment Outcomes Survey at Intake, 3 mo, 6 mo, and 1 year.
Chart review at 3 mo, 6 mo and 1 year, and as needed."
1664400|NCT01742130|Drug|sodium bicarbonate solution|
1664401|NCT01742130|Drug|Isotonic saline|
1954873|NCT03310762|Other|Alma Sana Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
1664652|NCT01740245|Device|Polyhexamethylene biguanide vaginal suppositories|
1954874|NCT03310762|Other|Simple Silicon Bracelet|Every time a child receives a vaccine, vaccinators will hole punchers to perforate shapes denoting the particular vaccine a child has received.
1954875|NCT03310749|Drug|Gemigliptin|A 7-day treatment period with gemigliptin 50 mg q.d., followed by a 5-day washout period; a 7 day treatment period with metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day
1954876|NCT03310749|Drug|Gemigliptin 50 mg q.d. + metformin 1000 mg twice a day|A 7-day treatment period with gemigliptin 50 mg q.d. + metformin 1000 mg twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d. followed by a 5-day washout period and a final 7-day treatment period with metformin 1000 mg twice a day
1664413|NCT01742065|Other|Auto Plus|Clinics randomized to the Auto-Plus arm will engage in all activities in the Auto arm (send an introductory letter to participants, then a FIT Kit, then a reminder letter encouraging the return of the FIT Kit) in addition to one other outreach effort.
1664414|NCT01742052|Drug|MT-1303-Low|
1664415|NCT01742052|Drug|MT-1303-Middle|
1664416|NCT01742052|Drug|MT-1303-High|
1664417|NCT01742052|Drug|Placebo|
1664418|NCT01742026|Procedure|Aspergillus PCR technique|Aspergillus DNA PCR technique
1664419|NCT01742026|Procedure|Aspergillus AGA technique|Aspergillus AGA technique
1664420|NCT01742013|Drug|GCJBP Laennec Inj.|Test drug
1664421|NCT01742013|Drug|Placebo|Comparator
1664422|NCT01742000|Dietary Supplement|Karinat|
1664423|NCT01742000|Drug|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
1664424|NCT01741987|Other|Optive ®|instilation of 1 drop each eye 4 times per day
1664425|NCT01741987|Other|Fresh Tears ®|instilation of eye drop 4 times a day (qid)
1664426|NCT01741974|Dietary Supplement|Karinat|
1664427|NCT01741974|Drug|Placebo|Sugar pill manufactured to mimic Karinat 500 mg tablet
1664428|NCT01741961|Procedure|Ahmed valve|The flexible plate 7 (FP7) model (New World Medical) was implanted in patients with uncontrolled glaucoma.
1664429|NCT01741948|Drug|Hormonal contraceptive|"The study will follow patients who are first time users of HCs for a full year after initiation. Patients will be followed every 3 months via questionnaires, blood examinations, and gynecologic examination, in case dyspareunia evolves.
First appointment (before initiation of HCs):
Questionnaire FSFI (Female Sexual Function Index) questionnaire. Blood collection for hormones levels and extraction of mononuclear blood cells. A gynecologic exam intended to rule out existing problem which causing dyspareunia.
3,6,9,and 12 months after initiation of HCs or anytime if a patient has dyspareunia:
Questionnaire evaluating possible influence of HCs use (dyspareunia, lubrication and libido).
FSFI questionnaire. Blood collection Gynecologic examination, designated to assess the cause of pain, including assessment of vestibular tenderness, muscle tightness and tenderness, pressure-pain thresholds measurement using vulvar algesiometer, pH measurement and vaginal swab for microscopy."
1664430|NCT01741922|Drug|ASA evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
1664431|NCT01741922|Drug|Acetylsalicylic morning|Patients will be assigned in a blind and randomized way to one of two parallel groups: group I with the control treatment during the first two months, namely, administration of aspirin 100 mg, in the morning and placebo in the evening and group II initially receiving the intervention, of administration of aspirin 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups, i.e., patients randomly allocated to group I, so having taken aspirin in the morning and placebo in the evening, will now receive the intervention treatment, namely, administration of ASA in the evening and placebo in the morning for another two months and vice verse.
1664432|NCT01741922|Drug|Placebos morning|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
1664433|NCT01741922|Drug|Placebo evening|Patients will be assigned to one of two parallel groups: Active comparator group during the first two months, namely, administration of acetylsalicylic acid 100 mg, in the morning and placebo in the evening and Experimental: Acetylsalicylic acid in the evening & placebo in the morning group, of administration of acetylsalicylic acid 100 mg in the evening, between (20.00 and 22.00 hours) and placebo in the morning. After that, patients will then undergo a washout period of 15 days to one month, during which all patients participating in the study will take their ASA doses during the daytime. After the washout period, participants will exchange groups
1664434|NCT01741909|Behavioral|education|after a baseline period, shorter intravenous treatment will be promoted by mail, posters, lectures, and pharmacy monitoring of treatment
1664435|NCT01741896|Procedure|Remote ischaemic preconditioning|The intervention is 4 cycles of upper limb ischaemic preconditioning. Each cycle consists of 5 minutes of blood pressure cuff induced ischaemia with 3 minutes of reperfusion. The ischaemic stimulus is induced by inflation of the cuff to 15mmHg above systolic pressure. The reperfusion stimulus is induced by cuff deflation. The RIPC stimulus is commenced at between 30-40 minutes prior to the administration of the IV contrast.
1664480|NCT01741532|Drug|Deferiprone oral solution|Deferiprone oral solution will be given twice daily for 18 months. Dose will be escalated every 6 weeks starting at 5mg/kg, and increasing to 10mg/kg and finally 15 mg/kg.
1664653|NCT01740232|Procedure|trephination|Artroscopic meniskal repair with trephination.
1720770|NCT00002676|Drug|dexamethasone|
1664436|NCT01741883|Behavioral|Side effect prevention training (SEPT)|SEPT is aimed to optimize patients' response expectations before the start of pharmacotherapy to prevent nocebo side effects during adjuvant endocrine treatment. SEPT is a three session cognitive-behavioural training. It includes psychoeducation about AET to provide a realistic view on AET, reduction of concerns about side effects and strengthening of necessity beliefs. Further contents are side effect management training and problem solving to enhance self-efficacy expectations about coping as well as imagination training to integrate positive aspects of medication into daily life.
1664437|NCT01741883|Behavioral|Attention Control group (ACG)|Supportive therapy includes common or unspecific factors such as elicitation of affect, a treatment context, empathy, reflective listening, and feeling understood. Supportive therapy thus provides a control condition for common factors and therapist attention, while lacking the specific intervention part. It will be delivered in the same frequency and at the same time points as the side effect prevention training (three individual sessions and three booster telephone calls).
1664438|NCT01741870|Dietary Supplement|Nutritional supplement|Subjects will receive 50 g/day of a soy protein-based nutritional supplement containing 9.5 g protein, 250 kcal energy and all essential micronutrients
1664439|NCT01741857|Biological|human umbilical cord derived MSC transplantation for SLE|
1664440|NCT01741844|Drug|No intervention|This is an observational study. Etravirine 200 mg will be adminstered twice daily in patients with Acquired Immune Deficiency Syndrome (AIDS).
1664441|NCT01741831|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally for a period of 24 weeks. For treatment naive (never received treatment for AIDS) patients: Darunavir 800 mg will be adminstered along with ritonavir 100 mg once daily. For experienced patients: Darunavir 600 mg will be administered along with ritonavir 100 mg twice daily.
1664442|NCT01741818|Other|Measuring IVC collapsibility index by bedside ultrasonography|
1664443|NCT01741805|Other|Severe Asthma|Demographic data, Spirometry, induced sputum, IgE, Aspergillus specific IgE
1664444|NCT01741792|Drug|Blinatumomab|Administered by continuous intravenous infusion over 8 weeks in the first cycle and 4 weeks in the second cycle.
1664445|NCT01741779|Other|Whole Body Vibration Training|The Whole body vibration training intervention consists of lower-body exercise in a vibration platform 3 times per wk for 12 wk. The subjects will perform static and dynamic exercises for the legs on the vibration platform. Dynamic exercises will be performed with slow controlled movements starting from an upright position into a 60 degree knee flexion (squat) and maximal heel elevation (toestand). Static exercises will be performed without movement in the joint angles described previously. The training volume will increase progressively over the 12-week training period by increasing the intensity of vibration, duration of the exercise set (30-60 sec), number of sets per exercise, and total duration of the training session, and decreasing the duration of rest periods (30-60 sec).The intensity of vibration and amplitude will also be increased progressively (25-30 Hz of frequency and from low to high amplitude).
1664446|NCT01741779|Other|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
1664447|NCT01741779|Other|Whole body vibration training & diet|Combination of whole body vibration training and hypocaloric diet
1664448|NCT01741766|Other|Stretching Training|The stretching training intervention consists of 38 whole-body stretching exercises, 3 times per week for 8 wk. Each stretch will be held in place for 30 seconds, with a 15 seconds of rest in between stretches.
1664449|NCT01741753|Drug|BKM120|Orally, every morning
1664450|NCT01741753|Drug|Abiraterone|Orally, 1000 mg, every morning
1664451|NCT01741753|Drug|Prednisone|Orally, 5 mg, every morning
1664452|NCT01741727|Drug|ABT-414|ABT-414 will be administered by intravenous infusion.
1664453|NCT01741714|Other|Sham chiropractic manipulative therapy|Sham manipulation
1664454|NCT01741714|Other|Chiropractic spinal manipulative therapy|Chiropractic spinal manipulative therapy
1664455|NCT01741701|Drug|Oxaloacetate (OAA)|
1664456|NCT01741701|Drug|Placebo|
1664457|NCT01741688|Biological|Tocilizumab|Tocilizumab was administered according to the local label.
1664458|NCT01741675|Behavioral|Questionnaire and monetary incentive|
1664459|NCT01741675|Behavioral|Questionnaire only|
1664460|NCT01741662|Other|neuropsychological evaluation|
1664461|NCT01741649|Procedure|Clorhexidine|Cleaning of the surgical site previous to the incision with a clorhexidine solution for five minutes.
1664462|NCT01741649|Procedure|Povidone|Cleaning of the surgical site previous to the incision with a povidone solution for five minutes.
1664463|NCT01741636|Other|educational intervention|Undergo Survivorship Care Planning
1664464|NCT01741636|Other|questionnaire administration|Ancillary studies
1664465|NCT01741636|Procedure|quality-of-life assessment|Ancillary studies
1664466|NCT01741623|Drug|Bisoprolol Fumarate Tablet 10 mg|10 mg tablet once a day
1664467|NCT01741623|Drug|Bisoprolol|10 mg tablet once a day
1664468|NCT01741610|Biological|Cristalloid and colloid coloading|Cristalloid coloading (Group L) Colloid coloading (Group C) No coloading (Group E)Placebo Comparator
1664469|NCT01741597|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
1664470|NCT01741597|Other|pharmacological study|Correlative studies
1664471|NCT01741597|Biological|tumor-homing peptide iRGD|Undergo tumor-homing peptide iRGD DCE-MRI
1664472|NCT01741584|Behavioral|stationary bike exercise|
1664473|NCT01741584|Behavioral|aerobic|
1664474|NCT01741571|Device|EBUS guided FNA with and without suction|"Device/procedure: lymph node tissue collection using needle with and without suction applied.
Four fine needle aspirations will be taken from each lymph node. Two with suction and two without suction applied."
1664475|NCT01741558|Drug|Methotrexate|The treatment group will receive a bolus dose of 0.05 mg/kg of methotrexate before primary angioplasty followed by 0.05 mg/kg per hour for 6 hours
1664476|NCT01741558|Drug|Riboflavin|We use riboflavin in placebo group to remain the double-blind fashion: methotrexate has a yellow color and riboflavin in that concentration has the same color.
1664477|NCT01741545|Biological|Pegylated-Interferon-lambda|
1664478|NCT01741545|Drug|Ribavirin|
1664479|NCT01741545|Drug|Daclatasvir|
1664481|NCT01741532|Drug|Placebo oral solution|Placebo oral solution will be given twice daily for 18 months. Dose will be escalated every 6 weeks starting at 5mg/kg, and increasing to 10mg/kg and finally 15 mg/kg.
1664482|NCT01741519|Drug|LDLL600|Comparison of 3 different doses LDLL600 in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
1664483|NCT01741519|Drug|Brevibloc|Comparison of 3 different doses Esmolol in long-term infusion. 54 PK samples, BP and ECG measurement time points, several local tolerability measurement time points.
1664484|NCT01741506|Drug|Dalteparin (Fragmin®)|
1664485|NCT01741493|Drug|ABT-494|Oral administration of ABT-494 capsules
1664486|NCT01741493|Drug|Placebo|Oral administration of placebo capsules
1664487|NCT01741493|Drug|Tofacitinib|Oral administration
1954877|NCT03310749|Drug|Metformin|A 7-day treatment period with 1000 mg metformin twice a day followed by a 5-day washout period; a 7-day treatment period with gemigliptin 50 mg q.d.+ metformin 1000 mg twice a day followed by a 5-day washout period and a final 7-day treatment period with gemigliptin 50 mg q.d.
1954878|NCT03310736|Diagnostic Test|Intrinsic Hepcidin IDx™ Test|ILS scientists developed the bioanalytical method for quantitation of human serum hepcidin using a Beckman FX automated liquid handling platform. The method uses a competitive ELISA format that has a proprietary sensitive and specific monoclonal antibody to hepcidin that captures native hepcidin in a sample. During the reaction a competition between a synthetic, bioactive, biotinylated hepcidin tracer and native hepcidin occurs. Bound biotinylated tracer is detected with a streptavidin-HRP conjugate and TMB substrate. Quantitation is based on an eight-point standard curve using validated, synthetic hepcidin calibrators. The standard curve and the hepcidin concentrations of patients samples are calculated using 4-parameter logistic curve fitting (Prism; Graphpad, Inc., La Jolla, CA). Serum hepcidin concentrations are expressed in ng/ml serum.
1664490|NCT01741467|Behavioral|RT-CGM|Dexcom Seven+
1664491|NCT01741454|Drug|Tamsulosin|0.4 mg by mouth once per day.
1664492|NCT01741454|Drug|Tolterodine ER|4 mg by mouth once a day.
1664493|NCT01741441|Procedure|laparoscopic total fundoplication|LTF was performed using a standard five-trocar technique in all cases and carried out by two expert surgeons who had previously performed more than 50 laparoscopic fundoplications. A floppy 360° total fundoplication of 2-2,5 cm was constructed after full esophageal mobilization and posterior crural repair with nonabsorbable sutures.
1664494|NCT01741428|Behavioral|Intervention (INT1)|"The course Program at the Feiring Heart Clinic will:
Clinical examination and ergospirometric testing, optimizing both treatment and prophylactic medication. Promoting physical Activity, changes in lifestyle, dietary changes/weight reduction, smoking cessation. In the follow-up period the participants will be contacted and report regularly through a web-based secure program (MedAxess)(such as: Activity-, dietary- and smoking habits). Each participant will have their own Mentor, helping keeping up the motivation. They will also meet regularly at the local doctors Office which reports relevant parameters to the Project (such as weight, BP, Lipoproteins, blood glucose/HbA1C)"
1664495|NCT01741415|Behavioral|Skills for Improving Distress Intolerance|
1664496|NCT01741402|Device|Virtual Reality Training|The participants of the study trained 10 balance games during 14 sessions
1664497|NCT01741402|Other|Physical Therapy|Patients of the control group was trained with balance exercises.
1664499|NCT01741376|Drug|Progesterone|Progesterone 200 mg twice daily
1664500|NCT01741376|Drug|Placebo|
1664506|NCT01741350|Behavioral|Community-friendly Health Recovery Program|Four weekly HIV risk-reduction groups and routine clinical services (i.e., daily methadone and case management).
1664507|NCT01741350|Behavioral|Time-and-Attention-Matched Control Condition|Four weekly support groups and routine clinical services (i.e., daily methadone and case management).
1664508|NCT01741337|Procedure|Adaptive servo-ventilation post-operative treatment for 6 months|
1664509|NCT01741324|Dietary Supplement|Vitamin D 25 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
1664510|NCT01741324|Dietary Supplement|Vitamin D 10 microg/d|The vitamin D supplement will be provided as a milk drink taken daily.
1664511|NCT01741324|Dietary Supplement|No extra vitamin D|Milk drink with no extra vitamin D (placebo)
1664512|NCT01741311|Behavioral|3H+ (Holistic Health for HIV)|Four weekly HIV-risk reduction groups and an additional booster group held at week twelve summarizing the previous sessions' content, designed for opioid-dependent individuals living with HIV.
1664513|NCT01741311|Behavioral|HHRP+ (Holistic Health Recovery Program)|12 two-hour group sessions addressing HIV risk reduction behavior and recovery for opioid-dependent individuals living with HIV.
1664514|NCT01741298|Behavioral|CHARMS|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
1664515|NCT01741285|Drug|Beclomethasone (QVAR)|Small particle treatment
1664516|NCT01741285|Drug|Beclomethasone (Clenil)|Course particle beclomethasone
1664517|NCT01741285|Drug|Fluticasone|Course particle treatment
1664518|NCT01741272|Procedure|Sling|Patients will use a sling for 6 weeks as per usual care. No active ROM allowed.
1664519|NCT01741272|Procedure|No sling|Patients may discontinue use of the sling as early as pain and comfort allow. Early active ROM is allowed for activities of daily living.
1664521|NCT01741233|Genetic|VitDgen|
1664523|NCT01741194|Drug|AC-1204|AC-1204 taken once daily, by mouth
1664524|NCT01741194|Drug|Placebo|Placebo taken once daily, by mouth
1664525|NCT01741181|Drug|Vitamin D supplementation|Vitamin D3 marketed by oneNine57
1664526|NCT01741181|Drug|Placebo Pill|Placebo pill supplied by oneNine 57 imported to Singapore with approval and import licence from HSA.
1664527|NCT01741168|Other|TLSO|Patients in the TLSO arm will remain on bed rest until fitted with a TLSO. They will wear the TLSO for 8-10 weeks and mobilized in the brace by a physiotherapist.
1664528|NCT01741168|Other|No Orthosis|Patients in the No Orthosis group will be mobilized immediately as tolerated by a physiotherapist with restrictions to limit bending or rotating through their trunk. They will be encouraged to return to normal activities after 8 weeks.
1664529|NCT01741155|Drug|SPI-1620 & Docetaxel|"Single Arm & Randomized Part:
On Day 1, the patient will receive standard docetaxel premedication followed by SPI-1620 11 μg/m2 administered intravenously over one minute. Patients will receive docetaxel 10 (±2) minutes following the infusion of SPI-1620. Docetaxel dose is 75 mg/m2 infusion. Patients will continue to receive SPI-1620 plus docetaxel once every 3 weeks until disease progression or intolerable toxicity. Overall 27 patients will be enrolled in the Single Arm Part. If 6 or more responses are observed in this group then the Randomized Part will be initiated. About 100 patient in the experimental arm will receive SPI-1620 & Docetaxel"
1664530|NCT01741155|Drug|Docetaxel|"Randomized Part-Control Arm (100 patient):
On Day 1 the patient will receive standard docetaxel premedication followed by docetaxel 75 mg/m2 by infusion over 1 hour. Patients will continue to receive docetaxel once every 3 weeks until disease progression or intolerable toxicity."
1664531|NCT01741142|Drug|ABT-436|Subjects receiving ABT-436
1664532|NCT01741142|Drug|Escitalopram|Subjects receiving escitalopram
1664533|NCT01741142|Drug|Placebo|Subject receiving placebo
1664534|NCT01741129|Device|Nasal CPAP (SLE)|PEEP: 4-6 cmH2O, Flow: 8 to 10 L/minute
1664535|NCT01741129|Device|Nasal IMV (SLE)|PIP: 15-20 cmH2O, PEEP: 4-6 cmH2O, Inspiratory time: 0.4-0.5 second, Rate: 20-30 /minute
1664536|NCT01741116|Drug|TKI258|Investigational treatment refers to TKI258 in this study Until Progression, unacceptable toxicity, withdrawal
1664537|NCT01741103|Drug|sitagliptin|sitagliptin 100mg by mouth once a day for 12 weeks
1664538|NCT01741103|Drug|Placebo|Take one by mouth daily for 12 weeks
1664539|NCT01741090|Biological|mesenchymal stem cell injection|Hepatic artery catheterization and mesenchymal stem cell injection will be used in alcoholic liver cirrhosis. And before and 1 month after injection, change of liver cirrhosis and portal hypertension will be evaluated.
1664540|NCT01741077|Dietary Supplement|folic acid|subjects take multivitamin supplement containing folic acid. Women were enrolled based on whether or not they were taking supplements.
1664541|NCT01741051|Device|HEPA Filter|
1664542|NCT01741038|Biological|AlloStim®|AlloStim® is derived from the blood of normal blood donors and is intentionally mismatched to the recipient. CD4+ T-cells are separated from the blood and differentiated and expanded for 9-days in culture to make an intermediary called T-Stim. AlloStim is made by incubating T-Stim cells for 4h with antibody coated microbeads. The cells with the beads still attached are suspended in infusion media and loaded into syringes. The syringes are shipped refrigerated to the point-of-care.
1664543|NCT01741038|Procedure|cryoablation|percutaneous ablation of a single metastatic tumor lesion usually in liver. The procedure is conducted under CT or ultrasound image-guidance.
1664544|NCT01741038|Other|Physician's Choice (PC)|Physician's Choice therapy can consist of best supportive care (BSC) or any US-FDA approved cancer drug (e.g. Cetuximab) administrated as a monotherapy at the manufacturer's recommended dose. The treatment schedule shall be prospectively determined and administered as tolerated
1664545|NCT01741025|Device|iFuse Implant System|Placement of iFuse implant system via surgery
1664546|NCT01741025|Other|Conservative Management|Medications for pain, physical therapy, cognitive behavour therapy
1954879|NCT03310723|Device|Face Mask preoxygenation|Standard face mask preoxygenation.
1664548|NCT01740999|Procedure|silicone arthroplasty|silicone arthroplasty
1664549|NCT01740999|Procedure|arthrodesis|arthrodesis
1664550|NCT01740986|Drug|SA09012 Low dose|Tablet, b.i.d
1664551|NCT01740986|Drug|SA09012 High dose|Tablet, b.i.d
1664552|NCT01740986|Drug|Placebo|Tablet, b.i.d
1664553|NCT01740960|Drug|delta-9-tetrahydrocannabinol|During the intervention phases, subjects will be randomly allocated to receive 1 of 3 doses Namisol®: 3 mg, 5 mg, 6,5 mg (or placebo) The washout period between the intervention periods will be at least 2 weeks.
1664554|NCT01740960|Drug|Placebo|On each intervention day the subjects will receive the same amount of drugs in order to insure the blinding of the study
1664555|NCT01740947|Drug|Selective decontamination of the digestive tract (SDD) (colistin sulfate, tobramycin, amphotericin B)|SDD suspension contains per dose of 10 ml 100 mg colistin sulfate, 80 mg tobramycin and 500 mg amphotericin B
1664556|NCT01740934|Other|Anatabloc Cream|subject will apply active cream topically, twice per day according to instructions
1664557|NCT01740934|Other|Placebo Cream|subject will apply placebo cream topically, twice per day according to instructions
1664558|NCT01740921|Drug|Liraglutide|Administered once daily
1664559|NCT01740921|Other|diet|reduction of caloric intake to promote weight loss
1664560|NCT01740921|Drug|Aspirin|300mg of Aspirin per day
1664561|NCT01740908|Other|Hyperbaric Oxygen Treatment|"Hyperabric oxygen will be delivered via a PerryPerry-Sigma Monoplace Hyperbaric Chambers. Oxygen is supplied by Air Gas, Seattle.
All gases will meet Health Standards for oxygen and air. The hyperbaric chamber technicians employed by Restorix Health are trained health personnel who will be assisting our study participant and monitoring the HBO treatment. Oxygen will be delivered at a pressure of 2.0 ATA for 90 minutes, once a day for 5 consective days."
1664562|NCT01740869|Other|Stem cells|
1664563|NCT01740856|Other|Rest three hours|Intervention group (IG), will maintain bed rest supine for two hours after the digital compression. After this period prescribed, patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk within the unit hemodynamic for about 10 minutes. Afterwards patients remain sitting out of bed in hemodynamics unit, until they are five hours, then they will be discharge.
1664564|NCT01740856|Other|Rest five hours|Control group (CG) maintain bed rest supine for four hours after the digital compression. After this period, the patients sit in bed with the head elevated at 45 degrees for 50 minutes and then walk into the unit hemodynamic for 10 minutes. After that patients receive discharge.
1664565|NCT01740843|Device|transcranial direct current stimulation (tDCS) (NeuroConn DC-stimulator)|The anode is fixed on the primary cortex and the cathode will be fixed on the contralateral supraorbital region.
1664566|NCT01740830|Device|Transcranial Direct Current Stimulation (tDCS) (Neuroconn DC-stimulator)|The anode will be fixed over the primary motor cortex. The cathode will be fixed over the contralateral supraorbital region.
1664567|NCT01740817|Drug|Intralipid 20%|30 ml/h for 48 h
1664568|NCT01740817|Drug|Saline|30 ml/h for 48 h
1664569|NCT01740791|Drug|GS-5816|3 days of monotherapy of GS-5816
1664570|NCT01740765|Other|24-hour energy expenditure|To assess 24-hour energy expenditure and substrate utilization subjects will spend 23 hours and 15 minutes each day in the metabolic chamber at the UNC NRI. Subjects will be requested to arrive at the study center each morning following a 10hour overnight fast. During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements and the study protocol (i.e. 50% or 150% of calorie requirements).
1664571|NCT01740752|Behavioral|UCAN+CBT|weekly manualized couple therapy plus weekly manualized individual CBT
1664572|NCT01740752|Behavioral|CBT|"weekly manualized higher dose of individual CBT"
1664573|NCT01740726|Behavioral|Behavioral Activation|18 weeks of 1-hour individual therapy focused on increasing rewarding behaviors. Therapy follows Behavioral Activation manual supported through previous research of this therapy for adolescents. BA intervention includes monthly booster sessions offered throughout 6-month follow up.
1664574|NCT01740726|Drug|Fluoxetine|Initial 10mg dose titrated as necessary to 40mg daily; weekly visits for 4 weeks, biweekly visits for next 6 weeks, monthly visits for remaining 8 weeks of active treatment and through 6-month follow up. Therapists will be available between sessions and throughout the follow-up interval to manage clinical concerns or emergencies.
1664575|NCT01740713|Drug|Deferiprone, dose level 1|a solution at 80 mg/mL will be administered orally
1664576|NCT01740713|Drug|Deferiprone, dose level 2|a solution at 80 mg/mL will be administered orally
1664577|NCT01740713|Drug|Deferiprone, dose level 3|a solution at 80 mg/mL will be administered orally
1664578|NCT01740700|Device|p-Branch®|Instead of making a large incision in the abdomen, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
1954880|NCT03310723|Device|OptiFlow preoxygenation|Preoxygenation using transnasal humidified rapid insufflation ventilatory exchange (THRIVE).
1664581|NCT01740674|Other|Electronic data collection|
1664582|NCT01740661|Other|Cryotherapy|The subjects will be exposed to a cold (~ 12° C) water immersion tub at the umbilical level for 20 minutes.
1664583|NCT01740661|Other|Control|The subjects will be exposed to a non-cold (~ 26° C) water immersion tub at the umbilical level for 20 minutes.
1664584|NCT01740648|Drug|trametinib|Trametinib will be given for 5-day lead-in period by mouth daily Monday-Friday starting at day -14 through -10 and concurrently for the duration of radiation therapy (approximately days 1-38).The dose of Trametinib will be escalated: 0.5 mg, 1.0 mg, 2mg. If the 2 mg dose level causes DLT (dose-limiting toxicity)in 2 out of 6 patients and the 1mg dose level was acceptable, then a 1.5 mg dose cohort will be used.
1664585|NCT01740648|Drug|fluorouracil|Will be administered as a continuous infusion over 120 hours at a dose of 225 mg/m2/day on Monday to Friday of every week starting day 1-38.
1664586|NCT01740648|Radiation|radiation therapy|Radiation therapy will be delivered to the pelvis during (approximately) days 1-33 (five days a week, Mondays through Fridays for 25 fractions) using a 3-field or 4-field 3-D conformal plan to the primary tumor, surrounding soft tissues, and at risk lymph node stations (peri-rectal, presacral, internal iliac, with or without external iliac) to a total dose of 45 Gy in 1.8 Gy daily fractions. A boost radiation field will be delivered during (approximately) days 36-38. The boost will encompass the primary rectal tumor and involved lymph nodes with a 2-2.5 cm margin, which should include the presacral space. The boost dose will be 5.4 Gy in 1.8 Gy fractions for a total dose of 50.4 Gy.
1664587|NCT01740635|Device|EPIC WheelS Training Program|Subjects will attend an initial assessment/training session and receive a customized home program from their Trainer, which is delivered by way of a portable, interactive computer tablet that can be used for practice in their home or other community venues. After 2 weeks of practice, subjects return for a second 1-hour training session. The Trainer updates their program and they continue practicing at home for another 2 weeks. Subjects will have a caregiver attend all training sessions and supervise their home training. Trainers monitor subject activity remotely and will contact subjects by telephone at the end of weeks 1 and 3 to promote program adherence. Participants in an extra wheeling sub-group will be instructed to perform additional, unstructured wheeling for 15 minutes, 5 days per week and document these on a simple calendar-style form provided.
1664588|NCT01740622|Other|Injury Prevention Measures|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
1664589|NCT01740609|Drug|Placebo|Placebo
1664590|NCT01740609|Biological|PF-06342674 Dose A|Single SC Dose
1664591|NCT01740609|Biological|PF-06342674 Dose B|Single SC Dose
1664592|NCT01740609|Biological|PF-06342674 Dose C|Single SC Dose
1664593|NCT01740609|Biological|PF-06342674 Dose D|Single SC Dose
1664594|NCT01740609|Biological|PF-06342674 Dose E|Single SC Dose
1664595|NCT01740609|Biological|PF-06342674 Dose F|Single IV Dose
1664596|NCT01740609|Biological|PF-06342674 Dose G|Single SC Dose
1664597|NCT01740609|Biological|PF-06342674 Dose H|Single IV Dose
1664598|NCT01740609|Biological|PF-06342674 Dose I|Single SC Dose
1664599|NCT01740609|Biological|PF-06342674 Dose J|Single IV Dose
1664600|NCT01740596|Device|C-Pulse® System Counterpulsation|The Sunshine Heart C-Pulse System is an implantable, non-blood contacting, non-obligatory, heart assist device. The system provides cardiac assistance through an extra-aortic balloon Cuff and ECG sense lead connected by means of a Percutaneous Interface Lead (PIL) to an external pneumatic Driver. The PIL is held secure externally, at the exit site, with a simple adhesive clip (C-Patch or similar) for immobilization of the external part of the PIL. The Driver is adjusted using a dedicated notebook computer (Programmer) with specialized software.
1664601|NCT01740583|Device|percutaneous annuloplasty|plication of the mitral valve annulus
1664647|NCT01740271|Drug|Epirubicin|
1720772|NCT00002676|Drug|methotrexate|
1664602|NCT01740570|Drug|Cabazitaxel|"Phase I Starting Dose: Cohort 1A) 25 mg/m2 by vein over 1 hour every 3 weeks. Cohort 1B) 20 mg/m2 by vein over 30 minutes every 3 weeks.
Phase II: Maximum tolerated dose from Phase I."
1664603|NCT01740557|Drug|Cytoxan|60 mg/kg/day by vein on Days -7 and -6.
1664604|NCT01740557|Drug|Mesna|60 mg/kg by vein on Days -7 and -6.
1664605|NCT01740557|Drug|Fludarabine monophosphate|25 mg/m2 by vein on Days -5 to -1.
1664606|NCT01740557|Procedure|T cell Infusion|Participants receive up to 1.5x10^11 T cells by vein (including both CXCR2 and NGFR transduced TIL) on Day 0.
1664607|NCT01740557|Drug|IL-2|720,000 IU/kg by vein every 8-16 hours for up to 15 doses on Days 1 to 5.
1664608|NCT01740557|Other|Questionnaire|Questionnaire completion about health and quality of life one (1) time a year for up to 15 years. Questionnaire should take about 15 minutes to complete.
1664609|NCT01740544|Other|Cathodal tDCS|Cathodal tDCS applied over the right PPC
1664610|NCT01740544|Other|Sham tDCS|Sham tDCS applied over the right PPC
1664611|NCT01740531|Biological|S-303 Treated Red Blood Cells (RBCs)|
1664612|NCT01740531|Biological|Conventional, untreated Red Blood Cells|
1664613|NCT01740518|Drug|polyethylene glycol, ascorbic acid|comparison of different solutions for bowel preparation
1664614|NCT01740505|Behavioral|Timing and Coordination|This intervention is based on progressively difficult stepping and walking patterns that promote the timing and coordination of stepping within the gait cycle. Small-group 60-minute classes twice weekly for 12 weeks.
1664615|NCT01740505|Behavioral|Aerobic Walking|Outdoor walking with progressive increases in exercise intensity. Small-group 60-minute classes twice weekly for 12 weeks.
1664616|NCT01740505|Behavioral|Stretching and Relaxation|Full-body stretching, range-of-motion exercises, and relaxation techniques. No specific gait training. Small-group 60-minute classes twice weekly for 12 weeks.
1664617|NCT01740492|Drug|Ketamine 0.15mg/kg|0.15mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
1664618|NCT01740492|Drug|Ketamine 0.3mg/kg|0.3 mg/kg ketamine delivered IV (in the vein) following clinician assessment in ER. Number of cycles: until discharge or 6 hours elapses.
1664619|NCT01740492|Other|Placebo|Placebo injection of 0.9% normal saline of a similar volume (0.05ml/kg)
1664620|NCT01740479|Procedure|Complete Revascularization Strategy|Staged PCI using second generation drug eluting stents (Promus Element Plus drug-eluting stent or newer version in this series is strongly recommended) of all suitable non-culprit lesions plus optimal medical therapy.
1664621|NCT01740453|Drug|ropivacaine 2 mg/ml|single
1664622|NCT01740440|Device|BMR Face|BMR Face used in accordance with manufacturer IFU
1664627|NCT01740414|Drug|MN-166 (50 mg) First|In this arm of the study participants were first maintained on 50 mg MN-166 BID for approximately 14 days, and were then switched onto placebo maintenance. The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo & MN-166).
1664628|NCT01740414|Drug|Placebo First|This arm of the study participants were first maintained on placebo for approximately 14 days, and were then switched onto 50mg MN-166 BID maintenance. . The subjective and analgesic effects of Oxycodone (0 mg, 15 mg and 30 mg) were tested under each of the two maintenance conditions (Placebo & MN-166).
1664629|NCT01740401|Drug|Cyclophosphamide|This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimumab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study
1664630|NCT01740388|Drug|Besifloxacin|one drop of besifloxacin ophthalmic suspension 0.6% administered to infected study eye(s) BID for 3 days.
1664631|NCT01740388|Drug|Vehicle|one drop of the vehicle of besifloxacin ophthalmic suspension administered to infected study eye(s) BID for 3 days.
1664632|NCT01740375|Procedure|esophagectomy|esophagectomy
1664633|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
1664634|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
1664635|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
1664636|NCT01740362|Drug|CP-690,550|10 mg (2 x 5 mg tablets), single dose
1664637|NCT01740336|Drug|GDC-0941|GDC-0941 will be administered QD orally for 5 consecutive days each week.
1664638|NCT01740336|Drug|Placebo|Placebo matching to GDC-0941
1664639|NCT01740336|Drug|Paclitaxel|Paclitaxel will be administered IV weekly for 3 out of 4 weeks in every 28-day cycle.
1664640|NCT01740323|Drug|Placebo|daily placebo for 6 weeks
1664641|NCT01740323|Drug|Curcumin|500 mg BID
1664642|NCT01740310|Behavioral|Maternal Vaccine Education|It is assumed that the women will also receive vaccine education materials from the OB/GYN practices as part of routine care. The intervention for all three arms will be conducted during routine prenatal office visits. Participants will complete a baseline questionnaire to assess attitudes regarding vaccination and will then be randomized to one of three enrollment arms and will be exposed to an intervention designed to take no longer than 20 minutes, so that patients can complete it during the time they are waiting to be seen. While participants are completing the handheld/electronic tablet device-based intervention, the study recruiter will observe them and document dose exposure to the messages being presented. The enrolled women will be contacted a month after the expected date of delivery and a follow up interview will be conducted to ascertain their vaccination status for receipt of influenza vaccine in pregnancy and Tdap during pregnancy or immediately post-partum.
1954881|NCT03310710|Device|Viabahn BX stent|Viabahn BX stent graft used as the branch device with a fenestrated EVAR graft
1664645|NCT01740284|Drug|Grazax + Aerius|
1664646|NCT01740284|Drug|Grazax + placebo|
1664654|NCT01740232|Procedure|Normal meniscal repair|Artroscopic meniskal repair without trephination.
1664655|NCT01740219|Behavioral|Capacity Enhancement|Churches in the Capacity Enhancement intervention will be invited to work with CRUZA staff over the course of a three month intervention to implement health promotion activities in their church and participate in capacity-building educational workshops. Participants may also receive technical assistance from Health Educators in order to implement their cancer education activities.
1664656|NCT01740219|Behavioral|Standard Dissemination|Churches in the Standard Dissemination arm will receive program materials with information about cancer prevention/early detection and health resources.
1664657|NCT01740206|Drug|Amphetamine and/or methylphenidate|Patients who took their stimulant medication the day of surgery.
1664658|NCT01740206|Other|Hold stimulant medication|Patients who held their stimulant medication the day of surgery.
1664659|NCT01740193|Procedure|TAP Block|While the terminal branches of T7 to L1 cannot be visualized under ultrasound as they pass between the internal oblique and the transverse abdominis muscles, they are expected to lie within this plane. The three muscular layers of the abdominal wall, however, can be easily identified under ultrasound guidance. A needle is advanced under ultrasound guidance towards the fascial plane that separates the internal oblique and the transversus abdominis muscles, at which point local anesthetic is deposited under direct visualization.
1664660|NCT01740193|Procedure|Ilioinguinal/iliohypogastric blockade|Ilioinguinal and iliohypogastric blockade is performed as an injection after palpation of the anterior superior iliac spine followed be a perceived loss of resistance with insertion of the needle, or may be infiltrated locally following herniorrhaphy exposure as anatomic landmarks can prove to be difficult to locate in the anesthetized pediatric patient.
1664661|NCT01740180|Other|Data entry|"This cohort describes the basic information about the patients (age, sex, weight, height, background) as well as acts required, treatment and results of imaging studies.
These data are extracted from patient records by each participating center and collected in an e-CRF."
1664662|NCT01740167|Behavioral|health promotion lifestyle program|Individual counseling, once a month, total 3 times.
1664663|NCT01740154|Procedure|transcranial magnetic stimulation|Undergo TMS
1664664|NCT01740154|Procedure|electromyography|Undergo EMG
1664665|NCT01740154|Other|survey administration|Ancillary studies
1664666|NCT01740154|Drug|sunitinib malate|Given PO
1664667|NCT01740141|Procedure|Plexus brachialis block|
1664668|NCT01740128|Device|Robotic body weight supported treadmill training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
1664669|NCT01740128|Other|Multimodal training|30-minute sessions will be conducted 3-4 times per week for a total of 48 sessions over 12 to 16 weeks.
1664670|NCT01740102|Procedure|RIPC|The remote ischemic preconditioning will consist of three sequential sphygmomanometer cuff inflations. The cuff will be inflated up to 200 mmHg for 5 minutes and then deflated for 5 minutes. This cycle will be performed three times in total. The entire preconditioning will therefore last for 25 minutes.
1664671|NCT01740089|Drug|Algeron|1.5 μg/kg or 2.0 μg/kg of body weight weekly subcutaneously
1664672|NCT01740089|Drug|PegIntron|1.5 μg/kg/week subcutaneously in combination with ribavirin
1664673|NCT01740089|Drug|Ribavirin|800-1400 mg/day orally
1664674|NCT01740076|Other|soy nuts|
1664675|NCT01740063|Drug|DAS181-F02 formulation|
1664676|NCT01740063|Drug|DAS181-F04 formulation|
1664677|NCT01740063|Drug|Placebo|
1664678|NCT01740050|Dietary Supplement|Very Low Calorie Diet (VLCD)|One subject group will lose 10% of initial body weight using a VLCD. There are no risks for the subjects in consuming the VLCD (Modifast, together with the recommended fruit and vegetables) as the macronutrient composition and vitamins/minerals content meet the Dutch recommended daily allowance.
1664679|NCT01740050|Procedure|RYGB|
1664680|NCT01740050|Procedure|LAGB|
1954882|NCT03310697|Other|Collection of blood and urine samples|For each child, a toxicological screening will be carried out on the blood and urine for the research of proconvulsive molecules by conventional technique on the one hand and by gas chromatography coupled with a mass spectrograph on the other hand.
1664683|NCT01740024|Biological|1 (Dose Response Skin Prick Tests)|3 different cat epithelium allergenic extracts at 3 different concentrations, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
1664684|NCT01740011|Procedure|Laparoscopic surgery|
1664685|NCT01739998|Dietary Supplement|functional oil|
1664686|NCT01739998|Dietary Supplement|Placebo|
1664687|NCT01739985|Drug|Dexamethasone + ondansetron + Placebo|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1.Administration of the saline 30 minutes before the end of surgery
1664688|NCT01739985|Drug|Dexamethasone + ondansetron + Droperidol|Administration of ondansetron and dexamethasone immediately after induction of anesthesia. Ondansetron is administered at a dose of 100 micrograms.kg-1, dexamethasone at a dose of 125 microg x kg-1Administration of droperidol 30 minutes before surgery at a dose of 50 micrograms.kg-1
1664691|NCT01739933|Drug|Dexmedetomidine|For patients in the dexmedetomidine group, dose will range from 0.15-1.5 mcg/kg/hr. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 0.75 mcg/kg/hr of dexmedetomidine. This dose range have been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS II study steering committee.
1664692|NCT01739933|Drug|Propofol|For patients in the propofol group, dose will range from 5-50 mcg/kg/min. For example, a 70 kg patient would receive 10.5 mL of study drug per hour, which would provide 25 mcg/kg/min of propofol. This dose range has been selected after literature review and discussions with critical care practitioners, investigational pharmacists, and the MENDS II study steering committee.
1664693|NCT01739920|Other|Povidone-iodine|Povidone iodine 5% drop will be instilled into conjunctival sac.
1664694|NCT01739920|Other|Saline Solution|1 drop of saline solution 0.9% will be instilled into conjunctival sac.
1664695|NCT01739907|Other|Iron fortified flavoured skimmed milk with or without vitamin D in iron deficient women|
1721199|NCT00003387|Drug|carboplatin|
1664696|NCT01739894|Drug|IP Paclitaxel|Each treatment cycle will consist of 21 days, with 14 days on treatment and 7 days off-treatment. Oxaliplatin will be administered intravenously (on Day 1 of each cycle). Paclitaxel will be administered intra-abdominally on Day 1 and Day 8 of each cycle. In particular, a needle will be inserted into the intraperitoneal injection port for normal saline to be injected intra-abdominally over one hour, followed by paclitaxel chemotherapy over a further one hour. Capecitabine will be taken by mouth from Day 1 to 14 of each cycle.
1664697|NCT01739881|Device|Olympus Ultrathin Bronchofibervideoscope (XP260F)|The bronchovideoscope will be used together with an assisted image-guided bronchoscopic navigation software system called LungPoint®, to view lungs in a real time 3D manner.
1664698|NCT01739868|Other|Biopsies of muscular and fat tissue|"3 half days of metabolic exploration including blood sample, urinary taking, OGTT (oral glucose tolerance test), biopsies of muscular and fat tissue:
1 visit the first year (inclusion visit)
1 visit at the end of 5 years of follow-up or in the appearance of type 2 diabetes
1 intermediary visit (in 3 years) or activated by the following conditions:
Escalation of the glycemia (increase of 0.1g / l of the glycemia and/or 0.3 % of the HbA1c)
Normalization of the glycemia (fasting blood glucose < 1 g/l)"
1664699|NCT01739855|Drug|Calciferol, calcium carbonate|
1664700|NCT01739842|Dietary Supplement|Kudzu extract|
1664703|NCT01739816|Behavioral|Medication review|"Polymedication Check (PMC) is a pharmacist's led medication review focusing medicines management, adherence issues and other drug related problems.
The PMC has been implemented in 2010 as a new cognitive service provided by any community pharmacist to patient with polypharmacy (n>3 drugs) on long term conditions (> months). This specialised medication review follows a structured predefined protocol and is reimbursed by swiss health insurances.
As an outcome, pharmacist may install a compliance support e.g. weekly filled pill organizer."
1664704|NCT01739803|Behavioral|Behavioral Contract|Intervention activities were performed by a study clinical pharmacist. Behavioral contract goal was achieving and maintaining IST adherence. Other components of the contract addressed: (a) motivation(s) or positive reinforcement for achieving IST adherence; (b) problems or barriers that may interfere with achieving IST adherence and possible solutions to overcome problems/barriers; (c) social support available to the RTR such as a significant other who may assist the RTR in following the IST dosing schedule; (d) tools/strategies the RTR may use to remind himself/herself to follow the IST dosing schedule; and (e) possible consequences of IST nonadherence (e.g., graft loss).
1664705|NCT01739790|Drug|N-Acetylcysteine|1800 mg twice daily for 8 weeks
1664706|NCT01739790|Drug|Placebo|Identical placebo manufactured to mimic appearance of intervention drug with identical frequency and duration.
1664707|NCT01739777|Biological|ucMSC|1 million mesenchymal cells per Kg weight injected intravenously in allogenic AB plasma
1664708|NCT01739777|Other|Controls|Autologous Serum will administrated as placebo
1954883|NCT03310697|Other|Clinical examination|The other clinical data, any other biological samples or additional examinations are done under the opinion of the clinician or the neuropediatrics.
1664710|NCT01739751|Device|pedometers|portable device that estimate the number of steps walked daily
1664711|NCT01739738|Device|Ureteral Stent|patients who need to receive stent as per standard of care
1664712|NCT01739725|Device|Stent insertion|The patient will receive the helical stent
1664713|NCT01739712|Behavioral|Sleep extension|There will be a consultation with families to help youth to be successful in extending their sleep.
1664714|NCT01739712|Behavioral|Fixed Sleep Duration|There will be a consultation with families to instruct youth to maintain the same average nightly sleep duration during the modification week. The purpose is to control for time and attention.
1664717|NCT01739686|Other|CASA Intervention|"CASA Intervention
The CASA (Collaborative Care to Alleviate Symptoms and Adjust to Illness) intervention includes 3 components:
A nurse (RN) follows structured algorithms to help patients with symptoms, specifically breathlessness, fatigue, pain, and depression.
A social worker provides structured counseling targeting adjustment to illness and depression if present.
A collaborative care model of care delivery, in which the nurse and social worker meet weekly with a primary care provider, cardiologist and palliative care specialist. This team makes medical recommendations to the intervention subjects' providers and supervises the nurse and social worker.
Most of the nurse and social worker visits are by phone."
1664718|NCT01739673|Other|Ultraviolet-A and riboflavin|
1664719|NCT01739660|Drug|Pegloticase|a single 8 mg iv (in the vein) dose before hemodialysis session
1664720|NCT01739647|Drug|AZD3293|Oral solution
1664721|NCT01739647|Drug|Placebo|Oral solution
1664722|NCT01739634|Drug|CASAD|CASAD is provided in 500mg capsules.
1664723|NCT01739621|Drug|Proellex 12 mg|
1664724|NCT01739621|Drug|Proellex 24 mg|
1664725|NCT01739608|Other|Invitation to screening|Invitation to screening
1664726|NCT01739595|Drug|enclomiphene citrate|oral, capsules, taken one time daily, for 3 months
1664727|NCT01739595|Drug|Placebo|Oral capsule taken one time daily for 3 months
1664728|NCT01739582|Drug|Androxal|
1664729|NCT01739569|Other|Dietary treatment|Dietary treatment with healthy lunch and snack meal during working hours
1664730|NCT01739556|Drug|Antiplatelet Regimen Modification (aspirin or ticagrelor)|
1664731|NCT01739543|Device|Hem-Avert|Application of Hem-Avert
1664732|NCT01739530|Biological|Repaircell|allogenic differentiated adipocyte
1664733|NCT01739517|Drug|Omegaven Therapy|After baseline labs, which have been collected no earlier than seven days prior to the initiation of therapy are obtained, therapy with Omegaven will be initiated at a starting dose of 0.5 g/kg/day infused over 12 hours. If tolerated, the dose will be increased to 1 g/kg/day, the goal dose. Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
1664734|NCT01739504|Procedure|Liposuction with Local Anesthesia|Liposuction under tumescent anesthesia for adipose tissue harvesting.
1664824|NCT01738867|Drug|Placebo|Matching placebo capsules to GSK1521498 or NTX
1665547|NCT01733420|Drug|Tempophore pulpotomy|
1664735|NCT01739504|Biological|Intra articular infusion of AD-SVF|"Adipose tissue is available in most patients for harvest through minimally invasive procedures such as liposuction. AD-SVF can be obtained in large quantities after processing of adipose tissue in the laboratory.
AD-SVF to promote tissue regeneration and repair with their ability to secrete various growth factors that can modulate host tissue environment.
Patient's AD-SVF combined with PRP are used for direct intra-articular injection after processing."
1664736|NCT01739491|Drug|No intervention|This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
1664737|NCT01739478|Other|Packing of abscess cavity|
1664738|NCT01739478|Other|External dressing|Application of external dressing whilst abscess cavity heals
1664739|NCT01739465|Procedure|Self expanding metallic stent (SEMS)|Self expanding metallic stent
1664740|NCT01739465|Procedure|Endoscopic radiofrequency ablation (ERFA)|Endoscopic radiofrequency ablation
1664741|NCT01739465|Procedure|Photodynamic therapy (PDT)|Photodynamic therapy
1664742|NCT01739439|Drug|gemcitabine hydrochloride|Given IV
1664743|NCT01739439|Radiation|hyperfractionated radiation therapy|Undergo hyperfractionated IMRT
1664744|NCT01739439|Radiation|intensity-modulated radiation therapy|Undergo hyperfractionated IMRT
1664745|NCT01739439|Radiation|radiosurgery|Undergo radiosurgery boost
1664746|NCT01739439|Procedure|diffusion-weighted magnetic resonance imaging|Correlative studies
1664747|NCT01739426|Device|Repair w/LigaSure|Surgical repair is carried out as normal except that a novel device is used: LigaSure V (TM) laparoscopic instrument (reference LS1500)
1954884|NCT03310671|Procedure|Echocardiogram|"Conventional transthoracic echocardiogram by an echocardiographer trained to perform and centered on aortic valve
Pick up from:
Mean transvalvular pressure gradient
Aortic valve
Aortic valve opening area
Aortic valve opening area adjusted for body mass index
Bicuspid or tricuspid aorta
Thickness of the upper valve> 3 mm"
1664749|NCT01739400|Drug|Macitentan 10 mg tablet, once daily.|Macitentan 10 mg tablet, once daily.
1664750|NCT01739387|Device|Flutiform® pMDI and Breath Actuated Inhaler (BAI)|Both devices contain placebo
1664751|NCT01739374|Other|reduced mesh implants|mesh for pelvic floor reinforcement
1664752|NCT01739361|Drug|Acetaminophen|
1664753|NCT01739361|Drug|placebo|
1664754|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 12 mg verubecestat tablet once daily, taken orally
1664755|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 40 mg verubecestat tablet once daily, taken orally
1664756|NCT01739348|Drug|Verubecestat (Part I and Part II)|Single 60 or 40 mg verubecestat tablet once daily, taken orally
1664757|NCT01739348|Drug|Placebo (Part I)|Single placebo tablet matching verubecestat treatment once daily, taken orally
1664758|NCT01739348|Drug|Verubecestat (Part II)|Single 40 mg verubecestat tablet once daily, taken orally
1664760|NCT01739322|Biological|Prick test Platanus acerifolia allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.
Four concentrations of Platanus acerifolia allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
1664762|NCT01739296|Other|Neutral insole with subtalar strapping (sham)|Neutral insole with subtalar strapping (sham)
1664763|NCT01739296|Other|Lateral wedge insole with subtalar strapping|Lateral wedge insole with subtalar strapping
1664764|NCT01739283|Other|GIP|
1664765|NCT01739283|Other|GLP-1|
1664766|NCT01739283|Other|Saline|
1664767|NCT01739270|Procedure|supraclavicular brachial plexus block|
1664768|NCT01739257|Behavioral|Medical Lecture|
1664769|NCT01739257|Behavioral|Dramatic Reading|
1664770|NCT01739244|Drug|SYL040012|Ocular topical administration of SYL040012 for 14 consecutive days
1664771|NCT01739244|Drug|Placebo|Ocular topical administration of placebo for 14 consecutive days
1664774|NCT01739218|Drug|Carboplatin|Carboplatin will be administered at a dose calculated according to the Calvert formula ([participant's glomerular filtration rate + 25] multiplied by the target area under the concentration-time curve [AUC] of 5 milligrams per milliliter per minute [mg/mL/min]), as intravenous [IV] infusion over 30-60 minutes [min] every 3 weeks).
1664775|NCT01739218|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 175 milligrams per meter-squared [mg/m^2] as IV infusion over 3 hours using a rate controlling device every 3 weeks, or at a dose of 80 mg/m^2 as IV infusion over 1 hour using a rate controlling device every week (only during Cycles 5 to 8).
1664776|NCT01739218|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 milligrams per kilogram [mg/kg] as IV infusion over 30-90 min every 3 weeks.
1664777|NCT01739205|Behavioral|CALM-D Intervention|Participants (Pts) randomized to the lifestyle intervention received a yr long, 17 session intervention. Pts were asked to wear a pedometer and record their food intake for at least the week prior to each session. The first 4 sessions were delivered weekly, followed by 4 sessions delivered biweekly and finally 9 sessions delivered monthly. Each session was approximately 1-2 hrs. At the beginning of each session anthropometric, physical activity and dietary data were collected. Participants were lead in a 5 min deep breathing exercise before the didactic portion of the session began. Sessions targeted a broad range of material related to diet, physical activity, and psychosocial well-being. Participants were given homework assignments to incorporate covered material into their daily lives. Participants randomized to the intervention arm received follow-up assessments at 6 and 12 months post randomization.
1664778|NCT01739192|Drug|Bupropion|Subjects will be maintained on oral bupropion or placebo during the study.
1664779|NCT01739179|Procedure|VP Shunt Surgery for laparoscopic insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted laparoscopically
1664780|NCT01739179|Procedure|VP Shunt Surgery for open insertion of the peritoneal catheter|Patients in this Study Arm will receive a VP Shunt inserted openly
1664781|NCT01739166|Other|Practice-tailored intervention to increase rates of targeted services|"Over a 6 month period, the Practice Facilitator (PF), offers individualized suggestions, strategies and tools for streamlining processes and incorporating new ideas into the flow of a practice's work day to increase their rates of delivery of the 3 targeted services of lead screening, obesity detection and dental decay prevention.
During the intervention visits the PF reviews a small number of recent well-visit charts. This allows for rapid feedback to a practice on their progress as they work toward reaching outcome measures. It also provides 'real time' feedback regarding the degree to which suggested interventions are working, allowing the PF to change the approach as needed."
1664782|NCT01739153|Other|Dietary intervention: CHEESE (High cheese intake)|
1664783|NCT01739153|Other|Dietary intervention: MEAT (High Meat intake)|
1664784|NCT01739153|Other|Dietary intervention: CARB (High Carbohydrate intake)|
1664785|NCT01739140|Behavioral|Yoga|
1664786|NCT01739127|Drug|Aripiprazole|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
1664787|NCT01739127|Drug|Risperidone/Quetiapine|To be prescribed and monitored by participant's attending physician (not given to participants as a part of the study).
1664788|NCT01739114|Procedure|"IPPV group"|"Infants randomized into the IPPV group will receive mask IPPV with an initial PIP of 20 cmH2O and PEEP of 5 cm H2O, and a ventilation rate of 40-60 inflations/min until spontaneously breathing, at which time CPAP will be provided."
1664789|NCT01739114|Procedure|SI group|"Infants randomized into the SI group will receive two initial sustained inflations with a PIP of 20 cmH2O. After the two initial SIs infants will receive PEEP of 5 cm H2O and then CPAP if breathing spontaneously or, if found to have apnea or laboured breathing, mask IPPV with a PIP of 20 cmH2O and PEEP of 5 cmH2O at a rate of 40 to 60 bpm until spontaneously breathing, at which time CPAP will be provided"
1664790|NCT01739101|Behavioral|Reproductive Life Plan|A structured discussion based on the Reproductive Life plan, including information about reproduction and a brochure with the same information.
1664791|NCT01739088|Other|Remote ischemic pre-conditioning stimulus.|Forty eight to 24 hours prior to the surgery, patient assigned to remote ischemic pre-conditioning stimulus (RIPC) will have blood pressure cuffs placed on both lower limbs around the upper thigh, and will then have the cuff inflated around the lower limb to a pressure 10 mmHg above systolic blood pressure for 5 minutes, followed by 5 minutes of cuff deflation. This will be done sequentially on each lower limb for two cycles on each limb. In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group. For each intervention, the legs will be covered by a drape, so that whether the cuff is being inflated around the leg or underneath the leg is not seen by any member of the health care team.
1664792|NCT01739088|Other|Sham Ischemic Pre-conditioning|In the control (sham Ischemic Pre-conditioning) group 48 to 24 hours prior to the surgery a cuff will be placed just underneath the upper thigh and the cuff will be inflated for 5 minutes, followed by 5 minutes of cuff deflation, done sequentially for two cycles on each side.In the operating room, after induction of anesthesia, the exact same procedure will be performed in the RIPC group.
1664793|NCT01739062|Genetic|Genetic risk assessment|
1664794|NCT01739049|Drug|Liraglutide|liraglutide
1664795|NCT01739049|Behavioral|Diet and Exercise|diet and exercise
1664796|NCT01739036|Biological|ChAd63 CS/ME-TRAP|Mixture of ChAd63 CS 5 x 1010 vp and ChAd63 ME-TRAP 5 x 1010 vp. Intramuscular needle injection.
1664797|NCT01739036|Biological|MVA CS/ME-TRAP|Mixture of MVA CS 2 x 108 pfu and MVA ME-TRAP 2 x 108 pfu. Intramuscular needle injection.
1664798|NCT01739036|Biological|ChAd63 CS/ME-TRAP/AMA1|Mixture of ChAd63 CS 5 x 1010 vp, ChAd63 ME-TRAP 5 x 1010 vp, and ChAd63 AMA1 5 x 1010 vp. Intramuscular needle injection.
1664799|NCT01739036|Biological|MVA CS/ME-TRAP/AMA1|Mixture of MVA CS 1.33 x 108 pfu, MVA ME-TRAP 1.33 x 108 pfu, and MVA AMA1 1.33 x 108 pfu. Intramuscular needle injection.
1664800|NCT01739036|Other|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately three weeks post MVA dosing.
1664801|NCT01739023|Biological|Autologous Human Schwann Cells|Schwann cells harvested from the sural nerve of the participant will be autologously transplanted into the epicenter of the participant's spinal cord injury.
1664802|NCT01738997|Device|Dilation 10 sec|
1664803|NCT01738997|Device|Dilation 2 min|
1664804|NCT01738984|Behavioral|MomZing Web Program|Online web platform that is accessed via a television connected to internet
1664805|NCT01738984|Behavioral|Standard Exercise DVD|Standard exercise DVD that demonstrates exercises a women does with an infant.
1664806|NCT01738971|Other|rapid access|Provision of box which the participant can take to local family planning clinic (contraceptive service) allowing rapid access (i.e. will be seen by a health professional for a consultation regarding contraception there and then).
1664807|NCT01738971|Other|one month progestogen only pill|Provision of 1 month supply of a progestogen only pill (levonorgestrel 35mcg - Norgeston, Bayer, UK)
1664808|NCT01738958|Biological|L. retueri|two tablets a day for 6 weeks
1664809|NCT01738958|Biological|Placebo|
1664810|NCT01738945|Drug|Amlodipine|10 mg/day for 12 weeks
1664811|NCT01738919|Procedure|Conservative treatment with splinting for 6 weeks.|Aluminum Karstam splints are used.
1664812|NCT01738919|Procedure|Operative treatment with extension block technique|Surgery with extension block technique. 6 weeks.
1664813|NCT01738906|Other|Orange juice|
1664814|NCT01738906|Other|maltodextrin|
1664815|NCT01738906|Other|Vodka|
1664816|NCT01738906|Other|butter cake MSF|chewing on 40 gram cake for 6 minutes and before swallowing expectorating the bolus in cup.
1664817|NCT01738906|Other|butter cake consumption|chewing for 6 min on 40 gram cake and then swallow it.
1664818|NCT01738893|Drug|Gabapentin 300 mg|Test product
1664819|NCT01738893|Drug|Gabapentin 300 mg|Reference product
1664820|NCT01738880|Drug|SVV|During the surgery, patients in group S receive additional fluids (400 ml of normal saline or 200 ml of colloid) when SVV is less than 13.
1664821|NCT01738880|Drug|CVP|Patients in group C receive additional fluids (400 ml of normal saline or 200 ml of colloid) when CVP is less 8 during the surgery.
1664822|NCT01738867|Drug|GSK1521498|White HPMC capsule containing 10 mg of GSK1521498
1664823|NCT01738867|Drug|Naltrexone (NTX)|Swedish orange gelatin capsule containing 25mg of NTX or 50mg of NTX
1664825|NCT01738854|Procedure|intracuff pressure by cuff pressure manometer|36 patients are randomly allocated according to random sequence of the intracuff pressure 40, 60 and 80 cmH2O. After insertion of LMA supreme, we confirm adequate ventilation. And then we measure OLP and leakage volume at intra-cuff pressure 40, 60 and 80 cmH2O adjusted by cuff pressure manometer according to random sequence of the intracuff pressure.
1664826|NCT01738841|Biological|Priorix-Tetra™|Single dose, subcutaneous injection
1664827|NCT01738841|Other|Safety data collection|Recording of adverse events, using diary cards
1664828|NCT01738815|Drug|Valproic Acid|500 mg orally, once daily for up to 30 days
1664829|NCT01738802|Dietary Supplement|Anti-oxidant and micronutrient|This group will be randomized to take the anti-oxidant and micronutrient supplement.
1664830|NCT01738802|Drug|Placebo|This group will take a placebo.
1664831|NCT01738763|Dietary Supplement|Pinitol|Three doses of Fruit Up® (diluted with mineral water to a final volume of 330 ml) were evaluated, and were equivalent to an intake of 2.5, 4.0 and 6.0 g of pinitol. The placebo beverage contained equal amounts of non-polyol carbohydrates with similar macronutrient composition and energy intake as that those obtained through the pinitol beverage, but excluding pinitol.
1664832|NCT01738750|Other|Cost Information Included|
1664833|NCT01738737|Device|Active Laser|18 points of application of active laser in the knee (frontal faces, lateral and medial)
1664834|NCT01738737|Other|Stretching exercises|7 stretching exercises for lower limbs lasting 30 seconds with 4 repetitions
1664835|NCT01738737|Device|placebo laser therapy|18 points of application of placebo laser in the knee (frontal faces, lateral and medial)
1664836|NCT01738724|Drug|Dienogest|Dienogest 2mg pills daily during 6 months
1664837|NCT01738724|Drug|Goserelin|Goserelin 10.8mg preloaded syringe subcutaneously at the start of the study and after 3 months
1664838|NCT01738724|Drug|Desogestrel|Desogestrel 75mcg pills daily during six months
1664839|NCT01738711|Behavioral|Cognitive behavioural therapy|Patient receive 2-6 sessions depending on individual need. first session is 1 hour duration with additional sessions approximately 30 minutes.
1664840|NCT01738698|Drug|SPD489 40mg|Oral administration of 40 mg once-daily for up to 12 weeks
1664841|NCT01738698|Drug|SPD489 100mg|Oral administration of 100 mg once-daily for up to 12 weeks
1664842|NCT01738698|Drug|SPD489 160mg|Oral administration of 160 mg once-daily for up to 12 weeks
1664843|NCT01738698|Drug|Placebo|Oral administration once-daily for 12 weeks
1664844|NCT01738685|Behavioral|Behavioral Intervention.|
1664845|NCT01738685|Other|Nutritional Education.|
1664847|NCT01738659|Dietary Supplement|normal sodium diet|normal sodium diet (120 mmol/daily) for 1 year
1664848|NCT01738646|Drug|Vorinostat|
1664849|NCT01738646|Drug|Bevacizumab|
1664850|NCT01738633|Behavioral|nutritional counseling|
1664851|NCT01738633|Behavioral|respirology counseling|
1664852|NCT01738620|Behavioral|psychological counseling|
1664853|NCT01738620|Behavioral|prevention of sleep disorders in ICU|
1664854|NCT01738607|Dietary Supplement|Psyllium|
1664855|NCT01738607|Dietary Supplement|Gum Arabic|Gum acacia dietary fiber
1664856|NCT01738607|Dietary Supplement|carboxymethylcellulose|dietary fiber
1664857|NCT01738607|Dietary Supplement|Placebo|
1664858|NCT01738594|Drug|carfilzomib|Given IV
1664859|NCT01738594|Drug|romidepsin|Given IV
1664860|NCT01738594|Other|laboratory biomarker analysis|Correlative studies
1664861|NCT01738581|Device|Repetitive Transcranial Magnetic Stimulation|Applied to the premotor cortex at 1 Hz at 90% resting motor threshold for 1200 pulses.
1664862|NCT01738581|Behavioral|Sensorimotor Retraining|For sensorimotor retraining, a subset of the Learning-based Sensorimotor Training program was followed
1664863|NCT01738581|Behavioral|Non-specific Therapy|A non-specific massage and stretching program directed to the hand, wrist and forearm
1664864|NCT01738568|Behavioral|High intensity aerobic training|High intensity aerobic interval training will be performed 12-weeks. Exercise training will last 1 hour per day, 5 days per week and include high intensity interval cycling at ~70-95% maximum workload for 4 minutes followed by 3 minutes of rest.
1664865|NCT01738568|Behavioral|Sedentary Control|Sedentary control participants will not perform any regular exercise for 12-weeks.
1664866|NCT01738555|Drug|amdoxovir 300 mg bid|2 x 150 mg capsules bid
1664867|NCT01738555|Drug|amdoxovir 500 mg bid|2 x 250 mg capsules bid
1664868|NCT01738542|Drug|Bosentan|Bosentan 62.5 mg/12 hours (first four weeks) and 125 mg/12 hours (eight weeks)
1664869|NCT01738542|Drug|Antiaggregant therapy|AAS 100mg/d or Clopidogrel 75mg/d
1664870|NCT01738542|Drug|Statins|
1664871|NCT01738542|Drug|Antihypertensive therapy|
1664872|NCT01738529|Device|CLE ileocolonoscopy|The patients enrolled including the control group, will be investigated respectively, by conventional colonoscopy and CLE in both the terminal ileum as colon. The degree and extent of Crohn's disease are assessed by conventional ileocolonoscopy (SI), CLE (selected parameters) and histology biopsies. Then, the correlation between histology (gold standard), SI and CLE is calculated. An intra-and inter-observer study follows on CLE parameters, where 3 observers are blinded with respect to each other. The pathologist is blinded to conventional and CLE parameters. CLE results are stratified in order to identify which of the recorded CLE parameters that correlate best with the two other methods.
1664873|NCT01738516|Procedure|Electroencephalography|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
1664983|NCT01737567|Other|Bright Narrow Band Imaging.|Using Bright Narrow Band Imaging to detect colonic adenomas.
1664984|NCT01737567|Other|White Light Endoscopy|Use of White Light Endoscopy to detect colonic adenomas.
1664874|NCT01738516|Procedure|Electroencephalography and additional experimental tasks|Epileptic patients, as in healthy volunteers will be offered a review of EEG recording equipment resting on EEG-HR 256-channel EGI © in operation since January 2012 in the Van Gogh Service Unit of Neurology Rennes University Hospital (hospital Pontchaillou). The EEG is a routine now included in the Phase I report some epileptic patients during presurgical investigation. Patients to be included in this research protocol pass all review on the new device EEG-HR 256 channels. In addition to the rest condition, shared by both groups of participants, the healthy control subjects participate in two additional experimental tasks to be performed during recording. A picture naming task and a task of spelling words represented by these images.
1664875|NCT01738503|Drug|RBP-6000|18% Buprenorphine Sterile Solution for subcutaneous (SC) injection using the ATRIGEL® Delivery System. Each injection of RBP-6000 is separated by a minimum of 28 days and will be given on alternate sides of the participant's abdomen.
1664876|NCT01738503|Drug|Subutex|Participants were inducted and stabilized (over a 14-day period) on SUBUTEX. Tablets are placed under the tongue until dissolved.
1664877|NCT01738490|Device|Bone anchored hearing implant|
1954885|NCT03310658|Device|Zip-Stitch Soft Tissue Closure System|The novel Zip-Stitch System employed a laparoscopic applicator, a series of bio-absorbable clips, and an application procedure to close the vaginal cuff during otherwise standard of care total laparoscopic hysterectomy.
1664879|NCT01738451|Drug|GSK2118436 75 mg|Each capsule contains 75 mg of GSK2118436A as the mesylate salt, micronized particles as active equivalents.
1664880|NCT01738451|Drug|Placebo|Matching placebo capsules will be administered in Part 2 of the study.
1664881|NCT01738438|Drug|Cabozantinib|
1664882|NCT01738425|Drug|GIC-1001; 125 mg oral tablets|"Single ascending doses (SAD) from 125 mg to 1000 mg;
Multiple ascending doses from 125 mg to 500 mg, TID over 7 successive days"
1664883|NCT01738425|Drug|GIC-1001 matching placebo|"Single ascending doses (SAD) [equivalent to active arm, 125 mg to 1000 mg]
Multiple ascending doses, TID over 7 successive days [equivalent to the active arm, 125 mg to 500 mg]"
1664884|NCT01738412|Device|Neurokeeper stroke detector|Monitoring stroke patients
1664885|NCT01738399|Dietary Supplement|Coffee|
1664886|NCT01738399|Dietary Supplement|Placebo|
1664887|NCT01738373|Drug|Plerixafor|Plerixafor will be prescribed independently by the physician, according to usual practice.
1664888|NCT01738360|Drug|Arsenic trioxide|"The study duration was 30 months (24 months recruitment + 6 months follow-up).Thirteen patients will be successively included in this study at 6 different dose levels of arsenic trioxide (0.075, 0.10, 015, 0.20, 0.25 and 0.30 mg / kg / day). The treatment should be administered by IV infusion over 2 hours of D1 to D4 (conventional hospitalization) and at D8, D11, D15, D18, D22 and D25. The protocol starts at the dose of 0.10 mg / kg / day. The stage at the dose of 0.075mg/kg/day is planned in case of toxicity with the first stage at the dose of 0.10mg/kg/day.
The course of study is as follows :
Pre-inclusion between D-35 and D-15
Ten injections during the first month distributed as follows : conventional hospitalization from D1 to D4 (one injection per day) and daily hospitalization day for injections at D8, D11, D15, D18, D22 and D25.
A telephone contact between D32 and D34
A consultation at D40 then monthly consultation at D60, D90, D120, D150 and D180"
1664889|NCT01738347|Drug|Arm 1 - GEH120714 (18F) Injection|Intervention is to administer GEH120714 (18F) Injection (100-270 Megabecquerel (MBq), single intravenous administration).
1954886|NCT03310645|Drug|BAY1817080|4 different doses over the course of study
1954887|NCT03310645|Drug|Matching Placebo|Matching placebo for BAY
1664892|NCT01738321|Other|Cuff pressure|Measuring endotracheal tube (ETT) cuff pressure
1664893|NCT01738308|Procedure|Healing Touch|"When enter PACU + usual standard of care.
The Healing Touch practitioner will be at the bedside when the patient is first brought to the PACU. The HT practitioner will center and then attune with the child, connecting their energy with the child and setting the intention for healing for the child's highest good. The practitioner will then place one hand on the center of the patient's chest in the high heart area. The practitioner will hold this position until they feel a deep connection and quieting within the patient's energy. When the patient is awake and parents have been called to the bedside the HT practitioner will energetically ground and release the patient,"
1664894|NCT01738308|Procedure|Healing Touch Sham Treatment|"The untrained in energy work study staff will be at the bedside when the patient is first brought to the PACU. The practitioner will then place one hand on the center of the patient's chest in the high heart area. This will continue until parents are called to the bedside"
1664895|NCT01738295|Drug|Donepezil administration|
1664896|NCT01738295|Drug|Placebo administration|
1664897|NCT01738282|Drug|Baclofen|
1664898|NCT01738282|Drug|Placebo (for baclofen)|
1664899|NCT01738256|Behavioral|Wellbeing intervention (ACT)|The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.
1664900|NCT01738256|Behavioral|Wellbeing intervention (Internet)|The intervention is Duodecim Virtual Health Check and Coaching where the subject gets feedback based on his/her health information and is provided with different weekly tasks regarding lifestyle changes. The tasks are developed based on principles of cognitive behaviour therapy (CBT).
1664901|NCT01738256|Behavioral|No intervention|No intervention
1664938|NCT01737931|Drug|Topical steroid (Dexamethasone)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for steroid: twice daily administration of Dexamethasone (1 mg/g cream) to the application sites after the patch removal
1954888|NCT03310632|Drug|Antroquinonol|Antroquinonol: 100 mg and corn oil 100 mg encapsulated in a gelatin capsule administered orally. Dose will be selected(200mg TID or 300mg TID with SOC) after phase I, then follow up the best dose for 40 Patients for the efficacy.
1954889|NCT03310619|Biological|JCAR017|Gene modified autologous T cells
1954890|NCT03310619|Drug|Durvalumab|Anti-PD-L1
1664902|NCT01738243|Drug|Hyaluronic Acid Gel injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of Hyaluronic Acid Gel is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of Hyaluronic Acid Gel are injected with the end point being adequate lowering with improved symmetry.
1664903|NCT01738243|Drug|Saline injection|The conjunctiva is anesthetized with Proparacaine Hydrochloride Ophthalmic Solution, 0.5%. The upper eyelid is everted and the conjunctiva just superior to the upper tarsal edge is exposed. Using a 30-gauge needle, a single bolus of saline is placed centrally in the subconjunctival levator-Muller plane. Small volumes (0.1 to 0.2 ml) of saline are injected with the end point being adequate lowering with improved symmetry.
1664904|NCT01738217|Procedure|Fluobeam|
1954892|NCT03310593|Drug|Cannabidiol|Cannabidiol as active intervention.
1664907|NCT01738178|Drug|Caffeine|
1664908|NCT01738178|Drug|Placebo|
1664909|NCT01738165|Device|KineSpring System|The KineSpring System is designed to treat pain and loss of function secondary to medial knee OA by absorbing joint overload.
1664910|NCT01738152|Other|HLA vaginal gel (HyaloGYN®),|Each participant will receive a HLA vaginal gel (HyaloGYN®), which is an over-the-counter, colorless gel to be administered for hydration and lubrication of the vaginal epithelium for women suffering dryness,as well as to the vulva for women suffering from vulvar symptoms. All participants will be instructed to insert the HLA gel into the vagina (with applicator) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The women with vulvar symptoms at the baseline assessment will additionally be instructed to apply the HLA gel onto the vulva (manually) daily for the first 2 weeks, and then 3 times per week for 10 weeks. The participants will be assessed at 12 weeks. Participants receiving benefit from HyaloGYN®, as operationalized by improvement in both vaginal pH and VAS score will continue using the product 3 times per week for another 12 weeks and will receive a final vulvovaginal assessment at 24 weeks post-HLA treatment initiation.
1664911|NCT01738152|Behavioral|questionnaires|Assessment Form as part of routine clinical care. Participants will be asked to complete questionnaires at the baseline initial evaluation, 4-6 weeks, 12-14 weeks, and 22-24 weeks. The study information collected will be found in the standardized Clinical Assessment Form that patients complete as part of routine clinical care, along with an additional survey pertinent to the aims of the study. At 24 weeks, participants will complete an additional questionnaire that will ask questions regarding their experience with HyaloGYN® and their acceptability of and satisfaction with the product. Study participants must see the FSM NP or GYN clinician for the targeted exams at the study follow-up time points (4-6 weeks, 12-14 weeks, 22-24 weeks). PhD follow-up visits can be based upon the treatment plan of the patient. The study questionnaires and moisturizer diaries will be completed and collected during follow-up appointments with the GYN clinician or FSM NP.
1664912|NCT01738139|Drug|Ipilimumab|"Dose Escalation Group Starting Dose: 1 mg/kg by vein on day 15. The first study cycle is 35 days. Each cycle after that is 21 days.
Dose Expansion Group Starting Dose: MTD from Dose Escalation Group."
1664913|NCT01738139|Drug|Imatinib Mesylate|"Dose Escalation Group Starting Dose: 400 mg by mouth once per day for 35 days. The first study cycle is 35 days. Each cycle after that is 21 days.
Dose Expansion Group Starting Dose: MTD from Dose Escalation Group."
1664914|NCT01738113|Other|Open Kinetic Chain exercise|"Hamstrings strengthening exercise
Quadriceps strengthening exercise
Hamstrings stretch
Hip extensors and abductors strengthening
Calf-muscles stretching
Strength exercise of ankle dorsiflexors & plantar flexors"
1664915|NCT01738113|Other|Closed kinetic chain exercise|"Foot sliding from sitting
Seated Toe Raises
Hamstrings and quadriceps co-contraction from sitting
Bridging exercise
Sitting-to-standing
Side-to side, forward and backwards weight shifting
Lunge exercise
Squatting exercise
Standing Toe Raises
Standing Hamstrings Stretch"
1664916|NCT01738100|Drug|Ticagrelor|
1664917|NCT01738100|Drug|Clopidogrel|
1664918|NCT01738100|Drug|Morphine Sulfate|
1664919|NCT01738100|Drug|Saline|
1664920|NCT01738087|Drug|NEXThaler 100/6 mcg DPI|
1664921|NCT01738087|Drug|Flixotide Accuhaler 500 mcg|Active comparator
1664922|NCT01738087|Drug|NEXThaler 200/6 mcg DPI|
1664923|NCT01738087|Drug|NEXThaler placebo|Placebo comparator
1664924|NCT01738074|Biological|trivalent rotavirus genetic reassortment vaccine|
1664925|NCT01738074|Biological|Placebo|
1664926|NCT01738061|Behavioral|Multidimensional lifestyle intervention|Lecture series to increase awareness of the relationship of lifestyle to chronic diseases Individualized review and discussion to understand own health problems Biweekly group meetings to stimulate motivation and exchange ideas
1664927|NCT01738048|Procedure|Reconstruction|Reconstructive surgery after mastectomy, either by expander or autologous tissue. Includes both primary and secondary reconstruction
1664928|NCT01738035|Drug|NEFECON|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
1664929|NCT01738035|Other|Placebo|All patients will receive a maximum recommended daily dose of an ACEI and/or ARB (or maximum tolerated dose not exceeding the maximum recommended daily dose) for the duration of the treatment and follow-up phases.
1664930|NCT01738022|Other|Administration of gas mixtures|
1664931|NCT01738009|Other|Induction of flow limitation|
1664932|NCT01737996|Drug|BI 207127 + faldaprevir|fixed dose combination
1664933|NCT01737983|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri was administered in 5 drops per day (10^10 colony-forming units) for 6 months.
1664934|NCT01737983|Dietary Supplement|placebo|The placebo was packed in identical bottles, had the same color, weight, smell, and taste of the probiotic formulation, was administered in 5 drops per day
1664935|NCT01737957|Device|Low-fluence PRP with 532nm green LASER|To administer low-fluence PRP in a single session for PDR
1664936|NCT01737957|Device|Full-Fluence PRP with 532nm LASER|To administer full-fluence PRP in two sessions for PDR
1664937|NCT01737944|Drug|Methotrexate (MTX)|Vibex MTX Device
1954893|NCT03310593|Drug|Placebo|Placebo intervention.
1664939|NCT01737931|Drug|Topical antihistamine (Diphenhydramine)|for SPM 962: 1 mg/24h patch for 48 hours as Acceleration period, then 2 mg/24h patch to the other site for 24 hours as Dose-escalation period, for antihistamine: twice daily administration of Diphenhydramine (10 mg/g cream) to the application sites after the patch removal
1664940|NCT01737918|Procedure|TOT|
1664941|NCT01737918|Drug|solifenacin|
1664942|NCT01737905|Drug|Epinephrine HFA-MDI (E004)|Single dose 125 mcg/inhalation, 2 inhalations
1664943|NCT01737905|Drug|Placebo-HFA|Single dose 0 mcg/inhalation, 2 inhalations
1664944|NCT01737892|Drug|Arm T Epinephrine Inhalation Aerosol HFA, 125 mcg, 1 inhalation|Epinephrine Inhalation Aerosol HFA, Single dose 125 mcg, 1 inhalation
1664945|NCT01737892|Drug|Arm C-Epinephrine Inhalation Aerosol CFC|Epinephrine Inhalation Aerosol - CFC, Single dose 220 mcg, 1 inhalation
1664946|NCT01737879|Drug|Peginesatide|All participants will receive peginesatide for the first 24 weeks.
1664947|NCT01737879|Drug|Epoetin alfa|All participants converted to epoetin alfa at week 25 for a total of 32 weeks
1664948|NCT01737866|Drug|AMG 423|omecamtiv mecarbil
1664949|NCT01737853|Drug|Ganforti|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
1664950|NCT01737853|Drug|Krytantek|Enrolled patients will be visiting their clinical site at month 2 and month 3, after starting the study medication; at the end of the third month of treatment, a cross-over maneuver will be indicated; all patients will undergo a follow-up scheme similar to the first period of the study (at month 5 and month 6)
1664951|NCT01737840|Drug|Pantoprazole|33 patients
1664952|NCT01737840|Drug|Ranitidine|33 patients
1664953|NCT01737827|Drug|INC280|INC280 will be administered orally and continuously on a twice a day dosing schedule.
1664954|NCT01737814|Drug|Saline|
1664955|NCT01737814|Drug|MST-188|
1664956|NCT01737801|Procedure|Lung function test|Lung function test.
1664957|NCT01737788|Procedure|Cervical occlusion|Women were randomized to receive cervical occlusion or no cervical occlusion in addition to a cervical cerclage (McDonald or Shirodkar cerclage). Cervical occlusion was performed with interrupted or continuous sutures, placed approximately 1 cm deep on each lip, and 0.5 cm apart with a nylon 2-0/3-0 suture.
1664958|NCT01737775|Procedure|Diaphragmatic amplitude measurement|Diaphragmatic amplitude is measured by M Mode ultrasonography the day before and after surgery
1664959|NCT01737762|Biological|HP802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x106 cells per mL every 14 days.
1664960|NCT01737762|Biological|Vehicle|
1664961|NCT01737749|Device|Neurokeeper stroke detector|Electrophisoloigcal monitoring
1664962|NCT01737736|Device|Neurokeeper stroke detector|Electrophisoloigcal monitoring
1664963|NCT01737723|Device|Neurokeeper stroke detector|Monitoring stroke patients
1664964|NCT01737710|Biological|Fluzone® Intradermal Vaccine|A 0.1mL single-dose, in a latex-free, pre-filled microinjection system with an ultra-fine micro-needle. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® Intradermal is approved for use in persons 18 through 64 years of age and will be purchased from Sanofi Pasteur, Inc.
1664965|NCT01737710|Biological|Fluzone® (Intramuscular) vaccine|A 0.5 mL single-dose delivered via syringe using single-dose vials. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs. Fluzone® for intramuscular injection is approved for persons 6 months and older and will be purchased from Sanofi Pasteur, Inc.
1954894|NCT03310580|Drug|Netarsudil Ophthalmic Solution 0.02%|Topical sterile ophthalmic solution
1954895|NCT03310580|Drug|Netarsudil Ophthalmic Solution 0.04%|Topical sterile ophthalmic solution
1954896|NCT03310580|Drug|Netarsudil Ophthalmic Solution Placebo Comparator|Topical sterile ophthalmic solution
1954897|NCT03310567|Drug|Epacadostat + pembrolizumab|Each patient would be administered epacadostat orally twice a day and pembroluzimab by infusion once in a cycle of 21 days
1664970|NCT01737684|Drug|Vibegron|50 mg tablet, oral
1664971|NCT01737671|Procedure|Ommaya Reservoir|Surgical catheter placement into the fourth ventricle of the brain.
1664972|NCT01737671|Drug|Methotrexate|2 mg into fourth ventricle of the brain via the Ommaya Reservoir for 4 days. Each patient will undergo three cycles with at least two weeks between each cycle.
1664973|NCT01737671|Drug|Leucovorin|5 mg/square meter per dose administered every 6 hours by vein or mouth.
1664974|NCT01737658|Other|Exercise Program|Exercise Program for Obese Adolescents
1664975|NCT01737632|Behavioral|Multidimensional Family Therapy (MDFT)|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
1664976|NCT01737632|Behavioral|Adolescent Residential Treatment|The Adolescent Treatment Program targets the adolescent's abuse or dependency on chemicals while simultaneously treating the comorbid symptomatology found in dual diagnosed patients. These goals are accomplished by using four primary forms of intervention: (1) Chemical Education; (2) Group, Individual and Family Counseling; (3) Twelve Step Work; and 4) Psychotropic Medication for Clinical Symptomatology Comorbid with Substance Abuse.
1664977|NCT01737619|Procedure|PET/CT Scan|PET/CT scan before surgery and sentinel lymph node mapping procedure.
1664978|NCT01737619|Procedure|Sentinel Lymph Node Mapping|Blue dye, a radioactive colloid, and/or an indocyanine green (IC-Green) dye injected into cervix during surgery.
1664979|NCT01737606|Device|Fast Cerebral Pulsatility Imaging|Cerebral ultrasonic exploration using with neuro-navigation system : 4 acquisitions on 12 or 6 section planes
1664980|NCT01737593|Drug|Acetaminophen|
1664981|NCT01737580|Drug|resiquimod|
1664982|NCT01737580|Drug|placebo gel|
1721200|NCT00003387|Drug|chemotherapy|
1954898|NCT03310554|Procedure|25cm suspended overlength biliary stents|The test group will be placed 25cm suspended overlength biliary stents in introhepatic bile duct in ERCP
1664985|NCT01737554|Other|Catheter Resistance Monitoring|Weekly measurement of resistance to flow in the lumen(s) of a CVAD with the commercially available Alaris® Syringe Module IV pump. The aim is to identify an increase in resistance greater than normal variation. Inline pressure measurements will be recorded at multiple flow-rates and resistance will be estimated from the gradient of the pressure-flow curve.
1664986|NCT01737541|Drug|Fluoxetine|
1664987|NCT01737541|Drug|Placebo|
1664988|NCT01737528|Procedure|Transcatheter Aortic Valve Replacement|Minimal invasive implantation of a biological prothesis in Aortic Position
1664989|NCT01737515|Other|Abdominal waist and hip circumference|Abdominal waist and hip circumferences are measured clinically with a ruler as part of the standard pre-operative physical examination
1664990|NCT01737502|Drug|Auranofin|Given PO
1664991|NCT01737502|Drug|Sirolimus|Given PO
1664992|NCT01737502|Other|Laboratory Biomarker Analysis|Correlative studies
1664993|NCT01737502|Other|Pharmacological Study|Correlative studies
1664994|NCT01737489|Behavioral|LACE|commercially available LACE program which is administered by computer as daily lessons. The participants will do this program for one month
1664995|NCT01737489|Behavioral|NOOK|will use an electronic reader (Barnes and Noble - NOOK device) to do speech tracking.will do this activity for approximately one hour per day for five days out of seven for a total of four weeks. The speech tracking activity will involve reading approximately two books within the one month time frame. The participants will listen to the book while reading an unabridged book in printed form.
1664996|NCT01737476|Procedure|Transcranial Magnetic Stimulation. PFC|
1664997|NCT01737463|Procedure|Endoscopic snare papillectomy|Endoscopic snare papillectomy (ESP) was performed by using diagnostic or therapeutic duodenoscope. A pancreatic duct stent was or was not inserted immediately after the excision.
1664998|NCT01737450|Drug|BKM120|
1664999|NCT01737437|Drug|group C|0.9% normal saline was applied to trachea and laryngoscope blade
1665000|NCT01737437|Drug|group L|10% Lidocaine was applied to the laryngoscope blade and 0.9% normal saline was applied to the trachea.
1665001|NCT01737437|Drug|group V|0.9% normal saline was applied to the laryngoscope blade and 10% Lidocaine was applied on trachea.
1665002|NCT01737437|Drug|group LV|10% Lidocaine was applied on laryngoscope blade and trachea.
1665003|NCT01737424|Drug|LC28-0126|LC28-0126
1665004|NCT01737424|Drug|Placebo|Placebo
1665005|NCT01737411|Drug|solifenacin|
1665006|NCT01737411|Procedure|cesa/vasa|surgical repair of USL
1665009|NCT01737385|Procedure|Measurement with O2C|Measurement of microcirculation using O2C light probes.
1665010|NCT01737359|Drug|amdoxovir 300 mg bid|2 x 150 mg capsules bid
1665011|NCT01737359|Drug|amdoxovir 500 mg bid|2 x 250 mg capsules bid
1665012|NCT01737359|Drug|tenofovir DF 300 mg qd|1 x 300 mg tablet once daily
1665013|NCT01737346|Drug|lomustine and procarbazine|1 cycle (4 weeks) includes CCNU 75mg/m2 (D1) and procarbazine 60mg/m2 (D11-D24)by mouth for up to 6 cycles
1665014|NCT01737320|Drug|short-course antibiotic treatment|"On day 7 of appropriate intravenous or oral antibiotic treatment for the bacteremic episode (day 1 is the first day of appropriate antibiotic therapy), patients will be randomized to:
Intervention group - antibiotic treatment stopped on day 7
Control group - antibiotic treatment continued for 14 days according to accepted hospital local guidelines."
1665015|NCT01737320|Drug|accepted prolonged antibiotic treatment|
1665016|NCT01737307|Drug|Fluoride varnish|Fluoride Varnish (NaF 5%)
1665017|NCT01737307|Other|Oral Hygiene|Oral hygiene followed.
1665018|NCT01737307|Drug|CPP-ACP|CPP-ACP paste was applied by patient, once daily.
1665019|NCT01737294|Drug|Qutenza exposure|Cutaneous patch
1665020|NCT01737281|Behavioral|Proactive outreach|Proactive contact (mail and phone) offering smoking cessation medications and telephone counseling.
1665021|NCT01737281|Behavioral|Usual care|Usual smoking cessation care from VA clinical staff.
1665023|NCT01737255|Other|Whole body MRI|Individuals will undergo whole body and brain MRI
1665024|NCT01737255|Other|Psychological questionnaires|All recruits will complete questionnaires at 6 time points to assess psychological impact
1665026|NCT01737216|Drug|Zoledronic acid plus EP/TP|Drug:EP/TP+Zoledronic acid EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles Zoledronic acid 4mg d1 every 3 months until bone metastasis, 4mg d1 every 1 month until progression
1665027|NCT01737216|Drug|EP/TP|Drug:EP/TP EP(VP-16 100mg/m2 d1-3;DDP 60-75mg/m2 d1) every 4 weeks, for 4-6 cycles TP(PTX 135-175mg/m2 d1;DDP 60-75mg/m2 d1) every 3 weeks, for 4-6 cycles
1665028|NCT01737203|Drug|Viagra|50 mg tablet on Day 1 of each period
1665029|NCT01737203|Drug|sildenafil ODT|50 mg tablet on Day 1 of each period
1665030|NCT01737203|Drug|sildenafil ODT|50 mg tablet on Day 1 of each period
1665031|NCT01737190|Other|PEEP guided by Esophageal pressure + Recruitment maneuver|"Upon patient recruitment Esophageal balloon will be inserted and esophageal / pleural pressure will be measured. Thereafter, Inspiratory pressures and PEEP will be adjusted according to well established criteria. Inspiratory pressure and PEEP will be adjusted to achieve the best lung compliance possible while not exceeding transpulmonary end Inspiratory pressure of 25 to 30 cm H2O, and at the same time maintaining a positive transpulmonary end expiarory pressure of not more than 5 cm H2O.
A recruitment maneuver with application of 40 cm H2O for up to 40 seconds will be performed."
1665071|NCT01736904|Drug|FOLFIRI regimen|irinotecan 180mg/m2 d1,leucovorin 400mg/m2 d1, 5-fluorouracil 400mg/m2 iv, 2.4g/m2 civ 46h, repeated every 2 weeks
1665072|NCT01736891|Drug|Rasagiline|Tablets, qd
1665073|NCT01736891|Drug|Placebo|Tablets, qd
1665074|NCT01736878|Drug|Sorafenib|
1665075|NCT01736865|Drug|Cholecalciferol|
1665076|NCT01736865|Drug|Placebo|
1665077|NCT01736852|Device|CRB|Labor induction using the CRB and Pitocin
1665032|NCT01737177|Drug|Bendamustine, Lenalidomide, Rituximab|"INDUCTION PHASE (COURSE 1-4)
Bendamustine: 70 mg/m2 on day 2 and 3 every 28
Lenalidomide: 10 mg/daily on day 1 to 14 of a 28 days course
Rituximab: 375 mg/m2 on day 1 every 28 days; only for the first cycle in the induction phase will start on day 8
CONSOLIDATION PHASE (courses 5-6)
Patients in CR and PR at the end of the induction phase
Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days course.
Rituximab: 375 mg/m2 on day 1 every 28 days
MAINTENANCE PHASE (courses 7-24)
Patients in CR or PR at the end of the consolidation treatment with Lenalidomide until disease progression or unacceptable toxicity up to 18 months (from month 7 to month 24)
- Lenalidomide: 15 mg/daily on day 1 to 21 of a 28 days"
1665033|NCT01737164|Behavioral|Aerobic Exercise|
1665034|NCT01737151|Radiation|stereotactic body radiation therapy|Undergo SBRT
1665035|NCT01737151|Radiation|four fraction split-course SBRT|four fraction split-course SBRT
1665036|NCT01737138|Procedure|RSD|Contrast renal angiography(iodixanol) was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
1665037|NCT01737138|Drug|medicine|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agent, statins, platelet aggregation inhibitor, anticoagulants and so on.
1665038|NCT01737125|Radiation|Magnetic Resonance Imaging (MRI)|"spatial high-resolution MRI multiplanar acquisition in T1 and T2 anatomical sequences
MRI acquisition in movements with dynamic sequences BEAT-IRT ( dynamic TrueFISP)"
1665039|NCT01737112|Drug|99mTc-3PRGD2|For patients in suspicion of lung cancer, single intravenous bolus injection of nearly 11.1 MBq/kg body weight of 99mTc-3PRGD2 on day one of the treatment period, whole-body planar and thoracic SPECT/CT to determine the accumulation of 99mTc-3PRGD2 in the tumors and the other parts of the body.
1665040|NCT01737099|Dietary Supplement|DHA-O|
1665041|NCT01737099|Dietary Supplement|Fish oil|
1665042|NCT01737099|Dietary Supplement|Placebo|
1665043|NCT01737086|Dietary Supplement|Lactobacillus reuteri DSM 17938 and zinc sulphate|
1665044|NCT01737086|Dietary Supplement|placebo|
1665045|NCT01737073|Behavioral|IVR self-management|A course of self-management training that includes 12 education and self-management skill modules presented over 12 consecutive weeks. Participants will be asked to practice each skill daily and report via IVR on their completion of the daily skill practice. They will receive a 10 minute call each week from a nurse care manager to discuss their weekly progress.
1665046|NCT01737073|Behavioral|Opioid monitoring|Monthly automated monitoring of prescription opioid use including pain relief, physical activity, pain-related interference, mood, adverse effects, adherence and satisfaction with treatment.
1665047|NCT01737073|Other|Enhanced usual care|Weekly automated wellness tip and usual clinical care
1665048|NCT01737060|Device|Reverse total shoulder arthroplasty|
1665049|NCT01737034|Other|dietary intervention by varying GI diets|The human study intends to characterise the partitioning of weight gain during refeeding and to affect the catch-up fat phenomenon by the glycemic index (GI) of the diet.
1665050|NCT01737021|Other|Psycho-education|The information given to parents will cover expected reactions that follow a PICU admission; how parents can help their child cope with these reactions; how to recognise warning signs; and sign-posting of appropriate follow-up services (if relevant). There will also be a follow-up telephone call to reinforce the information and to support parents in putting it in to practice, if appropriate.
1665051|NCT01737008|Drug|dacomitinib|Tablets are administered orally or through a G-Tube, and can be taken with or without food.
1665052|NCT01737008|Radiation|Radiotherapy|Intensity modulated radiation therapy (IMRT) delivered using 4 or 6 MV photons. Patients will receive either the standard dose fractionation radiotherapy or accelerated fractionation radiotherapy.
1665053|NCT01737008|Drug|Cisplatin|If selected for this arm, cisplatin will be administered intravenously every three weeks after receiving premedications.
1954899|NCT03310554|Procedure|30cm suspended overlength biliary stents|The test group will be placed 30cm suspended overlength biliary stents in introhepatic bile duct in ERCP
1665057|NCT01736982|Behavioral|Contingency Management|Participants earn reinforcement in the form of prizes for breath samples that test negative for cigarette smoking.
1665058|NCT01736982|Behavioral|Standard smoking cessation counseling|
1665059|NCT01736982|Drug|transdermal nicotine replacement [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)],|
1665060|NCT01736982|Behavioral|Breath sample monitoring|
1665061|NCT01736969|Device|RD047-023|Experimental hydrogel
1665062|NCT01736969|Device|Predicate Device|
1665063|NCT01736956|Procedure|Fetal Aortic Valvuloplasty|Fetuses in the intervention group will undergo in utero balloon aortic valvuloplasty via a transuterine, perventricular approach. Fetuses in the control group will have no invasive intervention while in utero.
1665064|NCT01736943|Drug|Bortezomib|Bortezomib will be given twice a week subcutaneously (under the skin) for two weeks in every 3 week cycle.
1665065|NCT01736943|Drug|Doxil|Doxil or LipoDox will also be given through a venous catheter (inside your vein). Doxil or LipoDox will be given over 60 to 90 minutes on Day 4 of every 21-day cycle.
1665066|NCT01736930|Device|Pump suspension|The study laptop will communicate to the pump causing suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
1665067|NCT01736917|Drug|Fosaprepitant|Fosaprepitant 150mg IV D3 for acute prophylaxis Fosaprepitant 150mg IV on Day 5 for delayed prophylaxis
1665068|NCT01736917|Drug|Dexamethasone|Dexamethasone 20mg PO daily on D1 and 2 for acute prophylaxis Dexamethasone 4mg PO BID on Days 6 through 8
1665069|NCT01736917|Drug|5HT3|Any 5HT3RA on D1-5; D1, 3 and 5 if palonosetron is used.
1665070|NCT01736904|Drug|wXELIRI regimen|irinotecan 90mg/m2 D1, capecitabine 1000mg/m2 bid po, D1-5,repeated every 7 days
1665078|NCT01736852|Drug|Pitocin|Labor induction using Pitocin alone
1665079|NCT01736826|Biological|Bloodwork, baseline|36 ml of blood are drawn at baseline (last month of pregnancy for groups P and T2, inclusion for group T1) in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
1665080|NCT01736826|Biological|Blood work, Months 1 & 2|36 ml of blood are drawn at 1 & 2 months after inclusion in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
1665081|NCT01736826|Biological|Bloodwork, Months -1 to -6|36 ml of blood are drawn at the third, fourth, fifth, sixth, seventh and eight months of normal pregnancy (corresponding to months -1 to -6 before comparative baseline; this group is included in the study early during pregnancy)in order to quantify the following: plasma free DNA concentration, plasma nucleosome concentration, hemoglobin, platelets, leukocytes, polynuclear neutrophils, mean corpuscular volume, monocytes, mean corpuscular hemoglobin, lymphocytes, polynuclear eosinophils, polynuclear basophils, D-Dimers, Fibrin monomers, Trophoblast microparticles, Angiogenic marker CD146.
1665082|NCT01736813|Drug|Maraviroc|Twelve patients with 300 mg/bid
1665083|NCT01736800|Drug|Topotecan|Patients will receive Topotecan intravenous treatment days 2-6 of each 28-day cycle at The Mehthodist Hospital Outpatient Infusion Center.
1665084|NCT01736800|Drug|Temozolomide|Temozolomide is taken on an empty stomach at night and should not be chewed. Patients receive Temozolomide on days 1-5 of a 28-day schedule.
1665085|NCT01736787|Dietary Supplement|Cauliflower Mushroom extract|Cauliflower Mushroom extract (1g/day)
1665086|NCT01736787|Dietary Supplement|Placebo|Placebo (1g/day)
1665087|NCT01736774|Other|Usual care intervention|The usual care intervention will include appropriate primary care as required including medication
1665088|NCT01736774|Other|Physiotherapy treatment|Exercise and manipulative therapy treatment for 10 weeks:The treatment intervention consists of two visits per week for the first four weeks (8 treatments) and one visit per week for the last six weeks (6 treatments)
1665089|NCT01736761|Drug|Darunavir, Ritonavir and Rilpivirine|
1665090|NCT01736748|Behavioral|Sensor based PA intervention|Children will be equipped with a heart rate monitor, a GPS receiver and an accelerometer for collection of heart rate, mobility and physical activity free-living data during a 7-day period. This will provide a 'spatio-behavioural diagnosis' using a map-based interactive web application. This data will be used to developed a tailored plan to promote physical activity in the child's every day environment.
1665091|NCT01736748|Behavioral|Traditional PA counseling|Children will be encouraged to enhance their physical activity levels using traditional behavioral approaches.
1665092|NCT01736735|Drug|CLP|
1665093|NCT01736735|Drug|placebo|
1954900|NCT03310554|Procedure|ordinary plastic biliary stents|The control group will be placed ordinary plastic biliary stents in introhepatic bile duct in ERCP
1665095|NCT01736709|Biological|2012-2013 trivalent seasonal influenza vaccine|trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
1665096|NCT01736696|Drug|tofacitinib|5 mg BID For 13 days and once on Day 14
1665097|NCT01736696|Drug|tofacitinib|10 mg BID for 13 days and once on Day 14*
1665098|NCT01736696|Drug|tofacitinib|20 mg BID for 13 days and once on Day 14
1665099|NCT01736696|Drug|tofacitinib|30 mg BID for 13 days and once on Day 14
1665100|NCT01736696|Drug|tofacitinib|60 mg tablet once a day (QD) for 14 days
1665101|NCT01736696|Drug|tofacitinib|50 mg tablets two times a day (BID) for 13 days and once on day 14
1665102|NCT01736683|Drug|Sotatercept|Sotatercept 0.1 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
1665103|NCT01736683|Drug|Sotatercept|Sotatercept 0.3 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
1665104|NCT01736683|Drug|Sotatercept|Sotatercept 0.5 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
1665105|NCT01736683|Drug|Sotatercept|Sotatercept 1.0 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
1665106|NCT01736683|Drug|Sotatercept|Sotatercept 1.5 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
1665107|NCT01736683|Drug|Sotatercept|Sotatercept 2.0 mg/kg subcutaneous (SC) once every 3 weeks (q3W) for 5 cycles
1665108|NCT01736670|Drug|Triamcinolone Acetonide spray|
1665109|NCT01736670|Drug|Triamcinolone acetonide cream|
1665110|NCT01736670|Drug|Alcohol spray|
1665111|NCT01736657|Device|Red blood cell exchange in sickle cell|One Red Blood Cell Exchange using Spectra Optia Apheresis System per enrolled patient
1665112|NCT01736644|Device|Electrocautery|Use of electrocautery in tourniquet and tourniquetless total knee replacement surgery
1665113|NCT01736644|Device|Bipolar sealer Aquamantys|Aquamantys use in tourniquet and tourniquetless total knee replacement.
1665114|NCT01736631|Behavioral|Cognitive behavioural therapy (CBT)|The CBT intervention will follow the model of social phobia by Clark & Wells (Clark & Wells, 1995; Clark, 2005). The main elements of CBT for social phobia include reducing self-focus, dropping safety behaviours, and testing negative cognitions.
1665115|NCT01736618|Device|S-ICD System|
1665116|NCT01736605|Procedure|Massage|Patients will receive a daily 20 minute massage in their hospital room on the first 3 days following surgery.
1665117|NCT01736605|Procedure|Massage combined with meditation|Patients will receive a daily 20 minute massage combined with meditation in their hospital room on the first 3 days following surgery.
1665118|NCT01736592|Drug|SAR422459|
1665163|NCT01736202|Biological|fat orally|Oral ingestion of palm oil or canola oil at timepoint zero
1665427|NCT01734252|Drug|Argatroban|Start: Argatroban dose [µg/kg x min] = 2.06 - 0.03 x SAPS II until maximum: 10 µg/kg/min
1954901|NCT03310541|Drug|AZD5363|AZD5363 400mg PO twice daily for 4 days on, 3 days off, every week
1954902|NCT03310541|Drug|Enzalutamide|Enzalutamide 160 mg PO once daily
1665120|NCT01736566|Other|"Main Study Experimental: Standard of Care + Whole Genome Sequencing (Genome Report)"|"Doctors and their patients will receive a Genome Report and a Family History Report.
There will be two sections of the Genome Report:
The General Genome Report, which will include highly penetrant disease mutations, carrier status for recessive disease, and pharmacogenetic associations.
The Cardiac Risk Supplement, which will contain genetic information found in the genome regarding cardiac diseases or a risk of cardiovascular diseases that can help with the care of the patient.
Extension Phase: Experimental: Standard of Care + Whole Genome Sequencing (Genome Report)
*In the main study participants are are randomized between Experimental and Placebo, in the Extension phase of the study participants all are in the Experimental Arm."
1665121|NCT01736566|Other|"Placebo Comparator: Standard of Care Only"|Doctors and their patients will receive a Family History report only
1665122|NCT01736540|Device|MRI scan|MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2*, respectively).
1665123|NCT01736527|Drug|LE Gel|Single drop of LE Gel 0.5% administered to the study eye on visit 2
1665124|NCT01736514|Drug|febuxostat|oral
1665125|NCT01736514|Drug|Allopurinol|oral
1665126|NCT01736501|Other|Genetics education at baseline|
1665127|NCT01736501|Other|Hypothetical genomic scenarios at follow-up|
1665128|NCT01736488|Drug|Fimasartan|Fimasartan 60mg
1665129|NCT01736488|Drug|Atenolol|Atenolol 50mg
1665130|NCT01736475|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) evaluation of ADVATE
1665131|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation of BAX 855
1665132|NCT01736475|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
1665133|NCT01736475|Biological|PEGylated Recombinant Factor VIII|On-demand treatment
1665134|NCT01736462|Drug|Mapracorat|One drop of mapracorat ophthalmic suspension, 3% four times daily, at approximately four hour intervals, for 14 days in both eyes.
1665135|NCT01736449|Drug|Bevacizumab|
1665136|NCT01736436|Drug|Treatment with APG101|Patients will be treated 12 weeks with 100 mg APG101 intravenous weekly
1665137|NCT01736436|Procedure|Bone marrow collection|During the study, bone marrow will be collected 4 times to assess study objectives
1665138|NCT01736436|Procedure|Blood drawings|During the study, blood will be drawn at different time points to assess study objectives
1665139|NCT01736423|Drug|YM060|oral
1665140|NCT01736410|Drug|Trastuzumab, TS ONE, Cisplatin|The initial dose of cisplatin is fixed to be 60 mg/m2 and intravenously administered over 1 hour on day 1 of the cycle. TS-ONE is orally administered consecutive 14-day followed by 7-day rest. The initial standard dose of TS-ONE is determined based on the body surface area tabled below. Trastuzumab is intravenously administered with the loading dose of 8 mg/kg followed by HER2-positive advanced GC 21 years or older No prior regimen HER2 protein HER2/neu detection procedure Tissue from (Gastric) Cancer FISH method IHC method negative positive HER-2 negative HER-2 positive Eligible 0 / 1+ 2+ 3+ HER-2 positive Eligible HER-2 negative iii Protocol S1/CDDP/Her V1.3 dated 21 May 10 maintenance dose of 6mg/kg in day 1 of each cycle. The study treatments are repeated every 3 weeks. Study treatment can continue until PD, but cisplatin can be skipped or discontinued if patients experienced unbearable toxicity which comes from cisplatin.
1954903|NCT03310541|Drug|Fulvestrant|500mg IM days 1, 15, 29 (cycle 2 day 1) and then every 4 weeks
1954904|NCT03310528|Behavioral|Interview questionnaire|Complete interview questionnaire regarding the composition and timing of their most recent food intake.
1665143|NCT01736384|Procedure|Gastric bypass or cholecystectomy|
1954905|NCT03310528|Procedure|Gastric ultrasound exam|Gastric ultrasound exam prior to upper GI endoscopy procedure.
1954906|NCT03310515|Behavioral|Risk reduction counseling|Subjects will receive comprehensive prevention package including HIV and safe sex counseling, provision of condoms and water-based lubricant, and STI screening and referral for treatment.
1665147|NCT01736358|Drug|Intranasal Ketoralac|15.75 mg of Sprix in each nostril 20 minutes before end of surgery
1665148|NCT01736358|Drug|Placebo|15.75 mg of placebo will be administered in each nostril 20 minutes before the end of surgery
1665149|NCT01736345|Genetic|Genetic Providers|Genetic providers (genetic counselors or nurses) will follow the standardized disclosure protocol for in-person and telephone disclosures whle completing a disclosure flow checklist.
1665150|NCT01736345|Other|Visual Aids|Visual aids targeted to facilitate communication of genetic test results were developed based on our preliminary studies and modified based on our initial pilot study.
1665151|NCT01736345|Other|Post-Disclosure Asessments|Within 72 hours of completion of disclosures, participants will be asked to complete post-disclosure survey again being the option to complete by the aforementioned means.
1665152|NCT01736345|Other|In-person Clinical Follow-Up|Participants who receive their test results in person will meet with a Physician, Physician Assistant or Nurse Practitioneras part of their in person disclosure session. Participants randomiZed to telephone disclosure will be recommendedto schedule an in-person clinical follow-up appointment with a Physician, Physician Assistant or Nurse Practitioner
1665153|NCT01736345|Other|6 Month and 12 Month Assessments|At 6 months and 12 months after disclosure participants will be asked to complete survey assessments.
1665154|NCT01736332|Drug|Vicks VapoInhaler|2 inhalations each nostril every 2 hours for 6 doses on day 1, one dose on morning of day 2
1665155|NCT01736332|Other|Poppy seeds|45 g in liquid at 9 am and 5 pm on day 1
1665156|NCT01736267|Device|Nucleus 24 (discontinued) and ABI541 Auditory Brainstem Implants (ABI)|Nucleus ABI541 Auditory Brainstem Implant (ABI) surgery followed by device activation, testing, and clinical assessment for five years following surgery.
1665157|NCT01736254|Drug|Evacetrapib|Oral administration
1665158|NCT01736254|Drug|Gemfibrozil|Oral administration
1665161|NCT01736228|Device|DIABECELL|two transplants of 10,000 IEQ/kg DIABECELL (administered at least 12 weeks apart)- total of 20,000 IEQ/kg
1665162|NCT01736215|Drug|Erythropoietin: Observational study|This is an observational study. Participants receiving erythropoietin (dosage and regimen will comply with Thai Food and Drug Administration approval package insert) will be observed.
1665196|NCT01735994|Other|Brochure|Brochure on the Female athlete triad
1665164|NCT01736176|Drug|Levodopa-Carbidopa Intestinal Gel|"Levodopa-carbidopa intestinal gel (LCIG) for upper-intestinal infusion is a suspension of levodopa (20 mg/mL) and carbidopa monohydrate (5 mg/mL) in an aqueous gel, administered continuously by a portable pump via a percutaneous endoscopic gastrojejunostomy (PEG-J) tube.
The rate of LCIG infusion was expected to be within the range of 1 to 10 mL/hour (20 to 200 mg of levodopa/hour) in most instances over a period of 16 consecutive hours."
1665165|NCT01736176|Procedure|Percutaneous Endoscopic Gastrostomy with Jejunal Extension (PEG-J)|
1665166|NCT01736176|Drug|Levodopa-carbidopa Immediate Release (LC-IR) Tablets|After LCIG initiation, participants could take prescribed oral levodopa-carbidopa immediate or continuous release (i.e., oral LC prescribed by the investigator) for nighttime use.
1665167|NCT01736163|Drug|Thyrogen|0.9 mg IM, administrated for 2 consecutive days
1665168|NCT01736163|Drug|131I|28 mCi or ≥ 1.036 GBq.
1665169|NCT01736163|Other|Thyroid Hormone Withdrawal|Stop taking hormone therapy
1665170|NCT01736150|Drug|Placebo|"Starting dose of 1 tablet (800mg), three times per day (2.4g/day)with meals.
If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet (800 mg). Three times daily with meals."
1665171|NCT01736150|Drug|Sevelamer carbonate|"Starting dose 1 tablet (800 mg), three times per day (2.4 g/day) with meals.
If serum phosphorus is higher than 5.5 mg/dL on Visit 3, 4, or 5, then dose increased by one additional tablet(800mg).Three times daily with meals."
1665172|NCT01736137|Other|Six minute walk test|If patients meet the criteria of the study, their data will be collected and will be interviewed to fill the Minnesota Living with Heart Failure Questionnaire (MLHFQ). They then will be taken to the hallway to perform the six minute walk test monitored with a heart rate monitor (Polar RS800 CX). After the test there will be a break of 20 to 30 minutes before repeating the walk test. During rest time, the patient will answer the general health survey questionnaire: Medical Outcome Study 36-item Short-Form Health Survey (SF-36).
1665175|NCT01736111|Behavioral|one way text|
1665176|NCT01736111|Behavioral|Personal feedback|
1665177|NCT01736098|Other|Energy Flux Exercise Intervention|Comparison of high, medium and low energy flux groups with all groups matching energy intake and expenditure
1665178|NCT01736085|Behavioral|Telephone counseling|Telephone counseling is conducted in the appropriate language (English and Spanish) by veteran counselors at the California Smokers' Helpline. Subjects will receive free proactive telephone counseling to help them set up quit smoking plans. The content of the counseling addresses both behavioral and cognitive issues that the individual smoker faces in his/her attempt to quit. It includes a 30-minute comprehensive pre-quit session (motivation, planning, setting of a quit date and the discussion of quitting aids including nicotine patch use) plus up to four 10-minute proactive follow-up calls. The counseling protocol has several distinguishing features: proactive follow-up counseling calls, a manualized (i.e., semi-structured) protocol and relapse-sensitive scheduling
1665179|NCT01736085|Behavioral|Voucher|"Subjects will receive a voucher for nicotine patches.
Subjects randomized into the voucher condition will receive a voucher that can be exchanged for two weeks' worth of free starter kit nicotine patches by calling a dedicated phone number (Quit Boost). The voucher will be mailed the day after the screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date."
1665180|NCT01736085|Drug|Nicotine patches|Subjects will receive nicotine patches directly sent to their home. Subjects randomized into the patch condition will receive two weeks' worth of free starter kit nicotine patches directly. The patches will be mailed directly to their home the day after screening intake. Subjects who smoke 11 or more cigarettes per day will receive 21 mg patches; smoke 10 or less per day will receive 14 mg patches. Subjects will be encouraged to start using these patches on their quit date.
1665181|NCT01736072|Procedure|Standard Laparoscopic Surgery|The research subjects will be randomized to Standard Laparoscopic Surgical procedure to resect their Rectal Cancer.
1665182|NCT01736072|Procedure|Robotic Assisted Laparoscopic Surgery|The research subjects will be randomized Robotic Assisted Laparoscopic Surgical procedure to resect their Rectal Cancer.
1665183|NCT01736059|Drug|CD34+ bone marrow stem cells intravitreal|
1665184|NCT01736046|Radiation|CT Enterography|"Diagnostic CT Enterography Scan (CTE)
Subjects will have their scheduled diagnostic CTE scan done according to St. Paul's Hospital radiology department standard procedures. Subjects will be randomly assigned to undergo a low dose CT Enterography scan either before or after the diagnostic scan. The radiologists who are blinded to the technique used will then interpret the scans to look for signs of Crohn's disease. The low dose scan will be compared to the standard scan in terms of it's ability to detect signs of Crohn's disease."
1665185|NCT01736033|Drug|Tamsulosin|1 tablet(0.2mg) orally q.d.
1665186|NCT01736033|Drug|Finasteride|1 tablet(5mg) orally q.d.
1665187|NCT01736033|Drug|Placebo|1 tablet(0.2mg) orally q.d.
1665188|NCT01736020|Drug|Dexmedetomidine|A low dose of dexmedetomidine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
1665189|NCT01736020|Drug|Propofol|A low dose of propofol is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
1665190|NCT01736020|Drug|Ketamine|A low dose of ketamine is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
1665191|NCT01736020|Drug|Nitrous Oxide|A low dose of nitrous oxide is used during scanning after dose piloting outside the scanner for memory effects and tolerability.
1665192|NCT01736020|Drug|Placebo|Placebo
1665193|NCT01736007|Device|308-nm excimer laser to alopecia patch|MED dosing as per protocol with beginning at 50 mJ/cm2 below MED with increases by 50mJ/cm2 every 2 treatments as tolerated. Maximum dosing would be 850mJ.Treatments given twice a week for 12 weeks.
1665194|NCT01736007|Device|Liquid light guide tip on laser|Sham treatment involves placement of liquid light guide tip developed by the laser company which attaches to the end of the hand wand and blocks the laser light from passing to the target. Patients are treated twice a week for 12 weeks.
1665195|NCT01735994|Behavioral|Healthy Weight|Eating Disorder Prevention Program for Athletes
1665197|NCT01735981|Other|Video game exercise using Dance Dance Revolution|use of the video-game, Dance, Dance Revolution as an exercise to improve gait and balance
1665198|NCT01735981|Other|hand-held video game|hand-held video games
1665199|NCT01735968|Drug|ST571 + BYL719|Evaluable patients must meet the minimum treatment and safety evaluation requirements of the study. Patients will be treated until they experience progression of disease, withdraw consent, or experience unacceptable toxicity. One study cycle equals 28 days.
1665200|NCT01735955|Drug|AMN107|AMN107 (nilotinib)
1665201|NCT01735942|Drug|Ingenol mebutate|
1665202|NCT01735942|Procedure|cryotherapy|
1665203|NCT01735929|Procedure|Neck Liposuction and Ultrasound Treatment|
1665204|NCT01735929|Procedure|Sham Treatment|
1665205|NCT01735916|Device|CRT-P Implant|"The Medtronic Consulta CRT-P (models C3TR01, C4TR011) dual chamber implantable pacemaker with cardiac resynchronization therapy (CRT-P) is a multi-programmable cardiac device that monitors and regulates the patient's heart rate by providing single or dual chamber rate-responsive bradycardia pacing, and sequential biventricular pacing.
The device senses the electrical activity of the patient's heart using the electrodes of the implanted atrial and right ventricular leads. It then analyzes the heart rhythm based on selectable detection parameters. The device responds to bradyarrhythmias by providing bradycardia pacing therapy.
Simultaneous or sequential biventricular pacing is used to provide patients with cardiac resynchronization therapy. The device also provides diagnostic and monitoring information that assists with system evaluation and patient care."
1665206|NCT01735916|Device|CRT-P OFF|Device programmed to minimal pacing at 40 beats/minute. Device and arrhythmia diagnostics may remain enabled.
1665207|NCT01735903|Procedure|Arm A - Non-Diabetic, Gait and Balance|"Arm A will enroll patients WITHOUT diabetes, but with peripheral neuropathy and lower limb pain, paresthesia, gait disturbances, or motor weakness and will follow the same protocol except the subject will NOT participate in blood flow testing performed at Colorado State University, and therefore do not include the inclusion/exclusion criterion that are specifically related to the blood flow assessment.
Subjects may have any combination of lower limb nerve decompression surgery of the listed surgical sites with or without the addition of Soleal Sling Decompression. Soleal Sling Decompression surgical procedure will require the use of a thigh tourniquet."
1665208|NCT01735890|Drug|CJ Amlodipine/Valsartan 10/160mg Novartis Exforge 10/160mg|single dose
1665209|NCT01735877|Other|Mirror therapy|During the mirror practices, patients were seated close to a table on which a mirror (35×35cm) was placed vertically. The practice consisted of non paretic-side wrist and finger flexion and extension movements while patients looked into the mirror, watching the image of their noninvolved hand, thus seeing the reflection of the hand movement projected over the involved hand. Patients could see only the noninvolved hand in the mirror; otherwise, the noninvolved hand was hidden from sight. During the session patients were asked to try to do the same movements with the paretic hand while they were moving the non paretic hand.
1665210|NCT01735877|Other|Control group|The control group performed the same exercises for the same duration but used the nonreflecting side of the mirror in such a way that the paretic hand was hidden from sight. The same therapist delivered the control therapy to the patients. Both the treatment and the control group received limb activation.
1665211|NCT01735864|Drug|Indirubin 200μg/g|"Dosage form: Ointment
Dose(s): Each gram of ointment containing 200 μg of indirubin
Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
1665212|NCT01735864|Drug|Indirubin 100 μg/g|"Dosage form: Ointment
Dose(s): Each gram of ointment contains 100 μg of indirubin
Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
1665213|NCT01735864|Drug|Indirubin 50 μg/g|"Dosage form: Ointment
Dose(s): Each gram of ointment contains 50 μg of indirubin
Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
1665214|NCT01735864|Drug|Indirubin 10 μg/g|"Dosage form: Ointment
Dose(s): Each gram of ointment contains 10 μg of indirubin
Dosing schedule: apply 0.5 g of ointment per 10 x 10 cm psoriatic lesion twice daily"
1665215|NCT01735851|Drug|Thoracic epidural analgesia|
1665216|NCT01735851|Procedure|Bilateral Paravertebral block|
1665217|NCT01735825|Device|paclitaxel-coated balloon catheter with Iopromide coating|Patients with coronary in-stent restenosis treated by drug eluting paclitaxel-coated balloon catheter
1665218|NCT01735825|Device|drug eluting stent with everolimus|Patients with coronary in-stent restenosis treated by drug eluting stent with everolimus
1665219|NCT01735825|Device|seal-wing paclitaxel-eluting balloon catheter|Patients with coronary in-stent restenosis treated by seal-wing paclitaxel-eluting balloon catheter
1665220|NCT01735812|Device|IceSense3 system|The IceSense3™ is a modern cryosurgical device that was designed by IceCure Medical for a variety of applications.
1665221|NCT01735786|Device|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
1665222|NCT01735747|Radiation|Radiotherapy|WBRT was given five times a week at 2 gray (Gy)/d until the whole brain radiotherapy dose reached 40 gray. The patients were given concurrent temozolomide (75mg/m2, orally) daily during radiotherapy until the end of radiotherapy.
1665223|NCT01735747|Drug|nedaplatin|nedaplatin (80mg/m2 i.v., day 1), 28 day schedule, performed four weeks after radiotherapy.A maximum of six cycles were applied.
1665224|NCT01735747|Drug|vincristine|vincristine (1.4mg/m2 i.v., day 1)28 day schedule,performed four weeks after radiotherapy.A maximum of six cycles were applied.
1665225|NCT01735747|Drug|Temozolomide|Temozolomide (200mg/m2 orally, days 1-5, Each cycle was 4 weeks ), performed four weeks after radiotherapy. A maximum of six cycles were applied.
1665226|NCT01735734|Device|Air cooling to CM site|
1665227|NCT01735721|Procedure|Open Sinus Lift|"A crestal incision was made on the mucosa of the edentulous ridge. The flap was elevated carefully and extended labially to expose the bone. A vertical releasing incision was made in the mesial end of the flap as needed. The mucoperiosteal flap was extended to expose the alveolar ridge and the lateral wall of the maxillary sinus. Then, a window was prepared using the piezoelectric device (Mectron, Italy); the Schneiderian membrane was then elevated conservatively according to the technique described by Vercellotti (2001).
The sinus membrane was meticulously detached and pushed superiorly to allow for the placement of bone graft material."
1665228|NCT01735708|Behavioral|HIVPASS|
1665229|NCT01735708|Other|Health Education|
1665425|NCT01734265|Drug|Depigoid 50% Grasses/50% Olea europaea (2000DPP/ml)|
1665230|NCT01735682|Device|Whole body vibration|The vibration frequency and amplitude used will be 30-40 Hz and 1mm, respectively. The total exposure to the vibration stimulation is 4 minutes.
1665231|NCT01735682|Behavioral|Conventional exercise|The conventional exercise training involves upper limb and lower limb strengthening exercises using sandbags.
1665232|NCT01735682|Behavioral|Control|The control treatment involves exercises of the upper limbs.
1665233|NCT01735669|Drug|Remifentanil|
1665234|NCT01735669|Drug|Nitrous Oxide|
1665235|NCT01735656|Device|Resolute stents|zotarolimus-eluting Resolute stents made by Medtronic Vascular, Inc (http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/DeviceApprovalsandClearances/Recently-ApprovedDevices/ucm294951.htm).
1665236|NCT01735643|Device|interactive videogame Wii Fit Plus|Use of the interactive videogame Wii Fit Plus für 12 weeks.
1665237|NCT01735643|Other|waiting|waiting for 12 weeks
1665238|NCT01735630|Drug|ELND005|
1665239|NCT01735630|Drug|Placebo|
1665240|NCT01735617|Drug|Hydrocortisone Modified Release Capsules|Patients with congenital adrenal hyperplasia standardised on conventional therapy is enrolled onto the study and treatment is switched to Chronocort, initially for pharmacokinetic assessment followed by longer-term biochemical and efficacy assessment
1665241|NCT01735604|Biological|anti-CD20-CAR vector-transduced autologous T cells|anti-CD20-CAR vector-transduced autologous T cells
1665242|NCT01735604|Other|genetically engineered lymphocyte therapy|genetically engineered lymphocyte therapy
1665243|NCT01735591|Dietary Supplement|Placebo|Placebo, 1 capsule a day from inclusion until the date of liver transplantation
1665244|NCT01735591|Dietary Supplement|Probiotic|Capsules with 3x10^9 colony forming units of: Lactococcus lactis PB 411 (50%), Lactobacillus casei PB 121 (25%), Lactobacillus acidophilus PB 111 (12,5%), Bifidobacterium bifidum PB 211 (12,5)
1665245|NCT01735539|Dietary Supplement|15g EAA bolus|Oral; in aqueous solution
1665246|NCT01735539|Dietary Supplement|4 x 3.75g Mixed EAA Pulses|Oral; in aqueous solution
1665247|NCT01735539|Dietary Supplement|15g EAA Bolus supplemented with 3g Arginine|Oral; in aqueous solution
1665248|NCT01735513|Device|Intra-aortic embolic protection management system; Embol-X|"The Embol-X system is positioned within the aorta to capture emboli, such as blood clots or tissue fragments, to prevent them from traveling through a patient's bloodstream during TAVI. The EMBOL-X system features a small, expandable, polyester-mesh filtration system that is placed inside the aorta above the aortic clamp during open-heart surgery or transaortic TAVI procedures, where it captures particles in the bloodstream that otherwise might have remained in the patient's circulatory system. A recent presentation characterized the removal of aortic cross-clamps as creating in some patients embolic showers which have the potential to cause neurocognitive complications, stroke and other organ damage. In documented procedures, 97% of EMBOL-X system filters showed detectable captured embolic matter, visible proof that the system is removing potentially dangerous emboli from the bloodstream."
1665249|NCT01735487|Other|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
1665250|NCT01735487|Other|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
1665251|NCT01735487|Other|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
1665252|NCT01735487|Other|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
1665253|NCT01735487|Other|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
1665254|NCT01735474|Other|Manual technique|"A manual technique is employed in the intervention group based on passive movement and stretching of the respiratory system.
The manual technique includes:
stretching of diaphragm. Mobilization. Potentiation of the respiratory muscles."
1665255|NCT01735474|Other|Placebo|Usual care
1665256|NCT01735461|Dietary Supplement|Calcium Carbonate|There is a regimen for dietary supplement intake that will be provided to study participants.
1665257|NCT01735448|Other|Focus group|"Initially, ten focus groups with an average sample size of 5-7 participants each will be performed in two communities within South Australia, one being Adelaide and the other Murray Bridge, this includes focus groups held with healthcare workers.
The proposed focus groups will be conducted by experienced mediators who have undertaken Aboriginal cultural awareness training and have experience in qualitative research methods. Both mediators have also been involved in all aspects of project development and consultation with Aboriginal Elders and key stakeholders since its conception.
We will be using topic guides (reviewed by Aboriginal Elders and researchers) that will be semi-structured with open-ended questions designed to encourage group discussion around smoking cessation and the use of pharmacotherapies in particular, in addition to other objectives identified during the consultation phase of this research."
1665258|NCT01735448|Other|One-on-one interviews|One-on- one interviews will be held with both medical clinicians and key stakeholders and will be conducted by existing TQEH (The Queen Elizabeth Hospital), Clinical Practice Unit employees, experienced in qualitative research. Informed consent will be required and the interview will be audio taped to allow analysis of the qualitative data. All interviews will remain anonymous, unless the interviewee prefers to be named. In this case, they will be named in the acknowledgement section of all publications and presentations. Moderator guides have been developed and reviewed in the same process undergone by the focus group moderator guides
1665259|NCT01735448|Other|Survey|A four page survey will be administered to all focus group and interview participants in addition to select cohorts including tobacco related special interest groups of the Thoracic Society of Australia and New Zealand (TSANZ). The survey will include demographic data, smoking history and current smoking status (questions related to smoking for current tobacco users include the Fagerstrom test for nicotine dependence, multiple Likert scales for cravings, motivation to quit, confidence etc.) and Likert scales examining perceptions, attitudes and knowledge about tobacco use, cessation, prevention, health and research in the Aboriginal setting.
1665260|NCT01735435|Other|Indirect Calorimetry|"The tight calorie group received calories with an energy goal determined by repeated REE measurements using indirect calorimetry.
IC measurements:after a fasting period of at least 6 hours at three time periods : on admission to the study,between 24-48 hours following surgery and on the 7th day of the study.Measurements were performed by an experienced nurse or dietician,the device was automatically calibrated before each measurement and the REE was recorded after 15 minutes."
1665426|NCT01734265|Drug|Depigoid 50% Grasses/50% Parietaria judaica (2000DPP/ml)|
1665545|NCT01733420|Drug|Biodentine pulpotomy|
1665261|NCT01735422|Drug|r-hFSH|Daily r-hFSH treatment will be administered subcutaneously at a starting dose according to the site's standard practice from Day 3-5 of menstrual cycle up to follicular development or 28 days. Dose can be altered according to ovarian response (reduced to 75 IU/day; increased to 225 IU/day).
1665262|NCT01735422|Drug|r-hLH|Ovulation triggering will be performed using a single injection of r-hLH injection subcutaneously at a dose of 825 or 2750 or 5500 or 11,000 or 22,000 IU as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
1665263|NCT01735422|Drug|u-hCG|Ovulation triggering will be performed using a single injection of 5000 IU of u-hCG as soon as follicles satisfy the criteria for follicular development, that is at least 1 follicle with diameter >= 18 mm, not more than 5 follicles with diameter >= 15 mm and with E2 levels less than 9000 picomoles per liter (pmol/L).
1665264|NCT01735409|Drug|ABX + DDP|ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
1665265|NCT01735409|Drug|ABX + DDP|ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
1665266|NCT01735409|Drug|ABX + DDP|ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
1665267|NCT01735396|Drug|Abiraterone Acetate|Abiraterone acetate 1000 mg orally daily (supplied as four 250 mg tablets) and prednisone 5 mg orally twice daily
1665268|NCT01735383|Drug|Etodolac Tablets USP 500mg|500 mg tablet once a day
1665269|NCT01735383|Drug|Etodolac Tablets USP 500 mg|500 mg tablet once a day
1665270|NCT01735370|Drug|Etodolac Tablets USP 500mg|500 mg tablet once a day
1665271|NCT01735370|Drug|Etodolac Tablets USP 500 mg|500 mg tablet once a day
1665272|NCT01735357|Dietary Supplement|EPA-rich triacylglycerol oil|
1665273|NCT01735357|Dietary Supplement|Placebo - olive oil (BP specification)|
1665274|NCT01735357|Dietary Supplement|DHA-rich triacylglycerol oil|
1665275|NCT01735344|Drug|Lisinopril Tablets 40 mg|40 mg tablet once a day
1665276|NCT01735344|Drug|Lisinopril|40 mg tablet once a day
1665277|NCT01735318|Drug|Lisinopril Tablets 40 mg|40 mg tablet once a day
1665278|NCT01735318|Drug|Lisinopril|40 mg tablet once a day
1665279|NCT01735292|Device|Automatic Respiration Transfer System- Timer|
1665281|NCT01735266|Other|Air colonoscopy|Colonoscopy will be performed with conventional air insufflation during colonoscope insertion.
1665282|NCT01735266|Other|Water exchange colonoscopy|Water exchange method (The air pump was turned off before colonoscopy. During colonoscope insertion, residual air in lumen was suctioned and 37°C water was infused into lumen to obtain lumen visualization) was used in whole or left colon. Air was insufflated until cecum was reached or appendix opening was seen.
1665283|NCT01735253|Procedure|laparoscopic roux en Y gastric bypass / open duodenojejunal bypass|routine GBP with 80cm roux and biliopancreatic limb
1665284|NCT01735240|Drug|AZD5069|AZD5069 15 mg (3x5 mg capsules) single administration
1665285|NCT01735240|Drug|Ketoconazole|Ketoconazole 400 mg (2x200 mg tablets)
1665286|NCT01735227|Drug|omeprazole|all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg(1 year) + aspirin 300mg(1 month)+ aspirin 100mg(long-term)and omeprazole group taking omeprazole 20mg/d
1665287|NCT01735227|Drug|Pantoprazole|On the day of admission , all patients taking clopidogrel loading dose 300mg + aspirin 300mg and the subsequent maintenance dose of clopidogrel 75mg + aspirin 300mg and omeprazole group taking omeprazole 20mg / d , pantoprazole group taking pantoprazole 20mg / d. Respectively, on the day of admission ( before medication ) , medication for 12-24 hours , medication after 72 hours , 30 days , each taken early morning fasting venous blood again , measuring AA 、ADP - induced platelet aggregation . And selected 30 days , 6 months and 12 months to record the patient's clinical adverse events ( including death , myocardial infarction , and any revascularization , stent thrombosis , recurrent angina , rehospitalization
1665288|NCT01735214|Drug|Prostaglandin Analogue -Containing IOP-Lowering Therapy|Patients with POAG or OHT on current IOP-lowering therapy who are prescribed a prostaglandin analogue -containing IOP-lowering therapy by the physician. The decision to prescribe a change in IOP-lowering therapy lies with the physician according to their standard practice.
1665289|NCT01735201|Drug|AGN-199201 Dose A|AGN-199201 Dose A applied once or twice daily to the face for 28 days.
1665290|NCT01735201|Drug|AGN-199201 Dose B|AGN-199201 Dose B applied once or twice daily to the face for 28 days.
1665291|NCT01735201|Drug|AGN-199201 Dose C|AGN-199201 Dose C applied once or twice daily to the face for 28 days.
1665292|NCT01735201|Drug|AGN-199201 Vehicle|AGN-199201 Vehicle applied once or twice daily to the face for 28 days.
1665293|NCT01735175|Drug|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
1665294|NCT01735175|Drug|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.
1665295|NCT01735149|Dietary Supplement|Kochujang Pills|Kochujang Pills (34.5g/day)
1665296|NCT01735149|Dietary Supplement|Placebo|Placebo (34.5g/day)
1665297|NCT01735136|Dietary Supplement|InSan Bamboo Salt|InSan Bamboo Salt (10g/day)
1665298|NCT01735136|Dietary Supplement|Placebo|Placebo (10g/day)
1665299|NCT01735123|Dietary Supplement|dietary intervention|hydrolyzed vs. nonhydrolyzed infant formula
1665300|NCT01735110|Procedure|transfemoral intervention (TFI)|
1665301|NCT01735110|Procedure|Transradial intervention|
1665302|NCT01735097|Dietary Supplement|Vitamin E|Vitamin E (200 mg, soft capsule)
1665303|NCT01735097|Dietary Supplement|Nigella sativa|Nigella sativa (200 mg, soft capsule)
1665304|NCT01735097|Dietary Supplement|Placebo|Placebo (refined oil in soft capsule with same color and size like that contains N. sativa)
1665305|NCT01735084|Biological|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.
Active ingredients
Each 0.5 mL dose contains:
2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg)."
1665306|NCT01735084|Biological|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
1665307|NCT01735071|Drug|bevacizumab and trabectedin|Arm A: bevacizumab (15 mg/kg) given as 1 hour infusion will be followed by trabectedin (1.1 mg/sqm) 3 hour iv infusion; to be repeated every 21 days until progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients
1665308|NCT01735071|Drug|bevacizumab, trabectedin and carboplatin|"Arm B: cycle 1- 6, bevacizumab given as 1 hour infusion will be followed by carboplatin AUC 4 and trabectedin 3 hour iv infusion.
Cycle 7- end of treatment, bevacizumab given as 1 hour infusion will be followed by trabectedin 3 hour iv infusion.
Patient enrolled in arm B will receive (cycle 1-6): trabectedin 0.8 mg/m2 ,carboplatin AUC 4 day 1 every 28 days and bevacizumab 10 mg/kg iv on day 1 and day 15.
From cycle 7 to disease progression, unacceptable toxicity, patient or physician decision to discontinue, or death patients will receive bevacizumab 15 mg/kg iv and trabectedin 1.1 mg/m2 day 1 every 21 days"
1665309|NCT01735058|Drug|Sodium Hyaluronate|Ultrasound guided injection of sodium hyaluronate; Fermathron ™, 20 mg/2ml of Sodium Hyaluronate, 3 weekly injections.
1665310|NCT01735058|Drug|Normal saline|Ultrasound guided injection of 0.9% normal sodium hyaluronate line solution, at 2 mL/syringe, 3 weekly injections.
1665311|NCT01735045|Device|Lagado LSH (mangofilcon A) Soft (hydrophilic) Contact Lens|Daily Wear
1665312|NCT01735045|Device|Benz 3GX (hioxifilcon B) Soft (hydrophilic) Contact Lens|
1665313|NCT01735019|Drug|Administration of remifentanil with TCI system|A given effect site concentration of remifentanil would be administered to subjects using TCI system. According to biased coin design, the given concentration of remifentanil is determined according to success or failure of just previously enrolled patient. If the former patient did not cough during anesthetic emergence at a given concentration (success), the next patient will be randomly allocated into the same concentration of remifentanil with 18/19 of probability or the lower concentration of remifentanil by 0.4 ng/ml with 1/19 of probability. If the former patient coughed during anesthetic emergence (failure), the next will be automatically allocated into the higher concentration of remifentanil by 0.4 ng/ml.
1665314|NCT01735006|Biological|HPV Vaccine|3 doses at month 0,1 and 6
1665315|NCT01735006|Biological|HEV vaccine|3 doses at month 0,1 and 6
1665316|NCT01734993|Drug|Tocilizumab|Participants will receive TCZ 162 milligrams (mg) SC injection once a week.
1665317|NCT01734980|Procedure|Endobronchial Ultrasound|The samples will be divided as 2 groups for comparison. Group A is the group of samples where we apply negative pressure syringe for needle suction. Group B is where no suction will be applied after needle insertion.
1665318|NCT01734967|Device|needle based CLE|"EUS-nCLE will be performed after EUS identification of the pancreatic tumor / lymph node / liver metastasis:
The confocal microprobe will be preloaded in a 19G FNA needle as previously described and advanced into the lesion under EUS guidance.
nCLE examination will follow after the intravenous administration of the contrast agent (2.5 ml fluorescein 10%).
Image data will be stored digitally for offline analysis."
1665319|NCT01734967|Procedure|EUS-FNA|Endoscopic ultrasound (EUS) is an established tool in pancreatic masses used both for diagnosis, but also for staging purposes. Additionally, EUS enables guided fine needle aspiration (FNA), which is currently recommended as the first-line procedure whenever a pathological diagnosis is required.
1665320|NCT01734954|Procedure|Sciatic nerve anesthesia blockade at bifurcation.|A proximal and distal initial scan and define the site to block the bifurcation. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% and a total volume of 20 mL.
1665321|NCT01734954|Procedure|Sciatic nerve blockade 2 cm beyond the bifurcation|A proximal and distal initial scan and define the sites to block: tibial and peroneal nerves separate distal 2 cm from the bifurcation site. A puncture with an insulated needle guided by ultrasound and injection of levobupivacaine circumferential in 0.5% 10 mL tibial nerve and 10 mL to the peroneal nerve.
1665322|NCT01734954|Drug|Levobupivacaine 0.5%: 20 ml|Levobupivacaine is a local anesthetic that is commonly use for anesthesia nerve blockade.
1665323|NCT01734954|Device|Portable Ultrasound Machine: Sonosite, M-Turbo, Bothell, WA|An ultrasound machine is a device that is widely used for the correct placement of the local anesthetic for anesthesia nerve blockade.
1665324|NCT01734954|Device|Insulated Needle, (Stimuplex; Braun, Melsungen, Germany)|This is a specific kind of needle that is widely used for anesthesia nerve blockade.
1665325|NCT01734954|Drug|supplemental oxygen|supplemental oxygen during the block and/or during surgery
1665326|NCT01734954|Drug|Midazolam|Intravenous midazolam for sedation during the block and/or during surgery
1665327|NCT01734954|Drug|Intravenous analgesics|Intraoperative administration intravenous of dipyrone 30-50 mg/Kg and or intravenous ketoprofen 100 mg or diclofenac 75 mg or ketorolac 30 mg
1665328|NCT01734954|Procedure|Saphenous nerve block|Depending on sensitive territory committed by the type of surgery suprapatellar saphenous nerve block guided by ultrasound with 100 mm Stimuplex needle and injection of levobupivacaine 0.5% (total volume: 5 ml).
1665329|NCT01734941|Drug|TSO|There is evidence of a relationship between ASD symptomatology and immune dysfunction suggests that immunomodulatory treatments effective in other autoimmune disorders might be investigated in ASD, including Trichuris Ova Suis (TSO), a helminth porcine whipworm
1665330|NCT01734941|Drug|Placebo|
1665331|NCT01734928|Drug|Pomalidomide|Pomalidomide 4 mg will be taken orally on Days 1-14 of a 21-day cycle.
1665332|NCT01734928|Drug|Bortezomib|Bortezomib 1.3 mg/m2 will be administered subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on Days 1, 8 of 21 days for cycle 9 and onward until disease progression.
1665333|NCT01734928|Drug|Dexamethasone|Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [>75 years old] will be taken orally on Days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on Days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression.
1665334|NCT01734915|Device|Circulating tumor cell chip|three tubes (6 teaspoons) of peripheral blood are drawn and are analyzed using the CTC chip
1665335|NCT01734902|Drug|Hyoscine butylbromide|sugar coated tablets for oral administration
1665336|NCT01734902|Drug|Hyoscine butylbromide|drops for oral administration
1665337|NCT01734889|Drug|Nitisinone|Oral suspension
1721201|NCT00003387|Drug|paclitaxel|
1665338|NCT01734876|Behavioral|Tactile Touch|Tactile Touch was performed for 10 times during a 8 week period.The method consists of a superficial whole body tactile touch, following a structural scheme. Participants in a horizontal position, in a tempered room. Aroma of lavendar and quiet music in the background.
1665339|NCT01734876|Behavioral|Rest To Music|Participants in horizontal position. Rest in a temperated room, aromas and quiet music in the background. Time: About 30 minutes.
1665340|NCT01734863|Radiation|External Beam Radiotherapy|
1665341|NCT01734850|Drug|Busulfan|Intravenous busulfan
1665342|NCT01734850|Biological|Cal-1 modified HSPC|Hematopoietic progenitor/stem cells (HSPC) modified with LVsh5/C46 (Cal-1)
1665343|NCT01734850|Biological|Cal-1 modified CD4+ T lymphocytes|CD4+ T lymphocytes modified with LVsh5/C46 (Cal-1)
1665344|NCT01734837|Device|DS-Ligature Clip|
1665345|NCT01734824|Drug|Denosumab|sc RANKL-inhibitor
1665346|NCT01734824|Drug|Teriparatide|daily subcutaneous injection of teriparatide
1665347|NCT01734824|Drug|Placebo Denosumab|one subcutaneous injection denosumab placebo
1665348|NCT01734824|Drug|Placebo Teriparatide|daily subcutaneous placebo injection
1665349|NCT01734811|Biological|Biological vaccine|Daily dose
1665350|NCT01734798|Radiation|Radiation|
1665351|NCT01734798|Drug|gemcitabine and cisplatin|
1665352|NCT01734798|Other|Radiotherapy and Drug|
1665353|NCT01734785|Drug|Linagliptin|tablet
1665354|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination.
1665355|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination
1665356|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination
1665357|NCT01734785|Drug|Empaglifozin placebo + Linagliptin placebo|Matching Empaglifozin + Linagliptin low dose
1665358|NCT01734785|Drug|Empagliflozin + Linagliptin|Fixed dose combination.
1665359|NCT01734772|Drug|dabigatran etexilate|multiple doses of dabigatran
1665360|NCT01734772|Drug|dabigatran etexilate|medium dose dabigatran
1665361|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
1665362|NCT01734772|Drug|ticagrelor|multiple doses of ticagrelor
1665363|NCT01734772|Drug|ticagrelor|loading dose of ticagrelor
1665364|NCT01734772|Drug|dabigatran etexilate|single dose of dabigatran
1665365|NCT01734759|Drug|Taste Test|"Before the taste test each participant will fill out an informed consent form and an enrollment survey. Each participant will receive 0.5 mL of each study medication in the taste test. During the taste test each medication in a class will be labeled with a color name so as to prevent any bias from preconceived taste perception. They will record their perception of the medications taste on a visual analog scale (VAS). An anaphlyaxis kit will be on hand in case of emergencies. Between samples participants will cleanse their palate with a saltine cracker and 30 mL of water. 5 different classes of medications will be tested.
Medications to be sampled and the corresponding dose of the test dose are:
Cephalosporins: cefdinir 12.5 mg, cefixime 10 mg
Penicillins: penicillin VK 12.5 mg, amoxicillin 12.5 mg
Analgesic/antipyretics: acetaminophen 16 mg, ibuprofen 10 mg
Steroids: prednisolone 1.5 mg, prednisone 0.5 mg
H2 receptor blockers: famotidine 4 mg, ranitidine 7.5 mg"
1665367|NCT01734733|Other|NTCELL|
1665368|NCT01734707|Dietary Supplement|Allicor|
1665369|NCT01734707|Drug|Placebo|Sugar pill manufactured to mimic Allicor 150 mg tablet
1665370|NCT01734694|Drug|Vancomycin|"Dose optimized vancomycin. Target trough: 15 - 20 mg/L for Health Care Associated Pneumonia, Osteomyelitis, Septic Arthritis, Endocarditis and Bacteremia;
Target trough: 10 - 20 mg/L for Acute Bacterial Skin and Skin Structure Infections;"
1665371|NCT01734694|Drug|Ceftaroline|"Dose based on package insert labeling
CrCL > 50 mL/min: 600 mg IV q12h
CrCL 31-50 mL/min: 400 mg q12h
CrCL 15-30 mL/min: 300 mg q12h
CrCL < 15mL/min: 200 mg q12h;"
1665372|NCT01734694|Drug|Daptomycin|"Dose based on renal function and literature dosing recommendations
CrCL ≥ 30 mL/min: 6 - 10 mg/kg IV q24h
CrCL < 30 mL/min: 6 - 10 mg/kg IV q48h"
1665373|NCT01734694|Drug|Linezolid|600 mg IV/PO q12h
1665374|NCT01734681|Drug|G-202|
1665375|NCT01734668|Device|In Vitro Diagnostic device to aid in diagnosis|
1665376|NCT01734616|Behavioral|Old Exercise|
1665377|NCT01734616|Dietary Supplement|Old Acute Cocoa|
1665378|NCT01734616|Dietary Supplement|Old 7 Day Cocoa|
1665379|NCT01734603|Procedure|experimental rehabilitation program|"Duration training = 40 min : 5 cycles of 6 min each Week 1 speed of the walking exercise fixed at 70% of the max walking test's speed done on the initial walking test speed of the walking recovery fixed at 40% Walking slope : 0% Increase of the speed = 0.1 km/h after each training without pain.
Week 2 Walking speed = average of the walking speeds done on week 1 Walking slope = 1% Recovery slope = 0% Increase of the slope = 0.5% after each training without pain.
Week 3 Walking speed = 70% of the maximal walking test's speed Recovery speed = 40 % of the maximal walking test's speed Slope = average of the slopes done on week 2 Increase of the speed = 0.1 km/h .
Week 4 Speeds = average of the walking speeds done on week 3 Walking slope = 1% Recovery slope = 0% Increase of the slope is 0.5% ."
1665380|NCT01734603|Procedure|conventional rehabilitation program|"Duration of the training 40 minutes (time excluding rest and warm up)
Initial intensity = 3.2 km per hour and slope at 0% Walking until pain 3/5, then stop until pain completely subsides.Resume of walking as soon as possible.
Increase :
Week 1: if the walking is possible during 8 minutes, increase of the slope of 0.5% in each training until 10% Week 2 :if the walking is possible during 8 minutes, increase of the speed 0.2 mile per hour until 3 mph Week 3 :if the walking is possible during 8 minutes, increase of the slope 2% at each training until 15% Week 4 : if the walking is possible during 8 minutes, increase the speed 0.2mph at each training as long as it is possible."
1665381|NCT01734590|Dietary Supplement|Carbohydrate based food mix 1|Carbohydrate based food
1665382|NCT01734590|Dietary Supplement|Carbohydrate based food mix 2|Carbohydrate based food
1665383|NCT01734590|Dietary Supplement|Control carbohydrate based food|Carbohydrate based food
1665384|NCT01734577|Procedure|Dry needling|Sterile monofilament needles
1665385|NCT01734577|Procedure|Sham needling|Applicator tubes from the sterile monofilament needles
1665386|NCT01734564|Biological|Hiltonol and autologous dendritic cells|Hiltonol and autologous dendritic cells
1665546|NCT01733420|Drug|White MTA pulpotomy|
1665387|NCT01734564|Radiation|Hiltonol, dendritic cells and radiation|Hiltonol, autologous dendritic cells and radiation therapy. Radiation therapy will pursue an abscopal effect.
1665388|NCT01734551|Drug|Morphine|"Start at 0.4mg/kg/day (divided every 3-4 hours, given with feeds. Dose may be increased 25% of initial dose until symptoms are stable, up to 1 mg/kg/day.
Once stable for 72 hrs, weaning may begin (decrease 10% of max dose, every other day). When total dose is <0.1mg/kg/day, may discontinue."
1665389|NCT01734551|Drug|Clonidine|Initial dose is 5 mcg/kg/day (divided every 3-4 hrs, given with feeds). Will increase 25% of initial dose every 12-24 hrs until stable, up to 12 mcg/kg/day. Dose is unchanged for 72 hours once stable, then may decrease by 10% every other day. If re-escalation is required, the previous dose may be used with 72 hours for stabilizing.
1665390|NCT01734538|Dietary Supplement|Omega-3 Complete|
1665391|NCT01734538|Dietary Supplement|Placebo capsule|
1665393|NCT01734512|Drug|Everolimus|Everolimus tablet will be taken daily by mouth with water. All patients will be given a dose of 5 mg/m2/dose daily.
1665394|NCT01734499|Behavioral|Coping Class|"A 4-hour structured program which will be offered once a month as the Coping Class by a certified facilitator of The Change Cycle. The coping class uses standardized materials and skills training. Standardized materials for the intervention arm will include Change Moves Me Participant's Guide/Journal, Locator Assessment Profile, The Change Cycle Color Model, and class evaluation. The structure of the class includes a profile of each stage to gain perspective and understanding, teaching personal change skills for each stage and a primary focus for movement to the next stage. The overall design follows an act as if philosophy, guiding participants through each stage of The Change Cycle, irrespective of which stage they are actually in."
1665395|NCT01734499|Behavioral|Standard of Care|Standard of Care. Three components of this: (1)Surveillance Program: all patients diagnosed with breast cancer are seen every six months for the first two years and yearly thereafter to rule out disease recurrence by history and physical exam at each visit in addition to the annual mammogram. (2)Local support groups centered at community cancer centers. These are generally attended by 12-16 women monthly; all breast cancer patients receive the information about these groups. Associated with these programs, some classes are offered sporadically in nutrition, and exercise. (3)Comprehensive Postoperative Rehabilitation which offers physical and occupational rehabilitation to all women, thus provides prevention and treatment of lymphedema and monitored shoulder range of motion.
1665396|NCT01734499|Behavioral|FACT-B Quality of Life|The FACT-B Quality of Life is a 44-item instrument that was developed by combining nine breast cancer-specific QL items with the FACT general QL instrument. The FACT-B consists of the following subscales: physical wellbeing (PWB), functional wellbeing (FWB), emotional wellbeing (EWB), social/family wellbeing (SWB), and breast cancer specific concerns (BCS).
1665397|NCT01734486|Drug|somatropin|0.9 UI/kg/week. Subcutaneous injection for 3 years
1665398|NCT01734486|Drug|somatropin|1.8 UI/kg/week. Subcutaneous injection for 3 years
1665399|NCT01734473|Dietary Supplement|Hydrolyzed casein protein|Amount provided is based on the fat-free mass of subject
1665400|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject
1665401|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
1665402|NCT01734473|Dietary Supplement|Hydrolyzed casein protein + carbohydrates + leucine|Amount provided is based on the fat-free mass of subject. Leucine (40% of essential amino acid content)
1665403|NCT01734473|Dietary Supplement|4 levels of hydrolyzed casein protein + carbohydrates|Amount provided is based on the fat-free mass of subject. The 4 levels are: 0, 0.02, 0.05, 0.15 g casein protein/kg fat free mass/hr. The ratio between protein and carbohydrates is fixed.
1665404|NCT01734447|Drug|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 12 months
1665405|NCT01734447|Drug|somatropin|1.2 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
1665406|NCT01734447|Drug|somatropin|2.4 IU/kg/week, one injection per day, in six days out of seven days, for 6 months out of 12 months (i.e. alternating periods of 6 months of treatment and non-treatment, respectively)
1665407|NCT01734421|Other|Control group|6-month implementation of recommendations of a Clinical Practice Guideline smoking cessation
1665408|NCT01734421|Device|Cell phone Aplication for Smarth Phone|
1665409|NCT01734408|Biological|alum-adjuvant 160U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 160U /0.5ml EV71 vaccine
1665410|NCT01734408|Biological|alum-adjuvant 320U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 320U /0.5ml EV71 vaccine
1665411|NCT01734408|Biological|alum-adjuvant 640U /0.5ml|inactivated vaccine (vero cell) alum-adjuvant 640U /0.5ml EV71 vaccine
1665412|NCT01734408|Biological|adjuvant-free 640U /0.5ml|inactivated vaccine (vero cell) adjuvant-free 640U /0.5ml EV71 vaccine
1665413|NCT01734408|Biological|0/0.5ml placebo|0/0.5ml placebo
1665414|NCT01734395|Drug|Galantamine|This is an observational study. Galantamine 8 mg/day will be administered for the first 4 weeks and later on the dose will increased up to 24 mg (if tolerable). Galantamine dose will be adjusted according to the investigator's discretion.
1665415|NCT01734382|Drug|Tocilizumab|Participants will receive tocilizumab IV infusions of 12 mg/kg (for participants less than [<] 30 kg) or 8 mg/kg (for participants </=30 kg) Q2W/Q3W/Q4W.
1665416|NCT01734356|Other|Skin biopsies|
1665417|NCT01734343|Device|HOYA iMics Y-60H|same-day bilateral cataract surgery with implantation of intraocular lens HOYA iMics Y-60H in one eye
1665418|NCT01734343|Device|PhysIOL microAY|same-day bilateral cataract surgery with implantation of intraocular lens PhysIOL microAY in one eye
1665419|NCT01734330|Behavioral|Cognitive behavioral therapy in group|
1665420|NCT01734330|Drug|Nicotine replacement|
1665421|NCT01734317|Device|Mepilex Transfer Ag|A soft silicone wound contact layer.
1665422|NCT01734304|Biological|DC vaccination for postremission therapy in AML|.DC vaccination
1665423|NCT01734291|Behavioral|Family psychoeducation|Family psychoeducational therapy every two weeks for six weeks in addition to treatment as usual administered by physicians
1665424|NCT01734278|Other|No intervention|This is a non-interventional study.
1665428|NCT01734239|Biological|Pneumovax™ 23|Vaccine contains 25 µg of each of the 23 pneumococcal polysaccharides serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F, and 33F
1665429|NCT01734226|Dietary Supplement|Prunus Mume Extract|Prunus Mume Extract (3.94g/day)
1665430|NCT01734226|Dietary Supplement|Placebo|Placebo (3.94g/day)
1665431|NCT01734213|Dietary Supplement|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
1665432|NCT01734213|Dietary Supplement|Placebo|Placebo (1.5g/day)
1665433|NCT01734200|Dietary Supplement|Eriobotyra Japonica Lindley Extract|Eriobotyra Japonica Lindley Extract (1.5g/day)
1665434|NCT01734200|Dietary Supplement|Placebo|Placebo (1.5g/day)
1665435|NCT01734187|Dietary Supplement|Fermented Cinnamon Vine Powder|Fermented Cinnamon Vine Powder (30g/day)
1665436|NCT01734187|Dietary Supplement|Placebo|Placebo (30g/day)
1665437|NCT01734174|Procedure|transesophageal echocardiography (TEE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the esophagus (which lies behind the heart) and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
1665438|NCT01734174|Procedure|thermodilution|A catheter is positioned in the pulmonary artery and the heart function is assessed via thermodilution which involves measuring the temperature of blood when a known volume of fluid is injected through the catheter to determine how quickly blood is carried from one part of the catheter to the other.
1665439|NCT01734174|Procedure|transthoracic echocardiography (TTE)|Echocardiography is an ultrasound-based imaging technique which can be performed through the chest wall and is performed routinely as a monitoring and diagnostic tool at different times in the course of one cardiac surgery.
1665440|NCT01734161|Drug|Dexamethasone|8mg IV dexamethesone given
1665441|NCT01734161|Drug|Placebo|Subjects randomized to placebo receive 50cc normal saline
1665442|NCT01734148|Behavioral|Relax To Sleep Program|The educational portion of the program will consist of a standardized educational booklet and a discussion with the PI and provides a brief overview will be given on normal sleep and sleep patterns, children's sleep needs, and the signs and consequences of sleep disturbance. Second, the educational booklet provides sleep hygiene info. The second component consists of of good sleep habits such as having a regular sleep-wake schedule, avoiding caffeine intake prior to sleep, avoiding stimulating activities near nighttime sleep, avoidance of naps during the day, ensuring that the child is exposed to natural light during the day, providing the child with opportunities to socialize during the day. Finally, the program consists of a relaxation breathing technique for the child.
1665443|NCT01734135|Other|Clinical Reminder|A note is sent to the primary care provider using the electronic medical record indicating the high BNP result and potential benefit of measurement of the left ventricular ejection fraction. A draft order is placed for an echocardiogram for the provider to accept or delete.
1665444|NCT01734109|Device|Quantum Negative Pressure Wound Therapy Device|To compare the additional benefit of Quantum Negative pressure wound therapy device with and without simultaneous irrigation.
1665445|NCT01734096|Other|Lower body negative pressure (LBNP)|Lower limbs are put in in LBNP device for one hour (-30 mbar)
1665446|NCT01734096|Drug|Candesartan cilexetil|candesartan cilexetil 16 mg once a day for 7 days cross over with placebo in control group, obesisty group and white coat hypertension group
1665447|NCT01734083|Device|Whole body vibration exercise|The whole body vibration will be delivered by a platform that can generate vibration signals (Powerplate). The total duration of vibration exposure per session will range from 4 to 6 minutes. The vibration bouts (30-45 seconds per bout) will be interspersed with a 1 to 2 minutes of rest period. While standing on the vibration platform, subjects will be instructed to repeat two exercises: (1) static semi-squats, and (2) dynamic semi-squats.
1665448|NCT01734083|Behavioral|Conventional exercise|The conventional exercise training will involve a combination of upper limb and lower limb stretching and strengthening exercises, balance training, and gait re-education.
1665449|NCT01734070|Other|Cherry consumption|Volunteers will eat 280 grams/day of pitted Bing cherries by replacing an equivalent amount of carbohydrate calories.
1665450|NCT01734057|Drug|recombinant human thrombopoietin (rhTPO); rituximab|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with rhTPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 28th day)
1665451|NCT01734057|Drug|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
1665452|NCT01734044|Drug|recombinant human thrombopoietin (rhTPO); dexamethasone|Patients in recombination treatment group take rhTPO( subcutaneously , 300U/kg for 14 consecutive days, followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 28th day), in combination with dexamethasone(intravenously , 40mg/d for 4 consecutive days)
1665453|NCT01734044|Drug|Dexamethasone|Patients in single treatment group take dexamethasone intravenously at 40 mg daily for 4 consecutive days.
1665454|NCT01734005|Dietary Supplement|Red Ginseng|Red Ginseng (1.4g/day)
1665455|NCT01734005|Dietary Supplement|Placebo|Placebo (1.4g/day)
1665456|NCT01733992|Drug|R348 Ophthalmic Solution, 0.2%|R348 Ophthalmic Solution, 0.2% single and multiple ascending dose
1665457|NCT01733992|Drug|R348 Ophthalmic Solution, 0.5%|R348 Ophthalmic Solution, 0.5%, single and multiple ascending dose
1665458|NCT01733992|Drug|R348 Ophthalmic Solution, 1.0%|R348 Ophthalmic Solution, 1.0%, single and multiple ascending dose
1665459|NCT01733992|Drug|Placebo|Placebo, single and multiple ascending dose
1665460|NCT01733979|Dietary Supplement|Heme-Iron Polypeptide|Heme-Iron Polypeptide (1g/day)
1665461|NCT01733979|Dietary Supplement|Placebo|Placebo (1g/day)
1665462|NCT01733979|Dietary Supplement|Heme-Iron|Heme-Iron (1g/day)
1665463|NCT01733979|Dietary Supplement|Organic Iron|Organic Iron (1g/day)
1665464|NCT01733966|Drug|Secnidazole, ciprofloxacine|"2g of microgranules of secnidazole. a single dose per day during 3 days.
1g of Ciprofloxacin (2 tablets of 500mg per day during 3 days)"
1665465|NCT01733966|Drug|Amoxicillin-Clavulanic Acid|3g of Amoxicillin-Clavulanic acid (3 powder packet of 1g per day during 10 days)
1665466|NCT01733953|Drug|Atorvastatin|6-Months of Atorvastatin (Lipitor); 40mg, oral, once daily.
1665467|NCT01733953|Drug|Sugar Pill (Placebo)|6-Months of placebo (sugar) pill; oral, once daily
1665468|NCT01733940|Device|Application of a dressing with clorhexidine gluconate in intravascular catheters.|
1665469|NCT01733940|Device|Application of a dressing without clorhexidine gluconate|
1665470|NCT01733927|Device|Rapid testing for HIV|The research team members were trained and certified in administering the OQA testing through the AIDS International Consortium in Philadelphia (WHCI), USA. During the recruitment process, participants were informed about the nature of the test, the length of time for results, and what procedures would be involved in self-administering the OQA test. After providing informed consent, including the release of information for research use, participants demonstrated their ability to properly take an OQA sample using a popsicle stick as a proxy for the testing device.
1665471|NCT01733914|Procedure|Acupuncture|Acupuncture in the following acupoints on the contralateral side of pain site: Jiantong, Zhongzhu, Houxi, and Quchi. The patient will receive 5 treatments (each lasts 30 min) per week for four weeks.
1665472|NCT01733914|Other|Control|Patients in the waiting list group received conventional orthopaedic therapy including physical exercise, heat or cold therapy. 50 mg diclofenac daily could be taken when the patient suffered from the pain. Injections or cortisone applications of any kind were not allowed.
1665473|NCT01733901|Procedure|RSD|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celcius Thermocool,Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About six to nine ablations at 10 W for 1 min each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
1665474|NCT01733901|Procedure|PCI|Percutaneous coronary intervention (PCI) is a non-surgical procedure used to treat the stenotic coronary arteries of the heart found in CHD. During PCI, a cardiologist feeds a deflated balloon or other device on a catheter from the inguinal femoral artery or radial artery up through blood vessels until they reach the site of blockage in the heart. X-ray imaging is used to guide the catheter threading. At the blockage, the balloon is inflated to open the artery, allowing blood to flow. A stent is often placed at the site of blockage to permanently open the artery.
1665475|NCT01733888|Device|Office Bleaching with 35 % Hydrogen Peroxide|In this group before starting the procedure the teeth intended to be treated will be cleaned with pumice and after that cheek retractors will be placed and exposed lip surface will be covered with petroleum gel. Thereafter, teeth will be dried and gingival Barrier will be applied to both arches, slightly overlapping enamel and interproximal spaces. Light curing of the gingival barrier will be done in a fanning motion for 10-20 seconds . Once the gingival barrier will be cured then homogeneous mixing of the powder and liquid will be done in powder pot, followed by application of thick layer of gel to all teeth undergoing treatment. The gel will be then left in place for 8 minutes and after that the gel will be removed using a surgical aspirator tip.
1665476|NCT01733888|Device|Icon Infiltration|In this group after taking pre-operative photographs the fluorosed tooth will be isolated using rubber dam and the Resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions. For this purpose, after rubber dam application tooth surface will be dried using cotton rolls and air syringe. Icon Etchant will be applied and left for 2 minutes followed by rinsing and air drying for 30 sec. After complete etching, Drying agent (99% ethanol), as supplied in the Icon kit. Resin infiltrant will then be applied and allowed to seep in for 3 minutes followed by light curing for 40 seconds followed by cleaning of the surface with pumice and rubber polishing cup and rinsing with water for 30 sec. After application, patient will be instructed neither to eat nor brush their teeth for 45 minutes.
1665477|NCT01733888|Device|Icon Infiltration twice|"In this group application of the resin infiltration shall be done similar to the procedure as explained for intervention Icon infiltration, but the resin infiltrant shall be applied twice."
1665478|NCT01733888|Device|Bleaching+Icon Infiltration|"In this group vital bleaching will be done using 35 % Hydrogen Peroxide (Pola Office, SDI, Australia), as explained in intervention bleaching; followed by wash over period of 20 days. After 20 days the patient will be recalled and on the day of appointment initially a new preoperative photograph shall be taken, then the fluorosed tooth will be isolated using rubber dam and the Resin infiltrant (Icon, DMG, Hamburg, Germany) will be applied as per manufactures' instructions, similar to intervention Icon Infiltration. For this group a postoperative photograph shall be taken after the application of RI and then the circle of post-operative recall shall be counted from here, that is, 1week, 1 month and 6 months respectively."
1665479|NCT01733875|Drug|CC-220 0.03 mg|A single dose of CC-220 0.03 mg will be administered orally once a day.
1665480|NCT01733875|Drug|CC-220 0.1 mg|A single dose of CC-220 0.1 mg will be administered orally once a day.
1665481|NCT01733875|Drug|CC-220 0.3 mg|A single dose of CC-220 0.3 mg will be administered orally once a day.
1665482|NCT01733875|Drug|CC-220 1 mg|A single dose of CC-220 1 mg will be administered orally once a day.
1665483|NCT01733875|Drug|CC-220 2 mg|A single dose of CC-220 2 mg will be administered orally once a day.
1665484|NCT01733875|Drug|Placebo|A single dose of placebo will be administered orally once a day.
1665485|NCT01733875|Drug|CC-220|CC-220 4 mg will be administered orally once a day
1665486|NCT01733875|Drug|CC-220|CC-220 6 mg will be administered orally once a day
1665487|NCT01733875|Drug|CC-220|CC-220 1 mg will be administered orally once a day in each of 2 study periods - once with food and once without food
1665488|NCT01733862|Other|Data collection|"Data sheet. Data will be collected and is planned to be analysed at the following time points:
Pre-vaccination period: Nov 2007 to Oct 2011, transition period: Nov 2011 to Oct 2012 and post vaccination period: Nov 2012 to Oct 2016."
1665489|NCT01733849|Other|Stool sample|Samples will be tested to determine the presence or absence of rotavirus.
1665490|NCT01733849|Other|Data collection|Log books
1665491|NCT01733836|Drug|Metformin|
1665492|NCT01733836|Drug|placebo|
1665493|NCT01733823|Radiation|76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole|
1665494|NCT01733810|Other|Cessation of Acid Suppressing Medications|Acid-suppressing medications are stopped for all participants the day after baseline assessment. Subsequent evaluations performed while participant is not on acid-suppressing medications.
1721419|NCT00003437|Drug|asparaginase|
1665495|NCT01733797|Device|Wooden spatula|Lollipop sticks placed between incisors
1665496|NCT01733797|Device|Therabite|Hand held device placed in mouth that exercises the jaw
1665497|NCT01733784|Other|Induced central apneas|
1665498|NCT01733771|Other|CAM treatments|CAM treatments last 10-30 minutes
1665499|NCT01733758|Drug|Albiglutide 30 mg weekly|Albiglutide will be available as a pen injector that delivers 30mg of albiglutide
1665500|NCT01733758|Drug|Albiglutide 50 mg weekly|Albiglutide will be available as a pen injector that delivers 50mg of albiglutide
1665501|NCT01733758|Drug|Placebo|Albiglutide matching placebo will be available as a pen injector
1665502|NCT01733758|Drug|Liraglutide 0.9 mg daily|Liraglutide will be available as prefilled multidose pens that can deliver 0.9 mg dose
1665503|NCT01733745|Other|SYSTANE® Lid Wipes|Pre-moistened eyelid cleansing wipes for topical ocular external scrubbing of eyelids and eyelashes
1665504|NCT01733745|Other|SYSTANE® BALANCE|Lubricant Eye Drops
1665505|NCT01733745|Dietary Supplement|SYSTANE® Vitamins|
1665506|NCT01733745|Other|Microfiber towels (as warm compresses, with or without saline eye drops)|
1665507|NCT01733732|Other|SYSTANE® BALANCE Lubricant Eye Drops|
1665508|NCT01733732|Other|SYSTANE® Gel|
1665509|NCT01733719|Procedure|ER plus RFA|
1665510|NCT01733719|Procedure|ER plus APC|2 litres/minute, 70 watts
1665511|NCT01733706|Device|No nicotine electronic cigarette|"The e-cigarette T-FUMOTM is a no nicotine electronic cigarette specifically designed to inactivate the early effects of the cessation of cigarette smoking, such as the craving caused by psychological reasons. It's formed by a filter which contains distilled water and food flavorings, an atomizer and a battery. On the opposite end to the filter there is a diode that lights up during aspiration. During the suction is generated hot air which, in contact with the liquid of the filter, generates steam which simulates the smoke of a traditional cigarette. The smoker has the sensation of smoking, but he does not suck the carcinogenic substances in traditional cigarettes and he does not assimilate nicotine."
1665512|NCT01733706|Other|Standard counseling|standard counseling
1665513|NCT01733693|Drug|Buprenorphine|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
1665514|NCT01733693|Drug|Methadone|Study participants will be randomly assigned 1:1 to buprenorphine (experimental/intervention) or methadone (active comparator). We will stratify by HIV status to ensure an equal number of HIV-infected participants in each group.
1954907|NCT03310515|Other|Social harm interview|Information regarding social harms (loss of privacy, stigmatization, interference with gainful employment, and coercion) will be solicited during bi-monthly study visits after enrollment in the study and will be recorded. Subjects who report social harms will be referred to speak with a social worker and/or a study counselor.
1665517|NCT01733667|Device|MediENT|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
1665518|NCT01733667|Device|MeroPack|MediENT will be assigned to either the right or left side and positioned between the turbinate and nasal wall of the side assigned. MeroPack will be place in between the turbinate and nasal wall of the side not assigned to MediENT
1665519|NCT01733654|Biological|RO4995819|The investigation of RO4995819 as adjunctive therapy in MDD patients is supported by preclinical and clinical evidence implicating dysfunction of glutamatergic pathways in the pathophysiology of depression and cognitive disorders, and accumulated evidence of the antidepressant and procognitive effects of mGlu2/3 antagonism.
1665520|NCT01733602|Device|transcranial direct current stimulation|
1665521|NCT01733589|Drug|Recombinant human endostatin|Recombinant human endostatin(7.5mg/m2/24h) Continued Pumping Into Vein through 5 days at week 1, 3, 5, and 7,combined with concurrent chemo-radiotherapy.
1665522|NCT01733589|Drug|Etoposide (50mg/m2) IV (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles|
1665523|NCT01733589|Drug|cisplatinum (50mg/m2) IV (in the vein) on day 1 and day 8 of a 28-day cycle for 2 cycles|
1665524|NCT01733589|Other|laboratory biomarker analysis|
1665525|NCT01733589|Other|CT perfusion imaging|
1665526|NCT01733576|Device|HD-tDCS|
1665527|NCT01733563|Procedure|Soft drink consumption|
1665528|NCT01733550|Device|Home iCare (study nurse)|the intraocular pressure is measured by iCare performed by the study nurse
1665529|NCT01733550|Device|goldmann applanation tonometry|the intraocular pressure is measured by goldmann applanation tonometry
1665530|NCT01733550|Device|home iCare (by patient)|the intraocular pressure is measured by the iCare performed by the patient him self
1665531|NCT01733537|Other|Free reflective, fluorescent vest|Motorcycle taxi drivers in the intervention arm will receive a free reflective, fluorescent vest
1665532|NCT01733537|Behavioral|Education|Both arms will receive brief, basic education about recommended measures to increase their visibility
1665533|NCT01733524|Behavioral|Pet Fish|Participants will receive a betta fish and the supplies to care for the fish for a one year time period.
1665534|NCT01733524|Behavioral|Picture of a fish|Participants will receive a picture of a betta fish.
1665535|NCT01733485|Drug|Aspirin|500 mg/8 h for 5 days
1665536|NCT01733485|Drug|Indomethacin|25 mg/8 h for 5 days
1665539|NCT01733459|Drug|DLBS3233|1 DLBS3233 capsule 100 mg once daily for 6 months
1665540|NCT01733459|Drug|Metformin XR|1 Metformin XR caplet 750 mg twice daily for 6 months
1665541|NCT01733459|Drug|Placebo caplet of Metformin XR|1 placebo caplet of Metformin XR twice daily for 6 months
1665542|NCT01733459|Drug|Placebo capsule of DLBS3233|1 placebo capsule of DLBS3233 once daily for 6 months
1665543|NCT01733446|Other|Continuation of High Frequency Jet Ventilation (HFJV)|In Group B, after cessation of anesthetic infusions, High Frequency Jet Ventilation (HFJV) will continue through the endotracheal tube. Patient will be extubated when awake. Respiratory Inductance Plethysmography (RIP) and Transcutaneous carbon dioxide (PtcCO2) measurements will continue for the duration of emergence.
1665544|NCT01733433|Procedure|Taping the ankle|Subjects will be taped in at the ankle for performing several exercises.
1665548|NCT01733407|Drug|L-serine|400mg/kg/d L-serine or placebo divided TID for year 1, then crossover of placebo arm so that all patients on 400mg/kg/d L-serine divided TID for year 2.
1665549|NCT01733407|Drug|placebo|400mg/kg/d divided TID for year 1 only.
1665550|NCT01733394|Drug|"Lamotrigine Generic A Lamotrigine Generic B Lamotrigine Brand"|
1665551|NCT01733394|Drug|lamotrigine|
1665552|NCT01733355|Radiation|[F18] T807|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
1665553|NCT01733342|Device|Celsite chemoport implantation|Celsite chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
1665554|NCT01733342|Procedure|local anesthesia|chemoport implantation will be done under local anesthesia using lidocaine.
1665555|NCT01733342|Device|Humanport chemoport implantation|Humanport chemoport implantation was done under local anesthesia, at anterior chest wall, under ultrasound guidance
1665556|NCT01733329|Drug|Misoprostol|At cord clamping 2 tablets (400 mcg) were placed in the patient´s buccal space by anesthesiologist.
1665557|NCT01733329|Drug|Folic Acid|At cord clamping 2 tablets (10 mg) were placed in the patient´s buccal space by anesthesiologist.
1665558|NCT01733316|Drug|RP103|
1665559|NCT01733316|Drug|Cystagon®|
1665560|NCT01733303|Behavioral|personalized core muscle training program|Participants are allocated to the exercise group will commence the personalized core training exercise with EMG biofeedback based on their testing results in muscle quality. The program will run for 3 months with patients attending for one hour three times a week. The age-matched control group will maintain their usual daily life activities without any specific instruction. The exercise training will be run by an experienced physiotherapist, who will encourage patients individually to progress at their own pace.
1665561|NCT01733290|Drug|Botulinum toxin A|A total of 100 units of BoNT-A will be injected deeply into the external sphincter at the 3, 6, 9 and 12 o'clock positions in approximate equal aliquot.
1665562|NCT01733290|Drug|Normal saline instillation|Normal saline instillation
1665563|NCT01733277|Other|Magnetic Resonance Imaging (MRI)|All participants from both arms will be subjected to MRI
1665564|NCT01732315|Behavioral|Email Notification|This study will use a targeted email reminder/recall intervention that addresses specific aspects of adolescent under-immunization.
1665565|NCT01732302|Other|Educational intervention|Primary health care centers (PHCC) in the intervention group will be visited twice by a pharmacist within a period of three months. At the first visit, an educational intervention will focus on two properties: on the one hand, feed-back of actual patient data of the PHCC illustrating the primary-health-care-specific characteristics of inappropriate prescribing in the elderly patient will be given. Education of relevant subjects will be given in relation to detected problems. On the other hand, a clinical routine regarding the performance of drug utilization reviews will be developed in cooperation with the health care providers. At the second visit 3 months later, the developed concept will be critically reviewed and eventually developed further.
1665566|NCT01732289|Genetic|genes|Draw blood for genetic screening
1665567|NCT01732276|Drug|gefitinib|
1665568|NCT01732263|Drug|SSP-004184|All subjects will take a single oral dose of SSP-004184 (SPD602) (50 mg/kg) on Day 1
1665569|NCT01732250|Drug|Colistin|IV Colistin with loading dose of 9 mil IU units, Maintenance dose 4.5 mil IU q12h, adjusted for renal function, for 10 days.
1665570|NCT01732250|Drug|Meropenem|IV meropenem, 2 gram q8h, adjusted for renal function, for up to 10 days.
1665571|NCT01732237|Drug|JNJ-42396302|A single dose of JNJ-42396302 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
1665572|NCT01732237|Drug|JNJ-42692507|A single dose of JNJ-42692507 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
1665573|NCT01732237|Drug|JNJ-53773187|A single dose of JNJ-53773187 100 micrograms (1 mL) will be administered orally with 240-mL non-carbonated water.
1665574|NCT01732224|Drug|Tenofovir + Telbivudine|Tenofovir (300 mg/day) plus telbivudine (600 mg/day).
1665575|NCT01732224|Drug|Tenofovir|In tenofovir arm subjects will receive tenofovir (300 mg) once daily.
1665576|NCT01732211|Biological|PD 0360324|100 mg Q2W or 150 mg Q2W via intravenous infusion based on protocol determined dose escalation/de-escalation criteria; 12 weeks Active Therapy;
1665577|NCT01732211|Other|Normal Saline for injection|normal saline Q2W via intravenous infusion for 12 weeks
1665578|NCT01732198|Biological|NU300|
1665579|NCT01732198|Biological|ActHIB|
1665580|NCT01732198|Biological|Prevnar 13|
1665581|NCT01733238|Drug|PNT2258|
1665583|NCT01733199|Other|questionnaires|Summons of patients and filling questionnaire.
1665584|NCT01733186|Biological|CARTISTEM®|
1665585|NCT01733173|Procedure|MRI with DTI and fMRI|When possible, the subject will undergo a post operative fMRI/ DTI scan as well as clinical language testing. If the subject develops CMS, the second fMRI will be performed as soon as possible. Some subjects may be severely impaired or have difficulty performing fMRI and clinical language testing tasks. In these instances, the fMRI and language testing may not be performed, or we may choose to perform resting state or passive fMRI tasks instead.
1665586|NCT01733147|Drug|Omega-3 free fatty acids|Baseline assessment: Measure waist and hip circumference, height, weight. Complete Gastroesophageal Reflux Questionnaire (GERQ). Blood draw for serum free fatty acid (FFA) profile. Clinical baseline blood draw: INR, LDL, AST and ALT. Single slice CT of abdomen. Endoscopy performed with biopsies, brushings, and mucosal impedance testing. Randomized to ω3 FFA preparation or placebo for six months. Telephone calls will be made every month to subjects to assess for adverse effects and reinforce compliance. Repeat assessment at six months following randomization. This will include anthropometry (similar to baseline), a blood draw as outlined at baseline, and endoscopy with research biopsies as outlined at baseline. Subjects will also fill out the GERQ.
1665638|NCT01732796|Drug|BI 207127|16 weeks BI 207127 followed by 8 weeks placebo to BI 207127
1665639|NCT01732796|Drug|Faldaprevir (BI 201335)|24 weeks of 201335
1665640|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
1665641|NCT01732783|Other|Observational|Observational of the Use of Vectibix® in Combination With Chemotherapy in Routine Clinical Practice for Patients With Wild-type RAS Metastatic Colorectal Cancer
1665587|NCT01733147|Drug|Placebo|Baseline assessment: Measure waist and hip circumference, height, weight. Complete Gastroesophageal Reflux Questionnaire (GERQ). Blood draw for serum free fatty acid (FFA) profile. Clinical baseline blood draw: INR, LDL, AST and ALT. Single slice CT of abdomen. Endoscopy performed with biopsies, brushings, and mucosal impedance testing. Randomized to ω3 FFA preparation or placebo for six months. Telephone calls will be made every month to subjects to assess for adverse effects and reinforce compliance. Repeat assessment at six months following randomization. This will include anthropometry (similar to baseline), a blood draw as outlined at baseline, and endoscopy with research biopsies as outlined at baseline. Subjects will also fill out the GERQ.
1665588|NCT01733134|Drug|Tolvaptan|Tolvaptan 30 mg. tablet for subjects enrolled prior to first 8 hours of coming to an emergency department. Repeated daily up to 5th day.
1665589|NCT01733134|Drug|placebo|Patient in the placebo group will receive tolvaptan in addition to standard therapy
1665590|NCT01733121|Drug|NBI-98854|25 mg capsule
1665591|NCT01733121|Drug|NBI-98854|50 mg capsule
1665592|NCT01733121|Drug|Placebo|
1665593|NCT01733108|Drug|Glyburide|One 1.25 mg tablet taken orally (by mouth) on Day 1 and Day 9.
1665594|NCT01733108|Drug|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
1665595|NCT01733095|Drug|ambrisentan|Ambrisentan (Volibris 5 mg film-coated tablets, Glaxo Smith-Kline) will be started at 5 mg every other day and increased to 5 mg daily after 4 weeks if tolerated well.
1665596|NCT01733069|Device|APTIMA COMBO 2 Assay (AC2 Assay)|APTIMA COMBO 2 Assay (AC2 Assay
1665597|NCT01733056|Biological|Flu Vaccine|Administration of Fluzone (Influenza Vaccine)
1665598|NCT01733043|Drug|Dexmedetomidine|
1665599|NCT01733043|Drug|Placebo|
1665600|NCT01733030|Drug|Seromycin|250 mg versus 500 mg versus placebo effects on conditioned fear generalization
1665601|NCT01733030|Drug|Seromycin|
1665602|NCT01733017|Behavioral|Sodium reduction|Teaching and skill building to reduce dietary sodium
1665603|NCT01733017|Dietary Supplement|omega 3 and lycopene supplements|omega-3 fatty acid supplements and juices containing lycopene
1665604|NCT01733017|Dietary Supplement|rice bran oil capsules|placebo capsules
1665605|NCT01733017|Behavioral|Generic dietary feedback from|Provided a summary of the 3 day dietary recalls at baseline, 3 months, and 6 months
1665606|NCT01733004|Drug|MM-141|
1665607|NCT01732991|Device|prostatic photo-vaporization (PVP)|Prostatic photo-vaporization using a lithium laser of 532nm wavelength (GREEN-LIGHT XPS™,American Medical Systems, Minnetonka, MN, USA) emitting by a fiber MoXy™ a maximum power of 180 W continuously. Using common practice and according to the CE labelling.
1665608|NCT01732978|Behavioral|Crying record|"Recording spontaneous crying is as soon as possible after birth. Crying is recorded twice during the first week of life.
Listening tests:
Tests will be conducted playbacks with the father and mother separately, and with a staff"
1665609|NCT01732965|Other|Phototherapy|
1665610|NCT01732965|Other|Phototherapy and Photochemotherapy|
1665611|NCT01732926|Drug|Idelalisib|150 mg tablet administered orally twice daily
1665612|NCT01732926|Drug|Rituximab|375 mg/m^2 single-use vials administered intravenously every 4 weeks (up to a total of 6 infusions)
1665613|NCT01732926|Drug|Bendamustine|90 mg/m^2 single-use vials administered intravenously for two consecutive days every 4 weeks (up to a total of 4-6 cycles as tolerated)
1665614|NCT01732926|Drug|Placebo|Tablet administered orally twice daily
1665615|NCT01732913|Drug|Placebo|Tablets administered orally twice daily
1665616|NCT01732913|Drug|Rituximab|375 mg/m^2 administered intravenously weekly for 4 weeks, then every 8 weeks (up to a total of 8 infusions)
1665617|NCT01732913|Drug|Idelalisib|150 mg tablets administered orally twice daily
1665618|NCT01732900|Other|Morphology|Embryos selected for transfer will be based upon morphology alone.
1665619|NCT01732900|Other|GemART assay|Embryos selected for transfer will be based upon morphology and GemART assay.
1665620|NCT01732887|Other|Cognitive fitness training|"Computer-based training of basic cognitive functions. It has activities under two headings,
General training applications
Memory training applications
Each individual session in both groups will include playing specific computer games for at least 1/2 hour a day, 3 days per week, throughout the 10 week interval."
1665621|NCT01732874|Drug|Expecta 200 mg|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 200mg Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
1665622|NCT01732874|Drug|Expecta 1 gram|Breastfeeding mothers who have given birth to premature infant 29 weeks or less will be randomized to receive 1 gram of Expecta. They will take once a day for 8 weeks or a shorter time if infant is discharged sooner from NICU.
1665623|NCT01732861|Drug|CC-292|CC-292-will be given twice daily on Days 8-28 of Cycle 1 and on Days 1-28 of the remaining 28-day cycles.
1665624|NCT01732861|Drug|Lenalidomide|Lenalidomde will be given once daily on Days 1-28 of 28-day cycles.
1665625|NCT01732848|Drug|BMS-986094/INX-08189|
1665626|NCT01732848|Drug|Placebo matching BMS-986094/INX-08189|
1665627|NCT01732835|Device|HAART 300 Annuloplasty Device|Implantation of HAART 300 Annuloplasty Device for aortic valve repair
1954908|NCT03310515|Other|Computer-Assisted Self Interviewing technique|Demographic, behavioral, and psychosocial factors associated with HIV acquisition will be assessed by CASI.
1665630|NCT01732809|Drug|group A|isovolumetric (0.02 mL) doses of 2 units of ABO injected on one side of the forehead and 2 units of ONA injected on the contralateral side
1665631|NCT01732809|Drug|group B|Patients received 2units/0.02 mL of reconstituted ABO on the left side of the forehead and 2 units/0.02 mL of reconstituted ONA on the right side.
1665632|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
1665633|NCT01732796|Drug|BI 201335 (Faldaprevir)|16 weeks of BI 201335 followed by 8 weeks placebo to BI 201335
1665634|NCT01732796|Drug|Ribavirin (RBV)|24 weeks of active RBV
1665635|NCT01732796|Drug|BI 207127|24 weeks of BI 207127
1665636|NCT01732796|Drug|BI 201335 (Faldaprevir)|24 weeks of BI 201335
1665637|NCT01732796|Drug|Ribavirin (RBV)|16 weeks of Ribavirin followed by 8 weeks of placebo to Ribavirin
1665642|NCT01732770|Biological|Denosumab|Denosumab 60 mg administered by subcutaneous injection once every 6 months.
1665643|NCT01732770|Drug|Zoledronic Acid|Zoledronic acid 5 mg administered by intravenous infusion once a year
1665644|NCT01732770|Drug|Placebo to Denosumab|Administered by subcutaneous injection once every 6 months
1665645|NCT01732770|Drug|Placebo to Zoledronic Acid|Administered by intravenous infusion once a year
1665646|NCT01732757|Drug|Alcaftadine 0.25%|One drop of Lastacaft® (Alcaftadine 0.25%) administered in both eyes on Day 0.
1665647|NCT01732757|Drug|Olopatadine 0.2%|One drop of Pataday™ (Olopatadine 0.2%) administered in both eyes on Day 0.
1665648|NCT01732757|Drug|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo (dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%) administered in both eyes on Day 0.
1665649|NCT01732744|Other|Physiological solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
1665650|NCT01732744|Other|Sodium hypochlorite|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
1665651|NCT01732744|Other|Alkaline Peroxide|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
1665652|NCT01732744|Other|Castor bean solution|The volunteers were instructed to brush the internal surface of complete dentures for 2 minutes, 3 times a day, after meals (breakfast, lunch and dinner) and use the following chemical immersion methods, only once a day after dinner: A - Control (Co): Physiological solution, for 20 minutes. B) 1% Sodium Hypochlorite, for 20 minutes. C) Polident Alkaline Peroxide, for 3 minutes. D) 2,0% Castor bean solution Ricinus communis, for 20 minutes. In addition, the participants were instructed to immerse their dentures in water during the night period, before going to sleep.
1665653|NCT01732731|Other|treadmill training|Home-based treadmill training will be administered to the children in the experimental group
1665656|NCT01732705|Behavioral|High intensity interval training|HIT will be conducted as 2 weeks of one legged high intense interval training (8 sessions every 2nd day). Each training session will consist of 10 x 1 min intervals on ergometer bicycle interspersed with 1 min recovery.
1665657|NCT01732692|Drug|MOVIPREP|MOVIPREP solution
1665658|NCT01732679|Other|rehabilitation|Description of specialized rehabilitation and Influence on activities, life satisfaction, psycho social aspects 6 and 12 months post discharge
1665659|NCT01732666|Drug|Nefopam|20 mg of Nefopam mixed in 100 ml of 0.9% saline IV immediately after induction of anesthesia.
1665660|NCT01732666|Drug|low dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.05µg/kg/min of remifentanil during anesthesia.
1665661|NCT01732666|Drug|high dose remifentanil|100 ml of 0.9% saline immediately after anesthesia induction and 0.3 µg/kg/min of remifentanil during anesthesia.
1665662|NCT01732653|Other|TT+VR|subjects will be walking on a treadmill while negotiating virtual obstacles provided by a computer simulation. The virtual environment will consist of obstacles, different pathways, narrow corridors and distracters, requiring modulations of step amplitude in two planes (i.e., height and width) coordinated with walking behaviour. The speed, orientation, size, frequency of appearance and shape of the targets will be manipulated according to individual needs following a standardized protocol.
1665663|NCT01732653|Other|TT alone|The participants will walk on the treadmill, their gait speed over-ground will be measured at the beginning of each week of training. Progression will include increasing the duration of each of the walking bouts and increasing walking speed.
1954909|NCT03310489|Behavioral|Digitalized cognitive-behavioral intervention for anxiety|An internet-based CBT, including telephone coaching
1954910|NCT03310489|Behavioral|Psychoeducation about anxiety|Psychoeducative material about anxiety in internet
1954911|NCT03310476|Other|Potatoes|Participants will follow the same protocol for each arm with a minimum of 1-week wash-out period between arms. For each arm, fasting blood will be collected then 200 g of potato will be consumed. Postprandial blood will be collected 15, 30, 60, and 120 minutes. Subjective satiety will be assessed using Visual Analogue Scale three times, as well as 48-hour subsequent dietary intake.
1954912|NCT03310463|Drug|ETX2514SUL|Single dose of up to 1000 mg ETX2514 and 1000 mg sulbactam given by concurrent 3-hr IV infusion
1665669|NCT01732627|Biological|MenACYW Conjugate Vaccine|0.5 mL, Intramuscular
1665670|NCT01732627|Biological|Meningococcal Polysaccharide Vaccine Groups A, C, Y, W 135 Combined|0.5 mL, Subcutaneous
1665671|NCT01732614|Procedure|Topcon Endpoint Management laser|
1665672|NCT01732601|Behavioral|Intensive Outpatient CBT|Sessions will be delivered 1-2 times a week for the first 4-6 weeks, based on need, and then weekly until 6 months. Therapy can continue up until one year.
1665673|NCT01732601|Behavioral|Standard Care|Treatment at step-down facilities
1721420|NCT00003437|Drug|cyclophosphamide|
1665674|NCT01732588|Drug|OZ439 120mg PIB|120mg dose (as free base) of OZ439 as a solution made up from powder in bottle (PIB)
1665675|NCT01732588|Drug|120 mg OZ439 caplet|120 mg (as free base) of OZ439 immediate-release (IR) caplet formulation containing nanoparticulate, administered directly via the oral route
1665676|NCT01732588|Drug|120mg OZ439 caplet via Enterion capsule|120 mg OZ439 (as free base) in an immediate release (IR) caplet formulation containing nanoparticulate,administered orally via the Enterion capsule and delivered directly to the proximal small bowel (PSB)
1665677|NCT01732575|Behavioral|Enrichment with meaning-generating activities|Gaps in the rehabilitation are identified by staff and researchers in dialogue. Staff gets relevant education. An intervention is tailored by staff and researchers to bridge the gaps. Consumers have a say and the intervention is revised accordingly. The intervention is implemented and continues for 14 months.
1665678|NCT01732562|Other|Patient e-Learning educational tool|Web based site with videos of TKR surgical animation, demonstrations of exercises and activities following surgery and conversations with surgeons, physiotherapist, occupational therapist and patients.
1665679|NCT01732549|Drug|Tasquinimod|A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
1665680|NCT01732549|Drug|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
1665681|NCT01732536|Drug|S8 Sinus Implant|Bilateral in-office placement of S8 sinus implant with 1350 mcg of mometasone furoate and continued steroid nasal spray (mometasone furoate, 200 mcg) once daily
1665682|NCT01732536|Procedure|Sham procedure|Bilateral in-office sham procedure and continued steroid nasal spray (mometasone furoate, 200 mcg) once daily
1665683|NCT01732510|Drug|MK-8226|MK-8226 administered IV at a weight-based dose every 2 weeks for 12 weeks.
1665684|NCT01732510|Drug|Placebo|Placebo administered IV every 2 weeks for a period of 12 weeks.
1665685|NCT01732497|Device|miraDry Treatment|Application of electromagnetic energy to heat the lower dermis.
1665686|NCT01732484|Procedure|intraocular lens implantation|
1665687|NCT01732471|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) will be administered orally at a dose of 20 milligram per kilogram per day (mg/kg/day) once daily for 8 days. If there is 30 percent (%) decrease in blood phenylalanine levels from baseline at the end of Day 8, then treatment will be continued at the same dose for further 6 weeks.
1954914|NCT03310437|Procedure|Primary PCI|Primary percutaneous coronary intervention in acute myocardial infarction patients
1954915|NCT03310424|Other|No active intervention.|No active intervention is undertaken. Collection of samples for bio-informatic analysis only
1665698|NCT01732393|Drug|oral quercetin capsules|10 cases in case group and 10 cases in control group. Patients in the intervention group were administered two, 250 mg Quercetin capsules daily for 3 weeks. Patients in the placebo group received two placebo capsules containing lactose .Patients were examined every other day for evaluation of initiation and severity of oral mucositis.
1665699|NCT01732393|Drug|Placebo|
1665700|NCT01732380|Drug|Raltitrexed|
1665701|NCT01732380|Drug|Oxaliplatin|
1665702|NCT01732380|Radiation|Radiotherapy|
1665703|NCT01732367|Drug|Lamivudine plus adefovir|Lamivudine 100mg QD for 96 weeks + Adefovir 10mg QD for 96 weeks
1665704|NCT01732367|Drug|Tenofovir|Tenofovir 300mg QD for 96 weeks
1665705|NCT01732341|Device|STENTYS self-apposing stent|Intervention to treat STEMI with the STENTYS self-apposing stent
1665706|NCT01732341|Device|VISION balloon-expandable stent|STEMI treatment with a VISION balloon-expandable stent
1665707|NCT01732328|Dietary Supplement|Calcium plus vitamin D|
1665708|NCT01732185|Genetic|Patient|Blood and histological samples will be done at day of the inclusion.
1665709|NCT01732172|Other|Sperm sample|Sperm sample
1665710|NCT01732159|Other|Checklist|he checklist will be administered to the patients by phone between 7 and 3 days before the surgery
1665711|NCT01732146|Drug|erythropoietin Beta|erythropoietin intravenous injection (5000 U/ 0.3 ml)1000 to 1500 U/kg/dose X 3 given every 24 hours with the first dose within 12 hours of delivery
1665712|NCT01732146|Drug|Placebo|
1665713|NCT01732133|Device|Nexfin|
1665714|NCT01732120|Procedure|Off-clamp partial nephrectomy|
1665716|NCT01732094|Drug|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards
1665717|NCT01732094|Drug|Corifollitropin alfa 150μg|Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin
1665718|NCT01732094|Drug|hpHMG|hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
1665719|NCT01732068|Drug|Triptorelin|Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards
1665720|NCT01732068|Drug|Corifollitropin alfa|Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle
1665721|NCT01732068|Drug|hpHMG|300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering
1665722|NCT01732055|Behavioral|Partner-Assisted Interpersonal Psychotherapy|
1665723|NCT01732055|Other|Treatment as Usual|Because treatment(s) are prescribed for subjects by the UNC Perinatal Psychiatry physicians, it is impossible for the investigators to list each potential medication and dosage that might be prescribed to women randomized to this condition. The medication regimens are individual, and some women may opt against medication altogether (and still be eligible to enroll). Women who refuse antidepressant medication will attend visits at the same intervals as those in the study arms for evaluation of safety and symptoms.
1665724|NCT01732029|Other|Normobaric hypoxia chamber|
1665725|NCT01732016|Other|Normobaric hypoxia chamber|
1665726|NCT01732003|Dietary Supplement|Omega-3 Complete|
1665727|NCT01732003|Dietary Supplement|Placebo Pill|
1665728|NCT01731990|Drug|Canakinumab (ACZ885)|Dosage form: solution for injection Strength: 150 mg/1 mL Mode of administration: subcutaneous use.
1665729|NCT01731990|Drug|Placebo|Matching placebo of Canakinumab
1665730|NCT01731977|Behavioral|Strengths-based family psychoeducation|Family psychoeducation in a group setting is performed every two weeks for eight weeks.
1665731|NCT01731964|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
1665732|NCT01731964|Device|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
1665733|NCT01731951|Drug|Imetelstat|Imetelstat Sodium administered as IV over 2 hours with treatment as long as participants derive clinical benefit or until study end. with the following dose and schedule: Starting doses are 7.5 mg/kg or 9.4 mg/kg from weekly to every four weeks based on indication as per arms.
1665734|NCT01731938|Biological|Fibrin Sealant (FS) Grifols|Fibrin Sealant (FS) Grifols: The maximum total volume of FS Grifols allowed to be applied at the target bleeding site by dripping or spraying was approximately 12 mL (equivalent to the full content of 2 FS Grifols kits).
1665735|NCT01731938|Device|Surgicel®|Up to four Surgicel® sheets applied to the target bleeding site according to Package Insert instructions and the surgeon's usual clinical practice.
1665736|NCT01731925|Drug|Lanreotide|Lanreotide at the dose of 120 mg will be injected every 28 days as the reference treatment to control the carcinoid syndrome in both arms.
1665737|NCT01731925|Drug|Placebo (for sunitinib)|
1665738|NCT01731925|Drug|Sunitinib|Sunitinib 37.5 mg daily
1665742|NCT01731899|Drug|agomelatine|Agomelatine 25 mg pills. Initial dose 25 mg at bedtime; can be increased up to 50 mg at bedtime; 12 weeks duration
1665743|NCT01731886|Procedure|Autologous peripheral blood stem cell transplant|Subjects deemed suitable by the principal investigator will receive melphalan 200 mg/m2 intravenously on days -2 and -1 or only on day -2, and will undergo autologous peripheral blood stem cell transplantation on day 0. Subjects will receive G-CSF subcutaneously daily beginning on day 5 and until blood counts recover.
1665744|NCT01731886|Drug|Lenalidomide|Administered orally at a dose 25 mg daily on days 1-21 of each 28-day cycle.
1665745|NCT01731886|Drug|Dexamethasone|Administered orally at a dose of 40 mg daily on days 1, 8, 15, 22 of each cycle.
1665746|NCT01731886|Procedure|Stem cell collection|Subjects may receive up to the maximum recommended high-dose of cyclophosphamide at 4 gm/m2 intravenously with mesna at a total of 2.4 gm/m2 intravenously or orally divided over 3 doses. Subjects then will receive mobilization using daily filgrastim (G-CSF) at 10 mcg/kg subcutaneously starting 24 hours after cyclophosphamide is completed and until stem cell collection. The use of AMD3100 (Plerixafor) is permitted. Peripheral stem cell collection will be performed at marrow recovery, usually when WBC is >2500 x 109 cells/liter; platelet count is >20 x 103/mm3.
1665748|NCT01731847|Procedure|the combination group|Patients received 12 sessions of NMES for 1 hour /day, 5 days/week within a period of 2-3 weeks. FEES was done before and after NMES for evaluation and guiding therapy. All patients subsequently received 12 sessions of traditional swallowing rehabilitation (50 minutes/day, 3 days/week) for 4 weeks.
1954920|NCT03310398|Behavioral|NeuroImaging|standard anatomical and functional imaging
1665750|NCT01731821|Procedure|pancreaticojejunostomy|"Nonstented stump closed pancreaticojejunostomy:
Close the pancreatic stump with interrupted inverting sutures around the papillary-like pancreatic duct.
A small full-thickness enterotomy was penetrated on the jejunal wall for connecting to the papillary-like pancreatic duct by placing 4-6 sutures from the periductal parenchyma to the whole-layer jejunum hole. After that, interrupted sutures between the front wall of pancreatic stump and the seromuscular jejunum were performed by 4-0 absorbable sutures to complete the anastomosis.
Duct-to-mucosa pancreaticojejunostomy:Two layer anatomosis with Duct-to-Mucosa pancreaticojejunostomy is performed by suturing the pancreatic parenchyma to the jejunal seromuscular layer and no stenting tube was used."
1665751|NCT01731808|Behavioral|Nursing counseling|The participants who were randomized in the intervention group received outpatient physician-prescribed wound care. Additionally, they received standardized education regarding diabetic foot care. The nurse-led outpatient intervention started a few days after randomization and went on for five weeks. The study nurses conducting the interventions were wound care nurses and trained in foot examination, foot care, education, and counseling. During a period of five weeks, the participants were provided with weekly, one-hour education, skill training, and counseling sessions on foot care. Each participant received a foot care kit with essential foot care material and a foot care diary.
1665872|NCT01730755|Drug|Ruxolitinib|Ruxolitinib 10 mg tablets twice daily
1954921|NCT03310398|Behavioral|Psychophysiological|Hear rate, Vagal Tone, Skin Conductance, and Startle Reflex Electromyogram
1665752|NCT01731795|Drug|Dexamethasone|Dexamethasone (20 mg/iv/daily/from Day 1 of randomization during 5 days, followed by 10 mg/iv/daily/ from Day 6 to 10 of randomization)
1665753|NCT01731782|Drug|bupivacaine|
1665754|NCT01731782|Drug|normal saline placebo (for bupivacaine)|Normal saline to mimic bupivacaine
1665755|NCT01731769|Procedure|vacuum assisted closure in experimental arm|
1665756|NCT01731769|Procedure|Axillary dissection|
1665757|NCT01731756|Other|Leaf extract of A. indica|Leaf extract of A. indica plus 6% salicylic acid will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
1665758|NCT01731756|Drug|Salicylic Acid (6%)|Salicylic acid (6%) will be applied on palmer keratotic lesion once daily on bedtime for 12 weeks.
1665759|NCT01731756|Other|Petroleum jelly|Petroleum jelly will be applied on palmer keratotic lesion once daily at bedtime for 12 weeks.
1665760|NCT01731743|Device|AT LISA tri 839MP|
1665761|NCT01731730|Drug|Placebo Injection|3mL solution for intrathecal injection; Vehicle formulation designed to mimic AYX1 Injection (with no active drug)
1665762|NCT01731730|Drug|AYX1 Injection 110 mg|3mL solution for intrathecal injection with 110 mg of AYX1
1665763|NCT01731730|Drug|AYX1 Injection 330 mg|3mL solution for intrathecal injection with 330 mg of AYX1
1665764|NCT01731717|Behavioral|Active monitoring|General physician performs monitoring every 2 weeks using the PHQ-9 depression scale.
1665765|NCT01731717|Behavioral|Bibliotherapy|"Patient works with self-help book Selbsthilfe bei Depressionen (Görlitz, 2010) under general physician's supervision."
1665766|NCT01731717|Behavioral|Online self-help|"Patient works with online self-help program Deprexis under general physician's supervision."
1665767|NCT01731717|Behavioral|Outpatient psychotherapy|Patient receives outpatient psychodynamic or cognitive-behavioural psychotherapy from a psychotherapist participating in the network.
1665768|NCT01731717|Procedure|Psychiatric treatment|Patient receives treatment from psychiatrist or general physician participating in the network, this includes psychopharmacotherapy. Treatment takes place within routine care, thus psychiatrists or general physicians individually determine the type of medication and are committed to follow the recommendations of the German S3-Guideline/National Disease Management Guideline for Unipolar Depression.
1665769|NCT01731717|Behavioral|Combined psychotherapy and psychopharmacological treatment|Patient receives psychotherapy combined with psychopharmacological treatment, if necessary in inpatient setting.
1665770|NCT01731717|Other|Control group: treatment as usual|treatment as usual
1665771|NCT01731704|Radiation|Stereotactic radiosurgery (SRS)|
1665772|NCT01731704|Radiation|Whole brain radiation therapy (WBRT)|External beam whole-brain radiation therapy 30 Gy in 10 fractions. Treatment will be delivered once daily, 5 fractions per week, over 2 to 2.5 weeks
1665774|NCT01731678|Procedure|Transcranial Magnetic Stimulation|The standardized treatment location will be the left DLPFC. Anatomical T1 images from the pre-intervention MRI will be loaded into our Transcranial Magnetic Stimulation (TMS) lab neuronavigation software (Brainsight2, Rogue Research, Montreal). Following 3D co-registration of the TMS coil with the patient's MRI images and head, the coil will be placed over the left DLPFC (tangential to scalp, angle of 45 degrees to midline). Interventional repetitive TMS (rTMS) (Magstim Rapid2, Wales, UK) will consist of 40 suprathreshold (120% RMT) pulses over 4 seconds (10 Hz) with an inter-train interval of 26 seconds. Treatment sessions will last 37.5 minutes (75 trains/3000 pulses). Treatments will occur on each weekday for three weeks (15 days total).
1665775|NCT01731652|Drug|TMX-101|
1665776|NCT01731639|Other|MSOME|The semen samples will be evaluated according to the 2010 WHO reference values. After ICSI 200 spermatozoa of each sample will be analyzed under high magnification (MSOME - x6600) and graded into four groups according to the presence or size of the vacuoles. Grade I: normal form and no vacuoles; grade II: normal form and ≤ 2 small vacuoles; grade III: normal form > 2 small vacuoles or at least one large vacuole and grade IV: large vacuole and abnormal head shapes or other abnormalities.
1665777|NCT01731613|Dietary Supplement|human milk fortifier|Then fortification with human milk fortifier will be initiated at different levels according to the body weight of infants, the protein concentration of human milk and blood urea nitrogen
1665779|NCT01731587|Other|Biological: MUC1 peptide specific immunotherapy|Eight consecutive weekly subcutaneous administration with reconstituted L-BLP25 (containing 806 microgram of BLP25 lipopeptide) followed by administrations at 6-week intervals, commencing at Week 14, until disease progression is documented.
1665780|NCT01731587|Drug|Cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (to a maximum of 600 milligram) of CPA will be given three days before the first L-BLP25 administration.
1665781|NCT01731574|Drug|dapivirine|
1665782|NCT01731574|Drug|miconazole|
1665783|NCT01731561|Drug|Rituximab (Arm B)|Rituximab infusion will be performed at D1 then ANCA status and CD19+ lymphocyte count will be monitored every 3 months, and patients will receive new 500 mg rituximab infusions either if CD19 are > to 0/mm3, or if ANCA are positive again or if ANCA titer significantly raises. All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
1665784|NCT01731561|Drug|Rituximab (Arm A)|Rituximab infusion will be performed at D1, D15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis.
1665785|NCT01731548|Radiation|hyperfractionated radiation therapy for both arms|1.5 Gy twice daily to 45 Gy in 30 fractions over 3 weeks for both arms
1665786|NCT01731522|Behavioral|EF condition|
1665787|NCT01731509|Other|Fetal endoscopic tracheal occlusion|FETO will be performed by placing a detachable balloon inside fetal trachea
1665918|NCT01730313|Drug|Placebo|
1721421|NCT00003437|Drug|cytarabine|
1665788|NCT01731496|Other|Telephone reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a telephone reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
1665789|NCT01731496|Other|Text Message reminder|One week prior to when a child is due for either their 2nd or 3rd HPV vaccine, their parent will receive a text message reminder to call to make an appointment to receive their next dose. A total of 3 reminders will be sent.
1665790|NCT01731470|Biological|Liposomes|Intravesical instillation of liposomes.
1665791|NCT01731457|Drug|etanercept|adding appropriate dose of etanercept to the perfusion fluid
1665792|NCT01731444|Drug|Phenylephrine|
1665793|NCT01731431|Other|Insulin|
1665794|NCT01731431|Drug|Glyburide|
1665795|NCT01731418|Behavioral|Narrative Exposure Therapy|Narrative Exposure Therapy (NET) is a treatment approach that was developed by a research group of the University of Konstanz (Schauer, Neuner, & Elbert, 2005, 2011). In NET, the patient repeatedly talks about the most arousing traumatic events in detail while re-experiencing the emotions associated with this event. In the process, the patient constructs a narration of his life, focusing on the detailed report of the traumatic experiences.
1665796|NCT01731418|Other|Treatment-as-usual|"Treatment-as-usual was defined as the commonly used psychotherapy for abused women in Iran, such as medical therapy and/or supportive counseling.
Regarding supportive counselling, the sessions included:
Life skill education CBT techniques ACT techniques Finding resources to stop violence Discussing marital and sexual conflicts with the presence of husbands Working on their children problems Improvement of communication skills"
1665797|NCT01731392|Dietary Supplement|Milk with Bifidobacteria|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
1665798|NCT01731392|Dietary Supplement|Milk with non replicating lactobacilli|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
1665799|NCT01731392|Dietary Supplement|placebo|A total of 36g (4 spoons) of powder milk per serving are diluted in 220 ml of water. Two servings per day are consumed orally, corresponding to 72g per day.
1665800|NCT01731379|Procedure|Surgical resection|Patients planned for elective inguinal, axillary or cervical lymph node dissection or parotidectomy , patients with rectal cancer undergoing rectal surgery and patients undergoing resection of a soft tissue tumour.
1665801|NCT01731366|Other|Whole grain|Whole grain diet: Participants consume more than 75g of whole grain per day (corresponds to the whole grain intake of the 90th percentile of the population)
1665802|NCT01731366|Other|Refined grain|Refined grain diet: Participants consume less than 10 g of whole grain per day (corresponds to the whole grain intake below the 10th percentile of the population)
1665803|NCT01731340|Dietary Supplement|Calcium Citrate|750mg
1665804|NCT01731340|Other|Low Dietary Calcium|450 mg
1665805|NCT01731340|Other|High Dietary Calcium|1200 mg
1665806|NCT01731327|Drug|tofacitinib modified-release (MR) formulation|A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
1665807|NCT01731327|Drug|tofacitinib modified-release (MR) formulation|A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
1665808|NCT01731314|Behavioral|Learning and Memory of Pain|
1665809|NCT01731301|Drug|Ribavirin|Ribavirin monotherapy will be started at a dose of 100 mg daily. After each successive week the dose of ribavirin will be increased by 100 mg increments daily as long as the hemoglobin remains greater than 10 gm/dl and/or there has not been a decline in the hemoglobin by more than 2 gms/dl from the pretreatment baseline.
1665810|NCT01731301|Drug|Peginterferon|After the patient has remained on their maximal tolerated dose of ribavirin for 1 week peginterferon alpha-2b will be initiated at a dose of 1.0 mcg/kg/week. This dose was chosen because it is known to be equivalent in achieving SVR when compared to the 1.5 mcg/kg/dose and is associated with less bone marrow suppression. The dose of ribavirin will be adjusted as needed.
1665811|NCT01731301|Drug|Boceprevir|Boceprevir will be added after the patient is on stable doses of ribavirin and peginterferon. The dose of ribavirin will be adjusted as needed.
1665812|NCT01731275|Drug|E6011|A single ascending dose (SAD) administration of E6011 is administered to 8 groups as a 30-minute intravenous infusion at a dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
1665813|NCT01731275|Drug|E6011 Matching Placebo|A SAD administration of E6011 Matching Placebo is administered to 2 participants in each of 8 groups as a 30-minute intravenous infusion at a placebo dose of either 0.0006, 0.006, 0.04, 0.2, 1, 3, 6, or 10 mg/kg. Each participant in each group will receive a single-dose only once. The study drug will not be administered to more than two participants on the same day, and the second participant must start the study treatment after at least a 2-hour interval from the start of the study treatment in the first participant. The subsequent ascending E6011 Matching Placebo dose groups will start approximately at least every 3 weeks following the study treatment in the first participant of each group.
1665814|NCT01731249|Biological|Placebo|10 actuations of placebo sublingual solution once daily 5 months a year and during 2 years
1665815|NCT01731249|Biological|Birch pollen allergen extract|Sublingual solution of Birch pollen allergen extract 300IR (10 actuations) once daily 5 months per year and during 2 years
1665816|NCT01731236|Dietary Supplement|Carnitine|Group 1: Carnitine supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
1665817|NCT01731236|Dietary Supplement|Choline|Group 2: Choline supplement for 2 months, No antibiotics, no aspirin for 3 months (1 month prior and during study)
1665818|NCT01731236|Drug|Antibiotics|Group 3: Carnitine or Choline for 2 months, antibiotic cocktail (Ciprofloxacin, Flagyl, Vancomycin, and Neomycin) for 1 week
1665819|NCT01731236|Drug|Choline and Aspirin|Group 4: Choline supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
1665919|NCT01730287|Drug|Control|The teeth in this group restored only by filling material,without liner application.
1665820|NCT01731236|Drug|Carnitine and Aspirin|Group 5: Carnitine supplement for 2 months plus aspirin 81 mg for 3 months (1 month prior to starting the study and 2 months during the study).
1665821|NCT01731223|Behavioral|Group treatment for insomnia|Experimental: Group treatment of insomnia The intervention is a group treatment based on cognitive and behavioral changing methods. It is including seven sessions during 10 weeks. Each session last for 2 hours with a 20 minutes pause. The intervention includes psycho education about sleep. Methods as relaxation, coping with worry, sleep restriction, stimulus control, sleep hygiene, stress coping strategies, strategies for coping with daytime symptom, identify and reformulate negative and dysfunctional thoughts about sleep, daytime functioning and stress and strategies for reducing hypnotics.
1665822|NCT01731210|Device|implantation of the new LV lead: NANO system.|
1665823|NCT01731197|Dietary Supplement|Dry-Blended Beverage|
1665824|NCT01731184|Drug|Midazolam|Midazolam (Hypnovel) at 0.04 mg /kg with morphine titration (first bolus: 0.1 mg/kg then 3 mg every 5 minutes).
1665825|NCT01731171|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
1665826|NCT01731171|Dietary Supplement|Inert Compound|Probiotic identical placebo 1 tablet by mouth daily
1665827|NCT01731158|Drug|Avastin in combination with Roferon-A|
1665828|NCT01731158|Drug|Afinitor|
1665829|NCT01731158|Drug|Sutent, Nexavar or Votrient|TKI
1665830|NCT01731145|Device|SNUMAP|Portable six-axis (tri-axial accelerometer and tri-axial gyroscope) motion sensing system
1665831|NCT01731132|Drug|Levonorgestrel IUD or Copper IUD|Women who initiate the use of an IUD at the time of the study.
1665832|NCT01731119|Drug|Latuda©|All subjects will be started on 20-40mg of Latuda© at night (suggested intake with food). Subsequently, the dose may be increased as clinically indicated and based on tolerability every 7 days by 20-40mg to a maximum of 160mg per day with food which may be given as a single or twice daily dose depending on participant's preference. The maintenance dose will be determined solely by the clinician in accordance with the best interests of each participant.
1665835|NCT01731067|Drug|Cocktail probe drugs|
1665836|NCT01731041|Drug|Ticagrelor 180mg|Patients will receive 180 mg of ticagrelor
1665837|NCT01731041|Drug|Ticagrelor 90mg|Patients will receive 90 mg of ticagrelor
1665838|NCT01731028|Drug|Somatropin|Somatropin powder and solvent for solution for injection
1665839|NCT01731015|Drug|Medical Grade Oxygen|At the study visits, MRI 'studies' will be performed using the same MR scanner (a 3.0-Tesla (T) TRIO MRI system (Siemens Medical Systems)). Lung morphology and function will be acquired using conventional 1H MRI followed by 1H MRI with oxygen as a gaseous contrast agent. For both series the subject will lie down in a supine position on the magnet bed with a standard 1H Torso coil for imaging. Subjects are scanned on room air and then the subjects are switched from room air to 100% oxygen and exhaled O2/CO2 are monitored (Oxigraf Capnograph) until steady state is achieved (in our experience ~ 1-2 minutes). The 100% oxygen MRI imaging is commenced (the average exposure time is usually 5-6 minutes with a maximum exposure of 15 minutes) after which the subjects are switched to room air. After steady state is achieved a second room air scan is completed.
1665840|NCT01731002|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.01%|
1665841|NCT01731002|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|
1665842|NCT01731002|Drug|Latanoprost ophthalmic solution|
1665843|NCT01730989|Dietary Supplement|Estromineral Serena Plus|
1665844|NCT01730989|Dietary Supplement|Estromineral|
1665845|NCT01730976|Dietary Supplement|Vitamin D 2,000 I.U.|
1665846|NCT01730950|Biological|bevacizumab|Given IV
1665847|NCT01730950|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1665848|NCT01730950|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
1665849|NCT01730950|Radiation|proton beam radiation therapy|Undergo proton beam RT
1665850|NCT01730937|Drug|sorafenib tosylate|Given PO
1665851|NCT01730937|Radiation|stereotactic body radiation therapy|Undergo SBRT
1665852|NCT01730924|Procedure|Pulmonary vein isolation using contact force sensing catheter|
1665853|NCT01730911|Other|Text message|Participants will receive daily text messages to report bleeding and cramping experienced, if they are randomized to this arm.
1665854|NCT01730898|Other|Study product containing lutein|delivered in capsule form
1665855|NCT01730898|Other|Study product containing lutein|delivered in capsule form
1665856|NCT01730885|Other|Comparison of different Blood Glucose Meters|
1665857|NCT01730872|Drug|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 4 days.
1665858|NCT01730872|Drug|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 4 days
1665859|NCT01730859|Other|Balance exercise and ankle taping|"Balance Exercises: The first group performed balance exercise which last for six weeks, 3 times a week, and 40 minutes each session. Each session started by several minutes of slow walking and progressive stretching of ankle, knee and hip muscles which was gradually increased in time and repetition. After that, balance exercises were performed.
Ankle taping: In second group Ankle joint taping continued for 6 weeks and was renewed three times a week."
1665860|NCT01730846|Drug|Doxazosin|"4 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study.
8 mg/day with 3-week lead-in medication period. Maintained at steady state for duration of the study. 5-day taper at the end of the study."
1665861|NCT01730846|Drug|Placebo|Placebo
1665862|NCT01730833|Biological|pertuzumab|Given IV
1665863|NCT01730833|Biological|trastuzumab|Given IV
1665864|NCT01730833|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1665865|NCT01730833|Other|laboratory biomarker analysis|Optional correlative studies
1665866|NCT01730807|Device|IntellaTip MiFi XP Catheter|Temperature controlled ablation catheter
1665867|NCT01730794|Other|NAVA ventilation|Neurally adjusted ventilatory assist
1665868|NCT01730794|Other|Conventional Lung Protective Ventilation|conventional protective mechanical ventilation
1665869|NCT01730781|Radiation|[11-C]OMAR|The radiotracer, [11-C]OMAR will be administered at no more than 10 micrograms at the beginning of each PET scan.
1665870|NCT01730768|Drug|AQW051|
1665871|NCT01730768|Drug|Placebo|
1665873|NCT01730742|Behavioral|Neuroeconomics task|After a night of wakefulness, participants performed the neuroeconomics task (shopping food items in a mock supermarket scenario).
1665874|NCT01730742|Behavioral|Portion Size Task|Participants are given a computer program that gives them the opportunity to choose the portions of a variety of food items that they would ideally like to consume
1665875|NCT01730742|Procedure|Blood sample|After a night of wakefulness, a blood sample was taken to assess the level and efficacy of circulating neutrophils, as well as to assay blood serum and plasma for the presence of hormones involved in hunger such as oxytocin and ghrelin
1665876|NCT01730729|Drug|cabergoline|Given orally
1665877|NCT01730716|Device|Human spinal cord stem cell implantation|Human spinal cord stem cell implantation in ALS patients.
1665878|NCT01730677|Drug|Lapatinib|lapatinib 1000mg, once daily
1665879|NCT01730677|Drug|Vinorelbine|Vinorelbine 20mg/m2, D1 and D8, every 3 weeks
1665880|NCT01730664|Drug|ertapenem|single dose of 2000mg ertapenem IV
1665881|NCT01730651|Radiation|Tomotherapy|"IMRT boost of gross LNs
Tomotherapy fraction size (Gy) = 0.4 x 진단 당시의 LN short diameter (cm) + 1.6 (pilot study range, 1.5-3.0 Gy)
Total dose(summation dose with 3D-CRT) (Gy10) (EQD2, α/β=10 Gy) = 5 x 진단 당시의 LN short diameter (cm) + 56 (pilot study range, 54.6-78.0 Gy)"
1665882|NCT01730638|Drug|• TF2 and 68 Ga-IMP-288|
1665883|NCT01730625|Behavioral|Cognitive behavioral therapy for anxiety|
1665884|NCT01730625|Behavioral|Attention Bias Modification Treatment|
1665885|NCT01730612|Drug|TF2 - 68 Ga-IMP-288:|ImmunoTEP
1665886|NCT01730599|Other|neurological exam|motor and cognitive functions
1665887|NCT01730586|Drug|Abraxane|220 mg/m2 administered by vein on Day 1. A cycle of therapy is defined as 21 days.
1665890|NCT01730560|Other|Treatment A|"The computer-based training task consists of a novel ramp-step search paradigm with a stimulus traversing the screen from left to right or right to left. Subjects are asked to pursue the stimulus (ramp phase) and then saccade to find its location when it suddenly jumps (step phase). The stimulus is an open spinning circle. At the end of each movement, the gap can be located at the top or at the bottom, and patients are asked to indicate this location by pushing the response button as quickly as possible.
The starting point will alternate between left and right. The training task includes 3 sessions with 100 movements each. Reaction Times and errors will be monitored online to ensure that the patient performs the task correctly.
Each treatment phase has the same pattern:
two visits in pre-tests evaluation (V1 and V2),
one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),
two visits after treatment (V4 at one week and V5 at one month)."
1665891|NCT01730560|Other|Treatment B|"Placebo treatment using the same computer-based training task, but including only the ramp phase.
Each treatment phase has the same pattern:
two visits in pre-tests evaluation (V1 and V2),
one visit to perform treatment (A or B) and to assess immediate and 2h post-effects (V3),
two visits after treatment (V4 at one week and V5 at one month)."
1665892|NCT01730547|Biological|Autologous mesenchymal stem cells|
1665893|NCT01730534|Drug|Dapagliflozin 10 mg|Oral dose (od)
1665894|NCT01730534|Drug|Placebo tablet|Oral dose (od)
1665895|NCT01730521|Behavioral|Exercise (Running)|the study foresees a measurement of iron biavailability in a resting and in a exercising phase and subjects will act as their own control during the study.
1665896|NCT01730508|Drug|Pegylated Interferon Alfa (Peginterferon Alfa)|Peginterferon alfa dosing and treatment duration are at the discretion of the investigator in accordance with China clinical practice and local labeling.
1665897|NCT01730495|Drug|Etanercept|Weekly subcutaneous injections of Etanercept 50 mg, for up to 12 months.
1665898|NCT01730482|Drug|[14C] AT1001|150 mg of [14C] labelled AT1001 will be administered as a solution (prepared by weighing 150 mg of AT1001 powder and dissolving in 100 mL of water). The entire solution will be swallowed orally. After ingestion of study medication, the dosing bottle will be rinsed with 50 mL of water and this will be ingested by the subject. This rinse procedure should be performed twice. Following the second rinse ingestion, the subjects should be instructed to drink additional water to bring the total volume ingested to 240 mL.
1665899|NCT01730469|Drug|AT1001 150 mg|AT1001 150mg is available as a capsule
1665900|NCT01730456|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
1665901|NCT01730417|Drug|no carrier added metaiodobenzylguanidine|Sequential imaging was performed to determine radiation dosimetry of high specific activity 123I-mIBG
1665902|NCT01730404|Drug|CHF6001 DPI|
1665903|NCT01730404|Drug|Roflumilast|
1665904|NCT01730404|Drug|Placebo|
1665905|NCT01730391|Other|Data collection|Collection of demographic data and vaccination history
1665906|NCT01730391|Other|CSF samples testing|CSF samples will be tested for the determination of N. meningitidis and other likely bacterial pathogens that cause bacterial meningitis (S. pneumoniae and H. influenzae)
1665907|NCT01730378|Biological|Prepandrix™|2 doses administered intramuscularly in the deltoid region of arm (non-dominant arm at Day 0 and dominant arm at Day 21).
1665908|NCT01730378|Biological|Fluarix™|1 dose administered intramuscularly in the deltoid region of non-dominant arm.
1665909|NCT01730365|Procedure|Core biopsy procedure|Core biopsy of suspicious lesion in lung, liver, breast, or colorectal liver metastasis.
1665910|NCT01730352|Drug|H. pylori triple therapy|Children up to 5 years: clarithromycin 15mg/kg, amoxicillin 50mg/kg, and/or furazolidone 7mg/kg Children above 8 years: doxycycline 4,4mg/kg if necessary Children able to swallow tablets or capsules, above 30kg: clarithromycin 500mg, amoxicillin 500mg, furazolidone 200mg, and/ or doxycycline 100mg, all 2 times per day, for 14 days.
1665911|NCT01730339|Drug|PF-06473871|Single dose administered by injection four different times
1665912|NCT01730339|Drug|PF-06473871|Single dose administered by injection three different times
1665913|NCT01730326|Drug|Paracetamol|1000 mg
1665914|NCT01730326|Drug|Dexketoprofen|50 mg
1665915|NCT01730313|Drug|Pyridoxine|
1665916|NCT01730313|Drug|Sodium Valproate|
1665917|NCT01730313|Drug|Phenytoin|
1665920|NCT01730287|Drug|Calcium Hydroxide|Calcium Hydroxide paste applied.
1665921|NCT01730287|Drug|Mineral Trioxide Aggregate(MTA)|MTA applied .
1665922|NCT01730287|Drug|CEM cement|CEM cement applied .
1665923|NCT01730261|Behavioral|Online Emotional Regulation Treatment|Emotional Regulation Training (EmReg) is a cognitive-behavioral approach which aims to increase awareness, and self-monitoring of affective states to improve self-regulation. EmReg combines didactic and experiential training, and emphasizes skill acquisition and generalization through examination of incidents of emotional dysregulation in one's life and completion of homework assignments. The treatment is divided into two phases: knowledge provision and practice facilitation. During the knowledge provision phase participants are introduced to the objectives and the main concepts of the treatment, to increase their familiarity with the terminology, and to the emotional regulation skills they acquire during the practice facilitation phase. During the practice facilitation phase participants receive training in emotional regulation skills, which they practice in-session with the guidance of the therapist and feedback from the group, as well as out-of-session as homework assignments.
1665924|NCT01730248|Drug|INC424|5 mg tablets administered orally twice daily
1665925|NCT01730248|Drug|BKM120|10 mg and 50 mg hard gelatin capsules administered orally once daily
1665926|NCT01730235|Other|MyMediHealth access|Patients who will be given access to a web-based medication scheduling and SMS-based reminder system.
1665927|NCT01730222|Drug|cisplatin|cisplatin at 30 mg/m2 on days 1 and 15
1665928|NCT01730222|Drug|capecitabine|capecitabine at 1250 mg/ m2 days 1-28
1665929|NCT01730222|Drug|gemcitabine|gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
1665930|NCT01730222|Drug|nab-paclitaxel|nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
1665931|NCT01730209|Drug|Everolimus|Everolimus once daily titrated to trough levels of 5-10 ng/ml.
1665932|NCT01730209|Drug|Placebo|
1665933|NCT01730196|Behavioral|Fit Body and Soul|
1665934|NCT01730196|Behavioral|Wellness Education|
1665935|NCT01730183|Other|Bone marrow derived stem cells|Intrathecal administration of autologous bone marrow derived stem cells upto a cell dose of equal or greater than 10(8)BMMNCs.
1665936|NCT01730157|Biological|ipilimumab|Given IV
1665937|NCT01730157|Radiation|yttrium Y 90 glass microspheres|Given via hepatic arterial infusion
1665938|NCT01730157|Other|laboratory biomarker analysis|Correlative studies
1665940|NCT01730066|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|"Patients will be given a mixture of maltodextrin ( a starch product often used i alimentary products) and two strains of probiotic bacteria ( L. plantarum 299 and L. plantarum 299v ) dissolved in water. They will gurgle and swallow the suspension from the day before surgery. Postoperatively they will be given the probiotic mixture via a nasogastric tubing twice a day and when the responsible surgeon find it suitable also orally as described above. When they can swallow no study product is given through the nasogastric tube.
Patients randomized 1:1 between groups"
1665941|NCT01730053|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
1665942|NCT01730053|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
1665943|NCT01730053|Drug|Ezetimibe|Ezetimibe over-encapsulated tablets orally.
1665944|NCT01730053|Drug|Placebo|Placebo for alirocumab and ezetimibe.
1665945|NCT01730040|Drug|Alirocumab|Alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
1665946|NCT01730040|Drug|Atorvastatin|Atorvastatin over-encapsulated tablets orally.
1665947|NCT01730040|Drug|Ezetimibe|Ezetimibe over-encapsulated tablet orally.
1665948|NCT01730040|Drug|Rosuvastatin|Rosuvastatin over-encapsulated tablets orally.
1665949|NCT01730040|Drug|Placebo|Placebo for alirocumab and ezetimibe.
1665950|NCT01730027|Drug|ADC3680|ADC3680 for 12 weeks plus montelukast for the last 2 weeks of the dosing period
1665951|NCT01730027|Drug|Placebo|Placebo for 12 weeks plus montelukast for the last 2 weeks of the dosing period
1665952|NCT01730027|Drug|montelukast|montelukast for 12 weeks
1665953|NCT01730014|Drug|148-0287-A-4.2mM-cartridge|In a dose-escalating design, healthy subjects will receive a single dose, injected subcutaneously.
1665954|NCT01730014|Drug|placebo|In a dose-escalating design, healthy subjects will receive 148-0287-A-placebo-cartridge, injected subcutaneously.
1665955|NCT01730014|Drug|148-0287-A-4.2mM-cartridge|In a dose-escalating design, subjects with type 1 diabetes will receive a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
1665956|NCT01730014|Drug|placebo|In a dose-escalating design, subjects with type 1 diabetes will receive 148-0287-A-placebo-cartridge in a single dose, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
1665957|NCT01730014|Drug|insulin glargine|In a dose-escalating design, subjects with type 1 diabetes will receive insulin glargine once daily, injected subcutaneously. Subjects will only be randomised to receive either treatment A or B.
1665958|NCT01730014|Drug|sodium chloride 0.9% w/v|In a dose-escalating design, subjects with type 1 diabetes will receive sodium chloride 0.9% w/v, injected subcutaneously daily. Subjects will only be randomised to receive either treatment A or B.
1665959|NCT01730001|Procedure|Early Intubation|
1665960|NCT01730001|Procedure|Late intubation|
1665961|NCT01729988|Procedure|Carotid body excision|"This surgery does not involve any study drug or investigational device.
The carotid body will be removed by the so called 'lateral approach' or a combined 'lateral and medial approach'. In all cases the target area was defined as the tissue in between the ECA and ICA, up to 5-6mm above the bifurcation point of the common carotid artery into the ECA and ICA. In a lateral approach the carotid bifurcation is not turned. A combined approach includes usually dissection of the superior thyroid vessel and turning of the carotid bifurcation."
1665962|NCT01729949|Dietary Supplement|Active Treatment Beverage|Strawberry and Blackcurrent extract
1665963|NCT01729949|Dietary Supplement|Placebo Treatment Beverage|without active components
1665964|NCT01729936|Behavioral|Sitting time Change Intervention|Intervention to find alternatives to substitute sitting time by doing the regular activities standing or walking.
1954926|NCT03310359|Dietary Supplement|Astaxanthin|The agent to be tested is astaxanthin, isolated from H. pluvialis following GMP standards. A GRAS notice (GRN000294) was accepted by the Food and Drug Administration (FDA) in January 2010. Agent is stored in capsules at room temperature.
1954927|NCT03310359|Other|Placebo|Matching placebo pill
1954928|NCT03310333|Drug|Propess® (dinoprostone)|"The inclusion begins after 12 hours of PROM for a pregnant woman who has an unfavourable cervix and no B streptococcus. The case is discussed during the obstetric staff every morning.
If the cervix is unfavourable (cervical Bishop's score <6), the information of the study is given to the patient and the consent collected.
An antibiotic is started at the beginning of the inclusion by amoxicillin (or clindamycin in case of allergy of amoxicillin) to prevent choroamnionitis."
1954929|NCT03310333|Device|cook cervical pipening balloon|• In dinoprostone vaginal group: the device is placed in vaginal fornix by the midwife for maximum 24 hours. If Propess ® is fallen before the first 12 hours, another one could be introduce if the cervix stayed unfavourable.
1665973|NCT01729910|Behavioral|Parent education / behavioral counseling|Providers and study personnel will be trained in the use of the NIH We Can! curriculum for group visits and brief motivational interviewing for individual visits and follow-up phone calls. Training will be conducted by the PI and Co-Investigators using a combination of online, self-study, and face-to-face formats totally at least/approximately 8 hours. At least one project team member will attend each group visit. Specifically, the American Academy of Pediatrics 15-minute Obesity Prevention Protocol will be utilized during individual visits. The intervention is designed to take place over a period of 10-12 weeks in the primary care office.
1665974|NCT01729910|Behavioral|Usual Care|Parents of children in the control group will receive usual care from their primary care provider as well as a copy of the NIH We Can! Parent Handbook.
1665978|NCT01729884|Biological|HER-2/neu peptide vaccine|Given ID
1665979|NCT01729871|Drug|rivaroxaban|rivaroxaban 20 mg orally, once-daily, administered preferably with the evening meal
1665980|NCT01729871|Drug|uninterrupted vitamin K antagonist (VKA)|dose-adjusted vitamin K antagonist (VKA) to achieve a recommended International Normalized Ratio (INR) of 2.0 to 3.0
1665988|NCT01729832|Procedure|breast reconstruction|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
1665989|NCT01729832|Procedure|intraoperative imaging|Undergo DIEP flap breast reconstruction using the StealthStation navigation system
1665990|NCT01729819|Drug|Tolterodine tartrate extended release capsules|
1665991|NCT01729819|Drug|Desmopressin orally disintegrating tablets|
1665992|NCT01729819|Drug|Placebo orally disintegrating tablets|
1665993|NCT01729806|Biological|Ipilimumab|Given IV
1665994|NCT01729806|Other|Laboratory Biomarker Analysis|Correlative studies
1665995|NCT01729806|Biological|Rituximab|Given IV
1665996|NCT01729793|Dietary Supplement|Digestive Enzyme #2|Contains dietary supplement proteases, lipases and carbohydrases
1665997|NCT01729793|Other|Placebo|Capsule containing microcrystalline cellulose
1665998|NCT01729780|Device|EEG-NF|
1665999|NCT01729767|Drug|Acyclovir|Patients who were randomly allocated to the Acyclovir group besides sticking with low salt diet will take the Acyclovir 400 mg pills for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and their tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
1666000|NCT01729767|Drug|Placebo|Participants who are randomly placed in placebo group, besides sticking with low salt diet will take the placebo (inert ingredient) for 10 days 5 times a day, then 3 times a day for next 10 days, and 2 times a day for the last 10 days. Patients would receive the medication in 2 sessions, first in the beginning of the study and the rest after 10 days. This way it would boost their compliance, and physicians would be aware of possible complications. Patients will report changes in their symptoms 10 days after initiating the drug and in 1, 3, and 6 month intervals. All changes in frequency and duration of vertigo attacks are recorded, and tinnitus and aural fullness is recorded in a 0(with no symptom) to 4 (very severe) scale.
1666001|NCT01729754|Drug|Tildrakizumab 200 mg|Tildrakizumab 200 mg administered SC
1666002|NCT01729754|Drug|Tildrakizumab 100 mg|Tildrakizumab 100 mg administered SC
1666003|NCT01729754|Drug|Tildrakizumab Placebo|Matching placebo to tildrakizumab administered SC
1666004|NCT01729754|Drug|Etanercept Placebo|Matching placebo to etanercept administered SC
1666005|NCT01729754|Drug|Etanercept 50 mg|Etanercept 50 mg administered SC
1666006|NCT01729741|Procedure|drain was inserted after thyroid surgery|insertion of drain after thyroid surgery
1666007|NCT01729728|Drug|Tapentadol|Tapentadol oral solution single dose (1mg/kg body weight)
1666008|NCT01729715|Behavioral|Internet|
1666009|NCT01729715|Behavioral|DVD|
1666010|NCT01729702|Other|blood sample collection|
1666011|NCT01729689|Other|counseling intervention|Undergo cognitive behavioral therapy
1666012|NCT01729689|Other|questionnaire administration|Ancillary studies
1666013|NCT01729689|Procedure|quality-of-life assessment|Ancillary studies
1666014|NCT01729676|Drug|Degarelix or GnRH agonist|Degarelix or GnRH agonist for treatment of prostate cancer according to physicians current practice
1666015|NCT01729663|Biological|CSF470 vaccine, BCG, Molgramostim|
1666016|NCT01729663|Drug|interferon alpha 2b|
1666017|NCT01729650|Behavioral|Physical and diet educational group|educational group of: physical activity program (basically walking) of 24 sessions over 12 weeks, and diet (16 sessions in the first 8 weeks, carried out by mental health nurses.
1666020|NCT01729585|Procedure|Massage Therapy|The Massage Therapy protocol consists of a series of 5 massages administered over 10 (+2) weeks. Length of time for each visit will be approximately 1.5 - 2 hours Typically, a series of treatments over time allows the body time to integrate tissue related changes and potentially maintain a more healthy musculoskeletal state. Based on expert opinion in the field of MT, following a series of massage treatments administered over time, one can anticipate tissue changes. By adding time between treatments, data will describe the ability of subjects to maintain changes over progressively longer periods of time. Treatment protocol will be based on the application of myofascial trigger point therapy (Timberlake, 1999) to musculoskeletal areas of the body often affected by disease progression in CF.
1666021|NCT01729572|Other|Tele-medicine monitoring of medication adherence|
1666022|NCT01729559|Drug|5000 Units unfractionated Heparin Q 8 hr|Venous thromboembolic prophylaxis medication
1666023|NCT01729559|Drug|30mg enoxaparin Q12 hr|Venous thromboembolic prophylaxis
1666024|NCT01729546|Device|7 Blood glucose monitoring systems|
1666025|NCT01729533|Other|ICSI|ICSI Sperm selection in the ICSI group is analyzed under a magnification of 400x using an inverted microscope. ICSI is performed in a micro-injection dish prepared with 4 µL droplets of buffered medium and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
1666026|NCT01729533|Other|IMSI|Sperm selection in the IMSI group is analyzed at high magnification using an inverted microscope equipped with high-power differential interference contrast optics. The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei ([1] smooth, [2] symmetric, and [3] oval configuration) and [4] normal nuclear chromatin content (if it contained no more than one vacuole, which occupies <4% of the nuclear area) are selected for injection.
1666027|NCT01729520|Other|Knee extension strength training|"Load experiment: Four knee extensions will be performed with the operated leg at 20, 14, and 8 RM loadings each, in a randomized order. Range of knee joint motion and time under tension for each repetition will be controlled for
Failure experiment: One strength training set of knee extensions will be performed with the operated leg at 10 RM loading until contraction failure. Range of knee joint motion and time under tension for each repetition will be controlled for"
1666028|NCT01729507|Other|tDCS|Stimulation will be performed with a DC stimulator MC Location of stimulation: Anode over the left dorsolateral cortex, corresponding with F3 (in 10-20 EEG system); cathode over the right temporal cortex Intensity: 2 mA Total duration: Constant stimulation for 20 minutes
1666029|NCT01729507|Behavioral|standardised behavioural therapy|"The standardised behavioural therapy will be performed according to the certified Smoke-free programme' of the of the Institute for Therapy Research ('Institut für Therapieforschung', IFT). The course leaders' manual specifies that the ideal number of participants is 8-12.
1 group session for 90 minutes/week for 7 weeks, 2 telephone calls of 10 minutes each, first after the fourth session 3 days after collective smoking cessation, second on day 3 after the last session."
1666030|NCT01729494|Drug|Alemtuzumab|Alemtuzumab will be dosed on day of transplant (Study Day 1) at dose of 30 mg given intravenously (IV) over a period of 2 hours after induction of anesthesia. Methylprednisolone IV will be administered 30-60 minutes prior to the administration of alemtuzumab.
1666031|NCT01729494|Drug|rabbit antithymocyte globulin|Rabbit antithymocyte globulin will be dosed post-operatively at a total cumulative dose of 4.0-6.0mg/kg given by days 5-10 post-transplant. It will be administered by local standards of care with the following recommendations. The initial intravenous intra-operative dose will be administered approximately one hour after the methylprednisolone dose. The first dose will be administered so that approximately 25% of the dose is infused prior to revascularization of the graft. Subsequent doses will be administered over a minimum of 4 hours. Premedication with acetaminophen 650mg p.o. and diphenhydramine 25mg p.o. prior to rabbit antithymocyte globulin dose will be given to reduce the incidence of infusion reactions.
1666032|NCT01729494|Drug|Belatacept|Belatacept will be administered via intravenous (IV) infusion according to the FDA approved dosage recommendations. Subjects randomized to belatacept arms will receive the first dose of IV belatacept (10 mg/kg) within 12-24 hours post reperfusion. The second dose will be given between post-transplant days 4 -6 (Study Days 5-7), and then study days 14, 28, 56, and 84 (12 weeks) and then subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial at 24 months (104 weeks). Study Day 1 is defined as the day of transplant.
1666033|NCT01729494|Drug|Tacrolimus|Tacrolimus will be administered orally twice daily (BID). The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally. Tacrolimus should be started post-transplant within 48 hours or when serum creatinine drops lower than 4mg/dL, whichever comes first. The initial targeted trough level of tacrolimus will be 8 - 12 ng/mL for Days 1 through 30, with dose reduction to achieve a 12-hour trough target of 5 - 10 ng/mL thereafter.
1666034|NCT01729494|Drug|Mycophenolate mofetil|The first dose of mycophenolate mofetil/EC mycophenolate sodium will be administered pre-operatively. Patients receiving mycophenolate mofetil will be dosed 1000 mg twice daily (2000mg/day). Patients receiving EC mycophenolate sodium will be dosed 720 mg twice daily (1440 mg/day). Dose may be increased for African American transplant recipients to mycophenolate mofetil 1500 mg twice daily (3000mg/day) or EC mycophenolate sodium 1080 mg twice daily (2160 mg/day).
1666035|NCT01729494|Drug|early cessation of steroids|"Glucocorticoid therapy will be administered as described. Methylprednisolone will be administered on Days 1 through 3. Additional tapering doses of glucocorticoids will continue to be given until Day 5 as below:
Day 1 (day of transplant): 500mg IV prior to alemtuzumab (Group A) or rabbit antithymocyte globulin (Groups B and C) Day 2: 250mg IV Day 3: 125mg IV Day 4: 80mg p.o. Day 5: 60mg p.o. No further steroids"
1666036|NCT01729481|Drug|Gemcitabine|1000 mg/m² iv weekly
1666037|NCT01729481|Drug|Erlotinib|100mg, once per day
1666038|NCT01729481|Drug|Oxaliplatin|85mg/m², q2weeks
1666039|NCT01729481|Drug|Folinic Acid|400 mg/m², q2weeks
1666040|NCT01729481|Drug|Irinotecan|180 mg/m², q2weeks
1666041|NCT01729481|Drug|5-FU|400 mg/m² Day 1; 2400 mg/m² 46 hour invusion, q2weeks
1666044|NCT01729455|Biological|BENLYSTA|"As prescribed.
Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus."
1666045|NCT01729455|Other|SLE treatment|"As prescribed.
At baseline, SLE treatment must include an immunosuppressant. During the registry, SLE treatment may include any of the following (alone or in combination): immunosuppressants, corticosteroids, antimalarials, other biologics, investigational agents for SLE, as clinically indicated."
1666046|NCT01729442|Other|Shear-wave ultrasound elastography (SWUE)|
1666047|NCT01729429|Behavioral|HPV brochure, recall, reminders|"HPV-vaccine specific brochure mailed before clinic visit
Telephone recalls after visit for those who complete pre-clinic survey and decline the vaccine
Telephone reminders for those who complete the pre-clinic survey and are late for receiving the 2nd and/or 3 doses"
1666048|NCT01729429|Behavioral|General Adolescent Vaccine Brochure|Participants were mailed a brochure describing the 4 recommended adolescent vaccines (HPV, meningococcal, tetanus diptheria acellular pertussis (TDAP), and influenza) 1-2 weeks before a clinic visit
1666049|NCT01729416|Other|Water Exchange Colonoscopy|"We will turn off the air pump. The colonoscope will be inserted into the rectum and gently advanced. We will suction air pockets as scope is advanced towards the cecum. Water will be infused when encountering closed up lumen. All the infused water will be suctioned out. We will use all other techniques used with conventional air method as needed. For example abdominal pressure, shortening of scope to reduce looping, change of patient position etc.
We will turn on air pump once cecum reached, or if unsuccessful with water method to open up a close lumen or to go past a tight turn.
On withdrawal we will continue air insufflation as needed, and closely examine for polyps and remove all visualized polyps. If there is any residual fluid, it will be suctioned out as the scope is withdrawn."
1666050|NCT01729416|Other|Air Colonoscopy|Air will be infused into the colon during colonoscopy.
1666051|NCT01729403|Drug|aleglitazar|150 mcg orally daily, 16 weeks
1666052|NCT01729403|Drug|metformin|patients will continue on their existing dose and regimen of metformin (but not more than the maximum dose specified in the label)
1666053|NCT01729403|Drug|placebo|orally daily, 16 weeks
1666054|NCT01729390|Other|Energy density and portion size feeding study|In a crossover design, adults are served breakfast and lunch, 1 day a week for 6 weeks. Breakfast is not varied across weeks. At 4 of the lunch meals, a salad first course will be served that needs to be eaten in its entirety. At these 4 meals the lunch entree will vary in energy density (100% and 133%) and portion size (100% and 133%). At the 2 lunch meals for which no first course is served, the lunch entree will be vary in energy density (100% and 133%) but be the same portion size (133%).
1666055|NCT01729377|Other|Interview|
1666056|NCT01729364|Drug|crystalloid|
1666057|NCT01729364|Drug|colloid|
1666058|NCT01729338|Drug|Velcade|Bortezomib induction: 1.3 mg/m2, given subcutaneously (SC) on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Bortezomib maintenance (even cycles [10,12,14, etc.]: 1.3 mg/m2, given SC on days 1 and 15. For patients who required VELCADE dose reductions during induction, the last administered mg/m2 dose of VELCADE will be the starting dose for maintenance, given on days 1 and 15. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. Patients who cannot tolerate SC VELCADE will be converted to the same dose, given intravenously (IV), per discretion of the treating physician.
1666059|NCT01729338|Drug|Cyclophosphamide|Cyclophosphamide: 300 mg/m2, given orally on days 1,8 and 15. Up to eight cycles lasting 28 days each will be administered. Patients will not receive any study drugs during the final week of each induction cycle. Patients who cannot swallow cyclophosphamide pills will be converted to the same dose, given intravenously (IV).
1666060|NCT01729338|Drug|Revlimid|"Lenalidomide (odd cycles [9,11,13, etc.]: 10 mg, given orally on days 1-21. Maintenance cycles will last 28 days and continue indefinitely, until disease progression, lack of tolerability, or death. On even cycles, patients will be prescribed enough lenalidomide to take at home, as instructed, for one cycle. This will be prescribed through the mandatory RevlimidREMS® program. If a dose of lenalidomide is missed, it should be taken as soon as possible on the same day. If it is missed for the entire day, it should not be made up.
Patients who take more than the prescribed dose of lenalidomide should be instructed to seek emergency medical care if needed and contact study staff immediately."
1666061|NCT01729325|Behavioral|Preventive Narrative Exposure Therapy|During Pre-NET the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. During two sessions a chronological overview of the whole life with a focus on traumatic events is developed and the most important traumatic experiences are processed.
1666062|NCT01729299|Drug|Exendin (9-39)|
1666063|NCT01729299|Drug|acyl ghrelin|
1666064|NCT01729299|Drug|saline|
1666065|NCT01729286|Device|PriMatrix Moist Wound Therapy|sharp debridement, PriMatrix, a dressing regimen that maintains a moist wound healing environment, and offloading
1666066|NCT01729286|Other|Standard of Care Moist Wound Therapy|sharp debridement, a dressing regimen that maintains a moist wound healing environment, and offloading
1666067|NCT01729273|Other|Diet and Exercise Intervention|Remote Dietary and Exercise Intervention Program
1666068|NCT01729260|Drug|Mebendazole|The mebendazole will be given by mouth three times every day on a 28 day cycle. it's in the form of 500 mg chewable tablets, to be taken with meals.
1666069|NCT01729247|Device|NIOX MINO® Instrument (09-1100)|
1666070|NCT01729234|Dietary Supplement|Nitrate|Dietary Supplement
1666071|NCT01729234|Dietary Supplement|Placebo|Dietary Supplement
1666072|NCT01729208|Device|Dual Focus Soft Contact Lens|
1666073|NCT01729208|Device|Single Vision Soft Contact Lens|
1666109|NCT01728909|Drug|Saline Nasal Spray|40 IU of the saline nasal spray will be administered once at the beginning of the visit.
1666110|NCT01728896|Other|Patient-controlled oral refeeding|
1666560|NCT01725230|Drug|Rosuvastatin|20-mg tablet
1666074|NCT01729195|Procedure|A ciprofloxacin containing bioabsorbable PLGA bone screw|The syndesmosis injury will be fixed the antibiotic releasing bioabsorbable bone screw or a standard metal screw. After surgery, the ankle will be immobilized in a cast for 6 weeks. The metal screw will be surgically removed at 8 weeks. The bioabsorbable screw will be left in place.
1666075|NCT01729156|Drug|Metformin|1000 mg metformin twice daily in 3 months
1666076|NCT01729156|Drug|Placebo|2 tablets twice daily in 3 months
1666077|NCT01729143|Other|24-hour energy expenditure and substrate utilization|Subjects spent two x 24-hour periods inside the metabolic chamber at the UNC NRI (black pepper and no pepper control) each separated by one week. Subjects were requested to arrive at the study center each morning in a fasted state (at least 10 hours). During each study day, subjects remained sedentary. All meals were provided and were tailored to each subject's specific energy requirements. Study meals (with the exception of the 1.5g of black pepper) were identical between the black pepper and no pepper control study days.
1666078|NCT01729130|Procedure|Adipose tissue biopsy|Adipose tissue biopsy is done at time of transplant surgery. There is a second needle biopsy done between 3-12 months post transplant surgery.
1666079|NCT01729117|Other|Meal Replacement|5 Meal Replacements/day will be given for 3 months and then 1/day for 9 months.
1666080|NCT01729117|Other|Standard Care|Standard Care only
1666081|NCT01729104|Drug|Carfilzomib|"Phase I Starting Dose: 20 mg/m2 by vein on Days 1, 2, 8, 9, 15, and 16 of Cycles 1-12. Cycles 13 and beyond, dose given on Days 1, 2, 15, and 16.
Phase II Starting Dose: MTD from Phase I."
1666082|NCT01729104|Drug|Lenalidomide|Phase I and Phase II: 20 mg by vein on Days 1-21 of each cycle.
1666083|NCT01729104|Drug|Rituximab|Phase I and II: 375 mg/m2 by vein on Days 1, 8, 15, and 22 of Cycle 1 and 2. For Cycles 3 - 12, given on Day 1. For Cycles 13 and beyond, given on Day 1 every other cycle for up to 24 months.
1666084|NCT01729091|Drug|Lenalidomide|10 mg by mouth daily Day -8 to Day -2.
1666085|NCT01729091|Drug|Melphalan|200 mg/m^2 by vein on Day -7.
1666086|NCT01729091|Procedure|NK Cell Infusion|"Part I Dose Escalation: Starting dose of Natural Killer (NK) cells 1 x 10^8 cells/kg infused on Day -5.
Part II Dose Expansion: Dose of Natural Killer (NK) cells is MTD from Part I Dose Escalation."
1666087|NCT01729091|Procedure|Stem Cell Infusion|Autologous stem cell infusion minimum cell dose of 2 e6 cells/kg on Day 0.
1666088|NCT01729091|Drug|G-CSF|5 mcg/kg/day subcutaneously on Day 0, and continuing until evidence of an absolute neutrophil count (ANC) of 0.5 x 109/L per 3 consecutive days.
1666089|NCT01729091|Drug|Elotuzumab|10 mg/kg by vein to be given on day -15 (out-patient) and day -8 (in-patient).
1666090|NCT01729091|Drug|Dexamethasone|28 mg by mouth 3 to 24 hours before Elotuzumab infusion plus 8 mg by vein 45 to 90 minutes prior to infusion.
1666091|NCT01729078|Dietary Supplement|Dietary intervention|three different diets ( high fat-low carb-low fiber/high carb-low fat - high fiber/high carb-low fat-low fiber)
1666092|NCT01729065|Other|Physical therapy intervention|Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
1666093|NCT01729052|Device|Acupuncture|
1666097|NCT01729026|Other|Shelter Dog Adoption|Veterans will choose a dog from the San Antonio Humane Society with the help a Humane Society adoption counselor and study staff and take it home to live with them. The dog will be a pet and not a service dog. Following adoption, Veterans and their dogs will receive eight weeks of free obedience training provided by a veterinarian.
1666098|NCT01729000|Other|Gloves|All staff must wear gloves for subjects that are in the experimental group.
1666099|NCT01728987|Drug|cholecalciferol|as in arm description
1666100|NCT01728987|Drug|placebo|capsule looking identical to the cholecalciferol capsule
1666101|NCT01728974|Other|Pharyngeal topical anesthesia|Pharyngeal topical anesthesia will be performed using 4% lidocaine spray
1666102|NCT01728961|Drug|Artemether/Lumefantrine (AL)|
1666103|NCT01728948|Drug|Sorafenib (Nexavar, BAY43-9006)|treatment (including dose, duration, modification) decided by the investigator
1666104|NCT01728935|Drug|Tenofovir disoproxil|Tenofovir disoproxil 300mg daily
1666105|NCT01728922|Dietary Supplement|5000IU vitamin D|Vigantol Oil
1666106|NCT01728922|Dietary Supplement|10000IU vitamin D|Vigantol Oil
1666107|NCT01728922|Other|Placebo|Placebo Oil
1666108|NCT01728909|Drug|Oxytocin|40 IU of the oxytocin will be administered intranasally for a one time dose at the beginning of the visit.
1666162|NCT01728480|Drug|entolimod|Given SC
1722212|NCT00003783|Drug|leucovorin calcium|
1666111|NCT01728883|Device|Home vision monitoring using myVisionTrack®|Patients will be asked to test their vision at home twice per week using myVisionTrack® during the study period.
1666112|NCT01728870|Other|Unique Diet+Partial Enteral Nutrition|Modulen - liquid dietary formula
1666113|NCT01728870|Other|Exclusive Enteral Nutrition (Modulen)|
1666114|NCT01728857|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1666115|NCT01728818|Drug|Gemcitabine|1000 mg/m² d1,8,15 q4weeks
1666116|NCT01728818|Drug|Afatinib|40mg flat dose, po, once daily
1666117|NCT01728818|Drug|Gemcitabine|1000 mg/m², d1,8,15 q4weeks
1666120|NCT01728792|Biological|TDV|TDV IM or SC injection
1666121|NCT01728779|Drug|Nelfinavir|Commercially available nelfinavir (1250 mg) will be administered orally twice daily for 14 days.
1666122|NCT01728779|Radiation|Stereotactic Body Radiation (SBRT)|15 Gy dose (per lesion site) of SBRT will be administered
1666123|NCT01728766|Other|Small for gestational age at delivery|Small for gestational age at delivery. gestational age at >37 weeks by and birth weight <2500 g
1666124|NCT01728766|Other|Post-term Infant, Not Heavy-for-dates|Appropriate for gestational age at delivery. Gestational age at >37 weeks and birth weight >2800 g
1666125|NCT01728753|Drug|Placebo|Placebo BID x 1 day, and Placebo BID x 4 days; Placebo TID x 1 day, and Placebo TID x 4 days
1666126|NCT01728753|Drug|Favipiravir|1200 mg TID on Day 1, then 600 mg TID on Days 2-5
1666127|NCT01728753|Drug|Favipiravir|2400 mg loading dose followed by 600 mg + 600 mg on Day 1, then 600 mg TID on Days 2-5
1666128|NCT01728753|Drug|Favipiravir|1800 mg BID on Day 1, then 800mg BID for Days 2 5
1666129|NCT01728740|Drug|Acarbose/Metformin FDC (BAY81-9783)|Acarbose/Metformin FDC (BAY81-9783)50mg/500mg, oral, single dose
1666130|NCT01728740|Drug|Acarbose (Glucobay, BAYG5421)|Acarbose (Glucobay, BAYG5421) 50mg, oral, single dose
1666131|NCT01728740|Drug|Metformin|Metformin 500mg, oral, single dose
1666132|NCT01728727|Other|UC-MSC transplantation|After enrolled, Participant will receive umbilical cord MSC transplantation of 1*10E6 cells/kg via hepatic artery. Participant will then be followed until 1 years study visit
1666133|NCT01728727|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
1666134|NCT01728701|Biological|PfSPZ Challenge|PfSPZ Challenge is a suspension of aseptic, purified, cryopreserved PfSPZ that are thawed and formulated in diluent on the day of administration.
1666135|NCT01728701|Biological|Normal Saline (NS)|Normal saline
1666136|NCT01728688|Other|PBSC transplantation|PBSCs were mobilized with recombinant human G-CSF at 5-10ug/kg/d for three days. then PBSCs were collected by means of apheresis. The collected PBSCs were infused into participant via hepatic artery
1666137|NCT01728688|Other|conventional treatment|Participants will receive conventional treatment and antiviral treatment.
1666138|NCT01728675|Other|Exercise|Participants will perform two isokinetic eccentric exercise bouts
1666139|NCT01728662|Procedure|ELVR Procedure|Lung Volume Reduction Procedure
1666140|NCT01728649|Other|Mild Hypothermia|Hypothermia will be achieved using the Zoll Thermogaurd XP technology with the Quattro catheter. This catheter has a 9.3 Fr diameter and is 43cm long. It will be placed in the patients femoral vein via Seldinger technique, before reperfusion is achieved. Hypothermia will be initiated prior to reperfusion. Once temperature has reached 33.5 degrees centigrade the patient will remain at that temperature for 12 hours after which the patient will undergo active gradual rewarming at 0.2 degrees centigrade per hour.
1666141|NCT01728636|Drug|Tranexamic Acid|intravenous administration of bolus and infusion for duration of surgical procedure
1666142|NCT01728623|Drug|E7080 capsule|E7080 is administered as continuous once daily dosing in an uncontrolled manner
1666143|NCT01728610|Dietary Supplement|Probiotic (Active high)|Higher dose of probiotic supplement
1666144|NCT01728610|Dietary Supplement|Probiotic (Active low)|Lower dose of probiotic supplement
1666145|NCT01728610|Dietary Supplement|Placebo|Placebo
1666146|NCT01728584|Drug|Rocuronium|NMB will be induced by intravenous (IV) administration of a bolus dose of 0.45 mg/kg rocuronium. NMB will be maintained using rocuronium infusion or additional bolus doses as needed for the management of NMB to the targeted depth according to the assigned treatment condition. - Standard NMB - administration of neuromuscular blocking agent (NMBA) titrated to a depth of blockade at a targeted TOF ratio of 10% (range: TOF count 2-3 to TOF ratio of 20%). - Deep NMB - administration of NMBA titrated to a targeted depth of 1-2 Post Tetanic Counts (PTCs) (range: 1-5 PTC).
1666147|NCT01728584|Other|Insufflation|"Insufflation (injection) of carbon dioxide will be used to induce pneumoperitoneum, which is presence of air or gas in the abdominal (peritoneal) cavity.
Standard insufflation pressure - a starting pressure of 12 mmHg will be used.
Low insufflation pressure - a starting pressure of 8 mmHg will be used."
1666148|NCT01728584|Drug|Sugammadex|NMB will be reversed with IV administration of 2 or 4 mg/kg sugammadex (depending on the depth of NMB) according to the approved label for sugammadex.
1666149|NCT01728571|Dietary Supplement|Vitamin D|
1666150|NCT01728571|Dietary Supplement|fish oil|
1666151|NCT01728571|Dietary Supplement|Vitamin D placebo|
1666152|NCT01728571|Dietary Supplement|Fish oil placebo|
1666153|NCT01728558|Other|Early goal Directed Sedation|
1666154|NCT01728558|Other|Standard care sedation|
1666155|NCT01728532|Device|Pulp Canal Sealer (Kerr)|permanent obturation of the root canal space with the aid of obturating points
1666156|NCT01728532|Device|PA0903|Sealing performed by the dentist , coronal obturation placed after the canal obturation
1666157|NCT01728519|Drug|AllerT SC|AllerT subcutaneous injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
1666158|NCT01728519|Drug|AllerT ID|AllerT intra-dermal injections on days 1, 7, 14, 21 and 56 - cumulative dose 440 microgram)
1666159|NCT01728519|Drug|Placebo SC|Placebo subcutaneous injections on days 1, 7, 14, 21 and 56
1666160|NCT01728519|Drug|Placebo ID|Placebo intra-dermal injections on days 1, 7, 14, 21 and 56
1666161|NCT01728506|Behavioral|Weight Loss and Exercise|Internet delivered, behaviorally based weight loss and exercise intervention
1666163|NCT01728480|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1666164|NCT01728480|Drug|cisplatin|Given IV
1666165|NCT01728480|Other|pharmacological study|Correlative studies
1666166|NCT01728480|Other|laboratory biomarker analysis|Correlative studies
1666167|NCT01728467|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 31-35 days
1666168|NCT01728467|Drug|Placebo, RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 31-35 days
1666169|NCT01728454|Drug|Placebo|
1666170|NCT01728454|Drug|Proellex 6 mg|
1666171|NCT01728454|Drug|Proellex 12 mg|
1666172|NCT01728441|Device|Paclitaxel Eluting Stent|
1666173|NCT01728441|Device|Paclitaxel Eluting Balloon|
1666174|NCT01728415|Other|exercise|Group A: high intensity exercise training Group B: moderate intensity exercise training C: Control group
1666175|NCT01728402|Procedure|blood draw, bone marrow procedure, or tissue biopsy|
1666176|NCT01728389|Procedure|Intrabone transplantation|Direct intrabone transplantation procedure of peripheral blood haematopoietic stem cells form HLA-matched sibling donors in patients with myeloid and lymphoid malignancies.
1666177|NCT01728376|Drug|Daptomycin|Intravenous daptomycin given at 7 mg/kg (ages 12-17 years); 9 mg/kg (ages 7-11 years); 12 mg/kg (ages 1-6 years) infused once daily, intravenously, over 30 or 60 minutes. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
1666178|NCT01728376|Drug|Comparator|Vancomycin, Semi-synthetic penicillin, First-generation cephalosporins, Clindamycin: administered per standard of care. Participants may be switched to oral therapy following completion of IV study drug administration provided they showed clear clinical improvement and the pathogen was susceptible to an oral agent.
1666179|NCT01728363|Drug|Antibiotic|Ticarcillin-clavulanate/Timentin is an antibiotic used to treat a wide variety of bacterial infections. Rifampin/Rifadin/Rimatane is an antibiotic and first line antituberculotic. Clindamycin/Cleocin is an antibiotic used to treat a wide variety of bacterial infections and serious bacterial infections.
1666180|NCT01728350|Behavioral|HOPE - Helping Others through Purpose and Engagement|
1666181|NCT01728337|Drug|Dysport|Dysport® was injected on the right side of the forehead and Xeomin® was injected on the left side of the forehead.
1666182|NCT01728337|Drug|Xeomin|Xeomin® was injected on the right side of the forehead and Dysport® was injected on the left side of the forehead
1666183|NCT01728324|Drug|BI 207127-placebo: 8-week treatment|8 weeks of placebo treatment
1666184|NCT01728324|Drug|Ribavirin: 24-week treatment|24 weeks of active treatment
1666185|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
1666186|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
1666187|NCT01728324|Drug|Faldaprevir: 24-week treatment|24 weeks of active treatment
1666188|NCT01728324|Drug|Ribavirin-placebo: 8-week treatment|8 weeks of placebo treatment
1666189|NCT01728324|Drug|BI 207127: 24-week treatment|24 weeks of active treatment
1666190|NCT01728324|Drug|Faldaprevir-placebo: 8-week treatment|8 weeks of placebo treatment
1666191|NCT01728324|Drug|Faldaprevir: 16-week treatment|16 weeks of active treatment
1666192|NCT01728324|Drug|Ribavirin: 16-week treatment|16 weeks of active treatment
1666193|NCT01728324|Drug|RBV: 24-week treatment|24 weeks of active treatment
1666194|NCT01728324|Drug|BI 207127: 16-week treatment|16 weeks of active treatment
1666195|NCT01728311|Drug|BAY1082439|BAY1082439 will be given orally once daily with a 21 days cycle. Dose will be started from 15mg.
1666196|NCT01728298|Biological|SLITone ULTRA HDM immunotherapy|
1666197|NCT01728285|Device|Electronic compliance device (Memozax®)|An electronic compliance device is distributed to patients allocated to the active arm
1666198|NCT01728272|Drug|blood concentration of metoprolol|measure blood concentration of metoprolol
1666199|NCT01728259|Drug|pomalidomide|Given PO
1666200|NCT01728259|Drug|bortezomib|Given IV
1666201|NCT01728259|Drug|dexamethasone|Given PO
1666202|NCT01728259|Other|Laboratory Biomarker Analysis|Correlative studies
1666203|NCT01728246|Drug|Tramadol/Paracetamol (APAP)|Celecoxib 200 milligram (mg) once daily for 4 weeks and fixed dose combination of Tramadol 37.5 mg/Paracetamol 325 mg thrice daily for 4 weeks as add-on therapy.
1666204|NCT01728246|Drug|Non-Tramadol/APAP|Celecoxib 200 mg alone once daily for 4 weeks.
1666205|NCT01728233|Drug|Dacomitinib|PF-299804 will be administered orally at a dose of 45 mg/day continuously until surgery, evidence of disease progression or onset of unacceptable toxicity.
1666206|NCT01728220|Drug|Inhaled NO|
1666207|NCT01728220|Other|Placebo|Nitrogen gas
1666208|NCT01728207|Drug|IMMU-114|hL243 is a humanized antibody that targets HLA-DR, which is found on various b-cell hematologic malignancies and in autoimmune diseases.
1666209|NCT01728194|Drug|Escitalopram|20 mg target dose for 12 weeks
1666210|NCT01728181|Drug|Tivozanib|The phase I study will test two dose levels of tivozanib (dose level 1: 1.0 mg and dose level 2: 1.5 mg) given daily for 3 consecutive weeks followed by one week break. Based on the phase I results, the dose of tivozanib will be chosen for the phase II study.
1666211|NCT01728181|Drug|Erlotinib|150 mg/day for 28 day cycle. No rest period.
1666212|NCT01728181|Other|Standard of Care treatment|This treatment will be determined by the study doctor and is considered standard of care.
1666213|NCT01728155|Drug|chemotherapy|
1666214|NCT01728142|Device|DANA Brief|The DANA Brief is a newly-developed neurocognitive test administered on a handheld computer that tests simple reaction time, procedural reaction time, code substitution, and spatial processing. The test also includes subtests for depression/distress, PTSD, and insomnia.
1666215|NCT01728142|Other|ANAM|The ANAM is a currently used test by military health care providers in evaluating cognitive performance after concussion.
1666216|NCT01728129|Device|DANA Rapid|The DANA Rapid is a neurocognitive test self-administered on a small handheld computer. The DANA Rapid subtests measure simple reaction time, procedural reaction time, and reaction time sensitivity.
1666291|NCT01727427|Drug|Heparin, fondaparinux, vitamin-K antagonists, aspirin|Parenteral or oral anticoagulant Antiplatelet agent
1722213|NCT00003783|Drug|mercaptopurine|
1666217|NCT01728129|Other|MACE|The MACE is currently the only standardized and Department of Defense-designated method for the initial evaluation of suspected concussion in military operational settings. The MACE documents the history of the injury-causing incident; assesses cognitive deficits in orientation, immediate memory, concentration, and delayed recalls; and involves a neurological screening by a clinician.
1666218|NCT01728116|Device|EndoBarrier|Endoscopically-delivered and removable device comprised of an anchor that is placed in the duodenal bulb and a 60 cm long impermeable liner that passes distal from the anchor point
1666219|NCT01728116|Procedure|Sham Procedure|Endoscopic evaluation but no device placement
1666220|NCT01728103|Device|APTIMA® Trichomonas vaginalis & APTIMA® COMBO 2® Assays|In Vitro Diagnostic Assays
1666221|NCT01728090|Other|hand sanitizer|alcohol-based, hydroalcoholic gel
1666222|NCT01728077|Drug|Brivaracetam|Flexible dosing, can up and down-titrate as needed.
1666223|NCT01728064|Drug|Placebo|Placebo capsules
1666224|NCT01728064|Drug|EPI-743 400 mg|
1666225|NCT01728064|Drug|EPI-743 200 mg|
1666226|NCT01728051|Drug|Melphalan|
1666227|NCT01728051|Device|Percutaneous Hepatic Perfusion|
1666228|NCT01728038|Behavioral|Cessation Counseling|Parental Smokers will be given brief cessation counseling, nicotine replacement therapy and Quitline connection.
1666229|NCT01728025|Drug|Ranolazine|
1666230|NCT01727986|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
1666231|NCT01727973|Drug|Doxycycline|Tab. Doxycycline 50 mg PO per day for 12 weeks
1666232|NCT01727960|Behavioral|Education and posture correction|a lecture concerning the fine posture for health and exercises
1666233|NCT01727947|Other|MSOME|A total of 200 spermatozoa of each sample will be analyzed under high magnification (x6600) and the incidence of SLV (sperm cells presenting at least one vacuole that occupied > 13% of nuclear area) in each sample will be assessed.
1666234|NCT01727934|Drug|Miravirsen sodium|Subcutaneous injection
1666235|NCT01727921|Device|22 gauge ProCore needle biopsy|22 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
1666236|NCT01727921|Device|25 gauge ProCore needle biopsy|25 gauge, EchoTip® ProCore™ High Definition Ultrasound Biopsy Needle
1666237|NCT01727908|Other|Endoscopy with staining of the mucosa|Staining of the gastric mucosa with acetic acid and Indigocarmine
1666238|NCT01727895|Dietary Supplement|Beta-glucan (Glucan #300®)|
1666239|NCT01727882|Behavioral|Brief feedback|A brief feedback was given on the results of the daily assessments, including a recommendation to the paroled offender and a email report was sent to the probation officer.
1666240|NCT01727882|Behavioral|Daily assessments|Daily assessment of stress, mental symptoms, alcohol and substance use during 30 consecutive days after parole.
1666241|NCT01727869|Drug|REGN1400|
1666242|NCT01727869|Drug|Erlotinib|
1666243|NCT01727869|Drug|Cetuximab|
1666244|NCT01727856|Device|Rehabilitation Measurement Tool|The Rehabilitation Measurement Tool represents a telerehabilitation tool for physical therapy.
1666245|NCT01727843|Drug|Tranexamic Acid|drug and placebo applied topically at end of surgery at hip site.
1666246|NCT01727843|Other|placebo|applied topically to surgical site in OR.
1666247|NCT01727830|Other|Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)|Blood drawn from volunteers
1666248|NCT01727817|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
1666249|NCT01727804|Other|Laser in caries prevention|
1666250|NCT01727791|Drug|pregabalin (Lyrica)|Subjects will receive a single 150 mg dose of pregabalin in the evening of Day 1, a 150 mg dose of pregabalin in the morning and evening of Day 2 and a 150 mg dose in the morning of Day 3.
1666251|NCT01727778|Biological|Anti-GRP78 monoclonal IgM antibody PAT-SM6|
1666252|NCT01727765|Other|inspiratory muscle training|Both groups will undertake six weeks of inspiratory muscle training (POWERbreathe, H&B International Ltd, UK), six days per week, with the only difference being the load set on the inspiratory muscle training device. For the real inspiratory muscle training group this load will be set to around 50% of maximal inspiratory mouth pressure and for the sham inspiratory muscle training group this load will be set to around 5% of maximal inspiratory mouth pressure.
1666253|NCT01727752|Procedure|Decompression|
1666254|NCT01727739|Device|Linvatec PLLA+TCP|Linvatec PLLA+TCP tibial interference screw fixation will be used in ACL reconstruction.
1666255|NCT01727739|Device|Linvatec PLLA|Linvatec PLLA tibial interference screw fixation will be used in ACL reconstruction.
1666256|NCT01727726|Drug|Brexpiprazole|tablet/capsule
1666257|NCT01727726|Drug|Seroquel XR|tablet/capsule
1666258|NCT01727726|Drug|Placebo|tablet/capsule
1666259|NCT01727713|Drug|Aripiprazole|Open Label: Once-Daily formulation of aripiprazole flex dose regimine
1666260|NCT01727700|Drug|Aripiprazole|Once-daily, tablet
1666261|NCT01727700|Drug|Placebo|
1666262|NCT01727687|Behavioral|behavioral training for crossing road|behavioral training programs for crossing road, such as verbal oral cues and simulated traffic scenes
1666263|NCT01727661|Behavioral|exercise testing with near-infrared spectroscopy|subjects will sit on the ergometer, resting heart rate and BP will be measured for at least 2 minutes. Before testing, each participant will be informed to perform cycling with 0 watt for 2 minutes. Then, exercise testing will be started at 30 watt, and increase 15 watt in male and 10 watt in female every minute until the termination criteria achieved.
1666290|NCT01727453|Drug|Bemiparina|"Group 2 (VKA oral anticoagulation: warfarin), which is the control group will receive VKA anticoagulation as before they had the bleeding episode, with regular monitoring by measurement of prothrombin time (INR). Patients taking acenocoumarol before bleeding episode will be treated with warfarin and the once who were receiving warfarin will continue with the same treatment. Treatment control is performed by measuring the INR periodically.
Randomization will be performed using sealed opaque envelopes that contain the treatment option that will be obtained through a list of random numbers generated by computer."
1666561|NCT01725230|Drug|Simvastatin|40-mg tablet
1666264|NCT01727661|Behavioral|lung function testing|"spirometry testing: Each participant will then place mouthpiece in mouth and close lips around the mouthpiece. Participants will inhale completely and rapidly and then exhale maximally until no more air could be expelled while maintaining an upright position. Values of FEV1 (forced expiratory volume in 1 second) and FVC (forced vital capacity) will be calculated immediately after the exhalation.
single-breath carbon monoxide diffusing capacity: Participants will sit on a firm and nose clips will then be attached and mouthpiece be placed in mouth. After participants perform several stable breathes, testing starts with a complete exhalation. Each participant will be instructed to inhale rapidly and completely and then hold for 10 seconds."
1666265|NCT01727661|Behavioral|quality of life|assessing quality of life using short-forum 36 (questionnaire)
1666266|NCT01727648|Behavioral|RT in sequential combination with dCIT|The participants will received 2 weeks of RT therapy using the ArmeoSpring and followed by 2 weeks of distributed CIT therapy. The treatment principles of RT and distributed CIT are the same with those described in the monotherapy of RT or dCIT, respectively.
1666267|NCT01727648|Behavioral|Distributed Constraint-Induced Therapy|The dCIT group will focus on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected UL in functional tasks for 1.5 hours/weekday over the 4 weeks. Participants in this group will focus on the intensive training of the affected arm in functional activities with behavioral shaping.
1666268|NCT01727648|Behavioral|Robot-Assisted Therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The ArmeoSpring (Hocoma AG, Switzerland) will be used in this project. It is a 5 degree-of-freedom skeleton mechanism that automates arm movement in a gravity-supported and computer-enhanced environment. The design of the arm support component of the ArmeoSpring is based on Wilmington Robotic Exoskeleton, an antigravity arm support. Instrumentation of the ArmeoSpring with position sensors at each joint enables it to be used as a 3D input device for computer game play with the hemiparetic arm. A custom software package named Vu Therapy will be also used in this project. Games were designed to simulate functional arm movements to provide training in a simple virtual reality environment.
1666269|NCT01727648|Behavioral|Dose-matched control therapy|Participants will receive 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). This group will received a structured protocol using conventional occupational therapy techniques such as neuro-developmental techniques with emphasis on functional tasks and muscle strengthening. The treatment protocol will include (1) passive range of motion exercises, stretching of the affected limb, or facilitatory and inhibitory techniques for 15 to 20 minutes, (2) fine motor or dexterity training for 20 minutes, (3) arm exercises or gross motor training for 20 minutes, (4) muscle strengthening of the affected upper limb for 15 to 20 minutes, and (5) activities of daily living or functional tasks training for 15 to 20 minutes.
1666270|NCT01727635|Other|body-mind-spirit group therapy|8-session therapy
1666271|NCT01727622|Drug|FDG-PET|Diagnostic: FDG-PET imaging to examine neuronal health
1666272|NCT01727622|Other|ASL-MRI|Arterial-Spin Labeled MRI to examine cerebral blood flow
1666273|NCT01727622|Procedure|Lumbar Puncture|Lumbar puncture to acquire a small amount of cerebrospinal fluid for protein level analyses. Note that this will not be required in all participants.
1666274|NCT01727609|Dietary Supplement|Milk feed (breast milk or formula milk)|
1666275|NCT01727596|Other|taping|Briefly, the patella was manually displaced medially, and maintained in the position by Tex Tape (Kinesio Holding Corporation, Albuquerque, NM)
1666276|NCT01727583|Dietary Supplement|meal intake|Intake of meals characterized by lipid composition
1666277|NCT01727583|Dietary Supplement|Placebo|
1666278|NCT01727570|Dietary Supplement|Whey Protein (Immunocal®)|The amount of Immunocal® whey protein the patient is required to take daily will be determined on an individual basis by the nutritionist according to the assessed protein deficit in the patient's diet.
1666279|NCT01727557|Procedure|regional anesthesia|Regional anesthesia will be compared to local anesthesia
1666280|NCT01727557|Procedure|local anesthesia|Regional anesthesia will be compared to local anesthesia
1666281|NCT01727544|Procedure|cartilage cap occlusion surgery|placement of a cartilage cap over the dome of the superior semicircular canal through a combined transmastoid and tegmen mini- craniotomy approach.
1666282|NCT01727531|Drug|Chloroquine diphosphate|250 mg chloroquine once a day by mouth beginning one week prior to beginning radiation therapy and continue for a total of five weeks
1666283|NCT01727505|Device|Sequence A: Conventional-Volume Guarantee|"This is a crossover study. Infants will be randomly assigned to one of two sequences.
In sequence A, the infant will undergo a 24-hour period of conventional mechanical ventilation followed by a 24 hour period of volume guarantee ventilation.
Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).
During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.
During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
1666284|NCT01727505|Device|Sequence B: Volume Guarantee-Conventional|"This is a crossover study. Infants will be randomly assigned to one of two sequences.
In sequence B, the infant will undergo a 24-hour period of volume guarantee ventilation followed by a 24 hour period of conventional mechanical ventilation.
Both conventional mechanical ventilation and volume guarantee ventilation will be provided by the same neonatal ventilator (AVEA, CareFusion Inc, Yorba Linda, CA).
During the 24 hour period of conventional mechanical ventilation, the infant will receive mechanical ventilation with the settings determined by the clinical team.
During volume guarantee ventilation, the set tidal volume to be maintained by the ventilator will be the average tidal volume delivered by the ventilator prior to start of study."
1666285|NCT01727492|Drug|Antioxidantia|
1666286|NCT01727479|Other|Ribose|After each of the 3km time trial (3 in total), participants will be asked to drink the experimental product (or placebo) incorporated in a sports drink.
1666287|NCT01727479|Other|Placebo|
1666288|NCT01727466|Behavioral|Facing Your Fears|FYF is a group cognitive behavior therapy that includes parent and child participation. Groups meet weekly for 1 1/2 hours duration, for 14 consecutive weeks.
1666289|NCT01727453|Drug|warfarin|Warfarin in anticoagulant dose
1666565|NCT01725191|Other|Pharmacological Study|Correlative studies
1666292|NCT01727414|Drug|OROS-Methylphenidate and placebo for inattentive type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
1666293|NCT01727414|Drug|OROS-Methylphenidate and placebo for combined type pts|Every participant receives low dose MPH, medium dose MPH, high dose MPH, and placebo for one week each in a triple-blinded fashion.
1666294|NCT01727401|Drug|Fondaparinux|Fondaparinux once daily sc injections at a dose of 2.5 mg if renal clearance of creatinine above 50 ml/min or Fondaparinux once daily sc injections 1.5 mg if renal clearance of creatinine between 20 and 50 ml/min
1666295|NCT01727388|Procedure|lateral decubitus|
1666296|NCT01727388|Procedure|supine decubitus|
1666297|NCT01727375|Other|Circadian light|"Artificial ceiling lighting throughout the day will be provided by the Philips HealWell system, CE marked, which is able to deliver varying light levels and warmer or cooler light according to the time of the day (circadian light). Emergency or examination lighting can be set on demand as circumstances require.
Lighting conditions at the patients bedside will be characterized by transformations on the time-series of light levels as measured by a luxmeter. The following metrics will be used for lighting characterization in a period of 24h: mean levels of bright and dark periods, contrast between bright and dark periods, clustering of bright and dark periods, and circadian variation."
1666298|NCT01727362|Other|Usual care + acupuncture|Patients of this group receive a semi-standardized acupuncture treatment over 6 month in addition to usual care
1666299|NCT01727362|Other|Usual care|Patients of this group receive usual care only
1666300|NCT01727349|Other|HbA1c measurement|
1666301|NCT01727349|Other|Oral Glucoce Tolerance Test|Oral Glucoce Tolerance Test
1666302|NCT01727336|Drug|Dalantercept and axitinib|
1666303|NCT01727336|Drug|Placebo and axitinib|
1666304|NCT01727297|Device|REVEAL Implantable cardiac monitor|
1666305|NCT01727284|Procedure|MR-guided cryoablation|
1666306|NCT01727271|Drug|Tenofovir|
1666307|NCT01727271|Biological|Pegylated interferon alpha-2b|
1666308|NCT01727258|Device|Mouth Rinse|Mouth rinse 12027-033 used twice daily for 28 days after brushing.
1666309|NCT01727258|Drug|Fluoride Toothpaste|Fluoride Toothpaste used daily for 28 days.
1666310|NCT01727258|Drug|Potassium Nitrate Toothpaste|Potassium Nitrate Toothpaste used daily for 28 days.
1666311|NCT01727245|Other|Obese|gastric bypass
1666312|NCT01727245|Other|Control group|Cholecystectomy and anti-reflux surgery
1666313|NCT01727206|Drug|Tocilizumab|
1666314|NCT01727193|Drug|Azathioprine|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 1 glucocorticoid + Azathioprine: Glucocorticoid (0.25mg/kg/d )plus Azathioprine at a starting dose of 50mg/d for 14 days, then increase up to 2mg/kg in 2 weeks.If no adverse events occurred , maintain the dose until 48 weeks.
1666315|NCT01727193|Drug|Leflunomide|The basic therapy of each group is cholinesterase inhibitors (pyridostigmine 36mg / kg / d). Group 2 glucocorticoid + Leflunomide: Glucocorticoid (0.25mg/kg/d )plus Leflunomide 20mg/d for adult, 10mg/d for child. if no adverse events occurred , maintain the dose until 48 weeks.
1666316|NCT01727180|Other|Questionnaire based on the McGill Pain Questionnaire|Interview questionnaire based on the short form of the McGill Pain Questionnaire
1666317|NCT01727167|Drug|200ppm CO for one hour|This is the study intervention. The treatment group will breath 200 ppm of CO for one hour over the three days immediately prior to surgery.
1666318|NCT01727167|Other|Control|This group will breath room air for one hour per day over the course of the three days immediately prior to surgery.
1666319|NCT01727154|Biological|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
1666320|NCT01727141|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
1666321|NCT01727141|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
1666322|NCT01727141|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
1666323|NCT01727141|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
1666324|NCT01727128|Drug|BKM120|
1666325|NCT01727115|Other|Infant Formula Feeding|"Assigned formula (Althera® or Nutramigen®) for a 4 weeks period.
If the challenge is positive: The children continue the assigned formula
If the challenge is negative: A Follow up formula is given
(Nan pro2) if child > 6 months
(Nan pro1) if child < 6 months"
1666326|NCT01727089|Biological|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
1666327|NCT01727089|Biological|Bevacizumab|Given IV
1666328|NCT01727089|Other|Laboratory Biomarker Analysis|Correlative studies
1666329|NCT01727089|Other|Pharmacological Study|Correlative studies
1666330|NCT01727076|Other|Laboratory Biomarker Analysis|Correlative studies
1666331|NCT01727076|Other|Pharmacological Study|Correlative studies
1666332|NCT01727076|Biological|Recombinant Human Interleukin-15|Given SC
1666333|NCT01727063|Procedure|Cell Therapy|Intramyocardial injection of autologous bone marrow-derived cells
1666334|NCT01727050|Device|Fibrin sealant spray|Fixation of mesh would be performed using fibrin sealant spray applied with a laparoscopic spray catheter
1666335|NCT01727050|Device|Mechanical stapling|Fixation of mesh would be performed using mechanical staplers
1666336|NCT01727037|Procedure|Bronchoscopic intrabullous autologous blood instillation|
1666337|NCT01727024|Drug|Tiotropium|Tiotropium via Respimat® device once a day
1666338|NCT01727024|Drug|Indacaterol|Indacaterol via Breezhaler® device once a day
1666339|NCT01727011|Radiation|IPAS|
1666340|NCT01726998|Other|Robot-assisted gait therapy|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
1666384|NCT01726582|Drug|Targeted chemotherapy prior to surgery|The molecular profile from the biopsy before surgery will point to a particular chemotherapy treatment.
1722214|NCT00003783|Drug|methotrexate|
1666341|NCT01726998|Other|conventional gait training|Two groups received 30 minutes conventional gait training including Neurodevelopmental Treatment(NDT) basically. Robot-assisted gait therapy for 30 minutes with Lokomat® (Hocoma, Zurich, Switzerland) daily for 4 weeks, and the conventional gait training group received additional daily conventional gait training with NDT for the same periods.
1666342|NCT01726985|Other|Parameter Based Clinical Disposition|"Parameter Based Clinical Disposition'
Physicians will initiate / titrate medications and obtain consults as usual but are highly encourage to keep patients in the hospital until at least 2 of the following 3 criteria are met:
NT-ProBNP reduction of > 23% from peak value during admission
Fluid Reduction of > 1.3L (orders for I/O q8h required)
Serum Sodium of > 135 mmol/L the day of planned discharge"
1666343|NCT01726946|Drug|VX-135|12 weeks of VX-135
1666344|NCT01726946|Drug|ribavirin|12 weeks of ribavirin
1666345|NCT01726933|Drug|LAS41008|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
1666346|NCT01726933|Drug|LASW1835|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
1666347|NCT01726933|Drug|Placebo|gastric resistant tablet, weekly up-titration up to maximal tolerated dosage
1666348|NCT01726920|Drug|naratriptan + naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
1666349|NCT01726920|Drug|naratriptan|Tablets containing naratriptan 2,5 mg
1666350|NCT01726920|Drug|naproxen|Tablets containing naproxen 500 mg
1666351|NCT01726907|Device|Robotic SMG resection|The surgical procedure and the considerations for surrounding neurovascular structures were similar to that of the endoscope-assisted SMG resection. The da Vinci surgical system (Intuitive Surgical Inc., Sunnyvale, CA) including a 30° dual channel endoscopic arm and two instrument arms was introduced. The SMG was retracted using the 5-mm Maryland forceps on the left and the dissection was conducted using a 5-mm spatula monopolar cautery or a Harmonic curved shears on the right. A Yankauer suction handled by a bed-side assistant could be used for counter traction of the gland which facilitated the dissection procedure.
1666352|NCT01726907|Device|Endoscopic SMG resection|An assistant held a 10-mm 30° rigid endoscope allowing the operating surgeon to use both hands. Surgical resection tools such as dissector and Harmonic scalpel (Harmonic Ace 23E®; Johnson & Johnson Medical, Cincinnati, OH, USA) was held in the right hand and a Yankauer suction or a Debakey forcep was held on the left for traction of the SMG. The dissection plane between the capsule of the SMG was conducted under magnified endoscopic view using the the blade of the Harmonic scalpel and the endoscopic dissector. Routine identification of the marginal mandibular branch of the facial nerve was unnecessary in SMG resection, since the dissection plane was always deep to the middle layer of the deep cervical fascia which includes the fascia of the gland. The Wharton's duct, facial artery and vein were ligated using the Harmonic scalpel or vascular clip.
1666353|NCT01726894|Device|Irreversible Electroporation|
1666354|NCT01726881|Device|Thermal stimulation|"Stimulation using a Thermal Sensory Analyzer:
2001, Maddock ltd., Israel."
1666355|NCT01726881|Device|Mechanical stimulation|Stimulation using Semmes-Weinstein-Monofilament Touch Test Sensory Evaluators
1666356|NCT01726881|Device|Transcutaneous Electrical Nerve Stimulator (TENS)|A portable stimulator designed to Physical treatment of pain. TENS - Cedar rehab X2. Chattanooga group.USA.
1666357|NCT01726868|Device|Liposorber LA-15 System|Six sessions of blood purification treatment with Liposorber LA-15 System.
1666358|NCT01726855|Procedure|vascularized finger dorsal fascial flap|
1666359|NCT01726842|Device|Pediatric Vision Scanner|Subject is scanned with a 2.5 second pediatric vision scanner device test.
1666360|NCT01726829|Device|MD-Logic Artificial Pancreas (MDLAP) system|
1666361|NCT01726829|Procedure|sensor augmented pump therapy|
1666362|NCT01726816|Drug|Probucol 250mg/day|Probucol 250mg + Placebo
1666363|NCT01726816|Drug|Probucol 500mg/day|Probucol 500mg + Placebo
1666364|NCT01726816|Drug|Placebo|Probucol matching placebo
1954932|NCT03310307|Drug|Vit D|50,000 IU
1954933|NCT03310307|Other|Placebo|
1666367|NCT01726777|Dietary Supplement|Control|Normal cheddar cheese
1666368|NCT01726777|Dietary Supplement|Vitamin D|Vitamin D3 supplemented cheddar cheese
1666369|NCT01726764|Other|St John's Wort|
1666370|NCT01726764|Drug|Metformin|
1666371|NCT01726751|Device|Spinal Cord Stimultion (SCS)|Electric stimulation of the spinal cord
1666372|NCT01726751|Device|Spinal cord nerve stimulation|
1666373|NCT01726738|Drug|BRAF inhibitor dabrafenib and MEK inhibitor trametinib|Patients will receive the BRAF inhibitor dabrafenib and MEK inhibitor trametinib orally at the RP2D determined in the Phase I/II study (BRF113220): trametinib 2mg QD and dabrafenib 150 mg BID on a continuous basis. A cycle will be defined as 3 weeks in duration. Cycles will be repeated until disease progression (clinical or radiological). Patients may remain on treatment after progression (at the discretion of the investigator) as long as they are still experiencing clinical benefit.
1954934|NCT03310294|Dietary Supplement|Placebo|one bottle of placebo (minidrink fermented with low-fat milk but without Lactobacillus rhamnosus and without FOS, and without viable bacteria 90 grams)per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
1666375|NCT01726712|Other|Supportive Care|Provide emotional support. Provide practical support. Support friend/family by helping him find information or help for those with HIV in the community
1666376|NCT01726686|Drug|Ropivacaine|100 ml Ropivacaine 10mg/ml in a continuous infusion pump set at 2 ml/hour
1666377|NCT01726686|Drug|Placebo|
1666378|NCT01726673|Device|Transcranial Direct Current Stimulation (tDCS)|
1666379|NCT01726673|Device|Placebo sham|
1666380|NCT01726660|Device|IMT Robotic Arm therapy|Interactive Motion Technologies (IMT) planar and wrist robots for robotic arm therapy
1666381|NCT01726634|Other|Elastic Tapping|
1666382|NCT01726621|Device|Medtronic MiniMed 620G or 640G Insulin Pump|Subjects to use the Medtronic MiniMed 620G or 640G Insulin Pump and Guardian Link transmitter to manage their diabetes for 4 - 6 weeks.
1666383|NCT01726608|Procedure|Comparison of active versus sham radiofrequency neurotomy with Simplicity III|
1958142|NCT01955499|Drug|Ibrutinib|Given PO
1666385|NCT01726582|Drug|standard FOLFIRINOX chemotherapy prior to surgery|A biopsy of the borderline tumor does not provide a molecular profile that can be used to target treatment. The treatment will be standard FOLFIRINOX chemotherapy regimen.
1666386|NCT01726582|Drug|Gemcitabine after surgery|Chemotherapy treatment with Gemcitabine.
1666387|NCT01726582|Other|No additional therapy after surgery|The molecular profile of the tumor that was removed during surgery points to a lack of treatment affect for available therapies. No additional therapy is recommended.
1666388|NCT01726582|Drug|Targeted chemotherapy after surgery|The molecular profile from the surgical specimen will point to a particular chemotherapy treatment.
1666389|NCT01726582|Radiation|Chemoradiotherapy (cXRT)|A radio-sensitizing chemotherapy agent (either Gemcitabine or Capecitabine) will be given. Using 3D conformal or IMRT techniques, patients will receive a total dose of 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions).
1666390|NCT01726569|Behavioral|film and trained counseling|Subjects will be asked to watch a 5-10 min film and participate in a 10-15 min pre-operative counseling session with a trained doctor/nurse. Subjects will also participate in a 5 min post-operative counseling session.
1666391|NCT01726569|Other|traditional counseling|Subjects will be not participate or participate in a pre-operative/post-operative counseling session with a rural hospital's doctor/nurse as usual traditional methods.
1666392|NCT01726556|Device|Rigid thoracoscope (Richard Wolf GmbH, Knittlingen, Germany)|Pleuroscopy using a rigid thoracoscope manufactured by Richard Wolf GmbH, Knittlingen, Germany
1666393|NCT01726556|Device|Semirigid thoracoscope (model LTF-160Y1, Olympus, Japan)|Pleuroscopy using a semirigid thoracoscope model LTF-160Y1, manufactured by Olympus Medical Systems Corporation, Tokyo, Japan
1666394|NCT01726543|Procedure|Canaloplasty and phacoemulsification|As soon as the two scleral flaps (deep and superficial -similar to deep sclerectomy) are dissected, the phacoemulsification is performed and a artificial lense is implanted. After excision of the deep flap the descemets window and ostia of Schlemm canal are created, the microcatheter is placed in the canal and is advanced 12 clock hours within the canal. Surgeon observes the location of beacon tip through sclera and injects the Healon GV. When the catheterisation of the canal is done, the distal tip is exposed and a 10-0 propylene suture is tied to the distal tip. Then the microcatheter is withdrawn and suture is pulled into the canal. As it appears at the other ostium of canal the microcatheter it separated from the suture. A loop is created, encircling the inner wall of Schlemm canal. Then suture loop is tightened to distend the trabecular meshwork inward, placing the tissues in tension, the locking nods are added. The superficial flap is sutured watertight to prevent bleb formation.
1666395|NCT01726543|Procedure|Non-penetrating deep sclerectomy and phacoemulsification|A fornix-based conjunctival ﬂap is dissected superiorly, and the sclera is exposed. A 5 x 5 mm scleral ﬂap is dissected anteriorly into clear cornea using a No. 69 Beaver blade. Then the phacoemulsification procedure is performed and a artificial lense is implanted. Afterwards second deep scleral ﬂap is dissected and excised leaving only a thin layer of deep sclera over the choroid. Anteriorly, the dissection is made down to remove Schlemm's canal and juxtacanalicular trabeculum. Excision of the corneal stroma is performed more anteriorly down to Descemet's membrane. This allows aqueous humor to percolate through the thin trabecular-Descemet's membrane. The superficial scleral ﬂap is then closed with two 10-0 monofilament nylon sutures.The conjunctiva is sutured down over the limbus with one interrupted 10-0 monofilament nylon suture at each corner.
1666396|NCT01726530|Drug|transdermal fentanyl patch (50 mcg/hour)|
1666397|NCT01726530|Drug|Placebo|
1666398|NCT01726517|Drug|LDV/SOF|LDV 90 mg/SOF 400 mg FDC tablet administered orally once daily
1666399|NCT01726517|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1666400|NCT01726504|Device|electro-acupuncture|Procedure: electro-acupuncture; Points:Tianshu (ST25) Fujie(SP14), Shangjuxu (ST37).Pierced the skin, needles are inserted 30to70mm into bilateral ST25 and SP14 vertically until piercing the abdominal muscle layer.Electric stimulator is applied to bilateral ST25 and SP14 with dilatational wave, 10/50 Hz and electric current 0.1-1.0mA. The participant's abdominal muscle twitching mildly is the appropriate dose. Bilateral ST37 are inserted 25-30mm and then twirling lifting and thrusting for 3 times.Local sour and heavy feeling is appropriate dose. Steady small twirling lifting and thrusting 3 times in all. 30 min/per day/per session.During the 8 weeks treatment, the first 2 weeks,5 sessions per week, and 3 sessions per week in the rest 6 weeks,28 sessions for each patients in total.
1666401|NCT01726504|Device|sham electro-acupuncture|Procedure:sham electro-acupuncture;Points:Sham Tianshu(ST25),sham Fujie(SP14),sham Shangjuxu (ST37).Sham points location:20mm away from ST25,middle of Spleen and Stomach Channel;30mm from SP14,middle of Spleen and Stomach Channel; one point beside ST37,middle of Stomach and Gallbladder Channel; Performance:The needle is inserted with needle of 0.30×25mm by 3-5mm. No twirling lifting and thrusting. The electric stimulator is applied to bilateral sham ST25 and sham SP14 with dilatational wave,10/50 Hz and electric current 0.5mA.The mental wire has been cut off with a same outlook as the treatment group.The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
1666402|NCT01726478|Drug|2.5 units Oxytocin|Administration of 2.5 units of oxytocin after clamping of umbilical cord
1666403|NCT01726478|Drug|10 units Oxytocin|Administration of 10 units of oxytocin after clamping of umbilical cord
1666404|NCT01726465|Drug|Methylprednisolone|Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.
1666438|NCT01726166|Procedure|Suprapubic Aspiration|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
1666566|NCT01725191|Drug|Tivantinib|Given PO
1666405|NCT01726465|Drug|N-acetylcysteine|Acetylcysteine is the N-acetyl derivative of the naturally occurring amino acid, L-cysteine. Chemically, it is N-acetyl-L-cysteine. The compound is a white crystalline powder which melts at 104°−110°C and has a very slight odor. Acetylcysteine may form cysteine, disulfides, and conjugates in vivo (N, N'-diacetylcysteine, N-acetylcysteine- cysteine, N-acetylcysteine-glutathione, N-acetylcysteine-protein, etc). No metabolites were identified. Acetylcysteine likely protects the liver by maintaining or restoring the glutathione levels, or by acting as an alternate substrate for conjugation with, and thus detoxification of, the reactive metabolite.
1666406|NCT01726452|Drug|Epirubicin|50mg/m2 on Day 1 of each cycle only (i.e. every 21 days)
1666407|NCT01726452|Drug|Cisplatin|60mg/m2 on day 1 of each cycle only (i.e. every 21 days).
1666408|NCT01726452|Drug|5 Flourouracil/ Capecitabine|5 Flourouracil(200 mg/m2/Day)as a continuous intravenous infusion every day for 21 days/3 weeks, Capecitabine (625 mg/m2 twice daily orally)for 21 days/3 weeks. The choice between administering 5 Flourouracil or Capecitabine is at the discretion of the investigator. 5 Flourouracil/ Capecitabine are given daily for the duration of each cycle (i.e. for 9 weeks pre-surgery and for 9 weeks post-surgery).
1666409|NCT01726452|Radiation|(41.4 Gy/23 fractions)|patient will receive 5 weeks of radiation therapy (41.4 Gy/23 fractions).
1666410|NCT01726452|Drug|Paclitaxel|50mg/ m2 Paclitaxel dose administered on Days 1, 8, 15,22 and 29. Dexamethasone, Chlorphenamine and Ranitidine given IV half an hour before commencing Paclitaxel.Once the Paclitaxel infusion is completed NACL 0.9%,100 ml will be infused IV over half an hour.After this infusion is completed Ondansetron or its equivalent diluted in 100mls NACL 0.9% will be given IV over half an hour on Days 1, 8, 15, 22 and 29.
1666411|NCT01726452|Drug|Carboplatin|Dose determined as per calculation,infused on Days 1, 8, 15, 22 and 29.
1666412|NCT01726426|Dietary Supplement|Probiotic|Each capsule Probiotics (Lactobacillus- 2 billion, Bifidobacterium- 1 billion, fructo-oligosaccharide): 1 capsule twice daily orally for 12 weeks
1666413|NCT01726413|Drug|GRC 17356|
1666414|NCT01726413|Drug|Matching Placebo|
1954935|NCT03310294|Dietary Supplement|Prebiotics and Probiotics|one bottle of the study product (minidrink with fermented low-fat milk added with Lactobacillus rhamnosus (Lactobacillus rhamnosus) and fructooligosaccharides (FOS),per day at breakfast until the end of the study (V5, day 140). At each visit, subjects were dispensed a sufficient amount of minidrinks until the next visit.
1666417|NCT01726387|Behavioral|Psychosocial Counseling|Depending on their condition, counseling assistants support patients in self-management support, enhancing self-efficacy, reducing psychological symptoms
1666418|NCT01726387|Behavioral|Usual Care|Depending on the conditions, patients get usual care of their general practitioner
1666419|NCT01726374|Drug|BEP(500)|"One cycle of BEP(500):
Etoposide 165 mg/m2 IV infusion - days 1, 2, 3 Cisplatin 50 mg/m2 IV infusion - days 1, 2 Bleomycin 30,000 IU IV infusion - days 1 (or 2), 8, 15"
1666420|NCT01726361|Behavioral|Multidimensional Treatment Foster Care|Out of home placement in MTFC family for 10-12 months
1666421|NCT01726361|Behavioral|Treatment as usual|Other kinds of out of home placement
1666422|NCT01726348|Drug|No intervention|This is an observational study. Darunavir will be administered as per the recommended doses and will be given orally every 4 weeks for a period of 24 weeks. For treatment-naive and treatment-experienced adult patients with no darunavir resistance associated substitutions: Darunavir 800 mg will be administered with ritonavir 100 mg once daily with food. For treatment-experienced adult patients with at least one darunavir resistance associated substitution: Darunavir 600 mg will be administered with ritonavir 200 mg twice daily with food.
1666423|NCT01726335|Drug|Risperidone prolonged release|Risperidone will be administered as intramuscular injection as 25 milligram (mg) every two weeks, from Week 1 to 50, wherein after Week 3, dose may be adjusted up to 50 mg at physician criterion. For first two weeks, previous oral antipsychotic drug will be maintained and the dose will be gradually decreased and will cease at Week 3.
1666424|NCT01726296|Other|educational intervention|Complete an educational intervention based on NCCN guidelines and disease-specific issues related to survivorship care
1666425|NCT01726296|Other|medical chart review|Complete patient medical chart audit
1666426|NCT01726283|Device|Corneal Cross-Linking|Corneal cross-linking procedure conducted during vision correction surgery.
1666427|NCT01726283|Drug|Riboflavin|Riboflavin will be instilled prior to corneal cross linking.
1666428|NCT01726270|Drug|tamsulosin|0.4 mg
1666429|NCT01726257|Device|Nellix System|
1666430|NCT01726244|Behavioral|Multidisciplinary Intervention|Health education sessions consisting in controlling disease and stress asociated to it, and modifying eating habits
1666431|NCT01726205|Drug|Pregabalin and normal saline infusion, PRG|
1666432|NCT01726205|Drug|Pregabalin and ropivacaine 02% infusion|
1666433|NCT01726205|Drug|Placebo drug, normal saline infusion|
1666434|NCT01726192|Procedure|Placement of a femoral catheter with the hydrolocalization technique|Placement of femoral nerve catheter with the hydrolocalization technique, using ropivacaine 0.6%
1666435|NCT01726192|Procedure|Placement of a femoral neurostimulating catheter|
1666436|NCT01726179|Device|Icon infiltration|"Patients and their guardians will be instructed to use dental floss to remove dental biofilm in both proximal sites once a day and to brush teeth with fluorated toothpaste twice a day. Besides that, test lesion will be infiltrated with a low viscosity resin (Icon, DMG, Hamburg, Germany). The test lesions will be treated using Icon (DMG, Hamburg, Germany) following the instruction for use.
A sub-sample with children with indication for a composite restoration in at least one proximal surface will be selected for the analysis of dental anxiety and stress."
1666437|NCT01726179|Device|control|"Patients and their guardians will be instructed to use dental floss to remove dental biofilm in both proximal sites once a day and to brush teeth with fluoridated toothpaste twice a day.
A sub-sample with children with indication for a composite restoration in at least one proximal surface will be selected for the analysis of dental anxiety and stress."
1666503|NCT01725659|Other|Robotics|subjects perform training of hemiplegic arm using an upper extremity robot
1666504|NCT01725659|Other|surface FES|subjects are provided with surface FES to the hemiplegic upper limb
1666505|NCT01725646|Drug|Omacor®|Subjects in 4 g and 2 g Omacor® will take this drug
1958143|NCT01955499|Other|Laboratory Biomarker Analysis|Correlative studies
1666439|NCT01726166|Procedure|Urinary Catheterization|Pain management will be performed as per our NICU protocols by administering 24% sucrose prior to both procedures to ensure adequate pain control. Additional or different analgesia may be used depending on the patient's specific clinical situation. We will use a chlorhexidine 0.05% with no cetrimide solution as the cleaning solution.
1666440|NCT01726153|Behavioral|Condom-HIM|The tailored on-line Condom-HIM intervention is composed of a single session involving activities to increase individuals self-efficacy and intention to use condoms.
1666441|NCT01726140|Procedure|Helmet CPAP|the patient will receive CPAP treatment, at a PEEP level of 10 cmH2O and a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will repeat a spontaneous breathing trial with a Venturi mask at FiO2 = 50%, for 15 minutes and than a blood gas analysis will be repeated: if the PaO2/FiO2 will be < 200 the patient will received a second treatment with CPAP; if PaO2/FiO2 will be >200, the patient will stop the treatment.
1666442|NCT01726140|Procedure|Venturi Mask|the patient will maintain spontaneous breathing, with a system for oxygen delivery at a FiO2 adjusted to maintain SpO2>95%, for six hours. After three hours of treatment a blood gas analysis will be evaluated and the patient will proceed with the treatment for three more hours. At the end of the six hours, the patient will do a trial for 15 minutes and after that a blood gas analysis will be repeated: if the PaO2/FiO2 will be < 200 the patient will go on with the control treatment; if PaO2 /FiO2 will be >200, the patient will stop the treatment.
1666443|NCT01726127|Other|Broccoli and Brussels Sprouts|
1666444|NCT01726127|Dietary Supplement|Cruciferous Complete|
1666445|NCT01726127|Other|Placebo|
1666446|NCT01726114|Device|Non-invasive Optical Glucose Monitor™|Test device
1666447|NCT01726114|Device|YSI blood glucose analyzer|Reference device
1666448|NCT01726088|Drug|Modafinil|we will compare the effect of modafinil and matching placebo on clinical and objective measures detailed above.
1666449|NCT01726075|Drug|COLIRIOBCN070660|One drop per eye twice a day during 24 months
1666450|NCT01726075|Drug|Placebo|One drop per eye twice a day during 24 months
1666451|NCT01726075|Drug|Brimonidine|One drop per eye twice a day during 24 months
1666452|NCT01726062|Behavioral|Motivational Interviewing plus Incentives|"Two hospital-based, face-to-face MI+ sessions
Two home-based MI+ sessions
Attendance at each session and for the establishment of a household smoking ban at two timepoints post-discharge"
1666453|NCT01726062|Behavioral|Conventional Care (CC)|Participants in this arm will receive brochures and a brief information meeting in the NICU.
1666454|NCT01726049|Drug|Sildenafil|Sildenafil administered orally 3 times per day 20 mg for the first 2 weeks, followed by 3 times 60 mg for 10 weeks
1666455|NCT01726049|Drug|Placebo|Placebo tablets 3 times per day 20 mg foor de first 2 weeks, followed by 3 times 60 mg for 10 weeks
1958144|NCT01955499|Drug|Lenalidomide|Given PO
1958145|NCT01955499|Other|Pharmacological Study|Correlative studies
1666458|NCT01726023|Drug|Ceftazidime-avibactam|Ceftazidime-Avibactam powder for concentrate for solution for infusion 2000 mg/500 mg
1666459|NCT01726023|Drug|metronidazole|Metronidazole 500mg/100ml solution for infusion
1666460|NCT01726023|Drug|Meropenem|Meropenem powder for solution for infusion 1000mg
1666461|NCT01726010|Device|22-G Procore Needle|
1666462|NCT01725997|Procedure|hook plate|Surgery with hook plate followed by physiotherapy
1666463|NCT01725997|Other|Physiotherapy|Patients will be following a program specific for AC joint dislocations
1666464|NCT01725958|Dietary Supplement|Nutritional supplement and protein shakes|
1666465|NCT01725945|Behavioral|Dietary Approaches to Stop Hypertension dietary pattern|The intervention will employ a series of small group and individual sessions, followed by periodic telephone contacts, to help participants make appropriate dietary changes and develop the skills to maintain these changes over the long term. The initial 3 months of intensive intervention will involve 8 group and 3 individual sessions for 45-60 minutes each. During the next 3 months, participants will receive counseling phone calls once per month for 20-30 minutes each call. Group session sizes may range from 8-15 participants.
1666466|NCT01725932|Behavioral|Culturally adapted CBT based Self Help|Intervention was based on our initial work using mixed methods, using mixed methods,in Pakistan. It focused on psycho-education, symptoms management, changing negative thinking, behavioral activation, problem solving, improving relationships and communication skills. One person from the family was involved in all cases. The intervention consists of 7 chapters. Manual can be used by the patient's or carers with at least 5 years of education. A member of the research team called them once every week to remind them of the next chapter and also to discuss any issues o problems that emerged during the previous week. This manual can be downloaded from PACT website (http://www.pactorganization.com/)
1666467|NCT01725919|Behavioral|CI therapy|constraint induced movement therapy
1666468|NCT01725906|Drug|empirical therapy|"Nexium (esomeprazole), 40mg, bid, 14 days, plus
Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus
Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs
Select either one of the drugs according to medication history Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
1666469|NCT01725906|Drug|Genotypic resistance guided therapy|"Nexium (esomeprazole), 40mg, bid, 14 days, plus
Amoxicillin (Amoxicillin Trihydrate), 1gm, bid, 7 days, plus
Flagyl (metronidazole), 500mg, bid, 7 days, plus either one of the following drugs
Select either one of the drugs according to genotypic resistance results Cravit (levofloxacin) , 250 mg, bid, D8-14 Klaricid (clarithromycin), 500 mg, bid , D8-14 Tetracycline, 500 mg, bid, D8-14"
1666470|NCT01725880|Other|Observation|
1666471|NCT01725867|Other|PT program|manual myofascial release for craniomandibular system for 30~40 minutes chin-in exercise within 10 minutes and as home exercise self-care education twice per week for 8 weeks
1666472|NCT01725867|Device|oral appliance|custom-made oral appliance: wear every night for 8 weeks, occasional drop is allowed self-care education
1666506|NCT01725646|Drug|Placebo|Subjects in placebo group will take this drug
1666562|NCT01725217|Biological|MenACWY-CRM|1 vaccination at visit 1, conjugate vaccine, Intramuscular (IM) injection
1666563|NCT01725204|Drug|Dasatinib + PegIFN|
1666564|NCT01725191|Other|Laboratory Biomarker Analysis|Correlative studies
1666473|NCT01725854|Behavioral|Relaxation Response training|Behavioral Relaxation Response Training (Benson-Henry Institute Relaxation Response Training) Participants randomized to the intervention group will participate in the six weekly RR sessions. Examples of in-group skill building exercises are mini relaxations, diaphragmatic breathing, introduction to imagery, and eliciting RR through Yoga. Presentations topics include Introduction to Mind/Body Medicine, Introduction to the RR, Experiential RR Sessions, and Introduction to Cognitive Restructuring. Home skill building assignments include relaxation focus practice, an appreciation journal, self-monitoring with Biodots (biosensor technology that helps participants to monitor and regulate their psycho-emotional state), physical activity, balanced nutrition, and progress notes.
1666474|NCT01725828|Device|Ultrasongraphy|Using the Ultrasound to determine the location of the CTM.
1666475|NCT01725828|Other|Palpation|Using digital Palpation to identify cricothyoid membrane
1666476|NCT01725815|Behavioral|HARP Intervention|The HARP intervention is a 6-week, 6-session, group format intervention to improve self-management of chronic medical diseases. Each group lasts 90 minutes and has 8-12 attendees. Between groups, participants work with partners from the group to troubleshoot problems and accomplish action plans identified during the session. At the end of the program, monthly alumni groups meet for six months to reinforce lessons from the intervention, monitor progress, and maintain peer support.
1666477|NCT01725802|Drug|levodopa and carbidopa solution for SC administration|
1666478|NCT01725802|Drug|Placebo|
1666479|NCT01725789|Drug|Ferinject®|"Ferinject®to be administered as IV drip infusion or undiluted bolus injection with a minimum administration time of 15minutes (for 1000mg single administration) for body weight ≥50 Kg or 6 minutes (for 500mg single administration) for body weight <50Kg .
Note, Ferinject® should be administered to a maximum of 20mg iron/kg. Therefore in patients with a body weight <50kg, administration of Ferinject® should be limited to 500mg at baseline . All patients with a serum ferritin value <15ng/mL and Hb<10g/dl at week 3 visit that a second dose (of 500mg iron or equivalent placebo) will be given.(Study group: Ferinject®500mg, Control Group:Placebo)"
1666480|NCT01725789|Drug|normal saline|Placebo will be in the form of normal saline administered over same time period as equivalent Ferinject® administration. IV drip infusion or undiluted bolus injection with a minimum administration time of 15 minutes (200mL as infusion or 20mL as bolus injection) for body weight ≥50 Kg or 6 minutes (100mL normal as infusion or 10mL as bolus injection) for body weight <50 Kg.
1666481|NCT01725776|Drug|Inhaled milrinone 5 mg|Inhaled milrinone 5 mg (as for the injectable solution)
1666482|NCT01725763|Other|Cardiac MRI|
1666483|NCT01725750|Device|Bright White Light (BWL)|"Participants will self-administer bright white light daily. Litebooks used for Bright White Light and Dim Red Light are identical except for the light which they emit. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
1666484|NCT01725750|Device|Dim Red Light (DRL)|"A device that appears identical to BWL Litebook but that uses red LEDs emitting DRL. Users are instructed to place it about 18 from their face and within 45º of the visual field for 30 minutes within half an hour of waking each morning, for 4 weeks. The participant may eat, read, watch TV, etc. while sitting in front of the box."
1666485|NCT01725737|Drug|GlyTI-M|
1666486|NCT01725737|Drug|Placebo|Placebo Comparator: starch
1666487|NCT01725724|Procedure|Autologous blood transfusion|Per- and postoperative transfusion of autologous salvaged blood collected with the Sangvia Blood Collection System.
1666488|NCT01725724|Procedure|Allogeneic blood transfusion|Transfusion of allogeneic blood according to the transfusion guidelines at each of the participating hospitals.
1666489|NCT01725711|Device|OPRA Implant System|
1666490|NCT01725698|Drug|Mesenchymal stem cell, HA-CaSO4, ¬BMP-2, and Implant|
1666491|NCT01725685|Drug|FF 400 mcg|FF will be available as 100 mcg strength administered as 4 inhalations from a DPI
1666492|NCT01725685|Drug|UMEC 500 mcg|UMEC will be available as 125 mcg strength administered as 4 inhalations from a DPI
1666493|NCT01725685|Drug|FF/UMEC 400/500 mcg|FF/UMEC will be available as 100/125 mcg strength administered as 4 inhalations from a DPI
1666494|NCT01725672|Drug|Metformin, 500 mg extended release tablet|In Part A and Part B of the study, Metformin 500 mg XR tablet will be administered with 240 millilitre (mL) water ; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
1666495|NCT01725672|Drug|Metformin, 1000 mg extended release tablet|In Part A and Part B of the study, Metformin 1000 mg XR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
1666496|NCT01725672|Drug|Glimepiride, 1 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 1 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
1666497|NCT01725672|Drug|Glimepiride, 2 mg immediate release tablet|In Part A and Part B of the study, Glimepiride 2 mg IR tablet will be administered with 240mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
1666498|NCT01725672|Drug|Metformin, 500 mg and Glimepiride, 1 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
1666499|NCT01725672|Drug|Metformin, 1000 mg and Glimepiride, 2 mg extended release film coated tablet containing release controlling polymers|In Part A of the study, 1 XR film coated tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
1666500|NCT01725672|Drug|Metformin, 500 mg and Glimepiride, 1 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 500 mg and Glimepiride 1 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
1666501|NCT01725672|Drug|Metformin, 1000 mg and Glimepiride, 2 mg extended release tablet coated with release controlling polymers|In Part B of the study, 1 XR tablet combination of Metformin 1000 mg and Glimepiride 2 mg will be administered with 240 mL water; 125 mL of LUCOZADE was administered every 30 mins for 4 hours after dosing.
1666502|NCT01725659|Other|Motor Learning|training of the hemiplegic upper limb with motor learning
1666507|NCT01725633|Behavioral|Progressive Stretching Group|Participants assigned to the progressive stretching group will be provided with a progressive stretching program that matches the aerobic training interventions in terms of program length (16 weeks), social interaction (all sessions will be supervised), and session duration (20-45 minutes/session, ± 10 minutes).
1666508|NCT01725633|Behavioral|Nonlinear Aerobic Training|Participants assigned to the nonlinear aerobic training arm will perform no more than 150 minutes per week of structured supervised aerobic training as part of clinical trial participation. Exercise performed outside the structured sessions (i.e., contamination) will be assessed via self-report of exercise behavior using the Godin-Leisure Time Exercise Questionnaire (GLTEQ). For ethical reasons, we will not instruct participants not to exercise outside the structured sessions, but we we will encourage participants to maintain their level of exercise behavior prior to study initiation.
1666509|NCT01725633|Other|Blood draw|At Weeks 4, and 8, all participants will have a complete blood count (CBC) test performed.
1666510|NCT01725633|Other|Cardiopulmonary Exercise Testing (CPET)|At the end of Week 6, participants repeat the CPET in the nonlinear aerobic training group.
1666511|NCT01725620|Drug|LBEC0101 (Etanercept 25mg)|
1666512|NCT01725620|Drug|Enbrel (Etanercept 25mg)|
1666513|NCT01725607|Drug|general anesthesia combined with dexmedetomidine infusion|general anesthesia combined with 1 μg/kg dexmedetomidine infusion after induction (Group D)
1666514|NCT01725607|Procedure|general anesthesia combined with TEA|general anesthesia combined with TEA (Group E)
1666515|NCT01725594|Drug|CAT 2003|
1666516|NCT01725594|Drug|Placebo|
1666517|NCT01725581|Procedure|Observed Structured Assessment Tool in Pelvic Examination|Participants will be asked to perform a pelvic examination including a speculum and bimanual examination on a pelvic model. They will be asked to approach the pelvic model as if it were a real patient.
1666518|NCT01725568|Device|BioMonitor|Implantable cardiac monitor
1666519|NCT01725555|Drug|Fasted treatment: AXL1717|
1666520|NCT01725555|Drug|Fed treatment: AXL1717|
1666521|NCT01725542|Drug|Asunaprevir, Daclatasvir, Ribavirin and Peginterferon alfa-2a|
1666522|NCT01725529|Drug|TMC435|TMC435 100 mg or 150 mg capsules taken orally (by mouth) with food once-daily for 12 weeks (Week 12).
1666523|NCT01725529|Drug|Peginterferon-alpha (PegIFNα-2a)|PegIFNα-2a (180 micrograms [μg] once weekly) administered as weekly subcutaneous (s.c.) (under the skin) injections of 0.5 mL for 24 or 48 weeks.
1666524|NCT01725529|Drug|Ribavirin (RBV)|Ribavirin 1000 or 1200 mg/day (taken as 100 mg or 200 mg tablets) depending on body weight (If body weight is < 75 kg the total daily dose of RBV will be 1000 mg, administered as 400 mg intake with food in the morning and 600 mg intake with food in the evening. If body weight is > or = 75 kg the total daily dose will be 1200 mg, administered as 2 x 600 mg per intake with food, morning and evening) for 24 or 48 weeks.
1666525|NCT01725529|Drug|Placebo|Matching placebo capsules taken orally with food once-daily for 48 weeks.
1666526|NCT01725516|Procedure|Myofascial release technique|
1666527|NCT01725503|Dietary Supplement|Creatine and Amino Acid supplement|
1666528|NCT01725490|Drug|metformin|Patients will be randomly assigned in a 2:2:1 ratio to receive metformin or identical-appearing placebo tablets orally for 7 months: metformin 500mg once and placebo twice a day in arm A, metformin 500mg three times a day in arm B, and placebo three times a day in arm C.
1666529|NCT01725477|Drug|methylen blue &normal saline|Washing after dye injection
1666530|NCT01725477|Drug|methylene blue|
1666531|NCT01725477|Drug|metheylne blue with normal saline|
1666532|NCT01725464|Device|oxygen cannular|Patient receives oxygen supplementation 5 LPM via oxygen cannular for 120 minutes after the operative
1666533|NCT01725451|Drug|Testosterone|Administered topically to axillae
1666534|NCT01725451|Other|Deodorant Spray|Administered topically to axillae
1666535|NCT01725451|Other|Deodorant and Antiperspirant Combination Spray|Administered topically to axillae
1666536|NCT01725451|Other|Deodorant and Antiperspirant Combination Stick|Administered topically to axillae
1666537|NCT01725438|Other|sample blood|
1666538|NCT01725425|Other|Control|The control is designed to determine average mood.
1666539|NCT01725425|Other|Increase Portion Size|The purpose is to determine whether a change in mood will occur.
1666540|NCT01725425|Other|Decrease Portion Size|The purpose is to determine whether a change in mood will occur.
1666541|NCT01725425|Other|Mixed Portions|The purpose is to determine if a change in mood will occur.
1666542|NCT01725412|Dietary Supplement|Thiamine 300mg PO once daily|
1666543|NCT01725412|Dietary Supplement|placebo|
1666544|NCT01725399|Other|Apple Juice|
1666545|NCT01725399|Other|Water|
1666546|NCT01725386|Drug|Capecitabine|Oral tablet(s) administered according to prescribing information
1666547|NCT01725360|Drug|montelukast|Adding montelukas to a preexisting treatment with inhaled corticosteroid and long-acting betamimetic in patients with well-controlled asthma.
1666548|NCT01725334|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a surgical procedure involving the implantation of a thin flexible wire called a lead. This device sends mild electric signals to an area of the brain. This study targets two different areas that we believe may be responsible for negative symptoms observed in patients with schizophrenia. There are two stages to DBS: (1) Insertion of the DBS electrodes (2) The connection of these electrodes to a battery under the collarbone.
1666549|NCT01725321|Other|Narrow band imaging|Colonoscopy with new narrow band imaging
1666550|NCT01725308|Drug|FK949E|Taken by mouth (orally).
1666551|NCT01725308|Drug|Placebo|Taken by mouth (orally).
1666552|NCT01725295|Other|NST|A form of physical therapy
1666553|NCT01725295|Other|Hydrotherapy|
1666554|NCT01725282|Drug|quetiapine extended release (XR)|Extended release tablets
1666555|NCT01725282|Drug|Placebo|matching tablets
1666556|NCT01725269|Drug|AIR001|All doses specified are the amount loaded into the I-neb AAD System nebulizer.
1666557|NCT01725256|Drug|AIR001 (sodium nitrite inhalation solution)|Dose arms specify dose loaded into the I-neb AAD System nebulizer
1666558|NCT01725243|Drug|Carbetocin|Carbetocin IV, over 1 minute following delivery. Doses: 10, 20, 40, 60, 80, 100, 120 or 140mcg
1666559|NCT01725230|Drug|Fostamatinib|100-mg tablet
1666567|NCT01725178|Behavioral|Cognitive and Physical training|"Physical training - Three 60-minute session per week. Participants will be divided in groups of 10, supervised by physiotherapists. Physical activity combines aerobic exercises, muscle strengthening, balance improvement, joint flexibility. Once a week the session is replaced by outdoor walking; once a month by dancing.
Cognitive training - The program alternates focuses on specific functions and recreational sessions. Each session will be followed by a lesson about cognitive processes (memory, learning, attention, thought), providing tips to overcome difficulties in daily life. Sessions will focus on attention, imagination, spatial memory, categorization; memory for terms, meanings, songs, faces, names; memorization of texts; goal management."
1666568|NCT01725165|Other|No LCT|No surgery or radiation therapy right after induction chemotherapy. Patients receive either systemic therapy (i.e. chemotherapy) or observation. The care received will depend on discretion of doctor.
1666569|NCT01725165|Other|LCT|"Patients receive local consolidation therapy (LCT) after induction chemotherapy. LCT is radiation, surgery, or both. If assigned to the LCT group, study doctor will decide if patient has radiation alone, surgery alone, or radiation combined with surgery.
Radiation therapy delivered using external beam radiation, with either 2D/conventional techniques, three-dimensional conformal therapy, intensity modulated radiation therapy (IMRT), stereotactic radiosurgery (SRS) or proton beam therapy (PBT), at discretion of treating radiation oncologist.
Surgical control of primary and metastatic sites of disease may include control of either or both sites of disease as determined by multidisciplinary group (medical oncologist, radiation oncologist, and surgeon)."
1666570|NCT01725152|Drug|Ganaxolone|oral suspension, given in 3 divided doses
1666571|NCT01725152|Drug|Placebo|oral suspension, given in 3 divided doses
1666572|NCT01725139|Drug|GSK2126458|GSK2126458 will be available as film coated tablet of dose strength 0.25 mg and 0.5 mg
1666573|NCT01725139|Drug|Placebo|Matching placebo will be available
1954937|NCT03310268|Other|0.454% Stannous fluoride (SnF2) and 0.072% sodium fluoride (NaF): 1450 ppm fluoride in total|Participants will be instructed to apply experimental dentifrice (containing 454% SnF2 and 0.072% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
1958146|NCT01951963|Drug|Ketamine|
1958147|NCT01951963|Drug|Morphine|
1666578|NCT01725113|Drug|Calcitriol|3 times weekly
1666579|NCT01725113|Drug|Paricalcitol|3 times weekly
1666580|NCT01725100|Drug|GSK1120212B (Standard DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a standard DMSO content of theoretical 11.3%.
1666581|NCT01725100|Drug|GSK1120212B (Lower DMSO content)|Each tablet contains GSK1120212B equivalent to 2 mg of GSK1120212 as drug substance. The coated tablets have a lower DMSO content approximately 9.5%.
1666582|NCT01725087|Drug|Matching Placebo|
1666583|NCT01725087|Drug|Low Dose GRT6005|
1666584|NCT01725087|Drug|Medium Dose GRT6005|
1666585|NCT01725087|Drug|High Dose GRT6005|
1666586|NCT01725087|Drug|Tapentadol|
1666587|NCT01725074|Behavioral|"Case Management CM CHD"|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced physician assistant. The case manager will carry out following tasks:
Biweekly/monthly telephone consultations or home visits
Identification of health or personal problems of the patient
Monitoring of medical parameters
Coordination of contact with health care providers if necessary
Support to the patient related to health status and environmental changes
Promote disease-self management through coaching
Counseling, that is focused on emotional support and active listening"
1666588|NCT01725074|Behavioral|Social Interaction|Identical as the CM CHD group, but with exclusion of medical control measures and the medical aspects.
1666589|NCT01725048|Drug|Mirtazapine|7.5mg by mouth once a day at night. If subject has not had a 50% or greater reduction in the PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable adverse effects, then the dose may be escalated first to 15mg by mouth every night and then to 30mg by mouth every night.
1666590|NCT01725048|Drug|Citalopram|Citalopram 10mg by mouth once daily. If the subject has not had a 50% or greater reduction in PHQ-9 depression assessment score, and if the subject is not experiencing unacceptable side effects, then the dose may be escalated first to 20mg by mouth every day and then to 40mg by mouth once a day.
1666591|NCT01725022|Other|Home Care|This is the interventional arm where patients receive the transplant care in their homes.
1666592|NCT01725009|Drug|Multiple 15-minute intravenous infusions of 1500 mg levetiracetam|Strength, 100 mg/mL; Form, concentrate for solution for infusion; Frequency, twice a day; Duration, 7 days
1666593|NCT01724996|Other|Clinical examination: chest wall tenderness|The physical examination includes the testing of chest wall tenderness: Palpation of chest wall tenderness in lying 30° elevation of chest position. Flat index with standardized pressure where spontaneous maximum pain is reported (reproducible vs. not reproducible pain vs. no pain). Negative control (right side of chest mid-clavicle intercostal 6/7), reproducible vs. not reproducible pain vs. no pain.
1666594|NCT01724983|Drug|ketamine|
1666595|NCT01724983|Drug|fentanyl|
1666596|NCT01724970|Device|ProSeal|Patients will be ventilated with PLMA
1666597|NCT01724970|Device|Supreme LMA|Patients will be ventilated with SLMA
1666598|NCT01724957|Procedure|Intracoronary ECG|Recording of icECG from the tip of PCI guidewire. The wire end is connected through alligator clips to V-lead from surface ECG
1666641|NCT01724567|Other|Interval Training|Interval training (IT) on an exercise bike 3 times a week, for the first 12 weeks, followed by 40 weeks of IT 2 times a week on exercise bike. Each training session consists of active intervals with a total duration of 16 minutes (durations intervals between 1 and 4 minutes) at 90% of maximal heart rate. Active intervals are separated by active pauses at 60% of maximal heart rate.
1666642|NCT01724567|Other|Weight Loss|Low calorie diet approx. 1000 kcal/day for 8 - 10 weeks to obtain a 10 - 15 % weight loss.
1666643|NCT01724554|Drug|Intravitreal Aflibercept Injection|Aflibercept administered to the eye intravitreally either every month or every other month.
1666644|NCT01724528|Drug|Febuxostat|Standard dose PO (per os) from Day 1 to Day 7 (can be continued up to DAY 9 at investigator's discretion)
1722215|NCT00003783|Drug|prednisone|
1666599|NCT01724944|Procedure|Systematic pelvic and aortic lymphadenectomy|Pelvic lymphadenectomy dissection began at the origin of the external iliac vessels and continued caudally along the medial border of the psoas muscle, with the lower limit of the external iliac lymphadenectomy being represented by the deep inferior epigastric vessels. The lateral boundaries of lymphadenectomy were delineated superficially by the fascia covering the psoas muscle and deeply by the fascia covering the internal obturator and levator ani muscles. Lymph nodes along the external iliac vessels were removed en bloc with those adjacent to the common iliac vessels. Aortic lymphadenectomy dissection began at the aortic bifurcation by removing the superficial intercavoaortic, precaval, and preaortic nodal groups. Lymph nodes located lateral to the vena (i.e., paracaval nodal group) were separated from the vena cava, then removed en bloc. Lymph nodes behind the vena cava are removed if enlarged. Removal of the lateroaortic nodes was performed up to the level of the left renal vein.
1666600|NCT01724931|Drug|LD-aminopterin|
1666601|NCT01724931|Drug|placebo|
1666602|NCT01724918|Drug|Lacosamide|
1666603|NCT01724905|Dietary Supplement|Modified Stop Light Diet (SLDm)|SLDm includes reduced energy pre-packaged meals (PM) for 6 months, encouraged consumption of low energy shakes and 35 fruits and vegetables (F/V) per week
1666604|NCT01724905|Dietary Supplement|Recommended Care Diet|RC diet includes traditional meal plans and 35 fruits and vegetables per week
1666605|NCT01724892|Drug|Dexamethasone|
1666606|NCT01724892|Drug|Loteprednol etabonate|
1666607|NCT01724879|Drug|Dasatinib|Dasatinib p.o. + Chemotherapy (Dexamethasone, Cyclophosphamide, Vincristine, Methotroxate, 6-Mercapto-Purine, Cytarabine, Vindesine, VP16 (Etoposide))
1666608|NCT01724866|Drug|HM10460A (45 μg/kg)|Single-dose subcutaneous injection
1666609|NCT01724866|Drug|HM10460A (135 μg/kg)|Single-dose subcutaneous injection
1666610|NCT01724866|Drug|HM10460A (270 μg/kg)|Single-dose subcutaneous injection
1666611|NCT01724866|Drug|Pegfilgrastim 6mg|Single-dose subcutaneous injection, per manufacturer's Prescribing Information
1666612|NCT01724853|Procedure|Surgery|Resection suspension interposition arthroplasty or Arthrodesis
1666613|NCT01724853|Other|Conservative|Injection
1666614|NCT01724840|Procedure|GraftJacket|Interposition with GraftJacket
1666615|NCT01724840|Procedure|Tendon Interposition|Tendon Interposition with the FCR tendon
1666616|NCT01724827|Device|ceramic (Empress CAD, Ivoclar Vivadent)|Leucite-reinforced glass ceramic (Empress CAD, Ivoclar Vivadent)
1666617|NCT01724827|Device|composite (Lava Ultimate, 3M Espe)|Nanohybrid composite resin (Lava Ultimate, 3M Espe)
1666618|NCT01724814|Drug|HM12460A|Single dose SC administration ranging from 1.2 nmol/kg to 19.2 nmol/kg of HM12460A
1666619|NCT01724814|Drug|Placebo|Singe dose SC administration of Placebo
1666620|NCT01724801|Radiation|whole brain radiation(WBI)|WBI (30Gy/3Gy/10 fractions) plus concurrent or sequential chemotherapy for 4-6 cycles
1666621|NCT01724801|Drug|Icotinib|administered orally at a dose of 125 mg 3 times daily
1666622|NCT01724788|Drug|FUROSEMIDE|Pharmaceutical form: Solution Route of administration: Intravenous
1666623|NCT01724788|Drug|FUROSEMIDE (HOE058)|Pharmaceutical form: Tablet Route of administration: Oral
1666624|NCT01724762|Other|Nursing Orientation|"Control group: patients who did not read the informative manual concerning bed bath and received only the unit's routine information
Intervention group: patients who received nursing orientation and read the informative manual concerning bed bath"
1666625|NCT01724736|Drug|Placebo|Celluose 10g - Matches the total dietary fiber content of NM504 as well as the color and taste. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
1666626|NCT01724736|Drug|NM504:|Cobiotic formula of GRAS ingredients with a total dietary fiber content of 10g. Subjects take 1 dose within 1h prior to either breakfast or lunch and a 2nd dose within 1h prior to the evening meal for 4 weeks.
1666627|NCT01724723|Drug|entecavir (BARACLUDE®)|entecavir 0.5 mg per day during and within 6 months after anti-tuberculous treatment
1666628|NCT01724697|Other|BMSC transplantation|Patients randomized to the intervention arm will be collected for bone marrow stem cells and then infused with these cells via hepatic artery.
1666629|NCT01724697|Other|conventional treatment & antivrial treatment|Participants will recieve conventional treatment and antivrial treatment.
1666630|NCT01724684|Other|Telehealth program|
1666631|NCT01724684|Other|Usual care|
1954938|NCT03310268|Other|1400 ppm fluoride as sodium monofluorophosphate (SMFP)|Participants will be instructed to apply negative control dentifrice (containing 1400 ppm fluoride as SMFP), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
1954939|NCT03310268|Other|Stannous Chloride (SnCl2) and 0.15% NaF: 1450 ppm fluoride in total|Participants will be instructed to apply positive control dentifrice (containing SnCl2 and 0.15% NaF, 1450 ppm fluoride in total), covering the full length of toothbrush head (full ribbon) and will brush twice daily (morning and evening) for one timed minute (in their usual manner) and expectorate.
1666636|NCT01724632|Behavioral|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
1666637|NCT01724619|Drug|[F-18] fluorinated dihydrotestosterone (FDHT)|
1666638|NCT01724606|Radiation|Whole Brain Radiotherapy (WBRT)|WBRT (30 Gy) will be delivered in 10 fractions. Standard opposed lateral fields with multileaf collimation blocking will be used. Treatment will be administered on business days and delivered over an approximate 2 week period. Dexamethasone may be given at the discretion of the treating physician but the dose cannot exceed greater than 16mg daily as it is a strong CYP3A4 inducer. Patients will also receive a proton pump inhibitor with dexamethasone.
1666639|NCT01724606|Drug|Sorafenib|The proposed three dose levels of sorafenib during dose escalation are 200 mg, 400mg, and 600 mg administered daily orally. Patients will be enrolled in cohorts of 3.The first three subjects will take sorafenib 200 mg daily within a few hours after the first RT fraction. Sorafenib will be continued concurrently with WBRT (1 fraction /day x 10 fractions) without breaks and then continued after WBRTfor a total of 21 days. If no dose limiting toxicity (DLT) is observed in a cohort of 3 patients until two weeks after completion of WBRT, the next dose level will be evaluated.
1666640|NCT01724580|Drug|Baricitinib|Administered orally
1666645|NCT01724528|Drug|Allopurinol|Standard dose, low dose or high dose (as per investigator's judgement at the time of randomization) from DAY 1 to DAY 7 (can be continued up to DAY 9 at investigator's discretion)
1666646|NCT01724515|Other|Lipid infusion and muscle biopsies|Subjects will undergo a baseline muscle biopsy, a lipid infusion for 5 hours (60 ml/hr), and a muscle biopsy after the lipid infusion.
1666647|NCT01724502|Behavioral|Exercise and muscle biopsies|Subjects will undergo a euglycemic clamp, VO_2 max determination, exercise periods and muscle biopsies.
1954940|NCT03310255|Diagnostic Test|H pylori Faecal Antigen|All patients will be screened for H. pylori using fecal Ag and positive patients will do endoscopy and biopsy.
1666650|NCT01724476|Drug|folate with B12|
1666651|NCT01724476|Drug|placebo|
1666652|NCT01724463|Other|Severe Sepsis Management Bundle|"Management Bundle includes:
Securing Intravenous Access
Obtaining Blood Culture
Antibiotic Administration
Goal Directed Fluid Bolus Therapy
Oxygen Administration
Measuring Serum Lactate Levels"
1666653|NCT01724450|Drug|Carvedilol|50mg/day for 24 weeks. The dose of carvedilol will be up titrate before the dose of 50mg/day
1666654|NCT01724450|Drug|Placebo|Placebo similar to the carvedilol up titration but wit no active drug.
1666655|NCT01724437|Device|catheter based pulmonary vein isolation|catheter based ablation using irrigated catheters and radiofrequency energy as in clinical practice
1666656|NCT01724424|Drug|Melatonin|20 mg oral single dose
1666657|NCT01724424|Drug|Melatonin|30 mg oral single dose
1666658|NCT01724424|Drug|Melatonin|50mg oral single dose
1666659|NCT01724424|Drug|Melatonin|100mg oral single dose
1666660|NCT01724411|Other|Resistant Starch type 3|Resistant Starch 3: 26g/day males for 11 days, 22 g/day females for 11 days
1666661|NCT01724398|Other|Conventional plus UC-MSC treatment|Received conventional treatment and umbilical cord mesenchymal stem cells transplantation by peripheral vein slowly for 30minutes. (1×105/Kg, once a week, 4 times).
1666662|NCT01724398|Other|Conventional plus PE treatment|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times).
1666663|NCT01724398|Other|Conventional plus UC-MSC and PE therapy|Received conventional treatment plus 2000 milliliter plasma exchange (every 3 days, 3 times). Meantime taken i.v umbilical cord mesenchymal stem cells transplantation slowly for 30minutes (1×105/Kg, once a week, 4 times), the first two times is taken after plasma exchange.
1666664|NCT01724398|Other|Conventional treatment|Received conventional treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
1666665|NCT01724385|Drug|intravitreal injection of bevacizumab|intravitreal injection of bevacizumab
1666666|NCT01724372|Drug|Antidepressant|
1666667|NCT01724372|Drug|Antipsychotic|
1666668|NCT01724359|Drug|Paliperidone ER|The recommended Paliperidone extended-release (ER) dose will be 6 mg/day. Some patients may benefit from higher or lower doses, in the range of 3 to 12 mg/day. Paliperidone ER will be administered orally once daily. Adjustment of the dosage will be done at the investigator's discretion.
1666673|NCT01724320|Drug|OTX008|OTX008 given daily without interruption, subcutaneously. Starting dose: 65 mg/day
1666674|NCT01724307|Procedure|Neurostimulation of stellate ganglion|An electrical nuerostimulation of the stellate ganglion up to 60 minutes
1666675|NCT01724281|Other|No intervention, only follow up|
1666676|NCT01724268|Drug|Pred + Meth|PREDNISOLONE 10mg orally ONCE DAILY and Methotrexate 25 mg / day
1666677|NCT01724268|Drug|Anti TNF + Meth|
1666678|NCT01724255|Other|questionnaire|
1666679|NCT01724242|Drug|Vaginal DHEA|
1666681|NCT01724216|Device|pulse sequences|Collect in vivo human data to demonstrate neurological Magnetic Resonance Imaging of subjects using a pulse sequence
1666682|NCT01724203|Dietary Supplement|Lactobacillus rhamnosus|
1666683|NCT01724203|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
1666684|NCT01724203|Dietary Supplement|Placebo|
1666685|NCT01724190|Drug|Vitamin D|
1666686|NCT01724190|Drug|Placebo|
1666687|NCT01724177|Drug|Lenalidomide|25 mg of Lenalidomide administered orally once daily
1666688|NCT01724164|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
1666689|NCT01724164|Behavioral|Robotic assisted therapy|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
1666690|NCT01724164|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected upper limb but there is no output of electrical stimulation.
1666691|NCT01724164|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
1666692|NCT01724164|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
1666693|NCT01724138|Drug|Deferasirox|Patients will start their deferasirox treatment with a dose of 20 mg/kg/day.
1666694|NCT01724125|Other|personal electronic medical record|
1666695|NCT01724112|Drug|LY2940094|Administered orally
1666696|NCT01724112|Drug|Placebo|Administered orally
1666697|NCT01724099|Drug|Euiiyin-tang|Korean medicinal herbal drug
1666698|NCT01724099|Drug|Placebo|Placebo drug, same odor and formula as Euiiyin-tang
1666699|NCT01724086|Drug|TMC647055|Type=exact number, unit=mg, number=150, form=capsule, route=oral. 3 or 4 capsules of 150 mg will be administered once daily.
1666700|NCT01724086|Drug|TMC435|Type=exact number, unit=mg, number=75, form=capsule, route=oral. 1 capsule of 75 mg will be administered once daily.
1666701|NCT01724086|Drug|Ritonavir|Type=exact number, unit=mg, number=30 or 50, form=tablet or solution, route=oral. 0.375 mL or 0.625 ml (80 mg/mL) solution will be administered once daily.
1666702|NCT01724086|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. 5 to 6 (1000 or 1200 mg) tablets will be administered once daily, divided in 2 daily doses. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment 5 or 6 (depending on bodyweight) tablets of ribavirin (equivalent to 200 mg/tablet) per day, divided in 2 daily doses for an additional 12 or 36 weeks.
1666703|NCT01724086|Drug|Pegylated interferon alpha-2a (PegIFN)|Type=exact number, unit=mcg, number=180, form=solution, route=subcutaneous injection. PegIFN 0.5 mL prefilled syringe equivalent to 180 mcg will be administered as a subcutaneous (under the skin) injection as follow-up (FU) treatment for 12 or 36 weeks based on follow-up treatment principles as described in the protocol. Patients meeting the Follow-UP (FU) treatment criteria specified in the protocol will receive treatment with Pegylated interferon alpha-2a (PegIFN) 0.5 mL prefilled syringe equivalent to 180 mcg administered as a subcutaneous (under the skin) injection for an additional 12 or 36 weeks.
1666704|NCT01724086|Drug|GSK2336805|Type=exact number, unit=mg, number=30 or 60, form=tablet, route=subcutaneous injection. GSK2336805 one or two 30 mg tablet(s) taken orally (by mouth) once daily for 12 weeks.
1666705|NCT01724073|Dietary Supplement|Leafy vegetable-fish sauce|
1666706|NCT01724073|Dietary Supplement|Leafy vegetable-fish/liver sauce|
1666707|NCT01724073|Dietary Supplement|Misola|
1666708|NCT01724047|Behavioral|Playground Intervention|Intervention is designed for children diagnosed with an autism spectrum disorder (ASD) included in a regular education k through fifth grade classroom for at least 50% of the school day. Schools will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. This study will take place at school. All intervention activities will be conducted during recess or lunch where children with autism may have the most difficulty interacting with peers. A total of 14-16 intervention sessions will be held with the child with autism, school personnel, and the child's classmates. The intervention will last approximately 3 months with a 3-month follow-up.
1666709|NCT01724047|Behavioral|STAT Intervention|This study will track the behavioral progress of children whose teachers receive training in these instructional methods. This study also will examine the ability and willingness of teachers to use these methods as they were designed. The study will last approximately 18 weeks (6 weeks of intervention, and a 3 month follow up visit). This study will take place at school. Classrooms will be randomized to one of two conditions. The conditions are: 1) Immediate treatment, where the training will begin immediately after baseline measures are completed. 2) Waitlist treatment, where the training will begin the following school year. All intervention activities will be conducted with a teacher during the school day but not during instructional time. Study staff will visit the school on a weekly basis to train your child's teacher on evidence-based strategies for teaching children with autism.
1666710|NCT01724034|Other|Abolish Lung Sliding|If there is no lung sliding, the patient will be promptly evaluated for pneumothorax or mainstream intubation.
1666711|NCT01724034|Other|Normal Lung Ultrasound|If the patient fails the spontaneous breathing trial and the lung ultrasound examination is normal - researchers will investigate venous thrombosis (deep vein thrombosis and/or pulmonary embolism) and rule out reversible airway obstruction. If the patient has the previous diagnosis of COPD, non invasive mechanical ventilation is indicated for facilitate weaning.
1666712|NCT01724034|Other|Pulmonary Interstitial Syndrome|"If lung ultrasound shows B pattern - cardiogenic pulmonary edema will be differentiated from Acute Respiratory Distress Syndrome (ARDS). If cardiogenic edema is a possibility, diuretics will be administrated (at least 40 mg of furosemide) or ultrafiltration will be performed. The main target is a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to titrate vasodilators (at least a 20% reduction in the systolic blood pressure) before the next spontaneous breathing trial."
1666713|NCT01724034|Other|Asymmetrical Lung Ultrasound|If lung ultrasound shows asymmetrical findings, the occurence of new or uncontrolled infection (pulmonary or extrapulmonary) will be investigated.
1666714|NCT01724034|Other|Simple Pleural Effusion|If the patient has pleural effusion without ultrasonographic signs of complications (any hyperechoic pattern or complex septated pattern), researchers will administrate diuretics (at least 40 mg of furosemide in 24 hours) or increase ultrafiltration - to achieve a negative fluid balance of, at least, 1000 ml before the next spontaneous breathing trial. Another possibility is to perform pleural drainage.
1666715|NCT01724034|Other|Complex Pleural Effusion|If there is pleural effusion with hyperechoic or septated pattern, another image exam will be performed and evaluated by the surgical team.
1666716|NCT01724021|Drug|Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone (CHOP)|Standard chemotherapy
1666717|NCT01724021|Drug|Cyclophosphamide, Vincristine, Prednisone/Prednisolone (CVP)|Standard chemotherapy
1666718|NCT01724021|Drug|Bendamustine|Standard chemotherapy
1666719|NCT01724021|Drug|Rituximab|1400 mg subcutaneously (SC), Day 1 Cycles 2-4
1666720|NCT01724021|Drug|Rituximab|375 mg/m2 IV, Day 1 Cycles 1-4
1666721|NCT01724021|Drug|Rituximab|375 mg/m2 intravenously (IV), Day 1 Cycles 1 and 4-8
1666722|NCT01724021|Drug|Rituximab|1400 mg SC, Day 1 Cycles 5-8
1666723|NCT01724008|Drug|Stannous Fluoride|Test dentifrice, participants will brush each of the 2 selected sensitive teeth each for 30 seconds followed by the whole mouth thoroughly for at least one minute.
1666865|NCT01722864|Drug|COV155|COV155 tablets
1722322|NCT00003819|Biological|QS21|
1666724|NCT01724008|Drug|Sodium Monofluorophosphate|Control dentifrice, participants will brush the whole mouth thoroughly for at least 1 minute.
1666725|NCT01723995|Radiation|low-level laser on nipples|The LASER HAND WL device, manufactured by MM Optics.
1666726|NCT01723982|Drug|Barusiban (FE 200440)|
1666727|NCT01723982|Drug|Placebo Comparator|
1666728|NCT01723969|Genetic|Tumour markers testing|Tumour markers testing in patients advanced or metastatic colo-rectal cancer.
1666729|NCT01723956|Procedure|Cryotherapy|This is involves freezing the lesions with a cryo gun using Nitrous Oxide for 3 minutes-- wait 5 minutes and then refreezing for 3 more minutes. This procedure uses the Wallach cryogun
1666730|NCT01723956|Procedure|LEEP|The cervix is anaesthetized with lidocaine and then a electric loop is applied to the cervical lesion which is cut with one pass. The LEEP machine used is the automatic Finesse Machine.
1666731|NCT01723943|Other|educational intervention|"Receive the What's Happening to the Woman I Love? booklet"
1666732|NCT01723943|Other|counseling intervention|Undergo Helping Her Heal educational counseling program
1666733|NCT01723943|Other|educational intervention|Undergo Helping Her Heal educational counseling program
1666734|NCT01723943|Other|psychosocial support for caregiver|Undergo Helping Her Heal educational counseling program
1666735|NCT01723943|Other|questionnaire administration|Ancillary studies
1666736|NCT01723943|Other|laboratory biomarker analysis|Correlative studies
1666737|NCT01723917|Dietary Supplement|PhytoSERM tablet|
1666738|NCT01723917|Dietary Supplement|placebo|
1666739|NCT01723904|Drug|Rotigotine|Application of Rotigotine up to 8 mg/24 h patches for 24 hours.
1666740|NCT01723891|Drug|Surfolase capsule|
1666741|NCT01723891|Drug|HT-002-01|
1666742|NCT01723852|Dietary Supplement|Vitamin D at 30 ug/day|
1666743|NCT01723852|Dietary Supplement|Vitamin D at 10 ug/day|
1666744|NCT01723839|Drug|Fludarabine, Cyclophosphamide, Rituximab, Lenalidomide|19 subjects are treated in stage-1 with FCR plus 5mg lenalidomide increasing to 10mg and 15mg in subsequent cycles depending on toxicity.
1666745|NCT01723826|Drug|Crenezumab|Participants will receive intravenous infusion of crenezumab every 4 weeks for 144 weeks.
1666746|NCT01723813|Biological|Tumor specific peptides: MAGE-3.A1 and / or NA17.A2|Each peptide will be given at a dose of 300 µg in 1 ml of sodium chloride 0.9%, every 3 weeks on 6 occasions, and will be administered at one site in arm or thigh, 20% of the dose intradermally and 80% of the dose subcutaneously.
1666747|NCT01723813|Biological|Galectin-3 inhibitor: GM-CT-01 systemic injections|Systemic injection of GM-CT-01: GM-CT-01 will be administered by slow intravenous infusions at a dose of 280 mg/m2, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination.
1666748|NCT01723813|Biological|Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration|GM-CT-01 will be injected peri-tumoral at a dose of 100 µg per tumor injected, on days +3, +6, +9, +12, +15, +18 after each of the 3rd, 4th, 5th and 6th vaccination. If a patient has one or two superficial metastases at day 43 of the treatment, one of these lesions will be treated. If a patient has more than two superficial metastases at day 43, two of these lesions will be treated.
1666749|NCT01723800|Drug|PI3K inhibitor BKM120|Given PO
1666750|NCT01723800|Drug|pemetrexed disodium|Given IV
1666751|NCT01723800|Drug|carboplatin|Given IV
1666752|NCT01723800|Other|laboratory biomarker analysis|Correlative studies
1666753|NCT01723800|Other|pharmacological study|Correlative studies
1666754|NCT01723800|Procedure|quality-of-life assessment|Ancillary studies
1666755|NCT01723774|Drug|PD0332991|
1666756|NCT01723774|Drug|Anastrozole|
1666757|NCT01723774|Drug|Goserelin|
1666758|NCT01723774|Procedure|Surgery (standard of care)|-Breast and axillary lymph node surgery
1666759|NCT01723774|Procedure|Tumor biopsy|
1666760|NCT01723748|Drug|genotropin|iii) intravenous exogenous bolus of GH (0.5 mg) followed by muscle and fat biopsies.
1666761|NCT01723735|Drug|Alirocumab|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1666762|NCT01723735|Drug|Ezetimibe|"Pharmaceutical form: overencapsulated tablet
Route of administration: oral"
1666763|NCT01723735|Drug|Ezetimibe Placebo|"Pharmaceutical form: capsule
Route of administration: oral"
1666764|NCT01723735|Drug|Fenofibrate|"Pharmaceutical form: tablet
Route of administration: oral"
1666765|NCT01723722|Drug|Methadone|Concentration is 1mg/mL administered every 12 hours given on sliding scale in response to last NAS score.
1666766|NCT01723722|Drug|Diluted Deodorized Tincture of Opium|Concentration is 1:24 dilution for a concentration of 0.4%
1666769|NCT01723683|Drug|Surfactant|
1666770|NCT01723670|Drug|CHF 5074 1x|oral tablet, 1x, once a day for 24 months
1666771|NCT01723670|Drug|CHF 5074 2x|oral tablet, 2x, once a day for 24 months
1666772|NCT01723670|Drug|Placebo|oral tablet,once a day for 24 months
1666773|NCT01723657|Drug|Ara-C|"Intermediate dose during induction phase to remission.
High dose during consolidation phase in patients with favorable cytogenetics and leukocyte index below 20."
1666774|NCT01723657|Other|Autologous peripheral blood stem cell transplantation.|"In patients with favorable cytogenetics with a Leukocyte index above 20.
Patients with normal karyotype, and one cycle of chemotherapy to achieve complete remission, without adverse molecular and/or minimal residual disease (MRD) characteristics, regardless availability of a matched donor."
1666775|NCT01723657|Other|Allogeneic matched related or unrelated donor transplant.|-Patients without favorable/intermediate characteristics.
1666776|NCT01723657|Drug|G-CSF|"Administration at induction phase to remission, days 0 to 7. G-CSF will not be initiated if the leukocyte count is over 30x10e9/L at diagnosis or will be interrupted if the leukocyte count during treatmen arises 30x10e9/L.
Administration at consolidation phase, days 4 to 6 (3 doses). G-CSF will be interrupted if the leukocyte count during treatment arises 30x10e9/L."
1666777|NCT01723657|Other|CD34+ selection.|-Patients with adverse prognosis with allogeneic peripheral blood stem cell (PBSC)tranplantation, CD34+ cell selection of the inoculum was performed.
1666778|NCT01723657|Other|Mylotarg purging before autologous PBSC transplantation|Patients without favorable/intermediate characteristics and without matched related donor.
1666779|NCT01723644|Other|the clinical reassessment arm|In the clinical reassessment arm, antibiotherapy is systematically started in the emergency department. The continuation, the discontinuation or the modification of the antibiotherapy initially prescribed in the ED were made at Day 1 and Day 5 based on clinical assessment. On Day 1, the aim of the clinical reassessment is diagnosis reassessment: to confirm or not the diagnosis of community-acquired pneumonia and to confirm or not the antibiotherapy. On Day 5, the aim of the clinical reassessment is to evaluate the possibility to stop the current antibiotherapy based on criteria for clinical stability defined by the Infectious Diseases Society of America
1666780|NCT01723644|Other|the procalcitonin arm|In the procalcitonin arm, initiation and discontinuation of the antibiotherapy is based on the antibiotic stewardship based on procalcitonin (PCT) cut-off ranges previously published. Re-evaluation of the clinical status and measurement of serum PCT levels is mandatory after 6-24 h in all persistently sick and hospitalized patients in who antibiotic are withheld. The PCT algorithm can be overruled by pre-specified criteria, e.g. in patients with immediately life-threatening disease. If the algorithm is overruled and antibiotics are given, an early discontinuation of antibiotic therapy after 3, 5 or 7 days is more or less endorsed based on PCT levels. In hospitalized patients with ongoing antibiotic therapy PCT levels are reassessed on days 3, 5 and 7 and antibiotics will be discontinued using the PCT cut-offs defined above.
1666781|NCT01723631|Device|Trap Myelin Test|
1666782|NCT01723618|Drug|CRD007|
1666783|NCT01723605|Procedure|insitu repair|closure of the uterine incision while the uterus initu
1666784|NCT01723605|Procedure|exteriorisation of the uterus|uterine closure while the uterus is exteriorised
1666785|NCT01723592|Dietary Supplement|Probiotics|Probiotics oral probiotic capsules for 7 days twice daily containing four lyophilised Lactobacillus strains,L.rhamnosus/ LbV96 (DSM 22560),L.jensenii /LbV 116 (DSM 22567),L.crispatus/ Lbv88 (DSM 22566),L.gasseri /LbV 150N (DSM 22583)
1666786|NCT01723592|Dietary Supplement|Oral lactose placebo|Placebo
1666787|NCT01723579|Drug|Nomegestrol acetate (NOMAC)|Oral tablet with daily release of 2.5 mg
1666788|NCT01723579|Drug|Estradiol (E2)|Daily release of 1.5 mg
1666789|NCT01723553|Drug|C-11 PiB|One time intravenous administration of ~740 megabecquerel (MBq) of [N-methyl-C-11]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
1666790|NCT01723540|Procedure|Minilaparotomy vs laparoscopy|MC-group will undergo ultrasonic dissection assisted minilaparotomy cholecystectomy ans patients in the LC-grout will undergo laparoscopic cholecystectomy
1666791|NCT01723527|Drug|Methadone|Clinic-Based Methadone Maintenance Treatment
1666792|NCT01723527|Drug|Buprenorphine|Clinic-Based Buprenorphine Maintenance Treatment
1666793|NCT01723527|Behavioral|Employment-based drug abstinence reinforcement|
1666794|NCT01723514|Drug|AMG 334|3 dose levels of AMG 334 administered as multiple SC doses in healthy subjects and migraine patients.
1666795|NCT01723514|Drug|Placebo|3 dose levels of Placebo administered as multiple SC doses in healthy subjects and migraine patients.
1666796|NCT01723501|Drug|0.25% chlorhexidine|0.44% chlorhexidine di-gluconate body wipes which would release 0.25% free chlorhexidine on application
1666797|NCT01723501|Drug|sterile water|Sterile water wipes (placebo)
1666798|NCT01723488|Radiation|[F18] T808|Dose for normal volunteer undergoing dosimetry evaluation will not exceed 20 mCi, dose for high probability of Alzheimer's and low probability Alzheimer's undergoing brain imaging only will not exceed 10 mCi
1666799|NCT01723475|Biological|BAY2010112|Subcutaneous (s.c.) administration once daily. Starting dose will be 0.5 µg ; dose will be escalated dependent on any dose limiting toxicities
1666800|NCT01723475|Biological|BAY2010112|Continuous intravenous infusion (c.i.v.) administration. Starting dose will be 5 µg ; dose will be escalated dependent on any dose limiting toxicities.
1666801|NCT01723436|Other|Hypothetical scenarios and related decisions|Surrogates are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
1666802|NCT01723410|Behavioral|Writing about people|Subjects will be asked to write about other people in their lives once a week for 6-weeks.
1666803|NCT01723410|Other|Writing about places, objects|
1666804|NCT01723397|Drug|Nasaleze Spray|Subjects are treated with over the counter Nasaleze cellulose powder nasal spray then challenged with allergen
1666805|NCT01723397|Other|Placebo spray|Subjects are treated with placebo nasal spray then challenged with allergen
1666806|NCT01723397|Biological|Allergen|Subjects are challenged with grass or ragweed allergen after treatment with Nasaleze or placebo
1666807|NCT01723384|Drug|Intermittent Oral Naltrexone|
1666808|NCT01723384|Drug|Placebo|
1666809|NCT01723371|Drug|Carvedilol|Carvedilol will be administered orally. The initial dose of carvedilol will be 0.05mg/kg/day divided into 2 doses. After two weeks, at subsequent weekly study visits, the dose of carvedilol will be increased incrementally to 0.1mg/kg in Week 2, 0.2mg/kg in Week 3, 0.4mg/kg in Week 4, 0.6mg/kg in Week 5, and 0.8mg/kg in Week 6, when the target dose of 0.8mg/kg/day (if weight is less than 62.5kg) or 50mg/day (if weight is greater than 62.5kg) is achieved. This dosage, assuming no adverse effects, will be maintained between Weeks 6 and 30 of the study. After the maintenance period from Week 6 to 30, patients will be weaned over 5 to 7 days or continued on a non-study drug supply.
1666810|NCT01723358|Device|Neuromuscular electrical stimulation (NMES)|The intervention will consist of a period of treatment with NMES. This treatment will involve 20-45 minute feeding therapy sessions during which NMES will be administered by an Occupational Therapist. Frequency of therapy sessions will be 4 times per week for the first 2 weeks (as in inpatient, if hospitalized) and then biweekly for 14 weeks for a total of 36 sessions (over 16 weeks). For patients who are discharged prior to the first 2 weeks of treatment, outpatient sessions will be biweekly.
1666811|NCT01723345|Drug|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
1666812|NCT01723332|Behavioral|Educational|"The first interaction will happen at study enrolment and will be educational in nature.
Following the session, the nurse will follow up with the participant to discuss any questions."
1666864|NCT01722877|Device|JetStream Navitus|Study to use Jetstream device for use of in-stent restenosis in femoral popliteal artery.
1666813|NCT01723332|Behavioral|Self management|"The second interaction will take place 2 months after enrollment and will focus on self management and communication skills.
Following the session, the nurse will follow up with the participant to discuss any questions."
1666814|NCT01723319|Device|HBLPADD coil deep TMS|20 daily deep TMS treatment
1666815|NCT01723319|Device|Sham|inactive treatment
1666816|NCT01723306|Genetic|Gene Modified T Cells|Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
1666817|NCT01723293|Behavioral|Exercise group|"The physical conditioning program included a total of three 55-60 minute sessions per week. Pregnant women started in 9-12 weeks and finished in 38-40 weeks, therefore, an average of 85 training sessions were planned for each participant. All subjects wore a heart rate (HR) monitor (Polar FT7, Finland) during the training sessions to ensure that the exercise intensity was light to moderate.
Each session included a 25-minutes of aerobic exercise, 10-minutes of strength exercise and balance exercise as well, and 10-minutes of pelvic floor muscles training."
1666818|NCT01723280|Drug|Oxygen|During and 2 hrs after surgery
1666819|NCT01723267|Other|3D follicles assessment|3D ultrasound evaluation in IVF treatment (vs 2D ultrasound)
1666820|NCT01723267|Other|2D follicles assessment|2D ultrasound in IVF treatment (vs 3D ultrasound)
1666821|NCT01723254|Biological|IGE-1|Intramuscular, multiple dose
1666822|NCT01723254|Biological|IGE-2|Intramuscular, multiple dose
1666823|NCT01723254|Biological|Saline|Saline (0.9% sodium chloride)
1666824|NCT01723241|Drug|XAF5, concentration A|
1666825|NCT01723241|Drug|XAF5, concentration B|
1666826|NCT01723241|Drug|XAF5, concentration C|
1666827|NCT01723241|Drug|Placebo|
1666828|NCT01723228|Drug|Rasagiline|
1666829|NCT01723228|Drug|Placebo|
1666830|NCT01723215|Behavioral|Active ABMT8|Active ABMT8 8 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
1666831|NCT01723215|Behavioral|Active ABMT4|Active ABMT4 4 active ABMT sessions (10 min. each, over 7-8 weeks) designed to promote adaptive threat attendance
1666832|NCT01723215|Behavioral|Placebo|Placebo: will receive 4 training sessions(10 min. each, over 7-8 weeks) using the same task and stimuli as in the active arms, but not designed to change attention patterns
1666833|NCT01723202|Drug|dabrafenib|150 mg orally twice daily given orally
1666834|NCT01723202|Drug|trametinib|150 mg orally twice daily and GSK1120212 (MEKi) 2 mg orally once daily given orally
1666835|NCT01723202|Other|Correlative Studies|"Signaling inhibition studies in tumor biopsies (10 pts in each arm; 5 pts per center)
BRAF mutation studies in circulating plasma DNA (all study patients)
Mechanisms of drug resistance in tumor biopsies or tumor blocks (5 pts in each arm)
Assess predictors of response (Archival tumor block/unstained slides in all study patients)
Pharmacokinetic studies (First 10 pts enrolled on each arm)
Pharmacogenomics studies (All study patients)"
1666836|NCT01723176|Procedure|Echocardiography|
1666839|NCT01723150|Drug|Ciprofloxacin|
1666840|NCT01723150|Drug|Ceftriaxone|
1666841|NCT01723150|Drug|Trimethoprim/sulfamethoxazole|
1666842|NCT01723150|Drug|Ertapenem|
1666843|NCT01723124|Procedure|Molecular Breast Imaging|Molecular Breast Imaging (MBI) utilizes small high resolution gamma camera detectors in a dual-detector configuration to image the breast following the administration of a radiopharmaceutical that accumulates preferentially in breast tumors.
1666844|NCT01723098|Behavioral|Exercise group|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
1666847|NCT01723059|Drug|Standard Triple Therapy|for 10 days
1666848|NCT01723059|Drug|Sequential Therapy|total 10 days
1666849|NCT01723046|Device|Training with new upper limb robot assisted therapy device|During 8 weeks, 3 times a week, 1 hour therapy sessions with the device
1666850|NCT01723020|Drug|AMG 232|Given an an oral tablet in escalating doses.
1666851|NCT01723007|Other|Supplement|The arms were assigned to receive the supplements and followed for 10 weeks. Every two weeks, the women returned to the clinic for evaluation biochemical, haemogram, anthropometric, bioimpedance, blood pressure and dietary. Weekly, returned to receive the supplements in a sealed box. They received guidance not to disclose what food were receiving the service if he found other women who also participated in the study.
1666852|NCT01722994|Device|Polyglactin 910 sterile synthetic absorbable suture (Ethicon)|Half of punch biopsy wounds are closed with each absorbablesuture
1666853|NCT01722994|Device|Chromic Gut Sterile absorbable Suture (Ethicon)|
1666854|NCT01722981|Procedure|Percutaneous tracheostomy|Three methods of percutaneous tracheostomy
1666855|NCT01722968|Drug|Bevacizumab|15mg/kg administered iv every 3 weeks in combination with paclitaxel 80mg/m2 iv weekly
1666856|NCT01722968|Drug|Paclitaxel|80mg/m2 iv weekly
1666857|NCT01722955|Other|Pre-warmed fluids|IV fluid will be stored at 41℃ set hot cabinet for 8hours
1666858|NCT01722955|Other|Room temperature fluids|Room temperature fluid will be stored at ambient temperature
1666859|NCT01722942|Procedure|ICD implantation|ventricular ICD implantation
1666860|NCT01722942|Drug|amiodarone hydrochloride|
1666866|NCT01722838|Behavioral|B-ME Intervention|B-ME is a behavioral intervention of HIV prevention risk reduction administered in a group format during a 2.5 day retreat (19 hours) format.
1666867|NCT01722825|Drug|LY2157299|Administered orally.
1666868|NCT01722812|Drug|Cromoglicate|Twice daily topical treatment for 14 days
1666869|NCT01722812|Drug|Placebo|Twice daily topical treatment for 14 days
1666870|NCT01722799|Device|Drug elluting Balloon (DEB)|Percutaneous transluminal coronary angioplasty with drug elluting ballon and Bare metal stent for rescue.
1666871|NCT01722799|Device|Drug elluting coronary stent (DES)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
1666872|NCT01722773|Device|Bipap (Respironics, Inc)|Bipap every night pressure at 15/5 with heated humidifier
1666873|NCT01722760|Procedure|measurements|
1666874|NCT01722747|Behavioral|Tobacco Free Teachers, Tobacco Free Society (TFT/TFS)|A 7-month intervention was conducted over one academic year & included the following core components: 1. A Lead Teacher (LT) in each school was appointed and trained to facilitate the program on-site; 2. A tobacco policy was implemented; 3. Study health educators and LTs conducted group discussions with teachers addressing 6 intervention themes; 4. Materials; 5. Support for tobacco use cessation. Schools randomized to delayed intervention control condition did not receive any intervention until after final data collection, when they were given a 3-month shortened intervention.
1666875|NCT01722734|Behavioral|Text message reminders|Patients in the two treatment arms receive six short text message reminders within 60 hours of treatment initiation at 12 hour intervals to remind them to take their malaria medication as prescribed.
1666876|NCT01722708|Drug|Clindamycin|Oral clindamycin 300 Milligrams*2/Day for a week
1666877|NCT01722708|Drug|Metronidazole|Oral metronidazole 500 Milligrams*2/Day for a week
1666878|NCT01722695|Other|Dialyzer comparison|"Each patient is treated by hemodialysis for one week (3 sessions) with each dialyzer type (Revaclear or FX).
The order of dialyzers used will be randomly assigned to the patient at randomization."
1666879|NCT01722682|Biological|Human pancreatic islet transplantation|
1666880|NCT01722669|Drug|isoquercetin or quercetin|Single dose PK/PD study
1666881|NCT01722656|Drug|Aflibercept|
1666882|NCT01722643|Behavioral|MAxIM|This new intervention, called MAxIM (MotivAtion, Incentives, Memory) uses: 1) motivation enhancement therapy (MET) (an existing evidence-based treatment for adolescent with diabetes) supplemented with cognitive behavior therapy (CBT) to enhance behavior change; 2) financial incentives for daily blood glucose testing and parental monitoring to provide frequent positive feedback; and 3) working memory training (WMT), a method for strengthening specific cognitive processes that support decision-making and future orientation. The interventions will be delivered to families at home via the internet.
1666883|NCT01722643|Behavioral|Usual Care|Usual Care reflects the standard treatment currently provided at the Children's Hospital at Dartmouth. Teens will be followed by their treating endocrinologist and receive the following standard services as part of that treatment—quarterly outpatient clinic visits, including an interval medical history and physical examination; routine laboratory assessment; review of glycemic control, medication adjustment, medical nutrition therapy, and diabetes self-management education; telephone consultations with a nurse/certified diabetes educator in their treating clinic are available as often as necessary between clinic visits.
1666884|NCT01722630|Drug|Dopamine|
1666885|NCT01722617|Other|Questionnaire|Patients in groups 2 and 3 will be asked to fill in questionnaires FLARE.
1666886|NCT01722604|Drug|brinzolamide 1% ophthalmic suspension|brinzolamide 1% ophthalmic suspension
1666887|NCT01722604|Drug|Azopt 1%|Azopt 1%, RLD
1666888|NCT01722591|Device|Cardiapex device|Cardiapex percutaneous transapical access and closure system
1666889|NCT01722578|Drug|L-ornithine L-aspartate|L-ornithine L-aspartate (6 ampules, each ampule containing 5 grams of the drug in 10 ml solution) to be diluted in 440 ml of Dextrose 5% (to make a total of 500 ml of solution), as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
1666890|NCT01722578|Drug|Placebo|Placebo (sterile water, 60 ml) diluted in 440 ml of Dextrose 5%, as intravenous infusion at the rate of 21 ml/hour, over 24 hours, for 5 days
1666891|NCT01722565|Procedure|laparoscopic abdominoperineal resection with a lightweight mesh (polypropylene and poliglecaprone 25)|
1666892|NCT01722552|Behavioral|adherence feedback|
1666893|NCT01722552|Behavioral|standard of care|
1666894|NCT01722539|Drug|Sulfadoxine-pyrimethamine|Tablets 500 mg sulfadoxine - 25 mg pyrimethamine will be given as single oral dose of ½ tablets per 10 kg of weigh: 1 tablet for weigh less than 20 kg, 1.5 tablets in 20-29 kg, and 2 tablets for children of weigh 30 or more
1666895|NCT01722539|Drug|Piperaquine|Piperaquine tablet 320 mg manufactured by Sigma Tau will be used at two treatment doses of 16-24 mg/kg at 24 hours intervals as follows: 1 tablets for weigh 15-19 kg, 1.5 tablets for 20-29 kg, and 2 tablets for 30-39 kg, and 2.5 tablets for 40 kg or more.
1666896|NCT01722539|Drug|Albendazole|One oral 200 mg will be given to children of 1-2 years and one oral dose of 400 mg to children older than 2 years. The treatment will be repeated at 4-months in the follow-up in accordance with the WHO guideline.
1666897|NCT01722539|Drug|Praziquantel|Praziquantel is a tremacide used for treatment of infections due to schistosomes. Praziquantel will be given as one dose of 40 mg/kg at enrolment and at 12 months follow up.
1666898|NCT01722526|Drug|Recombinant human acid sphingomyelinase|Administered intravenously every 2 weeks for 26 weeks
1666899|NCT01722513|Drug|Alprostadil ﹠control|control:Normal salin 1cc/kg/hr before and after angiography
1666900|NCT01722487|Drug|Ibrutinib|Ibrutinib will be supplied as hard gelatin 140-mg capsules for oral (PO) administration. Ibrutinib 420 mg (3 x 140-mg capsules) is administered orally once daily. The first dose will be delivered in the clinic on Day 1, after which subsequent dosing is typically on an outpatient basis. Ibrutinib will be dispensed to patients in bottles at each visit.
1666901|NCT01722487|Drug|Chlorambucil|Chlorambucil will be supplied as 2-mg tablets for PO administration. Chlorambucil is administered orally on Days 1 and 15 of each 28-day cycle. The starting dosage (Cycle 1) is 0.5 mg/kg. If well tolerated, the Chlorambucil dose can be increased starting at Cycle 2, with increments of 0.1 mg/kg on Day 1 of each cycle to a maximum of 0.8 mg/kg.
1666902|NCT01722474|Device|ASI Device|
1666903|NCT01722461|Device|Ulthera System|Focused ultrasound energy delivered below the surface of the skin
1667006|NCT01721733|Drug|Placebo|
1666904|NCT01722461|Device|Sham treatment|Ulthera System delivering no ultrasound energy
1666907|NCT01722435|Drug|Opiate Substitution Treatment|
1666908|NCT01722422|Drug|oxygen and saline|
1666909|NCT01722409|Drug|sevoflurane and 0.5 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX1 received a single dexmedetomidine dose of 0.5 μg/kg over 10 minutes.
1666910|NCT01722409|Drug|sevoflurane and 1 μg/kg dexmedetomidine|After induction of general anesthesia, Group DEX2 received a single dexmedetomidine dose of 1 μg/kg over 10 minutes.
1666911|NCT01722396|Dietary Supplement|Vitamin D|
1666912|NCT01722370|Drug|Oxygen|
1666913|NCT01722370|Drug|Medical air equivalent|
1666914|NCT01722357|Behavioral|Pedometer|Participants are provided with Omron Model HJ-151 pedometers and given instruction on how to use the pedometer to set goals for increasing physical activity. They are given diaries to track their daily step counts.
1666915|NCT01722357|Behavioral|Exercise Counseling|Manualized cognitive behavioral treatment program including goal setting, adding exercise throughout the day, physical limitations/injuries, maintaining motivation, benefits of exercise, FITT principles, exercise as recreation, and restructuring thoughts related to activity.
1666916|NCT01722344|Behavioral|Individual Placement and support (IPS)|IPS involves an employment specialist who is integrated within the mental health team, and carries out all phases of the vocational services, with a caseload on less than 25. The intervention is based on the 7 principles of IPS Supported Employment. The essence of these principles is an individualized and rapid search for competitive employment or education that avoids prolonged prevocational training and preparation. The intervention is integrated within the mental health services, with emphasis on client preference and choice regarding jobs, and with availability of on going job support and benefit counselling
1666917|NCT01722344|Behavioral|IPS plus|Individual Placement and Support + cognitive remediation and work-related social skills training, consists of the IPS intervention + 24 sessions of computer based cognitive training and 24 group based sessions of cognitive coping strategies and work-related social skills training.
1666918|NCT01722331|Drug|MK-3222 200 mg|
1666919|NCT01722331|Drug|MK-3222 100 mg|
1666920|NCT01722331|Drug|Matching Placebo|
1666921|NCT01722318|Drug|Plecanatide|
1666922|NCT01722318|Drug|Placebo|
1666923|NCT01722305|Drug|Dexamethasone|Given PO
1666924|NCT01722305|Other|Laboratory Biomarker Analysis|Optional correlative studies
1666925|NCT01722305|Other|Pharmacological Study|Optional correlative studies
1666926|NCT01722305|Drug|Pomalidomide|Given PO
1666927|NCT01722292|Drug|LY2940680|Administered orally
1666928|NCT01722292|Drug|Carboplatin|Administered IV
1666929|NCT01722292|Drug|Etoposide|Administered IV
1666930|NCT01722292|Drug|Placebo|Administered orally
1666931|NCT01722279|Procedure|Bariatric surgery|
1666932|NCT01722266|Drug|Liraglutide|"Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.
Patients randomized to 1.8 mg of liraglutide: They will start liraglutide 0.6 mg sc once daily for one week; will increase to 1.2 mg sc once daily for second week and will stay on 1.8 mg of liraglutide from third week onwards."
1666933|NCT01722266|Drug|Placebo|"Patients randomized to 1.2 mg of placebo: They will start placebo 0.6 mg sc once daily for one week and then increase to 1.2 mg once daily thereafter.
Patients randomized to 1.8 mg of placebo: They will start placebo 0.6 mg sc once daily for one week; increase to 1.2 mg sc once daily for second week and then to 1.8 mg sc once daily from third week onwards."
1666934|NCT01722253|Procedure|Electroacupuncture|Electrical stimulation device with frequency 2 Hz and 'frequency scanning mode'
1666935|NCT01722240|Drug|Liraglutide 1.2mg|
1666936|NCT01722240|Drug|Placebo|
1666937|NCT01722227|Drug|Liraglutide|
1666938|NCT01722227|Drug|Placebo|
1666939|NCT01722214|Biological|Adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 52 weeks). For Adalimibab group and Placebo group.
1666940|NCT01722214|Other|Placebo|Injection of placebo that is physicaly identical to adalimumab without the active ingredient at identical intervals.
1666941|NCT01722201|Drug|Risperidone Tablet 1 mg|1 mg tablet once a day
1666942|NCT01722201|Drug|Risperidone|1 mg tablet once a day
1666943|NCT01722175|Procedure|ALPPS surgery|
1666944|NCT01722175|Procedure|PVO surgery|
1666945|NCT01722162|Drug|Bevacizumab|
1666946|NCT01722162|Drug|Capecitabine|
1666947|NCT01722162|Drug|Levocetirizine|
1666948|NCT01722149|Genetic|Adoptive Transfer of re-directed T cells|Adoptive Transfer of 10e6 re-directed T cells in the pleural effusion
1666949|NCT01722136|Behavioral|Low Dosage|Exercise dose of 8kcal/kg/week
1666950|NCT01722136|Behavioral|High Dosage|Exercise dose of 14kcal/kg/week
1666951|NCT01722123|Other|Hypothetical scenarios and related decisions|Patients are exposed to three hypothetical medical scenarios that require varying levels of decision making. We will be assessing how this experience alters their subsequent choice to forego life sustaining therapy.
1666952|NCT01722110|Drug|Indomethacin Extended-Release Capsules USP 75 mg|75 mg tablet once a day
1666953|NCT01722110|Drug|Indomethacin Extended Release Capsules USP 75 mg|75 mg tablet once a day
1666954|NCT01722097|Drug|Rocuronium|
1666955|NCT01722097|Drug|placebo|
1667007|NCT01721733|Drug|EPI-743 15 mg/kg|
1667008|NCT01721733|Drug|EPI-743 5 mg/kg|
1667009|NCT01721707|Drug|Latanoprost+Brinzolamide combination|1 drop in each eye, 1x/day, at 9PM
1667010|NCT01721707|Drug|Latanoprost|1 drop in each eye, 1x/day, at 9PM
1667011|NCT01721694|Drug|azithromycin 1.5%/Loteprednol 0,5% + placebo|1 drop, AO, QID
1667012|NCT01721694|Drug|azithromycin 1.5% + Loteprednol 0,5% (separately)|1 drop, QID, AO
1667014|NCT01721668|Behavioral|Music Supported Rehabilitation|Music Supported Rehabilitation -using musical exercises to improve hand and arm motor functioning.
1667153|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
1666956|NCT01722084|Behavioral|Theory of planned behaviour (TPB) and social cognitive theory (SCT).|"TPB is appropriate to influence adolescents' behaviour related to the use of contraceptive methods and their health/information seeking behaviour. The SCT helped to find out strategies to improve communication about sexuality, to promote openness towards adolescents' sexuality among parents, community members and health providers and for health providers to adopt a more adolescent friendly attitude.The development of the strategies in the different countries is a dynamic process that is continuously being adapted. The target groups were driving the process of identifying, selecting and implementing interventions. Therefore, local institutions were involved in the intervention. Attention was paid to ensure that the interventions were in line with the existing local structures/policies and reinforce the local health system.Primary health care services had a key role in the interventions. Gender was a transversal topic throughout the intervention process."
1666957|NCT01722071|Drug|Placebo|Placebo intranasal administration, 3 puffs per nostril delivered approximately 30 minutes prior to scanning session.
1666958|NCT01722071|Drug|Oxytocin|Oxytocin intranasal administration, 24 IU, 3 puffs per nostril at 4 IU per puff delivered approximately 30 minutes prior to scanning session.
1666959|NCT01722058|Drug|Peptide application|
1666961|NCT01722032|Other|Childhood Obesity|
1666962|NCT01722019|Device|Tulip fiber|Laser ablation with a wavelength of 1470 nanometers will be performed, in combination with a new sort of fiber: the tulip tip fiber.
1666963|NCT01722019|Device|VNUS closure fast|Radiofrequent ablation will be performed in combination with the catheter 'VNUS closure fast'.
1666964|NCT01722006|Behavioral|Pairing condition|
1666965|NCT01722006|Behavioral|Pairing condition|20 mg methamphetamine or placebo on four 4-hour laboratory sessions
1666966|NCT01721993|Drug|T121|
1666967|NCT01721993|Drug|Zoledronic acid|
1666968|NCT01721980|Drug|GLPG0974|
1666969|NCT01721980|Drug|Placebo|
1666970|NCT01721967|Drug|Ranolazine|
1666971|NCT01721954|Drug|FOLFOX6m|
1666972|NCT01721954|Device|SIR-Spheres microspheres|
1666973|NCT01721941|Drug|Phase I Dose level -1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
1666974|NCT01721941|Drug|Phase I dose level 1|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
1666975|NCT01721941|Drug|Phase I Dose level 2|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
1666976|NCT01721941|Drug|Phase I Dose level 3|The dose of TH-302 will be mixed with doxorubicin 50mg to use as the chemoembolization mixture for transarterial chemoembolization (TACE).
1666977|NCT01721928|Device|Continuous venovenous hemodialysis|Continuous venovenous hemodialysis
1666978|NCT01721915|Drug|Vitamin D supplementation|The treatment group will receive an oral dose of 20,000 IU vitD weekly (equivalent to 2857 IU/day) as oily drops (Oleovit D3-drops; producer: Fresenius Kabi Austria GmbH, Linz)
1666979|NCT01721915|Drug|Placebo|
1666980|NCT01721902|Device|Autologous CD133+ Bone Marrow Stem Cells|Intra-myocardial injection of 2-3 x 10E6 CD133+ Bone Marrow Stem Cells
1666981|NCT01721902|Other|Carrier Solution|Intra-myocardial injection of carrier solution
1666982|NCT01721889|Radiation|Radiostereometric Analysis|The radiostereometric (RSA) patient exam (flexion and extension RSA images) presents additional radiation exposure to the patient above standard of care (additional radiographs). Assuming 120kV, using three protocols (two loaded and one unloaded) per RSA exam results in a typical effective dose of approximately 2.04mSv per exam(single lumbar spine RSA at 120kV yields 0.68mSv,). HBI recommends using 140kV for lumbar spine RSA and has conducted simulations to estimate the effective dose using higher kV settings. 140kV reduces the effective dose from 0.68mSv per spine RSA to 0.2mSV, resulting in a total effective dose per RSA exam of 0.6mSv. In comparison, the estimated effective dose for a single standard lumbar spine x-ray is 1.2mSv. This additional radiation exposure is considered to be minimal risk in consideration of the number of planar x-rays the patient will undergo as part of standard care, as well as average background radiation received by humans per year (3.1mSv).
1666987|NCT01721863|Other|Exercise training|Exercise group will undergo progressively aerobic exercise training with 40-85% maximal oxygen consumption for 40 minutes, 3 sessions per week for 12 weeks.
1666988|NCT01721850|Other|control formula|commercial stage 1 infant formula
1666989|NCT01721850|Other|intervention formula 1|infant formula with hydrolyzed protein (type I) and pre- and probiotics
1666990|NCT01721850|Other|intervention formula 2|infant formula with hydrolyzed protein (type II) and pre- and probiotics
1666991|NCT01721824|Behavioral|The IPS-MA method|During the first 6 months participants are usually offered 3 meetings with their mentor per month, lasting approximately 1 1/2 hours each. The following 6 months they are offered 1 meeting per month, lasting approximately 1 hour. The estimated duration of the IPS-MA intervention is 12 months, but since the needs of the participants are very individual, this may vary.
1666992|NCT01721811|Other|Hyperoxia|
1666993|NCT01721811|Other|Glucose|
1666994|NCT01721798|Device|Mirena levonorgestrel IUD|Intrauterine contraception system
1666995|NCT01721798|Device|Copper T-380a IUD|intrauterine contraception system
1666996|NCT01721785|Drug|GADOFOSVESET TRISODIUM 244 Mg in 1 mL INTRAVENOUS INJECTION, SOLUTION [Ablavar]|Gadofosveset will be used as a lymph-node specific MRI contrast agent and will be administered by manual injection as a single intravenous bolus during MRI.
1666997|NCT01721772|Biological|BMS-936558 (Nivolumab)|
1666998|NCT01721772|Biological|Placebo matching BMS-936558 (Nivolumab)|
1666999|NCT01721772|Drug|Dacarbazine|
1667000|NCT01721772|Drug|Placebo matching Dacarbazine|
1954944|NCT03310229|Radiation|plain chest x-ray|the participants will be subjected to plain chest x-ray with other tools to help diagnose pulmonary hypertension in haemodialysis patients
1667015|NCT01721668|Behavioral|Conventional Upper Extremity Therapy|-GRASP (Graded Repetitive Arm Supplementary Program-developed Janice Eng, PhD, PT/OT Jocelyn Harris, PhD, OT, Andrew Dawson, MD, FRCP, Bill Miller, PhD, OT) protocol will be used to improve arm and hand function in people living with stroke.
1667016|NCT01721655|Drug|Spironolactone|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day. The intervention will be enteral spironolactone 3 mg/kg once daily
1667017|NCT01721655|Drug|Placebo|Patients will continue to receive standard of care as if they were not enrolled in the study. All patients will receive oral chlorothiazide 40 mg/kg/day divided twice-daily, electrolyte supplementation as needed based on a standard algorithm, and if needed, rescue enteral furosemide 2 mg/kg/day.
1667018|NCT01721642|Device|Apica Cardiovascular ASC Access, Stability and Closure Device|Access, stabilisation and closure of trans-apical approach for TAVI
1667019|NCT01721629|Procedure|Sudden wean of nasal CPAP|
1667020|NCT01721629|Procedure|Gradual wean of nasal CPAP|
1667021|NCT01721616|Drug|Azithromycin|
1667022|NCT01721616|Drug|Cefazolin|
1667023|NCT01721603|Drug|Dabrafenib|150mg capsule by mouth twice daily
1667024|NCT01721603|Procedure|Gamma Knife Radiosurgery|This will be delivered using Gamma Knife technology. Patients will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
1667025|NCT01721590|Drug|Tongxinluo|Tongxinluo,3 capsules/time 3times/day for 1 year
1667026|NCT01721590|Drug|placebo|3 capsules/time，3times/day for 1 year
1667027|NCT01721577|Drug|AXL1717|IGF-1 receptor inhibitor
1667028|NCT01721564|Drug|Bosentan|62.5 mg Bosentan twice a day for 1 month 125 mg Bosentan twice a day for 5 months
1667029|NCT01721551|Other|Exercise|Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
1667030|NCT01721538|Other|Weight reduction program|
1667031|NCT01721538|Other|Lecture on healthy nutrition|
1667033|NCT01721512|Other|Breastfeeding|
1667034|NCT01721512|Other|Infant formula|
1667035|NCT01721499|Behavioral|Nutritional Counseling|weekly group and individual skills training to improve self control and decrease stress.
1667036|NCT01721499|Behavioral|Mindfulness Intervention|
1667037|NCT01721486|Drug|IV acetaminophen|IV acetaminophen 15 mg/kg (up to 1000 mg) over 15 minute infusion after IV placement in OR .
1667038|NCT01721486|Drug|PO acetaminophen|PO acetaminophen elixir 15 mg/kg (up to 1000 mg) administered approximately 90 minutes (+/- 30minutes) prior to induction of anesthesia in the pre-operative area.
1954945|NCT03310216|Procedure|Order I of visual inspection|Participants in group I are provided AI visual inspection system first and EDTRS later.
1667040|NCT01721447|Drug|Optison echocardiography contrast agent|Subjects undergoing transesophageal echocardiography who will receive the Optison contrast agent during the procedure to test if the image quality improves to provide accurate assessment of the presence of left atrial thrombus.
1667041|NCT01721434|Drug|Levosimendan|
1667042|NCT01721434|Drug|Placebo|Similar coloured placebo
1667043|NCT01721421|Other|extended treatment time|patients receive extended dialysis treatment time time of 6 hours
1667044|NCT01721421|Other|Standard treatment time|
1954946|NCT03310216|Procedure|Order II of visual inspection|The participants in Group II are provided EDTRS first and AI visual inspection system later.
1954947|NCT03310203|Diagnostic Test|Iron|Labelled iron
1667047|NCT01721395|Dietary Supplement|Agave Syrup|
1667048|NCT01721382|Drug|Sitagliptin|
1667049|NCT01721343|Behavioral|telephone-based intervention|Undergo telephonic monitoring
1667050|NCT01721343|Other|case management|Participate in an individualized conditioning program with an RCM
1667051|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM and PCM
1667052|NCT01721343|Procedure|physical therapy|Participate in an individualized conditioning program with an RCM
1667053|NCT01721343|Other|questionnaire administration|Ancillary studies
1667054|NCT01721343|Procedure|quality-of-life assessment|Ancillary studies
1667055|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care
1667056|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care
1667057|NCT01721343|Other|educational intervention|Participate in an individualized conditioning program with an RCM
1667058|NCT01721343|Procedure|management of therapy complications|Undergo enhanced usual care with an RCM
1667059|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM
1667060|NCT01721343|Procedure|assessment of therapy complications|Undergo enhanced usual care with an RCM and PCM
1667061|NCT01721330|Drug|Naltrexone|Up to 100mg of Naltrexone once a day for 6 weeks
1667062|NCT01721330|Drug|Placebo|Placebo twice a day for 6 weeks
1667149|NCT01720550|Drug|Astragalus Polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
1667063|NCT01721317|Drug|Ezogabine/Retigabine IR|Subjects received drug (dose strength 300 mg to 1200 mg) orally with or without food. The 3 daily doses are to be administered with approximately an 8-hour interval between them.
1667064|NCT01721317|Drug|Placebo|Matching placebo will be available
1667065|NCT01721304|Other|Adaptive Conjoint Analysis|Computerized survey to elicit patient preferences
1667066|NCT01721291|Drug|SALBUTAMOL|"In the LUNG DEPOSITION STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT SLOW INHLATION AND AGAIN AT FAST INHALTION;DOSAGE- 30 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION.
In the LUNG PHYSIOLOGY STUDY; SALBUTAMOL INHALED VIA RESEARCH NEBULISER at 3 PARTICLES SIZES OF 1.5 MICRONS, 3 MICRONS AND 6 MICRONS WILL BE GIVEN AT TWO DOSAGES OF 30 MICROGRAMS AND AGAIN AT 15 MICROGRAMS, ONE SINGLE INHALATION ONLY. IN ADDITION, SALBUTAMOL AT 200 MICROGRAMS INHALED VIA A STANDARD METERED DOSE INHALER WILL ALSO BE GIVEN AS A SINGLE INHALATION. ALL INHALATIONS WIL BE AT SLOW INHALTION IN THIS PART OF THE STUDY."
1667067|NCT01721239|Other|Standardized Followup program|Standardized written information, patient photos and three followup consultations.
1667068|NCT01721226|Device|Intervention Arm (computer-based CARE+ Corrections tool)|Study participants in the intervention arm will complete the computer-based CARE+ Corrections tool at baseline. The CARE tool provides tailored feedback based on the participants' responses to a series of questions included in the counseling session. Participants in this arm of the study recruited inside the DC DOC will receive typical discharge planning services as conducted by the correctional facility. Participants will be followed for six months after release/study enrollment. At the post-release baseline visit, participants in the intervention arm will receive a cell phone/SMS text messaging intervention consisting of using cell phone-delivered SMS text messages with the intent of improving linkage to community HIV care and adherence to ART (if prescribed.)
1667069|NCT01721226|Other|Educational video on opiate overdose prevention|Participants in the Control Arm will view an educational video on opiate overdose prevention in jail prior to release. Control arm participants will be followed after release/study enrollment, just like participants in the Intervention Arm, and Plasma Viral Loads will be collected from them at baseline and follow-up.
1667070|NCT01721213|Drug|Trobalt™|Trobalt™ is a potassium channel opener used as an adjunctive treatment for partial onset seizures (a form of epilepsy where a seizure begins in a specific area in one side of the brain), with or without secondary generalization in adults aged 18 years and above with epilepsy.
1667073|NCT01721174|Procedure|SEMS only|The SEMS (Niti-S biliary uncovered metallic stent; Taewoong Medical, Korea) would be placed.
1667074|NCT01721174|Procedure|EBRFA and SEMS|The radiofrequency ablation (RFA) catheter would be placed under fluoroscopic guidance across the biliary stricture. The Habib EndoHPB (EMcision UK, London, United Kingdom) radiofrequency ablation catheter is a bipolar RFA probe that is 8F (2.6 mm), 1.8 m long, compatible with standard (3.2-mm working channel) side-viewing endoscopes, and passes over 0.035-inch guidewires. The catheter has 2 ring electrodes 8 mm apart with the distal electrode 5 mm from the leading edge, providing local coagulative necrosis over a 2.5-cm length. Depending on the length of the stricture, sequential applications would be applied to complete treatment throughout the length of the stricture without significant overlap of treated areas. An uncovered SEMSs (Niti-S biliary uncovered metallic stent; Taewoong Medical, Gimpo City, Korea) would be placed after 2 sessions of EBRFA.
1667075|NCT01721161|Biological|BIIB033 (anti-LINGO-1 mAb)|100 mg/kg via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses).
1667076|NCT01721161|Drug|Placebo|via IV infusion once every 4 weeks for 20 weeks (a total of 6 doses)
1667077|NCT01721148|Drug|ASLAN002( BMS 777607)|100mg, 200mg, 300mg, 450mg, 600mg
1667078|NCT01721135|Drug|GSK2190915 100mg|Film coated oral tablet
1667079|NCT01721135|Drug|GSK2190915 200mg|Film coated oral tablet
1667080|NCT01721135|Drug|moxifloxacin 400mg|Film coated oral tablet
1667081|NCT01721135|Drug|moxifloxacin placebo|Film coated oral tablet
1667082|NCT01721135|Drug|GSK2190915 placebo|Film coated oral tablet
1667083|NCT01721109|Drug|EVG/COBI/FTC/TDF|Elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EVG/COBI/FTC/TDF) single-tablet regiment (STR) administered orally once daily with food
1667084|NCT01721096|Device|XIENCE PRIME - Long Length (LL)|Long Length
1667085|NCT01721096|Device|XIENCE PRIME - Core Size|Core Size
1667086|NCT01721083|Procedure|Procedure: Z-track|Subject received immunization by z-track
1667087|NCT01721083|Procedure|Procedure: Bunch|Subject receives immunization by bunch method.
1667088|NCT01721070|Drug|Sufentanil NanoTab (SUF NT) 15 mcg|Period 1: One dose of SUF NT 15 mcg administered sublingually
1667089|NCT01721070|Drug|Ketoconazole 400 mg, sufentanil NanoTab (SUF NT) 15 mcg|Period 2: Ketoconazole 400 mg administered daily for three days, SUF NT 15 mcg co-administered sublingually on the third day
1667090|NCT01721057|Drug|Placebo|Administered orally
1667091|NCT01721057|Drug|Baricitinib|Administered orally
1667092|NCT01721057|Drug|cDMARD|Conventional disease-modifying anti-rheumatic drug as a background therapy
1958155|NCT01945281|Drug|Caspofungin|
1958156|NCT01945281|Drug|Amphotericin B Deoxycholate|
1667095|NCT01721031|Procedure|DPNB|Patients receive DPNB 30min before extubation at the end of operation
1667096|NCT01721031|Drug|Tramadol|Patients receive intravenous tramadol 1.5mg/kg 30min before extubation at the end of operation.
1667097|NCT01721018|Biological|HSV1716 Intra-pleural delivery|
1667098|NCT01721005|Other|Subject education to pulse palpation|The subject is educated to pulse palpation by registered cardiac nurse. The education time is limited to 10 minutes and done according preplanned education model.
1667150|NCT01720550|Drug|Astragalus Polysaccharides 250 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours over 2 treatment cycles (8 weeks)
1667151|NCT01720537|Biological|PF-05335810 Dose A|Single SC Injection
1667152|NCT01720537|Biological|PF-05335810 Dose B|Single Subcutaneous Injection(s)
1667099|NCT01720992|Other|A theory-based action planning toolkit|The toolkit will be distributed to the participants for their use at home, like a 'homework assignment', for the purpose of enhancing their intention and practices of the suggested behaviours. The development of the booklet was guided by the theory of The Health Action Process Approach (HAPA), which suggests that one's intention can be foster by knowing that the new behaviour has positive outcomes as opposed to the negative outcomes that accompany the current behaviour; and planning (action planning and coping planning) serves as an operative mediator between intentions and behaviour (Schwarzer, 2008). Previous evidence has shown the applicability of the HAPA in changing people's health behaviours, e.g., physical exercise, breast self-examination, seat belt use, dietary behaviours, and dental flossing; and its generalizability has been confirmed by Schwarzer (2008).
1667100|NCT01720966|Procedure|Liver resection|Liver resection performed for metastatic disease from colorectal carcinoma
1667101|NCT01720953|Other|Mentalization Based Therapy|Fifty female patients diagnosed with BPD will undergo a year of intensive Mentalization Based Therapy that is designed to target domains of BPD pathology. The patients will be assessed at baseline and every 6 months over the treatment period.
1667102|NCT01720940|Drug|continuous vancomycin infusion|24-hour continuous infusion of vancomycin
1667103|NCT01720940|Drug|intermittent vancomycin infusion|
1667104|NCT01720901|Drug|Icotinib|Icotinib will be administered 250 mg one time by month, 3 times per day.
1667105|NCT01720888|Other|BM-MSCs|Intracoronary implantation of bone marrow-derived mesencymal stem cells
1667106|NCT01720875|Drug|Vorinostat Velcade Dexamethasone|
1667107|NCT01720849|Drug|Fampyra|The will be given as per normal patient treatment plan
1667108|NCT01720836|Biological|Vaccine + PolyICLC|The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.
1667109|NCT01720823|Device|home polysomnography (GETEMED)|
1667110|NCT01720823|Device|standard polysomnography (BRAINNET II)|
1667111|NCT01720797|Device|Micro-osteoperforation|Minimally invasive micro-osteoperforation procedure used to achieve rapid orthodontic tooth movement.
1667112|NCT01720797|Drug|Anesthestic|Topical or local anesthetic will be delivered in the area to be treated in accordance with standard practice.
1667113|NCT01720797|Other|Chlorhexidine|Prior to intervention subject will swish 5cc of chlorhexidine for one minute, twice. Following procedure Chlorhexidine rinses are to begin twice a day for a week.
1667114|NCT01720784|Dietary Supplement|Alginate dietary fiber|
1667115|NCT01720784|Dietary Supplement|Placebo|
1667116|NCT01720771|Dietary Supplement|probiotic tablet|Intake of one probiotic lozenge tablet per day
1667117|NCT01720771|Dietary Supplement|sugar pill|one tablet daily
1667118|NCT01720732|Behavioral|Lifeline NET|Short Version of Narrative Exposure Therapy
1667119|NCT01720719|Drug|atorvastatin|Oral atorvastatin 20mg, qd, for 24 weeks
1667120|NCT01720719|Drug|Vitamin E|Oral Vitamin E 300mg, qd, for 24 weeks
1667121|NCT01720706|Device|RFA Loosely wound thermal coil|"This new device uses radiofrequency energy to destroy kidney or liver tumours. It is called radiofrequency ablation.
This type of energy is simply an alternating current that passes from a coil (electrode) into the tissue causing heating of the tissue in the vicinity of the electrode."
1667122|NCT01720693|Procedure|Hypoperfusion of renal artery|The renal artery is occluded to 30% of it's baseline, prior to kidney tumour removal
1667123|NCT01720680|Radiation|Low dose multislice CT thorax|"All patients will have 2 low dose multi-slice CT's at visit 2: one CT pre-dose and one CT 1 to 3 hours post-dose."
1667124|NCT01720680|Device|AlphaCore® device|All patients will receive a stimulation therapy of 90 seconds delivered by the AlphaCore.
1667125|NCT01720667|Drug|Intravenous levetiracetam|Intravenous load of levetiracetam (40 to 60 mg/kg) following identification of EEG confirmed neonatal seizure.
1667126|NCT01720667|Drug|Intravenous phenobarbital|Intravenous load of phenobarbital (20 to 40 mg/kg)following EEG confirmation of seizure activity load.
1667127|NCT01720654|Behavioral|EPT|Standardized partner notification counseling and provision of 5 partner treatment packets containing: Printed information on signs, symptoms, diagnosis, and treatment of gonorrhea and chlamydia as well as information on local testing/treatment resources; 400 mg Cefixime and 1g Azithromycin.
1667128|NCT01720641|Behavioral|Internet|Referral and user instructions for Peru section of www.inspot.org partner notification website
1667129|NCT01720641|Behavioral|Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources.
1667130|NCT01720641|Behavioral|Internet and Referral Card|5 printed referral cards with information on syphilis signs, symptoms, diagnosis, treatment, and local resources; Referral and user instructions for Peru section of www.inspot.org partner notification website.
1667131|NCT01720628|Other|serum levels of angiogenin, bFGF, VEGF|Behçet's patients
1667132|NCT01720615|Drug|Propofol / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
1667133|NCT01720615|Drug|Sevoflurane / Remifentanil|General anesthesia: Loss of consciousness and standard clinical practice
1667134|NCT01720602|Drug|vorinostat|Given PO
1667135|NCT01720602|Drug|anastrozole|Given PO
1667136|NCT01720602|Drug|letrozole|Given PO
1667137|NCT01720602|Drug|exemestane|Given PO
1667138|NCT01720602|Procedure|positron emission tomography|Correlative studies
1667139|NCT01720602|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
1667140|NCT01720602|Radiation|fludeoxyglucose F 18|Correlative studies
1667141|NCT01720602|Other|laboratory biomarker analysis|Correlative studies
1667142|NCT01720589|Dietary Supplement|Melt (test oil)|
1667143|NCT01720589|Dietary Supplement|Corn oil (control)|
1667144|NCT01720576|Drug|REGN1033 (SAR391786)|
1667145|NCT01720576|Drug|Placebo|
1667146|NCT01720563|Drug|Astragalus polysaccharides 500 mg|PG2 (500 mg in 500 ml saline), t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
1667147|NCT01720563|Drug|Placebo|500 ml saline, t.i.w. via i.v. infusion for 2.5-3.5 hours during the CCRT
1667148|NCT01720563|Procedure|Concurrent chemoradiotherapy with PUL (cisplatin/tegafur plus uracil (UFT)/leucovorin) every 2 weeks|
1667154|NCT01720537|Biological|PF-05335810 Dose B|Single Intravenous Infusion
1667155|NCT01720537|Biological|Placebo|Single Intravenous Infusion
1667156|NCT01720537|Biological|PF-04950615 Dose A|Single Subcutaneous Injection(s)
1667157|NCT01720537|Biological|PF-04950615 Dose A|Single Intravenous Infusion
1667158|NCT01720537|Biological|PF-05335810 Dose C|Single Subcutaneous Injection(s)
1667159|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
1667160|NCT01720537|Biological|PF-05335810 Dose C|Single Intravenous Infusion
1667161|NCT01720537|Biological|Placebo|Single Intravenous Infusion
1667162|NCT01720537|Biological|PF-04950615|Single Subcutaneous Injection(s)
1667163|NCT01720537|Biological|PF-05335810 Dose D|Single Subcutaneous Injection(s)
1667164|NCT01720537|Biological|Placebo|Single Subcutaneous Injection(s)
1667165|NCT01720537|Biological|PF-05335810 Dose E|Multiple fixed dosages administered in subcutaneous injections, monthly for 3 months.
1667166|NCT01720537|Biological|PF-05335810 Dose D|Single Intravenous Infusion
1667167|NCT01720537|Biological|Placebo|Single Intravenous Infusion
1667170|NCT01720511|Dietary Supplement|Purple Rice|Incorporate one cup of purple rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
1667171|NCT01720511|Dietary Supplement|Brown Rice|Incorporate one cup of brown rice into dishes to be consumed at lunch and dinner each day for 4 weeks (equivalent of 4 ounces of uncooked rice/day).
1667172|NCT01720498|Drug|remifentanil|The effect site concentration of remifentanil
1667175|NCT01720472|Genetic|Biomarker studies|
1667176|NCT01720459|Dietary Supplement|Micronized trans-resveratrol|
1667177|NCT01720459|Dietary Supplement|Placebo|
1667178|NCT01720446|Drug|semaglutide|Once weekly doses of 0.5 mg semaglutide after an initial dose escalation step of 0.25 mg as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
1667179|NCT01720446|Drug|semaglutide|Once weekly doses of 1.0 mg semaglutide after an initial dose escalation step of 0.25 mg followed by 0.5 mg dose escalation as an add-on to the standard-of-care treatment. Administered subcutaneously (s.c., under the skin)
1667180|NCT01720446|Drug|placebo|"Once weekly doses volume-matched placebo, as an add-on to the standard-of-care treatment.
Administered subcutaneously (s.c., under the skin)."
1667181|NCT01720433|Procedure|intervention|The patient was placed in the Trendelenburg position (30°) and two manual lung inflations to a maximum pressure of 60 cm H2O for five seconds, with the valves on the operative ports fully open.
1667182|NCT01720420|Device|NobelReplace CC, NobelProcera Implant Bar|Implants titanium with conical connection, individualized titanium bar
1667183|NCT01720407|Drug|Imiquimod cream + surgery|Imiquimod (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks (i.e. a total of 20 applications), followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision at 5mm will be performed within a few days (equivalent to 2-stage surgery).
1667184|NCT01720407|Drug|Placebo + surgery|Placebo (5 times per week) applied to and extending 1cm beyond the lesion for a period of 4 weeks, followed by surgery performed four weeks after the last application of the topical treatment. If excision is intralesional, re-excision of 5mm of clinically healthy tissue will be performed within a few days (equivalent to 2-stage surgery).
1667185|NCT01720394|Device|Cervical Ripening Balloon, Cook Medical Inc.|Application of the cervical ripening double-balloon (filled with 2x 80ml) on day 1.
1667186|NCT01720394|Drug|Dinoprostone|Application of Propess-vaginal-insert, (Dinoprostone 10mg - Ferring Arzneimittel Ges.m.b.H., 1100 Vienna, Austria) for labor induction on day 1-3 in therapy arm 2.
1667188|NCT01720329|Dietary Supplement|Probiotics|Active comparator Arm. XXmls of XXX supplemented with XX of L. rhamnosus GG on a daily basis for six months
1667189|NCT01720329|Other|probiotic placebo|Placebo comparator arm -Participants randomized to placebo will receive XXmls of XXX G on a daily basis for 6 months.
1667190|NCT01720316|Drug|Glycine|Double-blind placebo controlled trial of glycine or placebo, followed by open-label glycine
1667191|NCT01720316|Drug|placebo|
1667192|NCT01720303|Drug|repaglinide|2 mg (tablets) before each main meal
1667193|NCT01720303|Drug|isophane human insulin|Injection s.c. (under the skin) at bedtime
1667194|NCT01720303|Drug|insulin|Injection s.c. (under the skin) twice daily
1667195|NCT01720290|Drug|repaglinide|Dose individually adjusted
1667196|NCT01720290|Drug|metformin|Dose individually adjusted
1667197|NCT01720290|Drug|metformin|Dose at 1000 mg/day
1958161|NCT01939197|Drug|ABT-450/r/ABT-267|Tablet
1958162|NCT01939197|Drug|ABT-333|Tablet
1667200|NCT01720264|Drug|Sitagliptin|Sitagliptin q 12 hours PO starting on Day -1 then given every 12 hours (total 10 doses) on Day 0, Day +1, +2 and Day +3.
1667201|NCT01720251|Drug|placebo|SC injections of placebo on days 1, 7, 14, 28 and 56
1667202|NCT01720251|Drug|AllerT low dose|SC injections of AllerT 25-50 micrograms on days 1, 7, 14, 28 and 56
1667203|NCT01720251|Drug|AllerT full dose|SC injections of AllerT 50-100 micrograms on days 1, 7, 14, 28 and 56
1667204|NCT01720238|Drug|Entecavir|0.5mg qd
1667205|NCT01720238|Drug|Lamivudine plus Adefovir Dipivoxil|Lamivudine:100mg qd Adefovir Dipivoxil:10mg qd
1667206|NCT01720225|Drug|Decitabine|20 mg/m2 by vein daily for 3 days (days 1-3) every 28 days.
1667207|NCT01720225|Drug|Azacitidine|75 mg/m2 subcutaneously or by vein daily for 3 days (days 1-3) every 28 days.
1667208|NCT01720212|Drug|YM178|oral
1667243|NCT01719887|Device|Conservative treatment|Conservative treatment with functional brace applied after 7 days of initial treatment with prefabricated cork splint.
1667209|NCT01720199|Other|Diario della Salute (DDS)|"DDS is composed by
tools for children and their parents on health and social and emotional well-being issues:
a diary for teens telling the story of four same-age students (e.g. experimenting with risky behaviors, conflicting feelings and thoughts, need for independence and control),
a diary for parents telling the experience of a mum and a dad with teenage children (e.g. problems in the relationship with teenage children, family conflict, parental disappointment, etc.);
five highly-standardized interactive lessons (2-4 hours each) on health issues administered by previously trained teachers."
1667210|NCT01720186|Device|PET/CT 4D imaging in a synchronized mode centered on the thorax.|
1958163|NCT01939197|Drug|Ribavirin (RBV)|Tablet
1667213|NCT01720160|Device|Barostim Neo system|Patients will be implanted with the Neo system.
1667214|NCT01720160|Other|Standard of care medical managment|
1667215|NCT01720147|Drug|Quercetin (dietary supplement)|"Quercetin will be given orally on a twice a day schedule starting with weight adjusted dose for a maximum total daily dose of 1500 mg/day, for 4 months (16 weeks). Pharmacokinetics (PK) data will be analyzed after each cohort of 3 patients and will be used to optimize the dosing schedule (if required)for subsequent patients.
An expansion cohort has been added to the study protocol. Up to 20 patients may be enrolled. The dose utilized will be the same as the max weight adjusted dose that showed biological activity in our last cohort of patients (subjects #10-12 from above)."
1667216|NCT01720121|Other|Printed, digital video disc|The three groups of patient received: 1)informative material in details about the cardiac catheterization provide by the researchers; 2)informative provide by a digital video disc; 3)the control group received the conventional informative provide by the nursing team.
1667217|NCT01720108|Drug|rivaroxaban and ASA|
1667218|NCT01720095|Drug|Niaspan|
1667219|NCT01720082|Procedure|Single incision laparoscopic appendectomy|A multiport device will be introducted through a 2-2.5 transumbilical incision. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
1667220|NCT01720082|Procedure|Multiport laparoscopic appendectomy|Three ports will be inserted as follows: One 10/12 umbilical port, one 5mm suprapubic (or right suprapubic)port, one 5mm or 10/12mm port in left iliac fossa (or left suprapubic). One additional trocar can be inserted following surgeons preference. Retraction of the appendix would be performed with a forceps. The mesoappendix will be divided with bipolar or monopolar cautery. The appendix stump will be ligated with suture loop or with an endo-stapler. The specimen will be delivered within a plastic bag or in any protected way (without any contact with the abdominal wall) via the umbilical port. Any fluid will be suctioned and washing performed if required. Fascial defects (10/12 trocars)will be closed with 2-O polydioxanone sutures and skin closed with 4-O non-absorbable sutures. No pelvic drain will be inserted. A three-band dressing will be applied in the end.
1667221|NCT01720069|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler device
1667222|NCT01720056|Drug|Verapamil|
1667223|NCT01720056|Drug|Kenalog 10|
1667224|NCT01720043|Drug|Velcade|Single dose of Velcade (1.0-1.3 mg/m2 dose)
1667225|NCT01720030|Drug|Levosimendan|Verum therapy
1667226|NCT01720030|Drug|Conventional therapy|Placebo therapy to safeguard blinding
1667227|NCT01720017|Other|Preclinical Manikin Training|During the preclinical manikin training, each subject will perform 10 intubations in a manikin with a difficult airway simulated by swelling the manikin tongue and placing it in a cervical collar.
1667228|NCT01720017|Other|Inservice Training|Inservice training will include review of a product information handout and a video demonstration.
1667229|NCT01720004|Other|Repeated hands-and-knees positioning during labour|Details are in the Arm Description.
1667230|NCT01719991|Other|Nurse case management and self-management support|"Case management: The intervention will focus on four main components: (1) A thorough evaluation of the patient's needs and resources; (2) Establishing and maintaining a patient-centered, individualized service plan (ISP); (3) Coordination of services among partners; and (4) Self-management support for patients and their families.
Self-management support: A standardized six-week program with interactive weekly group meetings led by two volunteer peer helpers (appointed trainers), who themselves have a chronic disease."
1667231|NCT01719978|Drug|3.6mL 2% Mepivacaine with 1:100,000 epinephrine|Local anesthetic with vasoconstrictor
1667232|NCT01719978|Procedure|Lower Third Molar Extraction|Lower Third Molar Extraction with LA + hyaluronidase (or placebo)
1667233|NCT01719978|Drug|Hyaluronidase|75RTU Hyaluronidase administration concomitant to the local anesthetic
1667234|NCT01719978|Drug|Placebo|1mL 0.9% saline administration concomitant to the local anesthetic
1667235|NCT01719965|Other|Interviews and Focus Group Discussions|
1667236|NCT01719952|Drug|Carbetocin|"IV carbetocin 100mcg, only in selected patient given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
pitocin 5 IU also given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group."
1667237|NCT01719952|Drug|Oxytocin|5 IU given as an intravenous bolus over 30 seconds by the anaesthetist following clamping of the umbilical cord only in patient that has been randomized to this group.
1667238|NCT01719926|Drug|Indomethacin|3 times per day from 2 days before until 5 days after chemotherapy. Escalating dosage each cohort.
1667239|NCT01719913|Other|High gluten|Refined grain/ gluten rich diet : Participants consume more than 25g of gluten per day (estimated to correspond to a gluten intake around the 90th percentile in the population)
1667240|NCT01719913|Other|Low gluten|Poor gluten diet: Participants consume less than 5g gluten per day (estimated to correspond to a gluten intake below the 10th percentile in the population)
1667244|NCT01719887|Procedure|Operative treatment|Operative treatment with open reduction and internal fixation using 4,5mm locking compression plate.
1667245|NCT01719887|Other|Physiotherapy|Physiotherapy is arranged to both groups at 3 and 9 wks.
1667248|NCT01719861|Drug|Desipramine HCL|Desipramine is a tricyclic antidepressant (TCA). All patients will start off with a 25 mg dose by mouth nightly (QHS), increasing weekly for 6 weeks. The target dose level at 6 weeks is 450 mg (maximum dosage) or the maximum tolerated dose (MTD) for each subject.
1667249|NCT01719848|Other|Measurements of parameters related with physical examinations for difficult airway prediction|
1667250|NCT01719835|Drug|Cyclophosphamide|750mg/m2 IV every 21 days
1667251|NCT01719835|Drug|Gemcitabine|1000mg/m2 IV Days 1, 8, 15 every 28 days
1667252|NCT01719835|Drug|Doxorubicin|50mg/m2 IV every 21 days
1667253|NCT01719835|Drug|Vincristine|1.4mg/m2 (max 2mg) IV every 21 days
1667254|NCT01719835|Drug|Prednisolone|40mg/m2 oral Days 1-5 every 21 days
1667255|NCT01719835|Drug|methylprednisolone|1000mg oral or IV Days 1-5 every 28 days
1667256|NCT01719835|Drug|Cisplatin|100mg/m2 IV Day 15 every 28 days
1667257|NCT01719822|Device|Yamax Digi-Walker CW-700|A pedometer with a daily step count target set by a physiotherapist.
1667258|NCT01719796|Procedure|Regional analgesia infusion|
1667259|NCT01719783|Biological|LAIV H5N2|2 doses provided intranasally
1667260|NCT01719783|Other|Intransal placebo|2 doses of placebo provided intranasally
1667261|NCT01719770|Drug|rocuronium|continuous application of rocuronium 0,25mg/kg/h (blinded), in case of shivering episode bolus sodium-chloride (blinded)
1667262|NCT01719770|Other|placebo|continuous infusion of sodium-chloride (blinded), in case of shivering episode application of rocuronium 0,25mg/kg (blinded)
1667263|NCT01719757|Drug|Oxycodone/Naloxone|Twice daily
1667265|NCT01719731|Behavioral|Education|This group will receive the psychoeducation
1667266|NCT01719731|Behavioral|Non-Education|This group will not receive the psychoeducation
1667267|NCT01719718|Procedure|Closure of hernia defect.|Laparoscopic ventral hernia repair with closure of the hernia defect (mesh augmentation technique).
1667268|NCT01719718|Procedure|No closure of the hernia defect.|Conventional laparoscopic ventral hernia repair without closure of the hernia defect (defect bridging technique).
1667269|NCT01719705|Drug|Placebo|Ninety minutes before surgery, the parturients receive two identical placebo capsules
1667270|NCT01719705|Drug|Pregabalin 300 mg group|Ninety minutes before surgery, the parturients receive two capsules of pregabalin 150 mg
1667271|NCT01719705|Drug|Pregabalin 150 mg group|Ninety minutes before surgery, the parturients receive one capsule of pregabalin 150 mg and one placebo capsule
1667272|NCT01719692|Drug|Rituximab|
1667273|NCT01719679|Behavioral|School Located Vaccine (SLV) Program|A community vaccinator will administer vaccines to students whose parents consent for their child to participate
1667274|NCT01719666|Procedure|MPFL reconstruction and lateral retinaculum release|MPFL is performed with a standard technique using gracilis tendon. A tunnel is performed at the femoral part with a bioabsorbable screw fixation and 2 bundles with suture fixation at the patellar side
1667275|NCT01719666|Procedure|conventional surgery|conventional surgery: MPFL reconstruction
1667276|NCT01719653|Drug|MiraLAX|MiraLAX consumed as described in each arm.
1667277|NCT01719653|Other|Gatorade|Gatorade consumed as described in each arm.
1667278|NCT01719653|Drug|MoviPrep|MoviPrep consumed as described in each arm.
1667279|NCT01719653|Drug|SUPREP|SUPREP consumed as described in each arm.
1667280|NCT01719640|Drug|infusion of UCMSCs|infusion of aUCMSCs at day 0, 7,14 and 21
1667281|NCT01719640|Drug|infusion BMMNCs|infusion of BMMNCs at day 0, 7,14 and 21
1667282|NCT01719640|Drug|insulin|intensive insulin care
1667283|NCT01719627|Drug|Maraviroc|Unique dose of Maraviroc 300mg
1667284|NCT01719627|Drug|TVD 300/200 QD|TVD 300/200 QD during 7 days
1667285|NCT01719627|Drug|Maraviroc|Unique dose of Maraviroc 600mg
1667286|NCT01719614|Drug|Metformin|Type=exact number, unit=mg, number=850, form=tablet, route=oral. Participants will receive single dose of metformin on Day 1 and Day 15.
1667287|NCT01719614|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet route=oral. Participants will receive 1 tablet of rilpivirine from Day 5 to Day 17.
1667288|NCT01719601|Drug|No intervention|This is an observational study. Immediate release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 25 mg, 50 mg or 100 mg every 4 to 6 hours depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
1667289|NCT01719588|Drug|No intervention|This is an observational study. Prolonged release tapentadol hydrochloride will be administered as per the recommended doses approved in Philippines. The recommended oral starting dose is 50 mg, 100 mg, 150 mg, 200 mg, or 250 mg every 12 hours, with or without food depending on the initial pain intensity and thereafter, the dose will be adjusted to maintain adequate analgesia with acceptable tolerability. The dosing regimen will be individualized according to the severity of pain being treated, the previous treatment experience, and the ability to monitor patients.
1667290|NCT01719575|Drug|Motilitone|
1667291|NCT01719575|Drug|Placebo|
1667292|NCT01719562|Procedure|magnetic resonance imaging|Undergo MRI scans
1667293|NCT01719549|Drug|Dovitinib|"Study treatment: TKI258 single agent on a 5 days-on/2 days-off schedule
Study drug: TKI258 capsule
Dose: 500mg p.o. qd
Every 3 weeks"
1667294|NCT01719536|Drug|Icotinib|Icotinib: 125 mg is administered orally three times per day.
1667295|NCT01719536|Drug|Chemotherapy|First-line chemotherapy: pemetrexed/cisplatin for 4 cycles. Maintenance treatment: pemetrexed.
1667296|NCT01719523|Drug|EPI-743|
1667384|NCT01718834|Biological|prophylactic peptide vaccine|synthetic peptide vaccine derived from HCV E1 and HCV E2 will be used for immunization of healthy volunteers
1722802|NCT00004186|Drug|ifosfamide|
1667297|NCT01719510|Other|Samples|"At time of delivery we will performed vaginal swabs in two groups: women tested positive for GBS at 35-37 weeks and women with risk of neonatal infection.
For both groups:
one swab for GBS detection by real-time PCR
the second swab for GBS detection by conventional bacteriological techniques and sent to the bacteriology laboratory.
For all women included will be achieved in the delivery room:
To the mother: A blood sample of 5 ml at the time of the implementation of the IV line.
A sampling of umbilical cord blood.
Newborns of mothers included (group 1 and 2) will have a search for GBS (standard culture) in the stools and the pharynx prior to return home.
For mothers, the collection of 3-5 ml of milk when breastfeeding."
1667298|NCT01719497|Drug|[C-11]OMAR|PET radioligand
1667299|NCT01719458|Drug|(S,S)-[11C]MRB|PET radioligand
1667300|NCT01719419|Drug|Placebo|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with placebo.
1667301|NCT01719419|Drug|Orlistat|Measured fatty food intake and appetite at a single lunch meal after the administration of modified sham feeding technique with orlistat.
1667302|NCT01719406|Behavioral|Intervention, behavioral lifestyle education|Twenty interactive weekly sessions that are scripted curriculum and peer led.
1667303|NCT01719380|Drug|LGX818|
1667304|NCT01719380|Drug|Cetuximab|
1667305|NCT01719380|Drug|BYL719|
1667306|NCT01719367|Drug|Atenolol|
1667307|NCT01719354|Other|Community Health center|Observation of the functioning and coordination of health care before discharge to own home.
1667308|NCT01719354|Other|Control|standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
1667309|NCT01719328|Behavioral|Vinyasa yoga|
1667310|NCT01719315|Other|Acoustical slow wave induction|Brief tones (50 millisecond duration) at a frequency of 0.8 and 2 Hz, a rate that approximates the natural cellular oscillations of cortical neurons during sleep, will be played in blocks of 15-20 during non-rapid eye movement (NREM) sleep. Blocks of active acoustic slow wave induction will be followed by blocks of equal duration without induction, in order to make comparisons between stimulation periods (ON) and no stimulation periods (OFF). Tone intensity will be manually adjusted so as to be above an individual participant's auditory threshold during waking, but still quiet enough as not to awaken the subject from sleep. Sham slow wave induction will consist of auditory tones played prior to sleep, and during sleep of insufficient timing and intensity to alter slow wave activity.
1954949|NCT03310138|Device|Real Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a minimally invasive brain stimulation technology that can focally stimulate the brain of an awake individual. A localized pulsed magnetic field transmitted through a figure-8 coil (lasting only microseconds) is able to focally stimulate the cortex by depolarizing superficial neurons, which induces electrical currents in the brain. TMS pulses that are delivered repetitively and rhythmically are referred to as repetitive TMS (rTMS). In this study TMS is being delivered with the MagVenture MagPro B60 coil.
1667314|NCT01719289|Behavioral|PROGRAVIDA|Women in the intervention group receive a program based on psycho-education and problem solving techniques, delivered by a nurse assistant at the women's homes. The program comprises 8 sessions, 6 during pregnancy and 2 after delivery. Intensity of depressive symptoms is assessed using the PHQ-9, at the beginning of the sessions. Women with severe depression are referred to the family doctor and are assessed for the need of antidepressant medication.
1667315|NCT01719276|Other|Graded Activity|The graded activity program to increase activity tolerance by performing individualized and submaximal exercises.
1667316|NCT01719276|Other|Supervised Exercises|The group will perform stretching exercises (gluteus maximus, hamstrings, triceps surae, lumbar paraspinal), strengthening muscles (rectus abdominus, obliques and lower rectus abdominis internal and external) and motor control exercises (muscle transversus abdominis and lumbar multifidus.
1667317|NCT01719263|Device|InterVapor® treatment plus Optimal Medical Therapy|Patients will be treated with the InterVapor System in 1 to 2 segments in the upper lobes of each lung (2 to 3 segments total). Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
1667318|NCT01719263|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema are published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
1667319|NCT01719250|Drug|Buparlisib|Given PO
1667320|NCT01719250|Other|Laboratory Biomarker Analysis|Correlative studies
1667321|NCT01719250|Other|Questionnaire Administration|Ancillary studies
1667322|NCT01719237|Drug|Ropivacine and Chloroprocaine mixture|Chloroprocaine is added to Ropivacaine
1667323|NCT01719237|Drug|Ropivacaine only|Ropivacaine diluted with normal saline instead of chloroprocaine
1667326|NCT01719185|Drug|Phentermine and B12|
1667327|NCT01719185|Drug|Phentermine|
1667328|NCT01719172|Device|Veriset™ Hemostatic Patch|Topical Hemostat
1667329|NCT01719159|Drug|Rituximab|25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
1667331|NCT01719133|Drug|placebo|saline solution
1667332|NCT01719133|Drug|Histamine|positive control
1667333|NCT01719133|Drug|AllerT1|synthetic peptide T1
1667334|NCT01719133|Drug|AllerT2|synthetic peptide T2
1667335|NCT01719133|Drug|AllerT3|synthetic peptide T3
1667336|NCT01719133|Drug|AllerT4|synthetic peptide T4
1667337|NCT01719133|Drug|AllerT5|synthetic peptide T5
1667338|NCT01719133|Drug|mix of AllerT1-T2-T3|mix of peptides T1, T2 and T3
1667339|NCT01719133|Drug|mix of AllerT4-T5|mix T4-T5
1667385|NCT01718834|Biological|therapeutic peptide vaccine|therapeutic peptide vaccine will immunize to HCV chronic HCV patients non responders to INF
1667481|NCT01718119|Drug|r-hCG|r-hCG(250mcg) injection subcutaneously
1667340|NCT01719120|Behavioral|Cognitive-Behavioral Therapy|CBT for insomnia aims at changing dysfunctional cognitive beliefs and maladaptive behaviors contributed to the maintenance of insomnia. It involves 4 main components including behavioral, cognitive, educational, and relaxation treatments.
1667341|NCT01719107|Dietary Supplement|L. reuteri DSM 17938 chewable tablets|2 chewable tablets with breakfast for 4 weeks
1667342|NCT01719107|Dietary Supplement|Placebo chewable tablets|2 chewable tablets with breakfast for 4 weeks
1667343|NCT01719081|Procedure|Sacroiliac Joint Injection|Medication injected into the sacroiliac joint: Bupivicaine 3ml 0.25% with epinephrine 1/200,000 and Depo-Medrol 40mg.
1667344|NCT01719055|Device|neurostimulation system|Trial stimulation period, followed by permanent implant of a neurostimulation system for subjects with a positive trial outcome
1667345|NCT01719042|Drug|Zofran (8mg)|Subject will take 8mg of Zofran before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
1667346|NCT01719042|Dietary Supplement|Ensure|Subject will drink one cam of Ensure before taking antibiotic regimen and will record symptoms in a diary just before taking medication and two hours after taking medication every day for two weeks
1667347|NCT01719029|Other|Low-Carbohydrate/Higher Fat Diet|
1667348|NCT01719029|Other|High Carbohydrate/Low fat diet|
1667349|NCT01719016|Procedure|Cardiac PET, Coronary catheterization|"Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:
N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress
Lexiscan - stress agent for PET scan
Patients would also undergo Coronary catheterization including the following drug administration and device usage:
Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).
Adenosine - stress agent during catheterization, 140 ug/Kg/min"
1667350|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
1667351|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
1667352|NCT01719003|Drug|Empagliflozin low dose qd|Empagliflozin low dose once daily
1667353|NCT01719003|Drug|Empagliflozin high dose qd|Empagliflozin high dose once daily
1667354|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
1667355|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
1667356|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
1667357|NCT01719003|Drug|Empagliflozin low dose bid|Empagliflozin low dose split twice daily
1667358|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
1667359|NCT01719003|Drug|Metformin 500 mg bid|Metformin 500 mg twice daily
1667360|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
1667361|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
1667362|NCT01719003|Drug|Metformin 1000 mg bid|Metformin 1000 mg twice daily
1667363|NCT01719003|Drug|Empagliflozin high dose bid|Empagliflozin high dose split twice daily
1667364|NCT01718977|Other|Body Weight Supported Treadmill Training|BWSTT protocol will consist of training of individuals with complete SCI on a treadmill with a body weight support system. BWSTT is assisted by three individuals who participate in training. One trainer provides support at the hip, and one trainer at each leg. The participant will be fitted with a harness while seated in their wheelchair and then wheeled up a ramp to the treadmill. Cables attached to the harness will be used to hoist the participant into a standing position. Appropriate body weight support will be set according to the suggested Hocoma locomotor training protocol, in which weight is added until the participant is in dynamic support as indicated by the dynamic gauge on the treadmill. Dynamic support is usually indicated at the weight where participants do not have knee-buckling during a static standing position; however, this may not be observed in all severe, motor-complete SCI participants.
1667365|NCT01718977|Other|Arm Cycle Ergometry Training|"Arm Cycle Ergometry Training ACET will be performed on an arm-cycle ergometer against individually determined levels of resistance. Upright hand cuffs will be used so that the hand will be placed with the thumb pointing downward, and the ergometer will be positioned so that the arm never exceeded the height of the shoulder.
The end objective is for the individual to complete 30-minutes of exercise in 2, 15-minute bouts. For safety reasons, stop criteria for individual sessions will be set and participants will have a rest period of 5 minutes and afterwards asked if they want to stop exercise, or resume the session."
1667366|NCT01718964|Drug|Cortisol 20 mg|
1667367|NCT01718964|Drug|Mannitol|Mannitol used as placebo
1667368|NCT01718951|Drug|golimumab|golimumab
1667369|NCT01718951|Drug|Pamidronate|pamidronate
1667370|NCT01718938|Drug|velusetrag dose 1|
1667371|NCT01718938|Drug|velusetrag dose 2|
1667372|NCT01718938|Drug|velusetrag dose 3|
1667373|NCT01718938|Drug|placebo|
1667374|NCT01718912|Drug|metronidazole-nystatin oral rinse|
1667375|NCT01718899|Biological|PVX-410|Approximately 10 patients will receive 6, bi-weekly, subcutaneous injections of a dose of PVX-410 in combination with an intramuscular injection of Hiltonol (Poly ICLC). Patients will complete a 12 week treatment phase and then will be followed for safety, immunogenicity and clinical response for 12 months
1667376|NCT01718886|Device|Obalon Gastric Balloon|
1667377|NCT01718873|Drug|Bevacizumab|5 mg/kg every 2 weeks for up to 24 weeks. After 24 weeks, those patients without disease progression will receive bevacizumab 7.5 mg/kg every 3 weeks until progression of disease or unacceptable toxicity.
1667378|NCT01718873|Drug|Oxaliplatin|85mg/m2 IV every 2 weeks for up to 24 weeks
1667379|NCT01718873|Drug|levo-folinic acid|200 mg/m2 IV before 5-fluorouracil infusion, every 2 weeks up to 24 weeks
1667380|NCT01718873|Drug|5-fluorouracil|400 mg/m2 IV bolus followed by 2400 mg/m2 IV infusion over 46 hours, every 2 weeks for up to 24 weeks (given in mFOLFOX-6 schedule)
1667381|NCT01718873|Drug|Capecitabine|1000mg/m2 by mouth, twice a day for 10 days, every 2 weeks for up to 24 weeks(given in mOXXEL schedule)
1667382|NCT01718860|Procedure|Quantitative measurement of neuromuscular transmission|Quantitative measurement of neuromuscular transmission with train-of-four watches.
1667383|NCT01718847|Drug|NOV120101 (Poziotinib)|16 mg PO once daily until disease progression or unacceptable toxicity development
1667473|NCT01718158|Drug|Ribavirin|
1667474|NCT01718158|Drug|Daclatasvir|
1667386|NCT01718808|Drug|Cetuximab|Cetuximab 500 mg/m2 every second week (days 1, 15, 29, etc.) until progression or unacceptable toxicity
1667387|NCT01718808|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid p.o. (750 mg/m2 if creatinine clearance 30-50 ml/min according to Cockroft-Gault formula, on days 1-14 every 3 weeks, restart on day 22
1667388|NCT01718795|Device|Bag-valve mask or laryngeal tube ventilation|"Interventions are either Bag-valve mask (BVM) or Laryngeal tube (LT) ventilation during CPR"
1667389|NCT01718782|Device|laryngeal mask Ambu AuraOnce|airway management and mechanical ventilation with laryngeal mask
1667390|NCT01718782|Device|laryngeal mask LMA Supreme|airway management and mechanical ventilation with laryngeal mask
1667391|NCT01718769|Other|questionnaire STAMP|Children will undergo an assessment using the STAMP Tool; a questionnaire including 3 questions with a summary score, according to which the nutritional risk level shall be determined. These children shall also undergo a complete dietician assessment in order to examine the validity of the STAMP Tool.
1667392|NCT01718756|Drug|Placebo|The placebo group received 12 hourly 20-mL i.v. boluses of 0.9% saline starting 20 min before induction of anaesthesia, followed by a constant infusion at 10 mL/h, for 48 hrs after surgery.
1667393|NCT01718756|Drug|Continuous infusion|"The continuous infusion group received 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a 12 hourly 20-mL i.v. boluses of 0.9% saline and a constant infusion at 10 mL/h of lornoxicam 0.13 mg/mL, for 48 hrs. after surgery"
1667394|NCT01718756|Drug|Scheduled|"The scheduled group received an 12 hourly 20-mL i.v. boluses of lornoxicam 0.8 mg/mL starting 20 min before induction of anaesthesia followed by a constant infusion at 10 mL/h of 0.9% saline, for 48 hrs after surgery (supplied by Xefo, JPI, Saudi Arabia), starting 20 min before induction of anaesthesia."
1667395|NCT01718743|Drug|Lenalidomide|Starting dose: 10 mg by mouth every day in a 28 day cycle.
1667396|NCT01718743|Drug|MLN9708|3 mg by mouth on days 1, 8, 15 in a 28 day cycle.
1667397|NCT01718743|Radiation|Questionnaires|Questionnaire completion on Day 1 of Cycle 1, 2 and beyond.
1667400|NCT01718717|Other|Thoracic Epidural Analgesia (TEA)|
1667401|NCT01718717|Other|TEA followed by Intravenous morphine|
1667402|NCT01718704|Device|Viberect device|Men who begin using the Viberect device 3 days after Foley catheter removal on a daily (or at least 4 times a week) basis for 7-10 minutes in a relaxed setting with sexual thoughts or foreplay for one year. Viberect method can be performed by the person's sexual partner.
1667403|NCT01718691|Drug|SyB L-0501|A dose of 90 mg/m^2/day of SyB L-0501 is administered on Day 1 and Day 2 as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times.
1667404|NCT01718691|Drug|rituximab|A dose of 375 mg/m^2 of rituximab is administered on Day 1 (Day 0 in Cycle 1 only) as an IV drip infusion, followed by 26-day observation. This is 1 cycle (28 days), which will be repeated for a maximum of 6 times. From Cycle 2, rituximab will be coadministered with SyB L-0501 on Day 1. However, if the investigator or sub-investigator judges that the coadministration is difficult, rituximab may be administered on Day 0.
1667405|NCT01718678|Drug|Melatonin|it is kind of drug
1667406|NCT01718678|Drug|Placebo|It is Placebo
1667407|NCT01718652|Drug|Canagliflozin (JNJ-28431754)|One 300 mg capsule-shaped tablet taken orally (by mouth) on Days 1 through 8.
1667408|NCT01718652|Drug|Cyclosporine|Four 100 mg capsules (400 mg total dose) taken orally 30 minutes before the last dose of canagliflozin (JNJ-28431754) on Day 8.
1667409|NCT01718639|Device|IQP-LH-101 tablet|Oral medical device in the form of a chewable tablet
1667410|NCT01718639|Device|IQP-LH-101 liquid|Oral medical device in the form of a liquid
1667411|NCT01718639|Other|Placebo|
1667412|NCT01718626|Drug|S1+Docetaxel|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks, Patients will receive S1+Docetaxel until progression
1667413|NCT01718626|Drug|S1+Docetaxel followed by S1|Drug: S1 40-60mg, bid, days1-14, every 3 weeks Docetaxel 50mg/m2, day1, every 3 weeks,for 4 cycles; S1 40-60mg, bid, days1-14, every 3 weeks Patients will receive S1+Docetaxel followed by S1 until progression
1667414|NCT01718613|Drug|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
1667415|NCT01718613|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
1667416|NCT01718600|Behavioral|Neuropsychological testing|
1667417|NCT01718587|Procedure|stem cell transplantation through interventional procedure|interventional procedure once
1667418|NCT01718587|Drug|antiviral therapy (lamivudine, other antiviral drugs)|lamivudine, 100 mg per day (oral dose); or adefovir dipivoxil 10 mg per day (oral dose); or grace entecavir 0.5-1mg per day (oral dose); or behalftelbivudine 600 mg per day (oral dose).
1667419|NCT01718574|Other|Self-help book|Participants have 6 weeks to complete a 12 chapter self-help workbook. The workbook addresses: (i) The enhancement of a sense of personal control; and (ii) The learning of emotional and instrumental coping responses
1667420|NCT01718561|Procedure|SARI|The use of Modified Simplified Airway Risk Index (SARI) as preoperative airway assessment and assessment of risk factor for difficult mask ventilation. Registration in Danish Anesthesia Database
1667421|NCT01718548|Dietary Supplement|Cordyceps Sinensis (CS) and Lingzhi|
1667422|NCT01718548|Dietary Supplement|Tea and Flour|Placebo
1667423|NCT01718535|Device|Spartan FRX CYP2C19 Test System|
1667424|NCT01718509|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
1667425|NCT01718509|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
1667426|NCT01718496|Drug|Morphine|patient with advanced COPD will randomly receive single dose Morphine to assess its effect on dyspnea and exercise tolerance
1667427|NCT01718496|Drug|Placebo|patients with advanced COPD on the other study arm will randomly receive Placebo
1667475|NCT01718158|Drug|Telaprevir|
1667476|NCT01718145|Drug|Daclatasvir|
1667428|NCT01718483|Drug|SPD489 (Lisdexamfetamine dimesylate)|50 or 70 mg administered orally, once-daily for up to 12 weeks
1667429|NCT01718483|Drug|Placebo|Administered once-daily, orally, for up to 12 weeks
1667430|NCT01718470|Procedure|Endotracheal tube|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before awakening (ETT group) and 1, 5, 10, 15, 30 and 60 min after extubation . The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
1667431|NCT01718470|Procedure|LMA|Hemodynamic variables were recorded at 8 moments: baseline, in the operating room one minute before anesthetic induction; 5 minutes after the end of surgery before tube replacement (LMA group); and 1, 5, 10, 15, 30 and 60 min after LMA removal. The last blood pressure and heart rate measurements were taken in the postoperative recovery room.
1667432|NCT01718457|Device|Endobarrier|
1667433|NCT01718444|Drug|Progestin|
1667434|NCT01718444|Drug|Clomiphene Citrate|
1667435|NCT01718431|Other|test meal|
1667436|NCT01718431|Other|reference meal|
1667437|NCT01718418|Other|test meal|
1667438|NCT01718418|Other|reference|
1667439|NCT01718405|Other|Cognitive function after exercise test|The individual subjects will participate in 3 sessions of either aerobic exercise, resistance exercise or rest, in a random order. Before and after each session, the subject will take computerized cognitive tests.
1667440|NCT01718405|Genetic|Blood sample analysis|In the first evaluation session blood samples will be taken from each subject and will be analysed for genetic polymorphism.
1667441|NCT01718392|Behavioral|Training|
1667442|NCT01718379|Drug|Lenalidomide|Lenalidomide:10 mg per day during 21 days
1667443|NCT01718379|Drug|Epoetin beta|Epoetin beta: 60,000 Units/week.
1667444|NCT01718366|Drug|Deferasirox, Vitamin D and Azacitidine|association of Deferasirox (group 1: 5-10-15/mg/kg/day according to dose level group), Vitamine D (100000U/week) and Azacitidine (75 mg/kg/day day1-day7)
1954950|NCT03310138|Device|Sham Transcranial Magnetic Stimulation|The MagVenture MagPro system has an integrated active sham that passes current through two surface electrodes placed on the skin beneath the B60 coil.
1954951|NCT03310125|Drug|Colchicine|0.5mg tablet, twice daily for 10 days
1954952|NCT03310125|Drug|Placebo|Placebo oral tablet, twice daily for 10 days
1667448|NCT01718340|Drug|Metformin|metformin tablet 500mg three time per day
1667449|NCT01718327|Drug|Sunitinib|sunitinib dose :37.5mg/day
1667450|NCT01718314|Drug|Sublingual Misoprostol|
1667451|NCT01718314|Drug|Lidocaine pump spray|
1667452|NCT01718314|Drug|Placebo (for Misoprostol)|Lactose filler, the pharmacy-produced pills identical to original misoprostol pill
1667453|NCT01718314|Drug|Placebo (for Lidocaine)|The pharmacy-produced sterile saline containing pump spray external characteristics identical to lidocaine pump spray
1667458|NCT01718288|Drug|iloprost|"The study, consists of two substudies, which deal with patients susceptible to medical therapy alone (substudy 1) or treated with classical surgical therapy (substudy 2).
For each substudy, pts will be divided into two groups, one that will receive conventional treatments but not prostanoids, other conventional treatments with addition of iloprost.
The 4 groups:
1A. Pts unsuitable to surgical or endovascular vascular therapy: conventional treatment
B. Pts unsuitable to surgical or endovascular vascular therapy: treatment with iloprost plus conventional treatment
A. Pts suitable to vascular surgical or endovascular therapy: conventional treatment
2B. Pts suitable to vascular surgical or endovascular therapy: treatment with iloprost plus conventional treatment"
1667459|NCT01718288|Drug|Standard Treatment (aspirin.....),|"The standard treatment, as has already been explained in the submission is the best treatment that the guidelines suggest for that specific type of patient with those complications and with stage 2b severe PAD.
correction of concomitant risk factors, physical exercise, antiplatelet, standard heparin /low molecular weight heparin, hemorheological/vasodilators such as pentoxifylline/buflomedil, propionyl-L-carnitine, Defibrotide) but not prostanoids"
1667460|NCT01718249|Other|Implantable neurostimulation system|
1667461|NCT01718236|Drug|Rocuronium + sugammadex|Administration of rocuronium 1 mg/kg, intubation at decrease in Single Twitch to 10% of baseline event. by the disappearance of visible spikes event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, neuromuscular blockade TOF count at 1-2.At the end of operation at PTC 1-2 sugammadex 4 mg/kg, at the TOF count 1-2, sugammadex 2 mg/kg, in the case of failure to achieve these values the anesthesiologist will wait until the minimum value of PTC 1-2 will be achieved. In can not intubate can not ventilate, and the failure of the introduction of laryngeal masks sugammadex 16mg/kg, immediately following the discovery of this fact and wait for the recovery of muscle strength. Time to recovery is recorded.
1667462|NCT01718236|Drug|Succinylcholine + Neostigmine|1mg/kg succinylcholine iodide, intubation after decrease in Single Twitch to 10% of baseline event. after the disappearance of visible fasciculation event. in the 60th seconds after administration of muscle relaxants. Anesthesia with sevoflurane according to the MAC, at the moment of 20-30% of the original value of Single Twitch rocuronium 0.3 mg / kg, maintaining TOF Count at 1-2.At the end of operation at TOF Count 1-2 atropine 0.01 mg/kg and neostigmine 0.03 mg/kg. If TOF not 1-2 wait.In can not intubate can not ventilate, wait for the spontaneous recovery. Time to recovery of muscle strength is recorded.
1667463|NCT01718223|Drug|photodynamic therapy|Undergo interstitial photodynamic therapy using temoporfin
1667464|NCT01718223|Procedure|therapeutic conventional surgery|Undergo surgical resection
1667465|NCT01718223|Other|laboratory biomarker analysis|Correlative studies
1667466|NCT01718223|Drug|temoporfin|Undergo interstitial photodynamic therapy using temoporfin
1667467|NCT01718210|Drug|GM-CSF medium|incubation of IVF embryos with a specific medium containing GM-CSF
1667468|NCT01718210|Drug|CONTROL|group of controls treated with a standard IVF medium
1667469|NCT01718184|Procedure|toric intraocular lens implantation|piggyback Sulcolflex toric intraocular lens implantation
1667470|NCT01718184|Procedure|Sulcoflex intraocular lens implantation|
1667471|NCT01718158|Biological|Peginterferon Lambda-1a|
1667472|NCT01718158|Biological|Peginterferon Alfa-2a|
1667482|NCT01718106|Device|implantation of a bioabsorbable polymer DES|implantation in patients with long coronary artery stenosis of a single long or two shorter overlapped bioabsorbable polymer DES
1667483|NCT01718093|Drug|Sitagliptin|up to 50 mg twice a day
1667484|NCT01718093|Drug|Metformin|up to 1000 mg twice a day
1667485|NCT01718093|Drug|Sitagliptin + Metformin|up to 50/1000 mg twice a day
1667486|NCT01718067|Device|VAKÜM system|15 minutes, twice a day.
1667487|NCT01718067|Other|conventional manual ELTGOL technique|20 minutes twice a day
1667488|NCT01718054|Dietary Supplement|Vascular ready-to-use supplementary food|Daily vascular ready-to-use supplementary food containing protein, energy and fortified with 1 x recommended daily allowance(RDA) of vitamins and minerals except for folic acid = 1mg and with no iron fortificant included and fortified with arginine and citrulline amino acids
1667489|NCT01718054|Dietary Supplement|Regular Ready-to-use supplementary food|Daily ready-to-use supplementary food containing protein, energy and fortified with 1 x RDA vitamins and minerals except for folic acid = 1mg and with no iron fortificant included.
1667490|NCT01718054|Drug|Chloroquine|
1667491|NCT01718041|Drug|Experimental: VRS-317|Active treatment arm
1667492|NCT01718028|Other|Propylene glycol 0.6% ocular emulsion|
1667493|NCT01718028|Other|Sodium chloride 0.9% saline solution|
1667494|NCT01718002|Behavioral|Educational video|The patient was asked to execute the technique used daily oral hygiene that, with the sequence, movements and technical procedures for its implementation evaluated and recorded an instrument to analyze the steps of oral hygiene. Subsequently, patients watched the video prepared individually in the ward where they were interned. After this step, the patient demonstrated again the procedure for oral hygiene. At this point the researcher also observed the sequence, movements and technical procedures used to analyze the steps of oral hygiene, using the same instrument for such employee initially.
1667495|NCT01717976|Behavioral|DISPO ED|primary care based nurse telephone support
1667496|NCT01717963|Drug|Naltrexone intramuscular suspension|A standard dosage of 380 mg / month of naltrexone intramuscular suspension will be administered
1667497|NCT01717963|Drug|Buprenorphine-naloxone|Buprenorphine-naloxone is administered daily and provided in accordance with existing guidelines for OMT in Norway (treatment-as-usual).
1667498|NCT01717950|Biological|Na-APR-1 (M74)/Alhydrogel®|The Na-APR-1 (M74) candidate vaccine contains the recombinant Na-APR-1 (M74) protein expressed by Nicotiana plants. Purified Na-APR-1 (M74) was subsequently adsorbed onto aluminum hydroxide gel (Alhydrogel®) and suspended in a solution containing 10 mM imidazole, 150 mM sodium chloride and 0.3% Empigen BB, with pH 7.4 ± 0.1. The final concentration of Na-APR-1 (M74) in the drug product is 0.1 mg/ml, whereas that of Alhydrogel® is 0.8 mg/ml. Different doses of Na-APR-1 (M74) will be delivered by injecting different volumes of the 0.1 mg/ml Na-APR-1 (M74) preparation.
1667499|NCT01717950|Biological|Gluco-Pyranosylphospho-Lipid A Aqueous Formulation|GLA-AF contains a synthetic monophosphoryl lipid A (MPL) molecule that has Toll-Like Receptor-4 agonist activity. MPL is itself derived from the lipopolysaccharide (LPS) of Salmonella minnesota, a natural TLR4 agonist that is pyrogenic and can induce toxic shock. LPS, and more specifically, its lipid A component, has long been known for its strong adjuvant effects; however, its high toxicity has precluded its use in a vaccine formulation.
1667500|NCT01717937|Procedure|Phase variance optical coherence tomography (PV-OCT)|Subjects will undergo standard, noninvasive optical coherence tomography (OCT) scans with an FDA-approved OCT device, and the data gathered by this device will be transferred to a separate computer for processing using novel software. This software is capable of utilizing the existing data to generate phase variance OCT images. There are no known risks associated with OCT scans.
1667501|NCT01717924|Procedure|peri-operative chemotherapy|Usual treatment strategy for gastric adenocarcinoma
1667502|NCT01717924|Procedure|Surgery first|strategy with a surgical procedure first, without the usual peri-operative chemotherapy
1667503|NCT01717911|Drug|Insulin|In the insulin therapy group (Humulin-N), subjects were instructed in the techniques for insulin injection and home capillary glucose monitoring. Two third daily dose was administrated before breakfast and one third at bedtime. Insulin doses were titrated every 3 days to achieve target fasting plasma glucose values between 90 and 130 mg/dl.
1667504|NCT01717911|Drug|Metformin|The titration of metformin was used 500 mg for an adjust unit in splitting dose with the same target to the maximum daily dose of 2550 mg (1000 mg twice daily and then 850 mg tid).
1667505|NCT01717911|Drug|Sitagliptin|The subjects treated with sitagliptin started with 100 mg before breakfast once daily. The dosage was fixed as 100mg per day. Decreased by 50mg if fasting blood glucose was <70mg /dl, discontinued the study if blood glucose was still <70mg/dl under sitagliptin 50mg per day.
1667506|NCT01717898|Drug|BEZ235|BEZ235 - 200 mg, 300 mg, or 400 mg; po, BID. BEZ235 will be supplied in 200 mg, 300 mg, and 400 mg sachets packaged in boxes.
1667507|NCT01717898|Drug|Prednisone|10/mg po daily. Prednisone can be modified at the investigator's discretion, but should not be discontinued.
1667508|NCT01717898|Drug|Abiraterone acetate|1000 mg, po. Abiraterone Acetate is supplied in 250 mg white tablets, four tablets are to be taken with a full glass of water on an empty stomach once daily.
1667509|NCT01717872|Device|Laryngoscope blade|The POGO score will be used to assess the percent of the glottis that can be seen with each of the blades lifting and not lifting the epiglotis
1667510|NCT01717859|Drug|Tocilizumab|All subjects will start at 4mg/kg. After 3 months, if DAS28 > 3.2, dosage will be escalated to 8 mg/kg.
1667511|NCT01717846|Drug|Group 1 or Orencia treated group|Group 1 subjects will be given subcutaneous abatacept, 125 mg once a week upto 6 months.
1667512|NCT01717846|Other|Group 2 (DMARDS treated group)|Arm 2 or Group 2 is for RA patients who are being treated wth non-biologic DMARDS who, with their doctor, have decided that they will not be receiving treatment with Abatacept in the next six months. These patients will not receive the study drug abatacept.
1667513|NCT01717833|Procedure|NEMS|NEMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously
1667514|NCT01717833|Procedure|Sham|Sham sessions of neuromuscular electrical stimulation
1667515|NCT01717820|Dietary Supplement|Freeze-dried whole-grape powder|Participants are provided the equivalent of two servings per day of freeze-dried grape powder in a double-blind, placebo controlled, randomized design to determine the impact of the phytochemical, resveratrol, on biomarkers of adipose metabolism and bone metabolism.
1667516|NCT01717807|Other|C11-Erlotinib PET/CT|
1667517|NCT01717794|Procedure|Thunderbeat technology|
1667518|NCT01717794|Procedure|Standard bipolar electrosurgery|
1667519|NCT01717781|Procedure|Thunderbeat technology|
1667520|NCT01717781|Procedure|Standard bipolar electrosurgery|
1667521|NCT01717768|Drug|TSX-002|TSX-002 are capsules with testosterone as the active ingredient.
1667522|NCT01717755|Other|Intra-arterial treatment|IA therapy has to be initiated within 6 hours of estimated time of basilar artery occlusion. If an appropriate thrombus or residual stenosis is identified, the choice of IA strategy wil be made by the treating neurointerventionalist. Choice of therapy depends on local approval and experience. If IA thrombolysis is the chosen strategy, a maximum of 22 mg of IA rt-PA or 1.500.000 Units of Urokinase may be given. Stenting is allowed in the presence of a high-grade vertebral artery stenosis or occlusion hampering adequate endovascular access to the basilar artery and in case of a residual high-grade basilar artery stenosis. The use of any other treatment strategy depends on local approval and experience, and is only allowed after prior approval of the steering committee.
1667523|NCT01717742|Drug|tPA|Intrapleural administration of tPA 4 mg in 10 ml (≤10 kg) or 20 ml (>10 kg) normal saline once daily for 3 days
1667524|NCT01717742|Drug|DNase|Intrapleural administration of DNase 5 mg diluted to 10 ml (≤10 kg) or 20 ml (>10 kg) normal saline once daily for 3 days
1667525|NCT01717742|Other|Placebo|Intrapleural administration of normal saline 10 ml (≤10 kg) or 20 ml (>10 kg)
1667526|NCT01717729|Procedure|Radiofrequency Ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, Calif) and a needle electrode with a 15-gauge insulated cannula that had 10 hook-shaped expandable electrode tines with a diameter of 3.5 cm at expansion (LeVeen; Radio Therapeutics).The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi)
1667527|NCT01717729|Radiation|iodine|The 125I seeds (0.8 mm in diameter and 4.5mm in length) were enclosed in a NiTinol capsule (China Institute of Atomic Energy, Beijing). These seeds could produce 27.4-31.5 keV X-ray and 35.5 Kev γ ray, with a half-life of 59.6 days. The radioactivity per seed ranged from 0.5 to 0.6 millicuries (mCi).
1667528|NCT01717716|Dietary Supplement|water with Sucralose|
1667529|NCT01717716|Dietary Supplement|water with HFCS|
1667530|NCT01717716|Dietary Supplement|water with glucose|
1667531|NCT01717716|Dietary Supplement|water with sucrose|
1667532|NCT01717703|Dietary Supplement|Water|
1667533|NCT01717703|Dietary Supplement|Fruit drink|
1667534|NCT01717703|Dietary Supplement|Cola|
1667535|NCT01717703|Dietary Supplement|1% chocolate milk|
1667536|NCT01717690|Drug|CHG antiseptic body cleanser|The intervention consists of daily bathing of all patients (MRSA-positive and MRSA-negative) on the intervention unit with CHG.
1667537|NCT01717677|Procedure|radical prostatectomy|
1667538|NCT01717677|Radiation|percutaneous radiation therapy|
1667539|NCT01717677|Radiation|permanent seed implantation|
1667540|NCT01717677|Procedure|Active Surveillance|
1667541|NCT01717664|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
1667542|NCT01717638|Biological|1 dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, single dose
1667543|NCT01717638|Biological|2 doses of Meningococcal (group B) multicomponent recombinant adsorbed vaccine|0.5 mL of Meningococcal (group B) multicomponent recombinant adsorbed vaccine, Intramuscular, two doses, two months apart
1667544|NCT01717625|Drug|Montelukast|a leukotriene D4 receptor antagonist; sodium salt is the active compound; structure in first source
1667545|NCT01717612|Drug|Thrombin|Among the thrombin group, the injection site was also aimed at the bleeding varices or varices with red color signs or at the most prominent varices. The injected agents consisted of lyophilized human Thrombin in calcium chloride solution containing thrombin 500IU/ml). (Floseal, Baxter Healthcare Corporation, CA, Hayward, USA)
1667546|NCT01717612|Drug|Histoacryl|The injection site was aimed at the bleeding varices or varices with red color signs or at the most prominent varices.
1667547|NCT01717599|Drug|Diclofenac|Diclofenac 90mg, 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
1667548|NCT01717599|Drug|normal saline|normal saline 2ml/A, IM(intramuscular) injection immediately after procedure of ERCP
1667549|NCT01717586|Drug|Pravastatin|Comparison of different drug dosages. Women will be instructed to take a pravastatin pill everyday starting the day of randomization and ending the day of delivery. The women will be divided into two cohorts. Each cohort will receive one of the following doses of pills: 10mg or 20mg.
1667550|NCT01717586|Drug|Placebo|Women will be instructed to take a placebo pill daily beginning the day of randomization and ending the day of delivery.
1667551|NCT01717573|Procedure|Deferred stenting|
1667552|NCT01717573|Procedure|Conventional treatment|
1667553|NCT01717560|Other|Collaborative, multidisciplinary, integrated care|"Collaborative, multidisciplinary, integrated care for hepatitis C
multidisciplinary model that combines expert care in five domains: (a) antiviral pharmacotherapy for HCV infection; (b) substance abuse treatment; (c) psychiatric evaluation and treatment; (d) primary medical care; and (e) intensive, client-centered, case management."
1667554|NCT01717547|Behavioral|Yoga-based treatment|
1667555|NCT01717534|Dietary Supplement|heat-treated lactobacilli or placebo|Daily supplement of sachet with 1 g of powder over a 5 months period.
1667556|NCT01717508|Behavioral|Cognitive Behavioral Therapy|12 sessions of cognitive behavioral therapy
1667557|NCT01717482|Drug|Metformin|
1667558|NCT01717482|Other|Placebo Comparator|Standard of Care Observation
1667559|NCT01717469|Device|Left ventricular pacing through coronary sinus tributaries (Attain StarFix)|Left ventricular pacing in patients with bradycardia
1667560|NCT01717469|Device|Right ventricular pacing (Medtronic)|Conventional right ventricular pacing in patients with bradycardia.
1667561|NCT01717456|Other|Education|Patient and caregiver will be taught which muscles are used in continence and defecation through the use of a training manual and anatomical drawings.
1667601|NCT01717157|Drug|Treatment A: DUROGESIC (8.4 mg fentanyl)|One DUROGESIC transdermal patch containing 8.4 mg of fentanyl applied on the skin for 72 hours.
1667562|NCT01717456|Dietary Supplement|Fiber supplements|Patients and caregivers will be taught to use fiber supplements to normalize stool consistency if patient reports diarrhea or constipation. Fiber supplements will be in the form of Metamucil beginning with 3.4 grams per day and increasing up to 13.6 grams per day if needed to control stool consistency.
1667563|NCT01717456|Drug|Laxatives or anti-diarrheals|"Miralax at a dose of one packet (17 grams) daily may be used for constipation if unresponsive to fiber. Dose may be titrated up to two packets (34 grams) daily if needed.
Imodium at a starting dose of 2 mg/day may be used for diarrhea if unresponsive to fiber. Dose of Imodium may be titrated down to 1 mg or up to 4 mg if needed."
1667564|NCT01717456|Behavioral|Pelvic floor muscle exercises|Patients will be taught how to perform pelvic floor muscle contractions during digital rectal examination by a nurse. They will be asked to squeeze 100 times daily.
1667565|NCT01717456|Behavioral|Tips on how to prevent fecal incontinence|"Examples of behavioral tips are Walk, don't run to the toilet and Squeeze before you lift objects or sneeze."
1667566|NCT01717456|Behavioral|Daily diary|Both groups will keep a daily diary, but amount of detail differs: Active comparator group records bowel accidents, bowel movements, Bristol Stool ratings of stool consistency, number of times they do pelvic floor exercises, study medications, and comments for the nurse to read. Placebo comparator group records only bowel accidents, bowel movements, and Bristol Stool scores.
1667567|NCT01717456|Other|Protective pads or garments|In both groups, patients will be permitted to use pads or protective garments to avoid embarrassment. They will be told that fecal leakage that is stopped by a pad or protective garment should still be recorded as fecal incontinence.
1667568|NCT01717404|Drug|Mexiletine|6-day treatment period during which the medication will be taken orally with an initial dose of: 200 mg every 8 hours for 3 doses on day 3, increasing to 300 mg every 8 hours on days 4 and 5 (6 doses), and increasing further to 400 mg every 8 hours on days 6-8 if no telemetry changes and no dose limiting side effects
1667569|NCT01717391|Drug|fluorothymidine F 18|A patient-specific bone marrow map will be designed from the pre-therapy FLT PET/CT imaging. A highly conformal radiation plan will be designed to spare active bone marrow.
1667570|NCT01717352|Behavioral|Weight Loss Education|
1667571|NCT01717352|Behavioral|Sleep and Eating Routine|
1667572|NCT01717339|Other|Sleep Study|
1667573|NCT01717326|Drug|Grazoprevir|100 mg tablet orally QD
1667574|NCT01717326|Drug|Elbasvir|Part A: 20 or 50 mg capsule orally QD Parts B, C, and D: 50 mg capsule orally QD
1667575|NCT01717326|Drug|Placebo to Elbasvir|Placebo to Elbasvir 20 or 50 mg capsule, orally, once daily for 12 weeks to maintain blind (Part A only)
1667576|NCT01717326|Drug|Ribavirin|Oral capsules BID at a total daily dose from 800 to 1400 mg based on participant weight
1667577|NCT01717313|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week.
1667578|NCT01717313|Drug|Placebo to Omarigliptin|Placebo to omarigliptin capsule administered orally once a week
1667579|NCT01717313|Drug|Metformin|If necessary, participants may have glycemic rescue therapy initiated with open-label metformin during Phase A of the study. Participants in the placebo treatment group who were not rescued with open-label metformin during Phase A will receive blinded metformin (starting at 500 mg orally twice daily with up-titration to 1000 mg orally twice daily) in Phase B. Participants in the omarigliptin treatment group who were rescued with open-label metformin in Phase A will continue open-label metformin during Phase B of the study.
1667580|NCT01717313|Drug|Placebo to metformin|During Phase B of the study, participants in the omarigliptin treatment group who did not initiate glycemic rescue therapy during Phase A will receive placebo to metformin for 30 weeks (Phase B of the study).
1667581|NCT01717313|Drug|Glimepiride|If necessary during Phase B of the study, participants will initiate open-label glimepiride as glycemic rescue therapy
1667582|NCT01717300|Drug|Anacetrapib 100 mg|100 mg tablet, oral, once daily for 24 weeks
1667583|NCT01717300|Drug|Placebo for anacetrapib 100 mg|Placebo tablet, orally, once daily for 24 weeks
1667584|NCT01717300|Drug|Anacetrapib 25 mg|25 mg tablet, oral, once daily for 24 weeks
1667585|NCT01717300|Drug|Placebo for anacetrapib 25 mg|Placebo tablet, orally, once daily for 24 weeks
1667586|NCT01717287|Drug|Raltegravir Film-coated Tablet|
1667587|NCT01717287|Drug|Raltegravir Chewable Tablet|
1667588|NCT01717287|Drug|Other Anti-Retroviral Therapy|At baseline, the investigator selected the other anti-retroviral therapies to be used in combination with raltegravir based on current treatment guidelines, the participant's treatment history, and prior anti-retroviral resistance testing
1667589|NCT01717274|Procedure|Hot saline irrigation|The surgical field is flushed with 20 cc of hot saline (45-50 degrees Celsius) at five minutes intervals. This is in contrast to the standard of care, room temperature (20-25 degrees Celsius) saline irrigation.
1667590|NCT01717261|Radiation|Single Pre-Operative Radiation Therapy|Dose escalation: 3 patients will receive 15 Gy in a single fraction. The following 3 patients will receive 18 Gy. The final 4 patients will receive 20 Gy.
1667591|NCT01717248|Drug|GCS-100|GCS-100 is a modified citrus pectin that binds to and sequesteres circulating galectin-3, a protein that has been shown to promote organ disease (fibrosis).
1667592|NCT01717235|Drug|Ropinirole hydrochloride CR Tablets 2mg|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
1667593|NCT01717222|Drug|Intraperitoneal Lignocaine|Patients will receive 100 ml of 0.2% lignocaine
1667594|NCT01717222|Drug|Intravenous Lignocaine|Intravenous group patients will receive 1.5mg/kg of lignocaine as bolus dose at induction and 2mg/kg/hour as continuous infusion until one hour after surgery
1667597|NCT01717196|Other|different volume aspiration|comparison between diagnostic yield of FNA on solid pancreatic masses performed with different aspiration volume (10 and 20ml) and without aspiration.
1667598|NCT01717183|Device|Urgo 310 3113|URGO 310 3113 dressing may be changed every 2 to 4 days, and left in place for up to 7 days, depending on the level of exudate and the wound condition
1667599|NCT01717183|Device|Placebo URGO 310 3113 dressing|
1667600|NCT01717170|Drug|Tocilizumab|Tocilizumab (4 mg/kg or 8 mg/kg)
1668335|NCT01711489|Drug|Mycophenolate mofetil|oral
1667602|NCT01717157|Drug|Treatment B: Transdermal System-Concept 1 (6.2 mg fentanyl)|One transdermal system-concept 1 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
1667603|NCT01717157|Drug|Treatment C: Transdermal System-Concept 2 (6.2 mg fentanyl)|One transdermal system-concept 2 patch containing approximately 6.2 mg of fentanyl applied on the skin for 72 hours.
1667604|NCT01717157|Drug|Treatment D: Transdermal System-Concept 3 (7.1 mg fentanyl)|One transdermal system-concept 3 patch containing approximately 7.1 mg of fentanyl applied on the skin for 72 hours.
1667605|NCT01717157|Drug|Treatment E: Transdermal System-Concept 4 (11.0 mg fentanyl)|One transdermal system-concept 4 patch containing approximately 11.0 mg of fentanyl applied on the skin for 72 hours.
1667606|NCT01717144|Behavioral|therapeutic education program|The educational program consisted of both individual and collective educational consultations with a therapeutic education nurse
1667609|NCT01717118|Biological|Bivalent Vaccines|
1667610|NCT01717118|Biological|Tetravalent Vaccine|
1667611|NCT01717079|Procedure|Sham rTMS|120 pulses 0.2Hz
1667612|NCT01717079|Procedure|rTMS|120 pulses 0.2Hz
1667613|NCT01717066|Drug|the ginsenoside Rg3|
1667614|NCT01717066|Drug|Placebo|
1667615|NCT01717053|Drug|Abiraterone acetate|1000 mg orally once a day for 6 months.
1667616|NCT01717053|Drug|Androgen deprivation|LHRH analog (at discretion of treating physician) will be administered over 6 months (for example, leuprolide acetate 22.5mg IM or goserelin acetate 10.8mg SC given every 3 months for 2 doses).
1667617|NCT01717053|Radiation|Radiation Therapy|Daily (Monday-Friday) for 8 weeks, final dose of 75-80 Gy
1667618|NCT01717053|Drug|Prednisone|5 mg tablet once daily for 6 months.
1667619|NCT01717040|Drug|Pioglitazone|Pioglitazone will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
1667620|NCT01717040|Drug|Placebo|Placebo will be initiated at a starting daily dose of 15 mg. After 7 days, the dose may be increased to 30 mg and after 35 days may be increased to a maximum of 45 mg per day.
1667621|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose, taken whole and under fed conditions
1667622|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J, single dose, taken whole and under fed conditions
1667623|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation K, single dose, taken whole and under fed conditions
1667624|NCT01717027|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation J or K, single dose, chewed and under fasted conditions
1667625|NCT01717014|Device|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients already selected to undergo an open LAR or proctosigmoidectomy using the Radial Reload Stapler
1667626|NCT01716975|Drug|EVP-6124|Arms 1, 2
1667627|NCT01716975|Drug|Placebo|Arm 3
1667629|NCT01716949|Radiation|Radiotherapy|45 up to 50.4 Gy; daily dose 1,8 Gy, 5 days per weeks
1667630|NCT01716949|Procedure|Hyperthermia|10 sessions, therapeutic time 60 min
1667631|NCT01716949|Drug|5-Fluorouracil|250 mg/m^2/d as continuous i.v. infusion on d1-14, 22-35 (may be preplaced by Capecitabine)
1667632|NCT01716949|Drug|Capecitabine|1650 mg/m^2/d oral intake d1-14, 22-35 (may be replaced by 5-Fluorouracil)
1667633|NCT01716949|Drug|Oxaliplatin|50 mg/m^2/d as 2-hour bolus infusion on d2, 9, 23, 30
1667634|NCT01716923|Biological|S-303 Red Blood Cells (RBCs) - Test|
1667635|NCT01716923|Biological|Conventional, untreated red blood cells (RBCs) - Control|
1667636|NCT01716910|Dietary Supplement|Combination of Lactobacillus acidophilus NCFM and cellobiose|
1667637|NCT01716897|Drug|E2609|
1667638|NCT01716871|Device|neurocryostimulation with Duo-cryo® device|organized in the morning and in the evening during 3days. The gaz is sprayed with Duo-cryo® device on dry skin over the ankle using a slow, regular, sweeping movement. The tip of the nozzle is kept 15 to 20 cm away from the skin. Neurocryostimulation is applied to patients for a duration of one minute by a trained staff
1667639|NCT01716871|Device|cryotherapy with Cold pack® or ice-cubes pack|"Patients receive 2 controlled applications a day (one in the morning and one in the evening) of cryotherapy with Cold pack® or ice-cubes pack (with average dimensions of 5 cm by 8 cm) to the injury site for a duration of 20 minutes. Furthermore, the patients are instructed to do 2 more applications of the ice-pack during the daytime to follow the usual recommendations.
The first and last sessions of each day must be supervised by the medical care Unit to insure standardized data collection for each group."
1667640|NCT01716858|Dietary Supplement|Sulforaphane-rich Broccoli Sprout Extract|
1667641|NCT01716832|Behavioral|Mindfulness Walking|Mindful walking in a small group twice a week for 60 minutes within 4 weeks.
1667642|NCT01716819|Other|Urine sample|dosages on one spot and 24h collection
1667643|NCT01716819|Other|Blood sample|dosages
1667644|NCT01716819|Other|Assessment of sleep apnea syndrome|
1667645|NCT01716819|Other|Electrocardiogram|
1667646|NCT01716819|Other|Glucose tolerance test|
1667647|NCT01716819|Other|Echocardiography|
1667648|NCT01716819|Other|cardiac and abdominal magnetic resonance imaging|
1667649|NCT01716819|Other|Ambulatory blood pressure monitoring|
1667650|NCT01716819|Other|Echotracking|
1667651|NCT01716819|Other|Pulse wave velocity|
1667652|NCT01716819|Other|Composition of body mass by Dual x-ray absorptiometry|
1667657|NCT01716793|Drug|Ara-C|"Intermediate dose during induction phase to remission.
High-dose during consolidation phase in patients with favorable cytogenetics."
1667716|NCT01716325|Other|Conventional|Weight loss, comparator - no ICT support; conventional live workshops for weight loss
1667658|NCT01716793|Other|Autologous transplantation|"In patients with normal karyotype and one cycle of chemotherapy to achieve complete remission.
In patients with other cytogenetics without HLA-Identical sibling."
1667659|NCT01716793|Other|Allogeneic HLA-identical sibling transplantation|"Patients without favorable or normal karyotype(and one course to CR).
Patients with normal karyotype who need two cycles of chemotherapy to achieve CR, and other cytogenetics."
1667660|NCT01716793|Other|CD34+ selection|In allotransplants, it is performed a CD34+ cell selection of peripheral blood stem cell transplantation.
1667661|NCT01716780|Other|Intervention|"Patients allocated to the intervention group will undergo prospective, proactive, integrated, structured pain treatment according to recent guidelines on cancer pain care"
1667662|NCT01716767|Other|Menthol|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
1667663|NCT01716767|Other|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the hand, wrist and forearm
1667664|NCT01716754|Drug|QGE031|QGE031 was supplied as 120 mg liquid in vial per 1 mL
1667665|NCT01716754|Drug|Omalizumab|Omalizumab was supplied as 150 mg lyophilisate in vial
1667666|NCT01716754|Drug|Placebo|Placebo to QGE031 and Omalizumab was supplied as QGE031 0 mg in vial per 1 mL
1667667|NCT01716741|Other|Enzyme analysis|
1667668|NCT01716728|Other|enzyme analysis|
1667672|NCT01716702|Behavioral|Couples Prostate Cancer Support Group|"The participants in the experimental group will receive 6 weekly online intervention sessions with a professional facilitator. In addition participants will be asked to complete relationship-enhancement exercises and readings in between sessions.
In the experimental group, participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks).
In the waitlist group, participants will not participate in the support group. Participants will be asked to complete questionnaires at three time points: 1)pre-intervention (baseline) 2) post-intervention (7 weeks), and 3) post intervention (13 weeks)."
1667673|NCT01716689|Drug|oral cyclophosphamide|50mg daily
1667674|NCT01716676|Other|Telemedicine CPAP monitoring (webpage and televisit)|
1667675|NCT01716676|Other|Standard CPAP monitoring|
1667676|NCT01716663|Device|Catheter Ablation|NAVISTAR® THERMOCOOL® SF Catheter with the CARTO® 3 System and the SOUNDSTAR® Ultrasound Catheter (with the CARTOSOUND® Software Module)
1667677|NCT01716637|Biological|Etanercept|
1667678|NCT01716637|Dietary Supplement|Curcum.Luteol.Theaflav.Lip.Acid,FishOil,Quercet.,Resveratr.|
1667679|NCT01716624|Drug|Oxybutynin|standard oral therapy
1667680|NCT01716624|Drug|Botulinum Toxin A injection|10 units/kg injected into the detrusor muscle using cystoscopy
1667681|NCT01716611|Drug|Tolvaptan|15 - 60 mg/day for 28 days
1667682|NCT01716611|Drug|placebo|
1667683|NCT01716598|Device|IPS System|TLD Therapy will be achieved bronchoscopically.
1667684|NCT01716585|Drug|ABT-450/r/ABT-267, ABT-333|ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
1667685|NCT01716585|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
1667686|NCT01716585|Drug|Placebo for ABT-450/r/ABT-267|Tablet
1667687|NCT01716585|Drug|Placebo for ABT-333|Tablet
1667688|NCT01716585|Drug|Placebo for ribavirin|Capsule
1667689|NCT01716572|Drug|Erythromycin|Intravenous 250 mg of erythromycin, single-dose, 30 minutes before the endoscopy
1667690|NCT01716572|Procedure|gastric lavage|gastric lavage by nasogastric tube with 1 liter of saline before the endoscopy
1667691|NCT01716546|Drug|Pazopanib|
1667692|NCT01716533|Procedure|Blood sampling|Blood sampling will be done at Day 0, at Day 14, at recurrence (if applicable) and at end of follow-up.
1667693|NCT01716533|Other|Stool sample collection|Stool samples will be collected around Day 0, around Day 14 and at recurrence (if applicable).
1667694|NCT01716520|Device|Umeclidinium/Vilanterol 62.5/25 mcg|Umeclidinium/Vilanterol 62.5/25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
1667695|NCT01716520|Device|Umeclidinium 62.5 mcg|Umeclidinium 62.5 mcg once daily in the morning via novel dry powder inhaler (NDPI)
1667696|NCT01716520|Device|Vilanterol 25 mcg|Vilanterol 25 mcg once daily in the morning via novel dry powder inhaler (NDPI)
1667697|NCT01716507|Procedure|Retinal Detachment repair|Comparing 23 gauge vs 20 gauge pars plana vitrectomy.
1667698|NCT01716481|Other|Mesenchymal stem cell|intravenous transplantation of autologous mesenchymal stem cells expanded with autologous serum
1667699|NCT01716468|Other|Ketogenic Diet|modified ketogenic diet
1667700|NCT01716455|Drug|SSP-004184|
1667701|NCT01716442|Drug|Rituximab|Per dose: Rituximab 375 mg/m2 (max.500mg/day). efficacy monitored by CD19 cell count. If CD19 cells are not depleted, second or third doses are given at 2-3 weeks interval.
1667702|NCT01716442|Drug|Placebo|
1667703|NCT01716429|Behavioral|Vegan diet|Vegan dietary approaches for weight loss
1667704|NCT01716429|Behavioral|Low calorie diet|Reduced calorie diet for weight loss
1667705|NCT01716416|Drug|Pazopanib|
1667706|NCT01716416|Drug|Cetuximab|
1667707|NCT01716403|Biological|Diagnostic: protocol designed to evaluate one or more interventions aimed at identifying a disease or health condition|
1667708|NCT01716390|Dietary Supplement|Drink that contains plant stanols|
1667709|NCT01716390|Dietary Supplement|Placebo drink|
1667710|NCT01716377|Drug|Venlafaxine|Sixty patients who present following a minor motor vehicle collision will be randomized to venlafaxine vs. placebo, and the ability of venlafaxine to decrease acute and persistent musculoskeletal neck pain will be assessed.
1667711|NCT01716364|Biological|Anti-LeY- scFv-CD28-ζ vector,.|
1667712|NCT01716351|Behavioral|Adapted Yoga Intervention for Implantable Cardioverter Defibrillator (ICD) Recipients|A weekly 80-minute standardized, repeatable adapted Yoga program designed for recipients of Implantable Cardioverter Defibrillators, including a 30-minute home practice CD.
1667713|NCT01716338|Drug|Glyburide|
1667714|NCT01716338|Drug|Placebo|
1667715|NCT01716325|Other|Self-management weight loss plan endorsement.|Self-management weight loss plan endorsement.
1667718|NCT01716299|Other|application of a confirmation test|Addition of confirmation test to serial testing algorithm, including dilution test
1667719|NCT01716299|Other|application of a confirmation test|use of rapid confirmation test
1667720|NCT01716286|Dietary Supplement|low fat vs. essence yoghurt|
1667721|NCT01716273|Other|Granulated Sugar|30 grams of granulated sugar is used to cover the wound area and this is held in place using a dry dressing pad , bandage and tape.
1667722|NCT01716273|Other|Debridement Dressing|1 Aquacel or Sorbsan dressing will be put over the wound, and held in place with a dry dressing pad, bandage and tape.
1667723|NCT01716260|Drug|Chloroquine|
1667724|NCT01716260|Drug|Primaquine|
1667725|NCT01716247|Other|Mammography (CESM) and MRI|The study consists of the addition of a single contrast enhanced digital mammography examination (CESM) to the routine screening of a woman at increased risk for breast cancer who is also having a breast MRI. Breast MRIs will be read by the radiologist reading breast MRIs on any given day. CESM is a dedicated system, derived from a standard digital mammography unit modified to deliver the dual or multiple energy exposures and visualization of combined images after IV contrast administration. If the patient is having her routine mammogram within 30 days of her MRI, CESM can replace that mammogram Patients will be randomly assigned to one of the radiologists trained to interpret CESM. That radiologist will read the CESM blinded to the results of the breast MRI.This process will be monitored by the research assistant No radiologist will read both the breast MRI and CESM on the same patient.
1667726|NCT01716234|Drug|Posaconazole 12 mg/kg/day BID|Posaconazole oral suspension 12 mg/kg/day divided into 2 doses (BID) (maximum 800 mg/day)
1667727|NCT01716234|Drug|Posaconazole 18 mg/kg/day BID|Posaconazole oral suspension 18 mg/kg/day divided into 2 doses (BID) (maximum 1200 mg/day)
1667728|NCT01716234|Drug|Posaconazole 18 mg/kg/day TID|Posaconazole oral suspension 18 mg/kg/day divided into 3 doses (TID) (maximum 1200 mg/day)
1667729|NCT01716234|Drug|Posaconazole 12 mg/kg/day TID|Posaconazole oral suspension 12 mg/kg/day divided into 3 doses (TID) (maximum 800 mg/day)
1667730|NCT01716221|Drug|bupropion & Citalopram|
1667731|NCT01716221|Drug|Bupropion & Placebo|
1667732|NCT01716221|Drug|Placebo & Citalopram|
1667733|NCT01716221|Drug|Placebo & Placebo|
1667734|NCT01716208|Drug|Ofatumumab + Fresh Frozen Plasma|
1667735|NCT01716195|Other|6 weeks of Radiotherapy|If tumor does not significantly shrink after initial chemotherapy
1667736|NCT01716195|Other|5 weeks of Radiotherapy|If tumor shrinks after initial chemotherapy
1667737|NCT01716169|Device|Helicoll|Helicoll Collagen I Wound Dressing
1667738|NCT01716169|Device|Standard of Care Dressings|Standard of Care wound dressings (e.g. Vaseline gauze)
1667739|NCT01716156|Drug|Grazoprevir|Grazoprevir, tablet, orally, 100 mg, once per day for 12 or 24 weeks, depending on Arm assignment
1667740|NCT01716156|Drug|Ribavirin|Ribavirin capsules, orally, twice per day, at a total daily dose from 800 to 1400 mg based on participant weight
1667741|NCT01716143|Procedure|radiofrequency catheter ablation|
1667742|NCT01716117|Device|Surpass Flow Diverter|Treatment of an intracranial aneurysm involves the placement of a specially designed metallic mesh tube in a vessel in the brain where an aneurysm is located. The device looks like a fishnet sock with both ends open. Each device is delivered through a small catheter (a long, flexible tube). The catheter containing the device is inserted and advanced into a vessel in the brain. The device is then placed in the brain vessel by releasing it from the catheter. Once the device is placed inside the brain vessel, it is intended to reinforce the area of the vessel that is weakened and bulging (the aneurysm), and to cause blood to flow down the vessel and away from the aneurysm. This procedure is called an endovascular aneurysm treatment because the device is delivered through the blood vessels.
1667745|NCT01716091|Procedure|irrigation in the peritoneal cavity|irrigation in the peritoneal cavity after uterine wall closed at cesarean
1667746|NCT01716052|Drug|placebo|Lactulose
1667747|NCT01716052|Drug|Ibuprofen|
1667748|NCT01716039|Drug|MTX 12.5|"once weekly oral dosing with MTX 12.5 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or >9).
Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
1667749|NCT01716039|Drug|MTX 25|"once weekly oral dosing with MTX 25 mg (n=40) two weeks prior to the initiation of adalimumab. Randomization will be stratified by disease activity (modified Mayo Score ≤9 or >9).
Subjects will receive 18 weekly doses of MTX in addition to doses of adalimumab"
1667750|NCT01716039|Drug|Adalimumab|Subjects will receive 18 weekly doses of adalimumab
1667751|NCT01716026|Drug|Bevazizumab intravitreal injection|Intravitreal injection of bevacizumab
1667752|NCT01716013|Device|BondEase|topical skin adhesive
1667753|NCT01716013|Procedure|CWCD|traditional closure methods of sutures, staples or adhesive strips
1667754|NCT01716000|Other|vaginal gel imaging|Imaging of vaginal gel distribution using two investigational techniques (low coherence interferometry and fluorimetry).
1667755|NCT01716000|Behavioral|computer aided self interview|Questionnaire to gather the perceptions and preferences of the subject with respect to the vaginal gel.
1667756|NCT01715987|Drug|Tenofovir Disoproxil Fumarate|300mg, oral daily for two years
1667757|NCT01715987|Drug|Entecavir|0.5mg oral daily for two years.
1667758|NCT01715974|Drug|G-CSF group|60 micrograms/day of G-CSF from the day of embryo transfer through the day of beta HCG test
1667759|NCT01715974|Drug|CONTROL|saline infusion every day from the day of embryo transfer through the day of beta HCG test
1667760|NCT01715961|Procedure|anthropometric measurement|To attest the muscular strength: hand grip test, balance test, up and go test
1667795|NCT01715662|Device|Wii Big Brain|Subjects in the control group will be trained using Wii Big Brain Academy Degree program which is a low-cost commercially available gaming software to improve cognitive function. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
1667836|NCT01715285|Drug|Prednisone|Prednisone 5 mg capsule will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
1668377|NCT01711125|Drug|Baclofen 30mg/day|30mg/day 10 mg t.i.d
1667761|NCT01715948|Device|CROS hearing aid|Participants were randomly assigned to be fitted with the CROS hearing aid either at the end of the first visit or at the end of the second visit. They were given a 2-week trial with the CROS and asked to refrain from wearing their BAHD during that time. At the end of the first visit, four participants were fitted with the CROS hearing aid and were subsequently tested with this device on their second visit, at which time they were instructed to use the BAHD for the next 2 weeks. This protocol was reversed in the other four participants, with testing after each device experience. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
1667762|NCT01715948|Device|Bone-anchored hearing device (BAHD)|All participants had received BAHD implantation prior to the study. They were randomly selected to continue wearing their BAHD for 2 weeks following the end of the first visit or the end of the second visit. Both devices were compared on head shadow effect reduction, speech perception measures in quiet and in noise, self-assessment questionnaires, and daily diaries.
1667763|NCT01715935|Drug|Everolimus|everolimus, 10 mg PO daily. Before nephrectomy: 6 continuous weeks of treatment and one week of rest After nephrectomy: 4 weeks courses (for metastatic patients only)
1667764|NCT01715922|Drug|Fluconazole|Induction treatment for 2 weeks: Fluconazole (1600mg/j) Consolidation treatment for 8 weeks: fluconazole (800 mg/j)
1667765|NCT01715922|Drug|Flucytosine|Flucytosine (100 mg/kg/j) for 2 weeks
1667766|NCT01715922|Procedure|lumbar punctures|lumbar punctures to control intracranial pressure
1667767|NCT01715909|Drug|Oseltamivir|Participants will receive standard dose (30 to 75 milligrams [mg]) or triple standard dose (90 to 225 mg) of oseltamivir orally daily for up to maximum of 20 days. Standard dose of oseltamivir according to weight (except infants): 30 mg twice daily for </= 15 kilograms (kg) body weight participants; 45 mg twice daily for 15 to 23 kg body weight participants; 60 mg twice daily for 23 to 40 kg body weight participants; and 75 mg twice daily for greater than (>) 40 kg body weight participants. Standard dose for infants is 3 mg/kg.
1667768|NCT01715896|Biological|Golimumab 50 mg|Participants received alternating doses of golimumab 50 mg (Weeks 0, 4, 8, 12, 16, 20, and 24) and placebo matched to mavrilimumab (Weeks 2, 6, 10, 14, 18, and 22) injections subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
1667769|NCT01715896|Biological|Mavrilimumab 100 mg|Participants received Mavrilimumab 100 mg injection subcutaneously every 2 weeks for 24 weeks in combination with stable dose of methotrexate (7.5 to 25 mg per week) through oral or parenteral route.
1667770|NCT01715883|Drug|Sodium Nitrite|Same as the details in Arm Description.
1667771|NCT01715870|Behavioral|Life style and food habits questionnaire|
1667772|NCT01715844|Dietary Supplement|L-citrulline|Patients will take 3-gr of L-citrulline/day for 7 days
1667773|NCT01715831|Drug|DMARDs|DMARDs may be added to the tocilizumab treatment in any visit, at the discretion of the investigator, according to the local prescription information and participant's tolerance. Study protocol does not specify any particular DMARD.
1667774|NCT01715831|Drug|Tocilizumab|Tocilizumab will be administered at 8 mg/kg IV dose every 4 weeks for 104 weeks
1667775|NCT01715818|Drug|Placebo|matching aleglitazar placebo tablet orally daily
1667776|NCT01715818|Drug|aleglitazar|150 mcg orally daily
1667777|NCT01715805|Drug|Cariprazine|Patients who meet eligibility will have 1-2 week screening period followed by blind placebo, followed by 8 week double blind treatment period on cariprazine with Antidepressant Therapy (ADT) or placebo with ADT for inadequate responders and ADT with single blind placebo for responders, followed by a 1-week safety follow-up period
1667778|NCT01715805|Drug|Placebo|Patients who meet eligibility will have 1-2 week screening period followed by blind placebo, followed by 8 week double blind treatment period on placebo with Antidepressant Therapy (ADT) for inadequate responders and ADT with single blind placebo for responders, followed by a 1-week safety follow-up period
1667779|NCT01715792|Other|Data collection|Data extraction from the CPRD GOLD and HES, and additional data obtained from complementary information provided by the GPs using a standardised questionnaire.
1667780|NCT01715779|Drug|Eltrombopag|Eltrombopag exposure
1667781|NCT01715753|Dietary Supplement|Protein supplementation|> 30g of high quality protein will be achieved three times a day by subjects in this group, with all or predominantly all from animal source and 60-70% of animal protein from beef.
1667782|NCT01715753|Behavioral|Diet counseling and group education lessons|Individual and group diet counseling to achieve a >10% weight loss
1667785|NCT01715714|Drug|Statin Recapture Therapy|Given 12h and 2h before CABG
1667786|NCT01715714|Drug|Placebo|Given 12h and 2h before CABG.
1667787|NCT01715701|Procedure|Paravertebral nerve blockade|Paravertebral nerve blockade using ropivacaine, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
1667788|NCT01715701|Procedure|Intercostal nerve blockade|Intercostal nerve blockade using ropivacaine, simulated paravertebral nerve blockade and PCA using hydromorphone or morphine.
1667789|NCT01715701|Procedure|Patient Controlled Analgesia|Simulated paravertebral nerve blockade, intercostal nerve blockade using saline and PCA using hydromorphone or morphine.
1667790|NCT01715688|Drug|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
1667791|NCT01715688|Drug|Saline|Administration of saline in the endotracheal tube cuff
1667792|NCT01715675|Dietary Supplement|Plant stanol enriched soy-based yoghurt|Plant stanol enriched soy-based yoghurt
1667793|NCT01715675|Dietary Supplement|Soy-based yoghurt without added plant stanols|Soy-based yoghurt without added plant stanols
1667794|NCT01715662|Device|Wii.n.Walk|Subjects will be trained using Nintendo Wii Fit (commercial fitness gaming software) for 40-minute sessions, 3x/week for 4 weeks. The intervention will initially be conducted in the clinic with a group of 3 participants and will graduate to in-home sessions starting from week 2.
1667835|NCT01715285|Drug|Abiraterone acetate|Abiraterone acetate tablets will be administered orally at a total dose of 1000 mg per day until disease progression, withdrawal of consent or unacceptable toxicity.
1667913|NCT01714687|Device|balloon sinus dilation|
1667796|NCT01715649|Behavioral|Patient education, self-monitoring of blood glucose and remote patient monitoring of blood glucose|In the intervention arm you will test your blood glucose 2 times a day (before and after a meal, activity or other event) using the glucose meter provided to you for use in this study and connect it to the Telehealth Unit. Every week the study team will review your blood glucose levels through the remote patient monitoring secure portal and send you a reminder through the Telehealth Unit with suggestions based on your blood glucose patterns. Once every month a study nurse will call you to review your blood glucose goals and discuss how you may be able to make changes in your health behaviors to improve your blood glucose levels. The study team will work with you to help you make changes to your behaviors that may improve your blood glucose.
1667797|NCT01715636|Drug|Eviplera = emtricitabine 200mg, rilpivirine 25mg, tenofovir 245mg|
1667798|NCT01715623|Biological|a blood sample|Dosage of Ig
1667799|NCT01715610|Drug|Clavulin|Patients will be randomized to the antibiotic or placebo arm via a random number generator.
1667800|NCT01715610|Drug|Randomization to Placebo|Patient's post-drainage of antibiotics will receive placebo and not receive antibiotics
1667801|NCT01715610|Drug|Clindamycin|Patients will be randomized to the antibiotic or placebo arm via a random number generator
1667803|NCT01715584|Other|Sevoflurane/oxygen/air/nitrous oxide|Patients in each arm will be randomized to receive either: 50 per cent oxygen, air, and sevoflurane or 50% nitrous oxide, oxygen and sevoflurane. They will then cross over to the other gas mixture. The depth of each the anesthetic will be varied from 0.8 MAC (minimum alveolar concentration) to 1.6 MAC in 0.2 MAC steps. Hemodyamic variables will be measured at each anesthetic concentration (average of five measurements). Time will be allowed for anesthetic agent equilibration. Paralysis and analgesia using rocuronium and fentanyl will be provided to ensure patients do not move at low (less than 1.0 MAC. It is estimated the time for the cross over experiment will be approximately six hours.
1667804|NCT01715571|Device|Viberect|"Men will be asked to perform vibratory stimulation of the penis in the privacy of their home, while focused on sexual thoughts for approximately 7-10 minutes (depending on erectile response) for 3 times a week, one day apart, throughout the four week period. Men can perform the stimulation once daily, as long as each session is more than 24 hours apart.
Men will record device use and intercourse attempts after device use in a diary."
1667805|NCT01715532|Drug|Huachansu|
1667806|NCT01715532|Other|TACE|
1667807|NCT01715519|Drug|Treatment (Viibryd)|
1667808|NCT01715506|Behavioral|Educational intervention|The educational intervention (EI), Relation Related Care (RRC), consists of a two-day seminar and one hour monthly guidance for six months. Course material, a book particularly designed for this intervention and dealing with person centered care and use of restraint, is distributed ahead of the course part of the intervention to all participants.
1667809|NCT01715493|Drug|lysozyme 90 mg|Lysozyme 90 mg three times daily for 4 weeks followed by placebo for 4 weeks (plus usual COPD medication)
1667810|NCT01715493|Drug|Placebo|Lysozyme Matching Placebo three times daily for 4 weeks followed by Lysozyme 90 mg three times daily for 4 weeks (plus usual COPD medication)
1667811|NCT01715480|Dietary Supplement|Broccosprouts® (Brassica Protection Products LLC) homogenate|"In the in-vitro part of the study, sulphoraphane will be added into the culture media used to grow and differentiate the erythroid cells from blood samples obtained from three Hb AA volunteers and three Hb SS subjects. The subjects will have a single clinic visit for the blood donation.
In the second part of the study, enrolled subjects will be asked to consume homogenates of broccoli sprouts by mouth daily for three weeks. They will have a maximum of five clinic visits for medical assessments and lab draws during this time. They will then have a final clinic visit after a washout period of six weeks."
1667812|NCT01715441|Drug|Sorafenib and irinotecan combination|
1667813|NCT01715441|Drug|Sorafenib monotherapy|
1667814|NCT01715441|Drug|Irinotecan monotherapy|
1667815|NCT01715415|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
1667816|NCT01715415|Drug|Ribavirin|Capsule (double-blind treatment period), tablet (open-label treatment period)
1667817|NCT01715415|Drug|Placebo for ABT-450/r/ABT-267|Tablet
1667818|NCT01715415|Drug|Placebo for ABT-333|Tablet
1667819|NCT01715415|Drug|Placebo for ribavirin|Capsule
1667820|NCT01715402|Procedure|liver surgery|this intervention type includes hepatectomies; wedge; segmentectomies etc...
1667821|NCT01715389|Other|MyAsthma Patient Portal|"Parents in the intervention group will use the MyAsthma Patient Portal to receive enhanced educational information on asthma and its treatment, identify concerns and goals related to asthma treatment, track progress toward goals and management of concerns monthly, and track asthma symptoms monthly.
Clinicians seeing intervention families at office visits will have access to information from the portal including concerns, goals, progress toward goals, and tracking of asthma symptoms."
1667822|NCT01715363|Drug|Oxaliplatin|
1667823|NCT01715363|Drug|Folinic Acid|
1667824|NCT01715363|Drug|Fluorouracile|
1667825|NCT01715350|Drug|PM012|"The drug will be taken with water within 30 minutes after breakfast and supper.
650mg/1 tablet, PO, 12weeks"
1667826|NCT01715350|Drug|Placebo|"The drug will be taken with water within 30 minutes after breakfast and supper.
650mg/1 tablet, PO, 12weeks"
1667827|NCT01715337|Other|pulmonary rehabilitation|3-week rehabilitation including exercise training, breathing therapy, psychosocial support, medical treatment etc.
1667828|NCT01715324|Drug|Adjuvant Growth Hormon|The treatment group will receive 2.5 mg of Saizen daily via subcutaneous injections, from the beginning of the ovarian reserve stimulation until the day of the ovulation triggering
1667829|NCT01715311|Drug|Indacaterol|Indacaterol once daily via single-dose dry powder inhaler
1667830|NCT01715311|Drug|Placebo to tiotropium|Placebo to tiotropium capsules for inhalation once daily
1667831|NCT01715311|Drug|Tiotropium|Tiotropium capsules for inhalation once daily
1667832|NCT01715311|Drug|Placebo to indacaterol|Placebo to indacaterol capsules for inhalation once daily
1667833|NCT01715298|Drug|NVA237|NVA237 (Glycopyrronioum bromide) as a powder for inhalation in single-dose capsules
1667834|NCT01715298|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
1667914|NCT01714687|Other|medical therapy|
1667837|NCT01715285|Other|Androgen deprivation therapy (ADT)|All participants will receive stable regimen of ADT, that is, lutenizing hormone releasing hormone (LHRH) agonists or surgical castration according to local guidelines until disease progression, withdrawal of consent or unacceptable toxicity.
1667838|NCT01715285|Drug|Abiraterone acetate Placebo|Placebo matched to abiraterone acetate will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
1667839|NCT01715285|Drug|Prednisone Placebo|Placebo matched to prednisone will be administered orally once daily until disease progression, withdrawal of consent or unacceptable toxicity.
1667840|NCT01715272|Device|TF037|
1667841|NCT01715272|Drug|Fleet enema|
1667842|NCT01715259|Drug|Abiraterone acetate: participants with end-stage renal disease|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
1667843|NCT01715259|Drug|Abiraterone acetate: matched control participants with normal renal function|abiraterone acetate 1000 mg (4 x 250 mg tablets) taken by mouth as a single dose in the fasted state on Day 1
1667844|NCT01715246|Other|Infant Formula|
1667845|NCT01715233|Drug|mDCF|Modified Dose Docetaxel, Ciplatin, and 5FU.
1667846|NCT01715233|Drug|mDCF|Modified Dose of Docetaxel, Cisplatin, and 5FU.
1667847|NCT01715220|Drug|sublingual nitroglycerine|A convenience sample of patients presenting to the Emergency Department will be randomized to receive either sublingual 0.4 mg doses of nitroglycerin or placebo. Pain prior to and at two minutes and five minutes after medication administration will be assessed using a visual analog scale. The medication will be either a 0.4 mg dose of nitroglycerin or a placebo. If pain is not completely relieved within five minutes, a second dose will be administered after blood pressure assessment. If the pain is not completely relieved after an additional two minute and five minute assessment or the pain returns, it will be treated in the standard manner at the discretion of the treating Emergency Physician
1667848|NCT01715207|Drug|Aliskiren|
1667849|NCT01715207|Drug|Atenolol|
1667850|NCT01715194|Device|Telemedicine intervention|Patients undergoing telemedicine intervention
1667851|NCT01715181|Other|Volunteer visits|Volunteers will visit 3 times per week with a visit duration of 30 minutes for each visit during the study.
1667852|NCT01715168|Drug|DOXIL/CAELYX|
1667853|NCT01715168|Drug|ATI-0918|
1667854|NCT01715142|Drug|Gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
1667855|NCT01715142|Drug|Abraxane|Administrated intravenously at a dose of 125 mg/m2 over 30 minutes weekly, on day 1, day 8, day 15 followed by one week of rest (before surgery of before starting of the next cycle depending on the cohort allocation)
1667856|NCT01715129|Drug|Triptorelin Pamoate 11.25mg|
1667857|NCT01715116|Device|Enhanced ICD programming|"VT monitor: > 166/min
fVT: > 182/min; via VF 60/80 intervals (number of intervals to start ATP after approximately 20 s); 3 x ATP (8 stimuli, 88%, scan 20 ms); shock 1-5: 35 J; redetection 30/40 intervals.
VF: > 250/min; via VF 60/80 intervals (number of intervals to start therapy after approximately 15 s); 1 x ATP (8 stimuli, 88%) during charging; all shocks: 35 J; redetection 30/40 intervals
SVT/VT discrimination is turned on, high rate time out is OFF
SVT/VT discrimination single chamber: stability, wavelet; SVT upper rate limit: 222/min
SVT/VT discrimination dual/triple chamber: P/R logic, wavelet; SVT upper rate limit: 222/min
T wave-oversensing and lead noise discrimination is turned on in all devices."
1667858|NCT01715103|Procedure|vaginal swabs by washing and cytobrush|vaginal swabs by washing and cytobrush
1667859|NCT01715090|Device|Web-based insulin titration|
1667860|NCT01715077|Drug|Ipilimumab at 3 mg/kg dose|
1667861|NCT01715064|Behavioral|Exercise|1 hour of moderate-intensity exercise
1667862|NCT01715051|Drug|D-serine|The molecular formula for D-serine is C3H7NO3. D-serine is being used in IND# 71,369 (D Javitt, PI) and in IND#76,940 (H Singer, PI). This approved D-serine will be purchased by the Research Pharmacy at Johns Hopkins and will be encapsulated into capsules containing 500 mg of D-serine.
1667863|NCT01715051|Behavioral|Cognitive Behavioral Therapy|CBT sessions will be offered weekly to both active medication and placebo arms. The National Institute on Drug Abuse (NIDA) published CBT treatment manual for cocaine dependence, written by Kathleen Carroll, Ph.D., will be utilized. The skills taught in this CBT manual include (1) self-monitoring and functional analysis of situational factors associated with craving or drug use; (2) learning alternative non-drug responses for handling high risk situations; and (3) general lifestyle modifications (e.g., increasing pleasant drug-free events, anger management, interpersonal skills, general problem-solving).
1667864|NCT01715051|Drug|Placebo|The Research Pharmacy at Johns Hopkins will produce matching placebo capsules.
1667865|NCT01715038|Dietary Supplement|LNS-PLW|"Dietary supplement: Lipid-based nutrient supplement
Lipid-based nutrient supplement for pregnant and lactating women (LNS-PLW)
Daily dose of LNS-PLW will be 20 g, packaged in one sachet"
1667866|NCT01715038|Dietary Supplement|LNS-Child|"Dietary supplement: Lipid-based nutrient supplement
Lipid-based nutrient supplement for infants and young children (LNS-Child)
Daily dose of LNS-Child will be 20 g, packaged in two 10 g sachets"
1667867|NCT01715038|Dietary Supplement|MNP|"Dietary supplement: Micronutrient powder
Micronutrient powder for infants and young children (MNP)
The MNP for children will be packaged in 1 g sachets, so that each day, the child will consume one sachet."
1667868|NCT01715038|Dietary Supplement|IFA|"Dietary supplement: Iron and folic acid nutrient supplement
Iron-folic acid tablets for pregnant and lactating women
Daily dose of iron-folic acid supplement will be one tablet containing 60 mg iron and 400 mcg folic acid"
1667870|NCT01715012|Biological|ACCS|ACCS is applied daily by spray to burn wound and skin graft donor site
1667871|NCT01715012|Drug|Saline|Saline is applied daily by spray to burn wound and skin graft donor site
1667872|NCT01714999|Procedure|Bursectomy|Bursectomy of the OB and PB are performed in the operation theatre under sterile conditions. In case of a laceration of the OB a leash, in case of PB a redon drainage (Charr. 10) is inserted. After application of a sterile bandage a cast is applied in both cases. Patient will receive AB for 5 days, the affected limb will be immobilized until removal of the stiches after 12-14 days.
1722904|NCT00004218|Drug|prednisolone|
1667873|NCT01714999|Procedure|Bursal reconstruction|The bursal laceration is treated within in ER setting. The wound is cleaned and thoroughly washed, if needed the wound margins are excised. The wound is then closed using simple suture and a plaster applied and removed 5 days later. Antibiotics are be administered for 5 days
1667874|NCT01714986|Behavioral|Affect School|
1667875|NCT01714986|Behavioral|Body Awareness Therapy|
1667876|NCT01714973|Biological|ACCS|Patients will receive ACCS spray, to half the breast and saline to the other half (blinded) after each of ten consecutive radiation therapy treatments. ACCS and saline will be sprayed onto the breast to deliver 0.01 ml/cm2.
1667877|NCT01714960|Drug|MRZ-99030 eye drops 5mg/mL|
1667878|NCT01714960|Drug|MRZ-99030 eye drops 20mg/mL|
1667879|NCT01714960|Drug|Placebo to MRZ-99030 eye drops|
1667880|NCT01714947|Drug|alisertib|
1667881|NCT01714908|Other|Erlotinib w Concurrent Radiotherapy|
1667882|NCT01714908|Other|etoposide/cis-platin (EP) w Concurrent Radiotherapy|Etoposide / Cis-platin w Concurrent Radiotherapy
1667883|NCT01714895|Other|High insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 1mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
1667884|NCT01714895|Other|Low insulin eu-hypoglycemic clamp|Primed intravenous insulin infusion at a rate of 0.3mU/kg/min is given during the whole study duration. Glucose is infused at a variable rate to maintain plasma glucose concentrations 'clamped' at pre-specified levels. Plasma glucose levels will be the same in both study arms.
1667885|NCT01714882|Behavioral|Stress Management & Resiliency Training|The couples in this group will attend the SMART in-person training class at the beginning of the study and will be taught a structured relaxation program.
1667886|NCT01714882|Behavioral|Stress Management DVD|The couples in this group will receive a Mayo Clinic Stress Management DVD.
1667887|NCT01714869|Other|Swedish Massage|Swedish Massage, once per week for 8 weeks, 60 minutes per session.
1667888|NCT01714856|Drug|Ropinirole hydrochloride CR 2mg Tablets|Ropinirole is an orally administered non-ergoline dopamine agonist. Ropinirole is indicated for the treatment of the signs and symptoms of idiopathic Parkinson's disease.
1667889|NCT01714843|Drug|ASP0456|oral
1667890|NCT01714843|Drug|placebo|oral
1667891|NCT01714830|Device|standars electromagnetic DUOLITH SD1|In the first group patients will be treated by ESWT once a week for 4 weeks. (Each time 3000 impulses, with 0.25 mJouls/M2 and 3 Hertz of frequency. After each 500 pulses, the probe position will be corrected, using trans-perineal ultrasound.
1667892|NCT01714830|Device|turn off standars electromagnetic DUOLITH SD1|In the control group, the same protocol is applied but with the probe being turned off.
1667893|NCT01714817|Biological|BMS-188667|
1667894|NCT01714817|Drug|Mycophenolate mofetil|
1667895|NCT01714817|Drug|Prednisone|
1667896|NCT01714817|Biological|Placebo matching with BMS-188667|
1667897|NCT01714804|Device|Accell Evo3 Prospective Use|
1667898|NCT01714791|Other|Usual care|Patients exercise at a heart rate corresponding to 65% of baseline Vo2peak. Each exercise training session takes 40-60 minutes. Exercise time is apportioned as follows: 42% on the treadmill, 33% on the circle ergometer and 25% on the arm cranking device. All patients exercise under close supervision 3 days per week for a total duration of 12 weeks.
1667899|NCT01714791|Other|Osteopathic treatment|"Patients receive 4 osteopathic treatments (OT). OT is performed in week 4, 5, 8 and 12 postoperative. Depending on what is found in the patient, treatments consist mostly of one or more of the following approaches:
Structural High Velocity Low Amplitude-techniques.
Muscle Energy Techniques.
General osteopathic mobilisations.
Functional techniques (Sutherland-, Jones-techniques,…) including inhibition techniques.
Fascia techniques.
Soft tissue- and connective tissue techniques.
Neurovisceral and neurolymphatic reflex techniques.
Fluidal techniques (lymphatic manipulative techniques,...).
Visceral manipulations.
Neurocranial and viscerocranial techniques."
1667900|NCT01714778|Other|e-Cigarette|
1667901|NCT01714765|Drug|Dovitinib|Cohort 0: 200mg, Cohort 1: 300mg, Cohort 2: 300mg, Cohort 3: 400mg, Cohort 4: 500mg. Cohort -1: 100mg
1667902|NCT01714765|Drug|Everolimus|Cohort 0: 5mg, Cohort 1: 5mg, Cohort 2: 10mg, Cohort 3: 10mg, Cohort 4: 10mg, Cohort -1: 5mg.
1667903|NCT01714752|Procedure|measure of left ventricular and diastolic pressure at exercise|
1667907|NCT01714726|Drug|MEDI2070|1 iv infusion on Week 0 and Week 4
1667908|NCT01714726|Drug|placebo|1 iv infusion on Week 0 and Week 4
1667909|NCT01714726|Drug|MEDI2070|1 sc injection of every 4 weeks for 100 weeks, starting at Week 12; open-label arm is available for all subjects upon completion of first placebo-controlled treatment period
1667910|NCT01714713|Drug|EVP-6124|Arm 1, 2
1667911|NCT01714700|Behavioral|High protein diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle).
1667912|NCT01714700|Behavioral|Standard diet, Resistance exercise|The progressive supervised resistance exercise training program was performed by all participants under supervision. They participated in an onsite supervised protocol for 12 weeks (six days per week); weeks 1-4 (Monday - pectorialis major, Tuesday - latissimus dorsi, Wednesday - femoral, Thursday - deltoid, Friday - biceps brachii, Saturday - triceps brachii muscle), weeks 5-8 (Monday and Friday- pectorialis major and triceps brachii, Tuesday and Saturday - latissimus dorsi and biceps brachii, Wednesday and Monday - femoral, Thursday and Tuesday - deltoid muscle), weeks 9-12 (Monday and Thursday - pectorialis major and latissimus dorsi, Tuesday and Friday - femoral and deltoid, Wednesday and Saturday - triceps brachii and biceps brachii muscle)
1667915|NCT01714674|Dietary Supplement|Dietary nitrate beverage|ingestion of single dose NaNO3 beverage two hours prior to exercise bout
1667916|NCT01714674|Dietary Supplement|NaCl beverage|ingestion of single dose NaCl beverage two hours prior to exercise bout
1667917|NCT01714661|Drug|EVP-6124|Arms 1, 2
1667918|NCT01714661|Drug|Placebo|Arm 3
1667919|NCT01714648|Drug|Triptorelin 0.2 mg|A single bolus of 0.2 mg triptorelin given 34-36 hours before oocyte retrieval.
1667920|NCT01714635|Device|Tecnis Multifocal Intraocular Lens|
1667921|NCT01714635|Device|Monofocal Intraocular Lens|
1667922|NCT01714622|Procedure|subtotal gastrectomy with gastroduodenostomy|
1667923|NCT01714622|Procedure|subtotal gastrectomy with Roux-en-Y gastrojejunostomy,|
1667924|NCT01714622|Procedure|total gastrectomy with Rou-en-Y esophagojejunostomy|
1667925|NCT01714609|Drug|Placebo|Placebo Comparator: Placebo
1667926|NCT01714609|Drug|Sorafenib|Sorafenib, 400 mg twice daily
1667927|NCT01714596|Other|PO versus IV antibiotics Route of administration evaluation|This is a study of oral (per os, (PO)) antibiotic therapy versus intravenous (IV) antibiotics in the treatment of acute infection after fixation of fractures and joint fusions. This is not a study of an experimental drug but a study of route of administration of standard use antibiotics. Antibiotic regimen options decision will be made by the Study Surgeon at each site in consult with local Infectious Disease experts based on local standard practices and bacterial susceptibilities.
1667928|NCT01714570|Drug|Piperacillin-tazobactam combination product|4.5g q6h, 5-10 days
1667929|NCT01714570|Drug|Imipenem|0.5g q6h, 5-10 days
1667930|NCT01714557|Drug|Piperacillin|4.0g q8h 3-5 days
1667931|NCT01714557|Drug|Piperacillin-tazobactam combination product|4.5g q8h 3-5 days
1667932|NCT01714544|Drug|Cloderm Cream|
1667933|NCT01714531|Behavioral|Telephone-Based Goal Management Training|
1667934|NCT01714531|Behavioral|Telephone-Based Attention-Control|
1667935|NCT01714505|Device|Diabetes Assistant (DiAs)|A medical platform that uses a smart-phone to connect to a continuous glucose sensor to insulin pump and run closed-loop control. The cell phone runs the Control to Range and is connected to work with the insulin pump and continuous glucose monitor to help keep the blood sugar in a desired range (80-180 mg/dL during the day) and help avoid hypoglycemia during the night.
1667936|NCT01714492|Device|Sigma Posterior Stabilizing Rotating Platform TKA Beaded Poly|Sigma PS RP TKA including a polyethylene insert with 4 beads
1667937|NCT01714479|Other|Leucine-enriched nutritional supplement|A protein and carbohydrate supplement with high levels of leucine
1667938|NCT01714479|Other|Placebo|
1667939|NCT01714466|Drug|NER1006|
1667940|NCT01714466|Drug|MOVIPREP|
1667941|NCT01714427|Drug|Dexamethasone|Two doses of 40mg dexamethasone (in 100 ml physiologic saline solution, respectively) will be administered intravenously prior to LPS instillation.
1667942|NCT01714427|Drug|Sterile isotonic saline|two doses of 100 ml physiologic saline solution will be administered intravenously prior to LPS instillation.
1667943|NCT01714414|Drug|FZD|
1667944|NCT01714414|Drug|3TC|
1667945|NCT01714414|Drug|EFV|
1667946|NCT01714414|Drug|AZT|
1667947|NCT01714401|Drug|ventolin 2.5mg|20 min nebulization of 2.5 mg of salbutamol
1667948|NCT01714401|Drug|Ventolin 5mg|20 min nebulization of 5 mg of salbutamol
1667949|NCT01714401|Drug|Atrovent 0.5mg|20 min nebulization of 0.5 mg of ipratropium bromide
1667950|NCT01714388|Drug|Remifentanil|1mcg/kg iv dose, followed by 5 minutes ECG recording
1667951|NCT01714375|Device|QuietDose Device|"The intervention will test the effectiveness of a noise exposure dosimeter, the QuietDose - that measures a worker's daily noise dose, as well as peak noise exposure, inside of the worker's hearing protectors. Workers and the study coordinator receive daily feedback about noise exposures (if the device was used outside of the study it would be safety personnel that received the feedback outside of the workers themselves). Such feedback will allow steps to be taken to minimize such exposures, such as behavioral adjustments and improved awarenessThe goal of this study is to determine whether daily assessment and feedback of workers' noise exposures leads to more effective use of hearing protection and prevention of noise-induced hearing loss."
1667952|NCT01714349|Procedure|Nerve Transfer|A nerve transfer procedure will be individualized to each patient's functional deficit.
1667953|NCT01714336|Drug|tranexamic acid|Tranexamic acid will be administered intravenously in two doses of 15 mg/kg. Each dose will be administered over a period of ten minutes, one dose just prior to incision and the second at initiation of wound closure.
1667954|NCT01714336|Drug|placebo|A similar dose of 0.9% sodium chloride (NaCL) will be administered intravenously in two doses over a ten minute period, one dose at incision and the other at initiation of wound closure.
1954953|NCT03310112|Behavioral|4-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 4 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
1667957|NCT01714310|Drug|lisdexamfetamine|Titration and open label treatment for 12 week study.
1667958|NCT01714310|Drug|Placebo|
1667959|NCT01714310|Drug|fluoxetine|
1667960|NCT01714297|Drug|dalteparin 5000 IU s.c.|All patients receive injections with either 5000IU dalteparin or saline in the same volume the evening before surgery. All patients receive 5000IU dalteparin 6 hours after surgery and every day from day 2 until day 35.
1667961|NCT01714284|Behavioral|Informative|The intervention consists in a simple informative counseling about the utility of weight loss for clinical control of psoriatic disease.
1668051|NCT01713582|Drug|OTX015/MK-8628|OTX015/MK-8628 10 mg, 20 mg or 40 mg capsules
1667962|NCT01714284|Behavioral|Diet and Exercise|The intervention consists in a 20 weeks quantitative and qualitative dietary plan for weight loss associated with physical exercise. The plan will be developed with the help of qualified staff (Dieticians) and elaborated in relation to individual needs of the patient.
1667963|NCT01714271|Behavioral|Home environs-based lifestyle counseling|Social learning theory-based behavior modification embedded in a social ecological framework is used to shape both the home environment and the lifestyle choices of the study participants to optimize their adherence to the Dietary Guidelines for Americans and the Physical Activity Guidelines for Americans.
1667964|NCT01714271|Behavioral|Cancer early detection|Conventional health education is used to increase study participant knowledge of practical strategies for detecting and treating common cancers early, before cancers have metastasized. Additional instruction is devoted to the biology and physiology of the cancer process. Although some mention will be made of the importance of maintaining a healthy weight for minimizing lifetime risk of certain cancers, most of the focus will be on episodic cancer screening, e.g., mammograms, PAP smears, colonoscopies, etc. for prevention of death from cancer.
1667965|NCT01714258|Procedure|cardiac output measurement|non invasive cardiac output estimation based on passive induced prolonged expiration in mechanically ventilated patients
1667966|NCT01714232|Device|Contour® PLUS BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1667967|NCT01714232|Device|OneTouch® SelectSimple™ BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1667968|NCT01714232|Device|Accu-Chek® Performa BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1667969|NCT01714232|Device|Accu-Chek® Active BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1667970|NCT01714232|Device|Freestyle Freedom® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1667971|NCT01714219|Procedure|Posterior reconstruction|
1667972|NCT01714206|Drug|Digoxin 0.5 mg|Two 0.25 mg tablets (0.5 mg total dose) taken orally (by mouth) on Day 1.
1667973|NCT01714206|Drug|Digoxin 0.25 mg|One 0.25 mg tablet taken orally on Days 2 through 7.
1667974|NCT01714206|Drug|Canagliflozin (JNJ-28431754)|One 300 mg tablet taken orally on Days 1 through 7.
1667975|NCT01714193|Drug|Oral contraceptive|One tablet (0.150 mg of levonorgestrel and 0.030 mg of ethinyl estradiol) taken orally (by mouth) on Day 1 and Day 9.
1667976|NCT01714193|Drug|Canagliflozin (JNJ-28431754)|One 200 mg tablet taken orally (by mouth) on Days 4 through 9.
1667977|NCT01714167|Genetic|intracerebral stem cell transplantation|Intracerebral transplantation of autologous bone marrow mesenchymal stem cell, 2-4 million stem cells per patient
1667978|NCT01714154|Drug|danoprevir|100 mg orally every 12 hours
1667979|NCT01714154|Drug|ritonavir|100 mg orally every 12 hours
1667980|NCT01714154|Drug|setrobuvir|200 mg orally every 12 hours
1667981|NCT01714141|Behavioral|Multi-component, technology based intervention|Motivational sessions were adapted from work done with young adults with HIV (MESA).
1667982|NCT01714141|Behavioral|Asthma education active control|
1667983|NCT01714128|Drug|Diagnostic Imaging ( 6α-[18F]fluoro-17β-estradiol (FES))|FES-PET/CT imaging
1667984|NCT01714115|Drug|Aflibercept|2.0 mg Intravitreal Injection, every 2 to 4 weeks
1667985|NCT01714102|Dietary Supplement|Placebo|Placebo manufactured to mimic resveratrol tablet
1667986|NCT01714102|Dietary Supplement|Resveratrol|Resveratrol PO BID for 30 days
1667987|NCT01714089|Drug|RNS60 125 ml|
1667988|NCT01714089|Drug|RNS60 250 ml|
1667989|NCT01714089|Drug|Interferon beta 1a|
1667990|NCT01714076|Other|cohort isolation|all patients hospitalised for bronchiolitis are nursed in one room together, separated from patients without bronchiolitis
1667991|NCT01714050|Behavioral|Cognitive-Behavioral Therapy (CBT)|
1667992|NCT01714050|Device|Light Therapy (LT)|SunRay (SunBox Company, Gaithersburg, MD)
1667993|NCT01714037|Drug|Debio 0932|Debio 0932 will be administered as daily oral tablets at a starting dose of 250 mg four times per day (QD).
1667994|NCT01714037|Drug|Cisplatin|Cisplatin 75 mg/m2 body surface area (BSA) will be administered on Day 1 of each 21-day treatment cycle.
1667995|NCT01714037|Drug|Pemetrexed|Pemetrexed 500 mg/m2 BSA will be administered on Day 1 of each 21 day treatment cycle.
1667996|NCT01714037|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 BSA will be administered on Days 1 and 8 of each 21-day treatment cycle.
1667997|NCT01714037|Drug|Docetaxel|Docetaxel 60 or 75 mg/m2 BSA will be administered on Day 1 of each 21-day treatment cycle.
1668052|NCT01713569|Device|Ulthera Treatment|Focused ultrasound energy delivered below the surface of the skin
1668053|NCT01713556|Drug|Propranolol|
1668054|NCT01713556|Other|Trauma reactivation|Trauma reactivation: script-driven mental imagery of the traumatic event
1958170|NCT01932216|Procedure|Cholecystectomy|Gallbladder removal
1668000|NCT01714011|Drug|Ziprasidone|"Ziprasidone's activity is primarily due to the parent drug. The multiple-dose pharmacokinetics of ziprasidone are dose-proportional within the proposed clinical dose range, and ziprasidone accumulation is predictable with multiple dosing. Elimination of ziprasidone is mainly via hepatic metabolism with a mean terminal half-life of about 7 hours within the proposed clinical dose range.
Steady-state concentrations are achieved within one to three days of dosing. The mean apparent systemic clearance is 7.5 mL/min/kg. Ziprasidone is unlikely to interfere with the metabolism of drugs metabolized by cytochrome P450 enzymes. Ziprasidone is well absorbed after oral administration, reaching peak plasma concentrations in 6 to 8 hours."
1668001|NCT01714011|Drug|Aripiprazole|Aripiprazole activity is presumably primarily due to the parent drug, aripiprazole and to a lesser extent, to its major metabolite, dehyrdro-aripiprazole. Steady state concentrations are attained with in 14 days of dosing. The mean elimination half lives are about 75 hours and 95 hours respectively. Elimination of aripiprazole is mainly through hepatic metabolism involving two P450 isozymes, CYP2D6 and CYP3A4. Aripiprazole is well absorbed, with peak plasma concentrations occurring within 3-5 hours; the absolute oral bioavailability of the tablet formulation is 87%. Absorption of aripiprazole is not affected by food.
1668002|NCT01713998|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668003|NCT01713985|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668004|NCT01713985|Device|Thermage|Radiofrequency treatment focusing radiofrequency energy
1668005|NCT01713972|Drug|dabrafenib|Given PO
1668006|NCT01713972|Drug|pazopanib hydrochloride|Given PO
1668007|NCT01713972|Other|Correlative studies|"Pharmacokinetic studies:
Blood draw for various time points:
Cycle 1 Days 1, 2, 3, 4 and 15; Cycle 2 Days 1, 2; and day 1 of Cycles 4, 6 and 12
Pharmacogenomic studies: Blood draw on Cycle 1 Day 1
Tumor genotyping: Archival tumor blocks or unstained slides
BRAF mutation quantification in circulating plasma DNA: Blood draw on Cycles 1-7 Day 1 and every other cycle thereafter; and at time of progression"
1668008|NCT01713959|Device|Ulthera System treatment|Ulthera System: Focused ultrasound energy delivered below the surface of the skin.
1668009|NCT01713959|Device|Sham treatment|Sham Treatment: Use of the Ulthera System with the system adjusted to deliver 0 energy.
1668010|NCT01713946|Drug|RAD001|
1668011|NCT01713946|Drug|Placebo|
1668012|NCT01713933|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
1668013|NCT01713920|Drug|SEVIKAR|
1668014|NCT01713907|Device|Ulthera® Treatment|Focused ultrasound energy delivered below the surface of the skin.
1668015|NCT01713894|Other|Decision Aid|
1668016|NCT01713894|Other|Standard|
1668017|NCT01713868|Behavioral|Safe Sleep Nursery Education|Nursery-based program for safe sleep
1668018|NCT01713868|Behavioral|Breastfeeding Nursery Education|Nursery-based program to promote breastfeeding
1668019|NCT01713868|Behavioral|Breastfeeding Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote breastfeeding delivered via email.
1668020|NCT01713868|Behavioral|Safe Sleep Mobile Health Messaging|Mobile messaging to provide multiple short culturally competent videos to promote safe sleep practices delivered via email.
1668021|NCT01713855|Biological|Inactivated Trivalent Influenza vaccine|
1668022|NCT01713842|Drug|TCZ|Tocilizumab at week 0, 4 and 8.
1668023|NCT01713829|Other|Cranberry Beverage|8 oz cranberry beverage consumed daily for 12 weeks
1668024|NCT01713829|Other|Placebo Beverage|8 oz placebo beverage consumed daily for 12 weeks
1668025|NCT01713803|Drug|Buprenorphine and naloxone|
1668026|NCT01713790|Device|Stochastic resonance whole-body vibration|Stochastic resonance whole-body vibration training program over 10 weeks, three times a week with 3 to 6 Hz, Noise 4.
1668027|NCT01713790|Device|Exergame|training program over 10 weeks, three times a week.
1668028|NCT01713790|Device|Leg press|training program over 10 weeks, three times a week.
1668031|NCT01713764|Behavioral|Low Carbohydrate Diet|
1668032|NCT01713764|Behavioral|American Diabetes Association Diet|
1668033|NCT01713764|Behavioral|Mindfulness and Positive Affect Skills|
1668034|NCT01713751|Other|Interrupted suturing|Skin is closed with interrupted mattress stitches using non-absorbable polypropylene [Prolene®]
1668035|NCT01713751|Other|Subcuticular suturing|Skin is closed with subcuticular stitches using non-absorbable polypropylene [Prolene®]
1668036|NCT01713738|Drug|rituximab|infusion of 4 weekly doses of 375 mg/m2 rituximab
1668039|NCT01713712|Behavioral|Nutritional Counseling|Patients will keep a daily diary of nutritional intake as well as physical activity. They will also follow up with the nutritional counselor six weeks postpartum.
1668040|NCT01713699|Procedure|lumbar puncture|
1668041|NCT01713686|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668042|NCT01713673|Drug|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668043|NCT01713673|Drug|Sham treatment|Study treatment using the Ulthera System, but delivering no ultrasound energy.
1668044|NCT01713660|Device|iFS Femtosecond Laser|corneal incisions created by the femtosecond laser
1668045|NCT01713647|Drug|Amlodipin, losartan, HCTZ|
1668046|NCT01713634|Other|Preflight|4-d controlled diet sessions will occur twice before flight.
1668047|NCT01713634|Other|In-flight|4-d controlled diet sessions will take place on flight days 15, 60, 120, and 180. Flight day 30 will only be monitored intakes (subject consume nominal intake)
1668048|NCT01713621|Drug|OZ439|OZ439 is a novel synthetic trioxolane antimalarial agent
1668049|NCT01713608|Drug|OZ439|OZ439 x mg once daily for 3 days with milk
1668050|NCT01713595|Drug|Hypertonic Saline Aerosol|A single 5ml dose of 7% Saline aerosol
1668056|NCT01713543|Other|physical therapy|Tailored physical therapy sessions to modify impairments in balance and/or gait and to transition high-risk participants to an evidence-based group exercise program.
1668057|NCT01713530|Drug|insulin degludec/insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration twice a day.
1668058|NCT01713530|Drug|insulin degludec|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration once daily.
1668059|NCT01713530|Drug|insulin aspart|Dose individually adjusted. For subcutaneous (s.c, under the skin) administration with the main meals 2-4 times daily in accordance with local labelling.
1668060|NCT01713517|Other|Indoor residual insecticide spraying (IRS)|Application of insecticide to interior walls of domiciliary structures to kill malaria vector mosquitoes which rest on walls after taking human blood meal
1668061|NCT01713517|Device|Long Lasting Insecticidal Nets (LLIN)|Provision of LLIN to all community members in the clusters allocated to the study arm. LLIN protect individuals from bites by malaria vector mosquitoes by providing a physical barrier and insecticidal and repellent effect.
1668062|NCT01713504|Biological|biologie sample|comparison of biomarkers between HES, HE biomarkers data and control arms
1668063|NCT01713478|Other|echocardiography|The patients and controls will be investigated by echocardiography, biomarkers, and ECG. After 1 year investigators will assess 1year mortality.
1668064|NCT01713465|Other|Computer based Metabolic Syndrome educational program|Individuals in the intervention group will receive metabolic syndrome related education using a touch screen interactive and bilingual multimedia enabled educational program
1668065|NCT01713452|Procedure|Purse string closure|"An incision around the stoma will be made with 2-3 mm circumferential margins. This dissection along the mucocutaneous junction will then be made to the fascial defect. Re-establishment of bowel continuity will them be performed. If the circumferential incision does not provide adequate exposure, the incision can be converted to an elliptical one. Thereafter, it will be closed primarily with staples, similar to the primary closure group.
Following ostomy closure, the subcutaneous tissues will be irrigated. A 2-0 monocryl subcuticular purse string stitch will then be placed and cinched to a 1cm diameter. This opening will then be packed with Nu-Gauze as a wick dressing.
Diameter of the skin defect should then be measured.
A postoperative photo will then be taken."
1668066|NCT01713452|Procedure|Primary closure|"An elliptical incision (extending transversely) will be made with 2-3 mm superior/inferior margins around the mucocutaneous junction. Dissection will then be made in a perpendicular fashion through the subcutaneous tissue with tapering near the fascial defect. Re-establishment of bowel continuity will then be performed.
Following ostomy closure, the subcutaneous tissue will be irrigated and the skin will be closed tight with staples placed at close intervals (<1.5cm). No subcutaneous drains will be placed.
Length of the incision should be measured in centimeters.
A postoperative photo will then be taken."
1668067|NCT01713439|Biological|Injection of allogeneic neuroblastoma cells|Patients will receive a fixed dose of IL-2 gene modified tumor cells (10^7/kg, 10^8 max) already shown to be safe from a previous protocol, and an escalating dose of Lptn transduced tumor cells, beginning at 10^4/kg and rising to 10^7/kg (10^8 max). Patients will be assigned to an appropriate dose level for injection # 1. Injection #2 will contain 10 times more Lptn transduced cells than injection #1, until the max dose (10^8) has been reached in the first injection. The dose of injections 3 through 8 will be the same as the dose of injection #2. Initial injection volumes will be <1ml and should be injected in a single site. Only if these first patients show no undue local toxicity (including tumor cell growth) will multiple injection sites be used for subsequent high cell-dose studies.
1668068|NCT01713426|Drug|Qutenza|Cutaneous patch
1668069|NCT01713426|Drug|Pregabalin|Oral capsule
1668070|NCT01713413|Device|Oxymizer|Using first the Oxymizer and 24 h later the conventional nasal cannula.
1668071|NCT01713413|Device|conventional nasal cannula|Using first the conventional nasal cannula and 24h later the Oxymizer
1668072|NCT01713400|Drug|Ustekinumab|One subcutaneous injection administered on day -1 and repeated on day +20 after transplant
1668073|NCT01713400|Drug|Placebo|Subcutaneous injection of sterile saline (identical volume to that of ustekinumab) administered via the identical route and schedule as ustekinumab.
1668074|NCT01713400|Drug|Tacrolimus (TAC)|Administered starting day -3 according to Blood and Marrow Transplant (BMT) Program standard operating procedures. TAC levels to be monitored and maintained at a target range of 3-7 given concurrent administration with sirolimus. Specific dose adjustments within this therapeutic range to be determined by the treating physician.
1668075|NCT01713400|Drug|Sirolimus|Administered initially as an oral loading dose on day -1. Thereafter, SIR to be administered as an oral regimen daily. The dose for both loading and ongoing administration to be dictated by the standard operating procedures of the BMT program. SIR levels to be monitored according to standard procedures. Dose adjustments to be made according to drug levels, with target range of 5-14ng/mL (therapeutic range by Abbott Architect instrument at Moffitt).
1668077|NCT01713374|Procedure|Mental stress|Subjects will be asked to perform complex mathematic operations at a very fast pace
1668078|NCT01713374|Other|no intervention|control visit
1668079|NCT01713374|Procedure|Myogenic activation|A pneumatic cuff will be inflated to suprasystolic pressure around both thighs and the subjects will be asked to perform plantar flexion exercises.
1668080|NCT01713374|Procedure|Cold pressure test|A hand will be placed in ice-cold water.
1668081|NCT01713361|Drug|ISIS-FXIRx Dose #2|Group B: ISIS-FXIRx dose #2 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
1668082|NCT01713361|Drug|ISIS-FXIRx Dose #3|Group C: ISIS-FXIRx dose #3 subcutaneously administered 7 times prior to total knee arthroplasty, and 2 times after surgery.
1668083|NCT01713361|Drug|Enoxaparin|Enoxaparin (40mg) will be administered by subcutaneous injection the evening prior to total knee arthroplasty (optionally), 6 to 8 hours after surgery, followed by daily injections for at least 8 additional days post surgery (a total of at least 9 consecutive days). [Except for Canadian region, in which the subcutaneous injection of enoxaparin the evening prior to total knee arthroplasty is expected, resulting in a total of at least 10 consecutive days of enoxaparin.]
1668084|NCT01713348|Device|FreeStyle Navigator|Masked CGM day 1 to 15, unmasked CGM days 15 to 100
1668085|NCT01713348|Device|Standard SMBG|Masked CGM days 1 to 15, standard SMBG days 15 to 86, masked CGM day 86 to 100
1668086|NCT01713322|Behavioral|Pain management education|Parents are provided with educational material on how to manage child pain during immunization.
1668087|NCT01713322|Behavioral|No pain management education|Control - parents receive general information about childhood immunization.
1668088|NCT01713309|Drug|Filgrastim|Filgrastim 300 ug daily for 7 days, subcutaneously.
1668089|NCT01713296|Drug|Pazopanib|
1668090|NCT01713283|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
1668091|NCT01713283|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1668092|NCT01713270|Procedure|renal sympathetic denervation|Contrast renal angiography was performed to localize and assess the renal arteries for accessibility and appropriateness for RSD. Once the anatomy was deemed acceptable, the internally irrigated radiofrequency ablation catheter(Celsius Thermocool, Biosense Webster, Diamond Bar, California) was introduced into each renal artery. then was maneuvered within the renal artery to allow energy delivery in a circumferential, longitudinally staggered manner to minimize the chance of renal artery stenosis. About four to eight ablations at 10 W for 1 minute each were performed in both renal arteries. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
1668093|NCT01713270|Drug|drug|Angiotensin converting enzyme inhibitors, angiotensin receptor antagonist, calcium antagonists, diuretic, beta adrenoceptor blocking agents, propafenone, amiodarone
1668094|NCT01713270|Procedure|Direct-Current Cardioversion|After renal sympathetic denervation, Persistent AF individual (except intracardiac thrombus) accept Direct-Current Cardioversion within one week. anticoagulation (INR 2.0 to 3.0) is recommended for at least 3 weeks prior to and 4 weeks after cardioversion.
1668095|NCT01713257|Dietary Supplement|Immunoenhancing diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
1668096|NCT01713257|Dietary Supplement|Isocaloric, isonitrogenous diet|Enteral feeding until Day 10 or the day of discharge if earlier than Day 10. The goal of caloric intake is 25 kcal/kg/day and protein 1.2 g/kg/day.
1668097|NCT01713244|Procedure|RFA assisted Hepatectomy|Using RFA to ablate and block the small vessels around the tumor before resection to reduce the spreading of the cancer cell.
1668098|NCT01713244|Procedure|Hepatectomy|Treat the advanced HCC with the hepatectomy only.
1668099|NCT01713231|Dietary Supplement|standard-dose vitamin D (400IU per day)|
1668100|NCT01713231|Dietary Supplement|high-dose vitamin D (2000 IU per day)|
1668101|NCT01713218|Drug|gemcitabine|Administrated intravenously at a dose of 1000 mg/m2 over 30 minutes weekly, week 1 to 4
1668102|NCT01713218|Drug|Vismodegib|150 mg capsule, oral, once daily
1668103|NCT01713218|Procedure|Neoadjuvant chemotherapy|Combination of gemcitabine and Vismodegib during a window interval (4 weeks) before surgery
1668104|NCT01713179|Drug|Ambroxol hydrochloride (Mucopect®, 60 mg, Boehringer Ingelheim)|
1668105|NCT01713166|Drug|plasmalyte solution|plasmalyte solution
1668106|NCT01713166|Drug|Hextend|Hetastarch administration instead of crystalloids until the total amount given reached 20 ml/kg, which is the maximally allowed daily dose. Afterward, plasmalyte solution infusion to meet the fluid requirements.
1668107|NCT01713153|Drug|Misoprostol|600 mcg misoprostol oral
1668108|NCT01713153|Device|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
1668109|NCT01713140|Other|1 strength training set performed until contraction failure|Electromyographic (EMG) activity of the vastus medialis (VM), vastus lateralis (VL), semitendinosus (ST) and biceps femoris (BF) muscles will be recorded during knee extensions performed in a knee extension machine in a single set performed until contraction failure. The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for.
1668110|NCT01713127|Drug|remifentanil infusion|
1668111|NCT01713127|Drug|Placebo|
1668112|NCT01713114|Other|Acute measures of satiety and food intake at next meal|
1668113|NCT01713101|Drug|Early intravenous tranexamic acid administration|Initial history taking and physical examination --> enrollment --> 1g bolus over 10 minutes followed slow infusion over 8 hours.
1668114|NCT01713101|Drug|placebo|
1668115|NCT01713088|Other|Multisystemic therapy|
1668116|NCT01713088|Other|YOT (usual services)|
1668117|NCT01713062|Device|Vitelene|THA
1668118|NCT01713062|Device|XLPE|THA
1668119|NCT01713049|Drug|18F-FLT|0.07 mCi/kg of 18F-FDG will be injected intravenously. The data acquisition will be started at 90 minutes after the injection using 2-D acquisition from a GE DISCOVERY ST PET/CT scanner (GE Medical Systems, Milwaukee, WI).
1668120|NCT01713036|Drug|Pimasertib|Part A: Subjects will receive unlabeled pimasertib capsules orally at a single dose of 60 milligram (mg) on Day 1. One hour after administration of the oral unlabeled pimasertib dose, the intravenous (IV) tracer dose of 9 kilobecquerel (kBq) [14C] pimasertib will be administered as a bolus injection. On Days 3-21 (except Day 8), subjects will receive unlabeled pimasertib capsules orally at a dose of 60 mg twice daily (BID). In the morning of Day 8, subjects will receive 60 mg unlabeled pimasertib capsules spiked with a dose of 2.6 megabecquerel (MBq) (70 microcuries [mcgCi]) of [14C] pimasertib orally. In the evening of Day 8, subjects will receive the evening dose of 60 mg pimasertib as unlabeled pimasertib capsules orally. Part B : Subjects will be administered with 60 mg BID unlabeled pimasertib as oral capsules continuously in cycles of 21 days until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow-up or death.
1668121|NCT01713023|Dietary Supplement|Glucose|The same described in Arm description
1668122|NCT01713023|Dietary Supplement|Fructose|The same described in Arm description
1668126|NCT01712984|Biological|Influenza Virus Vaccine USP Quadrivalent, (Zonal Purified Subvirion) 2012 2013 Formulation|0.1mL, Intradermal
1668127|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone® Intradermal|0.1mL, Intradermal
1723011|NCT00004252|Drug|semaxanib|
1668128|NCT01712984|Biological|Influenza Virus Vaccine USP Trivalent Types A and B (Zonal Purified Subvirion) Fluzone Intradermal|0.1mL, Intradermal
1668129|NCT01712945|Drug|Palifermin|Palifermin (Kepivance®) administered by intravenous bolus on days -5, -4. -3 prior to, and on days 8, 9 and 10 after each cycle of alemtuzumab, then again on 3 consecutive days at month 1 and month 3 after each cycle of alemtuzumab. Patients will be observed for adverse reactions for at least 1 to 2 hours following each bolus dose.
1668130|NCT01712945|Drug|Alemtuzumab|Initial treatment alemtuzumab will be administered as a fixed total dose of 60 mg IV over 5 consecutive days (12mg/day). For re-treatment at Month 12, alemtuzumab will be administered as a fixed total dose of 36mg IV over 3 consecutive days (12mg/day).
1668131|NCT01712919|Radiation|Intensity-modulated radiotherapy|Patients will be given intensity-modulated radiotherapy(IMRT)
1668132|NCT01712919|Drug|Concurrent chemotherapy with paclitaxel and nedaplatin|Patients will be given 2 cycles of concurrent chemotherapy with paclitaxel and nedaplatin
1668133|NCT01712919|Biological|Cetuximab|Patients will be given cetuximab weekly during radiation therapy
1668134|NCT01712906|Biological|3.50±0.25logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 3.50±0.25logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
1668135|NCT01712906|Biological|4.25±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 4.25±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
1668136|NCT01712906|Biological|5.00±0.25 logCCID50/ml|Attenuated Mumps vaccine (KMB-17) of 5.00±0.25 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
1668137|NCT01712906|Biological|0 logCCID50/ml|0 logCCID50/ml in adults (16-59 years old)，children (5-15 years old or 2-4 years old) and infants (8-23 months old) on day 0.
1668138|NCT01712906|Biological|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1)|Attenuated Mumps vaccine (Zhe Jiang Vacn Bio-pharmaceutical Co., LTD.; NO.20110528-1) in children (2-4 years old) and infants (8-23 months old) on day 0.
1668139|NCT01712893|Drug|Zoladex|Eligible patients were randomly divided into 2 groups, the intervention group should use Zoladex 3.6mg once a month up to 2-3 years combined with chemotherapy,and the control group should use chemotherapy alone followed by Zoladex
1668140|NCT01712880|Procedure|open debridement with modular exchange|
1668141|NCT01712880|Procedure|one stage exchange|
1668142|NCT01712867|Other|Omega-3 acid ethyl esters|4 capsules/day for 12 weeks
1668143|NCT01712867|Other|Phytosterol esters of omega-3|4 capsules/day for 12 weeks
1668144|NCT01712854|Drug|Budesonide|budesonide 80 mcg
1668145|NCT01712854|Drug|Symbicort|A combination of budesonide and long acting beta agonist: Budesonide 80 mcg and formoterol fumarate dihydrate inhaler 4.5 mcg
1668146|NCT01712828|Drug|Lenalidomide|25 mg Lenalidomide capsule will be administered orally once in the first period, and once with Quinidine in the second period
1668147|NCT01712828|Drug|Quinidine|300 mg of Quinidine will be administered orally every 12 hours for 1 day followed by 600 mg of Quinidine administered orally every 12 hours for the next 4 consecutive days
1668148|NCT01712828|Drug|Temsirolimus|25 mg/mL injection of Temsirolimus will be given directly into the vein over 30 minutes once in the second period and once with Lenalidomide in the third period.
1668149|NCT01712828|Drug|Diphenhydramine|Just before Temsirolimus is given, 25 mg of Diphenhydramine (Benadryl) will be given directly into the vein to decrease chances of an allergic reaction to Temsirolimus.
1668150|NCT01712815|Other|laboratory biomarker analysis|Correlative studies
1668151|NCT01712815|Other|pharmacological study|Correlative studies
1668152|NCT01712815|Other|questionnaire administration|Ancillary studies
1668153|NCT01712815|Radiation|fluorine F 18-clevudine|Undergo fluorine F 18-clevudine PET/CT scan
1668154|NCT01712815|Procedure|positron emission tomography/computed tomography|Undergo fluorine F18-clevudine PET/CT scan
1668155|NCT01712802|Other|Denture Adhesives: Cream|Using Polident as denture adhesive to compare its effect on PRO and subjective outcomes.
1668156|NCT01712802|Other|Denture Adhesives: Powder|Using Poligrip powder as denture adhesive to compare its effect on PRO and subjective outcomes.
1668157|NCT01712802|Other|Saline|work as control for Denture Adhesives: Cream and Powder
1668158|NCT01712789|Drug|Pomalidomide|Oral Pomalidomide at the starting dose of 4 mg on Days 1-21 of a 28-day cycle
1668159|NCT01712789|Drug|Dexamethasone|Oral Low dose Dexamethasone at the starting dose of 40mg/day (≤ 75 years old) or 20 mg/day (> 75 years old) on Days 1, 8, 15 and 22 of a 28-day cycle.
1668160|NCT01712776|Device|Vapocoolant (Pain Ease)|Topical stream 4-10 seconds duration to skin.
1668161|NCT01712776|Device|Nature's Tears Sterile Water|Topical stream 4-10 seconds duration to skin
1668162|NCT01712763|Drug|degarelix|50 women will be treated with degarlix 80 mg, in only one administration covering three months
1668163|NCT01712763|Drug|goserelin|50 women will be treated with decapeptyl 3.6 every month for three months
1668164|NCT01712737|Other|Dietary intervention|
1668165|NCT01712724|Other|combined resistance and aerobic training|For the group randomized to AT+RT, Patients will gradually be progressed from 1-2 sets and then from 10-15 repetitions and then increase resistance by 1.6-5 kg or increase the exercise band level and then reduced repetitions to 10 and repeated this process.
1668166|NCT01712711|Drug|H.pylori eradication|The regimen consists of Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)for two weeks
1668167|NCT01712685|Drug|18F-VM4-037|Drug being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans.
1668168|NCT01712685|Procedure|PET/CT|
1668170|NCT01712646|Drug|Intranasal Oxytocin|
1668174|NCT01712594|Device|Closed Loop Procedure (Medtronic)|The procedure A is the device running under normal conditions, procedure B will incorporate an induced calibration error.
1668175|NCT01712581|Other|Magnetic Resonance Imaging|
1668176|NCT01712568|Drug|Test Product (Ropinirole)|"one Tablet at 0 hour"
1668177|NCT01712568|Drug|Reference Product (REQUIP )|"one Tablet at 0 hour"
1668178|NCT01712555|Procedure|autologous fat grafting with PRP to anophthalmic orbits|
1954954|NCT03310112|Behavioral|2-week MBAT|The training is known as Mindfulness-Based Attention Training, or MBAT. The MBAT program is based on the principles of Mindfulness-Based Stress Reduction, but contextualized for military personnel using themes relevant to military life. The training content is comprised of four central themes: concentration, body awareness, open monitoring, and compassion. This content will be delivered in 4, 2-hour sessions over 2 weeks. Participants will be assigned homework mindfulness practice during the interval of course delivery as well as for the few weeks following the end of the course.
1668180|NCT01712516|Drug|QVA149|QVA149 was supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
1668181|NCT01712516|Drug|QAB149|QAB149 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
1668182|NCT01712516|Drug|NVA237|NVA237 was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
1668183|NCT01712516|Drug|Placebo|Placebo was supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI.
1668184|NCT01712503|Device|Phacoemulsfication cataract surgery and intra-ocular lens implant|
1668185|NCT01712490|Drug|brentuximab vedotin|Brentuximab vedotin (ADCETRIS®)1.2 mg/kg by IV infusion on Days 1 and 15 of each 28-day cycle
1668186|NCT01712490|Drug|doxorubicin|Doxorubicin: 25 mg/m2 by IV infusion on Days 1 and 15 of each 28-day cycle
1668187|NCT01712490|Drug|bleomycin|Bleomycin: 10 units/m2 by IV infusion on Days 1 and 15 of each 28-day cycle
1668188|NCT01712490|Drug|vinblastine|Vinblastine: 6 mg/m2 will be administered by IV infusion on Days 1 and 15 of each 28-day cycle
1668189|NCT01712490|Drug|dacarbazine|Dacarbazine (DTIC): 375 mg/m2 by IV infusion on Days 1 and 15 of each 28-day cycle
1668190|NCT01712477|Drug|Intravenous sedation using propofol|Patients will be given intravenous sedation for treatment of traumatic brain injury requiring mechanical ventilation
1668191|NCT01712477|Drug|Intravenous sedation with midazolam|patients with severe traumatic brain injury requiring mechanical ventilation and sedation will be sedated with midazolam
1668192|NCT01712464|Drug|Oxytocin vs. Placebo|FMRI measurement and blood examinations after 26 IU Oxytocin (Syntocinon)or placebo on two consecutive days
1668193|NCT01712451|Drug|salmeterol xinafoate, fluticasone propionate|LIPO-102
1668194|NCT01712451|Drug|Placebo|Placebo
1668195|NCT01712451|Drug|salmeterol xinafoate|Salmeterol
1668196|NCT01712438|Biological|Human cl rhFVIII|
1668197|NCT01712425|Biological|0-24 week prime/boost regimen|ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines, delivered intramuscularly
1668198|NCT01712425|Biological|0-8 week prime/boost regimen|ChAdV63.HIVcons (5x10^10 vp) and MVA.HIVconsv (2x10^8 pfu) HIV-1 vaccines, delivered intramuscularly
1668199|NCT01712412|Drug|IW-9179|
1668200|NCT01712412|Drug|Placebo|
1668201|NCT01712399|Biological|Mavrilimumab 100 mg|Participants will receive 100 mg mavrilimumab once in every 2 weeks (Q2W) subcutaneously for up to 3 years
1668202|NCT01712386|Dietary Supplement|Beetroot|
1668203|NCT01712386|Dietary Supplement|Beetroot placebo|
1668204|NCT01712373|Drug|Ginseng|it is kind of drug
1668205|NCT01712373|Drug|Placebo|it is placebo
1668206|NCT01712360|Drug|NAFT500 (pediatric)|Applied to both feet and groin area
1668207|NCT01712360|Drug|NAFT600 (pediatric)|Applied to both feet only
1668208|NCT01712360|Drug|NAFT500 (adult)|Applied to both feet and groin area
1668209|NCT01712360|Drug|NAFT600 (adult)|Applied to both feet
1668210|NCT01712347|Drug|Bevacizumab|Bevacizumab will be administered as per approved label.
1668211|NCT01712347|Drug|Chemotherapy|The protocol does not specify the chemotherapy regimen to be used, the choice of chemotherapy will be at the discretion of treating physician.
1668212|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari eRapid nebulizer.
1668213|NCT01712334|Drug|dornase alfa [Pulmozyme®]|Inhaled once daily by Pari LC Plus jet nebulizer.
1668217|NCT01712295|Drug|17% Salicylate with ethyl pyruvate|
1668218|NCT01712295|Drug|Salicylates|
1668219|NCT01712282|Behavioral|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulse reserve increase of 50%
1668220|NCT01712269|Procedure|Weight-loss (bariatric) surgery|Subjects will undergo bariatric surgery which will assist weight loss
1668221|NCT01712256|Biological|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
1668222|NCT01712243|Other|Light|
1668223|NCT01712230|Drug|GnRH agonist|"Drug: leuprolide acetate
Other Names:
Lupron 3.75 mg for depot suspension delivered by monthly intramuscular injection for 6 months"
1668224|NCT01712230|Behavioral|Supervised cardiovascular exercise|Supervised exercise, 4 days per week for 45 to 60 minutes per session for 6 months
1668225|NCT01712230|Drug|Placebo|Placebo
1668226|NCT01712217|Drug|AT13387|HSP90 inhibitor
1668227|NCT01712217|Drug|Crizotinib|ALK (anaplastic lymphoma kinase) and ROS1 (c-ros oncogene1, receptor tyrosine kinase) inhibitor
1668228|NCT01712204|Drug|Placebo|Placebo Capsule BID for 16 Weeks
1668229|NCT01712204|Drug|AC-201|AC-201 50mg Capsule BID for 16 Weeks
1668230|NCT01712204|Drug|Febuxostat|Febuxostat 80 mg QD for 16 Weeks
1668231|NCT01712191|Device|NUsurface Meniscus Implant|
1668232|NCT01712178|Biological|Adalimumab, current formulation|Current formulation adalimumab 40 mg every other week
1723012|NCT00004253|Drug|carboplatin|
1668233|NCT01712178|Biological|Adalimumab, new formulation|New formulation adalimumab 40 mg every other week
1668234|NCT01712165|Dietary Supplement|ANMUM Materna|
1668235|NCT01712165|Dietary Supplement|Control (milk powder)|
1668236|NCT01712139|Drug|Irbesartan and Hydrochlorothiazide|
1668237|NCT01712139|Drug|Avalide|
1668238|NCT01712126|Drug|Irbesartan and Hydrochlorothiazide|
1668239|NCT01712126|Drug|Avalide|
1668240|NCT01712113|Drug|Irbesartan|
1668241|NCT01712113|Drug|Avapro|
1668242|NCT01712100|Drug|Irbesartan|
1668243|NCT01712100|Drug|Avapro|
1668244|NCT01712087|Device|MedStream Programmable Infusion System|Intrathecal Infusion of Baclofen in the Treatment of Spasticity
1668245|NCT01712074|Drug|PF-05212377 (SAM-760)|30 mg QD of PF-05212377 (SAM-760)
1668246|NCT01712074|Other|Placebo|Placebo QD
1668247|NCT01712061|Drug|PF-04634817|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
1668248|NCT01712061|Drug|Placebo|Three or four tablets (50mg) daily for 12 weeks, depending on baseline renal function
1668249|NCT01712048|Procedure|Submucosal Injection EMR|"Selective saline injection is applied to the layer of tissue underneath the polyp in order to create a safety cushion for resection. EMR is then performed with a standard snare."
1668250|NCT01712048|Procedure|Underwater EMR|Polypectomy is performed under full water emersion without the use of submucosal injection.
1668251|NCT01712009|Drug|Naproxen|
1668252|NCT01712009|Drug|Loratadine|
1668253|NCT01712009|Biological|Pegfilgrastim|Commercially available pegfilgrastim (Neulasta®) will be used in the study, and is considered background therapy. Pegfilgrastim is administered as a single 6 mg subcutaneous injection 24 hours to 72 hours after completion of chemotherapy.
1668254|NCT01712009|Drug|Chemotherapy|The choice of chemotherapy regimen (agent, dose, and schedule) is at the discretion of the treating physician.
1668255|NCT01711983|Device|GORE® Septal Occluder|The GORE® Septal Occluder consists of an implantable occluder and a catheter delivery system. The occluder is comprised of five platinum-filled nickel-titanium (Nitinol) wires which form a frame covered with expanded polytetrafluoroethylene (ePTFE). The ePTFE is treated with a hydrophilic coating to facilitate echocardiographic imaging of the occluder and surrounding tissue during implantation. When fully deployed, the occluder assumes a configuration to prevent shunting of blood between the right and left atria.
1668256|NCT01711970|Drug|Paclitaxel|
1668257|NCT01711957|Procedure|Liver transplantation|Standardized technique of liver transplantation Organ procurement follow the rules of the Swiss transplant society
1668258|NCT01711944|Behavioral|Problem-Solving Skills Training|8-session manualized intervention to provide problem-solving skills training in the context of childhood cancer.
1668259|NCT01711931|Device|Implantation of everolimus-eluting bioresorbable vascular scaffold stent|
1668260|NCT01711931|Device|Implantation of everolimus-eluting stents|
1668261|NCT01711931|Device|Implantation of biolimus-eluting stents|
1668262|NCT01711918|Drug|Domperidone|oral tablet; dose is 10mg per tablet given up to 3 times daily.
1668263|NCT01711905|Dietary Supplement|Vitamin D3|daily dosage of 20 µg Vitamin D3 for 12 weeks
1668264|NCT01711892|Behavioral|Soccer training|
1668266|NCT01711866|Drug|Rotigotine|Rotigotine up to 16 mg / 24 hours, 4 weeks.
1668267|NCT01711853|Drug|Dabigatran Etexilate|Dabigatran Etexilate 75mg twice daily
1668268|NCT01711827|Drug|Isavuconazole|oral
1668269|NCT01711827|Drug|Prednisone|oral
1668270|NCT01711814|Drug|ASP015K|oral
1668271|NCT01711801|Drug|Placebo|Single ascending dose
1668272|NCT01711801|Drug|RO5545965|Single ascending dose
1668273|NCT01711801|Drug|RO5545965|Single dose, in fed and fasted state
1668274|NCT01711788|Procedure|Intrabone infusion of umbilical cord blood stem cells|
1668275|NCT01711775|Drug|aleglitazar|Single oral dose Day 1, repeated oral dose once daily Days 5-14
1668276|NCT01711762|Drug|GDC-0973|Single oral dose of [14C]-GDC-0973
1668277|NCT01711749|Drug|Crestor®|Reference formulation is rosuvastatin calcium tablets, 20mg, currently commercialized by AstraZeneca do Brasil Ltda., under the trademark Crestor®
1668278|NCT01711749|Drug|rosuvastatin calcium tablets|Test formulation is rosuvastatin calcium tablets, 20 mg, produced by Laboratorios Phoenix S.A.I.C.F/Argentina for GlaxoSmithKline Brasil Ltda.
1668279|NCT01711736|Biological|Quadrivalent influenza GSK2282512A vaccine|1 or 2 doses administered intramuscularly (IM) in deltoid muscle or anterolateral thigh on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
1668280|NCT01711736|Biological|Fluarix|1 or 2 doses administered IM in deltoid muscle or anterolateral thigh, on Day 0 (primed subjects) and on Day 0 and Day 28 (unprimed subjects) respectively.
1668281|NCT01711723|Drug|Darapladib 160 mg|Subjects in each group received one tablet orally of Darapladib 160 mg daily for 10 consecutive days. Tablets were taken with food, swallowed whole, not chewed.
1668282|NCT01711710|Device|Cohesive Gel Breast Implant|"Cohesive Silicone Gel-Filled Breast Implant insert under the submuscular with axillary incision in breast augmentation mammoplasty.
Remove tissue expander and insert Cohesive Silicone Gel-Filled Breast Implant in breast reconstruction."
1668283|NCT01711697|Radiation|stereotactic body radiation therapy|Undergo SBRT
1668284|NCT01711697|Drug|carboplatin|
1668285|NCT01711697|Drug|paclitaxel|
1668286|NCT01711697|Radiation|radiation therapy|Undergo radiation therapy
1668287|NCT01711684|Drug|Diphenylcyclopropenone (DPCP)|Topical application of study drug
1668288|NCT01711671|Drug|DKN-01 300 mg|300 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
1668289|NCT01711671|Drug|DKN-01 600 mg|600 mg IV infusion of DKN-01 administered twice per 28 day cycle on Days 1 and 15, plus lenalidomide/dexamethasone
1668290|NCT01711671|Drug|Standard of Care|Current approved standard of care
1668291|NCT01711658|Radiation|Intensity Modulated Radiation Therapy (IMRT)|70 Gy in 2 Gy fractions
1668292|NCT01711658|Drug|Cisplatin|100 mg/m2 on days 8 and 29
1668378|NCT01711125|Drug|Baclofen 75mg/day|75mg/day 25 mg t.i.d
1723013|NCT00004253|Drug|paclitaxel|
1668293|NCT01711658|Drug|placebo|1500 mg daily one week prior to radiation, followed by 1500 mg daily concurrent with radiation, followed by 1500 mg daily for 3 months
1668294|NCT01711658|Drug|Lapatinib|1500 mg daily one week prior to radiation, followed by 1500 mg daily concurrent with radiation, followed by 1500 mg daily for 3 months
1668295|NCT01711645|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed onto aluminum phosphate|55 postpartum subjects receive a single intramuscular (IM) 0.5 mL dose of Adacel® (Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed).
1668296|NCT01711632|Drug|Vemurafenib|Patients will receive vemurafenib at a dose of 960mg orally b.i.d. continuously in cycles of 4 weeks (28 days) as outpatient. A bone marrow aspirate and/or biopsy will be performed after the first cycle for research purposes only. After the completion of the third cycle, a repeat bone marrow aspirate and/or biopsy will be performed for assessment of response and evaluation of MRD. Following the third cycle assessments, patients who achieve complete response (CR) with detectable MRD or partial response (PR) may continue with vemurafenib for up to 3 additional cycles at the treating physician's discretion (Cycles 4-6). Patients who achieve CR without MRD will be observed as part of post-treatment followup, and may be re-treated with vemurafenib after relapse (as per below). Patients who achieve no response (NR) after the initial 3 cycles of vemurafenib will be removed from the study. They will be followed every 3 months as part of posttreatment followup for a total of 12 months.
1954956|NCT03310086|Device|Traditional fixed appliance|aligning and leveling of lower anterior teeth using traditional fixed appliance.
1668299|NCT01711593|Biological|Bronchoscopy, Segmental Allergen Challenge and Bronchoalveolar Lavage|On the first bronchoscopy day,BAL will first be performed in the lingual without instillation of diluent or allergen. A 2ml aliquot of isotonic diluent is instilled into the right upper lobe.The procedure is repeated in the right middle lobe with instillation of 2ml of standardized cat or mite allergen solution. A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae)or 1/30th(D.pteronyssinus)the threshold concentration.If on visual inspection through the bronchoscope there is no evidence of mucosal inflammation after 2 minutes a second segmental allergen challenge will be done in the right middle lobe using 2ml of full-dose allergen at the threshold concentration(Cat,D.farinae)or 1/3 the threshold concentration(D.pteronyssinus). This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent to obtain BAL fluid from the RUL and RML.
1668300|NCT01711593|Procedure|Phlebotomy|200 (40 teaspoons) ml of blood will be obtained from the subjects to collect different leukocyte populations. A second 200 ml of blood will be obtained from the Track 2 subjects 4 weeks later for isolation of T lymphocytes for functional studies.
1668301|NCT01711580|Other|EORTC QLQ-C30|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
1668302|NCT01711580|Other|EORTC QLQ-BN20|The EORTC QLQ-C30 is a questionnaire developed to assess the quality of life of cancer patients. It is supplemented by disease specific modules for e.g. Breast, Lung, Head & Neck, Oesophageal, Ovarian, Gastric, Cervical cancer, Multiple Myeloma, Oesophago-Gastric, Prostate, Colorectal Liver Metastases, Colorectal and Brain cancer which are distributed from the EORTC Quality of Life Department. Other disease specific modules are under development but not yet validated.
1668303|NCT01711580|Other|Hopkins Verbal Learning Test-Revised (HVLT-R)|The HVLT-R is a cognitive test to assess verbal learning and memory.
1668304|NCT01711580|Other|Stroop color-word test|The Stroop Color and Word Test is a brief five minute test which is used to assess brain dysfunction, cognition, and psychopathology.
1668305|NCT01711580|Other|Controlled oral word association test (COWA)|The COWA is a measure of verbal fluency that requires expressive language and executive functions.
1668306|NCT01711580|Other|Jamar hand dynamometer|The Jamar hand dynamometer is a screening instrument that is used to assess grip strength.
1668307|NCT01711580|Other|EORTC QLQ- FA13|The Fatigue Questionnaire (QLQ-FA13) is a 13-item questionnaire to assess fatigue in patients with cancer. It is meant to be used in conjunction with the EORTC QLQ-C30
1668308|NCT01711580|Other|Trail Making Test (TMT)|The TMT The Trail Making Test is a neuropsychological test of visual attention and task switching. It consists of two parts in which the subject is instructed to connect a set of 25 dots as fast as possible while still maintaining accuracy.
1668309|NCT01711567|Drug|tenofovir|tenofovir 300 mg qd
1668310|NCT01711567|Drug|entecavir|entecavir 0.5 mg qd
1668311|NCT01711554|Biological|Dinutuximab|Given IV
1668312|NCT01711554|Drug|Isotretinoin|Given PO
1668313|NCT01711554|Other|Laboratory Biomarker Analysis|Correlative studies
1668314|NCT01711554|Drug|Lenalidomide|Given PO
1668315|NCT01711554|Other|Pharmacological Study|Correlative studies
1954957|NCT03310086|Procedure|Corticision|Corticison, cortical bone incision without flap elevation, will be applied to the lower anterior teeth
1668325|NCT01711528|Drug|Bortezomib|Given SC
1668326|NCT01711528|Drug|Dexamethasone|Given PO
1668327|NCT01711528|Drug|Dinaciclib|Given IV
1668328|NCT01711528|Other|Laboratory Biomarker Analysis|Correlative studies
1668329|NCT01711515|Drug|Cisplatin|Given IV
1668330|NCT01711515|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
1668331|NCT01711515|Radiation|Internal Radiation Therapy|Undergo intracavitary brachytherapy
1668332|NCT01711515|Biological|Ipilimumab|Given IV
1668333|NCT01711515|Other|Laboratory Biomarker Analysis|Correlative studies
1668334|NCT01711489|Drug|isavuconazole|oral
1668336|NCT01711476|Behavioral|Placebo Comparator: Lifestyle counseling Dinner Diet ARM 2|In this Arm 2 group the PCOS will be assigned to dinner diet and we will compare the androgen levels Day 0 to androgen after DAY 90 of this diet also we will compare Glucose and Insulin response to OGTT Day 0 and Day 90, and ovulatory frequency along alll the 90 days of the Dinner diet
1668337|NCT01711476|Other|Active Comparator: Lifestyle counseling ARM 1|In the Arm 1 we will measure androgen levels and insulin and glucose response to OGTT at baseline DAY 0 and after 90 days on the dinner diet (Day 90) for comparison Also we will evaluate by weekly progesterone the ovulatory events
1668338|NCT01711463|Drug|Fluticasone Furoate/Vilanterol|50/25 or 100/25 or 200/25 mcg inhaled once daily for 7 days in each treatment period.
1668339|NCT01711463|Drug|Placebo|Placebo inhaled once daily for 7 days in each treatment period.
1668340|NCT01711450|Procedure|Paravertebral block|Injection of local anaesthesia into paravertebral space to provide analgesia
1668341|NCT01711450|Procedure|Control sham procedure|Injection of Normal saline into the paravertebral space
1668342|NCT01711437|Device|PEG-4000 with citrates and simethicone|1-4 bisacodyl 5-mg tablets (Lovoldyl) at 16:00, followed 2-3 hours later by 50 ml/kg (maximum 2 L) of PEG-CS solution. The patients were instructed to drink all solution in about 2-3 hours.
1668343|NCT01711437|Device|polyethylene glycol 4000 solution with simethicon|patients received a polyethylene glycol 4000 solution with simethicon (Selg Esse) starting at 3:00 p.m. the day before the colonoscopy at a dose of 100 ml/Kg (maximum 4 L). The patients were instructed to drink all solution in about 4-6 hours.
1668344|NCT01711437|Device|polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid|patients received a polyethylene glycol 3350 hyper-osmotic solution with ascorbic acid (Moviprep) a dose of 50 ml/Kg (maximum 2 L) with 25 ml/kg additional clear fluid after completing solution intake.
1668345|NCT01711437|Device|sodium picosulphate plus magnesium oxide and citric acid|patients received two sachets of sodium picosulphate plus magnesium oxide and citric acid (Picoprep), each diluted in 150 ml of water, at 14:00 and 6 hours later in the evening prior to the colonoscopy. Intake of at least 40-50 ml/kg of clear fluids
1668346|NCT01711424|Drug|OPTIVE PLUS®|Patients with dry eye prescribed OPTIVE PLUS® in accordance with physician standard practice.
1668347|NCT01711411|Device|PrePex device for male circumcision|PrePex is a sterile device for adult male circumcision, consisting of an inner ring, elastic ring, placement ring, and verification thread. Proper sizing is facilitated by a sizing accessory. The elastic ring is loaded on to the placement ring, which is then placed at the base of the penis. The inner ring is placed inside the foreskin. The elastic ring is then deployed around the foreskin, clamping the foreskin against the inner ring. PrePex is manufactured by Circ MedTech Limited, is certified CE - Class IIa in the European Union, and has been approved by the U.S. Food and Drug Administration.
1668348|NCT01711398|Drug|Drug|
1668349|NCT01711385|Behavioral|Enhanced intervention|Study patients are notified of their blood test result within 72 hours. Those identified as potentially pre-diabetic or diabetic, and randomized to the enhanced intervention arm, receive a tailored message about their modifiable risks and are advised to see their physician regarding their test results or are provided with a referral to one. They are given a letter to take to their physician that specifies the risk factors identified, the tests carried out for the patient and the exact numeric results. They receive a call at month 2 to see if they have followed up with a physician regarding their test results. If they have not seen a physician regarding their results, they are advised again to do so and reminded of their individual risk factors. At month 4 they are asked again if they have seen a physician regarding their test results. If they still have not seen a physician at this time the message is reinforced. They are contacted again by phone to schedule the 6-month recall visit.
1954958|NCT03310073|Biological|bOPV|Batch Number: 2042015
1668351|NCT01711359|Drug|Baricitinib|Administered orally
1668352|NCT01711359|Drug|Methotrexate|Administered orally
1668353|NCT01711359|Drug|Baricitinib Placebo|Baricitinib placebo administered orally once daily.
1668354|NCT01711359|Drug|MTX Placebo|MTX placebo administered orally once weekly.
1668355|NCT01711359|Drug|Folic Acid|Administered orally every day
1668356|NCT01711346|Biological|S303 Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled S303 Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
1668357|NCT01711346|Biological|Conventional, untreated Red Blood Cells (RBCs)|Each subject will receive one intravenous infusion of autologous radiolabeled Conventional, untreated Red Blood Cells (RBCs) in random order. Each infusion will be approximately 10 to 30 mL.
1668358|NCT01711333|Drug|Pletaal SR capsule|two capsules once a day of Pletaal SR 100mg Capsules
1668359|NCT01711320|Drug|Placebo|
1668360|NCT01711320|Drug|Omeprazole|
1668361|NCT01711307|Procedure|operative|
1668362|NCT01711307|Procedure|non-operative|casting within 48 hrs
1668363|NCT01711294|Device|19 G Flex Needle|Fine Needle Aspiration of PCL with a 19 G Flex needle. If unsuccessful, a salvage procedure will be done with 19 G or 22 G needle.
1668364|NCT01711294|Device|22 G Needle|Fine Needle Aspiration of PCL with a 22 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
1668365|NCT01711294|Device|19 G Needle|Fine Needle Aspiration of PCL with a 19 G needle. If unsuccessful, a salvage procedure will be done with 19 G Flex needle.
1668366|NCT01711281|Device|Intracardiac Impedance Measurement Algorithm (integrated in CRT-D device)|
1668367|NCT01711242|Drug|Capecitabine|
1668368|NCT01711242|Drug|Oxaliplatin|
1668369|NCT01711242|Radiation|Radiotherapy|
1668370|NCT01711229|Drug|IV acetaminophen|Ofirmev will be given 15 minutes prior to going to the OR
1668371|NCT01711229|Drug|oral acetaminophen|oral acetaminophen will be given preoperatively
1668372|NCT01711203|Other|Motor Control|Exercises and verbal cues to facilitate deep abdominal control and contraction for muscular stabilization/re-training.
1668373|NCT01711203|Other|General Strengthening|General abdominal and lower quarter musculature strengthening
1668374|NCT01711190|Procedure|trabeculectomy|Filtering surgery to reduce the intra-ocular pressure.
1668375|NCT01711177|Drug|placebo|Placebo
1668376|NCT01711177|Drug|travoprost|Travatan Z is administered to newly diagnosed glaucoma patient
1723119|NCT00004361|Drug|sodium citrate|
1668379|NCT01711125|Drug|Placebo|Placebo 3 matched tabs/day
1668380|NCT01711112|Drug|Docetaxel|Treatment will be continued until progression, unacceptable toxicity, or refusal
1668381|NCT01711099|Device|device for Extracorporeal Shockwave Myocardial Revascularization (ESMR) therapy|
1668382|NCT01711086|Device|Aerolizer Followed by Inspiromatic|Participants will receive Formoterol (Foradil) 12mcg via the Foradil Aerolizer inhaler while performing lung function as part of the and not differ from other routine follow-up
1668383|NCT01711086|Device|Inspiromatic followed by Aerolizer|Participants will receive Formoterol (Foradil) 12mcg via the Inspiromatic dry powder inhaler while performing lung function instead of getting it via the Foradil Aerolizer
1668384|NCT01711073|Drug|Mobilization with G-CSF and Mozobil|Treatment with drugs for mobilization of MSCs
1668385|NCT01711060|Drug|oxytocin|
1668386|NCT01711060|Procedure|balloon catheter|
1954959|NCT03310073|Biological|Pentabio|Batch number: 5050115 The vaccine shall be given intramuscularly.
1954960|NCT03310073|Biological|IPV|The vaccine shall be given intramuscularly.
1668389|NCT01711034|Drug|OPB-111077|"Dose escalation phase starting with dose of 100mg tablets on Day 1 and 4, and all remaining days of each 28 day cycle until disease progression or toxicity develops.
Dose expansion phase starting with daily dosing of 250mg for 28 day consecutive day cycles."
1668390|NCT01711021|Drug|d-Amphetamine Transdermal System|Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
1668391|NCT01711021|Drug|Placebo patch|Patches will be worn for 9 hours every day. After 9 hours the patch will be removed. Every day a new patch will be applied.
1668392|NCT01711008|Dietary Supplement|Cereal|
1668393|NCT01711008|Dietary Supplement|No breakfast|
1954961|NCT03310060|Drug|Tisseel|Tisseel® (Fibrin Sealant, 4ml, Baxter) was applied on potential bleeding sites: the femoral insertion of the posterior cruciate ligament, the lateral genicular artery after resection of the meniscus, the posterior capsule of the knee joint, the bony surfaces not covered by the implant as well as the pinholes (femur and tibia). The entire content of a 4 mL vial containing the active product was used
1954962|NCT03310060|Drug|Tranexamic Acid|Drug: Tranexamic acid Intravenous application of tranexamic acid 15mg/kg in 100 ml normal saline before surgical incision and 3 hours after surgery
1668396|NCT01710982|Drug|TZP-101|
1668397|NCT01710982|Other|Placebo|
1668398|NCT01710969|Behavioral|Individual intervention|34 weekly sessions of cognitive-behavioral Coping Power intervention, delivered in an individual one-to-one format
1668399|NCT01710969|Behavioral|Group Intervention|34 weekly sessions of Coping Power intervention, delivered in a small group format (6 children per gorup)
1668400|NCT01710956|Radiation|Arm 1: with twice-daily thoracic radiotherapy/ Arm 2: with once-daily thoracic radiotherapy|Arm 1: with twice-daily thoracic radiotherapy daily 1.5gy/fr. bid, total 45gy(30fr during 3weeks) Arm 2: with once-daily thoracic radiotherapy daily 2.4gy/fr. qd, total 60gy(25fr during 5weeks)
1668401|NCT01710943|Behavioral|Web-based Cognitive Behavioral Treatment|"Participants in this condition will be asked to complete 24 CBT sessions, 2 sessions/topics per week for 12 weeks. We expect that each session will be approximately 30 minutes in duration. Participants will be asked to complete the 18 core modules of the program during the first 9 weeks of the trial and then to re-visit important modules and complete optional modules of their choice during the final 3 weeks of the trial. They can choose to do this using a designated computer in a private room at their local VA or can complete these sessions in the privacy of their own home with their personally-owned computers. Participants can choose to complete each session on any day/time of their choosing in a given week."
1668402|NCT01710930|Other|Study of predictive factors|"Phase 1 : Inclusion of patients (V0) :
In the case of a participation agreement, data on age, profession, previous history, history of the disease and current treatments will be collected. Different tests will be performed at this visit.
Phase 2 : Determination of the baseline (V1) : Patients will be reviewed one month after V0 (V1). In the absence of exacerbation between V0 and V1, the examinations performed in routine practice will be used to determine the basic state of biological parameters of interest. During this visit, different tests will be performed.
Phase 3 : Quarterly monitoring of patients (V2-V9) : Patients will be followed every three months for 2 years (V2-V9)."
1668403|NCT01710917|Drug|Targinact® (oxycodon/naloxon)|
1668404|NCT01710904|Drug|Targinact® (oxycodone/naloxone)|
1954963|NCT03310047|Drug|Infusion, Lidocaine, 0.5%, 5 mL|A catheter-based perineural infusion of 5 mL Lidocaine 0.5%
1954964|NCT03310047|Drug|Infusion, Lidocaine, 0.5%, 10 mL|A catheter-based perineural infusion of 10 mL Lidocaine 0.5%
1668407|NCT01710878|Device|Intergard Synergy Graft|
1668408|NCT01710865|Other|Ultraseal Sealant|This is a newly developed hydrophilic sealant material.
1668409|NCT01710865|Other|Ultraseal Sealant|This is a previously existing hydrophobic sealant material.
1668410|NCT01710852|Drug|ISIS CRP Rx|
1668411|NCT01710852|Drug|Placebo|
1668412|NCT01710839|Drug|0.5mg Ranibizumab|intravitreal injections
1668413|NCT01710839|Procedure|Targeted Pan Retinal Photocoagulation|Targeted Pan Retinal Photocoagulation based on wide field angiography
1668414|NCT01710826|Biological|Genz-682452|Capsules for oral administration.
1668415|NCT01710826|Biological|Placebo|Placebo capsules matching the Genz-682452 capsules.
1668416|NCT01710813|Biological|alglucosidase alfa|Alglucosidase alfa IV infusion of 20 mg/kg; qow
1668417|NCT01710800|Drug|Esomeprazole|
1668418|NCT01710800|Drug|placebo|
1668419|NCT01710787|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
1668420|NCT01710787|Drug|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
1668421|NCT01710787|Drug|Placebo|3 unilateral intranasal sprays per dose
1668422|NCT01710774|Procedure|Telemedicine follow-up care|Telemedicine follow-up care for people with diabetes-related foot ulcers in municipal primary health care in collaboration with specialist health care
1668425|NCT01710748|Device|Polymer-Based Everolimus-Eluting Stent|Polymer-Based Everolimus-Eluting Stent
1668426|NCT01710748|Device|Polymer-Free Amphilimus-Eluting Stent|Reservoir-Based Polymer-Free Amphilimus-Eluting Stent
1668948|NCT01707004|Drug|mycophenolate mofetil|Given PO
1668427|NCT01710735|Procedure|Dry needling|Insertion of acupuncture needle into a myofascial trigger point.
1668428|NCT01710722|Drug|caffeine and ephedrine|Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
1668429|NCT01710722|Drug|Leptin A|Leptin A-200 20 mg subcutaneously once daily and placebo tablets of caffeine and ephedrine three times a day.
1668430|NCT01710722|Drug|caffeine, ephedrine, and leptin A|Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
1668431|NCT01710709|Drug|Aripiprazole|400mg or 300mg, intramuscular injections every 4 weeks.
1668432|NCT01710696|Drug|17-beta estradiol|5-15 mcg/kg daily for 2 years. Dose readjusted every 3 months. Administered orally
1668433|NCT01710696|Drug|17-beta estradiol|0.2 mcg daily for 12 months, dose escalated to 0.5 mcg daily for 12 months. Administered orally
1668434|NCT01710683|Behavioral|Care program|Care program with multimodal pain treatment including epidural steroid
1668435|NCT01710683|Behavioral|Care program|Care program with multimodal pain treatment including epidural steroid.
1668436|NCT01710670|Drug|Brivaracetam|"Strength: 200 mg (4 x 50 mg)
Form: oral tablet
Frequency: single dose
Description: All subjects will receive a single oral dose of Brivaracetam (BRV) 200 mg, given as 50 mg tablets times 4 followed by an adequate volume of water (approximately 200 ml) in 2 of the 3 crossover periods. This dose will be administered 30 minutes after the initiation of the Ethanol / Ethanol Placebo infusion on Day 1."
1668437|NCT01710670|Other|Ethanol|"Form: intravenous infusion
Frequency: continuous infusion
Description: The ethanol infusion rate is initially based on weight, height, age, and sex. Subsequently, the infusion rate will be adjusted based on Breath Ethanol Measurements to maintain Breath Ethanol Levels (and by extension, blood ethanol levels) of 0.6 g / L."
1668438|NCT01710670|Other|Brivaracetam Placebo|In 1 of the 3 crossover periods, all subjects will receive 4 Placebo tablets to match the 50 mg Brivaracetam (BRV) tablets. The Placebo tablet will contain the same excipients as the BRV tablets but without BRV.
1668439|NCT01710670|Other|Ethanol Placebo|In 1 crossover period subjects will receive Ethanol Placebo (5% glucose). On Day 1, the continuous infusion of Ethanol Placebo will begin with a 30 minute Loading Phase prior to administration of Brivaracetam (BRV) / BRV Placebo and will continue until 5 hours after administration of BRV/BRV Placebo. During the first 10 minutes, the infusion will be accompanied by an infusion of 5% Glucose via the same line in order to mask the sensation at the beginning of the Ethanol infusion.
1668440|NCT01710657|Drug|Lacosamide 50 mg|"Active Substance: Lacosamide
Pharmaceutical Form: Film-coated tablet
Concentration: 50 mg
Route of Administration: Oral use"
1668441|NCT01710657|Drug|Lacosamide 100 mg|"Active Substance: Lacosamide
Pharmaceutical Form: Film-coated tablet
Concentration: 100 mg
Route of Administration: Oral use"
1668442|NCT01710657|Drug|Placebo|Matching oral Placebo tablets twice daily for 16 weeks.
1668443|NCT01710644|Drug|Burlulipase|Burlulipase oral solution will be taken with meals and snacks for 5 to 7 days
1668444|NCT01710644|Drug|Placebo (Caramel in sterile water)|Placebo will be taken with meals and snacks for 5 to 7 days
1668445|NCT01710631|Drug|eszopiclone 3 mg|eszopiclone 3 mg (comprised of either two 1.5 mg tablets, or one 1 mg tablet and one 2 mg tablet).
1668446|NCT01710631|Drug|placebo|placebo
1668447|NCT01710605|Biological|Circulating tumor cells counting at baseline|20 ml blood sample collected before randomization
1668448|NCT01710592|Drug|Epirubicin|
1668449|NCT01710592|Drug|Oxaliplatin|
1668450|NCT01710592|Drug|Capecitabine|
1668451|NCT01710592|Drug|Docetaxel|
1668452|NCT01710579|Procedure|Anorectal 3D-high resolution manometry|Anorectal probe is used with a single-use protective sheath with an inflation balloon Control of balloon deflation Patient in left lateral decubitus position with hips flexed to 90° (this position is the most commonly use and the most convenient) Transanal insertion 2 minutes resting period: resting anal pressure will be evaluated the second minute of rest Sustained voluntary maximal squeeze for at least 30 seconds; the maneuver will be repeated once Valsalva Bear down maneuver; the maneuver will be repeated once Anorectal reflexes evaluation with 20-, 40- and 60-ml intra-rectal balloon inflation Probe removal
1668453|NCT01710579|Procedure|Anorectal radial endosonography (rotative 360° probe)|Patient in left lateral decubitus position with hips flexed to 90° Transanal probe insertion Evaluation of internal and external anal sphincter integrity and puborectalis muscle at rest
1668454|NCT01710579|Procedure|Dynamic anorectal endosonography (sagittal and radial)|Patient in left lateral decubitus position with hips flexed to 90° Rectum is filled with 50-ml water Probe is covered with a water-filled balloon to maintain the acoustic window for the ultrasound wave Transanal probe insertion Slow and manual rotation of the linear probe through 360° to identify the various layers constituting the anal wall (mucosa, IAS, EAS), the layer forming the rectal wall and the perirectal tissues (puborectalis muscle, bladder, and vagina or prostate) After the initial examination, the patient will be asked to make a defecation effort with the probe left in the same position
1668455|NCT01710566|Drug|Misoprostol|600 mcg oral misoprostol to be administered after delivery of baby and before placenta is expelled
1668456|NCT01710566|Drug|Oxytocin|10 IU oxytocin in Uniject will be administered after delivery of baby and before placenta is expelled
1954965|NCT03310034|Dietary Supplement|NAD-precursors|Intervention product containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan (total of 204 NE per serving) in a whey protein source for 31 days.
1954966|NCT03310034|Dietary Supplement|Control|Control product containing amino-acid mixture resembling whey-protein not containing the NAD+-precursors nicotinic acid, nicotinamide, and tryptophan. To be taken for 31 days.
1954967|NCT03310021|Biological|Andexanet alfa|fXa inhibitor antidote
1954968|NCT03310021|Drug|Apixaban|factor Xa inhibitor
1668495|NCT01710228|Drug|methylprednisolone|192 MG FOR 5 CONSECUTIVE DAYS EVERY 4 WEEKS FOR 10 MONTHS
1954969|NCT03310021|Drug|Rivaroxaban|factor Xa inhibitor
1954970|NCT03310021|Drug|Edoxaban|factor Xa inhibitor
1954971|NCT03310021|Drug|Placebo|Placebo
1954972|NCT03310008|Biological|NKR-2 cells|The intervention will consist of an infusion of NKR-2 cells administered concurrently to a standard chemotherapy every 2 weeks (14 days) for a total of 3 infusions within 4 weeks (28 days).
1954973|NCT03309995|Device|Lozenges|The participants will be instructed to take 6 lozenges daily over the time awake, evenly distributed, allowing the lozenge to dissolve in the mouth as slowly as possible.
1668461|NCT01710527|Drug|Metformin 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
1668462|NCT01710527|Drug|Glucophage 500mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 500 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 500 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
1668463|NCT01710514|Drug|FE 999913 vaginal tablet|
1668464|NCT01710501|Drug|Grazoprevir|Grazoprevir tablet, orally, once per day at assigned dose
1668465|NCT01710501|Biological|pegylated interferon alfa-2b|1.5 mcg/kg/week, administered as a weekly subcutaneous (SC) injection
1668466|NCT01710501|Drug|Ribavirin|Ribavirin capsule, orally, twice daily, at a dose of 800 to 1400 mg based on participant weight
1668467|NCT01710501|Drug|Placebo|Placebo to match grazoprevir tablets to maintain dose blinding
1668468|NCT01710488|Drug|Levofloxacin 1 tablet 500 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:
Levofloxacin 500 mg (1 tablet) once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
1668469|NCT01710488|Drug|Prulifloxacin 1 tablet 600 mg once a day|"Will be used, according to a randomization list pre-ordered, centralized, in blocks of 4 patients:
Prulifloxacin 1 tablet 600 mg once daily for 7-10 days. The prescribing and dispensing of the drug will be made by medical personnel not directly involved in the data collection procedures for the study, and nursing staff, and the Medical Investigator will not be aware of the type of treatment to the individual. The drugs will be administered in the morning, about two hours after food."
1668470|NCT01710462|Drug|Pantoprazole + Domperidone|
1668471|NCT01710462|Drug|Pantozol®|
1668472|NCT01710449|Drug|perfluorinated gas/oxygen mixture|Subjects are imaged with MRI one time in an proof of concept study for the use of perfluorinated gas / oxygen mixtures as an MRI contrast agent for lung function.
1668473|NCT01710423|Behavioral|Peer mentoring intervention ('Cooking with Friends')|"'Cooking with Friends' is a community-located, peer mentoring intervention aimed at improving home food preparation practices in families with young children.
The intervention was developed in an iterative, community-based research approach, and will be conducted in partnership with Early Head Start (EHS) at The Children's Hospital of Philadelphia. Cooking with Friends builds on existing monthly cooking classes at EHS that have proven popular with EHS families. Through 5 weekly classes, this intervention will explore topics of how to prepare healthy foods at home.
The peer mentoring component is a novel innovation to this intervention. The intervention pairs peer mentors to individual mentees in a community setting, to effect behavioral change among caregivers of young children."
1668474|NCT01710410|Device|active transcranial Direct Current Stimulation|Brief (20-min) application of weak electric current (e.g., 2 mA) to the scalp.
1668475|NCT01710410|Device|sham transcranial Direct Current Stimulation|Brief (30-sec) application of weak electric current (e.g., 2mA) to the scalp.
1668476|NCT01710397|Other|Rapid ART initiation|Subjects offered the intervention who are eligible for antiretroviral therapy under South African guidelines will be offered the opportunity to initiate ART immediately, if possible on the same day as testing positive for HIV. Rapid testing technologies and an accelerated schedule will be used to allow all steps required prior to initiating ART to take place in approximately a half-day period.
1668477|NCT01710384|Drug|betamethasone|
1668478|NCT01710371|Drug|18F-AV-133|296 MBq (8 mCi)
1668479|NCT01710371|Drug|10% Arginine Hydrochloride-R-Gene 10|
1668480|NCT01710358|Drug|Adalimumab|Administered SC
1668481|NCT01710358|Drug|Baricitinib|Administered orally
1668482|NCT01710358|Drug|Methotrexate|Administered orally
1668483|NCT01710358|Drug|Adalimumab Placebo|Adalimumab placebo administered SC.
1668484|NCT01710358|Drug|Baricitinib Placebo|Baricitinib placebo administered orally.
1668485|NCT01710345|Drug|Sufentanil NanoTab 20 mcg|
1668486|NCT01710345|Drug|Sufentanil NanoTab 30 mcg|
1668487|NCT01710345|Drug|Placebo NanoTab|
1668488|NCT01710332|Drug|Intravitreal Aflibercept Injection|"GROUP A - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, and Month 4 (four injections total).
GROUP B - Aflibercept 2 mg injected at Baseline, Month 1, Month 2, Month 3, Month 4, and Month 5 (six injections total)."
1668489|NCT01710319|Other|blood draw|a blood specimen will be obtained from each patient in the four groups. An optional blood draw after 30 days of initial blood specimen if indicated.
1954974|NCT03309995|Device|Placebo lozenges|Placebo lozenges
1668491|NCT01710293|Behavioral|Communication of Patients Lost to Follow-up to Providers|"The investigators will query the VA's database weekly to identify possible lost to follow-up events for a random sample of about half of the providers at our study sites. The queries will use the trigger criteria developed in our previous work for colorectal cancer, lung cancer, hepatocellular carcinoma, breast cancer, and bladder cancer. The list of trigger positive patients will be transmitted to a facility-level recipient who will either disseminate the information to existing facility individual cancer care coordinators/trackers or will review the charts of the triggered patients in order to determine whether these patients have been truly lost to follow-up or not. If patients are found to be lost to follow-up, the Facility Recipient or cancer care coordinator/tracker will communicate the need for follow-up to the PACT or primary care provider, using secure emails, phone calls, or in person, depending on which method of communication they deem most appropriate and effective."
1668492|NCT01710280|Dietary Supplement|High-fat meal containing native palm olein|
1668493|NCT01710280|Dietary Supplement|High-fat meal containing interesterified palm olein|
1668949|NCT01707004|Biological|filgrastim|Given SC
1954975|NCT03309982|Dietary Supplement|Plant polyphenol blend|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
1668496|NCT01710215|Other|FIT Screening Strategy|"Mailed outreach invitation to complete FIT, including a test kit (1-sample FIT, simplified instructions on how to perform the test, and return mailer with prepaid postage).
Two live phone reminders from project staff 2 to 3 weeks after the invitation to encourage screening completion.
Centralized processes to promote guideline-based follow up."
1668497|NCT01710215|Other|Colon Screening Strategy|"Mailed outreach invitation to complete a colonoscopy, including a number to call to schedule a colonoscopy.
Two live phone call reminders from project staff 2 to 3 weeks after the mailed invitation to encourage screening completion.
Centralized processes to promote guideline-based follow up."
1668498|NCT01710202|Drug|Hydrocortisone|Each subject in this group will receive one 20mg hydrocortisone capsule to be taken by mouth.
1668499|NCT01710189|Drug|TicoVac|Intramuscular immunisation to right deltoid muscle (Group 1) or right upper anterolateral thigh muscle (Group 2).
1668500|NCT01710176|Drug|epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3)|
1668501|NCT01710176|Drug|gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8)|
1668502|NCT01710176|Drug|trabectedin 1.3 mg/m2|
1668503|NCT01710176|Drug|high-dose ifosfamide 14 g/m2, given in in 14 days|
1668504|NCT01710176|Drug|etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3)|
1668505|NCT01710176|Drug|gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)|
1668506|NCT01710163|Drug|Lithium|Starting at 300 mg daily, weekly dose will be adjusted according to blood serum level (between 0.5 -0.8mEq/l) according to efficacy and tolerability.
1668507|NCT01710163|Drug|Aripiprazole|Starting at 10 mg daily, dose will be adjusted up to 15 mg daily according to efficacy and tolerability.
1668508|NCT01710150|Procedure|CTI ablation alone|
1668509|NCT01710150|Procedure|CTI ablation and Pulmonary vein isolation (PVI)|
1668510|NCT01710137|Drug|Varenicline|
1668511|NCT01710137|Drug|Placebo|
1668512|NCT01710137|Behavioral|Smoking Cessation Counseling|
1668513|NCT01710124|Other|Financial incentives|
1668514|NCT01710111|Device|Intervention Recipients Face Shield|Face shield and repeat hand hygiene measures
1668515|NCT01710098|Drug|Degarelix|subcutaneous injection
1668516|NCT01710085|Device|Diffusion weighted MRI (DW- MRI)- Philips Achieva 3.0T X, Netherlands, 2011|Recurrence in cervical and endometrial cancer patients who were treated with curative surgery is routinely investigated by MRI examination. MRI is diagnostic technique not requiring ionizing radiation and is based on magnetic fields.
1668517|NCT01710072|Drug|aspirin|
1668518|NCT01710059|Behavioral|Asthma Supervision|Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.
1668519|NCT01710059|Behavioral|Mobile Phone|Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
1668520|NCT01710059|Behavioral|Inhaled Corticosteroid Mobile Phone Application|The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.
1668521|NCT01710059|Behavioral|Beta2-adrenergic agonist Mobile Phone Application|The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
1954976|NCT03309982|Other|Placebo|A powder product that will be mixed into a drink and consumed immediately prior to eating a high-fat meal
1954977|NCT03309956|Device|Holter Monitor|A Holter monitor is a battery-operated portable device that measures and records your heart's electrical activity (ECG) continuously. Patients in this study will wear the monitor for 48 hours.
1668526|NCT01710033|Drug|Placebo|Placebo tables twice daily (BID) for 28 days
1668527|NCT01710033|Drug|CP-690,550 5 mg BID|CP-690,550 5 mg BID for 28 days
1668528|NCT01710033|Drug|CP-690,550 15 mg BID|CP-690,550 15 mg BID for 28 days
1668529|NCT01710033|Drug|CP-690,550 30 mg BID|CP-690,550 30 mg BID for 28 days
1668530|NCT01710020|Drug|CP-690,550|CP-690,550 10 mg oral powder for constitution
1668531|NCT01710007|Drug|1PC002|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
1668532|NCT01710007|Drug|Lipitor|Subjects should be instructed to take 1 capsule of study drug (1PC002 or atorvastatin) orally once a day, with or without food. Administration before bedtime or at regular time-interval is recommended.
1668533|NCT01709994|Drug|Aspirin|100 mg/day of aspirin
1668534|NCT01709981|Drug|Colchicine|Colchicine 1.2mg 1 to 2 hours prior PCI, followed by 0.6mg 1 hour later
1668535|NCT01709981|Drug|Placebo|Placebo 1 to 2 hours prior PCI, followed by Placebo 1 hour later
1668536|NCT01709968|Drug|MAGNOX 520®|un-organic granular magnesium complex, composed of Magnesium Oxide & Magnesium Oxide Monohydrate 865mg, Provides 520 mg of free elemental Mg ++); Oral administration once daily for 4 weeks
1668537|NCT01709968|Drug|placebo|Similarly looking placebo. Oral administration once daily for 4 weeks
1668538|NCT01709955|Dietary Supplement|Glucomannan|750 MG of Glucomannan in capsule form
1668539|NCT01709955|Other|Placebo|750 mg of Cellulose powder in a capsule form
1668540|NCT01709942|Drug|degarelix (long acting GnRH antagonist)|20 mg of degarelix the first day of menstrual cycle before starting with gonadotrophins administration
1668541|NCT01709942|Drug|cetrorelix 0.25mg|0.25mg of cetrorelix during treatment with gonadotrophins when estradiol levels were >300pg/ml
1668542|NCT01709929|Drug|insulin detemir|Administered subcutaneously (s.c., under the skin). Dose individually adjusted.
1668543|NCT01709903|Drug|QVA149|QVA149 110/50 µg capsules q.d. for inhalation, delivered via Novartis single dose dry powder inhaler (SDDPI).
1668950|NCT01707004|Radiation|total-body irradiation|Undergo total-body irradiation
1668544|NCT01709903|Drug|Fluticasone/salmeterol|Active fluticasone/salmeterol (500/50µg) b.i.d via a dry power inhaler Accuhaler® device.
1668545|NCT01709903|Drug|Placebo to QVA149|Placebo to QVA149 with SDDPI
1668546|NCT01709903|Drug|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol with Accuhaler
1668547|NCT01709890|Device|YO2(R) catheter|
1668548|NCT01709877|Procedure|Cholecystectomy|Multiport and single-port laparoscopic cholecystectomy in patient with symptomatic gallstone disease
1668549|NCT01709864|Drug|NVA237|NVA237 (glycopyrronium bromide) as a powder for inhalation in single-dose capsules.
1668550|NCT01709864|Drug|Placebo|Placebo powder for inhalation in single-dose capsules (matching those for NVA237).
1668551|NCT01709851|Device|Vascular microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular microdialysis using the GlucoMen(R)Day system
1668552|NCT01709851|Device|Vascular and subcutaneous microdialysis using the GMD-system|Glucose levels will be monitored by means of vascular and subcutaneous microdialysis using the GlucoMen(R)Day system
1668553|NCT01709838|Drug|ICL670 deferasirox|deferasirox
1668554|NCT01709825|Dietary Supplement|Probiotic- Bifidobacterium Bifidum|Bifidobacterium bifidum R0071 will be taken as a capsule once daily for 6 weeks.
1668555|NCT01709825|Dietary Supplement|Sugar Pill|Sugar Pill (Sucrose) will be taken as a capsule once daily for 6 weeks.
1668556|NCT01709825|Dietary Supplement|Probiotic- Lactobacillus helveticus|Lactobacillus helveticus R0052 will be taken as a capsule once daily for 6 weeks.
1668557|NCT01709825|Dietary Supplement|Probiotic- Bifidobacterium longum ss. Infantis R0033|Bifidobacterium longum ss. Infantis R0033 (Supplement C) will be taken as a capsule once daily for 6 weeks.
1668558|NCT01709812|Other|individualized patient support program|individualized patient support with compliance supporting tools
1668559|NCT01709812|Other|Standard care|
1668560|NCT01709799|Behavioral|Exercise|"Participants will do physical activity that raises heart rate to a target heart rate (THR)zone which is pre-calculated using the Karvonen Formula:
(THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate
Participants begin exercise regimen starting at 50% THR for intensity and gradually increase by 5% up to a maximum of 75% THR.
Activity duration begins at 10 mins./day and increases 5 mins. every week following to a maximum of 40 mins. Polar Heart Rate monitors are used to measure THR and save resulting data."
1668561|NCT01709799|Behavioral|Exergames|"Participants experience Wii Video Games in a standardized format, beginning with 15 mins of seated play per day on week one, and then increasing 5 mins./week on each week following up to a maximum of 40mins. of play.
Participants are made aware of the Target Heart Rate Zone for the week, but are not required to reach that zone during play. The THR is calculated by the Karvonen Formula:
THR={(max. heart rate- rest heart rate) x %intensity} + resting heart rate
Polar Heart Rate monitors are used to measure THR and save resulting data."
1668562|NCT01709799|Behavioral|Cognitive Training|"Posit Science INSIGHT program games are used for all cognitive training. Participants are exposed to (2) forty minute game sessions per day, for the cognitive training weeks #4,8,12,16.
INSIGHT Assessments are done at baseline, the start of each training week and at week 28."
1668563|NCT01709773|Procedure|Focal treatment|Focal treatment of high-grade cervical intraepithelial neoplasia using laser ablation, cryotherapy, or loop electrosurgical excision procedure
1668564|NCT01709760|Drug|Methotrexate|Methotrexate 15-25 mg/week
1668565|NCT01709760|Drug|ENIA11|ENIA11 25 mg, sc twice weekly
1668566|NCT01709760|Drug|Placebo|Placebo, sc twice weekly
1668567|NCT01709747|Drug|Hydromorphone Hydrochloride|Opioid for chronic pain
1668568|NCT01709734|Drug|galeterone|
1668569|NCT01709721|Drug|Hydromorphone Hydrochloride|Subjects who meet criteria for randomization, will be randomized in a 1:1 ratio to either the active arm or control arm.
1668570|NCT01709721|Drug|Hydromorphone Hydrochloride|Active Control Based on Dose Reduction
1668571|NCT01709708|Drug|Marcaine|Marcaine used as a topical local anesthetic to block the SPG by delivering Marcaine directly to the specific area of mucosa associated with the SPG.
1668572|NCT01709708|Drug|Saline|
1954978|NCT03309956|Device|Zio Patch|The Zio Patch is a small, adhesive, water-resistant single lead electrocardiographic monitoring device. Patients in this study will wear the patch for 48 hours.
1954979|NCT03309943|Drug|Propranolol|Participants will take one dose of Propranolol (40mg IR) on two separate occasions.
1668575|NCT01709682|Drug|Anti-Arrhythmia Agents (propafenone, flecainide, and/or sotalol, or amiodarone)|propafenone, flecainide, and/or sotalol as first-line drugs in patients without structural heart disease or amiodarone as a single drug or in combination in patients with structural heart disease or in case of first-line drug failure
1668576|NCT01709682|Procedure|re-ablation procedure|Reisolation of the PVs was performed by identifying the breakthrough site on the mapping catheter (NaviStar ThermoCool, Biosense-Webster Inc., Diamond Bar, CA). RF energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of ablation was complete PVI; this was confirmed when Lasso catheter mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
1668577|NCT01709682|Procedure|ILR implantation|"The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
Patients were provided with the Patient Assistant, a tool that allows each patient to store the ECG through the implanted device during symptoms; data were collected in order to analyze heart rhythm during symptomatic events."
1668578|NCT01709656|Biological|MSC|"human mesenchymal stem cells,1*10^4-6 cells /Kg , IV (in the vein) on day 1 of each 14-60 day cycle,1-6 times treatment.
a total of 24 weeks for follow up."
1668579|NCT01709656|Drug|"celecoxib, Celebrex®"|"non-steroid anti-inflammatory drugs (NSAID):celecoxib, Celebrex® 0.2g Bid(twice a day),PO (Per Os);a total of 24 weeks for follow up"
1668580|NCT01709643|Dietary Supplement|High fat breakfast|"The HF breakfast will consist of sausage rolls (saucijzenbroodjes), available at the local Albert Heijn (Albert Heijn B.V., Zaandam, The Netherlands)."
1668581|NCT01709643|Dietary Supplement|HF breakfast with protein|For the HFP breakfast, the subjects will consume 'Protifar' (Nutricia, Cuijk, The Netherlands) in addition to the sausage rolls.
1668582|NCT01709630|Drug|Magnesium sulfate infusion|Participants will be given magnesium sulfate infusion as part of their normal care for either preeclampsia, tocolysis, or neuroprotection.
1668583|NCT01709617|Dietary Supplement|Carbohydrate ingestion|Various types of carbohydrate ingested during and following exercise
1668584|NCT01709604|Procedure|CVVH|Ultrafiltration at 35ml/h/Kg
1668585|NCT01709604|Procedure|Standardized therapy regimens|"Standardized therapy regimens included the followings:
Remove all contaminated clothing
Gastric lavage
Receive activated charcoal as quickly as possible
Hemoperfusion with activated charcoal(160g)
Immunosuppression with methylprednisolone
Antioxidants (glutathione,1.2 gram iv twice a day)
Supportive care"
1668586|NCT01709591|Behavioral|Prenatal education|
1668587|NCT01709578|Drug|Sarilumab|Pharmaceutical form:solution Route of administration: subcutaneous
1668588|NCT01709578|Drug|placebo|Pharmaceutical form:solution Route of administration: subcutaneous
1668589|NCT01709578|Drug|hydroxychloroquine|Dispensed according to the local practice.
1668590|NCT01709578|Drug|methotrexate|Dispensed according to the local practice.
1668591|NCT01709578|Drug|sulfasalazine|Dispensed according to the local practice.
1668592|NCT01709578|Drug|leflunomide|Dispensed according to the local practice.
1668593|NCT01709552|Behavioral|Computer Intervention|Patients randomized to the computer intervention will complete the B-SAFER computer program during their emergency department visit.
1668594|NCT01709552|Behavioral|Control|Patients randomized to the control arm will receive a time-equivalent computer-based program unrelated to substance use or partner violence.
1668596|NCT01709526|Behavioral|Improvement after psychiatric inpatient treatment|Cognition, psychosocial functioning
1668597|NCT01709513|Drug|Atorvastatin|Atorvastatin over-encapsulated tablets.
1668598|NCT01709513|Drug|Ezetimibe|Ezetimibe over-encapsulated tablet.
1668599|NCT01709513|Drug|Alirocumab|Alirocumab SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
1668600|NCT01709513|Drug|Placebo|Placebo for alirocumab, ezitimibe and atorvastatin.
1668601|NCT01709500|Drug|LMT (atorvastatin, simvastatin, or rosuvastatin)|
1668602|NCT01709500|Drug|alirocumab|Alirocumab administered as a subcutaneous (SC) injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
1668603|NCT01709500|Drug|Placebo|Placebo matched to alirocumab administered as a SC injection of 1 mL into the abdomen, thigh, or outer area of the upper arm.
1668604|NCT01709487|Procedure|HIPEC|HIPEC with cisplatin 50 mg/m2 intraperitoneally at the end of surgery
1668605|NCT01709474|Drug|Vitamin D3 6000 IU|Subjects will receive 6,000 IU of vitamin D3 by mouth daily until the subject's serum 25(OH) level is ≥ 40ng/mL at which point the supplementation dose will be reduced to 4,000 IU/day. Note: Subjects weighing <40 kilograms (kg) at study entry will receive their dose five days a week and all other subjects seven days a week.
1668606|NCT01709474|Drug|Vitamin D3 400 IU|Subjects will receive 400 IU/day of vitamin D3 daily by mouth.
1668607|NCT01709435|Drug|Cabozantinib S-malate|Given PO
1668608|NCT01709435|Other|Laboratory Biomarker Analysis|Correlative studies
1668609|NCT01709435|Other|Pharmacological Study|Correlative studies
1668610|NCT01709422|Drug|Propofol|Propofol is the sedative drug used as an additional sedation to one of the study arm.
1668611|NCT01709422|Drug|Midazolam|Midazolam is one of the two conventional sedative drugs included in both arms.
1668612|NCT01709422|Drug|Meperidine|Meperidine is one of the two conventional sedative drugs included in both arms.
1954980|NCT03309943|Drug|Placebo|Participants will take one dose of Placebo on two separate occasions.
1668615|NCT01709396|Radiation|ED-TBI|Patients will receive 18Gy ED-TBI in 8 fractions of 2.25 Gy each, twice/day for 4 days. Following the final fraction of TBI and an allogeneic hematopoietic stem cell graft.
1668616|NCT01709383|Device|Transcranial Direct Current Stimulation|The tDCS treatments will be applied bilaterally, with the anodal electrode placed on the left temple and the cathodal electrode placed on the right temple. The tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
1668617|NCT01709383|Device|Sham Stimulation|The sham tDCS will be applied at the beginning of 60-minute speech-language treatment sessions for five days across a one-week period.
1668618|NCT01709370|Drug|Letrozole, PD 0332991|
1668619|NCT01709357|Other|Muscle energy technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed passive side flexion, contralateral to the muscle, taking the subject's head until the end-feel. Then, subjects performed an isometric contraction of 25% of their maximum force, for 5 seconds, while the therapist offered manual resistance. Afterwards the subject was let to relax in this position for additional 5 seconds. Side flexion was now increased until a new end-feel point was reached. This sequence was repeated 3 times. At the end, the therapist passively guided the cervical segment to the neutral position.
1668620|NCT01709357|Other|Passive stretching technique|The therapist, with one hand on the occipital bone and the other on the shoulder, performed a contralateral side flexion of the muscle passively until the maximum obtainable amplitude was reached, while subjects were asked to breathe steadily. During the breathing phase the therapist increased the side flexion until the end of the obtainable amplitude, this position was maintained. This procedure was repeated during 30 seconds. Finally the therapist passively guided the cervical segment to the neutral position.
1668795|NCT01708265|Procedure|Early mitral valve repair|Patients in the group of early mitral valve repair will be operated by way of routine mitral valve repair procedures in specialized centres.
1669339|NCT01704287|Drug|Temozolomide|Temozolomide per institutional standard.
1668621|NCT01709357|Other|Ischemic compression technique|"The therapist, with a pincer contact, applied gradual pressure on the latent trigger point of the upper trapezius muscle. Subjects had been previously asked to say when pain was moderate but bearable, a pain value of 7 in a 1 to 1o scale of pain (in which 1 corresponds to no pain and 10 do unbearable pain). At this point, pressure was maintained until pain levels were reduced to level 3. The therapist increased once more the pressure until the level of pain was 7 again. This procedure was repeated during 90 seconds."
1668622|NCT01709357|Other|Sham technique|The therapist was seated at the head of the treatment table, and with one hand on the occipital bone and the other on the shoulder, without executing any movement, for 30 seconds.
1668623|NCT01709344|Behavioral|PS-OT|
1668624|NCT01709344|Other|Usual care|Supportive and rehabilitation services available at DHMC
1668625|NCT01709331|Drug|Corifollitropin alfa|Corifollitropin alfa 150 μg by SC injection, once every 2 weeks for 52 weeks
1668626|NCT01709331|Drug|hCG|hCG 1500 or 3000 IU by SC injection twice a week; administered alone for 16 weeks (pre-treatment phase) and then in combination with corifollitropin alfa for 52 weeks (combined treatment phase)
1668627|NCT01709318|Drug|Nomegestrol acetate (NOMAC)|Daily release of 500, 700, or 900 μg.
1668628|NCT01709318|Drug|Etonogestrel (ENG)|Daily release of 75, 100, or 125 μg
1668629|NCT01709318|Drug|Ethinyl estradiol (EE)|Daily release of 15 μg
1668630|NCT01709318|Drug|Estradiol (E2)|Daily release of 300 μg
1668631|NCT01709305|Drug|Metformin|Metformin, 500 mg or 850 mg oral tablets, twice or three times a day (BID or TID) for a total dose of at least 1500 mg daily; administered with food.
1668632|NCT01709305|Drug|Sitagliptin|Sitagliptin, 100 mg oral tablet, once daily (QD); administered with or without food
1668633|NCT01709305|Drug|Acarbose|Acarbose, 50 mg oral tablets, TID (150 mg total daily dose); administered with the first bite of each main meal.
1668634|NCT01709305|Drug|Repaglinide|Repaglinide, 0.5 mg and/or 1 mg oral tablets, TID (up to 16 mg daily); administered within 30 minutes of each meal.
1668635|NCT01709305|Drug|Glimepiride|Glimepiride, 1 mg and/or 2 mg oral tablets, QD (up to 6 mg daily); administered before the first main meal of the day
1668636|NCT01709305|Drug|Gliclazide|Gliclazide, 30 mg oral tablets, QD or BID (30 mg to 120 mg total daily dose); administered with meal.
1668637|NCT01709292|Drug|Vemurafenib (All Groups)|960 mg by mouth 2 times a day 56 days prior to surgery (patients not planned for surgical resection will have a core biopsy at day 56.
1668638|NCT01709292|Drug|Vemurafenib (Post Surgery) - Group A + C|"Group A: 960 mg by mouth twice a day 2 weeks post-surgery. Restaged 8 weeks after resuming drug. If patients demonstrate either stable or regressing disease, they will continue on vemurafenib with restaging occurring every 8 weeks until they are no longer benefitting from the drug.
Group C: Patients not scheduled for surgical resection undergo a CT scan and core biopsy at day 56. Vemurafenib 960 mg by mouth twice a day, continued unless there is evidence of progressive disease on day 56 CT scan. Patients restaged every 8 weeks and continue vemurafenib until no longer benefitting from the drug. Patients evaluated for resectability after each CT scan is performed. If patient is scheduled for resection, then patient will continue vemurafenib until surgery and will follow the same treatment schema as patients in Groups A and B."
1668639|NCT01709292|Other|Post Surgery - Group B|Patients who have had a complete surgical resection, and who do not have evidence of metastatic disease will discontinue vemurafenib after surgery. Patients restaged with CT neck 8 weeks after surgery.
1668640|NCT01709279|Biological|adipose tissue derived stromal cells dosage|intra-coronary administration of autologous adipose tissue derived stroma cells
1668641|NCT01709266|Dietary Supplement|Probiotics|
1668642|NCT01709266|Dietary Supplement|Placebo|
1668643|NCT01709253|Radiation|proton beam therapy|hypofractionation study using proton beam therapy for prostate adenocarcinoma
1668644|NCT01709240|Device|BioWeld1 System|External skin layer closure of C-section incision by the BioWeld1 system. Removal of Chitoplast on day 4-7 post procedure.
1668645|NCT01709227|Drug|Furosemide|Patients randomized to the furosemide arm will be given 1 mg/kg intravenously every 6 hours for 2 doses and then as directed by CICU attending to augment urine output. Patients within this arm who have urine output <1 ml/kg/hr over 16 hours after the first dose of Lasix will be considered poor responders. These patients may be started on PD if clinically indicated. Those who show good response (urine output >1 ml/kg/hr over subsequent 16 hours) will continue furosemide as needed to augment urine output. If they subsequently develop oliguria or fluid overload unresponsive to diuretic therapy, these patients may later be started on PD at discretion of CICU attending with consultation of nephrology service.
1668646|NCT01709227|Procedure|Peritoneal Dialysis|Patients within the PD arm will begin PD with a standardized dialysis plan of 10ml/kg of 1.5% Dianeal™ with 1 hours cycles (5 minute fill, 45 minute dwell and 10 minute drain). Further PD management and discontinuation will be directed by CICU attending and Nephrology service.
1668647|NCT01709214|Drug|Cebranopadol (GRT6005) Low-Dose Range|
1668648|NCT01709214|Drug|Cebranopadol (GRT6005) High-Dose Range|
1668649|NCT01709214|Drug|Placebo|
1668650|NCT01709214|Drug|Oxycodone CR|
1668651|NCT01709201|Behavioral|Brief Intervention|Those in the intervention arm will undergo a 10-minute discussion with a trained interventionist aimed at encouraging decreased substance use.
1668654|NCT01709175|Behavioral|Strength Training|This is a 13 week strength training program. Sessions will be supervised by a Certified Exercise Physiologist in a group setting.
1668655|NCT01709162|Biological|Ipilimumab|
1668656|NCT01709162|Drug|Chemotherapy|
1668657|NCT01709149|Drug|CK-2017357|CK-2017357 125 mg tablets twice daily
1668658|NCT01709149|Other|Placebo tablets|Tablets
1668659|NCT01709149|Drug|Riluzole|Tablets
1668796|NCT01708252|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668797|NCT01708239|Other|Left rule, D-dimer measurement and complete ultrasonography in pregnant women.|Diagnostic strategy based on the LEFt rule, D-dimer measurement and complete ultrasonography
1668798|NCT01708226|Behavioral|Attention Modification Program|Computer-based attention training treatment designed to directly but implicitly modify biased attention patterns in anxious patients in service of symptom relief.
1668660|NCT01709136|Drug|Sirolimus|Single dose SRL pharmacokinetics and TAC steady state pharmacokinetics: This phase is applicable to both sets of patients: those with nephrotoxicity and those with hypertension. Patients will receive a single dose of SRL of 2 mg/m2. Blood sampling will be performed over a 24 hour stay in the Children's Hospital of Pittsburgh's Pediatric Clinical and Translational Research Center (PCTRC) - See more at: http://www.chp.edu/research/our-facilities/pctrc, and the sampling for 48 hour and 72 hour PK studies can be done at the outpatient lab. This phase can either be performed immediately after the 12-hour iothalamate GFR evaluation, or a few days later at the convenience of the subject.
1668661|NCT01709123|Drug|chromium niacinate|200ug or 500ug supplementation in pill form
1668662|NCT01709123|Drug|placebo|Placebo pill for chromium niacinate
1954981|NCT03309930|Behavioral|Comprehension Acquired Brain Injury|For study 1 participants will be exposed to 3 conditions as stated in previous descriptions and will last 1 to 2 sessions. Study 2 will begin with 1 session with the researcher lasting about 30 minutes. Then participants will be asked to complete practice at home for about 15 minutes each day for 2 weeks using a computer/iPad. Study 2 Post Testing and Maintenance Sessions 1 and 2: approximately 60 minutes per session.
1668668|NCT01709084|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, form=tablet, route=oral. Rilpivirine will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
1668669|NCT01709084|Drug|Efavirenz|Type=exact number, unit=mg, number=600, form=tablet, route=oral. Efavirenz will be administered in a fixed dose combination along with tenofovir disoproxil fumarate and emtricitabine, as a single dose tablet.
1668670|NCT01709084|Drug|Tenofovir disoproxil fumarate|Type=exact number, unit=mg, number=300, form=tablet, route=oral. Tenofovir disoproxil fumarate will be administered in a fixed dose combination along with rilpivirine and emtricitabine in Group 1, and along with efavirenz and emtricitabine in Group 2.
1668671|NCT01709084|Drug|Emtricitabine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Emtricitabine will be administered in a fixed dose combination along with rilpivirine and tenofovir disoproxil fumarate in Group 1, and along with efavirenz and tenofovir disoproxil fumarate in Group 2.
1668672|NCT01709071|Drug|IPV|
1668673|NCT01709071|Drug|Low dose Sabin-IPV|
1668674|NCT01709071|Drug|Low dose adjuvanted Sabin-IPV|
1668675|NCT01709071|Drug|Middle dose Sabin-IPV|
1668676|NCT01709071|Drug|Middle dose adjuvanted Sabin-IPV|
1668677|NCT01709071|Drug|High dose Sabin-IPV|
1668678|NCT01709071|Drug|High dose adjuvanted Sabin-IPV|
1668679|NCT01709058|Drug|Intramuscular/paravertebral injections of Oxygen-Ozone|"Medical Oxygen will be used as a part of the injected mixture (100% oxygen, 200 bar compressed gas in steel cylinder with valve 14 with an integrated reductive). For the generation of the Oxygen-Ozone mixture a certified equipment OZONOSAN alpha plus will be used according to the D.L. 46/97, EEC Directive 93/42, class 2A with a photometer. The mixture of O2-O3 is produced through a method called silent discharge. Intramuscular/paravertebral injections to 3 cm from the spinal medial line will be performed introducing 5-20 mL of oxygen-ozone to each point, at a concentration of 10-20 micrograms/mL, for a total volume of 40 mL"
1668680|NCT01709058|Other|Simulated intramuscular/paravertebral injections|The simulated treatment administration will mimic the treatment in the area to be treated by pricking the skin with the needle without drilling. A light massage will be practice by hand and the application area will be covered with a bandage adhesive leaving the patient in the prone position for 10-15 minutes.
1668681|NCT01709045|Other|Magnetic Resonance Imaging (MRI)|Multi-sequence MR protocol
1668682|NCT01709045|Radiation|Dual-Energy Computed Tomography (DECT)|
1668683|NCT01709045|Other|Ultrasound|
1668684|NCT01709045|Other|Transcranial doppler|
1668686|NCT01709019|Biological|Low dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
1668687|NCT01709019|Biological|Low dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & day 28)|0.5mL IM injections
1668688|NCT01709019|Biological|High dose RSV-F Vaccine with Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
1668689|NCT01709019|Biological|High dose RSV-F Vaccine without Adjuvant (Day 0); Seasonal TIV (Day 0 & Day 28)|0.5mL IM injections
1668690|NCT01709019|Biological|Placebo (Day 0 & Day 28); Seasonal TIV (Day 0)|0.5mL IM Injections
1668691|NCT01709006|Radiation|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions|Modulated radiotherapy (IMRT) using RapidArc® or Helical Tomotherapy® at a dose of 70 Gy in 33 fractions to the PTV (GTV) and 59.4 Gy in 33 fractions
1668692|NCT01708993|Drug|Pemetrexed and Reolysin (and safety run-in)|Pemetrexed: 500 mg/m², IV (10 min) - Day 1 every 3 weeks Reolysin: 4.5 x 10^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
1668693|NCT01708993|Drug|Pemetrexed|Pemetrexed: 500 mg/m² IV (10 min) - Day 1 every 3 weeks
1668694|NCT01708993|Drug|Docetaxel and Reolysin|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks Reolysin: 4.5x10^10 TCID50 IV (1 hour) - Days 1-3, every 3 weeks
1668695|NCT01708993|Drug|Docetaxel|Docetaxel: 75 mg/m² IV (1 hour) - Day 1 every 3 weeks
1668696|NCT01708980|Other|Six different strength training exercises|"Electromyographic (EMG) activity of the vastus medialis, vastus lateralis, semitendinosus and biceps femoris muscles of the operated leg will be recorded during 6 different strength training exercises. The six exercises performed unilaterally are: seated knee extensions and leg presses in machines (gold standard exercises), and the four other exercises are: sit-to-stands, squats, straight leg raises and seated knee extensions using an elastic band.
The relative loading will be 10 repetition maximum (RM). The absolute load (kilograms) corresponding to 10 RM of the 6 strength training exercises is defined a minimum of 3 days before the day where the EMG-data are recorded. Range of motion and time under tension for each repetition will be controlled for."
1668799|NCT01708213|Device|Aline HA|Implantable dermal filler
1668800|NCT01708200|Other|Memory Intervention|A comparison of two type of memory intervention protocols; a psychoeducational/intervention protocol versus a computerized memory protocol in a population of individuals with mental illness.
1668801|NCT01708187|Biological|Clarix™1k graft|"Group 1 will have standard peroneal repair surgery with the addition of the Clarix™1k tissue.
Group 2 will have standard peroneal repair surgery without the use of the Clarix™1k tissue."
1668697|NCT01708967|Procedure|pretreatment method for transnasal endoscopy|"Catheter-free method : The patient then takes simethicone (10cc). After that, the nasal cavity is sprayed with epinephrine (1cc) and lidocaine HCL (4%, 4cc).
Catheter inesertion method: After preparation steps the same as in the 'catheter-free' method, a 14 Fr. flexible catheter is coated with 2% lidocaine HCL gel and 8% lidocaine HCL spray. After that, the catheter is inserted into the patient's nasal cavity, and maintained about 1 minute for anesthesia. A 16 Fr. catheter is prepared by the same method with as the 14Fr. catheter. After the 14 Fr. cathter has been removed from the patient's nasal cavity, the 16 Fr. catheter is inserted into the patient's nasal cavity."
1668698|NCT01708954|Drug|Cabozantinib|Given PO
1668699|NCT01708954|Drug|Erlotinib|Given PO
1668703|NCT01708928|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668704|NCT01708915|Drug|nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
1668705|NCT01708915|Drug|placebo matching nonivamide + nicoboxil|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
1668706|NCT01708915|Drug|nonivamide + nicoboxil (Finalgon)|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
1668707|NCT01708915|Drug|nonivamide|2cm ointment line for a skin area of approximately 20 cm x 20 cm up to 3 times in a 24h period
1668708|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
1668709|NCT01708902|Drug|linagliptin2.5mg/metformin1000mg|linagliptin2.5mg/metformin1000mg BID
1668710|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
1668711|NCT01708902|Drug|Metformin 500mg|Metformin 500mg BID
1668712|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
1668713|NCT01708902|Drug|linagliptin2.5mg/metformin500mg|linagliptin2.5mg/metformin500mg BID
1668714|NCT01708902|Drug|linagliptin 5mg|linagliptin 5mg once daily
1668715|NCT01708902|Drug|Metformin 1000mg|Metformin 1000mg BID
1668716|NCT01708889|Biological|BMS-914143 (Peginterferon Lambda-1a)|
1668717|NCT01708876|Drug|Artesunate-mefloquine|
1668718|NCT01708876|Drug|Chloroquine|
1668719|NCT01708876|Drug|Primaquine|Given to P. vivax patients only. Delayed administration at day 28; 0.5mg/kg for children or 45mg for adults; normal G6PD activity (once daily administration for 14 days); moderate G6PD deficiency (once weekly for 8 weeks); severe G6PD deficiency (contraindicated / not given).
1668720|NCT01708850|Drug|Rivaroxaban|All specified in arm description. One arm study.
1668721|NCT01708837|Drug|Propofol|Propofol infusion rate is titrated to maintain the target BIS values
1668722|NCT01708824|Behavioral|Dietary|"Dietary intervention to meet the target of
<5 servings of red/processed meat weekly; <2 servings would be processed meat
2 servings of refined grains daily"
1668723|NCT01708824|Behavioral|Physical activity|"Physical activity intervention with the following targets:
General health target - 30 minutes of moderate-to-vigorous physical activity (MVPA) 5 days per week (i.e. 10 MET-hours/week);
Cancer outcome target - 60 minutes of MVPA 5 days per week (i.e. 18-20 MET-hours/week)"
1668724|NCT01708798|Drug|Eplerenone|
1668725|NCT01708798|Drug|Placebo|
1668730|NCT01708733|Drug|KSY|Chinese herbal formula
1668731|NCT01708720|Drug|IPV|
1668732|NCT01708720|Drug|Sabin-IPV|
1668733|NCT01708720|Drug|Adjuvanted Sabin-IPV|
1668734|NCT01708707|Drug|Buprenorphine|"The injectable formulation of buprenorphine (Buprenex; Reckitt Benckiser) will be prepared to a final concentration of 0.075 mg/mL in 100% ethanol and simple syrup USP to create a sublingual preparation.
Infants initial dose: 15.9 µg/kg per day in 3 divided doses with escalation/weaning based upon standardized scoring of NAS symptoms, using standardized Finnegan scoring Maximum dosage: 60 µg/kg per day Duration: Infants will receive buprenorphine until they are successfully weaned off of opioids and no longer show withdrawal symptoms, evidenced by low Finnegan scores. Mean use in other investigations was 24 days."
1668735|NCT01708707|Drug|Morphine Sulfate|Oral Morphine Sulfate Dosage: Morphine Sulfate Oral Solution 100mg/5mL Initially dosed at 0.4mg/kg per day in six daily doses Duration of medication administration dependent upon infant symptoms of neonatal withdrawal, with mean duration of use at Banner Good Samaritan Hospital currently averaging 25 days.
1668736|NCT01708694|Dietary Supplement|Amylose|One group of participants will consume a yogurt containing 45 g of amylose (the slowly digesting starch) for 3 months.
1668737|NCT01708694|Dietary Supplement|Amylopectin|"The second group will consume a yogurt containing 45 g of a different starch called amylopectin (the placebo) for 3 months."
1668738|NCT01708681|Dietary Supplement|Lean seafood|
1668739|NCT01708681|Dietary Supplement|Meat, egg, milk|
1668740|NCT01708668|Procedure|Epidural analgesia|
1668741|NCT01708668|Procedure|Combined spinal-epidural analgesia|
1668742|NCT01708668|Procedure|Continuous epidural infusion|
1668743|NCT01708668|Procedure|Intermittent epidural bolus|
1668802|NCT01708174|Drug|LDE225|Sonidegib for oral suspension was supplied in amber glass bottles. Sonidegib oral suspension was combined with the supplied reconstitution vehicle to a final concentration of 50 mg/mL.
1668803|NCT01708174|Drug|TMZ|Temozolomide capsules were obtained locally by the Investigator
1668804|NCT01708161|Drug|BYL719|BYL719 is a small molecule inhibiting PI3-Kinase.
1668805|NCT01708161|Drug|AMG 479|AMG 479 is a monoclonal antibody directed against IGF1-R.
1669340|NCT01704274|Other|Low Dose GTN 0.0285 mg/hr|Low Dose GTN
1668744|NCT01708655|Other|Sweat Evaporimeter measurement|"The forearm will be cleaned with distilled water. Mineral oil will be applied to the surface of the skin after each injection.
intracutaneous injection of 0.2 ml of atropine
Stimulation and inhibition of sweating in an adjoining test area. Assessment of sweat secretion with an evaporimeter for 10 minutes after:
Intracutaneous injection of 0.1 ml carbachol for stimulation of the cholinergic sweat secretion.
intracutaneous injection of 0.2 ml atropine to Inhibit cholinergic sweat secretion
intracutaneous injection of 0.2 ml beta-cocktail (atropine isoproterenol and aminophylline) for stimulation of beta-adrenergic sweat secretion .
The procedure would take about 45 minutes."
1668745|NCT01708642|Drug|Adrenaline|Adrenaline infusion 0.05 microgram / kg / minute
1668746|NCT01708642|Drug|Placebo|Intraoperative isotonic saline infusion as placebo for adrenaline.
1954985|NCT03309904|Other|Knee Control training program|10-minute training program to be performed at all team training sessions during the season.
1668751|NCT01708616|Drug|RO5285119|multiple doses
1668752|NCT01708616|Drug|RO5285119 placebo|multiple doses
1668753|NCT01708616|Drug|risperidone|single dose
1668754|NCT01708616|Drug|risperidone placebo|single dose
1954986|NCT03309891|Drug|GX-H9|subcutaneous injection (weekly or twice-monthly)
1954987|NCT03309891|Drug|Genotropin|subcutaneous injection (daily)
1954988|NCT03309878|Other|Laboratory Biomarker Analysis|Correlative studies
1954989|NCT03309878|Biological|Mogamulizumab|Given IV
1954990|NCT03309878|Biological|Pembrolizumab|Given IV
1668762|NCT01708577|Device|Validation of the IPANEMA - measurement system|Control of the body conditions under real life conditions during a sportive activity.
1668763|NCT01708564|Biological|rhFVIIa|Patients will be administered low, intermediate and high doses of rhFVIIa
1668764|NCT01708551|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668765|NCT01708538|Drug|CXL|corneal crosslinking
1668766|NCT01708525|Device|Ulthera® System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668767|NCT01708525|Other|Heavy Water|A tissue labeling model via the consumption of the stable isotope, deuterated water (heavy water). Heavy water consumed over the course of the 6-week study period for a direct kinetic measure of in vivo collagen synthesis. 60 ml (about 12 teaspoons) of heavy water (also called deuterated water or 2H2O), was consumed three times a day for the first five days. Starting on Day 6, two 60 ml doses of heavy water were consumed per day for the remaining 37 days.
1668768|NCT01708512|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668769|NCT01708499|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668770|NCT01708473|Drug|Advil|One (1) tablet 800 mg Advil one hour prior to treatment.
1668771|NCT01708473|Drug|Lortab|One (1) tablet 10/500 mg of Lortab one hour prior to treatment.
1668772|NCT01708473|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668773|NCT01708460|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
1668774|NCT01708447|Drug|L.M.X.4.® cream|A lidocaine topical anesthetic cream
1668775|NCT01708447|Other|A placebo cream|Placebo cream containing no anesthetic properties.
1668776|NCT01708447|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668777|NCT01708434|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin
1668778|NCT01708408|Genetic|Biomarker studies|
1668779|NCT01708382|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin
1668780|NCT01708369|Drug|Placebo|Orange juice administered 15 minutes before subjects take oseltamivir or aspirin
1668781|NCT01708369|Drug|Ethanol|Ethanol will be mixed with orange juice and subjects will drink the mixture 15 minutes before receiving oseltamivir or aspirin
1668782|NCT01708369|Drug|Oseltamivir|Oseltamivir 150 mg orally
1668783|NCT01708369|Drug|Aspirin|Aspirin 650 mg orally will be given
1668784|NCT01708356|Behavioral|Cycling on a residential route|
1668785|NCT01708343|Procedure|DIMMST|
1668786|NCT01708330|Drug|Lidocaine|2% Lidocaine gel
1668787|NCT01708330|Drug|Placebo gel|odorless, colorless gel will be used as a placebo
1668788|NCT01708317|Behavioral|ACASI|Youth who participated in this study completed the ACASI -- they provided details about their sexual history, and the software program used their responses to create a recommendation for chlamydia/gonorrhea testing. The information obtained through the ACASI was integrated into the emergency department (ED) electronic medical record. ED physicians and nurses were able to review the information and order chlamydia/gonorrhea testing if needed.
1668789|NCT01708304|Behavioral|RDAD|Exercise training for caregiver and care recipient. Behavioral modification training for caregiver.
1668790|NCT01708291|Behavioral|Mindfulness based stress reduction|an 8 week group intervention to teach mindfulness skills
1668791|NCT01708291|Behavioral|only pre and post evaluation measures|
1668792|NCT01708278|Drug|Quercetin|"COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take one of the following for 1 week
Quercetin 500 mg/350 mg of vitamin C and 10 mg niacin
Quercetin 1000 mg/350 mg of vitamin C and 10 mg niacin
Quercetin 2000 mg/350 mg of vitamin C and 10 mg niacin"
1668793|NCT01708278|Other|Placebo - sugar chew|COPD Subjects will be asked to avoid quercetin rich diet for one week and then asked to take placebo (sugar chew containing 350 mg of vitamin C and 10 mg niacin)
1668794|NCT01708265|Other|Watchful waiting|In case of watchful waiting a conservative treatment is performed, based on close monitoring of the patient for clear signs of deterioration that triggers facilitated surgery before left ventricular dysfunction is present.
1669341|NCT01704274|Other|High Dose GTN 0.057 mg/hr|High Dose GTN
1668806|NCT01708148|Dietary Supplement|Probiotics|lyophilised L. rhamnosus, L. jensenii, L. crispatus, L. gasseri and sodium alginate
1668807|NCT01708148|Other|Placebo|control group would receive a oral lactose placebo
1668808|NCT01708135|Behavioral|Use of smartphone app|
1668809|NCT01708122|Drug|Fentanyl|100 mcg in 1 mL intranasal spray
1668810|NCT01708122|Drug|saline|Sodium Chloride 0.9% intranasal spray
1668811|NCT01708109|Other|no measures taken to clear bile ductus|biliary calculus remain
1668812|NCT01708109|Procedure|clearance of bile ductus|biliary calculus removed at surgery
1668813|NCT01708096|Dietary Supplement|Modifast|2 weeks before gastric by-pass patients are treated with VLD, 1000 kcal/day
1668814|NCT01708096|Dietary Supplement|Normal diet|normal diet 2 weeks before gastric by-pass
1668815|NCT01708070|Behavioral|Asthma self-management|Patients in the intervention group will receive an asthma workbook, will make a contract to adopt behaviors they think will improve asthma, will be taught how to use a peak flow meter and specific chapters of the workbook will be used as templates for focused instruction during telephone follow-ups which will occur every week for 8 weeks and then approximately every 2 months.
1668816|NCT01708057|Drug|AZD8683|AZD8683 administered via inhalation
1668817|NCT01708057|Drug|Placebo|Placebo administered via inhalation
1668818|NCT01708057|Drug|Tiotropium|Tiotropium administered via inhalation
1668819|NCT01708044|Drug|Pramlintide acetate|
1668820|NCT01708044|Other|Placebo|Placebo Comparator
1668821|NCT01708031|Other|physiological signals|
1668822|NCT01708018|Procedure|WATSU|"WATSU (WaterShiatsu) is a gentle form of hydrotherapy that was established in the 1980s. The standardized 60min-intervention applied in this trial is called WATSU-Transition-Flow (Dull, 1997) and is adapted for the third trimester. The mother's abdomen is not being touched during the treatment.
The treatment takes place in a one-to-one hands-on-setting in the warm- water-therapy-pool (35°C, 95°F) of the University Hospital in Bern and consists of acupressure massage according to the Japanese massage-technique Shiatsu, in an attempt to harmonize the mother's energy-flow in the so called meridians (energy-channels) of Traditional Chinese Medicine. These meridians are also sought to be influenced by slow passive stretches of the mother's extremities. In addition, mobilization of her spine is being enhanced by gravity-free movements.
During the study, each participant in the intervention group will be treated twice with WATSU (60min treatment at day 1 and 4)."
1668823|NCT01708005|Drug|Lecitone®Se-Vitamin D3|"Lecitone®Se-Vitamin D3 is a dietary supplement combining the active ingredients in Lecitone®Se and 100 IU of vitamin D3. This dietary supplement comes in capsule form.
Participants take 2 capsules of Lecitone®Se -Vitamin D3 per day. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study."
1668824|NCT01708005|Drug|Placebo|The comparator is represented by placebo capsules of identical appearance (same size, same color and same smell) that Lecitone®Se-Vitamin D3 capsules.
1668825|NCT01707992|Drug|Laquinimod|
1668826|NCT01707992|Drug|Matching Placebo|
1668827|NCT01707992|Drug|Laquinimod|
1668828|NCT01707966|Drug|Orteronel|
1668829|NCT01707966|Drug|Placebo|
1668830|NCT01707953|Drug|Midodrine|Midodrine 5mg as capsule, administered twice (5 and 23 hours after end of surgery).
1668831|NCT01707953|Drug|Placebo|Placebo capsule to mimic midodrine
1668832|NCT01707940|Drug|Ketoconazole|Ketoconazole 400 mg / day
1668833|NCT01707940|Drug|BI 144807|BI144807 oral solution, intermediate dose
1668834|NCT01707940|Drug|BI 144807|BI144807 oral solution, intermediate dose
1668835|NCT01707914|Dietary Supplement|Chinese bayberry juice|Consume 500 mL CBJ/d (250 mL CBJ twice daily)
1668836|NCT01707914|Dietary Supplement|placebo|
1668837|NCT01707901|Drug|ONO-8539|Treatment
1668838|NCT01707901|Other|Placebo|Placebo
1668839|NCT01707888|Procedure|Thoracoscopy/VATS|Patients undergo major lung resection by thoracoscopic surgery or video assisted thoracoscopic surgery.
1668840|NCT01707875|Other|fetal brain neurosonography|fetal brain neurosonography according to the ISUG guidelines
1668841|NCT01707849|Drug|EVL arm|Patients will be randomized at day 28th post-transplant. This group will receive Tacrolimus+Everolimus.
1668842|NCT01707849|Drug|MMF arm|Patients will be randomized at day 28th post-transplant. This group will continue of current immunosuppressive regimen (Tacrolimus+MMF) / no everolimus introduction.
1668843|NCT01707823|Drug|acetylsalicylic acid|Given PO
1668844|NCT01707823|Other|laboratory biomarker analysis|Correlative studies
1668845|NCT01707810|Procedure|Piggyback method|In the piggyback method IVC was not clamped in any case. Implantation method of the grafted IVC in recipient IVC was not standardized, being defined by the responsible surgeon during the procedure. In the two groups, all patients were submitted to simultaneous arterial and portal revascularization, according to the routine of the service.
1668846|NCT01707810|Procedure|conventional method|
1668847|NCT01707771|Procedure|Roux-en-Y gastric bypass|Active Comparator: Roux-en-Y gastric bypass
1668848|NCT01707771|Behavioral|diet and lifestyle modifications|Active Comparator: diet and lifestyle modifications
1668849|NCT01707745|Procedure|Intravitreal Bevacizumab|
1668850|NCT01707732|Drug|Enoxaparin|Administration of Enoxaparin
1668851|NCT01707706|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1 , Anmian , Neiguan PC6 , Shenmen HT7 , Sanyinjiao SP6 , and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
1668852|NCT01707693|Behavioral|Lifestyle Physical Activity Intervention|Behavioral counseling
1668853|NCT01707693|Behavioral|Information / Attention Comparison|Information and attention comparison
1668854|NCT01707667|Drug|prucalopride|One 2 mg tablet orally administered on Day 1
1668855|NCT01707667|Drug|PEG 3350|13.8g polyethylene glycol (PEG) 3350 with sodium bicarbonate, sodium chloride, and potassium chloride as a solution in water. Administered twice orally on Day 1(once in the morning and once prior to lunch).
1669342|NCT01704274|Other|Placebo|Placebo
1668856|NCT01707654|Device|Nerve flap|Based on the Teoh et al.'s technique, we combined the nerve graft into the bipedicled heterodigital arterialized island flap and used this composite flap tissue for reconstructing complicated infected wound in the finger.
1668857|NCT01707641|Dietary Supplement|CD#2|patient will be asked to take 6 lozenges every day and let it dissolve slowly in the mouth
1668858|NCT01707641|Other|bicarbonate sodium mouthwash|Patients will be asked to wash their mouth with bicarbonate sodium several times per day
1668859|NCT01707628|Biological|influenza vaccination with influenza vaccine|
1668860|NCT01707615|Drug|GSPE|GSPE 240 mg/day (120mg bid)
1668861|NCT01707615|Other|lifestyle intervention|dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
1668862|NCT01707602|Biological|INTANZA® 15|intradermal vaccination
1668863|NCT01707602|Biological|Vaxigrip®|Intramuscular vaccination
1668864|NCT01707602|Biological|INTANZA® 15 T|transcutaneous vaccination
1668865|NCT01707589|Device|The new sensor is not on the market. We have named it Elfi-sensor.|Participating subjects will be monitored for one hour with a noninvasive sensor.The noninvasive sensor, the size of a penny, will be affixed to the skin, above the umbilicus, with pediatric adhesive tape. The monitor will record continuously the heart rate, cardiac rhythm, respiratory rate and body motion.
1668866|NCT01707576|Behavioral|consultation 10 days later|new depression screening
1668867|NCT01707563|Procedure|skin punch biopsy and molecular biology|
1668868|NCT01707563|Other|fibroblast culture and molecular biology|
1668869|NCT01707537|Biological|Euvichol|1.5mL/vial, 1vial at 2-week intervals twice
1668870|NCT01707524|Procedure|Randomized left versus right radial artery approach|Randomized left versus right radial artery approach
1668871|NCT01707498|Procedure|Scanning device|Patients will be asked to spell a text with a specific scanning device. The most appropriate contactor or clicking device will be chosen by a senior therapist.
1668872|NCT01707498|Procedure|RoBIK Brain-Computer Interface|Patients will be asked to spell a text with the BCI
1668874|NCT01707472|Biological|Simtuzumab|Subjects will receive simtuzumab 700 mg intravenously bi-weekly over 24 weeks, for a total of 12 infusions.
1668875|NCT01707446|Device|Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter)|In the intervention group, an alarm threshold at 75% of the baseline rSO2 value will be established. Based on predetermined algorithm the rSO2 will be maintained at or above 75% of the baseline measurements.
1668876|NCT01707446|Other|An alarm threshold at 75% of the baseline rSO2 value|If the threshold of < 75% from baseline is reached for > 1 minute an algorithm geared to restore rSO2 to baseline levels will be implemented.
1668877|NCT01707433|Other|Enzyme testing|Leukocyte activity measurement of Arylsulfatase B and N acetyl galactosamine 6 sulfatase (GALNS)
1668878|NCT01707420|Drug|Gabapentin|The active comparator, Gabapentin, is a structural analog of g-aminobutyric acid which has anticonvulsant properties. This study is a prospective randomized double-blinded trial examining the effectiveness of a single dose of liquid Gabapentin given 60 minutes prior to surgery for pain management in pediatric tonsillectomy/adenoidectomy pediatric patients.
1668879|NCT01707420|Drug|liquid placebo|Subjects randomized to the liquid placebo will receive an identical appearing liquid placebo of 0.4mL/kg.
1668880|NCT01707407|Drug|Pomalidomide|4 mg pomalidomide capsule administered orally once in the morning
1668881|NCT01707407|Drug|Ketoconazole|200 mg Ketoconazole tablet administered orally twice a day on Days 1-7.
1668882|NCT01707407|Drug|Fluvoxamine|50 mg Fluvoxamine tablet administered orally twice a day on Days 1-7.
1668883|NCT01707407|Drug|Carbamazepine|"100 mg Carbamazepine tablet administered orally once in the evening on Day 1
100 mg Carbamazepine tablet administered orally twice daily on Days 2-3
200 mg Carbamazepine tablet administered orally twice daily on Days 4-11"
1668885|NCT01707381|Drug|BOL-303259-X|Topical ophthalmic solution
1668886|NCT01707381|Drug|Timolol maleate|Topical ophthalmic solution
1668887|NCT01707368|Drug|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
1668888|NCT01707355|Behavioral|intervention - poster|
1668889|NCT01707342|Drug|Simeprevir (TMC435)|Treatment A: Simeprevir (TMC435) 50 mg; and Treatment B: Simeprevir (TMC435) 150 mg; will be followed 5 hours later by a single 10 minute intravenous infusion of [3H]-TMC435 (100 microcurie) 100 microgram in Period 1 and Period 2, respectively.
1668890|NCT01707329|Drug|Chemotherapy|Docetaxel 60-75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
1668891|NCT01707329|Drug|Icotinib+chemotherapy|Icotinib: 125 mg is administered orally three times per day. Chemotherapy: docetaxel 75mg/m2, 4 cycles; or pemetrexed 500mg/m2, 4 cycles.
1668892|NCT01707316|Drug|Treatment A: Canagliflozin 100 mg|Volunteers will receive one 100 mg over-encapsulated tablet of canagliflozin as a single oral (by mouth) dose on Day 1.
1668893|NCT01707316|Drug|Treatment B: Canagliflozin 300 mg|Volunteers will receive one 300 mg over-encapsulated tablet of canagliflozin as a single oral dose on Day 1.
1668894|NCT01707316|Other|Treatment C: Placebo|Volunteers will receive one matching placebo (inactive medication) capsule as a single dose on Day 1.
1668895|NCT01707303|Other|Early ICU rehabilitation strategies|Physical therapy - standard; Physical therapy, progressive resistance training for 2nd physical therapy session in Cohort II
1668896|NCT01707303|Other|Usual Care|All typically applied hospital rehabilitative services applied in the usual fashion
1668897|NCT01707290|Drug|Ivacaftor|150 mg tablet, oral use, every 12 hours (q12h)
1668898|NCT01707277|Other|Inspiratory muscle training|Patients were instructed to train at home twice daily for 20 minutes each session during 12 weeks with a threshold inspiratory muscle trainer (Threshold IMT®, Respironics Inc.). All of them were trained under the supervision of a physiotherapist and educated to maintain diaphragmatic breathing during training. The subjects started breathing at a resistance equal to 25-30% of their maximum inspiratory pressure for 1 week.
1668899|NCT01707277|Other|Usual care|Usual pahramacological treatment
1668947|NCT01707004|Drug|tacrolimus|Given PO or IV
1668901|NCT01707251|Drug|Intravenous Ibuprofen|800 mg Ibuprofen IV every 6 hours starting preoperatively (5 doses).
1668902|NCT01707251|Drug|Saline|Placebo control
1668903|NCT01707238|Device|etafilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
1668904|NCT01707238|Device|stenfilcon A|Participants wear a first pair of lenses for two weeks and then crossover and wear an alternate second pair of lenses for two weeks.
1668905|NCT01707225|Drug|Octreotide LAR Depot|The subject will be seen in clinic every 4 weeks (+/- 4 days) through week 24. During weeks 25-36 the subject will receive a telephone call every 4 weeks +/- 4 days, from the research nurse to assess for changes occurring after the study drug was stopped. Subjects will receive a physical exam and interview at each visit to assess for any sign of GI bleeding at home as per standard protocol for HeartMate II patients and for potential drug related side effects. Labs collected for research will include monthly basic metabolic panel (BMP), complete blood count (CBC), fructosamine and quarterly HGbA1C , VEGF, vWF, vWF activity assay, thyroid stimulating hormone (TSH), platelet function test and fibrinogen. Subjects will receive their monthly injection while in clinic for their every 4 weeks appointment. The subjects will be followed and data will be collected for 36 weeks, or for as long as they are enrolled in the study.
1668906|NCT01707212|Behavioral|Pain management education|Education about pain management during infant immunization
1668907|NCT01707212|Behavioral|No pain management education|Control - no education about pain management during infant immunization
1668908|NCT01707199|Drug|Artesunate + Sulphadoxine-pyrimethamine|"AS+SP will be administered according to the patient's age, based on a dose of 4mg artesunate/kg body weight once daily for 3 days plus SP at a dose of 25mg sulphadoxine/kg body weight single dose on the first day.
One co-blister pack of Artecospe will be used per patient and obtained via WHO from Guilin Pharmaceutical Co. Ltd., Shanghai China, with appropriate expiry date."
1668909|NCT01707173|Behavioral|Tailored education|Using information gleaned from interviews, educational print materials tailored to the participant's beliefs about infant safe sleep practices, will be mailed to the participants home at 2 separate times over a 6 month period along with a culturally relevant DVD with safe sleep information
1668910|NCT01707173|Behavioral|Standard Education|Participants will receive currently available publications about infant sleep from the American Academy of Pediatrics and the AAP at 2 separate times over a 6 month period along with a generic DVD about infant safety practices
1668911|NCT01707160|Drug|biphasic insulin aspart 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
1668912|NCT01707160|Drug|biphasic human insulin 30|One single dose of each trial drug separated by 4-10 days injected subcutaneously (s.c, under the skin) in random order
1668913|NCT01707147|Drug|Trajenta tablet|Linagliptin
1668914|NCT01707134|Drug|insulin aspart|Injected subcutaneously (s.c, under the skin) as meal time insulin
1668915|NCT01707134|Drug|human soluble insulin|Injected subcutaneously (s.c, under the skin) as meal time insulin
1668916|NCT01707134|Drug|insulin NPH|Will be administrated subcutaneously (s.c, under the skin) once or twice daily as basal insulin
1668917|NCT01707108|Device|Dental Implant (MIS Technologies)|MIS Technologies Ltd. C1 Dental implants
1668918|NCT01707095|Other|Unbundling of cords|The active electrode and camera cords will be place off opposite sides of the table and will not run adjacent to or in parallel with one another
1668919|NCT01707095|Other|Bundling of cords|The cords from the camera/active electrode will be bundled together along their lengths during a laparoscopic cholecystectomy.
1668920|NCT01707082|Drug|PF-06282999|Tablet, 10 mg, every 8 hours, 14 days
1668921|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
1668922|NCT01707082|Drug|PF-06282999|Tablet, 30 mg, every 8 hours, 14 days
1668923|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
1668924|NCT01707082|Drug|PF-06282999|Tablet, 100 mg, every 8 hours, 14 days
1668925|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
1668926|NCT01707082|Drug|PF-06282999|Tablet, 250 mg, every 8 hours, 14 days
1668927|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 hours, 14 days
1668928|NCT01707082|Drug|PF-06282999|Tablet, 350 mg every 8 hours or 500 mg every 12 hours, 14 days
1668929|NCT01707082|Drug|Placebo|Tablet, 0 mg, every 8 or 12 hours, 14 days
1668930|NCT01707082|Drug|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
1668931|NCT01707082|Drug|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
1668932|NCT01707082|Drug|midazolam|Tablet, 7.5 mg, single dose on Period 1 Day 1 and Period 2 Day 14
1668933|NCT01707082|Drug|PF-06282999|Tablet, dose to be determined (determined in Part A), every 8 or 12 hours, 14 days
1668934|NCT01707069|Biological|CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection|"Immunomic Therapeutics Inc. CryJ2-DNA-LAMP vaccine is a frozen product formulated in physiological saline and contains no preservative. The study product is packaged in a 1 ml volume in a 3 ml glass vial, with label complying with FDA requirements.
Subjects will receive CryJ2-DNA-LAMP plasmid vaccine by intramuscular injection. The dosing regimen for this group will be to receive three (3) additional booster doses (4 doses in total) at 14 day intervals."
1668935|NCT01707056|Other|Black Coffee|Taking Synthroid with 12 ounces of black coffee for 6 weeks.
1668936|NCT01707056|Other|Coffee with Milk|Taking Synthroid with 12 ounces of black coffee and 2 ounces of 2% milk for a period of 6 weeks.
1668937|NCT01707056|Other|Black Tea|Taking Synthroid with 12 ounces of black tea for a period of 6 weeks.
1668938|NCT01707056|Other|Water|Taking Synthroid with water for a period of 6 weeks.
1668939|NCT01707043|Drug|Taclonex|Subjects will be evaluated at baseline, Day 3 and Day 6 (or end of study).
1668940|NCT01707030|Other|Web-Based Brief Alcohol Intervention|Participants report their alcohol use and problems on line and receive feedback comparing them to national norms.
1668941|NCT01707030|Other|Usual Care|All patients will be receiving care in a Hepatitis C clinic. In some cases clinicians may counsel them on alcohol problems.
1668942|NCT01707017|Other|Strength training|
1668943|NCT01707004|Drug|decitabine|Given IV
1668944|NCT01707004|Drug|fludarabine phosphate|Given IV
1668945|NCT01707004|Drug|busulfan|Given IV
1668946|NCT01707004|Drug|cyclophosphamide|Given IV
1668951|NCT01707004|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
1668952|NCT01707004|Other|laboratory biomarker analysis|Correlative studies
1668953|NCT01706991|Device|Pediatric Vision Scanner eye scan|Subject is scanned with a 2.5 second pediatric vision scanner device test.
1668954|NCT01706978|Procedure|Bone Trephination|
1668955|NCT01706978|Procedure|Soft Tissue Trephination|
1668956|NCT01706965|Drug|Kuvan|20mg/kg using a daily dosing schedule. To increase tolerability, treatment will be initiated at 10mg/kg for the first week of the study. Given the short length of the trial, no dose adjustments will be made for changes in weight
1668957|NCT01706965|Drug|Multivitamin|Multi-vitamin will be used as an active control in this study. Will be dosed daily
1668958|NCT01706952|Drug|Cocaine|Pledgets soaked in 4% cocaine hydrochloride solution were placed intranasally (one side).
1668959|NCT01706952|Drug|Adrenaline|Pledgets soaked in 1/1000 adrenaline solution were placed intranasally (one side).
1668960|NCT01706939|Radiation|Reduced Dose Radiation|Reduced Dose Radiation (5600 cGy) dose radiotherapy with weekly Carboplatin
1668961|NCT01706939|Radiation|Standard Dose Radiation|Standard Dose Radiation (7000 cGy) dose radiotherapy with carboplatin
1668962|NCT01706926|Biological|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every 2 weeks for 24 weeks
1668963|NCT01706926|Biological|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every 2 weeks for 24 weeks.
1668964|NCT01706926|Biological|Mavrilimumab 150 mg|Mavrilimumab (CAM-3001) 150 mg injection subcutaneously every 2 weeks for 24 weeks.
1668965|NCT01706926|Other|Placebo|Placebo matched to mavrilimumab (CAM-3001) injection subcutaneously every 2 weeks for 24 weeks.
1668966|NCT01706913|Other|Dermatology consult|
1668967|NCT01706900|Other|Incubator Temp set to 36.5 degree|We will set incubator Temp to 36.5 so we can assess the outcome and compare the results with the placebo group.
1668968|NCT01706900|Other|Incubator Temp 37 degree|We will set incubator Temp to 37 degree as the routine embryo culture Temp since 1978 as the placebo arm.
1668969|NCT01706887|Other|Diet Amiloride|only arm of the trial
1668970|NCT01706874|Other|Periodontal prophylaxis|Periodontal scaling (every 6 months) plus mouthrinses plus toothbrushing (twice daily). Removal of adherent plaque and calculus with ultrasonic instruments and hand instruments, such as periodontal scalers and curettes, and polishing of the teeth
1668971|NCT01706861|Device|Celotres|Celotres following surgical removal of earlobe keloid.
1668972|NCT01706848|Other|Celotres|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
1668973|NCT01706848|Other|Surgical Closure by Standard of Care|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (Celotres), opposite side treated per standard of care.
1668974|NCT01706835|Drug|aldoxorubicin|
1668975|NCT01706822|Device|Covidien Radial Reload Stapler with Tri-Staple Technology|Case series of patients arlaedy selected to undergo a laparoscopic LAR using the Radial Reload stapler
1668976|NCT01706809|Other|blood sampels from vena rectalis superior and vena cubiti|
1668977|NCT01706796|Drug|PF-06273340|Oral solution, single dose, fasted
1668978|NCT01706796|Drug|PF-06273340|Immediate Release Tablet, single dose, fasted
1668979|NCT01706796|Drug|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fasted
1668980|NCT01706796|Drug|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fasted
1668981|NCT01706796|Drug|PF-06273340|Modified Release Tablet (short duration, MR1), single dose, fed
1668982|NCT01706796|Drug|PF-06273340|Modified Release Tablet (long duration, MR2), single dose, fed
1668983|NCT01706783|Drug|NNC0195-0092|Subcutaneous (s.c., under the skin) administration once weekly (Days 1, 8, 15 and 22) of 4 different doses of NNC0195-0092 in an escalating order
1668984|NCT01706783|Drug|Norditropin NordiFlex®|Subcutaneous (s.c., under the skin) administration daily for 28 days. The daily dosing will be the same as the pre-trial daily dose of human growth hormone (hGH) taken by the adult with growth hormone deficiency
1668985|NCT01706770|Device|enfilcon A|The Test device is a contact lens manufactured by CooperVision, Inc.
1668986|NCT01706770|Device|galyfilcon A|The Control device is a contact lens manufactured by Johnson & Johnson Vision Care.
1668987|NCT01706757|Device|go-cart|conducts exercises with the help of a go-cart
1668988|NCT01706744|Other|Intermediate care unit|
1668989|NCT01706744|Other|Local health care 1|
1668990|NCT01706744|Other|Local health care 2|
1668991|NCT01706731|Behavioral|Treatment as usual|Treatment as usual (TAU)is defined as the routine care provided to each individual patient at the geriatric psychiatry clinic of Maharaj Nakorn Chiang Mai Hospital.
1668992|NCT01706731|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy(CBT)includes psychoeducational components combined with cognitive interventions targeted at challenging negative automatic thoughts.
1668994|NCT01706705|Device|Intracavitary Applicator Placement|MRI-compatible applicator inserted using ultrasound guidance to verify tandem placement in the uterus. Tandem and ovoids, tandem and cylinders, or tandem and ring chosen to accommodate patient's tumor and vaginal anatomy.
1668995|NCT01706705|Other|Computed Tomography (CT)|CT scan performed after implant is placed in operating room. CT scan should take about 20 minutes.
1668996|NCT01706705|Other|Magnetic Resonance Imaging (MRI)|MRI scan performed after implant is placed in the operating room. MRI should take about 45 minutes.
1668997|NCT01706692|Biological|Adalimumab|all dosages, frequencies and durations prescribed
1668998|NCT01706692|Biological|Etanercept|all dosages, frequencies and durations prescribed
1668999|NCT01706692|Biological|Infliximab|all dosages, frequencies and durations prescribed
1669000|NCT01706692|Biological|Ustekinumab|all dosages, frequencies and durations prescribed
1669001|NCT01706692|Drug|Cyclosporine A|all dosages, frequencies and durations prescribed
1669002|NCT01706692|Drug|Fumaric acids|all dosages, frequencies and durations prescribed
1669003|NCT01706692|Drug|Methotrexate|all dosages, frequencies and durations prescribed
1669418|NCT01703598|Procedure|DBS surgery|Placement of DBS electrodes
1669004|NCT01706692|Drug|Other anti-psoriatic systemic treatments|all dosages, frequencies and durations prescribed
1669005|NCT01706679|Drug|ATX-101 (10 mg/ml)|
1669006|NCT01706679|Drug|ATX-101 (20 mg/ml)|
1669007|NCT01706679|Drug|Moxifloxacin (400 mg)|
1669008|NCT01706679|Drug|Placebo vehicle (PBS)|
1669009|NCT01706666|Drug|bortezomib|Given SC
1669010|NCT01706666|Drug|cyclophosphamide|Given PO
1669011|NCT01706666|Drug|lenalidomide|Given PO
1669012|NCT01706666|Other|laboratory biomarker analysis|Correlative studies
1669013|NCT01706666|Drug|dexamethasone|Given PO
1669014|NCT01706666|Procedure|quality-of-life assessment|Ancillary studies
1669015|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - low|
1669016|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - medium|
1669017|NCT01706653|Dietary Supplement|Polyphenol-enriched fruit-based drink - high|
1669018|NCT01706653|Dietary Supplement|Very low polyphenol fruit based drink (control)|
1669019|NCT01706627|Drug|10 mg Melatonin|Active Comparator: Drug: Melatonin 10 mg
1669020|NCT01706627|Drug|20 mg Melatonin|Active Comparator: Drug: Melatonin 20 mg
1669021|NCT01706627|Drug|Matched placebo|Matched placebo (identical formulation and delivery, without active ingredient)
1669022|NCT01706588|Drug|Diclofenac sodium|One single diclofenac injection into the surgical area before surgery but as soon as the anaesthetic has taken effect.
1669023|NCT01706575|Drug|Pegylated Interferon (Peginterferon) Alfa-2a|Peginterferon alfa-2a 180 mcg, subcutaneously (SC) once weekly for 48 weeks.
1669024|NCT01706575|Drug|Nucleos(t)ide Analogues (NA)|Nucleos(t)ide analogues includes adefovir, entecavir, lamivudine or tenofovir.
1669025|NCT01706562|Drug|Itraconazole|Itraconazole intravenous (IV) 200 mg twice daily for 2 days, a total of 4 doses and then 200 mg once daily until clinically significant resolution of neutropenia.
1669026|NCT01706536|Drug|Placebo|EP-101 Placebo AM + EP-101 Placebo PM
1669027|NCT01706536|Drug|EP-101 12.5 mcg|EP-101 12.5 mcg AM + EP-101 12.5 mcg PM
1669028|NCT01706536|Drug|EP-101 25 mcg|EP-101 25 mcg AM + EP-101 25 mcg PM
1669029|NCT01706536|Drug|EP-101 50 mcg|EP-101 50 mcg AM + EP-101 50 mcg PM
1669030|NCT01706536|Drug|EP-101 100 mcg|EP-101 100 mcg AM + EP-101 100 mcg PM
1669031|NCT01706523|Drug|STX209 (arbaclofen)|Long-term, daily, orally-administered STX209
1669032|NCT01706510|Drug|Ticagrelor|Ticagrelor 180 mg loading dose followed by 90 mg bid for 7 days ± 2 days
1669033|NCT01706510|Drug|Clopidogrel|Clopidogrel 600 mg loading dose followed by 75 mg Daily for 7 days ± 2 days
1669034|NCT01706497|Device|Cerebral tissue oxygen saturation monitoring, blinded|
1669035|NCT01706484|Drug|BNO 1016|comparison of different dosages of drug and placebo
1669036|NCT01706471|Drug|Everolimus + Low dose CsA +PD|Group A : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng. After 1 month reduce Neoral dose as following table and Certican starting 0.75mg bid then adjust Certican 3-8ng/ml. Myfortic continue until Certican trough level goes up >3 ng/mL. Steroid dose follows local protocol.
1669037|NCT01706471|Drug|Myfortic+ Standard CsA + PD|Group B : Initiation of 5mg/kg bid Neoral dose and 720mg bid Myfortic and then adjusting Neoral targeting 150-200ng/ml. After 1 month reduce Neoral dose targeting 100-200ng with no change of Myfortic dose. Steroid dose follows local protocol.
1669038|NCT01706458|Biological|sipuleucel-T|Given IV
1669039|NCT01706458|Biological|DNA Vaccine|Given ID
1669040|NCT01706445|Other|Other|inspiratory muscle training (IMT) + aerobic and strength training 8-week duration IMT twice a day (mostly at home) + 3 weekly sessions of inhospital resistance + aerobic training
1669041|NCT01706432|Radiation|hyperfractionated radiation therapy|Undergo hypofractionated radiation therapy
1669042|NCT01706432|Other|laboratory biomarker analysis|Correlative studies
1669043|NCT01706432|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
1669044|NCT01706419|Dietary Supplement|Fortified rice cold extruded kernel|
1669045|NCT01706419|Dietary Supplement|fortified rice warm extruded kernel|
1669046|NCT01706419|Dietary Supplement|fortiified rice hot extruded kernel|
1669047|NCT01706406|Behavioral|Brief psychoeducational intervention for female sexual arousal disorder|four 1.5 hour long group psychoeducational sessions, spaced 2 weeks apart for a total of 8 weeks.
1669048|NCT01706393|Dietary Supplement|probiotics (six probiotic cultures)|Effects of probiotics supplementation on intestinal microbiome; 2capsule bid orally for six weeks, 1capsule(500mg) Started eating probiotics one week prior of radiation therapy.
1669049|NCT01706393|Dietary Supplement|Placebo|Placebo intake for 6 weeks(including 5weeks of Rtx) and it take one tablet twice a day.
1669050|NCT01706380|Behavioral|Interactive voice response with personal feedback|Personal feedback is given at the end of each automated telephone follow-up call, and reports back to the patient whether his och her symptom status is better, worse or equal, compared to the previous telephone call.
1669051|NCT01706380|Behavioral|Interactive voice response without personal feedback|Control condition. Identical follow-up but without personal feedback.
1669052|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
1669053|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
1669054|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
1669055|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
1669056|NCT01706367|Biological|C. difficile vaccine|0.5 mL IM injection
1669057|NCT01706367|Biological|C. difficile vaccine +adjuvant|0.5 mL IM injection
1669058|NCT01706354|Procedure|Local Anaesthetic|Infiltration of local anaesthetic into the surgical site by the surgeon using a combination of 0.5% L-bupivicaine prior to incision and 1% lignocaine topically after the wound is opened. Maximum dose limits of 2mg/kg for bupivicaine, and 3mg/kg for lignocaine will be observed, recognising that these are additive.
1669134|NCT01705769|Other|High energy and micronutrient rich foods|High energy and micronutrient rich foods prepared by caregivers at home using ingredients provided to them
1669179|NCT01705366|Procedure|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee.
1669419|NCT01703572|Drug|OMP-52M51|
1669059|NCT01706354|Procedure|Regional anaesthetic|Ultrasound guided brachial plexus block. Supraclavicular will be the block performed unless there is a contraindication in which case axillary block may be used. A 1:1 mixture of 0.5% L-bupivicaine and 1.5% lignocaine with adrenaline (1 in 200,000) will be injected, up to a volume of 40ml but using a minimum of 25ml. Maximum dose limits of 2mg for bupivicaine and 7mg/kg for lignocaine with adrenaline will be observed, recognising that these are additive.
1669060|NCT01706341|Drug|administer acetate Ringer's solution|During cesarean section under spinal anesthesia, each acetate Ringer's solution is administered before delivery.
1669061|NCT01706341|Drug|acetate Ringer's solution containing no glucose|
1669062|NCT01706341|Drug|acetate Ringer's solution containing 1% glucose|
1669063|NCT01706328|Drug|FF/VI 100/25 Inhalation Powder NDPI|Subjects randomized to the FF/VI Inhalation Powder Novel Dry Powder Inhaler (NDPI) arm will receive a single inhalation of 100 mcg FF and 25 mcg VI via NDPI every morning for 12 weeks.
1669064|NCT01706328|Drug|Fluticasone Propionate/Salmeterol 250/50 Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of 250 mcg Fluticasone Propionate and 50 mcg Salmeterol via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
1669065|NCT01706328|Drug|Placebo Inhalation Powder NDPI|Subjects randomized to the Fluticasone Propionate/Salmeterol Inhalation Powder ACCUHALER/DISKUS arm will receive a single inhalation of placebo inhalation powder via NDPI every morning for 12 weeks.
1669066|NCT01706328|Drug|Placebo Inhalation Powder ACCUHALER/DISKUS|Subjects randomized to the FF/VI Inhalation Powder NDPI arm will receive a single inhalation of placebo inhalation powder via ACCUHALER/DISKUS once in the morning and once in the evening for 12 weeks.
1669067|NCT01706328|Drug|Salbutamol as needed|Salbutamol inhalation powder
1669068|NCT01706315|Drug|GSK2140944|GSK2140944 will be available as immediate release capsules of dose strength 100 mg and 500 mg
1669069|NCT01706315|Drug|Placebo|Matching placebo will be available
1669070|NCT01706302|Other|Data collection|The previous study has used four primary data sources: the General Practice Research Data (GPRD [recently re-named Clinical Practice Research Datalink (CPRD)], for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA). The extracted data are referred to as the EPI-FLU-018 BOD UK DB database. Weekly time series will be generated to estimate the RSV burden and characterize it in terms of incidence of GP consultations, hospitalizations and deaths for each of the respiratory and non-respiratory outcomes (including GP antibiotic prescriptions), stratified by age and risk group.
1954991|NCT03309865|Dietary Supplement|semi-vegetarian diet|semi-vegetarian dietary intervention: Duration of Therapy: 14 weeks;
1954992|NCT03309865|Drug|Vedolizumab Injection|vedolizumab (300mg) IV infusions at week 0, 2, 6, 14; Duration of Therapy: 14 weeks
1669074|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
1669075|NCT01706250|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
1669076|NCT01706250|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
1669077|NCT01706250|Other|PROACTIV (2.5% BPO) Renewing Cleanser|Available over the counter.
1669078|NCT01706250|Other|PROACTIV (2.5% BPO) Repairing Lotion|Available over the counter.
1669079|NCT01706250|Other|PROACTIV (2.5% BPO) Revitalizing Toner|Available over the counter.
1669080|NCT01706237|Device|Nexisvision shield|A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
1669081|NCT01706224|Procedure|Blood sample|Samples will be tested to determine the presence of anti-pertussis antibodies.
1669082|NCT01706224|Other|Data collection|Electronic Case Report Forms (eCRF)
1669083|NCT01706224|Other|Data collection|Questionnaires, active questioning.
1669084|NCT01706211|Drug|BRL 49653C|BRL 49653C 2 mg bid or placebo bid through weeks 1 to 24.
1669085|NCT01706211|Drug|Placebo|
1669086|NCT01706198|Drug|fluticasone furoate + vilanterol|once daily via a Novel Dry Powder Inhaler
1669087|NCT01706198|Drug|inhaled corticosteroid with or without a long acting beta2-agonist|ICS alone or in combination with a long acting bronchodilator
1669088|NCT01706185|Other|Data acquisition and analysis|Tumor tissue samples submitted for analysis together with a form containing clinical data previously collected and archived from patients with bladder cancer.
1669089|NCT01706172|Other|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
1669090|NCT01706172|Other|Injection of 1 ml of 0.8 Sterile water /0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine
1669091|NCT01706159|Drug|catridecacog|Catridecacog (recombinant factor XIII, rFXIII) will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week at a dose of 35 IU/kg
1669092|NCT01706159|Drug|placebo|Placebo will be administered as intravenous (i.v.) injections (at an approximate rate of 1-2 mL/min) once every second week.
1669093|NCT01706146|Drug|Non-coumadin Oral Anticoagulant|Administration of Non-coumadin Oral Anticoagulant for 30 days following episode of atrial fibrillation as detected by the Reveal XT device.
1669094|NCT01706133|Other|Factors associated with the use of emergency departments|Participants who were assigned to the intervention will be evaluated jointly by the medical service by a medical specialist in geriatrics and a nurse trained in gerontology and geriatrics. The doctor will monitor the apparition and / or aggravation of any geriatric syndromes already established by the specialty in geriatrics, namely, polypharmacy, delirium, dementia, depression, risk of falls, etc.. The nurse will monitor and follow up in four areas I. medical issues (pressure ulcers, infusion, mobility); II. Mental and emotional state and coping strategies with hospitalization; III. functionality, and IV. Atmosphere (A. Service status, architectural difficulties for mobility, bathing etc. B. Support Network, caregiver, and C. hardship)
1669095|NCT01706120|Drug|Bevacizumab|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 22 cycles
1669096|NCT01706120|Drug|Paclitaxel|• Bevacizumab 15 mg/kg i.v. on Day 1 every 3 weeks up to 6 cycles
1669097|NCT01706120|Drug|Carboplatin|• Carboplatin (AUC 5) on Day 1 every 3 weeks for up to 6 cycles
1723120|NCT00004363|Drug|chlorpropamide|
1669098|NCT01706094|Other|Head Position|"Head position during the first 48 hours from admission of patients with acute ischemic stroke.
This trial is organized as a cluster randomised trial to a policy of flat head position or upright head position. Clusters will be months, so that all patients admitted during a given month will be positioned either in the flat down head position (intervention) or upright head position (control). This will allow health teams to follow a monthly protocol without changing position between patients."
1669099|NCT01706081|Procedure|Acupuncture|Each treatment will be 30 minutes in duration. Patients will receive two acupuncture treatments each week for six consecutive weeks. Patients will be advised to continue their standard lymphedema treatments such as exercise or use of compression garments if these were in use prior to clinical trial participation.
1669100|NCT01706081|Procedure|Wait-list|For participants in the wait-list control group, follow-up objective and subjective assessments of lymphedema will be performed after approximately 6 weeks on the wait-list, before onset of acupuncture treatment, following 6 weeks of acupuncture treatment and about 3 months after completion of treatment. BMI will be measured at the same timepoints.
1669101|NCT01706055|Biological|Interferon beta-1b (Betaseron, BAY86-5046)|Subcutaneous injections of Betaferon 250 mcg every other day according to Product Characteristic.
1669102|NCT01706042|Other|legume meal|
1669103|NCT01706042|Other|white bread|
1669104|NCT01706016|Procedure|Thermic destruction of tissue by Laser using the Novilase device|
1669105|NCT01705990|Biological|SeV-G(NP) (0.2mL, 2x10^7 CIU)|Delivered intranasally by drops
1669106|NCT01705990|Biological|SeV-G(NP) (0.2mL, 2x10^8 CIU)|Delivered intranasally by drops
1669107|NCT01705990|Biological|Ad35-GRIN (0.5mL)|(1x10^10 vp) Delivered intramuscularly by standard syringe and needle injection
1669111|NCT01705964|Drug|IM epinephrine 1:1000|IM epinephrine 1:1000. The dose will be 0.2 mg for subjects 20-30 kg and 0.3 mg for subjects greater than 30 kg. This will be injected intramuscularly by an ED nurse into the anterior thigh muscles of the subject using a 1 ml syringe and a 23 gauge one inch needle.
1669112|NCT01705964|Other|No intervention|A sham band-aid will be applied to the anterior thigh of subjects who are randomized to the no intervention group.
1669113|NCT01705951|Other|Resistance Training (RT)|Resistance Training program 3x/week at 60 minutes per session for 12 weeks.
1669114|NCT01705951|Biological|Nicotine Replacement Therapy (NRT)|Nicotine patch for 12 weeks (21mg, 14mg, 7mg.) and referral to California Smoker's Helpline for 6 sessions of smoking cessation counseling.
1669115|NCT01705938|Drug|SP-333|
1669116|NCT01705912|Other|Complete intervention|The basic intervention, an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention. The intervention consisted of an individually designed home exercise program aiming at improving balance, muscle strength and walking ability. The program, which was made by the physiotherapist, should be performed three times a week. A minimum of 30 minutes of walking per week was recommended, encouring further walking on an individual basis. An assistant nurse made eight home visits to supervise, help and encourage performance of activities.
1669117|NCT01705912|Other|Basic intervention|The basic interventions was an occupational therapist assessed the home environment and gave advice, if necessary. Then participants were assessed by a physiotherapist concerning health and function pre and post intervention.
1669118|NCT01705899|Drug|Human Pancreatic Islets|Pancreatic islet tissue suspended in 150 - 300 ml of phenol red-free CMRL-1066 Transplant Media supplemented with 4% (w/v) HSA and 16mM HEPES in a 600ml transfer pack. Heparin will be administered at 70 IU/kg recipient body weight. Administered by intra-portal vein infusion. To be administered once, however, if full graft function is not achieved, a second or third dose of Pancreatic Islets may be given within 18 months of the first transplant.
1669119|NCT01705886|Procedure|Total Knee Arthroplasty|Patients undergoing manual (no robot used) surgery to replace of all 3 compartments of the knee
1669120|NCT01705886|Procedure|MAKO® Robot Assisted Medial Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial compartment of the knee
1669121|NCT01705886|Device|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
1669122|NCT01705886|Device|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
1669123|NCT01705886|Device|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
1669125|NCT01705847|Drug|GS-9820|GS-9820 tablets containing 200 mg of GS-9820 administered orally
1669126|NCT01705821|Device|Use of force sensing surgical curette|Use of a standard surgical curette outfitted with an in-line 6-axis force and torque transducer for collection of force data during surgery.
1669127|NCT01705821|Procedure|Removal of pituitary tumor using modified curette|
1669128|NCT01705808|Drug|Protein C concentrate|
1669129|NCT01705795|Drug|Mepolizumab (a-IL-5 antibody)|750mg mepolizumab four times over four months
1669130|NCT01705795|Drug|Placebo|Nacl four times over four months
1669131|NCT01705782|Biological|E. coli endotoxin, US standard|
1669132|NCT01705769|Other|Ready to Use Therapeutic Food-Centrally produced|Ready to Use Therapeutic Food-Centrally produced by an Indian company.
1669133|NCT01705769|Other|Ready to Use Therapeutic Food-Locally produced|Ready to Use Therapeutic Food prepared by the study team
1671819|NCT01684644|Behavioral|Treatment as usual|
1669135|NCT01705756|Drug|Kineret|Patients randomized to active drug will receive Kineret(Anakinra), 100 mg prefilled syringes for subcutaneous injection, once a day for 4 months. The syringes will arrive relabeled from the supplier (SOBI) to Sheba Medical Center. They will be stored at the PI's store room in a temperature controlled refrigerator.
1669136|NCT01705743|Drug|Sevoflurane+Nitrous oxide|60% nitrous oxide +40% oxygen+ Sevoflurane
1669137|NCT01705743|Drug|Sevoflurane|100% oxygen+ Sevoflurane
1669138|NCT01705691|Drug|Paclitaxel|80 mg/m2 IV over 60 minutes weekly for 12 weeks
1669139|NCT01705691|Drug|Eribulin|1.4 mg/m2 IV over 2 to 5 minutes on Days 1 and 8 every 21 days for 4 cycles
1669140|NCT01705691|Drug|Doxorubicin|60 mg/m2 IV over 15 minutes on day 1 every 21 days for 4 cycles
1669141|NCT01705691|Drug|Cyclophosphamide|600 mg/m2 IV over 30 minutes on day 1 every 21 days for 4 cycles
1669142|NCT01705678|Dietary Supplement|Krill oil|Krill oil 300 mg DHA/EPA daily for 6 weeks
1669143|NCT01705678|Dietary Supplement|Fish oil|Fish oil 500 mg DHA/EPA daily for 6 weeks
1669144|NCT01705652|Drug|Nexrutine|Nexrutine 500mg by mouth, three times per day, given prior to surgery or prior to and during radiation treatment.
1669145|NCT01705639|Drug|Melatonin|All subjects receive the same dose of melatonin
1669146|NCT01705600|Behavioral|Pain Verbalization Repression Rules|The involved subjects will be randomized to either a bracelet with receive verbal repression guidelines OR just a bracelet. They will receive typical physical therapy interventions for the treatment of low back pain (modalities, exercise, manual treatment) with the only change being the education of the one group to repress verblization of pain complaints. The bracelet is worn as a reminder of the rules given.
1669148|NCT01705574|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) FDC tablet administered orally with food once daily
1669149|NCT01705574|Drug|RTV|RTV 100 mg tablet administered orally with food once daily
1669150|NCT01705574|Drug|ATV|ATV 300 mg capsule administered orally with food once daily
1669151|NCT01705574|Drug|FTC/TDF|FTC/TDF (200/300 mg) tablet administered orally with food once daily
1669152|NCT01705574|Drug|E/C/F/TDF Placebo|E/C/F/TDF placebo tablet administered orally with food once daily
1669153|NCT01705574|Drug|RTV Placebo|RTV placebo tablet administered orally with food once daily
1669154|NCT01705574|Drug|ATV Placebo|ATV placebo capsule administered orally with food once daily
1669155|NCT01705574|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally with food once daily
1669156|NCT01705574|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablet administered orally with food once daily
1669157|NCT01705548|Radiation|Hypofractionated Radiosurgery|Radiation Therapy will consist of partial brain irradiation delivered to the metastatic brain tumor or resection cavity, delivered in 5 treatments with 2-3 treatments delivered per week.
1669158|NCT01705535|Behavioral|Individual supervised pelvic floor muscle exercises|Six individual treatments of 45 minutes by a physiotherapist specialized in pelvic floor disorders. Preparation of an individual adapted training program for the pelvic floor muscles. Encouragement to perform the pelvic floor muscle training program on a daily basis
1669159|NCT01705535|Other|Massage of the neck and back|six individual treatments of 30 minutes by a physiotherapist. The participants will get no instructions of pelvic floor muscle exercises.
1669160|NCT01705535|Behavioral|Standard information and guidance|Advice about diet and fiber supplements. Information about optimizing bowel emptying including use of medicine. Advice about use of antidiarrheal medication if appropriate.
1669161|NCT01705509|Drug|Ranolazine|The intervention will be ranolazine therapy after the initial CPET. The initial CPET will identify patients with underlying ischemia and serve as a baseline study. Patients whose CPET results meet the criteria for ischemia will be started on Ranexa 500mg BID and advanced within one week +/-4 days to 1000mg BID. A second CPET will be performed after 4 weeks +/- 4 days of maximum therapy. CPET results before and after therapy will undergo a statistical comparison. The initial off treatment CPET measurement will serve as the control to assess changes found during therapy.
1669162|NCT01705496|Radiation|[124I]FIAU|This is a single dose study of 5 mCi [124I]FIAU in subjects presenting with pain in a prosthetic knee or hip joint. Subject will receive two PET-CT scans after [124I]FIAU injection.
1669163|NCT01705483|Drug|ASP9853|oral
1669164|NCT01705483|Drug|Docetaxel|intravenous (IV)
1669165|NCT01705483|Drug|Paclitaxel|Taxol
1669166|NCT01705470|Drug|furosemide|
1669167|NCT01705470|Drug|placebo normal saline|
1669168|NCT01705457|Drug|Dietary Supplement: vitamin A|"25000 IU/day vitamin A for 6 months
1 Cap/Day
1 cap placebo/day for 6 month"
1669169|NCT01705457|Drug|placebo|
1669170|NCT01705444|Device|Foley Catheter and The Spanner Insertion|A Foley catheter will be inserted for 3-5 days, then a voiding trail will be attempted by the patient himself without the catheter. Then, the Spanner will be inserted into the same patient for another 3-5 days and an evacuation trail will be attempted also by the patient after removal of the Spanner. Treatment Satisfaction Questionnaire (TSQ) will be applied by the same person to the patient twice, once after removal of the Foley catheter and the second after removal of the Spanner.
1669171|NCT01705431|Behavioral|On Track|The purpose of the On Track intervention is to address a need raised by a day-treatment school in Lane County: Support for students transitioning from the day-treatment school (Lane School) to their district middle schools. Eligible students are currently attending Lane School, in middle school (Grades 6-8), with or at risk for Emotional Disturbance, and are preparing to transition to their district schools.
1669172|NCT01705405|Device|Software for acquiring ultrasound and endoscopic images|Use of a medical device to acquire ultrasound and endoscopic images
1669173|NCT01705392|Drug|Bevacizumab|Bevacizumab 10 mg/kg q3w
1669174|NCT01705392|Drug|Propranolol|Propranolol 80 mg x 1
1669175|NCT01705392|Drug|Enalapril|Enalapril 5 mg x 1
1669176|NCT01705392|Drug|Dacarbazine|dacarbazine 1000 mg/m2 q3w
1669177|NCT01705379|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|Immunization
1669178|NCT01705366|Procedure|Non-MAKO® Robot Assisted Total Knee Arthroplasty|Patients undergoing a non-MAKO® robot assisted surgery to replace one or more compartments of the knee.
1669263|NCT01704755|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267; ABT-333 tablet
1669180|NCT01705366|Procedure|MAKO® Robot Assisted Medial and PF Knee Arthroplasty|Patients undergoing a MAKO® robot assisted surgery to replace the medial and patellofemoral (PF) compartments of the knee
1669181|NCT01705366|Device|RESTORIS Multicompartmental Knee System|The RESTORIS Multicompartmental Knee (MCK) System components are intended for single or multicompartmental knee replacement used in conjunction with the MAKO® Robotic Arm Interactive Orthopedic System (RIO®). The components can be used for medial compartment, lateral compartment, patellofemoral compartment, or bicompartmental (medial and patellofemoral compartments) knee replacement. The device is intended to be used with bone cement.
1669182|NCT01705366|Device|Depuy Knee Replacement System|The Depuy Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
1669183|NCT01705366|Device|Stryker® Knee Replacement System|The Stryker® Knee Replacement System components are intended for use in total knee replacement. These components are intended for implantation with bone cement.
1669184|NCT01705340|Drug|Akt inhibitor MK2206|Given PO
1669185|NCT01705340|Biological|trastuzumab|Given IV
1669186|NCT01705340|Drug|lapatinib ditosylate|Given PO
1669187|NCT01705340|Other|laboratory biomarker analysis|Optional correlative studies
1669188|NCT01705314|Dietary Supplement|vitamin D supplements|Participants will receive 7mls of D-drops (14,000U/week of vitamin D)
1669189|NCT01705314|Dietary Supplement|placebo|7mls of placebo drops per week for 8 months.
1669190|NCT01705301|Device|WINCS|The experimental protocol will involve, after implantation of the DBS electrodes, the patient will have a single electrochemical recording electrode will be implanted along the same trajectory path as the electrophysiology and the DBS electrode
1669191|NCT01705288|Procedure|Laparotomy|Exploratory surgery for gynecologic diagnosis.Involves pre-operative counseling, the use of regional anesthesia (spinal or epidural pain management rather than intravenous narcotics), early eating after surgery, early walking, and certain goals for discharge from the hospital
1669192|NCT01705288|Drug|intravenous narcotics|given for pain management after surgery per physician orders
1669193|NCT01705288|Drug|standard anesthesia|inhalant or intravenous during surgery
1669194|NCT01705288|Drug|regional anesthesia|given by spinal or epidural infusion
1669195|NCT01705288|Drug|Non-steroidal anti-inflammatory drugs|given for pain management after surgery
1669196|NCT01705275|Drug|ONO-8539|ONO-8539
1669197|NCT01705275|Other|Placebo|Identical to ONO-8539 tablet but without active ingedient
1669198|NCT01705249|Drug|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|After a screening period of 12 weeks (three lunar months) in which the subjects still are on Trisekvens® followed by a treatment period of 24 weeks (six lunar months) in which the subjects are treated with Activelle®.
1669199|NCT01705236|Other|longitudinal assessment|OTC assessments
1669200|NCT01705223|Biological|DNA vaccine|4mg/dose, three doses at week 0,4,8
1669201|NCT01705223|Biological|DNA vaccine prime with the addition of electroporation|4mg/dose, three doses at week 0,4,8
1669202|NCT01705223|Biological|rTV boost|at week 16
1669203|NCT01705223|Biological|rTV boost|at week 24
1669204|NCT01705223|Biological|rTV boost|at week 32
1669205|NCT01705197|Drug|Avanafil 100 or 200mg|This study is designed as a double-blind, stratified randomized, placebo controlled, parallel group, multicenter, dose escalation study. For subjects with moderate to severe ED who have voluntarily signed the consent form, conduct screening and undertake the 4 weeks Free run-in period. For those who satisfy the study criteria during the review of subject's diaries composed during the free run-in period and the evaluation of inclusion/exclusion criteria at a future visit, drugs for each group are provided after randomized to Avanafil 100mg or placebo 100mg at a ratio of 2:1. At this time, subjects are random stratified to each group depending on their diabetes status.
1669206|NCT01705184|Drug|Cisplatin|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles of each sequence
1669207|NCT01705184|Drug|Bevacizumab|7,5 mg/kg, IV (in the vein) on day 1 of each 21 day cycle until progression for each sequence
1669208|NCT01705184|Drug|Pemetrexed|500 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. During 3 cycles for the 1st sequence and until progression for the 2nd sequence.
1669209|NCT01705158|Drug|carboplatin and liposomal doxorubicin|Carboplatin AUC5 and liposomal doxorubicin 40 or 50 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: 6 or until progression or unacceptable toxicity develops.
1669210|NCT01705145|Drug|Ivacaftor|
1669211|NCT01705119|Other|Standing|
1954993|NCT03309839|Other|Blood collection|A sample of an additional blood tube will be taken in parallel with the blood test carried out for the treatment.
1669217|NCT01705093|Dietary Supplement|flavonoid-rich freeze-dried strawberry powder|50g of flavonoid-rich freeze-dried strawberry powder
1669218|NCT01705093|Dietary Supplement|macronutrient-matched control powder|50g macronutrient-matched powder that will lack strawberry flavonoids
1669220|NCT01705067|Device|TKA with Journey II BCS Total Knee System|TKA with Journey II BCS Total Knee System
1669221|NCT01705041|Device|Diagnostics for All liver function test (LFT)|HIV clinic patients meeting targeted enrollment criteria will give fingerstick blood for use on investigational LFT in comparison to routine transaminase test performed at the clinic lab (gold standard)
1669222|NCT01705015|Behavioral|direct feedback about exercise|
1669223|NCT01705015|Behavioral|PLacebo|UCFit plus encouraged exercise
1669224|NCT01705002|Drug|Promitil|2 mg/kg dose IV
1669225|NCT01705002|Drug|Capecitabine|1000 mg dose BID PO for days 1-21 for Combination Cohort and on day 1-14 on Triple combination Cohort
1669226|NCT01705002|Drug|Bevacizumab|for Triple combination cohort an IV dose of 5 mg/kg on day 1 at 4 week interval. For the 3 weekly cohort an IV dose of 7.5 mg/kg at 3 week interval.
1669264|NCT01704755|Drug|Ribavirin (RBV)|Capsule
1669265|NCT01704729|Procedure|group1|Non-cycloplegic self-refraction +conventional glasses
1669266|NCT01704729|Procedure|group2|Cycloplegic subjective refraction by experienced optometrist +conventional glasses
1669227|NCT01704989|Procedure|SLT Laser|At the first treatment, SLT treatment will be delivered to 360 degrees of trabecular meshwork. At the first escalation of treatment, the superior 180 degrees will be retreated. Twenty-five non-overlapping shots per quadrant will be used with a starting power of 0.8 mJ and increments of 0.1 mJ (titrated to avoid large bubbles) with standard other settings (400 nm spot size, 3 nanosecond duration) using a Latina single-mirror goniolens. The IOP will be checked 1 hour post treatment and five days of guttae acular tds will be administered to the treatment eye following treatment. After 2 treatments of SLT, the laser treated arm of the study will follow the same pathway as the medical treatment arm.
1669228|NCT01704989|Drug|Prostagladin|Treatment will be initiated with latanoprost 0.005%. At the first IOP check (1-2 months), if the IOP has not reached target IOP, a second line agent will be added (β-Blocker unless contraindicated). If target IOP is still not reached, a third agent will be considered (topical carbonic anhydrase inhibitor). Treatment may be switched, instead, at the discretion of the clinician if the reduction of IOP with an agent is deemed to be no different than the pre-treatment IOP. Surgical therapy will be considered if target IOP is not met, or there is high IOP (>35 mmHg) or advanced damage at presentation.
1669229|NCT01704976|Device|SR-WBV|Participants will undergo a training program set over four weeks, three times a week with 3 to 6 Hz, Noise 4.
1669230|NCT01704976|Device|SR-WBV|Participants will undergo a training program set over four weeks three times a week with 1 Hz, Noise 1.
1669231|NCT01704963|Drug|PCI-32765|PCI-32765 will be administered in Cohort 1, Cohort 2 and CLL/SLL Cohort. In Cohort 1, single oral dose of PCI-32765 140 mg and 280 mg will be administered before daily oral doses of 420 mg per day for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter. In Cohort 2 and CLL/SLL Cohort, PCI-32765 560 mg and 420 mg per day, respectively will be administered daily for 35 days in Cycle 1 and for 28 days in Cycle 2 and thereafter.
1669232|NCT01704937|Drug|Fecal Microbiota Transplant (FMT)|"Reconstitution of normal flora by a stool transplant from a healthy individual to a C. difficile - infected recipient via colonoscopy or nasogastric tube"
1669233|NCT01704924|Device|Prevena|Device will be applied at end of procedure over closed incision
1669234|NCT01704911|Procedure|Transradial Coronary Intervention|
1669235|NCT01704911|Procedure|Transfemoral Coronary Intervention|
1669236|NCT01704911|Device|Coronary Stent System|Any kind of coronary stent system
1669237|NCT01704898|Drug|Efavirenz 600 Test-Stocrin 600 Reference|
1669238|NCT01704898|Drug|Stocrin 600 Reference-Efavirenz 600 Test|
1669239|NCT01704885|Behavioral|Play Intervention|
1669240|NCT01704885|Other|Questionnaires|
1669241|NCT01704872|Drug|ch14.18/CHO|
1669242|NCT01704859|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
1669243|NCT01704859|Dietary Supplement|Fish oil placebo|Fish oil placebo
1669244|NCT01704859|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
1669245|NCT01704859|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
1669246|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1capsule of BI 201335 NA 120 mg capsule
1669247|NCT01704846|Drug|BI 201335 NA 120 mg capsule|1 capsule of BI 201335 NA 120 mg capsule
1669248|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
1669249|NCT01704846|Drug|BI 201335 NA 40 mg capsule|3 capsules of BI 201335 NA 40 mg capsule
1669250|NCT01704833|Behavioral|Paranoia-Focused Cognitive Behavioral Therapy (PFCBT)|The PFCBT is a 15-week Program that includes weekly group and individual sessions.
1669252|NCT01704807|Device|foot orthotics|Experimental wore experimental orthotics throughout the study period as much of the day as possible.
1669253|NCT01704807|Device|Sham foot orthotic|Control group wore sham insoles as much of the time as possible for the duration of the study period.
1669254|NCT01704794|Dietary Supplement|Folic Acid + Paludrine + Jobelyn (500mg)|Combination of routine drugs + Jobelyn
1669255|NCT01704794|Drug|Folic Acid + Paludrine + Jobelyn (250mg)|Standard routine drugs for treatment of SCD with 250mg Jobelyn
1669256|NCT01704794|Dietary Supplement|Folic Acid + Paludrine + Jobelyn (2mg)|Combination of Paludrine + Folic Acid and Jobelyn 2mg (Sorghum bicolor extract)
1669257|NCT01704781|Drug|Lenalidomide|In Part A a dose escalation design is used (2,5; 5; 10; 25 mg). Part B will use the dose confirmed by Part A
1669258|NCT01704781|Drug|Lenalidomide placebo|Capsules are identical to the active Lenalidomide capsules used.
1669259|NCT01704781|Drug|Vacc-4X|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
1669260|NCT01704781|Drug|rhuGM-CSF|Granulocyte macrophage colony stimulating factor as a local adjuvant
1669261|NCT01704768|Behavioral|COPE/Healthy Lifestyles TEEN Program.|The COPE Program is the intervention curriculum delivered to one arm of the study. Each session of COPE contains 15 to 20 minutes of physical activity (e.g., walking, dancing), not as an exercise training program, but rather to build beliefs/confidence in the teens that they can engage in and sustain some level of physical activity on a regular basis. Those healthy lifestyle intervention programs that have employed exercise interventions only have not led to sustained changes in healthy lifestyle behaviors. Our program is designed to enhance healthy lifestyle behaviors and sustain them because life-long cognitive-behavioral skills are taught in the program. Because the COPE TEEN program is completely manualized for the teens and instructors, it can be easily implemented by health teachers in high school settings.
1669262|NCT01704768|Behavioral|Healthy Teens Attention Control Program|The Healthy Teens program is an attention control program that will assist in ruling out alternative explanations of the mechanism by which the intervention works. It will be standardized like the COPE program to insure that it can be evaluated. It will be administered in a format like that of the COPE intervention program, and will include the same number and length of sessions, except for that it will not include the theoretical active components of CBT and will not include theoretical mechanisms to produce our hypothesized changes in outcomes. Teens in the attention control group also will receive the sessions in their required health class. The difference between the two programs will lie in the content of the sessions, with the Healthy Teens program being focused on safety and common health topics/issues for teens (e.g., road safety, skin care, acne, sun safety).
1669267|NCT01704729|Procedure|group3|Cycloplegic subjective refraction by Rural Refractionist Program + conventional glasses
1669268|NCT01704729|Procedure|group4|Cycloplegic subjective refraction by an experienced optometrist +ready-made glasses
1669269|NCT01704716|Drug|Vincristine|given during Rapid COJEC and modified N7 therapy
1669270|NCT01704716|Drug|Aldesleukin|Aldesleukin is given during MRD Treatment for patients randomised to the arm with IL-2
1669271|NCT01704716|Drug|ch14.18/CHO|ch14.18/CHO antibody is given during MRD treatment
1669272|NCT01704716|Drug|Carboplatin|Carboplatin is given during induction Treatment (R3 randomisation: Rapid COJEC arm)
1669273|NCT01704716|Drug|Etoposide|Etoposide is given during Induction Treatment (both R3 randomisation arms)
1669274|NCT01704716|Drug|Cisplatin|Cisplatin is given during Induction Treatment (both R3 randomisation arms)
1669275|NCT01704716|Drug|Cyclophosphamide|Cyclophosphamid is given during Induction Treatment (both R3 randomisation arms)
1669276|NCT01704716|Drug|Doxorubicin|Doxorubicin is given during Induction Treatment (R3 arm modified N7)
1669277|NCT01704716|Drug|G-CSF|G-CSF is given during Induction Treatment
1669278|NCT01704716|Drug|Busulfan|In case i.v. busulfan is not available, the use of oral busulfan is permitted, although not recommended.
1669279|NCT01704716|Drug|Melphalan|Melphalan is given during MAT treatment
1669280|NCT01704703|Drug|panitumumab|Panitumumab 6,0 mg/kg day 1 i.v. 60 min
1669281|NCT01704703|Drug|FOLFIRI|Irinotecan 180 mg/m2 day 1 i.v. 30-90 min Folinic acid 400 mg/ m2 day 1 i.v. 120 min 5-FU 400 mg/ m2 day 1 Bolus 5-FU 2.400 mg/ m2 day 1 i.v. 46 hours
1669282|NCT01704690|Drug|S-1 and Paclitaxel|S-1 and Paclitaxel are used in the S-1 and Paclitaxel arm.
1669283|NCT01704690|Drug|Paclitaxel and Cisplatin|The paclitaxel and cisplatin combination will be used in the Paclitaxel and Cisplatin arm.
1669284|NCT01704690|Drug|5-FU and Cisplatin|The cisplatin and 5-fluorouracil combination will be used in the Cisplatin and 5-FU arm.
1669285|NCT01704677|Procedure|Lumbar total disc replacement|The surgical intervention consisted of replacement of the degenerative intervertebral lumbar disc with a artificial lumbar disc device in one or two of the lover lumbal levels (L4/L5 or/and L5/S1). The ProDisc consists of three pieces, two metal endplates and a polyethylene core that is fixed to the inferior endplate when the device is implanted, and is implanted through a retroperitoneal (or transperitoneal) access.
1669286|NCT01704677|Behavioral|Multidisciplinary rehabilitation|The intervention is based on a treatment model described by Brox et al (Spine 2003;28:1913-1921) and is also described in details by Hellum et al (BMJ, May 2011). It consisted of a cognitive approach and supervised physical exercise and was delivered by a team of physiotherapists and specialists in physical medicine and rehabilitation. The rehabilitation programme lasted for about 60 hours over three to five weeks.
1669287|NCT01704664|Dietary Supplement|Early postoperative enteral nutrition, based on standard elementary diet (Peptisorb)|Early postoperative enteral nutrition with standard elementary diet (Peptisorb), will start 20 hours post-surgery. The initial flow rate will be 8 ml/h, which will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition wil be continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins (commercially available two-chamber bag for peripheral access with 480 kcal of energetic value and 5.7g of N contained in standard amino acids).
1669288|NCT01704664|Drug|glutamine|The nutritional therapy of group II patients will start post-surgery. It will be based on early enteral nutrition with elementary diet (Peptisorb) with simultaneous parenteral nutrition with two-chamber bag with 480 kcal energetic value and 5.7g of N contained in standard amino acids administered via peripheral veins. Additionally, glutamine (100 ml of Dipeptiven) will be added to the two-chamber bag. The parenteral nutrition will be administered for five days.
1669289|NCT01704664|Dietary Supplement|oral diet enriched with arginine (Cubitan)|Preoperatively, group III patients will be given commercially available oral diet enriched with arginine (Cubitan, 1 package 3 times per day). Additionally, they were administered commercially available two-chamber bag with 480 kcal energetic value and 5.7g of N in standard amino acids via peripheral access. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with commercially available arginine-containing diet (Cubison) will start 20 hours post-surgery at an 8 ml/h flow rate; the rate will increase gradually, with the volume doubled every 24 hours, up to 100 ml/h and continued for six days. Simultaneously, commercially available two-chamber bags for peripheral access with composition identical to that used preoperatively will be administered via peripheral veins for five days.
1669290|NCT01704664|Drug|Perioperative parenteral immunonutrition (Dipeptiven, Omegaven)|Nutritional therapy of group IV will based on intravenous preparations. Two-chamber bags with 480 kcal energetic value and 5.7 g of N in standard amino acids were administered preoperatively. A solution of glutamine (Dipeptiven, 100 ml) and ω3-fatty acids (Omegaven, 100 ml) will be added to the bags. The duration of pre-operative preparatory phase ranged between 5 and 10 days (8 days on average). Enteral nutrition with elementary commercially available diet (Peptisorb) will be begun 20 hours post-surgery; it will start at an 8 ml/h flow rate and increased gradually, with the volume doubled every 24 hours, up to 100 ml/h. The enteral nutrition was continued for six days. During the initial five days post-surgery, the patients will be additionally supplemented parenterally via peripheral veins; similarly to the preoperative period, the content of two-chamber bag for peripheral access enriched with glutamine and ω3-fatty acids will be administered for five days.
1669291|NCT01704651|Drug|Alvimopan|Perioperative administration of oral alvimopan, 12mg twice daily, starting with 1 dose preoperative.
1669292|NCT01704651|Drug|Placebo|Perioperative administration of placebo, at same dosing interval as study drug.
1669293|NCT01704638|Drug|fluvoxamine|
1669294|NCT01704638|Drug|Digoxin|
1669295|NCT01704625|Procedure|Osteopathic Manipulative Treatment|The investigators wish to see if emergency medicine physicians can use osteopathic evaluation and OMT to reliably treat headaches. The results of the examination and treatment will be recorded, but will not be used to change treatment or to change additional tests.
1669296|NCT01704625|Procedure|Sham Osteopathic Manipulative Treatment|The sham group will receive 3 sham treatments.
1669297|NCT01704612|Drug|ropivacaine|patients received 20 mL ropivacaine 5 mg/mL on subgluteal nerve
1669338|NCT01704287|Drug|Dacarbazine|Dacarbazine per institutional standard.
1723121|NCT00004363|Drug|desmopressin|
1669298|NCT01704599|Drug|Humira Then Humira plus 3 B vitamins|Humira alone for 16 weeks then Humira plus 100 mg daily pyridoxine, 5 mg daily folic acid and 1000 mcg daily cyanocobalamin
1669299|NCT01704586|Radiation|Radioiodine I-131|Radioiodine will be used for ablation therapy, dosimetry and posttherapeutic whole body scan, as well as low dose I-131 imaging.
1669300|NCT01704586|Radiation|I-124|I-124 will be used for imaging to assess uptake inside and outside of thyroid bed, using PET/CT whole body scanning, followed by I-131 therapy as necessary as per protocol.
1669301|NCT01704573|Drug|2-[18F]-fluro-3-[2(S)-2-azethidinylmethoxy]-pyridine|"The study will be performed using an Investigational New Drug (IND) Application for the 2-[18F]FA radioligand. The 2-[18F]FA radiotracer allows us to measure nicotine receptors. The PET imaging technique used at these sessions allows us to measure the amount of light that 2-[18F]FA gives off in different regions of the brain, we can estimate how many nicotine receptors are in that region.
2-[18F]FA (radiotracer) is investigational, which means it is not approved by the United States Food and Drug Administration (FDA) for the way that it is being used in this research study. For this reason, we have received approval for all procedures in the current study including the use of 2-[18F]FA from the FDA."
1669302|NCT01704560|Other|Coversheet to Informed Consent|The intervention is a one page cover sheet to be affixed to the front of the standard permission form for the trial for which permission is being sought (attached to application). The form will identify the study as research and contain sections that include investigator contact information, the purpose of the study, a brief description of the study procedures, the alternatives, the voluntary nature, the risks, the potential benefits, a discussion of privacy and confidentiality, the costs and the payments. Each topic will also contain a reference to the page in the consent containing the full description of the topic. The form is designed to have a reading level no higher than 6th to 8th grade. Parents will also receive the full permission form, and all required signatures will still be collected on the permission form.
1669303|NCT01704534|Drug|Ustekinumab|subcutaneous injections of 45 mg or 90 mg (if the participant weighs more than 100 kg) on weeks 0 - 4 - 16 - 28
1669304|NCT01704521|Drug|PegInterferon|
1669305|NCT01704521|Drug|Ribavirin|
1669306|NCT01704521|Drug|Telaprevir|
1669307|NCT01704508|Drug|Artemether-lumefantrine|
1669308|NCT01704508|Drug|Dihydroartemisinin-piperaquine|
1669309|NCT01704495|Drug|AZD5069|AZD5069 oral capsules self-administered twice daily.
1669310|NCT01704495|Drug|Placebo|Placebo oral capsules self-administered twice daily.
1669311|NCT01704482|Drug|N-acetylcysteine|NAC bolus of 150 mg/kg in 250 mL of 5% glucose over 15 mins, followed by continuous intravenous infusion of 50 mg/kg in 250 mL of 5% glucose over 4 hrs, then 100 mg/kg in 1000 ml of 5% glucose over 20 hrs
1669312|NCT01704482|Drug|placebo|
1669313|NCT01704469|Procedure|The local anesthetic injection|
1669314|NCT01704456|Behavioral|Mindfulness-based Cognitive Therapy|The MBCT intervention will be administered in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
1669315|NCT01704456|Behavioral|Cognitive Behavioural Therapy|The CBT intervention will be administered to women in small group format (8-9 women). Each session will be 2.25-hrs in duration and there will be eight, weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, behavioural techniques such as progressive muscle relaxation, cognitive techniques to challenge unhealthy thinking patterns, and communication skills training.
1669316|NCT01704443|Behavioral|Group Psychoeducational Treatment|"The Group Psychoeducational Treatment consists of treatment in small group format (8-9 women). Each session will be 2.25 hours in duration and there will be four, bi-weekly sessions over the course of 2 months. Session content includes education about chronic pain, PVD, stress and sexual response, mindfulness practices, and cognitive techniques to notice thought patterns that contribute to increased pain.
Participants in the Waitlist Control Condition will receive this treatment at the end of the waitlist period (approximately 8 weeks)"
1669317|NCT01704443|Other|Waitlist control|No treatment will be provided during the 8 week Waitlist control period
1669318|NCT01704430|Dietary Supplement|Glutamine|Enteric L-Glutamine
1669319|NCT01704430|Dietary Supplement|Maltodextrin|Enteric Maltodextrin
1669320|NCT01704417|Drug|insulin degludec|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
1669321|NCT01704417|Drug|insulin glargine|Subjects will be randomised to a treatment sequence consisting of two treatment periods in which the subjects will receive IDeg and IGlar, respectively. Administered subcutaneously (s.c., under the skin) once daily. Dose individually adjusted.
1669322|NCT01704404|Drug|TD-4208|
1669323|NCT01704404|Drug|Placebo|
1669324|NCT01704378|Drug|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
1669325|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
1669326|NCT01704365|Biological|Low dose RSV-F Vaccine without Adjuvant|0.5ml IM Injection
1669327|NCT01704365|Biological|High dose RSV-F Vaccine with Adjuvant|0.5mL IM Injection
1669328|NCT01704365|Biological|High dose RSV-F Vaccine without Adjuvant|0.5mL IM Injection
1669329|NCT01704365|Biological|Low dose RSV-F Vaccine with Adjuvant [Bedside Mixing]|0.5mL IM Injection
1669330|NCT01704365|Biological|Placebo|0.5mL IM Injection
1669332|NCT01704339|Drug|QUTENZA|Single treatment with topical capsaicin 8%
1669333|NCT01704313|Procedure|Interrupted|Interrupted suturing technique used aroudn the heel of the vascular anastomosis
1669334|NCT01704313|Procedure|Continuous|Continuous suturing technique used for the anastomosis
1669335|NCT01704287|Biological|Pembrolizumab|IV infusion
1669336|NCT01704287|Drug|Carboplatin|Carboplatin per institutional standard.
1669337|NCT01704287|Drug|Paclitaxel|Paclitaxel per institutional standard.
1669343|NCT01704261|Drug|Omarigliptin|Omarigliptin 25 mg capsule administered orally once a week
1669344|NCT01704261|Drug|Matching placebo to Omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
1669345|NCT01704261|Drug|Glimepiride|Open-label glimepiride tablet(s) administered orally once daily for a total daily dose >=4 mg. In the event of hypoglycemia, the glimepiride dose may be down-titrated to a minimum dose of 1 mg daily.
1669346|NCT01704261|Drug|Metformin|Open-label metformin tablet(s) administered orally once or twice daily for a total daily dose >=1500 mg
1669347|NCT01704248|Device|Eye Drop Guide technique|"Wash the hands.
Shake and then uncap the bottle.
Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.
Use the lower lip of the cup to pull the lower lid down like what they normally do with the fingers.
Then place the upper lip down to cover the whole orbital rim area.
Tilt the head back if seated or standing.
Insert the bottle in the device all the way. Hold the bottle gently.
Look upward.
Squeeze the bottle one drop at a time until feel one drop instilled into the eye.
Close the eye 2-3 minutes.
For the non-seeing eye (best-corrected visual acuity ≤ 20/400) the participants should insert the bottle in the device before cover the eye then proceed with head tilt and look upward."
1669348|NCT01704248|Behavioral|Routine self-instillation technique|"Wash the hands.
Shake and then uncap the bottle.
Hold the bottle between the thumb, index, and/or middle finger of the dominant hand.
Lie down or tilt the head back if seated or standing.
Using the other hand, pull the lower lid down.
Hold the bottle over the eye and look up.
Squeeze the bottle one drop at a time until feel one drop instilled into the eye.
Close the eye 2-3 minutes.
For the participants using more than one medication after instilling one bottle the participants should wait 3-5 minutes between administering different medications in the same eye."
1669349|NCT01704235|Other|Demographic Form and Semi-Structured Interview Guide|"The demographic form will include the following items: age, age at immigration, years lived in the United States, Vietnamese speaking ability, and marital status. In addition for participants who are primary health care providers, the following items will be included: annual income before taxes, gender, race and ethnicity, specialty area of practice, and number of years practicing as a primary health care provider, practice setting, and country received Pap test training.
A semi-structured interview guide will also be used and will include possible probing questions. A semi-structured interview guide was developed with the research team."
1669350|NCT01704209|Drug|Fibroblast Treatment|
1669351|NCT01704209|Procedure|Vehicle|
1669352|NCT01704196|Drug|Nepicastat|120 mg of active drug and 100mg of riboflavin daily for 11 weeks or matching placebo containing 100mg of riboflavin daily for 11 weeks.
1669353|NCT01704196|Drug|Placebo|
1669354|NCT01704170|Device|Kona Externally Focused Ultrasound Therapy|
1669355|NCT01704157|Device|Cryo-Touch III|Study treatment at Day 0.
1669356|NCT01704118|Device|I-gel|Supraglottic airway device
1669357|NCT01704118|Device|ProSeal Laryngeal mask|Supraglottic airway device
1669358|NCT01704105|Behavioral|Water Quality|Hardware: Chlorine dispensers provided for free at communal water sources. Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the treatment of drinking water for all children living in the household.
1669359|NCT01704105|Behavioral|Sanitation|"Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, and new or upgraded pit latrine for each study compound. Upgrades may include structural improvements, plastic slabs, and superstructure improvements.
Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound."
1669360|NCT01704105|Behavioral|Handwashing|"Hardware: Handwashing dual tippy tap stations, including jugs for clean and for soapy water. Handwashing stations will be stocked with soap for the duration of the trial.
Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages that focus on handwashing with soap at critical times around food preparation, defecation, and contact with feces."
1669361|NCT01704105|Dietary Supplement|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) twice daily from ages 6 to 24 months.
Promotion: Local promoters will visit study compounds at least monthly during the first year and bi-monthly thereafter to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices. General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
1669362|NCT01704092|Drug|Dexmedetomidine|
1669363|NCT01704079|Drug|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime
1669364|NCT01704079|Other|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
1669365|NCT01704066|Other|Training and education|
1669366|NCT01704040|Drug|CNTO 3157 (healthy participants)|CNTO 3157 10 mg/kg, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with human rhinovirus type 16 (HRV-16).
1669367|NCT01704040|Drug|Placebo (healthy participants)|Placebo, as a single intravenous infusion, on Day 1, 24 to 72 hours prior to inoculation with HRV-16.
1669368|NCT01704040|Drug|CNTO 3157 (asthmatic patients)|CNTO 3157 10 mg/kg, as a single intravenous infusion, at Week 1 (Day 1), followed by 3 infusions of 3 mg/kg of CNTO 3157 at Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
1669369|NCT01704040|Drug|Placebo (asthmatic patients)|Placebo, as 4 intravenous infusions, at Week 1 (Day 1), Week 2 (Day 8), Week 3 (Day 15), and Week 4 (Day 22). The final infusion (Week 4) will occur 24 to 72 hours prior to inoculation with HRV-16.
1669370|NCT01704040|Other|HRV-16|Single inoculation of HRV-16 in a total volume of approximately 1.0 mL, administered as 2 instillations per naris.
1669416|NCT01703611|Other|Usual Nutrition Care|Usual nutrition care in India
1669417|NCT01703598|Device|Deep Brain Stimulation|Placement of Deep Brain Stimulation electrodes
1669371|NCT01704027|Radiation|Simultaneous integrated boost intensity-modulated arctherapy|"Three dose levels will be delivered at each fraction, 5 days a week, 30 fractions :
Pelvis : 55,5 Gy (1,85 Gy/fr)
Seminal vesicles : 66 Gy (2,2 Gy/fr)
Prostate : 72 Gy (2,4 Gy/fr)"
1669372|NCT01704027|Drug|Androgen deprivation|Patients will received androgen deprivation for a maximum of three years. This treatment can start six months before radiotherapy and at least the day one of radiotherapy.
1669373|NCT01704001|Drug|ART-123|380 U/kg/day or 130 U/kg/day(Subjects with severe renal impairment) for 6 days
1669374|NCT01703988|Drug|Nusinersen|Single IT injection for each dose
1669375|NCT01703975|Other|Training in pairs (Dyad training)|
1669376|NCT01703949|Drug|Brentuximab Vedotin|Given IV
1669377|NCT01703949|Other|Laboratory Biomarker Analysis|Correlative studies
1669378|NCT01703936|Other|Agricultural and life skills training program|
1669379|NCT01703923|Drug|FP01|
1669380|NCT01703923|Drug|placebo|
1669381|NCT01703910|Drug|Arm A chemotherapy|
1669382|NCT01703910|Drug|arm B chemotherapy|
1669383|NCT01703897|Device|Manometry and Impedance analysis|
1669384|NCT01703884|Drug|ASAQ|In the intervention area, obstetric, medical, drug-exposure histories will be collected at ANC visits. In addition, in the last trimester of the pregnancy (> 28 weeks of pregnancy), women will be systematically evaluated with malaria RDT for whether they have malaria parasites and treated effectively with ASAQ.
1669385|NCT01703858|Drug|BI 113608 PIB|powder for oral solution
1669386|NCT01703858|Drug|BI 113608|conventional tablet formulation
1669387|NCT01703858|Drug|BI 113608|conventional tablet formulation
1669388|NCT01703858|Drug|BI 113608|conventional tablet formulation
1669389|NCT01703858|Drug|pantoprazole 40 mg STADA|film-coated tablet
1669390|NCT01703858|Drug|BI 113608|conventional tablet formulation
1669391|NCT01703845|Drug|Tiotropium (high dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
1669392|NCT01703845|Drug|Tiotropium (low dose) + Olodaterol|Tiotropium + Olodaterol solution for inhalation
1669393|NCT01703832|Drug|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
1669394|NCT01703819|Drug|Neurexan®|0.6 mg / tablet, 6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
1669395|NCT01703819|Other|Placebo|6 tablets, 1 tablet every 30 minutes from -180 minutes to -30 minutes
1669396|NCT01703793|Drug|Test Product 49778|
1669397|NCT01703793|Drug|Test Product 10156|
1669398|NCT01703793|Drug|Vehicle (placebo)|
1669399|NCT01703767|Behavioral|Provider Education Workshop|Educational resources for physicians regarding the needs of GW1V patients.
1669400|NCT01703754|Genetic|Ad-RTS-hIL-12 and Veledimex|Oral activator ligand with adenoviral vector injection of cancer lesions
1669401|NCT01703754|Drug|Palifosfamide|Small molecule chemotherapy, IV administration
1669402|NCT01703741|Drug|Testosterone Gel (FE 999093)|
1669403|NCT01703728|Other|Highly purified menotropin (HP- hMG) treatment|No intervention: patients treated by highly purified menotropin for COS according to physicians' current practice
1669404|NCT01703715|Device|The Hydrant|"The Hydrant is a new form of drinking system that may be used to provide continuous access to hydration will be given to 20 patients. 10 of the patients will have mild cognitive impairment with Mini Mental State Examination less than 24 and 10 with normal cognitive function. Patients and staff will be interviewed to assess the feasibility of the hydrant."
1669405|NCT01703702|Drug|florbetapir (18F)|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
1669406|NCT01703689|Behavioral|Audit and Feedback|Descriptive statistics to each nursing home (NH) with regards to its own indicators of quality and residents' health status, and the same descriptive statistics on the sub-regional and regional levels were done to all NHs for comparative purposes.
1669407|NCT01703689|Behavioral|Cooperative Work|Nursing homes (NH)in the strong intervention group had two half-day meetings of cooperative work with a hospital geriatrician to identify NHs' weaknesses regarding quality of care and to establish strategies for overcoming these weaknesses.
1669408|NCT01703663|Device|EPAP|
1669409|NCT01703650|Drug|iopromide|"iopromide (370mgI/mL) enhanced perfusion CT will be performed within 14 days of operation.
In patients who are planned to receive chemotherapy, iopromide enhanced perfusion CT was performed twice; within 14 days before starting 1st cycle and within 14 days after finishing 2nd cycle.
iopromide (370mgI/mL) will be administered intravenously with an amount of 30mL (body weight[BW] <50kg) or 35 mL (50kg ≤BW <70kg) or 40 mL (70 kg≤BW <90kg) or 50 mL (90≤BW), followed by saline infusion (30mL).
Injection rate is as follows; 6.0mL/sec if BW is <50kg, 7.0 mL/sec if BW is 50kg≤and <70kg, 8.0 mL/sec if BW is 70≤and<90kg and 9.0mL/sec if BW is 90kg≤."
1669410|NCT01703650|Procedure|CT|"Perfusion CT will be performed by using a 320 channel MDCT
Patients are requested for fasting for at least 8 hours before CT scan.
Patients are requested for doing shallow breathing as slow as possible and wide strap is applied during CT scan.
Scan range is limited to the whole pancreas and it focuses to the pancreas tumor lesion.
During perfusion CT, 19 phases (ten phases with two seconds interval and six phases with three seconds interval and three phases with five seconds interval) are obtained in fifty three seconds.
ADIR 3D and SURE EXPOSURE 3D are applied during perfusion CT to minimize radiation dose."
1669411|NCT01703637|Drug|Sitagliptin|"before breakfast：a tablet of sitagliptin; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy
before dinner：a tablet of sitagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of saxagliptin's dummy"
1669412|NCT01703637|Drug|Vildagliptin|"before breakfast：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy
before dinner：a tablet of vildagliptin; a tablet of sitagliptin's dummy; a tablet of saxagliptin's dummy"
1669413|NCT01703637|Drug|Saxagliptin|"before breakfast：a tablet of saxagliptin; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy
before dinner：a tablet of saxagliptin's dummy; a tablet of vildagliptin's dummy; a tablet of sitagliptin's dummy"
1669414|NCT01703624|Drug|glycopyrronium bromide|glycopyrronium bromide suspension in HFA
1669415|NCT01703611|Other|MNT according to AND EBNPG for Type 2 DM|Six or more Medical Nutrition Therapy visits(education and counseling on diet, self management, and lifestyle changes) provided over a 12 month period according to Academy of Nutrition and Dietetic Evidence Based Nutrition Practice Guidelines (EBNPG)(www.guidelines.gov)
1669420|NCT01703559|Drug|Phentolamine mesylate ophthalmic solution|Ophthalmic solution, one drop each eye x 15 days
1669421|NCT01703546|Procedure|LAGB & LGCP|All study patients will have the following surgical procedures: Laparoscopic Adjustable Gastric Band & Laparoscopic Gastric Plication. % Excess Body Weight Loss will be monitored at each post op visit.
1669422|NCT01703533|Drug|NNZ-2566|Glycyl-L-2-Methylpropyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with strawberry flavored solution 0.5% v/v in Water for Injection.
1669423|NCT01703533|Drug|Placebo|Strawberry flavored solution and Water for Injection
1669427|NCT01703494|Biological|Fecal Microbiota Transplantation|Fecal microbiota transplantation (FMT) involves administering fecal material from a healthy individual (donor) to a sick patient (with relapsing C. difficile infection) to restore missing components of normal intestinal flora. After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive fecal microbiota transplantation (FMT) with a 300 mL donor fecal suspension delivered via colonoscopy.
1669428|NCT01703494|Biological|Sham Fecal Microbiota Transplantation|After completing at least a 10 day course of vancomycin for treatment of the most recent acute C. difficile infection, subjects will receive a sham fecal microbiota transplantation (FMT) with a 300 mL sham fecal suspension delivered via colonoscopy. This sham solution will be a reinfusion of the subject's own stool.
1669429|NCT01703481|Drug|JNJ-42756493: Part 1|Participants will receive 0.5 mg (starting dose) capsule of JNJ-42756493 orally (by mouth) once daily on Day 1 of Cycle 1. Dose of the study medication will be escalated sequentially till the dose limiting toxicity is achieved to determine the recommended part 2 doses (RP2D).
1669430|NCT01703481|Drug|JNJ-42756493: Part 2|Participants will receive JNJ-42756493 at the RP2D or below RP2D (maximum tolerated dose from Part 1) orally once daily on a 21 days cycle to confirm RP2D (in Part 2).
1669431|NCT01703481|Drug|JNJ-42756493: Part 3|Participants will receive JNJ-42756493 at first RP2D of 9 mg daily in Part 3 orally once daily on a 21 days cycle.
1669432|NCT01703481|Drug|JNJ-42756493: Part 4|Participants will receive JNJ-42756493 second RP2D of 10 mg intermittent dosing in Part 4 (with option to increase to 12 mg intermittent dosing based on phosphate level), orally on an intermittent schedule of daily for 7 days followed by 7 days off with a 28-day cycle.
1669433|NCT01703468|Drug|Oxcarbazepine|
1669434|NCT01703455|Drug|Sorafenib|400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles
1669435|NCT01703390|Drug|FOLFIRI + Cetuximab|
1669436|NCT01703390|Drug|modifiedFOLFOX6 + Cetuximab|
1669437|NCT01703364|Drug|Lenalidomide|"Lenalidomide: day 8-21 of cycle 1 and day 1-21 of cycles 2-6; Starting Dose: 5 mg (first 5 patients) and 10 mg (further 5 patients) increase Lenalidomide dose via dose levels (10)/15/20/25 mg/d every 28 days if no limiting toxicity occurs
Fludarabine: 25 mg/m2 iv d1-3 or 40 mg/m2 po d1-3; repeat every 28 days
Rituximab: 375 mg/m2 iv day 4 on cycle 1 and 500 mg/m2 iv day 1 on cycles 2-6; repeat every 28 days"
1669438|NCT01703351|Drug|0.5% ropivacaine|(n=48); continuous paravertebral infusion of local anesthetics (0.5% ropivacaine, 5cc/hr for 60 hours after operation) thorough catheter below the parietal pleura using On-Q® system(I-flow corp, Lake Forest, CA, USA)
1669439|NCT01703351|Drug|Fentanyl 500mcg + acupan 160mg + nasea 0.6mg|(n=48); IV PCA (Fentanyl 500mcg + acupan 160mg + nasea 0.6mg, 5cc/hr for 60 hours after operation, 0.5cc bolus if patients feel breakthrough pain)
1669440|NCT01703325|Drug|0.1% triamcinolone , 0.05% clobetasol propionate ointment|"Three finger nails are chosen from the equally average NAPSI scores which are evaluated by two independent dermatologists. Block randomization are performed to arrange such fingers into group A, B or C
Group A: Triamcinolone injection (10 mg/ml) on 4 sites for the pathology from both nail matrix (B) and nail bed (A) or 2 sites for the pathology from either nail matrix(B) or nail bed (A) as shown in picture, the EMLA was applied before injection
Group B: Apply Topical 0.05% clobetasol propionate ointment (Dermovate®) on the nail fold twice daily for 6 months
Group C: Controlled group"
1669441|NCT01703312|Drug|QGE031|Drug administered by subcutaneous injection
1669442|NCT01703312|Drug|omalizumab|Drug administered by subcutaneous injection
1669443|NCT01703312|Drug|placebo|Drug administered by subcutaneous injection
1669444|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
1669445|NCT01703286|Drug|Linagliptin|given once daily for 28 days
1669446|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
1669447|NCT01703286|Drug|Placebo|Placebo matching Linagliptin
1669448|NCT01703286|Drug|Placebo|Placebo matching Glimepiride
1669449|NCT01703286|Drug|Glimepiride|1 mg for 7 days followed by uptitration to 2 mg (given for following 21 days)
1669450|NCT01703273|Behavioral|manual based low key group intervention (innovation)|6 sessions offered over the course of 3-6 months focus on improvement of quality of life and psychosocial functioning . Topics covered are: 1) social competencies, 2) body image, 3) coping with mobbing and anger, 4) coping with stress, 5) life satisfaction, and 6) psychological well being. The planned intervention does not primarily focus on weight loss.
1669451|NCT01703273|Behavioral|standardized, manual based routine care|6 sessions offered over the course of 3-6 months with a focus on weight loss. The topics 1) causes, consequences and treatment options of obesity, 2) nutrition, 3) eating behaviors and problem solving strategies, 4) self esteem and emotional eating, 5) exercise, and 6) use of media, will be covered.
1669452|NCT01703260|Drug|Roflumilast|Roflumilast dose
1669453|NCT01703260|Drug|Pioglitazone|Pioglitazone dose
1669454|NCT01703260|Drug|Placebo|Pioglitazone placebo-matching dose
1669455|NCT01703260|Drug|Placebo|Roflumilast placebo-matching dose
1669456|NCT01703247|Procedure|Pulmonary vein isolation|
1669457|NCT01703247|Procedure|Ganglionated plexi ablation|
1669458|NCT01703247|Procedure|Linear Lesion Ablation|
1669459|NCT01703234|Drug|Ramipril|ramipril 10 mg/day during 3 months
1669460|NCT01703221|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly
1669461|NCT01703221|Drug|Sitagliptin|Sitagliptin 50 mg tablet administered orally once daily
1671820|NCT01684631|Device|Total Hip arthroplasty|
1669462|NCT01703221|Drug|Placebo to omarigliptin|Placebo to omarigliptin 25 mg capsule administered orally once weekly
1669463|NCT01703221|Drug|Placebo to sitagliptin|Placebo to sitagliptin 50 mg tablet administered orally once daily
1669464|NCT01703208|Drug|Omarigliptin|
1669465|NCT01703208|Drug|Placebo|
1669466|NCT01703195|Procedure|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) obtained pre-treatment and 4-6 weeks post-treatment.
1669467|NCT01703195|Procedure|Diffusion Weighted Magnetic Resonance Imaging (DWMR)|Diffusion Weighted Magnetic Resonance Imaging (DWMR) obtained pre-treatment and 4-6 weeks post-treatment.
1954996|NCT03309813|Device|Transcranial ExAblate|ExAblate Thalamotomy for Chronic Trigeminal Neuropathic Pain
1669469|NCT01703156|Procedure|Stress Test|
1669470|NCT01703156|Procedure|No Stress Test|
1669471|NCT01703143|Procedure|Laser ablation|Laser ablation of focal lesions in patients with medically refractory partial epilepsy.
1669472|NCT01703130|Procedure|Dose of of ropivacaine 0.75% used in block procedure|
1669473|NCT01703117|Drug|Riluzole|24 subjects between the ages of 60-85 will receive study drug.
1669474|NCT01703117|Drug|Placebo|24 subjects between the ages of 60-85 will receive placebo
1669475|NCT01703104|Drug|Paludrine + Folic Acid|This is the combination of routine drugs for treating sickle cell disease
1669476|NCT01703104|Dietary Supplement|Paludrine + Folic Acid + Jobelyn|Combination of routine drugs + Jobelyn
1669477|NCT01703091|Drug|Ramucirumab|Administered IV
1669478|NCT01703091|Drug|Placebo|Administered IV
1669479|NCT01703091|Drug|Docetaxel|Administered IV
1669480|NCT01703078|Drug|Ingenol once daily for two consecutive days|
1669481|NCT01703065|Drug|cabozantinib-s-malate|Given PO
1669482|NCT01703065|Other|laboratory biomarker analysis|Correlative studies
1669483|NCT01703052|Drug|CHF 6001 SD or placebo|Dry Powder Inhaler
1669484|NCT01703052|Drug|CHF 6001 MD or placebo|Dry Powder Inhaler
1669485|NCT01703039|Drug|Riluzole|
1669486|NCT01703039|Drug|Sertraline|
1669487|NCT01703039|Other|placebo|
1669488|NCT01703000|Device|Percutaneous coronary intervention (NG PROMUS)|Interventional coronary artery stenting with NG PROMUS study stent.
1669489|NCT01702987|Dietary Supplement|ubiquinol|ubiquinol supplementation was given for 1 month to 12 patients
1669490|NCT01702987|Dietary Supplement|placebo|placebo (identical in appearance to ubiquinol) was given for 1 month to 9 patients
1669491|NCT01702987|Drug|statin|statin was given for 1 month to 21 patients
1669492|NCT01702974|Drug|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
1669493|NCT01702974|Drug|Placebo tablets|Placebo tablets for vitamin D once daily and placebo tablets for PBA (phenylbutyrate) twice daily for 16 weeks.
1669494|NCT01702961|Drug|Melphalan|"Given on Day -1
Melphalan is administered according to the current SOP."
1669495|NCT01702961|Drug|Ara-C|200 mg/m2 IB BID given on Days -5, -4, -3, -2
1669496|NCT01702961|Drug|VP-16|200 mg/m2 IV BID given on Days -5, -4, -3, -2
1669497|NCT01702961|Drug|BCNU|BCNU 300 mg/m2 IV given on Day -6
1669498|NCT01702961|Drug|Rituxan|375 mg/m2 IB given on Days -6, +14, +21, +28
1669499|NCT01702961|Drug|Stem Cells|Stem cells given on Day 0
1954997|NCT03309813|Device|Sham Transcranial ExAblate|Sham ExAblate Thalamotomy procedure
1669502|NCT01702883|Other|Internet Survey|prompt to complete internet survey
1669503|NCT01702870|Procedure|Magnetic Resonance Imaging|
1669504|NCT01702857|Biological|Biological/Vaccine: 4 µg TDENV-PIV with Alum adjuvant|
1669505|NCT01702857|Biological|Biological/Vaccine: 1 µg TDENV-PIV with AS03B adjuvant|
1669506|NCT01702857|Other|Phosphate buffered saline|
1669507|NCT01702857|Biological|1 µg TDENV-PIV with Alum adjuvant|
1669508|NCT01702857|Biological|1 µg TDENV-PIV with AS01E adjuvant|
1669510|NCT01702831|Drug|Busulfan|Once daily intravenous (IV) busulfan at a dose of 3.2 mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -5 to -3), option 1 OR Once daily intravenous (IV) busulfan at a dose of 3.2mg/kg or equivalent pharmacokinetics directed dose for three consecutive days (days -6 to -4), option 2.
1669511|NCT01702831|Drug|Melphalan|"I.V. reduced dose of melphalan (140mg/m2) on day -2, followed by an autologous stem cell transplant on day 0 (day -1 will be a rest day) - this is referred to as Option 1 dosing schema OR I.V. reduced dose of melphalan (140mg/m2) on day -3 followed by autologous stem cell transplant on day 0 (days -2 and -1 will be rest days). This is referred to as Option 2"
1669512|NCT01702831|Drug|Lenalidomide|Oral lenalidomide 10mg per day (on all 28 days of a 28 day cycle) for the first three cycles and then escalated to 15 mg daily if clinically appropriate to do so. The lenalidomide maintenance will start on day 100 post ASCT and continue till disease progression.
1669513|NCT01702805|Procedure|Liberal Cell Transfusion|
1669514|NCT01702805|Procedure|Restricted red cell transfusion|
1669515|NCT01702792|Biological|Tumor Vaccine|Tumor cells obtained at the time of surgery are irradiated with 10,000 Gy and freeze fractured. Lysate at 1x107 tumor cell equivalent (TCE) will be used for vaccination with adjuvant, Montanide ISA 51 VG.
1669516|NCT01702779|Other|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
1669517|NCT01702779|Other|mechanical ventilation|Prospective, randomized clinical multicentric study in ICU (Intensive Care University)during weaning from mechanical ventilation.
1954998|NCT03309800|Drug|HL301|HL301: 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
1669520|NCT01702740|Drug|1 mg/kg CNTO 136|Type=exact number, unit=mg, number=1, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
1669521|NCT01702740|Drug|4 mg/kg CNTO 136|Type=exact number, unit=mg, number=4, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
1669522|NCT01702740|Drug|10 mg/kg CNTO 136|Type=exact number, unit=mg, number=10, form=powder for solution for infusion, route=intravenous use, every 2 weeks for 6 weeks.
1669523|NCT01702740|Drug|Placebo|Form=liquid for infusion, route=intravenous use, every 2 weeks for 6 weeks.
1669524|NCT01702727|Device|I-BiTTM game|30 minutes intervention weekly for 6 weeks.
1669525|NCT01702727|Device|Non-I-BiTTM game|30 minutes intervention weekly for 6 weeks.
1669526|NCT01702727|Device|I-BiTTM DVD|30 minutes intervention weekly for 6 weeks.
1669527|NCT01702714|Drug|RO5083945|multiple ascending doses
1669528|NCT01702714|Drug|carboplatin|up to 6 cycles
1669529|NCT01702714|Drug|cisplatin|up to 6 cycles
1669530|NCT01702714|Drug|gemcitabine|up to 6 cycles
1669531|NCT01702714|Drug|paclitaxel|up to 6 cycles
1669532|NCT01702701|Drug|Montelukast|montelukast 10mg po pill q day for 12 weeks
1669533|NCT01702701|Drug|Fluticasone|fluticasone 440mcg po q bid x 12 weeks
1669534|NCT01702688|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
1669535|NCT01702688|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
1669536|NCT01702675|Drug|ACH15 50 mg|ACH15 50mg capsule
1669537|NCT01702675|Drug|ACH15 250 mg|ACH15 250mg capsule
1669538|NCT01702675|Drug|ACH15 500mg|ACH15 500 mg capsule
1669539|NCT01702675|Drug|ACH15 - 1000mg|ACH15 500mg capsule - two 500mg capsules in single dose
1669540|NCT01702675|Drug|ACH15 - 2000mg|ACH15 500mg capsule (four 500mg capsules in one dose)
1669541|NCT01702675|Drug|ACH15 - 500mg|ACH15 - 500mg twice a day for 7 days
1669542|NCT01702675|Drug|Placebo 250 mg|Capsule manufactured to mimic ACH15 250 mg capsule
1669543|NCT01702675|Drug|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule
1669544|NCT01702675|Drug|Placebo 1000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (two 500 mg capsules in one dose)
1669545|NCT01702675|Drug|Placebo 2000mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (four 500 mg capsules in one dose)
1669546|NCT01702675|Drug|Placebo 500mg|Capsule manufactured to mimic ACH15 500 mg capsule Placebo 500mg (500 mg capsules twice a day for 7 days)
1669547|NCT01702662|Device|Photopill treatment|2 courses of 5 Photopill treatments within 14 days. In each treatment, 3cm of rectal tissue will be exposed, 2 minutes per cm, to low level light therapy.
1669548|NCT01702649|Drug|RPX2003 (Biapenem)|"Six (6) cohorts of 3 active or 8 subjects of 6 active are planned for evaluation.
Single dose followed by multiple dose, three times a day."
1669549|NCT01702649|Drug|Placebo|"Six (6) cohorts of 1 placebo or 8 subjects of 2 placebo are planned for evaluation.
Single dose followed by multiple dose, three times a day."
1669550|NCT01702636|Drug|Tranexamic Acid|
1669551|NCT01702636|Drug|Placebo|
1669552|NCT01702623|Drug|Oxcarbazepine|
1669553|NCT01702610|Radiation|IMRT Technique|
1669554|NCT01702610|Radiation|IMRT and accelerated hypofractionation technique|Intervention is the technique and accelerated fractionation used to treat GBM
1669555|NCT01702610|Radiation|neo-adjuvant TMZ followed by accelerated hypofractionated EBRT|Two weeks of neo-adjuvant TMZ followed by XRT+TMX followed by TMZ as adjuvant component
1669556|NCT01702610|Drug|Temozolomide and Accelerated Hypofractionation RT|
1669557|NCT01702597|Device|Whole body vibration (Galileo® Med M Plus, Novotec, Pforzheim, Germany)|Patients will train on a WBV platform, following a standardized protocol, aiming at improving strength, endurance and proprioception of both legs.
1669558|NCT01702597|Other|Physiotherapy|Patients will receive a standardized physical therapy.
1669559|NCT01702584|Procedure|stent assisted embolization|stent assisted embolization and anti-thrombotic management
1954999|NCT03309800|Drug|HL301(Placebo)|HL301(Placebo): 2Tab/day: 1 Tablet at once, 2 times a day, 7 days of treatment
1669561|NCT01702558|Drug|Capecitabine|In the Phase I component, participants will receive oral capecitabine twice daily at escalating doses up to 750 milligrams per meter squared (mg/m^2) to determine the MTD. In the Phase II component, capecitabine will be dosed at the MTD established in Phase I.
1669562|NCT01702558|Drug|Trastuzumab emtansine|Participants with breast cancer in the Phase I and II components will receive a dose of 3.6 milligrams per kilogram (mg/kg) via intravenous (IV) infusion every 3 weeks until disease progression, intolerable toxicity, withdrawal of consent. For participants with gastric cancer in the Phase I component, the dose will be 2.4 mg/kg via IV infusion every 3 weeks.
1669563|NCT01702532|Drug|Nicotine|Comparison of different dosage forms of nicotine
1669564|NCT01702519|Drug|nicotine|nicotine transdermal patch
1669565|NCT01702506|Drug|dacomitinib fasted|Overnight fasted subjects will receive a single 45 mg dose of dacomitinib
1669566|NCT01702506|Drug|dacomitinib fed|Subjects will receive a single 45 mg dose of dacomitinib with a high calorie high fat meal
1669567|NCT01702506|Drug|dacomitinib+antacid|Subjects will receive a single 45 mg dose of dacomitinib when there are treated with rabeprazole
1669568|NCT01702493|Drug|Cap SRT2104|Micronized free base in a 250 mg SRT2104 (active equivalents) capsule
1669569|NCT01702493|Drug|Tab SRT2104 slow release|New 250 mg SRT2104 mesylate salt slow release tablet
1669570|NCT01702493|Drug|Tab SRT2104 intermediate release|New 250 mg SRT2104 mesylate salt intermediate release tablet
1669571|NCT01702493|Drug|Tab SRT2104 fast release|New 250 mg SRT2104 mesylate salt fast release tablet
1669572|NCT01702493|Drug|Selected formulations of SRT2104 from Part 1|SRT2104 500 mg of selected formulation(s) from Part 1 in single-dose or daily for 7 days
1669573|NCT01702493|Drug|Selected formulations of SRT2104 from Part 1 single alternative dose|SRT2104 single alternative dose (other than 500 mg, but not to exceed 2000 mg) of selected formulation(s) from Part 1
1669755|NCT01701180|Drug|Oxytocin|24 IU; 3 puffs per nostril, each with 4 IU OXT
1669756|NCT01701180|Drug|Placebo|
1669574|NCT01702480|Drug|GSK2981710|Will be available as 10 g medium-chain triglycerides (MCT) powder sachet that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
1669575|NCT01702480|Drug|Placebo|Will be available as matching powder that will be mixed with 125 - 250 milliliters (ml) water in a shaker and taken within 15 minutes of completion of breakfast
1669578|NCT01702454|Biological|Fluarix Quadrivalent|1 or 2 doses administered intramuscularly (IM) in deltoid region depending on the priming status
1669579|NCT01702441|Drug|Subcutaneous AKB-9778|
1955000|NCT03309787|Behavioral|eHealth|Intervention Description: The pilot comprises of five components listed below which provide access to specialty obesity care to rural obese adults, and enhance it with technology (telehealth and remote monitoring): Team-based care; medical plan, nurses, psychologists, dietician, Health coaching, Weekly coaching sessions , Messaging and Remote Monitoring
1669585|NCT01702415|Drug|Zoledronic acid|Single dose, intravenous solution 5mg
1669586|NCT01702415|Drug|Placebo|
1669587|NCT01702402|Behavioral|Educational and Behavior Change intervention|"Integrate post-partum family planning education and counselling into 2nd Antenatal Home visit by CHW (at approximately 32 weeks of pregnancy) Integrate post-partum family planning education and counselling into post-partum visits by CHWs during first month Continue providing family planning education and counselling to women through CHW home visits after first month.
Promote discussion and acceptance of post-partum family planning methods among key household members.
Facility level Ensure availability of postpartum contraceptive methods such as progestin-only pill.
Ensure availability of post-partum family planning and post-natal services. Community level Increase community awareness of the importance of birth spacing and benefits of LAM Educate influential community members on the importance of birth spacing and benefits of LAM."
1669588|NCT01702402|Other|Comparison Group|A comparison area received standard government health services.
1669589|NCT01702389|Drug|Remifentanil|
1669590|NCT01702376|Drug|Retosiban 100 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet, one 100 mg tablet of retosiban and 7 retosiban matched placebo tablets
1669591|NCT01702376|Drug|Retosiban 800 mg|Subjects will be administered with single dose of one moxifloxacin placebo tablet and eight 100 mg tablets of retosiban
1669592|NCT01702376|Drug|Placebo|Subjects will be administered with one moxifloxacin placebo tablet and eight retosiban matched placebo tablets
1669593|NCT01702376|Drug|Moxifloxacin 400 mg|Subjects will be administered with one 400 mg moxifloxacin tablet and eight retosiban matched placebo tablets
1669594|NCT01702363|Drug|GSK573719|GSK573719 inhalation powder inhaled orally once daily for 52 weeks.
1669595|NCT01702350|Drug|GSK2251052|Oral formulation of an an antibacterial
1669596|NCT01702337|Other|Prevalence-based model|Static prevalence-based model to estimate vaccine effect over a one-year period at a steady state (when all women are fully vaccinated).
1669597|NCT01702324|Drug|DD-25|A topical DD-25 cream at 0.025% concentration.
1669598|NCT01702311|Drug|Bedtime insulin Aspart (Novolog)|Bedtime insulin aspart supplementation based on blood glucose value in the bedtime supplementation arm.
1669599|NCT01702298|Drug|Sitagliptin 100 mg/simvastatin 40 mg FDC|Sitagliptin 100 mg/simvastatin 40 mg FDC tablet administered once daily in the evening for 6 weeks
1669600|NCT01702298|Drug|Metformin|Participants will continue pre-study dose of metformin tablet(s) >=1000 per day
1669602|NCT01702272|Device|Procleix Dengue Virus Assay|in vitro diagnostic assay
1669603|NCT01702259|Device|Erchonia Scanner device (GLS)|The Erchonia® GLS device is made up of six independent diodes, each emitting 17 milliwatts (mW), 532 nanometer (nm) of green laser light.
1669604|NCT01702259|Device|Placebo device|Inactive Erchonia GLS.
1669605|NCT01702246|Drug|Simvastatin|40 mg, orally, once daily for 3 months
1669606|NCT01702233|Drug|Traumeel S inj|Traumeel S inj. 2 ml. subacromial 3 times at days 1, 8 and 15
1669607|NCT01702233|Drug|Fortecortin/Dexamethasone 8 mg/2 ml inj|Fortecortin/Dexamethasone 8 mg/2 ml inj. subacromial 3 times at days 1, 8 and 15
1669608|NCT01702233|Drug|Saline inj|Saline inj. 2 ml. subacromial 3 times at days 1, 8 and 15
1669609|NCT01702220|Behavioral|CBT|6-12 sessions of CBT in person or over the phone
1669610|NCT01702220|Other|ECC|6 biweekly sessions of ECC over the telephone
1669611|NCT01702207|Drug|Once Daily Tacrolimus|Subjects switched from the tacrolimus twice daily (Prograf®) to the once daily formulation (Advagraf®) to maintain a trough tacrolimus level of 5-8.
1669612|NCT01702207|Drug|Twice Daily Tacrolimus|Subjects are kept on Prograf® which is the Twice Daily Tacrolimus
1669613|NCT01702194|Drug|TD-1211 IV [C14]|
1669614|NCT01702194|Drug|TD-1211 PO [C14]|
1669615|NCT01702181|Drug|OPA-15406|0.3%, 1%, or 3% OPA-15406 topical ointment, applied twice daily for 28 days
1669616|NCT01702181|Drug|Tacrolimus|0.1% concentration of tacrolimus.
1669617|NCT01702181|Drug|Placebo|
1669618|NCT01702168|Other|Provider training: Cognitive Processing Therapy (CPT)|
1669619|NCT01702155|Drug|DFP-10917|
1669620|NCT01702129|Drug|anti-EGFR immunoliposomes loaded with doxorubicin|All patients were treated with anti-EGFR immunoliposomes Different dose levels (5, 10, 20, 30, 40, 50 and 60 mg doxorubicin/m2), at least 3 patients per dose level, treatment was given every 4 weeks
1669621|NCT01702116|Procedure|extralevator APR|"Extralevator Abdominoperineal Resection For Rectal Adenocarcinoma. The aim of this modified and more extensive procedure is to remove the levator muscle en bloc with the anal canal and the mesorectum, creating a more cylindrical specimen, so that the amount of tissue removed around the tumor will be larger, thereby reducing the probability that the CRM will be positive."
1669622|NCT01702116|Procedure|APR|standard Abdominoperineal Resection For Rectal Adenocarcinoma
1669623|NCT01702103|Drug|Mometasone furoate|
1669624|NCT01702090|Drug|TMC114/ritonavir|TMC114 800 mg (two tablets) once daily coadministered with ritonavir 100 mg (one capsule) once daily within 30 minutes after completion of a meal, and in combination with other ARVs.
1669625|NCT01702077|Procedure|Neurofeedback|
1669626|NCT01702077|Procedure|Sham feedback|
1669627|NCT01702064|Drug|Nilotinib|"Participants will remain on the same dose of nilotinib they have been receiving prior to enrollment on the trial. This will range from 300 mg PO BID to 400 mg PO BID.
Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose of ruxolitinib, based on the number of dose."
1669628|NCT01702064|Drug|Ruxolitinib|Dose escalation will follow a 3+3 study design. Dose modifications will not occur, as the purpose of this study is to determine the maximum tolerated dose, based on the number of dose limiting toxicities seen at a specific dose.
1669629|NCT01702038|Drug|Rituximab|1000 mg administered intravenously
1669630|NCT01702025|Drug|Placebo|Yellow corn meal in gel capsules
1669631|NCT01702025|Drug|Aminophylline|National Drug Code (NDC) 0143-1020-01
1669632|NCT01702025|Drug|Methazolamide|NDC 0781-1072-01
1669633|NCT01702025|Drug|Aminophylline+Methazolamide|NDC 0143-1020-01 and NDC 0781-1072-01
1669634|NCT01702012|Dietary Supplement|Almased Meal Replacement Powder|Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
1669635|NCT01702012|Behavioral|Group-Based Lifestyle Intervention|
1669636|NCT01701999|Biological|rBV A/B|rBV A/B injections will consist of a single 40 µg injection of total antigen (20 µg of Antigen A and 20 µg of Antigen B) adsorbed to 0.2% (wt/vol) Alhydrogel™, in a total dose volume of 0.5 mL. The vaccine will be administered by intramuscular injection in the deltoid muscle, preferably in the nondominant arm.
1669637|NCT01701986|Drug|Gemcitabine|"Phase I Starting dose of Gemcitabine: 75 mg/m2/ loading dose by vein targeting the desired steady state concentration of 20 µmolar on Day -6 and Day -4. This will be immediately followed by an infusion at a fixed rate of 10 mg/m2/min over varying lengths of time per study cohort.
Phase II Starting dose of Gemcitabine: Maximum tolerated dose (MTD) from Phase I."
1669638|NCT01701986|Drug|Clofarabine|Phase I and Phase II dose of Clofarabine: 40 mg/m2 by vein on Days -6 to -3.
1669639|NCT01701986|Drug|Busulfan|"Phase I and Phase II dose of Busulfan: Test dose of 32 mg/m2 by vein as an outpatient between Day -15 and Day -8, or on Day -9 as an inpatient.
Busulfan 4000 µMol-min by vein four consecutive days (Days -6 to -3), starting immediately after the completion of clofarabine. If not feasible to perform pharmacokinetic monitoring, patients receive fixed dose of 100 mg/m2/day for 4 days, which is expected to yield a median daily AUC of 4,000 µMol.min-1."
1669640|NCT01701986|Procedure|Stem Cell Infusion|Stem cell infusion on Day 0.
1669641|NCT01701986|Drug|Anti-Thymocyte Globulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1 for patients receiving a graft from a matched unrelated donor.
1669642|NCT01701986|Drug|Rituximab|375 mg/m2 by vein on Day -14 and Day -7 and then on Day +1 and Day +8 for patients with CD20+ disease.
1669643|NCT01701986|Drug|Filgrastim|5 mcg/kg/day subcutaneously starting on Day +7 until blood cell levels return to normal.
1669644|NCT01701986|Drug|Tacrolimus|0.015 mg/kg by vein beginning on Day -2, as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) is present.
1669645|NCT01701986|Drug|Mycophenolate Mofetil|1,000 mg by vein three times a day on Day 0 after cell infusion and will be changed to oral dosing (1:1 conversion) when tolerated.
1669646|NCT01701973|Drug|Sitagliptin|During Aim 1, given on one of two study days (other study day subjects receive placebo.) During Aim 2, given during both of two study days.
1669647|NCT01701973|Drug|Pegvisomant|During Aim 2, given 72 hours prior to one of two study days (Group B subjects only)
1669648|NCT01701973|Drug|Placebo|During Aim 1, given on one of two study days (other study day subjects receive sitagliptin.) During Aim 2, given on one of two study days (other study day subjects receive either L-NMMA, pegvisomant, or Exendin 9-39 pending their group assignment)
1669649|NCT01701973|Drug|L-NMMA|During Aim 2, given during one of two study days (Group A subjects only)
1669650|NCT01701973|Drug|Exendin 9-39|During Aim 2, given during one of two study days (Group C subjects only)
1669651|NCT01701947|Biological|Hemoleven|Replacement therapy
1669652|NCT01701934|Drug|Roflumilast|500 mcg, oral, once daily for 6 months
1669653|NCT01701934|Drug|Placebo|One placebo pill daily, for 6 months
1669654|NCT01701921|Drug|Pregabalin 75mg|Pregabalin 75mg by mouth one hour before surgery
1669655|NCT01701921|Drug|pregabalin 150 mg|pregabalin 150mg by mouth one hour before surgery
1669656|NCT01701921|Drug|Placebo|Sugar pill designed to mimic pregabalin capsule, by mouth one hour before surgery
1669657|NCT01701882|Drug|tenofovir/emtricitabine/rilpivirine|
1669658|NCT01701856|Drug|Interferon beta-1b|250 mcg, s.c., each other day for 12 months
1669659|NCT01701843|Drug|Cromoglicate|Twice daily topical treatment for 14 days
1669660|NCT01701843|Drug|Placebo|Twice daily topical treatment for 14 days
1669661|NCT01701817|Other|Patients with Atrial Fibrillation|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
1669662|NCT01701804|Drug|Chuna herbal medicine|120ml of Chuna herbal medicine(Ostericum koreanum, Eucommia ulmoides, Acanthopanax Sessiliflorus, Achyranthes bidentata, Psoralea corylifolia, Peucedanum japonicum, Cibotium barometz, Lycium chinense, Boschniakia rossica, and Cuscuta chinensis) taken twice a day 30 minutes after meals for 16 weeks
1669663|NCT01701804|Procedure|Chuna manual therapy|A type of Korean spinal manual therapy administered 5~10 minutes at physician's discretion once a week for 16 weeks. Applies mobilization using High-Velocity, Low-Amplitude thrusts to joints slightly beyond the passive ROM and manual force within the passive ROM without thrusts.
1669664|NCT01701804|Procedure|Acupuncture|Acupuncture using sterilized disposable needles, sized 0.30X40 mm. Needles left for 15~20 minutes, selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, using a total of 10~20 acupoints once a week for 16 weeks.
1669665|NCT01701804|Procedure|Bee-venom pharmacoacupuncture|Bee-venom pharmacoacupuncture using 30G sterilized bee venom. Selecting 6 acupoints(both BL23, BL24, BL25) and other acupoints at physician's discretion, concentration 10,000:1, 0.1 cc per acupoint, total amount injected 1.0 cc/session once a week for 16 weeks.
1669666|NCT01701791|Other|Computerized Decision Support System|
1669667|NCT01701778|Drug|Caudal Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg and dexmedetomidine 1µg/kg
Intravenous: 10 ml normal saline"
1669668|NCT01701778|Drug|Intravenous Dexmedetomidine|"Caudal: Levobupivacaine 0.25% 1ml/kg
Intravenous: dexmedetomidine 1µg/kg"
1669669|NCT01701778|Drug|Placebo|"Caudal: Levobupivacaine 0.25% 1ml/kg
Intravenous: 10 ml normal saline"
1669670|NCT01701778|Drug|sevoflurane|Induction and maintain anaesthesia
1669671|NCT01701752|Biological|FP-01.1 + Placebo|
1669672|NCT01701752|Biological|FP-01.1 + TIV|
1669673|NCT01701752|Biological|FP-01.1-Adjuvant + Placebo|
1669674|NCT01701752|Biological|FP-01.1-Adjuvant + TIV|
1669675|NCT01701752|Biological|Adjuvant + TIV|
1669676|NCT01701752|Biological|Placebo + TIV|
1669677|NCT01701752|Biological|FP-01.1|
1669678|NCT01701752|Biological|FP-01.1-Adjuvant|
1669679|NCT01701752|Other|Placebo|
1669680|NCT01701739|Drug|aleglitazar|Multiple doses of aleglitazar
1669681|NCT01701739|Drug|digoxin|Single dose of digoxin
1669682|NCT01701726|Other|acupuncture|In each session, acupuncture are applied bilaterally. Except the acupoints around the neck(ST9.GB20.non-acupoints 4) ,6 auxiliary needles will be punctured at 2mm lateral to each acupoints or non-acupoints.as to auxiliary needle we will not do any manipulation. We use transcutaneous electric acupoints stimulation to stimulate the acupoints and non-acupoints.
1669683|NCT01701726|Other|Sham acupuncture|In contrast to acupuncture, sham acupuncture is given at 4 sham points with skin penetration. Electroacupuncture is also applied.
1669684|NCT01701713|Device|DKI ED2011|
1669685|NCT01701713|Device|Sham-TDCS|
1669686|NCT01701700|Procedure|portable electronic magnifier|
1669687|NCT01701700|Procedure|optical aids|
1669688|NCT01701674|Drug|Ipilimumab|Pre-treatment with ipilimumab (cycle 1): Before the participant's tumor sample is taken to send to the lab for growing the TILs, they will start their first cycle of ipilimumab. This drug is given as an intravenous infusion (through a vein) over a period of about 90 minutes (an hour and a half). Cycle 2 of ipilimumab: About a week after the sample of the participant's tumor was collected for TIL growth (and 3 weeks after their first cycle of ipilimumab), participants will have their second cycle of ipilimumab. This will be another IV infusion, lasting about 90 minutes.
1669689|NCT01701674|Procedure|Tumor Infiltrating Lymphocytes (TIL)|Tumor sample for TIL growth in the lab: About 2 weeks after the participant's first cycle of ipilimumab, a sample of their tumor will be collected and sent to the lab for TIL growth. Growing the TILs takes about 6 weeks. If their sample has grown enough TIL cells, participants will continue with the next part of the study. Depending on how long the TILs take to grow in the lab, they may need to repeat some of their laboratory and imaging tests (blood draws, X-rays, and CT or magnetic resonance imaging [MRI] scans). TIL Infusion (inpatient): After completing lymphodepletion, participants will be admitted back into the hospital for IV infusion of the TIL cells.
1669690|NCT01701674|Drug|Administration of Lymphodepletion|Lymphodepletion (inpatient hospital stay for about 2 days plus outpatient drug dosing for 5 days): About 4 weeks after their second cycle of ipilimumab, participants will be admitted to the hospital for their first two days of receiving the chemotherapy drug, cyclophosphamide. This drug will be given as an intravenous (IV, meaning through the vein) infusion. After 2 days of receiving cyclophosphamide, if their study doctor thinks that they are well enough, you will be discharged from the hospital and will return for the next 5 days in a row for outpatient IV infusions of the second lymphodepletion chemotherapy, fludarabine.
1669691|NCT01701674|Drug|Cyclophosphamide as Part of Lymphodepletion|
1669692|NCT01701674|Drug|Fludarabine as Part of Lymphodepletion|
1669693|NCT01701674|Drug|High Dose IL-2|High dose IL-2 (continued inpatient): Participants will remain in the hospital following TIL infusion for receiving high dose IL-2 and recovery. The IL-2 will be given three times per day for about 3-5 days as an IV bolus (meaning through the vein, more quickly than other infusions - in about 15 minutes each dose). Participants will remain in the hospital for approximately 7-14 days until they have recovered from the IL-2 treatments.
1669694|NCT01701674|Biological|Adoptive Cell Therapy with TIL|
1669695|NCT01701661|Procedure|Operative treatment|stripping of main trunk or if previously removed, removal or ligating the refluating trunk
1669696|NCT01701661|Other|conservative treatment|Compression stockings class II
1669697|NCT01701648|Other|Laser CO2|Transplantation of autologous melanocytes using amniotic membrane as a substrate. Transplantation of suspension of autologous melanocytes.
1669698|NCT01701635|Behavioral|Disclosure intervention|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver information and skills for HIV disclosure till the caregiver discloses the HIV status to the child.
1669699|NCT01701635|Behavioral|Enhanced usual care|An adherence and disclosure specialist will meet with caregiver-child dyad at each clinic visit and provide caregiver with general health information without referencing HIV disclosure in their conversations till the caregiver discloses the HIV status to the child.
1669700|NCT01701622|Drug|febuxostat|"If baseline allopurinol dose < 300 mg daily, will initiate febuxostat 40 mg daily.
If baseline allopurinol dose > 300 mg daily, will initiate febuxostat 80 mg daily.
Febuxostat is to be continued for 4 weeks, with blood pressure assessments by clinic and ambulatory blood pressure measurement at baseline and after 4 weeks."
1669701|NCT01701609|Behavioral|Cognitive Remediation Therapy|
1669757|NCT01701154|Other|respiratory muscle strength training|
1669702|NCT01701596|Procedure|Immediate rotational atherectomy (RA)|Immediate RA in the treatment with nondilatable calcified lesion complicated by coronary dissection.
1669703|NCT01701596|Procedure|Delayed rotational atherectomy (RA)|Delayed RA in the treatment with nondilatable calcified lesion complicated by coronary dissection
1669704|NCT01701583|Drug|Omalizumab|Patients will receive omalizumab 300mg subcutaneously every 4 weeks for 12 weeks at the study center.
1669705|NCT01701570|Behavioral|Placebo Attention Control|The placebo attention control group will receive weekly phone calls to monitor their blood glucose levels.
1669706|NCT01701570|Other|Supervised Exercise Training|The 20-week aerobic exercise training intervention provides supervised exercise training sessions 3 times weekly following the HERITAGE study training model that was feasible in prior studies with older, sedentary overweight adults (55%maximal oxygen uptake (VO2max) for 30 minutes per session at study entry with progressive titration to 70-80% VO2max for 50 minutes).
1669707|NCT01701557|Other|slow fluid rate|10 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.25 times maintenance
1669708|NCT01701557|Other|fast fluid rate|20 mL/kg of NS intravenous bolus over the first hour followed by ¾ NS with potassium replacement at 1.5 times maintenance
1669709|NCT01701544|Device|NBM DBS|Deep Brain Stimulation targeting the Nucleus Basalis of Meynert
1669710|NCT01701531|Drug|RBCPF|
1669711|NCT01701518|Drug|Ozurdex|biodegradable 0.7mg dexamethasone implant
1669712|NCT01701505|Drug|400uL of Kovacaine Mist|2 unilateral intranasal sprays of 200uL each.
1669713|NCT01701505|Drug|200uL of Kovacaine Mist|2 unilateral intranasal sprays of 100uL each.
1669714|NCT01701505|Drug|120uL of Kovacaine Mist|2 unilateral intranasal sprays of 60uL each.
1669717|NCT01701479|Drug|ch14.18/CHO|
1669718|NCT01701479|Drug|Aldesleukin|
1669719|NCT01701479|Drug|Isotretinoin|
1669720|NCT01701466|Other|Aveeno cream|Twice a day
1669721|NCT01701466|Other|Flamazine cream|Twice a day, when there is dry desquamation
1669722|NCT01701466|Other|NeoVIDERM cream|Three times a day
1669723|NCT01701453|Drug|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)|P2Y12 inhibitor (clopidogrel, ticagrelor, prasugrel)
1669724|NCT01701440|Device|Biofusionary Bebe|
1669725|NCT01701414|Drug|Femoral nerve block: 25 mL of 0.5% bupivacaine|25ml of 0.5% bupivacaine will be injected along the nerve sheath. The nerve block will be administered by one of the physician co- investigators all of whom are emergency physicians and all of whom have been trained in the use of ultrasound and ultrasound guided nerve blocks.
1669726|NCT01701414|Drug|Placebo: 3cc of 0.9% Normal Saline|1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
1669727|NCT01701401|Drug|LDV/SOF|LDV/SOF 90/400 mg FDC tablet administered orally once daily
1669728|NCT01701401|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1669729|NCT01701388|Device|Ekso exoskeleton|The participants will receive 1 - 40 training sessions. The sessions will be 1 hour of device use including balance training, gait training and sit to and from stand training with rolling walker and/ or forearm crutches.
1669730|NCT01701375|Drug|PD 0332991|• PD 0332991 will be given orally days 1,2,3
1669731|NCT01701362|Drug|pregabalin|capsules, 150-600 mg/day administered in divided doses twice a day for 15 weeks after randomization
1669732|NCT01701362|Drug|placebo|capsules, placebo for pregabalin administered in divided doses twice a day for 15 weeks after randomization
1669733|NCT01701349|Drug|Fosbretabulin + paclitaxel + carboplatin|Fosbretabulin 200 mg/m2 IV infusion
1669734|NCT01701349|Drug|Placebo + paclitaxel + carboplatin|Paclitaxel 200 mg/m2, Carboplatin AUC 6 IV infusion
1669735|NCT01701336|Biological|Ad6NSmut, MVA-NSmut|2 doses Ad6NSmut at week 0 and 4, then 2 doses of MVA-NSmut at weeks 8 and 12. PEG-IFN/RBV therapy starts at week 10 after first vaccination
1669736|NCT01701323|Drug|Cytarabine|Given IV
1669737|NCT01701323|Procedure|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Given IV
1669738|NCT01701323|Biological|Filgrastim|Given SC or IV
1669739|NCT01701323|Drug|Fludarabine Phosphate|Given IV
1669740|NCT01701310|Drug|Ferric carboxymaltose|A minimum of 1 dose of 1000mg of intravenous ferric carboxymaltose will be administered at least 14 days prior to the date of operation.
1669741|NCT01701310|Drug|Ferrous Sulphate|(Control) 200mg twice a day of oral ferrous sulphate will be administered for a minimum of a two week period
1669742|NCT01701297|Drug|cotrimoxazole|Cotrimoxazole 960mg orally each day (two 480mg tablets)
1669743|NCT01701297|Drug|VSL#3 active|The prescribed dose was 2 sachets (containing 900 billion bacteria) orally each day for 48 weeks
1669744|NCT01701297|Drug|VSL#3 placebo|This was two placebo sachets identical to VSL#3 active sachet. The prescribed dose was 2 sachets orally each day for 48 weeks
1669745|NCT01701284|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
1669746|NCT01701271|Other|Hair loss prevention lotion|For greatest problems 20 drops on the scalp per day for 3 months. For minor problems 10 drops on the scalp three times per week for 3 months.
1669747|NCT01701258|Drug|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
1669748|NCT01701258|Drug|Placebo|single-dose placebo capsule
1669749|NCT01701245|Device|GammaCore|vagal stimulation
1669750|NCT01701232|Biological|rituximab|Patients will receive rituximab at a dose of 375 mg/m2 intravenously once a week for 4 weeks (on day 1,8,15,22)
1669751|NCT01701219|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg intravenous (IV) infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour) (dosing may be adjusted for renal function)
1669752|NCT01701206|Behavioral|HIV knowledge Intervention|
1669753|NCT01701193|Drug|Amino Acid|Dipeptide
1669754|NCT01701193|Drug|Saline|Placebo Comparator
1723122|NCT00004364|Drug|desmopressin|
1669758|NCT01701128|Other|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, subjects in the Speed TT had an increase in speed, depending on exercise tolerance of each participant. The TT velocity was increased by 0,2 km/h when the participant reached criteria.
1669759|NCT01701128|Other|Walking on treadmill|3 sessions/week, 24 weeks. The heart rate does not exceed 75% of maximum heart rate (220-age) of the participant and that blood pressure does not exceed 250/115 mmHg. During the first week, the TT velocity was adjusted to 80% of preferential walking speed of the participant. The following week, the participant was encouraged to reach 90% and 100% in the third week. From the fourth week, the TT velocity was increased by 0,2 km/h or the incline of the walking surface of TT was increased by 1% alternately when the progression criteria were met.
1669760|NCT01701128|Other|Control group|Training of the control group was characterized by light intensity exercises. For the first three months, participants performed regular exercise involving full range of motion to enhance their flexibility. For the last three months of the training programme, participants learned elements of Tai Chi and rhythmic movements of latin dance. Participants attended two 1-h supervised sessions per week and were asked to perform each week a third session at home, based on instructions in a document offered to the control group participants
1669761|NCT01701115|Procedure|Low Dose (20 ml) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:
Investigational group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 20 mL"
1669762|NCT01701115|Procedure|Control Dose (40 mL) Local Anesthetic Volume for Interscalene Block|"Anesthetic volume:
Control group: A 1:1 Mepivacaine 1.5%: Bupivacaine 0.5% mixture for a total of 40 mL"
1669763|NCT01701115|Drug|Low Dose (20 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
1669764|NCT01701115|Drug|Control Dose (40 mL) Local Anesthetic (Mepivacaine:Bupivacaine)|
1669765|NCT01701102|Procedure|Mepivacaine (24 mg) plus fentanyl|Mepivacaine (24 mg) and fentanyl (10 µg)
1669766|NCT01701102|Procedure|Mepivacaine (27 mg) plus fentanyl|Mepivacaine (27 mg) and fentanyl (10 µg)
1669767|NCT01701102|Procedure|Mepivacaine (30 mg) plus fentanyl|Mepivacaine (30 mg) and fentanyl (10 µg)
1669768|NCT01701102|Procedure|Mepivacaine|Mepivacaine 37.5 mg
1669769|NCT01701089|Drug|11C-L-deprenyl-D2|Intravenous injection of 11C-L-deprenyl-D2 before positron emission tomography (PET); up to 3 injections in total
1669770|NCT01701089|Drug|RO4602522|Multiple doses of RO4602522 for 14 days
1669771|NCT01701089|Drug|RO4602522|Multiple doses of RO4602522 for up to 17 days
1669772|NCT01701076|Drug|Bendamustine|"Induction treatment phase (cycle 1-6):
Bendamustine 75 mg/m2 i.v day 1 and 2
Lenalidomide 25 mg p.o. day 1-21
Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22
Pegfilgrastim 6 mg s.c., day 3 in case of severe neutropenia
Maintenance treatment phase (cycles 7-18):
Lenalidomide 25 mg p.o. day 1-21
Dexamethasone 40/20 mg p.o., day 1, 8, 15, 22"
1669773|NCT01701063|Drug|Telaprevir|100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
1669774|NCT01701063|Drug|Peginterferon alfa-2b|50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
1669775|NCT01701063|Drug|Ribavirin|200-mg capsules or 40-mg/mL solution for oral administration
1669776|NCT01701050|Other|Blood collection|Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
1669777|NCT01701037|Drug|dabrafenib|150 mg given PO
1669778|NCT01701037|Drug|trametinib|2 mg given PO
1669779|NCT01701037|Other|laboratory biomarker analysis|Correlative studies
1669780|NCT01701024|Drug|ACYC|ACYC active, topically applied to the face for 12 weeks
1669781|NCT01701024|Drug|ACYC vehicle|ACYC vehicle (placebo), topically applied to the face for 12 weeks
1669782|NCT01701011|Behavioral|Coping intervention|Positive reappraisal coping intervention
1669783|NCT01700998|Drug|Magnesium|
1669784|NCT01700998|Drug|Placebo|
1669785|NCT01700985|Drug|122-0551|Applied twice daily for two weeks
1669786|NCT01700985|Drug|Vehicle|Applied twice daily for two weeks
1669787|NCT01700972|Procedure|Myocardial perfusion imaging|The radionuclide Myoview will be administered once for the rest and stress myocardial perfusion imaging. The subsequent rest and stress imaging will be performed twice each - at 10 minutes and 30-45 minutes after radiotracer injection.
1669788|NCT01700959|Drug|melatonin|Melatonin 3mg time release will be given. Participants will be instructed to take one 3mg time released tablet by mouth approximately 1-2 hours before initiating sleep onset, preferably at the same time each night.
1669789|NCT01700959|Drug|placebo|Placebo tablets to match the melatonin will be comprised of inert substances.
1669790|NCT01700946|Drug|dexamethasone|given intravenously or orally
1669791|NCT01700946|Drug|vincristine sulfate|given intravenously
1669792|NCT01700946|Biological|rituximab|given intravenously
1669793|NCT01700946|Drug|clofarabine|given intravenously
1669794|NCT01700946|Drug|cyclophosphamide|given intravenously
1669795|NCT01700946|Drug|etoposide|given intravenously
1669796|NCT01700946|Biological|aldesleukin|given subcutaneously
1669797|NCT01700946|Drug|pegaspargase|given intravenously
1669798|NCT01700946|Drug|methotrexate|given intrathecally or intravenously
1669799|NCT01700946|Drug|mercaptopurine|given orally
1669800|NCT01700946|Drug|cytarabine|given intrathecally or intravenously
1669801|NCT01700946|Drug|mitoxantrone|given intravenously
1669802|NCT01700946|Drug|teniposide|given intravenously
1669803|NCT01700946|Drug|vinblastine|given intravenously
1669804|NCT01700946|Biological|natural killer cell infusion|undergo allogeneic natural killer cell infusion
1669805|NCT01700946|Other|laboratory biomarker analysis|correlative studies
1669806|NCT01700946|Drug|therapeutic hydrocortisone|given intrathecally
1669807|NCT01700946|Procedure|allogeneic hematopoietic stem cell transplantation|undergo allogeneic HSCT
1669808|NCT01700946|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
1669809|NCT01700933|Other|High-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:
5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 30 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
1669810|NCT01700933|Other|Low-Dosage Exercise Therapy|"Structure of the exercise program done three times per week, for eight weeks:
5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.) Four local exercises (3 series of 10 repetitions) 5-10 minutes of global exercise (cycling, walking on treadmill etc.)"
1669811|NCT01700920|Procedure|bone marrow aspirate|
1669812|NCT01700907|Drug|Desflurane|The patients in this arm will be given the general anesthesia with desflurane and be used the Aysis as the anesthetic machine.
1669813|NCT01700907|Drug|Sevoflurane|The patients in this arm will be given the general anesthesia with sevoflurane and be used the Aysis as the anesthetic machine.
1669814|NCT01700894|Behavioral|Walking Program + Motivational Interviewing Calls|
1669815|NCT01700894|Behavioral|Walking Program + Automated Calls|
1669816|NCT01700894|Behavioral|Walking Program|
1669817|NCT01700881|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
1669818|NCT01700881|Other|Supplement|Unrestricted diet with clinically insignificant amount of omega- 3 oils and vitamin E
1669819|NCT01700868|Other|Vegan diet|A diet devoid of any animal products. Low-fat, low-Glycemic Index, vegan diet.
1669820|NCT01700868|Other|American Diabetes Association guidelines|Participants will follow individualized diet plans following ADA guidelines
1669821|NCT01700855|Procedure|non-electroacupuncture|The same procedure as electroacupuncture except stimulation
1669822|NCT01700855|Procedure|Electroacupuncture|"Electrodes are applied to bilateral Hegu(L14) acupoints at the time of 1h before operation, and connected to Hwato Electronic Acupuncture Treatment Instrument (Model No. SDZ-V, Suzhou Medical Appliances Co., Ltd., Suzhou, China). The acupoints are stimulated at an intensity of 3~6 mA and a frequency of 2/30 Hz for 30 min. The highest intensity will be chosen at which the patient can tolerate."
1669823|NCT01700829|Drug|Ketamine|Single dose of 0.5 mg/kg of ketamine given intravenously (in the vein) over 40 minutes
1669824|NCT01700829|Drug|Midazolam|Single dose of 0.02 mg/kg of Midazolam given intravenously (in the vein) over 40 minutes
1669825|NCT01700816|Device|Bright light therapy|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
1669826|NCT01700816|Device|Sham light|The light box will be placed vertically on a patient table or bed side 2.5 feet away from the user's eyes daily from 8 am to 8:30 am.
1669827|NCT01700803|Drug|Povidone Iodine 10% vand cesarean section wound infections|
1669828|NCT01700803|Drug|Povidone Iodine 7.5% vand cesarean section wound infections|
1669829|NCT01700790|Drug|Lopinavir/ritonavir and ritonavir|Two tablets twice daily of Lopinavir/ritonavir 200 mg/50mg with 3 capsules of ritonavir 100 mg twice daily given with rifampin 600 mg daily
1669830|NCT01700777|Other|"HABIT-ILE"|"90 h of training with HABIT-ILE, in an intensive rehabilitation camp compared with a regular therapy program (groups are crossed-over afterwards)."
1669831|NCT01700751|Drug|brentuximab vedotin|
1669832|NCT01700738|Procedure|gastric ring surgery|
1669833|NCT01700738|Other|nutritional help|
1669834|NCT01700725|Other|Nasal Irrigation - Saline|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the saline solution by themselves using the study-provided kit which will include packets of salt powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 2% buffered saline solution. The solution is then delivered to the nasal cavity using neti pot."
1669835|NCT01700725|Drug|Nasal Irrigation - Xylitol|"Liquid-based nasal irrigation (NI) is performed using a nasal irrigation cup (neti pot), a simple hand-held vessel that uses the force of gravity to gently irrigate the user's nasal cavity. Subjects will be requested to perform NI twice daily. The subjects will prepare the Xylitol solution by themselves using the study-provided kit which will include packets of Xylitol powder and the neti pot; subjects will dissolve the powder in lukewarm tap water to achieve a 5% Xylitol solution. The solution is then delivered to the nasal cavity using neti pot."
1669836|NCT01700712|Dietary Supplement|Probiotic Lactobacilli reuteri|
1669837|NCT01700712|Dietary Supplement|Placebo|
1669838|NCT01700686|Other|Meal test and dexa scan|Body composition is determined by whole body deca scan and bone mineral density is determined dy dexa scans of the lumbar spine and the proximal femur.
1669839|NCT01700673|Drug|5-azacitidine and sargramostim|5-azacitidine will be administered days 1-5 of a 28 day cycle. sargramostim will be administered days 1-10 of a 28 day cycle. Treatment is planned for a total of 12 cycles.
1669840|NCT01700647|Other|Breath test- sampling using ENose|Patients give a sample of breath ( slow vital capacity breath, collected in Tedlar bag and immediately analysed and discarded)
1669841|NCT01700647|Other|Laryngoscopy and bronchoscopy|Detailed assessment of larynx and bronchus mucosa including autofluoresecence to fully define dysplasias if present or exclude them.
1669842|NCT01700621|Biological|Rotarix vaccine|one 1.0 ml dose of oral rotavirus vaccine at 9 months of age
1669843|NCT01700621|Biological|measles-rubella vaccine|one 0.5 ml subcutaneous dose of live attenuated measles-rubella vaccine
1669844|NCT01700608|Drug|plerixafor|plerixafor 240 mcg/kg/day at the hematopoietic recovery after chemotherapy
1669845|NCT01700595|Procedure|new technical intervention|Contractures and broad scars of the subjects are treated by this surgical intervention which is a reconstructive surgery that is performed by the transfer of preexpanded perforator flaps to the recipient sites of skin deficiency.
1669846|NCT01700569|Drug|Temozolomide|All the Patients are treated by oral Temozolomide 75 mg/m²/day every day during 42 days, 30 minutes after Folinic acid and 120 min before the radiation dose to the brain tumor. After one month rest, the maintenance phase consists of:Temozolomide is given orally (30 min after Folinic acid), at 200 mg/m²/day every day during 5 days: one course every month during 6 months (6 maintenance course).
1669847|NCT01700569|Drug|folinic acid at pharmacological dose is the escalated drug|
1669848|NCT01700569|Radiation|High voltage radiation therapy (linear accelerator)|Brain tumor field is irradiated Five days a week, during Stupp regimen during 6 weeks. During the sams time, Folinic acid and Temozolomide are given orally every days (six weeks).
1669849|NCT01700556|Other|Case Manager|"The following support will be provided by a case manager:
At least 3 sessions of individual face-to-face counselling (housing arrangements, disease awareness, problem solving) consisting of an initial and two reinforcing sessions four and eight months after enrollment.
Monthly follow-up telephone calls. Stress management training of the family caregiver and some practical items for management of patient care in the home.
Information about services/aid/certification/subsidies offered by the National Health Service, by municipal social services and by local voluntary organizations. Information on health services, support connecting to GPs and health service units (medical specialists, hospital services) and social services (municipal offices and public offices of any capacity)."
1669850|NCT01700556|Other|Assistive Technologies|The technologies to be employed are devices already widely used and marketed, are simple to use and do not require high technical expertise for installation and maintenance. The devices will be assigned to subjects in the UP-TECH treatment group after an evaluation of the home, made by the case manager. Such technologies include e.g.: access facilitated telephone, timed drug dispenser, and housing adaptations such as anti-slip strips; home leaving sensors; sensors to detect night falls; Gas and water leak sensors, and automatic lights.
1669851|NCT01700556|Other|light support|An information package illustrating the range of social and health services available in local community will be created. It will be delivered to the caregiver during home visits by the nurse.
1669852|NCT01700556|Other|3 preventive home visits by a nurse|The dyads will receive three home visits by a specifically trained nurse. Home visits will occur at enrollment and after 6 and 12 months. Each visit will occur with the following steps: telephone contact between the nurse and the family caregiver, a home visit comprising the administration of the UP-TECH questionnaire, counselling/training of the caregiver regarding patient assistance, feeding, ergonomics of the home environment, covers practical aspects of patient assistance, such as daily management of drug treatment, ergonomics of the home environment, stress management and care burden. In order to provide this information to the caregiver, the nurses will receive a specific training course.
1669853|NCT01700543|Procedure|Shoulder Arthroplasty|Implantation of the Sidus Stem-Free Shoulder follows standard shoulder replacement procedures.
1669854|NCT01700530|Drug|Statin|Statins (40mg/day)for 12 weeks
1669855|NCT01700530|Other|Exercise only|12 weeks of exercise training (5 days a week for 45-50 min a session)
1669856|NCT01700530|Other|Statins + Exercise|Statins (40mg/day of simvastatin) plus exercise training (5 days/wk for 45-50 min a session) for 12 weeks
1669857|NCT01700517|Other|Spinal anesthesia|spinal anesthesia
1669858|NCT01700517|Other|Femoral nerve block|Femoral nerve block
1669859|NCT01700517|Other|sciatic nerves block|sciatic nerves block
1669860|NCT01700504|Drug|Axillary lavage with gentamicin solution|Patients undergoing an axillary lavage with 500ml of normal saline followed by 500ml gentamicin solution
1669861|NCT01700491|Drug|Epidural Catheter 0.2% ropivacaine|0.2% ropivacaine into epidural space and saline into paravertebral space
1669862|NCT01700491|Drug|Paravertebral Catheter 0.4% ropivacaine|0.4% ropivacaine into paravertebral space and saline into the epidural space
1669863|NCT01700478|Drug|Misoprostol + vasopressin|400ug of misoprostol is given per rectum, one hour prior to surgery. Vasopressin is used at the time of surgery.
1669864|NCT01700478|Drug|Vasopressin|Vasopressin was used in all patients during surgery.
1669866|NCT01700426|Drug|Vitamin E|A commercial Vitamin E preparation (Aqueous Vitamin E®, 15 IU/0.3 ml; SilaRx, Inc, Spring Valley, NY) will be used for the study, also on the recommendation of the Children's Hospital Colorado (CHC) research pharmacist. The Vitamin E dose will be 18 mg/day for all subjects randomized to the Vitamin E group.
1669867|NCT01700426|Other|Placebo|The control group will receive an indistinguishable placebo preparation, which will be compounded by the CHC research pharmacy using the following inactive ingredients: purified water, polysorbate 80, sorbital, and propylene glycol. This suspension is stable for 6 months.
1669868|NCT01700413|Drug|Idarubicin|
1669869|NCT01700400|Drug|Everolimus|
1669870|NCT01700400|Drug|Pemetrexed|
1669871|NCT01700400|Drug|Carboplatin|
1669872|NCT01700400|Drug|Bevacizumab|
1669873|NCT01700387|Drug|onabotulinumtoxinA|All subjects will receive a minimum dose of 155 U Botulinum Toxin Type A Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven (7) specific head/neck muscle areas at Visits 2-5.
1669874|NCT01700387|Drug|Topiramate|"Subjects randomized to the onabotulinumtoxinA + topiramate group will receive:
Week 1: topiramate 25 mg qhs Week 2: topiramate 25 mg bid Week 3: topiramate 25 mg q am + topiramate 50 mg qhs Week 4: topiramate 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
1669875|NCT01700387|Drug|Placebo|"Subjects randomized to the onabotulinumtoxinA + placebo group will receive:
Week 1: placebo 25 mg qhs Week 2: placebo 25 mg bid Week 3: placebo 25 mg q am + placebo 50 mg qhs Week 4: placebo 50 mg bid Only one dosage adjustment (increase or decrease), based on efficacy or tolerability, may be made at the investigator's discretion. Subjects must maintain a dose of at least 50 mg/day to remain in the Treatment Period."
1669876|NCT01700348|Device|Airflosser|Use of Philips Airflosser
1669877|NCT01700348|Device|Manual Floss|Active Comparator
1669955|NCT01699711|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance. A daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during twelve months.
1672044|NCT01682759|Drug|Placebo to Omarigliptin|
1669878|NCT01700335|Drug|SyB L-1101|"SyB L-1101（rigosertib sodium） will be administered to two cohorts at either 1200 mg/day or 1800 mg/day.
The dose will be administered intravenously for 72 continuous hours (3 days), followed by 11-day observation period. The treatment period of 14 days (3 days of administration + 11 days of observation) constitutes 1 cycle.
The study will involve treatment through the second cycle, but treatment can be continued for 3 or more cycles if conditions for continued administration are satisfied."
1669879|NCT01700322|Procedure|Coronary stenting|All patients will receive a drug eluting stent as clinically indicated.
1669880|NCT01700322|Drug|Ticagrelor|Ticagrelor 180mg oral loading dose and 90mg b.i.d for 30 days following coronary artery stenting
1669881|NCT01700322|Drug|Clopidogrel|Clopidogrel 600mg loading dose + 75 mg once a day for 30 days following coronary artery stenting.
1669882|NCT01700322|Drug|Prasugrel|Prasugrel 60mg oral loading dose followed by 10mg once a day for 30 days following coronary artery stenting
1669883|NCT01700309|Behavioral|Young and Active|The intervention will consist of three meetings between the adolescent, the parents and the researchers, and weekly web-based health-counselling. The adolescents will set goals and make an individual activity plan on the web-page. During the study period all activity will be registered by the adolescents. The researchers will perform weekly counseling based on Selfdetermination Theory and Motivational Interviewing. The webiste also allows for the adolescents to communicate with eacother and with the counsler through a blog.
1669884|NCT01700296|Behavioral|Best care|"Best Care: subjects are randomly assigned to the Best care regardless MRC class and severity of symptoms through:
10 weeks of rehabilitation (2 hours, 2 times a week) by Region Zealand's instructions on sundhed.dk. COPD rehabilitation includes physical exercise, smoking cessation, medication, nutrition education and psychosocial support and patient education. Rehabilitation provided by a multidisciplinary effort with lung nurse, dietician and physiotherapist according to national and international guidelines (1.5) (6) (24) (25)
Outpatient follow-up every 3 months, a total of 5 visits, and during these visits various subjective, clinical, paraclinical and invasive parameters."
1669885|NCT01700283|Behavioral|exercise education and walking program|12-week moderate intensity walking program
1669886|NCT01700270|Drug|dovitinib (TKI258)|
1669887|NCT01700270|Drug|fluvoxamine|perpetrator drug; 7 days of dosing
1669888|NCT01700257|Radiation|CT scan & Early CDT Lung test|
1669889|NCT01700257|Other|CT scan & Early CDT Lung test|
1669890|NCT01700244|Device|Pacemaker implant|
1669891|NCT01700231|Procedure|Liver resection|Liver resection of patient with neoplastic hepatic tumors
1669892|NCT01700218|Other|telemonitoring|
1669893|NCT01700218|Other|control|
1669894|NCT01700205|Other|Type of Formula|infant formula
1669895|NCT01700192|Biological|MK-8237 tablets|MK-8237 12 DU rapidly dissolving tablets administered sublingually q.d.
1669896|NCT01700192|Biological|Placebo tablets|Placebo to MK-8237 rapidly dissolving tablets administered sublingually q.d.
1669897|NCT01700192|Drug|Rescue Medication: Self-Injectable Epinephrine|Self-injectable epinephrine (preferred dose of 0.30 mg) administered intramuscularly as needed for rescue medication.
1669898|NCT01700192|Drug|Rescue Medication: Loratadine tablets|Loratadine tablet 10 mg administered orally as needed for rescue medication.
1669899|NCT01700192|Drug|Rescue Medication: Olopatadine ophthalmic drops|Olopatadine hydrochloride ophthalmic drops 0.1% administered as needed for rescue medication.
1669900|NCT01700192|Drug|Rescue Medication: Mometasone furoate nasal spray|Mometasone furoate monohydrate nasal spray 50 mcg administered intranasally as needed for rescue medication.
1669901|NCT01700179|Drug|ACH-0143102|
1669902|NCT01700179|Drug|Ribavirin|
1669903|NCT01700166|Biological|Autologous Human Cord Blood derived Stem Cell injection|One time intravenous (in the vein) injection with two year follow-up
1669904|NCT01700153|Other|Robotic-assisted therapy|This robotic device is designed to intensively rehabilitate the upper limb. Indeed, this robot allows the patient to perform a lot of active, passive, or assisted exercises. The level of assistance is determined and provided by the robot in function of the patient capacity.
1669905|NCT01700153|Other|Classical therapy|conventional therapy will be performed by therapists specialized in neuro-pediatric rehabilitation
1669906|NCT01700140|Drug|SyB D-0701|Study drug patches [Low dose group (18.75 mg): SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 patch, High dose group (30.00 mg): SyB D-0701 15 cm2 patch + SyB D-0701 25 cm2 patch] assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
1669907|NCT01700140|Drug|Placebo|Study drug patches (Placebo group: SyB D-0701 15 cm2 placebo patch + SyB D-0701 25 cm2 placebo patch) assigned at the Case Registration Center are applied to either the right or left upper arm at 12 to 24 hours prior to the start of radiotherapy and left as is until 24 hours after completion of the third irradiation.
1669908|NCT01700127|Other|Breastfeeding|breastfeeding encouraged versus withheld
1669909|NCT01700114|Device|MelaFind|The device is used when a dermatologist chooses to obtain additional information on atypical skin lesions for a decision to biopsy.
1669910|NCT01700075|Drug|Conventional treatment|"Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.
Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.
Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day."
1669911|NCT01700075|Dietary Supplement|Weight loss treatment|Weight loss treatment by administering a healthy very low-calorie, low-fat vegetables and salt diet and includes an adjustment and modify eating behavior and increased physical activity.
1669912|NCT01700062|Dietary Supplement|Total Parenteral Nutrition (TPN)|Medium calorie ,Nonprotein calories 20 Kcal/Kg/day,Protein 1g/Kg,Fat emulsion 0.5 g/kg/day D1-D6 post OP standard calorie, Nonprotein calories 30 Kcal/Kg/day,Protein 1.5 g/Kg,Fat emulsion 50g/day D1-D6 post OP
1669913|NCT01700049|Drug|vismodegib (150 mg PO daily)|Biopsies will be performed on all participants at baseline, week 12 and week 24.
1669915|NCT01700010|Drug|Lapatinib and Paclitaxel|"Lapatinib comes in tablet form and is taken by mouth at a dose of 1,000 mg every day. Paclitaxel will be given through the vein (IV) at a dose of 80 mg/m2 on days 1, 8, and 15 at each 28 day cycle. If cancer does not progress and study treatment can be tolerated after 6 cycles of paclitaxel and lapatinib, paclitaxel will be stopped and lapatinib will continue until disease progression, side effects cannot be tolerated, participant is removed from or withdraws from study, or for other reasons.
Subjects with locally advanced disease who respond to treatment and are felt to be appropriate for local therapy may proceed to receive local therapy as deemed appropriate by the managing physician after a minimum of 6 cycles or upon achieving complete remission followed by an additional 2 cycles. Subjects who proceed to receive local therapy will be removed from protocol therapy. Subjects who elect not to receive or are not candidates for local therapy may continue treatment on protocol."
1669916|NCT01699997|Drug|Oxytocin|Intranasal spray with 40 IU of OXT
1669917|NCT01699997|Drug|Placebo|Intranasal spray with placebo solution
1669918|NCT01699971|Procedure|Hernia repair|Hernia repair admodum Lichtenstein with polypropylene mesh
1669919|NCT01699971|Procedure|Hernia repair|Hernia repair with Ultra Pro Hernia System (UHS)
1669920|NCT01699971|Procedure|Hernia repair|Hernia repair with Prolene Hernia System(PHS)
1669921|NCT01699958|Behavioral|Problem-solving intervention|Participants will receive 2 individual sessions teaching and reviewing problem-solving skills.
1669922|NCT01699945|Other|This is an observational study being conducted as a substudy of antoher trial.|
1669923|NCT01699932|Drug|Glimepiride+metformin (Amaryl M®) - HOE4900|"Pharmaceutical form:tablet
Route of administration: oral"
1669924|NCT01699919|Drug|Intravenous lignocaine|Intravenous lignocaine infusion is given in intraoperative period and till one hour post surgery.
1669925|NCT01699906|Other|Diet regimen to induce weight loss|Diet regimen to induce weight loss
1669926|NCT01699893|Other|unique arm|blood, nasal swab, skin biopsy, stool samples
1669927|NCT01699867|Device|Optical coherence tomography|Optical coherence tomography was used to image ex vivo breast tissue specimens.
1669928|NCT01699854|Drug|capsaicin patch (qutenza)|
1669929|NCT01699854|Drug|Placebo|
1669930|NCT01699828|Drug|Buspirone|The buspirone will be given once as a tablet and encapsulated for blinding.
1669931|NCT01699828|Drug|Placebo|Placebo will be lactose and encapsulated for blinding. A single capsule will be given.
1669932|NCT01699815|Drug|Acetaminophen|
1669933|NCT01699802|Other|Inhaled anaesthetic agent|
1669934|NCT01699789|Other|Quality Improvement Program|The quality improvement program is an evidence-based toolkit from prior studies (see Names above) that supported team leadership, case and care management, medication management, and Cognitive Behavioral Therapy for Depression. The Case management manual supported depression screening and monitoring/tracking of outcomes; patient education and activation, care coordination, and behavioral activation and problem solving. The toolkit includes education on depression and a community health worker manual.
1669935|NCT01699789|Behavioral|Resources for Services Expert Team|The expert team consisted for RS consisted of 3 psychiatrists, a psychologist expert in Cognitive Behavioral Therapy, a nurse care manager, a community engagement specialist, a quality improvement expert, and staff support. They team offered 12 web-based seminars to each community on components of collaborative care as well as site visits to primary care clinics on clinical assessment and medication management.
1669936|NCT01699789|Behavioral|Community Engagement and Planning Council|The CEP Council was supported by a workbook developed by the overall CPIC Council that provided principles, approach, agendas, and resources for the multi-sector planning meetings. The CEP Councils met twice a month for 4-6 months to develop their plan and met monthly during implementation of trainings. The study Council supported CEP meetings. Community leaders co-led trainings with study experts to help assure sustainability. Each CEP council had $15K to defray costs of venues, materials, and consultations, while the study provided that for RS.
1669937|NCT01699776|Drug|Ivabradine|7.5 my b.id. by mouth for 12-14 weeks
1669938|NCT01699776|Drug|Digoxin|1.25 mg once a day by mouth, for 12-14 weeks.
1669939|NCT01699763|Device|Contour® NEXT LINK BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1669940|NCT01699763|Device|OneTouch® UltraLink® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1669941|NCT01699763|Device|Nova Max Link® BGMS|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1669942|NCT01699750|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses, Phase 2
1669943|NCT01699750|Device|Senofilcon A contact lenses|Silicone hydrogel contact lenses, Phase 2
1669944|NCT01699750|Device|OPTI-FREE® PUREMOIST® MPDS|Contact lens care system, Phase 2
1669945|NCT01699750|Device|BIOTRUE®|Contact lens care system, Phase 2
1669946|NCT01699750|Device|Balafilcon A contact lenses|Silicone hydrogel contact lenses worn for 30 days, Phase 1
1669947|NCT01699750|Device|ReNu® Multiplus®|Contact lens care system used for 30 days, Phase 1
1669948|NCT01699737|Drug|JTT-851|
1669949|NCT01699737|Drug|Glimepiride|Encapsulated Glimepiride tablets
1669950|NCT01699737|Drug|Placebo for Active|
1669951|NCT01699737|Drug|Placebo for comparator|
1669952|NCT01699724|Drug|JZoloft|50 mg tablet on Day 1 of each period
1669953|NCT01699724|Drug|sertraline ODT|50 mg tablet on Day 1 of each period
1669954|NCT01699724|Drug|sertraline ODT|50 mg tablet on Day 1 of each period
1723353|NCT00004771|Drug|testosterone|
1669956|NCT01699698|Other|Tumor markers|Duodenal juice are collected using endoscope and cannula. Tumor markers of collected samples are analyzed. The marker concentration is applied to statistical analysis.
1669957|NCT01699685|Drug|QAB149|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
1669958|NCT01699685|Drug|Placebo|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
1669959|NCT01699685|Drug|NVA237|Capsule form in blister packs inhaled with the Novartis Concept 1 SDDPI
1669960|NCT01699672|Other|Group information|The patients will receive two 1.5-2 hour standardized validated group information sessions in addition to regular information from their doctors and nurses.
1669961|NCT01699659|Other|allergen immunotherapy|allergy shots
1669962|NCT01699646|Device|Neoventa S 21 ST-ANalysis of fetal heart|"Application of gold-trace scalp electrode"
1669963|NCT01699646|Procedure|CTG + FBS|Cardiotocography and fetal blood sampling on/from fetal skalp
1669964|NCT01699620|Procedure|BAHA implant insertion|The intervention is insertion of the Cochlear Bi300 to be used for bone anchored hearing aid.
1669965|NCT01699607|Drug|Amphetamine|All subjects will receive amphetamine to induce elevated dopamine levels in the brain at 0.5mg/kg
1669966|NCT01699594|Drug|Mannitol|Indirect bronchoprovocation agent being compared to direct bronchoprovocation agent (methacholine)
1669967|NCT01699594|Drug|Methacholine Chloride|Direct bronchoprovocation agent being compared to indirect bronchoprovocation agent (mannitol)
1669968|NCT01699581|Dietary Supplement|Nestle Impact Advanced Recovery|dose of Nestle Impact Advanced Recovery orally three times a day beginning on the morning following stem cell transplant and continued until the day of hospital discharge.
1669969|NCT01699568|Device|RFA|Each week since the surgery the implant stability will be measure with the Osstell mentor to verify the resonance frequence analysis, using the smartpeg number 21
1669970|NCT01699555|Biological|GNbAC1|Single dose intravenous (IV) GNbAC1 of 0.0025mg/kg, 0.025mg/kg, 0.15mg/kg, 0.60mg/kg, 2.00mg/kg or 6.00mg/kg
1669971|NCT01699555|Biological|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
1669972|NCT01699542|Device|WallFlex Esophageal RX Fully Covered Stent|Temporary placement of the WallFlex Esophageal RX Fully Covered Stent for treatment of refractory anastomotic esophageal strictures. The stent will be removed after 8 weeks (plus or minus 7 days) indwell
1669973|NCT01699542|Device|Esophageal Bougie Dilator Per Investigator preference|Commercially available Esophageal Bougie Dilator Per Investigator preference
1669974|NCT01699529|Device|Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system|The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
1669975|NCT01699503|Behavioral|Collaborative Dementia Care Program|Much of the intervention, facilitated by care coordinator, is targeted to co-manage or support the practice behavior of primary care clinicians, enhance self-management skills of both the care-recipient and the informal caregiver, and maximize the coping behavior of the patient and the informal caregiver.
1669976|NCT01699490|Drug|Fluoxetine + Valsartan|The curative effect of fluoxetine add-on valsartan 40 mg per day for 12 weeks therapy in the treatment of major depressive disorder.
1669977|NCT01699490|Drug|Fluoxetine + Placebo|The curative effect of fluoxetine add-on placebo therapy in the treatment of major depressive disorder.
1669979|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.7%|Ophthalmic Solution
1669980|NCT01699464|Drug|AR-12286 Ophthalmic Solution 0.5%|Ophthalmic Solution
1669981|NCT01699464|Drug|Timolol maleate ophthalmic solution 0.5%|Ophthalmic Solution
1669982|NCT01699438|Drug|Mesalazine|2400 mg q.d. for 8 weeks
1669983|NCT01699438|Drug|Placebo|3 tablets q.d. for 8 weeks
1669984|NCT01699425|Device|Ajust sling|
1669985|NCT01699425|Device|Classical transobturator sling|Control group
1669986|NCT01699412|Drug|Clobetasol|Rinse with a solution of clobetasol 0.05% associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
1669987|NCT01699412|Drug|Dexamethasone|Rinse with a solution of dexamethasone 0.1 mg/mL associated to nystatin 100,000 UI/mL, for 1 minute, during 28 days
1669988|NCT01699399|Procedure|water immersion|
1669989|NCT01699399|Procedure|water exchange|
1669990|NCT01699399|Procedure|air insufflation|
1669991|NCT01699386|Other|Control Study Formula|feed as lib
1669992|NCT01699386|Other|Experimental Study Formula|feed as lib
1669993|NCT01699373|Procedure|Ultrasound scan|Pre-procedural ultrasound scan was performed
1669994|NCT01699360|Drug|Cyclosporine A, Tacrolimus, Sirolimus|
1669995|NCT01699347|Drug|Intracystic injection of OK432 under US guiding|Intracystic injection of OK432 under US guiding
1669996|NCT01699334|Behavioral|Psychoeducational video|The educational video will explain the nature of whiplash injuries and provide a biopsychosocial model for neck pain incorporating both physiological and cognitive-behavioural aspects, reassurance and basic advice on pain relief.
1669997|NCT01699334|Other|Relaxation video|The comparison condition is a relaxation video detailing simple relaxation exercises such as breathing exercises which can be safely used by whiplash patients. The relaxation video contains no explanatory information concerning whiplash injuries or the related symptoms.
1669998|NCT01699321|Behavioral|Your Move (physical activity)|Materials that are provided will aim to increase a participant's minutes of physical activity.
1669999|NCT01699321|Other|Your Money (financial empowerment)|Materials that are provided to participants will direct them to resources for financial health.
1670000|NCT01699308|Drug|Genotropin (somatropin)|
1670001|NCT01699295|Behavioral|A+PAAC|academic lessons delivered by regular classroom teachers using moderate to vigorous physical activity (MVPA) for 20 minutes/day, 5 days/week.
1670002|NCT01699295|Behavioral|CON|lessons taught by regular classroom teachers using traditional/regular sedentary lessons
1670003|NCT01699282|Behavioral|VKA (antivitamin K) education|Evaluate benefits of a comprehensive patient education on oral anticoagulant compared to conventional hospital education
1670004|NCT01699282|Behavioral|conventional hospital education|Group thorough VKA education V.S. control group (conventional hospital education)
1670005|NCT01699269|Other|peritumoral glial cell infiltration|
1670006|NCT01699256|Behavioral|Guideline implementation as usual|Newsletters and Invitation to Meetings
1670007|NCT01699256|Behavioral|Enhanced guideline implementation strategy|Enhanced guideline implementation strategy
1670008|NCT01699230|Dietary Supplement|Omega 3|To show the existence of a atrial cardiomyocytes membranes modification in omega-3 supplemented patients with coronary atherosclerosis
1670009|NCT01699204|Dietary Supplement|N-acetylcysteine|N-acetylcysteine 600mg taken orally 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
1670010|NCT01699204|Other|Diesel exhaust|A placebo tablet taken 3 times daily for 6 days prior to exposure to diesel exhaust for 2 hours. The last supplement was taken the morning of the exposure
1670011|NCT01699204|Other|Filtered air|A placebo tablet taken 3 times daily for 6 days prior to exposure to filtered air for 2 hours. The last supplement was taken the morning of the exposure
1670012|NCT01699191|Dietary Supplement|Probiotic|
1670013|NCT01699191|Dietary Supplement|Placebo|
1670014|NCT01699178|Drug|Oral testosterone undecanoate|
1670015|NCT01699178|Drug|Transdermal testosterone gel (AndroGel)|
1670016|NCT01699165|Device|Nasal filter|Active nasal filter
1670017|NCT01699165|Device|Placebo nasal filter|Placebo nasal filter
1670018|NCT01699152|Drug|TG02 citrate|TG02 citrate capsules
1670019|NCT01699139|Device|positional device|Avoidance of supine positioning was achieved by use of the commercially available ZZoma Positional Device, which is the FDA cleared class II positional medical device. The device is 12 x 5.5 x 4 inches in size and made of lightweight semi-rigid synthetic foam. It is contained in the nylon material with an associated Velcro belt. Zzoma is a positioner worn around the upper torso to restrict patient movement from side to supine.
1670020|NCT01699139|Device|lumbar corset|A lumbar (abdominal) binder is made of an elastic fabric with Velcro closure. Subjects wore the prefabricated lumbar corset during sleep and were positioned ad lib.
1670021|NCT01699126|Device|CPAP|Continuous Positive Airway Pressure is the routine treatment of OSA, patients will be randomly assigned into CPAP treatment group
1670022|NCT01699126|Drug|Statin|Statin is an lipid lowering medication with anti-inflammatory effect.
1670023|NCT01699113|Drug|YF476|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:
YF476 100 mg; or
rabeprazole 20 mg; or
a combination of YF476 100 mg and rabeprazole 20 mg."
1670024|NCT01699113|Drug|Rabeprazole|"Subjects will be randomised to once daily treatment by mouth for 6 weeks with:
YF476 100 mg; or
rabeprazole 20 mg; or
a combination of YF476 100 mg and rabeprazole 20 mg."
1670025|NCT01699100|Other|device|Experimental: insole In-shoe plantar pressure measurements were performed in 26 patients with diabetic neuropathic feet at baseline condition, and 52 regions of interest (ROIs, with mean peak pressure > 200kPa or with the highest mean peak pressure in the forefoot area) were identified as suitable areas for removal of pegs. Data of in-shoe plantar pressures of the three insole conditions (pre-peg removal, post-peg removal, and post-peg removal plus arch support) were collected. Mean peak pressure (MPP) and pressure-time integral (PTI) were recorded for analysis.
1670026|NCT01699087|Procedure|Photorefractive keratectomy (PRK)|In this corneal surgical procedure, the outer corneal epithelial layer will be removed, after which the corneal stroma will be reshaped by excimer laser ablation to reduce or eliminate refractive errors.
1670027|NCT01699087|Device|ALLEGRETTO WAVE EYE-Q excimer laser system|The ALLEGRETTO WAVE EYE-Q excimer laser system is used for corneal stroma reshaping during PRK surgery
1670028|NCT01699074|Dietary Supplement|1 gram of White Korean Ginseng|1 gram of White Korean Ginseng
1670029|NCT01699074|Dietary Supplement|3 grams of White Korean Ginseng|3 grams of White Korean Ginseng
1670030|NCT01699074|Dietary Supplement|6 grams of White Korean Ginseng|6 grams of White Korean Ginseng
1670031|NCT01699074|Dietary Supplement|3 grams of Wheat Bran Control|3 grams of Wheat Bran Control
1670032|NCT01699074|Dietary Supplement|500mg of Korean Red Ginseng|500mg of Korean Red Ginseng
1670033|NCT01699061|Drug|Tivantinib|3 tivantinib tablets 120 mg administered twice daily with a meal starting on Day 2
1670034|NCT01699061|Drug|Placebo|Placebo tablet administered with a meal twice a day on Day 1
1670035|NCT01699048|Procedure|Hybrid (MIDCAB+PCI)|Hybrid approach (Minimally invasive of-pump revascularization of the left anterior descending artery (LAD) via left internal mammary artery (LIMA) bypass with consecutive percutaneous coronary intervention (PCI) in the rest arteries with drug eluting stents (DES). The revascularization will be performed in two stages within a 3-days interval
1670036|NCT01699048|Procedure|PCI|Multi-vessel PCI with DES
1670037|NCT01699048|Procedure|CABG|Coronary artery bypass graft (CABG) treatment
1670038|NCT01699022|Drug|Injection Cyclofem|"Injection Cyclofem contains 25 mg medroxyprogesterone acetate (MPA) and 5 mg estradiol cypionate as a microcrystalline suspension in 0.5ml aqueous solution and is supplied in vials.
Women were administered three consecutive monthly injections of Cyclofem for prevention of ovulation, and were followed until the 92nd day from the last (third) injection."
1670039|NCT01699009|Other|Plant based diet|
1670040|NCT01699009|Other|an unrestricted diet|
1670041|NCT01698996|Procedure|Packing vs No Packing|
1670042|NCT01698970|Other|1-Freeze-dried Probiotics provided in capsule (150 mg) containing 1,0x10E10 colony forming unit per capsule (test)|1- 6 test products/day
1670043|NCT01698970|Other|2- excipients (150 mg) in capsule (control)|2- 6 control poducts/day
1670044|NCT01698957|Other|Any patient eligible for an Ultrasound greater than or equal to 18 weeks gestation without a fetal or uterine anomaly.|bilateral Uterine artery Doppler readings pre- and during blood pressure measurement
1670045|NCT01698944|Drug|somatropin|Initial dose 0.5 IU/day and escalated up to maximum dose the first 6 months. Maximum dose 3.0 IU/day for 18 months. Injected subcutaneously (s.c., under the skin) daily
1670046|NCT01698931|Drug|repaglinide|1 mg before each main meal on three separate dosing visits separated by a wash-out period
1670047|NCT01698931|Drug|glyburide|5 mg before breakfast and before supper on three separate dosing visits separated by a wash-out period
1670048|NCT01698931|Drug|placebo|Before each main meal on three separate dosing visits separated by a wash-out period
1670079|NCT01698710|Drug|Albumin bound paclitaxel|Albumin bound paclitaxel will be administered into the mucinous cyst of pancreas in endoscopy procedure.
1670049|NCT01698918|Drug|Everolimus|Everolimus will be self-administered as a daily dose of 10mg (two 5mg tablets) taken orally continuously from study day 1 until progression of disease, unacceptable toxicity or withdrawal of consent. Everolimus should be taken at the same time every day. Everolimus tablets should be swallowed whole with a glass of water once daily, either consistently with food or consistently without food. Tablets should not be chewed or crushed.
1670050|NCT01698918|Drug|Letrozole|1st line study treatment: Letrozole will be self administered as a daily dose of 2.5mg continuously from study day 1 until disease progression, unacceptable toxicity or withdrawal of consent and should be taken at the same time every day, consistently with or without food. Everolimus and letrozole tablets should be taken together.
1670051|NCT01698918|Drug|Exemestane|2nd Line Study Treatment: If patients progress on everolimus + letrozole, patients will be offered everolimus + exemestane. Exemestane will be self administered as a daily dose of 25mg taken orally continuously until disease progression, unacceptable toxicity or withdrawal of consent and should be taken at the same time every day after a meal. Everolimus and exemestane tablets should be taken together.
1670052|NCT01698918|Drug|Alcohol-free dexamethasone mouth rinse|At the onset of symptoms suggestive of stomatitis patients must contact the study site. Upon confirmation of stomatitis at the site, patients in countries where the alcohol-free 0.5mg/5ml dexamethasone oral solution is commercially available will be randomly assigned to take either dexamethasone 0.5 mg/5ml mouth rinse or the standard of care used to treat stomatitis at the patient's center. The mouth rinse will be self administered at a daily dose of 10ml 3 times per day. Patients will be instructed to swish and expectorate the mouth rinse. Patients will also be instructed to fill out the Oral Stomatitis Daily Questionnaire (OSDQ) at home every day until the patient recovers. The mouth rinse will be self administered at a daily dose of 10ml 3 times per day.Patients will be instructed to swish and expectorate the mouth rinse.
1670054|NCT01698892|Drug|I.V Sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the I.V. sedation group
1670055|NCT01698892|Drug|sublingual sedation|Patients who will undergo bronchoscopy will be followed during one day. They will be randomized in the sublingual sedation group
1670057|NCT01698866|Biological|Vaccin GenHevac B Pasteur|
1670058|NCT01698840|Dietary Supplement|Vitamin D|
1670059|NCT01698840|Dietary Supplement|Placebo|
1670060|NCT01698827|Other|Tube assessment visits|Patients will return every 2 months for clinical questionnaire about leaks, obstructions or other dysfunctions of the tube. Objective tube examination for cracks, rupture, obstruction or dislodgement, along with replacement if necessary, will be carried out (total of 3 visits/6 months)
1670061|NCT01698814|Drug|AL-4943A Ophthalmic Solution|
1670062|NCT01698814|Drug|AL-4943A Ophthalmic Solution Vehicle|Inactive ingredients used as placebo
1670063|NCT01698801|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 of each 28-day cycle
1670064|NCT01698801|Drug|dexamethasone|40 mg oral dexamethasone once daily on Days 1, 8, 15 and 22 of each 28-day cycle
1670065|NCT01698788|Drug|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone
1670066|NCT01698775|Drug|Omarigliptin|Participants with moderate renal insufficiency will receive one omarigliptin 25 mg capsule orally once a week; participants with severe renal insufficiency or end stage renal disease will receive one omarigliptin 12.5 mg capsule orally once a week
1670067|NCT01698775|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin capsule administered orally once a week
1670068|NCT01698775|Drug|Glipizide|Phase A: Participants may receive open-label glipizide as rescue therapy up to Week 24 of the study. Phase B: Participants who received placebo to omarigliptin during Phase A and are not on background insulin therapy or who did not receive open-label glipizide or insulin as rescue therapy during Phase A of the study Week 1 through Week 24) will receive glipizide capsule(s) 2.5 daily up to a maximum of 20 mg daily (based on glycemic control) in a blinded manner during Phase B of the study (Week 24 through Week 54).
1670069|NCT01698775|Drug|Placebo to glipizide|Matching placebo to glipizide daily
1670070|NCT01698775|Biological|Insulin|Participants on insulin therapy at screening will continue insulin therapy during the study. Insulin glargine therapy may be administered as rescue therapy as determined by the investigator.
1670071|NCT01698762|Other|Multimedia Patient Decision Aids (MM-PtDAs)|Patient group will watch a DVD of information about their disease type.
1670072|NCT01698762|Other|Comparative Effectiveness Research Summary Guide (CERSG)|Patient group to read a booklet about their disease type.
1670073|NCT01698762|Behavioral|Questionnaires|Questionnaires completed at baseline, 3, and at 6 months.
1670074|NCT01698749|Drug|long acting intravitreal dexamethasone implant|Intravitreal ozurdex was given in diabetic patients with clinically significant macular edema and they were followed up for change in central macular thickness and visual acuity over a period of 6 months
1670075|NCT01698736|Device|Membrane filtration|Membrane filtration (Polysulfone)
1670076|NCT01698736|Device|Semiselective IA|Semiselective immunoadsorption (GAM peptide adsorber)
1670077|NCT01698723|Drug|Ribavirin|
1670078|NCT01698723|Drug|Placebo|
1670144|NCT01698164|Drug|estradiol plus MPA|Participants are given estradiol and synthetic progestin.
1955005|NCT03309761|Other|Blood test|6ml blood sample taken
1955006|NCT03310814|Other|Personalized nutrition|Receives individualized nutrition information
1670080|NCT01698697|Drug|insulin aspart|Bolus 0.1 U/kg administered simultaneously with a continuous infusion of 0.029 U/kg/h via a programmed insulin pump. A total dose of 0.35 U/kg is delivered to the subject in the 12 hour infusion
1670081|NCT01698684|Drug|Placebo|One dose 15 minutes before attempting intercourse
1670082|NCT01698684|Drug|Avanafil 100 mg|One dose 15 minutes before attempting intercourse
1670083|NCT01698684|Drug|Avanafil 200 mg|One dose 15 minutes before attempting intercourse
1670084|NCT01698671|Device|InterGard Synergy Vascular Graft|
1670085|NCT01698658|Other|ultrasound tomography|Undergo ultrasound tomography using SoftVue
1670086|NCT01698658|Procedure|magnetic resonance imaging|Undergo MRI of the breast
1670087|NCT01698645|Drug|PecFent® (fentanyl) nasal spray|
1670088|NCT01698606|Behavioral|Multidisciplinary, family-centered lifestyle intervention with behavioral counseling|Parent/caregiver education with skill training and practical activities revolving around healthy dietary choices, establishing an active versus a sedentary lifestyle, and behavioral aspects, while children will be engaged in active play.
1670089|NCT01698593|Drug|Bupivacaine 0.5%|
1670090|NCT01698593|Drug|Bupivacaine 0.5% + Epinephrine (1:200,000)|
1670091|NCT01698580|Other|On-site exercise|The program will consist of progressive balance, including postural orientation and anticipatory postural adjustments sensory-motor activities, and strengthening exercises to enhance balance and postural control and reduce falls. Exercises in the standing position will be prioritised in order to target balance control.Exercises will be both static and dynamic, and will get progressively more challenging, in order to reach the individual optimal level of balance and strength functional status.
1670092|NCT01698580|Other|home-based exercise|Participants will be provided with a detailed booklet containing safety precautions, instructions and photographs of exercises for use in exercise sessions at home and will be instructed to do the exercises preferably under the supervision of a relative or caregiver, in a suitable place (with good lighting and ventilation) and using proper support (close to a table or chair, or the corner of a wall). In the first four weeks of intervention the patients will stay for 30 minutes after the therapy sessions in order to learn the home exercises. The exercises will be reviewed, if necessary, after each session till the last week of intervention. All necessary equipment to undertake the exercise program will be provided.
1670093|NCT01698580|Other|Educational and behavioural|Sessions will address specific environmental and behavioural risk factors delivered by trained health professionals,lasting for 30 minutes and will use appropriate language for lay people.Each meeting will be consisted of a brief introduction on the core day topic with supporting audio-visual or graphic material, followed by group discussion in order to identify the beliefs and attitudes of participants regarding falls and any major restriction or barrier for the implementation of preventive strategies. Participants will be encourage to report their own experiences and beliefs. The activity will always end with the reinforcement of the core message of the session.
1670094|NCT01698580|Other|Management of modifiable risk factors|Postural hypotension: review of medications that may contribute to postural hypotension;Visual impairment: Participants identified as having visual problems will be referred to an ophthalmologist. The use of four or more medications or the use of psychotropic medication: A review of the risk-benefit of using specific medications will be undertaken, especially psychotropic and anti-hypertensive drugs; Foot problems and shoes: Guidance on the use of proper footwear, nail care and the treatment of cutaneous mycoses will be given; Undernutrition: Participants with a BMI lower than 22 kg / m2 and or a leg calf under 31cm will be oriented to increase their protein and calorie intake and will be referred to a nutritionist.
1670095|NCT01698580|Other|Usual care|The control group will receive a baseline assessment to identify risk factors for falls and will be referred to their clinicians with a report of individual modifiable risk factors to be managed without any specific guidance: referral to routine services, treatments or any specific orientation will be at the discretion of their primary clinicians. So, further management of each participant in the control group will be individualized, with no specific protocol. Interventions will be recorded. Participants will receive a leaflet with basic orientations for fall prevention.
1670096|NCT01698567|Drug|Antithrombin III|"ATIII will be dosed using the formula recommended by the manufacturer:
(goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)"
1670097|NCT01698567|Drug|Placebo|placebo (normal saline) after induction of anesthesia and before commencement of bypass. ATIII will be dosed using the formula recommended by the manufacturer: (goal activity - baseline activity) x weight (kg) x .714 (Assume: start with 35% activity [7], goal 120% activity[18], so dose = 120-35 x wt (kg) x .714, e.g. 5 kg infant: 85 x 5 x .714 = 303 units)
1670098|NCT01698554|Drug|bimatoprost formulation A solution|Bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
1670099|NCT01698554|Drug|bimatoprost solution 0.03 %|Bimatoprost solution 0.03 % (LATISSE®) applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
1670100|NCT01698554|Drug|vehicle of bimatoprost formulation A solution|Vehicle of bimatoprost formulation A solution applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
1670101|NCT01698554|Drug|vehicle of bimatoprost solution 0.03 %|Vehicle of bimatoprost solution 0.03 % applied to the upper eyelid of both eyes once daily for 4 months using the supplied applicator.
1670102|NCT01698541|Drug|Tacrolimus|Tested generic
1670103|NCT01698541|Drug|Tacrolimus|Original formulation used as comparator
1670104|NCT01698528|Device|Tablet Computer|
1670105|NCT01698476|Drug|vitamin D (cholecalciferol) and PBA (sodium phenylbutyrate)|Dose of interventions: 5,000 IU of vitamin D (cholecalciferol tablets) once daily and 500 mg PBA (sodium phenylbutyrate tablets) twice daily for 16 weeks.
1670106|NCT01698476|Drug|Placebo tablets|
1672118|NCT01682187|Drug|Lomustine|Administered orally
1955011|NCT03309618|Drug|low-dose combination of fluvastatin (10 mg) and valsartan (20 mg) (low-flu/val)|
1670108|NCT01698450|Device|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
1670109|NCT01698437|Device|Non-invasive intervention with focused ultrasound (ExAblate 4000)|Non-invasive brain intervention using MR-guided focused ultrasound
1670110|NCT01698398|Device|Incremental pump speed of CF-LVAD.|Peak oxygen consumption with fixed versus incremental pump speed.
1670111|NCT01698385|Other|Diet and exercise counseling|diet and exercise counseling, setting of specific goals, follow-up of achievements, laboratory tests and measurements
1670112|NCT01698372|Device|Prevena device (Group A)|This portable device is applied to initiate negative pressure therapy to a wound site.
1670113|NCT01698346|Biological|Pertussis vaccine|Vaccination during pregnancy with a pertussis containing vaccine
1670114|NCT01698333|Drug|122-0551|Applied twice daily for 2 weeks
1670115|NCT01698320|Drug|Placebo MDPI|Placebo MDPI (multi-dose dry powder inhaler) to match the active intervention.
1670116|NCT01698320|Drug|Albuterol MDPI|Albuterol MDPI (multi-dose dry powder inhaler or Spiromax®) 90 mcg/inhalation.
1670117|NCT01698307|Other|Enhanced Treatment Algorithm|The Enhanced algorithm features the early use of combined antimetabolite/adalimumab therapy, and treatment intensification based on ileocolonoscopic findings. Failure to achieve or sustain Deep Remission, which includes sustained normalization of the imaging studies, will result in treatment intensification, according to the steps outlined in the algorithm, irrespective of symptoms.
1670118|NCT01698307|Other|Conventional Step-care Algorithm|Step-care algorithm that specifies treatment escalation solely on the basis of symptoms quantified using the Harvey Bradshaw Score.
1670119|NCT01698294|Other|Clinical Observation|Participants maintain usual diet and undergo clinical observation
1670120|NCT01698294|Dietary Supplement|Flaxseed|Given PO
1670121|NCT01698294|Other|Laboratory Biomarker Analysis|Correlative studies
1670122|NCT01698294|Other|Questionnaire Administration|Ancillary studies
1670123|NCT01698281|Drug|Zoptarelin doxorubicin|
1670124|NCT01698281|Drug|paclitaxel|
1670125|NCT01698281|Drug|nab-paclitaxel|
1670126|NCT01698281|Drug|eribulin|
1670127|NCT01698281|Drug|pegylated liposomal doxorubicin|
1670128|NCT01698281|Drug|vinorelbine|
1670129|NCT01698281|Drug|gemcitabine|
1670130|NCT01698281|Drug|capecitabine|
1670131|NCT01698268|Procedure|TAP block|TAP Block will be performed under ultrasound guidance via Sonosite device with an in-plane technique by the anesthesiologist.
1670132|NCT01698268|Procedure|Local Infiltration|Local infiltration of 0.5 cc/kg of 0.25% ropivacaine will be administered by the surgeon.
1670133|NCT01698255|Behavioral|ENGAGE|
1670134|NCT01698255|Behavioral|Standard of Care Psychotherapy|
1670135|NCT01698242|Behavioral|Enhanced Training|"PCP-Level: A PCP randomized to the Enhanced Training (ET) group will receive: 1) a full and pocket sized copy of the current AHA Heart Failure (HF) Guidelines; 2) a summary of their patient's data collected at baseline, 6-month, and 30-month in-person study visits; and 3) an invitation to complete the CHART-designed online course in HF management for CME credit.
Patient Level: The ET patient-level intervention uses Community Health Workers (CHWs) to assist the patient in learning self-management behaviors to reduce the risk of hospitalization. The key objectives are to: improve heart failure knowledge; encourage use of HF management tools; and facilitate development of self-management skills. Each participant receives at least: six AHA educational mailings, six monthly home visits, and 18 phone calls by CHWs within the first six months of the intervention. The CHW then conducts monthly telephone visits for the subsequent two years (for a total of 30 months of follow-up)."
1670136|NCT01698242|Behavioral|Enhanced Education|"The Enhanced Education (EE) intervention follows a multi-level strategy in which both the patient and their PCP are intervened upon concurrently. The intervention provides nominal information through the mail. Randomization occurs at the PCP-level; patients are assigned to the EE group only if their PCP already has been randomized to this group.
PCP Level: Upon randomization to the EE group each PCP will receive a full-sized copy of the current American Heart Association (AHA) Heart Failure Guidelines within thirty days after randomization.
Patient Level: Upon their assignment to the EE group, patients will receive: Six AHA Tip-Sheet mailings (one Tip-Sheet to be mailed each of the first six months following group assignment); a telephone call, made by the CHART Research Assistant (RA), completed once during each of the first six months following group assignment and only to confirm that the patient received the Tip-Sheet mailing for that month."
1670137|NCT01698229|Other|Group 1|Collecting a small amount of cerebrospinal fluid (5 mL) from healthy children, ages 2 yrs - 8 yrs, who are already undergoing a lumbar puncture procedure at New York Presbyterian Hospital for clinical or diagnostic purposes.
1670138|NCT01698203|Drug|ropivacaine 0.75% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The group ropivacaine, an initial bolus of 0.75% ropivacaine at a volume of 0.1 ml / kg is first administered to the patient directly on the catheter.
1670139|NCT01698203|Drug|Placebo|In the placebo group, an initial bolus of saline 9 ‰ to a volume of 0.1 ml / kg will first be administered to the patient directly to the catheter. The patient will then continuous administration of saline 9 ‰ during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled of this solution, a flow rate of 9.53 ml / hour.
1670140|NCT01698203|Drug|ropivacaine 0.2% - device : wound catheter Silver™ 19 cm and Easypump™ 400 mL (BBraun)|The patient will then ongoing administration of ropivacaine 0.2% during the first 48 postoperative hours, using a diffuser extensible elastomeric ™ Easypump a volume of 400 mL to 460 mL filled (B Braun) of this solution, a flow rate of 9.53 ml / hour
1670141|NCT01698190|Procedure|Endoscopic ultrasound guided needle tissue acquisition.|Endoscopic ultrasound with fine needle aspiration (FNA) allows for the safe and efficacious sampling of solid lesions that are in close proximity to the gastrointestinal tract, including extraintestinal masses, subepithelial tumors, and peri-intestinal lymphadenopathy. Fine needle core biopsy (FNB) has the potential of accruing larger tissue samples during biopsies, which may make the procedure more efficacious. In our study, we are comparing the overall efficacy between these two needles which are currently both used as standard of care.
1670142|NCT01698177|Biological|Influenza vaccine|Seasonal inactivated trivalent vaccine
1670143|NCT01698177|Biological|Influenza vaccine|Seasonal inactivated trivalent vaccine
1672119|NCT01682174|Other|Control Drink|
1670145|NCT01698164|Drug|Ximingting Tablet|Participants are given phytoestrogen.
1670146|NCT01698164|Drug|estradiol plus progesterone|Participants are given estradiol and natural progesterone.
1670147|NCT01698138|Drug|Onabotulinumtoxin A|"30 transurethral injections, each of 1 ml solution containing 300 U Onabotulinumtoxin A (Botox ®, Allergan) in 30 ml of NaCl 0.9 %."
1670148|NCT01698138|Drug|Placebo|30 transurethral injections, each of 1 ml solution containing NaCl.
1670149|NCT01698125|Procedure|Abdominal surgery|Patients 65 years or older scheduled for abdominal surgery at Oslo University Hospital
1670150|NCT01698112|Dietary Supplement|Flaxseed High Dose|26 gram flaxseed intervention
1670151|NCT01698112|Dietary Supplement|Flaxseed Low Dose|13 grams flaxseed
1670152|NCT01698086|Other|Vestibular rehabilitation: balance and eye movement exercises|The Experimental group will perform 1-hour supervised intervention sessions 2x/wk for 6-wks, then 1x/wk for 8-weeks, for a total of 20 supervised sessions. The intervention is a progressive vestibular rehabilitation program comprised of balance and eye movement exercises as detailed in our preliminary study report. The balance training includes standing and walking tasks on varied types of compliant surfaces, base of support, head movements, visual input and eye-hand tasks. The tasks will progress from simple to more complex. Eye movement exercises will include voluntary saccadic eye movements and smooth pursuit movements. Vestibulo-ocular eye training will be performed while visually fixating on a stationary object, while moving the head up and down and side to side at various speeds, progressing from sitting to standing on firm and compliant surface. Participants in the Experimental group will be given items of the exercise program to perform as a home exercise program.
1670153|NCT01698073|Behavioral|mCOL|
1670154|NCT01698073|Other|AS+|
1670155|NCT01698060|Biological|ND1.1|
1670156|NCT01698047|Behavioral|Resiliency Class|See Arm Description
1670157|NCT01698047|Other|Case Management|See Case Management description
1670158|NCT01698034|Behavioral|Volunteering|Weekly volunteering with elementary school children in after school programs
1670159|NCT01698008|Device|Diabetes Doctor|Diabetes Doctor is a mobile application software. The mobile phone application allows a subject to register blood glucose values obtained from their fingerstick glucose meter readings, the type and amount of insulin they are administering, any notes they would like to document, and the date and time of each entry. All data will be entered by the subject manually. The data will be submitted through encryption coded private servers and can be retrievable by a physician on a password protected website for privacy. A physician will evaluate this information to recommend a change of the subject's insulin regimen. The recommended insulin regimen will be delivered to the patient using the same website and received by the subject on the same mobile application software.
1670160|NCT01697982|Behavioral|Living with Hope Program|"The Living with Hope Program involves viewing a short film entitled Living with Hope, which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope. Participants then choose to begin one of three hope activities: a) Write or ask someone to help you write one or more letters to someone begin to write a letter to someone, b) Begin a Hope Collection or c) begin an About Me Collection."
1670161|NCT01697982|Behavioral|LWH film|Participants will view the Living with Hope film which is based on the research team's grounded theory study, and shows cases of terminally ill persons and their family members talking about how they maintain their hope.
1670162|NCT01697969|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
1670163|NCT01697956|Drug|BDP|Beclomethasone dipropionate (BDP) 80 mcg/day (40 mcg/spray, 1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
1670164|NCT01697956|Drug|Placebo|Placebo (1 spray/nostril, once daily - total 2 sprays/day) as a nasal aerosol.
1670165|NCT01697943|Procedure|Roux-En-Y Pouch Reconstruction or Conventional Roux-En-Y Reconstruction|
1670166|NCT01697930|Drug|[18F] 4-L-Fluoroglutamine (2S,4R)|Thirty cancer patients will receive an injection of a 0.5 to 7.5mCi of [18F] 4-LFluoroglutamine (2S,4R) , followed by serial PET/CT scanning and blood draws, (at the direction of the investigator) over a period of 3.5 hours, on a single day. Each patient will be offered the opportunity to repeat the [18F] 4-L-Fluoroglutamine (2S,4R) injection and subsequent set of post-injection PET-CT scans, once, on a separate date. At the discretion of the investigator, scan 3 can be waived. Immediately prior to injection of the radiotracer, a blood sample will be obtained for measurement of serum glutamine level. The serum glutamine level will be assayed, if necessary, as part of an amino acid screen assay.
1670167|NCT01697917|Other|Total Gastrectomy or Proximal Gastrectomy|
1670168|NCT01697904|Procedure|Titration of oxygen during newborn resuscitation in delivery room|
1670169|NCT01697891|Device|Codetron ALTENS|ALTENS stimulation of a set of selected acupuncture points for 20 minutes in each treatment. Two treatments per week for a total of 12 treatments to be delivered within 8 weeks.
1670170|NCT01697878|Procedure|CPAP followed by atmospheric pressure|In the PACU, Patients receive 2 hours of continuous-positive-airway-pressure (CPAP) oxygen at 30% FiO2 treatment followed by 2 hours of oxygen treatment (6 L O2/min) that is part of standard of care at Massachusetts General Hospital
1670171|NCT01697878|Procedure|Atmospheric pressure followed by CPAP|In the PACU, patients receive 2 hours of Oxygen treatment (6L/min) that is part of standard-of-care at Massachusetts General Hospital, followed by 2 hours of Continuous Positive Airway Pressure (CPAP) treatment at 30% FiO2.
1670172|NCT01697865|Procedure|Transfer group|
1670173|NCT01697865|Procedure|Control group|
1955012|NCT03309618|Drug|placebo|
1955013|NCT03309605|Drug|ELX-02|ELX-02
1670176|NCT01697826|Drug|ClinSupV3 -soft gelatin capsule|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg clotrimazole
1670177|NCT01697826|Drug|ClinSupV3ER- Extended release tablet|3 day treatment with intravaginal formulation containing 100mg Clindamycin and 200mg Clotrimazole
1670178|NCT01697800|Drug|Tadalafil|
1670179|NCT01697800|Drug|Placebo|
1670218|NCT01697566|Behavioral|Questionnaires|Completion of questionnaires about diet and exercise at baseline, during treatment and at end of study. Questionnaires take about 30-40 minutes to complete.
1670219|NCT01697553|Other|home automation pack coupled to teleassistance service|
1723354|NCT00004772|Drug|Immune globulin|
1955014|NCT03309605|Drug|Placebo|Placebo
1670180|NCT01697787|Drug|Amodiaquine-Artesunate|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
1670181|NCT01697787|Drug|Artemether-lumefantrine|If necessary, the study drug will be crushed, dissolved in water and squirted into the mouth using a spoonful. Administration of the treatments will be directly observed. After drug administration, patients will be kept for at least 30 minutes in the clinic. A dose will be repeated in full if vomiting occurs within 30 minutes of administration and halved if vomiting is between 30 minutes and 1 hour post dosing.
1670182|NCT01697761|Other|Treatment Group|patients receive herbs-partitioned moxibustion for 2 cones and acupuncture for 30 minutes，3 times a week for 12 weeks
1670183|NCT01697761|Other|Control Group|patients receive shallow needing and bran-partitioned moxibustion with the stimulation same to the treatment group.
1670184|NCT01697735|Drug|Berberine;Atorvastatin or Rosuvastatin|Participants will receive 500mg Berberine twice a day for 8 weeks; Follow the previous administration program，participants will continue to receive 20mg Atorvastatin daily or 10mg Rosuvastatin daily.
1670185|NCT01697735|Drug|Atorvastatin or Rosuvastatin|Due to the different clinical prescriptions by different doctors and similar Efficacy in lowering lipids.Usually,Participants receive 20mg Atorvastatin daily or 10mg Rosuvastatin to treat hyperlipidemia.
1670186|NCT01697722|Drug|Extra-fine hydrofluoroalkane-beclometasone dipropionate|Increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via pMDI or BAI
1670187|NCT01697722|Drug|ICS / LABA via separate pMDI and / or BAI inhalers|A step-up from baseline ICS therapy via the addition of a separate long-acting beta-agonist with no change in baseline ICS drug or dose
1670188|NCT01697709|Drug|Quetiapine|Quetiapine pharmacotherapy for cannabis dependence
1670189|NCT01697709|Drug|Placebo|placebo capsules
1670190|NCT01697696|Drug|NVA237|NVA237 will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
1670191|NCT01697696|Drug|Long-acting beta 2-agonist (LABA)|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept 1 SDDPI
1670192|NCT01697696|Drug|Placebo|Placebo to match QAB149
1670193|NCT01697683|Drug|Probiotic Lactobacilli|Two capsules per day containing either probiotic lactobacilli or placebo for 12 weeks
1670194|NCT01697683|Drug|Placebo|
1670195|NCT01697670|Drug|Photodynamic therapy with Gliolan|Laser light illumination with red light at 635 nm using a cylindrical light diffuser (Model RD, Medlight SA) in a white diffusing inflatable balloon catheter (model CDB OEB, Medlight SA) at a fluence rate of 65.5 mW/cm2 over 153 s resulting in a total light dose of 10 J/cm2 is performed 3 hours after administration of 15mg/kg bodyweight Gliolan
1670196|NCT01697657|Drug|insulin detemir|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
1670197|NCT01697657|Drug|insulin NPH|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily in the morning and at bedtime for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
1670198|NCT01697657|Drug|insulin aspart|Subjects were dosed according to individual requirements. Injected subcutaneously (s.c. under the skin) twice daily before meals for 10 weeks after an initial 6-week titration in treatment period 1 followed by 10 weeks after an initial 6-week titration in treatment period 2
1670199|NCT01697644|Drug|somatropin|3 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
1670200|NCT01697644|Drug|somatropin|3 IU/m^2/day. Dose adjusted approximately every 3 months. Injected subcutaneously once daily
1670201|NCT01697631|Drug|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) at breakfast and evening main meals
1670202|NCT01697631|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) before lunch
1670203|NCT01697618|Drug|biphasic insulin aspart 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
1670204|NCT01697618|Drug|biphasic human insulin 30|Injected subcutaneously (s.c., under the skin) before breakfast and dinner, dosage adjusted throughout the trial according to individual needs
1670205|NCT01697605|Drug|BGJ398|
1670206|NCT01697592|Drug|Omarigliptin|Omarigliptin (MK-3102) 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
1670207|NCT01697592|Drug|Matching placebo to omarigliptin|Matching placebo to omarigliptin 25 mg capsule administered orally once weekly. Pre-study basal medications include: SUs (gliclazide, glibenclamide, or glimepiride); Glinides (nateglinide , mitiglinide, or repaglinide); BGs (metformin); TZDs (pioglitazone); and α-GIs (acarbose, voglibose, or miglitol).
1670214|NCT01697566|Drug|Metformin|"Participants gradually increase the dose of metformin by mouth as listed below:
Week 1: One capsule each day Week 2: One capsule 2 times each day Week 3: One capsule 3 times each day Week 4: Two capsules 2 times each day
After week 4, participant continues to take 2 capsules of metformin 2 times each day.
Each capsule is 425 mg."
1670215|NCT01697566|Other|Placebo|Placebo taken by mouth twice daily for 4, 30 day cycles.
1670216|NCT01697566|Procedure|Endometrial Biopsy|Endometrial biopsies obtained at baseline and after 4 months.
1670217|NCT01697566|Behavioral|Lifestyle Intervention|Lifestyle intervention consists of 16 in-person sessions offered over a 4 month period.
1670220|NCT01697553|Other|Home without automation pack coupled to teleassistance service|
1670221|NCT01697527|Biological|aldesleukin|Given SC
1670222|NCT01697527|Drug|fludarabine phosphate|Given IV
1670223|NCT01697527|Drug|cyclophosphamide|Given IV
1670224|NCT01697527|Other|laboratory biomarker analysis|Correlative studies
1670225|NCT01697527|Biological|NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL|Undergo NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL
1670226|NCT01697527|Biological|dendritic cell vaccine therapy|Given NY-ESO-1-157-165 peptide pulsed dendritic cell vaccine ID
1670227|NCT01697527|Radiation|fludeoxyglucose F 18|Undergo PET scan using [18F] FDG tracer
1670228|NCT01697527|Procedure|positron emission tomography|Undergo fludeoxyglucose F18 PET
1670229|NCT01697514|Drug|LY2940680|Capsule administered orally.
1670230|NCT01697514|Drug|LY2940680|Powder administered orally (may be sprinkled on soft food).
1670231|NCT01697501|Other|Interleukin 28B testing|Blood sampling for IL28B genotyping
1670232|NCT01697475|Behavioral|Motivational text messaging|Motivational text messaging was given for participants in the intervention group - 3 times a day, 3 times a week, for 6 weeks
1670233|NCT01697436|Drug|ribavirin [Copegus]|tablet under fed condition
1670234|NCT01697436|Drug|ribavirin [Copegus]|tablet under fasted condition
1670235|NCT01697436|Drug|ribavirin [Copegus]|oral solution under fed condition
1670236|NCT01697436|Drug|ribavirin [Copegus]|oral solution under fasted condition
1670237|NCT01697423|Drug|platelet-rich plasma|
1670238|NCT01697423|Drug|durolane|
1670239|NCT01697410|Drug|Terlipressin|continuous infusion of terlipressin (0.66ug/min-2.66ug/min) ,dosage modified acorrding to blood pressure
1670240|NCT01697410|Drug|Norepinephrine|continuous infusion with dose 7.5ug/min-30ug/min,modified acorrding to blood pressure
1670241|NCT01697384|Drug|histrelin acetate|52 week implant
1670244|NCT01697358|Device|Spinal Cord Stimulation (SCS)|Spinal Cord Stimulation (SCS) using the Medtronic Specify 5-6-5 multicolumn surgical lead. Subjects will undergo an SCS screening test and, if successful, an implantable neurostimulation system implant. Any SCS group subject not implanted will continue to be treated with OMM and will be followed as part of the SCS group.
1670245|NCT01697358|Drug|Optimal Medical Management (OMM)|The investigator and subject will determine an individual OMM treatment plan, which should include non-investigational pharmacologic agents and/or therapies.
1670246|NCT01697345|Drug|Testosterone|
1670247|NCT01697332|Drug|Hyperpolarized 129Xe gas|800cc of a gas mixture containing 129Xe and nitrogen will be inhaled by a subject. The subject will hold their breath for no more than 16 seconds while a MRI scan is performed. The gas mixture can contain between 20 and 100% xenon.
1670248|NCT01697319|Drug|BMN 110|Drug will be delivered through a 4 hour (approximate) IV infusion at a dosage amount of 2.0 mg/kg/week for up to 144 weeks of treatment.
1670249|NCT01697306|Drug|Gemcitabine 2 g|six weekly instillations of gemcitabine (Gemzar, Eli Lilly SpA), 2.000 mg diluted in 50 cc of saline
1670250|NCT01697306|Drug|BCG Vaccine|six weekly instillations of Connaught strain BCG (Immucyst) 1/3 dose (27 mg) diluted in 50 cc of saline
1670251|NCT01697293|Drug|Cyclophosphamide|Given IV
1670252|NCT01697293|Drug|Doxorubicin Hydrochloride|Given IV
1670253|NCT01697293|Other|Laboratory Biomarker Analysis|Correlative studies
1670254|NCT01697293|Drug|Paclitaxel|Given IV
1670255|NCT01697293|Procedure|Therapeutic Conventional Surgery|Undergo modified radical mastectomy, radical mastectomy, segmental mastectomy or lumpectomy with an axillary lymph node dissection or biopsy
1670256|NCT01697293|Drug|Triciribine Phosphate|Given IV
1670257|NCT01697280|Behavioral|Vaccine promotion messages|"The messages will be low-literacy, of very short duration, and will be delivered with the help of pictorial cards. These educational messages will include the following messages:
Vaccines can save a child's life
Children who are immunized on time are less likely to become ill
Unimmunized children can become disabled for life
Photograph of the nearest EPI center where vaccines are offered free of charge, as well as its address and timings."
1670258|NCT01697280|Other|Vaccination Verification.|EPI vaccinators/volunteers will identify and record details of un/under-vaccinated children less than 12 months old in households they visit during an NID, and update immunization registries maintained at the local EPI centers so these children can be reached in subsequent outreach activity.
1670259|NCT01697280|Other|Distribution of Plastic Pouches to retain vaccination card|At the start of this project, all EPI centers in the study areas will be provided with plastic pouches to be given to parents of all children coming to EPI centers for vaccinations. These pouches will be used to store a child's immunization card.
1670260|NCT01697267|Biological|Rituximab|Rituximab IV infusion 1000 mg x 1 dose at months 4, 8, 12, 16 and 20 and glucocorticoids. Four - six hour infusion. Treatment with rituximab will cease at month 20.
1670261|NCT01697267|Drug|Azathioprine|"Oral dosage form. Target dose is 2mg/kg; maximum daily dose is 200mg. This should be continued until month 24. The dose should then by reduced by 50% and azathioprine completely withdrawn at month 27.
The dose should be rounded down to the nearest 25mg. The dose may vary on alternate days e.g. 100mg one day, 150mg the next for patients on an overall dose of 125mg daily.
If patients are aged over 60 years, reduce the dose by 25%. If patients are aged over 75 years, reduce the dose by 50%."
1670262|NCT01697241|Other|Supervised exercise|Patients in the exercise groups will receive two types of exercise, delivered on separate days. One type of exercise is individualized, goal-based neuromuscular training (NEMEX-TJR) in groups with progression guided by the patient's neuromuscular function. The other type of exercise is individualized, intensive resistance training (RT) in groups with each exercise progression guided by load. Each of the two types of exercise will be offered weekly during the 12 week intervention period in sessions lasting 60-70 minutes. Thus, the entire exercise intervention consists of 24 sessions
1672120|NCT01682174|Other|Experimental Drink|
1670263|NCT01697241|Other|Patient education|The patient education program is designed to educate the patients about hip osteoarthritis during 3 sessions of 90 min. duration
1670264|NCT01697228|Dietary Supplement|Vitamin D|
1670265|NCT01697215|Other|AirWave|
1670266|NCT01697189|Behavioral|Fatigue management training|Experimental group took part in a single half-day (4 hours) fatigue management training grounded on Problem Based Learning (PBL).
1670267|NCT01697150|Device|DiAs Diabetes Assistant Wearable Artificial Pancreas Platform|Subjects will spend two nights in a non hospital setting while the Artificial Pancreas Device System is remotely monitored from an adjacent room. Artificial Pancreas Device System is composed of an Android-based cell phone platform operating with a DexCom sensor, OmniPod Insulin Management System and an Insulet iDex remote controller. Communication runs on a tablet. The Control to Range software will be capable of transmitting patient state data to a remote monitoring device. The subject will be trained on the open loop features of the cell phone platform user interface: DexCom displays, Insulin injection history display, bolus function. The subject may use the study pump per his/her usual home regimen and may make adjustments to his/her insulin based on symptoms or SMBG readings.
1670268|NCT01697137|Behavioral|Participant Video and Provider Cueing|Participants will watch a 5-minute video and then select a question about donation to discuss with their primary care provider (provider cueing).
1670269|NCT01697124|Behavioral|SPARK-EC|The CIA study was a 5 month physical activity change intervention that utilized the SPARK-EC curriculum as the intervention. The SPARK-EC curriculum was designed to be a quality, comprehensive physical activity program for the preschool setting. Pre-and Post-intervention assessments were conducted
1670270|NCT01697111|Drug|EE20/DRSP(BAY86-5300)|One tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day
1670271|NCT01697111|Drug|Placebo|One tablet (no active ingredient) / day and one tablet [0.02 mg of ethinylestradiol (β-CDC) and 3 mg of drospirenone] / day, for the first 24 weeks and the later 28 weeks, respectively
1670272|NCT01697111|Drug|Dienogest|Dienogest 1mg twice a day (bid)
1670273|NCT01697098|Drug|Dexamethasone 24 hours|
1670274|NCT01697098|Drug|Dexamethasone 12|
1670275|NCT01697085|Dietary Supplement|Sea buckthorn oil|
1670276|NCT01697085|Dietary Supplement|Placebo oil|
1670277|NCT01697072|Drug|Rilotumumab|Rilotumumab is a fully human monoclonal antibody immunoglobulin G, type 2 (IgG2) against human hepatocyte growth factor/scatter factor (HGF/SF) that blocks binding of HGF/SF to its receptor MET, inhibiting HGF/MET-driven activities in cells.
1670278|NCT01697072|Other|Placebo|Placebo
1670279|NCT01697072|Drug|Epirubicin|Epirubicin is an anthracycline cytotoxic agent.
1670280|NCT01697072|Drug|Cisplatin|Cisplatin is a non-cell cycle specific chemotherapeutic agent.
1670281|NCT01697072|Drug|Capecitabine|Capecitabine is an oral fluoropyrimidine.
1670282|NCT01697059|Drug|Piperacillin + Amoxicillin|
1670283|NCT01697046|Drug|Truvada and Isentress|"Subjects with reported high-risk behavior (and anticipated future high-risk behavior) but no exposure in the immediate past will be the focus of this study.
Participants will be prescribed raltegravir 400 mg BID + Truvada once daily. All study participants will receive a 4-days starter pack. Study participants will be instructed to start study drugs if they expect or experience an exposure of any mucous membrane (oral, urethral, anal) to semen. Subjects who expect or experience these exposures will be instructed to take 1 pill of Raltegravir 400mg and one pill of truvada, followed by a second dose of Raltegravir 12 hours later. From the second day onward, participants will be instructed to take Raltegravir 400 mg BID + Truvada once daily. The first dose should be taken no more than 6 hours before or 6 hours after the expected or actual exposure and continued for 28 days."
1670284|NCT01697020|Drug|Mercaptopurine 20mg/ml oral suspension|50mg
1670285|NCT01697020|Drug|Mercaptopurine 50mg tablet|50mg
1670286|NCT01697007|Biological|HIVIS DNA vaccine|
1670287|NCT01697007|Device|Zetajet|
1670288|NCT01697007|Device|Derma Vax Electroporation|
1670289|NCT01697007|Biological|Modified Vaccinia Ankara (MVA-CDMR)|
1670290|NCT01696994|Other|Laboratory Biomarker Analysis|Correlative studies
1670291|NCT01696994|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
1670292|NCT01696994|Procedure|Ultrasonography|Undergo TVU
1670293|NCT01696981|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
1670294|NCT01696981|Procedure|Sigmoidoscopy|Undergo a flexible sigmoidoscopy
1670295|NCT01696968|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
1670296|NCT01696968|Procedure|X-Ray|Undergo a chest x-ray
1670297|NCT01696955|Biological|Cetuximab|Given IV
1670298|NCT01696955|Other|Laboratory Biomarker Analysis|Correlative studies
1670299|NCT01696955|Drug|Tivantinib|Given PO
1955015|NCT03309501|Drug|Tong-Luo-Qu-Tong Plaster|for 14 days as two courses, daily 1 time.
1955016|NCT03309501|Drug|Qi-Zheng-Xiao-Tong Plaster|for 14 days as two courses, daily 1 time
1670302|NCT01696929|Drug|Tocilizumab|"Therapeutic/Pharmacologic Class of Drug:
Tocilizumab is a recombinant humanized anti-human interleukin-6 (IL-6) receptor monoclonal antibody of the immunoglobulin (Ig) gamma-1 subclass.
Type of Dosage Form:
Concentrate for solution for infusion.
Route of Administration:
Intravenous (i.v.) infusion."
1670303|NCT01696916|Procedure|6-minute walking test|submaximum exercise test
1670304|NCT01696903|Procedure|Pancreaticojejunostomy technique|The anastomosis between jejunum and remnant pancreas has a pivotal impact on the incidence of postoperative pancreatic fistula. by this novel technique the remnant pancreas is intubated into the jejunum without extensive manipulation.
1670305|NCT01696890|Device|integrated follow-up|close interaction between HF clinic and general practitioner in response to telemonitoring alerts. All subjects will be monitored daily for heart rate, blood pressure, and body weight, after which these data are transferred automatically to the general practitioner. This device is custom-made.
1670306|NCT01696890|Device|standard care|no interaction between HF clinic and general practitioner in response to telemonitoring alerts. General practitioner is responsible for adaptations to therapy according to clinical presentation of the patient.
1670307|NCT01696877|Drug|degarelix acetate|Degarelix Acetate is a gonadotropin-releasing hormone (GnRH) receptor antagonist. It works by decreasing the amount of testosterone in the body,which the tumor needs to grow.
1670308|NCT01696877|Drug|Cyclophosphamide|Cyclophosphamide as a potent enhancer of immune responses to GVAX. cyclophosphamide is used as an immune suppressor in many autoimmune disorders.
1670309|NCT01696877|Drug|GVAX|GVAX is GM-CSF-secreting allogeneic cell-based vaccine as immunotherapy for prostate cancer
1670310|NCT01696864|Device|Hand tutor rehabilitation device|A rehabilitation device for the hand
1670311|NCT01696864|Device|Arm tutor rehabilitation device|A rehabilitation device for the arm
1670312|NCT01696851|Other|tests and questionnaires|lung test, depression and self-efficacy questionnaires and Functional testing.
1670313|NCT01696838|Other|electroacupuncture|Patients receive electroacupuncture for 30 minutes with a stimulation frequency of 2 /100 Hz and a stimulation intensity varying from 0.1 to 1.0 mA.3 times per week,the duration is 12 weeks.
1670314|NCT01696838|Other|moxibustion|patients receive herbs-partitioned moxibustion for 2 cones，3 times a week for 12 weeks.
1670315|NCT01696825|Drug|Diazepam tablet, 5 mg, vaginal|Diazepam tablet, 5 mg, moistened and inserted vaginally
1670316|NCT01696825|Drug|Diazepam Suppository, 5 mg, vaginal|Compounded diazepam 5 mg suppository administered vaginally
1670317|NCT01696825|Drug|Diazepam Cream, 5 mg, Vaginal|Compounded diazepam cream, 5 mg, inserted vaginally
1670318|NCT01696812|Procedure|electrode position|
1670321|NCT01696786|Procedure|Oocyte cryopreservation|Oocyte (egg) cryopreservation (freezing) to preserve fertility
1670322|NCT01696773|Other|Tangerine tomato juice|Post-prandial feeding study
1670323|NCT01696773|Other|Red tomato juice|Post-prandial feeding study
1670324|NCT01696760|Drug|acetylsalicylic acid|325 mg twice a day
1670325|NCT01696760|Drug|enoxaparin|40 mg once daily
1670326|NCT01696760|Device|PCD|Wear PCD (Flowtron calf compression). Patients will continue to use PCDs for the duration of their hospitalization. If patients refuse to wear the PCDs, they will be withdrawn from the study.
1670331|NCT01696708|Other|31-Phosphorus RMN Spectroscopy|
1670332|NCT01696695|Drug|Capecitabine|First line capecitabine based oral tablet treatment in line with the effective Summary of Product Characteristics
1670333|NCT01696695|Drug|Chemotherapy|First line chemotherapy according to effective official Summary of Product Characteristics. The study protocol does not specify any particular therapy.
1670334|NCT01696682|Procedure|Narrowed Gastric Conduit|The gastric conduit will be formed much narrower in the intervention arm during minimally invasive esophagectomy
1670335|NCT01696682|Procedure|Widened Gastric Conduit|A widened gastric tube will be formed during the surgery
1670336|NCT01696669|Drug|Chemotherapy|"Vincristine, 2 mg/m^2 IV bolus, day 1.
Doxorubicin: 75 mg/m^2 per cycle, or 25 mg/m^2/day x 3 days, IV infusion, 1 hour (after dexrazoxane administration at the dose of 10:1).
Dexrazoxane: administered at a dose of 10:1, before doxorubicin only in adults.
Cyclophosphamide: 2100 mg/m^2 IV infusion, 6 hours, with MESNA protection, days 1 and 2.
MESNA: used with cyclophosphamide and ifosfamide. The total daily dose of MESNA is equivalent to at least 60% of the daily dose of cyclophosphamide or ifosfamide.
G-CSF: 5 micrograms/kg/day SC. It starts 24 hours after the last dose of chemotherapy and continues until the absolute neutrophil count is ≥ 750 mm^3/L.
Ifosfamide: 1800 mg/m^2/day IV infusion, 1 hour, days 1-5 of each cycle (9,000 mg/m^2 total maximum dose).
Window phase in high-risk patients (21-days cycle):
Gemcitabine: 1000 mg/m^2 IV, 90 minutes on day 1 and 8.
Docetaxel 100 mg/m^2, 2-3 hour infusion on day 8."
1670337|NCT01696669|Procedure|Surgery|Surgical intervention aiming to completely resect the tumor with negative margins.
1670338|NCT01696669|Radiation|Radiotherapy|On the primary tumor bed in case of unresectable tumors, resected tumors with inadequate margins, or those with histologic response <90%. Patients will receive radiotherapy 21 days after the completion of chemotherapy.
1670339|NCT01696656|Drug|Drug prescription pattern|Type, dosage, administration route and frequency of prescription of all adjuvant pharmacologic agents will be transcribed from hospital records
1670340|NCT01696643|Drug|CB-5945|
1670341|NCT01696643|Drug|Placebo|
1670342|NCT01696630|Drug|Xenon|
1670343|NCT01696630|Drug|Desflurane|
1670344|NCT01696617|Drug|Aripiprazole 6-week group|
1670345|NCT01696617|Drug|Aripiprazole 8-week group|
1670346|NCT01696604|Drug|GSK2849466|GSK2849466 will be available as capsules of dose strengths 0.01, 0.1, 1.0, and 2.5 mg.
1670347|NCT01696604|Drug|Placebo|Matching placebo capsules will be available.
1670348|NCT01696591|Biological|NEUROSTEM®-AD|NEUROSTEM®-AD was administered to eligible subjects in the early part of the Phase I clinical study. In this follow-up study, no intervention will be performed.
1670349|NCT01696578|Behavioral|BF-CBT and group physiotherapy|Multivitamin+10 individual therapy sessions (BF-CBT) and 10 group therapy sessions (physical exercises) on a weekly basis
1670350|NCT01696565|Drug|PG2|Injectable
1670351|NCT01696552|Procedure|TKR with Positioning Guides (PSPG)|TKR (Vanguard Total Knee System, Biomet) with PSPG (Signature, Materialise) technique
1670352|NCT01696552|Procedure|TKR with Conventional Technique|TKR (Vanguard Total Knee System, Biomet) with Conventional Technique
1670353|NCT01696539|Behavioral|Walking Intervention|Participants are provided with the current standard of prostate cancer care, and are additionally encouraged to walk 10,000 steps per day, as measured by pedometers provided at start of intervention. Once a week, participants will take part in a group walk with 7-8 other participants and a research nurse. Participants are also encouraged to keep a walking journal, in which they record the number of steps they walk each day. This journal is submitted to investigators at the end of the intervention period.
1670354|NCT01696539|Other|Standard of Care|Participants are provided with the current standard of prostate cancer care, but are not assigned to a physical activity intervention.
1670355|NCT01696526|Other|vitamin D fortified fish|fish containing vitamin D3
1723355|NCT00004776|Drug|topiramate|
1670356|NCT01696526|Other|conventional fish|fish containing low concentrations of vitamin D3
1670357|NCT01696513|Procedure|Suction|
1670358|NCT01696513|Procedure|Subcision|
1670359|NCT01696500|Drug|Intravenous immunoglobulin|
1670360|NCT01696487|Dietary Supplement|High oral Fructose challenge (150g per day for 28 days)|
1670362|NCT01696461|Drug|Plerixafor|
1670363|NCT01696448|Dietary Supplement|CAR-191|Patients will be randomized to the CAR-191 intervention group in a 3:1, CAR0-191:placebo ratio. There will be 30 patients in the CAR-191 treatment group.
1670364|NCT01696448|Other|Placebo|Patients will be randomised in a 3:1 ratio. There will be 10 patients in the placebo group.
1670365|NCT01696435|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
1670366|NCT01696435|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
1670367|NCT01696435|Dietary Supplement|Fish oil placebo|Fish oil placebo
1670368|NCT01696435|Dietary Supplement|Vitamin D placebo|Vitamin D placebo
1670369|NCT01696422|Biological|Dengue 1,2,3,4 (attenuated) vaccine|Dose 1000 PFU per virus (1,2,3,4) Route:subcutaneous
1670370|NCT01696422|Biological|TetraVax-DV Vaccine - Admixture TV003|Dose 1000 PFU per virus (1,2,3,4) Route: subcutaneous
1670371|NCT01696422|Other|Placebo|Route:subcutaneous
1670372|NCT01696409|Dietary Supplement|400 IU vitamin D3|Take 400 IU once/day for 2 months
1670373|NCT01696409|Dietary Supplement|2000 IU vitamin D3|2000 IU vitamin D3 once/day for 2 months
1670374|NCT01696396|Drug|AMG 181|Investigational Product. AMG 181 is a monoclonal antibody that binds the human alpha-4-beta-7 heterodimer
1670375|NCT01696396|Other|Placebo|Placebo control
1670376|NCT01696383|Drug|Travoprost 0.004%/Timolol 0.5% Fixed Combination (DuoTrav)|One drop self-administered topically to the study eye(s) once daily every evening at 8:00 pm for 12 weeks
1670377|NCT01696370|Drug|Trimetazidine|Trimetazidine 20mg three times per day for 3 months
1670378|NCT01696370|Other|Placebo capsule|one capsule three times per day for 3 months
1670379|NCT01696357|Device|Automated Device for Asthma Monitoring (ADAM)|Both groups of adolescents (asthma/non-asthma)wore a prototype ADAM device for 7 days as they went about their usual daily activities. At night, the device continued to monitor symptoms as it was placed in close proximity to the adolescent's head during sleep. The asthma group answered survey questions about the status of their symptoms and their usage of asthma medication every morning and every evening- entering their answers directly onto the monitoring device.
1670380|NCT01696344|Procedure|PVAI|
1670381|NCT01696344|Procedure|PVAI + ablation of extraPV triggers|PVAI followed by ablation of extra-PV triggers originating from sites other than pulmonary veins such as superior vena cava, ligament of Marshall, coronary sinus, crista terminalis, left atrial (LA) posterior wall and LA appendage
1670382|NCT01696331|Behavioral|Text Message Reminder|Sent TM reminder at beginning and end of each month that corresponded to required lab frequency. Patients were able to send autoresponses.
1670383|NCT01696318|Behavioral|Support for the Family Health Team|Participation in physical educator, dietitian and pharmacist in primary health care
1670384|NCT01696305|Device|Hyalobarrier|
1670385|NCT01696305|Device|Guardix-SG|
1670386|NCT01696279|Drug|Lanthanum carbonate|Subjects will receive Lanthanum carbonate orally at a total daily dose of 1500 mg to 3000 mg divided equally between three meals.
1670387|NCT01696279|Drug|Calcium carbonate|Subjects will receive Calcium carbonate orally at a total daily dose taken by the subject prior to starting the study or equivalent. For new subjects, dosing will be based on standard clinical practice. The total daily dose may be adjusted as appropriate, until the target serum phosphorus level is achieved or until a maximum daily dose of 6500mg is reached.
1670388|NCT01696266|Other|No treatment given|Patients will be asked to complete a two-part patient self-assessment questionnaire (SAQ) comprising a retrospective cross-sectional evaluation (Part 1), and a prospective observational evaluation (Part 2).
1670389|NCT01696240|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
1670390|NCT01696240|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
1670391|NCT01696227|Drug|Nissle 1917|Uropathogens will be challenged to share the same in vitro environment with Nissle 1917.
1670392|NCT01696214|Drug|Fluticasone 250 mg/salmeterol 50 mg|Drug: Fluticasone 250 mg/salmeterol 50 mg Participants will be assigned to a 24 week treatment with inhaled fluticasone/salmeterol or matching placebo
1670393|NCT01696214|Drug|Montelukast 10mg|Participants will be assigned to montelukast once a day for 24 weeks.
1670394|NCT01696214|Drug|Theophylline 400 mg|Participants will be assigned to theophylline once a day for 24 weeks
1670395|NCT01696214|Drug|ipratropium|Participants will be assigned to ipratropium 2.5 mL of 0.02% solution via mini nebulizer 3 times a day day for 24 weeks.
1670396|NCT01696201|Behavioral|Exercise group|"Supervised physical conditioning program of three 55—60 minute sessions per week during whole pregnancy (from week 9 to 38). Each session consists of 25-30 minutes of cardiovascular exercise,10 minutes of specific exercises (strength and balance exercises), and 10 minutes of pelvic floor muscles training.
Aerobic activity was prescribed at light to moderate intensity, aiming for 55-60 of maximal heart rate. All subjects wore a heart rate (HR) monitor (Polar FT7) during the training sessions to ensure that exercise intensity was light to moderate."
1670397|NCT01696188|Device|interscalene nerve catheter|
1670398|NCT01696162|Other|Algorithm based Exercise Videos|The algorithm will adjust the exercises in each session based upon the participant's feedback.
1670399|NCT01696162|Other|PDF Exercise Sheets|A sheet of six exercises with descriptions on how to perform them properly
1670400|NCT01696162|Other|Limited Exercise Videos|Video of 6 exercises that provide instruction on how to perform the exercises
1670604|NCT01694407|Drug|Placebo Vaginal Tablet|Vaginal Tablet containing no drug
1670401|NCT01696149|Device|transcutaneous electrical nerve stimulation|All subjects participated, randomly, in a 4 Hz TENS session, a 110 Hz TENS session, and a control (off-TENS) session. Each session consisted of a 20- minute stimulation period and a 10-minute follow up period.
1670402|NCT01696136|Device|Cardiac ablation for Atrial Fibrillation|Cardiac ablation for Atrial Fibrillation
1670403|NCT01696123|Drug|MLC601|It was described
1670404|NCT01696110|Drug|Bivalirudin|Patients would be given anticoagulant therapy with bivalirudin in acute myocardial infarction during emergency PCI operation.
1670405|NCT01696110|Drug|heparin|heparin monotherapy
1670406|NCT01696110|Drug|heparin plus tirofiban|combined use of heparin and tirofiban during PCI
1670407|NCT01696097|Behavioral|DASH diet counseling|Comparison of protein source (chicken and fish vs. pork) as part of DASH diet on blood pressure regulation and blood lipids.
1670408|NCT01696084|Drug|CPX-351|First induction: 100 units/m2 by 90-minute IV infusion on Days 1, 3, 5. Second induction: 100 units/m2 by 90-minute IV infusion on Days 1 and 3. Consolidation therapy: 65 units/m2 by 90-minute IV infusion on Days 1 and 3.
1670409|NCT01696084|Drug|7+3 (cytarabine and daunorubicin)|"First induction: 7+3 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 7 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1, 2, and 3.
Second induction: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2.
Consolidation therapy: 5+2 was administered as: cytarabine at a dose of 100 mg/m2/day on Days 1 through 5 by continuous infusion, and daunorubicin at a dose of 60 mg/m2/day on Days 1 and 2."
1670410|NCT01696071|Drug|Tiotropium 5 mcg qd|2 puffs (2.5 mcg each) in the evening 5 mcg in total and 2 puffs of matching placebo in the morning
1670411|NCT01696071|Drug|Tiotropium 2.5 mcg bid|2 puffs (1.25 mcg each) twice daily, in the evening and in the morning, 5 mcg in total
1670412|NCT01696058|Drug|Tiotropium|marketed product
1670413|NCT01696058|Drug|Placebo matching Olodaterol|one dose
1670414|NCT01696058|Drug|Tiotropium|marketed product
1670415|NCT01696058|Drug|Olodaterol|one dose
1670416|NCT01696045|Biological|Ipilimumab|
1670417|NCT01696032|Drug|SGI-110 and carboplatin|
1670418|NCT01696032|Drug|Treatment of Choice ( topotecan, pegylated liposomal doxorubicin, or paclitaxel)|Investigator may choose to treat with either topotecan, pegylated liposomal doxorubicin, or paclitaxel
1670419|NCT01696019|Other|Fast walking|Participants assigned to this group met with two group leaders three times per week in the morning in Jing An Park and were encouraged to walk quickly around a 400 meter circular route. Each session consisted of 10 minutes of warm-up stretching, 30 minutes of brisk walking, and 10 minutes of cool-down exercises. Prior to the first session, each participant was given a pedometer with their name on it. They were asked to take 100 steps and the sensitivity and positioning of the pedometer was adjusted to assure accurate measurement. At the termination of each session, the pedometers were collected and the number of steps taken by each participant at that session recorded. A record of the number of steps taken for every participant at each session over the 40 week period was maintained.
1670420|NCT01696019|Other|Tai Chi|Participants assigned to this group met with a Tai Chi master and assistant three times per week in the morning in Jing An Park or at a nearby gymnasium depending on weather conditions. Each session included 20 min of warm-up exercises (lower back and hamstring stretching, gentle calisthenics, and balance training), 20 min of Tai Chi practice, and 10 min of cool-down exercises.
1670421|NCT01696019|Other|Intellectual stimulation|Participants assigned to this group met with a group leader and an assistant for one hour three times a week in the morning at the neighborhood community center. Although direction was initially given regarding subjects for discussion, the participants decided on their own to organize and select topics themselves.
1670422|NCT01696019|Other|Contact and testing only|
1670423|NCT01695993|Device|Acupressure bands|Bilateral acupressure wrist bands (Sea-Band International, England), given to patients in trial Arms 2 and 3, are widely available and inexpensive (under $6.00 a pair).
1670424|NCT01695993|Other|Version 1 handout|The Version 1 handout has less information concerning the acupressure bands than the Version 2 handout.
1670425|NCT01695993|Behavioral|Version 1 MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery.
1670426|NCT01695993|Other|Version 2 handout|The Version 2 handout has more information concerning the acupressure bands than the Version 1 handout.
1670427|NCT01695993|Behavioral|Version 2 MP3|Patients will be given a portable MP3 player and relaxation MP3 that is about 12 minutes in length with a flute music background and guided imagery. The MP3 (for subjects randomized to Arm 3) has some additional information in it regarding relaxation.
1670428|NCT01695980|Procedure|ETT with non modified retractor|adenotonsillectomy
1670429|NCT01695980|Other|LMA with modified retractor|LMA with modified retractor
1670430|NCT01695967|Procedure|turbinate cauterization|
1670439|NCT01695928|Device|Extracorporeal shockwave therapy|1000 impulses
1670440|NCT01695928|Device|ESWT placebo|0 impulses, acoustic effect
1670441|NCT01695915|Procedure|Transabdominal ultrasound|Transabdominal ultrasound are applied to the subjects every third hour during the study and every hour for three hours after a bowel movement.
1670442|NCT01695902|Drug|Levosert-20|
1670443|NCT01695902|Drug|Mirena|
1670444|NCT01695876|Drug|AMG 357|Oral administration available in varying dose strength.
1670445|NCT01695876|Drug|Placebo|Matching placebo to AMG 357 containing no active drug
1670446|NCT01695863|Drug|comparing 2 drugs on their effect on the bowel preparation for colonoscopy|the effects of the drug on the colon preparation for colonoscopy
1670447|NCT01695850|Drug|MZRW|Patients are instructed to dissolve a sachet of granules (7.5g) in 150ml of hot water; they take this solution orally twice daily for 8 weeks.
1670448|NCT01695850|Drug|Senna|Patients are instructed to take 2 tablets at the bedtime for 8 weeks.
1670449|NCT01695850|Drug|placebo|The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
1670450|NCT01695837|Behavioral|Group A: Dietary counseling month 0-6 Group B: Dietary counseling month 3-6|
1670451|NCT01695824|Device|LAA occluder|The procedure is performed under transesophageal echocardiographic (TEE) guidance. After a transseptal puncture is performed, a pigtail catheter is maneuvered into the LAA to perform an LAA angiogram. Through the use of a combination of this angiographic and TEE information, a Watchman device, ranging in size between 21 and 33 mm in diameter, is selected. The device comes prepackaged in a catheter-based delivery system that is advanced into the LAA through a 12F transseptal sheath (outer diameter, 14F). Proper positioning and stability of the device are verified by TEE and angiography before device release.
1670452|NCT01695824|Procedure|RFA ablation|The left atrium (LA) and pulmonary veins (PVs) were explored through a transseptal approach. Real-time three-dimensional (3D) LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in 1 lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43◦C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43◦C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 seconds. The endpoint of circumferential PV isolation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from left atrial activity.
1670453|NCT01695824|Drug|Warfarin|"Warfarin was discontinued in 45 days after procedure in case of no trombus by TE for Watchman group
All patients in Warfarin group continued to receive Warfarin during hole study period with IMR from II to III."
1670454|NCT01695798|Biological|Injectable polio vaccine and Bivalent oral polio vaccine|"One dose of IPV given IM (arm, thigh) to infant aged 9-12 month after randomization.
There will be two groups Chronic Malnourished group and Non-Malnourished group. Each group has two arms, which were randomized on IPV+bOPV and bOPOV alone"
1670455|NCT01695772|Drug|5-FU based doublet chemotherapy|Standard 5-FU based doublet chemotherapy. Protocol did not specify any particular chemotherapy regimen. The choice of 5-FU based doublet chemotherapy was as per standard of practice and the dosage of 5-FU based doublet chemotherapy was as per product labels.
1670456|NCT01695772|Drug|bevacizumab|5 mg/kg every 2 weeks, up to 12 cycles pre- and postoperatively
1670457|NCT01695759|Drug|Epoetin alpha|The drug will be administered subcutaneously and the initial dose is 50 IU / kg. This dose will be administrated twice/week, totaling 100 U / kg / week.
1670458|NCT01695759|Drug|Eprex|The drug will be administered subcutaneously and the initial dose is 50 IU / kg. This dose will be administrated twice/week, totaling 100 U / kg / week.
1670459|NCT01695746|Drug|C.E.R.A.|Participants receiving 0.6 mcg/kg of C.E.R.A. once every two weeks for correction of anemia and conversion to C.E.R.A. dose 120, 200, or 360 mcg either once monthly; or 60, 100, or 180 mcg once every 2 weeks for maintenance of Hb according to local clinical practice or prescribing information will be observed.
1670460|NCT01695733|Biological|trivalent influenza vaccine|
1670461|NCT01695720|Procedure|VisionScope Imaging (VSI) Exam|The VisionScope Imaging (VSI) Exam [the system itself] is indicated for use in diagnostic and operative arthroscopic and endoscopic procedures to provide illumination, visualization, and the capture of still and motion pictures of an interior cavity of the body through a natural or surgical opening.
1670462|NCT01695707|Drug|Pioglitazone|see Arm Description
1670463|NCT01695707|Drug|Placebo (for pioglitazone)|see Arm Description
1670464|NCT01695694|Behavioral|supporting positive and healthy relationships|
1670465|NCT01695694|Behavioral|community support group|
1670466|NCT01695681|Other|Gluten-free diet|Dietary advice by clinical dietitian
1670467|NCT01695668|Drug|Lotemax|Ophthalmic corticosteroid. It decreases inflammation of the eye
1670468|NCT01695668|Drug|Restasis|Restasis is an immunosuppressive agent. Cyclosporine may reduce inflammation in the eye.
1670469|NCT01695616|Drug|Placebo|
1670470|NCT01695616|Drug|Active drug|
1670471|NCT01695603|Device|Intellivent|
1670472|NCT01695590|Drug|PRLX 93936|PRLX 93936 administered IV 3 days a week (Monday, Wednesday and Friday) for 3 weeks followed by a 9 day rest period = 1 cycle, multiple cycles may be administered
1670473|NCT01695577|Other|Multidisciplinary evaluation and VR|Multidisciplinary assessment and evaluation and VR - Vestibular rehabilitation and balance training. Individually adjusted exercises in groups twice a week for two months. Home exercise program.
1670474|NCT01695577|Other|Multidisciplinary evaluation|Multidisciplinary assessment and evaluation.
1670477|NCT01695551|Other|Data Collection Forms|Participants will be asked questions relating to pre-procedure items and be asked to complete an MMSE. Subjects receive standard of care surgery. Data collected from procedures before, during and after surgery.
1670478|NCT01695538|Other|Yoga|The subjects will be asked to practice Yoga poses at least 3 times a week at home, although daily Yoga will be encouraged. Participants will be trained in breathing exercises, postures and meditation. Each time they practice yoga will be for 1 hour and include breathing exercises, postures and meditation.
1670479|NCT01695525|Other|Yoga|Includes breathing exercises, postures, and meditation. Participant practices yoga at their home a minimum of 3 times per week for 1 hour per time. Participation can last for up to 1 year.
1670605|NCT01694394|Device|Implantable Cardiac Monitor (Confirm(R)ICM model 2102)|
1670606|NCT01694355|Drug|Vitamin D|
1670480|NCT01695473|Drug|BKM120|Two weeks after confirmatory biopsy, patients will begin taking 100 mg/day of BKM120. BKM120 will be given at this dose level orally once daily for 14 days prior to radical prostatectomy. Radical prostatectomy will be performed on the day of the last dose of BKM120 at day 14. No further drug will be administered after radical prostatectomy. For unforeseen delays in OR scheduling, up to 7 additional days of BKM120 may be administered prior to surgery.
1670481|NCT01695460|Drug|D3 Vitamin ®|"Vitamin D and placebo supplied as tablets in containers of 124. The containers must be kept in dry and not too hot environment.
All subjects randomized to vitamin D, will receive 100 micrograms of vitamin D3/day, equivalent to 4000 IU. Vitamin D is administered orally 1 time a day with breakfast."
1670482|NCT01695460|Drug|Placebo|
1670483|NCT01695447|Procedure|duct-to-mucosa|
1670484|NCT01695447|Procedure|invagination|
1670485|NCT01695447|Device|Internal stent|Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
1670486|NCT01695434|Other|MRI|All subjects will undergo a MRI.
1670487|NCT01695421|Procedure|Medium-frequency alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
1670488|NCT01695421|Procedure|Burst-modulated alternating current|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction.
1670489|NCT01695421|Procedure|Placebo|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be fixed on 5 mA.
1670490|NCT01695421|Procedure|Functional electrical stimulation|The subjects will receive stimulation to quadriceps and gastrocnemius for 5 days a week for 1 hour during 5 weeks. Electrical stimulation will be delivered through channel one with one electrode placed over the vastus medialis and the second electrode placed medial and distal to the greater trochanter. The channel two will be place on the gastrocnemius with one electrode positioned over the muscle belly and the second over the musculotendinous junction. The stimulus will be on for 10 seconds followed by a 30 second relaxation period at the first two weeks. Subsequently, the EMS stimulus will be on for 15 seconds followed by a 30 second relaxation period. The intensity will be turned up to the maximal tolerable intensity as reported by the subject (10-100 mA) observing muscular contraction
1670491|NCT01695382|Behavioral|Navigation|As per Arm description
1670492|NCT01695369|Device|Senofilcon A; Comfilcon A|Senofilcon A; Comfilcon A
1670493|NCT01695369|Device|Comfilcon A; Senofilcon A|Comfilcon A; Senofilcon A
1670494|NCT01695356|Drug|290-400 nm sunscreen|A broad UV spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm^2 layer of the product as indicated on the affected areas of the face.
1670495|NCT01695356|Drug|290-800 nm sunscreen|A UV-visible light spectrum sunscreen will be applied every 3 hours for 12 weeks. The affected surface will be covered with a 2 mg/cm^2 layer of the product as indicated on the affected areas of the face.
1670496|NCT01695343|Biological|KB001-A|
1670497|NCT01695343|Drug|Placebo Comparator|
1670498|NCT01695330|Drug|Subcutaneous bortezomib|Bortezomib will be administered SC at a dose of 1.0 mg/m2. Doses are to be administered on days 1, 4, 8, and 11 of a 28-day cycle. All other drugs used in combination with the SC bortezomib as well as their doses and schedules will be at the discretion of the Principal Investigator.
1670499|NCT01695317|Drug|Acetyl-L-carnitine|Week 1: 500 mg x 3, Week 2-12: 500 mg x 6
1670500|NCT01695304|Other|Ceramic water filter|In total, 120 households with a child 4-10 months old will receive a Cera Maji ceramic water filter for treatment of drinking water at initial entry into the study (intervention group), and 120 households with a child 4-10 months old at initial entry into the study will not receive a ceramic water filter (control group). The study duration will be 6 months. All households in the control group will receive a Cera Maji ceramic water filter when the study ends.
1670501|NCT01695291|Drug|Minocycline|Participants randomized to minocycline will receive approximately 2 mg/kg/day, the FDA-approved dose for minocycline. Participants will take either minocycline or pill placebo for 12 weeks.
1670502|NCT01695291|Other|Placebo|A placebo pill will be administered BID for 12 weeks.
1670503|NCT01695278|Behavioral|Telephone Counseling|Weekly telephone counseling intervention for 16 weeks, used to identify and overcome barriers to diabetes control and set goals for positive behavioral changes supplemented by monthly group classes on skill development.
1670594|NCT01694472|Biological|MAGE-A4 TCR Gene-Modified T Cells|The study consists of a 2-dose escalation scheme, and the patient receives twice in each dose. The starting dose is 1-3 x 10^9 cells of each TCR gene-modified cells and the second one is 3-8 x 10^9 cells of each TCR gene-modified cells. Two weeks after the first infusion the patient receives the same dose again, followed by infusions of IL-2 for 5 days. Thereafter, the patient receives peptide vaccinations on days 21 and 28.
1723356|NCT00004778|Drug|betamethasone|
1670504|NCT01695265|Device|Feel Breathe, restriction device ventilatory nasal in COPD|Device: Feel Breathe, restriction device ventilatory nasal The Feel Breathe (FB) consisted of a small adhesive strip that is place across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacture's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subjet was required to perform three identical submaximal exercises with intensity at 65% of VO2 Peak achieve during a first incremental cardiopulmonary exercise test CPET
1670505|NCT01695252|Other|MEMOS|Patient informed clinical outcomes supervision
1670509|NCT01695226|Drug|celecoxib|pre-operative celecoxib (400 mg) twice daily for two to three weeks
1670510|NCT01695226|Drug|Placebo|pre-operative placebo twice daily for two to three weeks
1670511|NCT01695213|Procedure|uncemented total hip arthroplasty|
1670512|NCT01695200|Dietary Supplement|Omega-3 fatty acids|
1670513|NCT01695187|Drug|NB-001 (0.3%)|Topical administration at least five times throughout the day
1670514|NCT01695187|Drug|Placebo|
1670515|NCT01695174|Drug|Xifaxan|
1670516|NCT01695148|Dietary Supplement|β-Carotene Biofortified Maize Flour|
1670517|NCT01695148|Dietary Supplement|White Maize Flour|
1670518|NCT01695135|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
1670519|NCT01695135|Drug|Placebo|Placebo (4 tablets) taken orally once daily
1670520|NCT01695135|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
1670521|NCT01695122|Drug|Valproic Acid|
1670522|NCT01695109|Drug|Liraglutide|sc injections of 0.6 mg Liraglutide daily for three continuous days.
1670523|NCT01695109|Drug|Placebo|0.9% NaCl, 0.2 ml
1670524|NCT01695096|Other|The Embryos will be cultured on a humidity free incubator|We will set the humidity level to 0.0% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
1670525|NCT01695096|Other|The Embryos will be cultured on a >95% humidity incubator|We will set the humidity level to 95% in the IVF incubator that will be used for culturing the Human embryos after ICSI procedure and we will monitor the outcome embryologically and clinically and record the results.
1670526|NCT01695070|Drug|Melatonin|4mg prolonged release melatonin oral tablets twice daily
1670527|NCT01695057|Drug|vorinostat|Given PO
1670528|NCT01695057|Procedure|therapeutic conventional surgery|Undergo surgery
1670529|NCT01695057|Other|laboratory biomarker analysis|Correlative studies
1670530|NCT01695044|Drug|PSMA ADC|PSMA ADC administered IV at 2.5 mg/kg Q3W for 8 cycles or 2.3 mg/kg Q3W for 8 cycles.
1670531|NCT01695031|Behavioral|Tailored asthma management program|web-based, computer-tailored asthma management intervention delivered every week for 4 weeks
1670532|NCT01695031|Behavioral|Generic web-based education|Generic, web-based asthma education
1670533|NCT01695005|Drug|LY3039478|Administered orally
1670534|NCT01695005|Drug|Prednisone|Administered orally
1670535|NCT01694992|Other|Early mobilization|The Intervention Group - Early Mobilization - will follow the early physiotherapy program within the first 24 - 48 hours after acute ischemic stroke, five times per week for 30 minutes plus time to spent out of bed (sitting).
1670536|NCT01694979|Other|Minimum expiration effort|Subjects perform a forced expiration at minimum effort
1670537|NCT01694979|Other|Moderate expiration effort|Subjects perform a forced expiration at moderate effort
1670538|NCT01694979|Other|Maximum expiration effort|Subjects perform a forced expiration at maximum effort
1670541|NCT01694927|Procedure|Autologous Mesenchymal Stem Cells|Expanded Intralesional Autologous Mesenchymal Stem Cells Transplantation
1670542|NCT01694914|Procedure|corneal graft|
1670543|NCT01694888|Other|lecture|Teaching documentation skill using lecture method
1670544|NCT01694875|Device|APTIMA HPV Assay|In Vitro Diagnostics Assay
1670545|NCT01694862|Procedure|Integrated FP/PNC service delivery|The intervention uses a procedural tool building on existing MoH procedures. It has nine components: strengthening protocols, guidelines and training materials for integrated HIV-SRH care; training, mentorship; developing a mentoring and supervisory package; improving provider capacity; ensuring availability of minimum levels of equipment and supplies for integrated services; support supervision; organizational change (including reviewing use of available rooms) and role clarification; improving availability of IEC/BCC materials on FP and HIV; strengthening the referral system between FP and ART and the data collection and recording systems.
1670546|NCT01694849|Drug|GFT505 80mg|
1670547|NCT01694849|Drug|GFT505 120mg|
1670548|NCT01694849|Drug|Placebo|
1670549|NCT01694836|Biological|s.c. injection|3 years of therapy followed by 2 years (seasons) of treatment-free observational period
1670550|NCT01694823|Drug|CS-ACI|"Procedure: Self-control. Cells Sheet-Autologous Chondrocyte Implantation(CS-ACI) includes an arthroscopy for harvesting of cartilage 6-8 weeks prior to the open cartilage surgery. Other Names:
Cells Sheet-Autologous Chondrocyte Implantation （CS-ACI）"
1670551|NCT01694810|Drug|2% NVN1000 Topical Gel|2% NVN1000 Topical Gel once daily for 4 weeks
1670552|NCT01694810|Drug|4% NVN1000 Topical Gel|4% NVN 1000 4% Topical Gel applied once daily 4 weeks
1670553|NCT01694810|Drug|8% NVN1000 Topical Gel|8% NVN1000 Topical Gel applied once daily for 4 weeks
1670554|NCT01694810|Drug|Vehicle Topical Gel|Vehicle Topical Gel applied once daily
1670555|NCT01694797|Drug|Metoprolol Succinate|
1670595|NCT01694459|Drug|Low-dose heparin|Bolus of 50 UI/Kg of heparin at the beginning of coronary interventions
1670596|NCT01694459|Drug|Standard dose heparin|Bolus of 100 UI/Kg of heparin at the beginning of coronary interventional procedure.
1670597|NCT01694446|Other|Intraduodenal glucose or fructose|
1670598|NCT01694433|Drug|Calcipotriene|1g daily BID
1670599|NCT01694433|Drug|Placebo|1g daily BID
1670556|NCT01694784|Behavioral|Quantitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the quantitative information sheet, harms will be communicated in absolute risks with accompanying fact box (i.e. box containing key facts and rates). In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and the screening test, a description of the possible benefits of the service, and a statement encouraging decision. As an adjunct to numerical information in paragraph form, fact boxes engage individuals to process information and improve understanding.
1670557|NCT01694784|Behavioral|Qualitative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the qualitative information sheet, harms will be communicated using verbal descriptors. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
1670558|NCT01694784|Behavioral|Narrative Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the narrative information sheet, harms will be communicated using patient narratives with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
1670559|NCT01694784|Behavioral|Framed Information Sheet|Patients will read an information sheet about one of the three exemplar services in one of four presentations: quantitative, qualitative, narrative, or framed. In the framed information sheet, harms will be communicated using a gain frame (as described in the arm section above) with accompanying fact box. In addition to information about harms, the information sheet will include the following information: a description of the disease to be detected and screening test, a description of the possible benefits of the service, and a statement encouraging decision.
1670560|NCT01694771|Drug|Tiotropium|Marketed dose
1670561|NCT01694771|Drug|Placebo matching Olodaterol|One dose
1670562|NCT01694771|Drug|Olodaterol|One dose
1670563|NCT01694771|Drug|Tiotropium|Marketed dose
1670564|NCT01694732|Drug|Varenicline|
1670565|NCT01694732|Drug|placebo|
1670568|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
1670569|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
1670570|NCT01694706|Drug|omeprazole|medium dose of omeprazole
1670571|NCT01694706|Drug|faldaprevir|medium dose of faldaprevir
1670572|NCT01694693|Drug|Orencia|No Intervention
1670573|NCT01694680|Dietary Supplement|Lutein-enriched-egg beverage (NWT-02)|Lutein, zeaxanthin and DHA-enriched-egg yolk combined with buttermilk beverage
1670574|NCT01694680|Dietary Supplement|Placebo|color-, taste- and energy-matched powder without enriched egg-yolk
1670575|NCT01694667|Drug|Omega-3 Fatty Acids|Omega-3 fatty acids will be delivered in orange-flavored pudding packets (Coromega®, Vista, CA). Each packet contains 650 mg of omega-3 fatty acids, 350mg of eicosapentanoic acid (EPA), 230mg of docosahexanoic acid (DHA) and 2,000 mg of fish oil 18/12, and will be given twice daily for a daily dose of 1.3 grams of omega-3 fatty acids (and 1.1 grams of DHA + EPA).
1670576|NCT01694667|Other|Placebo|Placebo packets will have same orange-flavored pudding as active Omega-3 fatty acids comparator with an identical appearance and taste, but will include safflower oil instead of the fish oil. One placebo packet will be given twice daily.
1670577|NCT01694641|Other|time-lapse morphokinetic evaluation|embryo selection for transfer based on a combind score made up of scores for kinetic parameters and standard morphology as seen on time-lapse
1670578|NCT01694628|Behavioral|CLIMB (COPD Lifestyle, Mood, and Behavior)|Cognitive Behavioral Therapy delivered to patients via telephone aimed to improve mood and decrease depressive symptoms.
1670579|NCT01694615|Procedure|Cryoprobe biopsy|
1670580|NCT01694615|Procedure|Forceps Biopsy|
1670581|NCT01694602|Biological|(non-radioactive) Oral deuterated 3-methylhistidine (D-3MH)|Oral dose of 9.0 mg (50 μmol) TAU-METHYL-L-HISTIDINE (METHYL-D3), Cambridge Isotope Laboratory, Cambridge, Massachusetts.
1670582|NCT01694589|Drug|LDE-225|LDE-225 capsules will be administered as a fixed dose of 800 mg daily for two weeks.
1670583|NCT01694576|Drug|Adjuvant chemotherapy with paclitaxel and nedaplatin|Patients receive 3 cycles of adjuvant chemotherapy consisting of paclitaxel and platinum after concurrent chemoradiation
1670584|NCT01694563|Device|Synergy Ablation System|"Patient will undergo an elective open cardiac surgical procedure to be performed on cardiopulmonary bypass for one or more of the following:
Coronary Artery Bypass Grafting (CABG)
Mitral valve repair or replacement
Aortic valve repair or replacement
Tricuspid valve repair or replacement The aim of the treatment is a complete bi-atrial Maze IV procedure which includes pulmonary vein isolation coupled with lesions made on both the left and right atria."
1670585|NCT01694537|Drug|DLBS1033|The study drug is enteric coated DLBS1033, which contain 490 mg bioactive protein fraction.
1670586|NCT01694537|Drug|placebo|Placebo is made with same size and shape with study drug.
1670587|NCT01694511|Procedure|HRME+CVC|High resolution magnification endoscopy with computed virtual chromoendoscopy and directed biopsy
1670588|NCT01694511|Procedure|conventional endoscopy|Conventional white light endoscopy with four-quadrant biopsy
1670589|NCT01694498|Drug|A: Desmopressin 25 µg|
1670590|NCT01694498|Drug|B. Desmopressin 50 µg|
1670591|NCT01694498|Drug|Placebo|
1670592|NCT01694485|Biological|AMG 181|Investigational Product AMG 181 is a monoclonal antibody that binds the human alpha-4-beta-7 heterodimer.
1670593|NCT01694485|Other|Placebo|Placebo Control
1670600|NCT01694420|Drug|(FDC) ELV/COBI/FTC/TDF|Antiretroviral treatment
1670601|NCT01694407|Drug|Tenofovir (TFV) Alone Vaginal Tablet|vaginal tablet containing 40 mg of TFV
1670602|NCT01694407|Drug|Emtricitabine (FTC) Alone Vaginal Tablet|Vaginal Tablet containing 40 mg of TFV
1670603|NCT01694407|Drug|TFV and FTC Combined Vaginal Tablet|vaginal tablet with 40 mg TFV and 40 mg FTC
1670607|NCT01694316|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
1670608|NCT01694303|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
1670609|NCT01694290|Other|Chemical Cold Pack|
1670610|NCT01694277|Drug|Masitinib|12 mg/kg/day
1670611|NCT01694277|Drug|Sunitinib|50 mg/day
1670612|NCT01694264|Drug|Entecavir|Entecavir (Baraclude (Bristol-Myers Squibb) 0.5mg.) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
1670613|NCT01694264|Drug|Placebo|Placebo of Entecavir (prepared by Bristol-Myers Squibb) will be taken orally on an empty stomach (2 hours after a meal or at least 2 hours before the next meal), once daily from 1 week before starting anti-TNFα and continue 72 weeks after anti-TNFα is administered.
1670614|NCT01694238|Procedure|Cruciate incision|
1670615|NCT01694238|Procedure|Circular incision|
1670616|NCT01694238|Other|Mesh enforced cruciate incision|
1670617|NCT01694225|Other|bubble packaging for monthly prescription|Monthly bubble packaging among women prescribed anti-estrogens
1670618|NCT01694212|Drug|Perioperative Diclofenac eye-drops administration|
1670619|NCT01694212|Drug|placebo|
1670620|NCT01694199|Device|Pulsed Radiofrequency Energy (PRFE)|The intervention is pulsed radiofrequencyenergy (PRFE).
1670621|NCT01694199|Device|No Pulsed Radiofrequency Energy (PRFE)|Sham (placebo) with no therapeutic device activity
1670622|NCT01694186|Drug|FAI insert|
1670623|NCT01694186|Drug|Sham injection|
1670624|NCT01694173|Other|Stem cell therapy- SPD artery|A total of 28 patients will be enrolled and randomized to four groups of 7 patients each. 7 patients will receive stem cell infusion into the superior pancreaticoduodenal artery. Another 7 patients will be given stem cell infusion into the splenic artery. The next batch of 7 patients will receive stem cell infusion from the peripheral intravenous route and 7 patients will act as controls undergoing a sham procedure with infusion of normal saline.
1670625|NCT01694173|Other|Stem cell therapy- splenic artery|7 patients will receive stem cells infusion through splenic artery.
1670626|NCT01694173|Other|Stem cell therapy-intravenous|7 patients will receive stem cells infusion through peripheral intravenous route.
1670627|NCT01694173|Other|Normal saline placebo -sham procedure|7 patients will receive infusion of normal saline and will act as control groups
1670628|NCT01694160|Drug|Paricalcitol|Zemplar (paricalcitol) 2ug daily, oral intake
1670629|NCT01694147|Device|PiCCO monitoring system|The EVLW measurement will be based on transpulmonary thermodilution method. This method was recently introduced as part of the PiCCO plus system (Pulsion Medical System, Munich, Germany), for monitoring severe sepsis patients being treated in medical ICUs. This method only used a single indicator (cold saline solution), and demonstrated a satisfactory correlation with the gravimetric method. A 4-F arterial catheter (PulsiocathPV2014L16; Pulsion Medical Systems, Munich, Germany) was positioned in the descending aorta via the femoral artery using the Seldinger technique. The femoral arterial catheter and a standard central venous catheter were connected to pressure transducers, and also to an integrated bedside monitor (PiCCO; Pulsion Medical Systems).
1670630|NCT01694134|Drug|Hydrocortancyl.|Patients will receive an intradiscal injection of hydrocortancyl.
1670631|NCT01694134|Drug|Lidocaine|
1670632|NCT01694121|Behavioral|MEN Count|The MEN Count model integrates HIV risk reduction and gender-equity counseling with housing and employment case management via multiple one-on-one sessions delivered by a peer case manager over 60-90 day period.
1670633|NCT01694121|Behavioral|Comparison|general health intervention for men, not inclusive of HIV or relationship health
1670634|NCT01694108|Biological|BCG-vaccine (SSI)|
1670635|NCT01694082|Behavioral|THRIVE|THRIVE stands for (Tertiary Health Research Intervention Via Email). Participants complete questions related to demographics and their alcohol use and receive brief personalized feedback based on this information, in addition to protective behavioral strategies, facts about alcohol and information about available resources to reduce their alcohol use.
1670636|NCT01694082|Behavioral|Brief brochure and assessment control|
1670637|NCT01694069|Drug|Piperacillin-tazobactam combination product|400 mg/kg/day as either intermittent or continuous infusion
1670638|NCT01694056|Other|Soy protein diet|4 weeks high protein diet (20 en%) with 25gr of soy protein per day
1670639|NCT01694056|Other|Control diet|4 weeks high mixed protein diet (20 en%)
1670640|NCT01694043|Other|Healthy Foods|While watching the tv show, participants will receive a healthy snack to eat (grapes and baby carrots).
1670641|NCT01694043|Other|Unhealthy Snack Foods|While watching the tv show, participants will receive an unhealthy snack to eat (potato chips and chocolate chip cookies).
1670642|NCT01694030|Other|Attachment security priming|
1670643|NCT01694017|Drug|Tenofovir|tenofovir 300 mg+ emtricitabine 200 mg + efavirenz 600 mg, once daily, for one year
1670644|NCT01694017|Drug|Zidovudine|zidovudine 300 mg + lamivudine 150 mg + nevirapine 200 mg , once daily, for a year
1670645|NCT01694004|Drug|Benzocaine Infusion into Duodenum|
1670646|NCT01693991|Behavioral|Meaning-Making intervention (MMi)|MMi and attention control sessions will take place weekly for 3 weeks at the patient's home or hospital, as the patient prefers. We will try to limit delays to no more than 1 week if needed (e.g., for recovery from treatment side-effects), but because the feasibility of this schedule is one of the research questions, if more flexibility is required we will not withdraw people from the study if the delay is longer, since a longer intervention period could be incorporated in a full-scale RCT. Dates and duration of each session will be tracked. MMi sessions will be conducted by 2 bilingual mental health professionals (nurse, social worker, or psychologist) with at least 1 year of clinical oncology experience and will be initiated within 1 week after randomization.
1670647|NCT01693991|Behavioral|Empathic visitor|This person will provide the basic ingredients fostering a good therapeutic relationship (i.e., trust, warmth, empathy, neutrality and authenticity) without further intervention or probing. The empathic visitor will be specifically instructed to avoid initiating discussions about meaning (e.g., how the patient interprets his feelings and thoughts, understands his/her illness and meaning in life), and focus discussions on what is currently happening (rather than on the interface between past and present).
1670648|NCT01693978|Behavioral|Prolonged Exposure Therapy|"Prolonged Exposure Therapy is considered the gold standard treatment for PTSD in psychiatry. It uses a cognitive-behavioral approach that repeatedly and systematically exposes patients to memories of their traumatic events to reduce fear and arousal. The PE therapy offered in this study will be based on procedures used by Foa and colleagues, described in their book-length treatment manual (Foa, Hembree, & Rothbaum, 2007)."
1670649|NCT01693978|Behavioral|Voucher-Based Reinforcement|Those in the PE+CM condition will also be able to earn voucher-based incentives for each therapy session that they attend as scheduled, with a maximum of $480 for full adherence to all sessions. Specifically, participants will earn $30 for attending Session 1, $40 for attending Session 2, $50 for attending Session 3, and $60 for attending Sessions 4 through 9. There will be no payment for Sessions 10 through 12. Because it is very important that participants attend sessions on schedule, voucher values will be reset starting from $30 if participants miss a scheduled session. Vouchers can be exchanged for goods and services in the community (e.g., gift cards to local retailers).
1670650|NCT01693965|Other|sputum samples|
1670651|NCT01693952|Biological|blood draw|
1670653|NCT01693926|Behavioral|Acute physical activity intervention|25 min of physical activity. The placebo arm will have 25 min of reading.
1670654|NCT01693926|Behavioral|placebo|
1670655|NCT01693913|Behavioral|cognitive behavioral exercise and nutrition over|
1670656|NCT01693913|Behavioral|nutrition and exercise education|
1670657|NCT01693900|Procedure|Pre-operative Ultrasound FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed under ultrasound guidance with an in-plane technique by a single study investigator in the preoperative area. Although possible without ultrasound guidance, using this technique allows for identification of specific tissue planes and precise placement of medication near the nerves responsible for postoperative pain. Using ultrasound, the superficial fascial layer of the iliopsoas muscle is identified at the anterior edge of the ilium, and a needle is placed just beneath that fascia. A high volume of local anesthetic is then injected under ultrasound guidance, ensuring cephalad spread of medication in an attempt to provide anesthesia of the lateral femoral cutaneous, femoral and obturator nerves.
1670658|NCT01693900|Procedure|Intra-operative FICB Group|Enrolled subjects will receive FICB with 50cc of 0.3% ropivacaine. Blocks will be performed intra-operatively under direct surgeon visualization, in the operating room. Unlike other approaches to hip replacement, anterior repair allows for direct visualization of the fascial layers described above. This allows for direct injection of local anesthetic beneath this fascia, potentially obviating the need for preoperatively performed, ultrasound guided, FICB.
1670659|NCT01693874|Behavioral|MBSR|Mindfulness-Based Stress Reduction
1670660|NCT01693874|Behavioral|control (health education)|health education
1670661|NCT01693822|Drug|Axitinib|"Axitinib treatment Axitinib is an oral VEGF-receptor inhibitor. Patients are prescribed a starting dose of 5mg twice daily, escalating to 10mg in absence of dose limiting toxicities.
Patients should stop axitinib treatment one week prior to day 1 week 9 percutaneous research biopsy of the primary renal tumour and restart 2-3 days post biopsy.
Doses should be taken approximately 12 hours apart and patients should be instructed to take their doses at approximately the same times each day.
Dose adjustments, including dose increase or dose reduction, are permitted and should be based on clinical judgement and the guidelines provided in the protocol."
1670662|NCT01693809|Drug|Caffeine|
1670663|NCT01693796|Other|blood and urine samples ; Echography|
1670664|NCT01693783|Biological|Ipilimumab|Given IV
1670665|NCT01693783|Other|Laboratory Biomarker Analysis|Correlative studies
1670666|NCT01693770|Procedure|MRgFUS|Focused ultrasound energy is accumulated into the target tissue (skeletal metastasis) thanks to the real time guidance of the MR images.
1670667|NCT01693718|Drug|Hydroxyurea|Hydroxyurea at 1gm(PO)12hrs x 11days(2gm/day). The first daily dose of hydroxyurea on days 1-5 is given 2 hrs prior to the first fraction of daily radiotherapy.
1670668|NCT01693718|Drug|5- Fluorouracil|"Start continuous infusion of 5-Fluorouracil at 800mg/m2/day x 5 days (120 hrs.
Radiation therapy is administered twice daily at 150 cGY per fraction, every other week with chemotherapy."
1670669|NCT01693718|Drug|Cisplatin|Cisplatin 100mg/m2 I.V. on the evening of the day 1, on cycles 1,3,and 5 only in 200cc NS IV over 2 h. Ensure adequate hydration to keep urine output > 100 cc/ hour.
1670670|NCT01693705|Procedure|Tracheostomy|
1670671|NCT01693692|Drug|TD-9855 Group 1|
1670672|NCT01693692|Drug|TD-9855 Group 2|
1670673|NCT01693692|Drug|Placebo|
1670674|NCT01693679|Drug|Telbivudine, Lamivudine, Adefovir ,Enecavir|investigational Telbivudine,600mg,daily,oral.comparator Lamivudine,100mg daily, oral,Adefovir,10mg,daily,oral,Enecavir,0.5mg,daily,oral.
1670675|NCT01693666|Behavioral|Lifestyle intervention|"To establish an effective contingency management behavioral program (LIFE), increasing adherence to nutritional recommendations and exercise guidelines during pregnancy.
To examine the impact of the LIFE program on weight gain restriction during pregnancy and postpartum weight loss in obese women in comparison to the RC group.
To examine the impact of the LIFE program on short- and long-term maternal and offspring outcomes at study enrollment, 34-36 weeks gestation and 3 months postpartum in obese women in comparison to the RC group."
1670677|NCT01693640|Drug|Abatacept|Weekly injections with Abatacept 125 mg over 6 months
1670678|NCT01693627|Device|Pinnacle/Corail with collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collared femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
1670679|NCT01693627|Device|Marathon/Corail with collar|Reversed hybrid THA using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collared femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
1670680|NCT01693627|Device|Pinnacle/Corail without collar|Uncemented THA using Pinnacle-100/Marathon XLPE(Depuy, Warsaw, IN) acetabular component and Corail(Depuy,Warsaw,IN)collarless femoral stem with 32mm Alumina Biolox Forte(Depuy,Warsaw,IN). Tantalum beads will be inserted into periprosthetic bone.
1672656|NCT01678066|Device|Bilateral cardiac output|
1670681|NCT01693627|Device|Marathon/Corail without collar|Reversed hybrid total hip arthroplasty using cemented Marathon XLPE(Depuy,Warsaw,IN) acetabular component and an uncemented Corail(Depuy,Warsaw,IN)collarless femoral component with 32 mm Alumina Biolox Forte(Depuy,Warsaw,IN)head. Tantalum beads will be inserted into periprosthetic bone.
1670682|NCT01693614|Drug|BKM120|100 mg once a day
1670683|NCT01693601|Drug|Panobinostat|PO TIW QOW or PO TIW QW
1670684|NCT01693601|Drug|Ruxolitinib|PO BID x 28 days
1670685|NCT01693588|Other|Pain Management Bundle|The Pain Management Bundle will be implemented for all postoperative neurosurgical patients admitted to nursing units at the University of Florida.
1670686|NCT01693575|Device|Pupil expansion with APX 100 device|Patients with small pupils (<4.5 mm) that would not dilate pharmacologically or small pupils that develop intraoperatively due to intraoperative floppy iris syndrome (IFIS) will be assigned to APX 100 device intervention during standard phacoemulsification cataract surgery. After creating two standard clear corneal incisions in the horizontal meridians, two APX 100 retractors will be inserted to the anterior chamber of the eye 180 degrees apart with special forceps, one retractor at a time, and will be located on the pupil's border between the iris and the anterior lens capsule. Then, the devices will be released from the forceps and the pupil diameter will expand. The next steps of the surgery will remain unchanged. After the implantation of the intraocular lens (IOL) in the capsular bag the APX 100 retractors will be removed the same way as inserted. The clear corneal incisions will then be closed by hydration.
1670687|NCT01693562|Drug|MEDI4736|MEDI4736 will be administered by IV infusion every 14, 21, or 28 days.
1670688|NCT01693549|Drug|Cabazitaxel|
1670689|NCT01693536|Behavioral|Lifestyle counselling|as in Arm Description
1670693|NCT01693510|Behavioral|Exercise and Nutrition Intervention|Both Intervention and Control participants and their care providers receive the new Health Canada guide on Healthy Weight Gain During Pregnancy. For the Experimental Group, the exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program to reach 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling.
1670694|NCT01693497|Behavioral|Dialogical exposure therapy|This 24-session treatment protocol includes cognitive-behavioral components integrated with a frame based on gestalt principles. There are four phases, safety, stabilization, confrontation and integration.
1670695|NCT01693497|Behavioral|Cognitive Processing Therapy (German Adaptation)|This is a German adaptation of Cognitive Processing Therapy, developed by Prof. P. A. Resick. This intervention includes cognitive restructuring, a focus on the traumatic memory and a focus on issues that are likely to be problematic in traumatized individuals.
1670696|NCT01693484|Drug|ICG (Indocyanine Green)|Diagnostic drug used for visualisation of blood perfusion in various tissues.Administered intravenously, 2X: 1X prior to anesthesia, and 1X after tourniquet on operative extremity has been released for at least 15 minutes. When excited by laser light source, it subsequently emits at a near infrared frequency.
1670697|NCT01693458|Behavioral|Appreciative Inquiry Change Agents (CA) program (NAMWEZA)|The intervention is based on an Appreciative Inquiry approach that comprises a 10-session program based on learning by doing rather than factual classroom type learning, although it includes discussion of relevant facts about HIV, and other STIs. The intervention is based on the template of Stepping Stones (Jewkes et al., 2008), which is internationally one of the most widely used participatory behavioral interventions targeting sexual health. The Stepping Stones curriculum was shortened and radically adapted from more than 20 sessions. However NAMWEZA borrows generously from many of the exercises and games. It also employs the successful experience of stratification by age and sex to engage 4 different working groups (younger and older, male and female).
1670698|NCT01693445|Drug|OIS (Oxaliplatin, Irinotecan, S-1)|"Dose level 1 treatment will be delivered as a 2-week cycle as bellows;
Oxaliplatin 85 mg/m²IV on day 1
Irinotecan 120 mg/m² IV on day 1
S-1 60 mg/m2/day PO on day 1-7
Dose escalation will be continued until more than one-third of the patients in a given cohort show dose limiting toxicities (DLT) during treatment cycle 1. If at least 2 patients are observed to have DLT, this dose level is defined as the maximum tolerated dose (MTD). If exactly 1 of the 3 patients treated show DLT, 3 additional patients are treated at the current dose level."
1670699|NCT01693432|Drug|DS (docetaxel+S-1)|"Treatment will be delivered as a 3-week cycle.
Docetaxel 60 mg/m²IV on day 1
S-1 80 mg/m2/day PO on day 1-14"
1670700|NCT01693419|Drug|GES (Gemcitabine, Erlotinib, S-1)|"Treatment will be delivered as a 3-week cycle.
Gemcitabine 1000 mg/m² IV on day 1, 8
Erlotinib 100 mg/day PO on day 1
S-1 60 mg/m²/day PO on day 1-14"
1670701|NCT01693393|Drug|Cyclosporine A|Patients will receive Cyclosporine A in a dose of ca. 2mg/kg/BW daily for a 16 week period
1670702|NCT01693380|Biological|Influenza vaccine|"Influenza vaccine: schoolchidren in the experimental group received IM administered:
From 6 to 9 years of age - 2 doses (0.5ml each) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart.
9 years of age and older: one dose (0.5ml) of the tri-valent innactivated influenza vaccine - Southern Hemisphere formulation, 2009 - one month apart."
1670703|NCT01693380|Biological|Control vaccine|"Schoolchildren from 6 to 8 years of age:
- One dose (0.5ml), IM administered, of Meningococcal C conjugate vaccine, and one dose (0.5ml), one month later, of varicella vaccine, IM administered."
1670704|NCT01693367|Device|DLS 5.0 (Dynamic locking screws)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP) and DLS 5.0
1670705|NCT01693367|Device|SLS (Standard locking screw)|Open reduction and internal fixation (ORIF) of the distal femur with a large fragment locking plate (LISS, LCP)and SLS (Standard locking screw)
1670706|NCT01693354|Device|Mid-dilution HDF|Mid-dilution HDF is a special, newly developed variant of online HDF which is characterized by a dedicated high-flux hemodialyzer named OLPUR MD able to support simultaneous pre- and post-dilution
1670707|NCT01693354|Device|HF dialysis|Standard hemodialyzers equipped with high permeability polyphenylene/polyethersulfone membranes
1670914|NCT01691690|Drug|Normal Saline Flush|Saline placebo will be infused intraoperatively.
1670708|NCT01693341|Other|Care-giver mediated training|A physical therapist visited each subject and the caregiver (of the intervention group) once weekly for about 90 min/session to teach patient-skills and caregiver-skills. The therapist first reviewed the condition of each patient and planned patient-specific training programs, continuously performed 12 weeks.
1670709|NCT01693328|Drug|PecFent® (fentanyl) nasal spray|
1670710|NCT01693315|Drug|AMA0076|
1670711|NCT01693315|Drug|Placebo|
1670712|NCT01693302|Other|Insulin|The timing of insulin delivery varies with each study visit. The dose is given based on carbohydrate content and blood glucose level. The insulin is given either 20 minutes before the meal, immediately before the meal, or 20 minutes after the meal.
1670715|NCT01693276|Drug|Gemcitabine|"gemcitabine 1000mg/m2 given on day 1,8, and 15 of a 28 day cycle for 2 cycles prior to chemoradiation and post RT.
Gemcitabine 450 mg/m2, 30-minute infusion, given weekly during chemoradiation for a total of 6 weeks."
1670716|NCT01693276|Drug|Abraxane|Abraxane® 100 mg/m2 given on day 1,8, and 15 of 28 day cycle for 2 cycles prior to RT and each cycle post RT
1670717|NCT01693276|Radiation|Radiation Therapy|IMRT Dose escalation: 60 Gy (2 Gy/fraction)
1670718|NCT01693263|Other|brachiocephalic fistula (BCF)|We will collect information from physical exams, blood tests, venogram, doppler, vein and artery tissue samples
1670721|NCT01693237|Other|Group psychotherapy|20 sessions of systemic and narrative group therapy
1670722|NCT01693237|Other|Group psychotherapy with feedback|20 sessions of systemic and narrative group therapy
1670723|NCT01693224|Device|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.
Manufacturer: Alere"
1670724|NCT01693224|Device|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.
Manufacturer: Alere."
1670725|NCT01693224|Device|Cepheid Xpert MTB/Rif assay|
1670726|NCT01693211|Device|Femtosecond Laser (VICTUS™ Femtosecond Laser Platform)|Capsulotomy and pre-fragmentation of the nucleus are performed by the femtosecond laser.
1670727|NCT01693211|Device|Manual (CCC technique with Utrata forceps)|Capsulorhexis and pre-fragmentation are performed manually.
1670728|NCT01693198|Procedure|Skin test with sterile extracts of different cyanobacteria|Skin test with sterile extracts of different cyanobacteria is performed on the volar aspect of the forearm. Typically, the results are read 15 minutes after performing the test. Test is regarded as positive when wheal of more than 3mm and flare appear within this time frame. Positive test indicates the existence of specific IgE to the extract in on skin mast cells .
1670729|NCT01693185|Drug|Remifentanil|continuous infusion 0.4 mcg/kg/min
1670730|NCT01693185|Drug|Midazolam|bolus injection
1670731|NCT01693185|Drug|Meperidine|bolus injection for 30 sec 1.0 mg/kg
1670732|NCT01693185|Drug|placebo (for remifentanil)|normal saline mimic diluted remifentanil
1670733|NCT01693185|Drug|placebo (for midazolam)|normal saline mimic to midazolam injection
1670734|NCT01693185|Drug|placebo (for meperidine)|normal saline mimic meperidine injection
1670735|NCT01693172|Behavioral|Early mobilization program|Early postoperative supervised aerobic exercise, resistance and flexibility training
1670736|NCT01693159|Device|ECA|In the experimental arm patients will be topically treated with the liquid glue ethyl-2-cyanoacrylate (ECA).
1670737|NCT01693159|Other|Standard topical treatment of the institution, e.g. Lotio|Standard treatment of the institution to treat painful cetuximab-induced rhagades
1670738|NCT01693146|Device|Nasal oxygen insufflation with a TNI® 20 oxy device|Nasal insufflation at a constant high flow of 15 L/min with oxygen addition starting at 0.5 L/min
1670739|NCT01693146|Device|Nasal insufflation of oxygen|Nasal insufflation of oxygen starting at at flow of 0.5 L/min.
1670740|NCT01693133|Other|Standard of Care: Moist Wound Therapy and Offloading|Standard of Care: Moist Wound Therapy and Offloading
1670741|NCT01693133|Other|EpiFix plus Standard of Care|Weekly application of EpiFix and Standard of Care
1670742|NCT01693120|Device|Medtronic Phased RF Ablation System|Phased RF ablation
1670743|NCT01693094|Behavioral|Decision Aid|"Cohort I will be managed with a decision aid (henceforth DA), and Cohort II will be managed without one. The patients in Cohort I will receive the DA, which they can complete in a separate room and take home. The decision aids include information on the disease/condition, treatment options, benefits, risks, scientific uncertainties, and probabilities of potential outcomes tailored to the patient's health risks factors. Additionally, it includes values clarifications such as describing outcomes in functional terms, asking patients to consider which benefits and risks matter most to them, and guidance in the steps of decision making and discussing their decision with family/friends. It is interactive and dynamic, helping patients clarify their preferences and come to a decision that feels best to them."
1670744|NCT01693081|Drug|VR040/Aspirair® inhaler|Dry Powder inhaled apomorphine
1670745|NCT01693081|Drug|placebo|
1672735|NCT01677390|Drug|everolimus|10 mg PO daily
1670748|NCT01693055|Device|UltheraTM 100 shots|UltheraTM 100 shots (infraorbital region 30shots, lateral orbital region 40shots, upper eyelid 30 shots) on the Rt, and Lt periorbital area, respectively using 1.5mm and 3.0mm probe
1670749|NCT01693042|Biological|intracoronary infusion of autologous bone marrow-derived cells|Intracoronary infusion into open vessel / bypass supplying previous (> 3 months) infarct area
1670750|NCT01693029|Drug|HX575 epoetin alfa|Solution for subcutaneous injection. The drug is administered subcutaneously at least once per week over 52 weeks. The dose will be individually titrated to maintain hemoglobin levels between 10 to 11 g/dL.
1670751|NCT01693029|Drug|US-licensed epoetin alfa|Solution for subcutaneous injection.
1670752|NCT01693016|Device|non-invasive measurement of Hb|
1670753|NCT01693016|Procedure|taking blood samples|
1670754|NCT01693003|Drug|Indacaterol|150 µg d.o. during the first 3 weeks
1670755|NCT01693003|Drug|Tiotropium|150 µg d.o. during 3 weeks
1670756|NCT01692990|Dietary Supplement|Fish oil|For 3 weeks 5 g/d in 10 capsules, providing 3.5 g long-chain n-3 fatty acids in the fish oil period. Cross-over between arms with 1 week of wash out
1670757|NCT01692977|Other|neuropsychological assessment|
1670758|NCT01692951|Other|serum sample|Serum samples from lung cancer patients were collected at the time of their diagnosis, prior to the initiation of treatment. Serum samples of control subjects were collected from a biobank
1670759|NCT01692925|Drug|turoctocog alfa|Trial product, 2000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
1670760|NCT01692925|Drug|turoctocog alfa|Trial product, 3000 IU/vial will be administered as an i.v. (intravenous) bolus injection.
1670761|NCT01692912|Other|Intensive Care|Rheumatologist aims to treat participant in order to achieve a disease activity score improvement of DAS28<2.6
1955020|NCT03308799|Drug|MC2-01 cream|MC2-01 (calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%) cream
1955021|NCT03308799|Drug|Cal/BDP combination|calcipotriene/betamethasone dipropionate, w/w 0.005%/0.064%
1955022|NCT03308799|Drug|Cream vehicle|Vehicle Cream
1670766|NCT01692873|Procedure|suspected pancreatic tumor|Realization of pancreatic surgery to obtain tumor biopsy and blood samples to realize biomarkers analyses.
1670767|NCT01692860|Other|Energy Restriction|Subjects consume 750 kcal/d of energy below their need
1670768|NCT01692834|Drug|Sandimmune® Injection|
1670769|NCT01692834|Drug|NeuroSTAT®|
1670770|NCT01692821|Drug|100% oxygen breathing|100% oxygen breathing - 30 minutes
1670771|NCT01692821|Drug|15% oxygen in N2 breathing|15% oxygen in N2 breathing - 30 minutes
1670772|NCT01692821|Drug|12% oxygen in N2 breathing|12% oxygen in N2 breathing - 30 minutes
1670773|NCT01692808|Drug|Vitamin D3 3000 UI daily|Vitamin D3 will be administered as an adjunct to corticosteroids or enteral nutrition at the doses of 3000 UI daily or 4000 UI daily
1670774|NCT01692808|Drug|Vitamin D3 4000 UI daily|This arm is intended for those at diagnosis treated with Corticosteroid or in Remission
1670775|NCT01692782|Drug|SEP-225289|SEP-225289 4mg once daily
1670776|NCT01692782|Drug|SEP-225289|SEP-225289 8mg once daily
1670777|NCT01692782|Drug|Placebo|Placebo once daily
1670778|NCT01692769|Drug|Normal Saline|Patients randomized to Normal Saline arm, will receive intravenous normal saline for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
1670779|NCT01692769|Drug|Ringer's Lactate|Patients randomized to Ringer's Lactate arm, will receive intravenous Ringer's Lactate for all resuscitation and maintenance fluid for a period of 24 hours commencing on presentation to hospital.
1670780|NCT01692756|Drug|Kenalog or placebo|
1670781|NCT01692756|Drug|Kenalog then Placebo|
1670782|NCT01692756|Drug|Kenalog|
1670783|NCT01692756|Drug|Placebo|
1670788|NCT01692717|Drug|Atorvastatin|10 mg
1670789|NCT01692717|Drug|Hydrochlorothiazide + Losartan|12.5 mg + 50 mg
1670790|NCT01692717|Drug|Hydrochlorothiazide + Losartan + Atorvastatin|12.5 mg + 50 mg + 10 mg
1670791|NCT01692704|Drug|Selective intra-arterial floxuridine and systemic gemcitabine and cisplatin|"Intra-arterial floxuridine:0.2 mg/KG/day for 14 days, repeated day 29. Overall 3 applications.
Systemic cisplatin: 25 mg/m2 at days 1 and 8, repeated day 22. Overall 8 applications.
Systemic gemcitabine: Three different dose levels will be tested; 600 mg/m2, 800 mg/m2, or 1000 mg/m2, at days 1 and 8, repeated day 22. Overall 8 applications."
1955030|NCT03308292|Other|Exercise|Aerobic exercise program
1670795|NCT01692678|Drug|Trabectedin|Type=exact number, unit=mg/m2, number=1.5, 1.2 or 1.0, form=solution, route=intravenous infusion. Trabectedin will be administered on Day 1 of each 21-day treatment cycle.
1670796|NCT01692678|Drug|Dacarbazine|Type=exact number, unit=g/m2, number=1, form=solution, route=intravenous infusion. Dacarbazine will be administered on Day 1 of each 21-day treatment cycle.
1670797|NCT01692652|Drug|topical loteprednol etabonate (lotemax 0.5%) with warm compress & ocular massage|
1670798|NCT01692652|Other|warm compress only group|
1670799|NCT01692626|Drug|Pimecrolimus|Pimecrolimus 1% topical cream applied twice daily for four weeks on one side of the face.
1670800|NCT01692626|Drug|Placebo|Placebo cream applied twice daily for four weeks on opposite side of the face from the Pimecrolimus side.
1670801|NCT01692587|Other|Protein restrictive diet|To begin a reduced protein diet
1670802|NCT01692574|Behavioral|Behavior Modification for Weight Loss|
1670803|NCT01692574|Behavioral|Alternative Approach to Weight Loss|
1670804|NCT01692574|Behavioral|Cognitive-Behavior Therapy for Depression|
1670805|NCT01692574|Behavioral|Depression Support and Education|
1670806|NCT01692548|Other|Neurofeedback|
1670807|NCT01692535|Procedure|Intubation|Intubation with one of the six videolaryngoscopes
1670808|NCT01692522|Procedure|Intubation|visualized blind intubation
1670809|NCT01692496|Drug|Pazopanib|Patients will receive oral pazopanib, 800mg once daily and treatment will continue until disease progression, development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient or investigator decision.
1670810|NCT01692483|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
1670811|NCT01692483|Drug|Prednisone|Prednisone or prednisolone 5 mg tablet taken orally twice daily
1670812|NCT01692470|Drug|No intervention|Patients will be taking rilpivirine hydrochloride as per the dosing regimen given on product insert approved in Philippines (ie, 1 tablet of 25 mg orally once a day) in combination with anti-retroviral (ARV) medications.
1670813|NCT01692457|Drug|No intervention|This is an observational study. Golimumab will be administered as per the recommended doses. Golimumab 50 mg will be given as a subcutaneous injection once a month, on the same date each month. For rheumatoid arthritis: Golimumab 2 mg/kg will be given as a 30 minute intravenous infusion at Weeks 0 and 4, then every 8 weeks thereafter.
1670814|NCT01692431|Dietary Supplement|EPA|High fat meal containing EPA
1670815|NCT01692431|Dietary Supplement|DHA|High fat meal containing DHA
1670816|NCT01692431|Dietary Supplement|Placebo|High fat meal containing negligible EPA/DHA content
1670819|NCT01692405|Device|NaviGo Bx™|The NaviGoBx™ system is a device and method that enables an accurate reporting of the exact longitudinal location and direction of the biopsy specimen along the needle notch as well as the accurate length of the specimen. Acquiring this information during the biopsy extraction session provides an accurate designation of the location of any later region of interest within the specimen itself to the longitudinal position along the needle mandrel.
1670820|NCT01692405|Procedure|biopsy sponge pad|the biopsy core is downloaded onto a biopsy sponge pad which is than entered into a biopsy cassette.
1670821|NCT01692379|Device|Solitaire FR device|Mechanical embolectomy in anterior large vessel occlusion
1670822|NCT01692379|Other|Medical treatment|Standard of care in acute ischemic stroke including intravenous rTPA
1670823|NCT01692366|Drug|SAR302503|"Pharmaceutical form:Capsule
Route of administration: oral"
1670824|NCT01692353|Other|Subject's usual brand (UB) tobacco product|For SMK: UB of cigarettes; For MSC: UB of moist snuff
1670825|NCT01692340|Other|Isotopically labeled lycopene, phytoene or phytofluene|We will administer 10 mg of labeled carotenoid mixed with olive oil and spread on an English muffin for consumption by participants.
1670826|NCT01692327|Dietary Supplement|High fat meal|
1670827|NCT01692314|Other|Resistance training|
1670828|NCT01692301|Drug|LCZ696|200 mg tablet
1670829|NCT01692301|Drug|Olmesartan|20 mg and 40 mg capsules
1670830|NCT01692301|Drug|LCZ696 matching placebo|LCZ696 Matching Placebo tablet
1670831|NCT01692301|Drug|Olmesartan matching placebo|Olmesartan matching placebo capsule
1670832|NCT01692301|Drug|amlodipine|amlodipine 2.5 mg or 5 mg tablets
1670833|NCT01692301|Drug|hydrochlorothiazide|hydrochlorothiazide 6.25mg, 12.5mg, or 25 mg tablets
1670834|NCT01692288|Behavioral|First Born® Program home visiting services|Family and first-born child are offered and/or receive weekly First Born® Program home visiting services between pregnancy and the child's third birthday. Families are eligible to enroll in the program from pregnancy up to two months after birth.
1670835|NCT01692275|Other|Medical Care + Chiropractic Care|Patients will receive chiropractic spinal manipulative therapy plus conventional medical care. Medical may include the following: education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
1670836|NCT01692275|Other|Conventional Medical Care Only|Conventional medical care may include the following: a focused history and physical examination; limited diagnostic imaging restricted to select volunteers (i.e., for example, those with radiculopathy); education about self-management, including maintaining activity levels as tolerated and local ice/heat application; pharmacologic management with the use of analgesics and anti-inflammatory agents; and additional therapies that may be applied for volunteers not responding to the initial interventions, including physical therapy and referral to a pain clinic.
1670837|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.
1670838|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.
1672736|NCT01677377|Drug|Risperidone|2mg, 3mg, and 4mg oral
1670839|NCT01692262|Drug|Intermittent dosing of AZD5363|Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.
1670840|NCT01692249|Other|immediate spa therapy|, with 18 days of therapy over 3 weeks; The standardized shoulder therapy program was designed by experienced spa therapy physicians. Spa mineral water and treatments are approved and controlled by the French authorities. Spa treatment included: bubble buses at 36°C for 15 minutes, applications of mineral matured mud at 45°C to the shoulder for 20 minutes, mineral hydrojet sessions at 39°C for 7 minutes and general mobilization in a collective mineral water pool at 35°C for 20 minutes supervised by a registered physiotherapist.
1670841|NCT01692223|Behavioral|qualitative interviews|A week before the participants return to the clinic to learn of their results, the RSA will call each participant to complete the Hospital Anxiety & Depression Scale (HADS), revised Impact of Events Scale (IES-R), & a questionnaire about their health behaviors, to establish baseline distress levels & health behaviors. A week later, participants will return to the Clinical Genetics Service to review their results with the genetics provider & discuss resultant therapeutic & management recommendations for the participants & their relatives. A week later, the RSA will call each participant to complete the HADS, IES-R again, to establish the safety of receiving these results. Participants will also be asked to complete the revised Multidimensional Impact of Cancer Risk Assessment (MICRA) measure. The RSA will also invite participants to complete an in-depth telephone interview.
1670842|NCT01692210|Drug|Dexmedetomidine|After induction of general anesthesia, a loading dose of dexmedetomidine (1 mcg/kg) given in 15 min followed by an infusion of the same medication at a rate of 0.4 - 0.7 mcg/kg/hour.
1670843|NCT01692197|Drug|E7070|400 mg/m2 intravenously over 1 hour on Day 1 and Day 8 every 3 weeks.
1670844|NCT01692197|Drug|Idarubicin|8 mg/m2 by vein over 1 hour daily for 3 days (Days 9-11).
1670845|NCT01692197|Drug|Cytarabine|1.0 g/m2 by vein daily on Days 9 - 12 (age <60 years) or Days 9 - 11 (age > 60 years).
1670846|NCT01692197|Drug|Dexamethasone|10 mg by vein daily for 3 - 4 days with cytarabine.
1670847|NCT01692184|Drug|50 mg AVL-292|
1670848|NCT01692184|Drug|100 mg AVL-292|
1670849|NCT01692184|Drug|200 mg AVL-292|
1670850|NCT01692184|Drug|350 mg AVL-292|
1670851|NCT01692184|Drug|Placebo capsules|
1670852|NCT01692171|Drug|Heparin, Low-Molecular-Weight|single intravenous administration of 3mg/Kg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
1670853|NCT01692158|Drug|Heparin, Low-Molecular-Weight|single subcutaneuous administration of 40 mg of the test drug and the comparator drug, according to randomization, in a crossover design, each administration separated by 6 days of washout.
1670854|NCT01692145|Drug|KCT-0809|
1670855|NCT01692145|Drug|Placebo|
1670856|NCT01692132|Drug|Prucalopride|Prucalopride 2 mg tablet/day orally for 12 weeks. For elderly patients (>65 years old), patients with renal impairment not requiring dialysis or patients with severe hepatic impairment, 1mg prucalopride once daily should be given.
1670857|NCT01692119|Behavioral|Regular, pharmacy based intervention|"Regular, pharmacy-based intervention conducted in cooperation with the treating physician:
Medication review at baseline: recording of all medicines currently taken (prescribed medication and self-medication), check for drug-related problems, consolidation of a medication plan.
Regularly (weekly): dose-dispensing of the medication (weekly dosing aid), discussion and counseling regarding medication, adherence, potential side effects, and signs and symptoms of cardiac decompensation; blood pressure and pulse measurement. If required: contact with patients' physician."
1670858|NCT01692106|Procedure|Procedure: Per Oral Endoscopic Myotomy (POEM)|lower esophageal sphincter muscle is sectioned through an unique endoscopic approach.
1670859|NCT01692093|Dietary Supplement|KM110329|KM110329, a functional food consist of four herbs which are shown to be beneficial for skin health
1670860|NCT01692093|Dietary Supplement|Placebo|Placebo
1670861|NCT01692080|Behavioral|Asthma education|Two separate asthma education classes are conducted to target two age groups: 6-10 yrs and 10-15 yrs. With the guidance of pharmacy faculty, student pharmacists develop innovative educational activities directed at three of the most common barriers to proper asthma control: avoidance of asthma triggers; compliance with asthma medications and proper usage of inhalers; and the importance of an asthma action plan. There is a different group of student pharmacists participating in each camp and this allows for variation in educational activities, all reinforcing the same important aspects of optimal asthma management. Students create age-appropriate activities for each group. Parents are required to attend camps with their child and participate in the asthma education sessions.
1670862|NCT01692041|Drug|ivy leaves dry extract|5 ml twice daily po
1670863|NCT01692041|Drug|Placebo|5 ml per os twice daily
1670864|NCT01692015|Other|Questionnaire on dietary history|
1670865|NCT01692015|Other|Questionnaire on nosebleed severity|
1670866|NCT01692015|Other|One week food diary generated by weighing foods|
1670867|NCT01692015|Procedure|Blood tests for full blood count, albumin, and indices of nutritional status|
1670868|NCT01692002|Dietary Supplement|Sodium propionate|Sodium propionate capsule or tablet
1670869|NCT01692002|Dietary Supplement|Sodium Chloride|Placebo capsule or tablet
1670870|NCT01692002|Procedure|Oral glucose tolerance test|
1670871|NCT01692002|Procedure|Intravenous glucose tolerance test.|
1670872|NCT01691989|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
1670873|NCT01691989|Drug|placebo|oral doses once a day for 26 weeks
1670874|NCT01691976|Drug|Oestrogen Patches|
1670875|NCT01691976|Drug|LHRHa|Luteinising hormone releasing-hormone agonists (LHRHa)
1670876|NCT01691963|Device|C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany)|"Endotracheal intubation will be achieved using a C-MAC® videolaryngoscope (Karl Storz, Tuttlingen, Germany) with a size 3 Macintosh blade.
The best possible view of the glottic inlet will be scored with the blade tip positioned in the vallecula.
Next, the view of the glottic inlet will be scored with the blade advanced further into the vallecula, until the epiglottis flips infero-posteriorly and becomes downfolded into the trachea.
The glottic view will be scored in both positions using the Cormack and Lehane classification system.
After successful intubation, the blade will slowly be withdrawn into the vallecula to elevate the epiglottis back to its normal position."
1670877|NCT01691937|Procedure|Continuous Paravertebral block with ropivacaine|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.2% ropivacaine is connected to paravertebral catheter, a 10ml bolus of 0.2% ropivacaine is injected via the paravertebral catheter, followed by an infusion of ropivacaine 0.2% at 6 ml/h for postoperative pain management.
1670878|NCT01691937|Procedure|Patient-controlled analgesia with sufentanil|Once arrival at the PACU, all patients were placed on a postoperative analgesic regimen that included patient-controlled analgesia with intravenous sufentanil (bolus 1μg, lockout time 10 min) and tramadol 100 mg IV for severe pain (NRS 6-10).
1670879|NCT01691937|Procedure|Continuous Paravertebral Block with Saline|Before anesthesia, continuous right thoracic paravertebral block of T7 is performed. After injection of 5 mL normal saline, a catheter (PAJUNK, Geisingen, Germany) is advanced medially the estimated distance to the paravertebral space. After injection of 1% lidocaine 15ml, the block level is tested by pinprick and recorded 15 minutes later. At the end of operation, syringe contained 0.9% saline is connected to paravertebral catheter, a 10ml bolus of 0.9% saline is injected via the paravertebral catheter, followed by an infusion of 0.9% saline at 6 ml/h for postoperative pain management.
1670880|NCT01691924|Drug|PBF-509|
1670881|NCT01691924|Drug|Placebo|
1670882|NCT01691911|Procedure|Remote preconditioning|Immediately after induction of anaesthesia, a standard, CE-approved tourniquet cuff will be placed around one arm of the patient. It will then be inflated to a pressure of 200mmHg for 5 minutes. For patients with a systolic blood pressure >185mmHg, the cuff will be inflated to at least 15mmHg above the patient's systolic blood pressure. The cuff will then be deflated and the arm allowed reperfuse for 5 minutes. This will be repeated so that each patient receives a total of 4 ischaemia-reperfusion cycles. In all other respects, the procedure and peri-operative care will follow the routine practices of the surgeons and anaesthetists involved.
1670883|NCT01691898|Drug|Obinutuzumab|Obinutuzumab 1000 mg will be administered by IV infusion on Day 1, 8, 15 of first 21-Day cycle and Day 1 of subsequent 21-day cycles for up to 8 cycles.
1670884|NCT01691898|Drug|Pinatuzumab Vedotin|Pinatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycles.
1670885|NCT01691898|Drug|Polatuzumab Vedotin|Polatuzumab Vedotin 1.8 or 2.4 mg/kg administered by IV infusion on Day 1 or 2 of every 21-day cycles.
1670886|NCT01691898|Drug|Rituximab|RTX 375 mg/m^2 administered by IV infusion on Day 1 of every 21-day cycles.
1670887|NCT01691885|Drug|Fluticasone Furoate|100mcg Once daily
1670888|NCT01691885|Drug|Vilanterol|25mcg Once daily
1670889|NCT01691872|Drug|Retigabine|Retigabine
1670890|NCT01691859|Drug|Mepolizumab|100 mg of mepolizumab will be injected subcutaneously (SC) once every 4 weeks
1670891|NCT01691846|Drug|aleglitazar+metformin|150 mcg aleglitazar given orally once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
1670892|NCT01691846|Drug|placebo+metformin|Oral doses of matching placebo once a day for 26 weeks. Patients will continue on their existing dose and regimen of metformin (≥ 1500 mg/day or individual maximally tolerated dose)
1670893|NCT01691833|Dietary Supplement|Vitamin D|Patients that are Vitamin D deficient and randomized to the treatment group will receive a 10,000 IU dose of Vitamin D.
1670894|NCT01691833|Dietary Supplement|Placebo|Patients that are Vitamin D deficient maybe randomized to the placebo group D.
1670895|NCT01691820|Procedure|Blood collection|Samples collected at Months 0, 4, 8, 12, 16, 20, 24, 28, 32, and 36.
1670896|NCT01691820|Procedure|Urine collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
1670897|NCT01691820|Procedure|Saliva collection|Samples collected at Months 0, 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, and 36.
1670898|NCT01691807|Drug|ofatumumab|treatment for NHL
1670899|NCT01691807|Drug|bendamustine|treatment for NHL
1670900|NCT01691794|Drug|Atazanavir|
1670901|NCT01691794|Drug|Ritonavir|
1670902|NCT01691781|Drug|Lisinopril|Each subject will receive one week of lisinopril and return for repeat for blood measurements.
1670903|NCT01691768|Drug|1% tenofovir gel|"Participants will be randomized to receive 1% tenofovir gel through either:
Public sector family planning services with 2-3 monthly provision and monitoring of 1% tenofovir gel and the use of QI methodology to promote reliable service delivery (intervention arm), or
The CAPRISA research clinics with monthly provision and monitoring of 1% tenofovir gel (control arm)."
1670904|NCT01691755|Drug|Placebo|oral doses once a day for 26 weeks
1670905|NCT01691755|Drug|aleglitazar|150 mcg orally once a day for 26 weeks
1670906|NCT01691742|Drug|MiraLax|MiraLax 17g powder daily for 5 days postoperatively following urogynecologic surgery
1670907|NCT01691742|Drug|Placebo|Placebo maltodextrin 17g powder daily for 5 days postoperatively following urogynecologic surgery
1670908|NCT01691742|Drug|Rescue Laxative|All participants will be instructed to take Milk of Magnesia with standard over-the-counter dosing as a recue laxative if the subject has not had a bowel movement by postoperative day 6.
1670909|NCT01691729|Device|Ostomy accessory|Wearing each of the devices for 10 days each
1670910|NCT01691716|Drug|Tendoactive|Food supplement containing mucopolysaccharides, type I collagen and vitamin C
1670911|NCT01691716|Behavioral|Eccentric training|Eccentric training program published by Alfredson et al 1998 (Am J Sports Med 1998 26: 360)
1670912|NCT01691703|Device|Videolaryngoscope and Bonfils|First, the Macintosh videolaryngoscope (Karl Storz, Tuttlingen, Germany) will be used to achieve the best possible view and space of the laryngeal inlet for the insertion and manoeuvring of the Bonfils® (Karl Storz, Tuttlingen, Germany). Once the anaesthesiologist considers the view achieved to be the best view possible, a picture will be taken using C-CAMTM for C-MAC (Karl Storz, Tuttlingen, Germany), not showing any part of the videolaryngoscope. Thereafter the Bonfils® intubation scope, which will be preloaded with the endotracheal tube, will be brought into position in front of the laryngeal inlet. Again a picture not showing any part of one of the two devices will be taken. Once the Bonfils® has entered the trachea, the tracheal tube will be placed in the correct position.
1670913|NCT01691690|Drug|Acetaminophen (paracetamol)|Acetaminophen IV (15 mg/kg).
1670915|NCT01691690|Drug|Midazolam|Midazolam (0.5mg/kg to maximum dose of 20mg) given 15-20 minutes before induction.
1670916|NCT01691690|Drug|Sevoflurane|Sevoflurane for anesthesia induction.
1670917|NCT01691690|Drug|Nitrous Oxide/Oxygen|Combination of NO2 & O2 for anesthesia induction.
1670918|NCT01691690|Drug|Propofol|Propofol 1-1.5 mg/kg to facilitate endotracheal intubation.
1670919|NCT01691690|Drug|Morphine|Morphine 0.1 mg/kg given prior to intubation.
1670920|NCT01691690|Drug|Ondansetron|Ondansetron (0.15 mg/kg, maximum dose of 4 mg) for postoperative nausea prophylaxis.
1670921|NCT01691690|Drug|Dexamethasone|Dexamethasone (0.25 mg/kg, maximum dose of 20 mg) for postoperative nausea prophylaxis.
1670922|NCT01691677|Drug|beclomethasone dipropionate 800 mcg/2 ml suspension for nebulization,one administration b.i.d. for 14 days|
1670923|NCT01691677|Drug|placebo 2 ml suspension for nebulization, one administration b.i.d. for 14 days|
1670924|NCT01691664|Radiation|Only radiation therapy|Patients only radiation therapy after surgery
1670925|NCT01691664|Other|Radiation therapy plus DC-CIK cellular therapy|Patients receive radiation therapy plus DC-CIK cellular therapy after surgery
1670926|NCT01691651|Procedure|Subcutaneous injection of botulinum toxin type A|Subcutaneous injection of botulinum toxin type A (2.5 units per application point) at two points in a nasal and temporal extent of the orbicularis muscle will be performed in the Botulinum toxin type A group.
1670927|NCT01691651|Drug|Botulinum Toxin Type A|2.5 units per point of application at two points in a nasal and temporal extent of the orbicularis muscle.
1670928|NCT01691625|Other|concurrent chemoradiotherapy plus DC-CIK immunotherapy|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation.
DC-CIK Immunotherapy:Mononuclear cells were collected aseptically with blood cell separator composition apheresis 3 days before concurrent chemoradiation, and cultured DC-CIK cells for 10 days. Cells were infused back to the patients in 3 times between the Chemoradiation intermittent period."
1670929|NCT01691625|Other|Concurrent chemoradiation only|"Radiotherapy:Patients will be conducted CT simulation, and three-dimensional conformal radiation therapy (3DCRT) or Intensity-modulated radiation therapy(IMRT)was performed. 1.8-2.0 Gy/fraction, 5 fractions a week, with a total dose of 60-66Gy will be delivered for all patients by 6-MV-X-ray of linear accelerator.
Chemotherapy: Patients will be concurrently administered with irradiation every 4 weeks with PT regimen (cis-platinum of 20 mg/m2/d, d2-5; PTX(paclitaxel)of 80mg/m2/d, d1,d8) for 4 cycles.The chemotherapy will be concurrently given with irradiation."
1670930|NCT01691612|Biological|installation of D. pteronyssinus allergens|We will perform bronchoscopy and segmental allergen challenges. Subjects will undergo bronchoscopy with segmental installation of 5 ml of D. pteronyssinus (DerP). BAL and lung biopsy of the allergen-challenged segments will be performed 48 hr later
1670931|NCT01691560|Drug|5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice|Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
1670932|NCT01691560|Drug|0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice|Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate
1670933|NCT01691560|Drug|Sodium monofluorophosphate dentifrice|Dentifrice containing 1000 ppmF as sodium monofluorophosphate
1670934|NCT01691560|Drug|Sodium fluoride dentifrice|Dentifrice containing 1100 ppmF as sodium fluoride
1670935|NCT01691547|Drug|UMEC /VI|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA) and vilanterol is a long-acting beta2 agonist (LABA). UMEC/VI (blended together) will be available as dry powder in the dose of 125 µg /25 µg per inhalation.
1670936|NCT01691547|Drug|UMEC|Umeclidinium is an inhaled long-acting muscarinic antagonist (LAMA). UMEC will be available as dry powder in the dose of 125 µg per inhalation.
1670937|NCT01691547|Drug|VI|Vilanterol is a long-acting beta2 agonist (LABA). VI will be available as dry powder in the dose of 25 µg per inhalation.
1670938|NCT01691547|Drug|FF|Fluticasone Furoate is a novel inhaled corticosteroid (ICS). FF will be available as dry powder in the dose of 100 µg per inhalation.
1670939|NCT01691534|Drug|TMC207 (J)|TMC207 400 mg Day 1; 300mg Day 2; 200mg Days 3-14
1670940|NCT01691534|Drug|PA-824 (PA)|PA-824 200mg Days 1-14
1670941|NCT01691534|Drug|pyrazinamide (Z)|1500mg Days 1-14 Dosed by Weight
1670942|NCT01691534|Drug|clofazimine (C)|clofazimine 300mg Days 1-3 and clofazimine 100mg Days 4-14
1670943|NCT01691534|Drug|Rifafour|Rifafour e-275 mg dosed by weight
1670944|NCT01691521|Drug|Mepolizumab IV|Mepolizumab 75 mg IV will be administered every 4 weeks with the last dose at Week 28
1670945|NCT01691521|Drug|Mepolizumab SC|Mepolizumab 100 mg SC will be administered every 4 weeks with the last dose at Week 28
1670946|NCT01691521|Drug|IV Placebo|Normal saline (placebo) will be administered IV every 4 weeks with the last dose at Week 28
1670947|NCT01691521|Drug|SC Placebo|Normal saline (placebo) will be administered SC every 4 weeks with the last dose at Week 28
1670948|NCT01691508|Drug|Mepolizumab|Mepolizumab is a fully humanised Immunoglobulin G antibody (IgG1, kappa) with human heavy and light chain frameworks.
1670949|NCT01691508|Drug|Placebo|Will be available as an equivalent volume of 0.9% sodium chloride.
1670950|NCT01691508|Drug|OCS (prednisone/prednisolone)|Oral Corticosteroid (prednisone/prednisolone)
1670951|NCT01691495|Drug|Fondaparinux|Physician adherence study to Fondaparinux prescribing information for patients with Superficial Vein Thrombosis (SVT) of the lower limbs
1670952|NCT01691482|Drug|Albuterol/salbutamol|Albuterol/salbutamol (daily)
1670953|NCT01691482|Drug|Ipratropium|Ipratropium (daily)
1670954|NCT01691469|Drug|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
1670955|NCT01691456|Drug|Montelukast sodium|Montelukast Sodium Oral Granules 4mg
1670956|NCT01691443|Procedure|pressure sensor and wrist shaker, not marked CE, developped by Texisense|
1723357|NCT00004778|Drug|dexamethasone|
1670959|NCT01691417|Device|Intermittent Sequntial Pnumatic Compression Leg Sleeves|
1670960|NCT01691404|Dietary Supplement|Epicatechin|Subjects will be asked to consume supplements containing 100mg of epicatechin daily
1670961|NCT01691404|Dietary Supplement|Quercetin|Subjects will be asked to consume 160mg of quercetin-3-glucoside daily
1670962|NCT01691404|Dietary Supplement|Placebo|Subjects will be asked to consume capsules containing placebo (cellulose) daily
1670963|NCT01691391|Behavioral|pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles|Patients will be treated with cetuximab. For pharmacodynamic purposes PET-imaging with 89Zr-labelled cetuximab will be performed. In addition, two [18F-]-FDG PET-CT will be performed to explore early response. Patients will undergo blood sampling and two skin biopsies for pharmacodynamic purposes of 89Zr-labelled cetuximab and kinase activity profiles, respectively.
1670964|NCT01691378|Other|Window to Hope|Psychotherapy - Group
1670965|NCT01691378|Other|Waitlist Control|Psychotherapy - Group
1670966|NCT01691365|Dietary Supplement|vitamins|a capsule of antioxidant vitamins 221mg of alpha tocopherol and 167mg of vitamin C and B-group vitamins (1.67 mg folic acid, 1.67mg vitamin B-2, 20 mg vitamin B-6, 0.134 mg vitamin B-12) or an identical placebo daily for 90 days
1670967|NCT01691365|Drug|Placebo|Placebo Capsule shell (Hydroxypropylmethyl cellulose, Hydroxypropylcellulose, Propylene glycol as stabilizer, Colour-Titanium dioxide)
1670968|NCT01691352|Procedure|Wick dressing|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2cm wound, a single suture will be placed in the middle). A moist, saline/betadine soaked gauze will then be gently packed into the wound spaces, on either side of the sutures. The gauze will be packed into the wound to the depth of ½ a cm, or ½ of the wound depth, whichever is greater. A single dry piece of gauze will then be secured over the top of the wound. Dressings and packing will be removed by the surgical team on post-operative day 2
1670969|NCT01691352|Procedure|No Wick|Once the fascia of the ostomy site is closed, the subcutaneous space will be irrigated with normal saline. The skin will then be reapproximated using an absorbable suture, spaced every 1 cm across the wound (i.e. for a 2 cm wound, a single suture will be placed in the middle). A single piece of dry gauze will then be secured over the top of the wound. Dressings will be removed by the surgical team on post-operative day 2
1670970|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
1670971|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® Intradermal 2012-2013 Formulation|0.1 mL, Intradermal
1670972|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® 2012-2013 Formulation|0.5 mL, Intramuscular
1670973|NCT01691339|Biological|Influenza Virus Vaccine: Fluzone® High-Dose 2012-2013 Formulation|0.5 mL, Intramuscular
1670974|NCT01691326|Biological|Fluzone®: Influenza Virus Vaccine, No Preservative: Pediatric Dose|0.25 mL dose, Intramuscular
1670975|NCT01691326|Biological|Fluzone®; Influenza Virus Vaccine, No Preservative|0.5 mL dose, Intramuscular
1670976|NCT01691313|Drug|Vanoxerine|single oral dose
1670977|NCT01691313|Drug|Placebo|single oral dose
1670978|NCT01691300|Other|ACT PET/CT|Old tracer but new indication
1670979|NCT01691287|Behavioral|Michael Method|
1670980|NCT01691274|Drug|PF-04895162|Tablets, 300 mg, single, 1 day
1670981|NCT01691274|Drug|PF-04895162|Tablets, 300 mg, twice a day, 14 days
1670982|NCT01691274|Drug|PF-04895162|Tablets, to be decided, twice a day, 14 days
1670983|NCT01691274|Drug|Placebo|Tablets, twice a day, 14 days
1670984|NCT01691261|Biological|PF-05206388|PF-05206388 will be provided as a Retinal Pigment Epithelium living tissue equivalent for intraocular use in the form of a monolayer of Retinal Pigmented Epithelial (RPE) cells immobilized on a polyester membrane. The membrane is approximately 6 mm x 3 mm and will contain a confluent layer of RPE cells, at a nominal dose of 17 mm2. The implant is intended to be life-long.
1670985|NCT01691248|Drug|fidaxomicin|"Fidaxomicin 200 mg tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Study drug treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).
Study drug treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
1670986|NCT01691248|Drug|Placebo|"Placebo tablet once daily from the start (+/- 2 days) of condition (prior to transplantation) or at the time of Fluoroquinolone initiation. Treatment will continue until 7 days after either neutrophil engraftment or the completion of any Fluoroquinolone antibiotic regimen (whichever occurs later).
Treatment will stop at onset of CDAD or no longer than 40 days of duration, even if other antibiotics are still administered or neutrophil engraftment extends beyond 40 days."
1670987|NCT01691235|Device|SIMpill device|The SIMpill device is an automated pill dispensing device that records a time stamp each time the device is opened and a dose of medication is taken. This works through a computer chip that is housed inside of the pill dispensing device that is activated each time the pill box is opened. Physicians can download this data and generate a precise account of the patient's adherence to the medication dosing schedule. In addition, if a dose is missed, the SIMpill device can be set to automatically notify the patient by text message if a dose is overdue.
1670988|NCT01691222|Device|Double lumen endotracheal tube tracheostomy|"Percutaneous tracheostomy in this study will be performed with the use of a dedicated double-lumen endotracheal tube.
The dedicated double-lumen endotracheal tube (Deas S.R.L, Italy) has an upper and a lower lumen. The upper one will be occupied by flexible fiberoptic bronchoscope while the lower one is exclusively dedicated to patient ventilation during the procedure. The lower lumen has a a semi-elliptical cross section. This tube will be placed in the patient airway with a direct laryngoscopy. After this intubation, a percutaneous dilatational tracheostomy will be performed with the standard techniques recognised in the literature."
1670989|NCT01691209|Device|Phoenix (BAY81-2996)|Topical formulation applied to the skin
1670990|NCT01691209|Drug|1% Hydrocortison cream|1% Hydrocortison cream applied to the skin
1670991|NCT01691170|Other|Stretching Hamstring|
1670992|NCT01691170|Other|Quadriceps Strengthening|
1724028|NCT00004030|Drug|VX-853|
1670993|NCT01691157|Other|Evidence based exercise protocol|An evidence based graduated exercise rehabilitation protocol will be provided and supervised by a physiotherapist. patients will receive 6 sessions of supervised physiotherapy
1670994|NCT01691157|Other|Usual physiotherapy without exercise|Will receive modified usual physiotherapy care that can consist of any physiotherapeutic modalities normally provided except exercise. this may consist of postural advice, taping, electrotherapy, acupuncture, manual joint mobilizations of the shoulder, cervical or thoracic spine.
1670995|NCT01691131|Other|Exercise training|Comparison of high intensity exercise training on land versus water.
1670996|NCT01691118|Drug|Fimasartan|
1670997|NCT01691118|Drug|Antihypertensive treatment|
1670998|NCT01691105|Other|Academic Detailing + Integrated Tobacco Order Set|"Physician will have access to:
NRT with dosing instructions Bupropion and varenicline with dosing instructions Automated referral to the CT Quitline Automated fax to PCP Discharge prescription prompt Quitline report sent to PCP 2 day call back from hospital call center"
1670999|NCT01691092|Drug|Ketamine|All subjects will receive ketamine to induce glutamate release in the brain
1671000|NCT01691079|Drug|ipratropium bromide|Inhaled ipratropium bromide administered before exercise.
1671001|NCT01691079|Drug|Placebo|Inhaled placebo administered before exercise.
1671002|NCT01691066|Behavioral|Infant Toddler Years PRT|
1671003|NCT01691053|Drug|Spironolactone|50mg once daily
1671004|NCT01691053|Drug|Placebo|Placebo
1671005|NCT01691040|Drug|NOX-H94|intravenous injection
1671006|NCT01691040|Drug|Placebo solution|intravenous injection
1671008|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
1671009|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
1671010|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
1671011|NCT01691014|Other|non-interventional study|Study with 4 arms/groups with 36 patients per group. In total 144 patients.
1671012|NCT01691001|Drug|Dexmedetomidine|dexmedetomidine(vs saline) 1 mcg/kg iv bolus during 10minutes, and then, 0.1 mcg/kg/h dexmedetomidine(vs saline) was infused.
1671013|NCT01691001|Drug|normal saline|
1671017|NCT01690975|Drug|Placebo|Placebo - single dose at start of each treatment period
1671018|NCT01690975|Drug|Benzonatate - 400 mg|Benzonatate - 400 mg single dose
1671019|NCT01690975|Drug|Benzonatate - 600 mg|Benzonatate - 600 mg single dose
1671020|NCT01690962|Other|Vegan diet and vitamin B12 supplement|A low-fat, vegan diet (no meat, fish, eggs or dairy products) and a vitamin B12 supplement in the form of 2000mcg of methylcobalamin
1671021|NCT01690962|Dietary Supplement|Vitamin B12 supplement|A daily vitamin B12 supplement in the form of 2000mcg of methylcobalamin
1671022|NCT01690949|Drug|PUR118|inhaled PUR118, BID
1671023|NCT01690936|Dietary Supplement|Almonds 43g/day|43 grams of almonds were supplemented to the 4 intervention arms but eaten at different times of day (with meals or alone as snacks) for 4 weeks. Control group was asked to avoid all nuts/seeds during the study period
1671024|NCT01690923|Device|Nasal mask|Nasal mask (Mirage Activa, Micro, FX)
1671025|NCT01690923|Device|Pillows mask|Nasal pillows mask (Swift FX)
1671026|NCT01690910|Device|Rifton Gait Trainer|
1671027|NCT01690910|Device|Front Wheeled Walker|
1671028|NCT01690897|Behavioral|Mindfulness-based treatment|The MIND Study treatment consists of eight 2-hour long weekly group psychoeducational sessions combining education, cognitive and behavioural theory, and mindfulness skills.
1671029|NCT01690884|Drug|Adenosine|Adenosine will be infused into the brachial artery at 0.125 mg/min for 15 minutes and then at 0.5 mg/min for an additional 15 minutes,
1671030|NCT01690871|Drug|BEZ235|Patients will be provided with an adequate supply of study treatment for self-administration at home. Unless otherwise warranted, new study drug packages will be provided to the patient at Cycle 1 Day 1 (start of treatment) and at Day 1 of each following treatment cycle. The first dose of BEZ235 (Cycle1 Day1) must be taken at the hospital.
1671031|NCT01690858|Other|blood sample|blood sampling at inclusion and throughout pregnancy when pregnant
1671032|NCT01690845|Device|MARS|Molecular adsorbent recirculating system (MARS®) can be used in patients with acute liver failure for bridging to liver transplantation. Studies reported that MARS® therapy improved the hemodynamic situation in patients with acute and acute on chronic liver failure. Several groups observed an increase in arterial pressure, systemic vascular resistance index, a decrease in portal pressure and improvement of renal blood flow. Furthermore, studies demonstrated that MARS therapy reduces ammonia levels and improves hepatic encephalopathy.
1671033|NCT01690832|Drug|standard saline infusion|i.v. 1 ml/kg/h saline infusion from 6 hours before the procedure to 12 hours after the procedure
1671034|NCT01690832|Drug|fenoldopam infusion|combination of i.v. 1 ml/kg/h saline infusion and fenoldopam administration (0.08 mcg/Kg/min) from 6 hours before the procedure to 12 hours after the procedure
1671035|NCT01690819|Procedure|Conventional Ventilatory Strategy|The conventional strategy will be the standard of care with a lower limit of tidal volume equal to 8 ml/Kg of predicted body weight and with a PEEP of 4 cmH2O
1671036|NCT01690819|Procedure|Protective Ventilatory Strategy|The protective strategy will consist of a tidal volume of 6 ml/Kg of predicted body weight, with a PEEP of 8 cmH2O
1671037|NCT01690780|Drug|Oral morphine|oral morphine 0.5 mg/kg (max 10 mg) every 6 hours as needed for 24 hours
1724121|NCT00004066|Biological|filgrastim|
1671038|NCT01690780|Drug|Ibuprofen|Ibuprofen 10 mg/kg (max 600 mg) every 6 hours as needed for pain (maximum 4 doses) for 24 hours following discharge from the emergency department
1671039|NCT01690767|Drug|2% lidocaine gel|Children < 7 kg and > 7 kg will receive 1 cc and 1.5 cc of 2% lidocaine gel, respectively
1671040|NCT01690767|Drug|Health Care Lubricating Jelly|Non-medicinal lubrication gel
1671041|NCT01690754|Other|Interactive Reminders|Daily SMS reminders sent to TB patients at a pre-specified time. They are asked to respond to the reminders. If a response is not received within two hours, they are sent another reminder for up to three per day.
1671042|NCT01690741|Drug|Nerofe|Nerofe administered intravenously 3x/week
1671043|NCT01690728|Behavioral|Physical Activity|The intervention program will continue for six month consisting of two weekly sessions of 40 min exercise supervised by physiotherapists. The supervised exercise program will take place at the training center Fitness.dk in Esbjerg and Kolding. It will be in cooperation with physiotherapists at the Therapy Department of Sydvestjysk Sygehus Esbjerg and the Therapy Department of Fredericia and Kolding Sygehus, Sygehus Lillebælt. The exercise program at the two centers will be equal. In addition the patients will be provided with free access to a fitness center. The patient will be encouraged to do at least 3.5 hours of moderate to vigorous physical activity per week.
1671044|NCT01690702|Drug|Epirubicin|
1671045|NCT01690702|Drug|nab-Paclitaxel|
1671046|NCT01690702|Drug|Cyclophosphamide|
1671047|NCT01690702|Drug|Docetaxel|
1671048|NCT01690689|Device|Implant surgery|surgery
1671049|NCT01690676|Dietary Supplement|Epicatechin|
1671050|NCT01690676|Dietary Supplement|Microcrystalline cellulose|
1671051|NCT01690663|Drug|Bupivacaine 0.25%|
1671052|NCT01690663|Drug|Dexamethasone|
1671053|NCT01690663|Drug|normal saline|placebo
1671054|NCT01690650|Drug|Oxygen|Oxygen exposure (100% oxygen) for 5 minutes, then 25 minutes with room air. Repeated twice. Continuously monitoring of the cerebral oxygen saturation (NIRS).5 replacements of sensor for reproducibility.
1671055|NCT01690637|Drug|Oseltamivir phosphate suspension|
1671056|NCT01690637|Drug|Placebo|
1671057|NCT01690624|Drug|BI 836858|Monotherapy with BI 836858 administered as intravenous infusion
1671058|NCT01690611|Procedure|Treadmill Walking|"Individuals will walk at a comfortable speed on a treadmill without holding on to the hand rails."
1671059|NCT01690611|Other|Visual Feedback|Real time feedback regarding body motion while walking.
1671060|NCT01690598|Drug|Veliparib|Veliparib (tablet) twice daily on days 1-3, 7-9, and 14-16 in a 28 days cycle. In phase I the starting dose is 30 mg x 2.
1671061|NCT01690598|Drug|Topotecan|2 mg/m² iv over 30 minutes on days 2, 8, and 15 in cycles of 28 days. Topotecan is dosed at a maximum body surface area of 2 m².
1671062|NCT01690585|Drug|Ferinject 1000 mg|
1671063|NCT01690585|Drug|Sodium chlorure 0,9 %|
1671064|NCT01690572|Device|Paclitaxel coated balloon catheter|Dilatation of the target lesion
1671065|NCT01690572|Device|"uncoated balloon catheter sprinter legend"|Dilatation of the target lesion
1671066|NCT01690559|Drug|Cipro (Ciprofloxacin, BAYQ3939)|Patient treated with Ciproxan without dilution treatment in daily clinical practice
1671067|NCT01690546|Drug|very low dose naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
1671068|NCT01690546|Drug|extended release naltrexone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
1671069|NCT01690546|Drug|buprenorphine/naloxone|On days 1-3, participants will receive buprenorphine/naloxone daily, starting at a dose of 4 mg, progressively decreasing to 2 mg on Days 2-3 and very low dose naltrexone at 0.25 mg to 1 mg on Days 1-3, 2 to 6 mg on Day 4 and 10 mg to 50 mg on Days 5-7. VIVITROL injection will be administered on Day 8 at 380 mg.
1671070|NCT01690533|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients treated with Moxifloxacin in daily clinical practice
1671081|NCT01690507|Drug|Decitabine|20 mg/m²/day for 5 days
1671082|NCT01690507|Drug|Cytarabine|
1671083|NCT01690507|Drug|aclacinomycin|
1671084|NCT01690507|Drug|Granulocyte colony-stimulating factor|
1671085|NCT01690507|Other|HLA haploidentical mononuclear cells infusion|
1671086|NCT01690494|Behavioral|PACT|Couple-based behavioral HIV/STI preventive intervention
1671087|NCT01690494|Behavioral|TAU|Standard treatment of care services provided to male offenders by the Criminal Court, Community Court or probation sites
1671088|NCT01690468|Drug|Triciribine|Triciribine (15, 25, 30, 35, or 45 mg/m^2) on days 1, 8, 15 every 21 days. To be given as a 60 minute IV infusion.
1671089|NCT01690468|Drug|Carboplatin|Carboplatin will be administered on day 1 every 21 days, as a 30 minute IV infusion after completion of TCN.
1671090|NCT01690442|Behavioral|Couples Based HIV/STI Risk Reduction Intervention (CHSR)|The intervention includes a combination of empowerment and couple self-efficacy building strategies, which are employed to help couples overcome resistance to risk reduction.
1671138|NCT01690169|Drug|NNC0113-0987|A single dose for oral administration, up to 7 dose levels will be investigated. If a non-tolerated dose level has been reached, the dose level will not be increased further.
1671091|NCT01690442|Behavioral|Renaissance Wellness Promotion (WP)|This intervention employs a psychoeducational approach to promote wellness, focusing on: maintaining a healthy diet on a low budget, exercising and fitness, stress reducing strategies and specific health related issues that affect IDUs, such as overdose.
1671092|NCT01690429|Device|Somnocheck micro|Study nights in sleep lab with standard polysomnography plus Somnocheck micro. The Somnocheck micro is a device with pulse oxymetry and nasal cannula, which can be worn like a wristwatch. It records information about sleep disordered breathing, oxygen saturation, and pulse wave.
1671093|NCT01690416|Procedure|Traditional palpation technique|
1671094|NCT01690416|Procedure|Ultrasound DNTP|
1671095|NCT01690403|Drug|rifapentine (M000473)|"Pharmaceutical form:tablet
Route of administration: oral"
1671096|NCT01690403|Drug|EFZ EMT TDF|"Pharmaceutical form:tablet
Route of administration: oral"
1671097|NCT01690390|Drug|Icotinib of routine dose|Icotinib of routine dose: 125 mg is administered orally three times per day.
1671098|NCT01690390|Drug|Icotinib of high dose|Icotinib: 250 mg is administered orally three times per day.
1671099|NCT01690377|Biological|PDC or myDC|PDC or myDC; first patient 0.3 * 10E6 PDC; second and third 1 * 10E6 PDC; fourth and fifth 3 * 10E6 PDC.
1671100|NCT01690364|Other|MEP monitoring with continuous infusion of vecuronium during general anesthesia|MEP monitoring with continuous infusion of vecuronium during general anesthesia
1671101|NCT01690364|Other|MEP monitoring with continuous infusion of cisatracurium during general anesthesia|MEP monitoring with continuous infusion of cisatracurium during general anesthesia
1671102|NCT01690351|Drug|PF-05089771|Oral dispersion TS formulation- fasted
1671103|NCT01690351|Drug|PF-05089771|Capsules TS formulation- fasted
1671104|NCT01690338|Drug|Vecuronium Bromide|Administrative protocol of Vecuronium Bromide is determined by each caregiver's clinical experience.
1671105|NCT01690338|Drug|Rocuronium|Administrative protocol of rocuronium is determined by each caregiver's clinical experience.
1671106|NCT01690338|Drug|Cisatracurium|Administrative protocol of cisatracurium is determined by each caregiver's clinical experience
1671107|NCT01690325|Drug|Docetaxel|
1671108|NCT01690325|Drug|Trastuzumab|
1671109|NCT01690325|Drug|Bevacizumab|
1671110|NCT01690325|Drug|Epirubicin|
1671111|NCT01690325|Drug|Cyclophosphamid|
1671112|NCT01690312|Dietary Supplement|Fish Oil|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of fish oil [620 mg of DHA and 150 mg of EPA], providing a total daily dosage of 4000 mg of fish oil [3080 mg of DHA+EPA].
1671113|NCT01690312|Dietary Supplement|Placebo|On Day 1 and Day 15, participants will receive a 2-week supply of study supplements and will be instructed to consume 4 capsules per day. Each capsule contains 1000 mg of olive oil, providing a total daily dosage of 4000 mg of olive oil.
1671114|NCT01690299|Drug|Apremilast|Apremilast 30 mg tablet orally BID
1671115|NCT01690299|Drug|Etanercept|Etanercept 50 mg evaluator/subject-blinded SC QW injection
1671116|NCT01690299|Drug|Placebo tablet|Placebo tablets BID
1671117|NCT01690299|Drug|Placebo injection|Once weekly evaluator/subject-blinded SC placebo (1 mL x 2 injections SC)
1671118|NCT01690286|Drug|JNJ-38518168 3 mg|One oral daily dose of JNJ-38518168 3 mg for 25 days.
1671119|NCT01690286|Drug|JNJ-38518168 30 mg|One oral daily dose of JNJ-38518168 30 mg for 25 days.
1671120|NCT01690286|Drug|JNJ-38518168 10 mg|One oral daily dose of JNJ-38518168 10 mg for 25 days.
1671121|NCT01690286|Drug|Ketoconazole 200 mg|Oral doses of ketoconazole 200 mg every 12 hours, from Day 22 through Day 25.
1671122|NCT01690273|Other|mobility exercise|30 minutes, twice a week
1671123|NCT01690273|Other|mobility and elastic resistance exercise|30 minutes, twice a week each exercises group. (total 1 hour)
1671124|NCT01690260|Drug|Bone Morphogenetic Protein 2|12 mg recombinant BMP-2 combined with an injection of 1-2 g collagen type 1.
1671125|NCT01690260|Procedure|Autologous bone graft|Autologous bone graft in connection with bone docking operation.
1671126|NCT01690247|Drug|Conventional plus UC-MSC|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
1671127|NCT01690247|Drug|Conventional plus placebo|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
1671128|NCT01690234|Procedure|Multidisciplinary intervention|Early coordinated multidisciplinary intervention. Physiotherapist, chiropractor, rheumatologist, psychologist, occupational physician, ergonomist and social worker/case manager.
1671129|NCT01690234|Procedure|Usual care|Intervention from physiotherapist, chiropractor, rheumatologist and social worker.
1671132|NCT01690208|Other|EMERALD|"Patients assigned to the EMERALD group will be followed up at a Diabetes Centre led by the nurses and supported by diabetologists, with a particular emphasis on individualizing HbA1c goals and selecting drugs based on clinical profiles to maximize benefits and minimize harm.
These patients will also undergo an intensive 3 to 4 months empowerment program where patients within the same group, and therefore sharing similar profiles, will return to the centre monthly to undergo a 2-3 hour activity session led by diabetes nurses, peer supporters and paramedics. Between medical visits, the nurses or HCA will telephone the patients at least once to provide support, help problem-shoot and remind them of their follow-up schedule."
1671133|NCT01690208|Other|Usual Care|Patients randomised to the usual care group will receive their routine care after the initial baseline comprehensive assessment & explanation of the JADE reports. A repeat comprehensive assessment will then be conducted at year 3.
1671134|NCT01690195|Drug|ABT-126|See arm description
1671135|NCT01690182|Dietary Supplement|Study test meal 1|Volunteers will be fed with a high volume, high energy density test meal.
1671136|NCT01690182|Dietary Supplement|Study test meal 2|Volunteers will be fed with a high volume, low energy density test meal
1671137|NCT01690182|Dietary Supplement|Study test meal 3|Volunteers will be fed with a low volume, high energy density test meal
1671139|NCT01690169|Drug|placebo|A single dose of oral placebo administered.
1724122|NCT00004066|Drug|docetaxel|
1671140|NCT01690143|Drug|Carfilzomib|Subjects will receive the appropriate dose of carfilzomib (according to assigned cohort in phase 1 and at the determined MTD in phase 2) on days -3 and -2. Carfilzomib will be infused over 30 minutes. Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
1671141|NCT01690143|Drug|Melphalan|Subjects will receive 200 mg/m2 of intravenous melphalan on Day -2. Administered as an intravenous push or a fast infusion according to institutional standard operating procedure (SOP). Prophylaxis of chemotherapy induced nausea and vomiting will follow institutional guidelines and SOPs.
1671142|NCT01690130|Device|Transcranial Magnetic Stimulation (Neuronetics)|Transcranial magnetic stimulation is a noninvasive brain stimulation that can focally stimulate the brain of an awake individual. A TMS pulse focally stimulates the cortex by depolarizing superficial neurons which induces electrical currents in the brain.
1671143|NCT01690130|Device|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS.The sham-TMS scalp discomfort will be matched to that of active TMS.
1671144|NCT01690117|Behavioral|GE-REACH-program|"The intervention program Resources to Enhance Alzheimer`s Caregivers Health -second step (REACH II) is a multimodal, individualized and structured multi-component intervention program for family caregivers"
1671145|NCT01690104|Drug|Rifampicin|
1671146|NCT01690104|Drug|Placebo|
1671147|NCT01690091|Drug|Metformini hydrochloridum (Siofor 1000 tbl, Berlin)|"Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
Titration:
500 mg per day(1/2 tbl 1000 mg once a day - in the morning) after a week increase the dose to 1 tbl á 1000 mg after two weeks increase the dose to 2 x tbl 1000 mg (in the morning and in the evening)"
1671148|NCT01690091|Drug|placebo|Patients will be randomized into 2 groups (A succession: MET-placebo, B succession: placebo-MET. After 3 months the treatment will be switched.
1671149|NCT01690065|Drug|Nilotinib+AD induction|"• Post-remission consolidation chemotherapy
4 courses of high-dose cytarabine will be given as post-remission therapy. Cytarabine 3 g/m2 will be administered in a 3-hour iv infusion every 12 hours on days 1, 3, and 5 (a total of six doses per course).
Nilotinib 400mg bid PO will be administered continuously during consolidation chemotherapy and for 2 years after the consolidation therapy or until allogeneic hematopoietic stem cell transplantation"
1671150|NCT01690052|Drug|Cevimeline|"Cevimlenine Vs Pilocarpine, cross over design. Two sequences were evaluated cevimeline first, then pilocarpine and pilocarpine first, then cevimeline. Each sequence was evaluated for 4 weeks with one week washout period in between both sequences. 15 patients were randomly assigned to a specific sequence by a research pharmacist independent from the study authors. The patients received 30mg of cevimeline three times a day and pilocarpine 5mg three times a day."
1671151|NCT01690052|Drug|Pilocarpine|Cevimlenine Vs Pilocarpine, cross over design, 4 weeks, one week wash out
1671152|NCT01690039|Drug|Furosemide-Fludrocortisone-Test (test for urinary acidification)|The presence of a lack of urinary acidification will be assessed by an appropriate test in all patients.
1671153|NCT01690026|Behavioral|Motivation interviewing based brief intervention|
1671154|NCT01690026|Behavioral|Standard Intervention|
1671155|NCT01690000|Drug|Melatonin|1 or 3 mg of melatonin PO each night for 12 months
1671156|NCT01689987|Drug|Cyclophosphamide|Given IV
1671157|NCT01689987|Drug|Dexamethasone|Given PO
1671158|NCT01689987|Drug|Hydroxychloroquine|Given PO
1671159|NCT01689987|Other|Laboratory Biomarker Analysis|Correlative studies
1671160|NCT01689987|Other|Pharmacological Study|Correlative studies
1671161|NCT01689987|Drug|Sirolimus|Given PO
1671164|NCT01689961|Behavioral|Structured + monitored nutrition and exercise intervention|The exercise intervention includes a custom-designed pregnancy-specific group walking class of 30-60 min. 1x/week and a prescribed at-home walking program for 10,000 steps/day. The nutrition intervention is a high protein (25% energy) low-fat dairy food plan designed to meet energy needs and with individualized counselling. The intervention will include 2 x/month weight monitoring and records of nutrition and activity to ensure adherence.
1671165|NCT01689948|Behavioral|Home rehabilitation therapy|12 sessions of home rehabilitation therapy
1671166|NCT01689935|Drug|20 % Aminolevulinic Acid|topical medication for ALA-PDT and i-PDT
1671167|NCT01689935|Device|Red light only|Red Light therapy
1671168|NCT01689935|Device|Blue light only|Blue light only
1671169|NCT01689922|Other|AlterG|All patients will begin an early postoperative rehabilitation program and standard PT no later than 4 weeks following surgery and continue for at least 6 weeks. The duration of standard PT program could be extended depending on the patient needs. The patients randomized to undergo (LBPP) treadmill training will have an additional 7-week 3 times a week training on the antigravity
1671170|NCT01689909|Drug|Zolpidem-CR|Zolpidem 6.25 mg or 12.5 mg in tablet form at nighttime 15 minutes before bed for 8 weeks
1671171|NCT01689909|Drug|Placebo|Placebo in tablet form at nighttime 15 minutes before bed for 8 weeks
1671172|NCT01689896|Drug|Testosterone Gel|
1671173|NCT01689896|Drug|Placebo Gel|
1671174|NCT01689883|Device|Current stimulator|This is a device developed by the investigators to produce sub-sensory electrical stimulation delivered via subcutaneous electrodes placed on the skin.
1671175|NCT01689870|Drug|Anti-OX40|Anti-OX40 will be administered i.v. over 60 minutes only in the first week on Days 1, 3 and 5
1671176|NCT01689870|Drug|Ipilimumab|Ipilimumab will be administered at 3 mg/kg i.v. over 90 minutes every 3 weeks for a total of 4 doses, starting on Day 1
1671177|NCT01689857|Device|Scarclinic™ Thin|Apply Scarclinic™ Thin on the scar and dispense 4 ea.for each participant for 3 month.
1671178|NCT01689857|Device|Scarclinic™ Normal|Apply Scarclinic™ Normal on the scar and dispense 4 ea.for each participant for 3 month.
1671179|NCT01689844|Behavioral|DASH Plus|DASH diet advice and guided shopping for high postassium foods at a local supermarket
1671180|NCT01689844|Behavioral|DASH - C|Brief DASH dietary advice, No shopping guidance at the local supermarket.
1671228|NCT01689441|Drug|Placebo|
1671181|NCT01689831|Biological|To confirm the potency of Aplisol formulated with newly produced Tuberculin PPD compared to PPD-S2 standard.|Comparison of different dosages of Aplisol PPD relative to reference standard PPD-S2.
1671182|NCT01689831|Biological|Reactivity of Aplisol compared to reference standard PPD-S2.|Reference standard PPD-S2 formulated to contain different dose concentrations.
1671183|NCT01689818|Other|exercise training|exercise training program which included aerobic exercise for 3 times per week.
1671184|NCT01689792|Drug|MOVIPREP|
1671185|NCT01689792|Drug|CitraFleet|
1671186|NCT01689779|Drug|100,000 IU cholecalciferol|active drug
1671187|NCT01689779|Drug|Placebo|comparator drug
1671188|NCT01689766|Drug|Technetium Tc 99m EC20|
1671189|NCT01689753|Device|TEGO connector®|
1671190|NCT01689753|Drug|Trisodium citrate|
1671194|NCT01689727|Drug|Technetium Tc 99m EC20|
1671195|NCT01689714|Drug|Tc 99m EC20|
1671198|NCT01689675|Behavioral|Computer based pain management|
1671199|NCT01689662|Drug|Tc 99m EC20|
1671200|NCT01689649|Drug|Topiramate|The patients will receive topiramate tablet twice daily orally up to 16 weeks.
1671201|NCT01689636|Drug|Tc 99m EC20|
1671202|NCT01689623|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral. TMC435 will be administered at a dose of 150 mg once daily from Day 4 until Day 15.
1671203|NCT01689623|Drug|Atorvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Atorvastatin will be administered as a single oral 40-mg dose on Day 1 and Day 13.
1671204|NCT01689623|Drug|Simvastatin|Type=exact number, unit=mg, number=40, form=tablet, route=oral. Simvastatin will be administered as a single oral 40-mg on Day 1 and Day 13.
1671205|NCT01689597|Drug|Morphine|Comparison of different dosages of drug
1671206|NCT01689597|Drug|Placebo|
1671207|NCT01689584|Genetic|salivary kit|The saliva samples will be made of selected related (DNA).
1671208|NCT01689571|Drug|CHF6001|
1671209|NCT01689571|Drug|Placebo|
1671210|NCT01689558|Drug|Recombine Endostatin|Recombine Endostatin is involved in the arm of Recombine Endostatin .Recombinant human vascular endothelial inhibin 7.5 mg/M2 / d dose add 250 ml of physiological saline, dilute in new adjuvant chemotherapy began to 8-21 days intravenous drip, at least 1 hour, a total of 1 cycle; The chemoradiation in cisplatin chemotherapy first day grace degrees 7.5 mg/M2 / d, 1-14 days, a total of one period of treatment
1671211|NCT01689545|Behavioral|Individual level|Index participants will participate in standard HIV VCT supplemented with 2 posttest counseling sessions, followed by 2 post-test skill-building support groups for HIV positive IDUs.
1671212|NCT01689545|Behavioral|Structural level|Community members will participate in 2 community-based HIV and IDU stigma videos combined with a series of visits with community outreach workers.
1671213|NCT01689545|Behavioral|Individual level standard of care|The education materials that are currently offered in Thai Nguyen will be delivered didactically by health workers on 1) the HIV situation in Vietnam; 2) consequences of drug use; 3) routes of HIV transmission; and 4) options for drug treatment.
1671214|NCT01689545|Behavioral|Structural level standard of care|Posters and billboards on HIV/AIDS transmission, leaflets on HIV/AIDS transmission available in health station, 15-minute monthly public broadcasts (via the village loudspeaker) on the consequences of HIV/AIDS and the number of HIV cases in the country and province will be delivered in communities.
1671215|NCT01689532|Drug|Sirukumab 100 mg|Sirukumab 100 mg subcutaneous (SC) injection, at Weeks 0, 2, and every 2 weeks through Week 52.
1671216|NCT01689532|Drug|Sirukumab 50 mg|Sirukumab 50 mg SC at Weeks 0, 4, and every 4 weeks through Week 52.
1671217|NCT01689532|Drug|Placebo|Between sirukumab injections, placebo SC at Weeks 2, 6, and every 4 weeks through Week 52.
1671218|NCT01689519|Drug|Placebo|Placebo supplied as tablets
1671219|NCT01689519|Drug|Vemurafenib|Vemurafenib supplied as tablets
1671220|NCT01689519|Drug|Cobimetinib|Cobimetinib supplied as tablets
1671221|NCT01689506|Drug|Volulyte|6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.
1671222|NCT01689506|Drug|Human Serum Albumin|5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.
1671223|NCT01689493|Behavioral|patient education and daily SMS|The proposed intervention will be based on several conceptual frameworks (Chronic Care Model and Medication Adherence Model) and adapt elements of prior successfully adherence interventions, including: collaborative care, patient education, tailoring of medication regimens, and daily mobile phone short message service (SMS).
1671224|NCT01689480|Other|FSHD training|The training will consist in 3 sessions of 35 min of training per week at home on an ergocycle. The training will be divided in (i) 2 sessions of 30 min aerobic exercises at a constant but moderate (60% of maximal aerobic power, MAP) intensity followed with 5 sets of 10 revolutions at near-maximal intensity and (ii) an interval-training session. This latter session will consist in 5 min warm-up at 40% MAP followed by 5 times 1 min at 80% MAP (recovery = 4 min at 40% MAP) followed by 5 min of active recovery. A systematic supervision of the sessions by the coach will be performed by phone, by using the heart rate recordings and values of Analogic Visual Scale for pain and fatigue.
1671225|NCT01689467|Dietary Supplement|Fermented Velvet Antler extract|Fermented Velvet Antler extract (1g/day)
1671226|NCT01689467|Dietary Supplement|Placebo|Placebo (1g/day)
1671227|NCT01689441|Drug|Calcitriol|
1671229|NCT01689402|Device|MRI Scan with the specified sequences below:|"Standard sequences: Axial T2, axial DWI, Sagittal T1, T2 flair og axial GRE-sequence.
Susceptibility weighted imaging (SWI)
Chemical Shift Imaging (CSI) multivoxel spectroscopi
Post contrast 3D box reconstruction"
1671230|NCT01689376|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off drug
1671231|NCT01689363|Drug|Hyaluronidase|Subjects received intradermal injections of 0.02 mL Amphadase® (hyaluronidase 150 USP units/mL) at two random sites on their forearms.
1671232|NCT01689363|Drug|Histamine|Subjects received one intradermal injection of 0.02 mL Histatrol® (histamine base 0.1 mg/mL) at one random sites on their forearms.
1671233|NCT01689363|Drug|Saline|Subjects received one intradermal injection of 0.02 mL saline at one random site on their forearm.
1671234|NCT01689350|Genetic|Genotype Detection|To Genotype cases in the experimental group and divide them into three groups, including extensive metaboliser (EM), intermediate metaboliser (IM) and poor metaboliser (PM).
1671235|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 30 microgram (mcg) as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
1671236|NCT01689337|Drug|Sprifermin (AS902330)|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
1671237|NCT01689337|Drug|Placebo|Placebo matched to Sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 weeks, starting from 2 weeks after MFx surgery.
1671238|NCT01689324|Biological|(ADACEL®): Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis|0.5 mL, Intramuscular
1671239|NCT01689311|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
1671240|NCT01689311|Drug|Ergonovine|Ergonovine, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
1671241|NCT01689311|Drug|Prostaglandin F2alpha|Prostaglandin F2alpha, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
1671242|NCT01689311|Drug|Misoprostol|Misoprostol, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
1671243|NCT01689298|Drug|Oxytocin|Oxytocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
1671244|NCT01689298|Drug|Carbetocin|Carbetocin, 10-10mol/L to 10-5mol/L; solution made in double-distilled autoclaved water and then tested in physiological salt solution.
1671245|NCT01689285|Drug|valacyclovir tablet|16 healthy adult volunteers (18-55 yr) will be exposed to one tablet
1671246|NCT01689285|Drug|valacyclovir oral solution|16 healthy adult volunteers (18-55 yr) will be exposed to 10 ml once
1671247|NCT01689272|Procedure|Kidney Transplantation from alive relative donor|Donor kidney sampling, preservation, transport and transplantation
1671248|NCT01689259|Drug|SL TNX-102 at 2.4 mg|1 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
1671249|NCT01689259|Drug|SL TNX-102 at 4.8 mg|2 TNX-102 SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing them.
1671250|NCT01689259|Drug|SL TNX-102-A at 2.4 mg|1 TNX-102-A SL Tablet at 2.4 mg held under the tongue until dissolution, without swallowing or chewing it.
1671251|NCT01689259|Drug|Cyclobenzaprine tablets|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
1671252|NCT01689246|Drug|TRx0237 150 mg/day|TRx0237 75 mg tablets will be administered twice daily.
1671253|NCT01689246|Drug|TRx0237 250 mg/day|TRx0237 125 mg tablets will be administered twice daily.
1671254|NCT01689246|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
1671255|NCT01689233|Drug|TRx0237 200 mg/day|TRx0237 100 mg tablets will be administered twice daily.
1671256|NCT01689233|Drug|Placebo|Placebo tablets will be administered twice daily. The active placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence the placebo group will receive a total of 8 mg/day of TRx0237.
1671257|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
1671258|NCT01689220|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
1671259|NCT01689207|Drug|Avibactam (AVI)|PART A: AVI IV infusion
1671260|NCT01689207|Drug|Aztreonam (ATM)|PART A: ATM IV infusion
1671261|NCT01689207|Drug|combination of Aztreonam - Avibactam (ATM-AVI)|PART A: ATM-AVI IV infusion. PART B and C: ATM-AVI IV infusions.
1671262|NCT01689207|Drug|Placebo|PART A, PART B, PART C: matching placebo IV infusions
1671263|NCT01689194|Drug|genexolPM + cisplatin|
1671264|NCT01689168|Behavioral|Counseling|Tobacco cessation counseling
1671265|NCT01689168|Procedure|Chiropractic adjustment|Full spine high velocity, low amplitude manipulation of the spine
1671266|NCT01689155|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1671267|NCT01689142|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
1671268|NCT01689142|Drug|Insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
1671269|NCT01689129|Drug|Insulin glargine new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
1671270|NCT01689129|Drug|Insulin glargine (HOE901) (Lantus)|Pharmaceutical form: solution Route of administration: subcutaneous
1671271|NCT01689116|Drug|Bardoxolone Methyl 20mg|Oral
1671272|NCT01689116|Drug|Bardoxolone Methyl 80mg|Oral
1671273|NCT01689116|Drug|Bardoxolone Methyl Placebo|Oral
1671274|NCT01689116|Drug|Moxifloxacin 400mg|Oral
1671275|NCT01689116|Drug|Moxifloxacin Placebo|Oral
1724304|NCT00004128|Drug|etoposide|
1671276|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment of alcohol use disorders
1671277|NCT01689103|Behavioral|Cognitive-behavioral treatment|Cognitive-behavioral treatment for alcohol use disorders
1671278|NCT01689090|Other|COX inhibitor|Administration of 1 drop voltaren 45 minutes before recordings of diameter changes of retinal vessels are initiated
1671279|NCT01689090|Other|L-NG-monomethyl arginine citrate|Intravenous administration of L-NMMA during recordings of diameter changes of retinal vessels
1671280|NCT01689090|Other|COX inhibitor + L-NG-monomethyl arginine citrate|Combination of interventions. Administration of an eye drop voltaren and 45 minutes later infusion with L-NMMA is started and recording of diameter changes of retinal vessels is performed
1671281|NCT01689077|Other|Therapeutic hypothermia|Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
1671282|NCT01689064|Procedure|Stamm Approach|
1671283|NCT01689064|Procedure|Posterior Septectomy|
1671284|NCT01689051|Other|human glucagon-like peptide 1 (7-36)amide|
1671285|NCT01689051|Other|human glucagon-like peptide 1 (9-36)amide|
1671286|NCT01689038|Drug|F17464|Single dose
1671287|NCT01689025|Drug|NNC0114-0006|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
1671288|NCT01689025|Drug|placebo|Administered subcutaneously (s.c., under the skin) every second week to a total of four doses.
1671289|NCT01689012|Behavioral|Facial Exercise|
1671291|NCT01688973|Drug|Erlotinib Hydrochloride|Given PO
1671292|NCT01688973|Other|Laboratory Biomarker Analysis|Correlative studies
1671293|NCT01688973|Drug|Tivantinib|Given PO
1671294|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 1
1671295|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 2
1671296|NCT01688960|Drug|nesvacumab (REGN910/ SAR307746)|Dose level 3
1671297|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 1
1671298|NCT01688960|Drug|aflibercept (ziv-aflibercept)|Dose level 2
1671299|NCT01688947|Drug|V116517 50-mg tablets|Taken orally twice daily
1671300|NCT01688947|Drug|V116517 30-mg tablets|Taken orally twice daily
1671301|NCT01688947|Drug|Pregabalin capsules|1-2 capsules taken orally twice daily
1671302|NCT01688947|Drug|Placebo|Tablets to match V116517 taken orally twice daily and/or placebo capsules to match pregabalin, 1-2 capsules taken orally twice daily
1671303|NCT01688934|Drug|V116517 50-mg tablets|Taken orally twice daily
1671304|NCT01688934|Drug|V116517 30-mg tablets|Taken orally twice daily
1671305|NCT01688934|Drug|Naproxen 500-mg capsules|Taken orally twice daily
1671306|NCT01688934|Drug|Placebo|Tablets to match V116517 and/or placebo capsules to match naproxen taken orally twice daily
1671310|NCT01688908|Procedure|Endoscopy Screening|"Upper G.I. endoscopy examination with Lugols Iodine in esophagus
Biopsy at the visually abnormal sites
Pathologic examination of all biopsy tissue specimens
Advise of regular re-examination will be given to participants who are diagnosed of moderate and severe dysplasia.
Advises of endoscopic or surgical treatment will be given to participants who are diagnosed of early upper G.I. carcinomas."
1671311|NCT01688882|Drug|QGE031|QGE031 will be evaluated at various dose levels and regimens, based on the impact on disease of the next highest dose level and regimen.
1671312|NCT01688882|Drug|Placebo|Placebo will be used to control for normal variability in disease severity.
1671313|NCT01688856|Device|Electrical stimulator|"The treatment period will be 13 weeks in duration, divided into two 6-week periods of actual treatment separated by 1 week to do mid-treatment assessments. Thus 12 weeks of actual treatment are provided over a 13 week period. Treatment consists of two components:
Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES groups but not for Cyclic NMES group during these sessions. To ensure that all 3 groups receive an equivalent dose of stimulation, the cyclic NMES group has slightly lengthened stimulated hand opening exercise sessions at home than the CCFES groups.)
Self-administered hand opening exercise performed 10 sessions per week at home using the device."
1671315|NCT01688830|Drug|Dabigatran|
1671316|NCT01688830|Drug|BI 655075|
1671317|NCT01688830|Drug|Placebo|
1671318|NCT01688817|Other|Physician's counseling|Colorectal cancer (CRC) screening was recommended to a patient personally by a PCP. The issue was discussed during a routine medical visit according to a standardized scheme. PCP provided a patient with a rationale for CRC screening in asymptomatic individuals and benefits of early treatment of the disease. A patient was told about colonoscopy-based screening program. A PCP provided patient with information on how colonoscopy is performed and how to prepare a bowel for the examination, and informed a patient about possible adverse events related to the procedure including post-polypectomy bleeding and bowel perforation. According to the scheme of the discussion screening modalities other than colonoscopy were not debated, unless a patient specifically asked about them.
1671319|NCT01688817|Other|Information leaflet|Patients were given leaflet on primary colonoscopy colorectal cancer screening program. A leaflet provided rationale for colorectal cancer screening and information on colonoscopy-based colorectal cancer screening program.
1671320|NCT01688804|Behavioral|Behavioral intervention to reduce sedentary time delivered via mobile smartphone|The overall goals of the intervention are to decrease overall sedentary time and to increase the number of breaks in sedentary time. The intervention approach combines an advanced smartphone device with an on-board accelerometer and a sophisticated smartphone application to: 1) monitor participants sedentary behavior in real time in their natural environment; and 2) use monitored data to deliver immediate, individually-tailored, goal-driven prompts and feedback to encourage substitute of sedentary behaviors with physical activity.
1671321|NCT01688791|Drug|Vintafolide|
1671322|NCT01688791|Drug|Carboplatin|
1671323|NCT01688791|Drug|Paclitaxel|
1671475|NCT01687439|Drug|Vinorelbine|25-30mg/m2, D1,8
1671324|NCT01688778|Behavioral|Telemedicine|"Monthly video consultations with a nurse as add-on to standard treatment. The nurse has access to bloodsugar- bloodpressure and weight measurements uploaded by the participants to a tablet computer directly from the devices.
Patients on Insulin measure bloodsugar twice a day (fasting and before their evening meal). Patients not on Insulin measure bloodsugar once a week (fasting and before their evening meal). All participants measure bloodpressure and weight once a week. The intervention lasts 32 weeks."
1671325|NCT01688739|Drug|AMG 334|6 dose levels of AMG 334/Placebo administered as single doses SC or IV in healthy volunteers and migraine patients.
1671326|NCT01688726|Other|SYSTANE® BALANCE eyedrops|
1671327|NCT01688726|Other|Minims® Saline 0.9% eyedrops|
1671328|NCT01688713|Drug|Icotinib|The patients will receive Icotinib in doses of 250mg thrice per day until disease progression or undue toxicity.
1671329|NCT01688700|Drug|Nimotuzumab combined with paclitaxel and cisplatin|"Nimotuzumab: 200mg, IV once a week for 6 weeks during chemotherapy (days 1,8,15,22,29,36).
Cisplatin: 75mg/m2,IV on days 1，22
paclitaxel: 90mg/m2, IV on days 1,8,22,29.
patients will receive radical operation 4-6 weeks after Neoadjuvant therapy."
1671330|NCT01688687|Procedure|Endoscopic submucosal dissection|
1671331|NCT01688674|Drug|10% dextrose|
1671332|NCT01688648|Drug|Lidocaine infusion|a bolus dose of Lidocaine 1.5 mg/kg after anesthetic induction with following infusion with 2 mg/kg/hr during the surgery and same dose during postoperative 24 hour in ICU.
1671333|NCT01688648|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion during anesthetic induction with 0.2 mcg/kg/hr followed by 0.3 ~ 0.7 mcg/kg/hr during the surgery
1671334|NCT01688635|Drug|LY2963016|Administered subcutaneously
1671335|NCT01688635|Drug|US Approved Lantus|Administered subcutaneously
1671336|NCT01688622|Behavioral|3months Exercise|training session consisting of a brief warm-up, followed by an approximately 45-min session of aerobic exercise at an intensity of 60-75% of the age-predicted maximum heart rate (approximately 300 kcal/day) and a 20-min muscle strength train- ing programme (approximately 100 kcal/day), followed by a brief cool-down period.
1671337|NCT01688609|Drug|lapatinib ditosylate|Given PO
1671338|NCT01688609|Drug|paclitaxel|Given IV
1671339|NCT01688609|Biological|trastuzumab|Given IV
1671340|NCT01688609|Procedure|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
1671341|NCT01688609|Other|pharmacological study|Correlative studies
1671342|NCT01688609|Other|laboratory biomarker analysis|Correlative studies
1671344|NCT01688583|Drug|Fentanyl matrix|Dose will be adjusted in accordance with patient's degree of pain and treatment response in the investigator's judgment.
1671345|NCT01688570|Drug|duloxetine|Single dose, orally (pill), 30 mg, taken 6 hours prior to start of the testing session. Subjects will only take a single dose of duloxetine once.
1671346|NCT01688570|Drug|Cyproheptadine|Single dose, orally, 8 mg, 6 hours prior to the start of the respective testing session. Subjects will take a single dose of cyproheptadine once.
1671347|NCT01688570|Drug|Placebo|Single dose, orally, 6 hours prior to the start of the respective testing session. Subjects take a single dose once.
1671348|NCT01688557|Device|Innovative colonoscopy (Olympus CF-HQ190F, NBI + Dual Focus)|NBI and Dual Focus options will be used to classify lesions according to Sano and Kudo classifications.
1671349|NCT01688557|Device|Conventional colonoscopy (Olympus CF-H180DL)|Conventional colonoscopy performed without innovative techniques used in experimental arm.
1671350|NCT01688544|Drug|Ilaprazole|Ilaprazole 10 mg for 7 days
1671351|NCT01688531|Drug|CD0271/CD1579, vehicle|
1671352|NCT01688518|Drug|Heated Lidocaine/Tetracaine Patch|
1671353|NCT01688518|Drug|5% Lidocaine Patch|
1671354|NCT01688492|Drug|Ipilimumab|Abiraterone acetate (JanssenBiotech, Inc/Johnson & Johnson) 1000 mg orally daily plus prednisone 5 mg orally twice daily will be administered continuously during the duration of the trial. Starting at cycle 3 (Combination Therapy), Ipilimumab (Bristol-Myers Squibb) will be infused intravenously (IV) once every 3 weeks for a total of 4 infusions.
1671355|NCT01688479|Drug|Calendula Weleda cream (Weleda AG, Sweden) contains extracts of marigold plant (Calendula Officinalis 10%), wool fat and sesame oil|
1671356|NCT01688479|Drug|Essex® cream (Schering-Plough), aqueous cream without parabens|
1671358|NCT01688453|Behavioral|Standard care management|The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
1671359|NCT01688453|Behavioral|The strengthened care management|"The strengthened care management is the addition of the standard care management and of additional interventions.
The standard-care management program consists of 5 collective sessions of 2 hr each about nutritional practices (food and physical activity) and on changes of nutritional behaviours. The sessions are organized in high schools by the healthcare team in collaboration with pediatricians, dietitians and the Sickness Insurance Primary Fund.
The additional interventions are strengthened solicitation and accompaniment, peer-led education, motivational interview, financial support for physical activity practice, cooking classes and meetings of multidisciplinary consultation."
1671360|NCT01688440|Other|#1 Respiratory Care Solution|Respiratory care solution.
1671361|NCT01688427|Behavioral|Standard IPV Assessment|Test the effectiveness of the eMOCHA DOVE application using mHealth technology for routine assessment of IPV vs. Pencil and paper at enrollment, delivery, and 2 months post birth.
1671362|NCT01688427|Behavioral|Standard DOVE Intervention|Intervention will be administered via eMOCHA tablet vs. home visitor over 6 sessions in 6 months.
1671363|NCT01688414|Procedure|photoacoustic imaging|Undergo PAI
1671364|NCT01688414|Procedure|fluorescence imaging|Undergo fluorescence imaging
1671365|NCT01688414|Procedure|robot-assisted laparoscopic surgery|Undergo robot-assisted laparoscopic surgery
1671476|NCT01687439|Drug|Cisplatin|25 mg/m2, D1-3
1671477|NCT01687439|Radiation|Radiotherapy|
1672737|NCT01677377|Drug|RBP-7000|60mg, 90mg, or 120mg
1671366|NCT01688401|Drug|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).
Standard dose: Cycle 1: 1 mg, intra-arterial (IA) delivery. Cycle 2: 2 mg, intra-arterial (IA) delivery.
Duration of treatment: Eight weeks total - two cycles of IA chemotherapy, separated by four weeks."
1671367|NCT01688388|Procedure|Intraoperative Radiotherapy|Intraoperative radiotherapy (IORT) is delivered after completion of the lumpectomy and sentinel node procedure. IORT is performed on mobile or fixed linacs with variable electron energies in the range of 6-12 MeV prescribed to a dose of 21 Gy, with the prescription dose covering at least 90% of the Planning Target Volume (PTV). PTV is defined as a 3D volume of 1-2 cm beyond the former macroscopic tumor edge (excluding skin, limit to anterior rib surface: 5 Gy). The choice of electron energy as well as the cone applicator size has to account for minimum PTV requirements. Tissue depth measurement will be documented by intraoperative sonography.
1671368|NCT01688375|Drug|Ursodeoxycholic Acid|UDCA administration will begin twenty-four hours after endoscopic or surgical procedure and will last fourteen days. UDCA dose will be administered at 750 mg/day, divided into three doses.
1671369|NCT01688362|Biological|Platelet Rich Plasma (PRP)|Subjects in this group will receive 2 injections with PRP. Subjects will have will have 15cc of blood drawn with the Arthrex ACP syringe. The blood will be placed into the Arthrex PRP centrifuge and spun at 1500 rpms for 5 minutes. The platelets will be drawn off to create the PRP for injection. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the PRP solution using a 22g needle. A dry sterile dressing will be placed on the injection site. This injection will Take place at time zero and then two weeks later it will be repeated.
1671370|NCT01688362|Drug|Corticosteroid|"Subjects in this group will receive one injection with corticosteroids and then one injection with local anesthetic two weeks later. For the first injection patients will have 15ml of blood drawn. This blood will then be discarded in a biohazard container. A 6ml solution of 4ml 0.25% Bupivacaine, 1ml 40mg Kenalog, and 1ml 4mg Dexamethasone will be prepared. A posterior glenohumeral injection under ultrasound guidance will be performed to inject the steroid solution using a 22g needle. A dry sterile dressing will be placed at the injection site.
For the second injection two weeks later patients will have 15 ml of blood drawn. This blood will then be discarded in a biohazard container. Using the same technique as in Visit 2, the investigator will inject a 6 ml solution of 2 ml sterile normal saline with 4 ml 0.25% Bupivacaine to the shoulder using ultrasound. A dry sterile dressing will be placed at the injection site."
1671371|NCT01688349|Other|analyze the role of glucocorticoid in AT distribution.|"The purpose of this trial is to investigate the impact of cortisol on adipose tissue functions, distribution and morphology. Patient with endogenous blood cortisol excess exhibit changes in adipose tissue, with fat gain in the upper trunk, face and neck leading to visceral obesity and features of the metabolic syndrome. The aims of this study will be
to compare the pattern of gene expression between visceral and subcutaneous adipose tissue in Cushing patients requiring an adrenalectomy as cortisol adenoma treatment;
to compare these patterns of gene expression with those of two control populations:1/ healthy metabolic subjects having a partial nephrectomy, 2/obese patients with similar degree of insulin resistance."
1671372|NCT01688336|Drug|FOLFIRINOX|"FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:
Oxaliplatin (85 mg/m2)
Leucovorin (400mg/ m2)
Irinotecan (180 mg/m2)
5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours"
1671373|NCT01688323|Other|Collect Blood and Survey Instruments|Each subject will be administered the appropriate surveys and blood draws over the course of the study.
1671374|NCT01688310|Procedure|Gomco Clamp with Tissue Adhesive|"According to WHO (2011), the Gomco clamp has …an impeccable safety record. In the USA, where it is estimated that well over 1 million neonates are circumcised each year, the Gomco clamp has become the leading instrument used to perform non-ritual male circumcision. Tissue adhesive is widely used in multiple areas of medicine; specifically, multiple observational studies and RCTs have shown cyanoacrylate tissue adhesives to be superior to suture closure in VMMC."
1671375|NCT01688310|Procedure|Open surgical circumcision|The World Health Organization, in its Manual for Male Circumcision under Local Anaesthesia, describes three open surgical techniques (forceps assisted, dorsal slit and sleeve technique), all three of which involve (a) exposure of subcutaneous tissues and (b) suturing for hemostasis and for skin closure.
1671376|NCT01688297|Biological|VXA-A1.1 Oral Vaccine|One or two doses of replication incompetent adenovirus oral tablet vaccine
1671377|NCT01688297|Biological|VXA Placebo Tablet|Off-white tablets similarly formulated to the active drug product tablets.
1671378|NCT01688284|Device|office hysteroscopy|Endometrial wash and biopsy is taken at the day around implantation window (day 14_to day 22)of the menstrual cycle from patients of recurrent miscarriages to evaluate the levels of uterine natural killer cells compared to control of females of normal reproductive outcome
1671379|NCT01688258|Procedure|Diagnostic swab|
1671380|NCT01688245|Behavioral|SMS Assessments & Feedback|Weekly pre-weekend drinking plan and post-weekend drinking outcome assessments with personlaized feedback
1671381|NCT01688245|Behavioral|SMS Assessments|Weekly post-weekend drinking outcome assessments
1671382|NCT01688206|Biological|Atezolizumab [TECENTRIQ]|Participants will receive atezolizumab at a fixed dose of 840 mg, intravenously every 2 weeks.
1671383|NCT01688206|Biological|Vanucizumab|Participants will receive escalating doses of vanucizumab (starting dose: 3 milligram [mg] per kilogram) and fixed dose of vanucizumab (MTD/RP2D: 30 mg/kg), intravenously every 2 weeks.
1671384|NCT01688167|Behavioral|MC and sexual risk reduction|Four group counselling sessions focused on male circumcision and sexual risk reduction
1671385|NCT01688154|Dietary Supplement|35 mg/Kg of grape seed proanthocyanidins extract (2 capsules)|
1671386|NCT01688154|Other|2 empty capsules|
1671387|NCT01688141|Other|Enhanced management|Specialist nurses providing enhanced CKD management using NICE guidelines and enhanced access to secondary care.
1671388|NCT01688128|Device|Phase I U-SMART (4 wks)|Intervention_Control Group, 4-weeks U-SMART(2 session/week); Control_Intervention Group, no intervention
1671389|NCT01688128|Other|Washout (2 wks)|2-weeks wash out period in both arms
1671390|NCT01688128|Device|Phase II U-SMART (4 wks)|Intervention_Control Group, no intervention; Control_Intervention Group, 4-weeks U-SMART(2 session/week, Crossover design)
1671478|NCT01687426|Drug|Brimonidine Tartrate 0.025%|1 drop in each eye daily four times a day for 14 days
1671479|NCT01687426|Drug|Vehicle|1 drop in each eye daily four times a day for 14 days
1671391|NCT01688115|Procedure|Video|The afternoon before the surgery session, a researcher will show to the child a video of the length of 6 minutes, using an I-pad. The video shows two clown doctors working constantly at Meyer Children's Hospital, which, through skits and gags, will tell the child how is an operating room and some devices and procedures used during the induction of anesthesia.
1671392|NCT01688115|Other|Standard care|In this arm orally information will be given by the nurse of the ward only to the parents of the child. Any additional information or explanation will be given to the child
1955036|NCT03306290|Drug|Serum dosage of antibiotic prophylaxis CEFOXITIN|"Three blood samples will be collected. These samples are specific for the research, and will be performed on the forearm opposite to the one used for Cefoxitin infusion.
Blood sample at the start of surgery (t0): at the end of the Cefoxitin infusion (~30 min), 1 tube (5 ml) of blood will be withdrawn
Blood sample at half way surgery (t1): 1 tube (5 ml) of blood will be withdrawn (if applicable)
Blood sample at skin closure (t2): 1 tube (5 ml) of blood will be withdrawn"
1671395|NCT01688089|Drug|ODM103|
1671396|NCT01688089|Drug|Placebo|
1671397|NCT01688089|Drug|Entacapone|
1671398|NCT01688089|Drug|Levodopa/carbidopa|
1671399|NCT01688076|Procedure|Botulinum Toxin A|Forehead will be injected with Botox.
1671400|NCT01688050|Device|Zenith® TX2® Low Profile Endovascular Graft|Zenith® TX2® Low Profile Endovascular Graft
1671404|NCT01688024|Drug|Mitomycin C|
1671405|NCT01688024|Drug|Normal saline|
1671406|NCT01687998|Drug|Evacetrapib|Administered Orally
1671407|NCT01687998|Drug|Placebo|Administered Orally
1671408|NCT01687985|Drug|BLI801 laxative - low dose|BLI801 laxative - oral solution
1671409|NCT01687985|Drug|BLI801 laxative - high dose|BLI801 laxative - oral solution
1671412|NCT01687959|Other|tissue sampling from peritoneum of the gallbladder|tissue sampling from peritoneum of the gallbladder during laparoscopic cholecystectomy after an acute attack of acute biliary pancreatitis
1671413|NCT01687933|Device|three-dimensional glasses(manufactor Vuzix,wrap 920)|The samples were randomly allocated to use three-dimensional glasses for 30 minutes in order to reliving labor pain.
1671414|NCT01687933|Other|usual care|Women in Control group did not use the glasses.
1671415|NCT01687920|Drug|BAY94-8862 (1.25mg)|
1671416|NCT01687920|Drug|BAY94-8862 (2.5mg)|
1671417|NCT01687920|Drug|BAY94-8862 (5mg)|
1671418|NCT01687920|Drug|BAY94-8862 (7.5mg)|
1671419|NCT01687920|Drug|BAY94-8862 (10mg)|
1671420|NCT01687907|Behavioral|Music|
1671421|NCT01687894|Drug|Vasopressins|Vasopressins propofol vasopressins sevoflurane
1671422|NCT01687894|Drug|Placebo|Placebo propofol & placebo sevoflurane
1671423|NCT01687894|Drug|propofol|vasopressin propofol & placebo propofol
1671424|NCT01687894|Drug|sevoflurane|vasopressins sevoflurane placebo sevoflurane
1671425|NCT01687881|Other|Chiropractic|Chiropractic Spinal Manipulative Therapy
1671426|NCT01687881|Other|Sham Chiropractic|Sham manipulation
1671427|NCT01687868|Drug|Dexmedetomidine|dexmedetomidine 0.7mcg/kg/hr continuous infusion
1671428|NCT01687855|Device|Ultrafast Magnetic Resonance Imaging|MRI was performed with a 1.5 superconducting magnet (Gyroscan Intera type, Philips Co. Holland) in a posterior and anterior neck coil. The sequence used to perform the ultrafast MRI was a fast gradient- echo plus sequence. Technical parameters included: echo time, 12 msec; repetition time, 2.3 msec; flap angle, 250; matrix, 192 × 512; section thickness, 7 mm. The imaging time per slice for this sequence was 0.92 sec. A total of 120 consecutive images were obtained as a single section, with a total imaging time of 110.4 seconds. MRI scanning was carried out with the subject first asleep, then whilst awake after 20 minutes in quiet respiration. All images were inputted to the PACS workstation.
1671429|NCT01687842|Other|Evaluation of 45,X Turner syndrome patients|Evaluation of 45,X Turner syndrome patients
1671430|NCT01687803|Behavioral|Physical Activity|Physical activity intervention that will consist of brisk walking or other aerobic-type activities (6 days per week), resistance exercise (using free weights, resistance bands or weight stacks for weight lifting, 3 days per week), and 'active lifestyle' activities such as gardening, dancing, participation in sporting activities. The total time spent in these activities will add up to ~60 min/day for 6 days/week (~360 minutes per week).
1671431|NCT01687803|Behavioral|Control|The control group will maintain their usual level of physical activity and participate in testing protocols, record keeping, and interviews.
1671432|NCT01687790|Device|molecular breast imaging (Discovery)|
1671433|NCT01687777|Biological|Mesenchymal Stem Cells (MSCs)|20.000.000 autologous MSCs included in the OrthADAPT membrane. Single dosage.
1671434|NCT01687777|Biological|OrthADAPT|
1671435|NCT01687764|Other|Attentional Bias Modification Treatment (ABMT) - Active|The ABMT consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the ABM condition, the target appears at the neutral-face location in all angry-neutral trials. Probe type (< or >) is not factorially counterbalanced but appears with equal probability for each of the following: angry-face location, probe location, or actor.
1671436|NCT01687764|Other|Attentional Bias Modification Treatment - Placebo|The Placebo protocol consists of 160 trials (120 angry-neutral and 40 neutral-neutral presentations). In the placebo condition, angry-face location, probe location, and actor are fully counterbalanced in presentation.
1671437|NCT01687764|Behavioral|Cognitive Behavioral Group Therapy|"FRIENDS for Life Australian protocol for the treatment of anxiety disorders in children"
1671438|NCT01687764|Behavioral|Psychoeducational Control Intervention|Psychoeducational control intervention provides only brief psychoeducational information about anxiety associated with general educational activities
1671480|NCT01687413|Radiation|Intensity-modulated radiation therapy (IMRT)|
1671481|NCT01687413|Drug|Cisplatin|
1671482|NCT01687400|Drug|decitabine|
1671483|NCT01687387|Drug|IPH2102 at 0.1 mg/kg|every 3 months
1671484|NCT01687387|Drug|IPH2102 at 1 mg/kg|every 4 weeks
1671485|NCT01687387|Drug|Placebo (normal saline solution)|every 4 weeks
1671439|NCT01687751|Drug|Dexmedetomidine|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.
The study drug will be started at a rate of 1.0 mL/hr.
The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
1671440|NCT01687751|Drug|Midazolam|"Study drugs will be administered by continuous subcutaneous infusion using a weight based protocol at a rate between 1.0 to 5.5 mL/hr.
The study drug will be started at a rate of 1.0 mL/hr.
The infusion rate is incremented by 0.5 ml/hr every 30 minutes until acceptable symptom control, bradycardia (heart rate < 40) or hypotension (systolic blood pressure < 80) prevent further increase or maximum infusion rate of 5.5 ml/hr, whichever comes first. Achievement of acceptable symptom control will be defined, for purposes of this trial, as a consensus between reports from patient, family care giver and attending registered nurse"
1671446|NCT01687699|Drug|Spironolactone|
1671447|NCT01687673|Drug|Temsirolimus|10 mg weekly will be administered intravenously over 30 to 60 minutes using an infusion pump starting on Cycle 1, Day 1 of study enrollment.
1671448|NCT01687673|Drug|Sorafenib:|200 mg tablet twice daily starting on Cycle 1, Day 1 of study enrollment after completion of temsirolimus infusion.
1671449|NCT01687660|Other|acupuncture|apply acupuncture to prevent the migraine attack
1671450|NCT01687647|Other|low-dose CT-scan AND induced sputum sample AND blood test|All subjects will receive a low-dose CT-scan, a blood test (ancillary study) and provide an induced sputum
1671451|NCT01687634|Behavioral|In-home Mentor Mother visits|Pregnant women will receive twice-monthly in-home (or telephone) visits from a Mentor Mother who will provide information about pregnancy, breastfeeding, nutrition, and infant care.
1671452|NCT01687634|Behavioral|Health Information Mailings|Pregnant women will receive twice-monthly mailings that will provide information about pregnancy, breastfeeding, nutrition, and infant care.
1671453|NCT01687621|Procedure|Diagnostic Algorithm for Community Based Worker for Omphalitis|After obtaining guardian informed written consent, newborns aged 1-10 days presenting to the health facility for routine or sick visits would undergo 2 independent, parallel evaluations; first, by a ZamCAT Field Monitor (community level worker from our existing study) and the second by a Zambian medical doctor (gold standard). A US board of pediatrics-certified pediatrician will perform a third independent assessment of a photo of the cord remotely. Using the on-site clinician as the gold standard, the community-based algorithm and the photo assessment will be tested for concordance and the sensitivity and specificity of the algorithm will be generated. Likewise, the remote pictorial assessment will be compared to the gold standard to determine reliability of diagnosis from photographs alone.
1671454|NCT01687608|Biological|AskBio009|Single dose IV injection
1671455|NCT01687595|Drug|HerpV and QS-21|HerpV (formerly AG-707 rh-Hsc70 Polyvalent Peptide Complex) in combination with adjuvant QS-21.
1671456|NCT01687595|Drug|Placebo|phosphate buffered saline.
1671457|NCT01687582|Drug|GLP-1 analog|GLP-1 analog treatment
1671458|NCT01687569|Other|Control Cracker Snack|Base cracker snack
1671459|NCT01687569|Other|Experimental Cracker Snack 1|Cracker snack containing test ingredient 1
1671460|NCT01687569|Other|Experimental Cracker Snack 2|Cracker snack containing test ingredient 2
1671461|NCT01687556|Other|topical EGCG application on acne|two times application of topical EGCG on acne lesion
1671462|NCT01687543|Dietary Supplement|L. plantarum 299 and L. plantarum 299v (+maltodextrin)|A suspension of Lactobacillus plantarum 299 and Lactobacillus plantarum 299v together with maltodextrin is distributed to the patients twice a day.
1671463|NCT01687543|Other|Maltodextrin|A suspension of maltodextrin (as placebo control) is distributed to the patients twice a day.
1671464|NCT01687530|Procedure|AMCA Bone Membrane.|AMCA Bone Membrane, as a bone stimulating aid for orthopedic trauma applications.
1671465|NCT01687517|Drug|Seasonal influenza vaccine available for the 2012-2013 vaccine campaign|Single injection of the vaccine at D0 (0.5mL intra-muscularly or subcutaneous for patient under anticoagulant treatment)
1671466|NCT01687491|Drug|ENOXA®|enoxaparine 100 UI/Kg subcutaneous injection
1671467|NCT01687491|Drug|LOVENOX®|enoxaparine 100 UI/Kg subcutaneous injection
1671468|NCT01687478|Drug|Olanzapine|Administered Orally
1671469|NCT01687478|Drug|Fluoxetine|Administered Orally
1671470|NCT01687478|Drug|Placebo|Administered Orally
1671471|NCT01687465|Procedure|Argon laser trabeculoplasty|With Argon laser trabeculoplasty (ALT), thermal energy is used directed towards the Trabecular Meshwork (the site of aqueous drainage from the eye),which causes focal scarring of trabecular meshwork, thus enable fluid drainage more effectively. However, this procedure may not be repeatable since it causes too much damage to the trabecular meshwork.
1671472|NCT01687465|Procedure|Selective laser trabeculoplasty|Selective laser trabeculoplasty is a relatively newer technology that uses a Nd:YAG laser to target specific cells within the trabecular meshwork. SLT does not cause coagulative damage to the trabecular meshwork, and thus has the advantage of being repeatable.
1671473|NCT01687452|Biological|Blood samples|
1671474|NCT01687439|Drug|Endostar|7.5mg/m2, D1-14
1671486|NCT01687374|Drug|1-84 parathyroid hormone|100 micrograms of 1-84 parathyroid hormone daily for 8 weeks, subcutaneous injection.
1671487|NCT01687374|Drug|Placebo|Saline injection daily for 8 weeks.
1671488|NCT01687361|Dietary Supplement|branched-chain amino acids (BCAA) supplementation|
1671489|NCT01687361|Drug|PLACEBO|
1671490|NCT01687348|Drug|lidocaine aguettant|
1671491|NCT01687335|Other|answering questionnare in differents time of the treatment|
1671492|NCT01687309|Drug|GSK2586184 800mg single and repeat dose|GSK2586184 800mg single dose and then twice daily dosing for 13 days
1671493|NCT01687309|Drug|Placebo-to-match GSK2586184|Placebo-to-match GSK2586184
1671494|NCT01687309|Other|GSK2586184 single dose taken with food|GSK2586184 single dose taken with FDA approved high fat, high calorie breakfast
1671495|NCT01687309|Other|GSK2586184 single dose taken without food|GSK2586184 single dose taken in a fasted state
1671501|NCT01687283|Drug|fluticasone propionate inhalation solution|1 mg BID inhalation for 12 weeks with one possible chance to change to 0.5 mg BID
1671502|NCT01687283|Drug|budesonide suspension|2 mg BID inhalation for 12 weeks with one possible chance to change to 1 mg BID
1671503|NCT01687270|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
1671504|NCT01687270|Drug|RBV|Ribavirin (RBV) 200-mg tablet(s) administered orally in a divided daily dose starting at 400 mg, subsequently adjusted (range: 200 to 1200 mg in a divided daily dose) based upon a number of factors including hemoglobin value, creatinine clearance, and weight.
1671505|NCT01687257|Drug|SOF|SOF 400 mg tablet administered orally once daily
1671506|NCT01687257|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1671507|NCT01687244|Drug|INSTILADRIN|The INSTILADRIN components will be mixed with a diluent. The total dose will be given as a single, one-hour intravesical administration which may, depending on clinical response, be repeated every 3 months up to a maximum of 4 instillations.
1671508|NCT01687231|Other|Non-neutropenic Diet|Non-neutropenic diet is without restriction.
1671509|NCT01687218|Drug|Oral FTC/TDF (Daily Emtricitabine/Tenofovir Disoproxil fumarate Tablet)|
1671510|NCT01687218|Drug|Rectal Daily TFV RG 1% gel (Rectally applied Tenofovir Reduced Glycerin 1% Gel)|
1671511|NCT01687218|Drug|Rectal RAI-associated TFV RG 1% gel (Receptive Anal Intercourse Associated rectally applied Tenofovir Reduced Glycerin 1% Gel)|
1671512|NCT01687205|Drug|1% Tenofovir Gel|
1671513|NCT01687192|Biological|HPV prophylactic vaccine Gardasil|3 injections: at Inclusion visit then 2 and 6 months after.
1671515|NCT01687166|Device|Blazer Open-Irrigated Ablation Catheter (Boston Scientific)|
1671516|NCT01687166|Device|FDA Approved Open-Irrigated Ablation Catheter|
1671517|NCT01687140|Drug|D-Cycloserine|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
1671518|NCT01687140|Drug|Placebo|Take one pill a day 4 times weekly immediately preceding the treatment session for two weeks of treatment (4 sessions weekly).
1671519|NCT01687127|Dietary Supplement|Folic acid|Supplement
1671520|NCT01687127|Dietary Supplement|5-methyltetrahydrofolate, calcium salt|Supplement
1671521|NCT01687114|Other|cranberry juice|27% cranberry juice
1671522|NCT01687101|Drug|STOPAIN topical gel|STOPAIN topical gel is topical menthol 6% gel applied as 2 to 4 pumps of gel applied behind the ears and to the occipital region of the neck in one or two applications within 2 hours of the onset of the migraine.
1671523|NCT01687075|Device|CR8 a drug eluting coronary stent|a drug eluting coronary device, made of Cobalt-Chromium alloy and integrally coated with i-Carbofilm™, loaded with formulated Sirolimus
1671524|NCT01687062|Other|FeSO4|
1671525|NCT01687062|Other|reduction of phytate|
1671526|NCT01687062|Other|NaFeEDTA|
1671527|NCT01687049|Drug|Red yeast rice|
1671528|NCT01687036|Device|Cryoablation|Cryoablation of Atrial Fibrillation Using a Novel Cryoablation System
1671529|NCT01686997|Procedure|Roux-en-Y Gastric Bypass|
1671530|NCT01686984|Other|Altered breath|
1671531|NCT01686958|Device|MR-Guided Transurethral US Ablation of Prostate Tissue|The technology is developed to treat patients with organ confined prostate cancer. The therapeutic endpoint of this technology is thermal coagulation of prostate tissue.
1671532|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end dose of 20 mg. For oral administration.
1671533|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg or 40 mg. For oral administration.
1671534|NCT01686945|Drug|semaglutide|Start doses of 5 mg and 10 mg with end doses of either 20 mg, 40 mg or 60 mg. For oral administration.
1671535|NCT01686945|Drug|placebo|Placebo semaglutide. For oral administration.
1671536|NCT01686945|Drug|placebo|Placebo semaglutide with carrier. For oral administration.
1671537|NCT01686932|Drug|Vildagliptin|vildagliptin 50mg BID for 8 weeks
1671538|NCT01686932|Drug|Sitagliptin|sitagliptin 100mg QD for 8 weeks
1671539|NCT01686919|Dietary Supplement|milk-free|milk-free diet during 8 preoperative weeks
1671540|NCT01686906|Procedure|Bowman layer graft implantation|For patients with progressive advanced keratoconus, a mid-stromal manual dissection is made and a donor isolated Bowman layer is positioned into the stromal pocket.
1671541|NCT01686893|Device|Nasal oxygen insufflation with a TNI 20 oxy device|Nasal oxygen insufflation with a TNI 20 oxy device
1671542|NCT01686893|Device|Standard Nasal Insufflation of oxygen|Standard Nasal Insufflation of oxygen
1671543|NCT01686880|Device|Sirsphere trans-arterial radioembolization|Patients will receive Sirsphere trans-arterial radioembolization before surgery
1671544|NCT01686867|Device|Improved, ventilated cookstove|"An improved, ventilated cookstove incorporates the following key elements: burner openings customized to the size and shape of the cooking utensils; a flue designed to draw air into the fire box and pass it out through a chimney; a chimney, vented to the exterior, of adequate height to create a draft; an exterior port that has bidirectional openings to prevent the backflow of smoke and an access port for the chimney that permits cleaning.
The investigators piloted cookstoves prior to the trial and compared their ability to reduce indoor air pollution, the reliability between cookstoves of the same type, the functionality over time, preferences and cultural compatibility, and cost. The investigators selected the the Envirofit G-3300/3355, a modified Stovetec cookstove with a chimney and a locally-made improved, ventilated cookstove for use in the trial."
1671547|NCT01686841|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1671548|NCT01686828|Drug|Acyline|300 mcg/mL administered subcutaneously (at Day 0, Week 2)
1671549|NCT01686828|Drug|Testosterone 1.62% gel|Transdermal Testosterone Gel (either 1.25g or 5g/d) for 4 weeks
1671550|NCT01686828|Drug|Letrozole|Letrozole oral aromatase inhibitor 5mg daily for 4 weeks
1671551|NCT01686828|Drug|Placebo gel (for Testosterone 1.62% gel)|placebo gel manufactured to mimic Testosterone 1.62% gel
1671552|NCT01686828|Drug|Placebo pill (for Letrozole)|Oral placebo aromatase inhibitor to mimic Letrozole 5mg/d
1671553|NCT01686802|Drug|oral morphine|
1671554|NCT01686802|Drug|Ibuprofen|
1671555|NCT01686789|Drug|Pegylated interferon alpha-2a|
1671556|NCT01686776|Other|123 I-HSA + 125 I HSA|Compare and validate the method of measuring albumine turnover rate
1671557|NCT01686750|Behavioral|Integrated care centers|
1671558|NCT01686737|Behavioral|Iyengar Yoga|"12 weeks of Iyengar yoga
2 weekly sessions of 60 minutes"
1671559|NCT01686737|Behavioral|Walking|"12 weeks of walking
2 weekly sessions of 60 minutes"
1671560|NCT01686724|Behavioral|Collaborative Life Skills Intervention (CLS)|CLS is a 12-week program and includes school, parent, and student components which are integrated via joint teacher, parent, and student meetings and use of integrated behavioral programs in the classroom, on the playground, and at home.
1671561|NCT01686724|Other|Business As Usual|
1671562|NCT01686711|Drug|AD-4833 15 mg|
1671563|NCT01686711|Drug|AD-4833 30 mg|
1671564|NCT01686711|Drug|Placebo|
1671565|NCT01686698|Dietary Supplement|VSL#3 (Original De Simone formulation)|VSL#3 (Original De Simone formulation) is a probiotic mixture of 8 proprietary strains, namely Streptococcus thermophilus, bifidobacteria and lactobacilli.
1671566|NCT01686698|Other|Placebo|Placebo will be formulated as identical in appearance and administered according to the same schedule as the active agent. Placebo contains maltose and silicon dioxide as inactive agent.
1671567|NCT01686672|Behavioral|Web Intervention|Behavioral
1671568|NCT01686659|Device|Continuous Noninvasive Hemoglobin Monitoring|Availability of data from a continuous noninvasive hemoglobin monitoring device (total hemoglobin [SpHb] and Pleth Variability Index [PVI]) to the clinicians in the operating room
1671569|NCT01686646|Drug|paracetamol + caffeine|paracetamol with caffeine
1671570|NCT01686646|Drug|paracetamol|paracetamol
1671571|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 200/25 mcg|Fluticasone furoate/ vilanterol will be available as 200/25 mcg Novel dry powder inhaler (NDPI) with 30 doses per device and 200/25 mcg per actuation
1671572|NCT01686633|Drug|Fluticasone Furoate/ Vilanterol 100/25 mcg|Fluticasone furoate/ vilanterol will be available as 100/25 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
1671573|NCT01686633|Drug|Fluticasone Furoate 100 mcg|Fluticasone furoate will be available as 100 mcg NDPI with 30 doses per device and 100/25 mcg per actuation
1671574|NCT01686620|Drug|BIOD-123|
1671575|NCT01686620|Drug|Lispro (Humalog)|
1671576|NCT01686607|Drug|Parenteral micafungin application|Oral
1671577|NCT01686607|Drug|Other parenteral antifungal drugs|Oral
1671579|NCT01686581|Drug|Onabotulinumtoxin A|Onabotulinumtoxin A (BOTOX®) administered according to physician prescription; all treatment decisions lie with the physician.
1671580|NCT01686568|Drug|Omega-3|Patients in this group will receive oral supplementation with EPA+DHA (3.9grams/day) for 6 months.
1671581|NCT01686568|Drug|placebo|
1671582|NCT01686555|Drug|ABT-199|Tablet
1671583|NCT01686555|Other|Placebo|Tablet
1671584|NCT01686542|Procedure|CPVI plus renal sympathetic modification|CPVI plus renal denervation to reduce atrial arrhythmia recurrence.
1671585|NCT01686542|Procedure|CPVI|CPVI alone to reduce atrial arrhythmia recurrence.
1671586|NCT01686529|Procedure|Autoconjunctival grafting|The pterygium head was lifted off the corneal surface by blunt dissection. The pterygium body was dissected from the underlying sclera and thereafter excised. A thorough removal of Tenon's capsule was performed in an area much greater than the pterygium body. Free conjunctival autografting after pteryigum excision was performed as follows: the desired size of the conjunctiva under the upper eyelid was marked and excised. No limbal tissue was included in the graft. The excised tissue was placed on the bare sclera and tightly sutured to the sclera and the limbal area. Finally the autograft edges were sutured to the conjunctiva all around.
1671624|NCT01686217|Drug|ASP015K IR|oral immediate release (IR)
1671625|NCT01686204|Other|Low fat dairy yogurt|Consumption of 12 oz of low fat dairy yogurt daily for 9 weeks
1671587|NCT01686529|Drug|Subconjuntival bevacizumab injection|The subconjunctival injection of bevacizumab was applied adjacent to the site of pterygium separation inside the healthy conjunctiva. The half of the dose (1.25 mg/0.05ml) was applied in the nasal inferior quadrant, and the other half of the dose was applied in the nasal superior quadrant.
1671588|NCT01686503|Drug|IPOL (Sanofi Pasteur) inactivated polio vaccine booster dose|Depending on study arm, participants will receive 0.2 mL intradermally, 0.1 mL intradermally, 0.5 mL intramuscularly, or 0.2 mL intramuscularly.
1671589|NCT01686490|Behavioral|Video/workbook for patients about to receive an AICD|will view the 3 completed sections of the video/workbook
1671590|NCT01686490|Behavioral|LiveSkills Video/Workbook for patients about to receive an AICD|This exploratory intervention first met in a focus group with healthcare professionals and another focus group with patients who already had received an automatic implantable cardiac defibrillator to learn more about what video and accompanying workbook material it would be helpful for patients to receive pre-inplantation. Another focus group was held with post-implantation patients asking them what additional knowledge would have been helpful. Three sections of the video with accompanying workbook were then produced and given to pre-inplantation patients. A focus group was then held with these patients after their procedure to ask them what had and had not proved helpful.
1671591|NCT01686477|Other|Unfortified Human donor Milk used to make up any shortfall in mother's own milk|
1671592|NCT01686477|Other|Fortified Human donor Milk used to make up any shortfall in mother's own milk|
1671593|NCT01686477|Other|Preterm Formula used when there is a shortfall in mother's own milk|
1671594|NCT01686464|Drug|prednisone and valacyclovir treatments|patients were administered prednisone as a single dose of 40 mg daily for 5 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.while taking valacyclovir 400 mg in three doses daily for 10 days.
1671595|NCT01686464|Device|Magnetic and Oxygen Treatment|MOMC treatment was given as daily 20 min section for 10 days with 2~3 days of intermission between. Oxygen therapy was given simultaneously at a flow rate of 2~3.0 L / min for the same duration during all acupuncture sections.
1671596|NCT01686451|Drug|XueZhiKang|Participants will receive 600mg of XueZhiKang twice a day for 4 weeks.
1671597|NCT01686451|Drug|simvastatin|Participants will receive 20mg of simvastatin daily for 4 weeks.
1671598|NCT01686438|Behavioral|Cognitive behavioral therapy for insomnia|A behavioral modification program consisting of 6 clinic sessions focused on sleep hygiene, stimulus control, sleep restriction, and cognitive restructuring.
1671599|NCT01686425|Procedure|Percutaneous transhepatic cholangiography vs. endoscopic biliary drainage|Percutaneous transhepatic cholangiography biliary drainage is compared tot endoscopic biliary drainage in the management of malignant biliary obstruction not amenable to ERCP
1671600|NCT01686412|Device|Electromagnetic Fields of Low Energy (EEFLE)|Are employed three sets of programs of different frequencies are modulated specifically for each group of patients in accordance with diagnostic (hepatocellular carcinoma, breast carcinoma and healthy subjects). These frequencies ranging between 0.1 and 114.000Hz.
1671601|NCT01686399|Behavioral|Nutritional and Activity Promotion|Multi disciplinary nutritional and behavioral messages to improve diet and activity levels
1671602|NCT01686386|Drug|Bendamustine|Phase I: dose escalation of Bendamustine Phase II: Dexamethasone will be given in combination with the MTD of Bendamustine and Lenalidomide in cycles lasting 28 days.
1671603|NCT01686386|Drug|Lenalidomide|Phase I: dose escalation of Lenalidomide Phase II: Dexamethasone will be given in combination with the Maximum Tolerated Dose (MTD) of Bendamustine and Lenalidomide in cycles lasting 28 days.
1671604|NCT01686386|Drug|Dexamethasone|Phase I and Phase II Dexamethasone fixed dose 40 mg/die
1671605|NCT01686373|Device|Activa Dose II Real tDCS|
1671606|NCT01686373|Device|Activa Dose II Sham tDCS|
1671607|NCT01686360|Behavioral|Decision Aid|
1671608|NCT01686347|Drug|ropivacaine|
1671609|NCT01686334|Biological|DC vaccine|Autologous WT1 mRNA-electroporated DCs
1671610|NCT01686321|Drug|Bendamustine and subcutaneous rituximab|
1671611|NCT01686308|Procedure|Yellow Intra Ocular Lens (IOL)|Standard operation with blue light filter Yellow IOL implantation
1671612|NCT01686308|Procedure|Conventional Intra Ocular Lens (IOL)|Standard operation with conventional IOL implantation
1671613|NCT01686295|Device|iRestore Hair Rejuvenation System|This study is to evaluate the effectiveness of the iRestore Hair Rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
1671614|NCT01686295|Device|sham device|This shame device will be a sham comparator to evaluate the effectiveness of the iRestore Hair rejuvenation System when used as directed in promoting hair growth in men and women with androgenetic alopecia 3 times a week for 30 minutes on non-consecutive days
1671615|NCT01686282|Dietary Supplement|Freeze-dried Blueberry Powder|8 weeks of freeze-dried taken in two doses of 22g each per day.
1671616|NCT01686282|Dietary Supplement|Placebo|8 weeks of freeze-dried taken in two doses of 22g each per day.
1671617|NCT01686269|Procedure|blood collecting|
1671618|NCT01686256|Drug|Tc 99m EC20|Each subject will receive 1 mg of folic acid injected 1-3 minutes prior to administration of Technetium Tc 99m EC20.
1671619|NCT01686243|Other|epidural needle placement with echogenic 17G touhy needles (Pajunk TouhySono)|Anesthesiologist will place epidural with aid of ultrasound and placement with echogenic 17G touhy needles (Pajunk TouhySono)
1671620|NCT01686243|Other|standard epidural placement|Anesthesiologist will place epidural within standard practice, with standard needles.
1671621|NCT01686230|Other|acupuncture|In each session, we treat bilaterally, 3 times a week and 2 days off a week, each patient in the acupuncture treatment groups will receive 12 sessions of acupuncture treatment over 4 weeks. The whole study period is 20 weeks including 4-week baseline period,4-week treatment period, and 12-week follow-up period. we will investigate at 0 day,4week,8week,12week,16week after randomization。
1671622|NCT01686230|Drug|Basic treatment|"Each group in the basic treatment，Foundation treatment including health education and basic drug therapy.
We recommend lifestyle modification for all patients. Modifications include increasing exercise; limiting alcohol consumption; and weight loss; quit smorking etc.
Basic medication： Aspirin: 100mg qd; Metoprolol：25mg bid; Ramipril:5mg qd; Atorvastatin:20mg qn."
1671623|NCT01686217|Drug|ASP015K ER|oral extended release (ER) at three dosing levels
1671626|NCT01686204|Other|Soy pudding|Consumption of 12 oz of low fat soy pudding daily for 9 weeks.
1671628|NCT01686165|Drug|belinostat|Given IV
1671629|NCT01686165|Biological|rituximab|Given IV
1671630|NCT01686165|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
1671631|NCT01686152|Drug|Imiquimod Cream, 3.75%|
1671632|NCT01686152|Drug|Zyclara®|
1671633|NCT01686152|Other|Vehicle of Test Product|
1671634|NCT01686139|Biological|ABMD-MSC|10-20 x 10^6 cells/20mL
1671635|NCT01686126|Drug|Levonorgestrel|Intrauterine device
1671636|NCT01686126|Drug|Metformin|oral medication
1671637|NCT01686113|Other|NEFA|
1671638|NCT01686113|Other|Sucrose|
1671639|NCT01686100|Procedure|No touch technique|The vein graft is harvested with its surronding tissues.
1671640|NCT01686100|Procedure|Conventional technique|The vein graft is stripped from its surrounding tissues.
1671641|NCT01686087|Behavioral|Monthly Booster Sessions of EX/RP|45 minute EXRP booster sessions each month
1671642|NCT01686087|Procedure|Visits with MD and independent evaluators|All patients will be followed carefully and evaluated by their study doctor and an independent evaluator to assess their symptoms.
1671643|NCT01686061|Other|No intervention- only one time survey|
1671644|NCT01686022|Other|Immunoblot|serum specific IgE binds to grass extract by immunoblot
1671645|NCT01686009|Drug|Intra-nasal ketamine|
1671646|NCT01685996|Drug|zonisamide|In addition to zonisamide vs placebo treatment, varenicline tablets will be dispensed with specific instructions to take at the recommended doses for smoking cessation Participants will receive brief smoking cessation counseling and referral to a quitline
1671647|NCT01685996|Drug|placebo|
1671648|NCT01685983|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Patients will receive 4 tablets of abiraterone acetate at least 1 hour before a meal or 2 hours after a meal any time up to 10 pm every day.
1671649|NCT01685983|Drug|Prednisolone|Type=exact number, unit=mg, number=5, form=tablet, route=oral. Patients will receive 1 tablet of prednisolone twice daily.
1671650|NCT01685970|Drug|High volume split-dose PEG|High volume split-dose PEG 2L/2L 2 times before the day and at the day of colonoscopy
1671651|NCT01685970|Drug|2 sachets of picosulfate|2 sachets of picosulfate 2 times for bowel preparation at the day of colonoscopy
1671652|NCT01685957|Behavioral|Standard dietary treatment (STD)|This group will receive 6 one-on-one sessions with a registered dietitian. Total time spent is 6½ hour. Dietary treatment is based national guidelines and counseling is individualized and tailored to the patient's needs and goals.
1671653|NCT01685957|Behavioral|"Ned i vaegt (NIV)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on the national dietary guidelines. Focus is to learn to make normal danish dishes in a more healthy way both ingredients, cooking, composition and quantity. They also learn about changing habits, making realistic goals and using their motivation."
1671654|NCT01685957|Behavioral|"Verdens bedste kur (VBK)"|"This group will receive 3 individual sessions and 3 group sessions. All sessions are with a registered dietitian. Total time spent is 15½ hour. The group sessions consist of 1 hour theory and 2½ hour cooking skills. The whole intervention is based on a danish self-help weightloss book which is based on new nordic diet and are a relative low-GI and high-protein diet. Focus is to learn to make new healthy dishes both ingredients, cooking and composition. They also learn about making realistic goals."
1671655|NCT01685944|Dietary Supplement|Live Pediococcus pentosaceus LP28|
1671656|NCT01685944|Dietary Supplement|Heat-killed Pediococcus pentosaceus LP28|
1671657|NCT01685944|Dietary Supplement|Placebo|
1671658|NCT01685931|Drug|Paliperidone Palmitate|One intramuscular injection of paliperidone palmitate flexible dose will be administered on Day 1, Day 8, and monthly thereafter.
1671659|NCT01685892|Drug|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams [mg]) on Day 1 of Cycle 1, 900 mg on Day 2 of Cycle 1, and 1000 mg on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
1671660|NCT01685892|Drug|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
1671661|NCT01685879|Other|Rice|Rice portion containing 50 g total carbohydrate
1671662|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
1671663|NCT01685879|Other|Rice|Rice portion that provides 50 g total carbohydrate.
1671664|NCT01685879|Other|Glucose Beverage|Glucose beverage that provides 50 g total carbohydrate.
1671665|NCT01685866|Device|Vein-Viewer Vision|A medical device called Vein-Viewer Vision
1671666|NCT01685853|Drug|Bisacodyl plus PEG-CS|"the day before colonoscopy: 3-4 bisacodyl tablets (according to patient bowel habit) at bedtime
the morning of colonoscopy: PEG-CS (2 litres) starting 5 hours before the exam"
1671667|NCT01685853|Drug|PEG 4 litres split|"the day before colonoscopy: 2 litres of PEG
the morning of colonoscopy: 2 litres of PEG starting 5 hours before the examination"
1671670|NCT01685827|Drug|Fexinidazole|
1671671|NCT01685827|Drug|Nifurtimox|
1671672|NCT01685827|Drug|Eflornithine|
1671673|NCT01685814|Drug|Lenalidomide, Bortezomib|Induction: two versus one novel drug maintenance: lenalidomide as a maintenance therapy
1671674|NCT01685814|Biological|autologous stem cell transplant|
1671675|NCT01685814|Biological|allogeneic stem cell transplant|
1671676|NCT01685801|Drug|Ivacaftor|150 milligram (mg) tablet orally every 12 hours up to 12 weeks.
1671677|NCT01685801|Drug|Placebo-matched-to-ivacaftor tablet|Orally every 12 hours up to 4 weeks.
1671678|NCT01685788|Other|No intervention|
1671679|NCT01685775|Procedure|Transvaginal/transumbilical|
1671680|NCT01685775|Procedure|Needlescopic with 3 trocars|
1671681|NCT01685762|Drug|Metformin|850 mg of metformin taken once daily by mouth for 4 weeks (weeks 1-4) and then twice daily by mouth for 8 weeks (weeks 5-12).
1671682|NCT01685723|Behavioral|Counseling group|Subjects in this group will receive treatments in the form of improved risk communication measures. These measures include brief advice by oncologist or oncology nurses, a special design leaflet, face-to-face individualized risk communication counselling by nurse counselor, and follow-up telephone counselling emphasizing on risk communication.
1671683|NCT01685723|Behavioral|General supporting|"Subjects in this group will receive:
Usual care by oncologist or nurse;
General care and support by nurse counselor (5 minutes);
Generic self-help smoking cessation booklet; and
Multiple telephone follow-ups (up to 8 sessions) to show support and care for patients' disease condition (5 minutes)."
1671684|NCT01685710|Drug|GTN patch|
1671685|NCT01685710|Drug|placebo comparator|This arm will be a placebo patch to the active drug patch to blind the trial.
1671688|NCT01685684|Drug|Oxycodone DETERx|40-160 mg total daily dose of oxycodone DETERx, divided into 2 doses, q12h
1671689|NCT01685684|Drug|Placebo|Placebo, divided into 2 doses, q12h
1671690|NCT01685671|Drug|NESP 60μg|Administrated NESP 60μg once subcutaneously
1671691|NCT01685671|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once subcutaneously
1671692|NCT01685658|Drug|Intravenous ketoprofen|Patients will recieve 100 mg of ketoprofen via slow intravenous perfusion. (100mg of ketoprofen powder for injection dissolved in 100 ml injectable isotonic solution)
1671693|NCT01685658|Drug|Intravenous paracetamol|Patients will receive 1g of paracetamol via slow intravenous perfusion. (100 ml of solution at 10mg/ml)
1671694|NCT01685645|Device|AlgiScan|The AlgiScan device will be used to monitor analgesia during surgery. The integrated nociceptive stimulator will be used on both legs.
1671695|NCT01685632|Procedure|Surgery with IPCH|"surgical debulking and extensive tumoral resection after laparotomy under general anesthesia
7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery and 3 samples during the 3 following days (at 24th, 48th and 72th hours).
6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum , each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
1671696|NCT01685632|Procedure|Without surgery and without IPCH|"The patients is opened and recused during the surgery because of extended carcinosis and closed without resection neither IPCH.
7 blood samples over 72 hours, including 4 samples under general anesthesia throughout surgery (2 hours before IPCH, 1.5hours after IPCH, 4 hours after IPCH) and 3 samples during the 3 following days (at 24th, 48th and 72th hours).
6 tissue biopsies, i.e. 2 from peritoneum disease-free and 2 from invaded peritoneum, each representing a volume less than 1 cm3 and 2 biopsies from healthy colonic tissue for the colon-related cancer and 4 biopsies (peritoneum n=2, tumoral tissue n=2) for ovarian-related cancer. All biopsies are done during the surgery under general anesthesia, and each biopsy per site before/after IPCH"
1671697|NCT01685606|Biological|cellular immunotherapy|A minimum of 1x108 CD3+ cells and maximum of 2x108 CD3+ cells/kg from a haploidentical donor irrespective of the number of CD34+ cells will be infused.
1671698|NCT01685593|Device|abdominal binder|
1671699|NCT01685593|Other|no binder|
1671700|NCT01685580|Device|Manufacturer (VPAP ST)|non-invasive ventilation in two pressure levels 7 days before surgery
1671701|NCT01685567|Device|MICHI NPS+f|Cerebral protection with carotid flow reversal
1671702|NCT01685554|Device|hypothermic CPB|maintenance of mild hypothermia during cardiopulmonary bypass
1671703|NCT01685554|Device|normothermic CPB|maintenance of normal body temperature during cardiopulmonary bypass
1671704|NCT01685541|Other|Maximum After Visit Summary Content|
1671705|NCT01685541|Other|Intermediate After Visit Summary Content|
1671706|NCT01685541|Other|Minimum After Visit Summary Content|
1671707|NCT01685541|Other|Usual AVS|
1671708|NCT01685528|Behavioral|CBT|6-8 weekly sessions of CBT, 1 of which is in person with the rest being over the telephone
1671709|NCT01685515|Drug|Oral Decitabine and Tetrahydrouridine|Oral Decitabine and Oral Tetrahydrouridine (THU) given 1-2 hours apart on 2 consecutive days over 8 weeks
1671710|NCT01685515|Drug|Placebo|Plain water will be dispensed at a similar volume and in the same containers as study drug. The water placebo has a similar appearance and taste to the study drug, since the study drug is highly diluted in water.
1671711|NCT01685502|Drug|Glucobay ODT (Acarbose, BAYG5421)|Patients treated with Glucobay OD under practical manner
1671712|NCT01685489|Drug|Docetaxel, PSK®|
1671713|NCT01685489|Drug|Docetaxel, Placebo|
1671714|NCT01685476|Device|Echodia® hand-held equipment|
1671715|NCT01685463|Device|Transcranial Magnetic Stimulation|Active TMS:1 Hz, 100% motor threshold TMS for 15 minutes, total 900 pulses. Electrical stimulation instead.
1671716|NCT01685463|Device|Sham Transcranial Magnetic Stimulation|The electrical current of the sham system is titrated to a level matching participants' ratings of active TMS. The sham-TMS scalp discomfort will be matched to that of active TMS.
1671717|NCT01685450|Device|Echodia® hand-held equipment|
1671718|NCT01685437|Biological|AA4500|2 injections separated by approximately 24 hours to 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles
1671719|NCT01685424|Drug|Etoricoxib|As per routine clinical practice in the United Kingdom
1671720|NCT01685411|Drug|Allopurinol|Day -8 (prior to transplant): Per institutional guidelines
1671721|NCT01685411|Drug|Keppra|Day -8 (prior to transplant): Per institutional guidelines
1671722|NCT01685411|Drug|Busulfan|Days -7 through -4 (prior to transplant): given intravenously (IV) infusion over 2 hours every 6 hours following dose, administration and pharmacokinetic monitoring per University of Minnesota institutional guidelines.
1672738|NCT01677364|Drug|Oxytocin|Arm - Induction of labour
1671723|NCT01685411|Drug|Cyclophosphamide|Days -3 and -2 (prior to transplantation): given as a 2 hour intravenous infusion with a high volume fluid flush and mesna per institutional guidelines. Dosing is based on actual body weight.
1671724|NCT01685411|Drug|Cyclosporine A|Day -3 (prior to transplant) and will be administered by mouth/intravenously (PO/IV) maintaining a trough level between 200 and 400 ng/mL. Adult initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. Children < 40 kg will be 2.5 mg/kg IV over 2 hours every 8 hours.
1671725|NCT01685411|Drug|Mycophenolate mofetil|Day -3 (prior to transplant): Recipients of umbilical cord blood will given a dose of 3 gm/day every 8 or 12 hours (> or = 40 kg) or 15 mg/kg 3 times per day (< 40 kg) for up to 30 days unless no engraftment.
1671726|NCT01685411|Biological|Allogeneic hematopoietic stem cell transplant|Day 0 (or Day+1/+2 to accommodate weekdays): Infusion of cells from related or unrelated donor bone marrow or single or double unrelated donor umbilical cord blood.
1671727|NCT01685411|Biological|Filgrastim|Beginning Day +1: Intravenously (IV) 5 mcg/kg once daily and continuing until the absolute neutrophil count is >2500 x 10^9/L or per institutional guidelines.
1671728|NCT01685411|Biological|antithymocyte globulin|Administered per institutional guidelines for recipients of umbilical cord blood transplant.
1671729|NCT01685398|Drug|0.5% timolol maleate eye drop|
1671730|NCT01685398|Drug|Normal saline|
1671731|NCT01685385|Other|Patients who will receive the BNP test|Patients in Diagnostic Intervention Group A will receive the point-of-care BNP test, in addition to all other diagnostics they receive in addition
1671734|NCT01685359|Drug|Epoetin Alfa|Intravenous administration for 4 weeks, three times a week (monday, wednesday, friday)
1671735|NCT01685346|Behavioral|biofeedback-mediated stress management (BFSM)|Therapist and study assistant meet with patient, attach sensors, record physiologic variables and train the patient in relaxation techniques including deep breathing, guided imagery, progressive muscle relaxation, autogenics. Patient is given a handheld thermometer to take home and practice self-regulation between visits, along with a recording sheet to indicate how often practice occurs.
1671736|NCT01685333|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Human Recombinant Epoetin) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
1671737|NCT01685320|Procedure|Forces applied by laryngoscope|Force and pressure distribution applied by direct or indirect laryngoscope during glottis visualization and intubation were measured using film pressure transducers.
1671738|NCT01685307|Dietary Supplement|Test meal|test meal is 150 g of beef cooked either at moderate or high intensity. Proteins are intrinsically labelled with 15N.
1671739|NCT01685294|Behavioral|Group IPT for Depression + TAU|Interpersonal psychotherapy (IPT) will be administered in 20 group 90-minute sessions over 10 weeks and 4 individual sessions (before group starts, in the middle of the group, at the end of the group, and one month after the group ends). These sessions will focus on improving your relationships with others, building healthy relationships, setting goals, and increasing coping skills. Additionally, participants will receive standard prison mental health treatment, individual therapy, medication, etc.
1671740|NCT01685281|Drug|Metadoxine (MG01CI)|MG01CI is an orally administered extended release formulation of metadoxine. Doses: 1400 mg and 700 mg and Placebo
1671741|NCT01685281|Drug|Placebo|Placebo tablets will be similar in appearance (color and size) to the investigational product
1671742|NCT01685268|Drug|AT13387|Regimen 1: AT13387, given as 1-hr intravenous infusion at starting dose of 220 mg/m2 once weekly for 3 weeks in a 4-week cycle. Regimen 2: AT13387, given as 1-hr IV infusion at starting dose of 120 mg/m2 on Day 1 and Day 2 weekly for 3 weeks in a 4-week cycle.
1671743|NCT01685268|Drug|abiraterone acetate|1000 mg PO daily.
1671744|NCT01685268|Drug|Prednisone|5 mg PO twice daily.
1671745|NCT01685255|Drug|INCB024360|
1671746|NCT01685255|Drug|tamoxifen|
1671750|NCT01685216|Biological|velaglucerase alfa|lyophilized powder, intravenous infusion, units, Every other week (EOW)
1671751|NCT01685203|Drug|ABT-450/r|Tablet; ABT-450; Capsule; ritonavir
1671752|NCT01685203|Drug|ABT-267|Tablet
1671753|NCT01685203|Drug|Ribavirin (RBV)|Tablet
1671754|NCT01685190|Radiation|Prostate alone IMRT|Participants will receive standard prostate IMRT of 74Gy in 37 fractions delivered over 7.5 weeks.
1671755|NCT01685190|Radiation|Prostate and pelvis IMRT|Participants will receive prostate and pelvis IMRT with a dose of 74Gy in 37 fractions delivered over 7.5 weeks to the prostate and 60Gy in 37 fractions delivered over 7.5weeks to the pelvis.
1671756|NCT01685164|Other|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.|Evaluation of uterine size and posture with ultrasound, IUD insertion, one year follow-up.
1671757|NCT01685151|Drug|Ramelteon SL (Dose 1)|Ramelteon tablets for sublingual administration
1671758|NCT01685151|Drug|Ramelteon SL (Dose 2)|Ramelteon tablets for sublingual administration
1671759|NCT01685151|Drug|Placebo|Placebo
1671760|NCT01685138|Drug|LDK378|Oral LDK378 750 mg once daily
1671761|NCT01685125|Drug|abiraterone acetate|Given PO
1671762|NCT01685125|Drug|dasatinib|Given PO
1671763|NCT01685125|Drug|prednisone|Given PO
1671764|NCT01685073|Drug|Zolpidem extended-release|nightly administration of zolpidem extended-release
1671765|NCT01685073|Behavioral|MET/CBT|a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants
1671817|NCT01684657|Drug|Asenapine|This is an atypical antipsychotic that blocks dopamine and increase the serotonin level.
1671766|NCT01685060|Drug|LDK378|Ceritinib/LDK378 was supplied as 150 mg hard gelatin capsules and were administered orally, once-daily at a dose of 750 mg on a continuous dosing schedule (5 x 150 mg capsules).
1671767|NCT01685034|Biological|"Allergy immunotherapy (allergy shots)"|
1671768|NCT01685021|Drug|MOR00208 (formerly Xmab5574)|
1671769|NCT01685008|Drug|MOR00208 (formerly Xmab 5574)|
1671770|NCT01684995|Behavioral|Brief physician advice|Brief physician advice to quit smoking
1671771|NCT01684995|Drug|nicotine patch|nicotine patch
1671772|NCT01684995|Behavioral|Individually Tailored Behavioral Skills training|Individually tailored behavioral skills training for smoking cessation
1671773|NCT01684982|Device|everolimus eluting stent|experimental arm of a comparison between drug eluting stents
1671774|NCT01684982|Device|sirolimus eluting stent|control arm of a comparison between drug eluting stents
1671775|NCT01684969|Drug|Haloperidol|0.5 mg iv x one dose
1671776|NCT01684969|Drug|Placebo|0.5 mg iv , one dose
1671777|NCT01684956|Procedure|Intradermal injection|
1671778|NCT01684956|Procedure|Subcutaneous injection|
1671779|NCT01684943|Other|Multiplex pharmacokinetic profiling|
1671780|NCT01684943|Other|Continuous insulin monitoring|
1671781|NCT01684930|Drug|Beetroot Juice (Beet-It Stamina Shot) & Supervised Exercise Training|The beverage is high in inorganic nitrate and bottled and supplied by James White Drinks. This supplement will be used in conjunction with supervised exercise training.
1671782|NCT01684930|Other|Placebo Comparator Beverage (Beet-It Stamina Shot) & Exercise Training|The beverage is identical in look and taste to Beet-It Stamina Shot but with active ingredient removed. It is also bottled and supplied by James White Drinks. This placebo supplement will be used in conjunction with supervised exercise training.
1671783|NCT01684917|Behavioral|Metabolomic and Energy Intake Restriction|Metabolomic inquiry followed by a 12 week energy intake restriction
1671785|NCT01684891|Drug|RG1662|multiple doses of RG1662
1671786|NCT01684878|Drug|Gemcitabine (Chemotherapy)|Participants administered gemcitabine at a dosage of 1000 milligrams per square meter (mg/m^2) intravenous (IV) infusion on Days 1 and 8 every 3 weeks.
1671787|NCT01684878|Drug|Paclitaxel (Chemotherapy)|Participants administered paclitaxel at a dosage of 80 mg/m^2 as 1 hour IV infusion on Days 1, 8 and 15 every 3 weeks.
1671788|NCT01684878|Drug|Pertuzumab|Participants administered pertuzumab 840 milligrams (mg) IV infusion on Day 1 of the first treatment cycle as a loading dose, followed by 420 mg on Day 1 of each subsequent 3 weekly cycle.
1671789|NCT01684878|Drug|Placebo|Participants administered pertuzumab matching placebo IV infusion on Day 1 of each 3 weekly cycle.
1671790|NCT01684878|Drug|Topotecan (Chemotherapy)|Participants administered topotecan at a dosage of 1.25 mg/m^2 as a 30 minute IV infusion daily on Days 1 to 5 every 3 weeks.
1671791|NCT01684865|Drug|Rituximab|Due to observational nature of the study protocol does not specify any dosing schedule for rituximab.
1671792|NCT01684852|Other|Medical device, drug-like|
1671793|NCT01684839|Device|Pedicled nerve flap|This nerve flap is a vascularized nerve graft
1671794|NCT01684826|Radiation|Angiographic run with new algorithm and low dose (50% dose)|Angiographic run with new algorithm and low dose (50% lower dose compared to Xper)
1671795|NCT01684826|Radiation|Angiographic run with predecessor algorithm and dose (100%)|Angiographic run with predecessor algorithm and dose (100% dose)
1671796|NCT01684813|Drug|Prasugrel.|Patients in this group will receive a loading dose of 60 mg prasugrel (6 x 10 mg tablets) followed by at least dose of 10 mg prasugrel (1 x 10 mg tablet). Beyond the second day after PCI, these patients will receive double antiaggregation therapy according to their physician´s criteria.
1671797|NCT01684813|Drug|Clopidogrel|Patients in this group will receive the standard dose of clopidogrel, a daily dose of 75 mg. Beyond the second day post-PCI, these patients will receive double anti aggregation therapy according to their physician's criteria.
1671798|NCT01684800|Drug|A. Desmopressin 10 microgram|1 orally disintegrating tablet every night during study period
1671799|NCT01684800|Drug|B: Desmopressin 25 microgram|1 orally disintegrating tablet every night during study period
1671800|NCT01684800|Drug|C: Placebo|1 orally disintegrating tablet every night during study period
1671801|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in normal ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
1671802|NCT01684787|Drug|Peginterferon alfa-2a + ribavirin in elevated ALT|peginterferon alfa-2a 180 mcg/weekly ribavirin 1000-1200 mg/daily
1671803|NCT01684774|Drug|Bupivacaine|
1671804|NCT01684761|Biological|Tcelna|Autologous pool of myelin reactive T-cells (MRTC) expanded ex vivo with immunodominant epitopes selected from the three myelin antigens, MBP, PLP and MOG on a per subject basis. Attenuated by irradiation to prevent further proliferation before releasing product for administration.
1671805|NCT01684761|Biological|Placebo|2 ml of Tcelna excipients, prepared daily as individual doses and irradiated before releasing product for administration.
1671806|NCT01684748|Drug|Olmesartan medoxomil|Crossover intervention comparing antihypertensive medication to no drug intervention.
1671807|NCT01684722|Dietary Supplement|Vitamin D|Vitamin D3 (cholecalciferol), 2000 IU per day.
1671808|NCT01684722|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
1671809|NCT01684722|Dietary Supplement|Vitamin D placebo|Vitamin D3 placebo
1671810|NCT01684722|Dietary Supplement|Fish oil placebo|Fish oil placebo
1671812|NCT01684696|Behavioral|Virtual experience|
1671813|NCT01684696|Behavioral|Videos|
1671814|NCT01684683|Drug|Theophylline|Theophylline 0.1 bid
1671815|NCT01684683|Drug|Placebo(for Theophylline)|Starch tablet manufactured to Theophylline 100mg (Theophylline Stained-Release Tablet)
1671816|NCT01684670|Behavioral|Speech sessions|Subjects will be instructed to use clear speech and increased effort when speaking.
1671818|NCT01684644|Behavioral|New Forest Parenting Programme|
1671821|NCT01684618|Procedure|Cerebral NIRS Oximetry + CPAP|CPAP flow pressure is increased for 5 minutes then 15 minutes with CPAP pressure at baseline. Repeated once
1671822|NCT01684605|Drug|NESP 60μg|Administrated NESP 60μg once intravenously
1671823|NCT01684605|Drug|CKD-11101 60μg|Administrated CKD-11101 60μg once intravenously
1671826|NCT01684579|Behavioral|Resistance Exercise|Resistance exercise will be performed 2 days per week for 18 weeks. The resistance training protocol will follow the Resistance Training Strategies for Individuals With Cancer (RTSFIC). The goals will be to keep intensity levels low at the outset (having lighter weights and more reps) and progress slowly and safely. Training prescriptions will be modified based on the training level of the patients and their progress.
1671827|NCT01684579|Behavioral|Aerobic Exercise|A 20-week aerobic walking exercise program will be developed for each participant based on results of initial exercise testing and prescribed to be done 5 or more days per week designed to progress from moderate exercise intensity, (50-70% maximum heart rate), to vigorous exercise intensity (75-85% maximum heart rate). Maximum heart rate (HR max) will be determined as the peak heart rate achieved during initial cardiopulmonary exercise screening. Heart rate during exercise will be monitored by participants using wrist monitors, already available through TREC Program. Patient progress will also be evaluated using a six minute walk test (6MWT), which will be conducted at TGP at baseline, 6, 12 and 18 weeks and, after completion of the intervention.
1671828|NCT01684579|Behavioral|Behavioral Group Counseling|The psychosocial component of the 20-week exercise program includes a 1 ½ hour support group offered prior to one of the weekly exercise classes.
1671829|NCT01684566|Device|episil(R)|episil® is a lipid-based liquid that spreads onto mucosal surfaces and transforms into a protective, strongly bioadhesive FluidCrystal® film after intraoral administration.
1671830|NCT01684566|Other|Oral hygiene procedures|Oral hygiene by using toothbrush, toothpaste, lip balm and dental floss (if available)
1671831|NCT01684553|Behavioral|Slow eating condition|The subjects were asked to eat their meal slowly during the slow eating condition
1671832|NCT01684553|Behavioral|Fast eating condition|The subjects were asked to eat their meal quickly during the fast eating condition
1671833|NCT01684540|Other|Medical Device, Drug-like|Ectoin Rhinitis Nasal Spray
1671834|NCT01684540|Drug|Sinupret forte|
1671835|NCT01684527|Other|Respiratory secretions obtained|
1671836|NCT01684514|Device|Confocal laser endomicroscopy|"Within recent years a new approach was introduced, wherein the microscopic structures of the intestinal mucous can be evaluated continuously in vivo during the endoscopic procedure. The technique is called confocal laser endomicroscopy (CLE). CLE functions by means of a laser device, which is inserted or build into an endoscope, and used as an illuminator of the lining of a small area and at a precise depth. The tissue is first added with fluorescence by intravenous administration. The reflection of the mucosa is captured in a focused area and magnified by which a two-dimensional image of mucosal microscopic structures is formed. This provides us with an optical biopsy, which can be compared with a similar microscopic image."
1671837|NCT01684488|Behavioral|Youth Readiness Intervention|The YRI brings together six empirically-supported practice elements shown to be efficacious across different mental health interventions, as well as methods intended to socialize youth and improve self-efficacy. Practice elements address the broad scope of problems evidenced in Sierra Leonean war-affected youth and enhance the YRI's pacing, which progresses through three phases traditionally used in trauma treatments (stabilization, integration, connection). The weekly intervention takes place over 10 sessions lasting approximately one hour and a half. Groups are divided by gender and age. Each group is paired with two interventionists of the same gender.
1671838|NCT01684488|Other|EducAid educational programming|EducAid is a charitable trust that provides free year-round education to over 1,500 youth, along with food, medicine, and shelter when needed. EducAid's education model aims to improve academic knowledge, self-efficacy, and attitudes toward school. Additionally, it aims to nurture hope for the future and a sense of normalcy through interactions with teachers, mentors, and peers.
1671839|NCT01684475|Drug|CJH1 (CLR4001)|
1671840|NCT01684462|Biological|Human Serum Albumin 20|Human Serum Albumin 20% 100cc albumin 1.25g/kg up to 100g (500ml) intravenously infused over 4~8h, commencing within 12 hours of stroke onset
1671841|NCT01684462|Drug|0.9 % Normal Saline|Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4~8h, commencing within 12 hours of stroke onset
1671842|NCT01684449|Drug|Gemcitabine + Rapamycin|"Gemcitabine + rapamycin at recommended dose of Phase 1. Recommended dose is defined as, the dose one level below of the (MTD). Being MTD, the dose of the cohort in which a maximum of one patient of 6 has presented dose-limiting toxicity (DLT).
Every three weeks until disease progression or unacceptable toxicity. The treatment will last for 6 cycles if there is not progression or intolerable toxicity.
Additionally, there will be a pharmacokinetic study in a minimum of 9 patients treated with the drug combination."
1671843|NCT01684436|Device|Punctal Plug|Punctal plugs inserted into the study eye on Day 1.
1671844|NCT01684423|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Subjects were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) IR tablet once daily under fed conditions for 30 days.
1671890|NCT01684111|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
1671891|NCT01684098|Drug|Tc 99m EC20|
1724411|NCT00005078|Drug|carboplatin|
1955052|NCT03299894|Procedure|systematic calculation of qSOFA|calculation of qSOFA for each patient
1671845|NCT01684423|Drug|Active comparator|Subjects received comparator as per standard of care. The dosage given was to be adjusted based on the individual body weight (low molecular weight heparin, fondaparinux) or international normalized ratio (INR) adjusted (vitamin K antagonist).
1671846|NCT01684423|Drug|Rivaroxaban (BAY59-7939) suspension|Subjects aged were administered with age- and body weight-adjusted oral dose of rivaroxaban (BAY59-7939) suspension under fed conditions twice daily.
1671847|NCT01684410|Biological|Alpha-1 HC 100 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 100 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
1671848|NCT01684410|Biological|Placebo|Phosphate Buffer Saline with Polysorbate (placebo) composed of the same elements listed for Alpha-1 HC, minus the 50 mg/mL of Alpha-1 HC. Placebo inhaled once daily for 21 days for a total of 21 inhaled treatments.
1671849|NCT01684410|Biological|Alpha-1 HC 200 mg|Alpha-1 HC is a sterile, liquid preparation of purified alpha1-proteinase inhibitor prepared from pooled human plasma. Alpha-1 HC 200 mg inhaled once daily for 21 days for a total of 21 inhaled treatments.
1671850|NCT01684397|Biological|Bevacizumab|Given IV
1671851|NCT01684397|Other|Laboratory Biomarker Analysis|Correlative studies
1671852|NCT01684397|Drug|Pazopanib Hydrochloride|Given PO
1671853|NCT01684397|Other|Pharmacological Study|Correlative studies
1671854|NCT01684384|Radiation|Functional Respiratory Imaging|HRCT scan at FRC and TLC as taken during an episode of exacerbation and after recovering.
1671855|NCT01684371|Other|Two oily solutions (Blue Dotted and Orange Dotted Elmore Oils)|Thirty participants received Blue Dotted Elmore Oil and another thirty received the Orange dotted Elmore Oil, they applied the oils three times daily on the affected knees for four weeks and stopped usage on the fifth week (flush out period) and on the 6 week, the two group switched to Orange and Blue Elmore Oil respectively. All throughout applications, they filled out their diaries to indicate changes in their mobility, moods, feeling of well being and ability to do their daily work at home or at work every week.
1671856|NCT01684358|Device|Sino-implant (II)|Sino-implant (II) (Shanghai Dahua Pharmaceutical Co, Ltd.; Shanghai, China), a contraceptive implant with two rods each of which contain 75 mg of levonorgestrel.
1671857|NCT01684345|Drug|Placebo|Solution for subcutaneous injection
1671858|NCT01684345|Drug|Dose 1 gevokizumab|Solution for subcutaneous injection
1671859|NCT01684345|Drug|Dose 2 gevokizumab|Solution for subcutaneous injection
1671860|NCT01684332|Other|Strawberry Jam|
1671861|NCT01684319|Dietary Supplement|Formula milk free of cow's milk protein|
1671862|NCT01684319|Dietary Supplement|Placebo|Infant formula milk
1671863|NCT01684306|Drug|Modafinil|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
1671864|NCT01684306|Drug|Placebo|Study subjects received, in a double blind fashion, either a single dose (100 mg) of modafinil or a placebo pill identical to the drug.
1671865|NCT01684293|Behavioral|Occupational therapy-based cognitive rehabilitation|Occupational therapy-based cognitive rehabilitation
1671866|NCT01684293|Behavioral|Psychoeducation/games|Psychoeducation/games
1671867|NCT01684280|Genetic|gender|Paired samples of abdominal subcutaneous and intrabdominal omental adipose tissue were obtained from men and women who underwent bariatric surgery.
1671868|NCT01684267|Device|Robotic Gait Rehabilitation (RGR) Trainer|
1671869|NCT01684241|Biological|RBL001/RBL002|Each participant will receive 8 repeated intranodal administrations of RBL001 and RBL002 during a time frame of 43 to 51 days.
1671875|NCT01684202|Drug|OPC-41061|orally administered at 3.75, 7.5, 15, or 30 mg once daily after breakfast for up to 11 days.
1671876|NCT01684189|Other|Patient registry|Patient registry without study intervention
1671877|NCT01684176|Behavioral|Complex tailored intervention|
1671878|NCT01684176|Behavioral|Usual care|
1671879|NCT01684163|Drug|GLYX-13 5 mg/kg|Intravenous administration of 5 mg/kg into arm.
1671880|NCT01684163|Drug|GLYX-13 10 mg/kg|Intravenous administration of 10 mg/kg into arm.
1671881|NCT01684163|Drug|Placebo|Intravenous administration of normal saline into arm.
1671882|NCT01684150|Drug|EPZ-5676|MLL-r and MLL-PTD 28-day continuous IV infusion of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity develops.
1671883|NCT01684137|Dietary Supplement|Joalis Bambi Analerg|
1671884|NCT01684137|Dietary Supplement|Joalis Bambi Bronchi|
1671885|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Analerg
1671886|NCT01684137|Dietary Supplement|Placebo|Sugar pill manufactured to mimic Joalis Bambi Bronchi
1671887|NCT01684124|Other|conservative O2 therapy|target lower O2 saturation
1671888|NCT01684124|Other|standard care|
1671889|NCT01684111|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
1673628|NCT01670084|Biological|rituximab|Given IV
1671892|NCT01684085|Behavioral|Explanation encouraging sleep|An explanation will be given about sleep, encouraging the patient to sleep - lorazepam 1mg will be offered to promote sleep.
1671893|NCT01684085|Behavioral|Explanation discouraging sleep|An explanation about sleep will be given, discouraging the patient from sleeping in the first night after the traumatic event.
1671894|NCT01684085|Drug|Lorazepam|Lorazepam 1 mg
1671895|NCT01684072|Biological|vaccine without gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
1671896|NCT01684072|Biological|vaccine with gelatin|use the upper arm flank deltoid muscle adheres to stick cohere place the skin after 75% ethyl alcohol disinfection the hypodermic injection
1671897|NCT01684059|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
1671898|NCT01684046|Device|Opti-Free® PureMoist® MPDS|
1671899|NCT01684046|Device|RevitaLens MPDS|
1671900|NCT01684046|Device|Habitual Contact Lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
1671901|NCT01684033|Device|Opti-Free® PureMoist® MPDS|
1671902|NCT01684033|Device|Biotrue™ MPS|
1671903|NCT01684033|Device|Habitual contact lenses|Silicone hydrogel contact lenses per participant's habitual brand, prescription, and replacement schedule worn on a daily wear basis for at least 8 hours a day, 5 days a week for the duration of the study. During the washout period, the contact lenses were worn on a daily disposable basis.
1671904|NCT01684020|Biological|ARTISS human fibrin sealant|
1671905|NCT01684007|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
1671906|NCT01684007|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
1671910|NCT01683981|Drug|L-Citrulline Malate|3 gr per day, oral, for 2 weeks
1671911|NCT01683955|Drug|Transexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
1671912|NCT01683955|Drug|Placebo|100mL 0.9% sterile saline
1671913|NCT01683929|Other|glucose|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing 75 gram glucose (oral glucose tolerance test (OGTT / GTT) All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.
The participants HR & BP will be monitored throughout the examination + 1 hour after.
In addition, the participants will be asked to complete a- 24 hr food questionnaire."
1671914|NCT01683929|Other|sweetner|"The participants will report to the lab after an overnight fast. Their BMI, HR and BP will be measured. An IV catheter will be inserted into the brachial vein and the participants will rest for half an hour. Participants will drink A beverage containing artificial sweetened drink. All the participants will be checked for level of: insulin, glucose, adrenalin norepinephrine, dopamine, catecholamines, cortisol, ghrelin, leptin, IGF-1 GH and other related hormones- before consuming the drink (time 0), and at 30, 60, 120, 180 minutes after.
The participants HR & BP will be monitored throughout the examination + 1 hour after.
In addition, the participants will be asked to complete a- 24 hr food questionnaire."
1671915|NCT01683877|Procedure|FloSeal application|After laparoscopic ovarian cystectomy, hemostasis will be performed using FloSeal (1 vial of FloSeal 5mL per unilateral ovarian cystectomy)
1671916|NCT01683877|Procedure|Electrocautery|After laparoscopic ovarian cystectomy, hemostasis will be performed using electrocautery
1671919|NCT01683851|Device|Isolite System|A type of isolation system used in dentistry. It protects soft tissues, and also has a mouth prop, which helps keep mouth open.
1671920|NCT01683838|Drug|Fampridine-SR|25mg bid (twice daily)
1671921|NCT01683838|Drug|Placebo|Placebo
1671922|NCT01683825|Drug|F-18 florbetapir PET|Cardiac PET images will be obtained following injection of F-18 labeled Florbetapir (Trade Name: Amyvid)
1671923|NCT01683812|Device|Cranial Cup|Study participants with dolichocephaly will be treated with the Cranial Cup for a minimum 12 hours per day.
1671924|NCT01683799|Behavioral|Cognitive Behavioral Therapy for Insomnia|6-week behavioral treatment for insomnia
1671926|NCT01683773|Biological|AERAS-402|Intramuscular needle injection 1x10^11 vp
1671927|NCT01683773|Biological|MVA85A|Intradermal needle injection 1x10^8 pfu
1671928|NCT01683760|Drug|Fluconazole|Prophylactic fluconazole administration in VLBW infants
1671929|NCT01683747|Drug|Tranexamic Acid|
1671930|NCT01683747|Drug|Control Intervention (Carrier fluid only)|
1671931|NCT01683708|Dietary Supplement|Symbiotic therapy|Patients randomized into the Symbiotic group received Prebiotic® in a dose of one sachet twice a day for at least 1 week preoperatively. Postoperatively the medication was reintroduced as tolerated, and continued until discharge from hospital. One 4,5 gr sachet of Prebiotic® contains at least 1010 living Bifidobacterium bifidum, 1010 living Streptococcus Thermophilus, 1010 living Streptococcus Salivarius, 3 109 Lactobacillus Acidophilus, 1010 living Lactobacillus Casei, 1010 living Lactobacillus bulgaricus and galactooligosaccharides (4,5 gr).
1671932|NCT01683695|Drug|AMG 557|AMG 557 will be administered as subcutaneous injections in the anterior abdomen of the subjects.
1724412|NCT00005078|Drug|paclitaxel|
1671933|NCT01683695|Drug|Matching Placebo|Placebo will be administered as subcutaneous injections in the anterior abdomen of the subjects.
1671934|NCT01683682|Drug|BIBF 1120|2 x 150 mg capsules, oral, daily (Start dose)
1671935|NCT01683682|Drug|Vinorelbine|25 mg/m2 i.v. on day 1 and 8 (three-week cycle)
1671936|NCT01683682|Drug|Carboplatin|AUC 5 i.v. on day 1 (three-week cycle)
1671937|NCT01683669|Other|Noisy-PSV 1|Noisy-PSV 1: different levels of variable pressure support (PS) will be randomized: a) PS variability equal to 0%, b) PS variability equal to 45%, c) PS variability equal to 90%.
1671938|NCT01683669|Other|Noisy-PSV 2|Noisy-PSV 2 : different levels of variable Pressure Support (PS) will be randomized: a) PS equal to Baseline and variability 0%; b) PS equal to Baseline and variability set in order achieve an increase or decrease of pressure of 5 cmH2O; c) PS equal to Baseline - 5 cmH2O and variability 0%; d) PS equal to Baseline - 5 cmH2O and set in order achieve an increase or decrease of pressure of 5 cmH2O.
1671939|NCT01683656|Drug|niacin/laropiprant|
1671940|NCT01683656|Drug|Placebo|Procedures for the manufacturing and testing of the placebo are compiled in the IMP/study drug dossier and comply with local regulatory requirements (by GMP certified manufacturer).
1671941|NCT01683643|Behavioral|SBIRT|Screening, brief intervention, and referral to treatment.
1671942|NCT01683643|Behavioral|Control Group|Control subjects will receive only their risk score and informational materials regarding the health risks of substance use.
1671943|NCT01683617|Behavioral|Coping skills and relaxation training with new technologies|
1671944|NCT01683617|Behavioral|Traditional coping skills and relaxation training|
1671945|NCT01683604|Other|Observational study|
1671946|NCT01683591|Procedure|High-resolution impedance manometry test|The test was performed as general guideline for high-resolution impedance manometry test. The parameter was obtained and analyzed using the Chicago classification for the liquid swallows with Takasaki's modification for pharyngeal function monitoring. Swallowing pattern and aspiration risk were defined using real-time assessment of high-resolution impedance manometry test.
1671947|NCT01683578|Other|Variable Ventilation|
1671948|NCT01683565|Drug|LCPUFA oil supplement|"2.5mL per day for 90 days
Daily Dose: EPA (338mg) + DHA (225mg) + GLA (83mg) + OA (200mg)"
1671949|NCT01683565|Other|Canola Oil Placebo|2.5mL per day for 90 days
1671950|NCT01683552|Drug|Aprepitant|125 mg on day 1; 80 mg on day 3; 80 mg on day 5
1671951|NCT01683552|Drug|Prednisone|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die),
1671952|NCT01683552|Drug|Fexofenadine|In the refractory group (VAS score ≥7), Aprepitant (125 mg on day 1; 80 mg on day 3; 80 mg on day 5) is administered after at least one week of standard systemic treatment (prednisone 25 mg/die and/or fexofenadine 180 mg/die)
1671953|NCT01683539|Behavioral|The Thinking Skills for Work Program|The Thinking Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, computerized cognitive practice, compensatory strategy training, and integration of cognitive and work services.
1671954|NCT01683539|Behavioral|The Cognitive Skills for Work Program|The Cognitive Skills for Work includes assessment of cognitive strengths and weaknesses and their relationship with work history, compensatory strategy training, and integration of cognitive and work services.
1671955|NCT01683526|Procedure|Direct laryngoscopy|
1671956|NCT01683526|Device|Video laryngoscopy (Glidescope)|
1671957|NCT01683513|Drug|GnRh agonist +1500E hCG|ovulation induction with GnRh agonist and 1500E hCG one hour after egg retrieval
1671958|NCT01683500|Device|shock wave therapy with Modulith SLK (Storz)|Three sessions with shock wave therapy, interval of one week.
1671959|NCT01683487|Procedure|Observation|Observational study only, no intervention.
1671960|NCT01683474|Device|Venus MedTech Aortic Valve Prosthesis|Percutaneous implantation of aortic valve of Venus-A
1671961|NCT01683461|Behavioral|Enhanced Counseling|Women in the enhanced counseling arm receive the following intervention package: a video prior to their HIV pre-test counseling session that prepares them for decisions they will have to make regarding HIV testing and PMTCT participation, a pre-test counseling session and post-test counseling session with their nurse midwife/counselor, and two additional post-test counseling sessions with the same nurse midwife at 6 and 10 weeks postpartum. Women in the enhanced counseling arm also have access to ongoing support groups and legal support if needed at the clinic.
1671962|NCT01683461|Behavioral|Standard of Care|Women in the standard of care arm receive HIV pre and post-test counseling at their first antenatal visit. The counseling provided to them adheres to international guidelines for HIV counseling and testing developed by US CDC and the World Health Organization.
1671963|NCT01683435|Other|HBA binding assay|HBA binding assay will be preformed on the discarded portion of semen analysis used for IVF.
1671966|NCT01683409|Drug|Baricitinib|Administered orally
1671967|NCT01683409|Drug|Placebo|Administered orally
1671968|NCT01683396|Drug|Placebo|Solution for subcutaneous injection
1671969|NCT01683396|Drug|gevokizumab|Solution for subcutaneous injection
1671970|NCT01683383|Device|Device (servo-regulated cooling)|Subjects in Arm 2 will be placed on cooling blanket connected to the Tecotherm Neo (Inspiration Healthcare LTD UK). Temperature will be monitored continuously and servo-regulated using a rectal temperature probe.
1671971|NCT01683383|Other|Control (standard practice)|Subjects in Arm 1 will receive passive or active cooling as per center practice with rectal temperatures being recorded every 15 minutes.
1672015|NCT01682941|Dietary Supplement|Arm II Soy-Almond Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy-almond bread. Afterwards 2 slices of soy-almond bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
1671972|NCT01683357|Procedure|Hepatectomy|"Intraoperative ultrasound (IOUS) criteria for tumor-vessel relations let maximizing the preservation of the hepatic vascular skeleton. Contact between colorectal liver metastases and a major intrahepatic vessel is not by itself a criteria for vessel resection: tumor exposure is not contraindicated.
If resection of a hepatic vein (HV), resection of the liver parenchyma drained by that vein is considered or not based on color-flow IOUS findings (hepatofugal blood flow in the feeding portal branch, evidence or not of communicating veins between adjacent HVs, evidence or not of accessory HVs).
Parenchymal transection is performed under intermittent clamping by the Pringle maneuver. Drains are always inserted and a chest tube is inserted in patients undergoing thoracophrenolaparotomy."
1671973|NCT01683331|Drug|Insulin treatment for hyperglycemia|
1671974|NCT01683318|Procedure|Thermal Pulsation therapy|
1671975|NCT01683292|Drug|Inhaled VR040|
1671976|NCT01683292|Drug|Placebo for VR040|Placebo arm
1671977|NCT01683279|Biological|Autologous CD19 CAR+ EGFTt + T cells|Autologous T cell modified to express a CD19 specific CAR and a truncated EGFRt tag
1671978|NCT01683266|Drug|HOE901-U300 (Insulin glargine new formulation)|
1671979|NCT01683266|Drug|Lantus (Insulin glargine)|
1671980|NCT01683253|Drug|Levodopa/Carbidopa(200mg/50mg)|
1671981|NCT01683240|Device|cholangioscopy (Frimberger)|cholangioscopy with Frimberger duodenoscope system by the company of Karl Storz GmbH
1671982|NCT01683227|Behavioral|Screening/motivational drug intervention|Screening and brief motivational intervention delivered in the ER to reduce drug use
1671983|NCT01683227|Behavioral|Motivational placebo intervention|Screening and brief motivational intervention delivered in the ER to reduce driving and traffic risk
1671984|NCT01683201|Procedure|Functional exercise class|Functional exercise class running twice weekly for six weeks from week 12 to week 18
1671985|NCT01683201|Procedure|usual care group|Usual care group adhere to post operative instructions given on discharge from hospital
1671986|NCT01683188|Drug|vemurafenib + HD IL-2|
1671987|NCT01683175|Drug|Erlotinib|
1671988|NCT01683175|Drug|cis-platinum|
1671989|NCT01683175|Drug|Vinorelbine|
1671990|NCT01683162|Drug|ClinOleic|the lipid of all-in-one, 0.5-3.5g/kg.d
1671991|NCT01683162|Drug|Lipofundin|the lipid of all-in-one, 0.5-3.5g/kg.d
1671992|NCT01683162|Drug|Intralipid|the lipid of all-in-one, 0.5-3.5g/kg.d
1671993|NCT01683149|Drug|Topotecan|Topotecan will be given by mouth as outlined in treatment arm.
1671994|NCT01683149|Drug|Sorafenib|Sorafenib will be given by mouth as outlined in treatment arm.
1671995|NCT01683136|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|"on the first day subjects will be randomized to receive sham stimulation or real stimulation. subject who received real stimulation on the first day will receive sham stimulation on the second day. Likewise, Subjects who received sham stimulation on the first day will receive real stimulation on the second day. After receiving stimulation subjects will perform a facemorph task which evaluates their empathic capabilities.
From the third treatment all subjects will recive a real stimulaitiobn: a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 10 Hz to the supplementary motor cortex and then a 20 seconds recess.each subject would undergo 5 sessions a week for 4 weeks"
1671996|NCT01683110|Drug|cabozantinib|
1671997|NCT01683097|Other|Standardized explanation|Standardized explanation provided on code status, advance directives and end of life care
1672000|NCT01683071|Drug|EXPAREL|EXPAREL 67 mg, 133 mg, or 266 mg
1672001|NCT01683071|Drug|Placebo|Normal saline 20 mL
1672002|NCT01683058|Drug|Aripiprazole IM Depot|Aripiprazole IM Depot 400 mg or 300 mg
1672003|NCT01683045|Device|The Estech COBRA® Surgical System|The Estech COBRA® Surgical System has been designed to create epicardial and endocardial lesions on the heart using temperature controlled radiofrequency (TCRF) ablation with the Estech COBRA surgical probes. Temperature control provides a meaningful endpoint, maintaining tissue at safe yet effective temperatures to produce the desired lesion set. Internal probe cooling and advanced suction helps to ensure reproducible transmural (full-thickness) endocardial or epicardial lesions.
1672004|NCT01683032|Drug|MPH|a capsule containing 20 mg
1672007|NCT01683006|Drug|Rocuronium|"Continuous application of Rocuronium (0.5 mg/kg body weight/hour).
Bolus application of placebo in case of shivering."
1672008|NCT01683006|Drug|Placebo|"Continuous application of placebo during therapeutic hypothermia.
Bolus application of Rocuronium (0.5 mg/kg body weight) in case of shivering."
1672009|NCT01682993|Other|Topography guided Excimer Laser treatment and Corneal Cross Linking|A topography guided excimer laser treatment will be performed prior to CCL in one session.
1672010|NCT01682993|Other|Corneal Cross Linking|A standard corneal cross linking procedure will be performed in this arm.
1672011|NCT01682980|Other|Strength training|The strength training will be delivered 2-3 times per week for 12 weeks, 5-8 repetitions maximum in 3 series. The patients must warm up 5 minutes on an ergometer cycle. The following muscle groups will be trained: Quadriceps and hamstrings, hip muscles (abductors and extensors), calf muscles. A home exercise program will be delivered including one leg exercises and balance exercises. Progression will follow a 2+ principle. For instance, when the study participant is able to perform 2 more repetitions, more loads are required.
1672012|NCT01682980|Other|Aerobic exercise|The aerobic exercise program include ergometer cycling for at least 45 minutes 2-3 times a week on 75-80% of max heart rate will be required.
1672013|NCT01682954|Behavioral|Lifestyle counseling|16-week nutrition, physical activity and behavioral intervention
1672014|NCT01682941|Dietary Supplement|Arm I Soy Bread|On day 0 or day 70 pharmacokinetic study of isoflavones over 24 hours will follow after consumption of 2 slices of soy bread. Afterwards 2 slices of soy bread/day will be consumed for 56 days and isoflavone metabolites will be assessed in urine at days 0, 28, 56, 70, 98, and 126.
1672043|NCT01682759|Drug|Omarigliptin|
1672016|NCT01682928|Drug|IV/Oral Hydration and Bedrest|"Maternal BP (sitting)
Pulse Pressure
Pulse
Urine Specific Gravity BID
Fetal Heart Rate
Maternal Body Weight US Procedures
AC/EFW
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
AFI (Baseline, day 3, 7 {or Discharge})
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:
1 Liter Water PO over 2 hours
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation
Strict I/O's
Vital signs"
1672017|NCT01682928|Other|Hydrotherapy|"Maternal BP (sitting)
Pulse Pressure
Pulse
Urine Specific Gravity BID
Fetal Heart Rate
Maternal Body Weight US Procedures
AC/EFW
Umbilical Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
o 1 hour +/- 30 minutes after submersion therapy
Uterine Artery Doppler Flow (Baseline, day 3, 7 {or Discharge})
o 1 hour +/- 30 minutes after submersion therapy
AFI (Baseline, day 3, 7 {or Discharge}) o 1 hour +/- 30 minutes after submersion therapy
ALL ITEMS ABOVE MUST BE COMPLETED BEFORE:
1 Liter Water PO over 2 hours
1 Liter IV Fluid Bolus (NS) then titrated to 75 ml\hr for duration of the study participation
Strict I/O's
Vital signs
HYDROTHERAPY TWICE DAILY FOR 3-7 DAYS o Blood pressure, pulse, pulse pressure, body weight, and fetal heart rate before and after submersion therapy"
1672018|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
1672019|NCT01682902|Drug|Faster-acting insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
1672020|NCT01682902|Drug|insulin aspart|Administration: Subcutaneous infusion. The subjects will remain on their own pump during the trial. Subjects will have blinded continuous glucose monitoring (CGM) throughout the trial (3 treatment periods of 14 days) and meal tests consisting of a standardised breakfast (liquid meal) will be performed on the 14th day of each treatment period.
1672021|NCT01682889|Dietary Supplement|Arginine|L-arginine-hydrochlorid (0.35 g/kg body weight) intravenously for 24 hours
1672022|NCT01682889|Dietary Supplement|Placebo|NaCl 0.9% intravenously for 24h
1672023|NCT01682876|Biological|MenACWY-CRM|The investigational meningococcal (groups A, C, Y, and W-135 vaccine) oligosaccharide diphtheria CRM197 conjugate vaccine (MenACWY-CRM) was administered intramuscularly in the nondominant arm
1672024|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
1672025|NCT01682863|Drug|QVA149|QVA149 will be supplied in a capsule form in blister packs for use in the Novartis Concept1 SDDPI
1672026|NCT01682863|Drug|QAB149|QAB149 and matching placebo will be supplied in capsule form in blister packs for use in the Novartis Concept1 SDDPI
1672027|NCT01682863|Drug|Placebo|To mimic QAB149
1672028|NCT01682850|Behavioral|Mindfulness Based Pulmonary Rehabilitation|Participants in this group will under go 10 sessions of mindfulness based pulmonary rehabilitation prior to surgery. Each session is about 2 hours long and consists of upper /lower extremity training, breathing exercises, and education.
1672029|NCT01682850|Other|Usual Care|
1672030|NCT01682837|Drug|Potassium chloride powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and again dinner, for a total of 40 meq K/day, for 4 weeks
1672031|NCT01682837|Drug|Potassium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
1672032|NCT01682837|Drug|Potassium magnesium citrate powder|1 sachet mixed with 250 ml water (providing 20 meq K) given at breakfast and dinner, for a total of 40 meq K/day, for 4 weeks
1672033|NCT01682837|Drug|Placebo|1 sachet mixed with 250 ml water given at breakfast and dinner, for a total of 2 sachets/day, for 4 weeks
1672034|NCT01682824|Behavioral|Three-Factor Eating Questionnaire (TFEQ)-R18v2|Completion of TFEQ-R18v2 questionnaire.
1672035|NCT01682824|Behavioral|Multifactor Screener|Completion of multifactor screener, a short assessment tool used to evaluate dietary intake of fruits, vegetables, percentage of energy from fat, and fiber.
1672036|NCT01682824|Behavioral|Eating Questionnaire-EMA (EQ-EMA)|Completion of Eating Questionnaire-EMA (EQ-EMA).
1672039|NCT01682798|Dietary Supplement|Placebo yoghurt|100g of placebo yoghurt will be taken at 10:00 am and 4:00 pm, respectively; 2 times per day.
1672040|NCT01682798|Dietary Supplement|"Yili Chang Qing Pro-ABB yoghurt (Formula 1)"|"100g of Yili Chang Qing Pro-ABB yoghurt will be taken by at 10:00 am and 4:00 pm, respectively; 2 times per day."
1672041|NCT01682798|Dietary Supplement|"Yili Chang Qing Pro-ABB yoghurt (Formula 2)"|
1672042|NCT01682772|Drug|Olaparib|Until objective disease progression, unacceptable toxicity or patient withdrawal for whatever reason
1672045|NCT01682759|Drug|Glimepiride|Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
1672046|NCT01682759|Drug|Glimepiride Placebo|
1672047|NCT01682759|Drug|Metformin|Participants will continue on their stable dose (>=1500 mg/day) of open-label metformin throughout the trial.
1672048|NCT01682759|Drug|Insulin Glargine|Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
1672049|NCT01682746|Drug|Photofrin (porfimer sodium) & photodynamic therapy.|"Intravenous (IV) Photofrin
This is a dose escalation study. Patients will receive Photofrin via an IV infusion approximately 24 hours prior to their tumor resection surgery and Photodynamic Therapy (PDT). Patients will be light sensitive immediately upon receiving the Photofrin and must observe photosensitivity & light precautions for a minimum of 30 days after the infusion.
Photodynamic Therapy (PDT)
After tumor resection, an optical fiber will be placed in the approximate center of the surgical cavity. Intralipid will be infused into the open tumor cavity while PDT is performed. The Intralipid will diffuse the light and ensure uniform delivery. Photoactivation of Photofrin is controlled by the total light dose delivered over the treatment time."
1672050|NCT01682733|Drug|Botulinum toxin|In this study, Botulinum toxin will be injected in half of the subjects not as a primary treatment modality for obesity, but to retard the muscular grinding gastric activity arount the suture insertion sites to see if it improves the durability of the gastroplasty.
1672051|NCT01682733|Device|Overstitch Endoscopic Suturing System|The gastroplasty will be accomplished by a series of intralumenally placed full thickness interrupted sutures through the gastric wall, using the FDA-approved (510K) endoscopic suturing device, the Overstitch Endoscopic Suturing System.
1672052|NCT01682720|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
1672053|NCT01682720|Drug|RBV|Ribavirin (RBV) 200 mg tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1672054|NCT01682720|Drug|Placebo to match SOF|Placebo to match SOF administered orally once daily
1672055|NCT01682720|Drug|Placebo to match RBV|Placebo to match RBV administered orally in a divided daily dose
1672056|NCT01682707|Procedure|laryngoscopy|tracheal intubation with two different techniques, track light and laryngoscopy.
1672057|NCT01682707|Procedure|track light|
1672058|NCT01682694|Dietary Supplement|Glucosamine and Chondroitin|Glucosamine (1500 mg) and Chondroitin (1200 mg)
1672059|NCT01682694|Dietary Supplement|placebo|
1672060|NCT01682681|Drug|Topiramate|This is an observational study. Participants with seizures receiving topiramate as per Investigator's discretion will be observed.
1672061|NCT01682668|Procedure|Bilateral subthalamic stimulation|
1672062|NCT01682642|Drug|Zoladex|after surgical vaporization patients are treated with Zoladex for 3 months before starting IVF treatment
1672063|NCT01682629|Other|Debriefing Script|"A debriefing script was designed for novice instructors to facilitate a 20-minute debriefing session. It was developed in iterative steps: (a) review of PALS learning objectives; (b) categorization of script content; (c) development of scripted language; (d) formatting into a cognitive aid and (e) pilot testing script for usability with subsequent edits before implementation in the study.
All novice instructors received the scenario 2 weeks prior to the study session. Instructors randomized to scripted debriefing were also given the script with no instruction on how to use it except on the day of the study, to use and follow the script as closely as possible during the debriefing session. All instructors held a clipboard while observing the simulation session; to hold the debriefing script and/or take notes. This allowed for blinding of the video reviewers as to which study arm the team had been randomized. Debriefing sessions were limited to 20-minutes in duration."
1672064|NCT01682629|Other|High Physical Realism Simulation|"High vs. Low Physical Realism Simulators A pre-programmed infant simulator was used for all simulation sessions. To create high physical realism (HiR), full simulator functions were activated (turned on) including vital sign monitoring, audio feedback, breath sounds, chest rise, heart sounds, palpable pulses, and vocalization. Low physical realism (LoR) groups had the identical simulator but the compressor was turned off, thus eliminating physical findings described above. In addition, the LoR simulator was connected to a monitor, but it only displayed the cardiac rhythm, and not pulse oximetry, respiratory rate, blood pressure, temperature and audio feedback present in the HiR group. All other aspects of the simulated resuscitation environment were standardized for all groups."
1672065|NCT01682616|Drug|ABT-199|ABT-199 is taken continuously once daily. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
1672066|NCT01682616|Drug|Rituximab|Rituximab will be given by intravenous infusion on day 1 of Months 1, 2, 3, 4, 5, and 6. May be reinitiated for an additional 6 months.
1672067|NCT01682603|Drug|Botulinum toxin A|BoNT-A (BOTOX 300U)
1672068|NCT01682590|Procedure|Renal Remplacement Therapy|"Investigators of each center will have the choice of the RRT technique based on their usual practice: intermittent hemodialysis, intermittent hemodiafiltration, continuous hemodialysis, continuous hemofiltration, continuous hemodiafiltration (typically the continuous techniques in the acute phase, followed by intermittent techniques after stabilization).
In case of life threatening conditions within the 48 hours after randomisation (hyperkalemia, metabolic acidosis or pulmonary edema) the RRT will be initiated as soon as possible.
In case of improvement of renal function within the 48 hours after randomisation (defined as the return of spontaneous urine output > 1000ml/24 hr or >2000ml/24hr with diuretics), RRT is not mandatory."
1672069|NCT01682577|Drug|Perindopril 4 mg tablets of PT Dexa Medica|Test product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
1672070|NCT01682577|Drug|Perindopril 4 mg tablets of Servier|Reference product was given as a single dose, under the procedure as described in the Section: Detailed description of the study.
1672071|NCT01682564|Drug|Candemore tablet|"Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg
dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
1672072|NCT01682564|Drug|Atacand tablet|"Initial dose : 4mg/day if SBP<140mmHg and/or DBP<90mmHg, 8mg/day if SBP≥140mmHg and DBP≥90mmHg
dose escalation : double dose if SBP≥100mmHg and DBP>60mmHg (maximum dose 16mg/day)"
1672073|NCT01682551|Drug|Chinese Medicine|"The participators in this arm will take 2g (powder in capsule) of Wu Zhu Yu Tang or placebo orally three times in the first day and one time in the second day."
1672074|NCT01682551|Drug|Acetalozamide|"If the participators have the history of AMS, he/she will be randomized to take Wu Zhu Yu Tang plus placebo of Acetalozamide or Acetalozamide plus placebo of Wu Zhu Yu Tang."
1672075|NCT01682538|Drug|Nitisinone, capsule|
1672076|NCT01682538|Drug|Nitisinone, suspension|
1672077|NCT01682525|Other|Frozen ovarian tissue|Use of ovarian tissue cryopreserved and stored at Boston IVF
1672083|NCT01682499|Drug|calcium gluconate and magnesium sulfate|Intravenous calcium gluconate and magnesium sulfate, 1g each agent in 100 ml D5W over 30 minutes, immediately before and after each dose of paclitaxel
1672084|NCT01682486|Device|BIP ETT (Bactiguard)|Ventilation of surgery patients during anesthesia using BIP ETT
1672085|NCT01682486|Procedure|Standard ETT|Ventilation of surgery patients during anesthesia using standard ETT
1672086|NCT01682473|Drug|ZSTK474|Two arms, each with serial cohorts receiving escalating doses.
1672087|NCT01682460|Drug|Refresh Tears Lubricant Eye Drops (Allergan)|Eye drops QID for 1 month
1672089|NCT01682434|Procedure|Laser in situ keratomileusis (LASIK)|Wavefront guided treatment in one eye, conventional in the other.
1672090|NCT01682421|Drug|Weak steroid (Flurolon, Allergan)|
1672091|NCT01682421|Drug|Potent steroid (Maxidex, Alcon)|
1672092|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)|1 x 150mg mannitol-based 38% drug-loaded tablet(orange reference)
1672093|NCT01682408|Drug|Fostamatinib - 3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed|3 x 50mg microcrystalline cellulose-based 13% drug loaded tablets,(blue) fed
1672094|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)|1 x 150mg mannitol based 38% drug-loaded tablet (batch variant A)
1672095|NCT01682408|Drug|Fostamatinib - 1 x 150mg mannitol based 38% drug loaded tablet (batch variant B)|1 x 150mg mannitol based 38% drug loaded tablet(batch variant B)
1672096|NCT01682408|Drug|Ranitidine|150 mg ranitidine
1672097|NCT01682395|Procedure|Resection and anastomosis|Resection of sigmoid colon with primary anastomosis
1672098|NCT01682395|Procedure|Resection and colostomy|Resection of sigmoid colon with end colostomy and Hartmann's pouch, followed at a later date by Hartmann's reversal as a second surgical procedure
1672099|NCT01682395|Procedure|Mesosigmoidopexy|Mesosigmoidopexy--the fixation of the sigmoid colon to lateral abdominal wall with concomitant shortening of the mesosigmoid length.
1672100|NCT01682369|Biological|TIV (Aggripal)|
1672101|NCT01682369|Biological|ATIV (Fluad)|
1672102|NCT01682356|Dietary Supplement|Beetroot Juice (BRJ)|double-blind placebo-controlled cross-over study
1672103|NCT01682356|Dietary Supplement|placebo|double-blind placebo-controlled cross-over study
1672104|NCT01682343|Dietary Supplement|Calcium|Milk-calcium supplement
1672105|NCT01682317|Behavioral|Eating Frequency|Thirty adults will be provided an 8-week standard lifestyle intervention, that includes a 1200-1500 kcal/day, < 30% energy from fat dietary prescription, and a physical activity goal of 200 minutes/week. Participants will be randomized to one of two conditions differing in EF using a prescription we have tested previously. One condition will limit the number of eating bouts/day to three (Three Meal), while the second condition will consume at least 100 kcal every 2 to 3 hours which should lead to approximately 6 eating bouts/day (Grazing).
1672106|NCT01682291|Behavioral|Life-style modifications|Weight loss of as little as 10 lbs (4.5 kg) Adoption of the Dietary Approaches to Stop Hypertension (DASH) eating plan Dietary sodium should be reduced to no more than 2.4 g of sodium per day Regular aerobic physical activity (at least 30 minutes per day)
1672107|NCT01682291|Dietary Supplement|Dietary supplements|combined pill (1 capsule/day containing Allium sativum (Dosage: 1,000 mg/day), Crataegus monogyna (Dosage: 500 mg/day), Orthosiphon (Dosage: 300 mg/day), Hibiscus sabdariffa (Dosage: 250 mg/day)
1672108|NCT01682278|Device|Removal of dental amalgam restorations|"Patients in the amalgam cohort will have all dental amalgam restorations removed and replaced with other restorative materials used in modern dentistry. Amalgam removal will be performed by the patient's regular dentist or another dentist chosen by the patient."
1672109|NCT01682265|Other|Stretta procedure|
1672110|NCT01682265|Other|Sham procedure|No radiofrequency delivered
1672111|NCT01682239|Other|RVAP|In this arm pacemaker leads will be placed in the RV apex.
1672112|NCT01682239|Other|RVSP|In this arm pacemaker leads will be placed in the RV septum.
1672113|NCT01682226|Device|CliniMACS Fractionation system (Arm A)|"7 days before transplant Admit to hospital. Line insertion 6 days before transplant Fludarabine (chemotherapy) Cyclophosphamide (chemotherapy) 5 days before transplant Fludarabine Thiotepa 4 days before transplant Fludarabine Thiotepa 3 days before transplant Fludarabine Start CSA and MMF 2 days before transplant Fludarabine and TBI (radiation therapy)
1 day before transplant TBI (radiation therapy) Day of transplant Transplant day (infuse cord blood) Day after cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
1672114|NCT01682226|Device|CliniMACS Fractionation system (Arm B)|"8 days before transplant Admit to hospital. Line insertion 7 days before transplant Fludarabine 6 days before transplant Fludarabine Cyclophosphamide 5 days before transplant Fludarabine Cyclophosphamide 4 days before transplant Rest 3 days before transplant TBI x 3 Start CSA and MMF 2 days before transplant TBI x 3
1 day before transplant TBI x 3 Day of transplant TBI x 2 then infuse cord blood
1 day after the cord blood transplant Infuse family member stem cells 7 days after transplant Start G-CSF"
1672115|NCT01682213|Drug|Dabrafenib|Following definitive surgical resection, eligible patients will receive dabrafenib at 150 mg twice a day by mouth for 4 cycles (± 5 days). One cycle is 28 days.
1672116|NCT01682200|Drug|ProOxy|Clean the face with ProOxy facial wash before spraying ProOxy on the face enough to wet it twice daily, upon waking up and before bedtime.
1672117|NCT01682187|Drug|LY2157299|Administered orally
1672121|NCT01682161|Drug|Paliperidone palmitate|Paliperidone palmitate will be administrated in accordance with each product's information. Recommended initial loading doses are 150 mg equivalent on Day 1 and 100 mg equivalent on Day 8, followed by subsequent once-monthly administration with 75 mg equivalent or flexible dose between 25 mg and 150 mg equivalent.
1672124|NCT01682135|Biological|Ramucirumab|Administered IV.
1672125|NCT01682109|Drug|Valacyclovir|
1672126|NCT01682096|Radiation|computed coronary angiography|Patients will be pre-medicated with atenolol 50 mg 1h prior to the scan.
1672127|NCT01682096|Procedure|Exercise stress echocardiography|Limited by symptoms
1672128|NCT01682083|Drug|Dabrafenib|Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt)
1672129|NCT01682083|Drug|Trametinib|Each tablet contains 0.5 mg or 2.0 mg of trametinib parent (present as the DMSO solvate)
1672130|NCT01682083|Drug|Placebos|The placebo capsules and tablets contain the same inactive ingredients and film coatings as the dabrafenib and trametinib study treatment
1672131|NCT01682070|Biological|SUBLIVAC FIX phleum prat.|Comparison of different dosages to placebo
1672132|NCT01682070|Biological|Placebo|
1672133|NCT01682057|Device|ROX ANASTOMOTIC COUPLER SYSTEM (ACS)|The ROX Anastomic Coupler (ACS) will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
1672134|NCT01682057|Device|ROX Anastomotic Coupler System (ACS)|
1955069|NCT03299283|Diagnostic Test|BioFire test platform|Analysis of analyte stability under various conditions as measured by BioFire test platforms
1672141|NCT01682031|Dietary Supplement|selenomethionine|Given PO
1672142|NCT01682031|Other|placebo|Given PO
1672143|NCT01682031|Drug|cisplatin|Given IV
1672144|NCT01682031|Radiation|radiation therapy|Undergo radiotherapy
1672145|NCT01682031|Procedure|quality-of-life assessment|Ancillary studies
1672146|NCT01682018|Device|lung volume reduction using the Zephyr device|lung volume reduction using the Zephyr device
1672147|NCT01682005|Other|Data interpretation|The data collected for each group will be fully de-identified, interpreted and analysed separately for the 2 databases (MarketScan Commercial and MarketScan Medicaid).
1672153|NCT01681979|Drug|Fluticasone propionate (with and without concurrent salmeterol)|"Fluticasone propionate is an inhaled corticosteroid used for the treatment of asthma, often in combination with the long-acting β-agonist salmeterol. For the primary endpoint, exposure status will be determined based on the individual receiving a prescription for the drug of interest (fluticasone propionate or another inhaled corticosteroid) in the 2 weeks immediately before the LMP date or during the first trimester of pregnancy.
Sensitivity analysis will be carried out categorising exposure based on mapping the duration of prescriptions based on the number of inhalers, number of puffs within an inhaler and the prescribed daily dose."
1672154|NCT01681966|Drug|PRF110- oily solution (Ropivacaine)|Post operative application of PRF110-oily solution (Ropivacaine)
1672155|NCT01681953|Drug|Lamazym|ERT, i.v. infusions weekly
1672156|NCT01681953|Drug|Placebo|Infusions weekly
1672157|NCT01681940|Drug|Lamazym|ERT, i.v. infusions weekly
1672158|NCT01681901|Procedure|ultrasound imaging|Undergo ultrasound
1672159|NCT01681888|Device|Sanger EMG Biofeedback Device|
1672160|NCT01681875|Other|very low nicotine content cigarettes|
1672161|NCT01681862|Behavioral|Personal Health Record|"Participants data collected during the scheduled blood pressure sessions will be uploaded to the church PHR system. Lay health workers (LHWs) will then have the capability to access the blood pressure readings and health behavior data through the Congregational Dashboard where they can display the information in easy-to-read charts and graphs that highlight the blood pressure trends across the measurements and changes in fruit and vegetable intake, level of physical activity and weight. The registry will also incorporate computerized health education modules through and evidence-based guidelines for blood pressure control and the NHLBI publications Your Guide to Lowering Blood Pressure and Facts about the DASH Eating Plan."
1672162|NCT01681849|Drug|Placebo|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
1672316|NCT01680679|Biological|Inactivated Trivalent Influenza Vaccine (TIV)|
1672317|NCT01680679|Biological|Inactivated poliovirus vaccine (IPV), trivalent|
1672163|NCT01681849|Drug|Paroxetine|Following a three month double blind phase, subjects will be treated with open label paroxetine at a variable dosage of 10-40 mg to reach individual therapeutic levels for three months.
1672164|NCT01681849|Other|Positron Emission Tomography (PET) Imaging|Participants will undergo positron emission tomography (PET) imaging of the brain with O-15 radiolabelled water with exposure to traumatic scripts
1672167|NCT01681823|Dietary Supplement|PectaSol-C Modified Citrus Pectin (MCP)|Oral administration of PectaSol-C MCP (4.8 grams in six capsules three times a day away from food).
1672168|NCT01681810|Drug|14 N Sodium Nitrite|oral formulation of sodium nitrite 40 mg TID for 12 weeks
1672172|NCT01681758|Other|IV fluid according to PPV|intravenous fluids
1672173|NCT01681758|Other|fluids according to standard care|
1672174|NCT01681745|Device|Treatment with Cryo-Touch III|
1672175|NCT01681732|Other|Personalized Care Plan|We will develop a personalized plan based on info collected in the primary visit
1672176|NCT01681732|Other|Control Standard Care|This is the standard care arm
1672177|NCT01681719|Device|WBV and Resistance|"use of WBV and resistance device during 03 months in elderly health people. The WBV used progressive increases of time and amplitude and the resistance training improves the weight.
For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.
For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
1672178|NCT01681719|Device|resistance & sham WBV|"used only resistance
For Resistance: performed in upper and lower limbs in weight machine Mega II Movement®, used guidelines from American College of Sports Medicine for elderly, with two series of 08 repetitions (75% weight of one RM), considered for RM calculation the maximum voluntary isometric contraction.
For WBV: used MY3 platform (Power Plate®, MY3, UK)off."
1672179|NCT01681719|Device|WBV & resistance sham|"used really the WBV, but sham for resistance training
For Resistance: performed similar movments in upper and lower limbs in weight machine Mega II Movement®, without using weights.
For WBV: used MY3 platform (Power Plate®, MY3, UK) frequency 35 hertz, tri-axial, amplitude 02 mm in adaptation and initial phases, increasing to 04 mm in phases intermediate and final. The time initial was 10 minutes, progressed to 15 min in second month, concluding with 20 min. Rest time between series remained 01 min."
1672180|NCT01681693|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
1672181|NCT01681680|Drug|Metformin|Subjects will be given an oral dose of metformin once per day for two days.
1672182|NCT01681667|Drug|Ibuprofen|ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
1672183|NCT01681654|Behavioral|Lifestyle Intervention|Participants in the Lifestyle Intervention will receive a 12-week individualized exercise and dietary program based on their exercise assessment and dual energy x-ray absorptiometry (DXA) scan results, will attend twice weekly group exercise classes, and perform their individualized at-home program an additional two times per week. In addition, participants will be required to attend six education sessions during the 12-week intervention.
1672184|NCT01681654|Behavioral|Maintenance Intervention|Patients randomized to receive the Maintenance Program Intervention following treatment will receive a Survivorship Care Plan outlining their physical activity, dietary, and health behaviour progress throughout the program, future goals, individualized maintenance strategies, and optional drop-in exercise sessions.
1672185|NCT01681641|Other|A psycho-social intervention|
1672186|NCT01681628|Behavioral|Thought Field Therapy.|Thought Field Therapy is a meridian based therapy, where clients tap on specific parts of their body, according to a particular protocol. This does not obliterate the memory of the trauma, but relieves the associated distress.
1672187|NCT01681615|Drug|Acetylsalicylate|1-2 drops
1672188|NCT01681615|Drug|Isotonic NaCl|1 drop
1672189|NCT01681602|Other|Aerobic exercise|Physical exercise in the intervention group will be delivered as an individually tailored program consisting of 4 weeks of adaptation exercise followed by 12 weeks of continuously supervised moderate aerobic exercise 1 hour three times a week. The participants can choose from treadmill, stationary bike and crosstrainer.
1672190|NCT01681589|Device|Transcranial Direct Current Stimulator (TDCS)|Group will receive active TDCS
1672191|NCT01681589|Device|Control Group|This group will receive Sham TDCS
1672192|NCT01681589|Other|Healthy Control Group|Healthy Controls will be involved in the Study. Healthy Controls will receive no Intervention. There will be 1 screening visit and 1 testing visits.
1672193|NCT01681576|Drug|Valsartan|Valsartan 320mg tablet once daily
1672194|NCT01681576|Drug|LCZ696|LCZ696 400mg tablet once daily
1672195|NCT01681563|Drug|Pentostatin|Lyophilized powder for intravenous administration.
1672196|NCT01681563|Drug|Cyclophosphamide|IV
1672197|NCT01681563|Drug|Ofatumumab|Liquid concentrate for solution for infusion.
1672198|NCT01681550|Drug|Incretin-based therapy|
1672199|NCT01681537|Drug|Lenalidomide|
1672200|NCT01681537|Drug|Mitoxantrone|
1672201|NCT01681537|Drug|Etoposide|
1672202|NCT01681537|Drug|Cytarabine|
1672203|NCT01681524|Drug|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET MPI analysis
1672318|NCT01680666|Procedure|central line placement|central line placement
1672319|NCT01680666|Device|Ultrasound|Ultrasound guided central venous access
1724413|NCT00005078|Drug|tirapazamine|
1672204|NCT01681511|Device|ICET™ TIC Foley Catheter|The device to be evaluated in this investigation is a silver-based antimicrobial coated Foley catheter connected to an antimicrobial anti-reflux accessory (ICET Inc, Norwood, MA). The closed system is referred to as the TIC system and is designed with the objective of reducing the incidence of CAUTI. The accessory is non-tissue contacting.
1672205|NCT01681511|Device|BARD® LUBRI-SIL® IC Foley Catheter|The LUBRI-SIL® I.C. antimicrobial 100% silicone Foley catheter incorporates a formulation consisting of BACTI-GUARD®* silver alloy coating and BARD® hydrogel.
1672206|NCT01681472|Drug|[6R] 5,10-methylenetetrahydrofolate|i.v. bolus injection
1672207|NCT01681472|Drug|Levoleucovorin|i.v. bolus injection
1672208|NCT01681446|Drug|interferon-alpha (IFN-alpha)|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
1672209|NCT01681433|Drug|OGX-427|OGX-427 started within 7 days of randomization, three loading doses of 600 mg IV within Week 1 if possible (up to 10 days of initiating treatment), followed by weekly doses of 800 mg IV
1672210|NCT01681433|Drug|Abiraterone Acetate|Standard therapy: Abiraterone Acetate 1000 mg PO daily
1672211|NCT01681433|Drug|Prednisone|Standard therapy: Prednisone 10-20 mg PO daily
1672212|NCT01681420|Behavioral|HIV Counseling and Testing|HIV counseling and testing in lieu of blood donation.
1672213|NCT01681420|Behavioral|Blood Donation|Blood donation without HIV counseling
1672214|NCT01681394|Dietary Supplement|Polyphenol-rich cocoa extract|250 g of chocolate cream supplemented with 2.3 g of polyphenol-rich cocoa extract (containing 1050 mg of total polyphenols)
1672215|NCT01681394|Dietary Supplement|Chocolate cream|
1672216|NCT01681381|Device|Tivoli® DES|Device:Tivoli® DES The Tivoli® DES drug eluting stent(Tivoli® DES) is an open cell balloon expandable cobalt chromium stent coated with a bio-gradable polymer (PLGA) containing rapamycin at a dose of 8 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug releasing in 1 week and approximately 80% releasing in 28 days. The polymer may be degraded in 3 to 6 months in human body. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 10、15、18、21、25、30、35 mm and diameters of 2.5、2.75、3.0、3.5、4.0 mm.
1672217|NCT01681381|Device|Firebird2® DES|The Firebird2® rapamycin-eluting stent (Firebird2® DES) is an open cell balloon expandable cobalt chromium stent coated with a biocompatible durable styrene-butylenes-styrene (SBS) polymer containing rapamycin at a dose of 9 micrograms per millimeter of stent length. In vitro assays have shown that about 50% of the drug elutes in 1 week and approximately 90% elutes in 1 month. This stent is supplied pre-mounted on a delivery catheter and is available in the following sizes: lengths of 13, 18, 23, 29, 33 mm and diameters of 2.25, 2.5, 2.75, 3.0, 3.5, 4.0 mm.
1672218|NCT01681368|Drug|Birinapant (TL32711)|47mg/m^2 intravenous (IV) on days 1, 8 and 15 of each 28 day cycle
1672219|NCT01681355|Other|Infant Formula|Standard cow's milk based infant formula with added prebiotic oligosaccharides, and a modified fat blend and protein composition
1672220|NCT01681329|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy addressing intolerance of uncertainty, positive beliefs about worry, negative problem orientation, and cognitive avoidance
1672221|NCT01681329|Other|Interpretation training|Computerized interpretation training using Word-Sentence Association Paradigm
1672222|NCT01681316|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: salvia miltiorrhiza and safflower
1672223|NCT01681316|Other|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of Chronic Stable Angina (2007).
1672224|NCT01681316|Drug|Placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
1672225|NCT01681303|Drug|AST-120|
1672226|NCT01681290|Drug|CBX129801|
1672227|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
1672228|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
1672229|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
1672230|NCT01681277|Drug|Placebo to BI 113608 PIB qd|powder for oral solution
1672231|NCT01681277|Drug|Placebo to BI 113608 PIB bid|powder for oral solution
1672232|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
1672233|NCT01681277|Drug|BI 113608 PIB bid|powder for oral solution
1672234|NCT01681277|Drug|BI 113608 PIB qd|powder for oral solution
1672235|NCT01681264|Drug|Morphine|
1672236|NCT01681264|Drug|Guanfacine 1mg|
1672237|NCT01681264|Drug|Guanfacine 2mg|
1672238|NCT01681264|Drug|Placebo|
1672239|NCT01681251|Other|Fluid titrated with the use of arterial pulse contour cardiac output monitor if SVV >13%|"Following induction of anesthesia, Voluven boluses of 250ml will be given if SVV increases above 10%. Further Voluven boluses will be given in 250ml aliquots should the SVV increase to greater than 10%. If a total of 55ml/kg of Voluven is given, the fluid will be changed to lactated ringers and no further colloid will be given, as this is the maximum dose recommend by the manufacturer.
Vasoactive agents (type and dose at the discretion of the attending anesthesiologist) may be given to maintain a mean arterial pressure that the clinical team feels adequate to maintain adequate organ perfusion. In the intervention group, however, vasoactive agents will not be given unless fluid administration has resulted in a maximal value of SV."
1672240|NCT01681251|Other|Fluid titrated at the discretion of the attending anesthesiologist|In the control group, the data from the FloTrac monitor will not be available to the anesthesia care provider. Fluid replacement will be at a rate and of a type that is entirely up to the anesthesiologist; the only stipulation being that Voluven is to be used should the provider desire to use a colloid solution.
1672241|NCT01681238|Procedure|Protocol group 2|ensure SpO2≥ 92%, MAP 65-100 mmHg, HR <100 bpm, Hb> 8mg/dL and temperature ≥ 36℃, the patients were then administrated a 200 ml colloid as a fluid challenge. The fluid challenge repeat until the SV failed to increase by a factor of 10%. If at this stage the DO2I can not be greater than 600 mL/m2, then dobutamine will be started at a dose of 2.5 μg/kg/min and increased by the same increment every 20 minutes until the described target is reached or until a maximal dose of 20 μg/kg/min is given. Dobutamine is decreased in dose or discontinued if the heart rate is above 120 beats per minute or shows signs of cardiac ischemia. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
1672242|NCT01681238|Procedure|Protocol group 1|The goal of this protocol is to ensure MAP> 65 mmHg, CVP 8-12 cmH2O. If meet the above requirements, do nothing, re-evaluate after 5min. If CVP <8 cmH2O, the patient will receive an additional 200ml colloid .If MAP beyond the scope of 65-100 mmHg, vasoactive agents will be administrated until achieve the goal. If 25mL/kg colloid given before goal is achieved, fluid challenges will then be performed with 200mL boluses of Ringer's lactate solution. Blood transfusions will be used to maintain a hemoglobin concentration over 8mg/dL
1672245|NCT01681212|Drug|Ipilimumab|
1672246|NCT01681212|Drug|Dacarbazine|
1672247|NCT01681199|Drug|Fluvastatin extended release tablet|
1672248|NCT01681186|Drug|LY2940680 Capsule(s) (Reference)|Administered orally as a capsule(s)
1672249|NCT01681186|Drug|LY2940680 Tablet (Test)|Administered orally as a tablet
1672250|NCT01681186|Drug|Lanzoprazole|Administered orally as a capsule
1672251|NCT01681186|Drug|Placebo Capsule(s)|Administered orally as a capsule(s)
1672252|NCT01681173|Dietary Supplement|Fiber|200ml drinks enriched with 7,5g of fiber (90% insoluble fiber, 10% soluble fiber), BID, over 24 months
1672253|NCT01681173|Dietary Supplement|Placebo|200ml Placebo, BID, over 24 months
1672254|NCT01681160|Other|procedure:maggot therapy|each times in maggot therapy continued for three days.wound assessment was done before and after any intervention
1672255|NCT01681160|Other|conventional therapy|patients receive ordinary treatment for diabetic foot
1672256|NCT01681147|Behavioral|2 online nutrition and exercise education classes|Two online nutrition and physical activity classes will accessed from a computer, android phone or a tablet. Each class is estimated to last about 1.5- 2 hours and will be accessed 6 weeks-3 months and 9 months
1672257|NCT01681147|Behavioral|Self monitoring of blood glucose levels|Self monitoring of blood glucose levels four times a day for four consecutive days once a month from 6 weeks-3 months through 9 months post partum
1672258|NCT01681134|Drug|Advagraf®|oral
1672259|NCT01681134|Drug|Prograf®|oral
1672260|NCT01681121|Drug|ADX-N05|150 mg once a day for 4 weeks followed by 300 mg once a day for 8 weeks
1672261|NCT01681121|Drug|Placebo|One capsule placebo to match ADX-N05 to be taken for 4 weeks followed by 2 capsules placebo to match ADX-N05 to be taken for 8 weeks
1672262|NCT01681108|Behavioral|Lifestyle counseling|Individualized meal planning and exercise regimen sessions will be developed for each participant
1672263|NCT01681095|Drug|Custodiol HTK|After cross-clamping of the aorta approximately 1-2 L of Custodiol-HTK was infused into the ascending aorta over 6-8 minutes. Additional doses of 100-200 ml were administered as needed. The cardioplegic solution was delivered at a temperature of 4°C - 10°C.
1672264|NCT01681095|Drug|Cold Blood Cardioplegia|After cross-clamping the aorta, at least 1000 mL of a 4:1 mixture of cold blood: cold crystalloid was administered at a pressure of 300 mmHg or less via a twin roller pump. Every 20 minutes an additional > 200 mL was administered in an antegrade/retrograde fashion throughout the remainder of the case. The cardioplegic solution was delivered at a temperature of 4°C - 8°C.
1672265|NCT01681082|Behavioral|Tai Chi training|24 form Yang style Tai Chi. 50 minute sessions, twice weekly.
1672266|NCT01681069|Dietary Supplement|IQP-VV-102|
1672267|NCT01681069|Other|Placebo|
1672268|NCT01681056|Behavioral|Autosuggestion for 30 days|
1672269|NCT01681043|Behavioral|protocol 'Quiet in the room'|"Protocol 'Quite in the room' between 10 p.m. and 6 a.m.
nurse nearby
no visits after 10 p.m.
decreased alarm sound in ventilator and monitor
decreased light intensity
no unnecessary conversations around the patient
medication should be limited to max 1-2 times in this time period
no unnecessary therapeutic or diagnostic procedures in this time period
earplugs and sleep masks"
1672270|NCT01681030|Biological|EVARREST™|EVARREST™ Fibrin Sealant Patch is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
1672271|NCT01681030|Biological|Topical hemostat|Equine collagen with Human Fibrinogen and Human Thrombin
1672272|NCT01681030|Other|Standard of Care|SoC is a composite of techniques/methods typically used by the surgeon to control bleeding after conventional methods (i.e. suture, ligation, cautery) are ineffective or impractical.
1672273|NCT01681017|Behavioral|HBB/ENC Training and Equipment|See the detailed description section
1672274|NCT01681017|Other|HBB/ENC supplies|Staffs associated with participating facilities receive HBB/ENC training and use related equipment.
1672275|NCT01681004|Device|iFuse Implant System|Placement of iFuse implant system via surgery
1672276|NCT01681004|Other|Non-surgical management|Medications for pain, physical therapy, SI joint injection and RF ablation
1672277|NCT01680991|Drug|Obinutuzumab|Multiple doses of obinutuzumab.
1672278|NCT01680978|Drug|aleglitazar|150 mcg orally daily, 6 weeks
1672279|NCT01680978|Drug|placebo|orally daily, 6 weeks
1672280|NCT01680965|Drug|Ofatumumab|"Phase I: test an escalating dose of ofatumumab at cohorts of 300 mg, 700 mg, and 1000 mg given on day 0 and 14 of study.
Phase II: Ofatumumab MTD on day 0 and 14; patients will be followed for total of 24 months (months 1, 3, 6, 12 after therapy, then at 18 and 24 months following therapy)"
1672281|NCT01680952|Drug|A) TEST|"Extended Release Tacrolimus (Advagraf®)
① Living The day before surgery: 0.2 mg/kg(morning dose) po, qd Morning on the day of surgery: 0.1 mg/kg po, qd After surgery, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.
② Cadaveric Before surgery at once : 0.1 mg/kg within 12hours before surgery. After surgery : 0.2mg/kg po. in the morning After that, the capacity is adjusted according to the trough level. clinical significance, electrolyte level.
Sirolimus (Rapamune®):
After surgery : 2mg/kg po. within 24hrs after reperfusion. After that, the capacity is adjusted according to the trough level."
1672282|NCT01680952|Drug|B) CONTROL|"Extended Release Tacrolimus (Advagraf®)
: Same as above.
Mycophenolate mofetil : After surgery : 500mg/kg po. within 24hrs after reperfusion. After that, daily dose: 1000mg bid"
1673629|NCT01670084|Drug|cyclophosphamide|Given IV
1672285|NCT01680926|Dietary Supplement|Almased|During the first week, all three main meals were replaced with 50 g of a protein-rich meal replacement (Almased) (=1100 kcal per day). During weeks 2-4, only two meals were replaced and a protein-rich lunch was allowed. During weeks 5-12, only dinner was replaced.
1672286|NCT01680913|Procedure|Ultrasound guidance|The intervention group's interspaces will be determined using the curved linear probe on a Zonare ultrasound using two views.
1672287|NCT01680913|Procedure|Palpation of Tuffier's line|Current clinical practice. Standard of care would have the attending anesthetist palpate the Tuffier's line to pinpoint the appropriate location for the spinal.
1672288|NCT01680913|Procedure|Spinal anesthetic|Subcutaneous local infiltration with a 25g needle we be performed prior to the spinal. Neuraxial technique will be attempted midline with a 25 gauge whitacre needle in the sitting position. Spinals will be attempted on either L2-L3, L3-L4, L4-L5 interspaces. The amount and type of local anesthetic/intrathecal narcotic will be left to the discretion of the Anesthetist.
1672289|NCT01680900|Drug|vilazodone|capsules once/day for 8 weeks. Dose starts at 10 mg for 7 days, increases to 20 mg/day for 7 days, increases to 40 mg/day at week 3 of unimproved.
1672290|NCT01680900|Drug|placebo capsules|placebo capsules matched to drug capsules.
1672291|NCT01680887|Drug|Varenicline|
1672292|NCT01680887|Drug|Placebo|
1672293|NCT01680874|Dietary Supplement|Probiotic|The intervention will consist of the subject taking the study medication once a day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
1672294|NCT01680874|Dietary Supplement|Placebo|The intervention will consist of the subject taking the placebo once a day for 4 weeks. day for 4 weeks. During hospitalization, patients will be followed daily for diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. Upon discharge from the hospital, patients will be contacted through weekly phone calls to assess diarrhea history, record of concomitant medications, adverse effects (AEs), and their response to treatment using a stool diary. At weeks 4 and 8, a stool sample will be collected, and the stool diary will be reviewed.
1672295|NCT01680861|Drug|Tacrolimus|Tacrolimus dosing (rTd) is planned, 0.1 mg/kg PO BID - beginning when serum Cr decreases to a level of <4 mg/dl (i.e., acceptable renal transplant function) postoperatively. Target tacrolimus trough levels during the first year post-transplant and thereafter will be 5-8 ng/ml.
1672296|NCT01680861|Drug|Everolimus|Everolimus initiated at 0.75 PO BID and will be adjusted in order to achieve target everolimus trough levels of 3-8 ng/ml.
1672297|NCT01680861|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|EC-MPS 720 mg PO BID - beginning on 1st postoperative day.
1672298|NCT01680861|Drug|Corticosteroids|Corticosteroids will be given as per our center protocol, i.e., a bolus of 500 mg of Methylprednisolone intravenously at surgery and daily x2, followed by 1.0 mg/kg, then 0.5 mg/kg orally until weaned off completely by 7-10 days postoperatively - the plan is for corticosteroids to be discontinued by 7-10 days postoperatively in both groups.
1672299|NCT01680835|Device|EverFlex™ Self-Expanding Peripheral Stent System|Using the EverFlex™ Self-Expanding Peripheral Stent System to treat
1672300|NCT01680809|Device|Compression stocking 15-20mmHg|Compression stocking with 15-20mmHg of compression
1672301|NCT01680809|Device|Compression stocking 20-30mmHg|Compression stocking with 20-30mmHg of compression
1672302|NCT01680796|Drug|Dovitinib|"Dose Level 0: 200 mg daily
Dose Level 1: 300 mg daily
Dose Level 2: 300 mg daily
Dose Level 3: 400 mg daily
Dose Level 4: 500 mg daily"
1672303|NCT01680796|Drug|Bortezomib|"Dose Level 0: 1.3 mg/m2 IV on days 1 and 8
Dose Level 1: 1.3 mg/m2 IV on days 1 and 8
Dose Level 2: 1.6 mg/m2 IV on days 1 and 8
Dose Level 3: 1.6 mg/m2 IV on days 1 and 8
Dose Level 4: 1.6 mg/m2 IV on days 1 and 8"
1672304|NCT01680796|Drug|Dexamethasone|Dexamethasone 20 mg will be given orally on Days 1, 2, 8, and 9 of each 21-day cycle.
1672307|NCT01680757|Device|LARIAT Suture Delivery Device and Accessories|
1672308|NCT01680744|Other|Hypothermia|The intervention will take place after consent for donation and research has been obtained and hemodynamic stability has been achieved (mean arterial blood pressure > 60 mmHg for more than one hour without an increase in vasopressors). Organ donors in the experimental group will either be actively warmed or allowed to spontaneously reach a body temperature of 34 °C.
1672309|NCT01680718|Drug|Intranasal oxytocin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 24 IU oxytocin (Syntocinon, Novartis Pharmaceuticals). 5 puffs per nostril (1 puff = 2.4 IU oxytocin).
1672310|NCT01680718|Drug|Intranasal vasopressin|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 20 IU vasopressin (American Regent Pharmaceuticals). 5 puffs per nostril (1 puff = 2 IU vasopressin).
1672311|NCT01680718|Drug|Intranasal placebo|Through the use of 1oz bottles attached with metered nasal pumps (1 puff = .1ml), participants will self-administer 5 puffs per nostril. Placebo consists of: 2 mls Glycerine and 3 mls purified water (methylparaben and propylparaben mixed according to purified water formula) for a total of 5 ml, which will be filtered with a 5mu filter (used previously; Bartz et al., 2010).
1672312|NCT01680705|Other|High Volume Saline Irrigation|High volume saline irrigation (240 ml)
1672313|NCT01680692|Drug|Ropivicaine|Infusion of local anesthetic for post-operative analgesia.
1672314|NCT01680692|Device|Continuous Femoral Nerve Catheter|Continuous femoral nerve catheter placed to deliver infusions of local anesthetic post-operatively.
1672315|NCT01680692|Device|Continuous Tibial Nerve Catheter|Continuous infusion of local anesthetic delivered through a tibial nerve catheter post-operatively.
1672328|NCT01680601|Procedure|Remote ischaemic preconditioning (RIPC)|RIPC will be performed by 3 cycles of 5 minute leg ischaemia induced by inflation of a blood pressure cuff to 40 mmHg above the patient's systolic pressure. This protocol will be performed at two phases: 24 hours before surgery and during anaesthesia immediately prior to surgery.
1672329|NCT01680601|Procedure|Placebo|
1672330|NCT01680588|Drug|[18F]NAV4694|
1672331|NCT01680562|Other|in-vivo skin tumor imaging via optical coherence tomography|optical coherence tomography imaging of skin lesion; digital dermoscopy imaging of skin lesion
1672332|NCT01680549|Drug|Gabapentin|Gabapentin 600mg PO pre-operatively and continued postoperatively 300 mg PO q8 hours x 3 days.
1672333|NCT01680536|Drug|maraviroc|
1672334|NCT01680523|Procedure|Radical hysterectomy|Piver-Rutledge type III hysterectomy New classification type C2 hysterectomy Open, vaginal, laparoscopic assisted, laparoscopic, robotic radical hysterectomy are all allowed
1672335|NCT01680523|Radiation|Tailored adjuvant therapy|After radical hysterectomy, intermediate risk group according to GOG protocol 92 criteria will receive adjuvant radiation therapy. High risk group will receive adjuvant chemoradiation therapy with weekly cisplatin (40mg/m2, IV for 6 cycles). Extended filed radiation therapy is allowed in case of common iliac lymph node or para-aortic lymph node metastasis. Intracavitary brachytherapy and nodal or parametrial boost is not allowed.
1672336|NCT01680523|Radiation|Primary chemoradiation therapy|Patient will receive primary radiation therapy including external pelvic irradiation, intracavitary brachytherapy, and parametrial or nodal boost. Extended filed radiation therapy is allowed in case of common iliac lymph node enlargement. Patients will receive concurrent weekly cisplatin (cisplatin 40mg/m2 for 6 cycles) during external radiation therapy.
1672337|NCT01680510|Dietary Supplement|Alga Dunaliella Bardawil|
1672338|NCT01680510|Other|Placebo (starch)|
1672339|NCT01680497|Device|Crosslinked hyaluronic acid dermal filler|All treatment details are at the discretion of the Investigator and should be guided by the Directions for Use. Up to 3 treatments will be administered: Initial treatment, optional top-up treatment at Day 14 post-initial treatment, and optional repeat treatment at Month 12 post-initial treatment.
1672340|NCT01680484|Dietary Supplement|Bitter chocolate|
1672341|NCT01680484|Dietary Supplement|Orange juice|
1672342|NCT01680471|Drug|Midazolam 0.03mg/kg|"This group will be injected intravenous midazolam 0.03mg/kg five minutes before the end of surgery.
If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
1672343|NCT01680471|Drug|Midazolam 0.05mg/kg|"This group will be injected intravenous midazolam 0.05mg/kg five minutes before the end of surgery.
If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
1672344|NCT01680471|Drug|Placebo|"This group will be injected intravenous normal saline five minutes before the end of surgery.
If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg."
1672345|NCT01680458|Drug|Fluconazole|"Candidiasis infection: The recommended dosage in children is 3 mg/kg once daily.
Cryptococcal infection: The recommended dosage in children is 6 mg/kg once daily. A dosage of 12 mg/kg once daily may be used, based on medical judgment of the patient's response to therapy.
Prophylactic administration for deep mycosis on Hematopoietic stem cell transplantation: The recommended dosage in children is 12 mg/kg once daily.
Absolute doses exceeding 600 mg/day are not recommended."
1672346|NCT01680432|Dietary Supplement|Probiotic fresh cheese|Participants in the intervention group were instructed to drink 30 grams of fresh cheese enriched with probiotics daily for 30 consecutive days.
1672347|NCT01680432|Dietary Supplement|Regular Cheese|
1672348|NCT01680419|Behavioral|Mission Reconnect|Multimedia package (audio, video, and print, web-based and downloadable to mobile devices) comprising an integrated program of (1) guided mind/body stress reduction and relaxation practices, (2) contemplative practices to engender and support appreciation, empathy and forgiveness for oneself and one's loved ones, and (3) video instruction in use of simple massage techniques with a partner for connection and stress reduction.
1672349|NCT01680419|Behavioral|PREP|"The Army's PREP for Strong Bonds program offers retreats for partnered soldiers to support reintegration and healthy relationships. PREP (Prevention and Relationship Enhancement Program) for Strong Bonds is a standardized, evidence-based program conducted in a weekend residential retreat format with experiential exercises. The Army Chaplain Corps trains chaplains to facilitate the program. The manualized program uses methods from cognitive behavioral therapy and communication-oriented marital enhancement programs developed by Markman et al. at the Denver University Center for Marital and Family Studies. Topics include communication, conflict management, commitment, friendship, sensuality, problem-solving, and emotional supportiveness, among others."
1672350|NCT01680406|Drug|Artemether-lumefantrine combination|
1672351|NCT01680406|Drug|Primaquine|
1672352|NCT01680406|Drug|Chloroquine|
1672353|NCT01680393|Device|Sequential compression device|a sequential compression device will be applied to the legs
1672354|NCT01680393|Other|TED stockings|TED stockings will be applied to the patients legs during surgery
1672355|NCT01680367|Procedure|wound care management|Receive transparent film dressing or Xeroform petroleum gel impregnated gauze dressing
1672356|NCT01680367|Procedure|wound care management|Receive native collagen wound dressing
1672357|NCT01680367|Other|questionnaire administration|Ancillary studies
1672358|NCT01680354|Procedure|ReLEx|
1672359|NCT01680354|Procedure|LASIK|
1672494|NCT01679327|Drug|Calcium folinate (CF)|
1672495|NCT01679327|Drug|5-FU|
1672360|NCT01680341|Drug|insulin degludec/insulin aspart|Twice weekly self-titration at intervals of 3-4 days, based upon a single pre-breakfast and pre-dinner SMPG (self-measured plasma glucose) value. For subcutaneous (s.c., under the skin) administration.
1672361|NCT01680341|Drug|insulin degludec/insulin aspart|Once weekly self-titration based upon the lowest of 3 pre-breakfast and 3 pre-dinner SMPG (self-measured plasma glucose) values. For subcutaneous (s.c., under the skin) administration.
1672362|NCT01680328|Other|19 injections|Subjects will receive 19 injections in randomised order of which 13 will be in the abdomen and 6 in the thighs. Out of the 19 injections, 2 are needle insertions only. The remaining 17 injections represent different combinations of injection speed and volume of sodium chloride 0.9% solution for injection. The order of the injection speed and volume combinations will be blinded for the subject and the pain will be evaluated by the subject on a VAS (Visual Analogue Scale).
1672363|NCT01680328|Drug|sodium chloride 0.9% solution|Solution for injection.
1672364|NCT01680315|Behavioral|low calorie yogurt|all participants consumed twice the low-caloric food (once with the low-calorie information and once with the high-calorie information)
1672365|NCT01680315|Behavioral|high calorie yogurt|all participants consumed twice the high-caloric food (once with the low-calorie information and once with the high-calorie information)
1672366|NCT01680302|Behavioral|High intensity exercise|
1672367|NCT01680302|Behavioral|Moderate intensity exercise|
1672368|NCT01680302|Behavioral|Control|Advised to follow current guidelines for physical activity, but exercise on their own.
1672369|NCT01680289|Procedure|Three adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime & Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after a similar period a third layer will be applied over cavity walls. Again, after 20 seconds, the layers will be gently air-dried and photopolymerized by 10 seconds with a LED photoactivation unit.
1672370|NCT01680289|Procedure|Two adhesive coats|After caries removal, enamel margins will be conditioned with phosphoric acid gel 37% by 15 seconds and dentin walls by 8 seconds. The etchant will be removed with use of water spray by 30 seconds. The water excess will be removed with a cotton pellet. The first layer of Prime & Bond 2.1 adhesive will be applied with a microbrush. After 20 seconds a second layer will be applied and after 20 seconds, the layers will be gently air-dried by 5 seconds. The two layers will be photopolymerized by 10 seconds with a LED photoactivation unit.
1672371|NCT01680276|Behavioral|PBS based staff training|"Please see published study protocol for more information:
http://www.biomedcentral.com/1471-244X/14/219"
1672372|NCT01680276|Other|Treatment as Usual|http://www.biomedcentral.com/1471-244X/14/219
1672373|NCT01680263|Device|Kinesiotaping|"Use of kinesiotaping on the painful area in the form of space correction. Kinesiotaping was repeated for 3 weeks with 1week interval"
1672374|NCT01680263|Procedure|NSAIDs/Physical therapy|Use of non-steroidal anti-inflammatory drugs and 10 sessions of daily physical therapy.
1672375|NCT01680250|Drug|Sirolimus|Sirolimus administration for 12 months followed by conventional therapy alone for additional 12 months
1672376|NCT01680237|Behavioral|Cognitive behavior therapy|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises as well as identification and correction of maladaptive thoughts about anxiety and its consequences.
1672377|NCT01680237|Behavioral|Exposure in-vivo|Treatment covers psychoeducation on the nature of anxiety and panic, interoceptive and intensified situational exposure exercises.
1672381|NCT01680211|Dietary Supplement|Salacia bark extract|
1672382|NCT01680211|Dietary Supplement|Salacia leaf extract|
1672383|NCT01680211|Dietary Supplement|Sesame seed extract|
1672384|NCT01680211|Behavioral|TLC|Lifestyle changes include diet, exercise, weight loss, etc.
1672385|NCT01680211|Other|Placebo|
1672386|NCT01680198|Drug|Paracalcitol|Patients in the experimental arm received 2 micrograms Paricalcitol capsules daily, for 12 weeks. This dose was adjusted based on clinical laboratory parameters and the maximum dose was 2 micrograms daily.
1672387|NCT01680198|Drug|placebo|
1672388|NCT01680185|Drug|Insulin lispro, Humalog (Eli Lilly) in insulin pump|all covered above
1672389|NCT01680185|Drug|Human insulin isophane, Humulin N (Eli Lilly)|all covered above
1672390|NCT01680185|Other|Standard of care|all covered above
1672391|NCT01680172|Drug|Ketamine|Single dose (0.5 mg/kg) of liquid ketamine 10mg/mL solution taken by mouth
1672392|NCT01680172|Drug|Placebo|Single dose of liquid placebo solution taken by mouth
1672393|NCT01680159|Drug|TA-650|
1672394|NCT01680146|Dietary Supplement|PRO+FAT|
1672395|NCT01680146|Dietary Supplement|PRO|
1672396|NCT01680133|Other|Hyperinsulinemic euglycemic clamp|
1672398|NCT01680107|Drug|d-cycloserine|
1672399|NCT01680107|Drug|placebo|
1672400|NCT01680107|Behavioral|cognitive-behaviour therapy|
1672401|NCT01680094|Drug|Panobinostat|20 mg panobinostat will be administered orally on days 1, 3, and 5 (TIW) every other week (QOW) for a period of 8 weeks while maintaining background HAART
1672402|NCT01680081|Other|Adenosine stress dynamic CT perfusion|
1672496|NCT01679327|Drug|Bevacizumab|
1672403|NCT01680068|Procedure|Pars plana vitrectomy and postoperative air tamponade|Pars plans vitrectomy, ILM peeling and air tamponade. No postoperative face down positioning. All patients need to be pseudophakic prior to intervention.
1672404|NCT01680042|Drug|Phenytoin paste|
1672405|NCT01680042|Drug|Placebo|
1672406|NCT01680029|Device|PBASE-system 2.0|
1672407|NCT01680016|Biological|Zagreb|Subjects received Zagreb schedule (2-1-1) i.e. 4 vaccinations of Rabipur at days 1 , 8 and 22
1672408|NCT01680016|Biological|Essen|Subjects received Essen schedule (1-1-1-1-1) i.e. 5 vaccinations of Rabipur at days 1, 4, 8, 15 and 29
1672409|NCT01680003|Drug|Hepar-P|
1672410|NCT01680003|Drug|Placebo for Hepar-P|
1672411|NCT01679990|Biological|PLX-PAD Low dose|
1672412|NCT01679990|Biological|PLX-PAD high doses|
1672413|NCT01679990|Biological|Double Placebo|
1672414|NCT01679990|Biological|high dose +Placebo|
1672415|NCT01679977|Device|Vibrational-proprioceptive Resistance Exercise Training|
1672416|NCT01679977|Device|Neuromuscular Electrical Stimulation Training|
1672418|NCT01679951|Drug|Placebo|Form=tablet, route=oral. Placebo will be administered once daily from week 0 to week 24.
1672419|NCT01679951|Drug|JNJ-38518168 (3 mg)|Type=exact number, unit=mg, number=3, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
1672420|NCT01679951|Drug|JNJ-38518168 (10 mg)|Type=exact number, unit=mg, number=10, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
1672421|NCT01679951|Drug|JNJ-38518168 (30 mg)|Type=exact number, unit=mg, number=30, form=tablet, route=oral. JNJ-38518168 will be administered once daily up to 24 weeks.
1672422|NCT01679951|Drug|Methotrexate|Participants must have been treated with and tolerated Methotrexate (MTX) treatment at dosages from 10 to 25 milligram per week (mg/week) inclusive, for a minimum of 6 months prior to the date of signing the informed consent at screening and must have a stable MTX dose for a minimum of 8 weeks prior to the date of signing the informed consent at screening and continue to receive the same MTX dose at Week 0 through Week 24.
1672423|NCT01679938|Behavioral|primary obesity prevention|"Training of child care providers.
Curriculum sessions for children. Child care providers will facilitate 12 interactive education sessions that focus on key obesity-related behaviors.
Family outreach activities. Child care providers and research staff will communicate behavior change messages to families through ten take-home activities focused on key obesity-related behaviors and through monthly family workshops at the child care center.
Maintenance activities. Over the six months following the main intervention, research staff will conduct eight booster sessions for the children and one booster session for the family that will build upon activities and behavior change messages of the main intervention."
1672424|NCT01679912|Other|phone to the call center|recommendations to phone to the call center for all the patients who have an acute attack
1672425|NCT01679899|Drug|Vildagliptin|Vildagliptin 50mg bid orally for 12 months
1672426|NCT01679899|Drug|Gliclazide MR|Gliclazide MR 60 or 120mg orally for 12 months
1672427|NCT01679886|Radiation|Rubidium PET|Rubidium PET
1672428|NCT01679873|Other|Assess one type of abstract in the randomized arm|Participants will be asked to assess only one abstract in his arm of randomization. Three reminders will be made
1672429|NCT01679860|Procedure|Clin A. CHOP-CAMPATH (Chemo-immunotherapy) + SCT|"Clin A:
CHOP-Campath (CHOP-C) for 2 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO on days +1 to +5; Campath-1H (alemtuzumab) dose escalation 3-10-20mg IV days - 2, - 1, 0 (first CHOP-C) or 30mg SC day 0 (second CHOP-C). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on days + 1 and 21 (first and second CHOP-C).
HYPER-C-HiDAM for 2 cycles: Methotrexate 1.5gr/m2 day +1; Cyclophosphamide 300mg/m2 every 12 hours days +2-3-4; ARA-C 2gr/m2 every 12 hours days +2-3-4; G-CSF 5μcg/kg/day starting from day +5 until peripheral blood stem cell harvest
Myeloablative regimen followed by autologous transplantation or Reduced intensity conditioning followed by allogeneic transplantation."
1672430|NCT01679860|Drug|Clin B (CHOP- CAMPATH) Chemo-immunotherapy|"Clin B:
CHOP-Campath (CHOP-C) for 6 cycles (every 21 days): Doxorubicin 50mg/m2 day +1, Vincristin 1.4mg/m2 day +1, Cyclophosphamide 750mg/m2 day +1, prednisone 100mg/m2 PO from day +1 to day +5¸ Campath-1H (alemtuzumab) 3-10mg IV on days - 1 and 0 ( first CHOP-C course) or 10mg SC on day 0 (for the following 5 C-CHOP courses). Methotrexate 12.5mg IT, Ara-C 40mg IT, Dexamethasone 4mg IT on day +1 of each CHOP-C course."
1672431|NCT01679821|Other|A questionnaire and a clinical examination|Seventy dental students of State University of West of Paraná - UNIOESTE, seventy patients treated at the UNIOESTE Dental Clinic that wore removable partial denture (partially edentulous) and seventy patients with double complete dentures treated in Center for Dental Specialties of Cascavel, Paraná, Brazil. Students in orthodontic treatment or with less than one year after the end of orthodontic treatment were excluded from the research. Patients wearing a complete denture in one maxillary and a removable partial denture in another maxillary, and patients wearing just one complete denture were not included in the research.
1672432|NCT01679795|Drug|Tibolone|
1672433|NCT01679795|Drug|Placebo|
1672434|NCT01679756|Procedure|Laparoscopic right hemicolectomy for cancer|After induction of anesthesia, a foley catheter and an NG tube will be inserted. All patients will have their NG tubes removed after the procedure. During the procedure patients will be placed in Trendelenburg position with 15 degrees of tilt and with a right side up (tilt to the left of 25 degrees). A Veres needle will be inserted and pneumoperitoneum induced and maintained at 12 mmHg for the entire duration of the procedure. Under direct vision, three 10-12mm trocars will be inserted in the left abdominal wall. The ileocolic vessels, the right colic vessels (when present), the right branch of the middle colic vessels and the right gastroepiploic vessels will be ligated intracorporeally at their origin using clips. Anastomosis are described in each arm description.
1672435|NCT01679743|Drug|Trastuzumab|Trastuzumab will be administered after GRN1005 in patients with HER2+ metastatic breast cancer.
1672436|NCT01679743|Drug|GRN 1005|GRN1005 will be administered at a dose of 550 mg/m2 as an IV infusion at a rate of 8.0 - 8.5 mL/minute on Day 1 of 21-day cycle ( 3 days) and a second dose will be given on the day of surgery (day 21) 3-6 h prior to surgery.
1672497|NCT01679314|Device|AlphaCore device|Each study group will go under the same treatment regimen and assessments.
1672437|NCT01679717|Other|Early mobilisation after CMC1-surgery|Comparison of early (two weeks) and conservative (six weeks) mobilisation after operation. Comparison of rigid and soft thumb splint.
1672438|NCT01679704|Dietary Supplement|Food products|
1672439|NCT01679691|Other|epidural anesthesia|the group in whom all patients will be subjected to epidural anesthesia intra- and post-operative
1672440|NCT01679678|Device|PolyHeal 2|PolyHeal is a sterile medical device
1672441|NCT01679678|Device|Polyheal|PolyHeal is a sterile medical device that is comprised of negatively charged 5-micron polystyrene microspheres suspended in
1672442|NCT01679665|Biological|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval
1672443|NCT01679665|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 4 weeks interval
1672444|NCT01679652|Drug|Nebivolol|Tablet i blinded in capsula
1672445|NCT01679652|Drug|placebo|
1672446|NCT01679639|Drug|aleglitazar|Single dose of aleglitazar in Periods 1, 2, 3
1672447|NCT01679639|Drug|rifampicin|Single dose in Periods 1 and 2; multiple doses in Period 3
1672448|NCT01679613|Drug|Nintedanib|low or medium dose depending on pilot part
1672449|NCT01679613|Drug|Nintedanib|low dose oral administration
1672450|NCT01679613|Drug|Ketoconazole|oral administration
1672451|NCT01679613|Drug|Nintedanib|low dose oral administration
1672452|NCT01679613|Drug|Nintedanib|low or medium dose depending on pilot part
1672453|NCT01679613|Drug|Ketoconazole|oral administration
1672454|NCT01679600|Device|Feedback-controlled robotics-assisted treadmill exercise|Progressive cardiovascular exercise using feedback-controlled robotics-assisted treadmill exercise. The first training session is defined to start at 40% of peak work rate (determined from a previous exercise test) to approach 40% of heart rate reserve (Borg scale approximately 11-14). The intensity will then be adjusted on the basis of continuous heart rate data and rating of perceived exertion indications by modulating the target work rate in 5% increments for every subsequent session to reach the target intensity. The target heart rate is set at 40% to 70% of heart rate reserve.
1672455|NCT01679600|Device|Robotics-assisted treadmill exercise|Conventional robotics-assisted treadmill exercise, where therapists focus on gait quality only.
1672456|NCT01679587|Drug|Molidustat (BAY85-3934)|20 mg molidustat as a single tablet
1672457|NCT01679587|Drug|Placebo|Single oral dose of matching placebo will be given in each treatment arm
1672458|NCT01679574|Drug|Letrozole|•Drug: Letrozole tablets (Femara; Novartis Pharma, Switzerland) 2.5 mg letrozole daily from day 3 of the menses for 5 days
1672459|NCT01679574|Drug|Clomiphene|•Drug: CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt) 100 mg CC for 5 days starting from day 3 of menstruation
1672460|NCT01679574|Drug|Metformin|•Drug: metformin HCl (Cidophage®; CID,Cairo, Egypt) metformin HCl 1500 daily for 3 months
1672461|NCT01679561|Drug|intralipid|intravenous intralipid 20% is given to the patients known to be have either recurrent failed IVF, RPL
1672462|NCT01679548|Procedure|Single-port LAVH|
1672463|NCT01679548|Procedure|Three-port LAVH|
1672464|NCT01679535|Behavioral|nutrition and hygiene education|Monthly education sessions about child feeding and hygiene for mothers of young children, conducted by local Kenyan community health workers
1672465|NCT01679522|Procedure|single-port laparoscopic surgical staging|single-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
1672466|NCT01679522|Procedure|Four-port laparoscopic surgical staging|Four-port laparoscopic surgical staging indluding total hysterectomy, pelvic lymph node dissection, and/or bilateral salpingooophorectomy, and/or para-aortic lymph node dissection
1672467|NCT01679509|Procedure|Single-port laparoscopic adnexal surgery|
1672468|NCT01679509|Procedure|Three-port laparoscopic adnexal surgery|
1672469|NCT01679496|Other|Food items|Food items with different fatty acid composition
1672470|NCT01679483|Drug|FloSeal application|At the completion of lymph node dissection, 2 vials of Floseal will be applied to each lymph node area.
1672471|NCT01679470|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions.
1672472|NCT01679457|Behavioral|ACT-Focused ERP|
1672473|NCT01679457|Behavioral|TAU-ERP|
1672474|NCT01679444|Procedure|Magnetic Resonance Spectroscopy|
1672475|NCT01679431|Other|Doppler-echocardiography|
1672476|NCT01679431|Radiation|Computed tomography|
1672477|NCT01679431|Other|Magnetic resonance imaging|
1672478|NCT01679431|Biological|Fasting blood sample|
1672479|NCT01679418|Device|Placement of a wound drain post surgery (Redon; Medicoplast)|The wound drain, type Redon Drainage 3.0 mm in diameter
1672480|NCT01679418|Other|No-drain after surgery|After surgery, no drain was put
1672482|NCT01679392|Drug|Ropivacaine|Unilateral, single shot, ultrasound-guided, transversus abdominis plane block with 20 ml ropivacaine (7.5 mg/ml)
1672483|NCT01679379|Procedure|Absorbable suture group|Skin is closed with subcuticular stitches using [Polyglactin 910 absorbable, synthetic, braided suture]
1672484|NCT01679379|Procedure|Non absorbable suture group|Skin is closed with subcuticular stitches using Polypropylene non absorbable monofilament suture
1672485|NCT01679366|Drug|Placebo|1 tablet 2 times daily
1672486|NCT01679366|Drug|Probiotics|1 tablet twice daily
1672487|NCT01679353|Drug|caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.5mL added to ropivacaine 0.15% 1.0 ml/kg was administered to Group R , Magnesium 50mg (Magnesium 10% 0.5mL)added to ropivacaine 0.15% 1.0ml/kg to Group MR.
1672488|NCT01679353|Drug|normal saline 0.5ml|
1672489|NCT01679340|Drug|S-1|Mode of administration: orally (capsules) Dosing schedule:80mg/m2, Bid,D1-14,every 3 week,for 8-10cycles
1672490|NCT01679340|Drug|oxaliplatin|Mode of administration: intravenously Doseing schedule: 65 mg/m2 D1,D8,every 3 week, for 6 cycles
1672491|NCT01679340|Drug|cisplatin|Mode of administration: intravenously Dosing schedule: 75mg/m2 D1,every 3 week,for 6 cycle
1672492|NCT01679327|Drug|Oxaliplatin|
1672493|NCT01679327|Drug|Xeloda|
1672498|NCT01679288|Device|Ultrasound (Trademark:VScan; Manufacturer:General Electrics)|Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
1672499|NCT01679275|Other|measuring cerebral oxygenation|
1672500|NCT01679262|Device|Guedel type color-coded OPAs|The OPAs was used four different sizes as No. 8 (80 mm, green), 9 (90 mm, yellow), 10 (100 mm, red), and 11 (110 mm, orange) in regular sequence. The curvilinear distance from the incisors to the tip of the epiglottis was measured by FOB (Olympus LF-GP; Olympus Optical Co., Tokyo, Japan) with tape marking via each size of OPAs. The distance from the distal end of OPA to the tip of the epiglottis was calculated by the difference between measured distance from the incisors to the tip of the epiglottis via each OPA by FOB and typical distance from the flange to distal end of each OPA via inside tube of OPA. When the size of OPAs was longer than distance from the incisors to the tip of the epiglottis, OPAs were partly withdrawn and repositioned the distal end of OPAs is placed just above the tip of epiglottis. Then, the length from the incisors to the flange of OPAs was measured. .
1672501|NCT01679236|Behavioral|Mindfulness Training for Smokers|The provides the Mindfulness Training for Smokers intervention (7 weeks long).
1672502|NCT01679236|Behavioral|Interactive Learning for Smokers|This provides the Interactive Learning for Smokers intervention (7 weeks long).
1672503|NCT01679210|Behavioral|Lifestyle Intervention|Stage-matched physical activity and diet intervention materials and health education.
1672504|NCT01679197|Drug|Metreleptin|
1672505|NCT01679158|Device|Using The IOP system from USGI to place suture anchors|"Sutures are placed in the distal body in one of three randomized techniques:
A = reduction in ring opening to antrum using plications B = continuous horizontal row, running from distal body into proximal antrum C = Control. Current V shape as Control"
1672506|NCT01679132|Device|Neo Baroreflex Activation Therapy System|
1672507|NCT01679132|Other|Standard of care medical management only|Patients will continue with medical therapy for standard of care of their hypertension.
1672508|NCT01679119|Drug|Cyclophosphamide|Cyclophosphamide 750mg/m2 IV, given day 1
1672509|NCT01679119|Drug|Vincristine|Vincristine 1.4mg/m2(max 2mg)IV given day 1
1672510|NCT01679119|Drug|Prednisolone|Prednisolone 100mg OD Oral given days 1-5
1672511|NCT01679119|Drug|Rituximab|Rituximab 375mg/m2 IV given day 1
1672512|NCT01679119|Drug|Inotuzumab Ozogamicin|Inotuzumab Ozogamicin 0.8mg/m2 IV given on day 2
1672513|NCT01679119|Drug|Gemcitabine|Gemcitabine up to 1g/m2 IV given day 1 and day 8 (Patients with ECOG PS 0-1: starting dose: 875mg/m2 (1st cycle). If tolerated can be escalated to 1g/m2 in cycle 2 and subsequent cycles. Patients with ECOG PS 2: starting dose 750mg/m2 (1st cycle). If tolerated can be escalated to 875mg/m2 in cycle 2 and then escalated to 1g/m2 in cycle 3 and subsequent cycles.)
1672514|NCT01679106|Other|TAP catheter with Ropivicaine|Patients will receive TAP catheter with continuous infusion of Ropivicaine.
1672515|NCT01679106|Other|Fentanyl IV PCA and placebo TAP catheter|Patients will receive placebo TAP catheter with Fentanyl IV PCA.
1672516|NCT01679093|Drug|ondansetron|ondansetron: 4 mg intravenous administration afer the induction of anesthesia.
1672517|NCT01679093|Drug|Droperidol|droperidol: 1.25 mg intravenous administration after the induction of anesthesia.
1672518|NCT01679093|Drug|Dexamethasone|dexametasone: 4 mg intravenous administration after the induction of anesthesia.
1672519|NCT01679080|Drug|Zoledronic acid|antiresorptive and calcium and vitamin D
1672520|NCT01679080|Drug|Teriparatide|anabolic and calcium and vitamin D
1672521|NCT01679080|Other|No active treatment|Calcium and vitamin D
1672522|NCT01679067|Procedure|colonoscopy with endoscopic biopsies|
1672523|NCT01679041|Drug|Alemtuzumab|Alemtuzumab 10 mg given IV on day 1 of the 5 day conditional regimen
1672524|NCT01679041|Drug|Fludarabine|Fludarabine 25mg/m2 daily given IV on days 1-5 of the 5 day conditioning regimen
1672525|NCT01679041|Drug|Cyclophosphamide|Cyclophosphamide is given 3 gm/m2 for mobilization, and then repeated during 5 day conditioning regimen w/ doses of 50mg/kg/day on days 1-4
1672526|NCT01679028|Drug|T89 Group A|150mg single dose on day 1
1672527|NCT01679028|Drug|Placebo Group A|150mg single dose
1672528|NCT01679028|Drug|Placebo Group B|300mg single dose
1672529|NCT01679028|Drug|T89 Group B|300mg single dose
1672530|NCT01679028|Drug|Placebo Group C|225mg bid
1672531|NCT01679028|Drug|T89 Group C|225mg bid
1672532|NCT01679002|Drug|BIA 2-093|
1672533|NCT01679002|Drug|Oxcarbazepine|
1672534|NCT01678976|Drug|BIA 2-093|Tablets containing BIA 2-093 in doses of 300 and 600 mg
1672535|NCT01678976|Drug|Oxcarbazepine|Tablets containing 300 mg and 600 mg of Trileptal®
1672536|NCT01678963|Drug|Squalamine lactate|Ophthalmic solution 0.2%
1672537|NCT01678963|Drug|Vehicle control|Ophthalmic solution vehicle control
1672538|NCT01678937|Procedure|Blood Draw - Rapamycin|Ten calcineurin-inhibitors (CNI) monotherapy or dual therapy (CNI+MMF) patients will have blood taken (40 ml=8 tsp.) 2 wks. prior to conversion, 3-6 months post successful conversion. 1) Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28-FOXP3+CD127low cells). 2) Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers shown to induce regulatory T cells (ILT3; ILT4), 3) Soluble HLA G, and 4) Liver function/drug levels. If problems develop during conversion (e.g. acute rejection, significant drug side effects) requiring discontinuation of rapamycin, MMF and/or reversion to CNI therapy, assays will not be performed. Monthly liver function/drug levels performed after successful conversion (standard of care).
1672539|NCT01678937|Procedure|Blood Draw from Control Subjects|"Ten healthy individuals will have blood drawn (40 ml = 8 teaspoons (tsps.)).Blood will be drawn at one time point for the following:
Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).
HLA microchimerism & HLA G"
1672569|NCT01678755|Drug|ABT-126|ABT-126 Low Dose
1672570|NCT01678755|Drug|ABT-126|ABT-126 High Dose
1672571|NCT01678755|Drug|Placebo|Placebo
1724659|NCT00004659|Procedure|irradiation|
1672540|NCT01678937|Procedure|Blood Draw - CyA|"Blood drawn from 10 patients on cyclosporine (CyA) (40 ml = 8 tsp.)). Blood will be drawn at one time point for the following:
Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).
HLA microchimerism & HLA G"
1672541|NCT01678937|Procedure|Blood Draw - Tacrolimus|"Blood drawn from 5 patients on Tacrolimus (40 ml = 8 tsp.) at one time point for the following:
Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).
HLA microchimerism & HLA G"
1672542|NCT01678937|Procedure|Blood Draw - MMF|"Blood will be drawn from 10 patients on mycophenolate mofetil (MMF) (40 ml or the equivalent of 8 teaspoons). Blood will be drawn at one time point for the following analysis:
Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).
HLA microchimerism & HLA G"
1672543|NCT01678937|Procedure|Blood Draw - Rapamycin|"Blood drawn from 10 patients on rapamycin (40 ml = 8 tsp.)) at one time point for the following:
Dendritic cell assays: myeloid vs. lymphoid (CD11c; CD123); maturation and ability to process antigens (CD83; CD205); markers that have been shown to induce regulatory T cells (ILT3; ILT4).
Regulatory/Suppressor Cells (CD4+CD25+FOXP3+CD127low; and CD8+ CD28- FOXP3+CD127low cells).
HLA microchimerism & HLA G"
1672546|NCT01678911|Drug|Gralise|"Subjects will start at 600mg and titrate up by 600mg a week for two weeks (to 1800mg), then remain on 1800mg steady state dose of medication (or placebo pills) for 2 weeks. If intolerable side effects occur, the dose may be reduced to last tolerable dose at the discretion of the PI. A 2-week down-titration will be used. Subjects will have 1 week of wash-out before repeating the above procedure for the other arm of the study (placebo or medication)."
1672547|NCT01678898|Drug|PRX-102|
1672548|NCT01678885|Behavioral|Digital Photography of Foods|The digital photography of foods method was developed to unobtrusively measure energy intake in naturalistic settings (e.g., cafeterias). Participants will be provided with cell-phones with digital cameras and cellular network capability. Participants were trained to take pictures of their food selection and plate waste and to send these pictures to the researchers over the cellular network. The participant will collect data in free-living conditions and these data will be collected in near real time.
1672549|NCT01678885|Other|doubly labeled water|Doubly labeled water, considered the gold standard for measuring energy intake in humans, was used to measure total daily energy expenditure during free-living conditions. DLW is used to obtain an accurate measure of total daily energy expenditure, which is equal to energy intake during energy balance.
1672550|NCT01678885|Device|IDEEA|The Intelligent Device for Energy Expenditure and Activity (IDEEA) will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
1672551|NCT01678885|Behavioral|low-calorie diet|Participants will be instructed to consume five packets of Health One per day, which provides 800 kcal and 125% of Recommended Daily Intake of vitamins and minerals. Additionally participants will be instructed to consume a meal consisting of 200 kcal to 350 kcal daily, which could consist of a portion-controlled meal replacement or a home-cooked meal. Participants will meet with a Registered Dietitian at weeks 0, 2, 4, and 6 and receive instructions on adhering to the meal plan.
1672552|NCT01678885|Device|Actical|The Actical will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
1672553|NCT01678885|Device|Sensewear Armband|The Sensewear armband will be used to measure the time spent engaging in active vs. sedentary behaviors, and the energy costs of these behaviors.
1672554|NCT01678872|Drug|RetinoStat|Long Term Follow up of patients who received RetinoStat in a previous study
1672555|NCT01678846|Behavioral|Good School Toolkit|The Toolkit uses a six step process to create a school wide intervention that engages teachers, students, administration, and parents to reflect on how they can promote quality of education in their school. The Toolkit articulates complex ideas (what is a good learning environment, a good teacher, how to create positive discipline without using violence) through booklets, posters and school initiated learning processes. Specific modules on alternative discipline techniques and how staff can use positive discipline are included in the Toolkit. The intervention includes sessions on knowledge, attitudes and opportunities to practice new behavioural skills. Work is led by teachers and students, and supported by visits from Raising Voices staff. The Toolkit can be reviewed at (http://www.raisingvoices.org/children/good_school_toolkit.php).
1672556|NCT01678820|Drug|Sitagliptin/Simvastatin FDC|Sitagliptin 100 mg/Simvastatin 40 mg fixed-dose combination tablet
1672557|NCT01678820|Drug|Sitagliptin|Sitagliptin 100 mg tablet
1672558|NCT01678820|Drug|Simvastatin|Simvastatin 40 mg tablet
1672559|NCT01678820|Drug|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet
1672560|NCT01678820|Drug|Placebo to simvastatin|Matching placebo to simvastatin 40 mg tablet
1672561|NCT01678820|Drug|Placebo to Sitagliptin/Simvastatin FDC|Matching placebo to sitagliptin 100 mg/simvastatin 40 mg FDC tablet
1672562|NCT01678820|Drug|Metformin|Participants will continue on their stable, pre-screening metformin daily dose of >= 1500 mg for at least 12 weeks prior to randomization and during the study
1672563|NCT01678820|Drug|Glimepiride|Following randomization, participants requiring glycemic rescue may receive open-label glimepiride initiated at a dose of 1 mg/day or 2 mg/day which may be up-titrated to 6 mg/day taken once daily with breakfast or the first main meal of the day.
1672564|NCT01678807|Biological|MK-8237 6 DU|
1672565|NCT01678807|Biological|MK-8237 12 DU|
1672566|NCT01678807|Biological|Placebo|
1672567|NCT01678794|Drug|Candesartan|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
1672568|NCT01678794|Drug|Placebo|4 mg once a day up to 13 day. dose will be doubled every 14-18 days as tolerated to a goal of 16 mg a day or highest dose tolerated
1672572|NCT01678742|Dietary Supplement|High-protein diet|"The high-protein diet is made up of 50% carbohydrate, 40% of protein and 10% of fat, providing 480 kcal.
A protein part of the high-protein diet is mostly composed of a grilled Jeju red horsehead fish, a special product of Jeju island in Korea."
1672573|NCT01678742|Dietary Supplement|Standard diet|The standard diet is made up of 60% carbohydrate, 20% of protein and 20% of fat, providing 480 kcal.
1672574|NCT01678716|Behavioral|EHC + BCC|This arm includes home visits to mothers with infants and young children. Frontline health workers will counsel and support mothers in relation to breastfeeding and complementary feeding practices
1672575|NCT01678716|Dietary Supplement|Micronutrient powders|"In this intervention arm, frontline health workers will visit households and promote and sell micronutrient powders to them. The micronutrient powder is sold by the brand name Pushtikona in Bangladesh and contains 15 micronutrients including iron, zinc, vitamin A, vitamin C, and others."
1672576|NCT01678716|Behavioral|Mass media|A nationwide mass media campaign of TV and radio spots on infant and young child feeding practices will be aired in 2011, 2012 and 2013. All intervention arms will be exposed to this campaign.
1672577|NCT01678703|Device|Laminaria, MedGyn Products, Inc. USA.|Insertion of Hygroscopic laminarias into the cervical canal for preparation prior to late surgical abortion. The number of laminarias is according to the cervical compliance.
1672578|NCT01678703|Drug|Misoprostol|Cervical preparation with vaginal Misoprostol 600 mcg overnight the day before the abortion
1672579|NCT01678690|Drug|Gemcitabine HCl Oral Formulation|Gemcitabine HCl Oral Formulation 80 mg/vial Subjects will be treated on Day 1 of the 7-day study treatment period
1672580|NCT01678677|Biological|NTHI vaccine GSK2838500A (formulation 1)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1672581|NCT01678677|Biological|NTHI vaccine GSK2838501A (formulation 2)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1672582|NCT01678677|Biological|NTHI vaccine GSK2838502A (formulation 3)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1672583|NCT01678677|Biological|NTHI vaccine GSK2838503A (formulation 4)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1672584|NCT01678677|Biological|NTHI vaccine GSK2838504A (formulation 5)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1672585|NCT01678677|Biological|NTHI vaccine GSK2838505A (formulation 6)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1672586|NCT01678677|Biological|NTHI vaccine GSK2838508A (formulation 7)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1672587|NCT01678677|Biological|NTHI vaccine GSK2838509A (formulation 8)|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1672588|NCT01678677|Drug|Placebo comparator|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1672589|NCT01678664|Drug|Everolimus|10 mg per day of everolimus during 24 months or until progression disease
1672590|NCT01678664|Device|embolization|2 sessions embolization with spheric particles
1672591|NCT01678664|Drug|Doxorubicin|2 sessions chemoembolization with 10 mg of lipiodol with 100 mg of doxorubicine
1672592|NCT01678651|Procedure|Stimulation with human FSH|Human FSH
1672593|NCT01678651|Procedure|Stimulation with recombinant FSH|Recombinant FSH
1672594|NCT01678638|Procedure|IH repair before NICU discharge|The IH repair is performed prior to NICU discharge (within 1-2 weeks of enrollment and randomization)
1672595|NCT01678638|Procedure|IH repair at 55-60 weeks post-menstrual age|The IH repair will be performed between 55-60 weeks post-menstrual age.
1672596|NCT01678625|Device|Train-of-four ratio calculation (T4-EMG)|TOF ratios will be compared between the EMG and AMG groups
1672597|NCT01678612|Other|Copper-alloy surfaced objects|Room assigned to the Experimental arm will be furnished with copper-alloy surfaced objects,i.e. bed-rails, bed-rail levers, IV poles, nurse workstation, HCW clipboards, sink handles.
1672598|NCT01678599|Drug|Benznidazole|All patients participating in this study will be treated with Benznidazole, 5mg/Kg/day PO BID for 60 days with a maximum daily dose of 300mg, as per routine care provided by MSF in rural communities in Aiquile. For patients > 60 kg, the total dose should be calculated (5mg/Kg x Weight x 60 days) and treatment duration should be adjusted/prolonged accordingly. This treatment is in accordance with the local recommendations from the Ministerio de Salud y Deportes de Bolivia.
1672599|NCT01678586|Other|Acupuncture or Sham Acupuncture|Acupuncture is when the needles go into the skin. Sham acupuncture is when the needles do not go into the skin. We will compare results between the two acupuncture therapy groups.
1672600|NCT01678586|Other|Gabapentin or Placebo|Gabapentin is a commonly prescribed drug used to treat neuropathic pain. The placebo will be used to mimic side effects common to gabapentin. The two medication treatment groups' results will be compared to each other.
1672601|NCT01678573|Drug|Treatment A: abiraterone acetate|250 mg/day tablet administered orally on Day 1 of each treatment period.
1672602|NCT01678573|Drug|Treatment B: abiraterone acetate|500 mg/day tablets administered orally on Day 1 of each treatment period.
1672603|NCT01678573|Drug|Treatment C: abiraterone acetate|1000 mg/day tablets administered orally on Day 1 of each treatment period.
1672604|NCT01678560|Device|Monitoring every 3 months by face-to-face visits|
1672605|NCT01678560|Device|Frequent remote monitoring|
1672606|NCT01678547|Device|Robot-assisted walking|The practice will included an add-on robot-assisted walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h and the BWS % will be decreased.
1672607|NCT01678547|Device|Treadmill Training|The practice will included an add-on treadmill walking therapy at variable speeds for 40 min with a partial body weight support (BWS). All participants will start with 30-40% BWS and an initial comfortable treadmill speed and the speed will be increased to a range of 1,0 to 2.5 km/h and the BWS % will be decreased.
1672608|NCT01678547|Other|Ground treatment|The practice will included ground walking therapy s for 40 min with therapist support.
1672609|NCT01678534|Drug|Allogenic mesenchymal stem cells from adipose tissue|
1672610|NCT01678534|Drug|Placebo|
1672611|NCT01678521|Procedure|LDL-apheresis|The acronym H.E.L.P. stands for Heparin-induced Extracorporeal Low-density-lipoprotein Precipitation. Antecubital veins served as blood access. The mean blood volume processed per session is of approximately 3000 ml.
1672612|NCT01678495|Other|Sulfur hexafluoride + ultrasounds|
1672613|NCT01678495|Drug|Recombinant tissue plasminogen activator|
1672614|NCT01678482|Device|light based device for treatment of acne|
1672615|NCT01678469|Other|blood sample|
1672619|NCT01678430|Drug|Ofatumumab|
1672620|NCT01678430|Drug|Chlorambucil|
1672621|NCT01678430|Drug|Bendamustine|
1672622|NCT01678417|Drug|131I-rituximab|
1672623|NCT01678404|Drug|131I-rituximab|
1672624|NCT01678391|Procedure|Common bile duct stone removal without fluoroscopy.|ERCP stone extraction technique without fluoroscopy involves: (1) catheter or catheter with wire access into the bile duct, (2) confirmation of biliary access with catheter aspiration of bile, (3) performance of endoscopic biliary sphincterotomy or balloon dilation to widen the bile duct opening to permit stone removal, (4) stone removal - number of stones seen on EUS should match the number removed.
1672625|NCT01678378|Behavioral|SHARP Intervention|Providers and staff located in high school school health centers (i.e., nurse practitioners, nurses,physicians, health educators, medical assistants) will be trained to address adolescent relationship abuse with school health center clients using knowledge, skills, and resources gained through the SHARP Intervention training. The training includes strategies to help youth recognize adolescent relationship abuse among themselves and their peers, to learn strategies to increase safety (harm reduction), and to utilize adolescent relationship abuse-related resources.
1672626|NCT01678365|Drug|ceftriaxone, metronidazole/ampicillin, gentamicin, and metronidazole|
1672627|NCT01678352|Biological|Tumor Lysate Vaccine|Cohort 1 Cohort 2 Cohort 3
1672628|NCT01678352|Drug|Imiquimod|Cohort 1 Cohort 2 Cohort 3
1672629|NCT01678326|Procedure|EUS-Rendezvous or direct intervention|
1672630|NCT01678326|Procedure|Advanced ERCP Biliary Access Techniques|
1672631|NCT01678313|Drug|Doxazosin 4 mg daily plus Celecoxib 200 mg every day (QD)|Study group
1672632|NCT01678313|Drug|Doxazosin 4 mg every day (QD)|Control group
1672633|NCT01678287|Drug|ASP1941|oral
1672634|NCT01678287|Drug|Placebo|oral
1672635|NCT01678235|Drug|Insulin glulisine|
1672636|NCT01678235|Drug|Insulin aspart|
1672637|NCT01678209|Other|fMRI scans|2 fMRI scans 6-8 weeks apart
1672638|NCT01678209|Drug|Atomoxetine arm|Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks
1672639|NCT01678209|Drug|Methylphenidate arm|Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.
1672640|NCT01678196|Behavioral|VA-CRAFT|VA-CRAFT is an on-line training program that teaches family members how to communicate and interact with Veterans to promote their engagement in needed mental health services for PTSD or Alcohol Use Disorders. 12 on-line sessions.
1672641|NCT01678196|Other|Control|Participants will have the opportunity to complete the VA-CRAFT training program after 3 months; otherwise no intervention
1672642|NCT01678183|Behavioral|Monthly Financial Incentive|A cash payment.
1672643|NCT01678183|Behavioral|Final Financial Incentive|One-time payment in cash for each full percentage of hemoglobin A1c decrease over the eight-month period of the study.
1672644|NCT01678144|Device|Mitral valve repair using Medentia Annuloplasty Ring|
1672645|NCT01678131|Drug|Vaniprevir 600 mg|Vaniprevir capsules, were administered orally, twice per day (BID) to achieve a final daily dose of 600 mg on Days 1 through 6; and a single dose of 600 mg, orally, on Day 7.
1672646|NCT01678131|Biological|Peg-IFN alfa-2b|Peg-IFN alfa-2b was administered at 1.5 µg/kg per week by subcutaneous injections on Days 1, 8, 15 and 21
1672647|NCT01678131|Biological|Ribavirin|Ribavirin capsules were administered on Days 1-21, orally, twice daily for a total daily dose of 600 - 1400 mg, depending on the participant's weight
1672648|NCT01678131|Procedure|Liver samples from FNA|Liver samples were collected from Day 7 up to Day 10 by FNA at 3 of 5 specified postdose timepoints.
1672649|NCT01678131|Drug|Vaniprevir 300 mg|Vaniprevir capsules were administered orally, twice per day to achieve a final daily dose of 300 mg on Days 1 through 6; and a single dose of 300 mg, orally, on Day 7.
1672650|NCT01678131|Procedure|Liver samples from CNB|Liver samples were collected from Day 8 up to Day 10 by CNB at 1 of 3 specified postdose timepoints.
1672651|NCT01678118|Behavioral|Patient Navigator|The pt navigator will phone (email, text, or other preferred method of contact) pts prior to the date of previously set individual goals (e.g. going to an appt, getting their cessation medications filled, etc) as a reminder & to discuss barriers such as finances, transportation or ambivalent motivation. In this manner, pts receive navigation services tailored to their individual needs & barriers. Once pts are connected with a cessation service (defined as either using cessation medication or at least 1 contact with a Quitline or community-based cessation counselor)or provider-prescribed cessation medication usage, continues the navigation intervention will be considered complete. W/I the 3 month engagement period, pts will receive up to 6 contacts from the Pt Navigator following referral from primary care provider. Consistent with recommended pt navigation practice, the navigator will provide feedback to primary care provider regarding cessation services that the pts are receiving.
1672652|NCT01678105|Drug|Dovitinib|Treatment continued until Disease Progression, Toxicity, or patient withdrawal
1672653|NCT01678092|Biological|omalizumab|
1672654|NCT01678079|Dietary Supplement|Encapsulated Calcium|The intervention is a multi-micronutrient powder containing enteric-coated calcium carbonate, in addition to ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg).
1672655|NCT01678079|Dietary Supplement|Non-capsulated Calcium|The comparator/control intervention is a micronutrient powder containing non-coated calcium (500, 1000 or 1500 mg elemental calcium from calcium carbonate), ferrous fumarate (60 mg of elemental iron) and folic acid (400 µg). This product will be similar in Ca dose, appearance, taste and texture to the experimental formulation but will not include the enteric-coating.
1672657|NCT01678053|Drug|onabotulinumtoxinA|Botulinum toxin A is injected into the larynx in order to treat vocal fold granulomas.
1672658|NCT01678053|Drug|omeprazole (proton pump inhibitor)|Standard therapy of anti-reflux medications using omeprazole or equivalent PPI.
1672659|NCT01678027|Drug|Placebo|Lansoprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 1 week.
1672660|NCT01678027|Drug|LAC triple therapy|Lansoprazole 30 mg, amoxicillin 1,000 mg, and clarithromycin 500 mg, all twice a day for 1 week.
1672661|NCT01678014|Procedure|Deep Brain Stimulation(DBS)|Deep Brain Stimulation(DBS)is a neurosurgical procedure which include the implantation of deep brain electrodes and the connect to an implantable pulse generator (IPG) that is implanted below the collarbone.
1672662|NCT01678014|Procedure|Capsulotomy|
1672663|NCT01678001|Drug|Xeomin|Group A will consist of 25 patients that receive Xeomin. Group B will contain the other 25 patients that receive the placebo saline solution. Post-injection treatment will be kept the same between the two groups. This will only consist of plantar fascial stretching done 3 times daily.
1672664|NCT01677988|Drug|Neo-adjuvant Chemotherapy|"Modified FOLFIRINOX chemotherapy Day 1 and Day 15 of 28 day cycles, for three (3) cycles with growth factor support.
Restaging # 1. (CT or MRI; use same modality as baseline staging unless otherwise indicated by Study Team)
Progressive Disease (PD) → Off study. Subsequent treatment per patient's primary MD.
Stable Disease (SD) or Tumor Response → Continue to Registration #2 for Chemoradiation."
1672665|NCT01677988|Radiation|Chemoradiation|"Chemoradiation may be administered at selected approved CTN sites.
Determination of resectability as reviewed and documented by MUSC-HCC GI Tumor Board.
Unresectable → Off study. Subsequent treatment per patient's primary MD.
Resectable → Continue to Registration #3 for Surgical Resection"
1672666|NCT01677988|Procedure|Surgical Resection|"Meets criteria for resectable* →pancreaticoduodenectomy (POD)
At time of resection, snap frozen tumor specimen sent for correlative biomarker studies"
1672667|NCT01677975|Procedure|FNA (fine needle aspiration)|
1672668|NCT01677962|Biological|Poly-ICLC|
1672669|NCT01677962|Biological|dendritic cell|
1672670|NCT01677949|Drug|Clofarabine|Days 1-5: Clofarabine 30 mg/m^2 for 0-30 years of age or 20 mg/m^2 for > 30 years of age intravenously (IV) over 2 hours
1672671|NCT01677949|Drug|Etoposide|Days 1-5: Etoposide 100mg/m^2 IV over 2 hours
1672672|NCT01677949|Drug|Cyclophosphamide|Days 1-5: Cyclophosphamide 300 mg/m^2 as a 30-60 minute infusion
1672673|NCT01677949|Biological|allogeneic hematopoietic cell transplantation|Between Days 28 and 42: infused independent of this study
1672674|NCT01677936|Other|Raisins|1 oz, 90 calorie packages of raisins will be administered to subjects in the raisin treatment arm
1672675|NCT01677936|Other|Snacks|100 calorie snack packs will be administered to the subjects in the snack group
1672676|NCT01677923|Drug|Metformin|Metformin 500 mg BID for 12 months
1672677|NCT01677910|Drug|Telotristat etiprate tablets (250 mg)|
1672678|NCT01677910|Drug|Placebo tablets|One placebo tablet administered three times daily
1672679|NCT01677897|Drug|Metformin|Adding Metformin to Abiraterone in case of PSA-Progression
1672680|NCT01677884|Drug|Bevacizumab|Every 3 weeks : 7.5 mg/kg intra arterial in 2 hours at D1
1672681|NCT01677884|Drug|Capecitabine|Every 3 weeks: 2000 mg/m²/d in 2 times/d from D1 to D4
1672682|NCT01677884|Drug|Irinotecan|Every 3 weeks: 200mg/m² in 30mn IV at D1 (if oxaliplatin in first line) or oxaliplatin 130mg/m² in 2h IV at D1 (if irinotecan in first line)
1672683|NCT01677871|Drug|2HRZE/4HR|Isoniazid + Rifampicin+Pyrazinamide+Ethambutol for initial 2 months floolowed by Isoniazid + Rifampicin for next 4 months
1672684|NCT01677871|Drug|2HRLE/4HR|Isoniazid + Rifampicin+ Levofloxacin+Ethambutol for initial 2 months followed by Isonizid + Rifampicin for next 4 months
1672685|NCT01677871|Drug|9HLE|Isoniazid+ Levofloxacin+ Ethambutol for 9 months
1672686|NCT01677871|Drug|9RLE|Rifampicin + Levofloxacin+ Ethambutol for 9 months
1672687|NCT01677858|Drug|Carfilzomib|Carfilzomib was administered as a 30-minute IV infusion on days 1, 8, and 15 of each 28-day treatment cycle.
1672688|NCT01677858|Drug|Dexamethasone|Dexamethasone was administered at a dose of 40 mg IV or orally (PO) on days 1, 8, 15, and 22 for the first 8 cycles; starting with cycle 9 dexamethasone was administered on days 1, 8, and 15.
1672689|NCT01677845|Radiation|Radiation|"Dose Level 1: 54 Gy; 3 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;
Dose Level 2: 55.8 Gy; 3.1 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions;
Dose Level 3: 57.6 Gy; 3.2 Gy per fraction; 3 days per week x 6 weeks for a total of 18 fractions."
1672690|NCT01677806|Procedure|Percutaneous vertebroplasty|Percutaneous vertebroplasty Placement of PMMA into vertebral compression fracture
1672691|NCT01677806|Other|Conservative therapy|Conservative therapy mainly consists of optimal pain medication. Pain management is titrated according to patients' needs, including analgesia, bed rest, and physical support (bracing).
1672692|NCT01677780|Drug|RO5045337|Participants will receive RO5045337 orally in doses ranging from 20 milligram per square meter (mg/m^2) to 1800 mg/m^2 daily, and up to 1500 mg dose twice daily on a variety of schedules including daily for up to 20 days and weekly dosing for 3 weeks in 28 day cycles until disease progression or unacceptable toxicity with maximum treatment duration of 24 months.
1672693|NCT01677754|Drug|RO4602522|Participants will receive RO4602522 orally once daily for 12 months.
1672694|NCT01677754|Drug|Placebo|Participants will receive placebo for RO4602522 orally once daily for 12 months.
1672695|NCT01677754|Drug|Donepezil|Stable dose as background medication
1672696|NCT01677754|Drug|Memantine|Stable dose as background medication in combination with AChEIs
1672697|NCT01677754|Drug|Rivastigmine|Stable dose as background medication
1672698|NCT01677754|Drug|Galantamine|Stable dose as background medication
1672699|NCT01677741|Drug|Dabrafenib|Dabrafenib is available as 10 mg, 25 mg, 50 mg or 75 mg capsules and as oral suspension (10 mg/mL for subjects unable to swallow capsules). Dabrafenib (either formulation) will be administered orally as a single dose on Day 1 and twice daily from Day 2, based on weight at the appropriate study dose level.
1672700|NCT01677715|Dietary Supplement|"Yili Mei Yi Tian active lactobacillus drink"|"100ml of Yili Mei Yi Tian active lactobacillus drink to be taken once per day at 10am daily during the 84-days intervention"
1672739|NCT01677351|Drug|Clonidine|4 mcg.kg-1, 20 minutes before cataract surgery
1672701|NCT01677715|Dietary Supplement|recombined milk drink contains no lactobacillus|100ml of recombined milk drink contains no lactobacillus to be taken once per day at 10am daily during the 84-days intervention
1672702|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 5mg/100ml)|Total 250mL milk (with lactoferrin 5mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
1672703|NCT01677702|Dietary Supplement|Yili Lactoferrin ShuHua Milk (Lactoferrin 10mg/100ml)|Total 250mL milk (with lactoferrin 10mg/100ml) will be taken once per day at 10am daily during the 84 days intervention.
1672704|NCT01677702|Dietary Supplement|Recombined low protein milk|Total 250ml of placebo milk will be taken once a day at 10am daily during the 84 day intervention.
1672705|NCT01677689|Drug|Apomivir®|Study Group: Apomivir® 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
1672706|NCT01677689|Drug|Placebo|Control Group: Placebo 1 capsule twice daily. All subjects will be treated for 5 days, and all drugs should be taken orally after meal.
1672707|NCT01677676|Biological|FP-01.1|IM injection
1672708|NCT01677676|Biological|FP-01.1-Adjuvant|IM injection
1672709|NCT01677650|Drug|Methadone|Methadone IV Pre-Induction of Anesthesia 0.15 to 0.5 mg/kg
1672710|NCT01677624|Device|E7040|E7040 of optimal particle size (-300 um, 300-500 um, or 500-700 um to fit in a target vessel, target lesion, or embolized area) as transcatheter study device will be administered .
1672711|NCT01677611|Drug|Trans-resveratrol extract from Polygonum Cuspidatum|Starting dose of 500 mg daily of either resveratrol to be administered on Day 1 and increased by 500 mg per day every 3 days to a maximum dose of 3 g per day in three divided doses if there was no hypoglycemia.
1672712|NCT01677611|Drug|Placebo|
1672713|NCT01677598|Drug|No intervention|No intervention will be administered during study. This will be an observational study in patients using ustekinumab as label-recommended or other/missed dose interval in Asia-Pacific countries
1955092|NCT03296072|Drug|0.254% w/w sodium fluoride and 5% KNO3|Dentifrice containing 0.254% w/w sodium fluoride (1150 ppm fluoride) and 5% KNO3; plus 0.25% PVM/MA copolymer and 2.5% sodium lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 millilitres [mL] of tap water for 10 seconds before expectorating again.
1955093|NCT03296072|Drug|0.454% w/w stannous fluoride|Dentifrice containing 0.454% w/w stannous fluoride (1100 ppm fluoride). Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
1672716|NCT01677559|Drug|MLN8237|
1672717|NCT01677559|Drug|nab-Paclitaxel|
1672718|NCT01677546|Device|CSII+BC+CL|Insulin pump bolus calculator wirelessly communicated with blood glucose meter (Contour Link)
1672719|NCT01677546|Device|CSII+BC|Insulin pump bolus calculator without wireless communication with blood glucose meter (Contour Link)
1672720|NCT01677533|Other|Data|The microsystem teams of providers, nurses, and clerks will receive monthly reports of their performance measures, which will include process and outcome data for smoking cessation and blood pressure control for veterans in their panel. The reports will provide lists of individual patients in the panel with unmet goals on VA performance measures. They will receive written informational material describing principles and practices of panel management and evidence-based guidelines for hypertension management and smoking cessation.
1672721|NCT01677533|Other|Panel Management Support|PMAs will meet regularly with the members of the microsystem team for one hour/week. The team will be asked to review progress on the health status of their patient panel and to plan strategies for improving their outcomes that the PMA will then implement. A PMA toolkit of panel management strategies will be established that will include guidelines for using VA databases to identify care gaps and reaching out to panel patients via phone and mail to intervene (e.g. reconnect patients to care with appointments, assess and enhance medication adherence, connect patients with VA services, motivational interviewing, and communication with the team about patient issues.
1672722|NCT01677533|Other|Education|The educational intervention will be administered throughout the duration of the study. Our initial educational focus will be on content (concepts of population health and panel management) and process (practice change methodology). Subsequent education will be process oriented, reviewing the changing system of care and discussing its functioning. Education will cover panel management strategies, microsystem theory and skills, and specific strategies regarding the management of hypertension and smoking cessation. It will include monthly seminars, reading materials, web-based modules, and skill building workshops, and PMA-conducted monthly academic detailing using panel data and feedback. After the first three months, academic detailing will only be implemented on an as-needed basis.
1672723|NCT01677507|Drug|Variation in eye pressure response to timolol and latanoprost treatment|Arm 1 is to test for variation in eye pressure response to timolol. Arm 2 is to test for variation in eye pressure response to latanoprost.
1672724|NCT01677468|Procedure|Intermediate embolization|TACE with substasis using gelfoam
1672725|NCT01677468|Procedure|Complete embolization|TACE with complete embolization using gelfoam
1672726|NCT01677455|Drug|ganetespib|Ganetespib 150 mg/m2 will be administered intravenously, twice weekly, for three consecutive weeks of each 4 week cycle.
1672727|NCT01677442|Procedure|no-intubated thoracic epidural anesthesia|VATS under no-intubated thoracic epidural anesthesia
1672728|NCT01677442|Procedure|double-lumen endotracheal intubated anesthesia|VATS under double-lumen endotracheal intubated anesthesia
1672729|NCT01677429|Device|VR movie + balance challenge|Computer Assisted Rehabilitation Environment Integrated Reality System used for the challenge of balance control
1672730|NCT01677429|Device|still pictures from VR|Monitoring only still pictures from the VR scene in a loop, no balance challenge
1672731|NCT01677429|Behavioral|Cognitive Behavioral Therapy|For the treatment of panic disorder
1672732|NCT01677403|Drug|Tobramycin|Nebulised 80mg twice daily
1672733|NCT01677403|Drug|Saline|Nebulised 5mls 0.9% Saline twice daily
1672734|NCT01677390|Drug|SGN-75|1-2 mg/kg IV every 21 days
1672741|NCT01677338|Drug|13C-uracil|PO, the Semi-solid Test Meal containing 100 mg of 13C-uracil . Perform the Breath Test.
1672742|NCT01677338|Drug|99mTc sulfur colloid|PO, the Solid Test Meal containing 500 uCi 99mTc sulfur colloid. Perform the Scintigraphy.
1672743|NCT01677325|Drug|Chinese herb (YiQiSanJu)|Chinese herb formula:Huangqi,huanglian,yinchen,ect
1955094|NCT03296072|Drug|5% KNO3|Fluoride free placebo dentifrice containing 5% KNO3 (0 ppm fluoride), 0.25% PVM/MA copolymer and 2.5% lactate. Participants will brush it on the buccal surfaces of their natural teeth for 25 timed seconds and then swish the resulting toothpaste slurry around the mouth, without further brushing, for a timed period of 95 seconds. After expectorating the slurry, the participants will gently rinse their mouths with 15 mL of tap water for 10 seconds before expectorating again.
1672746|NCT01677299|Drug|EFB0027 (metformin delayed release)|Comparison of enteric-coating to assess effect on PK
1672747|NCT01677299|Drug|EFB0026 (metformin immediate-release)|Active comparator
1672748|NCT01677286|Drug|Doxycycline 100 mg po bid x 12 months|100mg by mouth twice daily for 1 year.
1672749|NCT01677273|Dietary Supplement|Hydrolyzed casein|30 g protein/supplement, 4 supplements/visit
1672750|NCT01677273|Dietary Supplement|Intact casein|30 g protein/supplement, 4 supplements/visit
1672751|NCT01677273|Dietary Supplement|Intact whey protein|30 g protein/supplement, 4 supplements/visit
1672752|NCT01677260|Drug|500 mg metformin hydrochloride extended release caplet (test drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
1672753|NCT01677260|Drug|500 mg metformin hydrochloride prolonged release tablet (reference drug)|In each of the two study periods (separated by a washout of one week) a single and multiple dose of test or reference product was administered.
1672754|NCT01677247|Drug|Group I (Test) : Glimepiride 4 mg tablet of PT Dexa Medica|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
1672755|NCT01677247|Drug|Group II (Reference) : glimepiride (Amaryl) 4 mg tablet of PT Sanofi Aventis|In each of the two study periods (separated by a washout of one week) a single dose of test or reference product was administered.
1672757|NCT01677208|Drug|Danhong injection|A kind of injection made from two kind of Chinese herbs: Salvia miltiorrhiza and Safflower. 40ml Danhong injection added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion
1672758|NCT01677208|Procedure|Standard medical care|Standard medical care is in accordance with China Guideline for the diagnosis and treatment of acute ischemic stroke (2010), including medical care for vital signs, control of temperature, blood pressure and glucose, improving cerebral blood circulation, antiplatelet treatment and nutritional supportive care.
1672759|NCT01677208|Drug|placebo|0.9% saline added into 250ml 0.9% saline by an independent research nurse, sealed with brown bag in order to make the investigators and patients blinded, using brown infusion tube for infusion.
1672760|NCT01677195|Drug|ACCS100|ACCS100 is not absorbed. The dose is estimated based on the volume of the gastrointestinal tract. We estimate that the average human intestinal tract has a volume of approximately 4 liters. In the high dose group, the effective concentration in the gut is 0.75 milligrams per milliliter. In the low dose, the effective concentration in the gut is 0.375 milligrams per milliliter. The test article is made by filling gelatin capsules with 500 milligrams of ACCS100. There are no excipients used in the manufacturing process of the test article.
1672761|NCT01677195|Drug|Placebo|Placebo is calcium carbonate, USP. This calcium mineral does not absorb mycotoxins, specifically aflatoxin and fumonisin. This mineral has approximately the same physical appearance as active test article.
1672762|NCT01677182|Drug|Ramelteon|Ramelteon tablets for sublingual administration
1672763|NCT01677182|Drug|Placebo|Ramelteon placebo-matching tablets for sublingual administration
1672764|NCT01677169|Dietary Supplement|Noni juice|Ingestion of noni juice, a source of iridoids, daily for 30 days.
1672765|NCT01677169|Dietary Supplement|Placebo|
1672766|NCT01677143|Drug|Bupivacaine 5mg/ml|5 ml in trocar area
1672767|NCT01677104|Drug|GLP-1|GLP-1 and its analogues will be compared with placebo with and without prior DPP-IV inhibition
1672768|NCT01677104|Drug|Placebo|
1672769|NCT01677091|Other|Cervical vibration|Vibration of neck muscles during 10 minutes
1672770|NCT01677091|Other|Prism adaptation|Prism adaptation during 10 minutes
1672771|NCT01677091|Other|Conventional rehabilitation|conventional rehabilitation
1672772|NCT01677078|Device|Neuronavigation system|Neuronavigation
1672773|NCT01677078|Device|Standard localisation method|Manual localisation of the DLPFC using the standard localisation method (i.e. the '5-cm method')
1672774|NCT01677065|Drug|Oxycodone controlled-release test formulation|single dose administration of test formulation under fasted conditions
1672775|NCT01677065|Drug|Immediate-release reference drug|single dose administration of reference drug under fasted conditions
1672776|NCT01677039|Drug|Test formulation administered with water|single dose of 20 mg of test formulation with 240 mL of water
1672777|NCT01677039|Drug|Test formulation administered with 20% ethanol|single dose of 20 mg of test formulation with 240 mL of 20% ethanol in water
1672778|NCT01677039|Drug|Test formulation administered with 40% ethanol|single dose of 20 mg of test formulation with 240 mL of 40% ethanol
1672779|NCT01677013|Other|BMMCT|Bone marrow mononuclear cell transplantation via selective catheterization
1672782|NCT01676961|Biological|romiplostim|Given SC
1672783|NCT01676948|Drug|ACZ885|
1672784|NCT01676948|Drug|Canakinumab|
1672785|NCT01676948|Drug|Canakinumab|"Patients rolling over into this study from CACZ885G2301E1 (Cohort 1) will continue on their established canakinumab dose of either 4 mg/kg SC given every 4 weeks or 2mg/kg SC given every 4 weeks, until eligible for dose reduction.
Canakinumab-naïve patients"
1672941|NCT01675635|Drug|OxyNorm Capsules|dosage:5mg,l0mg and 20mg dosage form:capsule frequency:every 6h, duration:24 hours
1672786|NCT01676948|Drug|Canakinumab|Patients rolling over into this study from CACZ885G2301E1(Cohort 2) will receive a standard canakinumab dose of 4mg/kg SC given every 4 weeks, until eligible for dose reduction
1672787|NCT01676935|Drug|ABT-126|See arm description
1672788|NCT01676909|Behavioral|Living Well|Living Well will be implemented as a 12 session small-group intervention (4-8 persons). Groups will meet weekly for 75 minutes for three months (12 sessions). There will be 3 booster sessions after the 12 sessions, once a month for 3 months.
1672789|NCT01676909|Behavioral|Health Focused support and education|The comparison condition will be a once-weekly support and education group focusing on living with a chronic medical condition. Each of the 12 sessions will follow a basic structure that includes a review of the material presented in the previous session, new education content and discussion.
1672790|NCT01676896|Behavioral|Asthma in-school class|
1672791|NCT01676896|Behavioral|Asthma Day Camp|
1672792|NCT01676896|Behavioral|Health Promotion in-school class|
1672793|NCT01676883|Device|Bioelectric impedance|removal of calluses and corns by pedicure
1672794|NCT01676883|Device|Air displacement plethysmography|
1672795|NCT01676870|Behavioral|1x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 5min cool-down."
1672796|NCT01676870|Behavioral|4x4 aerobic interval training|"endurance training as walking/running uphill 3 times/week for 16 weeks (2 supervised sessions (treadmill) and 1 at home each week) at 90% of Hfmax. Warm-up 10 min at 70% of maximal heart frequency (Hfmax), 3 min active pause between each interval, 5min cool-down."
1672797|NCT01676870|Behavioral|traditional moderate training|moderate intensity treadmill training (50-70% of HRmax) for a minimum of 30min, 5 times a week for 16 weeks (2 supervised sessions and 3 or more home).
1672798|NCT01676844|Drug|Oral thin film therapy (Potassium acid phosphate oral thin films)|"Orally dissolving thin film. White, square oral thin film. 15 mm x 15 mm surface area. 1-2 mm film thickness. No markings.
Place a single OTF on the tongue, inside cheek or palate and allow to dissolve."
1672799|NCT01676844|Drug|Standard therapy (Potassium acid phosphate oral solution)|Each millilitre contains approximately 136mg Monobasic Potassium Phosphate Ph.Eur. (KH2PO4) equivalent to 1mmol Potassium (39mg) and 1mmol Phosphate (31mg Phosphorus). Manufacturer: Specials Products Ltd., Surrey, UK.
1672800|NCT01676831|Drug|Topical resiquimod 0.06%|topical resiquimod 0.06% dosing frequency begins at 3 times per week and evaluated every two weeks. Will be applied for a total of 8 weeks followed by 4 weeks rest and then followed by another 8 weeks of application with another 4 weeks rest.
1672801|NCT01676831|Drug|topical resiquimod 0.03%|topical resiquimod 0.03% applied initially 5 times weekly for 8 weeks with adjustments up or down based upon tolerability followed by 4 weeks rest followed by another 8 weeks of treatment followed by another 4 week rest period.
1672802|NCT01676818|Drug|eribulin mesylate|Given IV
1672803|NCT01676792|Drug|SR-T100 gel with 2.3% of SM in Solanum undatum plant extract|Self administered topical SR-T100 gel on lesion(s) including its peripheral normal skin approximately 1cm around the lesion with the amount of 0.02 g/cm squared with occlusive dressing once daily. Patients who is unable to tolerate with occlusive dressing is instructed 3 times daily in the morning, afternoon & before bed time. Medication should be reapply after bathing or cleaning.
1672804|NCT01676779|Biological|Dendritic cell therapy|Dendritic cell therapy IV and ID
1672805|NCT01676753|Drug|Dinaciclib & pembrolizumab treatment|Weekly dinaciclib in combination with every 3 week pembrolizumab
1672806|NCT01676740|Drug|Iron Supplement,|Pills to be swallowed
1672807|NCT01676740|Drug|Placebo|Daily administration of active drug or placebo
1672808|NCT01676714|Drug|Dovitinib|
1672809|NCT01676701|Drug|Tabalumab Auto-Injector|Administered SC by auto-injector
1672810|NCT01676701|Drug|Tabalumab Prefilled Syringe|Administered SC by prefilled syringe
1672811|NCT01676675|Biological|7.5μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 7.5μg /0.5ml, two doses, 21 days interval
1672812|NCT01676675|Biological|15.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 15.0μg /0.5ml, two doses, 21 days interval
1672813|NCT01676675|Biological|30.0μg /0.5ml|whole virus inactivated influenza H5N1 vaccine of 30.0μg /0.5ml, two doses, 21 days interval
1672814|NCT01676675|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 21 days interval
1672815|NCT01676662|Device|Solace Bladder Control System|Subjects may undergo treatment every 12 months until study completion.
1672816|NCT01676662|Device|Solace Sham Treatment|Sham procedure that resembles treatment with the Solace Bladder Control System
1672817|NCT01676649|Biological|Ipilimumab|3 mg/kg
1672818|NCT01676649|Drug|Carboplatin|AUC = 6
1672819|NCT01676649|Drug|Paclitaxel|175 mg/m2
1672820|NCT01676636|Drug|Traditional Tablet|The traditional tablets will be swallowed with liquid. Each tablet will contain 500 mg of calcium (as calcium carbonate), thus participants will be asked to take 3 per day.. Participants will be asked to take the tablets with a liquid of their choosing with a meal. Traditional tablets will function as a control in this study, as they represent what is widely available on the market in Bangladesh.
1672821|NCT01676636|Drug|Chewable tablets|Chewable tablets are chewed in the absence of additional water. Each chewable tablet will contain 300 mg of calcium (as calcium carbonate), thus participants will be asked to take 5 per day. Participants will be asked to consume the chewable tablets with a meal.
1672822|NCT01676636|Drug|Unflavoured Powder|The unflavoured powder with suspension agent will be tasteless and consumed by either adding it to a semi-solid food or drink of one's choosing. Appropriate foods for mixing with the powder will be at the discretion of the participants. This vehicle was selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. A similar product is Sprinkles, a multiple micronutrient powder developed at SickKids by Dr. Zlotkin.
1672823|NCT01676636|Drug|Flavoured Powder|The flavoured powder with suspension agent will be consumed by adding it to clean water with a meal. This vehicle was also selected on the basis that it would be easy to swallow, given the nausea associated with pregnancy. Similar products include oral rehydration salts or artificial juice flavour crystals.
1672942|NCT01675635|Other|Morphine tablet|dosage: 10mg and 20mg; dosage form: tablet; frequency: every 6h; duration: 24 hours.
1673630|NCT01670084|Drug|doxorubicin hydrochloride|Given IV
1672824|NCT01676623|Behavioral|Standard government health services|This intervention will be basic preventive and curative health services provided by the commune health centers. This includes antenatal care, postnatal care and basic nutrition related counseling.
1672825|NCT01676623|Behavioral|Alive & Thrive IYCF franchise services|This intervention includes intensive behavioral counseling to improve infant and young child feeding. A package of 15 counseling contacts that are quality assured and branded will be offered to families of infants and young children. Services might also include user fees.
1672826|NCT01676623|Behavioral|Mass media campaign|Alive & Thrive is implementing a nationwide mass media campaign in 2011, 2012 and 2013, with a focus on improving breastfeeding practices. The mass media intervention includes TV and radio spots as well as an internet site and a telephone hotline.
1672827|NCT01676597|Drug|pentoxifylline and rifaximin|Tab Rifaximin 400 mg thrice daily + Pentoxifylline 400 mg thrice daily for 12 weeks
1672828|NCT01676597|Drug|Pentoxifylline and placebo|Tab Pentoxifylline 400 mg thrice daily + Placebo thrice daily for 12 weeks
1672829|NCT01676584|Drug|RO6811135|single ascending doses sc
1672830|NCT01676584|Drug|placebo|single doses sc
1672831|NCT01676571|Drug|Lu AA21004|10 mg immediate-release (IR), one single dose, orally
1672832|NCT01676558|Drug|131I-rituximab|
1672833|NCT01676532|Other|Students attending SBHC|School based health clinic. This is a cohort study as such there is only one group of children who used the SBHC
1672834|NCT01676519|Procedure|PCI|percutaneous coronary intervention
1672835|NCT01676506|Drug|Ranibizumab|Intravitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2.
1672836|NCT01676506|Procedure|Ranibizumab Injection|
1672837|NCT01676493|Drug|Codeine|
1672838|NCT01676480|Behavioral|Endurance training|12 weeks of endurance training 3 times per week
1672839|NCT01676441|Procedure|Mesenchymal stem cell transplantation|
1672840|NCT01676428|Radiation|Radiotherapy|"The investigational treatment will be prescribed as a 2-tiered dose scheduled dependant on target size.
For lesions <5cm, a single fraction of 26Gy will be prescribed. For lesions ≥5cm a fractionated course of 14Gy by 3 fractions will be prescribed, delivered at least 48 hours apart."
1672841|NCT01676415|Drug|Prednisone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily
If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead
Antihistamines if an appropriate history of atopy is obtained
Systemic prednisone: Starting dose of 40mg for five days followed by a taper decreasing by 10mg every 5 days
Following completion of the oral corticosteroid: Course of topical mometasone until the end of the study"
1672842|NCT01676415|Drug|Topical mometasone|"Three-week course of a broad-spectrum antibiotic Amoxicillin/Clavulanate at a daily dosage of 875mg twice daily
If the subject is allergic to Penicillin and its derivatives or has had an adverse reaction to Amoxicillin/Clavulanate, a three-week course of clarithromycin instead
Antihistamines if an appropriate history of atopy is obtained
Standing course of topical mometasone at the standard dose of 2 sprays to each nostril once daily and will remain on the topical mometasone until the end of the study."
1672843|NCT01676402|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 4 mg dosage is administered as a 1 mL volume.
1672844|NCT01676402|Biological|TIV|2012/13, 2013/14 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
1672845|NCT01676389|Other|Sham OMM|Sham Osteopathic Manual Medicine (OMM).
1672846|NCT01676389|Other|Osteopathic Manual Medicine (Body Therapy)|OMM techniques include the following - paraspinal soft tissue myofascial release, rib raising, cervical spine soft tissue myofascial release, suboccipital inhibition, thoracic balanced ligamentous tension technique, thoracic lymphatic pump and pedal lymphatic pump.
1672851|NCT01676337|Other|Text message appointment reminder|Patients randomized to the intervention arm will receive text message appointment reminders including date, time, and location seven, three and one day prior to their scheduled clinic appointments. All appointment reminders will then be delivered automatically.
1672852|NCT01676311|Drug|Huperzine A|Huperzine A will be administered for 12 weeks as outlined in the Arm Description
1672853|NCT01676311|Drug|Placebo|Placebo Arm (blinded randomization) for Huperzine A Intervention
1672854|NCT01676298|Device|Spartan FRX CYP2C19 Test System|
1672855|NCT01676285|Drug|Metoprolol succinate|
1672856|NCT01676285|Drug|placebo|
1672857|NCT01676259|Drug|siG12D-LODER|The implantation of siG12D-LODERs is selected to meet current gastroenterology endoscopic ultrasound (EUS) biopsy procedures, proved to be highly effective and safe.
1672858|NCT01676259|Drug|Gemcitabine+nab-Paclitaxel|Gemcitabine+nab-Paclitaxel
1672859|NCT01676246|Drug|100 mg flupirtine intravenous|Administration of 100 mg flupirtine intravenous (3 mg solution intravenously, 1 vial Kadadolon® inject)
1672860|NCT01676246|Drug|100 mg flupirtine per os|Administration of 100 mg flupirtine per os (1 capsule Kadadolon®)
1672861|NCT01676246|Drug|400 mg flupirtine per os|Administration of 400 mg flupirtine (1 Kadadolon® S long retard tablet)
1672943|NCT01675622|Drug|Oxycodone|dosage: 5mg, l0mg and 20mg dosage form: capsule frequency: every 6h, duration: 5-8 days
1672944|NCT01675622|Drug|Morphine|Morphine tablets 10mg and 20mg, oral every 4-6 hours
1672945|NCT01675609|Drug|Placebo|1 drop in each eye daily for up to 35 days
1672946|NCT01675609|Drug|Brimonidine tartrate 0.025%|1 drop in each eye for up to 35 days
1672947|NCT01675596|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable subjects
1724660|NCT00004659|Procedure|radiosurgery|
1672862|NCT01676246|Procedure|induce delayed onset of muscle soreness (DOMS)|"The DOMS exercise protocol consists of two sets of 50 concentric/eccentric contractions of the calf muscles of one leg with a rest of 5 min in-between. The exercise is performed 22-26 h prior to medication. For pain measurements, muscle pain is stimulated by standing on tiptoes of one leg for 30 s, which requires a constriction of the affected calf muscles. The other leg is lifted and the subjects are allowed to hold on to a table to keep their balance. The pain intensity during this stimulation is then rated by means of a 10 cm visual analogue scale (VAS). The VAS is extended from no pain to intolerable pain with a precision of 1 mm. The stimulation is repeated with the other leg. The sequence of the legs is chosen randomly."
1672863|NCT01676246|Procedure|electric pain measurement|"The method has been described to be sensitive to quantify analgesic opioid effects. Painful 5 Hz sine waves electrical stimuli (increase of intensity 0.2 mA/s, from 0 to 20 mA), which predominantly activate C-fibres, will be applied via two gold electrodes placed on the medial and lateral side of the distal phalangeal joint (middle finger of the left hand as default-testing site).
During testing, subjects keep a button continuously pressed until they find the pain intolerably and interrupt the current by releasing the button. The electrical current at which this occurred is defined as pain tolerance, the target parameter of this pain model. Each value of pain tolerance is the median of five subsequent measurements obtained at an interval of 1 min."
1672864|NCT01676233|Drug|insulin glargine (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
1672865|NCT01676233|Drug|insulin glargine- new formulation (HOE901)|Pharmaceutical form: solution Route of administration: subcutaneous
1672866|NCT01676220|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]).
1672867|NCT01676220|Drug|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of non-insulin antihyperglycemic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
1672868|NCT01676207|Procedure|Coronary Angiography with collateral flow measurements|"Diagnostic coronary angiography and LV angiography
Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate
Right and left IMA CFI during a 1-minute ostial vessel occlusion
Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.
IMA angiography (left and right) during distal IMA and coronary occlusion."
1672869|NCT01676207|Procedure|Coronary Angiography with collateral flow measurements|"Diagnostic coronary angiography and LV angiography
Administration of 5'000 units of heparin i.v. and 2 puffs of oral isosorbide-dinitrate
Right and left IMA CFI during a 1-minute ostial vessel occlusion
Selection of the coronary artery for CFI according to stenotic lesion chosen for PCI or according to ease of access by the pressure sensor wire. Placement of a non-sensor wire in the left IMA. Two coronary CFI measurements (1-minute occlusion): the first with, the second without distal IMA balloon occlusion. Placement of a non-sensor wire in the right IMA. Two coronary CFI measurements: the first with, the second without distal IMA balloon occlusion.
IMA angiography (left and right) during distal IMA and coronary occlusion."
1672870|NCT01676194|Other|Intra-arterial administration of DC BeadsR|
1672871|NCT01676181|Procedure|Adenotonsillectomy|Total removal of tonsils and adenoid tissue with cold-steel
1672872|NCT01676181|Procedure|Adenotonsillotomy|Partial removal of tonsils with coblation and total removal of adenoids with cold steel
1672873|NCT01676129|Procedure|Nocipoint Therapy|
1672874|NCT01676129|Procedure|Physical Therapy|
1672875|NCT01676116|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
1672876|NCT01676116|Drug|liraglutide|Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
1672877|NCT01676116|Drug|exenatide|Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
1672878|NCT01676103|Dietary Supplement|Tyrosine|Tyrosine supplementation (500 mg 2 x daily) for 7 days
1672879|NCT01676103|Other|Placebo Comparator:Sugar Pill|Placebo sugar pills (2x daily
1672880|NCT01676064|Drug|ringer lactate solution|
1672881|NCT01676064|Other|restrictive fluid regime|
1672883|NCT01676038|Procedure|Pinless-Navigated Total Knee Arthroplasty|Brainlab VectorVision Knee 2.5 Navigation System
1672884|NCT01676038|Procedure|Conventional Total Knee Arthroplasty|Conventional technique.
1672885|NCT01676025|Procedure|PRA|
1672886|NCT01676025|Procedure|LA|
1672887|NCT01675999|Other|Perioperative simplified FOLFOX-4 chemotherapy|Preoperative chemotherapy
1672888|NCT01675999|Other|Perioperative FOLFOX4+Cetuximab chemotherapy|Preoperative chemotherapy
1672889|NCT01675999|Other|Surgery followed by FOLFOX4 chemotherapy|Preoperative chemotherapy
1672890|NCT01675986|Drug|hydroxyzine|75 mg
1672891|NCT01675986|Drug|Pregabalin|150 mg
1672892|NCT01675986|Drug|Lactose|4 g
1672893|NCT01675973|Drug|RANEXA|500mg BID up to 1000mg BID
1672894|NCT01675960|Drug|Gabapentin|The active drug is in a flavored glycerin based solution. The drug will be given orally or through a gastrointestinal tube. Titration up to a stable dose will take 22 days. The total stable dose is 40mg/kg/day. Once 7 days on this dose are finished, children will take 6 days to reduce their dose and begin their 3 day washout period.
1672895|NCT01675960|Drug|placebo|
1672948|NCT01675570|Drug|RX-10045|One drop of RX-10045 ophthalmic solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
1672949|NCT01675570|Drug|Vehicle for RX-10045|One drop of RX-10045 placebo solution will be instilled in each eye, twice a day, approximately 12 hours apart for 28 days.
1672896|NCT01675947|Drug|Sirolimus|Immunosuppressive agent. Blocks the T-lymphocyte activation and smooth muscle and endothelial cell proliferation that occurs in response to antigenic and cytokine (interleukin IL-2, IL-4 and IL-15) stimulation through either Ca2+-dependent or Ca2+-independent pathways. Sirolimus arrests cell cycle progression by direct interaction with two intracellular proteins (immunophilin FK binding protein 12 (FKBP-12) and the mammalian target of rapamycin (mTOR), a multifunctional serine-threonine kinase). In cells, sirolimus binds to FKBP-12, and the resulting sirolimus-FKBP-12 complex then binds to and inhibits mTOR.
1672897|NCT01675947|Drug|Lidocaine|Lidocaine 2%
1672898|NCT01675934|Procedure|Retroflexion with the adult colonoscope.|
1672899|NCT01675934|Procedure|Retroflexion with the pediatric colonoscope.|
1672900|NCT01675921|Other|Facebook group|Facebook will be used to remind participants to take the ACT survey once every month for 12 months.
1672901|NCT01675908|Procedure|Stent Dysfunction|Rate of stent dysfunction (%) which includes persistent hyperbilirubinemia or cholangitis that warrant stent exchange by another ERCP.
1672902|NCT01675908|Procedure|Complications|Rates of procedural complications (%) such as pancreatitis, perforation or hemorrhage during stent placement will be assessed.
1672903|NCT01675895|Drug|Levobupivacaine lidocaine spinal anesthesia|Spinal anesthesia
1672904|NCT01675895|Drug|levobupivacaine Spinal anesthesia|spinal anesthesia
1672905|NCT01675882|Biological|Viaskin Peanut 50 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 50 mcg peanut proteins as whole peanut extract
1672906|NCT01675882|Biological|Viaskin Peanut 100 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 100 mcg peanut proteins as whole peanut extract
1672907|NCT01675882|Biological|Viaskin Peanut 250 mcg|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing 250 mcg peanut proteins as whole peanut extract
1672908|NCT01675882|Biological|Viaskin Placebo|Subjects epicutaneously administered for 24 hours every 24 hours with a patch containing a matching placebo formulation
1672909|NCT01675869|Behavioral|Executive Training of Attention and Metacognition (ETAM)|ETAM is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent intervention groups. The ETAM groups will be 1 hour in length (except for the first session which will be 2 hours).
1672910|NCT01675869|Behavioral|Attention Control|Attention Control is an 8-week intervention involving weekly concurrent child (n=~6 per group) and parent groups that control for the effects of attention. The groups will be 1 hour in length (except for the first session which will be 2 hours).
1672911|NCT01675856|Other|Urgent endoscopy|Defined by oesophagogastroduodenoscopy within 6 hours of first presentation of Prince of Wales Hospital
1672912|NCT01675856|Other|Early endoscopy|Defined by oesophagogastroduodenoscopy within 24 hours of first presentation of Prince of Wales Hospital
1672913|NCT01675843|Procedure|Intrauterine insemination (IUI)|The male semen is obtained then processed by swim up technique and then introduced into the uterus by special catheter.
1672914|NCT01675830|Device|Heat Retention Head Wrap|Applied to infant's heads during the rewarming phase of CBP surgery
1672915|NCT01675804|Other|Computerized cognitive rehabilitation|- Computerized cognitive rehabilitation: 20 ninety-minute sessions of computerized cognitive rehabilitation.
1672916|NCT01675804|Drug|Ritalin|-drug therapy: 2 or 3 doses of 10 mg tablets of Immediate-release Methylphenidate (Ritalin) per day for 2 months.
1672917|NCT01675804|Other|Placebo CACR [PCACR]|PCACR: 20 ninety-minute sessions of Placebo computerized cognitive training.
1672918|NCT01675791|Biological|ALK tree AIT 0.5 DU|
1672919|NCT01675791|Biological|ALK tree AIT 1 DU|
1672920|NCT01675791|Biological|ALK tree AIT 2 DU|
1672921|NCT01675791|Biological|ALK tree AIT 4 DU|
1672922|NCT01675791|Biological|ALK tree AIT 7 DU|
1672923|NCT01675791|Biological|ALK tree AIT 12 DU|
1672924|NCT01675791|Biological|ALK tree AIT Placebo|
1672925|NCT01675778|Drug|Hydromorphone|a fixed dose (1 mg) of hydromorphone will be given to the study subjects
1672926|NCT01675765|Biological|Immunotherapy plus chemotherapy|live attenuated double deleted Lm
1672927|NCT01675765|Biological|Immunotherapy with cyclophosphamide plus chemotherapy|live attenuated double deleted Lm
1672928|NCT01675739|Behavioral|Short message service of mobile phone (SMS)|In SMS group, patients took 1st dose polyethylene glycol (PEG) 2L at 6-8pm the day before colonoscopy and then start to take 2nd dose PEG 2L after receiving Short message service of mobile phone (SMS) 6hours before afternoon colonoscopy.
1672929|NCT01675739|Drug|polyethylene glycol (PEG)|"No-SMS group took 1st 2L of PEG solution at 6-8 PM on the day before colonoscopy and started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy.
SMS group took 1st 2L PEG as same manner of No-SMS group and then started drinking the 2nd 2L PEG at about 6hours before the day of the colonoscopy after receiving scheduled SMS"
1672930|NCT01675726|Other|questionary on quality of life|
1672931|NCT01675713|Behavioral|Intensive lifestyle intervention|Lifestyle modification program focusing on increasing physical activity level, adjusting energy intake and learning coping strategies
1672932|NCT01675700|Drug|Nitroglycerin patch|Nitroglycerin 0.1 mg/hr patch
1672933|NCT01675687|Behavioral|Follow Up Support|inputs will be based on elements derived from cognitive behavioural therapy, acceptance and commitment therapy, mindfulness and awareness training
1672934|NCT01675674|Other|Dried blood spot test for MPS|The dried blood spot test uses a few drops of blood on filter paper to screen for mucopolysaccharidoses (MPS I, MPS II, MPS IVA and MPS VI in this study).
1672935|NCT01675661|Drug|N-Acetylcysteine|Study participants randomly assigned to the NAC arm will receive a 12-week course of N-Acetylcysteine (1200mg) twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
1672936|NCT01675661|Drug|Placebo|Study participants randomly assigned to the placebo arm will receive a matched placebo twice daily. All participants will concurrently participate in weekly medication management sessions and twice-weekly contingency management interventions.
1672937|NCT01675648|Drug|Lofexidine|
1672938|NCT01675648|Drug|Diazepam|
1672939|NCT01675648|Drug|Placebo for Lofexidine|
1672940|NCT01675648|Drug|Placebo for Diazepam|
1672950|NCT01675557|Dietary Supplement|Vitamin D3|a single oral dose of vitamin D3
1672951|NCT01675557|Dietary Supplement|Vitamin D2|a single oral dose of vitamin D2
1672952|NCT01675557|Dietary Supplement|Placebo|a single oral dose of placebo
1672953|NCT01675544|Procedure|Electrocardiogram|EKG voltage changes between admission and discharge
1672954|NCT01675544|Procedure|Six minute walk test|
1672955|NCT01675531|Drug|Targin|Single arm for Targin
1672956|NCT01675518|Drug|ASP7991|oral
1672957|NCT01675518|Drug|Placebo|oral
1672958|NCT01675492|Device|LASIK|Surgeons will perform wavefront-guided LASIK based upon measurements obtained with the iDesign System
1672959|NCT01675479|Device|LASIK correction of hyperopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
1672960|NCT01675466|Procedure|early laparoscopy|Laparoscopy under performed by the surgeon on duty or his/her deputy. The aim is to achieve this within 12 hours of randomisation. This will be performed under general anaesthetic and involve the necessary drugs. The procedure will require laparoscopy instruments. There will be a umbilical port which will be 10mm in size and one 5mm port below this. If pathology is found, a further port will be needed to perform treatment.
1672961|NCT01675466|Procedure|General anaesthesia|
1672962|NCT01675466|Device|Laparoscopic instruments|
1672963|NCT01675453|Drug|7.2% NaCl plus 6% hydroxyethyl starch 200/0.5|
1672964|NCT01675453|Drug|0.9% NaCl|
1672966|NCT01675427|Other|Interleukin 28B testing|Blood sampling for ILB28 genotyping
1672967|NCT01675414|Other|evaluation visit by a pediatric gastroenterologist|medical history, physical exam completed by pediatric gastroenterologist
1672968|NCT01675401|Other|Weight-loss treatment|A very-low energy diet (Modifast Intensive) for 4-5 weeks providing 2.1 MJ/day in order to reduce body weight. After 4-5 weeks a mixed solid energy-restricted diet up to 4.2 MJ/day with a recommended composition for the following 1-2 weeks. Then, a diet matching their energy requirements to maintain newly achieved body weights (weight-stable conditions) for at least 2 weeks.
1672969|NCT01675401|Other|No-weight loss treatment|Maintenance of habitual diet and physical activity for 8 weeks to maintain body weights.
1672970|NCT01675388|Other|Hypothermia|Hypothermia to 33.5 deg C
1672971|NCT01675375|Device|Eye Shield|one application following refractive surgery
1672972|NCT01675362|Drug|Antioxidant group|They will be receive vitamins A, C, E and selenium (Selenium ACE) Dosage: Two tablets before ESWL Then 2 tablets every 8 hours after ESWL for one week
1672973|NCT01675362|Drug|Calcium Channel Blockers|They will receive Verapamil (Isoptin 80 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every 12 hours after ESWL for one week
1672974|NCT01675362|Drug|Angiotensin receptor blocker group|They will receive Losartan (Cozaar 50 mg) Dosage: One tablet 2 hours before ESWL Then one tablet every day after ESWL for one week
1672975|NCT01675362|Drug|Placebo|They will receive placebo
1672976|NCT01675349|Biological|Prick test Chenopodium album allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.
Four concentrations of Chenopodium album allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
1672977|NCT01675310|Drug|medical nutrition therapy + metformin|
1672978|NCT01675310|Behavioral|Medical nutrition therapy|medical nutrition therapy
1672979|NCT01675297|Drug|Risedronate/Cholecalciferol combination|once a week
1672980|NCT01675297|Drug|Risedronate|once a week
1672981|NCT01675284|Biological|AT-301|Inactivated H5N1 Influenza Virion Vaccine
1672982|NCT01675271|Other|individual exercise|individual exercise and dietary prescription
1672983|NCT01675271|Other|general exercise|general exercise counselling
1672984|NCT01675258|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.
1672985|NCT01675245|Drug|No intervention|This is an observational study. Velcade will be administered as per the recommended regimen. (Velcade, 1.3 mg/m2/dose, administered intravenously on days 1, 4, 8 and 11, for 2 weeks)
1672986|NCT01675232|Other|Soak and smear|Corticosteroid ointment applied to wet skin once a day and dry skin once a day.
1672987|NCT01675232|Other|Dry Smear|Corticosteroid ointment applied to dry skin twice a day.
1672988|NCT01675219|Procedure|white light TUR-BT|traditional transurethral bladder tumor resection
1672989|NCT01675219|Procedure|blue light TUR-BT|photodynamic transurethral bladder tumor resection
1672990|NCT01675219|Drug|optimized MMC|six weekly optimized mitomycin-C instillations
1672991|NCT01675219|Drug|single immediate chemotherapy instillation|single immediate post TUR-BT epirubicin (2mg/ml, total of 100 ml) instillation
1672992|NCT01675206|Dietary Supplement|Vitamin K2 supplementation|
1672993|NCT01675193|Behavioral|Disinvestment protocol|Omission of population-based child vision screening visits at 6-9 and 14-24 months: Children in the intervention group will not be eye screened at age 6-24 months
1672994|NCT01675180|Other|Information|Women in the intervention group will recieve information and counseling on oral health care during pregnancy
1672995|NCT01675180|Other|Control|No intervention
1672996|NCT01675167|Drug|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 150-900 mcg twice daily
1672997|NCT01675167|Drug|Placebo|Matching Placebo Buccal Film twice daily
1672998|NCT01675154|Drug|SLx-4090 placebo|
1672999|NCT01675154|Drug|Orlistat Placebo|
1673000|NCT01675154|Drug|Orlistat|
1673001|NCT01675154|Drug|Slx-4090|
1673002|NCT01675141|Drug|Lenalidomide|10 mg oral daily, on days 1-21 of repeated 28 day cycles, to continue until disease progression or unacceptable toxicity.
1673003|NCT01675128|Drug|ISIS 183750|
1673004|NCT01675128|Drug|Irinotecan|
1673005|NCT01675115|Drug|BNG-1|BNG-1 3 grams TID for 4 weeks
1673006|NCT01675115|Drug|Aspirin|Aspirin 100 mg QD for 4 weeks
1673053|NCT01674738|Drug|Bevacizumab|7,5 mg/kg i.v. on day 1 (three-week cycle)
1673631|NCT01670084|Drug|vincristine sulfate|Given IV
1673007|NCT01675089|Drug|Zoledronic acid|The treatment group will receive 15-minute intravenous administration of zoledronic acid (5 mg) in a single dose at the time of kidney transplantation and vitamin D replacement. The aim of vitamin D replacement will be serum levels of 25 (OH) vitamin D above 30 ng/ml.
1673008|NCT01675076|Drug|Dabigatran|NOAC
1673009|NCT01675076|Drug|Rivaroxaban|NOAC
1673010|NCT01675076|Drug|Apixaban|NOAC
1673011|NCT01675063|Device|Retia Non-Invasive Sensors|Three adhesive sensor patches (similar to ECG patches) will be placed on the chest and a sensor similar to a pulse oximeter will be placed on the toe. The sensors will be connected to an electrical amplifier that produces a waveform.
1673012|NCT01675050|Drug|Cyproheptadine|4 weeks of cyproheptadine or placebo with crossover to the other
1673013|NCT01675050|Drug|sugar pill|4 weeks of cyproheptadine or placebo with crossover to the other
1673014|NCT01675037|Other|Biological evaluation|Complete hypothalamic-pituitary hormonal evaluation
1673015|NCT01675024|Drug|Rotigotine, Period 1|"Formulation: transdermal
Dosage: 2 mg / 24 hours once at Day 2
Frequency: once every 24 hours
Duration: from Day 1 to Day 3"
1673016|NCT01675024|Drug|Rotigotine, Period 2|"Formulation: transdermal
Dosage: 2 mg / 24 hours for 3 days from Day 7 to Day 9, 4 mg / 24 hours for 3 days from Day 10 to Day 12
Frequency: once every 24 hours
Duration: from Day 1 to Day 3"
1673017|NCT01675011|Device|Embozene® Microspheres|
1673018|NCT01675011|Device|Embosphere®|
1673019|NCT01674985|Biological|Microtransplantation|Infusion of G-CSF mobilized HLA-mismatched peripheral blood stem cells (G-PBSC)
1673020|NCT01674972|Other|Oral glucose tolerance test|Oral intake of 75 g glucose after overnight fast
1673021|NCT01674959|Radiation|concurrent chemoradiation|"postoperative Intensity-modulated radiotherapy (IMRT) combined with capecitabine for high risk gastric cancer patients Radiation: concurrent chemoradiotherapy Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 6MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
Postoperative chemotherapy regimen: capecitabine( 1,600 mg/m2 per day for 5 weeks)."
1673022|NCT01674946|Other|saline|intraduodenal perfusion
1673023|NCT01674946|Other|bile acid (CDCA, chenodeoxycholic acid)|intraduodenal perfusion
1673024|NCT01674946|Other|oleanolic acid|intraduodenal perfusion
1673025|NCT01674946|Dietary Supplement|oleic acid|intraduodenal perfusion
1673028|NCT01674920|Behavioral|Choices|The 12-week intervention included 1.5 hour classes each week. Topics included nutrition, physical activity, and psychosocial skills based in Resiliency.
1673029|NCT01674881|Other|Mindfulness-Based Cognitive Therapy|"MBCT consists of 8 sessions, incl. 1 whole-day session, weekly meetings of app. 2 hours duration. Daily homework (app. 30-45 min).
Group format (app. 20 persons pr. group). Two trained instructors will manage the groups, both are MSc cand.psych, PhD."
1673030|NCT01674881|Other|Waitlist|Waitlist: participants are offered the intervention (MBCT) after the completion of the main study
1673031|NCT01674868|Drug|fluoxetine|20 mg daily for 90 days starting day 5-10 after stroke.
1673032|NCT01674868|Drug|placebo|subjects will take one pill po daily for 90 days.
1673033|NCT01674855|Drug|PEG-G-CSF|Prefilled syringe, 6mg/day, single dosing per cycle, for 6 cycle
1673034|NCT01674855|Drug|G-CSF|Vial, 100ug/m2/day, multiple dosing per cycle(daily administration, up to 10 days), for 6 cycle
1673035|NCT01674842|Radiation|Radiation Therapy|Once daily, Monday - Friday for six weeks
1673036|NCT01674842|Drug|Cisplatin|Intravenously, once weekly for six weeks
1673037|NCT01674829|Biological|MA09-hRPE|
1673038|NCT01674816|Device|Repeated Measurements of Knee Alignment and Kinematics|Repeated Measurements of Knee Alignment and Kinematics using tools developed by Eiffel Medtech Inc.
1673039|NCT01674816|Device|Computer Guidance of Surgical Actions|Computer Guidance of Surgical Actions using tools developed by Eiffel Medtech Inc.
1673040|NCT01674803|Device|Orsiro|biodegradable polymer sirolimus eluting stent
1673041|NCT01674803|Device|Synergy|biodegradable polymer everolimus eluting stent
1673042|NCT01674803|Device|Resolute Integrity|durable polymer zotarolimus-eluting stent
1673043|NCT01674790|Behavioral|Aerobic training|One 20-min session of body weight support treadmill training at moderate to high intensity (60-70% heart rate reserve) 5 days/week for 6-weeks.
1673044|NCT01674790|Behavioral|Cognitive training|One 20-min session of cognitive training (computerized dual n-back training program) 5 days/week for 6 weeks.
1673045|NCT01674790|Behavioral|Range of motion exercise|One 20-min session of range of motion exercise (non-aerobic passive and active movement of upper and lower extremity) 5 days/week for 6-weeks.
1673046|NCT01674790|Behavioral|Unstructured mental activity|One 20-min session of unstructured mental activity (e.g., listening to light novels on tape) 5 days/week for 6-weeks.
1673047|NCT01674777|Drug|ASP1941|oral
1673048|NCT01674764|Procedure|Early surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
1673049|NCT01674764|Procedure|Late surgical intervention|Open surgical stabilization and decompression (anterior, posterior or circumferential); and/or Closed reduction and external fixation
1673050|NCT01674751|Other|Pre-ordering program|"During the 4 week intervention phase, participants use the pre-ordering program, receive a novel, smart receipt upon checkout that will detail the caloric and fat content of what they ordered, and receive price discounts for select low calorie and low fat items. The pre-ordering system is designed to provide the opportunity for the individual to see what is available along with nutritional information and to make a selection ahead of time."
1673051|NCT01674738|Drug|Pemetrexed|500 mg/m2 i.v. on day 1 (three-week cycle)
1673052|NCT01674738|Drug|Cisplatin|75 mg/m2 i.v. on day 1 (three-week cycle)
1724661|NCT00004660|Radiation|Radiotherapy|
1673054|NCT01674725|Drug|ABT-450/r/ABT-267, ABT-333|Tablet; ABT-450 coformulated with ritonavir and ABT-267, ABT-333 tablet
1673055|NCT01674725|Drug|Ribavirin|Tablet
1673056|NCT01674712|Drug|Fixed Combination of Fenofibrate/simvastatin 145/20 mg|Fenofibrate/simvastatin oval biconvex film-coated tablet, 145 mg / 20 mg, once daily, 12 weeks
1673057|NCT01674712|Drug|Simvastatin 20 mg|Simvastatin generic tablet over-encapsulated, 20 mg, once daily, 12 weeks
1673058|NCT01674712|Drug|Fenofibrate 145 mg|Fenofibrate, tablet, 145 mg, once daily, 12 weeks
1673059|NCT01674712|Drug|Fixed Combination of Fenofibrate/simvastatin 145/40 mg|Fenofibrate/simvastatin film-coated tablet 145 mg / 40 mg, once daily, 12 weeks
1673060|NCT01674712|Drug|Simvastatin 40 mg|simvastatin, generic tablet over-encapsulated, 40 mg, once daily, 12 weeks
1673061|NCT01674699|Device|EXCOR Pediatric|Ventricular Assist Device
1673062|NCT01674686|Drug|Sarpogrelate|Sarpogrelate 100mg twice a day
1673063|NCT01674686|Drug|Atorvastatin|Atorvastatin 80mg daily
1673064|NCT01674647|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg orally once daily; subjects with moderate renal impairment (ie, CrCl of 30 to 49 mL/min, inclusive) will receive the adjusted dose of 15 mg orally once daily in the study
1673065|NCT01674647|Drug|Vitamin K antagonist (VKA)|VKA orally once daily titrated to a target international normalized ratio (INR) of 2.5 (range 2.0-3.0, inclusive); the VKA type (eg, warfarin, acenocoumarol, phenprocoumon, fluindione, etc) will be assigned by the investigator according to local treatment standards
1673066|NCT01674634|Biological|XIAFLEX / XIAPEX|injection (0.58 mg after reconstitution with sterile diluent [0.3 mg/mL calcium chloride dihydrate in 0.9% sodium chloride])
1673067|NCT01674621|Drug|BA058 Placebo|BA058 Transdermal Microneedle Placebo Patch, 0 mcg, daily applications for 6 months
1673068|NCT01674621|Drug|BA058 Transdermal (50 mcg)|BA058 Transdermal Microneedle Active Patch, 50 mcg, daily applications for 6 months
1673069|NCT01674621|Drug|BA058 Transdermal (100 mcg)|BA058 Transdermal Microneedle Active Patch, 100 mcg, daily applications for 6 months
1673070|NCT01674621|Drug|BA058 Transdermal (150 mcg)|BA058 Transdermal Microneedle Active Patch, 150 mcg, daily applications for 6 months
1673071|NCT01674621|Drug|BA058 Injection (80 mcg)|BA058 Subcutaneous Injection, 80 mcg, daily injections for 6 months
1673072|NCT01674595|Biological|AVANZ olea|Immunotherapy Olea europaea
1673073|NCT01674582|Other|MRI, neuropsychological evaluation, blood sampling|"MRI at timepoints given above, neuropsychological testing after surgery, but before radiotherapy or chemotherapy.
Neuropsychological testing month 3 during treatment. Neuropsychological testing after 1 year. Neuropsychological testing after 2 years."
1673074|NCT01674569|Drug|X-82 oral|Dose escalation with oral X-82 until unacceptable toxicity develops
1673075|NCT01674569|Drug|ranibizumab (Lucentis)|Rescue treatment with intravitreal ranibizumab (Lucentis) as needed
1673076|NCT01674556|Drug|Gemzar|Gemcitabine in combination with ultrasound (US) contrast agent under sonication
1673077|NCT01674543|Other|Resistance Training|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.
Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
1673078|NCT01674543|Other|Concurrent Training|"The patients in this group will given a progressive concurrent training program, composed of aerobic and resistance training in the same session, twice per week (Tuesday and Thursday) for 20 weeks. Training sessions will performed at the same time of day (between 1 pm and 5 pm). the aerobic training will be conducted in Lifefitness 9700HR treadmill and the chosen exercises for resistance training focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.
A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
1673079|NCT01674543|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
1673080|NCT01674530|Drug|Lubiprostone|24 mcg Capsules to be given in the experimental arm with Placebo Of AMITIZA
1673081|NCT01674530|Drug|Lubiprostone|24 mcg Capsules with placebo of Lubiprostone ( Manufactured by Dr Reddy's Laboratories Ltd)
1673082|NCT01674530|Drug|Placebo|24 mcg capsules of both experimental Lubiprostone and AMITIZA
1673083|NCT01674517|Drug|Montelukast sodium chewable tablets 4mg and 5mg|Montelukast sodium chewable tablets 4mg and 5mg
1673084|NCT01674504|Drug|Montelukast sodium chewable tablets 4 mg and 5 mg|Montelukast sodium chewable tablets 4mg and 5mg
1673085|NCT01674491|Dietary Supplement|black soy peptide|black soy peptide: 4.5g/day for 8 weeks
1673086|NCT01674478|Dietary Supplement|Microlipid and fish oil|Fish oil will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which both will be continued until reanastomosis.
1673087|NCT01674478|Dietary Supplement|Microlipid|A small amount (ml) of Microlipid to match the amount of fish oil in ML/FO group will start with initial feeding after ostomy placement and Microlipid will start once infant tolerating enteral feeds at 20 ml /kg/d while weaning the Intralipid, which will be continued until reanastomosis.
1673221|NCT01673503|Device|Carl Zeiss Meditech VisuMax laser|Refractive lenticule extraction (ReLEx) with the Carl Zeiss Meditech VisuMax laser
1673632|NCT01670084|Drug|methotrexate|Given IV or IT
1673088|NCT01674465|Biological|Hypoxyprobe-1|Hypoxyprobe-1 is a biological marker used to detect oxygen levels in tissue;subjects will receive and intravenous solution for 20 minutes containing 500mg/m^2 two-three hours prior to their standard of care biopsy
1673089|NCT01674452|Behavioral|home-based group (HBG)|Participants in the home-based group (HBG) were advised to exercise, a minimum of 4 times per week, but they were encouraged to exercise a total of 5-7 days per week. After individual assessment, a group of home-exercise selected of the manual was explained and performed one by one. The home-exercises were re-executed at each fortnightly visit, when necessary corrections were made and the next step stipulated by manual was taken, according to the patient's progress.
1673090|NCT01674452|Behavioral|supervised exercise group (SEG)|Patients in the supervised exercise training group (SEG) participated in supervised individual exercise sessions 2 times per week. A physical therapist supervised these sessions. Exercise sessions included: 30 minutes of global exercises that involved stretching, range of motion, muscle strengthen and another 30 minutes of functional training (gait, balance and use of the arm in daily activities).
1673091|NCT01674439|Procedure|Supplementation of ADRC|Isolation of ADRC from half of the aspirated fat and supplementation of the fat grafts with these cells
1673092|NCT01674439|Procedure|Without supplementation of ADRC|Standard fat graft preparation
1673093|NCT01674426|Behavioral|Cognitive behavior therapy|16 sessions of 45 minutes each to review stress management
1673094|NCT01674413|Drug|Adalimumab|Adalimumab 40 mg q 2 weeks, with placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38
1673095|NCT01674413|Drug|Adalimumab PRN|"160 mg/80 mg Adalimumab at Weeks 0 and 2, followed by 1 syringe SC placebo q 2 weeks (except at Weeks 12/14, 24/26, and 36/38), with
PRNLOADing of 160 mg/80 mg Adalimumab at Weeks 12/14, 24/26, or 36/38 if most recent FCP is ≥167 mcg/gram of stool,
Or, placebo loading of 4 syringes/2 syringes at Weeks 12/14, 24/26, and 36/38 if most recent FCP is < 167 mcg/gram of stool."
1673096|NCT01674413|Drug|Placebo|1 syringe of placebo SC q 2 weeks, with additional placebo loading of 3 syringes/1 syringe at Weeks 0/2, 12/14, 24/26, and 36/38 Weeks.
1673097|NCT01674387|Device|acupuncture|30 patients (the EA group) receive the acupuncture treatment at nine acupuncture points: Dazhui (GV14), bilateral Jianzhongshu (SI15), bilateral Jingbailao (EX HN15), bilateral Jiaji (EX-B2) of cervical positive reaction plane (taking two pairs). Besides, bilateral Jianzhongshu (SI15) and bilateral Jiaji (EX-B2) receive the electro acupuncture treatment, with dilatational wave. All the needles retained for 20 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
1673098|NCT01674387|Other|comprehensive treatment|Other 30 patients (the matched group) receive the comprehensive treatment, including traction and low-frequency therapy. Each treatment 15 minutes, one treatment every other day, 10 times a course, and the treatment assessed after a course.
1673099|NCT01674387|Device|electro acupuncture|
1673100|NCT01674387|Device|traction|
1673101|NCT01674387|Device|low-frequency therapy.|
1673102|NCT01674374|Other|placebo|Given PO
1673103|NCT01674374|Procedure|quality-of-life assessment|Ancillary studies
1673104|NCT01674374|Other|questionnaire administration|Ancillary studies
1673105|NCT01674374|Drug|Vaccinium myrtillus/Macleaya cordata/Echinacea angustifolia extract granules|Given PO
1673106|NCT01674361|Drug|Bitopertin|Bitopertin once daily orally.
1673107|NCT01674361|Drug|Placebo|Placebo matched to bitopertin once daily orally.
1673108|NCT01674361|Drug|SSRI|Participants will continue their background SSRI treatment as per standard of care at the same dose taken during the 8 weeks prior to Day 1. Protocol does not enforce any particular SSRI drug or regimen.
1673109|NCT01674348|Drug|P2202|Novel oral drug with potent and selective 11 beta-hydroxysteroid dehydrogenase type 1 (11b-HSD1) inhibitory properties, being developed for the management of type 2 diabetes mellitus
1673110|NCT01674348|Drug|Placebo|Placebo
1673111|NCT01674335|Behavioral|Operant Learning|"The present therapist manual focuses on the operant learning approach, which emphasizes the use of positively reinforced activity quotas that are time and/or goal contingent, rather than pain-contingent, using a gradually increased activity-rest cycling approach (Fordyce, 1976).
This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
1673112|NCT01674335|Behavioral|Energy Conservation|"The present therapist manual focuses on the energy conservation approach, which emphasizes management of participant energy expenditure, and seeks to achieve a balance between accomplishing important day-to-day activities and resting in order to reduce or avoid pain and fatigue (Hammond, 2004).
This manual includes a total of 10 group sessions (duration: 2 hours each), two booster sessions at 3 and 6 months post-intervention (duration: 1 hour each) and a 1 follow-up session at 12 months post-intervention (duration: 1 hour). The 10 group sessions are held on a weekly basis for the 2 first months, and every 2 weeks for the remaining 3rd months."
1673113|NCT01674322|Drug|Ibrutinib|Type=exact number, unit=mg, number=50-140, form=solution, route=oral. Participants will receive a single oral solution dose of 50 mg to 140 mg -ibrutinib containing 1480 kBq (40 µCi) of 14C-labeled ibrutinib, with a total radiation burden of approximately 0.916 mSv.
1673114|NCT01674309|Drug|FOLFORINOX|INTRAVENOUS administration
1673115|NCT01674283|Drug|Glucagon|
1673116|NCT01674283|Drug|placebo|
1673117|NCT01674270|Drug|Degarelix|
1673118|NCT01674270|Drug|Casodex|
1673119|NCT01674270|Drug|LHRH Agonist|
1673120|NCT01674257|Other|USPIO (ferumoxytol)-enhanced MRI scan|Two separate MRI scans will form this intervention. A baseline scan followed by an infusion of USPIO (ferumoxytol), followed by another MRI scan.
1673121|NCT01674257|Radiation|18f-Fluoride PET/CT scan|
1673122|NCT01674257|Radiation|18F-Flurodeoxyglucose PET/CT scan|
1673123|NCT01674244|Behavioral|Integrative Exercise|
1673124|NCT01674244|Behavioral|Monitor Only Waitlist|
1673125|NCT01674231|Other|Grape in the form of freeze-dried whole grape powder|60g freeze-dried whole grape powder with 296mg polyphenols per day for 4 weeks.
1673126|NCT01674231|Other|Grape powder placebo|60g control food (matched for calories, low in polyphenols, and indistinguishable from active intervention) per day for 4 weeks.
1724665|NCT00004664|Behavioral|Exercise|
1673127|NCT01674218|Drug|Moxifloxacin|Moxifloxacin will be given orally to the following treatment groups, in combination with either PA-824 or PA-824 placebo: Treatment D: 400 mg + PA-824 placebo; Treatment E: 400 mg + PA-824 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
1673128|NCT01674218|Drug|PA-824|PA-824 will be given orally to the following treatment groups, together with either moxifloxacin or moxifloxacin placebo: Treatment B: 400 mg + moxifloxacin placebo; Treatment C: 1000 mg + moxifloxacin placebo; Treatment E: 400 mg + moxifloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
1673129|NCT01674218|Other|Placebo|Placebo tablets to match Moxifloxacin or PA-824 will be given orally, in combination with either moxifloxacin or PA-824: Treatment A: PA-824 placebo + moxifloxacin placebo; Treatment B: PA-824 400 mg + moxifloxacin placebo; Treatment C: PA-824 1000 mg + moxifloxacin placebo Treatment D: PA-824 placebo + moxafloxacin 400 mg. Subjects will cross-over to the next Treatment Group after a 6-day washout period.
1673130|NCT01674205|Biological|A/swine/Missouri/4296424/2006 (H2N3) x A/Ann Arbor/6/60 ca (H2N3 MO 2006/AA ca)|
1673131|NCT01674205|Biological|A/chicken/Hong Kong/G9/97 (H9N2) x A/Ann Arbor/6/60 ca (H9N2 G9/AA ca)|
1673132|NCT01674205|Biological|2012-2013 trivalent seasonal live attenuated influenza vaccine (FluMist®)|
1673133|NCT01674205|Biological|Vaccine placebo (Leibovitz-15 [L-15])|
1673134|NCT01674205|Biological|Vaccine placebo (FluMist®)|
1673135|NCT01674192|Drug|prucalopride|single dose of 2 mg prucalopride
1673136|NCT01674166|Drug|prucalopride|single dose 0.03 mg/kg prucalopride open label
1673137|NCT01674153|Procedure|Intra-dialytic exercise|Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
1673138|NCT01674140|Drug|anastrozole|Given orally
1673139|NCT01674140|Drug|everolimus|Given PO
1673140|NCT01674140|Drug|exemestane|Given orally
1673141|NCT01674140|Drug|goserelin acetate|Given subcutaneously or intramuscularly
1673142|NCT01674140|Drug|letrozole|Given orally
1673143|NCT01674140|Drug|leuprolide acetate|Given subcutaneously or intramuscularly
1673144|NCT01674140|Drug|tamoxifen citrate|Given PO
1673145|NCT01674140|Other|placebo|Given PO
1673146|NCT01674127|Drug|Methyldopa|
1673147|NCT01674127|Drug|Placebo|
1673148|NCT01674114|Procedure|TAP block|
1673149|NCT01674114|Procedure|control|
1673150|NCT01674101|Other|Endurance|Endurance exercise will consist of ambulating with assistive devices as needed, upper extremity (UE) ergometer, and/or playing the Wii.
1673151|NCT01674101|Other|Strengthening|Strengthening exercises will involve both UE's and LE's. For UE's, bicep curls, triceps curls, shoulder flexion, and/or press-ups from the therapy mat or wheelchair will be included. For the LE's, bridging, long arc quads, hamstring curls, calf raises in standing, single LE squats, and/or dorsiflexion (DF) in supine will be performed on the uninvolved extremity.
1673152|NCT01674101|Other|Stretching|Stretching will consist of ankle stretch into DF in supine or long sitting, hamstring stretch in supine with hip flexed to 90 degrees, and trunk extension in sitting.
1673153|NCT01674101|Other|Home exercise program|All participants will be given a tailored home exercise program (HEP) including endurance exercises, strengthening, and stretching exercises to be completed on days they do not have PT. If the participants return home, they will be asked to complete the HEP at least 3 days per week. The physical therapist will contact the participant weekly to modify the HEP if necessary and determine compliance.
1673154|NCT01674062|Drug|Pertuzumab|Loading dose 840 mg IV on Day 2 of Cycle 1, followed by 420 mg every 3 weeks thereafter, until disease progression or unacceptable toxicity.
1673155|NCT01674062|Drug|Trastuzumab|2 mg/kg IV once weekly, or as 6 mg/kg every 3 weeks, beginning on Day 1 of Cycle 1 and on Day 1 of each 3-week cycle thereafter until disease progression or unacceptable toxicity.
1673156|NCT01674049|Dietary Supplement|Immediate Nutrition|Nutritional supplement consumed either immediately following a 40min resistance exercise bout
1673157|NCT01674049|Dietary Supplement|Nutrition 3 hours Post-Bout|Nutritional supplement (600g low-fat chocolate milk) consumed three hours after the exercise bout
1673158|NCT01674049|Other|Resistance Exercise|A single 40 minute circuit-style bout of resistance exercise
1673159|NCT01674036|Drug|Genz-682452|Capsules for oral administration.
1673160|NCT01674036|Drug|Placebo|Placebo to Genz-682452
1673161|NCT01674010|Drug|ELND005|
1673162|NCT01674010|Drug|Lamotrigine|
1673163|NCT01674010|Drug|Valproic acid|
1673164|NCT01674010|Drug|Placebo|
1673165|NCT01673997|Drug|Metoprolol Succinate|Metoprolol Succinate ER Tablets 200 mg
1673166|NCT01673984|Drug|Decapeptyl® SR 22.5mg|22.5mg, intramuscular injection, given on day 1 / month 0 & month 6 (+/- 7 days).
1673167|NCT01673984|Drug|Decapeptyl® SR 11.25mg; Prostap® 3 DCS 11.25mg; Zoladex® LA 10.8mg|For Decapeptyl® SR 11.25mg: 11.25 mg, intramuscular injection For Prostap® 3 DCS 11.25mg: 11.25mg, depot injected subcutaneously For Zoladex® LA 10.8mg: 10.8mg, depot injected subcutaneously into anterior abdominal wall
1673168|NCT01673958|Other|Exercise|Comparison between stair descending and stair ascending training
1673169|NCT01673945|Device|EUS-guided fine needle aspiration|Each patient will undergo examination with the CLA-EUS or the FV-EUS, which will be selected based on the randomization process. FV-EUS will be performed using the newly available FV -EUS scope (TGF-Y0001-UC) that is compatible with last generation Aloka alpha 10. First, search of the presumed lesion will be performed and once visualize, its characteristics (size, echogenicity, margins, etc) will be recorded on data collection sheet. Fine needle aspiration will be performed under EUS guidance using a 19- ,22- or a 25-gauge fine needle or procore needles depending on endoscopist's preference
1673170|NCT01673932|Biological|UCBMC|Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
1673171|NCT01673932|Procedure|surgery|
1673172|NCT01673919|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
1673222|NCT01673490|Drug|Dutasteride/Tamsulosin|0.5 mg dutasteride/ 0.4 mg tamsulosin once daily for the duration of 180 day -treatment
1673633|NCT01670084|Drug|cytarabine|Given IV or IT
1673173|NCT01673906|Drug|Diagnostic work up|Patients will undergo MDCT, PET and EUS. Every attempt will be made to achieve a pre-operative cytologic diagnosis of any primary lesion by EUS-FNA. All diagnostic tests (MDCT, PET, EUS) should be performed during a two month time span, in this fixed order. The nuclear medicine doctor will be blinded of findings of MDCT. The gastroenterologist will be blinded about the findings of MDCT and PET until he has completed the diagnostic EUS. For ethical reasons, the findings of MDCT and PET will be disclosed to her/him, while the patient is still sedated in the operating room, just before the FNA. The minimal technical requirement for the techniques, the requested levels of clinical competence of the operators and the procedure for critical revision of radiological and cytological and histological specimens are detailed in the protocol. For PET any 68Ga -labeled-octreotide analogue will be allowed. Before EUS, an extended-esophagogastroduodenoscopy (until the Treitz) until will be performed.
1673175|NCT01673880|Drug|E2006|2.5 mg, 10 mg, and 25 mg E2006 tablets
1673176|NCT01673867|Biological|Nivolumab|
1673177|NCT01673867|Drug|Docetaxel|
1673178|NCT01673854|Drug|Ipilimumab|
1673179|NCT01673854|Biological|Vemurafenib|
1673180|NCT01673841|Procedure|Relative and absolute cerebral oxygen saturation (rScO2) measurements.|
1673181|NCT01673828|Drug|Allopregnanolone injection|Allopregnanolone intravenous solution in 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
1673182|NCT01673828|Drug|Placebo injection|Placebo intravenous solution, 0.9% sodium chloride injection with 6% sulfobutyl ether β-cyclodextrin sodium
1673183|NCT01673815|Other|Video (played on a computer monitor)|The intervention is a video (of the patient or caregiver's choice) which is played on a computer monitor during the fundoscopic examination.
1673184|NCT01673802|Drug|CT scan|Gadoxetate (Eovist) enhanced dual energy CT
1673185|NCT01673789|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 ~ 9 hrs.
1673186|NCT01673776|Device|PulsioFlex® Monitoring|"goal directed therapy according to PulsioFlex- measurements
femoral catheter
extended perioperative monitoring
nutritional supplementation, (if necessary)"
1673188|NCT01673750|Other|Questionnaire|The primary outcome, characterizing body image among HIV infected adolescents, will be measured using a questionnaire administered to study participants through Audio Computer Assisted Self-Interview (ACASI) technology.
1673189|NCT01673737|Drug|SAR260301|Pharmaceutical form: film-coated tablets Route of administration: oral
1673190|NCT01673737|Drug|Vemurafenib|Pharmaceutical form: film-coated tablets Route of administration: oral
1673191|NCT01673724|Drug|pramipexole|pramipexole
1673192|NCT01673724|Drug|Bromocriptine|bromocriptine
1673193|NCT01673711|Radiation|deuterated phenanthrene tetraol|Given PO
1673194|NCT01673711|Other|pharmacological study|Correlative studies
1673195|NCT01673711|Other|laboratory biomarker analysis|Correlative studies
1673196|NCT01673698|Device|ReShape Duo balloon|
1673197|NCT01673698|Other|Diet counseling|
1673198|NCT01673698|Other|Exercise counseling|
1673199|NCT01673685|Device|Portable Oxygen|
1673200|NCT01673672|Biological|CYT003|7 subcutaneous injections, weekly/biweekly within 10 weeks
1673201|NCT01673672|Biological|Placebo|7 subcutaneous injections, weekly/biweekly within 10 weeks
1673202|NCT01673659|Drug|Mometasone furoate|
1673203|NCT01673659|Drug|Nasonex Nasal Spray|
1673204|NCT01673659|Drug|Placebo nasal spray|
1673206|NCT01673620|Drug|Montelukast 10 mg/loratadine 10 mg|Montelukast 10 mg/loratadine 10 mg tablet administered once daily
1673207|NCT01673620|Drug|Placebo|Matching placebo tablet administered once daily
1673208|NCT01673607|Procedure|Biopsie liver|
1673209|NCT01673594|Drug|SODAS MPH|Adults with ADHD will receive open-label SODAS MPH
1673210|NCT01673594|Drug|Naltrexone|"Subjects randomized to the active double-blind group will receive Naltrexone HCl"
1673211|NCT01673581|Other|Survey|
1673212|NCT01673568|Device|ETO garments|patients wearing abdominal binder for 7 days postoperatively
1673213|NCT01673555|Drug|GSK1278863|GSK1278863
1673214|NCT01673555|Drug|Placebo|Placebo
1673215|NCT01673542|Drug|Lidocaine-Prilocaine 5%|
1673216|NCT01673542|Drug|DEXERYL|
1673217|NCT01673529|Drug|SB705498|1%, 3% and 5% (w/w) of SB705498 will be used in part A of the study. One dose will then be selected based on criteria explained in the protocol for use in Part B of the study.
1673218|NCT01673529|Drug|Placebo|Placebo to match SB705498 will be used in both Part A and Part B of the study.
1673219|NCT01673516|Procedure|The SymplicityTM Renal Denervation System|For patients who will be randomly assigned to undergo renal denervation (group RDN), the femoral artery will be accessed with the standard endovascular technique and the catheter will be advanced into the renal artery and connected to a radiofrequency generator. As in Simplicity HTN 1 and 2 trials, four-to-six discrete, low-power radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to four-six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm.
1673220|NCT01673516|Device|The HOTMAN® System|"Impedance Cardiography by HOTMAN system will evaluates non-invasively hemodynamic parameters in patients randomized to group Co"
1673358|NCT01672515|Device|Control group|
1673223|NCT01673451|Drug|E2006|Part A: 2.5 mg, 5 mg, 10 mg, 25 mg, 50 mg, and 75 mg E2006 administered as capsules
1673224|NCT01673451|Drug|Placebo comparator|E2006-matched placebo (Part A and Part B); Part B: dose level to be determined based on results of Part A, administered as capsules
1673225|NCT01673438|Drug|aldoxorubicin|
1673226|NCT01673425|Drug|Live Attenuated Influenza Vaccine|All participants will be given FluMist.
1673227|NCT01673412|Other|Psychological tests|social and economical level intellectual quotient (Raven's Progressive Matrices Standard) Coopersmith self-esteem inventory BECK Depression inventory Minimal Mental Status
1673228|NCT01673399|Drug|Atosiban|Bolus atosiban 6.75mg + infusion atosiban 18mg/u during 3 hours. once administered starting 1 hour before embryotransfer.
1673229|NCT01673399|Drug|placebo|
1673230|NCT01673386|Drug|Tivozanib Hydrochloride|
1673231|NCT01673386|Drug|Sunitinib|
1673232|NCT01673373|Device|iCAST™ Rx Stent System|All enrolled subjects will undergo primary stenting of the target lesion(s) by placement of the iCAST™ RX Stent System.
1673233|NCT01673360|Device|Elevate PC|List of AMS prolapse products
1673234|NCT01673360|Device|Mini Arc Pro|List of AMS Urinary Incontinence devices
1673235|NCT01673360|Device|RetroArc|List of AMS Urinary Incontinence devices
1673236|NCT01673347|Biological|Meniscal Allograft|Meniscal allograft
1673237|NCT01673334|Device|Fine Needle Aspiration (FNA) and Core biopsy (FNB)|
1673238|NCT01673321|Other|Dietary intervention|All snacks (arms) were randomly given to subjects to be consumed within 5 minutes, after 4 hours of consuming a standard breakfast.
1673239|NCT01673308|Drug|Lenalidomide|Lenalidomide 10 mg orally on days 1 to 21 of a 28-day cycle for at least 4 cycles until intolerance or disease progression.
1673240|NCT01673295|Drug|RTX infusions|RTX + Standard of Care
1673241|NCT01673295|Other|Standard of Care|Standard of Care only
1673242|NCT01673282|Drug|Lacosamide|Route of Administration: oral/subcutaneous Form and Dosage: Tablet (50 mg/100 mg/150 mg, 200 mg); Syrup (10 mg/ml); Solution for infusion (10 mg/ml).
1673243|NCT01673269|Other|Blood culture ( aerobic and anaerobic)|Blood culture 5 minutes and 30 minutes after the procedure
1673244|NCT01673256|Device|SJM Confirm ICM|
1673245|NCT01673243|Other|Questionnaire|Questionnaire data will be collected one time from parents who enroll on the study during their child's regular clinical visit. We will use a cross-sectional design to estimate the proportion of smoking parents of children with or surviving cancer, or sickle cell disease (SCD) who are willing to participate in tobacco trials, hypothetically offered in the context of their child's medical care. We will also examine the contribution of sociodemographic, environmental, and psychosocial variables, as well as, smoking behaviors as they relate to a parent's willingness to participate in a tobacco-related study.
1673246|NCT01673230|Procedure|cardiac surgery for ventricular dysfunction|For each included patient during the immediate post operative period, hemodynamic variables will be recorded (continuous arterial pressure, ECG, photoplethysmographic curve, CVP, wedge pressure, respiratory pressure), at rest (proclive 45°), during fluid expansion (physiological saline).
1673247|NCT01673217|Drug|decitabine|Given IV
1673248|NCT01673217|Biological|NY-ESO-1 peptide vaccine|Given SC
1673249|NCT01673217|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
1673250|NCT01673217|Biological|sargramostim|Given SC
1673251|NCT01673217|Biological|incomplete Freund's adjuvant|Given SC
1673252|NCT01673217|Other|immunohistochemistry staining method|Correlative studies
1673253|NCT01673217|Other|liquid chromatography|Correlative studies
1673254|NCT01673217|Other|mass spectrometry|Correlative studies
1673255|NCT01673217|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
1673256|NCT01673217|Other|laboratory biomarker analysis|Correlative studies
1673257|NCT01673217|Genetic|DNA methylation analysis|Correlative studies
1673258|NCT01673217|Other|enzyme-linked immunosorbent assay|Correlative studies
1673259|NCT01673204|Drug|Calcitriol|dosage of 0.5mcg administered orally once daily for 12 month
1673260|NCT01673204|Drug|Placebo|
1673261|NCT01673191|Drug|Dexamethasone intravitreal implant|
1673262|NCT01673191|Drug|Steroid plus NSAID eye drop combination therapy|
1673263|NCT01673178|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), once a week for 4 weeks
1673264|NCT01673178|Drug|25 mg PF-05231023|25 mg IV once a week for 4 weeks
1673265|NCT01673178|Drug|50 mg PF-05231023|50 mg IV once a week for 4 weeks
1673266|NCT01673178|Drug|100 mg PF-05231023|100 mg IV once a week for 4 weeks
1673267|NCT01673178|Drug|150 mg PF-05231023|150 mg IV once a week for 4 weeks
1673268|NCT01673165|Other|Skimmed mother's milk|Fortified skimmed mother's milk will be given to the skimmed mother's milk group. The fortifier is a standard fortifier we use in our population
1673269|NCT01673165|Other|Specialized Formula|Infants will receive our standard of care - specialized formula
1673270|NCT01673152|Dietary Supplement|Oligofructose|Dosing: children aged 7 to 12 years: 8g/day, children aged 12 to18 years: 15g/day Duration: 12 weeks
1673271|NCT01673152|Dietary Supplement|Maltodextrin|Dosing: children aged 7 to 12 years: 4g/day, children aged 12 to18 years: 6g/day, Duration: 12 weeks
1673272|NCT01673139|Behavioral|Interval exercise|4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 3 years.
1673273|NCT01673139|Behavioral|Moderate exercise|Moderate exercise with pulse about 70% of max pulse; 3 times a week for 3 years.
1673274|NCT01673139|Behavioral|Control|Given information on recommendations for physical activity.
1673275|NCT01673126|Device|Anodal tDCS|patients received anodal tDCS (on PFDL cortex) during 20 minutes preceded and followed by a behavioral assessment (Coma Recovery Scale Revised)
1673276|NCT01673126|Device|sham tDCS|Patient received a sham tDCS (5sec of stimulation). The device runs during 20minutes and the anode was placed over the DLPF cortex. A behavioral assessment preceded and followed the stimulation.
1673277|NCT01673113|Device|Zeltiq CoolSculpting device|"This is an FDA approved cooling device used for non-invasive and selective reduction of fat around the flanks, an area commonly referred to as the love handles."
1673278|NCT01673100|Behavioral|Physical Activity Promotion Intervention|Subjects in the experimental group (Physical Activity Promotion Telehealth Intervention) will receive messages on the study cell phone - approximately 2 to 3 messages every day. Depending on the subject's responses to the questionnaires at baseline (stages and processes of change) they will be given tips to help them engage in physical activity (such as messages to increase their self-efficacy or confidence, walking with a friend or spouse, breaking up physical activity bouts into 10 minutes bouts, etc.) and also to help them keep the physical activity appropriate. Walking will be primarily the suggested mode of activity.
1673279|NCT01673087|Drug|Metyrapone|750 mcg, oral, administered twice, 3.5 hours apart
1673280|NCT01673087|Drug|Dexamethasone|"Administered twice:
1.5 mg, oral, at 11 pm And 0.25 mg, oral, at bedtime at least one week before or after other administration."
1673281|NCT01673087|Drug|Cortrosyn|250 mcg, IV, bolus, in the afternoon.
1673282|NCT01673087|Drug|Corticorelin ovine triflutate|100 mcg, IV, over 30 seconds, in the afternoon.
1673283|NCT01673074|Drug|(PDT) Photodynamic therapy|photosensitizer
1673284|NCT01673061|Drug|Lidocaine|See associated Arm Description
1673285|NCT01673061|Drug|Vapocoolant|See associated Arm Description
1673286|NCT01673048|Procedure|3-Nail-ESIN in femoral shaft fractures|
1673287|NCT01673035|Behavioral|CBT, exposure and response prevention|This intervention entails different exercises aimed exposure to health anxiety stimuli.
1673288|NCT01673035|Behavioral|BSM, stress management and applied relaxation|BSM, this intervention comprises structured exercises aimed at reducing stress and controlling the anxiety response. One main component is applied relaxation.
1673289|NCT01673022|Drug|IC Green|IC Green
1673290|NCT01673009|Drug|Gleevec|Gleevec® will be dosed orally 440 mg/m^2/day (max 800 mg/day) for pediatric subjects and 800 mg/day for adult patients.
1673291|NCT01672996|Drug|Ioforminol 160 mgI/mL|Given as s single administration to the subject
1673292|NCT01672996|Drug|Ioforminol 200 mgI/mL|Given as a single administration to the subject
1673293|NCT01672996|Drug|Iopamidol 300 mgI/mL|Given as a single administration to the subject
1673294|NCT01672983|Drug|ABT-450/ritonavir, ABT-267|ABT-450 (tablet) dosed with ritonavir (capsule), and ABT-267 (tablet)
1673295|NCT01672957|Drug|Mycophenolate Mofetil|Protocol does not specify any regimen for treatment. The choice of treatment will be made prior to enrollment by the treating physician.
1673296|NCT01672957|Drug|Immunosuppressive Therapy|Protocol does not specify any particular immunosuppressive drug and regimen for treatment. The choice of immunosuppressive therapy will be made prior to enrollment by the treating physician.
1673299|NCT01672931|Other|Oocyte Measurement|
1673300|NCT01672905|Other|laboratory biomarker analysis|
1673303|NCT01672879|Biological|Simtuzumab|Simtuzumab administered by intravenous infusion over 30 minutes every 2 weeks
1673304|NCT01672879|Biological|Placebo|Placebo to match simtuzumab administered by intravenous infusion over 30 minutes every 2 weeks
1673305|NCT01672866|Biological|Simtuzumab|Simtuzumab administered by subcutaneous injection weekly
1673306|NCT01672866|Biological|Placebo|Placebo to match simtuzumab administered by subcutaneous injection weekly
1673307|NCT01672853|Biological|Simtuzumab|
1673308|NCT01672853|Biological|Placebo|
1673309|NCT01672840|Dietary Supplement|5g Cocoa Consumption|Daily consumption of 10g Extra Dark cholocate and a beverage containing 2.5g of cocoa powder for 8 weeks
1673310|NCT01672840|Dietary Supplement|10g Cocoa Consumption|Daily consumption of 20g Extra Dark cholocate and two beverage containing 2.5g of cocoa powder each for 8 weeks
1673311|NCT01672827|Drug|[18F]Flutemetamol|No drug is administered in this intervention. These are scanned images being reviewed, previously acquired in various GE-067 studies.
1673312|NCT01672814|Drug|riboflavin ophthalmic solution|Administration of riboflavin every 2 minutes for 20 minutes
1673313|NCT01672814|Device|Vedera KXS Microwave System|The Vedera KXS dose will be based on the pre-treatment manifest refraction spherical equivalent (MRSE), to be administered one day prior to the CXL procedure.
1673314|NCT01672801|Drug|Placebo|oral administration
1673315|NCT01672801|Drug|Nimodipine|oral administration
1673316|NCT01672788|Drug|Empagliflozin|empagliflozin tablets and metformin tablet
1673317|NCT01672788|Drug|Empagliflozin + Metformin|fixed dose combination tablet (low)
1673318|NCT01672788|Drug|Metformin|empagliflozin tablets and metformin tablet
1673319|NCT01672788|Drug|Metformin|empagliflozin tablet and metformin tablet
1673320|NCT01672788|Drug|Empagliflozin + Metformin|fixed dose combination tablet (low)
1673321|NCT01672788|Drug|Empagliflozin|empagliflozin tablet and metformin tablet
1673322|NCT01672775|Drug|AGS-16C3F|intravenous (IV) infusion
1673323|NCT01672762|Drug|ASP1941|oral
1673324|NCT01672749|Device|Growth guiding construct using TROLLEY system|Growth guiding construct using the DePuy Synthes TROLLEY Gliding Vehicles (GVs)
1673325|NCT01672749|Device|Spine based dual growing rod or rib based VEPTR|spine based dual growing rod or the rib based Vertical Expandable Prosthetic Titanium Rib (VEPTR, Synthes North America)
1673326|NCT01672736|Drug|ASP7487, Velcade, Dexamethasone|ASP7487- Oral (75, 100, 150 mg)BID Bortezomib- 1.3 mg/m2 IV on days 1, 4, 8, 15 of each 21 day cycle up to cycle 8 and days 1, 5, 15, 22 of each 35 day cycle beyond cycle 9 Dexamethasone- 20 mg on the day of Bortezomib administration
1673327|NCT01672723|Drug|Naltrexone|
1673634|NCT01670084|Drug|prednisone|Given PO
1673328|NCT01672710|Other|Hubbard detoxification program|A four to six week regimen consisting of daily, supervised, mild-moderate exercise as tolerated for 20 minutes, supervised, intermittent Finnish saunas (at about 140'F) sauna time with breaks and showers, gradually increased as tolerated to approximately 4 hours, dietary supplements including immediate release niacin in gradually increasing doses from 100 mg to a maximum of 5000 mg per day, salt and water, other vitamins, minerals and oils per Hubbard protocol.
1673329|NCT01672697|Behavioral|Physical Therapy (PT) and Behavioral Therapy (BT)|"Physical Therapy (PT) Protocol states that each participant in the treatment arm only will undergo a total of four 45-minute sessions with a certified pelvic floor (PF) physical therapist over the course of the 12 weeks. Routine monitoring of patient progress will be performed. Each session includes using the body core muscles and internal pelvic floor muscles, focusing on PF protection techniques, PF exercises, Core exercises, progression to full ADLs(activities of daily living), and an exercise routine.
Behavioral Therapy (BT) Instructions are given only to participants in the treatment arm after randomization at week-2 visit; handout provides specific instructions about appropriate diet, hygiene and level of activity during the 12 weeks of enrollment."
1673330|NCT01672684|Procedure|support group therapy|Complete at-home group video calling support sessions
1673331|NCT01672684|Other|educational intervention|Receive an educational workbook journal
1673332|NCT01672671|Drug|Doxorubicin, Paclitaxel, Cisplatin|Doxorubicin 25 mg/m2, IV weekly. Number of Cycles: 8 Paclitaxel 100 mg/m2, IV weekly. Number of Cycles: 8. Cisplatin 30 mg/m2, IV weekly. Number of Cycles: 8.
1673333|NCT01672658|Device|Sensory Kinetics Balance System|Subjects will participate in balance/gait/functional mobility training twice a week for 8 weeks.
1673334|NCT01672658|Other|Traditional Vestibular Rehabilitation|Subjects will perform traditional vestibular/balance rehabilitation which will include gait training, balance retraining, vestibular retraining, and functional mobility.
1673335|NCT01672645|Biological|NIC7-001|Intramuscular, multiple dose
1673336|NCT01672645|Biological|NIC7-003|Intramuscular, multiple dose
1673337|NCT01672645|Biological|Saline|Saline (0.9% sodium chloride)
1673338|NCT01672632|Other|Overfeeding|We overfed 40 young, healthy adults by 40% of their baseline energy requirements for 8 weeks. The diet consisted of 41% carbohydrate, 44% fat, and 15% protein.
1673339|NCT01672619|Procedure|dynamic craniotomy|Surgical technique of craniotomy spiral without detachment of dura mater
1673340|NCT01672606|Drug|Rocuronium|Partial neuromuscular blockade with rocuronium with a TOF 0.70
1673341|NCT01672593|Procedure|Endoscopy exploration and glue application|A forward-viewing fistula-fiberscope (EndoView, Outai Medical Equipment, Shanghai, China), with 15cm length and 5mm width of fiber optical wire, was inserted into the fistula tract to accomplish endoscopic visualization. Briefly, the fistula-fiberscope assisted procedure was carried out percutaneously, allowing the exposure of internal hole and the whole tracts, followed by insertion of this catheter with distal mixing device. Upon injection, two components, fibrinogen and thrombin, were mixed together in the mixing reservoir and yield a gelatin-like glue. This procedure was repeated in patients up to 3 times within 14-day FG treatment period.
1673342|NCT01672593|Drug|Anti-Bacterial Agents|Antibacterial therapy was given to patients with signs of systemic sepsis or local inflammation with pain.
1673343|NCT01672593|Dietary Supplement|Nutrition support|Nutritional replacement and bowel rest via enteral or parenteral nutrition.
1673344|NCT01672593|Procedure|PRFG preparation|As described in our previous work, platelet-rich cryoprecipitate and thrombin were obtained from 300-400ml whole blood of each patient enrolled in the PRFG group and then frozen at -20°C for storage.
1673345|NCT01672580|Behavioral|exposure to vitamin use|"Seed individuals in village are given daily adult multivitamin, with training on use and general nutrition information, along with coupons to distribute to others in village"
1673346|NCT01672580|Behavioral|exposure to water chlorination|"Seed individuals in village are given Clorox bleach for water purification, with training on use and general information on water hygiene, along with coupons to distribute to others in village"
1673347|NCT01672580|Behavioral|high in-degree|"Seed individuals for starting intervention are chosen on the basis of high (social network) in-degree"
1673348|NCT01672580|Behavioral|nominated by random|"Seed individuals for starting intervention are chosen on the basis of being named as a friend/alter of a randomly selected individual"
1673349|NCT01672567|Dietary Supplement|Egg supplementation|Daily consumption of 2 eggs for breakfast for 6 weeks
1673350|NCT01672567|Dietary Supplement|Egg substitute|Daily consumption of 1/2 cup of Egg Beater for breakfast for 6 weeks
1673351|NCT01672567|Dietary Supplement|Control diet|Daily consumption of high carbohydrate breakfast diet for 6 weeks, consisting of any of the following choices during each day of the treatment period: bagel, waffles, pancakes, or cereal and milk
1673352|NCT01672554|Drug|Quetiapine XR|Quetiapine XR will be titrated according to the following pattern: Seroquel XR 300 mg on day 1 and Seroquel XR 600 mg on day 2. On day 3, the dosage could be either maintained at 600 mg/day or continued up to 800 mg/day or if the 600 mg dose is not tolerated, the dose could then be reduced to 400 mg/day. Following this, subjects will be flexibly dosed, according to clinical judgment of the investigator, between 400 mg/day and 800 mg/day with minimum dose adjustments of 200 mg/day. This adjustment can be performed at anytime during the study but should not take place within a week from last cognitive assessment, planned at month 6. An overlap of at least 4 days but not more than 2 weeks with the previous antipsychotic will be allowed with decreasing doses on a two-week period.
1673353|NCT01672541|Behavioral|Dating Matters Comprehensive Approach|"The Dating Matters Comprehensive Approach includes:
6th, 7th, and 8th grade Student Curricula; Parent Programs for parents of 6th, 7th, and 8th graders; A communications campaign involving brand ambassadors, a text message campaign, and social media campaign; An online training about teen dating violence for educators; Developmental component: A guidance document for sites on assessing and informing local policies relevant to teen dating violence for comprehensive schools (likely to be substantial cross and within site variation on this component)"
1673354|NCT01672541|Behavioral|Standard of Care Safe Dates Approach|Safe Dates curriculum for 8th grade students
1673355|NCT01672528|Other|Interview|Patient participates in a face-to-face interview to facilitate development of the new disease specific questionnaire
1673356|NCT01672528|Other|Questionnaires|Patients will be sent questionnaires before their procedure, 8 - 12 after their procedure and at 1 and 5 years post procedure
1673357|NCT01672515|Device|RIPC group|
1673359|NCT01672502|Behavioral|Sleep health education provided via a web-based program|All firefighters in the experimental group and controls will be asked to complete an approximately 30 minute education session. This education session will split into two modules, module 1: an introduction to the program along with basic sleeps hygiene information and module 2: standard training. Topics covered in module 2 will include basic sleep physiology, the causes and consequences of sleep disorders, and fatigue countermeasures. We will emphasize strategies to maximize sleep and reduce fatigue both on and off work.
1673360|NCT01672502|Other|Sleep disorder detection and treatment|Firefighters in the intervention districts will complete a sleep disorders screening questionnaire. The questionnaire will focus on identifying individuals who show increased likelihood of suffering from obstructive sleep apnea, insomnia, shift work disorder, and restless legs syndrome using validated screening tools. Those assessed to be at high risk for one of these sleep disorders will be referred to a local AASM-accredited Clinical Sleep Disorders Service for evaluation and, if necessary, treatment. Diagnosis and treatment of sleep-related disorders will reduce the risk of fatigue-related accidents and improve the health and safety of affected individuals.
1673361|NCT01672502|Other|Optimization of Sleep in Fire Station|First, we will review and retrofit the sleeping quarters to provide a better environment for napping and sleep; light, noise, bed type, space, temperature, and location would all be considered and where possible, changes made to improve the sleeping environment. Secondly, we will work with management and union personnel to develop a 'sleep friendly' policy during the daytime, with specified protected times for naps during the day before the overnight work in order to reduce sleepiness during overnight work. Finally, we will upgrade the alerting systems, that is, we will work with management and union personnel to consider changing the policy that requires the sleeping areas of all stations to receive all alarm calls, even if that particular station is not required to attend the alarm.
1673362|NCT01672476|Drug|Placebo|Placebo
1673363|NCT01672476|Drug|Valsartan|Valsartan 80mg
1673364|NCT01672476|Drug|Fimasartan|Fimasartan 30mg
1673365|NCT01672463|Drug|OKN-007|"Dose escalation/PK cohort: 20 mg/kg, 40 mg/kg or 60 mg/kg OKN-007 via IV infusion, given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter.
Expansion cohort: MTD via IV infusion given 3x/week for the first 4 weeks, then 2x/week for the next 4 weeks, then 1x/week thereafter."
1673366|NCT01672450|Drug|Intratumoral Ipilimumab and Interleukin-2|Only 1 lesion, 0.5 -2 cm, will be treated. Interleukin-2, 3 mIU IT TIW x 2 weeks (days 1, 3 and 5), then BIW x 6 weeks (days 1 and 4). Escalating doses of Ipilimumab (0.1, 0.25, 0.5, 1, 2, mg) IT weekly x 8 weeks
1673367|NCT01672437|Other|Birth and parent preparation|4 sessions of birth and parent preparation in small groups of 6-8 couples. 3 sessions during pregnancy, 1 session following birth.
1673368|NCT01672424|Other|Ice Chips|11 ounces of ice chips given to the laboring parturient
1673369|NCT01672424|Other|Protein Drink|Patients will receive 11 ounces of a protein shake which contains 30 grams of protein
1673370|NCT01672398|Other|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
1673371|NCT01672385|Other|Telemonitoring plus self-management support|Patients in the intervention group receive automated telephone calls that ask about their health and self-care along with tailored health-related feedback. The patient's CarePartner receives health update reports about the patient and how they can help via e-mail. Urgent health problems are reported to the patient's health care team via fax or e-mail.
1673372|NCT01672372|Dietary Supplement|Max Stress B|Participants are to mix one vial per day of either placebo or actual supplement in 1 liter of water and drink over the course of the day
1673373|NCT01672372|Dietary Supplement|Placebo Max Stress B|
1673374|NCT01672359|Dietary Supplement|Ginkgo Synergy® and Choline|3 tablets 2 times per day with breakfast and dinner over 6 months
1673375|NCT01672359|Dietary Supplement|OPC Synergy® and Catalyn|3 tablets 2 times per day with breakfast and dinner over 6 months
1673376|NCT01672359|Dietary Supplement|Placebo|
1673378|NCT01672333|Drug|TOX|oxaliplatin 100mg/m2 IV over 2 hours at 1st day docetaxel 50 mg/m2 IV over 1 hour at 1st day capecitabine 625 mg/m2 PO for 14 days
1673379|NCT01672307|Drug|Minoxidil lotion 2%|Minoxidil lotion 2% is applied twice daily to one eyebrow.
1673380|NCT01672307|Drug|Placebo|Placebo is applied twice daily to the other eyebrow.
1673381|NCT01672294|Other|Preparation and life completion|Caregiver subjects will discuss life review, issues of forgiveness and heritage and legacy.
1673382|NCT01672294|Other|Attention Control|Caregiver subjects will listen to a non-guided relaxation CD with facilitator.
1673383|NCT01672281|Other|vibrox- vs. resistance training|Comparison between two exercise interventions
1673384|NCT01672268|Other|cardiac computed tomography|cardiac computed tomography, Transcatheter Aortic Valve Implantation, safety and efficacy
1673385|NCT01672255|Drug|Fluoxetine|20 mg week 1, 40 mg week 2, 60 mg week 3, 80 mg week 4-6
1673386|NCT01672255|Drug|Placebo control|20 mg Week 1, 40 mg Week 2, 60 mg Week 3, 80 mg Week 4-6
1673387|NCT01672242|Device|High-flow nasal cannula oxygen|Graded levels of HFNC will be applied and end-expiratory lung volumes measured by respiratory inductive plethysmography
1673388|NCT01672242|Device|Facial CPAP|Graded levels of CPAP will be applied by face mask and end-expiratory lung volumes measured by respiratory inductive plethysmography
1673463|NCT01671488|Drug|5FU|1 gm/m2/day x 96 hours beginning on day 1-4 and day 29-32 + 7 days
1673464|NCT01671488|Drug|Mitomycin|10 mg/m2, day 1 and 29 (day 29 can be + 7 days)
1673465|NCT01671488|Radiation|IMRT|54 Gy in 30 fractions at 1.8 Gy per fraction.
1673546|NCT01670721|Drug|Irinotecan|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
1673635|NCT01670084|Drug|mesna|Given IV
1673389|NCT01672229|Drug|Bortezomib|If improvements are seen at any dose level and patients have no DLTs, they will stay at their dose level until the end of the study. This is to avoid any possible toxicity while the patient is benefiting from their current dosing of bortezomib. If the continuous improvement in GVHD stalls at any point, or the GVHD progresses after the original improvement, while the dose level is maintained, then the dose will be increased to the next dose level. Patients will remain enrolled until exacerbation of the GVHD on increasing dose schedule or closure of the study. Clinical activity will be monitored every other week after the initiation of bortezomib until the study closes.
1673390|NCT01672216|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|
1673391|NCT01672216|Device|EMG-biofeedback alone|
1673392|NCT01672190|Other|Yoga Therapy Program|
1673393|NCT01672177|Behavioral|Chronic disease self-management training|Those in the intervention group will receive two hour long weekly training sessions for seven-eight months (a total of 56 hours of training).
1673394|NCT01672151|Drug|rapamycin|4mg oral administration on the first day, 2 mg/d oral administration for 3 months
1673395|NCT01672138|Procedure|Pulmonary Vein Antrum Isolation|Radio-frequency catheter ablation of pulmonary vein antrum
1673396|NCT01672138|Procedure|CFAE ablation|Catheter ablation of CFAEs
1673397|NCT01672138|Procedure|Isolation of non-PV triggers|Catheter ablation of triggers originating from extra-PV sites
1673398|NCT01672125|Other|circumferential measurements in different upper limb positions.|circumferential measurements in different upper limb positions, in 90 degrees forward flexion and depending position
1673399|NCT01672112|Drug|Oxycodone|Oral Oxycodone 5mg 6hrly/prn
1673400|NCT01672112|Drug|Codeine|Oral Codeine 60mg 6hrly/prn
1673401|NCT01672099|Dietary Supplement|nutrient enriched product|The intervention in this study consists of the consumption of two nutrient enriched yoghurt products. The participants consume the study products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
1673402|NCT01672099|Dietary Supplement|basic dairy product|The intervention in this study consists of the consumption of two basic yoghurt products. The participants consume the basic yoghurt products twice a day during 12 weeks, one yoghurt product (250 ml) during breakfast and one yoghurt product (250 ml) during dinner.
1673403|NCT01672086|Device|Stelkast Surpass Acetabular System implant|
1673404|NCT01672060|Behavioral|Nurse-Family Partnership (NFP)|Trained Public Health Nurses (PHNs) will deliver Nurse-Family Partnership (NFP) using specified pregnancy, infancy and toddler curricula. Following enrollment in the study, NFP PHNs will provide regular home visits to participants throughout the remainder of the participant's pregnancy, continuing through until the child's second birthday. In addition to offering standard care during each visit, PHNs will deliver NFP content using program materials relevant to the following domains: personal health, maternal role, environmental health, family and friends, life course development, and health and human services.
1673405|NCT01672060|Behavioral|Existing services|Participants allocated to the comparison group will receive all the usual perinatal programs and services offered within their Health Authority, including primary care and specialist physician services covered under BC's public healthcare system. These services vary across the province but may include: standard primary healthcare services; public health programs including prenatal classes, pregnancy outreach and home visiting by nurses or paraprofessionals; and a variety of targeted and universal parenting and early child development programs.
1673406|NCT01672047|Drug|Vitamin D2|"25（OH）D level <12 nmol/L 50000IU/weekX12week， 12-39 nmol/L 50000IU/weekX4week then，50000IU/month， 40-75 nmol/L 50000IU/month， 75-116.75nmol/L 25000IU/month，
＞116.75nmol/L stopped."
1673407|NCT01672034|Procedure|Laparoscopic gastric bypass surgery|
1673408|NCT01672021|Procedure|PET/MRI|PET/MRI
1673410|NCT01671995|Procedure|Nurse monitored heart failure program|Standard program for a heart failure clinic with information, education, drug titration
1673411|NCT01671995|Procedure|Standard primary health care|Standard care in primary care according to national guidelines but at the discretion of the primary care caregiver
1673412|NCT01671982|Other|Tenofovir Dose Adjustment|In subjects with a confirmed CLcr 30 to <50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
1673413|NCT01671969|Other|very low calorie diet|medically supervised diet
1673414|NCT01671956|Biological|Bertilimumab|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
1673415|NCT01671956|Biological|Placebo|IV infusion over 30 minutes, at Day 0, Day 14 and Day 28
1673416|NCT01671943|Device|Ice-Sense3TM|Ice-Sense Cryoprobe
1673417|NCT01671917|Other|Educational and exercise program|"4 (twice a week) group education sessions lasting 30 minutes plus an education booklet about knee replacement
4 (twice a week) sessions of an exercise programme lasting 1 hour"
1673418|NCT01671917|Other|Usual care|Information and counseling usually provided in orthopedics department and an information booklet about knee replacement.
1673419|NCT01671904|Drug|Bendamustine|Participants will receive intravenous (IV) infusion of bendamustine (90 or 70 milligrams per square meter [mg/m^2]) on Days 2-3 of Cycle 1 and Days 1-2 of Cycles 2-6.
1673420|NCT01671904|Drug|Obinutuzumab|Participants will receive IV infusion of obinutuzumab (100 milligrams [mg]) on Day 1 of Cycle 1; 900 mg administered on Day 2 of Cycle 1; and 1000 mg administered on Days 8 and 15 of Cycle 1 and on Day 1 of Cycles 2-6.
1673421|NCT01671904|Drug|Rituximab|Participants will receive IV infusion of rituximab (375 mg/m^2) on Day 1 of Cycle 1 and 500 mg/m^2 administered on Day 1 of Cycles 2-6.
1673422|NCT01671904|Drug|Venetoclax|Participants will receive multiple doses of venetoclax orally once daily.
1673423|NCT01671891|Radiation|radiation therapy|45-55Gy
1673424|NCT01671891|Drug|capecitabine (625mg/m2,bid,d1-5 qw)and oxaliplatin (85mg/m2 d1 qw)|radiotherapy concurrent chemotherapy(capecitabine+oxaliplatin)
1673425|NCT01671878|Other|Reference Glucose|
1673426|NCT01671878|Other|Test Food 1 (Cereal)|
1673427|NCT01671878|Other|Test Food 2 (Biscuit)|
1673544|NCT01670734|Drug|alirocumab SAR236553 (REGN727)|"alirocumab SAR236553 (REGN727) is a fully human monoclonal antibody that binds PCSK9 (proprotein convertase subtilisin/kexin type 9)
Pharmaceutical form:Solution for injection Route of administration: subcutaneous"
1673584|NCT01670448|Procedure|PECBLOCK under echoguidance|Performance of block under echography
1673428|NCT01671852|Drug|Mometasone furoate nasal spray|"Included patients will be randomized to a sequence of treatments including a medicated nasal spray and a saline nasal spray. The medicated group will receive Mometasone nasal sprays at the dosage outlined below for 8 weeks. The placebo group will receive saline nasal sprays for an equal duration. Informed consent of the parents or legal guardians will be obtained.
For patients that are between age 3 to 11 years and if they are randomized to the medicated group, they will use pediatric dosing of Mometasone nasal sprays, 1 spray (50 mcg) in each nostril once daily for 8 weeks. For patients that are older than age 12 and if they are randomized to the medicated group, they will use adult dosing of Mometasone nasal sprays, 2 sprays (100mcg) in each nostril twice daily for 8 weeks."
1673429|NCT01671852|Drug|Placebo|
1673430|NCT01671839|Device|Subcutaneous tissue release with the Cabochon System|Device: Subcutaneous tissue release
1673431|NCT01671813|Drug|brentuximab vedotin|Brentuximab vedotin will be given intravenously as outlined in treatment arm.
1673432|NCT01671800|Drug|Botulinum Type B|
1673433|NCT01671800|Drug|Placebo|
1673434|NCT01671787|Drug|GS-7340|Subjects are randomized to receive one of four different doses of GS-7340 over 28 days of therapy.
1673435|NCT01671787|Drug|Tenofovir disoproxil fumarate|Subjects will receive 300mg of Tenofovir disoproxil fumarate (TDF) over 28 days of therapy
1673436|NCT01671774|Drug|IMAB362|800 mg/m2 on d 1 of cycle 1. 600 mg/m2 on d 1 of every other cycle
1673437|NCT01671774|Drug|Zoledronic acid|4 mg on d 1 of cycle 1 and cycle 3
1673438|NCT01671774|Drug|Interleukin-2 (1 million IU)|1 million IU on day 1, 2 and 3 of cycles 1 and 3.
1673439|NCT01671774|Drug|Interleukin-2 (3 million IU)|3 million IU on day 1, 2 and 3 of cycles 1 and 3.
1673440|NCT01671748|Device|MIST ultrasound therapy|Low frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed.
1673441|NCT01671748|Other|Standard Care|Compression bandaging, non-adherent dressing, and debridement if required.
1673442|NCT01671735|Other|Survey|A clinical demonstration project funded by NCP will involve screening Veterans and enrolling veterans with pre-diabetes into the VA DPP program. This research project will recruit VA DPP eligible participants enrolled in the VA DPP program and Veterans enrolled in MOVE! that are VA DPP eligible as a comparison group. The research is not truly an intervention but similar to a program evaluation.
1673443|NCT01671722|Drug|Montelukast sodium|Montelukast sodium tablets 10mg
1673444|NCT01671709|Drug|Montelukast sodium|Montelukast sodium tablets 10mg
1673445|NCT01671696|Other|Cardiac MRI|Cardiac MRI
1673446|NCT01671670|Other|acupuncture|In this group, acupuncture is given according to traditional acupuncture theories.
1673447|NCT01671670|Other|sham acupuncture|Sham acupuncture points will be used in this trial, with needle penetration.
1673448|NCT01671631|Other|Measurement of intracoronary pressure|
1673449|NCT01671592|Biological|DC Vaccine|Alpha-type-1-polarized dendritic cells (αDC1) pulsed with apoptotic autologous tumor.
1673450|NCT01671579|Procedure|Bowel ultrasound|The ultrasound imaging will take place prior to the clinically ordered MRE exam. The subject will be asked to lie on the ultrasound table for approximately 60 minutes while a variety of ultrasound images are completed.
1673451|NCT01671579|Procedure|magnetic resonance enterography (MRE)|The subject will have a small intravenous (IV) catheter placed in on of their arms before the MRE exam. Medications called Glucagon and MultiHance will be given thru the IV catheter during the imaging study. The glucagon will decrease the movement of the intestines, which helps provide better images of the bowel. MultiHance is a contrast that helps create clearer MRE images. In addition to the MultiHance, the subject will be given an oral contrast medication called VoLumen to drink approximately 45 minutes before the MRE imaging is started. These medications are used for all clinically necessary MRE studies performed in children and adults at the UMHS. The MRE will take approximately 50 to 60 minutes to complete.
1673452|NCT01671566|Behavioral|Home based interval training|The participant in the intervention group will receive an individualized interval training program. The individualized adjustments in training load will be made from the results of the CPET-incremental and adjustments in training time from the results of the constant work rate 75% of peak work rate (Watt). The training will be home based and performed on a ergometer cycle 3 times a week for twelve weeks. During exercise they will wear a heart rate monitoring watch. The registered heart rate will be transferred to a webpage after the exercise session. Only the physiotherapist and participant have the access to this page. The physiotherapist and participant will have a weekly contact to promote compliance, provide feedback and if necessary adjust the training time or load. Progression in training load and time will be made when necessary to keep a relevant intensity.
1673453|NCT01671553|Behavioral|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above message. Additional telephone follow-up counseling at 1, 2, 3 and 8-week will be made to the participants in this group.
1673454|NCT01671540|Device|intrapulmonary percussive ventilation|
1673455|NCT01671540|Other|standard treatment|breathing control exercises
1673456|NCT01671527|Procedure|Transcranial magnetic stimulation (TMS)|We will test the sensory system and its interaction with the motor cortex by using TMS. For these tests, you will sit in a chair that looks like one you would find at the dentist's office. A nerve stimulator will be placed on the wrist of your right hand to stimulate the median and ulnar nerves. The intensity of the nerve stimulator will be gradually increased until the right thumb begins to twitch. A magnetic coil will be placed on the scalp on the left side of your head, overlying the brain's motor cortex, to stimulate the brain's output to the muscles in the opposite hand. This procedure will be repeated using the left wrist and the right side of your head.
1673457|NCT01671514|Dietary Supplement|Epicatechin-enriched dark chocolate|For experimental purposes, subjects will take one square of epicatechin-enriched dark chocolate per day for 90 days.
1673458|NCT01671514|Other|Low-epicatechin dark chocolate|As a placebo control, subjects will take 1 square of low-epicatechin chocolate per day for 90 days.
1673459|NCT01671501|Behavioral|Motivational Interviewing|
1673460|NCT01671501|Behavioral|Email Feedback|
1673461|NCT01671501|Other|Usual Care|
1673462|NCT01671488|Biological|Treatment|ADXS11-001 will be given at a dose of 1x109 cfu intravenously once every 28 days for 4 total doses. All 4 doses of ADXS11-001 will be 1x109 cfu.
1673467|NCT01671462|Device|BD HPV assay on Viper LT|
1673468|NCT01671449|Drug|S-1|S-1 : 40 mg/m2, twice daily, Day 1-14
1673469|NCT01671449|Drug|Cisplatin|60 mg/m2/day Day 1
1673470|NCT01671449|Drug|Oxaliplatin|130 mg/m2/day Day 1
1673471|NCT01671436|Behavioral|Central Meditation and Imagery Therapy|
1673472|NCT01671423|Drug|Prednisone|"See Prednisone arm description"
1673473|NCT01671423|Drug|Placebo|"See Placebo arm description"
1673474|NCT01671410|Drug|oral morphine|Oral morphine for the treatment of neonatal abstinence syndrome
1673475|NCT01671410|Drug|sublingual buprenorphine|Sublingual buprenorphine for the treatment of neonatal abstinence syndrome
1673476|NCT01671397|Behavioral|Diet and exercise counseling|Not needed
1673477|NCT01671397|Behavioral|Diet, exercise, sleep hygiene counseling|None needed
1673478|NCT01671384|Drug|Valproate, Levocarnitine|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:
Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)
The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
1673479|NCT01671384|Drug|Placebo|"All patients with diagnosis of SMA aged 2-15 years already registered in Myopathy Clinic of AIIMS will be recalled. Information will be sent to all Government Hospitals in Delhi that such a study is currently in progress and all the referrals will also be recruited. These patients and all those newly diagnosed at Myopathy Clinic, AIIMS will be randomized into two groups:
Group I (Physiotherapy + Placebos) Group II (Physiotherapy + Valproate and Levocarnitine)
The investigators will be blinded to the code of the medicine. It will be broken only at the end of the study or if there are any significant side effects. So one group will receive Valproate and levocarnitine and other group will receive Placebo and placebo."
1673480|NCT01671371|Other|Point-of-Care Ultrasound|Performance of a focused cardiac ultrasound including a qualitative assessment of left ventricular function, pericardial effusion, right ventricular strain, proximal ascending aortic diameter, and inferior vena cava size and collapsibility
1673481|NCT01671345|Behavioral|Intervention Video|A video intervention delivered prior to patients' visits with primary care physicians designed to increase use of active participatory communication (patient participation) behaviors, improved communication ratings, and improved medication adherence
1673482|NCT01671345|Behavioral|Control|Attention control
1955103|NCT03293706|Other|CHO Control 1 and 2 Glucose|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
1955104|NCT03293706|Other|CHO Experimental 1 Slowly Digested|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
1955105|NCT03293706|Other|CHO Experimental 2 Digestion Resistant|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
1955106|NCT03293706|Other|CHO Experimental 3 Low Sugar|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
1673487|NCT01671293|Behavioral|Multicomponent remote care model|A remote intervention based on counseling (telephone-based) was implemented. This counseling intervention is the core of the multi-component model, which also includes counseling through text messages, the purveyance of educational material, and self-monitoring equipment (pedometer & waist circumference measuring tape). The phone counseling is made by health centers professionals who have been trained to apply theories on behavioral change and decision-making. Phone counseling is conducted at least once a month. Messages are sent weekly and are related to the topics referred to in phone counseling sessions. The educational material and equipment -respectively- seek to provide additional information and foster the habit of self-monitoring progress and/or reversions in the change process.
1673488|NCT01671293|Other|Usual care|Usual care from health centers consisting of medical indication of physical activity and healthy eating recommendations, as well as referral to Dietitian if appropriate, an invitation to participate in educational activities at health centers and periodic inspection appointments
1673489|NCT01671280|Drug|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.
The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
1673490|NCT01671267|Behavioral|Strength training|
1673491|NCT01671267|Behavioral|Ergonomic|
1673492|NCT01671254|Dietary Supplement|FishOil|
1673493|NCT01671254|Dietary Supplement|CBE75|
1673494|NCT01671254|Dietary Supplement|CBE150|
1673495|NCT01671254|Dietary Supplement|placebo|
1673496|NCT01671241|Device|Polyethylene wrap|
1673497|NCT01671241|Device|Polyethylene wrap|
1673498|NCT01671228|Other|Decision Aid|The Yorkshire Dialysis Decision Aid (YoDDA) resource in web and paper format
1673499|NCT01671228|Other|Decision aid + patient stories|The Yorkshire dialysis decision aid (YoDDA) plus a set of narratives provided by patients on the treatment options (home and hospital haemodialysis; continuous ambulatory and automated peritoneal dialysis
1673500|NCT01671228|Other|Decision Aid + values task|The Yorkshire Dialysis decision aid (YoDDA) plus a set of questions to help patients explore what aspects of their life important to them about this decision (values clarification)
1955107|NCT03293706|Other|CHO Experimental 4 Maltodextrin|mixed in 237 ml/8 fl. oz. of a flavored non-caloric beverage; 1 time consumption
1673501|NCT01671189|Other|SMS Reminder Software Tool|The 150 patients in the intervention arm of the study will receive SMS reminders regarding their upcoming appointments. Working in parallel with the SMMC electronic medical records system, the software tool will automate reminders that request text responses from patients to either confirm or request to reschedule their upcoming appointments. This bidirectional text messaging system would not interfere with the clinics' existing reminder protocol.
1673502|NCT01671176|Device|4.5 mm bone anchored implant|Measure implant stability with Osstell ISQ
1673503|NCT01671163|Procedure|Endoscopic Ultrasound (EUS) for fiducial placement|Endoscopic Ultrasound (EUS) used for the placement of fiducial markers in tissue as outlined by the radiation oncologist
1673504|NCT01671150|Drug|endotoxin|Low-dose endotoxin (0.8 ng/kg of body weight): EC.O:113 administered once
1673505|NCT01671137|Other|Lactobacillus Rhamnosus Strain GG|Lactobacillus Rhamnosus Strain GG
1673506|NCT01671124|Other|Soline capsule|
1673507|NCT01671111|Drug|SSP-004184AQ|"Long term extension study of 8-75 mg/kg/d of SSP-004184AQ (equivalent to 7-68 mg/kg/d free acid or active form)"
1673508|NCT01671085|Drug|LY3015014|Administered SQ
1673509|NCT01671085|Drug|Placebo|Administered SQ
1673510|NCT01671072|Biological|TissueGene-C|TissueGene-C at 1.8 x 10^7 cells
1673511|NCT01671072|Drug|Normal Saline|Sodium chloride 0.9%, 3.5ml
1673512|NCT01671033|Behavioral|Biofeedback|Patients with panic disorder practice muscle relaxation with temperature biofeedback monitor, and send the temperature data to server via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
1673513|NCT01671033|Behavioral|Muscle Relaxation|Patients with panic disorder practice muscle relaxation via internet every day. Therapist gives comments and suggestions on line. Patients also have to complete some self-rating scales on browser every day or every week.
1673514|NCT01671020|Drug|Fimasartan|Period 1 fisrt administration of fimasartan 60mg Period 2 second administration of fimasartan 30mg
1673515|NCT01671020|Drug|Fimasartan|Period 1 first administration of fimasartan 30mg Period 2 second administration of fimasartan 60mg
1673516|NCT01670994|Biological|ALT-801|Intravenous infusion; 2 treatment cycles: on day 1, 3, 8, and 15 of each cycle
1673517|NCT01670981|Biological|ixmyelocel-T|12-20 transendocardial injections of 0.4 mL of ixmyelocel-T per injection into the left ventricle.
1673518|NCT01670981|Other|Placebo|12-20 transendocardial injections of 0.4 mL of vehicle control per injection into the left ventricle.
1673519|NCT01670955|Dietary Supplement|Jobelyn|Jobelyn is a sorghum bicolor extract marketed as dietary supplement
1673520|NCT01670955|Drug|Ferrous Sulphate + Folic Acid|Ferrous Sulphate 600mg, thrice daily + Folic Acid, 5mg daily
1673521|NCT01670942|Other|hypobaric chamber|We will use a large (26 tons) multi-place hyperbaric and hypobaric chamber at IMC in Murray, Utah (elevation 1500m or 4500ft, average ambient barometric pressure 645mm Hg). In the hypobaric study, the barometric pressure will be lowered to 554mm Hg (phase 1) or 471mm Hg (phase 2) over 20 minutes and held there for two hours.
1673522|NCT01670929|Drug|Progesterone|
1673523|NCT01670929|Other|Placebo|
1673524|NCT01670916|Dietary Supplement|probiotics|Capsule with 1 x 10**9 Lactobacillus rhamnosus GG and 1 x 10**8 Bifidobacterium BB12. Two capsules once a day. The capsules are opened and the content is dissolved in mother's milk or water if the baby is given any milk. In tube fed infants, two drops are given in the mouth and the rest in the nasogastric tube.
1673525|NCT01670890|Drug|TMZ|patients were treated with TMZ alone,Oral TMZ 50mg/m2/day,day 1 to 28,for 6 cycles
1673526|NCT01670890|Drug|TMZ plus CDDP|patients were treated with TMZ plus CDDP,CDDP was administered iv from day 1 to 3 with the total dose of 100mg and TMZ was administered orally 50mg/m2/day,day 1 to 28,for 6 cycles
1673527|NCT01670877|Drug|Neratinib|
1673528|NCT01670877|Drug|Fulvestrant|
1673529|NCT01670877|Drug|Trastuzumab|
1673530|NCT01670864|Behavioral|Counseling group|The content for the brief counseling group adopts a AWARD approach including asking the smoking habit, warning about the health risks associated with smoking, advising the smokers to quit, referring to specialized service, and repeating the above messages. A special designed health education card, based on the health education model, will be also provided to the participants. Additional telephone follow-up counseling (reminder) at 1-week & 1-month will be made to the participants in this group.
1673531|NCT01670864|Behavioral|SMS intervention group|The text messages are divided into two groups which target to smokers who are ready to quit and those who are not ready to quit. For smokers who are ready to quit, messages would be focused on practical advice and emotional support. For smokers who are not ready to quit, messages would be focused on motivating the smokers to have quit attempt.
1673532|NCT01670851|Device|Strattice|Perineal reconstruction and stoma reinforcement with Strattice
1673533|NCT01670825|Procedure|Pulsed radiofrequency|Local anesthetic injection and pulsed radiofrequency treatment x 6 minutes over each affected occipital nerve
1673534|NCT01670825|Drug|Corticosteroid injection|Corticosteroid and local anesthetic injection plus sham pulsed radiofrequency over each affected occipital nerve
1673535|NCT01670825|Drug|Local anethestic injection|
1673536|NCT01670812|Drug|FFP+HDMP+Rituximab|This is a single arm, multicenter clinical trial, and the regimen including Fresh frozen plasma 400ml IV day0, Rituximab: 375 mg/m2 IV day0(after infusion of FFP), methylprednisolone 1g/m2(up to 1.5g) IV day1-day5
1673537|NCT01670799|Drug|Ketorolac|This is a pilot (feasibility) trial to determine the availability, concentration and racemic mixture of a clinically indicated pain medication, ketorolac, in the peritoneal cavity and the subsequent effect on free floating ovarian cancer cells in patients after cytoreductive surgery for ovarian cancer.
1673538|NCT01670786|Procedure|pleurodesis|Comparison of two dosages of iodopovidone as an agent for pleurodesis in malignant pleural effusion
1673539|NCT01670773|Drug|CAT-1004|
1673540|NCT01670773|Drug|Salsalate + DHA|
1673541|NCT01670773|Drug|Placebo|
1673542|NCT01670760|Device|Zero-heat-flux thermometry|The zero-heat-flux thermometer will be placed on the subject's lateral forehead for the duration of the surgery to measure deep tissue temperature.
1673543|NCT01670747|Radiation|Chest computed tomography|
1673545|NCT01670721|Drug|AFLIBERCEPT|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
1673547|NCT01670721|Drug|Fluorouracil|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
1673548|NCT01670721|Drug|Leucovorin|Pharmaceutical form:Concentrate for solution for infusion; Route of administration: Intravenous
1673549|NCT01670708|Behavioral|HOPE|HOPE Court Judge provides warning hearing; random drug testing; violation hearing and jail/other sanctions for failed drug test or failure to comply with other probation conditions.
1673550|NCT01670708|Behavioral|Probation as Usual|Probation officer supervises following standard protocols.
1673551|NCT01670682|Procedure|ischia spinous fascia fixation|Subjects of this group were submitted to surgical treatment with ischia spinous fascia fixation.
1673552|NCT01670682|Procedure|Modified Pelvic Floor Reconstruction Surgery with Mesh|Subjects of this group were submitted to surgical treatment with Modified Total Pelvic Floor Reconstruction Surgery with Mesh.
1673553|NCT01670682|Device|polypropylene mesh(Gynemesh)|Pelvic floor reconstruction will be conducted using surgical mesh made from polypropylene.
1673554|NCT01670669|Drug|prucalopride|0.01 mg/kg/day to 0.03 mg/kg/day prucalopride (R108512) oral solution
1673555|NCT01670656|Drug|Nomegestrol acetate contraceptive vaginal ring (NOMAC-CVR)|Either 700 or 900 mcg NOMAC and 300 mcg E2 intravaginal ring for two 28-day cycles
1673556|NCT01670656|Drug|Etonogestrel containing contraceptive vaginal ring (ENG-CVR)|Either 100 or 125 mcg ENG and 300 mcg E2, intravaginally for two 28-day cycles
1673557|NCT01670656|Drug|Placebo|Placebo to match vaginal ring, intravaginally for two 28-day cycles
1673558|NCT01670656|Drug|Ibuprofen|Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
1673559|NCT01670643|Behavioral|Video camera magnifier|reading with video camera magnifier
1673560|NCT01670630|Procedure|Sheathed speculum examination|
1673561|NCT01670630|Procedure|Standard speculum examination|
1673562|NCT01670617|Other|Particulated Juvenile Articular Cartilage|Treatment of articular cartilage defects up to 7.5 cm2
1673563|NCT01670604|Drug|6% HES 130/0.4 in NaCl 0.9% (Voluven, Fresenius Kabi, Bad Hom-bourg, Germany)|
1673564|NCT01670604|Drug|Tetraspan, B. Braun, Melsungen, Germany|
1673565|NCT01670591|Behavioral|PS - Prevention in School|
1673568|NCT01670565|Drug|Belimumab|Belimumab (Benlysta®) decreases B-Cell survival and has been FDA approved for the treatment of systemic lupus erythematosus, another rheumatic autoimmune disease. Belimumab is a recombinant, fully human monoclonal antibody; it binds to the soluble human B lymphocyte stimulator (BLyS) with high affinity and inhibits its biologic activity. Prior research provides a robust rationale for the investigation of belimumab in combination with MMF (Cellcept ®) for the treatment of early diffuse cutaneous systemic sclerosis.
1673569|NCT01670552|Drug|Nimesulide + Pantoprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Naproxen + Esomeprazole placebo.
1673570|NCT01670552|Drug|Naproxen + Esomeprazole|1 tablet each 12 hours for 14 days plus 1 tablet each 12 hours for 14 days of the Nimesulide + Pantoprazole placebo.
1673571|NCT01670539|Device|HomMed Telemonitor|"A HomMed Telemonitor wireless telemonitoring system collects data on a daily basis, including heart rate, blood pressure, oxygen level, body temperature, weight, responses to 9 pre-programmed questions (including difficulty breathing, fatigue, limited activities, difficulty taking meds, pain). Telemonitored results are transmitted to the research office for analysis and contact to patient by clinical research nurses."
1673572|NCT01670526|Drug|Rivastigmine Transdermal Patch|Cholinesterase Inhibitor
1673573|NCT01670513|Drug|IDP-118 Low Strength|8 weeks
1673574|NCT01670513|Drug|IDP-118 High Strength|8 weeks
1673575|NCT01670500|Drug|Cisplatin|administered intravenously every 3 weeks for 4 doses
1673576|NCT01670500|Drug|Cyclophosphamide|administered with doxorubicin intravenously every 2 or 3 weeks for 4 doses
1673577|NCT01670500|Drug|Doxorubicin|administered with Cyclophosphamide intravenously every 2 or 3 weeks for 4 doses
1673578|NCT01670487|Device|Vapocoolant|Topical stream of 4 to 10 seconds duration to skin
1673579|NCT01670487|Device|Sterile water|Topical intervention of sterile water stream 4 to 10 seconds to skin.
1673580|NCT01670474|Drug|rt-PA (2mg/2mL) actilysis|At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. All catheters analyzed (fmDLC, polyDLC and siDLC) will be locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions: i.e. fmDLC, polyDLC amd siDLC.
1673581|NCT01670474|Drug|rt-PA|At the first catheter dysfunction (Qb < 250 ml/min) due to thrombotic event, the patient will receive rt-PA (2mg/2mL Alteplase vial - Cathflo, Boehringer Ingelheim, Ingelheim, Germany). Each lumen of the thrombosed catheter is locked with the exact volume (luminal volume) of rt-PA during 45 min. Each catheter analyzed in this study (i.e. fmDLC, polyDLC, siDLC) will be filled with rt-PA (2mg/2mL) if they are dysfunctional as described above in Arm/Group Descriptions.
1673582|NCT01670461|Behavioral|FACE|FACE intervention goal is to facilitate conversations about EOL care between adolescents and their legal guardians/surrogates to increase congruence in treatment preferences, to decrease decisional conflict, while supporting plans and actions, psychological adjustment and quality of life. Three 60 to 90-minute sessions in a dyadic format with a trained/certified interviewer. Session 1. The Lyon Family Centered Advance Care Planning Survey©. Session 2. Respecting Choices® Family-Centered Cancer Specific ACP Interview. Session 3. Completion of Five Wishes©.
1673583|NCT01670461|Behavioral|Standard of Care (SOC) Control|"Standard of Care (SOC) control will be provided with written information that encourages conversation the treatment team. At Children's National the following represent hospital policy:  … regarding advance directives … to honor each non-minor patient's wishes … to encourage and assist patients in determining and expressing their preferences regarding treatment decisions for use in the event they subsequently become unable to make such decisions. Upon admission if they do not have an advance directive, they should be given the Advance Directive Information Booklet and the Advance Directive Checklist. If they already have one, the patient is asked to provide a current copy, and it is placed in the medical record."
1673585|NCT01670435|Drug|Ciprofloxacin (BAYQ3939)|Patient treated with Ciproxan as a first line treatment in daily clinical practice
1673586|NCT01670409|Radiation|SMART|The PTV (planning target volume) of gross tumor will receive radiation dose of 66Gy, 2.2Gy per fraction and the PTV of subclinical disease will receive 54Gy, 1.8Gy per fraction,5 fraction per week.
1673587|NCT01670409|Drug|PF|Concurrent and adjuvant chemotherapy: Cisplatin, 80mg/m2, intravenous on day 1, 5fluorouracil 0.5/m2, intravenous on d1 to d4. Two cycles during radiation treatment on d1 and d28. Two additional cycles after radiation treatment, 4 weeks per cycle.
1673588|NCT01670370|Drug|R-GemOx|Rituximab Gemcitabine Oxaliplatin
1673589|NCT01670370|Drug|GemOx|Gemcitabine oxaliplatin
1673590|NCT01670357|Drug|DA-6034 3%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
1673591|NCT01670357|Drug|DA-6034 5%|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
1673592|NCT01670357|Drug|DA-6034 Placebo|Eye drop, 1 drop/each eye, 4 times/day, for 4 weeks
1673593|NCT01670344|Procedure|Treatment with investigational method (virtual implant positioning system)|
1673594|NCT01670344|Procedure|Treatment with surgical standard of care|
1673595|NCT01670331|Behavioral|Psychological preparation|"Session 1: Help patients understand their relationship to food. Patients complete a 'food diary' as 'homework'. Give information about lifestyle changes after surgery. Presents the model of 'stress' and how it influences 'overeating', to develop a more balanced lifestyle and better QoL.
Session 2: 'Intervention' using Compassion Focussed Therapy model to understand relationship to food from their diary. Help develop a 'minimising overeating plan' (a 'relapse prevention' plan). Help learn to meet needs in other ways than food.
Session 3: Focus on physical body. Current body image, explore hopes and expectations for after surgery. Consider how to manage changes to social reactions and sexual relationships that may occur."
1673596|NCT01670318|Device|platinum chromium everolimus-eluting stent (PROMUS Element by Boston Scientific, Massachusetts)|
1673597|NCT01670305|Procedure|Residual pockets will be treated by laser + photosensitizer|Experimental group: Residual pockets will be treated by laser + photosensitizer
1673598|NCT01670305|Procedure|Residual pockets will be treated only photosensitizer|Placebo Comparator: Residual pockets will be treated only photosensitizer
1673599|NCT01670305|Procedure|Residual pockets will be treated scaling and root planing|Active Comparator: Residual pockets will be treated scaling and root planing
1673600|NCT01670305|Procedure|laser + photosensitizer associated with scaling and root planing|Experimental group: furcation defects will be treated by laser + photosensitizer associated with scaling and root planing
1673601|NCT01670305|Procedure|furcation defects will be treated by scaling and root planing|Active Comparator: furcation defects will be treated by scaling and root planing
1673603|NCT01670279|Drug|Brexpiprazole|up to 3mg oral dose once daily
1673604|NCT01670279|Drug|Placebo|
1673605|NCT01670266|Drug|ONO-9054|
1673606|NCT01670266|Drug|Placebo|
1673607|NCT01670253|Behavioral|Group 1|"6 hour fast from all solid foods and milk beverages
2-hour thirst period before examination (patient may be in the period from 6 to 2 hours before the study drink any kind of clear liquids, ie liquids containing no milk products)
Approximately 2 hours before the time of examination please drink a glass (about 2 cups) clear sugary liquid - eg lemonade, apple juice, iced tea, soda or the like."
1673608|NCT01670240|Drug|Adalimumab|
1673609|NCT01670240|Drug|Placebo|
1673610|NCT01670227|Behavioral|PARENTCORPS|ParentCorps is a culturally-informed, universal intervention (for all children enrolled in Pre-K within an elementary school) designed to promote positive behavioral supports for children at home and in the classroom. ParentCorps includes two complementary components: 1) parent and child group intervention (13 2-hour sessions after school) for Pre-K students and their families; 2) professional development and individual consultation for early childhood teachers.
1673611|NCT01670214|Procedure|pulsed electromagnetic field|parameters of the pulsed electromagnetic field are frequency:10 Hz, intensity 4-5 mT, 6 sessions( 2 week) for placebo and phase 1 treatment ( 3 sessions in week) and added 6 sessions for phase 2 treatment. the solenoid diameter of instrument is 70 cm is placed around the head.
1673612|NCT01670201|Device|Mepilex Transfer Ag|Silver dressing
1673613|NCT01670188|Device|Pneumatic SCD - VenaFlow System (DJO Global)|
1673614|NCT01670175|Drug|Sirolimus, Cyclophosphamide, Topotecan|Dosing of cyclophosphamide and topotecan will be 25 mg/m2/dose and 0.8 mg/ m2 /dose respectively for dose levels 1 and 2. Level 3 dosing will escalate cyclophosphamide to 50 mg/ m2/dose. If level 1 dosing not tolerated, patients will be enrolled in level -1 cohort with cyclophosphamide and sirolimus administered only on days 1-14. If level -1 not tolerated, patients will be enrolled in level -2 with topotecan administration limited to days 1-7.
1673615|NCT01670162|Drug|Aflibercept|Intravitreal Injection 2mg/0.05mL Aflibercept
1673616|NCT01670149|Drug|Rifaximin|Tablets
1673617|NCT01670149|Drug|Placebo|Tablets
1673618|NCT01670136|Drug|1 dose of sildenafil|A single IV dose of sildenafil will be administered over 90 minutes with no greater than a 15-minute flush. Final dose to be determined based on at least the first 4 participants enrolled in Cohort 1; final dose expected to be a single dose between 0.25 and 0.5 mg/kg.
1673619|NCT01670123|Behavioral|Personalized Real-Time Intervention for Stabilizing Mood|Interactive mobile web-based behavioral intervention targeting symptoms of bipolar disorder
1673622|NCT01670097|Drug|Dexamethasone|"Group 1 Blinded Phase: 8 mg (2 capsules of 4 mg) given orally twice a day for 4 days, then 4 mg given orally twice a day for 3 days.
Open Label Phase Groups 1 and 2: 4 mg by mouth twice a day for 7 days."
1673623|NCT01670097|Drug|Placebo|Group 2 Blinded Phase: Two capsules by mouth twice a day for 4 days, followed by one capsule twice a day for 3 days.
1673624|NCT01670097|Behavioral|Questionnaires|Questionnaires completed at baseline and at day 7 and 14. It should take about 15 minutes to complete these questionnaires.
1673625|NCT01670097|Device|Spirometer|Patient to blow into spirometry machine 1 time a day to test lung function.
1673626|NCT01670097|Other|Phone Calls|Patient called by phone 1 time each day to ask about level of shortness of breath and to remind patient to take capsules. These calls should last about 5 minutes.
1673636|NCT01670084|Drug|dexamethasone|Given IV or PO
1673637|NCT01670084|Drug|leucovorin calcium|Given IV
1673638|NCT01670071|Drug|Paliperidone extended-release|Patients will receive 6 mg to 12 mg of paliperidone extended-release tablet once daily orally.
1673639|NCT01670071|Drug|Risperidone immediate-release|Patients will receive 3 mg to 7 mg of risperidone immediate-release tablet orally.
1673640|NCT01670045|Drug|Tocilizumab|Tocilizumab in accordance with the licensed label recommendation.
1673641|NCT01670032|Drug|Experimental: CD07223 1.5 % Topical Gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
1673642|NCT01670032|Drug|Experimental: CD07223 1.5% Topical Gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
1673643|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel BID|Eligible subjects are to apply study medication twice a day (BID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
1673644|NCT01670032|Drug|Placebo Comparator: CD07223 vehicle gel TID|Eligible subjects are to apply study medication three times a day (TID) for seven days. All lesions will be treated with study medication. Scheduled study visits will occur at Day 1, Day 3, Day 8 and Day 15
1673645|NCT01670019|Drug|Asenapine 5-20 mg daily|5 mg QHS, or 5 mg BID, or 5 mg QAM and 10 mg QHS, or 10 mg BID
1673646|NCT01670019|Drug|Placebo 1-4 tablets daily|One placebo tablet QHS, or one placebo tablet BID, or one placebo tablet QAM and two placebo tablets QHS, or two placebo tablets BID
1673647|NCT01669980|Drug|Ceftaroline fosamil|"Subjects ≥ 6 months: IV ceftaroline fosamil 15 mg/kg (or 600 mg if > 40 kg) infused over 120 (± 10) minutes q8h (± 1 hour)
Subjects < 6 months: IV ceftaroline fosamil 10 mg/kg infused over 120 (± 10) minutes q8h (± 1 hour)
Optional Oral Switch:
PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h
PO clindamycin 13 mg/kg/dose
PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
1673648|NCT01669980|Drug|IV Ceftriaxone and Vancomycin|"IV ceftriaxone 75 mg/kg/day (up to 4 g/day) divided equally every 12 hours (q12h) (± 2 hours) infused over 30 (± 10) minutes AND
IV vancomycin 15 mg/kg every 6 hours (q6h) (± 1 hour) infused over at least 60 minutes.
Optional Oral Switch:
PO amoxicillin clavulanate 45 to 90 mg/kg/day divided q12h
PO clindamycin 13 mg/kg/dose
PO linezolid 600 mg q12h (Cohort 1) or 10 mg/kg q8h"
1673649|NCT01669967|Drug|Lidocaine|Lidocaine 5 mg/kg in 250 ml of normal saline infused over 45 minutes.
1673650|NCT01669967|Drug|Diphenhydramine|Diphenhydramine 50 mg in 250 ml of normal saline infused over 45 minutes.
1673651|NCT01669941|Drug|IPTp-SP|3 tablets of sulfadoxine (500 mg) and pyrimethamine (25 mg) given at each ANC visit
1673652|NCT01669941|Drug|IPTp-DP|At each ANC visit: treatment with Dihydroartemisinin-piperaquine for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home and there may be a home visit to confirm that the tablets were taken.
1673653|NCT01669941|Drug|ISTp-DP|At each ANC visit, women will be screened for malaria using a combined HRP-2/ pLDH (P. falciparum/ pan-malaria) rapid diagnostic test, and if positive, treated with dihydroartemisinin-piperaquine. Each tablet will contain 40 mg dihydroartemisinin and 320 mg piperaquine. Treatment will be given for three days, with the daily number of tablets depending on the weight of the woman; two tablets for women weighing 24- 35.9kg, three tablets for women weighing 36 to 74.9 kg, and four tablets for women weighing 75kg or more. The first dose will be observed; the woman will be given the additional 2 doses to take at home
1673654|NCT01669928|Drug|Anti-hypertensive Medication -|"Patients will be taking their routine blood pressure lowering medication prescribed by their GP, different patients will be using different blood pressure lowering medication.
Dosing regimen either in the morning (between 06.00 and 11.00) or in the evening (between 18.00 and 23.00)."
1673655|NCT01669915|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day
1673656|NCT01669915|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
1673657|NCT01669915|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
1673658|NCT01669915|Dietary Supplement|Fish oil placebo|Fish oil placebo
1673659|NCT01669876|Dietary Supplement|Anatabloc(R)|Dietary supplement Anatabloc(R), as a mint-flavored lozenge, to be taken 2-3 times each day
1673660|NCT01669876|Dietary Supplement|Placebo|Placebo, as a mint-flavored lozenge, to be taken 2-3 times each day
1673661|NCT01669863|Device|ECMO|Use of veno-venous ECMO in non-intubated patients with ARDS
1673662|NCT01669863|Procedure|ECMO in non-intubated patients|Use of veno-venous ECMO in non-intubated patients with ARDS
1673663|NCT01669850|Device|Clipped anastomosis|The vascular clip devise will be used to complete the anastomosis during fistula creation.
1673664|NCT01669850|Procedure|Handsewn anastomosis|a handsewn anastomosis technique will be used during fistula creation.
1673665|NCT01669837|Device|Mesh fixation with surgical tissue glue|Laparoscopic inguinal hernia repair using surgical tissue glue for mesh fixation
1673666|NCT01669824|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Aspirin protect (enteric coated aspirin) 100 mg/single dose/day as long-term medication
1673667|NCT01669811|Drug|Esomeprazole (D961H) twice daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and in the evening
1673668|NCT01669811|Drug|Esomeprazole (D961H) once daily|One capsule of esomeprazole 20 mg (in the form of esomeprazole magnesium salt) will be administered in the morning and one corresponding placebo capsule in the evening
1673670|NCT01669785|Device|Group C|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
1673671|NCT01669785|Device|Group A|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
1673672|NCT01669785|Device|Group B|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
1673673|NCT01669772|Drug|DA-9701 and placebo|Prescribe 30mg of DA-9701(motilitone) t.i.d for 1 week and then crossover to placebo.
1673674|NCT01669772|Drug|Placebo and DA-9701|Administer placebo 1 tablet t.i.d for 1 week. After 1 week of washout, crossover to 30mg of DA-9701 t.i.d. for 1 week.
1673675|NCT01669746|Biological|Autologous cultured mixed population of dermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
1673676|NCT01669733|Other|Music|Recorded or live music will be played prior to surgery in the preoperative room. Subjects in the live music group and subjects in the recorded music group will listen to recorded music intraoperatively. An ipod with headphones will be given to the subject when she is being prepared to move to the operating room. The board certified music therapist will initiate recorded music (harp selections). Recorded music will be relaxing harp selections. The board certified music therapist will accompany the subject to the operating room and assure volume levels and electronic equipment function properly.
1673677|NCT01669733|Other|Standard of Care|The control group subjects will receive standard anesthesia, nursing and surgical care.
1673678|NCT01669720|Drug|Aflibercept|Aflibercept: 4mg/kg IV q2weeks until progression for a maximum of 2 years
1673679|NCT01669707|Drug|Endostar -Continued Pumping into+GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 120 hours and the dosage is 7.5mg/m2*5 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-4cycles.
1673680|NCT01669707|Drug|Endostar -injecting into +GP|Gemcitabine(G):1000mg/m2 intravenous injection on d1,8 q3w; Cisplatin (P):75mg iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-4cycles
1673681|NCT01669694|Other|Pelvic floor PT with biomarkers|Pelvic floor physical therapy and collection of urine for biomarker analysis.
1673682|NCT01669668|Procedure|radiofrequency ablation|Undergo RFA
1673683|NCT01669668|Procedure|laparoscopy|Undergo laparoscopic ultrasound
1673684|NCT01669642|Drug|Ketamine|participants who need ketamine sedation for abscess drainage or fracture reduction will be approached for enrollment. there is no comparison group. A predetermined dose of Ketamine will be administered over 5 seconds or less intravenously. Sedation provider will assess for effectiveness of sedation at one minute.
1673685|NCT01669629|Device|delefilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
1673686|NCT01669629|Device|etafilcon A|Daily wear soft contact lens for bilateral distance vision correction use.
1673687|NCT01669603|Dietary Supplement|Bifidobacterium lactis Bl-04|The study product will be a 2*109 cfus of probiotic Bifidobacterium lactis Bl-04 mixed with 1g of sucrose as a carrier.
1673688|NCT01669603|Dietary Supplement|Placebo|Placebo will be 1g of sucrose that has identical appearance, smell, and taste with the study product.
1673689|NCT01669603|Biological|Rhinovirus|rhinovirus for experimental challenge
1673690|NCT01669577|Procedure|analysis of blood samples and clinical features|clinical follow up and biochemical analysis blood at 4 time points:1-prehospital; 2-emergency room; 3- surgical center; 4-intensive care unit . 30 days follow up
1673691|NCT01669564|Other|Will use HIT patient feedback to activate patients.|"After completing the FAST, GIMO patients seeing a participating provider will receive(or not receive)HIT patient feedback, based on their providers' study group assignment. Feedback for each PRI will be personalized based on the medical history, family history, and other PRI reported on the FAST. A discussion of potential treatment options will be presented along with possible general referral resources. The patient will be encouraged to discuss the PRI with his or her physician.
Patients will be provided with a list of resources, customized to their study-designated PRI, that includes ongoing programs available both in the community and GIMO to help them with behavior change and mental HRQoL."
1673692|NCT01669564|Other|Patients will not receive HIT patient feedback.|After completing the FAST (standard of care in GIMO) GIMO patients seeing a participating provider will receive (or not receive) HIT patient feedback, based on their providers' study group assignment.
1673693|NCT01669538|Drug|Galantamine|
1673694|NCT01669538|Drug|Placebo|
1673695|NCT01669512|Biological|Control Regimen|ChAd63 ME-TRAP 5 x 1010 vp on Day 0 and MVA ME-TRAP 2 x 108 pfu on Day 56
1673696|NCT01669512|Biological|Low Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 25μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 25μg on Day 56
1673697|NCT01669512|Biological|Standard Dose Matrix M Regimen|ChAd63 ME-TRAP 5 x 1010 vp mixed with Matrix M-1 50μg on Day 0 and MVA ME-TRAP 2 x 108 pfu mixed with Matrix M-1 50μg on Day 56
1673698|NCT01669499|Drug|Dexamethasone acetate|
1673699|NCT01669499|Drug|Placebo|
1673700|NCT01669486|Other|CPOT, BPS|Scoring pain of the patients during nurses activity in ICU, in particular before and after nurses manoeuvers.
1673701|NCT01669473|Other|EHR Based Strategy to promote Safe and Appropriate Drug Use|"The printed tools presented in the intervention include:
Medication Review: a consolidated list of the medications a patient is currently taking.
Medication Sheet: a medication information sheet, including simplified prescription instructions, for each medication that a patient is newly prescribed.
Medication List: a table that lists all medications taken by the patient and provides an orientation on how to best organize and simplify their medication regimen"
1673702|NCT01669460|Other|Red Bull™ Sugar-Free Drink|Red Bull™ Sugar-Free Drink two (250mL) cans per day for 28 days
1673703|NCT01669447|Biological|ranibizumab|"Interventional study, prospective will be conducted in a single eye of twenty consecutive patients who will receive intravitreal ranibizumab for neovascular membrane active subfoveal choroidal active due to AMD and visual acuity of 20/40 and 20/320.
To establish the presence of active neovascularization evaluated the presence of leakage seen on fluorescein angiography and fluid, as seen in optical coherence tomography (OCT), located both intra and subretinal, or below the retinal pigment epithelium.
Treatment with ranibizumab will be offered after extensive Discussing the pathogenesis of AMD, the treatment alternatives, as well as the possible risks of treatment with ranibizumab. Term of consent shall be obtained prior to treatment."
1673861|NCT01668121|Drug|Symbicort Turbohaler|
1673707|NCT01669408|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 1L cold crystalloid solution (4°C) over 15 minutes
1673708|NCT01669395|Other|Early homebased rehabilitation after hospital admission|Training begins 3-5 days after discharge from hospital, performed by an occupational therapist and a physiotherapist from Gentofte Hospital in the first two weeks. From week three to six the training will be carried out by an occupational therapist and a physiotherapist from the local municipality (Gentofte municipality and Lyngby Taarbæk municipality). Training will take place at home twice a week for 6 weeks, each session lasting 45 minutes. The intervention is individualized and focuses on functional physical and compensatory training to help the patient to manage everyday life at home. A training program will be provided and the patient will be instructed to do the exercises every day
1673709|NCT01669395|Other|Usual care|After discharge from the hospital the patients are offered the usual symptom-oriented and preventive medical care and psychosocial support
1673710|NCT01669382|Device|percutaneous coronary intervention|after the intervention patients are randomized to either Angio Seal or Exo Seal
1673711|NCT01669369|Drug|Lithium Carbonate|400 patients were randomly divided into two groups according to sequence of entering the group: lithium carbonate group and control group (1:1). Patients in lithium carbonate group were treated with combinations of chemotherapy and lithium carbonate, the control group were treated with chemotherapy only. Patients were suggesting continuing this trial until the end of the chemotherapy regimen or being confirmed as disease progression by RECIST.
1673712|NCT01669369|Drug|Placebo|The shape,color and smell of placebo are similar to Lithium Carbonate tablet used in the treatment arm.Patients in this arm take placebo twice a day.
1673713|NCT01669356|Other|Parenteral supplement with enteral nutrition for patients after esophagectomy|
1673714|NCT01669356|Other|Enteral Nutrition alone for patients after esophagectomy|
1673715|NCT01669343|Drug|Letrozole|Active Comparator Arm receives 2.5 mg letrozole and Experimental Arm receives 5.0 mg letrozole
1673716|NCT01669330|Procedure|Nissen fundoplication|Laparoscopic Nissen fundoplication
1673717|NCT01669330|Procedure|Laparoscopic antireflux surgery ad modum Watson|Laparoscopic anterior fundoplication
1673718|NCT01669317|Other|8-ounce glass of cherry juice|You will be given an 8-ounce glass of cherry juice or artificial cherry juice to drink when you arrive at the Sleep Laboratory.
1673719|NCT01669317|Other|Artificial Cherry Juice|You will be given an 8-ounce glass of artificial cherry juice
1673720|NCT01669304|Drug|Verapamil|
1673721|NCT01669304|Drug|Sertraline|
1673722|NCT01669291|Drug|Bravelle and Menopur|Bravelle and Menopur are used for controlled ovarian stimulation (COH)
1673723|NCT01669291|Drug|Agonist|Agonist (Lupron) is used to suppress endogenous pituitary LH for the premature LH surges.
1673724|NCT01669291|Drug|Antagonist|Ganirelix acetate or cetrorelix acetate Agonist is used to suppress endogenous pituitary LH for the premature LH surges.
1673725|NCT01669278|Device|Endosheath|Flexible sheathed nasopharyngolaryngoscopy
1673726|NCT01669252|Drug|Eribulin|1.23 mg/m2 eribulin ready to use solution (equivalent to 1.4 mg/m2 eribulin mesilate) IV on Days 1 and 8 of every 21-day cycle, for 4 cycles.
1673727|NCT01669239|Drug|Liposomal Doxorubicin|"Six cycles of:
Trastuzumab 4 mg/kg loading dose on Day 1 of the first cycle, then 2 mg/kg on Days 8 and 15 of the first cycle and on Days 1, 8, and 15 of the subsequent cycles, every 3 weeks
Pertuzumab 840 mg loading dose on Day 1 of the first cycle, then 420 mg on Day 1, every 3 weeks
Liposomal doxorubicin 50 mg/m2 on Day 1, every 3 weeks
Paclitaxel 80 mg/m2 on Days 1, 8, and 15, every 3 weeks"
1673728|NCT01669226|Drug|PEip (weekly) and TCiv|IP: cisplatin 50mg/m2 and etoposide 100mg/m2, weekly, 4 times; 14 days later IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
1673729|NCT01669226|Drug|TCiv|IV: paclitaxel 175mg/m2 plus carboplatin AUC 5 or docetaxel 60-75mg/m2 plus carboplatin AUC 5
1673730|NCT01669213|Drug|ramosetron|before 5 minutes spinal anesthesia, injection of ramosetron 0.3 mg
1673731|NCT01669213|Drug|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 8 mg
1673732|NCT01669213|Drug|ondansetron|before 5 minutes spinal anesthesia, injection of ondansetron 4 mg
1673733|NCT01669213|Drug|placebo|before 5 minutes spinal anesthesia, injection of normal saline 5 ml
1673734|NCT01669200|Other|Medium Chain Triglyceride Oil|Differential changes will be compared in the test group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
1673735|NCT01669200|Other|Placebo Oil|Differential changes will be compared in the control group at one month and six months with respect to serum Beta-Hydroxybutyrate and insulin levels, and at six months with respect to cognitive scores.
1673736|NCT01669187|Other|Education brochure|
1673737|NCT01669187|Other|Live education and exercise instruction|Participants will receive one to two physical therapy visits consisting of education on the lymphedema risks and prevention factors, along with detailed information about what to except post-surgery as well as with radiation/chemotherapy. Additionally, those in the intervention group will be instructed on exercises to maintain or increase glenohumeral and scapulothoracic joint ROM post surgery and will be set up with a walking program.
1673738|NCT01669174|Drug|Placebo|
1673739|NCT01669174|Drug|BYM338|BYM338
1673740|NCT01669161|Device|Vivistim System|The Vivistim System provides vagus nerve stimulation (VNS) with rehabilitation movements.
1673741|NCT01669161|Other|Rehab Only|Rehabilitation without device implant and VNS
1673742|NCT01669148|Device|Tomosynthesis|The mean glandular radiation dose for each image will be approximately 145 millirads (mrad) for a standard size breast (4.2 cm compressed breast thickness).
1673743|NCT01669148|Device|Conventional|conventional (2D) imaging (standard mammography)
1673744|NCT01669135|Other|Spinal Anesthesia with cerebral oxygen saturation monitoring|
1673745|NCT01669122|Drug|nicotine|4 mg nicotine lozenge experimental
1673746|NCT01669109|Behavioral|Hatha yoga|
1955113|NCT03290456|Drug|Prednisone 5mg/day extended of 9 additional months|Prednisone 5mg/day orally during 9 Month + 1 mg/week tapering until 0mg.
1673748|NCT01669083|Drug|GSK557296 10 mg|10 mg single oral dose. Each subject will receive 2 tablets of 5 mg GSK557296 four times a day (QID).
1673749|NCT01669083|Drug|GSK557296 150 mg|150 mg single oral dose. Each subject will receive multiple tablets of 25 mg GSK557296 either 2, 3 or 4 times a day.
1673750|NCT01669083|Drug|GSK557296 dose 3|Dose to be determined as a single dose tablet based on half-life demonstrated in Cohort 1 and Cohort 2.
1673751|NCT01669083|Drug|GSK557296 dose 4|Dose to be determined by PK of prior doses, based on half-life demonstrated in prior cohorts.
1673752|NCT01669070|Drug|FF, 50 mcg|Novel dry powder inhaler
1673753|NCT01669070|Drug|FF, 100 mcg|Novel dry powder inhaler
1673754|NCT01669070|Drug|FF, 200 mcg|Novel dry powder inhaler
1673755|NCT01669070|Drug|FF, 250 mcg|Intravenous
1673756|NCT01669044|Drug|dexmedetomidine|dexmedetomidine: IV (in the vein)at 1μg/kg in 10 minutes as a loading dose, followed by a continuous infusion at 0.3μg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
1673757|NCT01669044|Drug|propofol|propofol: IV (in the vein)at 0.5mg/kg as a loading dose, followed by a continuous infusion at 0.5mg/kg/h.then adjust the infusion dose to maintain the ramsay scale at 3-4 scores.
1673758|NCT01669031|Other|Practice program|Each practice session (simulated visual field test on computer) takes 3-15 minutes
1673759|NCT01669018|Procedure|Lumbar plexus block using LUT technique|Lumbar plexus block guided by ultrasound and nerve stimulation with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse processes of L3 and L4 until an appropriate neuromuscular response is produced.
1673760|NCT01669018|Procedure|Lumbar plexus block using SSPS technique|Lumbar plexus block guided by ultrasound and loss of resistance (LOR) with the patient in the lateral position and the probe in the parasagittal plane inserting the block needle between the transverse process of L5 and the sacral bone until an appropriate LOR is produced.
1673761|NCT01668992|Behavioral|Family intervention|12-week parenting skills program for Burmese migrant and displaced children and families.
1673762|NCT01668979|Device|new system to detect Near Falls|We will invite healthy older adults with a history of falls to try the new system and assess whether the new system can induce, detect and quantify Near Fall episodes
1673764|NCT01668953|Other|Platelet Rich Plasma (PRP) Injection|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.
A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.
For the PRP preparation, the Arthrex ACP system will be used. This is a closed, double syringe system which uses 16 mL of whole blood drawn from the patient's contralateral arm, using a 19G butterfly needle. The blood is centrifuged at 1500 rpm for 5 minutes and extracts 4-7 ml of PRP. No anticoagulant will be used.
Fenestration of the tendon will continue as 3mL of PRP is injected into the common extensor tendon.
The remaining PRP will be sent for analysis of platelet, WBC, and RBC concentrations."
1673765|NCT01668953|Other|Whole Blood Injection|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.
A 22-gauge needle will then be placed into the tendon followed by 15-25 gentle strokes of dry needling in which the needle pierces the tendon at multiple sites.
6mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle.
Fenestration of the tendon will continue as 3mL of whole blood biologic agent is injected into the common extensor tendon.
The remaining 3mL will be sent for analysis of platelet, WBC, and RBC concentrations."
1673766|NCT01668953|Other|Dry Needle Fenestration|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine for local anesthetic.
3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.
A 22-gauge needle will then be placed into the tendon.
15-25 strokes or as many strokes required until tendon is softened of dry needling will be performed in which the needle pierces the tendon at multiple sites. No blood will be injected into the tendon."
1673767|NCT01668953|Other|Sham Injection|"The subcutaneous soft tissues of the lateral elbow will be infiltrated with 1% lidocaine (no epinephrine) for local anesthetic.
3mL of autologous whole blood will be drawn from the patient's contralateral arm, using a 19G butterfly needle, and discarded.
The superficial subcutaneous soft tissues will be re-entered however, the tendon itself will not be entered and nothing will be injected."
1673768|NCT01668940|Other|Lillipops Iced Soothies (4 flavours)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger. The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
1673769|NCT01668940|Other|Mr. Freeze Freezies|There are other commercially available freezies, such as Mr. Freeze. Mr. Freeze freezies contain simulated flavours of watermelon, cherry, blue raspberry and cream soda. However, there have been no reports, studies or claims that they are effective as a remedy for the treatment of NVP.
1673770|NCT01668940|Other|Lillipop Iced Soothies (Ginger flavour)|Lillipops Iced Soothies are naturally flavoured freezies developed in the United Kingdom for women with morning sickness. They are available in 5 different flavours: grapefruit and tangerine, lemon and mint, chamomile and orange, lime and vanilla, and ginger.The flavours are derived from steam distillation of the peels (grapefruit, tangerine, lemon, orange, lime), mint leaves, and chamomile flowers to release and collect their essential oils. Vanilla pods and ginger are macerated and their resin is used. These flavours were chosen because they may provide relief of symptoms as they are either traditional remedies for NVP, such as ginger, or soothing and refreshing flavours, such as chamomile, vanilla and citrus.
1673771|NCT01668927|Drug|Proton Pump Inhibitor|
1673772|NCT01668927|Drug|Bismuth|
1673773|NCT01668927|Drug|Metronidazole|
1673774|NCT01668927|Drug|Tetracycline|
1673775|NCT01668927|Drug|Furazolidone|
1673776|NCT01668927|Drug|Amoxicillin|
1673862|NCT01668121|Drug|Budesonide/formoterol Easyhaler|
1673777|NCT01668914|Procedure|IM-SLNB|IM-SLNB is performed according to the pre-operative lymphoscintigraphy
1673778|NCT01668914|Radiation|99mTc-SC|Two syringes of 0.25~0.5 mCi 99mTc-SC in 0.2~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
1673779|NCT01668914|Device|Histologic Examination|All IMSLNs were analyzed by histologic examination for future therapy planning.
1673780|NCT01668914|Device|LSG|lymphoscintigraphy was performed 0.5~1.0 hour before surgery
1673781|NCT01668901|Drug|warfarin|anticoagulation
1673782|NCT01668901|Drug|Aspirin|antiplatelet
1673783|NCT01668875|Other|Head down 30 degree postural drainage position|supine head down 30 degree on tilt table (intervention period in the treatment condition)
1673784|NCT01668875|Other|Horizontal supine lying|horizontal supine lying on tilt table (intervention period in the sham condition)
1673785|NCT01668862|Biological|Autologous Human Platelet Lysate|Subjects will receive one injection of Autologous Human Platelet Lysate in the lateral epicondyle space
1673786|NCT01668862|Drug|Corticosteroid|Subjects will receive one injection of Corticosteroid in the lateral epicondyle space
1673787|NCT01668849|Dietary Supplement|Grape extract|Grape extract self-administered by mouth daily for 35 days
1673788|NCT01668849|Drug|Lortab, Fentanyl patch, mouthwash|Lortab 5-10 mg Fentanyl patch 25 mcgs Mary's Magic Mouthwash
1673789|NCT01668836|Drug|Resveratrol|1 pill daily containing 500 mg/d of resveratrol for 30 days
1673790|NCT01668836|Behavioral|Caloric restriction|Diet of 1000kcal per day for 30 days
1673791|NCT01668823|Drug|HPPH|Given IV
1673792|NCT01668823|Drug|photodynamic therapy|Undergo photodynamic therapy with HPPH
1673793|NCT01668823|Procedure|therapeutic bronchoscopy|Undergo therapeutic bronchoscopy for endoscopic debridement
1673794|NCT01668797|Drug|Brexpiprazole|Brexpiprazole tablets 1 to 4 mg /day
1673795|NCT01668797|Drug|Placebo|Placebo comparator for 52 weeks
1673798|NCT01668745|Biological|Early measles vaccine|
1673799|NCT01668719|Drug|Bortezomib|Given SC or IV
1673800|NCT01668719|Drug|Dexamethasone|Given PO or IV
1673801|NCT01668719|Biological|Elotuzumab|Given IV
1673802|NCT01668719|Other|Laboratory Biomarker Analysis|Correlative studies
1673803|NCT01668719|Drug|Lenalidomide|Given PO
1673804|NCT01668693|Other|ERA (Endometrial Receptivity Array)|"The diagnostic tool ERA will be performed on all of the patients in order to allocate them in the group Receptive or Non Receptive and to predict the number of days of Progesterone administration necesary to obtain the Receptive prediction."
1673805|NCT01668693|Other|Personalized Embryo Transfer|When the ERA indicates receptivity, the patient will undergo the embryo transfer on the day indicated by the diagnostic tool.
1673806|NCT01668693|Other|Second ERA|A second ERA will be performed to confirm receptivity after further administration of Progesterone.
1673807|NCT01668680|Drug|CAPECITABINE, CELECOXIB and METHOTREXATE|daily oral treatment with CAPECITABINE, CELECOXIB and METHOTREXATE
1673808|NCT01668667|Drug|GSK1838262 600 mg|Drug: GSK1838262 600 mg/day Comparison of 3 doses
1673809|NCT01668667|Drug|GSK1838262 450 mg|Drug: GSK1838262 450 mg/day Comparison of 3 doses
1673810|NCT01668667|Drug|GSK1838262 300 mg|Drug: GSK1838262 300 mg/day Comparison of 3 doses
1673811|NCT01668667|Drug|GSK1838262 Placebo match|Drug; GSK1838262 placebo to match 600 mg, 450 mg, 300 mg doses
1673812|NCT01668654|Drug|retigabine/ezogabine|retigabine/ezogabine will be administered three times a day (TID) as add-on therapy based on weight
1673813|NCT01668641|Drug|GLPG0634|
1673814|NCT01668641|Drug|Placebo|
1673815|NCT01668615|Drug|all-trans-retinoid acid|10 mg three times a day oral administration for 4 months
1673816|NCT01668602|Other|Fast walking and FES|Fast treadmill walking with electrical stimulation delivered to the ankle dorsi- and plantar-flexor muscles
1673817|NCT01668602|Other|Fast treadmill walking|Fast treadmill walking without electrical stimulation
1673818|NCT01668563|Procedure|surgical management|Surgical clipping will be performed as soon as possible following randomization, according to standards of practice, and under general anesthesia. Aneurysms thought by the treating physicians to require deliberate permanent proximal vessel occlusion, construction of a surgical bypass, or other flow-redirecting treatments that do not directly clip the aneurysm will not be excluded; these non-ISAT aneurysms are expected to be more difficult lesions to manage surgically as well as endovascularly.
1673819|NCT01668563|Procedure|Endovascular management|Endovascular treatment will also be performed as soon as possible following randomization,according to standards of practice, and under general anesthesia. Details regarding type of coils, use of adjunctive techniques such as balloon-remodeling, stents or flow-diverters, as well as post-treatment medical management issues, will be left up to the physician performing the endovascular treatment.
1673820|NCT01668550|Drug|AZD0424|"AZD0424 will be administered as a flat dose orally once a day. One treatment cycle consists of 28 days of continuous drug administration with AZD0424, with the flexibility to introduce treatment breaks if required due to cumulative toxicity.
Combination agents and treatment regimen with AZD0424 will be confirmed and approved at a later date."
1673821|NCT01668537|Biological|LF formulation of IMVAMUNE®|
1673822|NCT01668537|Biological|FD formulation of IMVAMUNE®|
1673823|NCT01668524|Drug|ATS907|Single dose of each of three increasing concentrations
1673824|NCT01668511|Biological|ABT-981|Injection
1673825|NCT01668511|Biological|Placebo|Placebo Injection
1673826|NCT01668498|Drug|Erythromycin|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
1673827|NCT01668498|Drug|Doxycycline|Comparison of efficacy of Arm A erythromycin cream 2% daily at bedtime (doxycycline 100mg b.i.d.if skin toxicity CTC° ≥2) and Arm B doxycycline 100mg b.i.d. in patients with Metastatic Colorectal cancer (Ras wild-type)being treated with panitumumab.
1673863|NCT01668095|Other|Laboratory Biomarker Analysis|Correlative studies
1673925|NCT01667575|Drug|Clarithromycin|antibiotic of the quadruple therapy
1674315|NCT01664650|Dietary Supplement|Genistein|
1673828|NCT01668485|Procedure|Hypoglycemic and euglycemic glucose clamp|Each study participant will be subjected to a continuous infusion of insulin at a rate of 0.8 mU·kg−1·min−1 to induce hypoglycemia (blood glucose 2.8-3 mmol/l) for 30 minutes. At least two weeks later an identical insulin infusion will be administered and euglycemia (blood glucose 5 mmol/l) will be targeted. The order of these interventions will be subject to randomization.
1673829|NCT01668459|Drug|Cabazitaxel|25 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: maximum 6
1673830|NCT01668459|Other|Best Supportive Care|Best Supportive Care including single agent chemotherapy as determined by the patient's study physician
1673831|NCT01668446|Drug|Sildenafil|sildenafil tablets(50 mg) daily
1673832|NCT01668446|Drug|estradiol valerat|
1673833|NCT01668433|Drug|Regimens (Primaquine, Methylene blue)|Primaquine 45 mg single dose Or Methylene Blue 600 mg single dose followed by Methylene Blue 600 mg single dose or Primaquine 45 mg single dose.
1673834|NCT01668420|Other|thermal stimulation|hot and cold/warm and cool pads applying.
1673835|NCT01668407|Device|Robot-assisted walking (G-EO-System End Effector lower limb Robot)|A group A (GA) of subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the GE-O system device, according to individually tailored exercise scheduling. The practice will include robot-assisted walking at variable speeds for 45 min with a partial body weight support (BWS). All participants started with 30-40% BWS and an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h before BWS will be decreased.
1673836|NCT01668407|Procedure|Inpatient rehabilitation|"A group B (CG) of subjects (at least 40 subjects) will undergo inpatient rehabilitation consisting of a treatment cycle using the treadmill device, according to individually tailored exercise scheduling. The practice included treadmill walking at variable speed for 45 minutes. All participants will start at an initial treadmill speed of 1.5 km/h speed will be increased to a range of 2.2 to 2.5 km/h.
All the treatment consists of 20 sessions for the lower limbs, each lasting 45 minutes, 5 days a week for 4 weeks."
1673837|NCT01668394|Behavioral|Learning and coping arm|Participation of experienced patients as co-educators. Completion of two individual clarifying interviews. Teaching style: situated, reflective, inductive.
1673838|NCT01668394|Other|Control arm|Usual care. Teaching style: deductive.
1673839|NCT01668381|Procedure|radiofrequency ablation|the patients are prepared by local anesthesia and intravenous sedative.guided by the ultrasound,the antenna used for radiofrequency ablation ablation is placed in the tumor to destroy tumor tissues,the output power and duration are depended by the tumor volume and location.
1673840|NCT01668368|Other|esophageal balloon|esophageal pressure as a surrogate for pleural pressure
1673841|NCT01668355|Other|Patient Aligned Care Team (PACT)|A integrated healthcare model to coordinate and address physical health needs. The PACT model to be implemented here will be specially designed for individuals with serious mental illness.
1673842|NCT01668342|Behavioral|SMS assessments & feedback|Daily symptom assessments tied to tailored feedback
1673843|NCT01668316|Behavioral|Weight loss|"Participants will be prescribed a reduced calorie diet and asked to track their diet three days per week using the online USDA MyPlate SuperTracker. This record will be accessed by the RD in order to provide diet recommendations sent by email.
Participants will be given an exercise prescription, and encouraged to walk briskly with a provided pedometer or exercise at the campus Recreation Center every day. Participants will be asked to record the number of steps and other physical activity in a log book.
Participants will meet with the research staff every other week to measure weight, waist and hip circumference, and record the steps from the pedometer.
Participants will be encouraged to breastfeed their baby and provided with resources for pumping breast milk at work."
1673844|NCT01668303|Behavioral|Miami Juvenile Drug Court-MDFT|MDFT assesses and intervenes in five domains: 1) Interventions with the adolescent, 2) interventions with the parent, 3) interventions to improve the parent-adolescent relationship, 4) interventions with other family members, and 5) interventions with external systems.
1673845|NCT01668303|Behavioral|Miami Juvenile Drug Court -TAU|Each client is provided with a primary outpatient counselor who develops a treatment plan to address long-range goals. Family members are included in an assessment and treatment planning session at the beginning of treatment, but no formal family therapy is provided. Group therapy topics include self-esteem enhancement, decision-making skills, stress/anger management, communication skills, health education, teen pregnancy prevention, and occupational/career planning.
1673846|NCT01668277|Drug|7.2% NaCl|
1673847|NCT01668277|Drug|0.9% NaCl|
1673848|NCT01668264|Procedure|Echocardiograph|
1673849|NCT01668264|Procedure|Magnetic Resonance Imaging (MRI)|
1673850|NCT01668225|Procedure|Blood test|"Taking blood sample of the patient during the day 3, triggering day, oocyte collection day and pregnancy test day.
Taking the follicular fluid during the oocyte collection day"
1673851|NCT01668212|Procedure|Doppler ultrasound|Doppler Ultrasound
1673852|NCT01668199|Drug|TZP-101|
1673853|NCT01668186|Genetic|Next-generation panel|Molecular testing will be offered to participants whose mutations have not been found. Molecular testing will be done with a next-generation panel of 75 genes on a research basis. Genetic counselling services are available to participants.
1673854|NCT01668186|Other|Consultation in Ophthalmology|Participants seen in consultation will have an OCT (optical coherence tomography) eye exam and FAF (fundus autofluorescence) photography.
1673855|NCT01668173|Drug|AUY922|AUY922 will be administered as an intravenous infusion over 60 minutes, on a once weekly schedule. A cycle on study will be defined as 28 days. The dose to be studied are 70 mg/m2 and 55 mg/m2 if DLTs are identified in the first 3-6 patients. The same schedule of administration will be used for all patients in this trial.
1673856|NCT01668160|Procedure|Bead placement during revision hip replacement surgery|Tantalum beads will be placed in the surrounding pelvic and femoral bone and the polyethylene component during surgical treatment of failed primary THA components
1673857|NCT01668147|Drug|[11c] desmethyl-loperamide (dLop)|intravenous administration of 10-14 mCi of [11C] desmethyl-loperamide (dLop) with PET/CT imaging
1673858|NCT01668147|Drug|Ritonavir|Pretreatment with oral ritonavir for 3 days followed by intravenous administration of 10-14 mCi of [11C]dLop with PET/CT imaging
1673859|NCT01668147|Drug|Efavirenz|Pretreatment with oral efavirenz for 14 days followed by intravenous administration of 10-14 mCi of [11C]dLop with PET/CT imaging
1673860|NCT01668134|Radiation|Stereotactic radiation|
1673864|NCT01668082|Procedure|surgical resection of a brain tumor|The patient will undergo surgical removal of the tumor after infusion of 13C-glucose using standard neurosurgical technique, including frameless stereotaxy for surgical navigation, and microsurgical technique.
1673865|NCT01668069|Drug|Ondansetron|Ondansetron 4mg and a placebo capsule to be taken orally every 8 hours for 5 days.
1673866|NCT01668056|Drug|Ovulation induction with choriogonadotropin alfa|Administration of 250 micrograms of choriogonadotropin alfa subcutaneously when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
1673867|NCT01668056|Procedure|Aspiration of the dominant follicle|Aspiration of all follicles greater than 10mm in mean diameter when the dominant follicle of a natural menstrual cycle reaches 16mm or more of mean diameter. Aspiration will be guided by transvaginal ultrasound. Verify if this intervention is able to induce follicular wave emergence and synchronize the start of the flexible GnRH antagonist protocol of ovarian stimulation with the start of a follicular wave.
1673868|NCT01668056|Other|Control|Conventional flexible GnRH antagonist protocol of ovarian stimulation for in vitro fertilization, with gonadotropin star at the third day of a natural menstrual cycle.
1673869|NCT01668043|Drug|Antibody UB-421|UB-421 is administered by intravenous infusion
1673870|NCT01668030|Drug|Enzymatic agent|Enzymatic agent
1673871|NCT01668030|Drug|Bacitracin|
1673872|NCT01668017|Drug|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 30 mg twice a day (BID) in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
1673873|NCT01668017|Drug|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
1673874|NCT01668017|Drug|Pimasertib|Subjects with solid tumor will be administered with Pimasertib 60 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
1673875|NCT01668017|Drug|Pimasertib|Subjects with HCC will be administered with Pimasertib 30 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
1673876|NCT01668017|Drug|Pimasertib|Subjects with HCC will be administered with Pimasertib 45 mg BID in 21-day cycles until disease progression, intolerable toxicity, investigators decision to discontinue treatment or withdrawal of consent by the subject.
1673877|NCT01668004|Biological|Golimumab|GLM 50 mg subcutaneously once monthly.
1673878|NCT01667978|Drug|Norethindrone acetate|
1673879|NCT01667965|Behavioral|questionnaires|Questionnaires will be given before the patient watches a video educational tool to aid informed consent about palliative radiation therapy; and (2) after the patient watches the video educational tool. (3) If the patient receives PRT, a final questionnaire that assesses the patient's impression of the video will also be administered at the conclusion of radiation therapy.
1673880|NCT01667952|Genetic|Family History Questionnaire (FHQ)|"Consented subjects will be given the Family History Questionnaire (FHQ) to complete either in clinic or at home. Subjects who chose to complete the FHQ at home will be given a stamped envelope with a label. For participants who are children and cannot fill out the questionnaire on their own, the clinic RSA will instruct the parent, guardian, or legally authorized representative (LAR) present to fill out the questionnaire, reminding them that the You in the questionnaire refers to their child."
1673881|NCT01667952|Genetic|Salvia sample|The saliva samples will be collected in Oragene DNA Self-Collection Kits or a similar product. Patients will be instructed to donate about 2ml of saliva into a vial, which contains 2ml of product. Oragene or similar solution.
1673882|NCT01667952|Other|Blood sample|Subjects will be offered the option of a blood collection instead of saliva. For adult subjects who opt for blood collection, two tubes of blood (approximately 20cc) will be drawn from the utilizing a sterile technique. For subjects under the age of 18 who opt for blood collection, approximately 3-5cc of blood will be collected utilizing a sterile technique.
1673883|NCT01667939|Behavioral|Healthy Eating Index (HEI) in supervised pregnancies|Dietetic treatment was calculated according to height, weeks of gestation and weight, considering an energy intake of 30 kcal/kg of expected weight, distributing the resulting energy according to the percentage of macronutrients' adequation (55-65% carbohydrates, 10-20% fat and the remainder as proteins).16 On each nutritional visit, 24 hour dietary recall was done and analyzed using NutriKcal®VO software in order to evaluate the Healthy Eating Index (HEI), which is commonly employed to assess pregnant women's dietary adequacy (on a scale from 0-100), through the consumption of 12 components of food groups described previously. An improvement in diet was considered when the initial HEI score improved more than one point during the next nutritional assessment.
1673884|NCT01667926|Drug|Ketamine|ketamine infusions twice a week for three weeks, total of 6 infusions as augmentation of ongoing antidepressant regimen.
1673885|NCT01667926|Drug|Placebo|
1673886|NCT01667913|Other|6 minutes walking test|
1673887|NCT01667900|Drug|Dulaglutide|
1673888|NCT01667900|Drug|Placebo|Administered SQ in the placebo arms and to maintain the blind in the dulaglutide arms.
1673889|NCT01667874|Drug|Collatamp G sponge|Collatamp G is an antibiotic impregnated sponge
1673890|NCT01667848|Device|Optitherm® device activated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was only activated by the single scrub nurse in those patients randomized to group B.
1673891|NCT01667848|Device|Optitherm® device inactivated|The use of Optitherm® device, which was attached to the insufflation equipment in all of the patients but was inactivated in group A.
1673892|NCT01667835|Behavioral|Yoga Intervention|12 week 90 minute hatha yoga session offered three (3x) per week. Hatha yoga is a form of structured physical exercises known as asanas, combined with breathing exercises called pranayama, and relaxation techniques. The yoga intervention consists of 9 different yoga poses (asanas) and 3 different breathing exercises (pranayama) that can be easily replicated and readily performed by individuals who are middle-aged and older, overweight, unfit, or who suffer from a chronic illness.
1673893|NCT01667822|Behavioral|Continued self help CBT|After the initial Guided self help, patients in this arm continue the same self help program with 1 additional guiding session.
1673894|NCT01667822|Behavioral|Individual CBT|After the initial face of self help CBT, patients in this arm receive individual CBT. The cognitive behavior therapy used in the study will be based on the protocols with best empirical support.The therapy is delivered by the same psychologist as in the first face and the second face builds on the learning's from the first face.
1673895|NCT01667809|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
1673896|NCT01667809|Behavioral|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
1673897|NCT01667796|Dietary Supplement|Vitamin D3|
1673898|NCT01667783|Procedure|Gastric Banding|Laparoscopic Adjustable Gastric Banding using the LapBand
1673899|NCT01667783|Behavioral|Medical Weight Loss|Weight loss intervention using diet (meal replacments), physical activity and behavioral techniques administered with weekly one-on-one counselling by dieticians
1673900|NCT01667783|Procedure|Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass
1673901|NCT01667770|Procedure|decompression of Chiari malformation|Removal of a small section of bone at the back of the skull (posterior foramen magnum decompression) or upper cervical spine. During surgery, the covering of the brain (dura) is enlarged with a graft (autologous or non-autologous).
1673902|NCT01667744|Drug|Citalopram|10 mg/day
1673903|NCT01667731|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
1673904|NCT01667731|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1673905|NCT01667718|Drug|Bismuth|Bismuth 220mg b.i.d for 2 weeks
1673906|NCT01667718|Drug|Lansoprazole|Lansoprazole 30 mg b.i.d.for 2 weeks
1673907|NCT01667718|Drug|Levoﬂoxacin|Levoﬂoxacin 0.5 q.d. for 2 weeks
1673908|NCT01667718|Drug|Amoxicillin|Amoxicillin 1 g b.i.d. for 2 weeks
1673909|NCT01667692|Drug|azithromycin|Azithromycin (Zithromax, Azithrocin ) is an azalide, a subclass of macrolide antibiotics. Azithromycin is one of the world's best-selling antibiotics.[1] It is derived from erythromycin, with a methyl-substituted nitrogen atom incorporated into the lactone ring, thus making the lactone ring 15-membered.
1673910|NCT01667692|Drug|clarithmycin|Clarithromycin is a macrolide antibiotic used to treat pharyngitis, tonsillitis, acute maxillary sinusitis, acute bacterial exacerbation of chronic bronchitis, pneumonia (especially atypical pneumonias associated with Chlamydophila pneumoniae), skin and skin structure infections. In addition, it is sometimes used to treat legionellosis, Helicobacter pylori, and lyme disease.
1673911|NCT01667679|Drug|100 mg Sumatriptan Tablet and OPTINOSE Placebo delivered nasally|
1673912|NCT01667679|Drug|OPTINOSE SUMATRIPTAN delivered nasally and placebo tablet|
1673913|NCT01667666|Drug|Nebulized hypertonic saline|The first 5 patients will receive 3% hypertonic saline in a nebulizer, the second 5 patients will receive 4.5% nebulized hypertonic saline, the third group 6% nebulized hypertonic saline, and the fourth group of 5 patients will receive 7% nebulized hypertonic saline. The nebulizer is dosed 2-3 times a day for 36 hours.
1673914|NCT01667653|Dietary Supplement|Probiotic|Probiotic capsule once daily
1673915|NCT01667653|Dietary Supplement|Placebo|Placebo capsule once daily
1673916|NCT01667640|Radiation|sector irradiation|"Gross Tumor Volume (GTV) is defined as the visible margin of the resection on post- operative MRI and planning- CT-scan. The Clinical Treatment Volume (CTV) is the same as the GTV plus a 5 mm margin The Planning Treatment Volume (PTV) includes the CTV plus a 1mm margin.
A non-invasive immobilization is used for the planning CT and treatment delivery with an accuracy of ≤ 1mm.
Treatment planning will conform to ICRU 50/62 rules for coverage of GTV, CTV and PTV. Additionally, organs at risk are delineated according to the ICRU 62 rules.
Treatment with radiotherapy will start 2 to 3 weeks after surgery. The prescribed dose for the PTV is 30 Gy in 5 fractions.
Isodose distributions will be calculated through the target in three planes. Dose volume histograms will be reported."
1673917|NCT01667640|Radiation|whole brain irradiation|"For whole brain radiation the entire brain, the base of the skull and the meninges are included.
Radiation is performed fractionated with 40 Gy. The caudal boundary of the radiation-target volume is between the 2. and the 3. cervical vertebra. The radiation is performed via two lateral, opposing and isocentric contra fields. The face/ventral skull is shielded with individual blocs or MLC.
The used energy for the radiation fields should be between 6 and 16 MV. The specification point of the dose or the standardization point has to be chosen in that way that the point is in the middle of the target volume. The target volume is radiated within the tolerance range of 95% - 107 %. The maximum/minimum doses in the target volume and possible doses peaks are documented."
1673918|NCT01667627|Dietary Supplement|Bio-25|"Each capsule of the multispecies probiotic combination Bio-25 consists of 25 billion live bacteria.
Each type of bio-25 contains billions of live lactic acid bacteria in defined ratios of lyophilized Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasein, Lactobacillus casei, Bifidobacterium bifidum,Lactobacillus lactis, Lactobacillus rhamnosus,and Streptococcus thermophilus."
1673919|NCT01667614|Drug|spironolacone 25 mg tablets added to losartan|spironolactone 25 mg once daily added to losartan
1673920|NCT01667601|Other|Routine Care|Psychiatric outpatient care provided by the outpatient departments, e.g., medical consultation, brief education by psychiatric nurses and financial advices or referrals by social workers.
1673921|NCT01667601|Behavioral|Mindfulness-based program|The program was based on the psychoeducation programs by Chien et al and Lehman et al, as well as the 8-session Mindfulness-Based Stress Reduction Program by Kabat-Zinn(1990).
1673922|NCT01667601|Behavioral|Psychoeducation group|A 5-month patient psychoeducation group program (12 sessions) led by the research team will be provided.
1673923|NCT01667575|Drug|Esomeprazole|antisecretary drug of the quadruple therapy
1673924|NCT01667575|Drug|Amoxicillin|antibiotic of the quadruple therapy
1673926|NCT01667575|Drug|Bismuth Potassium Citrate|one of a component of a quadruple therapy
1673927|NCT01667575|Other|long duration (14 day)|
1673928|NCT01667562|Drug|Erlotinib|Daily oral doses administered until disease progression or unacceptable toxicity or death.
1673929|NCT01667549|Other|Timing of Diet and Flavor Experience|Groups differ in the timing and duration of exposure to flavored food experience.
1673930|NCT01667536|Drug|Drug: 99mTc-MIP-1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc-MIP-1404
1673931|NCT01667523|Dietary Supplement|Capsaicin|1.5 mg capsaicin administered intraduodenally
1673932|NCT01667523|Dietary Supplement|Cinnamaldehyde|70 mg per intervention administered intraduodenally
1673933|NCT01667523|Dietary Supplement|Placebo|Physiological saline
1673934|NCT01667510|Dietary Supplement|Cardio Mato (tomato extracted lycopene)|Soft gel capsule for oral use
1673935|NCT01667510|Dietary Supplement|Placebo|Soft gel capsule without test material
1673936|NCT01667497|Drug|Fampridine SR|
1673937|NCT01667497|Drug|Placebo|
1673938|NCT01667484|Drug|Adderall XR 5mg|
1673939|NCT01667484|Drug|Adderall XR 10 mg|
1673940|NCT01667484|Drug|Placebo|
1673941|NCT01667471|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
1673942|NCT01667445|Drug|Epimorph|Patient to receive 150ug of Epimorph with Spinal anaesthetic. Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
1673943|NCT01667445|Drug|Spinal analgesia|Patient to receive only Spinal anaesthetic (NO EPIMORPH). Injection Cocktail includes: 10mg Morphine, 30mg Ketorolac, 3.5ug/ml (385ug total) of Ropivicaine, 2.5ug /ml (275ug total) Epinephrine with the remainder of the solution made of Normal Saline to a total volume of 110ml.
1673944|NCT01667432|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a commercial product (PEGASYS®) was supplied as a solution in prefilled syringes.
1673945|NCT01667419|Drug|Vemurafenib|4 tablets of vemurafenib 240 mg each (total 960 mg) will be administered orally as per the schedule specified in the respective arm.
1673946|NCT01667419|Drug|Placebo|Placebo matching to vemurafenib will be administered orally as per the schedule specified in the respective arm.
1673947|NCT01667406|Drug|kisspeptin|kisspeptin doses between 1.6 and 12.8 nmol/kg subcutaneously
1673948|NCT01667393|Device|IDEV SUPERA Stent|
1673949|NCT01667393|Device|Percutaneous Transluminal Angioplasty|
1673950|NCT01667367|Drug|RG1662|Single oral dose
1673951|NCT01667367|Drug|placebo|Single oral dose
1955114|NCT03290456|Drug|Placebo 5mg/day extended of 9 additionnal months.|1mg/week orally tapering Prednisone until Month 1 + Placebo orally 5mg/day until Month 10
1673953|NCT01667341|Biological|GEN-003 with Matrix M-2|IM administration of GEN-003 Vaccine with 50ug Matrix M-2 Adjuvant.
1673954|NCT01667341|Biological|GEN-003|IM administration of GEN-003 Vaccine, antigens alone (without adjuvant).
1673955|NCT01667341|Biological|Placebo|IM administration of 0.5 mL dose of Dulbecco's phosphate buffered saline.
1673956|NCT01667328|Procedure|Massage therapy|Presurgical 15 minute massage performed by a licensed massage therapist
1673957|NCT01667328|Procedure|Standard of care|Control group will receive standard of care with no massage therapy
1673958|NCT01667315|Drug|Bupivacaine 0,375%|Positive or negative block results in a 1-mL reduction or increase in volume, respectively.
1673959|NCT01667302|Drug|Radiotherapy followed by chemotherapy|Radiotherapy Technique: IMRT Total dose: 50 Gy Per fraction: 2 Gy Chemotherapy: q3w Dexamethasone 40 mg d1-4 Ifosfamide 1200mg/m2 d1-4 Etoposide 60 mg/m2 d1-4 Cisplatin 20mg/m2 d1-4 Peg-asparaginase 2000 IU/m2 d1
1673960|NCT01667289|Radiation|Radiotherapy alone|Radiotherapy alone Technique: IMRT Total Dose: 50 Gy Per fraction: 2 Gy
1673961|NCT01667289|Drug|Concurrent chemoradiation|"Concurrent chemoradiation
Chemotherapy:
Methotrexate 40 mg/m2 weekly X 5 Radiotherapy Technique: IMRT Total dose: 50 Gy Per Fraction: 2 Gy"
1673962|NCT01667263|Drug|All-trans retinoic acid|
1673963|NCT01667263|Drug|Danazol|
1673964|NCT01667250|Device|GammaCore Active Device|
1673965|NCT01667250|Device|GammaCore Sham Device|
1673966|NCT01667237|Behavioral|Home-based pulmonary rehabilitation program|The rehabilitation program will be a self-monitored and minimally supervised home-exercise program. Exercise training modalities and intensity will be adapted to patient's individual condition. It will include aerobic and strength exercises 5 times a week for 4 weeks. Aerobic training will be done on a portable ergocycle. The target intensity will correspond to 60% of the maximal work rate achieved during the maximal progressive cardio-pulmonary exercise test, aiming for a cumulative time of 40 minutes per day. The heart rate, corresponding to an exercise level of 60% of max exercise capacity during the maximum exercise test, will be noted and patients will be instructed to train at this heart rate ± 10 beats. Muscle exercises will be performed using elastic bands and use of gravity.
1673967|NCT01667224|Dietary Supplement|Actiponin|The dried leaves of G. pentaphyllum leaves were extracted with 50% ethanol and filtered; the filtrate was concentrated under high pressure and high temperature. Damulin An and B, analytical marker of Actiponin, exist more 2.49% and 1.06% respectively in raw material.
1673968|NCT01667224|Dietary Supplement|Placebo|Amount and calorie of placebo are same with Actiponin.
1673969|NCT01667211|Drug|albumin-bound paclitaxel plus nedaplatin|intravenous albumin-bound paclitaxel, 175-200 mg/m2, d 1, was given every 3 weeks, combined with intravenous nedaplatin, 80- 100 mg/m2, d 2. At least 2 cycles will be completed for each patient, for whom responds to study treatment, 4-6 cycles will be completed.
1673970|NCT01667198|Procedure|Train the leaders course|Screening centre leaders randomized to the training intervention group will be invited to take part in a train-the-leaders course. The Train-the-leaders course will consist of three phases: (i) pre-training assessment, (ii) hands-on-training and (iii) post-training evaluation and feedback. The Train-the-leaders course will be run in polish by the team from the Maria Sklodowska-Curie Memorial Cancer Center and Institute on Oncology, Warsaw, which was trained in delivering such intervention by experts from the United Kingdom.
1674101|NCT01666223|Drug|Chenodeoxycholic Acid|1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
1725070|NCT00005836|Drug|oxaliplatin|
1673971|NCT01667198|Behavioral|Audit and feedback|Screening centre leaders randomized to the feedback group will receive (by e-mail and conventional mail) feedback on their individual screening colonoscopy quality indicators (adenoma detection rate and ceacal intubation rate) measured for the 2011 edition of the national screening program. The results will be presented in a league table in order to enable comparison with anonymous results of all endoscopists who performed at least 30 colonoscopies within the screening program. In addition, a link to a webpage containing data on individual and overall colonoscopy quality indicators over the last four years of the screening program will be provided.
1673972|NCT01667172|Device|Point-of-Care C Reactive Protein measurement on capillary blood|capillary blood fingerstick method to determine C Reactive Protein level in the blood
1673973|NCT01667159|Behavioral|Integrated Cognitive Behavioral Therapy|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions delivered at least 1-2x each week for 6 months.
1673974|NCT01667159|Behavioral|Standard Care|Intensive outpatient therapy with teens and their parents using a variety of eclectic treatments that characterize standard care for adolescents.
1673975|NCT01667146|Other|PHARLAP mechanical ventilation strategy|Pressure control ventilation to maintain tidal volume 4-6 ml/kg and plateau pressure ≤ 30 cmH2O while tolerating respiratory acidosis if pH > 7.15; daily staircase recruitment manoeuvre and individualised PEEP titration.
1673976|NCT01667146|Other|Control group mechanical ventilation strategy|Mechanical ventilation based on the ARDSnet protocol using volume control ventilation with tidal volume 6 ml/kg, plateau pressure ≤ 30 cmH2O and FiO2/PEEP titration according to a FiO2/PEEP/oxygen saturation combination chart. This has been modified for Australian and New Zealand practice to allow pressure control and pressure support ventilation.
1673977|NCT01667133|Drug|ponatinib - Phase 1|30 mg dose of ponatinib taken orally once daily for at least the first 6 patients. If no dose-limiting toxicities are observed, the next patients will receive 45 mg dose of ponatinib taken orally once daily. Once the recommended dose is confirmed, all patients may receive the recommended dose, at the investigators' discretion.
1673978|NCT01667133|Drug|ponatinib - Phase 2|Recommended dose of ponatinib as determined in the dose escalation phase. In addition, 3 patients will receive 15 mg dose once daily for 8 days for PK testing. These PK patients may be allowed to receive the recommended dose after PK testing is complete, at the investigators' discretion.
1673979|NCT01667120|Drug|Ketorolac|Ketorolac 0.5mg/kg IV q8h x 72h.
1673980|NCT01667120|Drug|placebo|
1673981|NCT01667107|Drug|Posaconazole|
1673982|NCT01667107|Drug|Calogen®|
1673983|NCT01667094|Drug|Intermittent, short infusion Ceftazidime|Ceftazidime 1g q8/24
1673984|NCT01667094|Drug|Continuous infusion Ceftazidime|Ceftazidime loading dose 1g infused over 30mins then 3g infused over 12h q12/24
1673985|NCT01667094|Drug|Intermittent, short infusion Meropenem|Meropenem 1g q8/24, infusion over 30 minutes
1673986|NCT01667094|Drug|Continuous infusion Meropenem|Meropenem initial loading dose of 500mg infused over 30 minutes followed by 1.5g infused over 12/24, q12/24
1673987|NCT01667094|Drug|Intermittent, short infusion Ticarcillin-clavulanate|Ticarcillin/clavulanate 3.1g q6/24
1673988|NCT01667094|Drug|Continuous infusion Ticarcillin-clavulanate|Ticarcillin-clavulanate loading dose 1.55g followed by 12.4g infused over 24/24 q24/24
1673989|NCT01667094|Drug|Intermittent, short infusion Cefepime|Cefepime 1g q8/24
1673990|NCT01667094|Drug|Continuous infusion Cefepime|Cefepime loading dose 500mg followed by 1.5g infused over 12/24, q12/24
1673991|NCT01667094|Drug|Continuous infusion Piperacillin tazobactam|Piperacillin tazobactam loading dose of 4.5g infused over 30 minutes followed by 18g infused over 24/24, q24/24
1673992|NCT01667094|Drug|Intermittent, short infusion Piperacillin tazobactam|Piperacillin tazobactam 4.5g q6/24
1673993|NCT01667081|Drug|Grazoprevir|Participants previously received study treatment with grazoprevir at the dose and frequency specified in the study protocol. Grazoprevir was not administered to participants in the course of this follow-up study.
1673994|NCT01667068|Other|Comprehensive non invasive cardiovascular examination|"Anamnesis with the participian
File recherche,Physical examination
Documentation of the carciovascular and antiretroviral medical therapy
Electrocardiogram
Transthoracic echocardiography
Exercise electrocardiogram
Measuring of the arterial media thickness
Exercise Montreal Cognitive Assesment test
Exercise the Grooved Pegboard test
Blood collection
Questionnaire to quality of life and health economics"
1673995|NCT01667029|Drug|Sulfasalazine|
1673996|NCT01667029|Drug|placebo|
1673997|NCT01666990|Drug|TwHF|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
1673998|NCT01666990|Drug|placebo treatment|Taken oral, three times per day, at a dose of 20 mg/time for 48 weeks.
1673999|NCT01666977|Drug|AMG 386|15mg/kg
1674000|NCT01666977|Drug|AMG 386|30 mg/kg
1674001|NCT01666977|Drug|AMG 386 Placebo|AMG 386 Placebo
1674002|NCT01666977|Drug|Pemetrexed|Pemetrexed 500 mg/m2
1674003|NCT01666977|Drug|Carboplatin|Carboplatin AUC 6
1674004|NCT01666964|Other|Blast Traumatic Brain Injury|Exposure during combat to blast-wave mediated Traumatic Brain Injury
1674005|NCT01666951|Drug|LCP-Tacro tablets|Tacrolimus
1674006|NCT01666951|Drug|Prograf|Tacrolimus
1674007|NCT01666938|Other|Diabetes Education Group|Diabetes Education Group: Diabetes Education for four month, one time per week.
1674008|NCT01666938|Other|Telephone Counseling|Telephone counseling: 12 phone calls for four months about physical activity. During the first and second month, was done four phone calls each month. During the third and fourth month, was done two phone calls per month.
1674009|NCT01666925|Biological|ChAd63 ME-TRAP / MVA ME-TRAP prime-boost immunisation|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu
1674010|NCT01666925|Biological|Rabies vaccine|2 x 2.5IU Verorab
1674011|NCT01666912|Drug|Contraceptive implant|
1674012|NCT01666899|Procedure|Skin and blood vessel procedures|Biopsies, skin blood flow studies and ultrasound studies will be performed as described.
1674013|NCT01666886|Device|Mandibular Advancement Device (MAD)|
1674014|NCT01666873|Procedure|patients that undergo a total knee prosthesis|
1674015|NCT01666860|Procedure|Anterior Lumbar Interbody Fusion procedure|
1674102|NCT01666223|Other|saline|100 ml saline
1674316|NCT01664650|Dietary Supplement|Placebo|
1725071|NCT00005837|Drug|oxaliplatin|
1674016|NCT01666847|Procedure|Milking the umbilical cord before cord clamping|The procedure will involve positioning the neonate below the level of the placenta and milking approximately 20cm of umbilical cord three times over 10-20 seconds total from the placental end to the neonate. The cord will then be clamped and the neonate handed to the awaiting medical team for routine care of a premature infant.
1674017|NCT01666821|Other|Follow-up observation|a epidemiologic survey of ocular diseases in an adult population (>45 years old) in Youyi Street, Baoshan District, Shanghai, China, conducted to determine the prevalence of AMD in the region. To this end, we utilized routine ocular examinations
1674018|NCT01666808|Drug|FACBC|FACBC is given intravenously prior to PET scan
1674019|NCT01666808|Radiation|Radiation therapy|External beam radiotherapy to prostate bed +/- pelvic lymph nodes; final dose of 66.6 Gy.
1674020|NCT01666782|Biological|Standard Trivalent Influenza Vaccine|Each 0.5 mL dose contains influenza split virus antigens formulated to contain a total of 45 mcg of influenza virus hemagglutinin, 15 mcg each from the 3 influenza virus strains in the vaccine.One dose given per patient.
1674021|NCT01666782|Biological|High-Dose Influenza Vaccine|Each 0.5 mL dose of Fluzone High-Dose contains influenza split virus antigens that are formulated to contain a total of 180 mcg of influenza virus hemagglutinin, 60 mcg each from the 3 influenza virus strains in the vaccine. One dose given per patient.
1674022|NCT01666769|Drug|Micafungin|4 mg/kg/day
1674023|NCT01666769|Drug|Micafungin|8 mg/kg/day
1674024|NCT01666769|Drug|Micafungin|Standard of care Dosing
1674025|NCT01666756|Dietary Supplement|Chinese herbal formulation PHY906|Given PO
1674026|NCT01666756|Drug|sorafenib tosylate|Given PO
1674027|NCT01666756|Other|laboratory biomarker analysis|Correlative studies
1674028|NCT01666756|Other|pharmacological study|Correlative studies
1674029|NCT01666743|Drug|Ceftaroline fosamil|IV ceftaroline fosamil 600 mg infused over 60 (± 10) minutes every 12 hours (dosing may be adjusted for renal impairment)
1674030|NCT01666730|Drug|metformin hydrochloride|Given PO
1674031|NCT01666730|Drug|oxaliplatin|Given IV
1674032|NCT01666730|Drug|leucovorin calcium|Given IV
1674033|NCT01666730|Drug|fluorouracil|Given IV
1674034|NCT01666730|Other|laboratory biomarker analysis|Correlative studies
1674035|NCT01666704|Drug|BMS-823778|Capsules, Oral, 2mg, Once daily, 1 year
1674036|NCT01666704|Drug|BMS-823778|Capsules, Oral, 15mg, Once daily, 1 year
1674037|NCT01666704|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0mg, Once daily, 1 year
1674038|NCT01666691|Drug|Beloranib|Subjects will receive ZGN-440 twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses. A range of doses will be evaluated.
1674039|NCT01666691|Drug|Placebo|Subjects will receive placebo twice-weekly subcutaneous injections for up to 12 weeks and a total of 24 doses.
1674040|NCT01666678|Drug|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fasting conditions
1674041|NCT01666678|Drug|Naproxen Sodium (Aleve, BAYH6689)|2 x Naproxen Sodium 220 mg under fasting conditions
1674042|NCT01666678|Drug|Diphenhydramine HCl|2 x Diphenhydramine HCl 25 mg under fasting conditions
1674043|NCT01666678|Drug|BAY98-7111|2 x Naproxen Sodium 220 mg / Diphenhydramine HCl 25 mg combination under fed conditions
1674044|NCT01666665|Drug|Metformin|Metformin up to 1000mg/m2 body surface area by mouth of feeding tube up to 3 times each day for 12 months
1674045|NCT01666665|Drug|Sugar pill|Sugar pill up to 3 times per day for 12 months
1674051|NCT01666639|Behavioral|Behavioral Medical Rehabilitation plus behavioral exercise therapy|"The Intervention Group is characterized by the same treatment as in the control group, plus a modification of the exercise therapy. An Behavioral Exercise Therapy (BET) is implemented in the usual care. The Behavioral Exercise Therapy is based on a goal-oriented and systematic combination of knowledge-, behavior-, and exercise-related elements. It had been developed prior as part of a multidisciplinary treatment and was adapted for this study. The Aims of BET are gradual improvements of individual coping competencies and self-management regarding back pain as well as long-term adherence to physical activity."
1674052|NCT01666639|Behavioral|Usual Behavioral Medical Rehabilitation|"The Behavioral Medical Rehabilitation (BMR), which is in this case the control group (usual care), consists of usual orthopedic medical care, exercise therapy, individual physiotherapy, psychological treatment elements (e.g. a pain management group), occupational therapy and back school. Pain medication is given if necessary. For the most part, the psychological elements draw a distinction between more traditional concepts or orthopedic rehabilitation and the BMR. The pain management group with its cognitive-behavioral principles comprises 9 sessions of 90 minutes each."
1674053|NCT01666626|Procedure|Ultrasound stiffness imaging|Subjects will undergo transabdominal ultrasound of the distal intestine. Distal intestine motion capture will be used for off-line stiffness assessment by two-dimensional speckle tracking. In addition, shear wave imaging will be used for real-time stiffness assessment.
1674054|NCT01666613|Drug|AZD8683|Solution for injection, administered as intravenous infusion Total dose of 100µg AZD8683
1674055|NCT01666613|Drug|AZD8683|Solution to be administered orally Total dose of 950 µg AZD8683
1674056|NCT01666613|Drug|AZD8683|Dry powder inhaled via New Dry Powder Inhaler, 540 µg delivered dose AZD8683
1674057|NCT01666613|Drug|AZD8683|Dry powder inhaled via Turbuhaler™, 600 µg delivered dose AZD8683
1674060|NCT01666587|Dietary Supplement|Antioxidant|
1674061|NCT01666587|Drug|Prostaglandin inhibitor (Ibuprophen)|
1674062|NCT01666574|Other|Test cereal 1, Oat-based|The study design is a lunch that will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
1674063|NCT01666574|Other|Test Cereal 2, Oat based|The study design is a two visit trial with each subject randomly receiving one of the cereals at each visit separated by at least a week. A lunch will be presented 4 hours after the start of breakfast. Subjects will be asked to eat until satisfied and food intake will be measured. The effect on hunger and satiety will be measured using visual analog scales before breakfast and at 30, 60, 120, 180, and 240 minutes following consumption.
1674064|NCT01666561|Other|Breakfast Test Cereal 1, Oat based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (a) one serving of oat based breakfast cereal 1.
1674065|NCT01666561|Other|Breakfast Test Cereal 2, Oat-based|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (b) an equicaloric amount of Oat based breakfast cereal 2.
1674066|NCT01666561|Other|Ready-to-eat cereal|The study design is a crossover trial with each subject receiving one of the cereals in each of three visits separated by at least a week will be enrolled to investigate the satiety impact of three breakfast cereals: (c) an equicaloric amount of the ready-to-eat cold cereal.
1674067|NCT01666535|Biological|Influenza vaccination|
1674068|NCT01666522|Drug|Vitamin D|vitamin D given orally as tablets at a dosage of 2000 IU/day for 4 months
1674069|NCT01666522|Other|Physical activity|Physical activity in the form of an exercise programme consisting of 60 minutes all inclusive warming up , strengthening, resistance and stretching exercises were instigated 3 times a week for 4 months.
1674070|NCT01666509|Device|Rossoseq™|
1674071|NCT01666509|Device|Placebo|
1674072|NCT01666496|Behavioral|Experimental Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
1674073|NCT01666496|Behavioral|Off the Shelf Video Game|Participants will play either the experimental or the control videogame for 6 weeks. Both interventions will be provided during 12 sessions, twice weekly for 6 weeks; each session will involve one and one-quarter hour of game play.
1674074|NCT01666483|Procedure|micro-laparoscopy|M-LPS hysterectomy was performed through one optical trans-umbilical 5 mm trocar and three 3 mm sovra-pubic ancillary ports. A 5 mm 0° endoscope and 3 mm laparoscopic instruments were utilized, choosing among graspers, cold scissors, suction/irrigation and bipolar coagulator.
1674075|NCT01666483|Procedure|Laparoendoscopic single site surgery|LESS hysterectomy was performed through a multi-channel single trocar inserted in the umbilicus using an open technique (1.5-2 cm cutaneous incision), as previously reported. Intra-abdominal visualization was obtained with a 0° 5-mm telescope with a flexible tip. Working straight 5-mm instruments were inserted into the remaining 2 ports, choosing among graspers, cold scissors, suction/irrigation bipolar coagulator and a multifunctional versatile laparoscopic device, which grasps, coagulates and transects simultaneously. In order to prevent clashing between instruments and surgeon's hands and to facilitate surgical manoeuvres, the combination of one 33 cm-long instrument with a 43 cm-long instrument was adopted. The umbilical fascia was closed with a figure-of-eight 0-Vicryl.
1674076|NCT01666470|Other|Questionnaires|DrHy-Q (Thai version) and WHOQOL-BREF-THAI will be asked
1674077|NCT01666457|Other|SOFFI|NICU nursing and multidisciplinary staff were trained to use the SOFFI infant driven feeding program. A small group of learners (20) were trained as resources via a 2-day course and the entire nursing staff received training during a 1-1.5 hour training lecture during their annual competencies.
1674081|NCT01666431|Drug|Lapatinib|
1674082|NCT01666418|Drug|Pazopanib/Paclitaxel|
1674083|NCT01666405|Device|Urgent(R) PC Neuromodulation System|The Urgent PC Neuromodulation System (Uroplasty, Inc., Minnetonka, MN, USA), device, is an easily administered neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. This method of treatment is referred to as percutaneous tibial nerve stimulation (PTNS).
1674084|NCT01666392|Dietary Supplement|Omega-3 fatty acid|Omega-3 fatty acid, Eicosapentaenoic acid+docosahexaenoic acid in capsule form
1674085|NCT01666392|Dietary Supplement|Placebo|Placebo
1674086|NCT01666379|Drug|Fentanyl|
1674087|NCT01666366|Procedure|Coronary artery bypass grafting|
1674088|NCT01666353|Radiation|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG)|PET/CT imaging with [18F] 2-deoxy-2-(18F)fluoro-D-glucose (FDG) is a potent diagnostic tool and is able to detect melanomas and other tumors, some of which are undetectable by CT.
1674089|NCT01666340|Other|Exercise intervention|Group asked to perform exercise at a given moderate intensity for a set time
1674090|NCT01666340|Other|Exercise intervention|High intensity exercise
1674091|NCT01666327|Drug|MT-1303|
1674092|NCT01666314|Drug|Orteronel|Orteronel tablets
1674093|NCT01666314|Drug|Orteronel Placebo|Orteronel placebo-matching tablets
1674094|NCT01666314|Drug|Prednisone|Prednisone 5 mg
1674095|NCT01666301|Drug|comparison between darbepoetin alfa and C.E.R.A. and different administration intervals|
1674096|NCT01666262|Biological|Vaccine A/17/CA/2009/38 (H1N1)|Pandemic Live Attenuated Influenza Vaccine (PLAIV) Candidate Strain A/17/CA/2009/38 (H1N1)
1674097|NCT01666262|Other|Placebo:Stabilizer|5% sucrose
1674098|NCT01666249|Biological|Immunoglobulin Anti-RhD|KamRho-D (Immunoglobulin Anti-RhD): single dose (300mcg/2mL), via intramuscular, up to 72h after delivery.
1674099|NCT01666236|Other|Triple Therapy|"The treatment (single group) will be treated with reduced-fluence Photodynamic Therapy (Visudyne -Verteporfin infused over 10 minutes at a dose of 6mg/m2 and following by activating light [wavelength of 689 nm] applied 15 minutes after the start of infusion with a light dose of either 25 J/cm2 for 83 seconds), followed by an Intra-vitreous triamcinolone (4mg/0.1ml) on the same day.
After 10 days, patients will be subjected to an injection of Intra-vitreous ranibizumab (0.5 mg/0.05 ml). After this first injection, Intra-vitreous ranibizumab will be repeated twice, on a monthly basis, for a total of three injections"
1674100|NCT01666223|Drug|Colesevelam|Colesevelam 3750 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
1674103|NCT01666223|Drug|Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg|Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
1674104|NCT01666210|Drug|OTX-DP (Dexamethasone punctum plug)|Sustained and tapered release of dexamethasone from hydrogel punctum plug
1674105|NCT01666210|Drug|Placebo Vehicle Punctum Plug|Hydrogel punctum plug without dexamethasone
1674106|NCT01666197|Drug|diclofenac potassium 25 mg tablet|diclofenac potassium 25 mg tablet
1674107|NCT01666197|Drug|placebo|placebo
1674108|NCT01666171|Drug|metformin hydrochloride|
1674109|NCT01666171|Other|clinical observation|
1674110|NCT01666171|Other|diagnostic laboratory biomarker analysis|
1674111|NCT01666171|Other|imaging biomarker analysis|
1674112|NCT01666171|Other|medical chart review|
1674113|NCT01666171|Procedure|digital mammography|
1674114|NCT01666158|Behavioral|Exercise|The exercise component will consist of 20 min of general exercise training, 3 days per week, alternating between aerobic and resistance training. The exercise program will be individualized based upon the baseline fitness test (according to the American College of Sport Medicine, ACMS, standard) and will include: a 5 min warm-up, either 25 min of aerobic exercise (starting at 30- 40 of heart rate reserve, HRR), or 25 min of resistance training (5 exercises targeting major muscle groups performed at an intensity of 8-12 repetition maximum), and a 5 min cool-down.
1674116|NCT01666132|Other|intramyocardial injection of BM cells|only intramyocardial, NOGA guided injection on BM cells.
1674117|NCT01666132|Other|intramyocardial / intracoronary injection of BM cells|combination of intramyocardial, NOGA guided injection of BM cells and intracoronary injection of those cells
1674118|NCT01666132|Other|Best medical therapy|initially no intervention; crossover to therapy 6 months after enrollment
1674119|NCT01666119|Drug|BEMA Buprenorphine NX films|BEMA Buprenorphine NX films (3.5/0.6 mg and 5.25/0.9 mg buprenorphine/naloxone) will be provided in 3.361 and 5.447 cm2 film sizes, respectively.
1674120|NCT01666093|Procedure|Angioplasty of the lower limbs vessels|Standard revascularization techniques will be used in the study
1674126|NCT01666067|Drug|placebo|
1674127|NCT01666067|Drug|vytorin|
1674128|NCT01666067|Drug|simvastatin|
1674129|NCT01666054|Other|PSV|Pressure Support Ventilation will be used until patient is extubated
1674130|NCT01666054|Other|PAV|Proportional Assist Ventilation will be used until patient is extubated.
1674131|NCT01666041|Drug|placebo|
1674132|NCT01666041|Drug|fenofibrate/omega|
1674133|NCT01666041|Drug|fenofibrate|
1674134|NCT01666028|Device|FlorenceD or similar closed loop glucose control system|Subject's glucose level will be controlled by the FlorenceD or similar automated closed loop glucose control system. The system comprises of FreeStyle Navigator® Continuous Glucose Monitoring (CGM) System (Abbott Diabetes Care, Alameda, CA, USA), Dana R Diabecare subcutaneous insulin infusion pump (Sooil Corp. Seoul, South Korea)or similar insulin pump, and MPC-based glucose control algorithm running on a portable computer.
1674135|NCT01666028|Device|CSII with real-time CGM|Subject glucose level controlled by usual insulin pump therapy in conjunction with real time continuous glucose monitoring (CGM)
1674136|NCT01666015|Other|EXERCISE (EX)|"This study will examine the effect of two phases of an EX program on several health related outcomes in pediatric patient undergoing autologous SCT. The first phase of the EX program will be an inpatient intervention and will begin when the child is hospitalized undergoing conditioning therapy and will continue until discharge.
The second phase will be a 10-week outpatient intervention, beginning once the child is discharged. We will utilize a mixed EX program, including supervised (at the University of Calgary) and home-based training incorporating the use of the Nintendo ® Wii device™ (Wii Fit, Wii Dance and Sports™ games)."
1674137|NCT01666015|Other|Standard Care|This group will be under standard care without any EX intervention.
1674138|NCT01666002|Device|Laser Treatment (Pulsed Nd:YAG 1064 nm Laser)|0.65 Millisecond Pulsed Nd:YAG 1064 nm Laser
1674139|NCT01665989|Behavioral|Group Lifestyle Program|
1674140|NCT01665989|Behavioral|Usual Care|Visits with a dietitian at nutrition services at MGH
1674141|NCT01665976|Drug|RO4917838|film coated tablet, single dose
1674142|NCT01665976|Drug|RO4917838|oral suspension, single dose
1674143|NCT01665976|Drug|RO4927838|hard gelatin capsule, single dose
1674144|NCT01665963|Device|TopClosure(c) System|
1674145|NCT01665963|Device|Pressure Bandage|
1674146|NCT01665950|Drug|Simvastatin|The study uses the Sequential Parallel Comparison design (SPCD), with two 4-week phases: n=30 subjects are randomized 1:1 to simvastatin versus placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 for a further 4 weeks. The SPCD will allow us to pool data from both phases to estimate the simvastatin treatment effect. Subjects who respond in phase 1, and all subjects who receive simvastatin in phase 1, continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
1674147|NCT01665950|Drug|Placebo|Subjects (n=15) are randomized to placebo add-on for 4 weeks, with the nonresponders re-randomized 1:1 to statin vs placebo for a further 4 weeks. Subjects who respond in phase 1 continue blinded treatment in phase 2 to preserve the blind, but only phase 1 results are analyzed. Dosage for simvastatin or matched placebo 20mg daily for 8 weeks.
1674218|NCT01665326|Other|Observational|This is a longitudinal study focused on the emerging natural history of Infantile Pompe disease, response to ERT using alglucosidase alfa (Myozyme) and response to Immune Tolerance Induction (ITI).
1674219|NCT01665274|Drug|Capecitabine|Capecitabine 1,000 mg/m² twice daily, d1-14, q3w
1674148|NCT01665937|Drug|STA-9090|"IV one time weekly for 3 weeks in 4 week cycles. Study treatment is given in 4-week time periods called cycles. Patients will receive STA-9090 for the first 3 weeks of each cycle and no treatment on the fourth week. STA-9090 will be given by intravenous (IV) infusion. IV infusions occur through an IV catheter (or tube) placed in the vein. Each infusion will last about 60 minutes.
During each cycles patients will have blood tests, pregnancy test, and EKG. Twenty to thirty days after the last dose, patients will return for a physical exam, blood tests, urine test, EKG, and CT or MRI of chest and abdomen."
1674149|NCT01665924|Drug|GLPG0634 100mg capsule once a day for 10 days|
1674150|NCT01665911|Drug|1.5 mg Sodium Fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
1674151|NCT01665911|Drug|1.5 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
1674152|NCT01665911|Drug|3 mg sodium fluoride in 100 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design.
1674153|NCT01665911|Drug|3 mg sodium fluoride in 200 ml milk|Each subject will use this product during one of the five treatment periods in the crossover study design
1674154|NCT01665911|Other|Non-fluoridated milk, 200 ml|Each subject will use this product during one of the five treatment periods in the crossover study design.
1674155|NCT01665898|Procedure|Cold Biopsy forceps|removal of polyps using cold biopsy forceps
1674156|NCT01665898|Procedure|Cold snare biopsy|Removal of colon polyps using cold snare biopsy
1674157|NCT01665885|Device|ZOLL Thermogard XP|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution). Cooling catheter placement at the earliest 30min after end of thrombolysis.
1674158|NCT01665885|Device|BARD/Medivance Arctic Sun 5000|Induction of hypothermia with 1L cold crystalloid infusions (0,9%NaCl or Ringer's solution) and simultaneous start of surface cooling.
1674159|NCT01665872|Behavioral|Cognitive-Behavioral Group Therapy|CBT Group
1674160|NCT01665846|Drug|Ferumoxytol|A dose of 4 mg/kg of ferumoxytol up to a maximum of 510 mg of elemental iron will be administered.
1674161|NCT01665820|Device|Auscultate with electronic or mechanical stethoscope (3M Littmann)|
1674162|NCT01665807|Biological|Intanza|Intanza influenza vaccine, trivalent split-virion, inactivated, approved for the 2012-2013 influenza season in northern hemisphere
1674163|NCT01665807|Biological|Vaxigrip|Influenza vaccine, trivalent, split-virion, inactivated, approved for the 2012-2013 influenza season in the northern hemisphere
1674164|NCT01665794|Drug|pomalidomide|Given PO
1674165|NCT01665794|Drug|carfilzomib|Given IV
1674166|NCT01665794|Drug|dexamethasone|Given PO or IV
1674167|NCT01665781|Drug|Erythropoietin|
1674168|NCT01665768|Drug|Everolimus and Rituximab|Everolimus: The initial dose of everolimus will be 2.5mg orally daily for a total of one year to maintain a target trough concentration between 3-15 ng/mL Rituximab: 375mg/m2 day +1 and then every 90 days for 1 year (a total of 4 infusions)
1674169|NCT01665755|Device|Upstroke Compression Defibrillation|
1674170|NCT01665755|Device|Precompression Defibrillation|
1674171|NCT01665742|Dietary Supplement|Supplement containing fish oil, vitamin C, alpha-tocopherol, green tea extract and lycopene|"1 x fruit juice fortified with salmon oil containing 1000mg EPA and 1000mg DHA daily for 8 weeks
AND
4 x film-coated tablets containing 561mg vitamin C, 389mg alpha-tocopherol, 416mg green tea extract and 15mg lycopene daily for 8 weeks
in conjunction with a weight management programme"
1674172|NCT01665742|Dietary Supplement|Placebo supplement|"1 x fruit juice fortified fortified with high oleic sunflower oil daily for 8 weeks
AND
4 x film-coated placebo tablets daily for 8 weeks
in conjunction with a weight management programme"
1674173|NCT01665703|Procedure|FDG PET/MR|Patients will be asked to undergo a voluntary gadolinium enhanced MRI with simultaneous acquisition of FDG-PET uptake within 4 weeks prior to surgery.
1674174|NCT01665690|Other|Patient delivered partner therapy|The study will provide communities with access to free PDPT for heterosexuals with gonorrhea or chlamydial infection. PDPT will be packaged to meet the requirements of the WA State Board of Pharmacy and will include 1gram of azithromycin, information about STD, condoms, and information about enclosed medication in English and Spanish. PDPT packs for gonorrhea will also include 400mg of cefixime.
1674175|NCT01665690|Behavioral|Targeted public health partner services|During intervention periods, communities will receive public health partner services (PS) provided by Disease Intervention Specialists (DIS). Diagnosing clinicians will triage their patients to receive PS based on defined criteria associated with not ensuring partners' treatment. PS will include an offer to notify partners for each index case. When DIS notify partners they will offer them the opportunity to obtain free medication at a local pharmacy, at a clinic (as available) or through the mail. DIS will also offer to refer partners for complete evaluations insofar as such care is available in local communities.
1674176|NCT01665677|Drug|Atorvastatin calcium|40 mg PO daily
1674177|NCT01665664|Other|Hypocaloric feeding|Daily calorimetry for the first 6 days will be performed with determination of REE and the required amount of calories needed for the next 24 hours. In this group only 20% of REE will be provided but not less than 300 kcal/day.
1674178|NCT01665651|Drug|Yougui granules|Yougui granules is traditional Chinese patent medicine used to treatment patients with kidney Yang deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
1674179|NCT01665651|Drug|Zuogui granules|Zuogui granules is traditional Chinese patent medicine used to treatment patients with kidney Yin deficiency. Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
1674180|NCT01665651|Drug|Yougui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
1674181|NCT01665651|Drug|Zuogui granules placebo|Granules, 11g/pouch, taking with water, 2 pouches, twice a day, three months.
1674182|NCT01665638|Drug|Canagliflozin 300 mg|Singe over-encapsulated 300 mg tablet of canagliflozin administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
1674183|NCT01665638|Drug|Placebo|Singe capsule of placebo administered orally (by mouth) on Day 1 of Treatment Period 1 or Day 1 of Treatment Period 2.
1674220|NCT01665274|Drug|Oxaliplatin|Oxaliplatin IV infusion, 130mg/m² d1, q3w
1674221|NCT01665274|Procedure|D2 resection|D2 resection
1674768|NCT01660425|Behavioral|Enhancement with psychosocial intervention|
1674184|NCT01665638|Drug|Somatostatin|A primed (50 mcg in 1 mL sterile 0.9% NaCl solution i.v. injection over 1 minute) constant (500 mcg/hour) i.v. infusion of somatostatin for 4 hours approximately 2 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2. The total dose of somatostatin administered during each period will be 50 mcg + 500 mcg/hour x 4 hours = 2050 mcg.
1674185|NCT01665638|Drug|C-peptide|Single bolus dose of 150 mcg synthetic human C-peptide in 1 mL water for injection administered i.v. (in the vein) approximately 3 hours after canagliflozin or placebo dosing on Day 1 of Treatment Period 1 and Day 1 of Treatment Period 2.
1674186|NCT01665625|Procedure|regional interventional chemotherapy group|The patients in experimental group were monitored by X-ray imaging. A 0.038 super-sliding guide wire was inserted after successful puncture, and when site of the pancreatic carcinoma was reconfirmed by conventional angiography, a 5F cobra catheter was used to place the port-catheter drug delivery system in the celiac artery (pancreatic head) or the hepatic artery (pancreatic body and tail). Finally, the port-catheter was embedded under the left upper chest.
1674187|NCT01665612|Device|Contact lens care solution|Comparison of clinical and subjective performation of the contact lens care solutions used with two types of contact lenses
1674189|NCT01665586|Drug|dexmedetomidine|"Spinal anesthesia regimen Group F: 6mg bupivacaine + 20mcg fentanyl (intrathecal) + o.4 cc 5% dextrose water Group C: 6mg bupivacaine + 0.4 cc normal saline + 0.4cc 5% dextrose water
dexmedetomidine 0.2~0.8 micro gram/kg intravenous administration after the sterilization of the spinal anesthesia level, and prehydration"
1674190|NCT01665573|Drug|PF-04457845|Acquisition of conditioning Administration of drug Extinction of conditioning
1674191|NCT01665573|Drug|Placebo|Acquisition of conditioning Administration of placebo Extinction of conditioning
1674192|NCT01665547|Drug|l-carnitine|3gm l-carnitine from day 1 to day 12 of the menstrual cycle
1674193|NCT01665534|Behavioral|High salt intake|During the high salt intake period, patients received a 10-20 mmol sodium diet plus sodium tablets (180 mEq/die) to achieve a 200 mmol intake /day for two weeks
1674194|NCT01665521|Other|HEART Pathway|During ED evaluation, patients are randomized to HEART Pathway or usual care arms.
1674195|NCT01665508|Drug|Nebivolol|Patient to start nebivolol and have repeat testing in 3 months
1674196|NCT01665495|Procedure|Extended pericardial drainage by catheter|Extended pericardial drainage will be done after pericardiocentesis by the insertion of a catheter to intermittently drain pericardial fluid till daily fluid return<30 ml.
1674197|NCT01665482|Other|A 2000 kcal test meal|
1674198|NCT01665482|Other|A 2000 kcal test meal which accounts for 7% fat exchange with carbohydrate|
1674199|NCT01665469|Dietary Supplement|Tomato extracted lycopene|
1674200|NCT01665469|Dietary Supplement|Placebo|
1674202|NCT01665417|Drug|Experimental|Icotinib: 125mg, oral administration, three times per day.
1674203|NCT01665417|Drug|Chemotherapy|Chemotherapy Regimen 1：Pemetrexe 500 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
1674204|NCT01665417|Drug|Chemotherapy|Chemotherapy Regimen 2：Docetaxel 75 mg/m^2 on Day 1, Cisplatin 75 mg/m^2 on Day 1, 21 days/1 cycle, 2/4 cycles totally, until progression, withdrawal of consent, or unacceptable toxicity.
1674205|NCT01665404|Drug|Fluvoxamine|Multiple doses of fluvoxamine
1674206|NCT01665404|Drug|RO4917523|Single dose of RO4917523
1674207|NCT01665391|Drug|fresolimumab|1 mg/kg total body weight administered intravenous (IV)
1674208|NCT01665391|Drug|fresolimumab|4 mg/kg total body weight administered intravenous (IV)
1674209|NCT01665391|Drug|Placebo|Placebo administered to match active treatment group
1674210|NCT01665378|Dietary Supplement|Multiple Micronutrient|"There is no current recommendation for weekly MM supplements for WRA. Therefore, we propose a supplement that contains: The same amounts of iron and folic acid as the weekly, pre-natal IFA supplement; An amount of vitamin D based on the Food and Nutrition Board's Recommended Daily Allowances (RDA); UNICEF/WHO/UNU recommended amounts of remaining nutrients (UNIMMAP recommendations). The supplement is taken weekly during pre-pregnancy.
Vitamin A (μg) 800 Vitamin D (IU) 600 Vitamin E (mg) 10 Vitamin C (mg) 70 Thiamine (mg) 1.4 Riboflavin (mg) 1.4 Niacin (mg) 18 Vitamin B6 (mg) 1.9 Vitamin B12 (μg) 2.6 Folic acid (μg)* 2800 Iron (mg)* 60 Zinc (mg) 15 Copper (mg) 2 Selenium (μg) 65 Iodine (μg) 150"
1674211|NCT01665378|Dietary Supplement|Iron and Folic Acid|The doses of weekly and daily iron (60mg) and folic acid (2800μg) are based on current WHO recommendations for WRA.
1674212|NCT01665378|Dietary Supplement|Folic Acid|It is unethical to have a placebo group as FA is universally recommended for WRA to prevent neural tube defects. Therefore, the control group will receive 2800 μg FA once a week during the pre-pregnancy period. This dosage is safe and meets the minimum recommended intake of 400 μg/d for Women of Reproductive Age (WRA). Recent studies have shown that a weekly dose of 2800 μg FA is as effective as a daily dose of 400 μg in improving folic acid and reducing homocysteine levels among WRA.
1674213|NCT01665365|Procedure|Remote ischemic perconditioning|Intermittent arm ischemia through four cycles of 5-min inflation and 5-min deflation of a blood-pressure cuff started in the ambulance before admission to primary percutaneous coronary intervention.
1674214|NCT01665352|Drug|TTP054|Administered orally once daily for 12 weeks.
1674215|NCT01665352|Drug|Placebo|Administered orally once daily for 12 weeks.
1674216|NCT01665339|Other|preload diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
1674217|NCT01665339|Other|control diet|All participants were prescribed a calorie-restricted diet (-200 to -500 kcal/d). Calorie requirements of each subject were estimated based on resting energy expenditure (REE) by using Harris- Benedict equation and also considering the physical activity levels. The diets were constructed to provide similar proportions of carbohydrates (55% energy), protein (15% energy) and total fat (30% energy).
1674222|NCT01665248|Other|18-F Sodium Fluoride Uptake in Positron emission tomography|
1675879|NCT01652313|Drug|Rasagiline|1 mg/day, tablets for 7 days, orally
1674223|NCT01665235|Drug|Amlodipine|The amlodipine - based antihypertensive treatment group (you can add a diuretic or other )
1674224|NCT01665235|Drug|ACEI / ARB|ACEI / ARB -based antihypertensive treatment group ( you can add the B - blockers or other)
1674225|NCT01665235|Drug|Aspirin or Clopidogrel|aspirin 100mg / d or Clopidogrel 75mg / d (anti-platelet agents)
1674226|NCT01665235|Drug|Atorvastatin|Atorvastatin 10 - 40mg / d ( statin therapy)
1674227|NCT01665222|Drug|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
1674228|NCT01665209|Drug|Morphine Sulfate|Morphine Sulfate 60mg Extended-release tablets
1674229|NCT01665196|Drug|18F-FDG|Intravenous injection of single dose of 18F-FDG before treatment and after 4-week treatment, respectively.
1674230|NCT01665183|Drug|ADI-PEG 20|
1674231|NCT01665170|Drug|Passiflora incarnata|3 x 1 tablet per day for 3 days
1674232|NCT01665170|Drug|Placebo|3 x 1 ablet per day for 3 days
1674233|NCT01665157|Dietary Supplement|Enimaclin®|"Enimaclin Colomil ® (Glico Co., Japan Osaka)，a low-residue diet package for each meal.
The duration of study is one day before colonoscopy."
1674234|NCT01665157|Other|Self-controlled diet|Self-controlled low residue diet.
1674235|NCT01665157|Drug|2L PEG-ELS|Normal volume of PEG-ELS
1674236|NCT01665157|Drug|low volume 1.5L PEG-ELS|Low volume PEG-ELS
1674237|NCT01665144|Drug|BAF312|Patients will be randomized to receive BAF312. BAF312 will be provided in a dose titration from 0.25 mg to a 2 mg dose.
1674238|NCT01665144|Drug|Placebo|Placebo
1674239|NCT01665131|Device|Cameron Health S-ICD SQ-RX|
1674240|NCT01665118|Device|Trusculpt (Radio Frequency) Device|
1674241|NCT01665105|Device|acupuncture|electroacupuncture at at Zusanli, electroacupuncture at Yanglingquan, and acupuncture at non-acupoint.
1674242|NCT01665092|Drug|Levo-Carnitine|
1674243|NCT01665092|Drug|placebo|
1674244|NCT01665079|Drug|Propofol|Propofol was administered by plasma TCI and a bolus dose was given by setting the initial plasma target between 12-16 μg/ml according to the anesthesiologist criteria. The protocol target range was selected based on previous experience using this model in the obese. After the patients reached this target, propofol infusion was stopped until the patients woke up (BIS>75). No other drugs were given during this period. Facemask ventilation was assisted only if necessary to maintain SpO2 > 90%. BIS data and propofol infusion data were automatically recorded every five seconds using the AnestFusor© program. Arterial blood samples of 4 ml for propofol assays were collected at 1, 2, 3, 5, 7 and 10 minutes after the initial bolus dose or until BIS > 75. After the patient woke up the study was considered finished and propofol infusion was restarted according to the anesthesiologist plan.
1674245|NCT01665066|Other|Own Brand cigarette|Smoke, 15 puff of, Own Brand cigarettes;
1674246|NCT01665066|Other|one high 2,4% nicotine|Smoke, 25 puff, of electronic cigarette one high 2,4% nicotine
1674247|NCT01665066|Other|original 7,4 mg nicotine|Smoke, 15 puff, of Categoria electronic cigarette 7,4 mg nicotine
1674248|NCT01665066|Other|nicotine free|smoke, 15 puff, of electronic cigarette nicotine free
1674249|NCT01665066|Other|Ego 9mg|smoke, 15 puff, of electronic cigarette Ego 9 mg
1674250|NCT01665053|Device|PROMUS Element Plus|A drug eluting coronary stent system
1674251|NCT01665053|Device|SYNERGY|A drug eluting coronary stent system
1674252|NCT01665040|Device|Neurostimulation device implantation|"Study subjects will undergo a screening-trial of neurostimulation using the Boston Scientific Corporation Precision Spectra neurostimulation system and may proceed to permanent implantation in the event of a successful screening trial.
Treatment will include spinal cord stimulation and may also include peripheral nerve stimulation, based upon the physician's subject-specific treatment plan."
1674253|NCT01665027|Procedure|vacuum|"Vacuum is an instrument that is using for helping delivery when there is no possibility of spontaneous delivery. First report of using vacuum was in 1962 by Solomon for delivery of fetal head (12). He suggested that using this instrument will lower pressure on fetal head and decrease delivery time (and then decrease fetal hypoxemia). Also it decreases spreading of incision and vascular injury (during manual maneuvers). Some studies confirmed these results (13, 14) and some others disagreed it (15, 16).
Considering with importance of fetal head delivery in a short time during C/S and to decrease maternal complications like lacerations and vascular injuries, this study was designed to compare the results of delivery by vacuum in C/S with routine methods for head extraction during difficult caesarean sections."
1674254|NCT01665027|Procedure|routine manual maneuvers for fetal head extraction|fetal head techniques like fundal pushing, pulling technique or reverse breech extraction
1674255|NCT01665014|Radiation|Total marrow irradiation|Mobilization of stem cells with the use of cytarabine 1.6 g/m2 followed by filgrastim 480 ug/d. Conditioning for the 1st autoHSCT: total marrow irradiation 4 Gy on days -3,-2,-1 (total 12 Gy). Conditioning for 2nd autoHSCT performed 3-4 months after the 1st one: melphalan 100 mg/m2 on days -2,-3 (total 200 mg/m2)
1674256|NCT01665001|Other|Treatment strategy: induction, consolidation, HSCT, maintenance|"Patients <55 years Ph-neg.: induction (daunorubicin, prednisone, vincristin, PEG-asparaginase), 2nd induction (if non-remission or MRD>0.1%; FLAM, MiniFLAM or FLAM-CAMP dependent on age and phenotype), consolidation (methotrexate, etoposide, cytarabine, cyclophosphamide, PEG-asparaginase). If MRD <0.01%: autoHSCT + maintenance (mercaptopurine, methotrexate) or multiagent maintenance (additionally daunorubicin, vincristin, prednisone); remaining patients: alloHSCT. Prophylaxis of leptomeningeal involvement: liposomal cytarabine intrathecally.
Patients >55 years, Ph-neg.: as above, reduced doses. AlloHSCT with reduced conditioning.
Patients Ph-pos.: as above, reduced doses in combination with continues imatinib. All intended for alloHSCT."
1674257|NCT01664988|Behavioral|muscular relaxation|muscular relaxation was done using Jacobson by contracting and relaxing selected groups of muscles until total relaxation
1674258|NCT01664988|Behavioral|breath control|breathing control techniques include deep diaphragmatic breathing and decrease breath rate to 6-10/min
1674259|NCT01664988|Other|control (routine care)|received routine care of clinic or health center and use drugs if necessary
1674260|NCT01664975|Drug|GDPT regimen|GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
1725262|NCT00005939|Radiation|brachytherapy|
1674261|NCT01664975|Drug|CHOP regimen|CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
1674262|NCT01664949|Drug|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A 1-2 drops in each eye as needed at least 2 times daily for 90 days.
1674263|NCT01664949|Drug|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (OPTIVE™) 1-2 drops in each eye as needed at least 2 times daily for 90 days.
1674264|NCT01664936|Radiation|Cerenkov emissions from the PET tracer 18F-FDG and the radiotherapeutic 131I|We will image (i) patients who are receiving a PET/CT scan for tumors in the head / neck region and (ii) patients with thyroid cancer after 131I radioablation. Two scans will be completed per patient, one of the primary tumors, as well as a 'background' scan of the contralateral side or, if tumor is there as well, of the forearm. The device to be used is an intensified charge-coupled device camera (Stanford Photonics, Palo Alto, CA) connected to a laptop PC. The camera will use a Quartz high-UV transmission 50 mm 0.8f lens. The Imaging device will be placed approximately 5 cm from the area of the patient to be imaged.
1674265|NCT01664923|Drug|Enzalutamide|160 mg, daily, by mouth.
1674266|NCT01664923|Drug|Bicalutamide|50 mg, daily, by mouth
1674276|NCT01664897|Drug|Erlotinib|Starting dose: 150 mg by mouth once daily in a 28-day cycle.
1674283|NCT01664845|Drug|metformin|metformin 500mg tid
1674284|NCT01664845|Drug|pegylated-IFN|pegasys 180 mcg qw
1674285|NCT01664845|Drug|ribavirin|ribavirin 800-1200 mg qd according to BW
1674286|NCT01664832|Device|S-nIMV|Synchronization of nasal breaths to infant's own respiratory effort
1674287|NCT01664819|Dietary Supplement|Antioxidant|
1674288|NCT01664819|Dietary Supplement|Placebo|
1674289|NCT01664806|Device|Covidien Triad monopolar generator|Blend mode (triverse pencil valleylab mode) 30 Watts will be used to perform a laparoscopic cholecystectomy.
1674290|NCT01664793|Behavioral|4 Pillars Immunization Toolkit|Pillar 1: Convenient Vaccination Services; Pillar 2: Patient notification about the importance of vaccination and availability of convenient services; Pillar 3: Enhanced Office Systems; Pillar 4: Motivation: Office immunization champion tracks progress towards a goal; Early delivery of donated vaccines for disadvantaged children, staff education, support of effort by research staff.
1674291|NCT01664780|Device|ARFI imaging|
1674292|NCT01664767|Other|Sulfur Thermal water|
1674293|NCT01664767|Other|Placebo|
1674294|NCT01664754|Drug|exemestane|Given PO
1674295|NCT01664754|Drug|pemetrexed disodium|Given IV
1674296|NCT01664754|Drug|carboplatin|Given IV
1674297|NCT01664754|Other|laboratory biomarker analysis|Correlative studies
1674298|NCT01664754|Other|pharmacological study|Correlative studies
1674299|NCT01664754|Other|questionnaire administration|Ancillary studies
1674300|NCT01664754|Procedure|quality-of-life assessment|Ancillary studies
1674301|NCT01664741|Drug|Nicotine patch - transdermal|
1674302|NCT01664741|Drug|placebo|
1674303|NCT01664728|Drug|Abiraterone acetate|Phase 2 maximum tolerated dose from Study COU-AA-001 taken orally once daily
1674304|NCT01664728|Drug|Glucocorticoid|prednisolone/prednisone 5 mg taken orally twice daily or dexamethasone 0.5 mg taken orally once daily
1674305|NCT01664715|Behavioral|150 Min/Week|Performs 150 min/wk of planned moderate intensity aerobic exercise.
1674306|NCT01664715|Behavioral|225 Min/Week|Performs 225 min/wk of planned moderate intensity aerobic exercise.
1674307|NCT01664715|Behavioral|300 Min/Week|Performs 300 min/wk of planned moderate intensity aerobic exercise.
1674308|NCT01664702|Dietary Supplement|Dairy Products|See the effect dairy product has on fat oxidation in overweight individuals expending the same amount of energy
1674309|NCT01664702|Dietary Supplement|Dairy Servings|Continue baseline consumption of one or fewer servings of dairy per day
1674310|NCT01664689|Procedure|Microcoaxial Phacoemulsification|
1674311|NCT01664676|Drug|Liraglutide|
1674312|NCT01664676|Drug|Placebo-liraglutide|
1674313|NCT01664663|Radiation|Standard radiochemotherapy to 68 Gy|
1674314|NCT01664663|Radiation|Dose escalated radiochemotherapy up to 84 Gy|
1674317|NCT01664637|Drug|10 mg TZP-102|One oval-shaped, opaque-white, hard gelatin capsule containing active ingredient will be taken orally three times a day for 12 weeks
1674318|NCT01664637|Drug|Placebo|One oval-shaped, opaque-white, hard gelatin capsule of placebo indistinguishable from active drug will be taken orally three times a day for 12 weeks
1674319|NCT01664624|Drug|Roflumilast|Roflumilast tablets
1674320|NCT01664624|Drug|Alogliptin|Alogliptin tablets
1674321|NCT01664624|Drug|Exenatide|Exenatide solution
1674322|NCT01664624|Drug|Placebo to roflumilast|Placebo-matching roflumilast tablets
1674323|NCT01664624|Drug|Placebo to alogliptin|Placebo-matching alogliptin tablets
1674324|NCT01664611|Procedure|Remote Ischaemic Conditioning administered via the inflation of a blood pressure cuff on the upper arm|Suprasystolic blood pressure cuff inflation for set periods to time to render a limb ischaemic followed by periods of deflation to allow for reperfusion.
1674325|NCT01664611|Procedure|Sham conditioning|Non therapeutic inflation of a blood pressure cuff that does not cause ischaemia/reperfusion injury
1674327|NCT01664585|Behavioral|Training group|The 60-minute training sessions include a few mobilization techniques for upper neck. In detail, three different exercises concentrated on postural and motor control will be taught during the first two training sessions. Progressively, two additional exercise movements aiming at postural and motor control will be taught in the next session. After eight weeks, two muscle strength exercises utilising therapeutic rubber band will be included into the program. The aim of the rubber band exercises is eventually to achieve the load of 80% of maximal voluntary contraction. The participants in the training group are also instructed to increase their amount of physical activity progressively according to the current physical activity recommendations.
1674328|NCT01664585|Behavioral|Control|The control group will receive six sessions of Transcutaneous Nervous Stimulation treatment (TNS) as a placebo treatment (0) and the participants in control group are recommended and encouraged to maintain their previous normal level of physical activity and exercise habits throughout the study without any supervision or home training programs.
1674329|NCT01664559|Drug|Ketorolac|Ketorolac 30mg intramuscular injection, 1cc volume
1674330|NCT01664559|Drug|Normal Saline|Placebo arm, 1cc of normal saline, 0.9%, intramuscular injection
1674331|NCT01664546|Procedure|Trophectoderm biopsy|
1674332|NCT01664533|Drug|Erlotinib|Erlotinib was supplied as tablets in the retail product Tarceva.
1674333|NCT01664520|Drug|Dexmedetomidine infusion|"Both static and dynamic autoregulation are assessed first during propofol infusion, before commencement of dexmedetomidine infusion. Dexmedetomidine infusion is commenced with a dose of 0.7 μg/kg/h and propofol infusion is stopped concomitantly. After 2 hours dexmedetomidine infusion, the static and dynamic autoregulation are assessed. If there are no signs of worsening of autoregulation, then the dexmedetomidine infusion is increased to 1 μg/kg/h and after 2 hours the static and dynamic autoregulation are assessed again. However, if autoregulation worsens during dexmedetomidine infusion, it will be stopped and further testing with dexmedetomidine will not be carried out. If autoregulation does not worsen with the 1 μg/kg/h dose then the dose will be increased to 1.4 μg/kg/h. After 2 hours infusion the dynamic and static autoregulation are assessed again.
Blood samples for determining dexmedetomidine plasma concentration are collected alongside with the autoregulation assessments"
1674334|NCT01664507|Drug|conventional dose epinephrine|conventional dose epinephrine : 0.5mg/kg + 0.9% normal saline
1674335|NCT01664507|Drug|low dose epinephrine|low dose epineprhine : 0.05mg/kg + normal saline
1674336|NCT01664494|Drug|Capecitabine|Capecitabine will be given according to the label text as monotherapy (1250 mg/m^2 twice daily) or combination therapy (800 to 1000 mg/m^2 or 1250 mg/m^2 twice daily) for 14 consecutive days followed by a treatment break of 7 days.
1674337|NCT01664273|Drug|Plasmid AMEP|"Cohorts of 3 patients will received increasing doses of plasmid AMEP:
50 μg, 100 μg, 250 μg and 500 μg. Starting dose will be the lowest dose.
Injection volume will remain constant at 200 μL.
Once-only treatment and intra-individual dose escalation will therefore not occur."
1674338|NCT01664260|Drug|N-acetylcysteine|0 - 8 week: 10 mg escitalopram a day + 1200 mg N-acetylcysteine twice a day
1674339|NCT01664260|Drug|Placebo|0 - 8 week: 10 mg escitalopram a day + 1200 mg Placebo twice a day
1674340|NCT01664247|Drug|insulin degludec|Administered s.c. (under the skin) once daily. Dose individually adjusted.
1674341|NCT01664247|Drug|placebo|Administered s.c. (under the skin) once daily. Dose individually adjusted.
1674342|NCT01664247|Drug|liraglutide|Administered s.c. (under the skin) once daily. Dose: 1.8 mg.
1674343|NCT01664234|Other|laryngoscopy with oxygen|Patients will be randomly assigned to laryngoscopy with or without simultaneous insufflation of oxygen at 4 L/minute. Oxygen will be provided by a flowmeter connected via rigid tubing to the track-mounted endotracheal tube on the AirTraq.
1674344|NCT01664234|Other|laryngoscopy without oxygen|Patients will be randomly assigned to laryngoscopy without simultaneous insufflation of oxygen at 4 L/minute.
1674345|NCT01664221|Drug|Epoetin Alfa|Intravenous administration of the drug, test or comparator, for 4 weeks, 3 times a week (monday, wednesday and friday).
1674346|NCT01664195|Drug|Epoetin Alfa|Intravenous single-dose administration of 100 IU/kg of the test drug (Eritromax) in the first period and intravenous single-dose administration of 100 IU/kg of the comparator drug (Eprex) in the second period, after 23-30 days of washout, or vice-versa.
1674347|NCT01664182|Biological|Bevacizumab|Given IV
1674348|NCT01664182|Other|Laboratory Biomarker Analysis|Correlative studies
1674349|NCT01664182|Drug|Pazopanib Hydrochloride|Given PO
1674350|NCT01664182|Other|Pharmacological Study|Correlative studies
1674351|NCT01664182|Drug|Sorafenib Tosylate|Given PO
1674352|NCT01664182|Drug|Sunitinib Malate|Given PO
1674353|NCT01664182|Biological|Trebananib|Given IV
1674354|NCT01664169|Other|laboratory biomarker analysis|
1674355|NCT01664156|Drug|Korean red ginseng|Korean red ginseng is a steamed form of Panax ginseng with preserved major constituents. It has been shown to possess more biological activity than panax ginseng.
1674356|NCT01664156|Drug|Placebo|
1674357|NCT01664143|Drug|Placebo|Multiple doses of placebo
1674358|NCT01664143|Drug|RO5508887|Multiple doses of RO5508887
1675884|NCT01652261|Drug|ABVD + FDG-PET/CT Scan treatment adaptation|
1674359|NCT01664130|Radiation|stereotactic body radiation therapy|Undergo SBRT
1674360|NCT01664130|Procedure|quality-of-life assessment|Ancillary studies
1674361|NCT01664130|Other|laboratory biomarker analysis|Correlative studies
1674362|NCT01664104|Drug|Tocilizumab|Tocilizumab will be administered in routine clinical practice in accordance with local label. Study protocol does not specify/enforce any treatment regimen.
1674363|NCT01664091|Radiation|Radiation Therapy|Given Monday through Friday over 5-7 weeks
1674364|NCT01664078|Device|Endovascular AAA repair with InCraft®|
1674365|NCT01664065|Drug|200 mg Ceftaroline fosamil|1 h infusion
1674366|NCT01664065|Drug|600 mg Ceftaroline fosamil|1 h infusion
1674367|NCT01664052|Device|ESS505 (Essure, BAY1454033)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
1674368|NCT01664052|Device|ESS305 (Essure, BAY1454032)|Unilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert inclusive of polyethylene terephthalate (PET) fibers (investigational device model ESS505) and contralateral placement of the current commercially approved Essure device, model ESS305 followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement. At the conclusion of the hysterectomy, the uterine cornua and fallopian tubes were sent to a pathology lab for histological preparation, and subsequent evaluation.
1674369|NCT01664052|Device|ESS505-A (Essure, BAY1454033)|Bilateral hysteroscopic placement of the permanent birth control system, Model ESS505 insert with minimal polyethylene terephthalate (PET) fibers (investigational device model ESS505-A) followed by tubal occlusion evaluation by hysterosalpingogram (HSG) approximately 60 minutes following insert placement. A subsequent HSG was performed prior to the subjects' scheduled hysterectomy procedures at 30 (group 3), 60 (group 2) or 90 days (group 1) post insert placement.
1674370|NCT01664039|Drug|Travoprost 0.004% ophthalmic solution|Ophthalmic solution without benzalkonium chloride (BAK), containing Polyquad® preservative
1674371|NCT01664039|Drug|Bimatoprost 0.01% ophthalmic solution|Ophthalmic solution containing benzalkonium chloride (BAK)
1674372|NCT01664026|Behavioral|Web-based lifestyle modification|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance.
1674373|NCT01664026|Behavioral|Web-based lifestyle modification +|Access to a web-based lifestyle modification program of 6-month duration that covers all aspects of a healthy lifestyle including physical activity, nutrition and weight maintenance plus telephone counseling support by health coaches on a weekly or bi-weekly basis.
1674374|NCT01664013|Drug|Nuronox|Reconstituted Neuronox® is injected at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.Actual dose and injection site should be adjusted individually considering the muscle mass, degree of spasticity, body weight, and response to any previous botulinum toxin injections.
1674375|NCT01664000|Drug|thioureidobutyronitrile|Kevetrin (thioureidobutyronitrile)
1674376|NCT01663987|Drug|tiotropium bromide|18 mcg QD
1674377|NCT01663987|Drug|Placebo|QD
1674378|NCT01663961|Drug|YM178 OCAS|oral
1674379|NCT01663961|Drug|Digoxin|oral
1674380|NCT01663935|Drug|Levodopa/carbidopa|This study will have an intent to treat goal. Anyone that fits the inclusion criteria for the study will be entered and receive study drug.
1674381|NCT01663922|Drug|Boceprevir|Boceprevir as Victrelis(r) 200mg capsules
1674382|NCT01663922|Drug|St John's Wort|Each Ucalm(r) tablet contains 300mg of St Johns Wort extract
1674383|NCT01663909|Behavioral|Guided imagery intervention|A 30-min DVD was developed which included general information on pain management as well as a section on guided imagery using sounds and images.
1674384|NCT01663883|Other|Isometric exercise|use of a handgrip for 3x2 minutes
1674385|NCT01663870|Behavioral|Audio Recorded Interviews|Audio recorded interview at beginning of visit and after using HealthATM website.
1674386|NCT01663870|Behavioral|Focus Group Session|Focus group session taking 60-90 minutes.
1674387|NCT01663870|Other|Website Session|10-15 minute session with the HealthATM website.
1674388|NCT01663870|Behavioral|Questionnaire|Questionnaire completion at end of audio recorded interview taking about 5 minutes.
1674393|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia w. extra support|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia plus extra therapist support.
1674394|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia|(Study 2) A 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia. Regular therapist support.
1674395|NCT01663844|Behavioral|Therapist guided Internet-CBT for insomnia and depression|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia and depression.
1674396|NCT01663844|Behavioral|Therapist Guided Internet-CBT for depression plus insomnia placebo|(Study 1) A 12 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. A placebo intervention for insomnia is added.
1674397|NCT01663831|Other|Mosquito topical repellent|Daily repellent use, before and after sleeping hours during the malaria season (6 months) in addition to the use of Long Lasting Insecticidal Nets during sleeping hours.
1674398|NCT01663818|Device|Tack-It Endovascular Stapler|
1674399|NCT01663805|Drug|Everolimus|Everolimus is started immediately after transplantation, the dosage of 1.5 mg twice a day, adjusted to achieve and maintain the blood level of 3-8 ng/mL.
1674400|NCT01663792|Other|Seaweed|Ten 500-mg capsules to be taken orally each day for 1 month
1674401|NCT01663792|Other|Placebo|Ten 500-mg capsules to be taken orally each day for 1 month
1674402|NCT01663792|Other|Placebo2|Ten 500-mg capsules to be taken orally each day for 1 month
1674403|NCT01663779|Procedure|Ultrasound guided radial artery catheterization.|Radial artery catheters will be placed with the assistance of bedside ultrasound.
1674404|NCT01663779|Procedure|Blind insertion of radial artery catheterization|Radial artery catheters will be placed by the palpation technique only.
1674405|NCT01663766|Drug|milatuzumab|Milatuzumab is a humanized anti-CD74 antibody that is administered intravenously.
1674406|NCT01663753|Device|18F-FDG-PET|
1674407|NCT01663727|Drug|Bevacizumab [Avastin]|Intravenous repeating dose
1674408|NCT01663727|Drug|Paclitaxel|Intravenous repeating dose
1674409|NCT01663727|Drug|Placebo|Intravenous repeating dose
1674410|NCT01663714|Biological|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab.|cycolophosphamide, vacristine, and pednisone (CVP) x6 cycles followed by tositumomab and iodine I 131 tositumomab. CVP will be repeated every 21 days for a total of six cycles. tositumomab and iodine I 131 tositumomab will begin within 56 days following the first day of the sixth cycle of CVP. Patient will undergo two dosing phase for the tositumomab and iodine I 131 tositumomab therapy.
1955121|NCT03289260|Drug|Imiquimod 5% cream|Patients receive topical Imiquimod therapy for 12 weeks.
1674413|NCT01663675|Genetic|karyotype|
1674414|NCT01663662|Drug|Tolvaptan|
1674415|NCT01663662|Drug|placebo|
1674416|NCT01663649|Behavioral|Deprexis|web-based treatment program for depression
1674417|NCT01663649|Behavioral|Wait-list|the wait-list group receives Deprexis after 6 month
1674418|NCT01663623|Biological|Placebo|Placebo
1674419|NCT01663623|Biological|Belimumab 10 mg/kg|Belimumab 10 mg/kg
1674420|NCT01663623|Drug|Azathioprine|Azathioprine
1674421|NCT01663610|Behavioral|VardagsSMART|VardagsSMART Internet-based course with therapist support during 6 weeks
1674422|NCT01663584|Procedure|Blood draw|
1674423|NCT01663558|Drug|imiquimod|
1674424|NCT01663558|Procedure|ablative|
1674425|NCT01663532|Drug|Aripiprazole IM Depot|
1674426|NCT01663532|Drug|Placebo|Matching Placebo
1674427|NCT01663519|Other|Custom made insoles 35 shore|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
1674428|NCT01663519|Other|Prefabricated insoles|Prefabricated insoles
1674429|NCT01663519|Other|55 shore Custom made insole|Insoles in Ethyl Vinyl Acetate (EVA) manufactured over an individual positive cast.
1674430|NCT01663493|Procedure|FNB|
1674431|NCT01663467|Drug|Ginkgo biloba|Ginexin-F 80mg tablet will be given twice a day for 6 months.
1674432|NCT01663467|Behavioral|modified TRT|"modified TRT (tinnitus retraining therapy) using smartphone and web based materials will be added with Ginkgo biloba.
Ginexin-F 80mg tablet will be given twice a day for 6 months."
1674433|NCT01663454|Behavioral|Cogmed Robomemo working memory training|The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
1674434|NCT01663441|Drug|NL201|mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
1674435|NCT01663441|Drug|NL201|mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
1674436|NCT01663441|Drug|NL201|The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
1674437|NCT01663441|Drug|rhIL-11|rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
1674438|NCT01663428|Other|Sup-ER Splint|
1674439|NCT01663428|Other|Currently accepted treatment|
1674440|NCT01663415|Drug|Enzalutamide|oral
1674441|NCT01663402|Drug|alirocumab|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1674442|NCT01663402|Drug|Placebo|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1674443|NCT01663389|Drug|GSK1322322 1000 mg containing radioactive 14C-GSK1322322|GSK1322322 1000 mg is a mesylate salt powder for injection containing 45.5 μCi radioactive 14C-GSK1322322 1000 mg as free base.
1674444|NCT01663389|Drug|GSK1322322 1200 mg containing radioactive 14C-GSK1322322|GSK1322322 1200 mg is a mesylate salt powder for oral solution containing 54.5 μCi radioactive 14C-GSK1322322 1200 mg as free base.
1674445|NCT01663376|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular injection of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 ~3x10e8 cells
1674446|NCT01663363|Device|LASIK correction of myopic refractive errors|Surgeons will perform wavefront-guided LASIK based upon measurement obtained with the iDesign System
1674447|NCT01663337|Behavioral|Cognitive Processing Therapy (CPT)|CPT is a highly structured course of therapy that focuses primarily on the cognitive restructuring of trauma related beliefs.
1674448|NCT01663337|Behavioral|Relapse Prevention (RP)|RP utilizes high-risk situation assessment/avoidance, drink refusal skills, assertiveness training,cognitive restructuring as well as other approaches to address issues of alcohol use/dependance.
1674449|NCT01663324|Device|rTMS intervention 1|"Low frequency rTMS (Magventure Mag Pro Option) applied over left temporoparietal cortex: 3000 stimuli of 1Hz rTMS (110% motor threshold); 1 minute break after 1000 and 2000 stimuli.
Arms: single site rTMS"
1674549|NCT01661309|Dietary Supplement|Methylcobalamin|Aimed at reducing plasma tHcy.
1675885|NCT01652261|Drug|BEACOPPesc|
1955122|NCT03289260|Drug|Placebo cream|Patients receive topical Doritin therapy for 12 weeks
1674450|NCT01663324|Device|rTMS intervention 2|"Repetitive transcranial magnetic stimulation (Magventure Mag Pro Option): 1000 stimuli of 20 Hz rTMS over the left DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporoparietal cortex (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over right temporoparietal cortex (110% motor threshold).
Arms: multisite rTMS"
1674451|NCT01663311|Device|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodman area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
1674452|NCT01663311|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 20 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold; followed by: low frequency rTMS ( Alpine Biomed Mag Pro Option) applied over left temporoparietal cortex, Butterfly-water-cooled-Coil (2000 Stimuli of 1 Hz each session), 110% motor threshold.
1674453|NCT01663298|Procedure|Dental implant surgery|Surgery involving placement of one dental implant, of either Astra Tech or Straumann system, is performed in all subjects within 2 weeks of screening examination. Implant placement is 1-stage, but can be either on edentulous ridges or in extraction sockets.This is not a randomized treatment arm/group design. The study is observational with regards to the analysis of tissue samples that are collected prior to the routine placement of implants. The implant choice is based upon patient needs and is not related to any outcome.
1674454|NCT01663285|Drug|Neoadjuvant Cisplatin and Gemcitabine|Cisplatin 70 mg/m2 through IV for 60 minutes on day 1 of each cycle. Gemcitabine 1,000 mg/m2 IV for 30 minutes on days 1 and 8 during each cycle. Treatment is expected to continue for up to 4 cycles. Chemotherapy will be followed by radical nephroureterectomy within 6 weeks (+/- 2 weeks) from the last date of chemotherapy.
1955123|NCT03289260|Procedure|Fulguration|Surgical Excision and Fulguration of condyloma
1674457|NCT01663259|Drug|Cetuximab|Before Radiotherapy patients you will receive a single loading dose of cetuximab. Patients will also have two additional biopsies before and after cetuximab to determine how the tumor is affected. A Cetuximab infusion will also be delivered once a week during radiotherapy.Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week. In order to evaluate swallowing problems from radiotherapy, patients will undergo an evaluation of swallowing by videofluoroscopy (VF). Quality of Life questionnaires will be given before therapy and periodically up to 36 months after therapy. In order to assess if the tumor was completely eradicated, CT-PET scan will be performed 3 months after the completion of therapy.
1674458|NCT01663259|Radiation|Radiotherapy|Radiation will be started (70 Gy in 35 fractions over 7 weeks to the gross tumor, 50-60 Gy to subclinical target volumes) five days a week until the total dose of radiation prescribed by the doctor is reached. Radiation will be delivered concurrent with weekly cetuximab 250 mg/m2, delivered on Monday or Tuesday each week.
1674459|NCT01663246|Procedure|Saliva Sample|Small plastic cups will be placed on the inside of subject cheeks, and held in place with gentle suction. These cups are attached to tubes which will allow the collection of saliva into a test tube. Saliva will also be collected from the glands underneath the tongue using a small gentle suction device, similar to the one used by a dentist. Saliva production will be stimulated by dabbing a mild citric acid solution that tastes like lemon onto the tongue using a Q-Tip. After this test, subjects will also be asked to chew wax to simulate saliva, and the saliva that accumulates in their mouth will be collected by spitting into a test tube.
1674460|NCT01663233|Drug|LCZ696|LCZ696 will use tablets available at a strength of 200mg. Patients will be instructed to take the prescribed medication once a day.
1674461|NCT01663233|Drug|Amlodipine|Amlodipine will use tablets available at a strength of 5 mg. Patients will be instructed to take the prescribed medication once a day.
1674462|NCT01663233|Drug|Placebo|Matching placebo to LCZ696
1674463|NCT01663194|Procedure|primary percutaneous coronary intervention, each groups|All primary PCI procedures were performed using the standard femoral approach with a 7-French guiding catheter for each patients. After administration of 5,000 IU of intravenous heparin (70 U/Kg) and a 300 mg loading dose of clopidogrel, direct stenting was performed whenever possible, and in the remaining cases, balloon pre-dilatation was performed. The operator determined the choice of stents (bare metal or drug-eluting stent).
1674464|NCT01663168|Drug|Rifabutin|
1674465|NCT01663155|Device|chest x-ray with or without CAD, lose dose CT scan|PA view, low dose CT scan
1674466|NCT01663116|Genetic|Stem cells|"first cohort: 1 million stem cells/kg administered at days 1, 8 and 15
second cohort: 2 million stem cells / kg administered at days 1, 8 and 15
third cohort: 4 million stem cells / kg administered at days 1, 8 and 15"
1674467|NCT01663116|Genetic|Placebo|"first cohort: 20 ml administered at days 1, 8 and 15
second cohort: 40 ml administered at days 1, 8 and 15
third cohort: 80 ml administered at days 1, 8 and 15"
1674468|NCT01663103|Drug|Rilonacept|12 weeks of treatment with rilonacept (subcutaneous injection with a loading dose of 320 mg, followed by 160 mg/wk)
1674469|NCT01663103|Drug|Placebo|Twelve weeks of treatment with placebo (subcutaneous injection of normal saline with a loading dose of 320 mg, followed by 160 mg/wk)
1674470|NCT01663090|Drug|Ferumoxytol|
1674472|NCT01663064|Device|Endovascular treatment (Zenith® p-Branch™ endovascular graft)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
1674473|NCT01663051|Device|Zilver Vena Venous Stent|Stenting iliofemoral venous outflow obstruction
1674474|NCT01663038|Drug|Clopidogrel|Clopidogrel and Aspirin separate combination, single dose
1674475|NCT01663038|Drug|Fixed dose combination of clopidogrel/Aspirin|Fixed dose combination of clopidogrel/aspirin
1674476|NCT01663038|Drug|Aspirin|
1674597|NCT01662089|Drug|Placebo drug supplement|Placebo drug instead of Zinc supplement
1674477|NCT01663025|Behavioral|Hand Reflexology|The hand reflexology will begin in theatre, before the local anaesthetic is administered and will continue until the patient is ready to leave the operating theatre.
1674478|NCT01663012|Drug|Etirinotecan pegol|
1674479|NCT01662999|Drug|Saxagliptin|
1674480|NCT01662999|Drug|Dapagliflozin|
1674481|NCT01662986|Drug|tiotropium bromide|18 mcg QD
1674482|NCT01662986|Drug|Placebo|QD
1674483|NCT01662973|Other|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1*10E6 UC-MSC/kg body weight for 12 weeks.
1674484|NCT01662973|Other|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
1674485|NCT01662960|Behavioral|Visual feedback therapy #1|A home based therapy involving modification of visual feedback.
1674486|NCT01662960|Behavioral|Visual feedback therapy #2|A home based therapy involving modification of visual feedback.
1674487|NCT01662947|Device|Blood pressure Transtek Wrist Blood Pressure Monitor, TMB-1117|Systolic, Diastolic pressure.
1674488|NCT01662947|Device|Blood pressure Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-2|Systolic, Diastolic pressure
1674491|NCT01662921|Drug|NPH|Long acting insulin NPH dosing will be titrated weekly derived from the patients current weight and gestational age
1674492|NCT01662921|Drug|Insulin LISPRO|Insulin lispro dosing will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
1674493|NCT01662921|Drug|Insulin glulisine|Insulin glulisine will be titrated weekly based on the patient's average SMBG readings from each meal during the past three days
1674494|NCT01662908|Drug|edoxaban tosylate|edoxaban tosylate (DU-176b), film-coated for oral use, 90 mg once daily (QD) for 10 days (±2 days) followed by 60 mg QD for a total of approximately 90 days of edoxaban treatment
1674495|NCT01662908|Drug|enoxaparin/unfractionated heparin|enoxaparin - administered by subcutaneous injection;1 mg/kg/ twice daily or 1.5 mg/kg once daily unfractionated heparin - started with 5000 IU bolus intravenous administration, 1300 IU/h continuous infusion, minimum of 5 days of treatment and stopped when target INR (2.0 - 3.0) is achieved.
1674496|NCT01662908|Drug|warfarin|tablet for oral use; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; 90 days treatment.
1674497|NCT01662895|Drug|Deferoxamine|Deferoxamine mesylate(62 mg/kg/day up to a maximum daily dose of 6000 mg/day) given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
1674498|NCT01662895|Drug|Normal saline|This is a placebo. Normal saline will be given by a continuous IV infusion for 5 consecutive days beginning within 24 hours of ICH symptom onset.
1674499|NCT01662882|Drug|florbetapir (18F)|IV injection, 370 MBq(10mCi), single dose
1674500|NCT01662869|Drug|5-Fluoruracil|Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m^2) IV bolus and then 2400 mg/m^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
1674501|NCT01662869|Drug|Folinic acid|Participants will receive folinic acid 400 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
1674502|NCT01662869|Drug|Onartuzumab|Participants will receive onartuzumab 10 mg/kg IV infusion on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
1674503|NCT01662869|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
1674504|NCT01662869|Drug|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
1674505|NCT01662856|Biological|Fibrin Sealant Grifols|Combination of 3 mL fibrinogen and 3 mL thrombin in separate syringes assembled on a syringe holder (6 mL of solution in total).
1674506|NCT01662856|Procedure|Manual Compression|Direct manual compression of target bleeding site with gauze/laparotomy pads.
1674507|NCT01662817|Behavioral|Intervention|PCP receives one day training in depression screening guidelines and uses guidelines for six months
1674508|NCT01662817|Behavioral|Control|PCP manages depression in the usual way for six months
1674509|NCT01662804|Drug|3F8 Monoclonal Antibody Combined with Interleukin-2|One cycle has 2 days of intravenous hu3F8 treatment, given about 7 days apart. rIL-2 is administered sc daily over 5 days, beginning on the second infusion of hu3F8. To limit side-effects, patients receive analgesics and antihistamines as premedications. Cycles are 21 days. Patients can have up to 4 cycles of treatment on this study within 18 months of starting hu3F8.
1674510|NCT01662791|Drug|Rifaximin|All individuals in the weight loss group (i.e., only the Case group) were offered open-label treatment with the poorly absorbed antibiotic, rifaximin, 550 mg PO BID for 14 days. Treatment will not depend upon the results of the bacterial overgrowth breath test. Thus, both normal and abnormal breath test subjects received antibiotic treatment.
1674514|NCT01662765|Procedure|Surgery|modified umbilectomy
1674515|NCT01662765|Other|conservative|this treatment will include conservative procedures under local anesthesia for patient comfort.
1674516|NCT01662752|Drug|Indocyanine green|Please see arm description
1674517|NCT01662739|Behavioral|Questionnaire|
1674550|NCT01661296|Other|RFH therapy|RFH therapy was administered by a single, controlled and localized delivery of radio frequencies into the lesion for 30-60 seconds under local anesthesia using a current field radio-frequency generator.
1674551|NCT01661296|Drug|Sodium stibogluconate|Six intralesional injections (one injection per week) of SSG 50mg/cm-2 area of lesions
1674518|NCT01662726|Drug|Irosustat|Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
1674519|NCT01662713|Device|OFDI|Imaging of skin
1674520|NCT01662700|Drug|Artesunate|
1674521|NCT01662700|Drug|Chloroquine|
1674522|NCT01662687|Drug|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.
Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24 hours) prior to start of chemotherapy."
1674523|NCT01662687|Drug|Kytril inj.+Kytril tab.|"Eligible patients were randomized to Sancuso patch or Kytril groups and received the assigned treatment for 4days.
Active Comparator arm:
Kytril inj. 3mg: administered by intravenous infusion at least 5 minutes, just before the first chemotherapy (Day 1).
Kytril tab. 1mg: administered twice a day by orally at Day 2~4."
1674524|NCT01662674|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 1000mg, for 1 day
1674525|NCT01662674|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
1674526|NCT01662661|Drug|JNJ-47910382 (suspension)|Type=exact number, unit=mg, number=200, form=suspension, route=oral. JNJ-47910382 administered on Day 1.
1674527|NCT01662661|Drug|JNJ-47910382 (tablet)|Type=exact number, unit=mg, number=200, form=tablet, route=oral. JNJ-47910382 administered on Day 1.
1674528|NCT01662648|Drug|Paliperidone ER|Paliperidone extended-release (ER) tablet in dose range of 3 to 12 milligram (mg) per day will be given orally for 6 months as per Investigator's discretion.
1674529|NCT01662622|Drug|Sevoflurane|"The design of experiment is referred to the Dixon up-and-down method. The first subject was designed to receive end-tidal sevoflurane concentration of 1.7%. For each subject, 30 min interval time was given. The isoelectric EEG was considered as significant when the isoelectric state last for more than 1min. The maximal burst suppression rate was recorded if isoelectric EEG was not reached. Heart rate and MAP, were recorded 2 and 1min before and 3 min after skin incision. Adrenergic reflexes positive cases were counted."
1674530|NCT01662609|Procedure|Endoscopic Ultrasound (EUS)|Ultrasound scope will be passed through the participant's mouth into their stomach and their pancreas will be evaluated completely by the ultrasound scope. If an abnormality is found in their pancreas, a biopsy may be performed to obtain a diagnosis.
1674531|NCT01662583|Other|Text Message|
1674532|NCT01662583|Other|Written reminder|
1674533|NCT01662570|Behavioral|Beverage Choice and Lifestyle Modification|The family-based BCLM intervention trained children and parents in self monitoring of sugar sweetened beverage intake and goal-setting, incorporated feedback and reinforcement, and provided water bottles and water filters to promote a reduction in sugar sweetened beverages and overall energy intake. 16 sessions were provided over a 6-month period.
1674534|NCT01662570|Other|Nutrition Education (NE)|This treatment for parents and children addressed a variety of topics in nutrition including benefits of fruits and vegetables, the food pyramid, vitamins, benefits of eating a variety of foods, and healthy beverage selections. No behavioral change training component was included. 16 sessions over 24 weeks was provided.
1674535|NCT01662557|Behavioral|Family Behavior Modification|5-month intervention for parents and children providing 15 sessions in behavioral skills training in self monitoring, Traffic Light Diet, goal setting, reinforcement and tasting sessions. Of the 15 sessions, 3 were structured as phone sessions.
1674536|NCT01662557|Other|Minimal Nutrition Information|Families assigned to MNI received a series of 15 mailings on topics related identifying a healthy body weight for children; energy balance and calorie requirements for children; MyPyramid for Kids; portion control; the benefits of physical activity and screen-time reduction; encouraging fruit and vegetable consumption; healthy snacks and smart shopping; and encouraging family meals.
1674537|NCT01662544|Procedure|Oxygen delivery|
1674538|NCT01662531|Biological|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
1674539|NCT01662518|Device|Dexamethasone drug delivery system (DDS-25)|350 mg Dexamethasone posterior segment drug delivery system (DDS-25) injection into the vitreous cavity at baseline
1674541|NCT01662492|Biological|Botulinum toxin type A Dose 1|Botulinum toxin type A Dose 1 intramuscular injections into specified muscles.
1674542|NCT01662492|Biological|Botulinum toxin type A Dose 2|Botulinum toxin type A Dose 2 intramuscular injections into specified muscles.
1674543|NCT01662492|Drug|Placebo (Normal Saline)|Placebo (Normal Saline) intramuscular injections into specified muscles.
1674544|NCT01661361|Procedure|blood levels|
1674545|NCT01661335|Drug|Ondansetron, dexamethasone, aprepitant|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no longer than 5 days; dexamethasone 0.2mg/kg (max 10 mg) IV or PO daily for at least 3 days, but no longer than 5 days; and aprepitant 3 mg/kg (max 125 mg) PO on day 1, and aprepitant 2 mg/kg (max 80 mg) PO on days 2 and 3 during the first investigational antiemetic cycle. During the next investigational antiemetic cycle, members of this arm will be crossed-over into the placebo arm, where the aprepitant will be replaced by placebo and the dexamethasone dose will be increased to 0.4 mg/kg (max 20 mg) daily.
1674546|NCT01661335|Drug|Ondansetron, Dexamethasone, placebo|Ondansetron 0.15 mg/kg (max 16 mg) IV or PO every 8 hours for at least 3 days, but no more than 5 days; dexamethasone 0.4 mg/kg (max 20 mg) IV or PO daily for at least 3 days, but no more than 5 days; and a PO placebo for 3 days during the first investigational antiemetic cycle. During the second cycle, members this group will be crossed-over to the experimental arm, where the placebo will be replaced by aprepitant and the dexamethasone will be decreased by 50%.
1674547|NCT01661322|Drug|Aspirin, Dipyradimole, Clopidogrel|Participants in the intensive antiplatelet group will receive Asp+Dip+Clop triple therapy for 28-30 days (to cover the period of maximum risk of recurrence) along with standard 'best care' (including lifestyle advice, BP and lipid lowering). Clop will be given as a loading dose of 300 mg,12 then 75 mg daily, Asp as a loading dose of 300 mg,22 then 75 mg daily, and Dip modified release 200 mg twice daily 9 for 28-30 days.
1674548|NCT01661309|Dietary Supplement|Inactive lozenge|Manufactured to mimic 1mg methylcobalamin lozenge
1674552|NCT01662466|Drug|Testosterone cream (0.5mg per gram)|Testosterone cream 2 gms per day applied transdermally to the left wrist to deliver 1.mg daily dose with estimated absorption of 100 ug per day testosterone
1674553|NCT01662466|Dietary Supplement|DHEA|DHEA 25mg tid
1674554|NCT01662466|Drug|Placebo|Carrier cream without added testosterone in the identical type of pump
1674558|NCT01662427|Other|Questionaire to assess Noctural Parkinson's Disease Symptoms|Questionaire to assess Noctural Parkinson's Disease Symptoms and quality of life
1674559|NCT01662414|Dietary Supplement|Whey protein|1 sachect (10 g) 2times/ day
1674560|NCT01662414|Dietary Supplement|Soy protein|1 sachect (10g) 2times/day
1674561|NCT01662401|Drug|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 3 ml for rectus sheath blocks and 4 ml for ilioinguinal blocks adding up to a total maximum dose of 14 ml.
1674562|NCT01662401|Drug|Bupivacaine|The volume of 0.25% Bupivacaine at 0.075 ml/kg without epinephrine is a maximum of 14 ml.
1674563|NCT01662388|Device|Separation ring|Separation ring placed along with automatrix band
1674564|NCT01662388|Device|automatrix band|band placed with a tightening device
1674565|NCT01662375|Other|Surveillance and interview|The interventional nature of the study is justified by the need for particular monitoring of patients in whom life support is withdrawn following the clinical team's decision. The questions posed to the patient's family and/or relatives, do not modify the care provided to the patient.
1674566|NCT01662362|Device|Testing Donor Specimens with ESA Chagas|Donors will be asked to return for a follow-up blood draw.
1674567|NCT01662349|Device|MOE Antimicrobial Plasma Treatment System|Plasma applied to back for up to 20 minutes, twice/week for 4 weeks
1674568|NCT01662323|Behavioral|GP's treating HF according the dutch guidelines|
1674569|NCT01662310|Drug|Paliperidone|Paliperidone extended-release (ER) oral tablet will be administered at a starting dose of 3 milligram (mg) up to 12 mg once daily for 8 weeks in Run-in or Stabilization phase, and 3-12 mg fixed dose oral tablet will be administered in DB phase. Participants who will enter open-label extension phase will receive paliperidone as 3-12 mg per day.
1674570|NCT01662310|Drug|Placebo|Participants who transitioned from run-in or stabilization phase will receive matching placebo to paliperidone ER once daily during DB phase of the study.
1955132|NCT03287908|Drug|AMG 701|Patients will receive IV infusions of AMG 701
1674573|NCT01662284|Drug|124I-NM404|124I-NM404 administered at either 5mCi or 3mCi on day 1. If PET/CT images are diagnostically inadequate and there are no dose-limiting toxicities at current dose, next patients will receive the next higher level of 7.5 or 10 mCi.
1674574|NCT01662258|Device|Point-of-Care diagnostic laboratory test|All POC tests are FDA-cleared.
1674575|NCT01662232|Dietary Supplement|Green tea beverage|
1674576|NCT01662232|Dietary Supplement|Green tea extract|
1674577|NCT01662232|Dietary Supplement|EGCG|
1674578|NCT01662232|Other|Placebo|
1674579|NCT01662219|Other|Superficial cervical plexus block for experimental group|15 ml of 0.25% Bupivacaine will be given for superficial cervical plexus block
1674580|NCT01662206|Dietary Supplement|Probiotic|2 capsules daily containing Lactobacillus gasseri, Bifidobacterium bifidum and Bifidobacterium longum (1.5 billion cells per capsule prior to expiration)
1674581|NCT01662206|Dietary Supplement|Placebo|2 capsules daily containing 348.25 mg of potato starch
1674582|NCT01662193|Dietary Supplement|vitamin D3 supplement|
1674583|NCT01662193|Dietary Supplement|calcium supplement|
1674584|NCT01662193|Dietary Supplement|vitamin D3 and calcium supplement|
1674585|NCT01662193|Dietary Supplement|placebo|
1674586|NCT01662180|Drug|Follicle Stimulating Hormone|All patients will receive a fixed 75 IU rec follicle stimulating hormone per day subcutaneous injection stimulation protocol starting from cycle day 3, 4 or 5. The intervention done in this study is conform normal stimulation protocol and is not the target of this study.
1674587|NCT01662167|Drug|Single|In the single dose regimen, 50 mg/m2 intramuscular methotrexate was given on day one and hCG level was measured on days four and seven. If the hCG level did not decrease by 15% between day four and seven, a second dose of methotrexate was injected on day seven, hCG level was measured weekly until a level of 15 mlU/ml or less was achieved
1674588|NCT01662167|Drug|Multipe|In the multiple dose regimen, 1 mg/kg/day intramuscular methotrexate was given on days one, three, five and seven and 0.1 mg/kg/day intramuscular Citrovoram factor was administered on days two, four, six and eight until serum hCG level decreased 15% in 48 hours or four doses of methotrexate was given weekly until serum hCG level of 15 mlU/ml or less was obtained
1674589|NCT01662154|Device|Neurometer assessment|Activity of nerve(s) to be blocked will be assessed with the Neurometer before and after administration of local anesthetic.
1674590|NCT01662154|Device|Nerve stimulator assessment|Activity of nerve(s) to be blocked will be assessed with the Stimuplex HNS 12 nerve stimulator before and after administration of local anesthetic.
1674591|NCT01662128|Drug|Xeloda|Xeloda as Adjuvant Therapy
1674592|NCT01662115|Drug|Nicotine gum|Patients will chew nicotine gum 3 times a day until discharge or 7 days, whichever comes first
1674593|NCT01662115|Other|Regular chewing gum|Patients will chew regular sugar-free gum 3 times a day until discharge or 7 days, whichever comes first
1674594|NCT01662102|Drug|Zevalin|Group A: Response consolidation with a single dose of 90Y-ibritumomab tiuxetan (Zevalin®) 0.4 mCi/Kg - Maximum dose: 32 mCi given with 2 doses of rituximab followed by observation for 24 months;
1674595|NCT01662102|Drug|Rituximab|Group B: Response maintenance with 375 mg/m^2 of rituximab every 8 weeks for 24 months (12 infusions)
1674596|NCT01662089|Drug|15 mg Chelate zinc supplement|15 mg Chelate zinc additional to standard 5% minoxidil
1725355|NCT00005964|Drug|prednisone|
1674598|NCT01662076|Other|Homeopathic Remedies|The homeopathic remedy will be administered as either 1 globule sublingual or 0.2 mL oral (depending on chosen formulation) up to 3 times per day. The homeopath will decide which formulation will be used. Homeopathic remedies prepared according to the standards as set out by Health Canada. The caregiver or patient will be asked to administer the homeopathic remedy at least 30 minutes before or after taking other medications, food and strong smelling substances (such as camphor, mint, or coffee).
1674599|NCT01662063|Drug|Tocilizumab|TCZ will be given as 162 mg SC QW or Q2W for up to 96 weeks.
1674601|NCT01662037|Drug|Bosentan|Bosentan 2mg/kg/dose twice a day and routinely therapy in children with functional single ventricle during the period of staged Fontan procedure with high risk of increased PVR.
1674602|NCT01662024|Device|Endoscopic gastric restrictive procedure|Endoluminal gastric tissue approximation using an incisionless/per-oral endoscopic suturing device for primary gastric restrictive procedures
1674603|NCT01662011|Device|mode of neurally adjusted ventilatory assist|patients ventilated with the mode of neurally adjusted ventilatory assist after corrective open-heart surgery
1674604|NCT01662011|Device|Mode of pressure support ventilation|Patients ventilated with the mode of pressure support ventilation after corrective open-heart surgery
1674605|NCT01661985|Drug|Azithromycin|In the randomized arm giver orally 1 g as a single dose. In the non-randomized arm given for 5 days 250mg 2x1 first day and 1x1 following four days.
1674606|NCT01661985|Drug|Doxycycline|Doxycycline tablets 100 mg 2x1 the first day and 100 mg daily for following eight days (following the Swedish tradition and experience since the 1970s of treating chlamydia)
1674607|NCT01661985|Drug|lymecycline|Lymecycline 300 mg twice daily for 10 days (Summertime due to less risk of phototoxic reactions)
1674608|NCT01661972|Drug|Capecitabine and aflibercept|"Capecitabine given on days 1-14 and off days 15-21. Dose: Phase 1 cohort 1 850mg/m2 Phase 1 cohort 2 1000mg/m2, Phase 2 RPTD.
Aflibercept will be held constant at 6 mg/kg, given intravenously every 3 weeks.
Both agents will be administered on a 21-day cycle."
1674609|NCT01661946|Drug|Bevacizumab|Bevacizumab is an off-label but cheaper treatment for diabetic macular edema.
1674610|NCT01661946|Drug|Ranibizumab|Ranibizumab is a vascular endothelial growth factor inhibitor designed for ocular use
1674611|NCT01661933|Biological|Necator americanus|Previously inoculated subjects will be further inoculated as previously undertaken with 20 3rd stage infective Na larvae (10 + 10 over 4 weeks). Four weeks after the 2nd inoculation, each participant will receive a micro-dose of gluten (10 mg daily) as pasta for 8 weeks, to be followed by a low-dose of gluten (50 mg daily) for 8 weeks. After this, a detailed assessment involving upper endoscopy and duodenal biopsy will be performed before deciding on an individual case basis that it is safe for the participant to proceed to challenge. A gluten challenge of 1 G (15-20 G of pasta or a ½ slice of standard white bread) twice weekly for 12 weeks will commence.
1674612|NCT01661933|Biological|Necator americanus|After completion of the previously planned challenge, volunteers will be invited to extend the gluten challenge. The extension is for 4 weeks total. The gluten challenge is stepwise: gluten 10 mg daily for one week, 50 mg daily for one week and finally 3 grams daily for 2 weeks. The outcome measure is serum tissue transglutaminase to be compared before and after the intervention.
1674613|NCT01661920|Other|Intervention group|Shorten the duration of antibiotic treatment from 7-10 days to 5 days.
1674614|NCT01661920|Other|Control group|Those antibiotic duration treatments which are not modified by their doctors.
1674615|NCT01661907|Procedure|Combined Epi-GA/PCEA|An epidural catheter will be placed before the induction of general anesthesia. General anesthesia will be induced and maintained as in the control group, with the addition of epidural anesthesia which will be maintained with the use of 0.5%-0.75% ropivacaine during surgery. Patient controlled epidural analgesia will be provided after surgery.
1674616|NCT01661907|Procedure|GA/PCIA|General anesthesia will be induced with midazolam, propofol, sufentanil and rocuronium. Anesthesia will be maintained with either intravenous (propofol), inhalational (sevoflurane with or without nitrous oxide), or combined intravenous-inhalational anesthetics. Additional opioids (remifentanil, sufentanil, fentanyl, or morphine) and muscle relaxant (rocuronium, atracurium, or cisatracurium) will be administered when deemed necessary by the attending anesthesiologists. Patient-controlled intravenous analgesia will be provided after surgery.
1674617|NCT01661894|Device|BrainPalTM|Brain-computer Interface (BCI) is a direct communication pathway between a human brain and an external device. It is a technology that enables people to interact with computers through their thoughts. Electroencephalography (EEG) is the best studied non-invasive interface facilitating such communication. The BCI system will take EEG recordings from the prefrontal cortex to determine the participants' state of attention with high specificity. The training program developed using this patented technology may be useful for individuals who experience difficulty with memory and sustaining their attention.
1674618|NCT01661881|Drug|Rituximab|
1674619|NCT01661881|Drug|Bendamustine|
1674620|NCT01661881|Drug|Cytarabine|
1674621|NCT01661868|Drug|Olaparib|Tablet formulation will be used.
1674622|NCT01661855|Drug|Riluzole|50mg once daily (QD) for 12 weeks for participants 6-11 years old; 50mg twice daily (BID) for 12 weeks for participants 12-17 years old
1674623|NCT01661855|Drug|Placebo|Placebo comparator once daily (QD) for 12 weeks for participants 6-11 years old; Placebo comparator twice daily (BID) for 12 weeks for participants 12-17 years old
1674624|NCT01661842|Other|conventional plus UC-MSC treatment|Received conventional treatment and taken i.v., once per 4 week, at a dose of 1×106 UC-MSC/kg body weight for 12 weeks.
1674625|NCT01661842|Other|Conventional plus placebo treatment|Received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks
1674626|NCT01661816|Behavioral|interview|psychological, emotional, family and social parameters
1674627|NCT01661790|Drug|Bevacizumab|Bevacizumab300mg&Cispltin30mg by intrapleural administration of each 2 week
1674628|NCT01661790|Drug|Cisplatin|Cisplatin 30mg,intrapleural administration,each 2 week
1674629|NCT01661777|Drug|Nasal steroid|
1674630|NCT01661777|Procedure|Myringotomy tube placement|
1674631|NCT01661777|Drug|Diuretic|
1674632|NCT01661777|Drug|Antihistamine|
1674633|NCT01661777|Behavioral|Low salt diet|
1674634|NCT01661764|Drug|Eicosapentanoic acid and docosahexanoic acid|1395 mg EPA plus 1125 mg DHA daily for 24 weeks
1674635|NCT01661764|Drug|Oleic Acid|Placebo
1674636|NCT01661751|Biological|ACYW135 Meningococcal Polysaccharide Vaccine|600 subjects were divided into three groups (200 subjects in each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
1674637|NCT01661751|Biological|A+C Meningococcal Polysaccharide Vaccine|300 subjects were divided into three groups (100 subjects in each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group AC Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
1674638|NCT01661738|Biological|Group ACYW135 Meningococcal Polysaccharide Vaccine|360 subjects were divided into three groups (120 subjects in each group), children (2~6 years of age), early youth (7~15 years of age) and adult (16~30 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
1674639|NCT01661725|Biological|Group ACYW135 Meningococcal Polysaccharide Vaccine|60 subjects were divided into three groups (20 subjects each group), adult (16~30 years of age), early youth (7~15 years of age) and children (2~6 years of age) to receive Group ACYW135 Meningococcal Polysaccharide Vaccine, 0.5 ml, one dose regime
1674642|NCT01661686|Device|Partially covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
1674643|NCT01661686|Device|Fully covered SEMS|Boston Scientific, Natick, United States diameter 18 mm, lengths of 10, 12 and 15 cm available
1674644|NCT01661673|Drug|EVP-0962|Arms: 1,2,3,4
1674645|NCT01661673|Drug|Placebo|Arm 5
1674646|NCT01661660|Other|observationnal|Observation during a physical exercise
1674647|NCT01661647|Device|3D knee kinematic assessment under local anesthesia|3D knee kinematic assessment under local anesthesia
1674648|NCT01661634|Drug|Ularitide|
1674649|NCT01661634|Drug|Placebo|
1674650|NCT01661621|Drug|Detrusitol 4 mg QD|Group 1
1674651|NCT01661621|Drug|Doxazosin 4 mg QD|Group 2
1674652|NCT01661608|Device|Using the EOS for gastric restriction|
1674653|NCT01661595|Drug|Sildenafil|50 mg/day for 4 weeks
1674654|NCT01661595|Drug|tadalafil|10 mg/day for 4 weeks.
1674655|NCT01661595|Drug|Placebo|Placebo 1 capsule per day for four weeks.
1674656|NCT01661582|Other|CT/PET Myocardial Perfusion Imaging using O-15 water|
1674657|NCT01661582|Other|Coronary blood flow measured by doppler echocardiography|
1674658|NCT01661569|Other|Headspace On-the-go app|Participants will be given access to a 45-day programme of mindfulness meditation, created and branded by Headspace. They will be encouraged to listen to one meditation podcast each day, or as frequently as possible over 8 weeks.
1674659|NCT01661556|Drug|Miconazole|Miconazole 2% cream will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion as indicated on the affected areas of the face.
1674660|NCT01661556|Drug|Hydroquinone|Hydroquinone 4% cream (Topical use), will be applied twice a day for 9 weeks. The affected surface will be washed and dried before application with a thin layer of the emulsion on affected areas of the face.
1674661|NCT01661543|Dietary Supplement|Beans|90g of beans per day for 5 out of 7 days per week will be given to participants for 6 weeks to determine the cholesterol lowering effects of various pulses.
1674662|NCT01661543|Dietary Supplement|Control (rice)|90g of rice per day will be given to the control group to demonstrate the cholesterol lowering effects of the experimental group.
1674663|NCT01661543|Dietary Supplement|Peas|90 grams of peas will be consumed 5 out of 7 days per week
1674664|NCT01661530|Dietary Supplement|Vitamin E enhanced soup|vitamin E enhancement is by virtue of the natural vitamin E content of the food ingredients
1674665|NCT01661530|Dietary Supplement|Non-enhanced soups|Similar looking and tasting soups with low vitamin E content by virtue of food ingredients
1674666|NCT01661517|Behavioral|Motivational interviewing and referral to treatment|
1674667|NCT01661504|Behavioral|Integrated Screening|The intervention arm will consist of the following components (described in detail below): a) integrated IPV/Sexual and Reproductive Health Screening, b) supportive care, c) safety planning and harm reduction counseling, d) supported referrals, e) booster counseling sessions
1674668|NCT01661478|Other|Training on motivational interviewing|
1674669|NCT01661452|Other|Referral to counseling services if desired|
1674670|NCT01661439|Drug|low molecular weight heparin (enoxeparine)|1mg/kg enoxeparine SC daily from 1st day of the menstrual cycle and continue daily throughout the pregnancy after documentation of pregnancy,and stopped in absence of fetal cardiac activity.
1674671|NCT01661426|Behavioral|Low-Carbohydrate Diet|Counseling/instruction on how to follow a healthy low-carbohydrate diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
1674672|NCT01661426|Behavioral|Low-Fat Diet|Counseling/instruction on how to follow a healthy low-fat diet for 6 months. One evening class/week for 8 weeks (8 total classes). Then one class every other week for 8 weeks (4 total classes). Then one class every four weeks for 8 weeks (2 total classes): 14 evening classes, total.
1674673|NCT01661400|Drug|Metronomic Cyclophosphamide|
1674674|NCT01661400|Drug|Thalidomide|
1674675|NCT01661283|Drug|everolimus|10 mg tablet once daily
1674676|NCT01661283|Drug|bevacizumab|10 mg/kg dose every 14 days
1674677|NCT01661270|Drug|Aflibercept|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
1725449|NCT00005988|Drug|methylprednisolone|
1674678|NCT01661270|Drug|Placebo|Pharmaceutical form: Concentrate for Solution for infusion; Route of administration: Intravenous
1674679|NCT01661257|Drug|Infliximab|
1674680|NCT01661244|Drug|RV568 single dose|Safety and tolerability of single escalating doses in normal human volunteers
1674681|NCT01661244|Drug|RV568 matching placebo single dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
1674682|NCT01661244|Drug|RV568 repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
1674683|NCT01661244|Drug|RV568 matching placebo repeat dose|Safety and tolerability of escalating repeat doses in normal human volunteers.
1674684|NCT01661231|Device|Astron/Pulsar-18 stent|Peripheral Vascular Intervention
1674685|NCT01661205|Device|Ablation procedure staged catheter ablation|AtriCure Bipolar System used in conjunction with a catheter ablation procedure performed 1-10 days apart
1674686|NCT01661192|Drug|AAT( Alpha 1 Antitrypsin)|
1674687|NCT01661179|Drug|Vandetanib 300mg|300 mg oral dose once daily (100 mg x 3 tablets)
1674688|NCT01661166|Drug|Fesoterodine|4 mg
1674689|NCT01661140|Drug|Methotrexate (stable dose)|Methotrexate (MTX) was administered weekly according to the subject's pre-study MTX dose
1674690|NCT01661140|Drug|Tocilizumab|8 mg/kg intravenously every 4 weeks for 72 weeks
1674691|NCT01661140|Drug|Methotrexate (tapering dose)|Tapering doses of methotrexate (MTX) were administered weekly from Week 24 to Week 56. Tapering doses depended on dose administered to the subject during the open label period. First tapering occurred at randomization (Week 24), second tapering at Week 32, third tapering at Week 40 and final tapering at Week 48.
1674692|NCT01661114|Drug|Gemcitabine|
1674693|NCT01661114|Drug|5-FU|
1674694|NCT01661114|Drug|Cisplatin|
1674695|NCT01661101|Drug|Dabigatran|Dabigatran 110 mg taken twice daily
1674696|NCT01661101|Drug|Placebo (for Dabigatran)|Dabigatran placebo taken twice daily
1674697|NCT01661101|Drug|Omeprazole|Omeprazole 20 mg capsule taken once daily
1674698|NCT01661101|Drug|Placebo (for Omeprazole)|Omeprazole placebo taken once daily
1674699|NCT01661088|Drug|FOLFIRINOX|"Starting dose levels as following:
Oxaliplatin 85mg/m2 intravenously over 120 minutes on day 1. Irinotecan 180mg/m2 intravenously over 90 minutes on day 1. NOTE: patients homozygous for the UGT1A1 (TA)7 promoter allele will be treated at an initial lower dose 140mg/m2 (please see Section 6.3.a) Leucovorin 400mg/m2 intravenously over 90 minutes on day 1. 5FU 400mg/m2 as bolus intravenous injection following leucovorin on day 1. 5FU 2,400mg/m2 infused intravenously as a continuous infusion over 46 hours following the bolus 5FU, beginning on day 1."
1674700|NCT01661088|Radiation|Intensity-modulated radiotherapy (IMRT)|The prescribed dose will be 50.0Gy in 2.0Gy per fraction. Heterogeneity of -5% to +10% is permitted provided that normal-tissue constraints are met. The minimal PTV dose is dictated by the normal-tissue constraints. A maximal PTV dose of up to +10% is permitted provided that normal-tissue constraints are met. The mean PTV dose should be as close as possible to 50 Gy.
1674701|NCT01661088|Drug|Gemcitabine during Radiation Therapy|Gemcitabine 1000mg/m2 infused over 100 minutes on days 1, 8, 22, and 29 during the 5-week course of radiation treatment.
1674702|NCT01661088|Drug|Gemcitabine following Radiation Therapy|"Two cycles (infusions) of gemcitabine alone are intended to be given, the first 21 to 28 days following completion of combined modality treatment.
A cycle of treatment is 14 days. A cycle of treatment may begin when ANC ≥ 1,000/mm3, platelets ≥ 100,000/ mm3 and all other treatment related toxicity has resolved to ≤ grade 1."
1674703|NCT01661062|Other|Cone Beam Computed Tomography (CT) Scan|Cone beam CT scan is considered a noninvasive procedure (meaning that the procedure does not require breaking the skin or any tools that physically enter the body). It will add a small amount of additional radiation dose (less than 1%) to the head and neck. The increase in the amount of radiation is only a very small amount more than what patients who get standard daily imaging receive. The amount of radiation from the cone beam CT scans is not significant (less than 1%) when compared to the amount of radiation generally received for treatment of head and neck cancer.
1674704|NCT01660997|Drug|MLN9708|
1674705|NCT01660997|Drug|Dexamethasone|
1674706|NCT01660971|Drug|Dasatinib|Given PO
1674707|NCT01660971|Drug|Erlotinib Hydrochloride|Given PO
1674708|NCT01660971|Drug|Gemcitabine Hydrochloride|Given IV
1674711|NCT01660945|Drug|placebo|
1674712|NCT01660945|Drug|vytorin|
1674713|NCT01660932|Drug|placebo|
1674714|NCT01660932|Drug|omega|
1674715|NCT01660919|Drug|placebo|
1674716|NCT01660919|Drug|rosuvastatin|
1674717|NCT01660906|Drug|Dasatinib|tablets, oral, 100 mg, Once daily, Up to12 months on study,
1674718|NCT01660893|Drug|Tetracaine HCl 3% and oxymetazoline HCl 0.05%|3 unilateral intranasal sprays per dose
1674719|NCT01660893|Drug|Tetracaine HCl 3%|3 unilateral intranasal sprays per dose
1674720|NCT01660893|Drug|Placebo|3 unilateral intranasal sprays per dose
1674721|NCT01660867|Drug|3% saline + oral placebo|nebulized epinephrine + 3% saline + placebo => nebulized epinephrine + 3% saline
1674722|NCT01660867|Drug|0.9% saline + oral dexamethasone|nebulized epinephrine + 0.9% saline + dexamethasone => nebulized epinephrine + 0.9% saline
1674723|NCT01660854|Biological|Heterologous challenge|challenge by the bites of 5 Plasmodium falciparum infected mosquitoes.
1674724|NCT01660854|Drug|Malarone treatment|Three days: 4 tablets 250/100mg per day
1674725|NCT01660841|Drug|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
1674726|NCT01660828|Other|remote ischemic preconditioning (RIPC)|RIPC protocol which consist of three 5-min cycles of bilateral forearm ischemia
1674727|NCT01660815|Drug|florbetapir (18F)|IV injection, 370 MBq (10mCi), single dose
1674728|NCT01660802|Drug|700 μg Dexamethasone|700 μg Dexamethasone intravitreal injection in the study eye on Day 1.
1674729|NCT01660802|Other|Sham|Sham administered in the study eye on Day 1.
1674730|NCT01660789|Behavioral|Physical activity, dietary counseling, coaching|Physical activity, dietary counseling, coaching
1674731|NCT01660763|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
1674732|NCT01660763|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for at least 48 hours. Patients may elect to remain in study for up to 72 hours.
1674736|NCT01660724|Procedure|Ultrasound guided arterial puncture|Arterial puncture is performed using simultaneously ultrasound in order to guide the passage of the syringe from the patient's skin to the artery
1674737|NCT01660724|Procedure|Conventional arterial puncture technique|Arterial puncture is performed using the conventional technique
1674742|NCT01660698|Dietary Supplement|Maltodextrin|maltodextrin powder
1674743|NCT01660698|Dietary Supplement|Probiotic|probiotic blended in maltodextrin powder
1674744|NCT01660685|Behavioral|Tracking|Participants will record their daily weight, physical activity steps and meal replacements online
1674745|NCT01660685|Behavioral|Journaling|Participants will journal to two online writing prompts: one on positive focus and one on goal setting
1674746|NCT01660685|Behavioral|Website|Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.
1674747|NCT01660685|Behavioral|Enhanced Usual Care|Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
1674748|NCT01660672|Drug|LEVETIRACETAM|liquid, 40 mg/kg loading dose and 30mg/kg every 12 hours via nasogastric tube for 3 days--this is standard dose. If primary outcome is not reached, dose escalation to 150, 225, and 300% standard, as needed, will be conducted.
1674749|NCT01660659|Device|Biomass Briquettes and Rocket stove|Biomass briquettes are made from dried peanut shells. Rocket stoves were designed to efficiently burn the briquettes
1674750|NCT01660646|Behavioral|Behavioral: community sensitization|Behavioral, enhanced case finding (ECF) by community sensitization via audiovisual presentation in local languages, a session for questions and answers and opportunity to provide sputum specimens for detection of TB
1674751|NCT01660633|Drug|High-Dose Melphalan HCL for Injection (Propylene Glycol-Free)|200 mg melphalan/m2 will be divided into two separate, consecutive doses of 100 mg/m2 administered on day -3 and day -2 prior to ASCT. The High-Dose Melphaln HCL for Injection (Propylene Glycol-Free) will be reconstituted to 5 mg/mL (also containing 270 mg/mL of Captisol®). The Melphalan HCL for Injection (Propylene Glycol Free) will be further diluted with normal saline to a concentration of no greater than 0.45 mg/mL and infused over 30 minutes ( + or - 3 minutes)via a central venous catheter.
1674752|NCT01660620|Drug|Betaxolol|
1674753|NCT01660620|Drug|topical betaxolol|given topically
1674754|NCT01660607|Biological|Conventional T cells (Tcon) and Regulatory T cells (Treg)|A baseline cell dose of conventional T cells of 1x10^6/kg will be used with escalation to the maximum tolerated dose up to 1x10^7/kg
1674755|NCT01660594|Other|CT calcium scoring|CT Calcium scoring was performed in the patients as an imaging test in addition to the traditional assessment on the same day of patients attending the chest pain clinic on the first visit. This was performed with standard protocol and the absolute calcium score was calculated.
1674756|NCT01660581|Biological|intramyocardial injection (electromechanical mapping based)|Patient will undergo 3D electric and mechanical intracardiac mapping; based on maps generated intramyocardial administration of autologous CD133+ cells or placebo will be performed.
1674757|NCT01660581|Biological|Placebo|Patients in the placebo group receive 0.9% NaCl solution with 0.5% solution of the patient's own serum.
1674758|NCT01660542|Drug|Neoadjuvant Chemotherapy with Docetaxel|Doxorubicin 60 mg/m2 plus cyclophosphamide 600 mg/m2 (day 1), IV (in the vein), every 21 days, a total of 4 cycles -> Docetaxel 100 mg/m2 (day 1) IV, every 21 days, a total of 4 cycles
1674759|NCT01660529|Biological|hTERT|
1674760|NCT01660503|Dietary Supplement|0 grams SCF|Given in snack foods (muffins and flavored beverage)
1674761|NCT01660503|Dietary Supplement|10 grams SCF|Given in snack foods (muffins and flavored beverage)
1674762|NCT01660503|Dietary Supplement|20 grams SCF|Given in snack foods (muffins and flavored beverage)
1674763|NCT01660490|Procedure|ORIF|Open reduction internal fixation of the proximal femur
1674764|NCT01660477|Drug|Isavuconazole|oral
1674765|NCT01660477|Drug|Lopinavir/ritonavir|oral
1674766|NCT01660464|Behavioral|CBT Based Self-help Workbook + Counseling Telepho|Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation. Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet.
1674769|NCT01660412|Drug|Standard of Care First|For the second injection, and randomly after that, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to ~7.40.
1674770|NCT01660412|Drug|ph Altered first|For the first injection, Sodium Bicarbonate will be compounded with Tc-99m SC, to raise the pH up to ~7.40. For the second injection, the standard of care will be given, and randomly after that either standard of care, or pH altered will be given.
1674771|NCT01660399|Drug|Boanmycin|Boanmycin 5-6 mg/m2 + DXM 5mg IVD or IM, day 3,5,10,12, 21days a cycle.
1674772|NCT01660399|Drug|Docetaxel|Docetaxel 75mg/m2, intravenous infusion, day 1.
1674777|NCT01660373|Drug|Tirofiban|0.4ug/kg/min for 30min followed by 0.1ug/kg/min
1674778|NCT01660373|Drug|Ticagrelor|loading dose(180mg) followed by maintenance dose(90mg bid)
1674779|NCT01660360|Biological|Tanibirumab|
1674780|NCT01660347|Biological|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
1674781|NCT01660347|Biological|Peripheral blood stem cell transplantation|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
1674782|NCT01660347|Procedure|Management of therapy complications|Undergo allogeneic PBSCT boost using the CliniMACS CD34 Reagent System
1674783|NCT01660334|Drug|Voriconazole|"Voriconazole Intravenous Solution 200 mg:
Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.
Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:
administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.
Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.
However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.
In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.
Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
1674784|NCT01660321|Drug|spinosad|A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
1674785|NCT01660295|Drug|Certoparin 3,000 IU Once Daily|Certoparin 3,000 IU subcutaneous injection once daily
1674786|NCT01660295|Drug|Certoparin 3,000 IU Twice a Day|Certoparin 3,000 IU subcutaneous injection twice a day
1674787|NCT01660295|Drug|Certoparin 8,000 IU Once Daily|Certoparin 8,000 IU subcutaneous injection once daily
1674788|NCT01660295|Drug|Certoparin 8,000 IU Twice a Day|Certoparin 8,000 IU subcutaneous injection twice a day
1674789|NCT01660256|Drug|OPC-12759|Instillation, 4 times/day for 4 weeks
1674790|NCT01660256|Drug|Placebo|
1674791|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 2.5μg|2.5 μg (2capsules) once daily for 8 weeks
1674792|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 5μg|5 μg (2capsules) once daily for 8 weeks
1674793|NCT01660243|Drug|Nalfurafine hydrochloride(MT-9938) 10μg|10 μg (2capsules) once daily for 8 weeks
1674794|NCT01660243|Drug|Placebo|Placebo (2capsules) once daily for 8 weeks
1674795|NCT01660230|Biological|3K3A-APC, diluted in 0.9% sodium chloride in water|
1674796|NCT01660230|Drug|0.9% NaCl in water|
1674797|NCT01660217|Other|A written Eczema Action Plan (EAP)|A written Eczema Action Plan (EAP) was given to the patients with their treatment regimen.
1674798|NCT01660204|Other|Preferred empirical treatment|The investigators are using a cluster-randomized cross-over design for preferred empirical treatment. One of the 3 treatment arms is used as preferred empirical therapy during a period of 4 consecutive months, after which preferred treatment will rotate to 1 of the other 2 regimens. The order of change is randomised per hospital, thereby controlling for inter-hospital variables and minimizing seasonal influences.
1674799|NCT01660191|Drug|Pitavastin 4mg|
1674800|NCT01660191|Drug|Atorvastatin 20mg|
1674801|NCT01660191|Drug|Rosuvastatin 5mg|
1674802|NCT01660152|Other|Sexual Health Inventory for Men (SHIM) questionnaire administration|Questionnaire will be completed prior to surgery and at 3, 6, 12 months and the compliance questionnaire at 3, 6, 12 months.
1674803|NCT01660152|Procedure|management of therapy complications|Receive VED
1674804|NCT01660152|Procedure|Daily vacuum therapy|Patients randomized to Group A or Group B following removal of catheter at first post op visit following surger. Daily vacuum therapy for approximately 10 minutes. Depending on which group randomized to erection held for 2 minutes or 5 mintues.
1674805|NCT01660126|Drug|Levothyroxine|The intervention will start with Levothyroxine 50 µg daily (reduced to 25 µg in subjects <50Kg body weight or if known coronary heart disease - previous myocardial infarction or symptoms of angina pectoris) versus matching placebo; at 3 months if the serum TSH level is <0.4 mU/L dose will be reduced by 25 µg; TSH >=0.4 and <4.6 mU/L, no change to dose; TSH >=4.6mUL, additional 25 µg. The process will be repeated at 12 months then annually. Mock titration will be performed in the placebo group. The maximum possible dose of Levothyroxine that will be prescribed is 150μg.
1674806|NCT01660126|Drug|Placebo|
1674807|NCT01659021|Drug|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
1674808|NCT01659021|Drug|Ofatumumab|Ofatumumab administered intravenously
1674809|NCT01659008|Drug|Estradiol|
1674810|NCT01659008|Drug|Lysteda|
1674811|NCT01658995|Drug|Doxycycline|Doxycycline 100 mg oral capsules twice daily for 10 days
1674812|NCT01658995|Drug|Placebo|Placebo, one capsule orally twice daily for 10 days
1674813|NCT01658982|Other|cardiopulmonary exercise testing|3 minute step test compared to 6 minute bicycle test
1674814|NCT01658956|Drug|GCSF administration on days 8 and 12 after chemotherapy|
1674815|NCT01658943|Drug|Akt Inhibitor MK2206|Given PO
1674816|NCT01658943|Drug|Fluorouracil|Given IV
1674817|NCT01658943|Drug|Oxaliplatin|Given IV
1674818|NCT01658943|Drug|Selumetinib|Given PO
1674821|NCT01658904|Drug|Carfilzomib|
1674822|NCT01658904|Drug|Melphalan|
1674823|NCT01658904|Drug|Filgrastim|
1674826|NCT01660087|Device|Biophotonic platform for VOC detection|Multiplex detection of VOCs with high sensitivity and specificity using a novel biophotonic device.
1674827|NCT01660074|Other|test food|All food, include reference food was tested in 50g available carbohydrate portion size.
1674828|NCT01660048|Procedure|SILS TEP repair|perform the laparoscopic total extraperitoneal inguinal hernia repair using a single port
1674829|NCT01660048|Procedure|Total extraperitoneal inguinal hernia repair|Conventional multiport laparoscopic total extraperitoneal inguinal hernia repair
1674830|NCT01660022|Drug|100mg OZ439 single oral dose|100mg OZ439 oral suspension single dose
1674831|NCT01660022|Drug|Placebo|Placebo
1674832|NCT01660022|Drug|300 mg OZ439 single oral dose|300mg OZ439 oral suspension single dose
1674833|NCT01660022|Drug|160mg Piperaquine single oral dose|160 mg Piperaquine tablet
1674834|NCT01660022|Drug|480mg Piperaquine single oral dose|480 mg Piperaquine tablet
1674835|NCT01660022|Drug|1440mg Piperaquine single oral dose|1440 mg Piperaquine tablet
1674836|NCT01660022|Drug|800 mg OZ439 single oral dose|800mg OZ439 oral suspension single dose
1674837|NCT01660009|Other|Glycemic clamping|During hypoglycemic clamping, individuals will have a blood glucose level of 50-60 mg/dL for approximately 1 hour prior to outcome measurements. During euglycemic clamping, individuals will have a blood glucose level of 85-99 mg/dL for approximately 1 hour prior to outcome measurements.
1674838|NCT01659996|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
1674839|NCT01659996|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate + Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
1674840|NCT01659996|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate|0.5 mL, Intramuscular
1674841|NCT01659983|Procedure|Primary wound closure|A wound will be sutured immediately after the operative procedure uisng non-absorbable monofilament suture or stapler at intervals of one centimeter apart and 0.5 cm back from a wound edge.
1674842|NCT01659957|Behavioral|Group Couples Counseling|
1674843|NCT01659957|Behavioral|One-on-One Couples Counseling|
1674844|NCT01659944|Drug|Eliglustat|Capsules for oral administration
1674845|NCT01659944|Drug|Metoprolol|Tablets for oral administration
1674846|NCT01659931|Drug|Montelukast|10 mg Tablet
1674847|NCT01659931|Drug|Singulair|10 mg Tablet
1674848|NCT01659918|Drug|Montelukast|
1674849|NCT01659918|Drug|Singulair|
1674850|NCT01659905|Drug|Montelukast|Chewable Tablet
1674851|NCT01659905|Drug|Singulair|5 mg Chewable Tablet
1674852|NCT01659892|Drug|Montelukast|5 mg Chewable Tablet
1674853|NCT01659892|Drug|Singulair|5 mg Chewable Tablet
1674854|NCT01659879|Behavioral|Multimedia information|
1674855|NCT01659879|Behavioral|verbal information|
1955139|NCT03284931|Drug|SAGE-217 high dose|high dose
1955140|NCT03284931|Drug|Placebo|placebo
1955141|NCT03284931|Drug|SAGE-217 low dose|low dose
1674869|NCT01659853|Drug|CD07805/47 gel 0.5%/CD07805/47 Vehicle|"To maintain masking, CD07805/47 gel 0.5% will be administered along with CD07805/47 gel vehicle.
During each treatment period (baseline to Day 15):
CD07805/47 gel 0.5%, topical, once daily and CD07805/47 gel vehicle, topical, once daily"
1674870|NCT01659853|Drug|azelaic acid gel 15%|During each treatment period (baseline to Day 15): azelaic acid gel 15%, topical, twice daily
1674871|NCT01659840|Radiation|Red laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
1674872|NCT01659840|Radiation|Infrared laser|On the pain points of muscle, laser was applied (8J/cm ²) with an interval of 48 hours between applications. In the joints with sensitivity, a dose of 4J/cm2 laser was applied with an interval of 48 hours between applications.
1674873|NCT01659827|Other|Marcaine|Injection of 2cc of Marcaine
1674874|NCT01659827|Other|0.5cc AmnioFix|Injection of 0.5cc of AmnioFix Injectable
1674875|NCT01659827|Other|1.25cc AmnioFix|Injection of 1.25cc of AmnioFix Injectable
1674876|NCT01659827|Other|Saline|Injection of 1.25cc of Saline
1674877|NCT01659801|Device|BunnyLens TR|BunnyLens TR IOL is an Aspheric Toric intraocular lens providing a precise, superior alternative to surgical treatment of pre-existing corneal astigmatism.
1674878|NCT01659788|Dietary Supplement|Coenzyme Q10 concomitant treatment|
1674879|NCT01659788|Dietary Supplement|Placebo|
1674880|NCT01659775|Drug|Sancuso patch|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.
Experimental arm: Sancuso patch (34.3mg) applied to upper, outer arm 2days (48-24hours) prior to start of chemotherapy."
1674881|NCT01659775|Drug|Zofran inj.+Zofran tab.|"Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.
Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5."
1674882|NCT01659762|Biological|autologous mesenchymal stromal cell|
1674883|NCT01659749|Behavioral|Metabolic camp|To use an recreational camp setting to instruct PKU females of reproductive age how to make responsible dietary and reproductive decisions.
1674884|NCT01659736|Device|TMS|Treatment will entail daily (5 days/week) sessions of TMS for 6 weeks.
1674885|NCT01659723|Drug|Hyperbaric Oxygen|100% oxygen at 240-250 kPa will be delivered to the patents for 80-90 minutes while sitting or lying in a hyperbaric oxygen chamber. Patients will receive treatment once every day, except week-ends, for 40 days.
1674886|NCT01659697|Behavioral|intensive lifestyle counseling|Intensive lifestyle counseling will include a bi annual visit of the primary physician and nurse, a group intervention about use of medical resources, healthy lifestyle a one to one intervention with a dietician about diet and a one to one intervention with a physiotherapist about exercise
1674887|NCT01659684|Biological|standard intravenous immunoglobulin|Human standard intravenous immunoglobulin (IVIG), 0.5 g/Kg of body weight, monthly after confirmation of primary gestational CMV infection
1674888|NCT01659671|Procedure|Uvulopalatopharyngoplasty|Uvulopalatopharyngoplasty: Resection of the soft palate 3 mm and tonsillectomy, amputation of the uvula to approx 1 cm, single sutures of the posterior pillar to the anterior pillar and of the soft palate.
1674889|NCT01659658|Drug|IXAZOMIB|IXAZOMIB capsules
1674890|NCT01659658|Drug|Dexamethasone|Dexamethasone tablets
1674891|NCT01659658|Drug|Melphalan|Melphalan tablets
1674892|NCT01659658|Drug|Cyclophosphamide|Cyclophosphamide tablets
1674893|NCT01659658|Drug|Thalidomide|Thalidomide capsules
1674894|NCT01659658|Drug|Lenalidomide|Lenalidomide capsules
1674895|NCT01659645|Drug|FACBC|Drug FACBC will be given intravenously (IV) over 2 minutes prior to performing the PET scan
1674896|NCT01659619|Drug|Erythromycin|125mg in normal saline single use infusion for 5 min.
1674897|NCT01659606|Biological|alemtuzumab|Conditioning: alemtuzumab 0.2 mg/kg/dose IV x 5 doses
1674898|NCT01659606|Drug|Fludarabine|fludarabine 30 mg/m2/dose IV x 6 doses
1674899|NCT01659606|Drug|Cyclosporins|
1674900|NCT01659606|Drug|Mycophenolate mofetil|
1674901|NCT01659593|Other|procog|3 to 5 people group program
1674902|NCT01659593|Other|Placebo|
1674903|NCT01659580|Drug|T89 high dose|225mg bid
1674904|NCT01659580|Drug|T89 Low dose|150mg bid
1674905|NCT01659580|Drug|Sanqi+Bingpian|225 mg bid
1674906|NCT01659580|Drug|Placebo|225mg bid
1674907|NCT01659567|Drug|Pegylated Interferon Alfa-2a|Pegylated interferon alfa-2a will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
1674908|NCT01659567|Drug|Ribavirin|Ribavirin will be administered according to the current standard of care and in line with current summaries of product characteristics/local labelling.
1674909|NCT01659554|Drug|Cisplatin|Cisplatin (75 mg/m2) prepared in 2L normal saline.
1674910|NCT01659554|Drug|Doxorubicin|Doxorubicin (25 mg flat dose) prepared in 500 ml dialysis fluid (glucose or icodextrin-based).
1674911|NCT01659541|Device|Expiratory muscle stimulator|The expiratory muscle stimulator consists of two small electrodes (wire leads) implanted on the surface of the spinal cord on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
1674912|NCT01659541|Procedure|Implantation of device|The expiratory muscle stimulator consists of two wire leads(each with two metal contacts) inserted onto the surface of their spinal cord on the lower back using a needle. The procedure to implant these wire leads is commonly used today for other purposes. This is a minimally invasive surgical technique with minimal risks. The wire leads are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box to stimulate the expiratory muscles and restore cough.
1674913|NCT01659515|Drug|Arbekacin Sulfate|Intravenous arbekacin in a total daily dose of 5-7 mg/kg
1674914|NCT01659502|Drug|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles
1725878|NCT00005640|Procedure|Gamma Probe|
1674915|NCT01659476|Other|Methacholine(MCh) Challenge Testing|"Visit 1: High-dose methacholine challenge test
Visit 2 or 3: Will be conducted in random order and subjects will perform one of two modified single-dose methacholine challenge tests at either visit. During these modified challenges, subjects will (a) perform five DIs from functional residual capacity (FRC) to total lung capacity (TLC) back to FRC, or (b) refrain from taking DIs prior to inhaling the previously measured single PC20 dose of methacholine."
1674916|NCT01659476|Other|Methacholine(MCh) Challenge Testing|"Visit 1: Baseline tests, and subjects will be randomized to complete either a high-dose methacholine using maximal expiratory flow-volume loop (MEFV), or a high-dose methacholine challenge with impulse oscillometry (IOS) and partial expiratory flow-volume loop (PEFV) and MEFV at each dose step.
Visit 2: Subjects will perform the opposite protocol, based on their first visit:"
1674917|NCT01659463|Other|ICON|LOW VISCOSITY RESIN WILL BE APPLIED IN EARLY PROXIMAL CARIES LESIONS
1674918|NCT01659463|Behavioral|instruction oral hygiene|Instructions diet and hygiene oral and topical fluoride
1674919|NCT01659450|Other|low energy dense|This group received a diet appropriate with their weight in the form of low energy density diet
1674920|NCT01659450|Other|control|This group received a diet appropriate with their weight in the form of an usual diet regarding the energy density.
1674921|NCT01659450|Other|diet|Calorie requirements of each subject were estimated based on resting energy expenditure (by the use of Harris-Benedict equation) and physical activity levels.
1674924|NCT01659424|Radiation|High Dose Rate Endorectal Brachytherapy (HDR-ERBT)|Combining pre-operative FOLFOX chemotherapy with HDR-ERBT (Radiation therapy) followed by surgery then additional FOLFOX chemotherapy to decrease the risk of distant metastasis and to maintain excellent locoregional control with decreased morbidity.
1674925|NCT01659411|Other|Observational|Yearly clinical visits
1674926|NCT01659398|Device|External Counterpulsation (EECP)|A noninvasive neuroimaging technique. Administration of 35 hours EECP therapy over a 7 week period. EECP to be administered for 1 hour, 5 times a week.
1674927|NCT01659372|Radiation|low level laser therapy|
1674928|NCT01659372|Drug|Naproxen|
1674929|NCT01659359|Device|Virtual reality glasses and Lidocaine|The samples were randomly allocated to use Virtual reality glasses and 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
1674930|NCT01659359|Drug|Lidocaine|The samples were randomly allocated to use 5 ml Lidocaine2% for decreasing pain and anxiety in episiotomy repair.
1674931|NCT01659346|Procedure|Endoscopic Variceal Ligation|Endoscopic Variceal Ligation every 3 weeks till eradication.
1674932|NCT01659346|Drug|Carvedilol|Carvedilol 3.125mg BD increased after 1 week to reach 6.25mg BD
1674933|NCT01659320|Drug|Minocycline|Minocycline 100 mg twice daily for 8 weeks
1674934|NCT01659307|Drug|Aspirin 75mg|Subjects randomised to aspirin 75mg will receive 1 container containing aspirin 75mg and 1 container containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
1674935|NCT01659307|Drug|Lactose powder|Subjects randomised to placebo will receive 4 containers of placebo, 2 containers containing placebo for the morning and 2 containers containing placebo for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
1674936|NCT01659307|Drug|Aspirin 1200mg|Subjects randomised to aspirin 600mg 12 hourly will receive 2 containers of aspirin 300mg each for the morning and 2 containers of aspirin 300mg each for the evening. Subjects will take one capsule from each container in the morning and one capsule from each container in the evening.
1674937|NCT01659294|Behavioral|Nurse Case Management|
1674938|NCT01659294|Behavioral|standard diabetologist care|routine care by diabetologist & team
1674939|NCT01659281|Drug|Artesunate|6 mg/kg/day for 2 days (total dose 12 mg/kg)
1674940|NCT01659281|Drug|Artesunate|4 mg/kg/day for 3 days
1674941|NCT01659281|Drug|Mefloquine|15mg/kg at T=0 and 10 mg/kg 6-24 hours later
1674942|NCT01659281|Drug|Mefloquine|8 mg/kg daily for 3 days
1674943|NCT01659268|Other|Simulation class|"The students will be submitted a simulation scenario in laboratory with low-fidelity mannequin for 60 minutes, in subgroups of 4-5 students. The simulated condition is a patient in respiratory failure which need of emergency interventions.
The approach concepts of anatomic, physiology and clinical interventions using LMA will be discussed during simulation."
1674944|NCT01659268|Other|Exhibition-dialogued class|"The students randomized to CG will be submitted to exhibition-dialogued class with duration of 60 minutes; after this, will go to practical activity in skill lab using the low-fidelity mannequin with duration of 35 minutes.
Each subgroup will be composed of 5-6 students for the practice activity which will last 45 minutes."
1674945|NCT01659255|Drug|ONO/GS-4059|ONO/GS-4059 capsule(s) once or twice daily (starting dose: 20 mg)
1674946|NCT01659242|Drug|Methotrexate plus sulfasalazine|"ARM 1(Methotrexate(MTX) plus Sulfasalazine(SSZ))
SSZ:Oral form, 2g/day, with escalation regime starting from 1g/day for the first week and increase to 1.5g/day in the next week and increasing to 2g/day by the third week. Total treatment period is 16 weeks. After reaching 2g/day, if patients conditions warrants (and no contraindication), SSZ may be increased at 0.5g per clinic visit) up to a maximum of 3g/day.
MTX:Kept at the highest optimal dose."
1674947|NCT01659242|Drug|Leflunomide|"ARM 2:Leflunomide(LEF)
LEF: Oral form, 20mg every other day for first 2 weeks then increasing to 20mg per day by the third week. Total treatment period is 16 weeks.
Methotrexate:Off"
1674948|NCT01659203|Radiation|IG-IMPT|Daily, Monday-Friday for about 6 weeks
1674949|NCT01659203|Radiation|IG IMRT|Daily, Monday-Friday for about 6 weeks
1674950|NCT01659190|Other|Oiled-limestone liniment|
1674951|NCT01659177|Drug|LY2140023|Administered orally
1674952|NCT01659164|Behavioral|Group treatment for adults with ADHD|14 weeks of group treatment for adults with ADHD
1675038|NCT01658462|Drug|Nintedanib|"200 mg x 2 per os daily from D2*
*No Nintedanib on days when docetaxel is administered"
1726174|NCT00011505|Drug|G-CSF|
1674957|NCT01659138|Drug|SAR339658|"Pharmaceutical form:solution for infusion
Route of administration: intravenous"
1674958|NCT01659138|Other|Placebo|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1674959|NCT01659125|Behavioral|"OCFighter"|OCFighter™ s an interactive, internet guided self-help (GSH) treatment program for obsessive-compulsive disorder (OCD). It uses the evidence based approach known as Cognitive Behavioral Therapy (CBT) and was adapted from the previously validated BT STEPS program for OCD. The program teaches the best practice CBT technique to help with OCD called exposure with ritual prevention (ERP).
1674960|NCT01659112|Other|Core Stabilization|A 6-week (3 days a week) exercise intervention including progressive core exercises was performed.
1674961|NCT01659112|Other|Traditional upper extremity rehabilitation|A 6-week (3 days a week) exercise intervention of the injured joint based on the recovery process was performed.
1674962|NCT01659099|Drug|GA101|in GA-ACBVP or in GA-CHOP 1000 mg on D1 and D8 (D8 in cycle 1 and 2)
1674963|NCT01659099|Drug|Rituximab|in R-ACBVP or in R-CHOP 375 mg/m² on D1
1674964|NCT01659099|Drug|Doxorubicin|in ACBVP : 75 mg/m² on D1 in CHOP : 50 mg/m² on D1
1674965|NCT01659099|Drug|Cyclophosphamide|in ACBVP : 1200 mg/m² on D1 in CHOP : 750 mg/m² on D1
1674966|NCT01659099|Drug|Prednisone|in ACBVP : 60 mg/m² from D1 to D5 in CHOP : 40 mg/m² from D1 to D5
1674967|NCT01659099|Drug|Bleomycin|in ACBVP 10 mg from D1 to D5
1674968|NCT01659099|Drug|Vindesin|in ACBVP 2 mg/m² from D1 to D5
1674969|NCT01659099|Drug|Vincristine|in CHOP 1,4 mg/m² on D1
1674970|NCT01659086|Biological|Investigational H9N2 vaccine GSK2654911A|2 or 3 doses of GSK2654911A (different formulations) followed by 1 or 0 dose of saline placebo respectively, depending in the treatment group. All doses to be administered intramuscularly (IM) in deltoid region of arm.
1674971|NCT01659086|Biological|Investigational H9N2 vaccine GSK2654909A|2 or 3 doses of GSK2654909A followed by 1 or 0 dose of saline placebo, respectively (treatment 5). All doses to be administered IM in deltoid region of arm.
1674972|NCT01659086|Biological|Placebo|1 dose of saline placebo administered intramuscularly (IM) in deltoid region of arm.
1674973|NCT01659073|Procedure|Caloric Vestibular Stimulation|
1674974|NCT01659060|Other|Flavanol-rich dark chocolate|The primary objective of this pilot RCT is to test the feasibility of design methods and procedures for later use on a larger scale. The secondary objective is to examine the acute and chronic effect of dark chocolate on endothelial function and blood pressure, among healthy pregnant women.
1674975|NCT01659060|Other|Placebo Chocolate|Placebo intervention
1674976|NCT01659047|Drug|GS-1101|150 mg taken twice daily by mouth
1674977|NCT01659034|Drug|Thienopyridine for 3 months|
1674978|NCT01658891|Drug|combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg|beclomethasone dipropionate 50µg + formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
1674979|NCT01658891|Drug|free combination of beclomethasone dipropionate 100µg + Formoterol fumarate 6µg|beclomethasone dipropionate 100µg, 1 inhalation b.i.d. for 2 weeks and formoterol fumarate 6µg, 2 inhalations b.i.d. for 2 weeks
1674984|NCT01658852|Drug|metronidazole|
1674985|NCT01658852|Drug|Placebo|
1674986|NCT01658839|Drug|Travoprost ophthalmic solution, 0.004% (new formulation)|Travoprost ophthalmic solution, 0.004%, new formulation
1674987|NCT01658826|Drug|AIC316|oral administration
1674988|NCT01658826|Drug|Valacyclovir|oral administration
1674990|NCT01658800|Biological|VAX161C vaccine|Recombinant H5 influenza vaccine, VAX161C
1674991|NCT01658787|Device|Endovascular aortic repair|Treatment with Gore Endovascular Aortic Products.
1674992|NCT01658774|Drug|Albendazole|Single 400mg dose
1674993|NCT01658774|Dietary Supplement|Vitamin C|500 mg Vitamin C
1674994|NCT01658761|Procedure|vitrectomy|Surgery
1674995|NCT01658748|Device|Week 0 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0, then this group has stimulators turned on.
1675039|NCT01658462|Drug|Docetaxel: increase of the dose|Dose can be increased to 100 mg/m² secondarily at cycle 2 on the initiative of the investigator
1675040|NCT01658449|Other|Inhalable Hypertonic saline 7% + Hyaluronan 0.1%|Administration of Inhalable Hypertonic saline 7% + Hyaluronan 0.1% 5 ml twice a day, after bronchodilator for one month.
1675041|NCT01658449|Other|Inhalable Hypertonic saline 7%|Administration of Inhalable Hypertonic saline 7% 5 ml twice a day, after bronchodilator for one month.
1674996|NCT01658748|Device|Week 12 Medtronic 3387 electrodes/Activa PC amygdala DBS|Subjects undergo the placement of a Leksell (Elekta, Atlanta, GE) stereotactic frame. Electrode trajectory planned using stereotactic software (BrainLab, Germany). Traditional trans-frontal trajectory used to implant Medtronic #3387 DBS electrodes bilaterally in the BLn. A curvilinear incision will be made 3 cm lateral to midline and 1 cm in front of the coronal suture. A burr hole will be placed with a high-speed drill for placement of a Stimloc device to hold the electrode in place. The dura will be opened, coagulated back and the cortex exposed, coagulated, and pierced. The electrode will be introduced using a cannula. Each electrode contact will be stimulated up to 7 V to confirm the absence of immediate side effects; first left, then right. Electrode wires will be tunneled under skin to upper chest and connected to Medtronic Activa PC dual channel pulse generator. Both groups keep stimulators off until week 0. This group has stimulators turned on at week 12.
1674997|NCT01658735|Device|H-Wave|Proprietary electrotherapy device using electrical stimulation of unique wave form and energy level that is delivered through transcutaneous electrodes to nerves and soft tissue for analgesic effect.
1674998|NCT01658735|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Electrotherapy device that delivers current at different frequency, amplitude, and wave form through cutaneous electrodes placed near body parts with pain for temporary analgesic effect. The study device is installed inside the same housing as the H-Wave Device and Sham Device, so that all appear the same. There are no identifying marks on the case that participants will recognize in order to maintain blinding.
1674999|NCT01658735|Device|Sham|The sham device is a TENS unit modified to have minimal electrical output. The device is installed in the same housing as the two active arms with equal weight, so that each device in the study appears identical.
1675000|NCT01658722|Drug|Bapineuzumab|
1675001|NCT01658696|Biological|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 2 x 10^8 pfu heterologous prime-boost immunisation
1675002|NCT01658696|Biological|Rabies vaccine|2 x 2.5IU Verorab
1675003|NCT01658683|Behavioral|Exercise Facilitator Intervention|The 50 week intervention includes 5 small group counseling teleconferences, 3 personal telephone calls and Heart Wise Exercise program demonstrations. During the teleconferences and personal telephone calls, the facilitator discusses the importance of exercise. Participants review their activity diaries, identify barriers to exercise maintenance experienced to date and brainstorm solutions as a group. In addition, the facilitator conducts community program demonstrations at Heart Wise Exercise program locations in Ottawa and Toronto for interested participants.
1675004|NCT01658670|Behavioral|Standard Care Exercise Group|The SC group is provided access to the exercise facility and regular facility staff for the 18 month study period.
1675005|NCT01658670|Behavioral|HEART Camp Exercise Group|The HC intervention group will be provided access to the exercise facility for the 18 month study period and will also receive cognitive-behavioral strtegies that address the intervention components of knowledge, attitudes, self-efficacy, behavioral self-management skills and social support.
1675006|NCT01658657|Drug|Hydrochlorothiazide|
1675007|NCT01658657|Drug|Lisinopril|
1675008|NCT01658657|Drug|Amlodipine|
1675009|NCT01658657|Drug|metoprolol|
1675010|NCT01658657|Drug|lisinopril/hydrochlorothiazide|This is a combination pill
1675011|NCT01658644|Other|Provision of Clinical Care Handout|Patients assigned to groups B or C will be provided with a paper or electronic version displaying either a list of the names and roles of their clinical care staff (group B), or a list of names and roles accompanied by the respective photograph of each clinician (group C). This document will be presented to the patient at the earliest possible time after admission to the hospital.
1675012|NCT01658631|Device|arterial pressure measurement (Nexfin, a noninvasive finger cuff system)|
1675014|NCT01658605|Drug|GSK1605786|500 mg twice daily administered orally
1675015|NCT01658605|Other|Placebo|500 mg twice daily administered orally
1675016|NCT01658592|Other|Deep brain stimulation|Stimulator setting is ON
1675017|NCT01658592|Other|Placebo|Stimulator setting is OFF
1675018|NCT01658579|Drug|HOE901-U300 (new formulation of insulin glargine)|
1675019|NCT01658579|Drug|Lantus (insulin glargine)|
1675020|NCT01658553|Drug|GSK1120212|GSK1120212 - placebo match oral dose on day 1 with GSK1120212 3 mg oral dose on day 15. GSK1120212 2mg and 2 tablets of GSK1120212 -placebo matched 0.5 mg oral dose daily from day 2 to day 14. 24 hour holter monitoring will be performed on day 1 and day 15 to compare the subjects cardiac repolarization while on placebo and after having received GSK1120212 for 14 days
1675021|NCT01658527|Drug|Orteronel|"Tak-700 will be administered until disease progression, diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
Upon progression, patient may stay on study medication until the initiation of a new therapy"
1675022|NCT01658527|Drug|Bicalutamide|Bicalutamide will be given at the standard daily dose of 50 mg PO (per os). Bicalutamide will be maintained until disease progression diagnosis of a second malignancy, patient refusal to continue the treatment, excessive toxicity precluding further therapy according to protocol and /or according to the responsible physician.
1675023|NCT01658514|Drug|Met DR|metformin delayed-release tablets
1675024|NCT01658514|Drug|Met XR|metformin extended-release tablets
1675025|NCT01658514|Drug|Placebo|
1675026|NCT01658501|Drug|50 mg PB1023|
1675027|NCT01658501|Drug|70 mg PB1023|
1675028|NCT01658501|Drug|100 mg PB1023|
1675029|NCT01658501|Drug|Placebo (0.9% Sodium Chloride)|
1675030|NCT01658501|Drug|Victoza®|
1675031|NCT01658501|Other|Diet and Exercise|
1675032|NCT01658501|Drug|Metformin|
1675033|NCT01658501|Drug|Sulfonylurea|
1675034|NCT01658501|Drug|Metformin and Sulfonylurea|
1675035|NCT01658488|Other|Non-fortified rice|Consumption of 2 servings of Non-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
1675036|NCT01658488|Other|Iron-fortified Rice|Consumption of 2 servings of Iron-fortified rice per day in women with iron deficiency anemia and measure serum iron and transferrin at baseline and end of study.
1675037|NCT01658462|Drug|Docetaxel|75 mg/m2 IV Day 1 / 3 weeks
1675454|NCT01655290|Other|Gadovist® (Gadobutrol), Multihance® (Gadobenate dimeglumin)|Other (Diagnostic)
1675042|NCT01658436|Drug|BEZ235 (Stage 1)|The investigational study drug used in this trial was BEZ235, which was supplied as 50mg, 200mg, 300mg, and 400mg solid dispersion sachets. Supply as 200mg and 50mg were provided for dose reduction. Patients were instructed to take the contents of one sachet of BEZ235 twice a day in the morning within 30 minutes after a light meal (breakfast).
1675043|NCT01658410|Drug|BQ-123|BQ-123 (Clinalfa, Läufelfingen, Switzerland) Dosage: 15µmol in two equal amounts (7.5µmol); in the first and last cardioplegia Route: intracoronary
1675044|NCT01658410|Drug|NaCl|NaCl, Route: intracoronary
1675045|NCT01658397|Behavioral|Fasting|Ten day fast
1675046|NCT01658384|Other|Observational Cognitive assessments|Observational
1675047|NCT01658384|Other|noninterventional, cognitive testing in tysabri treated patients|noninterventional, cognitive testing in Tysabri treated patients
1675048|NCT01658358|Drug|Lapatinib|"dose level I, II 1000mg po daily
dose level III, IV 1250mg po daily"
1675049|NCT01658358|Drug|Lipo-Dox|at the dose level reached on days 1 of a 21 days cycle. The recommended duration of combination treatment for each patient is at least 8 cycles,
1675050|NCT01658332|Other|blood samples|3 tubes (15 ml)
1675051|NCT01658319|Drug|fludarabine phosphate|Given IV
1675052|NCT01658319|Drug|methoxyamine|Given IV
1675053|NCT01658319|Other|laboratory biomarker analysis|Correlative studies
1675054|NCT01658319|Other|pharmacological study|Correlative studies
1675055|NCT01658319|Genetic|western blotting|Correlative studies
1675056|NCT01658319|Other|mass spectrometry|Correlative studies
1675057|NCT01658319|Genetic|DNA analysis|Correlative studies
1675058|NCT01658306|Procedure|remote ischemic preconditioning|RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the RIPC group will have the treatment twice a day for two weeks.
1675059|NCT01658306|Procedure|sham remote ischemic preconditioning|Sham RIPC consists of five 5-min cycles of right upper arm ischemia/reperfusion, induced by an automated cuff-inflator placed on the right upper arm which is inflated to 50 mmHg for 5mins followed by deflating the cuff for 5mins, each patient in the placebo RIPC group will have the treatment twice a day for two weeks.
1675060|NCT01658293|Behavioral|thermal stimulation|The heat and cold-water will be added to the thermal group for 30-40minutes a session daily,five sessions a week for six weeks.
1675061|NCT01658293|Behavioral|control group ergometer exercises|The control group will be given ergometer exercises with the similar duration as experimental group.
1675062|NCT01658280|Device|EBUS-TBNA|Patients allocated in the intervention group will undergo EBUS-TBNA procedure, performed in a bronchoscopy suite by the same operator under conscious sedation Three needle passes for each approachable station will be performed. The samples obtained will be examined on-site by experienced blinded cytopathologist.All specimens obtained will be send to definitive cytological and histological evaluation and the final diagnosis will be collected and reported on CRFs
1675063|NCT01658267|Other|nutritional supplement|2 servings per day
1955142|NCT03284762|Drug|Rivaroxaban (Xarelto, Bay59-7939)|Rivaroxaban is a direct Factor Xa inhibitor. In this non-interventional setting, the prescription and dosing scheme is up to the treatment physician, however, the recommended dosing scheme is 20mg/day (once daily) or 15 mg/day (once daily) in patients with reduced renal function
1675065|NCT01658241|Drug|panobinostat|40mg, three times a week, oral pill over 12 cycles, 4 weeks per cycle
1675068|NCT01658215|Drug|V0116 transdermal patch (Test treatment )|
1675069|NCT01658215|Drug|Nicotine transdermal patch (Reference treatment )|
1675070|NCT01658202|Drug|V0116 transdermal patch (Test treatment )|
1675071|NCT01658202|Drug|Nicotine transdermal patch (Reference Treatment )|
1675072|NCT01658176|Drug|PF-04691502|PF-04691502 administered orally at 8 mg as a continuous daily dosing schedule
1675073|NCT01658176|Drug|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
1675074|NCT01658176|Drug|Exemestane|Exemestane administered orally at 25 mg as a continuous daily dosing schedule
1675075|NCT01658150|Drug|isradipine|Isradipine is a medication that acts by blocking a specific type of receptor in the brain called a calcium channel
1675076|NCT01658137|Other|Prudent Diet|This intervention lasts 2 weeks (14 days).
1675077|NCT01658137|Other|Typical Western Diet|This intervention lasts 2 weeks (14 days).
1675078|NCT01658124|Drug|Tranexamic Acid|
1675079|NCT01658124|Drug|Placebo|
1675080|NCT01658111|Device|Robot Group|"The MIT-MANUS/InMotion2 (Interactive Motion Technologies, Inc., Watertown, MA, USA) system has two translational degrees of freedom (dof): shoulder abduction-adduction (ab-ad), elbow flexion-extension (flexext).
The robotic system supports the execution of reaching movements in the horizontal plane through an assist as needed control strategy. The robot can guide the movement of the upper limb of the patients and record end-effector physical quantities such as the position, velocity, and applied forces. The device is designed to have a low intrinsic end-point impedance (i.e., be back-drivable to easily carry the weight of the patient's arm, to execute movements without constraint and offer minimal resistance. A 3-dof force transducer is placed at the robots end-effector, as well."
1675081|NCT01658111|Procedure|Traditional physiotherapy|Active or passive exercises.
1675082|NCT01658098|Behavioral|edinburgh postpartum depression scale questionary|the investigators will apply the qusetionary one time only in the period of time described previously
1675083|NCT01658085|Device|ACE14S|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with ACE14S
1675084|NCT01658085|Device|HARMONIC FOCUS®|Total thyroidectomy (total bilateral extracapsular lobectomy) for Multinodular Goiter with HARMONIC FOCUS®
1675085|NCT01658072|Procedure|Peri-Articular Injection|Use of a different analgesic protocol, based on a peri-articular injection
1675086|NCT01658072|Procedure|Epidural Patient Controlled Analgesia (Epidural PCA)|Epidural analgesia pathway.
1675089|NCT01658046|Other|Neuromuscular electrical stimulation|Bilateral quadriceps NMES using a four-channel portable electrical stimulator. Biphasic symmetric constant current impulses with a pulse width 300 µs, a frequency of 50 Hz, and duty cycle of 10 s on and 20 s off was applied for 20 min per day, 2 days per week for 10 weeks.
1675090|NCT01658046|Other|Endurance training|Endurance training consists of 30 minutes of aerobic exercise (15 minutes on treadmill and 15 minutes on stationary bicycle) at 80% of maximal heart rate
1675091|NCT01658046|Other|Quadriceps strength training|Quadriceps resistance training was applied using free weights for 2 days per week for 10 weeks according to 1 repetition maximum, starting at 45% for two sets.
1675092|NCT01658033|Drug|Avastin + mFOLFOX6|"mFOLFOX6 regimen, repeated every 2 weeks: Oxaliplatin 85 mg/m2，ivgtt； Leucovorin 400 mg/m2,ivgtt； 5-FU 400 mg/m2，iv，and then 2400 mg/m2，civ46h；
Avastin: Avastin 5mg/kg q2w or 7.5mg/kg q3w"
1675093|NCT01658020|Drug|Zabofloxacin|Zabofloxacin 367mg tablet P.O. once daily for 5days and then Placebo P.O. once daily for 2days
1675094|NCT01658020|Drug|Moxifloxacin|Moxifloxacin 400mg tablet P.O. once daily for 7days
1675095|NCT01658007|Drug|Sirolimus|Adding sirolimus to established induction and consolidation chemotherapy for relapsed/refractory acute lymphoblastic leukemia
1675096|NCT01657994|Other|Combined functional electrical stimulation and robotic gait training|up to 18 sessions of approximately 45 minutes occurring over up to 9 weeks
1675097|NCT01657981|Drug|YM150|14C-labeled YM150, oral solution
1675098|NCT01657955|Drug|Bendamustine Hydrochloride Injection|
1675099|NCT01657955|Drug|Chlorambucil|
1675100|NCT01657942|Device|ExAblate MR Guided Focused Ultrasound|ExAblate MR Guided Focused Ultrasound - Local treatment of prostate lesions using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy.
1675101|NCT01657929|Biological|H5-VLP + GLA-AF|H5-VLP antigen and GLA-AF adjuvant. 2 injections at Days 0, and 21.
1675102|NCT01657929|Biological|H5-VLP alone|H5-VLP antigen alone. 2 injections at Days 0, and 21.
1675103|NCT01657929|Biological|H5-VLP + Alhydrogel(R)|H5-VLP antigen and Alhydrogel(R) adjuvant. 2 injections at Days 0, and 21.
1675104|NCT01657929|Biological|Licensed H5N1 vaccine|Licensed H5N1 vaccine. 2 injections given on Days 0 and 21.
1675105|NCT01657903|Drug|Sodium Fluoride|Toothpaste containing 1450 ppm F - EU level as NaF.
1675106|NCT01657903|Drug|Potassium nitrate|All study treatments contain 5% w/w KNO3.
1675107|NCT01657890|Drug|isavuconazole|oral
1675108|NCT01657877|Drug|Calcium sodium phosphosilicate|CSP high percentage weight by weight
1675109|NCT01657877|Drug|Sodium monoflurophosphate|500 to 1500 parts per million (ppm) of fluoride
1675110|NCT01657877|Drug|Placebo|No CSP and no fluoride
1675111|NCT01657864|Drug|Lamotrigine|Lamotrigine is an anticonvulsant drug used in the treatment of epilepsy and bipolar disorder
1675112|NCT01657851|Drug|dutasteride/tamsulosin|Duodart® 0.5 mg / 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
1675113|NCT01657851|Drug|dutasteride|Avodart® 0.5 mg together with Omnic® 0.4 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
1675114|NCT01657851|Drug|tamsulosin|Omnic® 0.4 mg together with Avodart® 0.5 mg - 1 dose at Day 1 of each treatment period. There are 2 treatment periods separated by approximately a 28-day washout period. All study drugs will be administered orally as capsules
1675115|NCT01657838|Drug|Isavuconazole|oral
1675116|NCT01657838|Drug|Ketoconazole|oral
1675117|NCT01657825|Drug|Isavuconazole|oral
1675118|NCT01657825|Drug|Warfarin|oral
1675119|NCT01657812|Drug|dexmedetomidine|"Dexmedetomidine, an alpha 2 agonist provides sedative, anxiolytic, anti-shivering, analgesic, and anaesthetic sparing effect. In addition α2-adrenoceptor agonists reduce central sympathetic outflow and attenuate the stress response associated with surgery.Unlike epidural anaesthesia, dexmedetomidine is easy to administer and no potential for neurological damage.
Date suggest that the dexmedetomidine reduces the stress response of surgery to the similar extent to epidural anaesthesia when used in conjunction with a standard general anaesthesia for abdominal surgery."
1675120|NCT01657799|Drug|Veliparib|High dose veliparib given continuously throughout the entire course of WBRT. One treatment of 3.0 Gy WBRT will be given daily 5 days per week (10 fractions) for a total of 30.0 Gy.
1675121|NCT01657799|Drug|Veliparib|Low dose veliparib given continuously throughout the entire course of WBRT. One treatment of 3.0 Gy WBRT will be given daily 5 days per week (10 fractions) for a total of 30.0 Gy.
1675122|NCT01657799|Drug|Placebo|Placebo given continuously throughout the entire course of WBRT. One treatment of 3.0 Gy WBRT will be given daily 5 days per week (10 fractions) for a total of 30.0 Gy.
1675123|NCT01657786|Dietary Supplement|administration of ondanstron and screening of genomic DNA|Thirty minutes before the end of surgery, ondansetron 0.1 mg/kg is administered intravenously. We assess an episode of PONV at first 2 h and 2-24 h after surgery. Genomic DNA was prepared and screened. The incidence of PONV is compared among genotypes in 5-HT3 receptor gene polymorphisms (5-HT3a: S253N; 5-HT3b: Y129S, -100_-102delAAG).
1675124|NCT01657773|Other|Ultrasound examination and Colonoscopy examination|
1675125|NCT01657760|Drug|citalopram|citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
1675158|NCT01657448|Drug|Methenamine and Methylthioninium chloride|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
1675159|NCT01657448|Drug|Phenazopyridine|• Ingesting two (02) tablets of the drug with a glass of water, every 8 hours for 3 days
1675126|NCT01657747|Other|Whole body diffusion-weighted MRI|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for this reason not eligible for the study.
During the whole body MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine.
During the whole body MRI examinations, a bowel relaxing injection (Buscopan) is also needed to reduce movement of the intestines."
1675127|NCT01657734|Other|MR imaging|MR imaging
1675128|NCT01657721|Behavioral|Cogmed Working Memory Training Program|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
1675129|NCT01657708|Other|Shared Decision Making|
1675130|NCT01657682|Drug|Crenolanib besylate|"Crenolanib besylate, 100 mg TID, taken orally at least 30 minutes pre- or post- meal. Patients will complete a daily diary to record the date, time and amount (number of tablets) of crenolanib taken and eating schedule.
Concurrent hydroxyurea (maximum 5g total daily dose x 14 days) is permitted during the first 28 days of study therapy."
1675132|NCT01657656|Dietary Supplement|Vitamin D|
1675133|NCT01657643|Dietary Supplement|Probiotics|
1675134|NCT01657643|Dietary Supplement|placebo|
1675135|NCT01657630|Device|Accu-Chek Combo System|12 weeks using the Accu Chek Combo System, which is an insulin pump system that offers a remote control integrating a bolus calculator, a blood glucose meter, data storage and analysis function.
1675136|NCT01657617|Radiation|Boost Stereotactic Body Radiation Therapy|"The dose and fractionation scheme utilized will be based on the location of the patient's residual disease. For patients with:
Peripheral Tumors: Treatment will consist of 2 fractions of radiation, with a minimum of 40 hours separating each fraction. Two fractions of 10 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 20 Gy. This will yield a total BED of 110 Gy.
Medial Tumors: Treatment will consist of 3 fractions of radiation, with a minimum of 40 hours separating each fraction. Three fractions of 6.5 Gy with inhomogeneity correction will be delivered to the prescription line at the edge of the PTV for a total of 19.5 Gy. This will yield a total BED 102.2 Gy."
1675137|NCT01657604|Drug|Peginterferon α2b|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily with at a starting target dose of 30μg/week. After confirmed MMR or at least 24 mo. after start of therapy, maintenance therapy (nilotinib will be discontinued) will start for a study duration of up to 5 years.
1675138|NCT01657604|Drug|Nilotinib|Patients will receive nilotinib 300 mg BID given as two 150 mg capsules twice daily for a study duration of up to 5 years.
1675139|NCT01657591|Drug|XL888|Level -1: XL888 30 mg; Level 1: XL888 30 mg; Level 2: XL888 45 mg; Level 3: XL888 90 mg; Level 4: XL888 135 mg
1675140|NCT01657591|Drug|Vemurafenib|Level -1: Vemurafenib 720 mg; Level 1: Vemurafenib 960 mg; Level 2: Vemurafenib 960 mg; Level 3: Vemurafenib 960 mg; Level 4: Vemurafenib 960 mg
1675141|NCT01657578|Drug|Omeprazole|administration of Omeprazole
1675142|NCT01657552|Drug|Eltrombopag|Each tablet contains 100 mg of Eltrombopag (Dose 200 mg)
1675143|NCT01657552|Drug|Boceprevir|Each capsule contains 200 mg of Boceprevir (Dose 800 mg)
1675144|NCT01657552|Drug|Telaprevir|Each tablet contains 375 mg of Telaprevir (Dose 750 mg)
1675145|NCT01657539|Dietary Supplement|Yogurt containing probiotics|patients assigned to this group will use a yogurt containing Bifidobacterium animalis once a day during 14 days before evaluation of the outcomes.
1675146|NCT01657539|Dietary Supplement|Placebo yogurt|Patients will use a yogurt without probiotics once a day during 14 days before evaluation of outcomes
1675147|NCT01657526|Biological|GSK Biologicals' Non-Typeable H. influenzae (GSK2838500A)|Administered intramuscularly (IM) in the deltoid region of non-dominant arm
1675148|NCT01657526|Biological|GSK Biologicals' Non-Typeable H. influenzae (GSK2838501A)|2 doses administered IM in the deltoid region of non-dominant arm
1675149|NCT01657526|Biological|Saline placebo|2 doses administered IM in the deltoid region of non-dominant arm
1675150|NCT01657513|Drug|subjects will receive either infliximab, adalimumab or etanercept|"The subjects receive treatment with a tnf-alfa blocking according to the official guidelines for the particular drug.
The study subjects will receive treatment with one drug only -
infliximab or
adalimumab or
etanercept
The consulting dermatologist decides which drug to use according to official guidelines"
1675151|NCT01657500|Other|Corneal donor storage in Optisol GS media solution|Donor tissue is preserved in the Optisol media until ready for implantation
1675152|NCT01657500|Other|Life 4°C solution for cornea storage|Donor cornea is stored in the Life 4°C media prior to implantation.
1675153|NCT01657487|Drug|Fluticasone/Salmeterol high dose|
1675154|NCT01657474|Other|Weekly application of EpiFix plus standard of care|
1675155|NCT01657474|Other|Biweekly application of EpiFix plus standard of care|
1675156|NCT01657461|Drug|Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|Standard therapy with Intravenous (IV) recombinant human tissue plasminogen activator (rtPA)
1675157|NCT01657461|Device|Solitaire revascularization device|Clot retrieval with the Solitaire revascularization device after patients have received standard therapy with intravenous tissue plasminogen activator
1675160|NCT01657435|Device|Ceramax Acetabular System|28mm Ceramic-on-ceramic Acetabular Cup System
1675161|NCT01657422|Behavioral|PACE+|Patients assigned to the intervention group will receive intervention strategies over a the course of 2 years including: (1) completion of a 45-minute office-based computer program resulting in an assessment and action plan for improvement in physical activity and nutrition behaviors; (2) a provider counseling session immediately following the computerized assessment, followed by (3) 12 phone calls and 24 mailings over a 24-month period conducted by PACE+ staff members
1675162|NCT01657409|Drug|BoNT-A (10 injection)|BoNT-A 100 U 10 injections
1675163|NCT01657409|Drug|BoNT-A (20 injection)|BoNT-A 100 U 20 injections
1675164|NCT01657409|Drug|BoNT-A (40 injection)|BoNT-A 100 U 40 injections
1675165|NCT01657396|Procedure|Standard Oral Hygiene|Current local standard of care - minimum q2h mouthcare with a green Toothette swab dipped in sterile water, with excess liquid aspirated using a Yankauer suction. Brushing of teeth (if applicable) with a toothbrush and standard toothpaste q12h. Replacement of Yankauer suction device daily.
1675166|NCT01657396|Procedure|SAGE Q-care q2|Oral hygiene provided with a commercial pre-packaged product (SAGE Q-care q2 Oral Cleansing and Suctioning System) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using Antiplaque solution (a cetylpyridinium based solution) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
1675167|NCT01657396|Procedure|SAGE Q-care q2 with Chlorhexidine|Oral hygiene provided with a commercial pre-packaged product with chlorhexidine (SAGE Q-care Rx q2 Oral Cleansing and Suctioning System with CHG) - minimum q2h mouthcare using the supplied applicator swabs and covered Yankauer suction device using supplied Perox-A-Mint (a hydrogen peroxide based oral hygiene solution) alternating with alcohol-free mouthwash. Brushing of teeth (if applicable) with supplied applicator using chlorhexidine oral rinse (solution containing 0.12% chlorhexidine) q12h. Use of a new kit (which includes new covered Yankauer suction device) daily.
1675168|NCT01657383|Procedure|HPB Surgery|Hepatopancreatico Biliary Surgery
1675169|NCT01657370|Drug|MK-1602|"Three administrations of the same dose of MK-1602 on separate days. All 3 doses are either 1, 10, 25, 50 or 100 mg of MK-1602. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).
Dosage form is film coated tablet for oral administration."
1675170|NCT01657370|Drug|Placebo|"Three administrations of placebo for MK-1602 on separate days. Dose 1: Taken at onset of migraine of moderate or severe intensity. Dose 2: Taken the evening before Visit 2. Dose 3: Taken at Visit 2, which is Day 4 post migraine treatment (Dose 1).
Dosage form is film coated tablet for oral administration."
1675171|NCT01657370|Drug|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,
Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans, opiates or other medication not explicitly excluded."
1675172|NCT01657357|Other|Routine followup|questionnaires
1675173|NCT01657331|Drug|Brentuximab Vedotin|Dose escalation in phase I of the study from 1.2-1.8 mg/kg, IV infusions over 30 minutes on day 1 of each 21-day cycle.
1675174|NCT01657331|Drug|Bendamustine|Dose escalation in phase I of the study from 60-100 mg/m2, IV infusion on days 1 and 2 of each 21-day cycle.
1675175|NCT01657331|Drug|Neulasta|(Non-experimental) Standard procedure prophylactic pegfilgrastim on day 3 of any subsequent cycle after cycle 1, or filgrastim for 5 to 10 days, per investigator's discretion.
1675176|NCT01657318|Other|Olivamine containing wound care products|Continuous wound care with Olivamine containing products until wound closure. Intake of dietary supplement of 1 capsule for 60 days.
1675179|NCT01657292|Drug|Oleogel-S10 ointment|Intraindividual comparison: One randomly assigned wound half is treated with Oleogel-S10 ointment and fatty gauze wound dressing
1675180|NCT01657292|Device|Octenilin® wound gel|Intraindividual comparison: The other wound half is treated with Octenilin® wound gel and fatty gauze wound dressing
1675181|NCT01657279|Other|Clinical scenarios|Clinicians will be randomized to a sequence of 5 clinical scenarios with a variable range of expected outcome [i.e. from low (<10%) to high (>50%) expected risk death at 30 days].
1675186|NCT01657240|Drug|PRO-118|instill one drop in each eye once a day for 21 days
1675187|NCT01657240|Drug|Olopatadine Hydrochloride|instill one drop in each eye once a day for 21 days
1675188|NCT01657227|Behavioral|Intervention to patients|"Multifaceted intervention consisting of:
Program of education and behavior modification: group sessions conducted by health educators for the patient and a relative (who usually do the food shopping or prepare meals) every 3 months over 2 years (total:8 sessions). Main contents: diabetes, hygiene/nutrition and physical exercise.
Monitoring of patient conditions by Informational Communication Technologies (ICT): patient will complete at home a web-based short questionnaire once a week and an expanded version once a month.
Short text messaging to patient's mobile based on information obtained from self-reported questionnaires. 3 types of messages: 1) Reminders for completing web-based questionnaires, the attendance at group sessions and the follow-up appointments, 2) General advice on good habits, 3) Custom messages to reinforce behavior change."
1675230|NCT01656889|Biological|HP-802-247|HP802-247 (fibrinogen solution & thrombin solution containing living, irradiated, growth arrested keratinocytes and fibroblasts) 260 µL (130 µL, one spray, of each solution) containing 0.5 x 106 cells per mL every 14 days.
1675231|NCT01656889|Biological|Vehicle|(fibrinogen solution & thrombin solution without cells)
1675288|NCT01656460|Radiation|Stereotactic radiation Arm 3|Dose Levels Dose per Fraction Total Dose 3 12 Gy 24 Gy
1675289|NCT01656460|Radiation|Stereotactic radiation Arm 4|Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
1675189|NCT01657227|Behavioral|Intervention to professionals|"Multifaceted intervention consisting of:
Educational intervention: Two theoretical and practical sessions to update knowledge on T2DM management and provide professionals with techniques to enhance the patient-centered clinical relationship model and the shared decision making model with the ultimate goal of improving patient adherence to treatment and self-care.
Computer-based clinical decision support system (CDSS): Implementation of an automated tool combining evidence-based knowledge with patient-specific information to assist clinicians in making clinical decisions in the management of T2DM patients.
Feedback: periodic mailing of personalized feedback reports with data on health results of all T2DM patients who are cared by the professional."
1675190|NCT01657227|Other|Usual care|Usual care for T2DM received in primary health care
1675191|NCT01657214|Drug|SAR125844|"Pharmaceutical form:Concentrate for solution
Route of administration: intravenous"
1675192|NCT01657201|Drug|SYP-1018 200mg|SYP-1018 200mg, Intravenous administration
1675193|NCT01657201|Drug|Voriconazole 200mg|Voriconazole 200mg, Intravenous administration
1675194|NCT01657188|Device|Cheyne-Stokes respiration by adaptive servoventilation|
1675195|NCT01657175|Other|Supportive care|"The patients will be randomized to control or supportive care groups.
The control group will be given care as usual wich include clinical follow-ups at the surgical department.
The supportive care group get in addition to the clinical follow-ups a supportive care programme including:
Discharge information about surgery and life after surgery together with their relatives.
Active telephone contacts 1/week th first month the 2/month up to six month after discharge by a specialized nurs.
Open telephone line were the patients can call the nursed ruing daytime. Discharge: approximately 2-4 weeks after surgery"
1675196|NCT01657162|Drug|Alendronate|Bisphosphonate
1675197|NCT01657149|Procedure|Lymphatic massage and individual physiotherapy|lymphatic massage and individual physiotherapy
1675198|NCT01657149|Procedure|individual physiotherapy only|individual physiotherapy only
1675199|NCT01657136|Drug|Ivabradine|comparison of different drugs
1675200|NCT01657136|Drug|Beta blocker|comparison of different drugs
1675201|NCT01657123|Other|ergometry|ergometry measurements
1675202|NCT01657123|Other|ergometry|Ergometry measurements
1675203|NCT01657110|Other|Tea tree oil|Pea-sized amount of tea tree oil medicated gel (containing 200mg/g tea tree oil) applied to the face twice daily for 12 weeks.
1675204|NCT01657097|Drug|INCS|
1675205|NCT01657097|Drug|Placebo|
1675206|NCT01657084|Device|CDA Mask|The CDA (Carbon Dioxide Accumulation) mask effectuates an increase in the inspired CO2 fraction, while allowing an adequate supply of fresh air to the patient.
1675207|NCT01657084|Device|Dummy mask|The dummy mask is similar in appearance to the treatment mask, but causes only a negligible change in blood gases
1675208|NCT01657071|Drug|YH14659|YH14659 capsule by oral
1675209|NCT01657071|Drug|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
1675210|NCT01657058|Dietary Supplement|Soluble viscous fibre blend powder in hydrophobic matrix|5g soluble viscous fibre blend pre-mixed into margarine (hydrophobic matrix) + white bread + jello
1675211|NCT01657058|Dietary Supplement|Soluble viscous fibre blend in pre hydrated form|0g soluble viscous fibre blend margarine + white bread +5g Konjac fibre prehydrated in jello
1675212|NCT01657058|Dietary Supplement|No soluble viscous fibre blend|0g soluble viscous fibre blend margarine + white bread + jello
1675213|NCT01657058|Dietary Supplement|Soluble viscous fibre blend premixed with ½ carbohydrate gel|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
1675214|NCT01657058|Dietary Supplement|No soluble viscous fibre blend, ½ carbohydrate jello|Margarine + white bread (1/2 carbohydrate) +5g soluble viscous fibre blend hydrated in jello with glucose
1675215|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
1675216|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
1675217|NCT01657045|Biological|JVS-100 or placebo|Injections will be delivered depending on sternal incision length.
1675218|NCT01657032|Dietary Supplement|Smectite|Eligible children received smectite (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
1675219|NCT01657032|Dietary Supplement|Placebo|Eligible children received placebo: glucose (3g) once a day till diarrhea stop with LGG (ATCC 53103) at a daily dosage of 6×10 9 colony forming units (CFU) in one dose for 7 days.
1675220|NCT01657032|Dietary Supplement|Lactobacillus GG|All children received LGG (ATCC 53103), dose 6×10 9 colony forming units (CFU), once a day for 7 days with placebo or smectite
1675221|NCT01657019|Drug|Lisdexamfetamine dimesylate|50 or 70 mg administered orally, once a day for 52 weeks
1675222|NCT01656980|Drug|Carmustine|As Experimental group, subjects will accept specified wafers of carmustine in the cavity while gliomas maximally be resected.
1675223|NCT01656980|Procedure|tumor resection surgery|For this group, subjects will accept routine tumor resection surgery and place no implant wafers.
1675224|NCT01656967|Device|AMBU Aura-I/aScope 2|Once ventilation is achieved, the patients in group A will be intubated through the shaft of Aura-I via the the Ambu aScope.
1675225|NCT01656967|Device|LMA Fastrach Single Use|The patients in group B will be intubated by ETT via the Intubating LMA as is standard procedure.
1675226|NCT01656954|Procedure|Passive Leg Raise (PLR)|From the supine position, the legs are elevated to 45 degrees above the resting surface for a period of 3 minutes. At completion,the legs are lowered to the resting surface.
1675227|NCT01656928|Behavioral|preschool-based nutritional intervention|6-month intervention administered once weekly by a nutrition expert consisting of joint meal preparation and activities for children and parents such as tasting and preparing nutritious, fresh foods.
1675455|NCT01655277|Procedure|Ultrasound Guided Adductor Canal Block|
1675232|NCT01656876|Behavioral|Mirror box training|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the visual feedback of the unaffected upper extremity reflected by the mirror.
1675233|NCT01656876|Other|mesh glove stimulation|The MG is a two-channel electrical stimulator providing synchronous or reciprocal sensory stimulation with variant amplitudes.
1675234|NCT01656876|Behavioral|conventional intervention|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach
1675235|NCT01656863|Other|Questionnaire|
1675236|NCT01656850|Other|Almond diet first, then NCEP Diet|whole almonds will be incorporated into a control diet which is a NCEP step 2 diet. Whole almonds will replace 20% daily calorie intake. Subjects were assigned to receive almond diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to NCEP Diet for 12 weeks
1675237|NCT01656850|Other|NCEP diet first, then Almond diet|NCEP diet first, then Almond diet. Subjects were assigned to receive NCEP diet for 12 weeks after a 2-weeks run-in period. After washout 2 weeks, change diet to almond diet for 12 weeks
1675238|NCT01656837|Behavioral|Comprehensive Community Treatment|
1675239|NCT01656837|Behavioral|MST-BSF|
1675240|NCT01656811|Drug|levalbuterol 90 mcg|90 mcg levalbuterol delivered via MDI 2 actuations of 45 mcg QID
1675241|NCT01656811|Drug|levalbuterol 180 mcg|180 mcg levalbuterol delivered via MDI 2 actuations of 90 mcg QID
1675242|NCT01656811|Drug|racemic albuterol 180 mcg|180 mcg racemic albuterol delivered via MDI 2 actuations of 90 mcg QID
1675243|NCT01656811|Drug|Placebo|Placebo 2 actuations QID
1675244|NCT01656798|Drug|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
1675245|NCT01656798|Drug|sildenafil citrate|2 mL of POS formulation of sildenafil citrate 10 mg/mL (equivalent to 20 mg dose), single dose
1675246|NCT01656785|Drug|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111MBq 68Ga-BNOTA-PRGD2 solution. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of cerebral infarction areas by Positron Emission Tomography / computed tomography (PET/CT)
1675247|NCT01656772|Device|Vdrive Lasso navigation|Remote robotic Lasso navigation
1675248|NCT01656772|Procedure|Manual Lasso navigation|Manually maneuver a Lasso catheter
1675249|NCT01656759|Drug|Evicel Fibrin Spray|10cc syringe dose, once at the end of TKA
1675250|NCT01656746|Procedure|therapeutic laparoscopic surgery|Undergo single incision laparoscopic surgery
1675251|NCT01656733|Drug|Nicotrol Inhaler|Nicotrol Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper Placebo Inhaler, 1-12 cartridges per day, for 6 weeks with a 6 week taper.
1675252|NCT01656720|Drug|1R, 2S-methoxamine hydrochloride|
1675253|NCT01656720|Drug|Placebo|
1675254|NCT01656707|Behavioral|ACRA|Ten weekly,60-minute therapy sessions including six individual, two parent/guardian and two joint (individual and parent/guardian).
1675255|NCT01656707|Behavioral|CBT|10 weekly, 60-minute sessions of augmented individualized CBT
1675256|NCT01656694|Device|DePuy Sigma HP Partial Knee|
1675257|NCT01656681|Dietary Supplement|THIAA|A tablet containing 400 mg tetrahydro iso-alpha acids, 3 times a day
1675258|NCT01656681|Dietary Supplement|Placebo|Placebo tablet
1675259|NCT01656668|Drug|BC1036|
1675260|NCT01656642|Drug|Atezolizumab|Atezolizumab will be administered q3w or q2w.
1675261|NCT01656642|Drug|Cobimetinib|Oral repeating dose
1675262|NCT01656642|Drug|Vemurafenib|Oral repeating dose, depending on arm/cohort
1675263|NCT01656629|Drug|Teriparatide|20 mcg subq daily for 3 months
1675264|NCT01656629|Drug|Alendronate|70 mg weekly for 3 months
1675265|NCT01656629|Dietary Supplement|calcium and vitamin D|
1675266|NCT01656616|Drug|Cyanide antidote administration|
1675267|NCT01656603|Biological|unlicensed CBU|infusion of unlicensed cord blood units
1675268|NCT01656590|Other|High Protein and Exercise Therapy along-with Nocturnal Enteral Feeding|"High Protein and Moderate Carbohydrate Nutrition designed by our nutritionist for every patient based on his/her nutrition requirements, age & gender
500 cc Formula - Nutren Replete with Fiber overnight [8 hours] via gastrostomy tube
Conditioning Exercise once daily"
1675269|NCT01656577|Drug|Pexacerfont|
1675270|NCT01656551|Drug|Gemcitabine|
1675271|NCT01656551|Drug|Pemetrexed|500 mg/m2 day 1 every 3 weeks
1675272|NCT01656551|Drug|Cisplatin|60 mg/m2 day 1 every 3 weeks
1675275|NCT01656525|Drug|Gantenerumab|75 mg subcutaneous doses every 4 weeks for 24 weeks
1675276|NCT01656525|Drug|Gantenerumab|105 mg subcutaneous doses every 4 weeks for 24 weeks
1675277|NCT01656525|Drug|Gantenerumab|225 mg subcutaneous doses every 4 weeks for 24 weeks
1675278|NCT01656525|Drug|Placebo|subcutaneous doses every 4 weeks for 24 weeks
1675279|NCT01656512|Drug|zolendronic acid|"patients will receive calcium & vitamin D daily in addition to bisphosphonates (zolendronic acid ) every 3 months in the dose of
Initial dose: (0.025) mg /kg
Subsequent doses ( 0.05) mg /kg.
Maximum dose of 4 mg."
1675280|NCT01656512|Drug|calcium & vitamin D|patients will receive calcium & vitamin D Dose of Calcium : 1500- 2000 gram elemental Calcium daily . Dose of Vitamin D ( calcitriol; one alpha) 800-1000 International Unit
1675281|NCT01656499|Dietary Supplement|Arabinoxylanoligosaccharides|
1675282|NCT01656499|Dietary Supplement|Maltodextrine|
1675283|NCT01656486|Radiation|Stereotactic Radiation|Treatment of pancreas with 30 Gy of radiation given in 5 fractions of 6 Gy each with stereotactic radiosurgery that could produce a fibrosis of the pancreas and a decrease in the production of exocrine portion of the gland.
1675284|NCT01656473|Other|MI and DBT|One individual session of Motivational Interview followed by 12 weeks of Dialectical Behaviour Therapy group skills training
1675285|NCT01656473|Other|MI and DBT|Individual Motivational Interview session plus 12-week Dialectical Behaviour Therapy skills group
1675286|NCT01656460|Radiation|Stereotactic radiation Arm 1|"Dose Levels Dose per Fraction Total Dose
1 8 Gy 16 Gy"
1675287|NCT01656460|Radiation|Stereotactic radiation Arm 2|Dose Levels Dose per Fraction Total Dose 2 10 Gy 20 Gy
1675290|NCT01656434|Drug|NOMAC-E2|NOMAC-E2 film-coated oral tablets containing 2.5 mg nomegestrol acetate and 1.5 mg 17ß-estradiol.
1675291|NCT01656434|Drug|NETA-EE|NETA-EE film-coated oral tablets containing 1 mg norethisterone acetate and 10 μg ethinylestradiol.
1675292|NCT01656434|Other|Placebo|tablet
1675293|NCT01656434|Drug|ethinylestradiol (EE)|EE 10 μg tablet
1675294|NCT01656434|Drug|ferrous fumarate|ferrous fumarate 75 mg tablet
1675295|NCT01656408|Drug|MK-8150|
1675296|NCT01656408|Drug|Placebo for MK-8150|
1675297|NCT01656395|Drug|MK-1029 10 mg|Parts I-II: Participants will receive MK-1029 10 mg tablets taken once daily (QD)
1675298|NCT01656395|Drug|MK-1029 30 mg|Parts I-II: Participants will receive MK-1029 30 mg tablets QD
1675299|NCT01656395|Drug|MK-1029 150 mg|Parts I-II: Participants will receive MK-1029 150 mg tablets QD
1675300|NCT01656395|Drug|Montelukast 10 mg|Parts I-II: Participants will receive Montelukast 10 mg tablets QD
1675301|NCT01656395|Drug|Placebo|Parts I-II: Participants will receive Placebo tablets QD
1675302|NCT01656395|Drug|MK-1029 1 mg or 3 mg|Part II: Participants will receive either MK-1029 1 mg or 3 mg tablets (dose to be determined based on results of interim analysis from Part I) QD.
1675303|NCT01656395|Drug|Montelukast 10 mg + MK-1029|Part II: Participants will receive Montelukast 10 mg tablets QD and MK-1029 tablets (dose to be determined based on results of interim analysis from Part I) QD
1675304|NCT01656382|Drug|ABLC|
1675305|NCT01656369|Procedure|Group I: delorme operation only.|A circumferential incision was made in the rectal mucosa approximately 1 cm away from the dentate line. Using electrocautery, the mucosa was stripped to the apex of the prolapse. The muscular layers of the rectal wall were reduced as the mucosa was stripped. Mucosal stripping continued past the apex of the prolapse and then continued inside the prolapsed segment to a point internally that is equivalent to the point of the initial mucosal incision. The underling muscle was plicated by vicryl 2/0.The muscle bite was taken longitudinally from 8 sides to reach a horizontal line of plication at the end. The mucosa was then reanastomosed.
1675306|NCT01656369|Procedure|delorme operation with post anal repair|In group II : post anal repair was added by making transverse incision 7cm behind the anal canal.dissection of intersphincteric plain,plication of internal sphincter by using 3/0 vicryl.The levator ani and external sphincter were then sutured to each other by vicryl 2/0 behind the anal canal followed by skin closure without drain.
1675307|NCT01656356|Biological|Avian Flu Vaccine|
1675308|NCT01656356|Biological|Placebo|
1675309|NCT01656343|Drug|Calcineurin inhibitors (CNI)|No Intervention
1675310|NCT01656343|Drug|Belatacept|No Intervention
1675311|NCT01656330|Drug|Rivaroxaban 20 mg twice daily|One rivaroxaban 20 mg tablet administered twice a day (b.i.d.) for 4 days (Days 1-4). Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 4 days.
1675312|NCT01656330|Drug|Rivaroxaban 20 mg once daily|One rivaroxaban 20 mg tablet administered once daily on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 20; unit=mg; route: oral use for 1 day.
1675313|NCT01656330|Drug|Profilnine SD|Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
1675314|NCT01656330|Drug|Beriplex P/N|Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
1675315|NCT01656330|Other|Saline|Single 100 cc bolus of saline administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact ; Number = 100; unit=cc; route : intravenous use use.
1675316|NCT01656317|Other|Early multidisciplinary rehabilitation|"Multidisciplinary rehabilitation consist of individualized stimulation and mobilisation.
The multidisciplinary team consists of a physician, a nurse, a physiotherapist, an occupational therapist and a clinical neuropsychologist."
1675317|NCT01656304|Biological|bevacizumab|Given IV
1675318|NCT01656304|Other|laboratory biomarker analysis|Correlative studies
1675319|NCT01656278|Procedure|Magnetic resonance imaging (MRI)|"Treatment algorithm based on conventional biochemical/clinical examinations AND MRI of unilateral 2nd to 5th MCP joints and wrist on dominant side. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one physically swollen joint and DAS28>3.2 AND/OR MRI-detected bone marrow oedema score > 0 (RAMRIS-score)"
1675320|NCT01656278|Other|Conventional biochemical and clinical examinations|"Treatment algorithm based on conventional biochemical and clinical examinations. Assessed month 0, 4, 8, 12, 16, 20, 24 with treatment intensification after predefined treatment algorithm in the case of unsatisfactory inflammatory activity, which is defined as the presence of at least one clinically swollen joint and DAS28>3.2"
1675321|NCT01656265|Drug|ARQ 197|Daily repeating dose of oral ARQ 197, twice a day just after meals. Dose of ARQ 197 will be escalated according to 3+3 rule.
1675322|NCT01656252|Drug|Phase I- Cytarabine & Eltrombopag|"Cycle 1= Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.
Eltrombopag (Open-Label) by mouth daily until platelet recovery or for 35 consecutive days, whichever occurs first. Phase I will determine the dose and schedule of Eltrombopag to be used in Phase II.
One cycle of consolidation therapy with high-dose cytarabine and eltrombopag will be received on study. Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
1675323|NCT01656252|Drug|Phase II- Sequence A|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.
Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 1st cycle of high-dose consolidation chemotherapy and placebo by mouth daily with 2nd cycle.
Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.
Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
1675377|NCT01655888|Drug|Tremelimumab|Tremelimumab is administered as endovenous infusion
1675456|NCT01655277|Procedure|Ultrasound Guided Femoral Nerve Block|
1675880|NCT01652300|Behavioral|two educational sessions|The test group had two educational sessions lasting 1 hour, focused on oral and dental health and especially on oral and dental health during pregnancy
1675324|NCT01656252|Drug|Phase II- Sequence B|"Cytarabine 3 g/m² IV twice daily on Days 1, 3 and 5 (Patients >60 years of age will receive cytarabine 1.5 g/m² IV per dose). Day 1 must start in AM.
Placebo by mouth daily with 1st cycle of high-dose consolidation therapy and Eltrombopag by mouth daily (dose and schedule as determined in Phase I) with 2nd cycle.
Eltrombopag/placebo will continue until platelet recovery or for 35 consecutive days, whichever occurs first.
Additional chemotherapy may be administered at the investigators discretion without eltrombopag."
1675325|NCT01656239|Drug|fedovapagon 1 mg|
1675326|NCT01656239|Drug|fedovapagon 2 mg|
1675327|NCT01656239|Drug|fedovapagon 4 mg|
1675328|NCT01656239|Drug|Placebo ( sugar pill)|
1675329|NCT01656226|Device|Eryfotona AK-NMSC® cream|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
1675330|NCT01656226|Other|Sunscreen SPF 50+|Cream, to be applied according to COLIPA standard at 2 mg/cm² in head and neck, twice a day before exposing to sun light morning and around lunchtime (about 4-6 hours later), for up to 6 months.
1675331|NCT01656213|Device|Computer-based target pursuit task (created using E-Prime software) and visual-feedback handgrip force transducer (CurrentDesigns 2012).|Subjects will be encouraged to perform the exercise 2-3 times per dialysis session depending upon mood, although will be permitted to skip sessions if they do not feel well or motivated. The laptop program time-stamps each session, and records a time-series of duration, force and accuracy of hand grip.
1675333|NCT01656187|Drug|Memantine|Memantine is a noncompetitive NMDA receptor antagonist used to help treat Alzheimer's disease.
1675334|NCT01656187|Drug|Placebo|Inactive ingredient matching the active medication in appearance
1675335|NCT01656174|Device|Procleix Dengue Virus Assay|in vitro diagnostic assay
1675336|NCT01656161|Drug|Triptorelin embonate 22.5 mg|
1675337|NCT01656148|Drug|Fampridine-SR|Subjects will all receive Fampridine-SR in an open label enrichment phase lasting four weeks. Those 40% improvin the most measured by SSST will go onto the intervention. Here randomization in a 1:1 key between Fampridine-SR and placebo will be undertaken. Treatment will be of either Fampridine-SR 10 mg BID or placebo BID for four weeks. Arms will be double blind.
1675338|NCT01656135|Other|Blood drawing for immune monitoring and questionnaires|
1675339|NCT01656122|Drug|abacavir|Dosing of ABC will be according to the WHO guidelines by weight band for twice daily dosing. The once daily dosing will use the same mg/day as the twice daily dosing for that weight band
1675340|NCT01656122|Drug|3TC|Dosing of 3TC will be according to the WHO guidelines by weight band for twice daily dosing. The once-daily dosing will use the same mg/day as the twice-daily dosing for that weight band
1675341|NCT01656109|Drug|boosted atazanavir (ATV/r)|ATV/r will be taken orally once daily with food plus standard dose of 2 NRTIs according to Thai National HIV treatment guideline
1675342|NCT01656096|Device|Renal sympathetic denervation (Symplicity ablation catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|
1675343|NCT01656096|Other|Sham procedure|
1675344|NCT01656070|Drug|oral cholecalciferol 1000000 UI (vitamin D3)|
1675345|NCT01656070|Drug|Placebo|
1675346|NCT01656057|Drug|Acetaminophen|Acetaminophen dissolved in 50 ml of water
1675347|NCT01656057|Drug|Metformin|Metformin + acetaminophen dissolved in 50 ml of water
1675348|NCT01656057|Drug|Colesevelam|Colesevelam + acetaminophen dissolved in 50 ml of water
1675349|NCT01656057|Other|Cholecystokinin-8|iv. infusion of CCK-8, 24 pmol/kg/hour for the first 60 minutes
1675350|NCT01656057|Other|Saline|iv. saline infusion 40 ml/hour for the first 60 minutes
1675351|NCT01656044|Procedure|wound care management|Receive SSD
1675352|NCT01656044|Procedure|wound care management|Receive NPT
1675353|NCT01656031|Drug|clofarabine|
1675354|NCT01656031|Drug|cytarabine|
1675355|NCT01656018|Drug|TMC278, Long acting (LA)|TMC278 long acting will be administered IM to the participants as follows: a single dose of TMC278 600 mg will be administered at baseline in Arm 2A and Arm 2B; at Months 2 and 4 in Arm 5A and Arm 5B. A single dose of TMC278 900 mg will be administered at Months 2 and 4 in Arm 4A and Arm 4B. A single dose of TMC278 1200 mg will be administered at baseline in Arm 1A, Arm 1B; Arm 3A, Arm 3B, Arm 4A, Arm 4B, Arm 5A and Arm 5B; at Months 2 and 4 in Arm 3A and Arm 3B.
1675356|NCT01656005|Biological|Carvedilol|Dose titration: 3.125mg bid for 1 week, 6.25mg bid for 1 week, 12.5mg bid for 4 weeks.
1675357|NCT01656005|Biological|Bisoprolol|Dose titration: 1.25mg od for 1 week, 2.5mg od for 1 week, 5mg for 4 weeks.
1675358|NCT01656005|Biological|Beclometasone/formoterol|2 puffs bid for first 5 weeks in each treatment arm
1675359|NCT01656005|Biological|Tiotropium|1 puff daily for first 4 weeks of each treatment arm
1675360|NCT01656005|Biological|Beclometasone|2 puffs bid for final week (week 6) of each treatment arm
1675361|NCT01655992|Drug|capecitabine|2500mg／m2／day divided into twice two weeks on one week off
1675362|NCT01655992|Drug|S1 generic|40mg／m2 bid four weeks on two weeks off
1675363|NCT01655979|Dietary Supplement|Whey Protein + Potassium bicarbonate|0.6 mmol WP/kg body weight + 90 mmol KHCO3 during bed rest
1675364|NCT01655979|Other|Control|Bed rest without dietary supplement
1675365|NCT01655966|Drug|vitamin D +pegylated interferon + ribavirin|Vitamin D: 1mcg once daily 48 weeks Pegylated interferon 160ug once weekly 48 weeks Ribavirin(> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
1675366|NCT01655966|Drug|pegylated interferon + ribavirin|pegylated interferon 160ug once weekly Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
1675367|NCT01655953|Dietary Supplement|High NaCl + KHCO3|7.7 mmol Na/kgBW/d + 90 mmol KHCO3
1675368|NCT01655953|Other|Control: high NaCl|7.7 mmol Na/kgBW/d
1675369|NCT01655940|Device|Somanetics cerebral oximeter|Somanetics cerebral oximeter
1675370|NCT01655940|Device|CASMED cerebral oximeter|CASMED cerebral oximeter
1675371|NCT01655927|Drug|Tranexamic Acid|
1675372|NCT01655927|Drug|Placebo: Saline|
1675373|NCT01655914|Drug|Flumazenil|
1675374|NCT01655901|Behavioral|Active video gaming|
1675375|NCT01655901|Behavioral|Passive video gaming|
1675376|NCT01655901|Behavioral|Resting|
1675378|NCT01655875|Drug|AMD3100|AMD3100 will first be administered at 240 mcg/kg (the FDA approved dose for mobilization of autologous PBSC) IV once daily prior to conditioning for 3 days (days -6, -5 and -4) in the first group of participants. If toxicity criteria are met, the dosing will be escalated in the second group of participants to 240 mcg/kg IV once daily prior to conditioning for 5 days (days -8, -7, -6, -5 and -4).
1675379|NCT01655862|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA injections at doses and frequencies as determined by the physician in accordance with clinical practice.
1675380|NCT01655849|Drug|z160|
1675381|NCT01655849|Drug|Placebo|
1675386|NCT01655823|Drug|Placebo|Sham treatment acting as control arm
1675387|NCT01655823|Drug|Tetrodotoxin|Comparison of different dosages of Tetrodotoxin
1675388|NCT01655810|Dietary Supplement|Vitamin D3|Multivitamin containing cholecalciferol 4000 units orally daily
1675389|NCT01655810|Dietary Supplement|Vitamin D3|Multivitamin containing cholecalciferol 600 units orally daily
1675390|NCT01655810|Dietary Supplement|Calcium carbonate|500 mg orally twice daily
1675391|NCT01655797|Behavioral|Cognitive behavior therapy for insomnia|Treatment comprised information about sleep and insomnia, methods for medication tapering, sleep hygiene, stimulus control, sleep restriction, progressive muscle relaxation, and dealing with sleep interfering thoughts.
1675392|NCT01655784|Procedure|Coil Embolization with larger Diameter Coils|Eighteen Coils placed in cerebral aneurysm
1675393|NCT01655784|Procedure|Coil Embolization with Standard Diameter Coils|Cerebral aneurysms will be embolized with standard diameter coils.
1675394|NCT01655771|Drug|TD-1211 Dose 1|
1675395|NCT01655771|Drug|TD-1211 Dose 2|
1675396|NCT01655758|Drug|0.5% timolol|
1675397|NCT01655758|Drug|timolol-dorzolamide fixed combination|
1675398|NCT01655758|Drug|Latanoprost|
1675399|NCT01655758|Drug|Travoprost|
1675400|NCT01655758|Drug|Bimatoprost|
1675401|NCT01655745|Procedure|FDG PET/MR|All patients will undergo a gadolinium enhanced MRI with simultaneous acquisition of FDG-PET prior to planned radical cystectomy and pelvic lymph node dissection
1675402|NCT01655732|Procedure|Atraumatic Restorative Treatment|ART is simple uninvasive technique involving removal of soft carious enamel and dentine by hand instrument only and then restore the cavity with adhesive restorative material.
1675404|NCT01655706|Drug|escitalopram|Patients will be given escitalopram for the first 8 weeks of the trial. At week 8, patients who are assessed as 'responders' will continue on escitalopram until study endpoint.
1675405|NCT01655706|Drug|aripiprazole|At Week 8, patients assessed as 'non-responders' will be given aripiprazole as an add-on treatment to escitalopram.
1675406|NCT01655693|Drug|Doxorubicin|
1675407|NCT01655693|Drug|Doxorubicin|
1675408|NCT01655693|Drug|Best Standard of Care|
1675409|NCT01655680|Drug|ABT-126|ABT-126 Middle Dose
1675410|NCT01655680|Drug|ABT-126|ABT-126 Low Dose
1675411|NCT01655680|Drug|ABT-126|ABT-126 High Dose
1675412|NCT01655680|Drug|Placebo|Placebo
1675413|NCT01655654|Behavioral|Physical activity|This intervention includes cardiorespiratory exercise, resistance exercise, flexibility exercise and neuromotor exercise.
1675414|NCT01655654|Behavioral|Dietary|Make at least one positive dietary change including or similar to a DASH diet snack substitution.
1675415|NCT01655654|Other|Primary care provider visit|Subjects with hypertension will be asked to visit their primary care provider seeking treatment options. If a subject does not have a primary care provider then they will be encouraged to obtain one and seek medical treatment.
1675416|NCT01655641|Drug|Tranexamic acid|"Drug: Tranexamic acid
1gm stat, preoperatively (30 mins) 10mg / kg body weight, 8 hourly for 5 days via IV For non-renal impaired subjects.
Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)"
1675417|NCT01655641|Other|Standard of care|Includes routine surgical care involved in preventing blood loss during and after surgery.
1675418|NCT01655628|Drug|GC chemotherapy plus CIK cells (Gemcitabine, Cisplatin, Autologous CIK cells)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
1675419|NCT01655628|Drug|GC chemotherapy (Gemcitabine, Cisplatin)|A total of 40 patients enrolled will be accept 4 cycles GC chemotherapy(every 4 weeks),then they will randomized divided into two groups. 20 patients will maintain autologous CIK cells for 8 cycles (every 4 weeks);the other 20 patients will not accept CIK cells treatment. Afer the all 40 patients have accomplished 4 cycles GC regimen chemotherapy plus CIK cells treatment or 4 cycles GC chemotherapy alone, the early effects will be assessed and long-term efficacy such as OS and PFS will be evaluated.
1675420|NCT01655615|Behavioral|Preventure programme|The interventions are conducted using manuals which incorporate psycho-educational, motivational enhancement therapy and cognitive-behavioural (CBT) components, and include real life 'scenarios' shared by local youth in with similar personality profiles. In the first session, participants are guided in a goal-setting exercise, designed to enhance motivation to change behaviour. Psycho-educational strategies are then used to teach participants about the target personality variable and associated problematic coping behaviours like avoidance, interpersonal dependence, aggression, risky behaviours and substance misuse.
1675448|NCT01655368|Behavioral|Interventional control of normal psychoeducational treatment|11 sessions + 1 booster session of psychoeducation (for schizophrenia or depression)
1675449|NCT01655316|Drug|Verapamil|
1675450|NCT01655303|Drug|Propranolol|
1675451|NCT01655303|Drug|Metoprolol|
1675452|NCT01655303|Drug|Verapamil|
1675421|NCT01655602|Procedure|Trichophytic closure upper edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
1675422|NCT01655602|Procedure|Trichophytic closure lower edge trimming|'Trichophytic closure technique' can be done by trimming upper or lower wound edge for about 1 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
1675423|NCT01655602|Procedure|Trichophytic closure both edge trimming|'Trichophytic closure technique' can be done by trimming upper and lower wound edge for about 0.5 millimeter (as Fig.1) before wound closure. Then the linear scar will be less visible after hair growth. Anyway, there is no exactly wound edge (upper, lower or both) that recommended for the excellent cosmetic results without any severe side effects. Therefore, this study was designed to determine which is the best trichophytic closure technique.
1675424|NCT01655576|Procedure|Placental drainage|After delivery of the newborn, umbilical cord at mothers end, will be left unclamped until delivery of the placenta.
1675425|NCT01655563|Drug|Tacrolimus|Tacrolimus, a calcineurin inhibitor, is the commonest immunosuppressive agent used for maintenance immunosuppression after solid organ transplantation. The mechanism of action involves binding to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin and calcineurin is then formed and the phosphatase activity of calcineurin is inhibited. This prevents the generation of nuclear factor of activated T-cells, a nuclear component, resulting in inhibition of transcription of lymphokines (interleukin-2, γ-interferon). The net result is the inhibition of T-lymphocyte activation.Tacrolimus is metabolized primarily by the CYP3A enzymes in the liver particularly the CYP3A5.
1675427|NCT01655524|Drug|ASSUAGE Protocol|75 mg of aminophylline injected intravenously 90 seconds following the radioisotope injection in the setting of regadenoson nuclear stress test of the heart.
1675428|NCT01655511|Drug|Tafamidis|240 mg, solution, single dose
1675429|NCT01655511|Drug|Tafamidis|480 mg, solution, single dose
1675430|NCT01655511|Drug|Tafamidis|TBD dose will be a single dose if < 720 mg or a loading dose followed by additional dose if > 720 mg.
1675431|NCT01655498|Device|vaginal bowel control system (LivSure)|
1675432|NCT01655485|Other|Patient teaching|The Social script application is an story book on the iPAD with photos and script explaining the steps of getting a medical image such as a CAT scan from the perspective of the child.
1675433|NCT01655472|Device|imaging follow up: MRI scan|.1 Psychiatric interview. 2. Questionnaires 3. Blood samples for triple test: alfa feto protein, HCG, E3 4. A thorough fetal ultrasound examination including anatomic screening on 23-24 weeks of pregnancy. 5. A detailed trans-vaginal neurosonographic multi-planer examination, on 32-34 weeks of pregnancy 6. Fetal MRI scan on 32-34 weeks of pregnancy, 7. Newborn brain transfontanelar ultrasonography ,within 2 months postpartum 8. Newborn medical examination within 2 months postpartum.
1675434|NCT01655472|Device|imaging follow up: Ultrasonographic examination|
1675435|NCT01655459|Procedure|Ultrasound exam of upper airway|LMA-position was evaluated with fiberoptic laryngoscopy. The ultrasound findings of pre- and post-LMA were compared.
1675436|NCT01655446|Behavioral|Mirror Therapy|This protocol includes 1 hour mirror therapy and 0.5 hour functional training in a session. The treatment intensity is 1.5 hours/day, 5 days/week, for 4 weeks. MT focuses on symmetrical bimanual movements and simultaneously observing the mirror visual feedback reflected by the unaffected upper extremity.
1675437|NCT01655446|Behavioral|Conventional Rehabilitation|Participants in this group receive a structured protocol based on occupational therapy such as neuro-developmental techniques and task-oriented approach. The treatment dose is matched to RR and MT groups.
1675438|NCT01655446|Behavioral|Robotic Rehabilitation|This protocol includes 5 to 10 min of warm-up, 1 hr of RR, and 15 to 20 min of functional activities training. The treatment intensity is 1.5 hours/day, 5days/week for 4 consecutive weeks. The RR session uses the robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany).
1675439|NCT01655446|Behavioral|Robotic rehabilitation with FES|This combined RR-FES treatment involves the same protocol as the RR regimen except that patients receive FES concurrently with RR.
1675440|NCT01655446|Behavioral|Robotic Rehabilitation with PI|The RR-PI protocol is the same as the RR-FES protocol described above except that the surface electrodes are attached to the same target muscles on the affected UL but there is no output of electrical stimulation.
1675441|NCT01655433|Device|Velomedix APLS device|Velomedix, Automated Peritoneal Lavage System
1675442|NCT01655433|Other|No Hypothermia Treatment|
1675443|NCT01655420|Procedure|LASIK|Laser eye surgery
1675444|NCT01655407|Drug|Autologous Engineered Skin Substitute|"The total burn wound area covered will range from 288 cm^2 to 5,600 cm^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.
ESS-W will be applied to the appropriate recipient site, according to the randomization schedule, by the surgeon using two pairs of forceps. Sufficient ESS-W sheets will be used to cover the recipient site. The ESS-W grafts will be stapled in place."
1675445|NCT01655407|Drug|Split-Thickness Autograft (AG)|"The total burn wound area covered will range from 288 cm^2 to 5,600 cm^2 (based on availability of matched-pair burn sites of similar area and depth) and this total grafting area will be divided equally for treatment with ESS-W and AG.
The AG regimen occurs in stages, beginning with excision of the burned skin, followed by temporary wound coverage (e.g. cadaveric skin allografts, porcine xenograft, synthetic or biologic dressings or medical devices) to achieve wound homeostasis, and completed by permanent wound closure using autologous skin."
1675446|NCT01655381|Drug|Tocilizumab|Tocilizumab 8 mg/kg administered intravenously.
1675447|NCT01655368|Behavioral|psychotherapeutic STEM modules|psychoeducational and psychotherapeutical group intervention. 8 sessions of psychoeducation + 3 sessions + 1 booster session of STEM module for schizophrenia or depression)
1675453|NCT01655303|Drug|Diltiazem|
1726175|NCT00011505|Procedure|Leukapheresis|
1675457|NCT01655264|Behavioral|Home-based self training exercises for weak upper extremity|Each subject in the control group will receive twelve 45-60 min sessions (3 sessions per week for 4 weeks) while seated. They will receive self-training upper extremity exercises that are based on conventional therapy using principles of motor control and will include training of upper extremity movements in order to achieve better use of the affected arm in ADL. Each subject will receive a list of exercises to be performed in his home using a stand-alone poster as targets for the movements. In addition, each subject will be asked to write the dates and duration of time he/she did the each exercise. They will be in contact with a therapist once a week to monitor the self training program and adjust the level of exercise.
1675458|NCT01655264|Behavioral|Tele-rehabilitation exercises for weak upper extremity|The experimental group will receive tele-rehabilitation upper extremity exercises treatment of comparable duration and intensity to those in the home-based self training exercise treatment group. However, the treatment will be delivered via the Gertner Tele-Motion Rehabilitation system with remote online monitoring by the therapist. Treatment feedback will be given in the form of Knowledge of results (game scores) and Knowledge of performance (feedback of compensatory movements made while using the upper extremity) to enhance motor learning. The software will generate a report which will include the duration and type of exercises performed by the subject. If needed, a personal attendant may provide physical support in the tele home mock-up room.
1675459|NCT01655251|Behavioral|Intervention|
1675460|NCT01655238|Other|BMI|Screening guideline to assess body mass index.
1675461|NCT01655225|Drug|LY3023414|Administered orally. Dose of 20 to 600 mg, as determined in Part A.
1675462|NCT01655225|Drug|Midazolam|0.2 mg administered orally once before LY3023414 on Day 1 and once after LY3023414 on Day 15.
1675463|NCT01655225|Drug|Fulvestrant|500 mg administered IM on Day 1 and Day 15 in cycle 1 and Day 1 every 28 days for additional cycles.
1675464|NCT01655225|Drug|Pemetrexed|500 mg/m2 administered IV once on Day 1 every 21 days
1675465|NCT01655225|Drug|Cisplatin|75 mg/m2 administered IV once on Day 1 every 21 days
1675466|NCT01655225|Drug|Abemaciclib|Administered orally
1675467|NCT01655225|Drug|Letrozole|Administered orally
1675468|NCT01655212|Drug|Valganciclovir|Infants will be treated with valganciclovir for 6 weeks, 32 mg/kg daily dose in two doses, oral solution.
1675469|NCT01655199|Drug|Combination ipratropium/salbutamol or placebo (nebulization)|For the visit 2, COPD patients will be randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. For the visit 3, the other intervention drug will be assigned. The bronchodilation obtained with the medication will allow to determine if the 3-min step test is sensitive by detecting an improvement of exertional dyspnea following bronchodilation.
1675470|NCT01655186|Drug|Bardoxolone Methyl|
1675471|NCT01655186|Drug|Placebo|
1675474|NCT01655160|Behavioral|MT with low-intensity group (MT-LI)|The MT-LI group will receive a 30-minute MT per session followed by a 30-minute functional training.
1675475|NCT01655160|Behavioral|MT with moderate-intensity group|The MT-MI group will receive a 60-minute MT per session followed by a 30-minute functional training.
1675476|NCT01655160|Behavioral|Mirror therapy with high intensity group|The MT-HI group will receive a 90-minute MT per session followed by a 30-minute functional training
1675477|NCT01655160|Behavioral|Control intervention group|The CI group will carry out a 30-minute conventional stroke rehabilitation training per session followed by a 30-minute functional training.
1675478|NCT01655147|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1,000, form=tablet, route=oral. Abiraterone acetate administered on Day 1 of Period 1, and Day 14 of Period 2.
1675479|NCT01655147|Drug|Rifampicin|Type=exact number, unit=mg, number=600, form=capsule, route=oral. Rifampicin administered on Days 8 to 13 of Period 2.
1675480|NCT01655134|Other|Blood simples|
1675481|NCT01655134|Other|Capillary punction|
1675482|NCT01655134|Other|Urine simples|
1675483|NCT01655121|Dietary Supplement|High protein high fiber diet|"A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
Each participant will receive nutritional counseling once month during six months."
1675484|NCT01655108|Drug|Minoxidil|Minoxidil 0.5% /2ml intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
1675485|NCT01655108|Drug|Saline|Physiological saline solution 0.9% , intradermal injection in the scalp ( mesotherapy), weekly sessions, ten weeks
1675486|NCT01655095|Drug|PEG|PEG 2L at 1800hrs the night before the test and 2L at 0500hrs the morning of the test.
1675487|NCT01655095|Drug|Prucalopride|Prucalopride 2mg will be administered at 0800hrs on the day of the test, at the same time the colon capsule is administered. Two hours later the position of the colon capsule will be assess with a Realtime Viewer. If the capsule has not reached the cecum a second dose of Prucalopride 2mg will be administered at that time.
1675488|NCT01655095|Drug|Picosalax|One sachet at 1800hrs the night before the test One sachet at 0500hrs the day of the test
1675489|NCT01655095|Drug|Bisacodyl|Bisacodyl 10mg in the evening three nights before the procedure and 10mg again two nights before the procedure.
1675626|NCT01653990|Drug|moxifloxacin|oral dose of 400mg moxifloxacin
1955152|NCT03281902|Procedure|Biopsy|Undergo tumor biopsy
1955153|NCT03281902|Procedure|Biospecimen Collection|Undergo collection of blood
1955154|NCT03281902|Other|Laboratory Biomarker Analysis|Correlative studies
1955155|NCT03281811|Drug|Aminolevulinic Acid Hydrochloride|Given topically
1955156|NCT03281811|Drug|Photodynamic Therapy|Undergo PDT
1955157|NCT03281811|Other|Quality-of-Life Assessment|Ancillary studies
1955158|NCT03281811|Radiation|Radiation Therapy|Undergo RT
1675490|NCT01655095|Procedure|Colon capsule|The colon capsule will be ingested at 0800hrs the day of the test. Seven hours will be allowed for the capsule to clear the bowel. The images will be reviewed by two endoscopists with experience reading video capsule endoscopy.
1675491|NCT01655095|Procedure|Colonoscopy|At 1500hrs on the day of the test all individuals will return to the endoscopy unit for a colonoscopy.
1675492|NCT01655082|Drug|V0116 transdermal patch|One patch per day (during 24 hours) for 21 days
1675493|NCT01655082|Drug|Nicotine transdermal patch|One patch per day (during 24 hours) for 21 days
1675495|NCT01655056|Drug|YM150|oral
1675496|NCT01655056|Drug|Placebo|oral
1675497|NCT01655043|Drug|Regadenoson|Regadenoson will be infused intravenously 0.4 mg/5 mL (0.08 mg/mL) as a single bolus.
1675498|NCT01655043|Drug|gadofoveset trisodium|All subjects to receive 5 ml IV gadofoveset trisodium contrast (Ablavar) at both stress and rest.
1675501|NCT01655017|Procedure|biopsy|adipose tissue biopsy (to evaluate inflammation and fibrosis)
1675502|NCT01655004|Drug|Exemestane|Exemestane is commercially available and will be obtained locally from the manufacturer. There are no experimental treatments in this study.
1675503|NCT01654991|Behavioral|Home Screening|Home-based STD screening using self-obtained urine samples and study paid postal return of samples.
1675504|NCT01654991|Behavioral|Clinic Screening|Clinic-based STD screening using self-obtained urine samples in a local university clinical setting.
1675505|NCT01654965|Other|Laboratory Biomarker Analysis|Correlative studies
1675506|NCT01654965|Biological|Pegfilgrastim|Given SC
1675507|NCT01654965|Other|Pharmacological Study|Correlative studies
1675508|NCT01654965|Drug|Tivantinib|Given PO
1675509|NCT01654965|Drug|Topotecan Hydrochloride|Given IV
1675510|NCT01654939|Drug|Rifaximin|All patients will be taking rifaximin 550 mg twice daily for one year for a diagnosis of hepatic encephalopathy
1675511|NCT01654926|Procedure|blood ultrafiltration|
1675512|NCT01654913|Device|hemoglobin measurement|"Non invasive hemoglobin measurements (Pronto 7 device and NBM-200 device)will be made with :
at baseline (simultaneous blood sample for a laboratory measurement of hemoglobin),
with the patient breathing oxygen via a face-mask (FiO2 50 ± 5%),
with the patient breathing oxygen via a face-mask (FiO2 90 ± 5%) (simultaneous blood sample for a laboratory measurement of hemoglobin)."
1675513|NCT01654900|Other|No intervention in this study|
1675514|NCT01654887|Other|Lung Ultrasound|Six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
1675515|NCT01654887|Radiation|Chest X-Ray|Posterior-Anterior and lateral views of the chest via chest radiography followed by a lung ultrasound which is comprised of six anatomic areas, delineated by the anterior, posterior, and mid- axillary lines will be systematically examined bilaterally, as per the modified Bedside Lung Ultrasound in Emergency (BLUE) protocol (Lichtenstein 2008). Ultrasound images will be obtained in longitudinal and transverse orientation, and recorded.
1675516|NCT01654874|Drug|99mTc-MIP-1404|
1675517|NCT01654861|Drug|Gemcitabine, Intravenous and oral Ascorbic Acid (Vitamin C)|Weeks 1,2,3: IV Gemcitabine 1000 mg / m² over 30 minutes followed by HDIVC 1.2 g / kg: 1.2 g/kg over 90 minutes for a dose ≤90 g and over 120 minutes for a dose >90g followed by 0.3 g / kg over 120 minutes; Week 4: no treatment.
1675518|NCT01654835|Other|low blood pressure alert|"A Low Blood Pressure condition as specified (SAP <80 mmHg)will trigger an page to be sent to all anesthesia providers in <1 min that will read: A Low Blood Pressure condition has been detected. Consider hemodynamic support."
1675519|NCT01654835|Other|standard of care|A Low Blood Pressure condition as specified (SAP <80 mmHg)will be monitored by treatment team upon detection, but additional paged alert will not be generated.
1675520|NCT01654822|Drug|topical application cervical spray|one time (2 puffs) topical application of 100µl AV2-DM antiviral spray( containing 50% AV2-DM and 50% olive oil)on the cervix
1675521|NCT01654822|Drug|topical spray on the cervix|one time (2 puffs) topical spray of 100 µl (90% olive oil and 10% d-limonene) on the cervix
1675522|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T0|
1675523|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T1|
1675524|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T0|
1675525|NCT01654822|Procedure|cervical swab with Cervex-Brush-Combi at T1|
1675526|NCT01654809|Biological|evaluated vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
1675527|NCT01654809|Biological|imported compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
1675528|NCT01654809|Biological|domestic compared vaccine|0.25 mL, Intramuscular (infant/children dose) 0.5 mL, Intramuscular (adult dose)
1675529|NCT01654796|Device|Low Field Magnetic Stimulation (LFMS)|The LFMS devices produces a unique magnetic field that may help alleviate symptoms of depression.
1675530|NCT01654796|Device|Sham LFMS|Sham LFMS looks and sounds like the active treatment but does not produce any magnetic stimulation.
1675531|NCT01654770|Device|video capsule endoscopy|
1675532|NCT01654770|Device|double balloon enteroscopy|
1675533|NCT01654731|Drug|Bezafibrate|
1675534|NCT01654731|Drug|placebo|
1675535|NCT01654718|Drug|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
1675536|NCT01654718|Drug|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
1675537|NCT01654705|Drug|Pantoprazole|Pantoprazole 40mg Delayed release tablets (Test Product)
1675538|NCT01654705|Drug|Pantoprazole|Protonix® Delayed Release 40 mg tablets (Reference product)
1675539|NCT01654692|Drug|Ipilimumab and Fotemustine|Ipilimumab: 10 mg/kg q3 weeks for 4 doses, q12 weeks starting at Week 24 Fotemustine: 100 mg/m2 q1 week for 3 doses, q3 weeks starting at Week 9
1675540|NCT01654679|Device|wIRA irradiation|wIRA irradiation for 20min prior to surgery. The distance between the light bulb and the skin surface was 27cm.
1675541|NCT01654679|Other|visible light only|visible light application at a distance of 27cm from the skin surface with for 20 min.
1675542|NCT01654666|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 200 mmHg for 5-min followed by deflating the cuff for 5-min.
1675543|NCT01654666|Procedure|Sham remote ischemic preconditioning|Sham remote ischemic preconditioning consisted of five 5-min cycles of bilateral arm ischemia/reperfusion, which is induced by an automated cuff-inflator placed on bilateral arm and inflated to 60 mmHg for 5-min followed by deflating the cuff for 5-min.
1675544|NCT01654666|Procedure|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid artery stenosis.
1675545|NCT01654653|Drug|Hypertonic sodium lactate|Administered at beginning of surgery as loading dose at 3 mL/kg body weight within 15 minutes. Additional fluid administered if needed and this was was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly.
1675546|NCT01654653|Drug|6% Hydroxy Ethyl Starch|Administered at beginning of surgery as loading dose at 3 mL/kgBW within 15 minutes. Additional fluid given if needed and this was managed similarly in both groups; the types and amount of additional fluid was measured and recorded. Surgery procedure and concomitant medication was managed similarly
1675547|NCT01654640|Drug|Metformin|metformin 500mg p.o. bid for 24 weeks
1675548|NCT01654640|Drug|Placebo (for metformin)|placebo 1T bid
1675549|NCT01654627|Device|Regenecure AMCA GBR Dental Membrane|Patients will undergo Guided Bone Regeneration (GBR) procedure using the Regenecure AMCA GBR Membrane
1675550|NCT01654627|Device|Geistlich Bio-Gide® collagen membrane|The Geistlich Bio-Gide® collagen membrane, a commercially available product, will be used in 10 patients.
1675551|NCT01654601|Drug|DWCZP|Multiple dose
1675552|NCT01654601|Drug|Clozaril|multiple-dose
1675553|NCT01654575|Drug|Methotrexate|Methotrexate 25mg/week for 16 weeks
1675554|NCT01654575|Drug|Placebo|Placebo tablets once a week for 16 weeks
1675555|NCT01654562|Drug|Simvastatin|Simvastatin 40mg daily by mouth for 5 weeks (4-6 week window) followed by 5 week washout period (4-6 week window).
1675556|NCT01654549|Drug|H.pylori eradication|Omeprazole (20 mg/BD)+ Amoxicillin (1 g/day)+ Bismuth subcitrate (240 mg/BD)+ Azithromycin (500 mg/BD)
1675557|NCT01654536|Drug|ciclesonide nasal aerosol|ciclesonide nasal aerosol 74 mcg (given as 1 actuation per nostril of 37 mcg ciclesonide nasal aerosol)
1675558|NCT01654536|Drug|ciclesonide nasal spray|ciclesonide nasal spray 200 mcg (given as 2 actuations per nostril of 50 mcg ciclesonide nasal spray)
1675559|NCT01654523|Device|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania|Awareness Enhancement and Monitoring Device for Treatment of Trichotillomania
1675560|NCT01654510|Behavioral|Cognitive Behavioral Therapy Group|This is a cognitive behavioral therapy group designed for homeless, unemployed people utelizing vocational rehabilitation services. The group is administered on a bi-weekly basis for four weeks, totalling eight sessions.
1675561|NCT01654510|Other|Vocational Services as Usual|
1675562|NCT01654497|Drug|Dexanabinol|"Dexanabinol: intravenous infusion over 3 hours, weekly (i.e., Day 1, 8, 15 and 22 of a 28-day cycle)
Nine dosing cohorts are planned, with the option to enroll additional cohorts based on safety and PK data.
Dose Level 1: 2 mg/kg
Dose Level 2: 4 mg/kg
Dose Level 3: 8 mg/kg
Dose Level 4: 16 mg/kg
Dose Level 5: 24 mg/kg
Dose Level 6: 28 mg/kg
Dose Level 7: 36 mg/kg
Dose Level 8: 40 mg/kg
Dose Level 9: 44 mg/kg"
1675563|NCT01654484|Drug|DE-117|Ophthalmic Solution, QD, 28 Days
1675564|NCT01654484|Drug|0.0015% tafluprost|Ophthalmic Solution, QD, 28 days
1675565|NCT01654484|Drug|DE-117 and 0.0015% tafluprost|Ophthalmic Solutions, QD, 28 days
1675566|NCT01654484|Drug|Placebo|Ophthalmic Solution, QD, 28 days
1675567|NCT01654458|Behavioral|GyneGals Support Group|12-week online (i.e. Internet-based), professionally-facilitated support group
1955159|NCT03279029|Biological|blood samples|blood samples
1675569|NCT01654432|Other|Paravertebral Blocks (PVB)|
1675570|NCT01654419|Device|Class II elastics and Sliding Jig|Class II elastics, 3/16 6 oz, used daily for 3 months 24 hours per day and sliding jig orthodontic device
1675571|NCT01654419|Device|Class II elastic alone|Elastics Class II alone, used 24 hours per day for 3 months from the hook of the upper canine to the first lower molar hook
1675572|NCT01654406|Device|Fractional CO2 laser and pulsed dye laser|Fractional CO2 laser: 50 mJ, 100 spots/cm2, a scan area of 4_4mm, static mode, and two passes Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
1675573|NCT01654406|Device|Pulsed dye laser|Pulsed dye laser: 5mm,1.5ms,8J,delay cooling device 30/30,one pass
1955160|NCT03279029|Biological|biopsy|biopsy of aortic valve
1675575|NCT01654380|Drug|LY2605541|LY2605541 is a solution. The concentration of LY2605541 is 100 U/mL
1675576|NCT01654380|Other|Insulin glargine|Insulin glargine is a 100 U/mL solution in 10 mL glass vial
1675577|NCT01654367|Drug|Zoledronic Acid and Aromatase Inhibitors|Zoledronic Acid and Aromatase Inhibitors as Adjuvant Therapy
1675578|NCT01654354|Drug|NEOVIST 370 INJ.(Iopromide 768.86mg)|
1675579|NCT01654354|Drug|Ultravist 370 INJ.(Iopromide 768.86mg)|
1675580|NCT01654341|Behavioral|Exercise, dietary and educational program|
1675581|NCT01654328|Drug|Sodium chloride tablets|sodium chloride 1g/10kg of body weight /day per os on day -2 and -1 before contrast exposure. With a maximum dose of 10 gram sodium chloride a day.
1675582|NCT01654328|Drug|Isotonic saline intravenously|isotonic saline (Nacl 0.9%) total 1000ml in 4 hrs or (in case of heart failure or severe renal failure) 12 hrs before and in 4 or in 12 hrs after contrast administration.
1675584|NCT01654302|Drug|Synera|70 mg lidocaine/ 70 mg tetracaine topical patch applied once for 12 hours
1675585|NCT01654302|Drug|Inactive patch|placebo patch applied once for 12 hours
1675627|NCT01653990|Drug|moxifloxacin-placebo|Oral dose of a pill of moxifloxacin-placebo
1675586|NCT01654289|Other|Mindfulness Meditation|"Training will consist of a standardized 8-week Mindfulness Based Stress Reduction (MBSR) program, including 2½ hour weekly sessions and regular at-home daily practice. Didactic sessions center on awareness of physical, emotional, cognitive, and interpersonal responses to stress. A half day meditation retreat on a weekend day at the end of week 6 will allow participants to practice their skills."
1675587|NCT01654289|Other|Exercise|Exercise training will primarily focus on walking or jogging, activities that are convenient, easy to teach and do not require special equipment. Individualized programs will be developed for those who have access to specific equipment, are unable to do walking/jogging, or prefer different types of exercise. Each weekly exercise session will include 1½ hours of didactic and 1 hour of group exercise. A half day exercise retreat designed to match the meditation retreat will occur the weekend of week 6. The retreat will include didactics, group discussion and activities, and individualized exercise practice.
1675588|NCT01654276|Drug|Febuxostat|One 40 mg tablet once a day for 6 months
1675589|NCT01654263|Biological|Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]|Prevnar 13 (PCV13) 13-valent pneumococcal conjugate vaccine. All doses given on Day 0. Group IA and IB (open-label): 0.5 mL intramuscular (IM) injection; Group IIA (open-label, randomized): 0.5 mL IM injection; Group IIB (open-label, randomized): 0.5 mL IM injection in the right arm and 0.5 mL IM in the left arm.
1675590|NCT01654250|Drug|NWP09|Methylphenidate, variable dose, daily dosing, 1 week duration
1675591|NCT01654250|Drug|Placebo|Placebo
1675592|NCT01654237|Other|questionnaires|185 industry workers divided in three sectors (factory, office and logistics) were assessed using the Nordic Musculoskeletal Questionnaire and lifestyle and work-related conditions questionnaires.
1675593|NCT01654224|Biological|High Dose Inactivated Influenza Vaccine|0.5 ml HDIV consisting of 180 mcg (60 mcg each strain) of influenza virus hemagglutinin
1675594|NCT01654224|Biological|Standard Dose Inactivated Influenza Vaccine|0.5 ml of standard dose inactivated influenza vaccine consisting of a total of 45 mcg (15 mcg each strain) of influenza virus hemagglutinin
1675595|NCT01654211|Drug|danoprevir|single iv infusion
1675596|NCT01654211|Drug|danoprevir|single oral dose
1675597|NCT01654211|Drug|placebo|single iv infusion
1675598|NCT01654211|Drug|ritonavir|oral doses
1675599|NCT01654198|Radiation|FDG-PET/CT scan|FDG-PET/CT is a type of imaging used currently to look for cancer. We are using it to look at inflammation within the joints.
1675600|NCT01654185|Drug|AI plus Dimethyldiguanide|AI 1 tablet per day Dimethyldiguanide 0.5 bid
1675601|NCT01654185|Drug|Aromatase Inhibitor|1 tablet per day
1675602|NCT01654172|Dietary Supplement|High Flavanol Cocoa|Total daily flavanol intake provided by the high flavanol drink is ~900mg
1675603|NCT01654172|Dietary Supplement|Low Flavanol Cocoa|
1675604|NCT01654159|Procedure|Monofocal IOL|Monofocal Intraocular lens will be implanted
1675605|NCT01654159|Procedure|Multifocal IOL|Multifocal IOL will be implanted
1675606|NCT01654159|Procedure|Toric IOL|Toric IOLS will be implanted
1675607|NCT01654146|Drug|Carboplatin|AUC5 by intravenous infusion over 30-60 minutes
1675608|NCT01654146|Drug|Carboplatin|AUC2 by intravenous infusion over 30-60 minutes
1675609|NCT01654146|Drug|Paclitaxel|175mg/m2 by intravenous infusion over 3 hours
1675610|NCT01654146|Drug|Paclitaxel|80mg/m2 by intravenous infusion over 1 hour
1675611|NCT01654133|Device|Endovascular repair of TAAA using branched stent graft|Repair of thoracoabdominal aortic aneurysms
1675612|NCT01654120|Drug|Liraglutide|SC, 1.8mg,QD, six months to one year
1675613|NCT01654120|Drug|Insulin|SC, will be titrated during the study, 4 times a day, 1 year
1675614|NCT01654107|Behavioral|Persistence Targeted Smoking Cessation|"8-weeks of smoking cessation counseling (Persistence Targeted Smoking Cessation)"
1675615|NCT01654107|Behavioral|Clearing The Air|8-weeks counseling + 12-weeks nicotine lozenge based on NCI protocol, Clearing The Air
1675616|NCT01654107|Drug|Nicotine lozenge|12-weeks 4mg nicotine lozenge
1675617|NCT01654094|Device|P6 Low Adherent Dressing|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
1675618|NCT01654094|Other|Standard of Care (SOC)|Each patient will have two similar, non-adjacent study sites. One site will be treated with P6 Low Adherent Dressing and the other site will be treated with the Standard of Care (SOC).
1675619|NCT01654081|Drug|Irinotecan|Irinotecan 125 mg/m2 on days 1, 8, 15 and 22 of every 6- week cycle
1675620|NCT01654068|Radiation|Conformal High Dose Intensity Modulated Radiation Therapy|Conformal High Dose Intensity Modulated Radiation Therapy 14Gy single fraction dosing using 6MV photons
1675621|NCT01654042|Other|Prolonged interval between PT testing|Patients in the intervention group will be scheduled for prothrombin time testing and dosing of warfarin every 12 weeks instead of every 4 weeks. This has been suggested in the latest edition of the ACCP guidelines as a possibility for very stable patients. In order to change this from a suggestion to a formal recommendation a study powered for clinically important outcomes is needed.
1675622|NCT01654029|Behavioral|Patient-Centred Communication Intervention|The intervention consists of three parts: 1) development of individualized communication care plans; 2) staff attendance at a workshop focused on communication and behavioral management strategies; and 3) implementation of a staff support system.
1675623|NCT01654016|Drug|Detralex|Detralex 500 mg twice daily for three month prior to surgery
1675624|NCT01654003|Other|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
1675625|NCT01654003|Other|OPTIMIZED|In the OPTIMIZED group, the haemodynamic monitor (Pulsiocath)will help to a goal-directed administration of fluid (250-500ml crystalloids or colloids).The cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI).
1726835|NCT00006340|Drug|arginine butyrate|
1675628|NCT01653977|Other|CONTROL|In the CONTROL group, the administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided to maintain standard pressure-related parameters within a normal range: MAP > 65mmHg, HR < 90/min, CVP >8-12< cm H20, urinary output > 0.5 ml/kg/h. In line with the conventional approach, other physiological parameters will also be targeted: T° > 35.5°C, Sp02 > 95%, lactate < 2.5 mmol/L, normalisation of the BE. The maximal infused volume of hydroxyethyl starch (Voluven®) will be 33 ml/kg.
1675629|NCT01653977|Other|OPTIMIZED|"In the OPTIMIZED group, the central venous catheter and the 4-French artery catheter (femoral or humeral access site) will be connected to a dedicated haemodynamic monitor (Pulsiocath, PV2024L; Pulsion Medical Systems AG, Munich, Germany).
The administration of fluid (250-500ml crystalloids or colloids) and cardiovascular supportive drugs will be guided by an algorithm taking into account standard parameters (HR, MAP, lactate, Hb), as well as static and dynamic volumetric parameters (SVI, CI, GEDVI, EVLWI, SVV, PPV, PVI)."
1675630|NCT01653964|Diagnostic Test|Molecular breast imaging|Molecular breast imaging performed with injection of Tc-99m sestamibi and a dedicated gamma camera (Luma Gem, Gamma Medica)
1675631|NCT01653951|Other|nurse-led care management or peer-led self management|
1675632|NCT01653938|Behavioral|video decision aid|
1675633|NCT01653925|Other|Dietary intervention first|The dietary intervention will be aimed to increase intake of ω-3 long chain fatty acids and to reduce intake of saturated and trans fatty acids. Three consultations with a nutritionist experienced in clinical trials will be planned over a 6-month period. An additional 2 consultations in the last 6 months with the study nutritionist will be planned for men allocated to the dietary fat intervention arm first. Then, after the 6 months of diet intervention, drug intervention with 5α-Reductase Inhibitor will be add to diet for the 6 following months.
1675634|NCT01653925|Drug|Drug (Dutasteride) intervention first|5α-Reductase Inhibitor will be taken daily in tablet dosage form (0.5 mg) taken orally for 12 months depend of the group. After 6 months of drug intake, dietary fat intervention will be add to treatment for the following 6 months. Three consultations with a nutritionist experienced in clinical trials will be planned over this 6-month period.
1675636|NCT01653899|Drug|IDN-6556|14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
1675637|NCT01653886|Other|Breakfast (1-2 hours, in the morning)|You will be required to taste small portions (1 to 2 bites) of 4 different breakfast meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy density is the ammount of enregy of kilocalories in one gram of the food.
1675638|NCT01653886|Other|Lunch (1-2 Hours, at midday)|You will be required to taste small portions of 4 different lunch meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
1675639|NCT01653886|Other|Dinner (1-2 hours, in the afternoon)|You will be required to taste small portions of 4 different dinner meals. You will be asked to reate the taste after each meal. Meals will vary in fat and energy density, and will consist of two high fat diets and a high carbohydrate diet. Energy densityis the ammount of enregy of kilocalories in one gram of the food.
1675640|NCT01653860|Behavioral|The Brøset anger management model|manualised structured cognitive treatment program 15 weeks (30 hours)
1675641|NCT01653860|Behavioral|Ordinary group treatment|group treatment 8 weeks (16 hours)
1675642|NCT01653847|Drug|Tacrolimus with MMF|Standard dose Tacrolimus and MMF. This will follow standard of care procedures at Northwestern Memorial Hospital's Comprehensive Transplant Center. MMF trough or area under the concentration time curve (AUC) shall not be used to adjust dosing. In this group, Tacrolimus will be initiated according to our practice. The Tacrolimus dose will be adjusted from day 3 on to achieve a target whole blood trough concentration of 8 ng/mL to 10 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be reduced to 6 ng/mL to 8 ng/mL. After month 6, the target level of Tacrolimus will be reduced to 4 ng/mL to 8 ng/mL.
1675643|NCT01653847|Drug|Group 2: Tacrolimus with Everolimus.|From day 5 on, the starting dose of Everolimus (0.75 mg bid) will be increased if the trough level is < 3 ng/mL, or reduced if the trough level is > 8 ng/mL. Tacrolimus will be initiated according to our practice. In this treatment arm, the Tacrolimus dose will be adjusted from day 3 on, to a target whole blood trough concentration of 4 ng/mL to 7 ng/mL. From month 2 until Month 6, the target Tacrolimus trough level will be 3 ng/mL to 6 ng/mL. After month 6, the Tacrolimus dose should be adjusted in order to achieve a target trough level of 2 ng/mL to 5 ng/mL. MMF dose will be initiated as 1 g b.i.d. (2 g/day). Adjustments should be made for adverse events including but not limited to gastrointestinal intolerance and a decrease in white blood cell (WBC).
1675644|NCT01653834|Biological|Harvesting and reinfusion of autologous lymphocytes|collect lymphocytes prior to pts starting RT/chemo and put them back after pt completes RT
1675645|NCT01653821|Procedure|Carotid body excision|
1675646|NCT01653808|Device|Elisio-210H|comparison of efficacy and biocompatibility of Elisio-210H dialyzer between conventional hemodialysis and on line hemodiafiltration
1675647|NCT01653808|Procedure|conventional hemodialysis|comparison of conventional hemodialysis with on line hemodiafiltration using Elisio-210H dialyzer
1675648|NCT01653808|Procedure|on line hemodiafiltration|comparison of on line hemodiafiltration with conventional hemodialysis using Elisio-210H dialyzer
1675881|NCT01652300|Behavioral|no education|women in the control group received no education
1676272|NCT01649284|Drug|afatinib|40, 30, and 20 mg film-coated tablets
1675651|NCT01653782|Behavioral|Kundalini yoga|Guided training twice a week for six weeks. Self instructing cd for home practice
1675652|NCT01653782|Behavioral|Self care advice|"Evidence based advice from caregiver about keeping active, exercise and a written self care pamphlet The Back book"
1675653|NCT01653782|Behavioral|Exercise|"Strength training at a gym supervised by a physical therapist twice a week during 6 weeks. Self training instruction was provided. A written self care pamphlet The Back book"
1675654|NCT01653756|Drug|IPI-145, a PI3K Inhibitor|Active drug
1675655|NCT01653756|Drug|Placebo to match IPI-145|Comparator
1675656|NCT01653743|Drug|MSJ-0011|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa [recombinant human Chorionic Gonadotropin, r-hCG]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of >=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
1675657|NCT01653743|Drug|urinary hCG (u-hCG)|Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 5,000 IU u-hCG intramuscularly dose within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of >=18 mm; not more than 3 follicles each with a mean diameter of >=16 mm and serum E2 level within an acceptable range for the number of follicle present, and not more than 2,000 pg/mL.
1675658|NCT01653743|Drug|Follitropin alpha|Low-dose step-up protocol involves starting dose of follitropin alfa as 75 International Units (IU) subcutaneously per day ,increments by 37.5 IU every 7 days (Day 8, 15, 28) will be done if no ovarian response will be observed for maximum of 28 days.
1675659|NCT01653730|Device|Eclipse 3 portable oxygen concentrator|
1675660|NCT01653730|Device|EverGo portable oxygen concentrator|
1675661|NCT01653730|Device|iGo portable oxygen concentrator|
1675662|NCT01653717|Procedure|Leukapheresis|Blood drawn through a needle in a vein in one arm, then passed though a machine to collect white blood cells, and then remaining blood returned back to patient through a needle in a vein in other arm. Procedure will take about 3 hours to complete.
1675663|NCT01653717|Drug|Fludarabine|25 mg/m2 by vein on Days -5 to Day -3.
1675664|NCT01653717|Drug|Cyclophosphamide|250 mg/kg by vein on Days -5 to -3.
1675665|NCT01653717|Procedure|T-cell Infusion|Beginning dose of genetically modified cells is > 5x10^7/m2 but less than or equal to 5 x10^8/m2 infused on Day 0.
1675668|NCT01653691|Procedure|Pulse-Dye Laser|Laser therapy will be applied to either one half or both halves of the subject's burn scar. Laser will be re-applied every 4-6 weeks for a total of 3 administrations.
1675669|NCT01653691|Procedure|Sham|No treatment to one side of subject's scar.
1675670|NCT01653678|Dietary Supplement|Vitamin D-3 (cholecalciferol), 2000 IU|
1675671|NCT01653678|Drug|Omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
1675672|NCT01653678|Dietary Supplement|Vitamin D placebo|
1675673|NCT01653678|Drug|Fish oil placebo|
1675674|NCT01653665|Drug|Leukine|Daily subcutaneous injection of either 3 or 6 micrograms per kilo per day, for either 4 or 7 days.
1675675|NCT01653665|Drug|Normal Saline|Patients in the randomised controlled trial may receive this placebo as a single daily subcutaneous injection. The volume will match that of the active drug.
1675676|NCT01653652|Dietary Supplement|Probiotic|
1675677|NCT01653652|Dietary Supplement|Maltodextrin|
1675678|NCT01653639|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 3000 IU vial size (600 IU/ml)
1675679|NCT01653639|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|50 IU/kg single dose using the 2000 IU vial size (400 IU/ml)
1675681|NCT01653613|Genetic|DNA analysis|
1675682|NCT01653613|Genetic|fluorescence in situ hybridization|
1675683|NCT01653613|Genetic|gene expression analysis|
1675684|NCT01653613|Genetic|microarray analysis|
1675685|NCT01653613|Genetic|mutation analysis|
1675686|NCT01653613|Genetic|polymorphism analysis|
1675687|NCT01653613|Genetic|reverse transcriptase-polymerase chain reaction|
1675688|NCT01653613|Other|laboratory biomarker analysis|
1675689|NCT01653600|Device|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
1675690|NCT01653600|Device|LifeStent|same to SMART STENT
1675733|NCT01653301|Drug|XELOX RT|"Xeloda: 1300 mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose), during the whole treatment time;
Oxaliplatin: 130mg/m2, days 1, 19, 38
RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week; In the XELOX-RT arm a boost of 5.4 Gy is delivered to the mesorectum corresponding to GTV, at 1.8 Gy daily, in 3 fractions, to a total dose of 50.4 Gy. The boost will be delivered at the end of the irradiation of the pelvis (sequential boost)."
1675883|NCT01652287|Other|Strawberry flavored yogurt|Placebo, strawberry yogurt, 4 ounces taken orally for 10 days
1955175|NCT03276884|Other|Experimental Infant Formula|amino acid-based infant formula powder
1955176|NCT03276884|Other|Control Infant Formula|amino acid-based infant formula powder
1675691|NCT01653587|Device|Percutaneous coronary intervention|Both transradial and transfemoral coronary angiography will be performed by the Judkins technique using arterial introducers with 6 French diameter and pre-molded catheters for selective catheterization of left and right coronary arteries.Percutaneous coronary intervention will be indicated when a culprit lesion is identified, with stenosis diameter severity ≥ 70%, with high probability of angiographic success, being ideally performed immediately after coronary angiography and left ventriculography. Patients with multiarterial coronary disease will be submitted to percutaneous coronary intervention after agreement among cardiologist, interventional cardiologist and thoracic surgeon. Procedures will be performed according to recommendations and provisions of current guidelines.
1675692|NCT01653574|Drug|Famitinib Malate|The starting dose of Famitinib Malate will be 25 mg/d. Two dose reductions will be allowed to 20 and then 15 mg/d.
1675693|NCT01653561|Drug|Apatinib|The starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
1675694|NCT01653548|Behavioral|Habituation Reminder Training|Participants will hear a unique sound after habituating to a personal stressor.
1675695|NCT01653548|Behavioral|Habituation Reminder|Participants will hear the habituation reminder outside of the lab via a cellular phone.
1675696|NCT01653548|Behavioral|Habituation|Participants will habituate to personally-relevant stressor.
1675698|NCT01653522|Drug|Triptan|
1675699|NCT01653522|Drug|Doxycycline|
1675700|NCT01653509|Device|Acyclovir patch|Patch containing acyclovir
1675701|NCT01653509|Device|Placebo patch|Patch without acyclovir
1675702|NCT01653496|Procedure|Enhanced recovery after surgery|The main 18 elements of ERAS program included are described in detail in the brief summary of the study
1675703|NCT01653483|Drug|GSK573719|Novel Dry-Powder Inhaler
1675704|NCT01653483|Drug|GSK573719matched-placebo|Novel Dry-Powder Inhaler
1675705|NCT01653470|Drug|Paclitaxel|
1675706|NCT01653470|Drug|5-Fluorouracil (5FU)|
1675707|NCT01653470|Drug|Carboplatin|
1675708|NCT01653470|Drug|Leucovorin|
1675709|NCT01653470|Drug|Irinotecan|
1675710|NCT01653470|Drug|Paclitaxel|
1675711|NCT01653470|Drug|BMS-906024|
1675712|NCT01653457|Drug|Memantine|"Patients randomised to this arm will receive memantine 20 mg daily. This dose will be reached following this schema:
1st week: 5 mg daily
2nd week: 10 mg daily
3rd week: 15 mg daily
From 4th week up to 24th week: 20 mg daily"
1675713|NCT01653457|Drug|Placebo|Patients randomised to this group will receive film-coated placebo tablets (similar to drug tablets.
1675714|NCT01653444|Drug|GC1119|biweekly, IV infusion
1675715|NCT01653431|Device|Transcranial direct current stimulation|
1675716|NCT01653418|Drug|Bortezomib|
1675717|NCT01653418|Drug|Carmustine|
1675718|NCT01653418|Drug|Etoposide|
1675719|NCT01653418|Drug|Cytarabine|
1675720|NCT01653418|Drug|Melphalan|
1675721|NCT01653418|Procedure|Stem cell infusion|
1675723|NCT01653392|Biological|Observational Intervention|This is an observational study, therefore no interventions are specified.
1675724|NCT01653379|Drug|DP001|DP001 softgel capsules; 55 ng to 550 ng per dose, administered 3 times weekly for 4 weeks
1675725|NCT01653366|Behavioral|Physical Activity Goal Setting|"Will include an initial physical therapy (PTA) consult to set exercise goals to increase physical activity by 6000 steps per week over the course of the trial, viewing of the Exercise and Breast Cancer digital video disc (DVD, followed by 10 regular phone calls or RN visits (weekly for the first month, then monthly) to follow up on whether or not those goals are being met and, if not, how best to meet them."
1675726|NCT01653353|Behavioral|peer physician-applied recommendation to the physicians|The peer physician-applied recommendation will include scientific information, practical recommendations to correctly supplement with calcium and vitamin D and a list of individual appraisals of the prescribed supplements among the residents.
1675728|NCT01653327|Drug|Ketamine|Twenty milligrams of ketamine will be dissolved in 4 mL of pharmaceutical cherry syrup and 1 ml of normal saline.
1675729|NCT01653327|Drug|Placebo|
1675730|NCT01653314|Drug|Megavec|
1675731|NCT01653314|Drug|Glivec|
1675732|NCT01653301|Drug|XELAC RT|"Xeloda 1650mg/m2 chronomodulated (h 8.00 a.m. 25% of total dose ; h 6.00 p.m. 25% of total dose; h 11.00 p.m. 50% of total dose) during the whole treatment time.
RT: pelvic treatment is the same for both arms: 45 Gy are delivered to the whole pelvis at 1.8 Gy daily, 5 times per week.
In the XEL-ACRT arm a boost of 10 Gy is delivered to the mesorectum corresponding to the GTV, at 1 Gy for fraction to a total dose of 55 Gy, in 10 fractions over 5 weeks, 2 times a week. The daily dose of the boost will be delivered twice a week immediately after the daily dose administered to the pelvis (concomitant boost)."
1675778|NCT01652963|Other|Reed and Clements Training Task|see study arm: Reed and Clements Training Task. Training task developed to improve cognitive mediation skills in people with intellectual disabilities.
1675734|NCT01653288|Behavioral|Coping Coach|Coping Coach is a self-guided web-based intervention that utilizes an interactive, developmentally appropriate, game-like format, to provide practical information and teach children adaptive coping strategies. Children are primary users of the intervention, with parent supervision. Modules (20-30 minutes each) can be repeated to solidify skills / learning. The feelings module targets recognition of emotions after potentially traumatic experiences. The appraisals module targets the connection of helpful or unhelpful thoughts to feelings and behavior. The avoidance module targets reducing reliance on avoidance as a (maladaptive) coping response. Promoting social support is folded throughout the intervention. Information will be provided to parents about how to access additional resources and when to get additional professional help.
1675735|NCT01653275|Other|Mediterranean Diet|Subjects will receive key foods (olive oil, walnuts, frozen portions of high n-3 LCPUFA fish) and instructed in the quantity to consume each week. Olive oil : minimum of 3 tablespoons per day. Walnuts:10.5 oz/week (1.5 oz/day). High n-3 LCPUFA fish: 3 or more fish meals per week. Additional guidelines for altering diet include incorporation of fruits, vegetables, legumes, and whole grains to replace sweets, white bread and starches, red meat and highly processed foods.
1675736|NCT01653262|Drug|Brivaracetam|
1675737|NCT01653249|Biological|Vaccine consisting of four HPV-16 E6 peptides in combination with Candin®|
1675741|NCT01653223|Drug|simvastatin|"In short statin group: 20 mg per day, start at 5-7 days before surgery and continue for 7 days.
In long statin group: 20 mg per day, start at 5-7 days before surgery and continue for 6 months."
1675742|NCT01653197|Behavioral|Control|No scratch off element
1675743|NCT01653197|Behavioral|Curiosity|The recipient will be prompted to scratch off for answer to question.
1675744|NCT01653197|Behavioral|Curiosity linked to Action|The recipient will be prompted to scratch off for answer only after he/she makes an appointment.
1675745|NCT01653184|Dietary Supplement|Omega-3 fatty acid|The purpose of our study is to evaluate the change in serum omega-3 index (blood level of omega-3 fatty acids) after 1 gram of omega-3 fatty acid supplementation versus 2 grams.
1675746|NCT01653171|Drug|Water (Placebo)|Water 100 mL
1675747|NCT01653171|Drug|Simethicone|200 mg (5 mL) in water for up to 100 mL, to take 20 minutes prior to examination
1675748|NCT01653171|Drug|N-acetylcysteine 500 mg|500 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
1675749|NCT01653171|Drug|N-acetylcysteine 1000 mg|1000 mg + Simethicone 200 mg in water for up to 100 mL, to take 20 minutes prior to examination
1675750|NCT01653158|Drug|CP-751,871|"CP-751,871 was given intravenously [IV] every 3 weeks in escalating doses ranging from 0.1 mg/kg up to 20 mg/kg.
Standard doses of Docetaxel were given every 3 weeks with CP-751,871. Study therapy was continued until disease progression, lack of tolerability for up to 17 cycles (approximately 1 year)."
1675751|NCT01653158|Drug|Docetaxel|Docetaxel up to 75 mg/m^2 was administered intravenously [IV] on Day 1 of each 3-week dosing cycle.
1675752|NCT01653145|Other|Diet A|Dietary
1675753|NCT01653145|Other|Diet B|Dietary
1675754|NCT01653145|Other|Diet C|Dietary
1675755|NCT01653132|Drug|Incobotulinum Toxin A|Twenty units (0.2 ml) of incobotulinum toxin A were injected into each parotid gland and 30 units (0.3 ml) to each submandibular gland for a total dose of 100 units using anatomical landmarks
1675756|NCT01653132|Drug|Placebo|Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
1675757|NCT01653119|Drug|Rosuvastatin|Both of the two groups will be given standard ACS treatment according to treatment guidelines during the following 1 year.
1675758|NCT01653106|Procedure|cryotherapy|Receive shaved ice
1675759|NCT01653106|Other|questionnaire administration|Participate in PROMS
1675760|NCT01653106|Other|pharmacological study|Correlative studies
1675761|NCT01653093|Procedure|3-Tesla magnetic resonance imaging|Undergo 3T MRI
1675762|NCT01653093|Procedure|diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
1675763|NCT01653093|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
1675764|NCT01653093|Procedure|magnetic resonance spectroscopic imaging|Undergo MR spectroscopy
1675765|NCT01653080|Procedure|dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI)|Studies will be performed on standard clinical MR Systems which are available on Campus. With the proposed imaging technique, we are able to acquire a 3D volume covering the orbit with a temporal resolution of approximately 15s. The affected eye will be immobilized to reduce motion artifacts. A routinely used MR contrast agent will be administered in a dose of 0.1mmol/kg bodyweight.
1675766|NCT01653067|Drug|Rituximab, Temsirolimus, DHAP, intravenous|Maximum tolerated dose of Temsirolimus Rituximab (375 mg/m²) Dexamethasone (120 mg) Cisplatin (100mg/m²) Cytarabine (2x2g/m²))
1675767|NCT01653054|Procedure|Anal Pap Smear, HPV DNA Testing|Anal Pap Smears and HPV DNA testing will be performed on all subjects.
1675768|NCT01653041|Drug|Everolimus|
1675769|NCT01653028|Drug|Alisertib|Given PO
1675770|NCT01653028|Other|Laboratory Biomarker Analysis|Correlative studies
1675771|NCT01653015|Biological|Trivalent Inactivated Vaccine|Influenza vaccination, 0.5 ml dose administered intramuscularly. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.5 ml dose four weeks later.
1675772|NCT01653015|Biological|Live Attenuated Influenza Vaccine|Influenza vaccination, 0.2 ml dose administered intranasally. Previously unvaccinated children who are less than 9 years of age at the time of immunization will receive a second 0.2 ml dose of the vaccine four weeks later.
1675773|NCT01653002|Other|No intervention|
1675774|NCT01652989|Behavioral|Weight loss maintenance intervention face-to-face|
1675775|NCT01652989|Behavioral|Weight loss maintenance intervention delivered via DVD|
1675776|NCT01652976|Drug|Dasatinib|Dasatinib 150mg PO daily on days 1-14 of each 14 day cycle
1675777|NCT01652976|Drug|mFOLFOX6|mFOLFOX6 (oxaliplatin 85mg/m2 IV, leucovorin 400mg/m2 IV, 5-Fluorouracil bolus 400mg/m2 IV, and 5-Fluorouracil 2400mg/m2 IV) on day 1 of each 14 day cycle
1675841|NCT01652664|Drug|Timolol, 0.5% or 0.25% ophthalmic solution|Patients 2 months to < 3 years of age received 0.25%
1675779|NCT01652950|Behavioral|Financial incentives|"The incentive arms comprised a Direct Payment Group, a Charity Incentive Group, a Lottery Pay-out Group, and a Choice Group. Members were offered the base program and supplementary communication described above. In addition, individuals were offered the equivalent of one of four possible incentive amounts depending on the level of participation in fitness-related activities. Enrollment into the trial took place for a period of 5 months, and the intervention took place over a period of 12 months following registration.
Level 1: <150 fitness points per month - equivalent to < 1 gym visit per month - no reward, up to Level 5, which was >3000 fitness points/month - equivalent to >20 gym visits/month."
1675780|NCT01652937|Drug|BIIB057|Oral
1675781|NCT01652937|Drug|Placebo|Oral
1675782|NCT01652924|Device|Mechanical ventilation with facial mask|This group includes patients with the randomization process are assigned to mechanical ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation. The size of the facial mask is used according to the age and ventilation parameters are: inspiratory pressure 10 cmH2O, PEEP 5 cmH2O, respiratory frequency and relation I/E according to age .
1675783|NCT01652924|Device|Manual ventilation with facial mask|"This group includes patients with the randomization process are allocated to manual ventilation with facial mask during induction of anesthesia, which will be maintained until to secure airway with endotracheal tube to determine the presence of gastric insufflation.
The size of the facial mask is used according to the age and ventilator y parameters are selected by the anesthesiologist."
1675784|NCT01652911|Device|Sernova Cell Pouch|The Cell Pouch™ is an implantable medical device for transplantation of donor islets for Type-1 diabetes as an alternative to the current standard of care using intraportal delivery of islets.
1675785|NCT01652898|Drug|LDLA202|Comparison of 3 different doses LDLA202, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
1675786|NCT01652898|Drug|ONO LDL50|Comparison of 3 different doses ONO LDL50, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
1675787|NCT01652898|Drug|Esmolol hydrochloride|Comparison of 3 different doses Esmolol, 40 PK samples, 40 BP and ECG measurement time points, 23 local tolerability measurement time points
1675788|NCT01652885|Drug|AN2728 Topical Ointment, 2%|AN2728 Topical Ointment, 2%
1675790|NCT01652859|Drug|Liposomal Amphotericin B|
1675791|NCT01652859|Drug|AmBisome|
1675792|NCT01651754|Biological|Seasonal influenza vaccination|single dose of influenza vaccination
1675793|NCT01651741|Dietary Supplement|Seaweed and Duolac7S|"Seaweed and probiotics is composed of seaweed and Duolac7S.
Seaweed:
Form: brown granule
Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)
Duration: 4 weeks of treatment period
Duolac7S:
The probiotics, Duolac7S, consist of 7 bacteria.
Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus.
Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (30 min after morning and evening meal)
Duration: 4 weeks of treatment period"
1675794|NCT01651741|Dietary Supplement|Seaweed and Duolac7S-P|"Seaweed and probiotics is composed of seaweed and Duolac7S-P(Placebo Duolac7S).
Seaweed:
Form: brown granule
Dosage and frequency: 1 pack (3 g), 2 packs per day (30 min after morning, and evening meal)
Duration: 4 weeks of treatment period
Duolac7S-P:
Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
1675795|NCT01651728|Drug|Simvastatin|Tablet 20 mg once daily for 30 days
1675796|NCT01651728|Drug|Placebo|daily for 30 days
1675797|NCT01651715|Drug|TAO1, oral homeopathic antibodies|"TAO1 comprises a mixture of homeopathic dilutions C12+C30+C200 (drug product is made by impregnation of pre-made tablets).
The investigational product will be taken for 7 days as follow:
Day 1: 3 tablets over the first 2 hours of treatment, then 3 tablets over the rest of Day 1.
Days 2-3: 5 tablets/day (intakes distributed evenly over the daytime). Days 4-7: 3 tablets/day (intakes distributed evenly over the daytime)."
1675798|NCT01651702|Device|Carto|Group of patients where Carto Express system will be used for electroanatomical mapping.
1675799|NCT01651702|Device|Ensite|Group of patients where Ensite Velocity system will be used for electroanatomical mapping.
1675800|NCT01651676|Other|VQ11 validation|"Two visits per patient are planned: V1 and V2.
For each visit, the pulmonologists ask the patients participating in the study to fill out the VQ11 questionnaire, which will be correlated to the other parameters (Likert scale, IPAQ, RFE, SGRQ,...)
LABD treatment consist in β 2 agonists or anticholinergic drug."
1675801|NCT01651663|Drug|Arbidol (Umifenovir)|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
1675802|NCT01651663|Other|placebo|Arbidol (Umifenovir)/Placebo will be administered at a dosage of 800 mg/day (2 capsules q.i.d.) for 5 days.
1675803|NCT01651663|Drug|Arbidol (Umifenovir)|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
1675804|NCT01651663|Other|placebo|Medically healthy exposed subjects will be administered Arbidol (Umifenovir)/Placebo at a dosage of 200 mg/day (2 capsules q.d.) for 10 days.
1675805|NCT01651650|Device|Inhalation through Chiesi NEXThaler DPI|Inhalatory manoeuvre through Chiesi NEXThaler DPI repeated at least twice in order to have two evaluable data set
1675806|NCT01651637|Drug|synthetic surfactant (CHF5633)|CHF5633 100 mg/kg; CHF5633 200 mg/kg synthetic surfactant sterile suspension in 3.0 ml glass vials with a total concentration of 80 mg/ml for intratracheal administration. Single administration
1675807|NCT01651624|Other|Invitation to screening|
1675808|NCT01651611|Behavioral|Motivational interviewing|The TTA will use motivational interviewing (MI) techniques to assess the participant's motivation and readiness to quit, suggest plans, and assist the participant in selecting a method of treatment.
1675842|NCT01652664|Drug|Travoprost Vehicle|Inactive ingredients used to maintain masking
1675882|NCT01652287|Drug|BB-12 supplemented strawberry yogurt|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
1675809|NCT01651611|Behavioral|Smoking cessation counseling|The TTA will provide information to the participant regarding evidence-based treatments for smoking cessation, including counseling and nicotine replacement therapy (NRT); assist in a quit plan; and discuss issues such as obtaining social support, staying in treatment, and dealing with lapses.
1675810|NCT01651611|Behavioral|Navigation to smoking cessation resources|The TTA will assist participants in obtaining NRT and getting connected to smoking cessation counseling services, such as the Smokers' Quitline and clinic-based programs.
1675811|NCT01651611|Behavioral|Social support|Meetings with the TTA will be a source of social support for the participant as they attempt to quit or stay quit.
1675812|NCT01651598|Drug|Placebo to BI 144807|multiple dose (bid)
1675813|NCT01651598|Drug|BI 144807|multiple dose (bid, low to high dose)
1675814|NCT01652833|Other|Physician Survey|Eligible physicians will be contacted via telephone to perform the physician survey. A standardised questionnaire will be used to collect information about the physician's awareness of the correct indication and appropriate administration of Vectibix and the physician's experience in the administration of Vectibix treatment in the previous 6 months
1675815|NCT01652820|Drug|Docetaxel 20mg/m2/week + carboplatin AUC 2/weekly - concomitant chemoradiation 2Gy/day|
1675816|NCT01652820|Drug|Docetaxel 40mg<7m2 d1,8, 21, 28+ gemcitabine 1200mg/m2 d1,8, 21, 28 + concomitant docetaxel 20mg/m2/w+carboplatin AUC 2/w+ concomitant RDT 2Gy/d|
1675817|NCT01652807|Behavioral|Hatha Yoga|The yoga intervention will last eight weeks and include two 90-minute sessions each week. Each yoga session will consist of the same series of 26 Hatha yoga postures, two breathing exercise, and two savasanas (i.e., a resting/relaxation posture), in a room heated to 104 degrees Fahrenheit, which aids in safe muscle stretching. Each participant will be given a yoga studio scan card valid for two months, and, like all yoga studio members, they will be required to scan their card prior to their yoga class.
1675818|NCT01652794|Radiation|stereotactic body radiation therapy|Undergo SBRT
1675819|NCT01652794|Drug|carboplatin|Given IV
1675820|NCT01652794|Drug|gemcitabine hydrochloride|Given IV
1675821|NCT01652794|Other|laboratory biomarker analysis|Optional correlative studies
1675822|NCT01652794|Other|pharmacogenomic studies|Optional correlative studies
1675823|NCT01652781|Drug|Azacitidine|5-day arm: azacitidine 75mg/m2 subcutaneously for 7 days every 28 days + best supportive care 7-day arm: azacitidine 75mg/m2 subcutaneously for 5 days every 28 days + best supportive care
1675824|NCT01652768|Other|Research Questionnaires|Hospital Anxiety and Depression Scale Pearlin & Schooler Caregiver Mastery Caregiver Assessment Tool Patient/Caregiver Satisfaction Survey
1675825|NCT01652768|Other|Palliative Care Team|"Week 1: Early palliative care intervention (immediately post-op) provided by the new palliative care brain tumor team (Social worker, advanced practice nurse (APN), medical oncology registered nurse).
Introduce the palliative care team concept.
Provide contact information for the palliative care team given
Administer Initial Patient and Caregiver Psychosocial Assessments (Appendix A)
Offer community resources to patient and caregiver (Appendix B)
Provide additional resources/referrals for any needs that are identified by patient or care partner during initial psychosocial assessment
Provide supportive care"
1675826|NCT01652768|Other|Educational Information Session for Patients and Caregivers|"Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver Week 5 through 7: The PRESENCE Project Social Worker and oncology RN will provide an educational class.
Intervention (Length of time for class = 2 hours):
Provide an educational class Moving Forward: Facing a Brain Tumor Diagnosis for patient and caregiver.
Provide additional resources/referrals for any needs that are identified by patient or care partner during the educational class.
Provide supportive care."
1675827|NCT01652768|Other|Contact every 2 weeks|"The PRESENCE Project APN and/or Presence Project Social Worker will contact the patient and caregiver via telephone or office visit every two weeks and as needed until the second medical oncology visit.
(Anticipated length of time for phone intervention or visit is 20 minutes; however, length of time for intervention is tailored to the patient and caregiver's needs):
Administer Patient and Caregiver Follow-up Assessment
Provide pain and/or symptom management intervention for any issues identified during the follow-up assessment
Provide resources/referrals for any needs identified during the social work follow-up assessment
Provide supportive care"
1675828|NCT01652768|Other|Follow-up Surgical Visit Session|"The PRESENCE Project APN will meet with patient and caregiver at the surgical follow-up visit, approximately two weeks after surgery.
Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):
Administer Patient and Caregiver Follow-up Assessment
Administer Symptom Assessment Tool
Provide pain and/or symptom management intervention
Provide supportive care"
1675829|NCT01652768|Other|Medical and/or Radiation Oncology Appointment Session|"The PRESENCE Project APN and/or Presence Project Social Worker will meet with patient and caregiver at the first medical and/or radiation oncology appointment (weeks 3 and 4).
Intervention (Anticipated length of time for visit is about 30 minutes; however length of time for intervention is tailored to the patient and caregiver's needs):
Administer Patient and Caregiver Follow-up Assessment
Re-assess pain and/or symptom management issues and /or intervention
Provide resources/referrals for any needs identified during the social work follow-up assessment
Provide supportive care."
1675830|NCT01652742|Drug|BI 135585 XX|one single dose
1675831|NCT01652729|Drug|Exenatide once weekly suspension|
1675832|NCT01652729|Drug|Sitagliptin|
1675833|NCT01652729|Drug|Placebo|Placebo oral capsule once daily
1675834|NCT01652716|Drug|Exenatide once weekly suspension|Exenatide suspension 2 mg weekly subcutaneous injection
1675835|NCT01652716|Drug|Exenatide twice daily|5 mcg twice daily for 4 weeks followed by 10 mcg twice daily for 24 weeks
1675836|NCT01652703|Biological|Evolocumab|Administered by subcutaneous injection
1675837|NCT01652703|Other|Placebo|Administered by subcutaneous injection
1675838|NCT01652690|Biological|Denosumab|This is an non-interventional study, therefore denosumab is administered as part of routine care and not for purposes of the study.
1675839|NCT01652677|Procedure|Transcranial magnetic stimulation|Transcranial magnetic stimulation is a noninvasive technique for including electrical currents in the cerebral cortex by means of time-varying magnetic fields.
1675840|NCT01652664|Drug|Travoprost 0.004% PQ ophthalmic solution|
1675877|NCT01652339|Drug|Lodivixx tab. 5/160mg|
1675843|NCT01652651|Behavioral|I Can Succeed ICS|ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
1675844|NCT01652638|Drug|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered subcutaneously.
1675845|NCT01652625|Drug|Yunnan Baiyao toothpaste|The patients were instructed to brush the teeth twice daily for 5 days, using 1 gram of Yunnan Baiyao toothpaste (equivocal to approximately 6-7 lines on a standard toothbrush) for 3 minutes. 6.5 milligrams of Yunnan Baiyao active extract were contained in 1 gram of the toothpaste.
1675846|NCT01652625|Drug|Placebo toothpaste|One gram of the placebo toothpaste was used twice daily by the control group patients. Except for the active Yunnan Baiyao extract, all ingredients contained in the placebo-toothpaste were the same as that in the experimental toothpaste.
1675847|NCT01652612|Other|PEEP|8 cmH2O PEEP throughout the period of OLV and 2nd TLV
1675848|NCT01652599|Drug|Eltrombopag and dexamethasone|Eltrombopag 50 mg PO days 5-32 Dexamethasone 40 mg PO days 1-4
1675849|NCT01652586|Drug|dexmedetomidine-remifentanil|
1675850|NCT01652586|Drug|midazolam-remifentanil|
1675851|NCT01652573|Drug|nasal salmon calcitonin|400 IU daily in two sprays (one to each nares)
1675852|NCT01652573|Drug|Saline Nasal Spray Placebo|
1675853|NCT01652560|Drug|bevacizumab|The patients will be treated with Avastin combined neoadjuvant chemotherapy
1675854|NCT01652547|Drug|Pasireotide sub-cutaneous formulation|Pasireotide, will be administered to all patients by s.c. injection, beginning with a dose of 300 μg administered three times daily (t.i.d.) for 2 weeks. If no pasireotide-related clinically meaningful/uncontrolled grade 3 or grade 4 adverse events occur the dose will be administered to all patients at an increased dose of 600 μg t.i.d. for 2 weeks, followed by 2 weeks of 900 μg t.i.d. and followed by 2 weeks of 1200 μg t.i.d. After the 8 weeks period, patients will be kept on treatment drug (highest dose without clinically meaningful/uncontrolled AEs) , switched to the corresponding pasireotide LAR dose and followed up for an extra 6 months.
1675855|NCT01652547|Drug|Pasireotide lon acting release formulation|At the start of the follow-up phase patients will be switched to pasireotide LAR administered intramuscularly every 28 days by using the following conversion algorithm so that the steady state PK exposure (Cmax and Ctrough) of pasireotide will be maintained: 300 μg s.c. t.i.d. fi 20mg LAR i.m. q 28 days 600 μg s.c. t.i.d. fi 40 mg LAR i.m. q 28 days 900 μg s.c. t.i.d. fi 60 mg LAR i.m. q 28 days 1200 μg s.c. t.id. fi 80 mg LAR i.m. q 28 days In addition, all patients will keep the treatment with pasireotide s.c. during the first 2 weeks of the LAR phase. The use of s.c. dosing during the initial 2 week period following the first LAR dose provides an appropriate level of medication during the LAR nadir.
1675856|NCT01652534|Drug|Amantadine|Amantadine 100mg daily, for a week, if it is tolerated Amantadine will increase to 1 tab twice a day. Amantadine will then be administered orally twice daily in the morning with breakfast and at noon with lunch (AM and NN).
1675857|NCT01652534|Drug|Placebo|Sugar Pill
1675859|NCT01652495|Drug|methylprednisolone acetate|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of methylprednisolone acetate
1675860|NCT01652495|Drug|Triamcinolone Acetonide|Single intrabursal ultrasound guided injection of 40 mg (1 ml) of triamcinolone acetonide
1675861|NCT01652482|Drug|5-fluorouracil|Standard 5-fluorouracil (5-FU) chemotherapy (400 milligram per square meter [mg/m^2] administered as intravenous bolus and then 5-FU 2400 mg/m^2 administered as continuous intravenous infusion over 46 +/- 2 hours) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
1675862|NCT01652482|Drug|Cetuximab|Cetuximab 400 mg/m^2 intravenous infusion as a loading dose on Day 1 Cycle 1, followed by 250 mg/m^2 intravenous infusion weekly until documented disease progression or unacceptable toxicity.
1675863|NCT01652482|Drug|Irinotecan|Standard Irinotecan chemotherapy (180 milligram per square meter [mg/m^2] administered as intravenous infusion over 60 +/- 30 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
1675864|NCT01652482|Drug|Leucovorin|Standard Leucovorin chemotherapy (400 mg/m^2 [racemic form] or 200 mg/m^2 [L-isomer form] administered by intravenous infusion over 120 +/- 10 minutes) or according to local standard-of-care prescribing information's, every 2 weeks until documented disease progression or unacceptable toxicity.
1675865|NCT01652482|Drug|MEHD7945A|MEHD7945A 1100 milligram (mg) intravenous infusion every 2 weeks until documented disease progression or unacceptable toxicity.
1675866|NCT01652469|Drug|Erlotinib|Erlotinib 150 mg/day p.o. continuously with 21 days cycle.
1675867|NCT01652469|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion every 21 days.
1675868|NCT01652456|Other|Addiction support|one consultation with an addiction specialist
1675869|NCT01652417|Drug|methylprednisolone bolus IV 15 mg/kg/d for 3 days.|methylprednisolone bolus IV 15 mg/kg/d for 3 days.
1675870|NCT01652404|Behavioral|Procalcitonin-guided treatment|The antibiotics duration will be determined by the serum procalcitonin level at day 5, 7 and 9.
1675871|NCT01652404|Behavioral|Conventional treatment|The antibiotics duration will be determined by treating physician.
1675872|NCT01652391|Device|Transcranial direct current stimulation (tDCS); DC-STIMULATOR (NeuroConn GmbH, Ilmenau, Germany)|
1675873|NCT01652378|Drug|ondansetron, lidocaine|"Ondansetron: Ondansetron (0.15 mg/kg) will be administered through the IV line over 15 min at a constant rate of infusion.
Lidocaine: Lidocaine will be administered as a 2mg/kg initial bolus over 5 minutes followed by a continuous intravenous infusion of lidocaine at a rate of 2mg/kg/hour for 55 min (60 min total infusion)."
1675874|NCT01652365|Behavioral|RDT Training and Subsidy Offered|
1675875|NCT01652365|Behavioral|Information/Education Campaign|
1675876|NCT01652339|Drug|Exforge tab. 10/160mg|
1675878|NCT01652326|Drug|Diazepam|
1675886|NCT01652248|Procedure|Cardiac resynchronisation therapy|Upgrade to CRT at the time of generator replacement
1675887|NCT01652235|Device|Zenith® p-Branch® or Zenith® Fenestrated AAA Endovascular Graft|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
1675888|NCT01652222|Other|CONEM-BETA + socio-educational training|4 socio-educative training sessions during 8 weeks, and caregivers will systematically play with their patients with CONEM-BETA therapeutic game during the last 4 weeks. The dyads will be assessed (primary timepoint). Caregivers will then continue using the game with their patients for an extra 6 weeks period as needed, to assess adherence and games preferences.
1675889|NCT01652222|Other|Socio-educational training only|4 socio-educative training sessions during 8 weeks
1675890|NCT01652209|Biological|Hearticellgram-AMI|
1675891|NCT01652196|Biological|aflibercept|4 mg/kg as a 1-hour IV(intervenous) infusion
1675892|NCT01652196|Drug|oxaliplatin|85 mg/m2 IV infused over 2 hours
1675893|NCT01652196|Drug|leucovorin|200 mg/m2 (Or levoleucovorin 100 mg/m2. If leucovorin is not available due to drug shortages the regimen should be administered with the leucovorin omitted) IV over 2 hours. Alternatively, leucovorin may be administered (via separate infusion lines) concurrently with oxaliplatin
1675894|NCT01652196|Drug|fluorouracil|400 mg/m2 IV bolus over 5-15 minutes, then 2400 mg/m2 continuous IV infusion over 46 hours.
1675895|NCT01652196|Other|Correlative Studies|Patients are required to have tissue available before enrolling on the study. A fresh biopsy is only required if there is insufficient material for analysis. Repeat tumor biopsies after 8 weeks of therapy are optional and will only be performed at the Ohio State University Medical Center.
1675896|NCT01652196|Procedure|DCE MRI|Images at weeks 0, and after 8 weeks +/- 1 week of treatment (after Cycle 2).
1675897|NCT01652196|Radiation|f18FDG-PET|18FDG-PET is a functional imaging technique that relies on tumor uptake of radiolabeled tracer 18 fluorodeoxyglucose (18FDG). FDG-PET is a widely-used imaging modality in the detection and monitoring of a variety of metastatic cancers, including colorectal cancer (99-102).
1675898|NCT01652196|Procedure|PET (positron emission tomography)|Correlative studies
1675899|NCT01652183|Drug|intravenous paracetamol|
1675900|NCT01652183|Drug|Placebo|
1675901|NCT01652157|Biological|CREON|pancreatic enzyme replacement therapy
1675902|NCT01652157|Biological|ZENPEP|pancreatic enzyme replacement therapy
1675903|NCT01652157|Biological|ULTRESA|pancreatic enzyme replacement therapy
1675904|NCT01652157|Biological|PANCREAZE|pancreatic enzyme replacement therapy
1675905|NCT01652157|Biological|other non-sponsor pancreatic enzyme replacement therapy|pancreatic enzyme replacement therapy
1675906|NCT01652157|Other|No pancreatic enzyme replacement therapy|Cystic fibrosis patients in the cystic fibrosis patient registry not receiving any pancreatic enzyme replacement therapy (approximately 10%)
1675907|NCT01652157|Biological|PERTZYE|pancreatic enzyme replacement therapy
1675908|NCT01652144|Drug|AT7519M|
1675909|NCT01652131|Other|Tetrastarch (130/0.4)|
1675910|NCT01652118|Drug|clarithromycin treatment for prophylaxis of bronchopulmonary dysplasia|
1675911|NCT01652118|Drug|Saline|
1675912|NCT01652105|Dietary Supplement|Standard diet versus standard VLCD (Prodimed)|
1675913|NCT01652092|Drug|Alemtuzumab 0.3 mg|0.3 mg/kg intravenously (IV) on days -12 through -10
1675914|NCT01652092|Drug|Cyclophosphamide|cyclophosphamide 50 mg/kg IV on days -9 through -6
1675915|NCT01652092|Drug|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -5 through -2
1675916|NCT01652092|Biological|Stem Cell Transplantation|"Unrelated donor bone marrow will be collected in the usual manner using established parameters determined by the National Marrow Donor Program. A minimum of 3 x 10^8 nucleated cells/kg recipient weight will be collected with a goal of ≥ 5 x 10^8 nucleated cells/kg recipient weight.
Umbilical cord blood selection will be per the current University of Minnesota Cord Blood Unit Selection algorithm. One or two units may be used to obtain the minimum cell dose. One of the UCB units selected for transplantation must contain ≥ 3.5 x 10^7 nucleated cells/kg recipient weight based on cell numbers at time of cryopreservation, and the total combined cell dose of both units must be > 5.0 x 10^7 nucleated cells/kg."
1675917|NCT01652092|Drug|Fludarabine phosphate 40 mg|40 mg/m^2 IV on days -5 through -2
1675918|NCT01652092|Drug|Melphalan|140 mg/m^2 IV on day -3
1675919|NCT01652092|Drug|Alemtuzumab 0.2 mg|0.2 mg/kg intravenously (IV) on days -14 through -10
1675920|NCT01652092|Drug|Busulfan|busulfan 0.8 or 1.1 mg/kg IV on days -9 through -6
1675921|NCT01652092|Drug|Fludarabine phosphate 30 mg|fludarabine 30 mg/m^2 IV on days -8 through -4
1675922|NCT01652092|Drug|MESNA|administered as per the standard institutional protocol.
1675923|NCT01652079|Drug|CRLX101|q 14 days
1675924|NCT01652066|Dietary Supplement|Mixture of probiotics|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
1675925|NCT01652066|Dietary Supplement|Mixture of probitiocs|effect of the consumption a mixture of probiotics ( dietary supplement tablet - dosage at least 10x7 cfu/g) during 7 weeks , once a day , healthy volonteers ) on the antigen specific antibody respense
1675926|NCT01652053|Device|Disc Nucleus Replacement (InterCushion DNP)|The device is intended for spinal arthroplasty in skeletally mature patients with leg pain due to a herniated disc with or without back pain, who are having a discectomy at one level from L2 -S1. These patients should have no spondylolisthesis at the involved level.
1675927|NCT01652040|Device|Resistance Training and Testosterone Patches|We are going to activate the knee extensor muscle group to lift ankle weights over 16 weeks and we are going to provide Tp to improve anabolic profile.
1675928|NCT01652040|Drug|Testosterone Patches|The investigators will provide Tp patches for 16 weeks for patients with Spinal Cord Injury.
1675930|NCT01652014|Drug|cyclophosphamide|Given IV over 1 hour on Day -6; after pre-hydration
1675931|NCT01652014|Drug|fludarabine phosphate|Given IV daily over 30 minutes for 5 days (Days -6 to -2)
1675932|NCT01652014|Drug|mycophenolate mofetil|Given PO 1.0 g BID Day 1-30
1675933|NCT01652014|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo double-unit allogeneic UCB transplant
1675934|NCT01652014|Procedure|umbilical cord blood transplantation|Undergo single allogeneic UCB transplant
1675935|NCT01652014|Procedure|double-unit umbilical cord blood transplantation|Undergo double-unit allogeneic UCB transplant
1675936|NCT01652014|Radiation|total-body irradiation|Undergo TBI
1675937|NCT01652014|Drug|tacrolimus|Given IV 0.03 mg/kg/d as continuous infusion over 24 hours starting Day -3 with dose adjustments to maintain level of 8-20 mg/ml
1675938|NCT01652014|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo single allogeneic UCB transplant
1675939|NCT01652014|Procedure|peripheral blood stem cell transplantation|Undergo irradiated allogeneic peripheral blood stem cell transplant
1675940|NCT01652001|Drug|Malic Acid|Oral spray for application into the oral cavity
1675941|NCT01652001|Other|Placebo|Oral spray for application into the oral cavity
1675942|NCT01651988|Drug|Ketamina-Propofol Combination|"After randomization to the study group, the patients were given:
Procedures < 10 minutes
Ketamine-Propofol Combination KETOFOL 1:1
Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)
Ketamine: cc/kg 0.04 (50 mg/cc = 2 mg/kg)
Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)
Ketamine-Propofol Combination KETOFOL 1:2
Propofol: 0.2 cc/kg (10 mg/cc = 2 mg/kg)
Ketamine: 0.02 cc/kg (50 mg/cc = 1 mg/kg)
Simple 1% lidocaine: 0,1 cc/kg (10 mg/cc = 1 mg/kg)
Procedures > 10 minutes
In addition to the initial bolus, an infusion was started:
KETOFOL 1:1
20 cc of propofol (10 mg/cc = 200 mg in total) 4 cc of ketamine (50 mg/cc = 200 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 66 cc 0.9% SSN
KETOFOL 1:2
20 cc of propofol (10 mg/cc = 200 mg in total) 2 cc of ketamine (50 mg/cc = 100 mg in total) 10cc lidocaine 1% simple (10 mg/cc = 100 mg in total) 68 cc 0.9% SSN
Speed infusion:
0,03cc/kg/min"
1675943|NCT01651975|Dietary Supplement|Thickenup|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
1675944|NCT01651975|Dietary Supplement|Thickenup Advance|given two 1-cc boluses of liquid contrast agent (barium), one 3-cc of thin liquid contrast, one 3-cc of paste, one cookie with contrast, one 20-cc bolus of liquid contrast, and one 20-cc bolus of thin liquid contrast. The patients are then studied in the anterior/posterior view with one 1-cc, one 3-cc, and one 20-cc bolus of thin liquid barium 1-4. At the end of the protocol patients are routinely administered products with either starch or gel based thickener to evaluate the swallowing safety of the thickened agent. The protocol includes a 3-minute limitation on total fluoroscopy time to ensure clinician and patient safety.
1675945|NCT01651962|Drug|Terbutaline|
1675946|NCT01651962|Drug|Fentanyl|
1675947|NCT01651962|Drug|0.9% NaCl|
1675948|NCT01651949|Biological|9vHPV Vaccine|9vHPV, V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3-dose regimen
1675949|NCT01651936|Drug|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
1675950|NCT01651936|Drug|Methotrexate|MTX dosed at the stable dose received upon study entry
1675951|NCT01651936|Drug|Dose-match placebo|Dose-matched placebo dosed orally BID
1675952|NCT01651923|Drug|Heparin|Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.
1675953|NCT01651884|Device|HD-tDCS (Soterix)|Subjects will be given individualized dose (number of electrodes and electrode placement) through High-Definition electrodes to target fMRI determined targets
1675954|NCT01651884|Device|Transcranial Direct Current Stimulation (Neuroconn)|
1675955|NCT01651871|Drug|S-555739 Dose 1|
1675956|NCT01651871|Drug|S-555739 Dose 2|
1675957|NCT01651871|Drug|Cetirizine HCl Dose 1|
1675958|NCT01651871|Drug|S-555739 placebo|
1675959|NCT01651871|Drug|Cetirizine HCl placebo|
1675960|NCT01651858|Drug|Nurigra Chewable tablet|1 tablet of 100mg, once a day
1675961|NCT01651832|Behavioral|SCAN|The Supportive Cancer Care Networkers intervention (SCAN) consists of an additional telephone support and symptom-related out-patient care management through Oncology Nursing. The SCAN intervention assesses patients' resources and barriers in utilizing health care services in order to meet their individual needs adequately and supports maintenance of therapy compliance. Thus, the SCAN offers a comprehensive mirroring the patients' medical and psychosocial care needs across changing sectors of health care.
1675962|NCT01651819|Procedure|Urological physical therapy|Individual patient attending with one hour duration beginning with Behavior therapy and education, teaching urinary maneuvers, water adequate intake. Second part is manual therapy an Kinesiotherapy with specific exercises, followed by patient repetition. Last part is constituted by electrotherapy for specific muscle stimulation and biofeedback.
1992247|NCT03322774|Behavioral|digital Cognitive Behavioral Therapy for Insomnia|"Cognitive Behavioral Therapy for Insomnia administered online through the Sleepio program. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long online video sessions with an animated figure called The Prof, which delivers the treatment."
1992248|NCT03322774|Behavioral|face-to-face Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia administered by experienced staff trained in behavioral sleep medicine. Treatment utilizes sleep restriction, stimulus control, and cognitive therapy. Treatment is administered through 6 weekly, hour-long face-to-face sessions with an experienced staff member trained in behavioral sleep medicine.
1992249|NCT03322774|Behavioral|Sleep Hygiene Education|Participants are provided with information about good sleep hygiene through 6 weekly emails. Participants practice good sleep hygiene as part of their sleep routine.
1675971|NCT01651780|Drug|Bivalirudin|Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
1675972|NCT01651780|Drug|Unfractionated Heparin|Unfractionated heparin is an anticoagulant.
1675973|NCT01651767|Drug|Placebo|Form=suspension, route=oral.
1675974|NCT01651767|Drug|JNJ-47910382|Type=exact number, unit=mg, number=30, 90, 300, 400 or 450, form=suspension, route=oral. Study drug will be administered once or twice daily
1675975|NCT01651585|Drug|Valacyclovir arrow|dosage form:500mg, dosage:8g/day, frequency: 4 a day duration: 23 weeks maximum
1675976|NCT01651572|Drug|Cisatracurium|"Cisatracurium (Nimbex):
initial dose: 0.2 mg/kg
maintaining dose: 0.1 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
1675977|NCT01651572|Drug|Rocuronium|"Rocuronium (Esmeron):
initial dose: 0.6 mg/kg
maintaining dose: 0.15 mg/kg (repeated anytime TOF-count reaches 2 twitches)"
1675978|NCT01651546|Behavioral|Intermittent catheterization test|I-CAT will be a self assessment questionnaire and a simple, comprehensive and quickly passed questionnaire.
1675979|NCT01651533|Behavioral|Mental Practice Group|Patients are administered rehabilitative therapy targeting their affected arms on 3 days/week during a ten week period. Directly after the therapy session, they participate in targeted mental practice session in which they cognitively rehearse the movement that they just physically practiced.
1675980|NCT01651533|Behavioral|Active Control Group|Individuals assigned to this group are administrated rehabilitative therapy targeting their affected arms in half four increments, occurring 3 days/week for 10 weeks. They also are administered an intervention in which they listen to a relaxation tape and/or tapes in which they receive instructions on exercises and information on stroke care.
1675981|NCT01651520|Drug|PET with 11C-Flumazenil|PET with 11C-Flumazenil.
1675982|NCT01651494|Drug|DAS181|DAS181-F04 is a recombinant neuraminidase that is delivered onto the cell surface of the upper and central airway topically and locally through an inhaler as an encapsulated dry powder. DAS181-F04; 20 mg single-dose each day via oral inhalation for 3 days; 6 subjects
1675983|NCT01651494|Other|Placebo|Placebo: White to off-white powder with Lactose Monohydrate and 5 % moisture; 20 mg single-dose each day via oral inhalation for 3 days; 3 subjects
1675984|NCT01651481|Drug|HCP1102|
1675985|NCT01651481|Drug|Singulair and Xyzal|
1675986|NCT01651468|Dietary Supplement|HEMOFIX|unique complex herbal mixture
1675987|NCT01651442|Behavioral|Behavioral Insomnia Therapy|Sleep hygiene, stimulus control, and sleep restriction presented in four sessions.
1675988|NCT01651442|Drug|Zolpidem|5mg or 10mg
1675989|NCT01651442|Drug|Trazodone|50mg to 150mg
1675990|NCT01651442|Behavioral|Cognitive Therapy|Cognitive restructuring, constructive worry, behavioral experiments presented in four sessions.
1675991|NCT01651429|Behavioral|Sleep deprivation|Participants will undergo 29 hours of sleep deprivation. They will wake up at 7:00 am on the day of the study and remain awake in the laboratory until 12:00 pm the next day.
1675992|NCT01651416|Drug|Artemether-lumefantrine combination|
1675993|NCT01651416|Drug|Dihydroartemisinin Piperaquine combination|
1675994|NCT01651416|Drug|Amodiaquine plus sulphadoxine-pyrimethamine combination|
1675995|NCT01651403|Drug|Tenofovir DF|"Participants weighing ≥ 17 kg will receive TDF one tablet administered orally once daily (150, 200, 250 or 300 mg tablets based on body weight).
Participants weighing < 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF oral powder in a dose of 8 mg/kg once daily up to a maximum dose of 300mg."
1675996|NCT01651403|Drug|TDF Placebo|"Participants weighing ≥ 17 kg will receive TDF placebo tablet administered orally once daily.
Participants weighing < 17 kg or ≥ 17 kg who are unable to swallow a tablet will receive TDF placebo oral powder once daily."
1675997|NCT01651390|Device|Percutaneous coronary intervention|Up to 140 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Pantera Lux drug coated balloon.
1675998|NCT01651390|Device|Percutaneous coronary intervention|Up to 70 patients meeting the inclusion criteria and none of the exclusion criteria are randomly selected and stratified according to diabetic status at screening are treated with the Orsiro drug eluting stent.
1675999|NCT01651377|Drug|Pramipexole|Participants will receive pramipexole ER 0.375, .075, 1.5, 2.25, and 3mg/d in an ascending-dose pattern.
1676000|NCT01651377|Drug|Placebo|Participants will receive matching placebo pills. The placebo group is included to maintain the blind, rather than as a comparison group.
1676001|NCT01651364|Drug|Placebo|Enrolled volunteers will be randomized on Day 8 to receive placebo (n=2) or study medication (n=8). Placebo serves only to maintain the blind and is not a comparator.
1676002|NCT01651364|Drug|Cabergoline|Enrolled volunteers that receive study medication (n=8) will receive cabergoline 0.25 mg twice weekly.
1676003|NCT01651351|Biological|Alpha1-proteinase inhibitor|GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
1676004|NCT01651351|Biological|Placebo: Human albumin 2.5%|Intravenous administration
1676005|NCT01651338|Procedure|acupuncture|The patients went through acupuncture for 8 -10 sessions and either once or two times a week. The number and the place of needles were 8 -12 for each patient which were located on the right place.
1676006|NCT01651325|Drug|Isavuconazole|oral
1676007|NCT01651325|Drug|dextromethorphan|oral
1676008|NCT01651312|Drug|14C-labeled YM178|oral solution (1.85 MBq)
1676009|NCT01651286|Procedure|nasal mask|Using the nasal mask instead of the full face mask during the induction of general anesthesia
1676010|NCT01651286|Procedure|full face mask|using a standard full face mask during the induction of general anesthesia.
1676011|NCT01651273|Drug|BMS-852927|Capsules, Oral, 0.25 mg, Once daily, 28 days
1676012|NCT01651273|Drug|BMS-852927|Capsules, Oral, 1.0 mg, Once daily, 28 days
1676013|NCT01651273|Drug|BMS-852927|Capsules, Oral, 2.5 mg, Once daily, 28 days
1676014|NCT01651273|Drug|Placebo|Capsules, Oral, 0 mg, Once daily, 28 days
1676015|NCT01651260|Other|Experimental ET Tube Securement Device|Experimental Hollister device with bite block was substituted for standard-of-care device during the study period.
1676016|NCT01651247|Procedure|Serum sample|Serum samples collected at pre-determined time points in previously completed studies (217744/085 and 213503/048) will be analysed to detect the presence of anti PCV-1 antibodies.
1676017|NCT01651234|Drug|GCC-4401|"Swedish Orange opaque hard gelatin capsules of size 1 with no markings for oral use
single dose
dosage
Cohort 1: 2.5-mg GCC-4401C
Cohort 2: 5.0-mg GCC-4401C
Cohort 3: 10-mg GCC-4401C
Cohort 4: 20-mg GCC-4401C
Cohort 5: 40-mg GCC-4401C
Cohort 6: 80-mg GCC-4401C"
1676018|NCT01651234|Drug|GCC-4401C|"Capsule, identical in appearance to GCC-4401C, for oral use
single dose
dosage
Cohort 1: 2.5-mg matching placebo
Cohort 2: 5.0-mg matching placebo
Cohort 3: 10-mg matching placebo
Cohort 4: 20-mg matching placebo
Cohort 5: 40-mg matching placebo
Cohort 6: 80-mg matching placebo"
1676019|NCT01651221|Other|Habituation|Habituation will be measured for each the conditions (olfactory, gustatory, olfactory and gustatory) of the study.
1676020|NCT01651208|Behavioral|Motivational Interviewing (MINT)|"We will hire a Latino and an AA nurse to deliver the interventions and will match their race/ethnicity with that of the subject. Past experience suggests that at 4-7 calls per subjects each lasting about 30-45 minutes, a nurse can carry a caseload of about 125-150 subject (we propose 125 per nurse) Each telephone encounter will have a patient centered approach having the following basic structure and goals:
a)Establishing a connection and reinforcing autonomy b)Empathizing with ambivalence and rolling with resistance.c)Coach the subject towards expressions of commitment."
1676021|NCT01651208|Behavioral|Mailed DVD|The DVD will have a documentary format that will engage subjects as the portrayed real patients relate their struggles and successes, that will entertain and ultimately motivate subjects to succeed in a similar way as the role models in the video. That personal connection will activate patients to address their own adherence issues and will show real life ways to deal with the health behaviors recommended post PCIS. Key concepts regarding adherence to medications and other behaviors will be imbedded in the story telling. The DVD will also feature a humanistic perspective of a cardiologist talking about his concerns for his patients that do not adhere to the antiplatelet therapy, the difficulties that his patients face, and the merit of the success stories he witnesses.
1676022|NCT01651195|Dietary Supplement|Probiotic|
1676023|NCT01651195|Other|Placebo|
1676024|NCT01651182|Drug|No tranexamic acid|Control
1676025|NCT01651182|Drug|Tranexamic Acid|
1676026|NCT01651169|Other|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.
Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity"
1676027|NCT01651169|Other|methylphenidate tablets and Inter-stimulus Intervals (ISI)|"We administer 2 single doses of methylphenidate tablets (10mg) separated by a week interval. A paired pulse protocols will be performed with ten single (unconditioned test pulse) and ten paired TMS pulses (conditioning and test pulse) in an intermixed randomized order.
Short interval cortical inhibition is measured with an Inter-stimulus Intervals (ISI) of 3 msec and a stimulator output of 80% RMT for the conditioning stimulus and 1mVT stimulation intensity for the test stimulus. ICF investigation is measured with an ISI of 13 msec), with the condition of an ISI of 50 msec (ISI 50) and both stimuli applied with 1mVT intensity). Long Interval Cortical Inhibition (LICI) is measured with ISIs of 100 msec (ISI 100), 200 msec (ISI 200), and 300 msec (ISI 300); both stimuli with 1mVT intensity."
1676028|NCT01651156|Drug|Tolvaptan|oral taken
1676029|NCT01651156|Drug|Placebo|
1676030|NCT01651143|Drug|SAR100842|"Pharmaceutical form: tablets
Route of administration: oral"
1676031|NCT01651143|Drug|Placebo (for SAR100842)|"Pharmaceutical form: tablets
Route of administration: oral"
1676032|NCT01651130|Drug|Carbetocin|Carbetocin IV, over 1 minute following delivery of the fetal head. Doses: 2, 5, 10, 15, 20 or 100mcg
1676034|NCT01651104|Biological|Adjuvanted Trivalent Influenza Virus Vaccine (aTIV)|A single 0.5 mL dose of study vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm.
1676035|NCT01651091|Other|Meditation Awareness Training|Psychotherapy Intervention
1676036|NCT01651091|Other|Treatment as usual|
1676037|NCT01651065|Behavioral|Microclinic Diabetes Education Program|"The microclinic intervention leverages different levels of social networks to positively influence behaviors relating to diabetes and other metabolic conditions through small treatment units called, 'microclinic groups (MC),' consisting of 2-6 friends and family members of the same social network, which lead to a larger network of 'classes' and cohorts.
The program provides MC subjects with shared access to health education and group support to promote glycemic and metabolic control through diet, exercise, and treatment adherence. MC members play a role in the collective effort to combat diabetes and solidifying self-management behavioral skills through peer-monitoring and encouragement of lifestyle behaviors."
1676038|NCT01651065|Behavioral|Control|
1676039|NCT01651052|Procedure|Heart Valve Surgery|Implant of an aortic valve, Model 11000
1676040|NCT01651039|Drug|Panobinostat, Lenalidomide and Dexamethasone|Each cycle is 28 days. Panobinostat will be given 20 mg: Days 1,3,5,15,17,19. Lenalidomide will be given 25 mg: Days 1-21. Dexamethasone will be given for patients 75 years old and younger a dose of 40 mg on Days 1, 8 and 15. Dexamethasone will be given for patients older than 75 years old, 20 mg on Days 1, 8 and 15.
1676041|NCT01651000|Drug|CTAP101 30 μg capsules|CTAP101 30 μg capsule taken daily at bedtime.
1676042|NCT01651000|Other|Sugar pill to CTAP101 30 μg capsules|Sugar pill capsule (placebo to CTAP101 30 μg capsule) taken daily at bedtime.
1676043|NCT01650974|Device|HFNOT|high flow nasal oxygen therapy
1676044|NCT01650961|Drug|Palonosetron|0.075 mg IV as bolus before induction of general anesthesia
1676045|NCT01650961|Drug|Normal saline|2 ml normal saline as bolus before induction of general anesthesia
1676046|NCT01650948|Device|RetnaGene AMD LDT|
1992250|NCT03322761|Combination Product|Systematic exercise training|Combination of standard medical treatment and systematic early exercise training in persons with MS.
1676048|NCT01650922|Procedure|phlebotomy|
1676049|NCT01650922|Procedure|biopsy|
1726836|NCT00006340|Drug|ganciclovir|
1992251|NCT03322761|Behavioral|Educational program|Informations regarding health benefits of physical activity and exercise.
1676050|NCT01650896|Other|Geriatric assessment review|Adjust medications, treat precipitants of delirium, one-on-one supervision of agitated violent patients
1676053|NCT01650870|Drug|Crystalline Lactulose|
1676054|NCT01650844|Other|School-Based Telemedicine Enhanced Asthma Management|
1676055|NCT01650844|Other|Enhanced Usual Care|
1676056|NCT01650831|Device|Modified BreathID|A new modified device, compared to the originally cleared BreathID measures breath from a subject via a nasal cannula
1676057|NCT01650818|Other|Aerobic exercise training|Intensity: heart rate corresponding to 40% peak VO2. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
1676058|NCT01650818|Other|Standard physical therapy (Stretching/Range-of-motion)|Intensity: N/A. Frequency: 5 sessions/week. Duration: 5 min warm-up + 20 min training + 5 min cool-down during the 1st month; 5 min warm-up + 30 min training + 5 min cool-down during the 2nd and 3rd month
1676059|NCT01650805|Drug|ponatinib|45 mg tablet, taken orally once daily
1676060|NCT01650805|Drug|imatinib (Gleevec/ Glivec)|400 mg tablet, taken orally once daily
1676061|NCT01650792|Drug|Aspirin|
1676062|NCT01650779|Biological|Agalsidase beta|Commercially available agalsidase beta 1.0 mg/kg administered as an intravenous infusion q2w up to Month 6.
1676063|NCT01650753|Dietary Supplement|Probiotic Powder|Bifidobacterium longum subsp longum AH1206 freeze dried and provided as a powder in a sachet (10^10 cells/sachet)
1676064|NCT01650753|Dietary Supplement|Placebo powder|powdered maltodextrin inthe same volume and the freeze dried probiotic in a similar size sachet
1676065|NCT01650740|Drug|Duloxetine|30 mg daily x 1 week followed by 60 mg daily
1676066|NCT01650740|Drug|placebo|small placebo capsule (30 mg duloxetine equivalent) x 1 week followed by 60 mg equivalent capsule daily
1676067|NCT01650740|Other|Study visits only|Weekly visits x 4 weeks followed by visits every 2 weeks
1676068|NCT01650727|Drug|Dinaciclib|Dinaciclib is given as a single intravenous (IV) dose on Days 1, 8, and 15 in Cycle 2 through Cycle 13 (28 day cycles) at a starting dose of 7 mg/m^2 up to a maximum dose of 14 mg/m^2.
1676069|NCT01650727|Biological|Rituximab|Rituximab 375 mg/m^2 will be administered IV on Day 1, 8, 15 and 22 in Cycle 1 (28 day cycle) and on Day 1 in Cycles 3-13 (28 day cycles).
1676070|NCT01650714|Other|Full thickness gastric biopsy|
1676071|NCT01650714|Procedure|Full thickness gastric biopsy|
1676072|NCT01650701|Drug|Rituximab|• Rituximab, 375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
1676073|NCT01650701|Drug|Lenalidomide|• Lenalidomide dose 20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
1676074|NCT01650701|Drug|Rituximab - CHOP|six cycles of R-CHOP in 21 day cycles followed by two 21 day cycles of 375 mg/m2 rituximab; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles
1676075|NCT01650701|Drug|Rituximab - CVP|eight cycles of R-CVP in 21 day cycles; and 7 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles,
1676076|NCT01650701|Drug|Rituximab - Bendamustine|six cycles of R-B in 28 day cycles and 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
1676077|NCT01650675|Behavioral|WIDUS computer-delivered, indirect brief intervention|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change drug use and risky sexual behavior, if any, without presuming those risks to be specifically present.
1676078|NCT01650675|Behavioral|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote RA blinding as to participant condition, focuses on proper infant nutrition using a computer-delivered, interactive format and videos.
1676079|NCT01650662|Drug|Cyclosporine A|In the CsA group, at least 5 min before balloon inflation and stenting, patients will receive an intravenous bolus injection of 2.5 mg/kg of CsA. In the control group, patients will receive only recommended treatments. CsA will be dissolved in normal NaCl 0.9% solution (final concentration 25 mg/ml) and injected slowly (over 20-30 seconds) via a catheter positioned in an antecubital vein at least 5 min before PCI, to allow for distribution of the drug.
1676082|NCT01650636|Behavioral|Patient-Partner Videotelephone-delivered Health Information (PP-T-HI)|Ten (10) 90-min sessions of Health Information delivered via videophones
1676083|NCT01650636|Behavioral|Patient-Partner Videotelephone-delivered Cognitive Behavioral Stress Management intervention (PP-T-CBSM)|Ten (10) 90-min sessions of T-PP-CBSM
1676084|NCT01650623|Behavioral|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
1676085|NCT01650623|Behavioral|Gait training alone|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training alone, without other tasks.
1676271|NCT01649297|Drug|empagliflozin (low dose bid)|Patients receive Empagliflozin low dose split twice daily
1727019|NCT00013377|Procedure|Low vision|
1992254|NCT03322735|Drug|Fludarabine|25-30mg/m2/day IV for 3 days
1992255|NCT03322735|Drug|Cyclophosphamide|cyclophosphamide 0.6-0.8g/m2/day IV for 2 days
1992256|NCT03322735|Biological|BCMA CAR-T|BCMA CAR-T cells will be administered after completion of the chemotherapy.
1992257|NCT03322722|Other|"VOIE LACTEE tool"|"VOIE LACTEE is a tool implemented in the neonatology service to evaluate the alimentary empowerment"
1676086|NCT01650610|Behavioral|Gait training executive functions tasks|The training will consist of 10 sessions, two times per week for five weeks, and consists of 30 minutes of global exercises that involves stretching, muscle strengthen and axial mobility exercises, and another 30 minutes of gait training in a dual-task condition associated with distracting tasks that require handling of the main executive functions: volition, self-awareness, planning, response inhibition, response monitoring and attention.
1676087|NCT01650597|Drug|JNJ-42165279 2.5 - 500 mg oral|Type=exact number, unit=mg, numbers=2.5, 10, 30, 100, 250 and 500, form=suspension, route=oral use. One single dose administered orally.
1676088|NCT01650597|Drug|Placebo|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
1676089|NCT01650597|Drug|JNJ-42165279 100 mg oral|Type=exact number, unit=mg, form=solution, route=oral use. One single dose administered orally.
1676090|NCT01650584|Drug|ISTA Tears|sterile ophthalmic solution
1676091|NCT01650584|Drug|Systane|Sterile ophthalmic solution
1676092|NCT01650558|Drug|Standard of Care prophylaxis|Daily trimethoprim sulfamethoxazole
1676093|NCT01650558|Drug|Chloroquine (CQ) prophylaxis|Discontinue standard of care and start weekly CQ.
1676096|NCT01650532|Behavioral|Yoga Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
1676097|NCT01650532|Behavioral|Stretching Condition|Classes lasting one hour, held 3 times per week for 8 weeks.
1676098|NCT01650519|Drug|IV ibuprofen|800 mg intravenous ibuprofen administered intravenously over 10 minutes.
1676099|NCT01650519|Drug|IV ketorolac|30 mg ketorolac for patients < 65 years of age (15 mg ketorolac for patients > 65 years of age) administered intravenously over no less than 15 seconds
1676100|NCT01650506|Drug|Metformin|Due to frequent GI upset in patients starting metformin the dose will be titrated up to the assigned dose level. The first metformin dose level will be 850 mg twice daily and be escalated to its maximum FDA approved dose of 850 mg three times daily. Dose escalation will follow the standard 3 + 3 design. Dose limiting toxicities will be determined during the first 5 weeks of therapy.
1676101|NCT01650506|Drug|Erlotinib|Erlotinib dosing will start and remain at 150 mg daily.
1676102|NCT01650493|Device|Clinpro 5000|Dentrifice containing 950ppm fluoride
1676103|NCT01650493|Device|MI Paste Plus|Dentrifice containing 950ppm fluoride
1676104|NCT01650493|Device|Tom's of Maine|Dentrifice that is fluoride free
1676105|NCT01650480|Other|HELP-COPD action plan|The trial specialist nurse trained in palliative aspects of respiratory care will arrange a meeting to suit the patients' clinical condition and convenience. During the meeting the HELP-COPD action plan will be worked through by the patient and study nurse, and any areas of concern will be identified. Based on the findings of the assessment, a range of actions points may be generated. All referrals will be made through the usual channels. Issues that have arisen from the assessment will be clearly recorded on the HELP-COPD action plan and by ensuring that all agencies and the patient have copies of the plan it is hoped that the planned action points will be reviewed and implementation facilitated. The action plan will be reviewed by the study nurse who will contact the patient at 1, 3 and 6 months to check progress with action points.
1676106|NCT01650454|Other|2 night polysomnography|Polysomnography
1676107|NCT01650454|Other|battery of neuropsychological tests|
1676108|NCT01650454|Other|virtual reality test|
1676109|NCT01650454|Other|subjective evaluation of sleep and somnolence|
1676110|NCT01650441|Drug|Beclomethasone dipropionate 100 µg + formoterol fumarate 6 µg|In this trial, patients will take two inhalations of the beclometasone dipropionate 100 µg and formoterol fumarate 6 µg combination therapy (Foster®) using a Dry Powder Inhaler (NEXThaler®) device in the morning and two inhalations in the evening, for a total of 4 inhalations a day (total daily dose: BDP 400 µg / FF 24 µg).
1676111|NCT01650441|Radiation|CT thorax|"CT scan of the thorax will be performed at 2 time points: baseline and after 6 months of treatment.
The CT scan will be performed with low dose radiation using the multi-slice CT scan. Scanning will be performed at Functional Residual Capacity and Total Lung Capacity (2 times 8 sec). The lung volumes will be controlled using adapted spirometry during the CT procedure. The radiation dose will be reduced by reduction of the tube current and voltage. These settings depend on the patients' weight (1mAs/kg). In addition to this there will be an increase in noise factor to further reduce the radiation dose."
1676112|NCT01650428|Biological|Bevacizumab|5 mg/kg, IV (in the vein) over 30-90 minutes, on day 1 of each 2 weekly cycles. Number of cycles: 1-5 (bevacizumab should not be administered during cycle 6).
1676113|NCT01650428|Drug|Irinotecan|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
1676114|NCT01650428|Drug|Oxaliplatin|165 mg/m2 IV (intravenous) over 1 hour on day 1 of two weekly cycle. Number of cycles: 1-6
1676115|NCT01650428|Drug|5-Fluorouracil|3200 mg/m2 IV (intravenous), continuous infusion over 48 hours starting on day 1 of two weekly cycle. Number of cycles: 1-6
1676118|NCT01650402|Drug|ACE inhibitor, calcium channel blocker|Daily, doses range depending on subject's response
1676119|NCT01650389|Biological|MVA85A|
1676120|NCT01650389|Biological|Candin|
1676121|NCT01650389|Biological|BCG Vaccine SSI|"All infants who test negative by HIV PCR will receive BCG vaccination at 8 weeks of age.
Infants who test positive by HIV PCR will not receive BCG vaccination."
1676122|NCT01650376|Drug|Olaparib|Olaparib will be administered orally on Days 1, 2, and 3 of each week until DLT or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of olaparib is 50, 100, 150 and 200 mg, taken twice a day will be used.
1676123|NCT01650376|Drug|Carboplatin|AUC 2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
1676174|NCT01649934|Behavioral|Implementation Intention|Implementation Intentions are a series of what/when/where statements that a participant will make to create automatic cues to complete a behaviorally advantageous action.
1676124|NCT01650376|Drug|Paclitaxel|60mg/m2 weekly for 3 weeks of a 4 week cycle. For patients who experience a complete response, the carboplatin and paclitaxel will be discontinued and olaparib monotherapy (400 mg, taken twice a day) will continue until disease progression and as long as the investigator feels they are benefiting from the treatment.
1676125|NCT01650363|Other|Acupuncture, homeopathy, osteopathy- and reflexology|a combination of the above mentioned treatments
1676126|NCT01650363|Drug|Homeopathic placebo medication|2-3 mm small spheric suger pils
1676127|NCT01650350|Drug|Naltrexone|
1676128|NCT01650337|Other|Smartphone Application|Smartphone application to help monitor caloric intake and expenditure
1676129|NCT01650324|Drug|DBPR108|DBPR108 capsules in four doses beginning at 25 mg and rising to 600 mg.
1676130|NCT01650324|Drug|matching placebo|Matching placebo capsules in four doses beginning at 25 mg and rising to 600 mg.
1676131|NCT01650298|Other|Drug (Direct thrombin or Factor Xa inhibitor)|Patient will stop or restart drug per cardiac device information (AT/AF diagnostics for prespecified AT/AF episode duration per day and total burden).
1676132|NCT01650285|Drug|Cabazitaxel|"Dose Level Day 1, 22, 43
5.0 mg/m2
10.0 mg/m2
15.0 mg/m2
20.0 mg/m2"
1676133|NCT01650272|Drug|5% MInoxidil milky lotion|Patient receive 5% MInoxidil milky lotion (Butylene glycol solvent)
1676134|NCT01650272|Drug|5% Minoxidil solution|Patient receive 5% Minoxidil solution (Propylene glycol solvent )
1676137|NCT01650246|Drug|lesinurad|Tablets, 400 mg QD
1676138|NCT01650233|Behavioral|Mindfulness-based stress reduction|
1676139|NCT01650207|Procedure|acupuncture|"All participants were received regular rehabilitation program, and received different interventions.
treatment frequency: 20 minutes per session, once daily, 5 times a week for 2 weeks"
1676140|NCT01650207|Procedure|TENS|
1676141|NCT01650207|Procedure|sham acupuncture|
1676142|NCT01650194|Drug|enzalutamide|oral
1676143|NCT01650194|Drug|abiraterone acetate|oral
1676144|NCT01650194|Drug|prednisone|oral
1676145|NCT01650181|Drug|Metformin|Patients with Steatohepatitis treated with diet, exercise and metformin
1676146|NCT01650181|Dietary Supplement|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with Steatohepatitis treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
1676147|NCT01650181|Dietary Supplement|Siliphos+ Selenium - Methionine + Alpha Lipoic Acid|Patients with fatty liver treated with diet, exercise, metformin and Siliphos (140mg) + Selenium (15 mcg) - Methionine (3mg) + Alpha Lipoic Acid (200mg), two tablets BID
1676148|NCT01650181|Drug|Metformin|Patients with fatty liver treated with diet, exercise and metformin
1676149|NCT01650155|Drug|BI 1005273 s.c.|injection
1676150|NCT01650155|Drug|BI 105273 i.v. Placebo|infusion
1676151|NCT01650155|Drug|BI 1005273 s.c. Placebo|injection
1676152|NCT01650155|Drug|BI 1005273 i.v.|infusion
1676153|NCT01650142|Other|No intervention|No intervention
1676154|NCT01650129|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected immediately before breakfast and dinner
1676155|NCT01650129|Drug|biphasic human insulin 50|Administered subcutaneously (s.c., under the skin) twice daily for 24 weeks. Injected 30 minutes before breakfast and dinner
1676156|NCT01650090|Drug|Inhaled Lipid Cisplatin (ILC)|ILC is provided as cisplatin in a lipid complex suspended in a saline solution. Every two weeks, the patient will receive 36 mg/m2 (measured as concentration of cisplatin) of ILC via nebulization. Treatment may continue for up to 1 year.
1676157|NCT01650051|Drug|Placebo of Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
1676158|NCT01650051|Drug|Phenazopyridine Hydrochloride Tables, USP 200 mg|"Deep brown maroon colored, film coated round biconvex tablet debossed 'AN obve '2' on one side and plain on the other side."
1676159|NCT01650038|Other|treatment with faecal transplantation (donor faeces)|faecal transplantation
1676160|NCT01650038|Other|treatment with faecal transplantation (own faeces)|faecal transplantation
1676161|NCT01650025|Dietary Supplement|VSL#3 active probiotic|
1676162|NCT01650025|Other|VSL#3 placebo|
1676163|NCT01650012|Drug|eplerenone|target 50 mg per day titrated down for hyperkalemia or hypotension
1676164|NCT01650012|Drug|Placebo|Placebo
1676165|NCT01649999|Drug|ASP015K|oral
1676166|NCT01649999|Drug|Placebo|oral
1676167|NCT01649986|Behavioral|Non-pharmacologic intervention|Diet and physical exercise
1676168|NCT01649986|Drug|Nutraceuticals (Armolipid Plus)|Patients assigned by their own general practitioner to receive nutraceuticals, along with non-pharmacologic intervention and prevention strategies, will have for 1 year also 1 capsule/day containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg,
1676169|NCT01649960|Drug|Rapamycin|Oral tablets were given in the dose of 0.5mg, 1mg, or 2mg once a day. This was a pilot study and the serum rapamycin levels were kept below 6ng/ml.
1676266|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
1727100|NCT00014261|Drug|temozolomide|
1676175|NCT01649934|Behavioral|Contact Clinic|Participants will be asked to sign a form indicating their need to contact the recommended clinics to make their appointments.
1676176|NCT01649921|Drug|Interferon-gamma, Recombinant|Interferon-gamma (Immukine, Boehringer-Ingelheim, Alkmaar, the Netherlands), 100mcg subcutaneously, on days 0-2-4-7-9-11. Interferon-gamma treatment will be initiated when the noradrenalin dose is reduced to 50% of maximum dose, ensuring that the sepsis-induced pro-inflammatory phase has passed
1676177|NCT01649921|Other|Saline 0.9%|subcutaneous administration on days 0, 2, 4, 7, 9, and 11.
1676178|NCT01649895|Drug|D-Cycloserine|Predicted to enhance the effects of exposure in internet-based cognitive-behaviour therapy
1676179|NCT01649895|Drug|Placebo|Placebo pills as adjunct to internet-based cognitive-behaviour therapy
1676180|NCT01649882|Procedure|US ETT (ultrasound endotracheal tube)|Subjects will have a brief (< 15 minutes) ultrasound exam of the neck after intubation. The cuff of the endotracheal tube as well as the aortic arch will be identified. The distance between the two structures will be measured and recorded.
1676181|NCT01649869|Drug|Valcyte (Valganciclovir hydrochloride) Powder for oral solution|Valganciclovir will be administered at 16mg/kg body weight twice daily
1676182|NCT01649869|Drug|Placebo|The placebo comparator will be commercially available Simple Syrup as 60-90% sucrose.
1676186|NCT01649843|Procedure|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia in some centers.
1676189|NCT01649804|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 104 weeks
1676190|NCT01649791|Drug|lenalidomide|Given orally
1676191|NCT01649791|Other|laboratory biomarker analysis|Correlative study
1676192|NCT01649791|Procedure|lymph node biopsy|Correlative study
1676193|NCT01649791|Procedure|bone marrow aspiration|Correlative study
1676194|NCT01649791|Other|pharmacological study|Correlative study
1676195|NCT01649791|Other|flow cytometry|Correlative study
1676196|NCT01649778|Drug|Pazopanib|Prospective Observational study collecting real world data on Pazopanib in patients with advanced or metastatic Renal Cell Carcinoma. Study is considered non-interventional, no drug will be provided. No study visits or procedures are mandated per protocol.
1676197|NCT01649765|Drug|belimumab 10mg/kg|belimumab 10mg/kg IV monthly
1676198|NCT01649765|Other|placebo|Normal Saline 250 ml
1676199|NCT01649752|Biological|Differentiated stem cells to endometrium is deposited in the uterine cavity through an IUI catheter|
1676200|NCT01649752|Biological|Undifferentiated MSC is deposited in the uterine cavity through an IUI catheter.|
1676201|NCT01649739|Drug|Levitra|There is 2 dosage:10mg Twice daily and 20mg Twice daily
1676202|NCT01649726|Procedure|Apnea test - control|
1676203|NCT01649726|Procedure|Apnea test - CPAP|
1676204|NCT01649713|Drug|Fluval AB vaccination|Vaccination with Fluval AB suspension for injection
1676205|NCT01649700|Biological|autologous adipose-derived mesenchymal stem cells|Patients will receive five infusions, one month apart, each comprising 5-7x10^7 cells of autologous adipose-derived mesenchymal stem cells.
1676206|NCT01649687|Biological|Allogeneic adult adipose-derived mesenchymal stem cells|Patients will receive intravenously one dose of 5-7x10^7 cells of allogeneic adipose-derived mesenchymal stem cells
1676207|NCT01649674|Drug|polyethylene glycole (PEG) solution|
1676208|NCT01649674|Drug|sodium picosulphate and magnesium citrate solution|
1676209|NCT01649661|Behavioral|questionnaire|
1676210|NCT01649648|Biological|Autologous cord blood|Baby's own umbilical cord blood
1676211|NCT01649635|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
1676212|NCT01649635|Drug|Prednisone|Pharmaceutical form: tablet Route of administration: oral
1676213|NCT01649635|Drug|Ciprofloxacin|Pharmaceutical form: tablet Route of administration: oral
1676214|NCT01649635|Drug|G-CSF (Granulocyte colony-stimulating factor)|Pharmaceutical form: solution Route of administration: subcutaneous
1676215|NCT01649622|Drug|Bendamustine|75 mg/m2 by vein twice daily for four days (Days 1-4). Cycles may be repeated every 3 to 10 weeks based on leukemia response for up to 12 courses.
1676216|NCT01649609|Drug|Reduction of standard immunosuppression|Low dose tacrolimus with low dose mycophenolic acid
1676217|NCT01649609|Drug|mTOR Substitution|Replacing tacrolimus (a calcineurin inhibitor) with sirolimus (an mTOR inhibitor) along with reduction of mycophenolic acid
1676220|NCT01649583|Device|Jaw Dynasplint System|Patients on the intervention arm will wear the Jaw Dynasplint® System for 30 minutes, 3 times per day each day during the cancer treatment period and for the first 3 months after primary or adjuvant based-radiation treatment (recovery period) is completed. Patients will maintain a daily patient log indicating the amount of time they used the Jaw Dynasplint® System.
1676221|NCT01649570|Drug|insulin aspart|Administrated subcutaneously (s.c., under the skin) three times a day before each meal for 24 weeks
1676222|NCT01649557|Drug|OPC-34712|oral administered once daily
1676267|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
1676268|NCT01649297|Drug|Empagliflozin (high dose qd)|Patients receive Empagliflozin high dose once daily
1676269|NCT01649297|Drug|empagliflozin (high dose bid)|Patients receive Empagliflozin high dose split twice daily
1676270|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
1727101|NCT00014274|Drug|carboplatin|
1676223|NCT01649544|Device|EPICOR|Intraoperatively, in addition to the usual gesture, it will be conducted a systematic exclusion-ligation of the left atrium and the establishment of electrodes atrial and ventricular pacing. The right pulmonary veins are isolated by dissection of the inter-atrial groove and application of the probe by biting on the atrial tissue, the procedure is identical on the left after dissection of the area between the left pulmonary artery and pulmonary veins. The use of ultrasound application will require 10 minutes to around the pulmonary veins using a multi-electrode probe set to deliver an output pulse from 15 to 100 Watts at a frequency from 3.5 to 4.6 MHz. Using EPICOR extends the operating time of 15 minutes.
1676224|NCT01649544|Drug|Amiodarone|
1676225|NCT01649531|Procedure|1 Implant|
1676226|NCT01649531|Procedure|2 Implants|
1676227|NCT01649505|Drug|fibrin sealant (Beriplast P, TISSEEL VH)|Applied topically
1676228|NCT01649505|Procedure|breast reconstruction|Undergo sharp dissection technique
1676229|NCT01649505|Procedure|breast reconstruction|Undergo electrocoagulation dissection technique
1676230|NCT01649492|Dietary Supplement|pineapple juice (Carrefour n°1) 500 ml/day 5 days|
1676231|NCT01649479|Biological|Antiphospholipid antibody tests|Each patient will be tested for antiphospholipid antibodies.
1676232|NCT01649479|Biological|Thrombophilia bloodwork|"Bloodwork will be drawn up for:
antithrombin, protein C, protein S
Factor V Leiden polymorphisms (F5 1691A)
prothrombin 20210A gene polymorphism (F2 20210A)
JAK2 617F Mutation
Homocysteine
Factor VIII"
1676233|NCT01649479|Other|Psychiatric evaluation|During this consultation, the Mini International Neuropsychiatric Interview will be used to screen for psychiatric symptoms. Should the latter be detected, a further consult with a psychiatrist or a psychologist will be organized; this second consult will include the Mood Disorder Questionnaire (MDQ), the Beck Depression Inventory (BDI), the Inventory for Depressive Symptomatology - Clinician (IDS-C) and the Structured Clinical Interview for Disorders (SCID, DSM-IV).
1676234|NCT01649466|Drug|LAF237|Vildagliptin will be used as commercially available tablets of 50mg.
1676235|NCT01649466|Drug|Protaphane|Protaphane will be used as commercially available injection pens
1676236|NCT01649453|Device|Pathwork® Tissue of Origin Test|
1955195|NCT03270202|Behavioral|PAI group|"physical activity defined as 100 weekly PAI during 1 year
smartphone application and a user-friendly activity wristband (Mio PAI Slice)"
1955196|NCT03270202|Behavioral|Usual care|Participants will be informed about, and encouraged to be active according to current recommendations for physical activity from the health authorities.
1676241|NCT01649401|Device|Standard nebulizer|"Nebulizer sessions for the patients will be administerd using our standard nebulizer: Micro Mist, ref 41894, Hudson RCI, distributed by Téléflex Médical."
1676242|NCT01649401|Device|PARI LC Sprint Sp nebulizer|"Nebulizer sessions for the patients will be administerd using the PARI LC Sprint Sp nebulizer.
Manufacturer: PARI GmbH Germany"
1676243|NCT01649388|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
1676244|NCT01649375|Drug|Secukinumab (75 mg)|Secukinumab 75 mg s.c.
1676245|NCT01649375|Drug|Placebo|Placebo
1676246|NCT01649375|Drug|Secukinumab (150 mg)|Secukinumab 150 mg s.c.
1676247|NCT01649362|Other|prefeeding oral stimulation program|"The intervention will start at 32 weeks PMA in a medically stable infant feed by gavage feeding for the infants born before 32 weeks' gestational age, and, as soon as clinical stability is acquired, for the infants born after 32 weeks.
The prefeeding oral stimulation program consists of a 15-minute stimulation program, delivered by the nurse or the medical staff, according to the stimulation program proposed by Fucile, Gisel and Lau. The program is going to be administered once a day for 14 consecutive days (for infants born before 32 weeks' gestational age), 15 to 30 minutes before a tube feeding. In infants born after 32 weeks' gestational age, stimulation program is going to be stopped when the infant attains 3 complete oral feedings by day."
1676248|NCT01649349|Device|two-piece nasogastric tube|one week period
1676249|NCT01649336|Drug|MEK162, MEK inhibitor; oral|multiple dose, escalating
1676250|NCT01649336|Drug|Paclitaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
1676251|NCT01649310|Other|whole body vibration|Exercises on the platform will be made in semi-squat position, static. In the first month training will be held for 10 minutes for the exercises on the platform, 30 seconds of vibration of low intensity, interspersed with rest 60 seconds while standing beside the platform. In the second month training will be held for 15 minutes, lasting 60 seconds of vibration and 30 seconds of rest in standing beside the platform. For the first two weeks training will have low intensity and the last two weeks training will have higher vibration. In the third month, training will be held for 20 minutes, 60 seconds of vibration and 30 seconds of rest while standing beside the platform. The intensity of the vibration will be high.
1676252|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
1676253|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
1676254|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
1676255|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
1676256|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose qd)
1676257|NCT01649297|Drug|empagliflozin (low dose qd)|Patients receive Empagliflozin low dose once daily
1676258|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
1676259|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
1676260|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
1676261|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
1676262|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
1676263|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose bid)
1676264|NCT01649297|Drug|Placebo|Patients receive placebo matching Empagliflozin (high dose bid)
1676265|NCT01649297|Drug|Placebo|Patients receive placebo matching empagliflozin (low dose qd)
1727386|NCT00016380|Drug|dexamethasone|
1676279|NCT01649258|Drug|granisetron transdermal system|Given granisetron transdermal system patch
1676280|NCT01649258|Drug|fosaprepitant dimeglumine|Given IV
1676281|NCT01649258|Other|laboratory biomarker analysis|Correlative studies
1676282|NCT01649245|Drug|Reiferon retard|Eligible subjects will be treated with Reiferon Retard® 160 µg weekly by subcutaneous injection for 48 weeks, together with weight-based oral ribavirin (1200 mg/day if body weight is >75 kg and 1000 mg/day if body weight is ≤ 75 kg) in divided doses.
1676283|NCT01649232|Device|Active tDCS|tDCS applied to left dorsolateral prefrontal scalp area through a saline-soaked pair of surface sponge electrodes (35 cm2). The anode electrode was placed over F3 (based on the 10-20 International EEG System) of each subject. The cathode was placed over the contralateral mastoid area. A constant current of 1.1 mA was applied for 25 min/day (administered for 12 alternated days).
1676284|NCT01649219|Behavioral|Exercise|
1676285|NCT01649206|Procedure|Percutaneous Radiofrequency Thermal Ablation|Percutaneous Radiofrequency Thermal Ablation (RTA) by using a RITA© StarBurst Talon needle (RITA Medical Systems, Fremont, CA). RTA is performed in each patient at Time 0.
1676286|NCT01649193|Other|Pulmonary rehabilitation|An eight week out-patient based programme consisting of twice weekly supervised exercise and educational sessions
1676287|NCT01649180|Drug|Axitinib|Axitinib 5 mg orally with food every 12 hours. One cycle=28 days.
1676288|NCT01649154|Procedure|Total Thyroidectomy with cut and tie technique vs Total Thyroidectomy with Ligasure Small-JAW vs Total Thyroidectomy with Harmonic Focus|
1676289|NCT01649141|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Trauma-Focused Cognitive Behavioral Therapy (TF-CBT) is a structured, 12-16 session outpatient intervention originally developed to treat Posttraumatic Stress Disorder (PTSD) and related emotional and behavioral difficulties in youth with a history of child sexual abuse. TF-CBT's eight components are delivered in 90-minute weekly sessions split evenly between children and their parents. These components are summarized by the acronym PRACTICE including: psychoeducation and parenting skills (P), relaxation (R), affective expression and regulation (A), cognitive coping (C), trauma narrative development and processing (T), in vivo gradual exposure (I), conjoint parent/child sessions (C) and enhancing safety and future development (E).
1676290|NCT01649115|Other|Healthy Lifestyles Passport|The participants will be provided with the Healthy Lifestyles Passport, and with each corresponding page, there will be an activity. Each participant in the Healthy Lifestyles Passport arm will receive the same education.
1676291|NCT01649102|Device|Tunneled Cuffed Catheter (Palindroom, Hemoglide Bard)|"A tunneled cuffed catheter is inserted, randomization between:
Palindroom
Hemoglide Bard"
1676292|NCT01649089|Procedure|Conization|Undergo cone biopsy
1676293|NCT01649089|Other|Quality-of-Life Assessment|Ancillary studies
1676294|NCT01649089|Other|Questionnaire Administration|Ancillary studies
1676295|NCT01649089|Procedure|Therapeutic Conventional Surgery|Undergo hysterectomy
1676296|NCT01649089|Procedure|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
1676297|NCT01649050|Drug|BGG492|
1676298|NCT01649050|Drug|Placebo|
1676299|NCT01649037|Drug|nor adrenaline and terlipressin|"IV bolus terlipressin at the dose of 0.5 to 1 mg every 6 hours with the maximum daily cumulative dose of 4 mg/day.
Continuous IV infusion of NA starting at 0.5 mg/h with doubling of dose after every 4 hours in case of no response.[ No response defined as MAP < 10, or 4 hr Urine output < 200 ml] with maximum dose upto 3 mg/h."
1676300|NCT01649037|Drug|step up terlipressin therapy|IV bolus terlipressin starting at 1.5 mg every 6 hours with increase in dose by 0.5 mg/6 hours in case of no response [< 25% decrease in s.creatinine] after every 48 hours. Maximum daily cumulative dose of 12 mg/day.
1676301|NCT01649024|Drug|Tremelimumab|Given IV
1676302|NCT01649011|Behavioral|Application of the initial evaluation|Initial evaluation involves the application of the previously spanish validated Rolland Morris Questionnaire and the new spanish Oswestry Disability Index
1676303|NCT01649011|Behavioral|Final application of scales|Application of the previously spanish validated version of the RMQ and the new spanish translation of the ODI 2 weeks after initial evaluation
1676304|NCT01648998|Drug|Fludrocortisone|single dose 500 mg, capsule
1676305|NCT01648998|Drug|Placebo|
1676306|NCT01648985|Other|diabetes in stroke and TIA|
1676307|NCT01648972|Drug|Gastrografin|
1676308|NCT01648972|Drug|Placebo|
1676309|NCT01648959|Other|EEG Recording|
1676310|NCT01648946|Biological|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin falls below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of hemoglobin levels is performed; if a patient's hemoglobin level is 9 g/dL or higher, no additional transfusion is necessary.
1676311|NCT01648946|Biological|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin falls below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of 1 RBC unit, a repetition of the hematocrit is performed; if a patient's hemoglobin is 7 g/dL or higher, no additional transfusion is necessary.
1676312|NCT01648933|Radiation|Rubidium PET|Myocardial Perfusion Imaging
1676313|NCT01648920|Device|NIOX MINO® Instrument (09-1100)|The NIOX MINO® Instrument (09-1100) is a 10 second test based on exhaled breath measured at a 50 ml/second flow rate.
1676314|NCT01648907|Other|Imaging exams|"Radiological examinations:
Standard x-ray: they include an x-ray of the cervical, thoracic, and lumbar spine (side-on), of the lumbar spine from the front and an x-ray of the pelvis from the front
MRI scan: are taken of the cervical, thoracic and lumbar spine and sacroiliac joints.
Bone densitometry: evaluation of bone densitometry of the lumbar spine and femoral neck.
Enthesis ultrasound: bilateral evaluation of entheseal insertions for the Achilles tendon, patella tendons and epicondyle tendons.
Biological tests :
Genetic test : DNA will be collected at the first visit from all centers. RNA will be collected at the inclusion visit in AP-HP centres only.
Serum will be collected by all centres at the initial visit, then in M6, M12 and M24 for the first two years of the study, then in M60.
Urine will be collected by all centres at the initial visit, then in M24 for the first two years of the study, then in M60."
1676315|NCT01648894|Procedure|Surgery after 11 weeks of delay after chemoradiotherapy.|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 11 weeks of delay after the end of chemoradiotherapy.
1676316|NCT01648894|Procedure|Surgery after 7 weeks of delay after chemoradiotherapy|Surgery consists carcinological resection of the rectal cancer with total excision of the mesorectum after 7 weeks of delay after the end of chemoradiotherapy
1676317|NCT01648881|Radiation|TEP-18FDG for every patient after aortic dissection|"Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
Example: 50 mg/m2, IV (in the vein) on day 5 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops."
1676318|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Excitatory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in patients with autism.
1676319|NCT01648868|Device|Transcranial Magnetic Stimulation (rTMS)|Inhibitory effects of Transcranial Magnetic Stimulation (rTMS) applied to the STS in healthy controls
1676320|NCT01648855|Other|Biological samples|To measure the levels of sFlt1, angiogenic and antiangiogenic factors at birth in maternal blood, umbilical cord blood and in the amniotic fluid
1676321|NCT01648829|Drug|Atorvastatin|Patients will receive randomly atorvastatin (20 mg day) for 30 days
1676322|NCT01648829|Drug|Pitavastatin|Patients will receive randomly pitavastatin (4 mg day) for 30 days
1676323|NCT01648790|Drug|Prasugrel ODT1 - Tablet|Administered orally as tablet.
1676324|NCT01648790|Drug|Prasugrel ODT2 - Tablet|Administered orally as tablet.
1676325|NCT01648790|Drug|Prasugrel ODT2 - Suspension|Administered orally as suspension.
1676326|NCT01648777|Device|L bupivacaine|"L-bupivacain solution CHIROCAINE® 5mg/ml, flakon de 20 ml): for the intravenous bolus of 10 ml
o (CHIROCAINE®1.25mg/ml, 200 mL/unit, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
1676327|NCT01648777|Drug|placebo|"Isotonic NaCl solution (9°/00) solution: for the intravenous bolus of 10 ml
Isotonic NaCl solution (9°/00) solution, 400 ml in the accufusor infused at 8ml/h during 48h00: for infusion during 48h00"
1676328|NCT01648764|Drug|LY2334737|Administered orally
1676329|NCT01648751|Drug|Vaginal estrogen|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
1676330|NCT01648751|Drug|Placebo|1 gram vaginally for 7 days, followed by 1 gram vaginally twice weekly thereafter
1676331|NCT01648738|Other|Spa therapy, exercise and educational therapy|During 5 days: Spa therapy (2 hours/day), exercises (30 min/day), educational therapy (45 min/day) including education on physical activities, work, and pain management
1676332|NCT01648738|Other|Usual care|Information, counseling, treatment usually provided for sub-acute and chronic low back pain and the back book
1676333|NCT01648725|Procedure|Hypnosis|A short preanesthetic hypnosis before induction of anesthesia
1676334|NCT01648725|Procedure|usual care|Standard care before induction of anesthesia
1676335|NCT01648712|Device|Balance surface, Carmeda heparin-coated surface|This study compares the influence of a Balance - coated CPB system in pediatric use versus the Carmeda TM heparin-coated system in platelet function preservation and hemostatic activation.
1676336|NCT01648699|Drug|Osmotic Release Oral System (OROS) hydromorphone|OROS Hydromorphone will be administered as either 8, 12, 16, 20, 24, 32, 36 or 40 mg oral tablet once daily in the morning. For all participants, 24-hour stable opioid dose (of either morphine or oxycodone) will be converted to a single daily dose of OROS hydromorphone using standard equi-analgesic ratios and dose will be increased if needed, but not more than 40 mg and not more frequently than every two days. The study drug will be administered up to 28 days.
1676337|NCT01648686|Procedure|Dental extraction|3 dental radiographies realised immediately, then 30 days, then 90 days after dental extraction
1676338|NCT01648660|Dietary Supplement|Lutein/ Zeaxanthin + Omega- 3- Fatty Acids|capsule with Lutein, Zeaxanthin, Omega-3-FA for two years
1676339|NCT01648634|Drug|Nebivolol|A 1.25mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol will be performed with 2 weeks periods. Full dose of nebivolol is 5mg/day (7.5mg/day for patients whose weight is>60kg)
1676340|NCT01648634|Drug|Placebo|A 1.25mg-test dose of nebivolol will be administrated to assess the treatment tolerance before randomization. A forced titration of placebo will be performed with 2 weeks periods. Full dose of placebo is 5mg/day (7.5mg/day for patients whose weight is>60kg)
1676341|NCT01648621|Behavioral|40 minute standardized education session|40 minute standardized education session based on the Living Well with COPD Patient's Education Tool on study enrolment to assess and improve understanding of disease and ability to monitor symptoms and recognize exacerbation
1676342|NCT01648621|Behavioral|Individualized action plan|Individualized action plan using the Living Well with COPD template with patient individualized modification to address management strategies for exacerbation of comorbidity developed during the initial 40 minute session with case manager.
1676343|NCT01648621|Behavioral|Individualized care plan|Individualized care plan for management of COPD and comorbidities developed by the case manager in consultation with family physician and specialists.
1676344|NCT01648621|Behavioral|Standardized reinforcement/motivational interviewing and action plan teach-back sessions|Standardized reinforcement/motivational interviewing and action plan teach-back sessions based on Living Well with COPD modules as well as assessment of symptoms, progress and problems, and problem solving by phone weekly for 12 weeks, then monthly for 9 months (21 sessions) (telephone script; NOTE: case managers will make up to 3 attempts to contact participants during each week of the 12 weeks of weekly phone calls before determining inability to contact the participant for that week.
1676384|NCT01648270|Drug|Cyclosporine|Session 3 Cyclosporine (2.5mg/kg/hr infused over 2 hr) Subjects then take oral cyclosporine 4.5 mg/kg twice daily, until session 4, continue oral cyclosporine 4.5 mg/kg twice daily for 5 days
1676385|NCT01648257|Drug|GSK1265744 Na Salt Tablets|Each tablet contains 30 mg of GSK1265744 sodium salt and excipients.
1676386|NCT01648257|Drug|GSK1265744 Free Acid Nanomilled Capsules|Each capsule contains 30 mg of nanomilled and spray dried GSK1265744 free acid, blended with excipients.
1676387|NCT01648257|Drug|GSK1265744 Free Acid Micronized Capsules|Each capsule contains 30 mg of micronized GSK1265744 free acid, blended with excipients.
1676345|NCT01648621|Behavioral|Tele-home monitoring|"Tele-home monitoring of SpO2, weight, dyspnea, sputum quantity and characteristics, and general well-being for maximum of 6 months.
Inclusion criteria for tele-home monitoring:
a. compatible phone line b. patient consent c. patient or caregiver demonstrated ability to use monitoring equipment d. patient unable to attend outpatient/community appointments for assessment and monitoring because of environmental barriers to access (e.g. physician's office only accessible by stairs) e. severe dyspnea on activities of daily living (Medical Research Council Questionnaire for Assessing Severity of Breathlessness [MRC] Class 4 & 5 or modified MRC [mMRC] 3 & 4) f. frequent ED visits (> 2) in last 12 months
5. 12 weeks of clinical stability with no ED visits."
1676346|NCT01648621|Behavioral|Coordinated and improved communication|Coordinated and improved communication between the patient, family caregivers, family physicians, specialists, and Community Care Access Centres (CCACs) facilitated by the case manager. This will include phone contact by case manager to family physicians and CCAC case manager if applicable after initial enrollment, education session and development of action plan, then monthly to report general status as well as after subsequent ED presentations/hospital admissions
1676347|NCT01648621|Behavioral|Priority access|Priority access to ambulatory clinics (Respirology and other specialties as required including Psychiatry) facilitated through the case manager.
1676348|NCT01648621|Behavioral|Dictated patient summary|Dictated patient summary sent by specialists (e.g. respirologists) to family physicians following each respiratory centre visit (every 12 weeks)
1676349|NCT01648621|Behavioral|in-hospital rehabilitation/self-management program|"Referral to an 8 week in-hospital rehabilitation and self-management education program for patients that are:
have had a recent exacerbation, but are now clinically stable;
symptomatic COPD including reduced activity levels and increased dyspnea despite pharmacological treatment;
have stabilized comorbidity (no evidence of active ischemic, musculoskeletal, psychiatric or other systemic disease); and
have sufficient motivation to participate."
1676350|NCT01648621|Behavioral|Smoking cessation|Referral to a smoking cessation program (as applicable)
1676351|NCT01648621|Behavioral|Action plan Respirologist|Individualized action plan developed with treating respirologist at the discretion of the attending respirologist.
1676352|NCT01648621|Behavioral|Web based self management materials|Referral to educational materials and resources (Living Well with COPD module printouts provided during COPD rehabilitation classes at a cost to the individual)
1676353|NCT01648608|Drug|Exemestane|Exemestane for neoadjuvant chemotherapy
1676354|NCT01648595|Drug|Fentanyl|In case group, 50 micrograms fentanyl was prescribed in two doses with an interval of 1 hour after being diluted in 4 cc normal saline
1676355|NCT01648582|Drug|Dulaglutide|Administered SC
1676356|NCT01648582|Drug|Insulin glargine|Administered SC per dosing titration schedule
1676357|NCT01648582|Drug|Metformin|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
1676358|NCT01648582|Drug|Sulfonylureas|Administered orally at pre-study prescribed dose, and is not being provided as part of the trial.
1676359|NCT01648556|Other|Blood tests and bone marrow biopsy repeated|"Blood tests are realized for the dosage of the TPO, the dosage of the antiplatelet antibodies, to measure isotopic lifetime of platelet.
The test in corticoids by the prednisone per os is realized too. The bone marrow biopsy is realized at the inclusion and during follow-ups if the haemogram is abnormal."
1676360|NCT01648543|Procedure|lumbar sympathetic ganglion block|
1676361|NCT01648530|Other|No Treatment|No Treatment
1676362|NCT01648517|Drug|chemotherapy|A1: docetaxel 60mg/m2 on Day 1 vinorelbine 20mg/m2 on Day 1 and Day 8 (DV) A2: gemcitabine 1000mg/m2 on Day 1 vinorelbine 25mg/m2 on Day 1 and Day 8 (GV) A3: docetaxel 75mg/m2 on Day 1 carboplatin AUC5 on Day 1 (DC) A4: gemcitabine 1000mg/m2 on Day 1 and 8 carboplatin AUC5 on Day 1 (GC)
1676363|NCT01648517|Drug|chemotherapy|Drug: Docetaxel 75mg/m2 IV on Day 1 Drug: Carboplatin AUC5 IV on Day 1
1676364|NCT01648504|Other|eGuide to Colonoscopy and in office ipad education|The investigators will follow patients who receive in office Ipad video education and at home web portal access to the Johns Hopkins eGuide to Colonoscopy.
1676365|NCT01648491|Procedure|Muscle Biopsy|Biopsy of thigh muscle to obtain stem cell core.
1676366|NCT01648491|Biological|Injection of autologous stem cells|After autologous stem cells have multiplied over 6 weeks time they are injected into the subjects urethra.
1676367|NCT01648478|Other|It is a hyperinsulinemic-euglycemic clamp.|"The hyperinsulinemic-euglycemic clamp includes three periods:
A basal period (from T-30 to T0)
The infusion of insulin at a constant rate (first level at 1 mUI.kg-1.min-1 and a second level at 2 mUI.kg-1.min-1) during 4 hours ( to obtain stable hyperinsulinemia)
The infusion of glucose at variable rate (so as to maintain euglycemia)"
1676368|NCT01648465|Drug|Everolimus|Everolimus 10mg(2x5mg)orally once daily until disease progression, unacceptable toxicity or consent withdrawal
1676369|NCT01648452|Biological|NT-501 CNTF-releasing implant|20 ng/day released into the eye
1955200|NCT03267316|Biological|CAN04|A fully humanized monoclonal immunoglobulin G1 (IgG1) antibody (hmAb) in aqueous solution administered by i.v. infusion.
1955201|NCT03266705|Drug|tafamidis|bioequivalence study
1676375|NCT01648335|Device|Immobilization of the shoulder in external rotation in a soft dressing called universal shoulder immobilizer (USI)|
1676376|NCT01648335|Device|Immobilization of the shoulder in internal rotation in a soft dressing called universal shoulder immobilizer (USI)|
1676379|NCT01648309|Other|Neuropsychological testing|This is an observational study
1676380|NCT01648296|Drug|[18F]FluorbetaOx|Fluorine 18-labeled FluorbetaOx
1676381|NCT01648283|Drug|racemic methadone HC1|IV racemic Methadone HC1 6 mg oral d5-methadon HC1 11 mg
1676382|NCT01648283|Drug|Oral deuterated racemic methadone HCl,|11 mg capsule once
1676383|NCT01648270|Drug|buprenorphine|"Session 1 Intravenous buprenorphine: 0.2 mg infused over 1 hr Session 2 Sublingual buprenorphine: 2 mg Session 3intravenous buprenorphine 0.2 mg infused over 1 hr beginning 1 hr after starting cyclosporine.
Session 4 Sublingual buprenorphine: 2 mg"
1727387|NCT00016380|Drug|ondansetron|
1676388|NCT01648244|Other|Computer-Assisted Decision Support|"The CADS software makes a recommendation about what medication changes are appropriate with potential alternates. CADS providers will either accept or reject the recommendation by the software.Providers with their patients are block randomized into CADS or Usual Care for 1 year. Patients associated with a CADS provider will upload their blood glucose data weekly and perform a 7-point glucose profile once per month. They will report major hypoglycemic events and hospitalizations at the time of their quarterly visit. Those getting usual care will be seen quarterly and will do self-monitoring of blood glucose and have A1c tests as determined by the provider but no less than twice a year."
1676389|NCT01648231|Drug|Reference Treatment: 1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine tablet and 1 x 100mg losartan tablet administered in fasted state
1676390|NCT01648231|Drug|Fixed Dose Combination 1: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
1676391|NCT01648231|Drug|Fixed Dose Combination 2: 1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state|1 x 5mg amlodipine / 100mg losartan tablet administered in fasted state
1676392|NCT01648218|Drug|Neutral protamine hagedorn (NPH) insulin|
1676393|NCT01648218|Drug|Regular human insulin or Insulin Aspart|
1676394|NCT01648218|Drug|Insulin glargine|
1676395|NCT01648205|Drug|Placebo|Matching Placebo will be given
1676396|NCT01648205|Drug|Ranolazine|Patients will receive ranolazine 1000mg bid or matching placebo
1676397|NCT01648192|Drug|Losmapimod for single dose|Film coated white tablet
1676398|NCT01648192|Drug|Losmapimod for repeat dose|Film coated white tablet
1676399|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Injection|1500 mg (mesylate salt) as free base, dissolved in sterile water for injection to a concentration of 100 mg/mL free base equivalent and sterilized via filtration. 15 mL of solution, equivalent to 1500 mg GSK 1322322, is the diluted into 0.9% Sodium Chloride Injection prior to infusion
1676400|NCT01648179|Drug|GSK1322322 (freebase) tablets|500 mg tablets for a 1500 mg total single dose (3 tablets). Taken with 240 mL of water
1676401|NCT01648179|Drug|GSK1322322 (mesylate salt) Powder for Oral Solution|1500 mg as a free base, dissolved in purified water to a concentration of 100 mg/mL free base equivalent. 15 mL of solution, equivalent to1500 mg GSK1322322 is administered orally with 225 mL of water
1676402|NCT01648179|Drug|GSK1322322 (freebase) tablets FED|Drug 500 mg tablets for a 1500 mg total single dose (3 tablets) (FED moderate fat meal) Taken with 240 mL of water
1676406|NCT01648140|Drug|GSK2336805 40 mg|20 mg tablet, round, 10-mm diameter, white to off-white, no markings
1676407|NCT01648140|Drug|GSK2336805 60 mg|30 mg tablet, round, 10-mm diameter, white to off-white, no markings
1676408|NCT01648140|Drug|Pegylated interferon alpha-2a|180 microgram per 0.5 mL prefilled syringe for single use
1676409|NCT01648140|Drug|Ribavirin|"200-mg tablet, capsule-shaped, light blue, film-coated, and debossed with 200 on 1 side and the logo 3RP on the other side"
1676410|NCT01648140|Drug|Telaprevir|375 mg film-coated tablet
1676411|NCT01648127|Drug|Ceftaroline|A single dose of ceftaroline fosamil 600 mg as a 1-hour continuous intravenous infusion
1676412|NCT01648114|Other|Antenatal Breastfeeding Intervention|The intervention will include a 20 to 30-minute one-to-one educational talk by a lactation expert explaining the facts of breastfeeding and answering participant questions. The educational intervention will focus on: (1) the importance of exclusive breastfeeding, (2) milk supply/demand and feeding on demand, (3) frequency of feedings, feeding cues, how to know an infant is getting enough milk, (4) avoiding artificial nipples until the infant is nursing well, (5) the importance of a good latch, (5) where to seek breastfeeding help and support, and (7) returning to work and continuing breastfeeding
1676413|NCT01648101|Drug|Retigabine 900mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 900mg/day over a 4 week Titration Phase). The subject will then continue to receive 900mg/day for the next 12 weeks (Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week transition phase, eligible subjects will start the OLE on retigabine 900mg/day.
1676414|NCT01648101|Drug|Retigabine 600mg/day|Study drug will be administered three times a day in a double blind manner. The starting dose of retigabine will be 300mg/day. This dose will be increased by 150 mg/day per week to reach the target dose of 600mg/day over 2 weeks. The subject will then continue to receive 600mg/day for the next 14 weeks (2 weeks of the Titration Phase and 12 weeks of the Maintenance Phase). Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. After a 4 week Transition Phase (3 weeks on retigabine 600mg/day, 1 week on retigabine 750mg/day) eligible subjects will start the OLE on retigabine 900mg/day.
1676415|NCT01648101|Other|Placebo|Study drug will be administered three times a day in a double blind manner. Subjects randomised to placebo will receive the same number, size and colour of tablets as the 600mg/day and 900mg/day treatment arms for the duration of the 4 week Titration Phase and the 12 week Maintenance Phase. Eligible subjects will then be offered an opportunity to enter an open label extension (OLE) study. The starting dose of retigabine will be 300 mg/day. This dose will be increased by 150 mg/day per week to reach dose of 750mg/day over the 4 weeks of the Transition Phase. On completion of the Transition Phase eligible subjects will start the OLE on retigabine 900mg/day.
1676416|NCT01648075|Dietary Supplement|Experimental: Probiotic enriched milk|Milk will be enriched with lactobacillus rhamnosus for the experimental group.
1676417|NCT01648062|Behavioral|Sleep Self-Regulation Using Mental Imagery|Comparison of two forms of mental imagery to instigate behaviors that assist in the sleeping process
1676418|NCT01648049|Behavioral|Integrated Cognitive Behavioral Therapy (CBT)|CBT treatment is an abbreviated protocol based on manualized, evidence-based treatments for geriatric insomnia (Lichstein & Morin, 2000) and geriatric depression (Thompson, Gallagher-Thompson, & Dick, 1995).
1676419|NCT01648049|Behavioral|Treatment as usual|Standard Care - Treatment as usual
1676420|NCT01648036|Drug|Unfractionated heparin|Dose: 18 IU/kg/hr, continuous intravenous infusion. Duration: up to 7 days or until ICU discharge or death
1676421|NCT01648036|Drug|Dalteparin|Dose 5000 IU, subcutaneous, daily
1676422|NCT01648023|Device|LC or ONCOZENE Bead with Gem-Cis or Gem-Carbo|
1676423|NCT01648023|Drug|Gem-Cis or Gem-Carbo|
1676424|NCT01648010|Device|TC-3 gel|One intravesical instillation of 40 cc of TC-3 hydrogel is instilled using catheter.
1676425|NCT01648010|Device|TC-3 gel mixed with Mitomycin C (MMC)|One intravesical instillation of 40 cc of TC-3 gel mixed with 40 mg MMC will be instilled using catheter
1676426|NCT01647997|Other|bacterial endotoxin challenge|iv administration of 2ng/kg bacterial endotoxin
1676427|NCT01647984|Dietary Supplement|Ritmonutra|Ritmonutra ® contains: 720 mg of Fish Oil with Omega-3, including 480 mg of EPA and 40 mg of DHA, Hawthorn (extract from Crataegus mongyna) 300 mg equivalent to 5.4 mg of vitexin, 4 mg of Astaxanthin and 36 mg of Vitamin E
1676428|NCT01647984|Dietary Supplement|placebo|
1676429|NCT01647971|Drug|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
1676430|NCT01647958|Device|EsophyX System with SerosaFuse fasteners|Transoral Incisionless Fundoplication (TIF)/Transoral incisionless esophago-gastric fundoplication
1676431|NCT01647945|Drug|Placebo|placebo pill
1676432|NCT01647945|Drug|FK506 level < 2 ng/ml|FK506 goal trough blood level < 2 ng/ml
1676433|NCT01647945|Drug|FK506 level 2-3 ng/ml|FK506 goal trough blood level 2-3 ng/ml
1676434|NCT01647945|Drug|FK506 level 3-5 ng/ml|FK506 goal trough blood level 3-5 ng/ml
1676435|NCT01647932|Drug|hydrochlorothiazide|hydrochlorothiazide according to clearance of creatinine; >50ml/min 25mg daily, 20-50ml/min 50mg daily amd <20ml/min 100mg daily.
1676436|NCT01647932|Drug|Placebo|Placebo according to clearance of creatinine; >50ml/min 1/2 pill daily, 20-50ml/min 1 pill daily amd <20ml/min 2 pills daily.
1676437|NCT01647919|Dietary Supplement|cogniVida™ 100 mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
1676438|NCT01647919|Dietary Supplement|Placebo|4 capsules of placebo identical to cogniVida™ once a day
1676439|NCT01647893|Drug|CTB-001|IV bolus or IV infusion
1676440|NCT01647880|Drug|Verum arm receiving Gilenya®|
1676441|NCT01647880|Drug|Active Comparator receiving Extavia®|
1676442|NCT01647867|Other|Met analysis on tissue and blood|10 mL of blood and 4 pieces of tissue (2 of tumor tissue, 2 of healthy tissue) all taken at the same time as surgery or bronchoscopy, depending on the stage of the disease
1676443|NCT01647854|Procedure|Teleconsultation|Teleconsultation in prehospital emergencies
1676444|NCT01647828|Drug|OMP-59R5|OMP-59R5 administered intravenously
1676445|NCT01647828|Drug|Gemcitabine|administered intravenously
1676446|NCT01647828|Drug|Placebo|administered IV
1676447|NCT01647828|Drug|Nab-Paclitaxel|administered intravenously
1676448|NCT01647815|Procedure|Ultrasound measures|Ultrasound will be used to measure the surfaces of the axillary and subclavian veins with the arms in different positions. Our goal is to compare the vein surface area available among different vein-position combinations. Our goal does not include testing specific devices.
1676449|NCT01647802|Device|"Standing attempts with the Vertic'Easy Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes.
1676450|NCT01647802|Device|"Standing attempts with the Turner Device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
1676451|NCT01647802|Device|"Standing attempts with the Tina device"|Included patients had never used any of the three devices evaluated in this study. Therefore the patient will make two attempts at standing on each device to enable him/her to get used to the device at the first attempt. A video recording will be made from a camera positioned laterally. Only the results of the second attempt will be a kinematic analysis and will be used for analyzes
1676452|NCT01647789|Drug|CFG920|
1676453|NCT01647776|Other|Stool DNA Test|Stool DNA test is done prior to the colonoscopy.
1676454|NCT01647776|Procedure|biopsies of rectal and colon mucosa|During the standard of care colonoscopy biopsies of rectal and colon mucosa will be taken for analysis of 15-PGDH pathway factors [levels of prostaglandin E2 (PG E2), and mRNA for 15-PGDH, COX-1 and COX-2 expression] as markers of risk of developing adenoma.
1676455|NCT01647776|Other|Questionnaires|A Food Frequency Questionnaire (FFQ), a Meat Preparation Questionnaire (MPQ), and a Physical Activity Questionnaire (PAQ), all developed at the University of Arizona Cancer Center will be used to collect dietary and physical activity data. Risk Factor Questionnaire (RFQ) developed by the University of Southern California will be used to collect general risk information. Stool (sDNA) test patient satisfaction survey.
1676456|NCT01647763|Procedure|Hemorrhoidal artery ligation with rectoanal repair|"Hemorrhoidal arteries will be detected using an ultrasound Doppler probe. The arteries will be sutured with at least 4 Z-sutures.
In the area with the 3 largest knots a purse string suture will be placed."
1676457|NCT01647763|Procedure|Stapled hemorrhoidopexy|A purse string suture will be placed just below the hemorrhoidal cushion. Fixing the suture around the shaft of a circular PPH 03 stapler (Ethicon Endo-Surgery). Hemorrhoids will be removed by firing the stapler. Sufficiency of the stapler line will be examined through a proctoscope. Eventual sources of bleeding will be sutured.
1676458|NCT01647750|Drug|Levothyroxine|Participants in the lower dose arm of the study will receive a lower dose of levothyroxine than their usual dose
1676459|NCT01647750|Drug|Levothyroxine|Participants in the standard dose of treatment will receive their usual dose of levothyroxine
1676460|NCT01647737|Dietary Supplement|MighTeaFlow|4-6 times daily
1676461|NCT01647737|Dietary Supplement|Xylitol|4-6 times daily
1676462|NCT01647711|Drug|Dose escalation followed by treatment with MTD|Fixed 3+3 dose escalation; expansion of MTD cohort
1676680|NCT01645696|Device|Medtronic iPro2 Professional CGM|continuous subcutaneous glucose monitoring for 72 hours
1676463|NCT01647698|Behavioral|Adaptive working memory training task|"The working memory training task will consist of an adaptive working memory computer program that will test and extend patients' working memory capacity.
Adaptive refers to the increase in the number of items that the patient is required to remember."
1676464|NCT01647698|Behavioral|Non-adaptive working memory training task (i.e. an active control task)|Active control task will consist of a non-adaptive working memory task.
1676465|NCT01647698|Behavioral|No training|No training during the experiment.
1676466|NCT01647685|Drug|Nanocort|Two weekly IV infusions of 150 mg Nanocort (PEG-liposomal prednisolone sodium phosphate).
1676467|NCT01647685|Drug|Methylprednisolone|Two weekly infusion iv methylprednisolone sodium succinate 125 mg infusion.
1676468|NCT01647685|Drug|Placebo|Saline solution (same solution brand as used to dilute/prepare Nanocort injection)
1676469|NCT01647672|Drug|Abraxane|Abraxane for neoadjuvant chemotherapy
1676470|NCT01647659|Drug|Trametinib tablet|2 mg, orally, on Day 1 of the dosing period
1676471|NCT01647659|Drug|Trametinib pediatric formulation|2 mg, orally, on Day 1 of the dosing period
1676472|NCT01647646|Drug|Seretide|Using Symbicort and Seretide for asthma control measurements Compared with efficacy and safety
1676473|NCT01647633|Other|Calcium Glycerophosphate Nasal Spray Wash|Nasal wash two to six times per day
1676474|NCT01647620|Drug|DPOC-4088|A 10-day oral dosing of DPOC-4088 prolonged release tablet (20 hr release formulation). Starting dose in dose step 1 is 100 mg daily.
1676475|NCT01647620|Drug|Placebo|A 10-day oral dosing of matching placebo prolonged release tablet.
1676476|NCT01647607|Behavioral|Young Women's Intervention (YWI)|This educational intervention uses print and web-based materials to focus on issues unique to young women with breast cancer, including career development, starting/raising a family, body image, and genetic predispositions to breast cancer.
1676477|NCT01647607|Behavioral|Physical Activity Intervention (PAI)|This educational intervention uses print and web-based materials that focus on developing and/or maintaining a healthy lifestyle for young women with breast cancer, including the benefits of exercise and resources to enhance physical activity after diagnosis.
1676478|NCT01647594|Behavioral|YWI|The YWI consists of print and web-based materials. Content for this group will include detailed information about issues facing young women with breast cancer, risks, discussion points and and resources. The following domains will be addressed: health/medical issues (i.e., side effects, breast cancer recurrence, long-term risks, genetic issues), psychosocial issues (coping, relationship and family concerns), beauty/body image, sexual functioning, fertility concerns, and work/school issues.
1676479|NCT01647594|Behavioral|Physical Activity|The PAI serves as the control group. This intervention consists of print and web-based materials, the content of which includes detailed information about the benefits of exercise in breast cancer survivors and discussion points, available options and resources to enhance physical activity after diagnosis.
1676480|NCT01647581|Device|Hemoclip Placement|Placement of hemoclip at polypectomy site for polyps at least 1cm in size
1676481|NCT01647581|Device|NO hemoclip placement|No hemoclip placement (placebo / sham)
1676482|NCT01647555|Drug|Cetuximab|First cycle: 400 mg/m2 Next cycles: 250 mg/m2
1676483|NCT01647555|Radiation|Radiotherapy|Curative dose: 66 to 70 Gy
1676484|NCT01647542|Drug|TAK-875|TAK-875 tablets
1676485|NCT01647542|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
1676486|NCT01647529|Drug|Ganciclovir|Treatment with topical ganciclovir ointment
1676487|NCT01647516|Drug|RPC1063|
1676488|NCT01647516|Drug|placebo|
1676489|NCT01647490|Procedure|Permanent Cardiac Pacemaker Implantation|
1676490|NCT01647477|Behavioral|interview|25 minutes of semi directive interview
1676491|NCT01647477|Behavioral|questionnaires|questionnaires to answer at baseline 45 minutes
1676492|NCT01647451|Drug|NNC0114-0006|Two i.v. (intravenous) doses administered 6 weeks apart.
1676493|NCT01647451|Drug|placebo|Two i.v. (intravenous) doses administered 6 weeks apart.
1676494|NCT01647438|Behavioral|Lifestyle Intervention|Participants will enroll in heart disease prevention group sessions focusing on physical activity, diet, weight, and stress management. Each group will have 6 to 8 participants who will attend 6 weekly, 90 minute group education sessions at Metropolitan Asian Family Services. During each session, participants will watch videos on the day's topic followed by discussion, activities, and assistance in setting realistic goals with attention to physical activity, diet, weight, and stress management. Participants will receive telephone support after each session and up to 12 weeks after they have completed the classes to help reinforce learning objectives.
1676495|NCT01647438|Other|Print Health Education|Participants will receive primary care referrals and print health education material about heart disease prevention in the mail.
1676496|NCT01647425|Behavioral|physician assessment|"Socio-economic conditions and general features: educational level, professional status...
Assessment of current and past use of tobacco: current smoking status reported by the patient; in lifelong non-smokers: previous history of passive smoking reported by the patient; breath carbon monoxide level; in past smokers: age of first cigarette, total reported duration of active smoking, breath carbon monoxide level...
in current smokers: age of first tobacco use, total reported duration of active smoking; Fagerström Nicotine Dependence Test...
Assessment of the current and past uses of alcohol: previous-year assessment using the CAGE questionnaire and the AUDIT Test; average weekly alcohol consumption over the last 12 months...
Assessment of current use of cannabis using the Cannabis Abuse Screening Test
Psychiatric assessment using the MINI 5.0"
1676497|NCT01647412|Drug|Growth Hormone|Humatrope will be administered daily to patients in a dose of .18-.20 mg/kg/week.
1676498|NCT01647412|Dietary Supplement|Nutraceutical Combination|
1676499|NCT01647412|Other|Exclusion Diet|Patients on the exclusion diet will adhere from consumption of all grain, corn, dairy, and carrageenan containing products.
1676500|NCT01647412|Other|Placebo Growth Hormone|
1676501|NCT01647347|Drug|Supra- and subgingival rinsing with 10% PVP-iodine|rinsing prior to and during subgingival ultrasonic debridement
1676502|NCT01647347|Other|Water|
1676503|NCT01647334|Radiation|Adaptive radiotherapy|
1676606|NCT01646242|Procedure|removal of eligible polyps using double biopsy technique|Cold forceps polypectomy using a standard- capacity forceps with double biopsy technique (two bites per one forceps pass)
1676504|NCT01647321|Behavioral|Active cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to actively pedal while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
1676505|NCT01647321|Behavioral|Passive cycling|The exercise program uses a stationary bike equipped with functional electrical stimulation (FES) of leg muscles. Participants are instructed to sit passively on the stationary bile while the FES is assisting. The training program is expected to be performed for one hour, three times a week for 12 weeks.
1676506|NCT01647308|Drug|ISIS-APOCIIIRX|3 doses of ISIS ISIS-APOCIIIRX on alternate days during the first week and then once-weekly doses for 12 weeks.
1676507|NCT01647308|Drug|Placebo|3 doses of placebo on alternate days during the first week and then once-weekly doses for 12 weeks.
1676510|NCT01647269|Procedure|Bilateral GPi Deep Brain Stimulation|Bilateral GPi Deep Brain Stimulation
1676511|NCT01647256|Drug|Nikkomycin Z|Capsule, 500 mg, single-dose
1676512|NCT01647243|Other|Preoperative strength training|Progressive strength training on group basis (not more than 3 subjects) 3 sessions weekly starting 4 weeks before the operation, in total 12 sessions Strength training 3 sessions weekly 4 weeks postsurgery
1676513|NCT01647217|Drug|Terpinen-4-ol|Lid scrub once or twice per day for one month.
1676514|NCT01647217|Other|Placebo|Lid scrub once or twice per day for one month
1676515|NCT01647204|Other|trained volunteer mealtime assistance|trained volunteers helped inpatients at lunchtimes with dinner tray preparation, encouragement and feeding if required
1676516|NCT01647191|Behavioral|intervention group|The investigators will use a variety of learning techniques, including lecture, brainstorming, small and large group activity, individual worksheets, role-play, and video player. For example, small teams of up to 5 participants will conduct role-plays; large groups also will be assembled to encourage talking about HCV-related risk reduction behavior.
1676517|NCT01647191|Behavioral|control group|The investigators will adopt previous treatment in the clinics to intervent the patients
1676518|NCT01647178|Procedure|TORQ assisted sternal closure|
1676519|NCT01647178|Procedure|Conventional closure|
1676520|NCT01647165|Drug|Bortezomib|Cycle 1-8: 1.0 mg/m2 SC at a concentration of 2.5 mg/ml or 1 mg/ml to the thighs or abdomen on days 1, 4, 8, 11 of a 21 day cycle for 8 cycles.
1676521|NCT01647165|Drug|Lenalidomide|Cycle 1: 15 mg oral daily on days 2-14 of 21 day cycle; Cycle 2-8: 15 mg oral daily on days 1-14 of a 21 day cycle
1676522|NCT01647165|Drug|Dexamethasone|Cycle 1: 10 mg oral or IV daily on days 2,4,5,8,9,11,12 of a 21 day cycle; Cycle 2-8: 10 mg oral or IV on days 1, 2, 4, 5, 8, 9, 11, 12 of a 21 day cycle
1676523|NCT01647152|Drug|Ustekinumab|
1676524|NCT01646853|Radiation|Megavoltage photon beam|initial dose:50Gy/2Gy/25f,5days/week escalation dose:4Gy/2Gy/2f
1676525|NCT01646853|Drug|cisplatin-fluorouracil chemotherapy|cisplatin 75 mg/m2 on day 1 with standard hydration fluorouracil 1000 mg/m2/day1 i.v. by continuous infusion from day 1 to day 4 of each cycle
1676526|NCT01646840|Drug|PF-04958242 capsule|Single dose of PF-04958242 0.35 mg oral capsule
1676527|NCT01646840|Drug|PF-04958242 oral solution|Single dose of PF-04958242 0.35 mg oral solution
1676528|NCT01646827|Drug|Aripiprazole IM Depot|One injection of 400 mg aripiprazole IM depot
1676529|NCT01646814|Drug|PL2200|PL2200, containing 325 mg aspirin active ingredient
1676530|NCT01646814|Drug|Aspirin tablets|325 mg aspirin tablets (USP)
1676531|NCT01646801|Device|NMB Balloon Catheter|patients treated by the NMB's Drug Ejecting Balloon
1676532|NCT01646788|Device|NMB Paclitaxel Drug Ejecting Balloon|NMB's PTA Balloon catheter with drug
1676533|NCT01646775|Drug|epidural fentanyl|withold epidural fentanyl
1676536|NCT01646749|Dietary Supplement|Differences in protein content (En%) of meals|The three applied conditions will differ in the relative protein content of the meals, including 5 En%, 15 En% and 30 En% from protein. Beef protein will be used as main meat protein source in the 15 En% and 30 En% protein conditions. The resulting macronutrient compositions of the diets will be En% Protein/Carbohydrate/Fat; 5/60/35, 15/50/35, and 30/35/35. All meals (breakfast, lunch, dinner) within each condition will have the same macronutrient composition. All food items, and the energy density, weight and volume of the meals will be the same between conditions. All snack items will be very low in protein content.
1676537|NCT01646736|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
1676538|NCT01646736|Drug|Cyclophosphamide|Cyclophosphamide 1.0 intravenous every month.
1676539|NCT01646736|Drug|GC|Prednisone or equivalent 1 mg/kg/d(up to 60 mg), gradually tapering to 7.5mg/d in 24 weeks.
1676540|NCT01646723|Behavioral|Volunteers Adding Life in Dementia (VALID) Program|"The VALID intervention will consist of 2 phases. First, volunteers will complete an assessment involving recording of a Life Story for each patient participant. This will include information on the patient's psychosocial history, occupational history, hobbies, interests and preferred activities using information from the LTC medical record and interviews with the patient and family members. Based on this information, a variety of potential psychosocial interventions will be developed for the individual with the assistance of the recreation therapist at the LTC. The second phase will involve implementation of the VALID intervention. Each individual with dementia will receive personalized pleasant activities for a minimum session of 30 minutes at a frequency of 3 times per week. One volunteer will complete the Life Story assessment and up to 3 volunteers may be involved with implementing the VALID program for each resident."
1676541|NCT01646710|Behavioral|Pretesting food based recommendations|
1676542|NCT01646697|Other|cytology specimen collection procedure|Undergo cytopathologic sample collection
1676544|NCT01646671|Drug|LCZ696|LCZ696 200 mg tablet once daily
1676545|NCT01646671|Drug|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily
1676546|NCT01646671|Drug|LCZ696|2 tablets of LCZ696 200 mg once daily titrated up from 1 tablet of 200 mg once daily plus other HTN medications
1676547|NCT01646645|Genetic|CMV-pp65 CTLs|Patients will be treated with CMVpp65-CTLs derived from their transplant donor. These will be patients with CMV seropositive transplant donors who have previously provided leukocytes for generation of CMVpp65-CTL and for whom such CMVpp65-CTL are available. The T-cells to be infused will be selected based on criteria mentioned in section 4.0 from our bank of GMP grade CMVpp65-CTL. T-cells will be administered by bolus intravenous infusion. In this phase II trial, patients will be treated at doses of 1 x 106 CMVpp65-CTL/kg/dose/week for 3 weeks. Patients will be observed for the following 3 weeks. Additional 3 week courses of CMVpp65-CTL may be administered if levels of CMV DNA in blood are still detectable despite disease stabilization or improvement.
1676548|NCT01646632|Behavioral|Physical exercise intervention|the experimental intervention included group- based progressive resistance training, balance training, and functional training, two times a week, one hour sessions, lasting 16 weeks.
1676549|NCT01646632|Behavioral|Lifestyle counseling|the control intervention included recreational sessions, including talks, video's, music, board games etc. No physical activity was involved in the control intervention.
1676550|NCT01646619|Drug|Magnesium Sulphate|"10% MgSo4 (100mg/ml) given in a dose of 250mg/kg IV q 24 hrly for 3 doses(2.5ml/kg).
Diluent: Dextrose 5%."
1676551|NCT01646619|Drug|Placebo|Normal Saline 0.9% Sodium Chloride is diluted in 5% Dextrose to be given as 2.5ml/kg IV q24 hrly for 3 doses.
1676552|NCT01646606|Procedure|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. The nurse will attach the probe to the electrical cord which is connected to the monitor. For each measurement, the duration of monitoring will be until a steady wave form is present on the oxygen saturation monitor, indicating a reliable measurement (consistent with current standard of practice). The nurse will document the maximum and minimum reading during the period. The nurse will detach the probe from the electrical cord, leaving the probe attached to the child. Hence, the child's probe will be attached to the electrical cord intermittently as well.
1676553|NCT01646606|Procedure|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Every 4 hours the nurse will complete and document a set of vital sign measurements, including oxygen saturation level, in keeping with current clinical practice. The reading will be displayed on the bedside monitor in the participants' room. At the completion of vital signs measurement, the nurse will not detach the electrical cord from the probe. Hence, the child's probe will be attached to the electrical cord continuously as well.
1676554|NCT01646593|Drug|Regorafenib (BAY73-4506)|160 mg BAY73-4506, 3 weeks on drug, 1 week off
1676556|NCT01646567|Drug|SHP-141C|Topical Cream
1676557|NCT01646567|Drug|Placebo to SHP-141C|Placebo Topical Cream
1676558|NCT01646567|Drug|Betamethasone Valerate|Topical cream, 0.02%
1676559|NCT01646567|Drug|Calcipotriol|Topical cream, 0.005%
1676560|NCT01646554|Drug|Modified FOLFOX6|
1676561|NCT01646554|Biological|Aflibercept|Targeted therapy
1676562|NCT01646554|Procedure|Surgery|
1676563|NCT01646528|Procedure|CLE examination for upper gastrointestinal tract|Routine upper GI endoscopy plus targeted CLE examination
1676566|NCT01646502|Biological|Esp protein|
1676567|NCT01646502|Other|Standard wound care|
1676568|NCT01646489|Drug|Miravirsen sodium|Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.
1676569|NCT01646489|Drug|Telaprevir|Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.
1676570|NCT01646476|Device|Covered stent (Bona stent pyloric/duodenal covered) insertion|self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
1676571|NCT01646476|Device|Uncovered stent (Bona stent, pyloric/duodenal) insertion|Self-expandable metallic stent placement was performed with a therapeutic endoscope (working channel ≥ 3.7 mm) using a through-the-scope method. All patients underwent procedures under conscious sedation with midazolam and pethidine. The length of the stricture was assessed either endoscopically or fluoroscopically; the length of the stent had to exceed that of the stricture by at least 3 cm. After the required stent length was determined, the stent was advanced through the endoscope over a guidewire until it passed across the distal end of the stricture. Then, the stent was deployed under continuous fluoroscopic control. For the Wave covered stent group, the stent was repositioned after deployment using the lasso under fluoroscopic guidance (if necessary), aligning the central portion of the stricture with the central portion of the stent which had reduced radial force and indentation. Stent positioning was confirmed endoscopically and fluoroscopically.
1676607|NCT01646229|Other|Polymyxin-B hemoperfusion|
1676608|NCT01646229|Other|Control|
1676645|NCT01645917|Device|Arctic Front Advance Cardiac CryoAblation system|Standard of care ablation for indicated paroxysmal AF patients with Medtronic's Arctic Front Advance Cardiac CryoAblation system
1676810|NCT01644448|Other|Standard Therapy|Topical Applications as directed by the investigator
1677481|NCT01639521|Biological|pegfilgrastim|Given SC
1676572|NCT01646463|Behavioral|CenteringPregnancy|CenteringPregnancy (CP) follows a standardized curriculum for group-based prenatal healthcare offered to groups of 10-12 women with similar due dates. In lieu of receiving a series of individually-delivered prenatal healthcare, participants meet 10 times over the course of pregnancy and early postpartum for 2 hour sessions, essentially pooling their minutes for each prenatal healthcare visit. The visit schedule adheres to the guidelines set forth by ACOG of monthly and then weekly visits close to birth. All sessions of CP include three core components of: (1) physical assessment (including blood pressure, weight, and fundal height assessment), (2) education and skills-building, and (3) support. Content topics for group discussion include nutrition, exercise, relaxation, understanding pregnancy problems, infant care and feeding, postpartum issues including contraception, comfort measures in pregnancy, sexuality and childbearing, abuse issues, parenting, and childbirth preparation.
1676573|NCT01646463|Behavioral|CenteringPregnancy with Mindfulness Skills|CenteringPregnancy with Mindfulness Skills contains the CenteringPregnancy (CP) content combined with training in mindfulness meditation and mindful movement/yoga. The mind-body methods have been adapted from those taught in the Mindfulness-Based Childbirth and Parenting (MBCP) course, which is a tailored version of the Mindfulness-Based Stress Reduction program delivered to pregnant women during the perinatal period. These practices include mindfulness meditation of the breath, body, feelings, thoughts, and emotions; body scan meditation; yoga postures practiced with mindful awareness of the body and the physical changes associated with pregnancy; and loving-kindness meditation. In addition, MBCP includes specific exercises in coping with stress, pain, and fear associated with pregnancy, childbirth, and early parenting with a focus on shifting the way participants relate to negative thoughts and emotions and cope with stress.
1676574|NCT01646450|Drug|Icotinib|Icotinib: 125mg, oral administration, three times per day.
1676579|NCT01646398|Biological|13-valent pneumococcal conjugate vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
1676580|NCT01646398|Biological|23-valent pneumococcal polysaccharide vaccine|A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
1676581|NCT01646385|Drug|etanercept|use as per routine clinical practice
1676582|NCT01646385|Drug|non-biologic anti-rheumatic drugs|use as per routine clinical practice (methotrexate, azathioprine, cyclophosphamide, cyclosporine, leflunomide, other)
1676583|NCT01646372|Other|Standard Simulation Based ACLS Refresher Teaching|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by practice simulated megacodes
1676584|NCT01646372|Other|Cognitive Aid based ACLS Refresher training|45min-1 hour time. 15 minutes didactic review of 2010 ACLS guidelines followed by simulated ACLS megacode practice focused on the use of Cognitive Aids to guide management.
1676585|NCT01646359|Device|1.Esophageal doppler monitor|1.Esophageal doppler monitor (CARDIO Q®, DELTEX MEDICAL. Brighton, U. K.)-inserted into the esophagus and positioned approximately 35-40 cm from the teeth. The position of OED prove was confirmed by continuously measuring blood flow velocity in the descending thoracic aorta and focused to find the optimum peak velocity and waveform signal.
1676586|NCT01646359|Device|2. philips Intelivue MP70 monitors|2.philips Intelivue MP70 monitors (Intellivue MP70, philips medical Systems, Suresnes, France) -a radial arterial cannula was inserted and arterial pressure waveforms were monitored through Philips Intelivue MP70 monitors. In the monitor, PPVauto was displayed in real-time. It based on automatic detection algorithms, kernel smoothing, and rank-order filters.
1676587|NCT01646346|Radiation|4D Conformal Image-Guided Partial Breast RT|External beam partial breast radiation to target a portion of the breast twice a day for 5 days.
1676588|NCT01646333|Behavioral|Memory and Problem-Solving Intervention|8 weekly 1 hour sessions of memory compensation and problem-solving strategies
1676589|NCT01646333|Behavioral|Supportive Therapy|8 weekly 1 hour sessions of non-directive supportive therapy.
1676590|NCT01646320|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
1676591|NCT01646320|Drug|Placebo matching with Dapagliflozin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
1676592|NCT01646320|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
1676593|NCT01646320|Drug|Metformin immediate release (IR)|Tablets, Oral, ≥ 1500 mg, Twice daily, Up to 52 weeks
1676594|NCT01646307|Drug|Atorvastatin|
1676595|NCT01646307|Drug|Rosuvastatin|
1676596|NCT01646294|Drug|YM178 modified release (OCAS)|oral
1676597|NCT01646294|Drug|YM178 immediate release (IR)|oral
1676598|NCT01646281|Drug|Vernakalant|10-minute infusion of 3 mg/kg vernakalant, followed by a 15 minute observation period. If the patient is still in atrial fibrillation, an additional 10-minute infusion of 2 mg/kg vernakalant will be given.
1676599|NCT01646281|Drug|Flecainide|10-minute infusion of 2 mg/kg (maximal 150 mg)
1676600|NCT01646268|Drug|Rotigotine|"Transdermal Patch
Content:
2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)
For early-stage Parkinson's disease, receive Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 24 week maintenance period"
1676601|NCT01646268|Drug|Placebo Patch|"Transdermal Patch
Size:
10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2
Subjects randomized to placebo will receive matching placebo patches"
1676602|NCT01646255|Drug|Rotigotine|"Transdermal Patch
Content:
4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)
For advanced-stage Parkinson's Disease, subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 12 week maintenance period"
1676603|NCT01646255|Drug|Placebo Patch|"Transdermal Patch
Size:
20 cm^2, 30 cm^2, 40 cm^2
Subjects randomized to placebo received matching placebo patches"
1676604|NCT01646255|Drug|L-dopa|Subject must be on a stable dose of L-dopa (either short-acting or sustained release [in combination with benserazide or carbidopa]) of at least 200 mg/day, administered in at least 2 intakes, for at least 28 days prior to Baseline.
1676605|NCT01646242|Procedure|removal of eligible polyps using cold snare polypectomy technique|Snare polypectomy using a mini (10 mm open diameter) size electrosurgical snare without application of electrocautery
1676609|NCT01646216|Behavioral|Split belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to move at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same or slightly different speeds.
1992259|NCT03322683|Procedure|Physiotherapy treatment with physium device.|This group will treated five times with the analgesic program of physium therapy. Each maneuver was performed once per session by slow and progressive. The whole procedure lasted no more than 45 minutes.
1676611|NCT01646190|Dietary Supplement|Preoperative Carbohydrate load|oral intake in the evening before surgery and 2-3h before intubation
1676612|NCT01646190|Procedure|individualized i.v fluids therapy|by Transoesophageal aortic US-Doppler done intraoperatively
1676613|NCT01646190|Behavioral|Fasting state after midnight|No preoperative glucose load
1676614|NCT01646190|Behavioral|No Nasogastric tube postoperatively|Withdrawal after complete awakening in operating room
1676615|NCT01646190|Behavioral|urinary catheter removal|at POD 1
1676616|NCT01646190|Behavioral|Oral liquids|0.3-0.5L oral liquids at 6h postoperatively on POD 0
1676617|NCT01646190|Behavioral|Stimulation of inspirex utilization|using 6-8 times/day to prevent pulmonary atelectasis
1676618|NCT01646190|Behavioral|Mobilization|First active mobilization 6h after surgery (2h on chair or 45° sitting in bed), >4h out of bed on POD1, >6h on POD2, complete at POD3
1676619|NCT01646190|Other|Preanesthetic medication|Preanesthetic oral medication before surgery
1676623|NCT01646151|Drug|Bimatoprost|Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
1676624|NCT01646138|Biological|Ca/04/2009/H1N1 Vero Grown Challenge Virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 1 mL of virus will be administered.
1676625|NCT01646125|Drug|AUY922|AUY922 was to be given by i.v. once weekly at 70 mg/m2 until disease progression, death or any other reason for discontinuation from study treatment.
1676626|NCT01646125|Drug|Docetaxel|Docetaxel was to be given i.v. once every 3 weeks at 75 mg/m2 until progression or unacceptable toxicity
1676627|NCT01646125|Drug|Pemetrexed|Pemetrexed was to be given once every 3 weeks at 500 mg/m2 until progression or unacceptable toxicity
1676628|NCT01646099|Behavioral|Internet-based sun protection education|Prior to summer, KTRs who agree to participate will receive a text message with their access code to the Internet intervention to access from their homes on a personal device. After online completion of baseline assessments, participants will be randomized to receive the intervention or general skin care information (control). Following the initial use, the participants may revisit the Internet intervention on a personal device or at the doctor's office on a tablet PC. Over the next 6 weeks, sun protection text reminders will be sent to intervention KTRs' cell phones and they will respond that they read the message. Control participants will receive text messages about general skin care.
1676629|NCT01646086|Behavioral|12 month behavioral weight loss intervention|The intervention for all groups will follow a standard behavioral weight loss protocol. Participants will meet in groups of up to 20 persons; groups will meet weekly for the first six months, then biweekly for two months and monthly for the remaining four months of the 12-month treatment period. Session content will be centered on behavioral goal setting and attention to caloric intake and physical activity. Participants will be asked to keep daily diet and physical activity logs.
1676630|NCT01646073|Biological|Adalimumab|adalimumab eow
1676631|NCT01646073|Biological|placebo|placebo
1676632|NCT01646060|Device|CM-1500|Blood Volume Monitor
1676633|NCT01646047|Dietary Supplement|multi-component nutritional supplement capsules|two capsules containing nutritional supplements per day for 6 months (vitamin C, mixed tocopherols/tocotrienols, vitamin D, fish oil, lutein, zeaxanthin, pine bark extract, benfotiamine, green tea extract, curcumin)
1676634|NCT01646047|Dietary Supplement|multi-component dietary supplement|placebo capsules
1676635|NCT01646034|Drug|carboplatin, thiotepa, and cyclophosphamide|tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
1676636|NCT01646034|Drug|chemotherapy (docetaxel, doxorubicin, cyclofosfamide, carboplatin, paclitaxel, gemcitabine)|"chemotherapy naïve;three cycles of docetaxel, doxorubicin, and cyclofosfamide
previously received anthracyclines without taxanes;three cycles of carboplatin and paclitaxel
previously received anthracyclines and taxanes;three cycles of carboplatin and gemcitabine"
1676637|NCT01646021|Drug|Ibrutinib|560 mg once daily continuous (without interruption) by mouth for 21-day cycles
1676638|NCT01646021|Drug|Temsirolimus|175 mg once daily intravenous infusion on Days 1, 8, 15 of the first cycle followed by 75 mg on Days 1, 8, 15 of each 21-day cycle
1676639|NCT01646008|Other|To measure carbon dioxide by capnography and arterial blood|Three times per day will be measured exhaled carbon dioxide and obtained in arterial blood sample.
1676640|NCT01646008|Other|to measure carbon dioxide by capnography and arterial blood|three times per day we will obtained arterial blood samples and measurements of carbon dioxide by capnography
1676641|NCT01645995|Dietary Supplement|Reformulated products|Subjects were asked to supplement their habitual diet with reformulated sugar-reduced products for 8 weeks. Subjects were provided with reformulated beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
1676642|NCT01645995|Dietary Supplement|Conventional products|Subjects were asked to supplement their habitual diet with conventional sugar products for 8 weeks. Subjects were provided with conventional beverages, sauces, condiments and snacks. They were asked to consume a minimum of 1 drink + 1 food portion intervention supplement daily, in exchange for habitually eaten equivalent foods.
1676643|NCT01645943|Procedure|Coronary angiogram|Routine coronary angiogram and revascularization if indicated
1676644|NCT01645930|Drug|IXAZOMIB|Patients will receive Oral IXAZOMIB (4.0 mg) on Days 1, 8, and 15; lenalidomide (25 mg) on Days 1 through 21; and dexamethasone (40mg) on Days 1, 8, 15, and 22.
1728069|NCT00020462|Biological|aldesleukin|
1676646|NCT01645904|Behavioral|Audiotaped Focus Group|Participation in a focus group regarding web-based program designed to improve communication of health and health history information among family members affected by Lynch syndrome.
1676647|NCT01645904|Behavioral|Demographic Questionnaire|Complete questions about demographics (age, race, marital status) and medical history. This visit should take about 1 hour to complete.
1676648|NCT01645904|Behavioral|Audiotaped Interview|"Group 2: Patients provide feedback regarding initial version of My Family Garden website.
Group 3: Patients provide feedback regarding final version of My Family Garden website."
1676649|NCT01645904|Behavioral|WAMMI Inventory|Patients complete Website Analysis and MeasureMent Inventory. This visit should take about 90 minutes to complete.
1676650|NCT01645891|Device|CDO electrochemical tissue oxygenation system|The TransCu O2® device is a non-invasive, electrochemical tissue oxygenation system intended for use with lower-cost wound dressings for the treatment of chronic wounds such as diabetic foot ulcers, venous leg ulcers, pressure ulcers and other skin wounds through the continuous diffusion of oxygen (CDO). The goal of CDO therapy is to continuously supply pure oxygen to an oxygen-compromised wound to aid in wound healing
1676651|NCT01645891|Device|Moist Wound Therapy|Moist Wound Therapy in combination with sham or deactivated device
1676652|NCT01645878|Behavioral|hands on|in hands on group it was instructed by direct help of instructor, mothers could ask questions and if necessary it was done again by researcher.
1676653|NCT01645878|Behavioral|hands off|In hands off group, was instructed by pictures, if mothers had questions, they could watch the pictures again
1676654|NCT01645878|Behavioral|routin breast feeding education|
1676655|NCT01645865|Behavioral|Control|Health facilities where PMTCT services are available in the traditional clinical setting with HIV testing and counseling, PMTCT support, and enrollment in care and treatment.
1676656|NCT01645865|Behavioral|Intervention|In addition to the 'Standard of Care', HIV-infected pregnant women and male partners within the PMTCT program are engaged in multi-directional mobile communication for PMTCT promotion with health care providers.
1676657|NCT01645852|Dietary Supplement|Optifast 800|Five units of Optifast 800 plus an unlimited volume of calorie-free fluids per day for one week prior to hepatic resection.
1676658|NCT01645839|Drug|Liposomal Cytarabine|50mg (5 mL) by slow intrathecal injection (1-5 minutes) directly into the cerebrospinal fluid (CSF) via a ventricular catheter directly into the lumbar sac during a lumbar puncture.
1676659|NCT01645826|Drug|Diltiazem Hydrochloride|The study agent will be diltiazem and will start at 60 mg po BID then titrated up very two weeks until at a maximum maintenance dose of 180mg po BID for six weeks.
1676660|NCT01645826|Drug|Sugar Pill|The placebo group of patients will be treated with sugar pill PO bid and return every two weeks for next titration dose (actually will be an unchanged concentration).
1676661|NCT01645800|Drug|Lysozyme hydrochloride|LYL 90mg capsule: Three times daily for 52 weeks.
1676662|NCT01645800|Drug|Placebo|Matching Placebo capsule: Three times daily for 52 weeks.
1676665|NCT01645774|Procedure|10s injections duration|10s injections duration
1676666|NCT01645774|Procedure|10s injection duration and waiting 10s before withdrawing the needle|10s injection duration and waiting 10s before withdrawing the needle
1676667|NCT01645774|Procedure|15s injection duration and waiting 5s before withdrawing the needle|15s injection duration and waiting 5s before withdrawing the needle
1676668|NCT01645774|Procedure|5s injection duration and waiting 15s before withdrawing the needle|5s injection duration and waiting 15s before withdrawing the needle
1676669|NCT01645761|Drug|Endonase|PPI- based triple therapy with endonase
1676670|NCT01645748|Drug|S-1|S-1 is an oral fluoropyrimidine derivative, based on the concept of biochemical modulation. It consists in a molar ratio of 1:0.4:1: tegafur, a prodrug that is slowly metabolized to 5-fluorouracil; gimeracil, which reversibly inhibits dihydropyrimidine dehydrogenase. In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively.
1676671|NCT01645748|Drug|S-1|Chemotherapy was comprised of docetaxel 30 mg/m2 on days 1 and 8, cisplatin 60 mg/m2 on day 1, and S-1 70 mg/m2 on days 1 to 14, with the regimen repeated every 21 days
1676672|NCT01645748|Drug|S-1|In patients with advanced gastric cancer, phase I study of S-1, docetaxel and cisplatin combination chemotherapy was reported and the recommended doses were 40mg/m2 bid (D1-D14), 60mg/m2 (D1) and 60mg/m2 (D1), respectively. Another phase II study of TPS as induction chemotherapy for locally advanced HNSCC was determined to be 70/70/60 mg∙m2/d every 3 weeks. However, the rate of grade 3-4 neutropenia was 75% at this recommended dose. To reduce the hematologic toxicities, we used the docetaxel weekly. Therefore following regimen was evaluated in this study; docetaxel 30 mg/m2 (D1, D8), cisplatin 60mg/m2 (D1), S-1 70mg/m2 (D1-D14) every 3 weeks.
1676673|NCT01645735|Drug|Ceftaroline fosamil|Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
1676674|NCT01645735|Drug|Ceftriaxone plus vancomycin|Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
1676676|NCT01645709|Drug|Verapamil|
1676677|NCT01645709|Drug|Placebo|
1676678|NCT01645696|Device|BD CGM with Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring for 72 hours.
1676679|NCT01645696|Device|BD CGM without Outer Layer|continuous (every 2 minutes) subcutaneous glucose monitoring over 72 hours.
1677482|NCT01639521|Other|laboratory biomarker analysis|Correlative studies
1676681|NCT01645566|Behavioral|instruction|"instructions about focusing on relevant task elements by posing two task-focusing questions (what is the patient's condition?, what immediate action is needed?) when feeling overwhelmed by stress (intervention-group)"
1676682|NCT01645475|Drug|Desmopressin lyophilisate (Melt)|Patient receives Desmopressin lyophilisate (Melt).
1676683|NCT01645449|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
1676684|NCT01645436|Other|exercise training|The intervention group will participate in combined inpatient physical training (aerobic + strength) over neoadjuvant chemotherapy. The intervention will include three weekly exercise sessions of 60-90 minutes, and will be held in child's room or in a pediatric gym specifically enabled on the aforementioned hospital, depending on the children's health status.
1676685|NCT01645423|Drug|Atorvastatin Calcium Tablets, 80 mg|Atorvastatin Calcium Tablets, 80 of Dr. Reddy's Laboratories Limited
1676686|NCT01645410|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
1676687|NCT01645384|Drug|Atorvastatin Calcium Tablets, 40 mg|Atorvastatin Calcium Tablets, 40 mg of Dr. Reddy's Laboratories Limited
1676688|NCT01645358|Device|Helmet (Starmed)|The helmet is a kind of interface similar to a hood to deliver NIV
1676689|NCT01645358|Device|Total Face mask (Respironics)|"The total face mask is the classical interface for NIV delivery"
1676690|NCT01645345|Device|Alma Lasers Accent RF Pixel handpiece|Treatment with fractionated RF Pixel device
1676691|NCT01645332|Drug|Placebo of DLBS3233|Placebo of DLBS3233 once daily for 12 weeks
1676692|NCT01645332|Drug|DLBS3233|100 mg DLBS3233 once daily for 12 weeks
1676693|NCT01645332|Other|Lifestyle modification|Each study subject will be provided with and instructed to follow a lifestyle modification (particularly regarding dietary advice and exercise) during the subject's participation in the study.
1676694|NCT01645306|Drug|Revacept|single intravenous injection
1676695|NCT01645306|Drug|Placebo|single intravenous injection
1676696|NCT01645293|Genetic|Genetically modified T cells # 1138|
1676697|NCT01645280|Drug|Placebo + methotrexate (MTX) (Group 1)|Placebo: form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
1676698|NCT01645280|Drug|Ustekinumab + MTX (Group 2)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
1676699|NCT01645280|Drug|Ustekinumab + MTX (Group 3)|Ustekinumab: type = exact number, unit = mg, number = 90, form = solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 12 weeks (Weeks 16 and 28) + MTX (pre-study dose)
1676700|NCT01645280|Drug|CNTO 1959 + MTX (Group 4)|CNTO 1959: type = exact number, unit = mg, number = 200, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28) + MTX (pre-study dose)
1676701|NCT01645280|Drug|CNTO 1959 + MTX (Group 5)|CNTO 1959: type = exact number, unit = mg, number = 50, form = powder for solution for injection, route = subcutaneous use, at Weeks 0, 4, then every 8 weeks (Weeks 12, 20, and 28)+ MTX (pre-study dose)
1676702|NCT01645267|Procedure|Hydroxyapatite|Use of artifical bonegraft material
1676703|NCT01645254|Drug|Argemone mexicana|30g, the powder decoction 2 times a day for 14 days
1676704|NCT01645241|Drug|gonadotropins plus GnRH antagonists|
1676705|NCT01645241|Drug|ganirelix|
1676706|NCT01645228|Radiation|coronary calcium score measurement|
1676707|NCT01645228|Biological|high sensitivity C reactive protein measurement|
1676708|NCT01645228|Procedure|ankle brachial index measurement|
1676709|NCT01645215|Drug|Fruquintinib|Fruquintinib is a capsule in the form of 0.25mg , 1mg and 5mg, oral, once a day.
1676710|NCT01645202|Procedure|Transcatheter Aortic Valve Implantation (TAVI)|Comparison of different types of valves
1676711|NCT01645189|Biological|Hunterase|once weekly, 0.5mg/kg IV infusion
1676712|NCT01645176|Drug|Hydroxychloroquine/Atorvastatin|Hydroxychloroquine 200-600 mg /day Atorvastatin 40 mg/day
1676713|NCT01645163|Behavioral|Counselling using mobile phones|Feasibility and acceptability of using mobile phones to improve complementary feeding practices.
1676714|NCT01645150|Behavioral|Progressive strength training|12 weeks of supervised progressive strength training
1676715|NCT01645137|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
1676716|NCT01645137|Other|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
1676717|NCT01645124|Drug|Hydroxyurea|
1676718|NCT01645124|Procedure|Phlebotomy|
1676719|NCT01645111|Drug|Clevidipine|
1676720|NCT01645098|Drug|Ketamine|1 mg/kg IV, additional doses of 0.5 mg/kg as needed
1676721|NCT01645098|Drug|Dexmedetomidine|0.5 mcg/kg/hr IV
1676722|NCT01645085|Drug|MCC-based 13% drug loaded tablets|50mg tablets, dosed as 2 tablets (100mg total)
1676723|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 100mg tablet
1676724|NCT01645085|Drug|MCC-based 13% drug loaded tablets|3 tablets (150mg total)
1676725|NCT01645085|Drug|Mannitol-based 38% drug-loaded tablet|One 150 mg tablet
1676731|NCT01645033|Other|computerized Cognitive Behavioral Therapy (CBT)|Standard treatment (as described in TAU) plus a short session using a computer program containing CBT to understand risks related to sexual and other behaviors and how those risks relate to spread of infections.
1728223|NCT00021320|Drug|fluorouracil|
1676732|NCT01645033|Other|Treatment as Usual (TAU)|"This is the infectious disease orientation that would normally be received at this clinic to address risky behavior. This orientation generally includes individual and group therapy sessions that discuss behaviors and the resulting risk of sexually or drug-related infections (for example: use of a condom). Sessions will generally include items such as:
Teaching about the treatment program
Teaching important ideas about sexual behaviors risks
Increasing knowledge about specific sexually transmitted diseases
Discussions of ways to reduce or minimize spread of diseases related to drug use [for example, Hepatitis and Human Immunodeficiency virus (HIV, the virus responsible for causing AIDS)]"
1676733|NCT01644994|Combination Product|intracavitary cisplatin-fibrin|single dose, local intracavitary application of cisplatin-fibrin after pleurectomy/decortication
1676734|NCT01644981|Other|blood sampling|blood sampling
1676735|NCT01644968|Drug|Cohort 1 anti-OX40|0.1 mg/kg anti-OX40 on days 1, 3, and 5
1676736|NCT01644968|Drug|Cohort 2 anti-OX40|.4 mg/kg anti-OX40 on days 1, 3, and 5
1676737|NCT01644968|Drug|Cohort 3 anti-OX40|2.0 mg/kg anti-OX40 on days 1, 3, and 5
1676738|NCT01644968|Biological|Tetanus Day 29|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 29
1676739|NCT01644968|Biological|Tetanus Day 1|Tetanus toxoid vaccine 0.5ml (5 LF/ml tetanus toxoid)on Day 1.
1676740|NCT01644968|Biological|KLH Day 1|1 mg KLH in 1 cc diluent subcutaneously on Day 1.
1676741|NCT01644968|Biological|KLH Day 29|1 mg KLC in 1 cc diluent by subcutaneous injection on Day 29.
1676742|NCT01644955|Drug|carboplatin|Carboplatin in a volume of 54 ml will be administered intracerebrally by convection enhanced delivery
1676743|NCT01644955|Procedure|Surgery|Patients will undergo surgery, which includes tumor resection and catheter placement, in the operating room.
1676744|NCT01644942|Other|Lipid accumulation analysis|The lipid accumulation will be assessed with muscular biopsies.
1676745|NCT01644929|Procedure|transcranial direct current stimulation (tDCS)|Anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks, then sham stimulation for 30 seconds on 15 days during 3 weeks
1676746|NCT01644929|Procedure|Sham stimulation, then tDCS|Sham stimulation for 30 seconds on 15 days during 3 weeks, then anodal tDCS of the ipsilesional motor cortex and cathodal tDCS of contralesional motor cortex (1.5 mA, 30 minutes) for 15 days during three weeks
1676747|NCT01644929|Procedure|Sham stimulation|Sham stimulation for 30 seconds on 15 days during 6 weeks
1676748|NCT01644916|Procedure|Integrated care|Integrated care will be provided with management of multifaceted group including, nurse educators, doctors, case manager and psychologists.
1676749|NCT01644916|Procedure|Usual control|Usual control group will be provided with usual standard procedures for management of COPD and psychiatric comorbidities.
1676750|NCT01644890|Drug|NK105|IV, Weekly
1676751|NCT01644890|Drug|Paclitaxel|IV, Weekly
1676752|NCT01644877|Drug|DAS181 dry powder, formulation F02|
1676753|NCT01644877|Drug|Lactose Placebo|
1676754|NCT01644864|Drug|0.375% ROPIVACAINE|
1676755|NCT01644864|Drug|placebo|
1676757|NCT01644838|Drug|Hyoscine|The samples were randomly allocated to inject of 20 mg of hyoscineIM in dilatation 3-5cm.
1676758|NCT01644838|Drug|Promethazine|The samples were randomly allocated to inject of 25 mg of promethazine IM in dilatation 3-5cm.
1676759|NCT01644825|Drug|paclitaxel|80 mg/m2 IV days 1, 8, 15 every 28 days
1676760|NCT01644825|Drug|pazopanib|orally, 800 mg orally daily
1676761|NCT01644812|Behavioral|Aerobic exercise|
1676762|NCT01644812|Behavioral|Stretching|
1676763|NCT01644799|Drug|idelalisib|oral
1676764|NCT01644799|Drug|lenalidomide|oral
1676765|NCT01644773|Drug|Crizotinib|"Starting dose level:
Initial Treatment Plan: 130 mg/m^2 per dose
Modified Treatment Plan per Amendment 1.0: 165 mg/m^2 per dose
The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.
The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.
Cycle 1 (28 days): once a day for 28 days
Cycles 2-26 (28 days each): once a day"
1676766|NCT01644773|Drug|Dasatinib|"Starting dose level: 50 mg/m^2 per dose
The dose of a single agent will be increased by approximately 30% in each subsequent cohort until the MTD of this combination is reached.
The doses of each agent will not exceed their single-agent MTD already determined for children with recurrent solid tumors.
Cycle 1 (28 days): starting on day 3, once a day for 28 days
Cycles 2-26 (28 days each): once a day"
1676767|NCT01644760|Procedure|Ultrasounds with controlled breathing|The patient will have cardiac, abdominal and thoracic ultrasounds with controlled and monitored inspiratory effort. This gesture takes about 40 minutes.
1676768|NCT01644747|Device|transcranial Direct Current Stimulation (tDCS) (Eldith DC NeuroConn Stimulator)|After locating the left DLPFC, ttt with active anodal tDCS with a current of 2 mA or sham over the left DLPFC will be directed by 30-minute session. Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during tDCS for any side effects or adverse events.
1676769|NCT01644734|Drug|Spiriva HandiHaler|
1676770|NCT01644721|Biological|Early measles vaccine|Standard Edmonston-Zagreb measles vaccine
1676771|NCT01644708|Behavioral|Self empowerment|"1. Group meeting, introducing the method and the assessment tools
Self-empowerment,
Handing over the journal,
Questionnaire about emotional states and motivations for losing weight and for change.
The group meetings, lasting one hour and a half, will take place every week, always on the same day and at the same time, for one year. During each meeting the participant weighs himself and he notes his weight down in his journal."
1676806|NCT01644474|Drug|Placebo (for Alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self--injection or by another designated person using the autoinjector.
1676807|NCT01644474|Drug|Placebo (for Ezetimibe)|One capsule orally once daily at approximately the same time of the day with or without food..
1676808|NCT01644461|Other|Autologous Human Platelet Lysate|All subjects will receive a single injection of Autologous Human Platelet Lysate in the nasolabial region
1676809|NCT01644448|Other|Autologous Human Platelet Lysate|Subjects will receive one dose of 5 ml of HPL with simultaneous micro-needling on day 2
1676772|NCT01644695|Procedure|Bony Anchoring Reinforcement System|Abdominal exposure was obtained via a lower horizontal incision, a vertical incision, or through a combination horizontal/vertical (ie fleur-di-lis) pattern. Exploratory laparotomy, lysis of intra-abdominal adhesions with hernia sac excision was performed prior to fascial closure. Primary closure of the abdominal fascia was performed with a combination of components separation and placement of biologic mesh over the fascial incision line in onlay fashion. Typically three bone anchors were used to secure the synthetic mesh at the pubic symphysis and two bone anchors to the ASIS bilaterally. The superior aspect of the marlex mesh was sutured to fascia avoiding any incorporation of the costal perichondrium. Quilting sutures were used to secure the mesh to the rest of the abdominal fascia.
1676773|NCT01644682|Other|IWFPL|Indoor house walls and floors will be plastered with lime (a traditional method known in the study areas) including treatment of outdoor breeding places with lime and bleaching powder to inhibit sandfly breeding
1676774|NCT01644682|Other|IDWL|Install durable wall lining containing deltamethrin to kill immature stage and as well as adult sand flies
1676775|NCT01644682|Other|ITN|Impregnation of existing bed-nets available in the community with slow release insecticide, deltamethrin
1676776|NCT01644669|Radiation|Intra-operative Radiation Therapy - IORT|Single dose of 20 Gy
1676777|NCT01644656|Device|ARFI ultrasound|ARFI imaging of the liver and spleen will be performed immediately before transjugular liver biopsy and HVPG procedures
1676778|NCT01644643|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
1676779|NCT01644643|Drug|Best Available Therapy|Patients randomized to receive Best Available Therapy will receive the best available standard of care (SOC) anti-infective therapy for their infection administered in accord with approved local label recommendation
1676780|NCT01644643|Drug|Metronidazole|Anti-infective, 500 mg (cIAI only) Patients randomized to receive CAZ-AVI for cIAI will also receive metronidazole (500 mg) administered by IV infusion in a volume of 100 mL at a constant rate over 60 minutes immediately following the CAZ-AVI infusion
1676781|NCT01644630|Procedure|Cemented crowns|"The final lithium disilicate crowns will be cemented with an adhesive cement after tightening the abutments with the torque indicated by the manufacturer and closing the screw access hole with white guttapercha. The abutment will be cleaned with ethanol. A retraction cord will be placed for cementation if indicated. The crown will be etched with hydrofluoric acid and subsequently silanized. A sufficient amount of cement will be filled in the crown without creating major excesses. When the crown is seated correctly, the cement will be light-cured for a few seconds to facilitate the removal of the now hard excess cement.
- Excess cement will be meticulously removed with a carbon scaler. The removal of all excess cement will be checked with an X-ray and by visual and tactile inspection."
1676782|NCT01644630|Procedure|Screw-retained crowns|The screw-retained crowns will be inserted and tightened with the torque indicated by the manufacturer. The screw access hole will to be closed with white guttapercha and a composite filling (Filtek, 3M ESPE).
1676783|NCT01644617|Drug|Placebo|Placebo rapidly dissolving tablets administered sublingually once daily
1676784|NCT01644617|Drug|MK-8237 6 DU|MK-8237 6 DU rapidly dissolving tablets administered sublingually once daily
1676785|NCT01644617|Drug|MK-8237 12 DU|MK-8237 12 DU rapidly dissolving tablets administered sublingually once daily
1676786|NCT01644604|Device|MDT-2211 Renal Denervation System|A percutaneous system that delivers radiofrequency (RF) energy through the luminal surface of the renal artery.
1676787|NCT01644591|Radiation|SRS|Lesions targeted with 20-24 Gy for 2 cm, 16-18 Gy for >2 to 2.5 cm, and 12-16 Gy for >2.5-3.5 cm on day 1.
1676788|NCT01644591|Behavioral|Cognitive Function Tests|7 cognitive function tests given at baseline and at 1, 4, 6, 9, and 12 months after Day 1 of radiation treatment.
1676789|NCT01644591|Behavioral|Questionnaires|3 questionnaires regarding quality of life and symptoms given at baseline and at 1, 4, 6, 9, and 12 months after Day 1 of radiation treatment. It should take about 40 minutes to complete the questionnaires.
1676790|NCT01644578|Procedure|Real-time imaging for MRI-guided procedures|Real-time imaging for improvement of workflow in MRI-guided procedures
1676794|NCT01644539|Dietary Supplement|Water with guar gum - Non Caloric|Infusion 500 ml of water with 3 gram of guar gum through a naso-gastric tube directly into stomach during a fMRI scan.
1676795|NCT01644539|Dietary Supplement|Chocolate milk - Oral Caloric|Ingestion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a tube in the mouth during a fmri scan.
1676796|NCT01644539|Dietary Supplement|Chocolate milk - Intra Gastric Caloric|Infusion of 500 ml of commercially available chocolate milk (Per 100mL; energy content of 354 kJ, 84 kcal, 3.5 g proteins, 12 g mono and disaccharide, 2.5 fat g, 0.5 g fibers) through a naso-gastric tube directly into stomach during a fMRI scan.
1676797|NCT01644526|Device|Hemoaccess Valve System|Device that allows blood to selectively flow into an arteriovenous graft to provide vascular access for dialysis then turn off the flow of blood to the graft in between dialysis sessions.
1676798|NCT01644500|Drug|Dulaglutide|Administered SC
1676799|NCT01644500|Drug|Glimepiride|Administered orally
1676800|NCT01644500|Drug|Placebo as Capsules|Placebo for glimepiride is administered orally as one to three capsules daily.
1676801|NCT01644500|Drug|Placebo as SC Injection|Placebo for dulaglutide is administered as one SC injection.
1676802|NCT01644487|Device|self-expanding nitinol stent|A group of patients who will undergo subsequent primary stenting following successful conventional balloon angioplasty
1676803|NCT01644487|Device|balloon angioplasty|A group of patients who will undergo routine conventional balloon angioplasty alone without stenting
1676804|NCT01644474|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
1676805|NCT01644474|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
1728224|NCT00021320|Drug|paclitaxel|
1676811|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive a single injection of Autologous Human Platelet Lysate for acne scarring
1676812|NCT01644435|Biological|Autologous Human Platelet Lysate|Subjects will receive two injections of Autologous Human Platelet Lysate at an interval of one month for acne scarring
1676813|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm A subjects will receive hair follicles transplants that are dipped in HPL before transplant
1676814|NCT01644422|Biological|Autologous Human Platelet Lysate|Study arm B subjects will receive hair follicles transplants that are dipped in HPL before transplant; followed by one HPL injection
1676815|NCT01644422|Other|Standard hair follicle transplant|Control arm subject will receive Standard hair follicle transplant
1676816|NCT01644396|Biological|Adalimumab|
1676817|NCT01644383|Behavioral|logotherapy|Logotherapy is therapy during which the interaction between the therapist and the client centres on the topic of meaning. The problems that the clients experience are presented to the client as inseparable parts of his everyday life. The client is then challenged to discover his/her meaning and to take responsibility in facing up to his/her problem. This approach is aimed at helping the client to deal and understand what his /her existences entail.
1676818|NCT01644370|Drug|HAART|as per Thai HIV Treatment guidelines
1676819|NCT01644357|Other|Pharmaceutical care|Pharmacist intervention, focused on the optimization of drug therapy, identification and resolution of drug related problems, resulting in best asthma control and quality of life. Pharmacists document their initial and monthly follow up encounters using a specified form. An action plan for self management of these patients was prepared and discussed aiming at early identification and treatment of an exacerbation episode. Meetings will be held weekly with intervention team to discuss action plan and measure of outcomes of all problems identified.
1676820|NCT01644344|Other|No-Xray|Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
1676821|NCT01644344|Other|Xray|
1676822|NCT01644331|Drug|Tolvaptan|IV furosemide plusTolvaptan (given at 0, 24 and 48 hours)
1676823|NCT01644331|Drug|Placebo|IV furosemide plus oral placebo (given at 0, 24 and 48 hours)
1676824|NCT01644292|Other|EPIC WheelS|EPIC WheelS is a user-centred program for wheelchair skills training that combines two structured 1-hour sessions with an expert trainer and four weeks of self-directed practice and training in the natural (home) environment.
1676825|NCT01644253|Biological|20 mg/kg TRU-016 + Rituximab|"TRU-016: 10 mg/kg for first dose, all subsequent doses 20 mg/kg, IV once weekly for 8 weeks followed by 4 monthly doses
Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV once weekly for 8 weeks followed by 4 monthly doses"
1676826|NCT01644253|Biological|10 mg/kg TRU-016 + Rituximab|"TRU-016: 6 mg/kg for first dose, all subsequent doses 10 mg/kg, IV on Day 1, 8 and 15, followed by 5 monthly doses
Rituximab: 375 mg/m2 for first dose, all subsequent doses 500 mg/m2, IV following TRU-016 schedule"
1676827|NCT01644253|Biological|TRU-016 20 mg/kg + Obinutuzumab|"TRU-016: 6 mg/kg on Day 1, 20 mg/kg on Day 8 and 15, then 20 mg/kg once a month for 5 months
Obinutuzumab: 100 mg on Day 1, 900 mg on Day 2, 1,000 mg on Day 8 and 15, then 1,000 mg once a month for 5 months"
1676828|NCT01644253|Biological|TRU-016 6-20 mg/kg + idelalisib + rituximab|TRU-016: 6 mg/kg on Days 15-36 weekly, 10 mg/kg on Days 43 and 50, then 20 mg/kg once a month for 5 months.
1676829|NCT01644253|Biological|TRU-016 10-20 mg/kg + ibrutinib|TRU-016: Dosed weekly for 8 weeks followed by 4 monthly intravenous (IV) infusions. The first dose will be 10 mg/kg and all subsequent doses will be 20 mg/kg.
1676830|NCT01644240|Drug|TD-8954|Intravenous infusion
1676831|NCT01644240|Drug|Placebo - saline|Intravenous infusion
1676832|NCT01644214|Other|6 month follow up for pessary check in the clinic setting|The standard of care is considered to be pessary checks every 3 months, therefore those that are checked every 6 months will be considered to be in the intervention group.
1676833|NCT01644201|Dietary Supplement|PolyGlycopleX® - PGX®|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
1676834|NCT01644201|Dietary Supplement|Rice Flour (placebo)|15g or 20g total daily dose, 5g pre-mixed with liquid meal replacement and consumed twice daily, 5g supplement granules sprinkled on food and consumed once of twice daily
1676835|NCT01644188|Drug|Alirocumab|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
1676836|NCT01644188|Drug|Placebo (for alirocumab)|1 mL subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using the autoinjector.
1676837|NCT01644188|Drug|Ezetimibe|One over-encapsulated tablet orally once daily at approximately the same time of the day with or without food.
1676838|NCT01644188|Drug|Placebo (for ezetimibe)|One capsule once daily orally at approximately the same time of the day with or without food.
1676839|NCT01644188|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose.
1676840|NCT01644175|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
1676841|NCT01644175|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a disposable auto-injector (also known as pre-filled pen).
1676842|NCT01644175|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
1676843|NCT01644162|Device|iVAPS ventilation|3 months of ventilation on iVAPS mode
1676844|NCT01644149|Device|Stratis Jet Injector|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
1676845|NCT01644149|Device|Needle and Syringe|Intramuscular administration of 0.5 mL of 2011-2012 Fluzone trivalent inactivated influenza vaccine
1676846|NCT01644149|Biological|2011-2012 Fluzone trivalent inactivated influenza vaccine|
1676847|NCT01644136|Procedure|robot-assisted laparoscopic surgery|Undergo standard robotic assisted laparoscopic prostatectomy
1676848|NCT01644136|Procedure|regional lymph node dissection|Undergo pelvic lymph node dissection
1676849|NCT01644136|Device|microsphere-mediated lymphocele prevention|Undergo microsphere-mediated lymphocele prevention
1676850|NCT01644110|Drug|INCB018424/CC-4047|For all patients the starting dose of ruxolitinib in this trial is 10mg twice daily po; pomalidomide will be administered at a permanent dose of 0.5 mg po once daily.
1676851|NCT01644097|Dietary Supplement|Lactobacillus plantarum strain 299v|Given PO
1676852|NCT01644097|Dietary Supplement|Lactobacillus acidophilus probiotic|Given PO
1676853|NCT01644097|Dietary Supplement|placebo|Given PO
1676854|NCT01644097|Other|laboratory biomarker analysis|Correlative studies
1676855|NCT01644097|Other|questionnaire administration|Ancillary studies
1676856|NCT01644097|Procedure|quality-of-life assessment|Ancillary studies
1676857|NCT01644097|Dietary Supplement|Bifidobacterium lactis probiotic supplement|Given PO
1676858|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
1676859|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
1676860|NCT01644084|Drug|Hydroxyethyl starch 130/0.4|Hydroxyethyl starch 130/0.4 as a priming of cardiopulmonary bypass circuit and/or as a fluid after cardiopulmonary bypass
1676861|NCT01644071|Drug|cipralex|one time 10 mg, tablet
1676862|NCT01644058|Procedure|Immediate loading|
1676863|NCT01644045|Device|Teleconsultation|Teleconsultation for the EMS in acute respiratory emergencies
1676864|NCT01644032|Other|Teleconsultation|Teleconsultation between paramedics and an EMS physician
1676865|NCT01644019|Procedure|Teleconsultation|Teleconsultation of an EMS physician in cases of suspected acute stroke
1676866|NCT01644006|Procedure|Teleconsultation|Teleconsultation of an EMS physician to support the paramedics in acute coronary syndromes
1676867|NCT01643993|Other|hCG at the Time of Embryo Transfer|hCG will be included in the 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
1676868|NCT01643993|Other|Control|Patients will have 20 microliters of media inserted during a mock embryo transfer immediately prior to actual embryo transfer.
1676869|NCT01643980|Drug|Vaginal micronized progesterone|200 mg vaginal route per day
1676870|NCT01643980|Device|Cervical pessary|Cervical pessary certified by European Conformity (CE0482, MED/CERT ISO 9003/EN 46003;Dr Arabin, lower larger diameter 70 mm, height 30 mm,and upper smaller diameter 32 mm)
1676871|NCT01643967|Other|sunflower oil|The research subjects allocated to this treatment arm will receive Sunflower Oil supplied by Philozon. Sunflower oil should be applied once daily for 60 days, it immediately after cleansing site where the lesion is present.
1676872|NCT01643967|Other|Ozone Therapy|The research subject will receive topical and rectal insufflation of ozone three times a week on alternate days for two months or at least 12 sessions.
1676873|NCT01643954|Procedure|robotic radical prostatectomy|robotic assisted surgery
1676874|NCT01643941|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
1676875|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
1676876|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
1676877|NCT01643941|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
1676878|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
1676879|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
1676880|NCT01643941|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
1676881|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
1676882|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
1676883|NCT01643941|Biological|SA3Ag vaccine|Phase 2 only: Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA3Ag vaccine.
1676884|NCT01643941|Procedure|Blood sample|Blood for immunogenicity will be collected from all subjects at various timepoints.
1676885|NCT01643941|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various timepoints.
1676886|NCT01643941|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of placebo which contains excipients of the vaccine formulation minus the active ingredients.
1676887|NCT01643941|Procedure|Blood draw|Blood for HIV, HBV and HCV screening will be collected prior to enrollment for Phase 1 subjects. Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
1676888|NCT01643941|Procedure|Colonization swab samples|Colonization swabs will be collected from all subjects at various timepoints.
1676889|NCT01643928|Biological|Rituximab-Pfizer (PF-05280586) x 3 courses|1000 mg intravenous infusion [IV] on Days 1 and 15 of each 24 week treatment course for up to 3 treatment courses
1676993|NCT01643135|Drug|tranexamic acid|Transamine acts as antifibrinolysis which looks alike 0.9% NaCl (placebo)
1676994|NCT01643135|Drug|0.9% NaCl|0.9% NaCL (NSS) is clear fluid which looks alike tranexamic acid
1676890|NCT01643928|Biological|Rituximab-EU+ Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-EU x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-EU on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
1676891|NCT01643928|Biological|Rituximab-US + Rituximab-Pfizer x 2 Courses|Subjects will receive Rituximab-US x 1 course followed by Rituximab-Pfizer x 2 courses. 1000 mg IV infusion of Rituximab-US on Days 1 and 15 of a 24 week treatment course followed by 1000 mg IV infusion of PF-05280586 on Days 1 and 15 of each 24 week course for up to 2 additional treatment courses
1676892|NCT01643915|Behavioral|No distraction method|Patients with conventional treatment. No distraction method during the treatment visits.
1676893|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film in a screen attached to the ceiling, just above the dental chair during the second treatment visit.
1676894|NCT01643915|Behavioral|Distraction method|Patients will see a cartoon film with with Rimax® multimedia eyeglasses that occlude the environment partially during the second treatment visit.
1676895|NCT01643902|Drug|tPA|IV tPA 0.9 mg/kg maximum of 90 mg. Administered by standard protocol. 10% of the dose by intravenous bolus injection, followed by infusion of the remainder over an hour. Treatment will be initiated within 4.5 hours of awakening with preferred target door to needle time of 60 minutes or less from ED arrival.
1676896|NCT01643889|Drug|Treatment A (domperidone 10 mg)|1 domperidone 10 mg capsule four times a day (q.i.d.) + 1 domperidone placebo capsule q.i.d. on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
1676897|NCT01643889|Drug|Treatment B (domperidone 20 mg)|2 domperidone 10 mg capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
1676898|NCT01643889|Drug|Treatment C (placebo)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin placebo capsule in the morning of Day 1.
1676899|NCT01643889|Drug|Treatment D (moxifloxacin)|2 domperidone placebo capsules four times a day (q.i.d.) on Days 1 to 3 and a single dose on Day 4 (13 doses in total), and 1 moxifloxacin 400 mg capsule in the morning of Day 1.
1676900|NCT01643876|Behavioral|Palatal brushing|Participants will be instructed to brush their palate with a manual soft-bristle brush after each meal and before sleeping for a period of 3 months. They will be asked to keep to their usual oral and denture hygiene routine during the trial to allow the isolation of the effect of palatal brushing.
1676901|NCT01643850|Drug|MCS110|Patients will receive up to 6 doses of MCS110 (3 or 5 or 10mg/kg) administered intravenously once every 4 weeks. Before each dosing, safety will be assessed.
1676902|NCT01643850|Drug|Placebo|Participants will receive a single dose of NaCl on day 1 through intravenous infusion.
1676903|NCT01643837|Other|Osteopathic Manipulative Treatment|OMT - Sacral Ligamenotus Articular Release; OMT - Lumbar Spine (L1-L2) and Lower Thoracic Spine (T10-12) Ligamentous Articular Release; OMT - Upper Thoracic Spine Ligamentous Articular Release (T1-T8); OMT - Cervical Spine Ligamentous Articular Release (C5-C7); OMT - Suboccipital Myofascial Release; OMT - Clavicular Ligamentous Articular Release; OMT - First Rib Ligamentous Articular Release; OMT - Ribs 2-8 Ligamentous Articular Release; OMT - Pectoral Pull; OMT - Sternal Ligamentous Articular Release; OMT - Direct Myofascial Release of the Diaphragm; OMT - Thoracic Lymphatic Pump; OMT - Fascial Release of Breast Tissue
1676904|NCT01643837|Other|Osteopathic Manipulative Light Touch Protocol (LT)|LT - Sacral Region; LT - Lumbar Spine and Lower Thoracic Region; LT - Upper Thoracic Spine Region; LT - Cervical Spine Region; LT - Suboccipital Region; LT - Clavicles; LT - First Ribs; LT - Ribs 2-8; LT - Pectoralis Muscles; LT - Sternum; LT - Respiratory Diaphragm; LT - Upper Thoracic Cage; LT - Lower Thoracic Cage
1676905|NCT01643824|Radiation|Proton Beam Therapy|"- Prescription dose to PTV as according to the following dose escalation schema: Arml 1: 60 GyE /10 fx, 6GyE fraction dose, 5 days/week, for HCC free from the alimentary tract (i.e., stomach, duodenum, esophagus, small and large bowel) (more than 2cm from clinical target volume), TLV30 <40%, and/or RLV30 <30%) Arm 2: 50 GyE /10 fx, 5GyE fraction dose, 5 days/week, for HCC close to the alimentary tract (less than 2cm from clinical target volume) but not contact with the alimentary tract, TLV30<50% and RLV30<40% Arm 3: 35 GyE /10 fx, 4GyE fraction dose, 5 days/week, for HCC contact to the alimentary tract (contact with clinical target volume), TLV30<60%, and/or RLV30<50%
- Dose prescription : 95% isodose volume of prescribed dose encompassed PTV"
1676906|NCT01643811|Procedure|gastrectomy|subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy
1676907|NCT01643811|Procedure|Endoscopic submucosal dissection|endoscopic submucosal dissection
1676908|NCT01643798|Procedure|Sham rTMS|The eSham system was implemented in conjunction with a specialized Neuronetics sham TMS coil. This coil has a metal plate hidden inside of it that blocks the magnetic field from affecting the brain. Scalp electrodes were used to mimic the feel of real rTMS. This approach has been validated in previous studies.
1676909|NCT01643798|Procedure|Real rTMS|An iron-core, solid-state figure-of-8 coil was used to stimulate the dorsolateral prefrontal cortex. The site of stimulation was estimated using the Beam F3 method based on the 10-20 EEG system.
1676910|NCT01643785|Drug|Second-line quadruple therapy with endonase|Compare Second-line quadruple therapy w/o pronase (endonase)
1676911|NCT01643772|Drug|OxyNorm® Capsules (Oxycodone Hydrochloride)|The subjects will be randomized to receive either a single dose of OxyNorm® Capsules 5, 10, 20mg, or multiple-dose OxyNorm® Capsules 10 mg for 13 times.
1676912|NCT01643759|Drug|buprenorphine|The subjects will be randomized to receive either a single dose of BTDS 5, or BTDS 10, or BTDS 20 for 7 days. Plasma concentrations of buprenorphine and norbuprenorphine will be analyzed to determine the following pharmacokinetic parameters: AUC0-t:pg•hr/ml-Area under the plasma concentration-time curve frame: predose,6,12,24,36,48,60,72,96,120,144,168,169,170,171,172,174,180,192,216,240 hours post-dose.AUC0-inf:pg•hr/ml-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: pg/ml-Maximum observed plasma buprenorphine concentration. Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of buprenorphine elimination.
1676913|NCT01643746|Device|Supera Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
1676914|NCT01643746|Device|Life Stent|Angioplasty and stenting will performed according to the guidelines of the Society of Interventional Radiology and the instruction for use for each stent. Patients will be allocated to Supera stent versus LifeStent based on block randomization (block size 4 patients).
1676915|NCT01643733|Device|Using Flow measurements to guide fistula angioplasty (Transonics)|Transonics flow measurements in the fistula would be used to guide the fistula intervention
1676916|NCT01643707|Behavioral|Evidence based guidelines and tools|Education, guidelines, tools
1676917|NCT01643694|Behavioral|Electronic intervention suggesting behavioral activity|3.6 Those randomized to the intervention will be asked to choose 1 self-directed activity from an electronically provided list sent to them weekly for 10 consecutive weeks. Each activity will take less than 5 minutes to complete. They will also answer 3-5 questions weekly (items taken from the survey items list submitted).
1676918|NCT01643681|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into lumbar intervertebral disc infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4x10e7 cells/1mL
1676919|NCT01643668|Drug|Busulfan|Busulfan as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
1676920|NCT01643668|Drug|Clofarabine|Clofarabine as part of reduced intensity conditioning prior to allogeneic stem cell transplantation
1676921|NCT01643668|Procedure|Allogeneic Stem Cell Infusion|Allogeneic stem cell transplantation after reduced intensity conditioning with busulfan / clofarabine chemotherapy
1676922|NCT01643655|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Into the Femoral Head infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e8 cells/3mL
1676923|NCT01643642|Other|Cognitive behavioral treatment/farmacotherapy intervention|Brief cognitive behavioral intervention/farmacotherapy; intake, treatment and ROM
1676924|NCT01643642|Other|Treatment As Usual|Other: Treatment As Usual
1676925|NCT01643629|Biological|Autologous Human Platelet Lysate (HPL)|Study arm A will include subjects receiving three doses of Autologous Human Platelet Lysate at an interval of one month each.
1676926|NCT01643629|Other|2 % Minoxidil and /or Finasteride|Control arm B subjects will receive Standard therapy (2% Minoxidil and/or Finasteride)
1676927|NCT01643616|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
1676928|NCT01643616|Drug|Prilocaine 1%|20ml Prilocaine 1% for distal sciatic nerve block (30ml Prilocaine 1% in outpatients)
1676929|NCT01643616|Drug|Ropivacaine 0.75%|10ml Ropivacaine 0.75% for distal sciatic nerve block (not in outpatients)
1676930|NCT01643616|Drug|Prilocaine 1%|10ml Prilocaine 1% for saphenous nerve block
1676931|NCT01643616|Device|ultrasound guidance|In group US the sciatic nerve localization and needle guidance is realized using ultrasound.
1676932|NCT01643616|Device|nerve stimulation technique|In the group NS sciatic nerve localization and needle guidance is realized using nerve stimulation technique. However, ultrasound is used observing (Observer) the procedure, but blinded for the physician (Anesthetist) performing the block.
1676933|NCT01643603|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
1676934|NCT01643603|Other|laboratory biomarker analysis|Correlative studies
1676935|NCT01643590|Biological|JVS-100 15 mg dose Injection|Intramyocardial Injection
1676936|NCT01643590|Biological|Placebo Injection|Intramyocardial Injection
1676937|NCT01643590|Biological|JVS-100 30 mg dose injection|Intramyocardial Injection
1676938|NCT01643577|Procedure|Acupuncture for gastroparesis|A series of acupuncture points selected for the treatment of gastroparesis will be used at each of the 10 acupuncture sessions
1676939|NCT01643577|Procedure|Acupuncture for musculoskeletal pain|Acupuncture points selected for the treatment of musculoskeletal pain will be used during each of the 10 acupuncture sessions
1676940|NCT01643538|Behavioral|Financial incentive|Participants will receive a direct financial incentive in the amount of $20 for each week when their daily pedometer step count equals or exceeds their goal at least 5 out of 7 days.
1676941|NCT01643538|Behavioral|Social Goal|Participants will be asked to identify a charity to which they would like to donate the payment for reaching their walking goal. Each week they will be asked to designate which charity should receive a donation if they meet or exceed their goal. If they meet the goal, they will be notified that a donation of $20 in their name has been sent to the charity.
1676942|NCT01643538|Behavioral|Personal financial incentives & social goals|Participants will be able to allocate their reward for reaching their walking goal: the $20 reward can be divided between personal financial incentive and a charitable donation. Each week, the participant will be asked to choose whether to keep, give, or split the reward, if they meet or exceed their goal. If they choose to send some of the money to charity, they will be asked to identify a charity to which they would like to donate the payment. If they meet their goal, they will be notified by email or mail (based on their preference), that a donation of the selected amount has been sent to the charity.
1676943|NCT01643538|Behavioral|daily pedometer use and weekly feedback|Daily use of pedometer for 5 months. Walking goal set based on level of walking during 2-week run-in period. Weekly feedback provided on meeting walking goal - defined as achieving goal number of steps for 5 of 7 days per week.
1676944|NCT01643525|Device|Nautilus NeuroWaveTM System|Non-invasive device designed to detect pressure signals from the skull to aid in the diagnosis of ischemic stroke.
1676950|NCT01643486|Other|iTouch phosphate counting program|After developing and pilot testing the iTouch phosphate counting program, the participants in the intervention arm will enter their meal into the program; the required number of phosphate binders will be calculated for the patient
1676951|NCT01643486|Other|Usual Care|The patients randomized to the usual care arm will continue to receive the usual dietary counselling and will input meal data into the iTouch program but no recommendations for the number of phosphate binders to be taken with the meal will be provided
1677054|NCT01642667|Drug|Prourokinase|a bolus of 1.2 million IU and an infusion of 4.8 million IU in 60 min.
1677055|NCT01642667|Drug|Placebo|
1676952|NCT01643473|Behavioral|Adherence Intervention|Patients randomized to the AI group will participate in 9 sessions with bilingual Health Coaches who will utilize a culturally tailored adherence checklist to identify patient's specific medication adherence barriers. Based on the patient's responses, the Health Coach will then engage in targeted patient-centered counseling to assist patients in developing individualized self-monitoring strategies to overcome these barriers and improve adherence behaviors.
1676953|NCT01643460|Procedure|98% Ethanol & Paclitaxel injection|Pancreatic cyst injection via Endoscopic Ultrasound (EUS)of 98% Ethanol with Paclitaxel (dose determined in relation to cyst size & amount of fluid aspirated from the cyst.
1676954|NCT01643447|Drug|Ulinastatin|Ulinastatin Preventing Postoperative Hepatic Failure in Hepatocellular carcinoma (HCC)
1676955|NCT01643447|Drug|Diammonium glycyrrhizinate|
1676956|NCT01643434|Drug|Spironolactone|Spironolactone (titrating dose from 12.5 to 50mg SID)
1676957|NCT01643434|Drug|Clonidine|Clonidine (titrating dose from 0.100-0.300mg BID)
1676958|NCT01643421|Other|Deep inspiration and positive expiratory airway pressure|It was used a device the combines deep inspiration and positive expiratory airway pressure in asthmatic subjects, for 5 weeks, twice a day.
1676959|NCT01643408|Drug|asparaginase Erwinia chrysanthemi|
1676960|NCT01643395|Other|vertebroplasty|Vertebroplasty consists in the injection of cement (PMMA) in the damaged vertebral body to prevent further collapse
1676961|NCT01643395|Other|conservative therapy|The study is a prospective, randomized trial comparing conservative treatment (brace) and vertebroplasty in acute (less than 15 days after trauma) traumatic vertebral compression fracture (VCF) type A according Magerl classification.
1676962|NCT01643382|Drug|Insulin|Insulin will be given in a continuous low dose infusion. The infusion will be adjusted based on the patient's blood sugar with the goal of keeping the level between 100-140 mg/dL
1676963|NCT01643382|Drug|Insulin, Asp(B28)-|Insulin will be given through subcutaneous injection every few hours based on the patient's blood sugar level.
1676964|NCT01643369|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
1676965|NCT01643369|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
1676966|NCT01643369|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
1676967|NCT01643356|Behavioral|Intervention to reduce excess weight gain during pregnancy|Intervention includes meetings with a nutrition counselor and/or psychologist where individualized eating plans will be developed and reviewed, and regular group meetings during which information about healthy eating for weight management will be discussed.
1676968|NCT01643330|Genetic|AAV1/SERCA2a (MYDICAR)|Single intracoronary infusion 1 x 10^13 DNase Resistant Particles (DRP) MYDICAR
1676969|NCT01643330|Genetic|Placebo|Single intracoronary infusion
1676970|NCT01643304|Behavioral|No drug|No drug intervention. The intervention is a questionnaire with quality of life and perception of menstrual bleedings. All subjects will complete both questionnaires.
1676971|NCT01643291|Procedure|Ultrasound|Ultrasound guidance for difficult lumbar punctures in the leukemic pediatric population.
1676972|NCT01643278|Drug|Dasatinib|Given PO
1676973|NCT01643278|Biological|Ipilimumab|Given IV
1676974|NCT01643278|Other|Laboratory Biomarker Analysis|Correlative studies
1676975|NCT01643278|Other|Pharmacological Study|Correlative studies
1676976|NCT01643265|Dietary Supplement|Whey Milk Protein|20 grams of Whey Milk Protein
1676977|NCT01643265|Dietary Supplement|Bovine Albumin Concentrate|20 grams of Bovine Albumin Concentrate
1676978|NCT01643252|Drug|riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
1676979|NCT01643252|Drug|placebo: 0.0% riboflavin ophthalmic solution with the KXL system|Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm^2 for 4 minutes
1676980|NCT01643239|Other|Hospital-based mCIT restraint of the unaffected arm and practice of the affected arm|the mCIT group with individualized intervention
1676981|NCT01643239|Other|Hospital-based mCIT|the mCIT group with individualized intervention
1676982|NCT01643239|Other|Hospital-based TR|OT or PT or therapist-based training
1676983|NCT01643226|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
1676984|NCT01643226|Drug|placebo solution|0.0% riboflavin ophthalmic solution
1676985|NCT01643226|Device|KXL System|30 mW/cm2
1676986|NCT01643213|Device|Non Boston Scientific SCS Trial Therapy|No procedures will be attempted as part of this study. This intervention refers to connection and activation of a previously implanted and programmed FDA-approved non Boston Scientific SCS trial system for 30 minutes of SCS therapy for pain
1676987|NCT01643213|Device|BSC approved SCS Trial Therapy w/ OMG|No procedures will be attempted as part of this study. This intervention refers to connection and activation of all Boston Scientific commercially approved SCS trial systems for 30 minutes of SCS therapy for pain
1676988|NCT01643200|Device|Zotarolimus-Eluting Peripheral Stent System|Various lengths and diameters of the Zotarolimus-Eluting Peripheral Stent System
1676989|NCT01643187|Dietary Supplement|Beverage fortified with 21 vitamins and minerals|The serving contains 4 grs. of protein, 12 grs. of carbohydrate, 1 gr of fat 9 mg of zinc, 12.5 mg iron, 160 µg of folic acid, 90 µg of iodine, 250 mg of vitamin A, 40 mg of vitamin C, 0.5 mg of vitamin B6, 0.9 µg of vitamin B12, 6 mg of niacin, 0.5 mg of vitamin B2, 0.5 mg of vitamin B1, 0.3 mg of copper, 5 mg of vitamin D3, 5 mg of vitamin E, 200 mg ofcalcium, 150 mg of phosphorous, 40 mg of magnesium, 17 µg of selenium, 0.17 µg of manganese, 1.8 mg of pantothenic acid and 8 µg of biotin.
1676990|NCT01643187|Dietary Supplement|Lactose-free milk|Serving contains 4 grs. of protein, 12 grs of carbohydrate and 1 gr of fat
1676991|NCT01643161|Behavioral|Treatment As Usual|Communicating the diagnosis to the patient's primary care doctor and neurologist. May include referrals for physical therapy or psychiatric evaluations, or referrals to community therapists or doctors.
1676992|NCT01643161|Behavioral|Guided Self-Help|A self-help workbook based on cognitive behavioral therapy, and four half-hour guidance sessions over a three-month period.
1678009|NCT01635413|Other|Laboratory Biomarker Analysis|Correlative studies
1676995|NCT01643122|Other|No drug|Patients with expected stable endometriosis management status (EMS), i.e. patients who have not planned a change in endometriosis treatment or a therapeutic surgical procedure in the next 12 weeks and have had no change in endometriosis treatment or therapeutic surgical procedure in the previous 4 weeks.lease specify as free-text; for drugs include daily dose, dosage form dosage frequency and duration (if appl. and possible for the OS/NIS).
1676996|NCT01643122|Other|No drug|Patients with expected change in endometriosis management status (EMS), i.e. patients who have planned a change in endometriosis treatment or a therapeutic surgical procedure during the next 12 weeks or have undergone a change in endometriosis treatment or a therapeutic surgical procedure in the previous 4 weeks.
1676997|NCT01643109|Other|Casting & CIMT|"A standardized CIMT protocol will be administered over a three week period. The first week will consist of wearing a below elbow cast on the non-hemiplegic limb followed by a two week CIMT camp (5 hours per day, 5 days per week) where the child/youth wears a constraint splint on the non-hemiplegic hand. The two week camp will follow a standardized CIMT camp protocol (Hand2Hand developed at HBKRH) that includes activities that focus on unilateral hemiplegic hand activity in the first week and increasing incorporation of bilateral hand activities in the second week. The camp protocol for CIMT is based on camp protocols utilized successfully in other paediatric research studies."
1676998|NCT01643096|Other|Zataria multiflora Boiss|Thermic effect of food of Zataria multiflora Boiss and comparison between hot and cold temperament people
1676999|NCT01643096|Other|Sumac|Thermic effect of food of Sumac and comparison between hot and cold temperament people
1677000|NCT01643083|Drug|Rifaximin|Rifaximin 400mg tid for 2 wk
1677001|NCT01643083|Drug|Placebo|Placebo for 2 week
1677002|NCT01643070|Drug|Capecitabine, Oxaliplatin|Induction chemotherapy - Capecitabine (1250 mg/m2 PO twice daily on D1-14 and oxaliplatin 130 mg/m2 on D1, every 3 weeks for 2 cycles) Preoperative chemoradiotherapy - Capecitabine 825 mg/m2 PO twice daily during radiotherapy and oxaliplatin 50 mg/m2/day on weekly.
1677003|NCT01643070|Radiation|Radiotherapy|Preoperative radiotherapy, 5040 cGy with 28 fractions
1677004|NCT01643057|Device|Stochastic Resonance Mattress|The infant's isolette mattress will be replaced with a specially designed mattress (non-commercially available, designed by engineers at the Wyss Institute, Harvard University) to provide gentle vibrations and sounds during mattress stimulations.
1677005|NCT01643044|Behavioral|Nutrition time control/placebo intervention|This time-control intervention, designed in part to help promote research assistant blinding as to participant condition, focused on proper infant nutrition using a computer-delivered, interactive format and videos.
1677006|NCT01643044|Behavioral|Computer-delivered, brief intervention on alcohol use|A single 20-minute interactive computer-delivered intervention designed to promote motivation to change prenatal alcohol use, without presuming the participant to be currently using alcohol while pregnant.
1677007|NCT01643031|Drug|Ticagrelor|Ticagrelor will be given (to patients with low response to clopidogrel randomized to the Ticagrelor group) at a dose of 180 mg given 1-2 hours before the coronary angiography, followed by 90 mg twice a day for 30 days after the PCI. After 30 days the patient's treatment will be switched back to clopidogrel (to complete 1 year of treatment).
1677008|NCT01643031|Drug|Continued clopidogrel|Patients with low response to clopidogrel randomized to continued clopidogrel treatment will be given an additional 300 mg of clopidogrel loading 1-2 hours before coronary angiography (in addition to the previous 300 mg load or chronic clopidogrel therapy the patient received), followed by 75 mg a day for 1 year after the PCI
1677009|NCT01643018|Procedure|laparoscopic surgery|In laparoscopy group three trocars is used. The first is 10 mm and inserted within the umbilicus for telescop, the second is 10 mm and inserted just below the xiphoid process, and third is 5 mm and inserted at the right upper quadrant of the abdomen.
1677010|NCT01643018|Procedure|open surgery|-open surgery group describes the patients treated with traditional open surgery. In open surgery group a right subcostal incision is used.
1677011|NCT01643005|Behavioral|Relationship Strengthening HIV Prevention Intervention|The relationship strengthening HIV intervention will build on the structure of the Nurturing Parenting Groups and will be integrated so that participants will receive the Nurturing Parenting Groups plus the relationship strengthening HIV intervention.
1677012|NCT01643005|Behavioral|Parenting Program Intervention|Nurturing Parenting curriculum delivered in a group format.
1677013|NCT01642979|Drug|Levamisole+cyclosporin A+Glucocorticoids|Levamisole 2.5mg/kg every other day cyclosporin A 1.5-2.5mg/kg every other day Glucocorticoids0.5-1mg/kg every day(prednisone)
1677014|NCT01642979|Drug|cyclosporin A+Glucocorticoids|cyclosporin A 1.5-2.5mg/kg every day Glucocorticoids0.5-1mg/kg every day(prednisone)
1677015|NCT01642979|Drug|Glucocorticoids|Glucocorticoids 0.5-1mg/kg every day(prednisone)
1677016|NCT01642966|Drug|Prasugrel|Prasugrel 10mg/day for 15 days
1677017|NCT01642966|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
1677018|NCT01642953|Dietary Supplement|Early recovery|The patients are started on sips of water on the first postoperative day. If they are tolerable, a liquid diet is started on the second postoperative day, and a soft diet on a third postoperative day for them. We have a plan to discharge the patients on the fourth postoperative day if they exhibit at least three times soft diet without specific complaint and had normal clinical status and physical examination.
1677019|NCT01642940|Drug|Prasugrel|Prasugrel 10mg/day
1677020|NCT01642940|Drug|Ticagrelor|Ticagrelor 90mg twice a day
1677021|NCT01642914|Drug|Linaclotide 290 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
1677022|NCT01642914|Drug|Linaclotide 145 micrograms|oral capsule, taken once daily each morning at least 30 minutes before breakfast
1677023|NCT01642914|Drug|Matching placebo|oral capsule, taken once daily each morning at least 30 minutes before breakfast
1677024|NCT01642901|Drug|Zoledronic acid|5 mg zoledronic acid infused intravenously over two hours (2.5mg per hour), given only once, within 21 days of acute traumatic spinal cord injury.
1677025|NCT01642901|Drug|normal saline 0.9%|Infusion of equivalent volume of 0.9% normal saline to that of the reconstituted zoledronic acid, given only once over two hours, occurring within 21 days of acute traumatic spinal cord injury
1677026|NCT01642888|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
1678010|NCT01635413|Other|Questionnaire Administration|Ancillary studies
1677027|NCT01642888|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
1677028|NCT01642875|Other|Enteral nutrition|Standard enteral diet is administered through a nasojejunal tube. Enteral nutrition is started on the 1st postoperative day and increased daily by 20-40 ml up to the estimated level.
1677029|NCT01642875|Other|Oral nutrition|Oral diet is started from the 2nd postoperative day and oral intake is advanced as tolerated
1677030|NCT01642862|Drug|Simvastatin|Comparison of pharmacokinetic parameters of different formulations (liquid vs tablet) and doses (20 or 40 mg) of simvastatin after single oral administration of the drug
1677031|NCT01642849|Dietary Supplement|high protein diet|6 months on HP diet
1677032|NCT01642849|Dietary Supplement|high carbohydrate diet|12 subjects will be placed on a hig carbohydrate diet for 6 months
1677033|NCT01642836|Behavioral|MMM|"a theory-based community team sports program designed specifically for overweight and obese children,
a home-based family intervention to reduce screen time, alter the home food/eating environment, and promote self-regulatory skills for eating and activity behavior change, and
a primary care provider behavioral counseling intervention linked to the community and home interventions."
1677034|NCT01642836|Behavioral|Health and Nutrition Education|"Enhanced standard care/health and nutrition education intervention:
notification of primary care providers about metabolic measures and blood pressure
state-of-the-art information-based health and nutrition education, including semi-annual home counseling visits, monthly health education newsletters for children and for parents/guardians, and a series of quarterly, community-based evening health lectures and Family Fun Nights"
1677035|NCT01642810|Behavioral|Acceptance-based behavioural therapy|Behavioral intervention focusing on acceptance, mindfulness and values-based living instead of focus on symptom control
1677036|NCT01642810|Other|Will vary per participant|Participants will continue pre-study treatment under their current licensed practitioners. Intervention may include drug treatment, physical therapy, or other
1677037|NCT01642797|Device|Confocal laser endomicroscopy (Pentax, EG3870K)|Confocal laser endomicroscopy with Targeted Biopsy
1677038|NCT01642797|Device|Standard White-light endoscopy (Pentax, 90i)|Standard White-light endoscopy with Standard Biopsy
1677039|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)|Primary PCI of culprit lesion in IRA with drug eluting stent (DES)
1677040|NCT01642784|Device|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES|Primary PCI of culprit lesion in IRA with drug eluting stent (DES) and PCI of the other critical lesion in IRA with another DES
1677041|NCT01642771|Drug|5-Fu/epirubicin/CTX following Docetaxel|Cycle 1-3: Docetaxel i.v. 75mg/m2 (One cycle = 21 days); Cycle 4-6: Fluorouracil i.v. 500 mg/m2, Epirubicin i.v. 75 mg/m2, Cyclophosphamide i.v. 500 mg/m2 (One cycle = 21 days)
1677042|NCT01642771|Drug|Docetaxel/capecitabine followed by XEC|Cycle 1-3: Docetaxel i.v. 75 mg/m2, Capecitabine, p.o., 1000 mg/m2，b.i.d (take Capecitabine for 2 weeks and withdraw for 1 week) (One cycle = 21 days); Cycle 4-6: Capecitabine, i.v. 1000 mg/m2, b.i.d (take for 2 weeks and withdraw for 1 week),Epirubicin, i.v. 75 mg/m2, Cyclophosphamide, i.v. 500 mg/m2 (One cycle = 21 days)
1677043|NCT01642758|Drug|Sodium 2,2 dimethylbutyrate|Oral capsules, dose 20 mg/kg/day, once per day for 26 weeks
1677044|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL
1677045|NCT01642745|Drug|Mannitol (Aridol)|single deep inhalation of dry powder per dose doses range from 0mg - 160mg (cumulative dose range 0mg-635mg).
1677046|NCT01642745|Drug|Methacholine (Provocholine)|two minutes of aerosol inhalation of concentrations of methacholine ranging from 0.03 - 256mg/mL every 20 seconds a deep inhalation is performed
1677047|NCT01642732|Other|Everolimus, lupron, bicalutamide, and radiation|"Everolimus - there are five dose levels (2.5mg. every 48 hrs.,2.5mg./day, 5mg./day, 7.5mg./day, and 10mg./day) based on the initial expectations of toxicity and the incidence of toxicity of subjects already treated. Subjects will be on one dose level throughout the study. Subjects will receive everolimus starting on study day 1.
Radiation therapy will start on day 60-70 (44 treatments, at 5 treatments a week for a little longer than 8 weeks).
Bicalutamide (50 mg. tablets daily) will begin on study day 10-14, approximately 2 months prior to Radiation Therapy.
Lupron injections will begin on study day 15 to 25, approximately 2 months prior to Radiation Therapy. The typical dose schedule is either one injection (22.5 mg. dose)every 3 months for a total of 8 injections or one injection (30 mg. dose) every 4 months for a total of 6 injections.
Radiation, bicalutamide, and everolimus will end between study day 120-130. Lupron will end at 24 months on study."
1677048|NCT01642719|Behavioral|Sleep restriction|Participants will be asked to reduce their time in bed (TIB) by 60 min below their median baseline TIB, and to maintain this sleep restriction every night for 12 weeks.
1677049|NCT01642719|Behavioral|Non-sleep restriction|Participants will be asked to maintain fixed bedtimes, wake-times, times in bed, and napping, consistent with each person's average baseline.
1677050|NCT01642693|Radiation|Low power laser in teeth after intrusive movement|Low power laser was aplied to premolar teeth under an intrusive movement to study histological changes and root resorption
1677051|NCT01642693|Other|Simulated laser in teeth with intrusive movements|Simulated laser in teeth with intrusive movements for histological and root resorption changes
1677052|NCT01642680|Other|A tailored physical activity program during chemotherapy|The early group will start the PA program during chemotherapy for 3 months, and after completion of chemotherapy for 3 months (total 6 months). The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
1677053|NCT01642680|Other|A tailored physical activity program after chemotherapy|The late group will start the PA program after completion of the chemotherapy for 6 months. The PA program will consist of two components: improvement of physical fitness and empowerment to adopt a healthy lifestyle. Longitudinal effects of this PA program will be evaluated at 5 time points: before chemotherapy; at start of the PA program and at 3, 6 and 18 months after start of the PA program. Safety parameters will be monitored throughout the study period.
1678011|NCT01635413|Other|Survey Administration|Ancillary studies
1677056|NCT01642654|Other|Exercise|The WG was submitted to a 16-week WEP, with combined aerobic and resistance exercises in three weekly sessions. Water temperature was approximately 30º C with an average ambient temperature of 34° C. The pool had water levels ranging between 1,20 and 1,40 meters deep.
1677057|NCT01642654|Other|Educational lectures|Educational lectures
1677058|NCT01642641|Procedure|Non-surgical Subgingival Debridement (SD)|SD is a conservative non-surgical procedure aimed at reducing dental plaque and calculus from the tooth root usually under local anaesthesia.
1677059|NCT01642641|Procedure|Simplified Papilla Preservation Flap|The simplified papilla preservation flap is a novel conservative surgical procedure aimed at the preservation of the tissues between the teeth. It has been shown to significantly reduce pocket depth and has faster re-vascularisation of the flap, when compared with other procedures.
1677060|NCT01642641|Procedure|Resective Periodontal Flap with Osseous Recontouring (RPFO)|RPFO is a surgical procedure that involves the resection of soft and hard tissue to obtain optimum tissue architecture and pocket reduction or elimination.
1677061|NCT01642628|Other|Mirror Education|Patients allocated to the experimental group will be given a small hand-held mirror and structured mirror viewing education verbally. In addition, they will receive a mirror viewing handout. This intervention will be given prior to mastectomy surgery. In addition, participants will receive all other standard care.
1677062|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
1677063|NCT01642615|Drug|Dexlansoprazole|Dexlansoprazole capsules
1677064|NCT01642615|Drug|Placebo|Dexlansoprazole placebo-matching capsules
1677065|NCT01642602|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsules.
1677066|NCT01642589|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine (Menactra®)|0.5 mL, Intramuscular
1677067|NCT01642589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed|0.5 mL, Intramuscular
1677068|NCT01642576|Behavioral|weight loss counselling|Diet counselling with or without sports trainers, over 8 months
1677069|NCT01642563|Procedure|Platelet transfusion|One dose of pathogen reduced platelets
1677070|NCT01642563|Procedure|Platelet transfusion|One dose of standard platelets
1677071|NCT01642550|Drug|RM-131|RM-131 (100 mcg) will be administered daily by subcutaneous injection for 28 days.
1677072|NCT01642550|Drug|Placebo|
1677073|NCT01642537|Device|Rhythmia Mapping System and the Rhythmia Mapping Catheter|Patients will undergo a diagnostic assessment with the Rhythmia Mapping System and the Rhythmia Mapping Catheter as part of the Electrophysiology Ablation Procedure.
1677074|NCT01642524|Biological|hypertonic saline mixed Dextran|single dose administered intravenously
1677075|NCT01642524|Biological|Saline solution|placebo - saline solution
1677076|NCT01642511|Radiation|99mTc-labeled Sulfur Colloid|Each patient received the 1 intraparenchymal injection of 99mTc-SC (0.5~1.0 mCi/0.5mL) in the tumor quadrant.
1677077|NCT01642511|Radiation|99mTc-labeled Sulfur Colloid|Two syringes of 0.25~0.5 mCi 99mTc-SC in 0.2~1.0 mL volume were injected intraparenchymally into 2 quadrants of breast, at the 6 and 12 o'clock positions.
1677078|NCT01642511|Procedure|Axillary Sentinel Lymph Node Biopsy|Sentinel lymph node biopsy
1677079|NCT01642511|Drug|Methylthioninium|Four milliliters of methylthioninium was injected subcutaneously above the primary tumor or around the biopsy cavity 10 min before surgery
1677080|NCT01642511|Device|Lymphoscintigraphy|Sequential anterior and lateral gamma imaging was performed with patients lying prone and by injection side just before surgery using a digital gamma camera computer system (Toshiba GCA-901A/HG).
1677081|NCT01642511|Procedure|Axillary Lymph Node Dissection|ALND was performed consequently if axillary SLNB was failure or axillary SLNs were positive.
1677082|NCT01642511|Procedure|Internal Mammary Sentinel Lymph Node Biopsy|Internal mammary sentinel lymph node biopsy
1677083|NCT01642498|Device|ROX COUPLER|The COUPLER will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein).
1677084|NCT01642485|Drug|Moxifloxacin 400 mg fasted|"Subjects receiving drug (400 mg moxifloxacin),having fasted overnight for 10 hours.
This is the standard probe for the assessment of assay sensitivity in Thorough QT (TQT) studies."
1677085|NCT01642485|Other|FDA breakfast|Calorie reduced FDA standard breakfast (58% fat, low carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a lesser effect on QTc compared to a carbohydrate rich breakfast should be observed.
1677086|NCT01642485|Other|Continental breakfast|High carbohydrate breakfast (>70% carbohydrates)- On the assumption that increases in C-peptide levels are responsible for the QTc shortening observed after a meal, a greater effect on QTc compared to a low carbohydrate breakfast (FDA standard breakfast) should be observed.
1677087|NCT01642485|Drug|Moxifloxacin 400 mg fed|Currently, there is no published data showing the effects of a single 400 mg oral dose of moxifloxacin on the ECG/QT/QTc after food.
1677088|NCT01642485|Procedure|Insulin Clamp|A euglycaemic/hyperinsulinaemic clamp, (DeFronzo, 1979) involves acutely raising the plasma insulin levels to a steady state and maintaining a state of euglycaemia with a glucose infusion, thereby effectively stopping endogenous insulin and C-peptide release. This technique will confirm whether hyperinsulinaemia has any effect on the QT/QTc interval.
1677089|NCT01642485|Drug|Placebo|Comparison of different meals effect on Moxifloxacin PK profile
1677090|NCT01642472|Drug|Ulipristal Acetate - open label|Ulipristal Acetate (PGL4001) tablets 10mg orally daily for 3 months (84 days) for each treatment course. There are four 3-month treatment courses in this study.
1677091|NCT01642459|Other|Same direction cannulation|The puncture direction of the arterial needle is same as the blood flow in every hemodialysis session.
1677092|NCT01642459|Other|Opposite direction cannulation|The puncture direction of the arterial needle is opposite to the blood flow in every hemodialysis session.
1677093|NCT01642446|Procedure|Precise hepatectomy|Precise hepatectomy
1677094|NCT01642446|Other|Combined intervention (chemoembolization/ablation)|transcatheter hepatic arterial chemoembolization and/or ablation
1677095|NCT01642433|Drug|Placebo|Placebo capsules, 3x daily
1677096|NCT01642433|Drug|Prazosin|Prazosin medication, 3x daily dosing, up to 15mg/day
1677166|NCT01641874|Procedure|Evidence based exercise|Quadriceps exercises and advice on aerobic exercises. Exercises are based on current evidence for the best exercises for osteoarthritic knee
1677097|NCT01642407|Drug|Sildenafil|Body weight > 20 kg: 20 mg TID (60 mg/day) Body weight ≤ 20 kg: 10 mg TID (30 mg/day) Treatment duration: 16 weeks in Part 1, until until sildenafil obtained marketing approval in Part 2
1677098|NCT01642394|Behavioral|Diabetes Self-Management Program|"The intervention will be performed by patients with type 2 diabetes and health professionals and it will be divided in 6 group sessions for two and a half hours each, on a weekly basis for 6 weeks. The session content includes techniques for dealing with problems in general, promotion of exercise, nutrition concepts, proper use of medication, effective communication and basic knowledge about diabetes and its complications. The sessions are supported with educational material.
Two leaders, previously trained in the DSMP, will lead each group. The leading status (patient or health care professional) is obtained after attending a 6-week structured program of training, a successful completion of 4 days of training sessions, and taking part in a full course for patients with a proven leader."
1677099|NCT01642381|Behavioral|"Full Motivational Interviewing (FMI)"|Relational and technical technical (directive) strategies in counselling sessions to significantly increase commitment strength to reduce drinking.
1677100|NCT01642381|Behavioral|"Spirit Only Motivational Interviewing (SOMI)"|Empathic and non-directive counselling based on Rogerian psychotherapy model.
1677101|NCT01642368|Other|The Optimum Omega-3 Fatty Acid Feeding Study|Assess whether swapping specific food ingredients in the diet can significantly improve polyunsaturated fatty acid blood profiles and improve a person's response to cognitive measures and physical fitness.
1677102|NCT01642355|Behavioral|Prevention Consult|In addition to usual care, patients will receive a prevention consult by a prevention fellow and attending following their intervention. The consult will include guideline based medical recommendations for optimization of the patient's medical regimen targeting dyslipidemia, hypertension and diabetes. In addition, each patient will be educated on the cardiovascular disease process and given detailed lifestyle recommendations on physical activity, improved nutrition, smoking cessation and medication adherence.
1677103|NCT01642355|Behavioral|Consult & Behavioral Intervention|In addition to usual care and prevention consult (as detailed above), patients will receive a full motivational intervention program by a trained motivational coach and text messages over 6 months.
1677104|NCT01642342|Other|laboratory biomarker analysis|Correlative studies
1677105|NCT01642342|Other|pharmacological study|Correlative studies
1677106|NCT01642342|Biological|recombinant albumin fusion protein sEphB4-HSA|Given IV
1677107|NCT01642316|Other|washback|students received 8 specific related formative test for that lesson. plus a pre-test and post-test, Michigan English language proficiency test
1677108|NCT01642316|Other|routin intervention|students only received two tests, Michigan test of English language proficiency as pre-test and post-test.
1677109|NCT01642303|Other|vodcasting|listening to downloaded vodcasting files
1677110|NCT01642303|Other|no intervension|Listen to student book listening files
1677111|NCT01642277|Drug|Solifenacin|5 mg for 4 weeks with option to increase to 10 mg for an additional 8 weeks
1677112|NCT01642264|Behavioral|WeBREATHe Training Program|The WeBREATHe Training Program is a web-based, interactive training program to teach pediatric respiratory therapists, nurses and nurse practitioners how to help their patients' parents to quit smoking.
1677120|NCT01642238|Drug|Ticagrelor + ASA + Bivalirudin|Single loading dose of Ticagrelor (180 mg given as two 90 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
1677121|NCT01642238|Drug|Clopidogrel + ASA + Bivalirudin|Single loading dose of Clopidogrel (600 mg given as two 300 mg tablets), plus single dose of ASA (one 81 mg tablet) + bivalirudin administered as 0.75 mg/kg IV bolus followed by 1.75 mg/kg/hour for 1 hour.
1677122|NCT01642212|Drug|Oral Budesonide Suspension (MB-9)|OBS suspension to be taken bid over a 16 week course of double blind therapy and OBS suspension to be taken qd to bid during a 24 week optional open label extension period
1677123|NCT01642212|Drug|Placebo|
1677124|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Peer Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by peers (i.e., other members of their weight loss group).
1677125|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss + Mentor Health Coach|Participants will receive a 12-month reduced intensity group behavioral weight loss program. During weeks that there are no group meetings, participants will be coached by a mentor (i.e., successful weight loser).
1677126|NCT01642199|Behavioral|Reduced Intensity Behavioral Weight Loss|Participants will receive 12 months of a reduced intensity group behavioral weight loss program.
1677127|NCT01642186|Drug|everolimus|
1677128|NCT01642186|Drug|letrozole plus leuprolide|
1677129|NCT01642186|Drug|combination of everolimus, letrozole and leuprolide|
1677130|NCT01642173|Device|Optical Coherence Tomography (C7 XR Dragonfly )|Evaluation of the coronary artery using Optical Coherence Tomography utilizing the Dragonfly OCT catheter following a clinically indicated angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLa2 inhibition or placebo.
1677131|NCT01642160|Behavioral|additional educational material|The internet-based intervention group would receive a weekly text or an email (based on the subject's preference). The content of the message asks about their approximate compliance over the past week. Based on their response, they will be directed to one of two internet web pages.
1677132|NCT01642160|Behavioral|Standard of care|participants will receive education from staff nurses as needed.
1677167|NCT01641861|Device|Papacarie®|Papacarie® is chemo-mechanical method for caries removal
1677168|NCT01641861|Procedure|Conventional method|caries removal by using rotary instrument.
1677169|NCT01641848|Device|INBONE™ Total Ankle Prosthesis with Long Talar Stem|INBONE™ Total Ankle Prosthesis with Long Talar Stem when used with a Calcaneal Stem
1677133|NCT01642147|Device|Transcranial Doppler (TCD)|A 2-MHz Transcranial Doppler probe (MULTI－DOP P2.2C; DWL, Elektronische Systeme GmbH, Germany) will be used to measure both sides of Vmca of both patients undergoing craniotomy and patients undergoing abdominal surgery. The signal will be range-gated to a depth of 45 to 60 mm at temporal bone window to achieve the optimal signal according to standard techniques. The measures will be recorded in the operation room before anesthesia, in the recovery room at extubation, 30, 60, 90, and 120 min after extubation.
1677134|NCT01642147|Procedure|jugular venous bulb catheterization|After local anesthesia, a jugular venous bulb catheter(16G, manufactured by Arrow International Inc. USA) will be placed in the dominant side. The proper placement of the tip of the catheter in the jugular bulb will be confirmed later by a postoperative lateral skull X-ray. SjvO2 (blood sample will be drawn slowly at a speed of 2ml per minute) will be measured before anesthesia, at extubation, 30, 60, 90, and 120 min after extubation.
1677135|NCT01642147|Procedure|Tumor removal surgery under general anesthesia|Surgery types include total or subtotal removal of tumors.For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
1677136|NCT01642147|Procedure|Radial artery catheterization|After local anesthesia, an intra-arterial pressure line(I.V. catheter and pressure line kit are both manufactured by Smiths Medical International Ltd. USA) will be inserted in radial artery. Sample blood will be drawn from the line before anesthesia, at tracheal extubation, and 30, 60, 90, 120 min after tracheal extubation.
1677137|NCT01642147|Procedure|Abdominal surgery under general anesthesia|For all surgical procedures, general anesthesia will be maintained with isoflurane (0.5-1.0 minimal alveolar concentration (MAC) expired), repeated boluses of fentanyl (1~2 µg/kg IV), and continuous vecuronium 50～70 IV. All patients will be mechanical ventilated with oxygen. During anesthesia, blood pressure and heart rate will be kept stable, within ±10% of the preoperative levels. Hematocrit (Hct) will be maintained higher than 30%. After surgery, tracheal extubation will be performed when patients regain full muscle strength, breathe spontaneously with acceptable oxygenation and normocapnia.
1677138|NCT01642134|Drug|aspirin+clopidogrel (Duoplavin)|100 mg aspirin ;75 mg clopidogrel 3º months
1677139|NCT01642121|Other|laboratory biomarker analysis|Correlative studies
1677140|NCT01642108|Drug|Sitagliptin|50 mg once per day
1677141|NCT01642095|Other|laboratory biomarker analysis|Correlative studies
1677142|NCT01642082|Biological|Dalantercept|Given SC
1677143|NCT01642082|Other|Laboratory Biomarker Analysis|Correlative studies
1677144|NCT01642069|Other|laboratory biomarker analysis|Correlative studies
1677146|NCT01642030|Drug|Placebo|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
1677147|NCT01642030|Drug|Hydromorphone|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
1677148|NCT01642030|Drug|Buprenorphine|Intravenous injection of approximately 5 mL administered via slow push over 5 minutes. Given 4 injections during the session with each injection separated by 1.5 hours.
1677149|NCT01642017|Drug|Pazopanib|Pazopanib will be administered orally at the starting dose of 400 mg/day in 28-days cycles ; barring limiting toxicities the dose of pazopanib will escalate in several steps (a maximum of 3 dose levels are defined : 400, 600 and 800 mg/day). The pazopanib will be administered at the same dosa until disease progression.
1677150|NCT01642004|Biological|Nivolumab|
1677151|NCT01642004|Drug|Docetaxel|
1677152|NCT01641991|Biological|BioThrax®|BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups
1677153|NCT01641991|Biological|BioThrax®|BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
1677154|NCT01641965|Device|Home pressure ventilator model Vivo 40 (BREAS Medical AB)|Nocturnal non invasive ventilation (Vivo 40)with minimum pressure support of 10 cm H2O (IPAP 14, EPAP 4). Parameters will be adjusted according to tolerance and to achieve PaCO2 < 45 mmHg and improve symptoms.
1677155|NCT01641952|Drug|Rituximab|Rituximab at a dose determined by the investigator, guided by the recommendation in the Summary of Product Characteristics.
1677156|NCT01641939|Drug|Taxane|Standard taxane (docetaxel 75 mg/m^2 IV every 3 weeks or paclitaxel 80 mg/m^2) IV once a week according to investigator choice.
1677157|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 3.6 mg/kg IV every 3 weeks
1677158|NCT01641939|Drug|trastuzumab emtansine|trastuzumab emtansine 2.4 mg/kg IV once a week
1677159|NCT01641926|Biological|PEG-Intron™|PEG-Intron subcutaneously (SC) once weekly for a total of 48 weeks
1677160|NCT01641926|Biological|PEGASYS™|PEGASYS subcutaneously (SC) once weekly for a total of 48 weeks
1677161|NCT01641913|Other|Absorbable sugars|Lactulose (1,000 mg) and mannitol (200 mg). For the liquid formulation, these sugars will be administered in 250 ml of water. After oral ingestion of the sugars in liquid form, urine will be collected every 30 minutes for the first 2 hours.
1677162|NCT01641900|Drug|eszopiclone|3 mg of eszopiclone for two consecutive nights (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
1677163|NCT01641900|Drug|placebo|placebo capsule for two consecutive nights. (Baseline Night and Experimental Night). Sleep spindle density (primary outcome) is measured for both nights. Memory consolidation (secondary outcome) is measured over Experimental Night.
1677164|NCT01641887|Other|Decision Aid|Patients will use a decision aid administered on a computer.
1677165|NCT01641874|Procedure|Exercise|Directional specific exercise
1677353|NCT01640561|Behavioral|MISC|The Mediational Interventions for Sensitizing Caregivers
1677170|NCT01641822|Drug|AZLI|Aztreonam for Inhalation Solution (AZLI) 75 mg 3 times daily combined with diluent administered using an eFlow nebulizer
1677171|NCT01641822|Drug|Placebo to match AZLI|Placebo to match AZLI 3 times daily combined with diluent administered using an eFlow nebulizer
1677172|NCT01641822|Drug|Tobramycin inhalation solution|Tobramycin inhalation solution (TIS) 300 mg 2 times daily using a PARI® LC Plus nebulizer and DeVilbiss Pulmo-Aide® air compressor
1677181|NCT01641783|Drug|nanoparticle Albumin-Bound paclitaxel|nanoparticle Albumin-Bound paclitaxel:125mg/m2 d1 iv
1677182|NCT01641770|Other|Nutritional beverage 10003RF|2 sachets per day
1677183|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
1677184|NCT01641770|Other|Dietary Counseling|Guidelines for dietary counseling include energy and nutrient requirements.
1677185|NCT01641757|Procedure|non-surgical periodontal therapy|dental scaling and root planing of full mouth will be done
1677186|NCT01641744|Behavioral|Systematic Training for Effective Parenting (STEP)|Parenting skills training class, 1x/week, 12 weeks
1677187|NCT01641744|Behavioral|Group Attachment Based Intervention (GABI)|Parent-child group, 3x/week, 26 weeks
1677188|NCT01641731|Other|Cow's milk|"Group I: Increase 2 mL until 10 mL, 10 mL until 50 mL, 20 mL until 100 mL and 50 mL until 200 mL was reached.
Groups II and III: Doubling dose until 1 mL, increase 2 mL until 20 mL, 5 mL until 50 mL, 10 mL until 100 mL and 20 mL until 200 mL was reached."
1677189|NCT01641718|Drug|Tissue glue|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with 2 mL of tissue glue.
1677190|NCT01641718|Device|Staples|The mesh fixation for the transabdominal preperitoneal patch plastic repair will be performed with ProTack (Covidien) and Securestrap (Ethicon) staples.
1677191|NCT01641692|Drug|GSK573719 Active treatment or Placebo|Eligible subjects will be randomised to a sequence of three treatments from 8 possible arms: 7 active drug doses (15.6mcg, 31.25 mc, 62.5mcg 125mcg or 250mcg GSK573719 once daily; 15.6mcg or 31.25 mcg GSK573719 taken twice daily) or matched placebo.
1677192|NCT01641692|Procedure|GSK573719 (Sub-group cohort)|Subjects at selected Sub-group sites (approximately 30% of the total population) will have additional serial assessments and procedures (including blood and urine samples for pharmacokinetic analysis) at the start (Day 1) and at the end (Days 14 and 15) of each treatment period. On Day 14 of each treatment period subjects will remain overnight at the clinic for 24-hour assessments, including spirometry, ECGs, and 24-hour Holter monitoring.
1677193|NCT01641692|Drug|Salbutamol/Albuterol|Salbutamol/Albuterol, short-activing beta agonist provided to all subjects to be taken as needed for the relief of asthma symptoms.throughout the study period, including washout periods
1677194|NCT01641666|Drug|Boceprevir|Boceprevir will be dosed orally at a dose of 800 mg three times daily (TID) for a total daily dose of 2400 mg.
1677195|NCT01641666|Drug|Peginterferon Alfa-2b 1.5 mcg/kg/week|Peginterferon alpha-2b will be administered subcutaneously at a dose of 1.5 mcg/kg each week.
1677196|NCT01641666|Drug|Ribavirin|Ribavirin will be administered orally at a dose of 800 mg/day to 1400 mg/day in two divided daily doses (BID).
1677197|NCT01641653|Other|Normal saline|Normal saline 2cc. one dose prior to OR
1677198|NCT01641653|Drug|Midazolam|1-2.5 mg
1677199|NCT01641640|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
1677200|NCT01641640|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1677201|NCT01641640|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
1677202|NCT01641627|Procedure|proprioceptive stimulation|tendon vibrations and plantar stimulation with a therapeuthic orthosis, 4x30 min/day during 14 days
1677203|NCT01641614|Procedure|Mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
1677204|NCT01641614|Procedure|mitral valve replacement|Mitral valve replacement (MVR) was performed using a metallic or bioprostheses substitution by interrupted suture. For the beating heart the prostheses was functionally tested before removal of the retrograde perfusion catheter and for the arrested heart the prosthesis was artificially tested by pumping saline into the left ventricle. The tricuspid valve repair was done following De Vegas' technique in both groups
1677360|NCT01640509|Radiation|treated by synchrotron radiation|treated by synchrotron radiation
1677205|NCT01641601|Device|Outpatient transcervical Foley balloon|A 30 cc transcervical Foley balloon will be placed in the outpatient setting prior to labor induction.
1677206|NCT01641588|Behavioral|posture: sitting or standing|Intervention: postural position - whether seated or standing. The person carries out a battery of cognitive executive functioning assessments delivered via a laptop and carried out with the laptop keyboard while either seated or standing.
1677207|NCT01641575|Drug|CO-1.01 and Cisplatin|CO-1.01 administered over 30 minutes followed by 75 mg/ml Cisplatin over 2 hours (both intravenous) on C1D1. CO-1.01 administered intravenously over 30 minutes on C1D8.
1677208|NCT01641549|Procedure|Emergency surgery|Emergency surgery (valve replacement or thrombectomy)
1677209|NCT01641549|Drug|Fibrinolytic therapy|Streptokinase (SK) at a dose of 0.25MU over 30 minutes followed by a 0.1MU/ hour infusion, or other fibrinolytic agent at standard doses
1677210|NCT01641536|Genetic|HB-110|Each patient will be administered HB-110 by Electroporation for 20 weeks based on the protocol and take one pill of Entecavir(0.5 mg) per day during the study period. The Dose of HB-110 will be determined by the classical 3+3 dose escalation schedule and dose levels are 1mg, 2mg, 4mg respectively. The number of patients will be ranged from 9 to 18.
1677211|NCT01641523|Device|CustomBone Service|customized hydroxyapatite cranial prosthesis
1677212|NCT01641510|Drug|Prasugrel|Loading with prasugrel 30 mg followed by daily administration of prasugrel 5 mg
1677213|NCT01641510|Drug|Clopidogrel|Loading with clopidogrel 600 mg followed by daily administration of clopidogrel 75 mg
1677214|NCT01641497|Radiation|3D conformational radiation|25 * 1.8 Gy in 5 weeks (=45 Gy)
1677215|NCT01641497|Radiation|IMRT|25 * 1.8 Gy in 5 weeks (=45 Gy)
1677216|NCT01641484|Procedure|local control at 19.8Gy|Day 14, full body TEP and pelvis MRI
1677219|NCT01641458|Other|5FU and capecitabine (Xeloda®) dosing based on DPYD genotype|Multiplex amplification of each sample is performed in an individual well of a 24-well plate using a Mastercycler platform. Template and Platinum Taq Polymerase (Life Technologies, Carlsbad, California) are added to an analyte-specific amplification mix (AutoGenomics Inc., Carlsbad, California). After amplification, the plate is transferred into the Infinity analyzer (AutoGenomics Inc.), followed by primer extension and hybridization of detection primers to individual oligonucleotides arrayed on the Bio-FilmChip. After hybridization, the BioFilmChips are washed and scanned in the Infiniti optics module. The Autogenomics DPYD assay is used to detect the presence of the four risk alleles (IVS14+G>A, c.1679T>G, HapB3/c.1129-5923C>G and c.2846A>T).
1677220|NCT01641458|Other|Therapeutic drug monitoring of 5FU|Repeated PK plasma sampling is done in all patients receiving 5FU. Blood is taken from venipuncture into one 5 ml heparin tube and into one 3 ml EDTA tube for the analysis of 5FU steady-state plasma concentrations in every (2-weekly) treatment cycle. Special attention has to be paid not to take PK blood from the site of drug infusion. For 5FU, PK sampling is done two hours before the calculated end of the 5FU pump on day 3 of every treatment cycle. The quantitative 5FU exposure expressed as the area-under-the concentration-time curve in mg•h/L is calculated from the measured steady-state plasma concentrations of 5FU and the duration of 5FU infusion. In all patients, 5FU doses for the second and subsequent administrations are adjusted to target a 5FU AUC between 20 and 30 mg•h/L
1677221|NCT01641445|Drug|Topiramate|Topiramate (200 mg daily)
1677222|NCT01641445|Drug|Placebo|Non-active sugar pill
1677223|NCT01641432|Behavioral|Tonic and Phasic Attention Training|"The Tonic and Phasic Alertness treatment task (TAPAT) consist of two consecutive rounds of a 12-minute continuous performance task in which continually varying, rich visual (e.g., scenes, objects, faces) or auditory stimuli (tones or complex sounds) are briefly displayed and participants are required to respond via a button press when they see a non-target item (90% of trials) or withhold button-press responding when the item is a pre-determined target item (10% of trials). Presentation of the target item is non-predictive and infrequent, disallowing the development of an executive strategy. Participants simply sustain attention to the task over a prolonged period of time (tonic attention), ignoring distractions, and inhibiting the pre-potent motor response when they see a target item (phasic attention).
Following the 24 minutes of TAPAT treatment participants will undergo one additional computer-based cognitive exercise, Multiple Object Tracking (MOT), for an additional 12 minutes."
1677224|NCT01641432|Behavioral|Active Comparator|Computer games chosen from a list of progressive visual/audiovisual games from the top-100 game list: sporcle.com. Training duration will be similar to that of experimental training.
1677225|NCT01641419|Drug|Placebo|2 ml of saline added to 30 ml of ropivacaine 0.5% solution for nerve block
1677226|NCT01641419|Drug|Dexamethasone 4 mg|2 ml of dexamethasone 4 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
1677227|NCT01641419|Drug|Dexamethasone 8 mg|2 ml of dexamethasone 8 mg solution added to 30 ml of ropivacaine 0.5% solution for nerve block
1677354|NCT01640561|Behavioral|UCOBAC|This nutrition/healthcare curriculum for children in poverty and affected by HIV was developed by an NGO operating in Uganda called UCOBAC (Uganda Community Based Association for Child Welfare) with support from UNICEF.
1677228|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER-(Triple Negative and ER-PR+Her-2-):Patients who respond to the first 4 courses of TEC with a Complete Remission will receive 4 more courses of TEC. Patients who respond to the first 4 courses of TEC with a Partial Remission or Stable Disease will then have their treatment changed to the non-cross resistant NAX regimen.Courses will be repeated every 21 days according to blood counts.A total of 4 courses will be given.
1677229|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|"Her-2 positive cases:Patients who respond to 4 courses of TEC with either a partial or complete remission will then receive 4 additional courses of Docetaxel plus Herceptin, and upon completion of the 4th course of DH they will undergo definitive surgery.A total of 4 courses will be given. Courses will be repeated every 21 days according to blood counts. Patients whose response after 4 courses of TEC is either stable disease or progression, will be treated with NTX."
1677230|NCT01641406|Drug|Docetaxel, Epirubicin, Cyclophosphamide/Navelbine, Capecitabine, Trastuzumab, Bevacizumab|ER+ Cases(ER+PR+Her-2- and ER+PR-Her-2-):After the first course of TEC if the SUV of the primary tumor is >5%, treatment will be TEC x 4 courses. If the Oncotype is low, patients will be switched to hormonal therapy x 6 months. If the Oncotype result is intermediate/high, patients will be NAX chemotherapy x 4 courses. If the SUV post course #1 TEC is <5%, subsequent treatment will depend on the Oncotype.If the Oncotype is low, the treatment will be hormonal therapy x 6 months. If the Oncotype is intermediate/high , the treatment will be NAX chemotherapy x 4. Surgery will be performed 6 weeks after the 4th course of NAX chemotherapy.
1677231|NCT01641393|Drug|EUR-1008 25,000 Units|EUR-1008 25,000 Units is a PEP with pancreas powder as the active ingredient.18 Pancreas powder contains various enzymes having proteolytic, lipolytic, and amylolytic activity. Each capsule contains approximately 25,000 Ph. Eur. lipase units. EUR-1008 25,000 consists of orally administered capsules containing enteric-coated beads.
1677232|NCT01641393|Drug|Kreon 25,000 Units|Kreon 25,000 is a PEP consisting of porcine-derived pancreatic enzymes.18 Each capsule contains approximately 25,000 Ph. Eur. lipase units. Kreon 25,000 consists of orally administered capsules containing enteric-coated spheres.
1677241|NCT01641354|Procedure|Hemiepiphysiodesis|Partial closure of growth plate to correct deformity
1677242|NCT01641341|Drug|Bifidobacterium infantis|once a day for seven to eight weeks
1677243|NCT01641341|Drug|Pancrelipase|Pancrelipase (one capsule prior to meals or snacks)
1677244|NCT01641341|Drug|Nitazoxanide|Nitazoxanide (500mg twice a day for 7 days)
1677245|NCT01641341|Drug|Placebo|Placebo capsule will not contain active treatment ingredients.
1677246|NCT01641328|Behavioral|Cogntive Activation Training|Mindfulness-based stress reduction - 30 minutes / class x 3 classes / week; optional home practice Tai Chi - 30 minutes / class x 3 classes / week; optional home practice Computer-based cognitive training - 20 minutes / class x 3 classes / week; optional home practice
1677247|NCT01641328|Behavioral|Waitlist Control / Home-based training|Computer-based cognitive training - 20 minutes / day Daily walking - 20 minutes / day Biofeedback relaxation Training - 20 minutes / day
1677248|NCT01641315|Biological|rabies vaccine|"Group 1: rabies vaccination was given to rabies exposed victims on day 0,3,7,14,28 with ERIG on day 0.
Group 2: rabies vaccination was given to healthy volunteers on day 0,3,7,14 with ERIG on day 0.
Group 3: rabies vaccination was given to healthy volunteers on day 0,3,7,28 with ERIG on day 0."
1677249|NCT01641289|Drug|Paracetamol|>50kg: Paracetamol 1gm PO/NG q6hourly for 72hours and afebrile for 24h (maximum total dose 4g/24 hours) plus intravenous Artesunate <50kg: Paracetamol 12.5-15mg/kg/dose q6hourly for 72hours and afebrile for 24h (maximum total dose 5 doses/24hours;75mg/kg) plus intravenous Artesunate
1677250|NCT01641289|Drug|No Paracetamol|"No paracetamol + Intravenous Artesunate
If temperature > 40°C, ibuprofen PO/PR will be administered in the absence of renal impairment and dehydration; 500mg paracetamol PO/PR will be administered in the presence of renal impairment or dehydration. Dengue testing will be done prior to the administration of ibuprofen."
1677251|NCT01641276|Device|Low intensity amplitude-moduled electromagnetic fields|Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.
1677252|NCT01641263|Behavioral|Sleep Education|Each 2-hour session, held once a week for 8 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion
1677355|NCT01640535|Drug|Montelukast + Levocetirizine|Tablet, Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
1677253|NCT01641263|Behavioral|Cognitve Behavioral Therapy|For each 2-hour session held once a week for 8 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
1677254|NCT01641250|Drug|RO5429083|Multiple escalating doses
1677255|NCT01641250|Drug|cytarabine|1000 mg/m2 iv daily for 5 consecutive days, up to 4 cycles
1677256|NCT01641237|Drug|sodium fluoride|fluoride as sodium fluoride
1677257|NCT01641237|Drug|no added fluoride in a silica base|no added fluoride
1677258|NCT01641224|Drug|Pinaverium|To test the effectiveness and safety of the formula for pain and diarrhea, we will randomly assign patients into one 3 groups: Pinaverium, TCM (Formula for pain and diarrhea) group, and placebo group, and treat them accordingly.
1677259|NCT01641224|Device|Atractylodes|Atractylodes (~10-15g)
1677260|NCT01641224|Device|Paeonia Lactiflora|Paeonia Lactiflora (~15-30g)
1677261|NCT01641224|Device|Tangerine Peel|Tangerine Peel (~10g)
1677262|NCT01641224|Drug|Ledebouriella Root|Ledebouriella Root (~10g)
1677263|NCT01641224|Drug|Radix codonopsitis|Radix codonopsitis (~10-15g)
1677264|NCT01641224|Drug|Radix curcumae|Radix curcumae (~10g)
1677265|NCT01641224|Drug|Fingered citron|Fingered citron (~10g)
1677266|NCT01641224|Drug|Tuckahoe|Tuckahoe (15g)
1677267|NCT01641224|Drug|Placebo|Placebo is blindly given to patients.
1677268|NCT01641211|Behavioral|Meducation device technique video|2-minute video that displays proper inhaler, diskus, and turbuhaler technique. The video will only be watched once at the medical visit. Children in this group will be given a wallet card so they can access the video via the Internet after leaving the asthma clinic.
1677269|NCT01641211|Other|Nutrition video|Children in this group will watch a 2-minute nutrition video.
1677271|NCT01641185|Procedure|radiation|radiation with protons or carbon ions
1677272|NCT01641172|Procedure|Dexa scan|"the DEXA scan to measure bone and fat will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have a DEXA scan at baseline, 1 month after the end of chemotherapy and after 1 year."
1677273|NCT01641172|Procedure|audiogram|"the audiogram will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have an audiogram at baseline, 1 month after the end of chemotherapy and after 1 year."
1677274|NCT01641172|Procedure|measurement of heart rate variability and baroreflex sensitivity|"the measurements (continuous assessment of heart rate and blood pressure using an non-invasive Finapress device) during 30 minutes will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have those measurements taken at baseline, 1 month after the end of chemotherapy and after 1 year."
1677275|NCT01641172|Procedure|Glucose tolerance assessment|"Glucose tolerance will be assessed by drinking glucose water and measuring glucose at baseline and 2 hours later. It will be performed one time in the healthy controls and the patients participating in the cross sectional part of the study.
The patients in the longitudinal part of the study will have an assessment at baseline, 1 month after the end of chemotherapy and after 1 year."
1677276|NCT01641172|Dietary Supplement|oral nutrition supplements|a set of 10 Oral Nutrition Supplements (ONS) will be offered combined with a questionnaire to measure appreciation and preference for these food products. All these tests and questionnaires will be performed longitudinally (before the first chemotherapy, on day 7 of the first course, before the second course, on day 7 of the second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy) and cross-sectional (1, 3, 5 and 7 years after chemotherapy).
1677277|NCT01641172|Behavioral|Two day food records|Two day food records will be used to investigate the actual dietary intake before the first and second course, during (on day 5 and 6) first and second course, 1 month after start of the last course, 7 months after the start of chemotherapy, and 1 year after the start of chemotherapy.
1677278|NCT01641172|Behavioral|Food Frequency Questionnaire|A Food Frequency Questionnaire (FFQ) will be used to investigate the usual dietary intake before the start of the first course, before and after the second course, 1 month after start of the last course, seven months after the start of chemotherapy, and 1 year after the start of chemotherapy (longitudinal), and 1, 3, 5 and 7 years after chemotherapy (cross-sectional).
1677279|NCT01641159|Drug|Buspirone|Study participants will be randomly assigned to receive either buspirone or matching placebo. Following dose escalation, the target at study day 10 is to achieve the highest tolerated dose not exceeding 60 mg. Participants who are unable to reach the 60 mg dose or who need to be reduced from 60 mg due to tolerability will be maintained on 15 mg, 30 mg, or 45 mg, whichever is the highest dose tolerated.
1677280|NCT01641159|Drug|Placebo|Study participants will be randomly assigned to receive either buspirone or matching placebo. Placebo tablets will be identical in color and size to the buspirone tablets.
1677281|NCT01641146|Behavioral|Enhanced Sexual Health Intervention for Men (ES-HIM)|ES-HIM is a six-session intervention for HIV-positive Black bisexual men who have histories of child sexual abuse. Guided by cognitive behavioral approaches and an ecological framework, ES-HIM effects sexual behavior change and psychological health improvement. Sexual risk reduction is framed from the perspective of being a triple minority (i.e., HIV-positive, ethnic and sexual minority). Issues of stigma and social isolation were discussed in regard to these identities. Sexual ownership focusing on individual responsibility for one's health and well-being was prioritized along with caring for sexual partners, family and community. Decisions regarding sexual behaviors and consequences were framed within a culturally congruent social context. Topics included: 1) the influence of gender and ethnicity; (2) early socialization regarding gender and culture, as well as adult experiences; (3) HIV stigma; and (4) recognizing stressors, including histories of personal trauma.
1677356|NCT01640535|Drug|Levocetirizine|Tablet, Matching placebo of Montelukast sodium 10 mg + Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
1728423|NCT00022685|Biological|epratuzumab|
1677282|NCT01641146|Behavioral|Health Promotion (HP) Comparison Arm|Health Promotion Intervention (HP) is the comparison arm. It is designed to control for the Hawthorne effect and reduce the likelihood that effects of ES-HIM could be attributed to special attention and group interaction. HP addresses health issues, including certain cancers, hypertension, diabetes, and heart disease, all of which are common among African American men, but did not focus on sexual behavior. Participants were taught that these diseases could be prevented by changing personal behaviors (e.g., increasing physical activity and healthy dietary practices, ceasing cigarette smoking and alcohol and drug abuse), or managed with early detection and screening behaviors.
1677283|NCT01641133|Biological|Synflorix™ (3-Dose)|3 doses administered intramuscularly
1677284|NCT01641133|Biological|Synflorix™ (2-Dose)|2 doses administered intramuscularly
1677285|NCT01641133|Biological|Synflorix™ (Single Dose)|1 dose administered intramuscularly
1677286|NCT01641133|Biological|Prevenar 13 ™ (Single Dose)|1 dose administered intramuscularly
1677287|NCT01641133|Biological|Prevenar 13 ™ (2-Dose)|2 doses administered intramuscularly
1677288|NCT01641120|Drug|Avonex|Intramuscular injection administered using 25 gauge or 30 gauge needle
1677289|NCT01641107|Drug|Ponatinib|"Treatment:
Patients will receive daily oral administration of Ponatinib at a dose of 45 mg/day for 6 weeks (defined as one course) for 8 courses, same dose and schedule, for a total of 48 weeks. Each patient will be followed for the subsequent 24 months, every 3 month, providing survival information and monitoring serious adverse event. Each patient should be treated for a minimum of 6 weeks. Patients must be discontinued from the trial in the event of myocardial infarction or stroke, or for development or progression of arterial disease necessitating revascularization. Once a complete hematologic response has been achieved, with a platelet count ≥ 50x109/L, patients can be treated with aspirin and/or a statin as clinically indicated, at investigator discretion."
1677290|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, Low Dose|Formoterol Fumarate in the Pressair DPI 6 micrograms, twice a day for 14 days
1677291|NCT01641081|Drug|Formoterol Fumarate in the Pressair DPI, High Dose|Formoterol Fumarate in the Pressair DPI 12 micrograms, twice a day for 14 days
1677292|NCT01641081|Drug|Foradil Aerolizer, Low Dose|Foradil Aerolizer 12 micrograms, twice a day for 14 days
1677293|NCT01641081|Drug|Foradil Aerolizer, High Dose|Foradil Aerolizer 24 micrograms, twice per day for 14 days
1677294|NCT01641081|Drug|Placebo|Placebo in the Pressair for 14 days
1677295|NCT01641068|Other|Cognitive Intervention|Participate in memory and thinking skills workshop
1677296|NCT01641068|Other|Educational Intervention|Participate in workshops focusing on increasing knowledge and education on the brain and cognition
1677297|NCT01641068|Procedure|Functional Magnetic Resonance Imaging|Undergo functional neuroimaging
1677298|NCT01641068|Other|Memory Intervention|Participate in memory and thinking skills workshop
1677299|NCT01641068|Other|Quality-of-Life Assessment|Ancillary studies
1677300|NCT01641068|Other|Questionnaire Administration|Ancillary studies
1677301|NCT01641055|Dietary Supplement|Salmon peptide|5g salmon peptide per day for 8wk.
1677302|NCT01641055|Dietary Supplement|Herring peptide|5g herring peptide per day for 8wk.
1677303|NCT01641055|Dietary Supplement|Cod protein|5g cod protein per day for 8wk.
1677304|NCT01641055|Dietary Supplement|Milk protein|5g milk protein per day for 8wk.
1677306|NCT01641029|Other|No intervention|There is no intervention
1677307|NCT01641016|Drug|efavirenz|May be taken as 600mg tablet, 200mg tablet or as part of a combination pill
1677308|NCT01640990|Drug|Saline|30mins run-in period
1677309|NCT01640990|Drug|GW328267X (total dose of 12mcg)|8 mcg/h for 1.5 hours (total dose of 12mcg)
1677310|NCT01640990|Drug|GW328267X (total dose of 40mcg)|10 mcg/h for 4 hours (total dose of 40 mcg)
1677311|NCT01640977|Procedure|Open PLIF (posterior lumbar interbody fusion)|The PLIF procedure achieves access to the degenerated disc from the back of the spine.
1677312|NCT01640977|Procedure|MAS PLIF|The MAS PLIF technique is a minimally invasive variant of the traditional PLIF procedure. It is similarly performed through a single midline posterior incision but is conducted through a more medialized posterior approach.
1677313|NCT01640964|Drug|Terlipressin acetate|IV bolus injection
1677314|NCT01640964|Drug|Serelaxin (RLX030)|Part A2: IV infusion for 2-3 hours; duration of infusion depends on time required for completion of MRA data acquisition; Part B: IV infusion for approximately 2 hours
1677315|NCT01640951|Drug|AIN457|
1677316|NCT01640925|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate 2% solution applied topically for full body bathing once every 48 hours
1677317|NCT01640925|Other|Standard bathing|The patient will be bathed using standard bathing (non-medicated cloths or soap and water) daily.
1677318|NCT01640912|Drug|RXI-109|Single intradermal injection of RXI-109 at incision sites
1677319|NCT01640912|Drug|Placebo|Single intradermal injection of placebo at incision sites
1677321|NCT01640873|Drug|MK-8655|Participants will receive MK-8655 as a single dose on Day 1. Participants will receive MK-8655, once a day (quaque die, q.d.), for 14 consecutive days (Day 3 through Day 16). MK-8655 doses may be adjusted downward based on the results of ongoing studies.
1677322|NCT01640873|Drug|Placebo|Participants will receive Placebo as a single dose on Day 1. Participants will receive Placebo, q.d., for 14 consecutive days (Day 3 through Day 16).
1677323|NCT01640847|Drug|High Intensity Focused Ultrasound (HIFU) in combination with ThermoDox|
1677324|NCT01640834|Drug|LY2409021|Administered orally
1677325|NCT01640834|Drug|Placebo|Administered orally
1677357|NCT01640535|Drug|Montelukast|Tablet, Montelukast sodium 10 mg + matching placebo of Levocetirizine dihydrochloride 5 mg, Once daily (before bedtime)
1677358|NCT01640522|Other|Collaborative Care|Collaborative care intervention to manage cancer-related symptoms
1677359|NCT01640522|Other|Enhanced usual Care|
1677326|NCT01640821|Behavioral|CdM? program|The program is conducted in small groups of 12 to 15 women for 14 weekly sessions (13 3h-evening sessions and 1 intensive-day session of 6 hours). Two health professionals (a registered dietician and a social worker or psychologist) lead the group. Sessions include lectures, guided self-examination and observations, group discussions, and practical exercises. Different topics are discussed during sessions such as enjoyment of physical activity and healthy nutrition, setting realistic objectives with regard to weight loss, and acceptation of their own and others' body image. A weekly food diary and group discussions are used to facilitate the recognition of internal cues of hunger and satiety and the identification of external influences on eating behaviors and food intake.
1677327|NCT01640808|Drug|NIK-333(peretinoin)|600mg (8 x 75mg tablets) orally, twice a day, continuously until recurrence of HCC, the patient's death, or termination or discontinuation of the entire study.
1677328|NCT01640808|Drug|Placebo|600mg (8 x 75mg tablets) orally, twice a day, continuously until recurrence of HCC, the patient's death, or termination or discontinuation of the entire study.
1677329|NCT01640782|Drug|Irinotecan, Leucovorin, 5-Fluorouracil, Docetaxel, Cisplatin|"Irinotecan (CPT-11) 180 mg/m2, given as 60 min. i.v. infusion on day 1 every 2 weeks followed by
Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by
5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 4 administrations.
After 3 weeks from last infusion:
Docetaxel (TXT) 75 mg/m2, given as a 1h i.v. infusion on day 1 followed by
Cisplatin (CDDP) 75 mg/m2, given as a 1h i.v. infusion on.day 1, every 3 weeks, for 3 cycles."
1677330|NCT01640782|Drug|Leucovorin, 5-Fluorouracil|"Leucovorin (LV) 100 mg/m2, given as a 2h i.v. infusion on days 1 and 2 every 2 weeks followed by
5-Fluorouracil (5-FU) 400 mg/m2 given as bolus, and then 5-Fluorouracil (5-FU) 600 mg/m2 given as a 22h continuous infusion on days 1 and 2, every 2 weeks for 9 administrations."
1677331|NCT01640769|Procedure|Image guided delivery of cardiac pacing leads.|Patients will be blindly randomized to image guided delivery of pacing leads during cardiac resynchronization therapy device implantation (study arm).
1677332|NCT01640769|Procedure|Standard delivery of cardiac pacing leads.|Patients will be blindly randomized to standard implantation of pacing leads during cardiac resynchronization therapy device implantation (control arm).
1677333|NCT01640756|Device|AqueSys Microfistula Implant|Placement of the AqueSys Microfistula Implant in the study eye
1677334|NCT01640743|Drug|Tacrolimus + Methylprednisolone|"Induction therapy:
Methylprednisolone (500 mg), thymoglobulins (1.5 mg/Kg/die, beginning 1 hour before transplantation) and 1 mg/Kg/die during the following 3 days.
Maintenance therapy:
Tacrolimus dosage will be 0.2 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
1677335|NCT01640743|Drug|Tacrolimus + Everolimus + Methylprednisolone|"Induction therapy:
Methylprednisolone (500 mg), thymoglobulins (2.5 mg/Kg/die, beginning 1 hour before transplant) and Mycophenolate mofetil (1000 mg) and no immunosuppressive therapy for the following 3 days (WOFIE hypothesis), and for day 4-5-6 thymoglobulins (1.0 mg/Kg/die).
Maintenance therapy:
Tacrolimus dosage will be 0.1 mg/kg of body weight and will be administered approximately 12 hours after chirurgical intervention twice a day (mornings and evenings). Dosage will be adapted on individual basis in order to gain pre-dose blood dosages according to indicated plasmatic levels"
1677336|NCT01640730|Drug|Kanglaite Injection|30gm IV infusion 5 days a week for 3 weeks every 28 days
1677337|NCT01640704|Behavioral|Computerized reminders about treatment guidelines to providers who care for hypertensive patients|
1677338|NCT01640691|Biological|Pandemic Influenza Vaccine (H5N1)|"Inactivated whole-virion vaccine
Administration route: Intramuscular Injection
Dosing schedule: 2 injections - at Day 1 and Day 22 separately
Dose(s): Each dose (0.5 mL) contains the 15 mcg hemagglutinin (HA) of influenza A (A/Vietnam/1194/2004)"
1677339|NCT01640678|Procedure|ReCell epidermal cell suspension grafting|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser) after which the prepared ReCell cell suspension will be sprayed on.
1677340|NCT01640678|Procedure|CO2 laser abrasion + UV-therapy|According to current standard of care procedures the treatment site will be superficially abraded using an ablative laser (10,600nm CO2 laser)
1677341|NCT01640665|Drug|Sorafenib|One cycle will consist of 4 weeks of treatment. The dose of Sorafenib will be 600 mg administered orally daily in divided doses.
1677342|NCT01640665|Drug|Capecitabine|Capecitabine will be given at a fixed dose of 2000 mg orally BID x 7 days every 14 days.
1677343|NCT01640652|Biological|MenPF-1.|A new vaccine against meningococcal disease.
1677344|NCT01640639|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
1677345|NCT01640639|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
1677346|NCT01640626|Other|Health Education package|Health Education package that covers key health messages about the proper personal hygiene practices will be given to school children in the intervention school. The package consisted of many items such as posters, comic book, song video, competitions, drawing activities, puppet show, etc.
1677347|NCT01640587|Drug|Mefloquine+Artesunate|One tablet of artesunate contains 40mg (Guilin Pharmaceutical Company, PRC). One tablet of mefloquine contains 250 mg mefloquine (Eloquine® (Medochemie Ltd., Cyprus) Standard three days regimen of artesunate-mefloquine given as 4mg/kg artesunate/day and 8 mg/kg of mefloquine/day on Days 0, 1 and 2
1677348|NCT01640587|Drug|Dihydroartemisinin-Piperaquine|DHA-Piperaquine (Duo-Cotecxin® Beijing Holley-Cotec Pharmaceuticals Co., Ltd, China) One tablet contains 40mg of dihydroartemisinin and 320 mg piperaquine. A weight-based regimen containing 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
1677349|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days and Primaquine 1 mg/kg once daily for 7 days
1677350|NCT01640574|Drug|Dihydroartemisinin-Piperaquine|Dihydroartemisinin-piperaquine + Primaquine: DHA-P 7mg/kg/day dihydroartemisinin and 55mg/kg/day piperaquine daily for 3 days Primaquine 0.5 mg/kg daily for 14 days
1677351|NCT01640574|Drug|Chloroquine|Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 1 mg/kg once daily for 7 days
1677352|NCT01640574|Drug|Chloroquine|o Chloroquine + Primaquine: Chloroquine 10, 10, 5 and Primaquine 0.5 mg/kg daily for 14 days
1677361|NCT01640496|Drug|Vitamin D3|3000 IU Vitamin D3 tablets (Cholecalciferol) will be used. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
1677362|NCT01640496|Other|Placebo|Placebo will be given to subjects. 28 pills per bottle. Subjects will be given 2 bottles to be taken for the duration of this study.
1677363|NCT01640483|Other|psychodynamic techniques.|the patients go through a time-limited (50 sessions, 45 minutes, 2 sessions/week) experimental treatment which exists of a sequence of four A phases (control conditions), one B phase (supportive techniques only), one C phase (interpretative techniques only), and one BC phase (mixed supportive/interpretative techniques).
1677364|NCT01640470|Device|Assistive Technology Provision and Tune-Up Intervention|"The home based AT Provision, Updating and Tune-Up (ATPUT) Intervention will consist of 5 components: 1) identification and prioritization of problematic activities by the assistance user and his/her principal, cohabitating caregiver; 2) in-residence assessment of the daily activities and social participation and preferences of the assistance user; 3) detailed review of the AT and human assistance that are currently being used; 4) recommendations by an occupational therapist for possible changes in the personal assistance strategy; 5) negotiation of an ATPUT Personal Plan with the assistance user and her/his principal caregiver.
The intervention occurs over a six week period and involves 3 to 6 visits from an occupational therapist."
1677365|NCT01640470|Device|Customary Care|Participants in the customary care group receive normal occupational therapy services.Occupational Therapy
1677366|NCT01640457|Drug|NOVOCART® Disc plus|Autologous Disc Chondrocyte Transplantation System (ADCT)
1677367|NCT01640457|Device|NOVOCART® Disc basic|ADCT (Media with no active cell component)
1677368|NCT01640444|Drug|FOLFIRI + bevacizumab|"Bevacizumab 5 mg/kg iv, followed by
Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by
Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 400 mg/m2 iv bolus, followed by
5-FU 2,400 mg/m2 for 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
1677369|NCT01640444|Drug|FOLFIRI + cetuximab|"Cetuximab in an initial 120-minute infusion on day 1 of 400 mg/m2, followed by 60-minute infusions of cetuximab at a dose of 250 mg/m2, once weekly
FOLFIRI:
Irinotecan 180 mg/m2 iv administered over a period of 30-90 minutes, followed by
Leucovorin (LV) 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 400 mg/m2 iv bolus, followed by
5-FU 2,400 mg/m2 for 46 h continuous infusion FOLFIRI will be given after the cetuximab infusion on day 1 of each period (every 2 weeks: 1 cycle)."
1677370|NCT01640431|Other|Lumbar stabilization exercises|The patients performed exercises for the transversus abdominis and lumbar multifidus muscles for an hour twice a week.
1677371|NCT01640418|Device|Mepilex® Border Sacrum dressings|Mepilex® Border Sacrum dressings
1677372|NCT01640405|Drug|modified FOLFOX6 + bevacizumab|"Bevacizumab 5 mg/kg iv, day 1, followed by
Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, day 1, followed by
5- Fluorouracil (FU)/Leucovorin (LV), day 1 and 2, as follow:
LV 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 400 mg/m2 iv bolus, followed by
5-FU 2.400 mg/m2 over 46 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
1677373|NCT01640405|Drug|FOLFOXIRI + Bevacizumab|"Bevacizumab 5 mg/kg iv, followed by
Irinotecan 165 mg/m2 iv administered over a period of 30-90 minutes, followed by
Oxaliplatin 85 mg/m2 iv administered over a period of 2 hours, followed by
LV 400 mg/m2 iv administered over a period of 2 hours, followed by
5-FU 3,200 mg/m2 for 48 h continuous infusion. This treatment will start on day 1 and will be repeated every 2 weeks (1 cycle)."
1677374|NCT01640392|Behavioral|MyLife MyStyle group-level intervention|Three 1.5-hour HIV behavioral risk-reduction group sessions conducted with up to 12 young African American/Black men (ages 18-29 years) over a 1-3 week period.
1677375|NCT01640379|Behavioral|Technology Enhanced Community Health Nursing|"Text-messaging (twice daily medication reminders w/ positive adherence messages, positive sexual health messages throughout the 30 day treatment period)
Enhanced community health nursing visit on day 3-5, includes DEBI STI/HIV prevention component (Sister to Sister Teen)"
1677377|NCT01640340|Drug|aprepitant|Given by mouth
1677378|NCT01640340|Drug|palonosetron hydrochloride|Given IV(intervenous infusion)
1677379|NCT01640340|Drug|ondansetron|Given PO
1677380|NCT01640340|Drug|dexamethasone|Given PO
1677381|NCT01640327|Biological|Trivalent influenza virus vaccine (TIVf)|A single dose (0.5 mL) of vaccine supplied in prefilled syringes was administered intramuscularly in the deltoid muscle, preferably of the non dominant arm
1677382|NCT01640314|Biological|Cell derived subunit trivalent nonadjuvanted vaccine|A single 0.5 mL dose of the cell derived subunit trivalent nonadjuvated influenza vaccine (TIVc) supplied in prefilled syringes and administered intramuscularly in the deltoid muscle (preferably) of the non dominant arm.
1677383|NCT01640301|Biological|Aldesleukin|Given SC
1677384|NCT01640301|Drug|Cyclophosphamide|Given IV
1677385|NCT01640301|Drug|Fludarabine Phosphate|Given IV
1677386|NCT01640301|Other|Laboratory Biomarker Analysis|Correlative studies
1677387|NCT01640301|Biological|WT1-Sensitized Allogeneic T-Lymphocytes|Given IV
1677388|NCT01640288|Drug|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas, single visit, < 1 hour
1677389|NCT01640288|Other|High Resolution CT of the Chest|High Resolution CT of the Chest, single visit
1677390|NCT01640275|Drug|Propofol|patients randomized to the propofol arm of the study will receive general anesthesia with propofol
1677391|NCT01640275|Drug|Isoflurane|patients randomized to the isoflurane arm of the study will receive general anesthesia with isoflurane
1677392|NCT01640262|Other|Multiparametric magnetic resonance imaging (mMRI)|A mMRI is performed before treatment of the patient and is compared to the standard diagnostic tools for evaluating the clinical stage and diagnose of prostate cancer
1677393|NCT01640249|Drug|Placebo|Capsules administered orally
1677394|NCT01640249|Drug|LY3006072|Capsules administered orally
1677395|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensors 3 days before hospitalization.
1677396|NCT01640223|Device|Dexcom7|patients will wear 2 Dexcom sensor one day before hospitalization
1677518|NCT01639183|Other|Standard Care|Standard daily oral hygiene care by caregivers of nursing home residents whatever that standard care may be.
1677397|NCT01640210|Device|JewelPUMP (insulin patch pump)|"The study will be proposed during the visit of selection.
Visit of inclusion:
This visit will take place after having received the consent of the patient. Women will be asked to achieve a pregnancy test. Patients will wear a JewelPUMP containing saline solution in parallel with their usual insulin pump. They will be trained to use JewelPUMP.
Patients treated with insulin pump will be instructed to reproduce the same programming between their usual pump and the JewelPUMP, they will use in parallel.
Volume infused will be evaluated during a period of basal and bolus with a precision scale.
Patient monitoring: Patient have to come back to the centre every 24 hours for 3 days. Study visit:
Patients will be asked to fill out a questionnaire of satisfaction to the JewelPUMPTM and Visual scales.
Volume infused will be evaluated with a precision scale, by comparison of weight of JewelPUMP and patients' usual pump"
1677398|NCT01640197|Dietary Supplement|Resveratrol|Transmax (Biotivia). 500mg (1 capsule) per day for 28 days.
1677399|NCT01640197|Other|Placebo|Methyl Cellulose. 1 capsule taken once daily for 28 days.
1677400|NCT01640184|Procedure|Parathyroidectomy|sHPT patients with enlarged glands (≥3)will be randomized into parathyroidectomy group or ultrasonic ablation group. Patients in parathyroidectomy will get parathyroid surgery.
1677401|NCT01640184|Drug|Active vitamin D|CKD patients suffered from sHPT with 1-3 enlarged gland(s) and without indication of parathyroidectomy will be randomized to oral medicine therapy group or ultrasonic ablation therapy group. Patients in oral medicine group will be treated by active vitamin D and other general treatments, such as dietary phosphate restriction and phosphate binders, according to the suggestions in KDIGO guidelines.
1677402|NCT01640184|Procedure|Ultrasonic ablation|CKD-sHPT patients with enlarged parathyroid gland(s) randomized into the ultrasonic ablation group will be treated by ultrasound guided percutaneous parathyroid gland radio frequence ablation. According to the indications of parathyroid surgery, the patients will be divided into two sub-groups. The outcomes of these patients will be compared to the oral medicine group and the parathyroidectomy group, respectively.
1677403|NCT01640171|Procedure|Xylocaine 2% Injectable Anesthetic|xylocaine 2% injection 0.1 cc
1677404|NCT01640171|Drug|Proparacaine Hydrochloride 0.5% Drop|Topical drop given first to the treated eye.
1677405|NCT01640171|Drug|Tetravisc 0.5% Gel|Gel applied to eye 3 times prior to treatment
1677406|NCT01640171|Drug|Acuvail|Anti-inflammatory drop given after treatment
1677407|NCT01640171|Drug|Intra-vitreal Anti-VEGF Drug|Intravitreal injection treating wet AMD or Diabetic Macular Edema or Retinal Vein Occlusion
1677408|NCT01640158|Other|Computerized Plasticity-based Adaptive Cognitive Training|Computerized plasticity-based adaptive cognitive training, up to 65 hours
1677409|NCT01640158|Other|Commercially available computerized training|Commercially available computerized training, up to 65 hours
1677410|NCT01640145|Dietary Supplement|Protein|Whey protein intake
1677411|NCT01640145|Other|Exercise|Unilateral low intensity exercise
1677412|NCT01640119|Dietary Supplement|Bicarbonate|bicarbonate administration
1677413|NCT01640106|Dietary Supplement|Omega-3|800 mg Omega 3 daily (600 mg DHA/200 mg EPA)
1677414|NCT01640106|Dietary Supplement|Placebo|
1677415|NCT01640093|Drug|Abiraterone acetate, 250 mg (uncoated, current commercial tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
1677416|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
1677417|NCT01640093|Drug|Abiraterone acetate, 250 mg (coated, reformulated tablet)|Type=exact number, unit=mg, number=250, form=tablet, route=oral. Administered once under fasted conditions.
1677418|NCT01640093|Drug|Abiraterone acetate, 500 mg (coated tablet, slower in vitro dissolution)|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Administered once under fasted conditions.
1677419|NCT01640080|Drug|Esketamine|Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
1677420|NCT01640080|Drug|Esketamine|Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
1677421|NCT01640080|Drug|Placebo|Form= intravenous infusion, route= intravenous use. One single placebo intravenous infusion administered on Day 1 and Day 4.
1677422|NCT01640067|Biological|Human Neural Stem Cells|Surgical microinjection of human neural stem cells on spinal cord of ALS patients
1677423|NCT01640054|Drug|Fostamatinib|Fostamatinib 100mg once daily
1677424|NCT01640041|Device|Radio-frequency Microstiumulator|All participants will receive leg implants and will be trained first in the clinical and subsequently perform stimulation-assisted exercises in the home - for an overall duration of 6 months post-implant. Subsequently, exercise programs will continue without stimulation. Patient condition will be assessed at 9, 12 and 24 months post-implant.
1677425|NCT01640015|Other|dietary intervention|a low frequency diet (3 meals/day) a high frequency diet (9 meals/day)
1677426|NCT01640002|Drug|Propantheline Bromide|15MG OF PROPANTHELINE BROMIDE, THREE TIMES DAILY FOR 02 MONTHS.
1677427|NCT01640002|Drug|Placebo|PLACEBO CAPSULE, 03 TIMES DAILY FOR 02 MONTHS
1677428|NCT01639911|Drug|Alisertib|Alisertib at the assigned dose by mouth (PO) twice a day for 7 days beginning on day 1 of a 21 day cycle.
1677429|NCT01639911|Drug|Pazopanib|Pazopanib at the assigned dose once a day continuously for the duration of treatment.
1677430|NCT01639898|Drug|Lenalidomide and dexamethasone|2 cycles of the lenalidomide-dexamethasone (Len-Dex) combination before radiation or intensive treatment
1677431|NCT01639898|Drug|Lenalidomide and dexamethasone|9 cycles of the Len-Dex combination
1677432|NCT01639885|Drug|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
1677433|NCT01639885|Drug|Interferon Alfa-2b|1ug/kg (max 100ug) 7 days before and 22 days after first treatment with gemcitabine
1677475|NCT01639547|Drug|Peginterferon alfa-2a plus Ribavirin|Peginterferon alfa-2a(pre-filled syringes 180 mcg/0.5 ml once a week) plus ribavirin(200 mg/Capsules, 1000~1200 mg daily in split doses (morning/evening)) for 36 or 48 weeks
1677476|NCT01639521|Drug|cisplatin|Given IV
1677477|NCT01639521|Drug|gemcitabine hydrochloride|Given IV
1677478|NCT01639521|Drug|methotrexate|Given IV
1677434|NCT01639885|Biological|p53 SLP|8.2.3 The p53 SLP vaccine consists of 9 synthetic 25-30 amino acids long overlapping peptides, spanning amino acids 70-235 of the wt-p53 protein (patent number WO2008147186). Peptides are prepared at the GMP facility of the Department of Clinical Pharmacy and Toxicology of the LUMC. At the day of immunization peptides (0.3 mg/peptide) were dissolved in dimethyl sulfoxide (DMSO, final concentration 20%) admixed with 20 mM phosphate buffer (pH7.5) and emulsified with an equal volume of Montanide ISA-51.The vaccine (2.7mL) is administered subcutaneously.
1677435|NCT01639872|Drug|Clozapine|Clozapine: target dose of 400mg per day with a maximum dose of 550mg per day
1677436|NCT01639872|Drug|Risperidone|Clozapine: target dose of 4mg per day with a maximum dose of 6mg per day
1677437|NCT01639859|Other|Elastography|The elastography in vivo will be performed before the prostatectomy. The elastography ex vivo will be performed after radical prostatectomy.
1677438|NCT01639846|Drug|RX-10045|RX-10045 Ophthalmic Solution, 0.09% At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
1677439|NCT01639846|Drug|Vehicle for RX-10045 arm|Vehicle of RX-10045 Ophthalmic Solution At Visits 3A and 4, a trained study technician will instill one drop of the assigned, masked study treatment, into each eye.
1677440|NCT01639833|Device|Veriset Hemostatic Patch|Topical hemostat
1677441|NCT01639833|Device|TachoSil®|Topical Hemostat
1677442|NCT01639820|Procedure|identification of sentinel nodes + full pelvic lymph-node dissection|identification of sentinel nodes + full pelvic lymph-node dissection
1677443|NCT01639820|Procedure|only identification of sentinel nodes (without pelvic lymph-node dissection)|only identification of sentinel nodes (without pelvic lymph-node dissection)
1677444|NCT01639807|Drug|Latanoprost|Latanoprost (0.005%) eye drops, once daily in the evening
1677445|NCT01639807|Procedure|SLT|Selective Laser Trabeculoplasty
1677446|NCT01639794|Drug|Vesitirim™ (Solifenacin)|Oral
1677447|NCT01639781|Dietary Supplement|Flavanol rich intervention|Flavanol intervention drinks contain (400 mg flavanols) flavanol rich drink 2 x 400 mg 2 times a day over 2 weeks
1677448|NCT01639781|Dietary Supplement|Flavanol free control|Calorically, micro- and macronutrient matched control drink free of flavanols flavanol free drink 2 times a day over 2 weeks
1677449|NCT01639768|Drug|SUBLIVAC FIX Birch|Comparison of different dosages to placebo
1677450|NCT01639755|Device|new texture shaped breast implants|breast implant surgery
1677451|NCT01639742|Device|New texture round breast implants|Breast implant surgery
1677452|NCT01639729|Drug|Treatment A: Sufentanil IV|Sufenta IV (50 mcg/mL) 15 mcg push over 1 minute (IV)
1677453|NCT01639729|Drug|Treatment B: Sufentanil NanoTab Sublingual|Single Sufentanil NanoTab 15 mcg given sublingually (SL)
1677454|NCT01639729|Drug|Treatment C: Sufentanil NanoTab Buccal|Treatment C: Single Sufentanil NanoTab 15 mcg given buccally (BU)
1677455|NCT01639729|Drug|Treatment D: Sufentanil NanoTab Oral|Single Sufentanil NanoTab 15 mcg swallowed (PO)
1677456|NCT01639703|Drug|Xenetix-CT perfusion imaging|Injection of 50 ml of Xenetix
1677457|NCT01639690|Genetic|Autologous CD34+ cells transduced with TNS9.3.55|Patients will receive Filgrastim followed by apheresis of peripheral blood stem cells. CD34+ cells will be purified and transduced ex vivo. Transduced cells will be frozen in several aliquots whenever possible while vector copy number determination and biosafety testing are performed. Patients will be treated in the outpatient and/or inpatient units, and receive intravenous busulfan (8mg/kg) as non-myeloablative conditioning. Patients will be administered 2-12 x 10^6 transduced CD34+ cells per kg in 1 or several infusions. A back-up of 2 x 10^6 untransduced CD34+ cells per kg will be preserved for every patient.
1677458|NCT01639677|Procedure|Laparoscopic gastric bypass|Laparoscopic gastric bypass surgery
1677459|NCT01639677|Procedure|Laparoscopic VBG|Laparoscopic vertical banded gastroplasty
1677460|NCT01639664|Device|High doses CPFA|High doses CPFA (coupled plasma-filtration adsorption) with AMPLYA™ (BELLCO ITALY): >0.20 L/kg/day of plasma treated in the first 3 days after randomization.
1677461|NCT01639651|Other|Posterior capsule stretching|Control group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation)for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) and revaluation immediately post-intervention and four weeks post-intervention.
1677462|NCT01639651|Other|Mobilization with movement|Mobilization group that will be submitted for an evaluation of shoulder range of motion (internal/external rotation) for both limbs, upper limb active movements to warm-up (five minutes), posterior capsule stretching (Cross-body stretch for 3 sets of 30 seconds) plus a mobilization with movement to improve internal rotation of the dominant shoulder (three sets of 10 repetitions)and revaluation immediately post-intervention and four weeks post-intervention.
1677463|NCT01639638|Drug|PROAPOPTOTIC PEPTIDE CIGB 300|CIGB 300,in INTRALESIONAL on day 3 of each 48 HOURS.
1677464|NCT01639625|Drug|CIGB300|CIGB300: 15 mg, 35 mg and 70 mg All groups will receive CIGB-300 for local application.
1677465|NCT01639612|Biological|ALD-451|ALD-451 iv
1677466|NCT01639599|Drug|Dexamethasone iv injection|Dexamethasone 5mg iv during anesthesia induction
1677467|NCT01639599|Drug|Dexamethasone, haloperidol|dexamethasone + haloperidol 1mg
1677468|NCT01639599|Drug|Dexamethasone, haloperidol|Active Comparator: dexamethasone + haloperidol 2mg
1677469|NCT01639586|Behavioral|respite platform|Impact of the respite platform patient care on health profit
1677470|NCT01639586|Behavioral|Day care|Impact of the day care on health profit of patient
1677471|NCT01639586|Behavioral|No access to a respite structure|Control group without access to a respite structure
1677472|NCT01639573|Drug|Campath|Pediatric patients with dcSSc are eligible for the clinical trial if they fulfill the inclusion and exclusion criteria of the trial. The inclusion and exclusion criteria are based upon those of the SCOT trial for adult dcSSc patients, which is the Phase 3 clinical trial in the United States comparing autologous HSCT to monthly high dose cyclophosphamide (CY) alone.
1677473|NCT01639560|Drug|Varenicline|1 mg of varenicline twice per day for 12 weeks and brief behavioral counseling
1677474|NCT01639560|Drug|Placebo|1 placebo tablet twice per day for 12 weeks and brief behavioral counseling
1677479|NCT01639521|Drug|vinblastine|Given IV
1677480|NCT01639521|Drug|doxorubicin hydrochloride|Given IV
1677483|NCT01639508|Drug|Cabozantinib|Patients will receive cabozantinib at an initial dose of 60 mg orally daily. The drug is taken continuously over a period of 28 days (4 weeks), which constitutes one treatment cycle. Dose modifications for drug toxicity are permitted as per a prescribed algorithm. During the Treatment Period subjects will receive cabozantinib until either disease progression, the occurrence of unacceptable drug-related toxicity or for other reason(s) for subject withdrawal.
1677485|NCT01639469|Behavioral|Structured exercise|Structured exercise includes stretching, strengthening, and balance exercises.
1677486|NCT01639469|Behavioral|Lifestyle exercise|Subjects will be taught lifestyle exercises and advised about mobility strategies
1677487|NCT01639456|Biological|CD3-/CD19- natural killer cells|Infused on Day 0. The final CD3-/CD19- product must contain at least 20% NK cells based on previous studies using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
1677488|NCT01639456|Biological|CD3-CD56+ natural killer cells|Infused on Day 0. The final CD3-/CD56+ product must contain at least 70% NK cells based on a previous study using this cell product processing technique. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
1677489|NCT01639456|Device|CliniMACS® CD3 and CD19 Reagent System|In combination used to simultaneously deplete CD3+ cells to remove T-lymphocytes and deplete CD19+ cells to remove B-lymphocytes (CD3-/CD19-). The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
1677490|NCT01639456|Device|CliniMACS® CD56 Reagent System|CliniMACS® CD3 and CD19 Reagent System will be used in addition to CliniMACS® CD56 Reagent System to enrich CD56+ NK cells. The entire cell product will be administered except in cases where the T cell count exceeds the T cell infusion threshold. In such situations, the product volume will be adjusted to meet the lot release criteria.
1677491|NCT01639456|Drug|Cyclophosphamide|Infused intravenously 60 mg/kg x day -5
1677492|NCT01639456|Drug|Fludarabine|Fludarabine 25 mg/m2 x days -6 through -2
1677493|NCT01639456|Drug|Aldesleukin|IL-2 subcutaneously at 6 million units every other day for 6 doses - begin evening of the NK cell infusion.
1677495|NCT01639430|Other|rectal, tympanal and temporal artery thermometry|"Temperature measurement was done once in all patients included within the first hour of patients´presentation to the emergency department.
Tympanal measurement was carried out by the use of infrared ear thermometry, temporal artery thermometry was done using infrared technology as well."
1677496|NCT01639404|Procedure|Umbilical Cord Blood Administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
1677497|NCT01639404|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
1677498|NCT01639391|Procedure|skin biopsy|biopsy 5mm maximum on healthy skin under local anaesthesia.
1677499|NCT01639378|Procedure|Renal Denervation|Symplicity Catheter System
1677500|NCT01639352|Biological|SOM230|Patients will be given a starting of 60mg of SOM230 via injection, intramuscularly every 28 days.
1677504|NCT01639326|Drug|Irinotecan high doses|Irinotecan dose of 300 mg / m² in patients UGT1A1 * 1 / * 1 and 260 mg / m² in patients UGT1A1 * 1 / * 28 intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m² intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
1677505|NCT01639326|Drug|Irinotecan standard doses|Irinotecan at a dose of 180 mg / m² intravenous infusion over 90 minutes and folinic acid at a dose of 400 mg / m intravenous infusion over 2 hours and 5-FU at a dose of 400 mg / m² intravenous bolus and 5-FU 2400 mg / m² intravenous infusion for 46 hours.
1677506|NCT01639300|Biological|GNbAC1|Single dose intravenous (IV) GNbAC1 2mg/kg or 6mg/kg
1677507|NCT01639300|Biological|GNbAC1 placebo|Single dose intravenous (IV) GNbAC1 placebo
1677508|NCT01639274|Other|COPD prevalence|Determine prevalence of COPD
1677509|NCT01639261|Drug|Interferon gamma 1b|Initial dose: 50µg s.c. three times/week, without fever >38,5 dose increase: 50µg/m² BSA three times/week
1677510|NCT01639248|Drug|ENMD-2076|250 mg per day in oral capsules in 28 day continuous cycles
1677511|NCT01639222|Drug|Calcium 500 mg and Vitamin D3 800 IU|Calcium 500 mg and Vitamin D3 800 IU chewable tablets
1677512|NCT01639222|Other|Low calcium meals|A normal Western European diet with reduced calcium content (400 mg per day).
1677513|NCT01639209|Procedure|Vitrectomy|Pars plana vitrectomy plus laser/cryotherapy
1677514|NCT01639209|Procedure|Pneumatic retinopexy|Pneumatic retinopexy plus laser/cryotherapy
1677515|NCT01639196|Other|Self-compassion writing|Participants are instructed to write about their chronic pain in a way that elicits self-compassion for 20 minutes once a week for three consecutive weeks.
1677516|NCT01639196|Other|Self-efficacy writing|Participants are instructed to write about their chronic pain in a way that elicits self-efficacy for 20 minutes once a week for three consecutive weeks.
1677517|NCT01639183|Device|Rotating-oscillating Power Toothbrush|A power toothbrush will be used twice daily for performing daily oral care on nursing home residents by their caregivers.
1677519|NCT01639170|Radiation|chest radiograph|"All enrolled patients underwent erect chest x-rays assessment. In all cases the diagnosis of pneumoperitoneum was based upon the plain film identification of subdiaphragmatic air on the upright posteroanterior chest radiograph.
All patients were transported from their hospital rooms to the radiology department in wheelchairs and remained in an upright position for more than 10 min before the chest radiographs were obtained. In all cases upright posteroanterior was obtained with the patient standing, using 183-cm distance, 125 kVp, phototimed exposure, and radiographic film with a wide exposure latitude.
The disappearance of intraabdominal free gas will be evaluated every 48h and will be defined as the loss of the"
1677520|NCT01639157|Drug|Buspirone|Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
1677521|NCT01639157|Drug|Placebo|Subjects will be maintained on oral placebo (0 mg administered 3 times daily) for 6 days each during the study in random order.
1677522|NCT01639144|Biological|PRP and PPP|Autogenous PRP and PPP
1677523|NCT01639131|Drug|Gemcitabine|intravenous gemcitabine 800mg/m2 on days 1 and 8
1677524|NCT01639131|Drug|Docetaxel|docetaxel 70mg/m2 on day 8 of each 21 day cycle
1677525|NCT01639131|Drug|Filgrastim or Pegfilgrastim|filgrastim (G-CSF) on days 9 through 15 or pegfilgrastim 6mg on day 9 or 10 of each cycle
1677526|NCT01639105|Procedure|Laser treatment|10 600 NM ABLATIEVE FRACTIONATED LASER
1677527|NCT01639092|Drug|Tenofovir|Tenofovir 300mg Daily Oral
1677528|NCT01639092|Drug|Tenofovir|Tenofovir 300mg Daily Oral
1677529|NCT01639092|Drug|Entecavir|Entecavir 1 mg daily Oral
1677530|NCT01639079|Behavioral|Internet Smoking Cessation Web Site|Internet Stop Smoking site (TC5) with several intervention elements from which the participants may choose as many as they wish. The links (URLs) to register for the study are: English: www.stopsmoking.ucsf.edu Spanish: https://www.stopsmoking.ucsf.edu/es/intro/home.aspx
1677531|NCT01639066|Drug|Tenofovir|Tenofovir 300mg daily Oral
1677532|NCT01639066|Drug|Entecavir|Entecavir 1 mg daily Oral
1677533|NCT01639066|Drug|Tenofovir|Tenofovir 300mg daily Oral
1955209|NCT03263078|Drug|Propofol|Anesthesia was introduced by intravenous administration of 2ug/kg Fentanyl, 1mg‧kg-1 Lidocaine, 1-2mg‧kg-1 Propofol and 0.8-1.2mg‧kg-1 Rocuronium. After the endotracheal tube was inserted, anesthesia was maintained with TIVA using Target-controlled infusion(TCI) system (Orchestra® Base Primea; Fresenius Kabi, Germany) based on the pharmacokinetics model proposed by Schnider et al. with a target effect-site concentration of 3.0~5.0mcg‧ml-1. We set up routine hemodynamic monitoring including electrocardiography, oximetry, NIBP, as well as PiCCO-Technology and cerebral oximetry.
1955210|NCT03263078|Drug|Sevoflurane|Anesthesia was introduced by intravenous administration of 2ug/kg Fentanyl, 1mg‧kg-1 Lidocaine, 1-2mg‧kg-1 Propofol and 0.8-1.2mg‧kg-1 Rocuronium. After the endotracheal tube was inserted, anesthesia was maintained with inhalation anesthetic (50% O2/Air with Sevoflurane 2%). We set up routine hemodynamic monitoring including electrocardiography, oximetry, NIBP, as well as PiCCO-Technology and cerebral oximetry.
1677536|NCT01639027|Drug|Drotaverine|40 mg Drotaverine hydrochloride (Do-Spa) IV injection at the start of the study and repeated every 2 hours up to a maximum 3 injections.
1677537|NCT01639027|Drug|Placebo|Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
1677538|NCT01639014|Drug|F2695|75 mg OD in 2 capsules
1677539|NCT01639014|Drug|placebo|2 capsules
1677543|NCT01638988|Drug|Metformin|"cycle 2000 mg of Metformin : Day 1 to day 30; beginning with 1/2 tablet by day with an increasing until 4 pills by day
to 6 cycle 2000 mg of Metformin : Day 1 ot day 30; 4 pills of Metformin by day Positive pregnancy test : 4 pills of Metformin by day until 12 weeks of pregnancy"
1677544|NCT01638988|Drug|Clomiphene citrate|Cycle 1: Day 3 to day 7; 50 mg; 1 tablet of Clomiphene Citrate by day Cycle 2: Day 3 to day 7; 100 mg; 1 tablet of Clomiphene Citrate two times a day Cycle 3 to 6 : Day 3 to day 7; 150 mg; 1 tablet of Clomiphene Citrate 3 times a day
1677545|NCT01638975|Behavioral|Response Inhibition Training Program|This is a computerized cognitive retraining program consisting of 8 sessions delivered over a 4-week period.
1677546|NCT01638962|Drug|Instruction on analgesic use for pain relief (acetaminophen and NSAIDs)|The PHARMA group receives instruction, by video and pamphlet, on how to best use acetaminophen and NSAID as pain management for knee OA.
1677547|NCT01638962|Other|Neuromuscular exercise|The exercise group receives 1 hour of supervised neuromuscular exercise two times a week for 8 weeks. Supervision is conducted by physiotherapists specially trained in using neuromuscular exercise and its principles.
1677548|NCT01638949|Behavioral|Memory assessment|Neuropsycological tests including clinical and original tests to compare differences between each populations.
1677549|NCT01638949|Biological|Circulating biomarkers measure|ELISA tests from blood samples to compare differences between each populations.
1677550|NCT01638949|Genetic|ApoE4|Evaluation of apolipoprotein E polymorphism as a risk factor.
1677551|NCT01638949|Other|Brain imaging examination MRI and PET examinations|Structural and functional MRI FDG-PET to compare differences between each populations.
1677552|NCT01638936|Drug|BT062 , intravenous administration|Dose escalation to determine dose limiting toxicities (DLTs) and/or the maximum tolerated dose (MTD)/recommended Phase II dose (RPTD) of BT062 in combination with lenalidomide/dexamethasone
1677553|NCT01638923|Drug|EV/DNG (Qlaira, Natazia, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placebo. A blister card consists of 28 pills, taken orally once a day for 7 cycles of 28 days each.
1677554|NCT01638923|Drug|placebo|Matching placebo to be taken orally daily for 7 cycles of 28 days each.
1677555|NCT01638910|Drug|EV/DNG (Qlaira, BAY86-5027)|Oral estradiol valerate and dienogest (2 days 3.0 mg estradiol valerate (EV), 5 days 2.0 mg EV + 2.0 mg dienogest (DNG), 17 days 2.0 mg EV + 3.0 mg DNG, 2 days 1.0 mg EV, 2 days placebo), one table oral daily for 13 treatment cycles (1 cycle = 28days)
1677602|NCT01638598|Drug|matching placebo|matching placebo in each dose level
1728424|NCT00022698|Drug|Capecitabine|
1677556|NCT01638884|Behavioral|Memory assessment|Neuropsychological tests including clinical and original tests to compare differences between each populations
1677557|NCT01638884|Other|Structural MRI|to compare differences between each populations
1677558|NCT01638884|Other|Functional MRI|to compare differences between each populations
1677559|NCT01638884|Other|Virtual reality / Memory assessment|to compare differences between each populations
1677560|NCT01638871|Behavioral|PainCOACH|The 8-week Internet-based pain coping skills intervention program includes 8 sessions. Each session takes 30-45 minutes to complete and includes text, illustrations, photos, animations, audio narration, interactivity, and delivery of personalized feedback. Users will be expected to complete 1 session per week.
1677561|NCT01638858|Drug|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
1677562|NCT01638845|Procedure|continuous perineural catheter|continuous perineural catheter
1677563|NCT01638832|Device|Transient Elastography (FibroScan), Echosens, Paris, France|
1677564|NCT01638832|Device|Controlled Attenuation Parameter (CAP), Echosens, Paris, France|
1677565|NCT01638819|Biological|Autologous Cord Blood Stem Cells|One infusion of 60 ml syringe of study product
1677566|NCT01638819|Biological|Placebo|Saline
1677567|NCT01638806|Procedure|Group I: Primary PCI|Patients are treated with Aspirin, ADP-blocker and heparin and field-triaged or transferred immediately to an invasive center for PPCI
1677568|NCT01638793|Device|Microcap (Oridion, Needham, MA, USA)|
1677569|NCT01638793|Device|Smart Capno Line Plus O2 (Oridion, Needham, MA, USA)|
1677570|NCT01638780|Dietary Supplement|placebo|A placebo will given for 30 days, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
1677571|NCT01638780|Dietary Supplement|resveratrol|resveratrol will be given for 30 days, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
1677572|NCT01638767|Drug|Contraceptives, Oral|0.150 mg desogestrel and 0.030 mg ethinyl estradiol tablets, USP. One tablet per day at the same time each day, from the beginning of the menstrual cycle.
1677573|NCT01638767|Drug|Contraceptive, Vaginal ring|etogestrel/ ethinyl estradiol slow release vaginal ring (11.4 mg/2.6 mg) to deliver 120 mcg etonogestrel/15 mcg ethinyl estradiol per day
1677574|NCT01638754|Procedure|Image guided Cardiac Resynchronization Therapy (CRT) device lead placement.|Participants will have a cardiac MRI scan prior to insertion of CRT device and an image guided map will be created to guide placement of Cardiac Resynchronization Therapy (CRT) pacing leads to the most optimal target on the patients heart.
1677575|NCT01638754|Procedure|optimizing myocardial lead placement for Cardiac Resynchronization Therapy (CRT) devices|optimal lead placement will be determined by 3D model of coronary vein anatomy, myocardial scar and mechanical dyssynchrony
1677576|NCT01638741|Behavioral|Rehabilitation goals of patients with gynaecological cancer.|Conversations with the nurse and supportive phone calls. Conversation are structured and placed 1 and 3 months after surgery. Phone calls are carried out at two and three months after surgery.
1677577|NCT01638715|Drug|Remicade|- Infliximab (Remicade®) will be administered i.v. at a dose of 3 mg/kg at 0 and 2 weeks, and 5 mg/kg at weeks 6, 14, and 22, 30, 38, and 46.
1677578|NCT01638715|Drug|Orencia|- Abatacept (Orencia®) will be given i.v. at weeks 0, 2, 4, and then every 4 weeks until week 48 at a weight adjusted dose: <60 kg Body weight (BW): 500 mg; >60-100 kg BW: 750 mg; alternatively, based on preference and shared decision between patient and physician, patients randomized to the abatacept arm may receive s.c. application at a dose of 125mg weekly.
1677579|NCT01638715|Drug|Ro-Actemra|- Tocilizumab (Ro-Actemra®) will be administered every 4 weeks at a dose of 8 mg/kg BW (maximum dose of 800 mg); The employed dosage will be calculated using manufacturer guidelines; alternatively, based on preference and shared decision between patient and physician, patients randomized to the tocilizumab arm may receive s.c. application at a dose of 162mg every week.
1677580|NCT01638715|Drug|Mabthera|"- Rituximab (Mabthera®) will be given as 1000mg at weeks 0 and 2, and then repeated at weeks 24 and 26.
Patients will receive 100 mg methylprednisolon i.v. before each infusion, as well as 1000mg paracetamol, as well as 50mg diphenhydramine hydrochloride (Dibondrin©)."
1677581|NCT01638702|Other|Follow up of complications|Follow up for complications leading or not to removal (occlusion, accidental removal, infection, catheter related thrombosis, leaking, pain...)
1677582|NCT01638689|Drug|Escitalopram|20 mg p.o.
1677583|NCT01638676|Drug|Vemurafenib|Vemurafenib (960 mg PO daily) in patients with unresectable BRAFV600E positive Stage IIIC and Stage IV melanoma
1677584|NCT01638676|Drug|Metformin|Metformin (500 mg PO BID x 2 weeks, then 850 mg PO BID)
1677585|NCT01638663|Drug|Tolvaptan|15 mg pr day for 1 day
1677586|NCT01638663|Drug|Placebo|1 tablet Unikalk 1 pr day for 1 day
1677587|NCT01638650|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTIs)|in accordance with current clinical HIV treatment guidelines
1677588|NCT01638650|Drug|ritonavir|100 mg bid orally, Days 1-14
1677589|NCT01638650|Drug|saquinavir [Invirase]|500 mg bid orally Days 1-7, 1000 mg bid orally Days 8-14
1677590|NCT01638637|Device|APTIMA Assays; PANTHER System|APTIMA Assays; PANTHER System
1677591|NCT01638624|Drug|Propofol|Propofol :Propofol is an anesthetic agent, has structure similar to that of known such as alfa tocopherol.
1677592|NCT01638624|Drug|Placebo|
1677593|NCT01638611|Drug|HIP2B|Total daily doses of 60, 120, 240, 480, and 720 mg are planned in five separate dosing cohorts. Single or split dose (depending on dose volume) will be given by subcutaneous injection in the abdomen to six subjects per dosing cohort.
1677594|NCT01638611|Drug|Placebo|Equal volumes of placebo will be given by subcutaneous injection in the abdomen to 2 randomized subjects per dosing cohort.
1677595|NCT01638598|Drug|matching placebo|matching placebo in each dose level
1677596|NCT01638598|Drug|Test drug|BI 1021958
1677597|NCT01638598|Drug|matching placebo|matching placebo in each dose level
1677598|NCT01638598|Drug|Test drug|BI 1021958
1677599|NCT01638598|Drug|Test drug|BI 1021958
1677600|NCT01638598|Drug|Test drug|BI 1021958
1677601|NCT01638598|Drug|Test drug|BI 1021958
1728425|NCT00022698|Drug|Irinotecan|
1677603|NCT01638598|Drug|matching placebo|matching placebo in each dose level
1677604|NCT01638598|Drug|matching placebo|matching placebo in each dose level
1677605|NCT01638585|Drug|urokinase|daily short infusions, i. e. i. v. application of 1.000.000 I.E. urokinase over 30 min. for at least 10 and up to 21 days during the 30 days after randomization
1677606|NCT01638559|Drug|Immunosuppression withdrawal|Participants will undergo gradual ISW in no less than 36 weeks and no more than 52 weeks with frequent monitoring of liver tests. All participants will be followed for 48 months ensuring a minimum of 36 months of follow-up after successful ISW.
1677607|NCT01638546|Other|Laboratory Biomarker Analysis|Correlative studies
1677608|NCT01638546|Other|Placebo|Given PO
1677609|NCT01638546|Drug|Temozolomide|Given PO
1677610|NCT01638546|Drug|Veliparib|Given PO
1677611|NCT01638533|Other|Pharmacological Study|Correlative studies
1677612|NCT01638533|Drug|Romidepsin|Given IV
1677613|NCT01638520|Drug|Pascolizumab|0.05mg/kg - 10mg/kg Pascolizumab according to dosing cohort
1677614|NCT01638520|Drug|Placebo|Saline (volume determined based on weight of patient, and cohort of enrollment)
1677615|NCT01638507|Device|Resolute Integrity Stent|Medtronic Resolute Integrity Zotarolimus-Eluting Coronary Stent System
1677616|NCT01638494|Dietary Supplement|Colecalcium supplement|Daily Ca2+ and VitD intake was determined using a previously validated written dietary questionnaire, filled by the parents with the help of a registered dietitian. Eventual assumption of Ca2+ and/or VitD supplements or fortified foods was also registered. All questionnaires were collected and analyzed using a specific software based on the Italian food composition tables (Winfood, Medimatica SRL, Martinsicuro, Teramo, Italy). All data were recorded in a specific clinical chart before statistical analysis. All subjects with less than 70% of the DRIs were invited to participate in a randomized trial aiming to investigate the efficacy of different nutritional interventions. The dietitian gave information to the parents on how to improve the consumption of foods rich in Ca2+ and VitD according to DRIs. No nutritional support products were prescribed in children enrolled in group 2.
1677617|NCT01638468|Device|AngioJet Ultra PE Thrombectomy System|Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
1677618|NCT01638455|Device|Noninvasive device|Noninvasive device
1677619|NCT01638442|Drug|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2797 administered orally with 240 mL room temperature tap water after an approximately 10 hour fast.
1677620|NCT01638442|Drug|CHR-2797|Two 60 mg capsules (120 mg dose) of CHR-2792 administered orally with 240 mL room temperature tap water within 30 minutes of receiving a high-fat meal.
1677622|NCT01638416|Other|Blood transfusion|Blood transfusion in ICU patients aged 18 and over.
1677623|NCT01638403|Drug|BF2.649|"BF2.649 is provided in capsules. One-quarter or one-half of BF2.649 tablet at 20 mg (corresponding to 5-, and 10 mg, respectively).
Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
1677624|NCT01638403|Drug|Vigil|"Modafinil is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.
Modafinil tablet at 100 mg are enclosed in gelatine capsules. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
1677625|NCT01638403|Drug|palcebo|"placebo is provided in capsules. The capsules are identical in appearance to ensure that neither the patient nor the investigator nor members of the clinical staff knows the identity of the study medication.
placebo consist of identical capsules containing lactose only. Patients should take 2 capsules per day with a glass of water. They will be instructed to take 1 capsule in the morning (after waking up, before breakfast around 8.00 a.m.) and 1 capsule at noon."
1677626|NCT01638390|Device|Treatment with the VisuMax™ Femtosecond Laser|The reduction or elimination of myopia from ≥ -1.00 D to ≤ -8.00 D with ≤ -0.50 D cylinder and MRSE ≤ -8.25 D.
1677627|NCT01638377|Drug|Naltrexone|50 mg/day for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
1677628|NCT01638377|Drug|Control|Placebo (Lactose Monohydrate) for 24 weeks. All participants will receive medical intervention in the form of medical management (MM) which will be delivered by a trained health care professional.
1677629|NCT01638364|Drug|alcoholic beverage|An appropriate amount of 95% USP ethyl alcohol will be mixed in orange juice and tonic water to obtain a drink equivalent to 3-5 standard drinks. The beverage will be consumed over a period of 15 minutes.
1677630|NCT01638364|Drug|non-alcoholic beverage|This beverage will be a mixture of orange juice and tonic water. The beverage will be consumed over a period of 15 minutes.
1677631|NCT01638351|Behavioral|Resistance exercise|Progressive resistance exercise training, 3 times a week for 12 weeks.
1677632|NCT01638351|Behavioral|Usual care|Participants in this arm will receive a brochure specific for type 2 diabetes mellitus about the general principles of exercise, nutrition, and diet. They are asked to maintain their activity level.
1677633|NCT01638338|Behavioral|Web assisted brief motivational interview on risky drinking|People allocated to this arm will be given a password to enter and follow a pre-decided set of questions and hints to reduce their drinking
1677634|NCT01638338|Behavioral|Face to Face|The counseling provided by the GPs will be done at month 0, 6, 12
1677635|NCT01638325|Drug|Insulin Lispro|Administered SC
1677636|NCT01638325|Drug|BC106 insulin lispro|Administered SC
1677637|NCT01638299|Device|Hypo-Hyper Minimizer (HHM) System|Adjustment of Insulin dosing during meal time
1677638|NCT01638273|Drug|Pregabalin 150mg|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after meal) for three days
1677639|NCT01638273|Drug|Pregabalin 75mg|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, after meal) for three days
1677640|NCT01638260|Drug|Liraglutide|Liraglutide once daily 1.8 mg injection subcutaneously, 26 weeks
1677641|NCT01638260|Behavioral|NEAT|Increasing NEAT by activating lifestyle interventions, combined with liraglutide once daily 1.8mg injections subcutaneously
1677642|NCT01638247|Drug|Tamoxifen|25 mg daily.
1677643|NCT01638247|Drug|Tamoxifen and GnRH analogue|"25 mg Tamoxifen daily and GnRH analogue:
Goserelin (10.8 mg s.c. after randomisation and after three months) or
Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
1677644|NCT01638247|Drug|Exemestane and GnRH analogue|"25 mg Exemestane daily and GnRH analogue:
Goserelin (10.8 mg s.c. after randomisation and after three months) or
Leuprorelin (11.25 mg s.c. after randomisation and after three months)."
1677645|NCT01638234|Dietary Supplement|Melatonin|melatonin 3 mg tab 1 tab po hs for 4 weeks
1677646|NCT01638234|Dietary Supplement|Placebo|starch pill
1677647|NCT01638208|Drug|VSL#3|Dosage Form: Capsules (Details as given below); Dose and duration of treatment: 1 capsule b.i.d for 8 weeks; Each capsule contains 112.5 Billion CFU of the following 8 strains of bacteria, 4 lactobacilli strains (L. acidophilus, L. plantarum, L. paracasei, L. delbrueckii subsp bulgaricus), 3 bifidobacteria strains (B. breve, B. infantis, B. longum) and 1 strain of S. thermophilus).
1677648|NCT01638195|Device|Focused Ultrasound|Focused Ultrasound
1677649|NCT01638182|Dietary Supplement|Placebo|27 participants received for three months 1 placebo capsule per day
1677650|NCT01638182|Dietary Supplement|Vitamin K1-capsules|27 participants received for 3 months 1 vitamin K1-capsule per day containing 52 µg of K1/day
1677651|NCT01638182|Dietary Supplement|Vitamin K2-capsules|27 participants received for 3 months 1 vitamin K2-capsule per day containing 75 µg of MK-7.
1677652|NCT01638169|Device|adding a heel|walking with and without heels on the gaitrite system
1677653|NCT01638143|Dietary Supplement|MenaQ7 M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
MenaQ7 M-1500 capsule
Gnosis P-1000 capsule
Gnosis M-1500 capsule
Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
1677654|NCT01638143|Dietary Supplement|Gnosis P-1000 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
MenaQ7 M-1500 capsule
Gnosis P-1000 capsule
Gnosis M-1500 capsule Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
1677655|NCT01638143|Dietary Supplement|Gnosis M-1500 capsules|"The study participants will receive three different types of capsules as a single dose (75 μg of MK-7/day):
MenaQ7 M-1500 capsule
Gnosis P-1000 capsule
Gnosis M-1500 capsule
Every two weeks, participants switch to another type of capsule; the washout period will therefore be two weeks."
1677656|NCT01638117|Other|PAC14028-Vehicle|PAC-14028 Cream Vehicle, Daily for up to 21 days
1677657|NCT01638117|Drug|PAC14028-0.1|PAC-14028 Cream, 0.1%, Daily for up to 21 days
1677658|NCT01638117|Drug|PAC14028-0.3|PAC-14028 Cream, 0.3%, Daily for up to 21 days
1677659|NCT01638117|Drug|PAC14028-1.0|PAC-14028 Cream, 1%, Daily for up to 21 days
1677660|NCT01638117|Other|Saline|Saline, Daily for up to 21 days
1677661|NCT01638117|Other|Positive|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
1677664|NCT01638091|Behavioral|Ex vivo module|Pre-test, ex vivo computerized training module, post-test
1677665|NCT01638091|Behavioral|In vivo practice-base learning phase|Prediction of polyp histology in real time, comparison to pathology reports, and review of cumulative individual performance.
1677666|NCT01638078|Drug|Thalidomide|Thalidomide, pill, 50 mg, once p.d., 6 weeks
1677667|NCT01638078|Drug|Placebo|Placebo, pill, once p.d., 6 weeks
1677668|NCT01638052|Drug|0.25% Bupivacaine + Clonidine|Patients will receive 2mL of 0.25% bupivacaine with 2mcg/ml of clonidine
1677669|NCT01638039|Other|Laboratory Tests|Stool, blood, urine and saliva samples
1677670|NCT01638026|Drug|TRIPTORELIN ACETATE, hCG|In the study group women will receive GnRH agonist (decapeptyl 0.2 mg) for oocyte maturation, followed by ovum pick-up which will be performed 35 hours later. Embryo transfer will be performed 48-72 hours after ovum pick-up. Luteal support will include HCG 1500 IU.
1677672|NCT01638000|Drug|Mirabegron|oral tablet
1677673|NCT01638000|Drug|Solifenacin succinate|oral tablet
1677674|NCT01637987|Procedure|Unassisted vein visualization|The traditional technique of vein visualization and palpation will be used to identify veins during the PIV insertion procedures. This involves the use of a tourniquet to facilitate venous pooling to see the vein and prevent vein rupture during cannulation. Nurse may use heat application to facilitate vein identification.
1677675|NCT01637987|Procedure|Wee Sight® Transilluminator|The Wee Sight® Transilluminator (Philips Children's Medical Ventures, Monroeville, PA) is a hand held, non-heat producing, light emitting diode (Class 2), battery operated device. The device is held adjacent to or under the subject's extremity to visualize the venous anatomy superficial veins absorb light and appear as dark lines against the surrounding illuminated tissues. Vein visualization improves with dimmed room lighting and a thin subcutaneous tissue layer. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the Wee Sight to assist in vein identification.
1677676|NCT01637987|Procedure|VeinViewer® (Christie Digital Systems, Cypress, CA)|VeinViewer near infrared light views hemoglobin up to 10 mm beneath skin. Hemoglobin absorbs the light while surrounding tissue scatters it providing a suitable contrast between the vein & surrounding subcutaneous tissue. This data is captured, digitally processed by video camera, and projected back onto the skin as a visual image of venous anatomy. Nurse will assess vascular anatomy using traditional techniques of visualization and palpation with tourniquet/heat application as needed, and add the VeinViewer to assist in vein identification.
1677677|NCT01637974|Drug|INTERCOAT administration|Applying INTERCOAT in the intrauterine cavity at the end of the hysteroscopic surgery
1677678|NCT01637961|Drug|Alisertib|Given PO
1677679|NCT01637961|Other|Laboratory Biomarker Analysis|Correlative studies
1677680|NCT01637948|Drug|Listerine mouthrinse|For six months
1677681|NCT01637948|Drug|Chinese Medicine mouthrinse|six months
1677682|NCT01637935|Drug|Pioglitazone|Pioglitazone tablets.
1677683|NCT01637922|Drug|BI 201335|BI 201335 for 9 days
1677684|NCT01637922|Drug|BI 201335|BI 201335 for 9 days
1728661|NCT00024193|Drug|cyclophosphamide|
1677685|NCT01637909|Drug|Control group who are advised for proper life style modification by the physician such as regular exercise and healthy diet without active intervention.|All the study subjects will undergo baseline brachial blood pressure measurement(OMRON HEM 7080IT), central aortic blood pressure measurement with Sphygmocor device(AtCor Medical), baseline laboratory, 24hr urine Na measurement, 24 hour ambulatory blood pressure and cardiopulmonary exercise test. These tests will be repeated at the 8th week.
1677686|NCT01637909|Dietary Supplement|Treatment group 1(Dietary intervention)|The dietary intervention is based on active education of the enrolled subjects based on Korean modified DASH diet. The enrolled subjects are advised to substitute processed white rice with whole grains such as barley. For protein, the subjects are advised to consume chicken and fish instead of red meat. Also, consumption of nuts are recommended where as processed foods containing high fructose corn syrup are not recommended. We will recommend to reduce salt intake by advising the subjects from adding table salts to their meals as well as adding salt during cooking. We will advise the subjects from eating pickles and condiments, which are the main source of salt in the Korean population. The degree of salt reduction before and after intervention will be assessed by 24 hour recall as well as measurement of 24 hour urine Na collection at baseline and at the 8th week. The compliance of the subjects will be assessed by 24hr recall as well.
1677687|NCT01637909|Other|Treatment group 2(dietary and exercise intervention)|The dietary intervention will be combined with exercise intervention. At baseline, the subjects will undergo evaluation for (1) cardiopulmonary function by undergoing cardiopulmonary exercise test and 3 minute step test 2) muscle strength assessment by hand grip test and 3) push ups to assess muscle endurance. After the initial evaluation, the subjects will be subjected to a course in aerobic exercise and muscle strengthening exercise developed by the Yonsei University Physical education department and will receive an educational DVD program. The subjects will each be given an electronic step counter to assess the degree of exercise. All the subjects in the treatment group 2 will be advised to undergo moderate to stenuous aerobic exercise for least 150 minutes /per week. Also, the subjects will be educated to perform muscle strengthening exercise as specificed in the educational program. The subjects will be asked to submit an exercise diary to assess the degree of compliance.
1677688|NCT01637896|Device|DEB+BMS|drug-eluting balloon predilation and bare metal stent implantation
1677689|NCT01637896|Device|POBA+DES|conventional balloon predilation and drug-eluting stent implantation
1677690|NCT01637883|Drug|benzydamine HCl|3 ml (4.5 mg) of benzydamine hydrochloride will be dripped on the cuff of the endotracheal tube 5 minutes prior to induction of general anesthesia
1677692|NCT01637857|Dietary Supplement|sham oligoantigenic diet associated to lifestyle instruction|sham oligoantigenic diet associated to lifestyle instruction
1677693|NCT01637857|Dietary Supplement|oligoantigenic diet|oligoantigenic diet associated to life style counseling
1677694|NCT01637844|Drug|Telbivudine|HBsAg- and HBeAg-positive pregnant women at 28-32 weeks of gestation are given with telbivudine (oral 600 mg/day) until 4 weeks after delivery. Newborn infants are administered 100-200 IU HBIG within 12 hours after birth and vaccinated against hepatitis B with yeast recombinant hepatitis B vaccine (10 µg) at 0, 1, and 6-month schedule. HBV DNA and ALT levels are measured before the use of telbivudine, at delivery, and 1-2 months after stopping the drug. HBV serological markers, including HBsAg, anti-HBs, and anti-HBc, HBeAg and anti-HBe are tested in infants at age of 7-12 months.
1677695|NCT01637831|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment completion of questionnaires assessing sleep and quality of life 1, 3 and 6 months after the start of effective CPAP treatment.
1677696|NCT01637818|Procedure|Lichtenstein's operation|
1677697|NCT01637818|Procedure|Mesh Plug Repair|
1677698|NCT01637818|Drug|Opiate|Postoperative pain therapy
1677699|NCT01637818|Drug|Paracetamol|Postoperative pain therapy
1677700|NCT01637818|Drug|non-steroidal anti-inflammatory drug|Postoperative pain therapy
1677701|NCT01637805|Biological|Antigen-specific cytotoxic T lymphocytes induced by dendritic cells infected by recombinant adeno-associated virus with CEA gene|AAV-DC-CTL: Intravenous infusion, 1×109 cells, day 14; one cycle every month; at least one cycle
1677702|NCT01637792|Other|Three 2-liter exchanges daily CAPD|CAPD regimen of three 2-liter daily exchanges
1677703|NCT01637792|Other|Four 2-liter exchanges daily CAPD|CAPD regimen of four 2-liter daily exchagnes
1677704|NCT01637779|Behavioral|Fact sheet|fact sheet about pain management during immunization
1677705|NCT01637766|Drug|Melphalan (intra-arterial infusion)|"Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.
The chemotherapy will be infused via a tiny soft plastic tube (called microcatheter) at the tumor site over approximately 30 minutes.
The drug of choice is melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.
We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts."
1677706|NCT01637753|Drug|Carmustine(BCNU)|Carmustine Sustained Release Implant
1677707|NCT01637753|Procedure|Surgery|Routine tumor resection surgery
1677708|NCT01637714|Drug|Multi-strain probiotics|"B. longum BORI: 1 x 109
B. bifidum BGN4: 1 x 109
B. lactis AD011: 1 x 109
B. infantis IBS007: 1 x 109
Lactobacillus acidophilus AD031: 1 x 109
three times a day, within 10 minutes after meal, per oral with water"
1677709|NCT01637714|Drug|Placebo powder|"same taste, shape, dosage as experimental drug
three times a day, within 10 minutes after meal, per oral with water"
1677710|NCT01637701|Procedure|PkEP|Plasmakinetic enucleation of the prostate
1677711|NCT01637701|Procedure|B-TURP|Bipolar transurethral resection of the prostate
1677712|NCT01637688|Dietary Supplement|Comparison of treatment with different amino acid formulas|Growth and amino acid status of a newly innovated amino acid formula and a commercial amino acid formula
1677713|NCT01637675|Drug|20 mg sildenafil citrate by mouth|20 mg sildenafil citrate tablets by mouth three times a day for 8 weeks
1728877|NCT00017095|Biological|filgrastim|
1677714|NCT01637675|Drug|sodium tanshinone IIA sulfonate diluted with 5% glucose solution,20mg sildenafil citrate by mouth|sodium Tanshinone IIA sulfonate injection 80 mg diluted with 5% glucose solution(0.9% sodium chloride injection will also be permitted if necessary) 250ml iv drip once a day for 8 weeks,as well as 20mg sildenafil citrate tablets by mouth three times a day for the same duration of treatment
1677715|NCT01637662|Drug|Natriuretic peptides|I.V. infusion between 0.2-3 microgram over 20 minutes
1677716|NCT01637636|Drug|tasimelteon|20mg, oral capsule, once, Days 1 and 12
1677717|NCT01637636|Drug|tasimelteon|20mg, oral capsule, once, Days 1 and 6
1677718|NCT01637636|Drug|Rifampin|600mg, oral capsules (2 x 300mg), once daily (QD), Days 2-11
1677719|NCT01637636|Drug|Ketoconazole|400mg, oral tablets (2 x 200mg), once daily (QD), Days 2-6
1677720|NCT01637623|Drug|Losartan|Losartan 50 mg daily for two weeks, then increased to 100mg daily for 4 weeks if asymptomatic. Remain at 50 mg daily for 4 more weeks or removed from study if symptomatic.
1677721|NCT01637623|Drug|Allopurinol|Allopurinol 300 mg daily for 6 weeks
1677722|NCT01637623|Drug|Placebo|Placebo capsule daily for 6 weeks
1677723|NCT01637584|Drug|Prazosin|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
1677724|NCT01637584|Drug|Placebo|The medication will be administered in the same manner, regardless of active or placebo, as the study physician and investigators, as well as the participants, will be blind to the type of medication they are taking.
1677725|NCT01637571|Drug|Dexilant|60mg of Dexilant QD for 12 weeks
1677726|NCT01637571|Drug|Dexilant Placebo|60mg of Dexilant placebo QD for 12 weeks
1677730|NCT01637545|Drug|Ramosetron|"G1 - Ramosetron 0.3mg i.v. just before the beginning of the surgery G2 - Ramosetron 0.3mg i.v. just after the end of the surgery and moving into the Recovery room
G3 - No medication but regular antiemetics injection if the patient want"
1677731|NCT01637532|Drug|tocilizumab and interferon alpha 2-b|"During first three chemotherapy cycles, tocilizumab and/or Peg-Intron are added.
Tocilizumab is given in a dose-escalation scheme (1,2,4,8mg/kg n=3) and Peg-Intron is adminstered subcutaneously 1.0ug/kg"
1677732|NCT01637532|Drug|Carboplatin and Caelyx or doxorubicin|Standard chemotherapeutic care given in every arm as standard care. A total of 6 cycles is the aim.
1677737|NCT01637480|Other|Lumbopelvic manipulation|High-velocity-low-amplitude thrust manipulation of the lumbopelvic region
1677738|NCT01637467|Other|Electrical muscle stimulation (EMS)|EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
1677739|NCT01637467|Other|Sham EMS|Sham EMS delivered to the quadriceps and gluteal muscles, twice daily, 30 minutes per session for up to 4 weeks.
1677740|NCT01637454|Drug|Noradrenaline|Patients in group B received a continuous infusion of noradrenaline at an initial dose of 0.5 mg/hour, designed to achieve an increase in mean arterial pressure (MAP) of at least 10mmHg or an increase in 4-h urine output to more than 200 mL. When one of these goals was not achieved, the noradrenaline dose increased every 4 hour in steps of 0.5 mg/hour, up to the maximum dose of 3 mg/hour
1677741|NCT01637454|Drug|Terlipressin|Patients in group A received terlipressin as an intravenous bolus of 0.5 mg every 6 h. If a significant reduction in serum creatinine level (≥1 mg/dL) was not observed during 3-day period, the dose of terlipressin was increased in a stepwise fashion every 3 days to a maximum of 2 mg every 6 hour
1677742|NCT01637441|Procedure|laparoscopic sacropexy|under laparoscopic vision, the vesico-vaginal space is dissected until the level of the bladder neck. a synthetic non absorbable mesh is placed between the bladder and the vagina. the mesh is sutured to the vagina and the apex (vaginal apex or uterus) and anchored to the prevertebral ligament in front of the promontorium.
1677743|NCT01637441|Procedure|vaginal mesh|after anterior sagittal colpotomy, the bladder is dissected under the fascia layer, and the paravesical fossa are entered. a synthetic non absorbable mesh is placed with 4 arms suspension (trans obturator or not). treatment of the apex is mandatory.
1677744|NCT01637428|Device|ActiveCare+S.F.T 3rd generation|Intermittent Pneumatic Compression Device
1677745|NCT01637402|Drug|Abiraterone Acetate|"Standard dose: 1,000 mg, once daily, oral administration
Increased dose: 1,000 mg, twice daily, oral administration"
1677746|NCT01637402|Drug|Prednisone|5 mg, twice daily, oral administration
1677747|NCT01637389|Other|Basic Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Basic Safe Water Program receives: the community meeting; installation of a Mesita Azul; a six month technical guarantee; one safe-storage container; training of one household member in operation and basic maintenance of the technology; training of at least one local resident in repair and system maintenance; and follow up after four to six months of the installation date.
1677748|NCT01637389|Other|Enhanced Safe Water Program|The intervention is community promotional meetings followed by household installations of a UV-based drinking water disinfection system (Mesita Azul). Households can opt-in at the meetings, or when the organization returns for installations in that community (~2 weeks later). Mesita Azul utilizes a 15-watt UV lamp to disinfect water and a closed mouth collection container for safe storage. The system utlizes UV-Tube technology developed as a method to disinfect water in low- and middle-income communities. The Enhanced program complements the Basic version with: a water quality analysis and presentation of results to households at the community meeting; a six-month money back guarantee; the provision of two safe-storage containers to facilitate access to disinfected water at different locations within the household; training of two household members in operation and basic maintenance of the technology; an additional follow up visit about two weeks after the installation date.
1677749|NCT01637376|Drug|Temoporfin|A single dose of 0.04 mg per kilogram of body weight of Temoporfin will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes and will not be flushed with sodium chloride or any other aqueous solution.
1677750|NCT01637363|Behavioral|Psychoeducation|6 x 2 hours of psychoeducation
1677751|NCT01637350|Procedure|digestive tract reconstruction|Subtotal gastrectomy with BillrothⅠ or BillrothⅡ, total gastrectomy with jejunal interposition or Roux-en-Y reconstruction
1677752|NCT01637337|Procedure|laparoscopic pyelolithotomy|laparoscopy
1677753|NCT01637337|Procedure|percutaneous nephrolithotomy|percutaneous nephrolithotomy
1677754|NCT01637311|Procedure|POEM|Peroral endoscopic myotomy (POEM) has recently been described as a new minimally invasive endoscopic myotomy technique intending a permanent cure from primary achalasia.
1677755|NCT01637285|Biological|PF-04856883|Dose A
1677756|NCT01637285|Biological|PF-04856883|Dose B
1677757|NCT01637285|Biological|PF-04856883|Dose C
1677758|NCT01637285|Biological|PF-04856883|Dose D
1677759|NCT01637272|Drug|SOM230|Pasireotide (SOM230) sc injection was provided as solution for injection in individual 1-point-cut 1 mL ampule, containing nominally 200 μg of pasireotide (as free base). Doses: 50, 100, 150 and 200 μg. Pasireotide im LAR depot injection was provided as micro particles powder in vials containing nominally 10, 20, 40 & 60 mg of pasireotide (as free base) & solvent for suspension for injection in ampules for the reconstitution of the LAR micro particles. Doses: 10, 20, 30, 40 or 60 mg
1677760|NCT01637259|Drug|arm 1 nucleotide analogue reverse transcriptase inhibitors and boosted protease inhibitors|NRTI + PI
1677761|NCT01637259|Drug|Arm 2 boosted protease inhibitors and maraviroc|PI + maraviroc
1677762|NCT01637259|Drug|Arm 3 nucleotide analogue reverse transcriptase inhibitors and maraviroc|NRTI + maraviroc
1677763|NCT01637246|Drug|Any Fixed Combination Therapy|Patients with POAG or OHT previously treated with monotherapy and currently treated with any fixed combination therapy. This was a retrospective chart review study, so no treatment was administered in this study.
1677764|NCT01637233|Drug|Arm 1 TNucleotide Analogue Reverse Transcriptase Inhibitors and Boosted Protease Inhibitors|NRTI+PI
1677765|NCT01637233|Drug|Arm 2 Maraviroc and Protease Inhibitors|maraviroc + PI
1677766|NCT01637233|Drug|Arm 3 Maraviroc and Nucleotide Analogue Reverse Transcriptase Inhibitors|maraviroc + NRTI
1677767|NCT01637220|Biological|Blood volume collected specifically for this study|"case patient: 10 ml after the anaphylactic reaction, and during the Allergology-Anesthesia consult 6 to 8 weeks after the shock le choc.
Control patients: 20 ml following neuromuscular blocking drug injection"
1677768|NCT01637207|Other|Palpation|Group A: Palpation Group
1677769|NCT01637207|Other|Ultrasound|Group B: Ultrasound Group
1677770|NCT01637194|Drug|everolimus|Given PO
1677771|NCT01637194|Biological|cetuximab|Given IV
1677772|NCT01637194|Other|pharmacological study|Correlative studies
1677773|NCT01637194|Other|laboratory biomarker analysis|Correlative studies
1677774|NCT01637181|Procedure|Endovenous laser ablation (EVLA)|EVLA with 940 nm Diode laser EVLA with 1470 nm Nd:Yag laser With both devices, obliteration of the varicose vein is obtained by heating the vein, using emission of laser light.
1677775|NCT01637168|Drug|Panax Ginseng + Ginkgo Biloba + Polyminerals + Multivitamin|A tablet, 2 times daily (12/12 hours).
1677776|NCT01637168|Drug|Ginkgo Biloba (Tebonin®)|A tablet, 2 times daily (12/12 hours).
1677777|NCT01637155|Drug|Cholecalciferol|One baseline oral dose of 50.000 UI to determine pharmacokinetics. After 28 days, patients take a period of 90 days of standardization of cholecalciferol based on baseline levels. After this period, patients receive a second oral dose of 50.000 UI to determine a second pharmacokinetics.
1677778|NCT01637142|Drug|LY2140023|Administered orally.
1677779|NCT01637142|Drug|14C-LY2140023|Administered IV.
1677780|NCT01637142|Drug|14C-LY404039|Administered IV.
1677781|NCT01637129|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation, repetitive at 1Hz
1677782|NCT01637129|Device|Sham Magnetic Stimulation|Sham Magnetic Stimulation
1677783|NCT01637103|Behavioral|Cognitive therapy of depression|Cognitive therapy will involve eight individual weekly sessions of 50 minutes with a Ph.D. student in psychology.
1677784|NCT01637103|Behavioral|Bright light therapy|Bright light therapy will consist of a 30-min daily morning exposition to a 10 000-lux BLT lamp during 8 weeks.
1677785|NCT01637090|Drug|Everolimus|"The study drug everolimus will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Everolimus should be administered orally once daily, preferably in the morning, at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed.
Everolimus will be administered orally as once daily dose of 10 mg continuously from study day 1 until progression of disease or unacceptable toxicity.
If vomiting occurs, no attempt should be made to replace the vomited dose. All dosages prescribed and dispensed to the patient and all dose changes during the study must be recorded."
1677786|NCT01637077|Drug|pregabalin|Given PO
1677787|NCT01637077|Drug|placebo|Given PO
1677788|NCT01637077|Other|questionnaire administration|Ancillary studies
1677789|NCT01637064|Drug|Acthar|Physicians will prescribe Acthar at their own discretion; however the recommended dose is 80 units subcutaneously twice a week.
1678495|NCT01631409|Procedure|PCA|Percutaneous coronary angioplasty
1677790|NCT01637051|Device|Zimmer NexGen® Trabecular Metal Technology (TMT), Monoblock|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).
The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
1677791|NCT01637051|Device|Zimmer NexGen® Trabecular Metal Technology (TMT), Modular|"A prospective randomized study where the patients are randomized too receive a monoblock tibial component with trabecular metal coating (TMT Zimmer NexGen®) or a modular tibial component (TMT Zimmer NexGen®). Both prostheses are available and approved by the FDA and CE. The only difference between the implants is that of the polyethylene insert (monoblock vs. modular).
The operations are performed at the Department of Planned Elective Surgery Z, Gentofte Hospital by two experienced TKA surgeons that will be included in the research group. During surgery a minimum of 4 Tantalum markers (0.8 mm) is inserted in the bone of the proximal tibia and 6 markers are inserted in the polyethylene insert."
1677792|NCT01637038|Other|RIPC|Those undergoing remote ischemic postconditioning. Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the unilateral upper limb and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
1677793|NCT01637025|Device|Oxidized cellulose strip|Single use, intra-operative application to the target bleeding site
1677794|NCT01637025|Device|Oxidized regenerated cellulose strip|A substance used to promote hemostasis (stops bleeding) based on oxidized regenerated cellulose
1677795|NCT01637012|Procedure|Implantation|index angioplasty with ALEX stent implatation
1677796|NCT01636999|Drug|50% Nitrous Oxide/50% Oxygen|The gas mixture is provided via the Sedara portable gas delivery system. This system is equipped with a non-rebreather mask which the patient holds over their mouth and nose. The delivery of the gas is only triggered by the patient's spontaneous breath. The gas machine will be provided to the patient to use as much as they like during the 60 minutes data collection period. The only dose which the machine allows to be administered is 50% Nitrous Oxide/50% oxygen.
1677797|NCT01636986|Device|Delefilcon A contact lenses|Silicone hydrogel contact lenses for daily wear, daily disposable use
1677798|NCT01636986|Device|Etafilcon A contact lenses|Hydrogel contact lenses for daily wear, daily disposable use
1677799|NCT01636973|Procedure|Vaporizing humidifier|Vaporizing humidifier applying during one-lung ventilation
1677800|NCT01636960|Biological|PegIFN alfa-2b|
1677801|NCT01636947|Drug|Aprepitant|Aprepitant (125 mg PO, QD) on Day 1, Aprepitant (80 mg PO, QD) on Days 2 and 3
1677802|NCT01636947|Drug|Aprepitant Placebo|Aprepitant Placebo (PO, QD) on Days 1, 2, and 3
1677803|NCT01636947|Drug|Ondansetron|Ondansetron (16 mg, IV, QD) on Day 1 and/or ondansetron (8 mg PO BID) on Days 2 and 3
1677804|NCT01636947|Drug|Dexamethasone|Dexamethasone (20 mg or 12 mg, PO) on Day 1
1677805|NCT01636947|Drug|Ondansetron Placebo|Ondansetron Placebo (PO, BID) on Days 2 and 3
1677806|NCT01636947|Drug|Rescue Therapy (granisetron, dolasetron, tropisetron or ondansetron; metoclopramide or alizapride).|Use of a rescue therapy for nausea and vomiting is permitted throughout the study. Permitted rescue therapies include a drug from among the following classes: 5-hydroxytryptamine (5-HT3) antagonists (granisetron, dolasetron, tropisetron or ondansetron), benzodiazepines, or benzamides (e.g., metoclopramide or alizapride).
1677807|NCT01636934|Drug|Minocycline|100 mg by mouth two times a day (200 mg/day) every day for 7 weeks, starting on the first week of chemoradiation therapy.
1677808|NCT01636934|Other|Placebo|1 capsule by mouth two times a day every day for 7 weeks, starting on the first week of chemoradiation therapy.
1677809|NCT01636934|Behavioral|Questionnaires|Questionnaires at baseline, timepoints during chemoradiation, and at treatment completion for 12 weeks.
1677810|NCT01636921|Drug|Sorafenib|200 mg orally twice daily (Maximum Tolerated Dose from Phase I of study) until disease progression.
1677811|NCT01636921|Procedure|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
1677812|NCT01636908|Drug|Sunitinib|50 mg once daily, oral use, 14 days
1677813|NCT01636908|Drug|Sorafenib|400 mg, twice daily, oral use, 14 days
1677814|NCT01636908|Drug|Erlotinib|150 mg once daily, oral use, 14 days
1677815|NCT01636908|Drug|Everolimus|10 mg once daily, oral use, 14 days
1677816|NCT01636908|Drug|Lapatinib|1250 mg once daily, oral use, 14 days
1677817|NCT01636908|Drug|Dasatinib|100 mg once daily, oral use, 14 days
1677818|NCT01636908|Drug|Pazopanib|800 mg once daily, oral use, 14 days
1677819|NCT01636908|Drug|Vemurafenib|960 mg twice daily, oral use, 15-21 days
1677820|NCT01636908|Procedure|tumor biopsy|
1677821|NCT01636908|Procedure|skin biopsy (optional)|
1677822|NCT01636895|Drug|Efficacy of suphladoxine/pyrimethamine as IPTp|3 tablets (single dose)given twice during pregnancy one month apart after quickening
1677823|NCT01636895|Drug|Efficacy of suphladoxine/pyrimethamine as IPTp|2 courses of 3 tablets of 500 mg N1-(5,6-dimethoxy-4-pyrimidinyl) sulfanilamide (sulfadoxine) and 25 mg 2,4-diamino-5-(p-chlorophenyl)-6-ethylpyrimidine (pyrimethamine)administered (at least 1 month apart) as DOTs to pregnant mother after quickening
1677824|NCT01636882|Biological|Coxsackievirus A21|
1677825|NCT01636869|Drug|Bupivacaine|"20 ml of 0.5% bupivacaine for single-shot femoral nerve block will be done at the beginning then another 20 ml of 0.5% bupivacaine for periarticular block will be performed at the end of operation.
Blood sample will be drawn at 60 min after femoral nerve block and before periarticular block, 15, 30, 45, 60 min after periarticular block."
1677826|NCT01636856|Behavioral|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
1677827|NCT01636856|Behavioral|Respiratory exercises, nasal dilator, nasal lavage|Respiratory exercises, nasal dilator, nasal lavage
1677828|NCT01636843|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin), once weekly.
1678496|NCT01631409|Procedure|CABG|Coronary artery bypass grafting
1677829|NCT01636843|Drug|placebo|Administered subcutaneously (s.c., under the skin), once weekly.
1677831|NCT01636817|Drug|NNC0109-0012|Administered subcutaneously (s.c., under the skin) once weekly.
1677832|NCT01636817|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly.
1677833|NCT01636804|Device|Quicksite|St. Jude Medical produced lead called Quicksite
1677834|NCT01636804|Device|Quickflex|St. Jude Medical produced lead called Quickflex
1677835|NCT01636791|Behavioral|Cognitive behavior therapy|Cognitive behavior therapy entails psychoeducational components, i.e. the patient is learns about the disorder and how to view it from a cognitive behavioral perspective. The most important part of the treatment is systematic behavior changes often targeted at exposure to feared stimuli. This is combined with cognitive interventions targeted at challenging negative automatic thoughts. All treatments will be delivered by licensed psychologists.
1677836|NCT01636791|Behavioral|Return to work|Participants randomized to this arm will receive an experimental treatment, based in cognitive behavioral therapy, with primary aim to help patients return to work. Interventions are aimed at solving work-related problems and comprises problem-solving training and systematic employer-patient meetings aimed at facilitating a gradual return to the workplace. Licensed psychologists deliver all treatments.
1677837|NCT01636778|Drug|SB-497115-GR|TPO receptor agonist to increase platelet count
1677838|NCT01636765|Drug|No Intervention|No intervention.
1677839|NCT01636752|Behavioral|Deprexis|Online self-help with and without e-mail-support
1677840|NCT01636739|Biological|Oral Rotarix®|2 doses administered orally.
1677841|NCT01636739|Other|Data collection|Additional information on intussusception will be collected through interview and by phone-contact.
1677842|NCT01636726|Drug|Inhaled LABA use|LABA prescription during the study period between Jan 1, 2002 and Dec 31, 2009
1677843|NCT01636713|Drug|GSK573719/VI 62.5/25|Inhalation via Novel Dry Powder Inhaler Once a day
1677844|NCT01636713|Drug|GSK573719/VI 125/25|Inhalation via Novel Dry Powder Inhaler Once a day
1677845|NCT01636713|Drug|Placebo|Inhalation via Novel Dry Powder Inhaler Once a day
1677846|NCT01636700|Drug|Tramadol 2mg/kg|2mg/kg
1677847|NCT01636700|Drug|Saline solution|saline solution- 1 dose
1677851|NCT01636674|Other|18F-fluordeoxyglucose positron emission tomography/ computed tomography|18F-fluordeoxyglucose positron emission tomography/ computed tomography for preoperative staging and post-operative follow-up
1677852|NCT01636661|Device|tDCS|transcranial direct current stimulation- non-invasive brain stimulation
1677853|NCT01636648|Device|Aortic Valve Replacement|Aortic Valve Replacement with Medtronic ATS 3f ENABLE® Aortic Bioprosthesis Model 6000
1677854|NCT01636635|Other|Calorie Restriction|Intervention consists of a calorically restricted diet regime designed and administered at the Weight and Wellness Center at Tufts University
1677855|NCT01636622|Drug|Vemurafenib|Starting dose of Vemurafenib: 480 mg by mouth mouth in the evening on Day 1 of Cycle 1, then twice a day starting on Day 2 for a 3 week cycle.
1677856|NCT01636622|Drug|Carboplatin|Starting dose of Carboplatin: AUC 5 by vein every 3 weeks.
1677857|NCT01636622|Drug|Paclitaxel|Starting dose of Paclitaxel: 100 mg/m2 by vein every 3 weeks.
1677858|NCT01636609|Drug|Cytarabine|"Phase I Arm A: Starting dose of Cytarabine 7.5 mg subcutaneous (SQ) twice daily (BID) for 10 days every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 10 mg SQ BID for 10 days.
Phase II (Randomized) Starting dose of Cytarabine: Maximum tolerated dose from Phase I."
1677859|NCT01636609|Drug|5-Azacytidine|"Phase I Arm B: Starting dose of 5-azacytidine 50 mg/m2 by vein (IV) or subcutaneously (SQ) daily for 7 days, on days 1-7 every 28 days. Dose escalation will proceed up to the Target dose level (dose level 0) 75 mg/m2 IV (or SQ) daily for 7 days, on days 1-7.
Phase II (Randomized) Starting dose of 5-azacytidine: Maximum tolerated dose from Phase I."
1677860|NCT01636609|Drug|Tosedostat|"Phase I: 120 mg by mouth daily. After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade >/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis.
Phase II: 120 mg by mouth daily. 120 mg by mouth daily during induction (i.e., first 28 days of therapy). After the first 4 weeks of therapy, a dose escalation to 180 mg daily may be considered for patients not achieving a CR provided the patient has not experienced any grade >/= 3 toxicity. Such instances should be discussed with the principal investigator and the sponsor and assessed on a case-by-case basis."
1677861|NCT01636596|Drug|Insulin LISPRO|Insulin is delivered in a pulsatile fashion. One treatment is approximately 10-15 units of insulin (exact dose based on weight) split into ten pulses delivered over one hour. Three treatments will be administered per session with one session per week for six month duration.
1677862|NCT01636583|Device|LSF water without meal|Composition of test meal: 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 1 mg of eluted Zn from LSF device of natural isotopic composition)
1677863|NCT01636583|Device|LSF water and inhibitory meal|Composition of test meal: Maize porridge and 67Zn-labelled LSF-fortified water (1 mg 67Zn as ZnSO4 + 0.44 mg of eluted Zn from LSF device of natural isotopic composition)
1677864|NCT01636583|Other|Fortified inhibitory meal with water|Composition of test meal: Maize porridge (1 mg 67Zn as ZnSO4 + 0.44 mg Zn as ZnSO4 of natural isotopic composition) and high purity water
1677865|NCT01636570|Drug|Placebo Comparator: Sugar Pill|Placebo will be given in identical gelcaps (as microcrystalline cellulose) as 2 per day for a period of 6 months.
1677866|NCT01636570|Drug|Vitamin D3 (cholecalciferol)|10,000 IU vitamin D3 will be given as 5000 IU gelcaps two per day for a period of 6 months.
1677867|NCT01636557|Drug|Sirukumab|Type=exact number, unit=mg, number=300, form=solution for injection, route=subcutaneous use, on Day 8
1678008|NCT01635413|Behavioral|Exercise Intervention|Undergo stretching and relaxation classes
1677868|NCT01636557|Drug|Midazolam|Type=exact number, unit=mg/kg, number 0.03, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
1677869|NCT01636557|Drug|Warfarin|Type=exact number, unit=mg, number= 10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
1677870|NCT01636557|Drug|Vitamin K|Type=exact number, unit=mg, number =10, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
1677871|NCT01636557|Drug|Omeprazole|Type=exact number, unit=mg, number=20, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
1677872|NCT01636557|Drug|Caffeine|Type=exact number, unit=mg, number=100, form=commercially available form, route=oral use, on Days 1, 15, 29, and 50
1677873|NCT01636544|Procedure|contralateral healthy tissue biopsy|At the time of surgery, a part of the specimen, plus a biopsy of the healthy (control) contralateral mucosa (i.e. right border of the tongue for a SCC of the left border, left cheek for a dysplasia of the right cheek and so on) will be harvested for research and immediately frozen at -80°C first in dry ice, then in a -80°C freezer.
1677874|NCT01636531|Drug|gantenerumab|High concentration liquid formulation (HCLF), single dose sc
1677875|NCT01636531|Drug|gantenerumab|Lyophilized formulation (LyoF), single dose sc
1677876|NCT01636518|Procedure|Standard of Care|Standard of care procedure as determined by treating physician for Atrial Fibrillation
1677877|NCT01636505|Drug|ghrh antagonist (cetrotide/orgalutran)|cetrotide/orgalutran 0.25 mg
1677878|NCT01636505|Drug|gnrh agonist (suprefact)|suprefact 5.5 ml
1677879|NCT01636492|Drug|bitopertin|Single oral dose
1677880|NCT01636492|Drug|placebo|Single oral dose
1677881|NCT01636479|Drug|SAR405838|Pharmaceutical form: Capsule Route of administration: Oral
1677882|NCT01636466|Drug|Everolimus|Everolimus will initially be dosed at 0.75 mg tablet taken orally twice a day. The dose will be adjusted to maintain serum trough concentrations of 5-8 ng/ml.
1677883|NCT01636453|Device|Stent assisted coiling with the Liberty Stent|Patients are implanted with the Liberty Stent as an assist to embolic coiling of their wide-neck, saccular, intracranial aneurysms and follow for 12 months
1677884|NCT01636440|Device|Conditioned Pain Modulation|Measure of the conditioned pain modulation with the nociceptive withdrawal reflex and ice water stimulation
1677885|NCT01636440|Device|Conditioned Pain Modulation|Suprathreshold electrical stimulation with 1.5 times the mean electrical pain detection threshold
1677886|NCT01636414|Procedure|Hemovac drain|The Hemovac drain is a device placed under your skin used to collect blood during surgery.
1677887|NCT01636414|Procedure|Re-infusion drain|This device is used during and after surgery to collect blood lost during this time and prepares the blood for possible reinfusion.
1677888|NCT01636414|Procedure|Tranexamic drain|Tranexamic Acid is a synthetic amino acid that prevents the breakdown of blood clots which reduces bleeding.
1677889|NCT01636401|Drug|aclidinium bromide 400 μg|
1677890|NCT01636401|Drug|aclidinium bromide placebo|
1677891|NCT01636388|Biological|allogeneic donor derived LMP specific cytotoxic T-lymphocyte|LMP CTLs will be give at 3 timepoints post allogeneic stem cell transplantation around days 60 to 100, then 30 days apart for the next 2 infusions.
1677892|NCT01636362|Device|Mepitel Ag|Mepitel Ag is an antimicrobial, meshed, non-adherent wound contact layer allowing passage of exudate and providing fixation and protection of tissues.
1677893|NCT01636349|Other|soccer exercise or continued daily lifestyle|Recreational soccer or continued unchanged lifestyle
1677894|NCT01636336|Other|Nicotine|Two doses of nicotine will be utilized in the study: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
1677895|NCT01636336|Other|Progesterone|Prometrium capsules containing 200 mg of micronized progesterone will be obtained from Solvay Pharmaceuticals, Inc. (210 Main Street West, Baudette, MN, 56623, phone (218) 634-3500, fax (218) 634-3540).
1677896|NCT01636323|Other|Nicotine|Subjects will be given two doses of nicotine: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). According to the Massachusetts Department of Public Health classification, cigarettes with a nicotine yield of 1.2 mg or higher are high nicotine cigarettes. The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
1677897|NCT01636310|Other|Nicotine|Two doses of nicotine will be utilized: a commercially available, high-yield nicotine cigarette (Marlboro Red; Phillip Morris brand) and a denicotinized cigarette (Murty Pharmaceuticals Inc., Lexington, KY). The high dose cigarettes contain 15.48 mg of nicotine and 16 mg of tar based on analysis by the Massachusetts Department of Public Health (MDPH, 1998). The low nicotine cigarettes contain 1.1 mg of nicotine and deliver 0.1 mg of nicotine and 2.8 mg of tar based on analyses provided by the manufacturer.
1677898|NCT01636297|Behavioral|Forced exercise|Exercise on a stationary bicycle 3 times per week for 8 weeks
1677899|NCT01636297|Behavioral|Voluntary exercise|Exercise on a stationary bicycle 3 times per week for 8 weeks
1677900|NCT01636297|Behavioral|No-exercise/control|No exercise intervention is given. This group serves as a control group.
1677901|NCT01636284|Biological|JX-594 recombinant vaccina GM-CSF|Enrolled patients will receive 5 weekly IV infusions on Days 1, 8, 15, 22, and 29. After Day 43, if their disease has improved or remained stable and they have not started other cancer therapy, they may be able to continue to receive JX-594 via IV infusion every three weeks. This treatment extension may continue until radiologic progressive disease, initiation of other cancer therapy, or patient withdrawal.
1677902|NCT01636271|Drug|darapladib|darapladib enteric coated tablets 160 mg
1677903|NCT01636271|Drug|placebo|placebo
1677904|NCT01636258|Behavioral|Stress Management|Every other week
1677905|NCT01636258|Behavioral|Diet|Every other week
1677906|NCT01636258|Behavioral|Exercise|Every week
1677907|NCT01636258|Behavioral|Culinary education|Every other week
1728878|NCT00017095|Drug|cyclophosphamide|
1677908|NCT01636245|Biological|three consecutive lots of EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
1677909|NCT01636245|Biological|placebo|placebo, two doses, 28 days interval
1677910|NCT01636206|Drug|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: ~1 year
1677911|NCT01636206|Drug|Placebo|Dosage Form: Ophthalmic Solution Dosage: placebo Frequency: BID Duration: ~1 year
1677912|NCT01636193|Biological|Oral Rotarix®|2 doses administered orally.
1677913|NCT01636193|Other|Data collection|Safety data will be collected through the check of health observation diary and interview of vaccinee's parent.
1677914|NCT01636180|Drug|Clopidogrel|repeated loading dose of clopidogrel (600 mg) in addition to high dose of clopidogrel continuous therapy for 30 days (150 mg/day)
1677915|NCT01636180|Drug|Clopidogrel|no repeated loading dose of clopidogrel with clopidogrel continuous therapy for 30 days (75 mg/day)
1677916|NCT01636167|Device|computerized intraoperative keratomer|computerized intraoperative keratomer can analyze the axis of corneal astigmatism accurately as well as rapidly by self-designed software during surgery
1677917|NCT01636154|Drug|Ixeris of sonchifolia Hance|KDZ40ml+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
1677918|NCT01636154|Drug|Panax notoginseng saponins|Xueshuantong450mg+0.9%N.S.250ml,ivdrip,qd of each 14-day cycle.Number of cycles:one.
1677919|NCT01636154|Drug|Ixeris of sonchifolia Hance combined with Panax notoginseng saponins|KDZ40ml+0.9%N.S.250ml,ivdrip;0.9%N.S.50ml,ivdrip;Xueshuantong450mg+0.9%N.S.250ml,ivdrip.qd of each 14-day cycle.Number of cycles:one.
1677920|NCT01636141|Drug|OLT1177 Gel|OLT1177 Gel - 3% or 5% administered topically to a defined area of one knee
1677921|NCT01636141|Drug|Placebo gel|
1677922|NCT01636128|Drug|difluoromethylornithine|500 mg oral for 14 days, combined with sulindac for 15 days
1677923|NCT01636128|Drug|Sulindac|150 mg oral for 15 days, combined with DFMO for 14 days
1677924|NCT01636102|Biological|Trivalent influenza virus vaccine (TIV)|A single 0.5 mL dose of the study vaccine supplied in prefilled syringes and administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
1677925|NCT01636089|Drug|bicarbonates|sodium bicarbonates 1,4%
1677926|NCT01636089|Drug|saline|sodium chloride 0,9%
1677927|NCT01636076|Drug|QMF149|delivered via Concept1 device
1677928|NCT01636076|Drug|Salmeterol|delivered via Accuhaler®
1677929|NCT01636063|Drug|Mifepristone|Mifepristone 200 mg capsulized orally once 24-48 hours prior to abortion procedure
1677930|NCT01636063|Drug|Misoprostol|Misoprostol 400 mcg buccally once 3 hours prior to abortion procedure
1677931|NCT01636050|Other|squat exercise training|Intervention may include squat exercise for 8 weeks
1677932|NCT01636037|Drug|levodopa/carbidopa (generic version of Sinemet)|Oral levodopa 900mg daily as tolerated.
1677933|NCT01636024|Drug|AZD7594|Suspension inhaled via Spira nebuliser
1677934|NCT01636024|Drug|Placebo to match|Matching placebo inhaled via Spira nebuliser
1677937|NCT01635998|Device|Boston Scientific Vessix Renal Denervation System|"Renal sympathetic denervation is modulation of the nerves which run along the renal arteries (the renal sympathetic nerves) with radiofrequency energy. This is the same energy source used to perform your heart ablation.
Boston Scientific Vessix Renal Denervation System, Boston Scientific, Inc., Quincy, Massachusetts"
1677938|NCT01635985|Drug|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250 µg AZD5423
1677939|NCT01635985|Drug|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
1677940|NCT01635985|Drug|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
1677941|NCT01635985|Drug|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
1677942|NCT01635985|Drug|AZD5423|dry powder inhaled via Turbuhaler, corr to approximately 200 µg lung deposited dose AZD5423
1677943|NCT01635985|Drug|AZD5423|dry powder inhaled via New Dry Powder Inhaler, corr to approximately 200 µg lung deposited dose AZD5423
1677944|NCT01635972|Drug|Isavuconazole|oral
1677945|NCT01635972|Drug|bupropion hydrochloride|oral
1677946|NCT01635946|Drug|Isavuconazole|oral
1677947|NCT01635946|Drug|atorvastatin|oral
1677948|NCT01635933|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color.
1677949|NCT01635933|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color.
1677950|NCT01635920|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
1677951|NCT01635920|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
1677952|NCT01635907|Drug|Dovitinib|
1677953|NCT01635894|Behavioral|Training|Women in both the practice nurse and specialist nurse groups were given supervised pelvic floor exercise training. After the initial training they were given a daily exercise regimen and seen at monthly intervals for three months. The practice nurses had attended a study day on supervising Pelvic Floor Muscle Training(PFMT)followed by practice sessions with patients overseen by the nurse specialist.
1677954|NCT01635881|Device|Emerge™ 1.20 mm PTCA Dilatation Catheter|"The Emerge 1.20 mm device is the next-generation Boston Scientific PTCA dilatation catheter. It is a sterile, single-use, intravascular medical device used to improve lumen diameter.
The catheter consists of a shaft with a balloon near the distal tip. The balloon is designed to provide an inflatable segment of known diameter and length at recommended pressures."
1677955|NCT01635855|Device|Belotero®|Hyaluronic acid dermal filler
1677956|NCT01635829|Drug|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Two tablets of telaprevir will be administered as per the dosing regimens for each part of both the panels.
1677957|NCT01635829|Drug|Phenytoin|Type=exact number, unit=mg, number=100, form=capsule, route=oral. Two capsules of phenytoin will be administered as per the dosing regimen in Part 2 of Panel 1.
1677958|NCT01635829|Drug|Carbamazepine|Type=exact number, unit=mg, number=200, form=tablet, route=oral. One tablet of carbamazepine will be administered as per dosing regimen in Part 2 of Panel 2.
1728879|NCT00017095|Drug|docetaxel|
1677959|NCT01635816|Biological|JE Vaccine existing facility|Will receive JE live attenuated SA 14-14-2 vaccine manufactured in the existing facility (250 infants).
1677960|NCT01635816|Biological|JE vaccine new plant lot 1|Will receive Lot 1 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
1677961|NCT01635816|Biological|JE vaccine new plant lot 2|Will receive Lot 2 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
1677962|NCT01635816|Biological|JE vaccine new plant lot 3|Will receive will receive Lot 3 JE live attenuated SA 14-14-2 vaccine manufactured in the new GMP facility (250 infants).
1677963|NCT01635803|Drug|Bevacizumab|1.25 mg bevacizumab administered by monthly interval for six months (6 injections).
1677964|NCT01635803|Drug|Ranibizumab|0.5mg ranibizumab administered by monthly interval for six months (6 injections).
1677965|NCT01635790|Drug|Ranibizumab|0.5 mg ranibizumab. Given as monthly intravitreal injections during 6 months
1677966|NCT01635790|Drug|Bevacizumab|1.25 mg of bevacizumab; Given as monthly intravitreal injections during 6 months
1677967|NCT01635777|Drug|Miltefosine|2.5 mg/kg/day for 12 weeks
1677968|NCT01635777|Drug|Miltefosine|2.5 mg/kg/day for 8 weeks
1677969|NCT01635764|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
1677970|NCT01635751|Drug|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, fasted)
1677971|NCT01635751|Drug|Pregabalin|GLA5PR GLARS tablet 150mg/day(Pregabalin 150mg once a day, after high fat meal)
1677972|NCT01635751|Drug|Pregabalin|Lyrica Capsule 150mg/day(Pregabalin 75mg twice a day, fasted)
1677973|NCT01635738|Biological|LP GMNL-133 capsule|One capsule with 2x10^9 (cfu) LP GMNL-133, once daily, PO
1677974|NCT01635738|Biological|LF GM-090 capsule|Arm: LF GM-090 group One capsule with 2x10^9 (cfu) LF GM-090, once daily, PO
1677975|NCT01635738|Biological|LP GMNL-133 +LF GM-090 capsule|One capsule with 4x10^9 (cfu) LP GMNL-133 +LF GM-090, once daily, PO
1677976|NCT01635738|Biological|Placebo|Placebo
1677977|NCT01635712|Drug|SNX-5422|Capsule dosed every other day for 21 days out of 28 day cycle. Dose escalation based on safety
1677978|NCT01635686|Drug|DWP422 25mg|
1677979|NCT01635686|Drug|ENBREL 25MG PFS INJ.|
1677980|NCT01635673|Other|Exercise intervention|Whole body vibration exercise 3 times per week
1677981|NCT01635660|Device|Intubation|Tracheal Intubation with the assigned video laryngoscope
1677982|NCT01635647|Biological|ChAd63 ME-TRAP and MVA ME-TRAP|ChAd63 ME-TRAP: 5 x 10^10vp MVA ME-TRAP: 1 x 10^8 pfu heterologous prime-boost immunisation
1677983|NCT01635647|Biological|Rabies vaccine|Two doses eight weeks apart into anterolateral thigh. 2 x 2.5IU Verorab
1677984|NCT01635634|Other|Cupping therapy|Cups are placed at the skin; local suction is created on the skin; it mobilizes blood flow; the suction is created by a mechanical device (Pneumatron, Pneumed, Germany)
1677985|NCT01635621|Drug|Olokizumab (OKZ)|"Subjects will receive one of the following treatment regimens as subcutaneous injection solution on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period:
OKZ 120 mg every 2 weeks
OKZ 240 mg every 2 weeks
OKZ 120 mg every 2 weeks, with a loading dose of OKZ 480 mg at Week 0
1.6 mL of OKZ drug substance presented in a glass vial with a 1.2 mL extractable volume at a concentration of 100 mg/mL in the formulation buffer, containing 25 mM sodium citrate, 90 mM sodium chloride, 0.02 % (weight/volume) polysorbate 80, pH 6.0."
1677986|NCT01635621|Drug|Placebo|Subjects will receive Placebo every 2 weeks as a subcutaneous injection solution (0.9% sodium chloride preservative-free for injection) on Weeks 0, 2, 4, 6, 8, 10, 12 and 14 of the Treatment Period.
1677987|NCT01635608|Drug|Acetaminophen|administration of 500 mg paracetamol
1677988|NCT01635608|Drug|Talinolol|administration of 50 mg talinolol
1677989|NCT01635608|Drug|Amoxicillin|administration of 500 mg amoxicillin
1677990|NCT01635608|Other|non-caloric water|administration of 240 ml water
1677991|NCT01635608|Other|caloric water|administration of 240 ml caloric water (containing 25.5 g sucrose)
1677992|NCT01635595|Procedure|Subtotal esophagectomy and gastric pull up|Subtotal esophagectomy and gastric pull up and radical thoracic (2,3,4R,7,8,9)and abdominal (15,16,17,18,19,20) lymphadenectomy
1677993|NCT01635595|Procedure|Subtotal esophagectomy at the azygos vein, total gastrectomy|Subtotal esophagectomy at the azygos vein, total gastrectomy and esophagojejunostomy and radical thoracic (2,3,4R,7,8,9) abdominal (15,16,17,18,19,20) lymphadenectomy.
1677994|NCT01635582|Other|Conventional hand exercise program|Exercises targeted to improve finger range of motion and hand strength.The exercises will be performed 30 minutes,four times per week for six weeks
1677995|NCT01635582|Other|Computer gaming hand exercise regimen|Computer gaming hand exercise regimen using common objects of daily life. The hand exercises are coupled with commercially available computer games and will be performed 30 minutes,four times per week for six weeks
1677996|NCT01635569|Behavioral|Group-based family cognitive-behavioural therapy|Baseline and post-12 sessions
1677997|NCT01635569|Other|Waitlist|Baseline and post-12 sessions
1677998|NCT01635556|Behavioral|Dialectical Behavior therapy|Weekly psychotherapy of both individual and group sessions
1677999|NCT01635530|Drug|Doxycycline|Doxycycline: 100mg tablet two times per day, four weeks
1678000|NCT01635530|Drug|Ceftriaxone|2 g intravenous once a day, three weeks
1678001|NCT01635504|Biological|Botulinum toxin A|Botulinum toxin A 50 units per side of the posterior cheek enlargement, injected into the masseter muscle and parotid gland (10 units into 5 points of the posterior cheek enlargement per side, giving a total of 100 units per patient)
1678002|NCT01635439|Drug|Propess|The vaginal insert is removed 24 h after the application. It is only to be removed earlier in case of the onset of active labour, the rupture of the membranes, or at the occurrence of hyperstimulation.
1678003|NCT01635439|Drug|Prostin E2|3 mg tab is placed in the posterior vaginal fornix. dose can be repeated every 6 hours till onset of active labour, the rupture of the membranes, or the occurrence of hyper-stimulation.
1678004|NCT01635426|Drug|Aspirin|Aspirin 75 mg daily for 2 months after meals
1678005|NCT01635426|Drug|Clopidogrel|Clopidogrel 75 mg daily for 2 months after meals
1678006|NCT01635413|Behavioral|Exercise Intervention|Undergo strength training classes
1678007|NCT01635413|Behavioral|Exercise Intervention|Undergo tai chi classes
1678012|NCT01635400|Drug|Irinotecan|irinotecan 180mg/m2 i.v. over 30 min d1,q2w
1678013|NCT01635387|Drug|aliskiren|150 mg once a day per 2 week with forced uptitration to 300 mg once a day, if tolerated
1678014|NCT01635374|Procedure|Per-Oral Endoscopic Esophagomyotomy|In this procedure, performed in the operating room under general anesthesia, a flexible endoscope is passed into the esophagus, a mucosal flap and a submucosal tunnel is created. This tunnel extends onto the stomach. The inner circular muscle layer of the lower esophagus and sphincter (LES) is identified and a myotomy is started 3-4cm distal to the mucosal flap and carried all the way onto the stomach. The mucosal opening is then closed with standard endoscopic clips. Patients will be admitted to the hospital and a gastrograffin esophagram will be performed on post-op day 2 to rule out esophageal leak. A standardized symptom checklist will be used to assess patient's prior to hospital discharge and on post-op days 4 and 7. All patient will have a 2 week post-op appointment.
1678015|NCT01635361|Other|New Medicine Service|The New Medicine Service is an intervention where patients prescribed a new medicine receive followup consultations with the pharmacist 7-14 days and 14-21 days after receiving the new prescription item
1678016|NCT01635348|Behavioral|motor skill gait exercise|The motor skill gait exercise is a task-oriented motor sequence learning approach to exercise to improve walking. The approach involves goal-directed stepping and walking patterns to facilitate use of the appropriate muscles at the appropriate timing relative to body position during gait through the task performance. Treadmill-assisted walking in brief intervals of small increased speed walking interspersed with usual walking speed are performed to induce the automatic rhythm and timing of gait. The exercise sessions are about 60 minutes, 2-3 times a week for 12 weeks or a total of 30-36 sessions.
1678017|NCT01635348|Behavioral|aerobic gait intervention|The aerobic gait intervention approach involves treadmill and overground walking with the gradual increases in the distance walked and speed of walking. The exercise approach provides walking practice, including on the treadmill to facilitate the timing of stepping during gait, while also facilitating a fitness or conditioning response, and endurance for walking activities. The exercise sessions are about 60 minutes, 2-3 times weekly for 12 weeks, or about 30-36 sessions.
1678018|NCT01635335|Behavioral|Latino STYLE|7-hour family-based workshop with 3-hour follow-up booster 3 months later
1678019|NCT01635322|Device|Polyaxial posterior spinal fusion system|posterior correction and fusion of the thoraco-lumbar or lumbar spine
1678020|NCT01635309|Other|Coronary CT Angiogram|pre-operative coronary CTA
1678021|NCT01635296|Drug|RO5045377|Multiple escalating oral doses, Days 1 to 10 of each 28-day cycle
1678022|NCT01635296|Drug|RO5045377|Multiple escalating oral doses, Days 1 to 5 of each 28-day cycle
1678023|NCT01635296|Drug|cytarabine|20 mg/m2 sc, Days 1 to 10 of each 28-day cycle
1678024|NCT01635296|Drug|cytarabine|1 gm/m2 iv, Days 1 to 6 of each 28-day cycle
1678025|NCT01635283|Biological|tumor lysate-pulsed autologous dendritic cell vaccine|Given ID
1678026|NCT01635283|Other|laboratory biomarker analysis|Correlative studies
1678027|NCT01635270|Radiation|mid-position radiation strategy|The midP strategy defines the target as the time weighted average tumor position (mid-position) plus an additional margin, computed specifically for each patient, that takes into account the tumor motion in each direction. This strategy can help to safely reduce toxicity while preserving treatment efficacy
1678028|NCT01635270|Radiation|ITV|The ITV strategy is the conventional one. It consists in defining the target as the volume covering the whole tumor motion.
1678029|NCT01635257|Other|Ultrasound scan|A multiorgan ultrasound was performed by an emergency physician sonographer before MCTPA. Pulmonary embolism was considered echographically present if compression ultrasound was positive for deep vein thrombosis or transthoracic-echocardiography was positive for right ventricular dysfunction or at least one pulmonary subpleural infarct was detected with thoracic ultrasound.
1678030|NCT01635244|Device|Aortic valve replacement|Clinically indicated aortic valve replacement will be performed using one of three approved tissue valves (Freestyle, Magna Ease, or Trifecta).
1678031|NCT01635231|Other|hypertonic saline|hypertonic saline 3.0% 7 ml/kg
1678032|NCT01635218|Drug|Individualized homeopathic treatment|A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
1678033|NCT01635218|Drug|Fluoxetine|20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
1678034|NCT01635218|Drug|Placebo|Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.
1678035|NCT01635205|Procedure|paraspinous anesthetic block|Paraspinous anesthetic block with lidocaine 1% in sensitized segments of the thoracolumbar region
1678036|NCT01635205|Procedure|subcutaneous puncture with no anesthetic effect|Subcutaneous puncture with injection needle (no substance will be injected)
1678037|NCT01635192|Biological|VSL#3|"The probiotic product VSL#3® comes in a powder (sachet) that is to be dissolved in half a glass of cold water before ingestion. Two sachets are ingested once daily over 2 weeks.
Each dose (sachet) contains 450 billion live (lyophilized) lactic acid bacteria (in defined ratios of the following strains: Bifidobacterium breve, Bifidobacterium longum, Bifidobacterium infantis, Lactobacillus acidophilus, Lactobacillus plantarum, Lactobacillus paracasei, Lactobacillus bulgaricus, Streptococcus thermophilus) and are delivered in a base of maltose and silicon dioxide."
1678038|NCT01635192|Biological|Placebo|Two placebo sachets containing maltose and silicon dioxide are given once daily over 2 weeks.
1678039|NCT01635179|Procedure|Cricoid pressure|The patient is intubated twice, once with a cricoid pressure and once with a sham-pressure, when performing a videolaryngoscopy.
1678041|NCT01635153|Dietary Supplement|Protein calorie supplement|Fortified porridge with 1062 kcal and 40 gm protein
1678042|NCT01635153|Dietary Supplement|Micronutrient|Dar-vite Multivitamin
1678329|NCT01632748|Device|Modified Neurotech Vital Device|5 minute stimulation
1678045|NCT01635127|Drug|Canakinumab|150mg s.c.
1678046|NCT01635127|Drug|Placebo|Constituent of canakinumab
1678047|NCT01635114|Dietary Supplement|resveratrol|150 mg resVida per day for 12 weeks
1678048|NCT01635114|Dietary Supplement|Placebo|Placebo for 12 weeks
1678049|NCT01635101|Drug|IV Acetaminophen|"7.5 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours;
10 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours;
12.5 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours;
15 mg/kg IV over 15 minutes, given q6h X 4 doses for 24 hours"
1678050|NCT01635101|Other|Normal Saline as Placebo|
1678051|NCT01635088|Drug|Mometasone furoate 220|dry powder inhaler QD for 28-43 days
1678052|NCT01635088|Device|KoKo Spirometry|
1678053|NCT01635088|Drug|Mometasone furoate 440|dry powder inhaler QD for 28-43 days
1678054|NCT01635088|Device|Oscillometry|
1678055|NCT01635075|Behavioral|Exercise|1-mile treadmill walk
1678056|NCT01635075|Behavioral|passive control|20 min inactivity
1678057|NCT01635062|Drug|Calcitriol|Subjects will receive calcitriol (up to 0.75 mcg daily) for 3 weeks.
1678058|NCT01635062|Drug|Placebo|Subjects will receive placebo for 3 weeks.
1678059|NCT01635036|Device|In-vitro fertilization using Eeva|Eeva will image embryos through cleavage stage (Day 3). Embryologists will use Eeva results along with traditional morphological grading to assist in selecting embryo(s) for transfer or freezing.
1678060|NCT01635023|Drug|AZD6244 Dosing Period 1|Treatment A, B, or C depending on randomization assignment
1678061|NCT01635023|Drug|AZD6244 Dosing Period 2|Treatment A, B, or C depending on randomization assignment
1678062|NCT01635023|Drug|AZD6244 Dosing Period 3|Treatment A, B, or C depending on randomization assignment
1678063|NCT01635023|Drug|AZD6244 Dosing Period 4|Treatment B
1678064|NCT01635010|Procedure|continuous positive airway pressure (CPAP)|CPAP pressure is individually prescript according to polysomnography for CPAP titration
1678065|NCT01634971|Procedure|Internal Drainage of Pancreatic Duct after pancreatomy|the Intervention name is: Internal Drainage of Pancreatic Duct after pancreatomy, a stent was placed in the pancreatic duct, external drainage of the stent is defined as control group(the stent will be tans-abdomen and as a drainage of pancreatic fluid), and internal drainage of the stent is defined as interventional(or experimental) group, with the stent very short(2cm) and placed in jejunum.
1678066|NCT01634958|Biological|Depigoid Phleum|Suspension for subcutaneous injection Build-up phase (day 1): 0,1mL + 0,2mL + 0,2mL s.c.injections in intervals of 30 minutes Maintenance phase: 5x single s.c. injection of 0,5mL every 4 weeks
1678067|NCT01634945|Drug|SP/amodiaquine|One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
1678068|NCT01634945|Dietary Supplement|FeFum fortified porridge|6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months.
1678069|NCT01634945|Drug|SP/Amodiaquine + FeFum fortified porridge|"One dose of SP (500 mg sulfadoxine plus 25 mg pyrimethamine, or half of the dose if body weight =< 10 kg) and three daily doses of Amodiaquine (1. Day: 200 mg, 2. Day: 200 mg and 3. Day: 100 mg, or half of the dose each day if body weight =< 10 kg), every three months, i.e. 3 times during 9 consecutive months.
6 times per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferrous fumarate) for 9 months."
1678070|NCT01634945|Dietary Supplement|Ferric pyrophosphate fortified porridge|6 days per week supply of iron fortified porridge (25 g portion containing 5.8 mg of iron: 2 mg as NaFeEDTA + 3.8 mg as ferric pyrophosphate) for 9 months.
1678071|NCT01634945|Other|Placebo|Placebo of SP/Amodiaquine every 3 months for 9 months. No dietary intervention.
1678072|NCT01634932|Other|Regular iron|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
1678073|NCT01634932|Other|Iron biofortified millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
1678074|NCT01634932|Other|Post-harvest iron-fortifed millet|Labeled iron as FeSO4 will be added as a tag to a test meal consumed over 5 consecutive days for breakfast and for lunch
1678076|NCT01634906|Drug|Temporary discontinuation of statin therapy|All statins, e.g. atorvastatin, simvastatin, fluvastatin, rosuvastatin, pravastatin
1678077|NCT01634893|Drug|Sorafenib combined with Hydroxychloroquine|"dose escalation of sorafenib combined with hydroxychloroquine (HCQ) to a maximum of sorafenib 400 mg PO BID plus HCQ 400 mg PO QD.
Drugs are given on an intermittent schedule of days 1-5/week in a 28-day cycle.
Sorafenib alone is given in cycle 1, and HCQ is added in cycle 2."
1678078|NCT01634880|Drug|Postoperative Radiotherapy and Panitumumab|"The starting panitumumab dose is 2.5 mglkg given once a week. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual weekly body weight.
Standard radiation 64-70Gy with 2.0 Gy daily fractions in 6-7 weeks. Panitumumab 2.5 mg/Kg IV, weekly during radiation (total of 6-7 doses)."
1678079|NCT01634854|Drug|Vaginal Misoprostol|Dosage: 25 µg every 4 hours up to a maximum of 4 doses until cervical change is consistent with a diagnosis of active labor Route of administration: Intravaginal
1678080|NCT01634854|Drug|Intravenous Oxytocin|"Dosage: 2 miu per minute increased in increments of 1-2 miu per minute every 30 minutes to establish an effective contraction pattern.
Route of administration: intravenous"
1678081|NCT01634841|Dietary Supplement|Walnuts|30 to 45g (1 to 1.5 oz) per day of walnuts
1678082|NCT01634841|Other|habitual diet|Dietary information will be provided
1678083|NCT01634815|Procedure|The Edge|measuring blood lactate
1678084|NCT01634802|Other|EMR Only|Clinics in this arm of the study will have a standard Electronic Medical Record (EMR) system installed - without a computerized decision support system.
1678124|NCT01634412|Drug|Cyclobenzaprine Tablet|1 x 5 mg cyclobenzaprine tablet, swallowed with 240 mL of room-temperature water
1678085|NCT01634802|Other|EMR+CDSS|Clinics in this arm of the study will have an Electronic Medical Record (EMR) system with Clinical Decision Support System (CDSS) enhancement implemented as alerts to aid the clinician in decision making.
1678086|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
1678087|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
1678088|NCT01634789|Drug|bazedoxifene|20 mg oral tablet, single dose
1678089|NCT01634789|Drug|bazedoxifene/conjugated estrogens|20 mg / 0.625 mg oral tablet, single dose
1678090|NCT01634776|Dietary Supplement|Flaxseed oil|Families will be asked to mix the contents of one capsule (1200 mg flaxseed oil or 1288 mg corn oil) into a cup of participants' food, twice a day.
1678091|NCT01634776|Dietary Supplement|corn oil|
1678092|NCT01634763|Drug|LDK378|
1678094|NCT01634724|Drug|a drug withdrawal during the long protocol|GnRHa (triptorelin,0.05mg/d) was injected stimulously with FSH before dominant follicles were ≥ 14 mm. When the diameter of one or more follicles was ≥ 14 mm, GnRHa (triptorelin,0.05mg/d) was withheld in the study group.
1678095|NCT01634711|Device|L-C Ligament|The L-C Ligament is a bioresorbable, three-dimensional (3-D) braided scaffold made from poly L-lactic acid (PLLA) fiber. One device is used to replace the ACL. The L-C Ligament is an interventional device. The L-C Ligament is comprised of three regions: (1) The femoral tunnel attachment site, (2) The ligament region (intra-articular zone), and (3) The tibial tunnel attachment site. For several months after surgery, the L-C Ligament replaces the function of the ACL. During this time, ligament tissue regenerates within and around the L-C Ligament, which is slowly absorbed and replaced by the ACL.
1678096|NCT01634698|Dietary Supplement|retinyl palmitate (UNICEF, Melbourne, Australia)|the patients received an oral dose of 1500 IU or 2500 IU, once.
1678097|NCT01634685|Radiation|Radiation|Radiation therapy will be administered daily, Monday-Friday, for a total of 28 treatments, delivered at 1.8 Gy/fraction.
1678098|NCT01634685|Drug|Bavituximab|Bavituximab will be delivered concurrently with the radiation therapy for 6 weeks (one time each week), followed by 2 weeks of bavituximab administration by itself.
1678099|NCT01634685|Drug|Capecitabine|capecitabine, will be delivered twice daily p.o. on the days of radiation treatment, at a dose of 825 mg/m2.
1678100|NCT01634659|Device|Delefilcon A contact lenses (DAILIES TOTAL1®)|Commercially marketed silicone hydrogel, single-vision contact lenses for daily wear, daily disposable use
1678101|NCT01634659|Device|Narafilcon B contact lenses (1-DAY ACUVUE® TruEye®)|Commercially marketed, silicone hydrogel single-vision contact lenses for daily wear, daily disposable use
1678102|NCT01634646|Dietary Supplement|Lyzme5|"Dietary Supplement (or placebo):
Lyzme5 (or the placebo) is to be mixed with 4 fluid ounces of a sugar free flavored drink (example: kool aid, crystal light, flavored tea drink, etc.).
Week one:
A single serving of the assigned material (Lyzme5 or the placebo) each day, 20 minutes before breakfast;
Week two:
Two (2) servings of the assigned material each day - the first, 20 minutes before breakfast and the second 20 minutes before the noon meal;
Week three through the end of the study:
Three (3) servings per day of the assigned material - the first, 20 minutes before breakfast, the second, 20 minutes before the noon meal, and the third, 20 minutes before the last meal of the day."
1678103|NCT01634620|Device|NIOX MINO® Instrument (09-1100)|"FeNO measurements will be performed according to the Perform FeNO Measurement guidelines on page 7 of the NIOX MINO® User Manual (February, 2011)"
1678104|NCT01634594|Drug|Group R|
1678105|NCT01634594|Drug|Group N|
1678106|NCT01634594|Drug|Group D|
1678107|NCT01634568|Drug|V81444|"Single ascending oral doses of V81444 and placebo
Multiple ascending oral doses of V81444 and placebo"
1678108|NCT01634555|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) 8 milligrams per kilogram (mg/kg), administered as an intravenous (IV) infusion on Day 1 of each 2-week cycle (except Cycle 1)
1678109|NCT01634555|Drug|Irinotecan|180 milligrams per square meter (mg/m²) administered IV on Day 1 of each cycle
1678110|NCT01634555|Drug|Folinic acid|400 mg/m² administered IV on Day 1 of each cycle
1678111|NCT01634555|Drug|5-Fluorouracil|400 mg/m² bolus over 2 to 4 minutes administered IV on Day 1 of each cycle, followed by 2400 mg/m² administered IV over 46 to 48 hours on Days 1 and 2 of each cycle
1678112|NCT01634529|Drug|V158866|Single ascending oral doses of V158866 and Placebo
1678113|NCT01634529|Drug|V158866|Multiple ascending oral doses of V158866 and Placebo
1678114|NCT01634516|Behavioral|Dietary support|Face to face intervention plus subsequent telephone support
1678115|NCT01634516|Behavioral|No dietary support|No face to face intervention or subsequent telephone support
1678116|NCT01634503|Genetic|GX-188E administered by electroporation|Patients will be assigned to three dose groups:1mg, 2mg, and 4mg. Each patient will be administered GX-188E by electroporation in entire study period. The Maximum Tolerated Dose of GX-188E will be determined by the classical 3+3 dose escalation schedule. The number of patients will be ranged from 9 to 18.
1678117|NCT01634451|Other|Bespoke on-line sedation education package|A bespoke on-line education package has been developed and will be accessible by all ICU nursing staff. They will have unique logins and the system will track their use and completion of the education package. There is a small multiple choice assessment at the end of the package.
1678118|NCT01634451|Other|Sedation specific outcome process feedback|Using statistical process charts, the data gathered from the Sedation quality Tools (SQATs) completed each shift by the ICU nurses, will be fed back highlighting sedation specific outcomes e.g. number of over sedated days per 1000 ventilator days.
1678119|NCT01634451|Device|Responsiveness monitoring; novel sedation monitor|Responsiveness monitoring (developed by GE Healthcare) is a novel technology used to monitor patient responsiveness and essentially alert ICU nursing staff when their patients may be over sedated.
1678120|NCT01634438|Drug|unfractionated heparin|unfractionated heparin
1678121|NCT01634425|Device|Alere Triage Meter Pro|Troponin and BNP measured on point of care meter.
1678122|NCT01634412|Drug|SL TNX-102 2.4 mg at pH 3.5|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 3.5, administered as 1 mL held under the tongue for 90 seconds without swallowing
1678123|NCT01634412|Drug|SL TNX-102 2.4 mg at pH 7.1|1 dose of 2.4 mg TNX-102 sublingual solution (2.4 mg/mL) in PBS at pH 7.1, administered as 1 mL held under the tongue for 90 seconds without swallowing
1679321|NCT01624727|Dietary Supplement|Omega 3 acid ethyl esters|Lovaza 3.6 g daily
1678125|NCT01634412|Drug|Cyclobenzaprine IV|1 dose of 2.4 mg cyclobenzaprine USP in PBS (0.6 mg/mL) at pH 7.4, administered intravenously as a 4 mL bolus injection over 30 seconds
1678127|NCT01634386|Drug|Torrent's Quetiapine Fumarate Tablets|
1678128|NCT01634373|Drug|Torrent's Quetiapine Fumarate Tablets|
1678129|NCT01634360|Drug|Perampanel|1mg once daily for two weeks, followed by 2mg once daily for 2 weeks; if they did not tolerate the 1 mg dose, subjects were withdrawn from the study. Subjects could be up-titrated to 3 or 4 mg in a sequential manner. Subjects could be down-titrated at any time to either 3, 2 or 1 mg in a sequential manner.
1678130|NCT01634347|Drug|Propranolol and memory reactivation|Propranolol will be administered once a week for a 3 or 6 week period. Each propranolol administration will be followed by memory reactivation.
1678131|NCT01634347|Drug|Placebo and memory reactivation|Placebo will be administered once a week for a 3 or 6 week period. Each placebo administration will be followed by memory reactivation.
1678132|NCT01634334|Behavioral|Real-Time Intervention|Lights and Sound Brief Coaching
1678133|NCT01634334|Behavioral|Usual Education|Participants will receive usual education about secondhand smoke and thirdhand smoke.
1678134|NCT01634321|Drug|Luphere depot 3.75mg(Leuprolide acetate 3.75mg)|
1678135|NCT01634308|Drug|Novosis(bongros/BMP-2)|
1678136|NCT01634308|Drug|Bio-oss|
1678137|NCT01634295|Drug|CKD-828 2.5/40mg|"Fixed dose combination of S-amlodipine 2.5mg and Telmisartan 40mg QD 2 weeks.
With the others investigation product placebo 4 tabs QD 2 weeks."
1678138|NCT01634295|Drug|CKD-828 5/40mg|"Fixed dose combination of S-amlodipine 5mg and Telmisartan 40mg QD 2 weeks.
With the others investigation product placebo 4 tabs QD 2 weeks."
1678139|NCT01634295|Drug|CKD-828 5/80mg|"Fixed dose combination of S-amlodipine 5mg and Telmisartan 80mg QD 6 weeks.
With the others investigation product placebo 4 tabs QD 6 weeks."
1678140|NCT01634295|Drug|S-amlodipine 2.5mg|"S-amlodipine 2.5mg QD 4 weeks
With the others investigation product placebo 4 tabs QD 4 weeks."
1678141|NCT01634295|Drug|S-amlodipine 5mg|"S-amlodipine 2.5mg QD 6weeks
With the others investigation product placebo 4 tabs QD 6 weeks."
1678142|NCT01634282|Drug|OPC-262|Orally administered once daily
1678144|NCT01634256|Dietary Supplement|Placebo|Placebo(3.0g/day)
1678145|NCT01634256|Dietary Supplement|Fermented turmeric|Fermented turmeric(3.0g/day)
1678146|NCT01634243|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
1678147|NCT01634230|Drug|OCR-002|daily dose: 10g infused over 24 hour
1678149|NCT01634204|Other|KiloCoach|"Study participants in this arm will use the program to record nutrition and physical activity on at least 4 days per week within the first and ad libitum within the second 3 months of the intervention period.
Study visits will be conducted at baseline as well as after 1, 3 and 6 months. After 12 months a follow up visit will be conducted."
1678150|NCT01634204|Other|Control|"Study subjects try to reduce their body weight on their own. They are free to exercise and/or change nutritional habits. Not allowed is taking part in any structured weight loss program.
Study visits will be conducted at baseline as well as after 1,3 and 6 months. A follow up visit will be conducted after 12 months."
1678151|NCT01634191|Drug|Apremilast|One oral 30 mg dose of apremilast
1678152|NCT01634178|Drug|Apremilast|One oral dose of 30 mg apremilast under fasted conditions
1678153|NCT01634178|Drug|Apremilast|one oral dose of 30 mg apremilast after a high-fat meal
1678154|NCT01634165|Drug|LY2963016|Administered subcutaneously
1678155|NCT01634165|Drug|Lantus|Administered subcutaneously
1678156|NCT01634152|Drug|Placebo|2 actuations once daily in the evening
1678157|NCT01634152|Drug|Tiotropium low dose mcg|2 actuations once daily in the evening
1678158|NCT01634152|Drug|Tiotropium high dose|2 actuations once daily in the evening
1678159|NCT01634139|Drug|Tiotropium low dose QD|2 actuations once daily in the evening
1678160|NCT01634139|Drug|Tiotropium high dose QD|2 actuations once daily in the evening
1678161|NCT01634139|Drug|Placebo|2 actuations once daily in the evening
1678162|NCT01634126|Behavioral|1 FIT kit|Patient receives 1 FIT
1678163|NCT01634126|Behavioral|2 FIT kit|Patient receives 2 FIT kits
1678164|NCT01634113|Drug|tiotropium-bromide|IMP
1678165|NCT01634113|Drug|tiotropium-bromide|IMP
1678166|NCT01634113|Drug|placebo|placebo matching tiotropium
1678167|NCT01634100|Drug|Probenecid|Probenecid
1678168|NCT01634100|Drug|Rifampicin|Rifampicin
1678169|NCT01634100|Drug|Empagliflozin|BI Drug
1678170|NCT01634100|Drug|Empagliflozin|BI Drug
1678171|NCT01634100|Drug|Rifampicin|Rifampicin
1678172|NCT01634100|Drug|Probenecid|Probenecid
1678173|NCT01634100|Drug|Empagliflozin (BI 10773)|BI Drug
1678174|NCT01634087|Drug|INCB039110|INCB039110 administered orally
1678175|NCT01634087|Drug|Placebo|Placebo administered orally
1678176|NCT01634061|Drug|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
1678177|NCT01634061|Drug|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
1678178|NCT01634061|Drug|BEZ235|BEZ235 will be supplied as 50mg, 100mg, 200mg, 300mg and 400mg SDS sachets. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
1678179|NCT01634061|Drug|BKM120|BKM120 will be supplied as 10mg and 50mg hard gelatin capsules. At each patient's visit, patient will reecive a prescription of an adequate drug supply for self administration at home.
1678497|NCT01631409|Device|Cardiospec|Cardiac shock wave therapy is implemented by device Cardiospec manufactured by Medispec Ltd.
1678180|NCT01634048|Dietary Supplement|High Protein, low calorie meal replacement|The high protein group will have meal replacements with added protein powder (to achieve 1.34g protein/kg body weight) and the control group will have standard meal replacements (0.8g protein/kg body weight). Meal replacements have been used in hundreds of previous human studies and are generally not found to be linked to any serious adverse effects.
1678181|NCT01634022|Procedure|Acupuncture|5 specific body acupoints (HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally) with gentle manual tonification every 10 min. Two acupoints along the midline of the head, GV-20 and GV-24.5 (Yintang), were also used with a 2 Hz current applied from GV-20 (−) to GV24.5 (+).
1678182|NCT01634009|Dietary Supplement|Soy-based RUTF (in double blind design)|Soy-based RUTF will be given in double blind manner
1678183|NCT01633996|Procedure|Acupuncture|Our acupuncture treatment protocol included: HT-7 and LI-4 on the hands bilaterally, and ST-36, SP-6, and LR-3 on the legs bilaterally, with gentle manual tonification every 10 minutes; and GV-20 and GV- 24.5 (Yintang), along the midline of the head.
1678184|NCT01633983|Drug|Methotrexate|7.5 mg per week p.o. escalating up to 15 mg per week
1678185|NCT01633983|Drug|Delayed treatment|Methotrexate 7.5 mg per week per os escalating to 15 mg per week
1678186|NCT01633970|Drug|5-FU|Participants will receive 5-FU 400 mg/m^2 IV q2w.
1678187|NCT01633970|Drug|Atezolizumab|Participants will receive IV atezolizumab (800 mg q2w or 1200 mg q3w) q3w.
1678188|NCT01633970|Drug|Bevacizumab|Participants will receive bevacizumab 10 mg/kg or 15 mg/kg IV q3w.
1678189|NCT01633970|Drug|Carboplatin|Participants will receive carboplatin IV q3w with target AUC of 6 mg/mL.
1678190|NCT01633970|Drug|Leucovorin|Participants will receive leucovorin 400 mg/m^2 IV q2w.
1678191|NCT01633970|Drug|Nab-paclitaxel|Participants will receive nab-paclitaxel 100 mg/m^2 IV qw.
1678192|NCT01633970|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV q2w.
1678193|NCT01633970|Drug|Paclitaxel|Participants will receive paclitaxel 200 mg/m^2 IV q3w.
1678194|NCT01633970|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV q3w.
1678195|NCT01633957|Other|Genotype-based Warfarin Initiation model|Based on previous retrospective study,investigators established a genotype-based warfarin model to estimate the drug dosage.
1678196|NCT01633957|Other|clinical factor-based warfarin initiation model|Based on previous retrospective study,investigators established a clinical factor-based warfarin model to estimate the drug dosage.
1678197|NCT01633944|Drug|Buprenorphine|Buprenorphine HCl Buccal Film at doses ranging from 75-600 mcg twice daily
1678198|NCT01633944|Drug|Placebo|Matching Placebo Buccal Film twice daily
1678199|NCT01633918|Behavioral|Internet-supported FeetEnergy approach|Three health education lessons and two homework's about increasing physical activity and reducing screen time
1678200|NCT01633918|Behavioral|Usual health education|Usual health education lessons
1678201|NCT01633892|Procedure|Fat Grafting|
1678202|NCT01633879|Behavioral|audio-CD parent education|audio CD stories in English and Spanish that support positive parenting practices
1678203|NCT01633879|Behavioral|health and success parent and school|Parenting education and school intervention
1678204|NCT01633853|Drug|Vitamin D2|Treatment with Vit D2.
1678205|NCT01633853|Drug|1,25(OH)2 Vit D3|Treatment with 1,25(OH)2 Vitamin D3(Rocaltrol).
1678206|NCT01633840|Other|Elemental E028 with added food allergens|Test materials containing liquid vehicle (Elemental E028)with added food allergens (active)
1678207|NCT01633840|Other|Elemental E028|Elemental E028 with no added food allergens
1678208|NCT01633827|Drug|Placebo pill|Subjects will receive a sugar pill (in combination with room air) during their placebo arm studies
1678209|NCT01633827|Drug|Sedative|Subjects will receive eszopiclone (in combination with medical oxygen) during their treatment arm studies
1678210|NCT01633827|Other|Room air|Subjects will receive room air (in combination with a sugar pill) during their placebo arm studies
1678211|NCT01633827|Other|Oxygen|Subjects will receive medical grade oxygen (in combination with eszopiclone) during their treatment arm studies
1678212|NCT01633814|Drug|Transdermal estradiol|transdermal estradiol, delivery rate 100 µg day-1
1678213|NCT01633814|Drug|Placebo|placebo patch.
1678216|NCT01633788|Drug|AGN-195263 0.1%|1 drop of AGN-195263 0.1% instilled in each eye twice daily.
1678217|NCT01633788|Drug|AGN-195263 0.03%|1 drop of AGN-195263 0.03% instilled in each eye twice daily.
1678218|NCT01633788|Drug|AGN-195263 0.01%|1 drop of AGN-195263 0.01% instilled in each eye twice daily.
1678219|NCT01633788|Drug|AGN-195263 Vehicle|1 drop of AGN-195263 vehicle (placebo) instilled in each eye twice daily.
1678220|NCT01633775|Procedure|Implantation of Ahmed glaucoma tube shunt, and Trabeculectomy with MMC|In the Ahmed implant group, the tube shunts used were the valved 184-mm2 surface area (Model FP7; New World Medical, Inc, Rancho Cucamonga, California, USA). In the Trabeculectomy group, a routine trabeculectomy surgery was performed.
1678221|NCT01633762|Drug|meropenem, gentamicin, vancomycin (together)|"4 days antibiotic treatment, per oral, once daily: vancomycin 500 mg (Vancomycin Hospira), powder for concentrate; gentamycin 40 mg (Hexamycin®), solution; meropenem 500 mg (Meropenem Hospira), powder for concentrate; The three drugs are dissolved and combined to a cocktail (with approximately 100 ml of apple juice)"
1678222|NCT01633749|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
1678261|NCT01633333|Other|Carbon dioxide insufflation|Carbon dioxide insufflation to obtain luminal view to facilitate colonoscope insertion, considered to be standard procedure.
1678262|NCT01633307|Other|Education|Teaching program
1678263|NCT01633294|Drug|Ampicillin + gentamicin|ampicillin 1 g every six hours and gentamicin 240 mg every day intravenously
1678264|NCT01633281|Procedure|acupuncture|Ten sessions of acupuncture at 2x per week over 5 weeks will be given to patients. The acupuncture points include a standard set of obligatory points and additional points based on symptoms.
1678223|NCT01633736|Other|Usual care plus progresive resistance training|Duration 8 weeks; two weeks of familiarisation with the intervention protocol without resistance (for familiarisation and neural adaptation) followed by 6 weeks progressive resistance (PR). The three times a week PR training will be as a home exercise program with fortnightly home visits to monitor/progress PR training. It comprises a 4 minute warm up and cool down with one exercise targeting the hip abductors and one the lateral rotators. Exercise prescription will follow existing guidelines for progressive PR training. Parents will be taught supervision by the researcher using clear explanations in words and pictures in a logbook. Logbooks have been found to facilitate compliance, dosage and motivation.
1678224|NCT01633723|Drug|DA-6886|"single dose study : DA-6886 1mg,2.5mg,5mg,10mg,20mg dosage (Dose-escalation)
multiple dose study : DA-6886 2.5mg,5mg,10mg or 5mg,10mg,20mg dosage (Dose-escalation)"
1678225|NCT01633723|Drug|Placebo of DA-6886|DA-6886 placebo
1678226|NCT01633697|Behavioral|Breathing|Breathing techniques
1678227|NCT01633697|Behavioral|Education alone|No special attention to breathing
1678228|NCT01633658|Dietary Supplement|cholecalciferol|a single dose of 2500 micrograms of cholecalciferol
1678229|NCT01633658|Dietary Supplement|25(OH)D|a single dose of 625 micrograms of 25(OH)D
1678230|NCT01633645|Drug|Bortezomib|Velcade
1678231|NCT01633645|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-days treatment cycle for a maximum of 8 cycles
1678232|NCT01633645|Drug|Cisplatin|Cisplatin 70 mg/m2 on day 1 of a 21-days treatment cycle for a maximum of 8 cycles
1678233|NCT01633632|Behavioral|Hatha yoga|30 minutes of instruction in Hatha yoga will be provided for 8 sessions.
1678234|NCT01633632|Behavioral|Cognitive behavioral therapy|8-sessions of cognitive behavioral therapy will be provided following a standardized curriculum.
1678235|NCT01633593|Drug|Donepezil|5 mg PO a day, during 2 weeks
1678236|NCT01633580|Drug|corifollitropin alfa|long acting FSH
1678237|NCT01633567|Behavioral|Culturally Targeted Cessation Program|The culturally targeted version of the behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
1678238|NCT01633567|Behavioral|Non-Targeted Cessation Program|Behavioral counseling intervention will consist of six group-based smoking cessation counseling sessions. Each smoking cessation therapy session will last approximately 90 minutes and will begin two weeks before the quit date. In addition, participants will be provided nicotine replacement therapy and peer support sessions will occur between the group sessions.
1678239|NCT01633541|Drug|AT-101|Patients will receive AT-101 40 mg orally two times a day.
1678240|NCT01633541|Drug|Docetaxel|Docetaxel (Taxotere) 75 mg/m2
1678241|NCT01633541|Drug|Cisplatin|Cisplatin 100 mg/m2
1678242|NCT01633541|Drug|Carboplatin|Carboplatin AUC (area under the curve) 6. Maximum dose of 700 mg
1678243|NCT01633528|Drug|Asprin|100 mg
1678244|NCT01633528|Drug|placebo|100mg
1678245|NCT01633515|Procedure|Intralesional cryotherapy|"The Intralesional cryotherapy technology (CryoShape; CryoShape™, U.S Patent Number 6,503,246; European Patent Number 1299043, FDA 510(k) Number K060928) had been developed for the treatment of hypertrophic scars and keloids. The cryoneedle is connected by an adaptor to a cryogun filled with liquid nitrogen, and is introduced into the BCC. After the BCC is completely frozen, the cryoprobe defrosts and is withdrawn.
Other relevant intervention: The cryotherapy will be performed under local anesthesia (bupivacaine). After the procedure topical antibiotic cream will be applied. Participants will be followed at the out patient clinic for an average duration of 5 month after cryotherapy (3 month post cyotherapy until the biopsy and then 1-2 month more until biopsy results are received)."
1678246|NCT01633502|Device|Conventional circulatory support|Control group treated with conventional circulatory support and observed in intensive care unit for a minimum of 48 hrs.
1678247|NCT01633502|Device|Impella cVAD|Control group treated with Impella cVAD for a minimum of 48 hrs.
1678248|NCT01633476|Drug|Valaciclovir|2g q.d.s. orally for 6 months (dose adjusted according to renal function)
1678249|NCT01633450|Other|Zinc biofortified rice|1.12 mg zinc per meal
1678250|NCT01633450|Other|Rice extrinsically fortified with zinc|1.12 mg zinc per meal
1678251|NCT01633437|Drug|CX157|CX157 Modified Release Tablet 125 mg administered twice per day on study days 4-11 and in the morning of study day 12.
1678252|NCT01633437|Other|Placebo|Placebo administered twice per day on study days 4-11 and in the morning of day 12.
1678253|NCT01633411|Device|Focal Cryoballoon Ablation System - 6 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
1678254|NCT01633411|Device|Focal Cryoballoon Ablation System - 8 seconds|"Ablation of Barrett's Esophagus using a Focal Cryoballoon ablation catheter. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
1678255|NCT01633411|Device|CryoBalloon Focal Ablation System - 10 seconds|"Ablation of Barrett's Esophagus using the Focal CryoBalloon Ablation System. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications."
1678256|NCT01633398|Genetic|Saliva Genetic testing|To compare the genetic variants between the two phenotypes of reduced versus preserved ejection fraction (HFrEF versus HFpEF)
1678257|NCT01633372|Drug|itacitinib|
1678258|NCT01633359|Drug|Intensive statin|the Intensive Atorvastatin protocol indicates that once 80mg Atorvastatin will be administrated before CAG, and then will be followed with 20mg Atorvastatin daily during the entire study period.
1678259|NCT01633359|Drug|Routine statin|the Routine Atorvastatin protocol indicates that 20mg Atorvastatin daily during the entire study period.
1678260|NCT01633333|Other|Water exchange colonoscopy|Water is infused and suctioned in a systematic fashion to obtain luminal view and for cleansing of the colon to facilitate colonoscope insertion. The carbon dioxide pump is turned off, only to be turned on during withdrawal from the cecum.
1678265|NCT01633255|Drug|18F-Fluciclatide|
1678267|NCT01633216|Biological|Bivalent OPV 2 week interval|Group A will receive 3 doses of bOPV at 6, 8 and 10 weeks of age (2-week interval between doses).
1678268|NCT01633216|Biological|Bivalent OPV 4 week interval|Group B will receive 3 doses of bOPV at 6, 10 and 14 weeks of age (4-week interval between doses).
1678269|NCT01633216|Biological|Monovalent OPV 2 week interval|Group C will receive 3 doses of mOPV1 at 6, 8 and 10 weeks of age (2-week interval between doses).
1678270|NCT01633216|Biological|Monovalent OPV 4 week interval|Group D will receive 3 doses of mOPV1 at 6, 10 and 14 weeks of age (4-week interval between doses).
1678271|NCT01633216|Biological|Trivalent OPV 4 week interval|Group E will receive 3 doses of tOPV at 6, 10 and 14 weeks of age (4-week interval between doses and similar to the current routine immunization schedule).
1678272|NCT01633203|Drug|epirubicin + cisplatin + capecitabine polychemotherapy|"EPIRUBICIN (LKM)at a dose of 50 mg/m2 over 15 minutes is administered every 21 days.
CISPLATIN (LKM) at a dose of 60 mg/m2 over 4 hours is administered every 21 days. Patients must receive standardized hydration per protocol.
CAPECITABINE (Xeloda®) at a dose of 625 mg/m2 BID (i.e. 1250 mg/m2/day) 30 minutes after meals from day 1 to day 21 of every cycle of chemotherapy.
Antiemetic therapy:
Dexamethasone 8 mg IV and Ondansetron (LKM) 8 mg IV o Granisetron (Kytril®) prior to chemotherapy
Rescue Ondansetron (LKM) 8 mg IV will be given during 24-hour hospitalization in case of emesis
Symptomatic antiemetic therapy with thiethylperazine will be prescribed.
Loperamide will be prescribed in case of diarrhea."
1678273|NCT01633177|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
1678274|NCT01633177|Drug|Omega-3 fatty acid (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
1678275|NCT01633177|Dietary Supplement|Vitamin D3 placebo|Vitamin D3 placebo
1678276|NCT01633177|Drug|Fish oil placebo|Fish oil placebo
1678277|NCT01633164|Behavioral|SCI Reinvention Protocol Participants|The intervention involves participation in a six week psychologically-based educational intervention. During the course, 8 specific skills are reviewed in order to specifically address reframing a person's method of looking at events, build confidence by focusing on personal strengths, develop methods of recognizing and appreciating the good in one's life and express gratitude for positive attributes. These skills are presented in a specific sequence so that participants can gain mastery of introductory concepts before undertaking those that are both more difficult and complex.
1678278|NCT01633164|Other|Waitlist Group|Wait list arm will begin study intervention after 4 1/2 months.
1678279|NCT01633138|Behavioral|Cognitive Remediation Therapy - Standard|Computerized cognitive remediation therapy provided three times per week for four weeks
1678280|NCT01633138|Behavioral|Cognitive Remediation Therapy plus Contingency Management|Standard cognitive remediation therapy plus monetary incentives based on performance provided three times per week for four weeks.
1678281|NCT01633125|Other|Group music therapy|The academically trained music therapist with previous relevant clinical experience will apply receptive and active music therapy techniques. The receptive methods will include music imagery,The active techniques will include musical improvisation and song writing.
1678282|NCT01633112|Drug|fingolimod|
1678283|NCT01633112|Drug|copaxone|copaxone
1678285|NCT01633086|Drug|nitric oxide gel|"st gel: sodium nitrites,BID local use X 28 days
nd gel: maleic/ascorbic acids ,BID local use X 28 days"
1678286|NCT01633086|Drug|placebo gel|placebo gel,BID local use X 28 days
1678287|NCT01633073|Device|LMA Supreme: control device|LMA Supreme will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
1678288|NCT01633073|Device|i-gel: comparison device|i-gel will be placed in children weighing 5-50kg based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, 2.5, or 3.0. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
1678289|NCT01633060|Drug|Fulvestrant|Intramuscular fulvestrant 500 mg (cycle 1 days 1 & 15 and once every cycle thereafter)
1678290|NCT01633060|Drug|BKM120|BKM120 100 mg once daily
1678291|NCT01633060|Drug|BKM120 matching placebo|BKM120 matching placebo, once daily
1678292|NCT01633047|Other|electrical stimulation|Intervention group that will be submitted to physical therapy exercises plus electrical stimulation (low frequency device with a current of 47 Hz with symmetrical, biphasic and pyramidal waveforms, with pulse duration of 1.5 s and interval of 1.8 s)
1678293|NCT01633047|Other|physical therapy exercises|Control group that will be submitted only to physical therapy exercises
1678294|NCT01633008|Behavioral|ACT Workshop|The ACT workshops will consist of a patient program and a corresponding parent program, each focusing on helping participants cope with the patient s pain more effectively using ACT techniques
1678295|NCT01632995|Drug|FTC 200 mg/TDF 300 mg fixed-dose combination tablet|Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
1678296|NCT01632982|Behavioral|standard treatment|the standard drug counseling offered to patients at the study site's methadone maintenance program
1678297|NCT01632982|Behavioral|MTS (Mobile Therapeutic System)|a novel, interactive, mobile phone-delivered psychosocial intervention designed to promote skills acquisition and reduce drug use among adults in methadone maintenance treatment
1678298|NCT01632982|Behavioral|mobile control|a mobile phone-based application that directs participants to the NIDA website's homepage
1678540|NCT01631097|Drug|Tivozanib hydrochloride|Single oral capsule 1.5 mg tivozanib hydrochloride
1678299|NCT01632969|Behavioral|The The Family Assessment of Treatment at the End of life (FATE ) survey|Study candidates will be contacted by mail with an initial contact letter with information explaining the study, and then will receive a follow-up phone call to discuss their participation in the study no later than 1 month following the posting of the initial contact letter. If a family member or next-of-kin chooses to participate, verbal informed consent will be obtained over the phone and a one-time telephone interview will be conducted.
1678300|NCT01632956|Behavioral|in-person support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
1678301|NCT01632956|Behavioral|virtual support group|Each support group will consist of 12 sessions. Thirty-two breast cancer patients of Chinese descent will be recruited to participate in the support groups (16 in the inperson groups and 16 in the virtual groups).
1678302|NCT01632943|Device|Symplicity renal denervation system|"Previous research has shown that disrupting the nerves of the kidney may successfully decrease blood pressure.
A less invasive approach to disrupting these nerves is to apply a brief high temperature near the nerves (renal denervation). This can now be done with an experimental medical device called the Symplicity renal denervation system. The System includes a catheter that is inserted into your blood vessels and an RF-generator."
1678303|NCT01632930|Other|urinary PCA3 test using Progensa® PCA3 assay kit (Gen-Probe)|urinary PCA3 test will be performed in patients before they undergo prostate biopsy for increased serum PSA and/or abnormal digital rectal examination. Patients with negative biopsies will be definitively enrolled in the study. The physician in charge will have knowledge of PCA3 test results and will be asked to determine the subsequent follow-up taking these results into account.
1678304|NCT01632917|Drug|ATX-101 - U.S.|US ATX-101, 10 mg/mL, one dosing session in the submental area
1678305|NCT01632917|Drug|ATX-101 - EU|EU ATX-101, 10 mg/mL, one dosing session in the submental area
1678306|NCT01632904|Drug|Ruxolitinib|Ruxolitinib will be orally self-administered at a starting dose of 10 mg (two 5 mg tablets) twice a day. Dose increases of 5 mg (1 tablet) in twice-daily increments are permitted after 4 weeks and again after 8 weeks of therapy for subjects who meet prespecified criteria for inadequate efficacy.
1678307|NCT01632904|Drug|Hydroxyurea (HU)|Hydroxyurea (500 mg capsules) will be orally self-administered at the dose that the subject was receiving previously. The dose may be increased after 4 weeks and again after 8 weeks of therapy to optimize efficacy for subjects meeting prespecified criteria.
1678308|NCT01632904|Drug|HU-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.
When adjustments are made to the ruxolitinib dose, the dose of HU-placebo will be adjusted concurrently."
1678309|NCT01632904|Drug|Ruxolitinib-placebo|"All placebo will be self-administered, and dosing will be the same as with the blinded dose.
When adjustments are made to the HU dose, the dose of ruxolitinib-placebo will be adjusted concurrently."
1955233|NCT03255512|Drug|Vericiguat (BAY1021189) + isosorbite mononitrate|"ISMN up-titration with 30 mg / 60 mg, about 7 days each, prior to start of vericiguat administration
Starting dose of 2.5 mg taken orally once daily with food, on a background of standard of care. Dose will be up-titrated to 5 mg and to 10 mg:
2.5 mg vericiguat for about 14 days followed by 5 mg vericiguat for about 14 days followed by 10 mg vericiguat for about 14 days
60 mg ISMN od on each day of vericiguat administration, taken 1 hour prior to vericiguat (in-house days) or together with vericiguat (out-patient days)"
1955234|NCT03255512|Drug|Placebo + isosorbite mononitrate (ISMN)|"ISMN up-titration with 30 mg / 60 mg, about 7 days each, prior to start of placebo administration
Placebo for about 14 days, once daily
60 mg ISMN od on each day of placebo administration, taken 1 hour prior to placebo (in-house days) or together with placebo (out-patient days)"
1678319|NCT01632865|Device|stenting|Apollo stent (MicroPort Medical, China),Neuroform stent (Stryker/Boston Scientific, USA) or Wingspan stent (Stryker/Boston Scientific, USA), et al.
1678320|NCT01632852|Biological|CSL362|"CSL362 is humanized monoclonal antibody that targets the alpha chain of the interleukin 3 receptor (IL3Rα; also known as CD123) and is optimised for enhanced activation of antibody-dependent cell-mediated cytotoxicity (ADCC) via natural killer cells.
CSL362 is a sterile solution for injection and will be administered by intravenous infusion to subjects in sequential, escalating dose level cohorts, at doses up to 12.0 mg/kg. CSL362 will be administered every 14 days for a total of 6 infusions per subject. The 6 infusions for each individual subject will contain the same dose of CSL362."
1678321|NCT01632826|Drug|Pomalidomide|4 mg daily for 21 days in a 28 day cycle until disease progression or other reasons for treatment discontinuation
1678322|NCT01632800|Device|High pulsed magnetic fields|Magnetic fields will escalate in strength
1678324|NCT01632761|Dietary Supplement|Vitamin D3 .|
1678325|NCT01632761|Drug|omega-3 fatty acids (fish oil)|
1678326|NCT01632761|Dietary Supplement|Vitamin D3 placebo|
1678327|NCT01632761|Dietary Supplement|Fish oil placebo|
1678328|NCT01632748|Device|Neurotech Vital Device|5 minute treatment
1678330|NCT01632735|Behavioral|Mobile Continuing Care|Behavioral: Mobile Texting 12-week intervention. Delivers daily Recovering monitoring, self-management feedback, and education/social support
1678331|NCT01632722|Drug|Bevacizumab, mFOLFOX, FOLFIRI|"ArmA (postoperative arm)
Postoperative mFOLFOX or FOLFIRI regimen, every 2weeks for 12cycles Bevacizumab 5mg/kg IV, every 2weeks for 11cycles beginning with cycle 2"
1678332|NCT01632722|Drug|Bevacizumab, mFOLFOX, FOLFIRI|"ArmB (perioperative arm)
Perioperative CTx mFOLFOX or FOFIRI regimen, every 2 weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2 weeks for 5cycles (cycles 1-5)
Postoperative CTx mFOLFOX or FOLFIRI regimen, every 2weeks for 6 cycles Bevacizumab 5mg/kg IV, every 2weeks for 5cycles(cycles 8-12)"
1678333|NCT01632709|Drug|Bupivacaine|one injection of 10ml of .25%
1678334|NCT01632709|Drug|Placebo|Dry needling
1678335|NCT01632696|Drug|I-124 PGN650 for PET/CT|I-124 PGN650 for PET/CT Day 1, Day 2 and 3.
1678336|NCT01632683|Device|C-MAC|C-MAC arm
1678337|NCT01632683|Device|Glidescope|Glidescope arm
1678338|NCT01632670|Other|Music therapy|The music played will be by MusiCure, by Niels Eje (slow, relaxing music designed for therapeutic use), and will be played from an audio pillow beneath the patient's head.
1678339|NCT01632657|Drug|Sumatriptan|Single subcutaneous injection sumatriptan 6mg (in 0.5ml) in recovery
1678340|NCT01632657|Drug|Placebo|Single injection saline 0.5ml subcutaneously in recovery
1678341|NCT01632644|Other|Survey/Interview|Each group will be surveyed and interviewed.
1678342|NCT01632618|Behavioral|Trunk Muscle Training+NMES|Progressive exercise program for the stabilizing muscles of the trunk, as well as neuromuscular electrical stimulation to the lumbar paraspinals
1678343|NCT01632618|Behavioral|Passive control intervention|Passive physical therapy approach to low back pain
1678344|NCT01632605|Drug|Sirolimus|Coated tablets, 1mg and 2mg available. Daily oral single dose with trough levels of 4-8ng/mL. Total intake for 6 months.
1678345|NCT01632592|Drug|Tesamorelin|The Growth Hormone Releasing Hormone analogue tesamorelin, 2mg subcutaneously daily by injection
1678346|NCT01632592|Drug|Placebo|placebo given by injection 2mg subcutaneously daily
1678350|NCT01632566|Drug|Placebo|Capsules administered orally
1678351|NCT01632566|Drug|LY3031207|Administered orally
1678352|NCT01632566|Drug|Celecoxib|Administered orally
1678353|NCT01632566|Drug|Simvastatin|Administered orally
1678354|NCT01632540|Drug|Beclomethasone Dipropionate (BDP) Nasal Aerosol|BDP nasal aerosol 320 mcg/day will be administered to all patients as 2 sprays in each nostril once daily.
1678355|NCT01632527|Drug|HuCNS-SC cells|HuCNS-SC cells transplantation directly into the subretinal space of one eye (Study eye) in a single transplant procedure.
1678356|NCT01632514|Drug|Cholecalciferol|100,000 U of cholecalciferol weekly for 4 weeks
1678357|NCT01632501|Device|Coronary stent - Tsunami|A coronary angioplasty was done
1678358|NCT01632475|Biological|Pneumostem®|"A single intratracheal administration
Low Dose Group (3 patients): 1.0 x 10^7 cells/kg, High Dose Group (6 patients): 2 x 10^7 cells/kg
* The subjects were administered with Pneumostem® in the earlier part of the phase I study. No drugs/biologics are administered during this part of the study."
1678359|NCT01632462|Drug|VSL#3|"This investigation will be a randomized, double-blind, placebo-controlled, cross-over trial. The study will include 30 children with CD and will be articulated in 6 months as follows. These children will be randomised to a treatment group receiving for 2 months either 1-2 packet containing 900 billion bacteria/day of VSL#3 according to their weight, and a group receiving the placebo drug. Assignment to therapy or placebo will be determined according to a computer-generated randomization scheme.. At the completion of the 8 weeks, a wash-out period of 6 weeks will be done, when no preparation will be administered. Then each patient will be switched to the other group and followed likewise for further 8 weeks."
1678360|NCT01632449|Drug|Test product|Dimethyl Fumarate (BG00012)
1678361|NCT01632449|Drug|Reference product|Dimethyl Fumarate (BG00012)
1678362|NCT01632436|Drug|Pixantrone|Experimental Drug
1678363|NCT01632423|Drug|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
1678364|NCT01632397|Behavioral|CBT-based counseling|Cognitive Behavior Therapy for PrEP adherence
1678365|NCT01632397|Behavioral|Health education and supportive counseling|Time matched general supportive therapy of the type commonly available from community therapists.
1678366|NCT01632384|Behavioral|Abstain from smoking for 24 hours|Compare smoking satiation to 24 hour smoking abstinence
1678367|NCT01632371|Device|Paclitaxel Eluting Balloon + Scoring Balloon|Scoring/cutting balloon lesion predilation; paclitaxel eluting balloon therapy
1678368|NCT01632371|Device|Paclitaxel Eluting Balloon|Standard balloon lesion predilation; paclitaxel-eluting balloon therapy
1678369|NCT01632358|Drug|TAP311 capsules|
1678370|NCT01632358|Drug|Placebo|
1678371|NCT01632345|Drug|Doravirine|Part 1: doravirine 25 mg, 50 mg (25 mg X 2), 100 mg, or 200 mg (100 mg X 2) tablet or placebo matching doravirine orally every morning with or without food for at least 24 weeks When the doravirine selected dose is determined after all participants reach Week 24, participants on other doses of doravirine will be switched to the selected dose for the remainder of the 96-week study. Part 2: Selected dose of doravirine (either 25 mg, 50 mg, 100 mg, or 200 mg) tablet or placebo matching doravirine orally every morning with or without food for 96 weeks
1678372|NCT01632345|Drug|Efavirenz|Efavirenz 600 mg tablet or placebo matching efavirenz orally at bedtime taken without food on an empty stomach for 96 weeks
1678373|NCT01632345|Drug|TRUVADA®|Open-label TRUVADA® (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate) tablet taken orally with food in the morning alone or with doravirine or placebo matching doravirine for 96 weeks
1678374|NCT01632332|Biological|HER-2/neu peptide vaccine|Given ID
1678375|NCT01632332|Other|laboratory biomarker analysis|Correlative studies
1678414|NCT01631994|Drug|metoclopramide|1 tablet of 10mg of oral dissolving metoclopramide will be taken by patient 45 minutes prior to ingestion of the capsule.
1678563|NCT01630850|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
1678376|NCT01632319|Behavioral|Combined Motivational Interviewing and Cognitive Behavioral Therapy|"8 sessions with study clinician, which focus on depressive symptom treatment and alcohol use Both courses teach coping skills for depression (CBT). However, one course focuses only on treatment for depression whereas the other provides also information tailored to the students' level of drinking and experience with regard to alcohol use.
In one course students are asked questions about their drinking, receive personalized feedback about it and are taught coping skills for their depressive symptoms"
1678377|NCT01632319|Behavioral|Cognitive Behavioral Therapy|Cognitive behavioral therapy is a type of therapy in which students will be taught coping skills for their depressive symptoms but they may or may not talk about alcohol consumption depending on the students' preference.
1678378|NCT01632306|Drug|LY2090314|LY2090314 administered IV
1678379|NCT01632306|Drug|FOLFOX|FOLFOX administered IV
1678380|NCT01632306|Drug|Gemcitabine|Gemcitabine administered IV
1678381|NCT01632306|Drug|Nab-paclitaxel|Nab-paclitaxel administered IV
1678382|NCT01632293|Behavioral|progressive resistance training|The exercise program uses guided progressive resistance training to provide an individualized program of strength training. The progressive resistance training intervention will consist of 12 weeks of guided resistance training twice weekly; in addition, subjects will be instructed to do one day of progressive resistance training at the home weekly.
1678383|NCT01632280|Device|Transcranial Direct Current Stimulation (tDCS)|"tDCS is a well-established, safe and noninvasive neuromodulation technique that is based on the application of a weak direct current to the scalp that flows between two electrodes—anode and cathode. Although there is substantial shunting of current in the scalp, sufficient current penetrates the brain to modify the transmembrane neuronal potential, and thus influence the level of excitability and modulate the firing rate of individual neurons.
In this study, participants will receive 10 daily sessions of tDCS (sham/real) over a period of two weeks."
1678387|NCT01632228|Drug|Bevacizumab|Participants will receive bevacizumab 15 milligrams per kilogram (mg/kg) IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
1678388|NCT01632228|Drug|Onartuzumab|Participants will receive onartuzumab 15 mg/kg IV infusion every 3 weeks until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
1678389|NCT01632228|Drug|Placebo|Participants will receive placebo matched with onartuzumab until disease progression, unacceptable toxicity, participants or physician decision to discontinue, or death.
1678390|NCT01632215|Drug|Gabapentine|Gabapentine 600 mg 01 dose
1678391|NCT01632215|Other|Sugar pill|Sugar pill 01 dose
1678392|NCT01632202|Device|Seprafilm|Seprafilm Adhesion Barrier (membrane) is a sterile, bioresorbable, translucent adhesion barrier composed of two anionic polysaccharides, sodium hyaluronate (HA) and carboxymethylcellulose (CMC). Together, these biopolymers have been chemically modified with the activating agent 1-(3-dimethylaminopropyl) -3- ethylcarbodiimide hydrochloride (EDC).
1678393|NCT01632202|Device|Sterile Saline Solution|For those randomized not to receive Seprafilm slurry, a syringe will be filled with 25ml of sterile saline.
1678394|NCT01632189|Drug|Varenicline|Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
1678395|NCT01632176|Behavioral|Brief, motivational interview and one booster session|This is a one session brief motivational interview-style intervention that follows a 9-step intervention algorithm. The intervention is delivered by a trained motivational interview interventionist. There is one booster call 10 days after the intervention/
1678396|NCT01632163|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form:solution
Route of administration: subcutaneous injection"
1678397|NCT01632163|Drug|Placebo|"Pharmaceutical form:solution
Route of administration: subcutaneous injection"
1678398|NCT01632150|Biological|Elotuzumab|Powder for solution, 400-mg vials, for infusion
1678399|NCT01632150|Biological|Thalidomide|50-mg capsules administered orally
1678400|NCT01632150|Biological|Dexamethasone|2- and 4-mg tablets (and various other strengths, as needed) administered orally and in 4- and 8-mg/mL (and various other strengths, as needed) solutions for intravenous administration
1678401|NCT01632150|Biological|Cyclophosphamide|50-mg tablets administered orally
1678402|NCT01632137|Drug|Rebamipide 2% ophthalmic suspension|Instill one drop into each eye 4 times a day for 4 weeks.
1678403|NCT01632137|Drug|Placebo (vehicle)|Instill one drop into each eye 4 times a day for 4 weeks.
1678404|NCT01632124|Other|Lung function measurement|Spirometry and measurement of diffusing capacity for carbon monoxide
1678405|NCT01632111|Other|Lung function measurement|Spirometry
1678406|NCT01632085|Device|The two groups SU and R are defined by the device with which intubation is performed after a first laryngoscopy done with the other device.|"Group SU (Single Use or Laryngobloc ®): the first laryngoscopy is performed with the R and the second laryngoscopy and the intubation is performed with the Laryngobloc ®.
Group R (Reusable handle+ disposable metal blade): the first laryngoscopy is performed with the Laryngobloc ® and the second laryngoscopy and the intubation is performed with the R."
1678407|NCT01632072|Dietary Supplement|Nutritional support|Nutritional support and counseling
1678408|NCT01632046|Drug|lactate and bicarbonate buffered dialysis solutions|Either PD-solution will be applied. Number of cycles and glucose concentration will be varied according to clinical needs. Sleep Safe system will be used and connected to Sleep Safe Cyclers in patient on CCPD.
1678409|NCT01632020|Drug|Placebo|2 capsules by mouth twice daily; minimum of 10 days, maximum of 21 days
1678410|NCT01632020|Drug|Metformin|850 mg (2 capsules) by mouth twice daily; minimum of 10 days, maximum of 21 days
1678411|NCT01632007|Drug|SYR-472|
1678412|NCT01632007|Drug|Alogliptin 25 mg|
1678413|NCT01632007|Drug|Placebo|
1729063|NCT00018135|Drug|calcium acetate|
1678415|NCT01631981|Drug|PGL2001 + Primolut-Nor 5|"PGL2001(estradiol sulfamate, E2MATE, ZK190628), Tablets, 1mg. 4 mg weekly for 4 weeks followed by 2mg weekly for 12 weeks.
Norethisterone acetate (NETA), Tablets, 5mg. Once daily for 16 weeks plus during follow-up."
1678416|NCT01631981|Drug|Placebo + Primolut-Nor 5|"Placebo, Tablets.4 tablets weekly for 4 weeks followed by 2 tablets weekly for 12 weeks.
Norethisterone acetate (NETA), Tablets, 5mg.Once daily for 16 weeks plus during follow-up."
1678417|NCT01631968|Procedure|Cement without antibiotic.|
1678418|NCT01631968|Procedure|Cement with erytromycin and colistin.|
1678419|NCT01631955|Drug|Ciprobay|Ciprobay (250mg, bid, oral)
1678420|NCT01631942|Drug|NNC172-2021|"Administered as subcutaneous (s.c., under the skin) injections every other day for two weeks.
Escalation to next dose level is based on a safety evaluation."
1678421|NCT01631929|Other|One bag|Infusion of dextrose and electrolytes using one bag
1678422|NCT01631929|Other|Two bags|Using 2 bags with different solutions with the same electrolyte content but different dextrose concentration (0% and 10%), administered simultaneously through the same intravenous line.
1678423|NCT01631916|Drug|corticosteroid|Dexamethasone 0.6 mg/kg/day or Methylprednisone 1 mg/kg/day
1678424|NCT01631903|Drug|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily for 4 months
1678425|NCT01631903|Drug|telepristone acetate 3 mg|3 mg, vaginal capsule, once daily for 3 months
1678426|NCT01631903|Drug|telepristone acetate 6 mg|6 mg, vaginal capsule, once daily for 3 months
1678427|NCT01631903|Drug|telepristone acetate 12 mg|12 mg, vaginal capsule, once daily, for 3 months
1678428|NCT01631903|Drug|telepristone acetate 24 mg|24 mg, vaginal capsule, once daily for 4 months
1678429|NCT01631890|Procedure|Endoscopic Ultrasound assisted endoscopic glue injection|N Butyl cyanoacrylate will be used for achieving initial hemostasis during active gastric variceal bleed and during follow up gastric variceal obturation. Endoscopic injection will be performed intravariceally using a therapeutic endoscope and a steel hubbed catheter, with N-butyl-2-cyanoacrylate. The cyanoacrylate will be injected without dilution with lipiodol. The tip of the endoscope will be coated with lipiodol to prevent sticking of glue to the endoscope. The injection catheter is primed with saline solution followed by injection of glue in 1ml aliquot to fill the dead space followed by injection of sterile water to flush the glue into the varix. The needle is withdrawn immediately after the glue injection to prevent tissue adherence.
1678430|NCT01631890|Procedure|Standard Endotherapy|Patients will be stabilized by giving i/v fluids, blood and blood products. Injection terlipressin will be given to all patients in a bolus dose of 2mg within 30 minutes of admission to the hospital. This would be followed by 1mg i/v 6hrly and will be continued for 5 days. If terlipressin cannot given then inj.somatostatin 500mcg IV bolus followed by 250mcg/hr continuous infusion for 5days.
1678431|NCT01631877|Drug|Enoxaparin with acenocoumarol|enoxaparin 100mcg/kg for 5days along with acenocoumarol 2mg to start with and dose to be adjusted for the target INR
1678432|NCT01631877|Other|placebo|injection placebo will be given for 5 days along with placebo tablets
1678433|NCT01631864|Drug|LCZ696|LCZ696 was provided as 400 mg tablets.
1678434|NCT01631864|Drug|amlodipine|amlodipine was provided as 5 mg tablets.
1678435|NCT01631864|Drug|Placebo|Matching placebo to LCZ696 and amlodipine.
1678436|NCT01631851|Behavioral|Cognitive-Behavioral Therapy (CBT) for Irritability|CBT is an individually administered behavioral interventions aimed at reducing irritability and disruptive behavior. There are 10 to 12 weekly sessions that are conducted with the child and the parent. During these sessions children are taught to recognize antecedents and consequences of problem behavior and to use emotion regulation and problem-solving skills to reduce irritability, aggression and noncompliance.
1678437|NCT01631838|Dietary Supplement|Tocotrienol-rich fraction 400mg|Tocovid Suprabio 200mg is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
1678438|NCT01631838|Dietary Supplement|Placebo|Placebo is taken twice daily (after breakfast and dinner) for 2 weeks. During postprandial day (Day 14), subjects are requested to consume breakfast meal containing 50g of fat and 100mL of milkshake, follow by capsule consumption
1678439|NCT01631825|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
1678440|NCT01631812|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
1678441|NCT01631799|Device|Femoral catheter|Femoral catheter was inserted at the beginning of surgery. After surgery ropivacaine was administered continuously for three days. In addition, patients received piritramide via patient-controlled analgesia. The amount of ropivacaine was measured.
1678442|NCT01631799|Device|Epidural catheter|The epidural catheter was inserted at the beiginning of surgery. After surgery ropivacaine was applied continuously for three days. In addition, patients received piritramide via patient controlled analgesia. The amount of ropivacaine was measured.
1678443|NCT01631773|Genetic|microRNA|Biological samples will be taken from subjects w/ Nasal polyps & AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
1678444|NCT01631760|Genetic|no intervention|We will be analyzing MicroRNA in subjects with Asthma Exacerbations by various age groups, Ages 5-12yrs, 13-55yrs, and 56-85yrs for genetic similarities and differences.
1678445|NCT01631747|Behavioral|Lifestyle Intervention Group|Women in the Intervention group will participate in a lifestyle program based on Moms'adopting a healthier diet and becoming more active for 24 months. Implementation is at approximately 15 weeks.Moms will meet individually with their Lifestyle Coach (LC)at least 3 times(more as needed, attend six sessions during pregnancy and one session after delivery. In addition moms will participate in monthly phone counseling sessions with Lifestyle Coach and complete daily tracking of diet & activity and use of pedometer
1678446|NCT01631747|Behavioral|Usual Care Group|Mom and family continue their typical eating, activity and other lifestyle habits for 24 months. They are invited to attend quarterly classes addressing prenatal wellness and family topics.
1678447|NCT01631708|Procedure|Erythrocytapheresis|"To achieve a blinded randomised trial, apheresis treatment will be used. Those in arm 1 will have erythrocytapheresis reducing iron levels and those in arm 2 will have plasmapheresis and their iron levels will not be reduced.
An apheresis machine will be used to remove red blood cells only from the erythrocytapheresis group. Subjects will have third weekly treatments until SF levels are reduced to ~100 ug/L in accordance with current guidelines."
1678448|NCT01631708|Procedure|Plasmapheresis|An apheresis machine will be used to remove blood plasma only from the plasmapheresis group. Those in arm 2 will have the approximate number of episodes of apheresis that would be required to reduce their SF to normal had they been randomised to the true treatment arm. Those in the sham arm will be offered to have venesection at their choice of venue or to have their SF normalised by erythrocytapheresis after the initial blinded part of the study. This will be done because it will not be known for some time if there is benefit from normalisation of SF and therefore leaving people with elevated SF that may be harmful.
1678449|NCT01631682|Drug|Propranolol|40mg single pill
1678450|NCT01631682|Behavioral|Reactivation|subject is re-exposed to CS+R on day 2 (code for CS that is both paired with shock and reactivated on day 2)
1678451|NCT01631682|Drug|Mifepristone|1800mg, 9 tablets
1678452|NCT01631682|Drug|Intranasal oxytocin|32 IU, 8 self-administered intranasal sprays, 4 in each nostril
1678453|NCT01631669|Drug|Celecoxib|200 mg Q 12 hours orally
1678456|NCT01631643|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
1678457|NCT01631630|Drug|Pioglitazone|Pioglitazone is a thiazolidinedione antidiabetic. It works by lowering blood sugar by making the cells of the body more sensitive to the action of insulin.
1678458|NCT01631630|Drug|Placebo|Placebo is an inactive tablet design to look exactly like pioglitazone
1678463|NCT01631604|Device|Walking aids and devices|Walking aids, e.g. braces, canes,orthoses, prosthetics, etc.
1678464|NCT01631604|Drug|Muscle/nerve injection|Injection to muscle or nerve
1678465|NCT01631604|Procedure|Corrective surgery|correction of spinal and bony deformities, muscle transfer, tendon elongation etc.
1678466|NCT01631604|Other|Physical therapy treatment|
1678467|NCT01631578|Procedure|Injection of an autologous mitochondria to the oocyte.|In the experimental group an autologous mitochondrial concentrate will be injected together with the sperm during ICSI. In the control group conventional ICSI will be performed.
1678468|NCT01631565|Behavioral|Early allocation to palliative care|Symptoms management (e.g. Pain, nausea, dehydration management).
1678469|NCT01631565|Behavioral|Nutritional counseling|Nutritional status evaluation and dietary supplementation according to the patient requirements.
1678470|NCT01631565|Behavioral|Psychoeducation.|Patient and care-taker psychoeducation, depression and anxiety evaluation.
1678471|NCT01631552|Drug|IMMU-132|IMMU-132 is administered on days 1 & 8 of 3 week treatment cycles. Up to 8 cycles will be given.
1678472|NCT01631539|Device|DC Bead™|chemoembolization with DC Bead™ loaded with Irinotecan
1678473|NCT01631539|Drug|Cetuximab|400 mg/m² IV at day 1 followed by 250 mg/m² IV weekly
1678474|NCT01631539|Drug|5 FU|every 2 weeks IV
1678475|NCT01631539|Drug|Irinotecan|every 4 weeks chemoembolization
1678476|NCT01631526|Dietary Supplement|vitamin D|vitamin D3 20,000 IU per day for 14 days followed by 10,000 IU per day for a further 7 days
1678477|NCT01631513|Drug|Nucynta ER|100 to 250 mg every 12 hours
1678478|NCT01631500|Behavioral|Conventional treatment|Conventional treatment
1678479|NCT01631500|Other|Integrative treatment|Person-centred dialogue combined with therapeutic acupuncture (mild manual acupuncture with deqi). Eight individual sessions, once a week, duration approximately 60 minutes
1678480|NCT01631500|Other|Therapeutic acupuncture|Eight individual sessions, once a week, with therapeutic acupuncture. The participants received acupuncture needles in the appropriate acupuncture points, in the same way as the integrative treatment model, but without person-centred dialogue.
1678481|NCT01631487|Drug|JNJ-39439335 10 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 10 mg.
1678482|NCT01631487|Drug|JNJ-39439335 25 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 25 mg.
1678483|NCT01631487|Drug|JNJ-39439335 50 mg|Multiple (once daily for 21 days) oral doses of JNJ-39439335 50 mg.
1678484|NCT01631487|Drug|Placebo|Multiple (once daily for 21 days) oral doses of matching placebo.
1678485|NCT01631474|Drug|CB-03-01|Topical cream, applied once a day
1678486|NCT01631474|Drug|Vehicle|Topical cream, applied once or twice a day
1678487|NCT01631474|Drug|CB-03-01|Topical cream, applied twice a day
1678489|NCT01631435|Other|Pillcam colon capsule and PillCam™ Prep Procedure|PillCam® Crhon capsule preparation will include a clear liquid diet and administration of a purgative sulfate-free polyethylene glycol electrolyte lavage (SF-ELS) solution (e.g. Nulytely) divided into two doses: the first dose on the evening before the exam and the 2nd dose on the morning of the exam day.
1678490|NCT01631435|Device|Ileocolonoscopy|"Conventional ileocolonoscopy Examination (same day or within 24 hours)of CE procedure
• Ileocolonoscopy with intubation of terminal ileum"
1678491|NCT01631422|Drug|RO4602522|Single radiolabeled dose
1678492|NCT01631409|Other|Treatment of CHD risk factors|Smoking cessation, low fat diet, body weight control, physical exercise program, and in some cases lipid-lowering medications, e.g. 3-hydroxy-3-methylglutaric acid-coenzyme A (HMG-CoA) reductase inhibitors, e.g. Simvastatin.
1678493|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of optimal medical treatment of Cohort I patient the life style modification is combined with one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) and lipid-lowering drugs (e.g. HMG-CoA reductase inhibitors).
1678494|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril.|In the course of maximal antianginal medical therapy a Cohort II patient is provided with more than one group of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
1678498|NCT01631409|Drug|Aspirin, Isosorbide mononitrate, Atenolol, Enalapril|In the course of maximal antianginal medical therapy a Cohort VI patient is provided with more than two groups of antianginal medications (e.g. Nitrates, Beta-blockers, ACE inhibitors, Calcium antagonists) combined with lowering-lipid drugs (e.g. HMG-CoA reductase inhibitors).
1678499|NCT01631396|Drug|Sugammadex vs. Neostigmine|"Sugammadex Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Sugammadex 2.0 mg/kg body.
Neostigmine Group (n=20) - anesthesia induced by Rocuronium 0.4mg/kg body, additional Rocuronium 0.1-0.2 mg/kg body as needed during surgery (not more than x2), muscular blockage reversal using Neostigmine 0.05 mg/kg body and atropine 0.1 mg/kg body."
1678500|NCT01631383|Drug|l-THP (l-tetrahydropalmatine)|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
1678501|NCT01631383|Drug|Placebo|Subjects will arrive the first day (Day 1) for admission and morning l-THP dosing. The l-THP will be dosed as one capsule 30 mg twice daily (matching placebo or l-THP) (total 60 mg daily). Participants will receive 7 total l-THP doses: two doses on Day 1 (morning and evening), two doses on Day 2 (morning and evening), 2 doses on Day 3 (morning and evening) and one dose the morning of Day 4 (cocaine administration day).
1678502|NCT01631370|Procedure|Renal denervation|The patients are examined prior to and 6 months after renal denervation. On the day of examination the patients will have blood samples taken and the hyperinsulinemic euglycemic clamp and muscle and adipose tissue biopsies will be performed.
1678503|NCT01631357|Drug|Arm 1: cytokine-induced killer cell + cisplatin + paclitaxel|TP regimen: intravenous infusions; paclitaxel, 135 mg/m2, day 1; intravenous injection cisplatin, 80 mg/m2, day 1; one cycle every month; up to 6 cycles. CIK cells: intravenous infusions; 5-6 × 109 CIK cells, days 14 and 15; one cycle every month; at least 6 cycles.
1678504|NCT01631357|Drug|Arm 2: cisplatin + paclitaxel|TP regimen: intravenous infusions; paclitaxel, 135 mg/m2, day 1; intravenous injection cisplatin, 80 mg/m2, day 1; one cycle every month; up to 6 cycles.
1678505|NCT01631344|Other|"Daily physical activity consultation, Using the Stage of change model"|Consultation of daily physical activity is provided, including selection of up to four pain relief exercises
1678506|NCT01631331|Drug|vismodegib|Given PO
1678507|NCT01631331|Procedure|Mohs surgery|Undergo Mohs surgery
1678508|NCT01631318|Procedure|dynamic contrast-enhanced ultrasound imaging|Undergo 3D contrast enhanced ultrasound imaging
1678509|NCT01631305|Drug|Levothyroxine|3 mcg/kg/day
1678510|NCT01631305|Other|Calcium magnesia|Placebo.
1678511|NCT01631292|Dietary Supplement|600 IU Vitamin D3|Once daily
1678512|NCT01631292|Dietary Supplement|2000 IU Vitamin D3|Once daily
1678513|NCT01631292|Dietary Supplement|4000 IU Vitamin D3|Once daily
1678514|NCT01631279|Drug|PR610|Dose escalation of PR610 to determine maximum tolerated dose for weekly administration
1678515|NCT01631266|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
1678516|NCT01631266|Biological|2 T.U. Tuberculin PPD RT 23 SSI|The 2 T.U. Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearm according to a double blind randomisation scheme
1678517|NCT01631253|Procedure|Laparoscopic ovarian cyst enucleation|
1678518|NCT01631227|Drug|Eprosartan|Eprosartan 450 mg
1678519|NCT01631227|Drug|Eprosartan Mesylate|Eprosartan mesylate 600 mg
1678520|NCT01631227|Drug|Placebo Eprosartan mesylate|Placebo Eprosartan mesylate
1678521|NCT01631227|Drug|Placebo Eprosartan|Placebo Eprosartan
1678522|NCT01631214|Drug|Romosozumab|Romosozumab sub-cutaneous injections and placebo alendronate (oral) for 12 months followed by open-label alendronate (oral) for at least another 12 months (until end of study)
1678523|NCT01631214|Drug|Alendronate|Oral alendronate and placebo AMG 785 sub-cutaneous injections for 12 months, followed by open-label alendronate, (oral) for at least another 12 months (until end of study)
1678524|NCT01631201|Drug|Rifalazil 25 milligram|Single dose of 25 milligram rifalazil to be administered on Day 1.
1678525|NCT01631201|Drug|Azithromycin 1 gram|Single dose of Azithromycin 1 gram to be administered on Day 1.
1678526|NCT01631188|Procedure|Minimally Invasive Aortic Valve|Patients having minimally invasive aortic valve surgery will have a pacing wire placed through the endovent catheter. The anesthesiologist will attempt to pace the ventricle with this wire if needed to wean from bypass.
1678527|NCT01631188|Procedure|Minimally Invasive Aortic Valve Surgery|The Anesthesiologist will advance a pacing wire through the Endovent Catheter under TEE in order to pace the heart when the subject is coming off the Cardiopulmonary bypass machine
1678528|NCT01631188|Device|Manipulation in OR surgical technique|Endovent and pacing wire when coming off cardiopulmonary bypass
1678529|NCT01631175|Behavioral|psychosocial treatment|psychosocial treatment, verbal therapy, relaxation exercises
1678530|NCT01631162|Other|Breath sample in all patients|Breath sample will be collected by a special nylon bag
1678531|NCT01631149|Drug|Surgical block (rocuronium; atracurium/mivacurium)|The surgical block will be varied by either induction of a deep block (via rocuronium infusion) or a moderate/normal block (using atracurium/mivacurium infusion)
1678532|NCT01631149|Drug|Surgical block (rocuronium; atracurium/mivacurium)|A surgical block will be induced by infusion of either rocuronium (deep block) or atracurium/mivacurium (normal/moderate block)
1678533|NCT01631136|Drug|Cisplatin|75 mg/m²
1678534|NCT01631136|Drug|Pemetrexed|500 mg/m²
1678535|NCT01631136|Drug|Cisplatin|80 mg/m²
1678536|NCT01631136|Drug|Gemcitabine|1250 mg/m²
1678537|NCT01631123|Other|Isocaloric high carbohydrate diet intervention|Time of 6 week, the last 6 days are standardized
1678538|NCT01631123|Other|Isocaloric high fat diet intervention|Time of 6 weeks; the first and the last 6 days are standardized
1678539|NCT01631110|Biological|Inflexal V|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V
1678541|NCT01631084|Other|JADE|"Patients are booked for reviews led by the doctor-nurse-HCA team every 2-4 months, preferably in a setting different from the busy clinics in order to facilitate group education and promote peer support.
Between each follow-up visit, the nurse or HCA will contact the patient by phone or email to remind them of the appointments (e.g. medical FU visit or laboratory tests), adhere to medications and healthy lifestyles, perform self glucose monitoring and provide psychosocial support, as appropriate."
1678542|NCT01631084|Other|DIAMOND|Patients randomized to the DIAMOND group will receive usual care after the initial baseline comprehensive assessment (CA), with repeat CA at 12 and 24 months.
1678543|NCT01631071|Biological|Virosomal influenza vaccine|Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL virosomal influenza vaccine
1678544|NCT01631058|Drug|Everolimus|"This is a 5-years prospective, randomized, exploratory, single-center, parallel group trial that includes renal transplanted elderly patients (≥ 60 years old) randomized between months 1 and 3 after transplantation to be maintained under MPS/TAC regimen or be switched to EVL/low-TAC.
Everolimus: initial dose of 1 mg BID. Doses will be adjusted in order to maintain Everolimus whole blood trough concentrations between 3-8 ng/ml.
Tacrolimus: initial dose of 0.1 mg/kg/day. Doses will be adjusted in order to maintain Tacrolimus whole blood trough concentrations between 2- 4 ng/ml thereafter.
Corticosteroids: as clinical practice."
1678545|NCT01631032|Drug|Qi-tonifying Chinese herbal products|Chinese herbal products in capsule, 3 times a day, 3gm (6PC of 500mg capsule) each time, total 9gm per day
1678546|NCT01631019|Behavioral|Mobile-phone-based Home Exercise Training Program|Patients in the mobile phone group were asked to perform daily endurance exercise training under mobile phone guidance, and the adherence was reported back to the central server. The level of endurance walking was re-assessed and re-adjusted initially on regular clinical visits every four weeks during the first three months. During this period of time, the adherence to protocol was reinforced by telephone from health professionals whenever patients missed one day of their walking training detected by the central system. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
1678547|NCT01631019|Behavioral|Home Exercise Training Program|all the subjects were assessed by an incremental shuttle walking test (ISWT) (24) for estimation of exercise endurance. Baseline spirometry and body mass index (BMI) were recorded. The adherence and compliance of the home-based exercise training program was assessed by monitoring the frequency of performance and the duration of the endurance walking program recorded on the central system every week. Patients were asked to continue their exercise program at home at a fixed walking speed, and return to the clinic at 1, 2, 3 and 6 months.
1678548|NCT01631006|Device|CPAP|A low or high CPAP pressure is delivered for 20 minutes
1678549|NCT01630993|Other|Umbilical Cord Milking|At birth, the infant will be held below the level of the placenta and umbilical cord will be milked 5 times after birth and before clamping the cord.
1678550|NCT01630980|Other|Tree nuts|Almonds, Brazil nuts, cashews, hazelnuts, macadamia nuts, pecans, pine nuts, pistachios and walnuts in whole, meal, or flour form
1678551|NCT01630967|Drug|Degarelix|Standard dosing and schedule for administration of degarelix will be used. 240mg s.c. loading dose, 80mg s.c. monthly maintenance dose.
1678552|NCT01630954|Procedure|Suction and evacuation|In single evacuation group women will be treated by suction evacuation and curettage is performed at the end of evacuation in one sitting. An ultrasound will be done later to examine completeness of evacuation. If there is significant amount of residual molar tissue or persistence of heavy bleeding a repeat curettage will be done . Women will be followed up with serum beta hcg 1 week after the evacuation and then weekly till the titer is negative. After three consecutive negative titre beat HCG estimation will be done at two weekly interval.
1678553|NCT01630954|Procedure|Suction and evacuation|In double evacuation group , women will be treated by suction evacuation and a thorough curettage will be avoided. A second evacuation with thorough curettage will be performed after 5 - 7 days of first evacuation.
1678554|NCT01630941|Drug|denosumab|Two doses of 60 mg in a solution of 1 ml, given as an subcutaneous injection with a 6 month interval
1678555|NCT01630928|Procedure|Renal sympathetic denervation|This is a mini-invasive trans-catheter procedure with access via a 6F introducer in one of the femoral arteries. The renal sympathetic nerves arise from T10-L2, arborize around the renal artery and primarily lie within the adventitia. A specialized radiofrequency (RF) ablation catheter is introduced into the renal arteries, first one side, then on the other. Usually, 4-6 two-minute treatments per artery using a proprietary RF generator with automated low power and built-in safety algorithms are sufficient to ablate the sympathetic afferent and efferent fibers.
1678556|NCT01630915|Drug|Torrent's Clopidogrel Tablets USP 75 mg|
1678557|NCT01630902|Drug|Torrent's Felodipine Extended-Release Tablets|
1678558|NCT01630889|Drug|FG-4592|Subjects previously randomized to FG-4592 will receive study medication on the same dosing frequency assigned at the last dose of the previous FibroGen study.
1678559|NCT01630876|Procedure|Vitrectomy only group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy only. The procedure will be done under retrobulbar anesthesia.
1678560|NCT01630876|Procedure|Combined therapy group|The patients who will underwent 23- gauge transconjunctival sutureless vitrectomy with concomitant posterior subtenon Triamcinolone acetate injection. For the posterior subtenon Triamcinolone acetate injection injection, a 1 ml of a 40 mg/ml of triamcinolone acetonide was given in the inferotemporal quadrant using a 27-gauge needle on 3-ml syringe. The conjunctiva and the Tenon's capsule were penetrated with the bevel of the needle toward the globe. The needle was advanced toward the macular area, taking care to remain in contact with the globe until the hub was firmly pressed against the conjunctival fornix and then the corticosteroid was slowly injected.
1678561|NCT01630863|Procedure|Photodynamic therapy|Photodynamic therapy is performed using verteporfin. Full dose of verteporfin is infused for 10 minutes, followed by laser delivery at 15 minutes from the start of infusion. Different light dose of PDT is applied to the patients at 50%, 40% and 30% of the full energy based on TAP study. The area of irradiation is set to the abnormal choroidal vascular hyperpermeability on ICGA corresponding to the leaking area on FA.
1678562|NCT01630850|Biological|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression may include remicade, thymoglobulin,prograf, solu-medrol, and cellcept. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
1678675|NCT01629875|Drug|Botox (Clostridium Botulinum A Toxin)|
1678564|NCT01630837|Other|frequency of oral hygiene|the frequency of oral hygiene was 12 to 12 hours, 24 to 24 hours, 48 to 48 hours and 72 to 72 hours.
1678565|NCT01630824|Other|Structured education program|structured education program after kidney transplantation
1678567|NCT01630798|Drug|GI heptapeptide|Investigational Agent Name: GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Investigational Agent Administration (see SOP in Appendix C) ASYNYDA-GGGSK-(5-FITC)-NH2 0.8 mg lyophilized powder per single-use amber vial Lyophilized powder reconstituted with 5 ml of 0.9% NaCl Final 100 µM concentration for single, one-time topical application Entire 5 ml volume (100 uM concentration) will be sprayed topically onto esophagus by the nurse/physician during the procedure through a standard endoscopy spray catheter (Olympus Medical, Tokyo Japan, PW-5V-1)
1678568|NCT01630785|Device|Intraoperative Neurophysiological Monitoring IONM|Intraoperative Neurophysiological Monitoring IONM device. Manufacturer: Inomed, Emmendingen, Germany
1678569|NCT01630772|Other|Physical therapy|Physical therapy in women with preeclampsia during the hospitalization
1678570|NCT01630772|Other|No physical therapy|Comparison of maternal and fetal hemodynamics in women with preeclampsia who underwent physical therapy and who did not have physical therapy
1678571|NCT01630759|Device|Telemonitoring|Use of telemonitoring facilities to monitor weight, blood pressure and blood sugar during pregnancy complicated by gestational diabetes
1678572|NCT01630759|Other|Control|The control group will receive usual diabetes/antinatal care. The outcomes from usual care will be compared with the outcomes from the telemonitoring group in order to ensure that it provides comparable care.
1678573|NCT01630746|Drug|TAK-438|
1678574|NCT01630746|Drug|TAK-438|
1678575|NCT01630733|Drug|Custirsen|Custirsen: Three loading doses of custirsen 640 mg IV over 2 hours administered in 5 to 9 days prior to Day 1 of Cycle 1, then custirsen 640 mg IV weekly every 21-day cycle
1678576|NCT01630733|Drug|Docetaxel|Docetaxel: 75 mg/m2 IV over 1 hour on Day 1 of every 21-day cycle
1678577|NCT01630720|Dietary Supplement|vitamin C or D therapy in acutely-hospitalized patients|vitamin C 500 mg twice daily versus vitamin D 5000 IU daily for 7 to 10 days
1678578|NCT01630694|Procedure|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
1678579|NCT01630694|Procedure|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck. You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
1678580|NCT01630694|Procedure|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute
1678581|NCT01630694|Procedure|3D Laser Scanning of the Head|Five scans will be collected from different angles, each scan taking approximately 3 seconds. Each scan will consist of a thin beam of light flashing of your head.
1678582|NCT01630694|Procedure|Measurements and Digital Photo's of the head, neck and Mouth|Prior to the photographs, certain bone and soft tissue areas such as angle of the jaw, neck and chin will be gently touched and marked with self-adhesive paper stickers. Using the self-adhesive paper stickers and a measuring tape, we obtain measurements of your head and neck.Digital Photographs of your Mouth - You will be also asked to open your mouth and a digital photograph of the back of the mouth will be taken, as well as, pictures of the front and side of the head and neck.
1678583|NCT01630694|Procedure|Ultrasound Exam of the Tongue|The ultrasound study of the tongue will be performed after the series of laser scans. You will be examined in the sitting position. A small,handheld, curved ultrasound instrument will be placed under the chin to take images of the tongue. This exam should take less than a minute.
1678584|NCT01630681|Behavioral|Internet-based stepped care|Interactive support and Cognitive Behavioral Therapy
1678585|NCT01630668|Dietary Supplement|One-a-Day L. reuteri NCIMB 30242 supplement capsule|Once per day, 12 weeks
1678586|NCT01630668|Dietary Supplement|One-a-Day placebo capsule|Once per day, 12 weeks
1678587|NCT01630655|Drug|Torrent's Felodipine Extended-Release Tablets|
1678588|NCT01630642|Drug|Torrent's Clopidogrel Tablets USP 75 mg|
1678591|NCT01630590|Drug|Cabozantinib|Starting dose of 60 mg by mouth every day of a 21 day cycle.
1678592|NCT01630590|Drug|Androgen Ablation Therapy|Androgen ablation therapy, either by means of luteinizing hormone-releasing hormone super-agonist (of any formulation), LHRH antagonist, or surgical castration given upon decision of study doctor.
1678593|NCT01630577|Other|volume expansion using modified gelatin|Volume expansion using modified gelatin was determined according to a procedure formulated by modifying guidelines produced by Weil and Henning. The maximum volume infusion during the study test was fixed at 400 ml.
1678594|NCT01630564|Drug|Ex vivo Expanded T Cells|Starting Dose 1: 1 * 10e6 T cells/kg infused through central venous catheter (CVC).
1678595|NCT01630551|Dietary Supplement|Fishoil supplement|1 capsule per day
1678596|NCT01630551|Dietary Supplement|Olive Oil|1 capsule per day
1678597|NCT01630538|Drug|Cyclophosphamide|Cyclophosphamide 1.5 mg/kg orally daily for 180 days adjusted for renal function
1678598|NCT01630525|Other|Neuropsychological assessment|Neuropsychological assessment : MMSE (Greco), RL/RI-16 items (Van der Linden 2003), visual retention test (DMS48), verbal fluency (Thurstone et Thurstone 1964), TMT A and B (Reitan 1956), DSST (Weschler 1997), Clinical Dementia Rating Scale (Hughes 1982), image naming DO80 (Deloche et Hannequin 1997), Similarities and Digit Span subscores of the WAIS (Weschler 1997), Anxiety and Depression (GDS), activities of daily living (ADL-Katz and IADL-Lawton).
1678599|NCT01630525|Other|ophthalmologic checkup|Vision work-up, 30 minutes (VA, non invasive retinal imaging : non dilated optic fundus picture or OCT, ocular tension).
1678600|NCT01630525|Other|Automated non-invasive oculometry|Automated non-invasive oculometry : 45 minutes with rest periods : horizontal and vertical pro- and anti-saccades, prediction, spatial decision (Monsiman et al. Brain 2005,128:1267-127, items detection (Rösler et al. Cortex 2005 ;41 :512-519) and exploration/curiosity of non congruent images and faces according to Daffner et al. Neurology 1992 ;42 :320-328 and Loughland et al. Biol Psychiatry 2002 ;52 : 338-348).
1678601|NCT01630512|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|The intervention consists of 8 weekly individual sessions of MBCT. Each session will be administered individually and will last 45 to 60 minutes.
1678602|NCT01630512|Behavioral|Cognitive Behavioral Therapy (CBT)|The intervention consists of 8 weekly individual sessions of CBT. Each session will be administered individually and will last 45 to 60 minutes.
1678603|NCT01630499|Behavioral|Tailored Lifestyle Intervention (TLI)|The intervention is a nutrition, physical activity, and behavioral weight management program that is tailored to the specific needs of breast cancer survivors.
1678604|NCT01630499|Behavioral|Commercial Weight Loss Program (CWLP)|This intervention is a generic, widely-available weight management program.
1678605|NCT01630473|Procedure|Corticotomy|After a periodontal full flap is dissected, by using small round burs, vertical lines (2 mm depth corticotomy) parallel to each root of the teeth in the anterior segment (canines and incisors) are created 5 mm beyond the apex in the maxillary bones and interconnecting the lines at the apex by horizontal corticotomies. Marginal bone crest is not touched by the surgical procedure.
1678606|NCT01630473|Procedure|Conventional orthodontics|Conventional orthodontic treatment
1678607|NCT01630434|Device|OCS Lung|OCS Lung will be used to preserve the donor lungs (Treatment Group).
1678608|NCT01630434|Device|Cold flush and storage|Donor lungs will preserved using standard cold flush and storage
1678609|NCT01630408|Drug|Paricalcitol|Paricalcitol oral capsules 1 mcg/day for 48 weeks
1678610|NCT01630395|Procedure|protective ventilation|low tidal volume and PEEP
1678611|NCT01630395|Procedure|Recruitment maneuver combined with protective ventilation|Low tidal volume, PEEP and recruitment maneuver
1678612|NCT01630369|Drug|insulin human (HR1799)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
1678613|NCT01630356|Behavioral|in-person counseling|The interventionist provided in person counseling on eliminating child exposure to tobacco smoke to at least one daily smoker and a non-smoker mother in the household. The counseling session emphasized the following issues: a) importance of healthy environment at home, b) health dangers of smoking and exposure to secondhand smoke, c) why and how to quit smoking, and d) how to keep home air smoke-free.
1678614|NCT01630356|Device|Demonstration of PM2.5 Pollution|The study team measured the particulate matter (PM2.5) in the air using the TSI AM 510 Aerosol SidePak to compare the quality of indoor air with outdoor air and demonstrate the effect of smoking on indoor air quality in the intervention households. After completing the Side Pack PM2.5 measurement, the interventionist immediately downloaded the data to a laptop to visualize the results through graphical presentation of the PM2.5 fluctuations to family members.
1678615|NCT01630356|Behavioral|Follow-up Counseling Calls|Interventionists made two follow-up counseling calls to the primary contact in the intervention households, usually a non-smoking mother at one and two months after the in-person counseling session. These calls aimed at a) assessing the progress in meeting the goals set earlier, b) counseling on barriers to the change, and c) encouraging study participants to maintain the success or to set new goals. These calls also provided opportunity for the participants to ask questions or clarify issues
1678616|NCT01630356|Behavioral|Printed material|"The intervention group families received the tailored and culturally adjusted educational brochure developed by the study team.
The control group received a brief educational leaflet on the hazards of SHS developed by the US Environmental Protection Agency."
1678617|NCT01630343|Drug|Paracetamol tablet and Tramadol capsule|Panadol 500mg tablet Q4H prn Tramadol 50mg capsule Q4H prn
1678618|NCT01630343|Drug|Panadol 500mg tablet, tramadol 50mg capsule|Regular Panadol 500mg tds with tramadol 50mg capsule tds for 3 weeks after injury
1678619|NCT01630330|Procedure|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
1678620|NCT01630330|Procedure|Ablation|Atrial Fibrillation Ablation with SmartTouch catheter
1678621|NCT01630317|Procedure|Peripheral line|Ultrafiltration therapy though peripheral line, two peripheral venous catheter will be placed in the arms.
1678622|NCT01630317|Procedure|Central line vein|Ultrafiltration therapy through central line, a central venous catheter will be placed in internal jugular or femoral vein.
1678623|NCT01630304|Behavioral|WelTel SMS service|"Weekly text message Mambo? (How are you?) to which participants are required to respond either Shida (problem) or Sawa (OK) within 48 hours. Shida responses and participants who do not respond are called by a clinician."
1678624|NCT01630291|Device|Electrode device|Lacrimal gland stimulation
1678627|NCT01630265|Other|Standard written discharge instructions|Group of caregivers who read the standard written discharge instructions prior to answering the questionnaire
1678628|NCT01630265|Other|Video Discharge Instructions|Group of caregivers who watched the 3 minute video covering the information in the standard written discharge instructions prior to answering the questionnaire
1678629|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
1678630|NCT01630252|Drug|Placebo|PGL5001 matching placebo (twice a day) for 8 weeks + one unique DMPA 150 mg injection
1678631|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
1678632|NCT01630252|Drug|Placebo|PGL5001 matching placebo (twice a day) for 20 weeks + DMPA 150mg injection. Second DMPA injection between 85 to 89 days after first injection
1678633|NCT01630252|Drug|PGL5001|PGL5001 320mg/day (160 mg twice a day) for 8 weeks + one unique DMPA 150 mg injection
1678634|NCT01630239|Procedure|Laser ablation|Laser ablation of hepatic tumors
1678676|NCT01629862|Device|Continuous positive airway pressure|CPAP at therapeutic pressure; ResMed S9 device in fixed pressure mode (Sydney, Australia).
1678635|NCT01630226|Drug|Neoadjuvant Cisplatin Chemotherapy|Patients will be treated with cisplatin chemotherapy at a dose of 75mg/m2 every three weeks for a total of four cycles (4 cycles of neoadjuvant chemotherapy).
1678636|NCT01630213|Dietary Supplement|Vitamin D3 + fish oil/fish oil placebo|Vitamin D3 2000 IU/day and fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo per day
1678637|NCT01630213|Dietary Supplement|Vitamin D3 placebo + fish oil/fish oil placebo|Vitamin D3 placebo/day + fish oil (840 mg of omega 3-fatty acids; Omacor)/fish oil placebo/day
1678638|NCT01630200|Drug|Roflumilast|Roflumilast coated tablet, 500µg oral application, once daily in the morning
1678639|NCT01630200|Drug|Placebo|Placebo coated tablet (visually identical to 500µg Roflumilast tablet), oral application, once daily in the morning
1678640|NCT01630187|Drug|Carbetocin|Administration of carbetocin 50 mcg , after clamping the umbilical cord
1678641|NCT01630187|Drug|Carbetocin|Administration of carbetocin 100 mcg , after clamping the umbilical cord
1678642|NCT01630161|Behavioral|Usual Care|Standard care includes routine assessment of smoking behavior and brief clinical intervention. Smoking counseling for all participants in the current study will be completed by a Certified Tobacco Treatment Specialist consisting consists of brief counseling (<15 minutes) based on the 5 A's Clinical Practice Guidelines; Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, Arrange for follow-up (Fiore et al., 2008). Patients receive information for local and state smoking resources (e.g., Quitline), pharmacotherapy options, and if interested, assistance with obtaining a prescription for pharmacotherapy. Follow-up with patients occurs at 2-weeks, only among those who are prescribed smoking medications (i.e., Varenicline, Bupropion).
1678643|NCT01630161|Behavioral|Smoking Relapse Prevention for Cancer Patients (SRP-CaP)|The proposed multimodal intervention consists of a series of easy-to-read relapse prevention booklets (Forever Free) that have shown to be efficacious with a general smoking population (Brandon et al., 2000; 2004), and digital video disk (DVD) customized to the needs of cancer patients (to be developed in Year One).
1678644|NCT01630148|Drug|Bemiparin|Bemiparin Sodium 3,500IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group (Moderate, High and Highest risk groups for thromboembolism) 6 hours after surgery and then daily for up to 7 days.
1678645|NCT01630135|Drug|Fluticasone furoate|55 mcg/day, intranasal, 2 weeks
1678646|NCT01630135|Drug|Placebo|Placebo, intranasal, 2 weeks
1678647|NCT01630109|Drug|Metoclopramide|A one time dose of either Metoclopramide 5 mg or 10 mg (or placebo) given orally 30 minutes prior to pill capsule endoscopy.
1678648|NCT01630109|Drug|Placebo|A placebo capsule made to look like the metoclopramide capsule.
1678649|NCT01630096|Drug|Nu-Lytely|Bowl prep solution.
1678655|NCT01630070|Device|Self-expandable drug eluting stent|Self-Expanding Paclitaxel-Eluting stent
1678656|NCT01630057|Drug|Adjunctive Zonisamide|Patients will be gradually down-titrated from the first add-on following a drug-specific scheme decided by the investigator. Discontinued from the first add-on, patients will remain on duotherapy until the end of the study, or until the clinical situation mandates withdrawal from the study, e.g. in case of seizure worsening or adverse events.
1678657|NCT01630057|Drug|Replacement with Zonisamide|Patients will continue to receive zonisamide as third drug
1678658|NCT01630044|Device|TNM device|Non-invasive neurostimulator, home-use treatment for up to 43 days.
1678659|NCT01630018|Drug|Topotecan|1.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
1678660|NCT01630018|Drug|Belotecan|0.5mg/m2 IV days 1,2,3,4,5 of each 21day cycle until 6cycle or disease progression
1678661|NCT01630005|Behavioral|talk therapy|Psychotherapy
1678662|NCT01629992|Other|Preoperative counseling|The intervention group received preoperative counseling by both orally and written. A written leaflet containing information was provided to each patient of this group.
1678663|NCT01629979|Procedure|Grafting with epidermal cells|"A superficial skin shaving excision will be obtained from pigmented skin using a dermatome. A cell suspension will be obtained by trypsinisation. Vitiligo skin will be dermabraded by Erbium: Yag laser after local anaesthesia. The cell suspension will be spread on the dermabraded skin area and fixed with dressings. Keratinocyte, and melanocyte counts will be performed on an aliquot of the cell suspension. One symmetrical patch of vitiligo will be chosen as control and left untreated.
Narrow-band UVB treatment: Four weeks after transplantation of epidermal cells, the grafted and control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments."
1678664|NCT01629979|Radiation|UVB treatment|the control patch will be treated by Narrow-band UVB. Treatment will be performed 2 times a week. Narrow-band UVB treatment will be performed for at least 3 months or 24 treatments.
1678665|NCT01629966|Drug|Placebo|Matching 10 mg and 20 mg placebo tablets, once per day, oral administration,
1678666|NCT01629966|Drug|Vilazodone|Vilazodone, 20mg, oral administration once per day.
1678667|NCT01629966|Drug|Vilazodone|Vilazodone, 40mg, oral administration once per day.
1678670|NCT01629914|Behavioral|Mindfulness Meditation|8-week, group-based mindfulness meditation intervention
1678671|NCT01629901|Device|ThermoNeuroModulation (TNM) Device|Non-invasive neurostimulator used for up to 20 minutes in a session.
1678672|NCT01629888|Other|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (3 test products/day)
1678673|NCT01629888|Other|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (3 control products/day)
1678674|NCT01629875|Drug|Generic equivalent of Clostridium Botulinum A Toxin|
1678677|NCT01629862|Device|Sham continuous positive airway pressure|CPAP at non-therapeutic pressure; ResMed S9 device using a ResMed sham mask (Sydney, Australia).
1678678|NCT01629849|Drug|Placebo to BI 1021958 qd|tablet
1678679|NCT01629849|Drug|BI 1021958 bid|tablets
1678680|NCT01629849|Drug|Placebo to BI 1021958 bid|tablets
1678681|NCT01629849|Drug|BI 1021958 qd|tablet
1678682|NCT01629823|Device|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage)|Continuous Positive Airway Pressure device (Resmed, Swift, Mirage): Participants will be randomized to one of three pre-set CPAP pressures: less than 1 cm water (H₂O), 5 cm H₂O or 10 cm H₂O. They will be instructed to use the CPAP device every night for 12 weeks. Methacholine airways reactivity will be measured at the end of these 12 weeks and again after a 2-week washout period, 14 weeks after randomization.
1678683|NCT01629810|Device|Whole body periodic acceleration (Exer-Rest)|Lying on the vibrating bed for 45 minutes per session for 10 sessions over 2 weeks.
1678684|NCT01629797|Behavioral|Educational script on Acne|An educational script on Acne will be presented by investigator
1678685|NCT01629784|Behavioral|Cutaneous Lupus educational script|Subjects will listen to a short informational script on Cutaneous lupus and skin protection
1678686|NCT01629758|Biological|Denenicokin|
1678687|NCT01629758|Biological|Nivolumab|
1678688|NCT01629745|Genetic|gene expression analysis|
1678689|NCT01629745|Other|flow cytometry|
1678690|NCT01629745|Other|laboratory biomarker analysis|
1678691|NCT01629732|Drug|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 12 or 24 weeks
1678692|NCT01629732|Drug|Daclatasvir|Film coated tablet, Oral, 60 mg, Once daily, 24 weeks
1678693|NCT01629732|Drug|BMS-986094|Capsule, Oral, 100 mg, Once daily, 12 or 24 weeks
1678694|NCT01629732|Drug|BMS-986094|Capsule, Oral, 200 mg, Once daily, 12 or 24 weeks
1678695|NCT01629732|Drug|BMS-986094|Capsule, Oral, 200 mg, Once daily, 24 Weeks
1678696|NCT01629732|Drug|Ribavirin|Film coated tablet, Oral, 1000 mg or 1200 mg based on weight, Twice daily, 12 or 24 weeks
1678697|NCT01629732|Drug|Placebo for BMS-986094|Capsule, Oral, 0 mg, Once daily, 12 or 24 weeks
1678698|NCT01629706|Device|Balafilcon A contact lens|Commercially marketed silicone hydrogel contact lens
1678699|NCT01629706|Device|Habitual contact lenses|Commercially marketed silicone hydrogel contact lenses as prescribed by eye care practitioner, brand and power
1678700|NCT01629706|Device|Renu multi-purpose solution|Commercially marketed solution for use in removing protein, cleaning, conditioning, and disinfecting contact lenses.
1678701|NCT01629706|Device|ClearCare|Commercially marketed hydrogen peroxide system for cleaning and disinfecting contact lenses
1678702|NCT01629706|Device|Habitual lens care|Lens care per habitual use
1678703|NCT01629693|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
1678704|NCT01629693|Device|Comfilcon A contact lenses|Silicone hydrogel contact lenses (sphere or toric) per subject's habitual prescription
1678705|NCT01629680|Drug|Moxaverine|Moxaverine-hydrochloride, coated tablets containing 150 mg moxaverine (Kollateral forte, Ursapharm. Saarbrücken, Germany), dosage: 900 mg, administrated per os in three equal doses of 300 mg at two hour intervals
1678706|NCT01629680|Drug|Placebo|coated tablets identical in number and appearance as the study drug
1678707|NCT01629667|Biological|Tralokinumab|Participants will receive Tralokinumab 400 mg IV infusion Q4W for 68 Weeks.
1678708|NCT01629667|Biological|Tralokinumab|Participants will receive Tralokinumab 800 mg IV infusion Q4W for 68 Weeks.
1678709|NCT01629667|Other|Placebo|Participants will receive placebo IV once every 4 Weeks (Q4W) for 68 Weeks.
1678710|NCT01629654|Behavioral|Health promotion program|"A 13 weeks organized program:
One group session about poststroke fatigue involving both patient and relatives
Two personal meetings, involving both patient and relatives
Three telephone meetings, involving only patient"
1678711|NCT01629628|Drug|Adalimumab|Subcutaneous adalimumab injections, loading dose of 160 mg and 80 mg on 0 and 2 weeks and maintenance of 40 mg every other week for the duration of the study.
1678712|NCT01629628|Drug|6 Mercaptopurine|6MP will be administered orally starting at a dose of 6MP of 50mg/day with escalating doses every 1-2 weeks as tolerated, to a target dose of 1-1.5 mg/kg.
1678713|NCT01629615|Drug|BKM120|BKM120 oral capsules. 100 mg daily in cycles of 28 days, until disease progression
1678714|NCT01629602|Procedure|the Boomerang Nerve Flap|The nerve branch was combined with the boomerang flap for simultaneous repair of soft tissue loss and PDN defect in these awkward areas.
1678715|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed (Adacel®)|0.5 mL, Intramuscular
1678716|NCT01629589|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed (BOOSTRIX®)|0.5 mL, Intramuscular
1678717|NCT01629576|Other|economic incentive|economic incentive for weight loss
1678718|NCT01629576|Other|economic incentive|economic incentive for weight loss
1678719|NCT01629563|Drug|PGL4001 5 mg|PGL4001 5 mg daily administration
1678720|NCT01629563|Drug|PGL4001 10 mg|PGL4001 10mg daily administration
1678721|NCT01629550|Procedure|skin disinfection prior catheter insertion|
1678722|NCT01629537|Procedure|Stellate Ganglion Block injection with ropivicane|For participants receiving the stellate ganglion injection with ropivicaine, a 22 g needle will be directed percutaneously to the anterolateral C6 vertebral body Using ultrasound guidance to avoid the nearby vascular structures and identify the appropriate vertebral level and tissue plane. After negative aspiration for blood and CSF, and digital subtraction, 2cc of Iohexol,(Omnipaque 180) will be injected through the needle under live fluoroscopy to visualize dye spread over the pre-vertebral plane At this point, 7 cc 0.5% ropivicaine will be injected and the needle will be removed.
1678723|NCT01629537|Procedure|Placebo Procedure|In participants randomized to the placebo injection, the same positioning, monitoring, sterile preparation and technique and local anesthesia protocol will be used. The 22 g needle will instead be placed in the subcutaneous, superficial tissues overlying the C6 tubercle, but superficial enough that the prevertebral fascial plane of the stellate ganglion will not be breached. Using fluoroscopic guidance, this needle will be injected with 2 cc of contrast dye to confirm superficial spread. The needle will then be injected with 5 cc of preservative free normal saline and the needle will be removed.
1678724|NCT01629511|Drug|Busulfan|"32 mg/m2 test dose by vein based on actual body weight given between Day -15 and Day -8.
Busulfan administered at dose calculated to achieve a systemic exposure dose of 4000 µMol-min in normal saline over 3 hours by vein every 24 hours on Days -6 to -3, starting one hour after the completion of Clofarabine."
1678725|NCT01629511|Drug|Clofarabine|30 mg/m2 diluted in NS to produce a final concentration of 0.4mg/mL by vein on Days -6 through -3.
1678726|NCT01629511|Drug|Gemcitabine|"Phase I Starting Dose: 275 mg/m2 by vein preceded by a loading dose of 75 mg/m2 administered as a bolus on Days -6 and -4.
Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
1678727|NCT01629511|Drug|Thymoglobulin|0.5 mg/kg by vein on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1 for patients receiving a graft from a matched unrelated donor.
1678728|NCT01629511|Procedure|Allogeneic Stem Cell Transplantation|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
1678729|NCT01629511|Drug|Filgrastim|5 mcg/kg subcutaneously 1 time each day starting 1 week after the transplant until blood cell levels return to normal.
1678730|NCT01629511|Drug|Tacrolimus|Starting dose of 0.015 mg/kg by vein as a 24 hour continuous infusion daily beginning on Day -2, adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no GVHD is present.
1678731|NCT01629511|Drug|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6 and +11 post transplant.
1678732|NCT01629498|Radiation|IMPT + SIB + Chemotherapy|"Phase I Starting Dose: For all SIBVi dose levels, the dose to the PTV will be kept constant at 60 Gy(RBE) in 30 fractions, which is biologically equivalent to 67 Gy(RBE) delivered in 2 Gy(RBE) fractions. We will start the SIB at the lowest dose level to SIBVi to 72 Gy(RBE) (SIBV72) in 30 fractions at 2.4 Gy per fraction. Fractions given once a day, 5 times a week for six weeks.
All patients will receive standard concurrent chemotherapy as prescribed by their treating medical oncologist.
Dose level 1 of 66-72 Gy(RBE) in 30 fractions used as the planned dose in the Phase II portion of the trial."
1678733|NCT01629498|Behavioral|Questionnaire|Symptom questionnaire completion before chemoradiation beings, each week during chemoradiation, each week until 16 weeks after chemoradiation is complete, every other week from Week 16 until 12 weeks after chemoradiation is complete, and at follow-up visits. The symptom questionnaire should take about 10 minutes to complete each time.
1678734|NCT01629498|Radiation|IMRT + SIB + Chemotherapy|"Phase I Starting IMRT Dose: 60 Gy (RBE) in 30 fractions. Phase I Starting SIB Dose: (72 - 84) Gy (RBE).
Fractions given once a day, 5 times a week for six weeks.
Dose level 1 of 66-72 Gy(RBE) in 30 fractions used as the planned dose in the Phase II portion of the trial."
1678735|NCT01629485|Behavioral|Online Video Curriculum|A video curriculum has been designed for the purpose of educating general surgery residents in laparoscopic hernia repairs. The curriculum covers topics from basic anatomy, selection of patients, management, and operative technique.
1678736|NCT01629485|Behavioral|Whole Task Mastery Training|Trainees will undergo whole task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of whole task tep repairs was established with performance measures of multiple staff surgeons previously.
1678737|NCT01629485|Behavioral|Part Task Mastery Training|Trainees will undergo part task mastery training in the TEP simulator. The benchmarks for mastery training in the setting of part task tep repairs was established with performance measures of multiple staff surgeons previously.
1678738|NCT01629472|Behavioral|VSLA + Gender dialogue groups|Dialogue groups discussing household discussion making and gender norms facilitated by IRC.
1678739|NCT01629459|Behavioral|Resistance exercise and protein supplementation|Resistance exercise training will occur 3x/wk for 12 wks at a physical therapy or cardiac rehabilitation facility near the participant's home. Participant will take 42 grams of supplementation protein daily.
1678741|NCT01629420|Drug|KLH-2109|
1678742|NCT01629420|Drug|KLH-2109|
1678743|NCT01629407|Other|Standard of Care|Patients with glaucoma treated with standard of care at the discretion of the physician. There is no specific treatment required for this study.
1678744|NCT01629394|Drug|Sugammadex|Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
1678745|NCT01629394|Drug|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
1678746|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
1678747|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg ( ideal body weight )
1678748|NCT01629394|Drug|Sugammadex|Single dose of 2 mg/kg corrected body weight [corrected body weight = ideal body weight + 40%( real body weight - ideal body weight)]
1678749|NCT01629394|Drug|Sugammadex|Single dose of sugammadex 2 mg/kg ( ideal body weight )
1678750|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50 μg/kg corrected body weight [corrected body weight = ideal body weight + 40%(real body weight - ideal body weight)]
1678751|NCT01629394|Drug|Neostigmine|Single dose of neostigmine 50μg/kg ( ideal body weight )
1678754|NCT01629368|Drug|Carbamazepine|Multiple doses of carbamazepine
1678755|NCT01629368|Drug|RO4917523|Single dose of RO4917523
1678756|NCT01629342|Behavioral|Standardized activities|"All patients do each of the following standardized activities over a course of 2 days:
treadmill walking (5 minutes, 1 and 2km/h)
staircase walking (1 floor, normal pace)
cycling with fixed load (5 minutes)
standing up from sitting position and sitting down again (x5)
standing up from supine position
turning from left to right and back while lying in bed
raising outstretched arm 90° (x5, standing position)
eating (5 minutes, sitting position)
drinking a glass of water
sleeping (6 hours)"
1678757|NCT01629329|Drug|Aspirin, Acetaminophen, Caffeine pills|One time dose of 2 pills each containing acetaminophen 250mg, aspirin 250mg and caffeine 65mg in each tablet. Simultaneous administration of placebo(5ml of saline administered IV)
1678758|NCT01629329|Drug|Prochlorperazine 10mg|One time dose of Prochlorperazine 10mg/2ml given IV slow push. Simultaneous administration of 2 unmarked placebo pills.
1678795|NCT01628978|Other|determination by auscultation|determination of depth of endotracheal tube placement by auscultation
1678759|NCT01629316|Behavioral|Text reminders, counseling, and link coordination|This is an intervention with text reminders, counseling that involves motivational interviewing, and link coordination
1678760|NCT01629316|Behavioral|Standard of care - control arm|The control arm is standard of care for each subject.
1678761|NCT01629303|Procedure|sacral nerve modulation|"After the definitive implantation, stimulators are placed in position ON (arm on-off) or OFF (arm off-on) for the first arm and in position OFF for the second arm during 8 weeks.
Then all the stimulators are switched OFF (both first and second arms) for 15 days.
Finally stimulators are maintained in position OFF for the first arm and switched ON for the second arm during 8 weeks"
1678762|NCT01629290|Device|Enamel Pro|Varnish treatment containing 5% NaF
1678763|NCT01629290|Device|Duraphat|Varnish treatment containing 5% NaF
1678764|NCT01629290|Device|Vanish|Varnish treatment containing 5% NaF
1678765|NCT01629290|Device|Placebo|Bland varnish containing no NaF
1678766|NCT01629277|Device|Closed-loop|Subcutaneous insulin delivery will be adjusted according to the computer-based algorithm advice, based on subcutaneous glucose readings
1678767|NCT01629277|Device|standard insulin pump|Subcutaneous insulin delivery will be administered according the standard insulin pump settings
1678768|NCT01629264|Device|Ocular Response Analyzer|To measure corneal biomechanics, specifically corneal hysteresis (CH) and the Corneal Resistance Factor (CRF). The devise measures in a non-contact manner, by analyzing the deformation of the cornea upon a defined pulse of air.
1678769|NCT01629264|Device|Scheimpflug measurement|A Scheimpflug camera will be used in a non-contact manner to assess topographical data from the anterior and posterior corneal surface as well as detailed data on corneal thickness.
1678770|NCT01629264|Other|Blood sample|A blood sample will be taken at 6 months after surgery to determine the levels of several hormones. The blood needed to détermine hormone levels during pregnancy will be acquired during the routine examinations that are performed during pregnancy. Here, blood is taken routinely and an additional volume is taken for the purpose of this study.
1678771|NCT01629251|Device|Closed-loop insulin delivery|Subcutaneous basal insulin delivery will be adjusted following the advice by a computer-based algorithm, based on subcutaneous sensor glucose readings. Standard or reduced meal insulin dosing will be performed in a randomised design.
1678772|NCT01629225|Drug|Candesartan|To investigate the response to candesartan among southwestern Han Chinese with essential hypertrension
1678773|NCT01629212|Drug|Tiropramide HCl 100mg|
1678774|NCT01629212|Drug|Octylonium bromide 20mg|
1678775|NCT01629199|Drug|rhEGF(recombinant human Epidermal Growth Factor)|
1678776|NCT01629199|Drug|placebo of rhEGF(recombinant human Epidermal Growth Factor)|
1678777|NCT01629186|Other|NPO with Nose-close and Abdomen-compression|Infants with body weight (BW) <5.0 kg and receiving nasal diagnostic or interventional FB were enrolled. Under NPO (0.5 L/kg/min), when infant's heart rate (HR) <80 beats/min or oxygen saturation (SpO2) <85% for more than 10 seconds, rescue NC-AC was initiated. It was performed by (1) increased NPO flow to 0.5-1.0 L/kg/min; (2) NC 1 second for inspiration; and (3) AC 1 second for expiration with simultaneously released nostrils. Repeat doing steps (2) and (3) at a rate of 30 cycles/min until HR, SpO2, and blood pressure (BP) returned to normal.
1678778|NCT01629173|Procedure|Dynamic impression insole|We sequentially padded (1)a 6.5-mm thick P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), and (2)a piece of metatarsal pad and arch support made of Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) to the bottom of the impressed 9-mm thick plastazote (15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) with double-sided adhesive tape in the forefoot region and just proximal to the first, second, and third metatarsal head region. We additionally padded a 2-mm thick Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the top of the impressed insole with double-sided adhesive tape.
1678779|NCT01629173|Procedure|Custom molded insole|The custom molded insole was made by sequentially padded Multiform (30 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), P-cell (21 Shore A hardness, Acor orthopedic Inc. Cleveland, Ohio, USA), Ethylene Vinyl Acetate (EVA)(40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany), and cork (50 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) on the positive plaster cast impressed by an impression box while holding the subtalar joint at a neutral position.
1678780|NCT01629173|Procedure|9-mm uncompressed Plastazote|We used 9-mm flat Plastazote(15 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
1678781|NCT01629173|Procedure|7-mm Ethylene Vinyl Acetate (EVA)|We used 7-mm flat Ethylene Vinyl Acetate (EVA) (40 Shore A hardness, Schein orthopadie service KG. Remscheid, Germany) as an insole
1678782|NCT01629147|Dietary Supplement|Biogaia|5 drops containing Lactobacillus reuteri Protectis
1678783|NCT01629147|Other|Placebo|5 drops
1678784|NCT01629134|Device|Crosslinked hyaluronic acid gel|All treatments are carried out according to the physician's experience and the Directions for Use
1678785|NCT01629121|Behavioral|education intervention|"The brain injury prevention education intervention included case scenarios as well as education about the benefits of bicycle helmet use. The intervention was designed to be sensitive to the age and educational level of the study participant and his or her parents. Educational materials were chosen to provide use of the five senses to enhance the learning experience. The intervention took place in the privacy of the patient's hospital room. The study was designed so as not to interfere with the hospital standard of care.
The proper way to fit the bicycle helmet was demonstrated."
1678788|NCT01629069|Behavioral|Mindfulness based Resilience Training|6 weekly group sessions
1678791|NCT01629004|Other|FOBT kit|Mailed FOBT kit with educational materials and mailed CRC screening invitation on behalf of family physician.
1678792|NCT01629004|Other|Mailed invitation|Mailed CRC screening invitation alone on behalf of family physician.
1678793|NCT01628991|Behavioral|behavioural program|interventional behavioural program
1678794|NCT01628991|Device|Iranian version of vaginal cones|intravaginal device(vaginal cone) for promote the pelvic floor exercises
1678796|NCT01628978|Other|determination by ultrasound|determination of depth of endotracheal tube placement by ultrasound
1678797|NCT01628965|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
1678798|NCT01628952|Drug|Transversus Abdominis Plane|PIA coelioscopic
1678799|NCT01628952|Drug|Curare|IAP coelioscopic
1678800|NCT01628939|Other|MRI of the lumbar spine|standard protocol, approximately 30 minutes
1678801|NCT01628939|Other|manual segmental examination of the lumbar facet joints|use of three different segmental facet joint provocation tests (spinal palpation, segmental rotation and springing-test) from Th12-L1 to L5-S1
1678802|NCT01628926|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
1678803|NCT01628926|Drug|Ropinirole|Ropinirole oral administration TID up to 15.0 mg/day
1678804|NCT01628926|Drug|Placebo|SPM962-placebo patch and Ropinirole-placebo tab
1678805|NCT01628913|Drug|BEZ235|BEZ235 400 mg bid p.o. (by mouth, twice daily)
1678806|NCT01628913|Drug|Everolimus|Everolimus 10 mg qd p.o. (by mouth, daily)
1678807|NCT01628900|Other|care management arm N°1 vs arm N°2|7 days for mono-antibiotherapy at hospital
1678808|NCT01628900|Other|Care management|Hospital vs home
1678809|NCT01628887|Other|Educational Intervention|Undergo Bilingual Breast Cancer Educational Intervention
1678810|NCT01628874|Device|J-Tip|Used once for both arms prior to lumbar puncture. The Experimental arm will receive 0.5 mL (5mg) of 1% Lidocaine. The Active Comparator arm will receive normal saline. This will occur after the cream has been placed for 30 minutes and wiped away and prior to the lumbar puncture.
1678811|NCT01628874|Drug|EMLA|In the Active Comparator arm, lidocaine 2.5% and prilocaine 2.5% cream placed over area where lumbar puncture will occur for at least 30 minutes. This same procedure will occur for the Experimental arm with a placebo cream instead. This will occur once prior to the J-Tip injection and lumbar puncture.
1678812|NCT01628874|Drug|Lidocaine|5 mg given via J-Tip once, repeat dosing as needed in the Experimental group. A placebo will be given in the Active Comparator group.
1678813|NCT01628861|Device|MyRestBreak 1.0|"Prompting software (MyRestBreak 1.0 copyright Vikram Sharma) will be installed on the work computer. A prompt with the message stand up, take a break is placed on the screen of the work computer for 1 minutes every 30 minutes, from the time the computer is switched on in the morning. The prompt is contained in a window 11x9 cm in the centre of the screen. The prompt cannot be removed or minimised, but work can continue in any windows visible around the prompt. The prompt is on the computer for 5 days."
1678814|NCT01628861|Behavioral|education talk and leaflet|A short educational talk, read from a script, regarding the health risks of prolonged sitting, stating that standing every 30 minutes could be beneficial. A short information leaflet stating with the same message is also provided.
1678815|NCT01628848|Drug|SPM 962|SPM 962 transdermal patch once a daily up to 36.0 mg/day
1678816|NCT01628848|Drug|Placebo|Placebo transdermal patch
1678817|NCT01628835|Behavioral|Low dietary glycemic index diet|Based on the national diet and physical activity recommendations for pregnant women (total energy intake, protein and vitamin etc.), counseling for a low dietary glycemic index diet will be provided
1678818|NCT01628835|Behavioral|National recommendation diet|Provision of food and dietary counseling according to the national prenatal nutrition recommendation without GI information
1678819|NCT01628822|Behavioral|Active relaxation|The length of follow-up will be 12 weeks.Patients will be seen once every seven days by a relaxation therapist for 5 weeks (6 sessions) and will be followed by the center physician investigator regarding drug therapy
1678820|NCT01628822|Behavioral|Placebo|Patients are been asked to relax alone in a quiet room. They are coming every 7 days for 5 weeks (6 sessions) and will be followed by the investigator regarding drug therapy
1678821|NCT01628809|Behavioral|Mindfulness-Based Stress Reduction|three-day mindfulness-based meditation retreat program
1678822|NCT01628796|Other|contrast material injection|using ultrasound to locate ac joint and injecting contrast material to ensure that the dye is actually in the joint
1678823|NCT01628783|Drug|escitalopram 10 mg|orally once daily
1678824|NCT01628783|Drug|Placebo|once daily
1678825|NCT01628770|Drug|Iron isomaltoside 1000|Iron molecule iron isomaltoside 1000 (Monofer) have been introduced in the market, which can be given in intravenous infusion forms, in a relatively short period of time, in a single setting, after calculation of the required dose. It can be given in a dose of 20mg/kg body weight.
1678826|NCT01628770|Drug|Ferrous sulphate|200mg twice daily
1678827|NCT01628731|Drug|furosemide|furosemide, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
1678828|NCT01628731|Drug|ethacrynic acid|ethacrynic acid, intravenous, continuous infusion, 0.2 mg/kg/h for 24 hours
1678831|NCT01628705|Other|Nutritional intervention|"The subjects were undergoing nutritional intervention was reduced by 500 kcal per day of habitual caloric intake.
The proportion of daily intake of macronutrient in the moderate-fat diet was: 30% fat (saturated fat <7%, monounsaturated 10-15% and polyunsaturated 10%, respectively to total calories), 15% of protein, and 55% of carbohydrates. The dietary cholesterol was less than 200 mg/day, fiber intake was increased to 25 grams per day (50% soluble fiber)."
1678901|NCT01628146|Device|SUPRACOR LASIK treatment|The SUPRACOR algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction.
1678832|NCT01628705|Dietary Supplement|Green tea|The patients drank secha green tea. Subjects of the INT group were instructed on how to prepare the green tea infusion. Each cup was prepared using 3g of dried green tea in 300ml of hot water (temperature 80°C)for 4 min. It was drunk fresh and without sugar. The treatment consisted of 2 cup/day of green tea, one in the morning and one at night. The amount of epigallocathechin-3-gallate was 498mg/day.
1678833|NCT01628692|Drug|Daclatasvir|Tablets, oral, 30 mg, once daily
1678834|NCT01628692|Drug|Simeprevir|Capsule, oral, 150 mg, once daily
1678835|NCT01628692|Drug|Ribavirin|Tablets, oral, 500-600 mg, twice daily
1678836|NCT01628679|Behavioral|Physical therapy treatment|Subjects will be given pelvic floor motor control,proprioception and relaxation exercises. This will be with and without the use of external surface Electromyography (EMG) biofeedback. Education will also be given on pain management, female sexual response and vestibulodynia. Subjects will also practice inserting vaginal inserts of graduating diameter into their vaginas, practicing the skills learned in physical therapy sessions.
1678837|NCT01628666|Drug|Incremental|Single dose of Cefazolin and Vancomycin preoperatively, bacitracin wash and cefalexin post operative.
1678838|NCT01628666|Drug|Conventional|Cefazolin preoperative
1678839|NCT01628653|Device|U-SMART|4-weeks' training
1678843|NCT01628627|Device|Frequency Modulated Neural Stimulation (FREMS) (Aptiva)|FREMS consisted of sequences of biphasic (negative and positive), asymmetric and electrically balanced pulses, composed of: 1) an active phase of high negative voltage spike (variable, max -300 V) and extra short duration (variable, 10-100 μsec, mostly ~40 μsec); followed by: 2) a recharging phase of low voltage and long duration (0.9 - 999 msec); pulse frequency was variable, ranging 1 to 1,000 Hz, mainly in the low range 1-50 Hz. Three cycles of 10 consecutive (one a day for 5 days/week) applications to both lower limbs were delivered.
1678844|NCT01628627|Device|sham treatment (Aptiva)|The sham treatment consisted of no electrical pulses delivered by the same device used to deliver the FREMS treatment and with the same treatment procedure and schedule.
1678845|NCT01628614|Other|Standard of Care|Patients with POAG or OHT. All care (including treatment and diagnostic procedures) provided is at the discretion of the participating physicians according to their clinical judgment and the local standard of medical care.
1678846|NCT01628601|Drug|Fixed combination 0.3 mg bimatoprost and 5 mg timolol|Patients with POAG or OHT prescribed GANfort® (fixed combination 0.3 mg bimatoprost and 5 mg timolol) treatment in a dose determined by the physician prior to study entry
1678847|NCT01628588|Drug|bimatoprost 0.01%|Patients with POAG or OHT prescribed Lumigan® (bimatoprost 0.01%) treatment in a dose determined by the physician prior to study entry
1678848|NCT01628575|Procedure|PAO|all patients underwent periodontal surgery for bone decortication followed by orthodontic treatment
1678849|NCT01628562|Drug|Esmolol|Esmolol 50 mcg/kg/min
1678850|NCT01628562|Drug|Remifentanil|Remifentanil 0.5 mcg/kg/min
1678851|NCT01628549|Drug|50 mg P005672|50 mg P0005672 taken daily for 84 days at doses achieving 0.75 or 1.5 mg/kg daily treatment
1678852|NCT01628549|Drug|Placebo|placebo capsule matching 50 mg or 100 mg capsules of P0005672 taken daily for 84 days
1678853|NCT01628549|Drug|100 mg P005672|100 mg P0005672 taken daily for 84 days a dose achieving 3.0 mg/kg daily treatment
1678854|NCT01628536|Dietary Supplement|Black cohosh|Remifemin 20 mg tablet orally twice per day x 4 weeks
1678856|NCT01628510|Device|Dandle Roo/Dandle Wrap|Infant remains in the Dandle Roo/Dandle Wrap throughout the NICU stay when the infant is lying in the isolette or crib, but is taken out for hands on care times or when held.
1678857|NCT01628510|Other|Traditional NICU Positioning|These methods aim at providing containment and flexion and may consist of interventions such as swaddling, use of boundaries around the infant, rolled blankets, Snuggly®, or Bendy Bumper®
1678858|NCT01628484|Other|prick lancet|For the pricking skin preparation, sterile prick lancets for 1mm point skin testing will be used. They are used for allergy diagnostics in daily routine.
1678859|NCT01628484|Other|Tape stripping|For the tape stripping in the skin preparation test conventional self adhesive tape by Tesafilm® is used.
1678860|NCT01628484|Other|Microneedle|To induce a large number of microchannels with a maximal depth of 150µm into the cornea layer a small patch of 351 tiny needles is used, which is on the market in the US and is intended for preparing the skin for transdermal application of topical dermatology products.
1678861|NCT01628471|Drug|decitabine in combination with genistein|decitabine IV infusion ( 10 hrs total), doses from 60 to 500 mg/m2 + fixed daily oral dose of 300 mg genisteine
1678862|NCT01628458|Procedure|radiofrequency ablation (RFA)|RFA with CELON bipolar probes. Settings: Power 30 watts, total energy 15 KJ.
1678863|NCT01628445|Drug|liraglutide|liraglutide titrated to 1.8 mg sc daily
1678864|NCT01628445|Drug|placebo injection|placebo injected sc daily volume equal to active comparator
1678867|NCT01628419|Behavioral|Health intervention|"physical activity program at the workplace - once a week with a certified trainer. (The program will include: aerobic exercises as well as resistance exercises). The employees will encourage to perform two additional workouts during the week.
Nutritional counseling for the kitchen staff Lectures - lectures will be given at each worksite on different topics: physical activity, nutrition, sleeping behaviour, mental aspects."
1678868|NCT01628406|Procedure|Treatment at the neurosurgery departement|Treatment at the neurosurgery departement
1678869|NCT01628393|Drug|RPC1063|oral, low dose, daily for 24 weeks
1678870|NCT01628393|Drug|placebo|oral, 1 capsule, daily for 24 weeks
1678871|NCT01628393|Drug|RPC1063|oral, high dose, daily for 24 weeks
1678902|NCT01628133|Procedure|ultrasound|sonographic evaluation of intestinal blood flow
1678872|NCT01628380|Procedure|Cytoreductive Surgery and HIPEC|"CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.).
HIPEC: Cisplatin (CDDP) (100 mg/m2 of body surface area) + Paclitaxel (175mg/m2 of body surface area). Closed/open technique, as preferred. Duration: 90 minutes. Mean Intra-abdominal Temperature: 42°C."
1678873|NCT01628380|Procedure|CRS alone|CRS: radical surgery, associated to any surgical procedure needed to obtain a zero or ≤ 0.25cm residual tumor (peritonectomy, bowel resection, diaphragmatic stripping, gastric resection, etc.)
1678874|NCT01628367|Procedure|Minimally Traumatic Tooth Extraction|"The surgeon will perform a minimally traumatic tooth extraction in the following fashion. Intrasulcular incisions will be performed with at 15-C scalpel around the tooth to be extracted.
A periotome will then be introduced into the periodontal ligament space in order to sever the subcrestal attachment and expand the periodontal ligament space. Elevators will be used to initiate luxation of teeth. After significant mobility has been achieved through elevation, forceps will be used only to deliver the tooth. Finally, the socket will be curetted to remove all granulomatous tissue and irrigated with sterile isotonic saline solution."
1678875|NCT01628367|Device|Immediate Implant Placement|A threaded titanium alloy implant with an internal hex connection and a Resorbable Blast Texturing (RBT) surface (Tapered Internal® Implant System, Biohorizons, Inc., Birmingham, AL, USA) will be placed using a surgical guide. Implant diameter of 3.8mm with lengths of either 12 or 15mm will be used. Implants will be placed approximately 3-4mm below the free gingival margin or 2-3mm below the cemento-enamel junction of adjacent teeth.
1678876|NCT01628367|Biological|Bone Graft Placement|Circumferential defects or dehiscences around the immediately placed implant will be grafted. enCore™ Combination Allograft (Osteogenics Biomedical, Lubbock, Texas, USA) will be used as the bone graft material.
1678877|NCT01628367|Biological|Membrane placement|A non absorbable d-PTFE membrane (Cytoplast® TXT-200, Osteogenics Biomedical, Lubbock, Texas, USA) will be trimmed to an appropriate size and shape to completely cover the implant site, and extend about 3-5mm beyond on the facial aspect. The membrane will be tucked under the sub-periosteal flap. Care will be taken to ensure that the membrane is resting on bone all around the socket margins. The membrane will be kept a minimum of 1.5mm from the adjacent tooth roots in the interdental area.
1678878|NCT01628367|Biological|Collagen plug placement|A bio-absorbable collagen wound dressing (CollaPlug®, Zimmer Dental, Carlsbad, CA, USA) will be trimmed to the appropriate size, so as to cover the socket
1678879|NCT01628367|Drug|Medications|Patients will be given amoxicillin 500mg 2 days prior to the surgery and will then continue for every 8 hours for 10 days. Patients will also take Ibuprofen 600mg every 6 hours for the first 3 days following the surgery, and then as needed for pain. Patients will also receive a prescription for Vicodin as needed for pain, every 4 to 6 hours
1678880|NCT01628354|Drug|Ranibizumab|All patients will receive an intravitreal injection of ranibizumab 0.5 mg at baseline (visit 1; month 0) then a subsequent intravitreal injection at month 1 (visit 2) and month 2 (Visit 3). Patients will be reviewed every month thereafter for 12 months at which time it will be determined whether the patient requires retreatment with ranibizumab 0.5 mg based on measurements of visual acuity, Optical coherene tomography (OCT) findings and clinical appearance. A drop of vision of >5 letters or increase in retinal thickness of >100 um on OCT will trigger re-treatment as long as 14 days has elapsed since last treatment.
1678881|NCT01628341|Drug|insulin|Patients will be asked to complete 2 self-assessment questionnaires
1678882|NCT01628315|Device|MRI|Annual MRIs as part of participation in the ASA study.
1678883|NCT01628302|Behavioral|Lowering salt in diet|Low salt diet (50mmol)for three weeks.
1678884|NCT01628289|Other|charging a co-payment for Diabetic Retinopathy screening|The intervention is charging a co-payment of HK$60 for the Diabetic Retinopathy screening.
1678885|NCT01628289|Other|free screening without charging a co-payment|The intervention is to provide free screening without charging a co-payment
1678886|NCT01628276|Behavioral|Cog Rehab|Cognitive rehab for MS patients
1678887|NCT01628263|Other|Follow up Clinic for High risk participants|Families where either or both parents are screened to be at risk of PTSD or depression are randomised in a 1:1 ratio to the intervention or control arm. Those in the intervention arm will receive an offer of a follow up clinic two months post discharge, staffed by the unit Clinical Psychologist, a PICU doctor and PICU nurse. Those in the control arm will not be offered a follow up clinic.
1678888|NCT01628250|Procedure|laparoscopic complete mesocolic excision|laparoscopic complete mesocolic excision would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications. Lap.CME facilitaes medial approach to complete the procedure. CME and HMA are the two arms of the medial approach utilized.
1678889|NCT01628250|Procedure|D3-laparoscopic colectomy|D3-laparoscopic colectomy would be applied on randomized group of patients suffering colon cancer and possessing no marked surgical anti-indications.
1678890|NCT01628237|Device|comparison of spinal cord stimulation|
1678891|NCT01628211|Procedure|Laparoscopy|second look laparoscopy to evaluate for peritoneal carcinosis
1678892|NCT01628211|Procedure|peritonectomy|for patients with PCI < 20
1678893|NCT01628211|Drug|Folinic Acid|20 mg/m2 IV given just before HIPEC for patients with PCI < 20
1678894|NCT01628211|Drug|5-Fluorouracil|400 mg/m2 IV given just before HIPEC in patients with PCI < 20
1678895|NCT01628211|Drug|Oxaliplatin|460 mg/m2 intraperitoneal hyperthermic perfusion for patients with PCI < 20
1678896|NCT01628211|Drug|systemic chemotherapy|according to national Italian (AIOM) guidelines and may include biotherapies for patients with PCI > 20
1678898|NCT01628185|Procedure|Repositioning|pain assessment at baseline then following routine care repositioning in bed
1678899|NCT01628172|Device|Biosense Webster Celcius Thermacool catheter|catheter-based sympathetic renal denervation
1678900|NCT01628159|Device|Lutonix Drug Coated Balloon|balloon angioplasty with a drug coated balloon
1729064|NCT00018135|Drug|aluminum hydroxide|
1678903|NCT01628120|Biological|Epoetin Hospira|Other ESAs may be used as rescue therapy provided they are not long acting.
1678904|NCT01628107|Biological|Epoetin Hospira|Rescue therapy including other ESAs (except for long-acting) may be used.
1678905|NCT01628094|Drug|RO5024048|
1678906|NCT01628094|Drug|RO5190591|
1678907|NCT01628094|Drug|RO5466731|
1678908|NCT01628094|Drug|ribavirin [Copegus]|
1678909|NCT01628094|Drug|ritonavir|
1678910|NCT01628081|Dietary Supplement|Alga Dunaliella Bardawil placebo|"Dosage Regimen and Treatment Groups
Daily oral administration of:
Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).
Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
1678911|NCT01628081|Dietary Supplement|Dunaliella Bardawil|"Dosage Regimen and Treatment Groups
Daily oral administration of:
Dunaliella, 6 capsules/day (3 capsules in the morning, 3 in the evening).
Placebo, 6 capsules/day (3 capsules in the morning, 3 in the evening)."
1678912|NCT01628068|Device|Left atrial appendage occlusion|Left atrial appendage occlusion with Amplatzer device plus aspirine plus clopidogrel during 3 months
1678913|NCT01628055|Biological|Privigen|10% liquid intravenous immunoglobulin at a single dose of 1.0g/kg, run at 0.5ml/kg/hr for the first 30 minutes, then increased to 2.5ml/kg/hr until complete (~3-4 hours depending on weight).
1678914|NCT01628055|Other|Normal Saline|"Normal Saline is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment. It contains no antimicrobial agents. The pH is 5.0 (4.5 to 7.0).
It contains 9 g/L Sodium Chloride with an osmolarity of 308 mOsmol/L and 154 mEq/L Sodium and Chloride.
The infusion will start at 0.5 ml/kg/hr for the first 30 minutes and then increased to 2.5 ml/kg/hr for 3-4 hours."
1678915|NCT01628042|Drug|Vibegron 100 mg|Vibegron tablets, orally, on Day 1
1678916|NCT01628029|Device|Litebook|Either light therapy or placebo light over 30 minutes within 2 hours of waking for 14 days.
1678917|NCT01628029|Drug|Melatonin|20 mg by mouth at bed time.
1678918|NCT01628029|Drug|Methylphenidate|5 mg by mouth twice daily.
1678919|NCT01628029|Drug|Placebo|One placebo capsule orally twice a day before 3 PM, and/or one placebo capsule at bedtime.
1678920|NCT01628029|Behavioral|Counseling Sessions|Counseling session with a counselor lasting about 30 minutes, either in person or by phone on Days 8 and 15 only.
1678921|NCT01628029|Behavioral|Questionnaires|Symptom and emotional well-being questionnaires completed on Days 1, 3, 8, 15, and 29.
1678922|NCT01628029|Behavioral|Study Diaries|Completion of diaries at the end of each day of the 14-day study period, explaining how much light received from Litebook, and a pill diary about medication.
1678924|NCT01628003|Device|Brain MRI|Brain MRI
1678925|NCT01628003|Device|MRI|Physical examination Neuropsychological testing Questionnaires
1678926|NCT01627977|Other|Dye of Lutein, Zeaxanthin and Brilliant Blue|dye composed of Lutein, Zeaxanthin and Brilliant Blue will be used during the vitrectomy surgery to dye the membranes
1678927|NCT01627951|Other|NF54|Volunteers will be infected with the NF54 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
1678928|NCT01627951|Other|NF135|Volunteers will be infected with the NF135 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
1678929|NCT01627951|Other|NF166|Volunteers will be infected with the NF166 strain of Plasmodium falciparum through the bites of 5 infected Anopheline mosquitoes.
1678930|NCT01627938|Drug|Dexrazoxane (DRZ) plus Mitoxantrone (MX)|Dosage: DRZ (600 mg/m2) : MX (12 mg/m2) ratio 50:1 DRZ infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
1678931|NCT01627938|Drug|Placebo plus Mitoxantrone (MX)|MX Dosage: 12mg/m2 Placebo infusion / MX infusion once every three months over a period of 12 months, i.e. 5 infusions
1678932|NCT01627925|Device|nasal mask and continuous positive airway pressure|nasal mask use instead of face mask application of continuous positive airway pressure during induction of general anesthesia
1678934|NCT01627899|Device|One Touch VerioIQ Blood Glucose Monitor|BGM with pattern alert technology and with associated pattern guide
1678935|NCT01627886|Drug|Ibandronate sodium|Ibandronate sodium Tablets 150 mg
1678936|NCT01627873|Drug|Remifentanil|In group A induction of anesthesia will be performed with Propofol (2mg/kg), Cisatracurium (0.15mg/kg)and continous infusion of Remifentanil (0.15mcg/kg/min).Anesthesia will be maintained by Sevoflurane with oxygen (Fi=40%)and air, with a MAC value to maintain BIS between 40 and 60. Intraoperative analgesia will be obtained with Remifentanil 0.15-0.25mcg/kg/min. Additional boluses of Cisatracurium (0.02mcg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum bolus of morphine (0.1mg/kg)and acetaminophen 1g will be administered. Propofol and remifentanil infusions will be interrupted at the end of wound closure.
1678937|NCT01627873|Drug|Fentanyl|In group B anesthesia will be induced by Propofol (2mg/kg), Fentanyl (2mcg/kg)and Cisatracurium (0.15mg/kg). Anesthesia will be maintained by Sevoflurane, oxygen (Fi=40%) and air and boluses of Fentanyl (50mcg). additional boluses of Cisatracurium (0.02mg/kg)will be administered as needed during surgery. At the beginning of closure of the peritoneum acetaminophen 1g will be administered.
1678938|NCT01627860|Drug|Topiramate add-on therapy|Type=range, unit=mg/day, number=25-200, form=tablet, route=oral use.
1678939|NCT01627860|Drug|Topiramate monotherapy|Type= range, unit= mg/day, number= 25-200, form= tablet, route= oral use.
1678940|NCT01627847|Drug|Ropinirole|
1678941|NCT01627834|Drug|Ropinirole|
1678944|NCT01627795|Drug|Oshadi D and Oshadi R|anti cancer agents
1678945|NCT01627782|Drug|Placebo|Form= intravenous infusion, route= intravenous (IV) use. IV infusions of placebo 2 times weekly or IV infusions of placebo 3 times weekly.
1679022|NCT01627106|Drug|Amiodarone|Administered IV as per product label
1678946|NCT01627782|Drug|Ketamine|Type= exact number, unit= mg/kg, number= 0.5, form= intravenous infusion, route= intravenous (IV) use. IV infusions of ketamine 0.50 mg/kg, 2 times weekly or IV infusions of ketamine 0.50 mg/kg, 3 times weekly.
1678947|NCT01627756|Other|Lung Ventilation|In the ventilated group, mechanical ventilation was done with the half of the initial tidal volume (i.e. 3-4 ml/kg, 250-300ml) during the aortic cross-clamp.
1678948|NCT01627756|Other|Non-ventilated Group|. In the non-ventilated group lungs were collapsed after completion of CPB until after weaning from the extracorporeal circulation.
1678949|NCT01627730|Other|pretest and posttest scores|pretest and post-test scores are calculated for relative growth scores
1678950|NCT01627717|Drug|Maraviroc (5 days)|Subjects will receive maraviroc 150 mg tablets (1 tablet) every 12 hours from days 1 to 5 inclusively.
1678951|NCT01627717|Drug|Maraviroc and boceprevir (14 days)|From days 6 to 19, inclusively, boceprevir 800 mg (4 capsules of 200 mg) every 8 hours with food will be given with maraviroc 150 mg (1 tablet of 150 mg) every 12 hours.
1678952|NCT01627704|Drug|Fluoroestradiol (18F)|2-4 MBq/kg body mass, one single IV injection
1678953|NCT01627691|Device|Lotus Valve System|"bioprosthetic bovine pericardial aortic valve
delivery system"
1678954|NCT01627678|Drug|Vacc-C5/GM-CSF|Arm 1=Arm A: Vacc-C5 with GM-CSF as adjuvant administered intradermally.
1678955|NCT01627678|Drug|Vacc-C5/Alhydrogel|Arm 2=Arm B: Vacc-C5 with Alhydrogel as adjuvant administered intramuscularly.
1678956|NCT01627665|Drug|D->R->C+R|one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
1678957|NCT01627665|Drug|D->R->C+D|one oral dose DABIGATRAN 300 mg -> RIVAROXABAN 40 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
1678958|NCT01627665|Drug|R->D->C+D|RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with one oral dose DABIGATRAN 300 mg
1678959|NCT01627665|Drug|R->D->C+R|RIVAROXABAN 40 mg -> one oral dose DABIGATRAN 300 mg -> 1g/day CLARITHOMYCINE with RIVAROXABAN 40 mg
1678960|NCT01627652|Other|altitude|the subjects will live one month at 3450 m altitude in the Jungfraujoch Research Station
1678961|NCT01627639|Drug|Acetazolamide|Acetazolamide (1 g IV per day or 2 g IV per day if coprescription of loop diuretics) or Placebo (saline serum) when pure or mixed metabolic alkalosis being present until planned extubation
1678962|NCT01627639|Drug|Placebo|Placebo
1678963|NCT01627626|Drug|Pilocarpine|"0.1% pilocarpine solution which diluted 2% pilocarpine hydrochloride eyedrop with 0.9% saline.
subjects were instructed to mouthwash with 10ml of solution for 1 minute."
1678964|NCT01627626|Drug|saline|0.9% saline solution
1678965|NCT01627613|Drug|AP301|"AP301 25 mg powder for reconstitution for solution for inhalation
Orally delivered doses of 87.6 mg AP301 are inhaled every 12 hours (± 30 min), for a total of 7 days."
1678966|NCT01627613|Drug|Saline solution|Placebo solution (0.9% physiologic NaCl) is inhaled every 12 hours (± 30 min), for a total of 7 days.
1678967|NCT01627587|Drug|GSK221149 750 mg|Treatment A: 750 mg GSK221149 single dose
1678968|NCT01627587|Drug|Ketoconazole|Treatment B: 400 mg of Ketoconazole single dose
1678969|NCT01627587|Drug|GSK221149 100 mg|Treatment C: 100mg of GSK221149 single dose
1678970|NCT01627587|Drug|GSK221149 750 mg Fasted|Treatment D: 750 mg of GSK221149 administered fasted
1678971|NCT01627587|Drug|GSK221149 750 mg + Food|Treatment E: 750 mg of GSK221149 administered with a high fat meal
1678972|NCT01627574|Behavioral|Motivational Intervention|There are two, 45-60 minutes sessions of tailored MI that occur at the enrollment of the study, and at 3 month follow-up.
1678973|NCT01627574|Behavioral|Didactic Educational Intervention|There are two, 45-60 minute didactic sessions designed to provide information and awareness for sexual health involving contraception and STI prevention. The first session occurs after enrollment in the study, the second at 3 month follow-up.
1678974|NCT01627561|Biological|Cervarix|2 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0 and Month 6 in the HPV_2D and HPV_2D CO Groups 3 doses administered intramuscularly in the deltoid muscle of the left arm at Day 0, Month 1 and Month 6 in the HPV_3D Group
1678975|NCT01627561|Biological|Priorix|1 dose administered intramuscularly in the deltoid muscle of the left/right arm at Day 0
1678976|NCT01627561|Biological|Infanrix|1 dose administered intramuscularly in the deltoid muscle of the left/right arm at Month 6
1678977|NCT01627548|Behavioral|Structured Approach Therapy|The SAT treatment is provided in 12 weekly 50-minute sessions and is fully manualized. First, couple-based exposure techniques are used to address anxiety about intimacy, increasing the traumatized person's ability to engage in social and relational behaviors that promote bonding and satisfaction. Second, as anxiety decreases, couple-based techniques are also used to increase the positive experiences the couple is having. These activities expose the traumatized person to positive feelings instead of anxiety, so that he/she may become desensitized to the anxiety caused by the closeness, and more comfortable engaging in intimate behaviors.
1678978|NCT01627535|Other|Interoperative Optical Imaging and Spectroscopy|Real time processing and display of i2DOS maps in the operating arena
1678979|NCT01627522|Procedure|TURP|Transurthral resection of prostate
1678980|NCT01627483|Other|Medication review|Assessment of risks of falls and fractures; medication review concerning fall-risk-increasing and fracture-preventing drugs; oral and written feed back of the results of the assessments and medication reviews to the hospital physician during the hospital stay and to the general practitioner 3 and 6 months after the hip fracture surgery.
1678981|NCT01627470|Device|CNAP-Monitor|Continuous non-invasive arterial blood pressure recording
1678982|NCT01627457|Device|Guided Exercise (GEx) system|30 CAD patients will wear the GEx system while they are trained during inpatient cardiac rehabilitation (phase II) in order to evaluate accuracy and safety of data like heart rate, breathing, ECG three times a week for about three weeks. In a second step these patients train at home (phase III) in order to evaluate practicability and technical problems of the GEx device three times a week for about three weeks.
1678983|NCT01627444|Procedure|Ear acupuncture|Ear acupuncture based on Chinese Map: ShenMen, Anxiety 1 and 2, Tension, Muscular relaxation.
1678984|NCT01627431|Drug|Acetylsalicylic acid|100 mg once per day
1678985|NCT01627431|Drug|Clopidogrel|75 mg once per day
1679023|NCT01627093|Other|Chart Review|Both retrospective and prospective patient charts reviewed to determine pretreatment characteristics, time to progression and overall survival of patients.
1678986|NCT01627418|Behavioral|Energy Voucher|Receive the intervention the first winter enrolled in the study. The intervention is a electricity voucher and a short pamphlet describing how to work out how much heat the voucher can buy.
1678987|NCT01627418|Behavioral|No intervention : control arm|Do not receive the money or pamphlet in the initial study year
1678988|NCT01627392|Behavioral|Smoking abstinence|6 hour smoking abstinence
1678989|NCT01627379|Drug|Cisplatin, 5-FU|"Arm A: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.
Chemotherapy will be administered every 3 weeks until progression of disease or any other reason for treatment withdrawal is fulfilled."
1678990|NCT01627379|Drug|Panitumumab|"Arm B: Cisplatin 80 mg/m2 IV infusion over 2 hours on Day 1, followed by 5-FU 1000 mg/m2 IV daily as continuous infusion over 24 hours, Day 1-4.
Panitumumab will be administered on Day 1 of each treatment cycle at a dose of 9 mg/kg prior to administration of chemotherapy.
Each treatment cycle is defined as 21 days. Patients are treated until progression of disease occurs or any other reason for treatment withdrawal is fulfilled."
1678991|NCT01627366|Other|Survivorship Care Plan|Receipt of a personalized survivorship care plan and an in-person session with a trained nurse to review the contents of the care plan.
1678992|NCT01627353|Procedure|Standard of care|Current Standard of Care at Rockyview General Hospital for Post Hysterectomy Pain Prevention(no wound infiltration and routine anesthetic protocol).
1678993|NCT01627353|Procedure|Pre-emptive wound infiltration|"The Wound Infiltration Group will receive 100 mL 0.125% marcaine plain distributed as follows: 50 mL subcutaneously prior to skin incision along entire length of planned incision line, 50 mL subfascially prior to fascial incision, with 10 mL infiltrated directly into the rectus muscles bilaterally.
The Anesthetic will be given as determined appropriate to the patient by the staff anesthetist with the addition of the following: 2 grams of Magnesium Sulphate, 10 mg of Dexamethasone, and 3 mg/kg of Lidocaine, half of which is given on induction and half of which is infused throughout the remainder of the case."
1678994|NCT01627340|Biological|Engerix™-B vaccine|3 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
1678995|NCT01627327|Drug|fluticasone furoate/vilanterol 100/25mcg|inhalation powder
1678996|NCT01627327|Drug|tiotropium bromide 18mcg|inhalation powder
1678997|NCT01627314|Biological|ProHema-CB|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
1678998|NCT01627314|Biological|Untreated CB|Cord Blood
1678999|NCT01627301|Device|Device-Guided Breathing using the RESPeRATE device|15 minutes of device-guided breathing daily for 8 weeks
1679000|NCT01627288|Radiation|Boost radiation|Many studies have utilized a sequential boost to deliver a total dose of 55 - 60 Gy to the pelvic sidewall (covering the lower pelvic lymph nodes), including 8-10 Gy that is usually delivered with brachytherapy (1-3). This study treatment plan will escalate the dose to pelvic and para-aortic nodal disease from 60 Gy in 2.4 Gy per fraction to 70Gy in 2.8 Gy per fraction in 3 dose cohorts, using an integrated boost technique utilizing the same number of fractions for all cohorts (25 fractions) while the elective volumes are held constant at 45Gy
1679001|NCT01627275|Biological|Naive T Cell Depleted Donor Lymphocyte Infusion|A single naive T-cell depleted donor lymphocyte infusion will be administered through a peripheral or central venous catheter greater than or equal to 60 days post allogeneic hematopoietic stem cell transplant.
1679002|NCT01627262|Drug|Mesalamine|3x1000mg mesalamine granules per day
1679003|NCT01627262|Drug|Placebo|3x1000mg placebo granules per day
1679004|NCT01627249|Drug|2.0 mg intravitreal aflibercept|Intravitreal injection of 2.0 mg aflibercept at baseline and up to every 4 weeks using defined retreatment criteria.
1679005|NCT01627249|Drug|1.25 mg intravitreal bevacizumab|Intravitreal injection of 1.25 mg bevacizumab at baseline and up to every 4 weeks using defined retreatment criteria.
1679006|NCT01627249|Drug|0.3 mg intravitreal ranibizumab|Intravitreal injection of 0.3 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
1679007|NCT01627236|Drug|methylprednisolone|methylprednisolone 1mg/kg intravenous drip qd，for 3 days glucocorticoid
1679008|NCT01627223|Drug|Lamivudine|"Lamivudine 100 mg p.o. q.d.
This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
1679009|NCT01627223|Drug|Entecavir|"•Entecavir 0.5 mg p.o. q.d
This process will be stratified by prolonged PT, < 4 sec / 4-6 sec / > 6 sec. Both lamivudine and entecavir will be taken once daily and the first dose of observational drug should be administered on Day 1. The observational period of individual subject will be 12 weeks; however, both treatments could be continued after the end of study based on physician's clinical judgment."
1679011|NCT01627184|Device|Dexcom G4 CGM System|
1679012|NCT01627171|Drug|Bisacodyl 10mg|Given at the start of the bowel preparation the day before colonoscopy
1679013|NCT01627171|Drug|Polyethelene Glycol|280g reconstituted in 4 liters of water
1679014|NCT01627171|Drug|Picosulfate sodium|Two sachets, Each sachet has 10mg dose
1679015|NCT01627158|Drug|Budesonide/formoterol Easyhaler|Budesonide/formoterol Easyhaler
1679016|NCT01627158|Drug|Symbicort Turbuhaler|Symbicort Turbuhaler
1679017|NCT01627158|Drug|Charcoal and Budesonide/formoterol Easyhaler|Charcoal and Budesonide/formoterol Easyhaler
1679018|NCT01627158|Drug|Charcoal and Symbicort Turbuhaler|Charcoal and Symbicort Turbuhaler
1679019|NCT01627145|Drug|Solifenacin|Solifenacin 5 mg qd,
1679020|NCT01627132|Drug|Dasatinib|100mg QD
1679021|NCT01627106|Drug|Vernakalant|Initial intravenous (IV) dose of 3 mg/kg (up to a maximum of 339 mg) over 10 minutes, followed by a 15 minute observation period and, if conversion to sinus rhythm does not occur within 15 minutes of the initial infusion, a second 10 minute infusion of vernakalant at a dose of 2 mg/kg (up to a maximum of 226 mg) will be administered.
1679024|NCT01627093|Behavioral|Questionnaires|Completion of 5 questionnaires before treatment begins, at each visit during treatment, and again at all follow-up visits. It should take about 30 minutes to complete the questionnaires each time.
1679025|NCT01627080|Other|Cardiac Biomarker Blood Draws|Blood (about 1 teaspoon) drawn to measure cardiac biomarkers at the following time points: within 12-24 hours of the start of radiation, one (1) time during the third week of radiation, within 48 hours after completion of radiation, and about 1 to 2 months after completion of radiation therapy.
1679026|NCT01627067|Drug|Everolimus|10 mg by mouth once daily.
1679027|NCT01627067|Drug|Exemestane|25 mg by mouth once daily.
1679028|NCT01627067|Drug|Metformin|500 mg by mouth per day for three days. If there are no dose limiting toxicities, the dose of metformin will be increased by 500 mg orally every three days to reach the target dose of 1,000 mg orally twice daily.
1679029|NCT01627054|Drug|AT7519M|Dose: 27 mg/m2, IV injection, 1 hour infusion Schedule: 27 mg/m2/day twice weekly x 2 weeks every 3 weeks (days 1, 4, 8 and 11)
1679030|NCT01627041|Drug|Cytarabine|Given IV
1679031|NCT01627041|Drug|Daunorubicin Hydrochloride|Given IV
1679032|NCT01627041|Drug|Decitabine|Given IV
1679033|NCT01627041|Other|Laboratory Biomarker Analysis|Correlative studies
1679034|NCT01627041|Other|Pharmacological Study|Correlative studies
1679035|NCT01627028|Procedure|Thai traditional massage|two hours of Thai traditional massage twice a week for 4 weeks
1679036|NCT01627015|Other|Modified infant follow-on formula|The modified infant follow-on formula has a different carbohydrate pattern than the standard formula
1679037|NCT01627015|Other|Standard infant follow-on formula|Infants are fed a commercial follow-on formula
1679038|NCT01627002|Biological|PA401|Part A of Study: Subcutaneous, 0.1mg to 50mg, single ascending doses Part B of Study: Subcutaneous, up to 17.1mg, single dose
1679039|NCT01627002|Other|Placebo|Subcutaneous
1679040|NCT01626989|Device|BiPAP auto Advanced|Auto Servo Ventilation Device
1679041|NCT01626989|Device|BiPAP auto SV4|Auto Servo Ventilation Device
1679042|NCT01626976|Drug|PF-06282999|Solution, doses range from 20 to 200 mg, single dose
1679043|NCT01626976|Drug|Placebo|Solution, single dose
1679044|NCT01626976|Drug|PF-06282999|Methylcellulose suspension, doses range 125 to 500 mg, single dose
1679045|NCT01626976|Drug|Placebo|suspension, single dose
1679046|NCT01626976|Drug|PF-06282999|Methylcellulose or simethicone suspension, doses range 200 to 500 mg, single dose
1679047|NCT01626976|Drug|Placebo|suspension, single dose
1679048|NCT01626976|Drug|PF-06282999|Methylcellulose or simethicone suspension, 500 mg dose, single dose
1679049|NCT01626976|Drug|Placebo|suspension, single dose
1679050|NCT01626976|Drug|PF-06282999|Simethicone or methylcellulose suspension, up to 1500 mg, single dose
1679051|NCT01626976|Drug|Placebo|suspension, single dose
1679052|NCT01626963|Procedure|Single-port access surgery|Surgery carried out through a single incision laparoscopic approach
1679053|NCT01626963|Procedure|Conventional Laparoscopic Access|Surgery through standard multiport laparoscopic approach
1679054|NCT01626937|Other|Non invasive ventilation|After nebulisation of bronchodilatators and administration of corticosteroid therapy, non invasive positive pressure ventilation will be started out of hospital and continuously in COPD patient with acute respiratory distress and respiratory acidosis, using a facial mask, with initial level of inspiratory pressure at 8 mmHg then according to VTe and/or respiratory rate; expiratory pressure at 4 mmHg then according to persistance of inspiratory work, level of FiO2 for an objective of SpO2 between 88 and 92%. In case of failure, NIV will be stopped and endotracheal intubation realized if indicate.
1679055|NCT01626937|Other|conventional medical treatment|Conventional medical treatment includes nebulization of bronchodilatators every 15-20 minutes until hospital and corticosteroid therapy. If indicate during out of hospital setting, endotracheale intubation will be realized. After admission in hospital, non invasive ventilation could be started.
1679056|NCT01626924|Drug|2-Iminobiotin|2-Iminobiotin is formulated as a 0.75 mg/ml isotonic, iso-osmotic, saline solution with a pH of 4. It is administered as a solution for I.V.infusion through a central catheter. Six pulse doses will be given in 20 hours. Dosage will starts with 0.2 mg/kg/dose, but may be adapted during the study.
1679057|NCT01626911|Procedure|Continuous regional arterial infusion of low molecular weight heparin in celiac trunk|Put a catheter to the celiac trunk through interventional technique. The approach to celiac trunk was via a femoral artery approach.The tip of the arterial catheter (4F) was placed in celiac trunk which could perfuse the pancreas.After that, continuous infusion of low molecular weight heparin through the catheter will be applied during the first 5 days after placement.
1679058|NCT01626911|Other|General treatment|Include fluid resuscitation, percutaneous drainage if needed, antibiotics,organ support, etc.
1679059|NCT01626898|Behavioral|HOLA en Grupos|HOLA en Grupos consists of four 4-hour group sessions that combine presentations by facilitators who are trained Latino MSM community members, activities, and scenes from a DVD, and is delivered over a period of two weeks to groups of about 10 participants. HOLA en Grupos is designed to increase HIV prevention knowledge, condom use and mastery, decrease barriers to risk reduction (e.g., health-compromising aspects of machismo), enhance sexual negotiation skills, and increase use of HIV testing, counseling, and treatment services among intervention participants.
1679060|NCT01626898|Behavioral|General Health intervention (comparison intervention )|The Spanish comparison condition consists of four Spanish-language 4-hour group sessions designed to increase participants' knowledge about cancer, diabetes, alcohol abuse, and cardiovascular disease, and is delivered over a period of two weeks to groups of about 10 participants.
1679061|NCT01626885|Drug|MP-214|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for four weeks, then flexible dose of MP-214
1679062|NCT01626872|Drug|MP-214 low dose|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
1679063|NCT01626872|Drug|MP-214 middle dose|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
1679173|NCT01625936|Drug|CRLX101 (Cerulean)|CRLX101 is an innovative tumor-targeting nanopharmaceutical.
1679064|NCT01626872|Drug|MP-214 high dose|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
1679065|NCT01626872|Drug|Risperidone|Participants continue in the same arm they were on in core trial A002-A4 (except placebo arm starts low or middle dose of MP-214) and will be re-randomized after Week 6 to low dose or middle dose of MP-214
1679066|NCT01626859|Drug|MP-214 low dose|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for twelve weeks.
1679067|NCT01626859|Drug|MP-214 middle dose|Patients who meet eligibility criteria will be administered a once daily oral middle dose of MP-214 for twelve weeks.
1679068|NCT01626859|Drug|MP-214 high dose|Patients who meet eligibility criteria will be administered a once daily oral high dose of MP-214 for twelve weeks.
1679069|NCT01626833|Drug|SOMATROPINE* : Norditropine® simplexx®|SOMATROPINE* : Norditropine® simplexx® - 15 mg/1,5 ml, injectable solution:Treatment with hGH is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of hGH treatment will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
1679070|NCT01626833|Biological|Placebo|Treatment with placebo is administered at a dose of 0.05 mg / kg / day (0.35 mg / kg / week) subcutaneously daily, preferably in the evening. The dose of placebo will be adjusted according to weight gain, and reduced by 10% if the serum values of IGF-I SDS above 2.5 on 2 consecutive determinations at 3-month intervals are discovered by the biologist.
1679071|NCT01626820|Biological|Fluviral®|1 dose administered intramuscularly in deltoid region of non-dominant arm at Day 0
1679072|NCT01626807|Behavioral|Walking School Bus|Children will have the option of walking to and/or from school with study staff who are trained in Safe Routes to School methods.
1679073|NCT01626794|Biological|VARIVAX™ VEP|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
1679074|NCT01626794|Biological|VARIVAX™ 2007 Process|Two 0.5 mL subcutaneous doses administered on Days 1 and 91
1679075|NCT01626794|Biological|M-M-R™ II|Two doses administered on Days 1 and 91 concomitantly with VARIVAX™ VEP or VARIVAX™ 2007 Process
1679076|NCT01626781|Device|Mapisal|Mapisal® ointment will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
1679077|NCT01626781|Other|Urea hand-foot cream|Urea hand-foot cream will be applied to hand and feet three times daily, as well as after washing hands. Treatment should start 2 days prior to the first chemotherapy cycle with capecitabine and will continue daily for the first 6 weeks of chemotherapy.
1679079|NCT01626742|Other|Ready to Drink Flavored Beverage|2 servings a day
1679080|NCT01626742|Other|Ready to drink flavored beverage w/ AN 777|2 servings a day
1679081|NCT01626729|Behavioral|Traffic Light|A kilocalories (calories) per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, and sodium per serving.
1679082|NCT01626729|Behavioral|Traffic Light+|A calories per serving label and a Traffic Light symbol with High/Med/Low text indicating amounts of saturated fat, total sugars, sodium, fiber and protein per serving.
1679083|NCT01626729|Behavioral|Facts Up Front|A label displaying calories, saturated fat, sodium, and total sugars per serving. Nutrient amounts were listed in grams/milligrams and % Daily Values (%DVs), which indicate whether a serving of food is high or low in a nutrient based on daily value recommendations for a 2,000 calorie diet, were included. This symbol was created based on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute, without the inclusion of nutrients to encourage.
1679084|NCT01626729|Behavioral|Facts Up Front+|A label displaying calories, saturated fat, sodium, and total sugars per serving. The label also showed two (out of the possible eight) nutrients to encourage with the highest %DV. Nutrient amounts were listed in grams/milligrams and %DVs were included. This symbol was based directly on the Facts Up Front symbol description provided by the Grocery Manufacturers Association and Food Marketing Institute.
1679085|NCT01626729|Behavioral|No label control group|No label control group
1679086|NCT01626716|Other|care management|patients who assigned to the intervention group will take 7 times phone calls from case manager
1679087|NCT01626703|Other|Reminding call|
1679088|NCT01626690|Device|Bair-Paws Warming Device|Bair-Paws device to be applied to patient and used for perioperative (including preoperative) warming.
1679089|NCT01626690|Device|Bair-Hugger Warming Device|Bair-Hugger device to be applied to patient and used for intraoperative warming (current standard of care at our institution).
1679090|NCT01626677|Biological|CARTISTEM|A single dose of 500㎕/㎠ of cartilage defect
1679091|NCT01626677|Procedure|Microfracture|Active control
1679092|NCT01626664|Biological|KW-0761|1.0 mg/kg weekly x 4 in cycle 1 then every other week until progression
1679093|NCT01626664|Drug|Pralatrexate|30 mg/m2 weekly for 3 weeks followed by 1 week of no therapy until progression
1679094|NCT01626664|Drug|gemcitabine plus oxaliplatin|gemcitabine 1000 mg/m2, followed by oxaliplatin 100 mg/m2 every 2 weeks until progression
1679095|NCT01626664|Drug|DHAP|dexamethasone 40 mg on Day 1-4, cisplatin 100 mg/m2 on Day 1 followed by 2 doses of cytarabine 2000 mg/m2 every 4 weeks until progression
1679096|NCT01626651|Drug|Ibrutinib|A single oral dose of 120 mg ibrutinib (3 x 40 mg capsules) on Day 1, and 40 mg (1x 40 mg capsule) ibrutinib on Day 7.
1679097|NCT01626651|Drug|Ketoconazole|Ketoconazole (400 mg [2 x 200 mg] once daily) will be orally administered on Days 4, 5, 6, 7, 8 and 9.
1679098|NCT01626638|Procedure|Confocal Micro Endoscopy|
1679099|NCT01626625|Drug|stem cells + hydroxy apatite|patient will be transplanted with stem cells and hydroxyapatite
1679100|NCT01626625|Other|autograft taken from iliac crest|patient will be transplanted with autograft
1679101|NCT01626612|Procedure|continuation of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
1679102|NCT01626612|Procedure|streamlining of the empirical antimicrobial therapy|ALL THE ANTIBACTERIAL IN WORN SYSTEMATIC
1679174|NCT01625936|Drug|Bevacizumab|
1729065|NCT00018135|Drug|Sevelamer|
1679103|NCT01626599|Device|ProGuardian|"The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.
The investigational system:
is not implantable and no surgical procedure is required for a human subject to use the devices;
is not for use in supporting or sustaining a human life; and
is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.
Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles."
1679104|NCT01626586|Behavioral|Group Therapy|Self-management Diabetes Protocol: Successful adjustment to daily diabetes management requires a wealth of clinical knowledge, solid problem-solving and coping skills to deal with the physical, social and emotional factors associated with caring for and living with a chronic illness, and motivation to take care of one's health.
1679105|NCT01626573|Drug|INCB039110|
1679106|NCT01626573|Drug|INCB039110 Placebo|
1679107|NCT01626560|Drug|Daptomycin|daptomycin 4-6mg/kg qd 10 - 14 days
1679108|NCT01626560|Drug|Vancomycin|Vancomycin 1g q12h 10 - 14 days
1679109|NCT01626534|Drug|Clopidogrel|600mg loading dose then 75mg/day
1679110|NCT01626534|Drug|trigagrelor|180 mg loading dose then 90 mg Twice a day
1679111|NCT01626521|Other|CT pulmonary angio, blood tests|CT pulmonary angiography to determine PE and laboratory blood tests to determine prothrombin fragments F1+2 in blood of COPD patients
1679112|NCT01626495|Biological|CART-19|Day 0: 10% of total dose Day 1: 30% of total dose if patient is stable (no significant toxicity) from prior dose.
1679113|NCT01626482|Other|Kinesio Taping|"The taping consisted of two strips of material in the form of I on both sides of the lumbar spine, from the sacroiliac joint to the ipsilateral transverse process of D12."
1679114|NCT01626482|Other|Placebo|The placebo taping consisted of two 10 cm length strips of the same material, adhered transversely to the skin of the paravertebral muscles fibers
1679117|NCT01626456|Drug|ALKS 9072, Low|IM injection, given monthly
1679118|NCT01626456|Drug|ALKS 9072, High|IM injection, given monthly
1679119|NCT01626443|Dietary Supplement|Myo-inositol + D-chiro-inositol + Folic acid|Myo-inositol (550 mg) + D-chiro-inositol (13.8 mg) + Folic acid (200 mcg); 2 x die
1679120|NCT01626443|Dietary Supplement|Folic acid|Folic acid (200 mcg); 2 x die
1679121|NCT01626430|Dietary Supplement|Gamma delta TRF|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
1679122|NCT01626430|Dietary Supplement|Placebo|50g of high fat meal will be given in a form of muffin and milkshake. A 200 mg, 400 mg gamma delta TRF or placebo will be incorporated into milkshake.
1679123|NCT01626417|Device|Tibion Bionic Leg|The device is a lightweight, wearable, portable, battery-powered, robotic leg orthosis that provides active assistance and resistance to lower limb movement according to the patient's intent to move.
1679124|NCT01626391|Drug|TRx0237|TRx0237 tablets 250 mg/day (given as 125 mg bid) for 4 weeks
1679125|NCT01626391|Drug|Placebo|Placebo tablets will be administered twice daily (b.i.d.) for 4 weeks. The placebo tablets include 4 mg of TRx0237 as a urinary and faecal colourant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
1679126|NCT01626378|Drug|TRx0237|TRx0237 100 mg tablet will be administered twice daily.
1679127|NCT01626378|Drug|Placebo|Placebo tablets will be administered twice daily. The placebo tablets include 4 mg of TRx0237 as a urinary and fecal colorant to maintain blinding; hence, the placebo group will receive a total of 8 mg/day of TRx0237.
1679128|NCT01626365|Procedure|non-thermosoftening|Intubation is performed with a double-lumen tube put into normal saline at room temperature.
1679129|NCT01626365|Procedure|thermosoftening|Intubation is performed with a double lumen tube put into warm normal saline (40°C).
1679132|NCT01626339|Drug|Intravitreal Ranibizumab|
1679133|NCT01626339|Drug|Intravitreal bevacizumab|
1679134|NCT01626326|Behavioral|San Francisco Stop Smoking iPhone app|iPhone app designed to help people quit smoking
1679135|NCT01626313|Behavioral|FOCUS Individualized Family Resiliency Training|Eight session psycho educational training for families to enhance communication and reduce stressors related to return to post-military life.
1679136|NCT01626287|Other|Frozen perineal pad|Frozen ice pads will be provided as per participants' request
1679137|NCT01626287|Other|Warm water soaked Black Tea Bags|warm water soaked black tea bags will be provided to participants' as per their request
1679138|NCT01626274|Device|LAVIMO in- ear sensor system|Long term vital signs parameters like heart rate, heart rate variability, breathing and oxygen saturation are measured via in- ear sensor system during 1 polysomnographic night
1679139|NCT01626261|Device|Magnetic and electric field´s impact on the implant|Examination of magnetic and electric field's impact on the implant regarding: stability detection threshold using different strength of magnetic and electric field
1679140|NCT01626222|Drug|Exemestane|Exemestane is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Exemestane according to the individual label. Commercially available Exemestane will be supplied as tablets of 25 mg strength for oral administration. Complete guidelines for management and administration of Exemestane can be found in the package insert. Exemestane will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet of 25 mg Exemestane orally. Package insert instructions should be followed. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Exemestane exactly as prescribed.
1679211|NCT01625559|Biological|MA09-hRPE|MA09-hRPE: 50,000 cells
1679141|NCT01626222|Drug|Everolimus (RAD001)|Everolimus (RAD001) is supplied by Novartis until Everolimus is commercially available for the study setting. Afterwards the investigator will prescribe Everolimus according to the individual label. Everolimus is formulated as tablets of 10 and 5 mg strength for oral administration. All study medication will be packaged into blister packs. The blisters should be opened only at the time of administration, as the drugs are both hygroscopic and light sensitive. Everolimus will be dosed starting on treatment Day 1. Patients will be instructed to take 1 tablet × 10 mg Everolimus orally with a large glass of water once daily at the same time each day with or without food. On the first day of each cycle, patients will receive an adequate drug supply (before commercial availability) or a prescription (after commercial availability) for self-administration at home. The investigator must emphasize compliance and will instruct the patient to take Everolimus exactly as prescribed.
1679142|NCT01626209|Drug|BKM120|This is a single arm study, with a starting dose of BKM120 at 80mg/day. Two dose levels: 80mg/day and 100mg /day will be tested in the dose escalation phase. At least 3 patients will be enrolled at each dose level and at least 6 evaluable patients required to be treated at the recommended Phase II dose(RP2D)/MTD dose. After dose escalation the 80mg/day and the 100mg /day dose levels will be expanded to evaluate up to approximately a total of 15 patients each (if 100mg is determined as the RP2D/MTD).
1679143|NCT01626196|Other|No intervention|This was an observational study
1679144|NCT01626183|Genetic|RNA analysis|
1679145|NCT01626183|Genetic|proteomic profiling|
1679146|NCT01626183|Other|laboratory biomarker analysis|
1679147|NCT01626170|Other|laboratory biomarker analysis|Correlative studies
1679148|NCT01626131|Behavioral|exercise training|"Participants will engage in 3 aerobic and resistance exercise sessions (~60-75 min total per session) weekly for 8 consecutive weeks.
Aerobic exercise will be performed for 30 minutes on a treadmill 3 times weekly. Before beginning, 10 min of stretches will be performed. Each exercise bout will begin and end with a 5-min warm-up and 5-min cool-down on the treadmill, not included in the prescribed exercise duration.
Eight resistance exercises will be performed immediately following the aerobic exercise: lat pulldown, triceps pushdown, seated chest press, upright row, bicep curls, leg press, shoulder press, and abdominal crunches. Participants will perform two sets of 10 repetitions of each. A rest interval of 60 seconds will be taken between exercises. Research staff will initially assist the participants in choosing the proper resistance to use, and weight will be increased once 15 repetitions can be performed while maintaining proper form."
1679149|NCT01626131|Behavioral|Stretching training|Participants will engage in stretching sessions that will focus on whole-body flexibility. Participants will perform 3 sessions per week (~60 min) of 3 sets of 14 stretches focused on the muscle groups targeted by the exercise training (i.e., deltoids, pectorals, lats, forearms and biceps, triceps, quadriceps, hamstrings, and groins). Each stretch will be performed for 20 seconds and a rest interval of 60 seconds will be taken between each set.
1679150|NCT01626118|Drug|Indomethacin|capsules, 40 mg, TID
1679151|NCT01626118|Drug|Indomethacin|capsules, 40 mg, BID
1679152|NCT01626118|Drug|Indomethacin|capsules, 20 mg, TID
1679153|NCT01626118|Drug|Placebo|capsules
1679154|NCT01626092|Drug|Campath-1H|A daily dose of 0.3 mg/kg IV over 2 hours will be administered on days - 12, -11, -10, -9, and -8.
1679155|NCT01626092|Drug|Clofarabine|"A daily dose of 40 mg/m2 will be administered IV over 2 hours on days -9,
-8, -7, -6, and -5."
1679156|NCT01626092|Drug|Melphalan|A single dose of 140 mg/m2 will be given IV on day -4 over 15 minutes.
1679157|NCT01626092|Radiation|Total Body Irradiation with Marrow Boosting|"Dose to total body 200 cGy in single dose
Dose to bone marrow of the following bones 800 cGy in 5 divided daily fractions (160 cGy x 5 doses ). Treated with up to 3 abutting VMAT photon arcs from top of head to maximum inferior border."
1679158|NCT01626092|Biological|Hematopoietic stem cell transplantation|Patients will be transplanted using either a related or unrelated allograft. The cell source may be marrow, peripheral blood or cord blood based on donor availability.
1679159|NCT01626092|Drug|Cyclosporine A|Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose IV; if the recipient body weight is <40 kg, dosing will be 3 times daily, and if > 40 kg, twice daily. An attempt will be made to maintain a trough cyclosporine level of 200 mg/L to 400 mg/L.
1679160|NCT01626092|Drug|Mycophenolate mofetil|Patients will receive mycophenolate mofetil (MMF) therapy beginning on day -3. Dosing of MMF will be 1 gram three times daily (total daily dose 3 grams/day) if the recipient is >50 kg, or 15 mg/kg/dose three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously.
1679161|NCT01626079|Device|MitraClip System|Percutaneous mitral valve repair using MitraClip System
1679162|NCT01626066|Drug|LUM015|LUM015 assigned dose given once by IV push
1679163|NCT01626053|Behavioral|ASMART|Motivational Interviewing, Stages of Change, Psychological Testing, Bio-psychosocial assessment, responsive diabetes education, support, Cognitive-behavioral interventions
1679164|NCT01626053|Other|Control Group|no intervention
1679165|NCT01626040|Drug|polyethylene glycol powder|A single group of children taking a polyethylene glycol powder preparation, dosage determined by patient weight, taken in one dose the day before colonoscopy
1679166|NCT01626014|Behavioral|Usual Care Educational Website|Using the control website: Participants access a website with standard ovarian cancer informational handouts.
1679167|NCT01626014|Behavioral|Prototype System|An interactive system for patients and their caregivers includes features allowing users to create their own profile, share a journal with others, and post to respective discussion forums. In addition, core intervention components include distress monitoring, educational items, details about the healthcare team and an areas to keep track of questions for providers.
1679168|NCT01626001|Procedure|4D CT scans|4 (or 5 for Cohort 2) 4DCT scans performed. 1 scan performed while breath held for less than 20 seconds. CT scans take about 5 minutes each to complete.
1679169|NCT01625988|Drug|LY2951742|Administered subcutaneously once every other week for 12 weeks
1679170|NCT01625988|Drug|Placebo|Administered subcutaneously once every other week for 12 weeks
1679171|NCT01625949|Procedure|Intracoronary stem cells injection|Intracoronary stem cells will be injected in the infarct related artery after a successful coronary dilatation and stenting autologous bone marrow stem cells from iliac crest 60 ml bone marrow will be extracted and purified for mononuclear cells which will be injected.
1679172|NCT01625949|Procedure|coronary dilatation and stenting|coronary dilatation and stenting
1679175|NCT01625923|Drug|Olanzapine|Subjects will initially start on olanzapine 2.5 mg per mouth daily. Subjects will return on days 7 and 14 to determine response to medication and medication dose can be increased to 5 mg and 10 mg, respectively, based on incomplete symptom response (mean change GCSI-DD < 0.5). The total dose of olanzapine will not exceed 10 mg daily during this study and subjects will continue on treatment for a total of 8 weeks.
1679176|NCT01625910|Behavioral|Behavioral counseling|Counseling of parents to improve their child's diet and physical activity
1679177|NCT01625897|Drug|MP-214 low dose|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for four weeks, then flexible dose of MP-214
1679178|NCT01625897|Drug|MP-214 high dose|Patients who meet eligibility criteria will be administered a once daily oral high dose of MP-214 for four weeks, then flexible dose of MP-214
1679179|NCT01625897|Drug|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral dose of risperidone for two weeks, then flexible dose of risperidone
1679181|NCT01625845|Drug|Pentoxifylline|Pentoxifylline 400 mg p.o. t.i.d. for 12 weeks
1679182|NCT01625845|Other|Placebo|Placebo pills will match the study drug for color, taste, texture, size, and smell. Participants will receive the same instructions as those randomized to pentoxifylline.
1679183|NCT01625845|Behavioral|Standard Treatment|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
1679184|NCT01625832|Procedure|intermittent coronary sinus occlusion|Patients undergo two 2-minute coronary balloon occlusions. Patients are randomized to CSO first or CSO second.
1679185|NCT01625819|Behavioral|Tai Chi|32 1-hour bi-weekly group sessions of Tai Chi instruction
1679186|NCT01625819|Behavioral|Resistance Band|32 1-hour bi-weekly group sessions of Resistance Band exercises
1679187|NCT01625819|Behavioral|Health Education|32 1-hour bi-weekly group sessions of health education
1679188|NCT01625806|Drug|RO4602522|Single oral dose
1679189|NCT01625806|Drug|ketoconazole|Multiple oral doses
1679190|NCT01625793|Drug|Interferon-alpha|Hepatitis C patients who are eligible to receive IFN-alpha treatment and enrolled in this study will be treated with pegylated IFN-alfa-2b or pegylated IFN-alfa-2a plus ribavirin at a dose of 800-1,400 mg/d as determined by the treating gastroenterologist. All medication administration is for purely clinical indications as dictated by treating physicians. Any and all diagnostic or treatment issues related to potential treatment with IFN-alpha will be conducted by treating clinicians. Subjects will be randomized to start their clinical (non-research) treatment following completion of baseline assessments or to delay the start of their clinical (non-research) treatment by 7 weeks.
1679191|NCT01625780|Procedure|3-layer block|"0.3 mL/kg of 0.25% bupivacaine (one injection in each layer) will be delivered by the 3-layer method using a standard 20-gauge block needle."
1679192|NCT01625780|Procedure|Single-shot block|0.3 mL/kg of 0.25% bupivacaine will be delivered by the standard, single-shot method using a 20-gauge block needle.
1679193|NCT01625767|Behavioral|AAT experiment|Smokers and nonsmokers complete AAT experiment
1679194|NCT01625754|Behavioral|Exercise|All individuals will be prescribed an exercise regimen according to their cardiac rehabilitation program
1679195|NCT01625741|Drug|Rituximab|2000 mg, IV, monthly, for 4 months (= 4 doses)
1679196|NCT01625715|Drug|Ketotifen|titrated dose: 1 mg once a day, then 1 mg twice a day then 2 mg twice a day
1679197|NCT01625702|Device|CellSearch® CTC kit|"Collect peripheral blood sample of 100 gastric cancer patients pre-chemotherapy treated with capecitabine/paclitaxel (XPa) and capecitabine/cisplatin (XP) and post two cycles of chemotherapy(response evaluation).
Blood samples will be transferred to central lab to detect CTCs by Cellsearch kit.
Tumor response evaluation will be performed after two cycles of chemotherapy by CT/MRI based on RECIST. Clinical data, including tumor stage, metastastic organ, chemotherapy regimen, objective response, progression free survival, overall survival, etc, will be collected according to study protocol."
1679198|NCT01625689|Biological|SIIL LAIV (live, trivalent seasonal influenza vaccine)|Dose: 0.5 mL, The viral strains in seasonal trivalent influenza vaccine (human, live attenuated) are antigenically similar to A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008 Type B, as per the WHO recommended strains for the Northern hemisphere 2011-12 influenza season
1679199|NCT01625689|Biological|Placebo|Inactive placebo will be identical to SII LAIV in appearance, ingredients, and concentrations, except it will be missing attenuated influenza virus.
1679200|NCT01625676|Other|Investigate efficacy of modified ciat schedule|2 hours of training over 15 days
1679201|NCT01625676|Other|examine the efficacy of standard treatment versus modified ciat schedule|2 hours of training over 15 days
1679202|NCT01625637|Behavioral|AAT-experiment|This AAT condition trains kids to avoid cigarettes
1679203|NCT01625637|Behavioral|AAT-placebo|This AAT condition is a no contingency continued assessment version (50% approach-cigarettes, 50% avoid cigarettes).
1679204|NCT01625624|Other|Carbohydrate Food Bar|Control Food Bar containing carbohydrate
1679205|NCT01625624|Other|Modified Carbohydrate Food Bar|Test Food Bar containing modified carbohydrate
1679206|NCT01625611|Drug|Naltrexone|Naltrexone 100 mg titrated over one week
1679207|NCT01625598|Procedure|Photography of the retina|Every subject will undergo photography of the retina in both eyes
1679208|NCT01625598|Procedure|Retinal photography|"Device
Subjects will have photography of both eyes"
1679209|NCT01625572|Procedure|Transversus abdominis plane blockade|Bilateral one time injection of local anaesthetic in the space between the transversus abdominis muscle and obliquus internus muscle preoperatively. Follow up for three days.
1679210|NCT01625572|Procedure|Morphine-patient-controlled-analgesia-device|Morphine-patient-controlled-analgesia-device for three days: 1mg/ml, Dosage 2mg bolus injection on demand every 10 minutes possible.
1679212|NCT01625546|Device|Whole Body Hyperthermia system|The Whole Body Hyperthermia system uses water-filtered infrared-A (wIRA) heat radiation. The rise in the body's core temperature is correspondingly rapid and well-tolerated. There are two phases of the thermal challenge, 1) Irradiation phase during which the patient lies recumbent with his/her head positioned outside the tent. The wIRA irradiators are arranged above the exposed upper part of the body; and 2) Heat retention phase during which the patient lies in the chamber with the walls of the tent positioned to retain heat.
1679213|NCT01625533|Procedure|Standard Coronary Angiography|Using standard coronary angiography (SA) for the diagnosis of coronary artery disease.
1679214|NCT01625533|Procedure|Dual-axis Rotational Coronary Angiography|Using dual-axis rotational coronary angiography (DARCA) for the diagnosis of coronary artery disease.
1679215|NCT01625520|Drug|SOM230 alone or in combination with RAD001.|SOM230 (pasireotide) 60 mg i.m. injection once every 28 days, +/- 2 days. RAD001 (everolimus) 10 mg per os daily.
1679216|NCT01625507|Behavioral|PANDA intervention|Participants will follow a menu plan and receive training in how to manage their diet in type 2 diabetes, following the recommendations of the Canadian Diabetes Association, 2008
1679217|NCT01625494|Drug|Irbesartan/Amlodipine (150/5mg)|Pharmaceutical form: tablet Route of administration: oral
1679218|NCT01625494|Drug|Irbesartan/Amlodipine (150/10mg)|Pharmaceutical form: tablet Route of administration: oral
1679219|NCT01625494|Drug|Irbesartan/Amlodipine (300/5mg)|Pharmaceutical form: tablet Route of administration: oral
1679220|NCT01625494|Drug|Irbesartan/Amlodipine (300/10mg)|Pharmaceutical form:tablet Route of administration: oral
1679221|NCT01625481|Device|Seal-V|Seal-V is applied adjunctively to cover the suture lines.
1679222|NCT01625468|Behavioral|Educational print materials and a coaching call|Intervention group participants receive three sets of mailed educational materials about making their home smoke-free and one coaching call.
1679223|NCT01625455|Drug|Aprepitant|Aprepitant will be given orally in a dose of 125mg on day 1 and 80mg daily on each subsequent day for a total of 7 days.
1679224|NCT01625455|Drug|Placebo|Placebo will be given orally for a total of 7 days.
1679225|NCT01625442|Drug|Saffron tablet|Saffron tablets 100 mg
1679226|NCT01625442|Drug|Barberry tablet|Barberry tablets 200 mg
1679227|NCT01625442|Drug|Placebo|Placebo tablets received daily for 45 days
1679228|NCT01625429|Drug|nab-paclitaxel|nab-paclitaxel 125mg/m2, day 1, 8, 15, q4w; carboplatin AUC 2, day 1, 8, 15, q4w; for HER-2 positive patients: trastuzumab loading dose 4mg/kg, then 2mg/kg, day 1, 8, 15, 22, q4w. All patients will receive up to four cycles except for unacceptable toxicity
1679230|NCT01625403|Drug|rhBNP|intravenous administration of rhBNP 0.01 µg/kg/min
1679231|NCT01625403|Drug|standard of care|standard of care for heart failure
1679232|NCT01625390|Drug|BAY86-6150|Four dose levels (6.5 µg/kg, 20 µg/kg, 50 µg/kg and 90 µg/kg) of BAY86-6150 will be studied.
1679233|NCT01625390|Drug|eptacog alfa [activated]|comparative PK/PD (pharmacokinetics/pharmacodynamics) evaluation
1679234|NCT01625390|Drug|BAY86-6150|Confirmation of recommended dose of BAY86-6150 to be evaluated further as determined in Part A.
1679235|NCT01625377|Drug|tacrolimus|Arm 1 : tacrolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to month 6 post-transplantation. Arm 2 : tacolimus (C0 6-10 ng/ml) from D3-D5 post-transplantation to 16 weeks post-transplantation at the latest.
1679236|NCT01625377|Drug|everolimus|Arm 1: no everolimus Arm 2: everolimus (C0 6-10 ng/ml) from randomization to month 6 post-transplantation
1679237|NCT01625377|Drug|Basiliximab|Basiliximab was supplied to the participating centers as marketed, i.e. in packs containing one vial of 20-mg powder, and water for injection (WFI). 20 mg at D0 and D4
1679238|NCT01625377|Drug|Mycophenolic Acid|Dose of 1440 mg/day from transplantation to month 6 post- transplantation
1679239|NCT01625377|Drug|Corticosteroids|Administration of oral corticosteroid therapy was at the discretion of the centers according to their usual practice
1679240|NCT01625364|Behavioral|SHARP program|Staying Healthy-Asthma Responsible and Prepared is an academic and counseling asthma health education program for older school-age students with asthma and members of their social networks including their family caregivers.
1679241|NCT01625364|Behavioral|Open Airways for Schools|OAS is a non-academic asthma health education program for elementary students with asthma and their parents.
1679242|NCT01625351|Drug|alemtuzumab|Patients receive alemtuzumab on days -14 through -12 (Day 0 = stem cell transplantation).
1679243|NCT01625351|Drug|fludarabine|Patients receive fludarabine phosphate on days -11 through -7. (Day 0 = stem cell transplantation.)
1679244|NCT01625351|Drug|sirolimus|"Patients receive sirolimus beginning on day -1 with taper beginning on day 90. (Day 0 = stem cell transplantation.)
Participants treated after activation of protocol revision 2.3 on 06/05/2014 have not and will not receive sirolimus as part of their therapy."
1679245|NCT01625351|Drug|Busulfan|Patients receive busulfan on days -6 through -3. (Day 0 = stem cell transplantation.)
1679246|NCT01625351|Drug|melphalan|Patients receive melphalan on days -2 and -1. (Day 0 = stem cell transplantation.)
1679247|NCT01625351|Biological|stem cells|Patients undergo CD3 depleted haploidentical hematopoietic stem cell transplant (HSCT) on day 0. Patients also undergo CD45RA depleted HSCT infusion on day 1. (Day 0 = stem cell transplantation.)
1679248|NCT01625351|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
1679249|NCT01625338|Drug|SOF|SOF 400 mg tablet administered orally once daily
1679250|NCT01625338|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1679251|NCT01625338|Drug|Peg-IFN|Peg-IFN 180 μg administered once weekly by subcutaneous injection
1679252|NCT01625299|Dietary Supplement|Gluten and dry milk|0.5 g/kg/day of gluten 0.5 g/kg/day of dry milk
1679253|NCT01625299|Dietary Supplement|Placebo|Rice flour 1.0 g/kg/day
1679254|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 2 days on-treatment, 5 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
1679255|NCT01625286|Drug|AZD5363 when combined with weekly paclitaxel.|AZD5363: oral capsule, twice daily in a weekly 4 days on-treatment, 3 days-off, schedule. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
1679256|NCT01625286|Drug|AZD5363when combined with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. AZD5363 and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
1679257|NCT01625286|Drug|A placebo in combination with weekly paclitaxel.|Either a 2/5 or 3/4 intermittent dosing schedule of placebo matched to AZD5363 based on the outcome of Part A. Dosage: oral formulation, twice daily. Treatment to begin the day following the first dose of paclitaxel and to continue until treatment withdrawal. Paclitaxel: intravenously once a week. placebo and paclitaxel will be received for 3 consecutive weeks, followed by one week off-therapy in 4-week cycles.
1679258|NCT01625273|Other|Lactobacillus paracasei paracasei strain F19|Provided in an infant formula, 10^8 CFU per day from 28 days to 6 months of infant age
1679259|NCT01625260|Biological|ALT-801|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 3, 5, 8 and 15 of each course.
1679260|NCT01625260|Drug|Gemcitabine|Intravenous infusion: 2 treatment courses and 1 maintenance course; on Day 1 and 8 of each course.
1679261|NCT01625247|Procedure|Surgical drainage|Postoperative abdominal drainage were connected to a 200-mL closed suction reservoir. The drainage was removed if there are drainage amount less than 20 mL and color was serous color.
1679262|NCT01625234|Drug|X-396 (ensartinib)|Oral, ALK inhibitor
1679263|NCT01625221|Device|Magnetic Anal Sphincter|The implantable single-use Magnetic Anal Sphincter (FENIX) device consists of a series of titanium beads with magnetic cores that are linked together with independent titanium wires forming an annular shape. The device is supplied sterile and is placed through an open incision.
1679264|NCT01625208|Procedure|Combined nerve block|Combined supraclavicular brachial plexus block plus ulnar or median nerve block (depending on the location of surgery)
1679265|NCT01625208|Procedure|Supraclavicular block|Standard supraclavicular brachial plexus block
1679266|NCT01625195|Dietary Supplement|omega-3 fatty acid supplementation|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 6 x 1 g fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide 1.2 g/d of DHA and 2.4 g/d of EPA (Ocean Nutrition Canada, Dartmouth, NS). All capsules will contain citrus flavor to mask the fishy taste and odor of the LC-omega-3 oil and will be provided to the participants monthly.
1679267|NCT01625195|Dietary Supplement|corn/soybean oil placebo|This study will use a randomized placebo-controlled double-blind design and the intervention period will be 6 months. Participants will be instructed to consume 6 x 1 g fish oil capsules/d, two capsules with each of the main daily meals. The placebo will be composed of corn/soybean oil as used in other randomized placebo-controlled trials. The daily treatment will provide
1679270|NCT01625169|Drug|Etravirine pharmacokinetics in breast milk and plasma|HIV+ pregnant women will receive etravirine 200mg PO BID for 14 days postpartum. PK will be done on postpartum days 5 and 14.
1679271|NCT01625156|Other|Laboratory Biomarker Analysis|Correlative studies
1679272|NCT01625156|Other|Pharmacological Study|Correlative studies
1679273|NCT01625156|Drug|Temsirolimus|Given IV
1679274|NCT01625156|Drug|Tivantinib|Given PO
1679275|NCT01625143|Other|laboratory biomarker analysis|Correlative studies
1679276|NCT01625130|Dietary Supplement|Broccoli sprout homogenate|Commercially available Broccosprouts® (Brassica Protection Products LLC) will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
1679277|NCT01625130|Dietary Supplement|alfalfa sprout homogenate|200 grams of alfalfa sprouts will be homogenized with water using a ratio of 1:1.2 in a clean blender. The homogenate will then be frozen in aliquots at -20 degrees C.
1679278|NCT01625117|Behavioral|A variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
1679279|NCT01625091|Drug|Naltrexone|The study involves taking the drug naltrexone for up to 4 months. This will be given in a single pill each day for 4 months.
1679280|NCT01625091|Drug|Placebo|Placebo is an inert pill that looks the same as naltrexone. The placebo will be taken once each day for up to 4 months.
1679281|NCT01625078|Device|Placement and use of Baska mask|Use of Baska mask as a supraglottic airway during general anesthesia
1679282|NCT01625052|Device|Placement and use of Baska mask|use of Baska mask as component of standard general anaesthetic
1729166|NCT00019071|Drug|cladribine|
1679285|NCT01625026|Drug|Obeticholic acid|Obeticholic acid 25 mg/day in three weeks
1679286|NCT01625026|Drug|Placebo|Placebo to obeticholic acid
1679287|NCT01625013|Device|Synvisc-One (G-F 20)|Synvisc G-F 20 will be injected in the symptomatic knee using a standard supine lateral approach using a 20-gauge needle. Patients will be treated at baseline and followed out to three years. Patients may return for retreatment as early as 4 months post their prior injection if they meet the retreatment criteria pain levels for Worst Knee Pain. If the subjects need another injection, the follow-up cycle will restart at Visit 1 and the subject will be seen every 6 months and followed-up for 3 years.
1679288|NCT01625000|Drug|MP-214 low dose|Patients who meet eligibility criteria will be administered a once daily oral low dose of MP-214 for six weeks.
1679289|NCT01625000|Drug|MP-214 middle dose|Patients who meet eligibility criteria will be administered a once daily oral middle dose of MP-214 for six weeks.
1679290|NCT01625000|Drug|MP-214 high dose|Patients who meet eligibility criteria will be administered a once daily oral high dose of MP-214 for six weeks.
1679291|NCT01625000|Drug|Risperidone|Patients who meet eligibility criteria will be administered a once daily oral dose of risperidone for six weeks.
1679292|NCT01625000|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks.
1679293|NCT01624987|Behavioral|NET for Forensic Offender Rehabilitation (FORNET): a variant of Narrative Exposure Therapy|During the proposed therapy, the client constructs a chronological narrative of his or her whole life which includes all traumatic experiences and perpetrated violent acts. All emotions, cognitions, sensory information, and physiological reactions are activated and linked to the autobiographical context.In five sessions the trained therapist and the client try to go through all important traumatic experiences and perpetrated violent acts. The sixth session is a group session with four to five clients. The group session is oriented on Interpersonal Psychotherapy and focuses on the role change from soldier to civilian.
1679294|NCT01624987|Other|Control group|The control group receives no intervention.
1679295|NCT01624974|Drug|MK-1029|MK-1029 150 mg tablets taken once daily (QD)
1679296|NCT01624974|Drug|placebo|placebo tablets (matching the MK-1029 150 mg tablets) QD
1679297|NCT01624974|Drug|montelukast (ML)|ML 10 mg tablets QD
1679298|NCT01624961|Biological|PfSPZ Challenge|PfSPZ Challenge are aseptic, cryopreserved P. falciparum sporozoites.
1679299|NCT01624948|Drug|Everolimus|Everolimus will be administered orally at a starting dose of 0.75 mg PO b.i.d. (1.5 mg/day). Everolimus whole blood trough levels will be monitored at pre-specified time points to achieve a range of 3-8 ng/mL. Group 1 patients will continue on prednisone and tacrolimus with a target whole blood trough level of 3-6 ng/mL.
1679300|NCT01624948|Drug|Mycophenolic acid dose reduction|Group 2 patients will undergo a 50% reduction of the mycophenolic acid (MPA) dose, and continue with tacrolimus (target trough level of 6-10 ng/mL), and prednisone.
1679301|NCT01624935|Behavioral|interpersonal psychotherapy|interpersonal psychotherapy
1679302|NCT01624857|Drug|Rosuvastatin|Rosuvastatin for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
1679303|NCT01624857|Drug|Placebo|Placebo for at least 5 days before the CABG surgery, then continue to take for a month after the surgery.
1679304|NCT01624844|Other|Geometrical calculation of dural sac volume|Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
1679305|NCT01624818|Behavioral|Cardiac habilitation program|physical activity three weeks
1679311|NCT01624792|Dietary Supplement|Olive oil|Dose: 7.0 g/day (= 7 capsules/day).
1679312|NCT01624792|Dietary Supplement|Fish oil|Dose: 7.0 g/day (= 7 capsules/day = 3.5g EPA+DHA/day).
1679313|NCT01624792|Dietary Supplement|Fish oil and placebo|Dose: 7.0 g/day (= 4 capsules/day fish oil = 2.0g EPA+DHA/day and 3 capsules/day olive oil).
1679314|NCT01624779|Drug|autologous adipose tissue derived mesenchymal stem cells|autologous adipose tissue derived mesenchymal stem cells 9x107cells / 3mL Day 1 and Month 1&2
1679315|NCT01624766|Drug|Everolimus|"Starting Dose (Everolimus + Anakinra): Everolimus 5 mg by mouth daily for a 28 day cycle.
Starting Dose (Everolimus + Denosumab): Everolimus 10 mg by mouth daily for a 28 day cycle.
Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalating Group."
1679316|NCT01624766|Drug|Anakinra|"Starting dose: 100 mg subcutaneously daily for a 28 day cycle.
Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalating Group."
1679317|NCT01624766|Drug|Denosumab|"Starting dose: 120 mg subcutaneously day 1 of a 28 day cycle.
Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalating Group."
1679318|NCT01624753|Device|confocal microscopy|During bronchoscopy, one side of the bronchial tree will be examined (either right or left) and targeted based on pre-procedure HRCT/CT scan findings. A 1.4mm diameter Alveoflex Confocal MiniprobeTM (MaunaKea Technologies, France) will be deployed down the working channel of the standard bronchoscope and advanced distally into the alveoli. Images are acquired by gentle contact providing real-time imaging and microstructural detail of the alveolus which will be continuously recorded during the procedure and stored for further morphometric and cellular analyses. Up to 10 bronchoalveolar areas will be observed and the location of the corresponding lung segment will be registered according to the international bronchial nomenclature.
1679319|NCT01624740|Device|Low Rate Stimulation|Stimulation was given at a rate of 2 Hz.
1679320|NCT01624740|Device|High Rate Stimulation|Stimulation was given at a rate of 1200 Hz.
1679322|NCT01624714|Drug|Alemtuzumab|alemtuzumab 12 mg IV x 5 daily doses at baseline, alemtuzumab 12 mg IV x 3 daily doses at month 12
1679323|NCT01624714|Drug|Alemtuzumab immunotherapy|Alemtuzumab 60 mg over 5 days for first annual cycle, then 36 mg over 3 days for subsequent annual cycle, and as needed cycles in subsequent years.
1679324|NCT01624701|Other|Ex vivo expanded cord blood cells|Cord blood cells will be expanded ex vivo using a combination of stem cell factor (SCF), thrombopoietin (TPO), Flt3 ligand and IGFBP2 with mesenchymal stromal cell (MSC) co-culture.
1679325|NCT01624688|Procedure|Tattoo Removal|Tattoo removal with q-switched laser treatment, repeated q-switched laser treatment, repeated q-switched laser treatment with fractional ablative laser treatment, and repeated q-switched laser treatment with fractional ablative laser treatment and then topical urea
1679326|NCT01624675|Drug|Risperidone|Subjects weighing less than 20 kilogram (kg) received risperidone 0.25 milligram per day (mg/day) up to Day 4. On Day 4, dose was titrated in increments of 0.25 mg/day (up to a daily dose of 1.0 mg) at the regular study visit thereafter till Week 8. Subjects weighing greater than or equal to (>=) 20 kg received risperidone 0.5 mg/day up to Day 4. On Day 4, dose was titrated in increments of 0.5 mg per day (up to a daily dose of 2.5 mg) at the regular visit thereafter till Week 8. The maximum daily dose for subjects weighing >= 45 kg was 3.0 mg. For subjects weighing >=45 kg, the maximum daily dose was 3.0 mg.
1679327|NCT01624675|Drug|Placebo|Subjects will receive placebo matching with risperidone orally up to 8 weeks.
1679329|NCT01624649|Drug|Methylphenidate hydrochloride|Form = tablet, route = oral, administered as a flexible dosage
1679330|NCT01624649|Drug|Atomoxetine|Form = tablet, route = oral;
1679331|NCT01624636|Drug|Placebo|
1679332|NCT01624636|Drug|LFG316|
1679333|NCT01624636|Drug|LFG316|
1679334|NCT01624610|Other|Dietary intervention|After a 14 day screening period, subjects will be randomized to 1 of 2 diets to treat their IBS symptoms. They will receive dietary instruction and are expected to remain on this diet for 4 weeks.
1679335|NCT01624597|Behavioral|In-vehicle video feedback|An in-vehicle video system will record driving errors and safety behaviors. A light on the system will blink to let the participant know that a driving error has been recorded. Parents will receive a weekly report card.
1679336|NCT01624597|Behavioral|Parent communication|Parents will receive instruction in teaching and effective communication about driving skills and driving safety. The intervention includes driving goals for teen drivers and parent communication strategies.
1679337|NCT01624584|Behavioral|Experimental treatment|six sessions of child anxiety treatment
1679338|NCT01624584|Behavioral|Traditional Treatment|six sessions of treatment consistent with current practice
1679339|NCT01624571|Drug|LD02GIFRO|comparison of different dosages of drug
1679340|NCT01624558|Device|In-line Carbon filter (Vapor-Clean)|Carbon filter placed in anesthesia breathing circuit.
1679341|NCT01624545|Other|cranial CT scan|Patients in this study arm will receive a cranial CT scan on day 2 and day 30 after evacuation of a chronic subdural hematoma in addition to neurological evaluation on day 2 and 30.
1679342|NCT01624532|Biological|rPA vaccine containing alhydrogel 1.0 mL|rPA vaccine containing alhydrogel 1.0 mL
1679343|NCT01624532|Drug|Normal Saline|Normal Saline 0.5mL
1679344|NCT01624532|Biological|rPA vaccine containing alhydrogel 0.5 mL|rPA vaccine containing alhydrogel 0.5 mL
1679345|NCT01624532|Biological|rPA vaccine containing alhydrogel 0.3 mL|rPA vaccine containing alhydrogel 0.3 mL
1679346|NCT01624519|Procedure|Blood Lactate Analysis|When an arterial lactate is deemed to be necessary as part of ICU management, a central venous and peripheral venous sample will also obtained within 5 minutes. All of the samples will be analyzed using the same analyzer as quickly as possible.
1679347|NCT01624493|Drug|Carboplatin|Carboplatin AUC4 on day 1 of 21-day cycle, for a maximum of 6 cycles.
1679348|NCT01624493|Drug|Gemcitabine|Gemcitabine escalations 800 and 1000 mg/m2 (as determined in phase I) on days 1 and 8 of a 21 day cycle, for a maximum of 6 cycles.
1679349|NCT01624493|Drug|Carboplatin|Carboplatin AUC 4 on day 1 of a 21 day cycle, for a maximum of 6 cycles.
1679350|NCT01624493|Drug|Gemcitabine|Gemcitabine 800 or 1000 mg/m2 (as determined in phase I) on days 1 and day 8 of 21-day cycle, for a maximum of 6 cycles.
1679351|NCT01624493|Drug|BNC105P|BNC105P as determined in phase I, on days 2 and 9 of a 21 day cycle for a maximum of 6 cycles, followed by single agent maintenance BNC105P 16 mg/m2 for a maximum of 6 additional cycles.
1679352|NCT01624480|Drug|Armodafinil|The armodafinil tablets to be used in this study contain 50 mg of armodafinil and the following inactive ingredients: lactose monohydrate, starch, microcrystalline cellulose, croscarmellose sodium, magnesium stearate, and povidone.
1679353|NCT01624467|Biological|Necitumumab|800 mg necitumumab, administered once per week IV
1679354|NCT01624454|Other|Laxabon|4 l PEG solution split dose cleansing
1679355|NCT01624454|Other|CitraFleet|Small volume osmotic bowelcleansing
1679359|NCT01624428|Drug|Varenicline|1 mg bid varenicline titrated over a 2 week period
1679360|NCT01624428|Drug|Placebo|1 mg bid placebo titrated over a 2 week period
1679361|NCT01624402|Behavioral|Education on Stroke and Depression (ESD)|"Each session begins by assessing the subject's and his/her family's level of information in a given area and by identifying misconceptions, thus guiding the selection of educational material.
Comprehending illness-related information is a process contaminated by pessimism, denial, misconceptions, and stigma. The role of the ESD therapist is to impart valuable information, despite these complexities.
Conveying information is a process. The ESD therapist needs to be aware of where the subject and family are in each session and offer information for which they have readiness to accept.
ESD therapists do not engage in additional interventions (e.g., cognitive behavioral therapy, interpersonal therapy, problem solving therapy)."
1679402|NCT01624103|Procedure|Upper limb surgery|Elderly patients undergoing upper limb surgery received 20 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
1679362|NCT01624402|Behavioral|Ecosystem Focused Therapy (EFT)|"EFT offers an action-oriented, new perspective about the subject's recovery;
It provides an adherence enhancement structure;
It offers a problem solving structure to the subject focusing on problems, valued by the subject, and pertinent to daily function;
It helps the family re-engineer its goals, involvement, and plans to accommodate the patient's disability;
It coordinates care with specialized therapists with the goal to increase patient participation in rehabilitation and social activities."
1679363|NCT01624389|Drug|F18-AV45|"This study will recruit a total of 200 evaluable subjects (50 cognitively normal volunteers, 100 MCI, and 50 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.
Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
1679364|NCT01624376|Drug|DLX105|10mg DLX105/injection injected into the fistula over a treatment period of 4 weeks.
1679365|NCT01624376|Drug|Placebo|Placebo injections are administered over the treatment period of 4 weeks.
1679366|NCT01624350|Device|Permacol collagen paste|Collagen paste intended to reinforce soft tissue where filling is required such as to repair fistulas, including anal and rectal fistulas.
1679367|NCT01624337|Drug|DHA-piperaquine|"Drug: Dihydroartemisinin piperaquine
40/320 mg tablets, 9 tablets total Arms: 2 day treatment course (4.5 tablets per day)"
1679368|NCT01624337|Drug|placebo|
1679369|NCT01624311|Other|Therapeutic Hypothermia|After obtaining written consent, patients are cooled to 33.5°C (+/- 1°C ) for 72 hours and and then rewarmed by 0.5°C per every 3 hours over 18 hours.
1679370|NCT01624311|Other|Standard of Care Therapy|Patients with hyperammonemia and encephalopathy requiring renal replacement therapy due to a urea cycle disorder or organic acidemia that were treated at Children's National Medical Center over the past 10 years.
1679372|NCT01624285|Drug|sorafenib tosylate|Given PO
1679373|NCT01624285|Other|placebo|Given PO
1679374|NCT01624285|Other|laboratory biomarker analysis|Correlative studies
1679375|NCT01624272|Device|Threshold® Inspiratory Muscle Trainer (Respironics® Health Scan Inc. Cedar Grove, NJ, USA).|Interval-based program consisting of seven cycles of 2-minutes work and 1-minute rest. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
1679376|NCT01624272|Other|Yoga Pranayama breathing exercises|Interval-based program. The sessions took place 5 times per week over a six-week period for a total of 30 sessions. All participants were familiarized with the breathing exercises over a two-day familiarization period at the beginning of the protocol.
1679377|NCT01624259|Drug|LY2189265|Administered SC
1679378|NCT01624259|Drug|Liraglutide|Administered SC
1679379|NCT01624259|Drug|Metformin|
1679380|NCT01624246|Drug|Ceftaroline fosamil/Avibactam (CXL)|IV infusion of CXL (combination of ceftaroline fosamil [600 mg] plus avibactam [600 mg]) infused over 60 (± 5) minutes.
1679382|NCT01624220|Radiation|Spinal SBRT (Standard Dose)|Group 1 and 2: Standard doses of radiation therapy to the normal esophagus while treating the tumor. Up to 2 groups of 10 participants enrolled.
1679383|NCT01624220|Radiation|Spinal SBRT (Higher Dose)|Group 3 and 4: Higher dose of radiation to esophagus than group before it, if no intolerable side effects were seen. 2 groups of 10 participants enrolled in the second part of study. Only participants who will receive a single spinal SBRT treatment are eligible for second part of study.
1679384|NCT01624220|Procedure|Gold Seed Implantation|4 gold seeds implanted into bones of spine: 2 gold seeds above and 2 gold seeds below the area of tumor to be treated.
1679385|NCT01624220|Behavioral|Questionnaires|Completion of questionnaire before radiation treatment starts, and 1 time a week for the next 4 weeks. It should take about 10 minutes to complete.
1679386|NCT01624207|Drug|generic formulation of atorvastatin (Atorva®)|Treatment with generic formulation of atorvastatin (Atorva®) once daily, for 8 weeks
1679387|NCT01624207|Drug|branded formulation of atorvastatin (Lipitor®)|Treatment with branded formulation of atorvastatin (Lipitor®)once daily, for 8 weeks
1679390|NCT01624168|Behavioral|Anxiety Management Education|written materials on management of anxiety for self-study
1679391|NCT01624168|Behavioral|10 week tai chi intervention|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week
1679392|NCT01624168|Behavioral|Enhanced tai chi instruction|10 weeks of instruction in Evidence Based Tai Chi meeting 2 times per week plus DVD for home practice
1679393|NCT01624155|Behavioral|Education|EMR referral to teratogen and contraception counseling
1679394|NCT01624142|Biological|Evolocumab (AMG145)|every month
1679395|NCT01624142|Biological|Evolocumab (AMG145)|every 2 weeks
1679396|NCT01624129|Drug|Fluticasone|Guideline-based treatment with fluticasone 0,5 ml (1-0-1), step-up or step-down after 3 months based on the histopathological findings
1679397|NCT01624116|Drug|Acarbose|Tab.Acarbose 50mg BD for one day in addition to existing medication to 10% of patients in each treatment arm.
1679398|NCT01624116|Other|Diet and lifestyle|Patients would follow a 1200 KCal Ramadan diet plan, and exercise for 30 minutes per day
1679399|NCT01624116|Drug|Metformin|Patients on metformin monotherapy prior to Ramadan will continue on it, in the same dose
1679400|NCT01624116|Drug|Metformin/ Glimepride|Metformin 500mg and Glimepride 1mg in a combination tablet. Dosage frequency BD
1679401|NCT01624116|Drug|Metformin/Sitagliptin|Metformin 500 and sitagliptin 50mg in a combination tablet,dosage frequency BD.
1679690|NCT01621542|Biological|WT2725|WT2725 injection Study drug will be administered every 1-4 weeks
1729358|NCT00027703|Other|placebo|Given IV
1679403|NCT01624103|Procedure|Upper limb surgery|Elderly patients undergoing upper limb surgery received 32 ml of LA volume (50:50 mixture of levobupivacaine 0.5% and lidocaine 2%) for US-SCB. An independent observer unaware of the LA volume recorded maximal pain intensity resulting from block placements, questioned the patients about possible unpleasant events linked to the performance of US-SCB and assessed patient's satisfaction.
1679405|NCT01624077|Biological|Regulatory T cells|Tregs will inject after liver transplantation
1679406|NCT01624064|Drug|Enalapril|2.5-20 mg/day
1679407|NCT01624064|Drug|Calcium Supplement|Calcium 2.5-20 mg/day
1679408|NCT01624051|Other|Standard dosing method arm: Cisplatin (chemotherapy) dosing based on body surface area|Cisplatin dosing calculated at the rate of 75 mg/m2
1679409|NCT01624051|Other|Experimental dosing method arm: Cisplatin (chemotherapy) dosing based on individual lean body mass|Cisplatin dosing calculated at the rate of 3.10 mg/kg lean body mass
1679410|NCT01624038|Drug|Hydroxyurea ,Epiao|"Hydroxyurea (Myers-Squibb, USA) was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week.
Erythropiotien therapy (rHuEPO - Epiao) from 250 to 500 IU/kg rHuEPO subcutaneously three times a week."
1679411|NCT01624038|Drug|hydroxyurea, blood transfusion|Hydroxyurea was administered in dosages ranging from 15 up to 35 mg/kg/day orally over 7 days/week. Hydroxyurea toxicity was defined as a white cell count of less than 2500/μL or a platelet count of less than 100,000/μL, in which case the drug was discontinued.
1679412|NCT01624025|Other|Docetaxel 60 mg/m2, epirubicin 60 mg/m2, q3wks|Both the patients with HER2 (+) and HER2 (-) patients will be treated with the same regimen.
1679413|NCT01624012|Device|NIV NAVA|Non invasive ventilation with neurally adjusted ventilatory assist
1679414|NCT01624012|Device|Nasal continuous positive airway pressure|Noninvasive respiratory support with continuous positive airway pressure
1679415|NCT01623986|Device|Mespere Venus 1000 System|An adhesive patch (connected to the Mespere Venus 1000 System) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with right atrial pressure values obtained by echocardiography(standard clinical practice)
1679416|NCT01623986|Device|Echocardiography machine|Use of ultrasound to estimate right atrial pressure from analyzing inferior vena cava (IVC).
1679417|NCT01623973|Other|specific training of paretic upper limb|nineteen individuals with chronic stroke was randomly assigned, after the first evaluation, into two groups: group without restriction (G1), subject only to the specific training of paretic UL, and restricted group (G2), which underwent specific training of paretic UL and use of the restriction of non paretic UL. The volunteers were evaluated before the beginning of the interventions, and the next day after completion of the 12 therapy sessions through the Fugl-Meyer Assessment
1679418|NCT01623947|Dietary Supplement|Placebo Beverage|1400 ml flavored, colored, artificially sweetened, non-caloric beverage divided into 6 servings provided prior to and during the 2.5 hr interval ride.
1679419|NCT01623947|Dietary Supplement|2.8 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 2.8 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
1679420|NCT01623947|Dietary Supplement|19.6 g Sustamine Beverage|1400 ml flavored, colored, artificially sweetened, beverage containing 19.6 g Sustamine divided into 6 servings provided prior to and during the 2.5 hr interval ride.
1679421|NCT01623921|Drug|standard care treatment|Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
1679422|NCT01623921|Drug|Celecoxib|Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
1679423|NCT01623921|Drug|Rosuvastatin|Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
1679424|NCT01623921|Drug|Combined therapy|Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
1679425|NCT01623908|Drug|Zoledronate|4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
1679426|NCT01623869|Other|Laboratory Biomarker Analysis|Correlative studies
1679427|NCT01623869|Biological|Trebananib|Given IV
1679428|NCT01623856|Other|laboratory biomarker analysis|Correlative studies
1679429|NCT01623843|Procedure|Arthroscopic Lavage|Lavage: inflammation debris caused from continual friction in the hip is washed out.
1679430|NCT01623843|Procedure|Arthroscopic Osteochondroplasty|"Osteochondroplasty: reshaping the hip ball and socket (osteoplasty or rim trimming)."
1679431|NCT01623830|Behavioral|Virtual Reality Exposure Therapy|Treatment will consist of 8 weekly sessions. Session 1: information gathering, treatment procedures and rationale. Session 2: Cognitive restructuring. Session 3: Breathing retraining and thought stopping. Session 4: Review cognitive restructuring and hyperventilation exposure. Sessions 5-8 Fear of flying exposure in the Virtual environment.
1679432|NCT01623817|Drug|Vancomycin HCL|"Loading dose of 30mg/kg via central or peripheral intraveous infusion during 2 or 3 hours.
Maintanance dose of vancomycin is 15mg/kg twice a day or 1g twice a day."
1679433|NCT01623804|Device|low intensity, pulsed ultrasound|1.5MHz, spatial average-temporal average intensity = 0.03W/cm2, pulsed (burst frequency 1kHz, burst duration 200µm, duty cycle 20%); self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months.
1679434|NCT01623804|Device|sham ultrasound|no ultrasonic energy emitted; self-administered to the medial side of the knee joint while sitting down for 20 minutes every day for 3 months
1679435|NCT01623778|Drug|Interferon Alfa-2a add on ADV|Interferon add on ADV for 48 weeks
1679439|NCT01623726|Procedure|Transcranial Direct Current Stimulation (tDCS)|"Transcranial Direct Current Stimulation. Daily sessions with a total of 10 days intervention. Each intervention will take place with a 2mA intensity during 20 minutes. The current will be delivered by Chattanooga Iontophoresis Dual Channel Delivery Device, that stands for a 2-channels tDCS device in which previous dosage can be set as default to maintain frequently used treatment parameters. Main features include (a) Beeping alerts if electrode fault for open current or high impedance, low battery, treatment completion or power left on; (b)automatic 30 second current ramp up and down during power on/off keeps patient comfortable; (c) Current can be set in 0.1 mA increments between 0.5 mA and 4 mA."
1679440|NCT01623713|Drug|iloperidone|Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
1679441|NCT01623713|Drug|Risperidone|Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
1679442|NCT01623687|Device|Component for acetabulum (Regenerex RingLoc cup)|A fibrous metal uncemented Regenerex RingLoc cup (Biomet, Warsaw, Il, USA)
1679443|NCT01623687|Device|Components for the acetabulum (Lubinus cross linked cup)|cemented Lubinus cross linked cup (Waldemar Link, Hamburg, Germany).
1679444|NCT01623687|Device|Arthroplasty components are for the femur (Cemented Lubinus SP II stem)|Cemented Lubinus SP II stem (Waldemar Link, Hamburg, Germany) with a ceramic 32 mm head.
1679445|NCT01623687|Device|Arthroplasty components are for the femur (Corail stem)|Uncemented HA-coated Corail stem with a ceramic 32 mm head (DePuy, Johnsson & Johnsson, USA).
1679446|NCT01623661|Other|hypertonic saline|hypertonic saline 3.0 % (7 ml/kg)
1679447|NCT01623648|Other|Arm 1 Whey Breakfast|The patients will be assigned to eat 42 g protein namely from Whey protein in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
1679448|NCT01623648|Other|Arm 2 No Whey Breakfast|The patients will be assigned to eat 42 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
1679449|NCT01623648|Other|Arm 3 Low Protein Breakfast|The patients will be assigned to eat 22 g protein from other sources in the breakfast (660 kcal), lunch (560 kcal) and dinner (280 kcal)
1679450|NCT01623635|Drug|Ropivacaine|"ADMINISTRATION OF STUDY DRUG All surgical port sites will be injected with 2 ml/each study drug prior to trocar insertion
Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the study drug will be delivered as an atomized spray in the following volumes:
each subdiaphragmatic area 3.5 ml + 3.5ml
surgical dissection site 3 ml
diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining medication with be atomized again onto the same areas, using the same volumes.
At the end of the case - this process will be repeated with the remaining drug (no repeat port site injections)."
1679451|NCT01623635|Drug|placebo (normal saline)|"ADMINSTRATION OF PLACEBO All surgical port sites will be injected with 2 ml/each placebo prior to trocar insertion
Immediately following insufflation the Optispray surgical spray device will be inserted into the abdomen and directed towards the diaphragms, dome of inflated abdomen, bowel peritoneum and surgical dissection site and the placebo will be delivered as an atomized spray in the following volumes:
each subdiaphragmatic area 3.5 ml + 3.5ml
surgical dissection site 3 ml
diffusely across the peritoneal surface (dome of the abdomen and surface of the visible bowel) 7 ml. At the end of the case the remaining placebo with be atomized again onto the same areas, using the same volumes.
At the end of the case - this process will be repeated with the remaining placebo (no repeat port site injections)."
1679452|NCT01623622|Drug|HC-58|once or more / week
1679453|NCT01623622|Drug|Placebo|once or more / week
1679454|NCT01623609|Drug|Naloxegol|Naloxol IR tablet 25 mg (naloxegol oxalate) commercial formulation
1679455|NCT01623609|Drug|Naloxegol|Naloxegol film-coated Phase III formulation 25 mg film-coated IR tablet
1679458|NCT01623583|Other|Enhanced Needle Phobia Intervention|"The enhanced intervention will include the standard intervention, with two enhancements:
The video will include a segment with a patient using and discussing the analgesic effects of the Synera patch
Before the intervention, a nurse will explain how Synera works and demonstrate its efficacy by having the patient apply it to the non-dominant forearm and leave it in place for 30 minutes, during the intervention. The patient will then be given the opportunity to gently poke 3 times an area of the forearm at least 3 inches from where the patch was applied, and then poke 3 times the center of the area where the patch was applied. The patient may repeat this process up to 3 times. The patient will be asked if he or she can feel the difference in sensitivity."
1679459|NCT01623583|Other|Standard Needle Phobia Intervention|"The standard intervention will include the following components:
Educational material and discussion with the social worker about the benefits of AVF/AVG over catheter.
Basic training on relaxation breathing
Brief video of a patient overcoming needle phobia
Exposure to a cannulation needle while practicing relaxation breathing, ending in the patients physically holding the needle"
1679460|NCT01623570|Drug|Pergoveris: 150IU r-hFSH + 75IU r-hLH|Fixed formulation of two recombinant gonadotropins
1679461|NCT01623570|Drug|Menopur: HMG-HP (150 IU)|Human Menopausal Gonadotropin is an urinary estract from menopausal women containing 150IU of FSH and 150 IU of LH-like activity (HCG)
1679462|NCT01623557|Biological|ChAd63-MVA CS|1 dose of ChAd63 CS 5 x 10^10 vp intramuscularly and 1 dose MVA CS 2 x 10^8 pfu intramuscularly 8 weeks later.
1679463|NCT01623557|Biological|ChAd63-MVA ME-TRAP|1 dose of ChAd63 ME-TRAP 5 x 10^10 vp intramuscularly and 1 dose MVA ME-TRAP 2 x 10^8 pfu intramuscularly 8 weeks later.
1679464|NCT01623557|Other|Controlled Human Malaria Infection Administered by Mosquito Bite|Approximately 3 weeks post MVA dosing
1679465|NCT01623531|Drug|Fibrinogen|Intravenous concentrated fibrinogen will be infused according to a hemostatic algorithm based on ROTEM (FIBTEM)
1679466|NCT01623518|Biological|ChAdOx1-NP+M1|"Dose escalation in a 3+3 study plan;
5 x10^8 vp, 5 x10^9 vp, 2.5 x10^10 vp, 5 x10^10 vp"
1679648|NCT01621971|Drug|intravenous milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled placebo (distilled water) and an intravenous bolus of milrinone (50 μg/kg) are administered
1679467|NCT01623505|Drug|Champix|"Participants receiving this treatment will start the medication on the day of the baseline assessment and set a target quit date within the 8 to 14 day period after baseline. Participants in this group will receive a 12-week supply of varenicline. Treatment will begin 2 weeks before the target quit date and continue for 10 weeks after the target quit date. Participants will be prescribed 0.5 mg once daily for 3 days, 0.5 mg twice daily for 4 days, and 1 mg twice daily for 11 weeks. Participants will be given the option of extending their treatment to a maximum of up to 24 weeks of varenicline.
All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
1679468|NCT01623505|Drug|Transdermal Nicoderm patch combined with gum or inhaler|"Participants receiving this treatment will set a quit date within 2 weeks after baseline assessment and apply the patch on that day. This group will follow the same regimen as the standard patch treatment, but is not limited to a fixed dosing strategy. Participants will be advised on the titration of patch (increase or decrease in dosage) to ensure elimination of withdrawal symptoms (maximum dosage of 35mg/day, maximum treatment of up to 22 weeks). Participants will be provided with either gum or inhaler to manage cravings.
All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation.
*Off-label dosage approved by Health Canada via No Objection letter."
1679469|NCT01623505|Drug|Transdermal Nicoderm patch|"Participants receiving this treatment group (standard treatment)will set a target quit date within the 2 weeks after baseline assessment and start to apply the patch on that day. This treatment will consist of a 10-week supply of nicotine patches. The initial dosage will be determined from the average number of cigarettes smoked each day as per the manufacturer's recommendation. Participants smoking ≥ 20 cigarettes per day will be prescribed 21 mg/24 hours for 6 weeks, 14 mg/24 hours for 2 weeks, and 7 mg/24 hours for 2 weeks. Participants smoking 11 - 20 cigarettes per day will be prescribed 14 mg/24 hours for 6 weeks, and 7 mg/24 hours for 4 weeks.
All participants will receive six 15-minute counselling sessions from a nurse-counsellor specializing in smoking cessation."
1679470|NCT01623492|Other|Subjects with diagnosis of Eisenmenger Syndrome|"Antibiotic recommendation for SBE prophylaxis and influenza vaccine
Contraception counseling, and recommendations regarding avoidance of pregnancy
Documentation and prescription of the specific medications:
Oxygen
Diuretic
ASA, Anticoagulant
CCB, BB, ACEI, ARB
Iron Supplementation
Allopurinol
PAH specific therapy"
1679471|NCT01623479|Drug|bimatoprost 0.03%|Subjects with hypotrichosis of the eyelashes using bimatoprost 0.03% (Latisse®) as prescribed by physician for at least 12 months
1679472|NCT01623466|Drug|levonorgestrel|transdermal contraceptive delivery system
1679473|NCT01623453|Biological|Autologous adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
1679474|NCT01623453|Biological|Autologous adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
1679477|NCT01623427|Procedure|Application of vacuum|The vacuum will be applied to the wound dressing of the umbilical port site using a 22 g needle on a 10 ml syringe passed percutaneously from the outside of the dressing into the gauze and the air around the gauze is evacuated.
1679478|NCT01623427|Procedure|No vacuum|Except for the vacuum, the wound dressing for the umbilical port site will be the same. No vacuum will be applied to the wound dressing of this group
1679479|NCT01623401|Drug|TR-701 FA|TR-701 FA 200 mg once daily
1679480|NCT01623388|Procedure|Oral glucose tolerance test for Phase I|Oral glucose tolerance test for Diabetic patients in phase I
1679481|NCT01623375|Drug|insulin degludec|A single dose of 0.4 U/kg body weight will be administered subcutaneously (s.c., under the skin).
1679482|NCT01623375|Drug|insulin degludec|A single dose of 0.04 U/kg body weight will be administered intravenously (i.v., into the vein).
1679483|NCT01623362|Other|Low-fluoride acidic dentifrice|550 ppm (mg/L) of sodium fluoride in pH 4,5; 12 months , 3 times a day.
1679484|NCT01623362|Other|conventional dentifrice|1100 ppm (mg/L) of sodium fluoride, pH 7 , 3 times a day for 12 months
1679485|NCT01623362|Other|neutral pH and low-fluoride dentifrice|500 ppm sodium fluoride, pH 7 , 3 times a day for 12 months
1679486|NCT01623349|Drug|BKM120 and Olaparib|Olaparib twice daily (starting dose 50 mg) and BKM120 once daily (starting dose 40 mg). Both drugs are given orally.
1679487|NCT01623349|Drug|BYL719 and Olaparib|Olaparib twice daily (starting dose 100 mg) and BYL719 once daily (starting dose 250 mg). Both drugs are given orally.
1679488|NCT01623336|Drug|BIP 48 (Peginterferon alfa 2b 48kDA)|BIP 48 (Peginterferon alfa 2b 48kDA)will be administered in a dose of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3, and for 48 to 72 weeks to genotype 1.
1679489|NCT01623336|Drug|Peginterferon alfa 2a 40kDA|Patients will receive Pegasys ® in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
1679490|NCT01623336|Drug|BIP 48 (Peginterferon alfa 2b 48kDA)|Patients will receive BIP 48 in a dosage of 180 micrograms, once a week, subcutaneous, for 24 to 48 weeks to genotypes 2 and 3 and for 48 to 72 weeks to genotype 1.
1679491|NCT01623323|Drug|Fluticasone Propionate|Fluticasone Propionate 400 μg
1679493|NCT01623284|Drug|C-11 PiB|One time intravenous administration of 740 megabecquerel (MBq) of [N-methyl-11C]2-(4'-methylaminophenyl)-6-hydroxybenzothiazole (PiB) (range 370 - 740 MBq).
1679494|NCT01623284|Drug|F-18 FDG|One time intravenous administration of 629 megabecquerel (MBq) of [18-F]-fluoro-deoxy-glucose (FDG) (range 555 - 740 MBq).
1679495|NCT01623271|Drug|Gabapentin|
1679523|NCT01622998|Drug|NicoDerm Patch|"Dosage: 21mg patch; 14mg patch; 7 mg patch Frequency: NRT patch application once per day Duration: 10 week treatment period
*Titration for experimental group (NRT+) based on smoking history, and option to increase dose if withdrawal symptoms are unmanageable."
1679524|NCT01622998|Drug|Nicorette Inhaler|Nicorette Inhaler: Box, 42 cartridges (4mg/cartridge) Dosage: Ad libitum Maximum dosage: 6-12 cartridges/day
1679496|NCT01623232|Biological|MAS-1 adjuvant and influenza HA antigen|"Vaccines will be administered IM in the deltoid muscle. HA antigen of each of three viral strains at doses of 1 micrograms, 3 micrograms, or 5 micrograms per viral strain adjuvanted with MAS-1 adjuvant and as nonadjuvanted standard dose TIV will be tested.
Treatment Group 1:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 1 micrograms HA of each of three viral strains in 0.08 mL sterile phosphate buffered saline (PBS).
Treatment Group 2:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 3 micrograms HA of each of three viral strains in 0.08 mL sterile PBS.
Treatment Group 3:each 0.3 mL dose will be administered as an emulsion containing 0.186 grams of MAS-1 oil vehicle and 5 micrograms HA of each of three viral strains in 0.08 mL sterile PBS."
1679497|NCT01623232|Biological|standard dose, inactivated trivalent influenza vaccine (TIV)|"Vaccine will be administered IM in the deltoid muscle. HA antigen of each of three viral strains as nonadjuvanted standard dose TIV will be tested.
4. Treatment Group 4:0.5 mL dose of licensed, unadjuvanted, standard dose influenza virus vaccine with 15 micrograms HA of each of 3 viral strains."
1679498|NCT01623219|Behavioral|Prolonged Exposure Therapy|Exposure therapy refers to several cognitive behavioral treatment programs that involve confronting feared but safe thoughts, images, objects, situations, or activities in order to reduce unrealistic fear and anxiety. Exposure therapy for PTSD involves prolonged, imaginal exposure to the patient's traumatic memory and in vivo (in real life) exposure to trauma reminders. Prolonged exposure (PE) is a specific exposure therapy program that consists of five components: (1) psychoeducation (2) training in controlled breathing, (3) prolonged imaginal exposure to the trauma memory conducted in therapy sessions and repeated as homework, (4) prolonged in vivo exposure implemented as homework, and (5) processing of the traumatic material to correct maladaptive cognitions.
1679499|NCT01623206|Drug|Desmopressin|"Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.
All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion."
1679500|NCT01623193|Other|All-blood cardioplegia|The treatment group will receive all-blood cardioplegia for myocardial protection during surgery
1679501|NCT01623193|Procedure|Standard cardioplegia|This arm will receive standard 4:1 cardioplegia for myocardial protection during surgery
1679502|NCT01623180|Device|Biofreedom™ Drug Coated Stent (DCS)|Biofreedom DCS implantation in high risk bleeding patients followed by 1 month DAPT
1679503|NCT01623180|Device|Gazelle™ Bare Metal Coronary Stent (BMS)|Gazelle BMS implantation in high risk bleeding patients followed by 1 month DAPT
1679507|NCT01623154|Other|Pranactin citric solution|All patients were required to drink the pranactic citric solution to diagnose H.pylori.
1679508|NCT01623141|Procedure|Pressure Pain measurement|The pressure pain thresholds were established using a manual pressure algometer. The investigated joints were the carpus, the metacarpophalangeal and the proximal interphalangeal joints
1679509|NCT01623128|Behavioral|Prenatal video|Participants are randomized to view either the intervention video or a sham video.
1679510|NCT01623115|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
1679511|NCT01623115|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
1679512|NCT01623115|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
1679513|NCT01623102|Drug|cisplatin and gemcitabine combination with Bevacizumab|Patients receive gemcitabine and cisplatin chemotherapy combined with Bevacizumab every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, cisplatin 75mg/m2 d1, Bevacizumab 7.5 mg / kg every 21 days.
1679514|NCT01623102|Drug|Gemcitabine combined with cisplatin chemotherapy|Patients receive gemcitabine combined with cisplatin chemotherapy every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Gemcitabine 1250mg/m2 d1, d8, + cisplatin 75mg/m2 d1.
1679515|NCT01623063|Procedure|Hysteroscopy|hysteroscopy with guided biopsies
1679516|NCT01623050|Device|SinuSys Dilation System|Sinuplasty
1679517|NCT01623037|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1679518|NCT01623024|Drug|Vitamin D|20.000 UI/week for 96 weeks
1679519|NCT01623024|Behavioral|Lifestyle counseling|Lifestyle counseling for 96 weeks
1679520|NCT01623011|Procedure|Arthroscopic Sub-acromial Decompression Surgery|The procedure involves insertion of the arthroscope into the glenohumeral joint where the joint surface is inspected along with the intra-articular portion of the long head of biceps and the joint surface of the rotator cuff tendons. The arthroscope is then inserted into the sub-acromial bursa which lies outside the rotator cuff tendons and beneath the acromion process of the scapula. In the bursa the acromion and superior surface of the rotator cuff are assessed to ensure the coracoacromial ligament and the AC joint remains intact. The projecting under surface of the distal part of the acromion is resected.
1679521|NCT01623011|Procedure|Shoulder Arthroscopy|This is the surgical comparison group. The procedure is performed under general anaesthetic. Patients will undergo a routine investigational arthroscopy. The operation will be performed in exactly the same manner as Group ASAD. The exception is they will not undergo the decompression (bone spur removal). Tissues will be visualised and the joint will be washed out. The time spent in theatre will be similar to that for Group ASAD. These measures provide the AO group with the characteristics necessary to provide a reasonable comparison and account for the placebo effects of surgery.
1679522|NCT01623011|Other|Active Monitoring with Specialist Reassessment|Patients will be advised that they will undergo active monitoring in the short term. They will attend a reassessment appointment 3 months after entering the study. Here, they will be asked to complete questionnaires related to their shoulder pain and undergo a clinical assessment for their shoulder. From an ethical standpoint it is emphasised that it is quite within normal practice to have a period of active monitoring.
1679525|NCT01622972|Drug|Polyethyleneglycol|Group 1 sachet's A and B made up to 1 litre with tap water once on day 1 and once on day 2. Group 2 2x sachet's A and B made up to 2 litres with tap water on day 1. Group 3 sachet's A and B made up to 1 litre with tap water once on day 1.
1679526|NCT01622959|Procedure|Acupuncture|"-Group Acupuncture: Receiving protocol of acupuncture. Acupuncture is performed by a trained certificied resident.
The protocols, which allow acupuncture points to be selected from a pool of pre-determined points for each condition, provide sufficient standardization to assist replication, yet are flexible enough to allow individualized treatments. These protocols also allow for additional points, such as 'ashi points', to be used at the discretion of the acupuncturist. The location of the points, angle of insertion and depth of insertion were sourced from a popular text 'A Manual of Acupuncture'.
-Group Morphine: Receiving 5mg of morphine followed by intravenous administration of 2,5 mg morphine each 5 min, until VAPS becomes <30%. Treatment failure is defined as VAPS>30 %, 30min after beginning of the protocol. In this case, analgesic treatment was administered according to the treating physician discretion."
1679527|NCT01622946|Drug|Tranexamic Acid|3g of tranexamic acid is topically applied after THA. The drugs is left for 15 minutes or 2 hours
1679528|NCT01622946|Drug|placebo|The patients will receive 3g topical TXA for 15 minutes or 2 hours after THA. 33% of the patients will receive 3g of TXA trough a suction drain for 15 minutes after total hip arthroplasty, then the suction drain is opened. 33% will receive the same amount of TXA but the suction drain will only be opened 2 hours after application. The other patients will receive a placebo in the same manner
1679529|NCT01622933|Biological|DC Vaccine + IFN|"Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection, or lower dose per sponsor's discretion.
IFN: 20 MU/m²/d (rounded to the nearest 1.0 million unit) administered IV x 5 consecutive days out of 7 (M-F) every week x 4 weeks."
1679530|NCT01622933|Biological|AdVTMM2/DC Vaccination|Vaccine: The dose target is 1x10e7 AdVTMM2/DC per intradermal injection.If cell counts are below the target, as few as 5x10e6 AdVTMM2/DC may be administered. However, at the discretion of the sponsor and/or the treating physician, a lower dose of DC that fulfills all of the other criteria for release may be administered on a case by case basis. If this occurs a dose exception form will be completed by the IMCPL, signed by the treating physician and filed in the subjects research records.
1679531|NCT01622920|Other|Ultrasound transducer|A hand-held ultrasound transducer will be placed on a central incisor and enamel thickness measurements recorded
1679532|NCT01622881|Drug|Normal saline|Normal saline 200mL : the infusion of 4mL/hr for post-operative 48 hours
1679533|NCT01622881|Drug|Nefopam|Nefopam 160mg (16 mL) mixed to normal saline 184 mL : the infusion of 4mL/hr for post-operative 48 hours
1679538|NCT01622855|Behavioral|PPRS|Video including psycho-education and modeling of adaptive behavioral coping strategies for use post-assault.
1679539|NCT01622829|Procedure|"Prescription for Activity and individual instructions"|"Structured education. Prescription for Activity. This contains an exercise programme which consists of a 30 minutes muscle strengthening exercises to be performed at home at least three times per week and an endurance sports, chosen by the patient, to be performed at least 2 times per week. Additional the physiotherapists advise them in being more active during their individual daily life ( e.g. using a bike for short distances, regular walking, abandon the lift/escalator)."
1679540|NCT01622829|Other|"Prescription for Activity, without instructions"|"Prescription with exercise programme. Prescription for activity. This contains an exercise program consisting of 30 minutes of muscle strengthening exercises to be performed at home at least three times per week, the patient also needs to perform in an endurance sport at least two times per week."
1679541|NCT01622829|Other|usual physiotherapy|physiotherapy, treatment as usual
1679542|NCT01622803|Procedure|parallel stent|bilateral parallel stent insertion (right and left side)
1679543|NCT01622803|Device|Y-stent (BONASTENT M-Hilar)|Bilateral Y-stent insertion (stent in stent type)
1679544|NCT01622790|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
1679545|NCT01622790|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
1679546|NCT01622790|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
1679547|NCT01622777|Drug|Rosuvastatin|20 mg daily of oral rosuvastatin for 12 weeks
1679548|NCT01622777|Drug|Placebo|100 mg of oral placebo with identical appearance, form and size than rosuvastatin, one tablet daily for 12 weeks
1679549|NCT01622764|Radiation|Molecular imaging with 89Zr-RO5323441|Bevacizumab at a dose of 10 mg/kg body weight i.v. in 90 min on day 1 will be given every 2 weeks in cycles of 6 weeks, until documented disease progression, unacceptable toxicity, patient refusal or patient's best interest. 89Zr-RO5323441 will be administered i.v. at a tracer dose of 5 mg (37 MBq) on day -3 and on day 11 of cycle 1 of bevacizumab treatment. Four PET scans will be performed (2 brain only PET scans and 2 whole body PET scans). Brain only PET scans will be performed 2 hours after each 89Zr-RO5323441 administration on day -3 and day 11. Whole body PET scans will be performed 4 days after each 89Zr-RO5323441 administration (before dosing with bevacizumab on day 1 and day 15).
1679550|NCT01622725|Procedure|Placing the resorbable mesh|Surgery for primary and secondary ventral hernia repair with placing of resorbable mesh.
1679551|NCT01622725|Procedure|Non-resorbable synthetic mesh.|Surgery for primary and secondary ventral hernia repair with placing of non-resorbable synthetic mesh.
1679552|NCT01622712|Device|Rebound HRD Mesh|Patients with unilateral inguinal hernia receive a nitinol containing large pore polypropylene mesh.
1679553|NCT01622699|Device|Transcutaneous Bilirubinometer|If a baby is jaundiced, the ward-nurse will perform a transcutaneous bilirubin measurement. It takes about 5 seconds to perform the measurement at the forehead or sternum of the baby. The device is a validated measurement-tool, which provides us with an estimated serum bilirubin-concentration. This is not an invasive procedure: A light-reflection is used to measure transcutaneous bilirubin.
1729422|NCT00027937|Drug|melphalan|
1679554|NCT01622699|Other|visual assessment of neonatal jaundice|To detect newborns with jaundice (who will possibly meet the criteria for phototherapy) there have been international guidelines formulated by the American Academy of Pediatrics. The standard of care at the neonatal- and maternity ward of our hospital to detect those newborns is visual assessment according to these guidelines.
1679555|NCT01622686|Behavioral|PictureRx medication label|Reformatted medication labels that adhere to current best practices for label design and also include illustrations
1679556|NCT01622673|Drug|Raltegravir|"Raltegravir 400 mg oral tablet taken with 240 mL water every 12 hours
Throughout the study, participants will continue to take raltegravir along with their other HIV medications. On the day of co-dosing and intensive pharmacokinetic (PK) sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
1679557|NCT01622673|Drug|TUMS® Ultra Strength|"3 tablets TUMS® Ultra Strength (US) 1000 mg
Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
1679558|NCT01622673|Drug|MINTOX® Maximum Strength|"20 mL MINTOX® Maximum Strength (MS)
Throughout the study, participants will continue to take raltegravir every 12 hours along with their other HIV medications. There will be a minimum of 2 days washout between treatment periods. On the day of co-dosing and intensive PK sampling, raltegravir will be dosed in the morning in a fasted state in all periods."
1679559|NCT01622660|Drug|Gemcitabine|Patients will receive gemcitabine 1200 mg/m2 intravenously on day 1 and day 8 and. Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
1679560|NCT01622660|Drug|Pazopanib|pazopanib 800 mg orally daily day 1 through day 21 (1 cycle = 21 days) Patients will receive 6 cycles of combination therapy (gemcitabine and pazopanib) unless disease progression or unacceptable toxicity occurs. Patients that achieve stable disease, a partial response, or a complete response after completion of 6 cycles, and who are not candidates for consolidation surgery, will be eligible to continue pazopanib monotherapy at the same dose and schedule until disease progression for a maximum of 18 additional cycles.
1679561|NCT01622647|Other|Nasal Continuous Positive Airway Pressure (NCPAP)|Subjects will receive NCPAP
1679562|NCT01622634|Behavioral|Sprint Interval Exercise|Participants will undergo sprint interval training on a cycle ergometer 3 times weekly for 6 weeks. Each training session begins with a 5-minute active warm-up. The warm-up is followed by 4-7 bouts of 30 seconds of all-out sprints and 4 minutes of active recovery.
1679563|NCT01622634|Other|Higher PRO Diet|Participants in the PRO and PRO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the high protein diet.
1679564|NCT01622634|Other|Higher CARB Diet|Participants in the CHO and CHO+EX groups will meet weekly with a diet specialist on staff to monitor their intake and compliance with the higher carbohydrate diet.
1679565|NCT01622621|Procedure|Sublobar Resection|Undergo surgery which removes a sublobar resection of the lung
1679566|NCT01622621|Radiation|Stereotactic Body Radiotherapy (SBRT)|54 Gy in 3 fractions
1679567|NCT01622608|Behavioral|Vaccine Information Kiosk|The study kiosk will remain in the waiting room of participating practices for the duration of the study. Interested parents will self-direct to the kiosk in the clinic waiting room either before or after their child's appointment. Following consent, parents will complete a survey that assesses socio-demographics, baseline vaccination intention, and vaccine-specific beliefs, attitudes and experiences. The kiosk will generate tailored educational messages about adolescent vaccines. Parents can utilize the kiosk as many times as they wish during the intervention period.
1679574|NCT01622543|Drug|Folfox plus Bevacizumab and reolysin|FOLFOX6/bevacizumab given every 14 days plus reolysin days 1-5 on cycles 1, 2, 4, 6, 8 and alternate cycles thereafter
1679575|NCT01622543|Drug|Folfox plus Bevacizumab|FOLFOX6/bevacizumab given every 14 days.
1679576|NCT01622504|Drug|MVP005|2 mg single dose administered intranasally
1679577|NCT01622504|Drug|MVP005|4 mg single dose administered intranasally
1679578|NCT01622504|Drug|Naloxone hydrochloride solution for injection with mucosal atomization device|2 mg single dose administered intranasally
1679579|NCT01622478|Procedure|Sentinel lymph node biopsy|Sentinel lymph node biopsy after neoadjuvant chemotherapy for the patients with clinically positive-nodes at presentation
1679580|NCT01622478|Drug|Neoadjuvant chemotherapy|Neoadjuvant chemotherapy for breast cancer patients with clinically positive-node at initial diagnosis
1679581|NCT01622478|Procedure|complete axillary lymph node dissection|Complete axillary lymph node dissection after sentinel node biopsy for estimation of false-negative rate of sentinel node biopsy
1679582|NCT01622478|Procedure|positron emission tomography and ultrasonogram|Routine evaluation of axillary nodal status using 18-fluorodeoxyglucose positron emission tomography and ultrasonogram before and after chemotherapy
1679583|NCT01622465|Behavioral|Ergometer cycling|Patients will participate of the exercises program with ergometer cycling and conventional exercises. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
1679584|NCT01622465|Behavioral|Conventional exercises|Patients will participate only of the conventional exercises program. The program will initiate after two weeks of the postoperative and will continue until three months of the postoperative
1679622|NCT01622218|Behavioral|Medical Clown|Presence of clowns on child's postoperative pain levels, anxiety levels of the child and the accompanying parent and the effect of the intervention on the total consumption of analgesics and on the post- surgery inflammatory markers
1729423|NCT00027937|Drug|paclitaxel|
1679585|NCT01622439|Drug|Valproate|Valproate is given in escalating doses to establish maximum tolerable dose when given together with standard treatment in patients with diffuse large B-cell lymphoma; this is the phase I part of the study. When maximum tolerable dose is established, this dose will be given to remaining patients in the phase II part of the study.
1679586|NCT01622439|Drug|Rituximab|Vill be given intravenously, 375 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
1679587|NCT01622439|Drug|Cyclophosphamide|Vill be given intravenously, 750 mg/m2, every second or third week depending on cycle length (14 or 21 days) for a total of 6 cycles.
1679588|NCT01622439|Drug|Doxorubicin|Vill be given intravenously, 50 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
1679589|NCT01622439|Drug|Vincristine|Vill be given intravenously, 1.2 mg/m2, every second or third week depending on cycle length (14 or 21 days), for a total of 6 cycles.
1679590|NCT01622439|Drug|Prednisone|Vill be given orally, 50 mg/m2, day 1-5 every cycle, for a total of 6 cycles.
1679591|NCT01622426|Dietary Supplement|tolerance to a new aminoacid based formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
1679592|NCT01622426|Dietary Supplement|Amino acid formula|Every 20 minutes, successive doses (0.1, 0.3, 1, 3, 10, 30 and 100 mL) of placebo (the commercially available Aaf Neocate, Nutricia, Milan, Italy) or of the study formula (Sineall, Humana, Milan, Italy) were administered.
1679593|NCT01622413|Procedure|joimax TESSYS|Transforaminal Endoscopic Surgery System
1679594|NCT01622413|Procedure|Microdiscectomy|Standard procedure for disc surgery
1679595|NCT01622400|Other|Therapeutic education HTA Vasc|The intervention program takes place in 3 phases. First, the education team realizes an individual educational diagnosis to define the objectives of the intervention according to each patient's needs. Secondly, patients assist to 3 to 5 group sessions lasting 2 hours with a dedicated nurse focusing on medical therapy explanation and blood pressure self measurement education - and with a dedicated nutritionist focusing on stress management and nutrition program. Patients can also have individual consultations with the dedicated nutritionist. Finally, an individual assessment permits to evaluate the benefits of the program for each patient and to define new objectives.
1679596|NCT01622387|Procedure|Coronary artery bypass (CABG) surgery using a radial arterial conduit|Use of radial artery as a bypass conduit/graft to the left circumflex coronary artery region of the heart in CABG surgery
1679597|NCT01622387|Procedure|Coronary artery bypass surgery using a long saphenous vein conduit|Use of long saphenous vein as a graft/conduit vessel to the left circumflex coronary artery region of the heart in CABG surgery
1679598|NCT01622374|Behavioral|Music|Ten minutes of music or silence were applied prior to dental procedures
1679599|NCT01622361|Drug|Adriamycin+Cyclophosphamide>Docetaxel|"Adriamycin 60mg/m2 + Cyclophosphamide 600mg/m2
Route: by slow intravenous bolus
Schedule: every 3weeks for 4 cycle
Docetaxel 75mg/m2
Route: intravenous as per local practice
Schedule: every 3weeks for 4 cycle"
1679600|NCT01622361|Drug|GnRHa with Tamoxifen|"Goserelin(GnRHa) 3.6mg
Route: subcutaneously under the abdominal skin
Schedule: every 4weeks for 6cycles (period of 34 days between 2 administrations must not be exceeded)
Tamoxifen 20mg/day
Route: Oral
Schedule: everyday"
1955248|NCT03250442|Device|PrevenaTM Device|The PrevenaTM Incision Management System covers and protects the incision from external contamination, while negative pressure removes fluid and infectious material from the surgical incision.
1955249|NCT03250442|Other|Standard Dry Dressing|These are customary dry dressings.
1679604|NCT01622335|Drug|Nitrous oxide|General anesthesia with Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
1679605|NCT01622335|Other|General anesthesia with oxygen|General anesthesia with(Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
1679606|NCT01622322|Drug|Nitrous Oxide|Nitrous Oxide, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
1679607|NCT01622322|Other|oxygen|Subjects will receive General anesthesia: (Air, 70%, O2 30%) 1-5 L, Sevoflurane 1-2%, ETCO2: 32-35 mmHg.
1679608|NCT01622309|Dietary Supplement|eggplant meal|13 g meal of eggplant/day, being 6,5 g in breakfast and 6,5g in dinner
1679609|NCT01622309|Other|cassava meal|13g cassava meal/day,being 6,5 g in breakfast and 6,5g in dinner
1679610|NCT01622296|Drug|Sodium bicarbonate|8.4% neutralizing solution
1679611|NCT01622296|Drug|Lidocaine|2% lidocaine with 1:100,000 ppm epinephrine
1679612|NCT01622283|Drug|Levocetirizine|Levocetirizine
1679613|NCT01622283|Drug|Cetirizine|Cetirizine
1679614|NCT01622270|Other|Indirect calorimetry, body composition , blood tests,3 days food records,Crohns disease activity index|Indirect calorimetry test by a indirect calorimeter (OHMEDA) body composition by a DEXA machine blood tests, 3 days food records, Crohns disease activity index
1679615|NCT01622257|Device|Cavitation US|The areas with localized fat are treated 2 times per week for 3 months using Aesthetic cavitation via ultrasonic cavitation machine (Cavi SMART, South Korea, supplied with one piece cavitation probe of 40 KHz, 3-6 watt(W)/cm^2 adjustable, 60W with 20cm^2 active surface).
1679616|NCT01622257|Drug|Metformin|Metformin hydrochloride (Glucophage 500 mg/tablet, Bristol-Myers Squibb, New York, USA). Medication is initiated in a step-up fashion every 5 days, from one tablet per day to three. This dose is maintained as tolerated throughout the 3 months of the study.
1679617|NCT01622257|Other|Cavitation US + Metformin|Combination of both Cavitation US + Metformin. the treatment duration lasts 3 months
1679618|NCT01622244|Other|Co-ordinated Access to Care from Hospital Emergency Departments|brief, intensive case management for frequent users of hospital Emergency Departments who have mental health and/or addictions problems
1679619|NCT01622244|Other|Coordinated Access to Care from Hospital Emergency Departments|Participants will receive brief, intensive case management to connect them to health and social services and supports in the community
1679620|NCT01622244|Behavioral|Counseling and Resource Education|Participants will receive usual care as well as an educational session and resource guide outlining community-based services
1679621|NCT01622231|Drug|Fluticasone furoate|55 mcg/day, intranasal, 12 weeks
1729424|NCT00027937|Drug|thiotepa|
1679623|NCT01622205|Other|Very early supported discharge (VESD)|A rehabilitation team made up of physiotherapists, occupational therapists and a stroke nurse from the stroke care unit continues the rehabilitation in the patient's home. The intervention has a person-centered approach which is based on who the person is: their context, their history, their next of kin, their individual strengths and weaknesses (28). Goal setting using questions as in the Canadian Occupational Performance Measure (29) takes part before the discharge. Examples of goals can be: to be able to go to the local store to buy milk, to be able to hang the laundry or to be able to travel on the tram to the daughter or how to manage the bills.
1679624|NCT01622205|Other|Ordinary rehabilitation|Ordinary rehabilitation
1679625|NCT01622192|Device|Florida Probe automated probe|Comparisons between the reproducibility of readings taken by an automated probe and a manual probe
1955250|NCT03249584|Device|OsteoCool™ RF Ablation|The OsteoCool™ RF Ablation system is indicated in the United States (US), Europe (EUR) and Canada (CAN) for patients with metastatic malignant lesions in a vertebral body, painful metastatic lesions involving bone (in the US, patients with metastatic lesions involving the bone must have failed or were not candidates for standard therapy) and, in EUR and CAN only, benign bone tumors such as osteoid osteomas.
1679628|NCT01622166|Behavioral|psychodynamic art therapy|2 sessions à 1.5 hrs /week, intervention duration 6 weeks
1679629|NCT01622153|Procedure|Formocresol application after pulpotomy preparation|1:5 Buckley's Formocresol dilution applied for 5 minutes or until hemostasis achieved
1679630|NCT01622153|Procedure|GENTLEray 980 Soft Tissue diode laser|Application to pulp chamber until hemostasis achieved
1679631|NCT01622127|Device|Parietex ProGrip™|ProGrip™ mesh is a lightweight (40g/m2) monofilament polypropylene or polyester mesh with resorbable polylactic acid (PLA) micro-grips, which provide self-gripping properties during the first few months after implantation.
1679632|NCT01622114|Other|Evaluation of the Association between the Menstrual Cycle and Weight Loss in Healthy, Overweight Premenopausal Women|2-arm parallel 6 month study with the obejective to examine the impact of the menstrual cycle on weight loss attempts in healthy overweight premenopausal women randomized to two different weight management programs. The women may not use hormonal contraceptive agents other than an IUD.
1679633|NCT01622101|Dietary Supplement|Thermogenic properties of Zantrex-3®|The present study was designed as a 2-arm randomised, placebo-controlled, double-blind crossover study. Each treatment was separated by >7 d washout period. Both treatments were administered as tablets. The Zantrex-3® compound contained yerba maté, caffeine, guarana, damiana, green tea, kola nut, schizonepeta, piper nigrum, ginseng, maca root, and cocoa nut. The content of xantines (caffeine and caffeine-like stimulants) accounted for 365 mg per serving (2 capsules) or 1095 mg (6 capsules) if given as a daily dose. The placebo supplement contained rice flower and could not be distinguished from the Zantrex-3® compound with regard to colour, taste, smell or ap-pearance.
1679634|NCT01622088|Drug|Dexpramipexole|Oral tablet 150 mg given twice daily up to 36 months
1679635|NCT01622075|Device|SeQuent® Please|SeQuent® Please with a length of 10mm,15mm,17mm,20mm and 26mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
1679636|NCT01622075|Device|Taxus Liberte|Taxus Liberte with a length of 8mm,12mm,16mm,20mm and 24mm and diameter of 2.5 mm, 2.75 mm, 3.0mm, 3.5mm and 4.0mm are to be used in the trial
1679637|NCT01622062|Biological|Purified Vero cell Rabies Vaccine (PVRV)|0.1 mL, 4 site 'one week' (4-4-4-0-0) Intradermal
1679638|NCT01622062|Biological|PVRV + purified Equine Rabies Immunoglobulin (pERIG)|0.1 mL of vaccine, 4 site 'one week' (4-4-4-0-0) administered intradermally + RIG (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
1679639|NCT01622062|Biological|PVRV + purified Equine Rabies Immunoglobulin (pERIG)|0.1 mL of vaccine, 4 site 'one week' (4-4-4-0-0) administered intradermally + RIG (volume to be calculated according to the patient' body weight) infiltrated into and around wound(s)
1679640|NCT01622049|Device|Selective Laser Photocoagulation of Communicating Vessels|Patients will be admitted to Tampa General Hospital. Laboratory tests and anesthesia assessments will be completed. Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. Surgery will be performed preferably under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. Surgery will be performed with standard operative fetoscopy equipment and techniques. A trocar will be introduced in the amniotic cavity of the recipient. An amniotic fluid sample will be obtained for microbiological studies, and genetic analysis for clinical care only. The amniotic fluid will be discarded after analysis. The communicating vessels will be located endoscopically and will be lasered with YAG laser energy. The procedure will be monitored both endoscopically and sonographically. The presence of fetal heart activity will be noted. An amniodrainage of the larger sac may be performed
1679641|NCT01622023|Procedure|intra-uterine insemination|Artificial insemination is the process by which sperm is placed into the reproductive tract of a female for the purpose of impregnating the female by using means other than sexual intercourse or natural insemination.
1679645|NCT01621997|Behavioral|operation inspection|"Retraining via operation inspection means that nurses check if patients can follow the taught skill during the procedure of bag exchange and correct wrong steps in one-to-one way every 2 months.
Retraining via verbal education means that nurses remind patients of key points of bag exchange through interactive quiz derived from above checklist every 2 months till 24 months"
1679646|NCT01621984|Other|Therapeutic Riding/ Hippotherapy Intervention|The Therapeutic Riding exercise intervention consisted exercises for warm up,transitions on the horseback, stretching exercises and exercises to strengthen muscles of trunk and four limps, games with balls and rings and walking of the horse to change directions as diagonal / lateral changes, cycles with open and closed eyes.
1679647|NCT01621971|Drug|inhaled milrinone|After performing the sternotomy and achieving stable hemodynamics, but before the initiation of CPB, inhaled milirinone and intravenous placebo (0.9% normal saline 0.05 ml/kg) are administered
1679689|NCT01621568|Drug|Sunitinib|50mg/day for 4 weeks daily, by mouth with 2 weeks off (6 week cycle)
1679649|NCT01621958|Behavioral|Repeated perturbation training|One session consisting of 24 slips total interspersed with 16 nonslip trials (1 block of 8 slips, 3 non-slips, 2nd block of 8 slips, 3 non-slips, a mixed block consisting of 8 slips and 10 non-slips). Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
1679650|NCT01621958|Behavioral|Minimal perturbation training|One session consisting of a single slip exposure. Retest consisting of one slip exposure at either 6 months, 9 months or 12 months.
1679651|NCT01621945|Biological|MenBvac|Blood test
1679652|NCT01621932|Procedure|Direct anterior approach with capsulectomy|Direct anterior approach with capsulectomy
1679653|NCT01621932|Procedure|Direct anterior approach without capsulectomy|Direct anterior approach without capsulectomy
1679654|NCT01621906|Device|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.
Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.
Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
1679655|NCT01621906|Device|18F-FLT-PET Imaging|"All patients will be imaged using FLT-PET scans at baseline (within 4 weeks of initiation of WBRT), 7-10 days after completion of WBRT and then 10-12 weeks after WBRT.
Patients will also be evaluated with MRI imaging at baseline and then 10-12 weeks after WBRT.
Patients will be followed with MRI every 3 months (+/- 7 days) for the first year and then every 6 months (+/- 7 days) thereafter which is the standard of care."
1679656|NCT01621893|Procedure|Subchondroplasty|
1679657|NCT01621880|Drug|bevacizumab|Patients receive bevacizumab IV over 30-90 minutes on day1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
1679658|NCT01621880|Drug|Methylprednisolone|Patients receive intravenous steroid over 5 consecutive days. The dosage was decreased gradually. The regimen repeats every other month for up to 4 courses.
1679659|NCT01621867|Drug|pGM169/GL67A|5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
1679660|NCT01621867|Drug|Placebo|5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
1679661|NCT01621854|Drug|NUC-1031|Cohort 1, Schedule A, NUC-1031 I.V. 1000mg/m2, Days 1, 8, & 15 every 28 days Cohort 1, Schedule B, NUC-1031 I.V. 500mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days Cohort 2, Schedule A, NUC-1031 I.V. 2000mg/m2, Days 1, 8, & 15 every 28 days Cohort 2, Schedule B, NUC-1031 I.V. 1000mg/m2, Days 1 & 5, 8 & 12, 15 &19 every 28 days
1679662|NCT01621828|Other|video|a video, showing the patient pathway to and from the Operating Theatre, about the operating room experience and environment.
1679663|NCT01621828|Other|leaflet|a written leaflet, about the operating room experience and environment.
1679664|NCT01621815|Behavioral|Video Game|Playing various video games: RPG, Race, FPS, Strategy
1679669|NCT01621789|Other|dye of lutein, zeaxanthin, trypan blue|dye composed of lutein, zeaxanthin, trypan blue
1679670|NCT01621776|Drug|Apidra|Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
1679671|NCT01621776|Drug|Humalog|Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.
1679672|NCT01621776|Drug|Novolog|Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
1679673|NCT01621763|Drug|Clopidogrel|Clopidogrel Tablets 300 mg
1679674|NCT01621750|Drug|Clopidogrel|Clopidogrel Tablets 300 mg
1679675|NCT01621737|Drug|Oxytocin|42 IU BID for six weeks
1679676|NCT01621737|Drug|Oxytocin|84 IU BID for six weeks
1679677|NCT01621737|Drug|Placebo|Vehicle placebo
1679678|NCT01621724|Genetic|WT1 TCR-transduced T cells|"Two patient cohorts:
Cohort 1 (up to 6 patients) = ≤ 2 x 107/kg WT1 TCR-transduced T cells
Cohort 2 (12 patients)= ≤ 108/kg WT1 TCR-transduced T cells"
1679679|NCT01621711|Behavioral|Linkage patient activation intervention|"Usual Care plus Linkage encompassed Usual Care with the exception that the six 45-min Linkage patient activation education groups replaced the six 45-min Usual Care medical education groups, plus a linkage phone call (and/or a facilitated email) with the patient, clinician, and Primary Care physician.
The patient activation intervention components -- 1) six 45-min Linkage sessions on activation regarding overall health behaviors and 2) a linkage phone call (and/or a facilitated email) with the patient, clinician, and PC physician -- were delivered by a clinical psychologist."
1679680|NCT01621698|Procedure|Early paravertebral block|In this group the local anaesthetic will be injected at the start of surgery soon after incision and normal saline at the end. These will be double blinded.
1679681|NCT01621698|Procedure|Late Paravertebral block.|In the late group local anaesthetic will be injected at close of surgery with normal saline at the start. This will be double blinded.
1679682|NCT01621685|Biological|biological/vaccine|Inhalation studies will immediately be terminated after a significant adverse response to a particular capsaicin dose and no further testing will occur.
1679683|NCT01621672|Drug|Revlimid|10 mg/day in the morning same time each day
1679684|NCT01621659|Behavioral|Multidisciplinary team intervention|Intervention arm receives regular assessments and treatments from cardiology team, clinical nutrition, pharmacist, exercise physiologist and physiotherapist
1679685|NCT01621646|Other|eggs or egg whites|2 eggs/day or 4 oz egg whites/day for 6 months
1679686|NCT01621633|Drug|LCZ696|
1679687|NCT01621620|Drug|Yohimbine|
1730034|NCT00034047|Procedure|Acupuncture|
1679691|NCT01621503|Device|NT-530P|intraocular pressure and central corneal thickness measurement
1679694|NCT01621477|Drug|clofarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
1679695|NCT01621477|Drug|cytarabine|Given on Day -9 and Day -8 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
1679696|NCT01621477|Drug|busulfan|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent
1679697|NCT01621477|Drug|Plerixafor|Given on Day -7 and Day -6 (Day 0 is first stem cell infusion). Drug class: Hematopoietic Stem Cell Mobilizer
1679698|NCT01621477|Drug|cyclophosphamide|Given on Day -5 and Day +4 (Day 0 is first stem cell infusion). Drug class: antineoplastic agent; immunosuppressive agent.
1679699|NCT01621477|Drug|antithymocyte globulin (rabbit)|Given on Day -4, Day -3, Day -2, and Day -1 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
1679700|NCT01621477|Biological|stem cells|Patients undergo T cell replete Hematopoietic stem cell infusion on Day 0 and Day +1. Patients undergo natural killer (NK) cell transplantation on day +6 (Day 0 is first stem cell infusion).
1679701|NCT01621477|Drug|Tacrolimus|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
1679702|NCT01621477|Drug|mycophenolate mofetil|Given on Day +11 (Day 0 is first stem cell infusion). Drug class: immunosuppressive agent.
1679703|NCT01621464|Device|Pacemaker with Closed Loop Stimulation (CLS sensor)|Crossover: 1 year at control group and 1 year at CLS group (randomized which group goes first)
1679704|NCT01621451|Drug|aspirin and/or clopidogrel|Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD. In immediate group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer.
1679705|NCT01621451|Drug|aspirin and/or clopidogrel|"Patients who have taken aspirin and/or clopidogrel and are found to have early gastric cancer or gastric premalignant lesions including adenoma and dysplasia by upper endoscopy will be stopped aspirin and/or clopidogrel for 7 days before EMR/ESD.
In 2 weeks group, the patient will receive oral proton pump inhibitor (pantoprazole 40mg per day) for 4 weeks after EMR/ESD to treat their post-EMR/ESD ulcer."
1679706|NCT01621425|Other|Lean body mass|Lean Body mass (DEXA scan and Bioelectrical Impedance Assessments) within one week prior to the first docetaxel dose
1679707|NCT01621425|Other|Total body weight|Total Body weight (TBW) (scale) within one week prior to the first docetaxel dose
1679708|NCT01621425|Other|bloodsampling|Blood samples will be taken during the first docetaxel administration of the first cycle, just before docetaxel infusion (t=0 min.), 30 min after start of infusion (t=30 min.), just prior to end of infusion (t=55 min.) and between 3 to 6 hours post start infusion following a limited sampling model
1679709|NCT01621399|Drug|Product 55394|Product 55394 vaginal gel in a prefilled applicator.
1679710|NCT01621399|Drug|Placebo Vehicle (non-treatment)|The vehicle vaginal gel in an applicator (placebo).
1679711|NCT01621386|Drug|Montelukast|Administered orally as a single daily 10 mg dose for 2 weeks
1679712|NCT01621386|Drug|Prednisone|Administered orally as a single daily 20 mg dose for 2 weeks
1679713|NCT01621373|Drug|propofol administration|Single IV bolus propofol start at 1 mg/kg. Dose will be adapted based on predefined scoring systems with +/-0.5 mg/kg.
1679714|NCT01621360|Procedure|Arthroscopic hip surgery|Hip arthroscopy
1679715|NCT01621360|Other|Physical therapy|Physical therapy aimed at strengthening and stabilization of the hip and appropriate analgesic and anti-inflammatory medication.
1679716|NCT01621334|Behavioral|Motivational Enhancement Therapy|Two personal feedback sessions with counselor using motivational interviewing strategies.
1679717|NCT01621334|Behavioral|Educational information|Educational brochure about legal, health and behavioral effects of intimate partner violence, substance abuse, and HIV risky behaviors
1679718|NCT01621321|Drug|Prednisolone|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 4 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
1679719|NCT01621321|Drug|Voriconazole|Voriconazole 200 mg BD for 6 months. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) 1 puff BD and as needed as per the SMART approach for control of asthma
1679720|NCT01621308|Other|Mode of insulin administration|There are no interventions in this observational study. Both treatment groups continue the mode of therapy the patient had before the start of the present study: continuous intraperitoneal insulin infusion with an implantable pump (MIP2007D) or subcutaneous insulin administration with multiple daily injections or continuous subcutaneous insulin infusion.
1679721|NCT01621282|Other|Education|A 6-month interactive course on critical appraisal
1679722|NCT01621282|Other|Conventional|Conventional method/no intervention
1679723|NCT01621269|Drug|Fingolimod|
1679724|NCT01621256|Drug|Ancrod|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
1679725|NCT01621256|Drug|Saline solution|Day 1: Intravenous infusion; Days 2, 4, and 6: Subcutaneous injections
1679726|NCT01621243|Drug|nab-paclitaxel|nab-paclitaxel dosed on Day 1, Day 8, Day 15 of each 28-day cycle
1679727|NCT01621243|Drug|gemcitabine|gemcitabine will be dosed on Day 1, Day 8, Day 15 of each 28-day cycle
1679728|NCT01621243|Drug|placebo|Placebo will be dosed daily
1679729|NCT01621243|Drug|Necuparanib|Necuparanib will be dosed daily
1730035|NCT00034047|Drug|Chinese Products|
1955261|NCT03244319|Drug|Edoxaban|Patients who are randomly assigned to edoxaban group will be received 60mg qd or 30mg qd (creatinine clearance 30-49ml/min, body weight <60kg or concomitant use of certain P-glycoprotein inhibitors).
1679732|NCT01621217|Drug|Cetuximab|Will be given weekly intravenously during study treatment.
1679733|NCT01621217|Drug|Mitomycin C|Will be given intravenously twice together with 5-Fluoruracil during study treatment.
1679734|NCT01621217|Drug|5-Fluoruracil|Will be given intravenously twice together with Mitomycin C during study treatment
1679735|NCT01621217|Radiation|Radiotherapy|Radiotherapy, once daily with a total dose of 54 Gy, given in 27 fractions.
1679736|NCT01621204|Drug|Eltrombopag|Participants are started on 50mg daily oral pill (or 25mg daily for patients of East Asian descent) as of 21 days before surgery. Dose may be adjusted based on platelet count monitoring (minimum 25mg; maximum 75mg).
1679737|NCT01621204|Drug|IVIG infusion|IVIG infusion (2 g/kg, over 2 days) given 7 (+/-2) days prior to surgery and additional infusions given as needed until 7 days after surgical hemostasis is achieved.
1679738|NCT01621191|Drug|Duloxetine|Administered Orally
1679739|NCT01621178|Drug|Dulaglutide|Administered SQ
1679740|NCT01621178|Drug|Insulin glargine|Administered SQ
1679741|NCT01621178|Drug|Insulin lispro|Administered SQ
1679742|NCT01621165|Drug|Addition of prazosin to usual care (add-on study)|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
1679743|NCT01621165|Drug|Placebo|Prazosin and placebo will be gradually titrated over 10 days to a final dose of 10 mg/day, given in divided doses (three times a day). During this time subjects will be monitored for adverse effects to prazosin and manic symptoms will be monitored. Vital signs will be monitored three times a day throughout the study. If a subject receiving prazosin or placebo develops distressing adverse effects, the dose will be decreased to the next lower dose.If there is a greater than 15 mg mercury postural fall in systolic bBP, dosing will be held at the previous day's dose.Subjects who do not tolerate prazosin or placebo will be discharged from the study.
1679744|NCT01621152|Other|Conventional management arm|Based on KDIGO guidelines and as per primary physician in the ICU
1679745|NCT01621152|Other|AKI sniffer instigated AKI management|After identification of patients with AKI by the sniffer, primary physicians will be notified about the development of the syndrome and will be given a copy of the KDIGO guidelines for management of AKI.
1679746|NCT01621139|Procedure|Acupuncture|Patients on mechanical ventilation greater than two days will be randomly assigned to real acupuncture group or sham acupuncture group
1679747|NCT01621126|Device|Intra-operative neuromonitoring (XLTEK/NATUS EP Protektor)|Device: Intra-operative neuromonitoring A XLTEK/NATUS EP Protektor machine (at MGH) or a Cadwell Cascade Elite neuromonitoring machine (at BWH), both FDA approved for intra-operative neuromonitoring, will deliver the electrical stimulus applied transcranially to stimulate the motor cortex, while motor evoked responses will be recorded from different myotomes from both upper limbs. Also the same equipment will deliver electrical stimulus to stimulate peripherally the median and ulnar nerves at the wrists, with recording of the thalamocortical potentials in the scalp channels.
1679748|NCT01621113|Drug|Dalfampridine|Dalfampridine 10 mg tablet, twice-daily, for 10 weeks
1679749|NCT01621113|Drug|Placebo|Placebo tablet, twice daily, for 10 weeks.
1679750|NCT01621100|Drug|OROS hydromorphone|Type= exact number, unit= mg, number= 4, form= tablet, route= oral, administered from 1st evaluation day (Day 1) to 2nd evaluation day (Day 15±2). Dosage adjustment: If NRS (Numeric Rating Scale) =4 or more then dose can be increased by 4mg until the average pain intensity for the past 24 hours is adjusted to lower than NRS 3. For the treatment of breakthrough pain, if necessary the one-time administration dose of quick-effect OROS Hydromorphone shall be 2mg up to the daily dosage of the study medicine, 12mg.
1679751|NCT01621087|Other|Safflower oil|Liquid safflower oil and safflower oil polyunsaturated margarine
1679752|NCT01621074|Dietary Supplement|Sodium bicarbonate|Ergogenic effect
1679753|NCT01621074|Dietary Supplement|Placebo|Placebo effect
1679754|NCT01621022|Drug|bupropion + nicotine gum|150 mg bupropion twice daily plus 4 mg nicotine gum as needed (up to 12 pcs/day)
1679755|NCT01621022|Drug|Active bupropion-Placebo gum|150mg bupropion twice daily plus placebo nicotine gum as needed (up to 12 pcs/day)
1679756|NCT01621022|Drug|Placebo bupropion-Placebo gum|Placebo bupropion twice daily + placebo nicotine gum as needed (up to 12 pcs/day)
1679757|NCT01621009|Drug|Active bupropion + counseling|"Medications-Pre-quit: 150 mg bupropion per day 7 days before quit attempt, then 150 mg twice daily for 4 days before quit attempt; then 150 mg bupropion twice daily for eight weeks.
Counseling-Pre-quit: two 10 minutes sessions before quit date; eight 10-minute sessions post quit date."
1679758|NCT01621009|Drug|Active bupropion, No counseling|"Medication - 150 mg bupropion per day starting week before quit day, then 150 mg twice daily 3 days before quit day, then 150 mg twice daily for eight weeks after quit day.
Counseling: No cessation counseling, only medication checks"
1679759|NCT01621009|Drug|Placebo medication + counseling|"Placebo bupropion once daily 7 days before quit day, then twice daily 4 days before quit attempt, then twice daily for 8 weeks after quit day.
Counseling: Two 10-minutes sessions before quit day, then eight 10-minutes sessions for eight weeks after quit day."
1679760|NCT01621009|Drug|Placebo medication, No counseling|"Pre-quit: Placebo medication once daily 7 days before quit day, then twice daily before quit day, then twice daily for 8 weeks after quit day.
Counseling: No counseling, just medication checks"
1679940|NCT01619761|Drug|Cyclophosphamide|Treatment Plan #2: 50 mg by vein on Day -7.
1955262|NCT03244319|Drug|Warfarin|All patients who are assigned to VKA group, bridging with warfarin and UFH is mandatory until INR reach therapeutic target range (INR 2-3). Warfarin dose will be adjusted for maintain therapeutic range (INR 2-3) during follow up period.
1955263|NCT03244319|Drug|parenteral anti-coagulant (UFH)|parenteral anti-coagulant (UFH)
1679761|NCT01620996|Behavioral|Minimal Intervention|There is no clear definition of this term and it has been used by many different groups to refer to attempts to alter behavior by providing very brief, focused interventions. A slightly more developed model guiding intervention is called the 5-A model. This refers to the acronym Ask, Advise, Assess, Assist and Arrange. This model has been endorsed by the US Public Health Department, who has incorporated the 5-A approach into their clinical practice guidelines (A Clinical Practice Guideline for Treating Tobacco Use and Dependence; A US Public Health Service Report. JAMA, June 20, 2000 - Vol 283 No. 24; see also http://www.surgeongeneral.gov/tobacco/tobaqrg.htm).
1679762|NCT01620996|Behavioral|Motivational Interviewing|"Motivational Interviewing has its roots in alcohol abuse counseling and was pioneered by Miller and Rollnick. It is an approach to counseling that is geared toward increasing an individual's motivation, or buy-in, to the work that needs to be done to reduce substance dependence. Miller and Rollnick offer the approach as a brief intervention (hence some confusion with the term minimal intervention) guided by the following mediators of change, which they call ingredients of change, summarized by the Acronym FRAMES:
FEEDBACK of personal risk or impairment Emphasis on personal RESPONSIBILITY for change Clear ADVICE to change A MENU of alternative change options Therapist EMPATHY Facilitation of client SELF-EFFICACY or optimism
These mediators/ingredients are delivered by the clinician using the following principles:
Express Empathy Develop Discrepancy Avoid Argumentation Roll with Resistance Support Self-Efficacy"
1679763|NCT01620996|Behavioral|Motivational Enhancement|"Motivational enhancement is the most comprehensive term and reflects the integration of two major theorists; Millner and Rollnick on the one hand, and Prochaska and his colleagues on the other. The work of Miller and Rollnick occurred within substance abuse, primarily alcohol abuse and is best summarized in the section above on motivational interviewing. As Prochaska's work, which initially began in the area of smoking cessation but quickly expanded to include wide-ranging health behaviours, developed Miller and Rollnick incorporated his work with theirs.Prochaska's model derives from his long term study of the process of behaviour change regardless of the model of intervention implemented.The model is often referred to as the stages of change model, or readiness to change model.
The stages of change model identifies five separate stages; precontemplation,contemplation, preparation, action, and maintenance
These stages are specific to different behaviours."
1679764|NCT01620983|Behavioral|Pain Coping Skills Training|
1679765|NCT01620983|Behavioral|Arthritis Education|
1679766|NCT01620983|Other|Usual Care|
1679767|NCT01620970|Drug|PF03446962|PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
1679768|NCT01620944|Drug|Atazanavir|Capsule, oral, 300 mg, Once daily (QD), 96 weeks
1679769|NCT01620944|Drug|Ritonavir|Tablets, oral, 100 mg, QD, 96 Weeks
1679770|NCT01620944|Drug|Lamivudine|Tablet, oral, 300 mg, QD, 96 Weeks
1679771|NCT01620944|Drug|Tenofovir/Emtricitabine|Tablets, oral, 300/200 mg, QD, 48 Weeks
1679772|NCT01620931|Drug|RO5469754|Single ascending doses, iv or sc
1679773|NCT01620931|Drug|Placebo|Single doses, iv or sc
1679774|NCT01620918|Procedure|normal healing abutment|Patient receives the normal, uncoated healing abutment on 1 of his (minimal 2) dental implants.
1679775|NCT01620918|Procedure|nano-structured healing abutment|Patient receives the nano-structured healing abutment on 1 of his (minimal 2) dental implants.
1679776|NCT01620905|Procedure|Manipulation|Single level cervical spine joint manipulation
1679777|NCT01620866|Other|Eye Movement Desensitization Reprocessing (EMDR)|EMDR is an effective treatment in PTSD but has never been tested in bipolar traumatized patients.
1679778|NCT01620840|Drug|Lacosamide 10mg/ml|intravenous administration up to 10 days
1679779|NCT01620827|Other|Hospital Landline Phone Calls|Follow-up phone calls are made from the hospital landline phones in a research office
1679780|NCT01620827|Other|Private Cell Phone Calls|Follow-up phone calls are made from the private cell phones of research assistants
1679781|NCT01620814|Drug|Dinoprostone|
1679782|NCT01620814|Drug|misoprostol|
1679783|NCT01620814|Drug|control|
1679784|NCT01620801|Biological|AAV8-hFIX19|One-time IV vector administration.
1679785|NCT01620788|Drug|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 50mg, oral, a day
1679786|NCT01620788|Drug|Indapamide / Losartan|1 tablet of Indapamide 1.5mg + Losartan 100mg, oral, a day
1679787|NCT01620788|Drug|Hyzaar®|1 tablet of Hyzaar®, oral, a day
1679788|NCT01620788|Drug|Hyzaar®|1 tablet of Hyzaar®, oral, a day
1679789|NCT01620775|Other|MRIs|Subjects will have an MRI scan to view specific images, and brain activity patterns thought to be affected in patients with KOA, chronic low back pain and diabetic patients with painful neuropathy. Healthy volunteers will undergo the same MRI scan that lasts about 90 min.
1679790|NCT01620775|Other|Pain testing|There will be a 1-1.5 hour session including pain tolerance testing.
1679791|NCT01620762|Drug|Cat-PAD|1 dose every 4 weeks
1679792|NCT01620762|Drug|Placebo|1 dose every 4 weeks
1679793|NCT01620749|Radiation|18F MEL050|Diagnostic intervention to establish the safety and biodistribution of MEL050 in participants with melanoma.
1679794|NCT01620736|Drug|Raltegravir|Raltegravir 400 mg po bid
1679795|NCT01620723|Other|New Breastfeeding Counselling|An intervention will be developed during the first part of the study. The intervention is supposed to consist of evidence based actions to support the metabolic adaptation of the newborn, establishment of the milk production of the mother and increase the breastfeeding self efficacy of the mother.
1679796|NCT01620723|Other|Treatment as usual|Health professionals offer the usual care for the breastfeeding mother
1679797|NCT01620710|Radiation|hypofractionated helical IMRT|hypofractionated helical IMRT of the prostate bed, 18 x 3 Gy
1679798|NCT01620710|Radiation|hypofractionated helical IMRT|helical IMRT of the prostate bed (18 x 3 Gy) and the pelvic lymph nodes (18 x 2.5 Gy)
1679799|NCT01620697|Procedure|Colorectal surgery|Colorectal surgery
1679800|NCT01620684|Drug|metyrapone|Overnight treatment (15 mg/kg at midnight and 15 mg/kg at 6 am)
1679801|NCT01620684|Drug|placebo|placebo capsules
1730036|NCT00034047|Drug|Nafarelin|
1679807|NCT01620645|Radiation|CT scan and PA chest X-ray|"All participants will receive a single high resolution CT scan of the chest. This will be performed using a low tube current, helical technique. Participants may also receive a plain chest X-ray if clinically indicated.
The total research protocol dose is 2 mSv. The dose from the chest X-ray is insignificant compared with the dose from the CT scan of the chest, therefore all this dose can be considered to be additional to standard of care. A dose of 2 mSv represents a risk of radiation induced detriment of approximately 1 in 10,000 and is equivalent to about 11 months of average natural background radiation in the UK."
1679808|NCT01620632|Procedure|Laparoscopy assisted ERCP|Patients will go the the Operating room and through laparoscopy will have an ERCP for their medical indication.
1679809|NCT01620619|Other|Arthroscopic Bankart Repair alone|Usual arthroscopic Bankart repair
1679810|NCT01620619|Procedure|Closure of rotator interval|Usual arthroscopic Bankart repair plus rotator cuff interval closure
1679811|NCT01620606|Behavioral|Cognitive Behavioral Therapy & Social Learning|Cognitive Behavioral Therapy & Social Learning
1679812|NCT01620606|Behavioral|Education and Support|Education about the GI system, nutrition and food safety
1679813|NCT01620593|Drug|Placebo and Castration|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient 500mg tablets of metformin or placebo, blinded to the patient and the study team.
1679814|NCT01620593|Drug|Metformin and Castration|All eligible subjects will be randomized in a 1:l manner to receive a bottle containing sufficient500mg tablets of metformin or placebo, blinded to the patient and the study team.
1679815|NCT01620580|Behavioral|Self-management|"Participants in the intervention group will receive printed self management strategies each of the 5 symptoms, a symptom diary with the self-management strategies and a 15 minutes discussion. The intervention script will instruct participants on how to use the printed strategies by PI and RA #1.
Week 3"
1679816|NCT01620580|Behavioral|Dietary Information|The control or usual care group will receive a symptom diary designed for the control group without any strategies and a 5 minutes discussion on how to complete the diary from RA# 1. The PI will make weekly follow up calls on the same schedule as the intervention group starting week 4 until week 7 for a total of 4 calls focusing on enhancing healthy eating skills & adherence to renal diet and fluid restriction without discussing any intervention with the group.
1679818|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
1679819|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
1679820|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
1679821|NCT01620554|Drug|BF2.649|1 capsule per week during 2 weeks
1679822|NCT01620554|Drug|Placebo|1 capsule per week during 2 weeks
1679823|NCT01620541|Procedure|Ankle Arthrodesis|All surgeons will employ a well-established technique of rigid internal fixation. In this technique, the joint is prepared by removing cartilage from the surfaces, the bones are positioned as desired, and screws and/or a plate are attached to compress the bones together and prevent motion. This technique obviates the need for a cast or external support. Patients are allowed to walk with weight bearing aids immediately. Radiographs are performed at 6 weeks to determine weight bearing status. Weight is allowed on the limb in increments over the 6 to 12 weeks after surgery.
1679824|NCT01620541|Procedure|Ankle Arthroplasty|Protocols are similar among participating centers. Each surgeon uses an anterior surgical approach between the tibialis anterior tendon and the toe extensor group, splints the ankles for 2 weeks, and restricts weight bearing for the first 6 weeks. Radiographs are performed at 6 weeks to determine weight bearing status. The study involves only FDA approved implants with which the surgeon has established experience.
1679825|NCT01620528|Drug|Elagolix|Elagolix Dose 1 for 6 month Treatment Period, Elagolix Dose 2 for the 6 month Treatment Period
1679826|NCT01620528|Other|placebo|Placebo for 6 Month Treatment Period
1679827|NCT01620515|Drug|NX-1207 2.5 mg|A single intraprostatic injection of NX-1207 2.5 mg followed by active surveillance.
1679828|NCT01620515|Drug|NX-1207 15 mg|A single intraprostatic injection of NX-1207 15 mg followed by active surveillance.
1679829|NCT01620502|Dietary Supplement|Omega-3 fatty acids|A daily treatment of 5 identical capsules of EPA (3.5 g/d), DHA (1.75 g/d) or placebo (high oleic oil), in single or divided administration for 2 (Study 1) or 8 weeks (Study 2)
1679830|NCT01620489|Drug|liraglutide|1.8 mg administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
1679831|NCT01620489|Drug|placebo|Administered once daily subcutaneously (s.c., under the skin) as add-on to the subject's stable pre-trial oral antidiabetic drug (OAD) and/or insulin regimen.
1679832|NCT01620476|Drug|liraglutide|5 mcg/kg for 21 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
1679833|NCT01620476|Drug|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 14 days. Injected subcutaneously once daily. Progression to the next dose level based on safety data
1679834|NCT01620476|Drug|liraglutide|5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days followed by 15 mcg/kg for 7 days. Injected subcutaneously once daily
1679835|NCT01620476|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
1679836|NCT01620463|Drug|liraglutide|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
1680297|NCT01616485|Drug|TA-1790|2 TA-1790 100 mg capsules
1730037|NCT00034060|Drug|Etanercept|
1955269|NCT03240393|Drug|INC280|cMET GCN ≥ 6 cMET GCN ≥ 4 and < 6 cMET mutations
1679837|NCT01620463|Drug|placebo|Single dose administered subcutaneously at four different dose levels: 2.5, 5.0, 10.0 and 15.0 mcg/kg. Following completion of each dose group, an evaluation will be performed to allow progression to the next dose group
1679838|NCT01620450|Drug|biphasic human insulin 30|Single dose of each formulation administered subcutaneously (s.c., under the skin) on two separate visits
1679839|NCT01620437|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-21 days will take place between dosing visits
1679840|NCT01620424|Drug|biphasic insulin aspart 30|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
1679841|NCT01620424|Drug|biphasic insulin aspart 50|Single dose administered subcutaneously (s.c., under the skin) on two dosing vists. A wash-out period of 2-28 days will take place between dosing visits
1679842|NCT01620411|Other|Comprehensive Medical Management|Standard of care for failed back surgery syndrome sustained while on active duty, primarily focused on physical therapy, medication including: opioid analgesics, muscle relaxants, non-opioid analgesics, etc.
1679843|NCT01620411|Procedure|Spinal Cord Stimulator|This arm combines comprehensive medical management (as above) with the trial and possible eventual permenant placement of a spinal cord stimulator, a common pain management procedure.
1679844|NCT01620398|Behavioral|BALANCE|
1679845|NCT01620398|Behavioral|Cardioprotective diet|Participants will be encourage to follow a generalized diet counseling prepared by dietitians based on low fat, low energy, low sodium and low cholesterol diets. They will receive a common folder composed by lists of foods that should be preferred or avoided. For example, avoidance of ultra processed foods, preference for boiled and baked foods rather than fried foods and recommendation of having at least five meals a day. This folder is equivalent of several that are given on ambulatories or hospital of Brazilian public health.
1679846|NCT01620385|Device|ciPDA|The ciPDA Research Platform device was designed as a research tool for cochlear implant research.
1679847|NCT01620359|Device|ExAblate MRgFUS|100% ablation of an up-to-2-cm breast cancer visible on an contrast-enhanced MRI with 5-10 mm margins around the primary tumor
1679848|NCT01620346|Procedure|Intracytoplasmic sperm injection (ICSI)|ICSI is routinely used to treat couples with infertility. Sperm selection in the ICSI group was analysed under a magnification of 400x using an inverted microscope. ICSI was performed in a micro-injection dish prepared with 4 µL droplets of buffered medium (Global® w/HEPES, LifeGlobal, Connecticut, USA) and covered with paraffin oil on a heated stage at 37.0 ± 0.5°C of an inverted microscope.
1679849|NCT01620346|Procedure|Intracytoplasmic morphologically selected sperm injection|IMSI is an established modified ICSI procedure that used an unstained real-time observation of spermatozoa under high-magnification. Sperm selection in the IMSI group is examined at high magnification using an inverted microscope equipped with high-power differential interference contrast optics (DIC/Nomarski). The total calculated magnification is x6.600. The sperm cells exhibiting normally shaped nuclei and normal nuclear chromatin content are selected for injection.
1679850|NCT01620333|Drug|biphasic insulin aspart 50|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
1679851|NCT01620333|Drug|biphasic insulin aspart 70|A single dose of 0.08 U/kg body weight, administered subcutaneously (s.c., under the skin) on two dosing visits in random order separated by 6-12 days
1679852|NCT01620320|Other|Stress echocardiography|Patients able to exercise will have a treadmill test + echography; the others will have a dobutamine echography.
1679853|NCT01620307|Drug|Sirolimus (Rapamune 2mg/day, Pfizer)|Sirolimus (Rapamune 2mg/day, Pfizer) or not for a course of 14 days.
1679854|NCT01620294|Procedure|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
1679855|NCT01620294|Procedure|surgical site infection|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
1679856|NCT01620281|Device|no!no!Back|Self treatments daily for 3 weeks, in up to three 10-minutes sessions
1679857|NCT01620268|Drug|Leflunomide and orotic acid|Daily dose of leflunomide adjusted to target steady state blood levels of 50 ug/mL to 100 ug/mL of the active metabolite plus 600 mg orotic acid
1679858|NCT01620255|Drug|Placebo|Placebo delivered subcutaneous injection, 3 doses separated by 4 weeks
1679859|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 1 delivered subcutaneous injection, 3 doses separated by 4 weeks
1679860|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 2 delivered subcutaneous injection, 3 doses separated by 4 weeks
1679861|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 3 delivered subcutaneous injection, 3 doses separated by 4 weeks
1679862|NCT01620255|Drug|PF-00547659 SC Injection|Drug Dose Level 4 delivered subcutaneous injection, 3 doses separated by 4 weeks
1679863|NCT01620242|Drug|Cabazitaxel|25 mg/m2 every 3 weeks by IV administration
1679864|NCT01620229|Drug|brentuximab vedotin|Given IV
1679865|NCT01620229|Other|laboratory biomarker analysis|Correlative studies
1679866|NCT01620229|Other|pharmacological study|Correlative studies
1679867|NCT01620216|Other|Antitumor Drug Screening Assay|Undergo pre clinical kinase inhibitor activity screening
1679868|NCT01620216|Drug|Dasatinib|Given PO
1679869|NCT01620216|Other|Laboratory Biomarker Analysis|Correlative studies
1679870|NCT01620216|Drug|Nilotinib|Given PO
1679871|NCT01620216|Other|Pharmacological Study|Correlative studies
1679872|NCT01620216|Drug|Ponatinib Hydrochloride|Given PO
1679873|NCT01620216|Drug|Sorafenib Tosylate|Given PO
1679874|NCT01620216|Drug|Sunitinib Malate|Given PO
1679875|NCT01620190|Other|Laboratory Biomarker Analysis|Correlative studies
1679876|NCT01620190|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1679877|NCT01620177|Drug|Alcohol(oral) and placebo|Subjects will be dosed to an approximate peak BAC of 0.065%. Subjects will be tested on the decline such that subjects will be at or above the goal BAC (0.05%) throughout the drive
1679878|NCT01620177|Drug|Cannabis(THC)(Inhaled) and Placebo|Cannabis vapor is produced from 500 mg either placebo (0% THC), approximately 2.5-3.5% THC (low dose), or approximately 6.0-7.5% THC (high dose) bulk cannabis plant material to yield doses of approximately 0, 12.5-17.5, or 30-37.5 mg THC
1679879|NCT01620164|Other|Psychophysical measurements of 3D perception|3D psychophysical performances using a categorization tasks and their underlying mechanisms measured with visual evoked potentials will be assessed in a randomized and comparative study. The order of psychophysical and visual evoked potentials experiments will be randomized between the L Dopa ON and OFF conditions. The randomization will be done by the clinical investigational center. The comparisons will be made between parkinsonian patient and control subjects, and between parkinsonian patients in L Dopa ON and OFF conditions.
1679880|NCT01620151|Procedure|Extended neck with standard support or pillow|Patient will undergo thyroid surgery with an extended neck
1679881|NCT01620138|Drug|Pasireotide|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at the dosage of 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for six months.
The patients with resistant prolactinomas will be treated with pasireotide at the dosage of 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
1679882|NCT01620138|Drug|cabergoline|"The patients with NFPA will be randomized into two groups: (A) the first one will be treated with pasireotide at 900 µg s.c. twice a day for 6 months; (B) the second one, with cabergoline 3 mg/week for 6 months.
The patients with resistant prolactinomas will be treated with pasireotide at 600 µg s.c. twice a day. After four weeks of treatment, the patients who normalize serum prolactin level will be maintained at the same dosage, the others who do not achieve normal prolactin level will have their dosage raised to 900 µg s.c. twice a day for six months."
1679883|NCT01620125|Dietary Supplement|Lactobacillus reuteri DSM 17938|Ordinary treatment against type 2 diabetes is supplemented with one tablet containing 100 million Lactobacillus reuteri DSM 17398, once daily for 12 weeks
1679884|NCT01620112|Drug|high Clonidine concentration|Clonidine 1 ml - 150 mcg on 20 ml de lidocaine 1,5% on axillary brachial plexus block for upper limb surgery
1679885|NCT01620112|Drug|low clonidine concentration|Clonidine 1 ml - 150 mcg on 40 ml of lidocaine 1,5% - single injection on axillary brachial plexus block for upper limb
1679886|NCT01620112|Drug|Lidocaine|Lidocaine 1,5% 20 ml 300 mg for single injection on axillary brachial plexus block for upper lim surgery
1679887|NCT01620112|Drug|Lidocaine 40 ml|Lidocaine 40 ml 1,5% 600 mg single injection for axillary brachial plexus block for upper limb surgery
1679888|NCT01620099|Drug|Extrafine treatment (Clenilexx(R) or Foster(R))|Following the initial evaluation (cross-sectional) patients will be switched to an extrafine equipotent dose of the same compound (extrafine beclomethasone dipropionate - Clenilexx(R) - if the patient was on ICS) or combination (extrafine beclomethasone dipropionate/formoterol - Foster(R) - if the patient was on ICS/LABA combination). After 3-months patients will be reassessed for lung function and asthma control
1679889|NCT01620086|Device|Active Repetitive Transcranial Magnetic Stimulation 1 Hz|active rTMS delivered at 1Hz frequency over temporal cortex
1679890|NCT01620086|Device|Active Repetitive Transcranial Magnetic Stimulation 10 Hz|active rTMS delivered at 10 Hz frequency over temporal cortex
1679891|NCT01620086|Device|Active control site Repetitive Transcranial Magnetic Stimulation at 1Hz|active rTMS delivered at either 1 Hz frequency over the vertex
1679892|NCT01620086|Device|Sham control site Repetitive Transcranial Magnetic Stimulation|sham rTMS delivered at 1Hz frequency over the vertex
1679893|NCT01620086|Device|Active control site Repetitive Transcranial Magnetic Stimulation at 10 Hz|Active 10 Hz rTMS delivered over the vertex
1679894|NCT01620073|Other|HIV counseling and testing|Male partner HIV counseling and testing
1679895|NCT01620060|Drug|Lurasidone|Lurasidone 20, 40,80, 120 or 160 mg/day oral single and multiple does of lurasidone for 12 days
1679896|NCT01620047|Drug|Fentanyl|Fentanyl 3 µg/ml continuously infused for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU)through a femoral nerve sheath catheter.
1679897|NCT01620047|Drug|Ropivacaine|Ropivacaine 0.1% delivered through a femoral nerve sheath catheter continuously for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
1679898|NCT01620047|Drug|Fentanyl|0.9% normal saline delivered through a femoral nerve sheath catheter in addition to a continuous intravenous infusion of fentanyl 3 µg/ml via a PCA pump for a 24 hour period at a basal rate of 10ml/hour starting from the time the patient entered the post anesthesia care unit (PACU).
1679899|NCT01620034|Radiation|Stereotactic Body Radiotherapy|Patients on the 11 day arm receive 4 fractions of SBRT every 3rd day. Patients on the 4 day arm receive 4 fractions of SBRT every day.
1679903|NCT01619969|Drug|celgosivir|100 mg capsules, 400 mg loading dose 200 mg bid
1679904|NCT01619969|Drug|placebo|Capsules of identical appearance containing starch
1679905|NCT01619956|Device|SLA dental implants|Dental implant with surface modification.
1679937|NCT01619761|Drug|Tacrolimus|Treatment Plan #1 + #2: 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no GvHD is present.
1679938|NCT01619761|Drug|Mycophenolate mofetil|Treatment Plan #1 + #2: 15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth Days -3 to Day +100 in the absence of GvHD.
1679939|NCT01619761|Drug|Rituximab|375 mg/m2 by vein on day -8 for CD20 positive participants.
1681536|NCT01606397|Drug|LY2409021|Administered orally (capsule)
1679906|NCT01619956|Procedure|Osteotome sinus floor elevation|"After locating the implant position by a round bur, the pilot drilling was performed to the depth approximately 1-2 mm away from the sinus floor boundary according to the depth taken from the pre-surgical radiograph. The cortical part of the implant bed was further widened to either 3.5mm for 4.1mm implants or 4.2mm for 4.8mm implants. Then the elevation of the maxillary sinus was achieved and developed using osteotome (Straumann Osteotome Kit, Straumann AG, Waldenburg, Switzerland) by light malleting to create a greenstick fracture on the compact bone of sinus floor and to increase diameters gradually till the final depth. The sinus membrane was tested again for any perforation by Valsalva manoeuvre."
1679907|NCT01619956|Procedure|Bone grafting|the autogenous bone chips harvested during the drilling procedure was mixed up with Bio-Oss® in approximately 1: 4 ratio. And the mixture was placed into the 'socket' by osteotomes when elevating the sinus membrane until the final depth.
1679908|NCT01619943|Other|no intervention|clinical follow up
1679909|NCT01619943|Other|no intervention|no intervention
1679910|NCT01619930|Behavioral|Physical activity without motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback.
1679911|NCT01619930|Behavioral|Physical exercise with motivational interviewing|Focus is on physical exercise, motivated by research findings that it has a positive effect on depressive symptoms. An individualized exercise program is constructed, to be followed by the respective participant. A user-friendly pulse watch will be mailed to participants. Exercise is monitored through online self-registration with automated feedback. An initial motivational interview (MI) per telephone is also conducted, to explore the intrinsic motivation to change in participants.
1679912|NCT01619930|Behavioral|Behavioral activation with rationale|A behavioral activation program, based on the TRAP-TRAC model according to which suffering individuals are trapped in a vicious circle of avoidance and ever fewer reinforcers, leading to increasing discomfort. To break free of this vicious circle, patients have to replace avoidance patterns with alternative coping strategies. Unlike previous applications of this program done in the U.S., this study will feature an internet-based administration. Approximately 15 minutes of electronic therapist support will be included per week.
1679913|NCT01619930|Behavioral|Behavioral activation without rationale|"A behavioral activation program without TRAP-TRAC rationale, but with some encouragement provided (Activate yourself and feel better!). Approximately 15 minutes of electronic therapist support will be included per week."
1679915|NCT01619904|Procedure|Goal-Directed Therapy|Peri-operative optimisation of fluid status, based on Oxygen Delivery
1679916|NCT01619904|Procedure|Standard Therapy|Following standard protocol during peri-operative period
1679918|NCT01619878|Drug|Artemether-lumefantrine (COA566)|One dispersible tablet taken orally twice a day during 3 days.
1679919|NCT01619865|Drug|68Ga-DOTATOC PET/C|1 -5 mCi 68Ga-DOTATOC (10-50 ugm DOTATOC)administered once via IV.
1679922|NCT01619839|Drug|NKTR-181|
1679923|NCT01619839|Drug|Placebo|Placebo dosing will be only in the double-blind randomization arm and will be identical in form to the Experimental NKTR-181
1679924|NCT01619826|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
1679925|NCT01619826|Behavioral|Physical Activity|Participants in this group partake in their regular afterschool activities, without intervention from the study staff.
1679926|NCT01619813|Drug|Docetaxel, Reolysin and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly beginning on day 1, cycle 1. Reolysin will be delivered as a 1-hour infusion days 1-5. On day 1 of each cycle, when both agents are given, the docetaxel will be given first. Prednisone 5 mg BID will be given beginning day 1. Each cycle is 3 weeks in length.
1679927|NCT01619813|Drug|Docetaxel and Prednisone|Docetaxel 75 mg/m2 will be delivered as a 1-hour infusion q 3 weekly. Prednisone 5mg BID will be given beginning Day 1. Each cycle is 3 weeks in length.
1679928|NCT01619800|Device|Blended Sensor Optimization (BSO)|"At wound check (POD#1 and 1 Week F/U), histograms from device interrogation obtained from patients in the BSO group are assessed, and these patients undergo optimization. A hall walk and stair climbing exercise will be performed and MV optimized using trending data to hit the following targets:
HR at Rest: 60 HR upon slow walking: 100 HR upon brisk walking: 115-120 HR upon climbing stairs: 130-135 Patients will undergo optimization, and be instructed that their device may have been optimized."
1679929|NCT01619800|Device|Accelerometer Alone (AA)|Patients in the AA group will also undergo device interrogation, and will perform a hall walk and stair climbing exercise. Afterwards, these patients will undergo a sham optimization by placing the PPM interrogation laptop device over there pacemaker, and instructing the patients that their device may have been optimized.
1679930|NCT01619774|Drug|GSK2118436|Starting dose 150 mg by mouth twice a day.
1679931|NCT01619774|Drug|GSK1120212|2 mg by mouth daily.
1679932|NCT01619761|Drug|Lenalidomide|"Treatment Plan #1: 10 mg by mouth on days -8 to -2.
Treatment Plan #2: 10 mg by mouth on days -7 to -2."
1679933|NCT01619761|Drug|Fludarabine monophosphate|Treatment Plan #1 + #2: 40 mg/m2 by vein on days -7 to -4.
1679934|NCT01619761|Drug|Melphalan|Treatment Plan #1: 140 mg/m2 by vein on day -4.
1679935|NCT01619761|Procedure|NK Infusion|Treatment Plan #1 + #2: The NK cell infusion administered intravenously on day -2 over a period of 30 minutes. The NK dose infused will be 5x 10^6/kg. Remaining cells will be discarded if not needed for laboratory studies.
1679936|NCT01619761|Procedure|CB Infusion|Treatment Plan #1 + #2: On Day 0, the unmanipulated products (smaller cord blood unit and the remnant of the larger unit) will be infused.
1682978|NCT01595074|Other|medical chart review|Correlative studies
1679941|NCT01619709|Other|Pet AV-45|AV-45 (Florbetapir F 18) : Bolus of 5 MBq/kg IV ; A 10-minutes Pet scan acquisition Starts at 50 minutes after injection.
1679942|NCT01619696|Procedure|Pelvic MRI and F MISO TEP|Pelvic MRI and F MISO TEP: before inclusion, 2 weeks after beginning and 7 weeks after completion of chemoradiotherapy.
1679943|NCT01619683|Drug|enclomiphene citrate|12.5 mg, 1 capsule, daily, oral. After 6 weeks of treatment, subjects will remain on 12.5 mg/day if their morning testosterone level is greater than 300 ng/dL. If a subject's testosterone is less than 300 ng/dL, the subject's dose will be increased to 25 mg/day
1679944|NCT01619683|Drug|Placebo|1 placebo capsule per day, oral
1679945|NCT01619670|Device|Apligraf|non adhesive layer
1679948|NCT01619644|Drug|sodium valproate|sodium valproate (HDAC inhibitor) with an oral dosage of 30 mg/kg/jour
1679949|NCT01619644|Drug|Placebo|Placebo with an oral dosage of 30 mg/kg/jour
1679950|NCT01619631|Behavioral|12-week Tai Chi intervention|Tai Chi classes will be conducted weekly for one hour each for 12 weeks. Classes will begin with warm-up exercises designed to loosen the body, increase awareness of alignment and structural integration, improve efficiency of breathing, incorporate mindfulness and imagery into movement.
1679951|NCT01619631|Behavioral|Education control group|The education control group will meet twice weekly for 12 weeks for one hour, and research staff will present didactic information modified from psychoeducation curriculums created by the Benson Henry Institute and a stress reduction study for depressed minority patients.
1679952|NCT01619618|Genetic|mutation analysis|
1679953|NCT01619618|Genetic|polymerase chain reaction|
1679954|NCT01619618|Genetic|polymorphism analysis|
1679955|NCT01619618|Other|laboratory biomarker analysis|
1679956|NCT01619605|Procedure|shrimp challenge|Patients with history of shrimp allergy and positive skin tests to shrimp were recruited for shrimp challenges After shrimp challenges, patients with anaphylaxis defined as anaphylaxis group, patients with mild reactions defined as mild reaction group, and patients without symptom defined as control group
1679957|NCT01619592|Device|webbased education (telemonitoring)|"Patients will be able to transmit their blood glucose values via the Internet to the diabetes professional and they will receive timely feedback. Timely will be defined as 'as agreed between the patient and the diabetes professional', e.g. every week on Friday afternoon."
1679958|NCT01619579|Device|AVACEN Thermal Exchange System|Non-invasive device forms vacuum around subject's hand, enabling efficient core body temperature adjustment using heating element inside device.
1679959|NCT01619566|Drug|Duloxetine|oral tablet, 30mg daily for 1 week (titration up) oral tablet, 60mg daily for 8 weeks (treatment) oral tablet, 30mg daily for 1 week (titration down, if needed)
1679960|NCT01619540|Other|Valsalva maneuver|
1679961|NCT01619527|Drug|darunavir|Type=exact number, unit=mg, number=400, form=tablet, route=oral. Two tablets as a single dose or a tablet in combination with cobicistat
1679962|NCT01619527|Drug|cobicistat|Type=exact number, unit=mg, number=150, form=tablet, route=oral. One tablet as a single dose or a tablet in combination with darunavir
1679963|NCT01619488|Device|Adjustable Gastric Band|"Surgical placement of an adjustable gastric band around the upper portion of the stomach.
Adjustments are made to the band through a subcutaneous port as needed to maintain appropriate restriction."
1679964|NCT01619462|Biological|Prevenar 13 and Synflorix|260 children will be randomized to receive either Prevenar 13 or Synflorix at 1-2-3 months. At 9 months 65 children in the Prevenar 13 arm and 65 children in the Synflorix arm will receive booster dose of Pneumovax and at 23 months all children will receive a micro dose of Pneumovax.Blood will be collected at 1, 4, 9, 10, 23 and 24 months to determine serotype-specific antibody responses. Nasopharyngeal swabs will also be collected to measure carriage of pneumococci and non-typeable Haemophilus influenzae.
1679965|NCT01619449|Procedure|Renal replacement therapy|Liver transplant recipients receiving continuous renal replacement therapy for duration of liver transplant surgery.
1679966|NCT01619436|Drug|Clonidine|bolus, clonidine 2 mg/kg IV
1679967|NCT01619436|Drug|Ringer lactato|1 ML ringer lactato IV, as placebo
1679968|NCT01619423|Drug|PledOx (2 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
1679969|NCT01619423|Drug|PledOx (5 µmol/kg)|PledOx is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles
1679970|NCT01619423|Drug|Placebo (0,9% NaCl)|Placebo (0,9% NaCl) is administered intravenously for up to 5 minutes, about 10 min prior to start of FOLFOX6 chemotherapy which will be administered day 1 and 2 every second week for up to 8 cycles.
1679971|NCT01619410|Biological|Linezolid|Linezolid 600 mg every 12 hours for 7 days
1679972|NCT01619410|Biological|Clindamycin|Clindamycin 300 mg po every 6 hours for 7 days
1679973|NCT01619397|Device|Test condom with new Xanthan gum condom coating|
1679974|NCT01619384|Behavioral|Mindfulness-Based Stress Reduction|An 8-week validated stress reduction program, designed to teach mindfulness.
1955287|NCT03236168|Drug|Ivermectin|A single weight based dose of ivermectin
1679976|NCT01619345|Drug|semaglutide|Subjects will be treated with two single doses of 10 mg semaglutide in a tablet. Dosing will be done on 2 dosing visits separated by 4 to 6 weeks.
1679977|NCT01619332|Drug|Placebo|Placebo will be given orally once daily for 28 days to patients assigned to placebo in a randomized and blinded manner
1679978|NCT01619332|Drug|Sitagliptin|Sitaglitpin will be given orally once daily for 28 days to patients assigned to this treatment in a randomized and blinded manner
1679979|NCT01619332|Drug|LEZ763|LEZ763 will be given orally once daily for 28 days in a randomized and blinded manner
1680298|NCT01616485|Drug|Sildenafil citrate|2 sildenafil citrate 50 mg capsules
1679980|NCT01619319|Other|Cognitive Remediation Therapy|auditory computer games designed to improve the speed at which people react when they hear something and at which they process that information.
1679981|NCT01619319|Other|computer games|computer games that that consist of word puzzles
1679982|NCT01619280|Drug|Sodium Nitroprusside|Each subject will receive one of five possible dosages of nebulized sodium nitroprusside. The dosage will be determined by the 3 + 3 dose escalation design. Only a maximum of six patients will be given a particular dosage. Arterial blood gases will be drawn at 0 min, 15 min, 30 min and 45 min during nebulized sodium nitroprusside administration. Vitals signs will be recorded every five minutes. No changes to ventilator settings or vasopressor dosage or fluid administration will be allowed.
1679983|NCT01619254|Behavioral|Hand washing with soap and hand finger nail clipping|Assess the impact of hand washing with soap and nail clipping on child health
1679984|NCT01619241|Other|PET/CT|F-18 FLT PET/CT
1679985|NCT01619228|Other|Vitamin B3 (Nicotinamide)|The assigned leg will be treated with a solution of Vitamin B3 (nicotinamide) in sterile water once a day for 14 consecutive days in an amount not to exceed 6 milligrams of Vitamin B3 (nicotinamide) per kilogram of body weight per day.
1679986|NCT01619202|Behavioral|Risk Anticipation -Perception Training|Web-based computer training program designed to teach novice teen drivers how to properly scan for hazards
1679987|NCT01619189|Biological|epithelial stem cells cultured|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
1679988|NCT01619189|Procedure|transplantation of cultured cells|transplantation of allogeneic or autologous limbal epithelial stem cells cultured on human amniotic membrane with no feeders
1679989|NCT01619176|Drug|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
1679990|NCT01619176|Drug|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
1679991|NCT01619176|Drug|leflunomide|leflunomide: 20mg/day for 3 months
1679992|NCT01619176|Drug|methotrexate|methotrexate: 7.5mg/week to 15mg/week for 3 months
1679993|NCT01619176|Drug|non-steroidal anti-inflammatory drug (NSAID)|NSAID: 100mg twice a day for 3 months
1679994|NCT01619176|Drug|leflunomide|leflunomide: 20mg/day for 3 months
1679995|NCT01619176|Procedure|Acupuncture|"30 minutes acupuncture every other day for 3 months.
Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20."
1679996|NCT01619163|Drug|Placebo|
1679997|NCT01619163|Drug|Prednisolone|low dose, 7.5 mg/day
1955288|NCT03236168|Drug|Permethrin 5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
1955289|NCT03236168|Drug|Malathion Shampoo 0.5%|Permethrin cream is used in conjunction with Malathion shampoo when ivermectin is contra-indicated
1680000|NCT01619137|Drug|water and soap|water and soap for 6-8 hours per day.
1680001|NCT01619137|Drug|Povidone-iodine And normal salin treatment|use of Povidone-iodine And normal salin treatment for irrigation of ununion laparatomy or episiotomy wound.
1680002|NCT01619111|Drug|standard chemo- or endocrine therapy|"standard chemo- or endocrine therapy:
Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)
Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
1680003|NCT01619111|Drug|standard chemo- or endocrine therapy + Lapatinib|"Lapatinib
+ standard chemo- or endocrine therapy:
Monochemotherapy (containing one of the following): docetaxel, paclitaxel, vinorelbine, capecitabine, NPLD (non-pegylated liposomal doxorubicin)
Endocrine therapy: aromatase inhibitors (anastrozole, letrozole, exemestane)"
1680004|NCT01619098|Other|Patient Navigator|In addition to usual care, the intervention adds the services of a community health worker, the Patient Navigator (PN), for study patients. The PN participates in bedside meetings, facilitates communication between the patient and the primary care team, conducts weekly outreach phone calls to further address patient needs, and makes reminder calls prior to all medical appointments to facilitate timely outpatient follow-up.
1680005|NCT01619098|Other|Usual care|Usual care includes provision of a Home Care Plan (HCP) to patients at discharge, and electronic transmission of HCP to PCP with telephone follow-up by primary care RN
1680006|NCT01619085|Drug|BIBF 1120|BIBF 1120 BID (twice a day)
1680007|NCT01619072|Other|Misoprostol + referral|800 mcg of sublingual misoprostol (four tablets of 200 mcg misoprostol) + standard of care (referral to higher level care)
1680008|NCT01619072|Other|Placebo + referral|Placebo (4 tablets resembling misoprostol) + standard of care (referral to higher level care)
1680009|NCT01619059|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily, Up to 52 weeks
1680010|NCT01619059|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, Up to 52 weeks
1680011|NCT01619059|Drug|Metformin IR|Tablets, Oral, ≥ 1500mg, Twice daily, Up to 52 weeks
1680012|NCT01619059|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0 mg, Once daily, Up to 52 weeks
1680013|NCT01619046|Biological|GreenGene™ F and an approved recombinant Factor VIII product|one 50 IU/kg, intra-venous infusion over 5 minutes, Infusion rate < 10 mL/min
1680014|NCT01619046|Biological|GreenGene™ F|intra-venous infusion, 30 ± 5 IU/kg infusions 3 times per week with dose escalation to 45 ± 5 IU/kg if appropriate, for 50 exposure days
1680015|NCT01619046|Biological|GreenGene™ F|"intra-venous infusion,
On-demand safety and efficacy substudy:
minor bleed = 10-20 IU/kg moderate bleed = 15-30 IU/kg major bleed = 30-50 IU/kg"
1680016|NCT01619046|Biological|GreenGene™ F|"intra venous infusion,
Surgical substudy:
Minor surgery including tooth extraction = Post in fusion FVIII level of 60-100% of normal. A single bolus infusion (30-50 IU/kg) beginning within one hour of the operation. Optional additional dosing every 12 to 24 hours as needed to control bleeding.
Major surgery = Pre- and post infusion FVIII level 80-120% of normal. Preoperative bolus infusion: 40-60 IU/kg. Verified 100% activity prior to surgery. Maintenance bolus infusion (40-60 IU/kg) repeat infusions every 8 to 24 hours, depending on the desired level."
1680017|NCT01619033|Drug|BF2.649|single dose 20 mg
1680299|NCT01616485|Drug|Placebo|2 placebo capsules for TA-1790 100 mg capsules
1730884|NCT00040872|Drug|thiotepa|
1955290|NCT03236428|Drug|Daratumumab|Daratumumab is a drug that may kill or stop cancer cells from growing through a variety of mechanisms by attaching to the CD38 molecule
1680018|NCT01619020|Dietary Supplement|Flaxseed Lignans|We will use a specially formulated dietary lignan supplement (Lignan Research Inc., San Diego, CA) as a source of lignans for the lignan challenge in the screening study and as a daily supplement in the intervention. It is a flaxseed extract that contains SDG (269 mg/g; 50 mg/capsule), pinoresinol diglucoside (160 mg/g), and lesser amounts of caffeic (50 mg/g), ferulic (40 mg/g) and coumaric acids (30 mg/g). Lignan capsules and placebo capsules will be prepared by Lignan Research, Inc., a well-established supplement company that follows GMP.
1680019|NCT01619007|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
1680020|NCT01619007|Drug|Standard of care|Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
1680021|NCT01618994|Procedure|Performing robotic supracervical hysterectomy|All groups were recorded, times and graded on their performance during a robotic supracervical hysterectomy
1680022|NCT01618981|Procedure|pace make active/inactive cross over|
1680023|NCT01618968|Drug|MTX|"Treatment A - 1 dose (4, 6, 8 or 10 tablets respectively to make up 10 mg, 15 mg, 20 mg or 25 mg MTX - per subject's dose group)
Treatment B - SC injection using VIBEX MTX device into abdomen (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)
Treatment C - SC injection using VIBEX MTX device into thigh (VIBEX MTX device pre-filled with 10 mg, 15 mg, 20 mg or 25 mg MTX)"
1680024|NCT01618955|Device|VIBEX MTX|Self-administration of Single Dose of SC MTX using Vibex MTX 10 mg, 15 mg, 20 mg or 25 mg Device
1680025|NCT01618942|Device|pressure algometer|
1680026|NCT01618929|Drug|Montelukast|Placebo and montelukast (5 mg for 6-14 years of age and 10 mg for 14-18 years of age once a day) will be given following one another in 4 weeks periods including a 2 weeks wash-out period in between in a cross over design.
1680027|NCT01618916|Drug|LY3015014|Administered SQ
1680028|NCT01618916|Other|Placebo|Administered SQ
1680029|NCT01618903|Drug|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution in the morning of Day 1.
1680030|NCT01618903|Drug|Levetiracetam|Levetiracetam single oral administration of 3 tablets of 500 mg immediate release tablet.
1680031|NCT01618890|Procedure|Hepatic venous pressure gradient measurement|"Perform baseline HVPG measurement, then start propranolol 20 mg orally twice daily (BID), increase the dose stepwise to maximum tolerated dose. After 4 weeks a second HVPG is performed.
In hemodynamic nonresponders from the study arm, repeated endoscopic band ligation is performed in daycare setting with intervals of 2-4 weeks.
In hemodynamic responders (HVPG second measurement< 12 mmHg or >20% reduction in HVPG compared to baseline) beta-blockers are continued until end of follow-up."
1680032|NCT01618877|Drug|Levetiracetam|Levetiracetam 1.500 mg (500 mg/ 5 mL vials) administered as a 45 minutes intravenous infusion diluted in 100 mL 0.9 % saline solution every 12 hours from the morning of Day 3 (it is the first day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
1680033|NCT01618877|Other|Placebo|15 mL 0.9 % saline solution added to 100 mL 0.9 % saline solution, administered as a 45 minutes intravenous infusion every 12 hours from the morning of Day 3 ( it is the 1st day in Part B) to the morning of Day 7 (it is the 5th day in Part B).
1680034|NCT01618864|Device|Luxe|Self treatment at home in the peri-orbital and cheeks areas. Frequency: Daily treatment for 4 weeks followed by bi-weekly treatments for additional 4 weeks.
1680035|NCT01618851|Radiation|Radiotherapy with IMRT and CyberKnife Boost|"Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used.
The prescribed PTV dose of 19.5 Gy shall be given in 3 fractions using the CyberKnife. At least three fiducials should be identified for each treatment. If fewer than three fiducials can be tracked, then additional fiducials will be placed, and the patient replanned. Fiducial locations in the images will be extracted and compared to the fiducial locations in the CT scans to estimate target movements.
For IMRT, Daily doses of 180 cGy are to be delivered to the PTV 5 days a week to a total dose of 4500 cGy in 25 fractions."
1680036|NCT01618838|Radiation|CyberKnife radiosurgery|"Treatment Planning:
Inverse planning using the CyberKnife planning system will be employed. The treatment plan used for each treatment will be based on an analysis of the volumetric dose including dose-volume histogram (DVH) analyses of the PTV and critical normal structures. The homogeneous CT model shall be used. Number of paths and beams used for each patient will vary and will be determined by the selected individual treatment plan. To reduce overall treatment time and total monitor units, 150-200 non-zero beams are recommended. No more than 250 beams shall be employed. Tuning structures shall be employed to minimize conformality index (CI) and new conformality index (nCI), preferably yielding values less than 1.20 and 1.25, respectively."
1680037|NCT01618825|Drug|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
1680038|NCT01618825|Drug|Lamotrigine|2 x 25 mg tablet once a day
1680039|NCT01618812|Procedure|Lateral lengthening osteotomy of calcaneus|Use of artificial bone graft
1680040|NCT01618799|Drug|Lamotrigine Tablets 25 mg|2 x 25 mg tablet once a day
1680041|NCT01618799|Drug|Lamotrigine|2 x 25 mg tablet once a day
1680042|NCT01618786|Other|SmartCell flooring|SmartCell (SATECH Inc., Chehalis, WA, USA) is a continuous rubber surface layer supported by an array of cylindrical rubber columns 14 mm in diameter, and spaced at 19 mm intervals. It has a surface hardness of 50 durometer. It has been reported to provide approximately 35% peak force attenuation during mechanical tests that simulate falls on the hip. It has also been reported to have minimal effect on balance and mobility of older women during activities of daily living. It will be covered with hospital-grade vinyl and will be inspected regularly for maintenance requirements.
1680043|NCT01618786|Other|Plywood flooring|Plywood flooring covered with the same hospital-grade vinyl as the SmartCell flooring.
1680044|NCT01618773|Drug|0.1% adapalene / 2.5% benzoyl peroxide|topical application
1680045|NCT01618760|Drug|Risperidone Tablet 1 mg|1 mg tablet once a day
1680046|NCT01618760|Drug|Risperidone|1 mg tablet once a day
1680047|NCT01618708|Device|Synvisc-One (hylan G-F 20)|6-mL IA injection
1680048|NCT01618708|Device|Placebo|6 mL injection of phosphate buffered saline
1680300|NCT01616485|Drug|Nitrostat|glyceryl trinitrate tablet, USP 0.4 mg
1680049|NCT01618695|Drug|E2007|"Core study:4 mg group:
Week 0 Once daily; 2 mg/day,
Week 1 to Week 18 Once daily 4 mg/day:
8 mg group: Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day,
Week 3 to Week 18 Once daily 8 mg/day:
12 mg group: Week 0 Once daily 2 mg/day, Week 1 Once daily 4 mg/day, Week 2 Once daily 6 mg/day, Week 3 Once daily 8 mg/day, Week 4 Once daily 10 mg/day, Week 5 to Week 18 Once daily 12 mg/day Extension study 4 mg group: Week 19 to Week 22 Once daily perampanel 4 mg/day, Week 23 Once daily perampanel 6 mg/day, Week 24 Once daily perampanel 8 mg/day, Week 25 Once daily perampanel 10 mg/day,
Week 26 to Week 75 or more Once daily perampanel 12 mg/day:
8 mg group: Week 19 to Week 22 Once daily perampanel 8 mg/day, Week 23 Once daily perampanel 10 mg/day,
Week 24 to Week 75 or more Once daily perampanel 12 mg/day:
12 mg group: Week 19 to Week 75 or more Once daily perampanel 12 mg/day"
1680050|NCT01618695|Drug|Placebo|"Core study:
Week 0 to Week 18 Once daily placebo, Week 19 to Week 22 Once daily placebo
Extension study
Week 19 to Week 22 Once daily placebo:
Week 23 Once daily perampanel 2 mg/day, Week 24 Once daily perampanel 4 mg/day, Week 25 Once daily perampanel 6 mg/day, Week 26 Once daily perampanel 8 mg/day, Week 27 Once daily perampanel 10 mg/day, Week 28 to Week 75 or more Once daily perampanel 12 mg/day"
1680051|NCT01618669|Drug|Regadenoson|Administered as an intravenous (IV) bolus
1680052|NCT01618669|Procedure|Single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI)|
1680053|NCT01618656|Drug|PF-04457845|Study medication will be administered at 4mg by mouth daily for four weeks.
1680054|NCT01618656|Drug|Placebo|Sugar pill
1680055|NCT01618643|Procedure|Acetic acid chromoendoscopy|"Prospective observational pilot study.
We would examine patients with Barrett's epithelium that is either healthy or has suspected areas of neoplasia. We will apply acetic acid spray to areas of healthy Barrett's metaplasia and time how long it takes for the aceto whitening to disappear. We will repeat this in cases referred with SM invasive cancer, intramucosal cancer, suspected high grade dysplasia and possible low grade dysplasia. We will record how long it takes for the acetowhitening to disappear. We will biopsy these areas to confirm the diagnosis.
We will correlate the histology to the aceto-whitening time to see if there is a correlation between the degree of neoplasia and the aceto-whitening time after acetic acid dye spray."
1680056|NCT01618630|Dietary Supplement|Dietary Supplement: Amino acids for six weeks|Amino acids in drinks between meals for six weeks.
1680057|NCT01618630|Dietary Supplement|Placebo|Placebo supplementation as drinks in between meals for six weeks
1680058|NCT01618617|Dietary Supplement|High dose Multistrain probiotic, 100 billion cfu/day|100 billion cfu live bacteria (60 billion cfu bifidobacterium cultures and 40 billion lactobacillus cultures).
1680059|NCT01618617|Dietary Supplement|Low dose Multistrain probiotic, 15 billion cfu/day|15 billion cfu live bacteria (9 billion cfu bifidobacterium cultures and 6 billion lactobacillus cultures).
1680060|NCT01618604|Procedure|Quantitative Sensory Testing|following the standardized protocol of DFNS
1680061|NCT01618604|Procedure|Conditioned Pain Modulation|test stimulus by hot thermode conditioned stimulus by cold water bath
1680062|NCT01618604|Procedure|Repetition of four QST parameters|"warm detection threshold (WDT)
cold detection threshold (CDT)
mechanical detection threshold (MDT)
mechanical pain threshold (MPT)"
1680063|NCT01618591|Drug|Single dose rifaximin 1650 mg|Rifaximin 1650 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
1680064|NCT01618591|Drug|Single dose azithromycin 500 mg|Azithromycin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
1680065|NCT01618591|Drug|Single dose levofloxacin 500 mg|Levofloxacin 500 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
1680066|NCT01618591|Drug|Single dose azithromycin 1000 mg plus loperamide|Azithromycin 1000 mg as a single dose plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not to exceed 16 mg/day for 2 days
1680067|NCT01618591|Drug|Single dose azithromycin 1000 mg plus placebo|Azithromycin 1000 mg as a single dose and placebo in lieu of loperamide
1680068|NCT01618578|Procedure|rubber hand illusion|"There were three consecutive trials of the RHI:
one control trial: asynchronous condition (3 Min.)
two experimental trials (conducted on both hands):synchronous condition (3 Min.),additionally watching the prosthesis being threatened (20 sec.)"
1680069|NCT01618565|Procedure|Hands-On Training|one-time, 30 minute hands-on training
1680070|NCT01618565|Procedure|Demonstration|30 minutes passive training
1680071|NCT01618552|Behavioral|SEE IT training|Standardized patient instructors provide a scripted intervention to train primary care physicians in the use of self-efficacy enhancing interviewing techniques (SEE IT) during office visits with patients who have coexisting depression and diabetes
1680072|NCT01618552|Other|Knowledge enhancement|Brief video clip designed to increase primary care physician awareness of new medication treatments for diabetes
1680073|NCT01618539|Drug|propofol|varying intravenous dosages
1680074|NCT01618526|Dietary Supplement|Western Style Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers (Arabinoxylans and Resist Starch) compared with a Western Style Diet with a low content of dietary fibers.
1680075|NCT01618526|Dietary Supplement|Healthy Carbohydrate Diet|Cross over design with two intervention diet: Healthy Carbohydrate Diet with approximally 55 grams of dietary fibers ( Arabinoxylans and Resistent Starch) compared with Western Style Diet with low content of dietary fibers
1680076|NCT01618513|Drug|Sandostatin® LAR|Intramuscular injections, dosage based on either GH or IGF-I levels.
1680077|NCT01618487|Procedure|Arthroscopic tenotomy|This is a surgical procedure where small incisions are made and a scope is used to see the tendon and release it.
1680078|NCT01618487|Procedure|Open tenotomy|This involves opening the skin on the arm up to expose the muscle and tendon. There is a total of 1 incision made.
1680079|NCT01618487|Procedure|Debridement and repair|This involves using an arthroscopic technique (using a scope and a small incision) to go in and remove any tissue that is diseased/does not belong and repairing the tear(s) in the tendon. There is a total of 1-2 incisions made.
1680080|NCT01618474|Drug|DX|Docetaxel 60mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day1-14; 3 weeks a cycle for 8 consecutive cycles.
1680343|NCT01616212|Other|Motivational Enhancement Therapy for adolescents|Motivational Enhancement Therapy for adolescents
1680081|NCT01618474|Drug|XELOX|oxaliplatin 130mg/m2, intravenous infusion, day 1; Capecitabine 1000mg/m2, oral administration, twice a day, day 1-14, 3 weeks a cycle for 8 consecutive cycles
1680082|NCT01618461|Behavioral|Drug indication icons|Icons illustrate the purpose of each medication
1680083|NCT01618461|Behavioral|Structured instructions|Graphical format shows what time(s) of day each medication should be taken
1680084|NCT01618448|Drug|Tolvaptan|Tolvaptan 15mg once daily
1680085|NCT01618448|Drug|Placebo|Placebo
1680086|NCT01618435|Biological|i-FACTOR|i-FACTOR mixed with autologous bone from the decompression placed in the operation site for enhancing fusion
1680087|NCT01618422|Other|Directly Observed Therapy (DOTS) plus|The regimen used to treat MDR-TB comprises 5 to 6 drugs to which the organism is or likely to be susceptible for the initial 6 months, and then 3 to 4 drugs subsequently. In addition, TB cases with rifampicin resistance but not amounting to MDR-TB are also at risk of unfavourable treatment outcomes. The availability of pretreatment susceptibility test results will provide a guide in selection of drugs in treating such cases.
1680088|NCT01618422|Other|Directly Observed Therapy (DOTS)|The DOTS strategy (current strategy) consists of the following measures: political commitment, case detection through bacteriologic evaluation, standardized treatment with supervision and patient support, an effective drug supply system, and a reporting and recording system that allows assessment of treatment. The standard regimen for treatment of new cases of pulmonary TB consists of 6 months treatment, with 4 drugs in the initial phase including isoniazid, rifampicin, pyrazinamide, and either ethambutol or streptomycin, followed by two drugs in the continuation phase including isoniazid and rifampicin. In the treatment of previously treated cases, a standard regimen consisting of 8 months treatment will be used.
1680089|NCT01618409|Behavioral|PictureRx card|An illustrated format of medication instructions that includes pictures of the medications and icons to illustrate their purpose
1680090|NCT01618396|Drug|Sedation drug (Propofol and Midazolam)|Septic patients, after intubation, were initially sedated with propofol. During the second day of mechanical ventilation, propofol infusion was interrupted. When the patient awoke, the sedative drug was changed to midazolam. Sedation target was a Ramsay Scale score of 4 to 5.
1680091|NCT01618383|Other|colonoscopy or rectosigmoidoscopy|Usual procedure
1680092|NCT01618370|Drug|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
1680093|NCT01618357|Radiation|Radiation|Patients will receive radiation therapy at a dose of 2.35 Gy per fraction to the breast and regional nodal region for 16 fractions to a total dose of 37.5 Gy. Treatments will be given Monday through Friday. Radiation therapy will start on day 1 of Veliparib.
1680094|NCT01618357|Procedure|Lumpectomy/Mastectomy|Resection of breast cancer.
1680095|NCT01618331|Behavioral|Regular exercise|Duration: 3 session each week, in 12 week. Intensity: 70 % of VO2max. Type: cycle-ergometer exercise.
1680096|NCT01618331|Dietary Supplement|Protein-carbohydrate supplementation|Dosage: 45g powder mixed in 0.5 L water After each exercise session, 3 times each week, in 12 weeks.
1680097|NCT01618305|Drug|Lamivudine/zidovudine|Participants will receive one lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet twice a day.
1680098|NCT01618305|Drug|Efavirenz|Participants will receive one 600 mg tablet of efavirenz each night.
1680099|NCT01618305|Drug|Raltegravir|Participants will receive one 400 mg raltegravir tablet twice a day.
1680100|NCT01618292|Procedure|Robotic sacral colpopexy|Patients who underwent robotic assisted sacral colpopexy for the treatment of pelvic organ prolapse
1680101|NCT01618266|Drug|dexamethasone intravitreal implant|dexamethasone intravitreal implant 700 μg administered into the eye according to physician judgment.
1680102|NCT01618253|Drug|Sorafenib|Sorafenib 400 mg PO bid will be started two weeks prior to initiation of radiation therapy (RT) and continue until the end of protocol specified radiation dose.
1680103|NCT01618253|Radiation|Conventional fractionation (2 Gy per day) external beam radiation therapy|"Patients will be stratified by the maximum diameter of HCC in any plane (≤10 cm or >10 cm) based on post-TACE, contrast enhanced MRI or CT. If only 1 lesion is present, the maximum diameter of that lesion in any plane determines stratification. If >1 but ≤3 lesions are present, the sum of the maximum diameter in any plane of all the lesions determines stratification.
The MTD will be determined utilizing a standard 3 + 3 dose escalation scheme (4 Gy increase per bin). For lesions ≤10 cm, the starting RT dose bin will be 42 Gy and escalate to a pre-determined maximum of 62 Gy if no DLT's are experienced. For lesions >10 cm, the starting RT dose bin will be 40 Gy and escalate to a pre-determined maximum of 52 Gy if no DLT's are experienced."
1680104|NCT01618240|Other|Muscle Strength Measurement|MRC score (0-60) is a clinical assessment of muscle power on abduction of the arm, flexion of the forearm, extension of the wrist, flexion of the leg, extension of the knee and dorsal flexion of the foot with the score of (0-5) on each measurement
1680105|NCT01618240|Other|Ventilator|A mechanical ventilator is used to assist or replace spontaneous breathing.
1680106|NCT01618227|Device|Joint Active Systems (JAS) Static progressive splint|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises throughout the study. Upon receipt of the splint, subjects will be instructed in proper application and use by their treating therapist or a representative of the company. Subjects will be instructed to follow the daily splint wearing protocol provided by the device manufacturer.
1680107|NCT01618227|Procedure|Rehabilitation without splinting|Subjects will have a standard rehabilitation program including physical or occupational therapy and home exercises without additional splinting.
1680108|NCT01618214|Drug|biphasic insulin aspart 30|Dose individually adjusted, administered subcutaneously (s.c., under the skin) twice daily.
1680109|NCT01618188|Drug|Faster-acting insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
1680110|NCT01618188|Drug|insulin aspart|A single dose of 0.2 U/kg body weight for subcutaneous (s.c., under the skin) administration.
1680206|NCT01617252|Device|Optiflow / Facial mask|J0: randomization (Optiflow® or facial mask), lung X-ray, kinesiotherapy H0 : clinical examination, blood gas, respiratory frequency H1 : clinical examination, blood gas, respiratory frequency H6 : clinical examination, blood gas J1: clinical examination, blood gas, respiratory frequency, lung X-ray, diaphragmatic echography, kinesiotherapy J2: clinical examination, blood gas, lung X-ray, kinesiotherapy Follow-up (until withdrawal of Optiflow or facial mask): clinical examination, blood gas, lung X-ray, kinesiotherapy
1680111|NCT01618175|Device|Home oxygen therapy|"Oxygen will be provided using a generator, through nasal prongs at a flow rate up to 1 L/min.
During home stay the parents will be guided on how to suspect signs of clinical deterioration. General treatment: If oxygen saturation by pulse oximeter is greater than 92%, the oxygen will be reduced by a quarter liter per minute while monitoring for 15 minutes. If oxygen saturation decreased to less than 92% of the child will remain with the best previous oxygen flow until the next visit. Once the child reaches - 0.06 l / min for 15 minutes, he will will be checked back on room air. Cessation of oxygen therapy: when the oxygen saturation remains above 92% on room air. Every day that no home visit was performed a phone call will be done and follow-up questionnaire will be filled daily, including oxygen saturation registration."
1680114|NCT01618149|Radiation|dual energy x-ray absorptiometry|before the surgery of total knee arthroplasty and after the surgery 6 months and 12 months
1680115|NCT01618136|Drug|E7449 alone|Will be administered as single agent orally, once daily (QD) continuously in 28-day cycles to determine the MTD. In these subjects, a food-effect component will be conducted under fed/fasted conditions to determine the effect of food on the bioavailability of E7449 administered orally QD.
1680116|NCT01618136|Drug|E7449 plus TMZ|Dose escalation,will be administered orally, once daily for 7 consecutive days along with 150 mg/m2/d TMZ administered orally, once daily for 5 consecutive days in 28-day cycles to determine the MTD of E7449 in combination with TMZ.
1680117|NCT01618136|Drug|E7449 plus carboplatin and paclitaxel|Dose escalation, E7449 will be administered orally, once daily continuously in 21-day cycles along with carboplatin and paclitaxel, which will be administered via i.v. infusion on Day 1 of the cycle only, to determine the MTD of E7449 in combination with carboplatin and paclitaxel.
1680118|NCT01618110|Device|Transcranial Magnetic Stimulation (Magstim, Rapid)|Superficial rTMS, directed at right PFC, power of 100% of MT, 10Hz for 4 seconds, intervals of 30 seconds, 42 trains.
1680119|NCT01618110|Other|Placebo Treatment|Sham coil (minimal magnetic field, same noise and feeling)
1680120|NCT01618097|Behavioral|DVD Decision Aid|Patients will receive the DVD decision aid to view, and follow up 3 days and 30 days post visit.
1680121|NCT01618097|Behavioral|Internet Based Decision Aid|Patients will receive the OA specific internet based decision aid to view, and follow up 3 days and 30 days post visit
1680122|NCT01618084|Device|Tritanium acetabular component|Total hip arthroplasty using a tritanium uncemented acetabular component
1680123|NCT01618071|Dietary Supplement|High-fat meals varying in their fatty acid composition|70 g fat incorporated into a muffin and milkshake meal, consumed following fasting baseline measurements
1680124|NCT01618058|Drug|No Investigational Product|"This study is observational in nature and no investigational product will be used.
Groups: ARV-Treated Participants, ARV-Naive Participants"
1680125|NCT01618045|Dietary Supplement|Fermented Papaya Preparation (FPP)|Participants will take fermented papaya preparation (FPP) for a total of 6 weeks (3 grams, three times each day for a total of 9 grams per day). The participants will attend 5 study visits and have their blood draw at each visit (5 total times).
1680126|NCT01618032|Other|HVLA|High velocity and low amplitude manipulation in traction of subtalar jonit
1680127|NCT01618032|Other|MWM|Mobilization with movement as Mulligan for increase dorsiflexion of the ankle in weight bearing
1680128|NCT01618032|Other|placebo|Manual contact during a period of time similar of teh other interventions
1680129|NCT01618019|Dietary Supplement|Omega-3 fatty acid|5 capsules/day of either n-3 PUFA, containing 2.09 g eicosapentaenoic acid and 1.165 g docosahexaenoic acid
1680130|NCT01618019|Dietary Supplement|Placebo|5 capsules/day of placebo containing sunflower with oleic acid (DSM Nutritional products, Switzerland)
1680131|NCT01618006|Drug|Aspirin|Aspirin 81mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
1680132|NCT01618006|Drug|Aspirin|Aspirin 325mg po daily x 7days or end of hospitalization. First dose administered on post op day 1.
1680133|NCT01618006|Drug|Aspirin|Aspirin 81mg po four times daily x 7days or end of hospitalization. First dose administered on post op day 1.
1680134|NCT01617980|Other|Multimodal hypoxia imaging|Patients with inoperable, stage III non-small cell lung cancer receive serial 18F-FMISO dPET-CT and functional MRI investigations prior, during and post radiation treatment
1680135|NCT01617967|Drug|ALN-TTR02|Ascending doses of ALN-TTR02 administered by intravenous (IV) infusion
1680136|NCT01617954|Device|MammaPrint|All subjects
1680137|NCT01617941|Drug|BGG492|
1680138|NCT01617941|Drug|Placebo|In patients not tolerating a dose of 75 mg BID BGG492/Placebo the dose can be decreased to 50 mg BID and this dose will be continued for the rest of the planned treatment. Those patients who are not tolerating 50 mg BID BGG492/Placebo will be discontinued from the trial.
1680139|NCT01617928|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Day 1 through day 7 of each cycle. Decisions to move to the next cohort will be based on evaluation of DLTs in the current cohort. Decisions will be made with a discussion between the Sponsor and the principal investigator to dose escalate or de-escalate or add more subjects to the cohort.
1680140|NCT01617928|Drug|carboplatin|Carboplatin will be administered on Day 3 of each cycle, intravenously.
1680141|NCT01617928|Drug|paclitaxel|Paclitaxel will be administered on Day 3 of each cycle, intravenously.
1680142|NCT01617889|Other|Experimental powdered milk-based infant formula with an alternate fat blend|formula to be consumed ad lib
1680143|NCT01617889|Other|A powdered milk-based infant formula, standard fat blend|formula to be consumed ad lib
1680144|NCT01617850|Other|Supervised physical exercise training x3 weekly for 12 weeks|Physical exercise training 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
1680209|NCT01617226|Drug|Vorinostat|Vorinostat (with azacitidine) combined therapy arm; 300mg twice daily for 7 days starting on day 3 of each cycle in 28-day cycles for up to 6 cycles.
1731301|NCT00043134|Drug|decitabine|
1680145|NCT01617850|Other|Supervised physical exercise training x2 weekly for 8 weeks|Physical exercise training is carried out for 1 hour per session. The exercise rehabilitation programme is carried out as group training with individual supervision. At each exercise session two-experienced physiotherapist are leading the physical exercise training. Standardized physical exercise guidelines for each training session is described and followed. It consists of the following interventions: Warm up, aerobe fitness, muscle strength training and individual education and instruction in life stills changes in relation to physical activity.
1680146|NCT01617837|Device|P6 acupressure band|Comparison between groups 0-48 hours postoperatively.
1680147|NCT01617837|Other|Placebo band|Comparison between groups 0-48 hours postoperatively
1680148|NCT01617824|Drug|Linagliptin|Linagliptin 5 mg tablets for 4 days
1680149|NCT01617824|Drug|Placebo|Placebo tablets for 4 days
1680150|NCT01617811|Procedure|epidural anesthesia and analgesia|"A thoracic epidural catheter (T8-10) was placed in group E. A bolus of 8ml 1% lidocaine with 0.375% ropivacaine was administered 15min before skin incision, followed by 5-8 ml/hr infusion during surgery in group E.
Postoperative analgesia by PCEA in group E (concentration: 0.1% ropivacaine + 0.1μg/ml sufentanil, loading dose: 4ml, infusion rate: 8ml/hr, bolus: 4ml, 1hr limit: 16ml) and lasting for 48hr and PCIA in group G (concentration: 1μg/ml sufentanil, loading dose: 4ml, bolus: 2ml, 4hr limit: 30ml).
Both group received general anesthesia maintaining with 1-2% end tidal sevoflurane together with TCI of propofol (target plasma concentration, 2-3µg/ml), continuous infusion of remifentanil (0.10 - 0.20 μg/kg/min) and cis-atracurium intermittently as needed."
1680151|NCT01617798|Drug|Supplemental metolazone diuresis|Patients in the Study Arm will receive supplemental diuresis with metolazone 2.5 mg per dobhoff tube twice daily, in addition to furosemide as the primary team sees fit.
1680152|NCT01617798|Drug|Placebo Comparator: Control-- furosemide (lasix) only|Control arm will receive furosemide as monotherapy for diuresis
1680153|NCT01617772|Drug|Atorvastatin|Atorvastatin 20 mg
1680154|NCT01617772|Drug|L-Carnitine|1000mg L-carnitine
1680155|NCT01617772|Drug|Placebo|Identically looking placebo
1680156|NCT01617746|Drug|Ambrisentan|5mg od two weeks
1680157|NCT01617746|Drug|Bosentan|62.5mg bd two weeks
1680158|NCT01617746|Drug|Placebo|bd for two weeks
1680159|NCT01617733|Drug|Pasireotide|4 Weeks pasireotide 0.6mg s/c injections twice daily followed by 24 weeks treatment with pasireotide LAR 60mg every 28 days with dose reductions if poor tolerability is encountered
1680160|NCT01617707|Drug|Midazolam plus propofol|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
1680161|NCT01617707|Drug|Midazolam|In both study arms, patients who were 20-70 years of age received an initial intravenous bolus of 0.05mg/kg of midazolam, while patients ≥71 years of age received an initial intravenous dose of 1mg of midazolam. After 2min following this initial dose of midazolam, the conventional sedation group received additional boluses as needed of 1 to 2 mg of midazolam at the discretion of the endoscopist, to target moderate sedation. The BPS group received an initial 0.5mg/kg bolus of intravenous propofol at 2min after midazolam administration. Subsequent incremental boluses of 10 to 20 mg of propofol were allowed to be given at the discretion of the endoscopist every 30s to target moderate sedation.
1680162|NCT01617694|Drug|dexmedetomidine|Fifteen minutes before the end of surgery, the first practitioner replace the syringe of remifentanil as new one; new syringe contains remifentanil in remifentanil group (Group R), and normal saline in dexmedetomidine group (Group D), respectively. There are no drug labeling in the new syringe, so the second practitioner can't know which drug was contained in the new syringe. Simultaneously, the second practitioner remifentanil concentration on monitor of TCI pump will be adjusted to 2.0 ng•ml-1. Ten minutes before the end of surgery, 10 ml of dexmedetomidine 0.5 mcg•kg-1 mixed with normal saline will be given for 5 min in Group D; in Group R, 10 ml of normal saline will be given by the first practitioner.
1680163|NCT01617694|Drug|Normal Saline|
1680164|NCT01617681|Drug|VAL489|Valsartan 3mg/kg oral solution
1680165|NCT01617681|Drug|VAL489 matching placebo|Valsartan 3 mg/kg oral solution
1680166|NCT01617668|Drug|LCL161|LCL161 was available as 300 mg, tablets, which was supplied in child-resistant bottles.
1680167|NCT01617668|Drug|paclitaxel|"Commercially available paclitaxel was sourced locally by each study site. Generic paclitaxel could be used for study treatment.
iv 80mg/m2"
1680168|NCT01617655|Drug|Alirocumab|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
1680169|NCT01617655|Drug|Placebo (for alirocumab)|Solution for subcutaneous injection in the abdomen, thigh, or outer area of the upper arm by self-injection or by another designated person using auto-injector (also known as pre filled pen).
1680170|NCT01617655|Drug|Lipid Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
1680171|NCT01617629|Biological|MUC1 Dendritic Cell Vaccine (Cvac)|"The recommended dosing regimen for CAN-003X is every 4 weeks for the first 3 doses and then every 12 weeks for 3 doses, for a total of 6 doses over 44 weeks (Regimen A, applicable to CAN-003 observational Standard of Care patients and CAN-003 Cvac patients that have progressed prior to the fourth dose of Cvac).
Patients who received more than 3 doses of Cvac in CAN-003 should continue with the CAN-003 dosing schedule (Regimen B; Cvac every 4 weeks for a total of 7 doses and then every 8 weeks for 3 doses, for a total of 10 doses over approximately 48 weeks)"
1680172|NCT01617603|Other|Cocoa Polyphenols|20g/d of product, two active products provide 20 mg/d epicatechin, on visiting occasions, an acute dose of 40g product to be given
1680207|NCT01617239|Biological|Virosomal influenza vaccine|"Virosomal influenza vaccine with the recommended vaccine composition for season 2011-2012:
15 μg HA antigen of A/California/7/2009 (H1N1)-like virus
15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus
15 μg HA antigen of B/Brisbane/60/2008-like virus
Intramuscular (i.m.) administration (M. deltoideus or M. vastus lateralis)"
1680173|NCT01617590|Drug|leflunomide|"Leflunomide 10-20 mg, orally, once daily for up to 48 weeks. Twelve weeks after the initial Leflunomide induction, patients were randomized into two groups (LEF+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing leflunomide use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.
Intravenous CTX was administrated once 200-400mg per 3 weeks."
1680174|NCT01617590|Drug|methotrexate|"MTX 7.5-15 mg, orally, once weekly for up to 48 weeks. Twelve weeks after the initial MTX induction, patients were randomized into two groups (MTX+CTX:LEF+MTX=2:1) if the DAS 28 were higher than 2.6, or continuing MTX use without dosing change. Then, the disease activity was assessed using DAS 28 every 12 weeks. The regimen should remain unchanged if the DAS 28 reached to less than 2.6, otherwise, a third (24 weeks) or fourth (36 weeks) DMARs should be added.
Intravenous CTX was administrated once"
1680175|NCT01617577|Drug|G-CSF; filgrastim|The drug is administered s.c. at a dose of 10 microg/kg daily for 5 days
1680176|NCT01617577|Drug|Placebo|vehicle (D5W or 5% dextrose solution) is administered subcutaneously daily for 5 days
1680177|NCT01617564|Drug|bipuvacain|PCB with 20ml bupivakain or sodium cloride 9mg/ml will be administered one hour following misorpostol administration (first dose).
1680178|NCT01617564|Other|NaCl|PCB with 20ml sodium chloride (9mg/ml) inactive (sham) comparator
1680179|NCT01617551|Drug|NG-monomethyl-L-arginine (L-NMMA)|Acute L-NMMA treatment (4,5 mg/kg loading dose followed by 3 mg/kg sustain infusion for 1 hour)
1680180|NCT01617538|Drug|atorvastatin|40mg per day,duration for 24 weeks
1680181|NCT01617525|Other|Controlled Feeding Dietary Intervention|All meals will be provided during each 4-week intervention period. Participants must consume all foods provided and must not consume any outside foods during each intervention period.
1680182|NCT01617512|Device|LIS302DL accelerometer|Recording for 24 hours accelerations related to daily physical activity of the patient.
1680183|NCT01617499|Behavioral|Physical activity|The worksite wellness program included cardiovascular health assessments, personal health reports, 8 weeks of pedometer-based walking and tracking activities, and weekly wellness sessions.
1680184|NCT01617486|Behavioral|BALANCE|The intervention will focus on the replacement of 'obesogenic' patterns (such as high soda intake, excess portion size, and sedentary activity) with 'energy' patterns (such as water consumption, appropriate portion size, and walking).
1680185|NCT01617473|Procedure|transplant with PBSCs|mobilized PBSCs for 2 consecutive days
1680187|NCT01617447|Drug|Placebo of Aripiprazole|administered orally once daily
1680188|NCT01617447|Drug|Aripiprazole|Flexibly dose administered orally once daily
1680189|NCT01617434|Drug|liraglutide|Maximum 1.8 mg administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
1680190|NCT01617434|Drug|placebo|Placebo administered s.c. (subcutaneously, under the skin) once daily in addition to the subject's stable pre-trial basal insulin analogue regimen plus/minus metformin.
1680192|NCT01617369|Device|Hypertonic Saline|2.8% NaCl x 4ml via nebulizer
1680193|NCT01617356|Other|Injection of 20% dextrose/ 0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 20% dextrose and 0.2% lidocaine.
1680194|NCT01617356|Other|Injection of 1 ml of 0.8 SW/0.2% lidocaine|Injection at 0, 1, and 2 months of 1 ml of a solution consisting of 0.8 sterile water and 0.2% lidocaine.
1680195|NCT01617343|Behavioral|hemifield eye patching (HEP) + optokinetic stimulation (OKS)|"Patients in this arm will wear standard spectacle frames containing noncorrective lenses to which right half-field patches are attached (hemifield eye patching, HEP). In case of patients already wearing prescribed glasses, the patches will be attached to their own glasses. The glasses will be worn all-day for the duration of the treatment phase (seven days) and only be removed for sleeping and face cleaning as well as for the duration of the daily OKS treatment sessions.
Furthermore these patients will receive daily sessions (20 minutes) of optokinetic stimulation (OKS). Therefore patients will be seated in front of a widescreen monitor, watching a black background with a pattern of various objects (size 1°), which coherently and continuously move to the left at a velocity of 10 °/s."
1680196|NCT01617330|Procedure|Bronchoscopy|Bronchoscopy with endobronchial biopsy sampling and bronchoalveolar lavage (BAL) 18 hours post exposure. Airway inflammation was assessed.
1680197|NCT01617317|Drug|Hyperimmune intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
1680198|NCT01617317|Drug|Intravenous immunoglobulin|Single intravenous infusion of 0.4g/kg of simple IVIG
1680199|NCT01617304|Other|Dietary intervention|Food made by different cooking methods (boiling/steaming versus frying) and with glucose or fructose water solution
1680200|NCT01617291|Other|Induced therapeutic hypothermia|induced therapeutic hypothermia
1680201|NCT01617278|Device|I-Scan 1|I-Scan 1 has contrast enhancement (CE)and surface enhancement (SE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.
1680202|NCT01617278|Device|HD Colon|High definition white light
1680203|NCT01617278|Device|I-Scan 2|I-Scan 2 has contrast enhancement (CE), surface enhancement (SE) and tone enhancement (TE). SE mode highlights light-dark contrast thereby providing more mucosal surface detail.CE mode digitally adds blue to darker areas providing detailed imaging of subtle mucosal irregularities.TE provides a uniform colour image and is intended for detailed inspection of distinct lesions.
1680204|NCT01617265|Procedure|Clinical Procedure to Prevent Oversedation|Sedation and analgesia will be administered according to a bundle of measures aimed at limiting oversedation, including repeated assessment of patients needs and graduate therapeutic response to control pain, discomfort, poor synchrony with the ventilator and agitation. The therapeutic options include non hypnotic anxiolytics, repeated IV hypnotics boluses, short-duration (6 hours) IV hypnotics infusion and round the clock IV hypnotics infusion.
1680205|NCT01617265|Procedure|Usual sedation practice|Sedation and analgesia will be administered according to the usual practices in each participating center.
1680208|NCT01617226|Drug|Azacitidine|Azacitidine both arms; 75mg/m^2 by subcutaneous injection for 7 days of a 28-day cycle for up to 6 cycles.
1731303|NCT00043147|Drug|methylprednisolone|
1680212|NCT01617200|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
1680213|NCT01617200|Drug|Placebo Asenapine|2.5 mg or 5 mg fast dissolving placebo asenapine tablets administered sublingually, same number of tablets are taken in the morning and the evening
1680214|NCT01617200|Drug|Olanzapine|15 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
1680215|NCT01617200|Drug|Placebo Olanzapine|15 mg film-coated placebo olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding.
1680216|NCT01617187|Drug|Asenapine|2.5 mg or 5 mg fast dissolving active asenapine tablets administered sublingually
1680217|NCT01617187|Drug|Placebo Asenapine|Fast dissolving placebo asenapine tablets (to match 2.5 mg and 5 mg active asenapine tablets) administered sublingually
1680218|NCT01617187|Drug|Olanzapine|5 and 10 mg film-coated active olanzapine tablets administered orally QD. The time of the active olanzapine dose (either morning or evening) is not disclosed in order to preserve blinding
1680219|NCT01617187|Drug|Placebo Olanzapine|Film-coated placebo olanzapine tablets (to match 5 and 10 mg active olanzapine tablets) administered orally
1680220|NCT01617174|Behavioral|Webcore telephone survey system|Patients will report pain and analgesic use through the automated telephone system, for 7 days in a row, once every 6 weeks. Data from diagnostic tests (CT Abdomen/Pelvis, Bone Scan, PSA, and circulating tumor cells) conducted during the study period will be collected from medical records by local personnel and entered into the secure online database quarterly, but no specific tests or schedules will be required in this observational study.
1680221|NCT01617161|Radiation|Proton Beam Therapy|5 days per week up to 9 weeks
1680222|NCT01617161|Radiation|Intensity Modulated Radiation Therapy|5 times per week up to 9 weeks
1680223|NCT01617135|Drug|CVT-301|
1680224|NCT01617135|Drug|Placebo|
1680225|NCT01617135|Drug|Sinemet (carbidopa/levodopa)|
1680226|NCT01617135|Drug|CVT-301|
1680227|NCT01617122|Biological|Bacteriophage OX174|Give first dose of bacteriophage (2 x 109 PFU/kg body weight (0.02 ml/kg)) at visit one. Obtain labs prior to vaccine, 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. 6 weeks after 1st vaccine, obtain blood, give 2nd dose of bacteriophage, obtain labs 15 minutes, 1 week, 2 weeks, and 4 weeks after vaccine. Selected patients may receive a tertiary vaccine.
1680228|NCT01617109|Dietary Supplement|Ca/Vit D|800IU vitamin D3 and 2000mg elemental calcium (as calcium carbonate); administered as 5 pills daily or 2 snack bars
1680229|NCT01617109|Other|Placebo|administered as 5 pills daily or as 2 snack bars
1680230|NCT01617096|Combination Product|Dapivirine Vaginal Ring|Dosage form: vaginal ring Dosage: 25mg Frequency: monthly Duration: 12 months
1680231|NCT01617096|Combination Product|Placebo Ring|Vaginal ring containing no drug substance
1680234|NCT01617070|Drug|Kuvan|Dosed at 20 mg/kg; PO; Phase 3, Phase 4
1680235|NCT01617070|Dietary Supplement|Large Neutral Amino Acid Therapy|Dosed by weight: weight x .5 = total tablets per day; PO; Phase 1, Phase 4; taken with food
1680236|NCT01617057|Drug|tiludronic acid|400 mg / day for 3 months
1680237|NCT01617057|Drug|Placebo|400 mg / day for 3 month
1680238|NCT01617044|Dietary Supplement|Probiotics|probiotics lactobacillus plantarum 299 (1x10x8 colony forming units)
1680239|NCT01617044|Dietary Supplement|Placebo|Placebo
1680240|NCT01617005|Drug|Tocilizumab|Participants will receive tocilizumab treatment according to effective official SPC. The study protocol does not enforce treatment initiation and also does not specify any treatment regimen.
1680241|NCT01616992|Drug|Bupivacaine|20 ML dose of 0.75% Bupivacaine Instillation (into bladder) 1 time during second study visit.
1680242|NCT01616979|Procedure|placing saline bag during cardiac displacement|For grafting to LCX territory, the heart is displaced using positioner and a suction-type epicardial stabiliser is applied to the target area. The degree of cardiac displacement and the LV compression by stabilisers are adjusted for maximal surgical access and minimal haemodynamic instability.
1680243|NCT01616966|Drug|Sevoflurane|Maintenance of anesthesia with sevoflurane 1.0 Vol%
1680244|NCT01616966|Drug|propofol|Maintenance of anesthesia with propofol
1680245|NCT01616953|Biological|Ixmyelocel-T|Twelve days after the bone marrow aspiration, alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with the cell therapy (Ixmyelocel-T)
1680246|NCT01616953|Procedure|Autogenous Bone Grafting|Alveolar grafting will be performed. Under local anesthesia, and possibly conscious intravenous sedation (depending on patient desire for sedation due to anxiety), alveolar grafting will be performed with an autogenous bone block harvested from an intraoral or extraoral site, according to standard of care.
1680247|NCT01616940|Behavioral|Enhanced Peer Intervention|"Eight 30-60 minute educational sessions with peer will occur in-person bi-weekly once participant is randomized to intervention:
Introduction and Assessment
HIV Transmission & Viral Life Cycle
Effective Communication and Self-Advocacy
Understanding Lab Values
HIV Medications
Drug Resistance & Adherence, and Understanding & Managing Side Effects
Disclosure and Stigma
Harm & Risk Reduction
Weekly check-ins will be by phone or in-person over 12 months. Check-in questions/tasks:
Are any services needed?
Have referrals or appointments been made?
Does patient need accompaniment to a visit?
Connect patient with services as needed.
Appointment reminders.
Overall well-being?
Schedule next peer contact."
1680248|NCT01616927|Drug|Lanreotide|Lanreotide will be administered once every 4 weeks as a subcutaneous injection
1680249|NCT01616901|Procedure|Spontaneous breathing trial|"5 spontaneous breathing trial will be tested by the patients in the same order :
7 cm H2O continuous positive airway pressure
T piece
7 cmH2O of pressure support
0 cmH20 of pressure support
7 cm H2O pressure support ventilation with 7 cmH20 of end expiratory pressure."
1680250|NCT01616888|Device|PTA with drug eluting balloon with paclitaxel|Angioplasty with drug eluting balloon with paclitaxel on femoropopliteal arteries
1680251|NCT01616875|Drug|Cabazitaxel + Cisplatin chemotherapy|Cabazitaxel 15mg/m2 followed by cisplatin 70mg/m2 given intravenously on day 1 of each 3 weekly cycle for 4 cycles prior to radical cystectomy.
1680252|NCT01616849|Drug|cisplatin and 5-Fu combined with nimotuzumab|"DDP+5-Fu DDP 100 mg/m2 intravenous infusion in day1, 5-Fu 1000mg/m2/d continuous intravenous infusion on days 1 through 4, both drugs are given every 3 weeks.
Nimotuzumab 200mg/d, intravenous infusion every week"
1680253|NCT01616836|Other|continuous FNB|femoral nerve block (ropivacaine 0.5%, 20 mL) with femoral nerve block infusion 48 h (ropivacaine 0.2%, 5mL/h), placebo local infiltration
1680254|NCT01616836|Other|single femoral nerve block|single femoral nerve block (ropivacaine 0.5%, 20 mL), placebo femoral nerve block infusion, placebo local infiltration
1680255|NCT01616836|Other|local infiltration analgesia|placebo fascia iliac block, placebo fascia iliaca infusion, local infiltration analgesia (tricompartmental injection of 150 mL ropivacaine 0.2%, ketorolac 30 mg, epinephrine 10 microg/mL)
1680256|NCT01616797|Behavioral|Computerized neurobehavioral intervention|Participants will complete the intervention by logging into a secure online website and complete computerized neurobehavioral tasks. Tasks will train the following - cognitive control, working memory and task shifting with two different tasks that engage these skills and positivity biases.
1680257|NCT01616784|Other|CSII (Insulin Pump) plus DAFNE|Medtronic MiniMed Paradigm Veo Insulin pumps (X54)
1680258|NCT01616784|Other|MDI (levemir® & quick acting insulin) plus DAFNE|Optimised MDI therapy using rapid and twice daily (Detemir/Levemir) long-acting insulin analogues
1680259|NCT01616771|Device|Macintosh laryngoscope|Glottis view assessment by direct visualization using Macintosh laryngoscope
1680260|NCT01616771|Device|GVL selected by weight|Glottis view assessment by GVL selected by weight which is usually selected first
1680261|NCT01616771|Device|smaller sized GVL|Glottis view assessment by GVL which is smaller in one size than GVL selected by age
1680262|NCT01616758|Drug|GTx-024 9mg|
1680263|NCT01616732|Drug|Testosterone|TU im
1680264|NCT01616732|Drug|placebo|placebo im
1680265|NCT01616719|Device|DTRAX Graft|DTRAX Graft is an allograft implant inserted to support spinal fusion.
1680266|NCT01616693|Biological|Rotavirus vaccine (Rotarix), oral polio vaccine (Bio-polio), zinc supplement and probiotic supplement (Culturelle)|"Oral rotavirus vaccine (Rotarix). 2 doses (1 ml) at 6 and 10 weeks of age.
Oral polio vaccine (Bio-polio). 3 doses (0.1 ml) at 6, 10 and 14 weeks of age.
Oral zinc sulphate syrup or placebo (1mg/ml; 5ml), given weekly starting 1 week pre-rotavirus vaccine dose 1 through 1 week post rotavirus vaccine dose 2.
Oral probiotic, Lactobacillus rhamnosus (Culturelle) or placebo (lx10^9; 20ml), given weekly starting 1 week pre-rotavirus vaccine dose 1 through 1 week post rotavirus vaccine dose 2."
1680267|NCT01616680|Drug|brentuximab vedotin|Given IV
1680268|NCT01616680|Other|laboratory biomarker analysis|Correlative studies
1680269|NCT01616680|Other|pharmacological study|Correlative studies
1680270|NCT01616667|Procedure|Total hip arthroplasty|The patients included is operated with a total hip arthroplasty due to primary osteoarthritis
1680271|NCT01616654|Drug|CD5789 25 µg/g cream|CD5789 25 µg/g cream applied once daily
1680272|NCT01616654|Drug|CD5789 50 µg/g cream|CD5789 50 µg/g cream applied once daily
1680273|NCT01616654|Drug|CD5789 100 µg/g cream|CD5789 100 µg/g cream applied once daily
1680274|NCT01616654|Drug|Tazarotene 0.1% gel|Tazarotene 0.1% gel applied once daily
1680275|NCT01616654|Drug|Vehicle cream|Vehicle cream applied once daily
1680276|NCT01616628|Behavioral|Fruit and vegetable rewards|Participants earn reward points at 50% the rate of how much they spend on fruit and vegetables. The earned reward points are distributed as money added to gift cards to be redeemed at the market.
1680277|NCT01616615|Drug|Aspirin|150 mg/day oral use
1680278|NCT01616615|Drug|placebo|1 capsule / day oral use
1680279|NCT01616602|Other|Prone Position|Patients were asked to lay on their abdomen for their elective colonoscopy.
1680280|NCT01616602|Other|Standard Position|The traditional left-lateral decubitus position
1680281|NCT01616576|Device|Control first, then Experimental|Control condition is currently marketed sound processing strategy.
1680282|NCT01616576|Device|Experimental first, then Control|Experimental condition is newly modified sound processing strategy.
1680283|NCT01616563|Behavioral|Dietary Intervention|Nutrition assessment, review of the basic principles of dietary intervention for metabolic syndrome with an emphasis on the clinical risk factors identified for each individual, joint goal setting to determine what dietary changes are feasible, considering intention and barriers to dietary behaviour change.
1680284|NCT01616563|Behavioral|Exercise Prescription and Fitness Program|Exercise tests (aerobic fitness, muscular and flexibility tests) recommended by the Canadian Society of Exercise Physiology (CSEP), followed by an individualized exercise plan including fitness assessments.
1680285|NCT01616550|Other|Assessment of pain using the Brief Pain Questionnaire|Patients will complete this questionnaire daily from surgery until discharge from the hospital
1680286|NCT01616550|Other|Assessment of pain relief using a Verbal Numeric Scale (VNS)|Patients will assess their pain daily from surgery until discharge from the hospital using the VNS
1680287|NCT01616550|Other|Assessment of patient' satisfaction with pain relief|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
1680288|NCT01616550|Other|Nurse's satisfaction with patient's pain relief and recovery|Will be assessed three times a day using a scale from 1 to 4 (1= very unsatisfied, 4= very satisfied)
1680289|NCT01616537|Other|QUALITY OF LIFE QUESTIONNAIRE|QASICC AND EORTC QLQ-C30 ADMINISTRATION 30 DAYS AFTER CVC IMPLANTATION
1680290|NCT01616524|Biological|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
1680291|NCT01616524|Biological|Pegylated interferon lambda (pegIFNλ)|Syringe, Subcutaneous, 180 μg, Once weekly, 12 weeks
1680292|NCT01616524|Biological|Pegylated interferon alfa-2a (pegIFNα-2a)|Syringe, Subcutaneous, 180 μg, Once weekly, 24 weeks
1680293|NCT01616524|Drug|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 24 weeks
1680294|NCT01616524|Drug|Ribavirin|Tablets, Oral, 400 mg, Twice daily, 12 weeks
1680295|NCT01616524|Drug|Daclatasvir|Tablets, Oral, 60 mg, Once daily, 12 weeks
1680296|NCT01616524|Drug|Placebo matching Daclatasvir|Tablets, Oral, 0 mg, Once daily, 12 weeks
1731304|NCT00043147|Drug|prednisone|
1680301|NCT01616472|Drug|Cumulative corticosteroid exposure|Cumulative steroid exposure will be modeled as cumulative dose (prednisone equivalent mg), cumulative days of exposure at any dose, cumulative days of exposure to doses ≥7.5mg and cumulative days of exposure to doses ≥20mg.
1680302|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830929A|Intramuscular injection
1680303|NCT01616459|Biological|Pneumococcal conjugate vaccine GSK2830930A|Intramuscular injection
1680304|NCT01616459|Biological|Synflorix™|Intramuscular injection
1680305|NCT01616459|Biological|Prevnar 13™|Intramuscular injection
1680306|NCT01616459|Biological|Infanrix hexa™|Intramuscular injection
1680307|NCT01616433|Behavioral|AFEP|Arthritis Foundation Exercise Program (10 weeks, twice a week, 60 minutes per session)
1680308|NCT01616433|Behavioral|"10 Keys to Healthy Aging"|"10 Keys to Healthy Aging. 10 week program, twice a week, 75 minutes per session."
1680309|NCT01616420|Other|Assisted-partner notification services|Assisted-partner notification services (aPS) is a public health service which notifies the partners of those who test positive for a communicable disease of their exposure.
1680310|NCT01616407|Drug|3,4-Methylenedioxymethamphetamine|75 mg per os, single dose
1680311|NCT01616407|Drug|Methylphenidate|40 mg per os, single dose
1680312|NCT01616407|Drug|Placebo|capsules identical to MDMA or methylphenidate but containing no active drug
1680313|NCT01616381|Drug|Sildenafil|PDE-5 Inhibitor
1680314|NCT01616381|Drug|Placebo|Placebo for sildenafil 40mg x 3 daily
1680315|NCT01616368|Behavioral|Mindful Eating and Living Course|An eight week course designed to teach mindfulness skills with an emphasis on mindful eating.
1680316|NCT01616355|Other|Sodium hypochlorite immersion|Dentures daily immersion in a 0.5% sodium hypochlorite solution for 3 minutes.
1680317|NCT01616342|Device|Spinal cord stimulator|Precise (TM) spinal cord stimulator from boston scientific, and comprehensive mdedical management.
1680318|NCT01616316|Procedure|subfascial flap|subfacial dissection to thyroid
1680319|NCT01616316|Procedure|subplatysmal flap|subplatysmal approach to thyroid
1680320|NCT01616303|Drug|Carboplatin & paclitaxel|Carboplatin (area under the curve (AUC) 6, administered intravenously in a single day for 6 cycles every three weeks [21 days]) plus paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks [21 days])
1680321|NCT01616303|Biological|Carboplatin & paclitaxel & oregovomab|Carboplatin (AUC 6, administered intravenously in a single day for 6 cycles every three weeks [21 days]) plus paclitaxel (175 mg / square meter, intravenously over three hours in one day to be repeated for 6 cycles every three weeks [21 days]) plus oregovomab (2 mg infused intravenously jointly during the 1st, 3rd and 5th chemotherapy cycle and 12 weeks after the 5th cycle).
1680322|NCT01616290|Drug|PRT-201|0.03, 1, or 3 mg single adventitial administration
1680323|NCT01616277|Biological|PF-06252616|1.0 milligram per kilogram of PF-06252616, IV infusion, single dose
1680324|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
1680325|NCT01616277|Biological|PF-06252616|3.0 milligram per kilogram of PF-06252616, IV infusion, single dose
1680326|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
1680327|NCT01616277|Biological|PF-06252161|10.0 milligram per kilogram of PF-06252616, IV infusion, single dose
1680328|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
1680329|NCT01616277|Biological|PF-06252616|3.0 milligram per kilogram of PF-06252616, Subcutaneous injection, single dose
1680330|NCT01616277|Drug|Placebo|Placebo for PF-06252616, Subcutaneous injection, single dose
1680331|NCT01616277|Biological|PF-06252616|10.0 miligram per kilogram of PF-06252616, IV infusion, repeat dose
1680332|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, repeat dose
1680333|NCT01616277|Biological|PF-06252616|20.0 milligram per kilogram of PF-06252616, IV infusion, single dose
1680334|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
1680335|NCT01616277|Biological|PF-06252616|40.0 milligram per kilogram of PF-06252616, IV infusion, single dose
1680336|NCT01616277|Drug|Placebo|Placebo for PF-06252616, IV infusion, single dose
1680337|NCT01616251|Other|Acute effect of animal and vegetable protein rich meals with comparable dietary fibers content on appetite sensation and energy intake|4-arm crossover study with the objective to examine if vegetable protein (beans and peas) can suppress subjective appetite (VAS and ad libitum EI) compared to isocaloric meals enriched with either red meat or egg with similar distribution of macronutrients and content of dietary fibers.
1680338|NCT01616238|Drug|Chemotherapy|Treatment for all pathways consists of Induction, Intensification (where applicable), Consolidation and Maintenance therapy during which combination chemotherapy is given for up to 2.5 years.
1680339|NCT01616225|Drug|Saizen (Human Growth Hormone)|Subjects will receive the standard protocol treatment, as well as adjuvant GH. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start 14 days before FSH start and will continue until the day of the HCG treatment.
1680340|NCT01616225|Drug|Saizen (Human Growth Hormone)|Subjects will receive the standard IVF treatment, as well as adjuvant GH as above. One 3.33 mg vial Human Growth Hormone(10 IU Saizen®) will be self-administered daily by subcutaneous injection. GH treatment will start on the same day as the FSH start and will continue until the day of HCG treatment.
1680341|NCT01616225|Drug|No Saizen Control (Standard IVF Protocol)|All patients will be administered an oral contraceptive (Marvelon®). FSH treatment (daily subcutaneous injections of 450 IU Gonal-F®; Serono Canada) must begin 4 days after OCP stop, providing both of the following criteria are met. Pituitary downregulation with GnRH antagonist (Cetrotide®, Serono Canada) 0.25mg daily (subcutaneous injection) and LH (Luveris®, Serono Canada) 75 IU daily (subcutaneous injection) will be initiated when one or both of the following criteria are satisfied. Monitoring will continue until a lead follicle reaches ≥18 mm, at which time HCG (Ovidrel®, Serono Canada) 250 mcg will be administered by subcutaneous injection. Oocytes will be retrieved 36 hours after HCG treatment. Luteal support for the endometrium (90 mg progesterone (8% progesterone gel; Crinone® gel), administered intravaginally once daily) will begin one day after oocyte retrieval and will be maintained at least until day 31 of gestation.
1680342|NCT01616212|Other|Motivational Enhancement Therapy /Adol and PW for parents|Motivational Enhancement Therapy for adolescents, Parenting Wisely for parents
1680344|NCT01616212|Other|Drug Education for adolescents, Parenting Wisely for parents|Drug Education for adolescents, Parenting Wisely for parents
1680345|NCT01616212|Other|Drug Education for adolescents|Drug Education for adolescents
1680346|NCT01616199|Drug|PX-866|"Phase 1 dose escalation: PX-866 in combination administered orally every day in 28-day cycles until progression or unacceptable toxicity.
Phase 2 combination: PX-866 and vemurafenib administered every day in 28 day cycles until progression or unacceptable toxicity.
Phase 2 single-agent: vemurafenib administered orally at labeled dose every day in 28 day cycles until progression or unacceptable toxicity."
1680347|NCT01616199|Drug|vemurafenib|vemurafenib is a B-Raf enzyme inhibitor
1680348|NCT01616186|Drug|Everolimus and sorafenib|"Starting doses: everolimus 5 mg daily and sorafenib 400 mg BID - taken fasting, no food 1 hour before or 2 hours after dosing
Everolimus and sorafenib are dosed continuously
(Note: everolimus and sorafenib are typically dosed in 28 day cycles, and sunitinib is typically dosed in 42 day cycles; for the purposes of this protocol to keep timing consistent, a cycle will be defined as 42 days of therapy)"
1680349|NCT01616186|Drug|Sunitinib monotherapy|"Starting dose: sunitinib 50 mg daily 4 weeks on, 2 weeks off - taken fasting, no food 1 hour before or 2 hours after dosing
(Note: sunitinib is typically dosed in 42 day cycles described above: 28 days treatment, 14 days off. For the purposes of this protocol, to keep timing consistent, a cycle will be defined as 42 days of therapy)"
1680350|NCT01616173|Drug|Dexamethasone|IV dexamethsone 8mg in 50mL (diluted in NS)
1680351|NCT01616173|Drug|Dexamethasone|8mg/2mL
1680352|NCT01616173|Drug|Saline|2mL
1680353|NCT01616160|Drug|mometasone furoate|2 sprays/nostril BID
1680354|NCT01616147|Behavioral|Intensive Lifestyle Intervention (ILI)|Women in the ILI arm will receive intensive counseling during pregnancy and group counseling after delivery regarding behavior, nutrition, and physical activity change. Visits to counselors will occur twice monthly with additional weekly telephone and internet contacts.
1680355|NCT01616147|Behavioral|Usual Care|Women in the usual care group will be offered group support classes approximately every 2 months during pregnancy and 3 months after pregnancy.
1680356|NCT01616134|Other|Korea red ginseng|Intervention group were administered with 4 capsules (2 g) each of powdered red ginseng (6-year old , rootlets) 40 minutes before breakfast, lunch and dinner, totaling 12 capsules (6 g) per day, for 12 weeks
1680357|NCT01616134|Other|Placebo|The subjects in the Control group were given the same quantity of placebos also three times a day for 12 weeks.
1680358|NCT01616121|Other|Usual treatment of patients with developing acute heart failure|
1680359|NCT01616121|Device|Lung Impedance-Guided Therapy|Non-invasive lung impedance monitor (RSMM Company, Tel Aviv, Israel)
1680360|NCT01616108|Drug|Bupivacaine|Differences in concentration from 0.75% to 3.0% are compared. Differences in volume for 1.0 mL to 3.0 mL are compared. Differences in compounding with addition of epinephrine will be used and compared to plain bupivacaine.
1680363|NCT01616069|Drug|epinephrine and levosimendan|epinephrine (0,06mcg/kg/min), levosimendan (0,2 mcg/kg/min)
1680364|NCT01616056|Biological|graft versus host disease prophylaxis/therapy|Wear bandage lenses
1680365|NCT01616056|Other|questionnaire administration|Ancillary studies
1680366|NCT01616056|Procedure|optical coherence tomography|Optional ancillary studies
1680367|NCT01616043|Procedure|Glyaderm|acellular dermis
1680368|NCT01616043|Procedure|STSG|autologous split skin only
1680369|NCT01616030|Other|Knee-extension strength training of the fractured limb|Daily knee-extension strength training with 3 x 10 repetitions using an intensity of 10 Repetition Maximum (RM) for the hip fractured limb started as soon as possible after surgery.
1680370|NCT01616004|Drug|N2O|
1680371|NCT01616004|Drug|Air|sham comparator
1680372|NCT01615991|Drug|Radiosynoviorthesis|Intraarticular administration from 111 to 222 Mbq yttrium-90 per joint
1680373|NCT01615978|Drug|liraglutide|5 mcg/kg daily for 14 days. Injected subcutaneously once daily
1680374|NCT01615978|Drug|liraglutide|Initial dose of 5 mcg/kg for 7 days followed by 10 mcg/kg for 7 days. Injected subcutaneously once daily
1680375|NCT01615978|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
1680376|NCT01615965|Other|tumor marker detection in lymph nodes|tumor marker detection in lymph nodes by quantitative PCR
1680377|NCT01615939|Drug|Bupivacaine|Bupivacaine 0.625% with epinephrine 1:300,000
1680378|NCT01615939|Drug|Ropivacaine|0.2% ropivacaine 5 ml/hr with a 5 ml bolus/hr.
1680379|NCT01615913|Drug|3 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 3% terbinafine (contains 3-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 3.99 mcg for terbinafine and 1.70 mcg for ketoconazole, respectively.
1680380|NCT01615913|Drug|6 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 6% terbinafine (contains 6-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 8.52 mcg for terbinafine and 2.03 mcg for ketoconazole, respectively.
1955295|NCT03233204|Other|Laboratory Biomarker Analysis|Correlative studies
1731536|NCT00048217|Drug|T-1249|
1955296|NCT03233204|Drug|Olaparib|Given PO
1955297|NCT03233204|Other|Pharmacological Study|Correlative studies
1680381|NCT01615913|Drug|8 mg terbinafine and 2 mg ketoconazole containing patch|A novel transdermal patch that is to be used to treat toenail onychomycosis with minimal body exposure to the antifungal drugs. The active substances in the patch are 8% terbinafine (contains 8-mg terbinafine/patch) and 2% ketoconazole (contains 2‐mg ketoconazole/patch). The average daily released drug amount estimated from in‐vitro skin permeation test were about 10.7 mcg for terbinafine and 2.17 mcg for ketoconazole, respectively.
1680382|NCT01615900|Other|Teleconsultation / Standard consultation|"Stage 1: randomization. Two arms: teleconsultation and standard consultation
Stage 2: calculation of Kidney Transplant Failure Score which will determine 4 sub-groups: teleconsultation high risk, teleconsultation low risk, standard consultation high risk and standard consultation low risk.
Stage 3: follow-up (2 years) according to the group:
Standard consultation low risk: consultation every 2 months during one year and then every 3 months during one year
Standard consultation high risk: consultation every 6 weeks during one year and then every 2 months during one year
Teleconsultation low risk: same follow-up as standard consultation low risk group but all the consultations are teleconsultations
Teleconsultation high risk: same follow-up as standard consultation high risk group but the follow-up will be intensified by the addition of an intermediate teleconsultation (between 2 consultations)"
1680383|NCT01615887|Drug|lisdexamfetamine sulfate|30mg lisdexamfetamine OD, increased to 70mg OD over 4 weeks and continued on 70mg OD for 4 weeks
1680384|NCT01615887|Drug|placebo|sugar pill
1680385|NCT01615874|Drug|MF/F Metered Dose Inhaler (MDI) 25/5 mcg|MF/F MDI 25/5 mcg, 2 inhalations twice a day (BID)
1680386|NCT01615874|Drug|MF/F MDI 50/5 mcg|MF/F MDI 50/5 mcg, 2 inhalations BID
1680387|NCT01615874|Drug|MF/F MDI 100/5 mcg|MF/F MDI 100/5 mcg, 2 inhalations BID
1680388|NCT01615874|Drug|BDP hydrofluoroalkane (HFA) 80 mcg|BDP HFA 80 mcg, 2 inhalations BID
1680389|NCT01615874|Drug|Montelukast tablets 5 mg (4 mg for children 5 years of age)|"Montelukast chewable tablets 5 mg once daily (QD) for children 6-11 years of age
OR
Montelukast chewable tablets 4 mg QD for children 5 years of age"
1680390|NCT01615874|Drug|Rescue medication: short-acting beta-2 agonist (SABA) MDI|albuterol MDI 90 mcg OR or salbutamol HFA MDI 100 mcg for rescue medication, taken as directed
1680391|NCT01615874|Drug|Rescue medication: Prednisone/Prednisolone|Prednisone/Prednisolone for rescue medication, taken as directed
1680392|NCT01615861|Procedure|IOL implantation|Micro-incision phacoemulsification cataract surgery (C-MICS) and IOL implantation with 1.8mm cartridge tip insertion technique.
1680393|NCT01615861|Device|IOL Implantation|Micro-incision phacoemulsification cataract surgery (B-MICS) and IOL implantation with 1.4mm wound-assist insertion technique.
1680394|NCT01615848|Other|mediterranean diet restricted calorie|1500 k/cal 30% fat
1680395|NCT01615848|Other|high protein diet|50 pcos diagnosed women will be assigned to high protein diet for 18 month
1680396|NCT01615848|Other|mediterranean diet restricted calorie|50 pcos women will be assigned to 1500 k/cal diet for 18 month
1680397|NCT01615835|Other|EnSite NavX System|EnSite NavX system is a 3D Mapping system
1680398|NCT01615822|Drug|OZ439 100mg|OZ439 100mg oral suspension, single dose
1680399|NCT01615822|Drug|OZ439 400mg|OZ439 400mg oral suspension, single dose
1680400|NCT01615822|Drug|MQ 250 mg, single dose|Mefloquine 250 mg tablet, single dose
1680401|NCT01615822|Drug|MQ 750mg, single dose|Mefloquine 750mg oral tablet, single dose
1680402|NCT01615822|Drug|Placebo|
1680403|NCT01615809|Drug|﻿AMPHOTERICIN B|The study drug will be administered by inhalation, to hospitalised patients or outpatients in the day hospital.The administration regimen for each Abelcet® nebulization will be 10 ml (50 mg) twice a week for the first week, and then from the second week onwards it will be 5 ml (25 mg) with a minimum separation of 72 hours between doses, until the neutrophil count is greater than or equal to 1500 cells/mm3.
1680404|NCT01615796|Drug|Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined|Subjects receive a single dose of GSK2140944
1680405|NCT01615796|Drug|Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined|Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
1680406|NCT01615783|Other|Subjects with COPD|Medicaid beneficiaries diagnosed with Chronic Obstructive Pulmonary Disease (COPD) and newly initiated on a maintenance medication
1680407|NCT01615783|Other|Subjects without COPD|Medicaid beneficiaries without a COPD diagnosis but having at least one medical or pharmacy claim during each year of the identification period
1680408|NCT01615770|Behavioral|cognitive behavior therapy|At each clinic session, staff met with participants individually for 30 minutes to develop cognitive and behavioral skills to resist urges to smoke. Staff used self-efficacy questionnaires to assess participants' confidence in their abilities to resist urges to smoke in specific situations and behavioral worksheets to help participants articulate treatment plans to be used in managing their behavior in these situations without smoking. Those participants randomized to extended CBT continued to work with treatment staff individually on the development and use of cognitive and behavioral cessation and relapse prevention skills. Treatment sessions, lasting approximately 30 minutes, were conducted at the San Jose clinic site at weeks 8, 12, 16 and 20.
1680409|NCT01615757|Drug|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 3 gm/m2 /dose
1680410|NCT01615757|Drug|Ara-c|IV formulation, administered as a 2 hr infusion in 1 pint of normal saline, BD on D1,3,5 at 2 gm/m2 /dose
1680411|NCT01615744|Procedure|Open Reduction Internal Fixation|Lateral approach through extensile lateral incision ( Benirschke), Reduction ( Soeur et Remy) and internal fixation with lateral plating with or without bone graft
1680412|NCT01615744|Procedure|Non-surgical management|Early active exercises and elevation to decrease swelling
1680417|NCT01615718|Procedure|low-intensity transcranial electrical stimulation|Subjects will undergo 20 minutes of low-intensity transcranial electrical stimulation of up to 2mA. During active stimulation, the current will be active for 20 minutes - however, during sham stimulation (placebo) the current will not be active for the full 20 minutes.
1680418|NCT01615718|Procedure|transcranial ultrasound|Subjects will undergo 20 minutes of transcranial ultrasound. During active stimulation, the ultrasound will be active for 20 minutes - however, during sham stimulation (placebo) the ultrasound will not be active for the full 20 minutes.
1680419|NCT01615653|Procedure|EUS|EUS Guided Therapy
1680420|NCT01615627|Drug|HypotonicTreprostinil Solution|Hypotonic Treprostinil Solution
1680421|NCT01615627|Drug|Eutonic Treprostinil Solution|Eutonic Treprostinil Solution
1680422|NCT01615614|Drug|Rilpivirine|Type=exact number, unit=mg, number=25, 50, and will be determined after treatment A and B analysis form=tablet, route=oral. Once or twice daily with a total daily dose of rilpivirine between 25 and 75 mg will be administered for 11 days.
1680423|NCT01615614|Drug|Rifabutin|Type=exact number, unit=mg, number=150, form=capsule, route=oral. Two capsules daily will be administered for 17 days.
1680424|NCT01615601|Drug|darunavir (PREZISTA)|Form = tablet, route = oral, Units = mg, number = 800 administered once daily
1680425|NCT01615601|Drug|etravirine (INTELENCE)|Form = tablet, route = oral, Unit = mg, number = 200, administered twice daily
1680426|NCT01615601|Drug|ritonavir|Form = tablet/capsule, route = oral, Units = mg, number = 100 administered once daily
1680427|NCT01615601|Drug|Other antiretroviral medications|Given as per Canadian Product Monograph
1680428|NCT01615588|Dietary Supplement|Manuka Honey|honey was weighed out to provide 25 g of available carbohydrate in 200 ml of water
1680431|NCT01615549|Procedure|Laparsocopic cholecystectomy|Perform laparsocopic cholecystectomy on a virtual reality devise
1680432|NCT01615536|Procedure|Canine fossa trephine technique|Patients undergoing standard ESS and a canine fossa trephine technique, which is a 6 mm puncture in the anterior wall of the maxillary sinus, to allow standard sinus debrider blades and instruments to pass into the sinus to clear polyps in the maxillary sinus.
1680433|NCT01615536|Procedure|Standard Endoscopic Sinus Surgery|Patients undergoing standard ESS without canine fossa trephination with clearance of the maxillary sinus polyps via a wide maxillary antrostomy (WMA) with use of curved debrider surgical blades and instruments.
1680434|NCT01615523|Other|MRI, EEG and cognitive testing|Sleep EEG and one MRI, executive function testing using Strrop test, BRIEF questionnaire and CantabEclipse
1680435|NCT01615510|Drug|Tapentadol immediate release|100 mg, single administration
1680436|NCT01615510|Drug|placebo|placebo, single administration
1680437|NCT01615497|Behavioral|Standard Treatment as Usual (TAU)|Treatment normally offered at this clinic which could include individual or group alcohol and drug counseling sessions one time per week lasting one hour each time.
1680438|NCT01615497|Behavioral|Web-based CBT4CBT for alcohol plus TAU|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus TAU
1680439|NCT01615497|Behavioral|Web-based CBT with minimal clinical contact|Subjects work with a computerized program that teaches skills for stopping alcohol and drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session. Plus 10 minute check in with clinician.
1680440|NCT01615484|Procedure|Transplantation of lungs obtained from Non-Heart-Beating Donors (NHBDs) after ex-vivo perfusion w/ STEEN Solution™|After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™, and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals and Duke University Medical Center based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP will be transplanted into recipients as per current clinical practice.
1680441|NCT01615484|Device|STEEN Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs.
1680442|NCT01615471|Behavioral|Group weight loss with companion internet|Monthly in-person group sessions with an companion internet weight loss intervention
1680443|NCT01615458|Behavioral|Chronic Care Model for Mood Disorders|CCM includes (1) patient self-management enhancement focused on promoting healthy lifestyles as coping strategies to minimize the negative impact of depressive, manic, and other affective symptoms; (2) provider support for evidence-based decision-making; and (3) enhanced access and continuity for anticipatory rather than reactive care.
1680444|NCT01615445|Drug|Resveratrol|Group A: resveratrol 1000 mg (500 mg twice) daily for 1 week then by tolerance and safety 2000 mg (1 000mg twice) daily for 3 weeks, followed by no medication for two weeks and then placebo for twice daily for 4 weeks.
1680445|NCT01615445|Drug|placebo|Participants will receive placebo daily for 4 weeks, followed by no medication for two weeks and then resveratrol 1 000 mg(500 mg twice) daily for 1 week, then by tolerance and safety 2 000 mg (1 000 mg twice) daily for three weeks.
1680446|NCT01615432|Device|V-PAP III ventilator|
1680447|NCT01615432|Device|Stellar 150 ventilator|
1680448|NCT01615432|Device|BiPAP vision ventilator|
1680449|NCT01615432|Device|V60 ventilator|
1680450|NCT01615406|Drug|99mTc MIP 1404|A single dose of 20 ±3 mCi intravenous (IV) injection of 99mTc MIP 1404
1680451|NCT01615393|Drug|ribavirin [Copegus]|Single oral dose of 400 mg tablets
1680452|NCT01615393|Drug|ribavirin [Vilona]|Single oral dose of a 400 mg capsule
1680453|NCT01615380|Behavioral|CBT+ Contact|In addition to the smoking cessation program, those in the CBT + CONTACT condition will enroll in a Wellness Program and will receive weekly wellness materials to read as well as receiving 4 sessions with a health educator in weeks 1, 4, 8 and 12 to discuss the wellness materials.
1680515|NCT01614938|Radiation|Intensity-modulated radiotherapy|a total dose of 66-70.4Gy in 30-32 fractions over 6-6.5 weeks planned to be delivered to the PTV of gross tumor
1680516|NCT01614938|Drug|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3, then 6 cycles of concomitant chemotherapy every week with cisplatin 30 mg/m2 D1
1680454|NCT01615380|Behavioral|CBT+ Exercise|Participants will receive an identical 12-week cognitive behavioral smoking cessation program delivered by YMCA staff and monitored by members of the research team to ensure fidelity of treatment delivery. In addition to the smoking cessation program, those in the CBT + EXERCISE condition will enroll in the 12-week YMCA Personal Fitness Program (PFP) where they will receive 4 sessions with a personal trainer in weeks 1, 4, 8 and 12 and will engage in aerobic exercise at least 3 times per week either in the PFP facilities or in other programs offered at the YMCA, such as aerobics classes.
1680455|NCT01615367|Other|Nutrition, Exercise, and Wellness (NEW) psychotherapy|NEW Tx is a flexible modular treatment such that modules are selected based on the needs of the individual to increase its generalizability across patients, settings, and providers as well as its acceptability to patients.
1680456|NCT01615367|Drug|Typically consists of at least one FDA-approved mood stabilizer|Pharmacotherapy will be conducted by experts in BD treatment and will follow the empirically-supported treatment algorithm for BD that has been developed and recently revised. The foundation of TAU is to maintain treatment with at least one Food and Drug Administration approved mood stabilizer. For TAU, medication and dosage changes are allowed as needed as long as the change is recommended based on the guidelines and participants remain on a mood stabilizer.
1680457|NCT01615354|Drug|Aleglitazar|Multiple oral doses
1680458|NCT01615354|Drug|Microgynon®|Multiple oral doses
1680459|NCT01615354|Drug|Placebo|Multiple oral doses
1680460|NCT01615328|Device|Cervios ChronOs|The ACDF surgery will be carried out with Cervios ChronOs after randomization procedure.
1680461|NCT01615328|Device|Bonion|The ACDF surgery will be carried out with Bonion after randomization procedure.
1680462|NCT01615302|Procedure|Mucosa advancement flap|Mucosa advancement flap will be performed at the starting point of the fistula in the rectum
1680463|NCT01615302|Other|Platelet rich plasma (PRP)|"The PRP will be injected into the fistula, after the mucosa advancement flap was created.
For the PRP we will need to take 55 millilitres of blood of the patient. This blood will be centrifuged into PRP."
1680464|NCT01615289|Dietary Supplement|Single intragastric instillation of 250 ml green tea extract|Intragastric instillation by feeding tube
1680465|NCT01615289|Dietary Supplement|Single intragastric instillation of 500 ml green tea extract|Intragastric instillation by feeding tube
1680466|NCT01615289|Dietary Supplement|Single intragastric instillation of 250 ml control solution|Intragastric instillation by feeding tube
1680467|NCT01615289|Dietary Supplement|Single intragastric instillation of 500 ml control solution|Intragastric instillation by feeding tube
1680468|NCT01615276|Device|Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES)|One our of one-legged neuromuscular electrical stimulation (NMES)
1680469|NCT01615276|Device|No Enraf Nonius Tensmed S84 for Neuromuscular electrical stimulation (NMES) NMES|No neuromuscular electrical stimulation (NMES) will be applied in the control leg
1680470|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a left double lumen tube
1680471|NCT01615263|Device|Lung isolation device|Lung isolation for one-lung ventilation with a bronchial blocker inserted through a 8.0 mm simple lumen endotracheal tube
1680472|NCT01615250|Biological|Intramyocardial implantation of stem cells|Intramyocardial implantation of autologous peripheral mononuclear cells with CD34+ stem cells by NOGA.XP navigation system. Сell concentration is 200 million cells in 1 ml.
1680473|NCT01615237|Behavioral|Audit and performance feedback (PF)|Quarterly, trained clinic staff will use a standardized chart audit tool to evaluate documentation of cessation assistance. The feedback report will show individual and clinic performance summaries of two targeted provider behaviors based on documentation in the chart: 1) percentage of smokers advised to quit, and 2) percentage of smokers who received quitting assistance. Quitting assistance will be fulfilled by documentation of any of the following provider behaviors: a) Faxing a referral to the New York State (NYS) Quitline, b) Chart documentation of providing cessation counseling; and/or c) discussing and or prescribing cessation medications. Reports will be given to the Dental Director, who will be instructed to distribute them to dental providers no later than 30 days following the end of the quarter.
1680474|NCT01615237|Behavioral|Financial Incentive (P4P)|We will review charts of all smokers to evaluate documentation of cessation assistance (i.e., prescription given for cessation medication, the provision of brief cessation counseling and/or a fax referral to the NYS Quitline or other local cessation support program). Sites will receive $20 for each patient with chart documentation of receiving tobacco cessation assistance. The P4P reimbursement will be offered quarterly with an annual cap of $5000 to each site as employees are salaried.
1680475|NCT01615237|Behavioral|Current Best Practices (CBP)|CBPs that will be implemented is consistent with the PHS recommended guidelines and is as follows: The dental care team will assess smoking status, deliver advice to quit, assess readiness to quit, provide patient education materials, a prescription for cessation pharmacotherapy and referral to the NYS Quitline, and document findings and treatment plan on the chart system. In New York State, the Quitline provides free medication for uninsured. As brief provider interventions have been shown to be effective, the recommended tobacco treatment protocol will require approximately 5-10 minutes.
1680476|NCT01615224|Drug|misoprostol|repeated doses of misoprostol. 400mcg of oral misoprostol given at 3, 5, 7 and 9 hours.
1680477|NCT01615211|Drug|Letrozole|Day 1 Letrozole 2,5mg 3 tablets Day 2 Letrozole 2,5mg 3 tablets
1680478|NCT01615211|Drug|Trilostane|Day 1 Trilostane 120mg twice and Day 2 Trilostane 240mg twice
1680479|NCT01615198|Drug|Olmesartan|10 mg, 20 mg, 40 mg capsules
1680480|NCT01615198|Drug|Placebo|Matching placebo of LCZ696 tablet, matching placebo of Olmesartan capsule
1680481|NCT01615198|Drug|LCZ696|100 mg, 200 mg tablets
1680482|NCT01615185|Drug|full-dose amisulpride|amisulpride 800mg/d
1680483|NCT01615172|Procedure|cannulation|The different types of cannulation (aortic versus axillaris) were compared in the postoperative period for neurological deficits in three time periods.(intraoperative, 5.POD, 3 month POD)
1680484|NCT01615159|Behavioral|Behavior and lifestyle counseling|20 week intervention period where one group gets behavior and lifestyle counseling and the other group gets no active intervention
1680485|NCT01615146|Other|Platelet Transfusion|"Patients allocated to the therapeutic platelet transfusion group will not receive routine prophylactic platelet transfusions. Platelet transfusions will be given to treat documented clinically relevant bleeding defined as WHO bleeding of grade 2 or greater. Patients may be transfused at the discretion of the treating physician. The indication for all platelet transfusions will be recorded by asking the ordering physician.
Patients allocated to the prophylactic platelet transfusions will receive a platelet transfusion when the measured platelet count is < 10 x 109/L. Patients may receive additional platelet transfusions at the discretion of the treating physician. The indication for all platelet transfusions will be recorded."
1680486|NCT01615120|Drug|GTx-758 125 mg|One 125 mg tablet once a day
1680487|NCT01615120|Drug|GTx-758 250 mg|two 125 mg tablets once daily
1680488|NCT01615107|Device|COOK RIPENENIG BALLOON+PITOCN|GROUP 2: insertion of the double balloon device and concurrent oxytocin administration.
1680489|NCT01615107|Drug|PITOCIN|: Oxytocin infusion alone (Standard Protocol
1680490|NCT01615107|Other|double balloonand oxytocin|balloonand oxytocin
1680491|NCT01615107|Other|ballon and oxytocin|double- balloon catheter device with concurrent oxytocin
1680492|NCT01615107|Procedure|double balloonand and oxytocin|balloon catheter device with concurrent oxytocin
1680493|NCT01615081|Other|The acute effect of malt extract versus sucrose on the response of glucose and insulin, subjective appetite sensations and ad libitum energy intake|2-arm crossover study for investigation of the effect of malt extract vs. sucrose on glucose, insulin, subjective appetite sensations and ad libitum energy intake.
1680496|NCT01615042|Drug|Lenalidomide|Oral capsule, daily, 50mg-100mg, one cycle (21 days)
1680497|NCT01615029|Drug|Part 1 (Dose Escalation): Daratumumab|Participants will receive intravenous (injection of a substance into a vein) infusion of daratumumab in an increased fashion from 2 milligram per kilogram (mg/kg) up to maximum dose of 16 mg/kg. Considering the safety and efficacy of dose in Part 1, recommended phase 2 dose (RP2D) for Part 2 of the study will be decided. A predose infusion of 10 percent (%) of the full dose of daratumumab will be administered a day before the first full infusion of the first cycle. Participants will receive 4 weekly infusions in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
1680498|NCT01615029|Drug|Part 2 (Dose Expansion): Daratumumab|Participants will receive RP2D as determined in Part 1 of the study. Participants will receive 4 weekly infusions of RP2D in the first 2 treatment cycles. From cycles 3 to 6 infusions will be administered every alternate week and monthly infusions will be administered from cycle 7 until disease progression.
1680499|NCT01615029|Drug|Lenalidomide|All participants (Part 1 and Part 2) will receive 25 mg lenalidomide orally (by mouth) from days 1 to 21 of each 28-day cycle until disease progression.
1680500|NCT01615029|Drug|Dexamethasone|All participants (Part 1 and Part 2) will receive 40 mg (20 mg intravenously [injection of a substance into a vein]) dexamethasone once weekly. Participants older than 75 years or underweight (body mass index [BMI] less than [<] 18.5), the dexamethasone dose will be administered at a dose of 20 mg once weekly until disease progression.
1680501|NCT01615016|Other|Minimally invasive endotracheal surfactant application|"What are the planned trial interventions?
MISurf: Minimally invasive intratracheal surfactant application without mechanical ventilation by feeding tube device
InSurE: Surfactant application by InSurE strategy (Intubation - surfactant - extubation sequence).
Both interventions will be performed by intervention teams. For the MISurf intervention, it was decided to use the minimally invasive method via feeding tube exclusively due to concerns about possibility of airway injury with the iv cannula device.
Surfactant Two porcine derived surfactant products have been used in the published trials for minimal invasive surfactant application, Curosurf© and Survanta©. Due to safety reasons we will use these products also in our pilot study however, only the latter is currently available in Canada. Hence we will use Survanta© 100 mg/kgBW, equivalent to 4 ml/kgBW per dose.19,20,26"
1680502|NCT01615003|Drug|Xuesaitong soft capsule|Xuesaitong soft capsule, soft capsule, Ingredients:PNS, Specification:0.33 per bag, once take two pills and twice a day during a month.
1680503|NCT01615003|Drug|Xuesaitong soft capsule Placebo|Xuesaitong soft capsule Placebo, soft capsule, once take two pills and twice a day during a month.
1680504|NCT01614990|Drug|Macimorelin|Subjects will receive macimorelin (1 mg/kg) and matching placebo (Powerade®) daily for 7 days.
1680505|NCT01614990|Drug|Placebo|placebo (Powerade®) daily for 7 days.
1680506|NCT01614977|Drug|Methylprednisoline|Methylprednisolone (Danalone) 1mg/Kg/dose twice daily for 14 days followed by 1mg/Kg/dose in the morning once daily for 14 days,
1680507|NCT01614964|Drug|AQ-13 Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'AQ-13 Treatment' Participants randomized to the AQ-13 arm will be treated with two (350 mg) capsules on days 1 and 2 and one (350 mg) AQ-13 capsule on day 3 for a total oral dose of 1750 mg of AQ-13 (5 capsules containing 350 mg apiece) over 3 days.
1680508|NCT01614964|Drug|Coartem Treatment|Adult Malian males 18 years of age or older with uncomplicated P. falciparum malaria who agree to participate and provide their informed consent will be randomized to receive treatment with either AQ-13 or Coartem. Intervention 'Coartem Treatment' Participants randomized to the Coartem arm will receive six doses of Coartem tablets over 3 days (each dose containing 80 mg artemether and 480 mg lumefantrine). Those six doses will be given at the time of diagnosis and 8 hours later on day 1, at 24 and 36 hours on day 2 and at 48 and 60 hours on day 3 for total doses of 480 mg artemether and 2880 mg lumefantrine over 3 days.
1680509|NCT01614951|Procedure|Perfusion of the lungs|Pulmonary perfusion with oxygenated blood during ECC.
1680510|NCT01614951|Drug|HTK Custodiol|Pulmoplegia before ECC.
1680511|NCT01614951|Other|Standard ECC|ECC after standard procedure
1680512|NCT01614938|Drug|Cetuximab|400 mg/m2 initial dose before radiation, then 250 mg/m2 weekly during radiation
1680513|NCT01614938|Drug|Cisplatin|2 cycles of induction chemotherapy every 3 weeks with cisplatin 80 mg/m2 D1-3
1680514|NCT01614938|Drug|Docetaxel|2 cycles of induction chemotherapy every 3 weeks with docetaxel 75 mg/m2 D1
1682979|NCT01595074|Other|laboratory biomarker analysis|Correlative studies
1680521|NCT01614886|Drug|Active Comparator|1-step titration group begin treatment with a rivastigmine patch 9 mg/day for 4 weeks, followed by a dose increase to 18 mg/day.
1680522|NCT01614886|Drug|ENA713|-3-step titration group will begin treatment with a rivastigmine patch 4.5 mg/day for 4 weeks, followed by a further dose increase of 4.5 mg/day at 4-week intervals up to the maintenance dose of 18 mg/day.
1680523|NCT01614873|Device|Servo-i® ventilator, MAQUET,Critical Care, Sweden|Electrical activity of the diaphragm will be obtained through a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden). Subject will be ventilated with a mouthpiece interface. NAVA will be compared to Pressure Support using the same ventilator. Once the pattern of breathing will be stabilized (10 minutes) in each condition (see arm) the following parameters will be recorded during 5 minutes and compared : tidal volume, inspiratory time, expiratory time, transcutaneous CO2 pressure, diaphragmatic Emg activity, delay between the inspiratory activity initiation and positive pressure initiation, delay between the end of the inspiratory effort and the end of pressurisation.
1680525|NCT01614821|Drug|PCI-32765|Taken orally, once daily in the morning
1680526|NCT01614808|Other|laboratory biomarker analysis|Correlative studies
1680527|NCT01614795|Biological|cixutumumab|Given IV, Days 1, 8, 15, and 22, dosage 6 mg/kg. Cixutumumab dose is based on weight (kg).
1680528|NCT01614795|Drug|temsirolimus|Given IV, Days 1, 8, 15, and 22 8 mg/m2 (maximum dose = 16 mg) (Cycle 1), Dose escalation to 10 mg/m2 (maximum dose = 20 mg). Temsirolimus dose is based on BSA.
1680529|NCT01614795|Other|laboratory biomarker analysis|Correlative studies
1680530|NCT01614782|Drug|MK-5823|"MK-5823 administered subcutaneously (doses ranging from 0.35 mg to 2.8 mg) once daily for 3 weeks. Doses may be adjusted downward based on safety, tolerability, and/or pharmacokinetic data. The decision to dose escalate will be based on accrued safety/tolerability data at the prior dose level.
In each arm, 6 participants will be randomized to receive study drug and 2 participants will be randomized to receive placebo."
1680531|NCT01614782|Other|Placebo|Matching placebo to MK-5823 administered subcutaneously once daily for 3 weeks.
1680532|NCT01614769|Drug|Placebo|Two gross-matched glimepiride placebo tablets taken on Day -1 and Day 1 of the three treatment periods.
1680533|NCT01614769|Drug|Glimepiride 2 mg|One placebo tablet and one 2-mg glimepiride tablet taken on Day -1 and Day 1 of the three treatment periods.
1680534|NCT01614769|Drug|Glimepiride 4 mg|Two 2-mg glimepiride tablets taken on Day -1 and Day 1 of the three treatment periods.
1680535|NCT01614769|Procedure|Hypoglycemic Clamp|On Day 1 of the three treatment periods, 180 minutes after drug treatment, a fixed-rate insulin infusion is combined with a variable-rate dextrose infusion to maintain plasma glucose concentrations at close to 50 mg/dL for 30 minutes.
1680536|NCT01614756|Biological|BMS-981164|
1680537|NCT01614756|Biological|Placebo matching with BMS-981164|
1680538|NCT01614743|Drug|IncobotulinumtoxinA|Experimental injection given at baseline and Week 16
1680539|NCT01614743|Drug|Bacteriostatic saline|Placebo at baseline, incobotulinumtoxinA at 16 weeks
1680540|NCT01614730|Device|Modified Neurotech Vital Device|verify no contraction is stimulated in the Modified Neurotech Vital.
1680541|NCT01614730|Device|Neurotech Vital Device|Checking there is a contraction of the pelvic floor muscle when the treatment is administered with the Neurotech Vital Device
1680542|NCT01614717|Device|CRT-P Implant|All patients will be implanted with a CRT-P device, then randomized to Treatment or Control Group
1680543|NCT01614691|Drug|SPARC1203|Active
1680544|NCT01614691|Drug|Placebo|Placebo
1680545|NCT01614678|Device|Lotrafilcon B contact lens with color, automated|Silicone hydrogel contact lens with color manufactured via an automated process
1680546|NCT01614678|Device|Lotrafilcon B contact lens with color, semi-automated|Silicone hydrogel contact lens with color manufactured via a semi-automated process
1680547|NCT01614665|Drug|Tacrolimus|oral
1680548|NCT01614652|Device|CardioKinetix Parachute Implant and All Appropriate Medical Therapy (AAMT)|CardioKinetix Parachute implant and all appropriate medical therapy
1680549|NCT01614639|Procedure|Acupuncture|A licensed acupuncturist will perform acupuncture for two 30 minute sessions.
1680550|NCT01614613|Device|Bayer G3 / Tatsu System|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1680551|NCT01614613|Device|Accu-Chek® Aviva Nano Meter/Accu-Chek® Aviva Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1680552|NCT01614613|Device|Freestyle Lite® Meter and Test Strips with ZipwikTM tabs|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1680553|NCT01614613|Device|OneTouch® Ultra®2 / OneTouch® Ultra® Blue Test Strips|Study staff performed Blood Glucose (BG) tested with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1680554|NCT01614613|Device|One Touch® VerioTM Pro/One Touch® VerioTM Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1680555|NCT01614613|Device|Truetrack® Meter/Truetrack® Test Strips|Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with diabetes. All meter BG results were compared with plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1680556|NCT01614600|Device|Nelfilcon A contact lenses|Commercially marketed hydrogel contact lenses for daily wear, daily disposable use
1680557|NCT01614574|Biological|velaglucerase alfa|60 U/kg every other week intravenous infusion
1680641|NCT01613846|Drug|Sorafenib+Pazopanib|Sorafenib (first-line) followed by Pazopanib (second-line)
1682980|NCT01595061|Drug|Cisplatin|Given IV
1680558|NCT01614535|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough during emergence|Targeted effect-site TCI remifentanil for preventing cough effectively during emergence from general anesthesia. For effect-site TCI of remifentanil, a TCI pump was used and pump operation was based on Minto and colleagues' pharmacokinetic model. By Dixon's up-and-down method, the predetermined effect-site concentration(Ce) of remifentanil was determined according to the cough response of the previous patient. The initial target Ce of remifentanil for the first patient was 2.0 ng/ml. If the patients did not cough throughout the peri-extubation period, the predetermined Ce of remifentanil for the subsequent patient was decreased by 0.4 ng/ml. If the patient coughed anytime around extubation, the predetermined Ce for the subsequent patient was increased by 0.4 ng/ml. The stopping rule, as well as for the requirement of at least six turning points in the same direction of the sequential allocation response graph, required the recruitment of more than 20 patients.
1680559|NCT01614522|Drug|ASLAN001|ASLAN001 500mg BID
1680560|NCT01614509|Procedure|intravitreal bevacizumab monotherapy|The monotherapy group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle.
1680561|NCT01614509|Procedure|combined therapy of posterior subtenon triamcinolone acetonide and intravitreal bevacizumab injection|The combined group receive intravitreal injection of 1.25 mg/0.05 ml bevacizumab and posterior subtenon injection of 40 mg/1.0 ml triamcinolone acetonide. The injections are performed using 0.5% proparacaine drops for topical anesthesia under sterile conditions. The bevacizumab is injected through the pars plana using a 30-gauge needle and triamcinolone acetonide is injected through the posterior subtenon area (near macula) by using a 27-gauge needle at the same time.
1680562|NCT01614496|Other|Algorithm for insulin administration|
1680563|NCT01614483|Other|Yellow cassava|Daily provision of 375 g boiled yellow cassava for 18 weeks, 6 days/week Daily provision of placebo capsule for 18 weeks, 6 days/week
1680564|NCT01614483|Other|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/ week Daily provision of placebo capsule for 18 weeks, 6 days/ week
1680565|NCT01614483|Other|White cassava|Daily provision of 375 g boiled white cassava for 18 weeks, 6 days/week Daily provision of B-carotene capsule (1400 µg B-carotene)
1680566|NCT01614470|Drug|Ivacaftor|150 mg tablet, oral use, administered twice a day (q12h)
1680567|NCT01614470|Drug|Placebo|oral use, administered twice a day (q12h)
1680568|NCT01614457|Drug|Ivacaftor|Ivacaftor 150 milligram (mg) tablet orally twice daily for 24 weeks.
1680569|NCT01614457|Drug|Placebo|Placebo matched to Ivacaftor tablet orally twice daily for 24 weeks.
1680570|NCT01614444|Other|Active Acupressure Treatment|Participant will receive 8 active acupressure treatments.
1680571|NCT01614444|Other|Placebo Acupressure Treatment|Participants will receive 8 placebo acupressure treatments.
1680572|NCT01614431|Drug|N acetyl cysteine|N acetyl cysteine to cystinosis patients with CKD stages 1 to 4
1680573|NCT01614431|Drug|N acetyl cysteine|N acetyl cysteine for cystinosis patients CKD stages 1 to 4
1680574|NCT01614418|Device|Endoscopic radiofrequency ablation catheter|Endoscopic radiofrequency ablation
1680575|NCT01614405|Drug|Truvada and Kaletra|one tablet of Truvada a day at standard dose of Tenofovir 300mg and Emtricitabine 200mg and four tablets of Kaletra once a day for a total dose of lopinavir 800mg and ritonavir 200mg for 6 months or less if adverse events occur
1680577|NCT01614366|Drug|AM 5 + DM 0|Amlodipine 5 mg + DMTA07 0mg, once daily
1680578|NCT01614366|Drug|AM 5 + DM 2.5|Amlodipine 5 mg + DMTA07 2.5mg, once daily
1680579|NCT01614366|Drug|AM 5 + DM 7.5|Amlodipine 5 mg + DMTA07 7.5mg, once daily
1680580|NCT01614366|Drug|AM 5 + DM 30|Amlodipine 5 mg + DMTA07 30mg, once daily
1680583|NCT01614340|Behavioral|Cognitive-Behavioral Pain Self-management Program|The main study intervention is training of the PTs on teams randomized into the intervention group in the evidence-based CBPSM program which has been translated for use in home health care with patients who have activity-limiting pain. The program is designed to be implemented in a manner that allows for maximal integration into routine PT care of home health patients. This will be possible because the CBPSM techniques, together with exercise and other PT techniques that constitute customary PT care, are reciprocally reinforcing. Both treatments (CBPSM and PT) encourage the use of similar behavioral and pain self-management coping skills to enhance behavioral activation, perceptions of self-efficacy, self-control, and personal mastery with regard to the management of pain.
1680584|NCT01614314|Other|Preceptorship|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of a nurse preceptorship, lasting one hour.
1680585|NCT01614314|Other|Auto-instructional guide|After attending a lecture and a video on the dressing of the tunneled central venous catheter, the subjects performed the procedure on a manikin simulator, with the aid of an auto-instructional guide, lasting one hour.
1680586|NCT01614301|Drug|dacarbazine (DTIC), Trofosfamide, Etoricoxib, Pioglitazone, Temsirolimus|"Dacarbazine (DTIC) 1000 mg/m2 day 1, every 3 weeks The total number of DTIC cycles should not exceed 6 cycles due to cumulative toxicity.
Temsirolimus: 15 or 25 mg iv weekly , week 1+.In the phase I part of the study the finally used dosis will be determined. Pioglitazone (Actos) 60 mg p.o. daily, day 1+. Etoricoxib (Arcoxia) 60 mg p.o. daily, day 1+. Trofosfamide (Ixoten) 50 mg p.o. thrice daily as metronomic angiostatically and immunomodulatory actingtherapy, day 1+. Treatment until disease progression or toxicity"
1680587|NCT01614288|Procedure|knee Arthroscopy|Patient undergoes a knee arthroscopy and HTO
1680588|NCT01614288|Other|No arthroscopy|Patient undergoes an HTO without knee arthroscopy
1680642|NCT01613846|Drug|Pazopanib+Sorafenib|Pazopanib (first-line) followed by Sorafenib (second-line)
1955300|NCT03230890|Device|HIRREM|HIRREM is a closed-loop, allostatic, acoustic stimulation neurotechnology intended to support auto-calibration of neural oscillations. The core technology is commercially available as a technique for relaxation. Scalp sensors monitor brain frequencies and amplitudes, and in real time, software algorithms translate specific frequencies into audible tones of varying pitch. These are reflected via earbuds in as little as 4-8 milliseconds. The in-office intervention for this study is administered as a series of up to twenty four, typically 1.5-2 hours sessions, comprised of 4-10 protocols (some eyes open, some eyes closed), lasting 6-40 minutes each, working at different scalp locations. Sessions are received over 12 days. Two sessions can be done in a half day. The intervention is received while comfortably seated in a zero gravity chair.
1955301|NCT03232125|Drug|Ramosetron|Randomly selected patients of the ramoseton group are given a 0.3 mg of ramosetron after induction.
1955302|NCT03232125|Drug|Normal saline|In contrast, patients in the control group are given the same volume of normal saline after induction and given a 0.3 mg of ramosetron after measurement of QTc interval.
1680593|NCT01614262|Other|Continuous Glucose Monitoring with treatment algorithm|those subjects randomized to Continuous Glucose Monitoring results will be placed in CareLink iPro Clinical Management system, the experimental treatment guideline/algorithm has been programmed into the system. Providers will make treatment decisions based off of results of CGM.
1680594|NCT01614249|Dietary Supplement|Soybean oil soft gels|Each participant will receive OmegaVia soybean oil soft gels to take orally, one soft gel taken three times per day in the morning, mid-day and in the evening after meals for a period of 8 weeks
1680595|NCT01614249|Dietary Supplement|Fish oil omega-3 EPA-rich soft gels|A total of 3.0g of OmegaVia fish oil omega-3 EPA-rich soft gels will be taken orally per day as one soft gel in the morning, mid-day and evening after meals for 8 weeks with bi-weekly follow-up visits.
1680596|NCT01614236|Drug|pregabalin|Patients in one set (40 patients/sct) will received 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA
1680597|NCT01614236|Drug|epidural|patients will be randomized similarly but will undergo surgery under epidural analgesia
1680598|NCT01614223|Procedure|ACP|Within two weeks of the initial visit, the RN, will retrieve a 10-12 mL blood sample from all patients. After the sample is retrieved, the patient will be asked to lie prone on the plinth to assist with blinding. The blood sample will be retained in the Arthrex ABS-10010S Double Syringe with Syringe Cap and then separated using a soft spin centrifuge for 5 min at 1500 rpm/rcf. Three to four mL of platelet rich plasma will be pulled into a smaller syringe that is wrapped in opaque tape to conceal the contents of the syringe. The ACP is injected into the torn region of the tendon.
1680599|NCT01614223|Drug|Corticosteroid (celestone) injection|Preparation of the blood sample is identical for patients in this group except that the blood sample will ultimately be discarded instead of injected. The syringe is blinded with opaque tape making it identical to the ACP group syringe and injected into the torn area of the tendon.
1680602|NCT01614197|Drug|Temsirolimus|Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
1680603|NCT01614197|Drug|Etoposide|100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
1680604|NCT01614197|Drug|Etoposide|For patients allergic to etoposide. 100 mg/m2 IV daily x 5 days on days 1-5.
1680605|NCT01614197|Drug|Cyclophosphamide|440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
1680606|NCT01614197|Drug|Methotrexate|"PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.
Age 1 - 1.99 give 8 mg of methotrexate
Age 2 - 2.99 give10 mg of methotrexate
Age 3 - 8.99 give 12 mg of methotrexate
Age ≥ 9 give 15 mg of methotrexate
PATIENTS WITH CNS 2 or 3 DISEASE
-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.
COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients >9 years of age"
1680607|NCT01614197|Drug|Hydrocortisone|"Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.
COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.
COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients >9 years of age"
1682981|NCT01595061|Drug|Gemcitabine Hydrochloride|Given IV
1680608|NCT01614197|Drug|Cytarabine|"For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1
Age 1 - 1.99 give 30 mg of Cytarabine
Age 2 - 2.99 give 50mg of Cytarabine
Age ≥ 3 give 70 mg of Cytabine
For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.
COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.
16 mg for patients age 1-1.99
20 mg for patients age 2-2.99
24 mg for patients 3-8.99 years of age
30 mg for patients >9 years of age"
1680609|NCT01614184|Drug|Fluorescein|Fluorescite® (fluorescein injection, USP) 10% fluorescein sodium diluted to from 1% to 0.001% in sterile saline, 0.25 ml injected intradermally peri-tumoral or peri-areolar. A single dose regimen.
1680610|NCT01614171|Biological|Human recombinant growth hormone|growth hormone treatment for 6 months (daily, weight based)
1680611|NCT01614158|Device|perimetry|perimetric examination using static stimuli, assessing the entire (80 degree) visual field with a fast thresholding algorithm (GATE) [Schiefer 2008] to know the extent/ magnitude of the visual field defect and its variability within the cohort and over time
1680612|NCT01614158|Other|D-BCVA|D-BCVA using EDTRS chart
1680613|NCT01614158|Other|RAPD|RAPD using swinging flashlight test
1680614|NCT01614158|Device|IOP|IOP using applanation tonometer
1680615|NCT01614158|Device|Spectralis OCT|RNFT and RNFV using Spectralis OCT (star scan, ring scan 2,8 mm and volume scan)
1680616|NCT01614158|Other|Fundus photography|Optic disk morphology will be documented by fundus photography
1680617|NCT01614132|Drug|maintenance chemotherapy (vincristin, cisplatin and CCNU)|maintenance chemotherapy of maximum of 8 cycles á 42 days
1680618|NCT01614132|Radiation|Radiotherapy|Radiotherapy of the partial brain
1680619|NCT01614119|Other|Hypoxic exposure|Subjects breath either normoxic or hypoxic (FiO2 = 12%) gas mixture
1680620|NCT01614106|Behavioral|Retention Clinic|The central components of the Retention Clinic will include: Primary HIV Care; Patient Navigator services (including Informational support, Educational information, Motivational/Emotional support, Skill Building activities); Mental Health Services; and On-Site Substance Abuse Treatment (including Motivational Enhancement Therapy and Cognitive Behavioral Therapy).
1680623|NCT01614067|Drug|GnRH antagonist|Subjects will receive 7 days of pre-treatment with the GnRH antagonist
1680624|NCT01614054|Other|Survey of patient's smoking habits|Nicotine replacement therapy (inhalers, patches, gum, lozenges) at the discretion of the health care provider
1680625|NCT01614041|Drug|Usual dose treatment of Tandospirone|Usual dose treatment of Tandospirone, oral, 30 mg/day
1680626|NCT01614041|Drug|Comparative high dose of tandospirone treatment|Comparative high dose of tandospirone treatment, oral, 60 mg/day
1680627|NCT01614028|Procedure|Total Hip Arthoplasty|
1680628|NCT01614015|Behavioral|Supervision|SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.
1680629|NCT01614015|Behavioral|Observational Supervision|One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
1680630|NCT01613989|Procedure|Prosthetic hip surgery, operated under manual control|: Hip replacement is performed in supine side position. Cup is positioned under manual control with the aid of a manual ancillary.
1680631|NCT01613989|Procedure|Prosthetic hip surgery operated under navigation based on EOS imaging|The patient will be installed in supine side position. The cup will be navigated with the technique based on EOS imaging. This technique requires the registration of the homolateral antero superior iliac spine and the homolateral postero superior iliac spine only. It does not require the registration of the pubis or any other controlateral points which are poorly accessible in the supine side position
1680632|NCT01613976|Drug|Panobinostat|
1680633|NCT01613963|Drug|Immunosuppressive Agents|Treatment with systemic corticosteroids and/or immunosuppressive agents Treatment with local corticosteroids and other drugs
1680634|NCT01613950|Drug|AUY922|AUY922 is a non-geldanamycin inhibitor of the heat shock protein 90 (HSP90).
1680635|NCT01613950|Drug|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
1680636|NCT01613937|Behavioral|Dulce Mother lifestyle training program|12 once weekly culturally tailored lifestyle management sessions
1680637|NCT01613924|Device|Split face: handheld acne heat based device (Zeno Hot Spot) and no treatment|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face and no treatment to every inflammatory acne lesion on the other half of the face at 6 hour intervals for a total of 3 treatments. Follow up will occur daily over a 5 day period.
1680638|NCT01613924|Device|Split face: handheld acne heat based device, Zeno Hot Spot, and topical benzoyl peroxide 4%|Subjects will apply the actual device to every inflammatory acne facial lesion on one half of the face at 6 hour intervals for a total of 3 treatments. Subjects will apply benzoyl peroxide to the other half of the face daily for 5 days.
1680639|NCT01613898|Biological|Blood tests|Blood tests
1680640|NCT01613872|Other|Mindfulness Based Stress Reduction|An 8 week protocol of stress reduction sessions using gentle yoga and breath meditation
1680647|NCT01613820|Drug|Ketamine|ketamine IV 0.25mg/kg infusions twice a week for 3 weeks as augmentation of ongoing antidepressant regimen.
1680648|NCT01613820|Drug|Scopolamine|Scopolamine 2ug/kg over 15 minutes twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
1680651|NCT01613794|Drug|Rosuvastatin|20 mg od
1680652|NCT01613781|Other|TOF count-guided partial NMB|TOF count-guided partial NMB Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
1680653|NCT01613781|Other|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
1680655|NCT01613755|Drug|Metformin, dipyridamole|Metformin 500 mg twice daily for four days Dipyridamole 200 mg twice daily for four days
1680656|NCT01613755|Drug|Metformin|Metformin 500 mg twice daily for four days
1680657|NCT01613729|Drug|Rosuvastatin 5 mg|Rosuvastatin 5 mg
1680658|NCT01613729|Drug|Rosuvastatin 10 mg|
1680659|NCT01613716|Drug|Ozurdex|Ozurdex .7 mg injected into the treated eye
1680660|NCT01613703|Drug|ONO-2952|1 mg to 200 mg QD at a single descending dose
1680661|NCT01613690|Drug|NVA237|NVA237 is administered via a BREEZHALER device
1680662|NCT01613677|Drug|BKM120|
1680663|NCT01613664|Drug|tisseel|The product will be given as a 2 mL bottle per patient, which will be spread along the staple line. If necessary, a second bottle of 2 mL is used. The precautions for use are described in the user manual.
1680664|NCT01613664|Other|no tisseel|the surgeon does not applied tissucol during the surgery
1680665|NCT01613651|Procedure|robot-assisted laparoscopic surgery|Undergo RALP
1680666|NCT01613651|Other|questionnaire administration|Ancillary studies
1680667|NCT01613651|Other|intraoperative complication management/prevention|Undergo placement of pelvic drain
1680668|NCT01613638|Other|meconium samples + maternal self-questionnaire|meconium samples + maternal self-questionnaire
1680669|NCT01613625|Procedure|Elastography|
1680670|NCT01613612|Procedure|core decompression|minimal surgical invention to drill a core to the femoral head to release pressure
1680671|NCT01613612|Procedure|Enriched BMCs implantation combined with core decompression|Patients are subjected to bone marrow aspiration from the anterior iliac crest. Mononuclear cells are enriched from patients' bone marrow by centrifuge, which are grafted with autologous cortical bone and implanted to the necrotic zone of the femoral head.
1680672|NCT01613599|Drug|Rituximab|Participants received rituximab at the discretion of their treating physicians.
1680673|NCT01613586|Drug|ASP3652|Oral
1680674|NCT01613586|Drug|Placebo|Oral
1680675|NCT01613573|Drug|somatropin AQ|somatropin injection 0.2mg/kg/w once per day, inject for 7 continuous days 4 weeks for cleaning period
1680676|NCT01613573|Drug|pegylated somatropin|Pegylated somatropin 0.2mg/kg/w once per week, for continuous 6 weeks Subcutaneous injection
1680677|NCT01613560|Drug|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
1680678|NCT01613560|Drug|AI+chemotherapy adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years after adjuvant chemotherapy
1680679|NCT01613560|Drug|AI adjuvant therapy|preoperative endocrinotherapy was performed by AI for 4-6 months;surgery;pathological evaluation after surgery;AI adjuvant therapy for 5 years
1680680|NCT01613547|Drug|Amoxicillin|80 mg/kg/day for 7 days
1680681|NCT01613547|Drug|Placebo|7 days
1680682|NCT01613534|Drug|Sucralfate|Argon plasma coagulation treatment followed by oral sucralfate (6 grams b.i.d.) for four weeks
1680683|NCT01613534|Drug|Placebo|Argon plasma coagulation treatment followed by placebo administration for four weeks
1680684|NCT01613521|Other|DCE-MRI and 18F-FMISO PET|DCE-MRIs: (i) Baseline DCE-MRI within two weeks before chemoradiation; (ii) Second DCE-MRI after the second week of chemoradiation (within a week); (iii) Third DCE-MRI three months after chemoradiation. iii. 18F-FMISO PET: Baseline 18F-FMISO PET within two weeks before chemoradiation (only 10 patients as a pilot study). iv. Clinical Follow-up: (i) Physical examination (every 3 months); (ii) Pap smear or cervical biopsy (every 3 months); (iii) follow-up imaging studies (CT and/or MRI) as per routine clinical follow-up of patients.
1680685|NCT01613508|Procedure|Direct Anterior Approach|
1680686|NCT01613508|Procedure|Mini-Posterior Approach|
1680687|NCT01613495|Drug|Placebo|After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
1680688|NCT01613495|Drug|Octreotide|They will be admitted to the inpatient unit of the OCTRI for testing six times. During each of these visits, testing will include measuring how well glucose (sugar) is processed, how much energy is burned off as heat, their amount of body fat, levels of the hormone ghrelin, and how much food is eaten at a meal. After the first study visit, subjects will begin monthly treatment with either the study drug or a placebo (an inactive substance), which will be continued for the first six months of the study. For the last six months of the study, subjects will be switched to the opposite treatment. During these study periods participants will return monthly for administration of study medication, physical examination, and blood draw to check liver enzymes.
1680689|NCT01613482|Radiation|cerebral prophylactic radiation|24Gy, 12 fractions of 2 Gy
1680690|NCT01613482|Drug|Trastuzumab|Weekly, 2mg/kg of corporal weight
1680691|NCT01613482|Drug|Other chemotherapy in association with Trastuzumab|other chemotherapy is possible to associate with Trastuzumab as well as a change of chemotherapy protocol is possible while maintening Trastuzumab 8 weeks is required between last injection of chemotherapy and first radiotherapy session
1680692|NCT01613469|Drug|5FU/Leucovorin|450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles during radiation (one cycle is the administration every day for 3 consecutive days, a cycle is 21 days)followed by 450 mg/m2 of 5-FU plus 50 mg Leucovorin given in 3 cycles after completion of radiation.
1680693|NCT01613469|Radiation|external beam photon radiation|45 Gy in 25 fractions (1.8Gy per fraction, 5 fractions per week)over 5 weeks.
1680694|NCT01613456|Dietary Supplement|Saccharomyces cerevisiae CNCM I-3856|2 capsules/day during 12 weeks
1680695|NCT01613456|Dietary Supplement|Placebo|"Capsule with comparable organoleptic properties and weight than the experimental product.
2 capsules/day during 12 weeks"
1680696|NCT01613430|Behavioral|Coach Training (COACH)|"Participants and their coaches receive Printed Educational Materials (PEM). Additionally, coaches will receive a 40-minute cancer-related training session led by a research staff member. The coaches will be provided basic information about different types of cancer screenings, how to schedule and keep medical visits, and how to communicate with health care providers about cancer screening. The session will be interactive, including short video presentations, role plays and exercises. Coaches will be given brochures on cancer screening for the three cancer types, a checklist for the coach and a Things to Remember diary checkup list, and resources addressing well-known barriers to cancer screening."
1680697|NCT01613430|Behavioral|Printed Educational Materials (PEM)|Participants and their coaches will be provided with educational brochures about cancer screening for colorectal, breast and cervical cancers at the completion of the baseline survey.
1680698|NCT01613417|Drug|gadoteridol|ProHance 0.1 mmol/kg
1680699|NCT01613417|Drug|gadobutrol|Gadovist/Gadavist 0.1 mmol/kg
1680700|NCT01613404|Other|No intervention|Patients will be treated with approved erythropoiesis stimulating agent (Eprex or Aranesp) will be administered according to actual clinical practice according to guidance in the current approved product monographs. All patients will receive treatments that are prescribed by their physician according to actual clinical practice.
1680701|NCT01613378|Other|No intervention|No intervention administered in this study
1680702|NCT01613365|Drug|Chlorhexidine Gluconate|Oropharyngeal and nasopharyngeal decontamination with Chlorhexidine Gluconate
1680703|NCT01613365|Drug|Placebo|Oropharyngeal and nasopharyngeal decontamination with placebo
1680704|NCT01613352|Other|Ambulatory surgery|Sentinel node mapping was done on the previous day and the patients were operated on first in the morning.
1680705|NCT01613339|Other|Balance training using Body awareness therapy|Once a week, 1 hour for 8 weeks.Body awareness training may be performed by physiotherapist. Exercises are performed in standing, sitting and lying. Exemple of exercies are weight-balancing in standing and relaxation exercises.
1680706|NCT01613326|Drug|NVA237|NVA237 50 μg inhalation capsules once a day, delivered via SDDPI
1680707|NCT01613326|Drug|Tiotropium|Tiotropium 18 μg once a day delivered via HandiHaler® device
1680708|NCT01613326|Drug|Placebo to tiotropium|Placebo to tiotropium 18 μg o.d. once a day delivered via HandiHaler® device.
1680709|NCT01613326|Drug|Placebo to NVA237|Placebo to NVA237 50 μg once a day delivered via SDDPI
1680710|NCT01613326|Drug|salbutamol/albuterol|salbutamol/albuterol given as a rescue medication via inhaler when needed
1680711|NCT01613313|Drug|Collagenase Clostridium Histolyticum|This is a dose escalation study in which subjects will sequentially receive single injections of 0.058 mg, 0.15 mg, 0.29 mg, 0.44 mg.
1680713|NCT01613287|Device|TheraSorb® - Ig flex|"TheraSorb® Treatment with one TheraSorb® Ig flex adsorber pair, used exclusively with the LIFE 18® apheresis system for extracorporeal application for IA therapy.
5 treatments performed over 5 to 8 consecutive days."
1680714|NCT01613274|Other|gum chewing|gum chewing three times a day for up to 20 minutes
1680715|NCT01613274|Other|no gum chewing|no gum chewing
1680716|NCT01613261|Drug|TAK-733 and alisertib|"TAK-733 will be administered orally once daily (QD) on Days 1 through 14 of the 21-day cycle.
Alisertib will be administered orally twice daily (BID) on Days 1 through 7 of the 21-day cycle."
1680717|NCT01613248|Drug|MK-1602|Single 1, 10, 25, 50 or 100 mg dose of MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve the various MK-1602 dose levels to be studied. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
1680718|NCT01613248|Drug|Placebo-matching MK-1602|Single administration of placebo-matching MK-1602 taken at onset of migraine of moderate or severe intensity. Dosage form is film coated tablet for oral administration. Dose is provided to participants as a blinded bottle of tablets packaged to achieve placebo study medication. Participants will be instructed to take all study medication from the bottle when they treat their migraine headache.
1680719|NCT01613248|Drug|Rescue medication|"If moderate or severe migraine headache pain continues 2 hours after dose of study medication or if migraine headache comes back within 48 hours,
Participants will be allowed to take their own rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs]), anti-emetics, triptans or other medication not explicitly excluded."
1680720|NCT01613235|Other|Induced hypertension|Blood pressure will be raised in order to improve cerebral blood flow (CBF). In case of a low cardiac output, inotropics will be added. Induced hypertension will be continued for at least 48 hours when patients show some improvement within the first 24 hours. After 48 hours, the dose of vasopressor will be tapered daily, and resumed in case of clinical deterioration. In patients who do not show any improvement within 24 hours, induced hypertension will not be continued.
1680722|NCT01613209|Drug|Candesartan cilexetil|candesartan 16 mg tablets p. o. for 14 days (morning), then candesartan 32 mg tablets for 28 day (morning)s,
1680723|NCT01613209|Drug|Olmesartan/Amlodipin|olmesartan/amlodipine 40/5 mg tablets for 14 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 28 days (morning), then olmesartan/amlodipine 40/10 mg tablets for 42 days (evening)
1680724|NCT01613196|Other|Positron Emission Tomography with 18F-Fluoro-deoxy-glucose|"2 or 3 FDG-PET scans will be performed in all patients : at inclusion*, end of treatment and 6 months after completion of treatment in cases of persistent uptake
*except if already done in the last 15 days."
1680727|NCT01613170|Drug|Toviaz|Toviaz 4mg daily
1680728|NCT01613170|Drug|Premarin|Premarin cream 1 g per vagina twice weekly
1680729|NCT01613170|Drug|Placebo cream|Placebo cream 1 g per vagina twice weekly, to mimic Premarin cream
1680730|NCT01613131|Drug|Mirena|Mirena (levonorgestrel-releasing intrauterine system), 52 mg (20 mcg/day), 5 year duration (study duration 6 months).
1680731|NCT01613131|Drug|Estradiol|Topical, .06%, Applied once daily for 50 days.
1680732|NCT01613131|Drug|Placebo Gel|Topical Gel, Applied once daily for 50 days, Placebo comparator.
1680733|NCT01613118|Drug|RE-021 (Sparsentan)|Oral, once-daily
1680734|NCT01613118|Drug|Irbesartan|Oral, once-daily
1680735|NCT01613105|Drug|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 upto three times a day with meals or as per investigators descretion.
1680736|NCT01613092|Drug|Incremental|Cefazolin and Vancomycin pre-op, bacitracin wash and postoperative cefalexin or clindamycin
1680737|NCT01613092|Drug|Cefazolin|Preoperative antibiotic
1680738|NCT01613079|Drug|Tripterygium wilfordii Hook F|Oral T2(Tripterygium wilfordii Hook F) 20mg thrice daily for 24 weeks.
1680739|NCT01613079|Drug|Methotrexate|Oral methotrexate 7.5-12.5mg per week for 24 weeks. The starting dose was 7.5mg per week, then increased to 12.5mg（max 0.3mg/Kg） per week in 4 weeks. Folic acid at the dose of 10mg per week were applied to all patients.
1680740|NCT01613066|Procedure|Intrabone Allogeneic Transplant|Unrelated single unit intrabone cord blood transplantation
1680741|NCT01613053|Drug|Glivec|800 mg per day
1680742|NCT01613040|Drug|Moxifloxacin|Single oral dose on Day 1
1680743|NCT01613040|Drug|Moxifloxacin|Single oral dose on Day 11
1680744|NCT01613040|Drug|RO4917838|Multiple daily low doses of RO4917838 for 10 days
1680745|NCT01613040|Drug|RO4917838|Multiple daily oral high doses of RO4917838 for 10 days
1680746|NCT01613040|Drug|RO4917838 placebo|Oral daily doses of placebo to RO4917838 for 10 days
1680747|NCT01613027|Biological|Rituximab|Rituximab administered according to prescribing information and normal clinical practice.
1680748|NCT01613014|Drug|ABT-436|Target dose - 400mg BID
1680749|NCT01613014|Drug|Matched Placebo - Sugar Pill|Target Dose - 2 pills BID
1680750|NCT01612988|Drug|BOMP|"Day-8 OMB prephase:
Ofatumumab 300 mg IV day -8 Methylprednisolone 100 mg TD IV day -8
BOMP cycle 1 and 2 :
Ofatumumab 1000 mg IV day 1 and day 15 Bendamustine 70mg IV day 2 and ady 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3 Methylprednisolone 100 mg TD IV day 15
BOMP cycle 3 to 6 :
Ofatumumab 1000 mg IV day 1 Bendamustine 70mg IV day 2 and day 3 Methylprednisolone 1000 mg/m² IV day 1, 2 and 3"
1680751|NCT01612975|Drug|Naproxen|Intervention arm involves administering 500mg Naproxen BID to participants and 40mg of Pantoprazole in tandem. Pantoprazole will negate gastrointestinal consequences of Naproxen and reduce the likelihood of a complication occurring. Participants will take Naproxen at the above dosage from the time of surgery to four weeks following surgery. They will attend scheduled check-ups where their vitals will be recorded, as well as laboratory indicators of gastrointestinal complications (creatinine levels, etc) for their safety. This experiment is double-blinded so neither investigators nor participants will know which arm of the study they belong to.
1680752|NCT01612975|Drug|Placebo|Inert, inactive placebo pill similar in appearance to naproxen allocation. To be taken twice daily for 4 weeks total along with 40mg pantoprazole.
1680753|NCT01612949|Other|photographing head and neck|Taking three photographs of head and neck-one photograph from front, one from left and one fron right. The photographs are analyzed by facial structure software to create face model.
1680754|NCT01612936|Biological|Bronchoscopy, Segmental Allergen Challenge and Broncheoalveolar Lavage|"On the day of the first bronchoscopy,BAL will first be performed in the lingula without instillation of diluent or allergen.Then, a 2-ml aliquot of isotonic diluent is instilled into the right upper lobe. Then, the procedure will be repeated in the right middle lobe with instillation of 2-ml of standardized cat or mite allergen solution.A test dose concentration of allergen is administered first consisting of 2 ml of allergen at 1/10th(Cat,D.farinae) or 1/30th(D. pteronyssinus) the threshold concentration.If on visual inspection through the bronchoscope, there is no evidence of mucosal inflammation after two minutes, a second segmental allergen challenge will be done in the right middle lobe using 2-ml of full-dose allergen at the threshold concentration(Cat,D.farinae) or 1/3th the threshold concentration(D.pteronyssinus).This dose will be predetermined by quantitative skin prick testing.A second bronchoscopy is performed 24 hours after delivery of allergen extract and diluent."
1680755|NCT01612936|Procedure|PET-CT imaging(13NN perfusion/ventilation, 18FDG inflammation, and CT imaging)|Imaging is first performed the evening prior to the 1st bronchoscopy.An IV catheter is placed.An attenuation correction is performed to remove image distortion using a chest CT volumetric scan.Subjects are instructed to exhale to the same mean lung volume of the CT scan and hold their breath for 20sec.Simultaneous with apnea,13NNsaline is injected IV and a series of PET scans is acquired.Then subjects resume breathing, matching their previous respiratory rate and tidal volume.After 3 min,within an interval of 1 min,spirometry and 2 deep inhalations are performed,followed by 1 min of washout. For the second imaging visit, which will occur 24 hour later, the imaging sequence will be repeated as described above, but will also include 18FDG infusion.At least 30 minutes after the 13NN injection,10mCi of 18FDG is infused. Then, images are collected over a 75 minutes.Venous blood is sampled at 5 different time points over a 40-45 minute time window to determine plasma radioactive levels.
1683599|NCT01590979|Drug|Placebo|two times a day, 12 hour intervals
1680756|NCT01612923|Other|Midwife|gynecological exam and ultrasound and contraceptive advice provided by midwife
1680757|NCT01612910|Drug|oral microencapsulated diindolylmethane|Patients receive oral microencapsulated diindolylmethane orally (PO) twice a day (BID) for 1 year in the absence of disease progression or unacceptable toxicity
1680758|NCT01612910|Other|laboratory biomarker analysis|Correlative studies
1680759|NCT01612897|Other|Computer based care reminders|Physicians in the intervention clinic will receive computer generated reminders to screen for autism among children of appropriate age visiting the clinic.
1680760|NCT01612884|Drug|Prasugrel|Prasugrel 60mg loading dose at time of PCI if clopidogrel non-responder
1680761|NCT01612884|Drug|Clopidogrel|Clopidogrel 300mg loading dose at time of PCI if clopidogrel responder
1680762|NCT01612871|Drug|Tamoxifen, Letrozole , Anastrozole, Exemestane|"Current first line metastatic hormone therapy treatment in hormone dependent breast cancer :
Tamoxifen 20 mg/day, Letrozole 2.5 mg/day, Anastrozole 1 mg/day, Exemestane 25mg/day"
1680763|NCT01612858|Drug|Metformin|Metformin at a dose of one 500mg tablet twice a day with meals for one week, after which the dose will increase to 500 mg three times a day with meals for the remaining 11 weeks of the study.
1680764|NCT01612858|Drug|Pioglitazone|Pioglitazone at a dose of one 30 mg tablet once per day for the 12 weeks of the study.
1680765|NCT01612845|Procedure|Arthroscopic repair without platelet rich fibrin|after the tendon is repaired, no additional procedures are performed and no PRF is administered
1680766|NCT01612845|Biological|PRF (vivostat ®) administration after rotator cuff repair|7cc. of autologous PRF are locally administered to the repair site after reconstruction of the rotator cuff
1680767|NCT01612832|Drug|Pregabalin|Patients in one group will receive 150 mg of PGL at 20:00 h the night before surgery and at 1.5 h before surgery, and will undergo surgery under general anesthesia (GA).
1680768|NCT01612832|Other|Control|pain treatment as customary in the department
1680769|NCT01612806|Device|PriMatrix|fetal bovine dermal scaffold
1680770|NCT01612806|Device|PriMatrix Ag|fetal bovine dermal scaffold with Ag
1680771|NCT01612806|Procedure|moist wound therapy|standard of care moist wound therapy
1680772|NCT01612793|Device|AlphaCore Device|multiple stimulation treatments per day for duration of hospitalization
1680773|NCT01612780|Device|XprESS Multi-Sinus Dilation Tool|Sinus balloon dilation
1680775|NCT01612754|Behavioral|Noise reduction work place rules|"Information conferences for all theatre staff (100%)on the detrimal effects of high noise levels in the operating theatre. Issue of workplace rules on handouts and poster on theatre doors: Ban of all mobile phones from theatre. Only conversations about the ongoing case are allowed. No restocking etc. during an operation and no work in this operating room concerning other patients (e.g. later on the list). Turnig of of unnecessary suckers, warming devices etc. . No in and out during the procedure.
Technical: Sound Ears (TM, Sound Ear A.S. Copenhagen, Denmark) taped to all 4 Walls. Optical Telephones."
1680776|NCT01612754|Behavioral|Presence of an examiner in the concerned theatre|Research Clerk present in theatre, writes on note pad.
1680777|NCT01612741|Drug|Acarbose (Precose/Glucobay, BAYG5421)|Oral Glucobay 25 titrated to Glucobay 50 three times a day with meals or as per investigators descretion.
1680778|NCT01612728|Other|Women without Arthralgia|For mild arthralgia, women will try the following interventions in the following order: 1) Weight-bearing exercise program, and 2) Glucosamine & Chondroitin supplements. For women with mild to moderate arthralgia, they will try to the following interventions in this order: 1) Acupuncture, 2) Indomethacin twice daily as needed, 3) Switch to a different aromatase inhibitor, and 4) Switch to tamoxifen.
1680779|NCT01612728|Drug|Women with Arthralgia|
1680780|NCT01612715|Other|Segmental Allergen Challenge|segmental allergen challenge
1680781|NCT01612702|Drug|Dexamethasone|Dexamethasone 10 mg intravenous administration
1680782|NCT01612689|Device|Accelerometer Device|A sensor platform that enables physiological monitoring in routine, home or office environments.
1680783|NCT01612676|Drug|FE 202158|
1680784|NCT01612663|Device|Pain relief by Acupuncture needle at non-specific site|
1680785|NCT01612663|Device|Acupuncture needle|
1680786|NCT01612663|Device|Acupuncture needle|
1680787|NCT01612663|Device|Acupuncture needle|
1680788|NCT01612650|Device|tomosynthesis|2 incidences 3D numeric mammography
1680789|NCT01612650|Device|2D mammography|2 incidences 2D analogic mammography
1680790|NCT01612637|Behavioral|Pelvic floor muscle training and lifestyle advice|Group 1 will be individually examined and instructed in pelvic floor muscle training before the intervention starts by specialized physiotherapists. The examination includes a vaginal or an anal examination. The women attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship and information that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss. The women will perform pelvic floor muscle training in the group and perform pelvic floor muscle training at home. The training will be individually planned according to the findings of the pelvic floor physiotherapist. The women in the intervention group fill in an exercise diary and also describe on a Visual Analog Scale if the training causes any bother.
1680791|NCT01612637|Behavioral|Lifestyle advice|Group 2 attend six group sessions within 12 weeks containing structured information about POP and the possible affection of POP on quality of life, exercising and sexual relationship. The lifestyle advice contains information about life style changes that could improve POP symptoms, such as bladder and bowel habits, coughing, heavy lifting, eating habits and weight loss
1680792|NCT01612598|Other|counseling intervention|Undergo PCI
1680793|NCT01612598|Procedure|quality-of-life assessment|Ancillary studies
1680794|NCT01612598|Other|questionnaire administration|Ancillary studies
1680795|NCT01612598|Other|educational intervention|Undergo PCI
1680796|NCT01612546|Drug|cyclodextrin-based polymer-camptothecin CRLX101|Given IV
1680797|NCT01612546|Other|Laboratory biomarker analysis|Correlative studies
1680798|NCT01612546|Other|Pharmacological studies|Correlative studies
1680863|NCT01612039|Drug|ASP3291|Tablet, 1,000 mg (four 250-mg tablets), twice a day, 8 weeks
1680864|NCT01612039|Drug|Placebo|Matching placebo tablets
1680799|NCT01612520|Behavioral|telecoaching|"The COACH program trains patients to 'drive' the process of achieving and maintaining the target levels for their risk factors while working in association with their GP. The telephone coaching is aimed at improving self-efficacy by adhering to the prescribed therapy and making relevant behavior changes.
The coaching model is a continuous five-stage coaching cycle: Stage 1. Finding out what the patient knows; Stage 2. Telling the patient what they should know; Stage 3. Assertiveness training; Stage 4. Setting an action plan; Stage 5. Reassessment at the next coaching session (monitoring).
The coach monitors and registers: the biomedical risk factors, the lifestyle/behavioral risk factors and use of the recommended medications. Coaching is focused on eliminating the knowledge gap and motivating the patient to apply the appropriate lifestyle and medical therapy."
1680800|NCT01612507|Drug|600 mg Ceftaroline fosamil|1 h infusion
1680801|NCT01612507|Drug|Placebo|1 h infusion
1680802|NCT01612507|Drug|600 mg Ceftaroline fosamil|2 h infusion
1680803|NCT01612507|Drug|Placebo|2 h infusion
1680804|NCT01612494|Drug|Hypertonic Saline|intravenous formulation of 3% hypertonic saline in a bolus dose of 10ml/kg over one hour
1680805|NCT01612494|Other|Normal Saline|intravenous formulation of normal saline in a bolus dose of 10ml/kg over one hour
1680806|NCT01612481|Procedure|chest radiography|surveillance by radiography of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
1680807|NCT01612481|Procedure|chest CT|surveillance by CT of chest every 3 months the first 2 years then every 6 month the third, forth and fifth years
1680808|NCT01612468|Drug|Liraglutide|1.8 mg/day subcutaneous
1680809|NCT01612468|Drug|Placebo|1.8 mg/day subcutaneous
1680810|NCT01612455|Behavioral|LINC Case Management|The 1st case management (CM) session will be at the Narcology Hospital and will follow a modified strengths-based case management curriculum. As part of this first session, the CM will show a 10 minute video clip produced by a Russian NGO of HIV-infected patients talking about accessing HIV care. The CM will also tell the patient what his/her CD4 cell count is and discuss what it means with the patient. The case manager will help the client identify the outpatient HIV clinic on a map and will discuss basic drug harm reduction ideas with the client. The remaining 4 CM sessions will happen over the following 6 months. Sessions may happen at the HIV clinic, NGOs, or in the community. The HIV CM helps the client understand the importance of HIV care, identify barriers to care acquisition and recognize one's own strengths, abilities and assets to reduce self-identified barriers to care. The HIV CM's primary aim is to have the client attend an appointment at the HIV outpatient clinic.
1680811|NCT01612442|Behavioral|nutrition and agricultural education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers and agricultural education delivered by agricultural extension agents, in addition to standard monthly child welfare services delivered by Ghana Health Service
1680812|NCT01612442|Behavioral|nutrition education|Mothers of children aged 6-24 months received monthly nutrition education delivered by community health volunteers in addition to standard child growth monitoring services provided by the Ghana Health Service.
1680813|NCT01612429|Dietary Supplement|Amino acid supplementation|Single arm study in which dialysis patients will receive up to 500 mL of NephrAmine® (5.4% amino acids for injection; B. Braun Medical, Inc) containing 26.8 grams of essential amino acids at 125 mL/h during each dialysis session (3 times weekly for 6 weeks)
1680814|NCT01612416|Device|RS-3000 OCT measurements|Ganglion cell, retinal nerve fiber layer and retinal thickness measurements of normal subjects, primary open angle glaucoma and normal tension glaucoma patients using RS-3000 OCT RetinaScan
1680815|NCT01612403|Dietary Supplement|zinc sulfate|every participant took two capsules of zinc sulfate per day for three months (each one 220mg)
1680816|NCT01612377|Drug|Prednisolone-Dipyridamole|Oral, QD
1680817|NCT01612377|Drug|Prednisone|Oral QD Prednisone 5mg
1680818|NCT01612377|Drug|prednisone|Oral, QD prednisone 7.5mg
1680819|NCT01612364|Procedure|thoracic sympathetic block|Thoracic sympathetic block is sympathetic block of upper limb described by Leriche e Fontaine em 1925. The block is performed under radioscopic view, positioning the needle lateral the body of thoracic vertebra T3, where infuse anesthetic solution. The theoretical advantage over the stellate ganglion is its greater specificity and efficiency. Solution block: 5ml ropivacaine 0,75% + 5ml de triamcinolone 2%
1680828|NCT01612338|Behavioral|Targeted|Targeted letter and booklet
1680829|NCT01612338|Behavioral|Enhanced Tailored|Tailored letter and booklet, enhanced family communication and support brochure
1680830|NCT01612325|Device|Holmium-166 polylactic microspheres|Radioembolisation with 600 mg of Holmium-166 microspheres with a patient liver size adjusted activity. The desired whole liver dose is 60 Gy.
1680831|NCT01612312|Procedure|Thrombectomy|Manual thrombectomy will be performed in the thrombus aspiration group using an aspiration catheter utilized in daily clinical routine (Eliminate, Terumo Europe, Leuven, Belgium). In the standard PCI group, patients will be treated by conventional PCI according to local practice without thrombectomy.
1680832|NCT01612312|Procedure|Standard percutaneous coronary intervention|In the standard percutaneous coronary intervention (PCI) group, patients will be treated by conventional PCI according to local practice without thrombectomy.
1680833|NCT01612299|Drug|Zortress® /Everolimus|"Standard immunosuppression: THY 1-1.5 mg/kg/d qd for a total of 6 mg/kg •TAC trough targets 0-3 mo 8-12 ng/ml 4-6 mo 6-10 ng/ml >6 mo 5-8 ng/ml•Myfortic® or CEL 360mg or 500mg po BID, and receiving THY then Myfortic® or CEL 720 mg or 1000mg PO BID once THY induction completed• COR 500mg MET IV pre-op,125mg MET IV q24h x 2 doses (Post-Op Days 1 &2) 20mg Pred PO daily x 2 wks 15mg Pred PO daily x 2 wks 10mg Pred PO daily x 4 wks 5mg Pred PO daily x 4 wks 5 mg Pred PO every other day through mon 12.
Experimental: TAC + Zortress® + COR In this arm patients will stop Myfortic®/CEL and start Zortress® at a dose of 1 mg PO BID with a target level of 3-8 ng/ml.At Zortress® level of at least 3 ng/ml TAC will be dosed to a target range as follows Randomization through mo 3 post-transplant 7-10 ng/ml 4-6 mo post transplant 5-8 ng/ml >6 mo post transplant 4-7 ng/ml."
1680834|NCT01612286|Drug|endostatin|Gemcitabine 1.0g/m2 d1,8 cisplatin 80mg/m2 endostatin 15mg/d 14days/cycle *4cycles
1680835|NCT01612273|Drug|Triflusal|Dose: 300mg bid, Mode of administration: oral, Duration: from randomization to 6 week, crossover-design.
1680836|NCT01612273|Drug|Aspirin|Dose: 150mg bid, Mode of administration: oral, from randomization to 6weeks, crossover-design.
1680837|NCT01612260|Drug|Shensong Yangxin capsule|ShenSongYangXin Capsule 4 granules t.i.d. po for 12weeks
1680838|NCT01612260|Drug|placebo Capsule|4 granules t.i.d. po for 12 weeks
1680839|NCT01612247|Drug|Cyclophosphamide and Methotrexate and Aspirin|Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
1680840|NCT01612234|Dietary Supplement|High palmitate or high oleate diet.|High palmitate diet composition: Fat, 40.4% kcal; palmitic acid, 16.0% kcal; oleic acid,16.2% kcal. High oleate diet composition: Fat, 40.1% kcal; palmitic acid, 2.4% kcal; oleic acid, 28.8% kcal
1680841|NCT01612221|Drug|N-acetylcysteine|N-acetylcysteine (NAC), 1200 mg Oral route 2 doses
1680842|NCT01612221|Other|Placebo arm|Sterile normal saline, diluted into 25 cc tomato juice, orally, x 1 dose. Then repeated 24 hours later.
1680843|NCT01612208|Device|Periarticular Locking Plate (NCB, Zimmer)|The proximal plate segment will be applied to the diaphysis using four 5.0 mm MotionLoc screws. The plate will not be compressed onto the femoral diaphysis to preserve periosteal perfusion and to enable controlled motion between the plate and the diaphysis. If desirable, temporary spacers of the NCB set may be used in the proximal plate segment to facilitate 1-2 mm plate elevation over the diaphysis. Only MotionLoc screws will be used for fixation of the NCB plate proximal to the fracture site.
1680844|NCT01612208|Device|MotionLoc Screw|The NCB Polyaxial Locking Plate System is indicated for temporary internal fixation and stabilization of fractures and osteotomies of long bones. These MotionLoc screws have a reduced 3.4 mm diameter mid-shaft section to bypass the near cortex. By avoiding rigid constraint in the near cortex, the MotionLoc screw design increases the working length of the screw, allowing for elastic flexion of the screw shaft within a controlled motion envelope in the near cortex.
1680845|NCT01612195|Procedure|Anal fistula plug|All patients have a draining seton for at least 6 weeks prior placement of the anal fistula plug. All patients are administered a general anesthetic and are operated in the lithotomy position. The seton is removed, but no curettage or irrigation of the fistula tract is performed. The plug is inserted through the internal opening, and pulled through the external opening until it fit snugly and its base is sutured to the internal sphincter with 2 interrupted 2-0 polyglactin 910 sutures. The tip of the plug is cut at skin level and not sutured. The external opening is left open to allow for drainage. The patient is instructed to restrict physical and sexual activity for 2 weeks postoperatively. Patients are seen in the post-operative clinic at 10 days, 6 weeks and 6 months as per protocol.
1680846|NCT01612182|Other|renal replacement therapy|renal replacement therapy : hemodialysis and/or CRRT(continuous renal replacement therapy )
1680847|NCT01612169|Behavioral|Patient Navigation (PN) Group|The patient navigator approach includes five functions: 1) establishing an effective working relationship; 2) encouraging identification and use of strengths, abilities and assets; 3) supporting client control over goal setting and the search for needed resources; 4) viewing the community as a resource and identifying informal sources of support; and 5) conducting case management as an active community based activity.
1680848|NCT01612169|Behavioral|Patient Navigator Plus Contingency Management (PN+CM) Group|Study participants randomized to this group will receive the patient navigation (PN) intervention as outlined above combined with contingency management (CM).
1680849|NCT01612156|Drug|2% lidocaine gel|2% lidocaine gel will be used to coat the urethral catheters and cotton tipped swab before use during the examination.
1680850|NCT01612156|Drug|Water based lubricant|Water based lubricant will be applied to all urethral catheters and cotton tipped swabs before use in the pelvic floor examination.
1680851|NCT01612143|Drug|setrobuvir|200 mg capsule formulation, single oral dose
1680852|NCT01612143|Drug|setrobuvir|200 mg tablet formulation, single oral dose
1680853|NCT01612130|Drug|100 mg of Valeriana officinalis L|A single dose of 100 mg of Valeriana officinalis L., 1 hour prior to surgical procedures
1680854|NCT01612130|Drug|Placebo 100mg|A single dose of 100 mg of placebo orally, 1 hour prior to surgical procedures
1680855|NCT01612104|Behavioral|Psychological First Aid|A cognitive behavioral (CBT) method structuring and focusing psychological therapy sessions with children and adolescents having been exposed to potential trauma
1680858|NCT01612078|Drug|Droxidopa|200mg/tab 2tablets, po, three times a week
1680859|NCT01612078|Drug|Placebo|200mg/tab, po, three times a week.
1680860|NCT01612065|Drug|Misoprostol|200 ug
1680861|NCT01612065|Drug|Misoprostol|Misoprostol vaginally, 400 ug
1680862|NCT01612052|Drug|Antibiotic Prophylaxis|Comparing the antibiotic treatment related to surgery
1680865|NCT01612026|Procedure|arterial cannulation by angiographic imaging|comparing successful arterial cannulation in case of non-cardiac vascular patient population.
1680872|NCT01612000|Biological|PanBlok|Intramuscular injection
1680873|NCT01612000|Biological|rHA adjuvant|Intramuscular injection
1680874|NCT01611987|Other|MStep|Participant will meet with instructor twice to learn how to exercise safely. Exercises will be demonstrated and practiced under the direct supervision of the instructor. Written details and pictures will be made. Variety in exercise will be encouraged to promote long-term adherence. Stretching, strengthening and relaxation exercises will be given. Persons will be given Thera Band® to facilitate resistance exercise training and instructed how to progress. Equipment such as Nordic Walking Poles, stationary bicycle, BOSU®, or exercise balls will be available. Rather than having a fixed rigid prescription, the aim is to get people to intuitively adjust the amount of resistance so they feel they are working without causing harm, they are not doing the same boring activity, week in week out.
1680875|NCT01611987|Other|General guideline approach|Individuals in the control condition will meet with the exercise instructor on two occasions during the first two weeks to review key components of public health guidelines for physical activity and health. In brief, the general guidelines for MS are (i) aerobic and endurance exercise for 30 minutes per session, 3 times per week at an intensity of 60% to 75% of heart rate peak; (ii) weight training for weak muscles, 2 days per week, on non-endurance days, 8 to 15 repetitions per exercise; and (iii) stretching daily with active or passive range of motion exercises, or attendance at Yoga or Tai Chi classes.
1680876|NCT01611974|Drug|Maribavir|Tablet for oral administration
1680877|NCT01611961|Drug|DT-LM|Intravenous infusion, Upto 6 dose levels have been studied i.e. 45, 60, 75, 90 105,and 120 mg/m2, Every 3 weeks.
1680878|NCT01611961|Drug|docetaxel|Intravenous infusion, 3 dose levels：60, 75, and 90 mg/m2, Every 3 weeks
1680879|NCT01611948|Drug|Aprepitant|125mg/day for 8 weeks
1680880|NCT01611948|Drug|Placebo|125mg/d placebo pill for 8 weeks
1680881|NCT01611948|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 8 weeks in conjunction with study drug or placebo.
1680882|NCT01611935|Drug|Vasopressin|After receiving greater than 6 units of blood product within the first 12 hours of admission, trauma patients will be randomized to either normal saline or vasopressin. Subjects will receive an initial 4 unit bolus followed by an infusion of 0 to 0.04 units titrated to maintain a mean arterial blood pressure of equal to or greater than 65 mmHg for a total of 48 hours.
1680883|NCT01611922|Other|Ophthalmic dye|Topically instilled for the purpose of assessing lid margin staining
1680884|NCT01611922|Device|Contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and power, worn for a minimum of 8 hours on the day of assessment, after which lenses will be removed and dye will be instilled.
1680885|NCT01611909|Drug|p-menthane-3,8-diol oil|Apply topically to affected area twice daily
1680886|NCT01611896|Dietary Supplement|Selenium|100 µg tablets. The dose of daily supplement of selenium is set at 200 µg (two tablets). The duration of the intervention period is between 24-30 months. This is defined by the time of ATD treatment withdrawal, which is scheduled between approximately 12-18 months after randomisation. Selenium supplementation will continue 12 months after withdrawal of ATD treatment.
1680887|NCT01611896|Other|Placebo|Placebo tablets, identical in regards to size, appearance, taste, smell, and solubility to the experimental intervention tablet will be produced by Jemo-Pharm A/S, http://www.jemo-pharm.dk/frame.cfm/cms/id=977/sprog=2/grp=6/menu=1/ (content as in section: Auxiliary agents). The placebo regimen will be identical to the selenium regimen, but consist of two non-active tablets per day for 24-30 months.
1680888|NCT01611883|Drug|Ezetimibe|10 mg oral dose once daily for 24 weeks
1680889|NCT01611883|Drug|Placebo|Placebo to match ezetimibe orally once daily for 24 weeks.
1955329|NCT03221738|Behavioral|App-Based Cognitive Behavioral Therapy|12-week Smartphone delivered CBT for BDD. In-person cognitive behavioral therapy (CBT) is an empirically supported treatment for BDD. The app-delivered CBT in this project includes modules such as cognitive skills (e.g., cognitive restructuring, core belief work), behavioral skills (e.g., exposure with ritual prevention), and perceptual retraining/mindfulness skills.
1955331|NCT03220438|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
1680890|NCT01611870|Device|AVAPS-AE|AVAPS-AE is the experimental ventilation mode of therapy in this study that includes a combination of already cleared therapy attributes.
1680891|NCT01611870|Device|AVAPS-AE mode of ventilator therapy|All participants will use the study device in the titrated to the AVAPS-AE mode of ventilator therapy for six weeks of home use.
1680892|NCT01611857|Drug|Tivantinib|Patients with advanced solid tumors will be treated with oral Tivantinib (120, 240, or 360 mg BID) daily for 14 days in cycles of 14 days.
1680893|NCT01611857|Drug|FOLFOX|The FOLFOX treatment regimen is started on Day 1 of each cycle and consists of 5-Fluorouracil (5-FU) 400 mg/m^2, 5-FU continuous IV 2400 mg/m^2 over 46 hours, leucovorin 400 mg/m^2 IV, and oxaliplatin 85 mg/m^2.
1680894|NCT01611844|Device|Medical device : micro-needle BD 1.5 mm 30G drug:Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:
1 intradermal injection of Tuberculin (5UI)
1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
1680895|NCT01611844|Device|medical device: lance 26G X 16mm drug: Tubertest® : tuberculin (purified protein derivative)|"2 intradermal injections are performed on each arm/bottom of the subject:
1 intradermal injection of Tuberculin (5UI)
1 intradermal injection of saline solution using Manthoux method or BD micro-needle. the method of injection is randomized: left or right"
1680896|NCT01611831|Behavioral|ACT in group|A protocol based on the main research studies describing the therapy and adapted for fibromyalgia treatment by our research group will be used. This protocol is available for the investigators. There will be 9 group sessions of 90 minutes duration each. Patients assigned to this arm will be allowed to occasionally take minor analgesics.
1680897|NCT01611831|Behavioral|Improved treatment as usual by General Practitioners|General practitioners (GPs) will administer treatment as usual to the patients with fibromyalgia. To enhance the intervention, the Clinical Guidelines on the Treatment of Fibromyalgia approved by the Health Services of Aragon will be provided to the GPs.
1680898|NCT01611818|Other|Low Intensity Internet-delivered psychotherapy|Patients will be contacted by a researcher trained in psychotherapy. Patients can ask for questions or advice to psychotherapists during the study
1680899|NCT01611818|Other|Self-guided Internet delivered psychotherapy|No contact with the therapists over the treatment period will be done.
1680900|NCT01611818|Other|Improved treatment as usual|Any kind of treatment administered by the GP to the patient with depression
1680901|NCT01611805|Drug|GSK1605786|Opaque Swedish orange body and cap.
1680902|NCT01611805|Drug|GSK1605786 Placebo|Opaque Swedish orange body and cap.
1680905|NCT01611779|Device|Encore Tongue Suspension System|The primary components of the Encore Tongue Suspension System consist of a suture passer, suspension line and bone screw.
1680906|NCT01611766|Procedure|Secondary Cytoreductive Surgery|Complete Cytoreduction
1680907|NCT01611766|Drug|Salvage Chemotherapy|
1680908|NCT01611753|Other|packed red blood cell transfusion|Patients wil be randomized en two groups, in the liberal group they must received transfusions immediately, as the objective was to maintain hemoglobin levels above 9.0 g/dL. In the restrictive group they will receive transfusion to maintain hemoglobin levels above 7.0g/dL
1680909|NCT01611740|Procedure|Analysis of the heart rate and respiratory characteristics / Telemonitoring system prototype developed by INSERM U-642|"Telemonitoring system prototype developed by INSERM U-642 with analysis of :
the variability of the cardiac cycle duration ;
the variability of respiratory cycle amplitude and duration ;
and their relationships."
1680910|NCT01611727|Drug|Cisplatin|Cisplatin chemotherapy will be administered as a 75 mg/m2 intravenous (IV) infusion every 3 weeks, for six cycles. Dexamethasone (8mg) will be administered once daily for three days after chemotherapy. Ondansetron (Zofran™) will be used for anti-nausea prophylaxis.
1680911|NCT01611714|Other|Audit-feedback|Clinicians will receive a short email educational message at regular intervals alerting them to the historic disparities in diagnostic workup for SAH in our department and reminding them of the increased risk of SAH among African-American patients.
1680912|NCT01611714|Other|Clinical Decision Support|"Clinicians receive an embedded real-time Best Practice Alert (BPA) of increased rates of SAH among African-Americans when they open the headache electronic charting template."
1680913|NCT01611701|Procedure|cryoballoon ablation|In Cryo group, 28mm balloon was introduced into the PV ostium with the best possible occlusion of the PV. Every step was controlled by fluoroscopy. Cryoenergy was applied for maximal 6 minutes per application for 2 times, resulting in a circumferential ablation lesion. Before the right superior vein was treated, a quadripolar catheter was placed in the superior vena cava to continuously stimulate the right phrenic nerve during cryoapplication. The application was stopped immediately in the case of diminished diaphragm movements.
1681114|NCT01609972|Device|Spinal Cord Stimulator|Non-inferior comparison of implantable spinal cord stimulators
1731537|NCT00048230|Drug|bortezomib|
1680914|NCT01611701|Procedure|Radiofrequency ablation|n RF group, reisolation of the PV was performed by identifying the breakthrough site. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation rate of 17 mL/min. Each lesion was ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s.
1680915|NCT01611688|Drug|NNC0215-0384|I.v.(intravenous) dose-escalation. Highest dose planned for i.v. administration is 10 mg/kg
1680916|NCT01611688|Drug|placebo|Administered i.v.(intravenous) or s.c. (subcutaneous, under the skin).
1680917|NCT01611688|Drug|NNC0215-0384|The s.c. (subcutaneous, under the skin) part will not start until at least two i.v. dose levels have been evaluated for safety and pharmacokinetics. Highest dose planned for s.c. administration is 4 mg/kg
1680918|NCT01611675|Drug|Vemurafenib|take orally, twice daily
1680919|NCT01611675|Drug|Leflunomide|take orally, once daily
1680920|NCT01611662|Drug|gemcitabine hydrochloride|Given IV
1680921|NCT01611662|Drug|cisplatin|Given IV
1680922|NCT01611662|Procedure|therapeutic conventional surgery|Undergo radical cystectomy
1680923|NCT01611662|Other|laboratory biomarker analysis|Correlative studies
1680924|NCT01611649|Dietary Supplement|Formula containing dairy lipids and plant oils|4 months consumption
1680925|NCT01611649|Dietary Supplement|Formula containing plant oils|4 months consumption
1680926|NCT01611649|Dietary Supplement|Formula containing dairy lipids and plant oils, DHA+ARA|4 months consumption, DHA+ARA supplemented formula containing dairy lipids and plant oils
1680927|NCT01611623|Drug|SNX-5422|Tablets dose every other day; dose escalation based on safety
1680928|NCT01611610|Other|Functional tests|"The ambulant patients will perform
MFM (20 items)
Hammersmith modified module - MHMFS
Timed tests (time to rise from the floor,...)
6 minute walk test
PedsQL - neuromuscular module"
1680929|NCT01611610|Other|Functional tests|"The non-ambulant patients will perform:
MFM (20 items)
Hammersmith modified module - MHMFS
Upper Limb Functional Items
Egen Klassifikation 2 questionnaire - EK2
PedsQL questionnaire - neuromuscular module"
1680930|NCT01611597|Other|Different standardized tasks with an accelerometer device|Patients will perform tests like hand grip (MyoGrip), pinch (MyoPinch), Moviplate, box and block test of hand function, Minnesota Manual Dexterity Test. The tests will be performed with the accelerometer device worn on the wrist.
1680931|NCT01611584|Drug|ALA-induced Fluorescence|ALA Dose- 20 mg/kg
1680932|NCT01611571|Drug|Risedronate|weekly risedronate
1680933|NCT01611571|Drug|Teriparatide|daily teriparatide
1680934|NCT01611571|Drug|Placebo Teriparatide|daily placebo of teriparatide
1680935|NCT01611571|Drug|placebo Risedronate|weekly placebo of Risedronic Acid
1680936|NCT01611558|Biological|Ipilimumab|
1680937|NCT01611545|Genetic|Pharmacogenomics|Utilizing pharmacogenomics to determine the most effective treatment
1680938|NCT01611506|Biological|Cetuximab|"Induction chemotherapy:
Cetuximab 400mg/m2 (loading dose) on day 1 Cetuximab 250mg/m2 weekly thereafter
Followed by:
Cetuximab 250mg/m2 weekly on day 1 during chemoradiation
Postoperative treatment:
3 cycles of Cetuximab 250mg/m2 weekly on day 1"
1680939|NCT01611506|Drug|Capecitabine|"Induction chemotherapy:
Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle
Postoperative treatment:
Capecitabine 1000mg/m2 twice daily from the evening of day 1 to the morning of day 15 within each 3 weeks cycle"
1680940|NCT01611506|Drug|Cisplatin|"Induction chemotherapy:
Cisplatin 80mg/m2 on day 1 of each 21 day cycle
Followed by:
Cisplatin 30mg/m2 weekly on day 1 during chemoradiation
Postoperative treatment:
Cisplatin 80mg/m2 on day 1 of each 21 day cycle"
1680941|NCT01611493|Device|Osseotite Prevail Implant|Osseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
1680942|NCT01611493|Device|Osseotite Non Prevail Implant|Osseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
1680943|NCT01611480|Drug|Imiquimod (topical use)|
1680944|NCT01611467|Drug|CC-223|20 mg oral CC-223 capsule containing a microtracer of [14C]-CC-223 solution
1680945|NCT01611467|Drug|CC-223|20-mg oral CC-223 tablet under fasting or fed conditions
1680948|NCT01611428|Drug|Ipragliflozin|Oral and Intravenous (i.v.)
1680949|NCT01611415|Drug|Ipragliflozin|Oral
1680950|NCT01611415|Drug|Furosemide|Oral
1680951|NCT01611389|Device|Prolonging atrioventricular (AV) delay.|Prolonging atrioventricular (AV) delay to maximum 350 ms.
1680952|NCT01611389|Device|Standard atrioventricular (AV) delay.|Standard atrioventricular (AV) delay - approximately 180/140 ms depending on heart rate.
1680953|NCT01611376|Device|Niccomo™ (Medis, Ilmenau, Germany) impedance cardiography|
1680954|NCT01611363|Drug|ASP1941|Oral
1680955|NCT01611363|Drug|Placebo|Oral
1680956|NCT01611350|Other|RCT 1- Testing the Effectiveness of Marketing Messages in Increasing Willingness to Pay|We are testing whether any marketing messages effect participants willingness to pay for the fuel efficient cookstoves. All marketing messages are true.
1680957|NCT01611350|Other|RCT 3-Measure the Effects of Fuel Efficient Cookstoves on Health, Fuel Use and Time Spent Collecting Fuel|Of those who accept the Novel Sales Offer, half the group will be randomly selected to start their free trial early while the other half will receive their free trial late. Those who receive their free trial late will serve as a control group for fuel consumption and Particulate Matter exposure in kitchens.
1680958|NCT01611350|Other|RCT 2- Testing the Effectiveness of the Novel Sales Offer and its ability to Increase Uptake of Purchasing Energy Efficient Cookstoves|We are testing whether households who receive the Novel Sales Offer have higher uptake than those households who receive the Traditional Sales Offer.
1680959|NCT01611337|Other|insight variation measure|insight variation between the firt week of hospitalization and 1 month later
1731538|NCT00048295|Drug|Alicaforsen|
1680960|NCT01611324|Drug|Mepivacaine chlorhydrate 2% in Sodium Bicarbonate 1.4%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium bicarbonate 1.4%
1680961|NCT01611324|Drug|Mepivacaine chlorhydrate 2% with epinephrine in NS 0.9%|4 mL mepivacaine chlorhydrate 20 mg/mL with epinephrine 5 mcg/mL diluted with 16 mL sodium chloride 0.9%
1680962|NCT01611311|Drug|BI 409306 BS|Medium dose film-coated tablet
1680963|NCT01611311|Drug|BI 409306 BS|High dose film-coated tablet
1680964|NCT01611311|Drug|Placebo|Film-coated tablet
1680965|NCT01611298|Biological|Tetanus|"Stem cell transplant donors will receive one dose of tetanus toxoid 0.5mL intramuscularly into deltoid or medial lateral thigh 7-10 days prior to bone marrow or peripheral blood stem cell harvest.
Stem cell transplant recipients will receive one dose of tetanus toxoid 0.5mL intramuscularly (or subcutaneously if platelet count less than 50,000/uL) into deltoid or medial lateral thigh 7-10 days prior to stem cell transplant (FIRST dose).
Stem cell transplant recipients will receive a subsequent dose of tetanus toxoid 0.5mL given intramuscularly into deltoid or medial lateral thigh (or given subcutaneously if platelet count is less than 50,000/uL) approximately 3 months following allo stem cell transplant. Patients must meet re-evaluation criteria to receive injection."
1680967|NCT01611246|Device|Iontophoresis System With Earset|iontophoresis of lidocaine-based solution for numbing tympanic membrane
1680968|NCT01611220|Behavioral|RePAN|The dissonance relapse prevention intervention consists of eight groups conducted by a psychologist who involves participants in interactive activities aimed to prevent relapse after discharge from the inpatient treatment
1680969|NCT01611207|Device|Negative Pressure Wound Therapy|KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations.
1680970|NCT01611207|Other|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline (basic and advanced methods of wound treatment)
1680973|NCT01611181|Drug|Hemoboost|200 mg specially processed haemoglobin and 30 mg iron dextran equivalent to 10.5 mg organically bound iron in 1 tablet twice daily.
1680974|NCT01611181|Drug|Kräuterblut|40 mg iron, 20 ml twice daily.
1680975|NCT01611181|Drug|Ferrofumerat|200 mg ferrous sulphate as 1 tablet twice daily.
1680976|NCT01611168|Other|Treatment Algorithms|subjects in the intervention group will receive diabetes care from a well-trained registered nurse (RN) who will follow approved treatment algorithms/protocols for glycemia, high blood pressure, lipids and microalbuminuria.
1680977|NCT01611155|Drug|venlafaxine|Given PO
1680978|NCT01611155|Drug|placebo|Given PO
1680979|NCT01611155|Other|questionnaire administration|Ancillary studies
1680980|NCT01611155|Other|quality-of-life assessment|Ancillary studies
1680981|NCT01611142|Biological|KW-0761 (mogamulizumab)|1 mg/kg administered intravenously weekly x 4 then every other week until progression
1680982|NCT01611129|Behavioral|Internet-based counseling|Stage 1 - introduction to the concept of the patient journey and presenting the participants series of questions which may help them to explore their journey through hearing loss; Stage 2 - patient journey model of PHI and 2 case examples will be presented. The PHI will be advised to compare their journey to the model presented and identify the similarities and differences; Stage 3 - communication partners' journey model will be presented and the PHI will be asked to consider how interactions between each other may affect various things in the physical, mental and social domains; and Stage 4 - patients will be encouraged to think about how the PHI & CP may influence each other during their journey through hearing loss, how they can overcome some of the difficulties they may be experiencing and to think about the potential benefits and the challenges from the audiological management.
1680983|NCT01611116|Drug|sodium chloride solution 0.9%|intravenous application added to standard chemotherapy on up to 8 predefined days during the course of study treatment
1680984|NCT01611116|Drug|temsirolimus|intravenous application added to standard chemotherapy on up to 16 predefined days during the course of study treatment
1680985|NCT01611103|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham stimulation for 20 to 60 minutes
1680990|NCT01611077|Drug|Candesartan cilexetil|Candesartan 16 mg tablets p. o. once daily for 14 days, 32 mg tablets once daily for 28 days
1680991|NCT01611077|Drug|Olmesartan medoxomil|Switch to olmesartan 40 mg tablets once daily for 42 days,
1680992|NCT01611077|Drug|Olmesartan/amlodipine|then switch to olmesartan/amlodipine 40/5 mg tablets once daily for 14 days, then olmesartan/amlodipine 40/10 mg tablets once daily for 28 days
1681275|NCT01608724|Drug|Saxagliptin|oral, 5 mg once a day (Q.D.)
1680993|NCT01611064|Drug|Oxygen|Pure oxygen delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
1680994|NCT01611064|Drug|Medical air|Pure medical air (21% oxygen content) delivered by simple adult oxygen mask at rate of 10 litres/minute. Commencing 3 minutes prior to tourniquet inflation and administered for a maximum of 45 minutes
1680995|NCT01611051|Drug|Drug: Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
1680996|NCT01611051|Drug|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
1680997|NCT01611051|Drug|rhG-CSF 5ug/kg/day|Patients were administered pegylated rhG-CSF 6 ug/kg/day from the 3rd day of every chemotherapy cycle. Chemotherapy regimen: EC (epirubicin 100 mg/m2 +cyclophosphamide 600 mg/m2) or ET (epirubicin 75 mg/m2 + docetaxel 75 mg/m2).
1680998|NCT01611038|Dietary Supplement|Methylselenocysteine|Methylselenocysteine capsule given daily
1680999|NCT01611038|Dietary Supplement|Placebo|Placebo capsule given daily
1681000|NCT01610999|Drug|Plerixafor|Plerixafor will be dosed according to actual body weight. Each dose will be capped at 24 mg (single vial). Plerixafor will be administered subcutaneously according to the assigned cohort starting two hours before the scheduled start of high dose chemotherapy.
1681001|NCT01610986|Dietary Supplement|Glucose-fructose|0.8 g/h glucose and 0.5 g/h fructose during training
1681002|NCT01610986|Dietary Supplement|Water|Only water intake during training
1681003|NCT01610973|Procedure|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
1681004|NCT01610973|Procedure|Endothelial descemet membrane graft|Standard Endothelial descemet membrane graft
1681005|NCT01610960|Device|Non invasive ventilation HELMET|The HELMET and HELMET NEXT modes will be tested by each patient.
1681006|NCT01610960|Device|Non invasive ventilation facemask (Respironics)|The facemask Respironics (Herrsching, Germany) will be used by each patient.
1681007|NCT01610947|Drug|Adalimumab, Etanercept, Golimumab or infliximab|Continuation of usual treatment with fixed intervals according to standard recommendations
1681008|NCT01610947|Drug|Adalimumab, Etanercept, Golimumab or infliximab|Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol
1681009|NCT01610934|Drug|liraglutide|The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. Patients who, due to adverse events, do not tolerate up-titration to 1.8 mg liraglutide will remain on 1.2 mg of liraglutide. The injection is administered once daily in the morning.
1681010|NCT01610934|Drug|Glimepiride|At randomisation patients will be initiated on their pre-study daily dose of glimepiride minus 0.5 mg. After one week the dose will be titrated (see below). Drug naïve patients will be initiated on an initial dosage of glimepiride of 0.5 mg for one week. Thereafter, glimepiride is increased to 1.0 mg and after another one week to 1.5 mg, and there after further up to 3 mg (if the average FPG during one week is above 6 mM). The dose of glimepiride can be increased up to 4 mg if average FPG is above 6 mM and no symptoms of hypoglycaemia are observed.
1681011|NCT01610921|Other|Bronchial provocation test|Provocation tests with adenosine dry powder and nebulized AMP (adenosine-5'monophosphate). The AMP provocation test is a standard test and consists of 14 doubling concentrations in a range of 0.04mg/ml to 320mg/ml. The aerosols will be inhaled during tidal breathing for 2 minutes. The dry powder adenosine also consists of 14 doubling steps with doses in a range of 0.01mg to 20mg.
1681012|NCT01610908|Other|The Schroth exercises treatment|"The Schroth approach consists of 3D scoliosis-specific exercises based on sensorimotor and kinesthetic principles. The goal of Schroth exercises is to teach patients to consciously maintain the correct posture in daily living activities in order to improve the curve, pain, and self-image. To achieve this goal, Schroth exercises focus on endurance and strength training of postural muscles. Schroth exercises also aim to improve posture motor control by repeating corrective movements with progressively less feedback and less passive support.
Dosage: 5 individual 1-hour long sessions, continued with the daily 45 minutes home exercise program. In addition, patients are required to come weekly for 1-hour long group sessions over the span of 6 months."
1681013|NCT01610908|Other|Global Postural Re-Education|The 6-month supervised Global Postural Re-education intervention involves active movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. These postures imply an active participation of the patient. Global Postural Re-education includes eight therapeutic postures, lying, sitting or standing, held for 15/20 min. each. Variously combinations are used during sessions chosen on based on the amount of pain, load capacity, age of the patient, and muscle chains to be stretched. Static and dynamic functions are also employed for about five minutes each sessions to use the recovered flexibility in functional activities Dosage: Weekly individual 1-hour long sessions, with daily 15 minutes home exercise program over 6 months.
1681014|NCT01610895|Other|Split-dose PEG Based Lavage (2L + 2L) with Low-Fibre Lunch Dietary instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM. Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.
Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast, a low-fibre lunch by 2 PM (Created from the table of acceptable foods) and then drink clear fluids until after the procedure is completed."
1681015|NCT01610895|Other|Split-dose PEG Based Lavage (2L + 2L) with Standard Dietary Instructions|"Patients will be instructed to arrive for colonoscopy at or after 10 AM.
Preparation Instructions: At 8pm the day before the colonoscopy drink 2L of PEG within 2 hours. Starting 5 hours before their arrival time on the day of Colonoscopy, drink the remaining 2L of PEG within 2 hours.
Dietary Instructions: Low fibre diet for 4 days prior to Colonoscopy. The day before Colonoscopy, low-fibre breakfast and then drink clear fluids until after the procedure is completed."
1681276|NCT01608711|Biological|AGS-1C4D4|Intravenous Infusion
1681018|NCT01610869|Drug|BIBF 1120|Patients will receive either cyclophosphamide (100mg)and oral BIBF 1120 (200mg bd) or cyclophosphamide (100mg) and placebo.
1681019|NCT01610856|Drug|Polyethylene Glycol|4 Litres of polyethylene glycol bowel preparation solution
1681020|NCT01610856|Drug|polyethylene glycol|Polyethylene glycol 4L given in two split doses of 2L each
1681021|NCT01610843|Other|Survey|Longitudinal surveys
1681022|NCT01610817|Other|InPAct : Information for Participating Actively in cardiovascular treatment|Educational guide presented by general practitioners to the patients. A first part of the guide contains some information on cardiovascular risk and on the benefits and risks of antihypertensive drugs. A second part of the guide consists of encouraging the patient to take an active part in monitoring of its treatment.
1681023|NCT01610791|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, total of 6 infusions
1681024|NCT01610778|Dietary Supplement|Placebo|
1681025|NCT01610778|Dietary Supplement|5-aminolevulinic acid phosphate|
1681026|NCT01610765|Drug|Novel Antiviral Drug|4 oral doses of a Novel Antiviral Drug: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
1681027|NCT01610765|Drug|Placebo|4 oral doses of placebo matching the a Novel Antiviral Drug assigned dose: 0.25 mg/kg/dose, 0.50 mg/kg/dose, 1.0 mg/kg/dose or 2.0 mg/kg/dose twice a week for 3 weeks during the time in which the 21 day administration of parenteral acyclovir is being administered. Subjects will be assigned a the higher dose of study drug after the DSMB and sponsor determine that reported adverse events and the PK data show that it is safe to increase dosing to the next higher level.
1681028|NCT01610752|Behavioral|SmartMoms|This intervention will cover many topics to help you learn about weight management during pregnancy. You will be taught how to use different tools provided to help you monitor your weight. We will ask you to record your body weight (using a scale we will provide) as well as your food intake and exercise habits.
1681029|NCT01610739|Drug|Indigocyanine green dye|Each patient will receive 1 injection of indigocyanine green dye using 2.5 mg/mL concentration of the imaging agent. 3mL of this mixture will be injected intravenously, followed by 10mL NS bolus, just prior to imaging with the SPY scope
1681030|NCT01610726|Procedure|Enhanced versus conventional recovery in colorectal surgery|Enhanced recovery (extended informations to the patients, change of anesthetic procedure, intravenous versus gas, and intensified mobilisation) versus conventional recovery
1681031|NCT01610713|Drug|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
1681032|NCT01610700|Drug|GW-1000-02|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. The maximum permitted dose of study medication was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
1681033|NCT01610700|Drug|Placebo|Each actuation of placebo delivered the excipients only.
1681034|NCT01610687|Drug|GW-1000-02|Contained THC and CBD as extract of Cannabis sativa L. Each 100 μl actuation delivered a dose containing 2.7 mg THC and 2.5mg CBD. The maximum permitted dose was eight actuations (22 mg THC and 20 mg CBD) in any three hour period, and 48 actuations (130 mg THC and 120 mg CBD) in any 24 hour period.
1681035|NCT01610674|Other|Intervention to improve perioperative diabetes care|"A step-wise implementation model is applied:
1) recommendations on optimal perioperative diabetes care (e.g. the administration of intravenous insulin, encouragement of diabetes self-management) are systematically translated into quality indicators; 2a) using these quality indicators, current care is measured by performing a medical record search among 400 patients in 6 hospitals; 2b) barriers and facilitators for optimal care are measured by performing interviews with professionals 3) based on this information an implementation strategy is developed; 4) implementation activities are enacted in 3 hospitals and 5) evaluated in a controlled before-after design in 6 hospitals providing before and after intervention 400 patients."
1681036|NCT01610674|Other|Usual perioperative diabetes care|Three hospitals that provide usual perioperative diabetes care serve as control hospitals.
1681037|NCT01610661|Other|Diet|Unrefined-carbohydrate refers to foods made with 100% whole grains (wheat, rice, corn). Refined-carbohydrate refers to foods made with white flour (e.g., bread, pasta) or white rice. Simple-carbohydrate refers to foods made with sucrose (50% glucose/50% fructose) and high-fructose corn syrup.
1681038|NCT01610635|Other|Reduced versus standard intervals between blood donations|Over a period of two years participants will be invited to give blood either at usual donation intervals or more frequently. Men will be invited to donate every 12, 10 or 8 weeks and women every 16, 14 or 12 weeks.
1681039|NCT01610622|Device|COstatus cardiac output measurement with isotonic saline|"Isotonic saline, which is the indicator, is injected to obtain COstatus cardiac output measurements.
No other interventions are made for the purpose of the study."
1681040|NCT01610609|Behavioral|Population Health Management Intervention|"This intervention includes:
Care manager led patient education to promote increased patient awareness of personal cardiovascular disease (CVD) risk and
Care manager led patient outreach to facilitate the treatment of eligible and appropriate patients with statins for primary CVD prevention"
1681041|NCT01610596|Drug|Halobetasol Propionate Lotion 0.05%|Apply twice daily for 1-2 weeks, not to exceed 50 grams per week
1681042|NCT01610596|Drug|Placebo|
1681078|NCT01610310|Device|BIIB017 (peginterferon beta-1a) Autoinjector|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by autoinjector once on either Day 1 or Day 22
1681079|NCT01610297|Drug|ICL670|Oral dose of ICL670 at 10 mg/kg daily
1681043|NCT01610570|Drug|Mithramycin|Phase I Portion: Mithramycin will be administered in escalating doses to children and adolescents intravenously over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression. If maximum tolerated dose (MTD) in this Phase differs from the recommended adult dose for Phase II, the protocol will be amended. Using a Simon two stage design, mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults with Ewing sarcoma with Ewings sarcoma - friend leukemia integration 1 transcription factor (EWS-FLI1) fusion transcript Both Phases will enroll patients simultaneously. Phase II Portion: mithramycin will be administered intravenously at 17.5 microgram/kg over 6 hours once daily for 7 days to be repeated every 28 days until unacceptable toxicity or disease progression to children and adults.
1681044|NCT01610557|Drug|Ranibizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.
*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
1681045|NCT01610557|Drug|Bevacizumab|"Series of three intravitreous injections of ranibizumab (0.3 mg)* or bevacizumab (1.25 mg) administered every 4 weeks for three 12-week periods. Following this crossover phase, eyes received ranibizumab or bevacizumab to which they were originally assigned and treated on an as-needed basis until study completion.
*Eleven doses of ranibizumab 0.5 mg were given to participants at the start of the study; after FDA approval of the 0.3 mg dose for DME, the protocol was amended and 0.3 mg was used for the remainder of the study (98% of all injections)."
1681046|NCT01610544|Drug|3'-deoxy-3'-18F fluorothymidine (FLT)|
1681047|NCT01610544|Other|PET/CT scan|
1681048|NCT01610531|Other|SAMScore questionnaire|Patients assessed at high risk according to the SAMScore
1681049|NCT01610518|Dietary Supplement|oat beta-glucan|4g dose for each arm of trial. Form (volume and viscosity) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
1681050|NCT01610518|Dietary Supplement|Placebo|Control without beta-glucan. Form (volume) varies between arms. 2h acute trial beginning between 8 and 10 am. Minimum 1 day wash out between arms.
1681051|NCT01610505|Device|KIneSpring System|Surgical treatment intended to reduce or eliminate pain and improve the function of a knee affected by medial compartment osteoarthritis.
1681052|NCT01610505|Device|High Tibial Osteotomy|Surgical treatment intended to reduce or eliminate pain and improve the function of a knee affected by medial compartment osteoarthritis.
1681054|NCT01610479|Drug|TAS-114 + S-1|
1681055|NCT01610466|Procedure|Laparoscopic bariatric surgery ex-vivo training curriculum|The training curriculum will consist of a cognitive, technical and non-technical components. Cognitive component will consist of self-directed readings and a faculty-led seminar. Technical component will consist of training to proficiency on cadaveric porcine laparoscopic jejunojejunostomy and gastrojejunostomy models. Non-technical component will consist of an introductory lecture on non-technical skills in surgery and a simulated crisis scenario with a debriefing session.
1681056|NCT01610453|Procedure|ultrasound examination|transabdominal and transperineal ultrasound examinations
1681057|NCT01610440|Biological|human umbilical cord mesenchymal stem cells|rehabilitation therapy plus human umbilical cord mesenchymal stem cells
1681059|NCT01610414|Biological|Herpes Zoster vaccine GSK1437173A|2 doses administered intramuscularly (IM) in deltoid region of non-dominant arm
1681060|NCT01610414|Biological|Placebo|2 doses administered IM in deltoid region of non-dominant arm
1681061|NCT01610401|Drug|Metformin|metformin 500 mg three times a day, for 3 days
1681062|NCT01610401|Drug|Pretreatment with metformin in combination of infusion of caffeine.|Pretreatment with metformin 500 mg three times a day for 3 days, in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes) prior to FMD measurement
1681063|NCT01610401|Drug|No pretreatment with metformin in combination with infusion of caffeine|No pretreatment with metformin in combination with pretreatment with caffeine (4 mg/kg intravenously over 10 minutes).
1681064|NCT01610388|Drug|500mg IV GSK1322322/placebo|500mg IV
1681065|NCT01610388|Drug|1000mg oral GSK1322322/placebo|1000mg oral
1681066|NCT01610388|Drug|1000mg IV GSK1322322/placebo|1000mg IV
1681067|NCT01610388|Drug|1500mg oral GSK1322322/placebo dose|1500mg oral
1681068|NCT01610388|Drug|1500mg IV GSK1322322/placebo|1500mg IV
1681069|NCT01610388|Drug|2000mg IV GSK1322322J/placebo|2000mg IV
1681070|NCT01610388|Drug|3000mg IV GSK1322322J/placebo|3000mg IV
1681071|NCT01610388|Drug|1000mg IV GSK1322322J/placebo|1000mg IV
1681072|NCT01610375|Other|Telephone Follow-up|This is a non-randomised observational study to assess the value of a symptom checklist to detect recurrence in women with endometrial cancer. Women will be telephoned using an evidence-based symptom checklist in parallel to the standard clinic-based follow-up. The researcher will call the participants 2 to 5 days prior to their scheduled clinic review dates to enquire about the presence of symptoms which may be indicative of disease recurrence. In addition, the researcher will also enquire about the participants' wellbeing and provide standard lifestyle resource on physical activity, diet and other lifestyle behaviours and supportive care when needed.
1681073|NCT01610362|Biological|Human Rabies Immune Globulin|HRIG 20 IU/kg and 40 IU/kg would be given once to the volunteers on day 0
1681074|NCT01610336|Drug|INC280|experimental
1681075|NCT01610323|Other|Exercise intervention|Exercise group: 12 weeks of moderate intensity physical training under individual supervision in a specialised conditioning center, with a goal of 3 1h-sessions/week (from 16 wks to 28 wks of gestation). Including aerobic and muscular training.
1681076|NCT01610323|Other|Standard Care|
1681077|NCT01610310|Device|BIIB017 (peginterferon beta-1a) Pre-filled syringe (PFS)|125 mcg of peginterferon beta-1a (BIIB017) subcutaneous injection (SC) administered by PFS once on either Day 1 or Day 22
1681084|NCT01610258|Other|Blood and placenta samples|"The placenta sample is realised, specially for the study, in surgical unit after the delivery.
The blood samples are taken, specially for the study, the day of admission and at time of delivery or seven days after the admission."
1681085|NCT01610245|Drug|Nitazoxanide|
1681086|NCT01610245|Drug|Oseltamivir|
1681087|NCT01610245|Drug|Placebo Oral Tablet|
1681088|NCT01610245|Drug|Placebo Oral Capsule|
1681089|NCT01610232|Device|Photon stimulation by light-emitting diodes (LEDs)|Treadmill training with the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate. The average power and power density on the skin were 100 mW and 39 mW/cm2, respectively. The treatment time was 45 min bilaterally in both thighs. These parameters led to an approximate fluence of 108 J/cm2.
1681090|NCT01610232|Other|Treadmill training|Treadmill training without the application of the phototherapy was performed twice a week for 6 months, each session lasting 45 min at intensities between 85% and 90% maximal heart rate
1681091|NCT01610219|Behavioral|Lifestyle Modification for Type 2 Diabetes Prevention|Family based behavioral intervention utilizing Traffic Light Diet, self monitoring, goal setting, reinforcement and a tool kit containing physical activity-promoting items
1681092|NCT01610219|Other|Nutrition and Physical Activity|This family based education program provided information on physical activity and healthy eating for parents and children.
1681093|NCT01610206|Drug|Gemcitabine|Patients will receive gemcitabine 1000 mg/m2 administered weekly on days 1 and 8 (30 minutes IV infusion) of each cycle for up to 6 cycles. Each cycle is 21 days.
1681094|NCT01610206|Drug|pazopanib|Patients will receive pazopanib 800mg PO daily on days 1-21 of treatment cycles
1681095|NCT01610193|Procedure|Appendicectomy|Also known as appendectomy, surgical removal of the appendix. Laparoscopic (single or 4 port), McBurney's incision, mid-line laparotomy, laparoscopic converted to open.
1681096|NCT01610180|Drug|Eltrombopag Olamine|"Subjects will initiate study medication at an oral dose of 50 mg/day (25 mg/day for East Asians and for patients with grade 1 serum liver tests impairment).
Treatment scheme and dose adjustments:
Initial dose : 50 mg/day for 14 days.
Next doses:
If platelet count <60000/µL, increase daily dose by 25 mg to a maximum of 150 mg/day for next 14 days in 14 days courses. If response criteria not met after 14 days of the maximum dose stop treatment (no response).
If platelet count >60000/µL and ≤200000/µL same dose for the next 14 days.
If platelet count >200000/µL and ≤400000/µL decrease the daily dose by 25 mg. Wait 14 days to assess the effects of this and any subsequent dose adjustments.
If platelet count >400000/µL, stop Eltrombopag; increase the frequency of platelet monitoring to twice weekly. Once the platelet count is <150000/µL, reinitiate therapy at a daily dose reduced by 25 mg."
1681097|NCT01610167|Device|NUPRO Classic Prophy Paste|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
1681098|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin with fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
1681099|NCT01610167|Device|NUPRO Sensodyne Prophy Paste with Novamin without fluoride.|Abrasive, flavored dental prophylaxis paste for cleaning and polishing teeth.
1681100|NCT01610154|Drug|Sitagliptin|Sitagliptin 100 mg QD for 12 weeks
1681101|NCT01610141|Other|Genotype-guided warfarin dosing|Applying a Pharmacogenetic-guided warfarin dosing algorithm derived from Chinese to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, body surface area, etc.), and VKORC1, CYP2C9 and CYP4F2 genotypes, to individualize the dosing of warfarin.
1681102|NCT01610141|Other|Non-genotype guided warfarin dosing|A Empiric fixed warfarin dose of 3 mg/day was given to the patients for at least 3 days. Following doses were adjusted according to the INR measurement.
1681103|NCT01610089|Other|stable isotope infusion|"Control subjects: [15N2-ureido] arginine (0.69 mg/kg); [5-13C,4,4,5,5-D4] citrulline (0.18mg/kg); 15N citrulline (0.03mg/kg); 15N sodium nitrate (0.003 mg/kg), [15N][18O3] potassium nitrate (0.03 mg/kg) and [18O][13C]urea (1 mg/kg)over 10 minutes. Followed by a 8-hour infusion of [15N2-ureido] arginine (0.69 mg/kg/hr); [5-13C,4,4,5,5-D4] citrulline (0.18mg/kg/hr), [15N][18O3] potassium nitrate (0.003 mg/kg/hr) and [18O][13C]urea (0.1 mg/kg/hr).
Citrullinemia type 1 subjects,[15N2-ureido] arginine (4.14 mg/kg); [5-13C,4,4,5,5-D4] citrulline (1.08 mg/kg); 15N citrulline (0.18mg/kg); 15N sodium nitrate (0.003 mg/kg), [15N][18O3] potassium nitrate (0.03 mg/kg) and [18O][13C]urea (1 mg/kg)over 10 minutes, followed by a 8-hour infusion of [15N2-ureido] arginine (4.14 mg/kg/hr); [5-13C,4,4,5,5-D4] citrulline (1.08 mg/kg/hr), [15N][18O3] potassium nitrate (0.003 mg/kg/hr) and [18O][13C]urea (0.1 mg/kg/hr)."
1681104|NCT01610076|Other|Code Status Video|"10 minute video about Code Status"
1681105|NCT01610063|Other|Pharmacogenomic algorithm|Genetic test results for 4 genes were put through algorithm and provided to physician for guidance prescribing medication.
1681106|NCT01610050|Drug|LFA102|
1681107|NCT01610037|Drug|QVA149|QVA149 110/50 µg will be supplied as capsules in blister packs for once daily inhalation using the Novartis Concept1 SDDPI
1681108|NCT01610037|Drug|Tiotropium|Tiotropium 18 µg will be supplied as capsules in blister packs for once daily inhalation using the HandiHaler SDDPI
1681109|NCT01610037|Drug|placebo|placebo to QVA149A and Tiotropium will be supplied in the appropriate capsule in blister packs for use in either the Novartis Concept1 SDDPI or the HandiHaler SDDPI
1681110|NCT01610024|Dietary Supplement|Beetroot Juice|Give subjects 500ml beetroot juice in the 24 hour period prior to class begins. They will receive this during 3 of the 6 weeks
1681111|NCT01610011|Dietary Supplement|Glycine administration|Glycine will be administered once as a 250 cc lemon-flavored beverage based on each subject's body weight. The drink concentration will be 0.4 g/kg glycine (not to exceed 30 grams). Subjects will have 10 minutes to consume the beverage.
1681112|NCT01609998|Biological|Seasonal Influenza DNA vaccine|VRC-FLUDNA063-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1); A/Victoria/361/2011 (H3), and B/Wisconsin/2010. DNA vaccine vials will be supplied at 4 mg/mL in single use vials. The 1 mg dosage is administered as 0.25 mL volume and the 4 mg dosage as a 1 mL volume.
1681113|NCT01609998|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
1681277|NCT01608711|Biological|gemcitabine|Intravenous Infusion
1681115|NCT01609959|Drug|Azilsartan|Azilsartan 20 mg or 40 mg (if blood pressure does not reach the target after 6 weeks) per day for 12 weeks
1681116|NCT01609959|Drug|Valsartan|Valsartan 160 mg per day
1681117|NCT01609946|Device|Realtime-Elastography, linear ultrasound probe, Hitachi EUB-900, Japan|
1681118|NCT01609946|Procedure|Cytology (FNAB) or Surgery|
1681119|NCT01609933|Drug|ABT-450/r|ABT-450 (tablets) dosed with ritonavir (capsules or tablets)
1681120|NCT01609933|Drug|ABT-267|ABT-267 (tablets)
1681121|NCT01609933|Drug|pegylated interferon alpha-2a (pegIFN)|pegylated interferon alpha-2a syringe
1681122|NCT01609933|Drug|Ribavirin (RBV)|Ribavirin (tablets)
1681123|NCT01609920|Drug|Gadofosveset enhanced MRL of axillary lymph nodes|A MRL of the axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
1681124|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 1)|Period 1(A) Period 2(B) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
1681125|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 2)|Period 1(C) Period 2(A) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
1681126|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 3)|Period 1(B) Period 2(C) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
1681127|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 4)|Period 1(C) Period 2(B) Period 3(A) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
1681128|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 5)|Period 1(B) Period 2(A) Period 3(C) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
1681129|NCT01609907|Drug|Rosuvastatin+Valsartan (Sequence 6)|Period 1(A) Period 2(C) Period 3(B) A: Rosuvastatin 20mg (once daily for 4 consecutive days), B: Valsartan 160mg (once daily for 4 consecutive days), C: Rosuvastatin 20mg plus Valsartan 160mg (once daily for 4 consecutive days)
1681130|NCT01609894|Dietary Supplement|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.
Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
1681131|NCT01609894|Dietary Supplement|Routine fortification of breast milk|Infants will be fed routine fortified breast milk.
1681132|NCT01609881|Drug|Acuvail|Dosing of drug 3 days prior to surgery
1681133|NCT01609881|Other|Placebo|Artificial tears qid for 3 days preoperatively
1681134|NCT01609868|Dietary Supplement|Powder protein modular|Infants will receive powder protein modular to achieve 4 grm/kg/day
1681135|NCT01609868|Dietary Supplement|Liquid protein modular|Infants will receive a commerically avaliable liquid protein modular to provide 4 grm/kg/day
1681136|NCT01609855|Drug|Hyoscine Butyl Bromide 20mg/2 ml i.v.|Hyoscine Butyl Bromide 20mg/2 ml i.v.is administered at time of caecal intubation
1681137|NCT01609855|Drug|Saline 2 ml i.v.|Administration of Saline 2 ml at time of caecal intubation
1681138|NCT01609842|Other|Multifaceted Intervention with pharmacist and IVR|An alerted inpatient pharmacists will bring the clopidogrel medication to the patient who has received a stent. The patient will return home and receive IVR messages about the importance of their medication as well as a refill reminder call.
1681139|NCT01609829|Procedure|SAFE (situation, all together, fly on, evaluate)|Video-assisted, structured debriefing after simulated critical airway-events.
1681140|NCT01609816|Drug|Dasatinib|Patients receive dasatinib PO every day (QD) for 6 months.
1681141|NCT01609803|Other|laboratory biomarker analysis|Correlative studies
1681142|NCT01609790|Biological|Bevacizumab|Given IV
1681143|NCT01609790|Other|Laboratory Biomarker Analysis|Correlative studies
1681144|NCT01609790|Other|Pharmacological Study|Correlative studies
1681145|NCT01609790|Other|Placebo|Given IV
1681146|NCT01609790|Biological|Trebananib|Given IV
1681147|NCT01609777|Procedure|SBAR|situation, background, assessment, recommendation
1681148|NCT01609764|Behavioral|One year fitness training|Regular training schedule of moderate intensity, at 50% of heart rate reserve, as available for the specific age group in fitness centres
1681149|NCT01609751|Dietary Supplement|Yakult|62 ml dose daily for 365 days. There must be a cold chain from supplier (Yakult UK) via the primary care centre to the trial participants.
1681150|NCT01609738|Device|Left ventricular septum pacing lead|A left ventricular septum pacing lead is permanently placed by introducing a custom lead with extended helix transvenously and, after positioning it against the RV septum, driving it through the inter-ventricular septum into the LV endocardial layer.
1681151|NCT01609725|Device|Subgingival scaling and root planing|Oral hygiene instruction and motivation will be provided altogether with scaling and root planing of all teeth affected by periodontitis under local anesthesia
1681152|NCT01609725|Device|Oral prophylaxis|One session of supraginigval calculus removal
1681153|NCT01609712|Procedure|Radiofrequency Kyphoplasty|"Radiofrequency kyphoplasty is a new form of surgical treatment. It injects an ultrahigh viscosity cement into the fractured vertebral body, using radiofrequency to achieve the proper consistency of the cement. This ultrahigh viscosity cement is designed to first restore proper height and alignment to the fractured vertebra and then to stabilize the fracture, thereby preventing further intravertebral motion and reducing pain.
The RF-Kyphoplasty is standard of care in our hospital. It is FDA and CE approved."
1681154|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
1681155|NCT01609699|Device|Treatment with Contour I-Y system|The Contour I - Y System is a non-invasive focused ultrasound, for body contouring purposes, designed to selectively disrupt sub-dermal fat cells at a designated focus employing focused ultrasound. All other types of tissue, such as blood vessels, muscles and peripheral nerves remain intact. There are no thermal effects. Fat cell destruction is achieved by ultrasound-induced mechanical effects during a very short exposure time.
1681156|NCT01609673|Drug|Everolimus|"On the day of conversion (day 1), 2 mg everolimus will be introduced in the morning and at night, as morning dose of CsA or Tac will be maintained and evening dose of CsA or Tac will be reduced by 50%.
In two days, 2 mg everolimus will be associated with 50% of CsA or Tac original dosage, both in the morning and evening. After that, everolimus dose will be adjusted to achieve a C0 target level of 6-10 ng/mL. Once target levels of everolimus are met, the CNI drug will be suspended."
1681157|NCT01609660|Dietary Supplement|Saccharomyces boulardii|100mg daily for seven days prior to surgery
1681158|NCT01609647|Drug|Prasugrel|Reloading with prasugrel 20mg and followed by daily administration of prasugrel 5mg for 30 days
1681159|NCT01609647|Drug|Clopidogrel|Reloading with clopidogrel 300mg and followed by daily administration of clopidogrel 75mg for 30 days
1681160|NCT01609634|Other|Test Product|Standard infant formula/follow-on formula with added scGOS/lcFOS and Nuturis®
1681161|NCT01609634|Other|Control Product 1|Control group 1: Standard infant formula/follow-on formula with added scGOS/lcFOS
1681162|NCT01609634|Other|Control Product 2|Control group: Standard infant formula/follow-on formula with standard fat droplets and without specific prebiotic oligosaccharides.
1681163|NCT01609621|Device|Retrograde tibiopedal arterial access|Retrograde, percutaneous arterial access of vessels at or below the tibioperoneal trunk, using a 21 gage needle or micropuncture introducer set, to facilitate crossing and treatment (e.g., angioplasty, stenting, atherectomy) of occlusive arterial lesions in the lower limb.
1681164|NCT01609608|Procedure|whole body vibration|to deliver mechanical oscillation to individuals at various frequencies, amplitudes, and accelerations for different durations. This technique has been applied for years to enhance strength, and improve bone mineral density and balance
1681165|NCT01609595|Drug|sodium 2,2 dimethylbutyrate|Oral capsule, dose 20 mg/kg/day, daily, for 26 weeks
1681166|NCT01609582|Drug|TAK-875|TAK-875 tablets
1681167|NCT01609582|Drug|TAK-875 Placebo|TAK-875 placebo-matching tablets
1681168|NCT01609556|Drug|IMGN853|Dose escalation study. Dosing on day 1 of every 21 day cycle.
1681169|NCT01609543|Drug|erlotinib [Tarceva]|150 mg orally daily, until disease progression, unacceptable toxicity or withdrawal due to any reason
1681170|NCT01609530|Procedure|Liquid Nitrogen Cryotherapy|Every two weeks for a total of 5 treatments or until the patient clears, patients in the cryotherapy arm will be treated with 5-7 seconds of freeze time maintaining a 1mm freeze halo around the wart.
1681171|NCT01609530|Procedure|Pulsed 1064nm Nd:YAG|Every 2 weeks for a total of five treatments or until the wart clears, patients in the laser arm will be treated with the Nd:YAG. The settings will be 180J, 20ms pulse width and 5mm spot size. For warts 3mm or less, a 3mm spot size will be used, 180J and 15ms. If the patient reports no response after treatment, including crusting or blistering, the energy will be increased by 10 J until 200J has been reached.
1681172|NCT01609517|Drug|Spinal anesthesia (heavy bupivacaine)|Spinal anesthesia with heavy bupivacaine of 6, 7, 8, 9, 10, 11 mg
1681173|NCT01609504|Procedure|ELRR BY TEM|The surgical technique of ELRR was as follows: mucosal incision included all the tatoo spots performed at admission staging, in order to excise a minimum of 1 cm of normal mucosa around the tumor, according to its diameter before NT
1681174|NCT01609504|Procedure|LTME|LAPAROSCOPIC TOTAL MESORECTAL EXCISION INCLUDING MESORECTAL (ACCORDING TO HEALD CRITERIA)
1681175|NCT01609491|Drug|phenylephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with phenylephrine or norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations phenylephrine (20 µg /ml) of Norepinephrine (10 µg/ml) will be used in the syringes
1681176|NCT01609491|Drug|norepinephrine|If the mean arterial pressure drops below 20% of the baseline value and/or below 90 mmHg, a syringe pump with norepinephrine (depending on randomisation) will be started. The anaesthetist will be blinded for the type of vasopressor. Concentrations Norepinephrine (10 µg/ml) will be used in the syringes
1681177|NCT01609478|Drug|indacaterol|indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
1681178|NCT01609478|Drug|placebo|placebo delivered via Concept 1 inhaler
1681179|NCT01609478|Drug|mometasone furoate|via Twisthaler inhaler
1681180|NCT01609452|Biological|Blisibimod|
1681181|NCT01609452|Other|Placebo|
1681182|NCT01609439|Drug|Vitamin D|Vitamin D 800 units for 4 weeks preoperatively
1681183|NCT01609439|Drug|Placebo|Placebo
1681184|NCT01609426|Genetic|DNA chip dedicated to the pharmacogenetic of steroids|direct DNA extraction from peripheral blood cells
1681185|NCT01609413|Dietary Supplement|AlgaeCal|One dose equals 3 times 180 mg of calcium, to be taken one time on the morning of the examination day.
1681186|NCT01609413|Dietary Supplement|Caltrate 600|One dose equals 1 capsule of 600 mg calcium, to be taken one time on the morning of the examination day.
1681187|NCT01609387|Dietary Supplement|Fit For me|
1681188|NCT01609387|Dietary Supplement|Davitamon|
1681189|NCT01609374|Device|M6-C Artificial Cervical Disc|Total disc replacement
1681190|NCT01609374|Device|Anterior plate system with corticocancellous allograft bone|Cervical fusion
1681191|NCT01609361|Other|Rehabilitation program|Rehabilitation program including specific anesthetic drugs, post operative fast track recovery (early diet, mobilisation, antalgics)
1681194|NCT01609335|Drug|F-18 FDG|One time intravenous administration of 17 millicurie (mCi) +/- 10%
1681195|NCT01609335|Drug|C-11 PiB|One time intravenous administration of 10-20 mCi
1681196|NCT01609322|Behavioral|Activity, Balance, Learning, and Exposure|An in-home intervention that integrates exposure therapy with cognitive restructuring, exercise, and a home safety evaluation.
1681197|NCT01609322|Behavioral|Fall prevention education|In-home, individual sessions with a health educator regarding fall prevention
1681198|NCT01609309|Procedure|Laparoscopic gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, laparoscopic distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.
The type of reconstruction will be selected according to the surgeon's experience and anastomotic procedure is performed extracorporeally using a mini-laparotomy."
1681199|NCT01609309|Procedure|Open gastrectomy|"After exclusion of T4b, bulky lymph nodes, or distant metastasis case by diagnostic laparoscopy, open distal subtotal gastrectomy and D2 lymph node dissection will be performed with curative treated intent.
The type of reconstruction will be selected according to the surgeon's experience."
1681201|NCT01609283|Biological|autologous mesenchymal stem cells|"There will be five treatment groups of up to five patients each. Groups 1, 2 and 4 will receive a single dose of cells. Groups 3 and 5 will receive 2 doses of cells separated by one month. Intrathecal injections into new subjects will be timed so that there is a minimum of one week between subject injections. The cell dose per group is as follows:
Group 1: single intrathecal dose of 1 x 107 cells
Group 2: single intrathecal dose of 5 x 107 cells
Group 3: one intrathecal dose of 5 x 107 cells followed one month later by a second intrathecal dose of 5 x 107 cells
Group 4: single intrathecal dose of 1 x 108 cells
Group 5: one intrathecal dose of 1 x 108 cells followed one month later by a second intrathecal dose of 1 x 108 cells"
1681202|NCT01609270|Device|CardioRoot graft|prospective single arm multi-center study to evaluate CardioRoot grafts implanted in a thoracic position.
1681203|NCT01609257|Biological|Norovirus Bivalent Vaccine|2 doses IM 28 days apart
1681204|NCT01609257|Biological|Saline Comparator|2 doses IM 28 days apart
1681205|NCT01609244|Device|Bilevel therapy (somnovent ST 22, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
1681206|NCT01609244|Device|servoventilation (Somnovent CR, Weinmann, Hamburg, Germany)|nighttime positive airway therapy for 6 weeks
1681207|NCT01609231|Drug|Dalotuzumab|Dalotuzumab will be administered intravenously after the completion of irinotecan infusion at a dose of 10 mg/kg once weekly.
1681208|NCT01609231|Drug|Irinotecan|Irinotecan 180 mg/m^2 will be administered intravenously once every two weeks either prior to dalotuzumab (Arm A) or after cetuximab (Arm B). Pre-medication at the discretion of the investigator, such as with dexamethasone or atropine will follow local, or country-specific standard of care.
1681209|NCT01609231|Drug|Cetuximab|Cetuximab will be administered intravenously prior to irinotecan at an initial dose of 400 mg/m^2 followed by weekly infusions of 250 mg/m^2. Pre-medication at the discretion of the investigator, such as with a histamine receptor antagonist or corticosteroid, will follow local, or country-specific standard of care.
1681210|NCT01609218|Drug|LY2140023|80 mg tablet LY2140023 monohydrate, administered orally
1681211|NCT01609218|Drug|Aqueous activated charcoal|75 g aqueous activated charcoal, mixed with water and administered orally
1681212|NCT01609205|Biological|Adalimumab|Adalimumab 40 mg eow (totally 27 doses/patient) manufactured by Abbott will be distributed as add-on therapy to DMARD
1681213|NCT01609192|Drug|Hydrea® (hydroxyurea )|treatment by hydroxyurea (20-30 mg/kg/day) for 6 months
1681214|NCT01609179|Drug|IPI-926|IPI-926 is administered orally as a capsule formulation, as a fixed dose in mg/day. Patients will be administered the same dose with same cycle length of IPI-926 and combination therapy that they were receiving in the original protocol at the time of transition into the extension study. The following are potential once-daily doses that patients are receiving in original protocols: 60 mg, 90 mg, 100 mg, 110 mg, 130 mg, or 160 mg.
1681215|NCT01609166|Drug|Allopurinol|Allopurinol 3% cream application in one side of the body, twice a day for 6 months
1681216|NCT01609166|Drug|Placebo|Placebo cream application in the other side of the body, twice a day for 6 months
1681217|NCT01609153|Drug|Olanzapine|Coated tablet 5-20 mg milligram(s) per day for 16 weeks
1681218|NCT01609153|Drug|Amisulpride|200-800 mg milligram(s)per day for 16 weeks
1681219|NCT01609153|Drug|Olanzapine and Amisulpride|"Zyprexa:
Coated tablet 5-20 mg milligram(s) per day for 16 weeks
Amisulpride:
Coated tablet 200-800 mg milligram(s)per day for 16 weeks"
1681220|NCT01609140|Drug|MPSK3169A|Dose regimen A, repeating subcutaneous injections every 4 weeks
1681221|NCT01609140|Drug|MPSK3169A|Dose regimen E, repeating subcutaneous injections every 4 weeks
1681222|NCT01609140|Drug|MPSK3169A|Dose regimen D, repeating subcutaneous injections every 4 weeks
1681223|NCT01609140|Drug|MPSK3169A|Dose regimen C, repeating subcutaneous injections every 4 weeks
1681224|NCT01609140|Drug|MPSK3169A|Dose regimen B, repeating subcutaneous injections every 4 weeks
1681225|NCT01609140|Drug|Placebo|Repeating subcutaneous injections of placebo every 4 weeks
1681226|NCT01609127|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each 21-day cycle
1681227|NCT01609127|Drug|Tesetaxel|Tesetaxel 15 mg/m2 orally once every 7 days for 3 consecutive weeks on Day 1, Day 8, and Day 15 of each 28-day cycle
1681228|NCT01609127|Drug|Capecitabine|Capecitabine 1250 mg/m2 orally twice daily (in the morning and evening after a meal; equivalent to a total daily dose of 2500 mg/m2) on Day 1 through Day 14 of each 21-day cycle
1681229|NCT01609101|Device|C-MAC ® videolaryngoscope|C-MAC ® videolaryngoscope
1681230|NCT01609101|Device|Coopdech® videolaryngoscope|Coopdech® videolaryngoscope
1681231|NCT01609101|Device|McGrath® Series 5 videolaryngoscope|McGrath® Series 5 videolaryngoscope
1681232|NCT01609101|Device|Glidescope® Cobalt videolaryngoscope|Glidescope® Cobalt videolaryngoscope
1681233|NCT01609101|Device|King Vision® videolaryngoscope|King Vision® videolaryngoscope
1681234|NCT01609101|Device|Venner® videolaryngoscope|Venner® videolaryngoscope
1681235|NCT01609101|Device|McGrath® MAC|McGrath® MAC (Aircraft Medical, Edinburgh, UK)
1681236|NCT01609088|Dietary Supplement|Erythritol-containing beverage|Orange flavored beverage containing erythritol
1681237|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 2.0 mg/kg/week over a period of approximately 4 hours per infusion for up to 192 weeks.
1681238|NCT01609062|Drug|BMN 110|Weekly IV infusions of BMN 110 at 4.0 mg/kg/week over a period of approximately 4 hours per infusion for 27 weeks, and will eventually transition to 2.0 mg/kg/week for up to an additional 166 weeks.
1683743|NCT01590017|Radiation|external beam radiation therapy|
1681239|NCT01609049|Drug|Peginterferon alfa-2a|Administration of treatment will be according to local recommendation under local labeling.
1681240|NCT01609049|Drug|Ribavirin|Ribavirin tablets twice daily orally will be administered depending on body weight, according summary product characteristics and prescribing of ribavirin in real clinical practice.
1681241|NCT01609023|Drug|Rituximab|Rituximab will be administered in combination with chemotherapy according to SPC and routine clinical practice.
1681242|NCT01609010|Drug|rituximab|375 mg/m2 rituximab i.v. weekly for 4 weeks
1681243|NCT01609010|Drug|interferon-a-2a|3 MIU/day interferon-a2a s.c. during Week 1, and 4.5 MIU/day s.c. 6 days per week during Weeks 2 through 5
1681244|NCT01608984|Procedure|Remote ischemic preconditioning (RIPC)|"3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion.
The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. In the CABG-arms, during extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations."
1681245|NCT01608984|Procedure|Coronary artery bypass grafting (CABG) without remote ischemic preconditioning protocol|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
1681246|NCT01608984|Procedure|Off-pump Coronary artery bypass surgery without remote ischemic preconditioning|The applied anesthesia protocol avoids the use of propofol. Drugs: isoflurane+sufentanil anesthesia Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required.
1681247|NCT01608958|Drug|Oxytocin|10 IU oxytocin in 500 ml infusion
1681248|NCT01608958|Drug|Oxytocin|10 IU oxytocin IM injection
1681249|NCT01608945|Drug|Hydrocortisone sodium succinate|100mg/day
1681250|NCT01608932|Procedure|Telemonitoring for frail patients with chronic diseases|"Patients are equipped with a telemonitoring kit that can be composed by a portable wrist clinic device, a digital weight scale and a glucometer for clinical parameters measuring, according to the pathologies of the patient. The equipment is completed by a gateway device for data transmission.
The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG, body weight and glycemia with a frequency set by the clinician in the personalized treatment plan. In the same protocol the clinician includes also the alarm thresholds that determine when the clinical measures are out-of-range. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the general practitioner in case of worsening of symptoms."
1681251|NCT01608919|Other|blood tests|thromboelastogram platelet mapping
1681252|NCT01608906|Drug|low dose intravenous heparin (LDIVH)|The LDIVH (experimental) group will receive a continuous heparin drip titrated to a prothrombin time (PTT) of 40-45. LDIVH subjects will have PTT tested within 24 hours prior to initiation of LDIVH. In addition, these subjects would continue to have a PTT tested every 6 hours until the PTT value falls between 40-45. All LDIVH subjects will have PTT values measured at least daily. This will continue until ICU discharge or a maximum of 28 days.
1681253|NCT01608906|Drug|Heparin|5000 units given subcutaneously three times a day until ICU discharge or a maximum of 28 days
1681256|NCT01608880|Drug|nitroglycerin ointment|Nitroglycerin ointment will be applied to mastectomy skin flaps at the end of surgery. A maximum of 7.5cm strip of 2% Nitroglycerin ointment will be applied (equivalent to a maximal dose of 45mg)
1681257|NCT01608880|Drug|Polysporin ointment|Polysporin ointment will be applied as the control ointment on the mastectomy flap skin at the end of surgery. A maximum of 7.5cm strip of ointment will be applied to the skin.
1681258|NCT01608867|Biological|OMP-54F28|dose escalation of 0.5, 1, 2.5, 5, and 10 mg/kg administered IV once every 3 weeks
1681259|NCT01608854|Other|Antibiotic Protocol|Patients were given postoperative antibiotics according to their randomization; antibiotic type and dosage were determined by the attending physician.
1681260|NCT01608841|Drug|Erlotinib|Erlotinib 100 mg 1# PO qd till disease progression
1681261|NCT01608815|Biological|Typhoid Vi polysaccharide|0.5 mL, Intramuscular
1681262|NCT01608802|Other|Palliative care|Regular appointments with an existing clinic nurse who has been trained in palliative care, the patient is asked about their physical, psychological, social and spiritual problems, and a care management plan devised with referral as necessary.
1681263|NCT01608802|Other|Standard care|Patients attend monthly for their ART monitoring and prescription filling, and a multiprofessional team is available as necessary.
1681264|NCT01608789|Device|Virtue® Male Sling|The Coloplast Virtue® Male Sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD).
1681265|NCT01608776|Device|MIST Therapy|The MIST Therapy System is used as a non-contact method of delivering ultrasound to treat chronic wounds.
1681266|NCT01608776|Other|SOC - Standard of Care|Standard of Care includes wound cleansing and debridement as needed, moist wound healing dressings, and offloading
1681267|NCT01608763|Behavioral|Check Your Drinking (CYD) personalized feedback intervention|The CYD provides problem drinkers with a personalized summary of their drinking that compares his or her drinking with that of the general population. The CYD also provides an assessment of the severity of the person's drinking problem.
1681268|NCT01608750|Drug|Pantoprazol|40mg/day, oral, 28 days
1681269|NCT01608750|Drug|Folic Acid|5 mg/day, oral, 28 days
1681270|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
1681271|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
1681272|NCT01608737|Drug|BI 201335|BI 201335 once daily high dose for 12 weeks
1681273|NCT01608737|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
1681274|NCT01608737|Drug|BI 201335|BI 201335 once daily low dose for 24 weeks
1731539|NCT00048308|Drug|pexelizumab|
1681278|NCT01608698|Drug|30 mcg ethinylestradiol/2 mg chlormadinone acetate|By orally 1 tablet before bedtime for 21 days and withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
1681279|NCT01608698|Drug|30 mcg ethinylestradiol/3 mg drospirenone|By orally 1 tablet before bedtime for 21 days then withdrawal 7 days after that start the new cycle. Total study period is 6 cycles of pills.
1681280|NCT01608672|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) treatment to glabellar lines as prescribed by the Investigator over at least 5 years.
1681281|NCT01608659|Drug|botulinum toxin Type A|Previous treatment with botulinum toxin Type A for treatment of facial lines
1681282|NCT01608646|Drug|S-1 plus oxaliplatin|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 14 with a single dose of oxaliplatin 130 mg/m2 will be administered as an 2-hour IV infusion following the morning dose of S-1 on Day 1. The combination therapy will be repeated every 3 weeks.
1681283|NCT01608633|Other|Spray and stretch|Physiotherapeutic technique which consist in stretching the muscle while a cold spray is applied on the skin.
1681284|NCT01608607|Other|Fructose-containing sugar sweetened beverages|Oral dietary fructose-containing sugar sweetened beverages in isocaloric exchange for other sources of carbohydrate (isocaloric trials) or hypercaloric exchange for beverages containing a non-nutritive sweetener or added to a control diet as a source of excess energy (hypercaloric trials)
1681285|NCT01608594|Drug|administration of ipilimumab10mg/kg|"Ipilimumab IV infusion:
Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery
After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart
Dose continued 12 weeks later for 4 additional doses given 12 weeks apart
Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
1681286|NCT01608594|Drug|administration of ipilimumab 3mg/kg + HDI|"Ipilimumab IV infusion:
Day 0 (within 1-2 weeks of baseline biopsy) every 3 weeks for 2 doses followed by definitive surgery
After surgery recover-y resume at the same dose for 2 additional doses given 3 weeks apart
Dose continued 12 weeks later for 4 additional doses given 12 weeks apart
Interferon Alfa-2b will be given concurrently with ipilimumab. Each patient will receive Interferon Alfa-2b at 20 MU/m²/day intravenously for 5 consecutive days out of 7 every week for 4 weeks, followed by 10 MU/m²/d subcutaneously every other day, 3 times each week for 2 weeks, followed by definitive surgery. After surgery recovery, Interferon Alfa-2b will be resumed at 10 MU/m²/d subcutaneously, every other day three times a week for 46 additional weeks."
1681288|NCT01608568|Device|Device is the type of suture used: Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during robotic assisted laparoscopic sacrocolpopexy (RALSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
1681289|NCT01608555|Drug|tobramycin|inhaled tobramycin 300 mg single dose OD for 28 days
1681290|NCT01608542|Drug|Fostamatinib 100mg|oral tablet
1681291|NCT01608542|Drug|Fostamatinib 200mg|oral tablet
1681292|NCT01608529|Device|Feel Breathe, restriction device ventilatory nasal|The Feel Breathe (FB) consisted of a small adhesive strip that is placed across the bridge of the nose during exercise. The FB was place following procedures for placement as indicated by the manufacturer's directions, while the placebo nasal, was placed over the nostrils of the subject, without interfering nasal breathing; thus, nasal airflow resistance was not increase. Each subject was required to perform three identical submaximal exercises with intensity at 50% VT1-VT2 under different breathing conditions. The breathing conditions were: oronasal, nasal and FB breathing. All participants performed three trials of stable load (50% VT1-VT2) for 10 minutes in the three conditions mentioned above, setting the cadence at 70-75 rpm, and controlling the same in all three exercise conditions.
1681293|NCT01608516|Radiation|68Ga-NODAGA-RGD PET/CT|200 MBq 68 Ga-NODAGA-RGD will be administered i.v. and images centred on the carotid area acquired
1681294|NCT01608503|Procedure|lung deflation|lung was deflated during respiration cycle
1681295|NCT01608503|Procedure|lung inflation|lung was inflated during respiratory cycle
1681296|NCT01608490|Device|RePneu Lung Volume Reduction Coil System|The LVRC group will undergo two bronchoscopic sessions under general or moderate sedation. During the procedure, subjects will be treated with Coils according to the Instructions for Use.
1681299|NCT01608451|Drug|Cholecalciferol|Inj Arachitol 300,000 I.U/ml IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
1681300|NCT01608451|Drug|Inj. Progesterone|Injection Progesterone 500 mg deep IM before each cycle of NACT (for total 4 cycles) and one injection before surgery.
1681301|NCT01608438|Device|Customizing the Body-Machine Interface|The intervention compares two ways of customizing the body-machine interface which will be used for subjects for 40 sessions (spread over 8 months). In one case (SCI static), the body-machine interface is static. In the other case (SCI Machine Learning), there is a machine learning algorithm that adapts to the movements made by the subject.
1681302|NCT01608425|Procedure|telemedicine consultations|Replacing 2 out of 3 patient visits to out-patient clinic at hospital with treatment at home from visiting nurse and telemedicine consultations with the specialist doctor.
1681303|NCT01608412|Drug|Tacrolimus|TACROLIMUS (C0 = 5-10 ng/mL) + MPS 1440 mg + Pred
1731540|NCT00048321|Drug|ISIS 104838|
1681304|NCT01608412|Drug|Everolimus|Everolimus (C0 = 6-10 ng/mL) + MPS 1440 mg + Pred
1681305|NCT01608399|Behavioral|Metacognitive therapy|Metacognitive therapy, 10 weekly sessions of 45-60 minutes duration each
1681306|NCT01608386|Procedure|IVC clamping|in right hepatectomy,use anterior approach and infrahepatic Inferior Vena Cava clamping.
1681307|NCT01608373|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr
1681308|NCT01608373|Drug|Intraperitoneal lidocaine irrigation group|Patients in Group P(intraperitoneal lidocaine irrigation group) receive a peritoneal lidocaine irrigation with 3.5mg/kg lidocaine and normal saline 100cc. 50cc of irrigation fluid will be spread below diaphragm and 50cc of irrigation fluid will be spread around the gall bladder.
1681309|NCT01608373|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
1681310|NCT01608360|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
1681311|NCT01608360|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
1681312|NCT01608347|Drug|LMWH+Folic acid|Patients will receive a fixed dose of 40 mg of enoxaparin subcutaneous daily. Treatment will start once positive pregnancy test and will be continued until abortion or delivery (if premature), or 37 weeks of pregnancy. Additionally, 500 micrograms Folic acid tablet once daily will be started once positive pregnancy test and continues until 13 weeks' of gestation.
1681313|NCT01608347|Drug|Folic Acid|Folic acid 500 micrograms daily once positive pregnancy test until the 13th week of pregnancy or abortion
1681314|NCT01608334|Drug|Fentanyl|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
1681315|NCT01608334|Drug|Sufentanil|1mg 0.5% bupivacaine + fentanyl 20 mcg + 1.8 ml glucose ( total 2.4-ml) VS 1mg 0.5% bupivacaine + sufentanil 5 mcg + 2.1ml glucose (total 2.4-ml) intrathecally.
1681316|NCT01608321|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
1681317|NCT01608321|Device|Sham device|Placebo Device that simulates active rTMS treatment
1681318|NCT01608308|Drug|IV Acetaminophen|1000mg IV acetaminophen over 15 minutes every 4 hours for up to 2 doses.
1681319|NCT01608308|Drug|Placebo|100 mL of 0.9% normal saline over 15 minutes in place of IV acetaminophen.
1681320|NCT01608295|Drug|Vilazodone; Viibryd|Subjects randomized to receive vilazodone blindly will have incremental dose titration of 10mg per day for the 1st week; 20mg per day the 2nd week; 40mg per day for the 3rd-12th week. Doses of the drugs will be adjusted according to individual tolerability and safety.
1681321|NCT01608295|Drug|Paroxetine; Paxil|Subjects randomized to receive paroxetine blindly will have incremental dose titration of paroxetine 10mg per day for the 1st week; 20mg per day for the 2nd week; and 30mg per day for the 3rd-12 week. Doses of the drugs will be adjusted according to individual tolerability and safety.
1681322|NCT01608282|Behavioral|OPEN website|The OPEN website includes interactive modules that allow users to prioritise their daily activities, set goals and find venues where they can participate in different types of activities according to their preferences and the local availability
1681323|NCT01608269|Drug|Abacavir/Lamivudine|one tablet once a day
1681324|NCT01608243|Biological|SLIT tablets of house dust mite allergen extracts|10 dosing days
1681325|NCT01608243|Biological|Matching placebo|10 dosing days
1681326|NCT01608217|Drug|delta-9-tetrahydrocannabinol (delta-THC)|delta-THC 1.5 mg (tablet)three times daily for a period of 3 weeks.
1681327|NCT01608217|Drug|Placebo|placebo (tablet) three times daily for a period of three weeks.
1681328|NCT01608217|Drug|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of 3 weeks
1681329|NCT01608217|Drug|Acetaminophen|Acetaminophen 1000 mg three times daily for a period of three weeks
1681330|NCT01608191|Behavioral|CBT follow up|11 weeks programme conducted via internet. CBT with focus on weight stability.
1681331|NCT01608165|Procedure|Surgical treatment for renal mass|Patients will be randomised to receive a partial nephrectomy as treatment for their renal cancer mass
1681332|NCT01608165|Procedure|Percutaneous Radiofrequency ablation|Patients may be randomised to undergo a radiofrequency ablation treatment for their renal cancer mass
1681333|NCT01608165|Procedure|Laparascopic or percutaneous cryoablation|Patients may be randomised to undergo cryoablation as treatment for their renal cancer mass
1681334|NCT01608152|Behavioral|Needs Analysis|Focus group discussion lasting about 1½ hours. Several weeks after focus group, return visit to provide opinions on game development.
1681335|NCT01608152|Behavioral|Video game|Instructions given at clinic visit on using video game through the internet. Participant asked to play game at home for 3 weeks.
1681336|NCT01608152|Behavioral|Interview|1 week after the 3-week period ends, interview conducted over the phone or at a clinic visit.
1681337|NCT01608139|Drug|Curcumin|Starting dose: 4 grams by mouth per day. During the first cycle only, Curcumin given on Day 1. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
1681338|NCT01608139|Drug|Sorafenib|Starting dose: 200 mg by mouth daily. During the first cycle only, Sorafenib given on Day 5. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
1681339|NCT01608139|Drug|Vorinostat|Starting dose: 100 mg by mouth daily. During the first cycle only, Vorinostat given on Day 3. Beginning with Cycle 1 Day 5, all agents will be administered continuously.
1681340|NCT01608126|Procedure|cervical block|"In brief, the superficial block was performed using a 22G needle (07 x 40 mm). The mixture injected was 15 ml of 0.5% bupivacaine + 10 ml of 1% lidocaine. Deep cervical plexus block was performed using a Stimuplex DR stimulating needle and the dose of anaesthetic used was 10 ml 0.5% bupivacaine + 5 ml 1% lidocaine applied in the vicinity of the C3 nerve root.
The MCPB performed using ultrasound-guidance aiming specifically for the interfascia space. Eighteen ml of 0.375% bupivacaine was injected into the interfascia space at the level of C3 vertebral body using a 22G needle (07 x 40 mm)."
1681379|NCT01607762|Drug|Quetiapine|Type= exact number, unit= mg, number= 100, form= tablet, route= oral administration. A single oral dose of two 50-mg quetiapine tablets will be administered after an overnight fast.
1681341|NCT01608100|Device|ARCHITECT STAT High Sensitive Troponin I Assay|"Test blood samples from the ARCHITECT STAT High Sensitive Troponin I Assay. Results obtained will be used to assess the prognosis of subjects for risk of ACM/MACE in the timeframes (30 days and 90 days) after the Emergency Department visit.
Troponin results will be compared to documented ACM/MACE events at the 30 day and 90 day time points after Emergency Department visit."
1681342|NCT01608087|Drug|BI 695502|BI 695502 single i.v. infusion
1681343|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
1681344|NCT01608087|Drug|bevacizumab|bevacizumab single i.v. infusion
1681345|NCT01608074|Procedure|Radical fimbriectomy|"Laparoscopic bilateral radical fimbriectomy :
Complete resection of the tubes, from the uterine tube (up against the uterus) to the fimbriae, with resection of the part of the ovary adjacent to the ovarian fimbriae (adhering to the ovary)"
1681346|NCT01608074|Other|Histopathology SEE-FIM|Anatomopathological study of surgical specimens
1681347|NCT01608061|Device|DBS-f on|deep brain stimulation of the fornix
1681348|NCT01608061|Device|DBS-f off|deep brain stimulation of the fornix turned off
1681349|NCT01608048|Device|transcutaneous electrical acupoint stimulation (TEAS);EA|TEAS group (conventional IVF + TEAS), electro-acupuncture (EA) group (conventional IVF + electro-Acu.), and control group (only conventional IVF) Parameter of TEAS or EA: frequency of 2/100 Hz；moderate electrical current. Treatments start from the day 3 of menstruation，once every two days, 30 min for each for two continuous weeks.
1681350|NCT01608035|Procedure|Sciatic catheter|presurgical sciatic catheter insertion
1681351|NCT01608035|Procedure|Stump catheter|intraoperative placed stump catheter
1681352|NCT01608022|Drug|PF804|45 mg p.o. daily and continuously (28-day treatment as one treatment cycle)
1681353|NCT01608009|Drug|Pazopanib and paclitaxel|Pazopanib 800mg od for 7 days, followed by 18 weeks of combination therapy (paclitaxel 80mg/m2 weekly and pazopanib 800mg od). Following the completion of combination therapy, patients will continue on maintenance pazopanib 800mg od until disease progression.
1681354|NCT01607996|Procedure|Epidural anesthesia|Epidural will be performed using carbostesin (0.1%), fentanyl (2 microg/ml) administered continuously at a rate of 6 to 15 ml/hour
1681355|NCT01607996|Drug|Patient controlled intravenous analgesia|Fentanyl 10 microg/ml at continuous flow of 10 to 20 microg/hour
1681356|NCT01607983|Drug|inhaled nitric oxide|20 parts per million (ppm) of inhaled nitric oxide
1681357|NCT01607970|Drug|Oxytocin|Oxytocin: 24 IU; 3 puffs per nostril, each with 4 IU OXT
1681358|NCT01607957|Drug|TAS-102|35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
1681359|NCT01607957|Drug|Placebo|Placebo tablets, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria are met.
1681360|NCT01607931|Behavioral|Exercise|1 hour of cycling at 50% of maximum power output
1681361|NCT01607918|Drug|D1-D5: (lansoprazole + amoxicillin ) D6-D10: (lansoprazole+clarithromycin +metronidazole)|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
1681362|NCT01607918|Drug|D1-D14: (lansoprazole + clarithromycin + amoxicillin)|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
1681363|NCT01607905|Drug|KPT-330|Subjects in this study will receive KPT-330 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 3 mg/m2 twice a week and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
1681364|NCT01607892|Drug|KPT-330|
1681365|NCT01607879|Drug|Standard of care ADT + (HMB + arginine + glutamine)|"1 packet of HMB+arginine+glutamine contains 1.5 g of the amino acid metabolite HMB + 7 g arginine and 7 g glutamine.
Take one packet twice daily for 3 months"
1681366|NCT01607879|Other|Standard of care ADT|Patient will receive standard of care androgen deprivation therapy (ADT) alone
1681367|NCT01607866|Procedure|Quadrant parotidectomy|Excision of one quadrant of the parotid gland which is comparable to half of the superficial lobe of the gland
1681368|NCT01607866|Procedure|Superficial parotidectomy|Excision of the whole superficial lobe of the parotid gland
1681369|NCT01607853|Drug|Daivobet® gel applied then removed after 10 minutes (+/- 2 minutes)|Once daily application, 3 weeks
1681370|NCT01607853|Drug|Daivobet® gel applied then removed after 20 minutes (+/- 2 minutes)|Once daily application, 3 weeks
1681371|NCT01607853|Drug|Daivobet® gel applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
1681372|NCT01607853|Drug|Daivobet® gel vehicle applied for 24 hours (+/- 2 hours)|Once daily application, 3 weeks
1681373|NCT01607840|Procedure|transcranial direct current stimulation|delivery of transcranial direct current stimulation or sham for 20 to 60 minutes
1681374|NCT01607827|Procedure|Polyp removal upon insertion and withdrawal|"Endoscopic procedures:
All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.
The endoscopist removed all visible polyps instantly regardless whether advancing the instrument to the cecum or pulling back."
1681375|NCT01607827|Procedure|Polyp removal upon withdrawal only|"Endoscopic procedures:
All polypectomies in the study groups were performed using the same techniques as in the standard care of non-study patients, using snare loops, hot biopsy forceps, with and without submucosal injection of saline/epinephrine. Polyps larger than 3 mm were removed by snare, polyps smaller than 4 mm were removed by cold biopsy. There were no differences upon insertion or withdrawal.
The endoscopist advanced the endoscope to the cecum without removing polyps. Upon withdrawal, all visible polyps were removed successively by standard techniques."
1681378|NCT01607762|Drug|Aripiprazole|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg aripiprazole tablet will be administered after an overnight fast.
1731906|NCT00039039|Drug|carboplatin|
1681380|NCT01607762|Drug|Olanzapine|Type= exact number, unit= mg, number= 5, form= tablet, route= oral administration. A single oral dose of a 5-mg olanzapine tablet will be administered after an overnight fast.
1681381|NCT01607762|Drug|Risperidone|Type= exact number, unit= mg, number= 1, form= tablet, route= oral administration. A single oral dose of a 1-mg risperidone tablet will be administered after an overnight fast.
1681382|NCT01607762|Drug|Paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral administration. A single oral dose of a 3-mg paliperidone tablet will be administered after an overnight fast.
1681385|NCT01607736|Behavioral|Virtual Gait Training|The intervention consisted of 12-minute virtual gait training sessions once daily for a total of 14 weekdays within a three-week period. The intervention video showed walking legs of a 30-year-old woman for female and a 46-year-old man for male participants. The video screen was adjusted in height such that it corresponded to the legs of the standing participant, with a mirror placed above it. Participants began the training session with a circa one minute of concentration on the upcoming intervention. Afterwards, the video was started. Participants were instructed to stand (when necessary, to sit) and observe the video and mirror, and to imagine themselves walking. Training sessions were supervised by a physical therapist who gave additional instructions and comments regarding participants' visual/kinesthetic imagination of themselves performing the observed movement. Verbal and physical reactions during training sessions were documented in written form and sometimes videotaped.
1681386|NCT01607723|Other|NAVA ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
1681387|NCT01607723|Other|PAV+ ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
1681388|NCT01607697|Behavioral|Mindfulness Training|Mindfulness Training
1681389|NCT01607684|Device|Magnetic Marker Imaging (MMI) with Magma 3D system|Magnetic Marker Imaging (MMI). It comprises of a high-resolution three-dimensional detector system, that detects passively and continuously the magnetic field of a magnetic marker capsule (1g, 6x12mm), which is taken orally by the subject. Changes in frequency, intensity and duration of oscillating marker movements allow us to delineate migrating gastric motor complexes. The Magnetic Marker Imaging takes up to 4 h in which the patient lies in a bed. Short interruptions (e.g. to visit the restroom) during this 4 h period are possible.
1681390|NCT01607671|Drug|Timolol maleate|Timolol 0.5% 1 drop twice daily to the effected eye for 4 weeks.
1681395|NCT01607645|Drug|decitabine|Given IV
1681396|NCT01607645|Drug|idarubicin|Given IV
1681397|NCT01607645|Drug|cytarabine|Given IV
1681398|NCT01607632|Behavioral|loving-kindness meditation|A 12-week duration, 90 minute per session loving-kindness meditation course
1681399|NCT01607619|Dietary Supplement|Anatabine|1mg anatabine in a mint-flavored mannitol lozenge
1681400|NCT01607593|Drug|sertraline (Zoloft)|Dosage form: Tablet, Dosage: over 25 mg/day, duration: Not defined
1681401|NCT01607580|Drug|low-dose glucocorticoid Methylprednisolone|patients receive low-dose glucocorticoid from day 5 post transplant
1681402|NCT01607554|Drug|Irinotecan|"180 mg/m2 Irinotecan intravenously over 60 minutes on day 1 of each cycle
Pre-medication for irinotecan: palonosetron 0.25 mg and dexamethasone 8 - 16 mg, both administered intravenously. Atropine 0.25 - 0.5 mg subcutaneously or IV is at the discretion of the treating physician"
1681403|NCT01607541|Behavioral|BCAP peer-driven intervention (PDI)|"The Brooklyn Community Action Project (BCAP) PDI entails structured sessions including the computerized CARE for Prevention tool, 3 peer education experiences, and 6 months of navigation for those HIV infected (if HIV-negative: total 3.5 hours of facilitated/computer intervention activities, plus peer education experiences; if HIV-positive: 5 hrs facilitated/computer activities, plus peer education experiences and navigation)."
1681404|NCT01607541|Behavioral|Control intervention|The control arm will receive a time- and attention-matched HIV counseling and testing intervention and for those found HIV-infected, an appointment with HIV services and reminders, the current standard of care.
1681405|NCT01607528|Dietary Supplement|Winclove-849|6 g of Winclove-849 containing Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Lactobacillus acidophilus W37, Lactobacillus brevis W63, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Lactococcus lactis W58 at a concentration of 2.5 x 109 cfu/g
1681406|NCT01607528|Dietary Supplement|Placebo|A similar looking and tasting powder with no active substances
1681407|NCT01607515|Other|Impedance cardiography|noninvasive measure of cardiac index by impedance cardiography.
1681408|NCT01607489|Radiation|Dual-energy computed tomography investigation|"1x 20ml Ultravist (370mg J/ml)3-5ml/s,
1x 70ml Ultravist (370mg J/ml)3-5ml/s Contrast agent administration"
1681409|NCT01607476|Drug|C11 PiB|One time intravenous administration of 8-22 millicurie (mCi) C11 PiB
1681410|NCT01607476|Drug|F18 Flutametamol|One time intravenous administration of 3-7 mCi F18 Flutametamol.
1681411|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|In the active TENS group, TENS at 80 pulsed currents per second (PPS) with a pulse duration of 200 μs were delivered for 20 minutes. Current amplitude was slowly increased until a level was reached that participants reported was the maximum level they could tolerate below pain threshold without noticeable muscle contraction and maintained this intensity.
1681412|NCT01607463|Procedure|Transcutaneous electrical nerve stimulation (Empi, USA)|"In the placebo group the TENS device had no current output although the power on indicator light remained active."
1681413|NCT01607450|Drug|GLP-1 Low Dose|0.5mmol/kg/hr GLP-1 for 12 hours prior to PET study
1681414|NCT01607450|Drug|GLP-1 Mid-Range Dose|1.5mmol/kg/min for 12 hours prior to PET study
1681415|NCT01607450|Drug|GLP-1 High Dose|4.0mmol/kg/min GLP-1 for 12 hours prior to PET study
1681416|NCT01607450|Drug|Saline|Normal saline placebo infusion for 12 hours prior to PET study
1681417|NCT01607424|Behavioral|cognitive remediation|RECOS: cognitive remediation for schizophrenia CRT: cognitive remediation therapy
1681418|NCT01607411|Drug|Fluoride|Fluoride Toothpaste
1681419|NCT01607411|Drug|Placebo|Fluoride free toothpaste
1681420|NCT01607398|Drug|ADOAIR250|250 mcg inhalation, twice daily, from week0 -12.
1681421|NCT01607398|Drug|Placebo|Placebo inhalation, twice daily, from week0 -12.
1681422|NCT01607385|Drug|GSK2330672|BID, repeat doses
1681423|NCT01607385|Drug|Placebo|BID, repeat doses
1681424|NCT01607385|Drug|GSK1614235|BID, co-dosed BID with last dosing day of active/placebo repeat doses
1681429|NCT01607333|Drug|Lamotrigine use|Lamotrigine prescription during the study period
1681430|NCT01607320|Drug|Raloxifene|Thirty PCOS patients treated with 3 cycles of 120mg/day of Evista (raloxifene) on days 3 to 7 following an initial provera withdrawal
1681431|NCT01607320|Drug|Clomiphene|Thirty PCOS patients treated with 3 cycles of 100mg/day of Clomid (clomiphene citrate) on days 3 to 7 following an initial provera withdrawal
1681432|NCT01607307|Drug|Oral/enteral TJ-100 solution|Oral TJ-100 solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent TJ-100 solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
1681433|NCT01607307|Drug|Oral/enteral placebo solution|Oral placebo solution (5 g tid, 15 g/day) given immediately before meals or every 8 h from preoperative day 3 to postoperative day 7 for 10 consecutive days. A diluent placebo solution given immediately after surgery and on postoperative day 1 via Argyle enteral feeding tube (10 Fr), which terminates in the jejunum to prevent aspiration pneumonia.
1681434|NCT01607294|Drug|ETC-1002|ETC-1002 Daily for 4 weeks
1681435|NCT01607294|Drug|Placebo|Placebo Daily for 4 weeks
1681436|NCT01607268|Procedure|Magnetic Resonance Spectroscopy Imaging|Proton magnetic resonance spectroscopy [1H-MRS] is an emerging imaging tool that allows for non-invasive assessment of brain neurochemistry in human subjects. This technique allows for in vivo quantification of the concentration of neurotransmitters and metabolites in discrete brain regions through detection of hydrogen nuclei in these molecules. Autonomic failure patients will undergo a single imaging session lasting 30 to 90 minutes (0.5-1.5 hours) in the Vanderbilt Human Imaging Institute.
1681437|NCT01607255|Drug|Indigo carmine|0.008% indigo carmine in water is used as a surface contrast agent to enhance visualization of diminutive polyps (adenoma) during screening colonoscopy
1681438|NCT01607255|Procedure|water (exchange) method|Residual pocket of air will be suctioned. Water is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions.
1681439|NCT01607255|Procedure|water (exchange) plus dye method|Residual pocket of air will be suctioned. Water with 0.008% indigocarmine is infused using a peristaltic pump to facilitate scope advancement until the cecum is reached. Dirty water will be suctioned and clean water is infused. Air will not be insufflated until the cecum is reached. Residual water is suctioned and air insufflated on scope withdrawal to facilitate biopsy and removal of lesions
1681440|NCT01607255|Procedure|air method|The colonoscope is inserted gently and advanced slowly using minimal air insufflation, if necessary, the assistant will provide abdominal compression or the patient's position will be changed to facilitate scope passage. The scope is inserted until the cecum is reached. Air is insufflated on scope withdrawal for visualization and water irrigation is used to remove any adherent feces covering the mucosa. Biopsy or polypectomy is performed where indicated.
1681441|NCT01607242|Other|Endoscopy of larynx|Endoscopic Laryngeal mobility assessment
1681442|NCT01607242|Other|Voice Handicap Index|Subjective Evaluation of Voice disorders
1681443|NCT01607242|Other|Swallowing Assesment|Swallowing function questionnaire
1681444|NCT01607229|Other|observation|no intervention used, observed measurements from 3 test devices compared to reference criterion measurement for total body water and body composition
1681445|NCT01607203|Drug|Decapeptyl Daily|Decapeptyl 0.2 mg SC once 1day
1681446|NCT01607203|Drug|pregnyl|5000 IU SC
1681447|NCT01607177|Behavioral|Daily text message reminders|Daily text message reminders to motivate patients to exercise in conjunction with an exercise information sheet.
1681448|NCT01607164|Behavioral|Healthy Mood Project Website|Self-help automated online mood management course based on cognitive-behavioral methods to control depressed mood.
1681449|NCT01607151|Other|Normothermia|72 hours of targeted temperature management to achieve normothermia (36-37°C)
1681450|NCT01607151|Other|Hypothermia|72 hours of targeted temperature management to achieve hypothermia (32-34°C)
1681451|NCT01607125|Drug|Vortioxetine (Lu AA21004)|encapsulated 20 mg tablets, orally, once daily for 13 to 14 days
1681452|NCT01607125|Drug|Placebo|capsules, orally, once daily for 13 to 14 days
1681453|NCT01607112|Biological|Fluarix/Influsplit SSW 2012-2013|1 dose administered intramuscularly (or deeply subcutaneously) in the deltoid region of the non-dominant arm
1681454|NCT01607099|Procedure|Compatibility|Patients asses the compatibility of the bowel cleansing procedure
1681455|NCT01607086|Drug|Cherry lamotrigine ODT|25mg, taken orally on one study visit
1681456|NCT01607086|Drug|Cherry Placebo|Taken orally on one study visit
1681458|NCT01607060|Drug|Lactulone|Patients will receive lactulone to daily laxation
1681459|NCT01607034|Drug|Dexpramipexole|150 mg single dose
1681460|NCT01607008|Other|MRI imaging|"3 total MRI imaging studies:
pre standard radiation treatment
during standard radiation treatment
post standard radiation treatment"
1681461|NCT01606995|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients with non-valvular atrial fibrillation who are prescribed rivaroxaban under routine treatment conditions to prevent stroke or non-central nervous system systemic embolism. Decision regarding dose and duration of treatment made at the discretion of the attending investigator
1681462|NCT01606982|Drug|MDV3100|oral
1681463|NCT01606969|Drug|scalp infiltration solution|Dex group: Dexmedetomidine 2mcg/ml-containing 2% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
1681464|NCT01606969|Drug|scalp infiltration solution|1:200000 epinephrine-containing 2% lidocaine scalp injection by neurosurgeon(dosage: according to incision length)
1681465|NCT01606956|Procedure|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
1681466|NCT01606956|Procedure|The cuff inflation by half the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
1681468|NCT01606917|Other|Intensive lifestyle counseling|Both dietary advice and individualized advice on increased regular physical activity
1681469|NCT01606904|Behavioral|Cognitive behavioral therapy -based weight loss program|CBT-based program includes 20 group visits
1681470|NCT01606891|Behavioral|multi-component/setting parent-targeted intervention|parents assigned to this group will be asked to participate in a program of home visiting, community parenting classes, and community food and physical activity resource links
1681471|NCT01606878|Drug|crizotinib|Given orally
1681472|NCT01606878|Drug|cyclophosphamide|Given IV
1681473|NCT01606878|Drug|topotecan hydrochloride|Given IV
1681474|NCT01606878|Drug|vincristine sulfate|Given IV
1681475|NCT01606878|Drug|dexrazoxane hydrochloride|Given IV
1681476|NCT01606878|Drug|doxorubicin hydrochloride|Given IV
1681477|NCT01606878|Other|pharmacological study|Correlative studies
1681478|NCT01606878|Other|laboratory biomarker analysis|Correlative studies
1681479|NCT01606878|Other|pharmacogenomic studies|Correlative studies
1681480|NCT01606878|Other|questionnaire administration|Ancillary studies
1681481|NCT01606852|Drug|Dexmedetomidine|loading dose (0.5 mcg/kg i.v.), followed by a continuous basal infusion (0.2-0.7 mcg/kg/hr) with 3 allowable patient-controlled self-boluses per hour (0.25 mcg/kg) each with a 20-minute lock-out. Study infusion up to 5 days.
1681482|NCT01606813|Other|Usual Care|Standard care
1681483|NCT01606813|Behavioral|Brief Physician Counseling|Primary Care Physician (PCP) will review a goal setting worksheet for weight loss with the participant and then collaboratively set a goal for weight loss.
1681484|NCT01606813|Behavioral|Referral and access to an internet weight control program|Participants will receive a login and password for the weight loss website. The website will encourage patients to set a new weight goal every 3 months and work towards a total weight loss goal of 10%. Patients will also receive an email prompt each week alerting them to new content and reminding them to check-in to the website to report their weight, intake and activity.
1681485|NCT01606813|Behavioral|Brief follow up email notes from PCPs|Patients will receive a biweekly email from their primary care physician on how they are doing with their weight loss.
1681486|NCT01606800|Drug|PEG-IFN alfa-2b|Pegylated interferon alfa-2b administered subcutaneously 1.5 mcg/kg/week
1681487|NCT01606800|Drug|ribavirin|Ribavirin 200 mg capsules administered orally daily based on weight
1681488|NCT01606787|Drug|mannitol|After induction of general anesthesia Normosol or Lactated Ringers , at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The treatment arm will receive a standard dose of 12.5 grams of mannitol (200 cc of a 6.25% mannitol solution) intravenously completely infused through an existing intravenous access catheter within 30 minutes prior to renal artery clamping.
1681532|NCT01606423|Drug|Placebo|Administered orally, single dose
1681533|NCT01606423|Drug|LY2409021|Administered orally, single dose
1681534|NCT01606410|Other|IPC|repeated cuff inflation (220 mmhg) around an upper limb for 5 minutes, followed by 5 minutes of reperfusion (repeated 4 times)
1681535|NCT01606397|Drug|Placebo|Administered orally (capsule)
1731907|NCT00039039|Drug|chemotherapy|
1955366|NCT03213340|Other|Catechin Cohort 1|- 4 capsules taken with water 1 hour prior to meal
1681489|NCT01606787|Other|placebo|After induction of general anesthesia Normosol or Lactated Ringers at a target infusion rate of 10cc/kg (+/- 1cc/kg), will be administered over the first hour of surgery. After the first hour of surgery IV fluid will be administered at 6cc/kg (+/- 1cc/kg) intended to maintain a minimum systolic blood pressure of 90-100mmHg and a minimum urine output of 0.5cc/kg/hour. The placebo arm will receive 200cc of normal saline completely infused within 30 minutes prior to renal artery clamping.
1681490|NCT01606774|Other|Modernized prenatal care|Home monitoring/phone surveillance/28 week ultrasound in place of 4-5 routine prenatal visits between 18 and 36 weeks
1681491|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 22.
1681492|NCT01606761|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 52.
1681493|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 23 through Week 52.
1681494|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 52.
1681495|NCT01606761|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 52.
1681496|NCT01606748|Biological|Necitumumab|"PK Run-In Period: Necitumumab administered on Day 3 of the 3-week PK run-in period as an intravenous (I.V.) infusion at an absolute dose of 800 mg
Treatment Cycles: Necitumumab administered on Days 1 and 8 of every 3-week cycle as an intravenous (I.V.) infusion at an absolute dose of 800 mg
Participants in Cohort 1 will receive necitumumab Process C drug product and participants in Cohort 2 will receive necitumumab Process D drug product"
1681497|NCT01606748|Drug|Gemcitabine|"PK Run-In Period: Gemcitabine administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 1250 milligram per square meter (mg/m2)
Treatment Cycles: Gemcitabine administered on Days 1 and 8 of every 3-week cycle as an I.V. infusion at a dose of 1250 mg/m2"
1681498|NCT01606748|Drug|Cisplatin|"PK Run-In Period: Cisplatin administered on Day 1 of the 3-week PK run-in period as an I.V. infusion at a dose of 75 mg/m2
Treatment Cycles: Cisplatin administered on Day 1 of every 3-week cycle as an I.V. infusion at a dose of 75 mg/m2"
1681499|NCT01606735|Drug|IBI-10090|dexamethasone
1681500|NCT01606722|Drug|Darunavir/ritonavir|Darunavir/ritonavir (800/100 mg once daily) monotherapy
1955367|NCT03213340|Other|Curcuminoid Cohort 2|- 2 capsules taken with water 1 hour prior to meal
1681503|NCT01606696|Behavioral|HIIT|Higher intensity interval training.
1681504|NCT01606696|Behavioral|Standard intensity non-interval training|Standard intensity non-interval training.
1681505|NCT01606683|Other|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.
Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae."
1681506|NCT01606683|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients.
1681507|NCT01606683|Other|No intervention|
1681508|NCT01606657|Procedure|Irrigation|The patient will receive irrigation as a part of their wound care
1681509|NCT01606657|Other|No Irrigation|The patient will not receive irrigation as part of their wound care
1681510|NCT01606644|Procedure|Hyperbaric oxygen|Inhalation of 100% oxygen for 90 minutes
1681511|NCT01606592|Behavioral|Panic Control Treatment (PCT)|Manualized, 13 sessions (60 min, sometimes extended to 90-120) completed in 12-16 weeks. Total duration 840-1080 min.
1681512|NCT01606592|Behavioral|Panic-Focused Psychodynamic Psychotherapy (PFPP)|Manualized, 19-24 sessions (45 min) completed in 12-16 weeks. Total duration 855-1080 min.
1681513|NCT01606592|Other|Waiting-list|Sparse telephone contact during 12 weeks, then re-randomization
1681514|NCT01606579|Drug|PRI-724|PRI-724
1681515|NCT01606579|Drug|PRI-724|PRI-724 in combination with dasatinib
1681516|NCT01606579|Drug|PRI-724|PRI-724 in combination with low dose ara-C therapy
1681517|NCT01606566|Drug|Amphinex induced PCI of bleomycin|Intravenous administration of 0.25 mg/kg Amphinex (day 0) followed by intravenous administration of bleomycin (15000 IU/m2, day 4) and laser light application (3 hours (+/- 1 hour) after bleomycin administration).
1681518|NCT01606553|Device|High-intensity IMT|High intensity short duration respiratory muscle training with a valve prototype
1681519|NCT01606553|Device|Sham High-intensity IMT|High intensity short duration respiratory muscle training using a sham valve prototype
1681520|NCT01606540|Drug|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after reposition.
Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after reposition. The following days placebo tablets.
Group C: Placebo tablets 1 week after reposition."
1681521|NCT01606540|Drug|Tablets Ibumetin and placebo|"Group A: Daily tablets Ibumetin, 600 mg x 3, 7 days after surgery.
Group B: Daily tablets Ibumetin, 600 mg x 3, 3 days after surgery. The following days placebo tablets.
Group C: Placebo tablets for 1 week after surgery."
1681522|NCT01606527|Drug|Ibuprofen 600mg orally three times daily|Ibuprofen is taken 600mg orally three times daily
1681523|NCT01606514|Behavioral|Bounce Back Now Website|Bounce Back Now is a web-based psychoeducation and self-help website
1681524|NCT01606488|Drug|Florbetapir F 18 (18F-AV-45)|Single IV bolus injection of 370 MBq (10mCi) florbetapir will be administered approximately 50 minutes prior to a 10 minute PET scan.
1681525|NCT01606488|Other|no intervention|
1681526|NCT01606475|Biological|Allogeneic islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
1681527|NCT01606462|Drug|Oxytocin|intranasal administration, 24 IU oxytocin; ; 3 puffs per nostril, each with 4 IU OXT
1681528|NCT01606449|Procedure|Surgical Therapy|"Open Anti-reflux fundoplication according to Nissen-Rossetti, floppy Nissen, Belsey MK IV,Collis Nissen, Collis-Belsey.
Minimally-Invasive fundoplication according to floppy Nissen, left thoracoscopic Collis-laparoscopic Nissen."
1681529|NCT01606436|Drug|Pomaglumetad methionil|Administered orally.
1681530|NCT01606436|Drug|Matching placebo|Administered orally.
1681531|NCT01606436|Drug|Moxifloxacin|Administered orally.
1681537|NCT01606384|Drug|VASOPRESSIN V1B RECEPTOR ANTAGONIST (SSR149415)|Pharmaceutical form: Capsule Route of administration: oral
1681538|NCT01606384|Drug|Placebo|Pharmaceutical form: Capsule Route of administration: Oral
1681539|NCT01606371|Drug|Placebo|Administered orally
1681540|NCT01606371|Drug|LY2409021|Administered orally
1681541|NCT01606358|Drug|Carboplatin and / or taxol chemotherapy|Patient with proven epithelial ovarian cancer and receiving carboplatin and / or taxol chemotherapy (usual care).
1681542|NCT01606345|Drug|Valrubicin|Eligible patients will receive percutaneous valrubicin beginning no sooner than 10 days following nephrostomy placement and within 6 weeks of tumor treatment/resection.
1681543|NCT01606332|Procedure|Interscalene block with nerve catheter|Interscalene block with ropivacaine 0.5% 10ml and placement of an indwelling nerve catheter with ropivacaine 0.2% @5ml/hr for 24 hours
1681544|NCT01606319|Drug|Acetaminophen|15 mg/kg every 6 hours as needed
1681545|NCT01606319|Drug|Ibuprofen|9.4 mg/kg every 6 hours as needed
1681546|NCT01606306|Drug|daily fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations twice daily
1681547|NCT01606306|Drug|Montelukast|Singulair®, 4 mg granules or chewable tablets by mouth once daily in the evening
1681548|NCT01606306|Drug|as-needed fluticasone propionate|Flovent® HFA, 44 mcg per inhalation, 2 inhalations, as needed for asthma symptoms
1681549|NCT01606293|Behavioral|Questionnaires|Completion of online surveys taking approximately 15 - 20 minutes.
1681550|NCT01606267|Other|health systems intervention: HEP+ICCM|In the HEP+ICCM intervention areas, HEWs will assess and treat childhood pneumonia with cotrimoxazole. The program will strengthen the capacity of HEWs to assess, classify and treat malaria (with ACTs), diarrhea (with ORS) and undernutrition (with therapeutic feeding) through refresher trainings and strengthening supervision, logistical support and the ICCM system overall.
1681551|NCT01606254|Drug|Paliperidone palmitate|Paliperidone palmitate aqueous suspension for injection 0.5, 1.0, 1.5 milliliter equivalent to 50, 100, 150 mg paliperidone respectively as intramuscular injection on Days 1, 8, 36 and 64.
1681552|NCT01606241|Drug|Cyclophosphamide|Given PO
1681553|NCT01606241|Other|Laboratory Biomarker Analysis|Correlative studies
1681554|NCT01606241|Biological|Multi-epitope Folate Receptor Alpha Peptide Vaccine|Given ID
1681555|NCT01606228|Drug|Paliperidone ER|Type= range, unit= mg/day, number= 3 to 12, form= tablet, route= oral use. Paliperidone ER 6 mg orally administered once daily for the first five days. Thereafter, flexible dosing in a range of 3 to 12 mg/day.
1681556|NCT01606215|Drug|Mesenchymal stem cells|1.0-2.0 million cells/kg body weight
1681557|NCT01606215|Drug|Placebo|Placebo
1681558|NCT01606202|Drug|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml):cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.7 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
1681559|NCT01606202|Drug|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three-hour period, and 48 actuations in any 24 hour period.
1681560|NCT01606189|Drug|GW-1000-02|Contains delta-9-tetrahydrocannabinol (THC) (25 mg/ml) and cannabidiol (CBD) (25mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
1681561|NCT01606189|Drug|GW-2000-02|Contains THC (25 mg/ml) as extract of Cannabis sativa L, with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg). The maximum daily exposure was set at 48 actuations per day.
1681562|NCT01606189|Drug|Placebo|Contains peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum daily exposure was set at 48 actuations per day.
1681563|NCT01606176|Drug|GW-1000-02|Each actuation of GW-1000-02 (100 μl) delivered a dose containing 2.5 mg delta-9-tetrahydrocannabinol (THC) and 2.5 mg cannabidiol (CBD). The maximum permitted dose of study medication was eight actuations in any three hour period (20 mg THC/20 mg CBD) and 48 actuations in any 24 hour period (120 mg THC/120 mg CBD).
1681564|NCT01606176|Drug|Placebo|Each actuation of placebo (100 μl) delivered the excipients only. The maximum permitted dose of study medication was eight actuations in any three hour period and 48 actuations in any 24 hour period.
1681565|NCT01606163|Biological|GC1102|"Description: GC1102 IV bolus injection during 10~ 30 seconds.
Amount: group1-3ml, group2-5ml, group3-8ml
Subject number: group1-8, group2-8, group3-8
Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
1681566|NCT01606163|Other|JW normal saline|"Description: Normal saline IV bolus injection through 10~ 30 seconds.
Each 3 subjects of this placebo comparator group will match with group 1,2,3 respectively. Placebo comparator subjects in each group will be treated with same condition of each group(group 1, group 2, group 3) except being administered JW normal saline.
Subject number: 9
Administration time: 1day, 2day, 3day, 4day, 5day, 6day, 7day(total: 7 times)"
1681567|NCT01606150|Drug|1% lidocaine|0.1 ml/kg of 1% lidocaine injected over lumbar puncture needle insertion site 2 minutes prior to procedure
1681568|NCT01606150|Drug|topical lidocaine|1 gram placed over lumbar puncture needle insertion point 30 minutes prior to procedure
1681569|NCT01606137|Drug|GW-1000-02|Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 μl actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.
1681574|NCT01606111|Drug|Cerebrolysin|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
1681575|NCT01606111|Drug|0.9% NaCl, saline|IV infusion, 50 ml/day, 10 days (treatment cycle will be repeated one and two months later if patient has a score of less than 7 in the extended Glasgow Outcome Scale on Day 30)
1681576|NCT01606098|Procedure|Surgery of the primary tumour|Surgical resection of the colon tumour
1681577|NCT01606098|Drug|Systemic treatment|"First line fluoropyrimidine-based chemotherapy with bevacizumab. The chemotherapy regimen is to the discretion of the local investigator, who may choose between:
5FU/LV or capecitabine or capecitabine + oxaliplatin(CAPOX)or 5FU + oxaliplatin(FOLFOX 4 or FOLFOX 7)or 5FU + irinotecan (FOLFIRI) or capecitabine + irinotecan(CAPIRI)"
1681578|NCT01606085|Behavioral|HF DM self care|Education in monitoring signs and symptoms of Heart Failure and Diabetes as well as self care instruction
1681579|NCT01606085|Behavioral|Usual Care|Educational materials on Heart Failure and diabetes at study enrollment. Full educational binder delivered at end of study.
1681580|NCT01606072|Drug|Desmopressin|20 patients in 5 groups 4 each, advancing progressively to each dose level.
1681581|NCT01606059|Drug|DW-0920|Dosage form: Extended release tablet Dosage: 2 tablets
1681582|NCT01606059|Drug|DW-0919|Dosage form: Extended release tablet Dosage: 1 tablet
1681583|NCT01606046|Device|vapocoolant spray|spray for 5 seconds from a distance of 30 cm just before the needle EMG
1681584|NCT01606046|Drug|topical anesthetic cream|application of EMLA cream on the needle electrode insertion site 60 minutes before the needle EMG
1681585|NCT01606033|Other|questionnaires|Anxiety and depression questionnaire, life quality questionnaire, adjustment strategy questionnaire, emotional regulation questionnaire, satisfaction survey
1681586|NCT01606033|Other|questionnaire|understanding of the implications of participating in a clinical trial
1681587|NCT01606020|Other|sleep deprivation|Overnight, the subjects stay in their homes (reading, watching TV, playing cards). Two experimenters will take turns to never leave them alone and avoid any micro-sleep.
1681588|NCT01606020|Other|No intervention|Overnight, the subjects stay in their homes. No intervention during this night
1681589|NCT01606007|Drug|Saxagliptin|Tablets, Oral, 5mg , Once daily, 24 weeks
1681590|NCT01606007|Drug|Metformin XR|Tablets, Oral, ≥ 1500mg/≤ 2000mg, Once daily, 24 weeks
1681591|NCT01606007|Drug|Dapagliflozin|Tablets, Oral, 10mg , Once daily, 24 weeks
1681592|NCT01606007|Drug|Placebo matching with Dapagliflozin|Tablets, Oral, 0mg, Once daily, 24 weeks
1681593|NCT01606007|Drug|Placebo matching with Saxagliptin|Tablets, Oral, 0mg, Once daily, 24 weeks
1681594|NCT01605994|Drug|BMS-933043|
1681595|NCT01605994|Drug|Placebo matching with BMS-933043|
1681596|NCT01605994|Drug|Antacid Buffer Predose Solution|
1681597|NCT01605981|Drug|AMN107|
1681598|NCT01605968|Device|BCT Silver Bandage|Activated carbon fiber impregnated with silver particles
1681599|NCT01605968|Device|Aquacel® Ag. Dressing|Antimicrobial primary dressing incorporating the unique gelling action of Hydrofiber® Technology with ionic silver for wounds that are infected or at risk of infection.
1681600|NCT01605942|Drug|Dexamethasone Drug Delivery System|Dexamethasone Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
1681601|NCT01605942|Drug|Placebo Drug Delivery System|Placebo Drug Delivery System administered into the study eye at the conclusion of cataract surgery on Day 1.
1681602|NCT01605929|Procedure|Retroclavicular Brachial Plexus Block and Catheter Insertion|A Sonosite ultrasound machine will be used to visualize the nerve and needle simultaneously. A Braun 18 g 4 inch Touhy needle with markings will be inserted into the skin and advanced toward the nerve. Once the optimal location is determined under ultrasound visualization, the local anesthetic, mepivacaine, will be injected beside the nerves. The dose of drug will be mepivacaine 1.5%, 0.5 cc/kg (with a minimum 30 cc and maximum of 50 cc.) A Braun 20 g closed tip polyamide catheter will be inserted next to the nerve and left in place to allow for additional medication to be given postoperatively.
1681603|NCT01605916|Drug|AZD6244|Tablet Oral bid
1681604|NCT01605903|Drug|Ibuprofen|Children in the ibuprofen group will be receive grape-flavored ibuprofen 100mg/5 mL. During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
1681605|NCT01605903|Drug|Acetaminophen|During the postoperative period, ibuprofen 10mg/kg (max dose 600 mg) will be dispensed Q6.
1955368|NCT03213340|Other|Flavonoid Cohort 3|- ~ 1 oz. serving consumed 30 minutes before meal
1681607|NCT01605877|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
1681608|NCT01605864|Drug|Efficacy of ceftaroline|Determining the efficacy of ceftaroline compared to other cephalosporins
1681609|NCT01605851|Device|Closure, Foramen Ovale|
1681610|NCT01605825|Drug|placebo/dalfampridine-ER|Sequence A: placebo in Period 1 and dalfampridine-ER in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
1681611|NCT01605825|Drug|dalfampridine-ER/placebo|Sequence B: dalfampridine-ER in Period 1 and placebo in Period 2. 10mg tablets, will be taken orally, twice daily approximately 12 hours apart
1681612|NCT01605799|Behavioral|IOK Killing Treatment|The IOK Killing Treatment is based on Cognitive Behavioral Therapy theory and principals and target maladaptive cognitions related to killing in war.
1681613|NCT01605799|Behavioral|Wait list control group|Participants in this group will not receive treatment; however, at the end of 6 weeks, they will be offered the option of receiving treatment.
1681614|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131 aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.
The 5μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
1681741|NCT01604811|Drug|Permixon® 160 mg|Oral administration - 160 mg twice daily.
1955371|NCT03211728|Drug|pregabalin|The intervention group receive pregabalin 150 mg 1 hour before surgery and 12 hours after initial dose.
1681615|NCT01605786|Biological|Lyophilised PEBS synthetic protein (PfPEBS)|"PfPEBS-LSP, is a synthetic polypeptide corresponding to amino acids 3112 to 3244 (131aa) from the Pf 11.1 antigen in 3D7 parasite sequence. It is presented as lyophilised product in multi-dose vials (containing 105 μg for 3 doses of 30 μg ), looking like amorphous white powder. The vaccine is produced by SYNPROSIS in France.
The 30 μg dose vaccine will be formulated extemporaneously in aluminium hydroxide adjuvant and given as a 2-dose schedule with a 28 day interval."
1681616|NCT01605786|Other|Rehydragel™ HPA|"Aluminium hydroxide adjuvant is being used as the adjuvant for the vaccine and will be used as the comparator in the control group. Vac4all is using Rehydragel™ (Manufacturer Reheis Inc.) which is a highly active protein adsorbent specially compounded for use as a fluid adjuvant. It has low oxide content and is carefully controlled for Al2O3 content and protein binding capacity. It has a lower viscosity than competing adjuvants, which makes it easier to process and handle.
Subjects in the control group will be administered a 0.5 ml injection in a 2-dose schedule at 28 days interval. Each injection will contain approximately 600 µg of Al(OH)3 per injected dose corresponding to 200 µg equivalent of Al3+, similar to the amount being administered in the vaccine group."
1681617|NCT01605773|Drug|repaglinide|Dose individually adjusted and conducted according to labeling
1681618|NCT01605773|Drug|glyburide|Dose individually adjusted and conducted according to labeling
1681619|NCT01605760|Drug|immunotherapy Staloral|Staloral (R) 300 is a sublingual solution of allergen extracts for allergen immunotherapy. During a 16 day incrementally increasing dose period, patients took daily increasing doses period, patients took 1-8 drops of the 100 IR/ml extract during the first 8 days. Then, on days 9-16, patients took 1-8 drops of the 300 IR/ml extract. Next, patients received maintenance treatment consisting of five applications of eight drops (equivalent to 0.5 mL) of 300 IR/mL extract five times a week. The mean duration of the treatment was 28.2 months (range: 3-36 months).
1681620|NCT01605747|Dietary Supplement|Culturelle|one capsule 2x per day per feeding tube
1681621|NCT01605747|Dietary Supplement|Placebo|one placebo 2x per day per feeding tube
1681622|NCT01605734|Procedure|TACE|After obtaining arterial access,a diagnostic visceral arteriogram will be performed to demonstrate arterial supply to the tumor and the presence of variant arterial anatomy.After having positioned the catheter within the artery feeding tumor,the chemoembolization mixture will be infused into th e artery until stagnant flow is observed.
1681623|NCT01605734|Drug|sorafenib combined with TACE|All patients will receive Sorafenib (800 mg/day) p.o. beginning four weeks after the first TACE and every day thereafter until patient death or premature withdrawal from study
1681624|NCT01605721|Device|XIENCE PRIMETM everolimus-eluting coronary stent|"Active prospective registration of patients receiving the following stent
: XIENCE PRIMETM"
1681625|NCT01605708|Drug|REGN846|Dose 1
1681626|NCT01605682|Dietary Supplement|Fresh berry extract.|Fresh berry extract containing 500mg, 250mg, 125mg per 60 kilos of body weight. Or placebo.
1681627|NCT01605669|Other|Tranthoracic Echocardiogram|standard measurement
1681628|NCT01605669|Device|Cardiac Ascultation Recordings with Electronic stethoscope|3M device
1681629|NCT01605656|Behavioral|Cognitive Interview|A research staff member will use a questionnaire to ask about many different health and social topics. The cognitive interview should take up to 45 minutes to complete.
1681630|NCT01605656|Behavioral|Questionnaires|"Phase I: Completion of a questionnaire about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.
Phase II: Completion of 2 questionnaires. The first questionnaire will ask about age, education level, income, and general health behaviors. This questionnaire should take about 20 minutes to complete.
The second questionnaire will ask about many different health and social topics. This questionnaire should take up to 45 minutes to complete."
1681631|NCT01605656|Behavioral|Focus Groups|"Phase I: There will be up to 8 women in each of the 5 focus groups.
Participants asked questions about personal and clinic-related factors that might make it more difficult to receive pap smear screenings. Participants also asked to discuss what might make it easier or encourage women to receive pap smear screenings. The focus group discussion should last 60-90 minutes."
1681632|NCT01605630|Behavioral|Family-based family cancer literacy intervention|family based counseling and materials provided in navajo/english including digital stories
1681633|NCT01605630|Behavioral|Control|standard of care
1681634|NCT01605617|Drug|Fesoterodine fumarate|PTNS + 4mg of fesoterodine fumarate for 12 weeks
1681635|NCT01605617|Drug|Placebo|PTNS + placebo for 12 weeks
1681636|NCT01605617|Procedure|Percutaneous Tibial Nerve Stimulation (PTNS)|PTNS is an FDA-approved procedure for the diagnosis of overactive bladder, given on a weekly basis. Participants will be given PTNS + either 4mg of fesoterodine fumarate or placebo for 12 weeks, and followed by 4 weeks of washout followed by 12 weeks of PTNS + the opposite treatment (placebo or fesoterodine fumarate).
1681637|NCT01605604|Behavioral|buddhist mind fullness|there are two group one group recieve Buddhist mindfulness group intervention 8 times second group recieve nothing
1681638|NCT01605591|Procedure|the DLT bending to the right|bending the bronchial lumen of DLT 60~90 degrees in the same side with the tracheal lumen
1681639|NCT01605591|Procedure|the DLT bending to the left|bending the bronchial lumen of DLT 60~90 degree opposed to the tracheal lumen
1681640|NCT01605578|Procedure|Biopsies|Abdominal and gluteo-femoral subcutaneous adipose tissue biopsies
1681641|NCT01605565|Procedure|A nasal brushing|A nasal brushing in every nostril
1681642|NCT01605552|Behavioral|Beating the Blues (BtB)|BtB is a widely used, empirically supported, computer-based, CBT program for depression designed for use in primary care clinics. BtB utilizes an interactive, multimedia format to deliver and eight 50-minute, weekly therapy sessions. General topics covered include identifying and challenging automatic thoughts, cognitive errors, core beliefs, and attributional styles; activity scheduling; problem solving; graded exposure; task breakdown; sleep management; and relapse prevention. In addition to session work, patients are assigned homeworks that are customized to their needs and reviewed at the start of each session. A progress report, including whether the patient is experiencing suicidal ideation, is generated at the end of each session.
1681742|NCT01604811|Drug|Tamsulosine Arrow LP|Oral administration - 0.4 mg daily.
1681743|NCT01604811|Drug|Placebo matching Permixon® 160 mg|Oral administration - twice daily.
1681744|NCT01604811|Drug|Placebo matching Tamsulosine Arrow LP|Oral administration - daily.
1684100|NCT01586975|Drug|Aspirin 81 mg|Aspirin 81mg QD
1681643|NCT01605552|Other|Usual Care|Patients randomized to usual care will be informed that they have clinically significant depressive symptoms and will be encouraged to follow-up with their primary care physicians, who will receive a letter from our team indicating that their patient has elevated depressive symptoms and was randomized to the control condition. The letter will also encourage physicians to follow-up with their patients and will provide a list of local mental health services. Like those in the intervention group, usual care patients will continue to have access to and will receive any medical and mental health services that are part of usual care in the targeted health care systems. Thus, there are no restrictions regarding the care that these patients can receive.
1681644|NCT01605539|Drug|Cannabidiol 400|Subjects in Arm CBD 400 will receive 400mg of Cannabidiol in each of the three test sessions
1681645|NCT01605539|Drug|Cannabidiol 800|Subjects in Arm CBD 800 will receive 800mg of Cannabidiol in each of the three test sessions
1681646|NCT01605539|Drug|Control|Subjects will receive a harmless, inactive pill to compare and validate the results of the other arms of the study
1681647|NCT01605526|Drug|RO5045337|Multiple escalating oral doses, Days 1-5 (1-3) of each 28-day cycle, up to 6 cycles
1681648|NCT01605526|Drug|doxorubicin|60 mg/m2 (75 mg/m2, 50 mg/m2) iv on Day 1 of each 28-day cycle, up to 6 cycles
1681649|NCT01605513|Drug|interferon|PEG-IFN-SA (new interferon) was injected subcutaneously one times per week for 12 times.
1681650|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
1681651|NCT01605487|Drug|Rupatadine|Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days
1681652|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days
1681653|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days,then 14 days washout period; Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
1681654|NCT01605487|Drug|Rupatadine|Placebo 4 Tab once daily during 7 days, then 14 days washout period; Rupatadine in Tab. 10mg, 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days
1681655|NCT01605487|Drug|Rupatadine|Rupatadine in Tab. 10mg: 4 Tab. once daily during 7 days, then 14 days washout period; Rupatadine in Tab 10mg: 4 Tab.(2 Tab. of Rupatadine + 2 Tab. of Placebo) once daily during 7 days, then 14 days washout period; Placebo 4 Tab once daily during 7 days
1681656|NCT01605474|Other|Patient discharged home after foley bulb placement.|The patient will be discharged home after fetal status is evaluated and noted to be reassuring. A 16 French foley bulb insufflated with 30 cc of normal saline will be placed and secured to the patient's inner thigh.
1681657|NCT01605474|Other|Inpatient|The patients will not be discharged home after assessment and placement of the foley catheter.
1681658|NCT01605461|Drug|BI 207127 NA|Single oral solution dose of BI 207127 NA combined with [14C]-BI 207127 NA
1681659|NCT01605448|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 weekly classes of meditation/yoga
1955372|NCT03211728|Drug|placebo|The placebo group receive placebo 150 mg 1 hour before surgery and 12 hours after initial dose.
1681661|NCT01605422|Other|Dietary pulses|beans, peas, chickpeas, lentils in whole or flour form
1681662|NCT01605409|Procedure|Emergency cardiopulmonary bypass under ongoing CPR|"Emergency cardiopulmonary bypass under ongoing CPR
Emergency cardiopulmonary bypass (ECMO: lifebridge (Sorin®) or cardiohelp(Maquet®) will be initiated percutaneously ultrasound guided, during CPR efforts at the Emergency department.
Cannulae and tubing in use will be heparin coated. ECMO flow will be set to 70ml/kgBW/min. Anticoagulation will achieved with unfractionated heparin and monitored using ACT."
1681663|NCT01605409|Procedure|Standard ACLS|"Standard ACLS Standard ACLS provided by EMS personnel according to current guidelines of the European resuscitation council.
Transportation:
Transport will be initiated as soon as the patient achieves ROSC in the field and transportation is feasible. All patients will be admitted to the ED at the Vienna general hospital.
Standard Post resuscitation Management:
After admission to the ED post resuscitation care and standardized intensive care treatment will be provided according to Utstein protocol and current standards for good clinical practice and according to ILCOR recommendations. A crossover to the ECPB group is possible, if indicated by good clinical practice. If so, it will be counted as treatment failure in the standard ACLS group.
If no ROSC can be achieved and the patient dies in the field pathological results will be obtained if feasible."
1681664|NCT01605396|Drug|Ridaforolimus|Participants receiving 10 mg PO (orally) QD (daily) of ridaforolimus in the triplet and 30 mg in the doublet may escalate to 20 mg QDx5 and 40 mg QDx5 respectively in the absence of grade 2 or above stomatitis in the initial cycle of treatment.
1681665|NCT01605396|Drug|Dalotuzumab|"10 mg/kg/week intravenously.
Note: Based upon evaluation of additional data the sponsor may adjust the starting dose of dalotuzumab, which may be changed to 7.5 mg/kg/week."
1681666|NCT01605396|Drug|Exemestane|25 mg PO QD
1681667|NCT01605383|Biological|XCEL-MT-OSTEO-ALPHA|Core decompression plus XCEL-MT-OSTEO-ALPHA
1681668|NCT01605383|Procedure|Standard treatment|Isolated core decompression
1681669|NCT01605370|Drug|Nebivolol|Nebivolol 2.5 mg once daily
1681670|NCT01605370|Drug|Metoprolol succinate|Metoprolol succinate 50 mg once daily
1681745|NCT01604798|Other|Serum proteomics|magnetic bead-based fractionation coupled with matrix-assisted laser desorption/ionization-time-of-flight mass spectrometry
1681746|NCT01604785|Drug|Propofol|Sub-anesthetic dose propofol: 0.25 mg/kg IV push to maximum dose of 30mg q5 minutes to a maximum of 5 doses
1681747|NCT01604785|Drug|Standard Treatment|Ketorolac, Diphenhydramine and Metoclopramide
1731908|NCT00039039|Drug|cisplatin|
1681671|NCT01605357|Drug|Induced, sustained hypernatremia using hypertonic saline|"Patients in the experimental arm will receive hypertonic saline to target a serum sodium goal of 150 - 160 mmol/L. All hypertonic saline will be administered intravenously.
Loading phase: Upon enrollment 23.4 % hypertonic saline (volume 20 cc) will be administered via a central venous catheter. A continuous infusion of 3% hypertonic saline will be administered at a rate of 30 cc per hour and titrated every six hours to target a serum sodium goal of 150-160 mmol/L.
Maintenance phase: Titrate serum sodium to 150-160 mmol/L using continuous 3% hypertonic saline infusion.
Discontinuation phase: After 5 days of completed therapy, begin to wean 3% hypertonic saline rate by 10cc every 6 hours. Discontinue hypertonic saline infusion after infusing at a rate of 20cc an hour for 6 hours.
Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines"
1681672|NCT01605357|Drug|Standard of care (hypertonic saline and mannitol; serum sodium)|Bolus dosing of hypertonic saline and mannitol are to be administered at the discretion of the provider to treat elevated intracranial pressure based on practice guidelines. Hyponatremia ( serum sodium < 135 mmol/L) is to be corrected at the discretion of the provider.
1681673|NCT01605344|Drug|FOLFIRI.|All patients will receive FOLFIRI infusion on day 1 and day 15.
1681674|NCT01605344|Drug|Atorvastatin|A subjects will receive atorvastatin 20 mg orally once daily given for two weeks starting on Day -14 during PERIOD ONE. ARM A will then receive no statin during PERIOD TWO. ARM B subjects will receive no atorvastatin during PERIOD ONE. ARM B subjects will receive atorvastatin 20 mg orally once daily for two weeks during PERIOD TWO (starting on Day 2). One cycle = 28 days.
1681675|NCT01605331|Drug|sustained-release recombinant human GH (SR-rhGH)|
1681676|NCT01605318|Drug|IMMU-130|This is a Phase I/II, open-label study of IMMU-130 administered in 21-day treatment cycles, once or twice weekly for 2 consecutive weeks followed by one week of rest to patients with metastatic colorectal cancer who have been previously treated with at least one prior irinotecan-containing regimen.
1681677|NCT01605305|Drug|FOLFOX6|OXA 100mg/m2 ivgtt 2h d1 LV 400mg/m2 ivgtt 2h d1 5FU 400mg/m2 iv. d1 5FU 2.4g/m2 civ 46h
1681678|NCT01605292|Procedure|Ultrasound guidance|Real time ultrasound guidance using ultrasound probe covered in sterile plastic, visualizing radial artery while needle passage attempted.
1681679|NCT01605292|Procedure|Palpation|Manual palpation for localizing radial artery for inserting needle.
1681680|NCT01605279|Drug|Dobutamine|Patients with low SVCF in the first 12 hours of life will be randomized to receive Dobutamine or Placebo. First dose: 5 microg/k/min; second dose: 10 microg/k/min; third dose: 15 microg/k/min; forth dose: 20 microg/k/min. Dobutamine concentration will be prepared in a 20 ml syringe and the dose will be adjusted so each 0.1 ml/kg per hour increase in flow rate would deliver the corresponding step-increase in the drug infusion dose. Dose increments will be 5, 10, 15, 20 microg/kg per minute The study drug was increased in a stepwise manner every 30 minutes until the optimal SVCF was attained and maintained for 60 minutes (SVCF-OP). Treatment duration: 24 hours of postnatal age, maintaining the infusion rate which achieves the SVCF-OP.
1681681|NCT01605279|Drug|Placebo|Patients with low SVCF in the first 12 hours of life will be randomised to receive Dobutamine or Placebo (dextrose 5% in water, D5W, as Placebo)
1681684|NCT01605240|Drug|Acetaminophen and Ibuprofen|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and ibuprofen (10mg/kg) at regular dosing intervals.
1681685|NCT01605240|Drug|Acetaminophen and Codeine|After their fracture is reduced, these patients will receive acetaminophen (15mg/kg) and codeine (1mg/kg) at regular dosing intervals.
1681688|NCT01605201|Biological|Tissue engineered cartilage graft|Autologous nasal chondrocytes expanded in vitro and cultured in a collagen type I//III scaffold
1681689|NCT01605162|Drug|TMZ|TMZ (at 150 mg/m2) will be administered orally according to the instructions on the product label, on Days 1 through 5 of the same 28-day cycle as E7016. TMZ capsules should be taken immediately after E7016. No food or drink intake, except water, will be allowed for 2 hours before or after administration.
1681690|NCT01605162|Drug|E7016|"E7016 capsules will be administered in the morning after at least a 2-hour fast. Subjects will be instructed not to eat or drink anything except water in the 2 hours prior and 2 hours after drug administration. Subjects will record the time at which they ate.
For the Single-Dose PK Period, 320 mg of E7016 will be administered once on Day -2. For the Multiple-Dose Treatment Cycle(s), 320 mg E7016 will be administered QD on Days 1 through 7 of each 28-day cycle."
1681691|NCT01605136|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
1681692|NCT01605136|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months
1681693|NCT01605110|Drug|Hyperbaric oxygen treatment|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of 100% oxygen at 2.0 atmospheres absolute (ATA) inside mono-place chambers for 90 minutes (at depth).
1681694|NCT01605110|Drug|Air sham|Patients that volunteer to participate in this study will be exposed to two treatments (one before surgery; one after surgery) of medical grade air (21%oxygen; sham) at 1.2 ATA inside mono-place chambers for 90 minutes.
1681695|NCT01605097|Radiation|HDR interstitial brachytherapy|2 treatments of 1000 cGy will be delivered to the entire prostate volume while escalating the dose to the visible disease to 1250 cGy
1681696|NCT01605084|Drug|Atazanavir|Capsule, Oral, 300 mg, Once daily (QD), 48 weeks
1681697|NCT01605084|Drug|Darunavir|Oral, Two 400 mg Tablets, Once daily (QD), 48 weeks
1681698|NCT01605084|Drug|Ritonavir|Tablet, Oral, 100 mg, Once daily (QD), 48 weeks
1681748|NCT01604772|Drug|Akt Inhibitor MK2206|Given PO
1681749|NCT01604772|Other|Laboratory Biomarker Analysis|Correlative studies
1681750|NCT01604759|Device|Polarized Reflectance Spectroscopy System|Fiber optic probe designed to measure polarized reflectance spectroscopy will be used to gather data from all study participants.
1681699|NCT01605084|Drug|Optimized NRTI backbone|"tablet/capsule, Noninvestigational products i.e. NRTI backbone will be administered according to their respective package inserts for 48 weeks
NRTI backbone are:
- Abacavir (300 mg), Tenofovir (300 mg), Didanosine (250 mg or 400 mg), Stavudine (30 mg or 40 mg), Emtricitabine (200 mg), Lamivudine (300 mg), Zidovudine (300 mg), EPZICOM® (600 mg Ziagen® + 300 mg Lamivudine), COMBIVIR® (150 mg Lamivudine + 300 mg Zidovudine)
The following NRTI combinations are prohibited in this study:
Didanosine + Stavudine
Zidovudine + Stavudine
Lamivudine + Emtricitabine"
1681700|NCT01605071|Drug|Estradiol|"1 week of transdermal estradiol (0.15mg)
1 week of transdermal placebo"
1681701|NCT01605045|Other|Fluoroscopy-save group|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
1681702|NCT01605045|Other|Standard technique|Coronary anatomy visualized under fluoroscopy, documented using the fluoroscopy-save function, and further visualized using cinematography only when higher quality is necessary (fluoroscopy-save technique) versus Coronary anatomy visualized and documented using cinematography alone (standard technique)
1681703|NCT01605032|Drug|Busulfan|Given IV
1681704|NCT01605032|Drug|Melphalan|Given IV
1681705|NCT01605032|Drug|Bortezomib|Given IV
1681706|NCT01605032|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
1681707|NCT01605032|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
1681708|NCT01605032|Other|Laboratory Biomarker Analysis|Correlative studies
1681709|NCT01605032|Other|Pharmacological Study|Correlative studies
1681712|NCT01605006|Device|NeuRx Diaphragm Pacing System (DPS)|The NeuRx DPS is a percutaneous, intramuscular, diaphragm stimulation system which is implanted using standard laparoscopic surgical techniques in an outpatient procedure. The implanted intramuscular diaphragm electrodes are connected to a four channel external stimulator at a percutaneous exit site. DPS is designed to help ALS patients breathe by providing conditioning stimulation of the diaphragm muscles. Recommended frequency of diaphragm conditioning is at least 3 times per day with each session lasting at least 30 minutes. Patients may find it helpful to use the DPS for longer periods to help with breathing. DPS may be used at the same time as non-invasive ventilation. Patents may also sleep with the DPS to assist with breathing difficulties at night.
1681713|NCT01604993|Other|Spinach soup|556 g of high Nitrate spinach soup that is orally consumed as a single dose for 7 days
1681714|NCT01604993|Other|Asparagus soup|556 grams of low nitrate asparagus soup that is orally consumed for a period of 7 days as a single does
1681715|NCT01604980|Dietary Supplement|Protein intake.|protein intakes will be varied at 0.2, 0.5, 0.7, 0.9, 1.0, 1.2, 1.5, 1.8 and 2.0g/kg/day
1681716|NCT01604954|Behavioral|Nutrient-label|A label indicating that the lunch they will eat is low in saturated fat and free from trans fat will be posted on the containers.
1681717|NCT01604954|Behavioral|Calorie-label|"A label indicating the amount of calories for a fixed serving plus information about daily caloric requirement (The recommended daily caloric intake for an average adult is 2000 calories) will be posted on the containers."
1681718|NCT01604954|Behavioral|No label|Lunches will be free from labels, so that no nutritional information will be provided to the participants(control group).
1681719|NCT01604941|Drug|SPD602|50 mg/kg/day orally twice daily for 24 weeks
1681720|NCT01604928|Drug|YM178|Oral
1681721|NCT01604928|Drug|tolterodine|Oral
1681722|NCT01604928|Drug|Placebo|Oral
1681723|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Normal saline 0.02mL/Kg added to ropivacaine 0.15% 1.5ml/kg was administered to Group R.
1681724|NCT01604915|Procedure|Caudal block|After inhalation induction of general anesthesia, caudal block was applied. Patients were randomly assigned in two groups. Dexamethasone 0.1mg/kg added to ropivacaine 0.15% 1.5ml/kg to Group DR.
1681725|NCT01604902|Other|4 mm punch biopsies|4 mm punch-biopsies from lesional and non-lesional psoriatic skin at day 0 and up to four times after treatment at the following days: 4, 14, 28 or 84.
1681726|NCT01604889|Drug|INCB024360|
1681727|NCT01604889|Drug|Placebo|Placebo
1681728|NCT01604889|Drug|ipilimumab|ipilimumab 3 mg/kg IV
1681729|NCT01604889|Drug|ipilimumab|Doses to be determined following the completion of Phase I of the study
1681730|NCT01604876|Device|light therapy 30 min morning and evening, three months|"Light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) [dimensions 50.2 x 32 x 15.4 cm] equipped with 3x36W Fluorescent bulbs (Osram 954), reflectors and a diffuser screen providing 10,000 lux at 30 cm eye level distance.
therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
1681731|NCT01604876|Device|light therapy 30 min morning and evening, three months|"200 lux light from a commercially available table-mounted lightbox (Brazil, Lumie, Cambridge UK) [dimensions 50.2 x 32 x 15.4 cm] To lower the intensity to 200 lux the bulbs are enwrapped with one layer of L299s neutral density filter (LEE Filters, Andover, UK).
Therapy consists of 30 minutes light exposure in the morning and evening during 3 months."
1681732|NCT01604863|Drug|HGS1036 + Paclitaxel + Carboplatin|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle. Paclitaxel 175 mg/m2 or 200 mg/m2, IV and carboplatin AUC 6.0 mg∙min/mL, IV every 3 weeks on Day 1 of each 21-day cycle.
1681733|NCT01604863|Drug|HGS1036 + Cisplatin + Etoposide|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and cisplatin 60-80 mg/m2, IV on Day 1 and etoposide 100-120 mg/m2, IV on Days 1, 2, and 3 of each 21 day cycle.
1681734|NCT01604863|Drug|HGS1036 + Docetaxel|HGS1036 10 or 20 mg/kg, IV once weekly in each 21-day cycle and docetaxel 75 mg/m2, IV on Day 1 of each 21-day cycle.
1681735|NCT01604850|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet was administered orally once daily.
1681736|NCT01604850|Drug|RBV|Ribavirin (RBV) tablets was administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
1681737|NCT01604850|Drug|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
1681738|NCT01604850|Drug|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
1681751|NCT01604746|Biological|Ross River Virus (RRV) Vaccine|Not applicable, no vaccine will be administered in this study. The RRV vaccine was administered in the precursor study.
1681752|NCT01604707|Other|Medical Yoga|Patients were randomly allocated to a control group receiving standard care, or a yoga group treated with Medical yoga for 1 hour, once a week, over a 12-week period in addition to the standard care.
1681753|NCT01604694|Procedure|TAP Block|An Ultra Sound-guided TAP block is performed after induction of general anesthesia prior to surgical incision. The syringes containing either saline 20 ml (placebo group) or levobupivacaine 20 ml are prepared by the hospital pharmacy under aseptic conditions.
1681754|NCT01604681|Dietary Supplement|Placebo|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
1681755|NCT01604681|Dietary Supplement|Flaxseed Oil|6 capsules per day, thirty minutes before lunch and dinner, eating 3 capsules (3 g) at a time.
1681756|NCT01604655|Procedure|Coronary CT Angiography|CCTA
1681757|NCT01604655|Procedure|Stress Test|Stress Test
1681758|NCT01604642|Other|blood tests and muscular biopsies|blood tests and muscular biopsies
1681759|NCT01604629|Drug|Reduced doses of anti-TNF|Standardized schedule of reduced doses of anti-TNF, reached either through the interval spacing of administration (adalimumab, etanercept or golimumab) or reducing doses of infliximab
1681760|NCT01604629|Drug|Stable doses of anti-TNF|Stable doses of anti-TNF according clinical practice based on approved summary product characteristics (SPC) and SER consensus about biological therapies in Ankylosing Spondylitis and other Spondylarthropathies, except Psoriatic Arthritis
1681761|NCT01604590|Radiation|Magnetic Resonance Imaging (MRI)|Magnetic Resonance Imaging (MRI) will be used to compare bevacizumab to the images of vessel and tumor structure.
1681762|NCT01604577|Behavioral|interactive educational intervention|Use of a concise, literacy-sensitive, physician-led, educational interaction with the patient.
1681763|NCT01604525|Behavioral|Tailored Web|The tailored website included 6 weeks of content about making healthy lifestyle choices, eating breakfast, exercising, reducing drinking and quitting smoking. Each week, participants were asked to check in with their past week's behavior, and to set goals for the next week's check-in.
1681764|NCT01604525|Behavioral|Peer Coaching|Participants chose a peer coach, who reviewed the participant's check-in data and goals, and provided personalized feedback to help the participant reach those goals. Interaction took place via personalized videos recorded each week and uploaded to a participant's web profile, and through pro-active phone calls to the participants each week.
1681765|NCT01604525|Other|Untailored Web|Content about lifestyle issues (music, travel, dating) was created for participants assigned to the control group. There was new web content each week for 6 weeks.
1681766|NCT01604512|Other|MRI perfusion and PET/CT scans|The MRI perfusion and PET/CT scans will be obtained within 12 weeks of each other. These scans are part of the standard of care for patients with brain tumors and uncertain tumor response or progression after treatment. Although every effort will be made to perform both MRI perfusion and PET/CT on the same day or during the same week, some patients may experience longer intervals between scans due to scheduling conflicts. The disease in question (radiation injury vs. tumor progression) may change slightly during this interval (e.g., the lesion may grow or shrink slightly), but no large changes are expected between the two scans. The patients may continue existing treatments in the interval between scans (e.g., steroids, chemotherapy), but the two scans must be performed before any change or new treatment occurs. Fusion images of MRI and PET/CT will not be reviewed by the neuroradiologist interpreting the MRI perfusion nor the nuclear medicine radiologist interpreting the PET/CT.
1681767|NCT01604499|Behavioral|Feedback letters|"Subjects receive feedback letters about the proportion of green, yellow, and red purchases in the cafeteria per month with comparisons to all employees and to the healthiest employees eaters"
1681768|NCT01604499|Behavioral|Feedback plus incentives|Subjects receive feedback letters plus small incentives to increase healthy (green-labeled) purchases in the next month
1681769|NCT01604460|Procedure|Resuscitation with torso plastic bag|Infant will be placed within 10 minutes of his birth into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. After his/her head is dried, the infant will receive a cloth cap. Resuscitation will occur in the delivery room and the infant will be wrapped in a blanket and taken to the nursery where he/she will remain in the plastic bag until 1 hour after birth.
1681770|NCT01604460|Procedure|Resuscitation-no plastic bag|Infant will be immediately dried and resuscitated in the delivery room per standard of care. The infant will be wrapped in a blanket and will receive a cloth hat before being taken to the nursery.
1681771|NCT01604447|Procedure|Hypothermia prevention with plastic bag|Upon removal from the incubator, infant will be placed into a plastic bag to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket and receive a cloth hat. The bag will be changed when soiled and the infant will remain in the bag for 72 hours or until discharge, whichever comes first. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
1681772|NCT01604447|Procedure|Hypothermia prevention without plastic bag|Upon removal from incubator, the infant will be wrapped in a blanket and receive a cloth hat, according to standard bundling practices. The infant's temperature will be monitored for 72 hours or until discharge, whichever comes first.
1681773|NCT01604434|Procedure|Incubator-torso bag|While being placed into an incubator, infant will be placed into a plastic bag to his/her axillae and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. The infant will be wrapped in a blanket over the plastic bag and will receive a cloth hat. He/she will remain in the bag for one hour.
1681774|NCT01604434|Procedure|Incubator-no plastic bag|Infant will be placed in the incubator, wrapped in a blanket, with a cloth hat, according to standard protocol.
1681775|NCT01604421|Procedure|Thermoregulation without plastic bag|One hour after birth, a blanket will be wrapped around the infant and he/she will receive a wool hat, according to standard practices. The infant's axillary temperature will be monitored for 24 hours or until discharge, whichever comes first.
1681893|NCT01603342|Drug|clopidogrel|Following a baseline punch biopsy, all subjects will then receive oral clopidogrel (Plavix®) over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy (B1) will be performed
1684101|NCT01586975|Drug|Aspirin >300 mg|Aspirin >300 mg QD
1681776|NCT01604421|Procedure|Thermoregulation with torso-covering plastic bag|One hour after birth, the infant will be placed into a plastic bag up to his/her axillae, and the bag will be folded and taped to itself to prevent it from covering the infant's nose or mouth. A blanket will be wrapped around the infant, and he/she will receive a wool hat. The infant will remain in the bag, which will be changed when soiled, for 24 hours or until discharge, whichever occurs first.
1681777|NCT01604408|Biological|LY2495655|Administered SQ
1681778|NCT01604408|Drug|Placebo|Administered SQ
1681779|NCT01604382|Drug|General Anesthesia|General Anesthesia as described above
1681780|NCT01604382|Drug|Neuraxial anesthesia|Neuraxial anesthesia as described above
1681781|NCT01604369|Procedure|Medtronic Freezor Max Cardiac Cryoablation Catheter|Cryoablation is performed using a sequential application technique point-by-point from the tricuspid annulus to the inferior vena cava. Ablation is performed at a target temperature of -80 ºC. Each application will last for 240 seconds.
1681782|NCT01604356|Procedure|Electro-acupuncture|Ten treatment sessions at our center during a two week period (5 sessions per week). Each session will last approximately 30 minutes. The intervention will involve the placement of acupuncture needles in a standard set of points across all patients, located on the head, around the eyes, on the abdomen, on the hands, feet, arms and legs. An electro-acupuncture device [Transcutaneous electrical nerve stimulator (TENS) unit by Lhasa OMS Inc.; model AWQ-104L] and will be used on four of the acupuncture points (two per session) located on the forehead, and side of the face/temple.
1681788|NCT01604330|Drug|Baclofen|Baclofen will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams three times a day; then the dose of baclofen will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
1681789|NCT01604330|Drug|Placebo|Sugar pill will be administered orally for a maximum of 52 consecutive weeks. For the first 3 days, patients will receive sugar pill in a dose of 5 milligrams three times a day; then the dose of sugar pill will be increased to a maximum of 300 milligrams a day. In case of intolerance, dosage can be decreased.
1681790|NCT01604317|Procedure|Torso bag during resuscitation|Infant's extremities and torso will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
1681791|NCT01604317|Procedure|Partial head covering plastic bag during resuscitation|Infant's torso, extremities, and portion of the head (face will be exposed) will be placed in a plastic bag during resuscitation after birth and maintained for 1 hour after birth.
1681792|NCT01604304|Procedure|flexible ureteroscopy|Flexible ureteroscopy will be use for 120 min max to treat renal stone. Laser, access sheath, baskets can be use to perform the technique.
1681793|NCT01604304|Procedure|extracorporeal shockwave lithotripsy|The lithotriptor is use with 1,1 Hz frequency and stop when patient get 1000 joules of energy or if there is a problem with tolerance of this treatment or if stone is broken
1681794|NCT01604278|Drug|NVA237 50 µg and indacaterol 150 µg|NVA237 50 µg and indacaterol 150 µg supplied as blistered capsules for inhalation.
1681795|NCT01604278|Drug|Placebo to NVA237 and indacaterol 150 µg|Placebo to NVA237 and indacaterol 150 µg supplied as blistered capsules for inhalation.
1681796|NCT01604265|Drug|Placebo|Contained peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl. The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
1681797|NCT01604265|Drug|Sativex|Contained delta-9-tetrahydrocannabinol (THC), (25 mg/ml):cannabidiol (CBD), (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each actuation delivered 100 μl (THC 2.5 mg and CBD 2.5 mg). The maximum permitted dose of study medication was eight actuations in any three hour period, and 48 actuations in any 24 hour period.
1681798|NCT01604239|Drug|Shinbaro Capsule|600mg twice a day (b.i.d) oral herbal medicine
1681799|NCT01604213|Drug|Metformin plus vildagliptin|Oral Metformin 850mg and vildagliptin 50mg, qd initially, up-titrated to BID if clinically necessary
1681800|NCT01604213|Drug|Metformin only|Oral Metformin 850mg QD, up-titrated to 850mg TID is clinically indicated
1681801|NCT01604200|Behavioral|focus group|key informant review
1681804|NCT01604174|Other|Interactive Virtual Telerehabilitation (IVT)|Rehabilitation after arthroplasty of knee using IVT
1681805|NCT01604174|Other|Standard care rehabilitation|Standard care rehabilitation after total knee arthroplasty
1681806|NCT01604161|Drug|somatropin|Collection of safety and efficacy data in connection with use of somatropin (Norditropin®) in daily clinical practice.
1681807|NCT01604135|Device|Corneal Collagen Crosslinking|Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
1681808|NCT01604122|Other|No drug|No drug.
1681809|NCT01604122|Other|No drug|No drug.
1681810|NCT01604109|Drug|10 % w/v CPP-ACP paste|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch
1681811|NCT01604109|Drug|the paste without CPP-ACP|Apply once a day at school by school teacher, following fluoride toothbrushing after lunch.
1684163|NCT01586468|Drug|WF10|0.5 mg/kg B.W.
1681812|NCT01604096|Other|Multifaceted information campaign|"Following is the description of the multifaceted intervention:
brochures targeted at the general population and available in general practices, pharmacies, local health services and on the web (also translated in eight languages)
posters (same distribution as brochures)
short videos transmitted in local TVs, websites of Local Health Authorities and in video terminals in some pharmacies
radio-spots transmitted in local radio stations
advertisements in local newspapers
banners on websites of local newspapers
newsletter on antibiotic resistance in Emilia- Romagna, available to physicians and pharmacists
training courses in counselling strategies, directed to a subgroup of GPs and paediatricians"
1681813|NCT01604057|Drug|ZT-034 Low Dose Nasal Spray|Nasal Spray
1681814|NCT01604057|Drug|ZT-034 Mid Dose Nasal Spray|Nasal Spray
1681815|NCT01604057|Drug|ZT-034 High Dose Nasal Spray|Nasal Spray
1681816|NCT01604057|Drug|Teriparatide|20 mcg subcutaneous daily
1681817|NCT01604057|Drug|Placebo|Nasal Spray
1681818|NCT01604044|Drug|Meropur 150 a day|one subcutaneous injection a day
1681819|NCT01604044|Drug|Gonal-f 150 plus Luveris 150|one subcutaneous injection a day
1681820|NCT01604031|Biological|B-CLL Vaccine|Patients will receive a fixed dose (2X10^7) of IL-2 secreting B-cells together with (2X10^7) of hCD40L expressing B-cells. Patients will receive doses of vaccine at 2 week intervals for 5 doses. Barring adverse events, an additional 11 doses of vaccine will be given, at 4 weekly intervals beginning on week 12 for a total period of one year or 16 vaccinations in total.
1681821|NCT01604031|Drug|Lenalidomide|Subjects will begin lenalidomide 5 mg orally daily on day zero and will continue daily dosing until week 60 (4 weeks after the final dose of vaccine).
1681822|NCT01604005|Radiation|Prophylactic Irradiation of Tracts (PIT)|21 Gy in 3 fractions
1681823|NCT01603979|Biological|AV-203|The antibody AV-203 is a humanized immunoglobulin G1/kappa (IgG1/κ) monoclonal antibody that targets the receptor tyrosine kinase (RTK) ERBB3 and inhibits ERBB3 activities. AV-203 will be administered as a 60 to 75-minute IV infusion once every 2 weeks until disease progression or unacceptable toxicity.
1681824|NCT01603940|Drug|Benazepril|Patients in this group will receive 20 mg of benazepril per day, orally, during 12 weeks.
1681825|NCT01603940|Drug|Losartan|Patients in this group will receive 100 mg of losartan per day, orally, during 12 weeks.
1681826|NCT01603927|Device|Narrow band imaging for 'optical diagnosis' of colonic polyps (Olympus).|Colonoscopists will narrow band imaging to provide an 'optical diagnosis' for colonic polyps found during routine colonoscopies performed for the diagnosis of symptoms or asymptomatic screening.
1681827|NCT01603914|Device|central venous catheter replacement (Arrowgard Blue plus Quad-Lumen CVC )|"Routine practices for the type of catheter of each participating Unit will be respected. Multilumen central venous catheter will be used (i.e Arrowgard Blue plus Quad-Lumen CVC set). Impregnated Catheter with antiseptics or with antibiotics will be allowed.The anatomical locations selected for the replacement of central venous catheter are: subclavian vein, internal jugular vein, femoral vein and the change will be addressed according to the randomization.
The dressing and maintenance of the catheter will be guided according with the Guides of The Centers for Disease Control and Prevention (CDCs) and a check-in lists will be fill in for each catheter.
A pre-defined stratified analysis will be performed according with: type of catheter, participating unit, and insertion site."
1681828|NCT01603901|Device|Regulated Negative Pressure-Assisted Wound Therapy Device|Negative pressure will be applied in the usual way that is normally applied in our Medical Center
1681829|NCT01603888|Other|no intervention|
1681830|NCT01603875|Biological|New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).|new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
1681831|NCT01603862|Procedure|ThinkingFit programme|Combined physical, cognitive and social stimulation activties.
1681832|NCT01603849|Radiation|Prophylactic Cranial Irradiation|Patients allocated to this arm will received treatment with whole brain radiotherapy 25 Gy in 10 fractions.
1681834|NCT01603810|Other|OCT|Optical coherence tomography of periocular basal cell carcinoma
1681835|NCT01603797|Behavioral|Guided internet-delivered acceptance and commitment therapy|The treatment program consisted of seven sections and was based on ACT.The first part was about creative hopelessness and was followed in the next section by an introduction to willingness and to the process of acceptance of pain. Information and assignments about committed action and values were also part of the treatment program. Mindfulness exercises were a regular feature in the program. The last part was about how to maintain learned strategies but also an evaluation of the program.
1681836|NCT01603784|Behavioral|Intensive Exercise|"Standardized aerobic training program that is individualized to each participant's fitness level, and supervised by a certified exercise specialist. Participants attend 3 training sessions per week for 6 months. The session begins with a 10-15 minute warm-up. Participants then exercise on a treadmill or stationary bike, followed by cool-down activities. Heart rate and rating of perceived exertion are used to evaluate exercise intensity. Participants begin at ~30 min/day 60-70% of HR max and/or an equivalent level of RPE, and progress to 45-50 minutes at 75-85% for HR max."
1681837|NCT01603784|Behavioral|Home Exercise|Exercise program consisting of stretching, range of motion, and simple yoga exercises designed to improve flexibility. Each participant has a 60-minute sessions with an exercise trainer to teach them how to perform the exercises correctly. They are also given diagrams illustrating the exercises, along with written instructions. They are instructed to perform these exercises at home at least 3 times per week for 30 - 45 minutes. They also go to the recreational center monthly to meet with an exercise trainer to ensure that they are doing the exercises correctly. Participants record their exercise activities on a calendar for the 6 months.
1681894|NCT01603342|Drug|placebo|Following a baseline punch biopsy, all subjects will then receive oral placebo over a period of approximately 3 to 4 days. Once the subject has successfully had 3 days of clopidogrel dosing, a second biopsy will be performed
1681838|NCT01603784|Behavioral|Cognitive Training|Computer-based training that is is administered 3 days per week for 8 weeks during months 5 and 6. The training program focuses on 3 types of cognitive processes: task coordination, prospective memory, and retrospective memory retrieval. One day of the week is devoted to each of the three cognitive processes. Some training sessions include a homework assignment for application and practice of the target cognitive processes in everyday activities.
1681839|NCT01603784|Behavioral|Health Education|"Weekly educational sessions are administered during months 5 and 6, conducted at the recreational center by research staff. Sessions last 1 hour, and cover health and other topics unrelated to exercise or cognition, such as nutrition, hearing loss, stroke, and saving energy in one's home. At the completion of each session, participants are given a homework assignment."
1681840|NCT01603771|Other|Blood Oxygen Level Dependent (BOLD) functional magnetic imaging (fMRI)|All participants complete MRI scans at baseline and at the end of month 6. Scanning sessions last approximately 30 minutes each and consist of two components: (1) High resolution T1-weighted MPRAGE anatomic images to provide detailed anatomy and maximum gray-white matter contrast for images and to allow any estimate of regional or whole-brain volume, and (2) Resting BOLD functional images to allow assessment of the functional connectivity in large scale networks.
1681841|NCT01603758|Drug|Ezetimibe|Ezetimibe 10 mg/day or placebo will be given for 6 weeks
1681842|NCT01603745|Drug|Zoely|1 pill every day
1681843|NCT01603745|Drug|Yasmin|1 pill every day
1681844|NCT01603719|Dietary Supplement|new infant formula with prebiotics and beta-palmitate|experimental infant formula as sole source of nutrition over first 12 weeks of life
1681846|NCT01603693|Device|Bio-Oss (by Geistlich)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
1681847|NCT01603693|Device|BondBone (by Augma)|Guided Bone Regeneration (GBR) will be done with no changes from the common (Dahlin 1988). Patients will be given local anasthesia, full thickness mucoperiosteal flap will be raised to expose the bone area that needs augmentation, bone substitute will be placed over the bony crater and covered with a collagen membrane (Bio-Gide, geistlich, FDA and CE approved). Mucoperiosteal flap will be sutured and patients will be instructed to a check-up routine as accepted after this kind of procedure.
1681848|NCT01603680|Procedure|Circumferential spread of the mepivacaine ultrasonographic guided around the median and ulnar nerves at the elbow|Homogeneous spread of 6 ml of mepivacaine 1% around the median and ulnar nerves in each one using several needle passes and active hydrodissection
1681849|NCT01603680|Procedure|Non circumferential spread in ultrasound-guided median and ulnar nerves block|Asymmetric spread of 6 ml of mepivacaine 1% in contact with median and ulnar nerves block in each one, using only one needle pass
1681850|NCT01603667|Drug|PG2|"STUDY DRUG DOSAGE:IV infusion of PG2 Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg PG2 Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of PG2 Injection 500 mg will be repeated daily for the subsequent 2 days.
ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
1681851|NCT01603667|Drug|placebo|"STUDY DRUG DOSAGE: IV infusion of Placebo Injection 500 mg in 500 ml Normal Saline at a rate of 200 mg/hr with infusion started within 3-6 hrs of stroke onset and infusion of a total of 500 mg Placebo Injection in 500 ml Normal Saline or 500 ml Normal Saline will be completed within 2.5~3.5 hrs. The same dose of Placebo Injection 500 mg will be repeated daily for the subsequent 2 days.
ROUTE OF ADMINISTRATION:Continuous IV infusion via a calibrated infusion pump DURATION FOR EACH PATIENT:90 days"
1681852|NCT01603654|Drug|sodium picosulphate magnesium citrate|Use of the product in colon cleansing before colonoscopy. Two sachets each containing 10 mg of sodium picosulfate, 3.5 g magnesium oxide and 12.0 g citric acid. The 2 doses are taken diluted in a glass water.
1681853|NCT01603654|Drug|low-volume PEG -ascorbic acid|THe product is used as colon cleanser before colonoscopy. It is supplied as a powder for oral use, to be reconstituted with 2 L of water and drunk as a solution. It consists of 100.0 g macrogol 3350 plus electrolytes (7.5 g sodium sulphate, 2.7 g sodium chloride, 1.0 g potassium chloride) and 4.7 g ascorbic acid.
1681855|NCT01603628|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A 4 U per kg of body weight (4 U/kg) into specified muscles of the lower limb.
1681856|NCT01603628|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A 8 U per kg of body weight (8 U/kg) into specified muscles of the lower limb.
1681857|NCT01603628|Drug|Normal Saline (Placebo)|Subjects will receive intramuscular injections of normal saline (placebo) into specified muscles of the lower limb.
1681858|NCT01603615|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A into the upper limb muscles and/or lower limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments. Treatment dosing will be according to investigator judgment not to exceed a maximum of 10 U per kg of body weight (10 U/kg) per treatment.
1681859|NCT01603602|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A 3 U per kg of body weight (3 U/kg) into specified muscles of the upper limb.
1681860|NCT01603602|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A 6 U per kg of body weight (6 U/kg) into specified muscles of the upper limb.
1681861|NCT01603602|Drug|Normal Saline (Placebo)|Subjects will receive intramuscular injections of normal saline (placebo) into specified muscles of the upper limb.
1681927|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
1681928|NCT01603134|Drug|Allopurinol|300 mg tablet once a day
1731909|NCT00039039|Drug|paclitaxel|
1681862|NCT01603589|Procedure|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
1681863|NCT01603589|Procedure|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
1681864|NCT01603576|Device|Prototype wide view suprachoroidal retinal prosthesis|Manufacturer = Bionics Institute, Australia
1681865|NCT01603563|Behavioral|Stepped Care TF-CBT|Stepped Care TF-CBT patients will receive step one: 3 (1 hr.) in-office therapist-led sessions over 6 weeks, the parent-child workbook (Stepping Together), scheduled weekly phone meetings (15 minutes), and information from the National Child Traumatic Stress Network website (via web or paper for those without access). Children who do not meet responder status will receive step two: 9 (1 to 1.5 hr.) in-office therapist-directed sessions of TF-CBT over 6 to 8 weeks.
1681866|NCT01603563|Behavioral|Standard TF-CBT|Standard TF-CBT patients will receive 12 (1 to 1.5 hr.) standard weekly in-office therapist-directed sessions over 12 to 14 weeks (Phase II only). The 2 additional weeks allow for scheduling difficulty. Standard TF-CBT includes child, parent and conjoint parent-child sessions addressing the core trauma treatment components discussed in section a.3 (e.g. stress management, skill building, gradual exposure, & trauma narrative etc.).
1681867|NCT01603550|Other|Sleep Deprivation|Sleep Deprivation
1681868|NCT01603550|Other|Energy Restriction|Energy Restriction
1681869|NCT01603524|Other|OMSC Group|"The OMSC Group will receive a multi-component intervention which includes:
Coaching and Outreach Facilitation Visits: Each practice will receive on-site support to implement the intervention components.
Practice tools and real time prompts: Practices will be provided with 4 tools to support the integration of evidence-based cessation practices into brief clinical encounters as part of a practice-level strategy.
Provider Training in Smoking Cessation Interventions: All clinic providers will be invited to a 3 hour training workshop on smoking cessation(CME).
Telephone follow-up support program: Clinics will be able to refer smokers embarking upon a quit attempt to the smoker's telephone follow-up counseling program."
1681870|NCT01603524|Behavioral|OMSC + Performance Feedback Group|The OMSC + Performance Feedback Group will receive the same intervention program as the OMSC group. In addition, clinicians will complete a one-hour audit and feedback session prior to the implementation of the OMSC program at their clinic. The goal of the audit and feedback is to increase provider self-efficacy in the delivery of smoking cessation interventions, raise awareness of the current delivery of evidence-based cessation practices, identify areas for improvement, and motivate providers to deliver evidence-based treatments.
1681871|NCT01603511|Device|Rewarming modality|A commercial charcoal heater will be applied to the torso or the head in two of the trials. The control trial involves shivering only.
1681872|NCT01603498|Drug|Dexamethasone|Dexamethasone 8mg
1681873|NCT01603498|Drug|Methylprednisolone|Methylprednisolone 40mg
1681874|NCT01603485|Drug|Lersivirine Immediate-Release (fasted)|Single 500 mg dose of Lersivirine Immediate-Release Tablets (2 x 250 mg)
1681875|NCT01603485|Drug|Lersivirine Modified-Release #1 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #1
1681876|NCT01603485|Drug|Lersivirine Modified-Release #2 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #2
1681877|NCT01603485|Drug|Lersivirine Modified-Release #3 (fasted)|Single 500 mg dose of Lersivirine Modified-Release Tablet #3
1681878|NCT01603485|Drug|Lersivirine Modified-Release (fed)|Single 500 mg dose of Lersivirine Modified-Release Tablet dosed with food.
1681879|NCT01603459|Drug|IncobotulinumtoxinA|"Subjects to receive up to 3 injection cycle, with the dose titrated from 400 units to up to 800 units.
For each injection session: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400-800 units, volume 2.0 mL per 100 units; Mode of administration: intramuscular injection."
1681880|NCT01603446|Drug|L-Arginine|NOW® L-Arginine powder
1681881|NCT01603433|Device|Sapheon™ Closure System|Sapheon™ Closure System for the treatment of incompetent saphenous veins.
1681882|NCT01603420|Drug|Luteinizing hormone-releasing hormone (LHRH)|Androgen suppression therapy using luteinizing hormone-releasing hormone (LHRH) agonists such as leuprolide, goserelin, buserelin, triptorelin.
1681883|NCT01603420|Drug|Docetaxel|Docetaxel 20mg/m2 IV every 7 days x 8 weeks.
1681884|NCT01603420|Other|Conformal Radiation Therapy (RT)|1.8 Gy(RBE) (or Gy for IMRT) per fraction,five fractions per week for a total dose of 79.2 Gy (RBE) (or Gy).
1681885|NCT01603407|Drug|Prednisone|daily prednisone (0.75 mg/kg/day) tablets for 36-60 months
1681886|NCT01603407|Drug|Prednisone|intermittent prednisone (0.75 mg/kg/day, 10 days on, 10 days off) tablets for 36 to 60 months
1681887|NCT01603407|Drug|Deflazacort|daily deflazacort (0.9 mg/kg/day) tablets for 36-60 months
1681888|NCT01603394|Drug|pregabalin|Pregabalin Capsules (150 mg - 600mg), Dose titration (4 weeks) and fixed dose (2 weeks) for a 6 week treatment period.
1681889|NCT01603381|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBT-I)|Behavioral management of insomnia
1958199|NCT01905943|Drug|Bendamustine|Participants will receive bendamustine everyday (qd) on Days 1 to 2 of each 28-day cycle from Cycle 1 to Cycle 6 as per invetigator's discretion.
1681892|NCT01603355|Drug|Tocilizumab|"Intravenous tocilizumab:
Patients less than 30 kg weight:10 mg per kg every 4 weeks Patients at or above 30 kg weight: 8 mg per kg every 4 weeks"
1682022|NCT01602419|Other|Patients using wilate as standard of care|Patients with von Willebrand Disease using wilate for a period of 2 years.
1681895|NCT01603329|Other|Increasing Medication Adherence through Physician Incentives and Messaging|"There are two treatments:
Physicians given financial incentives for improving patient medication adherence for all of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, and cholesterol (statins) medication vs. one of the following medications: oral diabetes medication, hypertension (ACEI or ARB) medication, or cholesterol (statins) medication.
Physicians given communication emphasizing the importance of improving adherence to all of the previous medication classes vs. one one of the previous medication classes.
When physicians are sent a communication regarding the opportunity to receive an incentive as part of our pilot, they will also receive a single patient sheet for each patient who has less than 80% adherence. For half of the arms, the investigators will make the patient sheets a bright, non-white, color, in order to further draw the physicians' attention to that specific paper in their chart."
1681896|NCT01603316|Behavioral|Food pantry only arm|Participants will have: 1x per week access to food pantry. 3 and 6 month follow-up Administer study follow-up, Survey, Medical Chart review/extraction, Measure & record patient weight/BMI
1681897|NCT01603316|Behavioral|Food pantry + Food voucher arm|Participants will have: 1x per week access to food pantry + 1x per month voucher to buy food *monthly voucher will be $230 *food receipts collected each month 3 and 6 month follow-up, Administer study follow-up Survey, Medical Chart review/extraction, Measure & record patient weight/BMI
1681898|NCT01603316|Behavioral|Food pantry + Grocery delivery|Participants will have: 1x per week access to food pantry + 1x per week grocery delivery *weekly grocery delivery will include: 5 lunches & 5 dinners 3 and 6 month follow-up , Administer study follow-up Survey, Medical Chart review/extraction , Measure & record patient weight/BMI. Patients will have the opportunity to request to the study team to cancel a weekly grocery delivery if there are unique circumstances (e.g. patient is away on vacation, delivered food is being stocked piled/unused, unexpected/unspecified food aversions).
1681899|NCT01603303|Behavioral|Questionnaires|Completion of 8 or 9 brief questionnaires at start of study and 6 and 12 months afterwards. Questionnaires should take about 45 to 50 minutes to fill out each time.
1681900|NCT01603303|Other|Education Materials|Participants receive written handout about ways to keep bones stronger during treatment with Aromatase Inhibitors (AIs) and ways to prevent AI side effects such as muscle aches, stiffness, sexual problems, and hot flashes.
1681901|NCT01603303|Other|Luvena|Use vaginally 2 or 3 times a week.
1681902|NCT01603303|Other|Hyalo-Gyn|Use vaginally 2 - 3 times a week.
1681903|NCT01603303|Other|Vaginal Lubricant|Water-based vaginal lubricant used during sexual activity.
1681904|NCT01603303|Behavioral|Interactive Internet-Based Website|Participants use an interactive, internet-based website called Tendrils: Sexual Renewal after Cancer before, during and after treatment with AIs.
1681905|NCT01603303|Behavioral|Telephone Counseling.|Telephone counseling for up to 30 minutes in weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24. The counselor will follow a manualized program and some sessions will be recorded.
1681906|NCT01603277|Biological|Anti-GM-CSF Monoclonal Antibody 400mg|Anti-GM-CSF Monoclonal Antibody 400mg
1681907|NCT01603277|Other|Placebo|Normal Saline
1681908|NCT01603264|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
1681909|NCT01603264|Biological|Herceptin|Concentrate for solution for infusion, sterile vial 150 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
1681910|NCT01603264|Biological|Herceptin|Concentrate for solution for infusion, sterile vial 440 mg, single-dose 6 mg/kg administered as 90-minute infusion on day 1
1681911|NCT01603251|Drug|Artemether-lumefantrine combination|Artemether-Lumefantrine (AL)combination; a placebo is given together with the first and fifth dose of AL
1681912|NCT01603251|Drug|Artemether-lumefantrine combination + single dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given once together with the first dose of AL. A placebo is given together with the fifth dose of AL.
1681913|NCT01603251|Drug|Artemether-lumefantrine combination + repeated dose Ivermectin|Artemether-lumefantrine (AL) combination + Ivermectin (200ug/kg) given together with the first and fifth dose of AL.
1681914|NCT01603238|Drug|[14C]-LC15-0444|A single oral administration of [14C]-LC15-0444 50 mg, containing 4.9 MBq [14C]. Subjects in the fasted state will receive the drug as a capsule, with 240 ml of water.
1681915|NCT01603225|Procedure|Transcranial Direct Current Stimulation (tDCS)|Delivery of transcranial direct current stimulation for 30-60 minutes or sham stimulation.This will be administered by two or more similar devices.
1681916|NCT01603212|Drug|Vemurafenib|"Phase I Starting dose: 720 mg by mouth twice a day for a 21 day cycle.
Phase II Starting dose: Maximum tolerated dose (MTD) from Phase I."
1681917|NCT01603212|Drug|IL-2|"Phase I Starting Dose: 7 million IU/m2 by vein on Days 2 - 5 of a 21 day cycle.
Phase II Starting Dose: Maximum tolerated dose (MTD) from Phase I."
1681918|NCT01603212|Drug|Interferon Alpha-2b|5 million U/m2 subcutaneously on Days 1 - 5 of a 21 day cycle.
1681919|NCT01603199|Dietary Supplement|High protein high fiber diet|A personalized high protein high fiber dietary plan will be provided to each participant from both groups. Each participant will receive nutritional counseling once a month during six months.
1681920|NCT01603186|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
1681921|NCT01603186|Drug|Quetiapine Fumarate|25 mg tablet once a day
1681922|NCT01603173|Drug|Quetiapine Fumarate Tablets 25 mg|25 mg tablet once a day
1681923|NCT01603173|Drug|Quetiapine Fumarate|25 mg tablet once a day
1681924|NCT01603160|Behavioral|Quality Improvement|"There are no interventions for the individual patient. The changes in processes developed by the quality improvement team will be made for all adults with sickle cell disease, not just adults who consent to interviews.
A proactive risk assessment methodology, Failure Modes, Effects, and Criticality Analysis (FMECA), will be used in two EDs to identify the vulnerabilities, risks, and weak points (failures) in the systems and processes involved in four key decisions of the ED-SCANS. Based on the aggregated results of the FMECA's, generalizable quality improvement interventions (QII's) will be developed and implemented with the purpose of changing the way emergency care for adults with SCD is delivered and organized."
1681925|NCT01603147|Biological|normal saline|saline 225 ml
1681926|NCT01603147|Biological|ch-mAb7f9|The single doses to be administered in each cohort are 0.2, 0.6, 2, 6, and 20 mg/kg, respectively. Volume to be administered 225 ml
1681929|NCT01603121|Drug|Lisofylline|Lisofylline single dose of 9 mg/kg continuous intravenous infusion over a 10 hour period, and lisofylline single dose of 12 mg/kg continuous subcutaneous infusion over a 10 hour period during the alternate period 1 week apart.
1681930|NCT01603108|Drug|Rifaximin|Rifaximin will be initiated post-LT, once the subject is able to tolerate oral medications/diet. Rifaximin will be dosed at 550mg twice daily for 90 days (+/- 10 days) post-LT.
1681931|NCT01603108|Drug|Placebo|Rifaximin placebo will be initiated post LT, once the subject is able to tolerate oral medications/diet. Rifaximin placebo dosed at 550 mg twice daily for 90 days (+/10 days) post LT.
1681932|NCT01603082|Drug|Ticagrelor|180 mg loading dose
1681933|NCT01603082|Drug|Clopidogrel|600 mg loading dose
1681934|NCT01603069|Drug|AZD3241 300 mg BID|The following dose escalation schedule will be used for 300 mg BID: 100 mg BID from Day 1 through Day 7. On Day 8, the patients will start maintenance treatment of 300 mg BID for the duration of the treatment period.
1681935|NCT01603069|Drug|AZD3241 600 mg BID|The following dose escalation schedule will be used for 600 mg BID: 100 mg BID from Day 1 through Day 7 and 300 mg BID from Day 8 through Day 14. On Day 15, the patients will start maintenance treatment of 600 mg BID for the duration of the treatment period.
1681936|NCT01603069|Drug|Placebo|Placebo to AZD3241 BID
1681937|NCT01603056|Biological|Pangramin SLIT HDM mix.|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
1681938|NCT01603056|Biological|Placebo|Up-dosing phase (vial 0 to vial 4) + maintenance phase (3 times per week), for 12 months.
1681939|NCT01603043|Drug|Al-78898A|0.400 milligrams (mg) per 50 microliters (μL) administered as an intravitreal injection
1681940|NCT01603043|Drug|Sham injection|Mock injection administered as an empty hub without needle
1681941|NCT01603030|Drug|moxifloxacin 0,5% + prednisolone 1%|1 gtt, 4x/day, 15 days
1681942|NCT01603030|Drug|moxifloxacin/prednisolone combination|1 gtt, 4x/day, 15 days
1681943|NCT01603017|Device|MRI therapy|5 treatments with magnetic field delivered to knee (n=50)
1681944|NCT01603017|Device|MRI therapy (off)|5 treatment where MRI therapy machine was switched off (both patient and therapist blinded to this by use of electronic 'prescription cards'). (n=50)
1681945|NCT01603004|Other|MRI|Patients will be treated with either sunitinib, everolimus, or traditional chemotherapy according to standard of care. Follow-up with imaging (either MRI or CT) will be performed approximately every 3 months. Unidimensional tumor measurement on standard CT and MRI sequences will be performed, according to guidelines from RECIST v1.1, which will be used to assess for progression of disease. Patients will be followed for up to 5 years. Upon evidence of disease progression, patients will be asked to undergo a post-treatment biopsy. If medically possible and safe, they will stay on the drug until the time of biopsy.
1681946|NCT01602991|Procedure|clinic-based nasopharyngoendoscopy|The study intervention is an in-office transnasal esophagoscopy. It is done in clinic, immediately after deciding the patient requires investigation of their upper gastrointestinal tract and the patient signs consent. The nasopharynx and oral pharynx is topically anesthetized. Since flexible scope is much thinner than a standard endoscopy, there is no requirement for intravenous sedation and thus, no requirement for specialized monitoring, nursing or recovery units. The procedure takes approximately 10 minutes. This study will be using the E.G. Scan II System.
1681947|NCT01602991|Procedure|Standard Endoscopy|The control procedure is standard endoscopy. Endoscopy will be performed as per standard clinic practice. It is typically scheduled within 2 weeks of seeing the patient in clinic. The patient will be required to fast for 6 hours prior to the procedure. In most cases, patients will require intravenous sedation. If sedation is used, the patient will be required to take the day off work and have someone drive them home. This is the standard treatment for patients who present with upper gastrointestinal symptoms post-bariatric surgery. Patients who choose not to participate in this study will still undergo endoscopy as per standard clinical practice.
1681948|NCT01602965|Procedure|Counseling Monthly Phone Calls|the dietician will call the patient at home, and invite them to answer 11 open questions.The questionnaire collects information about weight loss, behaviors that need to be changed, problem-solving as to how to make the changes and physical activity levels.
1681949|NCT01602965|Procedure|Self Help Informative Booklet|Self help informative booklet includes information on how to manage healthy weight, how to lose weight, physical activity and a simplified and abbreviated version of the main behavioural strategies
1681950|NCT01602952|Drug|Radotinib|50mg, 100mg or 200mg Capsule BID
1681951|NCT01602939|Drug|Cladribine and pegylated interpheron alpha-2a|"Cladribine (0.07 mg/Kg/day) s.c for 5 consecutive days each month for a total of 6 months.Cladribine daily doses could be increased up to 0.14 mg/Kg in the fourth, fifth and sixth cycles of therapy if no objetive response is achieved after the third cycle.
Pegylated Interpheron alpha-2a (1 mcgr/Kg) s.c weekly for a total of 6 months."
1681952|NCT01602926|Procedure|conventional surgical technique - Chevron-type distal metatarsal osteotomy|The conventional surgical technique is a Chevron-type distal metatarsal osteotomy, which is performed through a dorsomedial incision approximately 7 cm long. And osteotomy of the distal portion of the first metatarsal is made. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. The capital or distal fragment is stabilized in corrected position with screws. The internal fixation screws used in the conventional surgical technique do not require removal.
1681953|NCT01602926|Procedure|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity. A 2.0 mm Kirschner wire is placed percutaneously in a position medial to the proximal phalanx, and advanced proximally using fluoroscopic guidance until the proximal end of the wire is located in a stable position within the medullary cavity of the first metatarsal (see figures) .The distal end of the Kirschner wire is left outside the skin where it is cut to length and covered. The Kirschner wire is removed after six weeks.
1681978|NCT01602744|Other|STOPP/START screening tools for medication intervention|In the intervention arm the investigator will use the screening tools STOPP/START to screen the medications.
1682023|NCT01602406|Drug|LJM716|LJM716
1682024|NCT01602406|Drug|Trastuzumab|Trastuzumab
1681954|NCT01602926|Procedure|minimally invasive surgical technique|The minimally invasive surgical technique is a transverse subcapital distal metatarsal osteotomy, which is performed through a direct medial incision approximately 1 cm long. The osteotomy of the distal portion of the first metatarsal is made using fluoroscopic image guidance. The capital or distal fragment of the metatarsal is mobilized and displaced laterally an adequate amount to correct the hallux valgus deformity.
1681955|NCT01602913|Drug|Pravastatin alone|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease.
1681956|NCT01602913|Drug|Paroxetine alone|Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
1681957|NCT01602913|Drug|Pravastatin and paroxetine combined|Pravastatin is a member of the drug class of statins, also known as HMG-CoA reductase inhibitors, and is known to reduce the amount of cholesterol and other fatty substances in the blood. In addition, pravastatin is indicated to reduce the risk of myocardial infarction, revascularization and cardiovascular mortality in hypercholesterolemic patients who do not have clinically apparent coronary heart disease. Paroxetine is an orally administered selective serotonin reuptake inhibitor (SSRI) for the treatment of depression
1681958|NCT01602900|Drug|GSK356278|Investigational Medicinal Product
1681959|NCT01602900|Drug|Rolipram|Challenge Agent
1681960|NCT01602887|Drug|PD-0332991|isethionate hard capsule, 125 mg, single dose
1681961|NCT01602887|Drug|PD-0332991|"freebase hard capsule with a small particle size, 125 mg, single dose"
1681962|NCT01602887|Drug|PD-0332991|"freebase hard capsule with a large particle size, 125 mg, single dose"
1681963|NCT01602887|Drug|PD-0332991|oral solution, 50 mg, single dose
1681964|NCT01602874|Drug|Tigecycline|"Subject with cIAI:
Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
1681965|NCT01602874|Drug|Tigecycline|"Subject with CAP:
IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.
Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
1681966|NCT01602874|Drug|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:
Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.
In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
1681967|NCT01602874|Drug|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:
IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
1681968|NCT01602861|Drug|Spironolactone|"One tablet per day (25 mg Spironolactone/placebo) for the first three months. Subsequently dosage is increased to two tablets per day (50 mg Spironolactone/placebo) for the rest of the study.
In case of hyperkaliemia (>5,5 mmol/L) or intolerable side effects dosage will be reduced to one tablet per day (25 mg Spironolactone/placebo)."
1681969|NCT01602861|Drug|placebo|
1681970|NCT01602848|Other|Intensive care management and coordination|Care Management Teams comprised of social workers, community based care managers, and dedicated clinicians work to meet patients' needs in both the health care setting and the community. The CIDP model incorporates motivational interviewing, harm reduction, access to housing through our community partners utilizing a Housing First approach, and provides cellular phones for patients when needed, to better enable regular communication with program staff.
1681971|NCT01602848|Other|usual care|usual care including services for which patients are eligible via fee for service medicaid
1958200|NCT01905943|Drug|Chlorambucil|Participants will receive clorambucil qd on Days 1 and 15 of each 28-day cycle from Cycle 1 to Cycle 6 as per invetigator's discretion.
1681974|NCT01602796|Behavioral|School intervention|The ITACA intervention is a cognitive and social-influences approach to prevent tobacco consumption. The intervention is integrated in the curricula of the school, also schools are reinforced to follow a smoke-free school and strictly follow legislation about smoking in schools. The community component include annual meeting with adolescents parents and parents and teachers intensive group for smoking cessation.
1681975|NCT01602783|Other|11C Acetate Imaging|Single scan
1681977|NCT01602757|Drug|Synera|"Subjects received 4 Synera® patches for 2 hours in Session 1 and 4 patches for 12 hours in Session 4. During Study Session 2, subjects were randomly assigned to 4-hour applications of either 4 Synera® patches or 4 lidocaine/tetracaine patches without heat (no heat patches) and were crossed over during Study Session 3."
1681979|NCT01602731|Device|Automated Medication Dispensing Device|All patients had a pre-filled medication dispensing machine set up at their homes, filled by home health nurses once a month. Safety phone call was made by the AMDD company if doses were missed.
1681980|NCT01602718|Other|exercise training|Pilot study of independent home exercise training (walking or cycling exercise plus low level resistance exercise) for 3 months. Patients will be given specific recommendations for type, frequency, duration and progression of their program and will be contacted weekly by study staff to assess progress and evaluation for any problems. This is a 3 month exercise training intervention in 15 subjects (and 15 no-exercise controls).
1681981|NCT01602705|Other|Usual care|Practices in the usual care arm receive a one-off educational newsletter and support for searching for patients in their electronic health record in the form of downloadable searches
1681982|NCT01602705|Other|Feedback of Performance|Usual care (educational newsletter and support for searching) plus quarterly feedback of practice rates of high risk prescribing compared to a benchmark of the upper quartile of all practices in the year before
1681983|NCT01602705|Other|Feedback of Performance + Health Psychology Informed Intervention|Usual care (educational newsletter + support for searching) plus quarterly feedback plus health psychology informed intervention (persuasive communication and action planning) embedded in feedback
1681984|NCT01602692|Drug|Tumescent solution with dilute lidocaine and epinephrine|Tumescent Solution containing both dilute lidocaine (0.05%) and dilute epinephrine (1:1,000,000)
1681985|NCT01602692|Drug|Tumescent Solution with dilute epinephrine|Tumescent Solution containing dilute epinephrine (1:1,000,000) only
1681986|NCT01602679|Drug|oral micronized progesterone suspension|oral micronized progesterone (100 mg p.o.) suspension
1681987|NCT01602679|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
1681988|NCT01602666|Procedure|therapeutic conventional surgery|Undergo surgery
1681989|NCT01602666|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
1681990|NCT01602666|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1681991|NCT01602666|Drug|carboplatin|Given IV
1681992|NCT01602666|Drug|etoposide|Given IV
1681993|NCT01602666|Drug|ifosfamide|Given IV
1681994|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.20mJ/mm2, 2400 pulses once a week for 4 weeks.
1681995|NCT01602653|Device|Extracorporeal shock wave therapy STORZ MEDICAL Modulith SLK|an energy level of 0.10mJ/mm2, 2400 pulses once a week for 4 weeks.
1681996|NCT01602640|Drug|Morphine infusion|Conventional dose
1681997|NCT01602640|Drug|Fentanyl and Midazolam infusion|Conventional dose
1681998|NCT01602627|Drug|Hsp90 inhibitor AUY922|Given IV
1681999|NCT01602627|Other|pharmacological study|Correlative studies
1682000|NCT01602627|Other|laboratory biomarker analysis|Correlative studies
1682001|NCT01602601|Drug|Idursulfase|recombinant version of IDS produced from human fibroblast. idursulfase is approved for every week (EW) intravenous (IV) administration.
1682002|NCT01602601|Drug|GSK2788723|GSK2788723 is being developed by JCR and GSK for the treatment of Hunter syndrome
1682003|NCT01602588|Drug|Hydroxychloroquine|200mg bd from 14 days post surgery until clinical or radiological progression
1682004|NCT01602588|Radiation|Radiotherapy|Short Course radiotherapy
1682005|NCT01602575|Behavioral|Mindfulness based Stress Reduction Training (MBSR)|8 (2 hr) classes weekly of MBSR and required homework of MBSR practice approximately 30 minutes per day.
1682006|NCT01602562|Drug|VACV tablets (Adults or pediatrics) or granules (pediatrics)|A white to slightly yellowish white film coated tablet contains 556 mg of valaciclovir hydrochloride (500 mg of valaciclovir)). VACV granules have no or slightly specific odor.
1682007|NCT01602549|Drug|GSK962040 (25 mg tablet)|25 mg tablet
1682008|NCT01602549|Drug|Placebo|matching placebo tablet
1682009|NCT01602536|Behavioral|smoking cessation aides|All participants will receive 8 weeks of free nicotine patches, referral to the NCI's online Smokefree.gov Quit Guide, and instruction to set a quit date within 8 days of study start.
1682010|NCT01602536|Behavioral|Twitter|Twitter quit-smoking group
1682011|NCT01602523|Drug|Budesonide/formoterol|Budesonide/formoterol Spray inhaler 160/4.5 mcg daily 28 days
1682012|NCT01602523|Drug|Placebo|Placebo inhaler once daily 28 days
1682013|NCT01602510|Drug|Lamotrigine|in the double blind phase, lamotrigine 200mg/day will be used among half of eligible subjects after randomization
1682014|NCT01602510|Drug|Placebo|Placebo
1682015|NCT01602497|Device|rTMS|Patients undergone 10 session of high-frequency rTMS therapy over their left DLPFC
1682016|NCT01602497|Device|sham rTMS|Patients will undergo ten session of sham rTMS.
1682017|NCT01602484|Device|Pre-prepared Splint Pack composed by Medline|Applying splint by using pre-prepared splint pack
1682018|NCT01602484|Device|Bulk splint supplies|Applying splint by using the bulk splint supplies
1682019|NCT01602471|Drug|[F-18]RDG-K5|Approximately fifteen (15) patients with carotid artery stenosis > 69% will undergo an endarterectomy and will be imaged under PET/CT with [F-18]RGD-K5
1682020|NCT01602458|Procedure|Silicone Only Therapy (SOT)|SOT group will be instructed to wear the silicone for 23 hours/day, removing only for bathing. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. Compression free medical tape will be used to secure the silicone in place. Patients will be provided with 6 months of topical silicone therapy. If optimal results are achieved prior to 6 months of therapy, the treatment will be discontinued. Patients will also be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone.
1682021|NCT01602458|Procedure|Silicone Pressure Garment Therapy (SPGT)|"SPGT group will be instructed to use the Mepiform™ silicone only for 2 weeks during the interim before final fitting with the custom compression garment. A new piece of Mepiform™ silicone should be replaced weekly and applied to clean, dry skin. The patients will be instructed to wear the silicone for 23 hours/day, removing only for bathing.
The patient will continue to use the Mepiform™ silicone under the compression garment for the entire length of the study. The garment will be replaced after 3 months of wear, in order to ensure that optimal pressure and silicone management is applied to the area. Patients will be provided with Scar Management for Skin Grafts Homecare Instructions: Silicone and Compression Garment."
1684164|NCT01586468|Drug|NaCl Solution|NaCl Solution
1682028|NCT01602380|Drug|faslodex 500mg|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
1682029|NCT01602380|Drug|arimidex 1mg|oral tablet 1 daily
1682030|NCT01602380|Drug|faslodex dummy|2 x intramuscular injections at day 1, 14, 28 and every 28 days thereafter
1682031|NCT01602380|Drug|arimidex dummy|oral tablet 1 daily
1682032|NCT01602367|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 12 weeks
1682033|NCT01602367|Drug|BMS-823778|Capsules, Oral, 6 mg, Once daily, 12 weeks
1682034|NCT01602367|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 12 weeks
1682035|NCT01602367|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 12 weeks
1682036|NCT01602341|Drug|AN2728 Topical Ointment, 2% QD|AN2728 Topical Ointment, 2% QD
1682037|NCT01602341|Drug|AN2728 Topical Ointment, 0.5% QD|AN2728 Topical Ointment, 0.5% QD
1682038|NCT01602341|Drug|AN2728 Topical Ointment, 2% BID|AN2728 Topical Ointment, 2% BID
1682039|NCT01602341|Drug|AN2728 Topical Ointment, 0.5% BID|AN2728 Topical Ointment, 0.5% BID
1682040|NCT01602328|Biological|AC607|AC607 will be a single administration at a target dose of 2 x 10E6 hMSC/kg body weight
1682041|NCT01602328|Biological|Vehicle Only|The dose will be calculated and recorded in the same way as for AC607.
1682046|NCT01602302|Drug|bDMARD withdrawal (etanercept, adalimumab, infliximab, certolizumab, golimumab, tozilizumab, abatacept)|bDMARDS (etanercept, adalimumab, infliximab, certolizumab, golimumab, tocilizumab, abatacept) will be discontinued after baseline visit in all participants
1682047|NCT01602289|Biological|LY2875358|Administered IV
1682048|NCT01602289|Drug|Erlotinib|Administered orally
1682049|NCT01602289|Drug|Gefitinib|Administered orally
1682050|NCT01602276|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS
1682051|NCT01602263|Procedure|Transcranial Direct Current Stimulation (tDCS)|Anodal, Cathodal or Sham tDCS.
1682052|NCT01602250|Drug|placebo|Levobupivacaine 8 mg/min ropivacaine 8 mg/min
1682053|NCT01602250|Drug|Intralipid®|Levobupivacaine 8 mg/min ropivacaine 8 mg/min Intralipid® 120 ml in one min
1682054|NCT01602224|Drug|Placebo|Administered IV
1682055|NCT01602224|Drug|Dexamethasone|Administered orally
1682056|NCT01602224|Drug|Bortezomib|Administered SQ
1682057|NCT01602224|Biological|Tabalumab|Administered IV
1682058|NCT01602211|Other|Internet-Based Intervention|Receive full access to INSPIRE
1682059|NCT01602211|Other|Internet-Based Intervention|Receive access to an annotated list of existing resources for transplant and cancer survivors and delayed access to INSPIRE site
1682060|NCT01602211|Other|Medical Chart Review|Ancillary studies
1682061|NCT01602211|Other|Quality-of-Life Assessment|Ancillary studies
1682062|NCT01602211|Other|Questionnaire Administration|Ancillary studies
1682063|NCT01602198|Drug|Exelon [rivastigmine] transdermal patch|Exelon patch 1/day for six months
1682064|NCT01602198|Drug|Placebo transdermal patch|Placebo transdermal patch 1/day for 6 months
1682070|NCT01602159|Procedure|Open Bypass Surgery|Open Bypass Surgery with Autogenous vein or PTFE Graft
1682071|NCT01602159|Procedure|Angioplasty and Stenting|Angioplasty and Stenting of the superficial Femoral artery with Nitinol stent (Life Stent flexStar Stent System by Bard Inc. Tempe AZ).
1682072|NCT01602146|Other|ultramarathon running|"blood samples before and after ultramarathon
urinary samples before and after ultramarathon
voluntary ant electrically muscular forces measuring before and after ultramarathon
Broadband ultrasound Attenuation before and after ultramarathon"
1682073|NCT01602133|Procedure|peripheral venous puncture|Ultrasound imaging of the arm is performed. If a suitable vein is identified, a percutaneous puncture is performed under ultrasound guidance. Then, an intravenous catheter is inserted according Seldinger method.
1682074|NCT01602120|Drug|Lampalizumab|Lampalizumab 10 mg ITV injections as per the schedule specified in respective arms.
1682112|NCT01601808|Drug|Placebo|Orally once a day, continuously throughout the study
1682113|NCT01601808|Drug|Caprelsa (vandetanib)|Orally once a daily, continuously throughout the study.
1682114|NCT01601795|Drug|Sevoflurane|volatile Anaesthetic, duration during cardiopulmonary bypass
1682115|NCT01601795|Drug|Isoflurane|volatile anesthetic, duration during cardiopulmonary bypass time
1955389|NCT03206450|Procedure|Biospecimen Collection|Undergo collection of blood and provide saliva and semen samples
1955390|NCT03206450|Other|Laboratory Biomarker Analysis|Correlative studies
1955391|NCT03206450|Other|Questionnaire Administration|Ancillary studies
1682075|NCT01602107|Other|Pelvic Floor muscle strengthening exercises|Participants will attend regular physical therapy visits (weekly X 2 weeks, bi-weekly X 4 weeks, and continuing monthly) until the time of their surgery. they will then see the physical therapist for assessment, exercise and advice at 2 and 4 weeks after their surgery. During physical therapy visits, patients will receive two sessions of biofeedback training, and at each visit will work on strength and motor control exercises for their pelvic floor muscles.
1682076|NCT01602081|Device|reinforce soft tissue|reinforce soft tissue
1682079|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
1682080|NCT01602055|Drug|Azithromycin|Single dose 500 mg of film coated tablet
1682081|NCT01602029|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
1682082|NCT01602029|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
1682083|NCT01602029|Drug|Placebo|Placebo added to TAU
1682084|NCT01602029|Drug|Odansetron plus simvastatin|Ondansetron will be administered in 8mg once daily dose and Simvastatin 20mg taken as once daily dose
1682087|NCT01602003|Drug|LC15-0444 25mg bid|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
1682088|NCT01602003|Drug|LC15-0444 50mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
1682089|NCT01602003|Drug|Sitagliptin 100mg qd|Each patient was given 3 different bottles of study drugs that comprised of two morning bottles and one evening bottles. Each morning bottle contained LC15-0444 25 mg or 50 mg or Sitagliptin 100mg(depending on the randomized group) or its matching placebo while the evening bottle contained LC15-0444 25 mg or its matching placebo. Patient was instructed to take 1 tablet from each bottle at regular times in the morning and evening every day during the 24-week double-blind treatment period.
1682090|NCT01601990|Drug|Placebo group(once daily)|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks.
1682091|NCT01601990|Drug|LC15-0444 50mg qd|eligible patients were randomized to LC15-0444 50mg or placebo groups and received the assigned treatment for 24 weeks
1682092|NCT01601977|Device|AVAPS-AE|Novel ventilation mode (Omnilab - AVAPS AE algorithm)
1682093|NCT01601977|Device|Usual care|Non-invasive ventilation with standard ventilator
1682094|NCT01601951|Other|Procedural, Bone Marrow concentrate injection|This is strictly data collection and outcomes based. The procedure is not part of this study
1682095|NCT01601938|Dietary Supplement|selenium replacement|Selenium 500 mcg (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
1682096|NCT01601938|Dietary Supplement|Placebo|placebo (10 mL) mixed to 230 mL of normal saline will be infused continuously per day (10 mL/hour). Study drugs will be infused for 7 days.
1682097|NCT01601925|Other|supine extended position of the neck|we measure the distances from cricoid cartilage to C6 or C7 transverse process in supine neutral and extended position of the neck
1682098|NCT01601912|Drug|Atomoxetine|40 mg, 1 application
1682099|NCT01601912|Drug|Citalopram|20 mg, 1 application
1682100|NCT01601899|Drug|Stavudine|30 mg po BD if wt < 60kg, or 40 mg po BD if wt > 60kg
1682101|NCT01601899|Drug|Stavudine|20 mg po BD if wt < 60kg, or 30 mg po BD if wt > 60kg
1682102|NCT01601899|Drug|Tenofovir|300 mg po QD
1682103|NCT01601873|Device|Heparin-bonded vascular access graft|Heparin-bonded graft implantation for hemodialysis vascular access
1682104|NCT01601873|Device|Conventional ePTFE hemodialysis graft|non-heparin bonded conventional hemodialysis vascular access graft
1682105|NCT01601860|Other|Use of non-pharmacological|Evaluation of maternal and perinatal outcomes associated with the use of non-pharmacological
1682106|NCT01601847|Dietary Supplement|Cholecalciferol|Once the dietary intake of vitamin D has exceeded 200 IU/Day, the infants will receive placebo until they are 6 months of age adjusted for prematurity
1682107|NCT01601847|Drug|Cholecalciferol|Infants will receive cholecalciferol 400 IU/day PO until they are 6 months of age adjusted for prematurity
1682108|NCT01601834|Drug|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
1682109|NCT01601834|Drug|PF-06273340 or Placebo|PF-06273340 will be administered as an extemporaneously prepared solution for all doses. Correspondingly, placebo doses will be administered as solution.
1682110|NCT01601821|Drug|CsA+Rapamune+CS|Part 1: Rapamune will be given as a loading dose of 6 mg once followed by maintenance dose of 2 mg to achieve a target trough level of 8-15 ng/ml. Part 2: Rapamune dose will be adjusted to achieve a target trough level of 10-15ng/ml through 6 months
1682111|NCT01601821|Drug|CsA+MMF+CS|"The control arm is the standard local practice (official protocol) in Iran:
Cyclosporine + MMF + Corticosteroid. The time period is from pre-study screening / baseline evaluation up to 12 months for patients who are maintained on CsA + MMF + CS."
1682116|NCT01601782|Procedure|Ultrasound Scan|Subject will be required to lie flat for no longer than 3 minutes to complete a volume imaging ultrasound scan of the injured area. Following the volume imaging scan a conventional ultrasound scan will be completed as ordered by their clinician.
1682117|NCT01601782|Device|Ultrasound Scan using a General Electric Ultrasound Scanner Model Logiq E9 (model name).|The subject will be required to lie flat for approximately 5 to 10 minutes to complete a conventional ultrasound scan to x-ray the muscle and tendon injuries.
1682118|NCT01601769|Device|Vitom|Patients treated and diagnosed by vitom
1682119|NCT01601769|Device|Colposcopy|"a Carl Zeiss colposcope with a magnification power from 4x to 20x, with green filter.
Patients treated by colposcopy"
1682120|NCT01601756|Device|navigated revision knee arthroplasty|revision knee arthroplasty with the aid of a navigation system the navigation system is the Orthopilot System with a software specifically dedicated for revision operations (TKR 1.0). The system is from Aesculap AG (Tuttlingen).
1682121|NCT01601756|Device|conventional revision knee arthroplasty|revision knee arthroplasty using conventional instruments
1682122|NCT01601743|Behavioral|Sitting|Sitting for the same period of time and duration (30 minutes per session, 3 times per week, over 4 consecutive weeks).
1682123|NCT01601743|Behavioral|Running|Exercise (running) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
1682124|NCT01601743|Behavioral|Walking|Exercise (walking) for 30 minutes per session, 3 times per week, over 4 consecutive weeks.
1682125|NCT01601730|Drug|Modafinil and Escitalopram|Treatment 4: Modafinil 200 mg + Escitalopram 20 mg
1682126|NCT01601730|Drug|Placebo|Matching oral placebo capsules as control (Treatment 1: Modafinil 0 + Escitalopram 0).
1682127|NCT01601730|Drug|Modafinil|Treatment 2: Modafinil 200 mg + Escitalopram 0.
1682128|NCT01601730|Drug|Escitalopram|Treatment 3: Modafinil 0 + Escitalopram 20 mg.
1682129|NCT01601717|Drug|RTI-336|Four medication dosage groups (0 mg, 1 mg, 12 mg, 20 mg) administered in the form of a pill once per day for 10 days.
1682130|NCT01601717|Drug|Placebo|Matching placebo pill administered once per day for 10 days.
1682131|NCT01601704|Drug|NB32|Naltrexone SR 32 mg/Bupropion SR 360 mg/day. Administered in addition to the weight management program.
1682132|NCT01601704|Drug|PBO|Placebo. Administered in addition to the weight management program.
1682133|NCT01601704|Behavioral|Weight Management Program|A comprehensive weight management program will be administered in addition to the subject's study medication assignment. The program includes internet counseling by an accredited health and fitness professional and a nutrition and exercise program with goal setting and educational and tracking tools.
1682134|NCT01601691|Device|DuraSeal|Single dose of DuraSeal product with DuraSeal components diluted 1:1 in sterile saline injected between rectum and prostate
1682135|NCT01601678|Procedure|Peroral Endoscopic Myotomy (POEM)|Endoluminal submucosal myotomy of the distal esophagus/lower esophageal sphincter for treatment of achalasia(see Inoue et al. Endoscopy 2010) POEM procedure steps: Lavage, entry point 12-14cm above GEJ at the lesser curvature site, Inject 10ml saline with methylene blue, create 2cm entry point, advance endoscope into the submucosa, repeated submucosal injection and dissection of the submucosal tunnel up to 2-3cm into the cardia, dissect the submucosa close to the muscularis with repeated checks endoluminally, after completion of the submucosal tunnel flush with gentamycin, perform myotomy from proximal to distal starting 4-5cm below the entry point down to at least 2cm onto the cardia, after complete myotomy check for mucosal integrity, close the entry point with clips from distal to proximal
1682136|NCT01601678|Procedure|Laparoscopic Heller Myotomy (LHM)|laparoscopic myotomy of the lower esophageal sphincter as with standard achalasia therapy: after opening the phren-oesophageal ligament to mobilise distal esophagus distally and proximally, a 1.5- 2cm myotomy at the cardia with an approximately 6-8cm myotomy extension into the distal esophagus is made. As anti reflux procedure, a Dor hemifundoplication is preferred
1682137|NCT01601665|Device|SN6AT6 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 3.75 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
1682138|NCT01601665|Device|SN6AT7 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 4.50 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
1682139|NCT01601665|Device|SN6AT8 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 5.25 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
1682140|NCT01601665|Device|SN6AT9 Intraocular Lens|Acrylic intraocular lens with cylinder power at the IOL plane of 6.00 diopters. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
1682141|NCT01601665|Device|SN60WF Intraocular Lens|Acrylic aspheric monofocal intraocular lens. Intraocular lenses are implanted during cataract surgery as a replacement for the natural crystalline lens and are intended for long term use over the lifetime of the cataract subject.
1682142|NCT01601652|Drug|Omegaven|1 g/kg/d iv infusion over 24h
1682143|NCT01601639|Device|Endoscopic Band Ligation|Endoscopic band ligation device: 6 Shooter Saeed Multi-Band Ligator (Cook Medical/Endoscopy)
1682144|NCT01601639|Device|Argon plasma Coagulation (APC) for GAVE|APC treatment for gastric antral vascular ectasia (GAVE) Argon plasma coagulation device: ERBE VIO 300D (Elektromedizin GmBH)
1732319|NCT00052286|Drug|modafinil|
1682154|NCT01601613|Drug|activated recombinant human factor VII|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
1682155|NCT01601613|Drug|placebo|100 mcg/kg body weight administered i.v. (into the vein) followed by standard haemostatic replacement therapy (SHRT) at the Investigator's discretion.
1682156|NCT01601600|Drug|BYM338|BYM338
1682157|NCT01601600|Drug|Placebo|BYM338 Placebo
1682158|NCT01601587|Other|A psychoeducational group intervention.|"The intervention is an introduction seminar. It will be held over FOUR hours. Up to 15 patients can participate in each seminar. The content of the was developed based on study 1. The presentation about available treatment options and patient's rights are made by multi professional health personnel and user representatives. More specifically, this will be done under the following topics:
What is mental health?
Treatment options: orientation about individual and group based treatment modalities.
Former patients experience with their own treatment, self-help and participation.
How to influence and participate actively in the treatment and patient rights.
What can I do while I wait for treatment and where can I otherwise do to avoid aggravation?"
1682159|NCT01601574|Behavioral|Weight Watchers modified program|Weight Watchers: For people with Type 2 diabetes including (1) weekly standard in-person Weight Watchers meetings, (2) use of the standard Weight Watchers online program and tools, and (3) two scheduled telephone consultations with a Certified Diabetes Educator (CDE) who will assist the participant in tailoring the standard Weight Watchers program to accommodate the participant's diabetes-related status, with additional unlimited phone and email access to CDEs at the participant's request
1682160|NCT01601574|Other|Standard Care group|One session of in-person diabetic nutritional counseling with a registered dietitian, with follow-up written educational materials.
1682161|NCT01601561|Drug|Regular human insulin injection|"Hyperinsulinemic normoglycemic clamp from beginning of surgery until 8 hours after surgery.
Humulin R 5 mU/kg/min and a variable infusion of glucose."
1682162|NCT01601548|Behavioral|Mindfulness Based Cancer Recovery|Defined as practices or interventions that focus on the connection and integration of the mind and body and the ability for these connections to effect changes on physical, emotional and spiritual levels for the purpose of promoting health and well being. MBCR is a psycho-educational program developed by Dr. Linda Carlson. It is a step by step mindful-based stress reduction program (MBSR) designed to help cancer patients cope with their cancer diagnosis and treatment
1682163|NCT01601535|Drug|MLN8237|Every course will be 21 days. MLN8237 will be administered orally daily starting on day 1 through day 7.
1682164|NCT01601535|Drug|Irinotecan|Irinotecan will be administered intravenously during each course on study day 1 through day 5.
1682165|NCT01601535|Drug|Temozolomide|Temozolomide will be administered orally during each course on study day 1 through day 5.
1682166|NCT01601522|Procedure|Peanut protein|500 mg
1682167|NCT01601522|Procedure|Oat flour|500 mg Oat flour
1682168|NCT01601509|Drug|Nasal tramazoline with dexamethazone|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
1682169|NCT01601509|Drug|Nasal placebo|Every patient will undergo four assessments. Every assessment will consist of an overnight polysomnography with concomitant measurement of breathing route pattern (oral, nasal, oro-nasal breathing epochs) as previously described [7], along with a nasal resistance measurement. After baseline assessment and randomization patients of the first group will undergo a one-week therapy with nasal tramazoline and dexamethazone, while the patients of the second group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution). The second assessment will take place at the end of this one week regimen. A washout period of two weeks will follow. Subsequently, the third assessment will take place and next the patients of the first group will undergo a one-week therapy with nasal placebo (sodium chloride, 0.9% solution), while the patients of the second group will undergo a one-week therapy with nasal tramazoline and dexamethazone. Fourth assessment will then follow.
1682171|NCT01601483|Drug|MC-1101|1% Ophthalmic Solution TID
1682172|NCT01601483|Drug|MC-1101 Vehicle|Ophthalmic solution, TID
1682173|NCT01601470|Drug|LCZ696|LCZ696 400mg QD was administered alone for 4 days and in combination with sildenafil for 1 day
1682174|NCT01601470|Drug|Sildenafil|Sildenafil 50 mg single dose was administered alone for 1 days and in combination with LCZ696 400mg QD for 1 day
1682175|NCT01601457|Drug|activated recombinant human factor VII|90 mcg/kg body weight administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
1682176|NCT01601457|Drug|placebo|Administered intravenously as a slow, bolus injection after the patients had been anaesthetised and immediately before the first skin incision. A second dose was given if an intraoperative haemoglobin was less than 8.0 g/dl after salvaged red cells (RBC) had been re-transfused
1682177|NCT01601444|Device|Pletysmograph|Pletysmograph electrodes are applied to the thoracic wall
1682180|NCT01601418|Drug|YF476|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
1682181|NCT01601418|Drug|Placebo|Each subject took one capsule of YF476 (1, 5, 25 or 100 mg) or placebo on five separate occasions. Each capsule was taken with water 150 mL.
1682182|NCT01601405|Drug|YF476|Each subject took one capsule of YF476 100 mg twice daily on Days 1-6 and once on Day 7. Each capsule taken with water 150 mL.
1682183|NCT01601405|Drug|Placebo|On Days 0 and 14, each subject took a placebo capsule. Each capsule taken with water 150 mL.
1682184|NCT01601392|Procedure|transcranial direct current stimulation (Anodal)|The anodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the affected hemisphere.
1682185|NCT01601392|Procedure|transcranial direct current stimulation (Cathodal)|The Cathodal group will receive tDCS for 25 minutes at 2mA daily for 6 consecutive days on the unaffected hemisphere.
1682186|NCT01601392|Procedure|transcranial direct current stimulation (Sham)|The sham group will receive sham tDCS for 25 minutes daily for 6 consecutive days on the affected hemisphere.
1682187|NCT01601366|Device|LNG-IUS|"The study includes 2 treatment groups: Group I the LNG-IUS group where they will have a LNG IUS inserted for them"
1682188|NCT01601366|Drug|Combined oral contraceptives|Group II: will recite combined oral contraceptives for 6 months
1682190|NCT01601340|Drug|HQK-1001|HQK-1001 tablets, twice daily for 48 weeks
1682191|NCT01601340|Drug|Placebo|Placebo tablets, twice daily for 48 weeks
1682192|NCT01601327|Drug|Testosterone enanthate (Sustanon 250 mg)|Twenty-eight patients were treated with testosterone enanthate (TE),
1682193|NCT01601327|Drug|Human chorionic gonadotropin (hCG) (Pregnyl 5000 IU)|twenty-five patients were treated with human chorionic gonadotropin (hCG)
1682194|NCT01601327|Drug|Testosteron gel (Testojel 50 mg)|Twenty-four patients were treated with testosterone gel (TG).
1682197|NCT01601301|Device|PRECICE System|Lenthening of either the tibia or femur with the PRECICE System.
1682198|NCT01601262|Device|Low Intensity Extracorporeal Shock waves (Cardiospec 1000)|We will apply the cardiospec 1000 unit for LI-ESWL in the penile and inguinal areas, 300 shocks per area, total of 1500 shocks. Full description of treatment series can be seen in the detailed protocol.
1682199|NCT01601249|Procedure|Embryo selection based on polscope grading or morphology|In the experimental arm embryo grading will be performed by polscope rather than conventional morphology, and the best embryo/s for transfer will be selected by this method.
1682200|NCT01601236|Drug|Repository Corticotropin Injection|H.P. Acthar Gel (repository corticotropin injection) is administered via daily SC injection for 36 weeks in the three dose groups [8 U (0.1 mL), 16 U (0.2 mL), or 32 U (0.4 mL)].
1682201|NCT01601236|Drug|Placebo|Placebo contains the same inactive ingredients as H.P. Acthar Gel without the active pharmaceutical ingredient (API). Placebo is administered via daily SC injection for 36 weeks in equal volumes as the Acthar comparator volumes.
1682202|NCT01601210|Drug|Creatine monohydrate or placebo|Placebo, 2g, 4g, and 10g of creatine monohydrate
1682203|NCT01601197|Behavioral|Tactile stimulation|Immunizer will rub the ipsilateral limb before, during and after immunization injection(s)
1682204|NCT01601184|Drug|vismodegib|Hedgehog pathway antagonist Dosage: 150 mg orally with or without food at the same time every day
1682205|NCT01601184|Drug|Temozolomide|alkylating agent Dosage: Dose in Cycle 1 is 150 mg/m2 orally once daily for 5 days followed by 23 days without treatment. At the start of Cycle 2, the dose is escalated to 200mg/m2 orally once daily for 5 days
1682206|NCT01601158|Biological|Umbilical Cord Blood administration|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
1682207|NCT01601158|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
1682208|NCT01601145|Dietary Supplement|consumption of lozenges|Each subject two lozenges a day for 6 weeks
1682209|NCT01601132|Drug|theophylline|300mg (80mg/15ml elixir)
1682210|NCT01601132|Drug|colchicine|colchicine 0.6mg by mouth twice daily on Days 5-19, co-administered with theophylline 300mg (80mg/15ml) on the morning of Day 19
1682211|NCT01601119|Drug|Rebif|The subjects will receive Rebif as per the current practices or as directed by the physician.
1682212|NCT01601119|Other|Other: Disease modifying therapies (DMT)|The subjects will receive other DMTs as per the current practices or as directed by the physician.
1682213|NCT01601106|Drug|liposomal prednisolone|Two weekly dosages with 150 mg.
1682214|NCT01601106|Drug|Placebo|
1682215|NCT01601093|Drug|High dose|Ceftazidime 3g, iv, bid and Sulbactam Sodium 1.5g, iv, bid for 5-14days.
1682216|NCT01601093|Drug|Low dose|Ceftazidime 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
1682217|NCT01601093|Drug|Cefoperazone and Sulbactam Sodium (CFP/SUB)|Cefoperazone 2g, iv, bid and Sulbactam Sodium 1g, iv, bid for 5-14days.
1682218|NCT01601067|Behavioral|Integrated Prolonged Exposure Therapy|Prolonged exposure (PE) therapy is an evidence based practice for the treatment of PTSD. Components of PE included education about PTSD and exposure to avoided reminders of trauma.
1682246|NCT01600820|Other|3- Low fat drinkable fermented dairy product without plant sterols(control)|3 = Intervention 3 (1 control product/day)
1732320|NCT00052299|Drug|cytarabine|
1682219|NCT01601067|Behavioral|Seeking Safety|Seeking Safety (SS) teaching coping skills in behavioral, cognitive, and interpersonal domains so that people are able to make safe choices rather than drinking or PTSD-related behaviors such as avoidance.
1682220|NCT01601054|Device|Tantalum cage from Zimmer|A tantalum cage will be inserted through a left sided retroperitoneal approach
1682221|NCT01601041|Other|sonographic assessment of residual urine, urine culture|residual urinary volume assessed by ultrasound after bladder catheterization urinary cultures taken before and after prostate massage
1682222|NCT01601028|Drug|Hydroxychloroquine|Hydroxychloroquine 300 mg once daily p.o. for 12 weeks and go off medication for 4 weeks (total 16 weeks)
1682223|NCT01601028|Drug|Placebo|2cp/day for 12 weeks and go off medication for 4 weeks (total 16 weeks)
1682224|NCT01601015|Other|Manual Therapy|Manual therapy of Suboccipital soft tissue Inhibition is performed with patient in supine position. The patient's head leans against the physiotherapist's hands, which palpate suboccipital muscles by sliding fingertips until contacting posterior arch of atlas. At this point, a deep and progressive gliding pressure is applied, for 10 minutes. The purpose of this technique is to release suboccipital muscle spasm, which can be responsible for the mobility dysfunction of the occiput-atlas-axis joint.
1682225|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
1682226|NCT01601015|Other|Manual Therapy|Occiput-atlas-axis joint manipulation is performed in the same position as the previous technique. It is bilaterally administered and it consists of 2 phases: firstly, rotation with gentle head decompression with no flexo-extension and slight lateral flexion is performed, followed by small circumductions aimed at increasing arterial viscoelasticity and searching for adequate joint barrier through selective tension; secondly, a high speed thrust manipulation in pure rotation towards the side to be manipulated is performed, with a head helicoidal movement, with the aim of restoring the mobility of joints between occiput, atlas and axis, which enables to correct a global joint dysfunction.
1682227|NCT01601015|Other|placebo treatment|"The physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.
The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
1682228|NCT01601002|Drug|Mirtazapine|Mirtazapine 7.5 to 45 mg/day, once daily, 12 weeks open label
1682229|NCT01600989|Other|blood sampling|Blood samples will be taken at ICU admission, and 24h and 48h after admission, and at time of resolution of sepsis
1682230|NCT01600989|Other|blood sampling|Blood samples will be taken twice at a 7 day interval
1682231|NCT01600976|Drug|telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Multiple doses of 2 oral tablets of telaprevir will be administered every 8 hours on Days 1 to 5 and a single dose of 2 oral tablets of telaprevir will be administered in the morning on Day 6.
1682232|NCT01600963|Drug|Arm A Double-blind Phase: TMC207|Type=exact number, unit=mg, number=400 mg for the first 2 weeks and 200 mg 3 times per week for the remainder of the treatment period, form=tablet, route=oral administration.
1682233|NCT01600963|Drug|Arm B Double-blind Phase: Placebo|Form=tablet, route=oral administration, taken once daily for 2 weeks then 3 times per week for the remainder of the treatment period.
1682234|NCT01600963|Drug|Treatment Failure During Double-blind Phase: TMC207|Type=exact number, unit=mg, number=200 mg 3 times per week, form=tablet, route=oral administration.
1682235|NCT01600963|Drug|Treatment Failure During Follow-up Phase: TMC207|Type=exact number, unit=mg, number=400 mg once daily for 2 wks and 200mg three times per week for 22 weeks, form=tablet, route=oral administration.
1682236|NCT01600950|Drug|LY2963016|Single 0.3 U/kg dose administered subcutaneously
1682237|NCT01600950|Drug|Lantus|Single 0.3 U/kg dose administered subcutaneously
1682238|NCT01600937|Behavioral|Theoretical & practical exercise counseling|2 sessions/ per wk for 1 month
1682239|NCT01600911|Other|Low phytochemical diet(LPD), high phytochemical diet(HPD)|LPD is a basal diet which low in soy,vegetable and fruit and other plant food to approach low phytochemical. HPD is the diet which add two serving test vegetable in the lunch of LPD.
1682240|NCT01600885|Drug|Guanfacine|Subjects will be given 3mg of guanfacine before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
1682241|NCT01600885|Drug|Placebo|Subjects will be given a placebo before the fMRI scan. Then when in the scanner, a bolus of ketamine (0.23mg/kg over 1 min) will be given during the visual fixation scan. Immediately after completion of the 1 min bolus, the participant will receive a steady state ketamine infusion of 0.58 mg/kg/hour and brain activation will be measured during a spatial working memory task. The entire scan will last approximately two and a half hours and the ketamine infusion will be up to one hour and 15 minutes.
1682242|NCT01600859|Drug|E2609|"E2609 capsules: 5 mg, 25 mg, 50 mg, and 200 mg
E2609 doses: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg, 200 mg, and 400 mg
According to the randomized study design, participants who are assigned to receive E2609 will each receive a single assigned dose consisting of two capsules of E2609 or in some cases one capsule of E2609 and one of placebo"
1682243|NCT01600859|Drug|Placebo for E2609|"Placebo capsules
According to the randomized study design, participants who are assigned to receive placebo will each receive a single dose consisting of two capsules of placebo"
1682244|NCT01600820|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1 = Intervention 1 (1 test product/day)
1682245|NCT01600820|Other|2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit|2 = Intervention 2 (1 test product/day)
1682435|NCT01599104|Drug|Olmesartan|Olmesartan 20 mg capsule one daily
1682247|NCT01600807|Drug|Gemcitabine, Erlotinib, OSI-906|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD, OSI-906 dose to be determined BID
1682248|NCT01600807|Drug|Gemcitabine, Erlotinib|Gemcitabine 1000 mg/m2 d1,8,15; Erlotinib 100 mg QD
1682249|NCT01600781|Dietary Supplement|NutriniDrink/Fortini MF unflavoured (1.5kcal/ml)|During the 6-week Intervention period children allocated to group 1 will consume 2 bottles of study product per day (400ml in total).
1682250|NCT01600768|Drug|Beta-Lactams|infusion time: 30 mins or 1 hr
1682251|NCT01600768|Drug|Beta-Lactams|infusion time 4 hrs
1682252|NCT01600755|Biological|AMDC|Cell Treatment
1682253|NCT01600742|Drug|Vorinostat|"Run-in phase:
WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.
Vorinostat: 400 mg/day during WBRT, day 1 through day 7 every week till one day after WBRT.
Randomization phase:
WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.
Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
1682254|NCT01600742|Drug|Placebo|"Randomization phase:
WBRT: 2.5 Gy per fraction per day, day 1 through day 5 every week for 15 days, to a total dose of 37.5Gy.
Vorinostat or placebo: 400 or 300 mg/day during radiation therapy (based on the results of run-in phase), day 1 through day 7 every week till one day after WBRT."
1682255|NCT01600729|Drug|No Intervention|No intervention.
1682258|NCT01600703|Drug|Sitagliptin|Sitagliptin, 100mg, oral, single dose
1682259|NCT01600703|Drug|Placebo|Placebo, oral, single dose
1682260|NCT01600690|Other|Statin withdrawal|Patients are instructed to stop taking statin pills for the duration of the study. The rest of therapy will remain unchanged.
1682261|NCT01600677|Device|Computerized medication delivery unit|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. EMMA identifies each medication automatically-no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. EMMA will remain in the patient's home for a period of 90 days immediately following hospitalization. After 90 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit form the MDU, while addressing the transition period when medication-reconciliation problems are most common.
1682262|NCT01600677|Other|Usual care|Those hospitalized patients that meet all inclusion and exclusion criteria will receive medications from a dedicated pharmacy, but continue to make their medications in their usual way for the 90-day period immediately following discharge.
1682263|NCT01600664|Behavioral|Interactive computer game|Participants will use the interactive computer game installed on a convertible PC
1682264|NCT01600664|Behavioral|Convertible PC|Participants will be using the convertible PC without the interactive computer game
1682265|NCT01600651|Other|Recruitment Maneuver (RM) sham group|It 's when RM sequence precedes a shame evaluation period
1682266|NCT01600651|Other|Sham recruitment maneuver (RM) group|Group in which patients receive a sham sequence before the RM sequence
1682267|NCT01600638|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1682268|NCT01600625|Drug|oral minocycline hydrochloride treatment|Orally received 50 mg minocycline (Minocin, SK chemical, Seoul, Korea) twice a day for 2 months treatment
1682269|NCT01600612|Drug|carbetocin|10 ug of carbetocin will be given intravenously to patients with atonic postpartum hemorrhage
1682270|NCT01600612|Drug|misopristol|600 ug of misopristol will be given sublingually to patients with atonic postpartum hemorrhage
1682271|NCT01600612|Drug|oxytocin|30 IU of oxytocin will be given intravenously to patients with atonic postpartum hemorrhage
1682272|NCT01600599|Drug|Tranexamic Acid|intravenous 1g and topical 1g
1682273|NCT01600599|Drug|saline|100mls of topical saline
1682275|NCT01600573|Drug|pazopanib in combination with weekly topotecan|"Topotecan as an IV infusion over 30 minutes on days 1, 8, and 15 of a 28 day cycle and
Pazopanib orally once daily continuous dosing in the following dose levels:
Phase I Trial:
Dose level -I: Topotecan weekly 3mg/m2, Pazopanib 400 mg Dose level I: Topotecan weekly 4mg/m2, Pazopanib 400 mg Dose level II: Topotecan weekly 4mg/m2, Pazopanib 600 mg Dose level III: Topotecan weekly 4mg/m2, Pazopanib 800 mg
Phase II Trial:
Phase II will either use the MTD as determined in Phase I or a lower dose if deemed necessary."
1682276|NCT01600534|Behavioral|lifestyle counseling|Participants receive lifestyle counseling on healthy eating and physical activity through an internet-based program or self-directed educational program.
1682277|NCT01600521|Drug|A Natural Remedy for Rheumatoid Arthritis vs. Common Drugs|The comparisons of the efficacy and safety of the following treatments for rheumatoid arthritis: paeoniflorin (PAE) + Cervus and Cucumis polypeptide injection (CCPI), methotrexate (MTX) + leflunomide (LEF), and MTX + LEF + CCPI.
1682278|NCT01600508|Other|Videoconference stoma care|Stoma patients are randomized to videoconference stoma care or surgical outpatients clinic stoma care
1682279|NCT01600495|Other|Experimental TENS|Use of Transcutaneous Nerve Electrical Stimulation in the lumbosacral region for 30 continuous minutes in the active phase of labor (4-5 cm).
1682280|NCT01600482|Device|CELT ACD|The CELT ACD will be used to achieve hemostasis of the common femoral artery in patients on anticoagulation who are undergoing a percutaneous intervention procedure using a 6F procedural sheath.
1682281|NCT01600469|Drug|DAOI-B|250-1500 mg/day, oral, for 24 weeks
1682282|NCT01600469|Other|Placebo|placebo, oral, for 24 weeks
1682283|NCT01600456|Behavioral|Prolonged exposure (PE)|PE will include 10 weekly sessions of individual cognitive behavioral therapy.
1682284|NCT01600456|Other|PE plus Sertraline|PE plus sertraline will include 10 weeks of prolonged exposure therapy plus sertraline. The sertraline dose will be up to 200 mg daily for 10 weeks. There will also be frequent meetings with study psychiatrist. PE will be provided 1x weekly for 10 weeks.
1732321|NCT00052299|Drug|etoposide|
1682285|NCT01600443|Device|LoFric|Three catheterizations at least two hours apart using LoFric Primo 40 cm CH14.
1682286|NCT01600443|Device|SpeediCath|Three catheterizations at least two hours apart using SpeediCath 40 cm CH14.
1682287|NCT01600443|Device|SpeediCath Compact Male|Three catheterizations at least two hours apart using SpeediCath Compact Male 30 cm.
1682288|NCT01600430|Dietary Supplement|Cholecalciferol|200 IU/day given orally once per day as one of 4 doses of 0.5ml each given every 6 hours. Other 3 doses will be placebo (sterile water). Duration of 28 postnatal days
1682289|NCT01600430|Dietary Supplement|Cholecalciferol|800 IU/day given orally per day as 4 doses of 200 IU/0.5ml each every 6 hours. Duration of 28 postnatal days
1682290|NCT01600430|Dietary Supplement|Placebo|Sterile water 0.5ml given orally every 6 hours. Duration of 28 postnatal days
1682291|NCT01600404|Drug|antimuscarinic treatment|
1682292|NCT01600391|Behavioral|Usual care|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Usual care intervention that does not include use of visual cues to influence quality or adaptability of gait.
1682293|NCT01600391|Behavioral|Overground visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Overground visual cue training will involve stepping to targets, which are positioned to improve walking pattern according to needs identified in baseline assessment. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice.Overground visual cue training will be delivered by National Health Service therapists in participating National Health Service sites.
1682294|NCT01600391|Behavioral|Treadmill visual cue training|Walking rehabilitation for 1 hour, 2 times per week and 8 weeks duration. Treadmill training with visual cues will be delivered using a force-instrumented treadmill (CMill, Forcelink, NL). The Treadmill visual cue training will involve participants stepping to targets shone onto a treadmill. Treatment will progress from practice of improved stepping pattern (symmetry of stepping) and speed to practice of adjusting footfalls by avoiding targets randomly, as one might need to be able to do to avoid an obstacle or an uneven surface. Training will also involve turning practice. Treadmill visual cue training will be delivered by qualified physiotherapists at the University of Birmingham.
1682295|NCT01600365|Drug|Ophthalmic gel (placebo)|Ophthalmic gel (placebo): applied in affected eye 4 times daily for 10 days
1682296|NCT01600365|Drug|Ganciclovir|Ophthalmic gel ganciclovir 0,3%: applied in affected eye 4 times daily for 10 days
1682297|NCT01600339|Drug|CABAZITAXEL|The patients are planned to receive cabazitaxel at a starting dose of 25 mg/m(2) intravenously over 1 h, following premedication as accepted with cabazitaxel. Treatment cycles are every 3 weeks. All patients will receive primary GCSF support.
1682298|NCT01600326|Procedure|Tenotomy (no injection)|Subjects randomized to this group will fill out a pre-treatment pain survey and have a blood draw They will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti-inflammatory medications for 2 weeks before the study. Two weeks after enrollment subjects see their referring physician to begin physical therapy.
1682299|NCT01600326|Drug|Ultrasound guided platelet rich plasma injection|"Subjects will fill out a pre-treatment pain survey, then will undergo ultrasound and have blood drawn from their arm.
The blood sample will be separated into blood cells and plasma. The plasma portion of the blood (liquid minus the cells) will be injected into the tendon under sterile conditions. Ultrasound will help guide the injection. This is called Ultrasound guided platelet rich plasma injection.
Subjects will be be contacted by the investigator by telephone or email on day 7 and day 14 to complete another pain survey. Subjects must avoid non steroidal anti inflammatory medications for 2 weeks before the study and 2 weeks after the study.
Subjects will see their referring physician two weeks after treatment to begin physical therapy."
1682300|NCT01600313|Dietary Supplement|rice bran oil|Treatment group received the low - calorie diet with(30g/day) rice bran oil
1682301|NCT01600300|Device|Tesmac|Subjects were treated twice daily for five consecutive days, followed by two days untreated, and then treated twice daily for five more consecutive days.
1682302|NCT01600300|Device|Sham Tesmac device|Treatment with inactivated Tesmac device on the same schedule as the group treated with the active Tesmac device.
1682303|NCT01600287|Other|IAADS|"In automatic mode, the system requests an update of the BIS data every 5 seconds and calculates the BIS error (difference between the target and actual BIS value). This value along with the trends of BIS in the epoch of the last 30 seconds as well as in the last 5 minutes is passed on to a patient individualized, model based adaptive control algorithm. The algorithm uses the error to calculate an adjustment to the propofol delivery rate, but does not apply it immediately. Adjustments to the propofol delivery rate are only made every 30 seconds, taking into account the sum of previous six BIS error values, the trends of BIS in the epoch of last 30 seconds as well as in the last 5 minutes, time elapsed since the initiation of infusion, pharmacokinetics, the time delay factor between sensing and averaging of BIS data, the time delay factor between the change in infusion rate and the actual change in the plasma concentration of propofol as well as the peak effect of propofol."
1682304|NCT01600287|Other|Manual propofol administration|"In manual mode, the user can also control the propofol infusion rate manually, using the keyboard or the mouse of the PC. The PC displays a graph of the propofol delivery rate and trend of BIS value."
1682306|NCT01600248|Behavioral|Online ABBT for Chronic Pain in Military|Participants will complete an 8-module, self-paced, online program for chronic pain using Acceptance-Based Behavioural Therapy (ABBT) as the therapeutic modality.
1682307|NCT01600235|Drug|Phenylephrine|Phenylephrine (0.12mg/mL) Starting dose: 10cc/hr Titration: increase 10cc/hr every 30-60min, maximum 160cc/hr rate: increase systolic blood pressure (SBP) 10-25mmHg /hr Target: initially 20% increase of initial SBP, up to improving NIHSS score or SBP 200mmHg
1682308|NCT01600222|Drug|LEO 90100|Calcipotriol 50 mcg/g (as hydrate) and betamethasone 0.5 mg/g (as dipropionate)
1682309|NCT01600196|Procedure|Liver resection plus Thrombectomy|Liver resection plus Thrombectomy
1682310|NCT01600183|Device|UNFO-s|The UNFO-s is a foot orthosis used to treat congenital foot malformations in infants
1682311|NCT01600183|Procedure|cast|casting of the infant legs
1732422|NCT00052884|Drug|melphalan|
1682312|NCT01600170|Drug|Atorvastatin (generic Lipitor)|Atorvastatin is an FDA approved prescription drug which is frequently used to lower cholesterol levels.It is available in the form of tablets ranging in dose from 10-80mg.
1682313|NCT01600170|Drug|placebo|A substance containing no medication and prescribed or given to reinforce a patient's expectation to get well.
1682314|NCT01600157|Procedure|Ambulant laparoscopic nephrectomy|The patients with a renal cancer diagnosis with be schedule to enter the project if they meet the inclusion criteria of the project and the postoperative period will be recorded to identified the limiting factors for ambulant laparoscopic nephrectomy.
1682315|NCT01600144|Other|digital mammography|data collection
1682316|NCT01600131|Behavioral|Caregiver problem-solving|This is a problem-solving intervention for stroke caregivers that can be delivered shortly after the Veteran's in-patient stays followed by online, in-home sessions. The investigators will modify the traditional, problem-solving intervention by adding web-based training using interactive modules, factsheets, and tools on the investigators' previously developed and nationally available RESCUE Caregiver website (www.ciddr8.research.va.gov/rescue). The investigators will also provide on-line, skills training and application of the problem-solving approach via the RESCUE messaging center.
1682317|NCT01600131|Other|Standard Care|No intervention or treatment will be provided. The investigators will closely monitor the usual care that is provided to caregivers.
1682318|NCT01600118|Device|Extracorporeal shockwave therapy|1000 impulses
1682319|NCT01600118|Device|No extracorporeal shockwave|0 impulses, acoustic effect
1682321|NCT01600092|Biological|RotaTeq™ experimental formulation|
1682322|NCT01600092|Biological|RotaTeq™ existing formulation|
1682324|NCT01600053|Drug|Lenalidomide|Lenalidomide will be taken orally days 1-21 for up to six 28-day cycles (6 cycles = 1 course of Revlimid consolidation). Revlimid will be initiated at 5mg and can be dose escalated at the start of each cycle based on individual patient tolerability to a maximum of 25 mg. The total number of treatment cycles cannot exceed 12 cycles or two courses of six cycles each.
1682325|NCT01600040|Radiation|Proton radiation therapy|5 days per week (Mon-Fri) for 5-6 weeks
1682326|NCT01600027|Procedure|Fascia iliaca compartment block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
1682327|NCT01600027|Procedure|Fascia iliaca block|Fascia iliaca compartment block was performed as described by Dalens et al technique.
1682328|NCT01600014|Drug|Ingenol mebutate gel, 0.015%|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
1682329|NCT01600014|Drug|Vehicle gel|Topical field treatment once daily for 3 consecutive days within a 25 cm2 treatment area on the face or scalp of AKs present or emerging after an initial treatment with ingenol mebutate gel, 0.015%
1682330|NCT01600001|Drug|KWA-0711|
1682331|NCT01600001|Drug|Placebo|
1682332|NCT01599988|Dietary Supplement|Caseinate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Caseinate
1682333|NCT01599988|Dietary Supplement|Milk Protein Isolate|The test meal is a vanilla flavoured enteral drink, containing 1.5kcal/ml, 21% CHO, 6% protein and 5% fat. The 6% protein in this test meal is Milk Protein Isolate.
1682334|NCT01599975|Drug|Long acting methylphenidate|Treatment with long-acting methylphenidate, 36 mg a day as 2 tablets of 18 mg each.
1682335|NCT01599975|Drug|Long acting methylphenidate|18 mg tablets, 2 tablets daily by mouth x 2 weeks, then washout x 2 weeks, then crossover to 2 tablets of matched placebo x 2 weeks.
1682336|NCT01599975|Drug|Matched placebo|2 tablets of matched placebo daily by mouth
1682337|NCT01599962|Drug|Cinacalcet|single administration, 90mg
1682338|NCT01599962|Drug|Placebo|single administration
1682339|NCT01599949|Drug|Ibrutinib|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. 560 mg oral ibrutinib is to be administered once daily continuously until disease progression, unacceptable toxicity, or study end, whichever occurs first. Doses can be held or reduced based on the severity of and the recovery from side effects of the study drug.
1682340|NCT01599936|Biological|Anascorp|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
1682341|NCT01599923|Biological|Antivenin Centruroides (scorpion) equine immune F(ab')2|3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
1682342|NCT01599910|Other|Scribes|Scribe
1682343|NCT01599897|Biological|ID93 + GLA-SE|ID93 antigen and GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
1682344|NCT01599897|Biological|ID93 alone|ID93 antigen alone. 3 injections and Days 0, 28, and 56.
1958201|NCT01905943|Drug|Cyclophosphamide|Participants will receive cyclophosphamide qd on Days 1 to 3 of each 28-day cycle from Cycle 1 to Cycle 6 as per invetigator's discretion.
1682347|NCT01599871|Drug|theophylline|theophylline 100 mg, twice at day
1682348|NCT01599871|Other|placebo|Placebo
1682349|NCT01599858|Drug|YF476|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
1682350|NCT01599858|Drug|Omeprazole|There were 4 treatments as follows: YF476 25mg twice daily, YF476 100mg twice daily, placebo and omeprazole 20mg once daily. Each treatment was taken by mouth for 7 days. Each subject took 1 of the 4 treatments.
1682351|NCT01599832|Drug|pazopanib hydrochloride|Given PO
1682352|NCT01599832|Other|laboratory biomarker analysis|Correlative studies
1682353|NCT01599832|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo dynamic contrast-enhanced magnetic resonance imaging
1682354|NCT01599832|Other|pharmacogenomic studies|Correlative studies
1682436|NCT01599104|Drug|Placebo|Placebo to LCZ696 or Olmesartan
1682357|NCT01599806|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
1682358|NCT01599806|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
1682359|NCT01599806|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
1682360|NCT01599806|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
1682361|NCT01599793|Drug|cabozantinib|Given PO
1682362|NCT01599793|Other|laboratory biomarker analysis|Correlative studies
1682363|NCT01599793|Procedure|magnetic resonance imaging|Undergo MRI
1682364|NCT01599767|Device|Transcranial direct current stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation (either active or sham), 1x per day at 20 minutes per session.
1682365|NCT01599754|Drug|Axitinib|Axitinib 5 mg twice daily
1682366|NCT01599754|Drug|Placebo|Placebo twice daily
1682367|NCT01599741|Radiation|Low-dose DSA (83% reduction compared to normal dose) with novel X-ray imaging technology.|Digital Subtraction Angiography (DSA) of iliac artery with reduced dose settings (83% dose reduction expected) in combination with novel X-ray imaging technology.
1682368|NCT01599741|Radiation|Normal dose DSA with conventional X-ray imaging technology|Digital Subtraction Angiography (DSA) of iliac artery with normal dose settings in combination with conventional X-ray imaging technology.
1682369|NCT01599728|Drug|Urocortin 2, Urocortin 3 and Substance P|"After a 20-min infusion of intra-arterial saline, ascending doses of Urocortin 2 (3.6, 12 and 36 pmol/min [15, 50 and 150 ng/min] to achieve estimated end-organ concentrations of 0.6, 2 and 6 µg/L, respectively), Urocortin 3 1200, 3600 and 12000 pmol/min (5, 15 and 50 micrograms/min) [to achieve estimated end-organ concentrations of 199, 600 and 2000 micrograms/L respectively] and substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release [2, 4 and 8 pmol/min]) will be administered intra-arterially.
Baseline blood samples will be taken at the start of the study for full blood count, cholesterol, glucose, renal function Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent measurement of plasma Ucn 2 and 3 concentrations and other hormones."
1682370|NCT01599715|Behavioral|Instructional DVD|Participants randomized to this arm watched an eighteen minute bladder health instructional DVD at the conclusion of a successful baseline screening visit. This intervention occurred only once.
1682371|NCT01599715|Behavioral|Bladder Health Class|Participants randomized to this arm attended a two-hour bladder health instruction session that reviewed 3 primary self-care techniques that have been proven to prevent or lessen the severity of urinary incontinence. This session occurred only once 1-3 weeks subsequent to a successful baseline screening visit.
1682372|NCT01599702|Drug|Iron Isomaltoside 1000|1500-3000mg IV depending on HB level, sex and body weight
1682374|NCT01599676|Dietary Supplement|Citrulline|The subject will receive citrulline 10 g/day orally in the morning for 12 weeks.
1682375|NCT01599676|Dietary Supplement|Non essential amino acid|Non essential amino acid supplementation
1682377|NCT01599650|Drug|Ranibizumab|
1682378|NCT01599650|Procedure|Laser|laser photocoagulation
1682379|NCT01599637|Drug|IGE025|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
1682380|NCT01599637|Drug|placebo|Study medication will be supplied as a lyophilized, sterile powder in a single-use, 5-mL vial.
1682381|NCT01599624|Behavioral|Stress Resilience Training System (SRTS)|SRTS training provides both cognitive learning and training in a scientifically-designed stress resilience training approach designed to minimize the adverse effects of stress and also enhance its positive effects. In summary, the SRTS training comprises: (1) Cognitive rules and mental exercises based on expert knowledge and research; (2) Biofeedback stress control exercises based on proven HRV (Heart Rate Variability) algorithms developed by the Institute of HeartMath; and (3) E-Learning presentation of games and simulations to motivate younger trainees. The training is designed to familiarize participants with the iPad and the SRTS program. Participants will be told how to use the system and how often to use the system. SRTS program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
1682382|NCT01599624|Behavioral|Progressive Muscle Relaxation (PMR)|Progressive muscle relaxation is the systematic tensing and relaxing of 16 different muscle groups, starting with one's toes and ending with one's head (Jacobson, 1938; Conrad & Roth, 2007). PMR users are instructed to inhale as they tense the muscles and exhale as they release the tension. Participants will participate in a two-hour PMR training. PMR participants will be given iPADs with a video recording that guides the user through working each muscle group while instructing them to focus on positive thoughts and feelings and breathing techniques. PMR program participants will each be assigned an iPad to take home with them and practice the techniques for a period of two months.
1682383|NCT01599611|Procedure|Movement assessment battery for children - 2|A standardised test developed to identify developmental difficulties in children.
1684785|NCT01581398|Drug|Ypeginterferon alfa-2b|sc, qw, 24 weeks.
1682384|NCT01599598|Behavioral|Progressive Muscle Relaxation|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will listen to PMR instruction by way of a mp3 player.
1682385|NCT01599598|Behavioral|Coherence Advantage|Participants will be instructed to practice the techniques twice daily for 5-15 minutes per session, and subsequently use the techniques when confronted with a stressful event such as a project deadline, exam, skill evaluation, etc. Participants in this condition will practice the techniques while using a biofeedback device to recognize when they enter psychophysiological coherence.
1682386|NCT01599585|Behavioral|Behavioral Activation|Behavioral activation(BA)will be delivered in 8 weekly sessions via webcam for the in-home arm or face to face in the in-person arm. Behavioral activation attempts to help depressed individuals reengage in their lives through focused activation strategies.
1682387|NCT01599572|Other|zinc supplementation|30mg/day of zinc in the form of zinc gluconate
1682388|NCT01599559|Other|observation|observation
1682389|NCT01599559|Radiation|3D-Conformal Radiotherapy (3D-CRT)|Radiation treatment should start within 6-8 weeks after the end of chemotherapy.
1682390|NCT01599533|Other|blood samples|
1682393|NCT01599507|Drug|FG-4592|TIW dosing, capsule
1682394|NCT01599507|Drug|Placebo|TIW dosing, capsule
1682395|NCT01599494|Drug|MK-8962|"MK-8962 is supplied in a ready-to-use prefilled syringe containing
100 microgram (μg) or 150 μg corifollitropin alfa per 0.5 mL. Participants are randomized to receive a single subcutaneous (SC) injection of MK-8962 in the abdominal wall on Cycle Day 2 or Cycle Day 3. Dose of administered MK-8962 is weight-based. Participants who weigh 60 kilograms (kg) or less will be given 100 μg MK-8962 and those who weigh more than 60 kg will be given 150 μg MK-8962."
1682396|NCT01599494|Drug|recFSH|Recombinant Follicle Stimulating Hormone (recFSH) will be supplied as a ready-to-use solution in a 600 IU cartridge for SC injection via the recFSH Pen. Starting on Day 2 or 3 of the menstrual cycle (Stimulation Day 1), recFSH will be administered daily, each morning, via injections in the abdominal wall. A starting dose of between 150 - 300 IU will be administered and is fixed for the first week of stimulation. After 6 days, and based on each participant's individual response, the Investigator may decide to reduce the fixed dose for the remainder of the study. The maximum duration of stimulation is 19 days; recFSH will not be administered on the Day of hCG Administration.
1682397|NCT01599494|Drug|Ganirelix|0.25 mg/day SC injection in the upper leg, administered on Stimulation Day 5 up to and including Day of hCG Administration
1682398|NCT01599494|Drug|human Chorionic Gonadotropin (hCG)|Single dose of 10,000 or 5,000 IU hCG, administered via SC injection on Day of hCG Administration.
1682399|NCT01599494|Drug|Progesterone|Crinone 8% (90 mg) gel administered intravaginally via a single-use, one piece polyethylene vaginal applicator once-daily on Day of Oocyte Pick-up or 1 day later and continued for at least 6 weeks or either up to menses or up to a negative pregnancy test performed at least 18 days after Day of Oocyte Pick-up.
1682400|NCT01599481|Behavioral|Individual Career Management (ICM)|The intervention will be Individual Career Management (ICM) support for a six month period. ICM consists of individually tailored support to help an individual to obtain and retain in employment. ICM follows the seven principles of supported employment (often referred to an Individual Placement and Support), but includes the additional principles of career counselling, motivational coaching, education and training support, and specialist job retention support. The length and frequency of ICM support sessions is determined by the needs of the client.
1682401|NCT01599481|Behavioral|Standard Care|A package of psychological therapy delivered by an Improving Access to Psychological Therapies (IAPT) practitioner.
1682402|NCT01599468|Drug|Tranexamic Acid|10 mg/kg of tranexamic acid as induction dose within 12 minutes and 1mg/Kg/h as maintenance within the 2 following hours
1682403|NCT01599468|Drug|saline serum|The Placebo group received normal saline with the same volumes
1682404|NCT01599416|Dietary Supplement|U-relax|Oral U-relax Day 1-5: 2 capsuals before sleep Day 6-360: 1 capsual before sleep
1682405|NCT01599403|Procedure|Paravertebral Block|The paravertebral block consists of injection of local anesthetics into the area next to the spinal column and results in regional pain control. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
1682406|NCT01599403|Procedure|Intercostal Nerve Block|The intercostal nerve block will consist of placing a catheter which delivers pain medication into the area between the ribs. This technique of this block may be performed on multiple levels if there are extensive rib fractures and may be performed on both sides of the rib cage depending on injury.
1682407|NCT01599403|Procedure|Epidural Block|The epidural block consists of continuous infusion of local anesthetics into the epidural catheter placed into the epidural space (next to the spinal column) and results in regional pain control. This technique of this block may be performed at the appropriate level so the pain of rib fracture may be better controlled.
1682408|NCT01599390|Other|Data collection|"The study will use multiple primary data sources: the Nationwide Inpatient Sample (for hospitalisations) and the US National Vital Statistics System (for mortality), and weekly virology data from the Centers for Disease Control and Prevention (CDC) influenza surveillance program supplemented with literature data.
Weekly time series of the rates of various severe influenza-related health outcomes will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the CDC virology data, will be constructed to estimate the portions of the various outcomes that can be attributed to influenza. Next, the seasonal impact of influenza by age, risk status, and influenza subtype will be assessed. Finally, the potential burden that a quadrivalent vaccine could have prevented over the 12 year study period will be predicted."
1682409|NCT01599377|Drug|tofacitinib 10 mg|Cohort 1 will consist of 2 periods and 2 sequences. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 10 mg tofacitnib tablet under fasting conditions in period 1, followed by a 10 mg tofacitinib capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
1682410|NCT01599377|Drug|tofacitinib 5 mg|Cohort 2 will consist of 2 periods and 2 sequences. A total of 24 healthy subjects will be enrolled for this cohort. Subjects will be randomized to one of the 2 sequences. In sequence 1, subjects will receive a 5 mg tablet under fasting conditions in period 1, followed by a 5 mg capsule in fasting conditions in period 2. In sequence 2, the treatments will be reversed for period 1 and 2.
1682411|NCT01599364|Drug|Atazanavir, ritonavir, lamivudine|Lamivudine 300 mg 1 pill once-a-day, atazanavir 300 mg 1 pill with ritonavir 100 mg 1 pill once-a-day, taken together orally with a light meal
1682412|NCT01599351|Radiation|The radiographic-fluoroscopic system|Fluoroscopy was used during ERCP procedure. With automatic brightness adjustment, patients with thicker body will get greater radiation dose.
1682413|NCT01599338|Drug|Liraglutide|3 months of treatment by Liraglutide (self-administration). The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months.
1682414|NCT01599325|Drug|Azacitidine|Subcutaneous administration of azacitidine 75 mg/m^2/day for 7 days every 28 days optimally for at least 6 cycles until disease progression, unacceptable toxicity, or treatment discontinuation for any other reason
1682415|NCT01599312|Device|Forces exerted on teeth during intubation|Anesthesia will be induced in the conventional matter. The classic Macintosh laryngoscope will be placed in the patient's mouth and a tube will be brought into position in front of the glottis. Hereafter, one of the three videolaryngoscopes will be placed in the patient's mouth and the endotracheal tube will be actually passed through the vocal cords. The measurement of forces applied to the teeth will be performed using Flexiforce® sensors.
1682416|NCT01599286|Drug|Carbaglu|"Carbaglu Chemical Composition: N-carbamoyl-L-glutamic acid (NCG)
The daily dose will be 150 mg/kg/ day or 3.3 g/m2/day for patients >15 kg and will be administered for 7 days or until discharge, whichever is sooner. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube. Standard of care will prevail when choosing the mode of drug administration.
The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast-push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste."
1682417|NCT01599286|Drug|Placebo|
1682418|NCT01599286|Drug|Standard of Care Treatment|
1682419|NCT01599273|Drug|subconjunctival triamcinolone injection|Patients are randomized into two groups: Injection (Group 1) and observation-only controls (Group II). In Group I, patients were treated with 1-3 injections of 20 mg triamcinolone acetate using a 30-gauge needle into the subconjunctival region of the lid between the conjunctiva and Muller's muscle. Injections were stopped after 1-2 injections if both swelling and retraction resolved completely, or if one eye scored 0 and the contralateral eye scored 1, and there existed no patient concern after physician inquiry regarding function and cosmetic appearance.
1682420|NCT01599260|Other|Resistance Exercise|Two 30-minute individually supervised exercise sessions per week for 16-weeks
1682421|NCT01599234|Drug|Sativex|Contains delta-9-tetrahydrocannabinol (THC) (27mg/ml): cannabidiol (CBD) (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg:CBD 60 mg) in 24 hours.
1682422|NCT01599234|Drug|Placebo|Contains peppermint oil flavouring, 0.05%(v/v); quinoline yellow,0.005% (w/v) and sunset yellow, 0.0025% (w/v) colourants, in a and ethanol:propylene glycol (50:50) excipient.
1682423|NCT01599221|Device|EBA2|Surgical implantation of EBA2 medical device in subjects with lateral proximal femoral fractures treated
1682424|NCT01599208|Device|TMS|TRANSCRANIAL MAGNETIC STIMULATION
1682425|NCT01599195|Device|AudioDoc|AudioDoc will be used to identify the carotid and femoral bruit
1682426|NCT01599169|Dietary Supplement|Dietary supplement : B-Back® (α-casozepine, taurine, eleutherococcus senticosus, Extramel)|2 tablets/day after breakfast during 12 weeks
1682427|NCT01599169|Dietary Supplement|B-Back® placebo (without active compounds)|2 tablets/day after breakfast during 12 weeks
1682428|NCT01599156|Procedure|Reflexology|Reflexology is a therapy whereby diagnosis and treatment are done on the patient's feet. According to reflexology, our feet are a micro-cosmos of our bodies and contain all the body's systems and internal organs. The treatment is palpation and massage of specific reflex points that respond to the body organs. This massage or palpitation of reflex points improves the physical function of the corresponding organ or system
1682429|NCT01599143|Behavioral|Teaching Mindfulness-based Stress Reduction strategies|Daily meditation, Hatha yoga,and cognitive restructuring
1682430|NCT01599130|Drug|Entecavir|entecavir 0.5mg per day
1682431|NCT01599130|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180ug per week
1682432|NCT01599117|Drug|Placebo|Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company. Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
1682433|NCT01599117|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
1682434|NCT01599104|Drug|LCZ696|200 mg (one tablet) or 400 mg (2 tablets of 200mg) once daily
1732497|NCT00053222|Drug|arsenic trioxide|
1682437|NCT01599091|Other|Specimens collection|Tooth extraction will be preformed in the regular way regardless of the study. Patients will be asked permission to obtain the extracted tooth and excess of gingival remnants for further in vitro investigation in the main investigator's laboratory.
1682438|NCT01599078|Drug|Paclitaxel|Drug dosing is 3mcg/mm3 of artery treated with percutaneous revascularization. Drug will be administered via the TAPAS catheter and allowed to dwell for 5 minutes.
1682439|NCT01599078|Drug|Placebo|Saline will be administered intra-arterially via the TAPAS catheter following percutaneous revascularization. The dwell time will be 5minutes.
1682440|NCT01599065|Other|Magnet or Off-On|Randomized to ICD suspension using a magnet or turning the ICD off and then back on.
1682441|NCT01599013|Drug|Vinflunine, Gemcitabine|"Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal
Gemcitabine 750 or 1000 mg/m2, IV administration over 30 minutes (starting dose based on baseline creatinine clearance value), Day 1 and 8 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
1682442|NCT01599013|Drug|Vinflunine, Carboplatin|"Vinflunine 280 or 250 mg/m2, IV administration over 20 minutes (starting dose based on baseline creatinine clearance value), Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal
Carboplatin AUC 4.5, IV administration over 60 minutes, Day 1 every 3 weeks up to progression or unacceptable toxicity or patient's refusal"
1682443|NCT01599000|Drug|Artemether-lumefantrine combination|fixed-dose tablet, six doses over three days, according to weight group
1682444|NCT01598987|Drug|Introduction of everolimus with reduced cyclosporine or tacrolimus dose, the earliest 1 month and the latest 6 months after liver transplantation.|Immunosuppression after liver transplantation. Pediatric transplant recipients received a starting dose of 0.8 mg/m^2/dose in combination wit Cyclosporine A or 2.0 mg/m^2/dose in combination with tacrolimus, twice-daily. Thereafter, doses were adjusted to achieve everolimus C-0h blood trough level between 3 to 8 ng/ml.
1682445|NCT01598974|Procedure|Traditional Acupuncture|
1682446|NCT01598974|Procedure|Laser Acupuncture|
1682447|NCT01598961|Other|TOF count-guided partial NMB|Using partial neuromuscular blockade to maintain train-of-four response of two, TOF response measured by the neuromuscular transmission module (NMT module)
1682448|NCT01598961|Other|T1/Tc guided partial NMB|Using partial neuromuscular blockade to maintain T1/Tc amplitude of 50%, T1/Tc amplitude measured by the neuromuscular transmission module (NMT)
1682449|NCT01598961|Other|No NMB|to maintain no neuromuscular blockade during LSR monitoring except the intubation dose during anesthetic induction
1682450|NCT01598948|Drug|mipomersen|mipomersen 200 mg subcutaneously every week for 37 weeks (phase 1: 26 weeks; phase 2: 11 weeks)
1682451|NCT01598935|Other|nutrition|protein-based food
1682453|NCT01598909|Drug|Arnica|Application of Arnica ointment periorbitally
1682454|NCT01598909|Drug|Placebo ointment|Application of Arnica ointment, twice a day, for the period of one week.
1682455|NCT01598896|Drug|Dronabinol|Dronabinol titrated to 5 mg three times daily
1682456|NCT01598896|Drug|Clonidine|Clonidine 0.1 mg twice daily
1682457|NCT01598896|Drug|Placebo|One placebo capsule by mouth twice daily
1682458|NCT01598883|Drug|Heparin|150 U/kg
1682459|NCT01598883|Drug|ATryn|1000 IU
1682460|NCT01598870|Other|Diagnostic tests|Leukocyte count by automated counters; reagent strips for leukocyte esterase and for lactoferrin; ascitic fluid pH; leukocyte cytometry; bacterial DNA detection and quantification.
1682461|NCT01598857|Drug|Blisibimod|
1682462|NCT01598857|Drug|Placebo|
1682463|NCT01598844|Device|Transcatheter aortic valve replacement|Transcatheter aortic valve replacement via a transapical access
1682464|NCT01598831|Drug|ART-123|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days
1682465|NCT01598831|Drug|Placebo|Dose: 0.06 mg/kg/day up to a maximum dose of 6 mg/day for 6 days.
1682466|NCT01598805|Behavioral|electronic alerts|An eAlert is displayed in the electronic patient chart if no prophylaxis has been ordered within 6 h after admission or transfer.
1682467|NCT01598792|Biological|ADXS11-001|Escalating doses will be administered: 3.3 x 10e8,1 x 10e9 and 3.3 x 10e9 cfu to patient in 3 different groups. Dose-escalation will only occur if fewer than two patients in each group of six experience Dose Limiting Toxicity (DLT).
1682468|NCT01598766|Device|16 Channel SPEEDER Flex Coil|This is a 16 element MRI coil, flexible, lightweight. Multiple uses.
1682469|NCT01598753|Drug|Tramadol|"50 mg tablets titrated up to 2 tablets four times per day for a maximum dose of 400mg per day.
Minimum accepted dose of 200mg per day"
1682470|NCT01598753|Drug|Placebo|Pharmacological inactive tablet, 50mg tablets titrated to 2 tabs per day up to 400mg
1682471|NCT01598753|Behavioral|Cognitive Behavior Therapy for FM|Subjects will be seen for 8 weekly 50 minute sessions of Cognitive Behavior Therapy that has been specifically tailored for Fibromyalgia patients.
1682472|NCT01598753|Behavioral|Health Education|Subjects will receive 8 weekly 50 minute sessions of Health Education on Fibromyalgia
1682473|NCT01598740|Drug|CLP|Oral administration
1682474|NCT01598740|Drug|Spironolactone|oral administration
1682475|NCT01598727|Device|Fluobeam(TM) Imaging System (Fluoptics)|Use of 'Fluobeam(TM)' (Fluoptics) as an intraoperative real time fluorescence detection system during surgery
1682476|NCT01598714|Device|Darco shoe|Darco shoe
1682477|NCT01598714|Device|Podalux shoe|Podalux shoe
1682478|NCT01598714|Device|Standard dressing shoe|Standard dressing shoe
1682516|NCT01598389|Other|Feeding study|In a crossover design, siblings were served dinner once a week for 3 weeks. Across conditions, siblings were served the same dinner, but, 25 minutes before dinner, they either consumed in full or did not consume one of two preloads that varied in energy density. On the day when no preload was consumed, eating in the absence of hunger was assessed after dinner and defined as the number of calories consumed from snacks. Habitual dietary intake was assessed using 24-hour dietary recalls.
1684786|NCT01581398|Drug|Pegasys|sc, qw, 24 weeks.
1682481|NCT01598688|Other|Blood collection immediately after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion immediately after interrupting the drug infusion.
For peripheral blood collection, venous access will be established with a small gauge needle.
The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
1682482|NCT01598688|Other|Blood collection five minutes after interrupting CSA infusion|"Blood samples were collected from the peripheral venous access, from the catheter line used to infuse the drug and from the line not used for infusion five minutes after interrupting the drug infusion.
For peripheral blood collection, venous access will be established with a small gauge needle.
The discard method will be adopted for catheter lines collection. Each catheter line is washed with 20 ml of 0.9% normal saline solution, 5 mL of blood are collected and discarded. Using another syringe, the blood volume needed to perform the analysis will then be collected. Additionally, another blood sample will be collected from the catheter line not used to infuse the drug after the discard of 10 mL."
1682483|NCT01598675|Other|Same Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Control-Dual-belted treadmill belts respond to encourage symmetric gait
1682484|NCT01598675|Other|Different Belt Speeds|18 sessions of training (3X/week). 20 minutes/session on treadmill; 10 minutes/session overground 70-75%HRmax. Treadmill belts of dual-belted treadmill respond either to amplify asymmetric gait or encourage symmetric gait.
1682486|NCT01598649|Dietary Supplement|Fabricated foods with lupin protein|- Foods containing altogether 25 g lupin protein isolate (bread, roll, sausage, spread)
1682487|NCT01598649|Dietary Supplement|Mannitol|- Placebo capsules containing mannitol (four capsules per day)
1682488|NCT01598649|Dietary Supplement|Arginine|- Capsules containing arginine (four capsules per day with a total daily dosage of 1,6 g)
1682489|NCT01598649|Dietary Supplement|Fabricated foods with milk protein|Foods containing altogether 25 g milk protein isolate (bread, roll, sausage, spread)
1682490|NCT01598636|Procedure|Lateral tibial tunnel|To reduce the rehabilitation time after ACL revision surgery due to a better surgical technique
1682491|NCT01598623|Drug|Oxytocin|24 IU Intranasal, three times daily (morning, noon and evening, before meals) for 3 weeks (21 days).
1682492|NCT01598623|Behavioral|Social Skills Training|three times a week for three weeks.
1682493|NCT01598623|Behavioral|Placebo + Non Specific Counselling|
1682494|NCT01598610|Device|CONTOUR® PLUS Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick and palm blood using the CONTOUR® PLUS Investigational BG Monitoring System. Study staff test subject venous blood. All Blood Glucose (BG) results are compared to a reference laboratory glucose method.
1682495|NCT01598584|Drug|Mirtazapine plus gemcitabine|Mirtazapine,15mg/day for 3 days, If patients is durable, the dosage increase to 30mg/day, if the patient is durable, the doctor then will decided whether to increase to 45mg. Gemcitabine 1000mg/M2,d1,d8,q3w
1682496|NCT01598584|Drug|Gemcitabine, placebo|Gemcitabine 1.0g/m2,d1,d8,q3w placebo
1682497|NCT01598571|Drug|Fostamatinib|Fostamatinib 50 mg tablet
1682498|NCT01598571|Drug|Fostamatinib|Fostamatinib 100 μg [14C] R406 intravenous micro tracer dose
1682499|NCT01598558|Drug|Cu-64 Rituximab|Up to 14 mCi, iv
1682500|NCT01598545|Drug|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
1682501|NCT01598532|Device|MedX Health Phototherapy (light therapy)|The treatment period is 6 weeks (3x per week) for a total of 18 Transcranial LED treatments. Each treatment session is 30 minutes each.
1682502|NCT01598519|Behavioral|suicide intervention|"universal intervention:(1)students: 4 sections about cherishing life, coping strategies, suicide and depression disorder during 2 semesters, each session lasting 45 minutes.(2)gatekeeper: 4 sessions about teenagers psychological crisis intervention strategies during 2 semesters, 30minutes per session.
indicated intervention: (1)student: 2 semesters, 20 sessions' group life skill and cognitive-behavioral psychological training lesson, including Youth rational emotive group tutoring(eight classroom sessions), Coping skill group tutoring(six classroom sessions)and Behavior group tutoring(six classroom sessions), once a week, each session lasting 1.5hours.(2)gatekeeper: a social support net."
1682503|NCT01598506|Drug|Hydromorphone|Hydromorphone will be administered one time intrathecally to laboring patients to determine the ED50 for pain relief.
1682504|NCT01598493|Device|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
1682505|NCT01598493|Drug|Flamazine|Silver sulfadiazine cream
1682506|NCT01598480|Drug|Flamazine|Silver sulfadiazine cream
1682507|NCT01598480|Device|BCT Antimicrobial Dressing|Activated carbon fiber impregnated with silver particles
1682508|NCT01598467|Procedure|Robotic assisted sacrocolpopexy (RASC)|Robotic assisted sacrocolpopexy (RASC) will be performed with the Da Vinci Surgical robot (Intuitive Surgical). THe mesh used will be a Type I (Amid classification), polypropylene mesh
1682509|NCT01598454|Drug|racotumomab|Dosage form: intradermal injection. Dosage: 0.15 mg; 0.25 mg; 0.4 mg. Frequency: 3 biweekly injections or 6 biweekly injections. Duration: 4 weeks or 10 weeks.
1682510|NCT01598441|Drug|iloprost nebuliser solution|Iloprost nebuliser solution 500 ng/kg inhaled(10 min recommended) q3h for 2 days
1682511|NCT01598441|Drug|distilled water|1-2 ml aerosolized distilled water inhalation per session
1682512|NCT01598428|Procedure|anterior capsule polishing|polish the anterior capsule and the equator of capsule extensively with a Whitman Shepherd Double-Ended Capsule Polisher
1682513|NCT01598415|Drug|SAR113945|"Pharmaceutical form:Injection
Route of administration: Intra-articular"
1682514|NCT01598415|Drug|placebo|"Pharmaceutical form:Injection
Route of administration: Intra-articular"
1682515|NCT01598402|Drug|amoxicillin/clavulanic acid suspension|625 mg tid, start day 29 after the start of CRT until 14 days after the end of CRT
1732745|NCT00046033|Drug|Saquinavir|
1682517|NCT01598376|Procedure|7/0 vicryl suture|7/0 vicryl test suture placed as one of 3 everting sutures
1682518|NCT01598376|Procedure|5/0 vicryl test suture|5/0 vicryl test suture placed as one of 3 everting sutures
1682519|NCT01598363|Drug|Digoxin|Oral, Day 1 and Day 10
1682520|NCT01598363|Drug|Rosuvastatin|Oral, Day 1 and Day 10
1682521|NCT01598350|Device|Supramalleolar Orthoses (Cascade)|Walk wearing supramalleolar orthoses - three trial
1682522|NCT01598337|Drug|Aspirin|Patients continue their maintenance dose not inturrupted by surgery , 81 mg daily
1682523|NCT01598337|Drug|Tirofiban|Tirofiban infusion as specified by investigators to start after hemostasis been established
1682524|NCT01598337|Drug|Clopidogrel|75 mg orally started 6-8hours before surgery
1682525|NCT01598337|Drug|Prasugrel|10 mg daily as per instructions of investigators
1682526|NCT01598311|Drug|CB-183,315|oral, 250 mg bid for 10 days
1682527|NCT01598311|Drug|oral vancomycin|oral, 125 mg qid for 10 days
1682528|NCT01598298|Drug|duloxetine hydrochloride|Given PO
1682529|NCT01598298|Other|placebo|Given PO
1682530|NCT01598272|Dietary Supplement|Vitality product AM + Vitality product PM|Vitality AM: Tak 6 capsules daily for 56 days Vitality PM: Take 2 capsules daily for 56 days
1682531|NCT01598272|Dietary Supplement|Placebo|Placebo AM: Take 6 capsules daily for 56 days Placebo PM: Take 2 capsules daily for 56 days
1682532|NCT01598259|Drug|Melatonin|po 1 hour before bedtime
1682533|NCT01598259|Other|placebo|po, 1 hour before bed
1682534|NCT01598233|Device|Silimed Intragastric balloon|Intragastric balloon inflated with 650 ml of NaCl 0.9% mixed with 20 ml of methylene blue solution
1682535|NCT01598220|Behavioral|Computer-assisted cognitive remediation therapy|"Comparison of two groups:
The experimental group performs 48 sessions of computer exercices designed to remedy cognitive domains(attention, speed of processing, working memory,reasoning and problem solving) frequently affected in schizophrenia.
The intervention has a period 6 months , two sessions a week. All exercises provided a visual or verbal feedback to immediately terminate the execution.In addition to, the therapist after the sessions interactively explain the results and the strategies employed by the patient."
1682536|NCT01598220|Other|attentional task|The Control group performs 48 sessions of watching videos and answer questions about these videos, in a period of 6 months , two sessions a week.
1682537|NCT01598207|Drug|Marinol|5mg BID, orally for 1 month
1682538|NCT01598207|Drug|Placebo|5mg BID, orally for 1 month
1682539|NCT01598194|Device|Novel 22-gauge Core Biopsy Needle + Standard Biopsy Needle|Two passes performed with the standard 22-gauge or 25-gauge straight hollow core needle and two passes will be performed using the 22-gauge EchoTip® Procore™ needle. All passes will be taken from a single lesion and from the same endoscopic location.
1682540|NCT01598181|Device|tDCS NeuroConn DC-stimulator plus|Anodal tDCS, M1, cathode supraorbital left, 2 mA, 20 min, 5 consecutive days.
1682541|NCT01598181|Device|sham tDCS|similar montage and time as active. Stimulation fades out after 20 sec.
1682542|NCT01598168|Drug|Rivaroxaban|Rivaroxaban 15 mg bid until HIT excluded by local laboratory assay or platelets recovered. If HIT positive and platelets have recovered, patients will receive rivaroxaban 20 mg od until Day 30.
1682543|NCT01598155|Procedure|Group 1 - Supragingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):
Scaling, planning and polishing coronary surface;
Education and motivation for oral hygiene and daily supragingival biofilm control by the patient."
1682544|NCT01598155|Procedure|Group 2 - Supra- and subgingival biofilm control|"30 days after the end of periodontal treatment, participants assigned to this group, will receive every 3 months (over 24 months):
Scaling, planning and polishing of coronary surface;
Education and motivation for oral hygiene and daily supragingival biofilm control by the patient;
Subgingival scaling and root planning in sites with persistent bleeding on probing and probing depth unchanged."
1682545|NCT01598142|Procedure|Team 1|experienced endoscopist with a experienced assistant
1682546|NCT01598142|Procedure|Team 2|same experienced endoscopist with a new trained assistant
1682547|NCT01598129|Genetic|ONCOS-102|GMCSF encoding 3/5 chimeric adenovirus for intratumoral and intravenous injection on day 1, 4, 8, 15, 29, 57, 85, 113 and 141 tested in three different dose cohorts (3x10E10, 1x10E11 and 3x10E11) in combination with low-dose metronomic cyclophosphamide.
1682548|NCT01598116|Procedure|Urine collection and ultrasonography|Bagged urine collection and ultrasound at each visit
1682549|NCT01598116|Procedure|Urine collection|Bagged urine collection
1682550|NCT01598103|Drug|SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
1682551|NCT01598103|Drug|Placebo to SAF312|One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
1682552|NCT01598090|Biological|Peginterferon Lambda-1a|Syringes, subcutaneous (SC), 180μg, Once weekly, 24 or 48 weeks depending on response
1682553|NCT01598090|Biological|Peginterferon Alfa-2a|Syringes, SC, 180μg, Once weekly, 24 or 48 weeks depending on response
1682554|NCT01598090|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 24 or 48 weeks depending on response
1682555|NCT01598090|Drug|Telaprevir|Tablets, Oral, 750 mg, three times a day, 12 weeks only
1682556|NCT01598077|Drug|LJM716|
1682557|NCT01598064|Dietary Supplement|GK#10|GK#10, 1 pack tid
1682558|NCT01598064|Drug|Placebo|Placebo 1 pack tid po
1682559|NCT01598051|Drug|Rivaroxaban (Xarelto_ BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
1682560|NCT01598038|Other|Blood sample|Everolimus is determined in whole blood by validated high performance liquid chromatography with tandem mass spectrometry after protein precipitation
1682561|NCT01598025|Radiation|total-body irradiation (TBI)|
1682562|NCT01598025|Drug|thiotepa|
1682563|NCT01598025|Drug|fludarabine phosphate|
1682564|NCT01598025|Drug|melphalan|
1682565|NCT01598025|Biological|anti-thymocyte globulin|
1682566|NCT01598025|Procedure|allogeneic hematopoietic stem cell transplantation|
1682567|NCT01598025|Biological|peripheral blood stem cell transplantation|
1682568|NCT01598025|Other|laboratory biomarker analysis|
1682608|NCT01597713|Drug|placebo|Subjects will receive a single dose of oral placebo within each dose group
1682569|NCT01598012|Drug|Ayurved Siriraj Prasaplai with or without mefenamic acid|Prasaplai in capsule, 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain (as rescue medication)
1682570|NCT01598012|Drug|Placebo with or without mefenamic acid|Placebo in capsule (physically identical appearance as Prasaplai) 2 cap three times a day for 3 days. Mefenamic acid 500 mg prn for severe pain, every 6 hours (rescue medication)
1682571|NCT01597999|Radiation|MRI|magnetic resonance imaging (MRI) with Gadovist in early breast cancer with poor prognostic features
1682572|NCT01597986|Drug|isavuconazole|oral
1682573|NCT01597986|Drug|Oral Contraceptive (ethinyl estradiol / norethindrone)|contraceptive pill consisting of ethinyl estradiol and norethindrone
1682574|NCT01597973|Drug|colistin and meropenem|colistin standard loading dose, maintenance dose based on patients renal function meropenem- dose based on patients renal function
1682575|NCT01597973|Drug|colistin and placebo|colistin- loading dose standard, maintenance dosed based on patients renal function placebo- mimic meropenem (blinded)
1682576|NCT01597960|Other|Yoga|Those randomised to usual care plus the yoga intervention will be required to attend yoga classes twice a week for 12 weeks alongside their cardiac rehabilitation programme. There will be 24 yoga classes in total, of which, we require the participant to attend a minimum of 18. The yoga classes will be conducted by a teacher certified in yoga and cardiac rehabilitation and will encompass physical fitness (yoga poses), stress reduction (breath control and meditation) and positive lifestyle changes (diet, smoking and alcohol).
1682577|NCT01597947|Drug|ACHN-975|Intravenous single dose
1682578|NCT01597947|Drug|placebo|Intravenous single dose
1682579|NCT01597934|Drug|Group A (Zeffix, Sebivo, Hepsera)|Maintaining LAM/LdT+ADV combination Lamivudine 100mg / Telbivudine 600mg +Adefovir 10mg
1682580|NCT01597934|Drug|Group B (Baraclude, Viread)|Switching to ETV plus TDF combination Entecavir 1.0mg + Tenofovir 300mg
1682581|NCT01597908|Drug|Dabrafenib|dabrafenib 150 mg twice daily po
1682582|NCT01597908|Drug|Vemurafenib|vemurafenib 960 mg twice daily po
1682583|NCT01597908|Drug|Trametinib|trametinib 2 mg once daily po
1682584|NCT01597895|Drug|Maraviroc|Maraviroc 150 mg BID x 5 days with food
1682585|NCT01597895|Drug|Maraviroc + Boceprevir|Maraviroc 150 mg BID + Boceprevir 800 mg TID x 10 days with food
1682586|NCT01597895|Drug|Maraviroc + Telaprevir|Maraviroc 150 mg BID + Telaprevir 800 mg TID x 10 days with food
1682587|NCT01597869|Device|Endobronchial ultrasound|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions.
1682588|NCT01597856|Behavioral|SBIRT|"SBIRT Therapy overview-
Therapist explains purpose of the therapy.
Inquiry about Compensation examination-ask if Veteran has questions about determination process and address concerns.
Discuss relationship between PTSD and substance use- long-term substance use is a form of avoidance and barrier to recovery.
Discuss treatment needs, administer screening, provide feedback."
1682589|NCT01597843|Other|Education|Series of training sessions, in person and on line, to educate post superusers who will in turn educate post members on the utility and mechanics of use of MHV.
1682590|NCT01597830|Other|Mobility shoe|flat, specialized shoe
1682591|NCT01597830|Other|control shoe|control shoe
1682592|NCT01597817|Other|chitosan coated textile|chitosan coated cotton long sleeved shirts and pants.
1682593|NCT01597817|Other|chitosan free cotton long sleeved t-shirts and pants.|chitosan free cotton long sleeved shirts and pants.
1682594|NCT01597804|Procedure|Infection Prophylaxis and Management|"Undergo preoperative preparation with the Bathing Bundle"
1682597|NCT01597778|Biological|Haploidentical Bone Marrow Transplant|"The conditioning regimen consists of:
Fludarabine (Flu)30 mg/m2 IV Days -6, -5, -4, -3, -2 Cyclophosphamide (Cy) 14.5 mg/kg IV Days -6, -5 Total body irradiation (TBI) 200cGy Day -1
The GVHD prophylaxis regimen consists of:
Cy 50 mg/kg IV Days 3, 4 Tacrolimus (IV or PO) beginning Day 5 Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day 5 until Day 35"
1682598|NCT01597778|Biological|Double Umbilical Cord Blood Transplant|"The preparative regimen consists of:
Fludarabine 40 mg/m2 IV Days -6, -5, -4,-3, -2 Cyclophosphamide 50 mg/kg IV Day -6 Total Body Irradiation (TBI) 200 cGy Day -1 for patients who have received cytotoxic chemotherapy within the 3 months of enrollment or an autologous transplant within 24 months of enrollment or 300 cGy Day -1 for patients who have not received cytotoxic chemotherapy within the 3 months of enrollment and who have not received an autologous transplant within 24 months of enrollment.
The GVHD prophylaxis regimen consists of:
Cyclosporine beginning Day -3 with dose adjusted to maintain a trough level of 200-400 ng/mL.
Mycophenolate mofetil (MMF) 15 mg/kg po three times a day, maximum dose 1 g po TID beginning Day -3 until Day 35"
1958202|NCT01905943|Drug|Fludarabine|Participants will receive fludarabine qd on Days 1 to 3 of each 28-day cycle from Cycle 1 to Cycle 6 as per invetigator's discretion.
1682601|NCT01597752|Biological|Four different concentrations of Blomia tropicalis allergen extract, positive control and negative control|Four concentrations of Blomia tropicalis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
1682602|NCT01597739|Drug|JNJ-40346527|Type=exact number; unit=mg; number=100, form=capsule; route=oral use; twice daily.
1682603|NCT01597739|Drug|Placebo|Form=capsule; route=oral use; twice daily.
1682604|NCT01597726|Drug|Misoprostol|Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D&E, repeated once 3 hours after the first dose if needed
1682605|NCT01597726|Device|Laminaria|Laminaria tents inserted into the cervix 18 to 24 hours prior to D&E
1682606|NCT01597713|Drug|NNC 0148-0000-0362|Subjects will be randomised to receive a single dose of NNC 0148-0000-0362 orally within each dose group
1682607|NCT01597713|Drug|insulin glargine|As an active comparator, one standard dose will be given subcutaneously (s.c., under the skin) within each dose group
1682609|NCT01597713|Drug|NNC 0148-0000-0362|Single low dose administered orally in randomised order on three dosing visits separated by a wash-out period
1682610|NCT01597713|Drug|NNC 0148-0000-0362|Single high dose administered i.v. in randomised order on three dosing visits separated by a wash-out period
1682611|NCT01597713|Drug|NNC 0148-0000-0362|Single high dose administered orally in randomised order on three dosing visits separated by a wash-out period
1682612|NCT01597700|Drug|10mg Ezetimibe|1 tablet taken by mouth
1682613|NCT01597700|Drug|10 mg Ezetimibe - wash out period|1 tablet taken by mouth received after wash out period
1682616|NCT01597674|Drug|YF476|"There were 4 treatments: 3 dose levels of YF476 (5mg, 10mg, 25 mg) and placebo.
Each treatment taken by mouth once daily for 14 days (Study Days 1-14). Each subject took 1 of the 4 treatments."
1682617|NCT01597661|Drug|Exposure to any bupropion during the first trimester|"The primary exposure group will be: any exposure to bupropion during the time period from 28 days prior to the last menstrual period through the fourth lunar month. The use of bupropion in combination with other anti-depressants, exposure to SSRI anti-depressants, and exposure to non-SSRI anti-depressants, including tricyclic anti-depressants, during this time period will be explored.
Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
1682618|NCT01597661|Drug|Exposure to bupropion alone during the first trimester|"The secondary exposure group will be: bupropion exposure alone during the time period from 28 days prior to the last menstrual period through the fourth lunar month.
Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
1682619|NCT01597661|Other|Referent group: no exposure to any anti-depressant or anti-smoking drug during pregnancy|"The referent group will be defined as no exposure to any anti-depressant or anti-smoking drug at any time from 28 days prior to the last menstrual period through the end of pregnancy.
Mothers of identified infants are contacted within 6 months of delivery and invited to participate in the study by completing a telephone interview, conducted by trained study nurses. The interview addresses demographic, reproductive, and medical factors; medication and vitamin use; cigarette smoking, alcohol, and caffeine consumption, occupational exposures, and dietary intake. Exposure information is obtained directly from the mother in response to questions that focus both on indications for medication use and on medications themselves."
1682620|NCT01597648|Drug|Maraviroc|300 mg
1682621|NCT01597648|Drug|Combivir|1 tablet: lamivudine 150mg, zidovudine 300mg
1682622|NCT01597648|Drug|GSK2838510|Maraviroc 300mg, lamivudine 150mg, zidovudine 300mg
1682623|NCT01597635|Drug|Dose 1 GSK2586881|Low dose GSK2586881 administered intravenously
1682624|NCT01597635|Drug|Dose 2 GSK2586881|Medium dose GSK2586881 administered intravenously
1682625|NCT01597635|Drug|Dose 3 GSK2586881|Medium-High dose GSK2586881 administered intravenously
1682626|NCT01597635|Drug|Dose 4 GSK2586881|High dose GSK2586881 administered intravenously
1682627|NCT01597635|Drug|Placebo (saline)|Administered intravenously to match intervention
1682628|NCT01597622|Drug|Belimumab|10 mg/kg administered intravenously over 1 hour every 4 weeks
1682629|NCT01597609|Drug|sibutramine|10 mg, taken orally once per day for 12 weeks
1682630|NCT01597609|Other|sibutramine placebo|taken orally once per day for 12 weeks
1682631|NCT01597596|Biological|alglucosidase alfa|Intravenous (IV) infusion of alglucosidase alfa (4000 L material) 20 mg/kg every other week (QOW)
1682632|NCT01597596|Biological|alglucosidase alfa|IV infusion of alglucosidase alfa (160 L material) 20 mg/kg QOW.
1682633|NCT01597583|Behavioral|Use of MobileMedMinder|Use of an intervention to remind patients to take their medications.
1682634|NCT01597570|Device|Vascular Closure Device|To reduce the TTH(Time to hemostasis) and TTA(Time to ambulation)of common femoral artery(CFA) puncture site
1682635|NCT01597557|Drug|Magnesium Sulfate|2 grams intravenous drip over 30 minutes
1682636|NCT01597557|Other|Placebo|Normal Saline 50 ml intravenous drip over 30 minutes
1682637|NCT01597544|Procedure|CISC instruction pre-operatively|Patients allocated to the pre-operative CISC teaching group will be taught how to perform CISC by one of urogynecology nurses working at the Women's Health Care Centre. Patients will be allowed to practice until they feel comfortable with the technique. This should take approximately 30 minutes. The session will take place on the day of their pre-operative medical appointment (PAF), which normally occurs less than a month before the surgery. If a patient is not seen in PAF or is seen more than a month before her surgery, a separate appointment for CISC teaching during the month preceding the surgery will be organized. Post-operatively, a nurse from the hospital gynecology unit will review the technique to make sure the patient is still comfortable with performing CISC.
1682638|NCT01597531|Drug|Liraglutide|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily.
1682639|NCT01597531|Drug|Orlistat|Orlistat will be started initially at a dose of 60 mg taken with the evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day and the patients will be advised to take a multivitamin 2 hours before or after Orlistat addition to ensure adequate nutrition.
1682672|NCT01597310|Drug|Warfarin|single doses at specified time periods
1682673|NCT01597310|Drug|Dexpramipexole|multiple doses
1682737|NCT01596829|Dietary Supplement|Placebo|A capsule with microcrystalline cellulose matching the appearance and taste of the active comparator
1684787|NCT01581398|Drug|Ypeginterferon alfa-2b|sc, qw, 48 weeks.
1682640|NCT01597531|Drug|Liraglutide + Orlistat|Liraglutide will be started at 0.6 mg injected subcutaneously daily for 1 week and then increased as tolerated to 1.2 mg and then a 1.8 mg daily. Patients not tolerating a higher dose will be allowed to remain on the lower dose as long they tolerate the lower. Following titration of Liraglutide to a maximum tolerated dose, Orlistat will be started initially at a dose of 60 mg taken with evening meal. Additional doses will be added at breakfast or lunch every 1-2 weeks as tolerated. The patient will be advised to skip drug dosing if little or no fat is contained in the meal. Target dose will 60 mg three times a day.
1682641|NCT01597518|Drug|Riluzole|100mg BID first 24 hours after the injury; 50mg BID 2--14 days following the injury
1682642|NCT01597518|Drug|Placebo|Placebo 2x in first 24 hours; Placebo 2x day 2--14
1682643|NCT01597505|Drug|CB-183,315|250 mg bid for 10 days
1682644|NCT01597505|Drug|oral vancomycin|oral, 125 mg qid for 10 days
1682645|NCT01597492|Biological|Belimumab plus Early Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
1682646|NCT01597492|Biological|Belimumab plus Late Vaccination|Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
1682647|NCT01597479|Drug|Levobupivacaine|In dPNBs group, we performed ultrasound guided dPNBs on radial and median nerves using low concentration and low volume of long acting local anesthetic (0.125% levobupivacaine, 5 ml per nerve). Using low concentrations of levobupivacaine on target nerves could achieve a prolonged sensitive block in the surgical area without motor block of the hand.
1682648|NCT01597466|Device|Epidural catheter placement|Epidural space is located using Epidrum (Exmoor Innovations, Lisieux Way, Taunton, Somerset TA1 2LB, U.K.)
1682649|NCT01597466|Procedure|Epidural catheter placement|Epidural space is located using loss of resistance technique (saline solution)
1682650|NCT01597453|Behavioral|Lifestyle counseling|Ultrasound examinations of carotid arteries, aorta abdominalis, femoral arteries and lifestyle counseling
1682651|NCT01597440|Drug|N-carbamylglutamate|"Active NCG & Standard of Care Chemical Composition: N-carbamyl-L-glutamic acid (NCG) The daily dose will be 100 mg/kg/ day. The doses are to be divided into 2 equal doses and administered orally or enterally by nasogastric or gastrostomy tube (standard of care will prevail when choosing the mode of drug administration).
The tablets must be dispersed in a minimum of 2.5-10 ml of water and ingested immediately or administered by fast push through a syringe via a nasogastric or gastrostomy tube. The suspension has a slightly acidic taste.
This drug will be administered for 7 days after admission or until discharge (whichever is sooner)."
1682652|NCT01597440|Other|Standard of Care|Standard of Care
1682653|NCT01597427|Drug|Clonidine|Administration of 2 μg/kg of intravenous clonidine
1682654|NCT01597427|Drug|Placebo|Injection of placebo solution.
1682655|NCT01597414|Drug|Pertuzumab + trastuzumab|"Trastuzumab: loading dose of 8 mg/kg of body weight on cycle 1, followed by a maintenance dose of 6 mg/kg every 3 weeks.
Pertuzumab: loading dose of 840 mg on cycle 1, followed by 420 mg for subsequent cycles, every 3 weeks.
if T-DM1: 3.6 mg/kg IV, every 3 weeks."
1682656|NCT01597414|Drug|Pertuzumab + trastuzumab + metronomic chemotherapy|Pertuzumab and trastuzumab will be administered as in arm A. Cyclophosphamide: daily dose of 50 mg/day. if T-DM1: as in arm A
1955413|NCT03200847|Drug|Pembrolizumab with All-Trans Retinoic Acid|All the patients will receive 200mg Q3W pembrolizumab treatment plus the supplemental treatment of 150 mg/m2 All-Trans Retinoic Acid orally for 3 days surrounding each of the first four infusions of pembrolizumab
1682664|NCT01597375|Drug|Prasugrel|Participants will take a 60 mg loading dose. After they will take 10 mg by mouth daily if they weigh >60kg or 5 mg by mouth daily if they weigh <60 kg. They will take the drug for 4 weeks prior to the aspirin challenge/desensitization.
1682665|NCT01597362|Procedure|laparoscopy|Trocar access in laparoscopy
1682666|NCT01597362|Procedure|Laparoscopy|"The angle of the Veress needle insertion is 45 for non-obese women. After insertion of the needle, tests to determinate its correct positioning are: the double click test, the aspiration test, the handing drop test, serial intrabdominal gas pressure measurements.
The volume of CO2 inserted with the Veress needle depends on the intra-abdominal pressure. Adequate pneumoperitoneum should is determined by a pressure of 20 to 30 mm Hg and not by predetermined CO2 volume."
1682667|NCT01597362|Procedure|Laparoscopy|"Direct insertion of the trocar is performed without prior pneumoperitoneum. Infra-umbilical skin incision is wide enough to accomodate the diameter of a sharp trocar/cannual system. The abdominal wall is elevated by pulling on, by hands, two towel clips placed 3 cm on either side of the umbilicus, and the trocar is inserted at a 90°angle.
On removal of the sharp trocar, the laparoscope is inserted to confirm the presence of omentum or bowel in the visual field."
1682668|NCT01597362|Procedure|Laparoscopy|A small incision, 1 cm long, is made through the skin of the lower edge of the umbilical fossa. The skin and the subcutaneous adipose tissues are retracted with the Zimmerman dissectors. The anterior rectus fascia is incised with the scalpel. The dissection with the Zimmerman valves allows the exposure of the peritoneum. After the peritoneum is incised, the trocar is inserted under direct vision. The laparoscope is introduced and insufflation is started. At the end of the procedure the fascial defect is closed.
1682669|NCT01597349|Drug|FP01|Lozenge 3 times per day, low dose, high dose, or placebo for 48 hours.
1682670|NCT01597336|Procedure|Tissue plasminogen activator abscess flush|Thirteen ml of 10% tPA in saline at time of drain and twice daily thereafter.
1682671|NCT01597336|Procedure|Saline flush of abscess|Thirteen ml of saline is used to flush abscess at time of drain placement and twice daily thereafter.
1682674|NCT01597297|Drug|BIIB041 (PR Fampridine)|10 mg twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
1682675|NCT01597297|Other|Placebo|Twice daily, given orally. Doses of study treatment must be spaced at least 12 hours apart. If a dose of study treatment is delayed or missed, the participant should not dose again until their next scheduled dose. Tablets must be swallowed whole and should be taken without food.
1682676|NCT01597258|Drug|Crizotinib (Xalkori)|"XALKORI® Capsule 200 mg／XALKORI® Capsule 250 mg This surveillance is all cases surveillance based on Japanese regulation. Frequency and duration are according to Package Insert as follows.  The recommended dose schedule of crizotinib is 250 mg taken orally twice daily. Dosing interruption and/or dose reduction may be required based on patients' clinical status. "
1682677|NCT01597245|Drug|80 mg ixekizumab Dosing Regimen|Administered SC
1682678|NCT01597245|Drug|50 mg etanercept|Administered SC
1682679|NCT01597245|Drug|Placebo|Administered SC
1682680|NCT01597232|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
1682681|NCT01597232|Other|Maintenance of hemoglobin level more than 10g/dL|The patient's hemoglobin level is maintained more than 10g/dL perioperatively
1682682|NCT01597232|Other|Transfusion trigger based on experience|Determination of whether the patient need red blood cell transfusion or which hemoglobin level should be maintained is based on the physician's experience
1682683|NCT01597219|Procedure|Reduced intensity haplodentical stem cell transplant|Fludarabine 30mg/m2 IV days -6 to -2 Cyclophosphamide 14.5 mg/kg IV days -6 and -5 Total body irradiation 2Gy day -1 Stem cell transplant: day 0 Cyclophosphamide 50mg/kg days +3 & +4
1682684|NCT01597219|Procedure|Myeloablative haploidentical stem cell transplant|Total body irradiation 12Gy in 8 fractions days -9 to -6 Donor lymphocyte infusion day -6 Cyclophosphamide 60mg/kg IV days -3 & -2 Stem cell transplant day 0
1682685|NCT01597206|Device|Removable partial denture (Chrome Cobalt Distal extension)|For Group A: a distal extension removable denture will be constructed for patients with a reduced posterior dental arch
1682686|NCT01597206|Other|A reduced posterior dental arch|For Group B: Patients with a reduced posterior dental arch will not be provided with a removable denture and will be compared to patients in Group A
1682693|NCT01597167|Dietary Supplement|Magnesium sulfate|4 grams magnesium sulfate in 100 ml IV over 4 hours
1682694|NCT01597154|Behavioral|Lifestyle Counselling|Participants will take part in 2-3 group based peer-led sessions per week in which they will learn about healthy lifestyle choices
1682695|NCT01597141|Behavioral|Family-aided Assertive Community Treatment|The experimental treatment is a combination of family psychoeducation, assertive community treatment, supported education/employment and psychotropic medication.
1682696|NCT01597141|Behavioral|Enhanced standard treatment|In this arm, the subjects will receive the same psychotropic drugs, but will receive individual case management, family education and crisis intervention
1682697|NCT01597128|Device|Flex HD|Flex HD mesh for hernia repair
1682698|NCT01597128|Device|Strattice|Strattice mesh for hernia repair
1682699|NCT01597115|Procedure|Duplex ultrasonography|
1682700|NCT01597102|Other|No interventions|No intervention is planned in this study
1682701|NCT01597076|Dietary Supplement|iridoid enriched mixed fruit beverage|Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas & Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
1682702|NCT01597063|Device|SEQureDx Trisomy Test|Plasma samples obtained from maternal blood will be tested using the SEQureDx Trisomy Test, an in vitro diagnostic test that measures circulating cell-free fetal DNA. The test detects the relative quantity of chromosome 21, which is associated with trisomy 21.
1682703|NCT01597050|Drug|R932333|R393233 6% (60 mg/g), bid
1682704|NCT01597050|Drug|Placebo|Placebo, bid
1682706|NCT01597024|Other|Breakfast Study|Participants (male and female, lean and obese, children, teenagers, adults, and elderly) will take part in 4 morning sessions, consuming a test breakfast milk based beverage and appetite. Biomarkers in blood will be measured and behavioural questionnaires completed. We will also collect a single saliva sample from each participant to examine genetic traits related to appetite, food choice, body weight, and energy expenditure. There will be two milk based beverages, one protein enriched (30% protein from calories) and one normal protein (15% protein). Participants will be offered a morning snack buffet to assess ad libitum energy intake. Phase 1 will also include a subgroup of malnourished male and female elderly participants. However, this group will only complete two morning sessions during which they will consume a low protein and a high protein milk based beverage. Appetite will be recorded and libitum energy intake will be measured. In addition, 24hr energy intake will be recorded.
1682707|NCT01597024|Other|fMRI Study|We will fMRI scan normal weight and overweight subjects of both gender from the four different age groups only: 8-10, 13-17, 24-45 and 65-75 years. Participants will be measured twice, on separate days, either after an overnight fast or after a test meal, fed to satiation (because hunger will modulate the response to food presentation). The participants will conduct a computerised task that will be performed in the scanner to assess hedonic responses to food cues. Physiological biomarkers will be measured during both trials for the assessment of appetite hormone circulation. Saliva samples will be taken for DNA analysis. DNA extraction techniques will be used to examine genetic traits linked to appetite, food choice, body weight, and energy expenditure.
1682708|NCT01597011|Procedure|Fibrin Sealant|Use of fibrin sealant for mesh fixation in laparoscopic inguinal hernia repair,
1682709|NCT01597011|Procedure|Tissue-penetrating mesh-fixation|Use of tacks, staples or sutures for mesh fixation in inguinal hernia repair
1682710|NCT01596998|Drug|Levobupivacaine with epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz Sonosite M-Turbo®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% with 5 µg/mL epinephrine were injected.
1682711|NCT01596998|Drug|Levobupivacaine without epinephrine|The subjects were randomized to receive a unilateral TAP block. This was realized using a sterile technique, guided by ultrasound. Two operators with experience in ultrasound-guided regional blocks performed all procedures. A high-resolution linear U.S. transducer (L38x/10-5 MHz, Sonosite M-Turbo ®, Bothell, WA) and a Stimuplex 100 mm needle, 20 gauge (B. Braun Stimuplex, Melgusen, Germany) were used. After obtaining a clear view of the blocking plane, between internal oblique and transverse muscles, 20 ml of levobupivacaine 0.25% were injected.
1682712|NCT01596998|Other|Monitoring|Standard anesthetic monitoring was used, including continuous electrocardiogram, non invasive blood pressure and peripheral oxygen saturation. Later, under local anesthesia a permeable venous line and an arterial line were installed for blood sampling measures to determine local anesthetic plasma levels.
1682713|NCT01596998|Other|Determining the extent of the block|The extent of sensory block was measured by assessment of temperature, soft and hard touch using alcohol, cotton and pin prick respectively. These measurements were made every 10 minutes during the first hour and every 30 minutes to complete 4 hours.
1682716|NCT01596972|Device|dBest semi-quantitative urine pregnancy test|The dBest® semi-quantitative urine pregnancy test (Figure 2) is a graduated urine pregnancy test with five different levels of sensitivity: 25 IU/L, 100 IU/L, 500 IU/L, 2000 IU/L, 10000 IU/L. The test detects the level of serum hCG that corresponds to the range between that level and the level above it, i.e. the test would be positive at 500 if the hCG was either 501 or 1999. The tool was validated in a US sample of 196 women, where there was a correlation of 69% between urine hCG and serum hCG. Furthermore, the test had a 10% false negative rate (i.e. recording a level two gradations below the serum level) and a 6% false positive rate (i.e. recording a level two gradations above the serum level)
1682719|NCT01596946|Behavioral|Contact tracing mode test at clinic|
1682720|NCT01596946|Behavioral|Self-sampling at home - Sent Test Kit|
1682721|NCT01596933|Dietary Supplement|BioMega SDA®|Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
1682722|NCT01596933|Dietary Supplement|Sunflower oil high oleic|Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
1682723|NCT01596920|Other|Tissue|Allograft Tissue Cellular Repair Matrix
1682724|NCT01596920|Other|Control|Non-adherent Dressing
1682725|NCT01596907|Drug|Ephedrine sulfate with caffeine|Ephedrine sulfate 25-mg with caffeine 200-mg combination capsule to start 5 weeks after gastric bypass surgery at 3 times per day 4 hours apart.
1682726|NCT01596907|Drug|cellulose|sufficient cellulose to fill a placebo capsule identical to the active drug to be taken 3 times per day 4 hours apart for 6 months after gastric bypass surgery
1682727|NCT01596894|Drug|Azithromycin + Metronidazole|Azithromycin 7.5 mg/kg once daily (maximum 500mg) 5 consecutive days a week for the first 4 weeks and 3 consecutive days a week for the next 4 weeks +metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
1682728|NCT01596894|Drug|Metronidazole|Oral metronidazole 10mg/kg X2/day (maximum 1000mg) for 8 weeks.
1682729|NCT01596868|Drug|gemcitabine and cisplatin|Drug: gemcitabine and cisplatin The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
1682730|NCT01596868|Drug|docetaxel and cisplatin|Drug: Docetaxel and cisplatin The TP regimen consists of docetaxel at a dose of 75 mg/m2/day on day 1,and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1-3, The regime will be repeated every 3 weeks up to a total of 2-3 courses. Concurrent chemoradiotherapy is administrated with 3 cycles of weekly Cisplatin 80 mg/m2 starting on the first day of IMRT.
1682731|NCT01596855|Drug|FG-4592|TIW dosing, capsule
1682732|NCT01596855|Drug|Epoetin Alfa|TIW
1682733|NCT01596842|Drug|Omega-3 fatty acid ethylester 90|Omega-3 fatty acid ethylester 90, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
1682734|NCT01596842|Other|Olive oil|Olive oil, Dosage form :1g soft capsule, Dosage : one capsule, thrice a day, Duration : 12 weeks
1682735|NCT01596842|Other|cholecalciferol|if baseline 25-hydroxyvitamin D levels are < 15 ng/mL : 10,000IU/week, if baseline 25-hydroxyvitamin D levels are 16-30 ng/mL : 50,000IU/week, Duration : 12 weeks
1682736|NCT01596829|Dietary Supplement|Probiotic|Probiotic formula, 10 billion CFU in total once a day for up to 3 weeks
1732747|NCT00046033|Drug|Amprenavir|
1958203|NCT01905943|Drug|Obinutuzumab|Participants will receive obinutuzumab 1000 mg IV infusion on Days 1/2 (dose split over 2 consecutive days; 100 mg on Day 1 and 900 mg on Day 2), 8 and 15 of cycle 1, and on Day 1 of Cycles 2, 3, 4, 5, and 6. Each cycle is of 28-days duration.
1958204|NCT01905423|Drug|Albendazole and diethylcarbamazine|Albendazole 400 mg plus diethylcarbamazine 6 mg/kg once yearly vs twice yearly
1682741|NCT01596803|Procedure|Taking of blood|Taking venous blood samples to analyse oxidant stress
1682742|NCT01596803|Dietary Supplement|needle biopsy of the vastus lateralis muscle|T0 needle biopsy of the vastus lateralis muscle (analysis of oxidative stress and inflammatory markers)During 17 weeks supplementation by Vit E, C , Zn Se After 17 weeks: veinous blood samples and needle biopsy
1682743|NCT01596803|Dietary Supplement|Vit C Vit E Zn Se|T0 venous blood samples and needle biopsy of the vastus lateralis muscle During 17 weeks vit E 400mg/d, Se 200µg/d, Vit C 500mg/day, Zn 25 mg/d After the supplementation of 17 weeks:venous blood samples and needle biopsy of the vastus lateralis muscle
1682744|NCT01596803|Dietary Supplement|Placebo Vit E Placebo Vit C Zn Se|venous blood samples and needle biopsy
1682745|NCT01596790|Other|Blood analysis by EPISPOT and Cellsearch|For each patient, we will perform a counting of CTC before chemotherapy and then at different time points after chemotherapy, using both technologies: EPISPOT and CellSearch®.For the EPISPOT, we will need 15 mL of peripheral blood on EDTA tubes. For each patient, five blood samples will be done: D0, D14, D28, D42 and D56. These different time points will help us to determine when the best moment is for the evaluation of the CTC with this technology.For the CellSearch®, we will need 10 mL of peripheral blood on a specific CellSave tube. Only two samples will be perform: D0 and D28 because Cohen et al. (2008) reported that the best appropriated moment to appreciate the CTC progression is between 3 and 5 weeks after the initiation of the treatment.
1682746|NCT01596777|Drug|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice prepared before administration
1682747|NCT01596777|Drug|Loperamide placebo|200 ml apple juice
1682748|NCT01596777|Drug|Methylnaltrexone placebo|Methylnaltrexone placebo capsule (identical to MNTX IR and MNTX ER)
1682749|NCT01596777|Drug|Methylnaltrexone 12 mg sc.|RELISTOR 12 mg/0.6 ml Injektionslösung (Wyeth)
1682750|NCT01596777|Drug|Methylnaltrexone IR capsule|Methylnaltrexone bromide 500 mg IR capsule
1682751|NCT01596777|Drug|Methylnaltrexone ER capsule|Methylnaltrexone bromide 500 mg ER capsule
1682752|NCT01596777|Device|Colon Transit|3x1 capsules containing radio-opaque marker of 6 different shapes (in two consecutive study periods, capsules with different shapes of the markers are given)
1682753|NCT01596777|Drug|Sulfasalazine|500 mg Azulfidine® (Pharmacia)
1682754|NCT01596764|Drug|Loperamide placebo|200 ml apple juice
1682755|NCT01596764|Drug|Loperamide|20 ml Loperamid-ratiopharm® Lösung (ratiopharm) in 180 ml apple juice containing 4 mg of loperamide hydrochloride (prepared before administration)
1682756|NCT01596764|Device|Colon Transit|5 capsules containing radio-opaque markers of different shapes, respectively
1682757|NCT01596764|Drug|Sulfasalazine|Azulfidine® Tabletten 500 mg (Pharmacia/Pfizer) containing 500 mg immediate release sulfasalazine
1682758|NCT01596764|Drug|Placebo of MNTX and NLX|Placebo capsule (hard gelatine capsule containing multiple sugar spheres)
1682759|NCT01596764|Drug|Naloxone|Naloxone hydrochloride 20 mg Extended Release Capsule equivalent to 18 mg naloxone (hard gelatine capsule containing a single NLX-ER tablet and multiple sugar spheres)
1682760|NCT01596764|Drug|Methylnaltrexone|Methylnaltrexone bromide 150 mg extended release capsule equivalent to 122 mg methylnaltrexone (hard gelatine capsule containing multiple MNTX-ER micro tablets)
1682761|NCT01596751|Drug|PLX3397|Dosage Form: 100 mg or 200 mg capsules, Dosage: 400 - 1000 mg, oral administration
1682762|NCT01596751|Drug|Eribulin|Dosage Form: 1 mg per 2 mL (0.5 mg per mL); Solution (clear, colorless, sterile, packaged in glass vial) Dosage: 1.4 mg/m2, 2-5 min IV, Day 1, 8 q21 days
1682763|NCT01596738|Drug|Tranexamic Acid|"Tranexamic acid 50mg/ml, 15 mg/kg intravenous after anesthetic induction
Tranexamic acid 50mg/ml, 15 mg/kg intravenous after neutralization"
1682764|NCT01596738|Drug|Saline|"Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after anesthetic induction
Equivalent volume of saline, equal to that of 50mg/ml tranexamic acid at the dosage of 15mg/kg, intravenous after neutralization"
1682765|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
1682766|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
1682767|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
1682768|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
1682769|NCT01596725|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 2; intramuscular, deltoid, Day 0 and Day 21
1682770|NCT01596725|Biological|Saline Placebo|Placebo; intramuscular, deltoid, Day 0 and Day 21
1682771|NCT01596712|Drug|QGE031|QGE031 was supplied as liquid in 2 mL vial for subcutaneous injection.
1682772|NCT01596712|Drug|Placebo|Placebo was supplied as liquid in 2 mL vial for subcutaneous injection.
1682773|NCT01596699|Drug|Alemtuzumab|0.5 mg/kg (max 15 mg or max 6 mg), IV, Day -12 to Day -10 pre-HCT
1682774|NCT01596699|Drug|Busulfan|0.8 mg/kg/dose q6hrs or 1.1 mg/kg/dose q6hrs, IV, Day -9 to Day -6 pre-HCT
1682775|NCT01596699|Drug|Fludarabine|40 mg/m2 or 1.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
1682776|NCT01596699|Drug|Clofarabine|10 mg/m2 or 0.33 mg/kg, IV, Day -5 to Day -2 pre-HCT
1682777|NCT01596686|Drug|one of two possible colon preparation regimens|Patients are randomized to receive one of the two different preparation regimens for colonoscopy usually employed in our unit, polyethylene glycol or sodium picosulphate and magnesium citrate
1682809|NCT01596478|Behavioral|Cognitive Motivational Behavior Therapy|Participants will receive a combined motivational and cognitive-behavioral therapy, on an individual basis, for 60-minutes once per week for 12 weeks.
1682810|NCT01596478|Behavioral|12-week wait list|Participants will be randomly assigned to start treatment immediately or to go on a 12-week wait list (where they will start treatment 12 weeks from day of consent).
1682778|NCT01596673|Drug|45-mg hydrocodone bitartrate extended-release tablet (crushed or intact)|"Phase B:
Eligible subjects will be randomized to treatment sequence XY or YX whereby treatment X is 60 mL of a noncarbonated flavored beverage and treatment Y is hydrocodone bitartrate powder at a dose strength of 45-mg reconstituted in 60 mL of a noncarbonated flavored beverage.
Phase C:
Eligible subjects will be randomly assigned to 1 of 4 treatment arms:
Treatment A: intact placebo tablet, 60 mL noncarbonated flavored beverage, 1 crushed 45-mg hydrocodone bitartrate extended-release tablet.
Treatment B: intact placebo tablet, hydrocodone bitartrate powder at a dose strength of 45-mg in 60 mL of a noncarbonated flavored beverage and 1 crushed placebo tablet.
Treatment C: intact 45-mg hydrocodone bitartrate extended-release tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet Treatment D: intact placebo tablet, 60 mL noncarbonated flavored beverage, and 1 crushed placebo tablet."
1682779|NCT01596673|Drug|Placebo|Placebo will consist of 60 mL of a non-carbonated beverage without the addition of active treatment
1682780|NCT01596660|Drug|Bupivacaina 0.5%|Bupivacaina 0.5% 20cc
1682781|NCT01596660|Drug|placebo comparator|20 cc of saline solution 0.9%, to infiltrate each side.
1682782|NCT01596647|Drug|caffeine|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
1682783|NCT01596647|Drug|diclofenac|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
1682784|NCT01596647|Drug|omeprazole|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
1682785|NCT01596647|Drug|midazolam|single dose of the probe drug cocktail contains: caffeine, diclofenac, omeprazole and midazolam
1682786|NCT01596647|Drug|TKI258|dovitinib, 5 days on / 2 days off dose schedule
1682787|NCT01596634|Other|questionnaire administration|Ancillary studies
1682788|NCT01596634|Procedure|quality-of-life assessment|Ancillary studies
1682789|NCT01596634|Other|laboratory biomarker analysis|Correlative studies
1682790|NCT01596634|Dietary Supplement|bovine lactoferrin|Given PO
1682791|NCT01596621|Drug|Bendamustine hydrochloride|Bendamustine will be supplied in 20-mL, amber, single-use vials containing 100 mg of bendamustine hydrochloride as a white to off-white lyophilized powder. The drug will be labeled as study drug with the study number and batch number. Patients will be administered bendamustine hydrochloride 120mg/m^2 as a 60-minute infusion, and not more than 120 minutes, on days 1 and 2 of each 21-day treatment cycle for 6 planned cycles or up to 8 total cycles. Dose reductions or modifications may be made as appropriate. Day 1 only of the 21-day cycle may be ±1 day. Day 2 dosing should begin 24 ±4 hours after the start of the day 1 dose.
1682792|NCT01596608|Device|Magnetic Seizure Therapy (MagPro MST)|100% machine output at between 25 and 100 Hz, with coil directed over frontal brain regions, until adequate seizure achieved. Six treatment sessions, at a frequency of two or three times per week will be administered. If subjects fail to achieve the pre-defined criteria of remission at that point, the dose will be increased to the maximal stimulator output and 3 additional treatment sessions will be provided. This will be repeated a total of 5 times (i.e., maximum treatment number is 24). 24 treatments is typically longer that a conventional ECT treatment course. However, evidence does suggest that longer treatment courses may be needed with MST, particularly in more treatment resistant psychiatric conditions such as OCD and schizophrenia.
1682793|NCT01596582|Behavioral|Risk Assessment|Patients randomized to the experimental arm will be asked a complete the ACNI risk assessment tool after reviewing a web-based colorectal cancer decision aid. The ACNI uses a point based system to stratify patients into low (mean rate of ACN ~3%) versus intermediate/high (~ 8%) risk groups based on responses to 6 items: age (50-59, 60-69, 70+), sex (male/female), race/ethnicity (non-Hispanic black, other), smoking history (never, <20 years, 20+ years), daily alcohol intake (< 2 vs. >/=2 drinks) and use of non-steroidal anti-inflammatory drugs (ever, never). The index represents a prototype version of the Advanced Colorectal Neoplasia Index (Am J Gastroenterol 2015;110:1062-71).
1682794|NCT01596569|Device|Repetitive Transcranial Magnetic Stimulation (rTMS), MagStim|Daily rTMS treatment for one week. Sham TMS participants receive the same study procedures as patients receiving active TMS.
1682795|NCT01596569|Behavioral|Cognitive Intervention|"Cognitive intervention designed specifically to address the most common cognitive deficits (executive function and memory) in bTBI.
All participants receive weekly cognitive treatment sessions for 10 weeks."
1682796|NCT01596556|Drug|Nicotine|both groups will be given nicotine lozenges before a VO2 test and a HTT.
1682797|NCT01596556|Other|cigarette smoking|the smokers will smoke 2 cigarettes before a VO2 exam and a HTT.
1682798|NCT01596543|Other|partial and complete sleep deprivation|The subjects will visit our labs 4 times. The second visit will be used as the experimental control. During the third and fourth visits the subject will go through an exercise heat tolerance test and a measurement of their physiological efficiency after a partial and complete sleep deprivation, respectively.
1682799|NCT01596530|Drug|Drug-AZD8931|Active drug for biological activity
1682800|NCT01596530|Drug|Drug-Placebo|Placebo comparator for biological activity comparison
1682801|NCT01596517|Drug|Peginterferon alfa-2a plus ribavirin for HCV genotype 1|Patients with genotype 1: treatment with peginterferon α-2a (Roche, Basel, Switzerland) 180 μg/week and daily ribavirin dose of 1,000 mg (for patients with body weight <75kg) or 1,200 mg (for patients with body weight ≥75kg) for 48 weeks.
1682802|NCT01596517|Drug|Peginterferon alfa-2a plus ribavirin for HCV genotype 2/3|Patients with genotype 2 or 3: treatment with peginterferon α-2a 180 μg/week and daily ribavirin dose of 800 mg for 24 weeks.
1682803|NCT01596504|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution for injection self-administered with a pen-like injector (OptiClik®).
Route of administration: subcutaneous"
1682804|NCT01596504|Drug|Liraglutide|"Pharmaceutical form:solution for injection
Route of administration: subcutaneous"
1682805|NCT01596504|Drug|Insulin Glargine|Doses to be adjusted to maintain a fasting self-measured plasma glucose (SMPG) between 4.4 to 5.6 mmol/L (80 to 100 mg/dL)
1682806|NCT01596504|Drug|Metformin|If previously taken metformin to be continued at stable dose throughout the study
1682807|NCT01596491|Procedure|quantitative sensory testing (QST)|with QST the small-fibre function is tested by registering thermal and mechanical thresholds, so that changes in the sensory profile can by specified
1682808|NCT01596478|Behavioral|Treatment as Usual|Participants will receive Treatment as Usual, on an individual basis, for 60-minutes once per week for 12 weeks.
1682944|NCT01595399|Drug|atropine|Atropine 0.02 mg/kg IV
1682811|NCT01596465|Other|Self-Study using MP3 Player|"Participants in the interventional arm of the study were given an MP3 player which contained eight, 15-second heart sound files (7 pathologic heart sound files and 1 normal heart sound file) alternated with nine leisure songs. MP3 players could play files in order or shuffle files in random order. Each heart sound file was introduced by the narrated phrase Identify this sound,, followed by 10 beats of a heart sound recording, then the narrated identification of the heart sound. Participants were asked to use the MP3 player in order to improve their auscultation skills as often as they could and asked to record their activities while listening, but were given no further training."
1682812|NCT01596465|Other|Multimedia Lecture|Following the pretest, participants in the control arm received a 1-hour multimedia lecture (Power Point) taught by the same faculty member (AGK), which reviewed the pathophysiology, exacerbating and relieving factors, as well as visual diagrams of the heart sounds. The normal and seven pathologic heart sounds were played for participants during the lecture for a total of 2 minutes through high-quality home stereo speakers, exposing learners to 1280 beats in the 1-hour session. Abnormal sounds were taught in groups of systolic, diastolic and extra sounds, and were first introduced by name, and then as unknowns using mixed practice in each of the three sections.
1682813|NCT01596426|Drug|Sancuso|granisetron transdermal system
1682814|NCT01596426|Drug|IV granisetron|IV granisetron
1682815|NCT01596413|Drug|Sancuso|granisetron transdermal system
1682816|NCT01596413|Drug|IV granisetron|IV
1682817|NCT01596400|Drug|granisetron transdermal system|patch
1682818|NCT01596400|Drug|Granisetron IV|IV
1682819|NCT01596387|Drug|Propofol|General anesthesia will be induced administering propofol by effect site TCI system using our previously derived model, the target plasma concentration initially will be set at 4 mcg/ml. After loss of consciousness, rocuronium 0.6mg/kg, and remifentanil 0.2mcg/kg/min will be given to facilitate tracheal intubation. After intubation propofol target will be decreased to 3 for 10 minutes and then adapted to the needs of each patient to maintain stable BIS values between 40 and 50. At the end of surgery propofol infusion will be stopped, and patients will be transferred to the recovery unit extubated. Samples of 2.5 ml of arterial blood will be taken at 2, 5 and 10 min after every new target is set. Thereafter samples will be taken at 2, 5, 10, 15, 30, 60, 120 min after stopping drug infusion. Blood samples will be immediately centrifuged and then stored until analysis.
1682820|NCT01596335|Drug|TA-650|TA-650 at 5 mg per kg body weight on the day of TA-650 administration (day 0) is administered by intravenous infusion slowly over at least 2 hours.
1682821|NCT01596335|Drug|Polyethylene Glycol-treated Human Immunoglobulin (VGIH)|VGIH at 2 g per kg body weight on the day of VGIH administration (day 0) is administered by intravenous infusion slowly over at least 20 hours.
1682822|NCT01596309|Dietary Supplement|Cocoa extract|Participants will follow a hypocaloric diet during two periods of 4 weeks, each. Within these diets, participants will consume daily 2 ready prepared frozen meals containing cocoa extract (0.7 g per meal; 1.4g per day) or nothing (placebo).
1682827|NCT01596270|Drug|SAR245409|Pharmaceutical form: tablet Route of administration: oral
1682828|NCT01596257|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic stem cell transplant
1682829|NCT01596257|Device|CliniMACS|
1682830|NCT01596244|Behavioral|Microclinic|Microclinics consist of 2-8 individuals from pre-existing social networks (friends, relatives, coworkers, neighbors, etc) that voluntarily participate in ongoing education and medical monitoring from local health care professionals, learning and practicing diabetes management strategies, sharing much-needed medical supplies, and exchanging social support in the form of regular microclinic meetings.
1682831|NCT01596231|Dietary Supplement|Kudzu|Kudzu (2 mg) will be administered as a pretreatment 2 ½ hours before a drinking session to see if it will significantly reduce the number of drinks consumed during a single 1 ½ hours drinking session.
1682832|NCT01596231|Dietary Supplement|Placebo|Placebo will be administered as a pretreatment 2 ½ hours before a drinking session
1682833|NCT01596218|Drug|Brentuximab Vedotin|Starting dose is 0.6 mg/kg weekly x 3
1682834|NCT01596205|Behavioral|Robot assisted cognitive training|We developed total 17 software programs for cognitive training with robot which were intended to develop for improvement of following cognitive function;5 programs for memory, 2 for language , 1 for reasoning, 3 for working memory or speed of processing, 2 for calculation and 4 for visuospatial function.
1682835|NCT01596205|Behavioral|Conventional cognitive training group|"Experienced behavioral therapists who had been clinical neuropsychologists for 2 years instructed the participants in cognitive training. Thearpists were familiarized with manuals for cognitive training before study inception, and were instructed to adhere to the manual but were allowed to distribute time flexibly among the programs in the same cognitive domain.
In all sessions of conventional intervention group, the behavioral therapists showed several questions or instructions on the screen and then the participants answered to the questions with verbal or written words using paper and pencil."
1682836|NCT01596192|Other|PETCT|"CT-PET will be performed within 3 days from acute GVHD diagnosis. Each patient will receive 400-610 MBq (11-16.5 mCi) of 18F-FDG intravenously. After tracer injection, the patients will rest on a comfortable chair during the 18F-FDG-uptake period, and drink with 150-300mg Levolac (Fresenius Kabi, Austria) diluted in 1000-1500cc water. CT-PET will be initiated 45-50 min after injection of the 18F-FDG.ll scans will be performed on a Discovery STE PET/CT scanner (General Electric Medical Systems, Milwaukee, WI).
CT will be performed 45-50 minutes after drinking the diluted lactulose solution had been ingested. The CT images will be acquired from the diaphragm to the symphysis pubis. After IV administration of 100 ml of nonionic contrast medium at a flow rate of 2.5 ml/sec."
1682837|NCT01596179|Behavioral|Interactive navigational support|Interactive navigational support is provided by a nurse and social worker navigators
1682838|NCT01596179|Behavioral|Internet access|a netbook computer with internet access is provided to participants on the control arm.
1682839|NCT01596166|Drug|Ketorolac Tromethamine|Ketorolac 0.5 mg/kg (max 30 mg) IV
1732748|NCT00046072|Drug|E5564|
1682840|NCT01596166|Drug|Metoclopramide|Metoclopramide 0.2 mg/kg (max 10 mg) IV
1682841|NCT01596153|Dietary Supplement|Go Live|Enhanced Probiotic, one packet bid until 7 days after discontinuation of antibiotic
1682842|NCT01596140|Drug|Vemurafenib|Starting dose 720 mg by mouth twice a day (3 tablets in the morning and 3 tablets in the evening) for 28-day study cycle.
1682843|NCT01596140|Drug|Everolimus|Starting dose 5.0 mg by mouth daily for 28-day study cycle.
1682844|NCT01596140|Drug|Temsirolimus|Starting dose 15 mg daily over 30-60 minutes on Days 1, 8, 15, and 22 of each 28-day cycle.
1682845|NCT01596127|Drug|Intrathecal Rituximab|"Phase I: Starting dose Rituximab 10 mg intrathecally twice weekly until 2 consecutive CSF samples are negative for the presence of blast cells. Thereafter, rituximab 10 mg intrathecally weekly for additional 4 weeks, followed by intrathecal rituximab 10 mg administered once every other week for an additional 8 weeks.
Phase II Starting Dose of Rituximab: Maximum tolerated dose from Phase I."
1682846|NCT01596114|Other|Stopping treatment with TKI|stopping until loss of MMR
1682847|NCT01596088|Drug|Dexrazoxane|
1682848|NCT01596075|Drug|Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration.Patients developing grade I/II acute GVHD will be treated by IV or oral methylprednisolone 1-2 mg/kg/day and oral cannabidiol at a starting dose of 10 mg twice daily. Doses of cannabidiol can be escalated every day according to clinical response to a maximal dose of 600 mg/day,if no significant drug related side effects present (CTCAE3 grade>2). Cannabidiol will be given up to 90 days.
1682849|NCT01596062|Drug|Simulect®|Simulect® was provided to the study center in its commercial package containing a powder vial with 20 mg of active product and sterile water for injection. The solution should be used immediately after reconstitution. The infusion was prepared by adding at least 50 mL of physiologic or 5% glucose solution to the reconstituted solution (at least 100 mL for 40 mg of Simulect®). Simulect® was transported and kept in a cold environment (2-8°C) as recommended in the summary of product characteristics (SPC).
1682850|NCT01596062|Drug|Neoral®|Neoral® was provided to the study center in its commercial package as 10, 25, 50 or 100 mg soft capsules in thermoformed blister packs.
1682851|NCT01596062|Drug|Certican®|Certican® was provided to the study center in its commercial package as 0.75, 0.5 and 0.25 mg tablets in thermoformed blister packs.
1682852|NCT01596062|Drug|Myfortic®|Myfortic® was administered orally b.i.d. with a 12-hour interval. Tablets could be taken either with or outside meals but consistently throughout the study. To maintain the integrity of the enteric coating, tablets were not to be crushed. Myfortic® treatment was initiated either preoperatively or within 24 hours post transplantation according to local practice in each center. Starting dose was to be 2160 mg/day (1080 mg b.i.d.) for at least 2 weeks and for at most 4 weeks. Patients were then to receive 1440 mg/day (720 mg b.i.d.) until the end of the study. Myfortic® was administered as concomitant treatment to all patients, using the same regimen for all 3 study groups. It was provided to the study center in its commercial package as 180 and 360 mg gastro-resistant tablets.
1682853|NCT01596062|Drug|Corticosteroids|Corticosteroid i.v. therapy could be administered peri or per operatively according to local practice in each center with the same scheme for each patient in the center. Oral corticotherapy was to be initiated rapidly, within one week following transplantation, with a minimal dose of 20 mg/day. Thereafter, the dose was to be decreased according to local practice but oral corticosteroids were to be continued throughout the study with a minimal dose of 5 mg/day.
1682854|NCT01596049|Device|Self-fixating Mesh|Using Self-fixating Mesh for Inguinal Hernia Repair
1682855|NCT01596036|Behavioral|Early appointment (within 10 days)|Patients will receive an appointment to cardiac rehabilitation within 10 days from anticipated hospital discharge.
1682856|NCT01596036|Other|Routine referral (at 5 weeks)|Standard Referral to Cardiac Rehabilitation
1682857|NCT01596023|Device|Breathe NIOV Ventilator|Portable, non invasive open ventilation system
1682858|NCT01596010|Drug|2 mg estradiol / 1 mg norethisterone acetate (NETA)|A single dose of one tablet under fasting conditions separated by a wash-out period of 2 weeks (+0-2 days) between dosing visits. Administered orally.
1682859|NCT01595997|Drug|DLX105|intradermal injections (volume: 0.1 mL) of 0.02 mg (low dose cohort), 1 mg (high dose cohort) DLX105, days: Day 1, Day 4, Day 7 and Day 10
1682860|NCT01595984|Drug|cyclosporin + mycophenolate mofetil|antirejection drug, renal transplantation
1682861|NCT01595984|Drug|everolimus + mycophenolate mofetil|antirejection drug, renal transplantation
1682862|NCT01595971|Behavioral|Continuing education|Includes telemedicine, reminders, video conferences, educational materials for patients and consultants.
1682863|NCT01595971|Other|usual care|Received the usual care provided
1682864|NCT01595958|Drug|Cyclosporine A|Single intravenous bolus of cyclosporine A (2.5 mg/kg) at the onset of resuscitation
1682865|NCT01595958|Procedure|cardio-pulmonary resuscitation|usual care of cardiac arrest
1682866|NCT01595945|Procedure|Gastric bypass|Subjects with a planned gastric bypass surgery are followed-up for resting metabolic rate.
1682867|NCT01595945|Behavioral|Caloric restriction|Subjects receive caloric restriction as calculated by an online weight management program and are followed-up for resting metabolic rate.
1682868|NCT01595932|Dietary Supplement|α-galactosidase|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:
children < 20kg: 4 drops;
children > 20kg and < 40kg: 8 drops;
children > 40kg: 1 tablet."
1682869|NCT01595932|Dietary Supplement|Placebo|"Treatment was administered at the beginning of each meal (3 times a day) for 2 weeks:
children < 20kg: 4 drops;
children > 20kg and < 40kg: 8 drops;
children > 40kg: 1 tablet."
1682870|NCT01595919|Other|Nutritional Intervention|Ad libitum amounts of beverage at a meal
1682871|NCT01595906|Procedure|Ventilated Helmet|The ventilation system is installed on the inner part of the helmet and connected to a bellows and an energy source placed on the vest worn by the soldier. The system's working principal is based on air perfusion with a small ventilator.
1682872|NCT01595893|Drug|Oral Vitamin D 3|40,000 IE vitamin D3 per 70 kg body weight, given twice (2 weeks apart)
1682873|NCT01595893|Drug|Miglyol 812 N|Neutral oil of esters extracted from coconut and palm kernel
1682874|NCT01595880|Drug|gemigliptin and metformin HCl extended release|Coadministration of gemigliptin 50mg and metformin HCl extended release 500mg, for 1 day
1682875|NCT01595880|Drug|gemigliptin/metformin HCl extended release|Administration of combination of gemigliptin 50mg/metformin HCl extended release 500mg, for 1day.
1682876|NCT01595867|Drug|Placebo|Lactose (100 mg) placebo tablets crushed; single dose
1682877|NCT01595867|Drug|EMBEDA - morphine sulfate/ naltrexone hydrochloride|EMBEDA (morphine sulfate/naltrexone hydrochloride) 30 mg/ 1.2 mg extended release; capsule contents crushed; single dose
1682878|NCT01595867|Drug|morphine sulfate CR crushed.|Morphine sulfate controlled release 30 mg tablet crushed
1682879|NCT01595854|Drug|dabigatran etexilate|medium dose dabigatran
1682880|NCT01595854|Drug|Ticagrelor|high dose ticagrelor
1682881|NCT01595854|Drug|Ticagrelor|high dose ticagrelor
1682882|NCT01595854|Drug|dabigatran etexilate|low dose dabigatran
1682883|NCT01595854|Drug|dabigatran etexilate|medium dose dabigatran
1682884|NCT01595841|Drug|Sirolimus|3 mg po od loading dose for two days, then 2 mg po od for thirty days
1682885|NCT01595828|Drug|Pitavastatin|
1682886|NCT01595815|Other|Calcium ionophore|Oocytes were activated with calcium ionophore after ICSI
1682887|NCT01595815|Other|Strontium chloride (SrCl2)|Oocytes were activated with strontium chloride after ICSI
1682888|NCT01595802|Device|Nautilus NeuroWave|"The Nautilus NeuroWave device will be utilized on subjects with sub-arachnoid hemorrhage that undergo TCD measurements to diagnose Vasospasm. A recording will be obtained using the device each time a TCD measurement is made.
In this intervention, patients are recorded using the Nautilus Neurowave device."
1682889|NCT01595802|Device|Transcranial Doppler (TCD)|Subjects with sub-arachnoid hemorrhage undergo TCD measurements to diagnose Vasospasm. Patients that were detected to have a vasospasm using TCD will also be classified as having mild, moderate and severe vasospasm.
1682890|NCT01595789|Drug|Liraglutide|Liraglutide injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with placebo.
1682891|NCT01595789|Drug|Placebo|Volume-matched placebo injection pen is administered by the participant once daily by subcutaneous injection. It is given independent of meals. The starting dose is 0.6 mg volume-matched placebo. After 2 weeks the dose will be increased to 1.2 mg. The dose will be further increased after 4 weeks to 1.8 mg. After a total of 12 weeks of treatment, a wash-out period of 2 weeks follows. Subsequently, the participant will be crossed over to a second period of 12 weeks of treatment with liraglutide.
1682892|NCT01595776|Other|Endothelial progenitor cells intramuscular implant|After marrow stimulation the CD133+ cell count was monitored daily. Each leukapheresis collection was diluted with 10% acide citrate dextrose (ACD-A)CD133 immunomagnetic cell selections were performed . After loco-regional anesthesia and below the knee cutaneous disinfection, 45-48 ml of autologous CD133+ saline solution suspension is administered intramuscularly with 1 ml deep injection through 18G needle. The injections were so allocated: 10 ml in the anterior compartment of leg, 10 ml in the superficial posterior compartment, 10 ml in the deep posterior compartment, 10 ml in the lateral compartment and the remaining part in the foot.
1682893|NCT01595763|Other|D Dimer and ultrasonography|clinical history, Dimer D, ultrasonography
1682894|NCT01595750|Drug|Roflumilast 500|Roflumilast 500 mcg , 12 weeks of treatment
1682895|NCT01595750|Drug|Placebo|Placebo 500 mcg , 12 weeks of treatment
1682896|NCT01595737|Drug|Levosimendan|Levosimendan perfusion for 12 hours before surgery by a single route, at a dosage of 0.1µg/kg/min without receiving the loading dose.
1682897|NCT01595737|Drug|Placebo|Placebo group patients will receive a perfusion of 5% glucose solution. This clear solution, free of visible particles, will have 0.4mg of riboflavin sodium phosphate, 100mg of anhydrous alcohol and water for injection up to 1ml added to it. This solution will be calculated as a dose of 0.1µg/kg/min.
1682898|NCT01595724|Drug|Visanne (Dienogest, BAY86-5258)|Intake of Dienogest 2mg/day to treat Endometriosis according to regular clinical practice.
1682899|NCT01595711|Device|Pain Monitor|Measurement of cutaneous conductance
1682900|NCT01595698|Other|Physical Exercise|"The patients in this group will given a progressive resistance training program twice per week (Tuesday and Thursday) for 20 weeks. The training program followed the American College of Sports Medicine guidelines on resistance training for adults. Training sessions will performed at the same time of day (between 1 pm and 5 pm). The chosen exercises focused on the large muscle groups that are important for the patients' daily routines. The exercises include the leg press, leg curl, vertical traction, chest press, arm extension, arm curl and abdominal crunch using equipment manufactured by Technogym®.
Every training session will preceded by 5 minutes of warm-up on a Life Fitness® motorized stepper at a constant velocity of 4 km/h. A 1 RM test will be to determine the load settings, as performed in previous studies. The load will readjusted throughout training according to the results of a 1 RM test after the 2nd month of training (the 8th week of training) for each exercise."
1682901|NCT01595698|Other|Control|Patients in this group will to the CEPE twice per week (Tuesday and Thursday) for 20 weeks and performed the same training protocol as the RESEX group. However, the equipment load (weight on each apparatus) is kept at the minimum (below 5% of 1 Repetition maximum - RM) throughout the treatment, without modifying the protocol. Patients execute 2 sets of 15 repetitions with a 1-minute rest interval on all of the equipment.
1682902|NCT01595685|Drug|Telbivudine|Telbivudine 600 mg Daily Oral
1682903|NCT01595685|Drug|Entecavir|Entecavir 0.5 mg Daily Oral
1682904|NCT01595672|Device|AN69 hemofilter|An AN69 hemofilter (1.6 m2 surface area, 35-KD limit; Baxter Healthcare Corp. Deerfield, IL, USA) will be used for EHCVVH.
1682905|NCT01595672|Other|conventional treatments|Patients receive conventional treatments recommended by guidelines only.
1682906|NCT01595659|Behavioral|Passenger effect|Driving with risk accepting or risk averse passenger
1682945|NCT01595399|Drug|Placebo|an equivalent volume of normal saline to atropine IV
1682982|NCT01595061|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1682910|NCT01595633|Drug|Switching from adefovir (10mg/day) to tenofovir (300mg/day)|active comparator: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Adefovir 10mg/day Experimental: Nucleoside analogues (Lamivudine 100mg, Telbivudine 600mg, Entecavir 1mg, or Clevudine 30mg/day) + Tenofovir 300mg/day
1682911|NCT01595620|Other|Thermal|Thermal sensation/pain testing
1682912|NCT01595620|Device|Electrical|Electrical sensation/pain testing
1682913|NCT01595620|Other|Capsaicin|Intradermal Capsaicin
1682914|NCT01595607|Other|Diet Treatment|Participants will consume a controlled diet for 6 weeks where all meals will be provided by the facility. Participants will be instructed to eat all foods and only foods provided to them.
1682915|NCT01595594|Drug|Systemic Doxycycline and Sham aPDT|It will be prescribed a protocol of 100mg/day of Systemic Doxycycline for 14 days
1682916|NCT01595594|Drug|aPDT + Doxycycline Placebo|The aPDT protocol will consist in 5 applications on the experimental time 0, 1, 5, 7 and 14 days.
1682919|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
1682920|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
1682921|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
1682922|NCT01595568|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained therapist and co-facilitator
1682923|NCT01595555|Behavioral|Stress Free Now|8 week mindfulness online program with the following content: 8 Weekly lesson of the week (audio), 8 Weekly mindfulness practice (audio), Daily articles on concepts and information about stress, relaxation and mindfulness, Daily motivational quotes and tips, Biweekly email reminder to participate in the program.
1682924|NCT01595542|Behavioral|Modified Vaccine Consent Form|"Packet of written immunization materials for parents and students which includes the following:
Cover letter
Vaccine promotional flyer
Vaccine information sheets (one for adolescent vaccination and one for other vaccination)
Improved consent form
Note advertising a lottery for free movie tickets for returning the consent form
Self-addressed stamped envelope"
1682925|NCT01595529|Drug|Trimethoprim sulfamethoxazole, cefixime, or cephalexin|After five days of active drug, five additional days of one of the following: 1) Oral suspension 200 mg of sulfamethoxazole/40 mg trimethoprim per 5mL. 8 mg/kg/day Trimethoprim in 2 divided doses 2) Reconstituted oral suspension containing 100 mg of cefixime as a trihydrate per 5 mL for small children or 200 mg of cefixime as a trihydrate per 5 mL for large children 3) Reconstituted oral suspension 250mg anhydrous cephalexin per 5mL for small children and two packages of oral suspension of 250mg anhydrous cephalexin per 5mL for large children
1682926|NCT01595529|Drug|Placebo|After five days of active drug, five days of placebo with the same flavoring as active counterpart. Dosage, dosage form, frequency and duration would be matched to each active counterpart.
1682930|NCT01595503|Procedure|rTMS with fMRI-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied to the secondary auditory cortex during 10 daily 20-minute treatment sessions. An fMRI scan combined with a language task will be used to localize the secondary auditory cortex, followed by neuronavigation to identify the scalp location overlying the targeted cortex.
1682931|NCT01595503|Procedure|rTMS with landmark-based targeting|Inhibitory (low frequency) 1-Hz rTMS will be applied over the left temporoparietal cortex (TPC) during 10 daily 20-minute treatment sessions, with the stimulating coil located midway between the left temporal (T3) and parietal (P3) scalp landmarks, using the International 10-20 system for EEG.
1682932|NCT01595490|Behavioral|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
1682933|NCT01595477|Behavioral|Mind-Body Skills Group|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
1682934|NCT01595464|Behavioral|Mind-Body Skills Groups|Teaching mind-body skills such as meditation, biofeedback, guided imagery, and meditation in a group setting
1682935|NCT01595451|Procedure|Acupuncture|A licensed acupuncturist will perform acupuncture for six, 30 minute treatment sessions.
1682936|NCT01595438|Drug|Ceftazidime - Avibactam ( CAZ-AVI)|Ceftazidime 2000 mg and 500 mg of avibactam. Patients randomized to receive CAZ-AVI will receive an infusion of CAZ-AVI (2000 mg ceftazidime and 500 mg avibactam) every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 120 minutes
1682937|NCT01595438|Drug|Doripenem|500 mg of Doripenem. Patients randomized to receive Doripenem will receive an infusion of Doripenem 500 mg every 8 hours administered by intravenous (IV) infusion in a volume of 100 mL at a constant rate over 60 minutes
1682938|NCT01595438|Drug|Either switch to oral therapy: 500 mg of Ciprofloxacin (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
1682939|NCT01595438|Drug|or switch to oral therapy: 800 mg/160 mg of sulfamethoxazole/trimethoprim (oral)|Patients are eligible for oral switch after receiving 5 full days of IV therapy and have met protocol specified criteria for clinical improvement
1682940|NCT01595425|Drug|D961H Sachet 20 mg|Each volunteer will receive a D961H sachet 20 mg once in the morning for 5 days.
1682941|NCT01595425|Drug|D961H HPMC capsule 20 mg|Each volunteer will receive a D961H HPMC capsule 20 mg once in the morning for 5 days.
1682946|NCT01595386|Drug|Hydrocortisone|The drug will be bolused at 50mg/m2 followed by a continuous infusion that will start at 50mg/m2 for the first 48 hours and then be tapered as follows: 40mg/m2/day over 24 hours, 30mg/m2/day over 12 hours, 20 mg/m2/day over 12 hours, 10mg/m2/day over 24 hours, then off.
1682947|NCT01595386|Drug|Normal Saline|This will be bolused and infused in the same manner as the hydrocortisone arm to ensure blinding of study arm.
1682948|NCT01595373|Drug|Acyl ghrelin|Acyl ghrelin 12.5 pg/min infused continuously for 300 minutes
1682949|NCT01595373|Drug|Placebo (Ringer acetate)|Ringer acetate 2 microliter/min for 300 minutes
1682950|NCT01595360|Drug|Placebo|It is applied directly to the bleeding site after tooth extraction
1682951|NCT01595360|Drug|TT-173|It is applied directly to the bleeding site after tooth extraction
1682954|NCT01595334|Drug|Cetrorelix|Cetrorelix 0.25 mg/d would be administered by subcutaneous injection to women when the plasma LH is higher (>4.5 mIU/ml) in the study arm
1682955|NCT01595334|Drug|Luprolide Acetate|Women in the control arm would receive Luprolide acetate 1 mg/day by subcutaneous injection
1682956|NCT01595321|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
1682957|NCT01595321|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine|Vaccine will be administered one day after cyclophosphamide (day 1). One dose will be given prior to SBRT and FOLFIRINOX and four additional doses after FOLFIRINOX completion for a total of 5 doses. Additional Cy-vaccine boosts may be given every 6 months thereafter until disease recurrence.
1682958|NCT01595321|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy) will be administered over 5 days starting between 13-17 days after the first vaccine dose (Arm 2) or within 6-10 weeks of surgery (Arm 1).
1682959|NCT01595321|Drug|FOLFIRINOX|FOLFIRINOX will be administered over 6 cycles starting at least 14 days after SBRT (Arms 1 and 2) and at least 28 days after the first vaccine (Arm 2).
1682960|NCT01595308|Dietary Supplement|Pomegranate juice|Pomegranate juice
1682961|NCT01595295|Other|non interventional|
1682962|NCT01595282|Drug|Ketorolac|For subjects weighing over 50 kg, ketorolac 60 mg in 2cc administered via intramuscular injection 30-60 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ketorolac 30 mg in 1 cc administered via intramuscular injection 30-60 minutes before suction curettage procedure
1682963|NCT01595282|Drug|Ibuprofen|For subjects weighing over 50 kg, ibuprofen 800 mg tablet administered orally 60-90 minutes before suction curettage procedure. For subjects weighing 50 kg or less, ibuprofen 600 mg tablet administered orally 60-90 minutes before suction curettage procedure.
1682964|NCT01595269|Other|eHealth education|In addition to the face-to-face education process currently used at the CHR, Education mode 1 (control), Education mode 2 (static interface) and Education mode 3 (dynamic interface) will be used.
1682965|NCT01595256|Behavioral|muscular strength|12-week moderate intensity walking program
1682966|NCT01595243|Behavioral|telephone consultations about psychoeducation program|experimental group will receive seven instances of telephone follow-up or face-to-face education (the day before discharge and during the first, second, third, fourth, sixth, and eighth weeks after discharge).
1682967|NCT01595230|Procedure|Closing the mesenteric defects with clips during opration|The laparoscopic Roux-en-Y gastric bypass surgery will be performed as usual. The patient will receive the closing of the mesenteric defects (the Petersen´s space and the entero-enterostomy site).The closing will happen at the end of the operation, using clips (herniestapler).
1682970|NCT01595191|Other|Bach music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
1682971|NCT01595191|Other|Mozart music|"Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel)."
1682972|NCT01595178|Behavioral|Combined BNI|Combination brief negotiated interview (BNI) for patients who smoke and drink
1682973|NCT01595165|Procedure|Ultrasound guided subcostal TAP block|Under ultrasound guidance0.375% ropivacaine 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
1682974|NCT01595165|Procedure|Placebo Ultrasound guided subcostal TAP block|Under ultrasound guidance saline 10 ml will be injected between rectus abdominis and transverse abdominis and same study solution will be injected at subcostal transversus abdominis plane. This block will be done bilaterally.
1682975|NCT01595152|Drug|solifenacin succinate|8 mg once daily for 60 days
1682976|NCT01595152|Drug|fesoterodine|8 mg, once daily for 60 dyas
1682977|NCT01595087|Drug|Osteodex|Seven cohorts; Dose cohort 1; 0.1 mg/kg given every third week, maximum 7 times. Dose cohort 2; 0.3 mg/kg given every third week, maximum 7 times. Dose cohort 3; 0.6 mg/kg given every third week, maximum 7 times. Dose cohort 4; 0.9 mg/kg given every third week, maximum 7 times. Dose cohort 5; 1.2 mg/kg given every third week, maximum 7 times. Dose cohort 6; 1.5 mg/kg given every third week, maximum 7 times. Dose cohort 7; 3.0 mg/kg given every third week, maximum 7 times.
1682983|NCT01595061|Procedure|Therapeutic Conventional Surgery|Undergo local core biopsy or surgical excision
1682984|NCT01595035|Behavioral|psychoeducational|Patients randomized to the intervention group will receive written information about pain and pain treatment in a booklet before surgery and contacted by telephone 24, 48, 72 hours and 7 days after surgery to be coached in pain management
1682985|NCT01595022|Drug|Placebo: Flexi ring FR01|Intrauterine device, inserted once for 3 months
1682986|NCT01595022|Drug|Placebo: Flexi ring FR20|Intrauterine device, inserted once for 3 months
1682987|NCT01595022|Drug|Placebo: Ultra low dose levonorgestrel contraceptive system (LCS)|Intrauterine device, inserted once for 3 months
1682989|NCT01594983|Drug|LCQ908|
1682990|NCT01594983|Drug|Fenofibrate|Fenofibrate once daily 12 weeks
1682991|NCT01594983|Drug|Fish Oil|Fish Oil once daily for 12 weeks
1682992|NCT01594983|Drug|Placebo of LCQ908|Matching placebo of LCQ908
1682993|NCT01594983|Drug|Placebo of fenofibrate|Matching placebo of fenofibrate
1682994|NCT01594983|Drug|Placebo of fish oil|Matching placebo of fish oil capsule
1682995|NCT01594970|Drug|Bimatoprost 0.01%|1 drop in the affected eye(s), administered in the evening for 12 weeks.
1682996|NCT01594957|Drug|LCQ908|Participants will receive a single oral dose of LCQ908
1682997|NCT01594931|Drug|pyronaridine/artesunate|Tablets of fixed dose combination of pyronaridine and artesunate at a ratio of 3:1
1682998|NCT01594918|Drug|Cabazitaxel|25 mg/m2 or 20 mg/m2, IV, once every 21 days
1682999|NCT01594918|Drug|Mitoxantrone|4 mg/m2, 6 mg/m2, 8 mg/m2, 10 mg/m2, or 12 mg/m2, IV, once every 21 days
1683000|NCT01594918|Drug|Prednisone|5 mg PO BID
1683001|NCT01594918|Drug|Pegfilgrastim|6 mg, SC, once every 21 days
1683002|NCT01594905|Drug|Entecavir + Tenofovir (MDR group)|Entecavir 1.0mg + Tenofovir 300mg
1683003|NCT01594892|Radiation|Radiosurgery|Fractionated radiosurgery using intensity-modulated treatment planning and volumetric image-guided treatment delivery
1683004|NCT01594879|Device|MIrena(LNG-IUS), oral MPA|"General Name/Brand name: Mirena - SCHERING Active ingredient: levonorgestrel 52mg Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
General Name/Brand name:Farlutal tab. 500mg/ Pfizer Active ingredient: Medroxyprogesterone Acetate"
1683005|NCT01594866|Drug|escitalopram|escitalopram 20mg and 30mg p.o. daily, 6 weeks
1683006|NCT01594866|Drug|escitalopram|escitalopram 10mg p.o. for 1 week, and escitalopram 20mg p.o. for 3 weeks before randomized to placebo and experimental groups
1683007|NCT01594853|Behavioral|exercise training|The exercise program uses a local Curves® gym to provide an individualized program of strength and cardiovascular training. The program is expected to be performed for 45 minutes 4-6 days per week.
1683008|NCT01594840|Device|Changing chat|Diapers with tips
1683009|NCT01594827|Drug|Inhaled Vancomycin|On Days 1-28, subjects will receive nebulized Vancomycin. This will be supplied as a 250 mg solution to be nebulized two times a day for 28 days in 5cc sterile water. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
1683010|NCT01594827|Drug|Placebo (Sterile Water)|On Days 1-28, subjects will receive 5cc of a nebulized Placebo (Sterile water) twice a day. This is a taste (quinine 0.1mg/mL) matched nebulized placebo (sterile water). Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
1683011|NCT01594827|Drug|Rifampin|"Oral Rifampin by mouth for 28 days
>45 kg: 600 mg by mouth daily
35-45 kg : 450 mg by mouth daily
25-34.9 kg: 300 mg by mouth daily"
1683012|NCT01594827|Drug|Trimethoprim/Sulfamethoxazole (TMP/SMX)|"Oral trimethoprim/sulfamethoxazole (DS-160/800)
>45 kg: two DS tablets twice a day by mouth (320/1600)
25-45 kg: one DS tablet twice a day by mouth (160/800)"
1683013|NCT01594827|Drug|Doxycycline|"If sulfa intolerant or TMP/SMX Resistant, use instead oral doxycycline
>45 kg: 100 mg by mouth twice a day
35-45 kg : 75 mg by mouth twice a day iii. 25-34.9 kg: 50 mg by mouth twice a day"
1683014|NCT01594827|Drug|Mupirocin Intranasal Creme|Mupirocin 2% intranasal creme: half of single use tube applied into each nostril twice a day for 5 days.
1683015|NCT01594827|Drug|4% chlorhexidine gluconate liquid skin cleanser|Hibiclens 15cc liquid skin cleanser packets (4% chlorhexidine gluconate): use three packets once weekly for four weeks in the shower from the neck to toes, with attention on the axilla, groin, and buttocks.
1683016|NCT01594814|Procedure|RFA|radiofrequency ablation of slow pathway or accesory pathway
1683017|NCT01594801|Device|InsuPad|Use of the InsuPad for at least 3 times a day.
1683018|NCT01594775|Drug|Syntocinon (Oxytocin) nasal spray|two-times daily self-administration of nasal spray containing active substance (oxytocin) during five days after wounding.
1683019|NCT01594775|Drug|Placebo|two-times daily self-administration of nasal spray containing placebo during five days after wounding.
1683020|NCT01594762|Drug|Topical pexiganan cream 0.8%|14 days of treatment
1683021|NCT01594762|Drug|Topical placebo cream|14 days of treatment
1683022|NCT01594762|Other|Standard wound care|14 days of treatment
1683023|NCT01594749|Drug|Fosaprepitant dimeglumine|
1683024|NCT01594749|Drug|Fosaprepitant Placebo|
1683025|NCT01594749|Drug|Dexamethasone|
1683026|NCT01594749|Drug|Ondansetron|
1683027|NCT01594749|Drug|Dexamethasone Placebo|
1683028|NCT01594749|Drug|Ondansetron Placebo|
1683029|NCT01594749|Drug|Rescue Therapy|
1683030|NCT01594736|Drug|ORSIRO|due randomization ORSIRO will be implanted
1683031|NCT01594736|Device|XIENCE PRIME DES|due randomization XIENCE PRIME DES will be implanted
1683032|NCT01594723|Drug|120 mg LY2784544|Administered orally
1683033|NCT01594697|Drug|Metformin|
1683034|NCT01594684|Device|balloon angiolplasty - drug coated balloon (Cotavance, Medrad Inc.)|balloon inflation
1683035|NCT01594684|Device|drug coated balloon inflation (Cotavance, Medrad Inc.)|Balloon inflation
1683036|NCT01594684|Device|uncoated balloon (e.g. Admiral, Medtronic)|balloon inflation
1683037|NCT01594684|Device|balloon inflation, drug coated balloon (Cotavance, Medrad Inc.)|ballon inflation
1683158|NCT01594190|Behavioral|physical activity 15 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
1732828|NCT00046878|Drug|carmustine|
1683038|NCT01594671|Drug|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.
Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
1683039|NCT01594671|Drug|Tranexamic Acid|One dose before the closure of the knee joint: a solution containing 1g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) applied with a syringe diffuser.
1683040|NCT01594671|Other|haemostasia|The surgical habitual haemostasia: electrocoagulation of the bleeding tissues
1683041|NCT01594658|Procedure|Foam sclerotherapy|Foam application of 1% (Sklerol®, ICV Pharma, Bogota-Colombia), Reg INVIMA: 2002M-0001016, guided by ecography of insufficient superficial veins, doses from 10-40 cc of foam until obtaining endoluminal occlusion of the vein. The patient will rest for 8 minutes and then the leg will be covered with elastic bandage.
1683042|NCT01594658|Procedure|conservative|This arm only has medical standard handling (healings performed by the nurse group)
1683043|NCT01594645|Procedure|Sperm selection by conventional / polarized light microscopy|Selecting spermatozoa for ICSI using conventional and polarized light microscopy
1683044|NCT01594632|Drug|Jadelle|LNG containing subdermal contraceptive implant
1683045|NCT01594632|Drug|Sino-implant (II)|LNG containing subdermal contraceptive implant
1683046|NCT01594619|Drug|Naloxegol|Oral 25mg tablet
1683047|NCT01594619|Drug|Diltiazem XR|Oral 240mg tablet
1683048|NCT01594606|Behavioral|Animal-assisted intervention|The experimental group will receive 10 weeks of classroom training and hands-on experience working with dogs to teach them basic obedience skills. Each participant will work with the same dog each week. The active control group will receive 10 weeks of classroom training and will walk a different dog each week but will not teach obedience skills to the dogs.
1683049|NCT01594593|Behavioral|Acceptance and Commitment Therapy|group-based behavioral workshop to address cancer-related distress
1683050|NCT01594580|Other|Antimicrobial impregnated scrubs|Scrubs are impregnated with an antimicrobial product
1683051|NCT01594580|Other|Non-impregnated scrubs|
1683052|NCT01594567|Other|Dietary pulses|beans, peas, chickpeas, or lentils in whole or flour form
1683054|NCT01594515|Drug|BI 1015550|High dose powder for oral solution
1683055|NCT01594515|Drug|BI 1015550|Medium dose powder for oral solution
1683056|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
1683057|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
1683058|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
1683059|NCT01594515|Drug|Placebo|Solution for oral administration
1683060|NCT01594515|Drug|BI 101550|High dose powder for oral solution
1683061|NCT01594515|Drug|BI 1015550|Low dose powder for oral solution
1683062|NCT01594515|Drug|BI 1015550|Medium dose powder for oral solution
1683063|NCT01594515|Drug|BI 1015550|Medium dose powder for oral solution
1683064|NCT01594502|Drug|Dutasteride|0.5 mg daily
1683065|NCT01594502|Drug|Placebo|Placebo Comparator
1683066|NCT01594489|Drug|Aminophylline|"200 mg of aminophylline administrated intravenously as a short infusion, started in emergency department, before primary angioplasty and contrast medium administration
Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure
N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
1683067|NCT01594489|Drug|Hydration plus N-acetylcisteine|"Sodium bicarbonate (154 mEq/L in dextrose and H20) 3mL/kg for 1 hour before contrast medium, followed by an infusion of 1 mL/kg/h for 12 hours after procedure
N-acetilcysteine: intravenous bolus of 1200 mg before angioplasty and 1200 mg twice daily for the 48 hours after PCI"
1683068|NCT01594476|Drug|Levonorgestrel IUS|20 mcg levonorgestrel per day in intrauterine system for Mirena IUS Copper T intrauterine device
1683069|NCT01594463|Other|ultrasound examination|ultrasound examination between week 30+1 weeks to 31+6 weeks
1683070|NCT01594463|Other|ultrasound examination|ultrasound examination between 34+1 weeks to 35+6 weeks
1683071|NCT01594450|Biological|Biological mesh|patients will undergo the implantation of a biological mesh (after debridement and treatment of the infection) at the same time as the primary operation, or within one month of randomization.
1683072|NCT01594450|Procedure|without biological mesh|patients undergo traditional wound care (debridement and treatment of infection), without placement of a biological mesh. For arm B, the common wound care used follows the normal practice of the treating surgeon, except the placement of the biological mesh, which must not be performed within 6 months of randomization In cases of treatment failure at 6 months, patients of arm B are allowed to undergo any treatment which the treating surgeon views suitable, including a surgical procedure with implantation of a biological mesh
1683073|NCT01594437|Biological|TCN-202|Human monoclonal neutralizing antibody that recognizes a broadly conserved functional epitope on HCMV. One or two doses will be administered by intravenous infusion.
1683074|NCT01594437|Biological|Placebo|One or two doses administered by intravenous infusion.
1683075|NCT01594424|Drug|Tocilizumab|Tocilizumab 8mg/kg on Days 0, 15, 30, 45, 75, 105, 119, 135, 149, and 180
1683076|NCT01594424|Drug|Intravenous Immunoglobulin|All HS who meet criteria for desensitization will receive IVIG 10% (2.0 g/kg [maximum 140 g per dose] on days 1 and 30).
1683077|NCT01594398|Drug|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
1683078|NCT01594398|Drug|entinostat|10 mg, po, q14 days, until progression or intolerable toxicity
1683079|NCT01594398|Drug|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
1683080|NCT01594398|Drug|Erlotinib|Erlotinib: NSCLC pts beginning C2D1,150 mg, po, qd.
1683081|NCT01594398|Drug|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
1683082|NCT01594398|Drug|Exemestane|Exemestane: Breast cancer pts beginning C2D1,25 mg, po, qd.
1683159|NCT01594190|Behavioral|physical activity, 2 x 30 minutes/day|weight-bearing treadmill, pulsereserve increase of 50 %
1683160|NCT01594177|Drug|Afatinib|20 mg daily for 17 weeks (first two weeks every second day).
1683161|NCT01594177|Drug|Trastuzumab|First cycle: loading dose 8 mg/kg (day 1 q day 22), thereafter maintenance dose for 9 cycles: 6 mg/kg (day 1 q day 22).
1683084|NCT01594372|Procedure|Laparoscopic supracervical hysterectomy with sacropexy|Will involve laparoscopic entry to the abdomen to remove the uterus and suspension of the cervix and vaginal cuff to the sacrum with mesh. We will allow surgeons to conduct the surgery as they have perfected it
1683085|NCT01594372|Procedure|Vaginal hysterectomy with uterosacral colposuspension|Will involve removing the uterus vaginally followed by suspending the vaginal cuff to the high (proximal) uterosacral ligaments bilaterally restoring the vagina to its normal axis.
1683086|NCT01594359|Other|Biofortified beans|Comparison of two types of the common bean that are similar in all aspects except their iron concentration - one has a high iron concentration while the other has low iron concentration
1683087|NCT01594359|Other|BEAN|Placebo
1683088|NCT01594346|Drug|Alpha-Tocopherol|1,000 International Units, two times a day for 36 months
1683089|NCT01594346|Drug|Sugar Pill|
1683090|NCT01594333|Drug|Methotrexate|Tablet, Oral, Target dose 15-20 mg weekly plus 1.0 mg folic acid 6 days/week
1683091|NCT01594333|Drug|Placebo|Tablet, Oral, weekly plus 1.0 mg folic acid 6 days/week
1683092|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose A without Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
1683093|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1)|Dose B without Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
1683094|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose B with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
1683095|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose C with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
1683096|NCT01594320|Biological|Monovalent Avian Influenza VLP (H5N1); Adjuvant|Dose D with Adjuvant 1; intramuscular, deltoid, Day 0 & Day 21
1683097|NCT01594320|Biological|Saline placebo|Placebo; Intramuscular, deltoid, Day 0 & Day 21
1683098|NCT01593319|Drug|Ropivacaine|Local injection (fascia iliaca block) using 150 mg ropivacaine
1683099|NCT01593319|Drug|Natrium chloride|Placebo injection of Natrium chloride solution
1683100|NCT01593306|Drug|Paclitaxel, Cisplatin|intravenous paclitaxel infusion at 50mg/m2/week and cisplatin at 30mg/m2/week for 5 weeks. if supplement Chemo Radiotherapy is required then similar dose per week for 2 more weeks.
1683101|NCT01593306|Drug|Cisplatin|intravenous infusion of cisplatin 40mg/m2/week for 5 weeks. if I/C Brachytherapy is not feasible then supplement CRT given with similar dose of cisplatin for 2 more cycles.
1683102|NCT01593293|Drug|PemCarbo|Pemetrexed 500mg/m2, Carboplatin AUC5 intravenously q 3 weeks for 4 cycles, followed by pemtrexed 500mg/m2 q 3 weeks for maintenance therapy
1683103|NCT01593293|Drug|Pem only|Pemetrexed 500mg/m2 intrvenously q 3 weeks till progression or unacceptable toxicity.
1683104|NCT01593280|Device|TAP catheter|dosed with 20ml of Ropivacaine 0.5% at that time. Double lumen pump containing 700 ml of the Ropivacaine 0.2% will be attached to the TAP catheters in the recovery room. The time that this occurs will be recorded in the eMAR. The catheters will run at 7cc/hr/side for 50 hrs.
1683105|NCT01593280|Drug|intrathecal morphine|0.3 mg
1683106|NCT01593267|Procedure|coil embolization|Subjects randomized to endovascular therapy will be treated by one of two neurosurgeons expert in such treatment. All endovascular treatments will be accomplished using accepted techniques.
1683107|NCT01593267|Procedure|clip occlusion|Subjects randomized to surgical therapy will receive treatment from one of two neurosurgeons expert in surgery for ruptured aneurysms.
1683110|NCT01593241|Drug|Carboplatin|Stage IIA: 1 infusion Carboplatin AUC7 followed by 15 x 2 Gy involved node radiotherapy Stage IIB: 1 infusion Carboplatin AUC7 followed by 18 x 2 Gy involved node radiotherapy
1683111|NCT01593241|Radiation|Involved node RT|Involved node RT
1683112|NCT01593228|Drug|Iniparib (SAR240550/BSI-201)|"Pharmaceutical form:Solution
Route of administration: Intravenous"
1683113|NCT01593228|Drug|Carboplatin|"Pharmaceutical form:Solution
Route of administration: Intravenous"
1683114|NCT01593228|Drug|Doxorubicin HCL liposome injection|"Pharmaceutical form:Solution
Route of administration: Intravenous"
1683115|NCT01593228|Drug|Gemcitabine|"Pharmaceutical form:Solution
Route of administration: Intravenous"
1683116|NCT01593228|Drug|Irinotecan|"Pharmaceutical form:Solution
Route of administration: Intravenous"
1683117|NCT01593228|Drug|Paclitaxel|"Pharmaceutical form:Solution
Route of administration: Intravenous"
1683118|NCT01593228|Drug|Topotecan|"Pharmaceutical form:Solution
Route of administration: Intravenous"
1683119|NCT01593215|Drug|Yohimbine|Yohimbine capsule
1683120|NCT01593202|Behavioral|Dialectical behavior therapy|"16 weeks of Dialectical behavior therapy with one weekly session of individual therapy, one weekly session of multifamily skills training group, telephone coaching and ancillary family therapy and/or pharmacological treatment as needed.
The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
1683121|NCT01593202|Behavioral|Enhanced usual care|16 weeks of outpatient treatment in child and adolescent psychiatric clinics in Oslo, on average one weekly session of individual therapy and ancillary supportive. family and/or pharmacological treatment as needed.
1683162|NCT01594177|Drug|Paclitaxel|80 mg/m² i.v. given weekly on day 1 q day 8 for 12 weeks.
1683163|NCT01594177|Drug|Epirubicin|90 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
1683164|NCT01594177|Drug|Cyclophosphamide|600 mg/m² i.v. given on day 1 q day 22 for 4 cycles.
1683165|NCT01594164|Radiation|Cone Beam Computed Tomography|CBCT scan of upper airway, in upright position.
1732965|NCT00058448|Drug|docetaxel|
1683122|NCT01593189|Behavioral|KITS Program|This is a 4-month psychosocial intervention for children with developmental disabilities and behavior problems who are entering kindergarten and their caregivers. The intervention begins in the summer before kindergarten. The KITS intervention consists of: (a) child school readiness play groups to facilitate the development of self-regulatory, social, and early literacy skills (2 times per week in summer, 1 times per week in the fall); and (b) a bi-monthly psychoeducational support group to promote parent involvement in the child's early literacy and schooling and the use of effective parenting techniques
1683123|NCT01593176|Procedure|Placement of RSA beads|At the time of surgery sets of up to 9 RSA beads will be implanted on sides of the main fractures lines with the use of the inserter instrument and the image intensifier. In AO/OTA type 33A fractures two sets will be implanted - one in the femoral shaft and one in the distal femoral epiphysis. In AO/OTA type 33C fractures with an extra fracture line through the epiphysis, three sets will be implanted - one in the femoral shaft, one in the main lateral condyle segment and one in the main medial condyle segment. No beads will be planted in comminuted bone fragments. The fracture will then be plated with a LISS plate as it normally would.
1683124|NCT01593163|Drug|Ibuprofen EchoG|Infants in the experimental group (echoG treatment) received additional doses of ibuprofen only if PDA was still ≥ 1.5 mm at the time of the corresponding ibuprofen dose.
1683125|NCT01593163|Drug|Standard ibuprofen treatment|Infants received 3 doses of ibuprofen at 24-hour intervals, independently of ductal size, as long as additional doses were not contraindicated.
1683126|NCT01593150|Drug|Pradaxa|Pradaxa for 3 weeks prior to DC
1683127|NCT01593150|Procedure|TEE|Transesophageal echo to exclude LAA thrombus, followed by early DC.
1683128|NCT01593150|Other|Compare TEE guided cardioversion to Dabigatran + DC cardioversion|compare the two groups, TEE followed by early DC cardioversion with Dabigatran for 3 weeks followed by DC cardioversion.
1683129|NCT01593137|Drug|Liraglutide + metformin|"Liraglutide 1.8 mg/day + metformin >1500mg/day. Liraglutide will be administered once daily by subcutaneous injection, either in the abdomen, thigh or upper arm.
Patients will continue on metformin therapy as they were prescribed before enrolment."
1683130|NCT01593137|Drug|Glimepiride + metformin|"Glimepiride 4 mg/day + metformin >1500 mg/day. Tablets should be swallowed whole with some liquid before or during a substantial breakfast or, if none is taken, shortly before or during the first main meal.
Patients will continue on metformin therapy as they were prescribed before enrolment."
1683131|NCT01593124|Drug|Imiquimod|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
1683132|NCT01593124|Other|Placebo|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
1683133|NCT01593124|Drug|Nonoxynol-9|Participants first have sampling in the follicular and luteal phases of the menstrual cycle. Then participants receive 4 doses of HEC placebo gel in the luteal phase. Finally, participants are randomized to the order of IMiquimod, 2 doses vaginally, in the luteal phase and nonoxynol-9, 4%, 4 doses vaginally in the luteal phase.
1683134|NCT01593111|Other|Environmental Intervention|Home-based environmental intervention
1683135|NCT01593085|Behavioral|interview with a doctor for evaluating suicide risk|patients with cancer in palliative cares An interview and will be offered to this patient during his hospitalization to be held (with the collection of personal and family psychiatric history of the patient, family and social context, the assessment of chronic pain and fatigue and quality of life,assessment of anxiety, Evaluation of symptoms of depression,asessment of suicide risk)
1683136|NCT01593072|Drug|AVI-7537|"Cohort 1: AVI-7537 at 4.5 mg/kg IV; Cohort 2: AVI-7537 at 9 mg/kg IV;Cohort 3: AVI-7537 at 15 mg/kg IV; Cohort 4: AVI-7537 at 30 mg/kg IV
The amount of AVI-7537 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
1683137|NCT01593072|Other|Normal Saline Solution (NSS)|Normal Saline Solution (NSS)
1683138|NCT01594294|Device|AOSEPT® Plus contact lens solution|Hydrogen peroxide-based cleaning and disinfection system
1683139|NCT01594294|Device|ReNu MultiPlus® contact lens solution|Polyaminopropyl biguanide (PHMB) preserved multipurpose solution
1683140|NCT01594294|Device|Etafilcon A contact lenses|Hydrogel contact lenses worn on a daily wear basis for 14 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed every 2 weeks.
1683141|NCT01594294|Device|Lotrafilcon B contact lenses|Silicone hydrogel contact lenses worn on a daily wear basis for 30 days (Screening Phase) and 3 months (Investigational Phase). During the Investigational Phase, the contact lenses lenses were worn a minimum of six hours per day, 5 days per week, with a fresh pair dispensed monthly.
1683142|NCT01594294|Device|COMPLETE® MPS Easy Rub® Formula contact lens solution|PHMB 0.0001% and poloxamer 0.05% multipurpose solution
1683143|NCT01594281|Drug|Ranibizumab|
1683144|NCT01594281|Procedure|Laser photocoagulation|
1683145|NCT01594281|Procedure|Ranibizumab & laser photocoagulation|
1683146|NCT01594268|Drug|Everolimus|A prospective, open-label study to assess safety of Certican in kidney transplant patients
1683147|NCT01594255|Drug|sotrastaurin|
1683148|NCT01594255|Drug|sotrastaurin|
1683149|NCT01594255|Drug|placebo to sotrastaurin|
1683150|NCT01594255|Drug|Avelox|
1683151|NCT01594242|Other|Bortezomib|
1683155|NCT01594216|Drug|Ruxolitinib|
1683156|NCT01594216|Drug|Exemestane|
1683157|NCT01594203|Other|F18-FGD PET/CT|
1683166|NCT01594164|Radiation|High Resolution Computed Tomography|HRCT scan of upper airway, in supine position.
1683167|NCT01594151|Radiation|Cone Beam Computed Tomography|CBCT scan of upper airway at visit 1
1683168|NCT01594138|Other|Standardized questionnaires and a ubiquitous questionnaire|Columbia Suicide Severity Rating Scale, Suicidal Ideation Questionnaire,Peabody Caregiver Background Form,CCHMC Suicide History Form,and ubiquitous questionnaire(UQ ver.2011)
1683169|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
1683170|NCT01594125|Drug|Nintedanib low dose|twice daily oral dosing
1683171|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
1683172|NCT01594125|Drug|Nintedanib medium dose|twice daily oral dosing
1683173|NCT01594125|Drug|Nintedanib high dose|twice daily oral dosing
1683174|NCT01594099|Radiation|irradiation|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.
Brachytherapy :Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10)."
1683175|NCT01594099|Drug|Cisplatin|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.
Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).
Chemotherapy: Cisplatin (20mg /week) will be carry out in the 2nd to 6th week during radiation therapy."
1683176|NCT01594099|Drug|liposome paclitaxel|"EBRT: 3D-CRT pelvic radiation, 95%CTV DT 50.4Gy/28f. Radiation volume Cover the gross disease, whole uterus ,parametria, and regional lymph nodes area. Upper border：branching of abdominal aorta. Lower border: the inferior margin of obturator foramen.
Brachytherapy: Using an intrauterine tandem and colpostats. The total dose of A point is DT 20-25Gy/4-5f (EQD2=25-31.25 Gy，α/β=10).
Chemotherapy: Liposome paclitaxel (40mg /m2/2weeks) will be carry out in the 2nd ,4th,6th week during radiation therapy."
1683177|NCT01594086|Dietary Supplement|green tea powder|Consuming 2 g/day of green tea powder in three times divided for 3 months
1683178|NCT01594060|Drug|Insulin, regular - act rapid|4 shots of regular insulin: 3 before meals and one at bedtime.
1683179|NCT01594060|Drug|Insulin glulisine, Insulin glargine|1 shot glargine at bedtime 3 shots glulisine before meals
1683180|NCT01594047|Drug|ketamine infusion|Ketamine infusion scheme: 5mcg/Kg/min from induction od anaesthesia for 10 min, than 2,5mcg/Kg/min for 20 min and than 2 mcg/Kg/min to the end of surgery
1683181|NCT01594047|Drug|Methadone PCA|Methadone administered by a PCA system (dose 2 mg, lock-out 12min.)
1683182|NCT01594034|Procedure|expired air|collection of expired air from ventilator
1683183|NCT01594021|Drug|Gelatin 500 mL|intravenous administration
1683184|NCT01594021|Drug|Gelatin 50 mL|intravenous administration
1683185|NCT01594008|Other|Breakfast meal with placebo powder|Zero serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and placebo powder.
1683186|NCT01594008|Other|Breakfast meal with 2 serving equivalents of blueberries|Two serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
1683187|NCT01594008|Other|Breakfast meal with 4 serving equivalents of blueberries|Four serving equivalents (1 serving equivalent = ½ cup fresh raw blueberries) of blueberries in the form of a mixed side dish comprising frozen yogurt, sugar, and freeze-dried blueberry powder.
1683188|NCT01593995|Drug|Epidermal growth factor (EGF) ointment|"EGF Ointment evenly apply to skin lesion every 12 hr/ day. If the skin lesion has been no improvement even though EGF ointment applied for 8 weeks, stopped study and assess it as no effect"
1683189|NCT01593982|Other|repetitive Transcranial Magnetic Stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.
Site: Left Dorsolateral Prefrontal Cortex"
1683190|NCT01593969|Dietary Supplement|RUTF/Flax Oil|Ready to Use Therapeutic Food
1683191|NCT01593969|Dietary Supplement|RUTF/Flax Oil plus additional Fish Oil|Ready to Use Therapeutic Food
1683192|NCT01593969|Dietary Supplement|Standard RUTF|Standard formulation RUTF given according to National Guidelines
1683193|NCT01593956|Behavioral|tDCS|
1683194|NCT01593943|Behavioral|CHARM|CHARM will be conducted via three 30-minute counseling sessions delivered in the rural setting, with the first session required and the 2nd and 3rd sessions optional. The first two CHARM sessions will be for men only to build family planning (FP) and gender equity (GE) awareness and investment, and the third session will be for the couple with an emphasis on FP services, shared decision-making and marital communication. The three sessions can occur anytime within a 3 month timeframe but with a minimum of 1 week between sessions. All sessions and FP services (pill, condom, EC) will be provided at no cost to patients.
1683195|NCT01593930|Other|Lidocaine(IANB)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine
1683196|NCT01593930|Other|1 Articaine(Infiltration)|Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
1683197|NCT01593930|Other|2 Articaine(Infiltration)|Buccal infiltration of two 4% Articaine cartridges with 1/100000 epinephrine
1683198|NCT01593930|Other|Lidocaine(IANB)+1Articaine(Infiltration)|Inferior alveolar nerve block using one 2% Lidocaine cartridge with 1/80000 epinephrine + Buccal infiltration of one 4% Articaine cartridge with 1/100000 epinephrine
1683199|NCT01593878|Other|TV|test taken with TV on
1683200|NCT01593865|Procedure|BIMA Grafting|Both the left and the right internal mammary arteries are harvested and used to revascularize the two major coronary targets. Further coronary targets may be revascularized using either great saphenous vein or radial artery grafts, if present.
1683201|NCT01593865|Procedure|Left-only mammary artery grafting|These patients had only the left mammary artery harvested and used to revascularize the major coronary target. Great saphenous vein grafts and/or radial artery grafts were employed to revascularize the remaining targets.
1683202|NCT01593852|Radiation|Advanced image processing|Acquisition of x-ray images with reduced X-ray dose and advanced image processing
1683203|NCT01593852|Radiation|Regular image processing|Acquisition of x-ray images with regular X-ray dose and regular image processing
1683204|NCT01593826|Drug|Charcoal and Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
1683205|NCT01593826|Drug|Charcoal and Symbicort Turbuhaler|2 inhalations as a single dose
1683206|NCT01593826|Drug|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
1683207|NCT01593826|Drug|Symbicort Turbuhaler forte|2 inhalations as a single dose
1683208|NCT01593800|Dietary Supplement|Bio-25|Bio-25 is an innovative formula containing 11 different strains of unique probiotic bacteria and over 25 billion active bacteria in each capsule. All participants will receive either Probiotics (Bio-25,will be provided by SupHerb) or placebo pills blindly for six months. One day prior to each visit, subjects will be asked to consume lactose, fructose and sorbitol free foods, in order to avoid high base line of hydrogen from the presence of unabsorbed carbohydrates. Subjects will also be asked not to smoke 24 hours prior to each visit.
1683209|NCT01593787|Drug|LCZ696|100 mg, 200 mg, 400 mg tablets.
1683210|NCT01593774|Drug|Melatonin|Tablet melatonin 3 mg/day at 9 pm as intervention group
1683211|NCT01593774|Drug|Placebo|Placebo (with the same shape and taste as melatonin) at 9 pm as control group
1683213|NCT01593748|Drug|Gemcitabine and Pazopanib|Gemcitabine 1000 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Pazopanib 800 mg by oral tablet daily for a 21 day cycle.
1683214|NCT01593748|Drug|Gemcitabine and Docetaxel|Gemcitabine 900 mg/m2 by IV on day 1 and day 8 of a 21 day cycle. Docetaxel 100 mg/m2 by IV on day 8 of a 21 day cycle.
1683215|NCT01593735|Drug|MK-2748|MK-2748 tablets, orally, once daily for 7 days, dose level dependent on Panel assignment
1683216|NCT01593735|Drug|Placebo|Placebo tablets, orally, once daily for 7 days
1683217|NCT01593722|Drug|Diethylcarbamazine|single dose
1683218|NCT01593722|Drug|Ivermectin|single dose
1683220|NCT01593683|Behavioral|Psychological education program for nurses|Approximately 4 weekly one-hour group sessions led by study clinicians and 1 optional individual session with a single study clinician.
1683221|NCT01593670|Drug|Decitabine|administered intravenous (IV), 10 mg/m^2/day over 1 hour on days 1-5.
1683222|NCT01593670|Drug|Vorinostat|200 mg by mouth (PO) twice a day on days 6-15
1683223|NCT01593670|Biological|Interleukin-2|6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17
1683224|NCT01593670|Other|Natural killer (NK) cells|infusion intravenously (IV) over 15 to 60 minutes day 17
1683225|NCT01593657|Other|Mindful Movement and Breathing program|Participate Mindful Movement and Breathing program with an experienced yoga instructor. All movements can be done while in a bed (e.g. turning head, shrugging shoulders, bending knees, etc). Each session lasts approximately 15 minutes.
1683226|NCT01593657|Other|Questionnaire administration|Collected at baseline (before surgery), before and after each YST session, and at follow-up (two days after surgery).
1683227|NCT01593657|Procedure|The Observer Mobility Scale|Conducted by nurse and study coordinator prior to surgery and two days after surgery to assess mobility. Will ask patient to turn, sit, stand and walk as they are able.
1683228|NCT01593657|Procedure|Volumetric Incentive Spirometry|Conducted twice before and after each Mindful Movement and Breathing program to measure lung function. Mean of the two readings used.
1683229|NCT01593644|Drug|adenosine + dipyridamole|adenosine / dipyridamole combination given intravenously as a slow bolus at low doses
1683230|NCT01593631|Dietary Supplement|Acid lactase|capsules cotaining 3300 FCC units of acid lactase
1683231|NCT01593631|Dietary Supplement|Acid lactase|capsules containing 9000 FCC of acid lactase
1683232|NCT01593631|Dietary Supplement|Lyoph. yoghurt bacteria|capsules containing 2 billion lyoph. yoghurt bacteria
1683233|NCT01593631|Dietary Supplement|Acid lactase plus yoghurt bacteria|Capsules containing 3300 FCC of acid lactase and 2 billion lyoph. yoghurt bacteria
1683234|NCT01593631|Dietary Supplement|Placebo|Capsules containing di-calcium-phosphate
1683235|NCT01593618|Behavioral|UMFollowUp|Web-based internet resource for self-reported treatment summaries and psychosocial and physical well-being.
1683236|NCT01593618|Other|Standard of Care|Patients will receive information regarding their diagnosis, treatments, and ongoing health needs from their provider, but will not be provided access to the website.
1683237|NCT01593605|Dietary Supplement|Resveratrol|A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).
1683238|NCT01593605|Dietary Supplement|resveratrol /HMB|resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.
1683239|NCT01593605|Other|Placebo treatment|Placebo - one tablet taken twice a day by mouth
1683240|NCT01593592|Dietary Supplement|Lactobacillus reuteri|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and L. reuteri (is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475, will be delivered a dose of 1x108 CFU each strain, means giving daily chewable tablet containing 2x108 CFU/day) for 2 weeks followed by L. reuteri for another 2 weeks.
1683241|NCT01593592|Dietary Supplement|Placebo|Will receive triple therapy (omeprazole 20 mg b.i.d., amoxicillin 1000 mg b.i.d, clarithromycin 500mg b.i.d) and a placebo (1.5 mg per dose as chewable tablets) for 2 weeks followed by placebo for another 2 weeks.
1683242|NCT01593592|Drug|Omeprazole|All patients will receive omeprazole 20 mg b.i.d for 2 week
1683243|NCT01593592|Drug|Amoxicillin|amoxicillin 1000 mg b.i.d for 2 weeks
1683244|NCT01593592|Drug|Clarithromycin|clarithromycin 500mg b.i.d for 2 weeks
1683245|NCT01593579|Behavioral|Autonomic Function Tests|Patients will undergo Autonomic Function testing (AFT) before and 8 hours after Akt Inhibition therapy. AFT includes: Supine & standing heart rate & blood pressure, 10 minute head up tilt, cardiac output, sinus arrhythmia, hyperventilation, sustained handgrip, valsalva manuever, and cold pressor test.
1683246|NCT01593579|Other|supine and standing catecholamines|patients will have blood drawn from supine and standing catecholamines.
1683247|NCT01593566|Drug|0.25% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine
1683248|NCT01593566|Drug|0.5% Bupivacaine|Femoral nerve block using 0.25% versus 0.5% bupivacaine for analgesia after ACL reconstruction
1683249|NCT01593553|Other|ECG screening for atrial fibrillation|ECG screening for atrial fibrillation with intermittent ECG recording for 14 days. Introduction of anticoagulants in the case of atrial fibrillation.
1683250|NCT01593540|Device|metal-free interdental brush|one time per day
1683251|NCT01593540|Device|metal-core interdental brush|one time per day
1683252|NCT01593527|Drug|ACZ885|Canakinumab 150 mg s.c.
1683253|NCT01593527|Drug|Triamcinelone acetonide|Triamcinelone acetonide 40 mg i.m.
1683254|NCT01593514|Biological|MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
1683255|NCT01593514|Biological|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
1683256|NCT01593514|Biological|MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection. This vaccine should be administered subcutaneously.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
1683257|NCT01593514|Biological|1/5th dose MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) and MenACWY-CRM conjugate vaccine (Menveo, Novartis)|To obtain the one-fifth dose of MenACWY-PS, 0.5ml of a full dose of MenACWY-PS will be reconstituted, and then 0.4ml will be discarded prior to subcutaneous injection. The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered intramuscularly.
1683258|NCT01593514|Biological|Polysaccharide (subcutaneously)-conjugate|The MenACWY-PS polysaccharide vaccine, ( ACWYVax, GSK) is obtained by reconstituting the purified ACWY polysaccharides with the 0.5 ml water for injection.The MenACWY-CRM conjugate vaccine (Menveo, Novartis) is obtained by extemporaneous mixing just before injection of the lyophilized MenA component to be reconstituted with the MenCWY component. This vaccine is to be administered subcutaneously
1683259|NCT01593501|Dietary Supplement|vitamin D3|pharmaceutical grade D3
1683260|NCT01593488|Drug|liposomal cytarabine|given intrathecally in induction phase every 15 days until CSF response for up to 7 injections. Then it is given every 4 weeks during consolidation phase while patient awaiting bone marrow transplant. For those patients who are not candidates for a bone marrow transplant, the drug will be given every 3 months for 4 administrations (maintenance therapy)
1683261|NCT01593475|Radiation|Induction chemotherapy followed by CCRT|"Chemotherapy In one cycle (4-weeks), gemcitabine 1,000 mg/m2 will be given by 30-minute intravenous infusion on days 1, 8, and 15, and 1 hour infusion of CDDP was administered at a dose of 25 mg/m2 weekly diluted in 500 mL of normal saline to ensure adequate hydration 1 hour before the administration of gemcitabine. Gemcitabine 300mg/m2 will be given by 30-minute intravenous infusion weekly during CCRT will be started within 3 weeks after completion of 2 cycles of induction chemotherapy
Radiotherapy
- Total dose of PGTV and PCTV were 55 Gy, 22 fractions and 44 Gy, 22 fractions, respectively."
1683262|NCT01593462|Procedure|MRE (magnetic resonance enterography)|The MRE will take approximately 60 minutes to complete. Enrolled subject will have MRE imaging performed at about 4 weeks after treatment for small bowel crohn's disease begins, and when the treatment ends or changes or at 6 months, whichever comes first. The 4 week MRE will be for research purposes only, the treatment end,change or 6 month MRE may or may not be ordered by the treating physician as part of your routine care. If one is not ordered by the treating physician, the subject will have one performed because of the research study.
1683263|NCT01593462|Procedure|The Ultrasound scan, (UEI) Ultrasound Elastography Imaging with ARFI (acoustic radiation force impulse)|The US UEI will take about 60 minutes to perform. This exam will be performed by 2 different radiologists and you will have this completed 5 times over the course of the study. This imaging will be performed with the subject drinking oral contrast material. The US, UEI will be completed at baseline, 2 weeks, 4 weeks, 3 months and at treatment end/change or 6 months, whichever comes first.
1683264|NCT01593462|Behavioral|Study Questionnaires|"The subject and their parent will be asked to answer questionnaires 2 weeks after the first MRE and US exams and again after the last imaging examinations are performed at treatment end/change or 6 months, whichever comes first.
A Pediatric Crohn Disease Activity Index Assessment will be performed at baseline, 2 weeks, 4 weeks, 3 months, and at treatment end/change or 6 months, whichever comes first. The study questionnaires should take no longer than 10 to 40 minutes to complete."
1683265|NCT01593449|Behavioral|Community-based social networking intervention|Participation in this study lasts for 7 months and includes a baseline visit, an orientation visit, the 6 month intervention, and a 6 month assessment visit.
1683266|NCT01593436|Behavioral|mindfulness training|mindfulness interventions for 8 weeks for a group of menopausal insomniacs
1683267|NCT01593423|Behavioral|plant-based Homestead Food Production|The village model farm will be provided with the necessary inputs to establish their farm including saplings seeds etc.
1683268|NCT01593423|Behavioral|Homestead Food Production plus small pond aquaculture|In the case of the aquaculture arm a pond will be dug if there is not an existing pond and fingerlings and brood stocks will be provided. Hatcheries will be established if there is not one within a reasonable distance of the farms.
1683269|NCT01593423|Behavioral|a comparison group|No intervention.
1683270|NCT01593410|Drug|Lenalidomide|25 mg oral lenalidomide once daily on Days 1-21 every 28 days
1683271|NCT01593410|Drug|Dexamethasone|Cycle 1: 40 mg oral dexamethasone once daily on Days 8, 15, and 22. Cycle 2 and beyond: 40 mg oral dexamethasone once daily on Days 1, 8, 15, and 22
1684788|NCT01581398|Drug|Pegasys|sc, qw, 48 weeks.
1683272|NCT01593397|Drug|Propofol and Fentanyl administration|Propofol will be administered to all patients via infusion at a dose of 2 mg/kg lean body weight/minute. The infusion will stop once loss of consciousness is reached. Fentanyl will be administered via target controlled infusion to achieve a plasma concentration of 2 ng/ml.
1683273|NCT01593371|Drug|Metformin|Metformin 1000 mg fixed dose, twice daily (500 mg tablets x 2)
1683274|NCT01593371|Drug|Pioglitazone|Pioglitazone 30 mg fixed dose, twice daily (15 mg tablets x 2)
1683275|NCT01593345|Other|Mobility self-management with Mentor|will be offered an evaluation and treatment plan supervised by a qualified physiotherapist, accompanied by written and visual material to enhance mobility self-management skills, supported by telephone mentoring by physiotherapy students in the Professional Master's program. The components of the mobility self-management program will target skill enhancement of each senior to identify their functional limitations, set realistic goals for mobility improvement, develop a mobility action plan, carry out the plan, and then re-assess their function and mobility. Mobility self-assessment, personalized goals, and the action plan will be incorporated into a personalized workbook that the senior can use to monitor their function profile and serve as a communication aid during health care encounters.
1683276|NCT01593345|Other|Mobility self-management with guidebook|will be mailed an exercise guide targeting the key mobility limitations common in the elderly (range of motion, arm, leg, and core strength, and breathing). This guide has been developed and has been pilot tested on a small number of seniors and has been shown to be acceptable and feasible.
1683277|NCT01593332|Drug|Rituximab|two 500 mg rituximab infusions 2 weeks apart
1683278|NCT01593332|Drug|Rituximab|500mg,two times with two weeks interval
1683279|NCT01593046|Drug|GSK1265744 Oral|30mg tablet
1683280|NCT01593046|Drug|GSK1265744 LAP 800mg intramuscular injection|800mg Loading dose given at month 1 dose
1683281|NCT01593046|Drug|GSK1265744 LAP 200mg subcutaneous injection|200mg maintenance dose give at months 2 - 4
1683282|NCT01593046|Drug|GSK1265744 LAP 200mg intramuscular injection|200mg maintenance dose given at months 2 - 4
1683283|NCT01593046|Drug|GSK1265744 LAP 400mg intramuscular injection|400mg maintenance dose given at month 2 - 4
1683284|NCT01593046|Drug|TMC278 LA 1200mg intramuscular injection|1200mg Loading dose given at month 3
1683285|NCT01593046|Drug|TMC278 LA 600mg intramuscular injection|600mg Loading dose given at month 4
1683286|NCT01593046|Drug|GSK1265744 LAP 800mg intramuscular injection|800mg dose given quarterly (once every) 12 weeks
1683287|NCT01593033|Dietary Supplement|Fish oil and Micronutrient Supplementation|"0.9 mL highly purified fish oil (200 mg docosahexaenoic acid, 300 mg eicosapentaenoic acid) to be given daily for 6 months
1 RDA of all known micronutrients needed for normal child growth in powder form to be given daily for 6 months"
1683288|NCT01593033|Dietary Supplement|Micronutrient Supplement|1 RDA all known micronutrients needed for normal child growth to be given daily in powder form for 6 months 0.9 mL palm oil given daily for 6 months
1683289|NCT01593033|Drug|Placebo|10 g sugar in granule form to be given daily for 6 months 0.9 mL palm oil to be given daily for 6 months
1683290|NCT01593020|Drug|Paclitaxel|80 mg/m2 by vein over 1 hour on Days 1, 8, and 15 of each 21-day cycle.
1683291|NCT01593020|Drug|Eribulin|1.4 mg/m2 by vein over 2-5 minutes on Days 1 and 8 of each 21-day study cycle.
1683292|NCT01593020|Drug|5-Fluorouracil|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
1683293|NCT01593020|Drug|Epirubicin|100 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
1683294|NCT01593020|Drug|Cyclophosphamide|500 mg/m2 by vein on day 1 for 4 cycles (21 day cycle) at preference of treating physicians.
1683295|NCT01593020|Drug|Doxorubicin|50 mg/m2 by vein on day 1, over 72 hour continuous infusion or intravenous bolus, for 4 cycles (21 day cycle) at preference of treating physicians.
1683296|NCT01593007|Other|Inspiratory muscle training|All participants were instructed to use a Threshold® trainer for 30min a day, seven times a week over 12 consecutive weeks.10 Patients in the Control Group used a Threshold ® device without resistance, making them blind to the treatment. For the treatment group, inspiratory resistance of the Threshold® trainer was 30% of MIP, adjusted on a weekly basis to remain constant.
1683297|NCT01593007|Other|Control group|Patients from the control group were also assessed weekly to ensure homogenization of the learning effect for the manometer maneuver.
1683298|NCT01592994|Behavioral|RHANI WIves|The RHANI Wives intervention included four household individual sessions and two small group community sessions delivered over 6-9 weeks. The intervention was based on Social Cognitive Theory (SCT)10 and the Theory of Gender and Power (TGP). SCT application supported focus on HIV/STI knowledge and condom skills building, as well as safer sex social norms and motivation. TGP guided the intervention focus on problem solving and skills building toward marital communication; embedded in this was gender equity counseling and support. The TGP approach allowed women to take a more active and assertive stance with husbands. Group sessions reinforced individual session knowledge and skills building and provided local social support.
1683299|NCT01592981|Drug|Bortezomib|1.6 mg/m2 subcutaneous bortezomib on days1, 8 and 15 of 28 days cycle
1683300|NCT01592981|Drug|Cyclophosphamide|"Cyclophosphamide:250 mg/sq m, oral, days 1, 8 and 15 of each cycle in the experimental arm.
Cyclophosphamide:250 mg/sq m, oral, days 1, 2 and 3 of each cycle in the control arm."
1683301|NCT01592981|Biological|Rituximab|Rituximab: 375 mg/m2 i.v. infusion; days 1, 8, 15 and 22 of cycles 2 and 5 only
1683302|NCT01592981|Drug|Fludarabine|Fludarabine: 40 mg/sq m, oral, days 1, 2 and 3
1683303|NCT01592968|Radiation|Stereotactic Radiosurgery (SRS)|Dose based on largest diameter lesion as measured on volumetric MRI, as follows: 20-24 Gy for lesions 2 cm or less in size, 16-18 Gy for lesions >2-2.5 cm in size, and 12-16 Gy for lesions >2.5-3.5 cm in size. SRS performed on day 1.
1683304|NCT01592968|Radiation|Whole Brain Radiation Therapy (WBRT)|Fractionated radiation delivered to whole brain daily to deliver a dose of 30 Gy in 10 fractions.
1683305|NCT01592968|Behavioral|Questionnaires|Three (3) sets of quality of life (QOL) questionnaires completed 1, 4, 6, 9, and 12 months after assigned treatment.
1683306|NCT01592968|Behavioral|Cognitive Function Tests|7 cognitive function tests completed 1, 4, 6, 9, and 12 months after assigned treatment.
1683307|NCT01592955|Device|EYEOP1|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP1 device
1686023|NCT01572051|Behavioral|Phone Calls|Phone Calls
1683308|NCT01592942|Device|Histoacryl|cyanoacrylate glue fixation of mesh 1 ml
1683309|NCT01592942|Device|Progrip|self-gripping mesh
1683310|NCT01592942|Device|sutures (prolene 3-0)|non-absorbable suture fixation 3-0
1683311|NCT01592929|Radiation|Magnetic Resonance imaging|11 MRI scans per subject will be taken, one for each mouthpiece design of an inhaler.
1683312|NCT01592929|Other|Pharyngometry|Pharyngometry will be carried out in supine and upright position. 11 different mouthpieces will be evaluated in both positions.
1683313|NCT01592929|Radiation|Computed Tomography scan|One low dose CT scan of the upper airway will be taken. The scan will be taken at normal inhalation through a mouthpiece with moderate resistance.
1683314|NCT01592929|Radiation|Cone Beam Computed Tomography scan|One CBCT scan of the upper airway will be taken. The scan will be taken at normal respiration through a mouthpiece with moderate resistance.
1683315|NCT01592929|Other|Dental impressions|Dental impressions will be taken. These will be optically scanned before registration in the 3D imaging modalities.
1683316|NCT01592903|Genetic|Laparoscopic myomectomy. Following analysis and proliferation of cells isolated from removed human leiomyoma.|"Obtention of one part of removed human leiomyoma after surgery and maintained in 4ºC until procedures.
Sample digestion through controlled enzymes.
Isolated the Side Population from leiomyoma cell suspension by Flow cytometry .
Culture of these cells.
Morphological and genetic characterization.
Assessment of pluripotent potential from isolated cells.
Analysis of the degree of functionality."
1683317|NCT01592890|Drug|RO4917523|[14C]-labeled RO4917523, single oral dose
1683318|NCT01592890|Drug|RO4917523|[13C]-labeled RO4917523, single intravenous tracer dose
1683319|NCT01592864|Drug|Stannous Fluoride|dentifice
1683320|NCT01592864|Drug|Sodium Monofluorophosphate|dentifrice
1683321|NCT01592851|Drug|Stannous Fluoride|dentifrice containing stannous fluoride
1683322|NCT01592851|Drug|Sodium Monofluorophosphate|dentifrice containing Sodium Monofluorophosphate
1683323|NCT01592838|Other|Data collection|The participating centre will be requested to generate a coded list of all hospitalisations taken place during the study period (June 1st 2004- May 31st 2010) and analysed for changes in hospital pattern pre- versus post-rotavirus vaccination, in children aged ≤15 years.
1683324|NCT01592812|Device|electrical muscle stimulation|Duration of the stimulation 20 minutes
1683327|NCT01592786|Drug|Memantine Hydrochloride (HCl)|Memantine extended release 3-mg capsules; the dosages studied ranged from 3 - 15 mg/day; weight based dosing in 4 weight groups; oral administration. Dosing is once daily for up to 48 weeks.
1683328|NCT01592773|Drug|Memantine Hydrochloride (HCl)|"During the 6-week double-blind dosing titration/maintenance period, Memantine extended-release 3-mg and 6-mg capsules; oral administration. Dosing was once daily.
During open-label treatment: Memantine extended-release 3mg capsules; oral administration. The maximum target dosage was identified during the prior studies for each patient. Dosing was once daily."
1683329|NCT01592760|Device|air-Q SP|air-Q SP placement for airway maintenance.
1683330|NCT01592760|Device|air-Q|air-Q placement for airway maintenance.
1683331|NCT01592760|Device|i-gel|i-gel placement for airway maintenance.
1683335|NCT01592734|Drug|Polyethylene glycol with electrolytes|"Constipation treatment: 1-4 sachets/day according to the patient age. 1 sachet contains 6.9 g PEG-EL. Treatment period: 4 weeks.
Faecal impaction resolution: 4 sachets as initial dose and increasing 2 sachets a day until resolution or up to 7 days."
1683336|NCT01592734|Device|Polyethylene glycol|"Constipation: 0.7 g/kg/day in 2 divided doses for children of less than 20 kg. For children > 20 kg the daily dose was up to PEG 30 g daily. Treatment period: 4 weeks.
Faecal impaction resolution: 1.5 g/kg/day in 2 doses until resolution or up to 6 days."
1683337|NCT01592721|Biological|EGFR Antisense DNA|EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. Patients will receive a total of up to 4 weekly intratumoral injections of EGFR antisense (or less if there is no identifiable tumor) starting 2 weeks prior to radiation. Patients will receive standard radiation 70 Gy/200 cGy/daily, 5 days/week, with concurrent cetuximab 250 mg/m2, after a loading dose of 400 mg/m2 2 weeks prior to starting radiation.
1683338|NCT01592708|Other|Antiemetic anesthesia protocol|Intervention group consisted of patients undergoing maxillary osteotomy who received an antiemetic protocol designed to provide multimodal antiemetic therapy which have been shown to help prevent and/or treat postoperative nausea, combined with the elimination of anesthetic factors that may contribute to postoperative nausea and vomiting.
1683339|NCT01592695|Drug|Nicotine replacement therapy - transdermal nicotine patch|Medication selection will be determined based on individual participant preferences, medical history, and contraindications.
1683340|NCT01592695|Behavioral|Tailored behavioral intervention|Participants will receive a standard six session cognitive behavioral intervention for smoking cessation combined with supplemental treatment modules based on individual need and preference.
1683341|NCT01592695|Behavioral|Tobacco quit line referral|Participants assigned to this condition will receive a referral to their state tobacco quit line. The specific behavioral treatment that is provided will differ slightly depending upon the services available through the participant's state of residence.
1683342|NCT01592695|Drug|Nicotine replacement therapy - nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
1683423|NCT01592162|Drug|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
1683343|NCT01592695|Drug|Nicotine replacement therapy - nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
1683344|NCT01592695|Drug|Bupropion Sustained Release|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
1683345|NCT01592695|Drug|Varenicline|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
1683346|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine gum|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
1683347|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + nicotine lozenge|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
1683348|NCT01592695|Drug|Combination pharmacotherapy - transdermal nicotine patch + bupropion|Medication selection will be determined based on individual participant preferences, medical history, and contraindications
1683349|NCT01592695|Behavioral|Alcohol use risk reduction|Participants engaging in risky alcohol use may receive this six-session telephone-based behavioral intervention for reducing alcohol use.
1683350|NCT01592695|Behavioral|Behavioral activation for the treatment of depression|Participants with elevated depressive symptoms may receive this six-session telephone-based behavioral activation intervention.
1683351|NCT01592695|Behavioral|Behavioral management of post-cessation weight gain|Participants with concerns about gaining weight after quitting smoking may receive this six-session telephone-based behavioral self-management intervention designed to help attenuate post-cessation weight gain.
1683352|NCT01592682|Behavioral|Smokefree counseling|Smokefree counseling intervention involves group education sessions, follow-up phone calls, tobacco exposure lab report. Comparison is usual care with referral to local in-language smoking cessation services including quitline.
1683353|NCT01592669|Procedure|passive leg raising|bilateral PLR was achieved by raising the legs of patient
1683354|NCT01592656|Radiation|Functional Respiratory Imaging|CT-scan of thorax. At baseline, after 1 month and after 6 months.
1683355|NCT01592656|Other|Lung compliance measurement|At baseline
1683356|NCT01592656|Device|Non-invasive ventilation (Respironics)|Long-term non-invasive ventilation, starting at baseline until 6 months. At baseline the patients should have persisting hypercapnia (pCO2 > 45 mmHg) under optimal conservative treatment other than NIV. The patients can be hospitalised or being treated at home at inclusion.
1683357|NCT01592643|Device|Eye Shield|The thin shield is made of silicone. The materials used to make the corneal shield all have a history of use in medical devices, contact lenses, and/or corneal shields and have been used safely in the eye.
1683358|NCT01592630|Drug|0.2% ropivacaine|On-Q pumps containing 0.2% ropivacaine to be attached to TAP catheters
1683359|NCT01592630|Drug|Saline|On-Q pumps containing saline to be attached to TAP catheters
1683360|NCT01592617|Drug|S-488410|In multicenter HLA-blinded open study, patients will be vaccinated subcutaneously once a week with S-488410 (S-488401, S-488402, S-488403, 1mg each).
1683361|NCT01592604|Device|Compressive bandage|Compressive below knee bandage for 4 weeks in group A
1683362|NCT01592604|Device|Below knee walking cast|Below knee walking cast for 4 weeks
1683363|NCT01592578|Procedure|Ligation and Cyanoacrylate|Patients will be treated with ligation for esophageal varices and cyanoacrylate for gastric varices when necessary.
1683364|NCT01592578|Procedure|Ligation plus Sclerotherapy and Cyanoacrylate Group|Patients will receive sclerotherapy after first ligation for esophageal varices and cyanoacrylate for gastric varices when necessary
1683365|NCT01592565|Other|Diagnostic Cardiac Imaging|Cardiac Magnetic Resonance (CMR) offers superior image quality compared to echocardiography and nuclear imaging, and the ability to image both function and perfusion. Combining the superior image quality of CMR with the diagnostic information provided by exercise stress could result in a new, more accurate modality for diagnosing and evaluating coronary artery disease. This project is expected to show that CMR is at least equivalent to nuclear stress imaging and could potentially replace it in many instances, eliminating the need for radioisotope administration and the associated exposure of patients to ionizing radiation.
1683366|NCT01592526|Other|Endotoxin|Bolus injection of LPS 2 ng/kg IV at time = 2 hours (Study day A).
1683367|NCT01592526|Other|Endotoxin + Nicotine|Transdermal application of nicotine patch applied at time = -8 hours (midnight the day before Study day B) + bolus injection of LPS 2 ng/kg at time = 2 hours (Study day 2)
1683368|NCT01592513|Device|BIS monitor|"BIS is a monitor of anesthetic depth approved by the FDA. It incorporates time-domain, frequency-domain and bi-spectral analysis of the EEG. This analysis is displayed as a dimensionless number between zero (deep anesthesia) and 100 (awake).
BIS values between 80-90 represent values corresponding to light/moderate sedation.
BIS is a valuable tool for assessing the depth of sedation and guiding the administration of sedative drugs."
1683369|NCT01592500|Drug|MOD-4023|Once weekly subcutaneous injection
1683370|NCT01592500|Drug|Somatropin|Once daily subcutaneous injection of Genotropin
1683371|NCT01592448|Behavioral|Active Ingredient Icon|"Enhanced bottles will have a symbol, or icon, designed to draw attention to active ingredient information. The icon is a black hexagon containing two letters denoting the active ingredient of the medication (i.e. Ac for acetaminophen). Over-the-counter bottles will have the icon placed on the front of the bottle next to active ingredient information and on the back of the bottle in the drug facts to the left of the active ingredient information. Prescription bottles will have the icon placed below the directions for how to take the medication and will be accompanied by a brief statement indicating the medicine contains acetaminophen."
1683372|NCT01592422|Biological|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.
1683373|NCT01592422|Other|Best Supportive Care|Best Supportive Care in the absence of disease progression
1683374|NCT01592409|Drug|delta-9-tetrahydrocannabinol|A single cannabis cigarette (potency 12.5% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose.
1683424|NCT01592162|Drug|propofol 1% (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
1733019|NCT00058994|Drug|anecortave acetate|
1683375|NCT01592409|Drug|Placebo|A single placebo cannabis cigarette (0% THC) will be given to participants to smoke over a 10 minute period, ad lib. If the cigarette is not smoked in its entirety, the remainder will be weighed to estimate dose (as this is a double-blind study).
1683376|NCT01592396|Biological|Tralokinumab 300 mg|Participants aged 12 to 14 years and 15 to 17 years will receive a single dose of tralokinumab (CAT-354) 300 mg, subcutaneously on Day 1.
1683377|NCT01592383|Drug|erlotinib hydrochloride|Given PO
1683378|NCT01592383|Other|laboratory biomarker analysis|Correlative studies
1683379|NCT01592370|Biological|Nivolumab|
1683380|NCT01592370|Biological|Ipilimumab|
1683381|NCT01592370|Biological|Lirilumab|
1683382|NCT01592370|Biological|Daratumumab|
1683383|NCT01592370|Drug|Pomalidomide|
1683384|NCT01592370|Drug|Dexamethasone|
1683385|NCT01592357|Behavioral|Tai Chi exercise|A short and simple 8-forms Tai Chi routine will be used in this study. This routine has been previously standardized and field tested. Participants will be coached, by a certified Tai Chi instructor, in practicing the proper mechanics of executing each of the eight physical movements comprising the 8-forms of Tai Chi. A brief 5 minute period of walking calisthenics pertinent to Tai Chi movements, postures and diaphragmatic breathing will take place before training to warm up and after training to cool down. The Tai Chi training will be 2 times a week and the total exercise time, including warm-up and cool down, will be 50 minutes for each session. Over a period of 12 weeks, the participants will learn all 8-forms and continue practicing them for the final 12 weeks of the training period.
1683386|NCT01592357|Behavioral|Sham Exercise|"The sham exercise (control) group will be involved in low-intensity stretching exercises two times per week. These exercises will be designed as a sham exercise condition. A brief 5 minute period of walking will take place before the sham exercise to warm up and after the sham exercise to cool down. Sham exercise sessions will include stretching exercises of the neck, trunk and extremities. The total exercise time for the sham exercise group will be 50 minutes and participants will meet 2 times per week for a period of 24 weeks."
1683387|NCT01592344|Device|StimRouter - active stimulation|"The stimulation program settings for this arm are as follows:
Stim Settings
Waveform: Symmetric or Asymmetric
Phase Duration: 100-250 µsec
Pulse Rate: 50-100 Hz
Intensity: 0-30mA Time Settings
Constant Stim: On
Total Time: 6 hour"
1683388|NCT01592344|Device|StimRouter - Control|"The stimulation program settings for this arm are as follows:
Stim Settings
Waveform: Symmetric or Asymmetric
Phase Duration: 200 µsec
Pulse Rate: 1 Hz
Intensity: 0 mA Time Settings
Constant Stim: On
Total Time: 6 hour"
1683389|NCT01592331|Drug|Placebo|Single oral dose
1683390|NCT01592331|Drug|RO5508887|Single oral dose
1683391|NCT01592318|Drug|danoprevir|Fixed dose combination tablet with ritonavir, single oral dose
1683392|NCT01592318|Drug|danoprevir|Reference tablet, single oral dose
1683393|NCT01592318|Drug|ritonavir|Fixed dose combination tablet with danoprevir, single oral dose
1683394|NCT01592318|Drug|ritonavir|Reference tablet, single oral dose
1683395|NCT01592305|Drug|atazanavir|multiple oral doses
1683396|NCT01592305|Drug|danoprevir|multiple oral doses
1683397|NCT01592305|Drug|ritonavir|multiple oral doses
1683398|NCT01592305|Drug|tenofovir disoproxil fumarate|single oral doses
1683399|NCT01592292|Drug|Rituximab|Rituximab as per physician's discretion.
1683400|NCT01592292|Drug|Adalimumab|Adalimumab as per physician's discretion.
1683401|NCT01592292|Drug|Etanercept|Etanercept as per physician's discretion.
1683402|NCT01592292|Drug|Infliximab|Infliximab as per physician's discretion.
1683403|NCT01592279|Drug|liraglutide|
1683404|NCT01592279|Drug|Insulin injections|
1683405|NCT01592253|Drug|Sirolimus|Beginning on day, an initial maintenance dose of 2mg/day should be given. A trough level should be obtained between days 3 and 8, and the daily dose of sirolimus should be adjusted thereafter.
1683413|NCT01592227|Drug|Marketed paracetamol|Marketed paracetamol
1683414|NCT01592227|Drug|Experimental paracetamol formulation|Experimental paracetamol formulation
1683415|NCT01592214|Other|Placebo|Placebo: 4% Klucel® gel formulation, concentration 0, total daily volume 1.8 ml, 3 doses 8 hours apart on Day 1 and 1.2 ml, 2 doses 12 hrs apart on Days 2 to 5.
1683416|NCT01592214|Drug|XF-73 in 2% Klucel gel|XF-73 in a modified 2% Klucel® gel formulation: Part 1, #1: concentration 0.5 mg/g, twice a day in volume 0.3 mL/naris/dose, total dose 0.6 mg; Part 1, #2: 2.0 mg/g concentration, twice a day in volume 0.3 mL/naris/dose, total dose 2.4 mg; Part 2, #1: Concentration 0.5 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 0.9 mg, 2 doses 12 hours apart on Days 2-5, total volume 1.2 ml and total dose 0.6 mg ; Part 2, #2: 2.0 mg/g, 3 doses 8 hours apart on Day 1, total volume 1.8 ml, total dose 3.6 mg, 2 doses 12 hours apart on Days 2-5,total volume 1.2 ml and total dose 2.4 mg.
1683417|NCT01592214|Drug|XF-73 in 4% Klucel gel|XF-73 in a 4% Klucel® gel formulation: Part 2 #3: concentration of 0.5 mg/g and volume of 0.3 mL/naris/dose in 3 doses 8 hours apart on Day 1 and 2 doses, 12 hours apart on Days 2 to 5. Total daily volume of 1.8 ml on Day 1 and 1.2 ml on Days 2 to 5; and total daily dose of 0.9 mg on Day 1 and 0.6 mg on Days 2 to 5.
1683418|NCT01592201|Drug|Paliperdidone ER|Form = osmotic release oral system, route = oral
1683419|NCT01592201|Drug|Aripiprazole, olanzapine and risperidone (Antipsychotics)|Form = tablet, route = oral
1683420|NCT01592188|Behavioral|Cognitively-Based Compassion Training (CBCT)|CBCT is a 12 week program that begins by teaching mindfulness and attention. It then goes on to use new mindfulness skills to consider topics of compassion, or unbiased acceptance and compassion for all other people, both friends, unfamiliar people, and enemies.
1683421|NCT01592188|Behavioral|Mindfulness training|Mindfulness training will consist of 6 weeks training in mindfulness meditation.
1683422|NCT01592162|Drug|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
1733166|NCT00060385|Drug|cyclophosphamide|
1683425|NCT01592162|Drug|Propofol (Astra-Zeneca), NaCl 0.9%|propofol administered by a closed-loop system and saline
1683426|NCT01592162|Drug|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
1683427|NCT01592162|Drug|Propofol (Astra-Zeneca) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
1683428|NCT01592162|Drug|Propofol (B-Braun) and NaCl 0.9%|propofol administered by a closed-loop system and saline
1683429|NCT01592162|Drug|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (2 ng/ml, target controled infusion)
1683430|NCT01592162|Drug|Propofol (B-Braun) and remifentanil|propofol administered by a closed-loop system and remifentanil (4 ng/ml, target controled infusion)
1683431|NCT01592149|Other|No Drug|No intervention will be given to subjects, survey of loss of appetite in patients suffering from various healthcare disorders.
1683432|NCT01592136|Drug|ponatinib|Patients will receive ponatinib 45 mg orally as a single dose once daily with or without food. Each patient will receive daily ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent
1683433|NCT01592123|Procedure|The active anterior rhinomanometry|In this method, the airflow through 1 nasal cavity and the pressure gradient across this nasal cavity are measured simultaneously at each breath as recommended by the committee report on the standardization of rhinomanometry. All measurements were performed under the same standard conditions. Herein, all presented airflow values are the sum of inspiratory airflow of the right and left sides of the nose at 150 pascals (Pa). And, total nasal airflow (cm3/s) and airway resistance (Pa/cm3/s) values were used for statistical analyses.
1683434|NCT01592123|Behavioral|The Pittsburgh Sleep Quality Index (PSQI)|PSQI was developed to measure sleep quality during the previous month and to discriminate between good and poor sleepers. The self-administered scale contains 15 multiple-choice items that inquire about frequency of sleep disturbances and subjective sleep quality and 4 write-in items that inquire about typical bedtime, wake-up time, sleep latency, and sleep duration. Each component score ranges from 0 (no difficulty) to 3 (severe difficulty). The component scores are summed to produce a global score (range of 0-21). A PSQI global score >5 is considered to be suggestive of significant sleep disturbance.
1683435|NCT01592123|Behavioral|The Beck Anxiety Inventory (BAI)|The BAI is a 21-item self-report questionnaire that lists symptoms of anxiety. The respondent is asked to rate how much each symptom has bothered him/her in the past week. The symptoms are rated on a four-point scale, ranging from ''not at all'' (0) to ''severely'' (3). The instrument has excellent internal consistency and high test-retest reliability. The BAI has been widely used to measure severity of anxiety by self-report.
1683436|NCT01592123|Behavioral|The Van Dream Anxiety Scale (VDAS)|The VDAS provides the assessment of nightmare frequency and dream anxiety caused by frightening dreams during the preceding month. There are 17 self-rated questions in the scale. Twelve questions (1-4, 6, 11-17) that are tabulated in the scoring are weighted equally on a 0-4 scale. Question 5 is related to autonomic hyperactivity and consists of 12 symptoms. Each of 12 symptoms is also weighted on a 0-4 scale. Thirteen question scores are summed to yield a global VDAS score, which has a range of 0-42.
1683437|NCT01592110|Drug|risperidone-SABER|25 mg of risperidone-SABER administered as a subcutaneous (SC) injection of 0.25 mL
1683438|NCT01592110|Other|ZX003:risperidone-SABER and the DosePro System|50 mg risperidone-SABER administered as 0.5 mL via the DosePro Needle-Free Injection System
1683439|NCT01592110|Drug|risperidone-SABER|50 mg of risperidone-SABER administered as a SC injection of 0.5 mL
1683440|NCT01592110|Drug|Risperidone-SABER|100 mg of risperidone-SABER administered as a SC injection of 1.0 mL
1683441|NCT01592071|Other|Replace reactive foods with non-reactive foods|Subjects were provided with the test results and an individualized dietary plan based on replacing reactive foods with non-reactive foods as replacements per the Immuno Bloodprint results.
1683442|NCT01592045|Biological|ch14.18 -NCI|25 mg/m^2/day IV for four consecutive days
1683443|NCT01592045|Biological|ch14.18-UTC|17.5 mg/m^2/day IV for four consecutive days
1683444|NCT01592045|Biological|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF will be administered SC at a dose of 250 mcg/m^2/day for 14 days during Courses 1, 3, and 5.
1683445|NCT01592045|Biological|Aldesleukin (IL-2)|Aldesleukin (IL-2) will be administered IV at a dose of 3 MIU/m^2/day for the first week and at a dose of 4.5 MIU/m^2/day for the second week during Courses 2 and 4.
1683446|NCT01592045|Drug|Isotretinoin|"Isotretinoin (13-cis-retinoic acid; ISOT) will be administered by mouth over six courses as follows:
If weight > 12 kg: 80 mg/m^2/dose twice daily (total daily dose is 160 mg/m^2/day, divided twice daily).
If weight ≤ 12 kg: 2.67 mg/kg/dose twice daily (total daily dose is 5.33 mg/kg/day, divided twice daily)."
1683447|NCT01592032|Drug|Vancomycin antimicrobial-lock solution|Randomization of 5 patients into vancomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
1683448|NCT01592032|Drug|Teicoplanin antimicrobial-lock solution|Randomization of 5 patients into teicoplanin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
1683449|NCT01592032|Drug|Linezolid antimicrobial-lock solution|Randomization of 5 patients into linezolid antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
1683450|NCT01592032|Drug|Daptomycin antimicrobial-lock solution|Randomization of 5 patients into daptomycin antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
1683451|NCT01592032|Drug|Tigecycline antimicrobial-lock solution|Randomization of 5 patients into tigecycline antimicrobial-lock solution arm for 1, 3, 5, 7 and 10 days according to HPLC corrected by urea gradient. The arm can be stopped any time from day 1 to day 10 in case of antimicrobial concentration less than 1 mg/mL.
1683452|NCT01592019|Drug|Reference, Patch location thigh, batch 1|Reference, Patch location thigh, batch 1
1683453|NCT01592019|Device|Test, Patch location thigh, batch 2|Test, Patch location thigh, batch 2. Three probes will be inserted at each visit.
1733317|NCT00050050|Drug|Drug therapy|
1683454|NCT01592019|Drug|Reference, Patch location abdomen, batch 1|Reference, Patch location abdomen, batch 1
1683455|NCT01592019|Device|Test, Patch location abdomen, batch 2|Test, Patch location abdomen, batch 2. Three probes will be inserted at each visit.
1683456|NCT01592006|Drug|Peginterferon alfa-2a|Patients will be treated with pegylated interferon alfa-2a (Pegasys®) 180 mcg SQ per week for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
1683457|NCT01592006|Drug|Ribavirin|Patients will be given ribavirin 600-1200 mg PO per day for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
1683458|NCT01592006|Drug|telaprevir|Patients will be given telaprevir 750 mg tid (Incivek®) for 12 weeks, followed by pegylated interferon alfa-2a (Pegasys®) and ribavirin for another 36 weeks. Patients will be assessed at periodic intervals for safety and adverse effects. Following completion of therapy, patients will be followed for another 24 weeks to determine sustained response.
1683459|NCT01591993|Procedure|10% lactic acid test|To each subject, 10% lactic acid is applied to one nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
1683460|NCT01591993|Procedure|Placebo|To each subject, 0.9% saline solution will be applied to the contralateral nasolabial fold. This will be performed under humidity, temperature and pH control to avoid influence of these variables in the result of the test.
1683461|NCT01591980|Drug|Pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
1683462|NCT01591980|Drug|pregabalin|Pre-operatively, one of the 2 doses of pregabalin (100 or 150 mg) or placebo will be given to patients 1 hour before the surgery. Post-operatively, patients will receive daily (split in 2 equal doses) pregabalin 100 mg, pregabalin 150 mg, or placebo for the first 14 post-operative days.
1683463|NCT01591980|Drug|placebo|Identical placebo capsules will be administered in the same way.
1683464|NCT01591967|Device|Activator IV Adjusting Instrument|Activator (http://www.activator.com/products-page/) adjustment effects on BP and PR
1683465|NCT01591954|Device|Video Augmentation|Assessment of value of video-based navigation system
1683466|NCT01591941|Other|Core-PAC|"Core position and control movement strategy (Core-PAC):
Do warm-up prior to 6 weeks of regular soccer training for peak flexion angles and peak abduction moments at the knee during a side-cut (SC) and an unanticipated side-cut (USC) prior to kicking a soccer ball and a side-hop (SH) task."
1683467|NCT01591915|Other|MBSR|Participants in Intervention 1 and Intervention 2 will participate in an 8 week course of MBSR practice of homework assignments consisting of 20 min sessions, 6 days/week. Participants will be provided information material including a book of 20 pages introduction to mindfulness training, self-instructing CD, diary and training program. Only participants in Intervention 1 will partake in a structured group-formatted 8 week course that patients attend once a week for an average of 2 h. Led by a certified MBSR instructor, these weekly group sessions are focused on participant's experiences of mindfulness, and include yoga and meditation training. Four registered nurses, skilled in patient learning, have been educated as certified MBSR instructors.
1683468|NCT01591902|Drug|Tesamorelin|Daily 2 mg subcutaneous injections of tesamorelin
1683469|NCT01591902|Drug|Placebo-Control|3.0 mL vials
1683470|NCT01591889|Drug|Tinidazole|500 mg tablet
1683471|NCT01591889|Drug|Tinidazole|500 mg tablet
1683472|NCT01591876|Other|Intradialytic aerobic exercise|Participants in the intervention group will undertake moderate intensity aerobic exercise. Exercise modality will be recumbent cycling during the first two hours of haemodialysis sessions. Exercise prescription is set using a graded exercise test and anchored to a perceived level of exertion using the BORG scale. Training stimulus is maintained by the participant by increasing the cycling resistance when perceived exertion drops by one point at the current resistance level. Adherence and training volume is recorded during the intervention period.
1683473|NCT01591876|Other|Progressive Muscle relaxation|This is a sequence of stretching and relaxation of the major muscle groups of the body. Participants are initially given detailed information regarding the technique and then provided with a recorded version which they listen to for 30-40 minutes during dialysis sessions. Participants in this group are offered the exercise programme at the end of three months.
1683474|NCT01591863|Drug|fidaxomicin|"6 months-5 years 11 months: oral suspension, 32 mg/kg/day with a maximum dose of 400 mg/day, divided into two doses, every 12 hours for 10 days.
6 years-17 years 11 months: tablets, 200 mg every 12 hours for 10 days."
1683475|NCT01591850|Drug|RO5093151|Single oral dose
1683476|NCT01591850|Drug|atazanavir|Multiple oral doses
1683477|NCT01591850|Drug|ketoconazole|Multiple oral doses
1683478|NCT01591850|Drug|rifampicin|Multiple oral doses
1683479|NCT01591850|Drug|ritonavir|Multiple oral doses
1683480|NCT01591837|Biological|CSL Influenza Vaccine|The study vaccine (CSL Influenza Vaccine) is a sterile, thiomersal-free suspension containing 45 mcg total haemagglutinin antigen per 0.5 mL dose (15 mcg each of the three recommended influenza strains for the Northern Hemisphere 2012/2013 influenza season). The vaccine will be administered by intramuscular or subcutaneous injection.
1683481|NCT01591824|Other|Resonant oscillation|"Resonant sustained oscillations are applied in the following areas
general column.
lumbar muscles, and paraspinal muscles,
sacral decompression oscillatory
Opening by lateral vertebral lumbar rhythmic swing.
Balancing and pelvic decompression
Swing-lumbar vertebral rotation."
1683482|NCT01591824|Other|column exercise group|"paraspinal muscle stretching exercises
postural correction
mobilization exercises thoracic and lumbar
Motor control exercises"
1683483|NCT01591811|Radiation|Arm 1 Daily Boost of Radiation Therapy|Arm 1 Daily boost. IMRT at 2.7Gy x15 fractions. Total dose 40.50Gy. Daily Boost 0.5Gy to tumor bed x 15 fractions. Tumor Bed Total=48Gy
1683484|NCT01591811|Radiation|Arm 2 Weekly Boost of Radiation Therapy|Arm2: IMRT at 2.7Gy x 15 fractions. Total Dose=40.50 Gy. Weekly Boost 2Gy (on Friday). Tumor Bed Total 46.50Gy
1734059|NCT00057356|Drug|placebo|IV
1683485|NCT01591798|Procedure|Robotic surgery|Robotic assisted rectal resection
1683486|NCT01591798|Procedure|Laparoscopic surgery|Laparoscopic assisted rectal resection
1683489|NCT01591772|Other|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
1683490|NCT01591772|Other|Neuroimaging & Neuropsychological Evaluation|Will undergo structural and functional MRI scans on a Siemens 3T Magnetom Tim Trio research scanner located at the Citigroup Biomedical Imaging Center at Weill Cornell Medical Center (WCMC), which is adjacent to the MSKCC campus. Patients do not undergo routine clinical brain MRIs as part of their assessment and treatment, and the brain MRI scans to be performed in this study are for research purposes only. The MRI scan takes approximately 60 minutes to complete, and about 15 minutes will be required for instructions prior to initiating the study. The MRI studies will be reviewed by a neuroradiologist (Dr. Karimi) to rule out gross structural CNS abnormalities; in case any abnormalities considered to require clinical follow-up are detected, the subject will be contacted and referred for follow-up with their treating physician. Patients will undergo a brief neuropsychological test battery at MSKCC or at Citigroup Biomedical Imaging Center at WCMC
1683491|NCT01591759|Drug|Citicoline|2,000mg/day of citicoline taken as twice daily unit doses of 1,000 mg for the 8-week period of the clinical trial
1683492|NCT01591759|Drug|Placebo|Placebo arm of single-blind study
1683495|NCT01591733|Drug|FOLFIRINOX|Up to Eight-14 day cycles
1683496|NCT01591733|Drug|Capecitabine|Orally, for 10 days
1683497|NCT01591733|Radiation|Short Course Radiation|Five or ten days
1683498|NCT01591733|Procedure|Surgery|1-4 weeks after completion of capecitabine therapy
1683499|NCT01591720|Behavioral|Tailored Internet-based CBT for depression and anxiety|"This Internet-based CBT intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
1683500|NCT01591707|Behavioral|ISC+PRT Intervention|Teachers will be trained to implement an intervention in preschool ASD classrooms that provides a learning environment in which social and communication skills are focused on.
1683501|NCT01591681|Device|Pump suspension|The study laptop will communicate to the pump causing a suspension based on output from the algorithm which predicts hypoglycemia based on the continuous glucose sensor trend.
1683502|NCT01591668|Drug|Single Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Dose cohorts may be dosed with one of up to 4 possible total weekly doses (0.3 mg, 1 mg, 2 mg, 4 mg). Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
1683503|NCT01591668|Drug|Multiple Ascending Dose Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
1683504|NCT01591655|Drug|Mapracorat|1 drop of study medication into the study eye four times daily (QID) for 14 days
1683505|NCT01591655|Drug|Vehicle|1 drop of vehicle into the study eye QID for 14 days.
1683506|NCT01591629|Drug|Naloxone|Active Naloxone 18 mcg/kg intravenously over 60 minutes, 2mg IV push, 1mg IV push
1683507|NCT01591629|Drug|Delta-9-THC|Active Delta-9-THC (0.025mg/Kg) given intravenously over 20 minutes.
1683508|NCT01591629|Drug|Placebo|Placebo
1683509|NCT01591616|Drug|lidocaine and prilocaine|Appropriate dose of Oraqix based on weight will be given before tooth extraction
1683510|NCT01591603|Procedure|1 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 1 cm past the tip of the Tuohy
1683511|NCT01591603|Procedure|5 cm|A Tuohy needle will be advanced in-plane with the bevel cephalad to a point that lies between the tibial and common peroneal branches of the sciatic nerve. The catheter will be advanced 5 cm past the tip of the Tuohy
1683512|NCT01591590|Other|FDG PET-CT|All patients will undergo FDG PET-CT at inclusion and 2 weeks after
1683513|NCT01591590|Other|Diffusion MRI|All patients will undergo Diffusion MRI at inclusion and 2 weeks later
1683514|NCT01591590|Other|Blood samples (plasma preparation and CTC)|
1683515|NCT01591577|Other|Lapatinib/Temozolomide/radiation|Patients will be treated with a pulse dose of lapatinib every week and temozolomide 75 mg/m2 daily during radiation. Lapatinib will be administered beginning on the first day of radiation and temozolomide (+/-2 days). External beam fractionated regional radiation will be given on consecutive week days at 200 cGy daily doses to a total dose of 6000 cGy. Patients will have rest from temozolomide only for 2-4 weeks. Patients will continue with weekly pulse-dosing of lapatinib. After a 2-4 weeks rest(for temozolomide only) following completion of radiation therapy, temozolomide will be restarted as Cycle 1 at 150 mg/m2/day for 5 days out of every 28.Subsequent cycles can increase to 200 mg/m2/day as tolerated per investigator's judgment. Lapatinib pulse doses will be continued every week without interruption.Treatment will continue for 24 additional 28-day cycles of temozolomide if there is no evidence of progression.
1683516|NCT01591564|Behavioral|Interpersonal Psychotherapy for youth with SMD (IPT-SMD)|Youth will receive weekly therapy sessions for 16 weeks and then bi-weekly session until week 20. Parent sessions will also be included.
1683517|NCT01591551|Drug|Natalizumab (Tysabri)|300 mg IV every 4 weeks
1683518|NCT01591525|Behavioral|Education on risk factors for Type II Diabetes|one-on-one education provided by a nurse practitioner or physician
1683519|NCT01591525|Behavioral|Education on Type II Diabetes|one-on-one education about having Type II Diabetes, the possible complications and treatment options provided by a physician.
1683520|NCT01591525|Behavioral|Education on regular visits to a Primary Care Provider|one-on-one education about the importance of visiting a primary care provider (PCP) on a regular basis. Patients are also provided a list of PCP's accepting new patients within a 3 mile radius.
1683521|NCT01591499|Device|BIOFINITY® MF - AIR OPTIX® AQUA MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
1683522|NCT01591499|Device|BIOFINITY® MF - PUREVISION® MF|During the first period, the participant will be allocated at random either the test lens pair (Biofinity) or a comparator lens pair (Air Optix or Purevision); during the second period, the participant will crossover to the alternate lens pair. (Biofinity crossover to Air Optix or Purevision) (Air Optix or Purevision crossover to Biofinity)
1683523|NCT01591473|Drug|FluMist + Poly I:Poly C12U 50 ug|FluMist 0.2 ml and Poly I:Poly C12U 50 ug; 3 doses; nasal administration every 28 days
1683524|NCT01591473|Drug|FluMist + Poly I:Poly C12U 200 ug|FluMist 0.2 ml and Poly I:Poly C12U 200 ug; 3 doses; nasal administration every 28 days
1683525|NCT01591473|Drug|FluMist + Poly I:Poly C12U 500 ug|FluMist 0.2 ml and Poly I:Poly C12U 500 ug; 3 doses; nasal administration every 28 days
1683526|NCT01591473|Drug|FluMist + Poly I:Poly C12U 1250 ug|FluMist 0.2 ml and Poly I:Poly C12U 1250 ug; 3 doses; nasal administration every 28 days
1683527|NCT01591473|Drug|FluMist + Placebo|FluMist 0.2 ml and Placebo; 3 doses; nasal administration every 28 days
1683528|NCT01591460|Drug|boceprevir|800 mg three times daily for 24, 32 or 44 weeks
1683529|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 24, 32 or 44 weeks
1683530|NCT01591460|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously once a week for 4 weeks
1683531|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 24, 32 or 44 weeks
1683532|NCT01591460|Drug|ribavirin (Copegus]|1000 mg or 1200 mg orally once a day for 4 weeks
1683533|NCT01591447|Drug|solithromycin|A single oral dose of 1200 mg solithromycin (CEM-101)
1683534|NCT01591447|Drug|Solithromycin (CEM-101)|A single oral dose of 1000 mg solithromycin
1683535|NCT01591434|Device|AQUACEL®|Dressing to be changed as clinically needed or at least every seven days.
1683536|NCT01591434|Device|AQUACEL® Extra™|Dressing to be changed as clinically needed or at least every seven days.
1683537|NCT01591421|Drug|BKM120|PO; Once daily starting day 1 cycle 1, or 5 out of 7 days every week.
1683538|NCT01591421|Drug|Panitumumab|IV; Every two weeks starting day 1 cycle 1 (i.e. day 1 and 15 each 28 day cycle)
1683539|NCT01591408|Device|EEG biofeedback|EEG data is collected from the scalp. Data is decomposed in real time and a portion of the signal is fed back to the subject via a vibrating stuffed animal and visual cues.
1683540|NCT01591395|Procedure|laparoscopic total extraperitoneal hernia repair (single port vs. multiport)|comparison of single port laparoscopic TEP and multiport laparoscopic TEP repair for adult inguinal hernia
1683541|NCT01591382|Drug|Ketamine|Intravenous (IV) ketamine 0.2 mg/kg/hr for 24-48 hours postoperatively.
1683542|NCT01591382|Drug|Placebo|Patients who received ketamine-matching placebo were given saline infusions
1683543|NCT01591382|Drug|Hydromorphone PCA|Intravenous hydromorphone PCA
1683544|NCT01591356|Drug|siRNA-EphA2-DOPC|Starting dose: 450 ug/m2 by vein twice weekly on Days 1 and 4 of each 3 week cycle.
1683545|NCT01591343|Biological|Depigoid® (500 DPP/ml)|"Depigoid® D. pteronyssinus or Depigoid® 50% D. pteronyssinus / 50% D. farinae (500 DPP/ml).
Dose:
Week 0: 0.2 ml followed by 0.3 ml after 30 min Week 4, 8, 12, and 16: 0.5 ml Mode of administration: subcutaneous injection"
1683546|NCT01591330|Drug|LY2140023 Monohydrate (Reference)|80 mg tablet administered orally
1683547|NCT01591330|Drug|LY2140023 Monohydrate (Test - Low)|80 mg tablet administered orally
1683548|NCT01591330|Drug|LY2140023 Monohydrate (Test - Medium)|80 mg tablet administered orally
1683549|NCT01591330|Drug|LY2140023 Monohydrate (Test - High)|80 mg tablet administered orally
1683550|NCT01591317|Drug|Prasugrel|Tablets orally
1683551|NCT01591304|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
1683552|NCT01591291|Drug|Ondansetron + Brief Behavioral Enhancement Treatment|Ondansetron 4ug/kg twice daily
1683553|NCT01591291|Drug|Placebo + Brief Behavioral Enhancement Treatment|Placebo twice daily
1683554|NCT01591278|Other|Pulpotomy|Comparison of two different pulp dressing agents
1683555|NCT01591278|Other|Pulpotomy|Comparison of two different pulp dressing agents
1683556|NCT01591265|Procedure|compensatory extraction of upper FPMs|Routine clinical care group who will receive standard therapy of extraction of upper FPMs
1683557|NCT01591265|Procedure|no compensatory extraction of Upper FPMs|Intervention group: clinical care group who will receive non standard therapy of not extracting the upper FPMs.
1683558|NCT01591239|Behavioral|Home-Based Intervention|Parents will be trained through a 3 1/2-hour series on providing a 3-session drug and alcohol intervention program to their adolescent. The parent-led intervention will require parents to meet with their adolescent and work together to help strengthen family cohesiveness, enhance communication, and promote healthy life choices.
1683559|NCT01591239|Behavioral|Educational Group|Printed fact sheets will be delivered to parents in a single two-hour session. These fact sheets will provide general drug-related information from the public domain (e.g., substance use trends and well-known dangers of substance involvement), and focus on communication approaches and talking points when discussing substance use with their adolescent (e.g., why adolescents use; how the media may influence attitudes about substances).
1734060|NCT00057369|Drug|dalbavancin|
1683560|NCT01591226|Dietary Supplement|Caffeine|gelatine capsule 6mg/kg bodyweight 60min prior test
1683561|NCT01591226|Dietary Supplement|Sodium Citrate|0.5g/kg bodyweight diluted in 7dl water ingested 120-90min prior test
1683562|NCT01591226|Dietary Supplement|Mannitol|gelatine capsule filled with mannitol (100mg per capsule) ingested 60min prior test
1683563|NCT01591226|Dietary Supplement|Sodium Chloride|sodium chloride diluted in 7dl water 0.045g/kg bodyweight 120-90min prior test
1683564|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|High dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
1683565|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|Intermediate dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
1683566|NCT01591200|Biological|Allogeneic Mesenchymal Stem Cells|Low dose of Bone Marrow Derived Allogeneic Mesenchymal Stem Cells will be administered through the hepatic artery
1683567|NCT01591187|Other|Text messaging|Participants report on the smoking that takes place in their presence for a period of 7 days by responding to daily texted messages sent by the research team to their mobile phones. Parents will also be asked to report on the child's SHSe during the same 7-day period so that child and parent reports can be compared.
1683568|NCT01591187|Other|Questionnaire|Child and parent questionnaire data about attitudes, behavioral practices to control SHSe, and other socio-environmental factors will be obtained.
1683569|NCT01591187|Other|Interviews|Individual interviews with youngsters will provide additional qualitative information about the social context and conditions in the child's environment that maintain or contribute to avoidance of exposure.
1683570|NCT01591161|Drug|Mapracorat|1 drop of study medication into the study eye QID for 14 days
1683571|NCT01591161|Drug|Placebo|1 drop of vehicle into the study eye QID for 14 days.
1683572|NCT01591148|Drug|propofol|Morbidly obese subjects (body mass index greater than 40)and control subjects (body mass index 20-25) will be given propofol for induction of general anesthesia. Plasma samples will be taken to ascertain drug concentration over time.
1683573|NCT01591135|Drug|Paclitaxel plus 5-fluorouracil|5-ﬂuorouracil 300 mg/m2, d1-4, continuous infusion for 96 hours and paclitaxel 50 mg/m2 over 3 hours, d1 (week 1, week 2, week 3, week 4 and week 5); 5-ﬂuorouracil 600 mg/m2/d d1-3 and paclitaxel 175 mg/m2 d1(week 9 and week 13).
1683574|NCT01591135|Drug|Cisplatin plus 5-fluorouracil|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
1683575|NCT01591135|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
1683576|NCT01591135|Radiation|Radiation therapy|A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
1683577|NCT01591122|Drug|Placebo and prednisone|Placebo: Form=tablet, route=oral. Four tablets daily on an empty stomach. Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily.
1683578|NCT01591122|Drug|Abiraterone acetate and prednisone|Abiraterone acetate: Type=exact number, unit=mg, number=250, form=tablet, route=oral. Four tablets daily on an empty stomach Prednisone: Type=exact number, unit=mg, number=5, form=tablet, route=oral, twice daily
1683580|NCT01591083|Drug|esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden)|"Each enrolled patient receives an 80 mg loading dose of intravenous esomeprazole (Nexium®, AstraZeneca AB, Södertälje, Sweden) immediately after hemostasis was achieved spontaneously or by gastroscopy. Patients then received a 3-day continuous high dose (8 mg per hour) of esomeprazole infusion. Then, patients with Rockall score >=6 are randomized into the double oral dose group and the regular oral dose group. Patients with Rockall score <6 are assigned to the control group.
In the double oral dose group, patients receive 40 mg oral esomeprazole twice daily for 11 days and followed by 40 mg once daily for 14 days. In the other two groups, patients receive 40 mg oral esomeprazole 40 mg once daily for 25 days."
1683581|NCT01591070|Drug|Tacrolimus|0.1% tacrolimus once-weekly application for 10 weeks
1683582|NCT01591070|Drug|Tacrolimus|0.1% tacrolimus twice weekly application for 10 weeks
1683583|NCT01591057|Dietary Supplement|2 portions of fruit and vegetables per day|Consume 2 portions of fruit and vegetables per day
1683584|NCT01591057|Dietary Supplement|5 portions of fruit and vegetables per day|Consume 5 portions of fruit and vegetables per day
1683585|NCT01591057|Dietary Supplement|8 portions of fruit and vegetables per day|Consume 8 portions of fruit and vegetables per day
1683586|NCT01591044|Drug|Placebo|1 puff bid or 2 puffs bid
1683587|NCT01591044|Drug|R940343 1mg|R343 1mg, 1 puff bid
1683588|NCT01591044|Drug|R940343 2mg|R343 2mg, 2 puffs bid
1683589|NCT01591031|Drug|Sevoflurane|anesthesia induction with propofol, remifentanil and sevoflurane; afterwards tracheal intubation
1683590|NCT01591031|Drug|Rocuronium|anesthesia induction with propofol, remifentanil and rocuronium; afterwards tracheal intubation
1683591|NCT01591018|Procedure|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for min. 60 minutes
1683592|NCT01591018|Procedure|cardiac surgery|coronary artery bypass graft (CABG) heart valve replacement
1683593|NCT01591005|Procedure|sonolysis|continual transcranial Doppler monitoring with max. diagnostic intensity for 60 minutes
1683594|NCT01591005|Procedure|endarterectomy|carotid endarterectomy
1683595|NCT01591005|Procedure|carotid stenting|percutaneous transluminal angioplasty and stenting
1683596|NCT01590992|Behavioral|Exposure-based psychotherapy for somatic symptoms|Application of different types of exposure-based psychotherapeutic interventions (behavioral therapy), adapted for subjects with somatic symptoms (Somatoform Disorders/Functional Somatic Syndromes)
1683597|NCT01590992|Behavioral|Relaxation therapy|Progressive muscle relaxation (Jacobson)
1683598|NCT01590979|Drug|Ranolazine|1000mg, two times a day, 12 hour intervals
1683600|NCT01590966|Drug|administration of Cimzia®|Patients will be treated with prefilled syringes containing each 200 mg/ml Cimzia® every 2 weeks which will be administered subcutaneously (The first 3 injections, a dosage of 400mg Cimzia® subcutaneously will be administered).
1683601|NCT01590966|Drug|Immunoscintigraphy with radiolabeled Cimzia®.|All 20 patients will undergo an immunoscintigraphy with radiolabeled Cimzia®. Certolizumab pegol (Cimzia®) is an engineered humanized monoclonal antibody Fab' fragment with specificity for human TNF-α, manufactured in E. coli. The antibody fragment is subsequently purified and conjugated with high molecular weight polyethylene glycol (PEG) (40kDa). Lyophilized Cimzia® will be conjugated with S-HYNIC (a bifunctional chelator). The conjugate will be radiolabeled with Tc-99m by adding 0.1 mg Tricine, 0.01 mg SnSO4 and 750 MBq Tc-99m pertechnetate. A dose of 750 MBq Tc-99m Cimzia® will be injected intravenously.
1683602|NCT01590940|Procedure|Open inguinal hernia repair with mesh|
1683603|NCT01590914|Procedure|Fed Condition|Subjects will consume a 250ml liquid test meal (250kcal) before undergoing a 40min fMRI scan to assess the BOLD signal responses to visual and auditory responses to food and non-food cues.
1683604|NCT01590914|Procedure|Fasted Condition|Subjects will consume a 250ml control (water) before undergoing a 40min fMRI scan to assess BOLD signal response to visual and auditory food and non-food cues
1683605|NCT01590901|Drug|Probucol|250mg (1 tablet) bid. p.o for 14 consecutive days
1683606|NCT01590888|Drug|PBT2|250mg capsules administered orally once per day for 26 weeks
1683607|NCT01590888|Drug|PBT2|100mg capsules administered orally once per day for 26 weeks
1683608|NCT01590888|Drug|Placebo|Matching capsules administered orally once per day for 26 weeks
1683609|NCT01590875|Drug|Adenosine arm|In the adenosine arm, 25 patients will be randomized to received 2 doses of adenosine 12 mg IV, 5 minutes apart after pulmonary vein isolation. During this time, will monitor for pulmonary vein reconnection, second dose of adenosine will be given only if no reconnection after initial dose. In the observation arm, 25 patients will be randomized to 10 minute period of observation for pulmonary vein reconnection after documentation of pulmonary vein isolation.
1683610|NCT01590849|Drug|Contraceptives, Oral, Combined (Yaz®)|"After a counseling session concerning the advantages, disadvantages and side effects of contraceptive methods (COC or nonhormonal methods), the volunteers were divided into two study groups according to the method they chose to use as follows:
Case group: healthy women, users of COC containing 20 mcg ethynil estradiol and 3 mg drospirenone , 24 days of active pills, 4 days of pill-free interval (n=40).
Control group: healthy women, users of nonhormonal methods of contraception (condoms or copper IUD) (n=40).
Subjects were tested once before the introduction of the contraceptive method and again after 6 months of its use."
1683611|NCT01590836|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily (plus insulin aspart as bolus insulin as required).
1683612|NCT01590836|Drug|insulin degludec/insulin aspart|Single dose administered subcutaneously (s.c., under the skin).
1683613|NCT01590823|Drug|Dabigatran Etexilate 110 mg|All participants will receive a single dosage of dabigatran etexilate 110 mg at the start of their 4 hour dialysis session. Blood sampling will be conducted during and up to 48 hours after participant's dialysis session.
1683614|NCT01590810|Drug|MK-8150 2.0 mg|Single oral 2.0-mg dose of MK-8150
1683615|NCT01590810|Drug|MK-8150 10 mg|Single oral 10-mg dose of MK-8150
1683616|NCT01590810|Drug|MK-8150 40 mg|Single oral 40-mg dose of MK-8150 without food (fasted) and with food (fed)
1683617|NCT01590810|Drug|MK-8150 90 mg|Single oral 90-mg dose of MK-8150
1683618|NCT01590810|Drug|MK-8150 5.0 mg|Single oral 5.0-mg dose of MK-8150
1683619|NCT01590810|Drug|MK-8150 20 mg|Single oral 20-mg dose of MK-8150
1683620|NCT01590810|Drug|MK-8150 60 mg|Single oral 60-mg dose of MK-8150
1683621|NCT01590810|Drug|MK-8150 120 mg|Single oral 120-mg dose of MK-8150
1683622|NCT01590810|Drug|MK-8150 160 mg|Single oral 160-mg dose of MK-8150
1683623|NCT01590810|Drug|MK-8150 320 mg|Single oral 320-mg dose of MK-8150
1683624|NCT01590810|Drug|MK-8150 600 mg|Single oral 600-mg dose of MK-8150
1683625|NCT01590810|Drug|MK-8150 900 mg|Single oral 900-mg dose of MK-8150
1683626|NCT01590810|Drug|MK-8150 1200 mg|Single oral 1200-mg dose of MK-8150
1683627|NCT01590810|Drug|Placebo for MK-8150|Single oral dose-matched dose of Placebo for MK-8150
1683628|NCT01590810|Drug|MK-8150 50 mg|Single oral 50-mg dose of MK-8150
1683629|NCT01590810|Drug|MK-8150 100 mg|Single oral 100-mg dose of MK-8150
1683630|NCT01590810|Drug|MK-8150 200 mg|Single oral 200-mg dose of MK-8150
1683631|NCT01590810|Drug|MK-8150 400 mg|Single oral 400-mg dose of MK-8150
1683632|NCT01590810|Drug|MK-8150 500 mg|Single oral 500-mg dose of MK-8150
1683633|NCT01590797|Drug|Sitagliptin|Sitagliptin 100 mg once daily for 24 weeks
1683634|NCT01590797|Drug|Placebo|Matching placebo once daily for 24 weeks
1683635|NCT01590797|Biological|Insulin|Participants can be on on pre-mixed (mixture of rapid- and long-acting insulin) or intermediate- or long-acting insulin at a dose of at least 12 U/day.
1683636|NCT01590797|Drug|Metformin|At randomization, participants will be stratified according to their use of metformin (on or not on). All participants receiving metformin will be required to be on a daily dose of metformin at least 1500 mg per day.
1683637|NCT01590771|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet once daily for 24 weeks
1683638|NCT01590771|Drug|Placebo|Matching placebo to sitagliptin oral tablet once daily for 24 weeks
1683639|NCT01590771|Drug|Gliclazide|Participants will continue ongoing open-label therapy with gliclazide (dosed according to the China drug label) throughout the study.
1683640|NCT01590771|Drug|Glimepiride|Participants will continue ongoing open-label therapy with glimepiride (dosed according to the China drug label) throughout the study.
1683641|NCT01590771|Drug|Metformin|Participants will continue ongoing open-label therapy with metformin (at least 1500 mg daily) throughout the study.
1683642|NCT01590758|Drug|Topical pexiganan cream 0.8%|14 days of treatment
1683643|NCT01590758|Drug|Topical placebo cream|14 days of treatment
1683644|NCT01590758|Other|Standard wound care|14 days of treatment
1683645|NCT01590745|Device|EMS Therasonic 460 Primo Ultrasound therapy|1MHz / 1.0W/cm square probe for 15 minutes per session for 20 sessions.
1683646|NCT01590732|Drug|Romidepsin|Starting Dose: 8 mg/m2 by vein on Days 1 and 4 of a 14 Day cycle.
1734112|NCT00057759|Other|Placebo|Placebo
1683647|NCT01590732|Drug|Ifosfamide|5 gm/m2 by vein on Day 1 of a 14 Day cycle.
1683648|NCT01590732|Drug|Mesna|"5 gm/m2 by vein given with Ifosfamide over 24 hours on Day 1 of a 14 Day cycle.
2 gm/m2 by vein given over 12 hours starting after completion of ifosfamide plus MESNA on Day 1 of a 14 Day cycle."
1683649|NCT01590732|Drug|Carboplatin|mg to equal target area under curve (AUC) by Calvert equation of 5 mg/ml/min with a maximum of 750 mg by vein on Day 1 of a 14 Day cycle.
1683650|NCT01590732|Drug|Etoposide|100 mg/m2 by vein on Days 1 - 3 of a 14 Day cycle.
1683651|NCT01590719|Drug|Placebo|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
1683652|NCT01590719|Drug|Onartuzumab (MetMAb)|Repeating intravenous dose until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
1683653|NCT01590719|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 IV every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
1683654|NCT01590719|Drug|Folinic acid|Folinic acid 400 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
1683655|NCT01590719|Drug|Levofolinic acid|If folinic acid is unavailable: levofolinic acid 200 mg/m2 every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
1683656|NCT01590719|Drug|5-Fluorouracil|5-Fluorouracil 400 mg/m2 IV followed by 2400 mg/m2 IV infusion every 2 weeks until disease progression, unacceptable toxicity, or patient or physician decision to discontinue treatment
1683657|NCT01590693|Drug|Botulinum toxin A|The children in Group 2 underwent bilateral treatment with a total of 12 units/kg bodyweight Botox® (Allergan, California, USA). Four injection sites in each calf - two in the proximal third of the lateral and medial gastrocnemius bellies and two distally in the gastrocnemius-soleus complex - were administered. All injections were performed with electromyogram amplifier guidance to ensure intramuscular position. Children in both groups were treated with four weeks of below knee walking casts. Children in group 2 received the casts 1-2 weeks after botulinum toxin A treatment.
1683658|NCT01590680|Radiation|I-131 MIBG|The therapeutic dose (5-18 mCi/kg at investigator's discretion; any dose ≥12 mCi/kg requires stored stem cells) will be diluted in normal saline, and will be infused intravenously over 90-120 minutes.
1683659|NCT01590667|Device|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
1683660|NCT01590667|Device|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
1683661|NCT01590654|Drug|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
1683662|NCT01590654|Drug|Multiple Ascending Dose (MAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses).
1683663|NCT01590641|Drug|Single Ascending Dose (SAD) Cohorts GS-9620|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Single Ascending Dose (SAD) Cohorts will receive a single dose of GS-9620.
1683664|NCT01590641|Drug|Multiple Ascending Dose (MAD) Cohorts|This study will enroll cohorts of 6 eligible, unique subjects per cohort, randomized to either active drug or placebo (5:1) within each cohort. Subjects in Multiple Ascending Dose (MAD) Cohorts will receive GS-9620 once weekly for two weeks (QW x 2 doses)
1683665|NCT01590628|Drug|NiCord|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells
1683666|NCT01590615|Drug|Anti-HBV nucleoside/nucleotide therapy|Subjects with chronic HBV infection and with decompensated liver disease who are receiving or anticipated to receive anti-HBV nucleoside/nucleotide therapy will be identified at centers with liver disease expertise where subjects are monitored on a regular basis.
1683667|NCT01590563|Device|IUD|Insertion of a spherical IUD, one year follow-up
1683668|NCT01590550|Procedure|Use of citrate based dialysate|Use of heparin free citrate based dialysate
1683669|NCT01590537|Drug|Levonorgestrel (Mirena, BAY86-5028)|intrauterine system containing 52 mg levonorgestrel, with daily release of 20 mcg levonorgestrel
1683670|NCT01590537|Device|Copper IUD|Copper device, inserted intrauterine
1683671|NCT01590524|Behavioral|Guided Imagery and Progressive Muscle Relaxation|Daily implementation of the guided imagery and progressive muscle relaxation techniques additionally to weekly supervised sessions.
1683672|NCT01590485|Other|starch|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
1683673|NCT01590485|Other|saffron|100 mg in each capsule every 6 hours up to 48 hours (400 mg/day)
1683674|NCT01590459|Drug|VX-509|50 mg oral tablet
1683675|NCT01590459|Drug|VX-509 matching placebo|0 mg oral tablet
1683676|NCT01590446|Drug|BMN 111|SC injection, Part 1 single dose and Part 2 multiple dose.
1683677|NCT01590446|Drug|Normal Saline|SC injection, Part 1 single dose and Part 2 multiple dose
1683678|NCT01590433|Drug|Exenatide|Subjects will inject 5mcg of exenatide or identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
1683679|NCT01590433|Drug|Placebo|Subjects will inject 5mcg of exenatide or identically dispensed placebo subcutaneously 15 minutes before the morning and evening meal for the first 2 weeks of the study. At study week 2, subjects will increase to 10mcg twice daily for the remainder of the study.
1683680|NCT01590433|Behavioral|Dietary counseling|All subjects will also receive individualized dietary counseling. Subjects may or may not be asked to follow a reduced calorie diet in addition to receiving treatment.
1683681|NCT01590420|Device|CPAP S8- Scape / Resmed|The pressure for treatment is according to PSG titration
1684613|NCT01582711|Behavioral|Self Administered Therapy (SAT)|Self Administered Therapy (SAT)
1683687|NCT01590355|Radiation|Radiotherapy|Gross Tumour and Nodes: 70 Gy in 35 fractions over 7 weeks. High-risk nodal areas: 63 Gy in 35 fractions over 7 weeks. Low-risk nodal areas: 56 Gy in 35 fractions over 7 weeks
1683688|NCT01590355|Procedure|Transoral Robotic Surgery + Neck Dissection|Transoral robotic excision will be carried out using the da Vinci surgical robot.
1683689|NCT01590342|Drug|Diclofenac|Diclofenac 75 mg, two doses
1683690|NCT01590342|Drug|Placebo|Placebo, two doses
1683691|NCT01590329|Device|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micro graft involves the use of MoMelan Technologies suction blister system, which consists of a control harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to a commercially available sterile film dressing, placed on the surgical wound or prepared recipient site and the wound is then bandaged.
1683692|NCT01590316|Device|Cerebral NIRS oximetry|Cerebral NIRS oximetry during the first 72 hours of life.
1683693|NCT01590303|Drug|Vitamin C|Intravenous Vitamin C 1 gram every 8 hours for 28 days or discharge from intensive care unit
1683694|NCT01590303|Drug|placebo|placebo vehicle administered to match volume of treatment drug every 8 hours for 28 days or until discharge from ICU
1683695|NCT01590290|Other|financial compensation|financial monetary reimbursement
1683696|NCT01590277|Drug|Ethanol|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
Potential Randomizations:
placebo ethanol + and placebo iomazenil
active ethanol + placebo iomazenil
active ethanol + active iomazenil
placebo ethanol + active iomazenil"
1683697|NCT01590277|Drug|Iomazenil|"Subjects will receive in a randomized, double-blind, cross-over design, ethanol or placebo and/or iomazenil or placebo.
Potential Randomizations:
placebo ethanol + and placebo iomazenil
active ethanol + placebo iomazenil
active ethanol + active iomazenil
placebo ethanol + active iomazenil"
1683698|NCT01590264|Device|Bimodal rTMS|"High frequency (10 Hz) at 110% of the motor threshold TMS delivered over the left dorsolateral prefrontal cortex, subsequently, a low frequency TMS (1 Hz) at 110% motor threshold will be delivered over 31 minutes over the TPJ area, according to the protocol below.
DLPFC Stimulation Frequency 10 Hz Intensity 110% of motor threshold On 5 seconds Off 15 seconds Total Trains 80 per session Total pulses session 4000/session Duration session 26.6 minutes Total pulses (study) 40000
TPJ Stimulation Frequency 1 Hz Intensity 110% of motor threshold On 900 seconds Off 60 seconds Total Trains 2 per session Total Pulses session 1800 Duration session 31 minutes Total Pulses study 18000"
1683699|NCT01590251|Other|Yoga|Two yoga sessions per week for 8 weeks (one yoga session is instructional, the other is a practice session.
1683700|NCT01590251|Behavioral|Educational Counseling|One didactic session per week of approximately 50 minutes that provides information about chronic pain and substance abuse disorders.
1683701|NCT01590238|Biological|PRFM treatment|Study participants are treated in the initial visit, and at the 1 and 2 month follow-up visit. 4-8 cc of autologous platelet rich fibrin matrix (PRFM) is isolated from 9-18 cc of peripheral blood. PRFM is then injected intradermally in 0.10 cc aliquots in areas of alopecia for each treatment.
1683702|NCT01590225|Drug|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for 24 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
1683703|NCT01590225|Drug|Peginterferon alpha-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 24 weeks.
1683704|NCT01590225|Drug|Ribavirin|The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 24 weeks.
1683705|NCT01590225|Drug|Boceprevir|Boceprevir will be administered orally at a dose of 11.4 mg/kg three-times daily (TID) for up to 48 weeks. The boceprevir dose will be calculated based on 11.4 mg/kg and will then be rounded to the nearest 200-mg value for subjects in the oldest age group, or to the nearest 100-mg or 200-mg value for the subjects in the two youngest age groups.
1683706|NCT01590225|Drug|Peginterferon alfa-2b|Peginterferon alpha-2b will be administered subcutaneously at a dose of 60 μg/m^2 once weekly (QW) for 48 weeks.
1683707|NCT01590225|Drug|Ribavirin|"Drug: Ribavirin
The dose of ribavirin will be approximately 15 mg/kg/day administered orally in two divided doses (twice daily [BID]) for 48 weeks."
1683708|NCT01590212|Other|Mellow Bumps|Mellow Bumps is a six week group-based antenatal programme designed to support families with additional health and social care needs. It is intended to decrease maternal antenatal stress levels, increase expectant mothers' understanding of neonates' capacity for social interaction and emphasise the importance of early interaction in enhancing brain development and attachment. It is delivered non-didactically to maximise participant engagement and rapport. Each week there is one activity focused on the woman and another on a baby-related topic. The programme is designed to be offered between twenty to thirty weeks' gestation, to capture the period when the risk of miscarriage is low and fetal movement felt, but before major preoccupation with the delivery.
1683709|NCT01590212|Other|Chill-out in Pregnancy|Chill Out in Pregnancy (ChIP) is a relaxation programme that includes all the mother centred components of Mellow Bumps but none of the baby / mother-baby relationship components. It also runs for six weeks at two hours per week and is intended to decrease stress levels.
1683712|NCT01590173|Drug|Prednisolone and Heparin during COH for IVF|Low Molecular Weight Heparin (LMWH) (Enoxaparin Sodium, Clexane, Sanofi-Aventis, Australia) at a dose of 1 mg/kg/day and 5 mg prednisolone p.os (Prezolon; Nycomed Hellas SA) were to be initiated on the first day of injections in both protocols until the pregnancy test. In cases of pregnancy, prednisolone and enoxaparin were to be continued up to the 12th and 34th week, respectively
1683744|NCT01589991|Drug|Toothpaste|The volunteers brushed their teeth with 0.3 g of the assigned toothpastes, 3x/day.
1683745|NCT01589978|Device|PROMUS Element Plus Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent) and a drug product (a formulation of everolimus contained in a polymer coating).
1684005|NCT01587807|Drug|Placebo|Sucrose, glycine, sodium dihydrogen phosphate and polysorbate 80 (volume to match active dose)
1734253|NCT00065403|Device|Acupuncture|
1683713|NCT01590173|Drug|COH for IVF|Both GnRH agonists (long, starting at day 2 or 21) with Triptorelin acetate 0.1 mg (Gonapetpyl daily; Ferring, Kiel, Germany) and antagonists' with ganirelix 0.25 mg (Orgalutran; Organon, Oss, The Netherlands) or cetrorelix 0.25 mg (Cetrotide; Serono, Rome, Italy) protocols will be used; for ovarian stimulation both recombinant FSH (Puregon; Organon, Oss, Netherlands or Gonal F; Serono, Rome, Italy) and human menopausal gonadotrophin (Menopur; Ferring Pharmaceuticals, Langley, Berkshire, UK) will be used. Ovarian response will be monitored by ultrasonography, oocyte retrieval will be performed 36-38 hours after the hCG triggering and for luteal phase support 600 mg progesterone tablets (Utrogestan; Laboratoires Besins- Iscovesco, Paris, France) or gel 8% intravaginally (Vasclor; Verisfield Ltd, UK) will be applied.
1683715|NCT01590147|Procedure|Yoga therapy|receive YST
1683716|NCT01590147|Other|questionnaire administration|Ancillary studies
1683717|NCT01590147|Procedure|quality-of-life assessment|Ancillary studies
1683718|NCT01590147|Other|laboratory biomarker analysis|Correlative studies
1683719|NCT01590147|Other|assessment of therapy complications|Ancillary studies
1683720|NCT01590147|Procedure|management of therapy complications|Receive YST or CE
1683721|NCT01590147|Other|educational intervention|Receive CE
1683722|NCT01590134|Dietary Supplement|Dietary supplement of iron|1 tablespoon of a dietary iron supplement containing 2.64mg of elemental iron
1683723|NCT01590134|Drug|Ferrous sulphate|200mg coated dried tablet containing 65mg elemental iron, equivalent to prophylactic daily dose as defined by the British National Formulary
1683724|NCT01590121|Other|Aeroplane flight in the past- no active intervention for study|Aeroplane flight(s) previously taken by study participants
1683725|NCT01590121|Other|Questionnaire|Flight by aeroplane (previous)
1683726|NCT01590108|Drug|(Pyr1)apelin-13|(Pyr1)apelin-13 will be infused at 30 nanomol/min intravenously. This dose has been used in healthy volunteer and patients groups
1683727|NCT01590108|Drug|Saline|Saline
1683728|NCT01590095|Behavioral|Water quality|"Hardware: Free supplies chlorine tablets (Aquatabs; NaDCC) and a safe storage vessel to treat and store drinking water.
Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age."
1683729|NCT01590095|Behavioral|Sanitation|Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
1683730|NCT01590095|Behavioral|Hand washing|"Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles.
Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
1683731|NCT01590095|Behavioral|Water quality, Sanitation, Hand washing (Combined WASH)|"Hardware: Free supplies Aquatabs; (NaDCC) and a safe storage vessel to treat and store drinking water. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the treatment of all drinking water for children < 36 months of age.
Hardware: Free child potties, sani-scoop hoes to remove feces from household environments, latrine upgrades to a dual pit latrine. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on the use of latrines for defecation and the removal of human and animal feces from the compound.
Hardware: Hand washing stations, soapy water bottles located at hand washing locations, detergent soap to supply soapy water bottles. Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages that focus on hand washing with soap at critical times around food preparation, defecation, and contact with feces."
1683732|NCT01590095|Behavioral|Nutrition|"Supplement: Lipid-based Nutrient Supplement (LNS) delivered daily from ages 6 to 24 months.
Promotion: Local promoters will visit study compounds at least monthly to deliver behavior change messages modeled on those recommended in the Guiding Principles for Complementary Feeding of the Breastfed Child and the recent UNICEF Program Guide for Infant and Young Child Feeding Practices.General messages will include (1) practice exclusive breastfeeding from birth to 6 months of age and introduce complementary foods at 6 months of age while continuing to breastfeed; (2) continue breast feeding as you did before receiving LNS; (3) provide your child micronutrient-rich foods such as meat, fish, eggs, and vitamin A rich fruits and vegetables; and (4) feed your child at least 2-3 times per day when 6-8 months old and 3-4 times per day when 9-24 months old."
1683733|NCT01590095|Behavioral|Nutrition, Water quality, Sanitation, Hand washing|Each of the interventions described above for Water Quality, Sanitation & Hand washing (Combined WASH) Plus the intervention described above for nutrition.
1683737|NCT01590069|Drug|Aerosol IL-2|"Phase I starting dose: 1 mg in 3 mL volume of nebulized solution daily for 21 days of a 28 day cycle.
Phase II starting dose: Maximum tolerated dose from Phase I."
1683738|NCT01590069|Procedure|Symptom Assessment|Symptoms (self report), oximetry, and pulmonary function assessed prior to each nebulized dose of IL-2 using remote spirometry and pulse oximetry.
1683739|NCT01590056|Other|Electrophysiological recording|"During the surgery for bilateral DBS electrode implantation, electrophysiological recording from the STN will be made while patients are:
listening to nonverbal affect bursts corresponding to emotions
applying a simple go-no-go auditory test"
1683740|NCT01590043|Other|Salivary samples|Each participant will give a sample of saliva through spitting for 5 minutes in a sterile tube.
1683741|NCT01590030|Procedure|Laparoscopic dermoid cystectomy|Laparoscopy will be performed by pneumoperitoneum with CO2. A complete pelvic examination will be performed to exclude malignant disease. Ovarian capsule will be incised by scissors on mesial side in study group and antimesial side in control group. After cleavage plane identification the cyst enucleation will be completed by atraumatic dissection.
1683742|NCT01590017|Drug|cisplatin|
1683746|NCT01589978|Drug|Aspirin|Aspirin should be taken daily (81 mg) for 3 days prior to the procedure or as a peri-procedural loading dose of 250-500 mg. A maintenance dose of aspirin of at least 81 mg daily, or as indicated by the treating physician, should be continued indefinitely.
1683747|NCT01589978|Drug|P2Y12 antagonist|"Patients to take one of the following P2Y12 antagonists; maintenance doses to be continued per ACC/AHA/SCAI guidelines for PCI.
Clopidogrel: Per treating physician, peri-procedural loading dose (300-600 mg), subsequent maintenance dose (75 mg daily)
Prasugrel: Per treating physician, peri-procedural loading dose (60 mg), subsequent maintenance dose (10 or 5 mg daily per product labeling)
Ticagrelor: Per treating physician, peri-procedural loading dose (180 mg), subsequent maintenance dose (90 mg 2x daily); maintenance aspirin doses >100 mg may reduce ticagrelor effectiveness and should be avoided.
Ticlopidine: Per treating physician, if allergy/intolerance to clopidogrel, prasugrel, and/or ticagrelor, loading dose (500 mg), subsequent maintenance dose (250 mg 2x daily)"
1683748|NCT01589965|Behavioral|Financial incentive through lotteries|Introduction of financial incentives in the form of a lottery to remain/become STI-negative, which we believe is both replicable and relatively easy to scale-up.
1683749|NCT01589952|Drug|Pegalyted interferon, Entecavir|Pegalyted interferon: 90 micro gms subcutaneously once weekly for 24 weeks Entecavir: 0.5 mg orally once daily for 24 weeks
1683750|NCT01589926|Procedure|Bi-level positive airway pressure|BLPAP initiated for at least 16 hours per day for a minimum of 48hrs.
1683751|NCT01589926|Procedure|Sham CPAP|Sham CPAP initiated for at least 16 hours per day for a minimum of 48hrs.
1683752|NCT01589913|Behavioral|ICD-Forum|"The CBT based internet program ICD-Forum is designed to increase QoL, and decrease anxiety and depression in ICD-patients. The program includes a therapist moderated asynchronous discussion group and content focused modules following a six weeks schedule:
Introduction to participants and online system
Knowledge regarding ICDs
Strategies for behavior change
Psychological models for anxiety and depression
Strategies to cope with avoidance, anxiety and depression
Resume, evaluation, resolution of open questions, goal setting, good bye"
1683753|NCT01589861|Drug|BKM120 + lapatinib|BKM120 40, 60 or 80 mg/day per os for 28 days cycle associated to lapatinib 750, 1000 or 1250 mg/day per os for 28 days cycle until progression or toxicity
1683754|NCT01589835|Behavioral|Lifestyle changes|Green prescription with support from facilitator
1683755|NCT01589822|Biological|EVICEL Fibrin Sealant|Intraoperative
1683756|NCT01589809|Drug|nicotinamide|dose-escalation, 2-8 grams, oral
1683757|NCT01589796|Procedure|TAP block|injection of 20ml of Ropivacaine 0.5% in the proper place once it is identified
1683758|NCT01589783|Other|completion of a questionnaire|Completion of a questionnaire
1683759|NCT01589783|Other|Blood draw|A subset of 100 women will have a blood test to measure Vitamin D levels
1683760|NCT01589757|Other|Standard Care|Standard dietary advice for women with GDM with special emphasis on use of high fiber or whole grain carbohydrate foods with a medium to high GI. What's on Your Plate? and 3-dimensional food models will be used to teach servings size and meal planning. This groups will be provided with food substitution lists (key-foods method) composed of medium to high GI foods.
1683761|NCT01589757|Other|Low GI diet|"Nutrition education according to standard care similar to the control group with supplementary GI-education. GI-education will be taught using the Stop-Light-Method. This groups will be provided with food substitution lists (key-foods method) composed of low-GI carbohydrate-containing food. The GI-education tool(s) will build on standard care education where patients are taught which food groups contain carbohydrate."
1683762|NCT01589744|Device|Suction cup Hemostatic Intra-Uterine, device not marked CE (not marketed)|The haemostatic intra-uterine suction-cup is introduced in uterus and a depressure in this device is applied. This medical device is used for 5 minutes at maximum.
1683763|NCT01589718|Drug|Macugen|one intravitreal injection of Macugen prior to vitrectomy surgery
1683764|NCT01589718|Drug|Sham|The subject in cohort 2 will receive one sham comparator, sham injection prior to vitreous surgery.
1683765|NCT01589692|Procedure|Open Reduction and Internal Fixation|Internal fixation with a volar locking plating system
1683766|NCT01589692|Procedure|External Fixation|External Fixation with a bridging external fixator. Can be done with or without percutaneous pinning.
1683767|NCT01589692|Procedure|Percutaneous Pinning|Pinning with any number of Kirschner wires
1683768|NCT01589692|Procedure|Closed Reduction and casting|Closed reduction and immobilization with a cast and/or splint
1683769|NCT01589679|Other|standard of care|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
1683770|NCT01589679|Device|Metarsal Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is work for 60 minutes three times per day.
1683771|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 100 mL Spray-dried S/D-treated Plasma
1683772|NCT01589666|Drug|Spray-dried S/D-treated plasma|Infusion of 200mL Spray-dried S/D-treated plasma
1683773|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 500 mL Spray-dried S/D-treated plasma
1683774|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 750 mL Spray-dried S/D-treated Plasma
1683775|NCT01589666|Biological|Spray-dried S/D-treated Plasma|Infusion of 800 mL Spray-dried S/D-treated Plasma
1683776|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted by the subjects themselves according to the titration algorithm every second week. Administered subcutaneously (s.c., under the skin) twice daily.
1683777|NCT01589653|Drug|biphasic insulin aspart 30|Dose individually adjusted according to the directions given by the investigator. Administered subcutaneously (s.c., under the skin) twice daily.
1683778|NCT01589640|Other|Blink Tears lubricating Eye Drops|2 drops per eye drosed four times per day (8:00 Am, 12:00 PM, 4:00 PM and 8:00 PM)
1683779|NCT01589640|Other|Blink Gel Tears Lubricating Eye Drops|2 drops per eye dosed four times per day (8:00 AM, 12:00PM, 4:00 PM and 8:00 PM)
1683780|NCT01589640|Other|Systane Balance Lubricant Eye Drop|2 Drops per eye dosed four times per day ( 8:00 AM, 12:00 PM, 4:00 PM and 8:00PM)
1684131|NCT01586689|Behavioral|Oxford House|community-based recovery home for participants recovering from substance dependency
1683781|NCT01589627|Device|Wrist Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
1683782|NCT01589614|Drug|PH-797804|Tablet, 6mg, single
1683783|NCT01589614|Drug|PH-797804 + erythromycin|PH-797804: tablet, 6mg, single erythromycin: tablet, 400 mg, multiple
1683784|NCT01589601|Behavioral|Usual heart failure care|Usual heart failure care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
1683785|NCT01589601|Behavioral|Interdisciplinary palliative care|Interdisciplinary palliative care focused on symptom relief; assessment and management of anxiety, depression, and spiritual concerns; as well as advance care planning that includes definition of care goals, resuscitation preferences, and participation in the Outlook intervention.
1683786|NCT01589588|Device|Open Hudson Mask|Mask type 1 oxygen
1683787|NCT01589588|Device|Cluster headache mask with 3 L reservoir|Mask type 2 with oxygen
1683788|NCT01589588|Device|Mask 3|Mask type 3 oxygen
1683789|NCT01589588|Device|Carnét oxygen demand valve|mask type 3 oxygen
1683790|NCT01589588|Device|Carnét oxygen demand valve|mask type 3 placebo
1683791|NCT01589562|Drug|Megace 800mg/20ml|Megestrol acetate 800mg/20ml, Suspension, Single dose
1683792|NCT01589562|Drug|DW-ES(B) 625mg/5ml|Megestrol acetate 625mg/5ml, Nano suspension, Single dose
1683793|NCT01589549|Biological|Mesenchymal stromal cell therapy|One arm will be randomised to receive mesenchymal stromal cell therapy in addition to corticosteroid therapy
1683794|NCT01589536|Other|interval-rehabilitation|The Patients in the intervention group receive a Stationary psychocardiological interval-rehabilitation.The Interval rehabilitation is divided into individual psychological therapy with focus of Behavior therapy and relaxation therapy.
1683795|NCT01589523|Drug|Glycocholic Acid|10-15mg/kg body weight/day taken orally. Supplied as either liquid or 50mg capsules.
1683796|NCT01589510|Drug|bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution (Lumigan® 0.01%) as prescribed by physician per standard practice for up to 14 weeks.
1683797|NCT01589497|Drug|Rifampicin|Participants with body weight </= 50kg were administered one 450 mg tablet orally once daily. Participants with body weight >50kg were administered one 600 mg tablet orally once daily.
1683798|NCT01589497|Drug|Isoniazid|Participants were administered three 100 mg tablets or one 300 mg tablet once daily.
1683799|NCT01589497|Drug|Pyrazinamide|Participants with a body weight of 40-55 kg were administered two 500 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 500 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 500 mg tablets orally once daily.
1683800|NCT01589497|Drug|Ethambutol|Participants with a body weight of 40-55 kg were administered two 400 mg tablets orally once daily. Participants with a body weight of 56-75 kg were administered three 400 mg tablets orally once daily. Participants with a body weight of 76-90 kg were administered four 400 mg tablets orally once daily.
1683801|NCT01589497|Drug|Moxifloxacin|Participants were administered one 400 mg tablet orally once a day.
1683802|NCT01589484|Device|SWL - Compact Delta Dornier Med Tech|All patients will be submitted to a noncontrast computed tomography before to SWL. Patients will be submitted to SWL under the following conditions: outpatient, general anesthesia, 3000 impulses, rate of 90/min, discharged from hospital in the same day with alpha-blocker (doxazosin) during 30 days.
1683803|NCT01589471|Drug|intra-rectal Botulinum toxin A injection|intra-colic injection of 100 U of Botulinum toxin A as a single injection distributed amongst the four quadrants, 5 cm above anastomosis
1683804|NCT01589458|Drug|Toothpaste|1-min brushing with 1 g of the assigned toothpaste followed by a 10 mL purified water rinse
1683805|NCT01589445|Drug|Pioglitazone hydrochloride|77 patients were treated with pioglitazone hydrochloride (B001) for 3 months.Biomedical parameters were measured each month.
1683806|NCT01589445|Drug|Metformin hydrochloride|After the treatment with pioglitazone(001) for 3 months first and then patients were on one month washout period;in the washout period they were given metformin tablet 850mg once daily,then treated with 002 (metformin) for further 3 months. The same biomedical measurements were assayed.
1683807|NCT01589432|Drug|ABT-639|two 50 mg oral capsules
1683808|NCT01589432|Drug|Placebo|2 placebo capsules
1683809|NCT01589432|Drug|Lidocaine|3mg/kg infusion over 30 minutes
1683810|NCT01589419|Drug|veliparib|see arm description
1683811|NCT01589419|Drug|capecitabine|see arm description
1683812|NCT01589419|Radiation|radiation|see arm description
1683813|NCT01589393|Drug|Enoxaparin|Enoxaparin 30 mg subcutaneously twice daily for six doses starting 36-48 hours post traumatic injury.
1683814|NCT01589393|Other|Placebo|0.9% normal saline in equal volume to active comparator given subcutaneously twice daily starting 36-48 hours post traumatic injury for six doses.
1683815|NCT01589380|Drug|Fimasartan|"Fimasartan, Initial dose will be started with 30mg per day. At 12 months follow-up after the enrollment, dose titration up to 60 mg per day will be made with target blood pressure of 120/80.
Dose escalization from 30mg/day to 60mg/day will be performed in the case of follow-up systolic blood pressure is over 120. If the follow-up systolic blood pressure is less than 120, initial dose of 30mg/day will be maintained throughout the study duration. If hypotension (BP < 90/60) is developed, the study medication will be discontinued and the patient will be included safety outcome analysis and intention to treat analysis. Per protocol analysis will be also performed. The dose of placebo will be adjusted identically, according to the blood pressure criteria of fimasartan."
1683816|NCT01589380|Drug|Placebo|Placebo was used in phase 3 clinical trial of fimasartan (NCT00922480, NCT01135212, and NCT01258673). The same placebo, which is manufactures at Boryoung pharmaceutical company, will be used in this trial. After enrollment and randomization, placebo will be administered one capsule once daily in placebo group.
1683817|NCT01589367|Drug|Metformin|Metformin HCl 500mg(morning/evening) PO daily x 1week Metformin HCl 1000mg(morning)and 500mg(evening)PO daily x 1week Metformin HCl 1000mg(morning/evening) PO daily x 22weeks
1684132|NCT01586689|Behavioral|Safe Haven|professionally-staffed treatment facility
1683818|NCT01589367|Drug|Placebo|Letrozole 2.5mg PO daily + Placebo 1 tablet PO 2/day x 1week Letrozole 2.5mg PO daily + Placebo 2 tablet+ 1 tablet PO x 1 week Letrozole 2.5mg PO daily + Placebo 2 tablet PO 2/day x 22 weeks
1683819|NCT01589354|Procedure|Interscalene brachial plexus block|An interscalene block will be performed pre-operatively using ultrasound guidance and the peripheral nerve stimulator (with the patient awake) using 20 ml of 0.375% Ropivacaine.
1683820|NCT01589354|Procedure|Intra-articular Ropivacaine injection|The procedure will be done by the surgeon at the end of the operation, with an intra-articular injection of 20 ml 0.75% Ropivacaine through the arthroscopic cannula after closure of the anterior wound
1683821|NCT01589354|Device|Ultrasound guided technique|The block will be performed under U/S guidance
1683822|NCT01589354|Drug|Ropivacaine|20ml of 0.375% Ropivacaine
1683823|NCT01589354|Drug|Ropivacaine|20ml of 0.75% Ropivacaine injected by the surgeon at the end of the procedure
1683824|NCT01589341|Other|laboratory biomarker analysis|Correlative studies
1683825|NCT01589328|Other|Early Palliative care integrated with usual oncologic care|"Drug: The interventions consisted of the following:
(1) Nursing assessment of pain and depression mood (2) Pain control based NCCN guideline (3) Depression control by psychoeducation and/or consultation of psychiatrist specialist (4) Patient education"
1683826|NCT01589315|Device|focal ECT|FEAST, ECT, unidirectional stimulation
1683827|NCT01589302|Drug|ibrutinib|Patients receive ibrutinib orally (PO) once daily (QD) on days 1-28. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
1683828|NCT01589302|Other|Correlative laboratory samples|Blood samples will be collected and used for pharmacodynamic testing. Samples will be collected pre-dose on Cycle 1 Day 1 and 2 hours post-dose Cycle 1 Day 1, pre-dose on Day 2 and Day 8 of Cycle 1 and pre-dose on Day 1 of Cycles 2 and 3 and then every 3 cycles thereafter for 1 year (Cycle 15 Day 1). Samples will also be collected at the time of relapse and at any time when bone marrow biopsy is performed.
1683829|NCT01589302|Other|quality of life assessment|During screening, sociodemographic information (e.g., age, race, marital status) and reports of recent (last year) stressful events will be obtained. The assessment will consist of measures of emotional distress, depressive symptoms, and quality of life. Quality of life measures will be administered during screening and on Days 1 (±3), 8 (±3),, 15 (±3),, 22 (±3), of Cycle 1, Day 1 (±3), of Cycle 2 and on day 1 (±7) of Cycles 3, 6, and then every 3 months thru month 24.
1683830|NCT01589289|Device|Immunochromatographic HAT tests (DSD)|Immunochromatographic HAT diagnostic tests manufactured by DSD, Korea and FIND
1683831|NCT01589289|Device|Card Agglutination Trypanosoma Test|Card Agglutination Trypanosoma Test on whole blood and as dilution
1683832|NCT01589289|Device|TB POC Nucleic Acid Amplification Test (Molbio Diagnostics)|"TB POC Nucleic Acid Amplification Test: microPCR handheld device (Molbio Diagnostics PVT ltd, India)"
1683833|NCT01589289|Device|TB 3-marker RDT (Tulip diagnostics)|TB 3-marker RDT: ADA2/IFN-g/LAM (Tulip diagnostics, ltd, India) - pending availability for phase 3 validation
1683834|NCT01589289|Device|Cryptococcal Antigen Lateral Flow Assay (Immy)|Cryptococcal Antigen Lateral Flow Assay (Immy, USA)
1683837|NCT01589237|Drug|LCQ908|
1683838|NCT01589211|Behavioral|Brief advice|Brief advice of about 10 min accompanied by self-help material
1683839|NCT01589211|Behavioral|Compact cessation course|Compact cessation course on the basis of Motivational Interviewing (MI) and Cognitive Behavioural Therapy (CBT). Group setting. 2 x 120 min.
1683840|NCT01589211|Behavioral|Standard cessation course|Cessation course over 6 dates. Group setting.
1683841|NCT01589185|Drug|KBSA301|KBSA301 administered as a single intravenous infusion at dose 1, 2, 3 and 4.
1683842|NCT01589185|Drug|Placebo|Placebo administered as a single intravenous infusion
1683843|NCT01589159|Drug|Capecitabine|Drug:capecitabine 700mg/m2, twice daily on days 1-14.
1683844|NCT01589159|Drug|Etoposide|Etoposide 30mg/m2, once daily on days 1-7.
1683845|NCT01589146|Drug|Heparin, Low-Molecular-Weight|4 weeks heparin prophylaxis
1683846|NCT01589120|Behavioral|Video decision aid|Video decision aid of the goals of care
1683847|NCT01589107|Behavioral|video decision aid|video decision aid
1683848|NCT01589094|Drug|Gemcitabine and Cisplatin (DD GC)|Patients will receive six cycles of GC administered every 14 days. Gemcitabine 2,500 mg/m2 will be administered intravenously on day 1 and cisplatin 35 mg/m2 will be administered intravenously on days 1 and 2 of a 14 days cycle (with Peg GCSF). A total of six cycles of therapy will be administered followed by radical cystectomy with bilateral pelvic lymph node dissection (PLND)
1683849|NCT01589081|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study session day. The nicotine solutions (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg; and 1.5 mg/70kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
1683850|NCT01589081|Drug|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
1683851|NCT01589068|Drug|Intravenous Nicotine|Subjects will be given an IV challenge dose of nicotine or placebo in a constant volume of 2 mL on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (2 mL over one minute) has been safe in our IRB-approved studies of nicotine. Most investigators have administered nicotine over 10 seconds without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70 kg) will be administered first and the higher dose (2.0 mg/70kg) will be administered last.
1683852|NCT01589068|Drug|Progesterone|To stimulate the luteal phase of the menstrual cycle, Prometrium capsules containing 200 mg of micronized progesterone or placebo (lactose containing) capsules will be administered orally at 120 minutes before the injection of IV nicotine.
1684161|NCT01586481|Device|SANIDIAB|off-loading shoe
1683853|NCT01589055|Drug|Intravenous Nicotine|Subjects will be given an intravenous challenge dose of nicotine or placebo in a constant volume of 1 ml on any study day. The nicotine solution (1.0 mg/70kg or 1.5 mg/70kg or 2.0 mg/70kg) will be administered over 1 min. This rate of drug delivery (1 ml over 1 min) has been safe in our IRB approved studies of nicotine. Most investigators have administered nicotine over 10 sec without any adverse reactions. We concur with the IRB recommendation that the lower doses (1.0 mg/70kg and 1.5 mg/70kg;) should be administered first and the higher dose (2.0 mg/70kg) will be administered last.
1683854|NCT01589029|Drug|CANAKINUMAB (ILARIS®)|subcutaneous injection every 8 weeks
1683855|NCT01589003|Other|Low Glycaemic index growing up milk|Low Glycaemic index growing up milk
1683856|NCT01589003|Other|High GI growing up milk|High glycaemic index growing up milk
1683863|NCT01588964|Procedure|HIPEC|surgery plus HIPEC with the closed technique(perfusion of the abdominal cavity with a solution containing oxaliplatin 460 mg/m2 in 2L/m2 heated saline at 42°C).The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
1683864|NCT01588951|Drug|Cytarabine consolidation|Cytarabine-based consolidation per institutional standards.
1683865|NCT01588951|Drug|Allogeneic transplant|Allogeneic stem cell transplant per institutional standards.
1683866|NCT01588925|Device|Cochlear Implantation|Cochlear implantation using Hybrid L24 Implant
1683867|NCT01588925|Drug|Cochlear Implantation+dexamethasone|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window
1683868|NCT01588925|Drug|Cochlear Implantation+dexamethasone+hyaluronic acid|Cochlear implantation using Hybrid L24 Implant,dexamethasone (4mg/ml) in the round window and hyaluronic acid (10mg/ml) in the electrode array
1683869|NCT01588912|Drug|Telbivudine|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
1683870|NCT01588912|Drug|Tenofovir|If virologic response, which means HBV DNA < 50 IU/mL, is shown at 24 weeks, telbivudine monotherapy is maintained and in the event that virologic response is not shown, tenofovir add-on therapy is done
1683871|NCT01588912|Drug|Entecavir|Maintain the entecavir through the study period
1683872|NCT01588899|Device|MR-HIFU uterine fibroid treatment|A single treatment session for uterine fibroids with the MR-HIFU device.
1683873|NCT01588873|Drug|oc:E-E-desogestrel/vaginal ring:E-E -ethonogestrel|"The OC or vaginal ring will be used in 9 weeks periods followed by one week's break each.
After a wash-out period of at least 2 months of any previous hormonal contraceptives all examinations will be performed at the 1st to 5th day of the menstruation cycle at baseline and then at the 9th, 29th and 59th week and the last 1 month after stopping contraception.
Blood samples will be collected between 07 and 10 AM after an overnight fast and during the follicular phase or at any time in cases of amenorrhea. After centrifugation serum is filled in eight tubes with at least 2 ml of serum in each, and immediately frozen at -70ºC as well as one tube of plasma. Every tube will be marked appropriately. Fasting plasma glucose and HbA1c will be analysed at once at every appointment."
1683874|NCT01588847|Procedure|Spinal anesthesia with Bupivacaine hyperbar 0.5 %|Spinal anesthesia with Bupivacaine hyperbar 0.5 %
1683875|NCT01588847|Procedure|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane|General anesthesia with Sufentanil, Propofol and Rocuronium and Sevoflurane
1683876|NCT01588834|Procedure|breast biopsy|ultrasound-guided core needle biopsy of healthy, mammographically dense breast tissue
1683877|NCT01588821|Drug|Cabozantinib|60 mg daily by mouth
1683878|NCT01588808|Behavioral|Immobilization|Immobilization with protein (elderlY), immobilization without protein (elderly and young)
1683879|NCT01588795|Procedure|Percutaneous renal denervation and TMNS|Patients are treated with the renal denervation procedure after randomization and are maintained on standardized anti-proteinuric medications
1683880|NCT01588795|Drug|Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker , a diuretic , 25OH vitamin D3 and a statin|Patients are maintained on Standardized antiproteinuric medication regimen includes an angiotensin receptor blocker (irbesartan 300mg), a diuretic (furosemide 40mg or indapamide LP 1.5mg according to the eGFR), 25OH vitamin D3 and a statin (atorvastatin 20mg)
1683881|NCT01588782|Drug|Period 1: Abiraterone|1000 mg abiraterone acetate tablet administered orally on Day 1
1683882|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|400 mg ketoconazole tablets administered orally on Days 11 to 16
1683883|NCT01588782|Drug|Period 2: Abiraterone/Ketoconazole|1000 mg abiraterone acetate tablet administered orally on Day 14
1683884|NCT01588769|Biological|ALECSAT cell based immunotherapy|I.V. injected Cell Based Medicinal Product, containing between 10 million and one billion autologous Cytotoxic T cells and Natural Killer cells.
1683885|NCT01588756|Drug|AcSDKP-NH2 inuline|Once intravenous administration of 100 µg or less
1683886|NCT01588756|Drug|AcSDKP-NH2 Cr-EDTA|Once intravenous administration of 100 µg or less
1683887|NCT01588743|Drug|insulin aspart|Insulin Aspart will be administrated by insulin pump with an initial dose of 0.4-0.6u/kg body weight, of which 50% basal rate and the other 50% bolus dose. Time interval for administration will be as follows: 0-3Am-9Am-12Am-5Pm-9Pm-0Am. Specific adjustment will be made according to individual difference.
1684162|NCT01586481|Device|BAROUK|old shoe
1683888|NCT01588730|Device|Ankle Dorsiflexion Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living
1683889|NCT01588730|Procedure|Commercially Available Static Night splint|A commericially avilable static night splint will be worn for 4-6 hours during rest.
1683890|NCT01588717|Drug|Glycopyrrolate|glycopyrrolate 2 to 6mg/day
1683891|NCT01588704|Drug|Neoadjuvant Bevacizumab|Neoadjuvant Pemetrexed, Carboplatin and Bevacizumab followed by surgical resection
1683892|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at low frequency. Patients will receive this therapy dose for 3 weeks.
1683893|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at high frequency. Patients will receive this therapy dose for 3 weeks.
1683894|NCT01588691|Device|Eon-mini IPG (implantable pulse generator)|programming parameters set at lowest settings to deliver minimal power. Patients will receive this therapy dose for 3 weeks.
1683895|NCT01588678|Drug|DS-3078a|DS-3078a will be administered as oral capsules once daily and will be supplied in 5, 20, 50, and 150 mg capsules.
1683896|NCT01588639|Drug|Insulin (Scilin N, BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice.
1683897|NCT01588639|Drug|Insulin (Scilin R _BAY81-9924|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
1683898|NCT01588639|Drug|Insulin(Scilin M30_BAY81-9924)|Subjects are treated with recombinant human insulin-SciLin N, SciLin R and SciLin M30 (alone or in combination) in routine clinical practice
1683899|NCT01588626|Drug|AZD6140|tablet
1683900|NCT01588600|Other|Dietary Fiber|Fiber added to breakfast
1683901|NCT01588587|Drug|Sitagliptin|The dosage, frequency and duration for each sitagliptin are variant.
1683902|NCT01588587|Drug|Alogliptin|The dosage, frequency and duration for each alogliptin are variant.
1683903|NCT01588587|Drug|Vildagliptin|The dosage, frequency and duration for each vildagliptin are variant.
1683904|NCT01588574|Biological|MT10109|Botulinum toxin type A
1683905|NCT01588574|Biological|BOTOX(Registered trade mark)|Botulinum toxin type A
1683906|NCT01588561|Drug|Intravenous Nicotine|Subjects received a single infusion of nicotine, 1.5 mg/70kg (New England Compounding Center, Framingham, MA), administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
1683907|NCT01588561|Other|Saline - placebo|Subjects received a single infusion of saline, administered over 1 minute into the antecubital vein 10 minutes into their MRI scans.
1683908|NCT01588548|Drug|AZD1208|Dose of AZD1208 will be escalated from 120mg to a maximum tolerated dose
1683909|NCT01588535|Drug|benzocaine|benzocaine 10 mg/mL, five drops in affected ear canal each hour as needed
1683910|NCT01588535|Drug|placebo|placebo solution, five drops in affected ear canal each hour as needed
1683911|NCT01588522|Drug|compound 31543 Calcitriol|topical compound 31543 will be applied to the scalp twice daily 7 +/- 2 days prior to the dose of chemotherapy and continue the application twice daily for 3 months or until termination of chemotherapy treatment.
1683912|NCT01588509|Drug|Romosozumab|Administered by subcutaneous injection
1683913|NCT01588496|Biological|Evolocumab|Administered by subcutaneous injection
1683914|NCT01588496|Drug|Placebo|Administered by subcutaneous injection
1683916|NCT01588457|Drug|Lithium/Lithium Carbonate|Therapeutic dosage as indicated by participants condition with blood levels. LI will be dosed to attain LI of ≥0.5mEq/L.
1683917|NCT01588457|Drug|Divalproex|DV will be dosed to attain DV levels of ≥45mg/L.
1683918|NCT01588457|Drug|Lamotrigine|LM will be incrementally dosed up to 400 mg/day, or, in combination with DV, 200 mg/day. Dosage may be reduced for adverse effects to one half of the target dose.
1683919|NCT01588457|Drug|Quetiapine|QT will be started at 50 mg/day and titrated up to 300 mg as tolerated. QT will be discontinued if not tolerated at 100mg/day and the patient will be treated according to guidelines.
1683920|NCT01588444|Device|cortical FDBA|cortical mineralized freeze-dried bone allograft
1683921|NCT01588444|Device|Cancellous FDBA|CANCELLOUS FREEZE-DRIED BONE ALLOGRAFT (from LifeNet Health)
1683922|NCT01588431|Drug|Docetaxel, Cisplatin, Cetuximab and Bevacizumab (TPE-A) Followed by Concurrent Radiation, Cisplatin, Cetuximab and Bevacizumab (XPE-A), surgery|Induction therapy consists of 3 cycles of bevacizumab 15mg/kg on day 1, cetuximab weekly days 1,8,15 (loading dose of cetuximab 400mg/m2 on cycle 1, day 1, then 250 mg/m2 on all subsequent administrations), cisplatin 75mg/m2 on day 1, docetaxel 75mg/m2 on day 1, repeated every 21 days. After 3 cycles of induction therapy, patients will receive standard radiation 70-74 Gy/ 200 cGy/ daily, 5 days/ week with concurrent weekly cisplatin 30mg/m2, cetuximab 250mg/m2 and bevacizumab 15mg/kg every 3 weeks x 3. There is optional surgery for non-responders in the primary (stable disease) after TPE-A.
1683923|NCT01588418|Drug|Exenatide|Exenatide (5mcg) was administered in random order 30 min before OGTT-PET study, crossover study
1683924|NCT01588418|Drug|Placebo|Placebo was administered in random order 30 min before OGTT-PET study in the same subject
1683925|NCT01588405|Drug|UT-15C SR|Subjects will transition in the hospital from Remodulin to UT-15C SR within 5 days of the start of the transition. The dose of Remodulin will be decreased as the dose of UT-15C SR is increased over the 5 days. Once subjects have been transitioned from Remodulin, the dose of UT-15C SR will continue to be modified / titrated to the appropriate optimal dose for that subject throughout the rest of the study.
1683926|NCT01588392|Behavioral|Short bouts of structured physical activity|Short bouts of structured physical activity preschools will be asked to implement age-appropriate 10 minute structured physical activity routines within the classroom setting followed by 20 minutes of usual unstructured playtime activities. Intervention will be implemented for a total of 30 minutes during both morning and afternoon gross motor playtime 5 days/week for 6 months.
1683927|NCT01588392|Behavioral|Unstructured physical activity|Unstructured physical activity intervention will consist of 30 minutes of supervised unstructured free playtime twice. intervention will be delivered during both morning and afternoon gross motor playtime for 5 days/week for 6 months.
1734254|NCT00065416|Procedure|massage|
1683928|NCT01588379|Behavioral|Girls and mothers Afro-centric dance program|African-American girls and their mom's will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
1683929|NCT01588379|Behavioral|Girls, alone|African-American girls (without their mom's) will participate in an after school Afro-centric dance program for 3 days/week for 12 weeks. Both girls and the mothers will also receive weekly newsletter containing various health information.
1683930|NCT01588379|Other|Newsletter|Both girls and the mothers will receive weekly newsletter containing various health information.
1683931|NCT01588366|Drug|Placebo|Administered orally
1683932|NCT01588366|Drug|LY2409021|Administered orally
1683933|NCT01588353|Drug|Collagenase Clostridium Histolyticum|AK160 (Collagenase Clostridium Histolyticum) 0.58 mg
1683934|NCT01588340|Procedure|MRI (Magnetic resonance imaging)|Subject will complete a 15 minute scan in the MRI
1683935|NCT01588340|Procedure|Ultrasound exam|The subject will complete a noncontrast ultrasound procedure that will take approximately 25 minutes to complete
1683936|NCT01588314|Drug|Gabapentin|gabapentin 100 mg capsules
1683937|NCT01588314|Drug|placebo|compounded placebo capsules
1683938|NCT01588301|Behavioral|Attending for cervical cytology|A further invitation to attend for cervical cytology are going to be sent by mail to women
1683939|NCT01588301|Behavioral|Kit for Self-collected vaginal sample|Kit for self-collected vaginal sample are going to be directly sent at women's home
1683940|NCT01588288|Procedure|Galectin 3 dosage|Preoperative Galectin 3 dosage in plasma and water rinse of the needle aspiration biopsy.
1683941|NCT01588275|Device|mandibular repositioning appliance (MRA) (SomnoDent)|bibloc MRA type SomnoDent starting at 70% protrusion of the mandibula
1683942|NCT01588275|Procedure|Continuous positive airway pressure (CPAP)|Proper CPAP-pressure will be set for each patient separately.
1683943|NCT01588262|Other|Stressmanagement|Individual stepped-care approach stressmanagement by specially trained counsellor
1683944|NCT01588249|Dietary Supplement|Pasteurized maple syrup|
1683945|NCT01588249|Dietary Supplement|Placebo|
1683949|NCT01588223|Other|Lipid identification|The lipids are identified using Mass Spectrometry
1683950|NCT01588210|Other|Sealant application|"A high-viscosity glass-ionomer cement (KETAC™ MOLAR APLICAP 3M Espe, Germany) will be used.
All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam; tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
1683951|NCT01588210|Other|sealant application|"A white photopolymerizable Resin-Based sealant containing fluoride (Helioseal F®, Ivoclar Vivadent AG, Fürstentum Liechtenstein) will be used.
All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
1683952|NCT01588210|Other|sealant application|"A white photopolymerizable Resin-Based sealant (Concise 1930TM 3M Espe, Germany) will be used.
All sealants was applied following these steps: tooth isolation using cotton rolls or rubber dam (it was mandatory for both the RB sealants); tooth cleaning using a rotary brush mounted on a low-speed contrangle with a prophylaxis pasta without fluoride; enamel etching using 37% phosphoric acid (H3PO4) for 30 seconds; rinse thoroughly with water and dry; placement a thin layer of sealant material and cure according to manufacturer's instructions and finally occlusion adjustment, if necessary."
1683953|NCT01588197|Behavioral|MRI Feedback|Real Time fMRI Feedback
1683954|NCT01588197|Behavioral|MRI Feedback|Real Time fMRI Feedback
1683956|NCT01588171|Drug|Bemiparin|Bemiparin sodium 3,500 IU anti Xa/0.3 ml solution for injection in pre-filled syringe will be provided for each patient in Bemiparin group; subcutaneously 6 hours after delivery(vaginal and Caesarean)and then daily for up to 7 days.
1683957|NCT01588171|Drug|Enoxaparin|Enoxaparin sodium 40mg (equivalent to 4,000 IU anti-Xa activity) in 0.4ml water for injection will be administered subcutaneously 6 hours after the delivery( vaginal or abdominal)then daily up to 7 days post partum, for Enoxaparin group of patients.
1683958|NCT01588158|Drug|Acetaminophen|325 mg
1683959|NCT01588158|Drug|Vicodin|Vicodin 5/325 mg
1683960|NCT01588145|Drug|HM61713|BID or QD, PO X 21 day cycle Number of cycles: until progression or unacceptable toxicity develops
1683961|NCT01588132|Drug|Anfibatide|"To investigate the safety and tolerability of single intravenous dose of Antiplatelet Thrombolysin for Injection of 0.33,0.66,1.0,1.5,2.0,3.0,4.0,5.0μg (body weight 60kg) in healthy volunteers.
To investigate the safety and tolerability of continuous administration of three dose regimen: ① give intravenous injection of 3μg as the first dose and after 1.5 hours, infusion of the study product 0.12μg/h for 24 hours. ② give intravenous injection of 3μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours. ③ give intravenous injection of 5μg as the first dose and immediately infusion of the study product 0.12μg/h for 24 hours."
1683962|NCT01588093|Drug|Increlex|Increlex 120 micrograms/kg body weight single subcutaneous injection
1683963|NCT01588093|Drug|0.9% Saline|Placebo (0,1 ml of 0.9% Saline) single subcutaneous injection
1684001|NCT01587820|Drug|Intravenous cisplatin|100 mg/m2 cisplatin given intravenously once every 21 days (3 week cycle) for 3 cycles and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
1684002|NCT01587807|Drug|GSK1995057|inhaled dose (volume based on cohort)
1683964|NCT01588080|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Neurally adjusted ventilatory assist (NAVA), an adjunct that can only be used with the Servo-i ventilator, allows the patient to synchronize spontaneous respiratory effort with mechanical ventilation. NAVA uses the electromyographic signal of the diaphragm (Edi) to transmit this electrical activity back to the ventilator. The NAVA catheter is a functional gastric tube that has electrodes embedded within it and positioned at the level of diaphragm using an electrocardiogram signal. These electrodes continuously (every 5ms) detect the amplitude, duration, and frequency of the Edi and provide pressure support in proportion to this electrical activity. Proportionality is controlled by a NAVA factor (cmH20/microvolt) and is adjusted by the user.
1683965|NCT01588080|Device|SiPAP - placebo|The Infant Flow® SiPAP provides noninvasive support to neonates. CPAP and Biphasic modes are provided by the Infant Flow® SiPAP. CPAP is an elevated pressure (above atmospheric) and is used to increase a premature babies functional residual capacity (FRC). CPAP is a modality used for babies with both central apneas and mild/moderate increase work of breathing. CPAP increases the FRC and ultimately recruits collapsed alveoli and improves gas exchange in the lungs. BiPhasic, on the other hand, is a modality used for babies that require more respiratory support than CPAP can provide. In BiPhasic mode, respiratory rate (RR), inspiratory time (Ti), and peak inspiratory pressures (PIP) are set and not synchronized with the patients breathing efforts.
1683966|NCT01588028|Drug|CH5424802|Oral capsules taken twice daily
1683967|NCT01588015|Biological|tetanus-CMV fusion peptide vaccine|Given SC
1683968|NCT01588015|Other|laboratory biomarker analysis|Correlative studies
1683969|NCT01588002|Drug|danoprevir|multiple oral doses
1683970|NCT01588002|Drug|efavirenz|multiple oral doses
1683971|NCT01588002|Drug|ritonavir|multiple oral doses
1683972|NCT01587989|Drug|methotrexate|15-25 mg orally weekly, Weeks 1-12
1683973|NCT01587989|Drug|methotrexate|15-25 mg orally weekly, Weeks 13-24
1683974|NCT01587989|Drug|placebo|methotrexate placebo orally weekly, Weeks 13-24
1683975|NCT01587989|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 24 weeks
1683976|NCT01587963|Drug|Ascorbic Acid|66mg/kg/hour of peripheral intravenous Vitamin C infusion for 24 hour duration, maximum total of 200 grams
1683977|NCT01587963|Other|Ringers Lactate or Normal Saline|Fluid resuscitation will be given with NS or LR to achieve a same mean urine output of 0.5cc/kg/hour.
1683978|NCT01587950|Drug|Potassium Nitrate|250 μL of Potassium nitrate solution (either 5% or 2.5%)
1683979|NCT01587950|Drug|Placebo|Sterile Water
1683980|NCT01587937|Other|Antibiotic stewardship audit-and-feedback to prescribers of patients receiving 3rd or 10th day of targeted broadspectrum antibiotics|See primary outcome for list of targeted drugs. See citations for previous publications describing the intervention.
1683981|NCT01587924|Drug|GSK1278863|tablet
1683982|NCT01587924|Drug|rhEPO|injection
1683983|NCT01587911|Other|Whey|Preload containing complete whey protein.
1683984|NCT01587911|Other|Whey-CMP|Preload containing complete whey protein which is missing the CMP/GMP portion of the protein.
1683985|NCT01587911|Other|Control|Preload control matched for energy to the other 5 preloads.
1683986|NCT01587911|Other|CMP|Preload containing the CMP (casinomacropeptide) portion cleaved from complete whey protein.
1683987|NCT01587911|Other|MPI|Preload containing whole milk protein.
1683988|NCT01587911|Other|CPI|Preload containing sodium caseinate.
1683991|NCT01587885|Drug|Omeprazole 20 mg + Sodium Bicarbonate 1100 mg|Capsules, orally
1683992|NCT01587885|Drug|Omeprazole 20 mg|Tablets, orally
1683993|NCT01587872|Procedure|Fujinon EC-450BI5 double-balloon colonoscope|Colonoscopy with the test instrument
1683994|NCT01587859|Procedure|laparoscopic surgery|Nissen fundoplication; Collis Gastroplasty.
1683995|NCT01587846|Dietary Supplement|Administration of L.reuteri in children with abdominal pain|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
1683996|NCT01587846|Dietary Supplement|Administration of placebo in children with abdominal pain|Group of around 75 children which will receive placebo for 3 months. The placebo consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
1683997|NCT01587846|Dietary Supplement|Administration of L.reuteri in children with constipation|Group of around 75 children which will receive L. reuteri at a dose 100.000.000 CFU per dose plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The active study product consists of a citrus flavored 450 mg chewable tablet containing freeze-dried L. reuteri DSM 17938. The study product is a convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of freeze-dried L. reuteri, isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid. The total viable count of L. reuteri is 1x100.000.000 live bacteria (CFU)/tablet.
1683998|NCT01587846|Dietary Supplement|Administration of placebo in children with constipation|Group of around 75 children which will receive placebo plus lactulose in a dose 1-3 ml/kg, according to the stool frequency and consistency, for 3 months. The placebo study product consists of a citrus flavored 450 mg chewable convex tablet 10.3 mm in diameter, plain on both sides and with faint spots. It is composed of isomalt, xylitol, sucrose distearate, hydrogenated palm oil, lemon-lime flavoring and anhydrous citric acid.
1683999|NCT01587833|Drug|Benzodiazepine (BZD) use, defined by ATC codes|BZD prescription during the study period between January 1, 2001 and December 31, 2009
1684000|NCT01587820|Drug|Intra-arterial cisplatin|150 mg/m2 cisplatin given intra-arterially combined with sodium thiosulfate infusion given on days 1, 8, 15, for a total of 4 cycles, each cycle totaling 7 days and Radiotherapy: Primary tumor and upper neck will be treated with 2 Gy/fraction, once a day, five days a week to a total dose of 70 Gy/35 fractions/7 weeks
1684003|NCT01587807|Procedure|bronchoalveolar lavage|BAL
1684006|NCT01587768|Drug|Antibiotic prescription during the study period between January 1, 2004 and December 31, 2009|Antibiotics will be analysed overall, by class (tetracyclines, penicillins and betalactamics, cephalosporins, macrolides, aminoglycosides, quinolones and other antibiotics (sulphonamides &amp; others combinations)) and individually. The antibiotics administered to patients include: cefuroxime axetil, cefuroxime sodium, ceftazidime sodium, amoxicillin, amoxicillin/ clavulanate, ampicillin, ampicillin/cloxacillin, flucloxacillin, ticarcillin, and ticarcillin/ clavulanate.
1684007|NCT01587755|Other|TTOP|Patient is taken care of in an intensified, optimised manner
1684008|NCT01587755|Other|non-TTOP|Standard medical care
1684009|NCT01587742|Drug|CCB use|Prescription of CCB during the study period between January 1, 1996 to December 31, 2009. The CCBs administered to the patients include isradipine and lacidipine.
1684010|NCT01587729|Drug|Tricyclic AD (TCAs) and selective serotonin re-uptake inhibitors (SSRIs) antidepressants|TCA or SSRI prescription during the study period between January 1, 2001 and December 31, 2009. The TCAs and SSRIs administered to the patients include paroxetine and escitaloprim.
1684011|NCT01587716|Drug|GSK2339345 (Inhaled) Single Dose|250, 1000 and 2000 microgram (proposed doses)
1684012|NCT01587716|Other|Placebo (Inhaled) Single Dose|Inhaled 0.9% sodium chloride solution
1684013|NCT01587716|Drug|GSK2339345 (Inhaled) Repeat Dose|2000 microgram (proposed dose) administered 4 times a day for two consecutive days
1684014|NCT01587716|Other|Placebo (Inhaled) Repeat Dose|Inhaled 0.9% sodium cholride solution
1684015|NCT01587703|Drug|GSK525762|Begin at Dose Level 1 and increase up to 2 fold
1684016|NCT01587664|Device|NewBreez ILP|NewBreez ILP implantation
1684017|NCT01587651|Drug|Prasugrel Loading Dose|60mg given as six 10mg film coated tablets
1684018|NCT01587651|Drug|Prasugrel Maintenance Dose|10mg maintenance dose, given as one 10mg film coated tablet
1684019|NCT01587651|Drug|Ticagrelor Maintenance Dose|one 90mg film coated tablet
1684020|NCT01587638|Drug|carvedilol|carvedilol immediate-release (IR) and carvedilol controlled-release (CR)
1684021|NCT01587638|Drug|cardio selective betablocker|atenolol, metoprolol succinate, and metoprolol tartrate
1684022|NCT01587625|Drug|Oxytocin|
1955436|NCT03194633|Drug|Nifedipine controlled-release tablets (Adalat, BAYA1040)|Nifedipine GITS 60 mg (once per day)
1684024|NCT01587586|Biological|Pegasys|48 doses, solution, 48 weeks
1684025|NCT01587586|Biological|P1101, 48 doses|48 doses, solution, 48 weeks
1684026|NCT01587586|Biological|P1101, 24 doses|24 doses, solution, 48 weeks
1684027|NCT01587586|Biological|P1101, 12 doses|12 doses, solution, 48 weeks
1684028|NCT01587573|Other|saliva collection prior to clinically driven oral biopsy|cell free saliva to be used to measure mRNA and proteins by PCR and ELISA
1684029|NCT01587560|Device|PyroTITAN, Ascension Orthopedics, Inc.|All patients will be operated on with a shoulder resurfacing implant. In one arm of the study, the patients will receive an implant made of pyrocarbon. In the second arm, the patients will receive an implant made of Cobalt-Chrome. Aside from the materials, the implant are of the same design.
1684030|NCT01587560|Device|TITAN, Ascension Orthopedics, Inc.|
1684031|NCT01587534|Drug|Norzyme|Patients will be randomized to receive either pancreatic enzyme replacement therapy or placebo. Patients will use two capsules three times daily during main meals and one capsule three times daily during in between snacks. The pancreatic enzyme preparation under investigation is Norzyme ® 6 - 9 tablets per day.
1684032|NCT01587508|Drug|meloxicam/cyclobenzaprine hydrochloride|two oral capsules a day during approximately 07 days
1684033|NCT01587508|Drug|meloxicam - Movatec®|two oral tablet a day during approximately 07 days
1684034|NCT01587508|Drug|cyclobenzaprine - Miosan®|two oral tablet a day during approximately 07 days
1684035|NCT01587495|Drug|Ertapenem|Ertapenem will be administered by intravenous infusion per the FDA approved standard of care (1 gram q24 hours). as follows:
1684036|NCT01587482|Procedure|PacLitaxel Eluting Balloon Application|Stenting is a standard of care in revascularization for superficial femoral artery (SFA) atherosclerotic lesions. However, the Achilles' heel of this technique remains in-stent restenosis (ISR). While most of local therapies have failed to demonstrate significant benefit, studies for the treatment of SFA ISR are lacking and percutaneous transluminal angioplasty remains the current standard of care for this indication. Recent studies have shown successful results of drug eluting balloon in the treatment of SFA de-novo lesions and of coronary ISR.
1684037|NCT01587430|Drug|high dose ARA-C|high dose ARA-C consolidation together with high cumulative dose of anthracyclines daunorubicin, idarubicin, mitoxantrone(720-660 mg/m2)
1684038|NCT01587430|Drug|standard dose ARA-C|
1684039|NCT01587417|Drug|Placebo to BI 187004 CL|1 single dose per subject as oral solution
1684040|NCT01587417|Drug|BI 187004 CL|1 single dose per subject as oral solution
1684041|NCT01587404|Device|THERMOCOOL® SMARTTOUCH™ Catheter|Variable contact force as measured at the catheter tip within the left atrium
1684042|NCT01587391|Drug|Placebo to BI 163538 XX|1 single dose per subject as oral solution
1684043|NCT01587391|Drug|BI 163538 XX|1 single dose per subject as oral solution
1684044|NCT01587378|Drug|Metformin|Metformin 500 mg tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
1684045|NCT01587378|Drug|placebo|identical placebo tablets, 1 tablet x 2 daily the first week and then 2 tablets x 2 daily from the second week to delivery
1684046|NCT01587365|Biological|BMS-962476|
1684047|NCT01587365|Biological|Placebo matching with BMS-962476|
1684048|NCT01587352|Other|Laboratory Biomarker Analysis|Correlative studies
1684049|NCT01587352|Drug|Vorinostat|Given PO
1684050|NCT01587339|Drug|retigabine/ezogabine|oral - all doses
1684051|NCT01587339|Drug|lacosamide|oral - all doses
1684052|NCT01587339|Drug|zonisamide|oral - all doses
1684053|NCT01587339|Drug|pregabalin|oral - all doses
1684054|NCT01587339|Drug|eslicarbazepine|oral - all doses
1684055|NCT01587326|Drug|Escitalopram|escitalopram 10 mg/d to 20 mg/d
1684098|NCT01586988|Behavioral|IMAGE Intervention|Mothers in the intervention will receive four individual intervention sessions with a facilitator. The sessions will cover parenting and self care skills.
1684099|NCT01586975|Drug|Clopidogrel|Clopidogrel 75 mg QD
1684056|NCT01587313|Drug|Isosorbide dinitrate / hydralazine capsules|Group 1: Day 1:Two SR capsules; Day 8: One IR capsule Group 2: Day 1:Two SR capsules; Day 8: One IR capsule Group 3: Day 1:Two SR capsules; Day 8: One IR capsule Group 4: Day 1:One IR capsule and two SR capsules; Day 8: Commercial BiDil Tablet tid
1684057|NCT01587287|Device|Corneal power measurement|All subjects will be underwent a full ophthalmic examination including vision, auto- and subjective refraction, slit-lamp examination, non-contact tonometry, corneal power measurements with the 8 devices and fundus examination.
1684058|NCT01587274|Drug|Naproxen|Naproxen 500mg twice/ day x 10 days
1684059|NCT01587274|Drug|Cyclobenzaprine|Cyclobenzaprine 5-10mg three times/ day x 10 days
1684060|NCT01587274|Drug|Oxycodone/ acetaminophen|Oxycodone 5-10mg/ Acetaminophen 325-650 mg three times/ day x 10 days
1684061|NCT01587261|Drug|Vitamin C|Treatment Group will receive a dose of 66 mg/kg/hr of ascorbic acid injection for 24 hours after injury
1684062|NCT01587261|Drug|Placebo|Lactated Ringers solution will be given at a similar volume to what the treatment group will receive
1684063|NCT01587248|Device|Harmonic|Dissection with harmonic scalpel
1684064|NCT01587248|Procedure|electrocautery|Dissection in modified radical mastectomy
1684065|NCT01587235|Drug|Ezetimibe/simvastatin|Algorithm based treatment using 10/10mg, 10/20mg and 10/40mg ezetimibe/simvastatin combination tablets orally once daily.
1684066|NCT01587235|Drug|Other Statin|Participants are prescribed a statin (any other than Vytorin) as per routine standard of care
1684067|NCT01587222|Drug|Albumin|Albumin (20%) 1g/kg iv on day 1 and 80 g every 2 weeks during a period of 12 weeks.
1684068|NCT01587222|Drug|Midodrine|"Oral midodrine 5 mg / 8 hours for 12 weeks. The dose may be increased on day 7 10mg/8h.
If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
1684069|NCT01587222|Drug|Octreotide|"Octreotide by subcutaneous injection 0.1 mg every 8 hours for 12 weeks. The dose may be increased to 0.2 mg / 8 h on day 7.
If creatinine does not decrease ≥ 25% and systolic blood pressure is bellow 150 mmHg and diastolic 90 mmHg doses will be changed."
1684070|NCT01587196|Drug|Vivitrol|There are monthly injections of depot naltrexone for 3 months.
1684071|NCT01587183|Behavioral|Educational material control|Participants will be given educational materials on starting a running program using a run/walk approach.
1684072|NCT01587183|Behavioral|Group running style B|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
1684073|NCT01587183|Behavioral|Group running style A|Participants will attend a 4 hour group based training and 3, 2 hour follow up trainings.
1684074|NCT01587157|Procedure|capnography|
1684075|NCT01587144|Drug|Lucanthone|Lucanthone or Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks along with radiation and TMZ during the concomitant phase. In the maintenance phase, lucanthone/placebo will be administered along with TMZ on days 1-5 of a 28-day cycle for 6 cycles.
1684076|NCT01587144|Drug|Temozolomide (TMZ)|TMZ is administered at 75mg/m2 daily for 42 days during the concomitant phase. TMZ is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment. Cycles 2-6: At the start of Cycle 2, the dose can be escalated to 200 mg/m2, if the CTC nonhematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea, and vomiting), absolute neutrophil count (ANC) is ≥1.5 x 109/L, and the platelet count is ≥100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs.
1684077|NCT01587144|Radiation|Radiation|60 Gy administered in 30 fractions for 42 days in the concomitant phase.
1684078|NCT01587144|Drug|Placebo|Lucanthone or Placebo will be given as an oral at 10-15 mg/kg/day for 6 weeks along with radiation and TMZ during the concomitant phase. In the maintenance phase, lucanthone/placebo will be administered along with TMZ on days 1-5 of a 28-day cycle for 6 cycles.
1684079|NCT01587131|Biological|FVH1 - a DNA-based influenza vaccine|0.9 mg FVH1 vaccine
1684080|NCT01587118|Drug|Adjunctive asenapine|participants who are not responding fully to antidepressant therapy for PTSD will receive adjunctive asenapine (flexible dosing beginning with 5 mg sublingual once per day, titrated up to 10 mg twice per day, as tolerated) for a total of 12 weeks.
1684081|NCT01587105|Behavioral|Comprehensive Case Management Service|When a child enrolls in the CCM program, the child's parent will work together with the CCM team at Seattle Children's to develop a shared care plan for their child. This plan will include all of the child's routine health care needs and information about what to do when the child gets sick. The parent will also have 24 hour access to an on-call CCM nurse.
1684082|NCT01587092|Behavioral|WorkStation|Participants will be asked to attend 2 scheduled sessions per day of treadmill walking, which will replace their sitting desk time. Participants will complete 2 sessions per day for 6 months.
1684083|NCT01587092|Behavioral|Usual Working Condition|Participants will be asked to continue working at their desk in their usual manner.
1684084|NCT01587079|Drug|PT003|PT003 MDI administered as two puffs BID for 7 days
1684085|NCT01587079|Drug|PT001|PT001 MDI administered as two puffs BID for 7 days
1684086|NCT01587079|Drug|PT005|PT005 MDI administered as two puffs BID for 7 days
1684087|NCT01587079|Drug|Tiotropium inhalation powder|Taken as 1 capsule containing 18 µg of Tiotropium via the Handihaler DPI for 7 days
1684088|NCT01587066|Drug|Quetiapine fumarate|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
1684089|NCT01587066|Drug|Divalproex sodium|Efficacy of Quetiapine XR vs. Divalproex on Clinical Outcome, Quality of Sleep and Quality of Life in Bipolar Depression
1684090|NCT01587053|Other|therapeutic education program|
1684091|NCT01587040|Drug|SAR245408|Pharmaceutical form: capsule or tablet Route of administration: oral
1684092|NCT01587040|Drug|SAR245409|Pharmaceutical form: capsule or tablet Route of administration: oral
1684093|NCT01587027|Drug|Aminophylline|Aminophylline dosage form-tablet dosage-500mg
1684094|NCT01587027|Drug|Methazolamide|Methazolamide dosage form-tablet dosage-250mg
1684095|NCT01587027|Drug|Aminophylline and Methazolamide|Aminophylline 500mg orally and Methazolamide 250mg orally
1684096|NCT01587001|Dietary Supplement|N-acetyl-cysteine|900mg three times daily for 8 weeks
1684097|NCT01587001|Drug|Placebo|Matching placebo three times daily for 8 weeks.
1734969|NCT00070174|Drug|asparaginase|
1684102|NCT01586962|Drug|IFF flavor 316 282, Paracetamol, Pseudoephedrine|Single dose syrup containing a warmingflavor IFF 316282 in a syrup containing Paracetamol and pseudoephedrine
1684103|NCT01586949|Behavioral|Daily Challenge|Web-based behavioral intervention aiming to improve individuals' well-being.
1684104|NCT01586936|Drug|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
1684105|NCT01586923|Biological|RBC transfusion|RBC transfusion of different storage age
1684109|NCT01586897|Device|Medication Metronome|Providers allocated to intervention will see an additional feature when logging on to their electronic health record medication prescription interface that enables them to schedule future laboratory testing for the pre-defined subset of study-specific medications. New prescription or dose adjustment by the PCP of one of these pre-specified medications used to treat type 2 diabetes, hypertension, or hyperlipidemia will initiate the follow-up result monitoring, patient outreach, and PCP reminders that constitute the Medication Metronome system.
1684110|NCT01586897|Other|Usual Care|
1684111|NCT01586884|Procedure|Pressure/Conductance Catheter|"The physician will obtain right femoral arterial access and advance the pressure/conductance catheter to the LV utilizing the retrograde approach. Baseline dP/dt and stroke volume will be recorded in the patient's presenting rhythm.
The dP/dt and stroke volume will be measured during biventricular pacing. Hemodynamic measurements will be made with the tip of the pacing lead in the distal vessel, followed by repeat measurements with the lead positioned in the mid and proximal portions of the initially selected vein.
The pacing and hemodynamic measurements will be repeated with the CS lead positioned in two additional veins (if possible). The pressure/conductance catheter will be removed from the left ventricle after 30 minutes, regardless of the number of pacing sites identified/tested. The physician will make the choice of the LV lead placement based on the information gathered up to that point."
1684113|NCT01586845|Drug|voclosporin|Initial dose of voclosporin 0.8 mg/kg BID, then concentration controlled
1684114|NCT01586845|Drug|tacrolimus|tacrolimus as per labeled dose
1684115|NCT01586819|Drug|Botulinum Toxin|"The botulinum toxin will be injected into the wrinkles crow's feet. The injections will take about 10 minutes to complete."
1684116|NCT01586819|Procedure|Chemical Peel Only|After cleansing the face with a pre-treatment cleansed composed of water and alcohol, the Jessner's peel solution [a combination of resorcinol (14g), salicylic acid (14g), and lactic acid (85%) in ethanol (95%)] will be applied to the entire face with a large cotton swab. The mixture will be left in place for a few minutes, and then the face will be wiped clean with water. Next, the TCA peel [35% Trichloroacetic acid] will be applied around the eyes. After leaving in place for a few minutes, cool, iced washcloths will be applied and the face will be wiped clean with water. Wound care regimen will consist of dilute acetic acid and either Aquaphor or petroleum jelly.
1684117|NCT01586806|Drug|Bupivacaine Only|This is the control treatment arm. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic).
1684118|NCT01586806|Drug|Bupivacaine with 1 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 1 mg of dexamethasone. Total injection volume will be 15 ml.
1684119|NCT01586806|Drug|Bupivacaine with 4 mg of Dexamethasone|This is one of two treatment arms. Patients will receive an ultrasound-guided saphenous nerve block, consisting of 13 ml of 0.5% bupivacaine (a local anesthetic), mixed with 4 mg of dexamethasone. Total injection volume will be 15 ml.
1684120|NCT01586793|Device|Magstim Rapid2 Stimulator|1 Hz in 1 train of 20-minute duration (1,200 pulses per session) at 120% of the rMT.
1684121|NCT01586793|Device|Magstim Rapid2 Stimulator|10 Hz in 75 trains of 4-seconds duration, with 26-seconds intertrain intervals (3,000 pulses per session) at 120% of the rMT.
1684122|NCT01586780|Dietary Supplement|Protein drink|Test drink providing 9g protein
1684123|NCT01586780|Dietary Supplement|Reference meal|Control meal
1684124|NCT01586767|Radiation|Proton radiation therapy|Daily proton radiation therapy
1684125|NCT01586767|Radiation|Intensity-modulated radiotherapy|Daily intensity-modulated radiotherapy
1684126|NCT01586741|Procedure|Quill suture application for repair or polypropylene mesh|The first arm may be insertion of the-mesh The second arm may double row- suture The third arm may be conservative -training
1684127|NCT01586728|Other|Air - oxygen|"his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period)
nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 > 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.
During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 <= 90%."
1684128|NCT01586728|Other|Oxygen - Air|"nocturnal oxygen therapy with a stable flow to obtain a nocturnal SpO2 > 90% (oxygen period) while continuing his routine long term treatment during 6 weeks.
his routine long term treatment without nocturnal oxygen therapy during 6 weeks (air period) During the oxygen period, the oxygen flow will be at least 1.5l/min. This flow may be increased up to 2L/min in case of the presence of nocturnal periods with SpO2 <= 90%."
1684129|NCT01586715|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
1684130|NCT01586702|Behavioral|Patient centered structured support program|"Behavioural: Structured support program
Program with up to 8 outpatient appointments focusing on:
Measurement of risk factors
Assessment of medication intake
Monitoring of antithrombotic therapy
Joint agreement of an individual target plan
Target values for risk factors:
Blood pressure < 140/85 mmHg (<130/80 in diabetics), normal circadian profile
HbA1c <7.5%
Nicotine abstinence
LDL < 100mg/dl (< 70mg/dl in high risk patients)
Physical activity ≥ 30min >2 x / week
Targets for pharmaceutical treatment:
Platelet inhibitors for strokes / TIA of arterial etiology
Combined platelet inhibition over 3 months in symptomatic intra- or extracranial stenosis
Cumarins (INR 2-3) or new oral anticoagulants in AF patients
Statin treatment in patients with LDL >100mg/dl
Intervention strategies:
• According to Motivational Interviewing"
1684133|NCT01586689|Behavioral|Usual aftercare|control group - participants may or may not seek treatment on their own
1684134|NCT01586676|Behavioral|SAU|Supervision-as-usual
1684135|NCT01586676|Behavioral|MIA: STEP|Motivational Interviewing Assessment: Supervisory Tools for Enhancing Proficiency (MIA: STEP
1684136|NCT01586663|Device|Serial night time position splint|This group will use a serial night time position splint, adjusted monthly, during three months.
1684137|NCT01586663|Drug|Drug treatment|This patients will keep there drug treatment and will receive their splints on the end of the study.
1684138|NCT01586650|Other|aerobic training|The intervention comprises fifty minutes of walking at anaerobic threshold plus stretching exercises 3 times a week for 12 weeks.
1684139|NCT01586650|Other|Stretching exercises|Global stretching exercises will be performed for about 20 minutes 3 times a week for 12 weeks with supervision of specialized physiotherapists.
1684140|NCT01586637|Other|Art Therapy|This group performed dance classes and regarding the art therapy they have art classes where they learn how to use the drawing to express feelings. The classes were twice a week.
1684141|NCT01586637|Other|Walking|The group walked twice a week during one hour.
1684146|NCT01586611|Drug|5FU, leucovorin, oxaliplatin|Oxaliplatin 100 mg/m2 IV day 1 Leucovorin 400 mg/m2 IV day 1 5-FUl 400 mg/m2 IV day 1 5-FU 2400 mg/m2 IV continuous infusion over 46 hours starting day 1
1684147|NCT01586611|Drug|Gemcitabine|1000 mg/m2 IV weekly for 3 weeks then one week off
1684148|NCT01586598|Behavioral|sensory retraining protocol|"within one month after the surgery: facial massage and physical stimulation over lower face and lip, four times (20 minutes each time) a day
one to three months after the surgery: brush and physical stimulation over lower face and lip, four times (20 minutes each time) a day
three to six months after the surgery: brush, pin and physical stimulation over lower face and lip, four times (20 minutes each time) a day"
1684149|NCT01586572|Drug|mOPV1|Monovalent type 1 oral poliovirus vaccine (mOPV1) containing at least106 TCID50 of Sabin- strain poliovirus type 1.
1684150|NCT01586572|Drug|bOPV 1,3|The bivalent vaccine containing at least 106 CCID50 of Sabin poliovirus type 1 and 105•8 CCID50 of Sabin poliovirus type 3.
1684151|NCT01586546|Behavioral|Face-to-Face MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
1684152|NCT01586546|Other|Waitlist Control I|No intervention offered during study period. Intervention is offered after completion of study.
1684153|NCT01586546|Other|Waitlist Control II|No intervention offered during study period. Intervention is offered after completion of study.
1684154|NCT01586546|Behavioral|Online MBM Skills Group|Mind Body Medicine (MBM) Skills Groups provide a means for study participants to learn skills for taking care of themselves in a supportive small group setting. Participants will learn and practice a variety of specific MBM skills. These MBM skills will enable a participant to change the way she/he deals with the wide range of stressors at different stages of her/his cancer journey. Some of these MBM skills are meditation, guided imagery, biofeedback, writing, and drawing. These groups are designed to assist a participant in coming to know themselves better and in learning and using these tools that will help the participant to deal with the distress as only a small percentage of cancer patients in distress receive appropriate support.
1684155|NCT01586533|Drug|Zoenasa-1:4|Zoenasa Rectal Gel (4.0g mesalamine [5-ASA], 1.0g N-acetylcysteine [NAC]; 60ml)
1684156|NCT01586533|Drug|Mesalamine Enema|Mesalamine Rectal Suspension Enema (4.0g mesalamine [5-ASA], 60ml)
1684157|NCT01586507|Drug|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
1684158|NCT01586507|Drug|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
1684159|NCT01586494|Drug|ULTRAM ER|One dose of ULTRAM ER that is closest to 2 mg/kg, based on the participant's body weight and adjusting the dose in 25 mg increments.
1684160|NCT01586494|Drug|ULTRAM ER|The target dose for Group 2 will be the one that achieves a level of exposure similar to that seen with a single 200 mg ULTRAM ER dose in adults.
1684165|NCT01586455|Drug|Human Placental Derived Stem Cell|Infusions of thawed HPDSC to be given following UCB infusion.
1684166|NCT01586442|Drug|Eplerenone|Eplerenone 25mg once daily titrated to 50 mg once daily for 4 months
1684167|NCT01586442|Drug|Spironolactone|Spironolactone 12,5mg daily titrated to 25mg once daily for 16 weeks
1684168|NCT01586429|Other|Ultrasound guided femoral nerve block catheter analgesia compared with epidural analgesia for patients with knee OA (osteoarthritis)|
1684169|NCT01586416|Behavioral|Behavioral Intervention|Two or three one-hour sessions of an individual behavioral intervention led by a doctoral-level licensed psychologist during the first 12 weeks of chemotherapy. Intervention addresses modifiable behaviors for managing chemotherapy challenges.
1684170|NCT01586403|Biological|Dose 1|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. cohort 1 will receive 2.5 x 106 TIL 1383I TCR transduced T cells per kg body weight. Subject in cohort 1 will receive 2.5 x 10^6 TIL 1383I TCR transduced T cells per kg body weight.
1684171|NCT01586403|Biological|Dose 2|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 2 will receive 7.5 x 10^6 TIL 1383I TCR transduced T cells per kg body weight.
1684172|NCT01586403|Biological|Dose 3|Subjects will receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 3 will receive 2.5 x 10^7 TIL 1383I TCR transduced T cells per kg body weight.
1684173|NCT01586403|Biological|Dose 4|Subjects then receive a single infusion of autologous bulk TIL 1383I TCR transduced T cells supported with low dose IL-2. Autologous bulk TIL 1383I TCR transduced T cells means the infusion will consist of a polyclonal mixture of CD4+ and CD8+ T cells expressing the TIL 1383I TCR. Subjects in cohort 4 will receive 7.5 x 10^7 TIL 1383I TCR transduced T cells per kg body weight.
1684174|NCT01586390|Other|Functional treatment for ankle sprain using ankle cast|Functional treatment for ankle sprain using ankle cast
1684175|NCT01586390|Other|Ankle sprain treated with removable ankle support|Ankle sprain functionally treated with removable and adjustable ankle support
1684176|NCT01586364|Drug|Ospemifene|
1684177|NCT01586351|Device|Patch Augmentation and ACP injection|Patch augmentation and 4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
1684178|NCT01586338|Drug|Hylan G-F 20|Intra-articular injection (pre-filled glass syringe)
1684179|NCT01586325|Drug|JNJ-47910382 30 mg|JNJ-47910382 30 mg (0.6 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
1684180|NCT01586325|Drug|JNJ-47910382 90 mg|JNJ-47910382 90 mg (1.8 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
1684181|NCT01586325|Drug|JNJ-47910382 200 mg|JNJ-47910382 200 mg (4 mL of an oral suspension of 50 mg/mL of JNJ-47910382) administered once daily as monotherapy for 5 days.
1684182|NCT01586325|Drug|Placebo|Matching Placebo administered once daily as monotherapy for 5 days.
1684183|NCT01586312|Other|Allogenic mesenchymal stromal cells injection|Mesenchymal stem cells prepared from bone marrow of healthy donors and expanded for 3-4 weeks according to our procedure described in PEI Num. 10-134, authorized by the Spanish Medicine Agency
1684184|NCT01586312|Drug|Hyaluronic Acid|Intra-articular injection of 60 mg of hyaluronic acid (Durolane) in a single injection (3 ml)
1684185|NCT01586299|Drug|Ibuprofen|10 mg/kg every 8 hours until 24 hours after resolution of fever
1684186|NCT01586299|Drug|Acetaminophen|15 mg/kg every 6 hours until 24 hours after resolution of fever
1684187|NCT01586286|Drug|Nifedipine|Nifedipine - 0.2% concentration in a lanolin base; administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
1684188|NCT01586286|Drug|Placebo Ointment Base|Placebo administered twice per day for 28 days; as a vaginal ointment applied to vulvar and vaginal area
1684189|NCT01586273|Device|MR-HIFU treatment for pain palliation of bone metastases|A treatment session with the Philips Sonalleve MR-HIFU device for bone pain palliation with high-intensity focused ultrasound.
1684190|NCT01586260|Drug|DFMO|Subjects will receive twenty-seven (27) cycles of oral DFMO at a dose of 500 to 1000 mg/m2 BID on each day of a 28 day cycle.
1684191|NCT01586247|Dietary Supplement|Synbiotic|8g/day galacto-oligosaccharide + 10^9 CFU/day B.lactis
1684192|NCT01586247|Dietary Supplement|Placebo|8g/day maltodextrin
1684193|NCT01586247|Dietary Supplement|Prebiotic|8g/day galacto-oligosaccharide
1684194|NCT01586247|Dietary Supplement|Probiotic|10^9 CFU/day B.lactis
1684195|NCT01586234|Procedure|DSAEK with graft shaping and smoothing|"A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea
The tissue on the underside of the cornea (endothelium) will be scraped away
The graft from the donor cornea (previously smoothed with a laser) will be inserted through the incision and placed against the endothelium of the host cornea."
1684196|NCT01586234|Procedure|Standard DSAEK|"A 5mm incision will be made in the sclera (white portion) of the eye, approximately 1mm from the edge of the cornea
The tissue on the underside of the cornea (endothelium) will be scraped away
The graft from the donor cornea will be inserted through the incision and placed against the endothelium of the host cornea."
1684197|NCT01586221|Other|Music & Physical Therapy|Participants will receive combined Music Therapy and Physical Therapy for 6 Weeks. Two times per week for 1 hour.
1684198|NCT01586208|Drug|valproic acid (VPA)|Best dosage at the initial bolus of VPA in patient with satatus epilepticus refractarius (after benzodiazepine + phenytoin treatment)
1684199|NCT01586195|Drug|Vemurafenib|Vemurafenib 960 mg BID
1684200|NCT01586182|Radiation|Stereotactic Body Radiotherapy|Starting dose is 5.5 Gy x 2 boosts in addition to 57.24 Gy to the primary disease
1684201|NCT01586169|Drug|triple co administration at once of the combination of Albendazole + ivermectin + azithromycin|Albendazole 400mg + ivermectin according to the height + azithromycin according to the height at once
1686024|NCT01572051|Behavioral|Printed Material|Printed Material
1684204|NCT01586143|Drug|paracetamol|This is a clinical study that aims to investigate and compare the efficacy of transbuccal paracetamol 125 mg with that of paracetamol 1g administered intravenously in patients with acute pain of moderate intensity accepted to emergency room following a minor trauma of the lower limbs and/or superiors. To this end, several pain scoring will be performed using a visual analogue scale (VAS) at various times after drug administration.
1684205|NCT01586143|Drug|Placebo|
1684206|NCT01586130|Other|Exercise in eccentric or concentric mode|In this therapeutic field, isokinetic exercises seem to have a better efficiency than other, more frequently used, kinds of exercises such as isometric or isotonic exercises.
1684207|NCT01586117|Drug|Amifostine|intrarectal Amifostine administration 1500mg QD x 5 weeks
1684211|NCT01586065|Device|Continuous Glucose Monitor (CGM)|Use of CGM for 6 months
1684212|NCT01586065|Other|Fingerstick BGs only|No CGM - fingerstick BGs only
1684213|NCT01586052|Drug|Erythropoietin|250 IU/kg, Twice a week for 4 weeks
1684214|NCT01586039|Device|Visible light|We will compare the effects of two light sources, equated for visual stimulus (lux), on multiple non-visual responses to light including melatonin suppression before bedtime. We will compare a 90 lux exposure of a commercially available Compact Fluorescent Light (CFL) with a novel LED white light source that is depleted in the short-wavelength visible range (Biological Illumination LCC, FL).
1684215|NCT01586013|Drug|evaluation of propofol effect using BIS|propofol administered in target controlled infusion using the pharmacokinetic model of White
1684216|NCT01586000|Drug|10 µg/day E2 with NES 200® µg/day|10 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
1684217|NCT01586000|Drug|20 µg/day E2 with NES 200® µg/day|20 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
1684218|NCT01586000|Drug|40 µg/day E2 with NES 200® µg/day|40 µg/day E2 with NES 200® µg/day delivered by CVR continuously for 6 months (180 days)
1684219|NCT01585987|Biological|Ipilimumab|
1684220|NCT01585987|Other|Best Supportive care (BSC)|
1684221|NCT01585974|Other|No intervention|All dosage, frequency and duration for drugs will be under the decision of the treating physician
1684222|NCT01585961|Device|Catheter Ablation (NAVISTAR® THERMOCOOL® SF Catheter)|Administer anesthesia according to standard EP lab protocol, assess the fluid status of the subject (after each liter of infusate), determine if diuresis is necessary, and treat accordingly.
1684223|NCT01585935|Drug|SMOFLIPID|target dose: 3g/kg/d
1684224|NCT01585935|Drug|INTRALIPID|target dose: 3g/kg/d
1684225|NCT01585922|Procedure|noninvasive positive pressure ventilation (NPPV)|Use NPPV to treat the ARDS patients,and we choose the NPPV ventilators in which the FiO2 can be fixed, for example: the BiPAP Vision or V60 of Phillip Respironics.
1684226|NCT01585922|Procedure|invasive mechanical ventilation|Intubate and give invasive mechanical ventilation to the other group patients when they are allocated at once.
1684227|NCT01585909|Procedure|Gastroscopy|When gastroscopy is indicated for clinical reasons, duodenal biopsies to determine the activity of the brush border membrane enzymes intestinal alkaline phosphatase, maltase and lactase, as well as assessing brush border morphology are taken
1684228|NCT01585896|Other|Self-Help Group|The facilitated self-help group may last approximately 13 sessions. This treatment represents an empirically supported intervention for hoarding (Frost et al., 2011), based on a Facilitator's Manual (Maxner et al., 2010), which is a treatment manual based on the book Buried in Treasures: Help for Compulsive Acquiring, Saving, and Hoarding (Tolin, Frost, & Steketee, 2007).
1684229|NCT01585883|Behavioral|Self-management Intervention|Individual, face-to-face 7-session self-management intervention delivered by a specialist oncology nurse/clinical case manager as a home-based approach using a manual for each session. The intervention is delivered through scheduled home visits (7 sessions about one-hour in length), telephone coaching (2 sessions/week to reinforce use of strategies and for symptom monitoring: 15 minutes), and nurse moderated online peer chat or chat that is self-initiated at other times (7 weekly sessions about one hour in length).
1684230|NCT01585870|Drug|Sorafenib (Nexavar, BAY43-9006)|"Sorafenib (starting dose of 200 mg bid, level 1) administration will begin on Day 11 of Cycle 1, and will be administered twice daily continuously. If the combination is well tolerated, the dose will be escalated in new cohorts to 200 mg AM and 400 mg PM (level 2), then subsequently to 400 mg bid (level 3).
If sorafenib starting dose (level 1) is not well tolerated with eribulin, the sorafenib dose will be de-escalated to 200 mg qd (Dose Level -1) in a new cohort."
1684231|NCT01585870|Drug|Eribulin|Eribulin: 1.4 mg/m2 as an intravenous infusion on Days 1 and 8 of each 21-day cycle.
1684232|NCT01585857|Biological|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues.
1684233|NCT01585857|Biological|Autologous adipose derived stem cells administrated for intra-articular use|Each patient will receive one single administration of the cells and will be followed for 3 months. Each patients will be follow-up during one year with routinely examinations for safety issues. The first patient will be followed during 12 weeks before inclusion of the second patient.
1684234|NCT01585831|Drug|Testosterone gel 1%|Testosterone gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist after reviewing labs.
1684235|NCT01585831|Drug|Placebo gel|The placebo gel will be administered on a daily basis. The gel will be dispensed in a syringe, and the specific amount of gel to be applied each day will be determined by the study endocrinologist.
1684325|NCT01585194|Drug|Nivolumab|"Induction Phase:
1 mg/kg by vein for a total of four doses (week 1, 4, 7, 10). The induction phase continues through week 12."
1684392|NCT01584544|Drug|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
1684236|NCT01585818|Other|Low Glycemic Index (LGI) intervention arm|The general principles for the LGI intervention arm include the SDI principles and instructions on GI, identifying foods of different GI, switching to low GI food and having at least one low GI food per meal and suggested meals with recipes. Participants will also have the opportunity to attend sessions to learn how to cook meals with low GI.
1684237|NCT01585818|Other|Standard Diet Intervention|The general principles for the SDI arm are to provide an understanding of carbohydrates, be isocaloric based on assessment from the food diary/ recall and anthropometric measures, provide a personalised even distribution of carbohydrate throughout the day, have general recommendations such as reduction of fat, sodium, sugar and an increase in fibre. Participants will be provided with a list of carbohydrates to take during the intervention period and will be provided a supply of carbohydrates for that period
1684238|NCT01585805|Drug|Cisplatin|Given IV
1684239|NCT01585805|Drug|Gemcitabine Hydrochloride|Given IV
1684240|NCT01585805|Other|Laboratory Biomarker Analysis|Correlative studies
1684241|NCT01585805|Drug|Veliparib|Given PO
1684242|NCT01585792|Drug|TAK-875|
1684243|NCT01585792|Drug|TAK-875|
1684244|NCT01585792|Drug|Glimepiride|
1684245|NCT01585792|Drug|Placebo|
1684246|NCT01585779|Device|Contour 3D® implant for tricuspid valve repair|Tricuspid annuloplasty ring
1684247|NCT01585779|Device|Tri-Ad® implant for tricuspid valve repair|Tricuspid annuloplasty ring
1684252|NCT01585753|Drug|NRTI + PI|tenofovir zidovudine abacavir lamivudine emtricitabine ritonavir darunavir atazanavir lopinavir fosamprenavir
1684253|NCT01585753|Drug|maraviroc + PI|maraviroc ritonavir darunavir atazanavir lopinavir fosamprenavir
1684254|NCT01585753|Drug|maraviroc + NRTI|maraviroc tenofovir zidovudine abacavir lamivudine emtricitabine
1684255|NCT01585740|Drug|0.9% Normal Saline|Crystalloid fluid
1684256|NCT01585740|Drug|Ringer's Lactate|Crystalloid fluid
1684257|NCT01585727|Procedure|TME|Total mesorectal excision
1684258|NCT01585727|Procedure|TME|Total mesorectal excision
1684259|NCT01585727|Procedure|Neuromonitoring|Intraoperative neuromonitoring of pelvic autonomic nerves.
1684260|NCT01585701|Biological|AT13148|Days 1, 3, 5 of a weekly schedule in dose escalation cohorts of three patients. Continuous dosing until progression or unacceptable toxicity develops up to a maximum of 12 cycles.
1684261|NCT01585688|Drug|hLL1-DOX (IMMU-115)|hLL1-DOX is administered intravenously at one of 4 dose levels on days 1, 4, 8 and 11 of 21-day treatment cycles, with up to 8 cycles administered.
1684262|NCT01585662|Procedure|EUS-guided pancreatic pseudocyst drainage|EUS-guided pancreatic pseudocyst drainage by one 8 French naso-pancreatic tube or 2-3 two pig tails- stents.
1684263|NCT01585649|Drug|Lipegfilgrastim|Lipegfilgrastim 100ug/kg
1684264|NCT01585636|Drug|SQ109|Single oral dose
1684265|NCT01585623|Drug|SAR302503|"Pharmaceutical form:capsule
Route of administration: oral"
1684266|NCT01585623|Drug|omeprazol|"Pharmaceutical form:capsule
Route of administration: oral"
1684267|NCT01585623|Drug|metoprolol|"Pharmaceutical form:tablet
Route of administration: oral"
1684268|NCT01585623|Drug|midazolam|"Pharmaceutical form:solution
Route of administration: oral"
1684269|NCT01585610|Behavioral|DVD Intervention|Four theory-based intervention DVDs will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. DVDs focus on motivating smoking cessation among people with mobility impairments using Behavioral Activation as the primary theoretical construct. Short (< 5 min.) phone calls will also be placed to each participant in between DVD deliveries and after receipt of DVD 4.
1684270|NCT01585610|Behavioral|Standard Care Printed Materials|Four sets of standard smoking cessation printed materials will be provided to participants in this arm, the first in the home after Baseline assessment and the next 3 at 1-month intervals by mail. Short (< 5 min.) phone calls will also be placed to each participant in between materials deliveries and after the 4th and final set is sent by mail.
1684271|NCT01585597|Device|Zoll- Coolgaurd 3000|Goal temperature of 33 degrees Centigrade for a duration of 12 hours and then actively rewarmed by 0.2 degrees Centigrade per hour.
1684272|NCT01585584|Drug|Boceprevir|All patients will receive a 4-week lead-in with Peginterferon and Ribavirin therapy, followed by 24 weeks of Pegetron 1.5microg/kg + weight-based ribavirin + boceprevir 800mg tid. HCV RNA (Cobas TaqMan) will be measured at baseline and at treatment weeks 4, 6,8,12,16,20,24 and 28, and post-treatment weeks 12 and 24 (to obtain SVR-12 and SVR-24 results).
1684273|NCT01585558|Drug|Ospemifene (Dose 1)|
1684274|NCT01585558|Drug|Ospemifene (Dose 2)|
1684275|NCT01585558|Drug|Placebo|
1684277|NCT01585506|Other|No treatment given|"Patients to complete the WHO-5 Well-being Index questionnaire"
1684278|NCT01585506|Other|No treatment given|"Physicians to complete two questionnaires, Demographic Data and Disease and Treatment Course and Questionnaire of Potential Difficulties in the Period of Treatment Switching from Insulin to Its Analogues"
1684279|NCT01585493|Other|Treatment as usual|Treatment as usual. Patients will be affiliated with local out-patient clinics in secondary mental health services and they will have access to their own general practitioner. No formalized extra effort will be made to ensure treatment of physical disorders.Patients will be affiliated with local out-patient clinics in secondary
1684280|NCT01585493|Behavioral|Care coordinator|Treatment as usual plus a care coordinator (with a caseload of 25 patients) who will facilitate contact to primary care in order to ensure treatment of physical health problems,
1684391|NCT01584544|Drug|capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
1734970|NCT00070174|Drug|busulfan|
1684281|NCT01585493|Behavioral|CHANGE|"Treatment as usual plus affiliation to a staffmember (caseload 10) from a CHANGE team who will provide individualized, adjusted implementation of widely recognized interventions, such as smoking cessation programmes, motivational interviewing, psychoeducation plus patient involvement in monitoring health statusA multidisciplinary CHANGE team will be established. Team members will be health professionals with experience in smoking cessation programmes or exercise programmes for mentally ill, and experts with competence in dietary issues.
CHANGE treatment involve lifestyle coaching, education about diet and physical activity,16 networking and smoking cessation programs. The team members will act as lifestyle coaches for ten patients at a time, map lifestyle and explore and elicit patients' motivation for change."
1684282|NCT01585480|Behavioral|Weight Gain Prevention Intervention|"Behavioral Approaches
Distribution of pedometers
Traffic light labeling in worksite cafeteria and vending machines
Informational & Persuasive Messages
Stair use prompts
Posters, pamphlets, table toppers
Website
Social Approaches
a. Identification and training of influential employees (Peer Helpers) to shape healthy norms
Environmental Changes
Traffic light labeling
1/2 portions at 1/2 price
Walking routes
Introduction of healthier foods
Rearrangement of foods in the cafeteria
Adjusting serving spoon size"
1684283|NCT01585441|Drug|Finasteride|Finasteride is available as white, round 5 mg tablets. During the masked period, the tablets are re-formulated in capsules with inactive ingredients. The re-formulated finasteride capsules are indistinguishable from the placebo capsules.
1684284|NCT01585441|Drug|Placebo|Capsule with no active ingredients to mimic finasteride
1684285|NCT01585428|Drug|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
1684286|NCT01585428|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml in 5% dextrose in water (D5W) over 1 hr.
1684287|NCT01585428|Biological|Young TIL|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
1684288|NCT01585428|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight) over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
1684289|NCT01585415|Drug|Vemurafenib|Vemurafenib will administered orally twice a day at a dose of 960 mg from day -21 (+/- 7 days)until disease progression or patients are taken off protocol.
1684290|NCT01585415|Biological|Young TIL|Young TIL will be administered intravenously on day 0(1x10e9 to 2x10e11) in the Patient Care Unit over 20-30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.
1684291|NCT01585415|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
1684292|NCT01585415|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1684293|NCT01585415|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
1684301|NCT01585389|Genetic|gene expression analysis|
1684302|NCT01585389|Genetic|genetic linkage analysis|
1684303|NCT01585389|Genetic|microarray analysis|
1684304|NCT01585389|Other|immunohistochemistry staining method|
1684305|NCT01585389|Other|laboratory biomarker analysis|
1684306|NCT01585376|Genetic|mutation analysis|
1684307|NCT01585376|Genetic|nucleic acid sequencing|
1684308|NCT01585376|Other|laboratory biomarker analysis|
1684309|NCT01585350|Biological|MELITAC 12.1 + Montanide ISA-51 + lipopolysaccharide (LPS)|"Cohort 1 will be divided into three sub-groups and will receive:
Group 1a: MELITAC 12.1 + lipopolysaccharide (LPS)
Group 1b: MELITAC 12.1 + lipopolysaccharide (LPS) + Montanide adjuvant with vaccination #1
Group 1c: MELITAC 12.1 + lipopolysaccharide (LPS) adjuvant + Montanide adjuvant with all vaccinations"
1684310|NCT01585350|Biological|MELITAC 12.1 + Montanide ISA-51 + polyICLC|"Cohort 2 will be divided into three sub-groups and will receive:
Group 2a: MELITAC 12.1 + polyICLC adjuvant
Group 2b: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with vaccination #1
Group 2c: MELITAC 12.1 + polyICLC adjuvant + Montanide adjuvant with all vaccinations"
1684311|NCT01585324|Drug|peginterferon alfa-2a [Pegasys]|180 mcg subcutaneously weekly
1684312|NCT01585324|Drug|ribavirin [Copegus]|1000 mg or 1200 mg orally daily
1684313|NCT01585298|Drug|FTY720|
1684314|NCT01585285|Procedure|LIMA to SVG Bridge Technique|This surgical design use a composite-sequential venous graft to distribute left internal mammary artery (LIMA) inflow directly to the left anterior descending (LAD), but also to the other branches of the anterolateral territory thereby promoting a higher flow through the LIMA pedicle. It is constructed using a short saphenous vein graft (SVG) bridge interposed between the LAD and one (or more) other anterolateral targets, with the LIMA grafted on the hood of the SVG just above the LAD anastomosis.
1684315|NCT01585285|Procedure|Conventional CABG|Conventional coronary artery bypass grafting (CABG) strategy with left internal mammary artery (LIMA) graft to the left anterior descending (LAD) and separate sequential aorto-coronary saphenous vein grafts (SVG) to the others anterolateral targets
1684316|NCT01585272|Drug|ENA713|
1684317|NCT01585259|Drug|Anfibatide|Snake venom
1684318|NCT01585259|Drug|Placebo|Saline
1684319|NCT01585246|Drug|Saw Palmetto|1 of 3 doses of Saw Palmetto (320, 640, 960mg/day)
1684320|NCT01585246|Drug|soybean oil soft gel|placebo (soybean oil soft gel)
1684321|NCT01585233|Drug|ASKP1240|Intravenous
1684322|NCT01585233|Drug|Placebo|Intravenous
1684323|NCT01585220|Device|HA filler|The study device and comparator device will be intradermally injected to each left and right nasolabial fold according to the randomization.
1734971|NCT00070174|Drug|cyclophosphamide|
1684326|NCT01585194|Drug|Ipilimumab|"Induction Phase:
3 mg/kg by vein for a total of four doses (week 1, 4, 7, 10). The induction phase continues through week 12.
Maintenance Phase:
For patients who have not experienced disease progression or unmanageable toxicity by week 12:
Nivolumab 3 mg/kg by vein every 2 weeks until disease progression or unmanageable toxicity as deemed by the clinical investigator."
1684327|NCT01585181|Biological|PXVX0200|Single dose; liquid suspension after reconstitution with buffer; 2x108 to 2x109 CFU in a liquid suspension
1684328|NCT01585181|Biological|Placebo|Approx 2 grams of lactose reconstituted in water
1684329|NCT01585168|Drug|Memantine|Memantine is a low-side-effect NMDA receptor antagonist usually administered therapeutically to elderly persons with moderately severe Alzheimer's disease in typical doses of 10-20 mg daily. In this study, single doses of 40 mg are administered.
1684330|NCT01585168|Drug|Placebo|Identically appearing sugar pill, given orally
1684331|NCT01585155|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 22.
1684332|NCT01585142|Other|Test formula|Infant Formulas in powder in single-serve capsules (with a machine for dispensing, four consecutive formulas with customized composition
1684333|NCT01585129|Drug|Postpartum Antibiotics|Patients randomized into this arm will receive one additional dose of gentamicin (1.5 mg/kg) and clindamycin (900mg) in the postpartum setting.
1684334|NCT01585129|Drug|No postpartum antibiotics|Patients randomized into this arm will not receive any postpartum antibiotics after delivery. They will be managed identically to the other arm in terms of chorioamnionitis (fever pre-delivery). The groups will be managed identically if endometritis (post-partum fever) develops.
1684336|NCT01585090|Other|doing strengthening exercises of pelvic floor muscles|
1684337|NCT01585077|Biological|P. vivax infected mosquito bites|All volunteers will receive one dose of 2-4 P. vivax infected mosquito bites. All the mosquitoes will correspond to the same mosquito batch to make sure that all volunteers receive the same P. vivax strain.
1684338|NCT01585064|Other|DAS28-IOMS|Investigators randomized to DAS28-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a DAS28 score of < 2.4.
1684339|NCT01585064|Other|0SJ-IOMS|Investigators randomized to 0SJ-IOMS will be expected to adapt their therapeutic approaches in relation to the defined targets, i.e. to optimize adalimumab treatment according to individual patient's responses to treatment in order to achieve a swollen joint count of 0.
1684340|NCT01585064|Other|Routine Care (RC)|Investigators randomized to RC will NOT be expected to adapt their therapeutic approaches to a pre-defined target. They will optimize adalimumab treatment according to individual patient's responses to treatment as per routine care and according to their own judgment.
1684341|NCT01585051|Drug|25(OH) vitamin D|300 000 U intramuscularly, one dosage, in subjects with 25 (OH) vit D levels below 80 nmol/L, another dosage of 150 000 U after 3 months if 25(OH)vit D levels continue to be below 80 nmol/L.
1684342|NCT01585051|Drug|0.9 % NaCl|1 ml of 0.9 % of NaCl at the beginning and 0.5 ml of 0.9 % NaCl after three months
1684343|NCT01585038|Drug|Efavirenz|600mg orally every evening
1684344|NCT01585038|Drug|Rilpivirine|25mg orally once daily
1684345|NCT01585025|Drug|Obeticholic acid|Day -14 to Day 0 subjects will stop their usual diarrhoeal medication. Day 1 to Day 15 Obeticholic acid 25mg tablet will be administered to subjects once daily in the morning. Day 16 to day 28 normal diarrhoeal medication may be re-commenced.
1684346|NCT01585012|Device|Cervical cap (Focus Touch™ Conception System)|Cervical cap
1684347|NCT01584999|Biological|Blood transfusion|RBCs have been transfused in septic patient admitted in ICU
1684348|NCT01584986|Biological|ACP injections|Peripheral blood-derived, ex vivo expanded autologous angiogenic cell precursors (ACPs)
1684349|NCT01584960|Behavioral|endurance training|2 years of home-based endurance training
1684350|NCT01584947|Drug|Bupivacaine|Bupivacaine lozenge taken 3 times a day for two weeks
1684351|NCT01584947|Drug|Placebo|Placebo lozenge taken three times a day for two weeks
1684352|NCT01584934|Drug|Sodium oxybate|Treatment is started and continued for 6 weeks at patient's home. Patients receive 3g/night during the first week, and 4,5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4,5 g/night for 1 week, followed by 3g/night for 1 week. The next 2 weeks, patients are not treated.
1684353|NCT01584934|Drug|Placebo|Placebo treatment is started and continued for 6 weeks at patient's home. Patients receive 3 g/night during the first week and 4.5 g/night during the second week. After the second week, patients have their dose increased to 6 g/night during 6 weeks. A washout period of 4 weeks is installed to withdraw from treatment. Patients receive 4.5 g/night for 1 week, followed by 3 g/night for 1 week. The next 2 weeks, patients are not treated.
1684354|NCT01584921|Drug|Erythropoietin (Epoetin-beta, NeoRecormon®)|5000 IU/ml of NeoRecormon (Epoetin beta) is given subcutaneously as one ml before 10 O-clock a.m. on day 1,3,5,7,9,11 and 13. On day 1 and 3 5000 IU is given in one syringe and five ml of saline in total is given in five other syringes in order to maintain the double blinding. On day 2 six syringes of a total of 6 ml of saline is given in six syringes.
1684355|NCT01584921|Drug|Erythropoietin (Epoetin-beta, NeoRecormon®)|"30.000 IU of NeoRecormon (Epoetin beta) is given subcutaneously as a total of six ml (5.000 IU/ml) given in six syringes before 10 O-clock a.m. on day 1,2 and 3.
On day 5,7,9,11 and 13 six ml of saline in total is given in six syringes in order to maintain the double blinding."
1684356|NCT01584921|Drug|Placebo|1 ml of saline (Sodium Chloride 9 mg/ml) is given subcutaneously before 10 O-clock a.m. on day 1,2,3,5,7,9,11 and 13. On day 1,2 and 3 six ml in total is given in six syringes in order to maintain the double blinding.
1684357|NCT01584895|Behavioral|Cardiac Rehabilitation|A standard cardiac rehabilitation program consisting of 3 days per week of supervised exercise and education.
1684358|NCT01584882|Behavioral|CATI Tool|Using Screening for drug use, Brief Intervention, Referral to Treatment (SBIRT) as a model, a CATI tool was designed for the Electronic Dental Record which required assessment of 4 variables for patients reporting cigarettes use: 1) number of cigarettes daily, 2) how soon upon waking the first cigarette was smoked, 3) interest in quitting, and 4) previous quit attempts. Level of dependency was calculated and displayed in the health history using the Heavy Smoking Index. Pop-up provider scripts were generated using rule-based algorithms. Links to printable patient education materials on the quit line and on medications to help quit smoking were embedded in the scripts window. The tool automatically recorded tobacco-cessation details.
1684359|NCT01584869|Device|capsule endoscopy|
1684360|NCT01584843|Drug|GSK1358820|IM injection of Botulinum Toxin Type A
1684361|NCT01584830|Drug|Regorafenib (BAY73-4506)|Regorafenib BAY73-4506 will be given 3 weeks on/1 week off (160 mg od po.)
1684362|NCT01584830|Drug|Placebo|Placebo will be given 3 weeks on/1 week off (160 mg od po.)
1684363|NCT01584817|Other|telephone education|A repeated instruction by telephone on the day before colonoscopy was conducted
1684364|NCT01584804|Drug|Su-Huang antitussive capsule|Su-Huang antitussive capsule (0.45g) 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
1684365|NCT01584804|Drug|Sugar pill|Sugar pill 3 capsules Tid for 2 weeks (swallowed by warm water at 0.5-1h after each meal)
1684366|NCT01584791|Drug|clopidogrel napadisilate + aspirin|clopidogrel napadisilate 75mg + aspirin 100mg
1684367|NCT01584791|Drug|clopidogrel bisulfate + aspirin|clopidogrel bisulfate 75mg + aspirin 100mg
1684368|NCT01584778|Other|eosinophil cationic protein|Serum eosinophil cationic protein levels
1684369|NCT01584765|Drug|Prescription drugs with known hepatotoxicity|14 prescription drugs with known hepatotoxicity : Amoxicillin/clavulanate, nitrofurantoin, isoniazid, trimethoprim-sulfamethoxazole, duloxetine, valproate, interferon-beta, ciprofloxacin, lamotrigine, phenytoin, diclofenac, terbinafine, levofloxacin, aripiprazole
1684370|NCT01584752|Procedure|Gore-BioA Fistula Plug|Gore-BioA Fistula Plug
1684371|NCT01584739|Drug|AZD8683|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients)
1684372|NCT01584739|Drug|Placebo|Multiple dose, oral inhalation (Healthy volunteers) Multiple dose, oral inhalation (COPD patients
1684373|NCT01584726|Drug|Magnesium Sulfate|single dose of magnesium sulfate nebulization
1684374|NCT01584713|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
1684375|NCT01584700|Procedure|Renal Artery Denervation|Radiofrequency ablation of the renal artery sympathetic outflow tract.
1684376|NCT01584687|Biological|Omalizumab|The patients will receive Omalizumab according to their age and weight for 4 months.
1684377|NCT01584674|Device|KLOX Biophotonic System|KLOX Biophotonic System (KLOX KLGA0105-01 photo-converter gel and KLOX THERA lamp) will be administered twice a week for 6 weeks followed by a 6-week follow up period
1684378|NCT01584661|Behavioral|Dietary recommendations|
1684379|NCT01584648|Drug|dabrafenib|dabrafenib 150 mg twice daily
1684380|NCT01584648|Drug|dabrafenib plus trametinib placebo|dabrafenib 150 mg twice daily and trametinib placebo
1684381|NCT01584648|Drug|Trametinib|trametinib 2 mg once daily
1684382|NCT01584635|Procedure|Peroral Endoscopic Myotomy a less invasive treatment for Achalasia|In this study we will follow patients undergoing Peroral Endoscopic Myotomy at 1 and 6 months post surgery,1,2,3,4,and 5 years post surgery with esophageal high resolution Manometry and a Barium Esophagram when it is not standard of care. We will have you fill out a symptom questionnaire at each visit
1684383|NCT01584622|Device|CADence System|Non-invasive detection of > or equal to 50% stenosis in any of the major coronary arteries.
1684384|NCT01584609|Device|Penumbra System with Separator 3D|The Separator 3D is an additional Separator with a new tip configuration for the Penumbra System.
1684385|NCT01584609|Device|Penumbra System alone|The Penumbra System® is a new generation of neuro-embolectomy devices specifically designed to remove thrombus through aspiration.The treatment paradigm of this System involves the introduction of the Reperfusion Catheter through a guide catheter into the intracranial vasculature, and guided over an appropriate guidewire to the site of primary occlusion. The Reperfusion Catheter is used in parallel with the Separator and an aspiration source (Aspiration Pump) to separate the thrombus and aspirate it from the occluded vessel.
1684386|NCT01584596|Behavioral|Adapted Dietary Guidelines|"This group will receive dietary counseling to reduce their overall dietary food intake by 100 kcal/day, as prescribed by the dietary guidelines for the prevention of weight gain, and to follow an adapted eating pattern (to be determined from formative research in Phase I research).
The education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. During the adoption phase, participants will meet for one session per week for the first four weeks. During this session their interim weight will be recorded before they receive their session. During the adherence phase, participants will be contacted by telephone biweekly by a trained interventionist."
1684387|NCT01584596|Behavioral|Adapted Physical Activity Guidelines|The physical activity education sessions will be organized into two phases: an initial adoption phase and a subsequent adherence phase. The adoption phase will be for 1 hour and 45 minutes for the first 4 weeks with classes occurring once per week in conjunction with the DG education classes. During the adoption phase, participants monitor their own walking using pedometers and attend weekly group meetings to review the previous week's walking behaviors, discuss preferred strategies for success, and set personally relevant and incremental steps/day goals. During the adherence phase (the remaining 8 weeks), participants will continue with their self-monitoring and goal-setting (using their pedometers), with reduced contact with the study interventionists over the telephone (biweekly).
1684388|NCT01584570|Drug|0.5 mcg/kg IV infusion for 10 min, 1.0 mcg/kg IV infusion for 10 min|ECG monitoring for evaluation of QTc interval
1684393|NCT01584544|Drug|Capecitabine|oral pills, 1350mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
1684394|NCT01584544|Drug|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
1684395|NCT01584544|Drug|Capecitabine|oral pills, 1650mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation
1684396|NCT01584531|Drug|rigosertib|"Rigosertib sodium will be available as soft gel capsules in strengths of 280 mg and 70 mg. Rigosertib will be administered on an outpatient basis.
Patients will take a 560 mg dose (e.g., 2 x 280 mg capsules) of oral rigosertib in the morning and 280 mg dose (e.g., 1 x 280 mg capsules) of oral rigosertib every day of 21-day cycles. Rigosertib should be taken in a fasting state (defined by at least 30 minutes before next meal) BID at 12 hr intervals (with a window of 2 hr). Any vomited dose will be reported as a missed dose.
The patient will fill a diary indicating the day and time of drug intake."
1684397|NCT01584518|Drug|Furosemide|Based on clinical standard per clinician
1684398|NCT01584505|Drug|CHF1535 + CHF5992 dose 1 BID|CHF1535 + CHF5992 dose 1 BID for 14 days
1684399|NCT01584505|Drug|CHF1535 + CHF5992 dose2 BID|CHF1535 + CHF5992 dose 2 BID for 14 days
1684400|NCT01584505|Drug|CHF1535 daily dose|CHF1535 daily dose for 14 days
1684401|NCT01584492|Drug|beclomethasone+formoterol 50/6 (1 inhalation)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
1684402|NCT01584492|Drug|CHF 1535 50/6 (2 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
1684403|NCT01584492|Drug|CHF 1535 50/6 (4 inhalations)|CHF 1535 50/6 (fixed combination of extrafine beclomethasone dipropionate 50 µg + formoterol fumarate 6 µg/metered dose) administered via a pMDI with spacer
1684404|NCT01584492|Drug|Formoterol + Beclomethasone dipropionate|"Formoterol HFA pMDI 6 µg / actuation
Extrafine BDP HFA pMDI 50 µg/actuation"
1684405|NCT01584492|Drug|Placebo (6 inhalations)|Matched placebo via pMDI
1684406|NCT01584466|Drug|Paliperidone|"The starting regimen will be a 'loading dose' strategy whereby the first injection will be 234 mg given on treatment week 0,day 1 and 156 mg (2nd injection) will be given 1 week later (days 5-9). Both are recommended to be administered in the deltoid muscle (PI 2011). Following the second dose, monthly maintenance doses will be administered in either the deltoid or gluteal muscle (PI 2011). The monthly (± 7 days) maintenance dose will be 117 mg.
Discontinuation of oral antipsychotics is recommended after the subjects receive paliperidone palmitate injection on Week 0/day 1. Continued oral antipsychotics may be used only if necessary."
1684407|NCT01584453|Drug|Sodium Nitrite|A bolus of sodium nitrite solution (1.8 micromol in 10 ml PRe-diluted in 0.9% sodium chloride in a syringe) will be delivered over 30-60 seconds via intracoronary injection initiated during the re-establishment of antegrade epicardial flow with PPCI.
1684408|NCT01584453|Drug|Sodium Chloride Placebo|The control intervention is a bolus of 0.9% sodium chloride solution (prepared with an identical appearance to the sodium nitrite).
1684409|NCT01584440|Drug|AVP-923 (dextromethorphan/quinidine)|AVP-923 capsules administered twice a day over a 10-week period
1684410|NCT01584440|Drug|Placebo|Placebo capsules administered twice a day over a 10-week period
1684411|NCT01584427|Dietary Supplement|Healthy Carbohydrate Diet vs. Western Style Diet|Cross over study with two intervention diets. Healthy Carbohydrate Diet with approximally 55 g of dietary fibers (arabinoxylan and resistant starch)compared with western style diet with low content of dietary fibers.
1684412|NCT01584388|Drug|Rituximab|Rituximab 1000 mg IV times two doses, separated by approximately 15 days.
1684413|NCT01584375|Other|Flat midline head position|Infant's chin will be kept at a 90±5 degree angle to the bed (the chin and nose being in line with the sternum) throughout the first 168 hours of life.
1684414|NCT01584375|Other|Right flat lateral head position|Infant's head will be tilted 85-90 degrees to right side (approximately the entire chin beyond the right nipple line) throughout the first 168 hours of life.
1684415|NCT01584362|Drug|oxfendazole|administration of a single oral 1.0 mg/kg dose of oxfendazole
1684416|NCT01584362|Drug|placebo|single oral dose of placebo
1684417|NCT01584362|Drug|oxfendazole|administration of a single oral 3.0 mg/kg dose of oxfendazole
1684418|NCT01584362|Drug|oxfendazole|administration of a single oral 0.3 mg/kg dose of oxfendazole
1684419|NCT01584362|Drug|oxfendazole|administration of a single oral 10 mg/kg dose of oxfendazole
1684420|NCT01584362|Drug|oxfendazole|administration of a single oral 20 mg/kg dose of oxfendazole
1684421|NCT01584362|Drug|oxfendazole|administration of a single oral 30 mg/kg dose of oxfendazole
1684422|NCT01584336|Procedure|LATG|"After laparoscopic observation, the surgeon must check the possibility of laparoscopic surgery (without the serosal invasion of cancer or peritoneal metastasis or lymph node metastasis to splenic hilum). If the gastric cancer with serosal invasion or grossly lymph node metastasis to splenic hilum, operator must convert the operation method to open gastrectomy
The operator undergoes the laparoscopic total gastrectomy with lymph node dissection(including the status of lymph nodes - No #1,2,3,4sa,4sb,4d,5,6,7,8a,9,11p and 11d, and/or 12a).
The operator can choose any reconstruction method of esophagojejunostomy according to surgeon's preference.
After then, the operator performs the jejunojejunostomy."
1684423|NCT01584323|Dietary Supplement|Pomgranate pills|"Treatment arm will receive The POMx pomegranate 1,000 mg capsule a day for maximum of two weeks or until they deliver if occurs before
The POMx pomegranate 1,000 mg capsule contains at least 800 mg natural polyphenol using a pomegranate polyphenol standard and is comparable to mg/8 oz juice.(attached is confirmation Similarity of Pomegranate Juice and POMx Polyphenols)"
1684424|NCT01584323|Dietary Supplement|Placebo pills|The placebo group will receive placebo pills , for maximum of two weeks or until they deliver if occurs before The palecbo capsule contains gelatin and lactose. The capsuls are manufactured by the hospital pharmacy.All the components are medically approved fot use during pregnancy
1684425|NCT01584310|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
1684426|NCT01584310|Other|No STAMP using|No intervention
1684510|NCT01583543|Drug|Olaparib|400mg PO BID Continuous
1734972|NCT00070174|Drug|cyclosporine|
1684427|NCT01584297|Drug|Ketoconazole|Patients will receive ketoconazole, 400 mg three times a day. Study treatment period will be during 6 months or up to progression disease, unacceptable toxicity, death or withdraw from the study for any reason.
1684428|NCT01584284|Biological|GL-ONC1|A genetically-engineered vaccinia virus administered via intravenous infusion . Cohorts 1, 2, 3: Frequency: 1x in Week 1; Cohort 4: 1x again 1x in Week 2; Cohort 5: 1x Week 1, 1x Week 2, 1x Week 3, 1x Week 4.
1684429|NCT01584271|Device|Natural Ear Comfort(TM), a botanical ear drops product|"Ear Comfort(TM): active ingredients - Thyme essential oil & Camomile extract. Inactive ingredients: anhydrous glycerin and a small quantity of surfactant.
Dex-Otic(R): Dexamethasone sodium phosphate 1mg; neomycin sulfate 5mg; polymixin B sulfate 10,000 units.
Inactive ingredients: propylene glycol, sodium acetate anhydrous, phenyl mercuric acetate, purified water.
Otidin(R): Tetracaine HCL 0.5%; antipyrine 5% in anhydrous glycerin."
1684430|NCT01584258|Procedure|Laproscopic Prostatectomy|
1684431|NCT01584258|Radiation|Conventionally Fractionated Prostate Radiotherapy|Conventional fractionation delivered to a dose of 78 Gy in 2 Gy fractions.
1684432|NCT01584258|Radiation|Prostate SBRT|Prostate SBRT delivered to a dose of 36.25 Gy in 5 fractions.
1684433|NCT01584245|Other|Amino Acid formula|
1684434|NCT01584232|Drug|LY2189265|
1684435|NCT01584232|Drug|Insulin glargine|
1684436|NCT01584232|Drug|Sulfonylureas (SU)|
1684437|NCT01584232|Drug|Biguanide (BG)|
1684438|NCT01584206|Drug|Ezetimibe|10mg ezetimibe/day, at least 4 months
1684439|NCT01584193|Procedure|Ultrasound-guided subclavian vein puncture|Central venous access port implementation through ultrasound-guided subclavian vein puncture and Seldinger technique
1684440|NCT01584193|Procedure|Cephalic vein dissection|Central venous access port implementation through cephalic vein dissection and cutdown
1684441|NCT01584180|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's|Infusion of max. 1L cold crystalloid solution (4°C) over 15 minutes
1684442|NCT01584180|Device|EMCOOLS Brain.Pad|Passive external neck cooling with 1 EMCOOLS Brain.Pad
1684443|NCT01584167|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
1684444|NCT01584167|Device|EMCOOLS Flex.Pads|Passive whole-body surface cooling with 10 EMCOOLS Flex.Pads
1684445|NCT01584154|Procedure|cryoablation|cryoablation with an 8mm-tip catheter
1684446|NCT01584154|Procedure|radiofrequency ablation|radiofrequency ablation with a 4mm-tip catheter
1684447|NCT01584115|Biological|NY-ESO-1 combined with MPLA|Each patient will receive six doses of the formulation, administered intra-muscular, with an interval of 4 weeks between doses, and the first immunization performed 6 weeks after the completion of standard treatment. NY-ESO-1 (250 mcg) amd MPLA (100 mcg).
1684448|NCT01584115|Biological|NY-ESO-1 combined with MPLA vaccine|Immunization os cancer patients with NY-ESO-1 combined with MPLA vaccine
1684449|NCT01584102|Behavioral|group fitness + education|15 weeks biweekly group fitness + 15 weekly nutrition and physical activity education
1684450|NCT01584102|Behavioral|group fitness classes only|15 weeks biweekly group fitness
1684451|NCT01584076|Drug|Donepezil|"Oral Donepezil Daily
Initial Dosage: Donepezil 5 mg tablets will be used. 1/2 tablet (≈2.5 mg)/day for 8 to 17 year olds OR 1 tablet (5 mg)/day for ≥18 year olds.
Dosage Escalation: Donepezil may be increased by 1/2 tablet (≈2.5 mg)/day every 4 weeks if the amblyopic eye visual acuity has not improved by ≥5 letters or 1 logMAR line to a maximum dosage of 1 1/2 tablets (≈7.5 mg)/day for 8 to 17 year olds OR 2 tablets (10 mg)/day for ≥18 year olds."
1684452|NCT01584076|Other|Patching|Patching: 2 hours of daily patching will also be prescribed for 8 to 17 year olds only.
1684453|NCT01584063|Behavioral|Healthy MOMs Healthy Lifestyle Intervention|These women received the culturally tailored Healthy MOMs Healthy Lifestyle Intervention, which included social support from Women's Health Advocates (community health workers) and peers, and the Healthy MOMs curriculum. This intervention curriculum covered topics related to healthy eating, physical activity, and stress management during pregnancy and postpartum. General information about pregnancy and the postpartum period were also provided. This intervention was delivered during 10 group meetings and 4 home visits.
1684454|NCT01584050|Dietary Supplement|L-5-methyltetrahydrofolate (Metafolin ®)|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
1684455|NCT01584050|Dietary Supplement|folic acid|dosage: 1000 μg, frequency: once daily, duration: 12 weeks
1684456|NCT01584050|Dietary Supplement|Placebo|frequency: once daily, duration: 12 weeks
1684457|NCT01584024|Device|Resin infiltration|Baseline treatment of one caries lesion with resin infiltration therapy, in addition to preventative measures and behavioral modification.
1684458|NCT01584024|Device|Sham treatment|Baseline treatment of one caries lesion with sham treatment, in addition to preventative measures and behavioral modification.
1684459|NCT01584011|Other|taste measurement|Taste measurements with Electrogustometry and Filter paper test before and after surgery until one year after surgery
1684460|NCT01584011|Other|Symptom questionnaire|Answering a symptom questionnaire before and after surgery until one year after surgery
1684461|NCT01584011|Behavioral|Quality of life questionnaire|Answering a quality of life questionnaire before and one year after surgery
1684462|NCT01584011|Other|Nerve sample|Collect nerve samples from patients undergoing surgery because of vestibular schwannoma, chronic otitis media or cholesteatoma where the nerve cant be saved during planned operation.
1684463|NCT01583998|Behavioral|e-MBC|antidepressant treatment
1684464|NCT01583985|Other|Opioid-intensive prescribing strategy|The opioid-intensive arm emphasizes early use of strong opioid analgesics. Medications will be individually adjusted according to patient preferences and responses.
1684465|NCT01583985|Other|Opioid-avoidant prescribing strategy|The opioid-avoidant prescribing strategy emphasizes non-opioid medications from several drug classes. Medications will be individually adjusted according to patient preferences and responses.
1684466|NCT01583972|Dietary Supplement|retinyl palmitate|50,000 IU vitamin A in oil given within 48 h of birth from single-dose capsule
1684467|NCT01583972|Dietary Supplement|Placebo|edible oil used as diluent for vitamin A given within 48 h of birth from single-dose capsule identical in appearance to vitamin A capsule
1684468|NCT01583959|Drug|Folic Acid|Folic acid tablets 5 mg
1684469|NCT01583959|Drug|Placebo|Matched placebo to folic acid 5 mg tables, to be given for 4 days a week
1684470|NCT01583933|Device|Essix retainer|"The essix retainer is made in a thermoforming copolyester 0.75mm (0.30 , it processed gives a thickness of 0.015 approximately. Retainer will be used molar to molar. subjects in this arm will have this retainer for 24 hours a day for 6 months, they won´t have this device for food intake."
1684471|NCT01583933|Device|Hawley retainer|subjects in this arm will have the retainer for 24 hours a day for 6 months. During food intake they won´t have this device.
1684472|NCT01583920|Radiation|focal salvage HDR prostate brachytherapy|Treatment will be delivered using 192-Ir HDR afterloading. Dose prescription is 2 fractions of 13.5 Gy each, delivered 1 week apart.
1684473|NCT01583881|Procedure|renal denervation|Renal denervation
1684474|NCT01583855|Procedure|Catheter ablation for atrial fibrillation, manual|Ablation for atrial fibrillation will be performed manually
1684475|NCT01583855|Device|Ablation using Amigo remote catheter system|Atrial fibrillation ablation will be performed using the Amigo remote catheter system
1684476|NCT01583842|Radiation|124I-MIBG (no-carrier added)|"124I-MIBG (no-carrier added) Administration (infusion, 1-2 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.
Optional 124I-MIBG (no-carrier added) Administration & PET/CT scan 6 weeks later."
1684477|NCT01583842|Radiation|124I-MIBG (carrier added)|"124I-MIBG (carrier added) Administration (infusion, 60 minutes) followed by sequential PET/CT dosimetry scans on Days 0, 1, 2 and 5.
Optional 124I-MIBG (carrier added) Administration & PET/CT scan 6 weeks later."
1684478|NCT01583829|Behavioral|Neurofeedback|3 times per week for 45 minutes for a total of 40 sessions
1684479|NCT01583829|Behavioral|Cognitive Training|3 times per week for 45 minutes for a total of 40 sessions
1684480|NCT01583829|Other|Waitlist Control|6 30 minute calm breathing sessions over the course of 4 months
1684481|NCT01583816|Drug|Resiquimod 0.03%|topical application
1684482|NCT01583816|Drug|Resiquimod 0.01%|topical application
1684483|NCT01583816|Drug|placebo|topical application
1684484|NCT01583777|Drug|Belinostat|"On Day 1, a single dose of 14C-labeled belinostat (approximately 94 to 105 µCi, 1500 mg) will be administered to the patient as a 30-minute IV infusion.
After Cycle 1 evaluations are completed, and if it is in the best interest of the patient, patients may receive additional cycles of non-radiolabeled belinostat until disease progression, unacceptable toxicity, or initiation of new anticancer therapy. After Cycle 1, Day 21, non radiolabeled belinostat will be administered IV as a 30 -45 minute infusion of 1000 mg/m2 on Days 1 through 5 every 21 days."
1684485|NCT01583751|Procedure|videoendoscopic resection of pilonidal sinus|Resection of pilonidal sinus tissue with videoendoscopic approach.
1684486|NCT01583738|Drug|V0251|single dose
1684487|NCT01583738|Drug|placebo|single dose
1684488|NCT01583725|Procedure|Liquid meal responses|Subject ingests a meal-replacement shake and gut peptide levels are measured before and after intake.
1684489|NCT01583725|Behavioral|fMRI responses to food-cues|Subjects undergo a 40 min fMRI neuroimaging session while receiving auditory and visual food cues.
1684490|NCT01583712|Procedure|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract including endomicroscopic pictures taken every ten centimetres in the small bowel, gastric antrum, gastric corpus and esophagus.
1684491|NCT01583712|Device|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
1684492|NCT01583699|Procedure|Confocal laser endomicroscopy|Endomicroscopy of the upper gastrointestinal tract to capture endomicroscopic pictures from the small bowel, stomach and esophagus.
1684493|NCT01583699|Device|Confocal Laser Endomicroscope|Pentax EC-3870 CIFK with the ISC-1000 confocal endomicroscopy processor - Pentax, Tokyo, Japan and Optiscan Pty Ltd, Notting Hill, Victoria, Australia
1684498|NCT01583673|Other|Amino Acid Formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
1684499|NCT01583673|Other|Amino Acid formula|Subjects will be fed the assigned study formula from enrollment to 4 months (112 days) of age.Infants will be fed orally, ad libitum with the assigned formula
1684500|NCT01583660|Drug|celecoxib|200mg, PO.Bid, last from admission to hospital to one week after operation.
1684501|NCT01583660|Drug|Acetaminophen oxycodone|1 tablet(Acetaminophen 325mg oxycodone 5mg), Q6h orally take,last from admission to hospital to one week after operation.
1684502|NCT01583647|Drug|MK-0524A|1 tablet of MK-0524A (1g ER niacin/20mg laropripant) orally
1684503|NCT01583647|Drug|MK-0524A|2 tablets of MK-0524A (1g ER niacin/20mg laropripant) orally
1684504|NCT01583634|Device|Mespere Oximeter|Mespere oximeter provides non-invasive venous blood oxygen saturation.
1684505|NCT01583634|Device|Radiometer OSM-3 Co-Oximeter|OSM-3, a Radiometer manufactured hemoximeter, is intended for the photometric determination of hemoglobin.
1684506|NCT01583621|Dietary Supplement|Cholecalciferol|The participants will be randomized into one of the four groups. Group 0 will be placebo group, group 1 will receive monthly supervised dose of 18,000 IU (equivalent to 600 IU/day), group 2 will receive monthly supervised dose of 60,000 IU(equivalent to 2000 IU/day), and group 3 will receive 120,000 IU (equivalent to 4000 IU/day) vitamin D3 supplementation for 4 months (16 weeks).
1684507|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|1200 mg per os, once a day, 8 weeks
1684508|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|600 mg per os, twice a day, 8 weeks
1684509|NCT01583582|Dietary Supplement|Marealis Refined Peptide Concentrate|0 mg per os, daily, 8 weeks
1734973|NCT00070174|Drug|cytarabine|
1684511|NCT01583530|Biological|Single Dose Group: Belimumab IV 240 mg|Belimumab IV 240 mg administered on Day 0
1684512|NCT01583530|Biological|Single Dose Group: Belimumab SC 2 x 120 mg|Belimumab SC 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Day 0
1684513|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 240 mg|Belimumab SC 240 mg x 1 injection on Day 0
1684514|NCT01583530|Biological|Single Dose Group: Belimumab SC 1 x 200 mg|Belimumab SC 200 mg x 1 injection on Day 0
1684515|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 2 x 120 mg weekly|Belimumab 120 mg x 2 injections (equal to 240 mg) administered immediately one after the other on Days 0, 7, 14, and 21
1684516|NCT01583530|Biological|Multiple Dose Group: Belimumab SC 1 x 200 mg weekly|Belimumab 200 mg x 1 injection administered on Days 0, 7, 14, and 21
1684517|NCT01583517|Procedure|Biliary sphincterotomy|Cutting of the biliary sphincter muscle.
1684518|NCT01583517|Procedure|Pancreatobiliary sphincterotomy|Cutting of both the biliary and pancreatic sphincter muscles.
1684519|NCT01583517|Procedure|Sham|No sphincterotomy is performed in patients randomized to sham with normal SOM.
1684520|NCT01583504|Procedure|Ultrasound guided injection of steroid and local anaesthetic|2mls of 0.5% Bupivocaine and 25mg of hydrocortisone given as a single bolus via a 21G needle using sterile technique. The injection will be placed into the space between Kagers fat pad and the anterior aspect of the achilles tendon, into the area of maximal neovascularisation as seen on ultrasound scan.
1684521|NCT01583504|Procedure|High volume saline injection|After steroid and local anaesthetic has been delivered, a bolus of normal saline will also be infused into the space between Kager's fat pad and the achilles tendon through the same needle, using ultrasound guidance and sterile technique. At least 14mls will be given but up to 40mls could be used. Saline will be injected until the injector determines that the appearance of neovascularisation on ultrasound has disappeared.
1684522|NCT01583504|Behavioral|exercise programme|a bandage will be placed on the ankle for 48 hours and instructions given to rest the ankle. The patient will be verbally shown a programme of exercises to be done over the next 6 weeks to stretch the tendon and steadily build up load bearing on it. The exercises are also clearly shown on a leaflet which the patient takes home.
1684523|NCT01583491|Procedure|autologous platlet rich fibrin|one dose immediate after surgery
1684524|NCT01583491|Procedure|one side in control group|control group insert any things after surgery
1684525|NCT01583478|Biological|incobotulinumtoxinA|Eligible patients will receive Xeomin® doses of 20-, 40-, 60-, 80- or 100-units divided among 5 injection points (0.25 mL total) in the glabellar region on Day 0 of the study.
1684526|NCT01583465|Device|Aquamantys|Primary THA via the ASI approach will be performed using the Aquamantys Malleable Bipolar Sealer. The Aquamantys is a bipolar device that combines radio-frequency energy and saline to gently reach targeted tissue and provide a biomechanical seal. The saline acts as a conduit to allow the energy to penetrate the tissue from 1 to 2 mm where the collagen is transformed thus providing the seal. The saline also helps cool the tissue which allows for gentle handling of tissue, eliminating the black char that is a port for infection. The surgeon uses the Aquamantys to assist in tissue dissection, cauterize vessels, and to pre-treat fat pad in front of capsule prior to excision, to treat the entire anterior hip capsule prior to excision, treat oozing bone surfaces not covered by an implant.
1684527|NCT01583465|Device|standard electrocautery (Bovie)|Primary total hip arthroplasty via an anterior supine intermuscular approach will be performed with the assistance of standard electrocautery. The electrocautery is used in tissue dissection and to cauterize bleeding vessels.
1684528|NCT01583452|Other|Chewing Gum|The use of chewing gum as a preventive measure for post-operative ileus
1684529|NCT01583439|Drug|highly active antiretroviral therapy: Lopinavir/Ritonavir, Lamivudine, Zidovudine, Efavirenz, Tenofovir Disoproxil Fumarate, Emtricitabine|Atripla: one tablet administered orally once daily at bedtime, each tablet comprised of co-formulated: Efavirenz (EFV) 600mg, Emtricitabine (FTC) 200mg, Tenofovir disoproxil fumarate (TDF) 300mg(EFV/FTC/TDF). Note: the study will generally provide the fixed-dose combination Atripla, but it will also be permissible for the same drugs to be used at the same doses as individual components (or as Truvada, coformulated TDF/FTC). Other drug substitutions may be made per the protocol.
1684530|NCT01583426|Drug|nab-Paclitaxel|nab-Paclitaxel 125 mg/m² weekly for 12 weeks
1684531|NCT01583426|Drug|Paclitaxel|Paclitaxel 80 mg/m² weekly for 12 weeks
1684532|NCT01583413|Procedure|Daily SAT & SBT|Nurse and/or respiratory therapist led daily awakenings from sedation (spontaneous awakening trial, or SAT) and daily performance of a spontaneous breathing trial (SBT) among mechanically ventilated, critically ill patients in participating ICUs.
1684533|NCT01583400|Other|RESPECT-D|The RESPECT-D (Re-engineering Systems of Primary Care Treatment of Depression) intervention is a systematic approach to the assessment and management of depression within Primary Care. The essential components of the Collaborative Care model include prepared PCPs and practices, the Care Manager, and a Behavioral Health specialist all working in partnership with the patient. The trained depression care manager closely coordinates with primary care clinicians, supports treatment recommendations, patient education, appropriate follow-up to ensure adequate treatment, and coordination with a consulting psychiatrist.
1684534|NCT01583400|Other|RESPECT-D-E (Enhanced)|The RESPECT-D-E intervention includes all of the components of the RESPECT-D model, but also incorporates the enhanced digital health coaching program for depressive symptoms tool, is an on-line program with education, coaching, self-management techniques, symptom, side effect and medication adherence tracking for depression. Depressive symptoms, medication side effects and adherence data are automatically delivered to the Care Manager for use in treatment planning. The program provides tailored feedback, provides coaching on skills related to depression treatment (such as changing negative thoughts and avoiding relapse), and offers tools for tracking behavior change.
1684535|NCT01583387|Other|1-Increased water intake regimen|Arm 1-Intervention
1684536|NCT01583387|Other|2-Non-modified water intake regimen|Arm 2-Control
1684537|NCT01583374|Drug|Apremilast tablet 20 mg|PDE4-specific inhibitor
1684538|NCT01583374|Drug|Apremilast tablet 30 mg BID|PDE4-specific inhibitor
1684539|NCT01583374|Drug|Placebo|PDE4-specific inhibitor
1684540|NCT01583361|Drug|Oxaliplatin+S-1|S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
1735812|NCT00068068|Procedure|Chemotherapy|
1684541|NCT01583361|Drug|Adjuvant Oxaliplatin/S-1（SOX）|S-1：40~60mg bid，d1~14 q3W oxaliplatin：130mg/m2，iv drip for 2h，d1,q3W 8 cycles (6 months)
1684542|NCT01583348|Procedure|Cholangiography during transvaginal rigid-hybdrid NOTES cholecystectomy|During transvaginal rigid-hybrid NOTES cholecystectomy a intraoperative cholangiography is performed. After dissection of the Calot's triangle and distal clipping of the cystic duct, the cystic duct is incised and a regular cholangiography catheter is inserted. Contrast is injected and an image is obtained using an image-converter. After extraction of the catheter the cystic duct is clipped proximally. This intervention is performed in all patients included in the study.
1684543|NCT01583335|Behavioral|Lifestyle habits, including sleep and stress|The intervention group was offered up to 10 individual consultations focusing on improving diet, physical activity and sleep habits and reducing stress. Moreover, the intervention group was offered participation in monthly cooking classes and playing arrangements
1684544|NCT01583322|Drug|vargatef|"400 mg (200 mg twice daily) Route of administration= oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).
Continuous daily dosing until progression of disease or until criteria for interruption of treatment are met, no intake of Vargatef® (Nintedanib) on days of paclitaxel and carboplatin administration. The maximum time on monotherapy is 2 years."
1684545|NCT01583322|Drug|placebo|"Contains 0 mg of Vargatef® (Nintedanib) in capsules matching 100 mg and 150 mg of Vargatef® (Nintedanib) Route of administration: oral Twice daily (to be swallowed unchewed with a glass of water of about 250 mL. If taken twice the dose interval should be of around 12 hours at the same times every day, usually in the morning and the evening after food intake).
Continuous daily dosing until progression of disease or until criteria for interruption of treatment is met, no intake of placebo on days of paclitaxel and carboplatin administration.
The maximum time on monotherapy is 2 years."
1684546|NCT01583309|Procedure|online pre-dilution hemofiltration|Online pre-dilution hemofiltration was performed with a synthetic high-flux membrane and an infusate/blood flow ratio of one
1684547|NCT01583309|Procedure|online pre-dilution hemodiafiltration|Online pre-dilution hemodiafiltration was performed with a synthetic high-flux membrane with an infusate/blood flow ratio of 0.6 and a dialysate plus infusate rate of 700 ml/min.
1684548|NCT01583296|Behavioral|Music Relaxation Therapy (MRT)|music relaxation therapy and breathing at resting respiration rate
1684549|NCT01583296|Behavioral|Cognitive Behavioral Therapy (CBT) and heart rate variability biofeedback|cognitive behavioral therapy and heart rate variability biofeedback
1684550|NCT01583283|Drug|ACY-1215|Dose escalation up to 480 mg administered orally on Days 1-5, 8-12 and 15-19 of a 28 day dosing schedule.
1684551|NCT01583283|Drug|lenalidomide|Dosed on Days 1-21 of a 28 day cycle.
1684552|NCT01583283|Drug|Dexamethasone|Dosed on Days 1, 8, 15 and 22 of a 28 day treatment cycle.
1684553|NCT01583270|Dietary Supplement|Arabinoxylan|Porridge rich in arabinoxylan
1684554|NCT01583270|Dietary Supplement|Rye kernel|Porridge made of rye kernels
1684555|NCT01583270|Dietary Supplement|Arabinoxylan and rye kernels|Porridgde made of rye kernels and arabinoxylan
1684556|NCT01583270|Dietary Supplement|Semolina|Semoline porridge. control meal.
1684557|NCT01583257|Behavioral|Workout based on active video gaming|A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program
1684558|NCT01583244|Drug|No Intervention (subjects were previously treated with Orencia®)|No Intervention
1684559|NCT01583231|Other|Prewash|The intervention will be the addition of the prewash utilizing non-antimicrobial soap and water.
1684560|NCT01583218|Drug|Betrixaban|"Betrixaban 80 mg PO once daily (QD) for 35 day + 7 days.
Enoxaparin Placebo: Once daily, 6-14 days"
1684561|NCT01583218|Drug|Enoxaparin|"Enoxaparin 40 mg subcutaneous (SC) QD for 10 ± 4 days.
Betrixaban Placebo: once daily, 35 days"
1684562|NCT01583205|Behavioral|Coping Effectiveness Training - ALS|Eight coping effectiveness training counseling sessions.
1684563|NCT01583192|Procedure|skin preparation|skin preparation while be done either with chloride-hexidine 0,5% soluted in alcohol 70% or povidine-jodine 1% soluted in alcohol 70%
1684564|NCT01583179|Drug|Buprenorphine|added to nerve block, 0.3mg one time peripheral block use
1684567|NCT01583153|Other|Hospital Inpatient Rehabilitation|Those allocated to HI will be admitted to the adjacent rehabilitation hospital, Braeside Rehabilitation Hospital, for 10 days. As per the private sector, HI participants will receive twice-daily supervised physiotherapy comprising 1-1.5 hr class-based exercises and 1-1.5 hr one-to-one therapy. Prior to discharge, participants will be familiarised with the home programme as described in second arm. All participants will be required to complete a diary detailing programme adherence, healthcare utilisation, and social costs relating to carer-burden. Participants will attend the group-based sessions as per HO below for monitoring and progression of programme. An additional FIM outcome measure will be taken for this arm on admission and discharge from the inpatient rehab unit.
1684568|NCT01583153|Other|Hybrid Home Programme (HO)|The HO will be based on what is standard care in the local health district and guidelines for exercise in the elderly and those with osteoarthritis. Approximately 2 weeks post-surgery, participants allocated to the HO will attend 1 group-based exercise session in the Physiotherapy Department (Fairfield Hospital) where the home programme will be rehearsed and exercises individualised as required due to co-morbidities. The programme comprises general aerobic components as well as general functional and muscle-specific exercises focused on restoring knee mobility, lower limb strength, and normal neuromuscular co-ordination and gait patterns. Participants will be able to return for 2-3 sessions over the 6-week period.
1684569|NCT01583140|Behavioral|Wellness control|Participants in the Wellness Control arm of the study receive a variety of print materials focused on general health topics.
1684570|NCT01583140|Behavioral|Physical Activity Intervention|Participants in the Physical Activity Intervention arm of the study receive culturally-modified, individually tailored physical activity print materials.
1684571|NCT01583127|Behavioral|Positive Behavioral Interventions & Supports|Implementation of the School-Wide Positive Behavioral Interventions and Supports model across 4 school years.
1686180|NCT01570894|Drug|Quetiapine Fumarate|25 mg tablet
1684572|NCT01583114|Drug|perindopril|form:1 tablet contained 5 mg of perindopril; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
1684573|NCT01583114|Drug|placebo|form:1 tablet contained 5 mg placebo; posology: 1 intake per day, initiated at a dose of 2.5 mg (1/2 tablet) per day during one week, then 5 mg (1 tablet) per day during two weeks, then 10 mg (2 tablets), or the maximal dose tolerated, until the end of the study (36 months).
1684574|NCT01583101|Other|Receiving Highlighted Prompts|Prompts received by physicians were highlighted.
1684575|NCT01583101|Other|Receiving Non-highlighted Prompts|Prompts received by physicians were not highlighted.
1684576|NCT01583088|Device|phenique nerve stimulation NeurX™ (Synapse Biomedical)|phenique nerve stimulation NeurX™ (Synapse Biomedical)
1684577|NCT01583088|Device|sham phrenic nerve stimulation|sham phenic nerve stimulation
1684578|NCT01583075|Procedure|Circumferential pulmonary vein ablation|Circumferential pulmonary vein ablation
1684579|NCT01583075|Procedure|single ring pulmonary vein ablation|single ring pulmonary vein ablation
1684580|NCT01583062|Drug|Amoxicillin/clavulanic acid|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 1 then receives amoxicillin/clavulanic acid 625 mg orally every eight hours for four days.
1684581|NCT01583062|Drug|Amoxicillin plus placebo|Both groups receive amoxicillin/clavulanic acid 1.2 g intravenously every eight hours from admission up to 24 hours postoperatively. Group 2 receives oral placebo using the same schedule for the same duration as group 1.
1684582|NCT01583036|Drug|Digoxin Alone|Single administration of digoxin 0.25mg
1684583|NCT01583036|Drug|Digoxin + Retigabine|Increasing doses of retigabine (300mg, 450mg, 600mg, 750mg, 900mg, 1050mg and 1200mg) administered as TID doses over 44 days. Co-administration with digoxin (0.25mg) on days 10, 24 and 38.
1684584|NCT01583023|Drug|Bupropion|150mg daily for first week, 300mg daily thereafter for a total of 8 weeks
1684585|NCT01583023|Device|Active Repetitive Transcranial Magnetic Stimulation|Daily left DLPFC, at 110% motor threshold, with a frequency of 10 Hz. Stimulation will be applied in 5-second trains with a 10-second inter-train interval, for 30 trains per session. This treatment will be provided for the first 4 weeks of the study.
1684586|NCT01583023|Other|Placebo|150mg daily first week, 300mg daily thereafter for a total of 8 weeks.
1684587|NCT01583023|Device|Sham repetitive transcranial magnetic stimulation|Sham rTMS will also begin their treatment 5 times a week for 4 weeks in junction with pharmacotherapy (Wellbutrin). Sham rTMS will be delivered at a frequency of 10 Hz and stimulation will be applied in 5-second trains with a 20-second inter-train interval, for 30 trains per session.
1684588|NCT01583010|Device|ANV(R)|"Device: Advanced Needle Visualization Technology ®
Software update for SonoSites M-Turbo® and S-series™ ultrasound systems with enhanced 15-20Mhz ultrasound probe.
Arms: ANV ® Group"
1684589|NCT01582997|Drug|GSK2118436|Dose escalation with GSK2118436 may proceed until the overseas recommended phase III dose.
1684590|NCT01582984|Other|video or education session in addition to standard consent|Video added to standard consent + handout Video + education session added to standard consent + handout
1684591|NCT01582971|Other|Reflexology|Friend/family member trained in foot reflexology protocol by certified reflexologist; friend/family member provides 4 weekly sessions to patient
1684592|NCT01582958|Procedure|Osteopathic Manipulative Treatment (OMT)|Osteopathic Manipulative Treatment (OMT) is the therapeutic application of manually guided forces by an Osteopathic physician to improve physiologic function.
1684593|NCT01582958|Other|sham omt|Hands are placed on subjects the same as omt arm but no omt is provided.
1684594|NCT01582945|Drug|Ketamine|Ketamine IV 0.5mg/kg infusion twice a week for 3 weeks as augmentation of ongoing antidepressant regimen
1684595|NCT01582932|Drug|Calcipotriene 0.005% Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face).
1684596|NCT01582919|Other|Neuroimaging|
1684597|NCT01582893|Device|HCO1100|Dialysis
1684598|NCT01582893|Device|P210H|Dialysis
1684599|NCT01582880|Drug|Riboflavin|Used to treat donor cornea before implantation
1684600|NCT01582867|Device|ARTIS hemodialysis system|"Software versions:
Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01"
1684601|NCT01582854|Drug|Actovegin|Actovegin solution for infusion and Actovegin tablets
1684602|NCT01582854|Drug|Placebo|Actovegin placebo-matching solution for infusion and Actovegin placebo-matching tablets
1684603|NCT01582841|Procedure|MSI screening test|All individuals in the intervention arm who consent to participate in the HNPCC screening will have their tumors evaluated for MSI.
1684604|NCT01582828|Procedure|Epicardial (surgical) ablation|"Pulmonary vein isolation with bipolar clamps and bipolar box lesion
Epicardial atrial appendage closure"
1684605|NCT01582828|Procedure|Hybrid|"Epicardial (surgical) ablation
Pulmonary vein isolation with bipolar clamps and bipolar box lesion
Epicardial atrial appendage closure
Endocardial assessment after 6-8 weeks, checking for isolation and if necessary touch up by RF ablation"
1684606|NCT01582815|Drug|JNJ-40411813|Type= range, unit= mg, number= 25 to 150, form= capsules, route= oral administration. JNJ-40411813 will be administered twice daily during 8 weeks, following fixed and flexible schedules in which the dose can range from 25 mg to 150 mg.
1684607|NCT01582815|Drug|Placebo|Form= capsule, route= oral administration. Matching placebo will be administered twice daily during 8 weeks.
1684608|NCT01582789|Device|enfilcon A|enfilcon A daily wear soft contact lens
1684609|NCT01582789|Device|senofilcon A|senofilcon A daily wear soft contact lens
1684610|NCT01582776|Drug|Lenalidomide and GA101|1000mg of GA101 on D8, D15 and D22of cycle 1 and on D1 of cycles 2 to 6. Oral lenalidomide once daily at 10/15/20/25mg (phase I part) or at recommended dose (phase II part) on days 1 to 21 of a 28-day cycle for the first cycle and on days 2 to 22 of a 28-day cycle for cycles 2 to 6.
1684611|NCT01582737|Drug|Rivaroxaban(Xarelto, BAY59-7939)|Patients treated with Xarelto under practical manner for SPAF.
1684612|NCT01582724|Procedure|Self-care acupressure at three predefined points|Self-care acupressure, one minute for each point, starting 5 days before menstruation, once up to twice daily; when pain is present: twice daily up to five times
1684614|NCT01582711|Behavioral|SMS reminders|Short Message Service (SMS) text reminders
1684615|NCT01582711|Drug|isoniazid and rifapentine|rifapentine (PRIFTIN, RPT) 900 mg and isoniazid (INH) 900mg, once-weekly, for 12 weeks (12 doses)
1684616|NCT01582698|Biological|FSME-IMMUN 0.5 ml|Solution/suspension for injection (intramuscular injection into the deltoid muscle of the right or left upper arm). Dosage frequency of booster vaccination: dependent on serum TBE antibodies.
1684617|NCT01582685|Behavioral|Exercise|The participant will exercise for 16 weeks under supervision. The exercise regimen is increased slowly over 16 weeks.
1684618|NCT01582672|Drug|Standard Treatment|Standard treatment for Renal Cell Carcinoma
1684619|NCT01582672|Biological|AGS-003|Autologous Dendritic Cell product. Intradermal injections; 8 injections in the 1st year followed by quarterly boosters.
1684620|NCT01582659|Other|Telephone counseling|2 planned telephone counseling sessions are conducted.
1684621|NCT01582659|Other|Web access|Access to a web site with information about childhood constipation similar to the information given at the first visit to the clinic.
1684622|NCT01582646|Drug|Terbutaline sustained release 5 mg|Terbutaline 10mg oral per day (5 mg twice a day) during 28 days
1684623|NCT01582633|Biological|2012 trivalent influenza vaccine|"2012 trivalent influenza vaccine:
influenza A/California/7/2009 (H1N1)
influenza A/Perth/16/2009 (H3N2)
influenza B/Brisbane/60/2008 Single dose."
1684624|NCT01582620|Procedure|Telestroke|remote videoconference consultations
1684625|NCT01582607|Drug|Bupivacaine plain|2.0 mL (10mg) plain bupivacaine hydrochloride 0.5% intrathecally
1684626|NCT01582607|Drug|Ropivacaine plain|2.0 ml (15mg) plain ropivacaine 0.75% intrathecally
1684627|NCT01582607|Drug|Levobupivacaine plain|2.0 ml (10mg) plain levo-bupivacaine hydrochloride 0.5% intrathecally
1684628|NCT01582607|Drug|bupivacaine plain +fentanyl|2.0 ml (10mg) plain bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
1684629|NCT01582607|Drug|ropivacaine plain +. fentanyl|2.0 ml (15mg) plain ropivacaine 0.75% with 0.2 ml (10 μg) fentanyl intrathecally
1684630|NCT01582607|Drug|Levobupivacaine plain +fentanyl|2.0 ml (10mg) plain levo-bupivacaine 0.5% with 0.2 ml (10 μg) fentanyl intrathecally
1684631|NCT01582581|Behavioral|Telephonic CBT|Cognitive behavioral therapy, guided by computer, using the TAD protocol for treatment of Adolescent Depression, modified for delivery by a nurse or master's level clinician over the telephone in 15-18 sessions lasting 30-45 minutes at weekly intervals. Includes regular and standardized weekly monitoring by the treating clinician of depressive symptoms and factors affecting suicide risk.
1684632|NCT01582581|Behavioral|Wait List Control|Wait list control with measurement of key outcomes at baseline (week 0), and then weeks 3 and 5.
1684633|NCT01582568|Drug|Certolizumab|Certolizumab 200mg-400mg subcutaneous every 2 weeks for 8 weeks.
1684634|NCT01582555|Drug|saline nasal irrigation alone|control arm (group A) of generic saline irrigation alone, irrigating with 20 mL per nostril tid for a total of 120 mL daily irrigation
1684635|NCT01582555|Drug|dissolved N-Acetylcystine|intervention arm (group B), which included generic N-Acetylcystine of 200 mg dissolved in 200 mL saline irrigated as per group A, 20 mL per nostril given tid daily (for a total of 120 mg).
1684636|NCT01582542|Drug|Desmopressin|"Patients after radical cystectomy with orthotopic bladder reconstruction that suffer from night time urinary incontinence will be enrolled in the study. They will be given for a period of one month after informed consent, Desmopressin At a dosage of 0.1 MG per day. The rate of improvement of night time urinary incontinence will be measured."
1684637|NCT01582516|Biological|delta-24-RGD adenovirus|slow continuous microinfusion in and around the brain tumor during 44 hrs.by 4 temporary placed catheters
1684638|NCT01582503|Drug|MEMP1972A|Subcutaneous repeating dose
1684639|NCT01582503|Drug|MEMP1972A|Subcutaneous repeating dose
1684640|NCT01582503|Drug|MEMP1972A|Subcutaneous repeating dose
1684641|NCT01582503|Drug|placebo|Subcutaneous repeating dose
1684642|NCT01582490|Drug|Instillation - EXPAREL|Intravenous (IV) morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
1684643|NCT01582490|Drug|Infiltration - EXPAREL|IV morphine sulfate, hydromorphone, or oral oxycodone with acetaminophen (5/325 mg) will be permitted following surgery, as needed.
1684644|NCT01582477|Drug|EXPAREL 20 mL|EXPAREL 266 mg (undiluted)
1684645|NCT01582477|Drug|EXPAREL 40 mL|EXPAREL 266 mg diluted with preservative-free 0.9% normal saline to 40 mL.
1684646|NCT01582464|Behavioral|Social Marketing for protective headgear|"Social marketing was done using a CQI manner after each focus group with experts and with seniors using a structured interview approach with an iterative process to develop a progressive method of presenting information about head injuries and their input on a new prevention.
To measure changes in attitudes, the participants were given an attitudes questionnaire (PHAQ), & a demographic & functional status questionnaire. Input into the social marketing content was sought in a structured interview manner, and by using an audience response system with questions projected by power point. At the conclusion of the social marketing, the PHAQ was repeated and sent to participants 2 weeks after the focus group to gage stability of changes in attitudes."
1684647|NCT01582451|Drug|LY2605541|Administered once daily at bedtime by SQ injection
1684648|NCT01582451|Drug|Insulin glargine|Administered once daily at bedtime by SQ injection
1684649|NCT01582438|Drug|Access program - sildenafil citrate, Viagra, Revatio|The recommended dose is 20 mg TID for subjects with body weight > 20 kg and 10 mg TID for subjects with body weight ≤ 20 kg. If subject is 18 years of age or older, the recommended dose is 20 mg TID, regardless of body weight. If a subject was receiving a higher dose in study A1481156 and the investigator believes that the subject requires continued treatment on that dose, or if dose reduction is judged to be associated with pulmonary arterial hypertension (PAH) deterioration in a particular subject, the higher dose may be made available, as judged on an individual basis on discussion with the sponsor.
1684650|NCT01582425|Drug|Isavuconazole|oral
1684651|NCT01582425|Drug|Methadone|oral
1684652|NCT01582412|Drug|Isavuconazole|oral
1684653|NCT01582412|Drug|digoxin|oral
1684654|NCT01582399|Drug|ASKP1240|intravenous(IV) infusion and subcutaneous (SC)
1684688|NCT01582126|Other|Group balance training|Balance training i group with focus on core stability exercises and dual attention activities.
1736658|NCT00082394|Drug|Combivir|
1684655|NCT01582373|Behavioral|Cognitive-behavioral couple therapy|The treatment package will include the following: information about the nature of CBCT; education about PVD and how it impacts on sexuality; education concerning a multifactorial view of pain; relaxation techniques; vaginal dilatation exercises; cognitive restructuring exercises (replacing distorted or irrational beliefs about pain and sexuality by more realistic ones); distraction techniques focusing on sexual imagery; expansion of the sexual repertoire; and exercises to improve pain and sexuality-relevant couple interactions (e.g., communication skills training, modification of maladaptive partner responses to pain, emotional disclosure and validation exercises).
1684656|NCT01582347|Drug|RBP-6300|"Participants randomized to the RBP-6300 treatment arm take either 10, 20 or 30 mg/day RBP-6300 tablets during the Transfer Period (study days 1-7).
Oral RBP-6300 tablets containing 10 mg buprenorphine hemiadipate HCl and 10 mg naloxone HCl dehydrate."
1684657|NCT01582347|Drug|Subutex®/Suboxone®|"Participants randomized to the Subutex®/Suboxone® treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In, Transfer, and Transition Periods.
Participants randomized to the RBP-6300 treatment arm take the dosage of either drug on which they were previously stabilised during the Run-In and Transition Periods.
Sublingual Subutex® tablets containing 8 mg buprenorphine and and sublingual Suboxone® tablets containing 8 mg buprenorphine and 2 mg naloxone."
1684658|NCT01582347|Drug|Placebo for RBP-6300|"Participants randomized to the Subutex®/Suboxone® treatment arm take Placebo for RBP-6300 during the Transfer and Transition Periods.
Participants randomized to the RBP-6300 treatment arm take Placebo for RBP-6300 during the Transition Period."
1684659|NCT01582347|Drug|Placebo for Subutex®/Suboxone®|Participants randomized to the RBP-6300 treatment arm take Placebo for Subutex®/Suboxone® during the Transfer Period.
1684660|NCT01582334|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
1684661|NCT01582321|Biological|Typhoid vaccine|The typhoid vaccine is composed of purified polysaccharide from S. typhi capsule 25 micrograms contained in 0.5 ml solution
1684662|NCT01582321|Drug|Cantharidin|0.1% cantharidin solution in acetone from 0.7% stock solution of cantharone is prepared and applied immediately. 10 μl of cantharidin per disc.
1684663|NCT01582308|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg: one sitagliptin 100 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
1684664|NCT01582308|Drug|Saxagliptin 5 mg|Saxagliptin 5 mg: one saxagliptin 5 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
1684665|NCT01582308|Drug|Vildagliptin 50 mg|Vildagliptin 50 mg: one vildagliptin 50 mg tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
1684666|NCT01582308|Drug|Vildagliptin 50 mg BID|Vildagliptin 50 mg BID: one vildagliptin 50 mg tablet BID (twice daily), once in the morning following a fast of at least approximately 8 hours and once in the evening on Days 1 through 5 in one out of five treatment periods.
1684667|NCT01582308|Drug|Placebo|Placebo: one placebo for sitagliptin tablet once daily in the morning following a fast of at least approximately 8 hours on Days 1 through 5 in one out of five treatment periods.
1684668|NCT01582295|Drug|Cabozantinib|Starting dose 40 mg daily
1684669|NCT01582282|Dietary Supplement|placebo|fiber-free placebo
1684670|NCT01582282|Dietary Supplement|3.4 g psyllium BID|3.4 g psyllium BID for a total of 6.8 g/day (10.4g Metamucil)
1684671|NCT01582282|Dietary Supplement|6.8g psyllium BID|6.8g psyllium BID for a total of 13.6 g/day (20.8g Metamucil)
1684672|NCT01582269|Drug|LY2157299 monohydrate|Orally administered as tablets
1684673|NCT01582269|Drug|Lomustine|Orally administered as capsules
1684674|NCT01582269|Drug|Placebo|Orally administered as tablets
1684675|NCT01582243|Drug|Vildagliptin|Vildagliptin 50 mg plus metformin 500 mg as Single Pill combination (SPC)
1684676|NCT01582230|Drug|Vildagliptin|Patient will receive vildagliptin 50mg twice daily (bid) in addition to their stable dose of insulin with or without metformin for 24 weeks
1684677|NCT01582230|Drug|Placebo|Patient will receive matching placebo to vildagliptin in addition to their stable dose of insulin with or without metformin for 24 weeks
1684678|NCT01582204|Drug|124IcG250|Pts will undergo baseline disease assessment with CT scans (chest, abd & pelvis), 124I-cG250-PET/CT & Tc99mMDP bone scan. W/I 7 days of their lst 124I-cG250 PET/CT, pts will start tx with sunitinib or pazopanib, dosed in successive 6-week cycles. At selected time points during the sunitinib or pazopanib cycle 1, repeat imaging with CT scan & 124I-cG250 PET/CT will be performed. After cycle 2, pts will be followed per standard of care, i.e., pts will have a standard CT scan of the chest, abd, & pelvis with contrast after cycles 2, 3, 4 & 6 (or at the time of disease progression if prior to cycle 6) for determination of best response using RECIST 1.1. Each pt will have 2 124I-cG250-PET/CT scans: baseline & week 4 (during sunitinib or pazopanib tx). All experimental imaging will take place during tx cycle 1. There will be a dosimetry sub-study for pts willing to undergo 3 additional PET/CT scans, whole body counts, & serial blood sampling, following the lst inj of 124I-cG250.
1684679|NCT01582191|Drug|Vandetanib|Starting Dose: 100 mg by mouth daily in a 28 day cycle.
1684680|NCT01582191|Drug|Everolimus|Starting dose: 2.5 mg by mouth daily of a 28 day cycle.
1684681|NCT01582178|Procedure|Warm Water Immersion Colonoscopy|Colonoscopy using warm water (37°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
1684682|NCT01582178|Procedure|Cool Water Immersion Colonoscopy|Colonoscopy using room temperature water (20-24°C) infusion for colonoscope insertion and room air insufflation during colonoscope withdrawal.
1684683|NCT01582165|Drug|Rosuvastatin|Rosuvastatin 20 mg once daily vs placebo for 6 months
1684684|NCT01582165|Drug|Placebo.|Placebo once daily vs rosuvastatin for 6 months
1684687|NCT01582139|Device|Heart rate informed SSM+HMM|The Safety Supervision Module + Hyperglycemic Mitigation Module (SSM+HMM) of the Closed Loop is informed about heart rate during exercise. The goal is to demonstrate the feasibility of a modular insulin management system based on continuous glucose monitoring that additionally employs heart rate information to reduce exercise-related hypoglycemic episodes.
1684689|NCT01582113|Drug|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 500 mg or 250 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
1684690|NCT01582113|Other|Microcrystalline Cellulose|Microcrystalline Cellulose will be the placebo administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
1684691|NCT01582100|Device|Reletex|Neuromodulation device worn on the wrist
1684692|NCT01582061|Drug|Pasireotide sub-cutaneous formulation|Pasireotide will be administered twice a day until pasireotide is approved and reimbursed for commercial use in each respective country or until 31DEC15, whichever comes first
1684693|NCT01582048|Drug|immunosuppression|Conditioning with treosulfan 14 g/m2 day -6 to -4, fludarabine 30 mg/m2/24h day-6 to -2, ATG-Fresenius 20 mg/kg day -4 to -2, rituximab 500 mg/m2 day -1. Unmanipulated PBSC day 0. Postgrafting immunosuppression with mycophenolate mofetil (15 mg/kg TID) and sirolimus (2 mg QD).
1684694|NCT01582035|Drug|TMC647055|type=exact number, unit=mg, number=500, form=solution, route=oral use. Panel 1: TMC647055 is to be taken twice daily at a dose of 500 mg per day for 10 days.
1684695|NCT01582035|Drug|TMC647055|type=exact number, unit= mg, number=up to macimum 1000, form=solution, route=oral use. Panel 2: TMC647055 is to be taken twice daily at a maximum dose of 1000 mg for 10 or 14 days.
1684696|NCT01582035|Drug|TVR|type=exact number, unit= mg, number=1125, form=tablet, route=oral use. TVR is to be taken twice daily at a dose of 1125 mg for 10 days.
1684697|NCT01582035|Drug|TVR|type=exact number, unit=mg, number=1125 or 1500, form=tablet, route=oral use. In panel 2: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 10 or 14 days. In panel 3: TVR is to be taken twice daily at a dose of 1125 or 1500 mg for 6 days with on day 6 a morning dose only.
1684698|NCT01582035|Drug|TVR|type= exact number, unit= mg, number=750, form=tablet, route=oral use. TVR is to be taken every 8 hours at a dose of 750 mg for 12 weeks.
1684699|NCT01582035|Drug|PegFN|type= exact number, unit= mcg, number=180, form=solution, route=subcutaneous. PegIFN is to be injected once per week for 24 or 48 weeks.
1684700|NCT01582035|Drug|RBV|type=exact number, unit=mg, number=1000 or 1200, form=tablet, route=oral use. RBV is to be taken at 1000 or 1200 mg per day in 2 divided doses, depending on the weight for 24 or 48 weeks.
1684701|NCT01582022|Drug|Bupivacaine|local application for 5 minutes
1684702|NCT01582022|Drug|normal saline|local application for 5 minutes
1684703|NCT01582009|Drug|panobinostat|Given orally
1684704|NCT01582009|Drug|everolimus|Given orally
1684705|NCT01582009|Other|laboratory biomarker analysis|Correlative studies
1684706|NCT01582009|Other|pharmacological study|Correlative studies
1684707|NCT01582009|Other|liquid chromatography|Correlative studies
1684708|NCT01582009|Other|mass spectrometry|Correlative studies
1684709|NCT01582009|Other|enzyme-linked immunosorbent assay|Correlative studies
1684710|NCT01582009|Other|immunohistochemistry staining method|Correlative studies
1684711|NCT01581996|Drug|lanthanum carbonate|All patients will receive the following doses of lanthanum carbonate in random order for 10 -12 days each. O mg, 500 mg tid, 1000 mg tid, 1500 mg tid.
1684712|NCT01581983|Behavioral|Internet Mindfulness Meditation|one hour session each week for six weeks
1684713|NCT01581983|Behavioral|Individual Mindfulness Meditation|one hour session each week for six weeks
1684714|NCT01581970|Drug|Cyclophosphamide|Patients will be given oral cyclophosphamide 50 mg twice daily to be self-administered starting the first day of therapy with weekly cetuximab for 12 weeks or until disease progression.
1684715|NCT01581970|Drug|Cetuximab|The initial dose of cetuximab 400 mg/m^2 is administered over 120 minutes followed by weekly infusions of cetuximab 250 mg/m^2 intravenously (IV) over 60 minutes.
1684716|NCT01581957|Other|Specific Enteral Nutrition|Patients will receive a Specific EN. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
1684717|NCT01581957|Other|Standard Enteral Nutrition|Patients will receive an equivalent volume and caloric intake of standard formulation. The caloric target is 25 Kcal/kg/day to be reached on the third day post-initiation of EN (early enteral nutrition).
1684718|NCT01581944|Drug|2 Doses Goserelin|3.6mg administered monthly for 2 months prior to myomectomy
1684719|NCT01581944|Drug|3 Doses Goserelin|3.6mg administered monthly for 3 months prior to myomectomy
1684720|NCT01581931|Drug|Linagliptin/metformin|FDC
1684721|NCT01581931|Drug|Metformin|single tablet Metformin
1684722|NCT01581931|Drug|Linagliptin|single tablet Linagliptin
1684723|NCT01581918|Drug|Carbamazepine|Patients will receive Carbamazepine in first chemotherapy cycle as planned: - One tablet (200mg) at night on third day before chemotherapy; - One tablet (200mg) every 12 hours on second day before chemotherapy; - One tablet (200mg) every 8 hours from the day before until fifth day after chemotherapy.
1684724|NCT01581905|Procedure|Conventional Laparoscopic Hysterectomy (LH)|Patients assigned to this intervention will undergo conventional laparoscopic hysterectomy, either total or supracervical.
1684725|NCT01581905|Procedure|Robot Assisted Hysterectomy|Patients assigned to this group will undergo Robot-Assisted Laparoscopic Hysterectomy, either total or supracervical.
1684726|NCT01581892|Procedure|Osteosynthesis|To mix the cell suspension with osteogenic matrix and to use sheet and nails in order to consolidate the fracture
1684727|NCT01581879|Drug|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
1684728|NCT01581866|Drug|Ziprasidone Hydrochloride|Ziprasidone HCL Capsules, 20 mg
1684729|NCT01581853|Drug|Lopinavir/ritonavir 800 mg / 200mg|Lopinavir/ritonavir 800 mg / 200mg will be change from its approved posology (2 times daily)to once daily in patients with undetectable viral load and in stable treatment with Lopinavir/ritonavir 800 mg / 200mg in monotherapy for at least 6 months
1684730|NCT01581840|Drug|radiochemotherapy|Radiotherapy : PTV1 45 Gy 5 weeks PTV2 20 Gy 2 weeks Chemotherapy : 5Fu (400 to 1000 mg/m²) mitomycin : 10 mg/m²
1684731|NCT01581840|Drug|Panitumumab|3 or 6 mg/kg (according to dose level)
1684732|NCT01581814|Drug|Metformin|500 mg of Metformin per 3/die
1684733|NCT01581814|Drug|Yasmin;|1pill/day for cycles of 28 days (21 pills followed by 7 no-pill days)
1684734|NCT01581814|Drug|Metformin plus Yasmin|0.03 mg EE plus 3 mg of DRPS combined with 500 mg of metformin three times daily
1684735|NCT01581801|Procedure|Gastric Bypass|"Roux-en-Y Gastric Bypass This laparoscopic operation includes the division of the stomach in two parts. A proximal, smaller pouch (20-25 cc volume), is connected to the rest of the gastrointestinal tract through a gastro-jejunal anastomosis, whereas the distal gastric pouch is left behind but excluded from the transit of food.
An entero-entero anastomosis, with a Roux-en-Y type of reconstruction, allows the bile and pancreatic juices to mix with the nutrients at about 100-150 cm from the gastro-jejunal connection."
1684736|NCT01581801|Procedure|Sleeve Gastrectomy|Sleeve gastrectomy Laparoscopic SG involves a longitudinal resection of the stomach on the greater curvature from the antrum starting opposite of the nerve of Latarjet up to the angle of His The final gastric volume is about 100 mL.
1684737|NCT01581788|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
1684738|NCT01581775|Drug|Divalproex Sodium|Divalproex Sodium ER Tablets, 500 mg
1684739|NCT01581762|Procedure|EUS-guided FNA|EUS-guided FNA with two types of needles - conventional 22G needle (Sham control) and Procore needle (active comparator)
1684740|NCT01581749|Radiation|"TrueBeam stereotactic body radiosurgery"|36.25Gy to be delivered to the prostate in 5 fractions. There is only 1 arm in this study.
1684741|NCT01581736|Drug|U100 Humulin|Infused at a rate of 80/mU/m2 surface area per minute one time over 2 hours
1684742|NCT01581736|Other|Exercise|Single episode of exercise riding a stationary bike.
1684743|NCT01581723|Device|Monopolar diathermy|monopolar diathermy
1684744|NCT01581723|Device|Bipolar diathermy|bipolar diathermy
1684747|NCT01581697|Dietary Supplement|Oat bran|
1684748|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
1684749|NCT01581684|Drug|Placebo|Solution for oral administration
1684750|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
1684751|NCT01581684|Drug|BI 411034|Low dose solution for oral administration
1684752|NCT01581684|Drug|BI 411034|High dose solution for oral administration
1684753|NCT01581684|Drug|BI 411034|High dose solution for oral administration
1684754|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
1684755|NCT01581684|Drug|BI 411034|High dose solution for oral administration
1684756|NCT01581684|Drug|BI 411034|Medium dose solution for oral administration
1684757|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
1684758|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
1684759|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
1684760|NCT01581658|Drug|BI10773|BI10773 medium dose tablet single dose
1684761|NCT01581645|Device|Mobilaser|Patients will begin by collecting data at home without using the mobilaser. They will then be given the mobilaser to use at home for 6 weeks while they collect data on whether their gait has improved. They will then have to return the Mobilaser to the clinic and collect data at home for 3 days to see if there is a difference.
1684762|NCT01581632|Device|LipiScan/LipiScan IVUS|Evaluation of the coronary artery using near infrared spectroscopy using either a LipiScan catheter or a LipiScan/IVUS catheter following a clinically indicated coronary angiogram and endothelial function testing with a positive diagnosis of endothelial dysfunction. The procedure is repeated following 6 months of Lp-PLA2 inhibition.
1684763|NCT01581619|Radiation|External Beam Partial-Breast Irradiation|40 Gy in ten daily fractions over two weeks
1684765|NCT01581580|Procedure|Deep Brain Stimulation|
1684766|NCT01581541|Drug|PU-H71|PU-H71 is a synthetic HSP90 inhibitor which can bind both open and closed conformations of HSP90. It demonstrates extended tumor retention and client protein degradation, while being rapidly cleared from normal tissues. It has shown complete tumor responses and retained sensitivity to retreatment in vivo.
1684767|NCT01581528|Genetic|gene expression analysis|
1684768|NCT01581528|Other|cell culture procedure|
1684769|NCT01581528|Other|flow cytometry|
1684770|NCT01581528|Other|laboratory biomarker analysis|
1684771|NCT01581528|Other|metabolic assessment|
1684772|NCT01581515|Device|Promus Element everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
1684773|NCT01581515|Device|Xience Prime everolimus eluting coronary stent|Patients with native coronary arteries fulfilling all enrollment criteria will be randomly assigned to each DES group; either Promus Element or Xience Prime
1684774|NCT01581502|Other|This is an observational study.|This is an observational, not intervention, study.
1684775|NCT01581489|Procedure|Time to clamping of the umbilical cord after delivery|The time after delivery of the newborn until the midwife stops the circulation in the umbilical cord with a clamp.
1684776|NCT01581476|Drug|Statin|10mg daily for a minimum period of 2 years
1684777|NCT01581476|Drug|Ace Inhibitor|Starting dose of 5mg daily rising after 14 days to 10mg daily providing it is well tolerated for a minimum period of 2 years.
1684778|NCT01581476|Drug|Placebo|Participants receive statin placebo and ACEI placebo
1684779|NCT01581476|Drug|Combination therapy|Participants receive both active statin and active ACEI. Dose for Statins is 10mg daily. Dosing for ACEI starts at 5mg daily rising to 10mg after 14 days providing it is well tolerated. Both interventions last for a minimum of 2 years.
1684780|NCT01581463|Drug|Liothyronine, Sodium|Single 100-microgram (2 X 50 microgram) dose.
1684781|NCT01581450|Drug|Nitrous Oxide|35%
1684782|NCT01581450|Drug|Nitrous Oxide|50%
1684783|NCT01581437|Procedure|64 pole basket catheter|The 64 pole basket catheter expands into a small flexible balloon that conforms to the atrial anatomy.
1684789|NCT01581372|Other|Pharmacist care|Pharmacist prescribing, education, drug management
1684790|NCT01581359|Drug|Triptorelin acetate|"Triptorelin acetate Dosing regimen: 1 subcutaneous injection of 3,75 mg/28 days, total of 3 doses
Placebo Dosing regimen: subcutaneous injection of the same volume of physiological serum/28 days, total of 3 doses"
1684791|NCT01581346|Other|Exercise intervention|Pts were instructed to train at least 5 times/ week in the inpatient setting. After discharge pts were instructed to train in a home-based setting at least 3 times/week for a period of 8 weeks.
1684794|NCT01581320|Drug|Test group|Once a month, administration of DP-R206 & placebo for 16 weeks
1684795|NCT01581320|Drug|Reference group|Once a month, administration of Bonviva & placebo for 16 weeks
1684796|NCT01581307|Drug|FOLFOX7 (Folinic acid, 5-Fluorouracil, and Oxaliplatin)|The usual treatment if gemcitabine chemotherapy has failed is chemotherapy with a drug combination called FOLFOX (folinic acid, 5-FU and oxaliplatin) given through a vein every 2 weeks for 6-10 cycles. Participants will receive this treatment.
1684797|NCT01581307|Device|TheraSpheres|TheraSpheres are a medical device containing yttrium-90 (Y-90), a radioactive material that has been used previously in the treatment of liver tumors. Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver. TheraSpheres have restricted approval from the United States Food and Drug Administration (FDA) for the treatment of hepatocellular liver cancer; but has not yet been approved for the treatment of pancreatic cancer that has spread to the liver.
1684798|NCT01581281|Drug|Amitriptyline|Amitriptyline will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. The morning dose is a placebo pill. Dosing of amitriptyline will be weight-based.
1684799|NCT01581281|Drug|Topiramate|Topiramate will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance phase of the highest tolerated dose. Dosing of topiramate will be weight-based.
1684800|NCT01581281|Drug|Placebo|Placebo will be administered twice daily at home during the 8-week titration period followed by a 16 week maintenance period.
1684801|NCT01581242|Drug|Clevudine, Adefovir dipivoxil , Clevudine+Adefovir dipivoxil|Clevudine 20mg qd Days 1; Adefovir dipivoxil 10 mg qd Days 8;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 15
1684802|NCT01581242|Drug|Clevudine; Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 1; Clevudine 20mg qd Days 8; Adefovir dipivoxil 10 mg qd Days 15;
1684803|NCT01581242|Drug|Clevudine,Adefovir dipivoxil ,Clevudine +Adefovir dipivoxil|Adefovir dipivoxil 10 mg qd Days 1;Clevudine 20mg +Adefovir dipivoxil 10mg qd Days 8; Clevudine 20mg qd Days 15
1684804|NCT01581229|Procedure|noninvasive positive pressure ventilation|Patients in the NPPV group are ventilated using the CPAP or bilevel positive airways pressure S/T mode.
1684805|NCT01581229|Procedure|oxygen therapy|In the control group, Venturi masks are used to maintain SpO2 at 92% to 96% by adjusting the oxygen flow rates.
1684806|NCT01581216|Other|10 minute walk|Patients who walk a distance ≤ 300 meters in the 6-minute walk test will make a 10 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
1684807|NCT01581216|Other|20 minute walk|Patients who walk 300-450 meters in the 6-minute walk test will make a 20 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
1684808|NCT01581216|Other|30 minute walk|Patients who walk a distance less than 450 meters in the 6-minute walk test will make a 30 minute walk once a day for 5 days for 4 weeks in a 90-feet long corridor located at the palliative care unit.
1684809|NCT01581203|Drug|Asunaprevir (ASV)|
1684810|NCT01581203|Drug|Daclatasvir (DCV)|
1684811|NCT01581203|Drug|Pegylated-interferon alfa 2a (PegIFN)|
1684812|NCT01581203|Drug|Ribavirin (RBV)|
1684813|NCT01581190|Dietary Supplement|Bananas versus 6% carbohydrate beverage|Trained cyclists (N=14) completed two 75-km cycling time trials (randomized, crossover) while ingesting BAN or CHO (0.2 g/kg carbohydrate every 15 min).
1684814|NCT01581177|Drug|Albuterol DPI 25 mcg/inh|Albuterol DPI with 25 mcg Albuterol/inhalation
1684815|NCT01581177|Drug|Albuterol DPI 90 mcg/inh|Albuterol DPI with 90 mcg Albuterol/inhalation
1684816|NCT01581177|Drug|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
1684817|NCT01581177|Drug|Albuterol MDI 90 mcg/inh|Albuterol MDI with 90 mcg Albtuerol/inhalation
1684818|NCT01581164|Biological|Influenza vaccine|Influenza vaccine: Injection, post transplant
1684819|NCT01581164|Biological|Varicella vaccine|Varicella vaccine: Injection, post transplant
1684820|NCT01581151|Drug|Dexamethasone intravitreal implant|Patients will receive a Dexamethasone implant and ranibizumab, as needed. A comparison will be made between ranibizumab and Dexamethasone implant with rescue ranibizumab.
1684821|NCT01581151|Drug|Monthly Ranibizumab|30 days between treatments
1684822|NCT01581138|Drug|VX-222|400 mg tablets twice daily for oral administration
1684823|NCT01581138|Drug|telaprevir|1125 mg tablets twice daily for oral administration
1684824|NCT01581138|Drug|ribavirin|1000 mg per day for subjects weighing <75 kg and 1200 mg per day for subjects weighing ≥75 kg, dosed twice daily
1684825|NCT01581125|Behavioral|Sleep:wake 1|Sleep and Wake durations for arm 1
1684826|NCT01581125|Behavioral|Sleep:wake 2|Sleep and Wake durations for arm2
1684827|NCT01581112|Biological|Microbial transplant|Every subjects has 2 armpits and 2 feet. One armpit/foot is treated, the other is not treated.
1684828|NCT01581099|Procedure|Digestive Adaptations III surgery|
1684829|NCT01581073|Drug|Darbepoetin alfa|Darbepoetin alfa is used for targeting Hb level of 11-13g/dL in high Hb group, and 9-11g/dL in low Hb group.
1684830|NCT01581060|Drug|WX-554|Capsules of WX-554
1684898|NCT01580488|Drug|B LEO 35299 20 mg/g cream|once daily application, 3 weeks
1686248|NCT01570348|Drug|Tacrolimus|Given IV or PO
1684831|NCT01581034|Drug|PADMA 28|PADMA 28 is a biological drug registered in Switzerland. It contains 20 herbs from Tibet. 3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of PADMA 28 or placebo will be taken. One capsule contains 403mg.
1684832|NCT01581034|Drug|Placebo|3 times 2 capsules per day (30min to 1h before breakfast, lunch and dinner) of placebo will be taken. One capsule contains 403mg.
1684833|NCT01581021|Device|Pedicle screws|Screws that are placed into the pedicle of vertebral body.
1684834|NCT01581021|Device|Laminar Hooks|Hooks are placed over the lamina of the vertebral body
1684835|NCT01581008|Other|Collaborative Care to Alleviate Symptoms and Adjust to Illness|A palliative symptom management and psychosocial care intervention named Collaborative Care to Alleviate Symptoms and Adjust to Illness (CASA) that includes (a) evidence-based palliative symptom management of breathlessness, fatigue, and pain, provided by a nurse; (b) a 6-session structured psychosocial care protocol targeting depression and adjustment to illness, supplemented by informal (family) caregiver assessment and support, provided by a social worker or psychologist; and (c) brief weekly team meetings with the nurse, social worker/psychologist and a palliative care specialist, cardiologist, and primary care provider.
1684836|NCT01581008|Behavioral|Psychospiritual|A psychospiritual intervention that is home-based, self-guided, and requires minimal resources. It will be delivered in written modular form via US Mail along with brief weekly telephone support.
1684837|NCT01580995|Drug|Valacyclovir|Valacyclovir 500 mg po bid
1684838|NCT01580995|Drug|Placebo|Placebo tablet twice daily
1684839|NCT01580969|Drug|Bevacizumab|This is an open-label, multi-agent design. Bevacizumab will be administered in accordance with the FDA-approved dose for gliomas, 10mg/kg IV every 2 weeks. Bevacizumab will be continued every two weeks as long as tolerated. One cycle of bevacizumab will be 28 days, with treatments on day1 and day 15. Blood pressure, CBC, CMP, and urine protein level, either by UA or urine protein/creatinine ratio will be checked at the beginning of each cycle.
1684840|NCT01580969|Drug|Minocycline|Minocycline will be given by mouth twice a day starting at about half of the monotherapy maximal tolerated dose, 100 mg PO BID. Minocycline will be started on the day prior to radiation and continued until progression or intolerance. During the combined radiation, minocycline, and bevacizumab treatment, patients will be seen weekly with a CBC, CMP, and adverse event monitoring.
1684841|NCT01580969|Radiation|Radiation|Radiation planning will be individualized by the radiation oncologist based on the location of the current radiation field relative to prior radiation doses. The length and fractionation will be determined individually by the radiation oncologist.
1684842|NCT01580956|Other|VARIABLE-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
1684843|NCT01580956|Other|STANDARD-PSV ventilatory mode|The two ventilatory modes will be studied during 24h in intubated patients in random order.
1684844|NCT01580943|Drug|Chlorhexidine|Over a 72-h experimental non-brushing period, subjects abstained from all forms of mechanical oral hygiene and one group (test) used an 0.12% CHX mouthrinse with 0.05% CPC (Perioaid®), twice daily for 30 seconds and the other group (positive control) used a 0.2% CHX mouthrinse alcohol free (Corsodyl® Care), twice daily for 60 seconds. These regimens are suggested by the manufacturers in the instructions
1684845|NCT01580943|Drug|Chlorhexidine|"All subjects received a questionnaire using a visual analogue scale designed to evaluate their taste to the mouthrinse, which they had used (What is your opinion concerning the taste of the mouth rinse?). Subjects marked a point on a 10 cm long uncalibrated line with the negative extreme response (0) on the left and the positive extreme (10) at the right end. Then, they were also asked about side effects in an open answer (Did you feel any side effects caused by mouth rinse?, If so, what are they?)."
1684846|NCT01580930|Behavioral|exercise training|12 weeks, 5 days of week, 40 min per session of exercise training
1684847|NCT01580930|Behavioral|sedentary time reduction|participants provided with strategies to decrease sitting
1684848|NCT01580930|Behavioral|exercsie training plus sedentary time reduction|12 weeks of exercise training (5 days a week, 40 min per session) plus given strategies for reducing sitting time
1684849|NCT01580904|Behavioral|Intervention: Pharmaceutical Care|Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
1684850|NCT01580891|Drug|Naftifine HCl Cream 1%|Naftifine HCl Cream 1% applied topically once a day for 28 days.
1684851|NCT01580891|Drug|Naftin® (Naftifine HCl) Cream 1%|Naftin® (Naftifine HCl) Cream 1% applied topically once a day for 28 days.
1684852|NCT01580891|Drug|Placebo topical cream|Placebo topical cream applied topically once a day for 28 days.
1684853|NCT01580878|Drug|Butenafine Hydrochloride Cream, 1%|Butenafine Hydrochloride Cream, 1% applied twice daily for 7 consecutive days
1684854|NCT01580878|Drug|Lotrimin Ultra®|Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) applied twice daily for 7 consecutive days.
1684855|NCT01580878|Drug|Butenafine Vehicle|Butenafine Vehicle applied twice daily for 7 consecutive days.
1684856|NCT01580865|Drug|Tacrolimus vs. Mycophenolate mofetil for Induction Therapy in Lupus Nephritis|"Tacrolimus will be started in 45 patients at a dosage of 0.05 mg/kg/d divided into 2 daily doses at 12-hour intervals, and the dosage will be titrated to achieve 12-hour trough blood concentrations of 10-20 ng/mL in the first and second month and then 6-8 ng/mL thereafter.
MMF will be initiated in 45 patients at a dose of 750 mg twice daily (for patients > 50 Kg and eGFR > 60 ml/min), and advanced weekly to a maximum dose of 1,000 mg two times daily to achieve or MPA trough level > 3 mg/dL.
All patients will be received concomitant prednisone at a dose of 1 mg/kg/d (maximum 60 mg/d), with tapering by 5 mg/d every 2 weeks until a dose of 5 mg/d has been achieved, and this dosage will be maintained to the end of 24 weeks."
1684857|NCT01580852|Procedure|Dead Sea water|Subjects will immerse in mineral (dead sea) waters for twenty minutes twice daily for a period of 10 days
1684858|NCT01580852|Procedure|Pool water|Subjects will immerse in sweet(pool)waters for twenty minutes twice daily for a period of 10 days
1684859|NCT01580839|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
1684860|NCT01580839|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
1684861|NCT01580826|Other|pasteurization of mother's own milk|mother's milk heat treated at 62,5°C for 30 minutes with a Sterifeed® S75 TES pasteurizer.
1684899|NCT01580488|Drug|C LEO 35299 20 mg/g cream|once daily application, 3 weeks
1684862|NCT01580813|Drug|Acipimox|Subjects will take acipimox 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
1684863|NCT01580813|Drug|Placebo|Subjects will take a placebo pill 250mg (randomized and double-blinded) by mouth four times a day for six days prior to the visit and one dose the morning of study visit.
1684866|NCT01580761|Behavioral|Sleep restriction|14 days of sleep restriction, 4 hours of sleep per day.
1684867|NCT01580748|Drug|Roflumilast|500 microgram once daily for 16 weeks
1684868|NCT01580735|Drug|ARQ 197|"ARQ 197:360 mg bid (CYP2C19 EM) or 240mg bid (CYP2C19 PM)
erlotinib: 150 mg qd"
1684869|NCT01580722|Procedure|early reconstruction|patients underwent < 8 weeks reconstruction after injury
1684870|NCT01580722|Procedure|delay reconstruction|patients underwent > 8 weeks reconstruction after injury
1684871|NCT01580709|Procedure|Multiple brushings|Seven consecutive brush samples for cytology.
1684872|NCT01580709|Procedure|Multimodality tissue sampling|Single brush for cytology + single brush for FISH + cholangioscopy with site-directed biopsies
1684873|NCT01580696|Biological|E39 peptide vaccine|100mcg, 500mcg and 1,000mcg of lyophilized E39 peptide is suspended in bacteriostatic water for injection in individual cryovials and frozen. At the time of vaccine administration, the suspended peptide is thawed and mixed thoroughly with 250mcg GM-CSF in the syringe. This constitutes the E39 vaccine.
1684874|NCT01580696|Other|Clinical tracking for disease progression/recurrence|HLA-A2-negative patients or HLA-A2-positive patients who decline the vaccine will be followed clinically as matched controls for disease recurrence/progression. No experimental treatment will be administered to this group.
1684875|NCT01580683|Drug|Ascorbic Acid|Two 1 g capsules the evening prior to surgery, followed by one 1 g capsule every 12 hours starting the morning of the first postoperative day for 5 days.
1684876|NCT01580683|Other|Identical Placebo|Two capsules the evening prior to surgery, followed by one capsule every 12 hours starting the morning of the first postoperative day for 5 days.
1684877|NCT01580670|Drug|TA-650|TA-650 will be intravenously infused at 5 mg/kg as an induction regimen at Weeks 0, 2, 6. For subjects who meet the responder criteria, TA-650 will be administered at 8-week intervals thereafter until week 46. If the criteria for a dosage escalation are met, TA-650 will be administered at a dosage of 10 mg/kg.
1684878|NCT01580657|Behavioral|Detailed baseline interview, enhanced HIV intervention|Participants in this group will receive a detailed sexual behavior interview, similar to measures used in major intervention trials. This measure will identify the instances in which participants engaged in sexual behaviors with specific partners during a 90 day retrospective reporting period. Participants will then complete an empirically validated 60-minute session HIV-risk reduction intervention (Simbayi, Kalichman, Skinner et al., 2004) consisting of exercises to increase HIV/AIDS knowledge, motivation to reduce risk, behavior self-management skills, and sexual communication skills and reduce HIV-related stigma.
1684879|NCT01580657|Behavioral|General baseline interview, enhanced HIV intervention|Participants in this group will receive the same procedures as in (A) except that the behavioral measure will consist of single-item frequency questions regarding sexual behaviors during the prior 90 days, questions that do not lead the participant to focus on specific instances of behavior.
1684880|NCT01580657|Behavioral|No baseline interview, enhanced HIV intervention|This group will receive the same enhanced intervention procedures as in (A) and (B), but they will not be interviewed at baseline.
1684881|NCT01580657|Behavioral|Detailed baseline interview, standard of care intervention|Participants in this group will receive the same interview procedure as in (A) but instead of the enhanced intervention, They will undergo the standard clinical exam and health education that at the Spencer Rd. Clinic.
1684882|NCT01580657|Behavioral|General baseline interview, standard of care intervention|Participants in this group will complete the general baseline interview described in (B) and then receive the standard care at the clinic.
1684883|NCT01580657|Behavioral|No baseline interview, standard of care intervention|Participants assigned to this group will be consented on the day they are recruited, but will not receive further study contact on that day other than being scheduled to return for follow up assessments.
1684884|NCT01580644|Drug|GLPG0187 prodrug|
1684885|NCT01580618|Drug|normal saline|Injection of 60 ml normal saline twice a day for three days using the existing chest tube.
1684886|NCT01580618|Drug|TNK (Tenecteplase)|Injection of 4 mg of TNK with 59 ml normal saline into the existing chest tube twice a day for three days.
1684887|NCT01580605|Drug|somatropin|"Data are extracted from the French National Registry l'Observatoire National des Prescriptions et Consommations de Médicaments to where physicians report data about growth hormone treatment"
1684888|NCT01580592|Drug|Omalizumab|150mg, s.c., every 4 weeks
1684889|NCT01580592|Drug|Omalizumab|300mg, s.c., every 4 weeks
1684890|NCT01580592|Drug|Placebo|Placebo, s.c., every 4 weeks
1684891|NCT01580553|Drug|Levocarnitine Injection|Levocarnitine Injection:5ml:1g
1684892|NCT01580553|Drug|Levocarnitine placebo|L-Carnitine injection placebo (5ml:1g)
1684893|NCT01580527|Procedure|Total parenteral nutrition|Total parenteral nutrition in postoperative of pancreaticoduodenectomy
1684894|NCT01580527|Procedure|Enteral nutrition|Early enteral nutrition in postoperative of pancreaticoduodenectomy
1684895|NCT01580514|Drug|exenatide BYETTA® (Amylin-Lilly)|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.
Patients assigned to exenatide were treated with 10 μg subcutaneous and 10 μg intravenously injection of exenatide BYETTA® (Amylin-Lilly) 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
1684896|NCT01580514|Drug|Saline|"After informed consent was obtained, patients who met the enrollment criteria were randomly assigned to either the control group or the exenatide group.
Patients assigned to saline were treated with 10 μg subcutaneous and 10 μg intravenously injection of equivalent volume of normal saline 5 min before the onset of reperfusion. And twice daily 10 μg subcutaneous injection was continued on the following 2 days."
1684897|NCT01580501|Drug|Tadalafil and Sildenafil|PDE-5 Inhibitor; Low dosages will be 0.5mg/kg and high dosages will be 1.0mg/kg
1684900|NCT01580488|Drug|E LEO 35299 10 mg/g solution|once daily application, 3 weeks
1684901|NCT01580488|Drug|F LEO 35299 10 mg/g solution|once daily application, 3 weeks
1684902|NCT01580488|Drug|Daivonex® ointment|once daily application, 3 weeks
1684903|NCT01580488|Drug|Daivonex® ointment vehicle|once daily application, 3 weeks
1684904|NCT01580475|Other|Training - detraining - retraining|Thirteen women with type 2 diabetes followed a supervised aerobic and strength training program for 9 months, interrupted for 3 months (detraining) and resumed again for a period of 9 months (retraining).
1684905|NCT01580462|Other|Observational study|"Study plan - data collecting:
Patients will attend diabetes clinic as usual, with one additional visit in the middle of the 3-months period. During those visits - V0, V1 and V2, data from glucometers and insulin pumps will be downloaded."
1684906|NCT01580436|Procedure|Tricuspid Valve Annuloplasty|Concomitant Tricuspid Valve Annuloplasty in patients undergoing mitral valve surgery
1684907|NCT01580423|Drug|aprepitant|125 mg capsule
1684908|NCT01580423|Drug|placebo|capsule identical to aprepitant
1684909|NCT01580410|Drug|mitomycin C|Given by HIPEC
1684910|NCT01580410|Drug|oxaliplatin|Given by HIPEC
1684911|NCT01580410|Procedure|therapeutic conventional surgery|Undergo surgery
1684912|NCT01580410|Other|quality-of-life assessment|Ancillary studies
1684913|NCT01580410|Drug|hyperthermic intraperitoneal chemotherapy|Undergo HIPEC
1684914|NCT01580397|Drug|INNO-206|INNO-206 at a total dose of 350 mg/m2 (260 mg/m2 doxorubicin equivalent) will be administered as a 30 minute IV infusion every 21 days.
1684915|NCT01580371|Drug|CKD-581|CKD-581 qd for Day 1, 8 and 15 every 28days/Cycle
1684916|NCT01580358|Drug|Shen-Mai San|Shen mai san is composed of three herb medicines, Ginseng radis, Liriope spicata, and Schizandrae fructus and was manufactured into concentrated herbal extract and packed with 0.5g per capsule and labeled by Sun-Ten pharmaceutical company in Taiwan with good manufacturing practice (GMP).
1684917|NCT01580358|Drug|Starch|It was packed in granules with 0.5gm starch. Patients took eight granules three times per day for four weeks.
1684918|NCT01580345|Dietary Supplement|Docosa-hexaenoic acid (DHA)|400 mg/day of Docosa-hexaenoic Acid (algal DHA) will given to the pregnant women (in the active group) from ≤20 weeks of gestation through delivery.
1684919|NCT01580345|Dietary Supplement|Placebo|400 mg/day of placebo (corn/soy oil) will be given to the pregnant women from ≤20 weeks of gestation through delivery.
1684920|NCT01580319|Other|physical exercise|150 minutes per week
1684921|NCT01580306|Drug|BI 201335|Relevant treatment dose capsule (A) for oral administration
1684922|NCT01580306|Drug|BI 201335|Relevant treatment dose capsule (B) for oral administration
1684924|NCT01580280|Other|Thrust Manipulation|Upper cervical and upper thoracic thrust manipulation for 6-8 sessions over 2-4 weeks.
1684925|NCT01580280|Other|Non-thrust Mobilization and Exercise|Upper cervical and upper thoracic non-thrust mobilization and exercise for 6-8 sessions over 2-4 weeks.
1684926|NCT01580254|Drug|IOPIZE© Latanoprost eyedrops|patients will receive in each eligible eye one drop of IOPIZE© Latanoprost eyedrops once a day, in the evening (8pm), for two months
1684927|NCT01580254|Drug|GALAXIA© Latanoprost eyedrops|patients will receive in each eligible eye one drop of GALAXIA© Latanoprost eyedrops once a day, in the evening (8pm), for two months
1684928|NCT01580254|Drug|Latanoprost RATIOPHARM© latanoprost eyedrops|patients will receive in each eligible eye one drop of Latanoprost RATIOPHARM© Latanoprost eyedrops once a day, in the evening (8pm), for two months
1684929|NCT01580228|Drug|Dinaciclib|Dinaciclib administered intravenously over 2 hours at a dose of 7 mg/m^2 on Day 1, 10 mg/m^2 on Day 8, and 14 mg/m^2 on Day 15 in Cycle 1. Starting in Cycle 2 and thereafter, dinaciclib will be dosed at 14 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle for a total of 12 cycles.
1684930|NCT01580228|Drug|Ofatumumab|Ofatumumab administered intravenously at a dose of 300 mg on Cycle 1 Day 1, followed by 2000 mg on Cycle 1 Days 8, 15, and 22; Cycle 2 Days 1, 8, 15, and 22; followed 5 weeks later on Day 1 of Cycles 4-12.
1684931|NCT01580215|Device|Zephyr Endobronchial Valve (EBV)|• Implantation of at least one Zephyr EBV following Chartis assessment
1684932|NCT01580202|Drug|Entecavir|Entecavir 0.5mg daily per os
1684933|NCT01580202|Drug|Lamivudine|lamivudine 100mg daily per os
1684934|NCT01580189|Dietary Supplement|Whey protein|18g protein, immediately after training, 9 weeks
1684935|NCT01580189|Dietary Supplement|Chocolate milk|500ml chocolate milk, immediately after training, 9 weeks
1684936|NCT01580189|Dietary Supplement|Sugar|55-65g maltodextrin solution, immediately after training, 9 weeks
1684937|NCT01580176|Device|continuous GlucoseMonitor|The blood glucose and blood lactate levels will be taken continuously by the Continuous GlucoseMonitor and will be recorded twelve times.
1684938|NCT01580163|Drug|JITAI Combined with psychological intervention|tablet，Each tablet weight 0.4g
1684939|NCT01580163|Drug|Methadone|Oral Solution，1mg/ml
1684940|NCT01580163|Drug|Traditional Chinese Medicine JITAI|tablet，Each tablet weight 0.4g
1684941|NCT01580150|Other|Berries|Meals containing starch (bread) or sucrose are consumed with berries (150 g) or berry nectars (300 mL).
1684942|NCT01580150|Other|No berries|Meals containing starch (bread) or sucrose are consumed without berries.
1684943|NCT01580124|Procedure|PVI alone|PVI alone Pulmonary vein isolation alone in persistent atrial fibrillation
1684944|NCT01580124|Procedure|PVI + Defragmentation + linear lesions|PVI + Defragmentation + linear lesions AF ablation continuation aiming for AF termination
1684945|NCT01580111|Biological|Blood transfusion|The short storage arm; children were transfused with packed red cells of storage age 1-10 days; while for the Long storage arm; were transfused with packed red cells of 21- 35 days in storage.
1684946|NCT01580098|Other|Self-monitoring for patients with Diabetes mellitus type 2|Patients are submitting their vital parameters via a Web Portal or automatic devices to the hospital.
1684947|NCT01580098|Other|Nurse-monitoring for patients with Diabetes mellitus type 2|Nurses are submitting the vital parameters of the patient via mobile device.
1684948|NCT01580085|Other|polysomnography|full night supervised laboratory polysomnography
1685069|NCT01579279|Drug|Placebo|Placebo capsules
1684949|NCT01580072|Other|self-monitoring for patients with severe COPD|Intervention Group entering vital parameters via Web Portal or automatic call center.
1684950|NCT01580072|Other|nurse-monitoring for patients with severe COPD|Nurses are entering vital parameters of the patient with mobile devices.
1684951|NCT01580046|Drug|iodixanol|"coronary angiography, 32gI/100ml, 40～60 ml once injection
left ventricular, aortic root and selective coronary angiography, 32gI/100ml, 30～60 ml once injection"
1684952|NCT01580046|Drug|iopromide|coronary angiography, 370mgI/ml(0.769gIopromide/ml),5～8 ml once injection
1684953|NCT01580033|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered on one arm, intramuscularly, per 0.5ml dose
1684954|NCT01580033|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, intramuscularly, per 0.5ml dose
1684955|NCT01580033|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Yunnan Walvax Biotechnology Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
1684956|NCT01580033|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
1684957|NCT01580020|Biological|RFB002|0.5 mg/0.05 mL solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. Each vial contained ranibizumab in an aqueous solution (pH 5.5) with histidine, trehalose and polysorbate 20.
1684958|NCT01580020|Drug|Dexamethasone|Ozurdex (Dexamethasone): intravitreal implant as per commercial label (700 µg Dexamethasone; Dexamethasone was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only. Dexamethasone had to be stored according to label instructions and it had to be kept in a secure locked facility
1684963|NCT01579994|Drug|Ganetespib (STA-9090) and crizotinib|Ganetespib (STA-9090) is given intravenously (days 1 and 8 of a 21 day cycle). Crizotinib will be given at the FDA approved dose of 250mg orally twice daily in a continuous fashion.
1684964|NCT01579981|Procedure|Roux-en-Y Gastric Bypass|On two separate experimental days before, 1 wk, and 3 months after RYGB, subjects are given a liquid meal test during Exendin 9-39 (900 pmol/min/kg)or saline infusion. The order of the infusions is randomized. At end of study day an ad libitum meal is served.
1684965|NCT01579968|Drug|eptacog alfa (activated)|Safety and effectiveness data collection in connection with the use of eptacog alpha in daily clinical practice
1684966|NCT01579955|Drug|eptacog alfa (activated)|Prescription of eptacog alpha at the discretion of the physician
1684967|NCT01579929|Drug|LDE225, Etoposide and Cisplatin|In a standard, 3 + 3 dose escalation phase, two successive cohorts of ES-SCLC patients will receive LDE225 with etoposide and cisplatin with a dose of 200 mg to be reserved for de-escalation until the MTD is determined. Cohorts of at least 3 evaluable patients will be treated at each dose level of LDE225 (400 mg daily and 800 mg daily). One additional dose (200 mg daily) will be reserved for de-escalation. A minimum of 6 evaluable patients must be treated at the dose declared to be the MTD. Each cohort will consist of newly enrolled patients. An estimated total of 6 to 12 patients may be necessary to establish the MTD. Actual accrual will depend on the dose levels tested and the DLT observed. Upon completion of a minimum of four and a maximum of six cycles of LDE225 with etoposide and cisplatin, patients in each cohort with at least stable disease will receive maintenance LDE225 until disease progression or unacceptable toxicity.
1684968|NCT01579916|Biological|Trivalent Influenza Virus Vaccine|Trivalent vaccine is supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose phosphate buffer, egg allantoic fluid and approximately 10^7 FFU (fluorescent focus units) of each of 3 cold-adapted, attenuated 6:2 reassortant influenza strains: A/H1N1 (A/California/7/2009), A/H3N2 (A/Victoria/361/2011), B (B Wisconsin/1/2010). A single dose of investigational product was administered on Day 1.
1684969|NCT01579916|Other|Placebo|Placebo is suppllied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer. A single dose of investigational product was administered on Day 1.
1684970|NCT01579903|Drug|moroctocog alfa (AF-CC)|Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent); Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes
1684971|NCT01579903|Drug|moroctocog alfa (AF-CC)|Treatment B: 1000 IU + 2000 IU moroctocog alfa (AF-CC) vials and separate diluent syringes; Treatment A: 3000 IU moroctocog alfa (AF-CC) dual chamber syringe (including diluent)
1684973|NCT01578889|Biological|HIV-MAG vaccine|Participants assigned to receive the HIV-MAG vaccine will receive 3 mg of the vaccine with bupivacaine, alone or admixed with one of three doses of the IL-12 pDNA adjuvant.
1684974|NCT01578889|Biological|IL-12 pDNA adjuvant|Participants assigned to receive the IL-12 plasmid (IL-12 pDNA) adjuvant will receive one of three doses (total of 250 mcg, 1000 mcg, or 1500 mcg) of the adjuvant admixed with the HIV-MAG vaccine.
1684975|NCT01578889|Biological|VSV HIV gag vaccine|Participants assigned to receive the VSV HIV gag vaccine will receive a total dose of 1x10^8 plaque-forming units (PFUs) administered as 5x10^7 PFU in 1 mL by IM injection in both the left and right deltoids at Month 6.
1684976|NCT01578889|Biological|Placebo|Placebo will consist of sodium chloride for injection, USP 0.9%.
1684977|NCT01578889|Device|Ichor Medical Systems TriGrid™ Delivery System (TDS) electroporation (EP) device|The HIV-MAG vaccine, IL-12 pDNA adjuvant, and placebos for IL-12 pDNA adjuvant/HIV-MAG vaccines will be delivered IM into the deltoid by the Ichor Medical Systems TDS EP device.
1685070|NCT01579279|Drug|Duloxetine|Duloxetine capsules
1686249|NCT01570348|Radiation|Total-Body Irradiation|Undergo TBI
1684978|NCT01578876|Device|cardiac shock wave therapy(CSWT)|CSWT was performed with the MODULITH SLC SW therapy device (Storz Medical, Switzerland).Shock waves were triggered by the R-wave of the ECG when the instrument was activated. The shock wave energy was increased from an initial low level up 0.09 mJ/mm2 if the patient experienced no discomfort such as chest pain. Point-to-point combination treatment for the ischemic areas with 200 pulses delivered to each point was given.
1684979|NCT01578863|Other|Intervention program for obese children|The program includes physical activity, nutrition intervention and behavioral treatment and lasts for 6 months. The aim of the program is to promote weight loss and physical activity and to promote future healthy lifestyle.
1684980|NCT01578850|Drug|Etanercept|etanercept 50mg once weekly + methotrexate with or without other DMARDs
1684981|NCT01578850|Drug|placebo|etanercept placebo once weekly + methotrexate with or without other DMARDs
1684982|NCT01578837|Dietary Supplement|Ginseng|2.25g of encapsulated ginseng (1.5g American Ginseng and 0.75g Rg3-enriched Korean Red Ginseng)will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
1684983|NCT01578837|Dietary Supplement|Wheat Bran|2.25g of encapsulated 100% natural wheat bran will be administered in 6 identical capsules, 2 capsules with each meal (total 6 capsules per day).
1684984|NCT01578824|Other|Methacholine Challenge Test|Evaluation of airway hyperreactivity as assessed by doubling dose of methacholine with determination of PC20
1684985|NCT01579890|Drug|Diclofenac|diclofenac topical lotion
1684986|NCT01579877|Dietary Supplement|Herbal extract granule|The herbal extract granule, Yukmijihwang-tang granule, consists of 6 herbs. Ingredients: Rehmanniae Radix, Deoscoreae Radix, Corni Fructus, Hoelen, Alismatis Radix, Paeoniae Radicis Cortex. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
1684987|NCT01579877|Dietary Supplement|Placebo herbal extract granule|The Yukmijihwang-tang_Placebo has the same form, color and flavor as experimental intervention (Yukmijihwang-tang). The dosage, frequency and duration is also the same as experimental intervention (Yukmijihwang-tang).
1684988|NCT01579864|Drug|succinylcholine|Succinylcholine 1 mg/kg and a second dose if necessary. Rocuronium 0,4 mg/kg can be used as a rescue
1684989|NCT01579864|Drug|rocuronium|rocuronium 0,9 mg/kg with additional boluses of 0,3 mg/kg f necessary
1684990|NCT01579851|Drug|Sugammadex|"sugammadex
4 mg/kg : if there is no response to Train of Four stimulations and at least one response to the Post Tetanic Count
2 mg/kg : if there is at least two responses to Train of Four stimulations"
1684991|NCT01579838|Drug|Eculizumab|PNH and or atypical TTP classical protocols
1684992|NCT01579825|Other|Buffer|5 ml of oral buffer solution containing 64 mg of sodium bicarbonate plus 24 mg of sodium citrate. The buffer will be administered prior to each dose of OPV at 6, 10 and 14 weeks of age.
1684993|NCT01579812|Drug|Metformin|"Patients receiving primary surgical debulking followed by adjuvant chemotherapy will initiate metformin prior to primary surgery. Following surgery patients will be initiated on metformin prior to the initiation of chemotherapy.
Patients treated with neoadjuvant chemotherapy will be initiated on metformin prior to the initiation of chemotherapy. Following surgery patients will be initiated on metformin prior to the re-initiation of chemotherapy."
1684994|NCT01579799|Drug|L-lysine|Dose finding study for L-lysine
1684995|NCT01579786|Procedure|Acetaminophen and acupuncture|All patients will receive acetaminophen (maximum 3g/day) for all seven days after surgery and will receive acupuncture treatment at first day after performing surgery and thirty minutes before operation
1684996|NCT01579760|Drug|Aflibercept every 2 months|2.0 mg aflibercept intravitreal injections once per month for the first 3 months (M0, M1, M2), then every 2 months (M4, M6, M8, M10)
1684997|NCT01579760|Drug|Aflibercept monthly|2.0mg aflibercept intravitreal injections every month (M0-11)
1684998|NCT01579747|Procedure|Ultrasound|Using ultrasound for nerve localization when performing a sciatic nerve block via the lateral popliteal approach
1684999|NCT01579747|Procedure|Nerve stimulation|Using nerve stimulation for nerve localization in sciatic nerve blocks via the lateral popliteal approach
1685000|NCT01579734|Drug|Tamoxifen|1 tablet, 5 mg / day for 5 years
1685001|NCT01579734|Drug|Placebo|1 tablet day for 5 years
1685002|NCT01579721|Procedure|Single Incision Laparoscopic Surgery|Single incision laparoscopic surgery for rectal cancer
1685003|NCT01579708|Behavioral|Program SI! educational intervention|School-based educational program to improve the knowledge, the attitudes, and the habits of children, their parents and teachers, with respect to a healthy lifestyle behavior.
1685004|NCT01579695|Drug|Tesamorelin for injection|Daily 2 mg subcutaneous injections of Tesamorelin
1685005|NCT01579682|Behavioral|Family-Based Therapy (FBT)|12 sessions of FBT over the course of 6 months.
1685006|NCT01579682|Behavioral|Family-Based Therapy with Intensive Family-Focused treatment|FBT for 4 weeks then Intensive Family-Focused treatment (IFT) should the participant not make adequate weight progress within the time frame.
1685007|NCT01579669|Behavioral|Use of toolkit|Patient participants will be given access to the toolkit and will create a customized report for their provider. Team will send report to providers and ask them to schedule appointment with patient to discuss.
1685008|NCT01579656|Dietary Supplement|Salba|25g of ground Salba baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
1685009|NCT01579656|Dietary Supplement|Poppy|25g of ground Poppy Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
1685010|NCT01579656|Dietary Supplement|Flaxseed|25g of ground Flaxseed baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
1685011|NCT01579656|Dietary Supplement|Sesame|25g of ground Sesame Seeds baked into a bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal) with the addition of flour, inulin or canola oil. One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
1685228|NCT01578031|Other|Usual Care|Usual care.
1685012|NCT01579656|Dietary Supplement|Wheat Bran|Bran muffin matched for total available carbohydrate (50g), total dietary fibre (15g), and calories (494.5 kcal). One of five muffins (Salba, Poppy, Sesame, Flax, Bran) will be administered at each visit.
1685013|NCT01579643|Procedure|OCT guided laser-assisted lamellar anterior keratoplasty (LALAK)|"The top hat-shaped donor cornea graft with tapered brim will be cut using a femtosecond (fs) laser at the eye bank. An anterior diameter of 6.0 mm will be used. The depth of the anterior side cut will match the planned excimer ablation depth.
The host cornea bed will be prepared with an excimer laser.
Descemet's membrane will be peeled off the graft, and the graft sutured into the host bed."
1685014|NCT01579643|Procedure|Penetrating Keratoplasty (KP)|"A trephine is used to perform a full thickness cut of a round area of cornea from the both patient's and donor's cornea.
The donor cornea is then sutured where the patient's cornea was."
1685017|NCT01579617|Behavioral|BUtiful.|8 website sessions include themes that teach: gender empowerment, assertive communication skills, goal setting, pregnancy and STI/HIV risk, safer sex behaviors, proper condom use, positive attitudes and norms towards consistent condom use, contraception, partner involvement in safer sex, and responsibility for their own health.
1685018|NCT01579617|Behavioral|DIVAS.|Attention control arm: 8 website sessions that include topics on: healthy eating, choosing nutritional snacks, sugar and salt intake, physical activity, stress management, foods for beauty.
1685019|NCT01579604|Procedure|Nerve reconstruction|Under general anesthetic, the surgeon will make a cut on the back (dorsal) part of the forearm. The radial nerve will be identified and specifically the branches which control the supinator muscle and the remainder of the radial nerve (Posterior interosseous nerve or PIN). . The PIN branch will be stimulated to ensure that it is non-functional. Then, the supinator branch will be stimulated to ensure it is functioning and is appropriate for transfer. If appropriate, the supinator branch will be severed and connected to the EDC branch under the operating room microscope. After the surgery, the patient will be placed into a splint including the forearm and hand for 2-3 weeks.
1685020|NCT01579591|Other|VSL#3|1 sachet (4.5x1011 viable lyophilized bacteria)three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards.
1685021|NCT01579591|Other|Placebo|1 sachet, three times in a day, during RT and for 2 weeks before and for 4 weeks afterwards
1685022|NCT01579578|Drug|AZD8931|40 mg, oral dose twice daily
1685023|NCT01579578|Drug|Placebo|Placebo, oral dose twice daily
1685024|NCT01579578|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off.
1685025|NCT01579565|Drug|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced saline salt (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
1685026|NCT01579565|Drug|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
1685027|NCT01579552|Behavioral|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
1685028|NCT01579552|Behavioral|survey, questionaire|The intervention components (mailed tailored print materials followed by telephone-delivered Brief MI). Following enrollment into the study and completion of the informed consent form and baseline survey, participants will be randomized to the active intervention group or the attention control group. The data that will be used in the analysis will come from the baseline survey, medical records of breast imaging studies, and a 12-month follow-up questionnaire.
1685029|NCT01579539|Drug|Methylprednisolone|500mg i.v. infusion once a week for 6 weeks followed by 250mg i.v. infusion once a week for 6 weeks
1685030|NCT01579539|Drug|Esomeprazole|40mg i.v. infusion once a week for 12 weeks
1685031|NCT01579526|Drug|FP01|comparison of different dosages
1685032|NCT01579513|Drug|Methylprednisolone|Methylprednisolone at a dose of 30 mg/kg body weight and a concentration of 62.5 mg/cc. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
1685033|NCT01579513|Drug|Placebo|Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
1685034|NCT01579500|Drug|Botulinum toxin type A|Subcutaneous injection of botulinum toxin type A
1685035|NCT01579500|Drug|normal saline|Subcutaneous injection of normal saline
1685036|NCT01579487|Device|The Zeltiq System|This is a follow-up study from the initial treatments performed in 2010. No additional treatments will be performed.
1685037|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
1685038|NCT01579474|Drug|BI 201335 low dose|BI 201335 low dose with PegIFN/RBV
1685039|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
1685040|NCT01579474|Drug|BI 201335 high dose|BI 201335 high dose with PegIFN/RBV
1685041|NCT01579461|Drug|mirabegron|oral
1685042|NCT01579448|Biological|Shanchol™, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.
Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
1685043|NCT01579448|Biological|Shanchol™, killed, whole cell, bivalent, oral cholera vaccine|"This killed, whole cell, bivalent vaccine will be presented as a creamish white suspension. Upon storage, a white sediment and clear supernatant may be observed. The recommended dose (1.5ml) of the vaccine must be administered orally. The primary vaccination schedule consists of two doses given at an interval of two weeks. After vigorous shaking of the vial, 1.5 ml should be poured into the mouth of the recipient, followed by water ad libitum. The vaccine can alternatively be administered with a disposable syringe (without needle) after removing the contents from the vial and squirted into the mouth of the recipient.
Vaccine is administered in 1.5 mL vials by mouth in 2 doses, given 2 weeks apart. The vaccine appears as a creamy white suspension."
1685044|NCT01579448|Other|no intervention|No intervention will be given to this arm of past placebo recipients. To ensure that boosting was not due to natural exposure to Vibrio cholera, we will compare subjects in the boosting arm to this no intervention arm.
1685045|NCT01579435|Device|transcranial direct current stimulation|Active stimulation: duration: 20 mn, intensity: 2 mA; localisation : motor cortex or cerebellum; Placebo stimulation: duration: 9 seconds, intensity: 2 mA; localisation : motor cortex or cerebellum;
1685046|NCT01579422|Behavioral|social cognitive training|social cognitive training, 8-10 sessions
1685047|NCT01579409|Other|PNNS guidelines|Application of PNNS guidelines
1685048|NCT01579396|Device|septeX|12 h septeX CVVH treatment after cardiac surgery
1685049|NCT01579396|Other|standard therapy|standard therapy either pharmacological and /or continuous renal replacement therapy (CRRT)
1685050|NCT01579383|Biological|ALD403|Single Dose IV infusion on Day 1
1685051|NCT01579383|Biological|ALD403|Single Dose subcutaneous injection on Day 1
1685052|NCT01579383|Biological|Sumatriptan|Single Dose subcutaneous injection on Day 1
1685053|NCT01579370|Other|Quaternary ammonium|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
1685054|NCT01579370|Other|Bleach|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital."
1685055|NCT01579370|Other|Quaternary ammonium and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using quaternary-ammonium containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
1685056|NCT01579370|Other|Bleach and UV-C light|"Rooms from which a patient with a target organisms has been discharged (ie, a seed room) will be cleaned using bleach containing solutions. Room cleaning will proceed following standard cleaning protocols established at each study hospital. Then, the UV-C light-emitting device will be brought to the room to irradiate the room until 12,000 uWs/cm2 (for vegetative bacteria) or 22,000 uWs/cm2 (for C. difficile) has been delivered to entire room."
1685058|NCT01579344|Drug|Radioiodine therapy|Radioiodine therapy with NaI131
1685059|NCT01579331|Device|DCT (PASCAL© Tonometer) IOP and OPA measurement|"Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will undergo a series of 5 Dynamic contour tonometries to evaluate eventual differences among measurements.
Patients will be controlled for 30 days. A diurnal IOP curve performed though GAT, composed of 3 measurements (9am, noon, 4pm) will be taken 1 to 7 days before the DCT. At the end of the DCT measurements a last GAT will be taken to control eventual IOP changes versus previous GAT values obtained through the diurnal curve."
1685060|NCT01579318|Drug|IL-12 plasmid (pIL-12)|All subjects may receive up to six cycles of treatment consisting of two treatment days, Days 1 and 8, in a 28-day cycle. Patients will receive intratumoral injection of IL-12 plasmid (pIL-12) at a concentration of 0.5 mg/mL and a fixed volume of 0.25 mL per each 1.0 cm diameter of target region. Up to a maximum of 8 fixed volume injections per patient per day depending up on the size of each individual lesion, or affected areas in erythrodermic patients.
1685061|NCT01579318|Device|Electroporation|Electroporation of the target lesion will occur using the OncoSec Medical System (OMS). Six pulses at field strengths of (E+) of 1500 V/cm and pulse width of 100 μs at 1-second intervals will be administered to each previously injected region. Up to 8 target regions may be treated on Days 1 and 8 of each cycle. A total of three cycles may be completed at 4-week intervals.
1685062|NCT01579305|Device|Juvéderm® Volbella with Lidocaine|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
1685063|NCT01579305|Device|Restylane-L®|Up to 4.0 mL at the discretion of the Investigator to achieve optimal results
1685064|NCT01579292|Behavioral|Mobile phone based physical activity with intervention|This group will receive a mobile phone software program and a pedometer. Over a 5-month period, participants in this group will be asked to participate in 6 in-person sessions, wear a pedometer, use a mobile phone physical activity and diet diary, and respond to daily physical activity and diet messages or video clips.
1685065|NCT01579292|Behavioral|Pedometer Only|This group will receive a pedometer. Over a 5-month period, participants in this group will be asked to wear a pedometer.
1685066|NCT01579279|Drug|ABT-652 6 mg|6 mg capsules
1685067|NCT01579279|Drug|ABT-652 12 mg|12 mg capsules
1685068|NCT01579279|Drug|ABT-652 12 mg - 18 mg|12 mg - 18 mg capsules
1685071|NCT01579240|Other|Internet exercise program|12 voluntary weekly visits to website
1685072|NCT01579227|Device|Topical Tocotrienol (TCT)|Natural Form Vitamin E topical cream(TCT)
1685073|NCT01579227|Dietary Supplement|Oral Tocotrienol Capsules (TCT)|Natural Form Vitamin E Oral capsules (TCT)
1685074|NCT01579227|Device|Tamoxifen Cream|Tamoxifen cream
1685075|NCT01579227|Device|Placebo cream|Placebo cream
1685076|NCT01579227|Dietary Supplement|placebo capsule|placebo capsule
1685078|NCT01579201|Drug|Carbetocin|First patient: 70 mcg. Following doses according to biased coin design up-down sequential allocation method, with increments or decrements of 10 mcg. An unsatisfactory uterine tone will lead to an increment while a satisfactory uterine tone will result in either a decrement or no change.
1685079|NCT01579188|Drug|GV1001|Intradermal injection 0.84 mg ± 0.084 mg 3 times in Week 1 (Monday, Wednesday, and Friday) and once (Mondays) in Weeks 2, 3, 4, 6, 8, and 10, followed by boost injections given on Weeks 14, 18, 22, 26, and thereafter at 12 week intervals up to Week 98
1685080|NCT01579188|Drug|normal saline|two injections of normal saline injected in the same manner as the experimental drug, GV1001
1685081|NCT01579175|Other|Chewing gum|Sugar Free (Extra spearment) gum given to chew every 4 hours during waking hours for 15 minutes.
1685083|NCT01579149|Drug|plerixafor|Single subcutaneous (SC) dose of plerixafor (160 μg/kg, 240 μg/kg, or 400 μg/kg),
1685084|NCT01579149|Drug|Placebo|Single subcutaneous (SC) dose of placebo
1685085|NCT01579136|Behavioral|Home blood pressure monitor|The patients using home monitors checked their blood pressure on Monday, Wed, and Friday. They took 2 measurements 5 minutes apart after sitting 5 minutes in the left arm.
1685086|NCT01579123|Procedure|Angioplasty|With angioplasty, a catheter is guided to the portion of the artery that is narrowed or blocked off. A balloon that is attached to the end of the catheter will be inflated which dilates or expands the artery in the area where the narrowing or blockage is located. Based on the angiogram and extent of disease, the physician may place a stent (small mesh tube that is used to treat narrow or weak arteries in the body) during the angioplasty.
1685087|NCT01579123|Procedure|Laser atherectomy|Laser atherectomy uses a catheter that emits high energy light (laser) to unblock the artery. The catheter is moved through the artery until it reaches the blockage. Laser energy is used to essentially vaporize the blockage inside the vessel.
1685088|NCT01579110|Drug|levamisole|"Levamisole 2.5mg/kg(every other day) over six months.
Prednisone 1mg/kg for two weeks and then tapered off dosage over two months."
1685089|NCT01579110|Drug|Prednisone|Prednisone 1mg/kg for two weeks and then tapered off dosage over two months.
1685090|NCT01579097|Other|Oliclinomel N4|Oliclinomel is a PN product which provides the macronutrients (e.g., dextrose, amino acids, and lipids) for patients when oral or enteral nutrition is not possible, insufficient, or contraindicated
1685091|NCT01579097|Other|Compounded ternary parenteral nutrition admixtures|Study treatment will be administered for a minimum of 5 days up to a maximum of 14 days
1685092|NCT01579084|Drug|AGN-199201 Formulation A|AGN-199201 Formulation A applied to the face as per protocol twice daily.
1685093|NCT01579084|Drug|AGN-199201 Formulation B|AGN-199201 Formulation B applied to the face as per protocol twice daily.
1685094|NCT01579084|Drug|AGN-199201 Formulation C|AGN-199201 Formulation C applied to the face as per protocol twice daily.
1685095|NCT01579084|Drug|AGN-199201 Vehicle|AGN-199201 vehicle (placebo) applied to the face as per protocol twice daily.
1685096|NCT01579071|Procedure|CO2 or room air insufflation during ESD for gastric tumor|CO2 insufflation group : CO2 will be insufflated via the endoscope during procedure as needed, Room air insufflation group : Room air will be insufflated via the endoscope during procedure as needed
1685097|NCT01579058|Drug|bisoprolol|bisoprolol 5mg qd for 4 years
1685098|NCT01579058|Drug|placebo|placebo for 4 years
1685099|NCT01579045|Device|senofilcon A|bilateral daily use soft contact lens
1685100|NCT01579045|Device|etafilcon A|bilateral daily use soft contact lens
1685101|NCT01579045|Device|nelfilcon A|bilateral daily use soft contact lens
1685102|NCT01579045|Device|Filcon II 3|bilateral daily use soft contact lens
1685103|NCT01579045|Device|Filcon II 3|bilateral daily use soft contact lenses
1685104|NCT01579019|Drug|RO5024048|1500 mg po bid, 24 or 26 weeks
1685105|NCT01579019|Drug|RO5024048|1000 mg po bid, 24 or 26 weeks
1685106|NCT01579019|Drug|danoprevir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
1685107|NCT01579019|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc qw, 24 or 26 weeks
1685108|NCT01579019|Drug|ribavirin [Copegus]|1000 mg or 1200 mg po daily, 24 or 26 weeks
1685109|NCT01579019|Drug|ritonavir|100 mg po bid, Weeks 1 to 24 or Weeks 3 to 26
1685110|NCT01579006|Drug|Tocilizumab|
1685111|NCT01578980|Device|Outpatient Control-to-Range|Subjects will spend two nights (~42 hours) in a local hotel during which the AP Platform will be remotely monitored in an adjacent hotel room for validation that remote system monitoring can successfully occur.
1685114|NCT01578954|Drug|Lenalidomide|"Reinduction/Consolidation - dose escalation of lenalidomide: Level 1 - 25mg, Level 2 - 35mg, Level 3 - 50mg, PO, QD, 28 days.
Maintenance Lenalidomide - 10mg, PO, QD, continuous dosing, 12 months"
1685229|NCT01578018|Other|Measure DCAM levels in blood|Measure DCAM levels in blood
1737783|NCT00095082|Drug|insulin glargine|
1685115|NCT01578941|Other|Diary|"Each subject will be asked to keep a careful headache diary (appendix B) , and in that diary she will record onset and cessation of menstrual flow, days of menstrual headache (and migraine headache, specifically) experienced, days of functionally incapacitating headache experienced, any abortive/symptomatic medications taken, any days of work-related absenteeism (>4 hrs) related to acute MM headache and any unscheduled visits to a medical facility for acute treatment of MM."
1685116|NCT01578928|Drug|SOM230|
1685117|NCT01578811|Drug|Placebo|Dosage
1685118|NCT01578811|Drug|SK-MS10|Dosage
1685119|NCT01578811|Drug|SK-MS10|Dosage
1685120|NCT01578785|Drug|Glatiramer Acetate|Glatiramer acetate 20mg in 0.5ml for subcutaneous injection in a pre-filled syringe (PFS) is administered daily. Each PFS also contains 20mg mannitol dissolved in water for injection.
1685121|NCT01578785|Drug|Placebo|Matching placebo injection; 20 mg mannitol dissolved in 0.5 mL water for subcutaneous injection in a PFS is administered daily.
1685122|NCT01578772|Drug|Telmisartan|80mg tablets po daily for 6 weeks
1685123|NCT01578759|Procedure|Salpingectomy|Removal of the fallopian tubes
1685124|NCT01578746|Procedure|Direct lateral approach in total hip arthroplasty|The use of direct lateral approach in total hip arthroplasty
1685125|NCT01578746|Procedure|Anterior approach|The use of anterior approach in total hip arthroplasty
1685126|NCT01578733|Dietary Supplement|protein intake.|•Protein intakes will be varied at 0.2, 0.5, 0.7, 0.9,1.0, 1.2, 1.5, 1.8g, 2.0g/kg/day
1685128|NCT01578707|Drug|ofatumumab|"The ofatumumab (IV) dosage and schedule is 12 doses administered over 24 weeks or until disease progression, unacceptable toxicity.
Week 1: 300 mg initial dose Week 2 through 8: 2,000 mg (once weekly) Week 12, 16, 20 and 24: 2,000 mg (every 4 weeks)"
1685129|NCT01578707|Drug|ibrutinib|ibrutinib 420 mg (3 x 140-mg capsules) will be administered orally once daily until disease progression or unacceptable toxicity
1685130|NCT01578694|Procedure|MRI|T1 rho MRI
1685131|NCT01578694|Procedure|MRI|T1 rho MRI
1685132|NCT01578681|Procedure|Low Expiration Open glottis inferolateral (ELTGOL)|Place the affected lung in infralateral, asks the patient to make an inspiration without being forced to medium volume, and then a slow expiration with the glottis open, down to residual volume. If the therapist is present place the abdominal caudal hand at putting pressure cranial head and hand is placed over the rib cage at a pressure of closing the rib cage. Otherwise, the patient self-administered intertwining arms and abdominal rib at top exerting the same pressure. In case you have two lungs affected the art will take place on one side and then the opposite.
1685133|NCT01578681|Procedure|Stretching|Patient will be instructed to do muscle stretching of the thorax
1685134|NCT01578668|Drug|erlotinib|150 mg given orally (po), daily (QD), starting on the 4th day of each cycle, ending on the 21th day before the next cycle, and until disease PD
1685135|NCT01578668|Drug|pemetrexed|500 mg/m² intravenous (iv) over 15 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity or no more than 6 cycles
1685136|NCT01578668|Drug|cisplatin|cisplatin 20mg/m² iv on the 1st-3rd day (if PS<2) or 30 mg iv on the 1st-2nd day (if PS=2 or 3)of each cycle until PD or unacceptable toxicity or no more than 6 cycles
1685137|NCT01578668|Drug|erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
1685138|NCT01578655|Drug|cabazitaxel|Cabazitaxel (25mg/m² IV) is administered on day 1 of each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
1685139|NCT01578655|Drug|prednisone|Prednisone (10 mg PO) is administered daily until disease progression, unacceptable toxicity, or completion of 10 cycles
1685140|NCT01578655|Drug|custirsen sodium|Custirsen is administered as 3 loading doses (640 mg IV each) within 9 days, followed by weekly custirsen (640 mg IV) during each 21-day cycle until disease progression, unacceptable toxicity, or completion of 10 cycles
1685141|NCT01578642|Device|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components:
an electrical stimulation lead an implantable pulse generator (IPG) and an external programmer."
1685142|NCT01578629|Other|Vitamin E tocotrienol (TCT) capsules ; Low dose Aspirin|Vitamin E TCT capsules- 400-800 mg Aspirin- 81 mg
1685143|NCT01578629|Other|Placebo vehicle control|vehicle control compared to Vitamin E TCT pills
1685144|NCT01578603|Dietary Supplement|xylitol|6 g/day, for a month, by chewing 2g three times daily after meals.
1685145|NCT01578603|Dietary Supplement|casein phosphopeptide amorphous calcium phosphate complex|two pieces of the commercial presentation three times daily after meals
1685146|NCT01578590|Dietary Supplement|Lean minced meat (beef)|A piece of meat (135 grams, 35 g of protein) or an isonitrogenous-matched milk protein beverage
1685147|NCT01578577|Behavioral|EHMI|The EHMI intervention consists of multiple components, all leveraged by the Epic EHR platform (Verona, WI). The EHMI intervention 1) activates patients to review their medication list and identify any adherence-related concerns, 2) automates a process for providing plain language, patient-centered print medication information for new and refilled prescriptions, and 3) provides additional print tools to help patients more effectively engage their providers, consolidate their regimen, and generally promote safe use and adherence.
1685148|NCT01578577|Behavioral|Nurse Educator + EHMI|This intervention is a combination of the use of a nurse educator and the EHMI tools described in the EHMI intervention arm. A nurse educator perform the following: 1) perform medication and medical record review 2)assess adherence and medication problems 3) provide counseling to promote safe and effective medication use 4) follow-up with patients after their visit to confirm they have filled all prescriptions, and can accurately teach back their medicine regimen, 5) communicate with prescribing physician when problems are identified.
1685149|NCT01578564|Drug|SOR-C13|Intravenous solution for infusion, potential dose range 1.375 mg/kg to 6.12 mg/kg, dosing frequency 2 cycles with a cycle consisting of infusions on days 1-3 and days 8-10 followed by a 11 day off period
1685150|NCT01578551|Drug|Paclitaxel|200 mg/m² IV over 3 hours, day 1 of each cycle. Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy.
1737784|NCT00095082|Drug|insulin aspart|
1685151|NCT01578551|Drug|Carboplatin|"Carboplatin is administered at AUC= 6 mg/ml X min IV over 15-30 minutes, immediately following Paclitaxel infusion every 21 days
Paclitaxel + Carboplatin + Bevacizumab will be administered once every 21 days (Day 1) for up to 6 cycles. If subject has complete response, partial response, stable disease, or unacceptable toxicity. Bevacizumab with Metformin (Arm A) or Bevacizumab alone (Arm B) may continue as maintenance therapy"
1685152|NCT01578551|Drug|Bevacizumab|All patients will receive the drug at 15 mg/kg every 21 days, given immediately after completion of chemotherapy, starting with Cycle 1. After induction chemotherapy is completed (4 cycles), bevacizumab will continue at 15 mg/kg every 21 days until PD (provided neither PD nor toxicity requiring discontinuation has occurred) measured from date of first dose of bevacizumab.
1685153|NCT01578551|Drug|Metformin|1000 mg twice daily with food.
1685154|NCT01578538|Procedure|inguinal hernia repair|strangulated hernias will be repaired surgically
1685155|NCT01578525|Other|Pharmaceutical Care Service|Checking medication under safety considerations (medication at admission, hospitalization, discharge); recommendations for potentially inappropriate medication (PRISCUS-criteria),
1685156|NCT01578512|Behavioral|Face-to-Face|Face-to-Face behavioral weight loss
1685157|NCT01578512|Behavioral|Web-based|Web-based behavioral weight loss
1685158|NCT01578512|Behavioral|Single session|The core of behavioral weight loss, including calorie and activity prescriptions, are delivered in a single group treatment session.
1685159|NCT01578499|Drug|Brentuximab Vedotin|Brentuximab vedotin (1.8 mg/kg) will be administered intravenously over approximately 30 minutes once every 21 days and may continue as monotherapy for up to a total of 16 cycles (48 weeks)
1685160|NCT01578499|Drug|Methotrexate or Bexarotene|Methotrexate will be administered orally (5 to 50 mg) once weekly. Dose adjustment is guided by patient response and toxicity or Bexarotene will be administered orally (300 mg/m2) once daily with meals.
1685162|NCT01578473|Drug|Vitamin D2|oral softgel 2000 IU once daily 9 months
1685163|NCT01578473|Drug|Vitamin E|"oral softgels 400 IU and 200 IU 1 softgel of 400 IU daily
1 softgel of 200 IU daily 9 months"
1685164|NCT01578473|Drug|Testosterone Pellets|subcutaneous implantation pellets 75 mg based on testosterone levels from resulting bloodwork 9 months
1685165|NCT01578460|Device|Continuous Glucose Monitoring|Participants in the CGM group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using the iPro2 CGM.
1685166|NCT01578460|Device|Glucose Meter|Participants in the control group will be asked to monitor their blood glucose for 5 days for the 28th, 32nd and 36th week of gestation using a glucose meter.
1685167|NCT01578447|Drug|DepoSubQ Provera 104 in Uniject|DepoSubQ Provera 104 in Uniject
1685168|NCT01578447|Drug|Intramuscular DMPA|Intramuscular DMPA
1685169|NCT01578434|Drug|Vitamin D|Vitamin D: 6 lakh IU single im dose Calcium: 75 mg/kg calcium daily for 3 months vitamin D and Calcium: combination of above two
1685170|NCT01578434|Drug|Calcium Carbonate|Calcium: 75 mg/kg calcium daily for 3 months
1685171|NCT01578434|Drug|Vitamin D and Calcium|Vitamin D: 6 lakh IU single im dose. along with Calcium: 75 mg/kg calcium daily for 3 months
1685172|NCT01578421|Device|4 h online hemodiafiltration (FX 100, Polyflux 210, FXCorDiax)|4 h online hemodiafiltration with measurement of clearance and removal rate by split dialysate collection and bloodside measurements
1685173|NCT01578408|Procedure|Total Hip Arthroplasty|
1685174|NCT01578408|Device|Cemented Lubinus SPII stem (control arm)|Cemented Lubinus femoral stem. Cemented IP acetabular cup. (Link).
1685175|NCT01578408|Device|Uncemented HA Coated Corail stem|Uncemented hydroxyapatite coated Corail femoral stem. Cemented Marathon acetabular cup. (DePuy).
1685176|NCT01578395|Radiation|Low-dose radiation exposure|what: Cardiac CT; dosage: approx. 2-3 mSv; frequency: once
1685177|NCT01578395|Radiation|High-dose radiation exposure|what: cardiac catheterization procedures; dosage: approx. 75 mSv; frequency: once
1685178|NCT01578395|Other|No radiation exposure|Subjects not undergoing any radiation exposure
1685179|NCT01578369|Other|Exercise classes with pelvic floor muscle training|Supervised exercise classes which included pelvic floor muscle training. 3 sessions per week. 55-60 min per session, with 10 minutes of pelvic floor muscle training. At least during 22 weeks.
1685180|NCT01578343|Drug|Fludarabine, Mitoxantrone, Dexamethasone, Vorinostat|"Induction treatment (Total 4 cycles) FND D1-3 Fludarabine 25mg/m2 + NS 100mL iv over 30 min D1 Mitoxantrone 10mg/m2 + NS 100mL iv over 30 min D1-5 Dexamethasone 20mg IV or PO every 4 weeks Vorinostat D1-10 Vorinostat 200mg once daily PO (When vorinostat is concurrently administered with FND regimen, vorinostat will be administered 3 hours before chemotherapy)
Consolidation treatment for responders Patients not eligible for transplantation
Vorinostat maintenance up to 6 cycles
200mg twice daily for 14 consecutive days from D1 - 14 in a 21 day cycle
Delay of the start of the next cycle by up to 7 days will be acceptable.
If relapse or progression during maintenance, it will be stopped. Patients eligible for transplantation
High-dose chemotherapy followed by autologous stem cell transplantation"
1685181|NCT01578330|Drug|Fingolimod|Fingolimod 0.5mg orally once a day without food.
1685184|NCT01578304|Drug|Imidafenacin|Tablet, 12 weeks twice daily
1685185|NCT01578304|Drug|Fesoterodine|Tablet, 12 weeks once daily
1685186|NCT01578291|Behavioral|Parental information|An informational brochure indicating the study details
1685187|NCT01578291|Behavioral|Play therapy|Play therapy with a child life specialist
1685188|NCT01578278|Drug|Bepotastine besilate formulation|Nasal Spray
1685189|NCT01578278|Drug|Fluticasone propionate|Nasal Spray
1685190|NCT01578278|Drug|Bepotastine besilate-fluticasone propionate|Nasal Spray
1685191|NCT01578278|Drug|Placebo Comparator|Nasal Spray
1685192|NCT01578265|Drug|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
1685193|NCT01578265|Drug|Ondansetron Hydrochloride|8 mg tablet once a day
1685194|NCT01578252|Drug|Ondansetron Tablets USP 8 mg|8 mg tablet once a day
1685195|NCT01578252|Drug|Ondansetron Hydrochloride|8 mg tablet once a day
1685230|NCT01578018|Other|DCAM levels in blood|DCAM levels in blood
1738168|NCT00085943|Drug|Ziagen|
1685196|NCT01578239|Drug|Octreotide LAR|"In the experimental arm, 30 mg Octreotide LAR treatment will be given to the patients until the end of study for symptom control purpose, unless the patient progresses or dies.
In the active comparator arm, 60 mg Octreotide LAR treatment will be given to the patients every 4 weeks (i.m. injections) until the end of the study, unless the patient progresses or dies."
1685197|NCT01578239|Drug|177Lu-DOTA0-Tyr3-Octreotate|Four administrations of 7.4 GBq (200 mCi) 177Lu-DOTA0-Tyr3-Octreotate will be administered at 8±1-week intervals, which can be extended up to 16 weeks to accommodate resolving acute toxicity;
1685198|NCT01578213|Drug|Imatinib mesylate|"Capsules, hard 50 or 100 mg/Film-coated Tablets 100 or 400 mg
Total dosage per day: 800 mg
Oral use"
1685199|NCT01578200|Drug|Lanthanum Carbonate|
1685200|NCT01578200|Drug|Calcium Carbonate|
1685201|NCT01578187|Device|Hair2Go|Treatment with the device once under observation
1685202|NCT01578174|Drug|Dexmedetomidine|Dexmedetomidine(Dexmedetomidine 2 mL and normal saline 98 mL mixed -> 2㎍/mL) : the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
1685203|NCT01578174|Drug|Normal saline 0.9%|Normal saline 100mL(guess as 2㎍/mL):the infusion of 0.2㎍/kg/hr is started at 30 minutes before the procedure and the infusion dose is raised to 0.4㎍/kg/hr after completion of procedure
1685204|NCT01578161|Drug|Dexmedetomidine|There are four groups accoding to dosage of dexmedetomidine. Dexmedetomidine 0.25 microg.kg(-1),(group D0.25), dexmedetomidine 0.5 microg.kg(-1),(Group D0.5), dexmedetomidine 1 microg.kg(-1) (Group D 1) and normal saline(group P) is administered ivs. for 10mins when we are inducing each patient.
1685205|NCT01578161|Drug|0.9% Normal Saline|Placebo,Normal saline 10ml ivs. for 10min.
1685206|NCT01578148|Procedure|Noxipoint Therapy|"Patients will be treated with a TENS device, following Noxipoint Therapy guidelines:
Find the cause of the pain via Noxipoint: For each injured muscle/tissue, it is discovered that there are always a pair of points at the skin surface locations of its nociceptors that are painful at light press (named Noxipoints).
Stimulate the corresponding pair of Nocipoints following a narrowly defined combination of intensity/ frequency (inducing the C-fiber response) and duration (about 1.5-3 minutes) of TENS at the two targeted Noxipoints.
Repeat (a) to (b) above for each identified injured muscle group until all pain areas are eliminated or when the session time is up.
Instruct the subject not to use the newly recovered muscle/tissue too much an estimated rest period depending on his/her age."
1685207|NCT01578148|Procedure|Physical Therapy|"The 1.5-hour physical therapy in the control arm are provided both as standard of care and sham device comparison to Nocipoint Therapy, following these guidelines:
TENS stimulation (45 minutes):
• Electrodes will be placed around the patient-identified general pain area on the neck /shoulder for TENS. Rotate the electrode pads around the pain area and stimulate again.
Other modalities of PT per the therapist's choice:
Infrared treatment on the pain areas (about 15 minutes)
Manual therapy to cervical and/or rotator cuff areas (about 15 minutes).
Exercise and training:
Neck exercises: Range of motion exercises to include foraminal opening for about 15 minutes, and/or
Shoulder exercise: Range of motion exercises to include walking the arm on the wall, rotation of the upper arm for about 15 minutes
Hot/cold pack to the pain area for about 15 minutes"
1685208|NCT01578135|Drug|somatropin|Patients are to fill in a questionnaire at inclusion in registry
1685209|NCT01578135|Drug|somatropin|Patients are to fill in a questionnaire 6 months after inclusion into registry and then annually until adult height is reached
1685210|NCT01578122|Device|25mmHg ECS|"Thigh-length graduated elastic compression stockings applying 25 mmhg of targeted pressure at the ankle worn daily (from morning to night) for two years.
Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg)."
1685211|NCT01578122|Device|35 mmHg ECS|Thigh-length graduated elastic compression stockings applying 35mmhg of pressure at the ankle worn daily (from morning to night) for two years Before receiving the randomly allocated treatment, each patient will wear cotton, class III Varisma Comfort® stay-up stockings (20-36 mm Hg).
1685212|NCT01578109|Procedure|Bone Marrow Transplantation|Undergo BMT
1685213|NCT01578109|Other|Laboratory Biomarker Analysis|Correlative studies
1685214|NCT01578109|Other|Pharmacological Study|Correlative studies
1685215|NCT01578109|Drug|Sorafenib Tosylate|Given PO
1685216|NCT01578096|Behavioral|stress management|The study is a randomized, controlled,single-site, parallel group clinical trial comparing the effectiveness of CHW led diabetes education with CHW led diabetes education plus CHW led stress management in Latinos with Type 2 Diabetes.
1685217|NCT01578070|Biological|0.2μg Act-HIB®|0.2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
1685218|NCT01578070|Biological|ViscoGel® and 0.2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
1685219|NCT01578070|Biological|ViscoGel® and 2μg Act-HIB®|Pre-selected dose of ViscoGel® (from phase A) and 2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
1685220|NCT01578070|Biological|2μg Act-HIB®|2μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
1685221|NCT01578070|Biological|10μg Act-HIB®|Clinical standard dose of 10μg Act-HIB® vaccine, IM (intramuscular) on day 0 of phase B.
1685222|NCT01578057|Drug|tasimelteon|20mg, once
1685223|NCT01578057|Drug|Ethanol|0.6 g/kg ethanol (women) or 0.7 g/kg ethanol (men) in a total volume of 300 mL as a light cranberry juice cocktail, (consumed within 15 minutes).
1685224|NCT01578057|Other|Placebo tasimelteon|once
1685225|NCT01578057|Drug|Placebo ethanol|A total volume of 300 mL as a light cranberry cocktail (consumed within 15 minutes) with about 1 mL of supernatant of ethanol in the top
1685226|NCT01578044|Behavioral|Intervention|"Patient education: Patients will receive information on dabigatran, including risks, benefits and potential side effects. This information will be re-enforced during the study on a monthly basis during the IVR calls and during the pharmacy service calls to patients.
Tele-monitoring: We will use IVR technology to send patients an automated reminder to refill their dabigatran, rivaroxaban, and apixaban prescriptions. This call will be delivered on day 20 following each dabigatran, rivaroxaban, and apixaban prescriptions.
Pharmacists follow-up: If dabigatran, rivaroxaban, and apixaban have not been refilled, the pharmacy staff will contact the patient to assess reasons that the patient has not refilled the medication."
1685227|NCT01578031|Device|Positive Airway Pressure During Sleep (ResMed S9 Elite)|Positive airway pressure during sleep (ResMed S9 Elite).
1685231|NCT01577992|Drug|Levodopa test|Each patients with PD and MSA will be evaluated in two conditions : OFF (without dopaminergic treatment since 12h) and ON condition (after a L-DOPA dose. This dose will be 150% of the DOPA morning dose. The healthy volunteers will be evaluated in only one condition (without L-DOPA administration)
1685232|NCT01577992|Procedure|determination of objective and subjective pain threshold|Test without levodopa intake
1685233|NCT01577979|Behavioral|Text Message Reminder/Recall|Adolescents will be randomly selected from the participating private practices and safety net organization clinics. Parents of selected adolescents will receive a text message to alert them that their child is due for a vaccine or well-care visit. The text message will provide response instructions. The responses can be one of three options: 1) the parent will call the clinic to schedule a visit, 2) the parent would like the clinic to call them to schedule a visit, or 3) the parent would like to stop any future text message reminders. Parents who would like the clinic to call them to schedule an appointment will be contacted by their child's provider to set up a visit. Parents may receive up to 3 text message reminders, unless they chose to stop any future messages.
1685234|NCT01577979|Behavioral|Parent Preference|Parents of adolescents being seen within the managed care organization's intervention clinics will be asked about their reminder method preference at their child's 1st HPV immunization. The preference options include phone call, text message, or email. The preference for contact method will be recorded and utilized for the 2nd and 3rd dose reminders. The clinics' usual method of reminder will be used for all other parents.
1685235|NCT01577966|Drug|Sulfasalazine|"Sulfasalazine has been the parent aminosalicylate in use for over 40 years in the treatment of inflammatory bowel disease. The drug is a conjugate of sulfapyridine linked to 5-aminosalicylic acid. In inflammatory bowel disease, the 5-ASA component is the active moiety
Sulfasalazine is a prodrug that consists of sulfapyridine bonded to mesalamine (5-ASA). Sulfasalazine is cleaved by colonic bacterial azo-reductases into sulfapyridine and the 5-ASA moiety. 5-ASA is metabolized to N-acetyl-5-ASA by an enzyme in the intestinal epithelium and the liver and then excreted in the urine as a mixture of free 5ASA and N-acetyl-5-ASA."
1685236|NCT01577953|Drug|SB010|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.
Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board.
Dose levels:
Dose group A: 5 mg hgd40 in 2 mL solution (concentration: 2.5 mg/mL); Dose group B: 10 mg hgd40 in 2 mL solution (concentration: 5.0 mg/mL); Dose group C: 20 mg hgd40 in 2 mL solution (concentration: 10.0 mg/mL)."
1685237|NCT01577953|Drug|Placebo|"Three consecutive ascending dose groups (A, B, and C) are planned, with a total of 24 patients with asthma. Each dose group will consist of 8 patients (n=6 receiving active drug and n=2 receiving placebo). Each patient will participate in one dose group only.
Dose escalation to the second and third dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control, up to 4 hours after administration) of the preceding dose group by the Safety Board."
1685238|NCT01577940|Procedure|Infusion of ropivacaine|TAP block with ropivacaine 20 ml 0,5%. Catheter with infusion of ropivacaine 0,2% 5 ml/h 24 hours on one side of the abdomen.
1685239|NCT01577940|Procedure|Infusion of saline|TAP block with ropivacaine 0,5% 20 ml. Catheter with infusion of saline 5 ml/h 24 hours.
1685240|NCT01577927|Other|Usual home care|Usual home care consists in supporting drug and oxygen therapy, mechanical ventilation, GP's assistance,and periodical in-hospital visit.
1685241|NCT01577927|Behavioral|PT-assisted home rehabilitation|"Patient performs 50 min physical activity/working day autonomously by the help of a DVD. The physical activity consists in cyclette, calisthenic exercises, and training of the respiratory muscles.
Every two weeks, PT phones the patient for an educational reinforcement."
1685242|NCT01577914|Drug|Carvedilol Tablets USP 12.5 mg|12.5mg tablet once a day
1685243|NCT01577914|Drug|Carvedilol|12.5mg tablet once a day
1685245|NCT01577888|Device|Shockwave System Treatment|Shockwave System Treatment during vascular disease intervention.
1685246|NCT01577875|Device|NBI with magnification|After randomization of the subjects into two groups(1) NBI with magnification, 2) without magnification), one experienced endoscopist records its site, size, shape, and predicted histologic diagnosis on the every polyp observed and endoscopically resected. Two groups will be compared with each other.
1685247|NCT01577862|Drug|Colistin|2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
1685248|NCT01577862|Drug|Rifampicin|600 mg every 12 hours intravenously
1685249|NCT01577849|Drug|Vitamin D3|administration of Vitamin D3 24,000 IU
1685250|NCT01577849|Drug|DP-R206|administration of DP-R206 (150mg ibandronate / 24,000IU Vitamin D3)
1685251|NCT01577823|Device|Foley Catheter|
1685252|NCT01577810|Device|Near Infrared Spectroscopy|Use of Near Infrared Spectroscopy in outpatient setting to determine global cardiac output
1685253|NCT01577797|Behavioral|Text messages|Messages sent at random intervals 4 times per day during weeks 1 and 3. Subjects can also request messages if they are craving methamphetamine
1685254|NCT01577784|Drug|Pazopanib|800 mg / day of pazopanib in monotherapy.
1685255|NCT01577771|Biological|Prevnar13 (manufactured by Pfizer)|Prevnar13 administered IM in the antero-lateral thigh
1685256|NCT01577758|Drug|MLN0264|MLN0264 30-minute infusion on Day 1 of each treatment cycle
1685257|NCT01577745|Biological|MEDI0639|MEDI0639 is an immunoglobulin G1 lambda (IgG1λ) monoclonal antibody. MEDI0639 selectively binds to DLL4 and blocks its ability to bind to and activate signaling through the Notch receptors.
1685258|NCT01577732|Biological|Infanrix-IPV+Hib™|Single dose administered intramuscularly (IM) into the anterolateral side of the right thigh.
1685259|NCT01577719|Behavioral|Multimedia Lifestyle Improvement|"Online Goal setting to improve diet, physical activity or smoking behaviours
regular health messaging related to the participant's goal, sent by email or text messaging, based on participant preference.
Bi-weekly email reminder to report back on the current lifestyle goal and choose the next goal for upcoming 2 weeks."
1685260|NCT01577719|Behavioral|Usual Care|Participant will be refered to SAHARA study website to get information on healthy lifestyle and to get regular update for the course of follow-up.
1685261|NCT01577706|Drug|Alprazolam|Alprazolam, gel-capsule, 1mg, single-dose, 1-day
1685262|NCT01577706|Drug|Dextroamphetamine|Dextroamphetamine, gel-capsule, 20mg, single-dose, 1-day
1685263|NCT01577706|Other|Placebo|Placebo, gel-capsule, single-dose, 1-day
1685264|NCT01577693|Drug|dutasteride|novel dutasteride
1685265|NCT01577693|Drug|dutasteride|dutasteride soft gel capsule
1685266|NCT01577680|Drug|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719/VI (125mcg/25mcg) in Treatment Period 1
1685267|NCT01577680|Drug|Inhaled GSK573719|All subjects will receive GSK573719 (125mcg) once daily for seven days in Treatment Period 2
1685268|NCT01577667|Device|Intellivent; automatic mode implemented on a S1 ventilator|Intellivent allows an automatic adjustment of the following parameters: FiO2, PEEP and %VM according to adjusted parameters: Size, SpO2 and EtCO2
1685269|NCT01577654|Drug|EC145|2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks)
1685270|NCT01577654|Drug|EC145 + Docetaxel|"EC145 2.5 mg on Days 1,4,8,11 (Weeks 1 and 2 q3 weeks) +
Docetaxel 75 mg/m2 IV Day 1 q 3 weeks"
1685271|NCT01577654|Drug|Docetaxel|75 mg/m2 IV Day 1 q 3 weeks
1685272|NCT01577654|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
1685273|NCT01577628|Drug|Lipikar Balm AP|Daily application of Lipikar Balm AP starting at birth
1685274|NCT01577615|Behavioral|Patterned Experience|"The caregiver's hand over the shoulder area and the other hand over the lower extremities during feeding in the incubator, swaddling or holding outside the incubator.
Nonnutritive sucking will be offered to infants.
Blood work will be collected for inflammatory cytokines.
Saliva will be collected for genetic analysis
Saliva will be collected in 10 infant sub study for cortisol pre and post feedings
All scheduled feedings will include an opportunity for the infant to try feeding orally by bottle or breast while being held in a swaddled flexed position.
Once bottle feedings are initiated, infants will be observed twice a week utilizing the computer data acquisition system.
Follow up visits will occur at 2,6and 24 months corrected age."
1685275|NCT01577602|Other|Printed medication list|Provide a list of patient's current medication list as noted in the EMR
1685276|NCT01577602|Other|Open ended question|medical assistants begin medication reconciliation with a scripted open ended question.
1685277|NCT01577602|Other|Combined intervention|Combines the printed medication list with the open ended question
1685278|NCT01577589|Drug|600 mg ceftaroline fosamil in 50 ml infusion volume|IV infusion
1685279|NCT01577589|Drug|Placebo in 50 ml infusion volume|IV infusion
1685280|NCT01577589|Drug|600 ceftaroline fosamil in 250 ml infusion volume|IV infusion
1685281|NCT01577589|Drug|Placebo in 250 ml infusion volume|IV infusion
1685282|NCT01577589|Drug|600 mg ceftaroline in 100 ml infusion volume|IV infusion
1685283|NCT01577589|Drug|Placebo in 100 ml infusion volume|IV infusion
1685284|NCT01577550|Drug|BI 655066 (very high i.v. dose)|Single very high i.v. dose BI 655066
1685285|NCT01577550|Drug|Placebo, i.v.|Single i.v. administration of placebo
1685286|NCT01577550|Drug|BI 655066 (high s.c. dose)|Single high s.c. dose BI 655066
1685287|NCT01577550|Drug|BI 655066 (low i.v. dose)|Single low i.v. dose BI 655066
1685288|NCT01577550|Drug|BI 655066 (high medium i.v. dose)|Single high medium i.v. dose BI 655066
1685289|NCT01577550|Drug|BI 655066 (very low i.v. dose)|Single very low i.v. dose BI 655066
1685290|NCT01577550|Drug|BI 655066 (low s.c. dose)|Single low s.c. dose BI 655066
1685291|NCT01577550|Drug|BI 655066 (high i.v. dose)|Single high i.v. dose BI 655066
1685292|NCT01577550|Drug|Placebo, s.c.|Single s.c. administration of placebo
1685293|NCT01577550|Drug|BI 655066 (low medium i.v. dose)|Single low medium i.v. dose BI 655066
1685294|NCT01577537|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
1685295|NCT01577537|Drug|Placebo|Vaginal gel, daily for 7 days
1685296|NCT01577524|Drug|Povidone-Iodine|Subjects in the treatment group will receive 3.5% diluted Povidone Iodine solution in the surgical incision in a quantity sufficient to fill the wound to the level of the skin. The Povidone Iodine solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with normal saline solution.
1685297|NCT01577524|Drug|Saline|Subjects in the Placebo Comparator group will receive normal saline solution in a quantity sufficient to fill the wound to the level of the skin. The saline solution will be maintained in the incision for 3 minutes, after which it will be flushed from the wound with additional saline solution to replicate the saline wash procedure followed in the Treatment group.
1685298|NCT01577511|Biological|Samples and follow up|"Samples: Peroperative blood sample plus primary and metastatic tumor biopsies.
Follow-up: disease outcomes assessed at 24 months"
1685299|NCT01577485|Dietary Supplement|Probiotics in an pastille|Test group
1685300|NCT01577485|Dietary Supplement|Control pastille|Control group
1685301|NCT01577472|Drug|High Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
1685302|NCT01577472|Drug|Low Dose Clomiphencitrat|100mg of clomiphencitrate(Serophene®) are added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
1685303|NCT01577472|Drug|High Dose Placebo|Placebo is added to a high dose of HMG (450 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
1685304|NCT01577472|Drug|Low dose Placebo|Placebo is added to a low dose of HMG (150 IU of Merional®) in the early follicular phase of the stimulation (day 3 to 7).
1685305|NCT01577459|Drug|TR-701 FA with PSE|TR-701 FA Oral 200 mg oral with PSE
1685306|NCT01577459|Other|TR-701 FA Placebo with PSE|TR-701 FA Placebo Oral 200 mg with PSE
1685307|NCT01577446|Procedure|cardiac resynchronization therapy|Implantation of a CRT defibrillator with a standard right atrial, right ventricular defibrillator and left ventricular leads
1685308|NCT01577420|Other|Reflexology Sessions|One session per week performed by certified reflexologist for four consecutive weeks.
1685309|NCT01577420|Other|Placebo Sessions|One session per week performed by research aide for four consecutive weeks.
1685368|NCT01576874|Drug|Oxytocin|40 IUs of oxytocin administered intranasally one time
1685369|NCT01576874|Drug|placebo|placebo administered intranasally one time
1685310|NCT01577407|Drug|Nefopam|Subjects will be infused intravenously with nefopam (20mg/2mL) over a course of 30 minutes in a supine position. There will be a single administration of IV 20 mg nefopam and IV placebo. Each intervention will occur on a separate day.
1685311|NCT01577394|Other|oculomotor measurements|"The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.
Mean reflexive saccades latency Percentage of express saccades"
1685312|NCT01577381|Biological|RN6G|Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg
1685313|NCT01577381|Biological|Placebo|Intravenous, 11 doses, 30 minute infusion
1685314|NCT01577368|Drug|Piperacillin-Tazobactam continuous infusion|Piperacillin-Tazobactam 2gr (Loading dose DAY 1) plus Piperacillin-Tazobactam continuous infusion 8gr every 24 hours (DAY 1-14)
1685315|NCT01577368|Drug|Piperacillin-Tazobactam intermittent infusion|Piperacillin-Tazobactam intermittent infusion 4gr every 8 hours (DAY 1-14)
1685316|NCT01577355|Radiation|Drug|Single 30 mg oral dose containing 100 micro curies of LY2784544
1685317|NCT01577342|Drug|Moxifloxacin 0.5%|1 drop 4 times daily times 3 days post ranibizumab intravitreal injection
1685318|NCT01577329|Behavioral|Mindfulness meditation|Group class on mindfulness meditation. One hour weekly class led by nurse expert on meditation that includes mindfulness skills, body awareness skills and emotional awareness skills. Homework is assigned.
1685319|NCT01577316|Biological|Seasonal influenza vaccination|"2011-2012 Seasonal Trivalent Inactivated Influenza Vaccine (include A/California/7/2009 (H1N1)-like, A/Perth/16/2009 (H3N2)-like, and B/Brisbane/60/2008-like antigens) administered to 15ug without adjuvant, via intramuscular in pregnant and nonpregnant women.
It is recommended that vaccines for use in the 2012-2013 influenza season (northern hemisphere winter) contain the following:
an A/California/7/2009 (H1N1)pdm09-like virus;
an A/Victoria/361/2011 (H3N2)-like virus;
a B/Wisconsin/1/2010-like virus."
1685320|NCT01577303|Behavioral|Cognitive bias modification training program variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session, of one third is the neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word.
1685321|NCT01577303|Behavioral|Cognitive bias modification training program variant 2|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more positive word or face.
1685322|NCT01577303|Behavioral|CBM training program variant 3|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 3. Participant is exposed to two words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word.
1685323|NCT01577303|Behavioral|CBM training program variant 4|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
1685324|NCT01577303|Behavioral|Control training variant 1|Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 1. Participant is exposed to a pair of words -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words and is then asked to press the corresponding arrow button on a keyboard. A total of 192 word pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive word and the more negative word with equal frequency..
1685325|NCT01577303|Behavioral|Control training variant 2|Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
1685326|NCT01577290|Behavioral|Internet-administered Mindfulness Training Program|A 10 week, internet-administered mindfulness training program, featuring no therapist-support. 10 minutes of training, twice per day.
1685327|NCT01577290|Behavioral|Discussion group|Access to a discussion group with the possibility of sharing experiences, methods of relief, and the like.
1685328|NCT01577238|Drug|1% SPL7013 Gel|Vaginal gel, daily for 7 days
1685329|NCT01577238|Drug|Placebo|Vaginal gel, daily for 7 days
1685330|NCT01577225|Device|OPSITE POST-OP VISIBLE|Patient will be treated with OPSITE POST-OP VISIBLE dressing up to 14 days post surgery
1685331|NCT01577225|Device|Tape and Gauze|Patient will be treated with tape and gauze up to 14 days post surgery
1685332|NCT01577212|Radiation|Individualized dose escalation|Individualized dose escalation on the basis of the maximally tolerable dose to organs at risk - lung, esophagus, spinal cord, heart, brachial plexus
1685370|NCT01576861|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant Human Growth Hormone) 0,012 mg/kg every second day
1685333|NCT01577199|Drug|Low-dose Clomiphene|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed by clomiphene citrate 100mgon days 2-6 of the menstrual cycle with 225 international units of gonadotropins (eg Follistim , Menopur) starting on day 5
1685334|NCT01577199|Drug|High dose gonadotropins|Pretreatment with a 0.1mg estradiol patch in the luteal phase starting 10 days after the LH surge followed high dose gonadotropins (eg. Follistim. Menopur) 600IU starting on day 2 of the cycle
1685335|NCT01577186|Drug|Paliperidone ER|Participants will receive paliperidone ER tablet in flexible dose range of 3 to 12 milligram per day (mg/day) orally once daily up to Week 12 as per Investigator's discretion.
1685336|NCT01577173|Drug|MEHD7945A|1100 mg iv every 2 weeks
1685337|NCT01577173|Drug|cetuximab|400 mg/m2 iv loading dose, followed by 250 mg/m2 weekly
1685338|NCT01577160|Drug|Paliperidone ER|Participants will receive paliperidone ER 6 milligram (mg) orally once daily up to Week 12. Dose adjustment will be done at Week 2, 4 and 8 as per investigator's discretion based upon participant's CGI-I score.
1685339|NCT01577147|Other|Ovulation predictions products|Home diagnostics for ovulation prediction will be provided to study volunteers
1685340|NCT01577134|Behavioral|Social-cognitive resource intervention|Intervention group that receives a behavior change technique intervention to increase volitional strategies and physical activity.
1685341|NCT01577134|Behavioral|Social-cognitive resource intervention|Active control group that receives a behavior change technique intervention to increase volitional strategies and volunteering.
1685342|NCT01577134|Behavioral|no intervention|Passive control group that receives no intervention until the 8.5 months follow-up. Subsequently, they receive the information by mail the active groups received within the intervention.
1685343|NCT01577121|Drug|indomethacin|50 mg / 6 hours during 5 days
1685344|NCT01577121|Drug|placebo|50 mg / 6 hours during 5 days
1685345|NCT01577108|Dietary Supplement|Probiotic|oral taking 2 capsules before sleeping per day for 14 days
1685346|NCT01577108|Dietary Supplement|Placebo|oral taking 2 capsules before sleeping per day for 14 days
1685347|NCT01577095|Other|EA + Rosiglitazone|electroacupuncture and Rosiglitazone combined therapy on patient of type II DM
1685348|NCT01577095|Drug|TZD|Rosiglitazone 8 mg single dose
1685349|NCT01577082|Drug|CHF1535 200/6 µg|CHF 1535 (BDP/FF) 800/24 µg daily during 12 weeks
1685350|NCT01577082|Drug|BDP 100 µg|Beclomethasone Dipropionate 800µg daily during 12 weeks
1685351|NCT01577056|Dietary Supplement|Fish oil capsule|4g Omega capsule for 12 weeks
1685352|NCT01577056|Drug|HMG Coenzyme reductase|All FH subjects are on standard statin treatment during study period
1685353|NCT01577043|Drug|Racecadotril|Racecadotril, 30 mg per sachet, dosage 1.5 mg./kg./day
1685354|NCT01577043|Other|Placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per dose
1685355|NCT01577030|Dietary Supplement|Non-fat dairy|Add 4 daily servings per day of non-fat dairy (yogurt, milk, cheese) for a period of 4 weeks
1685356|NCT01577030|Dietary Supplement|Add 4 servings fruit|Add 4 daily servings of fruit (fruit cup, apple sauce, orange juice) and remove all dairy for a period for 4 weeks
1685357|NCT01577017|Drug|Letrozole|Women in group L will be assigned with Letrozole on night at day 5 to day 9 of the cycle
1685358|NCT01577004|Dietary Supplement|omega-3 fatty acid|Subjects will be given four 1 g capsules of fish oil providing 1.4 g/d of EPA and 1.0 g/d of DHA as ethyl esters (Ocean Nutrition, Dartmouth, NS), which is similar to the dose used in previous studies with MCI and AD (20, 21).
1685359|NCT01576978|Behavioral|hatha yoga|The women's group of Yoga will participate in ten week sessions of Yoga once a week for an hour. The sessions will be taught by instructor of Hatha Yoga. For the intervention were chosen 37 postures, three breathing exercises. The sessions were divided into three stages: quieting the mind , breathing rate and the heating of the main joints, postures and breathing exercises, meditation and relaxation. At the beginning and end of each session, we evaluated the pain intensity.Pregnant women in the control group Postural orientations will receive a booklet containing guidelines postural figures and explanatory text on some possible changes in the curvatures of the spine during pregnancy suggestions for positioning of the spine for daily activities, lying postures, sitting and standing. After ten weeks the two groups will be scheduled for the final collection of data.
1685360|NCT01576965|Drug|Fleet Enema (sodium biphosphate and sodium phosphate)|Those assigned to the mechanical bowel prep group will be asked to administer a single sodium phosphate enema rectally before going to bed the night before surgery. If stool is not clear in the morning, mechanical bowel prep subjects will administer one additional enema the morning of surgery
1685361|NCT01576952|Drug|ISV-303|Bromfenac in DuraSite
1685362|NCT01576952|Other|DuraSite Vehicle|DuraSite Vehicle
1685363|NCT01576939|Radiation|Intensity Modulated Radiation Therapy|"We are using thermoluminescent dosimeter (TLD) to measure the mucosal dose adjacent to the dental fillings in a standard, non-filling optimized IMRT (intensity modulated radiotherapy treatment) plan that is normally delivered in the clinic. If the measured mucosal dose exceeds 35 Gy, we will generate a filling optimized IMRT plan to reduce it to < 35 Gy. The new plan will be deemed acceptable and implemented only if it does not (1) compromise the tumor coverage, (2) increase the dose to either the remaining oral cavity or the spared parotid gland(s)."
1685364|NCT01576913|Other|Music listening|Listening to tempo music while cycling in an exercise test
1685365|NCT01576900|Behavioral|SyBeMeP (Systemized Behavioural Modification education Program)|"Standard video material will be developed to minimize variation of outcomes caused by differences in contents at each trial site.
Video material will be self-study program for PC with running time around 20 minutes. Contents will cover pathophysiology, diagnosis and treatment process, and be easy to understand for everyone with variety of examples. In treatment part, it will describe general principles of behavioural therapy (Adjustment of timing of fluid intake, Reducing alcohol and caffeine, Improving sleep hygiene including moderate exercise, room temperature, noise and lighting. if necessary, compressive stocking, late afternoon nap and leg elevation would be added)
During trial, patients will watch SYBeMeP at a specially prepared separate room with computer.
After watching the video, check-list on take-home message will be recorded by patients at the site to confirm patients' awareness after education."
1685366|NCT01576887|Drug|Bardoxolone Methyl 20 mg|Oral, once daily
1685367|NCT01576887|Drug|Placebo|Oral, once daily
1686251|NCT01570309|Other|Sugar pill|Oral capsule, once a week, 12 weeks
1685371|NCT01576848|Dietary Supplement|Protein|"Subjects will receive a drink containing 20 gram intrinsically labelled casein.
Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
1685372|NCT01576848|Dietary Supplement|Protein + carbohydrate|"subjects will receive a drink containing 20 gram intrinsically labelled casein plus 60 gram carbohydrates.
Half of the subject are young males (YOUNG)(age between 18 and 35 y) and half of the subjects are elderly males (OLD)(age between 70 and 85 y)."
1685373|NCT01576822|Other|This protocol will utilize a sauna as the primary method of detoxification.|"This study is a randomized, 2-arm, dose-finding safety and feasibility trial. After screening, informed consent and randomization, participants will complete a medically-monitored sauna-based detoxification program.
High Dose Participants randomized to this group will undergo a protocol consisting of 2 hours of sauna therapy per day, for a minimum of 5 days per week, completed in 3 weeks or less (21 days). (15 total sessions, 30 hours of sauna).
Low Dose Participants randomized to this group will undergo a protocol consisting of 1 hour of sauna therapy per day, for a minimum of 3 days per week, completed in 3 weeks or less (21 days). (9 total sessions, 9 hours of sauna)."
1685374|NCT01576809|Drug|IFF flavor 316 282, Paracetamol , Phenylephrine, Guaifenesin|Single dose syrup containing a warming flavor IFF flavor 316 282, in a syrup containing Paracetamol 500 mg + phenylephrine 10mg + Guaifenesin 200 mg per 30 ml syrup
1685375|NCT01576796|Radiation|Radiotherapy|"No additional dose (patients negative F-miso)
Radiation therapy is conducted under standard conditions of conformal radiotherapy:
The total dose was 66-70 Gy delivered in daily fractions of 2 Gy, 5 days a-week
With additional dose (patients positive for F-miso)
The dose in the PTVmiso increased until the maximum tolerable radiation by the lung."
1685376|NCT01576783|Drug|DHA+AA|200 mg DHA + 200 mg AA per day for 6 months
1685377|NCT01576783|Dietary Supplement|Placebo|400 mg corn oil per day for 6 months
1685380|NCT01576731|Drug|Tenofovir, Emtricitabine, Lopinavir/r|Combination drug
1685381|NCT01576731|Drug|Tenofovir, Emtricitabine, Raltegravir|Combination drug
1685382|NCT01576718|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.
During the treatment period, participants were randomized to 50, 100, 200 or 400 mcg of Fp one inhalation twice a day for a total daily dose of 100, 200, 400 or 800 mcg. Study drug was administered in the morning and in the evening."
1685383|NCT01576718|Other|Placebo MDPI|Placebo multidose dry powder inhaler (MDPI) in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
1685384|NCT01576718|Drug|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 250 mcg was used twice a day, once in the morning and evening, for a total daily dose of 500 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
1685385|NCT01576718|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
1685387|NCT01576692|Biological|Humanized anti-GD2 antibody|"A maximum of 6 courses of therapy may be given on the following schedule:
Courses 1, 3, and 5: Humanized anti-GD2 antibody + chemotherapy
Courses 2, 4, and 6: Humanized anti-GD2 antibody + chemotherapy, with or without natural killer (NK) cells (depending on availability of appropriate NK donor)
Humanized anti-GD2 antibody (hu14.18 K322A) dosage: 40 mg/m^2)/dose, over 4 hours daily
NK Cell dosage: minimum of 0.1 * 10^6 cells/kg; maximum of 400 * 10^6 CD45+ cells/kg, given once"
1685388|NCT01576692|Drug|Chemotherapy|"Chemotherapy may include the following at the dosages shown below:
cyclophosphamide: 400 mg/m^2 IV days 1-5
topotecan: 1.2 mg/m^2 IV days 1-5
temozolomide: 150 mg/m^2 PO at least 1 hour before irinotecan
irinotecan: 50 mg/m^2 IV over 1 hour daily for 5 days
carboplatin (AUC 8-dosing based on GFR), IV day 1 only
ifosfamide: 2 g/m2 IV days 1-3
etoposide: 100 mg/m2 days 1-3"
1685389|NCT01576692|Other|Cytokines|"Cytokines may be given at the following dosages:
interleukin-2: 1 million units/m^2 SQ beginning day 6 of each chemotherapy course and continued every other day for 6 doses
GM-CSF: 250 mcg/m^2/day beginning on day 7 or day 8 of chemotherapy course and continued daily through the nadir until ANC >2,000/mm^3"
1685390|NCT01576692|Biological|Natural killer cells|NK cells from haploidentical family donor will be infused on day 7 or 8, depending on course. NK cells may be infused in either the inpatient or outpatient setting by a physician, Physician Assistant, Nurse Practitioner, or qualified RN. Careful monitoring and supportive care during NK cell infusion will be guided in part by the Standard Operating Procedures for Lymphocytes Infusions in the St. Jude Nursing Policy & Procedure Manual.
1685391|NCT01576692|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
1685392|NCT01576679|Drug|Cathflo (Alteplase)|
1685393|NCT01576679|Drug|Saline|
1685394|NCT01576666|Drug|LDE225|
1685395|NCT01576666|Drug|BKM120|
1685396|NCT01576653|Other|Fungitell Assay in BAL|Fungitell Assay will be performed in BAL from patients with clinical suspicion of IFI
1685397|NCT01576640|Drug|NRT|Participants received nicotine replacement therapy in the form of nicotine gum/lozenge and nicotine patch
1685398|NCT01576640|Drug|Bupropion SR 150mg bid|Subjects were given bupropion SR 150 mg bid throughout the course of the study.
1685399|NCT01576640|Other|Relapse Prevention-Oriented Cognitive Behavioral Therapy|Subjects received relapse-prevention oriented cognitive behavioral therapy that was held weekly for 4 weeks, biweekly for 8 weeks, then monthly for 36 weeks.
1685400|NCT01576627|Dietary Supplement|zinc citrate|10 mg of zinc as either zinc citrate
1685401|NCT01576627|Dietary Supplement|Zinc Gluconate|10 mg of zinc as either zinc gluconate
1685402|NCT01576627|Dietary Supplement|Zinc oxide|10 mg of zinc as either zinc oxide
1685403|NCT01576614|Behavioral|Remote physician rounding|Use of Remote physician rounding using Remote Telepresence Robotics
1685404|NCT01576588|Drug|Rituximab|Rituximab (Rtx) antibody infusions will be administered on Day 1, 2, 3 (cycle 1) and Day 1 (cycles 2 to 4).
1685405|NCT01576588|Drug|Glucocorticoid|Glucocorticoid (either Dexamethasone or Methyl-prednisolone) infusions will be administered on Days 1 to 3 (cycles 1-4(6)) and should precede the Rituximab infusion.
1685406|NCT01576575|Drug|Buprenorphine|.2 mg IV or 2-4 mg sublingual
1685407|NCT01576575|Drug|Rifampin|600 mg orally for 7 days
1685408|NCT01576575|Other|grapefruit juice|8 oz at bedtime and 3oz in the morning.
1685409|NCT01576575|Drug|Ketoconazole|400 mg orally for 3-4 days
1685410|NCT01576549|Drug|LY2127399|Administered subcutaneously (SC)
1685411|NCT01576523|Biological|C1-esterase inhibitor - single intravenous dose|A single intravenous dose of C1-esterase inhibitor (Berinert) at 20 units per kg body weight will be administered to all subjects prior to receiving the first dose of subcutaneous C1-esterase inhibitor.
1685412|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous low dose|A low dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
1685413|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous medium dose|A medium dose of C1-esterase inhibitor will be administered subcutaneously twice a week for four weeks.
1685414|NCT01576523|Biological|C1-esterase inhibitor - subcutaneous high dose|A high dose of C1-esterase inhibitor will administered subcutaneously twice a week for four weeks.
1685415|NCT01576510|Behavioral|Prolonged Exposure (PE)|Prolonged Exposure (PE) therapy consists of ten 90-minute sessions. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation. The therapist helps the patient cognitively restructure his/her experience of the traumatic event. Each week the narrative is elaborated, becoming more detailed and exhaustive, until the patient habituates to it, extinguishing the anxiety it formerly aroused.
1685416|NCT01576497|Procedure|EUS-FNA|EUS-FNA with suction/10, 15, 20 to-and-fro motion vs. EUS-FNA without suction/10, 15, 20 to-and-fro motion Visual assessment as stoping rule: 20 to-and-fro motion at different site will be performed when EUS-FNA sampling with 10, 15, 20 to-and-fro motion is unsatisfactory.
1685417|NCT01576497|Device|EUS-FNA with suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
1685418|NCT01576497|Device|EUS-FNA without suction|For this prospective single-blinded randomized trial, two 10cc syringes was prepared. Two syringe was provided as same performance. However, one syringe is falsely made as suction syringe (fake one). During EUS-FNA, two syringe is randomly assigned and loaded by a nurse. Thus, operator was blinded which syringe is with suction or without suction.
1685419|NCT01576484|Drug|REGN727 (SAR236553)|REGN727(SAR236553) is an anti-PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody
1685420|NCT01576471|Biological|Trichuris suis ova (TSO)|TSO 7500: 7500 embryonated, viable TSO every 2 weeks X 10 weeks (up to 6 total doses)
1685421|NCT01576471|Biological|Placebo|Placebo: dose every 2 weeks X 10 weeks (up to 6 total doses)
1685422|NCT01576458|Drug|ursodeoxycholic acid|450 mg/day for 14 days
1685423|NCT01576458|Drug|Placebo|placebo
1685424|NCT01576445|Procedure|Mid-vastus approach|Mid-vastus approach to avoid patellar eversion and to minimise the muscle split.
1685425|NCT01576445|Procedure|medial parapatellar approach|medial parapatellar approach
1685426|NCT01576432|Behavioral|Assess pain with the NIPS score|In group 1 (BF+SSC), neonates dressed with a diaper were held in prone, in SSC with the mother; BF was started at least 5 minutes before heel lance and maintained during sampling. In group 2 (sucrose + SSC), neonates were held in prone between the mothers' breast at least 5 minutes before sampling and 2 ml 24% sucrose was given with a sterile syringe in the mouth 2 minutes before heel lance. In group 3 (SSC), neonates were held between the mother's breast as in group 2, but no sucrose was given. In group 4 (Sucrose), 2 ml 24% sucrose was administered through a sterile syringe in the mouth 2 minutes before heel lance to neonates laid on supine on a cot; the procedure was done in the presence of the mother. Mothers were allowed to speak or touch their babies in all the groups.
1685427|NCT01576419|Drug|PG201 tablet|One PG201 tablet and one celecoxib placebo capsule(after breakfast, in 30minutes), One PG201 tablet and one celecoxib placebo capsule(after dinner, in 30minutes)
1685428|NCT01576419|Drug|Celebrex capsule|One celecoxib capsule and one PG201 placebo tablet(after breakfast, in 30minutes), one celecoxib placebo capsule and one PG201 placebo tablet(after dinner, in 30minutes)
1685434|NCT01576393|Behavioral|Home-based Family Therapy|12 home-based family therapy sessions
1685435|NCT01576393|Behavioral|office-based family therapy|12 office-based family therapy sessions
1685436|NCT01576393|Behavioral|WHE|12 Women's Health Education Sessions
1685437|NCT01576380|Drug|TKI258|TKI258 is dosed on a flat scale of 500 mg, to be administered orally on a 5 days on / 2 days off dosing schedule which will be repeated every week.
1685438|NCT01576367|Biological|ACZ885|
1685439|NCT01576354|Drug|Prolonged-release Fampridine|10mg tablet twice a day (every 12 hours), orally
1685440|NCT01576354|Drug|Placebo|tablet twice a day (every 12 hours), orally (matched placebo is provided as oval-shaped, white to off-white, matrix tablets. Each tablet contains the following inactive ingredients: colloidal silicon dioxide, hydroxypropyl methylcellulose, magnesium stearate, microcrystalline cellulose, polyethylene glycol, and titanium dioxide)
1685441|NCT01576341|Drug|HX575 epoetin alfa (Sandoz)|Eligible patients are scheduled to receive HX575 (INN: Epoetin alfa) as a solution for injection in order to achieve or maintain the correction of renal anemia.
1685442|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 1
1685443|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 2
1685444|NCT01576328|Drug|Mesenchymal Precursor Cells (MPCs)|Single intravenous infusion of MPCs Dose 3
1685445|NCT01576315|Drug|Itraconazole/voriconazole|The two treatments will be administered orally for 6 months One doage of treatment permitted based on plasma levels will be performed after two weeks of treatment.
1685446|NCT01576302|Behavioral|Diaphragmatic breathing|Patients in this arm will be provided training in diaphragmatic breathing, taught its application in habit-reversal paradigm (to use after eating food and if urge to ruminate).
1685447|NCT01576302|Behavioral|Muscle relaxation|Progressive passive muscle relaxation
1685448|NCT01576289|Other|Histological analysis|Systematic histological analysis of biopsy specimens obtained during routine endoscopic examination
1685449|NCT01576276|Radiation|Integrated MR-PET scan|Integrated MR-PET scan using [11C]diprenorphine
1685450|NCT01576276|Drug|Ketorolac|3 administrations of ketorolac over course of study
1685451|NCT01576276|Drug|Morphine|3 administrations of morphine over course of study
1685452|NCT01576263|Drug|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg
1685453|NCT01576263|Drug|Autologous blood transfusion with ropivacaine|Local infiltration analgesia with ropivacaine 3 mg/kg, max 200 mg.
1685454|NCT01576250|Other|unilateral lower limb suspension|This is an intervention study, where each subject will undergo 12 days of unilateral lower limb suspension. Randomly, the dominant or the non-dominant leg of the subject will be suspended by attachment of a sling to a non-rigid ankle brace and to a harness on the upper body and unloaded from all weight bearing. The knee will be slightly flexed at an angle of 130°. Hip, knee and ankle will be fully mobile. The sling will be used during all locomotory activity, and the subjects will use crutches for walking.
1685455|NCT01576237|Other|blood donation|blood donation with preparative hemapheresis
1685456|NCT01576224|Device|"Removable splint omni med, Fischer Medical Aps, DK-2800 Lyngby, Denmark"|To be removed during training exercises three to five times a day
1685457|NCT01576211|Genetic|DNA methylation analysis|
1685458|NCT01576211|Genetic|RNA analysis|
1685459|NCT01576211|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
1685460|NCT01576211|Genetic|gene expression analysis|
1685461|NCT01576211|Genetic|nucleic acid sequencing|
1685462|NCT01576211|Genetic|polymorphism analysis|
1685463|NCT01576211|Other|laboratory biomarker analysis|
1685464|NCT01576198|Genetic|DNA analysis|
1685465|NCT01576198|Genetic|nucleic acid amplification|
1685466|NCT01576198|Other|diagnostic laboratory biomarker analysis|
1685467|NCT01576198|Other|medical chart review|
1685468|NCT01576185|Other|laboratory biomarker analysis|Correlative studies
1685469|NCT01576185|Drug|quizartinib|Via gavage
1685470|NCT01576185|Drug|sorafenib tosylate|Via gavage
1685471|NCT01576172|Drug|Abiraterone Acetate|Given PO
1685472|NCT01576172|Other|Laboratory Biomarker Analysis|Correlative studies
1685473|NCT01576172|Drug|Prednisone|Given PO
1685474|NCT01576172|Drug|Veliparib|Given PO
1685475|NCT01576159|Other|Running exercise|During this type of exercise intervention, subjects performed weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
1685476|NCT01576159|Other|Cycling exercise|During this type of exercise intervention, subjects performed a partial weight-bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
1685477|NCT01576159|Other|Swimming Exercise|During this type of exercise intervention, subjects performed a non-weight bearing exercise. This group participated in sessions of 40-min per day, three days per week, for a period of 12 weeks
1685478|NCT01576146|Drug|Etelcalcetide|Administered as an intravenous bolus three times a week at the end of each hemodialysis session at dosages up to a maximum of 15 mg.
1685479|NCT01576133|Behavioral|CAPABLE|Occupational therapy visits plus nursing visits plus handyman repair
1685480|NCT01576133|Behavioral|Attention visits|Participants in the attention control arm will receive 10 one hour visits over the course of 16 weeks. These visits will consist of sedentary activities
1685481|NCT01576120|Other|bowel prep regimen first boost 6 oz. and second boost 3 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.
In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)"
1685482|NCT01576120|Other|bowel prep regimen first boost 3 oz. and second boost 6 oz.|"Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure.
In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)"
1685483|NCT01576107|Other|Exercise counseling (behavior change techniques)|4-week exercise intervention for cancer patients of different entities and out-patient regimes.
1685484|NCT01576107|Other|Stress-management training|4-week stress-management-training for cancer patients of different entities and out-patient regimes.
1685485|NCT01576094|Drug|Milrinone|Before surgery, patients received milrinone (MR) (milrinone lactate 1 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to MR received 0.5 , 0.75 and 1 microg/kg per min
1685519|NCT01575821|Dietary Supplement|Eucalyptus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
1685520|NCT01575821|Dietary Supplement|Labiatae honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
1686020|NCT01572064|Procedure|Blood sample|1 fasted blood sample taken for metabolomics
1685486|NCT01576094|Drug|Levosimendan|Before surgery patients received levosimendan (levosimendan 2.5 mg/ml). Intravenous continuous infusion of the study drug through a separate central line started intraoperatively and was increased step-wise at predefined time points: dose 1, starting immediately after central lines were placed and maintained for the duration of the surgical procedure; dose 2, on NICU admission providing the patient was in stable haemodynamic condition; dose 3, starting after 2 hours of stability with dose 2, and maintained up to 48 hours IND infusion started. Accordingly, patients randomised to LEVO received 0.1 , 0.15 and 0.2 microg/kg per min, for doses 1, 2 and 3, respectively.
1685487|NCT01576081|Device|HEPHAISTOS|HEPHAISTOS unloading orthotic
1685488|NCT01576068|Other|Spirometry|Spirometry done in high-risk customers of community-pharmacies to detect airflow limitation
1685491|NCT01576042|Drug|amiodarone|The dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
1685492|NCT01576042|Drug|sotalol|The choice and dosage of antiarrhythmic medications will comply with the ACC/AHA 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
1685493|NCT01576042|Device|Biosense Webster's NAVI-STAR Thermo-Cool|The only ablation catheter that will be allowed in this study will be the Biosense Webster's NAVI-STAR Thermo-Cool catheter as it is the only catheter that has been approved by the FDA for sustained monomorphic VT due to prior myocardial infarction in adults.
1685494|NCT01576029|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
1685495|NCT01576029|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
1685498|NCT01576003|Drug|Glutamine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 days (6 months)
1685499|NCT01576003|Dietary Supplement|L-alanine|0.3 g/kg, taken orally/feeding tube every 12 hours/twice a day for 180 day (6 months)
1685500|NCT01575990|Behavioral|Making A Decision About CRC Screening|"Targeted by age and gender with 3 components.
Educational component
Values clarification exercise
Individualized decision making worksheet
The intervention or control condition is administered before the index visit with the patient's provider."
1685501|NCT01575990|Behavioral|Drivers 65 Plus|This text booklet is provided as an attention control for those in the control arm and like the intervention is administered prior to the index visit with the patient's provider.
1685502|NCT01575951|Radiation|MRI-DCE|"The treatment follows the standard practice including radiation dose and treatment volumes.
DCE-MRI imaging is to be performed immediately after CT simulation using the same immobilization device.
Pre-op DCE-MRI is performed and integrated into radiation simulation planning which is considered a standard technique for radiation oncologist to assess tumor volume and peritumoral edma. It will make radiation field more accurate and precise. This MRI is to be performed on the date of simulation immediately after CT simulation.
MRI image data is then transferred into radiation eclipse system, and integrated into the planning system for target contouring.
Follow the standard pre-operative radiotherapy technique using 3D conformal radiotherapy (3DCRT) or intensity modulated radiation therapy (IMRT) to deliver a total dose of 50 Gy at 2 Gy per fraction for trunk or extremity STS, or 45 Gy at 1.8 Gy per fraction for retroperitoneal STS, 5 treatments per week."
1685503|NCT01575938|Behavioral|HIV prevention intervention|"The 6-session HIV prevention intervention curriculum, LifeSkills, incorporates interactive activities, in-depth discussions, videos, games, and role-plays to help young transgender women develop, practice, and integrate new skills into real-life situations. Activities address each aspect our theoretical framework (information, motivation, behavior), including experiences that may pre-dispose young transgender women to HIV/STI risk. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention."
1685504|NCT01575938|Behavioral|Diet and Nutrition|The comparison condition is a 6-session group-based and manualized health promotion intervention. Participants will also receive HIV and STI testing and counseling prior to the start of the intervention.
1685505|NCT01575925|Drug|4 mg Oral POM + 40 mg Oral DEX|
1685506|NCT01575925|Drug|2 mg Oral POM + 40 mg Oral DEX|
1685507|NCT01575912|Other|experimental pain tests|
1685508|NCT01575899|Drug|Levofloxacin-Amox/clav.|Levofloxacin, 500 mg b.i.d., amoxicillin/clavulanate, 875mg/125mg b.i.d. and rabeprazole, 20 mg b.i.d. for 7 days.
1685509|NCT01575899|Drug|Clarithromycin-Amoxicillin|Clarithromycin, 500 mg b.i.d., amoxicillin, 1000 mg b.i.d. and rabeprazole 20 mg b.i.d. for 7 days.
1685510|NCT01575886|Other|Teachable Moment Communication Process|The Teachable Moment Communication Process intervention is designed to teach clinicians: (1) the skills necessary to recognize and foster teachable moments in clinical encounters, (2) strategies to effectively elicit the patients' perspective on health behavior change, and express their alignment with that perspective, and (3) the ability to respond to the patient in a non-confrontational manner while providing brief advice appropriate to the patient's expressed level of readiness to change. The Teachable Moment Communication Process intervention consists of two, 3-hour educational training sessions including didactic presentation, skill demonstration through video examples, skills practices with standardized patients, and feedback from peers and the trainers.
1685511|NCT01575873|Drug|Active denosumab|Active denosumab with placebo for risedronate
1685512|NCT01575873|Drug|Placebo for risendronate|Active denosumab will be administered with placebo risedronate
1685513|NCT01575873|Drug|Active risendronate|Active risendronate will be administered with placebo denosumab
1685514|NCT01575873|Drug|Placebo for denosumab|Active residronate will be administered with placebo denosumab
1685515|NCT01575860|Drug|Lenalidomide|
1685516|NCT01575834|Drug|Romosozumab|Administered by subcutaneous injection once a month (QM)
1685517|NCT01575834|Drug|Placebo|Administered by subcutaneous injection once a month (QM)
1685518|NCT01575834|Drug|Denosumab|Administered by subcutaneous injection once every 6 months (Q6M)
1685616|NCT01575145|Behavioral|Brief stop-smoking intervention|brief review of tips to help maintain smoking abstinence, using brochure
1685521|NCT01575821|Dietary Supplement|Citrus honey|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
1685522|NCT01575821|Dietary Supplement|Silan date extract|Parents were instructed to administer 10 grams of theirs child treatment product (single dose) within 30 minutes of the child going to sleep.
1685524|NCT01575795|Drug|Ticagrelor|Ticagrelor 360mg loading dose immediately pre prior percutaneous coronary intervention 360mg loading dose
1685525|NCT01575795|Drug|Ticagrelor|Ticagrelor 180mg loading dose 180mg loading dose
1685526|NCT01575782|Drug|Chloroquine|Daily intake of Chloroquine during radiotherapy
1685527|NCT01575769|Drug|RoActemra/Actemra (tocilizumab)|Tocilizumab 8 mg/kg every 4 weeks for 104 weeks
1685528|NCT01575756|Biological|Octafibrin|Octafibrin was supplied as a powder for reconstitution with water for injection.
1685529|NCT01575756|Biological|Haemocomplettan® P or RiaSTAPTM|Commercially available Haemocomplettan® P or RiaSTAPTM (same product with different names in different markets) were supplied as powders for reconstitution with water for injection.
1685530|NCT01575743|Behavioral|aerobic exercising|All participants take part in an aerobic exercise training program with a total weekly energy expenditure of 17.5 kcal/kg/week over the entire 12-week intervention period. The dose of exercise is determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM, American College of Sports Medicine, 2000). All trainings take place at a local public gym under supervision of previously trained exercise coaches from the Institute of Exercise and Health Sciences of the University Basel. Participants can choose between different training devices for cardiovascular training. Energy expenditure is assessed using the values of burned calories provided by the training devices based on age, weight and training performance. Heart rate is monitored during all training sessions with chest belt heart rate monitors (Polar®) to ensure training below the anaerobic threshold with heart rates between 60 - 75 % of the maximum heart rate.
1685531|NCT01575730|Procedure|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 37°C
1685532|NCT01575730|Procedure|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 460 mg/m², duration: 30 minutes, temperature 41°C
1685533|NCT01575730|Drug|Hyperthermic intraoperative Peritoneal Chemoperfusion|Dose: 200 mg/m², duration: 90 minutes, temperature 37°C
1685536|NCT01575704|Other|Exercise|Supervised exercise training (aerobic, resistance, flexibility), 5 times per week
1685537|NCT01575704|Other|Mental Training|Memorial/ mental training and relaxation, 5 times per week
1685538|NCT01575691|Drug|5-Azacytidine (5-aza)|Start at 75 mg/m^2 subcutaneously daily for 7 days.
1685539|NCT01575691|Drug|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
1685540|NCT01575691|Drug|All-Trans Retinoic Acid (ATRA)|45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
1685541|NCT01575678|Drug|Melatonin|blinded capsule 2-4 mg/day, oral use, for 4 weeks
1685542|NCT01575678|Drug|Lactose|blinded capsule 1/day, oral use, for 4 weeks
1685543|NCT01575665|Device|Partial Rebreathing Mask|Inducing normal CO2 for two hours a day for four weeks
1685544|NCT01575652|Other|Group using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level with use of ACEIs
1685545|NCT01575652|Other|Group not using angiotensin converting enzyme inhibitor|Measurement of peritoneal protein loss level without usage of ACEIs
1685546|NCT01575639|Drug|Oral prednisolone|Dose will be different in the two groups. the high dose group will receive 4 mg/kg/day. The usual dose group will receive 2 mg/kg/day
1685547|NCT01575626|Drug|Sevoflurane|"All active comparators of this study have the same intervention as mentioned ahead:
First IOP measurement will be performed just before anesthesia induction. Standard general anesthesia will be induced using propofol (5 mcg/ml) administered by target controlled infusion (TCI - Schnider model),fentanyl and rocuronium according to standard protocol of general anesthesia. The second IOP measurement will be performed just before tracheal intubation.
Following tracheal intubation, concentration of propofol will be decreased till 0 and anesthesia with sevoflurane will be started, followed by 3 more IOP measurements for different end-tidal sevoflurane concentrations (Consented patients will be randomly allocated to one of three groups as mentioned).
Total of 5 IOP measurements. IOP will be measured by the ophthalmologist via both TonoPen XL and Schioz devices."
1685548|NCT01575613|Drug|Artemether-lumefantrine combination|Focal screening and treatment in all households in malaria hotspots prior to the peak transmission season. Screening of a sentinel age group by rapid diagnostic tests; all parasitaemic individuals and household members of parasitaemic individuals will be treated.
1685549|NCT01575613|Biological|Bacillus thuringiensis|Treatment of all waterbodies within hotspots with Bti or Bs on weekly basis
1685550|NCT01575613|Biological|Long lasting insecticide treated net (LLINs)|Distribution of LLINs in all households in malaria hotspots; instruction about correct use.
1685551|NCT01575613|Biological|Indoor Residual Spraying (IRS)|6-monthly IRS with deltamethrin in all households malaria hotspots.
1685552|NCT01575600|Other|Intraoperative lactated Ringer's solution|After induction, IV access was established and children were randomly allocated to receive one of two interventions: Group 1, 10 mL/kg/h lactated Ringer's solution; Group 2, 30 mL/kg/h lactated Ringer's solution.
1685553|NCT01575587|Drug|Abiraterone: Treatment A|1000 mg abiraterone acetate administered in the fasting state
1685554|NCT01575587|Drug|Abiraterone: Treatment B|Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose
1685555|NCT01575587|Drug|Abiraterone: Treatment C|Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose
1685556|NCT01575587|Drug|Abiraterone: Treatment D|Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose
1685657|NCT01574781|Procedure|Blood draw|Blood is drawn at the appropriate time given their cohort inclusion.
1686312|NCT01569828|Drug|LCZ696A|
1685557|NCT01575574|Drug|GADOXETIC ACID|all patients will have a magnetic resonance with gadobutrol as reference for diagnosis; in participants an additional magnetic resonance will be done with the new contrast agent to verify if the diagnostic can be done.
1685558|NCT01575561|Drug|Lurasidone|Lurasidone 20-80 mg taken orally once daily
1685564|NCT01575535|Genetic|gene expression analysis|
1685565|NCT01575535|Other|flow cytometry|
1685566|NCT01575535|Other|fluorescence activated cell sorting|
1685567|NCT01575535|Other|laboratory biomarker analysis|
1685568|NCT01575535|Other|medical chart review|
1685569|NCT01575522|Other|Laboratory Biomarker Analysis|Correlative studies
1685570|NCT01575522|Drug|Tivantinib|Given PO
1685571|NCT01575509|Other|Berry product|Sugar infused dried lingonberry
1685572|NCT01575509|Other|Bread product|Brown bread
1685573|NCT01575509|Other|Bread product|Whole grain bread
1685574|NCT01575509|Other|Glucose control solution|Glucose solution with a corresponding amount of carbohydrates as provided by the bread test products
1685575|NCT01575509|Other|Glucose-fructose control solution|Control solution with a similar carbohydrate content as provided by the dried lingonberry test product
1685576|NCT01575496|Device|BrainSTIM Transcranial Stimulator|Cathodal stimulation of the auditory cortex with an anode (reference electrode) over the prefrontal cortex. Stimulation will be applied for 20 minutes at 2 mA.
1685577|NCT01575496|Device|BrainSTIM Transcranial Stimulator|Sham tDCS sessions will last 20 minutes.
1685578|NCT01575483|Drug|No Intervention (subjects were previously treated with Onglyza®)|No Intervention
1685579|NCT01575470|Biological|autologous bone marrow mononuclear cells|bone marrow harvest (5ml/kg of body weight) performed within 36 hours of injury, followed by single intravenous infusion of bone marrow mononuclear cells.
1685580|NCT01575457|Behavioral|Career Counseling and Motivational Interviewing|The Healthy Futures Program is an interactive, multi-session training program. There will be participants in 3 different intervention tracks (College/vocational school, Job, and Career Planning). Activities for all three tracks will occur simultaneously. The intervention group will receive the interactive, multi-session training program including newsletters and workshops. Comparison group participants will receive newsletters and be invited to participate in college and career planning workshops.
1685581|NCT01575418|Drug|Rectal formulation (RF) of tenofovir 1% gel|The RF is translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg.
1685582|NCT01575418|Drug|Vaginal formulation (VF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/ weight or w/w) of tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy)propyl]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. This formulation has been used in all clinical trials (vaginal, penile, and rectal) of tenofovir 1% gel to date.
1685583|NCT01575418|Drug|Reduced glycerin vaginal formulation (RGVF) of tenofovir 1% gel|Modified slightly from the original VF formulation, the RGVF has a lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobical effectiveness. The RGVF formulation with 2.75% HEC was used in MTN-007 (CONRAD IND 73,382; currently enrolling), which is the only clinical study of this formulation. The RGVF formulation has since been modified to increase the viscosity.
1685584|NCT01575418|Radiation|Radiolabeling of study drugs and semen|"Study products (i.e. the gel formulations) will be radiolabeled with 111In-DTPA, an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear medicine studies. The delivered dose per gel study product will be approximately 100 microCuries (µCi) to allow sufficient visualization for the imaging period.
Autologous whole semen collected from the participants at designated visits will be radiolabeled with a delivered dose of approximately 500 microCuries (µCi) of 99mTc-sulfur colloid, also an FDA-approved radiopharmaceutical commonly used in diagnostic nuclear studies. The study team at JHU has extensive experience administering these radiopharmaceuticals rectally. Both of these radiopharmaceuticals will be prepared and delivered by a commercial radiopharmacy and mixed by the study investigators with the respective gel and whole semen vehicles.
The study product and autologous whole semen will be loaded into calibrated syringes with luer lock adapter for dosing."
1685585|NCT01575405|Drug|Rectal formulation (RF) of tenofovir 1% gel|The RF is a translucent colorless viscous gel formulation containing 1% (w/w) of tenofovir (PMPA) formulated in purified water with EDTA, glycerin, methylparaben, propylparaben, carbopol, sodium carboxy methyl cellulose, and pH adjusted to 7. The RF is close to isoosmolar with an osmolality of 479 mOsmol/kg. Seven doses of this formulation will be used.
1685586|NCT01575405|Drug|Vaginal formulations (original VF and reduced vaginal glycerin formulation RGVF) of tenofovir 1% gel|The original VF is a transparent, viscous gel formulation containing 1% (weight/weight) of tenofovir (PMPA, 9-[(R)-2-(phosphonomethoxy) propyl]adenine monohydrate), formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben, hydroxyethylcellulose, and pH adjusted to 4-5. One dose of this formulation will be used, with 6 doses of the HEC placebo gel preceding it to balance out this study stage. The reduced glycerin formulation (RGVF) is a modification of the original VF - it has lower glycerin content than the VF and a significantly reduced osmolality (836 or 846 versus 3111 mOsmol/kg). Lowering the glycerin content lowered the viscosity, so the HEC concentration was increased by 10% (a change considered to be insignificant). The amount of parabens was increased by 10% each to improve the antimicrobial effectiveness. The RGVF formulation has since been modified to increase the viscosity. Seven doses of RGVF will be used in this study.
1685617|NCT01575119|Behavioral|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
1738807|NCT00099801|Drug|FTY720|
1685587|NCT01575405|Drug|Universal HEC Placebo Gel Formulation|The Universal HEC Placebo Gel contains hydroxyethylcellulose as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. The gel is isotonic and formulated at a pH of 4.4 to avoid disrupting the normal vaginal pH and has minimal buffering capacity to avoid the inactivation of sexually transmitted pathogens. Hydroxyethylcellulose is used to approximate the viscosity of microbicide gel candidates. Each pre-filled applicator will deliver approximately 4 mL of HEC placebo gel. Six doses of this gel will be used to balance out the VF stage of the study.
1685588|NCT01575379|Drug|Allopurinol|The allopurinol dosage will vary from 200 to 400 mg per day based on GFR. Subjects randomized to allopurinol will initially take 100 mg per day for four weeks. After that, they will be switched to 400 mg per day if their GFR is ≥50 ml/min/1.73 m2, 300 mg per day if their GFR is in the 25-50 ml/min/1.73 m2 range, and 200 mg per day if the GFR is in the 15-25 ml/min/1.73 m2 range. Allopurinol will be continued at this dosage throughout the study unless the GFR changes, in which case the dosage will be modified to that appropriate for the new GFR class.Subjects will be given four tablets per day to be taken orally following meals, two in the morning and two in the evening. A dosage of 100 mg will be given as a 100 mg tablet plus three placebo tablets, 200 mg as two 100 mg and two placebo tablets, 300 mg as three 100 mg and one placebo tablet, 400 mg as four 100 mg tablets. Subjects randomized to placebo will be given four placebo tablets.
1685589|NCT01575379|Drug|Placebo|Subjects will be given four placebo (inactive) tablets per day to be taken orally following meals, two in the morning and two in the evening.
1685590|NCT01575366|Behavioral|Tracking training|The paretic finger movement training at different velocities included two 5-week periods of five days per week, 2-hours per day phases. The frequency for the higher-velocity training is 0.8 Hz, whereas the lower frequency training is 4 times slower, at 0.2 Hz. The two periods are each followed by a 3-week baseline period. The subject is seated in front of a laptop computer with the paretic forearm resting on the arm of the chair in a quiet room at home. The position of the forearm is pronated. An electrogoniometer, composed of a potentiometer attached to a custom hand splint, is placed on the paretic index finger with the potentiometer centered at the metacarpophalangeal joint. To keep the training session time equal between the two training phases, the duration of each slow training trial is 5 sec, compared to 20 sec for each fast training trial. Ultimately, the total number of required finger extension/flexion training movements is equal between the two phases.
1685591|NCT01575353|Device|Venturi mask|The patients will receive oxygen delivered through a conventional Venturi mask. The FiO2 (color coded) will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients.
1685592|NCT01575353|Device|Nasal high-flow|The patients will receive oxygen delivered through the nasal high-flow system (Optiflow™). The FiO2 will be adjusted in order to obtain a SpO2 between 92% and 98% in hypoxemic patients and between 88% and 95% in hypercapnic patients. Gas flow will be set at 50l/min.
1685593|NCT01575340|Dietary Supplement|fish oil encapsuled|2 g/d (4 capsules of 500 mg)for 9 weeks
1685594|NCT01575327|Device|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal and collects the cardiorespiratory parameters
1685595|NCT01575327|Device|Manual settings with FreeO2 system in collection mode|FreeO2 system does not adjust oxygen flow but collects the cardiorespiratory parameters
1685596|NCT01575314|Device|stapling device|Stapling device include GIA 80, TA 45, endo GIA 60, endo GIA 45
1685597|NCT01575301|Drug|Exenatide, Liraglutide|Dosage, frequency and duration not specified by protocol
1685598|NCT01575288|Drug|Placebo|100g maltose 1/day
1685599|NCT01575288|Drug|High-dose trehalose|100g 1/day
1685602|NCT01575262|Behavioral|Non-cash incentives|Participants used their PAL card to self-monitor physical activity levels (intrinsic motivation) and minutes of physical activity were converted to points (1 minute of PA = 1 point; capped at 30 points per day) over the 12-week intervention period. Points were redeemed for rewards (extrinsic motivation) at week 6 and week 12.
1685603|NCT01575262|Behavioral|Self-monitoring physical activity levels|For those in the 'No Incentive' arm, participants used their PAL card to self-monitor their physical activity levels but did not collect points or earn rewards.
1685604|NCT01575236|Device|Guardian Laryngeal Mask|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
1685605|NCT01575236|Device|Supreme Laryngeal Mask Airway|ease of insertion, oropharyngeal seal pressure, fiberoptic position, ease of ventilation, occult blood, gastric insertion
1685606|NCT01575223|Device|NeilMed sinus rinse|High volume saline irrigation
1685607|NCT01575223|Device|Salinex|Low volume saline irrigation
1685608|NCT01575197|Biological|Human Rotavirus Vaccine|Rotavirus vaccine will be administered concomitantly with other routine Expanded Programme on Immunization (EPI) vaccinations at 6 & 10 weeks of age, 10 & 14 weeks of age, or 6, 10, & 14 weeks of age, depending on study arm assignment.
1685609|NCT01575184|Other|caudo-ipsilateral traction of shoulder|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the slight caudo-ipsilateral traction of shoulder will be applied without changing the degree of the head rotation.
1685610|NCT01575184|Other|The ultrasonographic measurements without shoulder traction|After the head rotation (0, 40, 80 degrees) to the contralateral side from the ultrasound measuring site, the no traction of shoulder will be applied.
1685611|NCT01575171|Behavioral|Nudge|"Behavioral economics recognizes that individuals often are not fully rational in the purely economic sense, but are subject to the influence of various social, environmental and cognitive factors in their decision making. And, one can take advantage of these findings to nudge individuals, in our case physicians, towards more optimal choices. Physicians randomized to the automated clinical decision support nudge will see the new optout prescribing procedure as part of their EHR interface. This will include initially prescribing the guideline-based medication, simvastatin 20mg. Nearly six months after this visit, physicians will receive a reminder via EHR to schedule a follow-up fasting lipid profile as recommended by ATP III guidelines."
1685612|NCT01575158|Drug|Citalopram|
1685613|NCT01575158|Drug|Clomipramine|
1685614|NCT01575158|Drug|placebo|
1685615|NCT01575145|Behavioral|Quitline facilitation intervention|brief quitline facilitation intervention
1685618|NCT01575119|Behavioral|Control intervention|Standard of care information, including distributing patent education brochure, to provide information regarding perioperative smoking
1685619|NCT01575119|Behavioral|Decision Aid|Decision Aid tool is presented by respiratory therapist, prompting a discussion with the provider (physician or physician assistant)about smoking around time of surgery
1685620|NCT01575119|Behavioral|Control|Standard of care information, including distributing patient education brochure, to provide information regarding perioperative smoking
1685622|NCT01575093|Other|The preparation regimen|Regimen includes administration of 4 Senna tablets 2 days before the procedure, 2-liters of PEG on the evening before the procedure, 2-liters of PEG on the morning of the procedure, 10mg Metoclopramide, two boosts (6-oz and 3-oz) of SUPREP oral sulfate solution and a 10mg Bisacodyl suppository
1685623|NCT01575080|Device|Contour TS Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm and forearm using the Contour TS Blood Glucose Monitoring System. All BG results are compared to a reference laboratory glucose method.
1685624|NCT01575054|Biological|botulinum toxin Type A|Double-Blind Study Phase (12 weeks): On Day 1, botulinum toxin Type A 300 U will be given by intramuscular injections into specified muscles of the lower limb, and an optional dose of 100 U may be injected into additional lower limb muscles. Open Label Study Phase: Up to 3 treatments with botulinum toxin Type A up to 400 U will be given by intramuscular injections to the lower limb approximately every 12 weeks over a 42 week period.
1685625|NCT01575054|Drug|Normal Saline|Double-Blind Study Phase (12 weeks): On Day 1, normal saline (placebo) will be given by intramuscular injections into specified muscles of the lower limb, and optional injections may be administered into additional lower limb muscles.
1685626|NCT01575041|Dietary Supplement|Sodium|Sodium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a sodium intake of 3 grams.
1685627|NCT01575041|Drug|Potassium|Potassium Chloride (provided by Microz, Geleen, Netherlands): 8 capsules per day which equals a potassium intake of 3 grams.
1685628|NCT01575041|Drug|Placebo|Placebo (cellulose, provided by Microz, Geleen, Netherlands): 8 capsules per day.
1685629|NCT01575028|Drug|Ropivacaine|The TAP block will be delivered with 0.2ml/kg of 0.2% Ropivacaine with 1:200,000 epinephrine bilaterally
1685630|NCT01575028|Drug|Bupivacaine|The local anesthetic at the incision sites will be injected by the surgeon.
1685631|NCT01575015|Device|Continuous renal replacement therapy (CRRT)|Patients allocated with intraoperative CRRT will have a dialysis catheter inserted and receive CRRT during liver transplantation
1685632|NCT01575015|Procedure|Standard intraoperative support|Patients allocated to standard intraoperative support will receive usual care (no CRRT).
1685633|NCT01575002|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 2 sessions of 20 minutes of tDCS stimulation (either active or sham)in a randomized order - each session will be separated by at least one week to prevent carry-over effects.
1685634|NCT01574989|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will either undergo (1) active low-frequency rTMS (1Hz continuous), (2) active high-frequency rTMS (10Hz, 2 second trains with inter-train interval of 28 seconds) or (3) sham rTMS (using a sham coil). Each session will last 20 minutes and will be conducted at 100% of the motor threshold.
1685635|NCT01574989|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will either undergo (1) active anodal tDCS, (2) active cathodal tDCS or (3) sham tDCS. Each session will last 20 minutes and will be conducted using 1mA with 35^2 electrodes.
1685636|NCT01574976|Behavioral|probabilistic choice|subjects should choose between low-certain outcome and high-uncertain outcome
1685637|NCT01574937|Drug|Cabozantinib|28 day cycle
1685638|NCT01574937|Drug|Abiraterone|28 day cycle
1685639|NCT01574924|Other|No intervention.|There are no interventions in this observational study.
1685640|NCT01574898|Drug|V0474 - A mg|Single oral administration
1685641|NCT01574898|Drug|V0474 - B mg|Single oral administration
1685642|NCT01574898|Drug|V0474 - C mg|Single oral administration
1685643|NCT01574898|Drug|V0018 - B mg|Single oral administration
1685644|NCT01574898|Drug|Niquitin® Fresh Mint 4 mg|Single oral administration
1685645|NCT01574885|Device|Halotherapy|The treatment consist of 10 session of micronized iodized salt (sodium chloride) inhalation in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
1685646|NCT01574885|Device|Placebo|The treatment consist of 10 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
1685647|NCT01574872|Device|Halotherapy|The treatment consist of 15 session of micronized iodized salt (sodium chloride) skin exposure in a chamber that reproduces the environmental characteristics of a natural salt cave. Each daily session last 30 minutes.
1685648|NCT01574872|Device|Placebo|The treatment consist of 15 sessions in a chamber that emulates the environmental characteristics of a natural salt cave but with no salt emanation. Each daily session last 30 minutes.
1685649|NCT01574859|Other|levothyroxine|titration of T4 according to biochemical values
1685650|NCT01574833|Device|pulsed electromagnetic field|PEMF treatment
1685651|NCT01574833|Device|sham|sham treatment
1685652|NCT01574820|Drug|placebo tablet|placebo tablet for 6 months
1685653|NCT01574820|Drug|rosiglitazone (4 mg)/day|rosiglitazone (4 mg)/day for 6 months
1685655|NCT01574794|Other|Muscle strengthening exercises|The group will perform 8-week home based muscle strengthening exercises with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist.
1685656|NCT01574794|Other|Muscle stretching exercise|The group will perform 8 week home based exercise intervention with 8 weekly supervised sessions which will be conducted by a rehabilitation specialist
1738898|NCT00084786|Drug|docetaxel|
1685658|NCT01574781|Procedure|Cheek swab/Saliva Sampling|In lieu of blood draw, male relatives may donate cheek swab or saliva sample. Children born to participating women can donate cheek swab or saliva sample soon after birth.
1685659|NCT01574768|Procedure|Lateral Pharyngoplasty|Tonsilectomy, microdissection of the superior pharyngeal constrictor muscle within the tonsillar fossa and sectioning of this muscle
1685660|NCT01574742|Drug|Minocycline|Minocycline 200 mg/day (2X100 mg) from day 1 to day 3 and Minocycline 400 mg/day (2X200mg) form day 4 until termination visit (day 35)
1685661|NCT01574729|Drug|Surgery combined with rAd-p53 gene therapy|Surgery combined with rAd-p53 gene therapy during surgery plus post-surgery chemotherapy
1685662|NCT01574729|Procedure|Surgery|Surgery plus post-surgery chemotherapy
1685663|NCT01574716|Drug|MORAb-004|IV, Days 1 and 8 of every cycle until disease progression
1685664|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
1685665|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
1685666|NCT01574716|Drug|Gemcitabine|IV, Days 1 and 8 of each cycle until disease progression
1685667|NCT01574716|Drug|Docetaxel|IV, Day 8 of every cycle until disease progression
1685668|NCT01574716|Drug|Placebo|
1685669|NCT01574703|Drug|placebo|All dosing to have taken place per study A3051123
1685670|NCT01574703|Drug|varenicline tartrate|All dosing to have taken place per study A3051123
1685671|NCT01574703|Drug|bupropion hydrochloride|All dosing to have taken place per study A3051123
1685672|NCT01574703|Drug|Nicotine Replacement Therapy Patch|All dosing to have taken place per study A3051123
1685673|NCT01574690|Device|Mespere Venus System|For this non-invasive system, an adhesive patch (connected to the Mespere Venus system) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with the CVP values obtained by RHC and physical exam
1685674|NCT01574690|Procedure|Right heart catheterization (RHC)|Invasive procedure to assess CVP. Standard of care.
1685675|NCT01574690|Procedure|Physical examination of jugular vein|Physicians assess CVP using the subject's jugular vein.
1685676|NCT01574664|Device|RFID Tag (Health Beacon)|The radiologist or surgeon will place the Health Beacons RFID Tag under ultrasonic or stereotactic guidance. The surgeon will use the Tagfinder to locate the lesion.
1685677|NCT01574651|Drug|QVA149|QVA149 110/50µg, once daily (q.d.) is administered via a single-dose dry powder inhaler
1685678|NCT01574651|Drug|Placebo to tiotropium|Placebo to tiotropium capsules daily (q.d.) for inhalation, delivered via proprietary inhaler (Handihaler®). Placebo tiotropium inhalation capsules were matched in size and color to tiotropium 18 μg q.d. inhalation capsules
1685679|NCT01574651|Drug|Placebo to formoterol|Placebo to formoterol capsules twice daily (b.i.d) delivered via Aerolizer® device. Placebo formoterol inhalation capsules were equally matched in size, shape and color to formoterol 12 μg b.i.d. inhalation capsules.
1685680|NCT01574651|Drug|Tiotropium|Tiotropium 18µg, once daily is administered via the manufacturer's proprietary inhalation device.
1685681|NCT01574651|Drug|Formoterol|Formoterol 12µg, twice daily is administered via the manufacturer's proprietary inhalation device.
1685682|NCT01574651|Drug|Placebo to QVA149|Placebo to QVA149 is administered via a single-dose dry powder inhaler. Placebo QVA149 inhalation capsules were equally matched in size, shape and color to QVA149 110/50 μg q.d. inhalation capsules
1685683|NCT01574638|Drug|Rifapentine (RPT)|Participants will receive 150-mg RPT tablets orally either once or twice daily, with total tablet number/dosage amount varying according to weight at entry and arm assignment and following dosing tables in the protocol.
1685684|NCT01574612|Drug|acyclovir/hydrocortisone cream|cream applied topically to lesion five times daily for five days
1685685|NCT01574599|Other|Occupational therapy- Repetitive Facilitative Exercise|Occupational therapy program - Repetitive facilitative exercise therapy protocol including 40 min of RFE and 20 minutes of task-specific activity. 3 treatment sessions weekly for a total of 4 weeks.
1685686|NCT01574586|Device|Bifurcation stenting|Bifurcation stenting using 2-link stent Nobori versus 3-link stent Xience
1685687|NCT01574573|Behavioral|Self support, group sessions|Self support,group sessions
1685688|NCT01574560|Behavioral|Brochure|Information regarding secondhand smoke and creating a healthy home environment.
1685689|NCT01574560|Behavioral|Counseling|Receives brochure and counseling sessions focusing on changing smoking behaviors and/or other health behaviors.
1685690|NCT01574534|Device|Drug eluting balloon|PCI using paclitaxel-eluting SeQuent® Please balloon, B. Braun Melsungen AG, Berlin, Germany
1685691|NCT01574534|Device|Drug eluting stent|PCI using paclitaxel-eluting Taxus Element® stent, Boston Scientific Corp, Natick MA
1685692|NCT01574508|Drug|Transient Continuous Subcutaneous Insulin Infusion|Patients will be given Continuous Subcutaneous Insulin Infusion during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital.
1685693|NCT01574508|Drug|Transient Multiple Daily Insulin Injections|Patients will be given Transient multiple daily insulin injections during two weeks confinement in the hospital. The initial dosage will be body weight (kg)*0.5, and will be adjusted according to the 7 points glucose monitoring records in the hospital
1685694|NCT01574495|Other|Error Augmentation|error augmentation for arm motor recovery in individuals with stroke
1685695|NCT01574482|Other|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
1685696|NCT01574482|Other|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
1685697|NCT01574469|Other|1-Low fat fermented dairy product enriched with plant sterol esters (0,8 g equivalent as free sterols) (test)|1 = Intervention 1 (2 test products / day)
1685698|NCT01574469|Other|2-Low fat fermented dairy product (control)|2 = Intervention 2 (2 control products/day)
1685699|NCT01574430|Procedure|PDT|30% or 50% verteporfin dose PDT was given to patients with CSC
1685700|NCT01574417|Dietary Supplement|control margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the control margarine is consumed together with a high-fat milkshake.
Daily consumption of 20 gram of a control margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
1685701|NCT01574417|Dietary Supplement|plant stanol-enriched margarine|"Subjects will undergo a postprandial test for 5.5 hours, in which 26.7gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake.
Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 3 weeks."
1685702|NCT01574404|Procedure|Polar body biopsy with PGS|PB biopsy and analysis by comparing the PB results to the FISH/microarray results
1685703|NCT01574391|Device|Epidrum|Epidrum is used
1685704|NCT01574378|Device|conventional closure|non barbed sutures used to close wounds Conventional three layer wound closure using non-locking sutures polyglactin 910 (Vicryl, Ethicon) and polyglecaprone 25 (Monocryl, Ethicon)
1685705|NCT01574378|Device|V-Loc 90|2-layer wound closure using V-Loc 90 barbed suture
1685706|NCT01574365|Drug|RTA 402|
1685707|NCT01574352|Behavioral|Small intervention|The control group are offered a weekly 1 hour training or activity session during six weeks. Furthermore two sessions where the parents are invited to participate in information about diet and exercise.
1685708|NCT01574352|Behavioral|Intervention camp|The children are participating in a 6 week day camp. The camp contains social activities, physical activity training, usual school classes and health education. All meals (healthy food) are consumed during the camp day.
1685709|NCT01574339|Device|EndoStim LES Stimulation System|"The EndoStim LES Stimulation System comprises three components: an electrical stimulation lead, an implantable pulse generator (IPG) and an external programmer.
The IPG and stimulation lead are to be implanted within the subject's body using conventional laparoscopy. The device programmer is to be used by the study investigator and/or a company technical representative."
1685710|NCT01574326|Drug|Placebo|Placebo for 0.8 g sachets of powder for oral suspension or 800 mg tablets
1685711|NCT01574326|Drug|Sevelamer carbonate|0.8 g sachets of powder for oral suspension or 800 mg tablets
1685712|NCT01574313|Procedure|stellate ganglion block|stellate ganglion block
1685713|NCT01574313|Drug|0.25mg, fludiazine|0.25mg of erispan@ (fludiazine), p.o. one dose only.
1685714|NCT01574313|Drug|25mg cephadol@ (diphenidol)|25mg cephadol@ (diphenidol) p.o. one dose only.
1685715|NCT01574313|Drug|200mg kentons@ (tocopherol nicotinate).|200mg kentons@ (tocopherol nicotinate) p.o. one dose only.
1685716|NCT01574300|Other|therapeutic interventions|All therapeutic interventions are allowed, and their details recorded and correlated with data from the collected biospecimens. Examples would include single or multiple agent chemotherapy or targeted therapeutics
1685717|NCT01574287|Drug|FACBC|Drug is give intravenously over 2 minutes at time of scan
1685718|NCT01574274|Drug|SC-PEG|11 doses Intravenously over one hour
1685719|NCT01574274|Drug|Oncaspar|16 doses Intravenously over one hour
1685720|NCT01574261|Drug|Placebo|Placebo for four months
1685721|NCT01574261|Drug|Inositol|Inositol 4g/die for four months
1685722|NCT01574248|Drug|icatibant|Subcutaneous at time 0 and 6 hours
1685723|NCT01574248|Other|Placebo|Subcutaneous at time 0 and 6 hours
1685724|NCT01574235|Biological|Nivestim®|
1685725|NCT01574222|Biological|autologous dendritic cell adenovirus CCL21 vaccine|Eligible patients will be assigned to a cohort and will receive intratumoral injections of Ad-CCL21-DC in conjunction with tumor sampling.
1685726|NCT01574196|Other|Autonomic nervous system activity records|The description of autonomic equilibrium is based on the use of non-invasive tools such as Holter-ECG monitor (24 hours) which is suitable for longitudinal follow up of cohorts of patients. This tool allows the analysis of instantaneous or delayed variability of the heart rate, in the Hertzian frequency domain after extraction and mathematical transformation of a temporal sequence of R-R spaces from the ECG signal.
1685727|NCT01574183|Drug|Vilazodone|up to 40 mg capsule daily
1685728|NCT01574183|Drug|Placebo|up to 40 mg capsule daily
1685729|NCT01574170|Other|Construction of a prognostic score (non-drug intervention types)|Record of clinical, histological and biological data and questionnaires data in patients starting a third line metastatic until progression
1685730|NCT01574157|Drug|Sodium bicarbonate|Participants will receive 0.5 meq of sodium bicarbonate per 1 kilogram of lean body weight daily. The total amount will be divided into twice daily doses.
1685731|NCT01574157|Drug|Placebo|Participants will receive an identical number of placebo tablets had they been assigned to the intervention. Placebo will be divided into twice daily doses and receive this for six months.
1685733|NCT01574131|Drug|Fenofibrate|Pill 54 mg or 160 mg tablets every day for 6 months Dosing-5mg/kg up to 160 mg for 6 months
1685734|NCT01574131|Drug|placebo|pill every day for 6 months
1685735|NCT01574118|Behavioral|Revisiting the Trauma memories|Patient engages in repeated revisiting of their trauma memory under the guidance of the therapist for about 40 minutes. During each revisiting trial the patient closes their eyes and verbally describes the trauma and the feeling and thoughts experienced during the trauma.
1685736|NCT01574118|Behavioral|Processing the trauma memories|The patient and therapist discuss the patient's experience during the trauma revisiting with the goal of helping the patient gain alternative perspectives of the trauma.
1685737|NCT01574118|Behavioral|Psychoeducation|Through patient handouts and didactic instruction, the patient learns about the common reactions to trauma and the rationale for exposure therapy.
1685738|NCT01574118|Behavioral|Trauma Memory Retrieval Trial|Prior to the start of Imaginal Exposure, the patient is asked to recall a threatening element of their trauma memory for 1 minute. This is followed by a 30-minute rest-period prior to beginning imaginal exposure.
1685739|NCT01574118|Behavioral|Exposure to video clips related to the patient's trauma|Patient is seated in front of a computer monitor and instructed to view a 30-min looped video clip that thematically resembles the patient's trauma.
1685740|NCT01574118|Behavioral|Breathing retraining|Patient is seated comfortably in a chair and instructed to breathe slowly and deeply in a relaxed manner.
1685741|NCT01574118|Behavioral|Exposure Homework|Therapist assists the patient in identifying trauma-related situations/activities that the patient is avoiding and encourages the patient to begin to confront these situations between sessions.
1685742|NCT01574118|Behavioral|Compound extinction|The patient repeatedly confronts the truama-related media clip while simultaneously listening to their own trauma script through headphones.
1685743|NCT01574092|Drug|Combination of two marketed drugs (irinotecan and cisplatin)|Irinotecan and Cisplatin will be administered weekly ambulatory, intravenous (iv), until to reach a total of 16 cycles. Cisplatin is administered first and then Irinotecan. Cisplatin 30 mg/m2/d (iv) in one hour,followed by Irinotecan 65 mg/m2/d iv in one hour. There is a one-week rest period every 4 cycles. The total treatment length including 16 cycles + rest weeks is 19 weeks.
1685744|NCT01574079|Other|Traditional Physical Therapy|Traditional physical therapy includes, but is not limited to, therapeutic exercise, functional mobility training, pre-gait and gait activities, electrotherapeutic modalities, and education.
1685745|NCT01574079|Other|Physical Therapy plus Mirror Therapy|The treatment group will receive traditional physical therapy intervention as described in the control group with the addition of mirror therapy. The participant will attempt to perform the flexion exercises with both lower extremities. The patient will be blinded to the affected lower extremity with a mirror, and will be looking at the image of the unaffected lower extremity superimposed on the affected lower extremity as he or she performs the activities.
1685746|NCT01574066|Procedure|Chest CT-scan|Patients with a suspicion of acquired pneumonia visiting the emergency department will do a chest CT-scan
1685747|NCT01574040|Behavioral|Promotion of stair climbing|"Application of labels on all UMC elevator doors stating:  If you take the stairs, you will burn 11 times more calories."
1685748|NCT01574040|Behavioral|Promotion of a low-salt soup alternative for the 'soup of the day'|"Promotion of a low-salt soup alternative for the 'soup of the day' in the UMC staff restaurant, using a sign stating: The cream soup contains 30% less salt and contributes to a healthy blood pressure."
1685749|NCT01574040|Behavioral|Promotion of a low-fat alternative for the butter croissants|"Promotion of a low-fat alternative for the butter croissants in the UMC staff restaurant, using a sign stating: This croissant contains 30% fewer saturated (unhealthy) fatty acids."
1685750|NCT01574040|Behavioral|Exchange of the basket positions of butter and margarine in the UMC staff restaurant between convenient and harder to reach locations|Exchange of the basket positions of butter and margarine in the UMC staff restaurant. In the usual (baseline) situation butter is positioned in the fridge and, therefore, less visible and harder to reach. Margarine is positioned on several convenient locations throughout the restaurant. During the two weeks intervention period these positions will be interchanged.
1685751|NCT01574027|Drug|Vitamin D3 (cholecalciferol)|One capsule per day for six months
1685752|NCT01574027|Drug|Placebo|One capsule per day for six months
1685753|NCT01574014|Behavioral|CBGT|Cognitive-behavioral group therapy
1685754|NCT01574014|Drug|Hydrocortisone|3 x 20 mg Hydrocortisone (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
1685755|NCT01574014|Drug|Placebo|Placebo (oral, 60 min. before MRI1, 60 min. before exposition in CBGT1 and 60 min. before exposition in CBGT2)
1685756|NCT01574001|Behavioral|Antismoking intervention with no early follow-up|"an anti-smoking intervention in line with the 5A's method without early follow-up; follow-up assessment will be limited to two visits: 3 and 12 months after stroke"
1685757|NCT01574001|Behavioral|Antismoking intervention with minimal early follow-up|"Anti-smoking intervention in line with the 5A's method (Ask, Advice, Assess, Assist, Arrange follow-up. The intervention will be carried out 5-7 days after stroke, before the planned discharge from the hospital. Seven days after discharge from a stroke unit a brief telephone/personal advice will be given aimed to motivate patients to quit smoking; follow-up assessment will include two visits: 3 and 12 months after stroke"
1685758|NCT01574001|Behavioral|Antismoking intervention with intensive early follow-up|"an anti-smoking intervention in line with the 5A's method will be given, including four follow-up visits within 6 weeks after discharge from the hospital (week 1, week 2, week 4, week 6 after stroke); follow-up assessment will include two visits: 3 and 12 months after stroke"
1685759|NCT01573988|Other|Increasing eating frequency|"The subjects receive the same breakfast with two sequences :
breakfast in one intake at 8:00
breakfast in four isocaloric intakes (8:00, 9:00, 10:00, 11:00) The sequence made twice : one for metabolic study and one for the study of eating behavior
The lunch during metabolic study is a standard meal The lunch during behavioural study is an ad libitum buffet test meal.
The administration order is determined by randomized allocation. The wash-out period is one to three weeks.
There are not diet or exercise interventions."
1685760|NCT01573975|Drug|5RA-5RCM|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + metronidazole 500mg b.i.d x last 5 days.
1685761|NCT01573975|Drug|5RA-5RCT|rabeprazole 20mg b.i.d + amoxicillin 1000mg b.i.d x 5 days + rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + tetracycline 1000mg b.i.d x last 5 days.
1685762|NCT01573975|Drug|10RCA|rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d x 10 days.
1685763|NCT01573949|Drug|Metformin|Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month for a duration of 3 months.
1685764|NCT01573936|Other|Physical therapy, occupational therapy, psycotherapy, medical consultations|The mean duration of the RP was 7.47 ± 4.45 months, but it was not standardized because this factor was not one of the parameters of interest for this study
1685765|NCT01573923|Biological|mesenchymal stem cells|Conventional therapy plus UC-MSC intravenous administration (4x107/40ml, once per three months, four times in one year)
1685766|NCT01573923|Biological|Conventional therapy|Conventional therapy without cell therapy
1685767|NCT01573910|Drug|Moxifloxacin ophthalmic solution, 0.5%|
1685768|NCT01573910|Drug|Ofloxacin ophthalmic solution, 0.3%|
1685769|NCT01573871|Other|Experimental Hydrolyzed infant formula|Experimental hydrolyzed infant formula to be fed ad libitum
1685770|NCT01573858|Other|Acupuncture treatment 1|Two sets of acupuncture points will be alternated every second treatment. The first set consists of CV3, CV 6, and ST 29 bilaterally，SP 6 and SP 9 bilaterally. Needles will also be placed in LI bilaterally and GV 20. CV 3, CV 6, ST 29, SP 6, and SP 9 will be connected to and electrical stimulator and stimulated with low-frequency EA of 2Hz, 0.3 ms.
1685771|NCT01573858|Other|Acupuncture treatment 2|Needles will be inserted to a depth of <5 mm, one in each shoulder and on in each upper arm at non-acupuncture points. Electrodes will be attached to the needles and the stimulator will be turned on at an intensity of zero (no active current) in order to mimic EA in the acupuncture treatment 1. No manual stimulation of the needles will be performed.
1686021|NCT01572064|Other|MRI Scan|1 single visit for MRI and MRS
1685772|NCT01573858|Other|CC|CC 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
1685773|NCT01573858|Other|CC placebo|CC placebo 50 mg every day for 5 days (day 3-7 of cycle), for a total of 4 cycles. Non-response will be defined after 4 weeks of CC Placebo administration with 3 consecutive weekly negative P4 and hCG levels. Then during the fifth week a higher dose consisting of one more tablet per day (up to 3 tablets per day at third or fourth cycles, if they remain non-responders) will be given 5 days.
1685774|NCT01573845|Behavioral|Healthy Eating + Eco-Friendly Campaign|"Participants receive a 6-month school-based campaign that includes:
A 22-lesson classroom curriculum
Homework activities that involve the family
Monthly parent newsletters
A food shopping and packing guide for parents
Food demonstrations
A poster contest
School wide announcements"
1685775|NCT01573845|Behavioral|Healthy Eating Campaign|"Participants receive a 6-month school-based campaign that includes:
A 22-lesson classroom curriculum
Homework activities that involve the family
Monthly parent newsletters
A food shopping and packing guide for parents
Food demonstrations
A poster contest
School wide announcements"
1685776|NCT01573832|Other|integrated client care group|receives integrated client care for wound treatment
1685777|NCT01573819|Drug|GSK356278|Cohort 1: A dose of 2mg per day for 10 days; Cohort 2: A dose of Xmg for 14 days. the dose will be determined from Cohort 1 not to exceed 14 mg; Cohort 3: a single dose of Ymg with a wash out of 7 days followed by 28 days of repeat dosing. The dose (Ymg) will be determined from cohort 1 and 2 not to exceed 14 mg.
1685778|NCT01573819|Drug|Placebo|Cohort 1, a placebo per day for 10 days Cohort 2, a placebo per day for 14 days Cohort 3, a single placebo with a wash out of 7 days followed by 28 days of repeat dosing of a placebo per day.
1685779|NCT01573806|Drug|Exenatide|Exenatide, dosed subcutaneously every 12 hours for 4 doses
1685780|NCT01573806|Drug|Exenatide vehicle|Exenatide vehicle, dosed subcutaneously every 12 hours for 4 doses
1685781|NCT01573793|Behavioral|Parenting Education|Will receive parenting educational materials hypothesized to enhance emotional and cognitive development
1685782|NCT01573793|Behavioral|Control Group - Safety Materials|Will receive safety and dental hygiene materials that have no bearing on emotional and cognitive development
1685783|NCT01573780|Drug|Smac mimetic TL32711|Given IV
1685784|NCT01573780|Drug|gemcitabine hydrochloride|Given IV
1685785|NCT01573780|Other|laboratory biomarker analysis|Correlative studies
1685786|NCT01573780|Other|pharmacological study|Correlative studies
1685787|NCT01573780|Procedure|biopsy|Optional correlative studies
1685788|NCT01573767|Drug|Fluticasone propionate 100mcg|all subjects recieve open-label Flovent twice daily duirng the run in and treatment period
1685789|NCT01573767|Drug|Placebo|Placebo inhalation powder during treatment period
1685790|NCT01573767|Drug|Vilanterol|subjects will recieve 4 weeks via NDPI during treament period
1685791|NCT01573754|Drug|Hydroxychloroquine|100 mg by mouth twice weekly
1685792|NCT01573754|Procedure|Phlebotomy|450 mL every 2 weeks
1685793|NCT01573741|Drug|Ketamine|a single infusion of ketamine hydrochloride (0.5 mg/kg) infused over 40 minutes
1685794|NCT01573728|Behavioral|Low dose exercise|Exercise totaling 50 minutes per week and low intensity
1685795|NCT01573728|Behavioral|Public Health Exercise|At least 150 minutes at moderate intensity
1685796|NCT01573715|Drug|NIMBEX|
1685797|NCT01573715|Drug|NIMBEX|
1685798|NCT01573715|Other|WITHOUT NIMBEX|
1685799|NCT01573702|Procedure|Stereotactic Radiosurgery|21 Gy daily for 5 days
1685800|NCT01573702|Drug|Erlotinib|150mg once daily
1685801|NCT01573689|Behavioral|Group intervention based on mutual aid.|Development of a mutual aid group and his actualization on children between nine and twelve years old who had lost one of their parents.
1685802|NCT01573663|Drug|Ambroxol and Levodropropizine|Ambroxol HCl 30mg & Levodropropizine 60mg, PO, Single dose
1685803|NCT01573663|Drug|Ambroxol|Ambroxol HCl 30mg, PO, single dose
1685804|NCT01573663|Drug|Levodropropizine|Levodropropizine 60mg, PO, single dose
1685805|NCT01573637|Drug|Raloxifene|The dose of raloxifene hydrochloride administered will be 60 mg/day. Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
1685806|NCT01573637|Drug|Lactosa (placebo arm)|Both placebo and the raloxifene will be administered over 6 months. Patients will take one single daily dose administered in the morning. Drug will be given orally in capsule form.
1685807|NCT01573624|Drug|FF/GSK573719|100/15.6
1685808|NCT01573624|Drug|FF/GSK573719|100/31.25
1685809|NCT01573624|Drug|FF/GSK573719|100/62.5
1685810|NCT01573624|Drug|FF/GSK573719|100/125
1685811|NCT01573624|Drug|FF/GSK573719|100/250
1685812|NCT01573624|Drug|FF|100
1685813|NCT01573624|Drug|FF/VI|100/25
1685814|NCT01573611|Dietary Supplement|Grape Powder|36 g of grape powder to be taken twice/day (total of 72 g/day) for 6 months
1685815|NCT01573611|Dietary Supplement|Placebo Powder|36 g of placebo powder to be taken twice/day (total of 72 g/day) for 6 months
1685819|NCT01573585|Behavioral|Usual Care|The Usual Care program will consist of 2 sessions a week for 45 minutes for a 6 week duration.
1685820|NCT01573585|Behavioral|FAST protocol|The Fast muscle activation and Stepping Training (FAST protocol) will be exercises emphasizing speed, small squats and protective steps, that will be progressed. This program will be 2 sessions a week for 45 minutes for 6 weeks in duration.
1685821|NCT01573572|Drug|pegaptanib sodium injection|0.3mg of Macugen in a single-use, prefilled glass syringe given every 6 weeks for 48 weeks
1685855|NCT01573286|Drug|Glucagon-Like Peptide 2|Patients will be treated with 20 ug/kg/day GLP-2, in two doses, given subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued for a total of 42 days.
1685822|NCT01573546|Behavioral|Aerobic Exercise|Participants will exercise for 6 months. In the initial 3-month supervised phase, patients will exercise 3 times a week at a level of 50-75% of their initial peak heart rate reserve (HRR) or at their peak heart rate without symptoms, or ST-segment depression > 1 mm, as determined at the time of their initial exercise test. Aerobic exercise consists of 10 minutes of warm-up exercises followed by 30 minutes of continuous walking or (stationary) biking. Each exercise session will conclude with a 10 minute period of cool-down exercises. During weeks 13 to 24 (i.e., home maintenance phase), participants will be asked to perform 3 aerobic sessions per week at home at 60-70% HRR.
1685823|NCT01573546|Behavioral|DASH diet|Participants in the DASH condition only receive instruction in modifying the content of their diet to meet DASH guidelines. Participants will be explicitly asked not to exercise and to focus their attention on what they eat. Participants will have been told (in the initial consent form) that the study is designed to study effects of two interventions (altering diet content and exercise) both of which have been shown to improve health. Participants will also be told that it may be easier or more effective for them if they focus first on learning to alter diet content, and they are free to exercise at the end of the 6-month period. Following an initial 1-day feeding period, participants, along with their study partners, will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 4 participants).
1685824|NCT01573546|Other|Health education control|The Health Education control group will receive weekly 30-min lectures on relevant, health-related topics but will not receive instruction in the DASH diet nor will exercise be promoted. These participants will be asked to maintain their usual dietary and exercise habits for 6 months until they are re-evaluated. These sessions are designed to provide useful information about medical aspects of CVD, but will not provide instruction in the DASH diet or exercise.
1685826|NCT01573520|Other|Monitoring of drug adherence|In the IC group, biological and drug adherence results are shown and discussed through a nephrologists leaded semi-structured motivation interviews at interval of 2 months.
1685827|NCT01573507|Other|sodium lactate infusion|3-6 hours continuous infusion of sodium lactate (20-40 mcg/kg/min)
1685828|NCT01573494|Other|Sampling of blood|7,5 ml of blood
1685829|NCT01573481|Other|pressure support ventilation|Patients in this group are ventilated during the night with pressure support ventilation mode. The level of the pressure support is the same as the previous day.
1685830|NCT01573481|Other|Pressure controlled ventilation|Patients in this group are ventilated during the night (10 PM to 9 AM) with pressure controlled ventilation mode. The level of inspiratory pressure is set to 20 cm H2O and the respiratory rate is adjusted to avoid any spontaneous breathing (respiratory rate > or equal to 12 breath per min).
1685831|NCT01573468|Drug|Tesetaxel|Tesetaxel 27 mg/m2 orally once on Day 1 of each cycle
1685832|NCT01573468|Drug|Placebo|Placebo orally once on Day 1 of each cycle
1685833|NCT01573468|Drug|Capecitabine|Capecitabine 1750 mg/m2/day orally twice daily (in 2 equally divided doses) on Days 1-14 of each cycle
1685834|NCT01573442|Drug|testosterone|10.4 mg
1685835|NCT01573442|Other|placebo|
1685837|NCT01573416|Other|ASSIST-linked brief intervention for hazardous and harmful substance use.|ASSIST-linked brief intervention will be applied to users achieving moderate risk scores in the ASSIST questionnaire. If after randomization are selected to enter the intervention group, they will receive a ten minute counseling carried immediately after the screening instrument. This intervention group will be re-evaluated after 3 months with the same ASSIST screening instrument.
1685838|NCT01573416|Other|Observation|Subjects who obtain a moderate risk score in the ASSIST screening questionnaire and after randomization are selected for the control group, will receive a brochure with substance-abuse information without any further conversation about the subject with the caregiver. This observation group will be re-evaluated after 3 months with the same ASSIST screening instrument.
1685839|NCT01573403|Drug|DLBS2411|1 caplet of DLBS2411 @250 mg and 1 placebo caplet, once daily
1685840|NCT01573403|Drug|DLBS2411|2 caplets of DLBS2411 @250 mg, once daily
1685841|NCT01573403|Drug|Placebo DLBS2411|2 placebo caplets of DLBS2411, once daily
1685842|NCT01573377|Drug|Metformin|425mg bid for morning and evening after meals, one week after treatment, increase the dosage to 850 mg bid. If the patients have side effects such as nausea, diarrhea and other gastrointestinal symptoms, the dose would be reduced to 425mg bid for 1 week, and try the dosage to 425mg tid again, until the maximum tolerated dose.
1685843|NCT01573377|Drug|Ethinylestradiol and Cyproterone Acetate|from the first day of bleeding of the menstrual cycle, daily oral administration of one pill for 21 days consecutively, then stopped taking the pill for seven days, and on the eighth day to start taking the pill again.
1685844|NCT01573351|Drug|Asunaprevir|
1685845|NCT01573351|Drug|Daclatasvir|
1685846|NCT01573351|Drug|Peg-interferon Alfa-2a|
1685847|NCT01573351|Drug|Ribavirin|
1685848|NCT01573338|Drug|Roniciclib (BAY 1000394)|oral administration twice daily in a 3 days on/ 4 days off schedule. Starting dose will be 2.5 mg bid and dose will be escalated or de-escalated depending on dose limiting toxicity.
1685849|NCT01573338|Drug|Etoposide|100 mg/m2 will be administered IV on Days 1, 2, and 3 of each 21 day cycle.
1685850|NCT01573338|Drug|Cisplatin|75 mg/m2 will be administered IV on Day 1 of each 21 day cycle after the etoposide infusion is complete.
1685851|NCT01573338|Drug|Carboplatin|Carboplatin will be administered IV on Day 1 of each 21 day cycle. The dose of carboplatin will be determined for each cycle using the Calvert's formula, to yield an AUC of 5 (mg/mL) • min.
1685852|NCT01573312|Drug|ASO3 Adjuvant|3.75 mcg of H5N1 hemagglutinin plus AS03, will be administered in 2 doses 28 days apart.
1685853|NCT01573312|Biological|Influenza A/H5N1 Vaccine|3.75 mcg of H5N1 hemagglutinin plus AS03 or 3.75 mcg of H5N1 hemagglutinin alone will be administered in two doses 28 days apart.
1685854|NCT01573299|Other|Mobilization of stroke patients|"In the first group (early vertical positioning)the patient can sit outside of the bed, the day after stroke onset. In the second group (progressively vertical positioning), the patient is progressively verticalised and is allowed to sit outside of the bed on the third day after the stroke onset."
1685856|NCT01573286|Drug|Glucagon like peptide-2|"Patients will treated with 5, 10 or 20 ug/kg/day of GLP-2, given twice daily by subcutaneous injection. The initial cohort of patients will be treated at 5 ug/kg (n=6), and if this dose is seen to be safe, and levels appropriate, the next group of 6 will be treated at 10 ug/kg/day. If this dose is seen to be safe, and levels appropriate, the final group of 6 will be treated at 20 ug/kg/day.
Patients will be given GLP-2 at the assigned dose, subcutaneously for 3 days (Phase 1). If the treatment is well tolerated, GLP-2 will be continued, at the same dose, for a total of 42 days."
1685857|NCT01573273|Drug|Oxytocin|intranasal administration, 40 IUs
1685858|NCT01573273|Drug|Saline|intranasal administration, 40 IUs
1685859|NCT01573260|Other|Argentinean Tango classes|Tango participants will attend an 1-hour Argentinean Tango classes twice a week during 12 weeks, with experienced professional tango instructors.
1685860|NCT01573260|Other|Simple pamphlet about the exercise in PD|Controls will follow their usual schedule of pharmacological treatment; will be provided by simple pamphlet about the exercise in PD, and will otherwise to go about their lives as usual.
1685861|NCT01573247|Drug|AKN-028|"Part 1 of the study is a sequential dose-escalation evaluation of AKN-028. Part 1 started as an accelerated intra-patient dose escalation design in one patient at a time (the N=1 portion), and has switched to standard 3 + 3 design with inter-cohort dose escalation when AUC of 12 μM*hrs has been reached. Starting dose of AKN-028 was 60 mg twice a day.
During Part 2 of the study AKN-028 will be administered at the dose level selected in Part 1. Patients will be treated for a maximum of 3 cycles (first cycle of 14 days followed by 2 cycles of 21 days), with at least a 7-day treatment-free period between cycles. Patients with significant benefit after 3rd cycle may continue treatment at discretion of the investigator for as long as the patient continues to show significant benefit."
1685862|NCT01573234|Device|MySkin patch|Hydrogel and polyurethane film
1685863|NCT01573234|Device|Gauze and Patch|Traditional Dressing
1685864|NCT01573208|Device|Custom guides|Symbios custom guides for TKA
1685865|NCT01573182|Biological|Zostavax|VZV seropositive donors 50 years and over will receive vaccination with a live attenuated herpes zoster vaccine (Zostavax) by the IM route 4 to 6 weeks prior to stem cell harvesting.
1685868|NCT01573156|Drug|Light activated WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/kg, or 4mg/kg using 753 nm laser light at a fixed power (150 mW/cm) and energy (200 J/cm) delivered through percutaneous optical fibres. The fibres are introduced into transparent needles that are positioned in the areas of interest under CT image guidance. After a minimum of 3 patients at each drug dosage (2 & 4 mg/kg) has been treated with a light energy of 200 J/cm, the general and local safety will be assessed. The safety results of the first 3 patients treated in each drug dose/number of fibres combination will be reviewed by the investigators prior to escalation to a higher drug dose/number of fibres combination.
1685869|NCT01573143|Drug|Rosuvastatin|Rosuvastatin (20 mg od) started not earlier than 8 days before surgery and continued until the 5th post-operative day included;
1685870|NCT01573143|Drug|Placebo|Placebo started not earlier than 8 days before surgery and continued until the 5th post-operative day included.
1685871|NCT01573130|Behavioral|Physical exercise program|An individualized physical exercise program, administered per internet. Some therapist-support will also be included.
1685872|NCT01573117|Device|RhinoChill|Nasopharyngeal cooling with the RhinoChill device
1685873|NCT01573117|Drug|Cold crystalloid infusions, 0.9%NaCl or Ringer's solution|Infusion of 2L cold crystalloid solution (4°C) over 30 minutes
1685874|NCT01573104|Other|Proteomic assay|Urine will be taken for proteomic assay at baseline, day 1 and day 2
1685875|NCT01573104|Other|Blood sampling|Point of care testing of blood for NGAL/BNP at baseline, day 1 and day 2
1685876|NCT01573104|Other|Biomarker sampling|Urine will be taken at baseline and day 1, day 2 for evaluation of renal biomarkers at later date
1685877|NCT01573091|Procedure|Cardiac Resynchronization Therapy|Any commercially available Cardiac Resynchronization Therapy devices with or without defibrillation backup (CRT-D/CRT-P) can be used upon discretion of the investigator according to current guidelines
1685878|NCT01573078|Behavioral|Questionnaire|Questionnaire consisting of the following validated surveys: Rome II criteria - Scale of Body Connection (SBC), Private Body Consciousness Sub-Scale (PBCS), Body Vigilance Scale (BVS), Emotional Processing Scale (EPS25)
1685879|NCT01573065|Behavioral|Counseling intervention with rapid HIV testing|Counseling intervention (modeled after Brief Negotiation Interview and Project RESPECT-2) coupled with rapid HIV testing. Telephone booster at 2 weeks.
1685882|NCT01573013|Dietary Supplement|iron fortified biscuits|10 mg of iron per day for 8 months, either in the form of NaFeEDTA
1685883|NCT01573013|Dietary Supplement|iron fortified biscuits|10 mg of iron per day for 8 months, in the form of FeSo4
1685884|NCT01573013|Dietary Supplement|iron fortified biscuits|EDTA fortified biscuit on a daily basis for 8 months
1685885|NCT01573013|Dietary Supplement|iron fortified biscuits|control biscuit on a daily basis for 8 months
1685886|NCT01573000|Biological|Iodine-131 Anti-B1 Antibody Versus Anti-B1 Antibody in Chemotherapy-Relapsed/Refractory Low-Grade or Transformed Low-Grade Non-Hodgkin's Lymphoma (NHL)|Subjects will be randomized to receive tositumomab and iodine-131 tositumomab (Arm A) or unlabeled tositumomab (Arm B). Subjects randomized to receive unlabeled tositumomab may crossover and receive radiolabeled Iodine-131 tositumomab following progression of their lymphoma. Response in both arms will be assessed at 7 weeks, 13 weeks, and then at 3-monthly intervals for up to 2 years.
1685887|NCT01572987|Device|Radiofrequency Ablation(RFA) by HALO device.|RFA or Surveillance every 2 months for 1 year.
1685888|NCT01572987|Device|Endoscopic mucosal resection(EMR) by mucosectomy kit.|EMR or surveillance every 2 months.
1685889|NCT01572961|Drug|acetylsalicilic acids (Aspirin)|single oral dose of 1g.
1685890|NCT01572961|Drug|Placebo|
1685948|NCT01572623|Drug|Atorvastatin|Reloading dose of Atorvastatin (80 mg at 12 hours and 40 mg at 6-8 hours before carotid artery stenting) versus no reload.
1685891|NCT01572948|Drug|roflumilast|The study drug (roflumilast, Daliresp™, Forest Laboratories, Inc.) is a targeted inhibitor of phosphodiesterase 4 and is given once daily via oral route. There is proven anti-inflammatory and anti-oxidant potential in both animal and human models
1685892|NCT01572948|Drug|placebo|The placebo (Forest Laboratories, Inc) is manufactured as an odorless and otherwise equivalent tablet to the roflumilast tablet, but contains no active ingredient
1685896|NCT01572909|Drug|Bendavia (MTP-131)|0.05 mg/kg/hr
1685897|NCT01572909|Drug|Placebo|Identically appearing placebo
1685898|NCT01572896|Behavioral|Taking Charge: Managing JIA Online|"In addition to standard medical care, adolescents in the experimental group will receive the Taking Charge: Managing JIA Online Internet self-management program. The intervention is a 12-module interactive multi-component treatment protocol - that consists of JIA-specific education, self-management strategies, and social support - that is available in English and French."
1685899|NCT01572896|Behavioral|Standard Medical Care and JIA Resource Center|"The control group is designed to control for the potential effects on outcomes of time, attention and computer use during the intervention and through the 9-month follow-up period. In addition to standard medical care, adolescents in the attention control group will be provided with access to a self-guided patient education study website, which will have two components: basic patient educational materials about JIA (JIA Resource Centre) and online assessments."
1685900|NCT01572857|Biological|urinary excretion of FLC immunoglobulin|"First phase :
Collection of four urine samples daily for 2 days:
Of the 24-hour urine
at 8 AM
at 12 AM
at 4 PM
On each of these urine samples, the following analysis will be performed:
Proteinuria
Albuminuria
Urinary FLC (Freelite ™)
Urine creatinine
Second phase:
Determination of creatinine in 24 hours by measuring the creatinine of 24 hours 3 days in a row."
1685903|NCT01572831|Other|PCT and clinical algorithm for stopping abx|In the experimental arm, antibiotics will be stopped based upon the PCT-guided algorithm. This PCT algorithm also incorporates clinical parameters to ensure utmost safety for the patients. These clinical parameters are; resolution of fever (temperature less than 38.3 and greater than 36.0), shock (on no vasopressors), and leukocytosis (<12,000 and >4,000).
1685904|NCT01572818|Procedure|phlebotomy|7 ml/kg without exceeding 500 mL
1685905|NCT01572818|Behavioral|dietary and lifestyle counseling|dietary and lifestyle counseling
1685906|NCT01572805|Drug|melatonin 3mg|To receive sublingual 3 mg melatonin before spinal of anesthesia .
1685907|NCT01572805|Drug|melatonin 6mg|To receive sublingual 6 mg melatonin before spinal of anesthesia .
1685908|NCT01572805|Drug|placebo|To receive sublingual placebo tablet before spinal of anesthesia .
1685909|NCT01572792|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) high dose, twice per day
1685910|NCT01572792|Drug|Aclidinium bromide/formoterol Fixed-Dose Combination (FDC)|Inhaled Aclidinium bromide/formoterol Fixed-Dose Combination (FDC) low dose, twice per day
1685911|NCT01572792|Drug|Aclidinium bromide|Inhaled Aclidinium bromide 400 μg, twice per day
1685912|NCT01572792|Drug|Formoterol Fumarate|Inhaled Formoterol Fumarate 12 μg, twice per day
1685913|NCT01572792|Drug|Placebo|Inhaled dose-matched placebo, twice per day
1685914|NCT01572779|Device|BSM device with bio-feedback|A postural bio-feedback device worn by subjects for 4-10hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group. The device records movement and muscle activity data relating to the lower back. Bio-feedback is delivered to the subject as an audible tone, visual cue or vibration and aims to prompt the subject to alter their posture or position in line with recommendations given by the treating practitioner. Four small sensors are adhered to the lower back and send data wirelessly to a data logger carried in the pocket by the subject (the size of a small mobile phone).
1685915|NCT01572779|Device|BSM device with no bio-feedback|The BSM device is worn as a placebo with no bio-feedback given to the subject. The subjects in the control group wear the device for 4-10 hours a day for 6 days spread across 6 weeks for the sub acute low back pain group and for 8 days spread across 10 weeks for the chronic group.
1685916|NCT01572766|Other|FRAX Assessment Tool|FRAX Assessment Tool is designed to assess risk for fracture based on country of origin, race, and other factors.
1685949|NCT01572610|Drug|RTA 402|once a day, oral administration
1686022|NCT01572051|Behavioral|Educational Course|2 Educational courses
1685917|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
1685918|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
1685919|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
1685920|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 50 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
1685921|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 120 mins, no food or liquid is allowed.
1685922|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 60 mins, no food or liquid is allowed.
1685923|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 30 mins, no food or liquid is allowed.
1685924|NCT01572753|Drug|semaglutide|Subjects will be dosed in the morning, for 10 days, after an overnight fast (liquid will not be allowed from 2 hours before dosing). Dose to be taken with 120 ml of water. During the post-dose fasting period of 15 mins, no food or liquid is allowed.
1685925|NCT01572740|Drug|liraglutide|Liraglutide administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
1685926|NCT01572740|Drug|placebo|Liraglutide placebo administered subcutaneously (s.c., under the skin) for 36 weeks combined with insulin therapy.
1685927|NCT01572740|Drug|insulin|All subjects will continue their pre-trial insulin therapy (basal, premixed or basal-bolus regimen) during the trial. Insulin dose is fixed for the first 16 weeks and for the subsequent 20 weeks, insulin dose is individually adjusted.
1685928|NCT01572727|Drug|Paclitaxel|intravenous paclitaxel 80 mg/m2 per week given until progression
1685929|NCT01572727|Drug|BKM120 matching placebo|"Buparlisib maching plaxcebo were supplied as 100 mg and 50 mg hard gelatin capsules.
Buparlisib placebo was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area."
1685930|NCT01572727|Drug|BKM120|Buparlisib (BKM120) were supplied as 100 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and was not adjusted to body weight or body surface area.
1685931|NCT01572714|Behavioral|Social Support Program|The social support program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Topics will include information on MS, disease modifying medications, preventive screening, community organizations, nutrition, cognitive problems, and hiring an aide.
1685932|NCT01572714|Behavioral|Physical Activity Program|The physical activity education program will consist of 3 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program.
1685933|NCT01572714|Behavioral|Physical Activity Plus Fatigue Management Education Program|The physical activity plus fatigue management education program will consist of 6 weekly, 1.25-hours, teleconference calls with 4 biweekly, 15 minute, follow-up one-to-one phone calls. Subjects in this program will learn MS-specific benefits of physical activity, how to use a pedometer to self-monitor their progress for increasing physical activity levels, and learn strategies for maintaining their progress in the program. In addition, subjects in this course will learn strategies to reduce fatigue, such as taking rest breaks and re-arranging workspace.
1685934|NCT01572701|Drug|99mTc-MIP-1404|20 (±3) mCi of study drug will be administered by IV injection as a slow bolus and flushed with approximately 10 mL of saline
1685935|NCT01572688|Drug|Melphalan|powder for injection, 200mg/m2, uses after reconstituted within 24 hours
1685936|NCT01572675|Drug|etorocoxib|Administered as 30 mg or 60 mg oral film-coated tablets
1685937|NCT01572675|Drug|celecoxib|Administered as 100 mg or 200 mg oral hard capsules
1685938|NCT01572662|Drug|Fludarabine monophosphate|40 mg/m2 by vein on Days -6 through -3.
1685939|NCT01572662|Drug|Busulfan|First two doses of Busulfan, 80 mg/m2 administered as an outpatient or as an inpatient to facilitate for this pharmacokinetically directed therapy. Busulfan is administered at the dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
1685940|NCT01572662|Procedure|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
1685941|NCT01572662|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as 24 hour continuous infusion daily adjusted to achieve therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
1685942|NCT01572662|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
1685943|NCT01572662|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
1685944|NCT01572649|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form:Solution for injection
Route of administration: subcutaneous"
1685945|NCT01572649|Drug|Placebo|"Pharmaceutical form:Solution for injection
Route of administration: subcutaneous"
1685946|NCT01572636|Drug|Laronidase|Administered 0.58 mg/kg/dose intravenously (IV) once a week beginning 12 weeks before planned hematopoietic stem cell transplant (HSCT) and resume same dosing regimen for 8 weeks after HSCT.
1685947|NCT01572623|Drug|Clopidogrel|Loading dose of Clopidogrel 600 mg versus 300 mg before carotid artery stenting
1738899|NCT00084786|Drug|gefitinib|
1685950|NCT01572597|Drug|10RAC+acetylcystein|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + N-acetyl-cystein 600mg b.i.d
1685951|NCT01572597|Drug|10RAC+metronidazole|10-days rabeprazole 20mg b.i.d + clarithromycin 500mg b.i.d + amoxicillin 1000mg b.i.d + metronidazole 500mg b.i.d
1685952|NCT01572558|Procedure|Appendectomy|Standard surgical treatment, normally laparoscopic appendectomy
1685953|NCT01572558|Drug|Conservative, non-surgical treatment|Non-surgical treatment, intravenous and oral antibiotics. Meropenem and Metronidazol will be used as intravenous antibiotics, Ciprofloxacin and Metronidazol will be used as oral antibiotics.
1685954|NCT01572545|Drug|Denosumab|Denosumab (injection), 60 mg, administered as a single subcutaneous injection once
1685955|NCT01572545|Drug|Zoledronic acid|Zoledronic acid (vial), 5 mg, administered once as a single 15- to 30-minute intravenous infusion
1685956|NCT01572532|Other|Screening treatment and referral|"Women who are symptomatic at any study visit will be immediately referred to the sub-district hospital for full evaluation and treatment and will be visited on the following day to follow clinical status and ensure referral compliance. Referral will be reinforced by arranging transportation to the sub-district hospital and payment of hospital fees if the family is unable to afford out-of-pocket expenses. CHWs will conduct a home visit to women with positive test results within 24 hours of receiving the results to initiate treatment. All asymptomatic women will be treated for positive test results. For symptomatic women, the CHW will confirm the woman's clinical and treatment status, and provide treatment to those women who have not already received the appropriate treatment at the sub-district hospital for their infection.
Antibiotic Treatment Regimens AVF: Oral clindamycin 300 mg per oral (po) twice daily (bid) for 5 days.UTI: Macrobid/Nitrofurantoin 100 mg po bid x 7 days."
1685957|NCT01572519|Drug|Phase 1, Cohort 1|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once daily.
1685958|NCT01572519|Drug|Phase 1, Cohort 2|Type=exact number, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily.
1685959|NCT01572519|Drug|Phase 1, Cohort 3|Type=exact number, unit=mg, number=450, form=capsule, route=oral use. Capsule is taken once daily.
1685960|NCT01572519|Drug|Phase 1, Cohort 4|Type=exact number, unit=mg, number=600, form=capsule, route=oral use. Capsule is taken once daily.
1685961|NCT01572519|Drug|Phase 2|JNJ-40346527 at the recommended dose determined in Phase 1
1955461|NCT03189862|Behavioral|Motor Skills Intervention|"The behavioral motor skills intervention (CHAMP) is an intervention strategy that uniquely addresses differences in children's developmental levels on an individualized basis. CHAMP does not equate to a one size fits all approach. Children will be in an environment that promotes opportunities for them to develop improvements in motor skills based on their specific individual needs and choices. The CHAMP intervention promotes a mastery climate that allows each individual child to be successful and learn while promoting intrinsic motivation and autonomy. CHAMP will be implemented 4x/week for 30 minutes across ≈30 weeks for ≈3000 minutes of intervention time."
1685968|NCT01572467|Genetic|RNA analysis|
1685969|NCT01572467|Genetic|gene expression analysis|
1685970|NCT01572467|Genetic|mutation analysis|
1685971|NCT01572467|Genetic|reverse transcriptase-polymerase chain reaction|
1685972|NCT01572467|Other|laboratory biomarker analysis|
1685973|NCT01572467|Other|medical chart review|
1685974|NCT01572454|Drug|Dexmedetomidine infusion|Dexmedetomidine infusion 0.2 mcg/kg/hr during anesthetic induction 0.3 - 0.7 mcg/kg/hr during the surgery
1685975|NCT01572454|Drug|Remifentanil infusion|Remifentanil infusion 0.05 - 0.3 mcg/kg/min during the anesthetic induction and surgery
1685976|NCT01572428|Procedure|Inspection with Narrow-Band Imaging(NBI)|Narrow-Band Imaging(NBI)of the colon rather than the standard white light in the inspection of the colon during colonoscopy.
1685977|NCT01572428|Procedure|Standard White Light|Use of Standard White Light on the colon rather than Narrow-Band Imaging(NBI)in the inspection of the colon during a colonoscopy.
1685978|NCT01572402|Other|Bagueutte Cheese Gourmet (Crocodille)|180g, energy 452.8 Kcal/1895.7 kJ, composition: carbohydrates 49,2 g (44,55%), proteins 18,5 g (16,74%), lipids 18,8 g (38,7%), of which saturated 6,8 g, monounsaturated 6,0 g, polyunsaturated 5,0 g.
1685979|NCT01572402|Other|Cous-cous sandwich|235 g, energy 455,88 Kcal /1907,4 kJ, composition: carbohydrates 59,54 g (52,24%), proteins 12,47 g (10,57% %), lipids 18,85 g (37,31%), of which saturated 6,2 g, monounsaturated 11,49 g, polyunsaturated 28,26 g
1685980|NCT01572402|Other|McCountry sandwich (McDonald's)|150g, 455 kcal/1903,72 kJ, composition: carbohydrates 31 g (27,25%), proteins 24 g (21,1%), lipids 26 g (51,43%), of which saturated 10 g (38,45%)
1685983|NCT01572376|Procedure|Infusion of autologous bone marrow stem cells after wound debridement.|Cleaning of the wound with heparinized saline, cell infusion and closing with suture.
1685984|NCT01572363|Drug|Sildenafil|50 mg once
1685985|NCT01572350|Other|Grid laser|Grid laser therapy acts as the standard to refer to as it is the treatment which is currently accepted by EMDDNT.
1685986|NCT01572350|Drug|Triamcinolone Acetonide|Triamcinolone 4 mg followed by modified grid laser therapy after 3-4 weeks
1685987|NCT01572350|Drug|Bevacizumab|Bevacizumab (1.25 mg initially, weeks 6 and 12) followed by modified grid laser therapy after3-4 weeks
1685988|NCT01572337|Procedure|Non-invasive ventilation|Early non-invasive ventilation will be given to patients at an early stage of acute respiratory failure
1685989|NCT01572337|Other|Standard care|
1686018|NCT01572090|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
1738989|NCT00085332|Drug|docetaxel|
1685990|NCT01572324|Drug|Oxaliplatin, Fluorouracil, Leucovorin, Capecitabine|HAI of Oxaliplatin and Fluorouracil: Oxaliplatin 130mg/m2 in split daily doses for 3 days, Fluorouracil 3000 mg/m2 in split daily doses for 3 days. Intraarterial Oxaliplatin plus intravenous Leucovorin 200 mg/m2 simultaneously over 2 hours followed by intraarterial Fluorouracil over 22 hours on Days 1-3 of each cycle, repeat every 21 days. After 4-6 cycles of HAI, maintenance treatment continue, Maintenance of Oral capecitabine 1,000 mg/m2 twice a day from days 1-14, Cycles were repeated every 21 days.
1685991|NCT01572311|Behavioral|Exercise Intervention|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with dual-task gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise) while answering cognitively challenging questions.
1685992|NCT01572311|Behavioral|Exercise Control|Goal of 150 minutes of structured exercise/week; minimum of 120 minutes from CCAA classes/week. The 75-minute class includes: 5-minute warm-up; 25 minutes of AE (70-85% maximum heart rate); 5-minute cool-down; 20 minutes of strength training; 5 minutes of core strengthening; 5 minutes of balance training; and 10 minutes of stretching. The 60-minute program is identical except: 15 minutes total for all strength training (including core) and 5 minutes of stretching. Following CCAA classes, participants continue with gait training where they are required to walk on a special mat with a designated walking pattern (beginner level Square Stepping Exercise). This will not include any dual-task challenges.
1685995|NCT01572285|Procedure|transforaminal dexamethasone injection|Subjects received transforaminal infiltration of lidocaine 1% 0.5mL and 1.5mL of Dexamethasone 10mg/ml
1685996|NCT01572285|Procedure|Sham|Sham procedure using a non-penetrating needle
1685997|NCT01572259|Drug|Growth Hormone|
1685998|NCT01572259|Other|interruption of the traitment with growth hormone|
1685999|NCT01572246|Other|Optimal placement of return pad|The ESU return pad will be placed in an optimal position in order to direct ME current away from the ICD pulse generators.
1686000|NCT01572233|Behavioral|Personalized Physical Activity and Psycho-Education (PPAPE) Program|"Effects of Personalized Physical Activity and Psycho-Education Program on Patients with HCV infection
The third and fourth year, will be examine on the 12, 24, 36, and 48 weeks during the interferon treatment."
1686001|NCT01572220|Other|UCA stress echocardiography or myocardial SPECT|Comparative Effectiveness of cardiac stress imaging modalities
1686002|NCT01572207|Behavioral|Immediate exercise|Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.
1686003|NCT01572207|Behavioral|Delayed exercise|Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
1686004|NCT01572194|Biological|Urinary levels of PIIINP as a marker of changes in renal function|The act under consideration is the determination of PIIINP urinary. The aim of the study is to show the predictive value of PIIINP urinary in assessing renal function in patients with mucoviscidosis receiving a lung transplant.
1686005|NCT01572181|Drug|Fludarabine IV- Busulfan IV (Busilvex®) - Anti-thymocyte globulines (Thymoglobuline®)|"IV fludarabine (30 mg/m²/day for 5 days)
IV Busulfan (Busilvex 3.2 mg/kg/day for 4 days) (the Busulfan dose is to be adapted to the weight of the child according to the drug label)
Anti-thymocyte globulines (Thymogolubuline, 2.5 mg/kg/day for 2 days)."
1686006|NCT01572168|Other|Acupuncture|Eight session of weekly acupuncture
1686007|NCT01572155|Procedure|Vagus stimulation 1|2 times 2 minutes (beginning and end of surgery) stimulation at 5 Hz, 500 micro s, 2.5 mA
1686008|NCT01572155|Procedure|Vagus stimulation 2|2 times 2 minutes (beginning and end of surgery) stimulation at 20 Hz, 500 micro s, 2.5 mA
1686009|NCT01572129|Drug|Clopidogrel|600 mg clopidogrel loading dose 6-8 h before diagnostic coronary angiogram
1686010|NCT01572129|Drug|Placebo|Placebo in addition to the chronic daily dose of 75 mg
1686011|NCT01572116|Drug|Lidocaine with Epinephrine+ Normal saline|PDL injection of 0/4 ml of lidocaine %2 with epinephrine,and Normal saline
1686012|NCT01572116|Drug|Lidocaine with Epinephrine + sufentanil|PDL injection of 0/4 ml lidocaine with epinephrine and0/4 ml sufentanil ( 0/04 μg)
1686013|NCT01572103|Dietary Supplement|Coffee|Administration of 4 cups of coffee per day for 1 month
1686014|NCT01572103|Dietary Supplement|coffee abstinence|total abstinence for both coffee and caffeine containing beverages
1686015|NCT01572090|Behavioral|Lifestyle Changes|"Hypocaloric diet providing a 1000 kcal/d deficit from total energy expenditure assessed by indirect calorimetry and physical activity determination.
Dietetic and physical activity counselling with a dietitian."
1686016|NCT01572090|Other|Adjustment of oral antidiabetics/insulin therapy|Continuation-discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice. In addition to the surgery, patients will have regular follow-up with an endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery as well for adjustment of antidiabetic medication. Adjustment of oral antidiabetics/insulin therapy consisting in continuation, adjustment or discontinuation of medical antidiabetic therapy if needed in accordance with good clinical practice.
1686017|NCT01572090|Procedure|Laparoscopic sleeve gastrectomy|The Laparoscopic sleeve gastrectomy SG-NG involves the removal of the mayor curvature of the stomach via a laparoscopic approach. In addition to the surgery, patients will have regular follow-up with a dietitian and endocrinologist for appropriate counselling on lifestyle changes (diet, physical activity and vitamin/mineral supplementation counselling) following bariatric surgery.
1686019|NCT01572077|Radiation|FTHA, FDG PET imaging.|Subjects will undergo PET scans on 2 different days using 2 separate tracers, FTHA(fluoro-6-this-hepadecanoic acid) and FDG(fluoro-2- deoxy-glucose).
1738990|NCT00085345|Drug|arsenic trioxide|
1686030|NCT01572025|Drug|Dehydroepiandrosterone|"Dehydroepiandrosterone (DHEA)(St Mary's Pharmaceutical Unit Cardiff and Vale) DHEA 75 mg capsule. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol
: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
1686031|NCT01572025|Drug|Placebo|"Matched Placebo containing no active ingredient. 1 capsule taken once daily for at least 12 weeks prior commencing ovarian stimulation protocol
: Stimulation protocol standard long down-regulation protocol, using human menopausal gonadotropin (HMG)"
1686032|NCT01572012|Drug|Ondansetron|Ondansetron solution 4 mg single administration
1686033|NCT01572012|Drug|Ondansetron + Hylenex|Ondansetron solution (4 mg) single administration + Hylenex recombinant (150 U) single administration
1686034|NCT01572012|Drug|Zofran ODT|Zofran ODT (8 mg) single administration
1686035|NCT01572012|Drug|Ondansetron solution|Ondansetron solution (4 mg) single administration
1686036|NCT01571999|Drug|Inhaled GSK573719|All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
1686037|NCT01571999|Drug|Inhaled GSK573719/vilanterol|All subjects will receive a single dose of GSK573719 (125mcg)/vilanterol (25mcg) in treatment period 2
1686038|NCT01571986|Procedure|Non-invasive ventilation|Non-invasive ventilation
1686039|NCT01571973|Procedure|pharmacotherapeutic follow-up|health education adjustment of dose improve compliance replacement of medication
1686040|NCT01571960|Biological|GEO-D03 DNA vaccine|Either a 0.3-mg (Group 1: study vaccine) or 3-mg dose (Groups 2 and 3: study vaccine) administered as a 1-mL IM injection into the deltoid
1686041|NCT01571960|Biological|MVA/HIV62B (MVA62B) vaccine|1 x 10^8-TCID50 dose of MVA62B vaccine, administered as a 1-mL IM injection into the deltoid
1686042|NCT01571960|Biological|Placebo for GEO-D03 DNA|Administered as a 1-mL IM injection into the deltoid
1686043|NCT01571960|Biological|Placebo for MVA62B:|Administered as a 1-mL IM injection into the deltoid
1686044|NCT01571947|Other|Acute Effects of Fats and Carbohydrate|Test meals were served in the form of muffin + milkshake. For high fat meals, 55g of test fat will be incorporated in muffins, whereas 22g of fat for low fat or high carbohydrate test meal. During study day, subjects were to consume the allocated test meal within 10 minutes.
1686045|NCT01571921|Dietary Supplement|Gamma-Delta Tocotrienol and Tocotrienol Rich Fraction|Single oral TRF or Gamma-Delta Tocotrienol dosage
1686046|NCT01571908|Drug|Magnesium perfusion|The patient receives during 15 minutes a perfusion of 60mg/kg of Magnesium sulphate before induction of anaesthesia.
1686047|NCT01571908|Drug|Rocuronium|Immediately after anaesthesia induction and loss of consciousness 0,6 mg/kg of rocuronium will be injected
1686048|NCT01571908|Drug|Placebo perfusion|The patient receives during 15 minutes a perfusion of 1 ml/kg of saline before induction of anaesthesia
1686049|NCT01571908|Drug|Succinylcholine|Immediately after anaesthesia induction at loss of consciousness 1 mg/kg of succinylcholine will be injected
1686050|NCT01571895|Drug|DF2156A|DF2156A is a novel small molecule that inhibits the biological activity of the CXC ligand 8 [CXCL8; formerly interleukin (IL)-8] through inhibition of the activation of CXCL8 receptors: CXCR1 and CXCR2. This specific inhibitor stems from a program of drug design of molecules intended to modulate chemokine action.
1686051|NCT01571882|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 10 mg of policosanols per unit|1- Intervention with test product ( 1.6g of plant sterol + 10 mg of policosanols/ day)
1686052|NCT01571882|Other|2- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) + 20 mg of policosanols per unit|2- Intervention with test product (1.6g of plant sterol + 20 mg of policosanols/day)
1686053|NCT01571882|Other|3- Low fat drinkable fermented dairy product with 1.6g of plant sterol (as free equivalent) but without policosanols (Active control)|3- Intervention with active control product (1,6 g of plant sterol/ day)
1686054|NCT01571869|Other|1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit|1-Intervention with test product (morning, evening or snack)
1686055|NCT01571869|Other|2- Low fat drinkable fermented dairy product without plant sterols (control)|2 - Intervention with control product (morning and/or evening)
1686056|NCT01571856|Drug|Zinc Sulfate|zinc sulfate solution, contains 20 mg. per 5 mL. dosage 2.5 mL. per day.
1686057|NCT01571856|Other|placebo|cornstarch powder diluted in distilled water, dosage 2.5 ml per day
1686058|NCT01571843|Other|Forearm exercise program|Participants assigned to forearm exercise will receive training in forearm strengthening exercises from a doctoral occupational therapy student. Participants will be taught 8 exercises and are performed at home. The exercise program is designed to take about 30 minutes per session.
1686059|NCT01571843|Other|Walking program|Walking will consist of 30 minutes at a moderate pace every other day for 52 weeks. The walking program for all participants constitutes the control/placebo comparator.
1686060|NCT01571817|Biological|Isolated Human Pancreatic Islets|
1686061|NCT01571804|Drug|Placebo|to receive two identical placebo capsules 1 hr before surgery
1686062|NCT01571804|Drug|pregabalin|one capsule of pregabalin 150 mg and one placebo capsule 1 hr before surgery
1686063|NCT01571804|Drug|pregabalin|two capsules of pregabalin 150 mg 1 hr before surgery
1686064|NCT01571791|Drug|Placebo|to receive saline infusion and intravenous fentanyl boluses, at 30 min before induction of anesthesia
1686065|NCT01571791|Drug|Ketorolac-Lidocaine|receive ketorolac-lidocaine infusion and intravenous saline boluses , at 30 min before induction of anesthesia
1686066|NCT01571778|Behavioral|Hand Hygiene before Donning Non-sterile Gloves|"In the No Intervention arm, healthcare workers will be assigned to first perform hand hygiene before donning non-sterile gloves prior to patient contact (usual practice). Samples will be obtained from hands prior to donning gloves and from the gloves after donning to determine total aerobic colony counts and to identify important hospital pathogens
In the Experimental arm, they will be instructed to don gloves without washing their hands as described."
1686067|NCT01571765|Other|MNCH programming in health district|training at health district level in management, data collection. Training at health centres in obstetrics and pediatrics and training in community of CHWs and bednet distribution
1686068|NCT01571726|Drug|Fluciclatide|7mCi
1686069|NCT01571700|Procedure|Catheterization Pacing|The second part of the study will include patients with pulmonary hypertension >5 who are scheduled for a cardiac catheterization for clinical reasons. We will at the conclusion of the routine catheterization, place two pacing catheters within the right atrium and right ventricle and pace the heart at a rate approximately 10% higher than sinus rhythm for 5 minutes. We will then measure dP/dT max in the ventricles, blood pressure and cardiac output using a Fick equation to assess hemodynamics. We will repeat this 3 times using different sites in the right ventricle while simultaneously obtaining echoes to assess mechanical synchrony.
1686070|NCT01571687|Dietary Supplement|antioxidant supplements|Intake of 6 tablets daily containing: 800 I.E. Vitamin E, 1000mg Vitamin C, 200000 I.E. Vitamin A, 600mg Acetylcystein.
1686071|NCT01571687|Dietary Supplement|Placebo|Intake of 6 identically appearing tablets daily containing placebo
1686072|NCT01571674|Procedure|Manipulation + Exercise Group|"First 2 sessions
High-velocity, low-amplitude manipulations to the thoracic spine.
Low-velocity mid to end-range mobilizations to the cervical spine.
Active Range of Motion Exercises for the cervicothoracic spine
Final 6 sessions
◦ Evidence based shoulder girdle exercise program"
1686073|NCT01571674|Procedure|Exercise Group|"First 2 sessions
◦ Active Range of Motion Exercises for the cervicothoracic spine
Final 6 sessions
◦ Evidence based shoulder girdle exercise program"
1686074|NCT01571661|Drug|GSK189075A|20mg, 50mg, 150mg, 500mg, 1000mg or Placebo
1686075|NCT01571661|Other|Placebo|Placebo
1686076|NCT01571648|Drug|Oral azacitidine|Patients will receive 300 mg dose of oral azacitidine administered once daily for the first 21 days of each 28-day treatment cycle.
1686083|NCT01571622|Dietary Supplement|Whey before Breakfast|After consumption of whey before breakfast samples will be taken every 30 minutes for quantification of glucose, insulin, GlP-1 and GIP
1686084|NCT01571622|Dietary Supplement|Water before breakfast|After water before breakfast the blood samples will be taken every 30 min for quantification of glucose, insulin, GLP-1 and GIP,
1686085|NCT01571609|Other|first phase insulin secretion (FPIR), Hyperinsulinemic euglycemic clamp (HEC), glucose tracer, and palmitate tracer|"FPIR: intravenous infusion of 20 % glucose 0.3 mg/kg in 2 minutes followed by blood sampling at times 0, 2, 4, 6, 8, and 10. Duration 10 minutes.
HEC: intravenous infusion of actrapid 1mU/kg/minute, simultaneous infusion of 20 % glucose at variable rate to reach plasma blood glucose level of 5 mmol/L. Duration 120 minutes
Glucose tracer: bolus of 3H3glucose (12µCi) followed by infusion of 3H3glucose (0,12 µCi/min). Duration 120 minutes.
Palmitate tracer:[9,10-3H]-palmitate 0,3 µCi/min. Duration 60 minutes."
1686086|NCT01571596|Drug|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injection every 28-days (up to 12 doses) based on a dosing algorithm and discretion of Investigator and Sponsor.
1686087|NCT01571583|Drug|Telaprevir|Type=exact number, unit=mg, number=375, form=tablet, route=oral. Patients will receive 2 oral tablets (750 mg) every 8 hours for 12 weeks.
1686088|NCT01571583|Drug|Pegylated interferon alfa-2a|Type=exact number, unit=µg, number=180, form=injection, route=subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 48 weeks.
1686089|NCT01571583|Drug|Ribavirin|Type=exact number, unit=mg, number=200, form=tablet, route=oral. Starting from 600 mg (3 tablets) per day on Day 1. This dose will become higher or lower based on blood results and the investigators opinion (to a goal of 1000 to 1200 mg/day [5 to 6 tablets] based on subject weight), twice daily regimen, for 48 weeks.
1686090|NCT01571570|Drug|TMC435 150 mg capsule|single oral dose of 150 mg TMC435 150 mg capsule
1686091|NCT01571570|Drug|TMC435 150 mg oral suspension (20 mg/mL)|single oral dose of 150 mg TMC435 oral suspension
1686092|NCT01571570|Drug|TMC435 150 mg oral solution (10 mg/mL)|single oral dose of 150 mg TMC435 oral solution
1686093|NCT01571570|Drug|TMC435 150 mg capsule concept K|single oral dose of 150 mg TMC435 capsule concept K
1686094|NCT01571570|Drug|TMC435 150 mg capsule concept L|single oral dose of 150 mg TMC435 capsule concept L
1686095|NCT01571557|Drug|dexamethasone 700 ug intravitreal implant|dexamethasone 700 ug intravitreal implant administered according to standard of care.
1686096|NCT01571544|Device|Thermal suit|Thermal suit
1686097|NCT01571544|Other|Conventional clothing|Conventional clothing
1686098|NCT01571518|Drug|late leukostim|injection of G-CSF (leukostim)5㎍/kg from day 5 of TAC chemotherapy
1686099|NCT01571518|Drug|early leukostim|injection of G-CSF (leukostim)5㎍/kg from day 2 of TAC chemotherapy
1686100|NCT01571505|Biological|IPV vaccination|Randomized IPV or OPV to children aged at 39weeks.
1686101|NCT01571492|Procedure|L2 Paravertebral catheter nerve block|A continuous L2 paravertebral catheter will be placed according to UPMC standard of care practices.
1686102|NCT01571492|Procedure|Continuous Lumbar plexus nerve block|A continuous unilateral lumbar plexus catheter will be placed according to UPMC standard of care practices.
1686182|NCT01570842|Other|Anthropometric measurements|All participants will have their waist circumference and waist to hip ratio taken as a measurement of central obesity.
1686104|NCT01571466|Drug|Vaccination|"Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)
-~ 1 x 10e8 pfu/ml
3 immunisations at week 0, 4 and 16"
1686105|NCT01571466|Drug|Placebo|3 immunisations at week 0, 4 and 16
1686106|NCT01571453|Drug|Vortioxetine (Lu AA21004)|10 mg/day
1686107|NCT01571453|Drug|Venlafaxine extended release|150 mg/day
1686108|NCT01571440|Dietary Supplement|No soluble corn fiber|Each teen will receive a package of fruit snacks containing 0 g soluble corn fiber two times per day
1686109|NCT01571440|Dietary Supplement|12 g soluble corn fiber|Each teen will receive a package of fruit snacks containing 6 g soluble corn fiber two times per day.
1686110|NCT01571427|Behavioral|Active social engagement group|Engage in 30 minutes conversation daily using internet/webcam, 5 days per week for 6 weeks, tracking of daily conversational amount outside of the trial by using a digital recording device, lasting effects will be assessed at the 3rd and 6th month after completion of the intervention
1686111|NCT01571427|Behavioral|Control group|No active intervention, weekly phone calls by interviewer to complete health/social engagement monitoring survey, tracking of daily conversational amount by using a digital recording device
1686112|NCT01571414|Drug|PA-824|200-mg tablets once a day
1686113|NCT01571414|Drug|Efavirenz (EFV)|600-mg tablets once a day
1686114|NCT01571414|Drug|Lopinavir/Ritonavir (LPV/r)|400-mg/100-mg tablets twice a day
1686115|NCT01571414|Drug|Rifampin (RIF)|300-mg capsules once a day
1686116|NCT01571401|Behavioral|Trying Activity for Kidney Cancer Survivors (TRACKS) Trial|Participants in both arms will be provided with six individual supervised exercise sessions with a physical activity specialist that will taper to an unsupervised program by the end of the intervention. Over the 4-week period, both groups will be required to attend two sessions per week for weeks 1-2, and one session per week for weeks 3-4 at the Behavioural Medicine Fitness Centre at the University of Alberta. In order to achieve the PA guidelines established by the current public health recommendations, additional unsupervised sessions will be prescribed.
1686117|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
1686118|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
1686119|NCT01571388|Drug|dacomitinib|Subjects to receive 30 mg tablets of dacomitinib on Day 1 of Period 1.
1686120|NCT01571362|Drug|ALO-02|20 to 160mg total daily dose of oxycodone, divided into symmetric doses and administered twice daily
1686121|NCT01571362|Drug|Placebo|oral placebo, divided into symmetric doses and administered twice daily
1686122|NCT01571323|Drug|Misoprostol|The misoprostol group (groupM) received 400 µg sublingually and infusion of lactated Ringer ( which one ampoule placebo dissolved it)
1686123|NCT01571323|Drug|Oxytocin|The oxytocin group(group O) received intravenous infusion of 20 units of oxytocin soon after delivery of the neonate and one tablet of placebo sublingually. (20 IU syntocinon dissolved in 1liter of lactated Ringer's solution) at the rate of 1000 ml over a 1h period, immediately after delivery of the neonate
1686124|NCT01571323|Drug|Oxytocin and Misoprostol|The combined misoprostol-oxytocin group(group MO) received 200 µg and 5 iu oxytocin bolus intravenously immediately after delivery of the neonate .
1686127|NCT01571297|Drug|RM-131|Double blind RM-131 will be studied with various doses and regimens from 10 to 100 μg for 35 days.
1686128|NCT01571297|Drug|Placebo|Placebo given subcutaneously for 35 days
1686129|NCT01571284|Drug|AFLIBERCEPT AVE0005|Pharmaceutical form:Concentrate for solution for infusion Route of administration: intravenous
1686130|NCT01571284|Drug|FOLFIRI|irinotecan, 5-FU and leucovorin
1686131|NCT01571271|Procedure|Laser Lithotripsy|Laser Lithotripsy
1686132|NCT01571271|Procedure|Electrohydraulic Lithotripsy|Electrohydraulic Lithotripsy
1686133|NCT01571258|Behavioral|Text Messaging|Participants in the intervention group will receive on average 4 texts per day consisting of weight related behavioral recommendations, knowledge based questions, and prompts to promote physical activity and weight monitoring. Texts are interactive and personally relevant based upon a baseline questionnaire.
1686134|NCT01571232|Drug|dexamethasone intravitreal implant|Ozurdex, 0.7 mg intravitreal dexamethasone implant, given at initial visit and at month 4 (visit 5)
1686135|NCT01571232|Drug|intravitreal bevacizumab|Avastin, 1.25 mg intravitreal bevacizumab, given at initial visit and Q1month for a total of 5 treatments.
1686136|NCT01571219|Biological|Infliximab|CT-P13(3mg/kg) administered as a 2-hour IV infusion per dose co-administered with methotrexate between 12.5 to 25 mg/week, oral or parenteral dose (dose and route must be maintained from Study CT-P13 3.1 and be maintained from the beginning to the end of the extension study) and folic acid(≥5mg/week, oral dose)
1686137|NCT01571206|Biological|Infliximab|CT-P13 (5mg/kg) administered as a 2-hour IV infusion per dose
1686138|NCT01571193|Dietary Supplement|Pomegranate extract|Pomegranate extract
1686139|NCT01571193|Dietary Supplement|Placebo|Placebo
1686140|NCT01571167|Drug|Placebo|Participants will receive varenicline or matched placebo from day 1 through day 7, then the same subjects will return within 2-4 weeks and assigned to each of the two remaining study medication conditions, and undergo the identical procedures (3-phase study).
1686250|NCT01570309|Drug|Ergocalciferol|Oral capsule, 50,000 units, once a week, 12 weeks
1686141|NCT01571167|Drug|Varenicline|For varenicline 1 mg, dosing will begin at 0.5 mg once daily (with 0 mg placebo to maintain blind of bid dosing) for days 1-3, will be increased to 0.5 mg twice daily for the days 4-6, and then reduced to 0.5 mg once daily on day 7. No medication is given on Day 8.
1686142|NCT01571167|Drug|Varenicline|For varenicline 2 mg, dosing will begin at 0.5 mg once daily for days 1-3 (with 0 mg placebo to maintain blind of bid dosing), will be increased to 0.5 mg twice daily for day 4, and increased to 1 mg twice daily on days 5-6, and then reduced to 1 mg once daily on day 7. No medication is given on Day 8.
1686143|NCT01571141|Device|Monogin|Gynaecological solution with polyhexamethylene biguanide, pH 4.0
1686144|NCT01571128|Other|Male-Specific Intervention Package|Combination HIV Prevention: Male-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
1686145|NCT01571128|Other|Female-Specific Intervention Package|Combination HIV Prevention: Female-Specific Intervention Package at the Mobile Health events and longitudinal follow up of cohorts.
1686146|NCT01571128|Drug|Pre-Exposure Prophylaxis (Females)|Females 18-24 who are out of school.
1686147|NCT01571128|Behavioral|Cash Transfer Cohort (Females)|Cash transfer for females (and their parents) who are aged 15-24 and enrolled in school.
1686148|NCT01571115|Behavioral|Physical Exercise|
1686149|NCT01571102|Behavioral|Therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 40min.
1686150|NCT01571102|Behavioral|Exercise therapy|week 1 - 4: 3 times/week, week 5 - 8: 2 times/week, duration 30 min.
1686151|NCT01571089|Behavioral|DBT-inspired anxiety treatment|In short, the treatment is 24 sessions consisting of skills-training strategies and exposure strategies. The idea is that the patient during the treatment will learn and practice the skills needed to handle exposures.
1686152|NCT01571076|Genetic|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
1686153|NCT01571076|Genetic|PGS|Preimplantation Genetic Screening of the embryos and posterior transfer of ongoing Day 5 blastocysts.
1686154|NCT01571076|Other|Prolonged culture|The embryos will be in prolonged culture and on going embryos transferred on Day 5 .
1686155|NCT01571076|Other|Prolonged culture|Prolonged culture of the embryos and posterior transfer of ongoing Day 5 blastocysts.
1686156|NCT01571063|Drug|Vitamin D3|Vitamin D3, 2.100 IU/d p.o.
1686157|NCT01571063|Drug|Placebo|Placebo Tbl. p.o.
1686158|NCT01571050|Drug|Purified water|Ingestion of 30 mL of purified water
1686159|NCT01571050|Drug|Fresh MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a fresh toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
1686160|NCT01571050|Drug|Fresh NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a fresh toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight.
1686161|NCT01571050|Drug|Aged NaF/SiO2 toothpaste|Ingestion of 49.5 mg of a toothpaste containing 1100 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
1686162|NCT01571050|Drug|Aged MFP/CaCO3 toothpaste|Ingestion of 31.9 mg of a toothpaste containing 1450 ppm total fluoride per kg body weight, diluted in 30 mL of purified water, to provide a total intake of 49.5 ug of fluoride/kg body weight. The toothpaste had been previously aged to simulate one year storage at room temperature.
1686163|NCT01571037|Drug|Inhaled, nebulized, Milrinone|1 mg/ml milrinone (dissolved in dextrose) and diluted in 0.9% normal saline in a 1:1 ratio to final drug concentration of 0.5mg/ml will be delivered via an IV pump at a fixed dose of 12 ml/hour which will run into a vibrating mesh nebulizer reservoir, connected to the mechanical ventilator circuit. Inhaled milrinone will begin at time of resumption of mechanical ventilation when initiating wean from cardiopulmonary bypass after LVAD implantation in the operating room, and run continuously for a total maximum duration of 24 hours OR until the patient is extubated whichever occurs first. Plasma milrinone levels will be assessed to determine if systemic milrinone absorption occurs after prolonged milrinone inhalation.
1686164|NCT01571037|Drug|inhaled nebulized milrinone|0.5 mg/ml inhaled nebulized milrinone deliver at 12 ml/hr continuously until either 24 hours or extubated.
1686165|NCT01571024|Drug|BKM120|BKM120 40 mg, orally, once daily.
1686166|NCT01571024|Drug|mFOLFOX6|mFOLFOX6 treatment will be as follows: Oxaliplatin: 85 mg/m2 IV, Leucovorin: 400 mg/m2 IV, 5FU bolus: 400 mg/m2 IV and 5FU infusion: 2400 mg/m2 IV.
1686167|NCT01571011|Behavioral|CURB|The intervention is made up of 14 internet modules based on behavioral activation, cognitive behavioral therapy, and interpersonal psychotherapy as well as motivational interviews in the primary care setting (to enhance behavior change). It is suggested that an adolescent navigates through 2 modules a week. The motivational interviews with the physicians occur directly before and after the adolescent is exposed to the website (at baseline and 3 months) in the providers office. The parents of the enrolled adolescents are also invited to navigate through their own, 3 module, parent internet program.
1686170|NCT01570985|Drug|Triamcinolone Acetonide|Triamcinolone 20 mg intraarticular injection with Lidocaine 10mg/ml 3 ml and variable amount of saline of 4 ml solution on day 1, day 7, day 17 and day 31st.
1686171|NCT01570985|Drug|Triamcinolone Acetonide|Patients in group 2 will receive intraarticular Triamcinolone 20 mg, 3 ml Lidocaine and physiological natrium chloride 9 mg/ml, comprising a total volume from 8 ml and upwards up to 20 ml
1686172|NCT01570972|Behavioral|Group Cognitive Behavioral Therapy|weekly
1686173|NCT01570972|Behavioral|Multifamily Group Psychoeducation|twice monthly
1686174|NCT01570959|Drug|Quetiapine Fumarate|300 mg tablet
1686175|NCT01570946|Behavioral|Lifestyle Modification|The mobile phone based intervention will use short messaging service (SMS or text messaging) to deliver education, treatment targets, advice, support and motivation.
1686176|NCT01570933|Device|NivNava|Non-invasive Nava ventilation mode on nasal cannula
1686177|NCT01570933|Device|Cpap|nasal Cpap on nasal cannula
1686178|NCT01570920|Behavioral|physical training|walking many times a week
1686179|NCT01570907|Drug|Quetiapine Fumarate|25 mg tablet
1738991|NCT00085345|Drug|ascorbic acid|
1686183|NCT01570842|Procedure|Tissue samples|Participants undergoing clinically indicated upper endoscopy and who consent to providing tissue samples will have 8 tissue samples taken for future research purposes.
1686184|NCT01570829|Drug|Dietressa|Safety and Efficiency of New Dosage Schedule
1686185|NCT01570829|Drug|Placebo|Safety and Efficiency of New Dosage Schedule
1686186|NCT01570816|Device|IRS-8 (8 channel implanted receiver stimulator)|Surgical implantation of an 8 channel pulse generator to stimulate paralyzed muscles of the lower extremities
1686187|NCT01570803|Device|S.M.A.R.T CONTROL Stent|Provisional stenting should be performed; the case that optimal ballooning response is not obtained (sub-optimal balloon response) should be enrolled. The procedure is usually done, as follows; After the guidewire is passed through the target lesion, predilation of the target lesion with an optimally sized balloon will be performed prior to stent implantation. Recommended, minimal balloon dilation time is 120 seconds. The sub-optimal balloon response is defined as a residual pressure gradient of >15 mmHg, residual stenosis of >30%, and flow-limiting dissection.
1686188|NCT01570803|Device|Complete SE Stent|same to SMART CONTROL Stent
1686189|NCT01570790|Drug|Combretastatin A-4 phosphate|27 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
1686190|NCT01570790|Drug|Combretastatin A-4 Phosphate|36 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
1686191|NCT01570790|Drug|Combretastatin A-4 Phosphate|45 mg/m2 CA4P IV infusion at baseline and every week for 4 doses
1686192|NCT01570777|Procedure|renal denervation and optimized medication regimen|Patients are treated with the renal denervation plus a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
1686193|NCT01570777|Procedure|optimized medication regimen|Patients are treated with a standardized optimal antihypertensive treatment which is adapted every month starting two month after randomization on the basis of home BP monitoring results at follow-up visits.
1686194|NCT01570764|Drug|Cyclophosphamide|Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
1686195|NCT01570764|Drug|Placebo|Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
1686196|NCT01570751|Drug|insulin degludec|Cross-over trial, part 1: Individually adjusted IDeg administered subcutaneously (s.c., under the skin) once daily for 16 weeks in each treatment period.
1686197|NCT01570751|Drug|insulin glargine|Cross-over trial, part 2: Individually adjusted IGlar administered subcutaneously (s.c., under the skin) once daily for the 16 week run-in period followed by 16 weeks in each treatment period.
1686198|NCT01570725|Behavioral|Virtual reality exposure|"The Green Valley, a non interactive, relaxing environment showing a mountain landscape around a calm lake is presented to the patient together with the relaxing music and soft sounds (birds' songs, the water flowing, etc). Having the impression of walking around the lake, patients can observe the nature and virtually seat on a comfortable deck chair, in order to become easily relaxed.
Patients were exposed to the virtual environment for the entire length of the operation."
1686199|NCT01570725|Behavioral|Music only|A relaxing music and nature sounds have been used to provide a calm atmosphere and reduce stress. In the Music group it was provided to the patients through earphones with no visual stimulation.
1686200|NCT01570712|Other|HOUSING FIRST PROGRAM|"Realization of a psychosocial organic evaluation and a citizen;
Support in the development and the maintenance of the housing;
Support in the diverse steps (administrative, judicial, financiers, etc.);
Support around addictions / alcohol;
Supportin the family and social relations, in the environment of the person -to favor the occupational integration, by prioritizing the insertion in ordinary environment(middle)
to favor the access and the preservation of the patient to the psychiatric and somatic care, to the devices and the departments favoring the social insertion and the integration."
1686201|NCT01570712|Other|traditional French services|"The person will not receive from intervention of the team of site, but the person can resort(turn) without limitation to all the range of services said  about common law  set up in the direction of the persons homeless persons, as well as to every type of care. She can too reach the housing and\or the restoring, but this by means of the existing devices"
1686202|NCT01570699|Genetic|COMT polymorphism|The COMT enzyme enables the degradation of brain monoamines such as Dopamine and is encoded by a single gene for which several polymorphisms are known, including the Val158Met polymorphism which has been widely studied in various psychiatric disorders including addictions, as well as in impulsivity
1686203|NCT01570686|Drug|Aliskiren|Aliskiren 300 mg once daily
1686204|NCT01570673|Behavioral|Group urotherapy|Children in this arm will receive group urotherapy in small groups with other children.
1686205|NCT01570673|Behavioral|Individual Urotherapy|Children will receive standard individual urotherapy in regular pediatric urology clinic.
1686206|NCT01570660|Drug|Pioglitazone|12 weeks of pioglitazone treatment
1686207|NCT01570634|Drug|Calcium Aluminosilicate Anti-Diarrheal (CASAD)|CASAD 3 500mg capsules po tid for 14 days with 4 weeks of follow up
1686209|NCT01570608|Drug|Ranibizumab|intravitreal injection 3 monthly injections thereafter as needed
1686210|NCT01570608|Drug|Verteporfin|Verteporfin photodynamic therapy standard fluence
1686240|NCT01570361|Drug|Drug Treatment|Drug therapy (either rate or rhythm control): Class I or class III, or AV nodal blocking agents such as beta blockers and calcium channel blockers in accordance with current atrial fibrillation management guidelines.
1686241|NCT01570348|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic BMT
1686242|NCT01570348|Drug|Cyclophosphamide|Given IV
1686243|NCT01570348|Drug|Fludarabine Phosphate|Given IV
1686244|NCT01570348|Other|Laboratory Biomarker Analysis|Correlative studies
1686245|NCT01570348|Drug|Mycophenolate Mofetil|Given PO
1686211|NCT01570595|Behavioral|Web-Based Tailored Smoking Cessation Intervention|"The Experimental group will be given an ID number to log in to the quit smoking program, and complete their first log-in with a research assistant. The online program is made up of 8 separate, weekly online sessions that take approximately 15-30 minutes to complete. The entire program is meant to be completed in 7 weeks. Participants are asked to provide an email address and/or cell phone number so reminders can be sent to complete the sessions. If participants are late completing a session, they will receive a call from clinic staff as a reminder. The standard care group will receive advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches)."
1686212|NCT01570595|Behavioral|Standard of Care|advice to quit, a quit-smoking brochure, and an offer of three months of nicotine replacement therapy (nicotine patches).
1686213|NCT01570582|Drug|carboplatin and paclitaxel|Subjects assigned to Arm I Neople taksoljuwa Latin week the first day of the week based outpatient / inpatient treatment receive it. The subjects first received taksoljureul given over 3 hours followed by 30 minutes will be administered Neople Latin week.
1686214|NCT01570569|Drug|Omeprazole|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
1686215|NCT01570569|Drug|Losartan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
1686216|NCT01570569|Drug|Dextromethorphan|Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
1686217|NCT01570569|Drug|Cocktail|"Group A : Thirteen healthy male subjects were given oral doses of 200 μg omeprazole, 2 mg losartan and 2 mg dextromethorphan individually and in combination of five drugs (cocktail) every other days.
Group B : Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days."
1686218|NCT01570569|Drug|Midazolam|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
1686219|NCT01570569|Drug|Caffeine|Thirteen healthy male subjects received 100 μg midazolam and 2 mg caffeine individually followed by five-drugs cocktail every two days.
1686220|NCT01570556|Other|Antibiotic treatment|In patients with positive urinary culture, seven days of antibiotics will be given orally according to the bacteriogram sensitivity.
1686221|NCT01570530|Procedure|Cardiac surgery|Atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
1686222|NCT01570530|Procedure|Cardiac surgery|Without atorvastatin therapy as prophylaxis against postoperative atrial fibrillation after cardiac surgery
1686223|NCT01570517|Device|IASD System|Implantation of the DC Devices Inc. IASD System
1686224|NCT01570504|Drug|Ivermectin|oral formulation
1686227|NCT01570478|Drug|Foster® NEXThaler® 100/6 µg/unit dose|Foster® NEXThaler® (beclomethasone dipropionate 100 µg plus formoterol 6 µg per actuation), 2 inhalations b.i.d. (daily dose of BDP 400 µg plus FF 24 µg)
1686228|NCT01570478|Drug|Seretide® Accuhaler® 250/50 µg/actuation|Seretide® Accuhaler® (fluticasone propionate 250 μg plus salmeterol xinafoate 50 μg per actuation), 1 inhalation b.i.d. (daily dose of fluticasone 500 μg plus salmeterol 100 μg)
1686229|NCT01570465|Other|Observation|Assess the impact of each type of severe infections (SI) over the 24-month overall survival of young patients with newly diagnosed acute myeloid leukemia along a predefined antileukemic treatment strategy.
1686230|NCT01570452|Procedure|colonic or colorectal resection|standard laparotomic resection of colon-rectum including right hemicolectomy, left hemicolectomy, sigmoidectomy, anterior resection
1686231|NCT01570413|Procedure|No Pelvic Exam|Will not receive pelvic examination.
1686232|NCT01570413|Procedure|Pelvic Examination|Pelvic examination will be performed.
1686233|NCT01570400|Behavioral|Internet-administered cognitive behavioral therapy (iCBT)|Established form of internet-administered cognitive behavioral therapy. Controlled progress, self-help modules with psychoeducative texts, assignments and homework. Therapist assisted.
1686234|NCT01570400|Behavioral|Cognitive bias modification training program variant 1|"Computerized, internet-based training program for implicit modification of cognitive bias of attention, variant 4. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe always follows the more negative word or face.
Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
1686235|NCT01570400|Behavioral|Cognitive bias modification training program variant 2|"Computerized, internet-based control training program, variant 2. Participant is exposed to a pair of words or a pair of faces -- either neutral-negative, neutral-positive, or negative-positive -- for 500ms-1000ms, followed by a probe (< or >) in the previous position of ONE of these words or faces and is then asked to press the corresponding arrow button on a keyboard. A total of 96 word pairs and 96 face pairs are shown during a session. One third is neutral-negative, one third is neutral-positive, and one third is negative-positive. The probe follows the more positive stimulus and the more negative stimulus with equal frequency.
Duration: approx. 10 min. per session. Frequency: Once every day for 2 weeks."
1686238|NCT01570374|Behavioral|Internet-based cognitive behavioral therapy (iCBT)|9 week internet-administered, therapist-assisted, controlled-progression cognitive behavioral therapy (iCBT). Individualized and disorder-specific.
1686239|NCT01570361|Device|Catheter Ablation|Treat subjects with Paroxysmal Atrial Fibrillation (PAF)
1686246|NCT01570348|Drug|Mycophenolic Acid|Given PO
1686247|NCT01570348|Other|Quality-of-Life Assessment|Ancillary studies
1686252|NCT01570296|Drug|Gefitinib and BKM120|Dose escalation study of gefitinib and BKM120 with expansion cohort
1686253|NCT01570283|Biological|Multi-virus-specific cytotoxic T lymphocytes|"The feasibility and safety of 3 different dose levels will be evaluated and will determine the maximum tolerated dose (MTD) level.
Dose Level One: 5x10^6 mCTLs/m2
Dose Level Two: 1x10^7 mCTLs/m2
Dose Level Three: 2x10^7 mCTLs/m2
There may be an option of administering 2 additional doses (at the same level the patient was receiving), 28 days after the first dose, in subjects that have a partial response after one dose or who receive other therapy that may affect the persistence or function of the infused CTL."
1686254|NCT01570270|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, single blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9.
1686255|NCT01570257|Procedure|lowering of the performance level of an adjustable Strata valve in a ventriculoperitoneal (VP) shunt for treating idiopathic normal pressure hydrocephalus|in the intervention group, the performance level(PL) of the valve of the VP shunt, preset at the highest PL (meaning highest resistance) is lowered stepwise in the follow-up period at 1,3 and 9 months postoperatively after implantation until improvement occurs or signs of overdrainage are encountered on a new CT scan of the brain. In the control group the PL is preset and fixed at the second lowest PL and these patients serve as a control group.
1686256|NCT01570244|Drug|levonorgestrel|multiple doses
1686257|NCT01570244|Drug|Ethinylestradiol|multiple doses
1686258|NCT01570244|Drug|levonorgestrel|multiple doses
1686259|NCT01570244|Drug|BI 201335|multiple doses
1686260|NCT01570244|Drug|Ethinylestradiol|multiple doses
1686261|NCT01570231|Device|bilateral limb ischemic preconditioning (Doctormate, IPC-906X)|Device: bilateral limb ischemic preconditioning (Doctormate, IPC-906X, produced by Beijing Renqiao Institute of Neuroscience)five cycles of 5 minutes bilateral upper limb ischemia-reperfusion performed by inflating tourniquets to 200 mmHg, twice daily for 180 consecutive days, along with conventional medical treatment.
1686262|NCT01570218|Behavioral|Music therapy|Music therapy arm: Intervention with 10 sections of music therapy will be performed, twice a week, during 45 days
1686263|NCT01570205|Drug|XG-102|single intravenous infusion
1955479|NCT03184571|Drug|BGB324; pembrolizumab|BGB324 is an Axl kinase inhibitor; pembrolizumab is a PD-1 inhibitor
1686269|NCT01570179|Drug|ideal BW based sugammadex reversal of moderate block|2 mg/kg sugammadex (based og ideal body weight)
1686270|NCT01570179|Drug|real body weight based sugammadex reversal of moderate block|2 mg/kg sugammadex (based on real BW)
1686271|NCT01570179|Drug|real body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on real BW)
1686272|NCT01570179|Drug|ideal body weight based sugammadex reversal of deep block|4 mg/kg sugammadex (based on ideal BW)
1686273|NCT01570166|Procedure|HR|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
1686274|NCT01570166|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
1686275|NCT01570140|Behavioral|Web portal|This study investigates the effects of the voluntarily use of a webportal and its educational content.
1686276|NCT01570127|Procedure|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
1686277|NCT01570127|Procedure|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 8 Acupuncture points, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral) were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
1686278|NCT01570127|Procedure|Sham Acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 8 same acupuncture points as in the standardized acupuncture group, GV4, GV3, BL24(bilateral), BL25(bilateral) and GB30(bilateral). Each session was 20 minutes long.
1686279|NCT01570127|Other|Waiting|No interventions were applied to the patients in this group.
1686280|NCT01570114|Device|Fully covered metallic colonic stent|Endoscopically insertion of fully covered metallic colonic stent
1686281|NCT01570101|Device|CE Marked Sapheon Closure System|"CE Marked Sapheon Closure System in closure of incompetent great saphenous veins GSV in a routine clinical setting."
1686282|NCT01570088|Dietary Supplement|Folic acid|One roll/bun per day fortified with 400 µg of folic acid
1686283|NCT01570088|Dietary Supplement|L-5-MTHF|One roll/bun per day fortified with 452 µg of L-5-MTHF
1686284|NCT01570088|Other|Placebo|Placebo contains no folic acids
1686313|NCT01569828|Drug|LCZ696A|once daily administration of 400 mg LCZ696 for 5 days
1686314|NCT01569815|Drug|LCZ696|LCZ696 400 mg once daily
1738992|NCT00085345|Drug|melphalan|
1686285|NCT01570075|Procedure|HR|SR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure.
1686286|NCT01570075|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
1686287|NCT01570062|Device|HEPA Filter|"Two HEPA filters will be placed in participant's homes (one in the bedroom and one in the main living area); each HEPA will run for 2 consecutive 7-day sampling sessions. During one of the 7-day sampling sessions, the HEPA filter will run without the internal filter in place (i.e., placebo filtration)."
1686288|NCT01570062|Device|HEPA Filtration Placebo|for one of the two 7-day sampling sessions, both HEPA filters placed in participants' homes will be run without the actual filter in the housing unit.
1686289|NCT01570049|Drug|Bendamustine|for injection
1686293|NCT01570023|Behavioral|Isometric Progressive Resistance Oropharyngeal Therapy|Tongue press exercises consist of pressing the tongue against the sensors. Isometric exercises will focus on the anterior and posterior sensor. Subjects will be given a target pressure value for both the anterior and posterior sensor locations for which to aim when doing the exercises. Visual feedback on the display will signal the subject that they have attained their target pressure goal.
1686294|NCT01570010|Other|new norwegian food based dietary guidelines|several means will be applied to guide participarts to cohere to the dietary guidelines including access to clinical nutritionists, free food, food discounts, cooking courses, cookbook/recipies, study website, organized physical activity, etc
1686295|NCT01569997|Other|MultiDisciplinary Team Meetings (MDTM)|The MDTM, between the memory experts and Nursing Home coordinating practitioners, could help the nursing home medical staff identify the cases of dementia and propose these residents an adequate healthcare project (supplementary investigations, therapeutic modifications, hospitalizations...)
1686296|NCT01569984|Radiation|Stereotactic body radiotherapy|Avastin 7.5 mg/kg IV x 2 doses 14 days apart
1686297|NCT01569971|Other|Assessment|In this study, through the use of focus groups and questionnaires, we will identify perceptions of transition from pediatric to adult care, transition readiness, disease knowledge, and self-management skills, and assess components of the St. Jude Children's Research Hospital (SJCRH) Sickle Cell Disease Transition Program. Participants will participate in focus groups to discuss transition and transition-related concepts and evaluate components of the transition program. Additionally, participants will complete questionnaires about specific aspects of the transition program and about current disease knowledge and management skills.
1686298|NCT01569958|Other|transcranial direct current stimulation|transcranial direct current stimulation applied to the motor cortex of both sides (1 mA, 20 minutes) for five consecutive days every month for 12 months
1686299|NCT01569958|Other|Sham stimulation|1 mA stimulation for 30 seconds every 900 seconds per session
1686300|NCT01569945|Drug|Clomifen, Ethinyl Estradiol|starting on day 2 or 3 of the cycle: 1 tablet of Clomifen each day, for 5 days in a row. Dose 50mg or in subsequent cycles, 25 mg or 100 mg or 150 mg. After the 5 days of Clomifen, one tablet of Ethinyl Estradiol 50 mg per day, for 5 days in a row or until beta hCG is injected
1686301|NCT01569945|Drug|Menotropins|Starting on day 2 or 3 of the cycle, a daily subcutaneous injection of 37.5 IU or 75.0 IU
1686302|NCT01569919|Biological|TroVax®|Dose of 1 x 10^9 TCID 50/ml, in 1ml, given on day 1 of weeks 1, 3, 6, 9, 12, 15, 18, 21, 24.
1686303|NCT01569919|Drug|Pemetrexed|500 mg/m^2 over 10 mins, given on day 3 of weeks 4, 7, 10, 13.
1686304|NCT01569919|Drug|Cisplatin|75mg/m^2 over 1 hour, given on day 3 of weeks 4, 7, 10, 13
1686305|NCT01569919|Dietary Supplement|Vitamin B12|1000μg intramuscular, Day 2 of weeks 3 and 12
1686306|NCT01569919|Dietary Supplement|Folic Acid|400μg oral daily from Day 2 of week 3 to Day 2 of week 16
1686307|NCT01569919|Drug|Dexamethasone|4mg BD, Days 2-6 of weeks 4, 7, 10, 13
1686308|NCT01569906|Radiation|Narrowband Ultraviolet B phototherapy|Twice weekly exposures for a total of 24 exposures using a standard phototherapy protocol.
1686309|NCT01569893|Other|Self-monitoring for patients with Dibetes mellitus|"Patients are equipped with a telemonitoring kit composed by a portable glucose meter and a gateway device for data transmission.
The patient can monitor his blood glucose level with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms."
1686310|NCT01569841|Drug|insulin degludec|Administered subcutaneously (s.c., under the skin) once daily.
1686311|NCT01569841|Drug|insulin glargine|Administered subcutaneously (s.c., under the skin) once daily.
1686315|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, placed on cymba concha
1686316|NCT01569789|Device|Vagus Nerve Stimulator|Voltage 2, place on the placebo area of the calf
1686317|NCT01569776|Other|Amino Acid formula|Amino Acid baby formula
1686318|NCT01569776|Other|Commercially available Amino Acid Formula|Hypoallergenic Baby formula
1686319|NCT01569763|Device|Aurora Endometrial Ablation|Endometrial Ablation using the Aurora Endometrial Ablation system
1686320|NCT01569763|Device|Rollerball Ablation/Resection|Hysteroscopic rollerball resection/ablation
1686321|NCT01569750|Drug|Part 1, Cohort 1|Type=exact number, unit=mg, number=280, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
1686322|NCT01569750|Drug|Part 1, Cohort 2|Type=exact number, unit=mg, number=420, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
1686323|NCT01569750|Drug|Part 1, Cohort 3|Type=exact number, unit=mg, number=560, form=capsule, route=oral use. Escalating doses of ibrutinib (starting on Day 3 for Cycle 1 and on Day 1 for subsequent cycles) administered once daily in with standard-of-care doses of R-CHOP until maximum tolerated dose is achieved.
1686324|NCT01569750|Drug|Part 2, Cohort 1|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed diffuse large B-cell lymphoma.
1686325|NCT01569750|Drug|Part 2, Cohort 2|Ibrutinib at the recommended Part 1 dose administered once daily with standard-of-care doses of R-CHOP in patients with newly diagnosed with B-cell non-Hodgkin lymphoma.
1686326|NCT01569737|Drug|ella|ella, single intake, tablet 30mg
1686327|NCT01569724|Other|oral glucose tolerance test (OGTT)|patients presenting an hypertriglyceridemia will have a oral glucose tolerance test (OGTT) in order to diagnose a carbohydrate metabolism disorder
1686328|NCT01569711|Procedure|Deep brain stimulation of nucleus accumbens|"Day0 : surgical placement of electrodes
M1 : stimulation of nucleus accumbens
M5 : stimulation of nucleus accumbens or associative territory of caudate nucleus (if no response observed with nucleus accumbens stimulation)"
1686329|NCT01569698|Procedure|acute extra renal replacement therapy|usual modalities of pediatric acute extra renal replacement therapy : Intermittent Hemodialysis, Continuous Renal Replacement Therapies, and Peritoneal Dialysis
1686330|NCT01569685|Drug|Venlafaxine|Tablets, once a day, max 375 mg day (maximal recommended dose)
1686331|NCT01569685|Drug|Sertraline|Tablets, once a day, maximum 200 mg/day (maximum required dose)
1686332|NCT01569672|Behavioral|Patient Navigator matched with subject|Subject is matched with a patient navigator. The patient navigator calls the patient. The amount of time between the abnormal test and treatment will be measured.
1686333|NCT01569672|Behavioral|Subjects are mailed informational/educational materials|Subjects will be mailed informational/educational materials. The amount of time between the abnormal test and treatment will be measured.
1686336|NCT01569633|Drug|Metclopramide|Dose of metoclopramide is 0.1miligram per kilogram every eight hours for 7-14 days.
1686337|NCT01569633|Drug|Erythromycin|Dose of erythromycin is 1 miligram per kilogram every eight hours
1686338|NCT01569633|Drug|placebo|The dose of sugar water is 1 ml per 8 hours.
1686339|NCT01569620|Behavioral|Best clinical practices plus culturally targeted print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the culturally relevant print materials developed for this study.
1686340|NCT01569620|Behavioral|Best clinical practices plus standard print materials|This intervention arm includes best clinical practices (or usual care at MSSM) and the standard CRC screening print materials developed by the Centers for Disease Control (CDC).
1686341|NCT01569620|Behavioral|Best clinical practices alone|This intervention arm includes best clinical practices (or standard/usual care at MSSM) and no additional print materials.
1686344|NCT01569594|Device|CorMatrix ECM for Carotid Repair|Subjects must be undergoing carotid endarterectomy with patch angioplasty closure
1686345|NCT01569581|Biological|100U/0.5ml in 6-11 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 6-11 months old on day 0, 28
1686346|NCT01569581|Biological|100U/0.5ml in 12-23 months old infants|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1750 infants aged 12-23 months old on day 0, 28
1686347|NCT01569581|Biological|100U/0.5ml in 24-35 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1500 children aged 24-35 months old on day 0, 28
1686348|NCT01569581|Biological|100U/0.5ml in 36-71 months old children|inactivated EV71 vaccine (KMB-17) of 100U/0.5ml (320Eu/0.5ml) in 1000 children aged 36-71 months old on day 0, 28
1686349|NCT01569568|Other|MRI scanning|1H MRS, DTI, FMRI
1686350|NCT01569568|Behavioral|Cognitive testing|Behavioral testing
1686351|NCT01569529|Behavioral|Online advertisement|Internet advertisement with messages tailored for young adult smoker's motivated to quit
1686352|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1mg, tid
1686353|NCT01569516|Drug|Octohydroaminoacridine Succinate Tablets|1st-2nd week, 1mg, tid 3rd -16th week, 2mg, tid
1686354|NCT01569516|Drug|Octohydroaminoacridine succinate Tablets|1st-2nd week, 1mg, tid, 3rd -4th week, 2mg, tid, 5th-16th week, 4mg, tid
1686355|NCT01569516|Drug|Placebo|0mg, tid
1686356|NCT01569503|Device|vagus nerve stimulation (VNS)|VNS therapy consists of an implanted pacemaker-like device that delivers mild, intermittently pulsed signals to the patient's left vagus nerve. Roughly the size of a small pocket-watch and weighing less than one ounce, the pulse generator is implanted in the patient's left chest area. A thin thread-like wire, attached to the generator, runs under the skin to the left vagus nerve in the neck
1686357|NCT01569490|Behavioral|Incentives for abstinence and treatment engagement|Treatment Incentives - incentives for biochemical verification visits, treatment engagement, and abstinence
1686358|NCT01569490|Behavioral|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
1686359|NCT01569477|Behavioral|Incentives for abstinence and treatment engagement|Treatment incentives - incentives for biochemical verification visits, treatment engagement and abstinence
1686360|NCT01569477|Behavioral|Attendance incentive|Attendance Incentives - incentives for only attending the biochemical verification visits
1686361|NCT01569464|Drug|Rotigotine|"Transdermal patch containing Rotigotine formulated in an adhesive matrix. Subjects were to be treated with their optimal dose which consisted of one of the dose strengths below:
Rotigotine 1 mg /24 hr, Rotigotine 2 mg/ 24 hr, Rotigotine 3 mg/ 24 hr, One patch every 24 hours
7 weeks (titration plus maintenance)"
1686362|NCT01569464|Other|Placebo|"Placebo patches titrated from 1 mg/ 24 hr - 3 mg/ 24 hr or until effective or maximum dose was reached.
Placebo 1 mg/ 24 hr, Placebo 2 mg/ 24 hr, Placebo 3 mg/ 24 hr, one patch every 24 hours.
7 weeks (titration plus maintenance)"
1955486|NCT03182907|Biological|Bezlotoxumab|A single intravenous (IV) infusion of 10 mg of bezlotoxumab per kg body weight. Dose may then be changed based on results from initial 12 participants.
1686365|NCT01569438|Drug|Gefapixant|BID
1686366|NCT01569438|Drug|Sugar Pill|Placebo
1686367|NCT01569425|Other|Dietary intervention|High Calorie breakfast and high calorie dinner
1686368|NCT01569412|Biological|Ertumaxomab|trifunctional antibody, infusion i.v., increasing doses, up to 10 infusions
1686369|NCT01569399|Other|rTMS (repetitive transcranial magnetic stimulation)|Frequency (10hz) 120% motor threshold 10 sessions
1686370|NCT01569386|Behavioral|Daily low intensity physical activity by the half squat|They take a meal three times daily. They are a time to do the manual work every day. They watch the TV for two hours every day. And they do a walk of 30 minutes every day. They do a specific exercise. They were trained to conduct 40kcal period(about 20 min.) for adding to the amount of energy consumption of low-intensity physical activity at baseline.Specific exercise that was done the half squat(max knee flexion 70 degree). This squat is carried out in two seconds round trip. This squat is carried out in two seconds round trip. They grab the edge of the table. They put half the weight of the lower limbs paralyzed side. This observer once a week, to record their behavior over 24 hours. Intervention period is up to a maximum of 12 weeks.
1686371|NCT01569386|Behavioral|stretch exercise and usual activity|They take a meal three times daily.They are a time to do the manual work every day.They watch the TV for two hours every day.And they do a walk of 30 minutes every day.They do whole body stretch exercise for 20 minute in a day. An observer once a week, to record their behavior over 24 hours.Their behavior was used to calculate the amount of energy consumption.They are informed of the kcal a day from the viewer.
1686372|NCT01569360|Device|Corset|the patients are assigned the use of a custome made corset during daytime
1686373|NCT01569347|Other|Interviews|Interviews
1686374|NCT01569347|Other|Blood sample|Blood sample
1686375|NCT01569347|Other|Hair sample|Hair sample
1686376|NCT01569334|Biological|blood samples|
1686377|NCT01569321|Device|MRI|
1686378|NCT01569321|Device|PET-CT scan|
1686379|NCT01569321|Device|PEM scan with ClearPemSonic|
1686384|NCT01569282|Procedure|Hepaticojejunostomy and gastroenterostomy|Standard surgical techniques
1686385|NCT01569282|Procedure|Stent strategy|Biliary and/or enteral stents on demand
1686386|NCT01569269|Behavioral|Yoga Intervention|"The yoga intervention will take place for one hour per week for six weeks. All sessions will be guided by a Registered Yoga Teacher (RYT) who is also a Licensed Clinical Social Worker (LCSW).
Each yoga session will follow a similar protocol. The introductory period (10 minutes) will focus participants on increasing interoceptive and proprioceptive capacity. The main segment is comprised of a series of yoga postures that progress from lying or seated postures that provide gentle muscle stretching to standing stretches that increase balance and flexibility. The postures will be introduced, practiced, and combined with breathing exercises for forty minutes.
The conclusion of the session will be comprised of 10 minutes of relaxation."
1686387|NCT01569269|Behavioral|Meditation Intervention|The meditation intervention will be conducted weekly for weeks. Each class will follow a similar protocol: During the one-hour meeting, participants will focus on developing attention to the breath. In a supine or seated position and with eyes closed, participants will be guided to attend solely to their breathing. As physical sensations, thoughts, and emotions begin to arise, participants will be taught to recognize, acknowledge, and accept the presence of the sensations or emotions and then to step back, release the thought or sensation, and refocus attention toward the breath At the conclusion of each meeting, the meditation instructor will encourage participants to voluntarily engage in daily meditation practices.
1686388|NCT01569269|Behavioral|Reiki|The Reiki intervention will be conducted for one hour per week for 6 weeks. Protocol for each session: Briefly meet with the Reiki practitioner to review experiences with symptoms of CIPN. Then, the participant will be directed to lie supine and fully clothed on a massage table. Beginning at the top of the head, the practitioner will move inferiorly and pause while holding their hands above, but facing the participant at each energy point until reaching the feet. Upon reaching the participant's feet, the participant will roll from the supine position to a prone position and the process repeated. After being guided to a seated position on the massage table, the practitioner will spend a few moments in conversation with the participation before ending the session.
1686435|NCT01568983|Dietary Supplement|Mana-juice|500 ml/day of a grape,cherry, bilberry,aronia juice 13g carbohydrates/100g 150mg K/100g
1686436|NCT01568983|Dietary Supplement|Optijuice|500 ml/day of a Grape,cherry, bilberry,aronia, black current juice 13g carbohydrates/100g 150mg K/100g
1686437|NCT01568970|Behavioral|Return-to-work Rehabilitation + Follow up|3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up
1686438|NCT01568970|Behavioral|Return-to-work rehabilitation|3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
1686389|NCT01569269|Other|Holistic Education|The psychoeducational intervention will be presented in a traditional classroom format with weekly one hour meetings taking place during the six week study period. Each class meeting will address specific aspects of CIPN. Participants will be presented with content related to basic neuroanatomy, physiology, the effects of chemotherapy on peripheral nervous system, how available allopathic treatments (pharmacological/psychopharmacological) can be helpful, and psychosocial issues related to CIPN. The final week of the psychoeducational group will include the identification of complementary interventions that may be of help to people living with CIPN.
1686390|NCT01569256|Drug|Cabergoline|Cabergoline tablet, Pfizer, Istanbul, Turkey, started on day of HCG, 0.5 mg/day for 8 days
1686391|NCT01569243|Other|Text messages|"Participants will receive diabetic medical care as usual.
Participants will be given an ActiHealth pedometer to measure daily activity.
In addition, they will be enrolled to receive the study text messages."
1686392|NCT01569243|Other|Usual care|"Participants will receive diabetic medical care as usual.
In addition, participants in the control group will be given an ActiHealth pedometer to measure daily activity (step counts will be used as a proxy for activity)."
1686393|NCT01569230|Procedure|Standardized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions) 9 Acupuncture points(SP9,GB34, ST36, ST35, Xiyan(EX-LE5), BL60, GB39, SP6 and KI3)were used for all the patients assigned to this group. Sterile Stainless Steel(25mm x 40mm) disposable acupuncture needles manufactured by Dong-Bang Acupuncture Co.(Korea) were used.
1686394|NCT01569230|Procedure|sham acupuncture|The treatment was applied twice a week for 6 weeks(12sessions). The sham acupuncture was applied on the 9 same acupuncture points as in the standardized acupuncture group. Each session was 20 minutes long
1686395|NCT01569230|Procedure|Individualized Acupuncture|The treatment was applied twice a week for 20 minutes for 6 weeks(12sessions)
1686396|NCT01569230|Other|Waiting|No interventions were applied to the patients in this group.
1686397|NCT01569204|Drug|Etoposide|
1686398|NCT01569204|Drug|Cyclophosphamide|
1686399|NCT01569204|Drug|Doxorubicin|
1686400|NCT01569204|Drug|Prednisone|
1686401|NCT01569204|Drug|Procarbazine|
1686402|NCT01569204|Drug|Dexamethasone|
1686403|NCT01569204|Drug|Dacarbazine|
1686404|NCT01569204|Drug|Brentuximab Vedotin|
1955487|NCT03182907|Drug|Placebo|A single IV infusion of placebo for bezlotoxumab consisting of either 0.9% sodium chloride or 5% dextrose.
1955488|NCT03181958|Device|NHFOV|Nasal high frequency oscillation ventilation (NHFOV) is used as the noninvasive supporting mode after extubation.
1955489|NCT03181958|Device|NCPAP|Nasal continuous positive airway pressure(NCPAP) is used as the noninvasive supporting mode after extubation.
1686408|NCT01569178|Procedure|Bone Marrow aspiration and intracoronary reinfusion|Bone marrow-derived progenitor cells are obtained from 50ml bone marrow aspirated under local anaesthesia from the iliac crest. Intracoronary infusion of the cells is performed via conventional percutaneous intracoronary intervention techniques using an over-the-wire balloon technique
1686409|NCT01569165|Procedure|cleansing teeth after topical fluoride therapy|washing with water 0, 15 or 30 min after APF treatment or cleansing teeth with cotton roll immediately following APF treatment.
1686410|NCT01569152|Drug|MK-8457 100 mg|MK-8457 100 mg dosed orally BID
1686411|NCT01569152|Drug|Dose-Matched Placebo|Dose-matched placebo dosed orally BID
1686412|NCT01569152|Drug|Methotrexate|MTX dosed at the stable dose receive upon study entry
1686413|NCT01569126|Drug|LY110140|Administered orally as capsules
1686414|NCT01569126|Drug|Placebo|Administered orally as capsules in the placebo arm and to maintain the blind in the 20 mg LY110140 (MD) arm
1686415|NCT01569113|Drug|Ulipristal Acetate (UPA) + ethinylestradiol/levonorgestrel (Microgynon)|UPA: 30 mg, 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
1686416|NCT01569113|Drug|placebo + ethinylestradiol/levonorgestrel|placebo: 1 tablet, single intake Microgynon 30mcg/150mcg, 1 tablet per day, 21-day intake
1686417|NCT01569087|Biological|empegfilrastim|Empegfilgrastim is supplied as solution for injection 3 mg/ml. Empegfilgrastim is to be administered 24 h after the chemotherapy at dose of 3 or 6 mg.
1686418|NCT01569087|Biological|filgrastim|Filgrastim should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Filgrastim should be administered daily for up to 2 weeks until the ANC has reached 10 000/mm3 following the expected chemotherapy-induced neutrophil nadir.
1686419|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 12 weeks
1686420|NCT01569074|Drug|Fostamatinib|Fostamatinib 100mg twice daily for 4 weeks, followed by150mg once daily up to Week 12
1686421|NCT01569074|Drug|Fostamatinib|Fostamatinib 75mg twice daily for 12 weeks
1686422|NCT01569074|Drug|Fostamatinib|Fostamatinib 50mg twice daily for 12 weeks
1686423|NCT01569074|Drug|Placebo|Placebo twice daily for 12 weeks
1686424|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT)
1686425|NCT01569061|Device|LCT-1000TM (Manufacturer: LiteCure)|low level laser therapy (LLLT) sham treatment
1686426|NCT01569048|Drug|Propofol and dexmedetomidine|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
1686427|NCT01569048|Drug|propofol and remifentanil|Both group : propofol effect site TCI 2-4 mcg/ml, Remifentanil group : remifentanil effect site-TCI 2-4ng/ml Dexmedetomidine group: dexmedetomidine 0.5mcg/kg loading and 0.5mcg/kg/hr infusion
1686428|NCT01569035|Drug|warfarin|3 mg warfarin oral tablet for 2 to 3 weeks
1686431|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|50 µmol capsules, taken orally, once a day for 28 days
1686432|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|100 µmol capsules, taken orally, once a day for 28 days
1686433|NCT01568996|Drug|broccoli sprout extract - sulforaphane (BSE-SFN)|200 µmol capsules, taken orally, once a day for 28 days
1686434|NCT01568983|Dietary Supplement|Placebo|500 ml/day Per 100g 6.25 g sucrose 6.25 g maltodextrin 1.3 g citric acid E330 (pH 3.0) 2.5 g Carmine solution E120 (4% carmine colouring agent) 0.025 g blueberry aroma Potassium sorbate E202 water
1686574|NCT01567943|Behavioral|Contingency Management|Behavioral reinforcement for alcohol abstinence
1686439|NCT01568957|Behavioral|Gait training|Twelve 30-minute sessions plus 10-minute stretching and warm up, provided 3 times per weeks for 4 weeks. Up to 6 weeks are allowed to complete the 12 sessions.
1686440|NCT01568944|Drug|Oral Antibiotic and Oral Rinse|PO Amoxicillin in 500 mg / Metronidazole 250 mg of each TID for 8 days plus 2 ounces of 0.12% chlorhexidine mouthrinse used BID
1686441|NCT01568944|Procedure|Standard Treatment|Full mouth scaling and root planing using hand instrumentation (curettes) and ultrasonic scalers
1686442|NCT01568931|Drug|Urokinase|intracoronary, urokinase, 200,000 Units, bolus
1686443|NCT01568931|Drug|Saline|intracoronary, saline, bolus 1 cc
1686444|NCT01568918|Drug|Tamsulosin hydrochloride|Participants will receive 0.4 mg/day tamsulosin hydrochloride from 5 days prior to the operation until hospital discharge.
1686445|NCT01568918|Other|Placebo|The placebo capsule matching the active study drug will be given daily from 5 days prior to the operation until hospital discharge.
1686446|NCT01568905|Other|Low level nicotine cigarette|smoke the study cigarette exclusively for one week
1686447|NCT01568905|Other|Intermediate nicotine level cigarette|smoke the study cigarette exclusively for one week
1686448|NCT01568905|Other|High level nicotine cigarette|smoke the study cigarette exclusively for one week
1686449|NCT01568892|Drug|dolutegravir 50 mg twice daily|Active dolutegravir plus failing background regimen (Day 1 to Day 7)
1686450|NCT01568892|Drug|dolutegravir placebo twice daily|Dolutegravir placebo plus failing background regimen (Day 1 to Day 7)
1686451|NCT01568892|Drug|Open-label dolutegravir 50mg twice daily|Open label dolutegravir plus optimized background regimen (from Day 8)
1686452|NCT01568879|Other|Control|The control group will receive care from their primary care physician that reflects the actual current care received by KPNC patients, but will not receive any treatment recommendations from the study protocol. The control subject will have regular monitoring of serum uric acid levels and will be provided with educational material and dietary counseling.
1686453|NCT01568879|Other|Gout Disease Management Program|The experimental group will utilize standard guidelines for the initiation of uric acid lowering treatments, and approved medications. The study protocol treatments include medication management, dietary guidelines, and basic educational materials on gout and its management. No non-formulary medications or devices will be used. The experimental procedure to be tested is the use of a structured protocol to manage and monitor standard treatments.
1686454|NCT01568866|Drug|Carfilzomib|Carfilzomib is administered over 30 minutes as an infusion.
1686455|NCT01568866|Drug|Bortezomib|Bortezomib is administered as a 3-5 second bolus IV injection or SC injection (in accordance with regulatory approval)
1686456|NCT01568866|Drug|Dexamethasone|Tablet for oral administration; On days when carfilzomib or bortezomib was administered, the dexamethasone was to be given 30 minutes to 4 hours prior to the carfilzomib or bortezomib dose.
1686457|NCT01568853|Drug|Norepinephrine|Intravenously, 10 ug/min, 24 hours
1686458|NCT01568853|Procedure|Open abdomen|IAH >=20 mmHg, and ACS emerged, such as low urine and decreased FiO2 quickly.
1686459|NCT01568853|Other|enteral nutrition|500-1500 kcal/day; Nasogastric tube feeding;
1686460|NCT01568853|Other|parenteral nutrition|3000 mL parenteral nutrition fluid, intravenously.
1686461|NCT01568840|Other|Global Postural Reeducation Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in manual therapy maneuvers and global postural reeducation treatment.
1686462|NCT01568840|Other|Segmental Exercises Group|Sessions happened once a week for 10 weeks, lasting 60 minutes each and consisted in segmental exercises (stretching and strengthening) treatment.
1686463|NCT01568827|Dietary Supplement|Blackraspberry Slurry|Blackraspberry slurry is 45 g blackraspberry powder mixed in 8oz. water. This is equivalent to 450 g fresh black raspberries.
1686464|NCT01568814|Drug|Low volume PEG|low volume polyethylene glycol 2 liter one time
1686465|NCT01568814|Drug|high volume PEG|high volume polyethylene glycol 4 lilter split-dosing 2L/2L two times
1686466|NCT01568801|Behavioral|SingaPACE|Individuals in the intervention group will go through an integrated program of community based health and social care, based on intake and ongoing evaluation by the SingaPACE team.
1686467|NCT01568788|Biological|Inactivated Influenza Vaccine|200 subjects were randomly assigned (60 children, 100 adults and 40 elders) to receive Inactivated Influenza Vaccine (Split virion) of Hualan Biologicals, 15ug HA/strain/0.5ml/syringe, one dose regime
1686468|NCT01568788|Biological|Inactivated Influenza Vaccine of Pasteur|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive the Inactivated Influenza Vaccine of Sanofi Pasteur, 15ug HA/strain/0.5 ml/syringe, one dose regime,
1686469|NCT01568788|Biological|Inactivated Influenza Vaccine of GSK|200 subjects (60 children, 100 adults and 40 elders) were randomly assigned to receive Inactivated Influenza Vaccine (Split virion) of GSK, 15ug HA/strain/0.5ml/syringe, one dose regime
1686470|NCT01568775|Drug|Aliskiren|All patient and subjects received single dose of aliskiren 300 mg in treatment period.
1686471|NCT01568762|Drug|VAK694|Intravenous infusion
1686472|NCT01568762|Drug|VAK694 placebo|Intravenous infusion
1686473|NCT01568762|Drug|QAX576|Intravenous infusion
1686474|NCT01568762|Drug|QAX576 placebo|Intravenous infusion
1686475|NCT01568749|Drug|Paracetamol|Paracetamol
1686476|NCT01568749|Drug|Paracetamol formulation 1|Paracetamol
1686477|NCT01568749|Drug|Paracetamol Formulation 2|Paracetamol
1686478|NCT01568749|Drug|Paracetamol formulation 3|Paracetamol
1686479|NCT01568749|Drug|Paracetamol formulation 4|paracetamol
1686480|NCT01568723|Genetic|response to therapy|evaluate specific markers for response to therapy at specific intervals pre and post therapy
1686481|NCT01568684|Other|Citalopram|Treatment
1686482|NCT01568645|Drug|Carvedilol|
1686483|NCT01568645|Drug|Imatinib|
1686484|NCT01568632|Drug|Imetelstat|
1686527|NCT01568203|Drug|AMG 579|3 dose levels of single oral dose administration of AMG 579 in healthy subjects (Part A), and 5 dose levels of single oral dose administration of AMG 579 in patients with schizophrenia or schizoaffective disorder (Part B)
1686528|NCT01568203|Drug|Placebo|Matching placebo control for AMG 579 at each dose level
1686529|NCT01568190|Biological|AVANZ MITE|Immunotherapy Dermatophagoides mix
1686684|NCT01567059|Drug|decitabine|Given IV
1686485|NCT01568606|Device|Body Composition Analysis InBody Scale|"Patients will have their ICD interrogated using a pacemaker Programmer specifically designed from one of the 4 pacemaker manufacturers: St. Jude, Medtronic, Guidant, and Biotronik. Depending on the type of pacemaker, interrogation can be done either wirelessly or by placing a wand over the pacemaker. The ICD will be turned to a monitor-only mode to disable risk of ICD shock by the supervising electrophysiologist. Patient will be asked to step on the InBody 520 scale to have their body composition analyzed. Patient will continue to have their ICD actively monitored. Analysis will take approximately 30 - 50 seconds. At the end of analysis, ICD device will be returned to default settings by supervising electrophysiologist."
1686486|NCT01568593|Device|T2750|1 drop in each eye 3 to 6 times daily during 84 days
1686487|NCT01568593|Device|Vismed|1 drop in each eye 3 to 6 times daily during 84 days
1686488|NCT01568580|Drug|GreenGene|Dose : 10 ~ 50IU/kg Administration method : intravenous infusion or bolus
1686489|NCT01568567|Dietary Supplement|Lactobacillus Reuteri DSM 17938|One stick pack in the morning and one stick pack afternoon/evening for 28 days.
1686490|NCT01568541|Drug|Regular toothpastes|One tooth brushing
1686491|NCT01568541|Drug|Children's toothpastes|One tooth brushing
1686492|NCT01568528|Drug|Oxytocin|OT intervention will be administration of OT intranasally at a dose of three 4 IU puffs per nostril for a total dose of 24 IU. This dose has been used in a number of other similarly designed challenge studies examining the effects of a single dose of OT (Kirsch et al. 2005; Kosfeld et al. 2005; Guastella et al. 2008a; Guastella et al. 2008b; Rimmele et al. 2009; Andari et al. 2010).
1686493|NCT01568528|Drug|Placebo|The PBO/control will consist of the OT vehicle only delivered as 3 puffs of saline per nostril for a total of 6 puffs. Each puff contains 0.1 ml in volume, so the total delivered will be 0.6 ml intranasally.
1686494|NCT01568515|Procedure|Electronic Message|Students enrolled in the intervention group received 7 electronic contacts over a 7-month period. Specifically, participants received 4 electronic education messages, 2 electronic reminder/education messages, as well as 1 baseline and 1 final assessment contacts. Up to 4 reminder contacts were used if surveys were not completed for both intervention and control group participants. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment. Up to 4 reminder contacts were used if surveys were not completed. Intervention & control groups were compared longitudinally for 7 months on the differences in HPV vaccine utilization and adherence, knowledge and attitudes about HPV, and the HPV vaccine (parallel design).
1686495|NCT01568489|Drug|HL-009 Liposomal Gel|a semi-transparent red-color gel and is supplied as a laminated tube
1686496|NCT01568476|Procedure|Distal|Blockade of both terminal branches of Sciatic nerve separately, distal to bifurcation
1686497|NCT01568476|Procedure|Interneural|Sciatic nerve blockade at the site of bifurcation
1686498|NCT01568450|Drug|Oxycodone|Oxycodone XL 20mg(20mg once a day, fasted)
1686499|NCT01568450|Drug|Oxycodone|Oxycodone XL 20mg/day(20mg once a day, after high fat meal)
1686500|NCT01568450|Drug|Oxycodone|Oxycodone 20mg/day (10mg twice a day, fasted)
1686501|NCT01568437|Procedure|TAP-Block|Block needle will be inserted out-of-plane to the ultrasound beam, perpendicular to the skin surface, until the tip lies deep between the fascia of the transversus abdominis muscle and the internal oblique muscle. 30 ml of the study solution in each side will be injected at this location and should be observed to spread in an anterior-posterior direction between two muscles. Each patient will receive a total dose of 60 ml of 0.25% bupivacaine (150 mg) + 1:200,000 epinephrine.
1686502|NCT01568437|Other|Conventional Managment|For these group.no TAP block administration. just conventional management for post operative pain.
1686503|NCT01568424|Device|CentriMag RVAS placement|Patients will be treated with a CentriMag RVAS
1686504|NCT01568411|Drug|TD-1211|Period 1
1686505|NCT01568411|Drug|TD-1211+ itraconazole|Period 2
1686506|NCT01568398|Drug|TAK-438|
1686507|NCT01568385|Drug|TAK-438|
1686508|NCT01568372|Other|Telephone follow-up|The intervention group received a telephone follow-up by a nurse on the 1st, 3rd, 5th and 10th postoperative day.
1686509|NCT01568346|Other|MRI|Breast MRI
1686510|NCT01568333|Drug|Decitabine|Decitabine 3.5mg/m2，ivdrip，qd x 3d, every four weeks for one cycle. It will be given three cycles.
1686511|NCT01568320|Device|Endovascular Treatment (Zenith)|Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the study device(s) into place in the aorta.
1686512|NCT01568307|Drug|Participants will be prescribed an approved selective serotonin re-uptake inhibitor (SSRI) antidepressant.|The choice of SSRI will be based on clinical judgement and prescribed in line with standard dosing approved by the Therapeutic Goods Administration (TGA).
1686513|NCT01568294|Drug|pomalidomide|2 mg or 4mg oral pomalidomide once per day on Days 1-21 of a 28-day cycle
1686514|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF with water.
1686515|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
1686516|NCT01568281|Drug|Anastrozole ODF|Each volunteer will receive a single dose of Anastrozole ODF without water.
1686517|NCT01568281|Drug|Arimidex tablet|Each volunteer will receive a single dose of Arimidex tablet with water
1686518|NCT01568268|Drug|Palonosetron|palonosetron 0.075 mg intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
1686519|NCT01568268|Drug|placebo control group|placebo intravenous injection over 10 seconds when nausea with NRS >= 4, or developement of retching or vomiting more than one time within three hour after the end of surgery.
1686520|NCT01568255|Drug|Ergocalciferol|Ergocalciferol therapy at 50,000IU for 8 weeks
1686521|NCT01568255|Drug|Placebo|placebo at 50,000IU for 8 weeks
1686522|NCT01568242|Device|Phacoemlsification|Transurgical measurement of temperature
1686523|NCT01568229|Drug|AMG 747|Three dose levels once-daily oral administration
1686524|NCT01568229|Drug|Placebo|Once-daily oral administration
1686525|NCT01568216|Drug|AMG 747|Three dose levels once-daily oral administration
1686526|NCT01568216|Drug|Placebo|Once-daily oral administration
1686573|NCT01567956|Drug|Placebo|500 mg inert substances modified release tablets, 500 mg bid; treatment duration 8 weeks
1740114|NCT00107445|Drug|EF5|Given IV
1686530|NCT01568177|Behavioral|Mental Stress Testing|Mental stress testing is used to test the mechanistic pathways through which biobehavioral variables are involved in the pathogenesis of MCD in women.
1686531|NCT01568177|Other|Peripheral Arterial Tonometry (PAT) Testing|PAT measurements will be used to predict ischemia in patients with MCD. PAT will be measured by Endo PAT 2000 (Itamar® Medical Ltd).
1686532|NCT01568177|Other|Heart Rate Variability (HRV)|Holter monitor will be used to measure heart rate and rhythm for approximately 24 hours.
1686533|NCT01568177|Other|RESPeRATE Breathing Trial|RESPeRATE Breathing will test whether a controlled breathing relaxation technique using an FDA-approved paced breathing device, RESPeRATE, helps with chest pain and shortness of breath and will test to see if this form of biofeedback or relaxation technique helps with heart rate variability during mental stress.
1686534|NCT01568177|Procedure|SPECT cardiac scan with 123I-mIBG and Myoview|Single Photon Emission Computed Tomography (SPECT) cardiac scan with 123I-mIBG and Myoview will be used to measure cardiac sympathetic activity.
1686535|NCT01568164|Device|PliCath HF System|This study is a multi-center, prospective, single-armed, study designed to evaluate the safety and efficacy of the BioVentrix PliCath HF System for left ventricular volume restoration in patients with ischemic cardiomyopathy.
1686536|NCT01568151|Behavioral|Clinic-directed intervention program|Clinic-directed intervention program: Subjects recruited at the Intervention Clinics will first be provided with Clinic-directed interventions including: 1)provider-directed interventions (computerized case-based education, evidence-based guidelines, ask the expert; 2)office-based systems (risk assessment forms, procedure monitoring, follow-up protocol, audit with feedback, chart reminders); and 3) waiting room materials.
1686537|NCT01568151|Behavioral|Individual Patient-Directed Program|If the subjects have not undergone colorectal cancer screening within 12 months of receiving the clinic-directed program, they will be provided with an individual patient-directed program consisting of the following stepped interventions: 1) tailored physician letter, easy-to-read educational materials, and an fecal occult blood test (FOBT)information sheet and card; 2) telephone counseling for those who do not respond to the letter; and 3) home visits by lay health advisors for those who do not respond to the letter or phone counseling.
1686538|NCT01568138|Device|PliCath HF System|To evaluate the safety and feasibility of the BioVentrix PliCath HF Epicardial Catheter-based Ventricular Reduction (ECVR) System for left ventricular (LV) volume reduction in heart failure (HF). The System utilizes anchors that are implanted into the scarred portion of the heart, rendering the ventricle smaller.
1686539|NCT01568125|Drug|Incretin-related drugs|DPP-IV inhibitors are administered via per os. GLP-L receptor agonists are administered via subcutaneous injections.
1686540|NCT01568112|Drug|BG00012 (dimethyl fumarate)|Each capsule contains 120 mg dimethyl fumarate (DMF). Fast titration involves taking one 120 mg capsule in the morning and one in the evening (240 mg daily) for one week, and then escalating to a dose of 480 mg daily (two capsules morning and evening) for the remainder of the study.Slow titration expands the dose escalation time to 4 weeks.
1686541|NCT01568112|Drug|BG00012 placebo|Placebo matching BG00012
1686542|NCT01568112|Drug|ASA|325 mg microcoated aspirin (ASA)
1686543|NCT01568112|Drug|ASA placebo|Placebo matching aspirin
1686544|NCT01568099|Biological|AFFITOPE® PD01A|s.c. injection
1686545|NCT01568099|Other|Control|Untreated control
1686546|NCT01568073|Drug|BIA 9-1067|5, 25 and 50 mg of BIA 9-1067 (once-daily)
1686547|NCT01568073|Drug|Entacapone|200 mg entacapone (concomitantly with each L-dopa/DDCI dose)
1686548|NCT01568073|Drug|Placebo|200 mg
1686549|NCT01568073|Drug|Levodopa|
1686550|NCT01568073|Drug|Carbidopa|DOPA decarboxylase inhibitor
1686551|NCT01568073|Drug|Benserazide|DOPA decarboxylase inhibitor
1686552|NCT01568060|Other|Infanrix-IPV data collection|Safety monitoring: recording of adverse events using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
1686553|NCT01568047|Drug|Placebo|once-daily
1686554|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 5 mg single-dose
1686555|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 15 mg single-dose
1686556|NCT01568047|Drug|BIA 9-1067|BIA 9-1067 - 30 mg single-dose
1686557|NCT01568047|Drug|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
1686558|NCT01568047|Drug|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
1686559|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 25 mg single-dose
1686560|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 50 mg single-dose
1686561|NCT01568034|Drug|BIA 9-1067|BIA 9-1067 - 100 mg single-dose
1686562|NCT01568034|Drug|Placebo|single-dose
1686563|NCT01568034|Drug|Levodopa/Carbidopa|Levodopa 100 mg Carbidopa 25 mg
1686564|NCT01568034|Drug|Levodopa/Benzerazide|Levodopa 100 mg Benzerazide 25 mg
1686565|NCT01568021|Other|No Intervention|No intervention was administered in this study.
1686566|NCT01568008|Drug|Bimatoprost 0.01% ophthalmic solution|Bimatoprost 0.01% ophthalmic solution eye drops at a dose and frequency as determined by the physician.
1686567|NCT01567995|Drug|Clobetasone Butyrate 0.05% Cream|Clobetasone Butyrate 0.05% Cream
1686568|NCT01567995|Drug|Vehicle (base cream)|Vehicle (base cream)
1686569|NCT01567982|Device|tDCS, prefrontal cortex and parietal cortex|tDCS is a non invasive brain stimulation methods. We will use two anodes to stimulate prefrontal and/or parietal cortex using 2mA current for 20 minutes.
1686570|NCT01567969|Behavioral|Intensive In-home Child and Adolescent Psychiatric Service|A six to seven month intensive intervention provided by a clinical team consisting of a master's-level clinician and a bachelor's-level mental health counselor delivering comprehensive psychiatric and case management services in the child's home. One or both members of the team works with the child and the family three times a week in the home. Delivery of direct and indirect services average 5.5 hours of service per week.
1686571|NCT01567969|Behavioral|Home-based Child Treatment Coordination|A six to seven month home-based case management service delivered by a master's level clinician. The coordinator meets with the child's parent/legal guardian in the child's home once a month and conducts weekly phone conversations to facilitate referral and access to appropriate mental health services for the child.
1686572|NCT01567956|Drug|Propionyl-L-Carnitine|500 mg modified release tablets, 500 mg bid; treatment duration 8 weeks
1740115|NCT00107458|Drug|valproic acid|
1686575|NCT01567930|Drug|Temsirolimus|Intervention: Temsirolimus IV Eligible patients will receive temsirolimus IV on days 1,8,15 every 21 days. Treatment will continue till disease progression or untolerable side effects
1686576|NCT01567917|Procedure|CRC surgery|"Patients will receive surgery for the treatment of CRC as routine clinical practice. These patients will be prospectively observed for the development of VTE(Group A; Doppler US cohort vs. Group B; Simple observation cohort)
- Doppler US is not an intervention. The Doppler US is a non-invasive test (ultrasonography) for the detection of VTE"
1686577|NCT01567904|Drug|Semuloparin sodium|"Solution for injection in single dose vials (10 mg/mL and 20 mg/mL)
Subcutaneous injection"
1686579|NCT01567865|Biological|JE live attenuated SA 14-14-2 vaccine|
1686580|NCT01567852|Drug|Ketamine|Ketamine (1.5mg/kg) will be given for induction, with room to titrate up to induction effect
1686581|NCT01567852|Drug|Methohexital|Methohexital (1.5mg/kg) will be given for induction
1686582|NCT01567839|Procedure|Mandibular buccal Infiltration injection|
1686583|NCT01567826|Drug|standard of care lipid therapy|"Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
Zocor, Lipitor [any dose] and Crestor [less than 40mg]"
1686584|NCT01567826|Drug|Aggressive lipid therapy|Patients will be randomized in a 1:1 fashion to receive either A) Rosuvastatin (Crestor) 40mg daily, or B) standard-care lipid-lowering therapy.
1686585|NCT01567800|Other|18F-Fluoroazomycin Arabinoside (18F-FAZA)|PET scan with the radiolabelled tracer 18F-FAZA
1686586|NCT01567787|Radiation|Proton Radiation for MPNST|30 CGE at 6 CGE/Fx
1686587|NCT01567787|Radiation|Proton Radiation for neurofibromas|25 CGE at 5 CGE/Fx
1686588|NCT01567774|Drug|Atorvastatin|os, 20 mg, once per day, for 30 days
1686589|NCT01567774|Drug|Rosuvastatin|os, 10 mg, once per day, for 30 days
1686590|NCT01567748|Procedure|BP Measurements at aorta, radial and femoral locations|The following additional research related procedures will be performed in patients recruited into the study: 1) a small cuff will be placed on one the finger of each subject to measure the pulse in the finger (Finapres); 2) a cannula will be placed in the femoral artery by the surgeon to measure femoral artery pressure; 3) for a period of two minutes immediately before and after the cardiopulmonary bypass a small cannula (the size of a pencil tip) will be inserted by the surgeon under direct vision into the aorta and 4) the information from each of these cannula will be recorded on a computer for later study.
1686591|NCT01567735|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TMC435 capsule is taken once daily for 12 weeks.
1686592|NCT01567722|Genetic|DNA analysis|
1686593|NCT01567722|Genetic|RNA analysis|
1686594|NCT01567722|Genetic|gene expression analysis|
1686595|NCT01567722|Genetic|polymorphism analysis|
1686596|NCT01567722|Other|biologic sample preservation procedure|
1686597|NCT01567722|Other|flow cytometry|
1686598|NCT01567722|Other|laboratory biomarker analysis|
1686599|NCT01567722|Other|medical chart review|
1686600|NCT01567709|Drug|Alisertib|Given PO
1686601|NCT01567709|Other|Laboratory Biomarker Analysis|Correlative studies
1686602|NCT01567709|Other|Pharmacological Study|Correlative studies
1686603|NCT01567709|Drug|Vorinostat|Given PO
1686604|NCT01567683|Drug|Imiquimod (topical use)|
1686605|NCT01567670|Drug|Naloxone|2 mg x 1-2
1686606|NCT01567670|Drug|naloxone placebo|h2o placebo spray
1686607|NCT01567657|Drug|pethidin hydrochlorid, midazolam|Pethidin hydrochlorid: 25 mg iv. at the beginning of the examination Midazolam: 1-2 mg iv. at the beginning of the examination. Repetitive given in a dosis of 1 mg iv. until a total amount of 7 mg iv.
1686608|NCT01567657|Drug|Propofol|"50 years and over: initial dose of 50-60 mg Propofol iv. Followed by bolus of 20-30 mg iv. until sedation is achieved.
< 50 years: initial dose 30-40 mg Propofol iv. Followed by bolus of 10-20 mg until sedation is achieved."
1686609|NCT01567644|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
1686610|NCT01567631|Procedure|intrahepatic Glisson's approach|Forty patients with liver disease were selected and divided into intrahepatic Glission's group as described in the detailed description.Total laparoscopic hepatectomy with intrahepatic Glisson's approach were performed. Operation began with division of liver ligaments, liver mobilization, followed by intrahepatic access to the Glissonian pedicle (containing arterial, portal, and bile duct branches ). A endoscopic stapler devices was used for Glissonian pedicle cutting and suture. Liver parenchyma was divided by harmonic scalpel combined with vascular stapler. The specimen was extracted through suprapubic incision.
1686611|NCT01567631|Procedure|classical hepatectomy|Forty patients with liver disease were selected and divided into classical laparoscopic hepatectomy group as described in the detailed description.Total laparoscopic anatomical hepatectomy with classical procedure were performed.The initial step is to dissect hepatic portal and expose the liver artery, portal Vein branch and the bile duct. Then endoscopic stapler devices were used to cut the canal mentioned above. Final step is to divide the liver parenchyma along the following ischemic delineation.
1686612|NCT01567618|Drug|Docetaxel|"Docetaxel 50mg/m2 iv drip, repeat every two weeks;
Efficacy will be evaluated every three cycles."
1686613|NCT01567618|Drug|Fluorouracil|Fluorouracil 400mg/m2 iv D1; Fluorouracil 2400mg/m2 civ 46 hours; repeat fortnightly and evaluate every two cycles
1686614|NCT01567605|Drug|Lidocaine lubricant|Subjects using this intervention will receive 30 mL of Lidocaine hydrochloride jelly (2%)
1686615|NCT01567605|Other|Placebo lubricant|Subjects using this intervention will receive 30 mL of placebo lubricant (no topical anesthetic)
1686616|NCT01567592|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
1686617|NCT01567566|Other|exercise rehabilitation program|6 week home based exercise rehabilitation program with 6 weekly supervised sessions using real time ultrasound as biofeedback to augment training in both treatment arms
1686685|NCT01567046|Other|laboratory biomarker analysis|Correlative studies
1686618|NCT01567553|Other|USPIO MRI - Gadolinium MRI|"USPIO MRI scanning will be performed at :
baseline, month 3, month 6, month 9 and month 12 for patients recruited prior to the 1st of May 2010.
baseline, month3, month 6 and month 9 for patients recruited between the 1st of May 2010 and the 31st of July 2010,
baseline, month 3 and month 6 for patients recruited between the 1st of August 2010 and the 31st of October 2010,
baseline and month 3 for patients recruited between the 1st of November 2010 and the 31st of January 2011,
baseline for patients recruited between the 1st of February 2011 and the 30rd of April 2011.
Gadolinium MRI scanning will be performed at baseline, month 3, month 6, month 9, month 12, month 18, month 24 and month 36."
1686619|NCT01567540|Drug|Sitagliptin|100 mg Sitagliptin daily for 15 weeks
1955490|NCT03181958|Device|NIPPV|Nasal intermittent positive pressure ventilation(NIPPV) is used as the noninvasive supporting mode after extubation.
1996673|NCT02417402|Other|Trained|The patients allocated to the Experimental group will be treated by physical therapists who carried out the training before treatment. The training will be designed to guide the physical therapists beliefs and attitudes to a biopsychosocial model; update knowledge contained in clinical practice guidelines; and enable physical therapists to identify, integrate and address psychosocial factors in patients with nonspecific chronic low back pain. Patients will receive 10 sessions of treatment over a period of five weeks (two sessions/week). Each treatment session has an estimated duration of 50-60 minutes.
1686623|NCT01567501|Drug|Levocetirizine Dihydrochloride tablets 5 mg|5 mg tablet once in a day
1686624|NCT01567501|Drug|Levocetirizine Dihydrochloride|5 mg tablet once in a day
1686625|NCT01567488|Drug|Everolimus|Everolimus 10mg/day
1686626|NCT01567488|Drug|octreotide LAR|30 mg each 28 days
1686627|NCT01567475|Drug|Everolimus and rituximab|One injection of Rituximab 375 mg/m2 per week during 28 days followed by one Rituximab infusion every other cycle at 375 mg/m2 associated with everolimus at 5mg or 10 mg every day or 5 mg every other day.
1686630|NCT01567436|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of scissors is used to remove the inner ring, and a bandage or gauze dressing is applied.
1686631|NCT01567423|Drug|ASAQ Winthrop® Sanofi Aventis|Artesunate 25mg / amodiaquine 67.5mg: 1 tab/day for 3 days in children 5 to 8.9 kg Artesunate 50mg / amodiaquine 135mg: 1 tab/day for 3 days in children 9 to 17.9 kg
1686632|NCT01567423|Drug|Coartem®, Novartis|"artemether 20 mg / lumefantrine 120 mg co-formulated tablets given as six twice-daily doses over three days:
tab/dose for children 5 to 14.9 kg (total 6 tabs)
tabs/dose for children 15 to 24.9 kg (total 12 tabs)"
1686633|NCT01567410|Other|e-learning|Braden scale and pressure ulcer classification
1686634|NCT01567410|Other|traditional classroom training|Braden scale and pressure ulcer classification
1686635|NCT01567384|Drug|OSI-906 and Pemetrexed|"Pemetrexed will be administered intravenously on day 1 of cycle 1 at a dose of 500 mg/m2 as a 10-minute infusion. Subsequent doses will be defined by tolerability.
OSI-906 will be administered orally twice daily (12 hours apart) at approximately the same times each day on a continuous schedule, beginning on Day 0 of cycle 1."
1686636|NCT01567371|Device|LiDCO rapid monitor|Technology which provides a continuous means of monitoring various hemodynamic parameters including cardiac output and pulse pressure variability.
1686637|NCT01567358|Biological|Infliximab|100mg/vial
1686638|NCT01567358|Biological|Infliximab|100mg/vial
1686639|NCT01567345|Device|Implantable pump with continuous flow|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Continuous morphine's flow is scheduled.
1686640|NCT01567345|Device|Implantable pump with programmable flow.|Insertion of an implantable pump filled up with the analgesic solution. Connection of the catheter to the intrathecal space. Programmable morphine's flow is scheduled.
1686641|NCT01567332|Device|SHAM - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Active coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).
6-week interval between two sessions."
1686642|NCT01567332|Device|SHAM inactive - MagproR30 - DGM-512 - 9016E0741 - Tonika elektronics A/S - Inactive coil|"For each patient, stimulation inactive (sham) and 1 Hz stimulation activates the healthy motor cortex (randomization). Active or sham session: Each session includes a series of 5 sessions of 20 'weekly (daily for 5 d) evaluation and pre-rTMS (T0 within 6 h before the procedure) and 1h post-rTMS (T1), at J8 (T2) and J21 (T3).
6-week interval between two sessions."
1686643|NCT01567319|Biological|Skin Prick Test|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
1686644|NCT01567319|Biological|Skin Prick Test - Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source,together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
1686645|NCT01567319|Biological|Skin Prick Test - No Atopic Subjects|Skin prick test of 4 concentrations of each allergenic source, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every subjects in duplicate on the volar surface of the forearm. Assessment of the wheal size after 15 minutes.
1686646|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
1686647|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
1688065|NCT01556438|Drug|Dexamethasone|Administered orally
1686648|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 1SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
1686649|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 2 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
1686650|NCT01567306|Biological|Allergovac Depot|Increasing dosages till the maintenance dose of 4SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
1686651|NCT01567306|Biological|Placebo|Increasing volumes of placebo. Afterwards, 3 maintenance doses are given at 4-weekly intervals.
1686652|NCT01567267|Behavioral|Experimental educational intervention|Educational intervention consisting of a 4-day-course in Evidence-based Medicine and Good Scientific Practice combined with the method of Problem-based Learning.
1686653|NCT01567267|Behavioral|Standard educational intervention|Educational intervention on the didactics of biology (4-day-course) not containing elements of Evidence-based Medicine, Good Scientific Practice or Problem-based learning.
1686654|NCT01567254|Behavioral|guided imaginary|Auditory guided imagery disk - will be prepared by Ronit Brooks, a clinical psychologist, who is engaged in guided imagery and by Livia Yanai, an art therapist.
1686655|NCT01567254|Behavioral|music ONLY|music. It will be equal in length to the auditory guided imagery disk
1686656|NCT01567241|Other|clinical hypnosis or relaxation music|25 minute tape recording
1686657|NCT01567228|Other|CHICA GIS (enhanced electronic medical record)|An electronic medical record enhanced with geographic information systems will assist physicians in directing patients to community resources for increasing physical activity, preventing dental caries or addressing school problems
1686658|NCT01567215|Procedure|silver nitrate|Application 1 - 2 times a week for 3 - 4 weeks
1686659|NCT01567215|Drug|Steroids|Dermovate creme group IV steroid. Application 2 times a day for 3 weeks or less if the granuloma disappears.
1686660|NCT01567215|Procedure|alcohol|Alcohol swabs 82% ethanol. Application 6 - 8 times a day, each time the parents change the diaper. Treatment for 3 weeks or less if the granuloma disappears.
1686661|NCT01567202|Procedure|Surgery|Maximum resection of the tumor (≥95%) with the help of conventional or intraoperative MRI neuronavigation. Confirmation will be proceeded by the contrast MRI within 72 hours after surgery.
1686662|NCT01567202|Drug|Chemotherapy|Temozolomide(TMZ), 200mg·m^-2·d ×5 days，28 days every cycle. 6 cycles of TMZ are recommended.
1686663|NCT01567202|Radiation|Radiotherapy|Standard dose, 4500 cGy to tumor with 3-cm margins, 1500 cGy boost to tumor bed.
1686664|NCT01567202|Biological|DC vaccination|Eight to ten million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
1686665|NCT01567202|Drug|blank placebo|Saline that has the same appearance with DC vaccine.
1686666|NCT01567189|Behavioral|Cardiac rehabilitation|"Training sessions: 8 weeks of supervised physical training sessions. Stress intensity will be calculated from the peak heart rate reached during stress test: 60-70% during the first month and 70-85% during the second one. Patients will be advised to do at least 1 hour of outdoor exercise with the same intensity on the days when they do not attend hospital.
Health education sessions and relaxation sessions: one per week.
Smoking and diet checking: as recommended by doctor."
1686667|NCT01567189|Behavioral|Cardiac rehabilitation|The only difference in the hospital's program is that training sessions will be out of hospital with the same target heart rate that in this case will be controlled with pulsometer or Borg scale. The recommended frequency of sessions will be: at least 5 days a week with a minimum of 1 hour / day.
1686668|NCT01567176|Biological|Blood sample|It is a single cross sectional study. All outcome measures will be taken during the investigation with physical examination, questionnaire and a blood sample
1686669|NCT01567163|Biological|Ramucirumab|ramucirumab 10 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1 of 3-week cycle
1686670|NCT01567163|Drug|Docetaxel|docetaxel 75 milligrams/square meter (mg/m^2) intravenous infusion administered on Day 1 of each 3-week cycle
1686671|NCT01567150|Device|Novel Dressing|Topical wound dressing
1686672|NCT01567124|Drug|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.
At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
1686673|NCT01567124|Drug|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.
The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
1686674|NCT01567124|Drug|Moxonidine|"Participants who are randomly assigned to the moxonidine/experimental group will be treated with moxonidine oral tablets for twelve weeks. Participants will begin their moxonidine treatment at 0.2mg dosage, which will be increased to 0.4mg over the first two weeks.
At the end of the twelve weeks of treatment, participants will be withdrawn from moxonidine over a period of two weeks."
1686675|NCT01567124|Drug|Placebo|"To examine the effects of moxonidine treatment, a placebo oral tablet will be used for comparison purposes.
The duration and number of placebo tablets participants will be required to take will be the same as the amount required in the moxonidine group."
1686676|NCT01567111|Procedure|11C-Metomidate Positron Emission Tomography|Dose of intravenous 11C-Metomidate injection is 440MBq and emission scanning of upper abdomen. PET/CT imaging will be done using the Discovery PET/CT VCT or 690 scanner (General Electric Medical Systems, Milwaukee, WI, USA)
1686677|NCT01567098|Procedure|single incision laparoscopic appendectomy|performing appendectomy through a single incision in the abdomen
1686678|NCT01567085|Drug|Eculizumab|"Eculizumab 1200 mg (4 vials) administered intravenously (IV) over 35 to 45 minutes.
Eculizumab 900 mg (3 vials) administered IV over 35 to 45 minutes."
1686679|NCT01567072|Drug|Ibuprofen|Treatment with Ibuprofen 600mg 3times a day in 7 days after Colles fracture diagnosis
1686680|NCT01567072|Drug|Ibuprofen|Treatment with Ibuprofen 600mg 3 times daily in 3 days after´diagnosis - Colles fracture
1686681|NCT01567072|Drug|Placebo|Only placebo treatment instead of NSAID painkillers
1686682|NCT01567059|Drug|tosedostat|Given PO
1686683|NCT01567059|Drug|cytarabine|Given IV
1686686|NCT01567033|Behavioral|PAT Curriculum + Health Information|Participants in the intervention group will receive the standard PAT curriculum plus information about healthy eating and an active lifestyle. This curriculum will be taught during up to 36 home visits in two years. Months 1-3 the visits are weekly; months 4-6 visits are biweekly; months 7-24 visits are monthly
1686687|NCT01567020|Other|Diagnostic|All participants will be evaluated with a battery of behavioral and electrophysiological measures to assess central auditory processing abilities.
1686688|NCT01567007|Behavioral|individual counseling|Consisting of three sessions within a maximum period of 3 months. We conducted a counseling, aimed at increasing physical activity, aiming to raise at least 2000 steps over the first week of monitoring. Furthermore, we discuss the importance of physical activity, such as overcoming barriers to physical activity and targets agreed between the parties. The pedometer is given along with a diary to record the number of steps and returned in the last session.
1686689|NCT01567007|Behavioral|group counseling|The counseling was conducted in groups (10-12 individuals) for 6 sessions at weekly intervals, and two sessions with fortnightly. Each session lasts 60 minutes. The advice is aimed at behavioral changes using the following approaches: advantages and disadvantages of behavior change, how to overcome barriers to physical activity, self-monitoring of physical activity by using the pedometer and setting goals (number of steps / day) in the short term and what to do in case of relapse (not accomplish what was represented) besides livings practices. As the GII and the goal is to raise at least 2000 steps daily on average, with the main focus physical activity in leisure time and transport
1686690|NCT01567007|Behavioral|aerobic training|The fitness program is held two times per week with individuals and groups with three sessions lasts for 40 minutes performed on a treadmill.
1686691|NCT01566994|Behavioral|TTM Tailored|This treatment is tailored on three occasions (baseline, 6, and 24 weeks) on each of the 14 TTM variables. This treatment provides both normative and ipsative feedback on each of the variables found to predict progress across specific stages
1686692|NCT01566994|Behavioral|Motivational Enhancement Therapy|This intervention will be driven by the manual developed by Carpenter et al. (2004) based on the USPHS recommendations for smokers not motivated to quit and for those who become ready to set a quit date.
1686693|NCT01566994|Behavioral|Integrated Treatment|This enhanced condition would combine MET, Reduction Counseling and NRT and TTM Tailoring.
1686694|NCT01566981|Procedure|Computerised support to the Diabetes type II patients|The randomly selected group of patients with diabetes type II will get software application and web based support to their usual healthcare process.
1686695|NCT01566968|Other|Cough challenge test|Cough challenge will be performed with Capsaicin, citric acid and prostaglandin E2.
1686696|NCT01566968|Other|24 hour ambulatory cough recording|Cough recording by using an ambulatory sound recording device.
1686697|NCT01566968|Other|Cough quality of life questionnaire|questionnaire designed to assess impact of cough on a person's life
1686698|NCT01566955|Procedure|transgastric adnexectomy|adnexectomy transgastrically with transvaginal support
1686699|NCT01566942|Drug|Oxaliplatin|In this arm, patients will receive the adjuvant chemotherapy with mFOLFOX6 regimen for 8 cycles. Oxaliplatin 85mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
1686700|NCT01566942|Drug|Irinotecan|In this arm, patients will receive the adjuvant chemotherapy with FOLFIRI regimen for 8 cycles. Irinotecan 180mg/m2, day1, every 2 weeks; Leucovorin 200mg/m2,day1,every 2 weeks;5-FU 400mg/m2,iv, day1, 5-FU 3.0g/m2, bolus for 46h,every 2 weeks
1686701|NCT01566929|Dietary Supplement|Low calorie diet treatment|Reduction of calorie intake to only 800 kcal/day by using LCD during 12 weeks
1686702|NCT01566916|Procedure|Total Hip Arthroplasty|
1686703|NCT01566890|Drug|regadenoson infusion with contrast-enhanced ultrasound|Subjects who are not having a pain crisis receive a 24-hour infusion of regadenoson. Contrast-enhanced ultrasound will be performed four times during the 24 hour regadenoson infusion
1686704|NCT01566890|Procedure|contrast-enhanced ultrasound|Subjects who are not having a pain crisis will have contrast-enhanced ultrasound performed up to four times over a two-day period. Time points will resemble the time course used for the Regadenoson Arm, although no investigational drug will be given.
1686705|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on adults with sickle cell anemia at baseline who are not having a pain crisis and performed again during a pain crisis
1686706|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy control subjects at baseline, on the first day of the study and 30 days later
1686707|NCT01566890|Procedure|contrast-enhanced ultrasound|Contrast-enhanced ultrasound will be performed on healthy volunteers (Technique Optimization Controls)
1686708|NCT01566877|Drug|AVI-7288|"Cohort 1: AVI-7288 at 1 mg/kg IV; Cohort 2: AVI-7288 at 4 mg/kg IV;Cohort 3: AVI-7288 at 8 mg/kg IV; Cohort 4: AVI-7288 at 12 mg/kg IV
The amount of AVI-7288 required to administer the required dose will be diluted to a volume of approximately 150 mL with normal saline solution (NSS) and given by IV infusion over 30 minutes once a day for 14 days. Infusions will be administered at approximately the same time each day."
1686709|NCT01566877|Other|Placebo|Normal Saline Solution (NSS)
1686710|NCT01566864|Behavioral|Improve clinic based measurement of blood pressure|This intervention seeks to improve BP control and reduce disparities through an organizational change and new skills development. To improve the reliability of BP measurement in clinics, new automated BP machines (Omron HEM-907XL) will be provided for each PCP. Medical assistants will be trained and certified in the proper use of the Omron machine by a master trainer. The will be trained to measure the arm circumference, choose the appropriate cuff and place it properly on the arm. They will be recertified yearly. Once activated, the Omron HEM-907XL will lead measurement for 5 minutes then perform a series of 3 BP measurements spaced by 30 seconds and present the man of these 3 measurements. The mean will be record in the electronic medical records.
1686740|NCT01566669|Drug|Parecoxib Sodium|Before incision, patients in Group P (n = 120) receive 40mg of parecoxib IV. Thereafter, parecoxib patients receive 40mg of parecoxib IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
1686711|NCT01566864|Behavioral|Provider education system to promote patient-centered care|The provider education intervention will address blood pressure control and disparities through audit and feedback. The intervention includes a hypertension dashboard and a linked provider-tailored education intervention. The latter aims to enhance provider communication skills during clinical encounters with hypertension patients, via teaching specific verbal behaviors with practice implications related to elicitation of hypertension treatment and adherence concerns. The dashboard is a web based tool linked to the electronic medical records that imports clinic measurements of BP and offers PCPs a quick assessment of the percentage of those achieving blood pressure control and receiving guideline-concordant care in their panel, clinic, and system overall and by patient race/ethnicity.
1686712|NCT01566864|Behavioral|Introduce care management system in clinics|The care management (CM) intervention will address blood pressure management and disparities through patient education, promotion of self-management, and the introduction of an organizational change through the addition of new team members. The CM team will contact patients with a BP of ≥140/≥90 (≥130/≥80 for patients with diabetes mellitus or chronic kidney disease) as identified through the electronic medical records for enrollment in care management services. Patients with a BP in these ranges will be referred to a CM program that emphasizes four key self-management behaviors: diet, physical activity, medication adherence, and self-monitoring. The self-management promotion program will consist of 3 one-on-one sessions either with a Pharm D. or R.D. over the course of 3 months.
1686713|NCT01566851|Other|Cardiovascular check-up|Cardiovascular check-up once a year in patients with rheumatoid arthritis
1686714|NCT01566838|Drug|Subpleural pain catheter with infusion of 0.125% bupivacaine|Patients in this arm will be provided with a subpleural pain catheter and instructions for removal when pump is empty (around 5 days time). The catheter will contain an infusion of 0.125% bupivacaine. The single lumen pain catheter is infused by a self deflating pump filled to 335ml, which delivers the infusate at a rate of 4ml/h. Pumps are expected to be empty in 4 to 5 days.
1686715|NCT01566838|Drug|Standard acute pain management|"A standard balanced anesthetic consisting of midazolam 0.01-0.03mg/kg, induced with propofol (1-2mg/kg) or etomidate, fentanyl (1-2 mcg/kg) and rocuronium (0.1mg/kg) and a potent inhalation agent (sevoflurane 1.5%-2.5%) during procedures.
Prior to emergence from anesthesia, patients will receive ketorolac 30mg IV, neuromuscular reversal agents, and ondansetron 4mg. Fentanyl will be given, as needed, to facilitate patient comfort and extubation.
The ASA guidelines for acute pain management in the perioperative period will be followed. Patients shall receive 1,000 mg of acetaminophen orally every 6 hours, scheduled for 5 days. Other drugs will be given on as needed basis (PRN) to maintain an analog pain scale of ≤ 3."
1686716|NCT01566825|Drug|Amitriptyline|amitriptyline 25 mg at 9:30 pm, day 10, and 50 mg at 1:30 am, day 11
1686717|NCT01566825|Drug|Placebo|placebo(white 8 mm Lichtenstein®) at 9:30 pm, day 10, and at 1:30 am, day 11
1686718|NCT01566812|Behavioral|Breast feeding optimization|Breast feeding optimization program extends from late pregnancy period to 6 months after birth. Prenatal intervention consists of individual and group counseling/education; perinatal intervention consists of in-hospital lactation support; postnatal intervention consists of home visit, counseling session, reminding telephone call and bulk SMS, special counseling for working mothers, breast pump rental, occupational-related support
1686719|NCT01566812|Behavioral|Usual care|Usual care applied in the hospital
1686720|NCT01566799|Drug|Metformin|metformin 500 mg/day po for 24 weeks.
1686721|NCT01566786|Drug|activated recombinant human factor VII|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
1686722|NCT01566786|Drug|placebo|Starting dose of trial drug 10 mcg/kg, escalating up to five dose tiers: 20 mcg/kg, 40 mcg/kg, 80 mcg/kg, 120 mcg/kg and 160 mcg/kg. Administered within the first 4 hours after the insult
1686726|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fasting conditions, single dose
1686727|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fasting conditions, single dose
1686728|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR1 under fed conditions, single dose
1686729|NCT01566760|Drug|fesoterodine fumarate|One capsule of 4 mg PF-00695838 Formulation SR2 under fed conditions, single dose
1686730|NCT01566760|Drug|fesoterodine fumarate|one extended-release tablet of commercially available fesoterodine fumarate 4 mg under fasting conditions, single dose
1686731|NCT01566747|Drug|Pazopanib|Pazopanib 800mg day to be given continuously until disease progression.
1686732|NCT01566734|Other|Cefazolin irrigation|after the surgery and before closing up the patients, 2 grams of cefazolin in 5 cc of distilled water was used to irrigate the patients
1686733|NCT01566734|Other|Normal Saline Irrigation|after the surgery and before closing up the patients, 150 cc of normal saline was used to irrigate the patients and in the last group
1686734|NCT01566721|Drug|Herceptin|Herceptin will be given as 600 mg SC (into thigh) on Day 1 of each 3-week cycle for up to 18 cycles.
1686735|NCT01566708|Behavioral|Neuro-Music Therapy immediately|20 patients are randomized to receive Neuro-Music Therapy immediately. Neuro-Music Therapy takes 5 days and comprises 9 consecutive 50-minutes sessions of individual therapy. Immediately before and after treatment extensive diagnostics are performed, including psychological assessment, functional neuroimaging and electro-physiological examinations.
1686736|NCT01566708|Behavioral|Neuro-Music Therapy after waiting time|20 Patients were randomized to receive Neuro-Music Therapy after a waiting period not exceeding 6 weeks. Within this waiting time, patients undergo exactly the same diagnostic procedure as the patients of the treatment group.
1686737|NCT01566708|Behavioral|Music-therapeutical stress management coaching|20 non-tinnitus controls matched in age, gender and hearing ability receive a music-therapeutical stress coaching program. This intervention is based on the main treatment components of the Neuro-Music Therapy for acute tinnitus with alterations of the tinnitus specific elements. Immediately before and after this five-day coaching, controls undergo exactly the same diagnostic procedure as the patients of the treatment group.
1686741|NCT01566669|Drug|Normal saline|Before incision, patients in Group C (n = 120) receive 2 mL of normal saline IV. Thereafter, they receive 2 mL of normal saline IV every 12 h for 48 h. 30 min before the end of surgery, a mixture of 6 mL of ropivacaine 0.25% and 2mg morphine was given epidurally. Epidural patient-controlled analgesia was initiated by using ropivacaine 0.125% (1.25 mg/ml) and morphine 0.005% (0.05 mg/ml) with a basal infusion rate of 2 ml/h, a demand dose of 2 ml, and a 15-min lockout.
1686742|NCT01566656|Drug|total lymphoid irradiation and anti-thymocyte globulin|"TLI Administration: TLI is administered ten times in 120 cGy fractions on day -11 through day -7 and day -4 through day -1.
ATG: Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg.
Mobilized PBSCs (Day 0): The desired cell doses (based on recipient body weight) for MRD and MUD transplants are around 4-8 x106 CD34+ cells/kg.
GVHD Prophylaxis: Cyclosporine A (CSP) 3 mg/kg IV from day-3 and Mycophenylate mofetil (MMF) 500 mg x 4/ day PO from day 0"
1686743|NCT01566643|Drug|RA5-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 5 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
1686744|NCT01566643|Drug|RA3-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 3 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
1686745|NCT01566643|Drug|RA7-RACM7|rabeprazole 20mg bid + amoxicillin 1g bid treated for 7 days, then rabeprazole 20mg bid + amoxicillin 1g bid + clarithromycin 0.5g bid + metronidazole 0.5g bid for other 7 days
1686746|NCT01566630|Drug|Placebo|Placebo to RLX030 as intravenous infusion for 72 hours
1686747|NCT01566630|Drug|RLX030|RLX030 1 mg/mL vials
1686748|NCT01566617|Other|Standard care and Pharmaceutical care|Pharmaceutical care is the direct interaction between the pharmacist and the drug's users in order to improve the therapeutic compliance among outpatients and promote adequate pharmacotherapeutic follow-up.
1686749|NCT01566617|Other|Standard care|These patients will only receive standard care, with out follow-up by the pharmacist
1686750|NCT01566604|Drug|NVA237|Delivered via a single dose dry powder inhaler
1686751|NCT01566604|Drug|Placebo|Delivered via a single dose dry powder inhaler
1686752|NCT01566591|Device|Deep TMS Treatment|24 TMS treatments over 6 weeks .
1686753|NCT01566591|Device|Sham Treatment|24 TMS treatments over 6 weeks
1686754|NCT01566578|Drug|Human recombinant epidermal growth factor|topical
1686755|NCT01566578|Other|Placebo cream|Dermal cream without EGF
1686756|NCT01566565|Drug|Theophylline and Bambuterol|Treatment 3: Theophylline, 300 mg plus Bambuterol, 20 mg
1686757|NCT01566552|Drug|AMBISOME|SINGLE DOSE AMBISOME FOR TREATMENT OF VISCERAL LEISHMANIASIS
1686758|NCT01566539|Drug|Intranasal Oxytocin (OT) 24 IU|Participants will self-administer a single dose of 24 international units (IU) oxytocin. Five puffs per nostril, each with 2.4 IU oxytocin. Ten puffs total.
1686759|NCT01566539|Drug|Intranasal Vasopressin (AVP)|Participants will self-administer a 1 ml solution containing 20 units of AVP. Five puffs per nostril, each with 2 International Units (IU) AVP. Ten puffs total).
1686760|NCT01566539|Drug|Intranasal Placebo|Participants will receive placebo sprays that are pH adjusted to comparable levels of the drugs given. Five puffs per nostril; ten puffs total.
1686761|NCT01566539|Drug|Intranasal Vasopressin (AVP) 40 IU|Participants will self-administer a 0.5 ml solution containing 40 international units (IU) of AVP. 5 puffs in total, each with 4 International Units (IU) AVP.
1686762|NCT01566539|Drug|Lorazepam|Subjects will take 1.0 mg of lorazepam orally 60 minutes prior to fMRI scan.
1686763|NCT01566526|Drug|dexamethasone intravitreal implant 0.7 mg|OZURDEX® administered at least twice in accordance with routine clinical practice as part of the Belgium Medical Needs Program.
1686764|NCT01566513|Behavioral|Community Connector|The participant randomized into this arm of the study is invited to work with a person trained as a community connector, someone who is trained in Intentional Peer Support but does not have a lived experience of mental illness.
1686765|NCT01566513|Behavioral|Peer Recovery Mentor|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
1686766|NCT01566513|Behavioral|Peer Case Manager|A participant randomized into this arm of the study is offered the chance to work with a Peer Recovery Mentor, who is trained in Intentional Peer Support.
1686767|NCT01566487|Drug|Quetiapine fumarate|Quetiapine fumarate tablets 300mg
1686768|NCT01566474|Drug|Omeprazole|Omeprazole 40 mg/day alone. Patients will take the capsule once in the morning before breakfast. This is the standard therapy for patients suffering from Barrett's esophagus.
1686769|NCT01566474|Drug|Melatonin|Omeprazole 40 mg/day + Circadin 6 mg/12 hours. Patients will take the Omeprazole capsule once in the morning before breakfast together with 3 tables of 2 mgs of Circadin (melatonin). In the evening, before dinner, patients will take 3 tablets of 2 mg of Circadin.
1686770|NCT01566461|Device|Drug-Coated Balloon (DCB)|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
1686771|NCT01566461|Device|PTA Balloon: Balloon Angioplasty|Subjects will be randomized 2:1 to the IN.PACT Admiral Drug-Coated Balloon (DCB) Arm or to the standard angioplasty balloon Arm
1686772|NCT01566448|Drug|Ketamine|20mg/5ml swish and spit four times daily
1686773|NCT01566435|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1686774|NCT01566435|Drug|Cisplatin|
1686775|NCT01566435|Drug|Fluorouracil|
1686776|NCT01566435|Radiation|Intensity modulated radiation therapy|
1686777|NCT01566435|Drug|Cetuximab|
1686778|NCT01566435|Procedure|Quality-of-life assessment|ACF baseline, IMRT baseline, Day 7, Week 12, months 6 and 12
1686779|NCT01566422|Drug|Vancomycin powder|patients randomized to this group will receive vancomycin powder in the surgical incision after posterior spinal fusion.
1686780|NCT01566409|Drug|Polyethylene glycol 3350|Powder for solution. Each sachet contains 13.125 g of macrogol 3350. Disimpaction dosage consists of 1,5 g/kg, maintenance treatment are adjusted according til the Bristol stool chart. The drug can be taken at anytime of the day and can also be divided. Treatment duration up to ½ year.
1686863|NCT01565850|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
1686967|NCT01564888|Procedure|Ulnar artery compression|Compression of ulnar artery for 2 hours with radial artery hemostasis
1686781|NCT01566409|Other|Placebo|Placebo will be manufactured and packaged as a powder to make it identical to the bags with the PEG 3350. The powder will comprise of a non-active substance, like a mild rehydration solution, which is a composition consisting of salt and sugar.
1686783|NCT01566383|Procedure|24-hr pH monitoring|"Visit 1
The following will be done:
A medical history including review of your current drugs;
Collection of demographic information;
A manometry, before the 24-hour pH testing, to find the junction between the esophagus and stomach;
24-hour pH testing will be done
Visit 2
You will return to the clinic 24 hours after the visit 1 and the following will occur:
The catheter will be removed from your nose; and
You will return the recording device"
1686784|NCT01566370|Drug|Zonisamide|titration of dose to 500mg oral, daily, over 8 weeks, then 6 weeks of treatment at that dose
1686785|NCT01566370|Drug|Placebo|placebo
1686786|NCT01566357|Other|Toothpaste|
1686787|NCT01566357|Dietary Supplement|Milk|
1686788|NCT01566357|Dietary Supplement|Fluoridated Milk|
1686789|NCT01566357|Drug|Tooth Mousse|
1686790|NCT01566357|Drug|MI Paste Plus|
1686791|NCT01566357|Drug|Elmex Erosion Protection|
1686792|NCT01566344|Other|PVC suppression therapy|Conventional heart failure therapy plus radiofrequency catheter ablation of PVCs as primary treatment and Amiodarone (tablets, loading dose of 600 mg per day for 4 weeks and 200 mg per day afterwards for at least 12 months) as secondary treatment in case of unsuccessful catheter ablation.
1686793|NCT01566331|Device|Baby-guardTM|Baby-guardTM system, through its ergonomic, three chamber, inflatable abdominal belt, engineered after studies of biomechanics and biophysics, that follows obstetric semiotics, that applies fundal pressure during the second stage of labor in the direction of the pelvic outlet, may be of maternal and fetus aid for a safe natural childbirth for their better outcomes
1686794|NCT01566318|Behavioral|Problem-Solving Therapy|6-8 sessions over 8 weeks, with booster
1686795|NCT01566305|Dietary Supplement|Buttermilk without added egg-yolk|Buttermilk without added egg-yolk
1686796|NCT01566305|Dietary Supplement|Buttermilk with added egg yolk|Buttermilk with added egg yolk
1686797|NCT01566305|Dietary Supplement|Skimmed milk with added egg-yolk|Skimmed milk with added egg-yolk
1686798|NCT01566305|Dietary Supplement|Skimmed milk without added egg yolk|Skimmed milk without added egg yolk
1686799|NCT01566292|Drug|BOTOX|Botulinum Toxin type A, 200-300 UI dilued in 6 ml of saline solution
1686800|NCT01566279|Drug|Everolimus|All patients will receive everolimus 10mg q.d.
1686801|NCT01566266|Drug|Amoxicillin|2 capsules of 250mg, 3 times per day during 1 week
1686802|NCT01566266|Drug|Placebo capsule|2 capsules of 250mg, 3 times per day during 1 week
1686803|NCT01566253|Drug|Acetaminophen, ketoprofen, morphine|Acetaminophen 0.5g, maximum 4g by day, 48 hours ketoprofen 100 mg, twice a day, 48 hours Morphine 10 mg, maximum 90 mg by day, 36 hours
1686804|NCT01566253|Drug|Acetaminophen, ketoprofen,morphine|Acetaminophen 1g/100 ml IV, maximum 4g by 24 hours, 48 hours Ketoprofen IV, maximum 0,2 gram by 24 hours, 48 hours Morphine IV,maximum 60mg by 24 hours, 36 hours.
1686805|NCT01566240|Drug|Paclitaxel|Paclitaxel 80 mg/m2 (capped at 160mg maximum total dose) weekly for 6 weeks i.e. on days 1, 8, 15, 22, 29 & 36.
1686806|NCT01566240|Drug|Carboplatin|Carboplatin AUC 2 (capped at 270mg maximum total dose) weekly for 6 weeks i.e. on day 1, 8, 15, 22, 29, & 36.
1686807|NCT01566240|Radiation|Radiotherapy|Radiotherapy comprising external beam 40-50.4Gy in 20-28 fractions plus intracavity brachytherapy to achieve a minimum total EQD2 dose of 78-86Gy.
1686808|NCT01566240|Drug|Cisplatin|Cisplatin 40 mg/m2 (capped at 70mg total dose) weekly for five weeks maximum, commencing in the first week of radiotherapy or as soon as blood counts have recovered from induction chemotherapy.
1686809|NCT01566227|Other|Questionnaire|3 surveys with 10 questions each: one before, during and after treatment
1686810|NCT01566214|Behavioral|Motivational Interview|For those subjects randomly assigned to the treatment group, information from their MIHART assessment interview and medical record review will be used to select intervention scripts optimally tailored to each subjects' unique configuration of beliefs and risk factors and they will be re-contacted by telephone at 2-weeks post-hospital discharge to deliver the Vet-HART intervention. The intervention will be administered by a trained research assistant via telephone, working from a semi-structured script tailored to each subject's representations and risk factors, the call will last about 15-30 minutes.
1686811|NCT01566201|Drug|anakinra|Inhibition of Interleukin-1 activity by anakinra (Kineret®) 100mg od, sc injection
1686812|NCT01566201|Drug|placebo|water for injection
1686813|NCT01566188|Dietary Supplement|omega-3 from vegetal origin|6 months of supplementation with omega-3 from vegetal origin
1686814|NCT01566188|Dietary Supplement|Placebo|6 months of supplementation with placebo
1686815|NCT01566175|Device|Neovac coronary sinus reducer|reducer
1686816|NCT01566162|Drug|Lurasidone|Lurasidone 40-80 mg taken orally taken once daily
1686817|NCT01566149|Drug|Mometasone Furoate/Formoterol Fumarate (MF/F) 100/5 mcg MDI|Two oral inhalations per dose
1686818|NCT01566149|Drug|Mometasone Furoate/Formoterol Fumarate (MF/F) 200/5 mcg MDI|Two oral inhalations per dose
1686819|NCT01566136|Behavioral|Rehabilitation Model of Care|The PCRM-CI model includes the following 5 components: rehabilitation management; dementia management; delirium prevention and management; staff education and support; and family/significant other support and education.
1686820|NCT01566123|Radiation|Neoadjuvant intensity-modulated radiation therapy (IMRT)|neoadjuvant intensity-modulated radiation therapy, single dose 2.0-2.4 Gy, total dose 50-56 Gy
1686821|NCT01566123|Radiation|intraoperative radiation therapy (IORT)|during surgery, 10-12 Gy (90% isodose) to the tumor bed or residual disease
1686822|NCT01566110|Dietary Supplement|Gluten Free Diet|Subjects assigned to the intervention group will receive a standardized dietary education intervention that will inform subjects and family members of the effects of gluten on the gastrointestinal tract and emphasize the need to adhere to a diet that is gluten-free. This intervention will be delivered by a dietician who is trained in celiac disease and gluten free diet.
1686894|NCT01565590|Drug|propofol|5-80 mcg/kg/min
1686895|NCT01565577|Biological|MenbVac|Blood test
1686968|NCT01564875|Drug|Simvast CR|Simvast CR Tab 20mg, 1 tablet once daily to be administered between 6 and 9 a.m.
1686823|NCT01566097|Device|Smoking Cessation Decision Aids|"The decision aids were developed through: 1) literature review; 2) qualitative interviews with Korean smokers from various backgrounds; 3) expert opinions. They were in the form of short educational videos (flash), displayed by Apple's iPad.
The decision aids contained the followings, in proper Korean social and cultural context:
Information on the risk of continued smoking and benefits of cessation
Messages that address common misbeliefs regarding smoking cessation services and medications
Information on possible smoking cessation options, their efficacy, side effects, costs, etc.
The choices given in the decisions aid were:
Behavioral only
Nicotine replacement therapy
Bupropion
Varenicline"
1686824|NCT01566084|Drug|Slow sodium tablets|The normal salt condition is maintained with 2300 mg / day in the form of slowly released salt (NaCl) tablets.
1686825|NCT01566084|Other|placebo|Placebo tablets are administered to maintain the low sodium condition.
1686826|NCT01566071|Other|Assessment of drive abilities|
1686827|NCT01566058|Device|BB Box available|The BB Box video system is provided to the mother during the hospitalisation of her premature baby.
1686828|NCT01566058|Other|No BB Box|The BB Box video system is not provided to the mother during the hospitalisation of her premature baby.
1686829|NCT01566045|Procedure|Core Needle TRUS Needle biopsy (Transrectal ultrasound)|Standard of care 12-core TRUS sextant needle biopsy of the medial and lateral margins of the right and left apex, mid-gland and base of the prostate
1686830|NCT01566045|Procedure|Core Needle MRI/US image fusion guided needle biopsy|Directed prostate needle biopsies at MR-image identified targets in addition to the standard ultrasound 12-14 core biopsies
1686831|NCT01566019|Procedure|Tumoral biopsy|Every enrolled patient undergoes tumoral biopsy
1686832|NCT01566006|Drug|Mycophenolate Mofetil (MMF) ,phosphodiesterase 5 inhibitors , CARNITINE|effect of MMF on diabetic nephropathy patients by evaluating its effect on proteinuria and progression of kidney disease of diabetic origin
1686833|NCT01565993|Device|Hemoclip|"A rotatable clip-fixing device Quickclip 2 standard was used (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan), with an opening diameter of 135º and a maximum insertion portion diameter of 2.6 mm"
1686834|NCT01565993|Device|Conventional Polipectomy|Disposable electrosurgical snares (Olympus Medical Systems Corp. Hachioji-shi, Tokyo, Japan) and an electrosurgery unit ERBE (ERBE Elektromedizin GmbH, Germany) were used for polyp resection
1686835|NCT01565980|Behavioral|symptom assessment|attention control receives a weekly symptom assessment phone interview for 6 weeks.
1686836|NCT01565980|Behavioral|Mindfulness Intervention|Participants will receive a weekly home-based mindfulness intervention, and symptom assessment phone interviews for 6 weeks.
1686837|NCT01565941|Drug|Insulin|IV insulin titration to target a blood glucose of 80-110 mg/dL
1686838|NCT01565941|Drug|Insulin|IV insulin titration to target a blood glucose of 150-180 mg/dL
1686840|NCT01565915|Device|Perlane-L|Perlane-L Injection in the midface
1686841|NCT01565915|Other|Non-treatment|Non-treatment Arm
1686842|NCT01565902|Drug|BAF312|Treatment with a single oral dose of 0.25 mg BAF312
1686843|NCT01565889|Drug|SOF|Sofosbuvir (SOF) 400 mg (1 × 400 mg tablet or 2 × 200 mg tablets) administered orally once daily
1686844|NCT01565889|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination (FDC) tablet administered orally once daily
1686845|NCT01565889|Drug|EFV|Efavirenz (EFV) 600 mg tablet administered orally once daily
1686846|NCT01565889|Drug|ZDV/3TC|Zidovudine (ZDV) 300 mg/lamivudine (3TC) 150 mg FDC tablet administered orally twice daily
1686847|NCT01565889|Drug|ATV|Atazanavir (ATV) 400 mg tablet administered orally once daily
1686848|NCT01565889|Drug|Ritonavir|Ritonavir (RTV) 100 mg tablet administered orally once daily
1686849|NCT01565889|Drug|FTC/TDF|FTC/TDF (200/300 mg) FDC tablet administered orally once daily
1686850|NCT01565889|Drug|DRV|Darunavir (DRV) 800 mg (2 × 400 mg tablets) administered orally once daily
1686851|NCT01565889|Drug|RAL|Raltegravir (RAL) 400 mg administered administered orally twice daily
1686852|NCT01565889|Drug|PEG|Pegylated interferon alfa (PEG) 180 μg administered once weekly by subcutaneous injection
1686853|NCT01565889|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1686854|NCT01565876|Device|"Minkal- Auxiliary device to alleviate backload"|"The participants will undergo 6 days of study. The first day of the study include medical examination, maximal oxigen consumption day and anthropometric mesurments.
Then The participants will undergo heat tolerance test 5 times (in different days).
first day- without load. second day- with back load of 40% of the body weight. third day- with back load of 40% of the body weight and the Auxilairy Device. fourth day- with back load of 60% of the body weight. fifth day- with back load of 60% of the body weight and the Auxilairy Device. The rectal temperature, skin teperature and heart rate will be mesured each day and compered afterwards."
1686855|NCT01565863|Behavioral|Progressive Goal Attainment Program|The Progressive Goal Attainment Program (PGAP) is a behavioral intervention originally developed in Canada at McGill University in order to increase return to work and community integration for individuals who receive worker's compensation. PGAP is the first disability program that is specifically designed to target the psycho-social risk factors of disability. The premise behind PGAP is that inactivity and attitudinal barriers increase work disability, and these issues are a primary cause of unemployment for individuals with physical and mental disabilities. PGAP is a structured, 10-week intervention that focuses upon helping clients develop a planned activity schedule to assist them in resuming desirable life activities.
1686856|NCT01565850|Drug|D/C/F/TAF|DRV 800 mg/COBI 150 mg/FTC 200 mg/TAF 10 mg FDC tablet administered orally once daily
1686857|NCT01565850|Drug|DRV|DRV 800 mg (2 × 400 mg tablets) administered orally once daily
1686858|NCT01565850|Drug|COBI|COBI 150 mg tablet administered orally once daily
1686859|NCT01565850|Drug|FTC/TDF|FTC 200 mg/TDF 300 mg FDC tablet administered orally once daily
1686860|NCT01565850|Drug|D/C/F/TAF Placebo|D/C/F/TAF placebo tablet administered orally once daily
1686861|NCT01565850|Drug|DRV Placebo|DRV placebo tablet administered orally once daily
1686862|NCT01565850|Drug|COBI Placebo|COBI placebo tablet administered orally once daily
1740261|NCT00108368|Drug|Risperidone|
1686864|NCT01565837|Drug|Ipilimumab|Ipilimumab 10mg/kg administered intravenously over 90-minute period every 3 weeks for a total of four doses as tolerated. Maintenance ipilimumab (10 mg/kg intravenously every 3 months) will be administered beginning Week 24, as long as there is clinical benefit in the opinion of the investigator using immune related response criteria, and there are no novel or unexpected Grade 3 or 4 toxicities.
1686865|NCT01565837|Radiation|Stereotactic Ablative Radiosurgery (SART)|Definitive radiotherapy will be administered to up to 1-5 lesions using SART techniques after initial dose of ipilimumab. Radiotherapy will be timed before start of 3rd cycle of ipilimumab treatment to maximize synergy (week 6).
1686866|NCT01565824|Other|web-based support|
1686867|NCT01565811|Procedure|perihepatic lymphadenectomy|Hepatic pedicle lymph node dissection according to the protocol of the prospective multicentric study.Namely the six main groups of lymph nodes removed (HA,hepatic artery; CA, celiac axis; BD, common bile duct).
1686868|NCT01565798|Other|Copper-alloy surfaced patient care objects|Copper-alloy surfaced bed rails, over bed tray tables, chair arms, nurse call devices, laptop and computer monitor bezels, and IV poles were placed into the patient ICU rooms.
1686869|NCT01565785|Behavioral|The FSM-DPI.|Nurses will assess key elements of family self-management (home care, child's care, practice, medications, watching child, recovery, development, family adjustment and parental support) and address any deficits to facilitate effective discharge and family management of child at home after hospitalization.
1686870|NCT01565772|Radiation|Proton Beam Radiation|45-55 Gy total, 1.8-2.2 Gy x 25 fractions Mon-Fri for 5 weeks
1686871|NCT01565772|Drug|Cisplatin|50 mg/m2 IV on days 1, 8 of cycles 1 and 2
1686872|NCT01565772|Drug|Etoposide|50 mg/m2 IV on days 1-5 on Cycles 1-2
1686873|NCT01565759|Drug|Lithium Carbonate|"The dose has been selected in order to achieve a therapeutic range of 0.6 - 0.8 mmol/L.
Dose titration Day 1: 1 capsule of 300 mg at bedtime Days 2 to 7: 1 capsule of 600 mg at bedtime Day 8: lithium serum levels will be tested and the dose will be adjusted proportionally to a target range of 0.6 - 0.8 mmol/L by increments of 150 mg or 300 mg."
1686874|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
1686875|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride (Xofigo, BAY88-8223) 100 kBq/kg
1686876|NCT01565746|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Expansion arm: Radium-223 dichloride (Xofigo, BAY88-8223) 50 kBq/kg
1686877|NCT01565733|Drug|biphasic insulin aspart 30|Biphasic insulin aspart 30 prescribed solely on the basis of clinical judgement. Initial dose, frequency of injections and further dosage amendments at the discretion of the treating physician.
1686878|NCT01565720|Drug|Isavuconazole|oral
1686879|NCT01565720|Drug|Placebo|oral
1686880|NCT01565720|Drug|Moxifloxacin|oral
1686881|NCT01565707|Drug|Solifenacin Succinate Suspension|Children aged 5 to 11 years and adolescents aged 12 to 17 years received solifenacin succinate liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
1686882|NCT01565707|Drug|Placebo|Children aged 5 to 11 years and adolescents aged 12 to 17 years received matching placebo liquid suspension once a day orally via syringe for 12 weeks along with non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB. The initial dose started with the equivalent of 5 mg in adults, referred to as pediatric equivalent dose (PED) of 5 mg (PED5), based on body weight for three weeks and was titrated up or down in up to three titration steps of three weeks each to reach the optimal dose. Titration up or down could lead to weight-based doses equivalent to doses in adults of 2.5 mg, 5 mg, 7.5 mg or 10 mg once daily and were referred to as PED2.5, PED5, PED7.5 and PED10. The minimum dose was PED2.5, and the maximum dose was PED10. The decision to titrate up or down was made by the investigator using information from the 7 day patient diary.
1686883|NCT01565707|Behavioral|Urotherapy|Non interventional diary assisted urotherapy consisting of overactive bladder (OAB) information, awareness, instruction, life-style advice and documentation of voiding habits and symptoms for OAB.
1686884|NCT01565694|Drug|Solifenacin succinate|oral
1686885|NCT01565681|Drug|ASP1240|infusion
1686886|NCT01565681|Drug|Placebo|infusion
1686887|NCT01565668|Drug|AC220|oral
1686888|NCT01565655|Drug|ASP015K|oral
1686889|NCT01565655|Drug|Placebo|oral
1686890|NCT01565642|Behavioral|Goals of care decision support|Decision aid and care plan meeting
1686892|NCT01565616|Drug|Conditioning Regimen with Bone Marrow Transplant|"The bone marrow transplant regimen is below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.
Day -8 BU 3.2 mg/ kg/dose IV
Day -7 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV
Day -6 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 0.5mg/kg IV
Day -5 BU 3.2 mg/kg/dose IV, FLU 35mg/m2 IV, ATG 1.0mg/kg IV
Day -4 FLU 35mg/m2 IV, ATG 1.5mg/kg IV
Day -3 FLU 35mg/m2 IV, ATG 1.5mg/kg IV
Day -2 ATG 1.5mg/kg IV
Day -1 Rest
Day 0 Stem cell infusion
Graft Versus Host Disease (GVHD) Regimen
Day -3 Calcineurin Inhibitor (Cyclosporine or Tacrolimus) therapeutic doses through day 180, then taper
Day 0 Stem cell infusion
Day +1 Methotrexate 7.5 mg/m2 IV
Day +3 Methotrexate 7.5 mg/m2 IV
Day +6 Methotrexate 7.5 mg/m2 IV
Day+11 Methotrexate 7.5 mg/m2 IV"
1686893|NCT01565590|Drug|Dexmedetomidine|0.2-1.5 mcg/kg/hr
1686896|NCT01565564|Behavioral|Shared glycaemic control care within the local three-tier's antenatal care network|"Individualized dietary and physical activity consultation plus group diabetes education
Self blood glucose monitoring
Insulin therapy if indicated
Self blood glucose monitoring
Insulin therapy institutions if indicated;"
1686897|NCT01565551|Other|N/A (Observational Study)|No Interventions: Observational Study
1686898|NCT01565538|Drug|Erlotinib|150 mg Given orally
1686899|NCT01565538|Drug|Pemetrexed|500mg/m2 Given IV
1686900|NCT01565525|Behavioral|Maternal focused intervention|This is a series of information given to mothers at child's well child visits (6 in all) starting at the newborn visit focused in maternal eating habits, using the mother as a potential 'agent of change' for the family and infant in modeling healthy eating habits.
1686901|NCT01565525|Behavioral|Ounce of Prevention|This intervention is given via a series of handouts given to mothers at their child's well visit from newborn period to one year of age, focusing on serving size and frequency and the introduction of new foods.
1686902|NCT01565512|Drug|Bupivacaine|A total of 100 mg bupivacaine (20 mL of 5 mg/mL solution) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
1686903|NCT01565512|Drug|Saline|A total of 20 mL on injectable saline(0.9% NS) administered once by subcutaneous injection while patient is under general anesthesia at end of operation.
1686904|NCT01565499|Drug|Nab-paclitaxel|The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.
1686905|NCT01565486|Device|Ultrasonic coagulation device (Harmonic ACE® scalpel)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
1686906|NCT01565486|Device|bipolar energy sealing system (LigaSure Precise)|Comparison of Surgical Outcomes Between Papillary Thyroid Cancer Patients Treated with the Ultrasonic coagulation device (Harmonic ACE® Scalpel) and the bipolar energy sealing system (LigaSure Precise) during Conventional Thyroidectomy
1686907|NCT01565460|Other|Sample Collection|Sample Collection: bile and pancreatic duct brushings and fluid samples will be obtained from the pancreatic stricture during endoscopic retrograde cholangiopancreatic procedure.
1686908|NCT01565434|Other|CR1 impact|
1686909|NCT01565421|Drug|IT-101|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression. (12mg/m2/dose)
1686910|NCT01565421|Drug|IT-101|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression. (15mg/m2/dose)
1686911|NCT01565421|Drug|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
1686912|NCT01565408|Drug|NNC0114-0006|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks. The trial comprises dose escalation up to four dose levels. Progression to next dose will be based on safety evaluation.
1686913|NCT01565408|Drug|placebo|Multiple subcutaneous (s.c., under the skin) doses administered every second week for six weeks.
1686914|NCT01565395|Drug|Incobotulinum Toxin A|Xeomin 70-100 units injected in the parotid and submandibular glands of subjects
1686915|NCT01565395|Drug|placebo|Sterile preservative free 0.9% saline
1686916|NCT01565382|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
1686917|NCT01565369|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
1686918|NCT01565356|Drug|florbetapir F 18|IV injection, 111 or 370MBq (3 or 10mCi), single dose
1686919|NCT01565343|Drug|florbetapir F 18|IV injection, 370MBq (10mCi)
1686920|NCT01565330|Drug|florbetapir F 18|single dose IV injection
1686921|NCT01565317|Other|Weight Achievement and Intensive Treatment (Why WAIT)|Weight Achievement and Intensive Treatment (Why WAIT) is a 12 -week multidisciplinary program for weight control and intensive diabetes management designed by the Joslin Diabetes Center for application in a multidisciplinary diabetes practice environment. Participants will be enrolled in a 12-week multidisciplinary intensive weight management including diet, exercise, behavioral and educational support. Participants will be enrolled in cohorts of 10-15 participants to encourage group interaction and support. Subjects will choose to come to the Joslin clinic every Tuesday or Wednesday evening for 2 hours. Participants will exercise for an hour and will attend a didactic session in the areas of nutrition, exercise and behavioral modifications.
1686922|NCT01565304|Behavioral|POWER Through Choices|10-session group-based sexual education curriculum
1686923|NCT01565291|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
1686924|NCT01565278|Drug|Soybean oil (Standard treatment)|1. Standard treatment: Soybean oil based emulsion: 0.25 g/kg/TPN day
1686925|NCT01565278|Drug|Soybean oil + Fish oil|Intralipid+Omegaven: 0.25 g/kg/TPN Intralipid day+0.4 g/kg/TPN Omegaven day for 6 months
1686926|NCT01565265|Drug|Pergoveris in long protocol with GnRH agonist|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
1686927|NCT01565265|Drug|Pergoveris in GnRH antagonist protocol|Ovarian hyperstimulation with recombinant FSH and recombinant FSH Ovulation induction with recombinant HCG Oocyte collection for ICSI
1686928|NCT01565252|Dietary Supplement|eggs enriched Omega-3|In second stage participants will receive two Omega-3 enriched hard-boiled eggs/day at breakfast for a three weeks period for each participant.
1686929|NCT01565239|Device|Fiix prothrombin time|The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
1686930|NCT01565213|Behavioral|CBT|group cognitive behavioural based therapy (CBT) administered by psychologists once a week for 12 weeks,
1686931|NCT01565213|Behavioral|MMI|group multimodal intervention (MMI) based on a protocol comprising a mix of existing group interventions and exercises borrowed from multiple techniques and therapeutic schools and administered by assistant nurses with brief training, including two sessions per week for 6 weeks.
1686932|NCT01565213|Behavioral|CAU|Care as usual by the GPs
1686933|NCT01565200|Drug|T-DM1|3.6 mg/kg iv every 3 weeks
1686934|NCT01565200|Procedure|89Zr-trastuzumab|Injection of 89Zr-trastuzumab for HER2 imaging
1686935|NCT01565187|Behavioral|Questionnaires|Transplant Effects Questionnaire, Response Evaluation Measure, Patient Health Questionnaire, Generalized Anxiety Scale, Alcohol Use Disorders Test, Body Image Questionnaire, Quality of Life Uniscale, Scales of Psychosocial Well-Being, Sense of Coherence Scale.
1686936|NCT01565161|Behavioral|Home-Based Health Coaching|"The 6-month intervention arm consists of 3 components:
In-home coaching visits with a health educator trained in motivational interviewing to encourage behavior change. In addition to 4 monthly in-home coaching visits, participants receive 4 monthly coaching phone calls to supplement the in-person visits.
Use of mobile technology to deliver health information by text message - participants receive messages twice weekly for 16 weeks and then weekly for 8 weeks of the program. Those without a phone capable of receiving text messages receive postcards by mail.
Printed materials, including educational handouts, newsletters, and activities highlighting target behaviors, sent monthly for 4 months."
1686937|NCT01565161|Behavioral|Mailed materials|"We designed materials for our control group focusing on Developmental milestones during early childhood to provide information that participants would find relevant and helpful for parenting, but that would also not influence intervention behaviors, such as TV viewing or household routines related to sleeping, eating, or television viewing.
Participants received 4 monthly mailing packages, each focusing thematically on one of four milestone domains: motor, language, cognitive and social/emotional. Educational materials were adapted from the Center for Disease Control's Positive Parenting Tips for Healthy Child Development, and the mailing included child-appropriate incentives to reinforce the concepts presented in the educational materials."
1686938|NCT01565148|Drug|iCo-007 350 mcg|iCo-007 (350 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (350 μg) at month 4
1686939|NCT01565148|Drug|iCo-007 700 mcg|iCo-007 (700 μg) as an intravitreal injection at baseline followed by another iCo-007 dose (700 μg) at month 4
1686940|NCT01565148|Drug|iCo-007 350 mcg and Laser|iCo-007 (350 μg) as an intravitreal injection at baseline followed 7 days later by laser photocoagulation. At M4, intravitreal injection of iCo-007 (350 μg) will be given as mandatory treatment. If the eye also meets retreatment criteria, it will also receive the second laser photocoagulation
1686941|NCT01565148|Drug|Ranibizumab and iCo-007 350 mcg|Ranibizumab (0.5 mg) intravitreal injection at baseline followed by iCo-007 (350 μg) intravitreal injection 2 weeks later; re-treatment with ranibizumab (0.5 mg) mandatory at M4 followed by iCo-007 (350 μg) 2 weeks later
1686943|NCT01565109|Drug|Docetaxel - Cisplatine - 5FU|2 cycles of Docetaxel - Cisplatine - 5 FU
1686944|NCT01565109|Radiation|Radiation of 45 Grays on 5 weeks|Radiochemotherapy with Oxaliplatine (J1, J15 et J29) - 5FU on 5 weeks
1686945|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
1686946|NCT01565096|Drug|Metformin|Metformin 1000 mg BID
1686947|NCT01565096|Drug|Vildagliptin|Vildagliptin 50 mg twice daily
1686948|NCT01565096|Drug|Glimepiride|Glimepiride at individual dose
1686949|NCT01565083|Drug|Pertuzumab|Loading dose of 840 mg on Day 1 of first 21-day cycle, followed by 420 mg on Day 1 of each subsequent cycle.
1686950|NCT01565083|Drug|Trastuzumab|Loading dose of 8 mg/kg on Day 1 of first 21-day cycle, followed by 6 mg/kg on Day 1 or 2 of each subsequent cycle.
1686951|NCT01565083|Drug|Vinorelbine|A dose of 25 mg/m^2 followed by 30-35 mg/m^2 on Days 2 and 9 of the first 21-day cycle and on Days 1 and 8 (or Days 2 and 9) of each subsequent cycle.
1686952|NCT01565070|Drug|Biofreeze|Use of Biofreeze ointment
1686953|NCT01565070|Other|Placebo|Use of placebo ointment
1686954|NCT01565057|Other|sedimenting meal|The active system quickly forms a sedimenting layer of small particles that contain most of the caloric content of the system. This system is made by adding finely grated cheese (particle size 0.5-2 mm) to yoghurt and consumption is followed by drinking 327 ml water.
1686955|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped is programmed to move in order to stimulate automatic motricity.
1686956|NCT01565044|Other|motor training|Subject will perform prehension exercises on an automated table. After the initiation of the arm movement, the target to be grasped will remain static in order to involve intentional motricity.
1686957|NCT01565031|Procedure|Step-wise down-titration according to international guidelines.|The medication will be adjusted according to each patient´s level of control. Depending on the state of control of asthma, the dose will be adjusted up or down (step-up therapy and step-down therapy, respectively) in accordance with GINA.
1686958|NCT01565018|Drug|Rotigotine PR 2.1.4|Treatment B: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Reference; drug product PR 2.1.4. Single application of 1 patch for 24 hours.
1686959|NCT01565018|Drug|Rotigotine PR 2.2.1|Treatment A: Rotigotine transdermal patch (2 mg/24 h [10 cm^2]). Test; drug product PR 2.2.1. Single application of 1 patch for 24 hours.
1686960|NCT01564992|Other|Identification of genes|Identification of genes which polymorphism or haplotype is associated with a complication of Parkinson disease, directly or with the interaction of treatment.
1996675|NCT02416531|Drug|Clobetasol propionate|Clobetasol propionate 0.05% ointment applied once daily at a dose of 1 g/application (1 g sachets) for 4 weeks.
1996676|NCT02416531|Radiation|Photodynamic therapy|Methylene blue 0.01% intralesional, λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
1686963|NCT01564927|Device|Electroacupuncture to right LI4 and LI11 (ITO, EX-160)|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
1686964|NCT01564927|Device|Sham Electroacupuncture to knee caps|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
1686965|NCT01564927|Device|Sham electroacupuncture to LI4 and LI11|Electroacupuncture at 2Hz, 0.4m/sec pulse duration
1686966|NCT01564914|Biological|Chimeric monoclonal antibody (TRC105) to CD105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
1996677|NCT02416531|Radiation|Low level laser therapy|λ = 660 ± 10 nm, P = 100 mW, PD = 510 mW/cm2, E = 4 J, ED = 20 J/cm2, t = 40 s, once a week for 4 weeks
1996678|NCT02415946|Procedure|Sinus floor augmentation (lateral)|
1996679|NCT02415946|Procedure|Sinus floor augmentation (transcrestal)|
1996680|NCT02415855|Drug|Dabigatran|
1686969|NCT01564875|Drug|Zocor|Zocor Tab 20mg, 1 tablet once daily to be administered between 6 and 9 p.m.
1686970|NCT01564862|Drug|vortioxetine (Lu AA21004)|Lu AA21004 capsules
1686971|NCT01564862|Drug|Duloxetine|Duloxetine capsules
1686972|NCT01564862|Drug|Placebo|Placebo matching capsules
1686973|NCT01564836|Behavioral|Imatinib treatment discontinuing|Ph+ CP CML patients who were treated with IM for more than 3 years in sustained MR4.5 or undetectable transcript for at least 2 years are enrolled
1686974|NCT01564823|Drug|Metronidazole|Metronidazole: 250 mg/8h. 3 months.
1686975|NCT01564823|Drug|Metronidazole|Metronidazole 250 mg/8h 3 months
1686976|NCT01564823|Drug|Azathioprine|Azathioprine: 2.5 mg/kg of weight/day. 3 months.
1686977|NCT01564823|Drug|Adalimumab|Adalimumab 160 mg then 80 mg. After 2 wk: 40 mg as maintenance.
1686978|NCT01564810|Drug|Cetuximab|On day 1 of a 14 day treatment cycle, patients received a 2-hour infusion of cetuximab (initial dose 400 mg/m2 in week 1, and 250 mg/m2 weekly during 1 hour thereafter) followed after 1 hour by chemotherapy of FOLFOX or FOLFIRI until progressive disease or unacceptable toxicity.
1686979|NCT01564810|Drug|chemotherapy of mFOLFOX6 or FOLFIRI|FOLFOX-4 (oxaliplatin, 85mg/m2 on day 1 infused during 2 hours;LV200mg/m2ondays 1and 2 infused during 2 hours, together with or following oxaliplatin; followed by FU 400 mg/m2 intravenous bolus then 600 mg/m2 intravenous infusion over 22 hours on days 1 and 2) FOLFIRI(irinotecan 180mg/m2 on day 1 infused during 2 hours; fluorouracil in a bolus of 400 mg/m2 and then continuous infusion for 46 hours of 2400 mg/m2)
1686980|NCT01564797|Behavioral|Home Health Party|An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
1686985|NCT01564771|Other|Non Intervention|This Is A Non Interventional Study
1686986|NCT01564758|Drug|Linezolid|"Vancomycin-resistant, E. faecium, including concurrent bacteremia: Linezolid for 600mg (IV or oral) every 12 hours for 14-28 days
Nosocomial infection, cSSTI: Linezolid for 600mg (IV or oral) every 12 hours for 10-14 days
Uncomplicated SSTI: Linezolid for 400mg oral every 12 hours for 10-14 days"
1686987|NCT01564745|Other|Functional respiratory evaluation|Each enrolled patients has a pulmonary function test before and after extubation, and repeatedly at D1, D3, D5 (if they are always hospitalized)
1686988|NCT01564732|Device|Standard-LAGB|The laparoscopic adjustable gastric banding (LAGB) procedure is a safe, effective, and durable treatment option for refractory morbid obesity and its related health consequences.5 This minimally invasive technique is now a popular approach for bariatric surgery, and it offers obvious advantages such as decreased operating time, shorter hospital stay (often same day surgery), and favorable complication rates as compared with other bariatric procedures.
1686989|NCT01564732|Device|Plicated-LAGB|"At the time of LAGB placement, plication sutures can be placed along the body & greater curvature of the stomach to tighten and cinch up the stomach in a sleeve-like orientation. It was recently reported that this modified technique of plicated LAGB could result in lower band slippage complication rates and faster, early weight loss."
1686990|NCT01564719|Behavioral|Holistic health|We conceptualize this as a holistic health intervention because it has components involving the mind, body, and spirit. The stress reduction program Williams LifeSkills, adapted for clergy; the 10-session online weight loss program Naturally Slim Foundations plus its 7-session online booster program, Naturally Slim Advanced; monthly phone conversations with Wellness Advocates who function as health coaches; $500 small grants to use to promote health; and three in-person workshops that cover the theology of the body and incarnation and provide the religious rationale for caring for the mind and body.
1686991|NCT01564706|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
1686992|NCT01564680|Other|placebo|normal saline
1686993|NCT01564680|Drug|Paracetamol|IV paracetamol infusion
1686994|NCT01564680|Drug|Lornoxicam|16 mg at skin closure and 8 mg 12 hours postoperative
1686995|NCT01564667|Behavioral|Attention Bias Modification Training Protocol|Attention Bias Modification computerized training sessions administered 2 times per week for 4 weeks making a total of 8 training sessions.
1686997|NCT01564641|Device|iDuo G2|single comparator
1686998|NCT01564628|Device|Acoustic recording. *CAD Patch System' Prototype no. 3.0. Manufactured by Acarix A/S, Denmark|
1686999|NCT01564615|Device|Umbilical catheterization (AgION )|Infants received a AgION impregnated catheter (4.0-5.0 F Lifecath PICC ExpertTM, Vygon, Ecouen, France).
1687000|NCT01564615|Device|Umbilical catheterization (ArgyleTM)|Infants received a polyurethane non-impregnated catheter (3.5-5.0 F ArgyleTM, Kendall, Tullamore, Iceland)
1687001|NCT01564602|Device|comparison multiple channel port laparoscopic surgery|to compare 2-channel single port and multiple channel port laparoscopic surgery
1687002|NCT01564576|Drug|Profound neuromuscular blockade (Rocuronium, Rocuronium bromide, sugammadex, Bridion)|Rocuronium dose will be adjusted to maintain a depth of NMB of zero response to train of four and a post tetanic count of no more than 10 responses. At the end of surgery patients will receive a single bolus dose of 4 mg/kg sugammadex according to ideal body weight + 40%12. Extubation will be performed when train-of-four ratios ≥ 0.9.
1687003|NCT01564563|Drug|standard therapy|Standard treatment of bleeding
1687004|NCT01564563|Drug|placebo|Placebo
1687005|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
1687006|NCT01564563|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
1687007|NCT01564550|Drug|Insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
1687189|NCT01563120|Drug|metformin|metformin up to 2550mg per day.
1687008|NCT01564550|Drug|insulin|Insulin is given as a constant infusion( 0,6 mU/kg/min) during the hyperinsulinemia period of the study lasting four and a half hour.
1687009|NCT01564550|Other|diet|The subjects ingest a three day isocaloric diet (55 % carbohydrate,30% fat, 15 % protein)prior to the study day.
1687010|NCT01564550|Other|no diet|The subjects will ingest a non-restricted diet prior to the study day.
1687011|NCT01564537|Drug|Ixazomib|Ixazomib capsules
1687012|NCT01564537|Drug|Lenalidomide|Lenalidomide capsules
1687013|NCT01564537|Drug|Dexamethasone|Dexamethasone tablets
1687014|NCT01564537|Drug|Placebo|Ixazomib placebo-matching capsules
1687015|NCT01564524|Procedure|Fat graft surgical procedure|The fat graft surgical procedure will concentrate the adipose stromal cells (ASCs) in the fat graft material. A blunt tip hollow cannula is used to aspirate approximately 200-400cc of fat tissue. The aspirated fat is divided into two portions: one portion will be processed as standard graft material, the other portion will be used in a processing step that concentrates the ASCs. The aspirated fat processed as standard graft material will be divided into small alioquots and centrifuged to separate the aqueous and oil layers, and transferred into 1ml syringes. Standard fat graft material will serve as a control treatment and will be injected into one area of the face. The ASC concentrated graft material will be processed so it first separates the ASCs in a brief collagenase digestion and then resuspends the ASCs in the native fat tissue from which the stromal cells were derived. The ASC concentrated fat will be injected into another region of the face.
1687016|NCT01564511|Device|Gait trainer treatment|Patients will be subjected to 40 minutes of repetitive locomotor therapy on the Gait Trainer (GTI) (Reha-Stim, Berlin, Germany), followed by 10 minutes of passive joint mobilization and stretching exercises. The first 40 min session will be divided as follow: 15 min gait training; 5 minutes at rest; 15 minutes gait training; 5 minutes at rest. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion.
1687017|NCT01564511|Other|Conventional treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
1687018|NCT01564498|Other|vegetable|200-300 g raw carrots or 300-500 g cooked potatoes
1687019|NCT01564485|Procedure|Cardiac CT|A cardiac CT involves a non-invasive test of the coronary arteries.
1687020|NCT01564485|Drug|Usual medical care|Patients would be treated by their primary care physicians with usual medical care with drugs such as lipid lowering medication, blood pressure lowering medications, and blood glucose lowering medications. The study will not specify which drugs to use and will it up to the individual physician's discretion.
1687021|NCT01564472|Other|PSG Scoring|No participants will be enrolled and no interventions, besides PSG scoring will be utilized.
1687022|NCT01564459|Drug|MK-6096|MK-6096 10 mg compressed tablets, taken once daily at bedtime for 14 days.
1687023|NCT01564459|Drug|Placebo|Matching compressed tablets, taken once daily at bedtime for 14 days.
1687024|NCT01564446|Other|Participants will receive a internet based secure message confirming adherence to post-discharge medication regimen|Participants will receive a internet based secure message via My HealtheVet (MHV), The VA's online medical record and secure messaging portal. The message will specify post-discharge prescribed medications and inquire about adherence to these medications.
1687025|NCT01564433|Procedure|Device: Electromechanical gait trainer|The experimental group will be subjected to 12-30 minute session (3 per week: Monday, Wednesday, Friday) of repetitive locomotor therapy on the Gait Trainer (Reha-Stim, Berlin, Germany), followed by 20 minutes of passive joint mobilization and stretching exercises. The GT-I consists of a double crank and rocker gear system, composed of two footplates positioned on two bars (coupler), two rockers, and two cranks that provide the propulsion. While using the gait trainer, individuals are secured in a harness and positioned on two footplates, whose movements simulate stance and swing phase, with a ratio of 60% to 40% between the two phases. The body weight was initially reduced by 30% and then progressively increased.
1687026|NCT01564433|Procedure|Convetional control treatment|The control group will be subjected to a conventional treatment that will consist of three different sets of exercises: 1) passive joint mobilization and stretching of lower limb muscles; 2) muscle strengthening exercises; 3) gait exercises. Each set of exercises lasted 10, 15 and 15 min, respectively with 2,5 min at rest between each set for a total of 40 minutes.
1687027|NCT01564407|Drug|ICX‐RHY‐013|"Drug Dosing for Cohorts as follows:
Cohorts (N=4)
Safety Cohort 1:
Empty control no injection
Vehicle only (0.5 ml of HypoThermosol solution)
5 million cells / cm² , single administration at Day 0
5 million cells/ cm² , single administration at week 4
5 million cells/cm² , single administration at Day 0 , repeat administration of this dose @ week 4
At day 0, the subject will receive a total of 3 different injections and at week 4 the subject will receive a total of 2 different injections.
Cohort 2: 2.5 million cells/ cm2, single administration Cohort 3: 5 million cells /cm2, single administration Cohort 4: 2.5 million cells/ cm2, repeat dose administration @ 4 weeks Cohort 5: 5million cells / cm2 repeat dose administration @ 4 weeks"
1687028|NCT01564394|Behavioral|Qigong|Classes will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. The classes will be led by a trained Qigong instructor and consist of postures, movements, deep breathing techniques and meditation. It will include eccentrically-biased Qigong movements with an emphasis on weight shifting and posture control. The continuous body movements coupled with progressively diminishing base of support, dynamic challenge to balance, and concentration on body positions requiring eccentric muscle activity should improve the levels of fatigue and quality of life in older prostate cancer survivors.
1687029|NCT01564394|Behavioral|Non-aerobic stretching|The non-aerobic stretching classes will serve as an attention control. They will be 60 minutes in duration, held two times a week, supplemented with home-based sessions over 12 weeks. They will be led by an Huntsman Cancer Institute (HCI) fitness specialist and will consist of light stretching exercises; while avoiding a focus on meditation.
1687030|NCT01564381|Dietary Supplement|ResA|90mg of resveratrol conjugated with arginine.
1687031|NCT01564381|Dietary Supplement|Resveratrol|90mg of resveratrol.
1687032|NCT01564381|Dietary Supplement|Placebo|Made up of cellulose.
1687190|NCT01563120|Drug|glybenclamide|glybenclamide up to 20mg per day.
1687033|NCT01564368|Procedure|diffusion-weighted magnetic resonance imaging|diffusion-weighted magnetic resonance imaging examination and subsequent radiologist interpretation
1687034|NCT01564355|Device|Steroid-eluting middle meatal spacer (Nasopore (TM) spacer impregnated with 1 cc of 40mg/mL triamcinolone liquid)|All study arms will receive bilateral Nasopore spacers impregnated with 1 cc of Triamcinolone to remain in the nasal cavity for 1 week post-operatively as per usual protocol.
1687035|NCT01564355|Drug|Post-op Oral Steroids|Post-operative oral prednisone 20 mg QD x 5 days , then 10 mg x 5 days, as per usual protocol.
1687036|NCT01564342|Procedure|wound irrigation with study fluid|wounds were either irrigated with sterile normal saline or tap water.
1687037|NCT01564329|Drug|endostar|Endostar TM 7.5mg/m2,intravenous drip, Day 1to Day 10;Pemetrexed 500mg/m2, intravenous drip, Day 6; Carboplatin AUC=5,intravenous drip, Day 6; 21 days as a cycle, 4 cycles in all.
1687038|NCT01564303|Drug|Acetylcysteine, Phosphodiesterase type 5 inhibitor ,Carnitine|to evaluate the effect of the above agents on Kidney functioning parameters
1687039|NCT01564290|Dietary Supplement|Probiotic yogurt|Lactobacilus Rhamnonsus 100000000 UFC per mL. Dosage 50 mL twice daily fo 5 days.
1687040|NCT01564290|Drug|Placebo probiotic|Lyophilized probiotic, containing 250 mg per sachet dosage to about 2 times a day for 5 days.
1687043|NCT01564264|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy after injections of 0.4 mci of Technetium 99 in the cervix and 4 mL of Patent Blue into the myometrium followed by standard retroperitoneal lymph node dissection
1687044|NCT01564251|Drug|GDC-0575|Participants will receive GDC-0575 orally at a starting dose of 15 mg.
1687045|NCT01564251|Drug|Gemcitabine|Participants will receive gemcitabine intravenously at a dose of 1000 mg/m^2 and/or 500 mg/m^2.
1687046|NCT01564238|Other|Low Na diet (1.3 g/d)|20 day controlled feeding study (live in) providing 1.3 grams per day of sodium.
1687047|NCT01564238|Other|High sodium diet (3.8 g/d)|20 day controlled feeding study (live in) providing 3.8 grams per day of sodium.
1687048|NCT01564225|Drug|EDI200|Cohort 1 will be dosed at 3 mg/kg/dose. Cohort 2 will be dosed at 10 mg/kg/dose. Both cohorts will receive 2 doses/week for a total of 5 doses.
1687049|NCT01564212|Other|standard airflow with forced air warming.|Subjects will lie on operating room bed with standard airflow and forced air warming.
1687050|NCT01564212|Other|laminar airflow with surgical drapes|
1687051|NCT01564212|Other|laminar airflow with forced air warming|Subjects will lie on operating room bed with laminar airflow and forced air warming.
1687052|NCT01564212|Other|standard airflow with surgical drapes|Subjects will lie on operating room bed with standard airflow on and surgical drapes surrounding bed.
1687053|NCT01564199|Drug|salmeterol / fluticasone propionate|100/1000 μg oral capsule
1687054|NCT01564160|Dietary Supplement|Fish Oil|Source of omega-3 fatty acids.
1687055|NCT01564160|Dietary Supplement|PCSO-524|Extract of Greenshell Mussel
1687056|NCT01564147|Other|immediate therapeutic education|Access to the course of immediate therapeutic education
1687057|NCT01564147|Other|therapeutic education delayed|Group receiving therapeutic education 6 months later (control group)
1687058|NCT01564134|Biological|hepatitis B vaccine|hepatitis B vaccine with 5ug,10ug,20ug,60ug HBsAg
1687059|NCT01564121|Drug|acid Zoledronic|Treatment with zoledronic acid will be initiated during hospitalization, the day after the removal of redundant. Intravenous injection of 4 mg. of zoledronate diluted in sodium chloride 9 / 1000 or a solution of 5% dextrose in intravenous over 15 minutes. In the absence of intolerance clinic, an infusion of zoledronic acid in the same doses and modalities will be performed in a hospital (on the occasion of a follow-up visit after surgery) at the 3rd, 6th, 9th and 12th weeks after the first, or 5 injections. )
1687060|NCT01564108|Drug|Ranibizumab|Series of intravitreal injections of Ranibizumab
1687061|NCT01564095|Drug|Tacrolimus|Marginal liver grafts are flushed with Tacrolimus (20ng/ml) solved in 1000 ml HTK preservation solution (duration: 15 min) ex vivo at the end of backtable preparation in the experimental group.
1687062|NCT01564095|Drug|HTK/Placebo|Marginal liver grafts are flushed with 1000 ml HTK preservation solution(duration: 15 min) ex vivo at the end of backtable preparation in the placebo group.
1687063|NCT01564082|Device|ETT First (GlideScope)|Patients will have the endotracheal tube (ETT) introduced into the pharynx under direct vision prior to GlideScope insertion. The ETT will then be advanced under GlideScope guidance into the trachea.
1687064|NCT01564056|Drug|HORMONOTHERAPY|"Hormonotherapy will be administered during 5 years following chemotherapy when allocated.
(Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
1687065|NCT01564056|Drug|CHEMOTHERAPY then HORMONOTHERAPY|"CHEMOTHERAPY regimen will be chosen amongst the following ones:
i) 4 cycles of TC (docetaxel + cyclophosphamide)
Docetaxel 75 mg/m² IV infusion at hospital every 21 days
Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days
ii) 4 cycles of AC (doxorubicin + cyclophosphamide)
Doxorubicin 60 mg/m² IV infusion at hospital every 21 days
Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days
iii) 4 cycles of MC (liposomal non pegylated doxorubicin [Myocet®]+ cyclophosphamide)
Myocet® 60 mg/m² IV infusion at hospital every 21 days
Cyclophosphamide 600 mg/m² IV infusion at hospital every 21 days
HORMONOTHERAPY (Tamoxifen, aromatase inhibitor or sequential hormonotherapy) is left to the investigator judgement in both groups (I and II)."
1687066|NCT01564043|Behavioral|website and pedometer|use of pedometer and website
1687067|NCT01564030|Other|Empty|overnight fast
1687068|NCT01564030|Other|Fluid|250mL apple juice
1687069|NCT01564030|Other|Solid|breakfast
1687070|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension fpor subcutaneous injection
Increasing concentrations to reach the following maintenance doses:
Group 1: 0.25 SPT"
1687071|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.
Increasing concentrations to reach the following maintenance doses:
Group 2: 0.5 SPT"
1687072|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.
Increasing concentrations to reach the following maintenance doses:
Group 3: 1 SPT"
1687073|NCT01564017|Biological|Allergovac depot|"depot sterile suspension for subcutaneous injection
Increasing concentrations to reach the following maintenance doses:
Group 4: 2 SPT"
1687074|NCT01564017|Biological|Allergovac depot|"Depot sterile suspension for subcutaneous injection.
Increasing concentrations to reach the following maintenance doses:
Group 5: 4 SPT"
1687075|NCT01564017|Biological|Allergovac depot|"Sterile suspension for subcutaneous injection.
Same number of administration as the active groups"
1687076|NCT01564004|Other|Clinical hypnosis or neuro-linguistic programming|20 minutes tape recording intervention
1687077|NCT01563991|Procedure|Normal fluid volume|Normal fluid group will receive lactated ringes at 8 cc / Kg/ hr total
1687078|NCT01563991|Procedure|Reduced fluid volume|Subject receives 80 cc/ hr LR during the peri-operative period
1687079|NCT01563978|Drug|fostamatinib|fostamatinib 100 mg twice daily
1687080|NCT01563978|Drug|placebo|placebo
1687081|NCT01563965|Dietary Supplement|Carbohydrate plus hydrolyzed protein beverage|The study group received 400 ml (evening drink) or 200 ml (3h prior to operation drink) of a solution containing 11% de protein (pea hydrolized proptein), 89% de carbohydrates (maltodextrin 79% and saccharose 21%) e 0% of lipids (Providextra, Fresenius Kabi, São Paulo, Brasil). All the patients fasted for solids at least 6 hours from the operation
1687082|NCT01563965|Other|Preoperative fasting of 8h|Conventional protocol of 8h fasting before an operation
1687083|NCT01563952|Device|Non-IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
1687084|NCT01563952|Device|IVUS guided intervention with Endeavor Resolute stent (zotarolimus-eluting stent, Medtronic)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
1687085|NCT01563952|Device|Non-IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
1687086|NCT01563952|Device|IVUS guided intervention with Nobori stent (biolimus A9-eluting stent, Terumo)|2x2 randomization by the treatment of IVUS-guided intervention vs. Non-IVUS guided intervention and the types of the implanted DES, Endeavor-R vs. Nobori.
1687087|NCT01563939|Drug|Remifentanil|"Remifentanil IV for continuous infusion: 0.025mcg/kg/min, increased by 0.025mcg/kg/min every 15 min if patient is not satisfied, to a maximum of 0.15mcg/kg/min.
Remifentanil IV for demand bolus: 0.2 mcg/kg, lockout 2 min, incrementally increased if patient is not satisfied by 0.2 mcg/kg to a maximum of 1.2 mcg/kg."
1687088|NCT01563926|Drug|somatropin|Dosed by individual needs as judged by the Investigator (trial physician). Injected subcutaneously (s.c./under the skin)
1687091|NCT01563900|Device|Auto-titration CPAP|An auto-titration CPAP will be set at a pressure between 5 to 15 cwp. This device delivers pressure as needed by the patient at any given time while using the device.
1687092|NCT01563900|Device|Sham-CPAP|The sham-CPAP device will be set at 4 centimeters of water pressure (cwp). An exhalation connector will be place between the mask interface and the tubing without the enlarged port to maintain blinding; the final pressure delivered to the participant will be 2 cwp.
1687093|NCT01563887|Behavioral|DD.com|Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
1687094|NCT01563887|Behavioral|DD.com + MI|Prior to starting and immediately after finishing the DiabetesDriving.com internet intervention, a one hour motivational interview will be conducted with participants. Internet intervention in which participants will complete 6 Cores, or classes over the internet, focusing on risk factors and prevention, detection, and management of hypoglycemia before and while driving.
1687095|NCT01563861|Genetic|RNA analysis|
1687096|NCT01563861|Genetic|gene expression analysis|
1687097|NCT01563861|Other|immunohistochemistry staining method|
1687098|NCT01563861|Other|laboratory biomarker analysis|
1687099|NCT01563848|Procedure|Cryoballoon ablation|After double transseptal puncture, selective PV angiography was performed to identify the PV ostia in 2 projections (right anterior oblique 30º, left anterior oblique 40 º). Baseline potentials of all PVs were recorded with a Lasso catheter (Biosense Webster, Inc., Diamond Bar, California). To assess the exact position of the inflated balloon in relation to the left atrial (LA)-PV junction, contrast medium was injected from the distal lumen of the cryoballon catheter . CBA was performed for a target time of 300 seconds. The right phrenic nerve was constantly paced from the superior caval vein during freezing at the septal PVs. After each freeze, PV conduction was revaluated by the Lasso catheter.
1687100|NCT01563848|Procedure|Implantation of loop recorder|"The RevealXT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
Patients were provided with the Patient Assistant, a toolthat allows each patient to store the ECG through the implanted device during symptoms: datawere collected in order to analyze heart rhythm during symptomatic events"
1687101|NCT01563848|Procedure|Radiofrequency ablation|Externally-irrigated tip (5-mm tip, Celsius Thermo-Cool, Biosense Webster, Diamond Bar, CA, USA). Temperature-controlled RF delivery was performed with a maximum power output of 50 W and temperature limit of 50 C. The catheter was irrigated using 0.9% saline infusion at a ﬂow rate of 20-40 mL/min during RF delivery and 2 mL/min between applications using a commercially available pump (Cool Flow, Biosense Webster).
1687102|NCT01563835|Drug|bupivacaine, fentanyl|10mL of 0.125% of bupivacaine plus 50 mcg fentanyl, injected through an epidural catheter.
1687103|NCT01563835|Drug|fentanyl|fentanyl IV PCA with boluses 25-50 mcg, 3-6 minute lockout.
1687104|NCT01563822|Biological|Follicular fluid|The intervention is flushing the uterine cavity with 2 ml of clear follicular fluid surrounding mature oocytes after ovum pick-up through an IUI catheter
1687105|NCT01563809|Drug|FSH+LH|75 IU of LH will be given from stimulation day 1
1687106|NCT01563809|Drug|FSH+LH|75 IU of LH will be given from stimulation day 1
1687107|NCT01563783|Procedure|Global Fibroid Ablation (GFA)|GFA is being used for the treatment of symptomatic uterine fibroids
1687108|NCT01563783|Procedure|Abdominal or Laparoscopic Myomectomy|Myomectomy is a procedure in which uterine fibroids are surgically removed from the uterus.
1687109|NCT01563783|Procedure|Uterine Artery Embolization (UAE)|UAE is a minimally invasive surgical procedure used to treat uterine fibroids.
1687110|NCT01563770|Dietary Supplement|Salvia miltiorrhiza extract|3 capsules of 500 mg Salvia miltiorrhiza extract, twice daily for four consecutive weeks
1687111|NCT01563770|Dietary Supplement|Placebo|3 placebo capsules, twice daily for four consecutive weeks
1687112|NCT01563744|Procedure|EGD-assisted administration of colonoscopy prep|Interventional group receive the first 2 liters of prep solution during EGD through the scope channel if colonoscopy expected the following day.
1687113|NCT01563744|Procedure|Control Group received standard prep by oral administration|Control group receive standard oral colonoscopy prep.
1687114|NCT01563731|Drug|all approved antihypertensive drugs; all approved statins|All drugs to be used at doses capable of bringing SBP and LDL-C to targets; only doses approved in each country.
1687115|NCT01563718|Drug|naltrexone for extended release injectable suspension|VIVITROL (naltrexone for extended-release injectable suspension) is supplied as a microsphere formulation of naltrexone for suspension, at a dose of 4cc (380mg of naltrexone base), administered by intramuscular injection to the buttocks (alternating sides monthly) for six months.
1687116|NCT01563705|Procedure|Different motor function tests|Time to rise from a chair, time to go from lying to sitting, time to go from lying to standing, time to cover 10 meters, time to climb 4 steps
1687117|NCT01563705|Procedure|Manual dexterity assessment|Purdue pegboard test
1687118|NCT01563653|Procedure|4 diagnostic tests for surgical success|Q-tip test, Bonney maneuver, TVT maneuver, clip strip test
1687119|NCT01563640|Other|permethrin insecticide|commercial permethrin insecticide impregnation of clothing before transmission season
1687120|NCT01563640|Other|washing|normal washing of school uniforms, without permethrin insecticide impregnation
1687121|NCT01563627|Other|blood sampling for drug resistance biomarkers|comparison of Inflammatory Factors, Immune and Angiogenic in Temporal Lobe Epilepsy
1687122|NCT01563627|Device|Magnetic Resonance Imaging|
1687123|NCT01563614|Radiation|Brain radiotherapy (WBRT alone, SRT/SRS alone or WBRT plus SRT/SRS)|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
1687124|NCT01563614|Drug|Lomustine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
1687125|NCT01563614|Drug|Liposomal cytarabine|Brain radiotherapy concomitant to lomustine and liposomal cytarabine chemotherapy.
1687126|NCT01563601|Drug|Obatoclax Mesylate, Carboplatine and Etoposide|"Obatoclax Mesylate:
30 mg fixed dose;administered IV on days 1-3 every 21 days for 6 cycles. Maintenance therapy (optional and only if documented CR or PR) with obatoclax mesylate is administered at the same IV dose on days 1-3 every 21 days until disease progression or death.
Carboplatin:
Dose targeted at AUC of 5; administered IV on Day 1 only every 21 days for 6 cycles
Etoposide:
100mg/m2 administered IV on Days 1-3 every 21days for 6 cycles"
1687127|NCT01563601|Drug|Carboplatin and Etoposide|"Carboplatin:
Dose targeted at AUC of 5 administered IV on Day 1 only every 21 days for 6 cycles.
Etoposide:
100mg/m2 administered IV on Days 1-3 every 21 days for 6 cycles"
1687128|NCT01563588|Behavioral|dietaty education, physical training, physiotherapy and SPA cares|12 days session of daily physical training, dietary education, physiotherapy and SPA cares in small group (less than 12 women) delivered in hydrothermal centers
1687129|NCT01563575|Other|fast-track implementation process|Undergo fast-track implementation process (WHO-HPH recognition Process), including: baseline data collection, quality plan, implementation for one year, follow-up data collection, revision of quality plan, external site visit and data validation
1687130|NCT01563562|Drug|Bardoxolone Methyl|Oral, Single dose
1687131|NCT01563536|Drug|ABT-267|Tablet
1687132|NCT01563536|Drug|ABT-450|Tablet
1687133|NCT01563536|Drug|ABT-333|Tablet
1687134|NCT01563536|Drug|Ritonavir|Capsule
1687135|NCT01563536|Drug|Ribavirin|Tablet
1687136|NCT01563523|Drug|activated recombinant human factor VII|Standard therapy in conjunction with three single doses of rFVIIa administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
1687137|NCT01563523|Drug|placebo|Standard therapy in conjunction with three single doses of placebo administered over a 3 hour period. Administered once the subject has received 8 units of PRBC
1687138|NCT01563510|Procedure|Laparoscopic operation|Fifty patients with early regional hepatolithiasis were selected and divided into laparoscopic hepatectomy group as described in the detailed description. Total laparoscopic anatomical hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound, choledochoscope and hepatic segmental staining were used selectively.
1687139|NCT01563510|Procedure|Open operation|Fifty patients with early regional hepatolithiasis were selected and divided into open group as described in the detailed description. The traditional open regular hepatectomy were performed, combined with cholecystectomy and bile duct exploration when necessary. The intraoperative ultrasound and choledochoscope were used selectively.
1687140|NCT01563497|Drug|PF-05089771|Oral dispersion TS formulation- fasted
1687141|NCT01563497|Drug|PF-05089771|Tablets TS formulation- fasted
1687142|NCT01563497|Drug|PF-05089771|Tablets TS formulation- fed
1687143|NCT01563471|Drug|activated recombinant human factor VII|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
1687144|NCT01563471|Drug|placebo|Subjects will be randomised to one of four treatment sequences. Subjects will receive single bolus i.v. injection of 40, 80 or 160 mcg/kg body weight of trial drug or placebo on each day of the three separate visits
1687145|NCT01563458|Drug|activated recombinant human factor VII|120 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 120 mcg/kg single bolus administration at completion of wound closure
1687146|NCT01563458|Drug|activated recombinant human factor VII|60 mcg/kg into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. 60 mcg/kg single bolus administration at completion of wound closure
1687309|NCT01562223|Other|motexafin gadolinium|
1688391|NCT01552733|Other|Standard of care|Rehabilitation Therapy
1687147|NCT01563458|Drug|placebo|Trial drug into the vein (i.v.) bolus injection first administered immediately prior to first skin cut. Repeated every two hours until approx. 30 minutes prior to expected start of the reperfusion of the transplanted liver. Single bolus administration at completion of wound closure
1687148|NCT01563445|Drug|activated recombinant human factor VII|Subjects will be randomised to receive a single intravenous dose of either 5, 20, 40 and 80 mcg/kg body weight. Administered within the first 4 hours after the insult
1687149|NCT01563445|Drug|placebo|Subjects will be randomised to receive a single intravenous dose. Administered within the first 4 hours after the insult
1687150|NCT01563432|Drug|Feburic®|80 mg*1 tablet
1687151|NCT01563432|Drug|TMX-67|40 mg*2 tablets
1687152|NCT01563419|Device|Indicator magnifying window (Izumi Planning Co.)|"IZUMI PLANNING CO,.LTD.Tokyo.Japan
Material: Polypropylene with polycarbonate lens"
1687153|NCT01563406|Other|15 second scrub|Scrub catheter hubs for 15 seconds before every access.
1687154|NCT01563406|Other|5 second scrub|Scrub catheter hubs for 15 seconds before every access.
1687155|NCT01563406|Drug|3.15% chlorhexidine/70% isopropyl alcohol|3.15% chlorhexidine gluconate in 70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters during half of the study period.
1687156|NCT01563406|Drug|70% isopropyl alcohol|70% isopropyl alcohol pads will be used to disinfect catheter hubs prior to accessing central venous catheters for the other half of the study period.
1687157|NCT01563393|Other|questionnaire STAMP and dietary|Children will undergo a complete evaluation by an investigating dietician and assessment by the STAMP tool in order to determine the extent of the nutritional risk on a numerical scale. According to findings children will get the dietary recommendations.
1687158|NCT01563393|Other|No intervention|The Placebo Comparator arm children got the classic care that practiced in hospitalization
1687159|NCT01563380|Biological|Platelet rich plasma|PRP ready to be injected was supplied in a syringe in a quantity of 8 ml for each knee. The entire procedure was done under complete aseptic precautions. The calcium chloride required for activation was given in a separate syringe in a ratio of 4:1. About 12-16 ml of platelet rich plasma was obtained by this method and it was used for application. To confirm sterility, culture and sensitivity of PRP was performed. Patient's peripheral blood platelet count and the prepared platelet concentrate's platelet count was performed and recorded. Number of tramadol injections given was also noted
1687160|NCT01563367|Drug|Iron isomaltoside 1000 (Monofer®)|All subjects randomised to this group will receive 1000 mg iron isomaltoside 1000 as a single dose infusion administered over 15 minutes
1687161|NCT01563367|Drug|Natriumklorid 9 mg/ml, Fresenius Kabi|All subjects randomised to this group will receive an infusion of 100 ml 0.9% sodium chlorid administered over 15 min.
1687162|NCT01563354|Drug|Pasireotide LAR|60 mg i.m. injected once every 28 days
1687163|NCT01563354|Drug|Everolimus|10 mg p.o. daily
1687164|NCT01563354|Drug|Pasireotide LAR + Everolimus|Pasireotide LAR 60 mg i.m. injected once every 28 days + Everolimus 10 mg p.o. daily
1687165|NCT01563341|Device|Deep brain stimulation|Study will be utilizing multiple brain electrodes simultaneously. The study will require at least two electrodes to be placed in one cerebral hemisphere (one for motor improvement and one for potential cognitive implications).
1687166|NCT01563328|Drug|DTG|50 mg q24h
1687167|NCT01563328|Drug|BCV|800 mg q8h
1687168|NCT01563328|Drug|TVR|750 mg q8h
1687169|NCT01563302|Drug|IONIS-STAT3Rx|Three-hour IV infusions on Cycle 0 Days 1, 3, 5, and weekly three-hour IV infusions in Cycles 1 and beyond, on Days 1, 8, and 15 of each cycle.
1687170|NCT01563289|Drug|Ibuprofen|3 times a day
1687171|NCT01563289|Drug|Placebo|3 times a day
1687172|NCT01563263|Biological|IC43|100 mcg
1687173|NCT01563263|Drug|Placebo|phosphate buffered saline (PBS) solution containing 0,9 % NaCl
1687174|NCT01563250|Device|Point of Care testing|"The investigators will implement 6 months of randomized testing periods, 2 weeks each. During this 2 week block, cardiac biomarkers will be tested at the bedside in the ED using the Triage Cardiac Panel that will test for CK-MB, Myoglobin, and Troponin I.
Each blood sample that is take for point of care testing will be saved. The plasma from the saved sample will be frozen and the sample will be sent to an off-site testing center for high sensitivity troponin testing.
All patients will be followed at the 30-day mark and those patients who are discharged home from the ED will be followed within 48 hours as well."
1687175|NCT01563237|Device|MIDI Arrow|Implantation of MIDI Arrow
1687176|NCT01563224|Drug|Baclofen 10mg|Baclofen 10mg single dose po
1687177|NCT01563224|Drug|Baclofen 60mg|Baclofen 60mg single dose po
1687178|NCT01563224|Drug|placebo|placebo
1687179|NCT01563198|Behavioral|Comfort Talk®|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post-training support, and access to a post-training support web module resulting in at least 20 hrs training.
1687180|NCT01563185|Drug|800 mg ibuprofen/26.6 mg famotidine|Oral tablet taken three time per day
1687181|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 0.5g|Dentifrice containing 1150 parts per million (ppm) fluoride as sodium fluoride / silica and 0.4% carbopol
1687182|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 1150 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
1687183|NCT01563172|Drug|Sodium fluoride / silica and carbopol, 1.5g|Dentifrice containing 250 ppm fluoride as sodium fluoride / silica and 0.4% carbopol
1687184|NCT01563172|Other|Fluoride free dentifrice|A non fluoride dentifrice was given to participants of each arm at washout period
1687185|NCT01563159|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2010- May 31st 2011) and analysed for rotavirus, in children aged ≤5 years.
1687186|NCT01563146|Other|Data collection|Each participating centre will be requested to generate a coded list of all stool samples taken during the study period (June 1st 2006- May 31st 2007) and analysed for rotavirus, in children aged ≤5 years.
1687187|NCT01563133|Procedure|EUS-FNA|Endoscopic ultrasound fine needle aspiration: ultrasound endoscopy of a lesion with aspiration of the lesion fluid through a needle
1687188|NCT01563133|Device|nCLE|needle-based Confocal Laser Endomicroscopy
1687191|NCT01563107|Radiation|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
1687192|NCT01563107|Procedure|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
1687193|NCT01563107|Procedure|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
1687194|NCT01563081|Drug|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered once daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning to infants aged between 6 months and 1 year old
1687195|NCT01563081|Drug|Levocetirizine|Clear solution, 0.50 mg levocetirizine dihydrochloride contains in one milliliter of the solution. Levocetirizine oral solution are administered twice daily at a dose of 2.5 mL (1.25 mg of levocetirizine) in the morning and evening before sleep to infants aged between 1 year and 2 years old
1687196|NCT01563068|Drug|Calcipotriene 0.005% Foam|Topical application applied twice a day for 15 days
1687197|NCT01563055|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
1687198|NCT01563055|Drug|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
1687199|NCT01563042|Drug|Intravenous (IV) single dose|GSK2434735 administered as a single intervenous dose at the beginning of the study
1687200|NCT01563042|Drug|Subcutaneous (SC) single dose|GSK2434735 administered as a single subcutaneous dose at the beginning of the study
1687201|NCT01563029|Drug|Fluticasone Furoate|current asthma medicine
1687202|NCT01563029|Drug|Fluticasone Propionate|Fluticasone propionate
1687203|NCT01563029|Drug|Placebo|placebo
1687204|NCT01563016|Dietary Supplement|glucose drink|participants will receive a drink rich in glucose
1687205|NCT01563003|Other|Cognitive Behavioral Therapy|This condition involves 16 weekly CBT sessions.
1687206|NCT01563003|Other|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
1687207|NCT01562990|Drug|Rituximab, CMC544, Gemcitabine and Oxaliplatine|"2 cycles of induction of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43.
2 cycles of consolidation of 56 days each, starting with the administration of R-CMC544 on day 1, followed by the administration of R-GEMOX on day 29 and 43."
1687209|NCT01562964|Behavioral|Hypnotherapy|Ten pain control hypnotherapy session will run for 50-60 minutes each. In the first session a thorough history will be taken of the patient's chest pain history together with both the sensory and affective components of their pain. If there is time, relaxation technique and self-hypnosis will be taught at this visit. In subsequent sessions, various techniques, including techniques that focus on direct suggestions and imagery work, will be applied and taught to the patient. The pain control techniques are all analgesic in nature - focusing on the reduction, but not the total removal of the pain. A small amount of pain is left behind to serve as a reminder that either something is wrong or that the patient needs to take it easy.
1687210|NCT01562964|Behavioral|Supportive therapy|Subjects in the Supportive therapy group will attend the Royal Brompton Hospital weekly for 10 weeks to meet with person of equal status to the hypnotherapist (e.g. a research assistant, not a medical practitioner) trained to provide counseling and support. Visits will last 50-60 min.
1687211|NCT01562951|Drug|ADALIMUMAB|Adalimumab at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly.
1687212|NCT01562951|Drug|Placebo|PLACEBO at 160/80 mg and maintained on 40 mg eow until next colonoscopy performed at week 48. If before week 48, an increase of more than 50% is observed in calprotectin and/or hsCRP from baseline, over two consecutive follow up visits 2 weeks apart, the colonoscopy will be performed earlier. If patients have still significant endoscopic lesions, adalimumab or adalimumab placebo will be intensified to 40 mg weekly
1687213|NCT01562938|Drug|Placebo|Placebo
1687214|NCT01562938|Drug|MEDI-557|MEDI-557 low-dose
1687215|NCT01562938|Drug|MEDI-557|MEDI-557 high-dose
1687216|NCT01562925|Dietary Supplement|Red wine|Red wine First dosage: 3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.5 ml per kg bodyweight (60-120 minutes before contrast medium exposure
1687217|NCT01562925|Dietary Supplement|White wine|White wine First dosage: 3.3 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 1.7 ml per kg bodyweight (60-120 minutes before contrast medium exposure
1687218|NCT01562925|Dietary Supplement|Beer|Beer First dosage: 7.8 ml per kg bodyweight (the evening before contrast medium exposure) Second dosage: 3.9 ml per kg bodyweight (60-120 minutes before contrast medium exposure
1687219|NCT01562912|Device|Radiofrequency Ablation Procedure|Application of radiofrequency energy will be delivered during PV antral isolation procedure and should be performed with a standard, open irrigated ablation catheter and a mapping system as the investigator would perform the procedure normally.
1687220|NCT01562912|Device|PVAC Ablation Procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter(PVAC)to eliminate potentials arising from the pulmonary veins.
1687221|NCT01562899|Drug|MEK162|Supplied as tablets of dosage strength 15 mg in high-density polyethylene bottles with child-resistant closure.
1687368|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: medium dose; intramuscular injection, deltoid
1688760|NCT01550783|Other|Questionnaire Administration|Ancillary studies
1687222|NCT01562899|Drug|AMG 479|Supplied as sterile liquid for intravenous infusion in vials in boxes. Until April 2013 a frozen formulation with a concentration of 30 mg/ml was used; from May 2013 onwards a refrigerated formulation with a concentration of 70 mg/ml was used.
1687223|NCT01562886|Drug|Rilpivirine|Rilpivirine 26mg
1687224|NCT01562873|Drug|Ruxolitinib|
1687225|NCT01562860|Procedure|Pronator Teres Release|Surgical release of median nerve compression
1687226|NCT01562860|Procedure|dual compression release|Both the carpal tunnel compression and the pronator teres compression will be released on the same day.
1687227|NCT01562860|Procedure|dual compression release|both procedures will be done on the same day
1687228|NCT01562860|Procedure|median nerve release only|only the carpal tunnel compression is released
1687229|NCT01562847|Drug|Nilotinib|Patients will be treated with 800 mg nilotinib daily.
1687230|NCT01562834|Drug|somatropin|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months (randomised trial period) followed by an 12-month open-label trial period with somatropin.
1687231|NCT01562834|Drug|placebo|Initial dosage 0.5 IU/day, injected subcutaneously (s.c., under the skin) once daily. Dosage will be adjusted monthly depending on clinical safety up to a maximum dose of 3 IU/day. Subjects are treated for six months. After treatment in the randomised trial period, placebo will be discontinued.
1687232|NCT01562821|Drug|activated recombinant human factor VII|An initial bolus dose of 50 mcg/kg body weight (BW) followed by 50 mcg/kg BW every second hour until completion of surgery
1687233|NCT01562821|Drug|activated recombinant human factor VII|An initial bolus dose of 100 mcg/kg body weight (BW) followed by 100 mcg/kg BW every second hour until completion of surgery
1687234|NCT01562821|Drug|placebo|An initial placebo bolus dose followed by placebo every second hour until completion of surgery
1687235|NCT01562808|Drug|Aripiprazole|single oral administration of aripiprazole
1687236|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
1687237|NCT01562795|Drug|nonsteroid anti-inflammatory drops|nonsteroid anti-inflammatory drops plus artificial tear substitute
1687238|NCT01562795|Drug|corticosteroids|corticosteroids plus artificial tear substitute
1687239|NCT01562795|Drug|artificial tear substitute|artificial tear substitute alone
1687240|NCT01562782|Other|Fructose + Glucose Beverage|Consumption of a sweet beverage (Fructose:Glucose 1:1, 3g/kg) over 1/2 hour. Blood sampling will occur before and after consumption of beverage.
1687241|NCT01562756|Other|HVLA-SM|High velocity, low amplitude spinal manipulation
1687242|NCT01562743|Drug|SPM 962|Tansdermal patch
1687243|NCT01562717|Drug|Ibuprofen|3 times a day
1687244|NCT01562717|Drug|Placebo|3 times a day
1687245|NCT01562704|Drug|Paracetamol (drug)|The objective of this study is to evaluate the mechanism of action of paracetamol (versus placebo) in the brain with new assessment tools (functional MRI and test inducing pain by thermal stimulation
1687246|NCT01562691|Procedure|Nasopore|Bilateral nasal packing using Nasopore without airway integrated
1687247|NCT01562691|Procedure|airway integrated Nasopore|post nasoseptoplasty with nasal packing using airway integrated Nasopore
1687248|NCT01562691|Procedure|airway-integrated Vaseline gauze|post nasal septoplasty with packing using airway-integrated Vaseline gauze
1687249|NCT01562678|Drug|Liraglutide|In the experimental arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject Liraglutide once per day for 18 days. Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week.
1687250|NCT01562678|Drug|Placebo|In the placebo arm of this randomized, placebo controlled, cross-over, double-blinded study to assess the effects of liraglutide. Subjects will self-inject placebo once per day for 18 days.
1687251|NCT01562652|Device|AposTherapy (All Phases of Step-cycle {APOS} system, APOS—Medical and Sports Technologies Ltd. Herzliya, Israel)|
1687252|NCT01562626|Drug|APS001F|APS001F infusion on Days 1,2,3 of each 28 day cycle.
1687253|NCT01562626|Drug|Flucytosine (5-FC)|oral doses on Days 11-15 and 18-22, each 28 day cycle
1687254|NCT01562626|Drug|10% maltose|10% maltose infusion will be administered on Days 1-5, 8-12, and 15-19, each 28 day cycle.
1687255|NCT01562587|Drug|activated recombinant human factor VII|A single bolus dose is administered. Injected intravenously
1687256|NCT01562587|Drug|activated recombinant human factor VII|A random order of a low/high dose of single dose is administered during two PK-assessment periods separated by a washout period of 48 hours to one month. Injected intravenously
1687257|NCT01562574|Drug|activated recombinant human factor VII|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
1687258|NCT01562574|Drug|placebo|Up to three doses administered after surgery. If bleeding persisted after the third dose of trial product, conventional transfusion would be administered
1687259|NCT01562561|Drug|repaglinide|2 mg at each main meal
1687260|NCT01562561|Drug|insulin NPH|Administrated subcutaneously (s.c., under the skin) either at bedtime or twice daily at breakfast and before dinner.
1687261|NCT01562548|Drug|Guaifenesin|high and low dose of Guaifenesin each given twice daily over a 4-day treatment period
1687262|NCT01562548|Drug|Placebo|no active ingredient
1687263|NCT01562535|Other|Pronation|"In this technique the arm is flexed 90 degrees and a gentle pronation is applied to the arm; then the arm is further flexed to 45 degrees until the clinician feels a click in the elbow meaning the re-accommodation of the radial head has been accomplished."
1687264|NCT01562535|Other|Supination|"The affected arm is in a 90 degrees flexion. The clinician will hold the arm by the elbow and then makes a gentle supination of the affected arm and flexion of the elbow until feeling the click and the child is able to move the arm without pain."
1687265|NCT01562522|Other|Psychological counseling|Attendance at 7 group sessions, consisting of 5-6 couples, preceded by an intake consultation. Total intervention time: 16 weeks.
1687369|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: high dose; intramuscular injection, deltoid
1688793|NCT01550484|Drug|18F-AV-133|222 MBq (6 mCi)
1687266|NCT01562509|Other|Implementation tools|"Professionals receive audit & feedback
Patients (and clinicians) have access to a website with information tailored to patients with an NHL. This website gives insight into the logistic processes of each diagnostic tool and into the patients' personal care pathway.
Standardization of diagnostic and evaluative request forms and reports for clinicians.
Supporting material for standardizing the procedure for multidisciplinary meetings."
1687267|NCT01562509|Other|Standard intervention|Standard intervention consists of audit&feedback
1687268|NCT01562496|Behavioral|Exercise|six-months long exercise intervention on a stationary virtual reality bike, 3-5 times a week, each session lasting 30-45 minutes at a target heart rate (60-85% heart rate reserve).
1687269|NCT01562483|Drug|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
1687270|NCT01562483|Drug|Placebo|Identical to the Namisol arm.
1687271|NCT01562470|Other|Cellulite reduction cream|1/8 tsp cellulite cream will be applied to the thigh twice daily - in the morning and at night, for a period of 16 weeks.
1687272|NCT01562457|Drug|activated recombinant human factor VII|Administered as a single dose. Injected as a slow intravenous injection over 2 minutes (from start to completion of injection)
1687274|NCT01562431|Other|Feed-back|Counselors will receive the results of the completed Signal-checklist completed by participants in the intervention group
1687275|NCT01562418|Behavioral|Ergonomic intervention|Ergonomic intervention, how to sit and work, an d muscle re education with a SurfaceElrctromyograph Biofeedback (SEMG biofeedback)
1687276|NCT01562418|Behavioral|Standard ergonomic intervention|Standard ergonomic intervention , how to sit and work with computers
1687277|NCT01562418|Behavioral|control group|general instructions no intervention
1687278|NCT01562405|Drug|ACE-011|Injection every 28 days, dose escalation levels from 15-45 mg
1687279|NCT01562405|Drug|Lenalidomide|15 to 25 mg days 1-21, given orally
1687280|NCT01562405|Drug|Dexamethasone|40 mg days 1,8,15,22; given orally
1687281|NCT01562405|Drug|Pomalidomide|Pomalidomide 4 mg daily on days 1-21
1687282|NCT01562392|Dietary Supplement|berries and vegetables|Daily (5 w) supplementation with specific vegetables and berries
1687283|NCT01562392|Dietary Supplement|control product|Supplementation (daily,5 w) with a control product without berries and vegetables.
1687284|NCT01562379|Dietary Supplement|Wheat Soy Blend (WSB++)|A wheat formulation containing protein from milk solids and soybeans, essential fats and sugar to provide optimal caloric density, and added vitamins and minerals.
1687285|NCT01562379|Dietary Supplement|Chickpea based complementary food supplement|A chickpea-based complementary food supplement with added milk powder, oil, sugar and added vitamins and minerals.
1687286|NCT01562379|Dietary Supplement|Rice based complementary food supplement|Locally developed rice based complementary food with and added vitamins and minerals.
1687287|NCT01562379|Dietary Supplement|Plumpy Doz|Plumpy Doz is a prepackaged ready-to-use complementary food supplement enriched with added vitamins and minerals.
1687288|NCT01562366|Device|Topaz|Radiofrequency micro debridement with Topaz will be used to treat the gluteal tendons following standard of care procedure
1687289|NCT01562366|Procedure|Iliotibial band release and trochanteric bursectomy|Standard of Care: An iliotibial band release and trochanteric bursectomy will be performed.
1687290|NCT01562340|Other|Pomegranate juice|Pomegranate juice (100 mL) 3 times per week (taken prior to hemodialysis session) for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
1687291|NCT01562340|Other|Pomegranate fruit extract|Pomegranate fruit extract in single capsule (1050 mg) daily by mouth for 4 weeks. Followed by 4 week wash-out (no intervention), then crossover to Comparator arm.
1687292|NCT01562327|Drug|Tocilizumab|Participants received tocilizumab according to individualized physician-prescribed regimens.
1687293|NCT01562314|Drug|GWP42003|1-5 capsules taken twice daily, 10 week treatment period.
1687294|NCT01562314|Drug|Placebo|1-5 capsules taken, twice daily. 10 week treatment period.
1687295|NCT01562301|Drug|Carboplatin|AUC 6 by vein 7 days after Anvirzel administration in a 21 dayc cycle.
1687296|NCT01562301|Drug|Docetaxel|75 mg/m2 by vein 7 days after Anvirzel administration in a 21 day cycle.
1687297|NCT01562301|Drug|Anvirzel|"Starting Cohort Dose: 6 mg/m2 given 3 times a day administered sublingually for a 21 day cycle.
Expansion Cohort Starting Dose: Maximum tolerated dose from"
1687298|NCT01562301|Behavioral|Questionnaires|Questionnaire completion regarding physical and mental at baseline, 7 days before chemotherapy, day 1 of chemotherapy, day 1 of cycles 2, 3, and 4, and at end of dosing visit.
1687299|NCT01562288|Genetic|DNA analysis|
1687300|NCT01562288|Genetic|gene expression analysis|
1687301|NCT01562288|Genetic|polymerase chain reaction|
1687302|NCT01562288|Other|enzyme-linked immunosorbent assay|
1687303|NCT01562288|Other|laboratory biomarker analysis|
1687304|NCT01562275|Drug|Ipatasertib|multiple doses
1687305|NCT01562275|Drug|Cobimetinib|multiple doses
1687306|NCT01562249|Other|orofacial myofunctional treatment protocol|Once a week for six weeks, the experimental group received a forty minutes session of orofacial myofunctional treatment. A home exercise program was prescribed during each session. The protocol implies in continuous and daily practices - participants were asked to perform exercises at least three times a day. After the first six weeks, the experimental group underwent four sessions for maintenance purposes (two sessions twice a month and two sessions once a month). The total treatment duration was of five months.
1687307|NCT01562249|Other|counseling|The instruction group underwent two supervised forty minutes therapy sessions along the six weeks following surgery. These sessions involved the perception of the stomatognathic system, especially in terms of adequate performance during mastication. Specific exercises were not given and patients were instructed to try to reproduce the adequate pattern of mastication at all meals (i.e. alternated bilateral, with lip closure; with coordination activity of the tongue and mandible).
1687308|NCT01562249|Other|Control Group|As the sEMG test-retest is a critical issue, participants of CG were also tested in two distinct moments (testing occurred with 1 year interval) in order to verify possible changes in the sEMG measurements as a result of retesting.
1687310|NCT01562210|Drug|Olaparib|"Olaparib will be given orally BID for 36 days, administrated with a 12 hour interval. Olaparib will start 2 days before RT and will continue for 2 days after the last RT fraction. Olaparib is also given during the non-radiotherapy days but no maintenance treatment is given after radiotherapy is finished.
The first cohort will receive Olaparib with a dose of 25mg BID combined with Cisplatin and RT. Thereafter in both with and without cisplatin arms dose escalation will follow to 50mg, 100mg, 200mg, 300mg and 400mg BID."
1687311|NCT01562210|Drug|Cisplatin|6 mg/m2 (5 days/week), 1-1.5 hr before the irradiation (week 1 to 5), given as a 5-minutes intravenous infusion.
1687312|NCT01562210|Radiation|Radiation|A total dose of 66 Gy will be given in 24 fractions from week 1 to 5, excluding the weekends.
1687313|NCT01562197|Drug|axitinib|The starting dose of axitinib (AG-013736) is 5 mg BID administered orally with food.
1687314|NCT01562197|Drug|Axitinib plus Lomustine|Lomustine 90mg/m²
1687315|NCT01562184|Device|Sham tDCS device|Sham tDCS
1687316|NCT01562184|Device|Soterix tDCS device|Active tDCS
1687317|NCT01562171|Other|Cooked Lentils|Consume food items containing one serving of (0.3 cups) of cooked lentils per day for the first 5 days, followed by one serving of (0.6 cups) of cooked lentils per day 5 times per week (equivalent of 3 cups cooked lentils per week) for the remainder of the 12-week schedule.
1687318|NCT01562171|Other|Potato-Based Foods|Control - Consumption of one serving per day of potato-based foods in matrices similar to those containing lentils in the same 12-week schedule, including the smaller serving size for the first 5 days.
1687319|NCT01562158|Procedure|standard therapy|Standard treatment of bleeding
1687320|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - low dose administered i.v. (into the vein)
1687321|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - medium dose administered i.v. (into the vein)
1687322|NCT01562158|Drug|activated recombinant human factor VII|Two days repeated treatment regimen - high dose administered i.v. (into the vein)
1687323|NCT01562158|Drug|placebo|Placebo
1687324|NCT01562145|Procedure|Blood sampling|Four mL venous blood samples were collected from all study participants after inclusion
1687325|NCT01562132|Drug|Flucytosine and fluconazole|Flucytosine 100mg/kg/day in 4 divided doses orally for 14 days given in combination with fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
1687326|NCT01562132|Drug|Fluconazole|fluconazole 1200mg orally once daily for 14 days, followed by 800mg orally once daily for 8 weeks, followed by 200mg orally once daily
1687327|NCT01562106|Procedure|Fluorescence-guided sentinel lymph node detection|During standard endometrial cancer surgery, ICG dye will be injected into the cervix to identify sentinel lymph nodes in the pelvis.
1687328|NCT01562093|Drug|corticosteroid nasal spray|fluticasone furoate 55 µg (formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, purified water) once daily in each nostril for 3 months
1687329|NCT01562093|Drug|placebo nasal spray|formula containing anhydrous glucose, dispersible cellulose, polysorbate 80, benzalkonium chloride, disodium edetate, and purified water, once daily in each nostril for 3 months
1687330|NCT01562080|Dietary Supplement|Armolipid Plus|one tablet per day during 12 weeks
1687331|NCT01562080|Dietary Supplement|placebo|one tablet per day during 12 weeks
1687332|NCT01562067|Device|ultrasound examination|ultrasound and doppler studies to evaluate size and vascularity of tumor during radiotherapy
1687333|NCT01562041|Drug|Ranolazine|twice per day for 14 days
1687334|NCT01562028|Drug|Erlotinib|Patients will be treated with erlotinib, 150 mg p.o., daily
1687335|NCT01562028|Drug|Bevacizumab|Patients will be treated with bevacizumab 15 mg/kg i.v. on day 1 of each 3-week cycle (+/- 3 days)
1687336|NCT01562015|Drug|Ganetespib|Ganetespib 200 mg/m2 administered 1 time per week for the first three weeks of a four week treatment cycle (Days 1, 8, and 15 of the 28 Day treatment cycle).
1687337|NCT01562002|Procedure|Stem Cell with Amniotic Membrane Transplant|Single stem cell expansion in amniotic membrane transplant
1687344|NCT01561963|Drug|Apremilast|"Each subject will receive the following 3 treatments in the same fixed sequence during the study (the study days are numbered sequentially across all 3 periods):
A single oral dose of 30 mg apremilast on Day 1 in Period 1;
A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;
Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3."
1687345|NCT01561963|Drug|Rifampin|"A single oral dose of 30 mg apremilast followed 5 minutes later by a 30-minute intravenous infusion of 600 mg rifampin on Day 5 in Period 2;
Once daily oral doses of 600 mg rifampin for 15 days (from Day 7 to Day 21) with a single oral dose of 30 mg apremilast co-administered with the rifampin dose on Day 20 in Period 3."
1687346|NCT01561950|Drug|eptacog alfa (activated)|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
1687347|NCT01561950|Drug|clopidogrel|Following a baseline biopsy (B0) subjects will receive oral treatment with an initial 300 mg loading dose followed by daily 75 mg doses for at least 3 additional days. If the target platelet inhibition (PI) is achieved, the subject will undergo punch biopsy 1 (B1).
1687348|NCT01561950|Drug|placebo|If subject is eligible to continue after clopidogrel treatment, three different doses of trial drug is administered i.v. as a slow bolus injection over two to three minutes followed by post-trial biopsies
1687349|NCT01561937|Drug|warfarin|After a baseline punch biopsy (B0), warfarin is administered over a period of approximately 7-14 days. Dose is adjusted individually to achieve INR target. Once a stable INR is achieved, a second biopsy (B1) will be performed
1687350|NCT01561937|Drug|eptacog alfa (activated)|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
1687351|NCT01561937|Drug|placebo|If the subject is eligible to continue in trial part B, trial drug will be administered i.v. as a slow bolus injection over 2 to 5 minutes in five different doses followed by two biopsies (B2) and (B3) 15 minutes and 5 hours and 15 minutes, respectively, after trial drug administration
1687352|NCT01561924|Drug|eptacog alfa (activated)|Subjects will be called to attend the clinic in a non-bleeding state. Blood samples will be drawn for thromboelastogram profiling and will be in-vitro spiked with different doses of activatated recombinant human factor VII.
1687353|NCT01561911|Drug|Chi Lob 7/4 (A chimeric monoclonal antibody)|3 patients will receive treatment at each dose level. Escalation from one treatment dose level to another will only be permitted once at least 3 patients have completed treatment without any DLTs. Starting weekly dose of Chi Lob 7/4 will be 0.5mg (giving a total dose per patient of 2mg divided over 4 weeks). Subsequent individual, weekly dose levels of 1.6mg, 5mg, 16mg, 50mg and 160mg (resulting in total patient doses of 6.4mg, 20mg, 64mg 200mg and 640mg respectively). Further dose escalation can continue to 240mg and 320mg dose per week (resulting in 960mg and 1280mg. Patients may be treated at a lower or intermediate dose level to define the MTD/BAD.
1687354|NCT01561898|Drug|Paliperidone extended-release (JNS007ER)|Type= range, unit= mg, number= 3-12, form= tablet, route= oral use. JNS007ER within the range of 3, 6, 9 and 12 mg will be orally administered once daily for 48 weeks.
1687355|NCT01561885|Other|Pathway-Based Care|Patients who are randomly allocated to Pathway Care will be treated by the Pathway Clinical Teaching Unit as well as other collaborative healthcare professionals (pharmacists, nurses, health educators, nutritionists, and social workers). The Pathway Care physicians will have access to the Clinical Care Plan on the QuadraMed, which is a detailed, organized, day-to-day treatment plan that includes pre-set orders and medications. Physicians for the patients on Usual Care will not have access to this information, and the collaborative healthcare will only be provided upon consultation.
1687356|NCT01561859|Behavioral|Cognitive Enhancement Therapy|Cognitive Enhancement Therapy (CET) consists of approximately 60 hours of computer-assisted neurocognitive training in attention, memory, and problem-solving; and 45 social-cognitive group sessions that employ in vivo learning experiences to foster the development of social wisdom and success in interpersonal interactions. CET begins with 3 months of weekly 1-hour neurocognitive training in attention, after which patients begin the weekly 1.5-hour social-cognitive groups. Neurocognitive training then proceeds concurrently with the socialcognitive groups.
1687357|NCT01561859|Behavioral|Enriched Supportive Therapy|"Enriched Supportive Therapy is an individual approach that includes the established principles of supportive therapy previously tested by our group, which are enriched by selected practice principles from the effective Personal Therapy. These manualized supportive therapeutic practices include active listening, correct empathy, appropriate reassurance, basic psychoeducation, including computer-based educational programs, reinforcement of health-promoting initiatives, the provision of case management, and reliance on the advocacy and advice of the therapist in times of crisis."
1687358|NCT01561846|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
1687359|NCT01561846|Dietary Supplement|CLA enriched cheese|This study was a 3-week, randomized, double blind, controlled, cross over clinical trial, conducted at the State Hospital Brotzu in Cagliari, Italy. The subjects were randomly assigned to eat 90g/d of the control or enriched cheese for 3 weeks, with a cross over after 3 weeks of washout. The study included 5 visits: 2 screening/baseline visits at weeks −1 and 0, 1 end of intake of 90 g/d of cheese visit at week 3, 1 end of the first wash out visit at week 6, and 1 end of treatment after crossing over visit at week 9. This procedure was subsequently repeated with a cheese intake of 45 g/d
1687361|NCT01561820|Behavioral|5-month aerobic exercise intervention|The 5-month aerobic exercise intervention is in accordance with the American Heart Association and American College of Sports Medicine physical activity recommendation for optimizing cardiovascular fitness in older adults.Exercise will consist primarily of walking on the treadmill.The goal of the program will be for participants to exercise at a moderate- to high-intensity, defined as 65-80% (ACSM guidelines) of heart rate reserve (HRR), for 30 minutes, 4 days per week.The duration of exercise will progress from 15-20 mins at 50% HRR the 1st week to 30 mins at 65-80% HRR by the end of the 6th week and thereafter.At the start of each session, exercise intensity will be gradually increased to 50% HRR(0.5[HRmax-HRrest]+HRrest)during a 10minute warmup period,and then to the individualized target heart rate training zone for the next 25-30 minutes.Participants will wear a digital heart rate monitoring device for the duration of the training session.
1687362|NCT01561807|Drug|VX-787|
1687363|NCT01561807|Drug|Placebo|
1687364|NCT01561794|Drug|Ciprofloxacin (Cipro, BAYQ3939)|"(1) Community-acquired pneumonia (CAP): 400 mg BID, i.e. every 12 ± 1 hours (For those with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days.
2) Hospital-acquired pneumonia (HAP): For the patient with Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1hours for 7 to 14 days For the patient with 30 ≤Ccr ≤60 mL/min, 400 mg BID, i.e. every 12 ± 1hours for 7 to 14 days 3) Secondary infection of chronic respiratory disease 400 mg BID, i.e. every 12 ± 1 hours (For those with of Ccr > 60 mL/min, 400 mg TID, i.e. every 8 ± 1 hours may be considered at the discretion of investigators) for 7 to 14 days."
1687365|NCT01561781|Drug|Digoxin|Oral tablets 0.25mg, single dose
1687366|NCT01561781|Drug|Vandetanib|Oral tablets, 300 mg, single dose
1687367|NCT01561768|Biological|Novavax Quadrivalent vaccine|Quadrivalent VLP vaccine: low dose; intramuscular injection, deltoid
1688883|NCT01549847|Drug|Placebo|Placebo PO BID
1687370|NCT01561768|Biological|Novavax Trivalent vaccine|Trivalent Dose; intramuscular injection, deltoid
1687371|NCT01561768|Biological|cTIV|Preconfigured dose; intramuscular injection, deltoid
1687372|NCT01561755|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin - 2gr/kg over 2 days of Privigen®
1687373|NCT01561755|Drug|Placebo|Placebo - 2gr/kg over 2 days of saline
1687374|NCT01561742|Drug|Minocycline|Minocycline will be given orally at 200 mg a day for 4 months
1687375|NCT01561742|Drug|Placebo|EquivalentPlacebo will be given
1687376|NCT01561729|Device|RightSpot pH Indicator|The RightSpot pH Indicator device is used to confirm proper placement of all types of gastric tubes used for gastric rest, suction, or medicating/feeding by measuring the pH of stomach aspirate. This device is intended for 1 (one) SINGLE USE. The probability of proper placement is higher when the pH is less than or equal to 4.5 and if aspirate has a typical gastric fluid appearance (grassy green, brown, colorless- with possible shreds of off-white mucus or sediment).
1687377|NCT01561729|Radiation|Chest radiograph|Chest radiograph will be taken after tube placement to verify proper positioning of the nasogastric or orogastric tube.
1687378|NCT01561716|Device|Wii Fit|This is a randomized, crossover study to evaluate the energy expenditure associated with Wii Fit games. After the baseline resting energy expenditure assessment, each participant complete the following physical activities on separate days in a random order, (1) 30-minute Wii Fit Aerobics Free Run, (2) 3 bouts of Wii Fit Aerobics (Advanced Step, Super Hula Hoop, and Rhythm Boxing in a random order) each lasting 10 minutes, and (3) 30-minute treadmill running/walking.
1687379|NCT01561703|Drug|Antibiotic|One of seven antibiotics (amoxicillin; amoxicillin/clavulanate potassium; azithromycin; cefaclor; cephalexin; cefdinir; or clindamycin) will be given at standard dosage that may be used for 7-10 days following surgery .
1687380|NCT01561690|Drug|ARRY-502, CRTh2 antagonist; oral|multiple dose, single schedule
1687381|NCT01561690|Drug|Placebo; oral|matching placebo
1687382|NCT01561677|Device|Continuous Positive Airway pressure-RESPIRONICS|obstructive sleep apnea syndrome survival ischemic stroke continuous positive airway pressure handicap
1687383|NCT01561677|Device|Sham Continuous Positive Airway pressure-RESPIRONICS|inefficient Continuous Positivie Airway pressure
1687384|NCT01561664|Other|muscle and fat biopsy|muscle and fat biopsy
1687385|NCT01561651|Other|Left Atrial Appendage Occlusion|Surgeon will occlude the left atrial appendage using a suture and/or a surgical stapler or a regulatory approved atrial appendage closure during the patient's cardiac surgery procedure.
1687386|NCT01561638|Procedure|Conventional Radiofrequency|pulsed radiofrequency will delivered at 45V for 2 cycles of 120 seconds(temperature not more than 42degree centigrade)
1687387|NCT01561638|Procedure|Pulsed Dose Radiofrequency|pulsed dose pulsed radiofrequency,we will set the machine to give 480 pulses each pulse of 45 volts for 20 milliseconds duration with a temperature limit of 42 degree centigrade)
1687388|NCT01561638|Procedure|Sham|will receive puncture for 4 minutes
1687389|NCT01561625|Other|exercise|resistance training exercise, 1 session, 3 exercises, 80% of max
1687390|NCT01561612|Behavioral|Breastfeeding promotion and support|Breastfeeding promotion and support according to the World Health Organization's Baby Friendly Hospital Initiative
1687391|NCT01561599|Drug|BB3|Daily intravenous administration of 2mg/kg for 4 days
1687392|NCT01561599|Drug|Normal Saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
1687395|NCT01561573|Device|Point of care ultrasound|A bedside ultrasound machine will be used to image the colles fracture during the fracture reduction process.
1687396|NCT01561560|Device|Delefilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
1687397|NCT01561560|Device|Narafilcon A contact lenses|CE-marked, silicone hydrogel, soft contact lenses for daily wear, daily disposable use, worn bilaterally for two weeks in either Period One or Period Two
1687398|NCT01561547|Behavioral|Kangaroo Mother Care|Infant wearing only diaper is held in skin-to-skin contact with mother with flannel blanket around both mother and infant. removal.
1687399|NCT01561547|Dietary Supplement|Sucrose|24% sucrose in volumes between .05 to 2 ml depending on weight of the infant, is inserted by dropper into the infants mouth two minutes before and/or during the painful procedure with up to 3 doses.
1687400|NCT01561521|Drug|AKF-1|1 drop AKF-1 0.025% in each eye at 2 separate times during a 14 day period
1687401|NCT01561521|Drug|AKF-1|1 drop AKF-1 0.035% in each eye at 2 separate times during a 14 day period
1687402|NCT01561521|Drug|AKF-1|1 drop 0% in each eye at 2 separate times during a 14 day period
1687403|NCT01561508|Drug|gamma-amino-butyric acid|gamma-amino butyric acid will be administered orally at a dose of 80mg/kg/day divided BID for one year.
1687404|NCT01561508|Dietary Supplement|Xylitol|The placebo group will be provided Xylitol powder dosed per body weight. Participants will be instructed to take powder orally twice a day for one year.
1687405|NCT01561495|Radiation|Proton Therapy|
1687461|NCT01561053|Biological|Immune globulin|Intravenous (human) immune globulin 5%
1687406|NCT01561482|Drug|Metformin|Metformin treatment will be started at 500 mg twice daily (dose level -2), in order to minimize gastrointestinal discomfort and, if no gastrointestinal toxicity grade greater than 1, will be increased to 500 mg with breakfast/1000 mg at bedtime (dose level -1) 4 days later (+/- 1 day allowed). If no gastrointestinal toxicity grade greater than 1, it will be increased to 1000 mg twice daily (dose level 0) 10 days later (+/- 2 days allowed), which is the target dose for the remainder of the study. If gastrointestinal toxicity grade greater than 1 occurs during these first 4 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1 and, then, the metformin dose will be increased to the next dose level.
1687407|NCT01561482|Drug|Simvastatin|The simvastatin dose at treatment initiation will be 20 mg once daily (dose level -1), taken at bedtime for 2 weeks. After these 2 weeks, the subject will have blood work and, if no AST/ALT/CPK elevation grade greater than 1, will be escalated to 40 mg once daily (dose level 0), taken at bedtime. If AST or ALT or CPK elevation grade greater than 1 during the first 2 weeks, the subject will be evaluated every 2 weeks until resolution of toxicity to grade less than or equal to 1, and then the simvastatin dose will be increased to dose level 0.
1687408|NCT01561469|Drug|Linezolid|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with linezolid according to routine medical care.
1687409|NCT01561469|Drug|Vancomycin|Patients with documented MRSA hospital-acquired or ventilator-associated pneumonia treated with vancomycin according to routine medical care.
1687410|NCT01561456|Drug|AXL1717|AXL1717 administered as oral suspension at 400 mg twice daily for 21 days per cycle; i.e. daily for up to four cycles
1687411|NCT01561456|Drug|Docetaxel|Docetaxel administered as a standard treatment (75 mg/m2 IV infusion over 1 hour) once every three weeks throughout the 4-cycle study
1687412|NCT01561430|Drug|LY2886721|One capsule administered orally once daily
1687413|NCT01561430|Drug|Placebo|One capsule administered orally once daily
1687414|NCT01561417|Drug|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
1687415|NCT01561417|Drug|activated recombinant human factor VII|One single dose administration, injected i.v. (into the vein)
1687416|NCT01561404|Drug|Everolimus|In patients that change of immunosuppressive therapy from calcineurin inhibitor (CNI)(tacrolimus or cyclosporine) to m-TOR (everolimus)has been clinically indicated, check if there is an increase in physical exercise capacity.
1687417|NCT01561391|Drug|activated recombinant human factor VII|Infused continuously at 50 mcg/kg/hr through Day 5 then at 25 mcg/kg/hr on Days 6 to10.
1687418|NCT01561391|Drug|activated recombinant human factor VII|Injected every 2 hours during surgery through Day 5, then every 4 hours for Days 6 to 10.
1687419|NCT01561391|Other|factor IX|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
1687420|NCT01561391|Drug|factor VIII|Patients with haemophilia A or B without inhibitors undergoing similar surgery were treated in accordance with local standard of care per physician's orders.
1687421|NCT01561378|Drug|Aspart insulin|40 IU of aspart insulin will be administered intranasally using a mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
1687422|NCT01561378|Drug|Placebo|200 microliters of normal saline will be administered per nostril using a mucosal atomizer device within 2 hours prior to surgery, and then four times a day for 7 days or until hospital discharge (whichever occurs first)
1687423|NCT01561365|Behavioral|Ottawa ankle rules|Ottawa ankle rules implementation
1687424|NCT01561352|Drug|activated recombinant human factor VII|If non-responding haemorrhagic cystitis to 24-hour trial of conventional therapy, 80 mcg/kg is administered i.v. for the first dose. If necessary, two additional doses of 120 mcg/kg can be administered i.v.
1687425|NCT01561326|Behavioral|Cognitive-affective barriers counseling|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
1687426|NCT01561326|Behavioral|Cognitive-affective barriers counseling via brochure|Culturally-relevant/sensitive barrier-specific messages drawn from a pre-developed library designed to counsel individuals regarding their specific barriers to adherence via brochure, e.g., by increasing risk-related knowledge, providing accurate outcome and self-efficacy expectancies, addressing health-related values and goals, moderating risk-related affect, or offering active plans and strategies to assist with self-regulation
1687427|NCT01561326|Behavioral|standard care|Cognitive-affective barriers (CAB) assessment delivered via phone; receipt of a notification letter from physician regarding abnormal Pap test result, need to undergo colposcopy, appointment date and clinic contact numbers; telephone confirmation and post-card appointment reminder
1687428|NCT01561313|Biological|Adalimumab|Subcutaneously 40 mg every other week (EOW) or every week (EW) (as dosing requires)
1687429|NCT01561300|Other|Nutrition intervention study with a black tea extract|"Tea extract: 1800 mg/day standardized Brooke Bond black tea extract equivalent to 400 mg flavonoids dissolved in 240 ml hot water.
Products will be consumed for 8 days. On measurement days tea will be given to the subjects as a single acute dose and 2 grams of sugar will be added.
On day 2-7 subjects will consume 3 cups or tea, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
1687430|NCT01561300|Other|Nutrition intervention study with a control|"Control: 1800 mg/day of a powder that gives a flavoured beverage with a color similar to black tea dissolved in 240 ml hot water.
Products will be consumed for 8 days. On measurement days control will be given to the subjects as a single acute dose and 2 grams of sugar will be added.
On day 2-7 subjects will consume 3 cups of control, each prepared with 800 mg product in 80 ml of boiling water and sugar added to subject's taste. First cup of tea will be taken as morning tea, 2nd at breakfast and 3rd in the evening. No milk will be added."
1687431|NCT01561287|Procedure|Dermal Autograft|Patients in the dermal autograft group will undergo harvest of a dermal autograft from the lower abdomen at the time of mastectomy, which will be used to cover the lower pole of the tissue expander.
1687965|NCT01557218|Other|Peach snack|Three 300-g bowls of fruits per table: three of peach slices
1687432|NCT01561287|Procedure|AlloDerm|The acellular dermal matrix used in our study is AlloDerm (LifeCell Corp., Branchburg, N.J.) The AlloDerm group will consist of patients without a suitable abdomen for autografting and those who declined the dermal autograft procedure. Patients in the dermal allograft group will have placement of AlloDerm over the lower pole of the tissue expander. Patients with a lower abdominal scar and sufficient abdominal laxity for autograft harvest will be offered this technique.
1687433|NCT01561274|Drug|2 ml bupivacaine|2 ml bupivacaine
1687434|NCT01561274|Drug|1.5 ml bupivicaine.|1.5 ml bupivicaine.
1687435|NCT01561261|Other|Continuous tissue perfusion monitoring by near-infrared spectroscopy (NIRS) and intramuscular pressure (IMP)|Continuous monitoring of tissue perfusion using NIRS in all 4 leg muscle compartments and IMP via indwelling catheters in anterior and deep posterior compartments. These measures will not provided in real time to treating physicians. All clinical care, including the diagnosis of ACS, will be according to the current standard-of-care practiced at each institution, Clinicians may use the indwelling IMP monitor to obtain up to 2 discrete measures of IMP if they encounter a clinical situation in which they would normally measure IMP as an adjunct in their normal standard-of-care for the monitoring and diagnosis of compartment syndrome. Patients who undergo fasciotomy will also have NIRS and IMP values recorded from all 4 leg compartments immediately before and after fasciotomy.
1687436|NCT01561248|Drug|polyethylene glycol solution for daily bowel lavage.|At admission,patients with severe EHEC infection received two liters of orally administered electrolytes- balanced polyethylene glycol solution for bowel lavage. Treatment was continued with one liter of polyethylene glycol solution daily for repetitive intestinal lavage during the clinical course.
1687437|NCT01561235|Other|Dose-reponse effect of protein on appetite and appetite-regulating hormones|3-arm meal study for investigation of the mechanisms responsible for the satiating effects of protein in three isocaloric test meals with a protein content of 14, 25 or 50 E% protein. A possible 4-h dose-response effect of protein was investigated on a number of appetite-regulating hormones/peptides, together with changes in subjective appetite sensations and sensory desires were evaluated and ad libitum energy intake.
1687438|NCT01561222|Drug|Calcitriol|0.25 ug per day for one year
1687439|NCT01561222|Drug|placebo|one pill per day
1687440|NCT01561209|Drug|Amitryptiline|Amitryptiline 5 mg before bedtime for 2 months
1687441|NCT01561209|Drug|Placebo|"Placebo pill
1 before bedtime"
1687442|NCT01561196|Procedure|arterial catheterisation|arterial catheterisation in Arterial Radialis
1687443|NCT01561183|Procedure|Indirect pulp capping (IPC)|"Procedure: IPC
The IPC will be performed as follow:
Anesthesia
isolation the tooth
access to the lesion
incomplete removal of carious tissue from the cavity walls
indirect pulp capping with ≈2 mm layer calcium enriched mixture cement
permanent filling with sandwich technique"
1687444|NCT01561183|Procedure|Direct pulp capping (DPC)|"Procedure: DPC
The DPC will be performed as follow:
Anesthesia
isolation the tooth
access to the lesion
complete removal of carious tissue from the cavity walls result in pulp exposure
preparation of clot-free pulpal mound
direct pulp capping with ≈2 mm layer calcium enriched mixture cement
permanent filling with sandwich technique"
1687445|NCT01561183|Procedure|Miniature pulpotomy (MP)|"Procedure: MP
The MP will be performed as follow:
Anesthesia
isolation the tooth
access to the lesion
complete removal of carious tissue from the cavity walls result in pulp exposure
intentionally removal of pulp horn (≈1 mm)
preparation of clot-free pulpal mound
direct pulp capping with ≈2 mm layer calcium enriched mixture cement
permanent filling with sandwich technique"
1687446|NCT01561183|Procedure|Full pulpotomy (FP)|"Procedure: FP
The FP will be performed as follow:
Anesthesia
isolation the tooth
access to the lesion
complete removal of carious tissue from the cavity walls result in pulp exposure
pulpotomy
preparation of clot-free pulpal mound
direct pulp capping with ≈2 mm layer calcium enriched mixture cement
permanent filling with sandwich technique"
1687447|NCT01561170|Device|Active Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive active devices. Both patients and investigator are blinded.
1687448|NCT01561170|Device|Placebo Pulsed Electro-Magnetic Field (PEMF)|One group of patients receive placebo devices. Both patients and investigator are blinded.
1687449|NCT01561131|Dietary Supplement|Whey protein|45g protein/d; Dosage 3x15g protein daily
1687450|NCT01561131|Dietary Supplement|Whey protein enriched with calcium|45g protein/d + 1000mg calcium/d; dosage: 15g protein + 333mg calcium x 3 daily
1687451|NCT01561131|Dietary Supplement|Soy protein|45g soy protein/d; dosage 15g soy protein x 3 daily
1687452|NCT01561131|Dietary Supplement|Maltodextrin|48g carbohydrate/d; dosage: 16g carbohydrate x 3 daily
1687453|NCT01561118|Other|Bicycle-Ergometer Training|"Performance adapted, hence individualised three times weekly bicycle-ergometer training during hemodialysis. Each training will last 30 to 50 minutes with 70-80% of the patient specific maximum workload over 12 weeks (36 training sessions - first part of the study compared to no intervention).
In the second part of the study both groups get the opportunity for another 12 weeks of individualised three times weekly bicycle-ergometer training during hemodialysis."
1687454|NCT01561105|Other|IMPACT|IMPACT is a collaborative care management program for late-life depression
1687455|NCT01561092|Drug|Escitalopram|5 or 10 mg escitalopram tablets administered orally once daily
1687456|NCT01561092|Drug|Placebo|Tablets
1687457|NCT01561079|Drug|Buprenorphine|Daily sublingual buprenorphine treatment of pregnant, opioid dependent women from up to 34 weeks gestation through one month of infant age.
1687458|NCT01561066|Procedure|Autologous platelet-rich fibrin glue (PRFG)|"Preparation of autologous platelet-rich fibrin glues (PRFG) The platelet-rich plasma (PRP) was separated by centrifugation from 300-400 ml whole blood for 6 min at 1000g, 22°C twice, keeping most of the platelets (50%-60%) in the plasma fraction. For 50g PRP from each patient, with citric acid (2.84mM) lowering and NaHCO3 (75mM) adjusting the PH value, thrombin solution was produced. On the other hand, cryoprecipitate was produced from the rest of the plasma. Frozen at -80°C for at least 6h and then thawed at 4°C, PRP went through centrifugation at 4000rpm/min for 5min.
PRFG application The application of the glues through the external opening of the fistula was controlled by the drainage tube through a double-syringe system with distal mixing device. The distance was based on fistulography to assure total occlusion of the internal hole. After the FG was instilled, any redundant glue was removed from the external openings."
1687459|NCT01561066|Drug|Octreotide|subcutaneous injection, 0.3mg/8h until enteral nutrition resolution
1687460|NCT01561053|Biological|Albumin|Human albumin 20%
1687462|NCT01561040|Dietary Supplement|Omega 3, Vitamins A, D3 and E|omega 3 1480 mg vitamin A 1,000 IU vitamin D3 2,000 IU vitamin E 60 IU
1687465|NCT01561014|Drug|erlotinib hydrochloride|Given PO
1687466|NCT01561014|Drug|oxaliplatin|Given IV
1687467|NCT01561014|Drug|fluorouracil|Given IV
1687468|NCT01561014|Radiation|radiation therapy|Undergo radiotherapy
1687469|NCT01561014|Procedure|conventional surgery|Undergo surgical resection
1687470|NCT01561014|Other|immunohistochemistry staining method|Correlative study
1687471|NCT01561014|Procedure|positron emission tomography|Correlative study
1687472|NCT01561014|Procedure|computed tomography|Correlative study
1687473|NCT01561014|Procedure|laboratory biomarker analysis|Correlative study
1687474|NCT01561014|Genetic|gene expression analysis|Correlative study
1687475|NCT01561014|Radiation|fludeoxyglucose F 18|Undergo F18 PET and CT scan
1687476|NCT01561001|Device|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours.
1687477|NCT01560988|Drug|Borage and Echium Seed Oils|4.0 g/day borage seed oil and 7.0 g/day echium seed oil. Pills will be taken three times per day for six weeks.
1687478|NCT01560988|Dietary Supplement|Corn oil pills|Corn oils pills will be taken three times per day for six weeks.
1687479|NCT01560975|Device|SENSIMED Triggerfish®|Portable investigational device using a contact lens sensor that monitors the IOP fluctuation continuously over 24-hours
1687480|NCT01560962|Drug|povidone iodine|
1687481|NCT01560962|Drug|Povidone-Iodine|
1687482|NCT01560962|Drug|Azithromycin|
1687483|NCT01560962|Drug|tobramycin-dexmethasone|
1687484|NCT01560949|Drug|Oxaliplatin|75 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
1687485|NCT01560949|Drug|Irinotecan|150 mg/m2 by vein on Day 1 of weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
1687486|NCT01560949|Drug|5-FU|2000 mg/m2 by vein over 46 hour continuous infusion, on Days 1 - 2 during weeks 1, 3, 5, 7, 9 and 11 for 12 weeks.
1687487|NCT01560949|Drug|Gemcitabine|350 mg/m2 by vein every week for 5 doses beginning Day 1 (days 1, 8, 15, 22, 29).
1687488|NCT01560949|Radiation|Radiation Therapy|External beam radiation therapy delivered 5 days/week +/- 2 days over 5.5 weeks with 18-MeV photons. 3D conformal RT, a total dose of 50.4 Gy 1.8 Gy/fraction (28 fractions).
1687492|NCT01560897|Drug|Oral C13|Ingestion of C13 and follow up of the ureogenesis
1687493|NCT01560884|Drug|Renazorb 1500 mg/day|Six subjects will be randomly assigned to receive SPI-014 1500 mg/day dose and 2 subjects to receive placebo
1687494|NCT01560884|Drug|Renazorb 3000 mg/day|Six subjects will be randomly assigned to receive SPI-014 3000 mg/day dose and 2 subjects to receive placebo
1687495|NCT01560884|Drug|Renazorb 4500 mg/day|Six subjects will be randomly assigned to receive SPI-014 4500 mg/day dose and 2 subjects to receive placebo
1687496|NCT01560884|Drug|Renazorb 6000 mg/day|Six subjects will be randomly assigned to receive SPI-014 6000 mg/day dose and 2 subjects to receive placebo
1687497|NCT01560871|Behavioral|High-intensity IMT plus walking|"The IMT intensity will be set at 60% of PImax which will be adjusted weekly and nose clip will be used. Frequency: 5x/week; 1x/day preferred. 6 Interval Levels: (6 efforts at each level): (1) 60s rest interval; (2) 45s rest interval; (3) 30s rest interval; (4) 15s rest interval; (5)10s rest interval; (6) 5s rest interval, trained to exhaustion.
For the walking program, each participant will be given a pedometer and a heart rate monitor so he/she can track daily step counts and heart rate during the study. The walking program will consist of walking every day at an intensity of hard to somewhat hard on the Rating of Perceived Exertion (RPE) scale. Participants will begin walking at least 15 minutes twice a day for 7 days a week and eventually progress to 45-50 minutes a day by the end of the six weeks."
1687498|NCT01560871|Behavioral|Low-intensity IMT plus walking|"The IMT training is about 15-20 minutes. Both groups will need to come in once a week for 15 to 20 minutes to probably readjust the IMT training intensity on the breathing device.
For the walking program, each participant will be given a pedometer and a heart rate monitor so he/she can track daily step counts and walking heart rate during the study. The walking program will consist of walking every day at an intensity of hard to somewhat hard on the Rating of Perceived Exertion (RPE) scale. Participants will begin walking at least 15 minutes twice a day for 7 days a week and eventually progress to 45-50 minutes a day by the end of the six weeks."
1687499|NCT01560845|Procedure|Autologous bone marrow stem cells infusion （ABMSCi） plus abdominal portal hypertension surgery|Immediately after the harvest of ABMSC, the modified Sugiura procedure was performed for the patients who were assigned to the study group. The time of ABMSC separation and purification was 2.5-3 hours which had to be completed before the conclusion of portal hypertension surgery (3-3.5 hours). ABMSC was infused into proper hepatic artery through right gastric artery during the portal hypertension surgery
1687500|NCT01560845|Procedure|open abdominal portal hypertension surgery|the modified Sugiura procedure was performed for the patients
1687501|NCT01560819|Drug|Gut Microbial Transplantation|Each participant received Gut Microbial Transplantation (GMT) as retention enema over a period of 1 hour (60mL enema every 15 minutes) daily for 5 days. Although 240mL of GMT solution was prepared for each participant, the final administered dose was dependent on the subject's comfort and willingness to proceed with the next enema, which was assessed after each enema infusion. Subjects were monitored for 30 minutes after GMT for any immediate adverse events and discharged.
1687502|NCT01560806|Other|Commune Hypertension Management|"People with high blood pressure will be invited to join the management programme, with monthly check-up, delivery of multi anti-hypertensive drugs and lifestyle consultation.
Antihypertensive drugs delivered to local patients included (1) low-dose hypothiazide diuresis, (2) calcium channel blocker and (3) ACEI"
1687995|NCT01557010|Drug|DWP05195|Tablets, oral administration, 300mg
1687503|NCT01560793|Biological|VAX161 [STF2.HA5 H5N1]|dose escalating, 2 intramuscular doses given 21 days apart
1687506|NCT01560767|Drug|Femoral Nerve Block|Under aseptic conditions, the femoral artery will be palpated immediately below the inguinal ligament and nerve stimulation will be used to identify the femoral nerve just lateral to the artery. Once the femoral nerve has been identified the block may be performed in the routine manner, using 30 ml of levobupivacaine 0.25%. The precise technique used will be noted on trial documentation.
1687507|NCT01560767|Drug|peri-articular infiltration|The peri-articular infiltration of multimodal agents will consist of 150 mg of levobupivacaine, 10 mg morphine and 30mg ketorolac diluted in 0.9% saline to make a volume 100 ml. (0.5ml 1:1000 adrenaline will be added to the mixture to reduce blood loss after the operation) Fifty ml of the mixture will be injected into the posterior, medial and lateral soft-tissues just prior to implantation of the TKA components. Care will be taken to avoid excessive infiltration in the area of the common peroneal nerve. Then, while the cement is curing, the anterior soft-tissues including the quadriceps mechanism, the retinacular tissues and the subcuticular tissues will be infiltrated with the remaining 50 ml of peri-articular injection.
1687508|NCT01560754|Drug|nicotine transdermal patch|Transdermal patches containing 7 or 14 mg nicotine or placebo with subjects titrating up until reaching their highest tolerated dose of 7 to 28mg/day.
1687509|NCT01560741|Device|Telemonitoring tools|Patients will go home with telemedicine tools to monitor efficacy and compliance of non-invasive home mechanical ventilation
1687510|NCT01560741|Device|Usual Care|The assessment of efficacy and compliance will be monitor at the end of third month. This is the date of the scheduled hospital visit.
1687511|NCT01560728|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|Individual psychotherapeutic approach occurring once per week for 12 to 20 weeks
1687512|NCT01560715|Biological|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
1687513|NCT01560702|Drug|Epinephrine|10-30 cc of 1/10000 diluted epinephrine will be injected at edges of an actively bleeding ulcer.
1687514|NCT01560702|Biological|Blood|5-20 cc autologous blood immediately withdrawn from the patient will be injected at edges of the actively bleeding ulcer.
1687515|NCT01560689|Drug|Budesonide/formoterol|800 µg/j twice a day, every day
1687516|NCT01560689|Drug|Placebo|Twice a day, every day
1687517|NCT01560676|Behavioral|HEALTH[e]TEEN|8 lessons over 6-8 weeks
1687518|NCT01560676|Behavioral|HEALTH[e]TEEN + CST|12 lessons over 6-8 weeks
1687519|NCT01560663|Drug|Docetaxel- Carboplatin|Docetaxel 75mg/m2 day 1 and Carboplatin(AUC6)day 1, each 21 days for 6 cycles.
1687520|NCT01560650|Device|CRRT|Difference dose of CRRT
1687521|NCT01560637|Drug|UT-15C (treprostinil diethanolamine)|UT-15C sustained release oral tablet for three times daily administration
1687522|NCT01560624|Drug|UT-15C (treprostinil diethanolamine)|UT-15C sustained release oral tablets for three times daily administration
1687523|NCT01560624|Drug|Placebo|Placebo (sugar pill) for three times daily oral administration
1687524|NCT01560611|Device|Near infrared spectroscopy|
1687525|NCT01560585|Drug|Isotretinoin|Isotretinoin 0.5 mg per kilogram body weight (rounded to nearest 10 mg) per day for 24 weeks
1687526|NCT01560572|Drug|tacrolimus OD, mycophenolic acid, prednisolone|tacrolimus maintenance 6-10 ng/ml, in the low dose tacrolimus group after 6 months fixed dose reduction of 50% tacrolimus through levels will be 3-5 ng/ml mycophenolic acid 2 dd 720mg, after 2 weeks reduced to 2 dd 540 mg in all groups methylprednisolone 500, 250, 125 mg on day 0, 1, and 2 in all groups prednisolone 1 dd 10 mg, and from week 6 prednisolone 7.5 mg in the standard immunosuppression and low dose tacrolimus group No prednisolone will be given the steroid free group
1687527|NCT01560559|Procedure|Peroral endoscopic myotomy|"An endoscopy is performed under anesthesia with orotracheal intubation. After submucosal saline injection, an entry point in the submucosal space is created at 10 cm above the cardia. The endoscope will create a 12cm long tunnel in the caudal direction by submucosal dissection, stopping at 2cm below cardia. Then the muscular circular internal layer is sectioned on a 9cm length, starting 3 cm below the submucosal entry point. At the end the submucosal entry point is closed with metallic clips. A scanner is performed after the procedure so as to check the esophageal wall integrity. Alimentation is progressively introduced at day 1.
This is a study of a procedure - peroral endoscopic myotomy (POEM). No new, unapproved device is used. All endoscopic tools are already approved for endoscopic submucosal dissection and associated complications (hemorrhage or perforation): dissection knifes, hot biopsy forceps, endoscopic metallic clips."
1687528|NCT01560546|Drug|Testosterone|50 mg/dose/day for 24 weeks
1687529|NCT01560546|Drug|Placebo|placebo on the skin for 24 weeks
1687530|NCT01560533|Behavioral|Interviews|Interviews will be done with patients
1687531|NCT01560520|Behavioral|Physical activity|Observation only
1687532|NCT01560507|Drug|varenicline (Chantix)|For the first 3 days after being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
1687533|NCT01560507|Drug|bupropion (Zyban)|After being switched from NRT (occurring at one week before the rescheduled quit date), smokers in this group will receive 150mg of bupropion once daily and 21mg nicotine patch for first 3 days; 150mg of bupropion twice daily and 21mg nicotine patch for 7 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
1687534|NCT01560507|Drug|nicotine patches|21mg nicotine patch for first 11 weeks; 14mg nicotine patch for next 2 weeks; 7mg nicotine patch for final 2 weeks.
1687996|NCT01557010|Drug|Control|Tablets, oral administration, Placebo
1687535|NCT01560494|Other|STAC curriculum|The STAC curriculum consists of theoretical preparation, case-based learning, proficiency-based virtual reality training, laparoscopic box training, and operating room participation.
1687536|NCT01560481|Drug|Step A: metformin glycinate 620 mg single dose|metformin glycinate 620 mg single dose
1687537|NCT01560481|Drug|Step A: metformin glycinate 1240 mg single dose|metformin glycinate 1240 mg single dose
1687538|NCT01560481|Drug|Step A: metformin glycinate 2480 mg single dose|metformin glycinate 2480 mg single dose
1687539|NCT01560481|Drug|Step A: metformin hydrochloride 1000 mg single dose|metformin Chlorhydrate 1000 mg single dose
1687540|NCT01560481|Drug|Step A: metformin glycinate 1240 mg,food intake|metformin glycinate 1240 mg, intake of food
1687541|NCT01560481|Drug|Step B: metformin glycinate 620 mg BID|metformin glycinate 620 mg BID, 8 days
1687542|NCT01560481|Drug|Step B: metformin hydrochloride 500 mg BID|metformin Chlorhydrate 500 mg BID, 8 days
1687543|NCT01560468|Drug|ITX 5061|300 mg given orally beginning at the time of liver transplantation and for 1 week post-transplant followed by 150 mg orally for an additional 21 days.
1687544|NCT01560455|Device|single stent|single stent
1687545|NCT01560455|Device|two stent|culotte
1687546|NCT01560442|Drug|Buprenorphine and Methadone Hydrochloride|To study the relation between pupillary diameter measured under scotopic conditions, and the pain thresholds measured at the time of peak and residual effect of methadone / buprenorphine in opiate-dependent patients following a substitution program.
1687547|NCT01560429|Procedure|Patient controlled epidural analgesia|Continuous epidural infusion rates were set to maintain pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in the post anesthesia care unit (PACU) following thoracotomy. Once stabilized patients were switched to Patient controlled epidural analgesia (PCEA) which meant they continued to receive 2/3rds of the dose as continuous background epidural infusions but they had the option to receive the remaining 1/3rd dosage via PCEA.
1687548|NCT01560429|Procedure|Continuous epidural analgesia|The continuous epidural analgesia (CEA) infusion rates were titrated to achieve pain scores of ≤ 3 on a numeric rating scale (NRS) of 0 to 10 while in post-anesthesia care unit (PACU) (as described for the PCEA group above). Those allocated to the CEA group remained on the same continuous epidural analgesia infusion which maintained the pain scores at ≤ 3.
1687549|NCT01560416|Drug|Fulvestrant|injection on day 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle
1687550|NCT01560416|Drug|Ganetespib|Intravenous, on days 1, 8 and 15 of each cycle
1687551|NCT01560403|Drug|Teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 12 months
1687552|NCT01560390|Drug|Rémifentamil + KETAMINE|All consecutive mechanically ventilated patients admitted in the ICU will be randomized to receive an infusion of 0.15 mg/kg/h of kétamine or placebo. Nurses and physicians will be blinded of the allocation arm. The infusion of ketamine will be stopped as soon as remifentanil will be discontinued by the physician.
1687553|NCT01560390|Drug|ketamine|to evaluate the impact of ketamine associated to an opioid for sedation of mechanically ventilated critically ill patients versus placebo. Sedation will be drive by nurses according to an algorithm. The investigators will evaluate the quantity of opioates used in each arm and the safety of ketamine.
1687555|NCT01560364|Other|renal replacement therapy|Prospective observational clinical multicentric study in ICU with acute renal failure requiring renal replacement therapy.
1687556|NCT01560351|Device|rTMS|Two sessions of repeated Transcranial Magnetic Stimulation (real rTMS and sham rTMS) are planned for each participant, at interval of 4 weeks, in a random order.
1687557|NCT01560325|Drug|CKD-516 inj.|CKD-516: 3.3~13mg/m2/day
1687558|NCT01560312|Device|Renal denervation (Symplicity® Catheter System™)|4-6 ablation in both renal arteries using the Symplicity® Catheter System™ (Ardian/Medtronic)
1687559|NCT01560299|Drug|Methimazole|Methimazole was stopped 24-48 before radio-iodine therapy
1687560|NCT01560299|Drug|Methimazole|methimazole discontinued 49-72 hours before radioiodine treatment
1687561|NCT01560299|Drug|Methimazole|methimazole discontinued 73-168 hours before radio-iodine treatment
1687562|NCT01560286|Biological|rAvPAL-PEG|Subcutaneous injection of rAvPAL-PEG administered from 1 time up to 5 times per week between 2.5mg up to a maximum of 375mg for 24 weeks.
1687563|NCT01560273|Device|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Posterolateral Fusion (PLF)
1687564|NCT01560260|Other|Laboratory Biomarker Analysis|Correlative studies
1687565|NCT01560260|Drug|Linsitinib|Given PO
1687566|NCT01560260|Other|Pharmacological Study|Correlative studies
1687567|NCT01560247|Procedure|Mechanical thrombectomy|Mechanical thrombectomy using a MindFrame device
1687568|NCT01560234|Drug|AZD8848|Single dose, oral inhalation (nebuliser solution)
1687569|NCT01560234|Drug|Placebo|Single dose, oral inhalation (nebuliser solution)
1687570|NCT01560221|Behavioral|Therapeutic Workplace|Participants can access stipend supported academic and job skills training for adults and/or receive wages or wage subsides for actual employment. Access to training and employment is contingent upon meeting therapeutic targets. Potential targets include, but are not limited to, drug abstinence and medication adherence.
1687571|NCT01560221|Drug|Methadone|Methadone in liquid form, with the dosage determined by physician on an individual basis. Anticipated dose range 30mg to 100mg daily. Methadone is administered daily at a methadone clinic for as long as enrollment in the methadone clinic is maintained.
1687572|NCT01560221|Drug|Buprenorphine|Subutex (buprenorphine hydrochloride) and Suboxone tablets (buprenorphine hydrochloride and naloxone hydrochloride) are approved for the treatment of opiate dependence. Subutex and Suboxone treat opiate addiction by preventing symptoms of withdrawal from heroin and other opiates.
1687573|NCT01560195|Drug|Pegylated rhG-CSF: 100µg/kg|Patients were administered pegylated rhG-CSF 100 ug/kg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
1688061|NCT01556451|Biological|Zoster Vaccine Live|Zoster vaccine live
1687574|NCT01560195|Drug|Pegylated rhG-CSF: 6mg|Patients were administered pegylated rhG-CSF 6mg once at the 3rd day of every chemotherapy cycle. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
1687575|NCT01560195|Drug|placebo and rhG-CSF 5ug/kg/d|Patients receiving chemotherapy and placebo in cycle 1 and rhG-CSF 5ug/kg/d in cycle 2 to 4. Chemotherapy regimen: docetaxel 75 mg/m2; carboplatin area under curve[AUC] 5 or cisplatin 75 mg/m2.
1687576|NCT01560182|Genetic|Autologous CD34+ stem cells transduced with ARSA encoding lentiviral vector|Autologous hematopoietic stem/progenitor cells collected from the bone marrow and transduced ex vivo with a Lentiviral vector encoding the human ARSA cDNA under the control of the human phosphoglyceratekinase (PGK) promoter. Dose: ≥ 2x10^6 transduced CD34+ cells/Kg (maximum 20x10^6) at bedside for infusion.
1687577|NCT01560143|Drug|Tigecycline|100 mg IV as a single infusion over 30 minutes
1687578|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss program|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention and an Internet-based behavioral weight loss program.
1687579|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss program + Groups|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and the option to attend group sessions.
1687580|NCT01560130|Behavioral|Shape Up Rhode Island + Online weight loss + Incentives|Participants assigned to this arm will receive the standard Shape Up Rhode Island statewide intervention, an Internet-based behavioral weight loss program, and monetary incentives for submitting self-monitoring information and for achieving clinically significant weight loss.
1687581|NCT01560117|Drug|Rituximab|Rituximab 375 mg/m2 i.v. every 2 months for 24 months
1687582|NCT01560104|Drug|Veliparib|
1687583|NCT01560104|Drug|Carboplatin|
1687584|NCT01560104|Drug|paclitaxel|
1687585|NCT01560104|Drug|placebo|
1687586|NCT01560091|Drug|silodosin|8mg PO Qday
1687587|NCT01560091|Procedure|Extra-corporeal shock wave lithotripsy|ESWL
1687588|NCT01560091|Drug|Tamsulosin|Tamsulosin 0.4mg PO Qday
1687589|NCT01560065|Dietary Supplement|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
1687590|NCT01560065|Dietary Supplement|myo-inositol + folic acid|4000mg myo-inositol + 400 µg folic acid
1687591|NCT01560052|Drug|methylprednisolone|"Original Cohort:
Oral methylprednisolone or placebo 0.8mg/kg/day with a maximum of 48mg/day x 2months, taper by 8mg/day every month, patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines
Low Dose Cohort:
Oral methylprednisolone or placebo 0.4mg/kg/day with a maximum 32mg/day and minimum of 24mg/day then reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.
Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy."
1687592|NCT01560052|Drug|Placebo|"Intervention: Drug: Placebo
Original Cohort:
Matching placebo tablets, all the patients will receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.
Low Dose cohort:
Matching placebo will be given reducing over 6-9months. All the patients will also receive optimal blood pressure control and full dose of ACE inhibitors or ARBs as recommended by guidelines throughout the trial.
Prophylactic trimethoprim/sulfamethoxazole (a single strength tablet daily or half a double strength tablet daily) will be used during the first 3 months after randomisation in the low dose cohort, for the prevention of severe PJP infection, unless there is a documented sulfa allergy"
1687593|NCT01560039|Device|TMS|Transcranial magentic stimulation of the motor cortex. Device Details : Model is Magstim TMS Rapid. Manufacturer : MAGSTIM CO LTD. Spring Gardens, Whitland, Carmarthenshire, Wales, U.K., SA34 0HR
1687594|NCT01560039|Other|Neurofeedback|EEG neurofeedback based on the primary motor cortex
1687595|NCT01560039|Other|Sham neurofeedback|Sham EEG neurofeedback
1687596|NCT01560026|Procedure|surgery|endometrial cancer with or without oophorectomy
1687597|NCT01560013|Drug|Naltrexone|Naltrexone, oral 50 mg per day.
1687598|NCT01560000|Dietary Supplement|Dietary fiber|Wheat, barley, oat and bran fibers added to a breakfast product
1687599|NCT01559987|Device|Manual Toothbrush only|ADA (American Dental Association) Reference Manual Toothbrush (MTB)
1687600|NCT01559987|Device|MTB + Waterpik Ultra Water Flosser 'High'|MTB + Waterpik Ultra Water Flosser 'High'
1687601|NCT01559987|Device|MTB + Floss (MTB+Floss)|MTB + Floss (MTB+Floss)
1687602|NCT01559974|Drug|Placebo|Placebo to 45'000 units of Cholecalciferol per month for 3 months
1687603|NCT01559974|Drug|Cholecalciferol|45'000 units of cholecalciferol per month for 3 months
1687604|NCT01559961|Drug|TTI-1612|Single intravesical 30-minute treatments with escalating doses of TTI-1612.
1687607|NCT01559935|Drug|carfilzomib|45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles.
1687608|NCT01559935|Drug|Dexamethasone|20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib.
1687609|NCT01559935|Drug|Clarithromycin|500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
1688884|NCT01549834|Drug|ABT-126|Low Dose
1687610|NCT01559935|Drug|Lenalidomide|25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
1687611|NCT01559935|Drug|Dexamethasone|40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed.
1687612|NCT01559935|Drug|Lenalidomide|10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
1687613|NCT01559922|Drug|Normal Saline|Administration of up to 2 study treatments administered 6 weeks apart
1687614|NCT01559922|Device|Artefill|Administration of up to 2 study treatments administered 6 weeks apart
1687615|NCT01559909|Device|Vacuum assisted socket technology (Harmony System, Otto Bock Healthcare)|The brim height of the socket will be systematically reduced
1687616|NCT01559896|Dietary Supplement|protein hydrolysate capsules and placebo capsules|Once in the study, 20 subjects will be randomly assigned to a group taking capsules containing 5 gr egg protein hydrolysate per day, and 20 to a group taking placebo capsules. The subjects consume the capsules during three consecutive days (period 1). Following a wash-out period of minimally four weeks, the treatments are crossed-over.
1687617|NCT01559883|Other|no intervention is being made|This is a Non-Interventional Study (NIS)
1687618|NCT01559857|Drug|Pioglitazone|30mg once daily for 12 weeks
1687619|NCT01559857|Drug|Sugar Pill|Placebo
1687620|NCT01559844|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 x 200 mg tablets) administered orally once daily
1687621|NCT01559844|Drug|Ribavirin|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1687622|NCT01559831|Biological|IXIARO|Vero-cell derived Japanese encephalitis (JE) vaccine IXIARO, 0.5 ml intramuscular
1687623|NCT01559818|Biological|IMM-101|IMM-101 10mg/mL, a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
1687624|NCT01559805|Behavioral|Positive Choices|A two-session, individually-focused intervention focusing on engagement in care, disclosure decision-making, and sexual risk reduction, with booster sessions after 1, 3 and 6 months.
1687625|NCT01559805|Behavioral|Personalized Cognitive Counseling|A one-session, individually-focused risk reduction intervention for MSM that has been selected by the CDC as a DEBI.
1687626|NCT01559753|Drug|Augmentin, Ceftriaxone, Cefotaxime, netilmycin, tobramycin|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.
Beta-Lactams:
Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS
Ceftriaxone : 2 g OD during 3 days, then 1 g OD
Cefotaxime : 2 g TDS during 3 days, then 1 g TDS
Aminoglycosides
Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)
Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
1687627|NCT01559753|Drug|compare 8 to15 days of antibiotic treatment|"All patients included in the study will be treated by a combination of antibiotics during the first 5 days, then by monotherapy for either 3 or 10 days according to their allocated group.
•
Beta-Lactams:
Amoxicillin + clavulanic Acid : 2 g TDS for 3 days, then 1 g TDS
Ceftriaxone : 2 g OD during 3 days, then 1 g OD
Cefotaxime : 2 g TDS during 3 days, then 1 g TDS
Aminoglycosides
Tobramycin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)
Netilmicin : loading dose of 10 mg/kg OD, then 8 mg/kg OD (adaptation in case of renal failure)
Dibekacin : loading dose of 6 mg/kg OD, then 5 mg/kg OD (adaptation in case of renal failure)"
1687628|NCT01559740|Drug|Bupivacaine|This is being used as the local anesthetic for the TAP blocks at either 0.25% or 0.125%. The block will be done once during the procedure.
1687629|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 15 mg/day.
1687630|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 30 mg/day
1687631|NCT01559727|Drug|prednisone|The patients with symptomatic heart failure are treated with prednisone at dose of 60 mg/day
1687632|NCT01559701|Drug|PF-00345439|5-80 mg twice-a-day for 12 months
1687633|NCT01559688|Behavioral|Accelerated Resolution Therapy (ART)|ART is a cognitive based therapy which integrates an eye movement technique while focusing on a problem (traumatic experience) during the therapy session.
1687634|NCT01559688|Behavioral|Waitlist|Fitness assessment or career counseling
1687635|NCT01559675|Drug|Hydrocortisone|Patients receive Hydrocortisone 100 mg at surgical incision followed by 100mg IV every 8 hours for the first 24 hours, followed by 75 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 8 hours for 24 hours, followed by 50 mg IV every 12 hours, followed by Prednisone 20 mg orally when oral diet is resumed
1687636|NCT01559675|Drug|Hydrocortisone|1/3 IV equivalent dose (IVED) (hydrocortisone equivalent of the patient's preoperative steroid dose) at surgical incision, followed by 1/3IVED for 24 hours, Patients subsequently treated with 1/4 IVED every 8 hours starting Postoperative day (POD 1), followed by 1/6 IVED every 8 hours on POD2 and every 12 hours starting POD 3. On POD 4 or when the patient was tolerating a regular diet, oral prednisone equal to the most recent IV hydrocortisone dose resumed
1687637|NCT01559662|Dietary Supplement|Sugared Chewing Gum (Juicy Fruit)|One stick of gum, 3 times daily from Postoperative day 1 to 7
1687638|NCT01559649|Behavioral|Establishing Validity and Reliability|Consecutive individuals admitted with suspected stroke will be recruited to participate. Individuals will undergo screening of swallowing and a videofluoroscopic swallow study within two hours. Eight screening items will be tested for validity and inter-rater reliability: 6 nonswallowing features and 2 swallowing features. Reliability in nursing observations of each screening item will be completed in all participants. Speech pathologists trained in the screening items will serve as the reference standard from which to compare reliability with registered nurses who routinely work on the hospital ward with stroke patients
1687639|NCT01559636|Biological|bivalent oral polio vaccine|vaccine given during immunization campaigns
1687640|NCT01559623|Procedure|retrospective data analysis|retrospective data analysis
1687641|NCT01559610|Other|Intervention Group|The patients were instructed by a nurse
1687642|NCT01559597|Biological|Tetanus toxoid vaccine|Two doses of tetanus toxoid vaccine separated at least 4 weeks. One arm receives the vaccine kept in cold chain and the other arm receives the vaccine kept in CTC
1688062|NCT01556438|Biological|LY2127399|Administered IV
1687643|NCT01559584|Radiation|ultraviolet A (UVA)|"0.5% solution of 8-methoxypsoralen (MOP) will be applied 20 minutes before UVA exposure (315-400nm).
UVA sessions will be carried out twice weekly aiming to achieve a phototoxic reaction, in the form of erythema and vesiculation. Once a phototoxic reaction will be achieved, the patient will be asked to rest until the reaction subsides and then resume the phototherapy sessions."
1687644|NCT01559584|Drug|Triamcinolone Acetonide|One monthly injections of intralesional triamcinolone acetonide
1687645|NCT01559558|Procedure|vaginal packing|vaginal packing after urodynamic studies, and repeat urethral pressure profile
1687646|NCT01559545|Drug|Metronidazole|Immediate release metronidazole 500 mg orally three times a day for 14 days
1687647|NCT01559545|Drug|Metronidazole-DRF1|Modified release metronidazole (DRF1) 500 mg orally three times a day for 14 days.
1687648|NCT01559545|Drug|Metronidazole-DRF2|Modified release metronidazole (DRF2) 500 mg orally three times a day for 14 days.
1687649|NCT01559519|Drug|Albumin|albumin 20% 1 g/Kg body weight for the first two days after TIPS followed by 0,5 g/Kg body weight at day 4 and then 0,5 g/Kg body weight once a week for three weeks.
1687650|NCT01559506|Device|Air Barrier System device|Device is deployed adjacent to the surgery site and activated.
1687651|NCT01559480|Drug|Desogestrel|Desogestrel 75 mcg Takes 1 capsule before bedtime for 6 months
1687652|NCT01559480|Drug|Placebo|Placebo capsule takes 1 capsule before bedtime for 6 months
1687653|NCT01559467|Other|Cardiovascular Magnetic Resonance Imaging|Routine clinical care plus cardiovascular magnetic resonance imaging early in the diagnostic process
1687654|NCT01559467|Other|Computed Tomography Angiography|Routine clinical care plus computed tomography angiography early in the diagnostic process
1687655|NCT01559454|Drug|Methadone|10-60 mg/day divided by 2-4 times a day for 6 months
1687656|NCT01559454|Drug|Buprenorphine/naloxone|4-16 mg/day divided by 2-4 times a day for 6 months
1687657|NCT01559441|Dietary Supplement|Beetroot Juice with oral fat load|140mL (9.6 mmol nitrate) beetroot juice (Beet It, James White drinks Ltd)
1687658|NCT01559441|Dietary Supplement|Carbohydrate control drink with oral fat load|140 mL (low-nitrate) carbohydrate control drink
1687659|NCT01559428|Dietary Supplement|Plant sterol-enriched margarine|Daily consumption of 20 gram of a plant sterol-enriched margarine (providing daily 3.0 gram of plant sterols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant sterol-enriched margarine is consumed together with a high-fat milkshake
1687660|NCT01559428|Dietary Supplement|Plant stanol-enriched margarine|Daily consumption of 20 gram of a plant stanol-enriched margarine (providing daily 3.0 gram of plant stanols), for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the plant stanol-enriched margarine is consumed together with a high-fat milkshake
1687661|NCT01559428|Dietary Supplement|Control margarine|Daily consumption of 20 gram of a control margarine, for a period of 4 weeks. At the end of the 4 weeks, subjects will undergo a postprandial test for 8 hours, in which 20 gram of the control margarine is consumed together with a high-fat milkshake
1687662|NCT01559415|Other|Meal replacement diet using Modifast|modifast intensive diet replacing all regular meals (500 kcal/d) for 5 weeks
1687663|NCT01559415|Other|Normal diet combined with Modifast diet|Combination of modifast and regular diet (1250 kcal/d) for 3 months
1687664|NCT01559402|Procedure|CPAP and 100% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cmH2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal carbon dioxide (CO2) level of 5 %. During emergence from anesthesia 100 % oxygen is used.
1687665|NCT01559402|Procedure|CPAP and 31% oxygen|During pre oxygenation and induction of anesthesia 100 % oxygen is used with a continuous positive airway pressure of 10 cm H2O, during maintenance of anesthesia a positive endexpiratory pressure of 10 cm H20 is used with controlled volume ventilation aiming at an end tidal CO2 level of 5 %. During emergence from anesthesia 31 % inspiratory oxygen or the inspiratory oxygen level needed to achieve a SpO2 of at least 96 % (if 31 % oxygen is not enough), is used.
1687666|NCT01559402|Procedure|No CPAP and 100% oxygen|This intervention follows a standard protocol without the use CPAP during induction of anesthesia.
1687667|NCT01559389|Drug|solifenacin succinate|5 mg daily up to 10 mg daily
1687668|NCT01559363|Drug|KD019 (tesevatinib)|
1687669|NCT01559350|Procedure|A right gastroepiploic artery in situ grafting|A right gastroepiploic artery in situ grafting in the right coronary artery system during OPCAB
1687670|NCT01559350|Procedure|A saphenous vein grafting|A saphenous vein grafting in the right coronary artery system during OPCAB
1687671|NCT01559337|Procedure|Nerve transfer|the dorsal branch was used as a pedicle nerve for reconstructing PDN defects
1687672|NCT01559324|Device|ECT|Bifrontal ECT, low dosage
1687673|NCT01559324|Device|ECT|Right unilateral electrode position, high dosage
1687674|NCT01559311|Device|CRT-P OFF|CRT Pacemaker
1687675|NCT01559311|Device|CRT-P ON|CRT Pacemaker
1687676|NCT01559311|Device|DDDR|Dual-chamber, rate-modulated pacemaker
1687677|NCT01559298|Drug|Aspirin (80 mg/d) + clopidogrel (75 mg/d)|Aspirin (80 mg/d) + clopidogrel (75 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months. Clopidogrel therapy will start within 24 hrs before the TAVI procedure in cases where a transfemoral approach is used and within 24 hrs after the TAVI procedure in cases where a transapical approach is used. The initial dose of clopidogrel will be of 300 mg followed by 75 mg/die. The duration of clopidogrel treatment will be of 3 months. Patients will be followed either by phone contact or clinical visits at 1- and 12-month follow-up.
1687678|NCT01559298|Drug|Aspirin|Aspirin (80 mg/d) Aspirin therapy will start at least 24 hrs before the TAVI procedure and continued for at least 6 months.
1687679|NCT01559285|Drug|0.75% ropivacaine concentration|0.75% ropivacaine 8ml was injected epidurally after induction of general anesthesia
1687680|NCT01559285|Drug|0.375% ropivacaine concentration|0.375% ropivacaine 8ml was injected epidurally after induction of general anesthesia
1687681|NCT01559285|Drug|0.2% ropivacaine concentration|0.2% ropivacaine 8ml was injected epidurally after induction of general anesthesia
1687764|NCT01558713|Drug|Bupivacaine + Fentanyl|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
1687682|NCT01559272|Drug|Paliperidone IR (Period 1)|Type= exact number, unit= mg, number=1, form= injection, route= intramuscular use. Single injection with 1 mg paliperidone IR in the gluteal or deltoid muscle.
1687683|NCT01559272|Drug|Paliperidone palmitate F015 (Panel A: treatment group 1)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique A, in the gluteal muscle.
1687684|NCT01559272|Drug|Paliperidone palmitate F015 (Panel A: treatment group 2)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 manufactured by milling technique B, in the gluteal muscle.
1687685|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 1)|Type= exact number, unit= mg, number= 75, form= injection, route= intramuscular use. Single injection with 75 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
1687686|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 2)|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
1687687|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 3)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
1687688|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 4)|Type= exact number, unit= mg, number=300, form= injection, route= intramuscular use. Single injection with 300 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
1687689|NCT01559272|Drug|Paliperidone palmitate F015 (Panel B: treatment group 5)|Type= exact number, unit= mg, number=450, form= injection, route= intramuscular use. Single injection with 450 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
1687690|NCT01559272|Drug|Paliperidone palmitate F016|Type= exact number, unit= mg, number=150, form= injection, route= intramuscular use. Single injection with 150 mg eq. 3-month formulation paliperidone palmitate F016 in the gluteal muscle.
1687691|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 1)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
1687692|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 2)|Type= exact number, unit= mg, number=525, form= injection, route= intramuscular use. Single injection with 525 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
1687693|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 3)|Type= exact number, unit= mg, number=350, form= injection, route= intramuscular use. Single injection with 350 mg eq. 3-month formulation paliperidone palmitate F015 in the gluteal muscle.
1687694|NCT01559272|Drug|Paliperidone palmitate F015 (Panel D: treatment group 4)|Type= exact number, unit= mg, number=175, form= injection, route= intramuscular use. Single injection with 175 mg eq. 3-month formulation paliperidone palmitate F015 in the deltoid muscle.
1687695|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 100 mg plus acetaminophen 250 mg
1687696|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 125 mg plus acetaminophen 250 mg
1687697|NCT01559259|Drug|Ibuprofen/acetaminophen|Two caplets of ibuprofen 150 mg plus acetaminophen 250 mg
1687698|NCT01559259|Drug|Ibuprofen|Two caplets of ibuprofen 200 mg
1687699|NCT01559259|Drug|Placebo|Two caplets of placebo
1687700|NCT01559233|Device|FPlus RF device for wrinkles and rhytide reduction|Six RF weekly treatments for face wrinkles and rhytides reduction using the FPlus device.
1687701|NCT01559220|Device|Deep Brain Stimulation|Implanted device
1687702|NCT01559194|Behavioral|Low Fat Diet plus exercise|Low fat diet plus exercise - Subjects were educated about a low fat diet plus exercise and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
1687703|NCT01559194|Behavioral|Low Carbohydrate diet + Exercise|Low carbohydrate diet plus exercise: Subjects were educated about a low carbohydrate diet and then followed for weight loss. They were also asked to monitor their physical activity by wearing a pedometer and recording the total steps walked every day.
1687704|NCT01559168|Device|UpholdTM LITE placement|Uphold TM LITE mesh is used for the surgical correction of pelvic organ prolapse.
1955497|NCT03179943|Drug|Atezolizumab|Patients will be administered atezolizumab intravenously on day 1 and day 22 of a 6 week cycle for the period of 8 cycles.
1687707|NCT01559129|Drug|Pomalidomide (CC-4047)|1 mg orally every day for 52 weeks
1687708|NCT01559129|Drug|Placebo|Placebo
1687709|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
1687710|NCT01559116|Drug|tiotropium|low dose
1687711|NCT01559116|Drug|olodaterol|one dose only
1687712|NCT01559116|Drug|tiotropium|high dose
1687713|NCT01559116|Drug|tiotropium + olodaterol|low dose + one dose only
1687714|NCT01559116|Drug|Placebo|placebo matching tiotropium+olodaterol FDC
1687715|NCT01559116|Device|Respimat|Respimat inhaler
1687716|NCT01559103|Biological|MEDI5117|Intravenous infusion administered over 60 minutes, will be one of the following doses: 30, 100, 300, or 600 mg
1687717|NCT01559103|Biological|MEDI5117 Placebo|Intravenous infusion administered over 60 minutes
1687718|NCT01559090|Drug|MEDI-546|Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
1687719|NCT01559090|Drug|MEDI-546|Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
1687720|NCT01559090|Drug|MEDI-546|Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.
1687721|NCT01559077|Drug|ALN-TTR02|Dose levels between 0.01 and 0.5 mg/kg by intravenous (IV) infusion
1687722|NCT01559077|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
1687723|NCT01559064|Device|Crosslinked hyaluronic acid gel (Juvéderm VOLUMA®)|All treatment details are at the discretion of the investigator and should be guided by the appropriate directions for use.
1687724|NCT01559051|Procedure|Lipoaspiration with Local anesthesia|Patients undergo a liposuction under local Anethesia. The AD-SVF are then isolated and infused IV and by inhalation delivery.
1687725|NCT01559025|Drug|Vildagliptin|Vildagliptin ( Galvus 50mg twice day) during one year
1687726|NCT01559012|Drug|Clonidine|transdermal clonidine patch 5 mg q. 5 days
1687727|NCT01558999|Drug|High concentration SI-614|1 drop in each eye 4 times a day
1687728|NCT01558999|Drug|Low concentration SI-614|1 drop in each eye 4 times a day
1687729|NCT01558999|Drug|Vehicle|1 drop in each eye 4 times a day
1687730|NCT01558986|Procedure|Cefazolin|Patients received intravenous cefazolin 1 gram within 30 minutes prior to skin incision;
1687731|NCT01558986|Procedure|Sterile water|Patients received sterile water only within 30 minutes prior to skin incision
1687732|NCT01558960|Drug|IVit Melphalan|IVit injections of Melphalan
1687733|NCT01558947|Drug|Peri-operative chemotherapy of ECX|Preoperative chemotherapy of ECX for 3 cycles(Epirubicin 50mg/m2 on day 1; capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of ECX for 3 cycles 4~6 weeks after surgery.
1687734|NCT01558947|Drug|Peri-operative chemotherapy of XP|Preoperative chemotherapy of XP for 3 cycles(capecitabine 1000mg/m2, 2 times / day, 1 to 14 days; cisplatin 60mg/m2 on day 1, need hydration, 21 day/cycle), operation after 2~4 weeks, and postoperative chemotherapy of XP for 3 cycles 4~6 weeks after surgery.
1687736|NCT01558921|Other|M1 scheme|short course 5 x 5 Gy radiation scheme is followed by six cycles of combination chemotherapy (capecitabine and oxaliplatin (CAPOX)) and surgery. FOLFOX4 may be given as alternative for CAPOX
1687737|NCT01558921|Other|standard long course chemoradiotherapy|long course chemoradiotherapy followed by surgery. Optional adjuvant chemotherapy (CAPOX or FOLFOX) is allowed in the control group.
1687738|NCT01558908|Biological|Administration of ERC|Patients will be treated with either 25 million, 50 million, or 100 million ERC by intramuscular injection.
1687739|NCT01558895|Radiation|Infrared ray heat treatment|Patients in experimental group accepted Infrared ray heat treatment in hepatic area for 30 minutes as well as conventional therapy.
1687740|NCT01558895|Other|conventional treatment|Conventional treatment consists of antiviral drugs, lowering aminotransferase and jaundice medicine.
1687741|NCT01558882|Device|Essure|Essure devices are deployed according to manufacturer's instructions for tubal sterilization.
1687742|NCT01558869|Drug|Capecitabine|1200 mg/m2 BD orally for 1 week of a 2-week cycle (i.e. 1 week on, 1 week off)
1687743|NCT01558869|Drug|Oxaliplatin|70 mg/m2 IV on day 1 of a 2-week cycle
1687744|NCT01558869|Drug|Irinotecan|130 mg/m2 IV on day 1 of a 2-week cycle
1687745|NCT01558856|Procedure|Unilateral electrode placement and testing|An electrode is placed near a sacral nerve with an anal motor response under general anesthesia. During and adjustment phase, the electode is connected to a test box which allows for adjustment of stimulation parameters. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
1687746|NCT01558856|Procedure|Bilateral electrode placement and testing|Two electrodes are placed, one near each sacral nerve under general anesthesia. During an adjustment phase, the electodes are connected to a test box which allows for adjustment of stimulation parameters. This can result in the use of one or the other, or both electrodes, thus increasing the chances of success and the possibility that the patient is eligible for an implant. After pinpointing stimulation parameters, the external test box is replaced by an implanted device.
1955498|NCT03179943|Drug|Guadecitabine|Guadecitabine will be administered subcutaneously on days 1 through 5 of the 6 week cycle for the period of 4 cycles
1687749|NCT01558817|Behavioral|Informed Assent|Patients receive informed assent approach toward in-hospital CPR outcomes. Patients are informed that their underlying chronic illness makes outcomes after CPR so poor that CPR is not performed while allowing them to disagree.
1687750|NCT01558817|Behavioral|Informational Brochure|An informational brochure about CPR will be given without a discussion with a physician.
1687751|NCT01558804|Other|Identifying group A strep carriers|At study entry and at 14 days: Standard culture for GAS and analysis of mRNA.
1687752|NCT01558791|Other|TBI handout|The intervention is an educational handout which covers key concepts found in the empirical literature and explicated in the VA/DoD mTBI practice guideline; (1) the meaning of a positive screen, (2) symptoms may be due to another condition, (3) most people with mTBI recover.
1687753|NCT01558778|Procedure|management of therapy complications|Undergo mechanical stimulation
1687754|NCT01558778|Procedure|musculoskeletal complications management/prevention|Undergo mechanical stimulation
1687755|NCT01558765|Other|Integrated rehabilitation|Integrated rehabilitation consisting of exercise training (3 times per week (1 hour) for 12 weeks) and psycho-educational care (5 consultations over 6 months by special trained nurses).
1687756|NCT01558752|Device|Total hip replacement with titanium shell and CORAIL stem|Total hip replacement with titanium shell and CORAIL stem
1687757|NCT01558752|Device|Total hip replacement with Modular Titanium Femoral Stem (Tri-lock)|Total hip replacement with modular titanium femoral stem (Tri-lock)
1687758|NCT01558739|Drug|INC424|Ruxolitinib was provided in 5 mg tablets, packaged in bottles. 15 - 20 mg (dose based on Baseline platelet count) twice daily.
1687759|NCT01558726|Behavioral|Case Management (Strength-Based)|To improve the cases sharing between CAPSad and other health institutions and individuals and increase the strengths of the patient to cope with problems related to the crack use.
1687760|NCT01558726|Behavioral|Usual Treatment|The usual treatment used for regular patients of CAPSad
1687761|NCT01558713|Drug|Bupivacaine- Fentanyl - Normal Saline|Bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
1687762|NCT01558713|Drug|Ropivacaine-Fentanyl-Normal Saline|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
1687763|NCT01558713|Drug|Levobupivacaine- Fentanyl- Normal Saline|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus, Normal Saline 0,9%, 10ml bolus
1687765|NCT01558713|Drug|Ropivacaine + Fentanyl|Ropivacaine 0,75%, 2ml (15mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus.
1687766|NCT01558713|Drug|Levobupivacaine + Fentanyl|Levo-bupivacaine 0,5%, 2ml (10mg)bolus, Fentanyl 50μg/ml, 0,2ml (10 μg)bolus
1687767|NCT01558700|Drug|Duloxetine|Duloxetine capsule 30mg once a day for one week, then 60mg once a day for 15 weeks, then 30mg once a day for one week.
1687768|NCT01558700|Drug|Sugar pill|Matching capsule given once a day for a total of 17 weeks.
1687769|NCT01558687|Drug|Drug (including placebo)|"Subjects will receive cilengitide monotherapy for 2 weeks (Weeks 1 and 2); thereafter, cilengitide will be given in combination with the standard treatment regimen during Weeks 3 to 36. The standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
Cilengitide monotherapy treatment will be given to subjects in Group A for another 10 months as maintenance treatment (Weeks 37 to 78). Subjects in Group A may continue to receive cilengitide maintenance treatment beyond 10 months (beyond Week 78) until occurrence of progressive disease (PD) or unacceptable toxicity, or withdrawal for any other reason. A 28-day safety follow-up will be performed after the last dose of cilengitide."
1687770|NCT01558687|Other|Standard therapy|In the first two weeks, treatment of subjects in Group B will be in line with the SoC. Thereafter the standard combination treatment of radiotherapy (RTX) plus Temolozomide (TMZ) will be administered for a maximum of 6 weeks (Weeks 3 to 8), followed by TMZ maintenance treatment starting 4 weeks after RTX (i.e., Week 13) for up to 6 cycles, 4 weeks per cycle.
1687771|NCT01558674|Drug|MK-7145|
1687772|NCT01558674|Drug|Furosemide|
1687773|NCT01558674|Drug|Torsemide|
1687775|NCT01558648|Behavioral|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
1687776|NCT01558648|Behavioral|Quality of Life instruments, FACT-E, Symptom Assessment Scale, Brief Pain Inventory and Daily Analgesic Log|Initial pre-operative assessment post-operative assessment in-hospital assessment at first post-operative visit (clinic visits, or by telephone or mail) assessments at 4, 8, 12, 18, and 24 months post-operatively (+/- 2 month window). For patients who have their surgery delayed, they may be asked to complete another, more updated set of pre-surgery surveys. For the dysphagia score and CT Scan vs EUS subset will be a dysphagia questionnaire, administered at the time of the initial clinic visit.
1687777|NCT01558635|Device|Maze III procedure with Cardioblate CryoFlex Surgical Ablation System|During planned mitral valve surgery, longstanding persistent AF was treated with the Cox Cryo Maze III procedure by using Cardioblate CryoFlex Surgical Ablation System. In addition, the Medtronic Reveal XT Insertable Cardiac Monitor, was implanted.
1687784|NCT01558596|Procedure|Preconditioning|Blood pressure cuff inflated to 200 mmHg in the upper extremity for 5 minutes to cause forearm ischemia by external compression of the brachial artery. This will be followed by 5 minutes of cuff deflation to allow for preperfusion. The ischemia-reperfusion cycle will be repeated 3 times for a total duration of 30 minutes, equally divided between ischemia and reperfusion.
1687785|NCT01558596|Procedure|Control|Blood pressure cuff inflated to 40-50 mmHg in the upper extremity
1687786|NCT01558583|Other|Rating and Ranking Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a rating and ranking format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
1687787|NCT01558583|Other|Discrete Choice Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a discrete choice format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
1687788|NCT01558583|Other|Balance Sheet Task|Individuals who are randomized to the rating and raking arm will be asked to complete an informational task in a balance sheet format. The task will help individuals clarify their opinions and preferences regarding colon cancer and prostate cancer screening.
1687789|NCT01558570|Procedure|Blood Draw|One time blood draw
1687790|NCT01558557|Other|Gluten Free Diet|Participants will be given a Gluten Free Diet for 2 weeks
1687791|NCT01558544|Procedure|surgery to remove ovaries or high dose chemotherapy|oophorectomy to remove a disease ovary.
1687792|NCT01558531|Device|DEB|paclitaxel-eluting balloon angioplasty
1687793|NCT01558531|Device|POBA|conventional balloon angioplasty
1687794|NCT01558505|Device|PEB|paclitaxel-eluting balloon angioplasty
1687795|NCT01558505|Device|POBA|conventional balloon angioplasty
1687796|NCT01558492|Drug|Carboplatin|AUC = 5 intravenously (IV) on day 1 of a 28 day cycle
1688063|NCT01556438|Drug|Bortezomib IV|Administered IV
1955507|NCT03176134|Drug|MK-1986|MK-1986 IV solution or oral suspension
1955508|NCT03176134|Drug|Comparator|Vancomycin IV, linezolid IV or oral, clindamycin IV or oral, flucloxacillin IV or oral, cefazolin IV, or cephalexin oral provided locally by the trial site and administered per local standard of care
1687797|NCT01558492|Drug|Paclitaxel|80 mg/m2 intravenously (IV) weekly on days 1, 8, and 15 of a 28 day cycle
1687798|NCT01558466|Drug|Sildenafil|50 mg tablet will be thoroughly crushed into powder form and diluted in 10 ml ora base suspension syrup agent and a dilution will be performed to prepare 5 mg/ml. All doses required for 48 hours will be available; solutions will be stored at 2-8 degrees C where solution should be stable for at least a month.
1687799|NCT01558466|Drug|diluent|The placebo will have an equal volume of diluent - Orabase syrup of the same colour and viscosity as the active comparator. Infants in this group will receive normal saline as placebo every 6 hours
1687800|NCT01558453|Drug|Oxaliplatin|"Oxaliplatin will be administered in a 130 mg/m² dose, 2 hour IV infusion, once every 3 weeks. Each cycle will last 3 weeks, or 21 days. Drug will be administered till progression disease or untolerable adverse event.
NOTE: patients with ≤ 12 months old will receive a 4,3 mg/kg dese (based on a 30 kg/m² conversion; i.e: in a 130 mg/m² dose, divided by 30)."
1687801|NCT01558440|Dietary Supplement|Infant Formula|A diet that is being fed to the young infants.
1687802|NCT01558440|Dietary Supplement|F-100|• F-100: The estimated PRSL for F-100 is 360 mOsm/L or 53 mOsm/100kcal and in a young infant growing normally this could exceed the excretory capacity of the kidney with the risk of hypernatremic dehydration. In the rehabilitation phase, however, severely malnourished children grow extremely rapidly and the potential solutes (e.g. protein, potassium) are deposited in lean tissue and do not present to the kidney for excretion. Thus, although the potential RSL is high, this has been assumed to be a theoretical risk for rapidly growing infants
1687803|NCT01558440|Dietary Supplement|Diluted F-100|300 ml of water is added to 1000 ml of f-100
1687804|NCT01558427|Procedure|Surveillance|Active clinical surveillance
1687805|NCT01558427|Procedure|Salvage treatment|Surgical removal of metastases, or stereotactic body radiotherapy of metastases.
1687806|NCT01558414|Procedure|SILS Cholecystectomy|Cholecystectomy performed by Single Incision Laparoscopic Surgery with the SILS TM device
1687807|NCT01558414|Procedure|FSIS cholecystectomy|Cholecystectomy performed by Flexible Single Incision Surgery with the flexible endoscope through a single incision at the umbilicus
1687808|NCT01558414|Procedure|Conventional laparoscopy|Minimally invasive cholecystectomy through the conventional laparoscopic approach using 3 ports (one 11-cm umbilical port and two accessory 5-mm ports).
1687809|NCT01558401|Other|Physical activity program|The activities are done in groups of no more than 25 individuals; these activities are standardized and agreed upon by the research team, which hold monthly meetings to conduct the study. Each physical activity session consists of 8-10 minutes of exercises aimed at stretching the major muscle groups (pectoral muscles, latissimus dorsi, cervical paravertebral, and posterior and anterior thigh muscles); 9 minutes of aerobic endurance activity (march/fast walk); 7-10 minutes of adapted strength exercises, power, and endurance training; 14-16 minutes of coordination, agility, and flexibility exercises, and 5-7 minutes of respiratory and relaxation exercises.
1687810|NCT01558388|Drug|Lactobacillus acidophilus|Lactobacillus acidophilus 500 million colony-forming units/tablets. One vaginal tablet daily for 10 days.
1687811|NCT01558388|Drug|Placebo|One vaginal tablet daily for 10 days.
1687812|NCT01558375|Drug|Water for injection|Placebo syringes will contain 0.67ml of sterile water for injection. This will be injecteda daily for 12 weeks.
1687813|NCT01558375|Drug|Anakinra|Anakinra will be supplied in single use pre-filed glass syringes with 27-gauge needles. Anakinra syringe will contain 100mg of anakinra at a volume of 0.67 ml. This will be injected subcutaneously daily for 12 weeks.
1687814|NCT01558362|Drug|123I-CMICE-013|2 intravenous doses of drug will be given one week apart. Doses will be equivalent to 1 rest dose and 1 stress dose. Serial nuclear imaging will follow dose injections.
1687815|NCT01558336|Drug|praziquantel|praziquantel 40 mg/kg oral tablets
1687816|NCT01558323|Drug|LCQ908|Participants will receive a single oral dose of LCQ908
1687817|NCT01558310|Drug|Ustekinumab|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. Group B will receive placebo at Week 0 and 4, and ustekinumab at weeks 12, 16, 28, 40 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
1687818|NCT01558310|Drug|Placebo|Subjects will be randomized into one of two groups. Group A will receive ustekinumab at week 0, 4, 16, 28, and week 40 and placebo at week 12 and 52. The subjects when assigned to ustekinumab, depending on body weight, will receive either 45mg or 90mg ustekinumab doses
1687819|NCT01558297|Behavioral|Motivational Interviewing|5 sessions of motivational interviewing over a period of 3 months.
1687820|NCT01558297|Behavioral|Nutritional Counseling|5 sessions of nutritional counseling over a period of 3 months.
1687821|NCT01558297|Behavioral|Treatment as usual with primary care physician|Participants will be encouraged to continue their care with their primary care physician.
1687822|NCT01558284|Drug|Neu-P11|Neu-P11 is a new Melatonin receptor-, Serotonin 5-HT- 1A and 5-HT- 1D - agonist and a serotonin 5-HT- 2B - antagonist
1687823|NCT01558284|Drug|Placebo|Placebo
1687824|NCT01558271|Drug|LY2189265|
1687825|NCT01558271|Drug|Placebo|
1687826|NCT01558271|Drug|Liraglutide|
1687827|NCT01558258|Behavioral|Mindful Awareness practices (MAPs)|Mindfulness meditation-based intervention, is a 6-week program adapted from an existing program at Mindfulness Awareness Research Center(MARC),UCLA.
1687828|NCT01558245|Drug|tissue kallikrein|Human urinary kallidinogenase can transform kininogen to bradykinin (kinin) and vasodilatory factors (kallidin)
1687829|NCT01558232|Device|Tibion Bionic Leg|The Tibion Bionic Leg is used as an adjunct in post-stroke and post-operative rehabilitative physical therapy. The leg is a lightweight, wearable, portable, battery-powered, motorized leg orthosis that provides active assistance and resistance to lower limb movement during walking, stair ascent and descent, and transfers from sitting to standing (and standing to sitting).
1687830|NCT01558219|Drug|cabacitaxel|Jevtana® (cabazitaxel) 16 mg/m2 IV in 1 hour on day 1 given every second week
1687831|NCT01558206|Other|Pulmonary artery CT Angiography|Performing Pulmonary artery CT Angiography for patients with signs and symptoms in favor of PTE.
1687832|NCT01558206|Other|Emergency Bedside Ultrasonography of chest|Performing Emergency Bedside Ultrasonography of chest at the time of presentation for patients with signs and symptoms in favor of PTE.
1688885|NCT01549834|Drug|ABT-126|High Dose
1687833|NCT01558193|Dietary Supplement|Placebo|"Placebo for DHA of identical appearance - based on olive oil
Placebo for vitamins/minerals of identical appearance"
1687834|NCT01558193|Dietary Supplement|Multi-vitamin/mineral|Each active tablet contained vitamins A (800µg); B1 (1.4mg); B2 (1.75mg); B6 (2mg); B12 (2.5mg); biotin 62.5 µg; folic acid 200 µg; niacin 20 mg; C (100mg); D (5µg); E (15mg); K (30µg); pantothenic acid (7.5 mg). In addition several minerals were administered: calcium (162mg); phosphorus (125mg); magnesium (100mg); potassium (40mg); chloride (36.3mg); iron (5mg); iodine (100µg); copper (500µg); manganese (2mg); chromium (40µg); molybdenum (50µg); selenium (30µg); zinc (5mg) as well as lutein (500 µg) . The placebo capsule was identical in color, size and appearance.
1687835|NCT01558193|Dietary Supplement|Docosahexaenoic acid|22:6 (n-3) docosahexaenoic each capsule contained 224.2mg and three were taken per day
1687836|NCT01558193|Dietary Supplement|DHA plus vitamins/minerals|The DHA and vitamin/mineral supplements are as above
1687837|NCT01558180|Behavioral|Telephone Care Management|series of phone calls from registered nurse to discuss behavioral suggestions for pediatric insomnia
1687838|NCT01558180|Behavioral|Usual Care|educational handouts on pediatric insomnia
1687839|NCT01558167|Drug|Bendamustine, Rituximab, Lenalidomide|"Bendamustine: 50 mg/m2, i.v., day 1+2 Rituximab: Cycle 1: 375 mg/m2, i.v. day 0; Cycle 2-6: 500mg/m2, i.v., day 1
Lenalidomide:
Dose level 1: Cycle 1-6: 2,5mg p.o., d1-28
Dose level 2: Cycle 1: 2,5mg p.o., d1-28; Cycle 2-6: 5mg p.o., d1-28
Dose level 3: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3-6: 10 mg p.o., d1-28
Dose level 4: Cycle 1: 2,5mg p.o., d1-28; Cycle 2:5mg p.o., d1-28; Cycle 3: 10 mg p.o.,d1-28, Cycle 4-6: 15 mg p.o.,d1-28
Dose level 5: maximal tolerated dose"
1687840|NCT01558154|Drug|Chinese herbs|Chinese herbs special for depression
1687841|NCT01558154|Procedure|acupuncture|six acupuncture point including DU20, EX HN3, EX HN1, PC6,HT7,SP6,special for depression
1687842|NCT01558154|Other|Psychotherapy|Thought Imprint Psychotherapy under lower Resistance State
1687843|NCT01558154|Device|Transcranial magnetic stimulation|Give magnetic stimulation at head
1687844|NCT01558141|Other|Aspiration without flushing follicles with culture media|Aspiration without flushing follicles with culture media.
1687845|NCT01558141|Other|Follicular Flushing|Flushing follicles with embryo culture media prior to aspiration.
1687846|NCT01558128|Drug|Amiodarone|Bolus given 150mg IV, then IV drip 1mg per hour infused for 6 hours, 0.5mg per hour infused for 18 hours.
1687847|NCT01558128|Procedure|Cardioversion|Cardioversion done if atrial fibrillation continues following 24 hour infusion of amiodarone. Cardioversion done following hospital protocol.
1687848|NCT01558115|Drug|Denosumab|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection.
The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.
Group # 1 (35 patients): Receive active drug for year 1 and year 2 of the study
Group #2 (17 patients): Receive placebo for year 1 and active drug for year 2 of the study"
1687849|NCT01558115|Other|Placebo|"The dose of denosumab is 60 mg every 6 months by subcutaneous injection. The placebo group will receive vehicle injections at the same time interval.
The 52 subjects will be randomly allocated (2:1) into treatment and placebo arms with the placebo group receiving a subcutaneous injection of vehicle in year 1. In year 2, those who were allocated to the study drug in year 1 will continue in year 2. Those who were allocated to placebo in year 1 will be crossed over to study drug in year 2.
Group # 1 (35 patients): Receive active drug for year 1 and year 2 of the study
Group #2 (17 patients): Receive placebo for year 1 and active drug for year 2 of the study"
1687850|NCT01558089|Drug|etanercept|according to SmPC and clinical practice
1687851|NCT01558089|Drug|methotrexate|according to SmPC and clinical practice
1687852|NCT01558063|Drug|Ketamine|Single dose of 0.1, 0.2, 0.3, 0.4 or 0.5 mg/kg of ketamine given intravenously over 40 minutes.
1687853|NCT01558063|Drug|Saline|Single infusion of saline given intravenously over 40 minutes.
1687854|NCT01558050|Dietary Supplement|red rice supplement|patricipants take a red rice supplement or placebo daily for 8 weeks
1687855|NCT01558011|Drug|Capecitabine, Oxaliplatin, Docetaxel|"Capecitabine: 500 mg film coated tablets; Oxaliplatin: 50 mg/ 10 ml; Docetaxel: 20 mg / 0.5ml vial.
Dosing Regimena: total of 6 cycles of modified XELOX regimen repeats every 2 weeks, and followed by 4 cycles of TX repeats every 3 weeks. After 10 cycles of treatment, patients may continue to treat with either of the regimen, preferably the one having the best efficacy."
1687857|NCT01557985|Drug|Bupivacaine|The volume of Bupivacaine per block will be 0.5 mL at 0.125%.
1687858|NCT01557972|Procedure|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger prediction power for the outcomes.
1687859|NCT01557972|Procedure|Blood pressure measurement based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes
1687860|NCT01557959|Drug|cisplatin|Given IV
1687861|NCT01557959|Biological|pegfilgrastim|Given SC
1687862|NCT01557959|Drug|erlotinib hydrochloride|Given PO
1687863|NCT01557959|Other|laboratory biomarker analysis|Optional correlative study
1687864|NCT01557959|Genetic|polymorphism analysis|Correlative study
1687865|NCT01557959|Other|pharmacogenomic studies|Correlative study
1687866|NCT01557959|Genetic|genetic linkage analysis|Correlative study
1687867|NCT01557959|Drug|docetaxel|Given IV
1687868|NCT01557946|Drug|citalopram|citalopram 20-40 mg daily
1687869|NCT01557933|Other|No interventions will be used|No interventions will be used
1687870|NCT01557920|Drug|Propofol|Propofol administration for induction of general anesthesia. Administration will be performed IV, using a Target Controlled Induction Pump.
1687871|NCT01557920|Drug|Sevoflurane|Sevoflurane will be administered via mask inhalation to achieve anesthesia.
1687872|NCT01557907|Device|Subcutaneous delivery via Medtronic Quick-Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
1687873|NCT01557907|Device|Intradermal delivery via the BD Research Catheter Set|Infusion rates and pre-meal bolus doses will be based on subjects known daily infusion rate and subject's reported insulin to carbohydrate ratio.
1687874|NCT01557894|Other|iSOFIE|Cognitive - Behavioral: Internet-administrated CBT for social phobia that contains 9 self-help text modules and exercises (i.e., behavioral experiments)
1687875|NCT01557881|Device|magnetic resonance imaging with positron emission tomography scanning|University Hospitals Seidman Cancer Center [SCC] will house the Philips Ingenuity TF PET/MR, which is a hybrid scanner that merges magnetic resonance imaging with positron emission tomography scanning. University Hospitals is one of only five hospitals in the world with this technology. The PET/MRI system consists of two imaging scanners used sequentially as in PET/CT. The 3Tesla MRI component provides the high resolution that is necessary for soft tissue contrast and functional information on perfusion, diffusion, or metabolism. PET provides information about cellular metabolism and receptor status.
1687876|NCT01557868|Device|hylan G-F 20|Three 2 cc injections at weekly intervals
1687877|NCT01557868|Device|1% sodium hyaluronate|Three 2 cc injections at weekly intervals
1687878|NCT01557842|Drug|Drug Treatment|Class I and III antiarrhythmic drug treatment.
1687879|NCT01557842|Device|Catheter Ablation|Radiofrequency catheter ablation and Class I and III antiarrhythmic drug treatment.
1687880|NCT01557829|Device|Posterior lumbar interbody fusion with a PEEK cage|PEEK cage suitable for oblique placement in the lumbar spine
1687881|NCT01557829|Device|Posterior lumbar interbody fusion with a Valeo OL cage|Posterior lumbar interbody fusion with a single Valeo OL ceramic cage.
1687882|NCT01557816|Drug|Naproxen|Naproxen for 7 days (3 days at 250 mg BID followed by 4 days at 500 mg BID) during either of the 2 treatment periods.
1687883|NCT01557816|Drug|Placebo|Placebo for seven days given BID during either of the 2 treatment periods.
1687884|NCT01557790|Radiation|Proton Radiation Therapy|
1687885|NCT01557777|Drug|Navitoclax|QD
1687886|NCT01557764|Drug|lapatinib ditosylate|Given PO
1687887|NCT01557764|Biological|trastuzumab|Given IV
1687888|NCT01557751|Genetic|Whole blood for genotyping|This study requires genotyping by extracting DNA from blood sample. A blood sample will be drawn once during visit 2 (day of surgery) or any other time prior to that after the signing of informed consent. Four vacutainers of which hold 8.5 mL will be drawn during this time totaling approximately 34 mL of blood which completes the genomic sampling portion of the study.
1687889|NCT01557738|Dietary Supplement|High Flavanol Trial|The experimental trial (high flavanol content) will involve the consumption of a beverage containing about 1000mg of cocoa flavanols.
1687890|NCT01557738|Dietary Supplement|Low Flavanol Trial|The placebo trial (low flavanol content) will involve the consumption of a beverage containing 75 mg of cocoa flavanols.
1687891|NCT01557738|Dietary Supplement|High Flavanol Trial; long-term|The experimental trial (high flavanol content) will involve the daily consumption of a beverage containing about 1000mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets of the beverage to take home with them.
1687892|NCT01557738|Dietary Supplement|Low Flavanol Trial; long-term effects|The placebo trial (low flavanol content) will involve the daily consumption of a beverage containing 75 mg of cocoa flavanols for 4 weeks. Subjects will be provided with 28 packets to take home with them.
1687893|NCT01557712|Drug|ketamine venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:
Intravenous injection on day 0 to 0.5 mg / kg of ketamine
D0 to D4: 75 mg of venlafaxine
D4 to D14: 150 mg per day of venlafaxine
D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
1687894|NCT01557712|Drug|Venlafaxine|"After a washout period of 7 days of psychotropic medications with the exception of cyamemazine and hydroxyzine:
Intravenous injection on day 0 to 0.5 mg / kg of placebo (saline serum)
D0 to D4: 75 mg of venlafaxine
D4 to D14: 150 mg per day of venlafaxine
D14 to D42: 150 mg daily of venlafaxine to 375 mg per day of venlafaxine if patient not responder"
1687895|NCT01557699|Biological|PMV via Puffhaler® device|The vaccine will be administered via a Puffhaler® device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
1687896|NCT01557699|Biological|PMV via SoloventTM device|The vaccine will be administered via SoloventTM device. A single dose of 10 mg of PMV (dry powder measles vaccine) will be used.
1687897|NCT01557699|Biological|Licensed Subcutaneous Measles Vaccine|This is a licensed formulation containing the live attenuated Edmonston Zagreb virus. A single dose of 0.5 ml will be given subcutaneously.
1687898|NCT01557686|Behavioral|Health counseling and exercise|The intervention is initiated during chemotherapy treatment (consolidation) in the outpatient clinic and continues for 6 weeks. The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and two health-promoting counseling sessions - Further, patients are fitted with a step counter pedometer.
1687899|NCT01557673|Dietary Supplement|NG bolus feeding over 5 min|Tube bolus (TB): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., administered via the NG tube over 5 min.
1687900|NCT01557673|Dietary Supplement|Continuous NG feeding over 4 h|Continuous tube drip feeding (TD): 400 ml of Resource® Energy Vanilla nutrient drink, Societe des Produits Nestle S.A., delivered via feeding pump through the NG tube over 4 h.
1687901|NCT01557660|Drug|inhaled treprostinil|0.6mg/mL inhalation solution, up to 12 breaths four times a day
1687902|NCT01557647|Drug|Inhaled treprostinil|0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID.
1687903|NCT01557647|Drug|Placebo|placebo inhalation solution
1687904|NCT01557634|Procedure|Overnight closed-loop insulin delivery|Basal insulin infusion rates on insulin pump will be directed by MPC algorithm using diluted versus non-diluted insulin
1687928|NCT01557413|Procedure|Intramedullary nail|the fracture was reduced and fix by an intramedullary humeral nail (Multilock, SYNTHES, Switzerland) using an open surgery. An anterolateral approach will be performed, the patient sit in beach chair position under general anesthesia. If required additional sutures will be authorized to fix the tuberosities.
1687963|NCT01557218|Other|Vegetable variety snack|Three 300-g bowls of vegetables per table: one each of cucumber slices, pepper strips, and grape tomatoes
1687964|NCT01557218|Other|Apple snack|Three 300-g bowls of fruits per table: three of apple wedges
1687905|NCT01557621|Behavioral|Collaborative Pop-Based R/R: Phone/Mail Group|Within each county, half of patients will be randomized to a phone/mail group (2 auto-dialer calls and 2 postcards) and the other half of patients will be put in a mail-only group (4 mailings). The following collaborative approaches will be utilized: patient addresses and phone numbers will be updated prior to recall for electronic Flat File Format practices; all notices to parents (auto-dialer calls and mailings) will appear to come both from the local public health department and providers who choose to have their name listed; all bad addresses and phone numbers will be updated by calling the last provider of care. Up to 4 notices will be sent to parents of children who are still not up to date for recommended immunizations.
1687906|NCT01557621|Behavioral|Collaborative Pop-Based R/R: Mail-Only Group|Parents will receive up to four mailings if their child appears in need of immunizations according to CIIS. The Collaborative method is the same as in the auto-dialer/mail group; however patients in this group will not receive telephone calls.
1687907|NCT01557621|Behavioral|Practice-based Recall|All practices will receive training on how to conduct practice-based recall using CIIS and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone) in order to assess the effect of these additional interventions.
1687908|NCT01557608|Procedure|Photon stimulation|The LED diode wavelength chosen for this study is 870 nanometers. When activated, the photon stimulator is preset to deliver 1800 Joules in a 7 minute treatment period. Patients will receive a total of 8 treatments, to both feet simultaneously, within a 14 day period depending on their schedule.
1687909|NCT01557608|Procedure|Placebo treatment|"For patients who receive the placebo treatment, the electronic control unit will be deactivated (i.e., no energy is delivered) even though the indicator lights will be illuminated when the power switch is turned to the ON position. Using this procedure, the research nurse who administers the treatments and collects the outcome data will be blinded to the patients' group assignment."
1687910|NCT01557595|Device|Polarized glasses designed to filter out blue light|"Participants will be given polarized glasses (yellow sun- glasses) which filter out blue light to wear only from sundown until bedtime for two weeks. They will be instructed to turn off fluorescent lights and only use household lamps for evening activities. They will be instructed not to drive while wearing the glasses. In addition to the oral instructions, they will also be given a written Instruction Sheet. Any oral insomnia agent will be held throughout the study, otherwise they are to follow their usual evening routines. This is an alternative treatment already in use in Dr. Fargason's practice for those patients who don't want to take sleep medications. This research focuses on the effectiveness of this treatment and involves questionnaires to do so."
1687911|NCT01557582|Device|Ventripoint Medical System|"The subjects will undergo a 2D echocardiography according to standard of care. An additional 5 - 10 minutes of scanning using VMS transducer attached to the echocardiography system to acquire images for 3-D reconstruction is required.
Within one day of the VMS image acquisition the subjects will also undergo cMRI according to hospital standards of care plus an additional 5 minutes to capture the PSSS required images."
1687912|NCT01557569|Drug|Atomoxetine|During the first 2 weeks and three days the dose of atomoxetine will be titrated up starting with 20 mg/day for first 3 days, 36 mg/day for next 4 days, 50 mg/day for next 3 days, and finally 80 mg/day until the final day of the study (week 10, day 7)
1687913|NCT01557569|Drug|placebo|participants in this group will receive 1 dose of placebo daily for the entire 10-weeks.
1687917|NCT01557504|Drug|Sitagliptin/metformin XR|Fixed dose combination tablet of immediate-release sitagliptin 50 mg and extended-release (XR) metformin 1000 mg (total daily dose, sitagliptin 100 mg and metrformin XR 2000 mg).
1687918|NCT01557504|Drug|Placebo|Matching placebo to fixed dose combination tablet of sitagliptin and metformin. Matching placebo tablets are same size, shape and color as the active product, but do not contain any markings.
1687919|NCT01557504|Drug|Metformin|Concomitant use of metformin is permitted during the study provided the participant has been receiving a stable metformin dose for at least 12 weeks prior to the dose of study drug. Administration of metformin will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
1687920|NCT01557504|Drug|Thyroid hormone|Concomitant use of thyroid hormone (eg, levothyroxine) is permitted during the study provided the participant has been receiving a stable dose for at least 12 weeks prior to study drug administration and is euthyroid as documented by thyroid stimulating hormone testing at prestudy. Administration of thyroid hormone will be withheld for 24 hours prior to study drug administration and for 24 hours postdose.
1687921|NCT01557491|Procedure|Straight Incision|The incision will be made at a 90 degree angle to the surface of the scalp
1687922|NCT01557491|Procedure|Bevelled Incision|The Incision will be made at a 45 degree angle to the surface of the scalp.
1687923|NCT01557478|Drug|Melatonin|20 mg melatonin gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
1687924|NCT01557478|Drug|match placebo|placebo gelatin capsule (1) taken orally after 21:00 hours each night throughout the study
1687925|NCT01557452|Drug|Givinostat|oral suspension, 0,75 mg/Kg b.i.d. in fed conditions
1687926|NCT01557439|Drug|Levocetirizine Dihydrochloride 5 mg Tablets|A single oral dose of Levocetirizine Dihydrochloride 5 mg Tablets
1687927|NCT01557426|Other|Ultrasound|A linear ultrasound transducer will be used with ultrasound gel to obtain an image of subcutaneous structures and tissues over the involved body site. Ultrasound video will be recorded whenever possible, however studies that are not recorded will still be included. Video recording will be initiated once the desired image is obtained. Appropriate measurements will be made and views identified using the features of the ultrasound machine. Scanning of the contralateral body segment will then be performed. The ultrasound probe will be thoroughly cleaned and disinfected between ultrasound scans.
1687962|NCT01557218|Other|Tomato snack|Three 300-g bowls of vegetables per table: three of grape tomatoes
1687929|NCT01557413|Procedure|Locked plate|the fracture was reduced and fix by a locking plate using an open surgery (SURFIX, Integra, France). A deltopectoral approach will be performed, the patient sit in beach position under general anesthesia. If required, additional sutures will be authorized to fix the tuberosities.
1687930|NCT01557400|Drug|Ataluren|Oral powder for suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20mg/kg in the evening).
1687931|NCT01557387|Other|Endoscopic techniques|All patients will undergo non-invasive endoscopic techniques considered standard of care in surveillance for dysplasia
1687932|NCT01557374|Drug|Tocilizumab, Abatacept|Tocilizumab: Roactemra 4-8 mg/kg/month and 162 mg/week Abatacept: Orencia 500-1000 mg/month and 125 mg/week
1687933|NCT01557374|Drug|Decrease Tocilizumab, Abatacept|"The decrease pattern is established on 4 consecutive stages :
IV Abatacept (500-1000 mg/month) and Tocilizumab(4-8 mg/kg/month):
Stage 0 : Perfusion /30 days Stage 1 :Perfusion/45 days Stage 2 :Perfusion/60 days Stage 3 :Perfusion/90 days Stage 4 :Stop
SC Abatacept (125 mg/week) and Tocilizumab (162 mg/week):
Stage 0 :Injection/7 days Stage 1 :Injection/10 days Stage 2 :Injection/14 days Stage 3 :Injection/21 days Stage 4 :Stop
If DAS 28 ≤ 2,6 (remission DAS persistent) on trimestrial visit: transfer to next stage for 3 months before next evaluation.
If DAS 28 > 2,6 et ≤ 3,2 (weak activity) : maintain ongoing stage
If DAS 28 > 3,2 : return to previous stage, (relapse according to European expert consensus)
In the case of relapse while the patient is in stage 0, the therapy modification is left to the investigator's free will, but the patient will be followed till the end of the study."
1687934|NCT01557361|Other|Accelerated RRT initiation|A dialysis catheter will be placed and RRT initiated as soon as possible and within 12 hours of eligibility. This 12 hour window includes the time needed to obtain consent.
1687935|NCT01557361|Other|Standard RRT initiation|"Patients will be carefully followed over a period of 7 days to identify potential indications for RRT. The trial team will ask that the clinical team consider RRT initiation if there are:
I. Criteria for persistent AKI (serum creatinine has not declined by more than 50% from value recorded at time of eligibility) AND
II. At least one of the following indications for RRT initiation:
Serum potassium ≥6.0 mmol/L, or
Serum bicarbonate ≤ 10 mmol/L, or
Evidence of severe respiratory failure, based on a PaO2/FiO2 <200 and bilateral infiltrates on the chest x-ray, or
By 72 hours after randomization, creatinine has not declined by more than 50% from that recorded at the time of randomization"
1687936|NCT01557335|Drug|Plavix® and PA32540|one Plavix® 300 mg loading dose in the PM of Day 1 one Plavix® 75 mg maintenance dose in the PM of Days 2-7 PA32540(delayed release aspirin 325 mg plus immediate release omeprazole 40 mg)
1687937|NCT01557335|Drug|EC aspirin (Bayer®) ,EC omeprazole (Prilosec®) , Clopidogrel (Plavix®)|One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 300 mg (loading dose) all One EC aspirin (Bayer®) 81 mg tablet plus one EC omeprazole (Prilosec®) 40 mg capsule plus one Clopidogrel (Plavix®) tablet of 75 mg (maintenance dose) all taken concomitantly in the AM of Days 2-7
1687938|NCT01557322|Biological|etanercept|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
1687939|NCT01557322|Drug|methotrexate (MTX)|This is a Non-interventional study. The data is being analyzed retrospectively. The data consists of 2 cohorts; biologic and non-biologic
1687940|NCT01557296|Dietary Supplement|dietary treatment: food of small particle size|Subjects with diabetes mellitus and gastroparesis. Insulin treatment. Dietary treatment with food of small particle size.
1687941|NCT01557296|Radiation|Validate X-ray diagnostic method.|Follow 20 radiopaque markers throw the ventricle by X-ray.
1687942|NCT01557296|Other|Can the motility be improved|Registered the gastric emptying after intervention. Comparing the registrations at the beginning and at the end of the study.
1687943|NCT01557296|Biological|postprandial plasma glucose|Measure the blood glucose response and gastrointestinal symptoms after a test meal
1687944|NCT01557283|Other|Enbrel treatment|Enbrel SC 50mg once weekly or 25mg twice weekly
1687945|NCT01557270|Drug|dexmedetomidine|ropivacaine 100 mg + 150 mcg dexmedetomidine, single shot perineural application
1687946|NCT01557270|Drug|saline|ropivacaine + saline placebo, single shot perineural application
1687947|NCT01557257|Drug|ALO-02|Day 1 (40 mg ALO-02 capsule, single dose) Days 2-5 (40 mg ALO-02 capsule, twice daily)
1687948|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
1687949|NCT01557257|Drug|ALO-02|Day 1 (80 mg ALO-02 capsule, single dose) Days 2-5 (80 mg ALO-02 capsule, once daily)
1687950|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose and 11.5 hours after the AM dosing on Days 2-5, (3) 23.5 hours after Day 5 dosing.
1687951|NCT01557257|Drug|OxyContin|Day 1 (40 mg OxyContin tablet, single dose) Days 2-5 (40 mg OxyContin tablet, twice daily)
1687952|NCT01557257|Drug|Naltrexone block|Naltrexone Hcl 50 mg tablet will be administered (1) 12.5 hours prior to, 30 minutes prior to, and 11.5 hours after Day 1 dosing, (2) 30 minutes prior to each dose of study drug on Days 2-5 dosing, (3) 11.5 hours after Day 5 PM dosing
1687960|NCT01557218|Other|Cucumber snack|Three 300-g bowls of vegetables per table: three of cucumber slices
1687961|NCT01557218|Other|Pepper snack|Three 300-g bowls of vegetables per table: three of yellow pepper strips
1687966|NCT01557218|Other|Pineapple snack|Three 300-g bowls of fruits per table: three of pineapple half-rings
1687967|NCT01557218|Other|Fruit variety snack|Three 300-g bowls of fruits per table: of each of apple wedges, peach slices, and pineapple half-rings
1687968|NCT01557192|Device|Low Field Magnetic Stimulation Device|The Low Field Magnetic Stimulation (LFMS) procedure is an application of a series of electromagnetic pulses to the brain lasting twenty minutes. Subjects will be given one 20 minute exposure to either the LFMS or sham electromagnetic field treatment.
1687969|NCT01557179|Device|Hyalofemme|The treatment in both groups was applied every 3 days for a total of 10 applications. Hyaluronic acid vaginal gel was supplied in a 30g aluminum tube with a vaginal applicator which provides a dose of around 5g
1687970|NCT01557179|Device|Estriol cream (Ovestin)|The treatment in both groups was applied every 3 days for a total of 10 applications;Estriol cream was supplied in a 15g vial with a prefilled applicator providing a dose of around 0.5 g
1687973|NCT01557153|Drug|Amlodipine|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
1687974|NCT01557153|Drug|Placebo|Starting dose will be 5mg/day for four weeks. All participants will be titrated up to the maximum of 10mg/day after 4 weeks. If they do not tolerate this dose, it will be reduced again to 5mg/day and they will continue on their maximum tolerated dose for 12 weeks (for a total of 16 weeks of medication or placebo)
1687975|NCT01557140|Drug|RASi plus carvedilol|Patients were randomly assigned to 2 groups, with 1 group receiving renin-angiotensin system inhibitors (enalapril) plus carvedilol and the other receiving renin-angiotensin system inhibitors (enalapril) plus placebo
1687976|NCT01557127|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients scheduled for treatment with sorafenib given in regular daily dose i.e. 800mg (400mg bid)
1687977|NCT01557114|Drug|Ipilimumab|"Induction: Treatment with ipilimumab will be administered on weeks 1, 4, 7 and 10 at 10mg/kg.
Maintenance: Ipilimumab will be administered intravenously over 90-minutes at 10 mg/kg every 12 weeks starting at week 24, for as long as the treating physician believes that there is a clinical benefit or for as long as patient is tolerant of therapy"
1687978|NCT01557114|Radiation|Radiotherapy|Radiation therapy 9 Grays in 3 Grays fractions Radiation therapy 15 Grays in 5 Grays fractions Radiation therapy 18 Grays in 6 Grays fractions Radiation therapy 24 Grays in 8 Grays fractions
1687979|NCT01557101|Procedure|COLON CAPSULE ENDOSCOPY ADHERENCE|An exploration with a COLON CAPSULE ENDOSCOPY eaten which capsule has a video-camera in both end to see the colon.
1687980|NCT01557101|Procedure|OPTICAL COLONOSCOPY ADHERENCE|An exploration with an OPTICAL COLONOSCOPY from the anus to see the colon.
1687981|NCT01557088|Other|Blood sampling from the Coronary Sinus and Aorta|Blood samples will be obtained from the aorta and the coronary sinus during the clinically scheduled angiogram and endothelial function testing.
1687982|NCT01557088|Procedure|Intravascular Ultrasound of the coronary artery.|Intravascular Ultrasound will be completed for those subjects testing positive for coronary endothelial dysfunction during a clinically scheduled angiogram and endothelial function testing.
1687983|NCT01557075|Drug|Atorvastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program
Atorvastatin 40 mg daily for 12 months after randomization"
1687984|NCT01557075|Drug|Pravastatin (High dose statin treatment)|"Patients will be randomly assigned to the type of statins. Randomization of statin therapy will be done 1:1 to one of two different statins on the web-based program
Pravastatin 20mg daily for 12 months after randomization"
1687985|NCT01557062|Other|Polysomnography|The Embla® S7000 was used to record full-night at the Sleep Institute (São Paulo, Brazil). The sensors were attached to the patient in a non-invasive manner using tape or rubber bands. The physiological variables were monitored simultaneously and continuously: 4 channels of EEG, 2 of EOG, 4 of EMG and 1 channel of ECG. Airflow detection was made through 2 channels using a pair of thermal sensors and nasal pressure. Respiratory effort of the chest and abdomen, were measured by respiratory inductance plethysmography. Oxygen saturation, were measured with a pulse oximeter. Sleep stages were visually scored in all the PSG according to standardized criteria for the investigation of sleep macrostructure.
1687986|NCT01557062|Other|Teperature measure|Core body temperature was assessed using a thermistor pill (sensor), which is an electronic device 2.23 cm in length and 1.06 cm in diameter that records body temperature and transmits it to a receptor located at the patient's waist called the Core Body Temperature Monitoring System (CorTempTM), that is powered by a silver oxide battery. The components of the sensor are encapsulated in epoxy resin and coated with silicone (HQ Inc., Florida, USA). To ensure that the sensor would be in the intestines and not the stomach, the pill was ingested at least 2 hours (h) before beginning temperature recording. The CBT was recorded every 30 minutes (min) between 10:00pm and 7:00am. The time of pill elimination is variable between individuals and may be as long as 48h.
1687987|NCT01557062|Other|Fibromyalgia Impact questionary|The FIQ is an instrument used to assess the quality of life specifically for patients with FM. This questionnaire consists of 19 questions related to functional capacity, employment status, general well being, psychological disorders and physical symptoms. The higher the score is, the greater is the impact of FM in the individual's quality of life. This questionnaire was validated for Brazilian's population in 2006.
1687988|NCT01557049|Other|Control Group|No physical intervention was given, patients were treated only with medication if necessary.
1687989|NCT01557049|Other|Global Reeducation Group|They were treated with medication if necessary and performed GPR session once a week, during 12 weeks. All the 6 postures from GPR were used during the study.
1687990|NCT01557036|Device|Pipeline Embolization Device|Aneurysms treated independent of study entry with the Pipeline Embolization Device. This is an observational, non-interventional study.
1687991|NCT01557023|Drug|barrier methods|
1687992|NCT01557023|Drug|barrier methods|
1687993|NCT01557010|Drug|DWP05195|Tablets, oral administration, 100mg
1687994|NCT01557010|Drug|DWP05195|Tablets, oral administration, 200mg
1687997|NCT01556997|Drug|XOMA 985|PERa/AMLb capsule taken once daily by mouth for six weeks
1687998|NCT01556997|Drug|Amlodipine Besylate|AMLb capsule taken once daily by mouth for six weeks
1687999|NCT01556997|Drug|Perindopril Erbumine|PERe capsule taken once daily by mouth for six weeks
1688000|NCT01556984|Other|DSA assay|All patients with diabetic foot perform a DSA assay. Before and after DSA, endothelial function will be measured.
1688001|NCT01556971|Drug|Botox|Appropriate patients will randomly receive 29 units of Botox or a saline solution injected in to the procerus and corrugator supercilii frown muscles.
1688002|NCT01556971|Drug|Saline Solution|29 units of saline solution will be injected in to the procerus and corrugator supercilii frown muscles of randomly chosen study participants.
1688003|NCT01556945|Biological|FMP1/AS02|The vaccine antigen FMP1 consists of a recombinant histidine-tagged (His6) fusion protein expressed in E. coli. The lyophilized pellet contained per vaccine vial 62.5 μg merozoite surface protein-142 (MSP-142) with 3.1% lactose as cryoprotectant in each 3 ml monodose vial. The pellet was reconstituted with AS02.
1688004|NCT01556945|Biological|RTS,S/AS02|The vaccine antigen RTS,S, is a recombinant subunit vaccine produced in, and purified from yeast cells. The final lyophilized pellet contained 62.5 μg RTS,S with 3.15% lactose as cryoprotectant per 3 ml monodose vial. The pellet was reconstituted in AS02 and each 0.5 ml dose contained 50 μg RTS,S.
1688005|NCT01556945|Other|AS02 adjuvant alone|AS02 adjuvant contains 50 μg monophosphoryl lipid A (MPL) and 50 μg Quillaja saponaria 21 (QS-21), 250 μl of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 ml.
1688006|NCT01556945|Other|Malaria challenge|Experimental challenge homologous strain of P.falciparum sporozoites. Mosquitoes infected with malaria approximately 17 to 19 days earlier and that contained sporozoites in their salivary glands. For each volunteer, five mosquitoes were allowed to feed over five minutes, after which they were dissected to confirm how many were infected, and the salivary glands scored.
1688007|NCT01556932|Drug|ABH gel|Given topically
1688008|NCT01556932|Other|placebo|Given topically
1688009|NCT01556919|Procedure|Standard of care endoscopy|standard of care endoscopy
1688010|NCT01556906|Drug|Lomitapide|Oral administration with escalating doses administered once daily
1688011|NCT01556893|Device|LenSx Laser|The LenSx laser system is a femtosecond laser that has received 510(k) clearance for anterior capsulotomy during cataract surgery (K082947), laser phacofragmentation during cataract surgery (K094052) and for use in the creation of a single and multi-plane arc cut/incisions in the cornea (K092647).
1688012|NCT01556880|Behavioral|Short Message Service (SMS)|A computer-based text message database was created. Messages prompted subjects to get rid of smoking and eating out, to persevere with the quit smoking attempt with the emphasis on the peer pressure on the smoking cessation by the smoking ban in restaurants. They encouraged them to overcome the barriers of healthy eating diet and physical activity with a block of text messages.
1688013|NCT01556867|Other|Cord care by simple debridement (soaping, rinsing and drying)|For children born during an experimental period of cord care will be done with a simple debridement (soaping and then rinsing and drying carefully)
1688014|NCT01556867|Other|Cord care with the use of antiseptics|"For children born during a control period, cord care will be done with an antiseptic whose choice is left to the discretion of the healthcare team.
In this essay, it opted not to impose an antiseptic. Indeed, the objective of the trial is to compare the two strategies for management of care."
1688017|NCT01556815|Procedure|Transarterial Chemoembolization (TACE)|Procedure:TACE TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated .
1688018|NCT01556815|Other|Sorafenib in combination with TACE|"Drug: Sorafenib All patients will receive Sorafenib (800 mg/day) p.o. beginning one week after the first TACE and every day thereafter until patient death or premature withdrawal from study.
Procedure: TACE
TACE will be carried out with an emulsion of 50mg doxorubicin with lipiodol in a total volume of 10-20 mL; additional embolisation will be carried out with gelatin sponge particles. TACE will be repeated every 4 weeks for 2 cycles; additional cycles will be offered if clinically indicated ."
1688019|NCT01556802|Drug|Minocicline|Minocicline 100mg oral twice a day for 5 days
1688020|NCT01556802|Drug|Placebo|Pills with vegetable fibers one pill oral twice a day for five days
1688021|NCT01556789|Biological|ONT-10|ONT-10 a liposomal synthetic glycolipopeptide antigen formulated with PET Lipid A adjuvant.
1688022|NCT01556776|Drug|lenalidomide|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
1688023|NCT01556776|Drug|Placebo|placebo or lenalidomide 5 mg daily on days 1-28 of the first 28-day cycle. If the 5 mg dose level is well tolerated, escalation to 10 mg daily on days 1-28 of cycle 2-6 is permitted; further escalations starting with the 7th cycle and up to the 12th cycle to 15 mg daily is permitted. If after 12 cycles of treatment subjects still present with MRD levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 13th cycle up to progression 20 mg daily is permitted. If after 18 cycles of treatment for subjects still present with MRD.levels of ≥ 10-4 in peripheral blood and previous dose levels are well tolerated, starting with the 19th cycle up to progression 25 mg daily is permitted. 25 mg is the maximal daily dose of lenalidomide
1688064|NCT01556438|Drug|Bortezomib SC|Administered SC
1688024|NCT01556763|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule per day for 21 days.
1688025|NCT01556763|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule per day for 21 days.
1688026|NCT01556763|Drug|Placebo|Matching placebo was administered as one capsule per day for 21 days.
1688027|NCT01556763|Drug|Antipsychotic therapy|Concomitant therapy with antipsychotic medication (aripiprazole [10 to 30 mg/day], olanzapine [10 to 20 mg/day], paliperidone [3 to 12 mg/day], or risperidone [2 to 16 mg/day]), taken at the same time each day as the EVP-6124 dose. Patients must have been taking concomitant therapy for at least 2 weeks at a stable dose to be eligible for the study.
1688028|NCT01556737|Dietary Supplement|High daidzein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
1688029|NCT01556737|Dietary Supplement|High genistein supplement|8 weeks exposure to the supplement, daily 100 mg of isoflavones
1688030|NCT01556724|Drug|0.1% or 0.2% ropivacaine nerve blocks|Either 0.1% or 0.2% ropivacaine will be infused at 7 mL/hr through lumbar plexus nerve block catheter based upon randomization, and can then receive a 6 ml bolus of either 0.1% or 0.2% ropivacaine. Additional pain relief will be available by nurse administered boluses of additional local anesthetic (from their randomized infusion) with a maximum dose of an extra 3 ml per bolus and limited to one bolus per hour. This bolus of their randomized local anesthetic will remain available until the nerve catheters are removed. Nerve block infusion rates may be increased to 9 ml/h for patients with increased pain without increased motor blockade as determined by the acute interventional perioperative pain service (AIPPS) or decreased to 5 ml/h for patients with increased motor blockade or weakness from the peripheral nerve block as determined by the AIPPS .All continuous lumbar plexus catheters will be removed on post operative day (POD) 2.
1688031|NCT01556698|Drug|NVN1000 Topical Gel|
1688032|NCT01556698|Drug|Topical Gel Vehicle|Placebo
1688033|NCT01556685|Other|clinical and neurological evaluation|The day of the usual IFN beta 1a IM injection
1688034|NCT01556685|Other|Blood Sample|For evaluation of interferon-related Nab
1688035|NCT01556685|Genetic|Blood Sample|genetic evaluation - predisposition to Nab generation
1688036|NCT01556672|Drug|Adalimumab|Adalimumab will be administered sub-cutaneously to all patients entering the study with a loading dose of 80 mg followed by 40 mg at week 1 and 40 mg every other week. Patients who did not have small bowel lesions detected will be in the study and receive adalimumab until week 12. Patients who had small bowel lesions detected will be in the study and receive adalimumab until week 24.
1688037|NCT01556672|Device|Capsule endoscopy|All patients will undergo capsule endoscopy (EndoCapsule EC type 1; Olympus) to treatment initiation (adalimumab) in order to detect the presence of small bowel lesions suggestive of Crohn's disease. Twenty-four (24) weeks after treatment with adalimumab was initiated, patients for whom small bowel lesions were detected will undergo a second capsule endoscopy to evaluate changes in bowel inflammation.
1688038|NCT01556659|Drug|Absence of Acenocoumarol|Dual anti-platelet therapy without the addition of Acenocoumarol.
1688039|NCT01556646|Drug|Tolvaptan|15 to 30mg qd titrated to sodium concentration
1688040|NCT01556633|Drug|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers on dialysis
1688041|NCT01556633|Drug|Tamiflu (oseltamivir)|Single dose of Tamiflu in volunteers with creatinine clearance from 10 to 30 mL/min
1688042|NCT01556607|Drug|MDT-637|Inhaled doses of MDT-637 over a 24 hour period at 3 visits
1688043|NCT01556607|Drug|Placebo|
1688044|NCT01556594|Drug|glucagon|glucagon solution for injection containing 1 mg of glucagon Single subcutaneous injection
1688045|NCT01556594|Drug|Low dose novel formulation|Low dose novel formulation
1688046|NCT01556594|Drug|high dose novel formulation|high dose novel formulation
1688047|NCT01556594|Drug|Medium dose novel formulation|Medium dose novel formulation
1688048|NCT01556581|Procedure|Usual Care (UC)|Initial management for all patients will include an activity-limiting profile for up to 30 days and a 10-day supply of medications if needed (NSAIDs and muscle relaxers). All patients will then receive advice and education about the favorable natural history of LBP and the advantages of remaining as active as possible. All patients will be recommended to follow-up with their primary care provider using normal procedures if they are not satisfied with their progress.
1688049|NCT01556581|Procedure|Early Physical Therapy (PT)|Patients in the early PT group will receive the same treatment as the usual care group, but will then be referred to physical therapy within 3 days. The physical therapy treatment will be based on the Treatment Based Classification system (an approach that places patients into either an extension-oriented, core strength/stabilization, or a spinal manipulation treatment group based on signs and symptoms).
1688050|NCT01556568|Drug|MEK162|
1688051|NCT01556542|Device|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation|paclitaxel-eluting balloon angioplasty followed by nitinol stent implantation
1688052|NCT01556542|Device|nitinol stent implantation|nitinol stent implantation
1688053|NCT01556529|Procedure|risk profile information|(1) patient on a regular basis receives individualized reports on his/her quantitative risk for 6 typical diabetes complications over the next 10 years, (2) standard T2DMP care, as outlined by AWMF diabetes guidelines
1688054|NCT01556529|Procedure|standard DMP care|standard disease management of T2DM care
1688055|NCT01556529|Procedure|standard DMP care|standard disease management of T2DM care
1688056|NCT01556503|Device|VivaScope System|VivaScope System, Model#s 1500 and 2500
1688057|NCT01556490|Device|TheraSphere|Yttrium 90 microspheres
1688058|NCT01556477|Drug|Azacitidine|Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
1688059|NCT01556477|Drug|azacitidine + lenalidomide|"Azacitidine 5-2-2 (75 mg/m2/day subcutaneously for 5 days, followed by a 2-day weekend break, followed by azacitidine 75 mg/m2/ day for 2 days every 28 days, no individual dose exceeding 200 mg) for 6 cycles.
Initial dose of lenalidomide is 10 mg 21/28 days, starting day 1 in each azacitidine cycle and leaving the last week before start of next azacitidine cycle free. The dose should increased to 25 mg day 1 in cycle 4 if no toxicity according to predefined criteria occurs. Total treatment period is 24 weeks."
1688060|NCT01556464|Device|Auto-adjusting CPAP|A CPAP device that auto-adjusts the pressure setting over the course of the night, depending on how the patient is breathing.
1688886|NCT01549834|Drug|placebo|Placebo
1688069|NCT01556399|Other|Tissue Sampling|A small sample of the duodenal adenoma will be obtained for molecular testing. The remaining adenoma will be sent for regular histological testing.
1688070|NCT01556373|Other|NA : non interventional study|NA : non interventional study
1688071|NCT01556347|Drug|Bortezomib, Thymoglobulin, (rATG), Rituximab, Gamimune N, (IVIG), Plasmapheresis (Multidrug Protocol)|Bortezomib, Thymoglobulin, (rATG), Rituximab, Gamimune N, (IVIG), Plasmapheresis
1688072|NCT01556334|Drug|Azithromycin|Azithromycin 1g po
1688073|NCT01556334|Drug|Erythromycin|Erythromycin IV then PO
1688074|NCT01556321|Dietary Supplement|placebo|Subjects will receive placebo (soy oil; 757 mg/capsule, 3 capsules with each breakfast, lunch and dinner) in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
1688075|NCT01556321|Dietary Supplement|green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ]|Subjects will receive green tea (757 mg/capsule [84.5 mg EGCG + 2.1 mg caffeine ], 3 capsules with each breakfast, lunch and dinner)in capsule form after their baseline measurement, which they have to consume daily for a period of twelve weeks.
1688076|NCT01556308|Procedure|Taking of liquid and top of blisters|the liquid and the top of blisters will be took.
1688077|NCT01556282|Device|TheraSphere|TheraSphere are microspheres with y-90 a radioactive material that will be injected into the liver through a blood vessel.
1688078|NCT01556256|Other|Caregiver-Related Intervention or Procedure|Undergo TMV+P
1688079|NCT01556256|Procedure|Music Therapy|Undergo TMV
1688080|NCT01556256|Procedure|Music Therapy|Undergo TMV+P
1688081|NCT01556256|Other|Quality-of-Life Assessment|Ancillary studies
1688082|NCT01556256|Other|Questionnaire Administration|Ancillary studies
1688083|NCT01556243|Procedure|therapeutic conventional surgery|
1688084|NCT01556243|Radiation|whole breast irradiation|
1688085|NCT01556230|Procedure|Surgical intervention for CNFA|(non-experimental) standard procedure
1688086|NCT01556230|Radiation|Radiotherapy for CNFA|(non-experimental) standard procedure
1688087|NCT01556217|Drug|JNJ-39393406|Type= exact number, Unit= mg, Number= 200, Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
1688088|NCT01556217|Drug|Placebo|Form= oral suspension, Route= oral administration. Oral suspension to be taken once with 240 mL (8 ounces of water) between 8:00 AM and 10:30 AM.
1688089|NCT01556204|Procedure|Robotic surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
1688090|NCT01556204|Procedure|Laparoscopic Surgery|The technique for resection of superficial and deep endometriosis will be performed in a standard fashion. All superficial lesions suspicious for endometriosis (pigmented and non-pigmented) will be completely resected until non-diseased peritoneal margins are visualized around the defect or will be fulgurized using bipolar energy; all deep lesions suspicious for endometriosis will be completely resected until non-diseased margins are visualized in the tissue surrounding the defect. Cystectomy(ies) will be performed for endometrioma(s). The fascia of any port greater or equal to 10mm will be reapproximated. Cystoscopy would only be performed when deemed appropriate by the surgeon (e.g., to assess for lower urinary tract injury in cases that require extensive ureterolysis).
1688091|NCT01556191|Drug|Gefitinib|250 mg per day (oral)
1688092|NCT01556191|Drug|Fulvestrant|500 mg (2 x 250 mg), IV by month with an additional 500 mg dose two weeks after the initial dose
1688093|NCT01556191|Drug|Erlotinib|150 mg per day (oral)
1688094|NCT01556165|Drug|rasagiline|1 mg/day, tablets, once daily, orally
1688095|NCT01556165|Drug|placebo|tablets, once daily, orally
1688096|NCT01556152|Drug|GRC 17536 (Medium Dose)|1 BD for 28 days
1688097|NCT01556152|Drug|GRC 17536 (Low Dose)|1 BD for 28 Days
1688098|NCT01556152|Drug|Placebo|Matching Placebo for 28 Days
1688099|NCT01556139|Device|Spirotiger|"The Training group perform 20 sessions of a specific training with Spirotiger, a device allowing respiratory muscle training with isocapnic hyperpnea.
The setting is the following:
volume/size of the breathing bag: 50% of the vital capacity (VC) and ventilation (VE= Tidal volume x respiratory rate) at 66% of the MVV aiming to reach 15 minutes of training without breaks. During the initial sessions, the patient can interrupt training every 5 minutes and recover.
increase in training: after 15 minutes of exercise VE is increased up to 75% of the MVV through modification of the volume of breathing bag or respiratory rate.
At the end of 15 minutes of exercise, further increases in ventilation are 10% of each previous step."
1688100|NCT01556126|Device|Amphilimus Eluting Stent (CRE8)|Sirolimus formulated coronary eluting stent
1688101|NCT01556113|Other|Omega diet|Eligible subjects will receive omega rich diet for 12 weeks with weekly appointments to obtain food records, draw serum samples and provide meals.
1688306|NCT01554397|Radiation|Intensity Modulated Radiation Therapy (IMRT)|45.0 Gy (intact) or 50.4 Gy (postoperative high-risk) in 1.8 Gy daily fractions over 5-5.5 weeks
1688103|NCT01556087|Behavioral|Distress Tolerance|7 individual sessions aimed at increasing distress tolerance skills
1688104|NCT01556087|Behavioral|Health Education|7 individual sessions with didactic health education information
1688105|NCT01556074|Behavioral|Yoga treatment|Biweekly 90-minute group yoga classes for 8 weeks and on non-class days participants will be asked to devote 15 minutes per day to a prescribed home yoga practice.
1688106|NCT01556061|Device|DMAC|The D blade will constitute the experimental treatment and in a cross over fashion will be tested against CMAC blade
1688107|NCT01556061|Device|CMAC|The CMAC Blade will constitute the active comparator treatment and in a cross over fashion will be tested against D-blade
1688108|NCT01556048|Behavioral|Behavioral Activation|Behavioral Activation for Major Depressive Disorder (BA; Martell, Addis, & Jacobson, 2001) is based on behavioral theories of depression, which posit that psychopathology occurs when active, goal-directed behavioral repertoires have been either unreinforced or punished. These aversive consequences tend to reinforce escape and avoidance behavior, such as passively ruminating on unmet needs and/or deprivations, rather than actively engaging the environment. BA employs operant conditioning principles to increase active, goal-directed behavioral strategies and decrease passive or avoidant behavioral strategies to help people engage with and obtain adequate reinforcement from their environment. Use of BA was based research suggesting that disengagement/avoidance is related to prolonged pathology after loss
1688109|NCT01556035|Drug|Lenalidomide|Patient orally treated with lenalidomide 25 mg daily for 21 days with 7 days rest of a 28 days cycle.Treatment maintained for 12 months unless progression
1688110|NCT01556022|Device|ADRCs processed by the Celution System|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to ADRCs, intramyocardial injections of ADRCs will be administered via the MYOSTAR injection catheter.
1688111|NCT01556022|Device|Placebo Comparator: Lactated Ringer's and Subject's Blood|Subjects will undergo liposuction under anesthesia. Lipoaspirate will be processed in the Celution System to isolate and concentrate ADRCs. When randomized to Placebo, intramyocardial injections of Placebo will be administered via the MYOSTAR injection catheter.
1688112|NCT01556009|Drug|Vismodegib|150 mg per day for 7 continuous months then randomized for 3 month intervals to 28 months.
1688113|NCT01556009|Drug|Aminolevulinic acid %20 topical solution|20% topical solution applied every three months from month 10, 13, 16, 19, 22. Applied and incubated for three hours.
1688114|NCT01555996|Behavioral|Early and Intensive Occupational Therapy|"Intervention group:Standard non-pharmacological prevention plus early and intensive OT. Begin in the first 24 hours in CCU admission. OT areas:1)Multi-sensory stimulation:Intense external stimulation, increase alertness,2)Positioning: Fixtures like dorxi-flexion splints, devices for preventing edema,etc,3)Cognitive Stimulation: Awareness, orientation, attention, memory, calculation, praxis and language,4)Training Activities of Daily Living (ADL): Keep a daily routine and independence in hygiene, grooming and feeding,5)Upper Limb Motor Stimulation (ULMS): Activate functional movement and strength ,6)Family involvement.
General Guidelines for intervention: Visit of an OT twice a day, 40 minutes each time, for 5 days; meeting of family training for promote strategies during the daily visit."
1688115|NCT01555996|Behavioral|Standard non-pharmacological delirium prevention|Non-pharmacological strategies are the first line of approach in the prevention of delirium. It is recommended to implement some of these strategies, which are: Reorientation protocol, including information 4 times a day about time, date, place and reason for hospitalization; early mobilization by physical therapist 3 times a day, corrected sensory impairment (use such as eyeglasses, hearing aids); environment management, use clock and calendar in the patient´s room, promote supervision of a professional or family to avoid physical restraints; sleep protocol, like lower light, noise and nighttime drug administration and finally, reduction of any anticholinergic drugs and minimize the use of benzodiazepines.
1688116|NCT01555983|Drug|Vaporization of Cannabis|Randomized, Controlled Crossover Trial of Vaporized Cannabis using different strengths of THC in patients with Central Neuropathic Pain Active Comparator: Vaporized High Dose 6.7% THC Active Comparator: Vaporized High Dose 2.9% THC Placebo Comparator: Vaporized Placebo THC
1688117|NCT01555970|Drug|N-Acetylcysteine (NAC)|Week 1: 1200 mg (one 600 mg capsule twice a day) Week 2: 2400 mg (two 600 mg capsules twice a day) Weeks 3-16: 3000 mg (two 600 mg capsules in the morning and 3 in the evening)
1688118|NCT01555970|Drug|Placebo|Week 1: one capsule twice a day Week 2: two capsules twice a day Weeks 3-16: two capsules in the morning and 3 in the evening
1688119|NCT01555957|Drug|intravenous lipid|intravenous given daily for 6 weeks
1688120|NCT01555931|Drug|Levonorgestrel-releasing intrauterine system|Placement within 48 hours of delivery
1688121|NCT01555918|Drug|Isavuconazole|oral
1688122|NCT01555918|Drug|Isavuconazole (IV)|intravenous (IV)
1688124|NCT01555892|Biological|LMP, BARF1 & EBNA1 specific CTLs: A|"Dose Level 1: 2 x 10^7 cells/ m2; 2 x 10^7 cells/m2
Dose Level 2: 2 x 10^7 cells/m2; 1 x 10^8 cells/m2
Dose Level 3: 1 x 10^8 cells/m2; 2 x 10^8 cells/m2"
1688125|NCT01555892|Biological|LMP, BARF1 & EBNA1 specific CTLs : B|"Dose Level 1: 2 x 10^7 cells/ m2; 2 x 10^7 cells/m2
Dose Level 2: 2 x 10^7 cells/m2; 1 x 10^8 cells/m2
Dose Level 3: 1 x 10^8 cells/m2; 2 x 10^8 cells/m2"
1688126|NCT01555879|Drug|Abatacept|As prescribed by a doctor for patient medical care.
1688127|NCT01555866|Drug|isavuconazole|IV
1688128|NCT01555853|Drug|Abraxane|
1688129|NCT01555840|Device|Magnetically Guided Capsule (MGCE)|"a) MGCE capsule The MGCE capsule is custom-made for observation of the stomach. It is 31 mm in length and 11 mm in diameter and equipped with two image sensors.
It contains a permanent magnet to enable magnetic guidance in the stomach by magnetic field. b) Guidance system The magnet guidance system is custom-made to guide the MGCE capsule inside the stomach. It has a footprint of 1m× 2m and generates a very low level magnetic fields. c) Conventional gastroscope"
1740262|NCT00108368|Drug|Olanzapine|
1688130|NCT01555827|Other|Ophthalmological examination & Questionnaire|"The following examinations will be performed, after pupil dilation:
Examination with SD-OCT (macular scans, macular volume, peri-papillary scan, retinal autofluorescence, infer-red and red-free imaging)
Colour photographs of the retinal, centered on the macula and on the optic nerve (digital non mydriatic retinal camera)
Wide-field colour and autofluorescence imaging (Optomap)
Measure of intra-ocular pressure (pneumotonometer)
The following informations will be collected through a standardized questionnaire, administered face-to-face during the inclusion visit, or at the moment of the verification of eligibility criteria:
Age, gender
educational level
smoking
cardiovascular diseases, current medications
scores at neuropsychological tests"
1688131|NCT01555814|Drug|Amisulpride|4-week open label amisulpride treatment
1688132|NCT01555801|Device|submucosal injection needle ; EUS|The patients will accepted submucosal injection of 5ml saline followed by ordinary endosonography(EUS) before surgery or endoscopic dissection.
1688133|NCT01555801|Device|ordinary endosonography(EUS)|These patients will be accepted ordinary EUS followed by surgery or endoscopic dissection.
1688134|NCT01555788|Device|Artificial Pancreas for DiaPort system with Zone-MPC algorithm|Artificial pancreas system uses the intraperitoneal route to deliver insulin (through DiaPort) in type 1 diabetic patients treated by basal-bolus insulin and external pumps.
1688135|NCT01555775|Dietary Supplement|P-CHO supplement|In the first trial, this group will drink a protein (P)-carbohydrate (CHO) supplement and in the second trial the fruit milk shake.
1688136|NCT01555775|Dietary Supplement|Fruit Milk Shake|The fruit content of the milk shake will be 100 g of strawberry and the amount of banana necessary to guaranty 0.8-1.2 g CHO • kg-1 BW • h-1.
1688137|NCT01555749|Drug|NNC172-2021|One injection administered subcutaneously (s.c., under the skin). Injection of maximum 1.2 mL
1688138|NCT01555749|Drug|placebo|One injection administered subcutaneously (s.c., under the skin)
1688139|NCT01555736|Drug|grass (80%) and rye (20%) pollens allergoids|comparison of two schemes of immunotherapy - preseasonal and perennial immunotherapy.
1688140|NCT01555710|Drug|Carboplatin|AUC 4 mg/mL/min 1 day every 21 days for a max of 6 cycles.
1688141|NCT01555710|Drug|Palifosfamide-tris|130 mg/m2/day 3 days every 21 days for a max of 6 cycles.
1688142|NCT01555710|Drug|Etoposide|100 mg/m2/day 3 days every 21 days for a maximum of 6 cycles.
1688143|NCT01555710|Drug|Carboplatin|AUC 5 mg/mL/min 1 day every 21 days for a max of 6 cycles.
1688146|NCT01555684|Procedure|percutaneous venoplasty to alleviate chronic cerebrospinal venous insufficiency|percutaneous venoplasty is where a balloon is inserted and inflated into the jugular vein has been developed to improve this drainage of the CNS, reduce venous hypertension and improve symptoms associated with MS
1688147|NCT01555671|Drug|Placebo|Bag B (placebo group), containing 10 mL of normal saline solution
1688148|NCT01555671|Drug|Meperidine|50 mg meperidine injection intramusculer
1688149|NCT01555658|Drug|Bivalirudin|Enrolled patients will be randomized 1:1 in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to IV bivalirudin (0.75 mg/kg intravenous bolus followed by 1.75 mg/kg during procedure and 1.25mg/Kg infusion)
1688150|NCT01555658|Drug|Unfractioned Heparin|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of stents>33 mm in length in the same coronary vessel, to IV UFH (60 IU/kg intravenous bolus followed by boluses with target activated clotting time 200—250 s)
1688151|NCT01555645|Behavioral|Stress management, in two steps|All patients start at the first step of the intervention program with a two hours psychoeducation in stress management. Patients, who don't report a decrease in stress related symptoms, after the first step will be offered an intensive stress management, either in individual or group format. Components included in the intervention concern 1) basic knowledge about cancer, treatment, healthy living and stress reactions, 2) self-awareness with help of diary for thoughts, feelings and behavior 3) instruction in various techniques on how to express negative feelings, how to communicate with others more effectively, how to change behaviors related to stress 4) training these techniques in real-life situations 5) cognitive restructuring 6) spirituality, derived from cognitive behavior therapy.
1688152|NCT01555632|Drug|atorvastatin calcium|Given PO
1688153|NCT01555632|Drug|placebo|Given PO
1688154|NCT01555619|Device|CRT-D System|Implantation of a CRT-D System
1688155|NCT01555606|Other|No intervention|Patients will not be administered any treatment as part of the study and will receive usual care. Patients will be evaluated for PROs by obtaining narratives and photographs.
1688156|NCT01555593|Device|Cardioline Exp'air by Medi-soft - Sorinnes (B)|FeNO measurement in four different moments, the first in the evening, the last three in the morning of the day after. These evaluations will be repeated when the patient enters the unit and after 15 days of rehabilitation activity
1688157|NCT01555580|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|Participants will receive one dose of GM-CSF (5 µg/kg) by subcutaneous injection for ten (10) consecutive days. The first dose of GM-CSF will be administered by the subject or caregiver under the observation and direction of the study staff during the baseline visit. The subject or caregiver will administer subsequent injections at home.
1688158|NCT01555567|Device|Electrical Stimulation|Electrical stimulation will be delivered 2 times per week
1688159|NCT01555567|Other|Eccentric Exercise|Eccentric Exercise will be delivered 2 times per week
1688193|NCT01555229|Device|Intermittent subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
1688307|NCT01554397|Drug|Cisplatin|Weekly infusion of 40 mg/m2 (80 mg max) x 5 weeks
1688160|NCT01555554|Drug|Propranolol Hydrochloride|"Propranolol will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first dose of the study drug (the PDR recommended starting dose of Propranolol XL- Extended Release). Patients will take one 60 mg pill on the morning of surgery.
On post operative day #1, patients will take one pill of receive propranolol XL 80 mg (once daily by mouth).
On post operative days #2-#9, patients will take one pill of propranolol XL 120 mg (once daily by mouth).
On post operative days #10-11, patients will take one pill of propranolol XL 80 mg (once daily by mouth).
On post operative days #12-13, patients will take one pill of propranolol XL 60 mg (once daily by mouth).
This will complete the course of propranolol."
1688161|NCT01555554|Other|Placebo|"The placebo pill will be taken for a total of 14 days. On the morning of the surgery, prior to entry into the operating room, patients will receive the first placebo pill to be taken once daily by mouth.
On post operative days #1-13, patients will take one placebo pill (once daily by mouth).
This will complete the course of the placebo."
1688162|NCT01555541|Drug|Ofatumumab|1000 mg IV days 0, 7, 14, 21
1688163|NCT01555541|Drug|Etoposide|10 mg/Kg IV over 24 hours daily, days 1-4
1688164|NCT01555541|Drug|Cytarabine|2000 mg/m2 IV twice daily, days 1-4
1688165|NCT01555528|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
1688166|NCT01555515|Procedure|implantation of autologous skin graft after ex-vivo treatment|Subcutan implantation of autologous skin graft after ex-vivo treatment
1688167|NCT01555515|Biological|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
1688168|NCT01555489|Drug|Ascorbic Acid|3x per week
1688169|NCT01555476|Drug|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL experimental suspension, administered orally, with a 48-hour washout between visits
1688170|NCT01555476|Drug|Ibuprofen|A single 5 mL dose of 200 mg ibuprofen/5 mL reference suspension, administered orally, with a 48-hour washout between visits
1688171|NCT01555463|Drug|Azelaic acid foam, 15% (BAY39-6251)|Azelaic acid twice daily topical application
1688172|NCT01555463|Drug|Vehicle foam|twice daily topical application
1688173|NCT01555450|Other|Patient Navigation|Insured people receive firstly a letter to inform them that a patient navigator is available to navigate them during the colorectal screening steps. A free telephone number and the navigator schedule is given. After a minimum of one week the patient navigator begins the telephone outreach.
1688174|NCT01555424|Dietary Supplement|High dose|This arm of the study receives a higher dose of the vitamin D fortified cheese (28,000IU/ 50g of cheddar cheese eaten once a week).
1688175|NCT01555424|Dietary Supplement|Reference dose|This arm of the study receives a lower dose of the vitamin D fortified cheese (200IU/ 50g of cheddar cheese eaten once a week).
1688176|NCT01555398|Dietary Supplement|HIP0901 capsule (Fenofibric acid) Fasting conditions/ Fed conditions|The study drug(HIP0901 capsule(Fenofibric acid, 135mg)) will be administrated under fed or fasting conditions
1688177|NCT01555385|Dietary Supplement|Breakfast juice|single dose (300 ml) in the morning of study day, 3 separate sessions (high-protein vs. high-carbohydrate vs. low-calorie juice), total duration 3 weeks
1688178|NCT01555372|Device|Hook Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with HP. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
1688179|NCT01555372|Device|Locking Plate|All participants will have an open reduction internal fixation. The affected upper limb will be temporarily fixed by a sling after admission. Under necessary test, general anaesthetic and antibiotic prophylaxis, the patients will be placed in a beach-chair position in an orthopaedic theatre. The operated side will be prepped and draped and a transverse incision will be made over the fracture site. The fracture ends will be identified, reduced and fixed with locking plate. X-ray was applied to check the grade of reduction before the operation is completed. Post-operative care will include early active mobilization managed by a standard physiotherapy rehabilitation regime.
1688180|NCT01555333|Drug|arbaclofen|A flexible dose titration will be utilized. Orally disintegrating tablets
1688181|NCT01555320|Drug|Qishen Yiqi Dripping Pills|One packet of Qishen Yiqi Dripping Pills (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
1688182|NCT01555320|Drug|Qishen Yiqi dripping pills dummy|One packet of Qishen Yiqi Dripping Pills dummy (0.52g) will be given three times a day in addition to regular western medications for the first 6 months, and regular western medications only for the subsequent 6 months.
1688183|NCT01555307|Other|Typical range of motion and muscle strengthening exercises, and balance exercises|Seven typical exercises, and three balance exercises, 10 times each, 3 times a day.
1688184|NCT01555307|Other|Typical group|Seven typical exercises, 10 times each, 3 times a day
1688185|NCT01555281|Drug|Nelfinavir|In phase II, the recommended dose of nelfinavir will be administered orally twice daily (in the morning and in the evening) on d1-d21 every 28 days for a maximum of 4 cycles
1688186|NCT01555281|Drug|Lenalidomide|25 mg of lenalidomide (capsules) will be administered orally daily on d1-d21 every 28 days for a maximum of 4 cycles
1688187|NCT01555281|Drug|Dexamethasone|40 mg (for patients <75 years) or 20 mg (for patients ≥75 years) of dexamethasone (tablets) will be administered orally once per day on d1, 8, 15 and 22 every 28 days for a maximum of 4 cycles
1688188|NCT01555268|Biological|trebananib|Given IV
1688189|NCT01555268|Drug|cytarabine|Given SC
1688190|NCT01555268|Other|laboratory biomarker analysis|Correlative studies
1688191|NCT01555268|Other|pharmacological study|Correlative studies
1688192|NCT01555242|Drug|Aneustat (OMN54)|100 mg active/capsule; oral administration; 28 days/cycle (up to 6 cycles total) 1,000 mg QD 2,000 mg QD 1,500 mg BID 2,000 mg BID 2,500 mg BID
1688270|NCT01554696|Drug|ASP015K|oral
1688271|NCT01554696|Drug|Placebo|oral
1690235|NCT01539174|Drug|cyclophosphamide|Given IV
1688194|NCT01555229|Device|Continuous subglottic secretion drainage|Subglottic secretion drainage is performed using a specially designed endotracheal tube with a separate dorsal lumen that opens immediately above the endotracheal cuff.
1688195|NCT01555216|Drug|Single injection posterior tibial nerve block|5 ml of 0.5% ropivacaine
1688196|NCT01555216|Drug|Posterior tibial nerve catheter|5ml bolus of 0.5% ropivacaine with 3 ml/h of 0.2% ropivacaine with a bolus every two hours
1688197|NCT01555203|Behavioral|liveWell: A healthy foundation for life|"liveWell is a unique online, mobile-compatible, multi-media, evidence-based program designed to help college students exercise, eat healthy, and manage stress. At the core of the Transtheoretical Model-based intervention is a computer-tailored behavior change intervention (CTI) that analyzes students' responses to reliable and valid assessments of key behavior change constructs using empirically derived pre-programmed decision rules. The rules determine which feedback users receive on how they are doing compared to their peers in their same stage. At follow-up, feedback is further tailored to how students are doing compared to their last session.
In addition to the CTI, completed three times during the semester, liveWell includes a dynamic portal that is populated with a variety of engaging and interactive stage-matched activities and resources. The portal provides more content and specifics on how to apply each of the processes and principles of change introduced in the CTI."
1688198|NCT01555190|Drug|myo-inositol 1500 gr|
1688199|NCT01555190|Drug|myo-inositol 2000 gr + folic acid 200 mcg|
1688200|NCT01555164|Drug|Ranolazine|Ranolazine tablet(s) administered orally
1688201|NCT01555164|Drug|Placebo to match ranolazine|Placebo to match ranolazine for the duration of the study
1688202|NCT01555164|Drug|Metformin|Metformin tablet(s) administered orally once daily
1688203|NCT01555164|Drug|Placebo to match metformin|Placebo to match metformin for the duration of the study
1688204|NCT01555164|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
1688205|NCT01555164|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
1688206|NCT01555151|Drug|Mometasone furoate|Mometasone furoate (MF) 80 µg once daily delivered via Concept1 device; MF 200 μg once daily delivered via Concept1 device; MF 320μg once daily delivered via Twisthaler® device or 800 μg once daily delivered via Twisthaler® device
1688207|NCT01555151|Device|Concept 1|A single dose dry powder inhaler (SDDPI)
1688208|NCT01555151|Device|Twisthaler|A single dose dry powder inhaler (SDDPI)
1688209|NCT01555138|Drug|Indacaterol|Indacaterol is delivered via a SDDPI.
1688210|NCT01555138|Drug|Salmeterol|Salmeterol/fluticasone is delivered via a MDDPI
1688214|NCT01555112|Drug|Topical AS101|AS101 15% ointment will be applied topically twice daily on external genital warts for up to 16 weeks.
1688218|NCT01555086|Procedure|Limited pelvic Lymphadenectomy|approximately 10-14 lymph nodes are removed
1688219|NCT01555086|Procedure|Extended pelvic Lymphadenectomy|approximately 20 lymph nodes are removed
1688220|NCT01555073|Drug|pregabalin/celecoxib|pregabalin/celecoxib; 75mg/400mg day of surgery and (75mg/200mg) twice a day for 13 days.
1688221|NCT01555073|Drug|pregabalin/placebo|pregabalin/placebo; 75mg/placebo day of surgery and (75mg/placebo) twice a day for 13 days.
1688222|NCT01555073|Drug|celecoxib/placebo|celecoxib/placebo; 400mg/placebo day of surgery and 200mg/placebo twice a day for 13 days.
1688223|NCT01555073|Drug|Placebo group|Placebo group, two placebo tablets day of surgery and twice a day for 13 days
1688224|NCT01555060|Dietary Supplement|ferrous gluconate|daily capsule of ferrous gluconate containing 38 mg of elemental iron
1688225|NCT01555047|Procedure|IUI|intrauterine insemination
1688226|NCT01555047|Procedure|IUI|intrauterine insemination
1688227|NCT01555034|Behavioral|movement therapy|exercise, nutrition, movement therapy
1688228|NCT01555034|Other|exercise plus nutrition|exercise, nutrition
1688230|NCT01555008|Drug|LX4211|Subjects will receive LX4211 once daily for 7 days
1688231|NCT01555008|Drug|LX4211 Placebo|Subjects will receive LX4211 placebo once daily for 7 days
1688232|NCT01554995|Drug|LCB01-0371|LCB01-0371 50mg (Cohort 1) 100mg (Cohort 2) 200mg (Cohort 3) 400mg (Cohort 4) 600mg (Cohort 5)
1688233|NCT01554995|Drug|Linezolid|Linezolid 600 mg (Cohort 9) none
1688234|NCT01554982|Drug|ferric citrate|Dose based on monthly serum phosphorus levels with goal of 3.5-5.5 mg/dL for all patients.
1688272|NCT01554683|Drug|Low/High/Placebo Dose Keppra (Levetiracetam)|Low Dose (2.5 mg/kg) High Dose (7.5 mg/kg) Placebo (Saline)
1688308|NCT01554384|Procedure|Xpert MTB/RIF assay|Automated nucleic-acid amplification test (fully integrated) test for TB
1688309|NCT01554384|Procedure|Smear microscopy|Smear microscopy involve sputum smear with either ziehl-neelsen or auramine-O staining of slides and light or fluorescence microscopy reading
1688757|NCT01550796|Behavioral|Cognitive Training|250 mg d-cycloserine or placebo taken orally one hour before Brain Fitness Program
1688235|NCT01554969|Drug|capecitabine + ganetespib|"Capecitabine will be started on Day 1 of the concurrent chemo-radiation phase at the specified dose, and is given orally twice daily for the entire duration of radiation therapy.
Ganetespib will be started on Day 1 of radiation therapy and is administered as IV infusion over 1 hour on days 1, 8, 15 for cycle 1 and then on days 29 and 36 for cycle 2.
In all patients, ganetespib monotherapy will be given up to 2 weeks prior to start of concurrent chemoradiation. Sequential biopsies will be taken at baseline and prior to the start of concurrent chemoradiation. In the dose escalation part of the study, the starting does of ganetespib is 60mg/m² once weekly, and capecitabine at a dose of 825 mg/m² twice daily."
1688236|NCT01554956|Biological|Human Plasminogen|Eye Drops
1688237|NCT01554943|Other|cardiac MRI|Patients will be submitted to extensive cardiac evaluation several years after completion of adjuvant chemotherapy
1688238|NCT01554930|Drug|Western therapy (mannitol, methylprednisolone, immunoglobulin, febrifuge)|Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
1688239|NCT01554930|Drug|Xiyanping injection plus western therapy|Xiyanping injection:5-10mg/kg/d (0.2-0.4ml/kg/d),qd ivgtt; Mannitol:0.5-1.0g/kg，q4h to q8h ivgtt; Methylprednisolone:1mg-2mg/kg·d,qd iv; Immunoglobulin：1g/kg; Others:febrifuge，sedative，etc.
1688240|NCT01554917|Drug|Iguratimod|taken orally, 2 tablets/day (bid)
1688241|NCT01554904|Device|Facial-Flex|Oral exercise device
1688242|NCT01554878|Procedure|knee surgery|Reparative, replacement or regenerative techniques, with or without associated osteotomy.
1688243|NCT01554865|Dietary Supplement|Optifast|1-2 sachets of Optifast daily as part of diet modification (partial meal replacement diet)
1688244|NCT01554865|Behavioral|Conventional diet counseling|
1688245|NCT01554852|Drug|Induction (intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone (CRD) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 & 12-15 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
1688246|NCT01554852|Drug|Induction (intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone (CTD) regimen|Days 1,8,15 (i.e. weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules. Initially 100 mg daily PO for 3 weeks, increasing to 200 mg daily PO Days 1-4 and 12-15 - dexamethasone 40 mg daily PO The cycle is repeated every 21 days
1688247|NCT01554852|Drug|Induction (intensive pathway) - carfilzomib, cyclophosphamide, lenalidomide, & dexamethasone (CCRD) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1 & 2, 8 & 9, 15 & 16 - carfilzomib 20*/36 mg/m2** IV (*carfilzomib 20 mg/m2 is only administered on days 1 and 2 of cycle 1; **carfilzomib will be dose capped at a body surface area of 2.2 m2) Days 1-21 - lenalidomide 25 mg daily PO Days 1-4, 8, 9 & 15, 16 - dexamethasone 40 mg daily PO This cycle is repeated every 28 days
1688248|NCT01554852|Drug|Induction (non-intensive pathway) - cyclophosphamide, lenalidomide, & dexamethasone attenuated (CRDa) regimen|Days 1 & 8 - cyclophosphamide 500 mg PO Days 1-21 - lenalidomide 25 mg daily PO Days 1-4 & 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
1688249|NCT01554852|Drug|Induction (non-intensive pathway) - cyclophosphamide, thalidomide, & dexamethasone attenuated (CTDa) regimen|Days 1, 8, 15, 22 (weekly) - cyclophosphamide 500 mg PO Continuously - thalidomide 50 mg hard capsules; initially 50 mg daily PO for 4 weeks, increasing every 4 weeks by 50 mg increments to 200 mg daily PO Days 1-4 & 15-18 - dexamethasone 20 mg daily PO This cycle is repeated every 28 days
1688250|NCT01554852|Drug|Consolidation (intensive & non-intensive pathways) - bortezomib, cyclophosphamide, & dexamethasone (VCD) regimen|Days 1, 4, 8 & 11 - bortezomib 1.3 mg/m2 SC or IV Days 1, 8, 15 - cyclophosphamide 500 mg PO Days 1-2, 4-5, 8-9 & 11-12 - dexamethasone 20 mg daily PO This cycle is repeated every 21 days
1688251|NCT01554852|Drug|Maintenance (intensive & non-intensive pathways) - lenalidomide maintenance|Days 1-21 - lenalidomide 10 mg daily PO This cycle is repeated every 28 days
1688252|NCT01554852|Drug|Maintenance (intensive & non-intensive pathways - protocol v5.0 only) - lenalidomide plus vorinostat maintenance|Days 1-21 - lenalidomide 10 mg daily PO Days 1-7 & 15-21 - vorinostat 300mg PO This cycle is repeated every 28 days
1688253|NCT01554852|Drug|High dose melphalan therapy and autologous stem cell transplant (intensive pathway only)|High dose melphalan therapy and autologous stem cell transplant to be given as per local practice
1688254|NCT01554839|Behavioral|"Family of Heroes"|One hour online educational tool
1688255|NCT01554839|Behavioral|Baseline and Follow up Surveys|Baseline and follow up questionaires completed online
1688256|NCT01554826|Biological|Influenza Split Vaccine|0.25ml, two doses (540 subjects were randomly assigned to receive the first dose, among them, 515 subjects received a boost dose); two doses were assigned to be vaccinated 4 weeks apart
1688257|NCT01554826|Biological|Inactivated Influenza Vaccine|0.25ml, two doses (270 subjects were randomly assigned to receive the first dose; among them, 263 subjects received a boost dose); two doses was administrated at 4 weeks apart
1688258|NCT01554813|Biological|Influenza split vaccine of 15 μg HA|60 subjects were assigned (20 infants, 20 children and 20 adults) to receive influenza vaccine (split virion), inactivated, 0.5ml, one dose regime
1688259|NCT01554813|Biological|Influenza split vaccine of 15 μg HA|558 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
1688260|NCT01554813|Biological|Influenza split vaccine|280 subjects were assigned to receive influenza split vaccine, 0.5ml, one dose regime
1688261|NCT01554800|Drug|ACP-501|A single dose infusion
1688262|NCT01554787|Drug|Chinese Herb Astragalus membranaceus|Astragalus membranaceus(AM)at a rate of 2.8g three times per day
1688263|NCT01554787|Other|Placebo|at a rate of 2.8g three times per day
1688264|NCT01554761|Procedure|phacoemulsification|After topical anesthesia with Alcaine, 3.0-mm clear corneal incisions were made. Torsional phacoemulsification was performed using the Infiniti Vision System with the OZil handpiece, a 45-degree Kelman miniflared tip, and DuoVisc viscoelastic (all from Alcon).
1688265|NCT01554761|Device|Pentacam (Oculus,Germany)examination|Total corneal astigmatism is obtained by Pentacam at every visit.
1688266|NCT01554748|Other|implant fixation with different techniques and designs|implant fixation cemented/uncemented
1688267|NCT01554735|Behavioral|Exercise and diet|24 weeks of exercise and diet counselling
1688268|NCT01554722|Procedure|Needle placement|In plane versus out of plane needle placement techniques
1688269|NCT01554709|Device|Aortic Cannulas (CardioGard)|Comparison of aortic cannulas during by pass surgery
1688273|NCT01554670|Procedure|RF micro-tenotomy|an additional bipolar RF-based device (TOPAZ, Arthrocare, Austin, TX) connected to a System2000 generator (Arthrocare, Austin, TX) was used to perform the micro-tenotomy. The device functions using a controlled plasma-mediated RF-based process (Co-ablation).The device was placed on the tendon perpendicular to its surface, for 500 milliseconds, and micro-debridement was performed at 5-mm intervals by a 2-row fashion, which covered most of the foot-print region of the supraspinatous tendon and at a depth of 3 to 5 mm
1688274|NCT01554657|Other|5 Days of Antibiotics|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia chosen by the intensive care unit team, and those in this group receive a goal of 5 days.
1688275|NCT01554657|Other|7 Days of Antibiotics therapy for pneumonia|The choice of the specific antibiotic is made by the treating intensive care unit attending physician. The patients will be randomized to two separate groups based on length of antibiotic therapy not specific antibiotics. Therefore, the actual antibiotic that will be given is not determined by the study. The patients all will receive antibiotics for pneumonia that is determined by the treating intensive care unit team, and those in this group receive a goal of 7 days.
1688276|NCT01554644|Device|Prontosan|Prontosan(TM) Wound Irrigation Solution (PHMB 0.1%, Betaine 0.1%) and Prontosan(TM) Wound Gel (PHMB 0.1%, Betaine 0.1%). Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
1688277|NCT01554644|Device|Saline|Saline Wound Irrigation Solution and inert Wound Gel. Dressings will be changed and the treatment procedure will be repeated daily with 30ml/40 ml wound solution and 30 ml wound gel for a period of 12 weeks.
1688278|NCT01554631|Drug|Acarbose (Glucobay ODT, BAYG5421)|
1688279|NCT01554631|Drug|Acarbose (Glucobay, BAYG5421)|
1688282|NCT01554592|Drug|Withdrawal of statin therapy|Participants currently received statin therapy will have their statin stopped for 12 weeks.
1688283|NCT01554592|Drug|Statin therapy|Participants will continue on stable statin therapy.
1688284|NCT01554579|Drug|Gefapixant|BID
1688285|NCT01554579|Drug|Sugar Pill|Placebo
1688286|NCT01554566|Dietary Supplement|honey|The subjects in the I/C group consumed 0.5 ml honey/kg/day in the first 12-week period (period 1) while the subjects in the C/I group did not receive honey as a control in period 1. After period 1 the subjects of each group exchanged their protocol for the following 12-week period (period 2).
1688287|NCT01554553|Procedure|Posterior crural repair|All patients receive gastrectomy, however patients randomized to the experimental arm will also receive posterior crural repair to determine if this will reduce GERD post sleeve gastrectomy.
1688288|NCT01554540|Drug|Cutaneous iontophoresis of treprostinil|Cutaneous iontophoresis of treprostinil 0.1mg/ml, on the forearm and the fingers. (charge 40-240 mC).
1688289|NCT01554527|Procedure|CPAP treatment|6 months of treatment with PAP (CPAP or BPAP)
1688290|NCT01554527|Other|No CPAP treatment|Children randomized to the comparison group will receive routine care
1688291|NCT01554514|Biological|rituximab|rituximab intravenously 100 mg every week for four doses
1688292|NCT01554488|Drug|Inhaled Fluticasone Propionate|Inhaled corticosteroid
1688293|NCT01554462|Dietary Supplement|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA + 650 mg DHA daily
1688294|NCT01554462|Dietary Supplement|Placebo dietary intervention (MUFA) in ADHD group|Placebo contains mono-unsaturated fatty acids (MUFA) in stead of poly-unsaturated fatty acids (PUFA), same energy value
1688295|NCT01554462|Dietary Supplement|Eicosapentaenoic acid / Docosahexaenoic acid|650 mg EPA and 650 mg DHA daily
1688296|NCT01554462|Dietary Supplement|Placebo dietary intervention (MUFA) in healthy control group|Placebo contains MUFA in stead of PUFA, same energy value
1688297|NCT01554449|Procedure|serious game reeducation|It's a daily session (45 minutes) of reeducation by serious game (kinect) compared to a daily session (45 minutes) of conventional reeducation
1688298|NCT01554449|Procedure|functional MRI|the functional MRI (siemens) will be done on 25 stroke patients and 12 healthy volunteers at baseline and at 6 weeks.
1688299|NCT01554436|Behavioral|neuropsychological assessment|"The main criterion of evaluation of the smoking abstinence will be made by the measure of the rate of carbon monoxide (CO) in the expired air between the study start and during the study until 6 months after inclusion.
The secondary criteria of evaluation are criteria of neuropsychological order, namely the performances in the tests listed: result of NART test,Continuous Performance Test (CPT), Trail Making test, Stroop test, Iowa gambling task. (IGT), Hayling test, N back test, fluence verbal test"
1688300|NCT01554423|Other|Testing and Counseling|Couples will receive information on the transmission and prevention of HIV and STIs, the meaning of test results, and health consequences.
1688301|NCT01554423|Behavioral|Brief Motivational Interview (BMI)|The brief motivational interview (BMI) to be tested in the RCT in Pretoria is a one-session, 45 minute intervention that will coordinate three, 15-minute modules with one module each to (1) reduce hazardous drinking; (2) reduce illicit drug use; and (3) promote condom use.
1688302|NCT01554423|Behavioral|Integrated Family and Cognitive Behavioral Therapy|The IFCBT model is 6 sessions in length and coordinates the delivery of 4 cognitive-behavioral group couples' sessions with 2 individual couples' sessions to prevent HIV and STI co-infections among adult drug users. IFCBT targets HIV risk and protective factors that operate across multiple ecological systems. The four group couples' sessions coordinate Rational Emotive Therapy and Problem Solving Therapy strategies to reduce HIV risk behavior and promote protective behaviors. The two individual couples' sessions utilize structural and strategic approaches to promote adaptive communication and shared responsibility for condom use and gender equality and to directly address and reduce any form of abuse between partners when present.
1688303|NCT01554410|Radiation|Intensity Modulated Radiation Therapy (IMRT)|45 Gy in 25 daily fractions (1.8 Gy per fraction)
1688304|NCT01554410|Drug|Cisplatin|Weekly infusion of 40 mg/m2 x 5 weeks (70 mg maximum)
1688305|NCT01554410|Drug|Gemcitabine|Weekly infusion x 5 weeks at escalating dose levels (50mg/m2, 75mg/m2, 100mg/m2, and 125mg/m2)
1688389|NCT01552759|Behavioral|Test meal|Subjects are presented with an ad libitum buffet meal.
1688310|NCT01554371|Drug|Eribulin in Combination w/ Cyclophosphamide|"Phase Ib Eribulin mesylate (mg/m2)
Level -1: 0.7 day 1, 8
Level 0 (start): 1.1 day 1, 8
Level 1: 1.4 day 1, 8
Cyclophosphamide (mg/ m2) Level -1: 600 day 1
Level 0: 600 day 1
Level 1: 600 day 1
Phase II The dose-expansion will enroll 40 patients with advanced breast cancer"
1688311|NCT01554358|Behavioral|Lifestyle intervention|The women in the intervention group will be given detailed advice about how to achieve the six evidence-based goals of the intervention,7-9 including: 1) reduction in 5-10% of initial body weight in women with body mass index (BMI) ≥24 kg/m2 through the reduction of at least 10% of total calories of their normal meals, 2) total fat intake <30% of energy consumed, 3) saturated fat intake <10% of energy consumed, 4) carbohydrate intake 55-65% of energy consumed, 5) fiber intake 20-30g per day, and 6) moderate or vigorous exercise for at least 30 min daily, seven days each week.
1688312|NCT01554345|Drug|vitamin E +Selenium|vitamin E 400 IU once 8 hrs before operation selenium 150 mic once 8 hrs before operation
1688313|NCT01554332|Device|Motor Cortex Stimulation using SJM EonC Stimulator|Patients will be randomized to receive either active stimulation the first 3 months followed by a one-month washout, followed by Sham Stimulation the next 3 months, vs. the reverse order of treatment, followed by single blind stimulation, and an open label phase.
1688314|NCT01554319|Drug|SB010|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).
Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board.
Dose group A : 5 mg hgd40/2 mL; Dose group B: 10 mg hgd40/2 mL; Dose group C: 20 mg hgd40/2 mL."
1688315|NCT01554319|Drug|Placebo (phosphate-buffered saline)|"Three ascending dose groups are planned (Groups A, B, C), each consisting of 12 male subjects. Each of the 3 dose groups will be divided into 2 subgroups. First subgroup: 4 subjects (n=3 active compound, n=1 placebo); second subgroup: 8 subjects (n=6 active compound, n=2 placebo).
Each dose group will be investigated with a new group of 12 subjects (n=9 active compound, n=3 placebo). Dose escalation to next dose level will occur after satisfactory review of safety and tolerability and after review of the pharmacokinetic data (exposure control) of the preceding dose cohorts by the Safety Board."
1688316|NCT01554293|Drug|Matching placebo|Matching Placebo, single dose
1688317|NCT01554293|Drug|PBL 1427 capsules|PBL 1427 capsules 20 mg and 150 mg, single dose
1688318|NCT01554280|Device|Fully coated, removable , self-expanding oesophageal stent|Insertion of the fully coated, removable, self-expanding oesophageal stent for the prevention of oesophageal strictures.
1688319|NCT01554267|Device|Laser-Assisted ICG Dye Angiography (SPY System)|7.5-10mg of ICG dye will be injected at 2 different time points during breast reconstruction with the assistance of the SPY system to determine areas of skin with poor blood flow. These areas are excised during the operation in order to decrease postoperative complications including mastectomy skin flap necrosis and reconstruction failure.
1688320|NCT01554254|Drug|TXA127|300mcg/kg/day, subcutaneous injection for up to 28 days
1688321|NCT01554241|Dietary Supplement|D3 2000 IU/day|2000 IU/day D3
1688322|NCT01554241|Dietary Supplement|D3 4000 IU/day|vitamin D3 4000 IU/day
1688323|NCT01554241|Dietary Supplement|D3 50,000 IU weekly|vitamin D3 50,000 IU/week
1688324|NCT01554241|Dietary Supplement|vitamin D3 800 IU/day|vitamin D3 800 IU/day
1688325|NCT01554228|Other|Observation|Observational study to examine changes in cognition following bariatric surgery after one year.
1688326|NCT01554215|Behavioral|Mom Power Intervention Group|attachment-based parenting program for parents in community setting led by trained and experienced facilitators.
1688327|NCT01554215|Behavioral|Mom Power Attentional Control Group|at home control, weekly mailings
1688328|NCT01554202|Behavioral|assessment of memory|
1688329|NCT01554202|Biological|circulating tPA dosage|
1688330|NCT01554202|Genetic|ApoE4|
1688331|NCT01554202|Other|Brain imaging examination MRI and PET examinations|
1688332|NCT01554189|Drug|MK-8325|MK-8325 capsules, orally, once per day for 5 days, at a dose determined by panel assignment (10-200 mg)
1688333|NCT01554189|Drug|Placebo|Placebo to match MK-8325 capsules, orally, once per day for 5 days
1688334|NCT01554176|Drug|Filorexant|Filorexant, one 10 mg tablet, orally, once daily at bedtime
1688335|NCT01554176|Drug|Placebo|Placebo, one tablet, orally, once daily at bedtime
1688336|NCT01554163|Drug|Etoricoxib 30 mg|Etoricoxib 30 mg tablet once daily for 12 weeks.
1688337|NCT01554163|Drug|Celecoxib 200 mg|Celecoxib 200 mg once daily for 12 weeks
1688338|NCT01554150|Behavioral|Method of Levels Cognitive Therapy|In MOL the therapist has two goals: to get the client to talk about his or her problem as it is currently being experienced, and to ask about disruptions, which are thought to indicate background thoughts coming into awareness. The assumption is that when somebody is experiencing problems that they feel they cannot solve, the only way for these to be properly resolved is for change to come from within that person. The MOL therapist helps the person redirect their awareness to think about the problem in more productive ways. It is present-focused, with the therapist asking questions relating to process rather than content. The therapist does not give advice and there is no homework. In MOL clients schedule sessions as and when they feel they need them and decide how long each session should be.
1688339|NCT01554137|Other|isokinetic strength training|The experimental group will follow a program of 18 sessions (3 sessions per week for 6 weeks) with a physiotherapy treatment (30 minutes) and occupational therapy (30 minutes), and a building session isokinetic concentric mode extensor and flexor muscles of the elbow extensors and wrist flexors.
1688340|NCT01554137|Other|passive motion|The control group will follow a program of 18 sessions of physiotherapy and occupational therapy combined with 18 sessions of passive motion in flexion-elbow extension, wrist flexion-extension on the isokinetic device
1688341|NCT01554124|Drug|Meropenem|"40 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age).
Treatment duration = 21 ± 7 days"
1688342|NCT01554111|Drug|Picosulfate sodium,|One sachet of picosalax will be given with at least 4 cups of clear fluids.
1688390|NCT01552733|Device|'Inmotion Arm Robot'|To improve limb function in those with limb impairment
1688343|NCT01554111|Drug|phosphosoda rectal enema|The patient will have an enema inserted into the rectum and the liquid contents of the enema will be squeezed into the rectum. The patient will need to hold in the enema for several minutes then can release it.
1688344|NCT01554111|Drug|Pico-Salax and Sodium phosphate enema|Pt will take one sachet of Pico-salax the evening prior to procedure and fleet enema 1 hour before leaving home on the morning of the procedure
1688345|NCT01554098|Procedure|Strategy : Supine first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal in the supine position and then with dynamic position change.
1688346|NCT01554098|Procedure|Strategy : dynamic first|The initial withdrawal in each of 4 segments of the colon: 1)Caecum, Ascending colon and Hepatic flexure 2) Transverse colon 3) Splenic flexure and descending colon 4) Sigmoid colon, will be performed in two different positions. The intervention in this arm will be withdrawal with dynamic position change first followed by the supine position.
1688349|NCT01554072|Other|Home based pulmonary rehabilitation with exercise|After each group will receive the randomization their booklets containing the exercise routine that should be performed at home., to be held three times a week for two consecutive months. Is also scheduled a visit to the laboratory biweekly Respiratory Functional Assessment in which patients demonstrate their exercise routine program RP semi-home settings for any load, postural corrections and execution of physical exercise, should be refocused.
1688350|NCT01554059|Drug|Bevacizumab|Bevacizumab 5mg/m2 D1,D15,D29,D43;
1688351|NCT01554059|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 D1,D57; Oxaliplatin 85mg/m2 biweekly * 6 doses 3-4 weeks after radical resection
1688352|NCT01554059|Drug|5-FU|5-FU 2800mg/m2 civ 48 hours D1,D57; 5-FU 2800mg/m2 civ 48 hours biweekly*6 doses 3-4 weeks after radical resection; 5-FU 200mg/m2/day civ D15-19,D22-26,D29-33,D36-40,D43-47;
1688353|NCT01554059|Radiation|Radiotherapy|2GY daily *20次
1688354|NCT01554046|Drug|Methylphenidate- Ritalin IR (Immediate Release)|"Duration of treatment- 4 weeks. Dosage- up to 3 times/day.
Ages 6-12, up to 25Kg - 35mg maximum per day.
Ages 6-12, above 25Kg - 50mg maximum per day.
Ages 12-65, above 25Kg - 80mg maximum per day."
1688355|NCT01554020|Dietary Supplement|Blood Sugar Take Care|One 1200 mg soft gel capsule administered 3X/day for duration of study
1688356|NCT01554020|Dietary Supplement|Placebo|One 1200 mg soft-gel capsule administered 3X/day for duration of study
1688357|NCT01554007|Other|Observation study|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
1688358|NCT01553981|Drug|Tadalafil|Tab. Tadalafil 20 mg every other day for 6 months
1688359|NCT01553981|Drug|Placebo|Shape , size, color and odor matched Tab. of inert material every other day for 6 months
1688360|NCT01553968|Other|Cycling|30 minutes of cycling at 50% of predetermined maximal performance
1688361|NCT01553955|Procedure|Venipuncture|Blood draw for purposes of training in platelet rich plasma concentration. Trainees will be in pairs and each will draw blood from the other for use in the concentration process.
1688362|NCT01553942|Drug|Afatinib|induction phase-two 4 week cycles. consolidation phase-twenty six 4 week cycles
1688363|NCT01553942|Radiation|Radiation|Daily, Monday-Friday
1688364|NCT01553942|Drug|Cisplatin|Day 1 of each cycle, IV infusion over 60 minutes
1688365|NCT01553942|Drug|Pemetrexed|Day 1 of each cycle, given as IV infusion over 10 minutes after cisplatin infusion
1688366|NCT01553942|Procedure|Surgery|Surgery to remove tumor
1688367|NCT01553929|Other|Physical Training and cognitive activity (EPC group)|The patients of the EPC group will realize 2 weekly sessions of 20 minutes of pédalage. During the exercise, the patients will realize a series of tests of decision-making and perceptive cognitive capacity.
1688368|NCT01553929|Other|Physical training (EP group)|The patients of the group (EP) will realize 2 weekly sessions of 20 minutes of pédalage.
1688369|NCT01553929|Other|control group|no physical training and no cognitive activity
1688372|NCT01553903|Drug|Tamoxifen,|Tamoxifen 20 mg/day during 5 years,
1688373|NCT01553903|Drug|Exemestane|Exemestane 25mg/day during 5 years
1688374|NCT01553903|Drug|Anastrozole|Anastrozole 1 mg/day during 5 years,
1688375|NCT01553903|Drug|Letrozole|Letrozole 2.5 mg/day during 5 years,
1688376|NCT01553890|Other|Blood sample|blood sample, venous blood, about 10 ml will be drawn from participants
1688377|NCT01553877|Dietary Supplement|Pushti packet|A food composed of roasted rice, roasted lentil, molasses and soybean oil
1688378|NCT01553877|Dietary Supplement|Rice based Ready to Use Complementary Food Supplements|A rice based diet.
1688379|NCT01553877|Dietary Supplement|Chick-pea based Ready to Use Complementary Food Supplements|A chick-pea based diet.
1688380|NCT01553851|Drug|GSK1120212|Trametinib (GSK1120212) is a selective MEK1 and MEK2 inhibitor with selective activity towards BRAF and RAS mutant cancer cell lines and hematopoietic cancer cells from AML and CML origins.
1688381|NCT01553838|Device|MRI guided prostate biopsy and TRUS guided biopsy|MRI guided prostate biopsy
1688382|NCT01552798|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|2 x 500 mg fast release aspirin tablets (1000 mg) and 2 x placebo acetaminophen caplets
1688383|NCT01552798|Drug|Acetaminophen|2 x 500 mg acetaminophen caplets (1000 mg) and 2 x placebo fast release aspirin tablets
1688384|NCT01552798|Drug|Placebo|2 x placebo acetaminophen caplets and 2 x placebo fast release aspirin tablets
1688385|NCT01552785|Device|Peripheral near infrared spectroscopy|Devices: NONIN 7600 EQUANOX with sensor Model 8004CA, INVOS 5100c with SAFB-SM, and FORE-SIGHT with medium sensor
1688386|NCT01552772|Drug|Aripiprazole IM Depot|400 mg intramuscular injection of aripiprazole
1688387|NCT01552759|Procedure|Postprandial responses|Subjects ingest a fixed meal, with blood draws to measure appetite hormone levels taken before and after the meal.
1688388|NCT01552759|Behavioral|Cold pressor test|Subjects then undergo the Socially-Evaluated Cold Pressor Test, with blood draws to measure appetite hormone levels taken before and after the test.
1740525|NCT00112645|Drug|melphalan|
1688392|NCT01552707|Biological|XCEL-MT-OSTEO-ALPHA|"Isolation and ex-vivo expansion of mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia, División de Terapias Avanzadas delBanc de Sang i Teixits. After expansion, MSCs are fixed in allogenic bone tissue and implanted in instrumented spinal fusion."
1688393|NCT01552707|Procedure|Standard treatment|Instrumented spinal fusion together with patient's bone iliac crest
1688394|NCT01552694|Drug|Sitagliptin|Oral, 100 mg/day for 2 months
1688395|NCT01552694|Drug|Placebo|oral, matching placebo daily for 2 months
1688396|NCT01552681|Biological|Baminercept|Subjects randomized to baminercept (2:1) will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
1688397|NCT01552681|Other|Placebo|Subjects randomized to placebo will receive 24 weekly injections of 100 mg administered subcutaneously starting at the Day 0 visit and ending at Week 23.
1688398|NCT01552668|Drug|Fidaxomicin|Receive 200 mg of fidaxomicin twice daily
1688399|NCT01552668|Drug|Placebo|Receive Placebo twice daily
1688400|NCT01552655|Radiation|Dual-time PET/CT (low-dose)|4 MBq/kg 18F-flour-deoxyglucose administered iv. PET/CT-scans performed 60 min and 180 min after injection.
1688401|NCT01552642|Behavioral|face-to-face meetings and access to a website|The intervention group will have 6 weekly face-to-face meetings and will have access to a website.
1688402|NCT01553786|Drug|Lenalidomide|Lenalidomide
1688403|NCT01553773|Drug|isoflavone|treatments: a gel with 17-β estradiol 0.01% (n = 15) and a gel with isoflavones (genistein 4%). The gels were applied once per day. the lenght of treatment was 24 weeks.
1688404|NCT01553773|Drug|Estradiol|a gel with 17-β estradiol 0.01%. Once per day. The lenght of treatment was 24 weeks.
1688405|NCT01553760|Procedure|Phacoemulsification using an ACM as the sole fluid source|A Tri-MICS system will be used with a sleeveless Kelman 20G tip through a 1.1mm CCI. A specialized 19G anterior chamber maintainer, with thin walls and a large internal diameter of 0.9mm will be inserted through a 1.1mm CCI.
1688406|NCT01553760|Procedure|Conventional Phaco|a conventional Phaco with sleeved Kelman 20G tip, through a 2.4mm CCI
1688407|NCT01553747|Drug|JNJ-27018966|Oral tablets twice daily
1688408|NCT01553747|Other|Placebo Comparator|Oral tablets twice daily
1688409|NCT01553721|Drug|udenafil|"Phase IIa - Udenafil Dose 1, Dose 2(Single dose)
Phase IIb - Udenafil(BID)"
1688410|NCT01553721|Drug|placebo|Phase IIa - placebo Phase IIb - placebo
1688411|NCT01553708|Drug|Epidermal growth factor with silver sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
1688412|NCT01553708|Drug|Silver zinc sulfadiazine cream|Compare the duration for complete partial thickness burn wound healing between sample (epidermal growth factor with silver sulfadiazine cream) and control (silver zinc sulfadiazine cream)
1688413|NCT01553695|Other|questionary|Subjects have to fill out a booklet of questionnaires
1688414|NCT01553695|Other|questionary|Subjects have to fill out a booklet of questionnaires
1688415|NCT01553682|Behavioral|Horizons+General Health Promotion (GHP)|Participants will attend the Horizons HIV Prevention Program with an extra workshop on nutrition health promotion. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. The nutrition health promotion workshop will give ideas on healthy nutrition and exercise. Participants will be asked to rate the workshop anonymously.
1688416|NCT01553682|Behavioral|Horizons+Motivational Enhancement Therapy (GMET)|Participants will attend the Horizons Plus HIV Prevention Program. Participants will attend a total of two (2) 5-hour workshops over 2 consecutive Saturdays. They will be led by African American health educators, and have about 8-12 other young women participants. The workshops will discuss gender and ethnic pride, self-esteem, good role models, and how to reduce risky sexual behavior. Participants will be asked to rate the workshop anonymously.
1688417|NCT01553669|Behavioral|reminiscence therapy|The subjects who are arranged to the experiment group will be intervened using the reminiscence therapy manual proposed by Watt and Cappeliez (2000). According to the manual, the group consisted of six weekly sessions of 90 min each. There will be about four people in each subgroup. During each weekly session, the memories recalled focused on a different theme.
1688418|NCT01553656|Drug|cabozantinib capsules|cabozantinib capsules administered as 25-mg and 100-mg strengths once-daily until disease progression
1688419|NCT01553656|Drug|cabozantinib tablets|cabozantinib tablets administered as 20-mg and 60-mg strengths once-daily until disease progression
1688420|NCT01553643|Drug|Chinese Herb Huang-Chi-Wu-Wu-Tang|Huang-Chi-Wu-Wu-Tang at a rate of 3g two times per day
1688421|NCT01553643|Drug|placebo|at a rate of 3g two times per day
1688422|NCT01553630|Procedure|RIA bone graft|Acute autogenous bone grafting with RIA graft at the time of surgical fixation.
1688423|NCT01553630|Procedure|Surgery without bone graft|Plating of fracture without bone graft
1688424|NCT01553617|Drug|6% hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution (VolulyteTM)|Study drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
1688425|NCT01553617|Drug|Human serum albumin|Control drug will be given as part of priming of the ECC and for volume therapy up to the maximum dosage of 50 mL/kg body weight/day
1688426|NCT01553604|Procedure|augmentation mammaplasty|Dressing is removed on the first postoperative day
1688427|NCT01553604|Procedure|augmentation mammaplasty|Dressing is removed on the 6th postoperative day
1688428|NCT01553591|Drug|JNJ-27018966|Oral tablets twice daily
1688429|NCT01553591|Drug|Placebo|Oral tablets twice daily
1688430|NCT01553578|Other|questionnaire administration|Ancillary studies
1688431|NCT01553578|Procedure|therapeutic touch|Receive healing touch therapy
1688432|NCT01553578|Behavioral|management of therapy complications|Receive healing touch therapy
1688433|NCT01553578|Behavioral|management of therapy complications|Receive guided imagery audiotapes
1688434|NCT01553578|Procedure|standard follow-up care|Receive standard care
1688758|NCT01550783|Other|Cervical Papanicolaou Test|Undergo standard of care Pap test screening
1688435|NCT01553565|Procedure|Cold polypectomy|All colorectal polyps up to 10 mm found except for tiny hyperplastic polyps in the rectum and distal sigmoid colon are removed. The technique is cold resection of the polyp without tenting and then suction of the transected polyp into a trap followed by submission to histopathological evaluation.
1688436|NCT01553539|Drug|therapeutic angiotensin-(1-7)|Given SC
1688437|NCT01553539|Other|laboratory biomarker analysis|Correlative study
1688438|NCT01553513|Other|[18F]-FDG positron emission computed tomography|"Patients will receive 20 mg furosemide and 20 mg butylscopolamine together with 370 MBq FDG. 120 minutes after the FDG application a ECG- and respiratory gated cardial PET acquisition will be performed, followed by a CT calcium scan, which will also be used for attenuation correction.
This will be followed by CT-angiography with the application of 80 ml contrast medium. Patients without betablocker and a heart rate of more than 70 / min will be treated with 50 - 100 mg metoprolol as long as there are no contraindications.
Subsequently, a 3D-mode whole body PET scan will be acquired followed by a low-dose CT transmission scan from the base of the scull to the iliac crest."
1688439|NCT01553513|Procedure|Invasive coronary angiography|ICA is performed via the femoral artery in three projections (RAO 30°, RAO 15° and LAO 45°) and, if necessary, also in further projections. All angiograms are recorded digitally and assessed quantitatively by two experienced readers, who are blinded to the PET/CT results (Quant-Cor, QCA, Siemens Medical Systems, Forchheim, Germany or Digital Cardiac Imaging Systems, Philips, Eindhoven, Netherlands). The mean stenosis of the vessel is assessed in two projections and the percentage of stenosis is calculated for each single segment. Stenoses are localized by means of the AHA (American Heart Association) classification. Occlusions of the vessels are documented and revascularization is performed immediately in patients with acute coronary syndrome (STEMI, NSTEMI).
1688440|NCT01553513|Procedure|Intravascular ultrasound and virtual histology|"During the procedure an intravascular ultrasound will be recorded in grayscale. Radiofrequency raw-data will be collected at the peak of the R-wave and a VH-IVUS data recorder is used to reconstruct a color-coded map. Acquired data will be evaluated with a dedicated software. The grayscale IVUS images will be analyzed frame by frame and used to measure the diameter of the vessel lumen, of the external elastic membrane (EEM) as well as plaque and media thickness (defined as EEM minus lumen). The plaque burden will be calculated.
A VH-IVUS analysis will be performed for each frame. Four plaque components will be color-coded: dense calcium white, the necrotic core red, fatty tissue light green and scar tissue dark green. color fractions are expressed as percentage of the plaque area and percentage of plaque volume.
Lesions will be classified: pathologic intima thickening, fibroatheroma with thin cap, fibroatheroma with thick cap, fibrotic plaque and fibro-calcified plaque."
1688441|NCT01553513|Other|Serum biomarkers|"A 20 ml blood sample will be obtained from each patient. The following biomarkers will be assessed: glucose level, HBA1C, cholesterol levels, LDL cholesterol, HDL cholesterol, triglycerides, fibrinogen, factor XIII, plasminogen, complement C3, TNF-alpha, IL-6, CRP, resistin, adiponectin, CD40, 5-lipoxygenase, MMP-9, MMP-1, osteopontin, osteoprotegerin, fetuin, FGF21.
ELISA and/or calorimetric assays will be used for the biochemical analyses of the serum markers."
1688442|NCT01553500|Dietary Supplement|glucomannan|glucomannan is administered at dosage of 5g/day in form of biscuits (6 biscuits/day)
1688443|NCT01553500|Behavioral|lifestyle intervention|hypocaloric diet (25-30 Kcal/kg/day) or isocaloric (40-45 Kcal/kg/day) and physical activity
1688444|NCT01553487|Other|Forearm vibration|All cases will be trained by forearm vibration device 5 times a week for six weeks period.
1688446|NCT01553448|Genetic|gene expression analysis|
1688447|NCT01553448|Genetic|protein expression analysis|
1688448|NCT01553448|Other|enzyme-linked immunosorbent assay|
1688449|NCT01553448|Other|immunohistochemistry staining method|
1688450|NCT01553448|Other|laboratory biomarker analysis|
1688451|NCT01553448|Other|medical chart review|
1688452|NCT01553435|Drug|Dextromethorphan|The study medicines shall be administered via tube.
1688453|NCT01553435|Drug|Placebo|The study medicines shall be administered via tube.
1688454|NCT01553422|Other|Fluid therapy (Saline Normal)|Saline Normal 1 Lit. during 30 minutes
1688455|NCT01553422|Other|Fluid therapy (Saline Normal)|saline Normal 1 lit during 30 minutes
1688456|NCT01553383|Device|"nasal peep valve Provent"|application of nasal peep valve vs dental device and cpap
1688457|NCT01553370|Other|Increased Dairy Intake|3 additional servings of low fat dairy will be consumed
1688458|NCT01553370|Other|Supplemental carbohydrate|Maltodextrin will be provided in an amount equal to the the energy content in the 3 supplemental servings of low-fat dairy.
1688459|NCT01553357|Drug|Lenalidomide, dexamethasone|"Enrolled patients received lenalidomide at a dose of 25 mg/d for 21 days and oral dexamethasone at a dose of 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, responding patients not eligible for SCT continued until 8 cycles of full-dose LD, if tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 mg/d on days 1-21 of each 28-day cycle.
Patients responding after 4 cycles and eligible for SCT proceeded according to single Centre transplant policy. Patients not responding after 4 cycles or progressing during this treatment were considered off-study."
1688460|NCT01553331|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|Laparoscopic cholecystectomy with diathermy hook starting from triangle of Calot
1688461|NCT01553331|Procedure|dissection of gallbladder in laparoscopic cholecystectomy|laparoscopic cholecystectomy with ultrasonic scissors starting from fundus
1688462|NCT01553318|Drug|Ketotifen|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg by mouth, twice a day or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg by mouth twice a day or the equivalent placebo.
1688463|NCT01553318|Drug|Placebo (Sugar Pill)|After meeting the full eligibility requirement, participants will be randomized. From week 1 to 2, subjects will receive either ketotifen 1 mg BID or the equivalent placebo. Thereafter, subjects will take ketotifen to 2 mg BID or the equivalent placebo.
1688464|NCT01553305|Other|Supervised high-intensity exercise programme|Six-weeks supervised high-intensity muscle strength training and physical fitness with training sessions twice a week followed by 6-weeks unsupervised high-intensity exercise programme.
1688465|NCT01553305|Other|Exercise programme|Supervised exercise programme
1690236|NCT01539174|Drug|doxorubicin hydrochloride|Given IV
1688466|NCT01553292|Device|ECALMIST|Labelled catheter at level of the lips (6 cm plus weight) will inserted through the vocal cords under direct vision using a standard laryngoscope without premedication while maintaining CPAP. 5 ml/kg surfactant syringe will be connected to the catheter hub and 0.25-0.5 ml was administered; then the syringe will be disconnected from the catheter to observe the surfactant moving up and down or coming back as indication of accurate intubation of the trachea. The surfactant the slowly administer by boluses of 0.25-0.5 ml over 20-30 seconds with 10 seconds apart. At the end of the procedure, the operator flushed the catheter with 0.5 ml of air before removing the catheter while maintaining CPAP
1688467|NCT01553292|Device|ECALMIST|Vascular catheter of 1.6 French size of 133 mm length 16 gauge used to deliver the BLES; a large volume surfactant while maintain CPAP
1688468|NCT01553279|Biological|V419 (PR5I)|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b conjugate [Meningococcal Outer Membrane Protein Complex], and hepatitis B [Recombinant] Vaccine 0.5 mL intramuscular injection at 2, 3 and 4 months of age
1688469|NCT01553279|Biological|Prevenar 13|Pneumococcal conjugate vaccine (13-valent, adsorbed) 0.5 mL intramuscular injection at 2 and 4 months of age
1688470|NCT01553279|Biological|NeisVac-C|Meningococcal group C polysaccharide conjugate vaccine adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
1688471|NCT01553279|Biological|MENJUGATE|Meningococcal group C conjugate vaccine adsorbed 0.5 mL intramuscular injection at 3 and 4 months of age
1688472|NCT01553279|Biological|MENITORIX|Haemophilus type b and meningococcal group C conjugate vaccine 0.5 mL intramuscular injection at 12 months of age
1688473|NCT01553279|Biological|M-M-RVAXPRO|Measles, mumps, and rubella vaccine (live)
1688474|NCT01553266|Behavioral|Mobile Diabetes Education Teams intervention|A MDET (one Registered Nurse and Registered Dietician) supports primary care physicians by providing diabetes management education to the PCPs' patients onsite, one to four times a month based on patient volume.
1688475|NCT01553240|Device|TMS and functional MRI (Magstim)|single and paired pulse low frequency TMS. 3T structural MRI scans, amplitude modulated continuous arterial spin labeling( CASL) perfusion imaging sequence optimized for 3T is employed for perfusion MR scans using GE FAIR sequence for parallel imaging.
1688476|NCT01553227|Device|ventilator|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
1688483|NCT01553175|Genetic|DNA analysis|
1688484|NCT01553175|Genetic|gene expression analysis|
1688485|NCT01553175|Genetic|mutation analysis|
1688486|NCT01553175|Genetic|protein expression analysis|
1688487|NCT01553175|Other|immunohistochemistry staining method|
1688488|NCT01553175|Other|laboratory biomarker analysis|
1688489|NCT01553162|Genetic|DNA analysis|
1688490|NCT01553162|Genetic|RNA analysis|
1688491|NCT01553162|Genetic|gene expression analysis|
1688492|NCT01553162|Other|laboratory biomarker analysis|
1688496|NCT01553123|Drug|Ulipristal Acetate|once daily, oral
1688497|NCT01553123|Drug|Iron|once daily, dried ferrous sulfate
1688498|NCT01553097|Other|Neurocognitive impairment observation|None - observational
1740526|NCT00112645|Drug|methotrexate|
1688502|NCT01553071|Drug|Fenretinide (4-HPR) plus Intravenous Safingol|"A course for this study is defined as the 5 days of treatment with Fenretinide (4-HPR) plus Safingol followed by 16 days of rest. A course is repeated every 21 days if there is no clinical evidence of disease progression for a maximum of six 5-day infusions.
Days 1-5 of every cycle: Day 1 Fenretinide (4-HPR) intravenous emulsion: 600 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Day 2 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 for 24 hours Given concurrently (at the same time) with: Safingol intravenous 210 mg/m2 for 24 hours Days 3-5 Fenretinide (4-HPR) intravenous emulsion: 1000 mg/m2 continuously for 3 days Days 8 and 15 : Weekly blood draw to monitor side effects requires a clinic visit for approximately 1 hour Days 6,7,9-14, 16-21 Rest and monitor side effects."
1688506|NCT01553032|Drug|Erbitux®|400mg/m2 initial dose, followed by weekly doses of 250mg/m2 Treatment duration: 7-8 weeks
1688507|NCT01553032|Radiation|Fractionated Radiotherapy|30-35 fractions of radiotherapy (6-7 weeks)
1688508|NCT01553019|Radiation|Proton radiation|Proton Radiation Therapy: R(0) negative ... 50.40 cobalt gray equivalent (CGE) at 1.8 CGE per fraction ; R(1) micro-positive ...54.00 CGE at 1.8 CGE per fraction; R(2) gross positive...59.40 CGE at 1.8 CGE per fraction
1688509|NCT01553019|Drug|Gemcitabine|Gemcitabine 300 mg/m2 infused over 30 minutes, weekly during proton therapy.
1688510|NCT01553006|Drug|cefditoren pivoxil|comparison of different dosages of cefditoren pivoxil
1688511|NCT01552993|Drug|paracetamol|Paracetamol mixture 20 mg/kg + pacifier and glucose
1688512|NCT01552993|Drug|sucrose|pacifier and sucrose
1688513|NCT01552980|Drug|S-1 and Oxaliplatin|"Oxaliplatin 85mg/m2 D1 and S-1 40mg/m2 BID D1-D10, repeat every two weeks;
Efficacy will be evaluated every three cycles."
1688514|NCT01552967|Drug|Capecitabine|"Oxaliplatin 85mg/m2 D1 and capecitabine 1g/m2 BID D1-D10, repeat every two weeks.
Efficacy will be evaluated every three cycles."
1688515|NCT01552954|Behavioral|Intensive education of low salt diet|For 8 weeks, dietitian will call patients to take the information according to pre-defined questionnaire, to check the daily diet habit and daily food taken, and to guide how to lessen sodium intake for 30 min at each call. The call will be done once a week for 8 weeks.
1688516|NCT01552941|Device|Cyberonics VNS System|Active Implantable Electrical Vagal Nerve Stimulator
1688517|NCT01552928|Drug|Anagrelide 0.5 mg|0.5mg Anagrelide single oral dose
1688518|NCT01552928|Drug|Anagrelide 2.5 mg|2.5mg Anagrelide single oral dose
1688519|NCT01552928|Drug|Moxifloxacin|400 mg Moxifloxacin single oral dose
1688520|NCT01552928|Drug|Placebo|Anagrelide placebo + Moxifloxacin placebo single oral dose
1688521|NCT01552915|Drug|Lisdexamfetamine dimesylate|Daily oral dosing in the AM of optimized dose, ranging from 30- 70 mg. 5 week dose optimization, 3 week dose maintenance
1688522|NCT01552915|Drug|Methylphenidate Hydrochloride|Daily oral dosing in the AM of optimized dose, ranging from 18-72 mg. 5 week dose optimization, 3 week dose maintenance
1688523|NCT01552915|Drug|Placebo|Daily oral dosing in the AM for 8 weeks
1688524|NCT01552902|Drug|Lisdexamfetamine dimesylate|Daily oral dosing in the AM ranging from 30- 70 mg. 4 week forced dose titration, 2 week dose maintenance
1688525|NCT01552902|Drug|Methylphenidate Hydrochloride|Daily oral dosing in the AM ranging from 18-72 mg. 4 week force dose titration, 2 week dose maintenance
1688526|NCT01552902|Drug|Placebo|Daily oral dosing in the AM for 6 weeks
1688527|NCT01552889|Behavioral|Collaborative Care|No direct treatment will be offered. We will make treatment recommendations to the patient, PCP and cardiologist. Referral to mental health specialist is also possible, depending on need. The nurse case manager will monitor treatment progress and patient status for duration of the intervention period.
1688528|NCT01552876|Device|etafilcon A|A daily wear contact lens
1688529|NCT01552876|Device|nelfilcon A|A daily wear contact lens
1688530|NCT01552876|Device|Filcon II 3|a daily disposable
1688531|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation A, single dose
1688532|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation E, single dose
1688533|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation F, single dose
1688534|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation G, single dose
1688535|NCT01552863|Drug|Oxycodone|One capsule of 5 mg PF-00345439 Formulation TBD, single dose
1688536|NCT01552863|Drug|Oxycodone|One capsule of 40 mg PF-00345439 Formulation H, single dose
1688537|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation A capsule with water and under fed condition
1688538|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation B capsule with water and under fed condition
1688539|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation C capsule with water and under fed condition
1688540|NCT01552850|Drug|Oxycodone|1X40 mg PF-00345439 formulation D capsule with water and under fed condition
1688541|NCT01552850|Drug|Oxycodone|40 mg oxycodone oral solution (5 mg/5 ml) with water and under fed condition
1688542|NCT01552837|Drug|Seroquel|for 4 weeks, 300 - 800 mg per day in 2 doses
1688543|NCT01552824|Procedure|CYSTO|Fetal cystoscopy will be performed by introducing a 2.2mm sheath with 1.0mm fetoscope into fetal bladder under ultrasound guidance. The fetoscope will be advanced and the posterior urethral valves will be coagulated by ND:YAG laser. If urethra atresia was diagnosed, a vesico-amniotic shunting will be placed. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
1740527|NCT00112645|Drug|methylprednisolone|
1688544|NCT01552824|Procedure|Vesico-amniotic shunt|In this arm, all patients randomly selected for this treatment will undergo vesico-amniotic shunting under ultrasound guidance. Maternal anesthesia will be conducted by epidural anesthesia and fetal anesthesia will be conducted by injecting fentanyl (15 μg/Kg) and pancuronium (2 mg/Kg) under ultrasound guidance of a 22 gauge needle into fetal arm muscle.
1688545|NCT01552629|Drug|QGE031|
1688546|NCT01552629|Drug|Placebo|
1688547|NCT01552629|Drug|Cyclosporine A|
1688548|NCT01552616|Procedure|Thermal-aided muscle activation|Thermal-aided muscle activation therapy will be provided to patients twice daily. Treatment will begin within 24 hours of admission and continue until patients are significantly ambulatory.
1688549|NCT01552603|Device|Artificial Pancreas Control Software|This master controller software is used in conjunction with two subcutaneous continuous glucose monitoring systems and two Omnipod pumps, one for administering aspart insulin (NovoLog) and one for administering glucagon (GlucaGen), to control blood glucose levels. The insulin and glucagon infusion rates are determined by an automated version of the Adaptive Proportional Derivative (APD) insulin and glucagon control algorithm.
1688550|NCT01552590|Drug|Tolvaptan|
1688551|NCT01552590|Drug|Placebo|
1688552|NCT01552564|Procedure|Index of microvascular resistance|
1688553|NCT01552564|Other|Cardiac magnetic resonance|
1688554|NCT01552564|Other|Blood markers|
1688555|NCT01552551|Behavioral|Assessment and education|PA Healthy Steps program
1688556|NCT01552551|Behavioral|Healthy Steps with Falls Case Management|Counseling to ensure that participants receive a physician assessment and home safety check
1688557|NCT01552551|Behavioral|Healthy Steps in Motion|Group exercise program
1688558|NCT01552538|Device|Cyberonics VNS System|Stimulation with an active implantable electrical vagal nerve stimulation device
1688559|NCT01552512|Dietary Supplement|Nutributter Program|Nutributter is a ready-to-use nutritional supplement that provides all vitamins and minerals required for healthy growth of infants 6 to 12 months of age. The paste is packaged in 20 gram sachets. One sachet corresponds to the recommended daily dose for a child.
1688560|NCT01552512|Other|Integrated Package|The integrated package of services are provided through the Haitian Ministry of Health and includes childhood vaccinations, family planning messages, diarrhea prevention and control (e.g. water purification methods, promotion of positive sanitation and hygiene practices such as hand washing), and the promotion of positive child feeding practices (e.g. exclusive breastfeeding for six months; increased frequency of complementary feeding; and dietary diversity).
1688561|NCT01552499|Other|Standard of care|
1688562|NCT01552499|Other|Applications of EpiFix|
1688563|NCT01552486|Other|Chiropractic Spinal Manipulative Therapy|Patients will receive a course high-velocity low-amplitude thrust spinal manipulation 3 times per week for 4 weeks.
1688564|NCT01552486|Other|Usual Care|Patients will be under the care of the their general physician and will be allowed the following medications: gabapentin, pregabalin, nortriptyline, amitriptyline.
1688567|NCT01552447|Other|EpiFix|Dehydrated placental tissue
1688568|NCT01552447|Other|Compression Therapy|Compression bandaging
1688569|NCT01552434|Drug|Temsirolimus|"Dose Escalation Group: Starting dose of Temsirolimus 5 mg by vein on Days 1, 8, 15, and 22 of each 28 day cycle.
Dose Expansion Group Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group."
1688570|NCT01552434|Drug|Bevacizumab|"Temsirolimus + Bevacizumab + Cetuximab Group Starting Dose of Bevacizumab: 2.5 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
Temsirolimus + Bevacizumab + Valproic Acid Group and Temsirolimus + Bevacizumab Group Starting Dose of Bevacizumab: 5 mg/kg by vein on Days 1 and 15 of each 28 day cycle.
Dose Expansion Groups Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group."
1688571|NCT01552434|Drug|Valproic Acid|"Starting dose of Valproic Acid 5 mg/kg rounded to nearest 250 mg by mouth on Days 1 - 7 and 15 - 21 of each 28 day cycle.
Dose Expansion Group Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group"
1688572|NCT01552434|Drug|Cetuximab|"Starting dose of Cetuximab loading dose 100 mg/m2, and maintenance dose 75 mg/m2 by vein on Days 1, 8, 15, and 22 of each 28 day cycle.
Dose Expansion Group Starting dose: Maximum tolerated dose (MTD) from Dose Escalation Group."
1688573|NCT01552421|Procedure|TV NOTES cholecystectomy|Transvaginal NOTES cholecystectomy
1688574|NCT01552408|Drug|0.3 mg ranibizumab|Cohort 1: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity.
1688575|NCT01552408|Procedure|Targeted Pan Retinal Photocoagulation|Cohort 2: Subjects will receive 4 mandatory intravitreal injections of 0.3 mg ranibizumab every 28 days (+/- 7 days). They will then be seen monthly (+/- 7 days) and will receive intravitreal injections of 0.3 mg ranibizumab on a PRN schedule per retreatment criteria based on the evaluating Investigator's assessment of disease activity. In addition, at V3 (Day 7) they will receive targeted pan-retinal photocoagulation (PRP) based on ultra wide 200º field angiography. After the first session of PRP, subject's will have ultra wide 200º field angiography performed every 3 months to indicate areas of peripheral ischemia, which will be selectively treated at V9 (Month 6), V21 (Month 18), and V28 (Month 25), preserving areas of more perfused retina. This will minimize any visual field loss secondary to nonselective pan-retinal photocoagulation.
1688576|NCT01552369|Other|Preemptive Therapy|Subjects monitored for CMV viremia with weekly CMV PCR testing. 900 mg of Valganciclovir given twice daily only after a positive CMV PCR test and stopped after PCR is negative for 2 weeks. Dosages may be adjusted for renal dysfunction
1688577|NCT01552369|Drug|Prophylaxis with Valganciclovir|All subjects in this arm are given 900mg valganciclovir daily for 100 days post transplantation. Dosage may be adjusted for renal dysfunction
1688578|NCT01552356|Other|Laboratory Biomarker Analysis|Correlative studies
1688579|NCT01552356|Drug|Pazopanib Hydrochloride|Given PO
1688580|NCT01552356|Other|Pharmacological Study|Correlative studies
1688581|NCT01552343|Drug|Desmopressin|Desmopressin orally disintegrating tablets. Female participants took a 25 μg tablet and male participants took a 75 μg tablet one hour prior to bedtime for one month.
1688582|NCT01552343|Drug|Placebo|Placebo to match the 25 μg tablet of active drug taken by female participants or the 75 μg tablet taken by males. One placebo tablet taken one hour prior to bedtime for one month.
1688583|NCT01552330|Drug|Primaquine and Pyronaridine-artesunate|"Subject will receive primaquine (PQ) then receive pyronaridine-artesunate (PA)after 1 week washout period and receive PQ together with PA for the third regimen after 8 weeks washout period
Primaquine:
- Dosage: 2 tablets
and
Pyronaridine-Artesunate:
- Dosage: 3 tablets"
1688584|NCT01552330|Drug|Primaquine and Pyronaridine-Artesunate|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.
Primaquine:
- Dosage: 2 tablets
and
Pyronaridine-Artesunate:
- Dosage: 3 tablets"
1688585|NCT01552317|Other|OxSalt care bundle|A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
1688586|NCT01552304|Other|Oxygen therapy|Besides perioperative routine care provided by anesthesiologists and surgeons, patients will receive postoperative oxygen supplementation with nasal prolong at 3 liters/min during the first 3 nights after surgery.
1688587|NCT01552304|Other|Control group|
1688588|NCT01552291|Dietary Supplement|Glutamine|30g oral glutamine / day for 5 days before surgery. Glutamine is an important nonessential amino acid and its intracellular concentration is much higher than that of other amino acids. Glutamine is released in large quantities from skeletal muscle and serves as an important carrier and donor of nitrogen
1688589|NCT01552291|Drug|Placebo|30g oral maltodextrin / day for 5 days before surgery
1688590|NCT01552252|Dietary Supplement|apple juice|unaltered(0% POs-Ca) commercially available apple juice
1688591|NCT01552252|Dietary Supplement|apple juice with 0.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 0.5% by weight to a commercially available apple juice
1688592|NCT01552252|Dietary Supplement|apple juice with 1% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1% by weight to a commercially available apple juice
1688593|NCT01552252|Dietary Supplement|apple juice with 1.5% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 1.5% by weight to a commercially available apple juice
1688594|NCT01552252|Dietary Supplement|apple juice with 2% POs-Ca|Phosphoryl Oligosaccharides of Calcium (POs-Ca) in the form of powder was added at concentrations of 2% by weight to a commercially available apple juice
1688595|NCT01552239|Radiation|IMRT/IGRT, Tumor resection, Brachytherapy|"All:
Preoperative IMRT with small safety margins (GTV according to MRT plus 1.5cm laterally / 3cm proximodistally) to 50Gy total dose, 2 Gy single dose, 5 fractions per week, daily IGRT with in-room CT (Tomotherapy)
Tumor resection after 4-6 weeks
Stratum C: Interstitial Brachytherapy to tumor bed with 15 Gy total dose, 3 Gy single dose b.i.d. in second week after tumor resection"
1688596|NCT01552226|Device|Continuous Preperitoneal Analgesia|Preperitoneal catheter placed at the completion of surgery in the standard fashion.
1688597|NCT01552226|Device|Continuous Epidural Analgesia|Epidural catheter placed prior to the operation in the standard fashion.
1688600|NCT01552200|Procedure|Group A-Standard Colonoscopy, then NaviAid™ G-Eye procedure|Standard Colonoscopy,NaviAid™ G-Eye procedure
1688601|NCT01552200|Procedure|Group B-NaviAid™ G-Eye procedure, then Standard Colonoscopy|G-Eye procedure, Standard Colonoscopy
1688602|NCT01552187|Drug|Colchicine|Colchicine 0.5 mg BID or colchicine 0.5mg (<70kg) 48 to 72 hours before surgery till 1 months after surgery
1688603|NCT01552187|Drug|Placebo|Placebo 48 to 72 hours before surgery till 1 months after surgery
1688604|NCT01552148|Other|USguided bilateral TAP block|23 patients receiving bilateral US guided transversus abdominis plane block with 20ml of 0.375% levobupivacaine on each side, under general anaesthesia (TIVA), after induction and before surgical start
1688605|NCT01552148|Drug|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8 min)
1688606|NCT01552148|Drug|Morphine Patient Controlled Analgesia|Morphine PCA i.v. (bolus 2mg, lockout 8min)
1688607|NCT01552122|Drug|Odanacatib|Odanacatib 50 mg compressed tablet will be administered orally, once-a-week, for 24 months
1688608|NCT01552122|Drug|Alendronate|Alendronate 70 mg compressed tablets will be administered orally, once-a-week, for 24 months; and a reduced dose of 35 mg will be administered in the same fashion to a subset of women, Japanese participants only, for the same 24-month duration.
1688609|NCT01552122|Other|Placebo (odanacatib)|One compressed tablet administered orally, once-a-week, for 24 months.
1688610|NCT01552122|Dietary Supplement|Cholecalciferol (Vitamin D3)|Two (2) 2800 IU compressed tablets administered orally, once-a-week, for 24 months.
1688611|NCT01552122|Dietary Supplement|Calcium carbonate|Dietary and supplemental sources, taken as needed, to ensure a total daily calcium intake of approximately 1200 mg.
1688612|NCT01552122|Other|Placebo (alendronate)|One compressed tablet administered orally, once-a-week, for 24 months.
1688613|NCT01552096|Drug|peritonsillar infiltration|1.5 ml around each tonsil, 3 minutes before surgical incision as per group description
1688614|NCT01552083|Other|screening of sleep apnea|2 validated screening questionnaires (Berlin questionnaire, Epworth scale)
1688615|NCT01552070|Behavioral|Recruitment maneuver|Recruitment maneuver will be performed immediately (within 2 minutes) after intubation, consisting of a continuous positive airway pressure of 40 cmH2O over 30 seconds.
1688616|NCT01552070|Other|without recruit maneuver|After oral intubation, each patient will be mechanically ventilated, with a tidal volume of 6mL/kg, a respiratory rate of 20 to 25 breaths/minute, a positive end-expiratory pressure (PEEP) of 5 cmH2O, and an FiO2 of 100%. PEEP titration according to FiO2 and ARDSnet.
1688617|NCT01552057|Drug|Duloxetine 60 mg|Duloxetine 60 mg taken orally once every day for 15 weeks
1688618|NCT01552057|Drug|Placebo|Placebo taken orally once every day for 15 weeks
1688619|NCT01552044|Drug|Spironolactone|25mg tablet once a day for 1 month
1688620|NCT01552044|Drug|Placebo|one tablet once a day for 1 month
1688621|NCT01552018|Drug|Saxagliptin|Saxagliptin 5 mg, 1 tablet per day for 3 months
1688622|NCT01552018|Drug|Placebo|Placebo, 1 tablet per day for 3 months.
1688623|NCT01552005|Drug|Saxagliptin|No Intervention
1688624|NCT01551992|Procedure|Quill suture vs. Interrupted suture|To compare two methods of polypropylene mesh attachment during laparoscopic sacrocolpopexy (LSC): running technique using self-anchoring 1 barbed delayed absorbable suture (Quill™ SRS, Angiotech Pharmaceuticals, Inc. Vancouver, Canada) versus interrupted technique using 0 non-barbed delayed absorbable suture (PDS II™, Ethicon, Somerville, NJ, USA).
1688625|NCT01551979|Device|Repetitive Transcranial Magnetic Stimulation|"intermittent Theta Burst (iTBS) pattern (20 trains of 10 bursts given with 8s intervals) will be applied at 80% of active motor threshold. Each participant will receive 600 pulses per session.
Sham participants will undergo the same procedures as those in the active rTMS group."
1688626|NCT01551966|Device|Wireless esophageal capsule endoscopy ( PillCam Eso2)|"This is a simple blind (blind for the lecture of the capsule endoscopy record) study to evaluate the diagnostic value of the capsule endoscopy for the detection and the control of esophageal varices, the feasibility, tolerance and safety of the capsule endoscopy compared to the conventional EGD under general sedation in children presenting with portal hypertension.
During one week, the patients will undergo two exams (capsule endoscopy and EGD under general sedation). The exams will be done by two different physicians.
For to asses the tolerance, after they completed both exams, the patients will be asked to answer a comfort score questionnaire.
In order to asses the safety of the capsule endoscopy, the patients will be followed for adverse events during 3 weeks after the completion of the capsule endoscopy."
1688627|NCT01551953|Behavioral|Tai chi|12 week tai chi class
1688628|NCT01551953|Behavioral|Mind-body breathing|12 week breathing class
1688629|NCT01551953|Behavioral|Education|12 week education class
1688630|NCT01551940|Drug|Botox injection|Local ultrasound-guided bilateral injection of botulinum toxin type A in parotid (35 UI/gland) and submandibular (15 UI/gland) glands.
1688631|NCT01551940|Drug|Placebo injection|A local ultrasound-guided bilateral injection of placebo (NaCl 0.9 %) in parotid (0.7 ml/gland) and submandibular (0.3 ml/gland) glands.
1688632|NCT01551914|Device|Ultrasonic Scissors (Ethicon)|Haemostasis using Ultrasonic scissors
1688633|NCT01551914|Device|Bipolar Electrosurgical instruments (Medtronic) (SLS- Clips)|bipolar, monopolar or clip coagulation techniques
1688634|NCT01551901|Device|Spinal fusion|Spinal fusion procedures in skeletally mature patients with symptomatic degenerative disc disease (DDD) at one or two contiguous levels from L2-S1 with up to grade 1 spondylolisthesis
1688635|NCT01551888|Drug|Aclidinium/formoterol 400/12μg|Aclidinium/formoterol 400/12μg fixed dose combination (FDC), one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Almirall inhaler
1688636|NCT01551888|Drug|Formoterol|Formoterol 12 μg one inhalation twice daily (morning and evening) for 4 days, then one inhalation (morning) on Day 5 via the Foradil® Aerolizer®
1688637|NCT01551862|Procedure|body contouring surgery of back, abdomen and thighs|simultaneous body contouring surgery of back, abdomen and thighs
1688638|NCT01551836|Drug|Paracetamol formulation 1|formulation 1
1688639|NCT01551836|Drug|Paracetamol formulation 2|Formulation 2
1688640|NCT01551823|Biological|Influenza Virus Vaccine(no Preservative )|Influenza Virus Vaccine(no Preservative) 2×0.25ml intramuscular injections
1688641|NCT01551823|Biological|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)2×0.25ml intramuscular injections
1688642|NCT01551810|Biological|Influenza Virus Vaccine|Influenza Virus Vaccine 0.5ml intramuscular injections
1688643|NCT01551810|Biological|Influenza Virus Vaccine(contains Preservative)|Influenza Virus Vaccine(contains Preservative)0.5ml intramuscular injections
1688644|NCT01551797|Drug|Paracetamol 500 mg|Standard Paracetamol formulation
1688645|NCT01551797|Drug|Paracetamol 1000 mg|Paracetamol Sustained Release formulation
1688646|NCT01551797|Drug|Paracetamol 750 mg|Paracetamol Sustained Release formulation
1688649|NCT01551758|Drug|FF/VI|FF/VI
1688650|NCT01551758|Other|Existing Maintenance Therapy|"Existing Maintenance Therapy:
Long acting bronchodilator therapy alone
ICS alone or in combination with a long acting bronchodilator
Triple maintenance therapy"
1688651|NCT01551745|Biological|Vigil™ Vaccine|Patients meeting eligibility criteria will receive Autologous Vigil™ vaccine will be supplied by Gradalis,Inc. Patients will receive 1.0 x 10e7 cells via intradermal injection one day each cycle for a maximum of 12 doses as long as sufficient material is available and subject is clinically stable. Additionally, patients will receive bevacizumab 10 mg/kg intravenously (prior to Vigil™ administration) every 2 weeks (4 weeks=1 cycle).
1688652|NCT01551745|Drug|Bevacizumab|Patients meeting eligibility criteria will receive bevacizumab 10 mg/kg intravenously every 2 weeks.
1688653|NCT01551732|Behavioral|ACT|10 session manualized cognitive behavioral anger control therapy
1688654|NCT01551732|Behavioral|ACT with RAGE-Control|10 session manualized cognitive behavioral anger control therapy augmented with interactive biofeedback videogame.
1688655|NCT01551719|Behavioral|Implemented procedure|Prescription following in vitro sensitivity test implemented with MIC/Breakpoint ratio and penetration of antibiotic in the site of infection.
1688656|NCT01551706|Dietary Supplement|ENI Patented Whole Grape Extract|ENI Patented Whole Grape Extract
1688657|NCT01551706|Other|Placebo|Placebo
1688658|NCT01551693|Drug|STA-9090|
1688759|NCT01550783|Other|Cytology Specimen Collection Procedure|Undergo home-based HPV screening
1688659|NCT01551680|Radiation|Radiation combined with iniparib (BSI-201)|"Dose escalation of iniparib is implemented according to the CRML method. Three patients will be included at the first dose level (2.8 mg/kg). As long as no DLT is observed, escalation will proceed in cohorts of three patients at least included at the next dose levels (4, 5.6, 8, 11.2 mg/kg). Once a DLT is observed, the CRML will be activated and will be used until the MTD has been found or until six patients have been treated at the highest dose level (11.2 mg/kg). A dose level of 2.0 mg/kg (dose level -1) is included in case the first dose level at 2.8 mg/kg is found to be the MTD.
Iniparib is given by iv infusion over 1 hour twice weekly. BSI 201 will start the week before the beginning of radiotherapy (W1) and will be continued during the entire irradiation (W2, W3, W4). It will be stopped after 8 injections.
RT is delivered five days a week over 3 weeks (W2, W3, W4) up to a total dose of 37.5 Gy. Each fraction delivers 2.5 Gy by two opposed tangential fields."
1688660|NCT01551667|Biological|Antibody assays for S. aureus|Antibody assays for S. aureus at Day 0, Day 2, Day 4, Day 7, Day 30 and Month 6.
1688661|NCT01551667|Biological|Basic blood work|Hemogramme + CRP on Days 0, 2, 4 and 7
1688662|NCT01551654|Device|Transcutaneous Electrical Nerve Stimulation (ITO Company )|A mobile small machine for nerve stimulation
1688663|NCT01551641|Other|chemoradiotherapy|Patients only receive concurrent chemoradiotherapy if their serum VEGF level decrease.
1688664|NCT01551641|Drug|thalidomide|Patients will be given thalidomide combined with concurrent chemoradiotherapy if their serum VEGF level increase or unchanged.
1688665|NCT01551641|Other|without thalidomide|Patients only receive concurrent chemoradiotherapy if their serum VEGF level increase or unchanged
1688666|NCT01551628|Drug|Recombinant human arginase 1 Peg5000|Patients will receive weekly IV infusions of PEG-BCT-100, until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent. For safety sake, each subject will receive an induction dose of PEG-BCT-100 500 U/kg and 1000 U/kg at week -2 and week -1, respectively. The study dose of PEG-BCT-100 1600 U/kg will be initiated at week 1 (Day1). Each escalation of dose level will be determined by the investigator according to each subject's tolerability and criteria for treatment discontinuation.
1688667|NCT01551615|Drug|Metformin 1000 mg|2 x 500 mg oral tablets
1688668|NCT01551615|Drug|Vandetanib 800 mg|2 x 300 mg and 2 x 100 mg oral tablets
1688669|NCT01551602|Drug|AK159|transdermal administration of teriparatide acetate
1688670|NCT01551602|Drug|MN-10-T|subcutaneous administration of teriparatide acetate
1688671|NCT01551602|Drug|Placebo|Multiple administration of placebo AK159
1688672|NCT01551589|Radiation|Involved Field Irradiation(IFI)|Involved Field Irradiation(IFI):only irradiate positive lymph node by CT or PET-CT Radiation: IMRT IMRT is administered with chemotherapy from week 1 to week 8PTV-GTV（primary tumor）：66-70Gy/33~35F，once a day, 5 times per week PTV-CTV（Clinical target,primary tumor extended 3cm in Axial）：50-56Gy/33~35f，once a day, 5 times per week PTV-GTVnd（positive node）：66-70Gy/33~35F，once a day, 5 times per week.
1688673|NCT01551589|Drug|docetaxel and cisplatin|Drug: docetaxel and cisplatin.Consists of docetaxel 60-80mg/m2 day 1 and cisplatin 25mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
1688674|NCT01551589|Radiation|Elective Nodal Irradiation (ENI)|The CTVn of ENI included the involved lymph node regions and clinically uninvolved lymph nodal stations according to the location of primary tumor. Lymph node station numbers 1/2/4/5/7, 2/4/5/7 and 4/5/7/16/17were included for upper, middle and lower thoracic ESCC in the ENI arm respectively.
1688675|NCT01551550|Procedure|GDD|The surgery includes conjunctival incision, placement and securing the GDD plate in one quadrant, paracentesis and tube insertion into the anterior chamber, tube fixation to the episclera.
1688676|NCT01551550|Procedure|Amniotic Membrane Graft|For subjects assigned to the treatment group, Amnioguard is used to cover the shunt tube. The conjunctiva is then closed.
1688677|NCT01551550|Procedure|Pericardial Graft|For subjects assigned to the control group Tutoplast is used to cover the tube. The conjunctiva is then closed.
1688678|NCT01551537|Other|Cervarix data collection|Safety monitoring: recording of all AEs during the study period using diary cards, follow-up visit or telephone contact.
1688679|NCT01551537|Other|Data Collection|All adverse events will be recorded by diary card, follow-up visit or telephone contact.
1688680|NCT01551524|Biological|mPEG-r-crisantaspase|IV infusion over 60 minutes of mPEG-r-crisantaspase given once every two or four weeks for two administrations. Based on non-clinical data, 500IU/m2 has been selected as the starting dose. Dose selection will proceed based upon safety and pharmacokinetic data but escalation will not exceed 100%
1688681|NCT01551511|Drug|Tetrahydrocannabinol|The add-on treatment consists of two phases: a step-up phase (day 1-5: 3 mg TID; day 6-10: 5 mg TID), and a stable dose phase (day 11-52: 8 mg TID). The dosage may be tapered to at least 5 mg TID, when 8 mg is not tolerated.
1688682|NCT01551511|Drug|Placebo|Identical step-up approach to the Namisol arm.
1688683|NCT01551498|Dietary Supplement|Anatabloc Supplement|Product, as mint-flavored lozenges (3 mg anatabine per lozenge), to be taken 3 times each day
1688684|NCT01551498|Dietary Supplement|Placebo|Placebo, as mint flavored lozenges, to be taken 3 times each day
1688685|NCT01551485|Drug|Zolpidem|The effect of Zolpidem 10 mg for the first night after surgery is asssessed using PSG
1688686|NCT01551485|Drug|Placebo|Pacebo tablet, blinded given on the first night after surgery
1688687|NCT01551472|Device|3DKnee™ System with Vitamin E UHMWPE Tibial Inserts|This device is part of a total knee replacement system utilized in treating patients who are candidates for primary cemented total knee arthroplasty or revision arthroplasty where bone loss is minimal and the collateral ligaments are intact. It is intended to aid the surgeon in relieving the patient of knee pain and restoring knee joint function.
1688688|NCT01551459|Drug|Dacarbazine|Dacarbazine: Patients will receive 1000mg/m2 every 21 days by IV until progression or unacceptable toxicity.
1688689|NCT01551459|Drug|Sunitinib|Sunitinib: Patients will take 50mg orally once a day, for 28 days followed by a 14 day break, until progression or unacceptable toxicity
1688690|NCT01551446|Drug|Bardoxolone Methyl|Oral, once daily
1688716|NCT01551199|Behavioral|Multiple Channel Exposure Therapy- Veterans|Individual therapy design completed over a 12-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
1688717|NCT01551186|Dietary Supplement|Lactobacillus rhamnosus GG|1 capsule containing 10 billion cells of Lactobacillus rhamnosus GG on a twice-daily basis
1740609|NCT00113061|Procedure|Exercise|
1688691|NCT01551433|Device|wireless pulse oximeter (Wipox)|In addition to the one Wipox measurement at the planned anastomotic site, the RSA will collect the systemic pulse oximeter reading, blood pressure, and heart rate at the time of the Wipox measurement. These measurements will be obtained as both internal controls of the accuracy of the Wipox (matching the Wipox pulse rate with the patient's), as well as additional variables to control for when assessing factors which might contribute to oxygen saturation at the anastomotic site. Pre-operative demographic information will be collected. This will include age, sex, any co-morbidities (cardiac, diabetes, respiratory), and use of pre-operative chemotherapy or chemo-radiotherapy.
1688692|NCT01551420|Device|Advanced upper limb prosthetic device|There are three versions of the advanced upper limb prosthetic device: shoulder configuration (SC, also known as shoulder disarticulation (SD)); humeral configuration (HC also known as transhumeral (TH)) and radial configuration (RC also known as transradial (TR)).
1688693|NCT01551407|Drug|Hexvix|50 ml Hexvix liquid instilled once into the bladder for 30 minutes prior to cystoscopy
1688694|NCT01551394|Drug|Meropenem|20 mg/kg every 8 hours (every 12 hours in the youngest age group: < 32 weeks GA and < 2 weeks postnatal age). The dose will be given as an infusion over 30 minutes. Treatment duration is 11 ± 3 days.
1688695|NCT01551394|Drug|Ampicillin + gentamicin or cefotaxime + gentamicin|"Ampicillin:
Neonates below 7 days: 50mg/kg every 12 hours Neonates 7-21 days: 50mg/kg every 8 hours Neonates and Infants from day 22 on: 50mg/kg every 6 hours
Gentamicin:
Neonates less than 32 weeks of corrected age: 5mg/kg every 36 hours Neonates 32 weeks and over of corrected age: 5mg/kg every 24 hours (pre-dose ('trough') concentrations should be less than 2mg/l) Infants over 28 days of postnatal age: once daily dose: initially 5-7mg/kg, then adjust according to serum-gentamicin concentration (pre-dose ('trough') concentrations should be less than 1mg/l)
Cefotaxime:
Neonates below 7 days of PNA: 50mg/kg every 12 hours Neonates and infants from day 7 of PNA: 50mg/kg every 8 hours Treatment duration is 11 ± 3 days."
1688696|NCT01551381|Drug|EV-077|twice daily oral administration
1688697|NCT01551381|Drug|Placebo|twice daily oral administration
1688698|NCT01551368|Drug|Nimodipine|Nimodipine 30 mg tablets will be self-administered by the subjects every 6 hours starting on the day that the ultrasound criterion for hCG triggering is met. The tablets will be taken for two days or until an LH surge is detected, whichever comes first. If no LH surge by 2 days, the hCG trigger (250 micrograms recombinant hCG) will be given followed by intrauterine insemination (IUI)in 40 hours. If the LH surge is detected, hcg will be given immediately and two IUIs will be performed 24 hours apart.
1688699|NCT01551368|Drug|Placebo|Identical inactive tablets.
1688700|NCT01551355|Behavioral|Children-Multicomponent intervention|"The intervened children were provided classroom educational and playful activities during 5 months, which included Sesame Workshop Healthy Habits storybooks, posters, videos, games, and songs (1 hour daily); a Healthy family day workshop (1 hour); and weekly health notes. Parents participated in 3 workshops and weekly notes containing positive health messages about nutrition and active lifestyles to share with their children. Teachers also participated in 3 centralized training sessions, plus personalized working sessions with a research supervisor (2 hours every 15 days), and received a teacher's guide."
1688701|NCT01551329|Drug|Ketalar (ketamine)|Intravenous Ketamine 0.5mg/kg
1688702|NCT01551316|Drug|MN-221|This drug is intravenously infused and delivers 1200 mcg to the patient in 1 hour duration. This dose is repeated over 4 days (Day 1 1200 mcg once; Day 2 1200 mcg twice; Day 3 1200 mcg twice; Day 4 1200 mcg once).
1688703|NCT01551316|Drug|Placebo|This intervention consists of a placebo intravenous infusion, one that contains no active medication. During the double-blind procedure, patients will be infused with placebo intravenously one time on Day 1, twice on Days 2 and 3, and one time on Day 4.
1688704|NCT01551303|Drug|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
1688705|NCT01551303|Drug|Placebo|Matched nasal spray placebo
1688706|NCT01551290|Drug|Infliximab|Form = solution for injection, route = intravenous (IV), Unit = mg/kg, number = 5, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with infliximab through Week 22 will receive infliximab at Weeks 30, 38, 46 and 54, and will receive placebo at Week 32 and 34.
1688707|NCT01551290|Drug|Placebo|Form = solution for injection, route = IV, administered on = Weeks 0, 2, 6, 14, and 22 and for extension phase: participants treated with placebo through Week 22 will receive infliximab at Weeks 32, 34, 38, 46 and 54 and will receive placebo at Week 30.
1688708|NCT01551277|Other|Placebo-BREATH STACKING|The control group used the same circuit in the intervention group, but without occlusion of the expiratory branch and followed the same protocol to capture the images, ie, basal respiration for five minutes, then three periods of breathing through the mask, the equivalent time the period of technical BS, and five minutes of respiration. The volunteers were instructed to maintain respiration during the period they were using the mask.
1688709|NCT01551277|Other|BREATH STACKING|In the intervention group used a silicon mask, involving the nose and mouth with two outputs, one containing the Wright spirometer MARK 8 analog output and the other was occluded. It was explained that the mask would only allow the air entering during inspiration, and that should inspire the volunteer gradually filling the lungs with air until you feel that completely filled with an average time of 20 seconds, as shown in figure 1 obtained during the method of BS. The end of the technique would be in two situations: when the volunteer asked for it through a hand gesture, or when prearranged by Wright spirometer, was observed by the researcher that there was no change in the inspired volume.
1688710|NCT01551264|Device|Foot Abduction Brace (FAB)|After clubfoot correction, the participants will wear the FAB 23 hours/day for 3 months and then wean to naps and nighttime (8-12 hours/day) for either 2 or 4 years depending on which arm they are in.
1688711|NCT01551238|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
1688712|NCT01551238|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
1688713|NCT01551225|Drug|Escitalopram|Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
1688714|NCT01551212|Drug|Everolimus (RAD001) as add-on|
1688715|NCT01551212|Drug|tacrolimus group|
1688718|NCT01551173|Drug|Fluvastatin sodium|Fluvastatin sodium Extended Release Tablets 80mg
1740986|NCT00114231|Drug|capecitabine|
1688719|NCT01551160|Other|A communication and team-working intervention|Medical Emergency Team (MET) briefings and formalised handover between MET staff and patient care teams
1688720|NCT01551147|Drug|ONO-6950|200 mg QD for 8 days
1688721|NCT01551147|Drug|Placebo|Placebo to match ONO-6950 tablets or over-encapsulated Montelukast tablets dosed in a similar manner
1688722|NCT01551147|Drug|Montelukast|10 mg Montelukast QD for 8 days
1688723|NCT01551134|Procedure|Fundoplication|Primary fundoplication
1688724|NCT01551134|Procedure|Fundoplication|Primary fundoplication
1688725|NCT01551121|Other|It will then allow them to intervene at the right time and the right place|The server works 24h/24 and 7d/7 and will send an alert to the care personnel via their computers and personal pagers if it detects an anomaly. Anomaly could be falls, high risk behavior (patient standing up on its bed), abnormal length of stay in the bathroom, prolonged inertia. It will then allow them to intervene at the right time and the right place. Geriatrician can also review images in order to determine the cause of the incident and then act on each patient prevention and care strategy.
1688726|NCT01551108|Behavioral|Intervention: limited behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents are also sent monthly healthy nutrition tips via text message targeting the child in order to provide these families with potentially health promoting information.
1688727|NCT01551108|Behavioral|Intervention: advanced behavioral strategies|Parents are given access to a website, formatted for a mobile phone. The website provides parents with a target steps/day goal for their child and parents are instructed to use their mobile phone to access the study website to record their child's step count each night. Parents also receive additional behavioral strategies based on the Social Cognitive Theory. The strategies are delivered through weekly articles posted on the website. Text messages are designed to prompt parents to encourage their child's physical activity, remind parents of behavioral concepts presented in the articles (article tip), and motivate parents to foster behavioral change in their child.
1688728|NCT01551095|Device|PEGJ tube|The self-propelled PEGJ feeding tube
1688729|NCT01551069|Drug|hydroxychloroquine (Z0188)|"Pharmaceutical form:tablet
Route of administration: oral"
1688730|NCT01551069|Drug|Placebo|"Pharmaceutical form:tablet
Route of administration: oral"
1688731|NCT01551056|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
1688732|NCT01551056|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
1688733|NCT01551043|Biological|CART-19|
1688734|NCT01551030|Drug|Buparlisib|Buparlisib will be administered at a dose of 100 mg orally once daily (two 50 mg capsules) continuously. Intra-patient dose reduction may be required depending on the type and severity of the individual toxicity encountered. Re-staging imaging studies will be performed after every two cycles of treatment (one cycle = 4 weeks). Patients may continue on study as long as they are tolerating therapy and are free of disease progression.
1688735|NCT01551004|Drug|CRS3123|CRS3123, a methionyl-tRNA synthetase inhibitor, will be supplied in 100 and 200 milligram capsules. Subjects randomized to active drug in Cohorts A through E will receive 100 mg, 200 mg, 400 mg, 800 mg and 1200 mg respectively, as a single oral dose.
1688736|NCT01551004|Other|Placebo|Matching placebo capsules will be given to 2 subjects of each cohort.
1688737|NCT01550978|Device|AnapnoGuard 100 System|AnapnoGuard™ 100 Respiratory Guard System is intended for airway management by oral/nasal intubation while providing continuous endotracheal cuff pressure control using non-invasive measurement and monitoring of carbon dioxide concentration in the subglottic space and evacuation of secretions from above the endotracheal tube's cuff.
1688738|NCT01550965|Biological|Adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
1688740|NCT01550926|Drug|120 mg orlistat|2 X60 mg capsule
1688741|NCT01550926|Drug|60 mg orlistat|60 mg orlistat
1688742|NCT01550926|Drug|orlistat experimental dose|experimental
1688743|NCT01550913|Behavioral|Sober Network Interpersonal Psychotherapy (IPT)|IPT will be administered in 16 group 90-minute sessions over 18-20 weeks and 3 individual sessions (at the beginning, middle and end of treatment). These sessions will focus on improving your relationships with others, building sober relationships, setting goals, and increasing coping skills.
1688744|NCT01550913|Other|Treatment as Usual|Women in the treatment as usual condition will either be referred to appropriate treatment in the community or continue their current substance use treatment.
1688745|NCT01550900|Drug|Metformin ER|Starting dose: 500 mg by mouth daily for 1 week with weekly increases of 250 mg daily to target dose of 1000 mg daily.
1688746|NCT01550900|Other|Placebo|Placebo tablets by mouth 1 time a day.
1688747|NCT01550887|Other|No intervention|No intervention will be performed on this study
1688748|NCT01550874|Behavioral|Motivation|Participants in the experimental group will be motivated by augmented behavior modification strategies aiming to increase performance by: (i) having access to the pedometer web page that allows them to view their automatically calculated goals, and get feedback about performance toward goals
1688751|NCT01550848|Drug|Abraxane and Gemcitabine|"ABX (Abraxane) 125 mg/m2，intravenous infusion，30min，day 1, 8, 15
GEM (Gemcitabine) 800 mg/m2，intravenous infusion，30min，day 1, 8, 15"
1688752|NCT01550835|Device|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Standard of care use of an embolic protection device
1688753|NCT01550835|Device|Emboshield NAV6® embolic protection system (Abbott Vascular, Santa Clara, CA)|Aspiration thrombectomy following stent deployment and prior to embolic protection device removal
1688754|NCT01550822|Other|HEALS|
1688755|NCT01550809|Other|iBolus|Insulin bolus calculated from data obtained through CGM
1688756|NCT01550809|Other|tBolus (traditional bolus)|Insulin bolus dose calculated using the standard procedure based on the insulin-to-carbohydrate ratio
1688761|NCT01550783|Procedure|Screening Method|Undergo standard of care Pap test screening
1688762|NCT01550783|Procedure|Screening Method|Undergo home-based HPV screening
1688763|NCT01550770|Drug|propofol|peripheral IV of propofol at increasing dose levels
1688765|NCT01550744|Drug|Ustekinumab 45 mg|Form = Injection, route = subcutaneous
1688766|NCT01550744|Drug|Ustekinumab 90 mg|Form = Injection, route = subcutaneous
1688767|NCT01550744|Drug|Placebo|Form = Injection, route = subcutaneous
1688770|NCT01550718|Behavioral|ESML-EX (Physical Activity Program)|ESML-EX consists of four weekly 90-minute classes. Each class includes exercises and a brief discussion of a specific health topic.
1688771|NCT01550718|Behavioral|ESML-Social (Social Activity Program)|"ESML-SOCIAL consists of four weekly 90-minute seminars. Each seminar includes discussion of a specific topic, open time for socializing, and a homework assignment to be completed prior to the next session."
1688772|NCT01550705|Drug|Isoniazid|Isoniazid 5 mg/Kg up to 300 mg per day. Oral tablets. 2 months.
1688773|NCT01550666|Behavioral|MOVE|MOVE Program group: MOVE consists of medication follow-up at the CHCS or ATCMHMR and meeting once a week for 9 months with a MOVE trainer in your home. You and your trainer will work on interviews for the first three visits that will talk about negative symptoms, thoughts, attitudes, and social skills that will help each of you develop goals together. Activities will be developed around improving initiation, enjoyment, success and outcome. These activities will be customized to you and will change based on your needs weekly throughout the 9 months
1688774|NCT01550653|Drug|liraglutide|Subcutaneous self-administration of liraglutide(Victoza)by pen. The starting dose is 0.6 mg once daily(day 0 to 7), followed by 1.2 mg once daily (day 8 to 35).
1688775|NCT01550653|Drug|Placebo|
1688776|NCT01550640|Drug|Remifentanil|bolus of remifentanil 1 µg/kg will be given 30 sec before induction to general anesthesia
1688777|NCT01550627|Other|extra fluid/iv fluid supplementation during phototherapy|The study group received an extra intravenous fluid intake of 20% of the total fluid demand per 24 hours of NaCl 0,9% during each two hour period of phototherapy (12h total per day). The extra fluid intake was interrupted during the 12 hours break of phototherapy.
1688778|NCT01550627|Other|Non extra fluid|Control placebo The control group received the previous fluid regime, as intravenous fluid was given constantly, without a specific guideline according to extra fluid intake.
1688779|NCT01550614|Genetic|Alferminogene tadenovec|One-time intracoronary infusion of Ad5FGF-4 (6x10e9 viral particles in buffer)
1688780|NCT01550601|Device|bariatric surgery|The longitudinal gastrectomy (sleeve gastrectomy) is a technique of bariatric surgery recently validated (HAS on 2008).It consists of the realization of a partial gastrectomy of 2/3 (Fundus, gastric Body +/- antrum). However, lot of technical disagreements are brought back by expert teams. The most important disagreement concerns the conservation or the exeresis of the gastric antrum. In fact, the conservation of gastric antrum could facilitate the gastric emptying and to decrease the RGO (main complication) and act on the regulations of hormones modulators of the insulino-secretion.
1688781|NCT01550588|Device|Device closure|PFO Amplatzer device closure
1688782|NCT01550588|Drug|Standard medical treatment|Standard Medical management using anti-coagulant therapy
1688783|NCT01550575|Device|Non Boston Scientific spinal cord stimulation system|Epidural spinal cord stimulation
1688784|NCT01550575|Device|Boston Scientific Precision Plus spinal cord stimulation system|epidural spinal cord stimulation
1688785|NCT01550575|Other|Non-spinal cord stimulation conventional medical management for chronic pain|May include chronic pain medication, interventional pain procedures, spine surgery, etc.
1688786|NCT01550562|Device|Boston Scientific Precision Plus spinal cord stimulation therapy|Epidural spinal cord stimulation (SCS) using the Boston Scientific Precision Plus SCS system
1688787|NCT01550549|Drug|florbetapir F 18|No study drug will be administered in this study - scans previously acquired in in Study A05(NCT00702143) and A07(NCT00857415) will be read
1688788|NCT01550536|Behavioral|Resistance and aerobic exercise|Following baseline measurements, sedentary women were enrolled in a 16-week exercise training program at the YMCA in La Jolla, CA. Exercise occurred 3 times per week, for 1.5 hours each time. Exercise consisted of stretching, 20 minutes of aerobic exercise on elliptical machines, and 3 sets of 10-12 repetitions to failure for each of ten weight lifting exercises: abdominal crunch, arm curl, arm extension, chest press, lat pull-down, leg curl, leg extension, leg press, seated row, and trunk extension. Women started at 65-75% of 1-repetition-maximum, and resistance was increased as necessary to maintain the number of sets and reps and to continue to work to failure. Exercise was monitored by a TechnoGym electronic key system, and trainers instructed and supervised subjects in the gym.
1688789|NCT01550523|Drug|IGF-1R/AS ODN|Patients will receive approximately 10 to 20 million IGF-1R/AS ODN treated tumor cells, encapsulated in diffusion chambers (maximum of 10), and re-implanted in the patient's abdomen within 24 hours after the surgery for a 24 hour period.
1688790|NCT01550523|Device|biodiffusion chamber|The biodiffusion chamber is a simple construct comprised of two Lucite rings sealed on either side with a 0.1u mesh filter (Durapore, the Millipore Corporation). Autologous tumor cells pretreated with the IGF-1R AS ODN and resuspended with 2ug of exogenous IGF-1R AS ODN are added to the chamber. Implantation of the chambers (maximum 10 chambers) occurs 24 hours post surgery for 24 hours.
1688791|NCT01550510|Drug|Ascorbic Acid|3x a week for 9 weeks
1688792|NCT01550497|Other|supervised spinal stabilization exercises|Supervised or unsupervised exercises to be done for 20 minutes at home, at least 5 times a week for the first 2 weeks and at least 3 times a week after 2 weeks. The supervised weekly physical therapy group will complete 8 weeks of weekly physical therapy. The unsupervised home exercise group will complete 8 weeks of a prescribed home exercise program.
1741979|NCT00119119|Drug|tocopherol|
1955525|NCT03168061|Drug|NC 6300|Part 1: NC-6300 at escalating doses starting at a fixed dose Part 2: NC-6300 at the RPII dose
1688800|NCT01550458|Drug|mibefradil|25 mg tablets for oral administration given for 7 days at a total daily dose beginning at 100 mg per day divided into four doses. Doses will be incremented in successive cohorts by 25 mg/day up to 400 mg/day.
1688801|NCT01550458|Other|Placebo|1 out of 6 patients per cohort will receive placebo tablets identical in appearance and number to the active mibefradil arm.
1688802|NCT01550445|Drug|Prednisolone|Those patients who fulfill the entry criteria enter in this prospective controlled trial of steroid withdrawal starting at three months after transplantation
1688803|NCT01550432|Dietary Supplement|Glutathione|1,130 mg/day or 2,260 mg/day for 8 weeks
1688804|NCT01550432|Dietary Supplement|N-Acetylcysteine|600 mg/day or 1,200 mg/day for 8 weeks
1688805|NCT01550432|Other|Placebo|Volume of liquid placebo product comparable to liposomal glutathione and 1 or 2 placebo pills/day.
1688806|NCT01550419|Drug|Atorvastatin|Patients will receive 40mg atorvastatin(one tablet) over night via enteral feeding tube or per os during they stay in ICU at most thirty days.
1688807|NCT01550419|Drug|Placebo|The smell and shape of placebo are the same as atorvastatin
1688808|NCT01550406|Device|Tachocomb|"A kind of Mesh:
ready-to-use hemostatic agent consisting of a collagen sheet coated on one side with human fibrinogen, bovine thrombin, and bovine aprotinin"
1688809|NCT01550406|Device|Polyglycolic acid (PGA) (Neoveil)|Polyglycolide or Polyglycolic acid (PGA) is a biodegradable, thermoplastic polymer and the simplest linear, aliphatic polyester.
1688810|NCT01550393|Genetic|proteomic profiling|
1688811|NCT01550393|Other|enzyme-linked immunosorbent assay|
1688812|NCT01550393|Other|laboratory biomarker analysis|
1688813|NCT01550393|Other|medical chart review|
1688814|NCT01550380|Drug|BKM120|NVP-BKM120 (BKM120) is an oral pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor belonging to the 2,6-dimorpholino pyrimidine derivative family.Supplied in 10mg or 50mg capsules. Starting dose: 100mg Once Daily
1688815|NCT01550367|Drug|Hydroxychloroquine|Continuous oral administration (at 600 mg/d) will be initiated prior to the first dose (day -14) given 14 days prior to initiation of the first dose of IL-2 and then daily or twice a day throughout all three treatment courses.
1688816|NCT01550367|Drug|IL-2|600,000 IU/kg IV bolus q 8 hrs x days 1-5 and 15-19 (maximum 28 doses - 14 per 5 day cycle) of each 84-day course
1688817|NCT01550354|Drug|administration of propofol|intravenous administration of propofol 2 mg/kg before intubation
1688818|NCT01550354|Drug|administration of alfentanil|intravenous administration of alfentanil 14 μg/kg before intubation
1688819|NCT01550354|Drug|administration of rocuronium|Intravenous administration of rocuronium 0.3 mg/kg before intubation
1688821|NCT01550315|Procedure|Pulsitile Arterial Tonometry (PAT) Protocol|"A blood pressure cuff will be placed on one upper arm (study arm; non-dominant), while the contralateral arm will serve as a control (control arm).
RH-PAT probes will be placed on one finger (finger II, III, or IV) of each hand (same finger on both hands). The fingers on either side of the one with the probe will be separated using soft sponge rings.
Continuous recording of pulsatile blood volume responses from both hands will be initiated.
After a 10-min equilibration period, the blood pressure cuff on the study arm will be inflated to 60 mm Hg above systolic pressure for 5 min. The cuff will then be deflated to induce reactive hyperemia, PAT recording will be stopped."
1688822|NCT01550315|Device|Calf Blood Flow in Reactive Hyperemia (CBF-RH)|Calf blood flow (CBF) will be determined using venous occlusion plethysmography and calibrated mercury strain-gauges during reactive hyperemia after a 5 min of ischemia of the distal limb. Strain-gauges will be applied to the widest part of the non-dominant calf (~10 cm below patella). Participants will remain quietly supine for 10 min with legs elevated on foam pads above the right atrium to achieve stable baseline measurements of CBF. The venous occlusion cuff is inflated for 4 seconds at 8 seconds intervals, while monitoring the change in resistance in the system, pressure inside the measuring cuff, and 5-10 determinations are performed
1688823|NCT01550315|Device|Evaluation of Forearm-Mediated Dilation|The arm will be kept extended and immobilized at heart level. Brachial artery diameter will be measured using a high resolution ultrasonography using a linear array probe with a 5 to 17 MHz frequency range. The brachial artery will be imaged in longitudinal sections, 5-10 cm proximal to placement of an occlusion cuff in the dominant forearm just below the antecubital fossa. The probe will be held with a stereotaxic holder with micrometer movement capabilities.
1688849|NCT01550133|Behavioral|Not Learned: Nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive beverage.
1688924|NCT01549587|Drug|0.07% Cetylpyridinium chloride|mouth rinse: rinse with 20 mL of mouth rinse for 30 seconds twice daily
1688925|NCT01549587|Device|dental floss|floss the whole mouth once daily
1688824|NCT01550302|Procedure|Superficial Cervical Plexus Block|"At the end of the lung surgery while subjects are still under general anesthesia, one of the investigators will perform superficial cervical plexus. First, a line extending from the mastoid process to C6 transverse process is drawn. The site of needle insertion is marked at the midpoint of the line connecting the mastoid process with Chassaignac's tubercle of C6 transverse process. After skin cleansing with chlorhexidine prep, using a fan technique with superior-inferior needle redirections, 15 ml of 0.25% bupivacaine will be injected alongside the posterior border of the sternocleidomastoid muscle 2-3 cm below and above the needle insertion site."
1688825|NCT01550302|Drug|Bupivacaine|Single dose of 37.5 mg of bupivacaine subcutaneously
1688826|NCT01550289|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
1688827|NCT01550289|Biological|Placebo: NaCl 0.9% solution|0.5 ml, Subcutaneous
1688828|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.
The SI treatment aims to release the suboccipital muscle spasm10 that maintains the occiput-atlas-axis joint dysfunction. This technique, which was administered for 10 minutes, uses a deep and progressive gliding pressure applied with the fingertips towards the posterior arch of atlas."
1688829|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.
The OAA manipulation was bilaterally administered and it attempts to restore the motion dysfunction of this complex. It is a structural technique performed on a vertical line along the odontoid process of axis; neither flexion nor extension is used, and lateroflexion is minimal."
1688830|NCT01550276|Other|Manual Therapy|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.
The combination of both treatments aims to determine whether this combination has greater effects than the separate application of each treatment. After receiving the treatment, the subjects in the experimental groups stayed for five minutes in the supine resting position, in neutral ranges of cervical flexion, extension, lateral flexion and rotation."
1688831|NCT01550276|Other|Placebo control|"All patients were assessed in the same conditions before the treatment, after the treatment (at 4 weeks), and at follow-up (after 8 weeks). Four treatment sessions (one session per week). Prior to each treatment session, the physiotherapist performed the vertebral artery test bilaterally, followed by a two-minute neck massage without lubricants and with no proven therapeutic effect, as a placebo for all study groups.
The control group received four sessions of placebo treatment, followed by ten minutes of resting position."
1688832|NCT01550250|Behavioral|Night-time compression system garment|Night-time compression system garment 8 hours per night for a minimum of 5 nights per week.
1688833|NCT01550250|Behavioral|Day-time compression sleeve|Standard care for lymphedema maintenance. Day-time compression sleeve with or without a glove/ gauntlet, providing a minimum of 30 mm Hg of pressure, for twelve hours per day, each day of the week.
1688834|NCT01550237|Radiation|radiotherapy daily verification reduced safety margins|curative radiotherapy to 78 Gy in 39 fractions with daily CT position verification and reduced safety margins (7mm)
1688835|NCT01550237|Radiation|radiotherapy weekly verification standard safety margins|curative radiotherapy to 78 Gy in 39 fractions with weekly orthogonal position verification and standard safety margins (10-15 mm)
1688836|NCT01550224|Drug|Temozolomide|100-200 mg/m2/d oral
1688837|NCT01550211|Device|Magnetoencephalograph (MEG)|Conducting a brain scan during a series of perceptual and linguistic tasks
1688838|NCT01550198|Device|Advanced hemodynamic monitoring|Comprehensive advanced hemodynamic monitoring
1688839|NCT01550185|Drug|eltrombopag olamine|Given PO
1688840|NCT01550185|Procedure|standard follow-up care|Receive standard care
1688841|NCT01550172|Behavioral|Sleep Behavioral Therapy A and NHMS|"The night home monitoring system provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.
Sleep behavioral therapy A uses a combination of cognitive exercises and behavior adjustments."
1688842|NCT01550172|Behavioral|Sleep Behavioral Therapy B and NHMS|"The night home monitoring system (NHMS) provides caregivers with reliable alerts and information regarding the whereabouts of the person with dementia during the night.
Sleep behavioral therapy B uses primarily behavioral adjustments."
1688845|NCT01550133|Behavioral|Learned: Non-nutritive beverage to Non-nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with non-nutritive sweetener everyday for two weeks.Half of these participants will then be tested against a non-nutritive beverage.
1688846|NCT01550133|Behavioral|Learned: Nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
1688847|NCT01550133|Behavioral|Learned: Nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
1688848|NCT01550133|Behavioral|Not Learned: Non-nutritive solid to Nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive solid.
1688882|NCT01549847|Drug|L-carnitine and piracetam|L-carnitine/piracetam (990mg/810mg) PO BID
1688850|NCT01550133|Behavioral|Not Learned: Non-Nutritive solid to Non-nutritive solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
1688851|NCT01550133|Behavioral|Not Learned: Non-nutritive beverage to Nutritive beverage|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a beverage food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a nutritive beverage.
1688852|NCT01550133|Behavioral|Not Learned: Non-Nutritive solid to Non-Nutritive Solid|For the learning phase of the experiment, random allocation will assign about 15 participants to consume a solid food product made with non-nutritive sweetener everyday for two weeks. Half of these participants will then be tested against a non-nutritive solid.
1688853|NCT01550107|Drug|Allopurinol|300mg b.d for 24 weeks
1688854|NCT01550107|Drug|Lactose tablets|matched placebo tablets b.d
1688855|NCT01550081|Other|Rate of perceived exertion|Exercise intensity controlled by Borg scale
1688856|NCT01550081|Other|Heart rate monitor|Exercise intensity controlled by heart rate monitors
1688857|NCT01550055|Drug|Cetuximab plus Irinotecan Synchronously|Combined with irinotecan 180 mg/m2 every 2 weeks, Cetuximab 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression
1688858|NCT01550055|Drug|Irinotecan and Cetuximab Subsequently|First, irinotecan 180 mg/m2 every 2 weeks till PD occured, discontinue it; then, cetuximab 400 mg/m2 day 1 followed by 250 mg/m2 weekly till disease progression.
1688859|NCT01550029|Behavioral|Counseling/Healthy Lifestyle|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting and to help develop knowledge and skills for quitting. Also, the National Cancer Institute's Clearing the Air guide to smoking cessation will be given to subjects. Some specific areas of focus for this intervention are developing a better understanding of reasons for smoking and the consequences of tobacco use and identifying ways for establishing a healthier lifestyle."
1688860|NCT01550029|Behavioral|Counseling/Managing Mood|"A trained counselor will meet with subjects for approximately 60 minutes each week during the 12-week treatment period to provide support for quitting smoking and to help develop knowledge and skills for quitting. Also, subjects will receive the National Cancer Institute's Clearing the Air guide to smoking cessation. Some specific areas of focus for this intervention are managing negative moods without smoking and overcoming other obstacles to quitting."
1688861|NCT01550016|Other|Observation|Clinical follow-up and laboratory investigations.
1688862|NCT01550003|Drug|Certolizumab Pegol (CZP)|"CZP will be administered subcutaneously as a fixed dose based on weight every 2 weeks (Q2W) or every 4 weeks (Q4W) throughout the study.
CZP will be provided by UCB as a CZP 200 mg/ml solution for single subcutaneous (sc) injection, in a single use prefilled syringe (PFS). Each PFS contains an extractable volume of 0.25 mL, 0.5 mL or 1 mL of CZP solution.
Eligible subjects will begin with 3 loading doses of CZP followed by a treatment dose for the duration of the study based on the weight range:
10 to < 20 kg: Loading dose = 50 mg Q2W (1 x 0.25 mL sc); treatment dose = 50 mg Q4W (1 x 0.25 mL sc);
20 to < 40 kg: Loading dose = 100 mg Q2W (1 x 0.5 mL sc,); treatment dose = 50 mg Q2W (1 x 0.25 mL sc);
≥ 40 kg: Loading dose = 200 mg Q2W (1 x 1.0 mL sc); treatment dose = 100 mg Q2W (1 x 0.5 mL sc);"
1688863|NCT01549990|Drug|Sevoflurane|maintenance of general anesthesia with sevoflurane
1688864|NCT01549990|Drug|desflurane|maintenance of general anesthesia with desflurane
1688865|NCT01549977|Drug|Febuxostat|Febuxostat tablets
1688866|NCT01549977|Drug|Placebo|Febuxostat placebo-matching tablets
1688867|NCT01549964|Drug|Fasiglifam (TAK-875)|Fasiglifam (TAK-875) tablets
1688868|NCT01549964|Drug|Sitagliptin|Sitagliptin tablets
1688869|NCT01549964|Drug|Placebo|Placebo-matching tablets
1688870|NCT01549951|Drug|Orteronel+Prednisone|Orteronel 400-mg plus prednisone 5-mg will be administered BID orally continuously throughout the treatment cycle of the study.
1688873|NCT01549925|Other|Standard Surgical resection|standard surgical resection using clamps and surgical ligatures
1688874|NCT01549925|Device|LIGASURE|resection using the FDA-approved LIGASURE device during omentectomy and resection of the recto-sigmoid portion of the colon
1688875|NCT01549899|Behavioral|In-person Cognitive Behavioral Therapy of Insomnia|In-person CBTi was be provided by a master's or doctoral level mental health counselor (e.g., social worker or psychologist). This treatment consisted of 6-sessions and included the same efficacious and commonly used modules of CBTi (i.e., sleep education & hygiene, stimulus control, progressive muscle relaxation, sleep restriction, and cognitive therapy).
1688876|NCT01549899|Behavioral|Internet Cognitive Behavioral Therapy of Insomnia|The ICBTi treatment is an online protocol developed by the National Center for Telehealth and Technology, with the PI (DJT) as the subject matter expert. The treatment consists of the same components as the in-person CBTi, but their mode of delivery was considerably different due to the constraints of its automated, online format. Each of the six ICBTi sessions was divided into lessons covering different aspects of each of the components. The lessons were presented as audio recordings accompanied by visual graphics and animations. For several lessons, interactive components were included, such as games, quizzes, and prompts for participants to schedule healthy sleep habits.
1688879|NCT01549873|Drug|propofol|Propofol adjusted to maintain the bispectral index at 40-60.
1688880|NCT01549873|Drug|Desflurane|Desflurane adjusted to maintain the bispectral index at 40-60.
1688881|NCT01549860|Device|MIST Therapy|Non-contact low frequency ultrasound therapy
1688887|NCT01549808|Other|mobilization|The patients are mobilized according to the mobilization protocol. The training concist of balance, muscle strength and staying power. Before the mobilization the patients ability to mobilization is evaluated according to contradictions and pre screening (exh 2,3). The primary nurse and the physiotherapist evaluate and allocate patients to mobilization stage. All patients is mobilized minimum 3 times at day (exh 2) and is supported as a minimum of two persons. Before each activity the patient must have a rest period of ½ hour. The patients security during mobilization is registried (exh 1,3). The mobilization stops if patients security is affected. During walk patients is followed by a chair, in order to prevent or cushion a fall.
1688888|NCT01549808|Other|mobilization|sitting, standing and walking
1688889|NCT01549795|Procedure|Liver transplantation|Liver transplantation using classic technique and avoiding proximal ilum dissection. The donor hepatic artery will be anastomosed to a jump graft connected to the Aorta. In case of positive margin of the bile duct at a frozen section analysis the liver transplant will be performed after an adjunctive pancreatodudodenctomy
1688890|NCT01549795|Radiation|45 Gy external radiations|45 Gy in 30 fractions, 1,5 Gy twice a day) and 5-FU iv infusion- 3 week treatment
1688891|NCT01549795|Radiation|Endoluminal bile duct Brachytherapy|Brachytherapy (20 Gy a 1 cm in 20-25h) - administered 2 weeks after radiotherapy completion
1688892|NCT01549795|Drug|Capecitabine|Capecitabine - administered till liver transplantation
1688893|NCT01549795|Procedure|Pre liver transplantation laparoscopic hand assisted staging|Pre liver transplantation laparoscopic hand assisted staging for sampling hepatic artery lymph nodes and assessing peritoneal disease.
1688894|NCT01549782|Dietary Supplement|Inulin and Fructo-oligosaccharide|6 gr daily of fibre (50% inulin and 50% FOS). Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
1688895|NCT01549782|Dietary Supplement|Maltodextrine|6 gr daily of maltodextrine. Patients underwent a 1-week run-in period before starting RT and continued taking the same products throughout the treatment course, until three weeks after RT was finished.
1688896|NCT01549769|Drug|Bardoxolone Methyl|Oral, once daily
1688897|NCT01549756|Behavioral|bulletin board and teleophone depth interview|qualitative based research
1688898|NCT01549743|Drug|Celecoxib|Celecoxib 200mg will be administered orally twice a day for 3 days
1688899|NCT01549743|Drug|Rebamipide|Rebamipide 100mg will be administered orally three times a day for 3 days
1688900|NCT01549743|Drug|Celecoxib plus Rebamipide|"Celecoxib plus Rebamipide same way as arm: celecoxib and arm: rebamipide"
1688901|NCT01549730|Procedure|18F-Fluoroazomycin Arabinoside (18F-FAZA)|A PET scan is an imaging test that uses special radioactive dyes to measure different aspects of how your cancer acts. In this study, a dye called 18F-Fluoroazomycin Arabinoside (18F-FAZA) will be used to measure hypoxia levels in tumours. Health Canada has not approved FAZA for general use, but has approved it for use in this study.
1688902|NCT01549717|Device|Fitting of a wireless telemetry device|Fitting of a Philips Intellivue Trx + SpO2 telemetry device. To be worn throughout patient stay except if being monitored using a standard bedside monitor or bathing.
1688903|NCT01549704|Drug|Ropivacaine|"Arm RP is receiving 30 ml of ropivacaine 7,5 mg/ml at first blockade (ACB) and after 45 minutes another blockade (ACB) with placebo (saline 30 ml).
Arm PR is receiving 30 ml of placebo (saline) at first blockade (ACB) and after 45 minutes another blockade (ACB)with ropivacaine."
1688904|NCT01549704|Drug|Saline|please see intervention description for ropivacaine
1688905|NCT01549691|Drug|Zopiclone|7.5 mg before sleep, the evening before surgery
1688906|NCT01549691|Drug|Alprazolam|0.5 mg at awakening, the day of surgery
1688907|NCT01549691|Drug|placebo|given night before surgery and at awakening, the day of surgery
1688908|NCT01549678|Other|Total contact insole|EVA insole shaped on patient´s foot.
1688909|NCT01549678|Other|placebo insole|EVA insole flat
1688910|NCT01549665|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1st infusion(1x1,000,000 hMSC/kg)IV, 2nd infusion(2x1,000,000 hMSC/kg)IV and 3rd infusion(3x1,000,000 hMSC/kg)IV if no complete response at 28 days.
1688912|NCT01549626|Dietary Supplement|Defatted flaxseed flour|30g defatted flaxseed flour per day for breakfast
1688913|NCT01549626|Dietary Supplement|Golden flaxseed flour|30 grams of golden flaxseed flour per day for breakfast
1688914|NCT01549626|Dietary Supplement|Whole brown flaxseed flour|30 grams of whole brown flaxseed flour per day for breakfast
1688915|NCT01549613|Drug|Daptomycin|• Daptomycin will be given in a one-time dose of 4mg/kg in a one-time dose to be infused over 2 minutes at the initiation of patient therapy in the RDTC cellulitis protocol.
1688916|NCT01549613|Drug|Vancomycin|• Vancomycin will be given in a dose of 15mg/kg at baseline and again at 12 hours to be infused over 1 to 2 hours.
1688917|NCT01549600|Dietary Supplement|psyllium|1 level tablespoon (~ 5.1 g psyllium husk in the psyllium product) mixed with at least 8 ounces of water, taken twice daily
1688918|NCT01549600|Dietary Supplement|Microcrystalline Cellulose|1 level tablespoon (~ 1.18 g MCC in the MCC product) mixed with at least 8 ounces of water, taken twice a day
1688919|NCT01549587|Drug|0.243% sodium fluoride|dentifrice: brush thoroughly twice daily
1688920|NCT01549587|Device|toothbrush|brush thoroughly twice daily
1688921|NCT01549587|Device|dental floss|floss the whole mouth once daily
1688922|NCT01549587|Drug|0.454% stannous fluoride|dentifrice: twice daily brush thoroughly for 2 minutes
1688923|NCT01549587|Device|toothbrush|twice daily brush thoroughly for 2 minutes
1688926|NCT01549574|Drug|crizotinib|Each subject in Treatment A will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 1 and each subject in Treatment B will receive a 250 mg single oral dose of crizotinib administered in a fasted state as 1x 250 mg Formulated Capsule on Day 5
1688927|NCT01549574|Drug|esomeprazole|Each subject in Treatment B will receive 40 mg daily dose of esomeprazole from Day 1 to Day 5
1688928|NCT01549561|Behavioral|Parent Training|16 weeks of parent training led by a trained group facilitator
1688929|NCT01549561|Behavioral|Youth Skills Training|16 weeks of one-on-one sessions with a trained youth skills coach
1688930|NCT01549548|Drug|Ponatinib|Patients will receive Ponatinib 45 mg by mouth as a single daily dose on an empty stomach (no food 2 hours prior to and after dosing) on day 1 and continuous once-daily dosing everyday thereafter. Each patient will receive daily Ponatinib until disease progression, unacceptable toxicity, or withdrawal of consent.
1688931|NCT01549535|Device|Colonoscopy done with:PeerMedical System and Olympus/Pentax/Fuji colonoscopy system|endoscopic diagnosis, treatment and video observation of the digestive tract, endoscopy and endoscopic treatment within the lower digestive tract (including the anus, rectum, sigmoid colon, colon and ileocecal valve) of adults patients
1688932|NCT01549522|Behavioral|bulletin board or telephone depth interview (TDI)|experiential based research. anonymous participation.
1688933|NCT01549522|Behavioral|interview regarding experiences and opinions as to condition and treatment|not a drug trial. experential/opinion based research.
1688934|NCT01549509|Biological|VRC-HIVADV014-00-VP Vaccine|All participants will receive one injection in their upper arm of 1 x 10^10 particle units (PU)/mL of VRC-HIVADV014-00-VP at study entry.
1688935|NCT01549496|Drug|Amlodipine|amlodipine 2.5 mg QD
1688936|NCT01549496|Drug|Diltiazem|diltiazem 120 mg qd
1688937|NCT01549470|Biological|VRC-HIVDNA009-00-VP|Administered as a 4 mg/mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
1688938|NCT01549470|Biological|Placebo vaccine|Administered as a 1-mL dose by IM injection in the deltoid muscle using the Biojector 2000 needle-free injection management system.
1688939|NCT01549457|Other|Cell phone text messages|Participants in the intervention arm will receive weekly text messages from the TB control clinic asking how they are.
1688940|NCT01549444|Other|presence of maternal risk factor for hypertension|
1688941|NCT01549431|Drug|Panobinostat|"Panobinostat will be supplied as 5-mg or 20-mg pink/opaque-colored, hard gelatin capsules. Panobinostat is administered orally three times per week.
Standard 3+3 design
3 out of 4 weeks"
1688942|NCT01549431|Drug|Carfilzomib|"Carfilzomib in Cycle 1 will be initiated intravenously at 20 mg/m² on Days 1 and 2 and escalated to 27 mg/m² for Days 8, 9, 15, and 16 of Cycle 1 and for the duration of treatment.
Standard 3+3 design
Days 1/2, 8/9 and 15/16 every 4 weeks"
1688943|NCT01549431|Drug|Dexamethasone|Dexamethasone (4 mg) must be given prior to each carfilzomib infusion during Cycle 1. Dexamethasone pre-dose should continue through Cycle 2 if fever is observed post-dose, Cycle 2 Day 1, or thereafter associated with the infusion of carfilzomib.
1688944|NCT01549418|Drug|Aspirin (ASA)|Usage or withdrawal of aspirin (75mg daily per os) 7 days before and 14 days after polypectomy
1688945|NCT01549418|Drug|Placebo|
1688946|NCT01549405|Other|İntercostal nerve block|Nerve block group was administered two levels intercostal block (11 and 12th ribs) with 0.5% bupivacaine with epinephrine before surgery.
1688947|NCT01549392|Device|DECT|DECT at tumor progression and 3 months later
1688948|NCT01549392|Device|MR spectroscopy|MR spectroscopy at tumor progression and 3 months later
1688949|NCT01549379|Radiation|Dynamic Contrast Enhanced CT scan|The neck will be scanned using 120 kVp, 50 mAs, 8 x 5 mm slices at intervals of 2.8 - 3.0 s for 3 min. Contrast (e.g. Visipaque 320) at a dosage of 0.7 ml/kg is injected at 4 ml/s through an antecubital vein after a delay of 6 s from start of scanning.
1688950|NCT01549366|Device|Aspen Spinous Process Fixation Device|The Aspen device will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
1688951|NCT01549366|Device|Pedicle Screws|Pedicle Screws will be placed as posterior fixation to Lateral Lumbar Interbody Fusion (LLIF) or Anterior Lumbar Interbody Fusion (ALIF)
1688952|NCT01549353|Behavioral|gum chewing|
1688953|NCT01549327|Other|Oncology Interactive Navigator|
1688954|NCT01549327|Other|Routine Care|
1688955|NCT01549301|Drug|Filgrastim|filgrastim, single dose, s.c., dosage: 5 mcg/kg
1688956|NCT01549301|Drug|Filgrastim|filgrastim, single dose, s.c., dosage: 10 mcg/kg
1688957|NCT01549301|Drug|Filgrastim|Filgrastim, i.v., single dose, dosage: 5 mcg/kg
1688958|NCT01549301|Drug|Filgrastim|Filgrastim, i.v., single dose, dosage: 10 mcg/kg
1688959|NCT01549288|Behavioral|modified Atkins diet|Carbohydrate restricted to 10 g/day (18-36 months) and 5 g/day (9-18 months), fat intake encouraged, proteins unrestricted
1688960|NCT01549288|Other|no dietetic input|continuation of anti-epileptic medication without any dietetic input
1688961|NCT01549262|Device|"Observe embryo development with Unisense FertiliTech A/S (EC Certificte DGM - 673)"|Observation of exact timing of embryo cleavages together with other morphology dynamics parameters.
1688962|NCT01549262|Device|Observe embryo development|Observe embryo development in the traditional manner
1688963|NCT01549249|Device|optical coherence tomography|spectral-domain optical coherence tomography
1688964|NCT01549236|Drug|Benznidazole 12,5mg or 100mg|"All 80 subjects recruited into the study will receive treatment with:
- Benznidazole (Laboratório Farmacêutico do Estado de Pernambuco -LAFEPE - Recife - Brazil; tablet 12.5mg or 100mg), 7.5 mg/Kg/day PO (actual range of 5.5-8.5 mg/Kg/d), divided in two daily doses, for 60 days."
1688965|NCT01549223|Drug|Oxytocin Infusion|500 mL bag of oxytocin (30 IU/500 mL) to be connected to the IV, and controlled per obstetrician request.
1688966|NCT01549223|Drug|Oxytocin Bolus|3 IU oxytocin and be given IV at time of baby delivery (Time 0). Up to two additional syringes can be given at 3 and 6 mins until uterine tone adequate (as per obstetrician on graded scale).
1955544|NCT03158363|Other|LPS, 36 hour immobilization and fast|LPS endotoxin is administered on study day 1 and immobilization and fast continue throughout study day 1 and 2.
1688969|NCT01549158|Drug|torasemide-PR|Single oral dose of torasemide PR 10 mg
1688970|NCT01549158|Drug|Furosemide-IR|Single oral dose of furosemide IR 40 mg
1688971|NCT01549158|Drug|torasemide-IR|Single oral dose of torasemide IR 10 mg
1688972|NCT01549145|Device|Nimbus Multifunctional Stimulator|A Multifunctional Stimulator (Nimbus by Newmedic, Hemodia) for clinical use. The stimulator is also dedicated for Electrical Promontory Stimulation (EPS)
1688975|NCT01549106|Drug|IPI-145|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm; ketoconazole drug interaction study
1688976|NCT01549106|Drug|Placebo|Single ascending dose up to 6 cohorts; multiple ascending dose up to 4 cohorts; food effect arm
1955545|NCT03154437|Biological|Emicizumab|Participants will receive emicizumab at a loading dose of 3 milligrams per kilogram (mg/kg) per week subcutaneously (SC) for 4 weeks, followed by a maintenance dose of 1.5 mg/kg per week SC thereafter. Treatment with emicizumab will continue until unacceptable toxicity, withdrawal of consent, participant or physician decision to discontinue treatment, death, the participant is able to obtain commercial drug after emicizumab becomes commercially available, or the sponsor decides to discontinue emicizumab clinical development, whichever occurs first.
1688980|NCT01549080|Drug|Yisuishengxue Granule|Yisui Shengxue Granules，produced by pharmaceutical factory of Guang'anmen Hospital, China Academy of Chinese Medical Sciences, is made from the herbs of Shan Zhu Yu (Fructus Corni), He Shou Wu (Radix Polygoni Multiflori), Shu Di Huang (Radix Rehmanniae Preparata), Huang Qi (Radix Astragali) and etc.Yisui Shengxue Granules：12g/bag， Registration Number：20110602； Yisui Shengxue Granules replacer (placebo)：12g/bag，Registration Number：20110519；Treatment group：Yisui Shengxue Granules，1 bag, tid, po； Control group: Yisui Shengxue Granules replacer (placebo), 1 bag, tid, po; Intervention for 12 weeks. Follow-up 3 months later after stopping the drug intervention.
1688981|NCT01549054|Drug|10-mg dose of E5501 2G tablet|Treatment A: Single 10-mg dose of E5501 2G tablet
1688982|NCT01549054|Drug|10-mg dose of E5501 cyclodextrin oral solution|Treatment B: Single 10-mg dose of E5501 cyclodextrin oral solution
1688983|NCT01549054|Drug|10-mg dose of E5501-P21% powder|Treatment C: Single 10-mg dose of E5501-P21% powder oral suspension
1688984|NCT01549054|Drug|10-mg dose of E5501 lipid-based oral|Treatment D: Single 10-mg dose of E5501 lipid-based oral suspension
1688985|NCT01549041|Drug|Asenapine 10 mg daily in the evening|The total daily dose of Asenapine will be given once daily in the evening
1688986|NCT01549041|Drug|Asenapine 5 mg twice daily|Asenapine will be given in two doses, 5 mg in the morning and 5 mg in the evening, daily
1688987|NCT01549028|Behavioral|mobile-based PR program.|Patients will be trained and monitored by mobile-based pulmonary rehbailitation program. By mobile, patients could undergo exercise training at home and the information of training parameters will be send to investigator. Investigator could monitor these patients by mobile. Patients will return to visit physian and receive six-minutes walking test to measure outcomes 3 months and 1 year later after mobile-based pulmonary rehabilitation program.
1688988|NCT01549015|Other|oral administration of Sodium [1,2-13C]-Acetate|single dose of 0.55 mg/kg 13C-Acetate given orally of via a naso-gastric tube
1688989|NCT01549002|Drug|Intranasal Fentanyl|Drug: Fentanyl 50 micrograms/mL Dosage: 2 micrograms per kilogram (maximum 100 micrograms) Drug delivery: Intranasal via mucosal atomization device (MAD® Nasal, Wolfe Tory Medical Inc., Salt Lake City, UT) Frequency: one-time dose
1688990|NCT01549002|Drug|Intravenous Morphine|Drug: Morphine Dosage: 0.1 milligrams/kilogram (maximum 8 milligrams) Drug delivery: Slow IV push Frequency: one-time dose
1688991|NCT01548963|Procedure|Intensive glycemia control|Blood glucose levels will be maintained by continuous insulin infusion (Actrapid, Novo Nordisk A/S, Bagsvaerd, Danemark - 50 IU/50 ml FR) within normoglycemia limits (4.4 - 6.1 mmol/l)
1688992|NCT01548950|Drug|Sildenafil singly or in association with Bosentan|Sildenafil, 1-4 mg/Kg/day (6-hour intervals) preoperatively, until development of pulmonary congestion (generally 1-4 weeks) or preoperatively, for 10-12 months, in association with bosentan (15.6-62.5 mg b.i.d.) if pulmonary congestion does not develop. Surgery will be performed at 1-4 weeks (short-term treatment) or at 10-12 months (medium-term treatment) if operability criteria are met (catheterization). In both cases (short and medium-term treatments), the drug or drugs will be kept for 6 months postoperatively, when final catheterization will be performed for efficacy testing.
1688993|NCT01548937|Drug|I-123 ADAM|"This study will recruit a total of 40 evaluable subjects (20 cognitively depressive, and 20 AD depressive), Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.
Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
1688994|NCT01548924|Drug|Dovitinib|Orally Dovitinib once a day and a five-day regimen of administration and then two days resting, in cycles of 28 days.
1688995|NCT01548924|Drug|Dovitinib + Paclitaxel|"Paclitaxel (80 mg/m2) : 1, 8, 15 and 21.
Dovitinib (100 mg, 200 mg,300 mg, 400 mg or500 mg; it depends on the level of the Phase 1 study in each patient): five days of treatment / two days off.
Each cycle will last for 28 days."
1688996|NCT01548911|Drug|gemtuzumab ozogamicin|Given IV
1688997|NCT01548911|Other|laboratory biomarker analysis|Correlative studies
1688998|NCT01548898|Device|Nd-YAG laser|All patients received 5 sessions (4 weeks apart) of long pulsed nd-YAG laser assisted hair removal on the affected area, emitting 1064 nm, with a fluence of 35-45 J/cm2 and pulse duration 10-30 msec adjusted to skin type and hair thickness. Laser was applied to all papules and plaques.
1688999|NCT01548885|Device|CONTOUR® NEXT EZ BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of CONTOUR® NEXT EZ BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1689073|NCT01548378|Other|Normal Saline|Day 0: 16ml of Normal Saline (32 injections ) Day 14: 16ml of Normal Saline (32 injections ) Day 28: 16ml of Normal Saline (32 injections )
1689000|NCT01548885|Device|FreeStyle Freedom Lite® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of FreeStyle Freedom Lite® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1689001|NCT01548885|Device|ACCU-CHEK® Aviva BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of ACCU-CHEK® Aviva BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1689002|NCT01548885|Device|TRUEtrack® BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of TRUEtrack® BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1689003|NCT01548885|Device|OneTouch® Ultra®2 BGMS|Study staff performed Blood Glucose (BG) testing with capillary fingerstick blood collected from subjects with diabetes and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® Ultra®2 BGMS was evaluated across the glucose range of the BGMs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
1689004|NCT01548872|Drug|HTK solution|50 ml/kg bolus in 2 minutes
1689005|NCT01548872|Drug|crystalloid cardioplegia solution|30 ml/kg bolus in two minutes
1689006|NCT01548859|Drug|Midazolam|0.2 mg/kg/saat continuous infusion of midazolam received during anaesthesia
1689007|NCT01548859|Drug|Sevoflurane|end tidal concentration of % 0,5-8
1689008|NCT01548846|Radiation|Tomotherapy|Patients receive radiotherapy by Tomotherapy for 7 weeks at the ENT
1689009|NCT01548833|Device|Delefilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
1689010|NCT01548833|Device|Narafilcon A contact lens|Silicone hydrogel contact lens for single use, daily disposable wear.
1689011|NCT01548833|Device|Filcon II 3 contact lens|Silicone hydrogel contact lens for single use, daily disposable wear
1689012|NCT01548807|Drug|Everolimus (RAD001)|
1689013|NCT01548794|Procedure|spinal anesthesia|To receive 2 ml heavy bupivacaine + 0,6 ml saline
1689014|NCT01548794|Procedure|spinal anesthesia|To receive 2ml bupivacaine +0,6 ml 1% lidocaine for spinal anesthesia.
1689015|NCT01548794|Procedure|infiltration anesthesia|To receive step by step local infiltration anesthesia as described by the Lichtenstein Institute.
1689016|NCT01548781|Behavioral|Impairment-based robotic intervention for reaching function|All participants will undergo 8 weeks of reaching practice in the ACT3D. Frequency and duration will be matched at three 1.5-hour sessions per week. All reaching practice will include abduction (gravity) loading standardized to the participant's motor abilities. The experimental group intervention will also include a horizontal viscous resistant element similar to pushing the arm through molasses.
1689017|NCT01548768|Drug|TNF inhibitors|"TNF inhibitors are an FDA approved class of medications indicated for the treatment of RA when initial treatment (usually with methotrexate) has failed to achieve remission of RA disease activity. TNF inhibitors are part of the standard of care management of RA.
The possible TNF inhibitors are: Remicade, Humira, Enbrel, Cimzia, Simponi."
1689018|NCT01548768|Drug|DMARDs|Standard of care treatment for RA, such as Methotrexate or other disease-modifying antirheumatic drugs.
1689019|NCT01548742|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness Based Stress Reduction (MBSR) is a group based treatment focused on progressive training in mindfulness meditation.
1689020|NCT01548742|Behavioral|Present-Centered Group Therapy (PCGT)|Present-Centered Group Therapy (PCGT) is a group therapy focused on current problems.
1689021|NCT01548729|Procedure|Combined pancreatic islet and lung transplantation|Combined pancreatic islet and lung transplant from the same donor for the treatment of patients with end-stage cystic fibrosis
1689022|NCT01548703|Drug|BCI-838|BCI-838 100 mg or matching placebo administered once daily for 7 days
1689023|NCT01548703|Drug|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
1689024|NCT01548703|Drug|BCI-838|BCI-838 or matching placebo administered once daily for 7 days; the dose of BCI-838 will be determined based on the safety and PK data from the preceding dosing arm.
1689025|NCT01548690|Drug|Ornithine phenylacetate|"Up to 36 patients will be enrolled into 2 groups [~18 with minimal renal dysfunction (Cohort 1) & ~18 w/ comprised renal function (Cohort 2)] and receive OCR-002 infusion for at least 72 hrs. OCR-002 will be administered in the vein and pharmacokinetics (pk) assessed for all subjects who receive the infusion.
The first 24 enrolled subjects received OCR-002 at 3 ascending dose levels (DLs 1-3) with a maximum target infusion rate equivalent to 10g/24h.
The remaining 12 patients (~6 Cohort 1 & ~6 Cohort 2) will be enrolled and receive identical quantities of OCR-002 at 20g/24hr continuously for 5 days (Dose Level 4)."
1689026|NCT01548677|Drug|trastuzumab|8 mg/kg of loading dose IV over 90 minutes for the first cycle, followed by 6 mg/kg IV over 60 minutes every 3 weeks for the 5 subsequent cycles.
1689027|NCT01548664|Other|Wii Fit|15 minutes of gaming activity on the Wii Fit™ following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
1689028|NCT01548664|Other|Lower Extremity Exercise|Fifteen minutes of lower extremity exercise that addressed balance, posture, weight shifting and strengthening provided bilaterally following each regularly scheduled 60 minute physiotherapy session, in a separate treatment area.
1689071|NCT01548378|Genetic|NL003|Day 0: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 14: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections) Day 28: 6mg of NL003 (24 injections of 0.5ml of NL003) and 4ml normal saline(8 injections)
1689072|NCT01548378|Genetic|NL003|Day 0: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 14: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections) Day 28: 4mg of NL003 (16 injections of 0.5ml of NL003) and 8ml normal saline(16 injections)
1742054|NCT00113854|Drug|Mannitol|
1689029|NCT01548651|Drug|Saxagliptin|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. All subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and C Reactive Protein (CRP), Intracellular Adhesion Molecule (ICAM), vascular cell adhesion molecule (VCAM), plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 months.
1689030|NCT01548651|Drug|Placebo|Subjects will be randomized to receive either Saxagliptin 5mg daily orally or placebo for 6 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, free fatty acids, plasma adipocytokines, plasma levels of inflammatory markers and CRP, ICAM, VCAM, plasma lipids, and glucose tolerance (75 gram oral glucose tolerance test) as well as measurement of liver and myocardial fat content and left ventricular systolic and diastolic function with magnetic resonance imaging/spectroscopy. All subjects will also undergo measurements of monocyte inflammatory proteins at baseline. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, inflammatory markers and adipocytokines, oral glucose tolerance test, monocyte inflammation, as well as hepatic/myocardial fat content determination and left ventricular function at the end of the 6 month treatment period.
1689031|NCT01548638|Drug|Galantamine ER|"The study will be performed using the 8mg and 16mg doses of galantamine hydrobromide-ER, which is currently marketed for the treatment of Alzheimer's disease. The dosing regimen, which follows FDA-approved guidelines, will be an initial 4 weeks of drug run-up at the lowest 8mg daily dose, followed by an additional one week of drug run-up at the higher dose of 16mg daily.
Participants will continue to take the 16mg daily during the 7-day quit week, for a total of 6 weeks of treatment with galantamine-ER."
1689032|NCT01548612|Drug|Sodium nitroprusside|Intravenous infusion of 0,5 mcg/kg/min for 240 minutes
1689033|NCT01548612|Drug|Glucose solution|Intravenous infusion of glucose solution 5% for 240 minutes
1689034|NCT01548599|Other|Multi-sectoral agricultural intervention|Participants in the intervention arm will receive a micro-finance loan and training on financial management and marketing skills. With the loan, each participant will receive vouchers to purchase the following items: the Money Maker hip pump, 50 feet of hosing, fertilizer, and government certified seeds. Participants in the intervention group will also receive training on the use of the Money Maker hip pump, a portable, low-cost, human-powered water pump developed by KickStart. Participants in the intervention group will also receive training from Kickstart on the use of the pump as well as complementary training in best horticultural practices.
1689035|NCT01548586|Device|Eldith DC stimulator ( Magstim Company Ltd. UK)|Anodal tDCS: Intensity of 2 mA , during 10 min Cathodal tDCS: Intensity of 2 mA , during 10 min Placebo type tDCS: Intensity of 0 mA during 10 min
1689036|NCT01548573|Drug|Dexamethasone|Given PO
1689037|NCT01548573|Procedure|Tandem autologous stem cell transplant|
1689038|NCT01548573|Drug|Cisplatin|Given IV
1689039|NCT01548573|Drug|Doxorubicin|Given IV
1689040|NCT01548573|Drug|Cyclophosphamide|Given IV or PO
1689041|NCT01548573|Drug|Etoposide|Given IV
1689042|NCT01548573|Drug|Bortezomib|Given IV
1689043|NCT01548573|Drug|Thalidomide|Given PO
1689044|NCT01548573|Drug|Melphalan|Given IV
1689045|NCT01548560|Drug|Dapivirine Vaginal Film|Dosage form: vaginal film Dosage: 1.25mg Frequency: 7 daily doses
1689046|NCT01548560|Drug|Dapivirine Vaginal Gel|Dosage form: vaginal gel Dosage: 0.5%, 2.5g Frequency: 7 daily doses
1689047|NCT01548547|Other|Simulation-based mastery learning|Hands-on coached deliberate practice on a simulator. Training until mastery achieved.
1689048|NCT01548534|Dietary Supplement|Dietary supplementation with fish oil.|Patients randomized in this arm will take 3 cans/day with fish oil : DHA is 1.56 g/d and EPA is 2.64 g/d.
1689049|NCT01548534|Dietary Supplement|Dietary supplementation with vegetable oil|Patients randomized in this arm will take 3 cans/day with vegetable oil : no DHA no EPA.
1689050|NCT01548521|Drug|Oxytocin|2 ui intranasal administration for the 3 first patients, 4UI for the 3 following patients.
1689051|NCT01548508|Other|Functionnal ElectroStimulation (FES)|Functionnal ElectroStimulation on lower limbs, 1h per day, 5 days per 7, during 6 weeks
1689052|NCT01548508|Other|SHAM|SHAM on lower limbs, 1h per day, 5 days per 7, during 6 weeks
1689053|NCT01548482|Other|Laboratory Biomarker Analysis|Correlative studies
1689054|NCT01548482|Other|Pharmacological Study|Correlative studies
1689055|NCT01548482|Drug|Temsirolimus|Given IV
1689056|NCT01548482|Biological|Trebananib|Given IV
1689057|NCT01548469|Other|Bio Mineral toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
1689058|NCT01548469|Other|Perio Total Care toothpaste|Frequency: 2 times everyday/Duration: 4 weeks/Dosage: 1ml at once
1689059|NCT01548456|Procedure|Intramedullary Nailing|Surgical treatment that includes closed or open reduction and stabilization of the femur fracture with an intramedullary rod inserted using antegrade or retrograde technique
1689060|NCT01548456|Procedure|Open Reduction Internal Fixation|Surgical treatment that includes open reduction internal fixation of the femur fracture with a dynamic compression plate
1689061|NCT01548443|Device|Medifoam H dressing|"Cover medifoam H on the wound for a week."
1689062|NCT01548443|Device|Duoderm THIN dressing|"Cover Duoderm THIN on the wound for a week"
1689063|NCT01548430|Drug|TTP4000|
1689064|NCT01548430|Drug|Placebo|
1689065|NCT01548417|Drug|Korlym (mifepristone)|600 mg/day, oral pill, 7 days
1689066|NCT01548417|Drug|Sugar Pill|600 mg/day, oral pill, 7 days
1689069|NCT01548391|Drug|HX-1171|20mg, 200mg, 500mg
1689070|NCT01548378|Genetic|NL003|Day 0: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 14: 8mg of NL003 (32 injections of 0.5ml of NL003) Day 28: 8mg of NL003 (32 injections of 0.5ml of NL003)
1689074|NCT01548365|Other|Infusion therapy nursing expert service|"The ITNE will assess the patient and treatment characteristics and use an evidence based decision making algorithm for the selection of the most suitable VAD.
If the VAD needed is a PICC or a midline ITNE will place it following hospital's protocols. If needed, ITNE will also educate and support patients and next of keens in the maintenance of the device at home.
If other devices such as peripheral catheters, central venous catheters (jugular or subclavian) or venous subcutaneous reservoirs are the preferable VADs for patients and treatment conditions, ITNE will work together with health professionals in charge of patients to activate the usual procedures to place the according device."
1689075|NCT01548339|Procedure|Laparoscopic cholecystectomy|3 trocars laparoscopic cholecystectomy
1689076|NCT01548326|Drug|Atorvastatin|one 40 mg Atorvastatin tablet orally per day for 10 days
1689077|NCT01548326|Drug|placebo|one Placebo tablet orally per day for 10 days
1689078|NCT01548287|Drug|AZD5213|AZD5213 doseA daily
1689079|NCT01548287|Drug|AZD5213|AZD5213 doseB daily
1689080|NCT01548287|Drug|AZD5213|AZD5213 doseC daily
1689081|NCT01548287|Other|Placebo|Placebo tablet daily
1689082|NCT01548274|Drug|Sarpogrelate|Sarpogrelate 300mg/day
1689083|NCT01548261|Procedure|Donating oral mucosal cells|Donating oral mucosal cells
1689084|NCT01548248|Drug|insulin detemir|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
1689085|NCT01548248|Drug|insulin aspart|Prescribed insulin detemir and insulin aspart based on the clinical judgement of the physician. The insulin preparations were prescribed by the physician solely as a result of a normal clinical evaluation. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any.
1689086|NCT01548235|Drug|biphasic insulin aspart 30|Prescribed biphasic insulin aspart 30 as part of routine care. Starting dose, dose titration and injection frequency determined individually by each physician.
1689087|NCT01548209|Drug|Dexmedetomidine|A single dose dexmedetomidine 0.5 mcg/kg IV. 30 min before end of the surgery
1689088|NCT01548209|Drug|Placebo|Placebo 0.5 mcg/kg iv. 30 min before end of the surgery
1689089|NCT01548196|Procedure|Standard Percutaneous nephrolithotomy|Percutaneous nephrolithotomy
1689090|NCT01548183|Behavioral|Lifestyle counseling|Weekly SMS assessments of risky sexual encounters with feedback
1689091|NCT01548170|Drug|Sunitinib|One capsule of sunitinib 50 mg orally. Single dose
1689092|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
1689093|NCT01548170|Drug|Sunitiinb and Ketoconazol|Sunitinib capsule 37.5mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
1689094|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 1 tablet of 200mg administered daily during 6 days.
1689095|NCT01548170|Drug|Sunitinib and Ketoconazol|Sunitinib capsule 25mg. Single dose Ketoconazol 2 tablets of 200mg administered daily during 6 days.
1689096|NCT01548157|Drug|HCP1007 / omarco and crestor|HCP1007 / Rosuvastatin plus Omega-3
1689097|NCT01548144|Drug|Crizotinib (Xalkori)|"Starting dose for Crizotinib - Groups A, B, C: 250 mg by mouth every other day, 1 or 2 times a day on Day 1 of a 21 day cycle. Participant told how often to take this drug.
Expansion Groups Starting Dose: MTD from Phase 1."
1689098|NCT01548144|Drug|Pazopanib|"Starting Dose for Pazopanib - Groups A, C, D: 200 mg by mouth daily in a 21 day cycle.
Expansion Groups Starting Dose: MTD from Phase 1."
1689099|NCT01548144|Drug|Pemetrexed|"Starting dose for Pemetrexed - Groups B + C: 200 mg/m2 by vein on Day 1 of a 21 day cycle.
Expansion Groups Starting Dose: MTD from Phase 1.
Starting dose for Pemetrexed Group D: 400 mg/m2 by vein every 3 weeks on Day 1 of a 21 day cycle.
Expansion Group Starting Dose: MTD from Phase 1."
1689100|NCT01548131|Behavioral|Psychoeducative group therapy|6 sessions during pregnancy and 1 after childbirth
1689105|NCT01548105|Other|Blood draw for the study participants|"These will include:
Procollagen 1-N propeptide levels (PINP)
Matrix metalloproteinase (MMP9)
Plasma Vitamin C levels"
1689106|NCT01548092|Drug|Adipose-derived stem cells without expanded|Administration will be intralesional injection of cells suspension. They will be placed into fistula walls
1689108|NCT01548066|Drug|Valproic Acid|spray 7.2% of sodium valproate on scalp twice a day (morning and evening) for 24 weeks
1689109|NCT01548066|Drug|Control placebo|spray vehicle without sodium valproate on scalp twice a day (morning and evening) for 24 weeks
1689110|NCT01548053|Other|PC-DATA tool|The implementation plan consists of educational sessions and a dementia care manager (DCM). The educational sessions consist of two components: a 1.5 hour group-based DATA tool implementation workshop with primary care providers (PCPs); and, a 1 hour follow-up session at study mid-point. The DCM will facilitate application of the DATA tool and provide direct support to PCPs during the study.
1689111|NCT01548040|Device|Kneehab XP|NMES using Kneehab XP on the affected leg,20 minutes, twice per day, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively
1689112|NCT01548040|Device|quadriceps TENS (at a minimal sensory input) using Kneehab XP|on the affected leg, 20 minutes, twice per days, 5 days a week. Subjects will begin use of the device at 6 weeks pre-operatively and continue through 6 weeks post-operatively.
1689314|NCT01546532|Drug|RLX030|RLX030 as intravenous infusion for 24 hours.
1955559|NCT03154229|Other|Smartphone-based decision-support|WHO guidelines have been adapted from paper onto a smartphone referred to as a Rehydration Calculator
1955560|NCT03154229|Other|Paper-based decision-support|WHO guidelines presented on paper
1689113|NCT01548027|Procedure|Local infiltration group|patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months around the wound by surgeon. The needle will be injected in subcutaneous tissue parallel to the wound.
1689114|NCT01548027|Procedure|TAP block|Surgical TAP block (sTAP: Patients would have 0.5 ml/kg of 0.25% bupivacaine if age < 6 months or 1 ml/kg if age > 6 months
1689115|NCT01548027|Other|No intervention|No intervention
1689116|NCT01548014|Dietary Supplement|VSL#3|children with severe Crohn's disease were assigned in a 1:1 ratio with either IFX 5 mg/kg q 12 weeks + concurrent immunomodulator + VSL#3 (4 sachets of 450 x 109 organisms per day) (Group A), or IFX 5 mg/kg q 8 weeks + concurrent immunomodulator (Group B).
1689117|NCT01548001|Drug|Iguratimod|25 mg/tablet, taken orally, 2 tablets/day (bid)
1689118|NCT01548001|Drug|Methotrexate|2.5 mg/tablet, taken orally once a week, 4 tablets/week (week 1-week 4) , 6 tablets/week (week 5- week 52)
1689119|NCT01547988|Other|Balance Training Intervention|The intervention group participated in a total of 24 one-hour training sessions over a period of 12 weeks. The training program utilized different size balls as a general tool in a series of progressively more difficult exercises targeting sitting, standing, and gait-related balance control. The program included exercises at five different levels of progressively more challenging balance exercises. Levels 1-4 focused on voluntarily controlled balance exercises, whereas level 5 also included perturbation exercises to trigger automatic compensatory stepping responses. All levels included attention-demanding dual task exercises that required subjects to simultaneously perform motor and cognitive activities.
1689120|NCT01547962|Device|Gintuit|"Gintuit is prepared in a S fold and trimmed to fit the prepared wound bed, with a standardized width of 5 mm and sutured in place with a 5/0 gut suture."
1689121|NCT01547962|Other|autologous Free Gingival Graft (FGG)|Autologous FGG harvested from the subject's palate, the width of the FGG will be 5 mm and sutured in place with a 5/0 gut suture.
1689122|NCT01547949|Dietary Supplement|tart cultivar Montmorency cherry juice|
1689123|NCT01547949|Dietary Supplement|placebo cherry fruit drink|
1689124|NCT01547923|Genetic|Blood sample for phenotypic and pharmacogenetic analysis.|Prior to treatment by 5-FU, a DPD deficiency is identified thanks to just one blood sample (lithium heparinate).
1689125|NCT01547923|Genetic|Blood sample for phenotypic and pharmacogenetic analysis.|Blood sample (lithium heparinate) will be taken prior to treatment but not analysed.
1689126|NCT01547910|Dietary Supplement|Fish Oil|Fish oil given in supplementary dose
1689127|NCT01547897|Drug|NOX-E36|0.5 mg/kg study drug or placebo as SC injections twice a week
1689128|NCT01547806|Drug|Filgrastim|Filgrastim will be administered as a single daily dose in a dose range of 10-16ug/kg/day subcutaneously for 5-7days
1689129|NCT01547806|Drug|Plerixafor|Plerixafor will be given on day 4, 8-10 hours before the day 5 apheresis, dose calculated according to patient weight
1689130|NCT01547806|Procedure|Apheresis|The minimum cluster of differentiation 34 (CD34)+ cell dose that must be collected in order to proceed with a single autologous transplantation is 2 x 106 CD34+ cells/kg.
1689131|NCT01547780|Radiation|PET|
1689132|NCT01547741|Drug|Doxorubicin|
1689133|NCT01547741|Drug|Cyclophosphamide|
1689134|NCT01547741|Drug|Docetaxel|
1689135|NCT01547741|Drug|Paclitaxel|
1689136|NCT01547728|Drug|Recombinant antithrombin (rhAT)|Subjects will receive an intravenous bolus of 500 units of recombinant, human antithrombin (rhAT, ATRYN ®). If the subject remains heparin-resistant, one more IV bolus of 500 units rhAT is given.
1689137|NCT01547715|Biological|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine
1689138|NCT01547702|Behavioral|Teacher Help for ADHD|"Teachers will review powerpoints other materials online and will have access to a study coach to assist with their understanding and practical application of the materials. Session descriptions follow:
Session 1: Provide information about ADHD characteristics, impact, diagnosis, etiology
Session 2: Help establish teacher's role; goal setting; introduce behaviour planning
Session 3: Help develop and implement behaviour program specific to the needs of students with Session 2 goals
Session 4: Help develop strategies re: classroom structure, work assignments, teacher-student relationship
Session 5: Help to use instructional interventions for ADHD
Session 6: Help to teach these students self-monitoring and self-evaluation skills; help teachers to evaluate progress, phase out behaviour program, and plan for relapses in unwanted behaviours"
1689139|NCT01547689|Biological|Human Umbilical Cord Derived MSC|20 million cells per subject（0.5×10^6 UC-MSCs per kg ） intravenous injection Infusion number:8 (Once every two weeks in the first month of each quarter) Time interval: two and a half months
1689140|NCT01547676|Procedure|robot-assisted laparoscopic surgery|Unclamped partial nephrectomy
1689141|NCT01547676|Procedure|robot-assisted laparoscopic surgery|Undergo clamped partial nephrectomy
1689142|NCT01547650|Other|Calculated CVP by using cardiac echogram|Before and after the correction of plasma volume
1689143|NCT01547637|Procedure|Obturator nerve block|Peripheral obturator nerve block using 10 ml of 2% lidocaine
1689144|NCT01547637|Procedure|Obturator nerve block|Ultrasound guided peripheral obturator nerve block
1689145|NCT01547624|Other|Neck specific exercises|Neck specific exercises 2 times/week for 3 month at a physiotherapist. Home exercises.
1689146|NCT01547611|Other|Customary treatment|The staff at the Neurosurgical clinic will give the patient ordinary pre- and postoperative information. The physiotherapist at the Neurosurgical clinic informs the patients what to avoid the first weeks after surgery and the importance of a good posture and ergonomic thinking in daily life. The patient is also instructed how to do exercises for the shoulder range of motion. Patients have ordinary post-surgery visit to the surgeon and to the physiotherapist about 6 weeks after the surgery, where physiotherapist instructs the patient in exercises for active neck range of motion.
1689147|NCT01547611|Other|Structured behavioural medicine program|The behavioural medicine program includes functional behavioural analysis of the problem, medical exercise therapy, strategies to increase self-efficacy in activities and problem-solving strategies for coping with disability.
1689148|NCT01547598|Drug|travoprost ophthalmic solution 0.004%|Travatan® Z (travoprost ophthalmic solution 0.004%) administered as 1 drop in the affected eye(s) once a day for 4 weeks.
1689187|NCT01547312|Drug|800 mg Grazoprevir|800 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
1690237|NCT01539174|Drug|vincristine sulfate|Given IV
1689149|NCT01547598|Drug|travoprost 0.004% / timolol 0.5% combination ophthalmic solution|DuoTrav® (travoprost 0.004% / timolol 0.5% combination ophthalmic solution) administered as 1 drop in the affected eye(s) once daily in the morning for 12 weeks.
1689150|NCT01547598|Drug|Bimatoprost ophthalmic solution 0.01%|LUMIGAN® RC (bimatoprost ophthalmic solution 0.01%) administered as 1 drop in the affected eye(s) once daily in the evening for 12 weeks.
1955561|NCT03154229|Other|Pre-Assessment of practices|Observation of baseline clinical practice.
1689152|NCT01547572|Procedure|The study group will get a video and leaflet on enhanced recovery|The study group will get a video and leaflet
1689153|NCT01547572|Procedure|The control group will receive a leaflet only|The control group will receive a leaflet only
1689154|NCT01547559|Drug|part1:teprenone|Teprenone 50mg tid after meal for Hp negative patients.
1689155|NCT01547559|Drug|part1:EAC-T|esomeprazole 20 mg, amoxicillin 1 g, and clarithromycin 500 mg, each twice daily followed by gastric mucosal protective therapy with teprenone 50mg three times daily for 11 weeks
1689156|NCT01547559|Drug|part1:EA-EMC-T|esomeprazole 20 mg plus amoxicillin 1 g, twice daily for 5 days, then esomeprazole 20 mg with clarithromycin 500 mg and metronidazole 500 mg, twice daily for another 5 consecutive days) followed by teprenone 50mg three times daily until 12 weeks
1689157|NCT01547559|Drug|part1:teprenone|Teprenone 50mg tid after meal for Hp positive patients.
1689158|NCT01547559|Drug|part2:GGA group|GGA 50mg three times daily plus diclofenac sodium 75mg once a day for patients with rheumatic diseases.
1689159|NCT01547546|Drug|GDC-0084|Multiple doses
1689162|NCT01547507|Device|AirWay Medix Closed Suction System|AirWay Medix Closed Suction System
1689163|NCT01547494|Other|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
1689164|NCT01547494|Dietary Supplement|mixture of omega3 and vitamins|mixture of omega3 and vitamins
1689165|NCT01547468|Procedure|Femoral Nerve Catheterization|A femoral nerve catheter will be placed prior to surgery in this group.
1689166|NCT01547468|Procedure|Intravenous Opioids|Intravenous opioids will be given after surgery to provide pain relief to subjects assigned to this group.
1689167|NCT01547455|Drug|Atorvastatin(Lipitor)|participants take 80mg Atorvastatin orally 12h before surgery with another 40mg 2h before surgery
1689168|NCT01547455|Drug|Placebo|Participants randomized to Control arm take 80mg placebo 12h before surgery with another 40mg 2h before surgery
1689169|NCT01547442|Device|Artisan Aphakia Intraocular Lens|Implantation of an intraocular lens
1689170|NCT01547429|Device|Artisan Aphakia Intraocular Lens|Implantation of lens to correct refractive error in aphakic eye
1689171|NCT01547416|Drug|epidural 250mL of 0.2% ropivacaine and 2 μg/mL of fentanyl, 5 mL/hr continuous infusion and 0.5 mL bolus dose|"Before the induction of anesthesia, epidural catheter was inserted in group GE at T8/9, T9/10, or T10/11 interspinous space with a 17-gauge Tuohy needle in lateral decubitus position and advanced 5 cm cephalad. .
Epidural analgesia was maintained using the patient-controlled analgesia technique containing 250 mL of 0.2% ropivacaine and 2 μg/mL fentanyl with setting of 5 mL/hr for continuous infusion and 0.5 mL of bolus dose. Lockout time was set to 15 min.
General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
1689172|NCT01547416|Drug|no epidural drug administered|"Patients allocated to general anesthesia group and DID NOT receive epidural anesthesia.
General anesthesia was induced with 2 mg/kg of propofol and 50 mg of rocuronium. After tracheal intubation, anesthesia was maintained with sevoflurane. All the patients were ventilated with controlled mode of 8 mL/kg of ideal body weight and respiratory rate was adjusted to maintain end-tidal carbon dioxide between 35-40 mmHg."
1689173|NCT01547390|Drug|Aspirin|
1689174|NCT01547390|Drug|placebo|
1689175|NCT01547377|Dietary Supplement|zinc and selenium supplementation|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
1689176|NCT01547377|Other|rosuvastatin + placebo|Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
1689177|NCT01547364|Drug|Saline|Injection of 10 ml of normal saline into the caudal epidural space
1689178|NCT01547364|Drug|Dextrose|Injection of 10 ml or dextrose 5% in water into the caudal epidural space
1689179|NCT01547351|Other|ARMS Questionnaire|The ARMS Questionnaire is a 2-part, 2-page survey, with each part comprising 7 questions on 1 page. Eligible patients will be administered part 1 of the survey when the patient presents with new relapse. Part 2 of the survey is to be completed 1 month (± 1 week) after initiation of treatment for relapse.
1689180|NCT01547325|Drug|NanoDOX 1% doxycycline monohydrate Hydrogel|1% doxycycline monohydrate hydrogel
1689181|NCT01547325|Drug|placebo hydrogel|placebo hydrogel
1689182|NCT01547312|Drug|Peg-Interferon|Polyethyleneglycolated Interferon alfa-2b at 1.5 ug/kg/week, administered subcutaneously, once a week, over the entire course of the study.
1689183|NCT01547312|Procedure|Liver Samples from FNA|Tissue samples are collected at 3 separate visits, with each collection consisting of 3-4 fine needle aspiration (FNA) passes through the liver, guided by ultrasound.
1689184|NCT01547312|Procedure|Liver Samples from CNB|Tissue samples are collected at 1 of six possible visits by core needle biopsy (CNB) of the liver.
1689185|NCT01547312|Procedure|Blood Samples|Blood is collected from multiple blood draws, with the total volume for each participant not expected to exceed 500 ml.
1689186|NCT01547312|Drug|Ribavirin|Ribavirin, 600-1400 mg administered orally, twice daily, over the entire course of the study.
1689188|NCT01547312|Drug|100 mg Grazoprevir|100 mg Grazoprevir administered orally, once per day, for 7 consecutive days.
1689189|NCT01547312|Procedure|Liver samples from CNB and FNA|Tissue samples from the liver are collected by CNB as part of standard of care, and also by FNA during a single visit.
1689193|NCT01547286|Biological|Standardized Cat Allergen Extract and Standardized Dust Mite Allergen|The route of administration will be topical application of the titrated allergen via nebulized droplets to the lungs. The starting dose of allergen will be 3 dose dilutions below the estimated provocative concentration of allergen that causes a 20% fall in Forced Expired Volume in 1 second delivered for 5 minutes at tidal breathing, followed by Forced Expired Volume in 1 second at 10-minute intervals until the lowest Forced Expired Volume in 1 second is established. If the percent of Forced Expired Volume in 1 second fall is < 20%, the next concentration is given, until the Forced Expired Volume in 1 second falls ≥ 20 percent. When this happens the Forced Expired Volume in 1 second will be followed at 10, 20, 30, 45, and 60 minutes, then hourly for 7 hours. The early asthmatic response is the maximum percent of Forced Expired Volume in 1 second fall between 0 and 3 hours and the late asthmatic response between 3 and 7 hours post allergen challenge.
1689194|NCT01547286|Radiation|Computed Tomography imaging, functional Positron Emission Tomography imaging|Physiology study using Computed Tomography and Positron Emission Tomography imaging with Nitrogen-13 saline as radiotracer; images obtained during the early and late phases after allergen challenge
1689195|NCT01547286|Drug|Nebulized methacholine inhalation|Standard methacholine challenge performed once to determine the subject's dose that causes a 20% fall in Forced Expired Volume in 1 second from baseline.
1689196|NCT01547273|Procedure|bone graft inside socket only|bone graft inside socket only
1689197|NCT01547273|Procedure|bone graft inside and outside socket|bone graft inside and outside socket
1689198|NCT01547273|Procedure|no bone graft|no bone graft
1689199|NCT01547260|Drug|Gemzar|Gemcitabine (Gemzar®), 1000 mg/m2 in 0.9% sodium chloride will be administered as intravenous infusion over 30 minutes, weekly for 3 weeks then rest for 1 week (days 1, 8, 15 of each 28-day cycle).
1689200|NCT01547260|Drug|Revlimid|Lenalidomide capsules will be taken orally in the morning each day on days 1-21 of each 28-day cycle. Phase I; Three subjects will be enrolled into each dose cohort for 15, 20 and 25 mg/day, respectively. Phase II; Lenalidomide at dose determined in Phase I, will be administered orally once daily for 21 days followed by 7 days rest.
1689201|NCT01547247|Device|soft straight distal cap D-201-14304 Olympus attached to the tip of the colonoscope|Colonoscopy with transparent cap attached to the tip of the colonoscope and water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
1689202|NCT01547247|Procedure|water immersion colonoscopy|Colonoscopy without transparent cap using water immersion during insertion phase and romm air insufflation during colonoscope withdrawal.
1689203|NCT01547221|Drug|clotrimazole|single application of 1%clotrimazole ear drop
1689204|NCT01547221|Drug|3% Boric acid|3% boric acid in 70% alcohol was prepared by phamaceutical department of Khonkaen Hospital
1689205|NCT01547208|Procedure|Immediate radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia is performed immediately after an appropriate ICD shock
1689206|NCT01547208|Procedure|Radiofrequency ablation of ventricular tachycardia|Radiofrequency ablation of ventricular tachycardia will be performed after an arrhythmic storm occurs
1689207|NCT01547195|Procedure|swim training|"Swimming training will be conducted with the implementation of the freestyle. The training will be held a week with 3 X 50 minutes for a period of 12 weeks.
Patients will be monitored by a frequency waterproof. When at the beginning of training are carried out five minutes of heating, followed by 40minutos swimming 5 minutes and cooling at the end of training."
1689208|NCT01547195|Procedure|Training walk|"The control group will perform walking exercise outdoors, monitored by a frequency, with the heart rate at anaerobic threshold assessed by cardiopulmonary exercise test.
The training of walking will last 50 minutes, three times per week for 12 weeks.
At the beginning of training, there will be a heating time of 5 minutes, followed by LA walk in cooling for 40 minutes and 5 minutes."
1689209|NCT01547182|Behavioral|Caloric restriction|Caloric restriction
1689210|NCT01547182|Behavioral|Aerobic Training|Walking
1689211|NCT01547182|Behavioral|Resistance Training|Lifting weights
1689212|NCT01547169|Drug|Placebo Comparator|saline, taken twice per day for a 3 week duration
1689213|NCT01547169|Drug|insulin detemir|10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
1689214|NCT01547169|Drug|insulin detemir|20IU insulin detemir, administered intranasally twice per day for a 3 week duration
1689215|NCT01547156|Device|Intervention group|
1689216|NCT01547143|Drug|IST and/or alloHCT|"1) Patients will be categorized by their initial serum ferritin level.
Mild ( ferritin<3,000 μg/L): close observation
Moderate (ferritin: 3,000-10,000 μg/L):
Initiation : cyclosporine 3mg/kg p.o.bid + dexamethasone 10mg/m2/d po. or i.v. (D1-3)
continuation: cyclosporine 3mg/kg p.o. bid (D4-56) + dexamethasone 10mg/m2/d (D4-14), then tapering.
Severe (ferritin>10,000 μg/L):
initiation : etoposide 100mg/m2/d i.v. + cyclosporine 2mg/kg i.v. q 12hours + dexamethasone 20mg/m2/d i.v. (D1-3)
continuation : etoposide 100mg/m2/day weekly (D15-49) + cyclosporine 2mg/kg i.v. q 12 hours? ? po. (D4-56) + dexamethasone 10mg/m2/d (D4-14), 5mg/m2/d (D15-28), 2.5mg/m2/d (D29-42), 1.25mg/m2/d (D43-56), then tapering off.
2) AlloHCT for refractory or reactivated cases."
1689217|NCT01547130|Drug|Normal (0.9%) saline|A total of 2L solution at lukewarm temperature (37.2-38.8 degrees Centigrade)consumed as bolus intake (8-16 oz in one to two minutes) alternating with yoga exercises.
1689218|NCT01547130|Drug|HalfLytely|A total of 2L solution prepared as per manufacturers instructions and sipped until bowel movements are clear.
1689219|NCT01547117|Radiation|Blood Volume|we will measure the amount of hemoglobin and myoglobin in the body by a procedure called carbon monoxide (CO) rebreathing. One teaspoon of blood is taken before and after a small amount of CO has been absorbed into the bloodstream.
1689220|NCT01547117|Radiation|Total Blood Volume|Using injection of iodinated I-131 tagged human serum albumin nominally 25 micro-Ci of radiation, blood samples are drawn before and 30 minutes after injection.
1689309|NCT01545349|Biological|Live attenuated influenza vaccine|0.2 mL pre-filled, single use intranasal spray
1689221|NCT01547117|Procedure|Exercise Capacity Test - Bicycle|subjects breath room air through a mouthpiece and exhale the air into a tube that connects to a machine (metabolic cart) that analyzes carbon dioxide and oxygen content, which allows the investigator to calculate the amount of oxygen they are using under resting and exercise conditions.
1689222|NCT01547117|Procedure|Posture Study|Blood pressure and heart rate will be measured while supine and then while standing for up to 30 minutes. Blood will be drawn in each position to measure hormones that regulate blood pressure and blood volume.
1689223|NCT01547104|Drug|Linagliptin|Linagliptin dosed 5 mg as add on therapy to an existing metformin therapy
1689224|NCT01547104|Drug|Glimepiride|Glimepiride 1-4mg (individually dosed) as add on therapy to an existing metformin therapy
1689228|NCT01547078|Biological|Lyophilized Plasma|Licensed plasma that has been lyophilized.
1689229|NCT01547078|Biological|Licensed Plasma|Plasma that has been authorized for transfusion.
1689232|NCT01547026|Behavioral|Implementation Intentions|In a 10 minute structured therapy session patients are assisted to build up implementation intentions to participate in the sports program.
1689233|NCT01547000|Drug|placebo|Administered up to 8 weeks.
1689234|NCT01547000|Drug|extended-release guanfacine (Intuniv)|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks.
1689235|NCT01546987|Drug|bicalutamide|Given orally
1689236|NCT01546987|Drug|buserelin|Given subcutaneously or intramuscularly
1689237|NCT01546987|Drug|flutamide|Given orally
1689238|NCT01546987|Drug|goserelin acetate|Given subcutaneously or intramuscularly
1689239|NCT01546987|Drug|leuprolide acetate|Given subcutaneously or intramuscularly
1689240|NCT01546987|Drug|orteronel|Given orally
1689241|NCT01546987|Drug|triptorelin|Given subcutaneously or intramuscularly
1689242|NCT01546974|Device|HME filter Twin Star 55, Drager Medical, Germany|
1689243|NCT01546974|Device|Heated humidification|
1689244|NCT01546961|Drug|Chloroquine|"Chloroquine phosphate GPO® (Government Pharmaceutical Organization, Thailand) 250 mg (equivalent to chloroquine base 150 mg).
Dosing will be at 0, 24, 48 hrs with 10 mg/kg on day 0 and day 1, and 5 mg/kg on day 2."
1689245|NCT01546948|Drug|Methadone|Patients in the methadone group will be administered 0.3 mg/kg of methadone intraoperatively: two-thirds of the dose (6 cc or 0.2 mg/kg of methadone) on induction of anesthesia as a bolus. The remainder of the dose (3 cc or 0.1 mg/kg of methadone) will be administered at approximately 1.5-2 hours before the end of the procedure.
1689246|NCT01546948|Drug|Hydromorphone|Patients in the hydromorphone group will receive 0.03 mg/kg of hydromorphone; two-thirds the dose (6 cc or 0.02 mg/kg) on induction of anesthesia, and the remainder of the hydromorphone (3 cc or 0.01 mg/kg) will be bolused 1.5-2 hours before surgery concludes.
1689247|NCT01546935|Drug|Oseltamivir|The dose of Oseltamivir will be 3 mg/kg 12 hourly for 5 days (seasonal influenza and 2009 H1N1) or 10 days (avian influenza) for children whose renal function is ≥ 30 mls/min/1.73m2.
1689248|NCT01546922|Drug|Hydrocortisone|Patients receive either a low dose HC (0.2-0.3 mg/kg body weight) for 10 weeks followed by 10 weeks of high dose HC (0.4-0.6 mg/kg body weight) or vice versa.
1689249|NCT01546909|Biological|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of TETRAVAC-ACELLULAIRE (0.5 mL) at Day 0
1689250|NCT01546896|Drug|buspirone+alprazolam|day 1~7: buspirone 10mg/d + alprazolam 0.5mg / day 8~28: buspirone 20mg/d + alprazolam 0.5mg / day 29~56: buspirone 20~30mg/d + alprazolam 0.5mg
1689251|NCT01546896|Drug|alprazolam|0.5mg/d
1689252|NCT01546883|Drug|Dabigatran etexilate (Pradaxa)|150mg bid or 75mg bid for a period of one year
1689255|NCT01546844|Other|Participation in Care4Life|Text message service to aid patients with self-management of type II Diabetes Mellitus. Includes online access to patient data and management of health goals.
1689256|NCT01546818|Biological|SAV001-H|A whole-killed HIV
1689257|NCT01546805|Drug|Zinc Supplement|The interventional group will be requested to take zinc supplements (50mg), once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
1689258|NCT01546805|Drug|Sugar pill|The control group will be requested to take placebo pills, once daily starting 5 days prior to Botox injections and to be continued for 5 days after injection.
1689259|NCT01546792|Behavioral|Combined lifestyle intervention|Exercise training, dietary advice, behaviour change counselling
1689260|NCT01546779|Device|Tri-Gym|40 CF patients performed airway clearance using the VISex, by exhaling against chosen resistance being motivated by visual feedback of raising colored balls. The level of resistance was set to cause longest expiration/volume, until mucus was transported from the peripheral to the central airways, to be expectorated by the subsequent cough.
1689261|NCT01546766|Device|Pupillometry testing.|
1689310|NCT01546571|Biological|POL-103A|POL-103A is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
1689311|NCT01546571|Biological|POL-103A without API|Placebo is administered intradermally, divided into 4 injections (0.2 mL each injection) into the volar surface of forearms and into the anterior upper thighs
1689312|NCT01546558|Drug|Metformin|Metformin 1000 mg bid on Days 1-10
1689313|NCT01546558|Drug|Ranolazine|Ranolazine 500 mg bid on Days 6-10
1689262|NCT01546753|Drug|Walnut Protein Powder|Dosing begins with a one-day walnut oral desensitization protocol. Starting at 0.1 mg protein and increasing every thirty minutes until a maximum dose of 6 mg is reached or until allergic symptoms develop. After the initial escalation day, subjects will continue daily dosing with dosing build-every two weeks to a maximum dose of 1500mg walnut protein at 34 weeks. A daily maintenance dose (1500mg or the highest dose reached by 34 weeks) will be given for 4 weeks followed by 5 gram oral food challenges to walnut and the second tree nut (at 38 weeks), after which the study will be unblinded. Active treatment subjects will continue on maintenance dosing for up to a total of 298 weeks of therapy. Subjects reaching a qualifying specific IgE to walnut and the test tree nut at any early time point will receive a tolerance oral food challenge to the tree nuts on and 4 weeks off therapy. All subjects will have an oral food challenge on and off therapy at 142 weeks and at 298 weeks.
1689263|NCT01546753|Drug|Oat Powder (placebo)|Subjects in the placebo group will undergo the same one-day desensitization protocol as the active treatment group, consuming a maximum dose of 6 mg of oat powder (initial day escalation phase). After the initial escalation day achieving at least 1.5 mg and up to 6 mg of oat powder, the dosing build-up will occur every two weeks through dose 24 (1500mg oat flour) at ~34 weeks. A maintenance dose will be given for 4 weeks followed by a 5 gram protein double blind, placebo controlled OFC to walnut and a 5 gram protein OFC to a second tree nut (at ~38 weeks), after which the study will be unblinded. Placebo subjects that fail the OFC will be crossed over to active treatment beginning with initial escalation day.
1689264|NCT01546727|Behavioral|Behavioral Family Intervention|Three months of weekly treatment delivered via alternating group based clinic visits and individual home visits followed by three months of every other week treatment alternating between clinic and home.
1689265|NCT01546727|Behavioral|Motivational Interviewing|Motivational interviewing will be delivered at the same frequency at the behavioral intervention with 4 in-person visits spaced at the first visit, month 3 and month 5. Phone calls will be conducted weekly during the first 3 months and every other week during months 4 through 6.
1689266|NCT01546701|Drug|Buprenorphine|2 mg sublingual tablet
1689267|NCT01546701|Drug|Morphine|0.1 mg/kg IV morphine
1689268|NCT01546688|Drug|Zonisamide at targeted daily doses of 100-500 mg/day|Each group received 2 doses a day (in the morning and evening) during the Titration Period, once a day (in the evening) or BID during the Maintenance Phase, comprising 25 mg, 50 mg, or 100 mg of ZNS capsules
1689269|NCT01546688|Drug|Placebo administered to match targeted daily doses of 100-500 mg/day|matching placebo
1689270|NCT01546675|Other|Skeletal Stabilization|Upper Limb Prosthetic Socket hypothesized to increase skeletal stabilization
1689271|NCT01546662|Dietary Supplement|E-RH-06|Capsules, 1 capsule/ 2 capsule, twice daily for 12 weeks
1689272|NCT01546662|Dietary Supplement|Placebo|1/ 2 capsules, twice daily for 12 weeks
1689273|NCT01546649|Drug|TAP-144-SR(6M)|
1689274|NCT01546649|Drug|TAP-144-SR(3M)|
1689275|NCT01546636|Other|Hypocapnic group|Patients will be ventilated to an ETCO2 of 30-32 mm Hg.
1689276|NCT01546636|Other|Normocapnic group|Patients will be ventilated to an ETCO2 of 40-42 mm Hg
1689277|NCT01546623|Drug|TAP-144-SR(6M)|
1689278|NCT01546623|Drug|TAP-144-SR(3M)|
1689279|NCT01546610|Other|insoles intervention|EVA insole with arch support and bar retrocapital
1689280|NCT01546610|Other|placebo insole|EVA insole flat
1689281|NCT01546597|Drug|Metformin|"Metformin 500 mg bid on Days 1-5
Metformin 850 mg bid on Days 6-10
Metformin 500 mg bid on Days 11-15
Metformin 850 mg bid on Days 16-20"
1689282|NCT01546597|Drug|Ranolazine|"Ranolazine 1000 mg bid on Days 11-15
Ranolazine 1000 mg bid on Days 16-20"
1689283|NCT01545479|Drug|captopril 25mg|renal blood oxygenation after captopril
1689285|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
1689286|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
1689287|NCT01545453|Drug|lebrikizumab|subcutaneous dose every 4 weeks
1689288|NCT01545453|Drug|placebo|subcutaneous dose every 4 weeks
1689289|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
1689290|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
1689291|NCT01545440|Drug|lebrikizumab|subcutaneous dose every 4 weeks
1689292|NCT01545440|Drug|placebo|subcutaneous dose every 4 weeks
1689293|NCT01545427|Drug|Imatinib mesylate|200 mg bid for 6 months
1689294|NCT01545427|Other|Placebo|Placebo coated to match appearance of Gleevec identically.
1689295|NCT01545414|Behavioral|ICBT|12 weeks of Internet-based Cognitive Behavioral Therapy with a focus on behavioral activation
1689296|NCT01545414|Behavioral|ICONTROL|12 weeks of Internet-based treatment with a focus on relaxation training
1689297|NCT01545401|Other|EMPOWER-PAR Intervention|"Implementation process is conducted in 3 phases:
I. Phase 1: Formation and training of the CDM team
II. Phase 2: Distributions of the intervention tools
Global CV Risks Self-Management Booklets
CPG to aid clinical decision making
III. Phase 3: Facilitation and support to implement the intervention"
1689298|NCT01545388|Drug|Sitagliptin|Sitagliptin, orally, 50 or 100 mg tablet (continuation of the pre-study dose)
1689299|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (single dose; two 250 mg tablets) for 24 weeks
1689300|NCT01545388|Drug|Metformin|Metformin, orally, 500 mg daily (divided dose; 250 mg tablet b.i.d.) for 24 weeks
1689301|NCT01545388|Drug|Placebo|Placebo to match metformin 250 mg tablets, orally, for 24 weeks
1689302|NCT01545375|Biological|Pneumococcal vaccine GSK2189242A|4 doses administered intramuscularly
1689303|NCT01545375|Biological|Placebo|4 doses administered intramuscularly
1689304|NCT01545375|Biological|Prevnar 13®|4 doses administered intramuscularly
1689305|NCT01545375|Biological|PedvaxHIB®|4 doses administered intramuscularly
1689306|NCT01545362|Procedure|Total knee arthroplasty|Total knee arthroplasty
1689307|NCT01545349|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
1689308|NCT01545349|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
1689315|NCT01546532|Drug|Placebo|Intravenous infusion of Placebo over 24 hours
1689316|NCT01546519|Drug|Vismodegib|oral repeating dose of 150 mg once daily
1689317|NCT01546506|Drug|Gutron® treatment|Midodrine 2.5 mg orally 3 times daily, 5 day-treatment.
1689318|NCT01546493|Procedure|MRI, qCT, motion analysis|MRI scan, quantitative computed tomography(QCT), 3D motion analysis after imaging
1689319|NCT01546493|Procedure|MRI, qCT, motion analysis|MRI scan, quantitative computed tomography(QCT), 3D motion analysis after imaging
1689320|NCT01546493|Procedure|MRI, qCT, motion analysis|MRI scan, quantitative computed tomography(QCT), 3D motion analysis after imaging
1689321|NCT01546467|Behavioral|Cognitive remediation|Cognitive remediation including feedback from neurocognitive assessment, psychoeducation about cognitive deficits, 30 hours of computer based drill and practise and strategy coaching based cognitive remediation, 1-3 collaborative meetings with cognitive specialist, participant, therapist and teacher, occupational therapist or other therapist (depending on participants rehabilitation situation) to enhance transfer of skills to daily functioning
1689322|NCT01546454|Drug|Ethinyl Estradiol-Levonorgestrel combination|0.03 mg ethinyl estradiol, 0.15 mg levonorgestrel oral daily for 21 days
1689323|NCT01546454|Drug|leuprolide acetate|single 22.5 mg subcutaneous depot suspension
1689324|NCT01546454|Drug|Estradiol|0.05 to 0.3 mg transdermal daily for 26 days
1689325|NCT01546454|Drug|Progesterone|50 to 100 mg vaginal suppositories twice daily for 13 days
1689326|NCT01546441|Behavioral|interprofessional assessment|assessment by interprofessional team
1689327|NCT01546441|Behavioral|usual care|usual care in primary care clinic
1689328|NCT01546428|Drug|INC280|
1689329|NCT01546415|Drug|Desferasirox|Initial Dose: 20 mg/kg/d. Dose modification according to protocol.
1689330|NCT01546402|Drug|Dexamethasone Drug delivery system (Ozurdex)|It is a sustained release intravitreal implant containing 700µg dexamethasone has been approved by the US-FDA (Food and Drug Administration).
1689331|NCT01546402|Procedure|Cataract surgery|Using a clear corneal incision, continuous curvilinear capsulorhexis, hydrodissection, phacoemulsification and irrigation/aspiration of the cortex will be performed. Foldable intraocular lens will be implanted in the capsular bag. All patients will receive standard postoperative topical steroid (betamethasone 0.1%), antibiotic (moxifloxacin 0.5%) and homatropine (2%) therapy.
1689332|NCT01546389|Biological|Sanaria™ PfSPZ Vaccine|30 subjects in 3 cohorts, 6 groups in different doses of PfSPZ vaccine via the intradermal route. Cohort 1 Medium Dose, Medium Aliquot: Group a: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 50 microliter (mcL) dose), Group b: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 50 mcL dose). Cohort 2: Medium dose, Low Aliquot: Group c: 10,000 PfSPZ in 2 divided doses (e.g., 5000 PfSPZ per 10 mcL dose), Group d: 10,000 PfSPZ in 8 divided doses (e.g., 1250 PfSPZ per 10 mcL dose), Cohort 3: High Dose, Low Aliquot; Group e: 50,000 PfSPZ in 2 divided doses (e.g., 25,000 PfSPZ per 10 mcL dose), Group f: 50,000 PfSPZ in 8 divided doses (e.g., 6,250 PfSPZ per 10 mcL dose)
1689333|NCT01546389|Drug|Chloroquine|Rescue therapy after challenge: 1500 mg chloroquine base orally, over 48 hours (600 mg at time 0 followed by 300 mg oral base at hours 6, 24 and 48)
1689334|NCT01546376|Radiation|Radiation therapy|External photon beam radiation therapy dosage 4000-7000 CGy
1689335|NCT01546376|Other|Venepuncture|Venepuncture for CD4 and viral load count at Week 0, Last week of Radiation, and 12, 24 Week follow up
1689336|NCT01546363|Other|Blood draw|phlebotomy
1689337|NCT01546350|Genetic|PGD|array CGH after blastocyst biopsy
1689338|NCT01546350|Procedure|PGD|PGD using blastocyst biopsy and testing of the biopsy by array CGH
1689339|NCT01546324|Procedure|Blood draw|Maternal blood draw at approximately 8-17 weeks gestation.
1689340|NCT01546311|Device|Pro Active Dynamic Accommodating Socket|Socket with bladders that instantaneously adjusts to volume fluctuations in the residual limb
1689341|NCT01546298|Other|Patch tests|Patch tests for allergic reaction
1689342|NCT01546285|Device|Blood Pressure Readings on B40 Patient Monitor|Simultaneous blood pressure reading on the Investigational B40 patient monitor and DINAMAP PRO1000 patient monitor
1689343|NCT01546272|Device|Insorb resorbable staples|Subcutanous suture using resorbable staples
1689344|NCT01546272|Device|Monocryl resorbable wire|Subcutanous suture using resorbable wire
1689345|NCT01546259|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
1689346|NCT01546246|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
1689347|NCT01546233|Behavioral|multidisciplinary education programme|Educate of self-care by Oncology nurses to relieve and prevent the fatigue of cancer chemotherapy, and provide the manual to read at home, take about 15 minutes. By using home exercise program, 30 minutes of physical education. Teaching and demonstration exercises of the muscles to breath and conservation of energy during exercise and record the exercise/walking diary, the nutritional education nutrition counseling, psychiatric assessment,self-care prevention of depression.
1689348|NCT01546233|Behavioral|standard education|standard education before and after chemotherapy
1689349|NCT01546220|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
1689350|NCT01546207|Procedure|catheter-based ablation|specific electrophysiological and mapping techniques of activation and entrainment mapping during ongoing VT. Substrate mapping and ablation (substrate modification.) catheter ablation - a medical procedure used to treat some types of arrhythmia
1689351|NCT01546194|Other|Phone call explaining the research project|A phone call on the day before surgery will be provided to subjects explaining the nature of the clinical trial
1689353|NCT01546155|Radiation|PET imaging|Up to a 120 minute PET scan using [11C]diprenorphine as the radiotracer
1689354|NCT01546142|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
1689355|NCT01546142|Drug|Placebo|Phosphate buffered saline placebo for injection
1689356|NCT01546129|Device|Dianatal Obstetric Gel (Cross-linked polyacrylic acid)|Dianatal (approx. 30 mL in total) will be intermittently administered to the birth canal after vaginal examination in labor using the Dianatal applicator or the syringe or the fingers. Dianatal Stage I is used during labor stage I, Dianatal Stage 2 is used during stage 2. After rupture of the membranes supplementary Dianatal is applied within 5 to 20 minutes.
1689357|NCT01546116|Drug|ADEFOVIR, LAMIVUDINE|Adefovir/10mg tablet/once a day/52week Lamivudine/100mg tablet/once a day/52week
1689358|NCT01546103|Dietary Supplement|Cholecalciferol|1000 IU by mouth, once daily for 3 months.
1689359|NCT01546103|Dietary Supplement|Cholecalciferol|5000 IU by mouth, once daily for 3 months.
1689360|NCT01546090|Drug|Alprazolam|preoperative administration of an orally 0.50 mg single dose
1689361|NCT01546090|Drug|placebo|placebo capsules were filled with starch
1689362|NCT01546077|Procedure|Placement of perineural catheters with Hydrolocalization technique using|Placement of perineural catheters in the popliteal region comparing two techniques. while the drugs used are the same (ropivacaine 0.6% for initial bolus and 0.2% for continuous technique) we will compare dosage required in each group
1689363|NCT01546064|Device|Choledocho-choledochostomy with T-tube|In the anastomosis between the common bile duct of the graft and the common bile duct of the recipient, a tutorial T-tube is inserted in the bile duct lumen and will be removed from the patient on third month postoperatively.
1689364|NCT01546064|Device|Choledocho-choledochostomy without T-tube|The termino-terminal anastomosis between common bile duct of the graft and common bile duct of the recipient is performed without any T-tube.
1689365|NCT01546051|Drug|BCI-838|BCI-838 100 mg and 300 mg or matching placebo administered as single oral doses under fasted conditions in a sequential design
1689366|NCT01546051|Drug|BCI-838|BCI-838 administered as a single 30 mg oral dose or matching placebo under fasted and fed conditions in a crossover design
1689367|NCT01546051|Drug|BCI-1038, BCI-1206 & BCI-1283|Three new pro-drugs administered as a 1 mg single oral doses under fasted conditions in a sequential design
1689368|NCT01546051|Drug|BCI-838|BCI-838 900 mg or matching placebo administered as a single oral dose under fasted conditions
1689369|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28-days.
1689370|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
1689371|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days.
1689372|NCT01546038|Drug|Decitabine|Decitabine given at 20 mg/m2 over 1 hour infusion for 5-days
1689373|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
1689374|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
1689375|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
1689376|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days
1689377|NCT01546038|Drug|Daunorubicin|Daunorubicin given using 60 mg/m2 for 3-days
1689378|NCT01546038|Drug|Cytarabine|Cytarabine 100 mg/m2 on days 1 through 7
1689379|NCT01546038|Drug|PF-04449913|PF-04449913 administered orally and continuously for 28 days (if randomized to receive PF-04449913)
1689380|NCT01546038|Drug|Low dose ARA-C (LDAC)|Low dose ARA-C (LDAC) administered at 20 mg SQ, BID on Days 1 through 10.
1689381|NCT01546025|Behavioral|Brief Motivational Counseling|One hour session of brief motivational counseling focused on reduction of heavy drinking.
1689382|NCT01546025|Behavioral|Relaxation training|One hour training in relaxation techniques
1689383|NCT01546012|Device|HYABAK®|Hyaluronic Acid eye drops CE marked, packaged in multidose ABAK® container (preservative free)
1689384|NCT01546012|Device|HYLO-COMOD®|Hyaluronic Acid eye drops CE marked, packaged in multidose COMOD® container (preservative free)
1689385|NCT01545999|Other|Brain Stimulation via Transcranial Magnetic Stimulation|"PAS-25 will consist of 180 PNS delivered to right median nerve, each paired with a single TMS pulse delivered over left DLPFC with an interstimulus interval of 25 ms. This ISI was designed to generate approximately synchronous arrival of both inputs in M1 and was reported to markedly enhance TMS-induced MEP following PAS-25.
Patients with schizophrenia will be asked to continue with a 2-week course (5 days/week) of daily PAS-25 or PAS-100 to assess potential of a repetitive course of PAS-25 on enhancing working memory in patients with Schizophrenia. One and seven days after the 2-week course PAS-25 or PAS-100, patients with schizophrenia will be assessed with the N-back task."
1689386|NCT01545986|Behavioral|Exercise|Participants attended standardized exercise (ex) sessions twice a week for six weeks for 12 sessions. Group speed differed for concentric contractions, sit to stand ex, walking, curbs, and stairs. The low velocity ex group performed a concentric contraction in two seconds, and high velocity group in one second or less. End range concentric hold, eccentric contraction, repetition (rep) rest and set rest were the same. Open chain ex was performed at 50% of one Repetition Maximum (RM) x 10 reps x one set and then 80% of 1RM x 10 reps x two sets. Curb height and 1RM was assessed at the first, fifth and ninth sessions. Manual stretching, balance ex, sit to stand support, level of aerobic ex, gait training, and functional training were assessed and progressed at any session.
1689387|NCT01545973|Other|Skin Moistening, Skin Denuding|Application of normal saline to skin and Tape stripping of the superficial skin
1689388|NCT01545960|Other|not applicable in this study|No actual interventions will be administered for this study.
1689463|NCT01545076|Biological|Placebo|2% human albumin administered by weekly SC infusions during the SC treatment period of the study.
1689389|NCT01545947|Drug|CC-223, erlotinib|"Dose escalation: Combination doses start with 15 mg CC-223 and 100 mg erlotinib, or 15 mg CC-223 and 150 mg erlotinib, administered in 28-day cycles. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.
Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
1689390|NCT01545947|Drug|CC-223, oral azacitidine|"Dose escalation: Combination doses start with 15 mg CC-223 and 200 mg oral azacitidine, administered in 28-day cycle. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.
Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
1689391|NCT01545947|Drug|CC-223, oral azacitidine|"Dose escalation: Sequential dosing starts with 200 mg of oral azacitidine administered on Days 1 through 7 of each 28-day cycle, followed by daily dose level of 15 mg CC-223 on Days 8 through 28. Combination dose levels increase sequentially using predefined regimens until non-tolerated dose levels are established and a maximum tolerated dose combination has been identified for further study.
Dose expansion: The maximum tolerated doses are evaluated further for evidence of preliminary efficacy"
1689392|NCT01545934|Behavioral|Lifestyle intervention|The intervention is a multicomponent program designed to prevent excessive gestational weight gain in obese women through modifications of diet, exercise, and behavioral strategies during pregnancy.
1689393|NCT01545921|Other|Quality Of Life questionnaires completion|"Before randomization, all patients will have to complete questionnaires in this order : QLQ-C15-PAL, MVQOLI and QUAL-E.
MVQOLI and QUAL-E will be completed again 3 days after the first completion at baseline. After this second QoL assessment, the order will be modified according to patient's randomisation : arm A, B, C or D."
1689394|NCT01545908|Other|Fecal transplant|Participants in this arm undergo 6 retention enemas,using stool specimen prepared from a healthy, screened unrelated donor.
1689395|NCT01545908|Other|Placebo enema|Patients will receive placebo enema, week 1, week 2, week 3, week 4, week 5, week 6
1689396|NCT01545882|Drug|Degarelix|Treatment will consist of a starting dose of 240mg injected subcutaneously (s.c) and monthly s.c. maintenance doses of 80mg for a total duration of 6 months.
1689397|NCT01545869|Procedure|Fractional carbon dioxide laser|SmartXide fractional carbon dioxide laser (DEKA, Florence, Italy). Parameters adjusted for: Power 20 watts, spacing 200 µsec, dwell time 300 µm, stacks 1.
1689398|NCT01545856|Drug|levodopa|levodopa use
1689399|NCT01545843|Behavioral|Sleep scheduling|8 hours vs. 6 hours time in bed for two weeks, with either 2 hour advance of risetime, or 2 hour delay of bedtime
1689400|NCT01545843|Drug|Fluoxetine|20-40 mg fluoxetine daily for 8 weeks
1689401|NCT01545830|Dietary Supplement|vitamin D3 (cholecalciferol)|Active intervention: 6,000 IUs taken by mouth daily for 6 months Active Comparator: 600 IUs taken by mouth daily for 6 months
1689402|NCT01545817|Drug|Pazopanib followed by everolimus|all patients will receive Pazopanib (800 mg once daily orally continuous dosing) until disease progression then second line everolimus (10 mg once daily orally continuous dosing)
1689403|NCT01545804|Drug|Lenalidomide|All enrolled patients will receive Lenalidomide, 25 mg orally daily, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
1689404|NCT01545791|Drug|insulin detemir|Administered once or twice daily depending on patients' needs. Dose adjusted for each patient at the discretion of their treating physician
1689405|NCT01545778|Drug|Tapentadol IR|Opioid naive patients exposed to tapentadol IR from July 2009 to December 2010.
1689406|NCT01545778|Drug|Oxycodone IR|Opioid naive patients exposed to Oxycodone IR from July 2009 to December 2010.
1689407|NCT01545765|Drug|Lidocaine 7% + Tetracaine 7% cream|Study drug will be applied with a different application time to one side of the face and anterior thigh according to the randomization list.
1689408|NCT01545752|Other|teaching by non-interactive CD|teaching book with non-interactive CD
1689409|NCT01545752|Other|Interactive CD|Teaching book with interactive CD
1689410|NCT01545739|Device|Evia/Entovis HF-T pacemaker for CRT therapy|Implantation of CRT pacemaker and standard follow-ups at pre-hospital discharge, and after 1, 3 and 6 months
1689411|NCT01545726|Drug|QAW039|QAW039 was supplied as capsules for oral administration.
1689412|NCT01545726|Drug|Placebo|Placebo was supplied as capsules for oral administration.
1689413|NCT01545700|Drug|Control-saline|Patients are randomized to receive saline 2 cc
1689414|NCT01545700|Drug|Dexamethasone 4 mg|Patients randomized to receive dexamethasone 4mg and 1 cc saline
1689415|NCT01545700|Drug|Dexamethasone 8 mg|Patients randomized to receive dexamethasone 8mg
1689416|NCT01545700|Drug|Control saline|Patients are randomized to receive saline 2 cc
1689417|NCT01545700|Drug|Dexamethasone 4 mg|Patients are randomized to receive dexamethasone 4 mg and saline 1 cc
1689418|NCT01545700|Drug|Dexamethasone 8 mg|Patients are randomized to receive dexamethasone 8 mg
1689419|NCT01545687|Dietary Supplement|Lactobacillus brevis CD2 lozenge|Dissolved orally
1689420|NCT01545687|Other|placebo|Dissolved orally
1689421|NCT01545674|Procedure|Blood Draw|Blood will be drawn from the mother and father
1689422|NCT01545661|Procedure|Sputum induction|Ultrasonic nebulisation 3% hypertonic saline nebulised for duration of 20 mins
1689423|NCT01545661|Procedure|standard routine expectorated sputum|Patients in the control group are trained by the research staff to produce sputum but no device is utilized. Sputum is spontaneously expectorated where possible
1689424|NCT01545648|Drug|Denosumab|"Formulation of Dosage forms
The vial presentations of denosumab contain 60 mg/mL denosumab, 17 mM sodium acetate, and 4.7% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL; or 70 mg/mL denosumab, 18 mM sodium acetate and 4.6% (w/v) sorbitol, at a pH of 5.2, filled to a target deliverable volume of 1.7 mL. The prefilled syringe (PFS) drug product contains denosumab at 60 mg/mL, 17 mM sodium acetate, 4.7% (w/v) sorbitol, and 0.01% (w/v) polysorbate 20, at a pH of 5.2, filled to a target deliverable volume of 1.0 mL.
Dosage: 120 mg, monthly for total of 6 months, then every 12 weeks for 2 doses, for a total treatment course of one year
Route of administration: subcutaneous injection"
1689510|NCT01544829|Dietary Supplement|Theobromine|Multiple doses of theobromine
1689511|NCT01544829|Dietary Supplement|Placebo|Placebo capsules
1689425|NCT01545635|Drug|Fibrinogen concentrate, Prothrombin complex concentrate and FXIII concentrate|"Fibrinogen concentrate Dose: 50 mg/kg BW fibrinogen concentrate if FIBTEM A10<7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single vial (1g) over 5 min
Prothrombin complex concentrate Dose: 20IE/kg BW PCC if EXTEM CT >90sec and FIBTEM A10>7mm Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min
FXIII concentrate Dose: 20 IU/kg BW Fibrogammin® P will be administered with the second dose of fibrinogen concentrate (=100 mg/kg) and if FXIII decreases below 60% as detected by laboratory measurements.
Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single dose over 10 min"
1689426|NCT01545635|Drug|Fresh Frozen Plasma blood type 0, A, B and AB|Fresh Frozen Plasma Dose: 15ml/kg BW if FibTEM A10 <7mm and/or ExTEM CT>90sec. Kind of application: Intravenously Frequency and rate of administration: Single-dose or repeated, each single U (200mL) over 5 min
1689427|NCT01545609|Other|Text messaging|Text messages to cell phone with education messages about the specific birth control they are using
1689428|NCT01545596|Behavioral|Notification Group|Anesthesia team receives notification when a double low condition exists. The anesthesia team makes a decision to intervene or not.
1689433|NCT01545570|Drug|GSK2376497|GSK2376497 Active Comparator
1689434|NCT01545570|Drug|0.9% sodium chloride|0.9% sodium chloride Placebo Comparator
1689435|NCT01545557|Device|Hyaluronic acid dermal filler gel|1 injection per indication and 1 touch-up injection if necessary
1689436|NCT01545531|Drug|Iohexol|Iohexol, a non-ionic, low osmolar, X-ray contrast medium (OmnipaqueR) that is safe and non-toxic and used for angiographic and urographic procedures, is eliminated from plasma exclusively by glomerular filtration [13]. Study subject will receive 5 ml of iohexol solution (Omnipaque 300, corresponding to 647 mg iohexol per ml or 300 mg iodine per ml) through peripheral IV or central Line infusion over 1-2 minutes followed by 10 ml of saline solution at baseline, day 100 and 1 year after HCT.
1689437|NCT01545518|Drug|IVIG|IVIG 2 mg/kg in two divided doses with placebo crossover
1689438|NCT01545505|Behavioral|Neuropsychological assessment|"A clinical evaluation with Impact of Events Scale-Revised, Child Post-Traumatic Stress Reaction Index, State-Trait Anxiety Inventory for Children, Children Depression Inventory and Emotion, activity and sociability.
A neuropsychological assessment with a emotional Go-No/Go, a visual search task, the Trail Making Test, 3 items of the WISC III ( and the Grober and Buschke Test."
1689439|NCT01545336|Drug|Anastrozole|1 mg tablet to be taken 1 time daily
1689440|NCT01545336|Drug|Placebo|1 mg tablet to be taken 1 time daily
1689441|NCT01545323|Genetic|One 20cm2/10cm2 autologous skin sheet graft|Adults will receive a graft of approximately 20cm2. Children under 16 years of age will receive a graft around half this size, around 10cm2 .The graft is derived from SPINK5 transduced cells
1689442|NCT01545310|Drug|SLV354|One dose of ABT-354
1689443|NCT01545297|Drug|Dexmedetomidine|The infusion begins at dexmedetomidine 0.3-0.4 mcg/kg/hr for 15 min, and then titrated down to 0.1-0.2 mcg/kg/hr.
1689444|NCT01545297|Drug|Propofol|The infusion begins at propofol 25-250 mcg/kg/min for 15 min, and then titrated to effect.
1689445|NCT01545297|Drug|Remifentanil|The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
1689446|NCT01545284|Drug|Acitretin|All patients will receive open-label single oral acitretin 10 mg capsule once daily as a starting dose. If well tolerated, the dose will be increased in the first 4 weeks to a maximum of 30mg/day. Patients will be instructed to take the treatment as a single oral dose with a meal.
1689447|NCT01545271|Drug|xenon gas|Inhalation via endotracheal tube of 50% xenon for 18 hours
1689448|NCT01545271|Device|Whole body cooling|Cooling of baby to reduce rectal temperature to 33.5 degree Centigrade(standard treatment)
1689449|NCT01545258|Other|Exercise|Physiotherapy supervised exercise training. 60 minutes 3 times per week
1689450|NCT01545232|Biological|1:1:1 Blood Transfusion Ratio|Group 1 will be randomized to receive the 1:1:1 ratio of plasma:platelets:RBC. Blood bank will prepare the initial container containing 6 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC; the blood bank will send the initial and all subsequent containers until notified of the discontinuation of the PROPPR transfusion protocol.
1689451|NCT01545232|Biological|1:1:2 Blood Transfusion Ratio|Group 2 will be randomized to receive the 1:1:2 ratio of plasma:platelets:RBC. The blood bank will prepare the initial container containing 3 units plasma, 0 units platelets and 6 units RBC, a second container containing 3 units plasma, 1 unit platelets (a pool of 6 units on average) and 6 units RBC, and the blood bank will send this sequence of 2 containers repeatedly, until notified of the discontinuation of the PROPPR transfusion protocol.
1689452|NCT01545219|Dietary Supplement|Prebiotic|8g/day xylo-oligosaccharide
1689453|NCT01545219|Dietary Supplement|Bi-07|10^9 CFU B. lactis / day
1689454|NCT01545219|Dietary Supplement|Synbiotic|8g/day xylo-oligosaccharide + 10^9 CFU Bi-07
1689455|NCT01545219|Dietary Supplement|Placebo|8g/day maltodextrin
1689456|NCT01545193|Other|Age and incidence of residual neuromuscular blockade|An older cohort is anticipated to have a higher incidence of residual neuromuscular blockade
1689457|NCT01545167|Genetic|blood sampling|blood samples obtained to extract biomarkers and dna for analysis, questionnaires
1689458|NCT01545154|Device|Transperineal Ultrasound|
1689459|NCT01545141|Drug|Chemokine modulatory regimen|Celecoxib: 200 mg twice/day M-F of the week prior to scheduled surgery rintatolimod: 200 mg i.v. administration M-F of the week prior to scheduled surgery IFN: i.v. administration, M-F of the week prior to scheduled surgery. Dose escalation evaluating 5, 10, and 20 MU/m2.
1689460|NCT01545089|Other|Mattress protector for days 1 and 2|A mattress protector is placed in the bed for the first two days and then removed for days 3 and 4.
1689461|NCT01545089|Other|Mattress protector for days 3 and 4|A mattress protector is not placed in the bed for the first two days and then added to the bed for days 3 and 4.
1689462|NCT01545076|Biological|IgPro20 (low dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:
0.2 g/kg body weight (low dose arm)"
1689464|NCT01545076|Biological|IgPro10|10% Immunoglobulin G (IgG) liquid formulation of human normal immunoglobulin (Privigen®) administered intravenously during Restabilization Period of the study and/or as Rescue Therapy during SC Treatment Period for subjects with a CIDP relapse.
1689465|NCT01545076|Biological|IgPro20 (high dose)|"20% liquid formulation (200 mg/mL) of human normal immunoglobulin for subcutaneous use administered weekly during the SC treatment period of the study according to the randomization:
0.4 g/kg body weight (high dose arm)"
1689466|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Intravenous (IV), 0 mg, Day One Only, One Day
1689467|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, 8 weeks
1689468|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Week 4 Only, One Day
1689469|NCT01545050|Biological|Placebo matching with BMS-945429|Injection, Subcutaneous (SC), 0 mg, Every 4 weeks, Up to 48 weeks
1689470|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 600 mg, Day One Only, One Day
1689471|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Week 8 only, One Day
1689472|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 300 mg, Day One Only, One Day
1689473|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Week 8 Only, One Day
1689474|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 400 mg, Day One and Week 4, 4 weeks
1689475|NCT01545050|Biological|BMS-945429|Injection, Intravenous (IV), 150 mg, Day One Only, One Day
1689476|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 100 mg, Every 4 weeks, Up to 48 weeks
1689477|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 48 weeks
1689478|NCT01545050|Biological|BMS-945429|Injection, Subcutaneous (SC), 200 mg, Every 4 weeks, Up to 96 weeks, depending on when subject enters this period
1689479|NCT01545037|Dietary Supplement|L. acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2®|Each capsule contains 50 billion cfu live of Lactobacillus acidophilus CL1285® + L. casei LBC80R® + L. rhamnosus CLR2® bacterias. The randomized subjects will consume 2 capsules per day at breakfast.
1689480|NCT01545037|Other|Placebo|The placebo capsules are identical in shape, taste, and smell yet are devoid of live bacteria.
1689481|NCT01545024|Drug|Sitagliptin, 50 mg once per day per os|Before and one year after treatment with DPP-IV inhibitor in diabetic patients with AND.
1689482|NCT01545011|Other|Inspiratory muscle training|Inspiratory muscle training
1689483|NCT01544998|Drug|Nesiritide|10 ug/kg
1689484|NCT01544998|Drug|Tadalafil|5 mg
1689485|NCT01544998|Drug|Placebo|The pharmacy will create a placebo subcutaneous injection volume to match the volume of Nesiritide dose.
1689486|NCT01544998|Drug|Saline load|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
1689487|NCT01544985|Drug|88% sucrose po solution|88% sucrose solution (Syrup B.P.)
1689488|NCT01544985|Drug|placebo po|sterile water
1689489|NCT01544972|Drug|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours.
1689490|NCT01544972|Drug|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
1689491|NCT01544959|Drug|fentanyl|Use of esmolol and metoprolol compared to use of fentanyl for hemodynamic control during general anesthesia. At induction, fentanyl (2 mcg/kg) is replaced by esmolol (1 mg/kg). During the case, with a standardised anesthesia, response to surgical stimulation will be medicated either by fentanyl (50 mcg aliquot) or metropolol (2.5 mg), for a maximum of 6 doses. After this, fentanyl will be given unblindly.
1689492|NCT01544959|Drug|beta-blocker (esmolol, metropolol)|esmolol is used at induction and lopressor during surgery instead of fentanyl in response to surgical stimulation.
1689493|NCT01544946|Drug|88% sucrose po|88% sucrose solution (Syrup B.P.)
1689494|NCT01544946|Drug|placebo po|sterile water
1689495|NCT01544920|Biological|peg-Interferon alfa-2a|peg-IFN (180 ug) was taken once weekly via subcutaneous injection.
1689496|NCT01544920|Drug|Ribavirin|RBV 200 mg tablets taken by mouth at a total daily dose of 1,000 mg (body weight <75 kilograms [kg]) or 1,200 mg (body weight ≥75 kg) with total daily dose divided into 2 dosings.
1689497|NCT01544920|Drug|Boceprevir|Four 200 mg BOC capsules taken three times a day by mouth for a total daily dose of 2,400 mg.
1689498|NCT01544907|Device|Conventional PTA|Use of conventional balloon for angioplasty only
1689499|NCT01544907|Device|Drug Eluting Balloon (DEB)|Use of DEB after conventional balloon angioplasty
1689500|NCT01544894|Drug|Raloxifene|60 mg/d for one year
1689501|NCT01544894|Drug|Strontium ranelate|2 g/d, for one year
1689502|NCT01544881|Drug|Technosphere Insulin Inhalation Powder|Inhalation Powder using the Gen2C inhaler
1689503|NCT01544881|Drug|Rapid Acting Analog|Subcutaneous Injection
1689504|NCT01544868|Other|Use of Stable Isotope to Measure Energy Expenditure and Protein Turnover|Two pre-dose urine specimens will be collected prior to an oral dose containing 0.22 g/kg total body water of 100% 18O water (or 1.2 g/kg per body weight of 10% 18O water) and 0.11 g/kg per body weight of 99.9% deuterium oxide. Then the patient will receive a single dose (4mg/kg, less than 2% of normal daily intake of 1.1g per person) of 15N glycine tracer. For this, patients will drink a dose of 15N glycine (4mg.kg 1dissolved in 20 ml of saline) mixed in 50 cc of apple juice or other liquid beverage, followed by a 50 cc wash of water. 24 hour urine collection will commence immediately. Twenty-four hour urines will be used for determining the 15N NH3 and 15N urea enrichment. Each urine container will contain 5 ml of 15N HCl for trapping the urinary ammonium. Urine will be collected each day for 3 days, for determination of the total urinary nitrogen, urea creatinine, and ammonia excretion.
1689505|NCT01544855|Dietary Supplement|omega-3 fatty acids|Participants will take 700 mg/d of EPA and 500 mg/d of DHA as ethyl esters for one month (Ocean Nutrition, Dartmouth, NS) which is about 10 times the current estimated intake of young adults (21). This corresponds to one capsule with breakfast and one capsule with diner.
1689506|NCT01544842|Drug|0.1 % tacrolimus ointment|applied topically to oral mucosa
1689507|NCT01544842|Drug|0.1 % triamcinolone paste|applied topically to oral mucosa
1689508|NCT01544842|Drug|Orabase paste|applied topically to oral mucosa
1689509|NCT01544829|Dietary Supplement|Theobromine|Single dose of theobromine
1689512|NCT01544816|Other|Snack Product|control food product
1689513|NCT01544816|Other|Snack Product|Experimental food product containing ingredient 1
1689514|NCT01544816|Other|Snack Product|Experimental food product containing ingredient 2
1689515|NCT01544803|Behavioral|eScreen|The eScreen brief Internet intervention for problematic alcohol and drug use offers self-screening, in-depth self-reporting, personalized feedback and treatment recommendations as well as an electronic diary. Progress over time is shown in diagrams detailing consumption levels.
1689516|NCT01544803|Behavioral|Alkoholhjalpen|An extensive Internet intervention for problematic alcohol use, Alkoholhjalpen,provides CBT- and MI-based psycho-education with a solution-oriented focus, electronic diary and moderated chat-forum.
1689517|NCT01544790|Procedure|Esophagectomy|In this monocenter prospective randomized controlled trial, we compare robot-assisted minimally invasive esophagectomy with conventional open transthoracic esophagectomy.
1689518|NCT01544777|Device|Study IOL|Aspheric IOL for correction of aphakia
1689519|NCT01544777|Device|Hoya iSert 751|Model 751 in one eye, standard IOL in other eye
1689520|NCT01544777|Device|Negatively aspheric IOL|Negatively aspheric IOL in both eyes
1689521|NCT01544764|Other|Assessment , Feedback, Incentives, and eXchange Program|The NC Immunization Branch uses Adolescent AFIX (Assessment, Feedback, Incentives and eXchange) Program, a quality improvement strategy developed by the CDC to improve the immunization practices and vaccination coverage levels of public and private health care providers. It has four main components: 1) Assessment of a provider's current immunization practices and vaccination levels, 2) Feedback of the assessment results and strategies to improve coverage levels, 3) Incentives to improve coverage levels, and 4) eXchange of information and resources necessary to facilitate improvement.
1689522|NCT01544751|Drug|Low dose metformin|500 mg twice a day
1689523|NCT01544751|Drug|Metformin|1000 mg twice a day
1689524|NCT01544751|Drug|Atorvastatin|20 mg/day
1689525|NCT01544738|Other|Aponeurotic stimulation (the diacutaneous fibrolysis method)|Treatment consisted of manipulating, with a hook, the aponeurotic tissues enrobing the heads of the upper-limb muscles. The manipulation consisted of back and forth mobilization, applied perpendicularly to the axis of the muscular fibers. The mobilization is performed with both hands; the therapist's non-dominant hand performs a manual mobilization whereas the dominant hand follows the movement with the hook. The hook allows the therapist to be very precise about the location of the tissues that are stretched. This stretch is realized at the level of the aponeurotic fibers presenting the greatest resistance to perpendicular movement. The shape of the hook is chosen to avoid discomfort or pain during manipulation. To spread the pressure exerted by the spatula on a very local point, it is important to fill completely the curved part of the hook with the adjacent soft tissues. We manipulated muscle from the proximal insertion towards the distal, giving special attention to the tendons.
1689526|NCT01544738|Other|Placebo stimulation|Placebo stimulation (PS) consisted of manipulating the skin along the same paths over the trunk, shoulder and arm muscles that were the targets for treatment in the AS group
1689527|NCT01544725|Drug|Procedural sedation with ketamine-propofol combination|"K= Kétamine P= Propofol RSS= Ramsay Sedation Score
At t0: 0.5 mg/kg of K (0.1 ml/kg of 5 mg/ml K) followed by 0.5 mg/k of P (0.1 ml/kg of 5 mg/ml P).
At t0 + 4 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).
At t0 + 8 min, if needed to obtain an optimal sedation (RSS of 4 or 5): 0.25 mg/kg of K (0.05 ml/kg of 5 mg/ml K) followed by 0.25 mg/kg of P (0.05 ml/kg of 5 mg/ml P).
At t0 + 12 min, if maximal doses have been reached (1 mg/kg of K + 1 mg/kg of P) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
1689528|NCT01544725|Drug|Procedural sedation with ketamine alone|"K= Ketamine I= Intralipid placebo
At t0: 1 mg/kg of K (0.1 ml/kg of 10 mg/ml K), followed by 0.1 ml/kg of I (physical placebo of propofol in the other arm).
At t0 + 4 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.
At t0 + 8 min, if needed to obtain an optimal sedation (Ramsay Sedation Score of 4 or 5): 0.5 mg/kg of K (0.05 ml/kg of 10 mg/ml K), followed by 0.05 ml/kg of I.
At t0 + 12 min, if maximal doses have been used (2 mg/kg of K) but the optimal sedation has not been obtained, the procedural sedation will be recorded as a failure in the analysis, and the patient will receive another procedural sedation product (at the discretion of the caregiver)."
1689529|NCT01544712|Procedure|core decompression with autologous bone marrow implantation|core biopsy with injection of 40 ml concentrated autologous bone marrow.
1689530|NCT01544712|Procedure|core decompression of the femoral head|core biopsy with injection of 40 ml saline solution in place of bone marrow.
1689531|NCT01544699|Device|tDCS (ELDITH)|tdcs (ELDITH, Neuroconn, Ilmenau, Germany) transcranial direct current stimulation
1689532|NCT01544686|Device|3M™ Tegaderm™ CHG IV and 3M™ Tegaderm™ Advanced IV|Patients receive the 3M™ Tegaderm CHG IV securement dressing or the 3M Tegaderm Advanced IV securement dressing after placement of a central venous catheter.
1689533|NCT01544673|Drug|linezolid|600 mg oral tablet twice daily for 4.5 days
1689534|NCT01544673|Drug|Placebo|500 mg oral placebo twice daily for 4.5 days
1689535|NCT01544647|Other|Usual spa protocol|In the first group, 4 treatments (massages, showers, mud and pool sessions) are provided 6 days a week during 3 weeks.
1689536|NCT01544647|Other|Active spa protocol|4 treatments (massages, showers, mud and pool sessions) are provided 3 days a week during 3 weeks then patients will follow an exercise program 3 days a week during 3 week.
1689537|NCT01544634|Drug|Propranolol|Propranolol: 10mg bd for 1 week, 20mg bd for 2 weeks, 80mg MR for 4 weeks.
1689538|NCT01544634|Drug|Placebo|Placebo tablets: 1 tab bd for 2 weeks, 1 tab od for 4 weeks
1689539|NCT01544634|Drug|Qvar 50|Qvar 50, 1 puff bd for 6 weeks
1689540|NCT01544634|Drug|Qvar 100|Qvar 100, 2 puffs bd for 6 weeks
1689541|NCT01544621|Other|Smoking cessation|Smoking cessation
1689578|NCT01544348|Biological|MEDI4212 5 mg Subcutaneous|A single dose of MEDI4212 5 mg injection subcutaneously on Day 1.
1689579|NCT01544348|Biological|MEDI4212 15 mg Subcutaneous|A single dose of MEDI4212 15 mg injection subcutaneously on Day 1.
1689580|NCT01544348|Biological|MEDI4212 60 mg Subcutaneous|A single dose of MEDI4212 60 mg injection subcutaneously on Day 1.
1689581|NCT01544348|Biological|MEDI4212 150 mg Subcutaneous|A single dose of MEDI4212 150 mg injection subcutaneously on Day 1.
1689542|NCT01544595|Drug|Secukinumab (AIN457)|"Secukinumab is a new type of psoriasis medication called a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17). IL-17 is believed to be partly responsible for inflammation (pain, swelling, redness). Researchers believe that IL-17 causes symptoms of plaque-type psoriasis like plaques and scales. A product that targets IL-17 therefore may help to relieve these symptoms and conditions."
1689543|NCT01544595|Drug|Placebo|Placebo
1689544|NCT01544569|Genetic|DNA analysis|
1689545|NCT01544569|Genetic|fluorescence in situ hybridization|
1689546|NCT01544569|Genetic|gene expression analysis|
1689547|NCT01544569|Genetic|gene mapping|
1689548|NCT01544569|Genetic|microarray analysis|
1689549|NCT01544569|Genetic|polymerase chain reaction|
1689550|NCT01544569|Genetic|protein expression analysis|
1689551|NCT01544569|Other|laboratory biomarker analysis|
1689552|NCT01544569|Other|medical chart review|
1689553|NCT01544530|Other|Cold isotonic fluid and central venous hypothermia catheter|20-30ml/kg of isotonic crystalloid resuscitation fluid will be used for induction. Hypothermia (32-33 degrees C) will be sustained until organ procurement using an FDA approved central venous catheter connected to an external temperature regulating system
1689554|NCT01544517|Drug|Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)|amoxicillin tablets 1 g; esomeprazole tablets 40mg; tinidazole tablets 500mg; levofloxacin tablets 500 mg
1689555|NCT01544504|Drug|Norepinephrine|Approximately 4.65 mL of a norepinephrine solution (400 mM, 82.3 mg/mL) will be applied topically to the study drug application site prior to each radiotherapy treatment (approximately 25-28 treatments).
1689556|NCT01544491|Drug|RAD001|Everolimus (C0 trough level of 3-8 ng/mL) in combination with reduced dose tacrolimus and steroids withdrawal at 6 months after transplant
1689557|NCT01544491|Drug|MMF|MMF (Cellcept®): 600mg/m2/dose twice daily (1200 mg/m2/day) in combination with tacrolimus (Prograf) and standard dose steroids
1689558|NCT01544478|Biological|V501|HPV types 6, 11, 16, and 18 vaccine 0.5 mL by intramuscular injection at Day 1, Month 2, and Month 6
1689559|NCT01544465|Behavioral|Structured Physical Activity|Rehabilitation evaluation and 8 weeks of physical therapy
1689560|NCT01544465|Behavioral|Sleep hygiene education|Educational materials on insomnia published by the American Academy of Sleep medicine
1689561|NCT01544452|Procedure|MR colonography and MR of the liver|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
1689562|NCT01544452|Procedure|Standard diagnostic evaluation|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
1689563|NCT01544439|Procedure|stabilizing appliance|The reversible occlusal therapy be made by the same dental technician and will be adjusted by the same dentist, therapist represented by the researcher. Will be played simultaneous occlusal contacts in centric relation position and malocclusion by canine and protrusive guides. The patients will be assessed at weekly intervals (between the query and the following board installation) and then biweekly during the period of 90 days. There shall be a gradual reduction in the daily use of the plate, and the first two weeks the device is indicated for 24 hours a day, being removed only for eating and cleaning. At each visit clinical follow-up, shall be established a gradual reduction in the time of use so that the last three weeks of treatment are achieved 8h/day use.
1689564|NCT01544439|Procedure|Non-occluding splint, counseling|The non-occlusive splint (placebo) will also be made by the same dental technician. They did not interfere with the occlusal tooth gear, ie, do not alter the position of closing jaws. They are adjusted based on the verification of the occlusion, so that the card does not interfere with movements or maximum intercuspation excursive lateral and protrusion, so that only the patient's teeth come into contact, without interference from the resin and the acrylic staple . The assessment of these patients occur at the same intervals recommended for patients in the experimental group being established on the same treatment protocol with respect to the daily use of the splint.
1689565|NCT01544426|Procedure|Office hysteroscopy and endometrial snip|Office hysteroscopy with endometrial snip
1689566|NCT01544426|Procedure|Office hysteroscopy|Office hysteroscopy
1689567|NCT01544413|Procedure|Laparoscopic sentinel lymph node biopsy|During the operation, endoscopic marking was perfomed using Tc 99m HSA and indocyanine green around tumor. Then we identify the sentinel lymph node with laparoscopic probe. Laparoscopic sentinel lymph nodes were dissedted and evaluated them at the backtable in the operating room.
1689568|NCT01544387|Other|Bed Rest|"Subjects are admitted to their labor and delivery room and will spend the majority of their day in their hospital bed, usually in a reclined or sleeping position
Subjects will be instructed to refrain from walking or engaging in any extraneous activity, including lifting or spending any extended period of time out of bed
Subjects may have limited bathroom privileges"
1689569|NCT01544387|Other|Activity|"Subjects are admitted to their labor and delivery room and will spend the majority of their time in their hospital bed
Subjects will be given the opportunity of 3 periods of walking around their room and/or the hall on labor and delivery each day, each period consisting of approximately 20 minutes - this is the minimum activity level required for the study. Subjects are permitted more activity as desired."
1689570|NCT01544374|Other|Tracking & Feedback|Systems based intervention tracking oncology consultations and feeding back information to surgeons
1689571|NCT01544361|Other|Placebo|A single dose of placebo matched to MEDI7814 intravenous infusion over at least 60 minutes on Day 1.
1689572|NCT01544361|Biological|MEDI7814, 1 MG/KG|A single dose of MEDI7814, 1 mg/kg intravenous infusion over at least 60 minutes on Day 1.
1689573|NCT01544361|Biological|MEDI7814, 3 MG/KG|A single dose of MEDI7814, 3 mg/kg intravenous infusion over at least 60 minutes on Day 1.
1689574|NCT01544361|Biological|MEDI7814, 10 MG/KG|A single dose of MEDI7814, 10 mg/kg intravenous infusion over at least 60 minutes on Day 1.
1689575|NCT01544361|Biological|MEDI7814, 20 MG/KG|A single dose of MEDI7814, 20 mg/kg intravenous infusion over at least 60 minutes on Day 1.
1689576|NCT01544348|Other|Placebo|A single dose of placebo matched to MEDI4212 subcutaneous injection or intravenous infusion on Day 1.
1689577|NCT01544348|Biological|Omalizumab|A single flexible dose of omalizumab between 150 to 375 milligram (mg) injection based upon participant's Immunoglobulin E (IgE) levels and body weight subcutaneously on Day 1.
1689582|NCT01544348|Biological|MEDI4212 300 mg Subcutaneous|A single dose of MEDI4212 300 mg injection subcutaneously on Day 1.
1689583|NCT01544348|Biological|MEDI4212 300 mg Intravenous|A single dose of MEDI4212 300 mg intravenous infusion over 120 minutes on Day 1.
1689584|NCT01544335|Other|Bioimpedance Spectroscopy|BIS used to measure fluid in arm
1689585|NCT01544322|Drug|ME-344|"experimental drug, dose escalation with 5 planned dose cohorts of 1.2 mg/kg, 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8, and 15. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.
Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2 days each week. Cycle 1 at the highest dose level is 3 weekly IV infusions on days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
1689586|NCT01544309|Drug|Atorvastatin|"Atorvastatin 10 mg (atorvastatin 10 mg tablet x 1 or atorvastatin 5 mg tablet x 2), orally,once daily for 12 months.
(When not reach the LDL-C level of target in the Japan Atherosclerosis Society [JAS] Guidelines [GL] after 3 months, had the atorvastatin [ATV] dose of 20 mg.)"
1689587|NCT01544309|Drug|Rosuvastatin|"Rosuvastatin 5 mg (rosuvastatin 5 mg tablet x1 or rosuvastatin 2.5 mg tablet x 2), orally, once daily for 12 months.
(When not reach the LDL-C level of target in JAS GL after 3 months, had the rosuvastatin [RSV] dose of 10 mg.)"
1689588|NCT01544296|Drug|KHK6188|
1689589|NCT01544296|Drug|Placebo|
1689592|NCT01544270|Dietary Supplement|Yogurt-like snacks|twice a day 120 g for four weeks
1689593|NCT01544257|Other|osteopathic manipulative treatment|Patients from this group received osteopathic treatments twice a week for the entire length of stay in the unit.
1689594|NCT01544257|Procedure|Usual care|Patients from control group received standard care plus osteopathic evaluation only, according to the same schedule as the study group.
1689595|NCT01544244|Procedure|GSC physical therapy|Global Shoulder Concept physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
1689596|NCT01544244|Procedure|Standard physical therapy|Standard physical therapy sequence for shoulder tendonitis. The procedures used in this protocol refer to physical therapy sequences, not to devices or drugs.
1689597|NCT01544231|Biological|Plasma NGAL level|The plasmatic level of Neutrophil Gelatinase Associated Lipocalin is measured in ng/ml/
1689598|NCT01544205|Other|fMRI-based neurofeedback|5 sessions lasting one hour each
1689599|NCT01544192|Drug|Gingko Biloba|2x60 mg Gingko Biloba (Vega Natural, Konya, Turkey)
1689600|NCT01544192|Drug|α−tocopherol|2x300 mg α−tocopherol
1689601|NCT01544192|Drug|Placebo|control group did not receive oral neuroprotective agent
1689602|NCT01544192|Drug|Antioxidant formula|2x1 tablet AOF
1689607|NCT01544166|Drug|Gadobutrol (Gadavist, BAY86-4875)|Single intravenous bolus injection of gadobutrol 0.1 mmol/kg BW in term newborns to infants <2 years of age.
1689608|NCT01544153|Behavioral|WEB|Usual services available through www.BecomeAnEX.org, a publicly available, evidence-based smoking cessation website.
1689609|NCT01544153|Behavioral|Social Network|"Proactive communications from established members of the community (Integrators) designed to integrate study participants into the online social network on BecomeAnEX.org."
1689610|NCT01544153|Behavioral|Nicotine Replacement Therapy (NRT)|A free 4-week supply of nicotine replacement therapy (patch, gum, or lozenge), provided as an over-the-counter product, meaning that no additional support or guidance will be provided to parallel the experience subjects would have if they purchased NRT on their own.
1689611|NCT01544140|Drug|Midazolam|Oral syrup 7.5 mg, single dose
1689612|NCT01544140|Drug|vandetanib|Oral tablets, 800 mg, single dose
1689613|NCT01544127|Behavioral|Motivational Interviewing to Address Suicidal Ideation (MI-SI)|1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
1689614|NCT01544127|Behavioral|Motivational Interviewing to Address Suicidal Ideation (MI-SI)- Revised|1 or 2 in-person MI-SI sessions (50 mins.) on an inpatient unit, plus a telephone follow-up MI-SI session (30-50 mins)
1689615|NCT01544114|Drug|VIMOVO 250/20|250 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
1689616|NCT01544114|Drug|VIMOVO 375/20|375 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
1689617|NCT01544114|Drug|VIMOVO 500/20|500 mg naproxen/20 mg esomeprazole magnesium oral tablet administered twice daily for up to 6 months
1689618|NCT01544101|Other|Vegan Diet|Vegan diet, which is devoid of animal products and minimal in fat
1689619|NCT01544101|Dietary Supplement|dietary supplement omega3 fatty acids aand vitamins|mixture of omega3 fatty acids aand vitamins
1689620|NCT01544088|Behavioral|Group Cognitive Behavioral Treatment (GCBT)|GCBT is a 14 week intervention that includes components of exposure (imaginal and in vivo), cognitive restructuring, and relapse prevention.
1689747|NCT01543074|Dietary Supplement|Garlic Oil Placebo|1 pill = 0 mg garlic oil/day
1689621|NCT01544088|Behavioral|Present Centered Group Treatment|The active comparison treatment is a 14 week treatment that focuses on here and now problems, especially problem solving skills concerning ongoing stressors.
1689622|NCT01544075|Behavioral|Pain neurophysiology education (PNE) and psychologic inoculation (PI)|3 sessions of PNE+PI are given which include education on pain neurophysiology and applying the PI technique for which subjects are asked to refute sentences which are read by the therapist.
1689623|NCT01544075|Behavioral|Neck school (NS)|3 sessions of NS which includes advice on posture, ergonomics and on performing activities.
1689624|NCT01544062|Drug|IV acetaminophen|Total of 6 doses of 1,000 mg IV acetaminophen at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
1689625|NCT01544062|Drug|Placebo|Total of 6 doses of 100 mL of normal saline at the following time points: (1) immediately after anesthesia induction, but prior to the incision, (2) at the end of surgery with (3) four additional doses administered postoperatively in the ICU every 6 hours for the first 24 hours.
1689626|NCT01544036|Drug|perflutren|Contrast Enhanced Ultrasound is performed during continuous intravenous infusion of Definity (drug) to assess changes in renal blood flow during the study
1689627|NCT01544010|Behavioral|Stage-Tailored Manual|Manual with 5 sections for each Stage of change delivered at baseline
1689628|NCT01544010|Behavioral|Stage Tailored Feedback Report|Tailored printed feedback reports based on assessments of stages of change were delivered at baseline, 6 months and 12 months.
1689629|NCT01544010|Behavioral|Moderate TTM-Tailored Feedback Report|Tailored printed feedback report based on assessment of stages of change, Pros, Cons, and Temptations were delivered at baseline, 6 months and 12 months.
1689630|NCT01544010|Behavioral|Full TTM-Tailored Feedback Report|Tailored print feedback report based on assessment of Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
1689631|NCT01544010|Behavioral|Enhanced TTM+Addiction Tailored Feedback Report|Tailored print feedback report based on assessment of Addiction level (# cigarettes/day),Stages, Pros, Cons, Temptations, 10 Processes of Change were delivered at baseline, 6 months and 12 months.
1689632|NCT01543997|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
1689633|NCT01543997|Behavioral|Supportive Education|This intervention will provide educational lectures on disability, sleep hygiene, and current research on depression and nondirective, supportive discussions about these topics.
1689634|NCT01543984|Other|Tailored Physical Activity|Tailored Physical Activity (3*50 min/week in 10 weeks)
1689635|NCT01543984|Behavioral|Health Counselling|Health guidance (1,5h)
1689636|NCT01543971|Drug|TXA127|TXA127 : 300mcg/kg per day for 5 days, injection
1689637|NCT01543971|Drug|Neupogen (filgrastim)|Neupogen : 10mcg/kg per day for 5 days, injection
1689638|NCT01543958|Drug|Sevelamer carbonate|Patients will be administered two 800 mg tablets of Sevelamer carbonate orally three times a day for 8 weeks.
1689639|NCT01543958|Device|Sevelamer carbonate|
1689640|NCT01543945|Drug|Dexamethasone|4 mg iv before induction for high and extremely high risk
1689641|NCT01543945|Drug|Ondansetron|4 mg iv before ended surgery 30 min
1689642|NCT01543945|Drug|Dimenhydrinate|1 mg/kg iv before ended surgery 30 min
1689643|NCT01543932|Drug|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the double dose of clopidogrel and after 15 days and 30 days we will control the responsivness of the study drug.
1689644|NCT01543932|Drug|Prasugrel|Patient will be randomized to this intervention will receive in the first time prasugrel and after 15 days and 30 days we will control the responsivness of the study drug.
1689645|NCT01543932|Drug|Ticagrelor|Patient will be randomized to this intervention will receive in the first time Ticagrelor and after 14 days and 28 days we will change their therapy with the high clopidogrel dose or Prasugrel (dual crossover).
1689646|NCT01543919|Drug|PH-797804|0.25 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
1689647|NCT01543919|Drug|PH-797804|1 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
1689648|NCT01543919|Drug|PH-797804|3 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
1689649|NCT01543919|Drug|PH-797804|6 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
1689650|NCT01543919|Drug|PH-797804|10 mg oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
1689651|NCT01543919|Drug|Placebo|Placebo oral tablet plus tiotropium bromide 18 microgram once daily for 12 weeks
1689652|NCT01543906|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
1689653|NCT01543893|Behavioral|Video instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks
Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
1689654|NCT01543893|Behavioral|Personal instruction|"Participants will receive an elastic resistance tubing, an internet link and a poster with instructions to perform four different elastic resistance exercises Participants are encouraged to perform the exercises daily on weekdays during the next two weeks In addition to the video group, this group will also receive personal instruction during the two weeks.
Link to exercises: http://www.jobogkrop.dk/Ondt-i-muskler-og-led/Ondt-i-nakke-skulder-og-arm/Elastikoevelser-for-nakke-skulder-og-arm"
1689655|NCT01543880|Drug|somatropin|Prescribed at the discretion of the treating physician according to product labelling
1689656|NCT01543867|Drug|somatropin|Prescribed at the discretion of the treating physician according to product labelling
1689657|NCT01543854|Drug|RLX030|Intravenous infusion of RLX030 over 20 hrs
1689658|NCT01543854|Drug|Placebo|Intravenous infusion of placebo over 20 hours
1689659|NCT01543828|Drug|indacaterol|delivered via single-dose dry-powder inhaler
1689660|NCT01543828|Drug|placebo|delivered via single-dose dry-powder inhaler
1689748|NCT01543061|Device|OPTIVEtm Plus|1 drop in each eye four times a day for a period of 30 (± 3) days
1689749|NCT01543061|Procedure|No treatment|One month of contact lens wear with no eye drop use
1689661|NCT01543815|Behavioral|Well-Being Therapy based on Web Mobile Technology|The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others.
1689662|NCT01543815|Behavioral|Cognitive Behavior Therapy|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems.
1689663|NCT01543815|Other|Standardized Care Management|CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
1689664|NCT01543802|Drug|pazopanib|Treatment with pazopanib 800 mg qd for 21 days followed by resection of the tumor after a 7-14 days break
1689665|NCT01543789|Procedure|Intraperitoneal mesh placement|Mesh placement inside the peritoneal cavity.
1689666|NCT01543789|Procedure|Preperitoneal mesh placement|Mesh placement between peritoneum and muscle layer.
1689667|NCT01543776|Drug|abiraterone acetate|Given PO
1689668|NCT01543763|Drug|PZP115891, PCI-24781|"PCI-24781: oral, 30 to 75 mg/m2 b.i.d. Cycle 1, Days -7 to -4 and Cycle 1 and ongoing - Days 1-5, 8-12, 15-19
PZP115891: oral, 400 - 800 mg qd 28 days per cycle"
1689669|NCT01543750|Drug|4-Aminopyridine|
1689670|NCT01543750|Drug|Placebo|Placebo
1689671|NCT01543737|Device|3ml hyaluronic acid (DUROLANE)|DUROLANE Hyaluronic acid 20mg/ml
1689672|NCT01543737|Device|2ml hyaluronic acid, (HYALGAN)|HYALGAN Hyaluronic acid 10mg/ml
1689673|NCT01543724|Drug|Lithium|10mg/kg/day for 12 weeks
1689674|NCT01543698|Drug|LGX818|
1689675|NCT01543698|Drug|MEK162|
1689676|NCT01543698|Drug|LEE011|
1689677|NCT01543685|Drug|Indomethacin|40 mg TID capsules
1689678|NCT01543685|Drug|Indomethacin|40 mg BID capsules
1689679|NCT01543685|Drug|Indomethacin|20 mg TID capsules
1689680|NCT01543685|Drug|Celecoxib|200 mg capsules
1689681|NCT01543685|Drug|Placebo|Capsules
1689684|NCT01543659|Drug|89Zr-DFO-huJ591|The first 10 patients enrolled in the study will undergo serial whole-body scans to allow assessment of 89Zr-DFO-huJ591 biodistribution. There will be no intervening changes in therapy between the scans. The first 10 patients enrolled will also have serial blood samples drawn for PK analysis (2 -3 mL per time point). The remaining 90 patients enrolled (Patients 11−100) will have only 1 whole-body scan, at a time point to be determined based on the results for the first 10 patients. Biopsies are not mandatory, but highly recommended for the scientific purposes of the study. If feasible and the patient consents, all patients will undergo either or both of the following: (a) core biopsy of soft tissue site of disease; (b) core biopsy of bony site of disease. These biopsies will be performed following the last whole-body scan, prior to initiation of a new intervening therapy, and no more than 4 weeks after 89Zr-DFO-huJ591 administration.
1689685|NCT01543633|Drug|Propofol|Propofol will be infused using a computer controlled delivery system running the program STANPUMP. Loss of consciousness will be defined as loss of response to auditory stimulus (button press).
1689686|NCT01543607|Device|Radiofrequency ablation catheter (Habib EndoHBP)|Catheter placement into bile duct
1689687|NCT01543581|Drug|Vismodegib|Oral vismodegib, 150mg per day for 12 weeks.
1689688|NCT01543581|Drug|Placebo|
1689689|NCT01543568|Drug|aflibercept 2.0 mg|Intravitreal aflibercept injection 2.0 mg
1689690|NCT01543555|Drug|Atorvastatin|Atorvastatin 80mg anytime within 18 hours before surgery. A postoperative 40mg atorvastatin dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg atorvastatin daily for the next seven days.
1689691|NCT01543555|Drug|Placebo|Matching placebo 80mg anytime within 18 hours before surgery. A postoperative 40mg matching placebo dose administered at least 12 hours after the 80mg loading dose. Subsequently, 40mg placebo daily for the next seven days.
1689692|NCT01543542|Radiation|Whole Brain XRT 30Gy/10 fractions with|30 Gy of whole brain external beam radiation delivered in 10 fractions. Simultaneous in-field boost of brain lesions to 60 Gy.
1689693|NCT01543529|Drug|RO4917838|Single dose of RO4917838
1689694|NCT01543529|Drug|Placebo to RO4917838|Single dose of placebo to RO4917838
1689695|NCT01543529|Other|Alcohol|Standard alcoholic drink
1689696|NCT01543490|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 2 weeks
1689697|NCT01543490|Other|Vehicle|Placebo twice daily for 2 weeks
1689698|NCT01543464|Drug|Chemotherapy: Temozolomide|Vaccine: 250 microgram IDO5 peptide + 250 microgram Survivin peptide + 500 microL Montanide every 2nd week Adjuvants: 75 microgram GM-CSF + 1 application Imiquimod every 2nd week
1689699|NCT01543451|Drug|Elsiglutide|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
1689700|NCT01543451|Drug|Placebo|24 mg administered s.c. once daily for 4 consecutive days from Day 1 chemotherapy
1689701|NCT01543438|Other|Video Prescription (additional education)|receives video prescriptions
1689702|NCT01543412|Drug|FOLFIRI|Irinotecan 180 mg/m2 iv on day 1, Leucovorin(l-form) 200 mg/m2 iv on day 1,2 5-FU 400 mg/m2 iv bolus on day 1,2 5-FU 600 mg/m2 iv by ci for 22 hrs on day 1,2 repeated every 2 wks
1689703|NCT01543399|Drug|Tibolone|Experimental group will use 2.5mg of tibolone for 30 days
1689704|NCT01543399|Drug|Placebo|patients of the placebo group will use placebo one a day for 30 days
1689705|NCT01543386|Drug|Curcumin|The aim of this study is to determine if an oral loading-dose of curcumin can improve vascular endothelium reactivity in patients with moderate cardiovascular risk
1689706|NCT01543373|Device|Amphilimus Eluting Stent|Sirolimus formulated coronary eluting stent
1689707|NCT01543373|Device|Bare Metal Stent|Bare metal coronary stent
1689708|NCT01543360|Procedure|Axillary strategy|The first two attempts at central venous catheterization will be performed via the distal approach (axillary vein). The third and fourth attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The same puncture material/devices will be used in both arms of the study.
1690238|NCT01539174|Drug|prednisone|Given PO
1689709|NCT01543360|Procedure|Subclavian strategy|The first two attempts at central venous catheterization will be performed by the medial approach (subclavian vein). The third and fourth attempts at central venous catheterization will be performed by the distal approach (axillary vein). The same puncture material/devices will be used in both arms of the study.
1689710|NCT01543347|Drug|Temocillin|Antibiotic treatment
1689711|NCT01543334|Biological|Blood sampling|Blood samples will be harvested in one sequence at any time during the week set for the study. In patients receiving multiple antibiotics, multiple samples can be made (without exceeding the study of three antibiotics, ie a maximum of 6 tubes per patient). Two 3-ml tubes of blood will be collected for beta-lactams and glycopeptides (Sample A taken at half the time of the dosing interval and sample B at 30 minutes before the next dose). When patients receive continuous antibiotic treatment, both samples must be made at least 6 hours apart.
1689712|NCT01543321|Drug|Tetrabenazine|"Treatment with tetrabenazine consists in:
5-week titration to a maximum dose of 200 mg / day
5 weeks at stable dose
2 weeks in wash-out
The treatment will be blinded for patients and investigators"
1689713|NCT01543321|Drug|Placebo|"Treatment with placebo consists in:
5-week titration to a maximum dose of 200 mg / day
5 weeks at stable dose
2 weeks in wash-out
The treatment will be blinded for patients and investigators"
1689714|NCT01543282|Device|Endosonography guided fine needle aspiration cytology ( Cook Medical, Boston Scientific)|Patients will be randomized either to receive EUS-FNA with a 22 g needle or 25 g needle. EUS-FNA passes will be performed without stylet until sample adequacy or until a maximum of 5 FNA passes in pancreatic lesions or 3 FNA passes in other lesions. In case of inadequate sample after 3 passes, or needle failure, cross over to the other type of needle is allowed.
1689715|NCT01543269|Drug|ZYT1|Oral dose of ZYT1 in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
1689716|NCT01543269|Drug|Placebo tablets|Oral dose of Placebo in fasting condition with 240±10 ml of water at sitting position in ambient temperature.
1689717|NCT01543256|Device|WallFlex™ Biliary RX Fully Covered Stent System RMV|Temporary placement of the WallFlex Biliary RX Fully Covered Stent for treatment of benign biliary strictures secondary to chronic pancreatitis. The stent will be removed after 12 months indwell.
1689718|NCT01543256|Device|Commercially available Plastic Stent Per Investigator preference|Temporary placement/exchange of multiple biliary plastic stents for treatment of benign biliary strictures secondary to chronic pancreatitis. Stents will be removed after cumulative indwell of 12 months.
1689719|NCT01543243|Device|Stochastic resonance whole-body vibration A|"Immediate effects (one minute after intervention): over 5 sets with 6 Hz, Noise 4 and than 1 Hz, Noise 1.
Long term effect: over four weeks, three times a week with 6 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1."
1689720|NCT01543243|Device|Stochastic resonance whole-body vibration B|"Immediate effects (one minute after intervention): over 5 sets with 1 Hz, Noise 1 and than 6 Hz, Noise 4.
Long term effect: over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 6 Hz, Noise 4."
1689721|NCT01543230|Device|Total hip replacement|Total hip arthroplasty (THA) using CoMplete™ Acetabular Hip System
1689722|NCT01543217|Other|RT management|Patients assigned to the RT management arm will receive a 1-hour educational in-service conducted by a respiratory therapist case manager. The patient education session will include general information about COPD, direct observation of inhaler techniques, a review and adjustment of outpatient COPD medications, smoking cessation counseling, recommendations concerning influenza and pneumococcal vaccinations, encouragement of regular exercise, and instruction in hand hygiene.
1689723|NCT01543217|Other|Ususal care|Routine respiratory care.
1689724|NCT01543204|Drug|Etanercept|Administered by subcutaneous injection
1689725|NCT01543191|Drug|PUR118|low dose and high dose for 3 doses, BID
1689726|NCT01543178|Drug|open-label rifaximin|550 mg three times a day (open-label)
1689727|NCT01543178|Drug|double-blind placebo|3 times a day (double-blind)
1689728|NCT01543178|Drug|double-blind rifaximin|550 mg three times a day (double-blind)
1689729|NCT01543165|Drug|Ketorolac and nefopam balanced analgesia|Sequential intravenous administration of ketorolac and nefopam
1689730|NCT01543165|Drug|Balanced analgesia using ketorolac and morphine|Sequential intravenous administration of ketorolac and morphine
1689731|NCT01543165|Drug|Pain control with single analgesics (ketorolac)|This arm do not use balanced analgesia. Instead, ketorolac IV administration followed by 50cc normal saline administration (for blinding) will be used in this group.
1689737|NCT01543139|Dietary Supplement|Valproate+Cytidine+Creatine|Valproate: 300mg/day, Cytidine: 1g every other day, Creatine: Week0-1: 3g/day Week1-12: 5g/day
1689738|NCT01543139|Dietary Supplement|Valproate+Cytidine|Valproate: 300mg/day, Cytidine: 1g every other day
1689739|NCT01543139|Drug|Valproate|Valproate: 300mg/day
1689740|NCT01543113|Other|sequencing|sequencing
1689741|NCT01543100|Other|blood and bone marrow samples|"Specific tests of the study will be realized from :
Blood samples: 2 EDTA tubes and 1 tube without anticoagulant per included patient.
Bone marrow: 3 ml collected during of myelogram punction made for the diagnosis.
In all cases, no additional sampling will be performed."
1689744|NCT01543074|Dietary Supplement|BSE placebo|2 pills = 0 micromoles of Sulforaphane/day
1689745|NCT01543074|Dietary Supplement|Garlic oil|1 pill = 30 mg garlic oil/day
1689746|NCT01543074|Drug|BSE|2 pills = 200 micromoles of Sulforaphane/day
1689750|NCT01543061|Device|Blink Contacts® Eye Drops|1 drop in each eye four times a day for a period of 30 (± 3) days
1689751|NCT01543048|Other|Study Follow-Up|Colposcopy (+/- biopsies), cytology, and virology tests will be performed at the time of conization and during the follow-up period (6, 12, 24 months). HPV expression will be assessed by centralized validated marketed tests (Hybrid Capture 2, RLA genotyping, PreTect® HPV-Proofer) and by a real time PCR measuring E2, E6 and E7 viral load of HPV 1.
1689752|NCT01543035|Drug|stop statin and switch to an antiretroviral drug with less impact on lipid metabolism|Switch from a boosted PI or efavirenz based ART regimen to etravirine 400 mg/day once daily for patients in need of lipid lowering drugs (statin) after one month wash out of statin
1689753|NCT01543022|Device|Symphony|The Symphony system has been developed for superficial implantation without the need to enter the chest. It allows for complete patient mobility and provides counter pulsation therapy for up to 30 days in hospitalized patients.
1689754|NCT01543022|Procedure|The operative approach is limited to an infraclavicular incision similar to that used for placement of a pacemaker|The vascular graft is surgically attached (anastomosed) to the subclavian artery. The symphony device is implanted into a pocket below the pectoralis muscle on the anterior chest and attached to the graft. The driveline is tunneled out through the skin and attached to the drive console.
1689755|NCT01543009|Other|Emla + Local Warming|In this arm Emla is applied 60 minutes before the procedure and then the site of venepuncture is warmed by an electric heating sand pad at the temperature of 40°C for 5 minutes before performing cannulation
1689756|NCT01542983|Behavioral|Brief behavioral treatment for insomnia and bright light|daily bright light exposure; 2 sessions for insomnia
1689757|NCT01542983|Behavioral|treatment as usual|Standard treatment for fatigue and insomnia
1689758|NCT01542970|Dietary Supplement|Placebo|Olive oil
1689759|NCT01542970|Dietary Supplement|Omega-3 fatty acids|Omega-3 PUFA treatment comprises of maternal supplementation of 3 capsules of Pikasol® (1g capsules containing 640 mg ω-3 PUFA) 2 times daily during pregnancy and lactation.
1689760|NCT01542970|Dietary Supplement|Refined coconut and peanut oil without L. reuteri|2x20 drops daily to the mother from gw 20 and from birth to the child during the first year of life
1689761|NCT01542970|Dietary Supplement|L. reuteri|The L. reuteri supplementation comprises of L. reuteri suspension 109 colony forming units (CFU) in oil (refined coconut and peanut oil) (20 droplets x 2 daily) to the mothers during pregnancy and 108 CFU (5 droplets x 1) to the children during the first years of life
1689762|NCT01542957|Behavioral|Combined Cognitive Behavioral and Dilemma-Focused Therapy|7 2-hour sessions of Group Cognitive Behavioral Therapy for Depression + 8 individual sessions of a Dilemma-Focused Intervention + 1 3-hour final group session. Manualized.
1689763|NCT01542957|Behavioral|Cognitive Behavioral Therapy for Depression|Cognitive Behavioral Therapy for Depression. Format: 7 2-hour sessions in group + 8 individual sessions + 1 3-hour final group session. Manualized.
1689764|NCT01542944|Drug|TevaGastrim|TevaGastrim 10 mg/kg SC will be administered in the evening for 4 days prior to apheresis.
1689765|NCT01542931|Drug|TPF induction chemotherapy|Docetaxel (at a dose of 75mg/m2 of body surface area) was administered as a 2-hour intravenous infusion, followed by intravenous cisplatin (75 mg/m2), administered during a period of 2 to 3 hours. After completion of the cisplatin infusion, 5-Fu (750 mg/m2/day) was administered during a period at least 8 hours for 5 days. Induction chemotherapy was given every 3 weeks for 2 cycles, unless there was disease progression, unacceptable toxic effects, or withdrawal of consent by the patient.
1689766|NCT01542918|Drug|Lenalidomide|"Formulation of Dosage forms: 5 mg, 10 mg, 15 mg and 25 mg capsules.
Dosage: 10 mg - 30 mg (Treatment 1 and Treatment 2)
Route of administration: Oral"
1689767|NCT01542918|Drug|Rituximab|"Formulation of Dosage forms: 100 mg/IO mL and 500 mg/50 mL solution in a single-use vial
Dosage: 375 mg/m2, intravenous (Treatment 2, Cycle 1 only); 25 mg intraventricular injection (Treatment 2, all cycles)
Route of administration: Intravenous (Treatment 2, Cycle 1 only); Intraventricular injection (Treatment 2, all cycles)"
1689768|NCT01542905|Dietary Supplement|Korean Red Ginseng|Korean Red Ginseng Capsule (1g/day) for 8 Weeks
1689769|NCT01542905|Other|Placebo|Placebo Capsule (1g/day) for 8 Weeks
1689770|NCT01542892|Other|Exercise Intervention|Participants will complete exercise sessions 3 times per week for 6 months. The exercise sessions will involve walking, lower extremity strength exercises, flexibility, and balance training.
1689771|NCT01542892|Dietary Supplement|Supplement Intervention|Participants will be randomly assigned to receive either the nutritional supplement or placebo. The participants will consume on beverage immediately after each exercise session.
1689772|NCT01542879|Procedure|WB-DW-MR scan|
1689773|NCT01542879|Procedure|18F-FDG PET scan|
1689774|NCT01542879|Drug|Ferumoxytol|
1689775|NCT01542866|Device|Health Management Tool (HMT)|utilization of software specific for measuring vision impairment on a mobile computing platform (ie HMT) which allows subjects to perform home monitoring tests
1689776|NCT01542827|Other|Biofreeze|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
1689777|NCT01542827|Other|Placebo|The gel will be applied at 2.5 ml per 500 cm2 to the upper trapezius and neck muscles by a gloved technician
1689778|NCT01542814|Device|3Dimensional Mammography|The FUJIFILM 3DM examination is a 4-view mammogram which includes CC and MLO views of each breast. For each view, a routine (0-degree) mammogram will be acquired followed immediately in the same compression by a second mammogram offset at 4 degrees.
1689779|NCT01542814|Device|2D FFDM|Standard of care screening mammogram.
1689780|NCT01542801|Drug|Norfloxacin|Norfloxacin 400 mg per day
1689781|NCT01542801|Drug|ciprofloxacin|Ciprofloxacin 750 mg per week
1689782|NCT01542788|Drug|SOF|Sofosbuvir (SOF) 400 mg tablet administered orally once daily
1689783|NCT01542788|Drug|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
1689784|NCT01542788|Drug|Placebo to match SOF|Placebo to match SOF was administered orally once daily.
1689785|NCT01542788|Drug|Placebo to match RBV|Placebo to match RBV was administered orally twice daily.
1689786|NCT01542775|Behavioral|Aerobic Exercise Group|12 weeks Aerobic exercise
1689787|NCT01542775|Behavioral|Control Group|maintaining usual activities
1690239|NCT01539174|Other|laboratory biomarker analysis|Correlative studies
1689788|NCT01542762|Drug|LMWH|"Each hospital will use a LMWH according to their own preferences.
Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for the duration of the immobilization (average 6 weeks). If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
1689789|NCT01542736|Drug|Carboplatin|Administered concurrently with craniospinal radiation.
1689790|NCT01542736|Drug|Vincristine|Administered concurrently with craniospinal radiation.
1689791|NCT01542736|Radiation|24 Gy|Craniospinal radiation.
1689792|NCT01542723|Drug|LMWH|"Each hospital will use a LMWH according to their own preferences.
Prophylactic dosage of LMWH (for example nadroparin 2850 IE s.c.) once daily for 8 days. If the patient's weight is more than 100kg a double dose of LMWH will be given (in case of Nadroparin 5700 IE s.c. once daily)."
1689793|NCT01542710|Drug|Ganfort|Bimatoprost/Timolol fixed combination
1689794|NCT01542710|Drug|Duotrav|Fixed combination of Travoprost and Timolol
1689795|NCT01542697|Drug|intraperitoneal nebulisation of magnesium sulphate|intraperitoneal nebulisation of 1.5 gm of magnesium sulphate with 2 ml of normal saline
1689796|NCT01542684|Drug|Azacytidine|Starting dose: 40 mg/m^2 intravenously (IV) or subcutaneously (SQ) daily for 4 days.
1689797|NCT01542684|Drug|GM-CSF|250 mcg/m^2 IV or SQ one day (the next day) after completion of azacytidine treatment, for 3 consecutive days.
1955578|NCT03152045|Behavioral|Communication Intervention|In this study, Investigators are testing the feasibility, acceptability, and preliminary efficacy of a systems intervention that asks adolescents to report their risk behaviors before their encounter. Both clinicians and patients will receive a Feedback Guide that gives them tips on effective ways to communicate about these behaviors.
1689800|NCT01542645|Drug|Methadone|Methadone (0.3 mg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
1689801|NCT01542645|Drug|Fentanyl|Fentanyl (12 mcg/kg) will be administered intraoperatively, with half of the dose given at induction of anesthesia (over 5 minutes) and the remainder administered as an infusion over the next 2 hours.
1689802|NCT01542632|Biological|Takeda's Tetravalent Dengue Vaccine Candidate (TDV)|TDV subcutaneous injection
1689803|NCT01542632|Biological|TDV New Formulation|TDV New Formulation subcutaneous injection
1689804|NCT01542632|Drug|Placebo|Placebo subcutaneous injection
1689805|NCT01542632|Drug|New Formulation Placebo|New Formulation placebo subcutaneous injection
1689806|NCT01542619|Biological|rVIIa-FP|Recombinant VIIa-FP (rVIIa-FP) is a fusion protein linking coagulation factor VIIa with albumin and will be administered by intravenous infusion in escalating doses up to 1000 mcg/kg. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of study product and continuing for 7 days after study product has been administered.
1689807|NCT01542619|Biological|Placebo (0.9% normal saline)|Placebo will be administered by intravenous infusion. Participants will receive pre-treatment with an oral anticoagulant starting 7 days prior to administration of placebo and continuing for 7 days after placebo has been administered.
1689808|NCT01542606|Device|NORMA-SENSE|The NORMA-SENSE gen 3 polymer matrix is stained by blue or green color on a pale yellow background when the pH level of the fluid in contact with it is greater than the cutoff value, and the user can consider any stain of color, which is different from the original background, as a positive result of the test.
1689809|NCT01542593|Device|Ureteral catheterization - Cook Urological Inc. open end ureteral catheter 5FR|"During a planned procedure involving ureteroscopy or ureteral stenting, after retrograde pyelography and insertion of a safety wire, ureteral catheterization will be performed using Cook Urological Inc. open end ureteral catheter 5FR for the purpose of measuring exact ureteral length.
Measurement results will be compared to measurements performed on CT scan (obtained before surgery)."
1689810|NCT01542580|Device|Vanguard SSK 360 with PS Bearing|non-constrained tibial bearing
1689811|NCT01542580|Device|Vanguard SSK 360 with PSC bearing|constrained tibial bearing
1689812|NCT01542580|Device|Vanguard DA 360|Dual-articulation device, only cleared in EU
1689813|NCT01542567|Drug|Abitren|SUPPOSITORIES 50 Mg 2 SUPPOSITORIES A WEEK
1689814|NCT01542567|Drug|Placebo|Placebo suppositories
1689815|NCT01542554|Other|Low glycaemic index diet|Diabetic subjects will be given dietary advice with emphasis on low glycaemic index diet
1689816|NCT01542554|Other|Usual diabetic diet|Diabetic subjects will be given dietary advice without mention about glycaemic index
1689818|NCT01542528|Behavioral|IBBS|Combination of computer-presented brain exercises with a physical education curriculum designed to enhance sustained attention, inhibitory control and other executive capacities. Groups of 10 students incorporating the Good Behavior Game. Two-hour sessions four days a week: classroom with computers (45-60 mins) plus sports activities in the gymnasium (45-60 mins) extending over a total 15 weeks (60 sessions).
1689819|NCT01542515|Procedure|Meniscal allograft arthroplasty of the carpometacarpal joint of the thumb|"The surgical procedure will involve the use of human meniscal allograft tissue that will be provided by industry. The meniscus will be contoured into a T shape. The T-shaped meniscus allograft is then inserted into the arthritic thumb CMC joint and secured with two suture anchors."
1689820|NCT01542502|Drug|Anakinra|Anakinra 100 mg daily subcutaneous injection
1689821|NCT01542502|Drug|Placebo|Placebo daily subcutaneous injection
1689822|NCT01542489|Drug|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
1689823|NCT01542489|Drug|insulin aspart|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
1689824|NCT01542489|Drug|human soluble insulin|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
1689966|NCT01541254|Device|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)|Low profile Visualized Intraluminal Device (LVIS and LVIS Jr.)
1689825|NCT01542476|Drug|insulin detemir|Prescribed by the physician solely as a result of a normal clinical evaluation. The physician determines the starting dose and frequency, as well as later changes to either dose or frequency, if any
1689826|NCT01542463|Drug|insulin detemir|Prescribed at the discretion of the physician
1689827|NCT01542450|Drug|insulin detemir|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
1689828|NCT01542450|Drug|insulin NPH|Single dose of 0.3 U/kg administered subcutaneously (s.c. under the skin) in each treatment period separated by a washout period of 4-28 days
1689829|NCT01542437|Drug|BIBW 2992|"All patients will receive: BIBW 2992 40mg every 24 hours orally, where a cycle corresponds to complete this treatment for 28 days; option 30mg/day dose reductions, according to established criteria.
Not to be compared with any other drug."
1689830|NCT01542424|Drug|biphasic insulin aspart 30|Prescribed at the discretion of the physician
1689831|NCT01542424|Drug|insulin detemir|Prescribed at the discretion of the physician
1689833|NCT01542385|Procedure|Stent|Percutaneous coronary intervention: reperfusion with a thrombectomy catheter or a small balloon angioplasty catheter, followed by coronary stenting
1689834|NCT01542372|Drug|Medication augmentation|
1689835|NCT01542372|Behavioral|CBT|
1689836|NCT01542359|Other|Yogic practice|breathing, meditation, physical postures
1689837|NCT01542359|Other|Conventional Exercise|Standard physical exercises such as toe touch in standing, curl ups, push ups, leg lifts
1689838|NCT01542346|Procedure|subcutaneous adaption|
1689839|NCT01542333|Genetic|gene expression analysis|
1689840|NCT01542333|Genetic|proteomic profiling|
1689841|NCT01542333|Genetic|reverse transcriptase-polymerase chain reaction|
1689842|NCT01542333|Genetic|western blotting|
1689843|NCT01542333|Other|immunohistochemistry staining method|
1689844|NCT01542333|Other|laboratory biomarker analysis|
1689845|NCT01542333|Procedure|spectroscopy|
1689846|NCT01542320|Dietary Supplement|Lactobacillus reuteri DSM 17938|1 x 10e8 colony forming units in 5 drops (0.17ml)daily from study enrollment to study conclusion. Duration based on rotavirus vaccine administration.
1689847|NCT01542320|Other|Placebo|Solution without active Lactobacillus reuteri
1689848|NCT01542307|Biological|Oxygen|Oxygen is inhaled for 30 minutes during migraine attack
1689849|NCT01542307|Biological|Room air|Placebo
1689850|NCT01542294|Drug|s1|60-90mg/m2/d P.O. day 1-14, repeated every 21 days
1689851|NCT01542294|Drug|Oxaliplatin|130mg/m2 d1 repeated every 21 days
1689852|NCT01542281|Dietary Supplement|Whey protein and dietary supplements|Whey protein and dietary supplements in addition to pre-hab exercise
1689853|NCT01542281|Other|prehab exercise|minimum 4 weeks and maximum 8 weeks; 3 times a week
1689854|NCT01542268|Drug|pentoxifylline|Patients will take 800mg/day, via oral, of pentoxifylline. 400 mg of pentoxifylline each 12 hours (during meals time).Period: 3 months.
1689855|NCT01542268|Drug|pentoxifylline placebo|Patients will take 800mg/day, via oral, of pentoxifylline placebo. 400 mg of pentoxifylline placebo each 12 hours (during meals time).Period: 3 months.
1689856|NCT01542255|Drug|vinblastine|1 mg/m2 vinblastine given three times per week administered intravenously.
1689857|NCT01542255|Drug|Cyclophosphamide|60 mg/m2 cyclophosphamide taken orally every day for 3 weeks with one week rest
1689858|NCT01542255|Drug|dacarbazine|15 mg/m2 dacarbazine given three times per week for 3 weeks with 1 week rest
1689859|NCT01542242|Drug|Liraglutide|Liraglutide 0.6 mg SQ daily for one week, increase to a maximum dose of 1.8 mg SQ daily by 6 weeks, and subsequent continuation for the remainder of a year.
1689860|NCT01542229|Behavioral|PE + TAU|12 weekly sessions of Prolonged Exposure in addition to Treatment As Usual
1689861|NCT01542229|Behavioral|Treatment As Usual|TAU will receive support services through the VA potentially inclusive of case management, psychotropic medication management, and/or supportive counseling
1689862|NCT01542216|Behavioral|Nutrition and Exercise Group|Patients randomized to this arm will receive nutrition and exercise consultations. Exercise consultations will home- and institution-based.
1689863|NCT01542216|Behavioral|Yoga and Stretching Group|Patients randomized to this arm will receive consultations on yoga and stretching exercises.
1689864|NCT01542190|Drug|Ketorolac Tromethamine|ketorolac tromethamine 0.4%
1689865|NCT01542151|Other|Time of labor induction|Assigned time of labor induction - morning or evening
1689866|NCT01542138|Drug|Desonide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
1689867|NCT01542138|Drug|Niacinamide|Once-a-day applying on axillar hyperpigmentation for 9 weeks
1689868|NCT01542138|Drug|Placebo|Humectant placebo cream
1689869|NCT01542125|Drug|Liposomal Lidocaine|4% Liposomal Lidocaine
1689870|NCT01542125|Drug|Placebo|Tubes were visually identical to the Liposomal Lidocaine tubes.
1689871|NCT01542112|Other|PSactive model|"The model is designed to address the main issues that lie at the core of initiatives to manage patient expectations and improve patient satisfaction. It is a structured interventional set of activities, which gives the clinician an opportunity to meet patient expectations and improve patient satisfaction.
The interventional model is comprised of teachable-learnable interpersonal communicative steps occurring between the clinician and the patient which are: Gather information on the patient's expectations and perception of the hospitalization, respond, provide relevant information and document the intervention."
1689872|NCT01542112|Other|No treatment|Patients in this arm receive the usual routine in the department.
1689873|NCT01542099|Drug|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during double lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.
For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. And, step size of dose is 0.5ng/ml."
1690240|NCT01539174|Other|pharmacological study|Correlative studies
1689874|NCT01542099|Drug|Remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during single lumen tube intubation. For this allocation of dose of remifentanil the investigators use up-and-down method.
For the first patient, the dose of remifentanil would be fixed at 6.0 ng/ml which we predict as EC50. Step size of dose is 0.5ng/ml."
1689875|NCT01542086|Procedure|Myocardial SPECT|
1689876|NCT01542086|Procedure|64-channel coronary CT angiography (CCTA)|
1689877|NCT01542073|Drug|68Ga-BNOTA-PRGD2|Intravenous injection of one dosage of 111 MBq 68Ga-BNOTA-PRGD2. Tracer doses of 68Ga-BNOTA-PRGD2 will be used to image angiogenesis of myocardial infarction area by positron emission tomography / computed tomography (PET/CT)
1689878|NCT01542060|Drug|biphasic insulin aspart 30|Administered via an insulin injection device. Dosages varied according to individual patients' medical requirement as determined by their attending clinician
1689879|NCT01542047|Drug|Carboplatin|Carboplatin will be administered intravenously over approximately 30 minutes on day 1 of each cycle. The dosage used will be 5 AUC for the first 5 cycles, and will be increased to 6 AUC for the sixth cycle.
1689880|NCT01542047|Drug|Pazopanib|Pazopanib will be administered orally at 200 to 800 mg/kg2. It will be given either on days 1 through 21 of each 3-week cycle, or if needed, it will be given on days 3 through 19.
1689881|NCT01542034|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
1689882|NCT01542034|Drug|Placebo|Phosphate buffered saline placebo for injection
1689883|NCT01542021|Drug|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 4 ± 1 day before radical prostatectomy, depending on treatment arm.
1689884|NCT01542021|Drug|degarelix injection|Treatment will consist of a single 240 mg injection of degarelix 7 ± 1 day before radical prostatectomy, depending on treatment arm.
1689885|NCT01542021|Drug|androgen deprivation therapy|
1689886|NCT01542008|Behavioral|Customized Adherence Enhancement (CAE)|CAE consists of the application of a series of up to four psychosocial treatment modules based upon a baseline evaluation of adherence vulnerabilities/needs. The standardized modules (Psychoeducation, Modified Motivational Enhancement Therapy, Communication with Providers, Medication Routines), are assigned based upon pre-established criteria designed to fit the needs of the patient.
1689887|NCT01542008|Behavioral|broadly-directed, non-individualized education (EDU)|"EDU will consist of 4 core in-person sessions using the patient work-book from the NIMH funded study, Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD), and following the general educational format of the Collaborative Care control intervention in the STEP study. EDU addresses BD treatment broadly, including diagnosis and management, and the sessions will review the materials and allow time for questions as needed."
1689888|NCT01541969|Device|CR Neuromodulation|"Ear level device which delivers patterned sound stimulation.
The experimental arm will use the device fitted according to audiologist training given by the manufacturer/funder. An individually specified sound stimulation algorithm is hypothesised to interrupt tinnitus generating activity in the brain. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks participants will be unblinded and continue with the same experimental intervention. In weeks 13-36 participants will be asked to wear the device every day for 4 hours, in continuous blocks of at least 1 hour."
1689889|NCT01541969|Device|Tinnitus masking|The active comparator uses the same ear level device and also delivers patterned sound but the stimulus will be determined according to an algorithm predicted not to break up tinnitus generating activity in the brain. It may have a masking effect. For the first 12 weeks participants will be asked to wear the device every day for 6 hours, and in blocks of time not less than 1 hour. After 12 weeks, the participants will be unblinded and the device algorithm will be reprogrammed in the same way as the experimental intervention. In weeks 13-24 participants will be asked to wear the device for 6 hours per day, in continuous blocks of at least 1 hour. In weeks 25-36 they will be asked to continue using the device every day for 4 hours, in continuous blocks of at least 1 hour.
1689890|NCT01541956|Drug|Metformin|500 mg twice daily
1689891|NCT01541956|Drug|vildagliptin|Vildagliptin 50 mg twice daily
1689892|NCT01541943|Drug|Atorvastatin|Once daily, administered orally, 8 week
1689893|NCT01541943|Drug|Losartan|Once daily, administered orally, 8 week
1689894|NCT01541943|Drug|Placebo|Once daily, administered orally, 8 week
1689895|NCT01541943|Drug|HL-040XC|Once daily, administered orally, 8 week
1689896|NCT01541930|Drug|GK567|Once or twice daily, for 14 days, up to 30 g per day
1689897|NCT01541917|Behavioral|Web-based coping skills training|This intervention comprises a 12-week interactive, multi-component, multimedia online training that consists of instruction in specific self-management strategies, disease education, and social support. The content is rooted in cognitive-behavioral principles of disease self-management. In addition to the web-based modules, the intervention consists of monthly telephone support for 3 months by a trained bilingual health coach (research nurse) to review material and help enhance motivation.
1689898|NCT01541917|Behavioral|Online disease education|"The online disease education intervention provides access to an online resource center containing links to 12 educational websites about Juvenile Idiopathic Arthritis. Participants will be asked to review one educational website per week over the course of 12 weeks. Participants also will receive three monthly phone calls by a bilingual nurse health coach to discuss the participant's efforts at managing his/her disease."
1689899|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.015%|PRO-118 Ophthalmic Solution 0.015 % applied qd during 21 days
1689900|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.015 %|PRO-118 Ophthalmic Solution 0.015 % applied twice to day during 21 days
1689901|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied qd during 21 days
1689902|NCT01541904|Drug|PRO-118 Ophthalmic Solution 0.020 %|PRO-118 Ophthalmic Solution 0.020 % applied twice to day during 21 days
1689903|NCT01541904|Drug|Placebo Ophthalmic Solution|Placebo Ophthalmic Solution applied qd during 21 days
1689965|NCT01541267|Drug|aliskiren, eplerenon, telmisartan|aliskiren (Rasilez 300 mg, Novartis Europharm eplerenon (Inspra 50 mg, Pfizer Europe) telmisartan (Micardis 80 mg, Boehringer Ingelheim)
1742179|NCT00121355|Device|safety glide|
1689906|NCT01541865|Device|Renal Denervation|percutaneous renal denervation using the Vessix RF balloon catheter
1689907|NCT01541852|Drug|Losmapimod|One tablet of Losmapimod 7.5mg twice daily
1689908|NCT01541852|Drug|Placebo|One tablet twice daily
1689910|NCT01541826|Dietary Supplement|Chokeberry Extract|Consumption of 2 x 250 mg chokeberry extract capsules daily for 12 weeks.
1689911|NCT01541826|Dietary Supplement|Placebo capsule|Color-matched rice powder pill, 2 x 250 mg/day for 12 weeks
1689912|NCT01541826|Dietary Supplement|Chokeberry extract capsule, acute|Chokeberry extract capsule, 2 x 250 mg, one-time dose.
1689913|NCT01541774|Device|Phoenix Atherectomy System|Evaluate the procedural safety and effectiveness of the Phoenix Atherectomy™ System for the treatment of de novo and restenotic atherosclerotic lesions located in native peripheral arteries as assessed through 30 day follow-up. Further evaluations of device performance ensuring no prostenotic response as assessed through six month follow-up.
1689915|NCT01541748|Other|Axis|Coloplast's Axis™ Allograft Dermis consists of solvent-dehydrated, gamma-irradiated, preserved human collagen. It is restricted to homologus use as a soft tissue graft for horizontal and vertical soft tissue augmentation of thickness and length.
1689916|NCT01541735|Drug|Pantoprazole|The pantoprazole will be administered in capsules of 40mg. The dose will be 1 capsule per day during 45 days.
1689917|NCT01541735|Drug|placebo|Placebo 40 mg dose.
1689918|NCT01541709|Drug|imatinib|The patients will receive 400 mg per day of imatinib for 4 weeks, and then 600mg per day (300 mg po bid) for 4 weeks if tolerable to 400 mg per day, and then 800 mg per day (400 mg po bid)
1689919|NCT01541683|Other|PEG solution (Fortrans®) and Mentholyptus Drops (Halls®)|Patients will be instructed to drink 4 Liters of PEG solution (FORTRANS®) split into 2 days while sucking on sugar-free mentholyptus drops (2 L at 7-9 pm on the day prior to the colonoscopy while continuously sucking on Halls®, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure while continuously sucking on Halls®)
1689920|NCT01541683|Other|PEG solution (Fortrans®)|4 liters of PEG solution (FORTRANS®) split into 2 days (2 L at 7-9 pm on the day prior to the colonoscopy, and 2 L on the day of the colonoscopy to be completed a minimum of 1.5 hours before the procedure)
1689922|NCT01541657|Other|Ankle Joint Mobilization|The posterior ankle mobilization treatment is a manual therapy technique that consists of gently gliding your ankle in the backward direction through a pain free range of motion. This is a common therapy technique used by athletic trainers for the treatment of ankle sprains. The objective of this therapy technique is to glide the ankle into the area which restricts range of motion and gently stretch the restricted area. To begin this treatment, a certified athletic trainer with experience in applying this therapy technique will provide mild traction to the ankle joint to lightly distract the bones of the ankle joint. The athletic trainer will then apply two sets of joint mobilizations which will each last 2 minutes. Each repetition will consist of gently gliding the ankle joint in the backward direction until an area of restriction is reached. The athletic trainer will push into the restriction and then glide the ankle back to the starting position.
1689923|NCT01541657|Other|Foot Massage|The foot massage treatment is a manual therapy technique that consists of gently rubbing the bottom of your feet with both hands like kneading dough. To begin the treatment, you will be asked to lie comfortably on a treatment table you're your feet hanging slightly off the edge. The athletic trainer with experience in applying this therapy will place his hands on the bottom of your foot and begin to massage your feet from your toes down to your heel. The athletic trainer will perform 2 sets of 2 minutes of massage with 1 minute rest in between sets.
1689924|NCT01541657|Other|Calf Stretching|The calf stretching treatment is a technique that is commonly used in sports and rehabilitation. You will be asked to place your foot on a slant board located next to a wall with your heel positioned below your toes on the slant board. You will be asked to lean towards the wall until you feel tension in your calf muscles that feels like a good stretch. You will perform 2 sets of 3 stretches that are held for 30 seconds each. Between each stretch, you will rest for 10 seconds. Between each set, you will rest for 1 minute.
1689925|NCT01541644|Device|Acupuncture|Participants will receive acupuncture treatment twice weekly for 2 weeks, then once per week for 4 weeks, and then biweekly for 4 weeks.
1689926|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel Tablet - 40mg/kgBWT given once Albendazole Tablet - 400mg once
1689927|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel- 40mg/kgBWT Albendazole - 400mg once
1689928|NCT01541631|Drug|Praziquantel and Albendazole|Praziquantel- 40MG/KG ONCE Albendazole - 400mg once
1689929|NCT01541618|Other|MSDX Complex-1 Biomarker test|MSDX Complex-1 Biomarker test
1689930|NCT01541605|Drug|methylphenidate|tablets for oral use
1689931|NCT01541605|Drug|Placebo|tablets for oral use
1689932|NCT01541592|Other|Dietary fat|On the study day, each participant will receive 100 grams of a randomly assigned fat via a nasoduodenal tube. The oil will be infused at a rate of ~1 tablespoon per hour so that the total infusion time will be 6 hours.
1689933|NCT01541579|Other|Cx601|120 million cells administered by intralesional injection.
1689934|NCT01541579|Other|Saline solution|24 mL saline solution by intralesional injection
1689935|NCT01541553|Procedure|Cryotherapy|"Cryotherapy of all visible AKs (4-8 lesions, baseline lesions) in the selected treatment area"
1689936|NCT01541553|Drug|Vehicle|Field treatment with vehicle gel once daily for 3 consecutive days.
1689937|NCT01541553|Drug|Ingenol metabute|Field treatment with vehicle gel once daily for 3 consecutive days.
1742180|NCT00121355|Device|autocover needle|
1689938|NCT01541540|Behavioral|e-Counseling plus Usual Care|28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12. Each email will contain an e-link to lifestyle counseling activities designed to enhance motivation and skill to initiate and maintain lifestyle change. e-Counseling includes video-based education and counseling as well as e-tools to self-monitor and reinforce adherence to self-management behavior for exercise, diet, prescribed medications and smoke-free living.
1689939|NCT01541540|Behavioral|Control|The control group will receive general educational material on heart healthy living. 28 emails will be sent proactively over a 12-month period. Emails will be sent weekly for the first 4 months, biweekly from months 5 to 8, and monthly from months 9 to 12.
1689940|NCT01541527|Biological|blood test|One blood test entering in the usual follow-up of the patient
1689941|NCT01541501|Device|Pachymetry|Healthy volunteers recruited among subject that underwent a routine ophthalmologic evaluation or among both students and workers at our clinic, will be submitted to CCT measurement through four different instruments: Scheimpflug camera tomography, SD-OCT, anterior chamber SD-OCT, and finally with US pachymeter.
1689942|NCT01541488|Drug|BI 1021958|tablet
1689943|NCT01541488|Drug|BI 1021958|drinking solution / tablet
1689944|NCT01541488|Drug|Placebo to BI 1021958|SRD part: oral administration in fasted state, FE part: oral administration in fasted state and after standard high fat breakfast
1689945|NCT01541475|Drug|Bupropion, Escitalopram|Week 0-1: Escitalopram 10mg, Bupropion 150mg Week 2-3: Escitalopram 10mg, Bupropion 300mg Week 4-8: Escitalopram 20mg, Bupropion 300mg
1689946|NCT01541475|Drug|Escitalopram|Week 0-3: Escitalopram 10mg Week 4-8: Escitalopram 20mg
1689947|NCT01541462|Other|Weaning|Decrease assistance provided by the ventilator
1689949|NCT01541410|Device|Vascutek Hybrid Graft|Single Group Assignment
1689950|NCT01541397|Drug|Sapropterin|20 mg/kg, orally, daily, 1 year or patient chooses to discontinue therapy
1689951|NCT01541384|Device|Vitality GlowCaps|"The main research instrument is an electronic pill bottle called GlowCaps that has the ability to transmit reminder messages via email, text, and phone to the subject, and adherence data to special servers. The messages will be sent twice a day, if a subject misses a dose of their immunosuppression medication (tacrolimus). Each time the pill bottle is opened (or not opened), a date- and time-stamped wireless signal is sent to the Vitality server via the AT&T cellular network. No extra cellular or wireless service is required from subjects for the GlowCap to function.
Note: GlowCaps are a Class 1 Medical Device registered with the FDA. Because of this Class 1 designation, they are not subject to FDA testing or approval."
1689952|NCT01541371|Drug|Paliperidone ER|Paliperidone Extended Release (ER) 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral (by mouth) tablets depending on Investigator's discretion once daily for 12 weeks.
1689953|NCT01541358|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
1689954|NCT01541358|Procedure|positron emission tomography/computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
1689958|NCT01541332|Drug|Pomalidomide|Pomalidomide administered to 3 cohorts of subjects at escalating doses of 2 (cohort 1), 3 (cohort 2) and 4 mg/dose (cohort 3) per orem (PO). Doses are to be administered once-a-day, for the first 21 days, as part of a 28-day treatment cycle, followed by a 7-day rest period.
1689959|NCT01541332|Drug|Pegylated Liposomal Doxorubicin (PLD)|"Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
PLD will be given at a dose of 5.0 mg/m2 as a 60 minute IV infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle."
1689960|NCT01541332|Drug|Dexamethasone|Dexamethasone will be given at a dose of 40 mg/dose IV. Doses are to be administered on days 1, 4, 8, and 11 of the 28-day cycle.
1689961|NCT01541293|Drug|Lidocaine|100mg of liquid lidocaine, single dose, instilled into the uterine cavity via a flexible trans-cervical catheter immediately prior to laminaria insertion.
1689962|NCT01541293|Drug|Normal Saline|5mL of normal saline, instilled into the uterus via a flexible trans-cervical catheter immediately prior to laminaria insertion.
1689963|NCT01541280|Drug|Azacitidine|Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year provided the patients has a platelet count of >15 x 109/L without transfusion for at least 2 successive days, and an absolute neutrophil count of >1 x 109/L without growth factor for at least 2 successive days, and no acute GVHD greater than grade I and no clinical evidence of life-threatening infection. AZA is given 32 mg /m²/day subcutaneously for 5 days every 28 days (
1689964|NCT01541280|Other|DLI|"Donor lymphocyte infusion (DLI) is to be given from day +126 (week 18) in patients without immunosuppressive therapy for at least one month and following 3 cycles of AZA, and without clinical signs of GVHD, and without uncontrolled infection and without a recent history of >grade 2 acute GVHD. DLI are schedules every 8 weeks. There are 3 DLI scheduled.
If first cycle of AZA is postponed beyond day 56 (maximum to Day 100), all subsequent cycles and DLI will be post poned too."
1689967|NCT01541228|Device|Photodynamic therapy with light dose of 70 J/cm2 using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp.
Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.
Patients randomized so that half of them would receive a light dose of 70J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA. Treatment repeated twice with two weeks interval."
1689968|NCT01541228|Procedure|Photodynamic therapy with 100J/cm2 light dose using a broad-band red light source|"Patients take part in intraindividual (left-right) comparison study when having at least 2 non-hyperkeratotic actinic keratoses (AK) on the left and right sides of the face/scalp. Punch biopsies in 3.5 millimetres diameter performed to confirm the diagnosis of AK.
Patients randomized so that half of them would receive a light dose of 100J/cm2 as their first split face/scalp treatment on the left side. Photodynamic therapy with the light dose of 70 J/cm2 using a broad-band red light source (570-670 nm,Curelight®, PhotoCure, Oslo, Norway) and 20% 5-ALA.Treatment repeated twice with two weeks interval."
1689972|NCT01541202|Drug|rhNRG-1|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
1689973|NCT01541202|Drug|Placebo|10 hours per day i.v drip for the first 10 days (0.6ug/kg/day), followed by weekly 10 minutes i.v bolus (0.8ug/kg/day), from the 3rd week for 23 weeks
1689974|NCT01541189|Drug|Valsartan|80 mg/day for 2 weeks, up-titrated to 160 mg/day for further 8 weeks
1689975|NCT01541176|Other|Absence of corticotherapy post-transplantation|No study treatment
1689976|NCT01541176|Drug|Corticotherapy post-transplantation|"Prednisone or prednisolone orally for at least one year post-transplantation with the following minimal doses :
D1 to D14 : 20 mg/day,
D15 to M1 : 15 mg/day,
M1 to M3 : 10 mg/day,
M3 to M12 : 5 mg/day."
1689977|NCT01541150|Behavioral|neuropsychological questionnaires|Due to this study population (inmates), the investigators have decided to classify the protocol as and interventionnal study.
1689978|NCT01541137|Drug|Diclofenac|oral diclofenac 75 mg, a 44-hour iv-infusion of diclofenac 150 mg/24h, oral diclofenac 75 mg x 2, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
1689979|NCT01541137|Drug|parecoxib/ valdecoxib|oral valdecoxib 40 mg, a 44-hour iv-infusion of parecoxib 80 mg/24h, IV-PCA programmed with morphine boluses of 2-3 mg and a lock-out time of 5-15 minutes
1689980|NCT01541137|Device|patient controlled epidural analgesia|epidural catheter, epidural loading dose of 1 ml/10 kg of 0.15% bupivacaine with fentanyl 6 µg/ml. Thereafter a continuous infusion was started at 1 ml/10 kg/h. In the PACU PCEA-patients could take incremental doses of 3 ml with a 8-15 min lock-out time
1689981|NCT01541124|Drug|Opioid|10 mg/pill, po, each 6h, during 6m
1689982|NCT01541111|Drug|Magnesiun|75mg pills; each 12h; 12wk
1689983|NCT01541098|Biological|Lyophilized Plasma|Licensed plasma that has been lyophilized.
1689984|NCT01541098|Biological|Licensed Plasma|Plasma that has been authorized for transfusion.
1689985|NCT01541085|Drug|Darunavir/Ritonavir (DRV/r)|Darunavir/Ritonavir (DRV/r) + Tenofovir/Emtricitabina regimen
1689986|NCT01541085|Drug|Efavirenz (EFV)|Efavirenz (EFV) + Tenofovir/Emtricitabina regimen
1689987|NCT01541072|Drug|Pegfilgrastim|Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation
1689988|NCT01541072|Drug|Filgrastim|Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils >= 0.5 G/L)
1689989|NCT01541059|Drug|Placebo injection|Injection of saline solution into the vestibular capsule of each tooth to be extracted.
1689990|NCT01541059|Drug|Ropivacaine injection|Ropivacaine is injected into the vestibular capsule of each tooth to be extracted.
1689991|NCT01541046|Biological|Biogaia L. reuteri DSM 17938|Freeze-dried Lactobacillus reuteri DSM 17938 suspended in oil. Brand Name Active Agent: BioGaia™
1689992|NCT01541046|Biological|Probiotic Placebo|Description of Placebo: contains same excipients as Active Agent, without the active ingredient
1689993|NCT01541007|Drug|Cabazitaxel|25 mg/m2 every three weeks
1689994|NCT01541007|Drug|weekly cabazitaxel|10 mg/m2 dag 1,8,15,22. Cycle length is 6 weeks
1689995|NCT01540994|Radiation|radiation therapy|Stereotactic Body Radiation Therapy
1689996|NCT01540981|Device|MIST Therapy|FDA cleared non-contact ultrasound device. Delivers low frequency ultrasound via a fine saline to the wound area.
1689997|NCT01540981|Other|Standard of Care|Standard of Care consists of pressure relief, wound cleansing and dressing as needed
1689998|NCT01540968|Behavioral|Nutrition & physical exercise|Patients will be randomly assigned to intensive individual nutritional counselling including oral nutritional supplements and a specifically designed exercise program combining strength and balance training.
1689999|NCT01540955|Behavioral|Improving Cognition with group intervention|Participants attend 5 weekly group sessions that are 2 hours each, delivered by a trained therapist. Sessions focus on specific aspects of attention, memory, multi-tasking and encoding. Homework assignments are practiced between classes. Goals are set for improved functioning.
1690000|NCT01540942|Dietary Supplement|nutrition treat|intestinal nutrition treat :female：REE（Kcal/d）=655+9.6W+1.7H-4.7A; male：REE（Kcal/d）=66+13.7W+5.0H-6.8A;[W=weight（Kg）；H=height（cm）；A=age（year）]
1690001|NCT01540942|Other|surgery|bowel resection
1690002|NCT01540916|Other|Increase minute ventilation|Respiratory rate will be increase in order to have a 30% increase of minute ventilation
1690003|NCT01540916|Other|Decrease minute ventilation|Respiratory rate will be decrease in order to have a 30% decrease of minute ventilation
1690004|NCT01540903|Biological|PfSPZ Challenge|Aseptic, purified, vialed, cryopreserved, fully infectious NF54 Plasmodium falciparum sporozoites (PfSPZ Challenge)
1690005|NCT01540903|Biological|Saline|Saline
1690006|NCT01540877|Procedure|Application of capsaicin 0.6%|topical application of 0.6% capsaicin on the volar forearm
1690007|NCT01540877|Procedure|Application of local anesthetics (EMLA plaster)|topical application of EMLA on the volar forearm
1690008|NCT01540877|Procedure|Application of 1 capsaicin 0.6% and 2. EMLA|topical application of 1. 0.6% capsaicin and 2. EMLA on the volar forearm
1690009|NCT01540877|Procedure|Application of 1. EMLA and 2. capsaicin 0.6%|topical application of 1. EMLA and 2. 0.6% capsaicin on the volar forearm
1690010|NCT01540864|Drug|HPP404|Administered orally once daily for 26 weeks
1690011|NCT01540864|Drug|Placebo|Administered orally once daily for 26 weeks
1690012|NCT01540851|Behavioral|Care Navigator|Subjects assigned to the Care Navigator intervention group will receive 10 calls from a care navigator after discharge from the hospital for 5 months after their total knee replacement.
1690013|NCT01540851|Other|Standard Post-Operative TKA Care|Subjects assigned to the Standard Post-Operative TKA Care group will receive the current standard of care for post-operative care
1690014|NCT01540838|Drug|Infusion with paracetamol|The administration of 250 mg/kg/24 hours cefotaxime during the first 4 days as continuous intravenous infusion, each single infusion lasting for 12 hours (to prevent degradation of the agent), combined with high-dose paracetamol orally; the first dose is 30 mg/kg, then 20 mg/kg every 6 hours for 4 full days.
1690015|NCT01540838|Drug|Bolus without paracetamol|The control intervention consists of 250 mg/kg/24 hours cefotaxime administered traditionally with intermittent i.v. boluses and the place bo of paracetamol orally, both repeated every 6 hours (qid) for 4 days.
1690016|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
1690017|NCT01540825|Drug|BI 113608|High dose powder for oral solution
1690018|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
1690019|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
1690020|NCT01540825|Drug|Placebo|Powder for oral solution
1690021|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
1690022|NCT01540825|Drug|BI 113608|High dose powder for oral solution
1690023|NCT01540825|Drug|BI 113608|High dose powder for oral solution
1690024|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
1690025|NCT01540825|Drug|BI 113608|Medium dose powder for oral solution
1690026|NCT01540825|Drug|BI 113608|Low dose powder for oral solution
1690027|NCT01540812|Drug|Vincristine in induction|
1690028|NCT01540812|Drug|Daunorubicin in induction|
1690029|NCT01540812|Drug|Prednisone in induction|
1690030|NCT01540812|Drug|Metotrexato in induction|
1690031|NCT01540812|Drug|Cytarabine in induction|
1690032|NCT01540812|Drug|Hydrocortisone in induction|
1690033|NCT01540812|Drug|Idarubicin in induction-2|
1690034|NCT01540812|Drug|Fludarabine in induction-2|
1690035|NCT01540812|Drug|Ara-C in induction-2|
1690036|NCT01540812|Drug|G-CSF in induction-2|
1690037|NCT01540812|Drug|Dexamethasone in consolidation-1|
1690038|NCT01540812|Drug|Vincristrine in consolidation-1|
1690039|NCT01540812|Drug|Metotrexato in consolidation-1|
1690040|NCT01540812|Drug|PEG-ASP in consolidation-1|
1690041|NCT01540812|Drug|Dexamethasone in consolidation-2|
1690042|NCT01540812|Drug|ARA-C in consolidation-2|
1690043|NCT01540812|Drug|PEG-ASP in consolidation-2|
1690044|NCT01540812|Drug|Dexamethasone in consolidation-3|
1690045|NCT01540812|Drug|Vincristine in consolidation-3|
1690046|NCT01540812|Drug|Metotrexato in consolidation-3|
1690047|NCT01540812|Drug|PEG-ASP in consolidation-3|
1690048|NCT01540812|Procedure|allogeneic HSCT|
1690049|NCT01540812|Procedure|Allo HSCT with reduced-intensity conditioning|
1690050|NCT01540799|Device|ATI Neurostimulation System|ATI Neurostimulator (NS-100) and Remote Controller (RC-200)
1690051|NCT01540786|Procedure|High resolution urodynamic assessment|
1690052|NCT01540786|Procedure|Conventional urodynamic assessment|
1690053|NCT01540773|Drug|Amino acid supplement|An orally administered supplement of the proprietary amino acid derivative
1690054|NCT01540773|Drug|Placebo|A non-active orally administered supplement of the proprietary amino acid derivative
1690055|NCT01540760|Drug|MCAF5352A|Multiple ascending doses
1690056|NCT01540760|Drug|Placebo|Matching MCAF5352A, multiple doses
1690057|NCT01540747|Dietary Supplement|Myo-inositol + folic acid + melatonin|Myo-inositol (2000mg)+ folic acid (200 mcg)+ melatonin(3 mg)
1690058|NCT01540747|Dietary Supplement|Myo-inositol + folic acid|Myo-inositol (2000mg) + folic acid (200 mcg)
1690059|NCT01540734|Drug|Marketed paracetamol|Marketed formulation
1690060|NCT01540734|Drug|Experimental paracetamol formulation|Experimental formulation
1690061|NCT01540721|Drug|Marketed paracetamol|marketed formulation
1690062|NCT01540721|Drug|Experimental paracetamol formulation|Experimental formulation
1690063|NCT01540708|Drug|SERETIDE Rotacaps|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
1690157|NCT01539824|Biological|Mycobacterium obuense|IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
1690064|NCT01540708|Drug|SERETIDE Diskus|The study will be conducted in 3 parts with an adaptive design where pharmacokinetic data analysis follows each part to enable a decision on whether progression to the subsequent parts is required. Thirty six subjects will be enrolled in each part. Part A will test an alternative version of the Rotahaler with a lower airflow resistance. The study will then test one or more of the following options depending on the outcome of part A. If progressed, part B will test modified Rotacap formulations including: (1) modified blend formulation, (2) reduced capsule fill weights, (3) different capsule types. Part B will also test other versions of the Rotahaler with intermediate airflow resistance. Part C will test the lower strength FP/salmeterol (100/50 mcg or lower) and/or a new unit dose DPI device (BUDI). In each arm, subjects will be administered 7 doses (3.5 days bid) with PK sampling following administration of the 7th dose on the morning of Day 4.
1690065|NCT01540682|Drug|MLN8237|Three dose levels of MLN8237 are planned:30, 40 and 50 mg po bid.
1690066|NCT01540682|Drug|Cetuximab|~ 1 week prior to the initiation of radiation therapy and continuing for a grand total of 12 weeks.
1690067|NCT01540682|Radiation|Radiotherapy|Radiotherapy will be administered in 2-Gy fractions, 5 days a week to a total dose of ~70 Gy.
1690068|NCT01540669|Dietary Supplement|Polydextrose, low dose|4g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
1690069|NCT01540669|Dietary Supplement|Polydextrose, medium dose|8g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
1690070|NCT01540669|Dietary Supplement|Polydextrose, high dose|12g polydextrose powder will be mixed with beverage and consumed once per day for 2 weeks
1690071|NCT01540669|Dietary Supplement|Placebo powder|Placebo powder will be mixed with beverage and consumed once per day for 2 weeks
1690072|NCT01540656|Device|Transcutaneous mechanical nerve stimulation (TMNS) (FERTI CARE)|"A medical vibrator (FERTI CARE personal, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum of the glans penis. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.
A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
1690073|NCT01540643|Device|Iliac Leg Graft|Zenith® Spiral-Z® AAA Iliac Leg Graft
1690076|NCT01540604|Drug|CRD007|
1690077|NCT01540591|Drug|intralipid|IV infusion of intralipid 20% between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
1690078|NCT01540591|Drug|Saline|Saline 0.9% IV infusion between day4 and 9 of ovarian stimulation & another dose when got pregnant within the 1st week of positive pregnancy test
1690079|NCT01540578|Other|laboratory biomarker analysis|Correlative studies
1690082|NCT01540552|Other|medical chart review|
1690083|NCT01540552|Procedure|computed tomography|
1690084|NCT01540552|Procedure|computer-aided detection/diagnosis|
1690085|NCT01540539|Drug|REGN1154 or placebo|Participants will receive active drug or placebo
1690086|NCT01540526|Drug|axitinib|7 mg PO BID days 1-14 in 21 day cycles.
1690089|NCT01540500|Drug|Tasimelteon|5.66 mg dose on Day 1 and Day 8
1690090|NCT01540500|Drug|Fluvoxamine|50 mg Dose on Days 2-8
1690091|NCT01540487|Drug|linagliptin/metformin(high dose)|patient would take fixed dose combination tablets of linagliptin /metformin (high dose) and single linagliptin and metformin (High dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
1690092|NCT01540487|Drug|Linagliptin/metformin(low dose)|patient would take fixed dose combination tablets of linagliptin /metformin (low dose) and single linagliptin and metformin (Low dose) tablets single dose in random order, and each dosage will be separated in 42 days interval.
1690093|NCT01540474|Biological|Group 1: 10 ug FMP012 with 2 ug GLA-SE|Biological/vaccine; E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipid A Stable emulsion (GLA-SE), a proprietary adjuvant
1690094|NCT01540474|Biological|Group 2: 10 ug FMP012 with 5 ug GLA-SE|E-coli expressed antigen FMP012 will be adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
1690095|NCT01540474|Biological|50 ug FMP012 with 5 ug GLA-SE or 2 ug GLA-SE|E-coli expressed malaria antigen FMP012 adjuvanted with Glucopyranosyl lipd A stable emulsion (GLA-SE), a proprietary adjuvant
1690096|NCT01540461|Drug|Brivanib|Tablets, Oral, 800 mg, Once daily, Until withdrawal of consent, disease progression or until unmanageable toxicity
1690097|NCT01540448|Procedure|Laparoscopic Right Hemicolectomy|We perform the Right Hemicolectomy (RH) with a 3 trocars technique. The procedure starts with the identification and sectioning of the ileocolic vessels at their origin. Next, is possible to divide the mesentery towards the terminal ileum, which was sectioned by laparoscopic linear stapler. The procedure continues with the incision of the Houston's ligament and the retroperitoneal dissection of the cecum and ascending colon up to the right flexure by pulling the terminal ileum upwards. During this maneuvers and eventually after the incision of the hepato-duodenocolic ligament, is possible to identify and cut the right colic vessels and, if necessary, the middle colic vessels and the Henle's venous branch.With the right colon and proximal transverse completely mobilized, it is possible to section the colon with a linear laparoscopic stapler and to create a 4-6 cm service incision to remove the specimen and perform an extracorporeal ileo-colic isoperistaltic mechanical anastomosis.
1690128|NCT01540188|Behavioral|Family Intervention to Address Drug Use and HIV in Vietnam|"Intervention for IDUs: there are 4 sessions of the intervention with the following titles: My family, my health, my actions, my community.
Intervention for family members: there are 4 intervention sessions for family members covering the following topics: my family, my responsibility, my support and my community"
1690196|NCT01539512|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
1742245|NCT00121823|Biological|MVA ME-TRAP|
1690098|NCT01540448|Procedure|Laparoscopic Left Hemicolectomy|We routinely perform the Left Hemicolectomy (LH) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing LH the Inferior Mesenteric Artery (IMA) is usually tied immediately below the origin of the Left Colic Artery (LCA) while in presence of benign disease, to preserve the IMA, the dissection is performed along the course of the vessel, sectioning progressively the sigmoid arterial branches close to the colonic wall. When left colon is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to section the distal colon and finally perform a termino-terminal mechanical anastomosis.
1690099|NCT01540448|Procedure|Anterior Rectal Resection|We routinely perform the Anterior Rectal Resection (ARR) with a 3 trocars technique eventually placing the 4th trocar in the left flank if needed. The procedure started with the division of the gastro-spleno-colic ligament and the subsequent mobilization of the left colic flexure. Then is possible to identify and section the inferior mesenteric vessels. Performing ARR the Inferior Mesenteric Artery (IMA) is usually tied at origin but in particular cases it can be tied immediately below the origin of the Left Colic Artery (LCA). When left colon and is completely mobilized from the retroperitoneum along the avascular plane between the mesocolon and perirenal fat is possible to perform a partial or total mesorectal excision. Usually a termino-terminal mechanical anastomosis is performed at the end of the procedure.
1690100|NCT01540435|Drug|Bevacizumab|Bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) + FOLFOXIRI in a biweekly schedule, 6 cycles preoperatively, 6 cycles postoperatively
1690101|NCT01540409|Drug|AVI-4658 (Eteplirsen)|Eteplirsen will be administered once weekly via an IV infusion. There are two treatment groups, 30 mg/kg and 50 mg/kg.
1690102|NCT01540396|Behavioral|Dietary modification and medications|Patients diagnosed with gestational diabetes will receive dietary advice and instruction on blood glucose monitoring from their regular prenatal doctors, consistent with standard of care practices. Medications (glyburide, insulin) will be used as needed to assist with blood glucose control.
1690103|NCT01540383|Behavioral|Intensive integrative aphasia therapy|Intensive language therapy (3 weeks, 5 days/week, >=2 hours/day) provided in regular clinical setting and consisting of a combination of language systematic and communicative-pragmatic treatment
1690104|NCT01540383|Behavioral|Waiting list control group|Control group starts intensive language therapy after a 3-week waiting period.
1690105|NCT01540370|Other|No Treatment|No treatment
1690106|NCT01540357|Behavioral|Mindfulness-based therapy|Treatment was performed as group therapy at two training weekends which were separated by an interval of 7 weeks (eleven hours/weekend) and in four further two-hour sessions (week 2, 9, 18 and 22).
1690107|NCT01540357|Behavioral|Treatment after waiting time|Treatment was performed after completion of the active arm.
1690108|NCT01540344|Procedure|CRS|complete macroscopic cytoreduction (CC-0/1)
1690109|NCT01540344|Drug|HIPEC|bidirectional hyperthermic intraperitoneal chemotherapy (HIPEC) with 400 mg/sqm 5-FU + 20 mg/sqm folinic acid IV and 300 mg/sqm oxaliplatin IP
1690110|NCT01540331|Device|"model 1000 PNT vacuum controller (the vacuum device for ocular suction)"|A Pneumatic Trabeculoplasty treatment, composed of 3 single PNT applications at day 0, 7 and 90. Each treatment consist in a ocular pneumatic suction of 500inchHg administered for 60 seconds in perilimbal region through the device (model 1000 PNT vacuum controller). This suction is then repeated after a 5 minutes pause.
1690111|NCT01540318|Procedure|Abdominal Ultrasound (FAST examination)|Use of FAST abdominal ultrasound exam
1690112|NCT01540305|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|rTMS was administered by means of a NEURO-MS (NEUROSOFT LTD®, Russia) with a focal 8-shaped 70 mm coil. Stimulation parameters were 1-Hz, 20-min trains (1200 pulses/day) at 100% of resting MT, once a day, 5 days a week, for 2 weeks.
1690113|NCT01540305|Device|Sham repetitive transcranial magnetic stimulation|The sham treatment was performed using the Neurosoft ® sham coil. A metal plate placed inside this coil prevents the magnetic field from stimulating the cortex. This coil looks and sounds like an active coil.
1690114|NCT01540292|Biological|Mesenchymal Stem Cells (MSC)|MSC (1.5-2 cells/kg BW) IV injection, twice at 4 weeks apart
1690115|NCT01540266|Procedure|Information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
1690116|NCT01540266|Procedure|no information structuring|Students were independently shown one of two videos in which the same physician conveyed the identical 28 items of information to an older patient (played by an actor) in either structured or non-structured form
1690117|NCT01540253|Drug|PI3K inhibitor BKM120|Given PO
1690118|NCT01540253|Drug|docetaxel|Given IV
1690119|NCT01540253|Other|pharmacological study|Correlative studies
1690120|NCT01540253|Other|questionnaire administration|Ancillary studies
1690121|NCT01540253|Other|laboratory biomarker analysis|Correlative studies
1690122|NCT01540240|Drug|Zidovudine|Low dosage AZT arm: AZT 200 mg/3TC 150 mg(zidovudine 100 mg 2 caps/lamivudine 150 mg 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
1690123|NCT01540240|Drug|Zidovudine|Standard AZT arm: AZT 300 mg/3TC 150 mg(Combivir 1 cap) twice a day. Nevirapine 200 mg 1 cap twice a day.
1690124|NCT01540227|Drug|Regular Treatment for Syphilis|"Drug: Benzathine Penicillin G (Bicillin)
Dose: 2.4 million units
Mode of Administration: intramuscular injection
Duration of Treatment: one dose
Health Canada approved indication: Yes"
1690125|NCT01540214|Other|Pre- and postoperative evaluations|"At baseline before surgery and at 6 and 12 months after surgery: questionnaires, bladder diary, pelvic examination with additional ultrasound (one extra outpatient clinic visit at 6 months compared to standard care).
At baseline before surgery and at 12 months after surgery: urodynamics with additional urine sampling (one extra outpatient clinic visit at 12 months compared to standard care).
At time of surgery: additional cystoscopy."
1690126|NCT01540201|Other|Conventional I:E ratio|conventional I:E ratio of 1:2 is applied. Ventilator : Datex-Ohmeda Aestiva/5 ® model
1690127|NCT01540201|Other|I:E = 1:1 ratio|I:E ratio of 1:1 is applied Ventilator : Datex-Ohmeda Aestiva/5 ® model
1690156|NCT01539837|Drug|Placebo|Feriprox placebo administered orally at the same dosing volume as the 20mg/kg/day feriprox per day
1690129|NCT01540175|Other|Blood samples obtained|Research participants agree to have blood samples obtained at the time of diagnosis before any chemotherapy, if available, and prior to high dose chemotherapy regimen with autologous HSCT as well as on days 14, 21, 28, week 8 and months 3, 6, 12 and 18 after autologous HSCT. Research participants with high risk neuroblastoma may also agree to have blood samples taken before and twice in the recovery period (days 0, 7 and 15-18) of Induction chemotherapy courses one and four.
1690130|NCT01540136|Drug|Nedaplatin|Nedaplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
1690131|NCT01540136|Drug|Cisplatin|Cisplatin 100mg/m2(3 weekly),D1,D22,D43 of RT
1690132|NCT01540123|Dietary Supplement|Berry drink|Cold pressed berry drink standardised to contain 500mg of berry polyphenols
1690133|NCT01540123|Dietary Supplement|Control|Sugar matched control containing berry flavouring and no phytochemicals
1690134|NCT01540110|Drug|Neoadjuvant Docetaxel and Cyclophosphamide|"5.1.1 Docetaxel Docetaxel at a dose of 75 mg/m2 will be administered by intravenous infusion over 90 minutes (AFTER completion of cyclosphosphamide 600 mg/m2) on D1 every 21 days for 6 cycles using nonpolyvinylchloride tubing.
Standard premedication with oral dexamethasone 8 mg bd on D-1, D1 and D2 will be administered. Alternatively, intravenous dexamethasone 8 mg before docetaxel followed by oral dexamethasone 8 mg bd on D1 and D2 can be given.
Routine prevention of chemotherapy induced emesis will be administered (see 5.2.2)
5.1.2 Cyclophosphamide
Cyclophosphamide 600 mg/m2 by slow intravenous infusion over 10 minutes (BEFORE docetaxel) will be administered every 21 days for 6 cycles.
No premedications are required except for routine prevention of chemotherapy induced emesis (see 5.2.2)"
1690135|NCT01540084|Drug|propofol|For induction, 25 mg of meperidine and 2.5 mg of midazolam were administered in both groups. In the cocktail group, one milligram per kilogram body weight of 1% propofol emulsion (Baxter Healthcare Corp., Irvine, CA) was slowly infused by an automated pump (Terufusion syringe pump TE-331, Terumo Corporation, Tokyo, Japan). To maintain conscious level of patient in the conventional group to be at moderate or deep level, 25 mg of meperidine and/or 2.5 mg of midazolam were administered as necessary, whereas patients in the cocktail group were continuously administered with 1% propofol at the rate of 1 mg/kg/hr. An additional 0.5 mg/kg bolus was administered as needed to achieve the designed conscious level.
1690136|NCT01540071|Drug|NRX 194204|NRX 194204 is an oblong, soft, gelatin capsule and will be taken once a day
1690137|NCT01540058|Other|Cancer Type ID test|"CancerTYPE ID is a real-time RT-PCR assay that measures and interprets the differential expression of 92 genes as a molecular correlate for tumor classification. The test classifies 28 main tumor types and 50 subtypes using an algorithm incorporating gene expression data from a reference database of 2,094 tumor specimens. CancerTYPE ID is used, in conjunction with other clinical and diagnostic procedures, to help identify tumor type and histological subtype. The performance characteristics and reproducibility of the test have been published previously (Erlander et al., 2011 ; Kerr et al., 2012).
CancerTYPE ID is conducted on formalin-fixed paraffin-embedded (FFPE) tumor specimens at bioTheranostics' high complexity laboratory, which is certified by Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and approved by the State of New York."
1690138|NCT01540058|Other|No test Empiric strategy|Empiric strategy
1690139|NCT01540032|Behavioral|Low salicylate diet|Patients will avoid foods from the 'high salicylate' group completely. They can eat foods from the 'low salicylate' group freely and just eat foods from the medium group occasionally, and not in large amounts.
1690140|NCT01540032|Behavioral|Normal diet|Patients will eat their usual diet.
1690143|NCT01539980|Device|Sericin scaffold|Device: wound dressing containing silk sericin A scaffold from silk sericin-polyvinyl alcohol-glycerin blending are applied on one half of the skin graft donor site Device: fine mesh gauze impregnated with paraffin and 0.5%chlorhexidine acetate (Bactigras, Smith&Nephew, London, UK) are applied on the other half of the skin graft donor site
1690144|NCT01539967|Procedure|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:
position of 4 trocars and insertion of a nasogastric tube
dissection and mobilization of the greater curvature of the stomach
preparation of the stomach for division
gastric partition
extraction of the gastric remnant
postoperative surveillance"
1690145|NCT01539941|Behavioral|Medication integration protocol|MIP is a 5 session protocol. The first session consists of pretreatment assessment activities using measures administered during routine clinical intake. The following sessions, MIP Sessions 1-4, are meant to be delivered sequentially, commencing sometime after session 2 or 3 of treatment, that is, after completion of initial treatment contracting and engagement interventions that will usually be focused on ASU-related referral problems for this population. The proposed pilot work will shed light on the optimal timing for MIP Sessions 1-4.
1690146|NCT01539928|Other|Dual FDG-PET/CT|Conventional FDG-PET/CT preformed after 1 hour and additional PET/CT 3 hours after injection
1690147|NCT01539915|Drug|BCT194|Topically applied BCT194 cream (0.5%)
1690148|NCT01539902|Biological|Human Umbilical Cord derived MSCs|Human Umbilical Cord derived MSCs treatment for lupus nephritis via infusion
1690149|NCT01539902|Drug|Cyclophosphamide|Cyclophosphamide based immunosuppressive agent for treatment for lupus nephritis
1690150|NCT01539889|Radiation|99mTC-PulmoBind|DFH-12 (PulmoBind) is a peptide derived from human adrenomedullin (hAMI-52). Adrenomedullin (AM) is a 52-amino acid peptide produced by many tissues in the body, including the vascular endothelium. 3 radiolabeled doses of PulmoBind will be used in this study (5mCi, 10mCi and 15mCi) 5 healthy subjects per dose for the 5 mci and the 10 mci groups but 10 subjects will be used for the 15 mci group.
1690151|NCT01539876|Procedure|Fine needle aspiration assessing tumour TNFa levels|Fine Needle aspiration will be done X5: 1 hr pre-treatment, 1hr post treatment,24 hrs post treatment, 48 hrs post treatment, and following last chemotherapy cycle
1690152|NCT01539863|Other|maintenance care|Participants will receive treatment at regular intervals during the study, a maximum of 12 and a minimum of 4 treatments as decided by the treating chiropractor
1690153|NCT01539863|Other|Treatment as needed|Participants may never receive treatment, there is no upper limit
1690154|NCT01539850|Device|OMS102|Subjects will receive implanted OMS102 System.
1690155|NCT01539837|Drug|Deferiprone|20mg/kg/d or 30mg/kg/d Deferiprone divided into two equal doses (morning and evening), every day for 6 months
1743133|NCT00127972|Drug|nevirapine|
1690158|NCT01539824|Radiation|SBRT|The CyberKnife system is normally used for the treatment of cancerous tumours in cases where the type and position of the tumour and the condition of the patient indicate that treatment may be curative. In this study, the CyberKnife is being used in an experimental way to deliver a targeted dose of stereotactic body radiation with extreme accuracy in order to damage a single tumour growth (metastasis) in the liver.
1690159|NCT01539811|Procedure|Surgical incision and drainage of diabetic foot infection|Incision and drainage of diabetic foot infection with or without amputation of toes or the forefoot, depending on the condition of the foot
1690160|NCT01539811|Drug|Short course antibiotics|Short course (<2 weeks) of antibiotics will be prescribed
1690161|NCT01539811|Drug|Long course antibiotics|Long course (>2 weeks) of antibiotics will be prescribed
1690162|NCT01539798|Other|Oral saline|Ingestion of 2 L of 0.9% saline solution over 1h
1690163|NCT01539798|Other|Intravenous saline|Infusion of 2L of 0.9% saline solution over 1h
1690164|NCT01539785|Procedure|Secondary citoreduction|The eligible patients, after anesthesia preparation will be submitted to a surgical complete cytoreduction attempt that consist in the removal of all macroscopically visible tumor nodules from the visceral and parietal peritoneum. To obtain a complete cytoreduction, different procedures are required, as described by Sugarbaker (30), which may include omentectomy, splenectomy, diaphragmatic, pelvic,parietal peritonectomy and / or visceral, bowel resection, hepatic resection and cholecystectomy.
1690165|NCT01539785|Procedure|Hyperthermic intra-peritoneal chemotherapy (HIPEC)|If the patient is randomized to make chemo-hyperthermia, surgery will be followed by HIPEC with the closed technique, that consist in the perfusion of the abdominal cavity with a solution containing cisplatin (CDDP) 75 mg/m2 in 2L/m2 heated saline. The solution is heated and perfused with two special pumps (Hyperex, Korea or Stoeckert munich). The temperature of inflow and outflow of the solution, will be maintained, respectively, between 41 ° and 42.5 ° C. The intraperitoneal temperature will be maintained at 41.5 ° C and monitored by thermometers inserted into the subphrenic space and into the pelvis. After 60 minutes of perfusion the surgical incision will be open after removal of the entire solution. The global temperature will be measured by thermometer inserted into the esophagus and rectum. A Swan-Ganz catheter will be kept in place during the HIPEC for monitoring cardiovascular function.
1690167|NCT01539746|Procedure|TAVI without BAV|Avoidance of balloon valvuloplasty (BAV) of the native aortic valve before valve deployment
1690168|NCT01539746|Procedure|TAVI standard procedure|TAVI standard procedure including BAV before valve deployment
1690169|NCT01539733|Drug|Olanzapine|After randomisation to olanzapine treatment, olanzapine will be started at an initial dose of 2,5 - 5 mg orally or intramuscularly, after 2 hours subsequent titration of dosage will be based on clinical judgement with a maximum of 20 mg per 24 hours divided over a maximum of 3 gifts. Sustenance dose will consist of half of the total titrated dose per 24 hours in one gift.
1690170|NCT01539733|Drug|Haloperidol|After randomisation to haloperidol treatment, haloperidol dosing will be titrated, with repeated dosing of 0,5 - 2mg orally or subcutaneously every 40 minutes until signs of delirium diminish, with a maximum of 20 mg orally or 10 mg subcutaneously per 24 hours. Sustenance dose will consist of half of the total titrated dose per 24 hours in one or two gifts.
1690171|NCT01539720|Drug|Ulipristal acetate|30 mg tablet
1690172|NCT01539720|Device|levonorgestrel IUS|Levonorgestrel IUS, 52mg placed intrauterine
1690173|NCT01539707|Drug|Solifenacin succinate|oral suspension
1690174|NCT01539681|Drug|Sorafenib (Nexavar, BAY43-9006)|Subjects should be treated with sorafenib in compliance with the recommendations written in the local product information.However, the decision on the duration and dose of treatment is at the discretion of the prescribing physician.
1690175|NCT01539655|Drug|vandetanib|Oral tablets, 300 mg, single dose
1690176|NCT01539655|Drug|omeprazole|Oral capsules, 40 mg, multiple doses
1690177|NCT01539655|Drug|ranitidine|Oral tables, 150 mg, multiple doses
1690178|NCT01539642|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
1690179|NCT01539642|Drug|Placebo Sufentanil NanoTab PCA System|Placebo NanoTab dosed sublingually every 20 minutes as needed for pain for up to 48 hours. Patient may elect to remain in study for up to 72 hours.
1690180|NCT01539629|Device|Cardiac pacing|Cadiac pacing via a pulse generator and implaned intracardiac leads.
1690181|NCT01539616|Drug|ZYH7|ZYH7 4mg given once orally in the morning before breakfast, for 8 weeks.
1690182|NCT01539616|Drug|ZYH7|ZYH7 8 mg given once orally in the morning before breakfast, for 8 weeks.
1690183|NCT01539616|Drug|ZYH7|ZYH7 16 mg given once orally in the morning before breakfast, for 8 weeks.
1690184|NCT01539616|Drug|Fenofibrate|Fenofibrate 160 mg given once orally in the morning before breakfast, for 8 weeks.
1690185|NCT01539603|Device|Drug eluting balloon + Bare metal stent|PCI using Sequent Please and then Coroflex Blue
1690186|NCT01539603|Device|drug eluting stent (Zotarolimus-eluting stent)|conventional PCI using Endeavor Integrity
1690187|NCT01539590|Drug|BB3|Daily intravenous administration of 2 mg/kg BB3 for four (4) days
1690188|NCT01539590|Drug|Normal saline|Daily intravenous administration for four (4) days. The volume of normal saline will vary by estimated weight.
1690189|NCT01539577|Drug|dexamethasone 700 μg intravitreal implant|dexamethasone 700 μg intravitreal implant administered according to general clinical practice.
1690190|NCT01539564|Drug|Minocycline HCl Microspheres|
1690191|NCT01539551|Other|check BNP and lactate|we will collect patients's blood samples on Day 0, Day1 and Day2
1690192|NCT01539538|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab dosed sublingually q 20 minutes as needed for pain for at least 48 hours and up to 72 hours
1690193|NCT01539538|Drug|morphine IV PCA|1 mg morphine administered IV q 6 minutes as needed for pain for at least 48 hours and up to 72 hours
1690194|NCT01539525|Behavioral|Motivational Interview|Motivational Interview provided by either a Nurse or Computer
1690195|NCT01539525|Other|Treatment as Usual|Subjects given a brochure listing relevant recovery resources in the local area.
1690234|NCT01539174|Biological|rituximab|Given IV
1690197|NCT01539512|Drug|Rituximab|Rituximab administered intravenously 8 times through Week 20: Day 1: 375 mg/m^2, and 500 mg/m^2 thereafter
1690198|NCT01539512|Drug|Placebo to match idelalisib|Placebo to match idelalisib administered orally twice daily
1690199|NCT01539473|Drug|TR-701 FA with Tyramine|TR-701 FA 200 mg oral and Tyramine
1690200|NCT01539473|Drug|Placebo-controlled withTyramine|Placebo-controlled and Tyramine
1690201|NCT01539460|Procedure|minimally invasive surgery|Subcutaneous fat and apocrine sweat glands were removed by suction under tumescent anesthesia,and the remaining tissue and glands, tightly attached to the epidermis-dermis interface, were completely removed with scissors through the initial small incision.
1690202|NCT01539447|Drug|Naproxen|• Group 1: Naproxen 500 mg twice daily for three weeks following surgery beginning postoperative day #1
1690203|NCT01539447|Drug|placebo|• Group 2: Placebo twice daily for three weeks following surgery beginning postoperative day #1
1690204|NCT01539434|Behavioral|Behavioural intervention|Patients in the behavioural intervention group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active. The behavioural intervention to support physical activity behaviour includes weekly motivational interviewing telephone calls for the first month, two telephone calls for the following two months and thereafter monthly telephone calls.
1690205|NCT01539434|Behavioral|Usual care group|Patients in the usual care group will get a personal meeting with the physiotherapist and get advice about the value of physical activity and also get recommendations on how to be physically active.
1690206|NCT01539421|Behavioral|Use of Home exercise computer program|After a 30-minute rest period the study patient performed a series of 4 representative exercises from the Wii under direct supervision by an investigator. Five minutes' rest was allotted between each exercise. The patient was instructed to exercise at his/her own pace, with a maximal duration of 5 minutes per exercise. The Oxycon Mobile was worn throughout this exercise, and the metabolic measurements listed above were recorded over the last 30 seconds of each exercise. The exercises included running in place, upper arm movements, stepping in place, and obstacle course.
1690207|NCT01539408|Drug|Misoprostol|single dose of 400 mcg misoprostol administered sublingually
1690208|NCT01539408|Procedure|surgery Manual vacuum aspiration (MVA)|standard surgical treatment
1690209|NCT01539395|Other|MSDx Complex-1 Biomarker Test|A biomarker test for the level of MSDx Complex-1
1690210|NCT01539382|Procedure|Cerebral oxygenation intervention|The protocol for interventions to increase cerebral oxygenation levels above 60% optimizing pH, PaO2, PaCO2, bispectral index, central venous pressure, mean arterial pressure, venous oxygen saturation, and hematocrit. In addition, cerebral perfusion pressure of 70-80 mm Hg and flow >2.0 l/min/m2 will be maintained during cardiopulmonary bypass. In the ICU, temperatures will be maintained below 38 degrees by administering antipyretics or cooling, and dexmedetomidine will be used if the patient is agitated.
1690211|NCT01539369|Other|Healthy eating diet (Diet A) or healthy eating diet combined with advice to increase fibre intake (Diet B) to at least 25g/day|"Participants were randomly assigned to one of two parallel arms:
Diet A:healthy eating without extra advice to increase fibre intake or Diet B: healthy eating with extra advice to increase fibre intake to a minimum of 25g/d. Healthy eating advice was based on the British Heart Foundation booklet: Food Should Be Fun And Healthy. Participants following Diet A were encouraged to eat breakfast cereals and were provided with complementary cereals and snacks low in fibre. Participants following Diet B were encouraged to eat high fibre breakfast cereals and to incorporate wheat bran fibre in other meals. Complementary high fibre cereals and snacks were provided."
1690212|NCT01539343|Drug|Antimicrobial Solution|Antimicrobial solution, consisting of minocycline in combination with 30mg/ml of a chelator (EDTA) in 25% ethanol solution (HEAL solution), instilled in central venous catheter (CVC) catheter for 2 hours once daily for a minimum of 5 consecutive days. Lock therapy also received once weekly for two additional weeks.
1690213|NCT01539330|Drug|Voriconazole|"At beginning of study visit 1 (0-12 h): 6 mg/kg, IV (in the vein) over a period of 120 min
at beginning of study visit 2 (12-24 h): 6 mg/kg, IV (in the vein) over a period of 120 min
at beginning of study visit 3 (24-36 h): 4 mg/kg, IV (in the vein) over a period of 80 min
at beginning of study visit 4 (36-48 h): 4 mg/kg, IV (in the vein) over a period of 80 min
at beginning of study visit 5 (48-60 h), 6 (60-72 h) and 7 (72-84 h): 200 mg po"
1690214|NCT01539330|Other|microdialysis|long-term microdialysis over study days 1-4 (visits 1-7)
1690215|NCT01539317|Drug|Topical liquid lidocaine|active intervention drug numbs the hypersensitive mucosa of the vulvar vestibule
1690216|NCT01539317|Drug|Topical saline|saline applied to the vestibule mucosa will not reverse the local tenderness
1690217|NCT01539304|Drug|CITUS Dry Syrup|Pranlukast 10% dry syrup, b.i.d.
1690218|NCT01539304|Drug|Placebo|Placebo dry syrup, b.i.d
1690220|NCT01539278|Procedure|Adenotonsillectomy|Tonsils and adenoids are surgically removed
1690221|NCT01539278|Other|Observation alone / no intervention|Patients are observed over time, no surgery is done, subjects complete QOL questionnaires at set intervals
1690222|NCT01539265|Drug|silodosin|
1690223|NCT01539265|Drug|silodosin|
1690224|NCT01539265|Drug|placebo|
1690225|NCT01539252|Procedure|Single dialyzer|Hemodialysis treatment using a single Baxter dialyzer - considered standard hemodialysis treatment.
1690226|NCT01539252|Procedure|Two dialyzers|Hemodialysis treatment using a two Baxter dialyzers in parallel.
1690227|NCT01539239|Device|Hydrus Aqueous Implant|The Hydrus Aqueous Implant is a crescent-shaped nitinol device intended to be a permanent implant placed through the trabecular meshwork into Schlemm's Canal, immediately following placement of a monofocal IOL.
1690228|NCT01539239|Procedure|Cataract surgery|A monofocal intraocular lens (IOL) placed during the cataract surgery.
1690229|NCT01539226|Drug|Placebo Vaginal Ring|Vaginal Ring containing 25 mg Dapivirine
1690230|NCT01539213|Drug|secukinumab (AIN457)|anti-IL-17 antibody
1690231|NCT01539200|Dietary Supplement|ONS+JDR|Oral Nutritional Supplement with Jacques-Delacroze Eurythmic training
1690232|NCT01539200|Dietary Supplement|JDR|Jacques-Delacroze Eurythmic training with placebo ONS
1690233|NCT01539187|Device|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy
1690241|NCT01539161|Device|Implantable Cardiac Monitor|9529 Reveal XT Implantable Cardiac Monitor as well as the use of 9539 Reveal XT Patient Assistant.
1690242|NCT01539161|Procedure|Standard of Care|Standard of care arm including exam, ECG and Holter every 6 months, and an Echo, Chest X-Ray and Stress test every 12 months.
1690243|NCT01539135|Drug|Methylene Blue|20 cc methylene blue instilled above the cuff once after intubation for the duration of the surgical procedure
1690244|NCT01539122|Device|Zimmer TM Glenoid|The Zimmer TM glenoid will be used for the glenoid shoulder replacement component.
1690245|NCT01539122|Device|Cemented Glenoid|A cemented glenoid will be used for the glenoid component of the total shoulder replacement.
1690246|NCT01539109|Behavioral|Rehabilitation|Patients will receive training upon tasks of daily living. They will perform these exercises in our laboratory under the supervision of qualified personnel.
1690247|NCT01539109|Procedure|Noninvasive brain stimulation: tDCS|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (2mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered to patients in the experimental group for 2 hr each day for 5 days a week for 2 weeks in conjunction with therapy for the affected hand.
1690248|NCT01539109|Procedure|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
1690249|NCT01539096|Procedure|tDCS: noninvasive brain stimulation|TDCS is a method of noninvasive stimulation of the brain. Using electrodes placed in saline-soaked sponges, low level of direct current (1mA) is delivered over the scalp. This intervention is considered safe and noninvasive because it does not involve implantation or injection or any skin penetration. In the present study, tDCS will be delivered for 1 hr each day for 3 days a week for 5 weeks in conjunction with constraint-induced movement therapy for the affected hand.
1690250|NCT01539096|Behavioral|Constraint induced movement therapy (CIMT)|Patients with stroke affecting the hand will receive constraint-induced movement therapy (CIMT) to re-train movements of the affected hand. Training will involve practicing tasks of daily living with qualified personnel. Training will be delivered for 1 hr each day for 3 days a week for 5 weeks. Patients will also be asked to use their affected hand in daily activities at home for 5 hrs a day while wearing a mitt on the unaffected hand.
1690251|NCT01539096|Procedure|Sham tDCS: placebo noninvasive brain stimulation|Placebo set-up for noninvasive brain stimulation will be similar to that for the active tDCS; sponge electrodes would be placed on the scalp and connected to a batter-operated device. Patients will not receive the effective level of direct current as would delivered in active tDCS intervention. But patients will not be able to decipher whether they are receiving active or placebo tDCS.
1690252|NCT01539083|Drug|Thalidomide|Thalidomide 100 mg tablet, orally.
1690253|NCT01539083|Drug|Bortezomib|Bortezomib 1.3 milligram per square meter (mg/m^2) solution for injection subcutaneously (SC).
1690254|NCT01539083|Drug|Cyclophosphamide|Cyclophosphamide 300 mg/m^2 orally.
1690255|NCT01539083|Drug|Dexamethasone|Dexamethasone 20 mg orally.
1690256|NCT01539083|Drug|Prednisolone|Prednisolone 50 mg orally.
1690257|NCT01539070|Behavioral|Eating and physical activity counseling|"The parents of overweight children will be invited to attend a total of 6 group sessions (the group will be comprised of 6 children with their parents) on a weekly basis, in which 5 aspects will be dealt with 1) Dietary culture, risk-benefit practices, 2) The process of feeding (acquisition/preparation/service Eating behaviors), 3) Physical activity habits, 4) Importance of weighing/measuring oneself and its meaning, 5) feedback and evaluations. These aspects and contents will be distributed throughout the 6 sessions.
There will be two more individual session, at 3 and 6 months respectively, for the reinforcement of recommendations provided for the modification of dietary behaviors and physical activity."
1690258|NCT01539057|Drug|Fibrinogen|"The dose of fibrinogen should be calculated at 1 g of fibrinogen in order to obtain an increase in plasma fibrinogen value of 0.29 g / L to reach a final value of 2.9 g / L.
Fibrinogen ampoules powder prepared with water dilution and located in a serum at a concentration of 2g/100 ml, which will be administered by intravenous infusion for 10 minutes.
Administration before surgery starts"
1690259|NCT01539057|Drug|Saline|the same dose in volume of water dilution will be administered. The potential dose of fibrinogen required to obtain a final plasmatic reading of 2.9 g / L. will be computed. A serum will contain the corresponding ml of water dilution. Administered before surgery starts
1690260|NCT01539044|Drug|Neostigmine, atropine|0.05 mg/KG NEOSTIGMINE AND 0.02 MG/ KG ATROPINE at TOF 2
1690261|NCT01539044|Drug|Sugammadex|4 mg/kg sugammadex will be given stat at the end of surgery at PTC 1-2
1690262|NCT01539031|Drug|E2020|"Subjects in the Group-10 mg:
Week 1 to 4: Once daily donepezil 10 mg and placebo matching donepezil 5 mg, Week 5 to 28: Once daily donepezil 10 mg and placebo matching donepezil 23 mg, Week 29 to 32: Once daily donepezil 5 mg, 10 mg and placebo matching donepezil 23 mg, Week 33 to 52: Once daily donepezil 23 mg"
1690263|NCT01539031|Drug|E2020|"Subjects in the Group-23 mg:
Week 1 to 4: Once daily donepezil 5 mg and 10 mg, Week 5 to 28: Once daily donepezil 23 mg and placebo matching donepezil 10 mg, Week 29 to 32: Once daily donepezil 23 mg, and placebo matching donepezil 5 mg and 10 mg, Week 33 to 52: Once daily donepezil 23 mg"
1690264|NCT01539018|Drug|Sorafenib|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity alone.
1690265|NCT01539018|Drug|sorafenib plus tegafur-uracil|Sorafenib 400 mg p.o. twice daily until progression or intolerable toxicity and TEGAFUR-URACIL 125mg/m2 PO BID For 4 weeks and to be repeated on day 36 till progression or intolerance
1690266|NCT01538992|Device|Standard steerable Marinr RF ablation Catheter (5F or 7F)|Intervention: Device: Standard steerable Mariner Radiofrequency ablation Catheter (5F or 7F)
1690267|NCT01538979|Biological|BM32|Subcutaneous injection of 20 micrograms of each of the protein components of BM32 adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
1690384|NCT01538017|Drug|Xiapex|Collagenase Clostridium Histolyticum
1690385|NCT01538017|Procedure|Percutaneous needle fasciotomy|Percutaneous needle fasciotomy ad modum Lermusiaux and Debeyre
1690268|NCT01538979|Biological|BM32|Subcutaneous injection of 40 micrograms of each of the protein components of BM32 adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks for a total of 3 injections before each pollen season and one boost injection after pollen season
1690269|NCT01538979|Biological|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every four weeks before each pollen season and one injection after pollen season for a total of 7 injections
1690270|NCT01538966|Drug|Pegvisomant|
1690271|NCT01538966|Drug|Somatostatin Receptor Ligand (SRL)|
1690272|NCT01538953|Other|handwashing|participants received weekly in-home handwashing promotion and soap as needed
1690273|NCT01538953|Other|flocculent-disinfectant for water treatment|participants received a supply of flocculent-disinfectant product for water treatment and instruction in how to use it
1690274|NCT01538953|Other|water treatment with sodium hypochlorite|participants received a supply of dilute sodium hypochlorite and instruction to treat drinking water with it
1690275|NCT01538940|Biological|Intradermal vaccine|15ug
1690276|NCT01538940|Biological|Intramuscular vaccine|15ug
1690277|NCT01538927|Drug|Fibrin Sealant|Fibrin Sealant 4ml (Baxter Tisseel)
1690278|NCT01538927|Drug|Suture|Black silk 000
1690279|NCT01538914|Procedure|paravertebral block|Postoperative pain is controlled with local analgesics via PVB.
1690280|NCT01538914|Procedure|PCA|Postoperative pain is controlled with intravenous PCA.
1690281|NCT01538901|Other|photodynamic therapy|Methyl-aminolaevulinate 16% cream (Metvix) will be applied on the treated area under occlusion for 3 hours. It follows irradiation with visible red light at a peak wavelength of 630 nm (Actilite CL128) with a single dose of 37 J/cm2.
1690282|NCT01538901|Drug|imiquimod 5% cream|250 mg imiquimod 5% cream will be applied over night for a total of 3 nights in the week, for duration of 4 weeks
1690283|NCT01538888|Procedure|WHOLE BODY VIBRATION|03 MONTHS, TWICE PER WEEK
1690284|NCT01538875|Drug|Hydralazine|Patients with an hypertensive crisis during pregnancy will receive 5mg IV every 15 minutes until high blood pressure is controlled (Maximum number of doses: 3).
1690285|NCT01538875|Drug|Labetalol|Patients with an hypertensive crisis during pregnancy will receive 20 mg of Labetalol IV. After 15 minutes if the crisis continue, 40 mg IV. After 15 minutes if the crisis continue, 80 mg IV. Then, if the crisis continue, 80 mg IV every 15 minutes (maximum dose: 300 mg IV in total).
1690286|NCT01538862|Drug|Granulocyte Colony Stimulating Factor (GCSF)|G-CSF 10mcg/kg/d SQ for 7 days
1690287|NCT01538849|Drug|Esomeprazole 40mg|1 tablet = Esomeprazole 40 mg
1690288|NCT01538849|Drug|YH4808 A mg|1 tablet = YH4808 A mg
1690289|NCT01538849|Drug|YH4808 B mg|1 tablet = YH4808 B mg
1690290|NCT01538849|Drug|YH4808 C mg|YH4808 C mg = 2 x YH4808 B mg
1690291|NCT01538836|Behavioral|Weight loss with normal protein intake|Goal of 8 to 10% weight loss while consuming the recommended daily allowance of protein (i.e, 0.8 grams of protein per kg body weight per day).
1690292|NCT01538836|Behavioral|Weight loss with protein supplementation|Goal of 8 to 10% weight loss while consuming 150% of the recommended daily allowance of protein (i.e., 1.2 grams of protein per kg body weight per day).
1690293|NCT01538797|Drug|YF476|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100 mg), placebo and ranitidine 150 mg. There were at least 7 days between consecutive Treatment Days.
1690294|NCT01538797|Drug|Ranitidine|There were 5 treatments: 3 dose levels of YF476 (5, 25 and 100mg), placebo and ranitidine 150mg. There were at least 7 days between consecutive Treatment Days.
1690295|NCT01538784|Drug|YF476|"Two groups of six subjects received single rising oral doses of YF476 capsules or matching placebo. Each subject received 2 doses of YF476 and 1 dose of placebo. 4 subjects received active and 2 placebo at each dose level, as follows:
Group A YF476 0.5, 25 and 100mg by mouth Group B YF476 5.0, 50 and 100mg by mouth
Groups A & B were dosed alternately, at weekly intervals"
1690296|NCT01538771|Drug|Darbepoetin alfa|Darbepoetin alfa 300ug intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
1690297|NCT01538771|Drug|Control Saline|Same volume of saline intracoronary bolus infusion via over-the-wire balloon before the 1st ballooning and conventional treatment
1690298|NCT01538758|Other|Us guided needling|"Us guided needling is a therapeutical technique treating calcifying tendinitis of the shoulder. Calcifications in the rotator cuff tendon are visualised with ultrasound. Under ultrasound guidance a 20 gauge needle is inserted in the calcification. Lidocaine 1% in a 1cc syringe is injected in the calcification and aspirated. The calcification is flushed until the fluid is clear. Sometimes it is not possible to flush the calcification. In this case the calcification will be fragmented.
After flushing or fragmentation of the calcification, 20 mg triamcinolone with 1cc lidocaine 1% will be injected in de subacromial bursa under us guidance."
1690299|NCT01538758|Other|corticosteroid injection|Us guided subacromial bursa injection with 20 mg triamcinolone with 1cc lidocaine 1%.
1690302|NCT01538732|Drug|alitretinoin|30mg capsules (Alitretinoin)will be taken peroral once daily with a meal. Study treatment will be given for a total duration of up to 24 weeks
1690303|NCT01538719|Drug|Rilonacept|Patients randomized to active study drug will receive Rilonacept 320 mg subcutaneously (SQ) on day 0 and 160 mg SQ each week for 5 additional weeks
1690304|NCT01538719|Other|Placebo|Patients randomized to placebo will receive saline subcutaneously (SQ) on day 0 and each week for 5 additional weeks
1690305|NCT01538706|Other|Hospital-based home care|Low-intensive intravenous antibiotics b) intravenous low-toxic chemotherapy c) blood samples drawn from the central venous catheter or peripheral vein d) subcutaneous injections e) nutrition treatment f) pain management (e.g. controlling an intravenous morphine pump g) supportive care e.g. changing dressings.
1690490|NCT01537185|Biological|SPWCV+Alum 300 mcg|3 injections 28 days apart
1690492|NCT01537172|Drug|Placebo|Placebo to match ONO-4053 tablets, dosed in a similar manner to ONO-4053
1690311|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects
1690312|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by healthy subjects under charcoal block
1690313|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by COPD patients
1690314|NCT01538667|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|50 mg single powder dose of 99mTc labeled ciprofloxacin PulmoSphere inhalation powder inhaled by bronchiectasis patients
1690316|NCT01538641|Drug|Rituximab, Gemcitabine, Oxaliplatin|Rituximab:375 mg/m2; on day 1 of each 14 days cycle. Gemcitabine:1,000 mg/m2 on day 2 of each 14 days cycle. Oxaliplatin:100 mg/m2; on day 2 of each 14 days cycle. Total number of cycles: 6 cycles.
1690317|NCT01538628|Device|SpaceOAR System|Fiducial marker placement followed by randomization to treatment group, i.e., 10mL SpaceOAR hydrogel injection, or control group, i.e., no injection of SpaceOAR hydrogel.
1690319|NCT01538589|Drug|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
1690320|NCT01538576|Drug|insulin aspart|Prescribed by the physicians as a result of normal clinical practice
1690321|NCT01538563|Drug|rigosertib sodium|Patients will receive escalating doses of ON 01910.Na (250 mg/m2 to 4450 mg/m2) intravenously by 24 hour continuous infusion once every week (3 weeks per cycle), until evidence of disease progression, intolerable adverse events, or withdrawal of patient consent.
1690322|NCT01538550|Procedure|Flexible sigmoidoscopy|Flexible sigmoidoscopy screening is offered once only
1690323|NCT01538550|Procedure|iFOBT|Biennial screening with iFOBT
1690324|NCT01538537|Drug|rigosertib sodium|ON 01910.Na will be supplied as a sterile, concentrated solution (75 mg/ml) in labeled, sealed glass vials. ON 01910.Na concentrated solution (75 mg/ml) must be diluted before intravenous administration. The starting dose will be 50 mg/m2 over 24 hour infusion daily for 3 days. A fresh infusion must be prepared for each day of the 3-day continuous infusion. This 3-day continuous treatment followed by 11 days without administration of study drug will constitute 1 Cycle. Cycles can be repeated every 2 weeks. The dosing of ON 01910.Na will be based on body surface area (BSA). In the absence of toxicity that would cause accelerated dose escalation to cease, drug doses are planned to escalate every 3 weeks.
1690325|NCT01538511|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) three times daily immediately before breakfast, lunch and dinner for 4 weeks. Dose individually adjusted
1690326|NCT01538511|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin) twice daily immediately before breakfast and dinner for 4 weeks. Dose individually adjusted
1690327|NCT01538485|Drug|Cholecalciferol|weekly dose (based on 70IU KG body weight/day)
1690328|NCT01538472|Drug|Y Zevalin|Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
1690329|NCT01538472|Drug|In Zevalin|Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
1690330|NCT01538472|Drug|Rituxan|"250 mg/m2 by vein on Day -21 and on Day -14.
1000 mg/m2 by vein on Days +1 and +8."
1690331|NCT01538472|Drug|BCNU|300 mg/m2 by vein on Day -6.
1690332|NCT01538472|Drug|VP -16|200 mg/m2 by vein every 12 hours on Days -5, -4, -3, and -2.
1690333|NCT01538472|Drug|Ara-C|200 mg/m2 by vein every 12 hours on Days -5, -4, -3,and -2.
1690334|NCT01538472|Drug|Melphalan|140 mg/m2 by vein on Day -1.
1690335|NCT01538472|Procedure|Stem Cell Infusion|Autologous stem cell infusion on Day 0.
1690336|NCT01538472|Drug|G-CSF|5 mg/kg by vein daily starting Day 0 till recovery of granulocytes of 4.0 x 109/L.
1690337|NCT01538459|Drug|Dexamethasone|8mg (2cc 4mg/cc Solution) mixed with 20 cc 0.25% bupivacaine in one syringe resulting in 364 µgm/cc for injection in perineural space. One time dose during nerve block preoperatively.
1690338|NCT01538459|Drug|Bupivacaine|Control Group receives 20 cc 0.25% bupivacaine without any adjuvants
1690339|NCT01538446|Drug|Modification of Prasugrel based on a biological assay|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
1690340|NCT01538446|Drug|prasugrel / clopidogrel|fixed dose of prasugrel 5 mg
1690341|NCT01538446|Device|Verify Now|Monitoring with VerifyNow P2Y12, 2 weeks after initiation of 5 mg of maintenance dose of prasugrel, reduction of antiplatelet therapy if there is high on-treatment platelet inhibition (HPI) or increase in dosing if there is high on-treatment platelet reactivity (HPR) Device: VerifyNow point of care assay VerifyNow (ACCUMETRICS San Diego USA)
1690342|NCT01538420|Drug|GLPG0492|Oral solution
1690343|NCT01538420|Drug|Placebo|Placebo oral solution
1690605|NCT01536392|Behavioral|Questionnaires|Completion of 3 questionnaires at study visits taking about 5 minutes each time.
1955594|NCT03145883|Other|Home-Based Aerobic Exercise|
1690344|NCT01538407|Other|Strength Training|The exercises will be performed in standard strength training equipment. Prior to each of the strengthening exercise sessions, a warm up phase is performed by 5-10 minutes of ergometer cycling at a moderate intensity. Muscle strengthening exercises will be performed according to the standard progressive resistance and overload principle. The exercise programme consists of three exercises performed with three sets of 10 repetitions at 60%-85% of patient's 10RM. Training load will be progressed by means of bi-weekly estimates of muscle strength to ensure a constant load of 60%-85% RM. Exercises are: 1. Leg extension, 2. Leg press, and 3. Forward lunges.
1690345|NCT01538394|Drug|Varenicline|
1690346|NCT01538394|Drug|Nicotine patches|
1690347|NCT01538394|Drug|Placebo (nicotine patches)|
1690348|NCT01538381|Drug|Afatinib|Afatinib for 2 weeks at a dose of 40 mg/day
1690349|NCT01538381|Other|Observation|Observation
1690350|NCT01538355|Other|Prolonged Fasting|Patients enhance their regular diet with an initial 7-day fasting episode.
1690351|NCT01538355|Other|Ketogenic low glycemic load treatment|6 months of ketogenic low glycemic load treatment from the study outset.
1690352|NCT01538355|Other|Control diet|Patients stay on their regular diet.
1690353|NCT01538342|Other|3 Biopsies|3 biopsies: 2 lesional and 1 non-lesional
1690354|NCT01538342|Other|2 biopsies|
1690355|NCT01538342|Other|biopsy|1 biopsy ok healthy skin
1690356|NCT01538329|Drug|Amantadine|200mg / day once daily in the morning and at noon - oral administration -
1690357|NCT01538329|Drug|placebo|200mg / day once daily in the morning and at noon - oral administration -
1690358|NCT01538316|Dietary Supplement|Quercetin supplement|500 mg/d quercetin (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by genistein and placebo supplement.
1690359|NCT01538316|Dietary Supplement|Genistein supplement|100 mg/d genistein (+ vitamin C + folic acid + vitamin B3) over a period of six months; crossover design (6 month-periods): followed by placebo and quercetin supplement.
1690360|NCT01538316|Dietary Supplement|Placebo|vitamin C + folic acid + vitamin B3 over a period of six months; crossover design (6 month-periods): followed by quercetin and genistein supplement.
1690361|NCT01538277|Procedure|Contact Force during ablation|Radio Frequency Ablation procedure with real-time contact force information known to the operator
1690362|NCT01538277|Other|Standard ablation procedure|Standard ablation procedure
1690363|NCT01538251|Drug|Propionyl-L-Carnitine|Modified release tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
1690364|NCT01538251|Drug|Placebo|Tablets containing 500 mg of propionyl-L-carnitine. one tablet twice a day.
1690365|NCT01538238|Drug|pazopanib|pazopanib 800mg qd until progression or unacceptable toxicity
1690366|NCT01538225|Drug|Sativex®|"THC:CBD 1:1 ratio oromucosal spray. A titration period is required to reach optimal dose. The number and timing of sprays may vary between patients.
Duration: 2 weeks"
1690367|NCT01538225|Drug|Placebo|"Placebo
Same frequency and dosage form as Sativex.
Duration: 2 weeks"
1955595|NCT03145155|Behavioral|Integrating services for noncommunicable diseases in continuum of care for mothers and children|The intervention package will comprise of two components, (1) utilization of CoC card and (2) health education on CoC in maternal, newborn and child health (MNCH), NCD and nutrition. The CoC card will be distributed to mothers by midwives at the time of receiving ANC. The CoC card includes CoC services from first antenatal care(ANC) to last postnatal care(PNC) including four ANC, skilled birth attendance (SBA) and four PNC and essential services. Pregnant women will get stickers if they receive above services. Health education will be given by Public Health Supervisors 2 at the health facilities. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
1955596|NCT03145155|Behavioral|Ordinary health education for pregnant women|The ordinary health education intervention will cover schedule for ANC, delivery and PNC; danger signs; birth preparedness and nutrition. Health education will be given three times during pregnancy and one time during postpartum period with pamphlets and posters.
1690370|NCT01538173|Drug|250ml HES 6%|Application twice a day 250ml HES 6% for three days postoperatively.
1690371|NCT01538173|Drug|9% NaCl 500ml|Application twice a day 500ml 9% NaCl for three days postoperatively.
1690372|NCT01538160|Drug|recombinant factor VIIa|single dose of 20ug/kg of recombinant factor VIIa along with tranexamic acid of 4 gram a day for 7 days following surgery
1690373|NCT01538108|Device|PTA Balloon catheter with paclitaxel|patients treated by the NMB's PTA Balloon catheter with paclitaxel
1690374|NCT01538108|Procedure|Plain Balloon angioplasty (PBA)|PBA
1690375|NCT01538095|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
1690376|NCT01538095|Other|Laboratory Biomarker Analysis|Correlative studies
1690377|NCT01538095|Other|Pharmacological Study|Correlative studies
1690378|NCT01538095|Biological|Trebananib|Given IV
1690379|NCT01538069|Other|Exercise training|It consisted of three sessions/week, on non-consecutive days. The aerobic protocol consisted of a warm-up (strengthening exercises, 10 minutes), aerobic exercise (30 minutes in the first month and 45 minutes in the last two months) and cool-down (strengthening exercises, 10 minutes). The aerobic exercise intensity was established by heart rate levels that corresponded to anaerobic threshold, 10 heart rates down and 10 heart rates up, assessed by cardiopulmonary exercise testing. The strength training consisted of eight exercises attending the major muscle groups and the intensity was determined by 50-60% of one-repetition maximum (1-RM) and the progression of the training will be monthly: first month (a series of 12 repetitions with 50% 1-RM), second month (1 set of 15 repetitions with 60% 1-RM) and third months (2 sets of 10 repetitions with 60% 1-RM).
1690380|NCT01538069|Other|CPAP group|The CPAP treatment will be according to protocol of the Department of Psychobiology. Titration will be perform after randomization with ventilation device servo-assisted so as to ensure positive pressure within the first 24 hours of treatment. The treatment will be for three months.
1690381|NCT01538069|Other|Exercise and CPAP group|The patients randomized for this group will perform both Exercise protocol and CPAP treatment at the same time for three months.
1690382|NCT01538056|Device|Fenestrated Endovascular Graft|Modified endovascular graft with fenestrations to allow for blood flow to vital visceral vessels such as the renal arteries and SMA (Superior Mesenteric Artery).
1743134|NCT00127972|Drug|efavirenz|
1690386|NCT01537991|Radiation|Radiotherapy|All patients will receive radiotherapy to the primary lung tumour and any demonstrated nodal involvement. Patients will be given radiotherapy of a dose between 58 and 65Gy in 20 fractions. Dose will be determined by the patients' group.
1690387|NCT01537978|Other|Video gaming for enhanced function after spinal cord injury.|Spinal cord injured indviduals will play Nintendo Wii sports games for an 8 week period.
1690388|NCT01537965|Device|Fibroscan® of Echosens, Aixplorer® of Supersonic Imagine, Aplio XG of Toshiba, QRS software developed by Pr I.Bricault, Acuson S2000 of Siemens|"Five ultrasounds exams are realised:
elastography with Fibroscan®
ultrasound elastography in supersonic mode with Aixplorer®
ultrasound analysis of the surface liver with QRS software,
quantification of acoustic structure with Aplio XG,
elastography ARFI with Acuson S2000."
1690389|NCT01537939|Behavioral|ASUKI Step Worksite Pedometer Intervention|The intervention required participants to accumulate 10,000 steps each day for six months, with a 3-month follow-up period. Steps were recorded onto a study-specific website. Participants completed a website-delivered questionnaire four times to identify socio-demographic, health, psychosocial and environmental correlates of study participation. One person from each team at each university location was randomly selected to complete physical fitness testing to determine their anthropometric and cardiovascular health and to wear an accelerometer for one week.
1690390|NCT01537926|Drug|N-acetylcysteine|NAC 600mg capsule or matching Placebo , 1 twice daily for 90 days, then increase to NAC 1,200mg or matching placebo, 2 capsules twice daily for 270 days.
1690391|NCT01537926|Drug|Placebo|sugar pill manufactured to minic NAC 600mg capsule
1690392|NCT01537900|Drug|Grazoprevir|GZR 100 mg tablet by mouth q.d. for 7 days.
1690393|NCT01537887|Drug|LY2484595|Administered orally once daily for 10 days.
1690394|NCT01537887|Drug|Placebo|Administered orally once daily for 10 days.
1690395|NCT01537887|Drug|Moxifloxacin|Single dose administered orally.
1690396|NCT01537874|Behavioral|Motivational Interview|30 - 45 minutes in-person session to deliver results of nicotine air monitor and discuss home smoking ban using motivational interview techniques
1690397|NCT01537874|Behavioral|Usual best practices|Standard care delivered using informational materials
1690398|NCT01537861|Drug|Filgrastim|
1690399|NCT01537861|Drug|Bortezomib|
1690400|NCT01537861|Drug|Carfilzomib|
1690401|NCT01537861|Drug|Dexamethasone|
1690402|NCT01537861|Drug|Cyclophosphamide|
1690403|NCT01537861|Drug|Thalidomide|
1690404|NCT01537861|Drug|Lenalidomide|
1690405|NCT01537861|Drug|Pomalidomide|
1690406|NCT01537848|Procedure|EUS guided transmural drainage|Puncture of the collection is done under EUS guidance using a linear echoendoscope (FG-3830UT, Pentax or Olympus GF-UCT140/180 or forward viewing scope (Olympus)) with a 19G echoTip needle or a cystotome (Cook Medical Inc.). Then a 0.035 guidewire is inserted in the collection and the hole is enlarged with a cystotome (Cook Medical) or a 6.5F diathermic sleeve (Endoflex) and sometimes if needed a 6-8mm CRE balloon (Boston Scientific) before stenting with one or two double pigtail plastic stents (Cook Endoscopy, Endoflex). A nasocystic drain was also put whenever needed. If only a single stent could be placed in the first attempt, a subsequent procedure is scheduled for insertion of additional stents after dilation of the tract. There isn't any specific drug given during the procedure.
1690407|NCT01537835|Other|Antimicrobial Scrubs|Participants will be randomized to one of three types of scrubs. There will be a control (standard scrubs without antimicrobial properties) and two scrubs with reported antimicrobial properties.
1690408|NCT01537822|Procedure|Hysteroscopic morcellator|Morcellation will be performed with the HM (TRUCLEAR, Smith & Nephew, Andover, USA). The rotary blade is used for polypectomy and removal of residual placental tissue; the reciprocating blade is used for myomectomy. The blade has a window-opening at the end with cutting edges through which tissue is aspirated by means of a vacuum source. The removed tissue is discharged through the device, collected in a pouch and made available for pathology analysis.
1690409|NCT01537822|Procedure|Resectoscope|Resectoscopy will be performed with a rigid 8.5 mm bipolar resectoscope (Karl Storz GmbH, Tuttlingen, Germany), equipped with a 0 or 30 degree optic. Normal saline is used for distension and irrigation of the uterine cavity. Fluid balance is closely monitored using a Hystero pump (Richard Wolf GmbH, Knittlingen, Germany) or Hysteromat pump (Karl Storz GmbH, Tuttlingen, Germany).
1690410|NCT01537809|Dietary Supplement|Vitamin D3|Subjects are told to take vitamin D daily for 6 months.
1690411|NCT01537809|Dietary Supplement|Vitamin D3|Subjects are asked to take vitamin D orally, daily for six months.
1690412|NCT01537796|Behavioral|In-Person weight loss|Participants will attend weekly group intervention meetings. These sessions will address barriers associated with altering physical activity participation and dietary intake. Group discussions will be facilitated by the interventionist and interactive participation will be encouraged. Participants will be provided with written materials at each meeting to supplement group discussions. Paper diaries will be provided each week to assist participants with self-monitoring of calorie and fat consumption, and physical activity minutes and intensity. Participants will return the diary to the intervention staff each week for review and constructive feedback.
1690413|NCT01537796|Behavioral|FIT weight loss|Intervention materials will be provided and mailed weekly to participants. Participants will be provided with the BodyMedia® FIT System that includes a wearable device to monitor physical activity and energy expenditure, a display device to provide feedback on achievement of energy expenditure and physical activity goals, and web-based software to assist with self-monitoring of dietary intake and to provide feedback on goal achievement. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
1690447|NCT01537536|Drug|EndoTAG-1|EndoTAG-1 (22 mg/m2 liposomal paclitaxel) + Paclitaxel (70 mg/m2) Weekly i.v. infusions of EndoTAG-1 and paclitaxel for 12 weeks followed by subsequent treatment with the standard FEC regimen (Fluorouracil 500 mg/m2, Epirubicin 100 mg/m2, Cyclophosphamide 500 mg/m2) once every 3 weeks for 3 cycles of therapy followed by surgery.
1690448|NCT01537523|Procedure|community-care program|community nurse care, physiotherapy
1690491|NCT01537172|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 10 mg, 30 mg, 100 mg, 300 mg, 600 mg, 900 mg as a single dose administered by mouth once daily, depending on the outcome of the previous dose.
1690414|NCT01537796|Behavioral|FIT-BT weight loss|Participants will be provided with intervention materials that are mailed weekly to them. Participants will be provided with the enhanced BodyMedia® FIT System that includes a wearable device with Bluetooth® technology to allow participants to receive real-time feedback on calories expended and physical activity on their smart phone. This also supports self-monitoring of dietary behaviors and body weight. Participants will attend one introductory session in which a tutorial of the components of the enhanced FIT System will be provided. Participants will also receive a one-hour lesson on basic guidelines of the weight loss intervention. Once per month participants will receive a scheduled 10 minute intervention telephone call with the intervention staff.
1690415|NCT01537783|Drug|Chlorhexidine gluconate|Scrubs applied once a day for 5 days
1690416|NCT01537783|Drug|Mupirocin|Nasal mupirocin applied topically to both nostrils twice a day for 5 days
1690417|NCT01537770|Procedure|Percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
1690418|NCT01537770|Procedure|Lidocaine injection|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine). 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. 2 ml of 1% Lidocaine is injected in each needle. Bone cement is prepared on the bench simulating the vertebroplasty-procedure.
1690419|NCT01537757|Drug|MK-8931|Single dose, administered as oral capsules
1690420|NCT01537744|Drug|oral 5-azacitidine in combination with romidepsin|"DOSING REGIMEN(S):
Table 1: Dose Escalation Schedule Dose Level Dose and Schedule a, c 5-Azacitidine (PO) Romidepsin (IV)
Level -1b 100mg daily days 1-14 8mg/m2 days 8 and 15
Level 1 200mg daily days 1-14 8mg/m2 days 8 and 15
Level 2 300mg daily days 1-14 8mg/m2 days 8 and 15
Level 3 300mg daily days 1-21 8mg/m2 days 8 and 15
Level 4d MTD 8mg/m2 days 8, 15, and 22
Each cycle will last 28 days.
Subjects will be enrolled in Level -1 if the MTD is reached in the subjects enrolled in Level 1.
On days when both agents are administered, oral 5-azacitidine should be administered at the start of the romidepsin infusion.
Level 4 is optional and decisions whether to initiate this level will be based on discussions between the study investigator and Celgene."
1690421|NCT01537731|Procedure|vaginal or laparoscopic hysterectomy|vaginal hysterectomy or laparoscopic hysterectomy
1690422|NCT01537718|Device|REPLY 200|REPLY 200 pacemaker
1690423|NCT01537705|Drug|Neuron012703 (Medical Food)|2 capsules twice daily for sixty days.
1690424|NCT01537692|Drug|BDP HFA Nasal Aerosol|BDP HFA Nasal 80mcg
1690425|NCT01537692|Drug|BDP HFA Nasal Aerosol|BDP HFA Nasal 320mcg
1690426|NCT01537692|Drug|BDP HFA Inhalation Aerosol (QVAR)|BDP HFA Oral 320mcg
1690427|NCT01537679|Behavioral|Kirtan Kriya meditation|Meditation will be taught to 20 caregivers and supervised by Helen Lavretsky, M.D during their first visit. Meditation Kirtan Kriya will be performed for 12 minutes every day at the same time of the day for 8 weeks. Compliance will be monitored during visits and by daily diaries that will be reviewed at each visit.
1690428|NCT01537679|Behavioral|Relaxation|Participants in the relaxation group will be asked to relax in a quiet place with eyes closed while listening to the music on the relaxation CD for 12 minutes every day at the same time for 8 weeks.
1690429|NCT01537666|Drug|AeroVanc|Vancomycin hydrochloride dry powder for inhalation
1690430|NCT01537666|Drug|IV vancomycin hydrochloride|Vancomycin hydrochloride solution for intravenous administration
1690431|NCT01537653|Drug|SAR231893 (REGN668)|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
1690432|NCT01537653|Drug|placebo|Pharmaceutical form:Solution in a vial Route of administration: Subcutaneous injection
1690433|NCT01537640|Biological|SAR231893 (REGN668) DP1|Pharmaceutical form:solution Route of administration: subcutaneous
1690434|NCT01537640|Biological|SAR231893 (REGN668) DP2|Pharmaceutical form:solution Route of administration: subcutaneous
1690435|NCT01537627|Other|Physical training|"Aerobic exercises (treadmill and cycloergometer): Initially, the intensity is targeted at 60% of maximal capacity and it increases weekly until 110% of maximal capacity. Exercises duration: at least, 20 minutes.
Resistive exercises (multi gym station; muscle groups: biceps, triceps and quadriceps): Initially, the intensity is targeted at 70% of one maximum repetition (1RM) and it increases weekly until 121% of 1RM. Exercises duration: 3 sets of 8 repetitions. Both exercise training are performed 3 times per week during 6 months."
1690436|NCT01537627|Other|Physical training|Callisthenic and breathing exercises are performed during 1 hour, 3 times per week during 6 months. The exercises are divided in 7 different sets and the degree of difficulty of the exercises progresses according to the set.
1690437|NCT01537614|Drug|COLIMYCINE inhalation|2 MILLION UI
1690438|NCT01537614|Drug|COLIMYCINE injectable|2 MILLIONS UI
1690439|NCT01537601|Procedure|Circumcision|Circumcision
1690440|NCT01537601|Other|Antibiotic prophylaxis alone|Antibiotic prophylaxis alone
1690441|NCT01537588|Other|Autograft STG harvest from ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on same limb that is undergoing ACL reconstruction
1690442|NCT01537588|Other|Autograft harvest contralateral to ACL-deficient leg|Semitendinosus-gracilis graft harvest is undertaken on limb contralateral to that undergoing ACL reconstruction
1690443|NCT01537575|Biological|intravenous immunoglobulins|One course of Intravenous Immunoglobulins 0.4 g/kg/die for 5 consecutive days
1690444|NCT01537575|Biological|Saline solution|Placebo
1690445|NCT01537562|Other|Timing of IUC insertion|Patients randomised to early insertion had their IUC inserted on day 5-9 after mifepristone treatment while patients randomised to delayed insertion had the IUC insertion at about 3 to 4 weeks after mifepristone.
1690446|NCT01537549|Drug|alpha-lipoic acid and L-acetyl carnitine|alpha-lipoic acid and L-acetyl carnitine capsules, 600mg/1.5g daily for 6 months
1690489|NCT01537185|Biological|SPWCV+Alum 600 mcg|3 injections 28 days apart
1743135|NCT00127972|Drug|trizivir|
1690449|NCT01537510|Behavioral|STAR - Study of Technology to Accelerate Research|In 14 pediatric practices, to conduct a cluster-randomized controlled trial to examine the extent to which computerized point of care decision alerts to pediatric primary care providers, with or without direct-to-parent communications, will increase adoption of comparative effectiveness research evidence on childhood obesity for children 6 to 12 years of age with a BMI ≥ 95th percentile.
1690450|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
1690451|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
1690452|NCT01537497|Drug|PF-05175157|One single oral dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
1690453|NCT01537497|Drug|Placebo|One single oral dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
1690454|NCT01537484|Procedure|Massage Therapy|Swedish Massage for 1 hour for 8 weeks, Light Touch Bodywork for 1 hours for 8 weeks.
1690455|NCT01537471|Drug|Placebo|Placebo
1690456|NCT01537471|Drug|Meclizine|Meclizine 12.5 mg
1690457|NCT01537471|Drug|Meclizine|Meclizine 25 mg
1690458|NCT01537458|Procedure|follow-up of isolated tricuspid valve repair|follow-up of patients that underwent TV repair in the past.
1690459|NCT01537432|Drug|secukinumab|secukinumab
1690460|NCT01537432|Drug|placebo|placebo comparator
1690461|NCT01537419|Behavioral|Attachment-Based Family Therapy|Although ABFT therapists implement behavior focused and psychoeducational interventions, the model is primarily a process oriented, emotion focused treatment guided by a semi-structured treatment protocol. ABFT aims to improve the family's capacity for problem solving, affect regulation, and organization. This strengthens family cohesion which can buffer against depression, suicidal thinking, and risk behaviors.
1690462|NCT01537419|Behavioral|Family-Enhanced Non-directive Supportive Therapy|Family-Enhanced Non-directive Supportive Therapy (FE-NST) is a 16 week therapy designed to control for the non-specific effects of psychotherapy with suicidal youth. FE-NST aims toward relief or reduction of symptoms without expectation of change in the basic personality structure. We have added a parent component to: a) control for parent involvement and b) improve the generalizability and safety of the FE-NST treatment. This enhancement consists of 5 potential parent sessions beginning with a family safety plan in the initial treatment session that will be monitored regularly throughout the treatment. The remaining 4 parent psycho-education sessions offer parents knowledge, skills and support to improve management of the suicidal teen.
1690463|NCT01537406|Radiation|BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY|LONG TERM OUTCOMES OF A MULTICENTRE CONTROLLED CLINICAL TRIAL OF BREAST IRRADIATION USING INTENSITY-MODULATED RADIATION THERAPY
1690464|NCT01537393|Biological|Cornea tissue transplant|Cornea tissue preserved either 7 or less days or 8 to 14 days.
1690465|NCT01537380|Drug|Cefazoline|Injection of CEFAZOLINE (4 grams) 30-60 min before skin incision. A second injection will performed every 4 hours during the surgery
1690466|NCT01537367|Behavioral|Enhanced contact plus behavioral skills|The enhanced contact plus behavioral skills arm is the longer experimental arm.
1690467|NCT01537367|Behavioral|Enhanced contact only|The enhanced contact only arm is the shorter experimental arm.
1690468|NCT01537367|Behavioral|Standard of Care|The standard of care arm is the comparison group arm that receives only standard clinical services.
1690469|NCT01537354|Drug|Curosurf®|Initial dose is 2.5ml/kg (200 mg/kg phospholipid) administered via endotracheal tube. Subsequent doses if needed are 1.25 mL/kg (100 mg/kg phospholipids).
1690470|NCT01537354|Drug|Survanta®|Initial dose is 4 mL/kg (100 mg/kg phospholipids) administered via endotracheal tube. Subsequent doses if needed are 4 mL/kg (100 mg/kg phospholipids).
1690471|NCT01537341|Behavioral|Traditional Treadmill|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
1690472|NCT01537341|Behavioral|Split-belt|Participants will complete the intervention in 12-weeks, 3 times per week sessions.
1690473|NCT01537328|Other|Total knee replacement rehabilitation|After total knee arthroplasty, patients will be assigned to an outpatient rehabilitation clinic, based upon geography. Patients will be enrolled randomly into one of two rehabilitation programs (PROG or TRAD). Both rehabilitation programs will take place over 12 weeks. Both groups will receive treatment for range of motion, activities of daily living and gait training, as well as a home exercise program.
1690474|NCT01537315|Drug|Hydroxychloroquine|200 mg capsule daily for 10 +/- 4 days, then 200 mg twice daily till end of study (duration approximately 6 months)
1690475|NCT01537315|Other|Matching Placebo|matching placebo capsule 200 mg daily for 10 +/- 4 days and thereafter 200 mg twice a day for duration of study, approximately 6 months
1690476|NCT01537302|Device|CTO crossing in femoropopliteal arteries CONNECT II|CTO crossing in femoropopliteal arteries using the Ocelot System
1690479|NCT01537276|Procedure|diagnose under real-time fluoroscopy|radiologists evaluating the tubal patency under fluoroscopy real-timely.Findings of fluoroscopy were blind to the investigators when the static radiographs were re-analyzed by the same team of radiologists.
1690480|NCT01537263|Device|Ultrasound Perfusion Imaging|Sonographic unit Phillips IU 22, 5ml SonoVue ultrasound contrast agent per examination, Duration: 1h
1690481|NCT01537250|Drug|Levofloxacin 500 mg placebol|oral form,,once adily,7~10 days
1690482|NCT01537250|Drug|Levofloxacin 500 mg placebol|oral form,,once adily,7~10 days
1690483|NCT01537250|Drug|Nemonoxacin 3 tablets|oral form,once daily,7~10 days
1690484|NCT01537224|Other|Measure of the electrophysiological activity of the subthalamic nucleus|Local field recording of the subthalamic nucleus by mean of externalized electrodes in the immediate postoperative periode.
1690485|NCT01537211|Device|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
1690486|NCT01537211|Device|C leg compared to subject's mechanical leg (Otto Bock)|comparison of different prosthetic knees
1690487|NCT01537185|Other|Placebo|3 cohorts of normal saline injection
1690488|NCT01537185|Biological|SPWCV+Alum 100 mcg|3 injections 28 days apart
1743398|NCT00129714|Other|cervical collar|
1690493|NCT01537159|Device|3 Tesla (3T) Siemens Total imaging matrix (TIM) Trio whole-body system|Each MR scanning session will include the pre-contrast multi-slice T2-weighted MRI with fat-saturation and T1-weighted MRI which are regularly acquired in clinical protocols. Following these acquisitions, high-spatial and temporal-resolution DCE-MRI will be performed. The total duration of a research MR session is expected to be less than 45 min.
1690494|NCT01537146|Drug|Ropivacaine|Bolus infusion via catheter/6H for 24H
1690495|NCT01537146|Drug|Ropivacaine|Intra operational bolus infusion. Bolus infusion via catheter /6H for 24H
1690496|NCT01537133|Drug|fluticasone|Dry Powder Inhaler: 250 mcg/puff, one puff, twice a day
1690497|NCT01537133|Drug|Placebo|Dry Powder Inhaler: Placebo
1690498|NCT01537120|Drug|Vildagliptin|
1690499|NCT01537120|Drug|Placebo|
1690500|NCT01537107|Drug|vismodegib|Given PO
1690501|NCT01537107|Drug|sirolimus|Given PO
1690502|NCT01537107|Procedure|positron emission tomography|Correlative studies
1690503|NCT01537107|Procedure|computed tomography|Correlative studies
1690504|NCT01537107|Other|pharmacological study|Correlative studies
1690505|NCT01537107|Other|laboratory biomarker analysis|Correlative studies
1690506|NCT01537107|Radiation|fludeoxyglucose F 18|Correlative studies
1690507|NCT01537094|Dietary Supplement|Placebo|
1690508|NCT01537094|Dietary Supplement|Vitamin C 250 mg once daily|
1690509|NCT01537094|Dietary Supplement|Vitamin C 1,000 mg once daily|
1690510|NCT01537081|Drug|Mucinex|Mucinex combines immediate-release (IR) and modified-release guaifenesin in a bilayer tablet. Each tablet was 600 mg of guaifenesin and taken by mouth with a full glass of water.
1690511|NCT01537081|Drug|Immediate-release Guaifenesin|Each tablet was 200 mg of immediate-release (IR) guaifenesin and taken by mouth with a full glass of water.
1690512|NCT01537081|Drug|Placebo|Placebo tablets in two formulations to match either Mucinex or IR guaifenesin taken by mouth with a full glass of water
1690513|NCT01537068|Drug|Desvenlafaxine|Desvenlafaxine oral dose ranging from 50 to 100 mg/day
1690514|NCT01537068|Drug|Placebo|Matching placebo pills
1690515|NCT01537055|Drug|levofloxacin-based sequential therapy|levofloxacin-based sequential therapy for 10 days〔lansoprazole 30mg and amoxicillin 1g for the first 5 days, followed by lansoprazole 30mg, levofloxacin 250mg, and metronidazole 500mg for another 5 days (all given twice daily)〕
1690516|NCT01537055|Drug|levofloxacin-based triple therapy for 10 days|lansoprazole 30mg and amoxicillin 1g, and levofloxacin 250mg for 10 days (all given twice daily)
1690517|NCT01537042|Drug|Rotigotine|"Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.
Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal."
1690518|NCT01537042|Drug|Placebo|"Transdermal patch; Patches matching to active treatment patches in size and appearance.
Up to 3 weeks of Titration,
2 weeks of Maintenance,
Up to 4 days of Taper Period."
1690519|NCT01537029|Drug|Doxorubicin|Dosed by the patient's treating physician according to local standard of care.
1690520|NCT01537029|Drug|Cyclophosphamide|dosage form: IV, Dosage, frequency, and duration: According to local standard of care
1690521|NCT01537016|Device|PROMOGRAN|PROMOGRAN® is a protease modulating dressing, formulated as a bioresorbable amorphous open-pored matrix constructed of 45% oxidised regenerated cellulose (ORC) and 55% bovine collagen
1690522|NCT01537016|Device|Tielle|Tielle is a hydropolymer foam dressing that is designed to provide optimal wound healing
1690523|NCT01537003|Device|Promogran|Promogran is a collagen/ORC dressing which modulates the wound environment
1690524|NCT01537003|Device|Coban 2 layer|Compression bandage
1690525|NCT01536977|Other|quality-of-life assessment|Ancillary studies
1690526|NCT01536977|Other|questionnaire administration|Ancillary studies
1690527|NCT01536977|Behavioral|management of therapy complications|Undergo BBT-I
1690528|NCT01536977|Behavioral|cognitive assessment|Ancillary studies
1690529|NCT01536977|Behavioral|educational intervention|Undergo BBT-I
1690530|NCT01536964|Drug|morphine|2.5mg of morphine will be given post Prasugrel administration with a further 2.5mg 5 minutes later
1690531|NCT01536964|Drug|saline|2.5ml of saline will be given post Prasugrel followed by a further 2.5ml as a comparator for the morphine
1690532|NCT01536951|Drug|LY3009104|administered orally
1690533|NCT01536951|Drug|Placebo|Administered orally
1690534|NCT01536951|Drug|moxifloxacin|Administered orally
1690535|NCT01536938|Drug|LEO 90100|
1690536|NCT01536938|Drug|Calcipotriol|
1690537|NCT01536938|Drug|Betamethasone|
1690538|NCT01536886|Drug|LEO 90100|
1690539|NCT01536886|Drug|Betamethasone plus calcipotriol|
1690540|NCT01536886|Drug|Ointment vehicle|
1690541|NCT01536886|Drug|LEO 90100 vehicle|
1690542|NCT01536873|Drug|Dolutegravir|Eligible patients will receive DTG 50 mg given orally BID
1690543|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
1690544|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
1690545|NCT01536860|Other|Dietary Intervention|300 ml of liquid food product
1690546|NCT01536847|Other|Dietary Intervention|300 ml of liquid food product
1690547|NCT01536847|Other|Dietary Intervention|300 mL of liquid food product
1690548|NCT01536847|Other|Dietary Intervention|300 ml of liquid food product
1690550|NCT01536808|Other|Cardiac RMI|Cardiac RMI
1690551|NCT01536808|Other|Analysis telomere|Analysis telomere
1690552|NCT01536808|Other|Stress test|Stress test
1690553|NCT01536808|Other|echocardiography|echocardiography
1743399|NCT00129714|Other|physiotherapy|
1690556|NCT01536782|Procedure|Bolus|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).
Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
1690557|NCT01536782|Procedure|Gravity|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).
Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
1690558|NCT01536782|Device|Pump|"The patients will be randomized into 3 different groups: Bolus, Gravity, and Pump. The randomization process will be based on age and estimated caloric needs (i.e if we have three 60-year-old patients whose estimated kcals needs are ≤ 1900kcals/day, then each patient will be randomized to either of the groups).
Each patient from each group will be receiving tube feeding education to their by RD. For consistency reasons, the same type of tube feeding formula (1.5 kcal/ml, no fiber) will be used. Patients' weight, tube feeding tolerance, and amount of estimated calories and protein met will be monitored weekly."
1690559|NCT01536756|Other|Exercise Intervention -- Physical Rehabilitation Program|"The intervention group will participate in a Physical Rehabilitation Program which includes a 60-minute training session at a frequency of 3 times a week over a total of 12-week duration. The training session consists of 45 minutes of warm-up stretching and circuit training. This includes 3 stations of aerobic exercises for physical work up of different body parts, and 3 stations of strengthening exercises of major muscles groups at 3 sets of 10 repetitions. The final 15-minute training session will be the cooling down exercise with emphasis on stress management incorporating mindful breathing, stretching and body awareness exercise."
1690560|NCT01536756|Other|Wait List Control Group|The subjects of the control group will be asked to maintain their usual activities while awaiting for the physical rehabilitation program at the 12-week waiting time. They will be allowed to receive any other usual medical services including social services and psychotherapy but not physiotherapy services. At the end of the 3rd month, the control group will be recruited into the Physical Rehabilitation Program. Patients in the control group will then join in as the intervention group and follow the intervention and assessment protocol.
1690561|NCT01536743|Drug|PD0332991|"30 patients with recurrent ovarian epithelial carcinoma demonstrating Rb-proficiency and absent or low expression of p16 will be registered to receive PD0332991 once a day by mouth in the morning on an empty stomach.
PD0332991 will be administered daily for 3 weeks followed by 1 week off treatment (28 day cycle)."
1690562|NCT01536730|Behavioral|Homework Intervention Strategy|"Participants assigned to intervention will receive a condom ditty bag containing 50 condoms (5 each of 10 types), a variety of 50 lubricants, an instructional DVD, and instructions for the intervention."
1690565|NCT01536704|Drug|Nicotine (2 mg)|2 mg nicotine lozenge in two formulations
1690566|NCT01536704|Drug|Nicotine (4 mg)|4 mg nicotine lozenge in two formulations
1690567|NCT01536691|Drug|ramosetron|ramosetron 0.3 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
1690568|NCT01536691|Drug|ondansetron|ondansetron 16 mg iv D1 aprepitant 125 mg po D1, 80 mg po D2, 80 mg po D3 dexamethasone 12 mg po D1, 8 mg po D2-4
1690571|NCT01536665|Drug|liraglutide|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
1690572|NCT01536665|Drug|placebo|Administered subcutaneously (s.c., under the skin) once daily for 4 weeks.
1690573|NCT01536652|Drug|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
1690574|NCT01536639|Drug|biphasic insulin aspart 30|Administered by subcutaneous injection. The physician determined the starting dose and frequency, as well as later changes to either dose or frequency, if any
1690575|NCT01536626|Drug|biphasic insulin aspart 30|Prescription at the discretion of the treating physician
1690576|NCT01536613|Drug|biphasic insulin aspart 30|The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
1690577|NCT01536600|Drug|biphasic insulin aspart 30|The insulin dose and regimen was individualised at the physician's discretion
1690578|NCT01536587|Drug|Salmeterol|At visit 1 the sympathetic activity will be registered using microneurographic recordings of efferent muscle sympathetic nerve activity (MSNA) in the peroneal nerve and respiration over 2 hours, after 20 minutes of recording, 1 dose of placebo will be administered and after a further recording period of 45 minutes a dose of salmeterol 50 µg will be administered which will be followed by a further period of data registration. At visit 2 following 4 weeks of inhaled treatment with salmeterol the same procedures will be performed but a placebo inhalation will not be performed.
1690579|NCT01536574|Drug|Requip PR|Eligible patients will be dispensed medication to uptitrate their REQUIP PR dose (2, 4, 6, 8mg respectively) during the first 4 weeks of treatment. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control.
1690606|NCT01536392|Behavioral|Study Drug Diary|Study drug diary to record times that study drugs taken, and to record any nausea or vomiting experienced.
1690607|NCT01536379|Drug|Belimumab|Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
1743587|NCT00131183|Drug|Nebido|
1690580|NCT01536561|Biological|Radiolabeled Monoclonal Antibody Anti-B1 for the Treatment of B-Cell Lymphomas (Tositumomab and Iodine I 131 Tositumomab)|131-I anti-B1 is the product of 131-I labeling of the anti-CD20 murine monoclonal antibody and the anti-B1 antibody itself is an intact IgG2a murine monoclonal antibody which has specificity far the CD20 antigen on human B cells. Anti-B1 is a clear, colorless liquid. 131-I labeling of the anti-B1 antibody will be carried out by iodogen technique. Trace labeling of the antibody will involve the labeling of approximately 1 to 3 mg of antibody with 5 mCi of 131-I.
1690581|NCT01536548|Procedure|Skin drawing|Mark direction and angle for cannulation with a pencil on the skin
1690582|NCT01536548|Procedure|No skin drawing|Standard practice; i.e. no marks on skin to help find correct direction and angle for introducing needles
1690583|NCT01536535|Drug|Mesalamine|Pentasa comes in 500mg capsules, and doses will need to be rounded to the nearest 500mg increment, with a maximum dose of 76 mg/kg/day. The average dose for the pediatric population will be approximately 70 mg/kg/day. Patients will be allowed to escalate to the final dose over 4 days to minimize side-effects such as headache.
1690584|NCT01536535|Drug|Prednisone|Initiate treatment with prednisone, 1-1.5 mg/kg/day, (maximum 40-60 mg in a single morning dose, either as tablet or liquid equivalent), rounded up to the nearest 5 mg value. This dose will be continued for 2 weeks to assess response.
1690585|NCT01536535|Drug|Corticosteroids followed by mesalamine (Pentasa)|500 mg capsules 70-75 mg/kg per day
1690586|NCT01536522|Biological|Allergen|Inhalation of allergens by allergic patients with or without asthma, will be used to define mechanisms underlying the development of airway inflammation.
1690587|NCT01536522|Dietary Supplement|low caloric shake|participants will be provided a low caloric dietary shake
1690588|NCT01536509|Behavioral|Telehealth Behavioral Treatment (TBT)|Families in the TBT condition will receive three individually-tailored behavioral intervention sessions in addition to the online education intervention with 1) guided problem-solving and behavior management training tailored to the unique needs and/or barriers of the family, and 2) discussion of the patient's adherence since the previous session. In addition, patients in the TBT condition will be signed up for text message reminder service offered free of charge via www.mymedschedule.com. These are generic reminder text messages are used to assist with adherence in adolescents. Intervention sessions will be conducted via telehealth delivery with trained postdoctoral psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
1690589|NCT01536509|Behavioral|Education Only (EO)|Families in the EO condition will receive three individual sessions in addition to the online education intervention to review 1) online educational intervention material to answer questions participants have, 2) educational brochures from the Crohn's and Colitis Foundation of America (CCFA), which contain additional information (e.g., Guide for Parents, Living with IBD, Guide for Kids and Teenagers), and 3) general healthy lifestyle recommendations (e.g., sleep, exercise, etc.). Sessions will be conducted via telehealth delivery with trained postdoctoral clinical psychology fellows or masters-level graduates using webcams, supplied by the study, and SkypeTM free software.
1690590|NCT01536496|Biological|Blood product transfusion based on conventional coagulation tests.|Transfusion of blood products.
1690591|NCT01536496|Biological|Blood product transfusion based on rapid thrombelastography (r-TEG) results.|Transfusion of blood products.
1690592|NCT01536483|Drug|Butyrate enemas|"Seven enemas
Possibility to delay from 24 to 48 hours the procedure in case of clinical poor tolerance(maximum two enemas postponed and delayed at PND12 and PND13)
The study remains blinded for the investigation team through the intervention of a clinical research nurse
According to the procedure previously described by Nakaoka et al. (2009), a lubricated Foley catheter Ch 6 will be introduced into the rectum, the balloon will be inflated with 1 ml water for injections. Butyrate solution will be placed in a bag placed 50 cm above the child. Therefore, treatment administration will be performed at a controlled pressure of 50 cm H2O without any manual intervention
Installation time and retention is setted at 15 minutes
Treatment units will be directly placed in the incubator 30 min before the procedure to warm the enema to +36°C
Per-treatment clinical monitoring of the tolerance will be performed by a neonatologist"
1690593|NCT01536470|Other|noradrenaline|The primary objective of the study is to compare two strategies of intraoperative blood pressure management in high-risk surgical patients: 1- Continuous infusion of noradrenaline to maintain arterial blood pressure of no more than 10% below its baseline value; 2- Conventional treatment of hypotension (defined as a blood pressure of below 80 mmHg or a decrease of more than 40% from baseline) using intravenous bolus of Ephedrine chorhydrate.
1690594|NCT01536470|Other|Ephedryne chorydrate|
1690595|NCT01536444|Device|Momelan Technologies Epidermal Graft Harvesting System|The procurement of the epidermal micrograft involves the use of the MoMelan Technologies suction blister system which consists of a control box that creates the vacuum necessary to create the microblisters and a harvester. The device is applied to the subject's thigh to create blisters. The epidermal micrografts are then harvested and transferred to Tegaderm™ and then placed on the surgical wound and the wound is bandaged.
1690596|NCT01536431|Drug|Pro insulin peptide|Patients will receive 10 micro gr of the peptide every 2 weeks (12 doses).
1690597|NCT01536431|Drug|Pro insulin peptide|Patients will receive 10 micro gr of the peptide monthly (ever 4 weeks, 6 doses) and saline injections monthly alternating with the peptide (2 weeks interval between the drug and saline).
1690598|NCT01536431|Drug|Saline|Patients will receive 0 micro gr of peptide, but have saline injections every 2 weeks (controls).
1690599|NCT01536418|Drug|GSK1605786A|500 milligrams once daily, orally administered for 12 weeks
1690600|NCT01536418|Drug|GSK1605786A|500 milligrams twice daily, orally adminstered for 12 weeks
1690601|NCT01536405|Biological|MMRV (AMP)|Measles, mumps, rubella, and VZV vaccine made with an alternative manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
1690602|NCT01536405|Biological|MMRV (2006 process)|Measles, mumps, rubella, and VZV vaccine made with the 2006 manufacturing process. Participants will receive two 0.5 mL subcutaneous injections.
1690603|NCT01536392|Drug|Granisetron|34.3 mg of granisetron formulated in a transdermal patch replaced every 7 days. At cycle 1, participants receive granisetron by vein prior to IV cisplatin and prior to administration of transdermal patch.
1690604|NCT01536392|Drug|Ondansetron|8 mg of ondansetron by mouth three times a day starting with cisplatin administration and continued for 72 hours after chemotherapy infusion.
1690656|NCT01536041|Drug|ONO-6950|20 mg QD, single dose
1690608|NCT01536379|Drug|Placebo|Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)
1690609|NCT01536366|Drug|BIA 9-1067|25 mg BIA 9-1067 (single-dose)
1690610|NCT01536366|Drug|Repaglinide|0.5 mg repaglinide (single-dose)
1690611|NCT01536353|Drug|AGSAV301|tablet, q.d.
1690612|NCT01536353|Drug|Exforge 10/160|Tablet, q.d.
1690613|NCT01536314|Drug|Memantine EBIXA®|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
1690614|NCT01536314|Drug|Placebo : lactose|The aim of this study is to evaluate if memantine administered during 4 weeks beginning 2 weeks before surgery induces a decrease of painful intensity 3 months after surgery, compared to placebo group.
1690615|NCT01536301|Drug|Standard Care morphine hydrochloride|Post-operative analgesia including morphine (patient controlled analgesia).
1690616|NCT01536301|Drug|Oxycodone|Post-operative analgesia including oxycodone (patient controlled analgesia).
1690617|NCT01536288|Drug|Rhodiola crenulata|Rhodiola crenulata:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
1690618|NCT01536288|Drug|placebo|Placebo:capsules, 800 mg daily for 7 days before ascent and 2 days during mountaineering
1690619|NCT01536275|Other|Late parenteral nutrition|Withholding parenteral nutrition during the first 7 days of ICU stay
1690620|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
1690621|NCT01536262|Device|Respimat|Respimat inhaler
1690622|NCT01536262|Drug|Tiotropium + Olodaterol|Tiotropium and Olodaterol FDC once daily inhalation
1690623|NCT01536262|Drug|Olodaterol|Olodaterol once daily inhalation
1690624|NCT01536262|Device|Respimat|Respimat inhaler
1690625|NCT01536262|Device|Respimat|Respimat inhaler
1690626|NCT01536249|Drug|Dexpramipexole|Single Oral Dose
1690627|NCT01536249|Drug|Cimetidine plus Dexpramipexole|Multiple Oral Doses
1690628|NCT01536236|Device|ANS Eon™ Implantable Pulse Generator (Permanent Implant)|Appropriate programming based on subject's preference of programs.
1690629|NCT01536236|Device|Placebo|Placebo
1690630|NCT01536223|Drug|PF (cisplatin and 5-fluorouracil) group|the group the patients using PF(cisplatin and 5-fluorouracil )neoadjuvant chemotherapy 3 cycles of neoadjuvant chemotherapy at day1,22 and 43 with cisplatin 100mg/m2 and 5-fluorouracil 4000mg/m2 civ 120 hours And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2.
1690631|NCT01536223|Drug|TPF (docetaxel plus cisplatin and 5-fluorouracil) group|"3 cycles of TPF neoadjuvant chemotherapy at day1,22 and 43 with docetaxel 75mg/m2,cisplatin75mg/m2 and 5-fluorouracil 2400mg/m2 civ 96 hours .
And then chemoradiation using IMRT with 2 cycles of cisplatin concurrent chemotherapy at 80mg/m2."
1690632|NCT01536210|Drug|YY-162|YY-162(Ginkgo extract 30mg + Ginseng extract 50mg) 1T/Three times a day(Tid) for 8 weeks, PO medication
1690633|NCT01536210|Drug|Placebo|Placebo 1T/ Three times a day (tid) for 8 weeks, PO medication
1690636|NCT01536184|Behavioral|Circle of Security (COS)|COS is a community based, visually supported, individualized attachment protocol appropriate for use with preschoolers and children and their parents/caregivers. It is based on attachment theory of John Bowlby and Mary Ainsworth and integrates neuroscientific principles of emotional regulation and attachment. The protocol contains both educational and therapeutic components. The goals of the intervention include increasing caregiver sensitivity and appropriate responsiveness to their child through increasing their capacity to recognize and understand their child's cues, and increasing caregiver self-reflection on their own caregiving behaviour.
1690637|NCT01536171|Other|running with normal running shoes and barefoot|shod condition: normal running shoes barefoot condition: running with no shoewear
1690638|NCT01536158|Drug|Oral paracetamol|Patients will receive oral paracetamol 15 mg/kg per dose every 6 hours for 3 days.
1690639|NCT01536158|Drug|Oral ibuprofen|Patients will receive oral ibuprofen at an initial dose of 10 mg/kg, followed by 5 mg/kg at 24 and 48 h.
1690640|NCT01536145|Drug|CP-751,871|CP-751,871 was given at doses ranging from 0.025 mg/kg up to 20 mg/kg IV every 4 weeks until disease progression or lack of tolerability
1690641|NCT01536132|Drug|Levosimendan|0.2 micrograms/kg/min is administered intravenously without bolus for 6 hours every two weeks.
1690642|NCT01536132|Drug|Placebo|Placebo (same appearance than active drug) is administered with the same dosing regime
1690643|NCT01536119|Behavioral|Coparenting Breastfeeding Support Intervention|The intervention group will receive standard care offered to breastfeeding women in the hospital and community with the addition of a multifaceted coparenting breastfeeding support intervention, which will include an in hospital discussion, a video, workbook, breastfeeding booklet, and access to a secure website. Additionally, two follow-up phone calls will be made at 1 and 4 weeks postpartum. This intervention has been designed with coparenting elements and contains extensive breastfeeding information.
1690644|NCT01536106|Other|Autologous Bone marrow mononuclear cells|Intracoronary administration of concentrated BMMNC on the same day of BM aspiration using point of care technology.
1690645|NCT01536106|Other|Placebo control|Intracoronary infusion of autologous peripheral blood.
1690646|NCT01536093|Other|oropharyngeal administration of own mother's colostrum|application of 0.2 mL of colostrum to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
1690647|NCT01536093|Other|oropharyngeal administration of sterile water|application of 0.2 mL of sterile water to the infant's oropharyngeal mucosa every 3 hours for 3 days from the postnatal 48 to 96 hours.
1690648|NCT01536067|Biological|ofatumumab|Given IV
1690649|NCT01536067|Drug|bortezomib|Given SC
1690650|NCT01536067|Other|laboratory biomarker analysis|Correlative studies
1690651|NCT01536054|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|Given SC
1690652|NCT01536054|Drug|sirolimus|Given PO
1690653|NCT01536054|Other|laboratory biomarker analysis|Correlative studies
1690654|NCT01536054|Biological|sargramostim|Given SC
1690655|NCT01536041|Drug|ONO-6950|200 mg QD, single dose
1690657|NCT01536041|Drug|Montelukast|10 mg Montelukast, QD single dose
1690658|NCT01536041|Drug|Placebo|Placebo to match ONO-6950 tablets or leukotriene receptor antagonist (LTRA) tablets dosed in a similar manner
1690659|NCT01536028|Drug|biphasic insulin aspart 30|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
1690660|NCT01536028|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
1690661|NCT01536028|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
1690662|NCT01536028|Drug|insulin aspart|A single dose administrated subcutaneously (s.c., under the skin) on four separate dosing visits in random order with a washout of 1-2 weeks in-between
1690663|NCT01536015|Drug|Rotigotine|"Strength and Form: 4 - 8 mg patches, one patch applied every 24 hours
Dosage and Frequency: One patch every 24 hours
Duration: 10 weeks"
1690664|NCT01536015|Drug|Placebo|"Frequency: One patch applied every 24 hours
Duration: 10 weeks"
1690665|NCT01536002|Drug|Propofol|Intravenous infusion over 30 min of Propofol 3-4 mg/kg body weight
1690666|NCT01535989|Drug|Inotuzumab Ozogamicin|starting dose 0.8 mg/m2, d1 administration, q4wks
1690667|NCT01535989|Drug|Temsirolimus|starting dose of 15mg, weekly administration, q4ws
1690668|NCT01535976|Drug|Placebo|"Placebo Comparator: Placebo
.9 normal saline infusion"
1690669|NCT01535976|Drug|Ketamine|Ketamine infusion .5mg/kg bolus followed by 1.5 mcg/kg/minute until end of case
1690670|NCT01535950|Drug|LFG316|
1690671|NCT01535950|Drug|Placebo|Placebo will be administered as sham injections. Sham injections will involve placement of the syringe hub against the sclera, without use of a needle.
1690672|NCT01535937|Drug|Ketamine|0.5 mg/kg IV over 40 minutes
1690673|NCT01535937|Drug|Midazolam|0.025 mg/kg IV over 40 minutes
1690674|NCT01535924|Drug|gemcitabine hydrochloride|Given IV
1690675|NCT01535924|Drug|bendamustine hydrochloride|Given IV
1690676|NCT01535911|Other|Energy restricted Ketogenic Diet (ERKD) (Metabolic Nutritional Therapy)|Adult subjects with newly diagnosed glioblastoma will be referred to the study. Residual tumor size will be determined using MRI imaging. Subjects will be placed on ERKD while they are being treated with radiation therapy and standard of care chemotherapy. After completion of radiation therapy, tumor size will be determined using MRI. If the tumor has decreased in size or remained the same (stable disease), the subjects will be continued on the ERKD for an additional 6 weeks. Total calories consumed by each subject will be targeted to 20 to 25 kcal/kg/day. If the tumor has decreased in size or the size has remained the same then subjects will be continued on the ERKD for as additional 6 weeks and a repeat MRI will be obtained.
1690677|NCT01535898|Other|MRI scanner with sequence|The intervention for the patients is the additional 10 minutes in the MRI scanner with sequence. The intervention for the volunteers is the scan, which will take a total of 30 minutes. The volunteers will have two more additional studies at 1-2 week intervals. Both the patients and volunteers will also need to fill out a questionnaire.
1690678|NCT01535885|Biological|Cytotoxic T Lymphocytes|Patients will be studied in cohorts of 3. Eligible patients will receive a single Multi-Virus CTL line infusion 28-100 days after their transplant. The dose will start at dose level 1 (2.0 x 106/kg). After each cohort of 3 patients has been treated at each of the dose levels, decisions will be made if the next high or lower dose level should be used.
1690679|NCT01535872|Dietary Supplement|Dehydroepiandrosterone|DHEA in 25mg capsule. 1 capsule taken 3 times daily for up to 5 months.
1690680|NCT01535859|Drug|Cabergoline|Cabergoline in 0.5mg tablet. 1 tablet daily for 8 days.
1690681|NCT01535859|Drug|Placebo|1 tablet daily for 8 days.
1690682|NCT01535846|Behavioral|Conscious food tasting intervention|Six weekly 2-hour workshops
1690683|NCT01535833|Procedure|Device- Robotic sacral colpopexy|To assess robotic sacral colpopexy for female patients with stage 2 pelvic organ prolapse
1690684|NCT01535820|Drug|Treatment A: ORTHO EVRA patch (NGMN + EE) with an adhesive overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock with an adhesive overlay applied over the transdermal contraceptive system for 7 days.
1690685|NCT01535820|Drug|Treatment B: ORTHO EVRA patch (NGMN + EE) without an overlay|NGMN: type= exact number, unit= mg, number= 6, form= transdermal patch, route= transdermal use. EE: type= exact number, unit= mg, number= 0.75, form= transdermal patch, route= transdermal use. A single patch is applied to the buttock without an overlay for 7 days.
1690686|NCT01535807|Device|CorMatrix extra cellular matrix (ECM)|"Cormatrix ECM group will receive the CorMatrix ECM during surgery for the closure of the pericardium according to the specific recommended surgical technique.
No Intervention group will not receive the CorMatrix ECM during surgery, leaving the pericardium open according to current standard of care."
1690687|NCT01535781|Drug|Tranexamic Acid|1 g of tranexamic acid as a bolus immediately before surgery 3 g of tranexamic acid in 24hours postop.
1690688|NCT01535781|Drug|Placebo|Identical syringe and drip used as in the intervention, to ensure blinding.
1690689|NCT01535768|Drug|Aqueous Suppressant Eye Drops|"Aqueous suppressant eye drops added stepwise to achieve IOP between 7-10mmHg. First, a beta blocker eye drop (timolol 0.25% 1 gtts in study eye BID OR timolol 0.5% 1 gtts in study eye BID).
Next, a topical carbonic anhydrase inhibitor eye drop. (brinzolamide 1% 1 gtts in study eye TID OR dorzolamide 2% 1 gtts in study eye TID) Next, a topical alpha agonist eye drop. (brimonidine 0.1% 1 gtts in study eye TID OR brimonidine 0.15% 1 gtts in study eye TID).
Next, a topical prostaglandin analogue eye drop. (latanoprost 0.005% 1 gtts in study eye qhs OR travoprost 0.004% 1 gtts in study eye qhs OR bimatoprost 0.01% 1 gtts in study eye qhs OR bimatoprost 0.03% 1 gtts in study eye qhs) Finally, stop the topical carbonic anhydrase inhibitor eye drop and start oral acetazolamide. (acetazolamide 250mg PO OD)"
1690690|NCT01535755|Device|protocol|In this group, the patients were weaned as the protocol.
1690691|NCT01535755|Other|physician's orders|In this group, the patients were weaned as the clinicians' order.
1743657|NCT00131742|Drug|lamivudine|
1690696|NCT01535716|Behavioral|hemodynamic optimization strategy driven by the ECOM|"goal directed hemodynamic therapy is based on the ECOM evaluation of stroke volume variation (SVV) & cardiac index (CI).
goals:
SVV < 11%
IC > 2,2 ml/min/m²
During the anesthesia"
1690697|NCT01535716|Behavioral|standard management strategy|"goal directed hemodynamic therapy will be set and performed by the attending anesthetist, based on the analysis of further clinical parameters: Standard monitoring : heart rate, saturation index
Diuresis > 0,5ml/kg/h
Blood pressure , PAM > 65 mmHg
Pulse pressure variation
CVP 8 to 12 cmH20
Visual aspect of the heart
Overload signs During the anesthesia"
1690698|NCT01535690|Other|photodynamic therapy and periodontal debridement|At least two teeth (one with PD ≥ 7 mm and another with PS ≥ 5 mm) were randomly assigned (by coin toss) to one of the treatments: with (test group) or without PDT (control group). After random allocation, all patients received full-mouth ultrasonic debridement using an ultrasonic scaler for 1 hour. Specific tips were used. PDT was performed on only one side of the mouth and the initial step was subgingival irrigation with 0.005% methylene blue dye. To avoid contamination of the control sites with the dye, the methylene blue was applied only inside the periodontal pockets and a high-powered suction device controlled the flow. Two minutes after applying the photosensitizer, the low power laser - AsGaAl was applied for 90 seconds.
1690699|NCT01535677|Drug|Dapagliflozin + Glucophage tablet fasted|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fasted state
1690700|NCT01535677|Drug|Dapagliflozin/metformin IR FDC tablet fasted|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fasted state
1690701|NCT01535677|Drug|Dapagliflozin + Glucophage tablet fed|Single oral doses of 5 mg dapagliflozin and 850 mg Glucophage® tablets administered together in the fed state
1690702|NCT01535677|Drug|Dapagliflozin/metformin IR FDC tablet fed|single oral dose of dapagliflozin/metformin (5 mg/850 mg) IR FDC tablet in the fed state
1690703|NCT01535664|Other|Withdrawal of dalfampridine-ER 10mg|"Withdrawal of dalfampridine-ER 10mg (7 days on study drug followed by withdrawal period of 10 days, followed by on study drug until study completion)
On drug Day-7 (visit 1) through Day 1 (visit 2)
Off drug Day 5±2 days (visit 3) through Day 11±2 days (visit 4)
On drug Day 15±2 days (visit 5)"
1690704|NCT01535651|Behavioral|Teen Outreach Program with Media Enhancement (TOP4ME)|Persons participating in TOP will receive text messages weekly in addition to TOP
1690705|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
1690706|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
1690707|NCT01535638|Drug|BI 207127|Medium dose film-coated tablet
1690708|NCT01535625|Device|Momo stent|Patients with PCI
1690709|NCT01535612|Device|PaQ™ insulin infusion device|Basal/bolus insulin therapy administered by CSII for 4 weeks. First two weeks is transition period to identify correct basal rate for the patient, second 2 weeks is treatment period to evaluate efficacy of CSII device.
1690710|NCT01535599|Drug|AL-60371, 0.3% Otic Suspension|
1690711|NCT01535599|Other|AL-60371 Vehicle|Inactive ingredients used as a placebo comparator
1690712|NCT01535586|Device|CPAP versus MAD|Cross over design
1690713|NCT01535573|Drug|Citalopram|20 mg once per day for 9 weeks
1690714|NCT01535573|Drug|Citalopram|40 mg per day for 9 weeks
1690715|NCT01535573|Drug|Placebo|0 mg per day for 9 weeks
1690716|NCT01535560|Drug|AL-60371, 0.3% otic suspension|Investigational otic suspension intended for the treatment of acute otitis externa
1690717|NCT01535560|Drug|AL-60371 Vehicle|Inactive ingredients used as placebo
1690718|NCT01535547|Drug|isavuconazole|oral
1690719|NCT01535547|Drug|tacrolimus|oral
1690720|NCT01535521|Device|Sleep Position Trainer (SPT)|
1690721|NCT01535508|Drug|Liquid Vitamin D|300 IU/Kg/day not to exceed 10,000 IU/day.
1690722|NCT01535495|Drug|Propranolol|Propranolol XL 120mg by mouth once daily
1690723|NCT01535482|Behavioral|Cognitive Therapy|Cognitive therapy (CT) will consist of 12 to 16 individual CT sessions on a weekly basis plus 3 booster sessions.
1690724|NCT01535482|Behavioral|Enhanced Usual Care|Enhanced usual care (EUC) will consist of the usual care that individuals receive for suicide prevention in the community, assessment and referral services provided by study staff, and weekly telephone calls lasting 15-30 minutes provided by study therapists to ensure patient safety and to provide some support.
1690725|NCT01535469|Drug|Fluconazole|Fluconazole 800mg orally daily for 2 weeks, then 400mg daily for 8 weeks
1690726|NCT01535456|Procedure|FLT-PET scans|FLT-PET scans prior to treatment, after Cycle 1, after Cycle 4
1690728|NCT01535417|Drug|Shinbaro Capsule|Herbal drug (Ledebouriellae Radix, Achyranthis Radix, Acanthopanacis Cortex, Cibotii Rhizoma, Glycine Semen, Eucommiae Cortex)
1690729|NCT01535417|Drug|Celebrex|
1690730|NCT01535404|Device|Implantation procedure for a St-Jude Medical pacemaker system with right ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous ventricular and if applicable a right atrial lead
1690731|NCT01535404|Device|Implantation procedure for a St-Jude Medical pacemaker system with left ventricular apex pacing|Implantation procedure for a St-Jude Medical pacemaker system with a transvenous left ventricular (coronary sinus) and if applicable a right atrial lead
1690732|NCT01535391|Drug|Nilotinib|Administered orally at the dose of 300 mg twice daily (total daily dose 600 mg daily) for 24 months (study core), and indefinitely if it is in the interest of the patient (the drug will be given free-of-charge after 24 months to all those patients achieving the CMR4 at 24 months and in absence of safety concerns). Nilotinib dose is increased to 400 mg BID in case of suboptimal response or failure (with the exception of patients who will fail for progression to ABP: in case of progression to ABP, the patient will not be treated with study drug and the choise of the treatment will be up to the physician).
1743658|NCT00131755|Drug|diazoxide|
1690733|NCT01535365|Other|Heat|Application of heat pack to the back or neck sprain.
1690734|NCT01535365|Other|Cold|Application of ice pack to the back or neck sprain.
1690737|NCT01535326|Procedure|air insufflation|insufflate air during the insertion of colonoscopy
1690738|NCT01535326|Procedure|water immersion|infuse water during insertion, aspirate water during withdrawal
1690739|NCT01535326|Procedure|water exchange|infuse and remove water during insertion phase of colonoscopy
1690740|NCT01535313|Device|OnControl BM-Biopsy system|Bone marrow biopsy at posterior iliac crest
1690741|NCT01535300|Procedure|Ultrasonography of the trachea|Ultrasonographic measurement of the minimal transverse tracheal diameter
1690743|NCT01535274|Other|Inspired oxygen fraction / end tidal carbon dioxide|"Following induction of anesthesia, FIO2 and minute ventilation will be sequentially adjusted to achieve:
FIO2 30% (70% nitrogen), PETCO2 30mmHg - supine position.
FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position.
FIO2 100%, PETCO2 30mmHg - beach chair position.
FIO2 100%, PETCO2 45mmHg - beach chair position.
FIO2 30% (70% nitrogen), PETCO2 30mmHg - beach chair position."
1690744|NCT01535261|Drug|Ranibizumab 0.5 mg/0.05 ml|Patients will receive the first dose at Baseline, as an intravitreal injection with a standard dose of 0.5 mg/0.05 ml. Patients will receive at least 3 study treatments at monthly intervals (Day 1, Month 1 and Month 2). The last mandatory dose during treatment initiation will be administered approximately 60 days after the first study treatment. If there is no improvement in VA over the course of the first 3 injections, continued treatment is not recommended and the patient may receive alternative treatment at the investigator's discretion.
1690745|NCT01535248|Other|Transthoracic Echocardiography|Patients undergoing ERCP will have surveillance with transthoracic echocardiography with exams occurring every 10 mins or more often if needed to evaluate for the presence of intra-cardiac air associated with ERCP insufflation.
1690746|NCT01535235|Drug|Lisinopril|Lisinopril 20mg QD x 24 weeks
1690747|NCT01535235|Drug|Placebo|Placebo QD x24wks
1690748|NCT01535222|Drug|MDCO-2010|MDCO-2010 solution for infusion. Dosage: Pump priming dose; Loading dose infusion over 6 minutes; Maintenance infusion for duration of surgery
1690749|NCT01535222|Drug|Placebo|Commercially available NaCl
1690750|NCT01535209|Radiation|stereotactic body radiotherapy (SBRT)|18Gy in 1 fraction for resection cavity <2cm in maximum diameter, 15Gy in 1 fraction for resection cavity 2.1-3cm in maximum diameter, 15Gy in 1 fraction or 25 Gy in 5 fractions over 5 days for resection cavity 3.1-4cm in maximum diameter, 25 Gy in 5 fractions over 5 days for resection cavity >4cm in maximum diameter
1690751|NCT01535209|Radiation|Whole-Brain Radiotherapy (WBRT)|10 x 3 Gy to whole brain
1690752|NCT01535196|Drug|Vigantol oil and MCT oil|Vigantol oil, 9 ml, 180 000 IU at the 0,1,2,3,6 month (5 times in the study) MCT oil as placebo, 9 ml, 0,1,2,3,6 month (5 times in the study)
1690753|NCT01535183|Drug|Irinotecan combination chemotherapy|"Irrinotecan 300㎎/㎡ d0 IVS mixed with D5W 500mL over 90min with atropine (-30 min)
VCR 2㎎/㎡ d0 IV push
Etoposide 100㎎/㎡ d0-d2 IV over 1hr
Carboplatin 450㎎/㎡ d0 IV over 8hrs
Cyclophosphamide 1,000㎎/㎡ d1 IVS with mesna"
1690754|NCT01535170|Dietary Supplement|bovine Lactoferrin|Patients will receive either bLF (10 mg/Kg/day) (Westland Co-operative Dairy Company, New Zealand) or placebo (starch) as control. The dosage of bLF is based on the mean hLF intake that very low body weight neonates ingest with mother's fresh milk in the first 2 weeks of life (30-150 mg/d) [16] and bLF 200 mg bid is found to be effective to suppress Helicobacter pylori [17].
1690755|NCT01535157|Drug|Fenretinide/LXS + Ketoconazole|Starting dose is: Fenretinide/LXS 800 mg 4-HPR/m2/day and Ketoconazole 400 mg/day
1690756|NCT01535144|Device|Fracture compressing screw ZfW 102 Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
1690757|NCT01535144|Device|Fracture compressing screw titanium Königsee Implantate GmbH|Comparison of two metallic implantable fracture compressing screws
1690758|NCT01535131|Procedure|palatoplasty|procedure to close cleft palate
1690761|NCT01535079|Drug|Placebo|Single administration
1690762|NCT01535079|Drug|Ibuprofen 35 mg|Single administration
1690763|NCT01535079|Drug|Ibuprofen 25 mg|Single administration
1690764|NCT01535079|Drug|Ibuprofen 15 mg|Single administration
1690765|NCT01535079|Drug|Strefen|Single administration
1690766|NCT01535066|Procedure|acupuncture therapy|Receive acupuncture
1690767|NCT01535066|Procedure|sham acupuncture|Receive sham acupuncture
1690768|NCT01535053|Biological|Dactinomycin|Given IV
1955612|NCT03133234|Drug|osimertinib|Oral dose of 80mg once daily
1955613|NCT03131219|Biological|ALXN1210|Single loading dose on Day 1, followed by regular maintenance dosing beginning on Day 15, based on weight.
1955621|NCT03129581|Behavioral|Dietary Counseling|Counseling to only eat during a restricted amount of time.
1690769|NCT01535053|Drug|Leucovorin Calcium|Given PO
1690770|NCT01535053|Drug|Methotrexate|Given IV and IM
1690771|NCT01535053|Other|Quality-of-Life Assessment|Ancillary studies
1690772|NCT01535040|Drug|memantine hydrochloride|Estimate participation, accrual, adherence, and retention of cancer survivors who smoke and are randomized to receive memantine (10 mg twice daily) or a matching placebo for 12 weeks.
1690773|NCT01535040|Drug|placebo|Placebo by mouth through completion of 12 weeks.
1690774|NCT01535027|Drug|teriparatide|teriparatide 20 ug/day, sc.
1690775|NCT01535027|Drug|teriparatide and raloxifene|teriparatide 20 ug/day sc. raloxifene 60mg oral daily
1690776|NCT01535027|Drug|teriparatide and alendronate|teriparatide 20 ug/day sc. alendronate 70mg oral weekly
1690787|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
1690788|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
1690789|NCT01534962|Drug|Ranolazine|Oral administration, BID; for a maximum of 112 days.
1690790|NCT01534962|Drug|Placebo|Oral administration, BID; for a maximum of 112 days.
1690791|NCT01534949|Biological|rituximab|375 mg/m2 by intravenous [IV] infusion
1690792|NCT01534923|Behavioral|surveys|The intervention will be the audio-recording of the physician-patient consultation, patient and doctor surveys. These audio recordings will be coded. It will also include follow-up phone calls with patients.
1690793|NCT01534910|Drug|aged garlic extract|2400 mg a day
1690794|NCT01534910|Drug|placebo|placebo
1690795|NCT01534897|Drug|GSK2118436|150mg twice per day orally for 28 days (42 days if Iodine-131 scan on Day 25 shows new uptake)
1690796|NCT01534884|Biological|rituximab|1000 mg by intravenous (IV) infusion. Each patient may receive 2 courses of treatment.
1690797|NCT01534871|Behavioral|Exercise|Subjects will be enrolled in a 12-week community cardiac rehabilitation program. The program consists of two one hour exercise sessions per week and one one hour education session per week. For the exercise sessions the subjects will perform aerobic exercise at 60-80% of heart rate reserve. Education sessions will cover heart healthy eating, setting health-related goals, exercise, nutrition, healthy weight, medication, smoking cessation and stress/coping.
1690798|NCT01534858|Device|Prontosan Wound Gel X|Prontasan Wound Gel X will be applied topically as a thin layer to the entire grafted area immediately after transplant and with each dressing change.
1690799|NCT01534845|Drug|Temozolomide (Temodal)|RT with daily temozolomide (75 mg/m2/day, 7 days/week) from the first to the last day of radiotherapy) and adjuvant TMZ chemotherapy (150-200 mg/m2 po qd for 5 days q 28 days for 6 cycles)
1690800|NCT01534832|Device|Innervision Surgical Smoke Removal System|Smoke removal by electrostatic precipitation
1690801|NCT01534819|Device|Aptus Heli-FX EndoAnchor System|Placement of the Aptus Heli-FX™ EndoAnchor System in subjects for the prevention of graft migration and the treatment of Type Ia endoleak or Aptus Heli-FX EndoAnchor System placed at the time of initial endograft implantation, either to prevent endograft migration and Type Ia endoleak, or to treat Type Ia endoleak evident at the time of implantation.
1690802|NCT01534819|Procedure|AAA/TAA endograft placement|Use of the Aptus Heli-FX EndoAnchor System (Heli-FX) during either primary placement of a AAA/TAA endograft.
1690803|NCT01534806|Drug|Ketorolac|Ketorolac(0.5mg/kg) IV push
1690804|NCT01534806|Drug|Placebo|Sodium Chloride 0.9% - 10 mL IV push
1690805|NCT01534793|Procedure|Holmium Laser Enucleation of the Prostate (HoLEP)|Under regional or general anaesthesia Urethroscopy to check the location of the prostatic capsule Enucleation of the prostatic lobes (median if present, then lateral lobes)Hemostasis Morcellation Device : LUMENIS Laser
1690806|NCT01534780|Procedure|laparoscopic ventral herniotomy|Laparoscopy in general anesthesia are performed with placement of Physiomesh intraperitoneally. Fixation of the mesh is performed with 1 of 3 possible devices
1690807|NCT01534780|Device|Protack|fixation of mesh with protack
1690808|NCT01534780|Device|Securestrap|fixation of mesh with Securestrap
1690809|NCT01534780|Device|Glubran|fixation of mesh with Glubran
1690810|NCT01534754|Drug|Mesalazine plus Lactobacillus casei|Active Mesalazine 800 mg, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
1690811|NCT01534754|Drug|Mesalazine placebo plus Lactobacillus casei placebo|Mesalazine 800 mg placebo, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for oe year.
1690812|NCT01534754|Drug|Mesalazine 800 mg|Active mesalazine 800 mg, 2 tablets/day and Lactobacillus casei placebo, 1 sachet/day for 10 days/month for one year.
1690813|NCT01534754|Drug|Lactobacillus casei|Mesalazine 800 mg placebo, 2 tablets/day and active Lactobacillus casei, 1 sachet/day for 10 days/month for one year.
1690814|NCT01534741|Other|dialyzer comparison|Each patient will be treated by post-dilution online hemodiafiltration once with each dialyzer type (FX CorDiax 60or FX 60 ) The order of dialyzers used will be randomly assigned to the patient at the time of randomisation by lot. Every subject will be treated one time with each dialyzer. In order to achieve controlled conditions, the mid- or end-week session data will be used, only.
1690815|NCT01534741|Device|Dialyzer|Comparison Dialyzer FX60 versus Cordiax60
1690816|NCT01534715|Drug|IMGN529|
1690817|NCT01534702|Drug|clofarabine, cytarabine, idarubicin|"Treatment is stratified according to patients age (< 60 years vs. ≥ 60 years).
Medication:
Patients < 60 years:
idarubicin 7.5 mg/m2 iv, days 1 + 3
cytarabine 750 mg/m2 iv, days 1 to 5
Patients ≥ 60 years:
idarubicine 6 mg/m2 iv, days 1 + 3
cytarabine 750 mg/m2 iv, days 1 to 5
Clofarabine will be given in escalating doses to cohorts of at least three patients:
Clofarabine:
level -1: 15 mg/m2 iv, days 1 to 5
level 1: 20 mg/m2 iv, days 1 to 5
level 2: 25 mg/m2 iv, days 1 to 5
level 3: 30 mg/m2 iv, days 1 to 5
level 4: 35 mg/m2 iv, days 1 to 5
Patients will be recruited according to a 3+3 design. New cohorts will be initiated depending on toxicity of the previous cohort during the first induction cycle. Enrollment will begin with dose level 1."
1690818|NCT01534689|Device|Erchonia FX-405™ Laser|The Erchonia FX-405™ dual diode laser light is directed at the great toenail at a distance of approximately 6 inches above the toenail. The dual wavelengths of 405 nm and 635 nm are activated simultaneously for 10 minutes of total treatment administration time.
1690819|NCT01534676|Procedure|Transfusion|A routine medical procedure to transfuse packed red blood cells.
1690820|NCT01534676|Biological|Blood|"Processing of RBC for transfusion include the following:
Fresh
Stored
Washed
Frozen (Cryopreserved)"
1690821|NCT01534676|Procedure|Chelation therapy|(non-experimental) A medical procedure that involves the administration of chelating agents to remove heavy metals from the body.
1690822|NCT01534663|Drug|Glutamine and Fish Oil Supplementation|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
1690823|NCT01534663|Drug|Placebo|This is a prospective, randomized double-blind, placebo-controlled study design. 38 subjects will be randomized to two groups (19 patients in each group), one taking active fish oil and glutamine supplementation and the other taking placebo for 90 days.
1690824|NCT01534637|Drug|aprepitant|Given PO
1690825|NCT01534637|Drug|gemcitabine hydrochloride|Given IV
1690826|NCT01534637|Drug|capecitabine|Given PO
1690827|NCT01534637|Drug|fluorouracil|Given IV
1690828|NCT01534637|Procedure|radiation therapy|Undergo radiation therapy
1690829|NCT01534637|Other|questionnaire administration|Ancillary studies
1690830|NCT01534637|Procedure|quality-of-life assessment|Ancillary studies
1690831|NCT01534637|Procedure|nausea and vomiting therapy|Receive aprepitant
1690832|NCT01534637|Procedure|management of therapy complications|Receive aprepitant
1690834|NCT01534585|Drug|Icotinib|"Oral Icotinib begins on day 1 and continues until completion of radiotherapy. Phase I:The initial plan is to accrue 6 patients to each dose level (125mg, qd and bid and tid) in each cohort. If one or none of six patients have dose limiting toxicity (DLT), then escalation will proceed. If DLT occurs in two or more patients at a dose level, then escalation will be stopped. The dose level below that at which two of six patients experience a DLT is defined as the maximum-tolerated dose. A minimum of 4 weeks of observation is required after completion of radiation within each Icotinib dose level before accrual to the next level.
Phase II:According to the maximum tolerated dose, 50 patients will been recruited."
1690835|NCT01534585|Radiation|intensity-modulated radiotherapy|The nasopharyngeal regions and upper neck with IMRT plans will be generated and approved for each patient, whereas the low-neck and supraclavicular regions will be used with a conventional anterior field. A total of 70-76Gy at 2.12-2.3Gy/fraction/d will be given to the GTVnx, the GTVnd will receive 66-70Gy at 2.0-2.12Gy/fraction/d, the CTV1 will receive 60-66Gy at 1.8-2.0Gy/fraction/d, and the CTV2 received 56-60Gy at 1.7-1.8Gy/fraction/d with IMRT. The low-neck and supraclavicular regions will receive 50-60Gy at 2.0Gy/fraction/d with conventional radiotherapy. Target prescription dose and critical structures limit dose are planned according to the RTOG0225 trial.
1690836|NCT01534585|Drug|Paclitaxel and Cisplatin|AC that consisted of two cycles of paclitaxel 135 mg/m2 on day 1 plus cisplatin 30 mg/m2 on days 1-3 will start 4 weeks after the end of CRT.
1690837|NCT01534585|Other|Quality of life|The EORTC QLQ-C30 and H&N35 of the Chinese version, which is obtained from the Quality of Life Unit, EORTC Data Center in Brussels, Belgium, is available and easily completed by our patients are chosen for this study. Patients will complete the questionnaire before treatment and after treatment and one month after treatment and three months after treatment and one year after treatment.
1690838|NCT01534585|Genetic|Epidermal growth factor receptor status|EGFR expression and mutation before treatment.
1690839|NCT01534572|Dietary Supplement|Lactobacillus|Intervention (2 weeks) with a strain of Lactobacillus
1690840|NCT01534572|Dietary Supplement|Bifidobacterium|Intervention (2 weeks) with a strain of Bifidobacterium
1690841|NCT01534559|Other|Medicines Management Outpatient service|New customised clinical pharmacy service (medicines management clinic and follow-up phone calls)
1690842|NCT01534546|Drug|Oxaliplatin capecitabine|capecitabine：1000 mg/m2 ，bid, d1~14 oxaliplatin：130mg/m2，iv drip for 2h，d1
1690843|NCT01534546|Drug|Oxaliplatin S-1|S-1: 40~60mg bid，po, d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1
1690844|NCT01534546|Drug|Oxaliplatin S-1|S-1: 40~60mg bid，d1~14 （S-1：BSA <1.25m2, 40mg bid, 1.25m2≤BSA≤1.5m2,50mg bid, BSA>1.5m2, 60mg bid） oxaliplatin：130mg/m2，iv drip for 2h，d1 S-1 monotherapy as the same dose and schedule of the above
1690845|NCT01534533|Dietary Supplement|Placebo|one gelatine capsule containing starch per day, for 12 months
1690846|NCT01534533|Dietary Supplement|Lutein group|one gelatine capsule containing 20mg lutein per day, for 12 months
1690847|NCT01534533|Dietary Supplement|Combination group|one gelatine capsule containing 20mg lutein and 20 mg lycopene per day, for 12 months
1690848|NCT01534533|Dietary Supplement|Normal lutein control group|subjects without early atherosclerosis, treated with one gelatine capsule containing 20mg lutein per day, for 12 months
1690849|NCT01534520|Drug|Lidocaine|Intravaginal insertion of 4mL 2% lidocaine gel
1690850|NCT01534520|Drug|Placebo|KY Jelly
1690851|NCT01534494|Drug|Psilocybin|two doses of 0.3 mg/kg PO and 0.4 mg/kg PO, separated by 4 weeks in combination with 12 weeks of manualized outpatient psychosocial treatment including preparation, debriefing, and motivational enhancement therapy.
1690852|NCT01534481|Biological|Donor Milk|Donor milk provided by the Human Milk Banking Association of North America
1690853|NCT01534481|Dietary Supplement|Preterm Formula|Preterm Formula determined by center practice.
1690854|NCT01534468|Biological|Monovalent Influenza Subvirion Vaccine, H7N7|At study entry, all participants will receive one IM injection of approximately 45 micrograms of inactivated Monovalent Influenza Subvirion Vaccine, H7N7.
1690855|NCT01534455|Drug|Lapatinib + 1,23 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
1690856|NCT01534455|Drug|Lapatinib + 1,76 mg Eribulin|Lapatinib 1000 mg/day + Eribulin 1,23 mg/m2 i.v. on day 1 and 8, q21
1690857|NCT01534442|Drug|Atropine|1 mg as a bolus and the and infusion of 80 ng/kg/min for either 105 or 145 minuts.
1690858|NCT01534442|Drug|Placebo|
1690859|NCT01534429|Procedure|Quantitative Sensory Testing|Quantitative Sensory Testing and Neurophysiologic Testing to be done Pre-operatively and at 3 and 6 months post-operatively.
1690862|NCT01534403|Biological|Epratuzumab|Epratuzumab 600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles (ie, Weeks 0, 1, 2, 3, 12, 13, 14, 15, 24, 25, 26, 27, 36, 37, 38, 39, 48, 49, 50, 51, 60, 61, 62, 63, 72, 73, 74, 75, 84, 85, 86, and 87)
1690863|NCT01534390|Device|In-line microfilter (Supor IV Filter; Pall Corporation, Port Washington, New York)|use of in-line microfilters with a pore size of 0,2 mcm and 1,2 mcm (only if parenteral nutrition is administered) at all intravenous accesses
1690866|NCT01534364|Other|calorie restriction|Calorie Restriction to 60% of the calculated daily energy rate from day -7 until day -1 (included) pre-surgery (day 0 corresponds to day of surgery)
1690867|NCT01534351|Drug|Finasteride|Finasteride 5 mg oral tablet taken once daily.
1690868|NCT01534351|Drug|Tamsulosin|Tamsulosin 0.2 mg oral capsule taken once daily.
1690869|NCT01534351|Drug|Finasteride-matching placebo|Matching placebo to finasteride 5 mg oral tablet taken once daily.
1690870|NCT01534351|Drug|Tamsulosin-matching placebo|Matching placebo to tamsulosin 0.2 mg oral capsule taken once daily.
1690871|NCT01534338|Behavioral|Mindfulness Meditation|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
1690872|NCT01534338|Behavioral|Sleep Education|Participants will attend weekly 2-hour classes for a total of 6 weeks and participants will monitor their sleep with a daily sleep diary.
1690873|NCT01534325|Device|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.
The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.
The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.
The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
1690874|NCT01534325|Device|Control|"The participants in the Control arm of the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the placebo. During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.
The use of the placebo is done by the control study participants during the day every day throughout the study period. The placebo can be easily used by the participants themselves in their regular environment and does not require professional assistance."
1690875|NCT01534325|Device|SD|"The participants in the study receive basic nutrition guidance by MD and clinical dietician and make daily use of the device under study (called SD). During the 13 weeks study period, the participants get to meet clinical dietician/MD once in every 2 weeks for guidance and supervision and for on -going monitoring of physical parameters such as body weight and waist circumference.
The use of the SD device is done by study participants during the day every day throughout the study period. The device under study can be easily used by the participants themselves in their regular environment and does not require professional assistance.
The device under study is expected to affects the satiety, energy homeostasis and metabolic control centers in the brain and by that to reduce food intake and lead to weight loss.
The device under study is a device- not a medication and not a surgical procedure, and it does not involve any of such elements."
1690876|NCT01534312|Drug|CGMP protein|Casein glycomacropeptide purified powder dissolved in 300 ML water once daily
1690877|NCT01534312|Drug|Maximal oral 5ASA|4800 grams/day of Mesalazine (Asacol/Mezavant)
1690879|NCT01534286|Drug|Theramine|Theramine 2 capsules 3 times per day
1690880|NCT01534286|Drug|Theramine- like placebo|Theramine-like placebo capsules 2 three times daily
1690881|NCT01534273|Drug|LY2886721|Administered orally.
1690882|NCT01534273|Drug|Placebo|Administered orally.
1690883|NCT01534260|Drug|sorafenib, vorinostat and bortezomib|Escalating dose cohorts of sorafenib, vorinostat and bortezomib. The first cohort will receive sorafenib from day 1 to 14, vorinostat will be given on days 1-4 and 8-12, and bortezomib will be given on days 1 and 8. This will be followed by 7 days of rest. Therefore each cycle will be 21 days.
1690884|NCT01534247|Drug|CAZ-AVI|Infusion
1690885|NCT01534247|Drug|metronidazole|Infusion
1690886|NCT01534247|Drug|CAZ-AVI + metronidazole|Infusion
1690887|NCT01534234|Device|PARADYM RF SONR|SonR CRT Optimization
1690888|NCT01534234|Device|PARADYM RF SONR|Echocardiography Optimization
1690889|NCT01534221|Device|Biomatrix drug eluting stent|Biomatrix drug eluting stent
1690890|NCT01534208|Drug|Androxal|Androxal, oral, 12.5 mg capsule, taken once daily. Dose may be increased from 12.5 mg to 25 mg if indicated
1690891|NCT01534195|Drug|Prednisolone Sodium Phosphate Ophthalmic Solution 1%|One drop in each eye, four times/day for 8 days.
1690892|NCT01534195|Drug|Tears Naturale II Ophthalmic Solution|one drop in each eye, four times/ day (QID) for 8 days
1690893|NCT01534182|Drug|Fingolimod|0.5 mg orally once a day
1690894|NCT01534182|Drug|Interferon beta - 1a (IFN)|44 mcg subcutaneously three times a week
1690895|NCT01534182|Drug|Glatiramer acetate (GA)|20 mg subcutaneously once a day
1690896|NCT01534169|Drug|Dexamethasone|The course of treatment will be last for 3 months. The intrathyroid injection of dexamethasone will be performed using a 25-gauge (0.25-mm) needle under ultrasound guidance. The injection will be performed in both lobes of the thyroid. The dosage of dexamethasone is 5mg (1.0 ml) in each lobe, twice a week during the first month of the treatment. The treatment strategy will be changed to once a week in the second month and twice a month in the third month; the dosage of dexamethasone is the same as in the first month.
1690897|NCT01534143|Other|pharmacological study|Correlative studies
1690898|NCT01534143|Drug|tacrolimus|Given IV
1690899|NCT01534143|Drug|sirolimus|Given PO
1690900|NCT01534143|Biological|anti-thymocyte globulin|Given IV
1690901|NCT01534143|Drug|fludarabine phosphate|Given IV
1690902|NCT01534143|Drug|busulfan|Given IV
1690903|NCT01534143|Drug|bortezomib|Given IV
1690904|NCT01534143|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
1690905|NCT01534143|Other|laboratory biomarker analysis|Correlative studies
1690906|NCT01534130|Device|Acupuncture|Participants will receive five sessions of verum acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
1690907|NCT01534130|Device|Sham acupuncture|Participants will receive five sessions of sham acupuncture in the first week after randomization, three sessions in the second and third weeks after randomization, and two sessions in the forth week after randomization.
1690908|NCT01534117|Biological|Platelets|1 unit of platelets
1690909|NCT01534117|Drug|DDAVP|Desmopressin 0.3mcg/kg IV x 1
1690910|NCT01534104|Procedure|preoperative fMRI. DTI and DSI with tractography|W/I approx 4-6 weeks of the fMRI, DTI & DSI, neurological/physical testing & brain MRI showing tumor &/or edema located in or near (<2 cm) the motor cortex (precentral gyrus), motor pathway (corticospinal tract), language cortex (Broca's area, Wernicke's area), &/or language pathway (arcuate fasciculus) Preoperative MRI for surgical planning (approximately <48 hours before surgery*) fMRI to localize gray matter DTI, DSI & tractography to localize white matter, DSI & updated fMRI (Optional) Most patients will undergo surgery w/i 48 hrs of their preoperative MRI. For some patients, the MRI results will be used for preoperative counseling. In this subset of patients, we expect that surgery will occur w/i 3-4 months of the MRI. Brain tumor resection as per the treating neurosurgeon Electrical stimulation to localize gray &/or white matter structures if clinically necessary according to the standard of care at MSKCC Postoperative neurological/physical examination (<48 hours after surgery)
1690911|NCT01534091|Behavioral|Pedometer with supervision|
1690912|NCT01534091|Behavioral|Pedometer without supervision|
1690913|NCT01534078|Drug|Brentuximab Vedotin|2 doses administered 14 days apart; followed by combination therapy with AVD for 4-6 cycles; 1.2 mg/kg
1690914|NCT01534078|Drug|Adriamycin, vinblastine, and dacarbazine|Combination therapy with brentuximab for 4-6 cycles; 25 mg/m2 Adriamycin; 6 mg/m2 Vinblastine; 375 mg/m2 Dacarbazine
1690915|NCT01534065|Device|Barricaid|Implanted intra-operatively during discectomy
1690916|NCT01534052|Drug|MDV3100|Oral
1690917|NCT01534039|Device|Sur-Fit Natura|ConvaTec Moldable Skin Barrier for ostomy patients
1690918|NCT01534039|Device|FormaFlex|Hollister skin barrier for ostomy patients
1690919|NCT01534026|Drug|Aspirin|Current dose
1690920|NCT01534026|Other|withdrawal of aspirin|Stopping current dose of aspirin
1690921|NCT01534013|Device|The Imperial College Closed-Loop Insulin Delivery System|The Imperial College closed-loop insulin delivery system comprises 3 main components: the glucose sensor, the control algorithm and the insulin delivery system.
1690922|NCT01534000|Procedure|Cardiac computed tomographic angiography (CCTA)|Patients will (on top of the standard clinical evaluation with a functional-based stress-test) be examined with a Cardiac CT scan. In the control group, the Cardiac CT will be blinded for clinical evaluation and only used retrospectively for research purpose.
1690923|NCT01533987|Dietary Supplement|Juice Plus|Juice Plus is the combination of Juice Plus+® Garden Blend, Juice Plus+® Orchard Blend and Juice Plus+® Vineyard Blend.
1690924|NCT01533974|Other|Acceptance & Commitment Therapy (ACT)|We will use a five-session (90 minutes per session) group-delivered adaptation of Dr. Bricker's ACT treatment program.
1690925|NCT01533974|Other|Cognitive Behavioral Therapy (CBT)|The control condition will be the current group-delivered CBT smoking cessation program at GH.
1690926|NCT01533961|Drug|SCYX-7158|
1690927|NCT01533961|Drug|Placebo|
1690928|NCT01533948|Drug|axitinib|Given PO
1690929|NCT01533948|Other|laboratory biomarker analysis|Correlative studies
1690930|NCT01533935|Drug|Placebo|placebo matching tiotropium + olodaterol
1691091|NCT01532869|Drug|Placebo|Subcutaneously weekly, Weeks 0-48
1690931|NCT01533935|Drug|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + olodaterol 5 mcg once daily
1690932|NCT01533935|Drug|tiotropium + Olodaterol|tiotropium 5 mcg + olodaterol 5 mcg once daily
1690933|NCT01533935|Drug|Tiotropium|tiotropium
1690934|NCT01533935|Drug|Olodaterol|Olodaterol 5 mcg once daily
1690935|NCT01533935|Device|Respimat|Respimat inhaler
1690936|NCT01533922|Drug|Placebo|placebo matching tiotropium + olodaterol FDC
1690937|NCT01533922|Drug|Tiotropium|Tiotropium 5 mcg once daily
1690938|NCT01533922|Drug|Olodaterol|Olodaterol 5 mcg once daily
1690939|NCT01533922|Drug|tiotropium + olodaterol|tiotropium + olodaterol 5 mcg once daily
1690940|NCT01533922|Drug|Tiotropium + Olodaterol|Tiotropium 2.5 mcg + Olodaterol 5 mcg once daily
1690941|NCT01533922|Device|Respimat|Respimat inhaler
1690942|NCT01533896|Behavioral|Grow Nicely|Grow Nicely is a multimedia educational tool, developed at Vanderbilt University that teaches why and how to help children reach and maintain a healthy weight.
1690943|NCT01533883|Device|Cardioband adjustable band|Cardioband is an adjustable sutureless annuloplasty band designed for mitral valve repair by a transfemoral approach. Cardioband is intended to remodel the annulus by deployment and fixation along the posterior annulus of the mitral valve, in order to correct mitral regurgitation. Adjustment can be performed on a beating heart, to optimize correction of mitral regurgitation.
1690944|NCT01533870|Drug|NKTR-118|Oral 25 mg
1690945|NCT01533870|Drug|Rifampin|Oral 600 mg
1690946|NCT01533857|Dietary Supplement|hot water|Hot water and placebo capsule
1690947|NCT01533857|Dietary Supplement|Black tea and phenolic acids|Black tea extract and capsule with phenolic acids
1690948|NCT01533818|Drug|Amoxicillin|"80-100 mg/kg/day in 2 divided doses for 7 days
For convenience dose divided into six weight bands Table 2: Dose of amoxicillin Weight band Amount per dose Daily dose Lower Limit (mg or units /kg/d) Upper Limit (mg or units /kg/d) Amoxicillin - desired range 75-100 mg/kg/day (25mg/ml (125mg/5ml); twice daily orally)* 1.8-1.9 kg 3.0 ml 150 mg 75.4 100.0 2.0-2.4 kg 4.0 ml 200 mg 80.3 100.0 2.5-2.9 kg 5.0 ml 250 mg 83.6 100.0 3.0-3.9 kg 6.0 ml 300 mg 75.2 100.0 4.0-4.9 kg 8.0 ml 400 mg 80.2 100.0 5.0-5.9 kg 10.0 ml 500 mg 83.5 100.0"
1690949|NCT01533818|Drug|Sugar Syrup|It will be given 2 times/day for 7 days
1690950|NCT01533805|Other|Pilates exercises with stabilization|This group will focus on exercises with core stabilizing muscles. The frequency will be 16 sessions lasting 1 hour.
1690951|NCT01533805|Other|Classic Pilates|This group will make Pilates exercises its focus is on mobilization exercises of the lumbar spine. The frequency will be 16 sessions lasting 1 hour.
1690952|NCT01533792|Procedure|Supra/subgingival scaling using periodontal curette scraping|The experimental group received supra and subgingival therapy with periodontal curettes
1690953|NCT01533792|Procedure|Supra and subgingival scaling|The experimental group received supra and subgingival scaling.
1690954|NCT01533766|Drug|CombiflexOmega|intravenously over 5 days infusion
1690955|NCT01533766|Drug|SmofKabiven|intravenously over 5 days infusion
1690956|NCT01533753|Drug|Gabapentin|Gabapentin will be administered orally at a starting dose of 300mg at bedtime (titration encouraged to desired effect and tolerability per treating physician). Maximum dose allowed will be 300mg three times a day. One cycle is defined as 28 +/- 7 days.
1690957|NCT01533753|Drug|Venlafaxine|Venlafaxine will be administered orally at the starting dose of 37.5mg daily (titration allowed to desired effect and tolerability per treating physician). Maximum dose allowed will be 75mg per day. One cycle is defined as 28 +/- 7 days.
1690958|NCT01533740|Drug|fluorouracil/irinotecan/levo-folinic acid/bevacizumab|standard first line chemotherapy with: bevacizumab 5 mg/kg intravenous (i.v.) infusion on day 1; irinotecan 180 mg/m2 i.v. infusion on day 1, levo-folinic acid 200 mg/m2 i.v. infusion on day 1, 5-fluorouracil 400 mg/m2 i.v. bolus on day 1 and 2,400 mg/m2 i.v. infusion over 46 hours; infusions repeated every 2 weeks
1690959|NCT01533727|Drug|Autologous CIK Transfusion plus Chemotherapy|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w; CIK infusion D14 q3w
1690960|NCT01533727|Drug|chemotherapy alone|vinorelbine 25-30mg/m2 d1, d8 q3w; DDP 75mg/m2 d1 q3w; pemetrexed 500mg/m2 d1 q3w; carboplatin AUC 5/6 q3w;
1690962|NCT01533701|Other|Fetal scalp blood scalp, amniotic fluid, maternal blood and umbilical cord sampling|Fetal blood sampling is conducted when a non reassuring cardiotocographic pattern occurs to detect fetal hypoxia during labor. Amniotic fluid, maternal blood is sampled in cases of fetal blood sampling. Umbilical cord blood sampling is conducted at delivery.
1690963|NCT01533688|Drug|Golytely (polyethylene glycol electrolyte lavage solution) and placebo|4 liters of polyethylene glycol electrolyte lavage solution (PEG-ELS-(GoLytely))+ placebo given the evening prior to the colonoscopy
1690964|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) + placebo|split dose (2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters Golytely + placebo
1690965|NCT01533688|Drug|split dose of Golytely (polyethylene glycol electrolyte lavage solution) and bisacodyl|split dose ( 2 L taken the evening before and 2 L taken the morning of the colonoscopy) of 4 liters of Golytely + bisacodyl 10 mg
1690966|NCT01533675|Other|Hydrogen peroxide|Once daily topical application of 3% hydrogen peroxide using a cotton-tipped applicator
1690967|NCT01533675|Other|Saline|Once daily topical application of normal saline, using a cotton-tipped applicator
1690968|NCT01533662|Drug|phenylephrine infusion|patients from 60 to 75 years receiving 100micrograms of phenylephrine infusion
1690969|NCT01533662|Drug|patients receiving saline infusion|patients more than 60 years receiving 100micrograms of saline infusion
1690970|NCT01533649|Behavioral|Andrews/Reiter approach to epilepsy|"The Andrews/Reiter approach to epilepsy is a systematic semi-directive, multi-modal counseling intervention that integrates conventional therapies, educational modules, psychological interventions and relaxation techniques in order to assist the individual in improving self-defined life quality. Face-to-face counseling sessions and supervision with telephone calls are based on a standardized workbook (Taking Control of Your Epilepsy) as an on-going step-by-step guideline."
1955634|NCT03125824|Device|Soliton Acoustic Wave Device|Treatment of tattoos with Soliton Acoustic Wave Device as an accessory to laser
1690971|NCT01533649|Behavioral|Relaxation/Meditation|Subjects who participate in the relaxation control group will attend weekly relaxation sessions that will employ the following relaxation techniques: meditation, progressive muscle relaxation, autogenic training.
1690972|NCT01533623|Device|Mandibular Advancement Device|Nightly wearing time
1690973|NCT01533610|Procedure|Stellate ganglion block|Local anesthesia applied to the stellate ganglion in the neck
1690974|NCT01533597|Drug|Solifenacin|Solifenacin (5mg, qd, oral)
1690975|NCT01533597|Drug|Solifenacin plus Tamsulosin|Solifenacin (5mg, qd, oral) plus Tamsulosin (0.2mg, qd, oral)
1690976|NCT01533571|Procedure|Immediate implant placement with simultaneous bone grafting|"Flapless surgery is used for surgical implant installation.
Implant is placed in the cingulum position of adjacent teeth incisal edge.
After placement of optimal implant the remaining gap between the implant and the surrounding bony walls should be at least 2 mm or should be need for GBR of buccal plate outside the socket.
Two types of bone graft materials will be applied for two groups of patients: Group I - natural bovine bone grafting material + resorbable natural soft tissue membrane; Group II - processed human allograft + resorbable natural soft tissue membrane .
Crown can be fixed on abutment if there is initial stability under 35 Ncm insertion torque. If insertion torque will be less, crown should be bond to neighboring teeth using composite material."
1690977|NCT01533558|Drug|caspofungin|normal dosage for caspofungin, not adapted for the study
1690978|NCT01533545|Drug|Mepivacaine with epinephrine|Ultrasound-guided infraclavicular brachial plexus block with mepivacaine 400 mg (10 mg/mL) mixed with epinephrine 200 μg (5 μg/mL)
1690979|NCT01533545|Drug|Plain mepivacaine|Ultrasound-guided infraclavicular brachial plexus block with plain mepivacaine 400 mg (10 mg/mL)
1690980|NCT01533532|Drug|KLH-2109|
1690981|NCT01533532|Drug|KLH-2109|
1690982|NCT01533532|Drug|KLH-2109|
1690983|NCT01533532|Drug|placebo|
1690984|NCT01533519|Drug|Neuropeptide Y|Intranasal administration will be administered with a nasal drug delivery device.
1690985|NCT01533506|Drug|stiripentol|Stiripentol up to 30 mg/kg/day to control seizures
1690986|NCT01533493|Drug|Placebo|Memantine-matched placebo will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
1690987|NCT01533493|Drug|Memantine Hydrochloride|Memantine will be prescribed following approved FDA dosing guidelines for Alzheimer's dementia, beginning at 5mg in AM and increasing in BID doses by 5mg weekly to a maximum dose of 10mg BID.
1690988|NCT01533493|Drug|OROS-Methylphenidate|OROS-Methylphenidate will be openly prescribed, starting with an initial dose of 36mg/day and titrated to optimal response to a maximum daily dose of 1.3mg/kg or 108mg/day, whichever is lower, according to clinician judgment. During titration, dose will be increased on a weekly basis in 36mg/day increments. The dose may be reduced by 18 or 36mg/day increments if adverse effects occur or if the subject discontinues treatment.
1690989|NCT01533480|Drug|Zirgan|0.15% ganciclovir gel(Zirgan)
1690990|NCT01533480|Drug|genteal gel|0.3% Hypromellose gel
1690991|NCT01533467|Device|Perineal protection device|Use of the device during delivery and inspection afterwards to see the tears.
1690992|NCT01533454|Other|Financial Incentives|Incentive arm participants will be able to earn incentives for meeting specified weight loss targets or step goals. They will be offered a choice between traditional (payments with certainty) and behavioral(payments paid via lottery) incentives.
1690993|NCT01533441|Dietary Supplement|Vitamin K2|4 months retrospective period and 4 months dairy product + treatment (vitaminK2 or placebo) intervention
1690994|NCT01533428|Drug|Capsaicin 8%|Capsaicin 8% transdermal delivery system
1690995|NCT01533428|Drug|Placebo|Placebo Patch
1690996|NCT01533415|Device|CES treatment using Alpha-Stim technology|Treatment involves the passage of micro current levels of electrical stimulation across the head via electrodes placed bilaterally on the ears. The current used in this device is no stronger than the current that naturally occurs in the human body. Treatment is delivered using a current equal to 0.5 Hz for a period of 60 mins. Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the functional devices to deliver treatment at a therapeutic level of <1 mA. The current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
1690997|NCT01533415|Device|Shame CES Treatment|Treatment will be self-administered on a daily basis 5-7 days per week.The manufacturer of the device, Electro medical Products, Inc. will provide the devices for the study. They will alter the devices so they cannot emit an electrical current. The ability for the device to emit a current cannot be altered by the participant. Participants will be required to log the date, time, and duration of treatment. The logs will be provided by the PI and will be collected weekly. Participants will also be required to complete the Hamilton Anxiety Rating Scale (HAM-A) and the Hamilton Depression Rating Scale 17 (HAM-D17) at baseline and at weeks 1, 3, and 5.
1690998|NCT01533402|Behavioral|therapist support|Weekly therapist support without CBT-interventions
1690999|NCT01533402|Behavioral|Internet-delivered CBT|Internet-delivered cognitive behavioural therapy with therapist support
1691000|NCT01533389|Drug|Silodosin|"Drug: silodosin dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks
Arms: Placebo"
1691001|NCT01533389|Drug|Placebo|dosage form : capsule dosage : placebo 4mg*2 (8mg) frequency and duration : QD, 4weeks
1691002|NCT01533376|Drug|Timolol|0.5% timolol maleate ophthalmic gel-forming solution applied once
1691003|NCT01533376|Drug|Preservative free artificial tear gel.|Preservative free artificial tear gel applied topically twice a day.
1691004|NCT01533363|Procedure|Stapled hemorrhoidopexy|
1691005|NCT01533363|Procedure|Milligan Morgan|
1691006|NCT01533337|Procedure|Free dorsal digital flap|The dorsal digital flap, including both dorsal branches of the proper digital nerves, was designed on the dorsum of the donor finger between the distal third of the proximal phalanx and the distal interphalangeal joint.
1691007|NCT01533324|Drug|S-1 combined with Leucovorin|S-1 capsules 80mg/m2/d BID one week on and one week off Leucovorin tablets 50mg/d BID one week on and one week off
1691008|NCT01533298|Drug|CombiflexOmega peri|intravenously over 3 days infusion
1691009|NCT01533298|Drug|SmofKabiven peripheral|intravenously over 3 days infusion
1691010|NCT01533285|Biological|Placebo|Placebo is Treatment A and C. Form=saline solution for intramuscular (IM) injection (Injection of a solution into a muscle), route = IM, Unit = mL, number = 0.5 administered on Day 1 of Period 1 and Period 2.
1691011|NCT01533285|Biological|Salmonella typhi vaccine (Typhim Vi)|Salmonella typhi vaccine (typhoid vaccination) in Treatment B and D; Unit = mg, number = 0.025, form = solution for intramuscularly (IM) injection, route = IM administered on Day 1 of Period 1 and Period 2.
1691012|NCT01533272|Drug|Tenofovir, emtricitabine, maraviroc|experimental drug
1691013|NCT01533272|Drug|Tenofovir, emtricitabine, lopinavir/r|Lopinavir/r 400mg BID
1691014|NCT01533259|Drug|Stribild|Elvitegravir (EVG) 150 mg/cobicistat (COBI) 150 mg/emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen (STR) administered orally once daily with food
1691015|NCT01533246|Drug|linsitinib|Oral Linsitinib 150mg, twice a day, days 1- 28
1691016|NCT01533246|Other|laboratory biomarker analysis|Correlative studies
1691017|NCT01533233|Procedure|thoracoscopic lobectomy and mediastinal lymph node dissection|
1691018|NCT01533220|Drug|naphazoline hydrocloride|02 drops into each nostril, 04 times a day for 05 days
1691019|NCT01533220|Drug|Naphazoline hydrocloride + Pheniramine Maleate + Panthenol|02 drops into each nostril each 12 hours for 05 days
1691020|NCT01533207|Other|Clinical Observation|Patients followed clinically
1691021|NCT01533207|Drug|Docetaxel|Given IV
1691022|NCT01533207|Drug|Doxorubicin Hydrochloride|Given IV
1691023|NCT01533207|Biological|Filgrastim|Given subcutaneously (SC)
1691024|NCT01533207|Drug|Gemcitabine Hydrochloride|Given IV
1691025|NCT01533207|Biological|Pegfilgrastim|Given SC
1691026|NCT01533194|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1691027|NCT01533194|Biological|Wild-type Reovirus|Given IV
1691028|NCT01533181|Other|Laboratory Biomarker Analysis|Correlative studies
1691029|NCT01533181|Drug|Linsitinib|150 mg given orally (PO) twice a day (BID)
1691030|NCT01533181|Other|Pharmacological Study|Correlative studies
1691031|NCT01533181|Drug|Topotecan Hydrochloride|1.5 mg/m^2 intravenously (IV) or 2.3 mg/m^2 orally (PO)
1691032|NCT01533168|Genetic|cytogenetic analysis|
1691033|NCT01533168|Genetic|nucleic acid sequencing|
1691034|NCT01533168|Other|diagnostic laboratory biomarker analysis|
1691035|NCT01533168|Other|laboratory biomarker analysis|
1691036|NCT01533168|Other|medical chart review|
1691037|NCT01533155|Drug|Nektar 118|Oral 25 mg tablet
1691038|NCT01533155|Drug|Quinidine|Oral 200 mg tablet
1691039|NCT01533155|Drug|Quinidine placebo|Oral Tablet
1691040|NCT01533155|Drug|Morphine|10 mg/ml, intravenously
1691041|NCT01533142|Procedure|Bariatric surgery|"Patients will be treated with one of two bariatric procedure::
sleeve gastrectomy or gastric bypass"
1691042|NCT01533142|Procedure|Bariatric surgery|Surgical methods vary between hospitals: Voss: sleeve gastrectomy, Haugesund: gastric bypass (Roux-en Y),SUS: gastric bypass (Roux-en Y); Førde: biliopancreatic diversion with duodenal switch (BPD / DS) and sleeve gastrectomy
1691043|NCT01533129|Drug|Testogel 50 mg transdermal gel|50mg testosterone gel implementation on every night
1691044|NCT01533129|Drug|Testosterone 250mg injection|The testosterone 250mg ester IM injections performed in three weeks.
1691045|NCT01533116|Drug|BIA 9-1067|
1691046|NCT01533116|Drug|Placebo|
1691047|NCT01533116|Drug|levodopa/carbidopa|
1691048|NCT01533116|Drug|levodopa/benserazide|
1691049|NCT01532336|Drug|NVC-422 Solution, 0.3%|NVC-422 Ophthalmic Solution dropped onto the eye
1691050|NCT01532336|Drug|NVC-422 Vehicle Solution|NVC-422 Vehicle Ophthalmic Solution dropped onto the eye
1691051|NCT01532323|Other|Taking of saliva before and after gustatory stimulation|Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)
1691052|NCT01532310|Drug|belimumab|Belimumab is a recombinant, human, IgG1λ monoclonal antibody for the treatment of systemic lupus erythematosus
1691053|NCT01532297|Device|Citrate dialysate (CiDi)|Use during chronic dialysis 3x/week
1691054|NCT01532297|Device|Standard dialysate (StDi)|Use during chronic dialysis 3x/week
1691055|NCT01532284|Other|Polar Body Biopsy|PB biopsy (PBB) will be performed between 9 and 12 hours after ICSI using laser or the mechanical procedure. PB1 and PB2 will be removed simultaneously (both at the same time) and transferred to different tubes for the chromosomal analysis.
1691056|NCT01532258|Behavioral|Go! Foods for You without Weekly MA Support.|"Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.
Each day participants receive educational materials related to the nutritional science of a Mediterranean diet. Each week (1) a new theme for the daily educational materials is presented and (2) participants are asked to schedule activities on a built in calendar and practice the activity throughout the week."
1691057|NCT01532258|Behavioral|Go! Foods for You with Weekly MA Support.|"Participants access and utilize an 8-week online program which provides educational materials and weekly activities based on a Mediterranean diet and dietary practices that have been associated with healthy weights.
In addition to the 8-week online program, participants receive weekly support by Medical Assistants (MA) over the phone or by email to establish a relationship and maintain program adherence by discussing the previous week's behavioral goals and setting weekly behavioral goals."
1691058|NCT01532245|Other|two lung ventilation (TLV)|During two-lung ventilation (TLV) and OLV 8 ml•kg-1 tidal volume was used.
1691059|NCT01532245|Other|one lung ventilation (OLV) without PEEP|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated.
1691060|NCT01532245|Other|One lung ventilation (OLV) with positive end-expiratory pressure (PEEP)|During OLV, ventilation periods of ten minutes, with and without 5 cmH2O positive end-expiratory pressure (PEEP) were alternated
1691088|NCT01532895|Drug|Hydromorphone HCI OROS|type= exact number, unit= mg, number=4, form= tablet, route= oral use. One tablet administered once a day. The dose may be increased if the level of pain increases or if the pain-killing effect is insufficient.
1691061|NCT01532232|Drug|placebo|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy & equivalent dosing & side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians & tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
1691062|NCT01532232|Drug|varenicline|Pts will receive the standard 12-week dosing regimen consisting of 1 mg po of study drug twice daily for 11 weeks,along with smoking cessation counseling, for 11 weeks with an initial dose titration to full strength during the 1st week as follows: 0.5 mg po once daily for 3 days titrated to 0.5mg po twice daily for 4 days. 154 pills will be supplied for the 12 week tx. In order to compensate for any accidentally dropped or lost pills during the study duration, a total of 175 pills will be given to the patient. Along with smoking cessation counseling, for 11 weeks. Pts will receive their medication from the MSK Pharmacy & equivalent dosing & side effect education from our Tobacco Cessation Nurse Practitioner. Tx with the study drug will begin after the initial counseling session. Physicians & tobacco cessation nurses will be blinded regarding pts' assignment to medication or placebo tx arm. Likewise, pts will not be informed as to which medication condition they have been assigned.
1691063|NCT01532219|Behavioral|Internet-delivered Psychodynamic Treatment|Ten weeks of guided self-help + therapist contact, via the Internet.
1691064|NCT01532219|Behavioral|Internet-delivered structured support|Ten weeks of therapist contact, via the Internet.
1691065|NCT01533090|Drug|polyethylene glycol (PEG)|SELG-ESSE 1000 4 L: 2L THE DAY BEFORE OF COLONOSCOPY AND 2 L THE SAME DAY OF COLONOSCOPY
1691066|NCT01533090|Drug|PEG low volume with bisacodyl|Lovolesse + Lovoldyl 2L of Lovolesse with 2 or 3 tablets of bisacodyl the day before of colonoscopy or 2L of Lovolesse with 2 or 3 tablets of bisacodyl the same day of colonoscopy
1691067|NCT01533077|Drug|BIA 9-1067|50 mg of BIA 9-1067 (single-dose)
1691068|NCT01533077|Drug|Sinemet® 100/25 mg|immediate-release levodopa/carbidopa 100/25 (single-dose).
1691069|NCT01533038|Device|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the European Union, Australia, New Zealand, Canada, Serbia, and Turkey. It was developed for the intended use of soft tissue approximation and for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
1691070|NCT01533038|Procedure|Transurethral Resection of the Prostate|Transurethral Resection of the Prostate (TURP) is a surgical procedure which removes prostatic tissue by electrocautery dissection. During the procedure the tissue at the bladder neck and the adjacent adenoma are resected in quadrants. Resection continues into the midportion of the gland and concludes at the apex. Any remaining residual tissue is cleared, leaving a void from verumontanum to bladder neck.
1691071|NCT01533025|Procedure|anterior cruciate ligament reconstruction|single bundle anterior cruciate ligament reconstruction with Achilles allograft
1691072|NCT01533012|Procedure|Pressure difference|Peak inspiratory pressures difference between two lungs
1691073|NCT01532999|Behavioral|Mindfulness Based Stress Reduction|MBSR is a manualized program involving 8 weekly classes and a single 6-hour silent retreat session based on a systematic procedure to develop enhanced non-reactive awareness of the moment-to-moment experience of perceptible mental processes.
1691074|NCT01532999|Behavioral|Present Centered Group Therapy|The comparison control group will be PCGT, which was initially developed for use as a control group in a VA multi-site study that tested the effects of Trauma-Focused Group Therapy. Correspondingly, PCGT serves as a credible control for the nonspecific effects of a group-based intervention (i.e. controls for time, attention, expectation of recovery, and recognition of the illness).
1691075|NCT01532986|Other|Coordinated care management for Parkinson's disease|Nurse care managers will use standardized assessment tools and care coordination protocols to address unmet needs of Veterans with PD, and collaborate with these Veterans and their families, providers, and community partners to manage PD care.
1691076|NCT01532986|Other|Educational handout|"To minimize potential bias from participants' awareness of randomization arm assignment, the investigators will provide to all study participants (intervention arm and usual care arm) on enrollment a brief educational handout on Parkinson's disease that is available in the VA's Healthwise for Life handbook (page 273). This information includes a definition of PD, its symptoms, and several suggestions for managing PD such as medications and regular exercise."
1691077|NCT01532973|Drug|Elbasvir|Elbasvir was administered orally by tablet(s)
1691078|NCT01532973|Drug|Placebo|Dose-matched placebo tablets were administered orally.
1691079|NCT01532960|Biological|poly-ICLC|poly-ICLC
1691080|NCT01532960|Biological|9 Peptides from Her-2/neu, CEA, & CTA|9 synthetic peptides derived from Her-2/neu, CEA & CTA derived breast cancer proteins.
1691081|NCT01532960|Biological|Peptide-tet|A class II MHC-restricted helper peptide derived from tetanus toxoid protein.
1691082|NCT01532947|Procedure|post placement|placement of an endocanalar post
1691083|NCT01532934|Behavioral|motivational enhancement therapy|Four 45-minute MET sessions
1691084|NCT01532934|Other|standard care|
1691085|NCT01532908|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous, up to 15 infusions over 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
1691086|NCT01532908|Drug|Telaprevir (Part 1)|Two 375 mg tablets, 3 times a day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
1691087|NCT01532908|Drug|Sofosbuvir (Part 2)|One 400 mg tablet, 1 time per day up to 56 days; option for extended treatment through 84 days if viral load undetectable at day 56
1691089|NCT01532882|Drug|Diosmin|tablet, 600mg, PO, 1 tab per day during 28 days
1691090|NCT01532882|Drug|Placebo|tablet, PO, 1 per day during 28 days
1691092|NCT01532869|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Weeks 0-48
1691093|NCT01532869|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously weekly, Week 48-96
1691094|NCT01532856|Drug|Thalidomide, Cyclophosphamide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Cyclophosphamide - 50mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally(two pulses the first two cycles in days 1-4 and 15-18 and then a single pulse in each other cycle) during 9 cycles of 28 days.
1691095|NCT01532856|Drug|Thalidomide, Dexamethasone|Thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle Dexamethasone - 40mg orally, in three pulses (days 1 to 4, 9 to 12 and 17 20) odd cycles and a single pulse treatment in pairs cycles, during 9 cycles of 28 days each cycle
1691096|NCT01532856|Drug|Thalidomide, Melphalan, Prednisone|thalidomide - 200mg per day, orally, during 9 cycles of 28 days each cycle; melphalan - 4 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle; prednisone - 40 mg/m2, days 1-7, orally, during 9 cycles of 28 days each cycle
1691097|NCT01532843|Drug|PegIFN alfa-2b|Peginterferon alpha-2b 1.5 μg/kg per week s.c.for 48 weeks
1691098|NCT01532830|Device|GammaCore device|
1691099|NCT01532817|Device|The AlphaCore Device|A single 90 second stimulation to the vagus nerve on the right side of the neck
1691100|NCT01532804|Drug|bevacizumab, oxaliplatin and 5FU combination|"Bevacizumab 5 mg/kg administered as an iv infusion for 1h30, then for 1h and for 30 min. at the following cycles, respectively.
Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles)"
1691101|NCT01532804|Drug|Bevacizumab, oxaliplatin and raltitrexed combination|"Bevacizumab 7.5 mg/kg administered as an iv infusion for 1h30, then administered for 1h and 30 min at the following cycles, respectively.
Oxaliplatin 130 mg/m² administered as an iv infusion for 2h Raltitrexed 3 mg/m² administered as an iv infusion for 15 min"
1691102|NCT01532765|Procedure|Pars plana vitrectomy and epiretinal membrane peel|23 gauge pars plana vitrectomy with diluted intravitreal triamcinolone for visualization
1691103|NCT01532765|Procedure|ILM peel assisted by ICG|Indocyanine green dye is prepared from 25mg powder vial from AKORN INC., 10 mL diluent provided in kit. This is further diluted to final concentration of 0.5mg/mL using 50% sterile dextrose solution
1691104|NCT01532765|Procedure|CE-IOL|Cataract extraction by phacoemulsification and insertion foldable posterior chamber intraocular lens implant
1691105|NCT01532739|Behavioral|Cognitive training|The cognitive training consists of 10 weekly 2-hour sessions. It is run with groups of MCI participants and their study partners (who help with reinforcing the strategies in everyday activities). The program provides information about memory and lifestyle factors in the first two weeks, followed by training and practice over the next eight weeks on empirically-supported cognitive strategies known to be effective at supporting day-to-day remembering in MCI. Participants learn to apply a core set of strategies (spaced retrieval, memory book logging) across a variety of common memory problems (e.g., remembering names, appointments, etc). To enhance the likelihood that these strategies will transfer to other settings beyond training, participants are also taught a memory problem solving approach that will cue them to recognize situations in which they need to: (1) stop and remember something, (2) select and apply an appropriate memory strategy, and (3) monitor that it is working.
1691106|NCT01532726|Drug|ESL|ESL 400/800/1200 mg tablets once daily
1691107|NCT01532713|Procedure|oxygen administration|nasal O2 5L/min via nasal cannula
1691108|NCT01532700|Drug|Ofatumumab with GSK2110183|"GSK2110183 125mg OD continuously
Ofatumumab 300mg IV first dose, 2000mg weekly x 7 doses, then 2000mg monthly x 4 doses"
1691109|NCT01532687|Drug|Gemcitabine Hydrochloride|Given IV
1691110|NCT01532687|Other|Laboratory Biomarker Analysis|Correlative studies
1691111|NCT01532687|Drug|Pazopanib Hydrochloride|Given PO
1691112|NCT01532687|Other|Placebo|Given PO
1955635|NCT03125213|Drug|AL-3778|AL-3778 tablets
1955636|NCT03125213|Drug|Peginterferon Alfa-2A|Peginterferon Alfa-2A for subcutaneous injection
1691115|NCT01532661|Other|observational study|data collected by investigators
1691116|NCT01532648|Drug|Budesonide|One budesonide-MMX® 9 mg tablet plus current oral 5-aminosalicylic acid (5-ASA) regimen daily in the morning after breakfast.
1691117|NCT01532648|Drug|Placebo|One tablet indistinguishable from budesonide MMX 9 mg tablet plus current oral 5-aminosalicylic acid (5-ASA) regimen daily in the morning after breakfast.
1691118|NCT01532648|Procedure|Procedure/Surgery: Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores.
1691119|NCT01532635|Radiation|Total Body Irradiation (TBI)|TBI twice daily for 4 days and occurs 6 to 9 days prior to the transplant. Total radiation dose is 12 Gy.
1691120|NCT01532635|Biological|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
1691121|NCT01532635|Drug|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
1691122|NCT01532635|Drug|Tacrolimus|Tacrolimus is started the day before the transplant and stops a few months after transplant.
1691123|NCT01532635|Drug|Mycophenolate Mofetil (MMF)|MMF is started the day before transplant and stops a few weeks after transplant.
1955637|NCT03125213|Drug|Placebo Oral Tablet|Placebo to Match AL-3778 tablet
1955638|NCT03124459|Drug|ACE-083|Part 1 - Recombinant fusion protein. Part 2 - Recombinant fusion protein or buffer solution.
1955639|NCT03124355|Drug|placebo sugar pill|placebo single oral dose
1955640|NCT03124355|Drug|Pyridostigmine Pill|pyridostigmine bromide 30 mg single oral dose
1955641|NCT03124355|Drug|Galantamine Pill|Galantamine hydrobromide 8mg single oral dose
1955642|NCT03124355|Device|Vagal stimulation|Vagal stimulation will be given at 50 Hz during the tilt table tests
1955643|NCT03124355|Device|Sham vagal stimulation|Sham vagal stimulation will be given at 0.01 mA during the tilt table tests
1691124|NCT01532635|Biological|Hematopoietic Stem Cell Transplant (HSCT)|"CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed using donor cells from two related donors.
The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem cells."
1691125|NCT01532622|Dietary Supplement|Blueberry Powder|Patients will take 30 grams of blueberry powder daily for up to 30 days
1691126|NCT01532622|Other|Placebo Powder|Patients will take 30 grams of placebo powder daily for up to 30 days.
1691127|NCT01532609|Behavioral|MMT CARE|Intervention group service providers received four training sessions (plus reunion sessions) on MMT protocol, reducing stigma and its impact, maintaining positive interactions with clients, and motivational interviewing skills. The participating providers are required to conduct three individual motivational sessions with their clients upon completion of the intervention sessions.
1691128|NCT01532596|Behavioral|Mindfulness-Based Stress Reduction|8-week standardized mindfulness meditation training program
1691129|NCT01532583|Other|Gynaecological examination, a supine stress test, questionnaires|Gynaecological examination, a supine stress test, questionnaires
1691130|NCT01532570|Drug|TA-650|TA-650 will be intravenously infused at a dosage of 5 mg/kg slowly over a period of more than 2 hours at the first administration (weeks 0), 2, and 6, and then every 8 weeks up to week 46. If the criteria for a dosage escalation are met at the evaluation after week 30, TA-650 will be administered at a dosage of 10 mg/kg after week 30.
1691131|NCT01532544|Drug|Ilomedin and Integrilin|Continuous infusion
1691132|NCT01532544|Drug|low molecular weight heparin.|
1691133|NCT01532531|Device|"GEMORE Multi-Function Electrotherapy Stimulator"|"The Collateral Meridian Therapy (CMT) group patients received, according to the CMT protocol described previously (5), CMT at the selected points with the CMT Electrotherapy Stimulator (GEMORE Multi-Function Electrotherapy Stimulator; GM390TE, GEMORE Co Ltd, Taiwan) to treat the affected OA knee. The 6-minute treatment (electrotherapy was set at 40 Hz biphasic and 30 mA) comprises reduction and enhancement procedures on the specific points. Each patient received CMT twice per week for three weeks during the study."
1955647|NCT03123419|Behavioral|Appointment reminders|The purpose of the Gardasil study is to increase the rates of Gardasil vaccination in the Maternal Fetal Care Center. This will be done by reminding patients via text to come for their follow up vaccine appointments.
1691135|NCT01532466|Drug|Rocuronium|All patients were given oxygen via a face mask. The patients were then administered with the following medications intravenously: the rocuronium group received rocuronium 0.06 mg kg-1, and the control group received the same volume of normal saline 30 s before the injection of an IV fentanyl bolus (1.5 mcg kg-1, within 2 s).
1691136|NCT01532453|Device|MD-3511356|Every morning MD-3511356 should be applied liberally to those skin areas exposed to direct sunlight before exposing to the sun.
1691137|NCT01532453|Other|Standard Sun Protection Measures|Self-provided commercially available sunscreen products, corresponding to the dosage recommendations on the product.
1691138|NCT01532414|Drug|Androxal|oral, capsules, taken one time daily, for 3 months
1691139|NCT01532414|Drug|Placebo|Oral capsule taken one time daily for 3 months
1691140|NCT01532401|Other|sodium chloride|sodium chloride 500mg
1691141|NCT01532401|Other|Methylcellulose crystalline|Methylcellulose 37 ml
1691145|NCT01532362|Drug|Apricoxib|As part of the trial, forty eligible subjects will be randomly assigned to receive Apricoxib 400 mg orally once daily or no drug intervention for a 7 day period (Days 0-6) prior to surgical resection of the lung tumor but between the two surgeries.
1691146|NCT01532349|Drug|Cholecalciferol|Children will be randomly allocated to receive either cholecalciferol supplementation 4000 IU per day 400 IU/day. We are proposing a supplementation dose of 4000 IU/day in children with CKD, which is considered a safe dose by KDOQI standards; vitamin D2 doses as high as 10,000 IU/day have been given to French patients with CKD for > 1 year with no evidence of vitamin D toxicity. Cholecalciferol will be provided in both tablet and liquid form, based on the ability to tolerate and preference of the subject. Participants will be monitored for signs of 25D toxicity (hypercalcemia, hyperphosphatemia, hypercalciuria) during the follow up period of 1 month and 3 months from baseline.
1691147|NCT01532206|Other|Blood pressure cuff insufflation|Blood pressure cuff will be inflated to a pressure of 200mmHg for 5 minutes. This will be repeated x 3, separated by 5 minutes.
1691148|NCT01532193|Other|Decreased oxygen concentration|"The oxygen concentration is decreased during the in Vitro embryo culture."
1691149|NCT01532180|Device|aura6000 System|The aura6000 device is an implanted hypoglossal nerve stimulator designed to maintain wakeful muscle tone of the tongue during sleep. It is implanted through a short surgical procedure. The implant is programmed to provide the optimal stimulation parameters for the patient. The therapy is controlled by a hand-held remote control allowing the patient to start, stop, and pause the therapy during times of sleep.
1691150|NCT01532154|Drug|Fampridine|As prescribed and taken after the last menstrual period prior to becoming pregnant or anytime during the pregnancy
1691151|NCT01532141|Drug|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
1691152|NCT01532141|Drug|Rasagiline|1 mg rasagiline (single-dose)
1691153|NCT01532128|Drug|rasagiline|1 mg rasagiline (single-dose)
1691154|NCT01532128|Drug|BIA 9-1067|50 mg BIA 9-1067 (single-dose)
1691158|NCT01532102|Drug|AP611074|
1691159|NCT01532102|Drug|Placebo|Placebo gel manufactured to appear identical to AP611074 5% gel
1691163|NCT01532076|Procedure|Cellularized composite graft augmentation|liposuction, cell isolation, embedding of SVF cells in fibrin gel, wrapping around hydroxyapatite granules
1691164|NCT01532076|Procedure|Acellular composite graft augmentation|Open reduction and internal fixation using acellular augmentation with fibrin embedded granulated hydroxyapatite
1691165|NCT01532063|Procedure|INTUBATION IN INTENSIVE CARE UNIT|Standard intubation procedure used in Intensive Care Unit
1691166|NCT01532050|Device|Mandibular Advancement Device ( MAD)|
1691167|NCT01532037|Other|Cognitive behavioural therapy based self help|Comparison of cognitive behavioural therapy based pure self help and guided self help (support of a therapist) compared to treatment as usual
1691168|NCT01532037|Other|Treatment as usual|Usual care from healthcare professionals with regard to patients symptoms of fatigue
1691169|NCT01532024|Other|Microdose of NAP|Delivery of NAP at microdose (<100mcg) by direct pulmonary administration followed by fibreoptic confocal microendoscopy
1691170|NCT01532011|Drug|Erlotinib|"Dose escalation group starting dose: 75 mg by mouth daily for a 28 day cycle.
Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
1691171|NCT01532011|Drug|Pralatrexate|"Dose escalation group starting dose: 15 mg/m2 by vein on days 1, 8, and 15 of a 28 day cycle.
Dose expansion group starting dose: Maximum tolerated dose (MTD) from dose escalation group."
1691172|NCT01531998|Drug|Lenalidomide|Induction Phase: 25 mg by mouth daily on Days 1-14. Maintenance Phase: at last tolerated dose from Induction Phase day 1-21 every 28 days for up to 12 months and then may be reduced to 10 mg.
1691173|NCT01531998|Drug|Bortezomib|"Induction Phase: 1.3 mg/m2 by vein daily on Days 1, 4, 8 and 11.
Maintenance Phase: 1.3 mg/m2 by vein or last tolerated dose on Day 1 and Day 8."
1691174|NCT01531998|Drug|Siltuximab|"Induction Phase Starting Dose: 11 mg/kg by vein on Day 1.
Maintenance Phase: 11 mg/kg intravenous every 21 days, or maximum tolerated dose from induction therapy."
1691175|NCT01531998|Drug|Dexamethasone|"Induction Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12.
Maintenance Phase: 20 mg by mouth on Days 1, 2, 4, 5, 8, 9, 11, 12. If participant still on Dexamethasone, when entering Maintenance Phase, dose reduced to 20 mg a week."
1691176|NCT01531998|Behavioral|Questionnaires|M. D. Anderson Symptom Inventory Module (MDASI-MM) completed Day 1, Day 8 of Cycle 1 - 8, and on Day 1 of Cycle 9 and beyond.
1691177|NCT01531972|Drug|SEP-228432|40 mg, orally, once daily for 3 days followed by 200 mg orally, once daily for 5 days
1691178|NCT01531972|Drug|SEP-228432|40 mg orally once daily for 3 days followed by ≤ 300mg, orally once daily for 5 days
1691179|NCT01531959|Drug|Midodrine|Patients will be randomized to blinded to 20 mg of midodrine
1691180|NCT01531959|Drug|Placebo|Patients will be randomized to blinded placebo control
1691181|NCT01531946|Procedure|MRI Scan|"Patients will have to spend additional 10min in the scanner.
Additional scan modalities used:
Perfusion without contrast: Arterial spin labeling (ASL) with the ability of showing signs of ischemia.
Diffusion tensor imaging (DTI): Has a higher sensitivity than DWI in displaying local ischemic lesions.
An overall 20min scan period."
1691182|NCT01531933|Drug|DLBS3233|For the first 4 weeks, subjects should take DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
1691183|NCT01531933|Drug|Placebo of DLBS3233|For the first 4 weeks, subjects should take placebo of DLBS3233 at the dose of 50 mg once daily. For the next (or last) 8 weeks, all subjects who do not respond well (poor responders) to the study regimen will receive a titrated dose of 100 mg once daily, while the (good) responders will remain at the previous dose regimen. Good responders are defined as those who achieve 2h-PG level of < 140 mg/dL or a decrease of 2h-PG level of ≥ 10% from baseline; otherwise will be called poor responders. At every study visit, subjects will be provided with an education on lifestyle modification given by the assigned nutritionist.
1691184|NCT01531920|Drug|alcohol + placebo|Part A alcohol + placebo
1691185|NCT01531920|Drug|alcohol + perampanel|Part A: alcohol + perampanel
1691186|NCT01531920|Drug|perampanel + alcohol|Part B: perampanel + alcohol
1691187|NCT01531920|Drug|placebo + alcohol|Part B: placebo + alcohol
1691188|NCT01531907|Other|Study visit procedures|"Anthropometric measurements to include:
Weight, height, and BMI.
Waist and hip circumference
Triceps skinfold thickness
Measurement of supine abdominal thickness A baseline blood sample (15ml)is taken before receiving a standard polycal drink (75g glucose load) Three further blood samples (15 ml) will be taken, at the time points 20, 60 and 120 minutes after glucose loading. In 10 subjects (5 lean and 5 obese) we will take an additional blood sample (up to 50 ml) at baseline into heparin to grow osteoclasts in culture. Visit duration - approximately 3-4 hours."
1691189|NCT01531894|Drug|GSK2110183|an oral, low nanomolar pan-AKT kinase inhibitor
1691190|NCT01531868|Other|Video|Video of physician
1691191|NCT01531868|Other|Video|Video of physician
1691192|NCT01531868|Other|Video|Video of physician
1691193|NCT01531868|Other|Video|Video of physician
1691194|NCT01531868|Other|Video|Video of physician
1691195|NCT01531868|Other|Video|Video of physician
1691196|NCT01531855|Other|Reducing post-exercise rapid-acting insulin (insulin lispro or aspart) dose|Dosage after exercise
1691198|NCT01531829|Drug|Recombinant tissue plasminogen activator (rt-PA)|Low dose (50mg/2h) rt-PA plus LMWH
1691199|NCT01531829|Drug|Low Molecular Weight Heparin|0.1ml/10kg,q12h,5-7 days
1691200|NCT01531816|Device|Early Rehabilitation intervention|"Passive mobility: cycle ergometer
Active mobility: interactive video-game (X Box 360 Kinect) Each intervention will be applied for a maximum of 2 days respectively. If a participant is unconscious on Day 1 and receives the passive intervention, and thereafter becomes alert and cooperative on day 2, then he/she can receive the active intervention."
1691201|NCT01531803|Drug|Kedbumin 25%|"Albumin (Human) 25% solution for intravenous (IV) infusion in the dosage strength of 250g human albumin /L, supplied in 50 mL type II vial (each vial containing 12.5g human albumin).
The dose will be 0.5 to 1g/kg body weight (2 to 4 mL/kg of 25% albumin)."
1691202|NCT01531790|Drug|Carboplatin|d1, AUC 5, i.v.
1691203|NCT01531790|Drug|Pemetrexed|d1, 500 mg/m2, i.v.
1691204|NCT01531790|Drug|Endostar|d2-d21, continuous Endostar intravenous infusion, 7.5 mg/m2/d, 15 mg/m2/d or 30 mg/m2/d, etc.
1691205|NCT01531790|Drug|Centrum|1 tablet/day
1692082|NCT01525615|Drug|placebo to tiotropium+olodaterol|comparator
1691206|NCT01531777|Drug|Apatinib|500 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
1691207|NCT01531777|Drug|apatinib|750 mg,p.o.,qd, until disease progression or intolerable toxicity or patients withdrawal of consent.
1691208|NCT01531764|Drug|BIBW 2992 in combination with vinorelbine|Patients will receive BIBW 2992 and vinorelbine chemotherapy. BIBW 2992: 40 mg oral (tablet) once daily Vinorelbine: 25 mg/m² on days 1 & 8 in a 3-weekly course, intravenous, short infusion of about 10 minutes
1691209|NCT01531751|Device|High Cut-off Hemodialysis|During dialysis the patients will undergo the first cycle of chemotherapy according to the current standard of care for subjects with advanced cardiac AL amyloidosis. Measurements of FLC and cardiac biomarkers will be done before and after each dialysis session. High cutoff HD will be continued during the first chemotherapy cycle. After the first cycle the end-of-treatment evaluation will take place.
1691210|NCT01531751|Drug|Chemotherapy|Chemotherapy will be based on alchilators, proteasome inhibitors, steroids, IMiDs.
1691211|NCT01531725|Device|Percutaneous coronary intervention|Percutaneous coronary intervention
1691212|NCT01531712|Drug|Gemcitabine|1000mg/m2 / / 40mg/m2
1691213|NCT01531712|Radiation|Radiotherapy|50.4 Gy
1691214|NCT01531712|Drug|Tarceva|100mg/day
1691215|NCT01531712|Drug|Oxaliplatin|100mg/m2 (only in QT)
1691216|NCT01531699|Drug|ALT005 Ophthalmic Prep Solution|single application for up to 6 hours
1691217|NCT01531699|Other|saline control|single application for up to 6 hours
1691218|NCT01531699|Drug|Comparator Product|single application for up to 6 hours
1691219|NCT01531686|Procedure|Intraosseous delivery of CT contrast dye|Delivery of CT contrast through intraosseous vascular access at the proximal humerus for CT examination.
1691220|NCT01531673|Drug|VX-661|Tablet, taken once daily (qd)
1691221|NCT01531673|Drug|ivacaftor|Tablet, taken every 12 hours (q12h)
1691222|NCT01531673|Drug|VX-661 placebo|Tablet, taken once daily (qd)
1691223|NCT01531673|Drug|ivacaftor placebo|Tablet, taken every 12 hours (q12h)
1691224|NCT01531673|Drug|VX-661|Tablet, taken every 12 hours (q12h)
1691225|NCT01531673|Drug|VX-661 placebo|Tablet, taken every 12 hours (q12h)
1691226|NCT01531660|Behavioral|step-up jogging program|
1691227|NCT01531647|Drug|danoprevir|100 mg q12h Days 8-21
1691228|NCT01531647|Drug|raltegravir|400 mg q12h Days 1-4 and 18-21
1691229|NCT01531647|Drug|ritonavir|100 mg q12h Days 8-21
1691230|NCT01531634|Behavioral|Dynamic Cognitive Intervention Group|Twelve meetings of a Dynamic Cognitive Intervention group.
1691231|NCT01531621|Other|Biomarker sampling|Blood samples every 8-12 weeks
1691232|NCT01531595|Drug|Bevacizumab plus alternating Xelox/Xeliri|3 cycles of XELOX+bevacizumab alternating with 3 cycles XELIRI+bevacizumab until disease progression
1691234|NCT01531569|Other|BeneFlax - 38% secoisolariciresinol diglucoside (SDG)|0.8g of BeneFlax (contains 300mg SDG) given once by mouth
1691235|NCT01531556|Other|Honey spiked with known concentration of tutin and hyenanchin|Prepared honey will contain 5.1 mg/kg tutin and 23 mg/kg hyenanchin; honey dose will be calculated based on body weight, such that each subject receives 1.8 mcg per kg body weight of tutin.
1691236|NCT01531543|Device|V.A.C.- Vacuum assisted closure laparostomy (KCI)|Primary Vacuum Assisted Closure (V.A.C.)laparostomy was indicated after surgery in patients with severe peritonitis. VAC laparostomy was performed using sandwich technique (semi-permeable foil - intraabdominal foam - dynamic sutura of the fascia - foam inserted subcutaneously - non-permeable foil) and connected to the active suction of 125mmHg.
1691237|NCT01531530|Biological|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|The vaccine is mixed with salt water and given by mouth.
1691238|NCT01531530|Other|Placebo|Corn starch and baking soda are mixed with salt water and given by mouth.
1691239|NCT01531517|Drug|Royal Jelly and Panthenol (PedyPhar® Ointment)|"the following will be done to each patient depending on the number of the visit:
Assessment of the patient for inclusion/exclusion criteria
Informed consent process
Medical history of the patient
Blood withdrawn for investigation
Drainage of the ulcer if there is a collection
Revascularization as needed and indicated by APSV done at visit 0.
Swab from the ulcer for culture and micro-organism count: on detailed visits only.
Debridement as needed.
Dressing:
Inspection and assessment of the ulcer
Irrigation using 500 ml of saline or as required.
Drying of the ulcer (leave to dry)
Spread a layer of 3 - 5 mm of PedyPhar on a dressing and then apply the dressing to the ulcer
Fix the dressing to the ulcer"
1691240|NCT01531517|Drug|Panthenol Ointment|"the following will be done to each patient depending on the number of the visit:
Assessment of the patient for inclusion/exclusion criteria
Informed consent process
Medical history of the patient
Blood withdrawn for investigation
Drainage of the ulcer if there is a collection
Revascularization as needed and indicated by APSV done at visit 0.
Swab from the ulcer for culture and micro-organism count: on detailed visits only.
Debridement as needed.
Dressing:
Inspection and assessment of the ulcer
Irrigation using 500 ml of saline or as required.
Drying of the ulcer (leave to dry)
Spread a layer of 3 - 5 mm of Panthenol on a dressing and then apply the dressing to the ulcer
Fix the dressing to the ulcer"
1691242|NCT01531491|Procedure|Rebreathing tube|750 ml rebreathing tube will be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 50 mmHg.
1691243|NCT01531491|Procedure|No rebreathing tube (Nothing)|750 ml rebreathing tube will not be connected between the corrugated tube and the tracheal tube of a patient. Target partial pressure of the end-tidal carbon dioxide is 30 mmHg.
1691313|NCT01530919|Procedure|Minimally invasive radioguided parathyroidectomy|After the patient is prepared for surgery and under local anesthesia, the initial incision by the surgeon will be 2-3 cm. The surgeon will dissect in the designated quadrant until the parathyroid gland is identified.
1691314|NCT01530906|Procedure|Repetitive transcranial Magnetic Stimulation (rTMS)|10 TMS sessions of 20 trains of 5s with 55s interval cross train, at a frequency of 10 Hz and 110% of motor threshold intensity of the left DLPFC.
1691244|NCT01531478|Other|Unique medical visit of the study|"The visit will be with an oncologist specialized in the long-term follow-up of cured pediatric cancer patients. The examination will consist in weight and height measurements, a clinical examination and a measurement of arterial pressure. The list of drugs taken in the last two years, as well as all health issues encountered since the cancer treatment, will be collected. Success in education, career and, family status will also be discussed.
After the medical examination, patients will be offered a visit with a psychologist in order to assess their psychopathological outcomes. This questionnaire is a interquestionnaire designed to screen axis I psychopathological conditions. It includes an evaluation of all types of risk-taking behavior (alcohol, drugs, anorexia and bulimia)."
1691245|NCT01531465|Other|Pulmonary Function Testing & esophageal pressure monitoring|Infants who are currently on NCPAP will have pulmonary function testing (PFTs)and esophageal pressure performed while on 2 different settings of NCPAP. These infants will then be transitioned HFNC and will undergo PFTs and esophageal pressure while on different HFNC settings. The infant will then be returned to NCPAP at the same settings they were on prior to any study interventions.
1691246|NCT01531465|Other|Pulmonary function testing and esophageal pressure|Infants who are currently on HFNC will have pulmonary function testing (PFTs) and esophageal pressure performed while on 2 different settings of HFNC. These infants will then be transitioned NCPAP and will undergo PFTs and esophageal pressure while on 2 different NCPAP settings. The infant will then be returned to HFNC at the same settings they were on prior to any study interventions.
1691247|NCT01531452|Drug|Oxaliplatin|130mg/m2 d1,repeated q21d
1691248|NCT01531452|Drug|s1|80mg/m2/d, d1-14,repeated q21d
1691249|NCT01531439|Drug|Naloxone|Naloxone infusion 0.5 mcg/kg/hr
1691250|NCT01531439|Drug|Naloxone|Naloxone infusion 2.5 mcg/kg/hr
1691251|NCT01531426|Device|near infrared spectroscopy (INVOS®, Covidien)|Measurement of regional cerebral oxygen saturation with non-invasive near-infrared INVOS® (In-Vivo Optical Spectroscopy) monitor by Covidien.
1691252|NCT01531413|Other|Oxygen Insufflation|At the end of the case, abdomen will be desufflated with CO2 then insufflated with oxygen
1691253|NCT01531400|Other|self-selected music|Investigators played self-selected background music in the music group
1691254|NCT01531387|Drug|Hydroxyurea|Hydroxyurea will be administered once daily, in either capsule form (300mg, 400mg, or 500mg) or as a liquid formulation (100mg/ml). Dosing will commence at 20 mg/kg/day. Dose escalation will occur in 5 mg/kg/day increments, adjusting every 8 weeks unless hematological toxicity occurs.
1691256|NCT01531361|Drug|Vemurafenib|"Dose Escalation Group Starting Dose: 240 mg by mouth twice a day for a 28 day cycle.
Dose Expansion Group Starting Dose: Maximum tolerated dose (MTD) from dose escalation group."
1691257|NCT01531361|Drug|Sorafenib|"Dose Escalation Group Starting Dose of Sorafenib: 200 mg by mouth twice a day for a 28 day cycle.
Dose Expansion Group Starting Dose: Maximum tolerated dose (MTD) from dose escalation group."
1691258|NCT01531361|Drug|Crizotinib|"Dose Escalation Group Starting dose of Crizotinib 250 mg by mouth daily for a 28 day cycle.
Dose Expansion Group Starting Dose: Maximum tolerated dose (MTD) from dose escalation group."
1691259|NCT01531348|Other|BM-MSC|Bone marrow-derived mesenchymal stem cells 1 million cells in balanced salt solution 100 microlitres will be injected into the vitreous cavity.
1691260|NCT01531335|Dietary Supplement|Hypocaloric hyperproteic nutrition|15 kcal per kg of body weight and 1.7 grams of protein per kg.
1691261|NCT01531335|Dietary Supplement|Standard care|25 kcal per kg of body weight
1691262|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
1691263|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
1691264|NCT01531322|Biological|13-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection, 0.5 mL, only one dose
1691265|NCT01531309|Drug|AGO178|AGO178 is administered as a sublingual tablet.
1691266|NCT01531283|Drug|unacylated ghrelin|IV, UAG (4.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
1691267|NCT01531283|Drug|acyl ghrelin|IV, AG (1.0 µg/kg/hr), one time, duration of study visit (approximately 5 hours)
1691268|NCT01531283|Drug|combined acyl and desacyl ghrelin|IV, the combination of AG (1 µg/kg/hr) and UAG (4 µg/kg/hr), one time, for the duration of the study visit (approximately 5 hours)
1691269|NCT01531283|Drug|saline|IV, saline, one time, for the duration of the study visit(approximately 5 hours)
1691270|NCT01531244|Biological|dactinomycin|Given via ILI
1691271|NCT01531244|Drug|melphalan|Given via ILI
1691272|NCT01531244|Biological|Conditionally replicative adenovirus 3/5-delta|Given via ILI
1691273|NCT01531218|Drug|azithromycin|azithromycin, oral use, 500mg per day for 3 days in total. Total dose 1500mg
1691274|NCT01531218|Drug|Placebo|
1691275|NCT01531205|Drug|Androgen Ablation|All patients will receive luteinizing hormone-releasing hormone (LHRH) agonist therapy (leuprolide or goserelin acetate) concurrent with Cabazitaxel, before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
1691276|NCT01531205|Drug|Cabazitaxel|Intravenous treatment with Cabazitaxel 25 mg/m^2 is given on day 1 every 21 days. A cycle of chemotherapy will be defined as 21 days. A total of four cycles of combination therapy are planned for a total duration of 12 weeks (before surgery), starting within 3 weeks of protocol entry, to be given concurrent with hormone therapy.
1691277|NCT01531205|Drug|Salvage Therapy|Patients will undergo 4 cycles of chemotherapy in conjunction with LHRH agonist therapy (before surgery) subsequent to which they will have their serum Prostate-specific antigen (PSA), bone scan, abdominal pelvic computed tomography (CT) or magnetic resonance imaging (MRI) repeated. Patients with a detectable metastatic diseases will be removed from the study. Salvage surgery will be performed within 8 weeks after the completion of Cabazitaxel chemotherapy. For patients who achieved undetectable PSA following surgery, androgen deprivation therapy will be discontinued.
1691315|NCT01530906|Procedure|Repetitive transcranial Magnetic Stimulation SHAM|Sham treatment will be performed with a placebo coil. The same coil as coil used for rTMS, but it does not deliver magnetic field.
1691278|NCT01531205|Drug|Neoadjuvant Treatment - Hormonal Therapy|All treatment will be given on an outpatient basis. Treatment should start within 3 weeks of protocol entry. All patients will receive androgen ablation with LHRH agonist therapy in conjunction with the 4 cycles of Cabazitaxel for neoadjuvant chemohormonal therapy. Androgen ablative therapy will be discontinued before surgery. A course of bicalutamide 50 mg daily orally for 14-21 days is recommended for patients starting LHRH agonist therapy and suspected to be at risk for tumor flare, e.g., significant obstructive urinary symptoms and will be optional in other patients.
1691279|NCT01531205|Drug|Neoadjuvant Treatment - Cabazitaxel|"All treatment will be given on an outpatient basis and should start within 3 weeks of protocol entry. Intravenous treatment with Cabazitaxel is given on Day 1 every 3 weeks. A cycle of combination therapy will be defined as 3 weeks. A total of 4 cycles of combination therapy are planned before surgery for a total duration of 12 weeks.
Cabazitaxel will be administered before surgery by one-hourly infusions via central or peripheral intravenous access at a dose of 25 mg/m^2 as a one hour intravenous infusion in combination with oral prednisone 10 mg administered daily throughout Cabazitaxel treatment. It is advised that all patients receiving Cabazitaxel have a reliable form of venous access, e.g., central venous catheter to ensure their ability to receive therapy without undue delay."
1691280|NCT01531192|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
1691281|NCT01531192|Drug|Nystatin|50000 unit/3 times a day, both for orally and by orogastric route
1691282|NCT01531179|Drug|Lactobacillus reuteri|Lactobacillus reuteri 100 million CFU/day for 3 months
1691283|NCT01531179|Drug|Placebo|Placebo for 3 months
1691284|NCT01531166|Drug|pegylated Interferon-alpha 2a|Pegasys 180mcg/PFS/ subcutaneous injection / Once a week
1691285|NCT01531153|Drug|Galantamine|8mg or 16mg
1691286|NCT01531153|Drug|Placebo|Placebo dose.
1691287|NCT01531140|Drug|polyethylene glycol +Bisacodyl|Polyethylene glycol (Fortrans) p.o. 30 ml/kg/2days + Bisacodyl p.o.10-15 mg/day for 2 days
1691288|NCT01531140|Drug|Polyethylene glycol|Polyethylene glycol p.o.: 60 ml/kg/days
1691289|NCT01531140|Drug|Sennosides|Sennosides 1tbl/8kg for 2 days
1691290|NCT01531114|Drug|ticagrelor|Patients will be randomized to this arm to receive loading dose of ticagrelor
1691291|NCT01531114|Drug|prasugrel|Patients will be randomized to this arm to receive loading dose of prasugrel
1691293|NCT01531088|Behavioral|Active medication monitoring|Active medication monitoring system providing consultant pharmacists with alerts representing potential adverse drug events.
1691294|NCT01531075|Biological|ENGERIX-B (HBV Vaccine)|ENGERIX-B (Hepatitis B Vaccine) 20 mcg, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
1691295|NCT01531075|Biological|Sci-B-Vac|Sci-B-Vac (Hepatitis B Vaccine) 10 μg/ml, A series of 3 doses (1 mL each) given on a 0-, 1-, 6-month schedule.
1691296|NCT01531062|Drug|Nigella sative|Nigella sativa seed extracts, 300 mg capsule bid, for 56 days
1691297|NCT01531062|Dietary Supplement|black sticky rice|300 mg capsule bid, 56 days
1691298|NCT01531049|Drug|varenicline|days 1.-3 0,5mgx1/day, days 4.-7 0,5mgx2/day, day 8 to the 12weeks 1mgx2 /day
1691299|NCT01531049|Drug|Nicotine cutaneous patch 15mg/16h|One patch for 16hours/day and duration of 8 weeks.
1691300|NCT01531049|Drug|Nicotine cutaneous patch 10mg/16h|One patch 16hours/day and duration of 8 weeks
1691301|NCT01531049|Other|Placebo cutaneous patch|No active medication.O ne patch 16hours and duration for 8 weeks
1691302|NCT01531036|Device|3D Ultrasound elastography by means of shear wave propagation into breast tissue|Aixplorer Supersonic Imagine Ultrasound System with 3D probe for real-time elastography
1691303|NCT01531010|Device|Ventilation protocol delivered by the SLE5000 ventilator|"In pressure-limited ventilation arm, preferentially wean pressure till weaning criteria achieved, then wean rate.
In volume-targeted ventilation arm, set target volume at 5ml/kg and wean rate. In both arms, aim to keep blood gases within normal limits."
1691304|NCT01530997|Radiation|Intensity Modulated Radiotherapy (IMRT)|All patients will receive IMRT. Dose painting IMRT will be used and all doses will be specified to the planning target volume (PTV). The high risk planning target volume (PTV-HR) and standard risk planning target volume (PTV-SR) will be treated to the following respective total doses: 60 Gy and 54 Gy. The dose per fraction to the PTV-HR and PTV-SR will be 2 Gy per day and 1.8 Gy per day, respectively. The PTV-HR will include the gross tumor and the PTV-SR will include the lymph nodes at risk for harboring micro-metastatic disease (i.e. subclinical disease).
1691305|NCT01530997|Drug|Cisplatin|Cisplatin, 30mg/m2, will be given intravenously over 60 minutes weekly during IMRT; 6 total doses for a total of 180 mg/m2. It is preferred that the doses be administered on days 1, 8, 15, 22, and 29, and 36 of IMRT; however, this is not mandatory.
1691306|NCT01530997|Procedure|Limited surgical evaluation|4 to 14 weeks after completion of CRT, patients will have at least a biopsy of the primary tumor and limited neck surgery to remove those lymph nodes that were involved with cancer prior to CRT.
1691307|NCT01530984|Drug|Ipilimumab|Ipilimumab 3 mg/kg on day 1 of a 28 day cycle for 6 cycles.
1691308|NCT01530984|Drug|GM-CSF|GM-CSF 250 mcg/m2 SQ on days 1-14 for 6 cycles.
1691309|NCT01530971|Drug|Supplemental 3LPM oxygen via canula|Parturients will receive supplemental oxygen (3LPM) via nasal canula
1691310|NCT01530958|Behavioral|CKD Registry|"Primary care providers (PCPs) will have access to a Chronic Kidney Disease (CKD) registry for patient care. The registry will:
identify patients with CKD
notify PCPs of a patients' CKD status
provide PCP outreach with NKDEP guidelines and patient educational materials"
1691311|NCT01530958|Behavioral|ATSM + Health Coach|Patients with CKD will participate in an Automated Telephone Self Management (ATSM) program, which blends automated phone calls with live targeted call-backs from a health coach. Patients will receive bi-weekly automated calls for 52 weeks in their native language, consisting of pre-recorded queries pertaining to CKD management, preventive services, and lifestyle changes. Patients will interact with the system using a touch-tone keypad; Out-of-range values or invalid responses will prompt a live call-back within 24-48 hours by a health coach.
1691312|NCT01530958|Behavioral|Usual care|"Primary care providers will manage their patients with CKD per usual care.
Patients will receive usual care."
1691397|NCT01530373|Drug|Clonidine|oral clonidine 0.1 mg daily for 3 weeks
1691316|NCT01530893|Dietary Supplement|Flavanone - supplement|acute single optimal dose
1691317|NCT01530893|Other|Flavanone - food|acute single dose
1691318|NCT01530893|Other|Flavanone - placebo|acute single dose (flavanone free)
1691319|NCT01530893|Dietary Supplement|Isoflavone - supplement|acute single optimal dose
1691320|NCT01530893|Other|Isoflavone - food|acute single optimal dose
1691321|NCT01530893|Other|Isoflavone - placebo|acute single dose (isoflavone free)
1691322|NCT01530893|Dietary Supplement|Isoflavone - metabolite supplement|acute single optimal dose of commercial product
1691323|NCT01530893|Dietary Supplement|Flavan-3-ol - supplement|acute single optimal dose
1691324|NCT01530893|Other|Flavan-3-ol - food|acute single optimal dose
1691325|NCT01530893|Other|Flavan-3-ol - placebo|acute single dose (flavan-3-ol free)
1691326|NCT01530893|Dietary Supplement|Anthocyanin - supplement|acute single optimal dose
1691327|NCT01530893|Other|Anthocyanin - food|acute single optimal dose
1691328|NCT01530893|Other|Anthocyanin - placebo|acute single dose (anthocyanin free)
1691329|NCT01530880|Drug|Intravenous Ibuprofen|Ibuprofen 400 mg/100 mL intravenous (IV) over 30 minutes, followed by a continuous infusion of 2000 mg/500 mL at 85 mg/hour (21 mL/hour) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first
1691330|NCT01530880|Drug|Acetaminophen (Standard of Care)|Acetaminophen 650 mg via oral/nasogastric tube every 6 hours as needed for T>=38.3 C (100.9 F) for up to post bleed day 14 or discharge from the Neuro ICU, whichever comes first.
1691331|NCT01530841|Device|Nocturnal ventilation|Home ventilation only the mode AVAPS will be used if the patient is randomized in the experimental group.
1691332|NCT01530815|Drug|Bupivicaine Infusion|Investigators and Caregivers will be blinded to either 0.9% Normal Saline or 0.5% Bupivicaine infusion between the mesh and abdominal wall
1691333|NCT01530802|Procedure|clipping of uterine arteries during laparoscopic myomectomy|For laparoscopy standard instruments were used.For vascular clamping we used titan made YASARGIL vessel clips. The patient is put in a 20° Trendelenburg. The surgeon coagulates a 3-4 cm long segment of peritoneum over the ileopsoas muscle. Along the coagulated segment the peritoneum is opened. The surgeon identifies the ureter at its crossing over the common iliac vessels. After medializing the ureter, the pararectal space is opened and the internal iliac artery is identified and dissected till the origin of the uterine artery. The uterine artery is isolated over a distance of about 2 cm. The vascular clip is placed over the uterine artery. Yasargil Clips are applied exclusively in patients of intervention group. Myomectomy is performed in identical fashion in both groups. At the end of myomectomy the vessel clips are removed. The metroplasty is controlled for hemostasis after reopening of the uterine vessels.
1691334|NCT01530776|Behavioral|Healthy Lifestyle Group|Electronically-mediated, behavioral intervention during and after pregnancy encouraging mothers to eat healthy, exercise, and return to their early pregnancy weights by 1 year postpartum
1691335|NCT01530763|Drug|Ceftaroline fosamil|"Treatment Group 1:
Drug: Ceftaroline fosamil Children ≥ 6 months: IV ceftaroline fosamil 12 mg/kg for subjects weighing ≤ 33 kg or 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)
Children < 6 months: Ceftaroline fosamil 8 mg/kg over 60 (± 10) minutes q8h (± 1 hour)"
1691336|NCT01530763|Drug|Ceftriaxone|"Treatment group 2:
75 mg/kg/day up to 4 g/day IV in equally divided doses, each infused over 30 (± 10) minutes q12hr (± 2 hours)"
1691337|NCT01530763|Drug|amoxicillin clavulanate|"Oral Switch for Treatment Groups 1 and 2:
PO amoxicillin clavulanate 90 mg/kg/day divided q12h in subjects with infections due to susceptible organisms on or after Study Day 4 (a minimum of 7 IV doses required if randomized to ceftaroline.)"
1691338|NCT01530737|Drug|Antithrombin III|Patients randomized to receive Antithrombin concentrate will receive a dose of AT to achieve a target value of 1.2U/ml.
1691339|NCT01530737|Other|Saline Placebo|Patients randomized to the control group will receive a placebo consisting of normal saline in a volume equivalent to the volume of antithrombin the same patient in the treatment group would have received and administered by anesthesia and perfusion in the exact same manner as the AT is administered in the treatment group.
1691340|NCT01530724|Other|low-fat diet|low-fat diet
1691341|NCT01530724|Other|low-carb diet|low-carb diet
1691342|NCT01530711|Drug|Terlipressin and albumin|"Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase < 10 mmHg and the creatinine values decrease <25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.
Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day."
1691343|NCT01530698|Biological|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase (for antigen loading), active TLR4 and CD70 (for activation). Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
1691344|NCT01530698|Biological|autologous dendritic cell vaccine|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intranodally 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations
1691345|NCT01530685|Dietary Supplement|Glycabiane|2 gelule per day for 4 months
1691346|NCT01530685|Dietary Supplement|placebo|2 gelules per day for 4 months
1691347|NCT01530672|Device|MBIO POC combined HIV syphilis test ( SnapEsi)|Venipuncture for routine ANC screening plus additional for device validation purposes.
1691348|NCT01530659|Drug|NT-501|Study participants will undergo surgery to have an NT-501 Encapsulated Cell Therapy implant placed into the study eye.
1691349|NCT01530646|Behavioral|Weight loss|-750kcal/d
1691350|NCT01530646|Dietary Supplement|Soy|2 x 25g/d SPC
1691351|NCT01530646|Dietary Supplement|Whey|2 x 25g/d WPI
1691352|NCT01530620|Drug|Propiverine hydrochloride ER (extended release)|45 mg capsule (1x1/d)
1691353|NCT01530620|Drug|Propiverine hydrochloride IR (immediate release)|15 mg tablet (3x1/d)
1691354|NCT01530607|Drug|Standard cyclophosphamide|AC (3 mos/4 cycles), CAF (6 mos/cycles), TAC (6 mos/cycles), CEF (6 mos/cycles) AC followed by taxane (6 mos/8 cycles), CMF (6 mos)
1691398|NCT01530360|Device|cerebral oximeter|INVOS 5100c + SAFB-SM SOMASENSOR NONIN EQUANOX 7600 + sensor model 8000CA
1691355|NCT01530607|Drug|Goserelin (Zoladex)|Chemotherapy in Arm 1 plus Goserelin given one week before first chemotherapy dose. Goserelin is given once every 4 weeks during chemo
1691356|NCT01530594|Drug|Lenalidomide/Low dose Dex|Lenalidomide/Low dose Dex (LLD)
1691357|NCT01530594|Drug|Bortezomib/Lenalidomide/ Low dose Dex|Bortezomib/Lenalidomide/ Low dose Dex (BLLD)
1691358|NCT01530594|Drug|Lenalidomide|Lenalidomide/Low dose Dex (LLD
1691359|NCT01530581|Procedure|G-PB Transplant|G-PB Transplant
1691360|NCT01530581|Procedure|G-BM Transplant|G-BM Transplant
1691361|NCT01530568|Other|Xpert|This arm receives the GeneXpert test
1691362|NCT01530568|Other|Smear|This arm receives smear microscopy
1691363|NCT01530555|Drug|Rabbit ATG, Thymoglobuline (Genzyme)|"Rabbit ATG, Thymoglobuline® (Genzyme) 1.5 vials/10kg (3.75mg/kg) daily for 5 days given as an intravenous infusion over 12-18 hours.
Ciclosporin (CSA) 5mg/kg/day orally from day +1 for a minimum of 6 months"
1691364|NCT01530542|Drug|oxycodone hydrochloride|oxycodone hydrochloride 5 mg tablet under fasted conditions
1691365|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 5 mg tablets under fasted conditions
1691366|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fasted conditions
1691367|NCT01530542|Drug|oxycodone hydrochloride|2 x oxycodone hydrochloride 7.5 mg tablets under fed conditions
1691368|NCT01530542|Drug|marketed oxycodone hydrochloride|1 x oxycodone hydrochloride 15 mg tablet under fed conditions
1691369|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as an immediate-release powder-in-capsule formulation
1691370|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
1691371|NCT01530529|Drug|PF-05180999|Single dose of 120 mg of PF-05180999 administered to fasted subjects as a modified-release formulation
1691372|NCT01530529|Drug|PF-05180999|Single dose of 30 mg of PF-05180999 administered to fed subjects as a modified-release formulation
1691373|NCT01530516|Device|Brackets plus Forsus springs|Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
1691374|NCT01530516|Device|Xbow plus full brackets|Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
1691375|NCT01530503|Drug|capecitabine and mitomycin|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food plus bolus IV infusion mitomycin C 6 mg/m2 day 1.
Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
1691376|NCT01530503|Drug|Capecitabine|"oral capecitabine 2000 mg/m2 day 1-14 in two divided doses taken with food.
Cycles will be repeated in both arms every 3 weeks till progression, unacceptable toxicity, medical decision or patient's refusal or for a maximum of 6 months"
1691377|NCT01530490|Drug|Cabergoline and Hydroxyethyl Starch|0.5mg
1691378|NCT01530490|Drug|Hydroxyethyl Starch|0.5 mg cabergoline administration 8 days
1691379|NCT01530477|Device|Lunar Prodigy (GEHC)|Lunar Prodigy (GEHC) used to obtain Skeletal, and/or Body Composition measurements
1691380|NCT01530477|Device|Lunar iDXA (GEHC)|Lunar iDXA (GEHC) used to obtain Skeletal, and/or Body Composition measurements
1691381|NCT01530477|Device|Discovery A (Hologic|Discovery A (Hologic) used to obtain Skeletal, and/or Body Composition measurements
1691382|NCT01530464|Drug|Aminophylline|Drug will be administered as a single oral dose of 500mg, followed by a 48h washout period.
1691383|NCT01530464|Drug|Ambrisentan|Drug will be administered as a single dose of 5mg, followed by a 48h washout period
1691384|NCT01530464|Drug|Aminophylline plus ambrisentan|Drugs will be given as single doses of 500mg (aminophylline) and 5mg (ambrisentan), followed by a 48h washout period
1691385|NCT01530451|Drug|Desmopressin|120mg OD
1691386|NCT01530451|Drug|Placebo|one tab OD
1691387|NCT01530438|Other|MRI + 18FDG-PET + neuropsychological assessments ; 18FDG performed especially for the research|"At T0 and T9 or 12 monts, are performed :
Imaging : fMRI at rest and anatomical MRI
Neuropsychological assessments : general cognitive functioning, theory of mind, executive functions ..."
1691388|NCT01530412|Other|Pulmonary Rehabilitation|Patients undergo pulmonary rehabilitation for two hours twice a week for seven weeks. The first hour comprises of an individualized exercise programme and the second hour consists of an educational component. Patients are also required to undergo inspiratory muscle training five days a week for thirty minutes and exercise for an additional three days a week for thirty minutes.
1691389|NCT01530399|Drug|MDCO 1|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 1: load 15 μg/kg; infusion 30 μg/kg/h; CPB prime 0.11 μg/mL priming volume
1691390|NCT01530399|Drug|MDCO 2|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 2: load 30 μg/kg; infusion 60 μg/kg/h; CPB prime 0.22 μg/mL priming volume
1691391|NCT01530399|Drug|MDCO 3|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 3: load 60 μg/kg ; infusion 120 μg/kg/h; CPB prime 0.44 μg/mL priming volume
1691392|NCT01530399|Drug|MDCO 4|MDCO-2010 will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with MDCO-2010. MDCO 4: load 90 μg/kg; infusion 180 μg/kg/h; CPB prime 0.65 μg/mL priming volume
1691393|NCT01530399|Drug|Tranexamic Acid|Tranexamic acid will be administered as a loading dose followed by a continuous infusion until sternal closure. In addition, the CPB reservoir will be primed with tranexamic acid. The flow rates will be the same as for MDCO-2010.
1691394|NCT01530399|Drug|Saline|A loading dose of saline will be followed by a continuous infusion of saline until sternal closure. In addition, the CPB reservoir will be primed with saline. The flow rates will be the same as for MDCO-2010.
1691395|NCT01530386|Drug|Lacosamide|Lacosamide will be given orally in 50 mg tablets twice a day for 7 days. The dose will increase weekly by 100 mg per day to a target dose of 300 mg per day. Once the target dose of 300 mg per day has been achieved for 9 days, a 2-day tapering of Lacosamide will occur by 100 mg per day.
1691396|NCT01530373|Drug|solifenacin|oral solifenacin 5.0 mg daily for 3 weeks
1691399|NCT01530347|Device|Easy Check|Collection of paired measurements of capillary blood glucose using reference method and data generated by the non invasive study device. Samples will be obtained at specific time points during 4 hours: at fasting, and after consuming standard liquid meal at 60, 120, 180 and 240 minutes.
1691400|NCT01530334|Drug|Gefitinib 250mg|Gefitinib 250mg once daily
1691401|NCT01530321|Other|Spinal Manipulation|5 minutes of high velocity, low amplitude thrust to cervical and upper thoracic spine.
1691402|NCT01530321|Other|Light Massage|5 minutes of light pressure massage to the neck and upper back
1691403|NCT01530308|Drug|Haloperidol|An oral dosage of 1mg twice daily at 12am and 8pm.
1691404|NCT01530308|Drug|Placebo|An oral dosage of 1mg twice-daily at 12am and 8 pm.
1691405|NCT01530295|Drug|DOCETAXEL|75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: 3 times pre-op and 3 times after surgery
1691406|NCT01530282|Other|Invasive method|Esophageal and gastric catheters to measure respiratory mechanics (static and dynamic)
1691407|NCT01530282|Other|Non invasive method|Non_invasive method: airway pressure measured during a 150-200 ms at the beginning of inspiration
1691408|NCT01530269|Drug|C11-Sodium Acetate|PET Imaging with C11-Sodium Acetate
1691409|NCT01530256|Biological|ALD518|160 mg IV q 4 weeks for 4 doses
1691410|NCT01530256|Biological|ALD518|320 mg IV q 4 weeks for 4 doses
1691411|NCT01530256|Biological|ALD518|640 mg IV q 4 weeks for 2 doses
1691412|NCT01530243|Drug|Placebo|same as tolterodine and terazosin dose
1691413|NCT01530243|Drug|Terazosine|2 mg BID
1691414|NCT01530243|Drug|Tolterodine|2 mg daily
1691415|NCT01530243|Drug|Tolterodine + Terazosin|2mg daily and 2mg BID
1691416|NCT01530230|Drug|oxytocin|Intravenous bolus dose given during 1 minute after clamping of the umbilical cord
1691417|NCT01530217|Drug|Ibuprofen.|Ibuprofen Group will be receive a dose of non-steroidal antiinflammatory drug ibuprofen 400 mg. All the participants will be watched to ensure that they took the drugs 1 hour prior to treatment. A second dose of ibuprofen (400 mg), will be administered a every 8 hours after the first dose during 48 hours.
1691418|NCT01530204|Procedure|Physical Therapy for knee OA|8-12 sessions of knee-focused physical therapy and a home-based conditioning program.
1691419|NCT01530204|Behavioral|Cognitive Behavioral Therapy for Pain CBT-P|8-12 session pain-focused Cognitive Behavioral Therapy
1691420|NCT01530204|Other|Enhanced Treatment as Usual|Information about state-of-the-art pharmacotherapy for osteoarthritis is communicated to the primary care physicians of participants.
1691422|NCT01530165|Behavioral|Life style counseling|The main goals of intervention will focus mainly on: Weight reduction ≥ 5% , moderate intensity physical activity ≥ 30 min daily, dietary fat <30 proportion of total energy, saturated fat <10%, Fiber ≥ 15g/1,000 kcal There will be 9 sessions during the two years course of follow-up
1691423|NCT01530152|Procedure|Truwiev PCD laryngoscope|"The aim of the method evaluation study is a comparing study of Truview PCD™ laryngoscope vs. Macintosh laryngoscope. The result of this study will form a basis for a possible recommendation of the Truview PCD™ laryngoscope in our organisation.
The laryngoscopes are compared according to their ability to visualize the glottis area measured by the Cormack Lehane (CL) grade and the time used to get the best CL grade. (See figure 1.) A registration of any damage of tissue/teeths caused by the laryngoscopes, and a possible decrease of the saturation will also be made."
1691424|NCT01530139|Behavioral|Level 1|Level 1 - Participants will receive personalised dietary advice based on their dietary intake data alone.
1691425|NCT01530139|Behavioral|Level 2|Level or Group 2: Participants will receive personalised dietary advice taking dietary intake and phenotypic data into account.
1691426|NCT01530139|Behavioral|Level 3|Level or group 3: Participants will receive personalised dietary advice taking dietary intake, phenotypic and genotypic data into account.
1691427|NCT01530139|Behavioral|Level 0|Level 0 - Control group - Investigators will provide non-personalized dietary advice for improved food choice based on standard population healthy eating guidelines.
1691428|NCT01530126|Biological|B-TCP + 0.3 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 0.3 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
1691429|NCT01530126|Biological|B-TCP + 1.0 mg/ml rhPDGF-BB in buffer|B-TCP mixed with sodium acetate buffer and 1.0 mg/ml rhPDGF-BB and placed into osseous defect once at baseline visit.
1691430|NCT01530126|Biological|B-TCP +buffer|B-TCP mixed with sodium acetate buffer and placed into osseous defect once at baseline visit.
1691431|NCT01530087|Device|CASTLE barrier|Prototype barrier to be used in place of current two piece device
1691432|NCT01530074|Procedure|Temporary blocking of mandibular nerve|IM. Lidocaine 2% 7.2ML
1691433|NCT01530061|Other|Egg Breakfast|Egg, Toast and Jelly
1691434|NCT01530061|Other|Bagel Breakfast|Bagel, Cream Cheese and Yogurt
1691435|NCT01530048|Drug|insulin aspart|A single bolus injection of 0.2 U/kg administered subcutaneously (s.c., under the skin) on two separate dosing visits with a wash-out period 2-15 days in-between
1691436|NCT01530035|Other|physical training|training
1691437|NCT01530022|Drug|Lacosamide (LCM)|"LCM 300 mg:
LCM 50 mg and LCM 100 mg white, film-coated oral tablets and Carbamazepine Immediate Release (CBZ-IR) matching placebo capsules.
Two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.
Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period"
1691438|NCT01530022|Drug|Carbamazepine Immediate Release (CBZ-IR)|"CBZ-IR 600 mg:
CBZ-IR 200 mg oral tablets over-encapsulated to double-blind capsules with an overfill.
LCM matching placebo tablets two times daily (morning and evening) during the first 2 weeks of each Titration Period and during the Taper Phases.
Three times daily (morning, mid-day, and evening) during last week of each Titration Period and 3-week Treatment Period."
1691439|NCT01530009|Drug|Amoxicillin|A liquid preparation of amoxicillin will be administered via a nasoduodenal catheter as a one time dose of 20 mg/kg.
1691440|NCT01530009|Other|Placebo|A liquid placebo will be administered via nasoduodenal catheter to patients based on random assignment.
1691489|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension BID
1691878|NCT01526863|Dietary Supplement|HA egg|Daily dose of HA egg or placebo for 6 months
1691441|NCT01529996|Procedure|Pulse Dye Laser/YAG laser|This study involves treatments with two types of lasers, Pulsed dye lasers (PDL) and the 1064 nm Nd: YAG. Both lasers are FDA approved to treat vascularities in the skin.
1691442|NCT01529983|Procedure|Laser treatment|The treated sites are both lower eyelids and lateral orbits. Each side will be randomized to receive 1550nm-fractionated laser treatment on one side and the contralateral side will receive micro-focused ultrasound treatment every 6-8 weeks for a total of 2 treatments
1691443|NCT01529957|Drug|Nemonoxacin Malate Sodium Chloride|Nemonoxacin Malate Sodium Chloride,intravenous injection,once daily
1691444|NCT01529944|Drug|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
1691445|NCT01529944|Drug|somatropin|Results from a genetic testing for the PTPN11 mutation will be collected retrospectively for 24 subjects with Noonan syndrome previously treated with somatropin in accordance with the S/GHD/004/N00 protocol and in the follow-up trial GHNOO-1658.
1691446|NCT01529931|Device|Hair2Go|Hair2Go treatment once a month for 6 months
1691447|NCT01529918|Other|CANRISK (Canadian Diabetes Association Assessment)|Self-risk assessment questionnaire for diabetes
1691448|NCT01529892|Drug|A single oral 5 mg of duterium labeled methamphetamine|
1691449|NCT01529879|Device|New Abutment Connection implant|New abutment connection implant
1691450|NCT01529879|Device|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
1691451|NCT01529866|Device|New Abutment Connection implant|New abutment connection implant
1691452|NCT01529866|Device|Nanotite Certain Tapered implant|Nanotite certain tapered (standard abutment connection) implant
1691453|NCT01529853|Drug|SAR156597|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1691454|NCT01529853|Drug|Placebo (for SAR156597)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1691455|NCT01529840|Drug|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
1691456|NCT01529840|Drug|somatropin|Retrospective data collection based on data obtained from a prospective, open-label, randomised, parallel-group trial (S/GHD/004/NOO) combined with a present follow-up visit
1691457|NCT01529827|Drug|fludarabine phosphate|Given IV
1691458|NCT01529827|Drug|melphalan|Given IV
1691459|NCT01529827|Radiation|total-body irradiation|Undergo TBI
1691460|NCT01529827|Drug|tacrolimus|Given IV or PO
1691461|NCT01529827|Drug|mycophenolate mofetil|Given IV or PO
1691462|NCT01529827|Drug|methotrexate|Given IV
1691463|NCT01529827|Other|laboratory biomarker analysis|Correlative studies
1691464|NCT01529827|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
1691465|NCT01529827|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
1691466|NCT01529814|Device|Implant with new abutment connection|New abutment connection implant system
1691467|NCT01529814|Device|Nanotite Certain Tapered implant|Nanotite Certain Tapered (standard abutment connection) implant
1691468|NCT01529801|Device|Osseotite Certain Tapered Group A|Osseotite Certain Tapered with different surface roughness
1691469|NCT01529801|Device|Osseotite Certain Tapered Group B|Osseotite Certain Tapered with different surface roughness
1691470|NCT01529801|Device|Osseotite Certain Tapered Group C|Osseotite Certain Tapered with different surface roughness
1691471|NCT01529788|Drug|Right lateral orbital injection of Botox Cosmetic or Dysport|Right lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL [7.5 units] per injection point) divided among 4 injection points (0.05mL [2.5units]) on Day 0 of the study
1691472|NCT01529788|Drug|Left lateral orbital injection of Botox Cosmetic or Dysport|Left lateral orbital injection of Botox Cosmetic or Dysport (10 units and 30 units, respectively) divided among 4 injection points (0.05 mL [7.5 units] per injection point) divided among 4 injection points (0.05mL [2.5units]) on Day 0 of the study
1691473|NCT01529775|Device|Osseotite Certain Tapered Prevail|Osseotite implant with platform switching feature
1691474|NCT01529775|Device|Osseotite Certain Tapered|Osseotite implant with non-platform switching feature
1691475|NCT01529749|Drug|EFV/FTC/TDF + Losartan|EFV/FTC/TDF --> oral, 600/200/245 mg, od Losartan --> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24H in week 12.
1691476|NCT01529749|Drug|EFV/FTC/TDF|600/200/245 mg, od, oral
1691477|NCT01529749|Drug|FTC/TDF + MK-0518|FTC/TDF --> 200/245 mg, oral MK-0518 --> 400 mg, oral
1691478|NCT01529749|Drug|FTC/TDF+MK-0518+Losartan|FTC/TDF --> 200/245 mg, oral MK-0518 --> 400 mg, oral Losartan --> -> initial dose 50 mg/24h, in patients with good tolerance, dose will be increased to 100 mg/24n in week 12.
1691479|NCT01529736|Procedure|High torque insertion|Osseotite implant placed with high insertion torque forces
1691480|NCT01529736|Procedure|Low torque insertion|Osseotite implant placed with low insertion torque forces
1691481|NCT01529710|Drug|Myrrh|Subjects will be treated by Mirazid as 600 mg oral (Soft Gelatin Capsules) for 6 consecutive days or 40mg/Kg body weight of Praziquantel as a single oral dose. Subjects will be evaluated for success of treatment at 12 weeks of treatment. Evaluation will be done by examining urine or stool samples for Schistosomiasis including egg counts for the positive cases.
1691482|NCT01529697|Behavioral|Active Feedback|The inhaler will be fitted with a device that makes an audio recording of the inhaler use. This audio data will be downloaded to a computer program, analyzed for assessment of whether the steps involved in using the inhaler have been performed correctly. This information will be discussed with the patient.
1691483|NCT01529684|Drug|radio-labeled OSI-906|Part A: oral solution of 14C-OSI-906
1691484|NCT01529684|Drug|OSI-906|Part B: oral tablets OSI-906
1691485|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
1691486|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
1691487|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
1691488|NCT01529671|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily (BID)
1691490|NCT01529658|Procedure|Renal hypothermia|"Within 10 seconds of clamping the renal vessels, the kidney will be encased with saline ice slush for a period of 10 minutes. The slush will be created from sterile saline using an operating room slush machine. The slush is applied by the surgeon and lightly packed around the kidney to ensure complete coverage with at least a 2 cm layer. Slush removal is performed by the surgeon beginning at the 10 minute mark. Enough slush is removed to uncover the tumour area. Surgical incision of the kidney begins as soon as the tumour area is uncovered.
When reconstruction of the kidney is complete, the slush is completely removed from the surgical field and the clamps are removed from the renal vein and artery."
1691491|NCT01529645|Biological|Acellular pertussis vaccine|Acellular pertussis (aP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
1691492|NCT01529645|Biological|Tetanus, reduced diphtheria, and acellular pertussis vaccine (adsorbed)|Tetanus, reduced diphtheria, and acellular pertussis (TdaP) vaccine was administered with different antigen doses intramuscularly in the upper deltoid region of the subject's non-dominant arm.
1691493|NCT01529645|Biological|Licensed TdaP booster vaccine|Licenced TdaP booster vaccine was administered intramuscularly in the upper deltoid region of the subject's non-dominant arm.
1691494|NCT01529645|Biological|Diphtheria and tetanus vaccine (adsorbed, reduced antigen content, Germany)|To ensure all subjects receive a tetanus and diphtheria booster vaccination, an injection was administered on Study Day 30, one month after the administration of the investigational vaccine.
1691495|NCT01529645|Other|Saline solution|Subjects received one injection of saline solution at one month after vaccination.
1691496|NCT01529632|Drug|QVA149|QVA149 110/50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
1691497|NCT01529632|Drug|NVA237|NVA237 50 ug supplied as capsules in blister packs for inhalation via SDDPI, once daily
1691498|NCT01529632|Drug|QAB149|QAB149 150 ug supplied as capsules in blister packs for inhalation via SDDPI , once daily
1691499|NCT01529632|Drug|Placebo|Placebo capsules provided in blister packs for inhalation via SDDPI, once daily
1691500|NCT01529619|Drug|Rivastigmine transdermal patch|
1691501|NCT01529606|Other|Composite restoration and tooth cleaning|Standard preventive treatment will be repeated on semi-annual (6-month) recall visits. All composite restorations will be placed according to the manufacturer's instruction.
1691502|NCT01529606|Procedure|Plasma treatment|plasma treatment after preparation and for caries prevention
1691503|NCT01529593|Drug|Temsirolimus|"Starting dose: 25 mg by vein weekly.
Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled."
1691504|NCT01529593|Drug|Metformin|"Starting dose: 500 mg titrated over first 3 weeks.
Expansion cohort: Once MTD is determined, or at maximum tolerated dose level explored (Level 5) if MTD is not reached, additional 14 patients enrolled"
1691505|NCT01529580|Behavioral|Non-Verbal School Aged Children with Autism (NVSACA) Intervention|"The intervention has 3 components:
One-on-one play based intervention: administered by the interventionist at the school for 1 hour, three times a week, each week for the 5 month duration of the intervention.
Parent training: at the beginning of the 5th month of intervention, parents will receive training once a week for an hour during the remaining four weeks of intervention.
Teacher training: in month 2 of the intervention, the teacher will receive 2 1.5 hour training sessions along with a weekly in-class coaching given as needed following completion of the second session of training."
1691506|NCT01529567|Behavioral|Cognitive Behavioral Therapy without exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, and guided behavioral change aiming to increase quality of life and flexibility.
1691507|NCT01529567|Behavioral|Cognitive Behavioral Therapy with exposure|10 week internet-delivered cognitive behavioral therapy, including mindfulness training, education about the negative effects of excessive avoidance and control behaviors on IBS symptoms and quality of life, guided behavioral change aiming to increase quality of life and flexibility, and systematic exposure to IBS symptoms and aversive situations.
1691510|NCT01529541|Drug|Anagliptin|Anagliptin 100mg, tablet, twice a day (BID)
1691511|NCT01529541|Drug|Sitagliptin|Sitagliptin 100mg, tablet, once a day (QD)
1691512|NCT01529528|Drug|Anagliptin|Anagliptin 100mg, tablet, BID
1691513|NCT01529528|Drug|Anagliptin|Anagliptin 100mg, tablet, BID
1691514|NCT01529528|Drug|Placebo of Anagliptin|Placebo of Anagliptin 100mg, tablet, BID
1691515|NCT01529515|Drug|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
1691516|NCT01529515|Drug|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
1691517|NCT01529515|Drug|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
1691518|NCT01529515|Drug|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
1691519|NCT01529515|Drug|Placebo (20% Intralipid emulsion)|Form= injection, route= intramuscular use. One injection every three months up to the patient has a relapse event or meet discontinuation criteria.
1691520|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 3 days storage time. The same 14 subjects will be included in every arm of the study.
1691521|NCT01529502|Procedure|Red blood Cells auto-transfusion|Withdrawal from the same 14 overweight volunteers of one unit of red blood cells and auto-transfusion after 40 days storage time.
1691522|NCT01529502|Drug|Inhaled Nitric Oxide (iNO) administration|Subjects will breath iNO (80ppm) for 10 minutes before, during and for one hour after the autologous old-blood transfusion.
1692077|NCT01525615|Device|Respimat inhaler|Respimat inhaler
1691523|NCT01529489|Other|Resisted/Aerobic physical training|COPD, aerobic physical training in cicloergometer, resisted physical training in cicloergometer, oxygen uptake kinetic, heart rate kinetic.
1691524|NCT01529489|Other|Interval physical training in elliptical equipament|Control group (healthy individuals), interval physical training, elliptical equipment, oxygen uptake kinetic, heart rate kinetic.
1691525|NCT01529489|Other|Interval physical training in elliptical equipament|COPD, interval physical training, elliptical equipament, oxygen uptake kinetic, heart rate kinetic
1691526|NCT01529489|Other|Resisted/Aerobic physical training|Control group, aerobic physical training in cicloergometer, resisted physical training in leg-press oxygen uptake kinetic heart rate kinetic
1691527|NCT01529476|Drug|Levofloxacin|levofloxacin 500 mg,QD,7~10 days
1691528|NCT01529476|Drug|Nemonoxacin|Nemonoxacin 500mg,QD,7~10 days
1691529|NCT01529450|Drug|LDE225|800-mg (4 200-mg capsules/day) capsule
1691530|NCT01529437|Drug|sublingual immunotherapy|Sublingual immunotherapy is provided in an extract form under IND 13485 and dosed safely through a maintenance dose of 12 months.
1691531|NCT01529437|Drug|placebo sublingual immunotherapy|SLIT placebo will be the same color and consistency of the active drug arm to provide double blinding
1691532|NCT01529424|Drug|ISIS apoC-III Rx|Dose 1
1691533|NCT01529424|Drug|ISIS apoC-III Rx|Dose 2
1691534|NCT01529424|Drug|ISIS apoC-III Rx|Dose 3
1691535|NCT01529424|Drug|Placebo|Dose 1
1691536|NCT01529424|Drug|Placebo|Dose 2
1691537|NCT01529424|Drug|Placebo|Dose 3
1691538|NCT01529411|Drug|Vinflunine|Vinflunine 320 mg/m2 IV infusion in 20 minutes every 21 days (280mg/m2 if PS=1, age ≥ 75 years, previous pelvic radiotherapy or creatinine clearance < 60ml/min).
1691539|NCT01529411|Other|Undefined (standard care)|All the current interventions used by each institution for the study disease.
1691540|NCT01529398|Other|Sensorimotor training (SMT)|The group realized 16 weeks of sensorimotor training, twice a week, with duration of 30 minutes each session. The intervention included agility and coordination exercises, perturbation training and stretching exercises. Also, the participants received orientation about the knee osteoarthritis.
1691541|NCT01529398|Other|Resistance training (RT)|The group realized 16 weeks of resistance training for the quadriceps and hamstring muscles, twice a week, with duration of 30 minutes each session. The intervention included strength leg raises, simple quadriceps and hamstring strengthening with cuff weights realized in 3 sets of ten repetition maximum(10RM) for each muscle group. The group also realized stretching exercises for lower limbs and received orientation about the knee osteoarthritis.
1691542|NCT01529398|Other|Control group (CG)|Patients in this group also received information about knee osteoarthritis and realized the same warm-up and cool-down intervention realized in the interventional groups. During 16 weeks they went to the ambulatory twice a week to perform 5 minutes of stationary bicycle and 5 minutes of stretching exercises for lower limbs.
1691543|NCT01529385|Device|mild compression diabetic sock|A diabetic sock that provides mild compression (18-25mm Hg) is to be worn everyday for four weeks
1691544|NCT01529385|Device|Standard diabetic sock|A diabetic sock that is not designed to provide compression is to be worn everyday for four weeks
1691545|NCT01529372|Device|PARADISE percutaneous renal denervation|Intravascular ultrasound emission
1691546|NCT01529359|Dietary Supplement|Lactibiane Tolerance|Probiotics combination 2 gelules per days during 6 weeks
1691547|NCT01529359|Dietary Supplement|Placebo|Placebo 2 gelules per days for 6 weeks
1691548|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 1600 mg oral solution administered once to the subject on Day 1 postoperatively
1691549|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
1691550|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 450 mg oral solution administered once to the subject on Day 1 postoperatively
1691551|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
1691552|NCT01529346|Drug|PF-05089771|A single dose of PF-05089771 150 mg oral solution administered once to the subject on Day 1 postoperatively
1691553|NCT01529346|Other|Placebo|Placebo tablets for ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
1691554|NCT01529346|Drug|Ibuprofen|2 X 200 mg tablets of ibuprofen administered orally once to the subject on Day 1 postoperatively
1691555|NCT01529346|Other|Placebo|Placebo solution for PF-05089771: A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
1691556|NCT01529346|Other|Placebo|Placebo solution for PF-05089771:A single dose of Placebo solution administered once to the subject on Day 1 postoperatively
1691557|NCT01529346|Other|Placebo|Placebo tablets for Ibuprofen: 2 X 200 mg placebo tablets administered orally once to the subject on Day 1 postoperatively
1691558|NCT01529333|Device|Middle Ear Implant with MET V Transducer|The MET V System is indicated for use in addressing the amplification needs of adults, 18 years of age and older, who have mixed hearing loss.
1691559|NCT01529320|Drug|Adventan® (methylprednisolone aceponate 0,1%)|Doses: 1/4 FTU (Finger Tip Unit) during 5 days (Day 7-Day 11). Procedure: Patch Test (Nickel sulphate 5%) during 2 days (Day 0- Day 2.
1691560|NCT01529307|Drug|TAS266|TAS266 IV infusions given weekly
1691561|NCT01529294|Drug|Iloperidone|
1691562|NCT01529281|Dietary Supplement|Branch Chain Amino Acid (BCAA)|Supplementation lasted for a total of 12 days; this was based on previous research showing a positive with BCAA supplementation on markers of muscle damage. Participants ingested 10 g, twice per day (morning and evening) of BCAA . The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The BCAA was in powder form where each serving was mixed with ~300 ml of water.
1691563|NCT01529281|Dietary Supplement|Placebo - asparmate|Supplementation lasted for a total of 12 days. Participants ingested an equivalent looking volume to 10 g of BCAA, twice per day (morning and evening) of placebo (aspartame based artificial sweetener). The BCAA supplement contained a ratio of 2:1:1 (leucine, isoleucine and valine, respectively). The artificial sweetener was in powder form where each serving was mixed with ~300 ml of water.
1691698|NCT01528345|Drug|Dovitinib Placebo|Dovitinib Placebo (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
1691564|NCT01529268|Drug|DR cysteamine bitartrate capsule|"600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline"
1691565|NCT01529268|Other|DR cysteamine bitartrate placebo|"600 mg/day (four 75 mg capsules twice daily) for patients ≤ 65 kg at baseline
750 mg/day (five 75 mg capsules twice daily) for patients >65 - 80 kg at baseline
900 mg/day (six 75 mg capsules twice daily) for patients >80 kg at baseline"
1691566|NCT01529255|Drug|telbivudine (ROADMAP)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
Stopping rules:
The participants who achieve HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.
The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.
Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
1691567|NCT01529255|Drug|Telbivudine (Standard of Care)|"Patients will receive oral telbivudine 600mg, daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
Stopping rules:
The participants who achieve HBeAg seroconversion and HBV DNA<300copies/ml with over 12 months consolidation treatment in EFFORT study will discontinue treatment.
The participants who don't meet the rules above will continue their previous treatment and follow up at the interval of 12 weeks until they finish the 156 weeks therapy or achieve the stopping rules.
Follow up： The participants who stopped treatment will follow up at the interval of 12 weeks for 52 weeks. Of these patients, if they have confirmed virologic relapse during follow-up period, they will be excluded from the trial."
1691568|NCT01529242|Drug|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
1691569|NCT01529242|Drug|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
1691572|NCT01529216|Device|DIAMOND System|Electrical stimulation to the fundus
1691573|NCT01529203|Drug|Botulinum Toxin Type A (Azzalure)|Powder for solution for injection
1691574|NCT01529203|Device|Restylane ranges|Hyaluronic acid (HA) 20 mg/mL + Lidocaine 0.3% (Restylane® Lidocaine, Restylane® Perlane™ Lidocaine, Restylane® SubQ Lidocaine, Restylane® Lip Volume, Restylane® Lip Refresh)
1691575|NCT01529190|Drug|Pregabalin|Effect of Preoperative Pregabalin on Pain Intensity. 300mg of pregabalin before surgical incision
1691576|NCT01529190|Drug|Placebo|placebo
1691577|NCT01529177|Drug|Metformin / clomid / hCG|Metformin 1000 mg daily for a week then twice daily for 2 weeks then 3 tomes daily for 6 months.
1691578|NCT01529177|Drug|Clomiphene citrate / hCG|Clomiphene citrate 50 mg daily for one month, then twice daily for 2 months then 3 times per day for 3 months.
1691579|NCT01529164|Drug|Endostatins (Endostar)|7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity
1691580|NCT01529164|Drug|Oxaliplatin|85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity
1691581|NCT01529164|Drug|Leucovorin|200mg/m2 iv d1 ,repeat every 14 days
1691582|NCT01529164|Drug|5-fluorouracil|400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
1691583|NCT01529151|Other|Osteopathic Manipulative Treatment (OMT)|Direct action OMT procedures, including HVLA, involve the application of a force in the direction of restricted joint motion in order to resolve somatic dysfunction. Indirect techniques, including counterstrain, balanced ligamentous tension and myofascial release, entail applying a force away from the restrictive barrier of a joint or soft tissue structure.
1691584|NCT01529151|Other|Vestibular Rehabilitation Therapy (VRT)|Participants categorized as having a peripheral motion hypersensitivity will receive habituation exercises that reproduce the provocative motion, seated and standing balance exercises with gaze stabilization, kinesthetic and proprioceptive retraining. Participants will be given a monthly exercise log at onset and will be asked to report exercise levels at subsequent follow up periods.
1691585|NCT01529138|Drug|Axitinib|Combination treatment with temsirolimus and axitinib
1691586|NCT01529138|Drug|Temsirolimus|Combination treatment with temsirolimus and axitinib
1691587|NCT01529125|Drug|zidovudine, lamivudine, nevirapine|
1691588|NCT01529112|Drug|Lenvatinib|
1691589|NCT01529112|Drug|Lenvatinib matched placebo|
1691590|NCT01529112|Drug|BSC|
1691591|NCT01529099|Device|SIGMA HP PARTIAL KNEE|SIGMA HP PARTIAL KNEE
1691592|NCT01529073|Drug|Nitazoxanide|Nitazoxanide 500 mg bid po for 4 weeks, followed by nitazoxanide 500 mg bid plus pegylated interferon alpha 2b 1.5 mg/kg/week sc plus weight-adjusted ribavirin po for 48 weeks.
1691595|NCT01529047|Behavioral|Personalized Feedback Intervention|Printed or electronic form containing personalized information about health-relevant behaviors
1691596|NCT01529034|Drug|USL261|
1691599|NCT01528995|Device|Medtronic Interstim II-3058|impulse generator
1692078|NCT01525615|Drug|tiotropium+olodaterol (low dose)|2.5 µg tiotropium + 5 µg olodaterol
1691600|NCT01528995|Procedure|Anal bulking injection|"Permacol injection:
four submucosal injections are administered at the 12, 3, 6 and 9 o'clock positions, above the level of the dentate line. The injection produces a bulge in the mucosa"
1691603|NCT01528969|Dietary Supplement|xylitol|Subjects will chew 2 pieces of xylitol chewing gum (1,5 g/pellet) three times a day in the experimental group for a five-week period.
1691604|NCT01528969|Dietary Supplement|sorbitol|Subjects will chew 2 pieces of sorbitol chewing gum (1,5 g/pellet) three times a day in the control group for a five-week period.
1691605|NCT01528956|Genetic|DNA methylation analysis|
1691606|NCT01528956|Genetic|RNA analysis|
1691607|NCT01528956|Genetic|gene expression analysis|
1691608|NCT01528956|Genetic|nucleic acid sequencing|
1691609|NCT01528956|Genetic|polymorphism analysis|
1691610|NCT01528943|Drug|Prostacycline|Continuous infusion peri -and 6 hours postoperatively of prostacycline 1 ng/kg/min
1691611|NCT01528943|Drug|Isotonic saline|same volume as the group that are allocated to prostacycline
1691612|NCT01528930|Drug|Amikacin|500 mg, once daily for 2 years
1691613|NCT01528891|Drug|Dexmedetomidine|0.5 micrograms/Kilogram one time bolus 5 minutes prior to the end of surgery
1691614|NCT01528891|Other|Placebo|
1691615|NCT01528878|Radiation|Stereotactic Radiosurgery using the CyberKnife System.|"Radiation: Stereotactic Radiosurgery using the CyberKnife System. The CyberKnife system has been cleared by the U.S. Food and Drug Administration (FDA) to treat lesions, tumors and conditions, anywhere in the body when radiation treatment is indicated. To address movement of target lesion during the respiratory cycle, the Synchrony™ option will be used.
The Synchrony option precisely tracks tumors in or near the target organ as they move, enabling the highly focused beams of radiation to destroy the tumors with minimal injury to adjacent normal tissue. The Synchrony option records the breathing movements of a patient's chest and combines that information with sequential x-ray pictures of tiny markers inserted inside or in the proximity of the tumor to enable precise delivery of radiation during any point in the respiration cycle. The CyberKnife system with the Synchrony option enables reduced normal tissue exposure by using smaller treatment margins and increased accuracy."
1691616|NCT01528865|Drug|Lamivudine|"Creatinine Clearance (mL/min): ≥50, Recommended Dosage of Epivir: 150 mg twice daily or 300 mg once daily.
Creatinine Clearance (mL/min): 30-49, Recommended Dosage of Epivir: 150 mg once daily.
Subjects will be taking drug for 16 weeks."
1691617|NCT01528865|Drug|Tenofovir disoproxil fumarate|300 mg once a day p.o. for 16 weeks.
1691618|NCT01528852|Drug|Chlorhexidine 4%|4% liquid solution used for cord cleaning once daily for 10 days
1691619|NCT01528852|Drug|Chlorhexidine 4%|Chlorhexidine 4% liquid solution used for cord cleaning once daily for 10 days
1691620|NCT01528852|Other|Control cord cleaning solution|Mild soapy solution used to clean cord once daily for 10 days
1691623|NCT01528826|Drug|vinorelbine plus oxaliplatin|Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks
1691624|NCT01528813|Device|Er:YAG laser + amorolfine lacquer|To each compromised ungual unit randomly assigned to this group it will be applied a single session of Er:YAG laser to the ungual lamina in the beginning of study. Onwards, amorolfine lacquer will be applied weekly for a period of 06 months.
1691625|NCT01528813|Drug|Amorolfine lacquer|To each compromised ungual unit randomly assigned to this group, it will be applied amorolfine lacquer weekly for a period of 06 months.
1691626|NCT01528800|Drug|Vitamin K1|10mg orally three times a week for 12 months
1691627|NCT01528800|Drug|Chrystalline Lactose|10mg orally three times a week for 12 months
1691628|NCT01528787|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.01%|Netarsudil (AR-13324) Ophthalmic Solution 0.01% q.d.
1691629|NCT01528787|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.02%|Netarsudil (AR-13324) Ophthalmic Solution 0.02% q.d.
1691630|NCT01528787|Drug|Netarsudil (AR-13324) Ophthalmic Solution 0.04%|Netarsudil (AR-13324) Ophthalmic Solution 0.04% q.d.
1691631|NCT01528787|Other|Netarsudil (AR-13324) Vehicle Ophthalmic Solution (Placebo)|Netarsudil (AR-13324) Vehicle Ophthalmic Solution, q.d.
1691632|NCT01528774|Other|Blood Draw|Approximately 40 cc of blood will be drawn from participants at a time when they are having blood drawn for routine or treatment-related purposes. Sequential samples may be obtained in the same manner from selected patients to allow exploration of potential correlation of CTC with response to treatment, progression-free survival and overall survival.
1691633|NCT01528761|Behavioral|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a cognitive-behavioral intervention to teach participants the behavioral skills to engage in independent physical activity. Participants will engage in supervised physical activity delivered two times a week during months 1 to 3 at the William G. White, Jr. Family YMCA in Winston-Salem, NC. During months 4 to 6, supervised sessions will be held once per week, and sessions will be held once per month in months 7 to 9. Participants will engage in completely independent physical activity in months 10 to 12. PBPA participants will also be able to earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity. Lowe's Foods, a regional grocery chain, will donate the food. Participants in the PBPA intervention also will receive a 12-month membership to the William G. White, Jr. Family YMCA at no cost.
1691634|NCT01528761|Other|Healthy Aging (HA)|The HA group will receive a health education intervention based on topics from several sources, including the National Institute on Aging's Age Pages, University of Pittsburgh's 10 Keys to Healthy Aging; and Stanford University's Successful Aging program, among other topics . The HA intervention will receive ongoing staff contact, and will provide participants with excellent information on health-related topics. Biweekly 45-minute lectures will be given during months 1 to 6, and once per month during months 7 to 9. After each session, participants will engage in a 15-minute stretching routine. During months 10 to 12, no lectures will be given. After completion of the 12-month assessments, participants will receive a 12-month membership to the YMCA at no cost.
1691876|NCT01526889|Drug|Conventional Therapy|Conventional Therapy administered in accordance with its prescribing info.
1691635|NCT01528748|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a behavioral intervention that addresses the unique behavioral characteristics of chronically depressed individuals, most of which are highly relevant for alcoholics as well. CBASP has a structured, individualized, and collaborative (patient and clinician) design. The intervention emphasizes teaching effective coping strategies and employing motivational, cognitive, behavioral, and interpersonal techniques. Individual therapy (1 hour) sessions occur on a weekly basis for a total of 20 sessions over a period of 21 weeks.
1691636|NCT01528735|Drug|BI 207127 NA|one fix dose
1691637|NCT01528735|Drug|peginterferon|per package insert
1691638|NCT01528735|Drug|Ribavirin|per weight BID
1691639|NCT01528735|Drug|Ribavirin|per weight BID
1691640|NCT01528735|Drug|BI 207127 NA|one fix dose
1691641|NCT01528735|Drug|BI 201335 NA|high dose
1691642|NCT01528735|Drug|BI 201335 NA|low dose
1691643|NCT01528735|Drug|peginterferon|per package insert
1691644|NCT01528722|Drug|Bupivacaine|0.25% 20ml administered intraperitoneal
1691645|NCT01528722|Other|Normal saline|sodium chloride 0.9% solution
1691646|NCT01528709|Drug|Atorvastatin 80 mg daily|Atorvastatin 80 mg daily for 1 year
1691647|NCT01528709|Drug|Atorvastatin 10 mg daily|Atorvastatin 10 mg daily for 1 year
1691648|NCT01528696|Device|Silverlon|"Patients will be randomized to either receive a silver dressing. Patients who receive a silver dressing will have that dressing replaced on postoperative day number 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
All patient will be evaluated by the visiting nurse on postoperative day 4 or 5 and have their wounds photographed. All patients will be contacted for a brief survey 6 weeks postpartum."
1691649|NCT01528696|Device|Standard Dressing|Standard island dressing. Patients who receive a standard dressing will have that dressing removed on postoperative day 2. This will be left in place until the patient is seen for follow up by the visiting nurse.
1691650|NCT01528683|Radiation|Carbon Ion Radiotherapy|Treatment with carbon ion radiotherapy using the rasterscanning technique
1691651|NCT01528657|Other|Ventricular Pace Suppression (Vps)|Unnecessary ventricular pacing is avoided by promoting intrinsic conduction. In case of intrinsic conduction, the device switches from a DDD mode to an ADI mode.
1691652|NCT01528657|Other|Intrinsic rhythm support (IRSplus)|All parameters of the AV hysteresis functions are set in a way to maintain spontaneous AV conduction of the patient's heart as long as possible.
1691653|NCT01528644|Dietary Supplement|alginate beads containing ferrous gluconate|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 3 placebo capsules (each containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
1691654|NCT01528644|Dietary Supplement|ferrous gluconate in a capsule|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule and 2 placebo capsules (each containing 50mg of dextrose) followed by a cola jelly (200ml)and cola drink (200ml) will be given to the volunteer. Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
1691655|NCT01528644|Dietary Supplement|ferrous gluconate in a capsule in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate in a capsule together with 2 calcium capsules (each containing 300mg of calcium phosphate)followed by cola jelly (200ml) and cola drink(200ml)will be given to the volunteer . Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
1691656|NCT01528644|Dietary Supplement|alginate beads with ferrous gluconate in presence of calcium|After insertion of the cannula and collection of baseline blood sample a single dose of approximately 20mg of iron as ferrous gluconate incorporated into alginate beads (approximately 22.2g)and added to cola jelly (200ml) will be given to the volunteer together with 2 calcium capsules (each containing 300mg of calcium as calcium phosphate, 1 placebo capsule (containing 50mg of dextrose)and cola drink (200ml). Once consumed, further blood samples will be taken at specified time points during 6 hour cannulation time. A minimum of 7 days wash out period will take place prior next intervention.
1691657|NCT01528631|Other|D-Fagomine|30 mg (initial dose), with 50 grams of sucrose in 200 ml of water.
1691658|NCT01528631|Other|D-Fagomine|0 mg (control) blended with 50 grams of sucrose in 200 ml of water.
1691659|NCT01528618|Drug|gemcitabine and cisplatin|The GP regimen consists of gemcitabine at a dose of 1,000 mg/m2 by intravenous (i.v.) infusion over 30 min on day 1 and day 8, and cisplatin 80 mg/m2 by i.v. infusion for 4 h on day 1 only
1691660|NCT01528618|Drug|5-Fluorouracil and cisplatin|The FP regimen consists of 5-Fluorouracil 1,000 mg/m2/day which was administered as a continuous intravenous infusion for 96 hours after completion of the cisplatin on days 1( 80 mg/m2 i.v. infusion for 4 h)
1691661|NCT01528605|Dietary Supplement|placebo|Placebo, one gelatine capsule containing starch per day, for 96 weeks
1691662|NCT01528605|Dietary Supplement|low lutein|one gelatine capsule containing 10mg lutein per day, for 96 weeks
1691663|NCT01528605|Dietary Supplement|high lutein|one gelatine capsule containing 20mg lutein per day, for 96 weeks
1691664|NCT01528605|Dietary Supplement|lutein plus zeaxanthin|one gelatine capsule containing 10mg lutein and 10mg zeaxanthin per day, for 96 weeks
1691665|NCT01528605|Dietary Supplement|high zeaxanthin|one gelatine capsule containing 10mg zeaxanthin per day, for 48 weeks
1691666|NCT01528605|Dietary Supplement|zeaxanthin plus lutein|one gelatine capsule containing 10 mg lutein and 15 mg zeaxanthin per day, for 48 weeks
1691668|NCT01528579|Other|Neck Specific Exercises|2 times a week for 3 months followed by encourages to continue on their own
1691697|NCT01528345|Drug|Fulvestrant|Fulvestrant (in solution) injected intramuscularly at a dose of 500 mg once on Week 1 Day 1, Week 3 Day 1 and Week 5 Day 1 and subsequently once every 4 weeks on Day 1 of the week.
1691669|NCT01528579|Behavioral|Behavioral approach combined with neck specific exercises|Behavioral physiotherapeutic approach combined with neck specific exercises 2 times a week for 3 months. Exercises will be chosen from a well defined and structured frame of exercises.
1691670|NCT01528579|Other|Prescribed Physical activity|Physical activity without neck specific exercises for 3 months
1691671|NCT01528566|Behavioral|Tai Chi|The experimental group received three sessions of Sun Tai Chi (TC) a week for 20 weeks (20-to-40 minute exercise plus a 5-minute rest per session). Sun TC includes 6 basic and 6 advanced forms designed for all ages with arthritis seeking a joint-safe exercise routine.
1691672|NCT01528566|Behavioral|Attention control|The attention control group participated in health education, culture related activities and other activities for a total of 20 weeks. The attention control protocol was standardized in terms of teaching content, materials and duration. The length and frequency of the activities carried out in this group closely matched those in the TC group.
1691673|NCT01528553|Device|8plate|12 mm or 16 mm plate. 24 mm or 36 mm screw
1691674|NCT01528553|Device|Staples (Richards, Smith & Nephew)|Staples (3 on each side)
1691675|NCT01528540|Drug|Placebo|This group will include placebo.
1691676|NCT01528540|Drug|Antioxidant plus Pregabalin|This group will contain combination of antioxidant cocktail and pregabalin
1691677|NCT01528514|Dietary Supplement|Curcuminoids|Curcuminoids in capsule form, 4 capsules four times daily (4 grams/day)
1691678|NCT01528514|Other|Placebo|Placebo in capsule form, 4 capsules 4 times/day
1691679|NCT01528501|Drug|Panobinostat (LBH589)|
1691680|NCT01528488|Other|EVOZAC Calming Skin Spray|EVOZAC Calming Skin Spray should be sprayed to the skin in the total face, three times per day
1691681|NCT01528488|Other|Physiological saline|Physiological saline was used as the placebo of EVOZAC® Calming Skin Spray and should be also sprayed on the total face, three times per day
1691682|NCT01528475|Behavioral|Pre-hospital cooling|Patients in this arm will receive pre-hospital cooling by paramedics. This treatment includes placement of surface ice-pacs on the neck, groin, and axillae; midazolam to prevent shivering; initiation of an intravenous infusion of cold saline; and wrist and ankle bands with text to remind in-hospital clinicians to continue therapeutic hypothermia.
1691683|NCT01528462|Other|Expedited Treatment of Sleep Disorders|Patients in this arm will undergo an expedited polysomnogram (if clinically necessary) and early treatment of any sleep disorders. Sleep-related disorders will be managed with the currently recommended therapies; patients with obstructive sleep apnea will be treated with positional therapy, continuous positive airway pressure (CPAP), etc., and those with restless legs syndrome will be treated with standard treatments such as iron, or dopaminergic agonists. Patients will also be counselled on improving their sleep hygiene and adjusting the timing of their medication administration to optimize efficacy. Furthermore, patients will receive information handouts.
1691684|NCT01528449|Biological|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
1691685|NCT01528449|Biological|B.microti diagnostic blood tests|the interventions/procedures are investigational diagnostic tests for B.microti (PCR and IFA).
1691686|NCT01528436|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
1691687|NCT01528436|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed.
1691688|NCT01528436|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant should continue to receive rehabilitation therapy at least 3 days per week until the study completion.
1691689|NCT01528423|Procedure|XtremeCT|The scanning protocol for each subject will be as follows: Non-dominant, non-fractured distal radius x 2 with repositioning between scans Non-dominant, non-fractured distal tibia x 2 with repositioning between scans using XtremeCT device and Non-dominant forearm x 2 with repositioning between scans Non-dominant lower leg x 2 with repositioning between scans using standard pQCT device
1691690|NCT01528410|Device|ALFApump removal of ascites|Implanted ALFApump, removing produced ascites according to programmed schedule
1691691|NCT01528410|Procedure|Large volume paracentesis for removal of ascites|Large volume paracentesis - standard of care, removing ascites according to patient need
1691692|NCT01528397|Procedure|pedicled nerve graft|A pedicled nerve graft harvested from the dorsal branch of the PDN can be used for reconstruction of such defects. The graft is based on the second dorsal metacarpal artery.
1691693|NCT01528384|Drug|ADI-PEG 20|4.5, 9 and 18 mg/m2 dosage weekly dosing intramuscular until progressive disease
1691694|NCT01528371|Drug|Midazolam|"Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.
Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.
Investigators take venous line on the upper limb and inject the drug (midazolam at dose of 0.02mg/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.
10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.
Investigators inject an additional sedative agent and the dental treatment is started."
1691695|NCT01528371|Drug|Normal Saline Solution (NSS)|"Investigators select subject from patients for whom the doctor has ordered intravenous sedation. Inclusion criteria is SBP>=140mmHg or DBP>=90mmHg measuring when the patient sits on dental chair and has settled down for 5 minutes. Informed consent is obtained from the patient.
Patient conducts Japanese version of STAI and VAS about anxiety to dental treatment.
Investigators take venous line on the upper limb and inject the drug (saline solution at dose of 0.004ml/kg) intravenously. Investigators measure blood pressure, heart rate, and oxygen saturation every 2 minutes until 10 minutes after drug administration.
10 minutes later, patient conducts Japanese version of STAI and VAS about anxiety to dental procedure again.
Investigators inject an additional sedative agent and the dental treatment is started."
1691696|NCT01528345|Drug|Dovitinib|Active Dovitinib (in tablet form) taken orally at a dose of 500 mg (i.e., 5 x 100mg tablets) on a 5 days on/2 days off dosing schedule
1691877|NCT01526876|Drug|clevidipine butyrate|intravenous infusion dose range 1.0 mg/hr - 32 mg/hr titrate to blood pressure effect duration of infusion: 6 hours
1691699|NCT01528332|Device|Pain Relief Patch|The Pain Relief Patch is a non CE-marked device that is worn on the painful area of the back, where it shines light (453 ± 7 nm, maximum 42 ± 6 mW/cm2 and average 20 ± 1 mW/cm²). It will be used 5 times over 14 days for 30 minutes each time.
1691700|NCT01528332|Device|Control PRP device|The Control PRP device is also a non CE-marked device. It is similar in appearance to the active Pain Relief Patch, except that it shines light of a different wavelength(531 ± 7 nm, maximum 0.4 ± 0.1 mW/cm² and average 0.2 ± 0.05 mW/cm²) for just 5 seconds before it turns off. Participants in the control arm will be treated with the control PRP device 5 times over 14 days for 30 minutes each time.
1691701|NCT01528319|Device|MG-1|Being embedded in the area of glenohumeral instability by arthroscopic Bankart repair method.
1691702|NCT01528306|Biological|HP802-247|"Wounds up to 12 cm2: 1 spray each component (0.5 x 106 cells per mL allogeneic human keratinocytes and fibroblasts) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods
Larger wounds:
(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each"
1691703|NCT01528306|Other|Placebo|"Wounds up to 12 cm2: 1 spray each component (thrombin solution and fibrinogen solution) applied weekly as a topical spray for up to 4 weeks in each of 2 treatment periods
Larger wounds:
(>12 cm2 and ≤ 24 cm2) 2 sprays each; (>24 cm2 and ≤ 36 cm2) 3 sprays each; (>36 cm2 and ≤ 48 cm2) 4 sprays each"
1691704|NCT01528293|Device|ActiVAC System|The ActiV.A.C. System will be applied in a customary manner per manufacturer's recommendations. Acticoat Flex 7™ will be applied as contact layer on the wound surface. Open cell foam is then applied over the top of the Acticoat Flex 7™. Adherent transparent occlusive material will be applied over the open cell foam. The tubing is then attached after cutting a small aperture through the occlusive material. Negative pressure will be set at 125mmHg on continuous suction. Sponge and canister will be replaced 2 time a week.
1691705|NCT01528293|Other|Compression therapy|Compression Therapy Profore™ multi-layered compression bandaging system will be utilized. This includes the application of a contact layer dressing using Acticoat Flex 7™. The compression bandage will be applied per manufacturer's recommendations.
1691706|NCT01528280|Biological|Vaccination against hepatitis A|Vaccination against hepatitis A (2 doses) into the deltoid muscle of the nondominant arm twice, i.e., at 0 and 6 months.
1691707|NCT01528280|Other|No Intervention|No Intervention
1691708|NCT01528267|Other|Autologous blood|50mls of autologous blood injected into each of 3 bronchopulmonary segments.
1691709|NCT01528267|Other|Normal saline|50mls of normal saline injected into each of 3 bronchopulmonary segments.
1691710|NCT01528254|Drug|Placebo to vildagliptin|
1691711|NCT01528254|Drug|vildagliptin|Patients will be instructed to take one tablet (50 mg oral) of vildagliptin in the morning and one tablet in the evening with or without food.
1691712|NCT01528254|Drug|Metformin|Metformin should be taken in a twice daily (bid) regimen during or after meals at the same time as vildagliptin.
1691713|NCT01528241|Drug|ABP688|Carbon 11 labeled ABP688 will be administered intravenously as a slow intravenous push.
1691714|NCT01528228|Device|TENS Treatment with functional or disabled unit|TENS treatment will be standardized and will consist of 20 minute sessions three times per day at the manufacturer's recommended settings for both functional and disabled TENS units.
1691715|NCT01528215|Device|OsseoSpeed EV|OsseoSpeed EV implants; Ø 3.6, 4.2, 4.8 mm in lengths of 9,11 and 13 mm
1691716|NCT01528215|Device|OsseoSpeed TX|OsseoSpeed TX implants; Ø 3.5, 4.0 and 5.0 mm in lengths of 9,11 and 13 mm
1691717|NCT01528202|Dietary Supplement|Cherry juice|30 mLs preceding morning meal and 30 mLs preceding evening meal each day for 7 days.
1691718|NCT01528202|Dietary Supplement|Fruit juice cordial|fruit flavoured juice concentrate
1691719|NCT01528189|Other|Hyperinsulinemic normoglycemic clamp|Patients will receive an IV infusion of 2 mU/kg/min (0.12 U/kg/hour) starting in the operating room. Dextrose 20% will be titrated to maintain blood glucose between 4 and 6 mmol/l. At the end of surgery, the insulin infusion will be stopped and the dextrose infusion weaned off in the postanesthesia care unit.
1691720|NCT01528189|Other|Standard glucose management|Blood glucose levels will be treated by a standard insulin sliding scale.
1691721|NCT01528176|Drug|10,000 IU of cholecalciferol for a total of 8 weeks|Subjects were treated with weekly oral administration of 10,000 IU of cholecalciferol for a total of 8 weeks in order to correct the vitamin D deficiency.
1691722|NCT01528163|Drug|Cabazitaxel|from 20 mg/m2 to 25 mg/m2. Intravenous injection every three weeks.
1691723|NCT01528163|Drug|Methotrexate|From 40 mg/m2 (first cycle) to 50 mg/m2. Intravenous injections every three weeks.
1691724|NCT01528137|Biological|talactoferrin|Given PO
1691725|NCT01528137|Other|laboratory biomarker analysis|Correlative studies
1691728|NCT01528111|Drug|LX7101 (0.125%)|Subjects will receive 0.125% LX7101
1691729|NCT01528111|Drug|LX7101 (0.25%)|Subjects will receive 0.25% LX7101
1691730|NCT01528111|Drug|LX7101 Vehicle|Subjects will receive vehicle
1691731|NCT01528085|Drug|Nilotinib|Nilotinib, p.o Chemotherapy (Dexamethasone, Methotroxate, Cyclophosphamide (optional), Vincristine, Vindesine, Cytarabine, 6-Mercapto-Purine)
1691732|NCT01528072|Device|Dynesys Spinal System|Dynesys Spinal System will be used for all subjects
1691733|NCT01528059|Procedure|Stomach-small intestine reconstruction|Billroth II or Roux en Y reconstruction will be performed after gastric resection in stomach patients co-morbid with type 2 diabetes
1691734|NCT01528046|Drug|Vincristine|Vincristine (VCR) = 1.5 mg/m^2/day (maximum dose 2 mg), days 1 and 8, administered as intravenous (IV) bolus over 1-5 minutes
1691735|NCT01528046|Drug|Irinotecan|Irinotecan (IRN) = 50 mg/m^2/day, days 1-5, IV over 60 minutes
1691736|NCT01528046|Drug|Temozolomide|Temozolomide (TEM) = 50 mg/m^2/day by mouth (PO) Days 1-5
1691737|NCT01528046|Drug|Metformin|Metformin (MET) = dose as per dose escalation, divided twice a day (BID), PO continuously for the 21 day cycle.
1691799|NCT01527487|Drug|Cyclophosphamide|Cyclophosphamide will be given as an IV infusion (600 mg/m2) on Day 1 of each treatment cycle over approximately 30 minutes, or per institutional standard.
1691800|NCT01527487|Drug|Docetaxel|Patients assigned to Treatment Arm 2 will receive docetaxel 75 mg/m2 IV on Day 1 of each treatment cycle every 3 weeks.
1746293|NCT00154362|Drug|Oxcarbazepine|
1691738|NCT01528033|Device|Vacuum Assisted Closure®|"Vacuum Assisted Closure® (V.A.C.®) Therapy within a maximum study treatment time of 42 days.
VAC® Therapy Systems used within the trial are ActiV.A.C.®, InfoV.A.C.®, V.A.C. Freedom®, V.A.C. Via® and VAC Ulta®. All used systems are equally eligible for the treatment of subcutaneous abdominal wounds and should be used according to availability and local preferences within the trial site.
Systems differ regarding user surface and display and processing of data. For the treatment of subcutaneous abdominal wounds the V.A.C.® Granufoam Dressing (size medium and big) is recommended."
1691739|NCT01528033|Other|Standard conventional wound therapy|Standard conventional wound therapy (SCWT) according to institutional clinical standards within a maximum study treatment time of 42 days
1691740|NCT01528020|Behavioral|Dialectical Behavior Therapy|DBT is a cognitive behavioral approach to treatment that synthesizes change based strategies characteristic of behavior therapy and validation strategies consistent with acceptance based treatments through application of dialectical principles and techniques. Based on a combined capability deficit and motivational model which states that 1) adolescents with suicidal behaviors and borderline features lack important interpersonal, self-regulation and distress tolerance skills, and 2) personal and environmental factors often both block and/or inhibit use of behavioral skills that adolescents do have, and at times reinforce dysfunctional behaviors. The primary adaptation for adolescents is the inclusion of family in the DBT skills training portion of therapy as well as a much greater inclusion of parents in the management of high suicide risk.
1691741|NCT01528020|Behavioral|Individual and Group Supportive Therapy|The aim of IGST is relief or reduction of symptoms, the promotion of personal growth including enhancement of adolescents' strengths/coping skills and capacity to use environmental supports and to help suicidal adolescents increase their sense of self-esteem. Treatment aims to reduce suicidal behavior and emotion dysregulation by helping the adolescent learn to trust and validate themselves. The overarching assumption in IGST is that adolescents become suicidal for a variety of reasons, but they often report feeling isolated, misunderstood, unloved and unwanted. IGST Interventions include providing a strong therapeutic alliance where the therapist provides an environment that is completely trusting and validating to counter the experience of the depressed/suicidal youth.
1691742|NCT01528007|Drug|Naltrexone pharmacotherapy|Naltrexone 50mg when graving to gamble.
1691743|NCT01528007|Drug|Placebo|Placebo pill with no active ingredients.
1691744|NCT01527994|Drug|Aprepitant|Aprepitant 125 mg oral tablets
1691745|NCT01527994|Drug|Placebo pill|Placebo oral pill- inactive compound
1691746|NCT01527981|Behavioral|Cognitive behavioral therapy for adherence and depression|Cognitive-behavioral therapy for adherence and depression (CBT-AD) is a weekly, psychosocial treatment focusing on depression and patients' adherence to diabetes self-care. Treatment consists of weekly one-hour sessions for approximately 10 sessions.
1691747|NCT01527968|Drug|Tranexamic Acid|TXA as 10mg/kg x 1 dose in 100mL normal saline over 15 minutes prior to the procedure then an infusion of 1mg/kg/hr during the procedure + placebo (normal saline as the dummy for eACA.)
1691748|NCT01527968|Drug|Epsilon Aminocaproic Acid|eACA as 150mg/kg in 250mL of IV normal saline over 15 minutes prior to the procedure then an infusion of 15mg/kg/hr during the procedure + placebo (normal saline as the dummy for TXA).
1691749|NCT01527968|Drug|Normal Saline|Control Normal Saline x 2 infusions as the double dummy for TXA and eACA.
1691750|NCT01527955|Other|Kelee Meditation|The participants were instructed on how to perform Kelee Meditation (KM) at the initial session. This was followed by a comprehensive review of the Kelee principles and reference points over the subsequent 12 weeks. At the beginning of each weekly session, a group meditation was performed, which was followed by individual introspection and contemplation. Participants recorded their observations and experiences in a KM journal. Each participant had the opportunity to share his own journal entry and to ask questions about his own observations and experiences since starting KM. Participants were encouraged to perform the KM practice 10 minutes twice daily throughout the 12 weeks of the study.
1691751|NCT01527942|Drug|Acetaminophen|Intravenous Acetaminophen 1,000 mg IV
1691752|NCT01527942|Drug|Placebo|Placebo - IV administration 0.9% 100 ml Sodium Chloride (NaCl)
1691753|NCT01527929|Drug|Cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
1691754|NCT01527916|Drug|placebo|Placebo Comparator
1691755|NCT01527916|Drug|donepezil|Active Comparator
1691756|NCT01527916|Drug|ABT-126|low dose, middle dose, high dose
1691757|NCT01527903|Drug|Propofol infusion|IV propofol 2% at a rate of 1.0 mg kg-1 h-1, increments or decrements of 0.1 mg kg-1 h-1
1691758|NCT01527903|Drug|Midazolam infusion|midazolam at a rate of 0.1 mg kg-1 h-1, increments or decrements of 0.05 mg kg-1 h-1
1691759|NCT01527890|Drug|Fentanyl|intravenous patient-controlled analgesia
1691760|NCT01527877|Drug|BKM120|"Patients will be instructed to take BKM120 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day. The patient will be dosed on a flat scale of mg/day and not be adjusted to body weight or body surface area. If vomiting occurs no attempt should be made to replace the dose.
• BKM120 should be taken 1-hour following a light meal. Please note that patients must avoid consumption of Seville orange (and juice), grapefruit or grapefruit juice, grapefruit hybrids, pummelos and exotic citrus fruits from 7 days prior to the first dose of study drug and during the entire study treatment period due to potential CYP3A4 interaction. Regular orange juice is allowed."
1691761|NCT01527864|Drug|pegylated endostatin and Paclitaxel-Carboplatin|Dosage：10mg/m2
1691762|NCT01527864|Drug|Placebo and Paclitaxel-Carboplatin|Dosage：10mg/m2
1691763|NCT01527838|Biological|Single FT1050 treated UCB unit|Ex-vivo CXCR4 upregulated hematopoietic progenitor cells, cord blood
1691764|NCT01527825|Biological|Trivalent influenza vaccine (seasonal)|"Single 0.5ml dose of Southern hemisphere 2012 TIV, formulation containing:
An A/California/7/2009 (H1N1)pdm-like virus
An A/Perth/16/2009 (H3N2)-like virus*
A B/Brisbane/60/2008-like virus * A/Wisconsin/15/2009 and A/Victoria/210/2009 are A/Perth/16/2009-like viruses for use in the 2012 Southern Hemisphere winter. This vaccine is the same as the vaccine used for the 2011 Southern hemisphere influenza season."
1691765|NCT01527825|Biological|Normal saline|0.5ml normal saline will be used as 'placebo' vaccine to maintain blinding
1691801|NCT01527474|Drug|escitalopram|participants will be initiated at a dose of 10mg/day which will be adjusted by the study clinician based on the presences of depressive symptoms and side effects up to a maximum of 20mg/day.
1691766|NCT01527812|Procedure|Femoral nerve block|We will perform an ultrasound guided femoral nerve block. For locating the nerve a 5 cm, 6-13 MHz linear probe (Sonosite Turbo M, Bothwell WA, USA) will be used. After the examination of the anatomy of the femoral artery we will fix the probe transversal to the thigh below the inguinal crease and above the ramification of deep femoral artery and make skin marks on this position. A 22 G 50 mm long Stimuplex BBraun needle will be used. 15 ml 2 % lignocaine will be injected.
1691767|NCT01527786|Drug|Desvenlafaxine|50mg-100mg everyday for 12 weeks over 7 study visits
1691768|NCT01527760|Drug|Viscum album ethanolic extract manufactured according to Homoeopathic pharmacopoeia of India (H.P.I.)|Ten drops of Drug in 30 ml of distilled water with a frequency of three times a day for a duration of 12 weeks
1691769|NCT01527747|Drug|Saxagliptin|5 mg daily
1691770|NCT01527734|Drug|Tetrodotoxin|15ug and 30ug once or twice a day for 1 or 2 days.
1691771|NCT01527734|Drug|placebo|1ml once or twice a day for 1 or 2 days.
1691772|NCT01527721|Procedure|Corneal Collagen Cross-Linking (CxL)|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. The UVA radiation source was UV-XTM Zurich, . Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well, in order to sustain the necessary concentration of the riboflavin. Moreover, balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
1691773|NCT01527721|Procedure|Corneal Collagen Cross-Linking combined with t-PRK|For tCxL group, the topo-guided PRK preceded the CXL. The epithelium was mechanically removed with a hockey knife and ablation was performed in a 9.0 mm zone with a maximal intended ablation depth of 50μm. No adjuvant Mitomycin-C was applied in any case. For the photorefractive ablation we used the Allegretto Wave 200 Hz (1.0071-1-0.81/1.208 software/ WaveLight AG, Erlangen, Germany) with the T-CAT ablation profile.
1691774|NCT01527708|Procedure|Corneal Collagen Cross-linking (CXL)|Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well.
1691775|NCT01527695|Drug|ER tablet 25 mg AZD3241|2 tablets twice daily for Day 1
1691776|NCT01527695|Drug|ER tablet 100 mg AZD3241|1-6 tablets twice daily from Day 2 until Day 56±3 days
1691777|NCT01527695|Drug|Placebo for AZD3241 25 mg|2 tablets twice daily for Day 1
1691778|NCT01527695|Drug|Placebo for AZD3241 100 mg|1-6 tablets twice daily from Day 2 until Day 56±3 days
1691779|NCT01527682|Drug|Latanoprost, Dorzolamide|"Latanoprost 0.005% ophthalmic solution given once a day at nighttime (9.00 PM)
Dorzolamide 2% ophthalmic solution given three times a day as a monotherapy, two times a day if in combination with latanoprost"
1691780|NCT01527669|Drug|LipoCol Forte capsules|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
1691781|NCT01527669|Drug|Lovastatin Tablet|The pharmacokinetic study of red yeast rice capsule compared to lovastatin tablet in healthy subjects.
1691782|NCT01527656|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
1691783|NCT01527643|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin) on two separate dosing visits. A wash-out period of 6-12 days will take place between dosing visits
1691784|NCT01527630|Drug|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-21days
1691785|NCT01527617|Other|Cranberry|beverage containing cranberry at a dose of 15.2 ounces per day for 56 days.
1691786|NCT01527617|Other|Non-Cranberry beverage|Placebo Comparator - beverage absent cranberry at a dose of 15.2 ounces per day for 56 days.
1691787|NCT01527604|Other|Avenanthramide-enriched oats|avenanthramide-enriched oats, delivered as muffins at a dose of 2 muffins per day for 56 days.
1691788|NCT01527604|Other|Refined flour absent avenanthramides|refined flour absent avenanthramides, delivered as muffins at a dose of 2 muffins per day for 56 days.
1691789|NCT01527591|Biological|Pneumococcal Conjugate Vaccine 13 (PCV13)|A single intramuscular dose of 0.5 mL.
1691790|NCT01527565|Drug|biphasic insulin aspart 70|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
1691791|NCT01527552|Drug|biphasic insulin aspart 50|A single dose of each formulation administered subcutaneously (s.c., under the skin) on 2 dosing visits separated by a wash-out period of 6-12 days
1691792|NCT01527539|Drug|biphasic insulin aspart 30|Dose individually adjusted. Injected twice daily immediately before breakfast and dinner. Administrated subcutaneously (s.c., under the skin)
1691793|NCT01527513|Drug|Eslicarbazepine acetate (BIA 2-093)|Eslicarbazepine acetate (ESL) tablets 200 mg and the matching placebo will be supplied. Treatments will be administered by oral route, once-daily, in the evening. The dose will be rounded to the nearest 100 mg unit. Half tablets may be used for dose adjustment if necessary.
1691794|NCT01527513|Drug|Placebo|Treatments will be administered by oral route, once-daily, in the evening.
1691798|NCT01527487|Drug|Eribulin|1.4 mg/m2 IV (Days 1 & 8), given short (≤15 minute) IV infusion, per institutional standard
1691875|NCT01526889|Drug|LFG316|LFG316 administered intravitreally (IVT)
1691802|NCT01527448|Drug|Quetiapine XR (seroquel)|During the study period, subjects will be receiving a treatment with Quetiapine XR. The starting dose of quetiapine that subjects will receive is 50mg. The response to the treatment of quetiapine will determine whether the study doctor will increase the dosage of the subject's quetiapine. If the study doctor increases the quetiapine during the study, the maximum dosage allowable during the study is 300mg.
1691803|NCT01527422|Drug|Cyclophosphamide, Doxorubicin, Vincristine and Prednisone|Rituximab will be administered on day 1 of courses 1-6 at 375 mg/m2 concurrently with CHOP-R.All patients will receive antiemetics priorchemotherapy.Courses will be repeated every 14 days.If blood counts don't allow re-treatment on day 14 the counts will be repeated at least twice per week until recovery allows re-treatment.The aim is to achieve a dose that will be as close as possible to 250 mcg and that will result in grade 0 or grade 1A or 1B toxicity at the most. The dose of PEG-Filgrastim will initially be fixed at 3 mg until dose level +3 is reached (which includes 250 mcg Leukine) at which time the dose of Neulasta will be escalated if necessary. All patients will receive Neulasta as a subcutaneous injection on the day 3.
1691804|NCT01527409|Behavioral|Tailored health partnership program|"When intervention group participate in the tailored program, they can receive various information which is related with three strategic areas (exercise, diet, and posttraumatic growth).
Three areas are based on the transtheoretical model (TTM), social cognitive theory, PRECEDE-PROCEED model, and Health behavior model.
Patients will be received tailored manual and workbook for health tele-coaching that help them to lead their healthy life.
The health tele-coaching will be operated sixteen times for 24 weeks. Intervention group will be provided three contents (exercise, diet, and posttraumatic growth) from health partners. The health partners took a certificate that is related with health, leadership and coaching.
Also, patients will be provided a workshop for leadership that is dealt with controlling their healthy life. It will be proceeded for four hours. Three hours is for the leadership, and the last one hour is for presentation of their health mission statement."
1691805|NCT01527409|Behavioral|Usual care and health education workshop|"While intervention group participate in the tailored health partnership program, control group can receive various information which is related with ten contents for health management (smoke and drinking, diet, exercise, posttraumatic growth, distress, pain, comorbidity, sleep disturbance, pain, and energy conservation). They will be provided a workshop and booklet for a health education for four hours.
Twelve month later, they will be provided the tailored health partnership program which is especially dealing with exercise, diet, and posttraumatic growth as same as the intervention group."
1691806|NCT01527383|Biological|V212|V212 viral antigen for Herpes Zoster (HZ), 0.5 mL subcutaneous injection per dose, in a 4-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
1691807|NCT01527383|Biological|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL subcutaneous per dose, in a 4-dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
1691808|NCT01527370|Biological|Zoster Vaccine Live|One approximately 0.65 mL injection subcutaneously on Day 1
1691809|NCT01527357|Biological|Fibrocaps (PRO-0601)|Human fibrinogen and thrombin powder Single application during surgery
1691810|NCT01527357|Device|Gelatin sponge|Single application during surgery
1691811|NCT01527331|Behavioral|video decision aid|cpr video decision aid
1691812|NCT01527318|Drug|Fibrate treatment|Patients will receive a dosage of 400mg Bezafibrate every day during 28 weeks
1691813|NCT01527305|Drug|Paliperidone palmitate|Participants will receive 1 intramuscular (into muscle) injection of 150 milligram (mg) on Day 1 and 1 injection of 100 mg on Day 8. Participants will also receive the last 2 paliperidone intramuscular injections between 50 - 150 mg (based on effectiveness and safety profile), on Day 36 and Day 64.
1691814|NCT01527292|Radiation|Stereotactic Radiation Therapy|SRT only
1691815|NCT01527292|Radiation|SRT with Vertebral Augmentation Procedure|SRT with VAP
1691816|NCT01527279|Drug|antazoline|Patients assigned to antazoline group will be administered antazoline in boluses of 50mg diluted to 10cm3 every 5 minutes up to cumulative dose of 250mg or conversion of AF to SN. Drug administration will also be stopped in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
1691817|NCT01527279|Drug|0.9% saline|Patients assigned to control group will be administered 0.9% saline in boluses of 10cm3 every 5 minutes up to cumulative volume of 50cm3, conversion of AF to SN or in case of serious adverse event or conversion of AF to different supraventricular arrhythmia. BP will be measured before every injection.
1691818|NCT01527266|Dietary Supplement|Carbohydrate drink|sucrose beverage
1691819|NCT01527266|Dietary Supplement|Placebo mouth rinse|placebo; non-caloric sweetened beverage for use as a mouth rinse
1691820|NCT01527253|Other|Synergistic food basket|A low glycemic index diet enriched in dried legumes and wholegrain cereals is compared with a control regime lacking these functional ingredients for their ability to ameliorate different markers associated with the risk for developing cardiometabolic disease
1691821|NCT01527240|Drug|Ciclosprin A|The dose in this study was 2 mg / kg, administered within 15 min after beginning of thrombolysis. The treatment of the study consists of a single bolus injection. This dose was chosen according to the results of tolerance in myocardial infarction and unknown pharmacodynamic and safety data
1691822|NCT01527240|Drug|Injectable Saline Solution.|Saline Solution is administered once 15 min after thrombolysis.
1691823|NCT01527227|Other|questionnaires|The research will examine effects of personal, familial, societal and intergenerational characteristics on parentification, the effects of parentification on the quality of life of the child and what encourages a better quality of life.
1691824|NCT01527214|Radiation|CT scan and education|GPs get direct access to chest CT scans for their patients. The GPs will be offered special training related to the diagnosis of lung cancer in general practice.This will be done by offering training sessions and written material. The training will include risk groups, alarm symptoms, symptom complexes and interpretation of CT scan descriptions.
1691825|NCT01527201|Procedure|Arthroscopic debridement|Surgeon will debride, or remove, worn out cartilage.
1691826|NCT01527188|Biological|100IR|100IR sublingual tablet of
1691827|NCT01527188|Biological|300IR|300IR sublingual tablets of
1691828|NCT01527188|Biological|500IR|500IR sublingual tablet of
1691829|NCT01527188|Other|Placebo|Placebo sublingual tablet of
1691830|NCT01527175|Other|Approach for ultrasound-guided subclavian venous catheterization|Each SCV catheterization was performed under ultrasound-guidance with supraclvicular or infraclavicular approach.
1691831|NCT01527162|Device|SAFO worn|Child wears their prescribed SAFO for 14 days by random assignment
1691832|NCT01527162|Other|SAFO not worn|Child does not wear their prescirbed SAFO for 14 days by random assignment
1691833|NCT01527149|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous HDC-ASCT
1691834|NCT01527149|Drug|Cyclophosphamide|Given IV
1691835|NCT01527149|Drug|Cytarabine|Given IV
1691836|NCT01527149|Drug|Dexamethasone|Given IV or PO
1691837|NCT01527149|Drug|Doxorubicin Hydrochloride|Given IV
1691838|NCT01527149|Other|Laboratory Biomarker Analysis|Correlative studies
1691839|NCT01527149|Drug|Methotrexate|Given IV
1691840|NCT01527149|Biological|Ofatumumab|Given IV
1691841|NCT01527149|Drug|Vincristine Sulfate|Given IV
1691842|NCT01527136|Drug|entolimod|Given IM or SC
1691843|NCT01527136|Other|pharmacological study|Correlative studies
1691844|NCT01527136|Other|laboratory biomarker analysis|Correlative studies
1691845|NCT01527123|Drug|GSK2585823|CLDM1%/BPO3%
1955671|NCT03114527|Drug|Ribociclib|Orally bioavailable, highly selective small molecule inhibitor of CDK4/6
1691847|NCT01527097|Drug|Atorvastatin|Drug: Atorvastatin 80 mg for 6 months following by 40 mg for additional 6 months once daily.
1691848|NCT01527097|Drug|Atorvastatin placebo|Atorvastatin 80mg during 6 month and 40mg in additional 6 month period once daily.
1691849|NCT01527084|Procedure|surgical intervention after percutaneous catheter drainage|Patients who are not improving by day 10 after PCD insertion will be included in the present study and are randomized to group A (early surgery i.e. between 10-15days after PCD insertion ) or group B (Extended treatment with PCD with saline irrigation for more than 15days after PCD insertion)
1691850|NCT01527058|Drug|68Ga-BNOTA-PRGD2|"Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors
Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs"
1691851|NCT01527045|Drug|Atorvastatin Calcium|Given PO
1691852|NCT01527045|Drug|Cyclosporine|Given PO
1691853|NCT01527045|Drug|Fludarabine Phosphate|Given IV
1691854|NCT01527045|Other|Laboratory Biomarker Analysis|Correlative studies
1691855|NCT01527045|Drug|Mycophenolate Mofetil|Given PO or IV
1691856|NCT01527045|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
1691857|NCT01527045|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
1691858|NCT01527045|Radiation|Total-Body Irradiation|Undergo TBI
1691859|NCT01527032|Drug|melphalan, thalidomide and dexamethasone|
1691860|NCT01527019|Drug|Norfloxacin|Norfloxacin Pills, 400 mg twice daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
1691861|NCT01527019|Drug|Cephalosporins|Cephalosporins Caps, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
1691862|NCT01527019|Drug|Cephalosporins|Cephalosporins Oral Suspension, 400 mg once daily. Treatment time will range according to sex and age (male and elderly subjects will receive 7 days of treatment, while female subjects who are 18-59 years old will receive 3 days of treatment)
1691863|NCT01527006|Drug|perampanel|During the titration period, participants started at a set daily dose of 0.015 mg/kg and had doses up-titrated at 1-week intervals (6 titration steps) to a maximum daily dose of 0.18 mg/kg. During the Maintenance Period, participants continued taking perampanel oral suspension once daily at the dose level they achieved at the end of the Titration Period. During the extension phase, participants continued taking perampanel oral suspension once daily, at the dose level achieved at the end of the treatment phase of the core study to a maximum daily dose of 0.18 mg/kg. The maximum total daily dose a participant was allowed was 12 mg.
1691864|NCT01526980|Drug|biphasic insulin aspart 30|Administrated subcutaneously (s.c., under the skin) once daily before dinner for 30 days in each treatment period
1691865|NCT01526980|Drug|biphasic insulin aspart 70|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and lunch for 30 days in each treatment period
1691866|NCT01526980|Drug|biphasic human insulin 30|Administrated subcutaneously (s.c., under the skin) twice daily before breakfast and dinner for 30 days in each treatment period
1691867|NCT01526954|Device|TissuGlu Surgical Adhesive|TissuGlu Surgical Adhesive to be used prior to closure of the large tissue flap in abdominoplasty cases.
1691868|NCT01526941|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
1691869|NCT01526941|Drug|biphasic insulin aspart 70|Dose individually adjusted. Administered subcutaneously (s.c., under the skin) three times a day for 1 week in each treatment period. A wash-out period of 2-6 weeks will take place between treatment periods
1691870|NCT01526928|Drug|Rociletinib|"Phase 1: Rociletinib will be administered in escalating dosages in a period of 21-day cycles
Phase 2: Rociletinib will be administered daily"
1691871|NCT01526915|Procedure|Bone curettage + PRF|Bone curettage and PRF insertion
1691872|NCT01526915|Procedure|Bone curettage alone|Bone curettage without PRF insertion
1691873|NCT01526902|Device|omafilcon A / PC 1-D MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses.
1691874|NCT01526902|Device|lotrafilcon B / Air Optix MF|Subjects were randomly assigned into either the omafilcon A/PC 1-D MF lenses with +0.75D over-correction in the non-dominant eye or the lotrafilcon B/Air Optix MF lenses then crossed-over into the alternative pair of study lenses
1691879|NCT01526850|Biological|Biological: mesenchymal stem cell|Mesenchymal stem cells, 1-2×107, bone marrow injection, once a week for the first four weeks; whether to continue after four weeks depends on patients' symptoms.
1691880|NCT01526850|Drug|Cyclosporine and Glucocorticoid|Calmodulin inhibitors such as cyclosporine, combined with Glucocorticoid 0.5-1mg/kg/d ,to the end of the study.
1691881|NCT01526837|Drug|Avastin|Topical Avastin plus Collagen Sponge placed in surgical cavity after resection of recurrent brain tumor. Dosing range: 0.25 mg/ml - 25 mg/ml.
1691882|NCT01526824|Dietary Supplement|omega-3 polyunsaturated fatty acids (Lovaza)|Lovaza, 1 gram orally daily
1691883|NCT01526811|Device|Endurant Stent graft|Endurant Stent graft implantation
1691884|NCT01526798|Device|Theralite (high cut-off hemodialysis)|Hemodialysis with Theralite dialyzer alternating with standard high-flux dialyzer
1691885|NCT01526798|Device|Conventional high-flux dialyzer|
1691886|NCT01526785|Drug|Alglucosidase alfa|4000 L alglucosidase alfa administered by IV infusion at the same dose and dose regimen used for the patient's routine treatment prior to the study for 52 weeks.
1691887|NCT01526772|Procedure|Endoscopy|Transoral endoscopy versus transoral endoscopy
1691888|NCT01526759|Dietary Supplement|LM pectin (10%)|15 days 1 daily consumption of a drink with 10g pectin added
1691889|NCT01526759|Dietary Supplement|gelatin|15 days 1 daily consumption of a drink with 10g gelatin added
1691890|NCT01526746|Drug|Tasimelteon|20mg capsule, once
1691891|NCT01526746|Drug|Tasimelteon|20mg, once
1691892|NCT01526733|Drug|Sham Injection|
1691893|NCT01526733|Drug|Recombinant human hyaluronidase PH20|
1691894|NCT01526733|Drug|Insulin aspart|
1691895|NCT01526733|Drug|Insulin lispro|
1691896|NCT01526707|Drug|inhaled steroid|inhaled budesonide for 7 days
1691897|NCT01526694|Drug|Bendamustine + Dexamethasone + Thalidomide|Bendamustine + Dexamethasone + Thalidomide in patients with multiple myeloma (MM) patients after treatment with lenalidomide and bortezomib or which are ineligible to one of these drugs.
1691898|NCT01526681|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve tissue scaffold at the time of surgery
1691899|NCT01526681|Other|Standard Treatment, Autogenous Nerve Graft, Direct Suture, etc.|Historical Control from Established Literature
1691900|NCT01526668|Behavioral|Follow-up strategy|Comparison of different follow-up strategies
1691901|NCT01526668|Behavioral|No contact after discharge|
1691902|NCT01526655|Procedure|Abdominal total hysterectomy|Abdominal total hysterectomy through a low transverse abdominal wall incision
1691903|NCT01526655|Procedure|Robot assisted laparoscopic hysterectomy|Robot assisted laparoscopic total hysterectomy
1691904|NCT01526642|Device|Non Invasive Ventilation|NIV during night
1691905|NCT01526616|Drug|Metformin|Metformin 850 mg twice a day for six months
1691906|NCT01526616|Drug|Metformin plus Spironolactone|Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
1691914|NCT01526590|Drug|Definity Contrast|While the patient is still sedated from their EUS and before tissue sampling, the patient will receive a dose of Definity intravenously through their peripheral IV access after being agitated. The dose of Definity will be 10 microliters/kg given in one to two doses, and will not exceed 2cc.
1955672|NCT03114527|Drug|Everolimus|mTOR inhibitor
1691918|NCT01526564|Drug|Acetylcarnitine|Administration of enteric-coated tablets with warm water at half an hour after meals, 1g (2 tablets) each time, 3 times a day, and the interval at or >4 hours for 8 weeks
1691919|NCT01526564|Drug|Placebo|3 t.i.d, two plates per time
1691920|NCT01526551|Other|HPV Vaccine and HPV-related Health Education|Increased education of HPV-related diseases and HPV vaccine
1691921|NCT01526551|Other|Reduction of barriers|Eliminate structural and financial barriers to being vaccinated
1691922|NCT01526538|Drug|d-cycloserine|50 mg d-cycloserine
1691923|NCT01526538|Drug|sugar pill|placebo
1692079|NCT01525615|Drug|tiotropium + olodaterol (high dose)|5 µg tiotropium + 5 µg olodaterol
1691924|NCT01526525|Drug|Tramadol|Tramadol 1.5mg/kg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of tramadol 0.15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®)
1691925|NCT01526525|Drug|Ketamine|ketamine 10mg bolus IV 30min before the end of the surgery and co instantaneously the CIV infusion of ketamine, in subanesthetic doses, 0,15mg/kg/h started with continuous infusion in an adjustable flow disposable pump (paragon®). Ketamine's dose was altered so as not to exceed the 300mg/24h.
1691926|NCT01526525|Drug|Tramadol|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients.The aim was that the Tramadol 24h dose would not exceed 600mg
1691927|NCT01526525|Drug|Morphine|If NRS scale was ≥3, PPI scale ≥2 and the algometer count ≤0,5Kg it was assumed as a non acceptable pain treatment. Tramadol 50mg IV bolus was firstly administered to the patients and if the NRS scale was not decreased at least about 2 points after 30 minutes, morphine 2mg IV was then administered and it could be repeated
1691928|NCT01526525|Procedure|sedation|If the patient had sedation score >2 then the analgesic infusion would be stopped, the patient would be assessed again in 1 hour and the infusion would start with the same or decreased flow.
1691929|NCT01526525|Procedure|rescue analgesia|Meanwhile - 45min,2h,6h,12h and 24h- if the patients had acute pain, the physician would call the anesthesiologist and a new assessment would take place with the relative interventions.
1691930|NCT01526525|Drug|Parecoxib|An hour before the end of the surgery all patients were administered with parecoxib 40mg (IV)
1691931|NCT01526525|Drug|paracetamol|30min before the end of the surgery paracetamol 20mg/kg (IV).
1691932|NCT01526512|Drug|metroCX|cyclophosphamide 50mg PO d1-28 capecitabine 1500mg PO d1-28; every 28days
1691933|NCT01526499|Drug|Docetaxel and Cyclophosphamide (TC)|Docetaxel 75mg/m2 IVGTT D1 Cyclophosphamide 50mg PO D1-21;every 21days
1691934|NCT01526499|Drug|Docetaxel (T)|Docetaxel 75mg/m2 IVGTT D1;every 21days
1691935|NCT01526486|Procedure|Videoscopic procedure|Minimally invasive, three port approach, (using a laparoscope to perform a procedure previously performed through open surgery).
1691936|NCT01526486|Procedure|Open, traditional approach|Open surgical procedure, with sartorius muscle transfer.
1691937|NCT01526473|Biological|AVX901|Dosing will consist of AVX901 at 4 x 10E8 IU intramuscularly, given every 2 weeks for a total of three doses.
1691938|NCT01526460|Drug|Atorvastatin|80 mg
1691939|NCT01526460|Drug|Rosuvastatin|40 mg
1691940|NCT01526460|Drug|Placebo|no statin loading dose
1691941|NCT01526447|Procedure|Craniosacral Therapy|Standardized therapy protocol (according to Upledger): Still point technique, diaphragm release, compression-decompression and lift techniques of the cranial bones, facial balancing in the region of shoulder and pelvis and somato-emotional unwinding
1691942|NCT01526447|Procedure|Sham Craniosacral Therapy|Standardized sham protocol: Placing hands on various parts of the clothed body for two minutes each time without therapeutic intention
1691943|NCT01526421|Other|monetary reinforcer|Participants randomized to the reinforcer arm will receive gift cards at the completion of screening procedures.
1691944|NCT01526408|Drug|Famciclovir|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months on drug).
1691945|NCT01526408|Drug|Placebo|Patients will be instructed to take 6 250mg pills orally for the first 7 days (Week 1: 2 pills every 8 hours or three times per day) at home. Patients will take a maintenance dose of one 250 mg pill twice a day for 77 days (11 weeks, total 3 months).
1691946|NCT01526395|Drug|Propofol|"The major intervention proposed in this study is the introduction of low dose IV propofol for sedation prior to ECT treatment at C.S.M Medical University. The investigators will use a dose of 0.25 to 0.50 mg/kg of IV propofol. The maximum dose of 0.50 mg/kg is not sufficient for anesthesia (i.e., to make unconscious), but should provide a light level of sedation and be amnestic, meaning the patient should have memory loss for the period of time around the ECT procedure itself. The propofol dose will be titrated upwards (from an initial dose of 0.25 mg/kg) with successive treatments in increments of 0.05mg/kg, until it is just sufficient to be lightly sedating. ECT will be administered 30 to 60 seconds after propofol is injected. ECT may be given up to three times per week."
1691947|NCT01526382|Device|PiCCO monitoring (PULSION)|Patients are monitored with PiCCO system.
1691948|NCT01526382|Procedure|central venous catheter|patients in this arm can receive central venous catheter
1691949|NCT01526369|Drug|Trastuzumab|
1691950|NCT01526369|Drug|Paclitaxel|
1691951|NCT01526369|Drug|Lapatinib|
1691952|NCT01526356|Drug|Placebo|Study cream is applied nightly to the affected areas on the face.
1691953|NCT01526356|Drug|Rapamycin|Study cream is applied nightly to the affected areas on the face. Low Dose
1691954|NCT01526356|Drug|Rapamycin|Study cream is applied nightly to the affected areas on the face. High Dose
1691955|NCT01526343|Device|Reveal XT implantation|The implantation of the Reveal XT device will be performed at the time of surgery before the planned median sternotomy or thoracotomy.
1691956|NCT01526330|Drug|YH14618|A mg/disc
1691957|NCT01526330|Drug|YH14618|B mg/disc
1691958|NCT01526330|Drug|YH14618|C mg/disc
1691959|NCT01526330|Drug|Placebo|0mg/disc
1691960|NCT01526317|Drug|Crestor 10mg(Rosuvastatin 10mg), Glucodown OR SR 750mg(Metformin SR 750mg)|For co-administration,Crestor 1 tablet and Glucodown 1 tablet a day for 5 day.(1 period) For separate administration, Crestor 1 tablet a day for 5 day and Glucodown 1 tablet a day for 5 day.
1691961|NCT01526304|Other|no intervention|No intervention, only observational study
1691962|NCT01526278|Drug|Maxmarvil®|Drug : Maxmarvil® 1tablet one time in clinical trial, PO medication
1691963|NCT01526265|Behavioral|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days, 30 days, 6 months, and 12 months (among those eligible).
1691964|NCT01526265|Behavioral|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
1692080|NCT01525615|Device|Respimat inhaler|Respimat inhaler
1746746|NCT00152750|Drug|APO-clonidine|
1691965|NCT01526265|Behavioral|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. As a motivation to quit smoking, the participant's deposit will be matched by the study investigators in a rate of 3:1.
1691966|NCT01526265|Behavioral|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, which will be matched on a rate of 3:1 by the study investigators (M), and the payout for quitting on this arm will be (Y+M) x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
1691967|NCT01526265|Behavioral|Collaborative Rewards|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. If participants quit smoking by their target quit date, and that is confirmed by cotinine or anabasine tests, they will receive a monetary award from the study investigators. On top of that, participants will receive an additional monetary amount for each member of their group who also quits smoking. These participants will interact through a chat room, which will help motivate them to quit smoking."
1691968|NCT01526239|Other|Colorectal cancer screening pamphlet|Colorectal cancer screening pamphlet
1691969|NCT01526226|Device|Respiratory support HFNC|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
1691970|NCT01526226|Device|Respiratory support NCPAP|In the cross over study 2 types of respiratory support are compared; HFNC versus nCPAP
1691971|NCT01526213|Drug|Fexofenadine|This randomized, open-label, single-dose, 3-way crossover study in healthy volunteers will be conducted in the CTRC. Once subjects are identified as eligible to participate, based on their screening evaluation and according to inclusion/exclusion criteria, they will undergo 3 phases. By randomized crossover design, the subject will receive fexofenadine with water, grapefruit juice, or furanocoumarin-free grapefruit juice.
1691972|NCT01526200|Procedure|Contrast-enhanced intraoperative ultrasound|After entering the abdominal cavity, liver mobilization is achieved by dissecting the round and falciform ligaments. IOUS is carried out with a standard 3-6 MHz convex probe, and a 7.5-10 MHz micro convex probe. Staging was completed by CE-IOUS using the standard 3-6 MHz convex probe and the dedicated 1.88-3.76 MHz harmonic frequency probe. In all patients, 2.4 mL of sulphur-hexafluoride microbubbles (SonoVue®, Bracco, Milan, Italy) are injected through a peripheral vein by the anesthesiologist.
1691973|NCT01526174|Drug|Golimumab|Intratympanic injection 0.3ml First Arm: 1 injection Second Arm: 4 injections
1691977|NCT01526148|Drug|Lithium|Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels > 0.6mEq/L.
1691978|NCT01526148|Drug|Quetiapine|Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
1691979|NCT01526135|Drug|Arm B : mFolfirinox|"Arm B : mFolfirinox every 14 days, 12 cycles, 24 weeks.
mFolfirinox : Oxaliplatin (Eloxatin®) 85 mg/m² D1 over 2 hours, followed by Irinotecan (Campto®) 150 mg/m² D1 over 90 minutes to begin 30 min. after the Folinic acid infusion is started.
Folinic acid 400 mg/m² (racemic mixture) (or 200 mg/m² if L-folinic acid is used), IV infusion over 2 hours.
5-FU 2.4 g/m² IV continuous infusion over 46 hours (1200 mg/m²/ day)"
1691980|NCT01526122|Drug|G0041(75/100mg)|G0041(75/100mg) 2 capsules(Clopidogrel 75mg & Aspirin 100mg in 1 capsule), PO
1691981|NCT01526122|Drug|Clopidogrel & Aspirin|Clopidogrel 75mg 2 tablets & Aspirin 100mg 2 capsules, PO
1691982|NCT01526109|Behavioral|Strength training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of strength training twice a week consists of six exercises for major muscle groups: leg press, bench press, lat pull down, knee extension, knee flexion and Abdominal (3 sets of 10-12 repetitions at 60-80% of 1 RM with 3 min interval between sets and between workouts).
1691983|NCT01526109|Behavioral|Control group|Participants will undergo a training program set for the three functional groups of ten minutes duration, followed by thirty minutes of functional exercises twice a week (2-3 sets of 30 sec. At intervals of 60 s between stimuli) carry out a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk without intensity
1691984|NCT01526109|Behavioral|Whole-body vibration training group|Participants will undergo a training program set for the three functional groups, which lasted ten minutes, followed by thirty minutes of exercise stimuli to whole-body vibration twice a week (2-3 sets of 30 sec. with frequency of stimulation at 30 Hz with 60 s intervals between stimuli), the platform will hold a range of six functional exercises combining squats and isometric or dynamic exercises for the upper limbs and trunk.
1691985|NCT01526096|Drug|G-CSF|G-CSF will be self-administered shot daily for 4 days pre-transplant. Up to 8 doses of G-CSF may be given. G-CSF will also be administered once daily under the skin beginning 5 days after your stem cell infusion until your white blood cell count is high enough
1691986|NCT01526096|Drug|Plerixafor|Plerixafor (self-administered shot)prior to the beginning of the stem cell collection. Up to 4 doses of plerixafor may be given.
1691987|NCT01526096|Procedure|Apheresis|Stem cell collection begins on day 5 and can last up to 3 days depending on the number collected.
1691988|NCT01526096|Drug|Melphalan|Melphalan chemotherapy 100mg/m2 for 2 days after your admission into the hospital for your ASCT procedure.
1691989|NCT01526096|Procedure|Stem cell re-infusion|Stem cells are thawed and reinfused back into the body via a catheter in the vein.
1691990|NCT01526096|Drug|Basiliximab|Basiliximab (20mg) given by IV infusion (through the vein) 20-30 minutes the day after ASCT.
1691991|NCT01526096|Device|CliniMACS CD25 microbeads and cell sorter|The stem cells collected during apheresis will be counted and treated with CD25 microbeads and processed by a special device called a CliniMACs machine which removes the regulatory T cells from you stem cell product.
1691992|NCT01526083|Other|Lacosamide|Strength: 200 mg, Form: Tablet, Frequency: Twice daily, Duration: 9 days
1691993|NCT01526083|Other|Warfarin|"Strength: 5 mg, Form: Tablet, Frequency: 1 single dose in each period
In total, during the two periods, each healthy volunteer will receive 2 single doses 3 weeks apart.
Duration: single dose"
1691994|NCT01526070|Drug|Intravitreal injection of Aflibercept|
1691995|NCT01526057|Biological|PF-05280586|1000 mg, IV on days 1 and 15
1691996|NCT01526057|Biological|MabThera|1000 mg, IV on days 1 and 15
1691997|NCT01526057|Biological|Rituxan|1000 mg, IV on days 1 and 15
1691998|NCT01526044|Device|Freestyle Navigator|Continuous glucose monitoring by subcutaneous measurement in the interstitial fluid
1691999|NCT01526031|Procedure|1:10,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)
1st visit : SC 0.4ml of 1:10,000 BV at 4 points (0.1ml for each points)
2nd visit : SC 0.6ml of 1:10,000 BV at 6 points (0.1ml for each points)
3rd visit : SC 0.8ml of 1:10,000 BV at 8 points (0.1ml for each points)
4th to 16th visit : SC 1.0ml of 1:10,000 BV at 10 points (0.1ml for each points)"
1692000|NCT01526031|Procedure|1:30,000 bee venom (BV) acupuncture|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)
1st visit : SC 0.4ml of 1:30,000 BV at 4 points (0.1ml for each points)
2nd visit : SC 0.6ml of 1:30,000 BV at 6 points (0.1ml for each points)
3rd visit : SC 0.8ml of 1:30,000 BV at 8 points (0.1ml for each points)
4th to 16th visit : SC 1.0ml of 1:30,000 BV at 10 points (0.1ml for each points)"
1692001|NCT01526031|Procedure|normal saline injection|"after skin test for hypersensitivity to bee venom (0.05ml of 1:30,000 bee venom, SC at LI11)
1st visit : SC 0.4ml of normal saline at 4 points (0.1ml for each points)
2nd visit : SC 0.6ml of normal saline at 6 points (0.1ml for each points)
3rd visit : SC 0.8ml of normal saline at 8 points (0.1ml for each points)
4th to 16th visit : SC 1.0ml of normal saline at 10 points (0.1ml for each points)"
1692002|NCT01526031|Procedure|physiotherapy|"Physiotherapy treatment will be provided at each visit after bee venom or saline injection.
transcutaneous electrical nerve stimulation (TENS) for 15 minutes
transcutaneous infrared thermotherapy (TDP) for 15 minutes
manual physical therapy for 15 minutes
simple home exercise program"
1692003|NCT01526018|Behavioral|Podee bottle|Infants will acclimate to the Podee bottle over the course of several weeks. All infants will consume meals from the Podee and their usual bottles.
1692004|NCT01526005|Drug|Transdermal Nicotine Patch|1 patch per day; dosages of 21 mg/day for 4 weeks, 14 mg/day for 2 weeks, and 7 mg/day for 2 weeks; 8 weeks total
1692005|NCT01526005|Drug|Transdermal Placebo Patch|1 patch per day; 8 weeks total
1692006|NCT01525992|Behavioral|Community pharmacist-led diabetes education program|A trained pharmacist will counsel each patient based on his/her individual needs about medications, life style and self-care. The pharmacist will use a checklist to document the type of education delivered to each patient. A glucometer is provided for each patient in this arm to monitor blood glucose daily. Three to six visits to the community pharmacy are set during the 6-months study period. At each visit, medication related problems and self-care issues are discussed with the patient and the glucometer test strips are provided for the following month. A telephone call will be made to each patient between visits to ensure adherence to drug therapy and resolve any problems .
1692007|NCT01525992|Other|Usual care|The baseline and 6-month follow-up visits to the community pharmacy will be required. If the physician prefers more visits to his office during the study period, it will be granted. The glucometer and a training session about diabetes self-care will be provide at the end of study for control group patients.
1692008|NCT01525979|Behavioral|Task-related unilateral arm training|The training tasks will involve daily activities with unilateral proximal or distal upper extremity movements for 5 days/week for 1.5 hours/day for 4 consecutive weeks.
1692009|NCT01525979|Behavioral|Task-related bilateral arm training|This intervention emphasizes UE movements (gross or fine motor tasks) involved in daily activities but focus on both UEs moving synchronously. The duration and intensity of treatment will also be 5 days/week for 1.5 hours/day for 4 consecutive weeks.
1692010|NCT01525979|Behavioral|Robot-assisted bilateral arm training|The Bi-Manu-Track used in this project (Reha-Stim Co., Berlin, Germany) enables the symmetric practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension. Each movement has 3 computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed, range of motion, and resistance individually adjustable; (2) active-passive, with the unaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance.
1692011|NCT01525979|Behavioral|Robot-assisted unilateral arm training|The robot-assisted unilateral arm training group will use mode 1 and 3: (1) passive, affected arm being moved by the machine with speed and range of motion individually adjustable; and (2) active, with the affected arm actively moving. This training program will add an additional mode: active-resistance, with the affected arm/wrist actively moving against resistance.
1692012|NCT01525966|Drug|carboplatin|Given IV
1692013|NCT01525966|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1692014|NCT01525966|Other|laboratory biomarker analysis|Correlative studies
1692015|NCT01525953|Drug|Chemotherapy|Chemotherapy according to standard
1692016|NCT01525953|Radiation|Radiotherapy|Radiotherapy according to local standard
1692017|NCT01525940|Device|PillCam Colon Capsule Endoscopy (Given® Diagnostic System)|2nd-generation CCE is 11.6x31.5 mm size, slightly bigger than previous capsule. It has 2 images with an angle of view increased to 172° degrees for each image. CCE-2 captures 35 images/sec. when in motion and 4 images/sec. when virtually stationary. Capsule battery life is at least 10 hours. The Recorder is an external receiving/recording and transmitting unit that receives data transmitted by the capsule. The portable Recorder consists of an antenna array which attaches to the body, a receiver and memory for accumulation of data during the exam. Data transmission is done via high capacity digital link. Workstation is a modified standard personal computer for reviewing videos generated from images acquired by the capsule, interpretation, analysis of acquired data and generating reports.
1692018|NCT01525927|Drug|chemotherapy|Chemotherapy for three cycles prior to radiotherapy
1692019|NCT01525927|Radiation|radiotherapy|Standard radiotherapy for non-responders vs reduced dose radiotherapy for responders.
1692020|NCT01525927|Radiation|Reduced dose radiotherapy|Patients who achieve a response to chemotherapy then go on to receive reduced dose radiotherapy.
1692021|NCT01525914|Drug|Dutasteride|dutasteride 0.5mg daily
1692081|NCT01525615|Device|Respimat inhaler|Respimat inhaler
1692022|NCT01525901|Drug|Insulin-Like Growth Factor-1 (IGF-1)|IGF-1 and placebo will each be administered for 3 months with a four-week washout period in between. IGF-1 will be administered for 3 months subcutaneously.
1692023|NCT01525901|Drug|Normal saline|Saline solution will be administered for three months subcutaneously.
1692027|NCT01525862|Device|Sinus Balloon Dilation Tool|transnasal sinus balloon dilation procedure
1692028|NCT01525849|Device|Balloon Sinus Dilation|Balloon sinus dilation using the XprESS Multi-Sinus Dilation Tool or the FinESS SInus Treatment
1692029|NCT01525849|Procedure|Functional Endoscopic Sinus Surgery|Endoscopic sinus surgery, specifically, maxillary antrostomy and uncinectomy with optional anterior ethmoidectomy
1692030|NCT01525836|Drug|rituximab; recombinant human thrombopoietin (rhTPO)|patients in recombination treatment group take Rituximab( intravenously ,100 mg weekly for 4 consecutive weeks); in combination with Rh-TPO( subcutaneously , 300U/kg for 14 consecutive days,followed by flexible treating dosage so as to keep the platelet count above 50×10^9/L until the 29th day)
1692031|NCT01525836|Drug|Rituximab|patients in recombinant treatment group take Rituximab intravenously at 100 mg weekly for 4 consecutive weeks（Day 1,8,15,22)
1692032|NCT01525823|Drug|BMS-754807 (IGR-IR/IR Inhibitor)|Tablets, Oral, 100mg, Once daily, Days 1 - 5 and 15 - 17
1692033|NCT01525823|Drug|Metformin|Tablets, Oral, (1000mg on Days 3 - 9) and (2000mg on Days 10 - 17), Once daily
1692034|NCT01525810|Drug|Peginterferon Lambda-1a (BMS-914143)|Observational study - No Intervention [subjects were previously treated with Peginterferon Lambda-1a (BMS-914143)]
1692035|NCT01525771|Other|Docetaxel|"The study medication will be administered every 3 weeks for a maximum of 8cycles. A study medication will be given to the patients.
Docetaxel (-1 to 3 level)mg/m2 IV(D1) every 21 days (-1 level: 40, 1 level: 60, 2 level: 80, 3 level: 100)
Xeloda 937.5 mg/m2/ day PO, twice a day(D1-D14) every 21 days
Cisplatin 60mg/m2 IV (D1) every 21 days"
1692036|NCT01525758|Drug|SI000413|1 Tablet = 200mg, (400mg, 600mg or 800mg vs. placebo) for 8weeks
1692037|NCT01525758|Drug|microcrystalline cellulose|identical number of tablets to active drug groups
1692038|NCT01525745|Radiation|Radiosurgery/SBRT|1, 3 or 5 SBRT treatments
1692039|NCT01525745|Radiation|External Beam Radiation Therapy|10 consecutive days of standard radiation
1692040|NCT01525732|Procedure|Per Oral Endoscopic Myotomy|
1692041|NCT01525719|Drug|Everolimus|10 mg everolimus
1692042|NCT01525706|Drug|Ethanol and Paclitaxel Injection|Endoscopic ultrasound will be used to locate and assess the pancreatic cyst. The fluid contents will be aspirated using a fine needle and sent for tumor marker analysis and cytology. With the needle maintained in the same position, 99% ethanol will be injected into the cyst. After 3-5 minutes of lavage, the entire volume of fluid will be removed from the cyst. The same volume of paclitaxel minus 1 mL [3mg/ml diluted in normal saline from original concentration of 6mg/mL] will be injected and left in the cyst. The needle is then retracted and the procedure completed. Patients will receive oral prophylactic antibiotics for 5 days after the procedure. Clinical follow up with MRI imaging with be done at 6, 12, 18, and 24 months. For those with a persistent cyst at 12 months, a repeat EUS FNI procedure will be done.
1692043|NCT01525680|Other|Hydrocortisone augmented Prolonged Exposure Therapy|11 sessions of PE. 20 minutes prior to final eight sessions, 30 mg hydrocortisone is administered.
1692044|NCT01525680|Other|Prolonged exposure therapy with placebo administration|11 sessions of PE. 20 minutes prior to final eight sessions, placebo is administered.
1692045|NCT01525667|Biological|150M PLX-PAD|Single course, multiple IM injections
1692046|NCT01525667|Biological|300M PLX-PAD|Single course, multiple IM injections
1692047|NCT01525667|Biological|Placebo|Single course, multiple IM injections
1692048|NCT01525654|Behavioral|Peer Support Program|Partners, are interested in having a support person to talk with while others. Coaches initiate contact, usually via phone but can use email or face to face, with their Partner. During this initial contact, partners determine how often to speak up to a total of 6 months. Peer Support discussions focus on sharing information, education, support related to living with RA.
1692049|NCT01525641|Drug|Mirapex LA|Pramipexole Hydrochloride Hydrate
1692050|NCT01525628|Drug|midazolam|CYP3A probe drug
1692051|NCT01525628|Drug|BI 201335|HCV protease inhibitor
1692052|NCT01525628|Drug|tenofovir|nucleoside analogue
1692053|NCT01525628|Drug|caffeine|CYP1A2 probe drug
1692054|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
1692055|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
1692056|NCT01525628|Drug|midazolam|CYP3A probe drug
1692057|NCT01525628|Drug|caffeine|CYP1A2 probe drug
1692058|NCT01525628|Drug|pegylated interferon|HCV treatment
1692059|NCT01525628|Drug|BI 201335|HCV protease inhibitor
1692060|NCT01525628|Drug|BI 201335|HCV protease inhibitor
1692061|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
1692062|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
1692063|NCT01525628|Drug|BI 201335|HCV protease inhibitor
1692064|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
1692065|NCT01525628|Drug|ribavirin|HCV treatment
1692066|NCT01525628|Drug|ribavirin|HCV treatment
1692067|NCT01525628|Drug|ribavirin|HCV treatment
1692068|NCT01525628|Drug|pegylated interferon|HCV treatment
1692069|NCT01525628|Drug|ribavirin|HCV treatment
1692070|NCT01525628|Drug|caffeine|CYP1A2 probe drug
1692071|NCT01525628|Drug|tolbutamide|CYP2C9 probe drug
1692072|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
1692073|NCT01525628|Drug|midazolam|CYP3A probe drug
1692074|NCT01525628|Drug|BI 201335|HCV protease inhibitor
1692075|NCT01525628|Drug|BI 207127|HCV polymerase inhibitor
1692076|NCT01525628|Drug|ribavirin|HCV treatment
1692085|NCT01525589|Drug|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths: 1 mg/vial and 4 mg/vial
1692086|NCT01525576|Behavioral|Booster|3 week booster program + 2 additional weeks two months later for follow-up.
1692087|NCT01525550|Drug|sunitinib|Sunitinib capsules will be given orally at continuous daily dosing with a starting dose of 37.5 mg. One cycle is equal to 28 days.
1692088|NCT01525537|Drug|administration of sufentanil|10 microgram sufentanil were given when SPI above 50 for more then 20 sec
1692089|NCT01525537|Drug|sufentanil|sufentanil was given at standard practise
1692090|NCT01525524|Device|Transcranial Direct Current Stimulation|In active stimulation(active Transcranial Direct Current Stimulation), the anode is placed over the left dorsolateral prefrontal cortex and the cathode is placed over the right prefrontal cortex. They are located five centimeters ventrally of the primary motor area, which are located five centimeters laterally of the central point of the scalp (which is located on the intersection of the sagittal and median curves). The device will deliver a charge of 2mA for 30 minutes.
1692091|NCT01525511|Drug|A|"Subject will receive primaquine (PQ) then receive dihydroartemisinin-piperaquine (DHA-PQP)after 1 week washout period and receive PQ together with DHA-PQP for the third regimen after 8 weeks washout period.
Primaquine:
1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)
Dosage: 2 tablets
DHA-PQP:
1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg
Dosage: 3 tablets"
1692092|NCT01525511|Drug|B|"Subject will receive primaquine (PQ) then receive PQ together dihydroartemisinin-piperaquine (DHA-PQP) after 1 week washout period and receive DHA-PQP for the third regimen after 8 weeks washout period.
Primaquine:
1 tablet of primaquine phosphate contains: 26.3 mg (15 mg base)
Dosage: 2 tablets
DHA-PQP:
1 tablet of Eurartesim contains: DHA 40 mg: piperaquine 320 mg
Dosage: 3 tablets"
1692093|NCT01525459|Procedure|Glioma resection|Patients will be treated with the standard surgical therapy - glioma resection.
1692094|NCT01525459|Other|Blood sampling|Blood samples used for measuring studied parameters will be taken within 10 days before surgery, one day after surgery and once more within 10 days following the operative procedure.
1692095|NCT01525446|Radiation|SBRT with proton beam radiation|4 consecutive days for the delivery of 48 Gy (tumors 3 cm or less) or 5 consecutive days for the delivery of 60 Gy (tumors of > 3 cm)
1692096|NCT01525433|Behavioral|DVD|Participants will received a mailed DVD containing culturally appropriate information about the importance of cervical cancer screening
1692097|NCT01525433|Behavioral|Promotora|Participants will receive a home visit from a lay community health educator ('Promotora') and will be shown a DVD containing culturally appropriate information to educate participants about the importance of cervical cancer screening
1692098|NCT01525420|Behavioral|Acceptance Therapy (ACT)|ACT
1692099|NCT01525420|Other|Cognitive Behavioral Therapy (CBT)|CBT
1692100|NCT01525407|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
1692101|NCT01525407|Drug|Atorvastatin Calcium|Given PO
1692102|NCT01525407|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo myeloablative allogeneic PBSC transplant
1692103|NCT01525394|Drug|Lenvatinib|32 mg will be administered orally as three 4 mg and two 10 mg capsules as a single dose.
1692104|NCT01525394|Drug|Moxifloxacin 400 mg|Moxifloxacin 400 mg will be administered orally as one 400 mg tablet.
1692105|NCT01525394|Drug|Placebos (matched to 4 mg and 10 mg lenvatinib capsules).|The Placebo dose will consist of three 4 mg and two 10 mg placebo capsules.
1692106|NCT01525368|Behavioral|cognitive intervention|Complex modular cognitive intervention focussing on memory aspects (e.g. internal memory strategies, external memory aids), other cognitive functions (e.g. attention) as well as social interactions.
1692108|NCT01525316|Dietary Supplement|Bovine Lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 8 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
1692109|NCT01525316|Dietary Supplement|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 8 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
1692110|NCT01525303|Behavioral|Behavioral Treatment for Chronic Headache- Exercise Version|This behavioral treatment program consists of behavioral approaches to headache management: progressive muscle relaxation, stress-management training, and biofeedback. Skills for these techniques are presented during the clinic sessions, and supplemented with workbooks and audio CDs. In addition, all participants will receive a graduated exercise prescription of 20-30 minutes of moderate-intensity exercise, five days per week. They will be instructed to assess the intensity of their exercise using the Borg perceived exertion scale. Client contact sessions are as follows: Clinic Session (CS)1; Phone Session (PS) 1 (end of week1), CS 2 (end of week 4); PS 2 (end of week 6); CS 3 (end of week 8).
1692111|NCT01525290|Drug|Alteplase|Intravenous tissue plasminogen activator (Alteplase) 0.9 mg/kg body-weight up to a maximum of 90 mg, 10% as bolus, 90% over 1 hour as infusion
1692112|NCT01525290|Drug|Placebo|lyophilised powder to be reconstituted as solution indistinguishable from the active drug
1692162|NCT01525004|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine
1692163|NCT01524991|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 Days 1 & 8 (all cycles)
1692164|NCT01524991|Drug|Cisplatin|Cisplatin 70 mg/m2 Day 1 (all cycles)
1692113|NCT01525264|Behavioral|KIM-CHI|The intervention is based on cultural characteristics and context and focuses on changing (1) beliefs about breast cancer and screening, (2) knowledge of breast cancer and screening, (3) self-efficacy of confidence in one's ability to complete all the steps necessary for obtaining a mammogram including requesting a referral for mammogram from a physician. The KIM-CHI program also incorporates strategies for enhancing spousal support (perceived support received from husband). To standardize delivery of culture-relevant health behavior change information related to breast cancer screening to groups of women and their husbands separately, the KIM-CHI program uses a DVD with Korean role models, native Korean language, and male physician authentication as well as inclusion of spouses.
1692114|NCT01525264|Behavioral|Healthy Wife Control Group|Intervention group of couples who received education about importance of Healthy diet
1692115|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 2.5 mg, Single-dose
1692116|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 5 mg, Single-dose
1692117|NCT01525238|Drug|Dapagliflozin|Tablet, Oral, 10 mg, Single-dose
1692118|NCT01525225|Drug|Metformin immediate release (IR)|Tablet, Oral, 1000 mg, twice daily, 1 day
1692119|NCT01525225|Drug|Saxagliptin|Tablet, Oral, 5 mg, single-dose, 1 day
1692120|NCT01525225|Drug|Metformin IR|Tablet, Oral, 1000 mg, twice daily, 5 days
1692121|NCT01525225|Drug|Saxagliptin/Metformin XR FDC|Tablet, Oral, 2.5 mg Saxagliptin/1000 mg Metformin extended release (XR), Single-dose of 2 tablets. Fixed dose combination (FDC).
1692122|NCT01525225|Drug|Metformin XR|Tablet, Oral, 500 mg, Single-dose of 4 tablets
1692123|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 25 mg, Once daily, 3 days
1692124|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 100 mg, Once daily, 3 days
1692125|NCT01525212|Drug|BMS-929075|Oral Suspension, ≤ 400 mg, Once daily, 3 days
1692126|NCT01525212|Drug|BMS-929075|Oral Suspension, (≤ 800 mg, Once daily) OR (≤ 400 mg, Twice daily), 3 days
1692127|NCT01525212|Drug|Placebo matching BMS-929075|Oral Suspension, 0 mg, Once daily, 3 days
1692128|NCT01525212|Drug|Placebo matching BMS-929075|Oral Suspension, 0 mg, (Once daily for ≤ 800 mg group) OR (Twice daily for ≤ 400 mg group), 3 days
1692129|NCT01525173|Drug|0.1% brimonidine tartrate ophthalmic solution|1 drop of 0.1% brimonidine tartrate ophthalmic solution 3 times per day for 12 weeks.
1692130|NCT01525173|Drug|0.01% bimatoprost ophthalmic solution|1 drop of 0.01% bimatoprost ophthalmic solution once per day for 12 weeks.
1692131|NCT01525173|Drug|0.2% hypromellose lubricant eye drops|1 drop of 0.2% hypromellose lubricant eye drops 3 times per day for 12 weeks.
1692132|NCT01525173|Drug|latanoprost 0.005% ophthalmic solution|1 drop of latanoprost 0.005% ophthalmic solution once daily as run-in therapy for 30 days only.
1692133|NCT01525147|Biological|YHB1411-2: Level 2|IV infusion
1692134|NCT01525147|Biological|YHB1411-2: Level 3|IV infusion
1692135|NCT01525147|Biological|YHB1411-2: Level 4|IV infusion
1692136|NCT01525147|Biological|YHB1411-2: Level 5|IV infusion
1692137|NCT01525147|Biological|Placebo|IV infusion
1692138|NCT01525147|Biological|YHB1411-2: level 1|IV infusion
1692139|NCT01525134|Device|"Alere Determine lateral-flow urine lipoarabinomannan assay"|"lateral-flow (point-of-care) urine test to detect the lipoarabinomannan (LAM) component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.
Manufacturer: Alere"
1692140|NCT01525134|Device|"Alere Clearview ELISA urine LAM assay"|"ELISA-based urine test to detect the lipoarabinomannan component of the M. tuberculosis antigen in the urine of TB suspects, in vitro.
Manufacturer: Alere."
1692141|NCT01525121|Other|Expiratory Rib Cage Compression|The therapist hands were positioned on the lower ribs, and the force was applied every two breaths only during the expiration, synchronizing the maneuver rate with the patient's respiratory rate. Then, the patients underwent a suctioning procedure, and a hyperinflation maneuver consisting of a 10 minutes period under pressure support ventilation of 35 cmH2O was done. In control intervention instead of the compressive maneuver the patients were kept on normal ventilation.
1692142|NCT01525108|Behavioral|Self monitoring of blood pressure|Electronic blood pressure device is provided for patients and he/she will be trained to measure blood pressure at home once daily(same time each day). A logbook is also provided to document the daily blood pressure level.
1692143|NCT01525108|Other|Usual Care|Four visits to the physician's office at 4th, 12th, 24th week in the study period with usual advice giving practice of the staff. At the end of the trial period, an electronic blood pressure device will be given to each patient in this arm.
1692144|NCT01525082|Drug|capecitabine|Given PO
1692145|NCT01525082|Drug|temozolomide|Given PO
1692146|NCT01525082|Biological|bevacizumab|Given IV
1692147|NCT01525069|Drug|Floxuridine|
1692148|NCT01525069|Drug|Dexamethasone|
1692149|NCT01525069|Drug|Gemcitabine|
1692150|NCT01525069|Drug|Oxaliplatin|
1692151|NCT01525056|Radiation|ct and mri scans|ct and mri scan preradiation and postradiation
1692152|NCT01525056|Radiation|ct, mri and pet scan|ct, mri and pet scans preradiation and postradiation
1692153|NCT01525056|Radiation|ct, mri and pet scans|single arm with ct, mri and pet scans pre and post radiation
1958217|NCT01874353|Drug|Olaparib 300mg tablets|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
1692160|NCT01525017|Biological|Combig-DC (allogeneic dendritic cells) Cancer Vaccine|Cryopreserved dendritic cell suspension of 10 million cells per ml in heat-inactivated plasma, supplemented with 10% dimethyl sulfoxide (DMSO).
1692161|NCT01525004|Drug|High-Dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
1692165|NCT01524991|Drug|Ipilimumab|Ipilimumab 10 mg/kg Day 1 (start cycle 3)
1692380|NCT01523106|Drug|L-carnitine|dietary supplement
1955678|NCT03112057|Diagnostic Test|harmonic generation (HGM) microscopic methods.|a frequency-dependent optical microscopy system with a near-infrared light source with a wavelength of 1230 nm was used to detect the diseased site and normal skin.Use erbium-Jacob (Er-YAG) laser exfoliation. the participants need to lie down, wear goggles. The lens sucker device to help fix the skin examination site. Based on the experience of the past 118 subjects, the participants did not discomfort. The total time of the laser irradiation on the same skin is no more than 30 minutes, the maximum laser power is no more than 0.15 watts, irradiation in the skin of the total energy of the laser does not exceed 270 joules. After the experiment, the investigators immediately check the skin for the participants
1692169|NCT01524965|Procedure|Immediate mobilisation after locking-plate osteosynthesis|"Immediate passive range of motion exercises are begun postoperatively, after 3 weeks, active unloaded mobilisation begins after three weeks and active, loaded use is allowed 6 weeks postoperatively.
Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
1692170|NCT01524965|Procedure|Standard mobilisation after locking plate osteosynthesis|"Immediately postoperatively the arm is held in a sling, active mobilisation of healthy joints and pendel exercises are befun. Passive range of motion exercises of the shoulder are begun 3 weeks postoperatively. Active mobilisation begins after six weeks.
Surgical procedure is open reduction of the fracture and internal fixation of the fracture using a locking plate using standard deltopectoral approach and AO principles in fracture management."
1692171|NCT01524965|Device|Osteosynthesis with a locking plate (Philos)|Standard open reduction and internal fixation using a deltopectoral approach. Fracture fixation is done using a locking plate (Philos, Synthes) following the AO principles of fracture management.
1692172|NCT01524952|Device|combined thermal and electrical muscle stimulation (cTEMS)|cTEMS in three 60-minute sessions per week for 8 weeks
1692173|NCT01524939|Drug|immunoglobulin G|Intravenously administer a single dose of the product (2g/kg) for at least 12 hours
1692174|NCT01524926|Drug|Crizotinib (PF-02341066)|For patients of 15yo and older, Capsules of 200 and 250 mg Daily dose of 500, 400 or 250 mg/day depending on toxicitie; for patients younger than 15yo, 280 mg/m²/dose BID, with reductions allowed to 80% as first reduction and to 60% as second reduction respectively of the initial dose.
1692175|NCT01524913|Drug|Hyaluronic acid|1 cc hyalgan to be injected into superior joint space
1692176|NCT01524913|Drug|Corticosteroid|1cc celestone (6 mg/cc) will be injected into the joint space
1692177|NCT01524913|Drug|Lactated Ringers|1 cc lactated ringers solution will be injected into the joint space
1692178|NCT01524887|Biological|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion every 2 weeks over 18 months
1692179|NCT01524887|Biological|Human albumin 0.25%|Intravenous infusion every 2 weeks over 18 months
1692180|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
1692181|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
1692182|NCT01524874|Dietary Supplement|Vitamin D3|10,000 IU per Day for 12 Weeks
1692183|NCT01524861|Drug|Placebo|a placebo tablet bis in die for 12 months
1692184|NCT01524861|Drug|alpha-lipoic acid|alpha-lipoic, tablets of acid 400 mg bis in die (800 mg/day), for 12 months
1692185|NCT01524861|Drug|L-acetyl carnitine|L-acetyl carnitine tablets, 500 mg bis in die (1000 mg/day), for 12 months
1692186|NCT01524848|Drug|Pazopanib|Two (2) tablets of 400 mg given once daily continuously
1692187|NCT01524809|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
1692188|NCT01524809|Drug|biphasic insulin aspart 70|Dose individually adjusted. Administrated subcutaneously (s.c., under the skin) three times a day for 15 days in each treatment period. A wash-out period of 2-8 weeks will take place between treatment periods.
1692189|NCT01524796|Other|No intervention. Non-interventional study|No intervention. Non-interventional study
1692190|NCT01524783|Drug|Everolimus|After randomization, patients will receive everolimus once daily until disease progression, intolerable toxicity, or consent withdrawal
1692191|NCT01524783|Drug|Everolimus Placebo|After randomization, patients will receive everolimus placebo once daily until disease progression, intolerable toxicity, or consent withdrawal
1692192|NCT01524770|Biological|Dulaglutide|Administered by subcutaneous (SC) injection
1692193|NCT01524757|Drug|Pantoprazole|pantoprazole 40mg 1dd1; 12 months
1692194|NCT01524744|Drug|Pimecrolimus ointment|Case group used drugs 3 times a day for 2 months and then didn't eat or drink for 20 minutes after use
1692195|NCT01524744|Drug|Adcortyl|triamcinolone acetonide 0.1% in orabase
1692196|NCT01524731|Drug|Saline|Normal Saline
1692197|NCT01524731|Drug|Dexamethasone|4 mg
1692198|NCT01524731|Drug|Dexamethasone|8 mg
1692199|NCT01524718|Radiation|Imaging with two X-ray image intensifiers|Two fluoroscopy apparatus one in the AP plane and the other as the axial plane.
1692203|NCT01524679|Drug|Pegylated interferon alfa-2a plus nucleos(t)ide(s)|Pegylated interferon alfa-2a, s.c. 180 μg 1x/wk in addition to nucleos(t)ide(s)
1692204|NCT01524653|Drug|Rosuvastatin|20 mg po od
1692205|NCT01524653|Drug|Placebo|20 mg po od
1692206|NCT01524640|Biological|Killed Bivalent (O1 and O139) whole cell oral cholera vaccine|1.5 ml single dose oral administration on day 0 and day 14
1692207|NCT01524640|Biological|Placebo|1.5 ml oral administration on day 0 and day 14
1692208|NCT01524627|Drug|Varenicline|Varenicline will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
1692452|NCT01522612|Drug|5-fluorouracil|Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
1692209|NCT01524627|Drug|Placebo|Placebo will be prescribed to non-abstinent smokers at the same doses as have been demonstrated to be clinically effective for Varenicline: 0.5 mg twice a day for 3 days and then 1mg twice daily for the remainder of the treatment course of 8 weeks.
1692210|NCT01524614|Procedure|nasal mask|nasal mask use instead of face mask
1692211|NCT01524601|Drug|Rosuvastatin|20 mg rosuvastatin for 4 weeks
1692212|NCT01524575|Drug|gemcitabine and oxaliplatin|gemcitabine 1000mg/m2 IV q2week and oxaliplatin 85mg/m2 IV q2week
1692214|NCT01524510|Radiation|CT scan|low dose radiation scan without contrast without and with MRA
1692215|NCT01524510|Device|Alice PDx polygraphy|Alice PDx polygraphy (Respironics)
1692216|NCT01524497|Drug|Trazodone|75mg tablet/150 mg tablet
1692217|NCT01524497|Drug|Placebo|Reference drug: trazodone hydrochloride prolonged-release tablet placebo (corresponding dummy drug of 75mg, 150mg active drug)
1692218|NCT01524471|Procedure|Per Oral Endoscopic Myotomy|
1692219|NCT01524458|Procedure|Per-Oral Endoscopic Myotomy|To perform myotomy for lower esophageal sphincter using endoscope through a long submucosal tunnel
1692220|NCT01524445|Other|bortezomib retreatment due to relapse|Patients who received bortezomib-containing chemotherapy as first-line treatment for MM, experienced partial response or better, and were re-treated (second-line) with bortezomib (for at least 3 cycles) due to a relapse of the disease after a treatment free interruption of at least 6 months
1692221|NCT01524432|Drug|Anti-fungal agent (Clotrimazole) loaded microcapsules|Clotrimazole loaded microcapsules padded on socks and the patient should wear the socks every day for 2 weeks
1692222|NCT01524432|Drug|Placebo|No drug loaded microcapsules socks
1692223|NCT01524406|Drug|HPP593|Oral, twice a day.
1692224|NCT01524406|Drug|Placebo|Oral, twice a day.
1692225|NCT01524380|Drug|Ginkgo biloba extract|400mg/day, twice a day, 10 weeks
1692226|NCT01524380|Drug|Placebo|twice a day, 10 weeks
1692227|NCT01524367|Drug|saline|We administrate the normal saline (single bolus, 0.01ml/kg) intravenously at time of oral cavity sealing.
1692228|NCT01524367|Drug|Dexmedetomidine|We administrate the dexmedetomidine (single bolus, 1 ug/ks) intravenously at time of oral cavity sealing.
1692229|NCT01524354|Procedure|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol under control of cerebral state index at 40-60 points
1692230|NCT01524354|Procedure|maintenance of anesthesia|intraoperative maintenance of anesthesia with propofol according to recommendations of the manufacturer
1692231|NCT01524341|Drug|KAE609|KAE609 was supplied as capsules for oral use.
1692232|NCT01524315|Drug|Vitamin B1-ratiopharm|300 mg Thiaminchloridhydrochlorid, once, intravenous, preoperative
1692233|NCT01524315|Drug|Placebo|100 ml normal saline, intravenous, preoperative
1692234|NCT01524302|Drug|Ceftaroline|600 mg Q12h
1692235|NCT01524302|Drug|Levofloxacin|750 mg QD
1692238|NCT01524250|Drug|corticosteroids|1250mg of oral prednisone daily for 3 days
1692239|NCT01524250|Drug|corticosteroids|1000mg IV methylprednisolone daily for 3 days
1692240|NCT01524237|Drug|LY2979165|Capsules administered orally
1692241|NCT01524237|Drug|LY2140023|Tablets administered orally
1692242|NCT01524237|Other|Placebo|Administered orally
1692243|NCT01524237|Other|Ketamine|Administered intravenously (IV)
1692244|NCT01524224|Drug|LY2495655|administered intravenously
1692245|NCT01524211|Device|Zenith® t-Branch|The t-Branch Endovascular Graft (Zenith® t-Branch) is a tubular graft with four branches and a covered stent at the proximal end that contains barbs for additional fixation of the device. The purpose of the branches is to allow uninterrupted blood flow to visceral vessels of the aorta. The graft is designed to be connected with celiac, superior mesenteric and two renal arteries via self-expanding covered bridging stents. Although the standard Zenith t-Branch has four branches, it is anticipated that a small number of custom-made three branch devices will be included in this study for those patients in whom one of the visceral vessels is chronically thrombosed.
1692246|NCT01524198|Drug|Budesonide|500 mcg budesonide plus Albuterol plus ipratropium bromide (IB) nebulization, 3 doses back to back
1692247|NCT01524198|Drug|Normal saline|0.5 ml to 1.5 ml normal saline (to complete 3 mls total volume), plus albuterol plus ipratropium bromide nebulizations 3 doses back to back
1692248|NCT01524185|Behavioral|FamilyLive|Multi-therapist family mental health treatment for families with a history of intergenerational neglect and trauma
1692249|NCT01524185|Behavioral|Standard Mental Health Treatment|Standard trauma-informed mental health treatment
1692250|NCT01524172|Behavioral|Yoga Based Psychotherapy Group|YBPG promotes self-regulation (attention span and physical and verbal expression/outbursts); self-soothing (breathing and movement techniques that physiologically calm when the child encounters stress or reminders of trauma); competency (successful social interaction, appropriate expression of needs and feelings, healthy coping with stress or crisis); self-awareness (of thoughts and feelings by first increasing awareness of the body and its sensations through yoga); self-esteem (positive self-regard, increase accomplishments and awareness that all individuals have different abilities); and safety and personal boundaries (establishing personal boundaries and respecting others' personal boundaries, differentiate safe and unsafe behaviors and situations).
1692251|NCT01524172|Behavioral|Standard Mental Health Treatment|Trauma and evidence informed therapy
1692252|NCT01524159|Dietary Supplement|bromelain capsule|Bromelain group received bromelain capsule for 12 weeks period. The 1050 mg dosage of bromelain was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
1692253|NCT01524159|Dietary Supplement|placebo (wheat starch)|Placebo group received placebo capsule (wheat starch) for 12 weeks period. The 1050 mg dosage of wheat starch was divided into three capsules and to be taken two (2 x 350 mg) after breakfast and another one (350 mg) after dinner. The capsules should be taken two hours after the meals.
1692377|NCT01523145|Behavioral|Rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (4 sessions over 6 months)
1692254|NCT01524146|Procedure|Photodynamic Therapy|"PDT is a therapeutic approach that specifically targets neoplastic cells.
• PDT involves three components:
Photofrin or a similar Photosensitizing agent that would be injected 3 days prior to laser activation of the agent.
Laser System - For laser energy delivery to activate the photosensitizing agent and induce tumor tissue necrosis
Optic Fiber - Delivery Fiber used along with the laser system to achieve Photoactivation of the photosensitizing agent.
Technique:
Subjects will be injected with Photofrin or similar drug. 3 days post injection, the subject will receive photodynamic therapy during an Endoscopic Retrograde cholangiopancreatography (ERCP) procedure. Subject will undergo stenting as part of standard of care procedure post photodynamic therapy.
Subject may undergo multiple photodynamic therapy sessions with a gap of at least 3 months."
1692255|NCT01524133|Drug|Sertraline|Initial baseline dose of 25 mg/day. Clinician will attempt to titrate patients to at least 100 mg/day and up to 200 mg/day if tolerated by week 8.
1692256|NCT01524133|Behavioral|Prolonged Exposure Therapy|up to 13 sessions of prolonged exposure
1692257|NCT01524120|Device|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
1692258|NCT01524120|Device|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
1692259|NCT01524120|Device|Endoscopy (EPK-i, Pentax, Tokyo, Japan)|Patients will undergo white-light endoscopy. Any mucosal lesions will be recorded and findings will be compared to histopathological and clinical results.
1692260|NCT01524120|Device|Endomicroscopy (iCLE, Pentax, Tokyo, Japan)|Patients will undergo endomicroscopy. Data will be recorded and findings will be compared to histopathological and clinical results.
1692261|NCT01524094|Drug|Systemic chemotherapy alone (oxaliplatin, 5-fluorouracil, isovorin)|Oxaliplatin 100 mg/ m2 as a 2 h iv infusion + 5-fluorouracil 400 mg/ m2 iv bolus + Isovorin 100 mg/ m2 as a 2 h infusion followed by 5-fluorouracil 2400 mg/ m2 as a 46 h infusion. Each cycle is given every other week until 12 cycles have been administered.
1692262|NCT01524094|Procedure|Cytoreductive surgery (CRS) plus postoperative intraperitoneal chemotherapy (5-fluorouracil, isovorin)|Cytoreductive surgery has the goal of completely resecting all visible tumor tissue in the abdomen. Sequential postoperative intraperitoneal chemotherapy has the purpose of an adjuvant treatment to eradicate microscopic residual tumor and prevent recurrences in the abdomen. The chemotherapy regimen consisted of intraperitoneal 5-fluorouracil 550 mg/ m2 and intravenous isovorin 30 mg/ m2 day 1-6 med cycles every 4-6 weeks. Six cycles were planned.
1692263|NCT01524081|Drug|Metronidazole, Cefuroxime|"administration of Cefuroxime 1.5 g and Metronidazole 1g in 2 following intravenous infusions 60 minutes prior the surgery.
- Cefuroxime in 100ml saline
- Metronidazole in 500ml saline"
1692264|NCT01524081|Drug|Amoxicillin (+ clavulanic acid) and Fluconazole|"Administration of amoxicillin (+ clavulanic acid) 2.4 g and Fluconazole 800mg in 2 following intravenous infusions 60 minutes prior the surgery.
- 2x amoxicillin in 100ml saline
- Fluconazole in 500ml saline"
1692265|NCT01524081|Drug|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery
- 100ml saline solution
- 500ml saline solution"
1692266|NCT01524081|Drug|Placebo|"Administration of saline infusion (Natrii chloridum: 9,0 g/l) 60 minutes prior the surgery
- 2x 100ml saline solution
- 500ml saline solution"
1692267|NCT01524068|Drug|Standard Steroid Treatment|One gm of methylprednisolone i.v., on day 0, followed by 40 mg/day i.v. on days 1-4, and days 6-12 (or the p.o. prednisone equivalent). Methylprednisolone 100 mg i.v. will be administered on days 5 and 13. Steroid doses will then be 20 mg methylprednisolone i.v. (or p.o. prednisone equivalent) from days 14-28, and then reduced thereafter at the discretion of the PI at each site.
1692268|NCT01524068|Drug|The Standard Steroid Treatment, Plasma Exchange and rituximab|The Standard Steroid Treatment and, after insertion of a dialysis/apheresis catheter into a central vein, followed by initiation of the PEX and rituximab regimens.
1692269|NCT01524055|Device|Single-Balloon-Enteroscopy with Air as insufflation gas.|Single-Balloon-Enteroscopy will be performed using Air as insufflation gas to inflate the intestine for complete examination.
1692270|NCT01524055|Device|Single-Balloon-Enteroscopy with CO2 as insufflation gas.|Single-Balloon-Enteroscopy will be performed using CO2 as insufflation gas to inflate the intestine for complete examination.
1692271|NCT01524042|Procedure|Pants for colonoscopy|We divide the patients into group 1 and group 2. The group 1 wear a conventional single pants and group 2 wear a novel double pants.
1692272|NCT01524016|Drug|68Ga-DOTATATE|Intravenous injection of one dosage of 72-185MBq (2-5 mCi) 68Ga-DOTATATE solution. Tracer doses of 68Ga-DOTATATE will be used to image tumors by Positron Emission Tomography / computed tomography (PET/CT)
1692273|NCT01524003|Procedure|cryotherapy|cryotherapy treatment of the uterine cervix
1692274|NCT01524003|Procedure|Colposcopy|Colposcopy, biopsy and LEEP based on the pathology results
1692275|NCT01523990|Drug|TG-2349|Supplied as oral liquid formulation in pre-filled glass syringe. Two dose strengths, 25 mg TG-2349 (25 mg/mL in PEG 400, 1.1 mL fill) and 200 mg TG-2349 (50 mg/mL in PEG 400, 4.1 mL fill), are filled into 5-mL type 1 glass syringes. Required doses during clinical study are to be dispensed using the combination of the two dose units. The entire content of the syringe is to be taken by mouth.
1692276|NCT01523990|Drug|placebo|Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
1692277|NCT01523977|Drug|Everolimus|Orally, daily days 1-32 per assigned dose level
1692278|NCT01523977|Drug|Prednisone|40 mg/m2/day orally 3 x daily days 4-32
1692279|NCT01523977|Drug|Vincristine|1.5 mg/m2 IV daily on days 4, 11, 18, and 25
1692280|NCT01523977|Drug|PEG-Asparaginase|2,500 U/m2 IV 1 x daily on days 5 and 18
1692281|NCT01523977|Drug|Doxorubicin|30 mg/m2 IV on days 4 and 5
1692282|NCT01523977|Drug|Dexrazoxane|300 mg/m2 IV on days 4 and 5
1692283|NCT01523964|Other|Testing with EIM|
1692284|NCT01523938|Behavioral|Hypnotherapy|Pre- (one session) and postoperative (two sessions) Hypnotherapy
1692316|NCT01523678|Drug|Filgrastim|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
1746825|NCT00159523|Biological|placebo|
1692285|NCT01523925|Behavioral|dCIT|This dCIT group focuses on restriction on movement of the unaffected hand by placement of the hand in a mitt for 6 hours/day and intensive training of the affected upper extremity in functional tasks 1.5 hours/weekday, for 4 weeks. The level of challenge will be adapted based on patient ability and improvement during training. Patients will be encouraged to initiate the designed therapeutic functional activities.
1692286|NCT01523925|Behavioral|BAT|The BAT group concentrates on the simultaneous movements of both the affected and unaffected upper extremity on robot for 1.5 hours/day, 5 days/week for 4 weeks.
1692287|NCT01523925|Behavioral|Control intervention group|The conventional intervention group is designed to control for the duration and intensity of patient-therapist interactions and therapeutic activities (1.5 hours/day, 5 days/week, for 4 weeks). Therapy in the control intervention group will involve training for coordination, balance, and movements of the affected upper extremity, as well as compensatory practice on functional tasks with the unaffected upper extremity or both upper extremities.
1692288|NCT01523925|Behavioral|Functional electrical stimulation|
1692289|NCT01523912|Device|Radiofrequency ablation of dysplastic mucosa (HALO)|Gastric ablation is performed using the HALO Ablation System (BÂRRX Medical Inc., Sunnyvale, CA, USA). A HALO90 ablation catheter, which is mounted on the tip of an endoscope, is used. Radiofrequency energy is delivered at 40 W/cm2 and 15 J/cm2 via a 13 x 20 mm electrode. All patients will have two RFA sessions 8 weeks apart with the same area being ablated in consecutive endoscopies. The precise area to ablated in the second RFA session is determined by referring to careful measurements that utilized gastric landmarks (a typical notation may specify that the lesion extends from 2 to 5 cm proximal of the pylorus in the 5 o'clock position and is 4 cm wide) as well as to digital image recordings that are taken during the first RFA.
1692290|NCT01523899|Device|Xpert MRSA/SA SSTI|Use of Xpert MRSA/SA SSTI assay
1692291|NCT01523899|Diagnostic Test|Standard culture|
1692292|NCT01523886|Drug|Rocuronium|Intravenous use: 0.3 mg/kg before intubation and 0,7 mg after intubation followed by infusion with 0,3-0,4 mg/kg/h
1692293|NCT01523886|Drug|Rocuronium|Intravenous use: 0,3 mg/kg followed by NaCl-infusion
1692294|NCT01523860|Drug|Rituximab, Mitoxantrone, Bendamustine|Rituximab will be supplied as 375 mg/sqm for i.v.administration.Mitoxantrone will be supplied as 8 mg/sqm for i.v.administration.Bendamustine will be supplied as 90 mg/sqm for i.v.administration
1692295|NCT01523847|Drug|MBVD (Myocet+BVD)|"MBVD will be scheduled as follows:
Myocet 25 mg/mq i.v. day 1 and 15 Bleomycin 10 mg/mq i.v. day 1 and 15 Vinblastine 6 mg/mq i.v. day 1 and 15 Dacarbazine 375 mg/mq i.v. day 1 and 15"
1692296|NCT01523834|Drug|Panobinostat|"Induction Phase: Patients will receive panobinostat for 6 courses (1 course = 28 days). Consolidation phase (courses 7-12). Maintenance phase (course 13-end of therapy).
Panobinostat should be taken p.o. at the dose of 40 mg/day 3-times every week (QW) as part of a 4 week treatment cycle. The dose of panobinostat may be modified: the 1st dose adjustment consists in the modification of drug administration from 3 times every week (QW) to 3 times every other week (QOW). Levels lower than 30 mg 3 times QOW is not permitted."
1692297|NCT01523821|Biological|Alpha-1-Proteinase Inhibitor Human|Given IV
1692298|NCT01523821|Other|Laboratory Biomarker Analysis|Correlative studies
1692299|NCT01523821|Other|Pharmacological Study|Correlative studies
1692300|NCT01523808|Drug|GRASPA|Each patient will receive one administration of GRASPA . A stepwise increase of 4 single doses of GRASPA will be administered to cohorts of 3 patients per dose
1692301|NCT01523795|Other|Motion-controlled video gaming|Play of motion-controlled video games for one hour
1692302|NCT01523795|Other|Traditional video gaming|Participants played traditional video games for one hour
1692303|NCT01523795|Other|Television watching|Participants watched television for one hour
1692305|NCT01523769|Procedure|Umbilical Cord Milking|Approximately 10 cm of umbilical cord was milked toward the baby immediately following delivery. (The blood remaining in the umbilical cord after delivery is squeezed in the direction from the placenta (remaining inside the uterus) toward the newborn baby.)
1692306|NCT01523756|Device|test product 1: new ostomy base plate with Coloplast as manufacturer|test product 1 is tested first
1692307|NCT01523756|Device|test product 2: new ostomy base plate with Coloplast as manufacturer|test product 2 is tested first
1692308|NCT01523743|Device|SpeediCath Compact|The SpeediCath Compact intermittent catheter is used for single-use urinary bladder drainage through the urethra.
1692309|NCT01523743|Device|Standard care|The coated intermittent catheter normally used by subject
1692310|NCT01523730|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment), washout period ≥ 1 month between the testing weeks. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Active treatment will be delivered at 90% resting motor threshold intensity. Stimulation will be administered at 20 Hz with 25 stimulation trains of 30 stimuli each with an inter-train interval of 30 sec at equivalent stimulation parameters as those used in our pilot trial. Stimulation Site: Advanced neuronavigation methods will be used to target rTMS to the dorsolateral prefrontal cortex following a T1 weighted MRI scan.
1692311|NCT01523730|Device|Sham Repetitive Transcranial Stimulation (rTMS)|Subjects will undergo two testing weeks (active and sham rTMS treatment) administered in a randomized order, to which both experimenter and participant will be blind. There will be a washout period of at least one month between the testing weeks to ensure that any changes in cortical function induced by rTMS have returned to baseline. rTMS treatment sessions will take place twice daily on days 1-3 of each test week. Sham Condition: A single-wing tilt rTMS coil position producing somatic sensation (contraction of scalp muscles) with minimal direct brain effects will be used (same stimulation parameters and site as active condition).
1692312|NCT01523704|Device|BIOTRONIK Home Monitoring System|Home Monitoring system transfers implantable device's data to the main server via internet.
1692313|NCT01523704|Device|BIOTRONIK Home Monitoring System with In-office Follow-up|
1692314|NCT01523691|Behavioral|Repeated sleep restriction and recovery|Repeated cycles of sleep restriction and sleep recovery
1692315|NCT01523691|Behavioral|Control sleep|Regular amounts of sleep across study protocol
1746899|NCT00160511|Drug|Levetiracetam|
1692317|NCT01523678|Drug|Paclitaxel|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
1692318|NCT01523678|Drug|Carboplatin|All subjects will receive standard treatment with paclitaxel followed by carboplatin intravenously during 18 weeks. Filgrastim (Neupogen) will be given prophylactically on day 5. An additional dose will be given on day 6 in case of severe neutropenia during the course of the trial.
1692319|NCT01523639|Drug|Metformin/Placebo|"The starting dose of Metformin/Placebo is 500 mg p.o. twice daily for 7 days (daily dose 1000 mg p.o.). Dose will be increased to 1000 mg p.o. twice daily at day 8 (daily dose 2000 mg p.o.) unless no toxicity ≥ 2 due to IMP occurs.
Duration of treatment: 24 weeks"
1692320|NCT01523626|Other|Total body Computed Tomography.|"The CT protocol for the intervention group consists of a two-step whole-body acquisition (from vertex to pubic symphysis) starting with Head and Neck Non Enhanced CT (NECT) with arms alongside the body.
The preferred technique for the second complementary scan is a split-bolus intravenous contrast directly after repositioning of the arms alongside the head, and this second scan covers thorax, abdomen and pelvis. Participating centers however are free to choose their own technique as long as intravenous contrast is given for the chest and abdominal part of the TBCT."
1692321|NCT01523626|Other|Conventional imaging and selective CT scanning.|"The control group will be evaluated according to a conventional trauma protocol with X-rays (of the chest and pelvis), ultrasonography (Focused Assessment with Sonography for Trauma (FAST)) and selective CT scanning.
Indications for the selective CT scanning are pre-defined and based on the combined local protocols of the participating centers."
1692322|NCT01523613|Device|Chemfil ROCK Glassionomer restoration|High-viscous glassionomer restoration of Chemfil ROCK used as posterior dental filling material.
1692323|NCT01523613|Device|Fuji IX GP Extra Glassionomer restoration|High-viscous glassionomer restoration of Fuji IX GP Extra used as posterior dental filling material.
1692324|NCT01523600|Behavioral|Whole body vibration training|The intervention comprises a 10-week individually supervised, progressive WBV training done twice a week on a side-alternating device with simultaneous body transferring and slight squatting exercises. At the week one, the duration of a single training bout is 1 x 1 min, and the number of 1 min bouts is weekly increased by one until five bouts is reached. During weeks 4 - 10, the training comprises 5 x 1 min bouts with 1 min rest periods between. During weeks 1 to 3, vibration frequencies are 12 and 18 Hz, which are used alternately. Thereafter, also 26 Hz may be used instead of 18 Hz. In addition, the amplitude of vibration is increased progressively according to a specified protocol. A detailed training diary is kept.
1692325|NCT01523600|Behavioral|Wellness group|The intervention comprises a 10-week supervised group training done once a week with the focus on stretching and flexibility exercises done mostly in a sitting position. The duration of a single training session is 45 minutes. A training diary is kept.
1692326|NCT01523587|Drug|afatinib|Afatinib taken once daily, continuously until disease progression or unacceptable toxicity.
1692327|NCT01523587|Drug|erlotinib|erlotinib taken once daily
1692330|NCT01523561|Behavioral|dance group|"The dance intervention took place twice weekly for a period of 1 year under the guidance of two dance class teachers. The duration of the class was 75 min. and the dance training was always carried out to popular music. The dance choreography was adjusted to the level of the participants' skills in order to make them feel successful in their exercise. During the intervention year, the theme of dance styles varied from hip hop, jazz and contemporary dance. African dance was used in the warm up section. The dance class always ended with a relaxation. The dance intervention had a focus on emphasizing the participants' resources and creates a feeling of affinity. Listening to signals from the body, reducing focus on the performance and become part of the movement was encouraged."
1692331|NCT01523548|Drug|Carbon Monoxide|150 ppm x 3 hours once weekly (week 1) 150 ppm x 3 hours twice weekly (week 2) 150 ppm x 3 hours three times a week (week 3-16)
1692332|NCT01523535|Behavioral|repeated cycles of short sleep|- 3 nights of 4 hours of sleep followed by a single recovery night of 8 hours; repeated for 4 cycles
1692333|NCT01523522|Other|Myoblast injection|Autologous myoblast injection in the anal sphincter
1692334|NCT01523522|Procedure|saline solution injection|saline solution injection in anal sphincter
1692335|NCT01523509|Device|Radiographic contrast agent. Sodium Iodide.|Application of Sodium Iodide contrast topically to tooth immediately followed by radiograph.
1692338|NCT01523483|Drug|Progesterone|Two micronized progesterone capsules (Utrogestan® 200 mg, i.e. 400 mg of micronized progesterone in sunflower oil) placed into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
1692339|NCT01523483|Drug|placebo vaginal capsules|Two placebo capsules placed (soy lecithin and sunflower oil) into the posterior vaginal fornix once daily for up to 36+6 weeks of gestation.
1692340|NCT01523470|Device|BIPAP Synchrony|BIPAP Synchrony is a machine for non-invasive ventilation for acute hypercapnic respiratory failure in chronic obstructive airway disease exacerbation. It is a temporary measure. It is proven to be effective and reduce mortality and intubation in COAD exacerbation. However, the method of withdrawal of the machine remained controversial.
1692341|NCT01523457|Drug|Folfirinox|"Oxaliplatin 85 mg/m2 IV infused over two hours, followed by
Leucovorin 400 mg/m2 IV over two hours
Irinotecan 135 mg/m2 IV over 90 minutes (concurrent with leucovorin during the last 90 min of the leucovorin infusion)
5-FU 300mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46 hours
FOLFIRINOX is a chemotherapy regimen. It is made up of the following four drugs:
FOL - folinic acid (leucovorin), a vitamin B derivative that modulates/potentiates/reduces the side effects of fluorouracil; F - fluorouracil (5-FU), a pyrimidine analog and antimetabolite which incorporates into the DNA molecule and stops DNA synthesis; IRIN - irinotecan (Camptosar), a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating; and OX - oxaliplatin (Eloxatin), a platinum-based antineoplastic agent, which inhibits DNA repair and/or DNA synthesis."
1692378|NCT01523145|Other|Control Group|usual follow-up Standard follow-up at the participating heart center
1748289|NCT00176527|Drug|isotretinoin|
1692342|NCT01523444|Behavioral|computer-assisted Screening & Brief Advice|"The computer-facilitated screening and brief advice (cSBA) intervention is a self-administered, computer-facilitated screening that asks about lifetime and past-12-month use of substances followed by scientific information about how substance use affects health and true-life stories illustrating the health risks of substance use. The cSBA program prints out a Report Form with the screening results, risk level, and talking points designed to prompt a 2 to 3-minute provider/teen conversation about the health effects of substance use, which recommends abstinence."
1692343|NCT01523444|Behavioral|computer-assisted Screening & Brief Advice Plus|The cSBA+ intervention contains cSBA intervention elements plus the delivery of a brief, two-session motivational enhancement therapy (MET) intervention to be delivered a Behavioral Health Counselor (BHC) at the clinic immediately after meeting with the primary care provider. In the first session of this intervention, youth should be encouraged to think about: (1) The role alcohol and drugs play in his/her life; (2) His/her personal goals for changing alcohol and drug use; (3) Strategies for reaching and maintaining goals. The goal at the end of the session is positive movement in the direction of abstinence or change. The aim of the second session is reinforcement of goals set forth in the prior meeting with the BHC.
1692344|NCT01523431|Drug|Irinotecan Injection [Camptosar]|CPT-11 will be administered according to UGT1A1 genotypes. Patients with UGT1A1 *1/*1 or heterozygous UGT1A1*1/*28 or *1/*6 will receive standard dose of CPT-11. Patients with homozygous UGT1A1*28/*28, *6/*6 or *28/*6, will be randomized in a 1:1 ratio to receive standard dose of CPT-11 or 50% reduced dose of CPT-11.
1692345|NCT01523431|Drug|5-fluorouracil|The 5-FU dosage will remain the standard.
1692346|NCT01523431|Drug|Leucovorin|The LV dosage will remain the standard.
1692347|NCT01523418|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The treatment with Xarelto 10mg tablets should comply with the recommendations. Rivaroxaban 10mg OD, 6-10 hours post-op, provided hemostasis has been achieved, for a period of 2 weeks (TKR) & 5 weeks (THR)
1692348|NCT01523392|Drug|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
1692349|NCT01523392|Drug|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
1692350|NCT01523379|Drug|Parecoxib|90mg Parecoxib i.v. two times a day, two days in a row
1692351|NCT01523379|Drug|Placebo|NaCl i.v. two times a day, two days in an row
1692352|NCT01523366|Drug|Ticagrelor|Min - 90mg/Max - 180mg tablets (loading dose)
1692353|NCT01523366|Drug|Clopidogrel|75mg (once daily)/Max - 600mg tablets (loading dose)
1692354|NCT01523353|Behavioral|Exercise Intervention|4 week personalised exercise program on a static cycle. Supervised in a hospital environment
1692355|NCT01523327|Other|measuring protein creatinin ratio,serum uric acid|"A non-deproteinized Jaffe reaction is employed to measure creatinine and urinary protein measured by an automated colorimetric assay using pyrogallol red and sodium molybdate.
Measuring of serum uric acid by(2,4,6-tribromo-3-hydroxybenzoic acid)TBHBA by uricase method."
1692356|NCT01523314|Drug|dexamethasone - Cyclodextrin eye drops|The study eye will receive the dexamethasone NP eye drops 3 times a day for 3 months. The subject will be handed an eye drop bottle at each monthly visit for self administration of the eye drops. Each eye drop container is to be marked with a date when first opened and discarded after 1 week (unless it contains a preservative).
1692357|NCT01523314|Other|intravitreal Avastin injection +/- macular laser|The study eye will receive standard laser and intravitreal injections of Avastin for 3 months. Complete eye examination will be performed prior to drug administration.
1692358|NCT01523301|Drug|Rotigotine|"Transdermal Patch
Content:
2 mg /24 h (10 cm^2), 4 mg /24 h (20 cm^2), 6 mg /24 h (30 cm^2), 8 mg /24 h (40 cm^2)
For early-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 2 mg/24 h to 8 mg/24 h) for a maximum 4-week Titration Period, then 8 week Maintenance period
For advanced-stage Parkinson's disease, Subjects received Rotigotine patches in escalating weekly dose (starting with daily doses 4 mg/24 h to 16 mg/24 h) for a maximum 7-week Titration Period, then 8 week Maintenance period"
1692359|NCT01523301|Drug|Placebo|"Transdermal Patch
Size:
10 cm^2, 20 cm^2, 30 cm^2, 40 cm^2
Subjects randomized to placebo received matching placebo patches"
1692360|NCT01523275|Drug|Mitomycin -C|Topical mitomycin-C at a dosage of 0.4mg/ml will be applied to cottonoid pledgets and placed into the radial incisions for 3 minutes.
1692361|NCT01523275|Other|Saline application|Isotonic saline will be applied to cottonoid pledgets and placed into the patient's radial incisions for 3 minutes as the placebo intervention.
1692362|NCT01523262|Procedure|preconditioning|peripheral preconditioning induced by brief, intermittent constriction of blood supply to an arm
1692363|NCT01523262|Procedure|Normal surgery, with sham intervention without inflating arm cuff|
1692365|NCT01523236|Drug|Mometasone furoate|50 mcg/actuation Nasal Spray
1692366|NCT01523236|Drug|Nasonex®|50 mcg/actuation Nasal Spray
1692367|NCT01523236|Drug|Placebo|Nasal Spray
1692368|NCT01523223|Biological|therapeutic allogeneic lymphocytes|Undergo CD8 memory T-cell infusion
1692369|NCT01523210|Other|physiotherapy|thirty minutes passive flexion and extension of the elbow joint by a physiotherapist
1692370|NCT01523197|Device|BiPAP ventilation, auto-trilevel ventilation|Noninvasive ventilation including fixed BiPAP ventilation and auto-trilevel ventilation. Using the same IPAP, treatment include one night with BiPAP ventilation mode 1, one night with BiPAP ventilation mode 2 and one night with auto-trilevel ventilation mode. Each treatment last 8 hours for each night.
1692371|NCT01523184|Drug|Placebo Capsule|This is the placebo capsule
1692372|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 10 mg under investigation
1692373|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 20 mg under investigation
1692374|NCT01523184|Drug|YKP10811 Drug Product Capsule|The drug product, YKP10811, 30 mg under investigation
1692375|NCT01523171|Drug|SAR302503|"Pharmaceutical form:capsule
Route of administration: oral"
1692376|NCT01523158|Biological|Allergovit grass or birch|subcutaneous injection of immunotherapy once weekly for 7 weeks prior to birch pollen season.
1692379|NCT01523119|Drug|Ondansetron|Orally Disintegrating Tablets 8 mg
1748547|NCT00171106|Drug|valsartan|
1692381|NCT01523106|Other|Placebo|Patients will receive placebo, which will be manufactured by the same supplier as L-carnitine and appears identical. Patients will take an equal number of pills (8 pills/day).
1692382|NCT01523093|Drug|Ondansetron|Orally Disintegrating Tablets 8mg
1692383|NCT01523080|Drug|Acetaminophen|Extended release Gel tabs 650 mg
1692384|NCT01523067|Drug|Vasomera (PB1046)|Single dose of Vasomera
1692385|NCT01523067|Drug|0.9% Sodium Chloride|Placebo injection
1692386|NCT01523054|Drug|Metoprolol- Toprol XL|Extended release tablet, 200mg once daily for 4 days
1692387|NCT01523054|Drug|Metoprolol- Lopressor|Immediate release tablet, Day 1 50 mg four times daily, Day 2, 3 and 4 100 mg twice daily
1692388|NCT01523041|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
1692389|NCT01523041|Drug|biphasic insulin aspart 70|A single dose administrated subcutaneously (s.c., under the skin)
1692390|NCT01523041|Drug|biphasic insulin aspart 50|A single dose administrated subcutaneously (s.c., under the skin)
1692391|NCT01523028|Other|Soluble Coffee|"Amounts of chlorogenic acids will be normalized to body weight (3.1 mg CA / kg BW). Coffee will be reconstituted in 200 mL hot water and consumed 3 times in a row (min 1-week interval), alone or with a breakfast:
200 mL coffee or
200 mL coffee + 2 bread rolls + honey
200 mL coffee + 1 bread roll + peanut butter"
1692392|NCT01523015|Other|preoperative chemo- and chemoradiotherapy|2 cycles of triple regimen chemotherapy consisting of docetaxel (75mg/m2 iv infusion), oxaliplatin (130mg/m2 iv infusion) and 5-fluorouracil (750mg/m2 iv infusion followed by fractionated irradiation (total dose 45Gy in 25 fractions of 1,8Gy) combined with chemotherapy consisting of 3 cycles of 1-day chemotherapy with docetaxel (50mg/m2 iv infusion) and oxaliplatin (85mg/m2 iv infusion
1692393|NCT01523015|Procedure|Surgical resection|The extent of surgery will be associated with the topographic type of carcinoma of the esophagogastric junction: type I - subtotal esophagectomy with superior gastric resection, splenectomy and two-field mediastinal lymph node dissection; type II and III - total gastrectomy with distal esophagectomy, splenectomy and D2 with mediastinal inferior lymph node dissection.
1692394|NCT01523002|Drug|Metoprolol and Pyronaridine : artesunate|"On Day 1, subjects will receive a single oral 100 mg dose of metoprolol tartrate. On Day 8 and Day 9, subjects will receive a once daily oral dose of Pyramax as follows:
55 - < 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)
≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate)
On Day 10, a 100 mg dose of metoprolol will be coadministered with Pyramax at the above dose.
On Days 98 - 100, subjects will receive Pyramax once daily at the same dose described above."
1692395|NCT01523002|Drug|pyronaridine:artesunate|"In the first period, subjects will receive 3 days of Pyramax as follows:
55 - < 65 kg: 3 tablets (180:60 mg pyronaridine:artesunate)
≥ 65 kg: 4 tablets (180:60 mg pyronaridine:artesunate) followed by a 57 day follow-up period. In the second period, subjects will receive 3 days of Pyramax at the dose described above."
1692396|NCT01522989|Drug|PD-0332991|"Stage 1:
PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10
Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:
Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3
In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
1692397|NCT01522989|Drug|5-FU|"Stage 1:
PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10
Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:
Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3
In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
1692398|NCT01522989|Drug|Oxaliplatin|"Stage 1:
PD-0332991 daily Days 1-7 in escalating doses 5-FU 400 mg/m2 Day 8 Leucovorin 400 mg/M2 Day 8 5-FU continuous Infusion over 46 hours, 2400 mg/M2 Days 8-10
Stage 2: 3 cohorts of subjects each will be treated with the dose of PD-0332991 determined to be the recommended Phase 2 dose in Stage 1 of the study with 5-FU at the doses above but on different schedules:
Cohort 1: 5-FU bolus on Day 7 and infusion Days 7-9 Cohort 2: 5-FU bolus Day 9 and infusion Days 9-11 Cohort 3: 5-FU bolus Day 1 and infusion Days 1-3
In Stage 3, PD-0332991 and 5-FU will be given at the doses and schedule determined in Stages 1 and 2 of this study with the addition of oxaliplatin 85 mg/m2 given on the same day as the 5-FU bolus."
1692399|NCT01522976|Drug|Azacitidine|Given SC or IV
1692400|NCT01522976|Other|Laboratory Biomarker Analysis|Correlative studies
1692401|NCT01522976|Drug|Lenalidomide|Given PO
1692402|NCT01522976|Drug|Vorinostat|Given PO
1692403|NCT01522963|Drug|Nicotine lozenge|A single dose of nicotine lozenge will be given at various timepoints relative to completion of a somewhat stressful task
1692404|NCT01522950|Drug|Nebivolol|5 mg daily or 10 mg daily
1692405|NCT01522950|Drug|atenolol|25 mg daily or 50 mg daily
1692406|NCT01522950|Drug|placebo|one tablet daily
1692407|NCT01522937|Radiation|individualized Stereotactic Body Radiation Therapy (SBRT)|The individualized SBRT involves two treatment phases. The first phase of treatment involves receiving three fractions of SBRT, followed by a 1-month break and assessment of liver function with a blood test - Indocyanine Green (IC-Green). The second phase of treatment involves receiving two more fractions of SBRT, whose doses are adjusted to account for tolerance of the first phase of treatment.
1692408|NCT01522924|Other|Counseling practice sessions|Dental students will complete the first questionnaire before a tobacco cessation lecture and the second questionnaire after the lecture, counseling practice sessions using standardized patients and a debriefing session.
1692453|NCT01522612|Drug|leucovorin|Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
1692454|NCT01522599|Other|ARDS-Net Strategy|Treatment according to the ARDS-Net protocol (The Acute Respiratory Distress Syndrome Network N Engl J Med 2000; 342:1301-1308May 4, 2000)
1692455|NCT01522599|Other|ECCO2-R|Ventilation with Tidal Volume of 4 ml/kg PBW and low flow CO2 removal
1692409|NCT01522911|Device|WATCHMAN LAA system (Percutaneous left atrial appendage closure)|The WATCHMAN LAA system (Altritech Inc., Plymouth, MN),Percutaneous occlusion systems have been developed as an alternative to anticoagulation for stroke prevention. Briefly, transseptal puncture is performed to gain access to the left atrial appendage (LAA). Thereafter LAA angiography is performed. After an optimal device size is chosen based on LAA measurements by fluoro and echocardiography the occluder is implanted into the orifice of the left atrial appendage under fluoroscopy and TEE-guidance. The size of the device is chosen to be 10% to 20% larger than diameter of the LAA ostium to have stable positioning of the device. Every procedure is performed under local anaesthesia. Heparin is given during implantation procedure to achieve an activated clotting time of at least 250.
1692410|NCT01522898|Procedure|AV nodal ablation|Percutaneous catheter ablation of the AV node.
1692411|NCT01522898|Drug|Medical Ventricular Rate Control|Ventricular Rate Control with target ventricular rate of 90 beats per minute.
1692412|NCT01522885|Device|KatGuide versus conventional method (forceps)|According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
1692413|NCT01522885|Procedure|Chest tube insertion|The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
1692414|NCT01522872|Drug|TH-302|
1692415|NCT01522872|Drug|TH-302 and Dexamethasone|
1692416|NCT01522872|Drug|TH-302 Dose Escalation and Dexamethasone in Combination with Bortezomib|
1692417|NCT01522872|Drug|TH-302 Dose Escalation and Dexamethasone in Combination with Pomalidomide|
1692418|NCT01522859|Device|Telehealth monitoring system (Honni Med)|The system is uploaded with personal information including: monitoring start time; clinical observations (blood pressure, heart rate, oxygen saturations); and questions relating to symptoms. The patient is instructed on use and observed monitoring. The patient is monitored daily for a period of six months. The monitoring session lasts approximately 10 minutes during which the patient attaches a finger probe and blood pressure cuff and responds 'yes' or 'no' to the set questions. Daily data is transmitted via a phone line to a secure server to be downloaded and reviewed by a Telehealth nurse.If one or more of the clinical observations is outside normal limits the appropriate healthcare intervention is utilised.
1692419|NCT01522846|Drug|Heparin|Heparinized flush solution contained heparin concentration of 2 unit/ml and continuous flow of the flush solution was 5 ml/h at 300 mmHg.
1692420|NCT01522820|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given intranodally
1692421|NCT01522820|Other|Laboratory Biomarker Analysis|Correlative studies
1692422|NCT01522820|Other|Pharmacological Study|Correlative studies
1692423|NCT01522820|Drug|Sirolimus|Given PO or PEG
1692424|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
1692425|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
1692426|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
1692427|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fed state
1692428|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a suspension in the fasted state
1692429|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a short-duration osmotic capsule in the fasted state
1692430|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fasted state
1692431|NCT01522807|Drug|PF-05190457|100 mg single oral dose of PF-05190457 is administered as a long-duration osmotic capsule in the fed state
1692432|NCT01522794|Drug|NOX-H94|single i.v. infusion
1692433|NCT01522794|Drug|Placebo solution|single i.v. infusion
1692434|NCT01522768|Drug|Afatinib and Paclitaxel|All patients receiving therapy on trial with afatinib and trastuzumab will continue on afatinib and trastuzumab until disease progression or intolerable toxicity. All additional patients will be enrolled on afatinib and paclitaxel. Patients will be treated with afatinib and paclitaxel combination. Patients will receive oral afatinib 40 mg daily plus paclitaxel 80 mg/m^2 intravenously on day 1, 8, and 15 of a 28-day cycle.
1692436|NCT01522729|Drug|Fentanyl|Single-dose of intrathecal fentanyl [25ug] Duration of fentanyl : 3.5 hours
1692437|NCT01522729|Drug|Placebo comparator|placebo [NaCl]
1692438|NCT01522716|Biological|Mesenchymal stromal cells|Allogenous mesenchymal stromal cells, to be injected intravenously at a dose of 1-2 million/kg at a frequency of once a month (frequency may be changed during the study if deemed appropriate by investigators) for 6-9 months.
1692439|NCT01522703|Drug|Broccoli Sprouts|100g of either broccoli or alfalfa sprouts will be eaten daily in a sandwich or wrap form.
1692440|NCT01522703|Drug|Placebo|Alfalfa Sprouts
1692441|NCT01522690|Other|Different walk tests with an accelerometer device|Subjects will performed three walk tests of 50 meter at different speeds, a six minute walk test, a walking test of 30 seconds then a test to measure the maximum force of extension and knee flexion on each leg. The walk tests will be performed with the accelerometer device (Locometrix) worn in a belt
1692442|NCT01522677|Drug|PDT with 5-ALA radiosensitization|Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
1692443|NCT01522664|Drug|DEDN6526A|Multiple ascending doses
1692444|NCT01522651|Drug|Ranolazine|Ranolazine 750 mg tablet administered orally twice daily
1692445|NCT01522651|Drug|Dronedarone low dose 1|Dronedarone 225 mg capsule administered orally twice daily
1692446|NCT01522651|Drug|Dronedarone low dose 2|Dronedarone 150 mg capsule administered orally twice daily
1692447|NCT01522651|Drug|Ranolazine placebo|Placebo to match ranolazine administered orally twice daily
1692448|NCT01522651|Drug|Dronedarone placebo|Placebo to match dronedarone administered orally twice daily
1692449|NCT01522625|Drug|tenofovir disoproxil fumarate 300mg per day|tenofovir disoproxil fumarate 300mg per day for 3 years
1692450|NCT01522625|Drug|Placebo|Placebo, identical to TDF in appearance, once daily for 3years
1692451|NCT01522612|Drug|Cetuximab|500 mg/m2 on day 1, Every 14 days Intravenously
1692456|NCT01522586|Drug|DWP09031|DWP09031 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
1692457|NCT01522586|Drug|Placebo|placebo comparator 50mg/100mg/400mg/200mg/800mg/1200mg/1600mg/2000mg single dosing
1692458|NCT01522573|Procedure|EUS guided ERCP|Endoscopic ultrasound guided (EUS) endoscopic retrograde cholangiopancreatography (ERCP)
1692459|NCT01522560|Other|Feedback group|"Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
This group is going to have a 'coaching meeting' every month with the Chairman of Department of Pediatric Anesthesia to identify strengths and weaknesses and create strategies for improvement, based on the Multiscore Feedback (MSF)."
1692460|NCT01522560|Other|Control group|Besides the standard evaluation at the end of the rotation, in both groups, residents will receive every week a Multiscore Feedback (MSF) evaluation from the faculty, the patients' parent, and the coworker. Also, for every resident a baseline self assessment will be applied at the beginning and at the end of the rotation.
1692461|NCT01522547|Drug|pomalidomide|Pomalidomide orally for 84 days daily in doses ranging from 0.5 mg to 4.0 mg
1692462|NCT01522534|Drug|Mepivacaine|mepivacaine 1% 20 ml corresponding to 200 mg
1692463|NCT01522534|Drug|Morphine|Morphine alone with a placebo nerve block
1692464|NCT01522521|Drug|AK156|zoledronic acid (i.v.)/year + daily calcium and vitamin D for 2 years
1692465|NCT01522521|Drug|Placebo|placebo (i.v.)/year + daily calcium and vitamin D for 2 years
1692466|NCT01522508|Procedure|tetanic stimulation|as test stimulus a painful tetanic stimulation is used
1692467|NCT01522495|Device|SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)|Intravenous(1X) in conjunction with SPY Imaging (1 arm)
1692468|NCT01522495|Device|SPY Imaging|SPY Imaging to assess tissue perfusion
1692469|NCT01522482|Dietary Supplement|High saturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats.
1692470|NCT01522482|Dietary Supplement|Saturated fatty acids and fish oil meal|"Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for saturated fats and fish oil.
The dose of fish oils was equivalent to two portions of oily fish."
1692471|NCT01522482|Dietary Supplement|High unsaturated fat meal|Volunteers consumed a single test meal breakfast containing 53 g of fat, of which 50 g was substituted for unsaturated fats. It provided a fatty acid profile representative of a typical UK diet.
1692472|NCT01522469|Drug|Crenolanib Besylate (CP-868,596-26)|Subjects will take crenolanib 200mg/m2/day divided in three doses daily (preferably every eight hours), taken orally at least 30 minutes pre or post meal until disease progression, death, or the patient discontinues treatment for adverse events, investigator's judgment, or other reasons. Patients who are able to proceed to allogeneic stem cell transplant will be able to resume crenolanib therapy post-transplant in an attempt to maintain remission.
1692473|NCT01522456|Drug|Epiduo Gel|Once-daily application of fixed dose of adapalene 0.1% and benzoyl peroxide 2.5% in an aqueous based gel.
1692474|NCT01522456|Drug|Retin-A Micro Microsphere 0.1%|Once-daily application of tretinoin gel, 0.1% by weight, in a formulation of porous microspheres in an aqueous gel.
1692478|NCT01522430|Procedure|Renal angiography followed by renal sympathetic denervation|Radiofrequency catheter based therapy for renal denervation: Symplicity catheter will be advanced into the renal artery and connected to a radiofrequency generator. As previously described, four-to-six discrete, low-power radio frequency treatments will be applied along the length of both main renal arteries. At least four radiofrequency applications will be delivered in each renal artery, unless this is not feasible for anatomical reasons.
1692479|NCT01522430|Procedure|Renal angiography alone|Procedure will start with a local anesthesia of the femoral site to allow the placement of a 4-Fr sheath in the femoral artery, which allows a minimal risk of bleeding to the patient. Using JR-4 or similar diagnostic catheter, a selective renal angiography will be realized.
1692480|NCT01522417|Drug|Short Tirofiban|25 mcg/kg i.v. bolus followed by a 0.15 mcg/kg/min i.v. infusion during a PCI plus 1 to 2 hours post-PCI.
1692481|NCT01522417|Drug|Eptifibatide|180 mcg/kg bolus followed by a 2.0 mcg/kg/min infusion for 12 to 18 hours, with a second 180 mcg/kg bolus 10 min after the first.
1692482|NCT01522417|Drug|Long Tirofiban|25 ug/kg i.v. bolus followed by a 0.15 ug/kg/min i.v. infusion for 12 to 18 hours post-PCI.
1692485|NCT01522391|Drug|DPK-060 1% ointment|DPK-060 1% ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
1692486|NCT01522391|Drug|Placebo for DPK-060 ointment|Placebo for DPK-060 ointment applied to the skin, two applications per day using approximately 3 mg ointment per cm2
1692487|NCT01522378|Drug|123 iodine metaiodobenzylguanidine|10 millicurie (mCi) (370 MBq)
1692488|NCT01522365|Device|Abutment-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
1692489|NCT01522365|Device|Implant-supported XiVE CAD/CAM bridge|One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
1692490|NCT01522352|Procedure|Aortic valve replacement by bioprosthesis|Comparison of short and mid-term hemodynamic performance between three types of stented pericardial aortic valves: Trifecta aortic valve (St. Jude Medical), Mitroflow aortic valve (Sorin Group), Magna Ease (Edwards Lifesciences)
1692491|NCT01522339|Device|GE OPTIMA MR430s with HDX/GE Electronics|MRI scan(s) for no longer than 60 minutes
1692492|NCT01522326|Drug|Ibuprofen|Ibuprofen 400mg tablet. Take one dose by mouth.
1692493|NCT01522326|Drug|Metoclopramide|Metoclopramide 10mg tablet. Take one tablet by mouth.
1692494|NCT01522300|Other|Evaluation of the Tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study.
1692495|NCT01522300|Other|Avaluation of a medical device: the tomosynthesis|An exam by tomosynthesis will be realised at the inclusion of the patient in the study
1692496|NCT01522287|Behavioral|Computer-Assisted Cognitive Behavior Therapy (BT STEPS)|BT STEPS is a computer-assisted self help treatment for OCD. Clients work through the program at their own pace.
1692497|NCT01522274|Behavioral|Moderate intensity exercise|Brisk walking on a treadmill for 56 minutes 3x per week.
1692498|NCT01522274|Behavioral|Health education|Videos
1692499|NCT01522261|Other|Mechanical Bowel Prep|Patients randomized to MBP will complete procedure per standard instructions.
1692500|NCT01522261|Other|No Mechanical Bowel Prep|Patient randomized to fleets enemas only prior to surgery
1692501|NCT01522248|Biological|Trivalent Inactivated Influenza vaccine|0.5 ml IM once only
1692502|NCT01522235|Drug|Double blinded IVIg|Participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment IVIg, at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
1692503|NCT01522235|Other|Double blinded Placebo|Participants will receive placebo (5% albumin) at 2.0 gm/kg over 2-4 consecutive days. A maintenance treatment with placebo (5% albumin) at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later. All participants will proceed to the single blind Second Observation Period.
1692504|NCT01522235|Other|Single Blinded IVIg|This is the single blind Second Observation Period. All participants will receive study treatment with IVIg, at 2.0 gm/kg over 2-4 consecutive days. A maintenance study treatment at 1.0 gm/kg, over 1-2 consecutive days will occur three weeks later.
1692505|NCT01522222|Procedure|continuous, mechanical ventilatory support|Those in the treatment group will receive ventilation, intermittent positive pressure ventilation, while their heart is arrested. The subjects will have their lungs ventilated six times per minute with a tidal volume equal to 7-10 milliliters per kilogram. This range, when combined with a consistent PEEP of 5cm of water pressure, will allow for the peak inspiratory pressure to be maintained at or below 40cm of water pressure. In addition, the FIO2 will remain consistent at the same level that was needed to maintain the pulse oximetry at 94% as well as the end-tidal CO2 at 35mmHg.
1692506|NCT01522209|Procedure|Liver Surgery|R0 Resection of Liver Metastases after Planning with preoperative imaging data and comparison with intraoperative contrast enhanced ultrasound
1692507|NCT01522209|Device|Contrast Enhanced Ultrasound|The contrast enhanced Ultrasound imaging is performed before and during the operation using Sonovue contrast agent (2.5ml iv preop, 4.5ml iv intraop)
1692508|NCT01522209|Radiation|CT Scan (standard)|A staging CT of the liver/abdomen with the minimal possible dosage for aquiring sufficent triphasic data in a 64-line helical scan
1692509|NCT01522209|Radiation|Primovist MRI (3 Tesla)|an MRI scan of the liver with Primovist contrast agent including late phase as addition to the preop staging according to the protocol
1692510|NCT01522196|Drug|Varespladib|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
1692511|NCT01522196|Other|Placebo (Normal Saline)|48 hour continuous infusion delivered intravenously (IV)at a rate of 110µg/kg/hr.
1692512|NCT01522157|Dietary Supplement|Low-fat Diet|Low-fat Diet is provided for a breakfast and a lunch.
1692513|NCT01522157|Dietary Supplement|Low-carbohydrate Diet|Low-carbohydrate Diet is provided for a breakfast and a lunch.
1692514|NCT01522157|Dietary Supplement|Mediterranean Diet|Mediterranean Diet is provided for a breakfast and a lunch.
1692515|NCT01522144|Behavioral|Computerized Decision support|Using a clustered randomized method, computerized decision support, embedded in the electronic health record, was offered to selected primary care practices and outcomes of asthma care were compared to those practices without the computerized decision support.
1692516|NCT01522131|Procedure|bioresorbable membrane alonewill be used for regeneration of the periodontium(control)|bioresorbable membrane with laser will be used for regeneration of the periodontium(test)
1692517|NCT01522118|Device|ExAblate 2100; InSightec|"Patients with biopsy proven locally non-advanced T2 prostate cancer identified at 3T MR examination including dynamic contrast enhanced (DCE-with time to peak and mean transit time evaluation) and candidate to radical prostatectomy will undergo Magnetic Resonance guided Focused Ultrasound (MRgFUS) ablation. The procedure is carried out either under general anesthesia or spinal block.
MR images allow correct identification of the target as well as vital structure to avoid during energy delivery. Treatment safety and efficacy is monitored in real time using MR thermometry. Adjustments of energy direction and intensity can be made according to the real time monitoring. Pre- and post-ablative MR examinations will serve to analyze differences of DCE features of the neoplastic tissue; therapy-induced alterations will also be compared to histopathology findings from whole section prostate specimens"
1692518|NCT01522105|Drug|Daptomycin|One dose of daptomycin given at an age appropriate dosage (3-24 months 6mg/kg; 2-6 years 10mg/kg; 7-11 years 8mg/kg; 12-16years 6mg/kg)
1692519|NCT01522092|Drug|escitalopram|5mg-20mg, tablet, od, 12 months
1692520|NCT01522079|Procedure|Air stacking manuever|Electrocardiogram signals were recorded for analyses of heart rate variability during air stacking in supine and sitting position
1692521|NCT01522066|Procedure|Perineural catheter|Patients in the experimental group will receive a single dose of local anesthetic though an indwelling catheter both before and after surgery.
1692522|NCT01522066|Procedure|Single-shot block|Patients in the control group will receive a single shot of local anesthetic, in standard fashion, before surgery.
1692523|NCT01522053|Procedure|Catheter-over-needle|Patients in the experimental group will receive a perineural catheter placed by the catheter-over-needle method.
1692524|NCT01522053|Procedure|Catheter-through-needle|Patients in the control group will receive a perineural catheter placed by the traditional catheter-though-needle method.
1692525|NCT01522040|Drug|Magnesium Sulfate|Continuous magnesium drip, titrated to effect until patient's symptoms improve
1692526|NCT01522040|Drug|Placebo|Simple saline drip, without active drug
1692527|NCT01522027|Procedure|Percutaneous tracheostomy|Twenty ICU patients will receive percutaneous tracheostomy via insertion of a needle/catheter connected to a nerve stimulator.
1692528|NCT01522014|Device|Secure-Fit™ arc-deposited Hydroxylapatite (HA) shell - surface ceramic and an Alumina Bearing Couple (ABC) ceramic insert and Ceramic C-taper head|
1692529|NCT01522014|Device|Secure-Fit™ arc-deposited hydroxylapatite shell, a Crossfire® insert and a Ceramic C-taper head|
1692530|NCT01522001|Behavioral|Shared Care model|"First visit at cardiac ambulatory approximately 14 days after discharge includes physician examination by cardiologist and counseling from nurse specialized in cardiac rehabilitation.
Dietary counseling with dietician
Exercise (1 hour, 2 timer pr week for 12 weeks)
Smoking cessation if smoker with educated smoking cessation instructor
Patient education and psychosocial support in 2 individual consultations and 8 group based consultations with experienced nurse
Examination by the patient´s general practitioner 8-12 weeks after discharge."
1692531|NCT01521988|Procedure|Atrial flutter ablation|Radiofrequency ablation of Atrial flutter
1692532|NCT01521988|Procedure|Atrial flutter ablation and pulmonary vein isolation|Radiofrequency ablation of atrial flutter and pulmonary vein isolation using cryoablation
1692534|NCT01521962|Drug|Alogliptin|Alogliptin tablets
1692535|NCT01521962|Drug|Insulin|Insulin injection
1692536|NCT01521949|Drug|Acai Juice Product|2 ounces of Acai Juice Product twice daily.
1692537|NCT01521936|Dietary Supplement|cholecalciferol|Given PO (lower dose)
1692538|NCT01521936|Other|pharmacological study|Correlative studies
1692539|NCT01521936|Dietary Supplement|cholecalciferol|Given PO (higher dose)
1692540|NCT01521936|Other|laboratory biomarker analysis|Correlative studies
1692541|NCT01521923|Biological|Certolizumab Pegol + Methotrexate (MTX)|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at dosage strength of 200 mg/ml.
On a maintenance dose of 200 mg every 2 Weeks (Q2W) until Week 102. On a maintenance dose of 200 mg every 4 Weeks (Q4W) until Week 102/ Placebo (PBO) 1 syringe every 4 Weeks (Q4W).
CZP and PBO administration to be staggered 2 Weeks apart to maintain blind.
The MTX treatment is to remain between 15-25 mg/week."
1692542|NCT01521923|Biological|Placebo + Methotrexate (MTX)|"1 syringe of Placebo every 2 Weeks and MTX.
The MTX treatment is to remain between 15-25 mg/week."
1692543|NCT01521910|Dietary Supplement|low protein diet|"An iso-caloric low protein diet of 0.6 g/kg/day was prescribed during the whole study duration.
The same dietician gave nutritional advices at least every three months during the whole study period. Patients were also seen by the same doctor during each visit for the whole study period.
Supplementation of Calcium of 500mg/day.
Urine albumin losses >= 2 g/day wre replaced by increasing dietary protein on a gram-for-gram basis, only if the patient was compliant with the prescribed low-protein diet."
1692544|NCT01521910|Dietary Supplement|normal protein diet|"The patients pre-study diet during the whole study period
Patients were also seen by the same doctor during each visit for the whole study period."
1692545|NCT01521897|Biological|7-valent vaccine injection|For primary immunization, three doses of Prevenar 0.5 mL should be injected subcutaneously with an interval of at least 27 days between each dose. For booster immunization, one dose of Prevenar 0.5 mL should be injected subcutaneously, at least 60 days after the 3rd dose.
1692546|NCT01521884|Other|SC anti-TNF|SC anti-TNF
1692547|NCT01521871|Procedure|Skin wound closure by tissue glue|The glue is used both as closure device and as wound dressing.
1692548|NCT01521871|Procedure|Skin wound closure by conventional suture + dressing|Suture: Intracutaneous skin closure, by running, absorbable suture (Caprosyn 4-0) Dressing: Conventional textile dressing (Mepor)
1692549|NCT01521845|Drug|omega 3|3 gram omega 3 (400mg EPA and 200mg DHA) 12hours before PCI
1692550|NCT01521832|Drug|SEN0014196|5 mg single oral dose
1692551|NCT01521832|Drug|SEN0014196|25 mg single oral dose
1692552|NCT01521832|Drug|SEN0014196|75 mg single oral dose
1692553|NCT01521832|Drug|SEN0014196|150 mg single oral dose
1692554|NCT01521832|Drug|SEN0014196|300 mg single oral dose
1692555|NCT01521832|Drug|SEN0014196|600 mg single oral dose
1692556|NCT01521832|Drug|SEN0014196|300 mg single oral dose (females)
1692557|NCT01521832|Drug|SEN0014196|100 mg multiple oral dose
1692558|NCT01521832|Drug|SEN0014196|300 mg multiple oral dose
1692559|NCT01521832|Drug|SEN0014196|100 mg BID multiple oral dose
1692560|NCT01521832|Drug|SEN0014196|100 mg BID multiple oral dose (females)
1692561|NCT01521819|Radiation|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
1692562|NCT01521819|Drug|Lucentis|Intravitreal injection of Lucentis as needed.
1692564|NCT01521793|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
1692565|NCT01521780|Procedure|MRI|Participants undergo volumetric & diffusion weighted (DW) MRI. Participants are scanned twice, with an intervening fifteen minute walk between the scans.
1692566|NCT01521780|Procedure|Pathology|Participants who are undergoing surgical resection of HCC per their standard of care treatment, will submit tumor samples for biomarker analysis.
1692567|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml. During Visit 3, blood samples totaling 22 ml, are collected at least 6-18 hours post-resection, and every other day up to a week until discharge. At follow up Visit 4, 5.5 ml of blood is collected.
1692568|NCT01521780|Procedure|Blood Samples|Blood is collected from participants during screening Visit 1 - 24.5 ml, and follow up Visit 4 - 5.5 ml.
1692569|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of extended release capsules
1692570|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
1692571|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
1692572|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
1692573|NCT01521767|Drug|tolterodine tartrate|4 mg single dose of microspheres in powder blend
1692574|NCT01521728|Other|Resistance Exercise|Resistance will be administered using a series of adjustable cuff weights for the upper limbs and hip flexion. Knee flexion and extension will be administered with a weight bench using a leg exercise attachment and free weights.
1694118|NCT01509898|Device|Water jet|use of water jet for a month
1692575|NCT01521728|Other|Endurance Exercise|Endurance will be administered using a minicycle. It can be used from a sitting position (chair or wheelchair) for lower limb exercise and then placed on a tabletop for upper limb use.
1692576|NCT01521728|Other|Stretching/Range-of-Motion|"Stretching and range of motion exercise is widely accepted as a standard of care for ALS management."
1692577|NCT01521715|Drug|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until progression or occurrence of intolerable toxicity.
1692578|NCT01521702|Drug|Neoadjuvant chemotherapy|four bi-weekly cycles of gemcitabine (intravenous infusion of 1000mg/m2 over 30 minutes) and oxaliplatin (intravenous infusion of 100mg/m2 over 2 hours,
1692579|NCT01521702|Procedure|surgery and Adjuvant chemotherapy|surgery and Adjuvant chemotherapy must be started within eight weeks after surgery and is based on the standard regimen using six cycles of gemcitabine (Gem 1000mg/m2 over 30 minutes) on days 1, 8, 15 every 4 weeks.
1692580|NCT01521689|Drug|Rituximab|Low doses of sub cutaneaous rituximab
1692581|NCT01521676|Genetic|molecular alteration|research of molecular alteration
1692582|NCT01521663|Drug|IPX159|
1692583|NCT01521663|Drug|Placebo|
1692584|NCT01521650|Dietary Supplement|Probiotics|Patients will gurgle and swallow a mixture of probiotic bacteria
1692585|NCT01521637|Procedure|Neuromuscular Electrical Stimulation of m. quadriceps femoris|Neuromuscular Electrical Stimulation of m. quadriceps femoris by using a commercially available muscle stimulator
1692586|NCT01521637|Procedure|Sham-treatment: no NMES|Sham comparator
1692587|NCT01521624|Drug|Metformin|Metformin 1000 mg Daily in two divided doses plus advice for lifestyle modification
1692588|NCT01521611|Radiation|Targeted radiotherapy|Yttrium-90 labelled anti-CD66 monoclonal antibody.
1692589|NCT01521598|Drug|SKL11197|SKL11197 drug product contains 150 mg of active ingredient. Dosing will be three times per day.
1692590|NCT01521598|Drug|Placebo|This is the placebo. Patients will be randomized the placebo.
1692591|NCT01521585|Drug|SEN0014196|50 mg oral once daily tablet
1692592|NCT01521585|Drug|SEN0014196|200 mg oral once daily tablet
1692593|NCT01521585|Drug|Placebo|oral once daily tablet
1692594|NCT01521572|Drug|Salbutamol sulphate|bronchodilator test, beta2-agonist, short-acting, six hours duration, 400 micrograms.
1692595|NCT01521559|Procedure|Macular Laser Photocoagulation|
1692596|NCT01521559|Drug|Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)|
1692597|NCT01521546|Drug|eplerenone|25mg tablet, once daily by mouth for 12 months
1692598|NCT01521546|Drug|placebo|one tablet by mouth daily for 12 months
1692599|NCT01521533|Drug|NOX-A12|"Pilot Group (NOX A12 single agent, and combined with VD):
3 cohorts of 3 patients will receive treatment with NOX A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX A12 and VD will start. The combination of NOX A12 and VD will follow a dose titration design beginning at 1 mg/kg NOX A12 (cycle 1) proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX A12 in combination with VD. This is followed by consolidation in cycles 4-8 when NOX-A12 will be kept at the highest individually titrated dose.
Expansion Group (NOX A12 in combination with VD):
Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
1692600|NCT01521520|Drug|ferumoxytol|Ferumoxytol at a dose of between 1 and 6 mg iron/kg body weight (maximum 510 mg/injection) will be administered via intravenous injection. Ferumoxytol will be administered with each series of MRIs.
1692601|NCT01521507|Device|LipiFlow System|In-office device treatment for meibomian gland dysfunction by a physician
1692602|NCT01521507|Device|Warm Compress Therapy + Lid Scrub|At-home daily warm compress therapy and lid hygiene
1692603|NCT01521494|Drug|PA21|
1692604|NCT01521494|Drug|PA21|
1692605|NCT01521494|Drug|PA21|
1692606|NCT01521494|Drug|PA21|
1692607|NCT01521494|Drug|Placebo|
1692608|NCT01521481|Other|Triple inguinal nerve block.|Ultrasound-guided genitofemoral, iliohypogastric and ilioinguinal nerve block with ropivacaine 5 mg/ml, 150 mg.
1692609|NCT01521481|Other|Unilateral subarachnoid anesthesia|Subarachnoid anesthesia with hyperbaric bupivacaine 10 mg/ml, 12 mg, homolateral to inguinal hernia.
1692610|NCT01521455|Drug|HCP0910|250/50, BID for 2 weeks
1692611|NCT01521455|Drug|Seretide Diskus|250/50, BID for 2 weeks
1692612|NCT01521442|Behavioral|Mindful Yoga Therapy|Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
1692613|NCT01521442|Behavioral|Wait-list Control|Participants will receive Mindful Yoga Therapy intervention after 12 weeks from being enrolled. Veterans will participate in twice weekly Mindful Yoga Therapy, which includes meditation, breathing practices, mindful movement, and guided rest (yoga nidra), as well as daily home practice.
1692614|NCT01521416|Other|Data collection|"Data of patients diagnosed with acute respiratory illness is extracted from General Practice Research Database (GPRD), Hospital Episode Statistics (HES), the Health Protection Agency (HPA), Office of National Statistics (ONS), and National Health Service (NHS) Reference Costs, during the period January 21st 2001 and March 31st 2009 inclusive.
All analyses of primary care data (GPRD) and separately for secondary care (HES) data will be repeated for all eligible patients, and the subset of patients with a linkage to additional data (HES, ONS). All analysis including secondary care data will be restricted to the subset of patients with linked HES data. Estimates of average burden per patient and total burden in the UK will be performed. Burden is defined as both resource use and cost. Annual incidence and burden will be calculated."
1692615|NCT01521403|Drug|Metronidazole|3x500 mg/day for 10 days
1692616|NCT01521403|Drug|Placebo|3x1 tablet per day for 10 days
1692617|NCT01521390|Drug|GSK573719 62.5 mcg (one strip)|GSK573719 62.5 mcg delivered by 1 strip configuration of novel dry powder inhaler
1692618|NCT01521390|Drug|GSK573719 62.5 mcg(two strips)|GSK573719 62.5 mcg delivered by 2 strip configuration of novel dry powder inhaler
1692619|NCT01521390|Drug|GSK573719 125 mcg (one strip)|GSK573719 125 mcg delivered by 1 strip configuration of novel dry powder inhaler
1692620|NCT01521390|Drug|GSK573719 125 mcg(two strips)|GSK573719 125 mcg delivered by 2 strip configuration of novel dry powder inhaler
1692621|NCT01521390|Drug|Placebo|Placebo, no active ingredient
1692622|NCT01521377|Drug|Placebo Moxifloxacin|Single dose placebo oral tablet Moxifloxacin
1692623|NCT01521377|Drug|Moxifloxacin|Single oral dose tablet Moxifloxacin (400mg)
1692624|NCT01521377|Drug|GSK573719/Vilanterol 125/25mcg|Single inhalation from GSK573719/Vilanterol 125/25mcg DPI once daily
1692625|NCT01521377|Drug|GSK573719|Single inhalation from GSK573719 500mcg DPI once daily
1692626|NCT01521377|Drug|GSK573719/Vilanterol 500/100mcg|Single inhalation from GSK573719/Vilanterol 500/100mcg DPI once daily
1692627|NCT01521377|Drug|Placebo DPI|Single Inhalation from matching Placebo DPI once daily
1692628|NCT01521364|Drug|Addition of different doses of clarithromycin.|"At week 1, 250mg clarithromycin once a day will be added to linezolid therapy during two weeks.
At week 3, 500mg clarithromycin once a day will be added to linezolid therapy during to weeks."
1692629|NCT01521325|Drug|Amatuximab|Subjects will receive one infusion of radiolabeled amatuximab.
1692630|NCT01521312|Drug|saxagliptin|5mg a day for 11-14 weeks
1692631|NCT01521312|Other|placebo pill|one tablet a day for 11-14 weeks
1692632|NCT01521299|Drug|Hydroxyurea|oral hydroxyurea on days 1,8 and 15
1692633|NCT01521286|Other|Data collection|HZ and PHN booklet questionnaire and zoster brief pain inventory (ZBPI) questionnaire.
1692634|NCT01521273|Other|Bean varieties|10 x 50 g/ arm
1692635|NCT01521260|Procedure|placebo|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of rinsing with a placebo solution (saline with appearance of chlorhexidine + CPC) and 1 minute of saline rinsing.
1692636|NCT01521260|Procedure|Chlorhexidine|Implants with peri-implantitis lesions will be surgically exposed, followed by a mechanical cleansing using curettes and gauzes and cotton pellets soaked in saline, 1 minute of chemical cleansing using 0,12% chlorhexidine + cetylpyridinium chloride (CPC) without alcohol (Perio-aid®) and 1 minute of saline rinsing.
1692637|NCT01521247|Other|Asthma Transition Program|Asthma Education.
1692638|NCT01521234|Behavioral|Feedback of daily walking activity|Participants will wear accelerometers every weekday during in-patient rehabilitation to monitor walking activity. Feedback of daily walking activity will be provided to the patients' treating physiotherapists to assist with goal-planning around walking.
1692639|NCT01521221|Other|Hand grip maneuver|Hand grip on blood pressue cuff slightly inflated at 50-70% of maximal force for 1 minute
1692640|NCT01521208|Device|LUCAS (Lund University Cardiac Assist Sysrem)|LUCAS device will be placed on patients suffering a cardiac arrest and continuous chest compressions will be performed, even while defibrillation is being applied
1692641|NCT01521208|Other|Manual chest compressions|Manual CPR according to 2010 ERC guidelines will be performed
1692642|NCT01521195|Device|Extracorporeal blood flow via ECMO machine|"Extracorporeal Membrane Oxygenation (ECMO) machine can provide complete support of heart and lung function.
Extracorporeal blood flow will be given at baseline rate, increased by 25% and decreased by 25%"
1692643|NCT01521182|Other|1-Fermented Dairy Product (test)|1 = Intervention 1 (test product)
1692644|NCT01521182|Other|2-Milk-based non-fermented dairy product (control)|2 = Intervention 2 (control product)
1692645|NCT01521169|Other|1 - low-fat dairy fermented product (drinkable) enriched with plant sterols (0,8g /day equivalent as free sterols).|1 = Intervention with test product 1 (0,8g of plant sterol/day)
1692646|NCT01521169|Other|2 - low-fat dairy fermented product (drinkable) enriched with plant sterols (1,6g /day equivalent as free sterols).|2 = Intervention with test product 2 (1,6g of plant sterol/day)
1692647|NCT01521169|Other|3 - low-fat dairy fermented product (drinkable) without plant sterols.|3 = Intervention 3 (1 control product/day)
1692648|NCT01521156|Other|1- low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
1692649|NCT01521156|Other|2- low-fat dairy fermented product (drinkable) enriched with experimental plant sterols-esters (1,6g /day equivalent as free sterols).|2 = Intervention 2 (1 test product/day)
1692650|NCT01521143|Biological|Cvac|Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.
1692651|NCT01521143|Biological|Placebo|"Injections were done at 4 anatomical sites, 1 injection in each of the upper portions of both arms and both thighs.
Placebo consisted of the Cvac formulation buffer (5% HSA, 10% DMSO) with 0.9% simethicone provided in 1 mL vials that had been cryopreserved and stored at the manufacturing facility."
1692652|NCT01521130|Drug|Levetiracetam|Medication doses are defined on a mg/kg basis. Dosage form, frequency and titration schedule is based on accepted clinical practice.
1692653|NCT01521117|Drug|Donepezil|Use 1 capsule (5 mg) of donepezil once per day for first 21 days than donepezil 10mg qday for 21 days.
1692654|NCT01521078|Behavioral|Check Your Drinking University version|The CYDU is an internet-based intervention that provides a personalized feedback summary which compares the participant's drinking to that of other university students. The CYDU is a modified version of the Check Your Drinking screener which has been validated in four separate randomized controlled trials. The primary modification of the CYDU is that the population norms used for comparison are those of university students (in the USA or Canada).
1692655|NCT01521065|Device|IRay|Approved dose of Anti-VEGF injection given at Day 0 followed by treatment with 16 Gy dose of IRay up to 14 days later.
1692656|NCT01521052|Device|dTMS treatment (H1 Coil)|All subjects will receive prefrontal deep rTMS of H1 Coil (42 trains of 2 seconds, 10 Hz, with 20 seconds inter-train intervals, up to 120% of motor threshold), for 4 weeks, 5 days a week, overall 20 sessions.
1692657|NCT01521039|Procedure|Blood samples|2-3 tablespoons of blood weekly for the first 100 days (about 14 weeks) following allogeneic transplant. In addition a blood sample will be obtained before starting the chemotherapy or radiation regimen for the transplant, in the day of the transplant and if your doctor suspects that you have acute graft-versus-host disease.
1692658|NCT01521026|Behavioral|Cognitive Training|12-week compensatory cognitive training in group format
1692689|NCT01520766|Device|prefabricated glass fiber reinforced composite post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
1692659|NCT01521013|Behavioral|Supported self-care|"Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
Subjects will be contacted (by telephone) by their coach, initially at weekly intervals. The frequency of calls will thereafter be mutually determined by subject and coach, but will not exceed weekly calls during the first 3 months, or monthly calls from months 3 to 6. Calls will last an average of 10 minutes. The coach will follow a script to educate/ motivate/guide the subject in the use of the Workbook."
1692660|NCT01521013|Behavioral|Unsupported self-care|Subjects will receive a package of depression self-care materials, to include the Antidepressant Skills Workbook, a mood monitoring tool, an informational video on depression, information for family members, and information on additional resources (reading materials, internet sites, community groups).
1692661|NCT01521000|Device|Garment Sleeve|compression sleeve (20 to 30 mm of Hg)
1692662|NCT01520987|Drug|BIA 9-1067|5 mg, 25 mg, and 50 mg of BIA 9-1067 (once-daily).
1692663|NCT01520987|Drug|Placebo|once-daily
1692664|NCT01520974|Other|ProBiora3 mints|Probiotic mint tablet taken once daily for 12 weeks containing ProBiora3, a combination of three known healthy bacteria
1692665|NCT01520974|Other|Placebo tablet|Mint tablet taken once daily for 12 weeks without the ProBiora3 combination of three known healthy bacteria
1692666|NCT01520948|Behavioral|Exercise-based behavioral therapy|Pelvic floor muscle exercise training, bladder training, fluid management, constipation management
1692667|NCT01520948|Behavioral|Behavioral control|Mirrored star drawing
1692668|NCT01520935|Other|Data collection|"The study, will use four primary data sources: the General Practice Research Database (GPRD, for mild outcomes), the Hospital Episode Statistics database (HES, for hospitalizations), the Office of National Statistics mortality database (ONS, for mortality), and weekly virology data from the Health Protection Agency (HPA).
Weekly time series of the rates of various influenza-related health outcomes in the various databases, such as office visits for acute otitis media and hospitalizations for pneumonia will be constructed. Statistical models, guided by weekly numbers of cases of laboratory-confirmed influenza and respiratory syncytial virus (RSV) contained in the HPA virology data, to estimate the portions of the various outcomes that can be attributed to influenza will be constructed. Finally, the seasonal impact of influenza by risk status, vaccination status, and seasons in which a well-matched versus mismatched influenza vaccine was used, will be assessed."
1692669|NCT01520922|Biological|Ofatumumab|Ofatumumab (ARZERRA™) is an immunoglobulin G1κ (IgG1κ) human monoclonal antibody that specifically recognises a distinct epitope encompassing both large and small extracellular loops on the human CD20 molecule expressed on B cells and binds to this site with high affinity with a dissociation half-life of approximately 3 hours. Ofatumumab induces more efficient complement-dependent cytotoxicity (CDC) mediated cell lysis in vitro, compared to rituximab, especially in low CD20 density cells.
1692670|NCT01520922|Drug|Bendamustine|Bendamustine is a cytostatic drug which structurally combines a purine-like benzamidazol nucleus and a bifunctional alkylating nitrogen mustard group.
1692671|NCT01520909|Drug|Eltrombopag|Thrombopoietin receptor agonist
1692672|NCT01520909|Drug|Placebo|Placebo with no active pharmaceutical ingredient
1692673|NCT01520896|Drug|NKTR-118|Oral 25 mg
1692674|NCT01520896|Drug|Ketoconazole|Oral 400 mg
1692675|NCT01520870|Drug|PF-299804 (Dacomitinib)|Dacomitinib will be administered orally at a dose of 45 mg/day, until disease progression, unacceptable adverse side effects or study end.
1692676|NCT01520857|Procedure|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under spinal anesthesia
1692677|NCT01520857|Procedure|Transabdominal Preperitoneal repair of inguinal hernia|Transabdominal Preperitoneal (TAPP) repair of inguinal hernia using CO2 pneumoperitoneum under general anesthesia
1692678|NCT01520844|Biological|blood sampling|blood sampling
1692679|NCT01520831|Drug|biphasic insulin aspart 30|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
1692680|NCT01520831|Drug|biphasic insulin aspart 50|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
1692681|NCT01520831|Drug|biphasic insulin aspart 70|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
1692682|NCT01520831|Drug|insulin aspart|One single dose of 0.3 U/kg body weight administered subcutaneously (s.c., under the skin) at one of four study days
1692683|NCT01520818|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being obese with a body mass index (BMI) exceeding 30 kg/m^2 will receive BIAsp 50
1692684|NCT01520818|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner. Randomised subjects being lean and overweight with a body mass index (BMI) of maximum 30 kg/m^2 will receive BIAsp 70
1692685|NCT01520818|Drug|biphasic human insulin 30|Administered subcutaneously (s.c., under the skin), twice a day
1692686|NCT01520805|Drug|CPI-613|CPI-613 drug product, provided in concentrated form at 50 mg/mL, must be diluted with D5W prior to administration. CPI-613 is to be infused intravenously (IV) via a central venous catheter. The dose of CPI-613 will be either the Maximum Tolerated Dose (MTD) or the highest No-Significant- Adverse-Effects-Dose-Level (NOAEL), as determined from the nearly completed Phase 1 dose-escalation clinical trial in patients with hematologic malignancies (i.e., Cornerstone Study# CL-CPI-613-009 or Wake Forest Study# CCCWFU 29109, under IND 107,800).
1692687|NCT01520792|Drug|Paracetamol (drug)|Randomized, single-center, placebo-controlled, double-blind, cross-over in 100 healthy volunteers meeting the inclusion criteria and receiving 2g of paracetamol orally or placebo on two study periods separated by one week.
1692688|NCT01520766|Device|prefabricated titanium post|posts: diameter of 1.4 mm; length of 13 mm adhesively luted within the root canal using self-adhesive resin cement and direct composite cores using an etch-and-rinse adhesive were built up crown preparation was performed, while the finishing line for the final restoration was set at least 2 mm apical the composite build-up in dentin to ensure a proper dentin ferrule design
1692690|NCT01520753|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast, lunch and dinner
1692691|NCT01520753|Drug|biphasic insulin aspart 70|Administered subcutaneously (s.c., under the skin) at breakfast and lunch
1692692|NCT01520753|Drug|biphasic insulin aspart 50|Administered subcutaneously (s.c., under the skin) at dinner
1692693|NCT01520740|Device|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
1692694|NCT01520740|Device|Emphysematous Lung Sealant|4 Subsegments treated - 2 each bilaterally
1692695|NCT01520727|Drug|BIA 9-1067|single ascending doses in up to 8 sequential groups of 8 healthy young male subjects
1692696|NCT01520727|Drug|Placebo|single-dose
1692697|NCT01520714|Device|Medtronic 4195 active fixation LV lead and Medtronic passive fixation LV lead|1:1 randomization between Medtronic active fixation 4195 LV lead and another FDA approved passive fixation Medtronic LV lead. Fluoroscopic images will be taken at implant in a supine position and again at 3 month follow-up in different postural positions with capture thresholds of the LV lead taken at each postural position.
1692698|NCT01520701|Device|bandage skin Hydrotac®|Patients randomized to the arm with bandage skin will benefit from the application of the bandage skin hydrogel (Hydrotac®) at least 5 hours per day for the duration of treatment (the first day last day of radiotherapy).
1692699|NCT01520701|Drug|Ialuset®|Patients randomized to receive reference of the application of cervical Ialuset® on skin throughout the treatment period (the first day to last day of radiotherapy).
1692706|NCT01520675|Procedure|surgery|Drainage procedure
1692707|NCT01520675|Procedure|Endoscopic therapy|pancreatic sphincterotomy, removal of calculi, stenting, ESWL
1692708|NCT01520662|Other|Implementation of a secure web-based patient Wellness Portal|Patients in intervention practices will review and update their wellness records, risk factor information, allergy and contraindication profile, and personal preferences through the Wellness Portal before they visit their primary care provider.
1692709|NCT01520649|Drug|NSI-189 Phosphate|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
1692710|NCT01520649|Drug|microcrystalline cellulose capsules|The first cohort will be administered 40 mg once daily (q.d). The second cohort will be administered 40 mg twice daily (b.i.d). The third cohort will be administered 40 mg three times daily (t.i.d).
1692711|NCT01520636|Procedure|standard physiotherapy|daily physiotherapy aiming at preventing complications, going with the patient progress capacities, passive mobilisation, sitting as soon as possible, walking when possible, respiratory physiotherapy. 15-20 minutes total per day
1692712|NCT01520636|Procedure|experimental physiotherapy|physiotherapy as described above added to verticalisation as soon as possible; active, intense and repeated motor exercises for limbs and trunk with all the available techniques. 60 minutes total per day.
1692713|NCT01520623|Other|Serum concentration /Serum inflammatory|Allografted patients with myeloablative conditioning for an haematological malignancy. Patients will be followed for at least 12 months after transplantation and blood samples drawn before conditioning and once a week for 12 weeks after transplantation to analyze the serum concentration of Complement factors (C3, C4, B factor), Complement regulatory proteins (C1-inhibitor, I and H Factors) and analysis of the surface expression of Complement regulatory molecules such as CD46, CD55 and CD59 and the serum inflammatory cytokine levels
1692714|NCT01520584|Dietary Supplement|Vitamale|men will receive the vitamale dietary supplement compared to a sham pill
1692715|NCT01520571|Procedure|Non-Computer Assistance TKA|Non-Computer Assistance Total Knee Arthroplasty
1692716|NCT01520571|Procedure|Computer Assistance TKA|Computer Assistance Total Knee Arthroplasty
1692717|NCT01520558|Biological|CNDO-109-AANK Cells|Single dose, infusion
1692718|NCT01520545|Drug|Gablofen® 3 mg/mL (baclofen injection)|This is a prospective twelve-month Phase IIIb clinical safety trial followed by a 2-year, Phase IV study that will be conducted at clinical trial sites that are experienced with the use of intrathecal baclofen. Patients will be followed for the duration of their treatment with Gablofen® (baclofen injection) 3 mg/mL using the SynchroMed® II Programmable Pump or until the study is terminated.
1692719|NCT01520532|Other|Magnetic Resonance Imaging (MRI)|MRI's will be performed on all subjects at Enrollment and Pre-Discharge (Post Ablation). Subjects with a positive MRI (cerebral lesion) at the Pre-Discharge will undergo an MRI at the 1 month follow-up visit.
1692720|NCT01520519|Drug|Rituximab|375 mg/m2 intravenously on Day 1, Day 8, Day 15, and Day 22, then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
1692721|NCT01520519|Drug|PCI-32765|420 mg (3 * 140-mg capsules) orally started on Day 2 of cycle 1 once daily and will be continued daily.
1692722|NCT01520506|Device|Covidien OneShot™ System|Placed percutaneously, the OneShot™ balloon catheter is advanced into the renal artery using a routine femoral approach in a cardiac catheterization laboratory setting. RF is applied with pre-programmed time and intensity in each of the renal arteries.
1692723|NCT01520493|Other|Submaximal exercises|Consists of a 3-min unloaded exercise, followed by a progressive RAMP protocol (10 watts/min) up to 70% of peak workload followed by 3 min. of cycling at constant workload (70% peak workload) (total exercise duration of 25 min.).
1692724|NCT01520467|Drug|Anastrozole|Anastrozole (1mg/day), administered orally for 18 months
1692725|NCT01520467|Drug|Placebo|1 placebo tablet /day administered orally for 18 months.
1692726|NCT01520454|Drug|Saline|IV saline at 0.83 mL/kg/hr for six hours
1692727|NCT01520454|Drug|Intralipid|Intralipid in either low-dose or high dose (10% vs. 20%) at 0.83 mL/kr/hr for six hours
1692728|NCT01520454|Dietary Supplement|Water|Water by mouth
1692729|NCT01520454|Dietary Supplement|oral fat|Soybean oil by mouth at 1.25 g/kg x 2 doses
1692730|NCT01520454|Drug|Heparin|Heparin bolus of 1000 units followed by 800 u/hr, adjust per partial thromboplastin time (PTT), for 5.5 hours
1692731|NCT01520441|Drug|BOTOX|A total of 200 units of BoNT-A diluted in 4ml of preservative free saline will be injected into the right prostate lobe (i.e. transition and peripheral zones). A similar injection template with 1.0ml volume injections of saline will be injected into the left prostate lobe (2 injections in transition zone, 2 injections in peripheral zone for total volume of 4ml).
1692732|NCT01520428|Behavioral|Motivational Interviewing, CBT and E-mail support|Motivational Interviewing, elements of Cognitive Behaviour Therapy and E-mail support
1692733|NCT01520415|Drug|Bupivacaine|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
1692734|NCT01520415|Drug|Saline|2ml per injection up to a maximum of 8ml (4 identified trigger points) per visit
1692735|NCT01520402|Drug|Warfarin|Enrolled subjects on a fixed vitamin K diet followed a standard warfarin dosing algorithm with daily point-of-care INR checks to goal INR ≥ 2 for two consecutive days, then to baseline INR≤1.2 off warfarin. Genotyping for common and rare polymorphisms in CYP2C9, VKORC1, and CYP4F2 performed at study entry and unblinded at completion. Plasma Vitamin K and S-warfarin levels are obtained at goal INR ≥ 2 and study exit (INR ≤1.2 off warfarin).
1692736|NCT01520389|Drug|MM-151|MM-151
1692737|NCT01520389|Drug|MM-151 + irinotecan|MM-151 + irinotecan
1692738|NCT01520376|Behavioral|Counselling|Visit by a psychiatrist at day-30 and day-180 after discarge
1692739|NCT01520363|Drug|dextromethorphan|The DM group will take 5mg/kg/day orally in 2 divided doses 12 hours apart for the 3 month period of the study. The pharmacists will dispense the DM to the study participants.
1692740|NCT01520363|Drug|placebo|The placebo will be dispensed to equal the volume of DM of 5mg/kg/day. It is taken orally in 2 divided doses 12 hours apart during the study period of 3 months. The Research pharmacist will dispense the placebo to the participants.
1692741|NCT01520350|Drug|Low dose Adjunctive Aripiprazole|low-dose 2-5mg/d for 8 weeks
1692742|NCT01520350|Drug|placebo|Placebo
1692743|NCT01520337|Device|oral tablet dye for detection of polyps during colonoscopy|oral tablet dye for improved detection of
1692744|NCT01520324|Device|oral delivery mucosal stain|200mg methylene blue MMX tablet taken prior to colonoscopy
1692745|NCT01520311|Device|eSVS Mesh|Patients with multi-vessel coronary artery disease who require SVG CABG of the Right Coronary Artery and the Circumflex Artery due to atherosclerotic Coronary Artery Disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
1692746|NCT01520298|Drug|Placebo|For the control group, a total of 100 mLs of 0.9% sodium chloride will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mL/min). A beyond use expiration of 6 hours will be placed on the container. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
1692747|NCT01520298|Drug|Acetaminophen IV|For the treatment group, a total of 100 milliliters (mLs) of acetaminophen (1000 mg) will be transferred to a Hospira LifeCare container and infused over 15 minutes (6.7 mLs/min). A beyond use expiration of 6 hours at room temperature will place on the container, as recommended by the manufacturer. All admixture manipulations will be completed by the pharmaceutical staff according to the chapter 797 guidelines in the U.S. Pharmacopoeia. The treatment period will begin after admission and randomization, and will continue until surgical intervention.
1692748|NCT01520285|Drug|Zanidip|Lercanidipine hydrochloride (10mg/tablet)once per day
1692749|NCT01520285|Drug|Felodipine sustained-release tablet|Felodipine sustained-release tablet (5mg/tablet)
1692750|NCT01520246|Genetic|gene expression analysis|
1692751|NCT01520246|Other|laboratory biomarker analysis|
1692752|NCT01520233|Genetic|RNA analysis|
1692753|NCT01520233|Genetic|gene expression analysis|
1692754|NCT01520233|Other|laboratory biomarker analysis|
1692755|NCT01520220|Drug|LY2784544|LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
1692758|NCT01520194|Other|women attending reproductive health clinics|women visiting BEMFAM´s clinics from January 2012 until Narch 2013 filled a self-administered questionnaire based on psychometric scale developes by Zhu TC et al
1692759|NCT01520194|Other|medical records|medical chart review of patients assisted January 2009 to December 2010
1692760|NCT01520181|Drug|Beta-lactam oral challenge|Oral daily dose, according to patient's weight, of amoxicillin or other suspected beta-lactam will be administered for 5 consecutive days
1692761|NCT01520142|Drug|JNJ-26528398|In Study Part 1, the participant will receive an oral solution of JNJ-26528398 3 mg once daily for 7 days. The same dosing regimen is planned for Part 2, but may be adjusted (lower dose and/or fewer dosing days) based on the data from Part 1.
1692762|NCT01520142|Drug|Placebo|In both Study Part 1 and Part 2, the participant will receive an oral solution of matching placebo once daily for up to 7 days.
1692763|NCT01520129|Other|Interpersonal and social rhythm therapy|IPSRT Subjects will receive weekly 45 minute sessions of IPSRT for 20 weeks. IPSRT sessions focus on reducing symptoms by teaching patients to: a) increase regularity of social rhythms and regulate sleep-wake cycles; b) resolve interpersonal problems that contribute to mood symptoms (role dispute, role transition, grief, or interpersonal deficits); and c) recognize and accept the symptoms of subthreshold BP disorder (psychoeducation). Although we train therapists in techniques that are specific to each component, in practice, these strategies are administered flexibly and fluidly, without distinct boundaries between modalities. During the course of a session, therapists move seamlessly among the techniques, according to patients' needs.
1692764|NCT01520116|Drug|Stage 1 - ATS907 - Dose 1|QD and/or BID dosing for 28 days
1692765|NCT01520116|Drug|Stage 1 - ATS907 - Dose 2|QD and/or BID dosing for 28 days
1692766|NCT01520116|Drug|Stage 1 - ATS907 - Dose 3|QD and/or BID dosing for 28 days
1692767|NCT01520116|Drug|Stage 1 - ATS907 - Dose 4|QD and/or BID dosing for 28 days
1692768|NCT01520116|Drug|Stage 1 - Vehicle|QD and/or BID dosing for 28 days
1692769|NCT01520116|Drug|Stage 2 - ATS907 - Dose A - to be selected based on Stage 1|QD and/or BID dosing for 4 days
1692770|NCT01520116|Drug|Stage 2 - ATS907 - Dose B - to be selected based on Stage 1|QD and/or BID dosing for 4 days
1692771|NCT01520116|Drug|Timoptic|0.5%
1692772|NCT01520103|Drug|Vinorebine, Everolimus|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw Everolimus: oral 5 mg/d d1-21 3qw until progress
1692773|NCT01520103|Drug|Vinorelbine|Vinorelbin: i.v. 25 mg/ m² d1, d8, d15 3qw until progress
1692774|NCT01520077|Drug|vytorin|Patient will take once per day by mouth Vytorin 10/40mg. Will take it for 24 weeks and then continue or discontinue treatment at that time and be monitored for 24 more weeks. Should there be no improvement by the initial 24 weeks then they will no longer be in the study.
1692775|NCT01520051|Drug|Mepolizumab|3 monthly intravenous infusions of 750 mg
1692776|NCT01520051|Drug|Placebo|3 monthly intravenous infusions with saline
1692777|NCT01520038|Radiation|Proton therapy|
1692778|NCT01520038|Radiation|IMRT|
1692779|NCT01520025|Radiation|PET MPI imaging with 18F-Fluorodeoxyglucose|"Exercise Stress Testing. All patients will undergo a symptom-limited exercise treadmill test using the Bruce protocol after a 24 hour high fat, low carbohydrate diet and an overnight fast. Persantine Stress Testing: Subjects who have undergone Persantine stress protocol for the PET or SPECT will follow the same protocol. A high fat, low carbohydrate diet for 24 hours and a 12 hour overnight fast will precede the study stress scan. Anti-anginal medications will be withheld on the morning of the exercise test.
18FDG (370 mBq) will be injected at either peak exercise or within 1 hour of peak.
Patients will be imaged 60 minutes after radiotracer injection in the supine position in a Discovery 690/VCTLYSO PET system (GE Healthcare, Milwaukee, Wisconsin)"
1692780|NCT01520012|Drug|YH4808 100 mg|Period1: YH4808 100 mg bid fasting condition for 7days Period2: YH4808 100 mg bid fed condition for 7days
1692781|NCT01520012|Drug|YH4808 100 mg|Period1: YH4808 100 mg bid fed condition for 7days Period2: YH4808 100 mg bid fasting condition for 7days
1692782|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fasting condition Period2: YH4808 300 mg fed condition(standard meal) Period3: YH4808 300 mg fed condition(high fat meal)
1692783|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fed condition(high fat meal) Period2: YH4808 300 mg fasting condition Period3: YH4808 300 mg fed condition(standard meal)
1692784|NCT01520012|Drug|YH4808 300 mg|Period1: YH4808 300 mg fed condition(standard meal) Period2: YH4808 300 mg fed condition(high fat meal) Period3: YH4808 300 mg fasting condition
1692785|NCT01519999|Behavioral|Shared Decision Making for Colorectal Cancer Screening|Age-eligible adults in the intervention communities will be exposed to the shared decision-making intervention when they are seen in the primary care clinics (N=all patients 50-75 years seen during the study period who are non-adherent to CRCS recommendation). Additionally, among patients with primary care visits scheduled one week or more before the visit, they will be randomized to receive either a mailed decision aid booklet or an informational flyer on shared decision making and CRCS prior to the visit. Patients with primary care visits scheduled less than one week prior to the visit will not be mailed materials in advance. The effect of the pre-visit materials on referral to SDM session and CRCS adherence between these groups will be compared. They will also be exposed to shared decision-making tools and resources available through the community-wide intervention activities.
1692786|NCT01519986|Dietary Supplement|Vitamin D3|Supplement of vitamin D3
1692787|NCT01519986|Dietary Supplement|Placebo|Placebo
1692788|NCT01519973|Radiation|SPECT/CT processed with Evolution for CardiacTM software|SPECT/CT to be compared with PET/CT
1692789|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, Weeks 1- 48
1692790|NCT01519960|Drug|peginterferon alfa-2a [Pegasys]|Body surface area adapted doses of 45-180 mcg subcutaneously weekly for 48 weeks, after Week 48 for Group B patients who have not experienced HBeAg seroconversion
1692792|NCT01519921|Drug|peginterferon alfa-2a [Pegasys]|Peginterferon alfa-2a (Pegasys) 180 mcg subcutaneously once a week for 48 weeks
1692793|NCT01519908|Device|CRT-D (Medtronic)|Biventricular implantable cardioverter defibrillator, post marketing release
1692794|NCT01519895|Behavioral|Telephone intervention|counseling and education support
1692795|NCT01519882|Other|Placebo|"Placebo patches size equivalent to 4, 6 & 8 mg/24 h. Daily application of Placebo patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.
Optimal or maximal dose will be maintained for 4 Weeks followed by a de-escalation by 2 mg/24 h every other day."
1692796|NCT01519882|Other|Rotigotine|"Rotigotine patches of 4,6 & 8 mg/24 h. Daily application of Rotigotine patches starting at 4 mg/24 h. Dose will be up-titrated weekly by increments of 2 mg/24 h until optimal or maximal dose is reached. Maximal dose is 16 mg/24 h.
Optimal or maximal dose will be maintained for 4 weeks followed by a de-escalation by 2 mg/24 h every other day."
1692797|NCT01519869|Drug|neoadjuvant chemotherapy|platinum-based neoadjuvant chemotherapy followed by interval surgical debulking with platinum-based adjuvant chemotherapy
1692798|NCT01519856|Drug|piribedil (Clarium)|oral tablets, 50 mg
1692799|NCT01519843|Device|transcranial direct current stimulation tDCS|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)
1692800|NCT01519843|Device|transcranial magnetic stimulation TMS|TMS (The Magstim Company Ltd, UK) Magstim 200² with a figure-of-eight coil was used to determine the hot spot eliciting consistent movements in the contralateral hand
1692801|NCT01519830|Drug|Iron carboxymaltose (Ferinject)|Intravenous iron
1692802|NCT01519830|Drug|Placebo|0.9% NaCl solution
1692803|NCT01519817|Biological|GI-6301 (Yeast Brachyury Vaccine)|GI-6301 is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
1692804|NCT01519804|Drug|Placebo|Matching onartuzumab (MetMAb) placebo iv, Day 1 of each 21-day cycle
1692805|NCT01519804|Drug|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
1692806|NCT01519804|Drug|onartuzumab|15 mg/kg iv, Day 1 of each 21-day cycle
1692807|NCT01519804|Drug|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
1692808|NCT01519791|Biological|Certolizumab Pegol|"Prefilled syringes containing an injectable volume of 1 ml of solution for injection CZP for single use at a dosage strength of 200 mg/ml.
Injections will be given subcutaneously. CZP 400 mg at Baseline, Week 2 and Week 4, followed by a maintenance dose of 200 mg every 2 Weeks until Week 50."
1692809|NCT01519791|Other|Placebo|2 syringes Placebo at Baseline, Week 2 and Week 4, followed by 1 syringe Placebo every 2 Weeks.
1692810|NCT01519791|Biological|Methotrexate|The MTX treatment is to be initiated at a dose of 10 mg per Week (oral tablets at the strength of 2.5 mg/tablet). The MTX dosage should be escalated by 5 mg every 2 Weeks such that the maximum dosage of 25 mg per Week is achieved by Week 6 to Week 8. Patients who could not tolerate ≥ 15 mg/week MTX by Week 8 were withdrawn while the maximum tolerated dose per patient (optimized dose) was maintained to Week 52.
1692811|NCT01519778|Drug|TR701 FA|1 tablet 200 mg once daily
1692812|NCT01519765|Drug|Buccal Misoprostol|Buccal rather than Vaginal misoprostol for induction of labor
1692813|NCT01519765|Drug|Vaginal misoprostol|Vaginal rather than buccal misoprostol for induction of labor
1692814|NCT01519752|Drug|Oxiconazole Nitrate Cream 1%|Oxiconazole Nitrate Cream 1% applied to affected area once a day for 28 days
1692815|NCT01519752|Drug|Oxiconazole Nitrate Cream 1% (Oxistat®)|Oxiconazole Nitrate Cream 1%(Oxistat®)applied to affected area once a day for 28 days
1692816|NCT01519752|Drug|Placebo|Placebo applied to affected area once a day for 28 days
1692817|NCT01519739|Device|MediGuide™|MediGuide™ system will be used to guide CRT implants
1692818|NCT01519726|Drug|Midazolam|
1692819|NCT01519713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, Intramuscular
1692820|NCT01519700|Drug|EP2006|Eligible patients will be teated with EP2006
1692821|NCT01519700|Drug|Filgrastim|Eligible patients will be teated with Filgrastim
1692822|NCT01519687|Drug|levotofisopam|50 mg on Day 1, 50 mg TID on Days 2 through 6, and a single dose of 50 mg on Day 7
1692823|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) twice daily. Individually adjusted dose.
1692824|NCT01519674|Drug|biphasic insulin aspart 30|BIAsp 30 will be injected subcutaneously (under the skin) once daily. Individually adjusted dose.
1692825|NCT01519674|Drug|sitagliptin|Subjects will continue on their pre-trial sitagliptin treatment.
1692826|NCT01519674|Drug|metformin|Subjects will continue on their pre-trial metformin treatment.
1692827|NCT01519661|Drug|TBM100|Tobramycin inhalation powder was assigned as four capsules at 28mg dosage strength. It was inhaled b.i.d in the morning and in the evening via the T-326 Inhaler.
1692830|NCT01519622|Other|Questionnaire|Questionnaire to be distributed among sick elderly in the community
1692831|NCT01519609|Drug|bowel prep before endoscopy|bowel prep before colonoscopy
1692832|NCT01519596|Procedure|quality-of-life assessment|Ancillary studies
1692833|NCT01519596|Other|counseling intervention|Receive lifestyle-related counseling
1692834|NCT01519596|Behavioral|exercise intervention|Undergo physical activity intervention
1692835|NCT01519596|Other|educational intervention|Receive educational materials
1692836|NCT01519596|Procedure|standard follow-up care|Undergo usual care
1692837|NCT01519583|Behavioral|Basic Intervention|Participants will have the goal of obtaining 10,000 steps/day. In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and staff will provide a behavioral intervention to improve physical activity levels
1692838|NCT01519583|Behavioral|Enhanced Pedometry|Intensity Enhanced Pedometry: Participants will have the goal of obtaining 10,000 steps/day at least 30 minutes in moderate intensity (i.e., at a cadence of at least 100 steps/min). In addition, participants will attend a meeting once a week with study staff, during which pedometers will be checked, and the staff will provide a behavioral intervention to improve physical activity levels.
1692839|NCT01519583|Behavioral|Control Group|Maintain usual physical activity, and return for follow-up measures.
1692840|NCT01519570|Other|An informational packet regarding shingles and the HZV was sent to patients identified by the EMR|The EMR generated a list of patients aged 60 or older without HZV documentation. Patients were categorized into two subgroups based on activated electronic patient portal (EPP) status. Randomized patients from each subgroup received an informational packet regarding shingles and the HZV by either the EMR or USPS mail, depending on EPP status. A pharmacist reviewed the medical chart of interested patients to assess if the HZV was clinically indicated; eligible patients were mailed a HZV prescription.
1692841|NCT01519557|Drug|DAR-100A|15mg or 0.5mg of DAR-100A intravenously over 30 minutes for 5 days, 9 days off then again for 5 more days
1692842|NCT01519557|Drug|Placebo|Placebo
1692843|NCT01519544|Drug|Temazepam|Temazepam 7.5mg capsule to be taken by mouth at bedtime for one night only.
1692844|NCT01519544|Drug|Acetazolamide|Take Acetazolamide 125mg tablet by mouth at bedtime for one night only.
1692845|NCT01519531|Drug|Placebo|Oral, daily-dosing for 14 days; matching number of placebo capsule(s) with active arm
1692846|NCT01519531|Drug|VIA-3196|Oral, daily dosing for 14 days
1692847|NCT01519518|Drug|unfractionated heparin|70 units/kg body weight intravenous
1692848|NCT01519518|Drug|Bivalirudin|intravenous bolus of 0.75 mg/kg followed by infusion of 1.75 mg/kg per hour
1692936|NCT01518803|Dietary Supplement|Western-style breakfast|The experimental meal will be administered early in the morning as breakfast, containing butter, bread 82 slices), chocolate milk (200 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight.
1692849|NCT01519505|Behavioral|Lifestyle intervention|INDIVIDUAL INTERVENTIONS They were programmed to come the nurse office three times (1 ½ -2 hours each). Individual intervention efforts outside of weight control and other intervention groups were also supported. In fact, this kind of intervention was similar to the group intervention but one-by-one participant subject. GROUP INTERVENTIONS Six-hour educational programme structured in 2 to 4 sessions with 5 to 15 participants. We called all participants to remind them their group schedule (date/hour). The methods used in the group intervention were variable depending on the experience of the manager, group member' s needs and skills available (empowerment). Results were based on motivation, support from the other members, peer support and positive feedback.
1692850|NCT01519492|Drug|AFN-12520000|Two tablets taken in both the morning and evening on an empty stomach for a total daily dose 400 mg
1692851|NCT01519479|Other|Palliative Care Consultation|Intervention patient would receive an inpatient palliative care consultation to focus on comprehensive symptom assessment, create goals of care/treatment plan which include recommendations and referrals.
1692852|NCT01519479|Other|Control|The control group would receive usual care and could receive a palliative consult if ordered by the treating provider
1692853|NCT01519466|Device|FreeStyle InsuLinx|FreeStyle InsuLinx is a blood glucose meter with a built-in insulin calculator feature.
1692854|NCT01519466|Device|FreeStyle Freedom Lite|FreeStyle Freedom Lite is a blood glucose meter
1692855|NCT01519453|Behavioral|Home Based Asthma Education|4 home based and 3 phone based sessions with community asthma outreach worker to provide families with asthma education
1692856|NCT01519427|Drug|Akt inhibitor MK2206|Given PO
1692857|NCT01519427|Drug|selumetinib|Given PO
1692858|NCT01519427|Other|laboratory biomarker analysis|Correlative studies
1955703|NCT03107026|Drug|dasotraline 4mg|dasotraline 4mg tablet once daily
1955704|NCT03107026|Drug|dasotraline 6mg|dasotraline 6mg tablet once daily
1955705|NCT03107026|Drug|Placebo|Placebo tablet once daily
1692862|NCT01519401|Drug|3 mg drospirenone and 20 µg ethinyl-estradiol|
1692863|NCT01519401|Drug|3 mg drospirenone and 30 µg ethinyl-estradiol|
1692864|NCT01519388|Other|Spontaneous breathing|study of the swallowing of boluses of water and yogurt under spontaneous breathing
1692865|NCT01519388|Device|Elysée 150®|Study of the swallowing of boluses of water and yogurt while under mechanical ventilation
1692866|NCT01519349|Biological|rAAV1.CMV.huFollistatin344|"First cohort - Low Dose: 2E11 vg/kg with single leg injection (n=3 sIBM)
Second cohort: 3E11 vg/kg per quad (n=3 sIBM; 3 BMD)
Third cohort: 6E11 vg/kg per quad (n=3 sIBM; 3 BMD)"
1692867|NCT01519336|Drug|danoprevir|100 mg q12h
1692868|NCT01519336|Drug|darunavir|600 mg q12h
1692869|NCT01519336|Drug|ritonavir|100 mg q12h
1692870|NCT01519323|Drug|vemurafenib|Cohort 1 (participants >=45 kg): starting dose level 720mg; next dose level 960 mg Cohort 2 (participants <45 kg): starting dose 480 mg
1692871|NCT01519310|Other|Antibiotic (metronidazole and ciprofloxacin)/probiotic|"Antibiotic cocktail/yogurt as follows:
Group 1: antibiotics for 1 week, followed by probiotics for 3 weeks; Group 2: antibiotics for 1 week, followed by no probiotics for 3 weeks. Group 3: no antibiotics for 1 week, followed by probiotics for 3 weeks."
1692872|NCT01519297|Drug|Irbesartan|150mg orally for one dose
1692873|NCT01519284|Drug|BIA 9-1067 5 mg|BIA 9-1067 OPC, Opicapone 5 mg
1692874|NCT01519284|Drug|Entacapone|Entacapone 200 mg
1692875|NCT01519284|Drug|Placebo|placebo (four times a day)
1692876|NCT01519284|Drug|levodopa/carbidopa|standard release levodopa/carbidopa 100/25 mg (single-dose)
1692877|NCT01519284|Drug|BIA 9-1067 15 mg|BIA 9-1067 OPC, Opicapone 15 mg
1692878|NCT01519284|Drug|BIA 9-1067 30 mg|BIA 9-1067 OPC, Opicapone 30 mg
1692879|NCT01519271|Drug|Exelon Patch (rivastigmine transdermal system)|"The Exelon Patch (rivastigmine transdermal system) is a Cholinesterase Inhibitor approved by the FDA to treat Alzheimer's and Parkinson's Disease Dementia.
5-10cm2 (4.6-9.5 mg of rivastigmine/24 hours )"
1692880|NCT01519271|Drug|Placebo Patches|The placebo patches will appear identical to the medication patches however they will be inactive (they will not contain rivastigmine).
1692881|NCT01519258|Device|NAVA ventilation|Mechanical ventilation with the mode NAVA (neurally-adjusted ventilatory support), delivered by the Servoi Mechanical Ventilator (Maquet, Sweden) after the placement of an esophageal catheter. Nava will be titrated before the initiation of data collection to offer the same level of ventilatory assistance as the conventional mode used by the ICU team previous to enrollment in the study.
1692882|NCT01519258|Other|Pressure Support ventilation|Patients will receive usual care during the period of ventilation on the Pressure Support. The same ventilator, the Servoi (maquet, Sweden) will be used.
1692883|NCT01519245|Drug|Tranexamic Acid|Solution containing 2 grams (20mL) tranexamic acid + normal saline (50mL), for a total volume of 70mL poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction.
1692884|NCT01519245|Drug|normal saline|A total volume of 70mL of normal saline poured over the heart as a 'cardiac bath' prior to sternotomy closure near the end of surgery. Total duration of immersion is approximately 10 minutes, until mediastinal chest tubes are connected to suction. Identical in appearance to the trial drug, and is visually indistinguishable.
1692885|NCT01519232|Radiation|Liver Irradiation|Patients already scheduled to undergo radiation treatment
1692886|NCT01519219|Radiation|Hepatic Irradiation|Patients who take part in this study are required to be scheduled for hepatic irradiation. For the purposes of this research, they will undergo IC-GREEN testing within 2 weeks prior to the start of radiation therapy
1692887|NCT01519206|Device|Ulthera System Treatment|Focused ultrasound energy delivered below the surface of the skin.
1692934|NCT01518842|Biological|Intravitreal Bone Marrow Stem Cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
1692888|NCT01519193|Behavioral|Narrative Exposure Therapy for violent offenders (NETvo)|During NETvo the client, with the assistance of the therapist, constructs a chronological narrative of his whole life with a focus on exposure to traumatic stress and also on perpetrated violent acts. Empathic understanding, active listening, congruency and unconditional positive regard are key components of the therapist's behavior who asks in detail for emotions, cognitions, sensory information, and physiological reactions, linking them to an autobiographical context. Positive emotions and cognitions reported for violent acts are linked to the respective past. During four sessions the most important traumatic experiences and perpetrated violent acts are processed. In the fifth session plans and ideas for the future are developed to assist the children to reintegrate themselves into society.
1692889|NCT01519167|Drug|Dexmedetomidine|0.1 - 1.0 mcg/kg/hr IV
1692890|NCT01519167|Drug|Midazolam|0.025 - 2 mg/kg IV
1692891|NCT01519167|Drug|Fentanyl|0.5 - 3 mcg/kg IV
1692892|NCT01519154|Drug|Propofol|Only Propofol titrated for induction, followed by Propofol 10 mg/h as maintenance infusion
1692893|NCT01519154|Drug|Ketamine-Propofol|Propofol titrated plus additional Ketamine 1 mg/kg at induction, followed by Propofol 10 mg/h as maintenance infusion
1692894|NCT01519128|Drug|Treatment A: Digoxin|Type=exact number, unit=mg, number=0.5, form=tablet, route=oral. Digoxin administered on Day 1.
1692895|NCT01519128|Drug|Treatment B: TMC278|Type=exact number, unit=mg, number=25, form=tablet, route=oral. TMC278 administered for 16 days, with digoxin administered in the morning on Day 11.
1692896|NCT01519115|Other|early physical therapy intervention|instruction in home care program to be followed for first six weeks after ACF surgery
1692897|NCT01519115|Other|usual care|one physical therapy visit in hospital following ACF surgery
1692898|NCT01519102|Device|Dual Hormone closed-loop system|The closed-loop system is composed of three components: continuous glucose system, insulin infusion pumps that infuses insulin and glucagon and a control algorithm that decides on the infusion rates based on sensor readings.
1692899|NCT01519089|Drug|CP-690,550|10 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
1692900|NCT01519089|Drug|CP-690, 550|5 mg BID, continuous treatment for 16 weeks under blinding, 10 mg BID, continuous treatment for 4 weeks and variable dose (5 mg or 10 mg), continuous treatment for 32 weeks.
1692901|NCT01519076|Device|Pulse Therapeutics (PTI) Magnetically-Enhanced Diffusion (MED)|The PTI MED System is a magnetic-controlled infusion system which uses external energy (magnetic energy) to drive an agent (tPA) to the desired target (blood clot).
1692902|NCT01519063|Drug|Naltrexone and memantine|Naltrexone 50mg memantine 20mg
1692903|NCT01519063|Drug|Naltrexone and Placebo|Naltrexone 50 mg Placebo
1692904|NCT01519050|Behavioral|mitral valve repair|Mitral valve repair in patients with degenerative mitral regurgitation
1692905|NCT01519037|Drug|calcimimetic agent (cinacalcet)|one dose of oral cinacalcet, 60mg
1692906|NCT01519037|Drug|placebo|one dose of oral placebo
1692907|NCT01519011|Drug|oral azacitidine|oral azacitidine 300-mg once daily for 3 total doses with two 150-mg tablets (fasted and fed) or three 100-mg tablets (fasted).
1692908|NCT01519011|Drug|oral azacitidine|300-mg (three 100-mg tablets) once daily for 21 days of a 28-day cycle.
1692909|NCT01518998|Drug|Fimasartan , Amlodipine, Placebo|Fimasartan 60mg, Fimasartan 30mg, Amlodipine 5mg, Amlodipine 10mg, Placebo, Fimasartan 60mg/Amlodipine 5mg combination, Fimasartan 60mg/Amlodipine 10mg combination, Fimasartan 30mg/Amlodipine 5mg combination, Fimasartan 30mg/Amlodipine 10mg combination
1692910|NCT01518985|Drug|Bendavia|Bendavia for infusion Intravenous infusion (0.25mg/kg/hr) for 4 hours
1692911|NCT01518985|Drug|Sterile saline (0.9%)|Sterile saline for infusion (0.9%) Intravenous infusion for 4 hours
1692912|NCT01518985|Other|Cigarette smoking|One unfiltered cigarette will be smoked at approximately 30 minutes post-study-drug administration start.
1692913|NCT01518972|Drug|Prazosin|"Form: Prazosin will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg"
1692914|NCT01518972|Drug|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg"
1692915|NCT01518959|Drug|Cholecalciferol|180.000 IU monthly
1692916|NCT01518959|Drug|oleum neutralicum|Placebo comparator, 9 ml monthly
1692917|NCT01518946|Drug|Midodrine HCl|dose at the subject's current dose level
1692918|NCT01518946|Drug|Placebo|single dose of matching placebo
1692919|NCT01518933|Drug|Silibinin (Legalon-SIL)|20 mg/kg Silibinin (Legalon SIL), as per randomization schedule, will be administered daily as a 2-h infusion for 14 days.
1692920|NCT01518933|Drug|Saline|Placebo
1692921|NCT01518920|Drug|PF-04958242|PF-04958242 0.35 mg oral solution
1692922|NCT01518920|Drug|PF-04958242|PF-04958242 0.27 mg oral solution
1692923|NCT01518920|Drug|Placebo|Placebo oral solution
1692924|NCT01518907|Biological|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Subdermal dose
1692925|NCT01518894|Drug|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
1692926|NCT01518894|Drug|PF-04958242|PF-04958242 0.20 mg oral solution Q24 hours for 14 days
1692927|NCT01518894|Drug|PF-04958242|PF-04958242 oral solution Q24 hours for 14 days (dose to be determined)
1692928|NCT01518894|Drug|Placebo|Placebo oral solution Q24 hours for 14 days
1692929|NCT01518881|Drug|TKM-100201|IV Infusion
1692930|NCT01518881|Drug|Placebo|IV infusion
1692931|NCT01518855|Drug|Nifedipine (Adalat, BAYA1040)|
1692932|NCT01518855|Drug|Amlodipine (Norvasc)|
1692933|NCT01518855|Drug|Diovan|
1692935|NCT01518803|Dietary Supplement|Mediterranean-style breakfast|"The experimental meal will be administered early in the morning as breakfast, Cardioliva olive oil, bread (2 slices), tomatoes (half piece), fruit juice (200 mL), skim milk (150 mL). The amount of fat administered will be the equivalent to 0.75 g per kg of body weight."
1692971|NCT01518491|Drug|NanoDOX Hydrogel|NanoDOX Hydrogel will be applied three time weekly to the wound for eight weeks along with VAC therapy
1748548|NCT00171119|Drug|valsartan|
1692938|NCT01518777|Other|Half-dose isotope for NuclearStressTest|Half-dose of tracer or radioisotope will be used for Nuclear stress test of the heart. This is imaging test of the heart to see the function of arteries of the heart.
1692939|NCT01518764|Dietary Supplement|Red Wine Polyphenols 600mg/day|
1692940|NCT01518764|Dietary Supplement|placebo|
1692941|NCT01518738|Behavioral|breath attention training|4 week training
1692942|NCT01518738|Behavioral|working memory attention training|4 week training
1692943|NCT01518725|Dietary Supplement|Vitamin D|The vitamin D supplementation will consist of a capsule of 100 mcg of vitamin D/d, to be taken throughout the day. Participants will achieve 100 mcg by taking 2 x 25 mcg capsules per day. One will be taken at each time point (i.e., morning and evening) throughout the day. They will take the vitamin D supplement for the 6 month intervention period
1692944|NCT01518725|Dietary Supplement|Placebo|Participants in the placebo group will receive a capsule containing the inactive ingredients that include cellulose and silica to create a gel-like substance
1692945|NCT01518712|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
1692946|NCT01518712|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/850, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 850, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
1692947|NCT01518699|Drug|Ha44|study drug at low, moderate and high dose single exposure
1692948|NCT01518699|Drug|Ha44 Placebo|Ha44 Vehicle Gel without Ha44
1692949|NCT01518699|Drug|Moxifloxacin Placebo|Moxifloxacin Placebo
1692950|NCT01518699|Drug|Moxifloxacin|moxifloxacin 400mg
1692951|NCT01518686|Device|Octopus 900 perimeter (Haag Streit AG, Koeniz, Switzerland)|"We used the following six combinations of Goldmann8,1 stimulus size, stimulus luminance and angular velocity: V4e (64mm², 103', 320cd/m²) at 5°/s, III4e (4mm², 25.7', 320cd/m²) at 5°/s, I4e (0.25mm², 6.45', 320cd/m²) at 2°/s (for the assessment of the blind spot), I3e (0.25mm², 6.45', 100cd/m²) at 5°/s, I2e (0.25mm², 6.45', 32cd/m²) at 3°/s, I1e (0.25mm², 6.45', 10cd/m²) at 3°/s, I1a (0.25mm², 6.45', 4cd/m²) at 2°/s .
The peripheral five isopters, consisting of 24 vectors (every 15° meridian), were presented in random order, while the innermost isopter (I1a) consisted of 12 vectors (every 30° meridian)"
1692952|NCT01518673|Procedure|Blood test|Analysing X-ray induced genetic effects in pediatric patients directly after a computer tomography scan.
1692953|NCT01518660|Behavioral|Training|Bi-weekly progressive resistance training
1692954|NCT01518647|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy is a new third wawe cognitive therapy with the key treatment elements: acceptance, personal values and goals
1692955|NCT01518634|Drug|Imipramine treatment|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
1692956|NCT01518634|Drug|Placebo|Two-week of wash-out, one week of 10 mg study drug, 10 weeks of 25-75 mg study drug, four weeks of phasing-out and finaly two weeks after ther last dose of study drug to monito adverse events.
1692957|NCT01518621|Radiation|Radiation|Whole brain radiation
1692958|NCT01518621|Drug|Radiation plus erlotinib|Radiation 3Gy x10 plus erlotinib 150 mg q d, from the day before radiation start, through last day of irradiation
1692959|NCT01518608|Drug|Alfentanil 0.5mg/ml (Rapifen , Janssen-Cilag)|"Induction dose(0µg/kg,10µg/kg,20µg/kg,30µg/kg,40µg/kg,50µg/Kg,and 60µg/kg) 12 patients in each dose group.
Pentothal 4mg/kg Rocuronium 0.6 mg/kg"
1692960|NCT01518595|Drug|bosentan|pts. will receive bosentan for 3 months
1692961|NCT01518595|Drug|Placebo|pts. will receive placebo for 3 months
1692962|NCT01518582|Device|Cervical arthroplasty surgery with Granvia-C|Discectomy and Cervical arthroplasty according to standard practice of the surgeon
1692963|NCT01518569|Drug|ulinastatin|ulinastatin 5000 unit/kg iv before the initiation of CPB
1692964|NCT01518569|Drug|placebo|placebo (the same amount of normal saline) iv before the initiation of CPB
1692965|NCT01518556|Drug|Idarubicin|"In the phase I study, idarubicin dose is increased step by step as follows: 12 mg/m2/day for 3 days IV in the 1st step; 15 mg/m2/day for 3 days IV in the 2nd step; 18 mg/m2/day for 3 days IV in the 3rd step.
In the phase II study, idarubicin dose is the maximum tolerated dose that is determined from the phase I study or 18 mg/m2/day for 3 days ."
1692966|NCT01518530|Device|Occiflex Robotic Intervention System|Occiflex is a robotic system which is comprised of a cradle moved in a three dimension space with six degrees of freedom. It allows the therapist to tailor a personalized course of 3-D mobilization of the head and neck.
1692967|NCT01518517|Drug|GRASPA|one injection of GRASPA 150 IU/kg at each cycle of chemotherapy
1692968|NCT01518517|Drug|L-asparaginase|3 to 4 Injections of Native E.coli asparaginase 10000IU/m² (every 3 days) at each cycle of chemotherapy
1692969|NCT01518504|Other|Thoracic Mobilization|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will apply a small amplitude, quick thrust at end of range.
1692970|NCT01518504|Other|Sham|The subject will be in a prone position and the physical therapist will first identify the upper thoracic spine region. The physical therapist will then cross his or her hands and place them on opposite sides of the spinous processes using the pisiforms as the contact area. The subject will be asked to exhale and upon exhalation the physical therapist will not apply any other force than light hand contact.
1692972|NCT01518491|Other|VAC Alone|Patients will receive VAC therapy three time weekly for eight weeks
1692973|NCT01518478|Drug|Fluzone® Intradermal (Sanofi Pasteur Inc.)|"Fluzone® Intradermal trivalent vaccine is a clear-to-slightly opalescent, preservative-free suspension containing formaldehyde-inactivated split influenza viruses for intradermal delivery of 0.1 mL via an ultra-fine micro-needle. The vaccine is supplied as a single-dose, in a latex-free, pre-filled microinjection system. The active substance is prepared from influenza viruses propagated in embryonated chicken eggs.
Fluzone® Intradermal is standardized according to United States Public Health Service (US PHS) requirements and is formulated to contain HA of each of the following three influenza strains recommended for the 2011-2012 influenza season: A/California/07/2009 X-179A (H1N1)-like virus, A/Perth/16/2009 (H3N2)-like virus, and B/Brisbane/60/2008-like virus."
1692974|NCT01518465|Drug|dalteparin|Given SC
1692975|NCT01518465|Drug|lenalidomide|Given PO
1692976|NCT01518465|Drug|dexamethasone|Given PO
1692977|NCT01518465|Other|laboratory biomarker analysis|Correlative studies
1692978|NCT01518452|Behavioral|Cogmed JM working memory training|daily training for 5 weeks on a computerized program for training working memory; a total of 25 training sessions. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
1692979|NCT01518452|Behavioral|Cogmed JM working memory training after waiting|Waiting after baseline testing for 8 weeks. Daily training on a computerized program for training working memory for 5 weeks. 25 training sessions in total. Program: Cogmed JM - preschool version of program: 15-20 minutes training per day
1692980|NCT01518439|Device|Alpha 200®|inspiratory capacity is increased with the use of constant pressure device: Alpha 200®
1692981|NCT01518439|Device|Alpha 200® + physiotherapist|inspiratory capacity is increased with the use of constant pressure device (Alpha 200®) combined with the manual pressures techniques to increase cough by the physiotherapist
1692982|NCT01518439|Device|Cough Assist®|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®)
1692983|NCT01518439|Device|Cough Assist® + physiotherapist|increased inspiratory capacity and mechanical exsufflation with the use of insufflation-exsufflation device (Cough Assist®) combined with the manual pressures techniques to increase cough by the physiotherapist
1692984|NCT01518439|Other|physiotherapist|manual pressures techniques to increase cough applied by the physiotherapist
1692985|NCT01518426|Device|EEG Recording (Emotiv)|"Record EEG during auditory oddball paradigms:
with Emotiv EEG headset EMOTIV CAP (see http://www.emotiv.com)
with 3 electrodes : 3 different types of electrodes at the time (needle, cupule 5mm, cupule 10mm)"
1692986|NCT01518413|Drug|sorafenib|sorafenib (50 and 200 mg tablets) orally twice daily, on a continuous schedule at a starting dose of 150mg/m2/dose.
1692987|NCT01518413|Drug|irinotecan|irinotecan (70 mg/m2/dose) orally, concurrently, once daily,starting at the beginning of the 21 day cycle,repeated every 21 days
1692988|NCT01518387|Drug|Lanthanum Carbonate (BAY77-1931)|
1692989|NCT01518374|Drug|Florbetapir F 18|370 MBq (10 mCi)
1692990|NCT01518348|Biological|Patch Test|Patch Tested with Gold sodium thiosulfate, 0.075 mg/cm2 in hydroxypropylcellulose · Hydrocortisone-17-butyrate, 0.020 mg/cm2 in polyvinylpyrrolidone· Methyldibromoglutaronitrile, 0.0053 mg/cm2 in polyvinylpyrrolidone·Bacitracin, 0.60 mg/cm2 in hydroxypropylcellulose· Parthenolide, 0.0030 mg/cm2 in polyvinylpyrrolidone· Disperse blue 106, 0.050 mg/cm2 in polyvinylpyrrolidone· Bronopol, 0.25 mg/cm2 in polyvinylpyrrolidone
1692991|NCT01518335|Procedure|Platelet rich plasma injection|50ml of blood drawn into a 60cc with 10cc of anticoagulant is processed using MAGELLAN® Autologous Platelet (Arteriocyte Medical Systems, Cleveland Ohio)to separate out approximately 3-6 cc of platelet rich plasma, which is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
1692992|NCT01518335|Procedure|Placebo Comparator: Placebo/Standard of Care|50ml of blood is drawn into a 60cc with 10cc of anticoagulant and is then discarded. 4 cc of saline solution is mixed with 1 cc of 1 % Lidocaine (xylocaine) and 1 cc of 0.25 % Marcaine (bupivacaine) and injected into the site of injury under USG guidance.
1692993|NCT01518322|Device|NIOX MINO®|Fractional Exhaled Nitric Oxide (FeNO) will be measured with the NIOX MINO®
1692994|NCT01518309|Drug|pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth at 20, 40, or 60 mg doses
1692995|NCT01518296|Device|Medtronic-Dantec Urodynamic System|Urodynamic test is test performed in order to assess whether there is a urinary incontinence and underlying cause. During this test the woman is asked to empty her bladder and then two transducers are inserted, one into the bladder and the other into the rectum, then the bladder is filled with physiological solution and the patient is asked to urinate. During bladder emptying urinary flow velocity is measured and the pressures in the abdomen and bladder are recorded for later evaluation
1692996|NCT01518283|Drug|Cabazitaxel 10 mg/m2|Cabazitaxel 10 mg/m2 in a 1-hour infusion on days 1, 8, 15 and 22 of 5-week cycles.
1692997|NCT01518270|Other|No treatment|No treatment will be provided
1692998|NCT01518257|Biological|botulinum toxin Type A|A single 200U (2 mL) dose of botulinum toxin Type A injected into the intra-articular space of the study knee on Day 1.
1692999|NCT01518257|Drug|Normal Saline|A single 2 mL dose of Normal Saline (placebo) injected into the intra-articular space of the study knee on Day 1.
1693000|NCT01518244|Drug|Brinzolamide/timolol maleate fixed combination|
1693001|NCT01518231|Procedure|autologous hematopoiesis stem cell transplantation|Every participant will be transplanted with about 4 million autologous peripheral blood stem cell(CD34+) through cerebral artery.
1693002|NCT01518231|Drug|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
1693003|NCT01518231|Drug|Warfarin|warfarin 2~6mg,qd,po(patients with fibrillation atrial);
1693004|NCT01518231|Drug|Atorvastatin|atorvastatin 20mg,qd,po
1693005|NCT01518231|Drug|Edaravone|edaravone 30mg,bid,ivgtt.
1693006|NCT01518231|Drug|Aspirin|aspirin 100mg,qd,po(patients with no fibrillation atrial)
1693007|NCT01518231|Drug|Warfarin|warfarin 2~6mg,qd,po(patients with fibrillation atrial)
1693008|NCT01518231|Drug|Atorvastatin|atorvastatin 20mg,qd,po
1693009|NCT01518231|Drug|Edaravone|edaravone 30mg,bid,ivgtt
1693010|NCT01518218|Behavioral|laying-on-of-hands|The intervention group received laying-on-of-hands every weekday for 1 year along with conventional medicine. The control group did not undergo any alternatives to OPT.
1693147|NCT01517243|Drug|Sunitinib|Sunitinib 50mg by mouth daily for 4 weeks followed by a two week rest
1693011|NCT01518205|Device|LDL-apheresis|"The patient of the Arm LDL-apheresis in addition to standard therapy, will undergo a cycle of LDL-apheresis.
LDL-apheresis will be performed with B.Braun Avitum H.E.L.P. System. Apheretic treatment scheme: 10 apheretic sessions carried out as follows: the first 2 with a 3 day distance (i.e. 2 treatments in one week), successively 1 session per week (every 7 days).
To perform the treatment, the forearm surface veins will be punctured by means of 17 Ga needles, as an alternative a two-ways CVC will be used."
1693012|NCT01518192|Drug|doxycycline|100 mg bid; 15 days
1693013|NCT01518192|Drug|cefuroxime axetil|500 mg bid; 15 days
1693014|NCT01518179|Device|Made-to-Measure Compression Gloves|Made-to-Measure Compression Gloves in addition to routine follow up and treatment.
1693015|NCT01518179|Other|Routine follow up and treatment|Control
1693016|NCT01518166|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
1693017|NCT01518166|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
1693018|NCT01518166|Drug|atorvastatin|One single dose of 40 mg. Tablet
1693019|NCT01518166|Drug|lisinopril|One single dose of 20 mg. Tablet
1693020|NCT01518166|Drug|griseofulvin|One single dose of 500 mg. Tablet
1693021|NCT01518166|Drug|digoxin|One single dose of 1 mg. Tablet
1693022|NCT01518153|Drug|Fludarabine|40 mg/m^2 by vein on Day -6 to -3.
1693023|NCT01518153|Drug|Melphalan|140 mg/m^2 by vein on Day -2.
1693024|NCT01518153|Drug|Alemtuzumab|50 mg by vein on Day -1.
1693025|NCT01518153|Procedure|Stem Cell Infusion|Reduced intensity stem cell transplant on Day 0.
1693026|NCT01518153|Drug|Tacrolimus|0.015 mg/kg by vein as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml (target is 10 ng/ml). Tacrolimus is changed to oral dosing when tolerated. Tapering should start on approximately Day +24 with intention to be completely off drug by approximately Day +35.
1693027|NCT01518153|Drug|Methotrexate|5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
1693028|NCT01518153|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
1693029|NCT01518153|Procedure|Low Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 3 * 106 CD3+ cells/kg between Day +56 and +64.
1693030|NCT01518153|Procedure|High Dose Donor T-Cells|Planned Donor Lymphocyte Infusion CD3+ cells: 1 * 107 CD3+ cells/kg between Day +56 and +64.
1693031|NCT01518140|Device|Oxygen Delivery Devices|"Participants receive air through VapoTherm for 1 hour, and then on an as needed basis for up to 4 hours. Participants then receive air through bilevel positive airway pressure (BiPAP) for up to 30 minutes, followed by 30 minutes using non-rebreather mask."
1693032|NCT01518140|Behavioral|Questionnaires|2 Questionnaires completed at baseline taking about 10 minutes to complete. At end of visit, questionnaire completion taking about 5 minutes to complete.
1693033|NCT01518127|Other|intravitreal injection of autologous bone marrow stem cells|intravitreal injection of autologous bone marrow stem cells
1693034|NCT01518114|Behavioral|Exercise Training|Exercise will be performed under continuous telemetry monitoring and medical supervision. Each session will include 5-10 worm-up, 30 min of aerobic activity on treadmill or bicycle ergometer followed by 10-15 min of stretch and relaxation exercise. Blood pressure will be obtained before the onset and at the end of each session. Participants will be requested to rest and observed 15-30 min before going home. The exercise intensity will be monitored and adjusted, per protocol, according to RPE using the Borg scale.
1693035|NCT01518101|Drug|Vildagliptin/ Metformin|Single pill combination of Vildagliptin/ Metformin (50/1000 mg).
1693036|NCT01518101|Drug|Liraglutide|1.2 mg once daily by commercially available injection pens
1693037|NCT01518101|Drug|Metformin|1000 mg tablets twice daily
1693038|NCT01518088|Dietary Supplement|Dietary Fiber|Dietary fiber will be added to study foods
1693039|NCT01518075|Other|Spontaneous Breathing|"Evaluation of breathing - swallowing interaction without non invasive mechanical ventilation. Patient breath spontaneously.
Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size."
1693040|NCT01518075|Other|Non Invasive Mechanical Ventilation|Evaluation of breathing - swallowing interaction with non invasive mechanical ventilation. Patient breath under non invasive mechanical ventilation. Measurements of respiratory and swallowing parameters were monitored using respiratory inductive plethysmography. Swallowing was monitored noninvasively. Two bolus sizes were used, (5, 10 ml), in random order. Five sets of two boluses were studied, taking care not to use the same bolus size twice consecutively. The study participants were blinded to bolus size.
1693041|NCT01518062|Drug|somatropin|4 IU/m^2 body surface for 4 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
1693042|NCT01518062|Drug|somatropin|Initial dose 4 IU/m^2 body surface the first year, then 6 IU/m^2 body surface for 3 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
1693043|NCT01518062|Drug|somatropin|Initial dose 4 IU/m^2 body surface the first year, then 6 IU/m^2 body surface, the second year and finally 8 IU/m^2 body surface for 2 years (main period). In extension period subjects continue the reached dose until final height. Administered as once daily subcutaneous injection
1693044|NCT01518062|Drug|oestrogen|Treatment with oestrogen was administered if spontaneous puberty had not occurred by age 12 years and was initiated in the extension period after at least four years of somatropin treatment
1693045|NCT01518036|Drug|somatropin|2.9 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
1693046|NCT01518036|Drug|somatropin|4.3 IU/m^2/day. Administered as once daily subcutaneous injection until final height is reached
1693047|NCT01518023|Other|Interview, questionnaire, updated biochemical tests|Patients will be interviewed and questioned about nutritional status, diet, drugs and diagnosis/clinical course of diabetes. Routine biochemical tests will be searched and if necessary updated.
1694721|NCT01505426|Drug|metformin|oral, concomitant use
1693048|NCT01518010|Behavioral|Play game|Participants engage in non-game activity (establish baseline) 7 * 1 hr weekly; play single-player game 7 * 1 hr weekly; play multi-player game 7 * 1 hr weekly.
1693049|NCT01517997|Procedure|Paclitaxel coated balloon angioplasty.|Infrapopliteal angioplasty using a paclitaxel coated balloon.
1693050|NCT01517997|Procedure|Infrapopliteal Primary Drug Eluting Stenting|Infrapopliteal primary stenting using drug-eluting stent(s)
1693051|NCT01517984|Drug|Tacrolimus (CNI) Withdrawal|"Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
Subjects without any clinical acute rejection (AR) in the first 6 months, without borderline or acute rejection on the 6 month biopsy, and without donor-specific antibody (DSA) at anytime, including the 6 month test will be randomized (2:1) to tacrolimus (CNI) withdrawal."
1693052|NCT01517984|Drug|Standard Immunosuppressive Therapy|Recipients of living-donor kidney allografts are given induction therapy with rabbit antithymocyte globulin (RATG, Thymoglobulin®) and treated with a regimen of mycophenolate mofetil (MMF), prednisone and tacrolimus.
1693053|NCT01517971|Other|laboratory biomarker analysis|Correlative studies
1693054|NCT01517958|Other|Respiratory Distress Group|Diagnostic lung ultrasound.
1693055|NCT01517958|Other|Control Group|Lung ultrasound
1693056|NCT01517945|Behavioral|AIM materials and assessments|Part 1 will be used to develop & refine the intervention & assessment materials with 10 participants. We will adapt two previously validated CBM tasks, attention modification & interpretation modification to create two novel AIM programs (designated AIM-Neutral & AIM-Meaning), each of which targets both attention & interpretation biases for fear of breast cancer recurrence. Participants will complete the assessment battery & 1 30-minute session of each version of the intervention (AIM-Neutral & AIM-Meaning) & will provide feedback about the recruitment procedures, stimuli, & assessments. Part 2 will be a proof-of-concept, small scale, single-blind, placebo-controlled RCT of AIM. One hundred eleven participants will be randomized to receive either AIM-Neutral (n=37), AIM-Meaning (n=37), or computer placebo (CP; n=37). The AIM & CP conditions will involve completion of 8 30-minute sessions Participants will be instructed to complete 2 sessions per week for a total of 4 weeks.
1693057|NCT01517932|Drug|dexmedetomidine|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.
Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.
Patients in this arm received dexmedetomidine 0.2μg/kg i.v. during 10 minutes 1 hour before the end of surgery"
1693058|NCT01517932|Drug|saline placebo|"In this arm,midazolam(0.03-0.05mg/kg), propofol(1.5-2.5mg/kg),sufentanil(0.6-0.82μg/kg )and rocuronium(0.8-1.0mg/kg) were used in anesthesia induction.
Anaesthesia was maintained with propofol（4-6mg kg-1h-1），remifentanil (0.1-0.2 μg kg-1 min-1）and sevoflurane（1%).Propofol was titrated to maintain intraoperative Narcotrend values between 20 and 46.
Patients in this arm received saline placebo of the same volume i.v. during 10 minutes 1 hour before the end of surgery"
1693059|NCT01517919|Behavioral|Peer-Led Self-Management|"The PLSM intervention is designed to improve and sustain participants' self-management and health-related gains associated with type 2 diabetes. The role of peer leaders is to provide support for (1) ongoing self-management efforts (including the 5-step action-planning process), (2) psychosocial and emotional adjustment, and (3) linkage to needed health care resources.
PLSM intervention will consist of three main components provided by the Peer Leaders: weekly self-management support sessions; outreach telephone contacts and inbound telephone call from participants."
1693060|NCT01517906|Behavioral|Identity Intervention Program|Cognitive behavioral strategies will be used by trained nurse-therapists to facilitate the participant's: a) identification of a small collection of personally meaningful and feasible desired possible selves, b) prioritization of the desired possible selves as short and long-term goals, c) identification, elaboration, implementation and evaluation of cognitive and behavioral strategies to achieve the desired possible self selected as the goal, and d) identification of internal and external barriers that interfere with achieving the possible self goal and utilization of active problem solving strategies to overcome the barriers.
1693061|NCT01517906|Behavioral|Supportive Psychotherapy for the Eating Disorders|SPI is a 20-week program with a one-hour individual psychotherapy session scheduled each week. The SPI is organized in three stages: 1) Stage 1 (Sessions 1-8) including assessment of the current and past ED history, collection of personal and family history, and identification of problems contributing to the ED; 2) Stage 2 (Sessions 9-16) aims include exploration of underlying emotional problems, increased self-disclosure and expression of feelings, and fostering independence; and 3) Stage 3 (Sessions 17-20) includes continued exploration of underlying problems and implications for future behaviors and termination.
1693062|NCT01517893|Drug|Simvastatin|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
1693063|NCT01517893|Drug|Placebo|Sig: 40 mg PO daily for 1 month, increased to 80 mg PO daily for 5 months if low dose tolerated
1693064|NCT01517880|Drug|Sialic Acid Extended Release (SA-ER)|SA-ER will be administered in doses of 3000mg per day or 6000mg per day
1693065|NCT01517880|Drug|Placebo|Subjects will be randomized to the placebo arm for the first 24 weeks of the study. Then, subjects in this arm will be re-randomized into either the 3,000 mg per day or 6,000 mg per day arm for the remaining 24 weeks of the study (total study duration 48 weeks).
1693068|NCT01517854|Drug|Sildenafil|20 mg Revatio (sildenafil citrate) three times a day
1693069|NCT01517854|Drug|Placebo|Placebo identical to Revatio (sildenafil citrate) three times a day
1693070|NCT01517828|Drug|Sedation by ketamine|"Kétamine (50mg/5ml, Panpharma): for a posology of 2 mg/kg: dose of 0.2 ml/kg Intranasal administration with a 1 ml syringe. Kétamine is a derivated of phencyclidine with a sedative, anesthesic, analgesic and amnesiant activity. Ketamine keeps also a protective reflex of upper respiratory tracts.
One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
1694722|NCT01505426|Drug|Placebo|oral
1693071|NCT01517828|Drug|Sedation with Midazolam|"Midazolam (phyal of 5mg/5ml, Mylan S.A.S.) for a posology of 0.2 mg/kg: dose of 0.2 ml/kg Instillation in intranasal with a syringe of 1 ml. Midazolam is an imidazobenzodiazépine, witj a sedative and hypnotic activity,anxiolytic, anti convulsive and muscle relaxant proprieties.
One injection will be done and if after 7 minutes, newborn is not correctly sedated another dose of same product will be done."
1693072|NCT01517815|Drug|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 no overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:
in 13 no overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.
in 13 patients no overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
1693073|NCT01517815|Drug|Doripenem or Piperacillin/Tazobactam|"This arm is composed of 26 overweight patients, Antibiotic (Doripenem or Piperacillin/Tazobactam) is chosen by the intensivist in charge of the case:
in 13 overweight patients, Pipéracilline/tazobactam will be administered in 4g IV (1h) and then 16g/24h IV continuously. Piperacillin/Tazobactam plasma dosage: after the first dose and then every 12h.
in 13 patients overweight: doripénème will be administered in 1g/8h with a 4h IV infusion. Doripenem plasma dosage: after the first dose and then twice a day, at peak and residual value."
1693074|NCT01517802|Drug|Abiraterone acetate|Type=exact number, unit=mg, number=1000, form=tablet, route=oral, abiraterone acetate once daily
1693075|NCT01517802|Drug|Prednisone|Type=exact number, unit=mg, number=5, form=tablet, route=oral, prednisone or prednisolone twice daily
1693076|NCT01517789|Device|Visual evoked potentials monitoring during neurosurgery - Vision monitor MonOpera®|"Visual assessment (visual field, visual acuity, pattern visual evoked potential) are realised before and after surgery.
Flash and steady state visual evoked potential are measured during the surgical procedure at different times."
1693079|NCT01517763|Device|Conventional CPAP Therapy|HC244 devices without Thermosmart or SensAwake
1693080|NCT01517763|Device|Fixed pressure ICON™ without ThermoSmart™|Fixed pressure CPAP therapy using ICON™ without ThermoSmart™ or SensAwake™
1693081|NCT01517763|Device|Auto ICON™ with SensAwake™ and ThermoSmart™|APAP therapy using Auto ICON™ with SensAwake™ and ThermoSmart™
1693082|NCT01517750|Device|ICON Auto CPAP™ with Thermosmart heated tube|ICON Auto CPAP™ with heated humidification and the use of a heated tube
1693083|NCT01517750|Device|ICON Auto CPAP™ without Thermosmart heated tube|ICON Auto CPAP™ without heated humidification or the use of a heated tube.
1693084|NCT01517724|Drug|Bortezomib|1.3mg/sq m, subcutaneous injection, days 1, 8, 15 and 22 of 28 day cycle; maximum of 8 cycles
1693087|NCT01517698|Drug|Placebo|placebo to RO4917523 orally once a day for 12 weeks
1693088|NCT01517698|Drug|RO4917523 0.5 mg|0.5 mg orally once a day for 12 weeks
1693089|NCT01517698|Drug|RO4917523 1.5 mg|1.5 mg orally once a day for 12 weeks
1693090|NCT01517685|Dietary Supplement|Organic flax seed oil|2 tablespoons of organic flax seed oil are eaten daily for 8 weeks.
1693091|NCT01517685|Dietary Supplement|fish oil|5 grams (1 tsp.) of fish oil is eaten per day for 8 weeks.
1693092|NCT01517672|Behavioral|Cognitive Trauma Therapy for Battered Women (CTT-BW)|10 individual sessions of this form of cognitive therapy, with a trained therapist.
1693093|NCT01517659|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1693094|NCT01517646|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1693095|NCT01517633|Device|BirthSign|When leakage from the vagina occurs, the woman will wet the indicator lines of the device with the body fluids.
1693096|NCT01517620|Drug|Total Glucosides Paeony Capsules|Total Glucosides Paeony Capsules, oral, 0.3 gram per capsule, 3 capsules tid, 24 weeks
1693097|NCT01517607|Other|Mesalazine|Patient's treated with oral Mesalazine
1693098|NCT01517568|Drug|liraglutide [3H]|A single dose of 0.75 mg will be given as a subcutaneous injection
1693099|NCT01517555|Drug|liraglutide|Administered as a subcutaneous injection. Initial dose 0.6 mg daily, adjusted to 1.2 mg daily in week 2 and escalated to 1.8 mg daily in week 3
1693100|NCT01517555|Drug|placebo|Administered as a subcutaneous injection. Given as daily volume of 100 mcl, 200 mcl and 300 mcl respectively
1693101|NCT01517555|Drug|paracetamol|One single dose of 1 g. Tablet
1693102|NCT01517542|Other|Nutritional Counseling|2 groups: 1 with nutritional counseling and other with usual diet without nutritional counseling
1693103|NCT01517503|Behavioral|Cognitive Therapy|This interventions will target: (a) behavioral dysfunction, (b) situation-specific negative thinking and cognitive distortions, and (c) underlying dysfunctional beliefs or cognitions assumed to be related to the patient's current depression and risk of future depression. A maximum of 20 45-minute sessions will be provided over 16 weeks, with sessions generally held twice weekly for the first 6 weeks and once weekly for the next 8 weeks.
1693148|NCT01517243|Drug|Temsirolimus|Temsirolimus 25mg IV weekly for 4 weeks followed by a two week rest
1693191|NCT01516918|Biological|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
1748549|NCT00171132|Drug|valsartan|
1693104|NCT01517503|Behavioral|Acceptance and Commitment Therapy|This interventions will use (a) acceptance, (b) commitment, (c) mindfulness, and (d) behavior change processes to produce reduction of depressive symptoms. A maximum of 20 45-minute sessions will be provided over 16 weeks, with sessions generally held twice weekly for the first 6 weeks and once weekly for the next 8 weeks.
1693105|NCT01517490|Other|Insulin pump|Insulin pump therapy
1693106|NCT01517490|Other|Multiple daily insulin injections|Multiple daily insulin injections
1693107|NCT01517490|Procedure|Bariatric surgery|Pre-operative weight loss and bariatric surgery.
1693108|NCT01517490|Other|Medical therapy for type 2 diabetes|Medical glucose-lowering therapy and non-surgical weight-lowering interventions.
1693109|NCT01517477|Device|iStent|Implantation of One iStent through a small temporal clear corneal incision.
1693110|NCT01517477|Device|iStent|Implantation of Two iStents through a small temporal clear corneal incision
1693111|NCT01517477|Device|iStent|Implantation of Three iStents through a small temporal clear corneal incision
1693112|NCT01517464|Genetic|SGT-94|SGT-94 will be given at doses of 0.6, 1.2, 2.4, 3.6 and 4.8 mgDNA/infusion(Doses 0-5, respectively)twice weekly for 3 weeks out of 4 in dose levels 0 to 4, and for 5 weeks out of 6 for dose level 5 (also 4.8mg DNA). Intravenous infusion will occur over 1 to 2.5 hours in 5% dextrose,with a final volume of SGT-94 and dextrose of 100 mL to 250 mL, depending on dose level.
1693113|NCT01517451|Radiation|Radiation Therapy|7.25 Gy every other day fractions to a total dose of 36.25 Gy (total of 5 fractions)
1693114|NCT01517451|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) for 4 months total, greater than or equal to 1 month prior to SBRT.
1693115|NCT01517438|Behavioral|agitation|agitation score after desflurane anesthesia
1693116|NCT01517412|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Solution for injection; Route of administration: Subcutaneous
1693117|NCT01517412|Device|Self-injector pen device (OptiClik®)|
1693118|NCT01517412|Drug|Metformin|To be kept at stable dose (≥1.5 g/day) throughout the study.
1693119|NCT01517399|Drug|tivantinib|three oral 120 mg tablets administered twice a day
1693120|NCT01517399|Drug|omeprazole|One 40 mg oral capsule once alone and once again with tivantinib
1693121|NCT01517399|Drug|s-warfarin|One 10 mg oral tablet once alone and once again with tivantinib
1693122|NCT01517399|Drug|caffeine|One 200 mg oral tablet once alone and once again with tivantinib
1693123|NCT01517399|Dietary Supplement|vitamin K|One oral 5 mg tablet on multiple days when and around warfarin administration
1693124|NCT01517399|Drug|digoxin|One oral 0.25 mg tablet once alone and once again with tivantinib
1693125|NCT01517399|Drug|midazolam|Intravenous 1.5 mg dose once alone and once again with tivantinib
1693126|NCT01517386|Procedure|thoracic surgery|unilateral thoracic surgery under paravertebral block and general anesthesia
1693127|NCT01517373|Drug|Placebo|Combination of tablets and capsules, a total of 3 pills/dose, administered once daily for 84-days
1693128|NCT01517373|Drug|PF-04937319 10 mg|Combination of tablets and capsules, dose of 10 mg, a total of 3 pills/dose, administered once daily for 84-days
1693129|NCT01517373|Drug|PF-04937319 50 mg|Combination of tablets and capsules, dose of 50 mg, a total of 3 pills/dose, administered once daily for 84-days
1693130|NCT01517373|Drug|PF-04937319 100 mg|Combination of tablets and capsules, dose of 100 mg, a total of 3 pills/dose, administered once daily for 84-days
1693131|NCT01517373|Drug|Glimepiride|Combination of tablets and capsules, dose of up to 6 mg, a total of 3 pills/dose, administered once daily for 84-days
1693132|NCT01517360|Drug|Oxytocin|Oxytocin 40 IU, intranasal inhalation
1693133|NCT01517360|Other|Placebo|Placebo, matched to Oxytocin, intranasal inhalation
1693134|NCT01517360|Behavioral|Social Cognitive Skills Training|The training utilizes skill building techniques that are commonly used in psychiatric rehabilitation. These include breaking down complex social cognitive processes into their components and automating these skills through repetition and practice. The training programs will include 12 sessions and will be administered in a small group format (6-8 participants per group) twice a week for 6 weeks. Each training session will last for about 90 minutes (1 hour training and 30 minutes between drug administration and start of training).
1693135|NCT01517347|Drug|Interleukin-2|Patients receive low dose interleukin-2(Daily 1×106 IU per square meter of body-surface area) on days 60 after unmanipulated blood and marrow transplantation. Interleukin-2 treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity.
1693136|NCT01517334|Drug|Minocycline HCl Microspheres|
1693137|NCT01517321|Drug|MK-0431/ONO-5435|Double-blind period (12 wk); 50 mg QD. The double-blind period will be followed by a 40 week open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
1693138|NCT01517321|Drug|Placebo, MK-0431/ONO-5435|Double-blind period (12 wks); placebo QD. The double-blind period will be followed by a 40 wk open label extension period where MK-0431/ONO-5435 could be titrated from 50 mg to 100 mg QD.
1693139|NCT01517308|Drug|pegylated interferon alpha 2a + ribavirin|Comparison of different duration of drugs (48 weeks vs. 24 weeks)
1693140|NCT01517295|Drug|Hydrocodone|Dose: Standard prescribed dose Frequency: Once Duration: Once
1693141|NCT01517282|Biological|MOR103|Anti-GM-CSF monoclonal antibody
1693142|NCT01517282|Other|Placebo|Placebo to anti-GM-CSF monoclonal antibody
1693143|NCT01517269|Behavioral|Parent education with human patient simulator|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management using teaching vignettes and practice with human patient simulator
1693144|NCT01517269|Behavioral|Standard care|After child is newly diagnosed with Type 1 diabetes, parents will receive 3 teaching sessions over 12 weeks, after baseline data collected, at 1 month, and at 3 months, covering hypoglycemia, hyperglycemia and pattern management without the use of a simulator
1693145|NCT01517256|Behavioral|Living Everyday Above-and-beyond Pain (LEAP)|8-week multidisciplinary group therapy aiming consisting of education about the nature of chronic pain, pacing and goal setting, mindfulness medication techniques, cognitive reflections on beliefs, impulses and obsessions, physical activation, and medication management.
1693146|NCT01517256|Other|Wait-listed|Patients are wait-listed while awaiting participation to the LEAP program.
1693149|NCT01517230|Behavioral|Local radio campaign to reduce under-five child mortality|"The media campaign is designed by Development Media International. It includes short spots and long format programs broadcast by rural community radios. Major topics to be addressed include: diarrhoea, water and sanitation, acute respiratory infections, fever/malaria, antenatal consultations, delivery in health facilities, breastfeeding, and child nutrition. The intervention is planned to start in March 2012 after completion of fieldwork for the baseline survey and will continue for 2.5 years."
1693150|NCT01517217|Procedure|No girdle|No girdle is used for the first five postoperative days
1693151|NCT01517217|Procedure|Girdle|Girdle the first five postoperative days
1693152|NCT01517204|Device|Direct laryngoscope (Macintoish laryngoscope)|Direct laryngoscope was used to facilitate the intubation of left-sided DLT.
1693153|NCT01517204|Device|Trachway(R) intubating stylet|Trachway(R) intubating stylet was used to facilitate the intubation of left-sided DLT.
1693154|NCT01517178|Device|New ostomy base plate (SS)|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
1693155|NCT01517178|Device|Standard Care base plate|The base plate is applied to the skin around the stoma and an ostomy bag is clicked onto the base plate.
1693156|NCT01517165|Drug|Pioglitazone|
1693157|NCT01517165|Drug|Placebo|
1693162|NCT01517074|Drug|Sirolimus|Subconjunctival injection
1693163|NCT01517035|Procedure|Stem Cell Transplantation|Myeloablative conditioning (Flu/Cy/TBI) followed by CD3/19/34 selected stem cell graft.
1693165|NCT01517009|Drug|Docetaxel|60 mg/m2, 1 gift every 3 weeks, in total 4 gifts
1693166|NCT01517009|Drug|cisplatin|60 mg/m2, one gift every three weeks, in total 4 gift
1693167|NCT01517009|Drug|Capecitabine|1875 mg/m2 in two equally divided doses day 1-14, repeated every three weeks, in total 4 cycles
1693168|NCT01517009|Procedure|D1extra-resection|An extended lymphadenectomy compared to a D1 resection for gastric cancer
1693169|NCT01516996|Drug|docetaxel and cisplatin|"The neoadjuvant consists of docetaxel 75mg/m2 day 1 and cisplatin 75mg/m2 days 1 to 3, repeat every 3 weeks, for 2 cycles.
CCRT: cisplatin 75mg/m2 is administered on day 1 of week 7,10 and 13 on current with RT"
1693170|NCT01516996|Radiation|IMRT|"IMRT is administered with chemotherapy from week 7 to week 13
GTV（primary tumor）：68-70Gy/35~38 F，once a day, 5 times per week
CTV（Clinical target）：56-66Gy/30~36f，once a day, 5 times per week
GTV-ln（positive neck region）：66-70Gy/33~36 F，once a day, 5 times per week
CTV-ln（negative neck region）：50-54Gy/28~30F, once a day, 5 times"
1693171|NCT01516996|Biological|Nimotuzumab|Nimotuzumab was administered 200 mg IV over 1 hour on day 1,once a week, for 13~14 weeks
1693172|NCT01516983|Drug|icotinib|"Level 1: Standard whole brain radiation therapy plus icotinib 125 mg Tid (375 mg per day) from day1 until disease progression or intolerable toxicity.
Level 2: Standard whole brain radiation therapy plus icotinib 250 mg Tid (750 mg per day) from day1 until disease progression or intolerable toxicity.
Level 3: Standard whole brain radiation therapy plus icotinib 375 mg Tid (1125 mg per day) from day1 until disease progression or intolerable toxicity.
Level 4:Standard whole brain radiation therapy plus icotinib 500 mg Tid (1500 mg per day) from day1 until disease progression or intolerable toxicity."
1693173|NCT01516983|Radiation|Whole brain radiotherapy|Whole Brain Radiation Therapy (WBRT) for total dose of 37.5Gy in 15 daily fractions beginning after Day 7.
1693174|NCT01516970|Drug|Darunavir/Ritonavir (DRV/r)|Darunavir (DRV) type=exact number, unit=mg, number=800, form=tablet, route=oral use. Tablet is taken once a day, for 28 days; Ritonavir (r) type=exact number, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
1693175|NCT01516970|Drug|Lopinavir in fixed combination with Ritonavir|type=exact number, unit=mg, number=400/100, form=tablet, route=oral use. Tablet is taken once or twice a day, for at least 28 days and a maximum of 30 days.
1693176|NCT01516970|Drug|Zidovudine|type=exact number, unit=mg, number=250, form=tablet, route=oral use. Tablet is taken twice a day, for at least 28 days and a maximum of 30 days.
1693177|NCT01516970|Drug|NRTIs|The NRTIs (including tenofovir/emtricitabine [Truvada], lamivudine/zidovudine [Combivir]) will be administered as per the individual Summary of Product Characteristics (SmPCs) at the discretion of either the treating physician or Investigator.
1693178|NCT01516970|Drug|Efavirenz|type=exact number, unit=mg, number=600, form=tablet, route=oral use. Tablet is taken once a day, for at least 28 days and a maximum of 30 days.
1955717|NCT03100240|Procedure|Modified Supper Long Protocol|In Modified Supper Long Protocol, GnRH-a was used twice in mid-luteal phaes
1955718|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|5 mg orally once daily for 20 weeks
1955719|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|10 mg orally once daily for 20 weeks
1955720|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|20 mg orally once daily for 20 weeks
1955721|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|30 mg orally once daily for 20 weeks
1693186|NCT01516931|Procedure|repetitive Transcranial Magnetic Stimulation (rTMS)|1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
1693187|NCT01516931|Behavioral|counseling|Placebo monthly by general counseling for 12 months.
1693188|NCT01516918|Drug|VX-222|tablet, 400-mg twice daily
1693189|NCT01516918|Drug|telaprevir|tablet, 1125-mg twice daily
1693190|NCT01516918|Drug|ribavirin|tablet, 1000-mg per day for subjects weighing <75 kg and 1200 mg per day for subjects weighing ≥75 kg, twice daily
1955722|NCT03098979|Drug|Neladenoson bialanate (BAY1067197)|40 mg orally once daily for 20 weeks
1693193|NCT01516892|Biological|onabotulinumtoxinA|Participants received 155 U of onabotulinumtoxinA approximately every 12 weeks for 108 weeks. OnabotulinumtoxinA was administered as 31 intramuscular injections in 7 head/neck muscle areas.
1693194|NCT01516879|Biological|Evolocumab|Administered by subcutaneous injection once a month
1693195|NCT01516879|Biological|Placebo|Administered by subcutaneous injection once a month
1693196|NCT01516879|Drug|Atorvastatin|Background lipid lowering therapy: 10 mg or 80 mg atorvastatin orally once daily.
1693197|NCT01516879|Drug|Ezetimibe|Background lipid lowering therapy: ezetimibe 10 mg orally once a day
1693198|NCT01516879|Other|Diet Only|Diet only, no lipid lowering background drug given
1693199|NCT01516866|Procedure|Sodium Fluoride (NaF) Positron Emission Tomography/Computed Tomography (PET/CT) imaging|Subjects who will be enrolled will be those who will be starting treatment (as part of standard of care or as part of another trial) with either a microtubule directed chemotherapy regimen (cohort A), or AR-directed therapy (cohort B). All subjects will have a baseline NaF PET/CT scan (baseline #1), performed within days prior to starting either chemotherapy or AR-directed therapy. A subset of subjects (up to 20 subjects per site, 60 total) will undergo a second NaF PET/CT scan (baseline #2) within 1-8 days of the initial scan to determine repeatability of NaF PET/CT scanning. Subjects in cohort A will undergo another NaF PET/CT scan at week 8 (+/- 1 week). Subjects in cohort B will undergo two additional NaF PET/CT scans at weeks 6 and 12 (+/- 1 week).
1693200|NCT01516853|Device|Non-contrast MRI|Non-contrast MRI will be performed on each subject, at both 1.5T and 3.0T. Different MRI sequences (spin-echo and gradient-echo) will be used, with varying acquisition parameters (e.g., echo times, spatial resolution).
1693201|NCT01516840|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily for 21 days, followed by 15 mg once daily
1693202|NCT01516840|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
1693203|NCT01516840|Drug|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
1693204|NCT01516840|Drug|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
1693206|NCT01516814|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg twice daily for 21 days, followed by 15 mg once daily
1693207|NCT01516814|Drug|Unfractionated heparin|To be adjusted to maintain the activated partial thromboplastin time (aPTT) prolongation (1.5 to 2.5 times the control)
1693208|NCT01516814|Drug|Warfarin|To be adjusted on the basis of prothrombin time-international normalized ratio (PT-INR) values target range (1.5 to 2.5)
1693209|NCT01516801|Other|PSA flyer|A mailed low-literacy informational patient flyer about the PSA test
1693210|NCT01516788|Other|Phototesting|Single MED dose on Day 2
1693211|NCT01516775|Other|clear fluid ingestion|drinking of clear fluid in preoperative period
1693212|NCT01516762|Drug|Radium-223 dichloride (BAY88-8223)|One injection to be administered every 4 weeks up to 6 injections. The dose per injection is 50 kBq/kg body weight.
1693213|NCT01516749|Drug|anakinra|Anakinra is supplied in individual pre-filled glass syringes 100mg/0.67mL each. It will be injected subcutaneously once daily for 8 continuous weeks.
1693214|NCT01516736|Drug|LA-EP2006|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle LA-EP2006 is injected s.c. post chemotherapy application.
1693215|NCT01516736|Drug|Neulasta®|Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle Neulasta® is injected s.c. post chemotherapy application.
1693216|NCT01516723|Device|Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)|Recanalization of totally occluded coronary arteries
1693217|NCT01516710|Procedure|Open liver resection|Patients will be operated with open liver resection for colorectal metastasis
1693218|NCT01516710|Procedure|Laparoscopic liver resection|Patients will be operated with laparoscopic liver resection
1693219|NCT01516697|Procedure|experimental|Non-invasive cardiac output monitoring using thoracic electric bioimpedance analysis via ICON® in addition of the standard monitoring during cesarean section.
1693220|NCT01516697|Procedure|Control|Data obtained from the non-invasive cardiac output monitor,ICON®, are not available for the anesthesia care providers.
1693221|NCT01516684|Drug|placebo administration|Given topically
1693222|NCT01516684|Drug|EMLA|Given topically
1693223|NCT01516684|Drug|propofol|Given IV
1693224|NCT01516684|Drug|fentanyl citrate|Given IV
1693225|NCT01516658|Device|Hydrogel coil|at least one Hydrogel coil have to use for embolization
1693226|NCT01516658|Device|Bare platinum coil|only bare platinum coil have to use for embolization
1693227|NCT01516645|Drug|KHK2898|injection
1693228|NCT01516632|Behavioral|SMS USA|Intervention participants receive text messages daily pre-and post-quit. Everyone receives messages 14 days prior to the Quit day, and through the day after Quit. Then, participants are 'pathed' to particular messages based upon their self-reported smoking status at Day 2 and Day 7 post quit, respectively. Those who are successful at quitting receive messages aimed at relapse prevention whereas those who have slipped receive messages aimed at getting the person to recommit to quitting and trying again.
1693229|NCT01516619|Drug|Romiplostim|"Romiplostim will be administered subcutaneously at a dose of 250 μg on the 1st, 3rd and 5th days after the last day of chemotherapy delivery and, then, every two days until the achievement of 75.000 plt/μL.
In the case of unsuccessful use of romiplostim after the second chemotherapy course, dose escalation to 500 μg/day, with the same above-mentioned schedule, will be indicated after the third course and for all the further courses, with a maximum of 8."
1693230|NCT01516606|Drug|clarithromycin, oral, high dose|2 g/day clarithromycin (once a day) for 14 days followed by 7 days interval to be repeated for 4 cycles in total
1693231|NCT01516593|Drug|Induction Phase|"dd -2 to 1: Methylprednisolone
dd 0-1, Cyclophosphamide, associated on day 0 with Vincristine
dd 2, Rituximab
dd 7, Methotrexate
dd 14, Rituximab
dd 15, Etoposide
dd 21, Methotrexate
dd 29, Rituximab and Doxorubicin
dd 36, Rituximab and VCR
At the end of this induction phase, subsequent treatment will be performed according to the objective response:
pts in CR: consolidation phase followed by bulky site irradiation
pts in PR: consolidation phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation
pts with SD after induction or PD during or after induction: intensification phase followed by BEAM conditioning regimen supported by ASCT and bulky irradiation"
1693232|NCT01516593|Drug|Consolidation Phase (on day +50)|"dd 1-2: cytarabine twice a day
dd 3 and 11: rituximab
dd 11-13: leukapheresis for PBPC collection."
1693233|NCT01516593|Drug|Intensification phase|"One or two courses of R-IVAC or R-ICE chemoimmunotherapy regimen, every three weeks as debulking.
CTX (dd 1) associated with rituximab on dd 3 and 10, followed by PBPC collection (dd 11-13);
AraC every 12 hours for four days (dd -5 to -2) supported by reinfusion of CD34+ cells (dd 0), rituximab infusion (dd -1 and +11) and second in-vivo purged PBPC collection (if needed)."
1693234|NCT01516593|Drug|BEAM conditioning|BCNU on dd 1; VP-16 every 12 hours on dd 2-5 and araC every 12 hours on dd 2-5; melphalan on dd 6, followed by the reinfusion of CD34+ cells
1693235|NCT01516593|Radiation|Consolidation radiotherapy|At the end of the whole program, patients will be evaluated for involved-field irradiation with 6-10 MeV photons and a dose of 36 Gy (2 Gy/d, five fractions a week). Three subgroups of patients will be considered for radiotherapy
1693236|NCT01516580|Drug|Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|"Prephase (COP) for all groups followed by:
in group B: 4 courses: 2 COPADM + 2 CYM, with MTX 3g/m² in group C: 6 courses: 2 COPADM + 2 CYVE + 2 maintenance courses, with MTX 8g/m², in 4h in C1, in 24h in C3 (except the 1st course) and CNS positive patients receive additional IT before each CYVE courses and HDMTX between CYVE courses."
1693237|NCT01516580|Drug|Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C|LMB chemo as in the comparator arm Rituximab 375 mg/m² i.v.: 6 injections: two doses at 48h interval are given at D-2 and D1 of the 2 first courses (COPADM) and one dose at the beginning of the 2 following courses (CYM or CYVE).
1693238|NCT01516567|Drug|Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Rituximab|6 courses of Dose Adjusted-EPOCH-Rituximab Rituximab 375 mg/m² i.v.: one injection at each of the 6 courses of EPOCH.
1693239|NCT01516554|Drug|Testosterone undecanoate|40 mg twice daily
1693240|NCT01516554|Drug|placebo|twice daily
1693241|NCT01516541|Other|Background care|Guidelines-based medical care
1693242|NCT01516541|Drug|Placebo|Matching dalcetrapib placebo orally daily
1693243|NCT01516541|Drug|dalcetrapib|600 mg orally daily
1693244|NCT01516528|Procedure|Spirometry|Assessment of lung function by spirometry
1955723|NCT03098979|Drug|Placebo|Orally once daily for 20 weeks
1693247|NCT01516502|Other|low-level laser therapy|An infrared (the low-level laser, class IIIb) gallium aluminum arsenide (Ga-Al-As) diode laser device (MediUm-TECH Medizingeräte GmbH, Germany) with a wavelength of 810nm and a maximum power output of 150mW in the continuous wave mode
1693248|NCT01516489|Behavioral|Stage 1|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to.
1693249|NCT01516489|Behavioral|Stage 2|Patients who are prescribed an FOBT kit in one of the PVAMC Primary Care clinics (i.e., Module B or C) will be randomly assigned by day to one of 4 study arms. All FOBT kits will include a card with a description of the arm that the patient has been randomized to. The exact dollar amounts for the Voucher-Based Incentive, Lottery-Based Incentive, and Raffle-Based Incentive arms will be based on the results of Stage 1.
1693250|NCT01516476|Drug|Placebo|Placebo for 12 weeks
1693251|NCT01516476|Drug|RO6807952|multiple doses for 12 weeks
1693252|NCT01516476|Drug|RO6807952|multiple doses for 12 weeks
1693253|NCT01516476|Drug|liraglutide|liraglutide for 12 weeks
1693254|NCT01516463|Drug|Collagenase Santyl|Applied topically (2 mm thickness once daily)
1693255|NCT01516463|Biological|Bacitracin|Applied topically (2 mm thickness) once daily
1693256|NCT01516450|Drug|GSK1550188 IV|Single IV dose of belimumab 200 mg
1693257|NCT01516450|Drug|GSK1550188 SC|Single SC dose of belimumab 200mg
1693258|NCT01516437|Procedure|Blood collection|Blood collection at Day 0 (all subjects) and at Month 6 (COPD subjects) for the analysis of serology, cell-mediated immune response.
1693259|NCT01516437|Procedure|Swab collection|Nasopharyngeal and oropharyngeal swabs collection at Day 0 (All subjects) and at exacerbation visits (COPD subjects).
1693260|NCT01516437|Procedure|Sputum collection|Sputum collection at Day 0 and at exacerbation visits (COPD subjects)
1693263|NCT01516411|Behavioral|Mobile Intervention for Lifestyle Eating/Exercise @ Stanford|Participants are randomized to one of 4 groups, each of which uses a different Smartphone app to promote health behavior change
1693264|NCT01516372|Drug|GEn 1200mg|1200 mg of Gen administered as a single dose
1693265|NCT01516372|Drug|Gen 6000 mg|6000 mg of Gen administered as a single dose
1693266|NCT01516372|Drug|GEn Placebo|Placebo to match GEn Tablets
1693267|NCT01516372|Drug|Moxifloxacin Placebo|Placebo to match Moxifloxacin
1693268|NCT01516372|Drug|Moxifloxacin|400 mg Moxifloxacin administered as a single dose
1693269|NCT01516346|Drug|Isosorbide Dinitrate|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 placebo capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm.
1693360|NCT01515722|Behavioral|Health education intervention (HEI)|"<Part 1> Understanding OAB
<Part 2> Behavioral/lifestyle modification
<Part 3> Bladder training
<Part 4> Understanding antimuscarinics"
1693270|NCT01516346|Drug|Isosorbide Dinitrate + Hydralazine|Enrolled subjects will be randomized in a blinded fashion to 1 isosorbide dinitrate capsule TID + 1 hydralazine capsule TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs. Subjects receiving isosorbide dinitrate will be given 20mg PO q8am, 2pm, and 8pm and will be titrated up to 40mg PO q8am, 2pm, and 8pm. Subjects receiving hydralazine will be given 37.5mg PO q8am, 2pm, and 8pm and will be titrated up to 75mg PO q8am, 2pm, and 8pm.
1693271|NCT01516346|Drug|Placebo|Enrolled subjects will be randomized in a blinded fashion to 2 placebo capsules TID. In addition, all subjects will receive a single in-lab dose of 0.4 mg of sublingual nitroglycerine (open label) before randomization to the blinded study drugs.
1693272|NCT01516333|Other|High GL 107|Three meals a day
1693273|NCT01516333|Other|Medium GL 76|Three meals a day
1693274|NCT01516333|Other|Medium GL 68|Three meals a day
1693275|NCT01516333|Other|Low GL 48|Three meals a day
1693276|NCT01516320|Procedure|Roux-en-Y Gastric Bypass|A surgical technique in which the stomach is stapled into a smaller pouch and then attached directly to the small intestine, bypassing the rest of the original stomach. The goal of the surgery is weight loss.
1693277|NCT01516320|Procedure|Laparoscopic adjustable gastric banding|A surgical technique in which an inflatable silicone device placed around the top portion of the stomach, creating a smaller gastric pouch. The goal of the surgery is weight loss.
1693278|NCT01516320|Procedure|Vertical Sleeve Gastrectomy|A surgical technique in which a large portion of the stomach is removed, leaving only a smaller gastric pouch. The goal of the surgery is weight loss.
1693279|NCT01516307|Biological|OPT-822/OPT-821(30 μg/100 μg) + Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37. OPT-822 and OPT-821 are combined at time of injection.
1693280|NCT01516307|Biological|Phosphate Buffer Saline (PBS) + Cyclophosphamide|Subcutaneously on week 1, 2, 3, 5, 9, 13, 17, 25, and 37.
1693281|NCT01516294|Radiation|Iray|The Oraya IRay stereotactic radiotherapy device will be used to deliver a 16 Gy dose of radiation to the macula. The radiotherapy will be delivered in a single session utilizing three sequential beams, each depositing 5.3 Gy at the macula through calculated scleral entry points, crossing the pars plana region of the eye, and overlapping at the same region of the macula.
1693282|NCT01516268|Drug|Sufentanyl|"As intervention 1cc sufentanyl is added to bupivacain in case group for TAP block.
As comparator 1cc normal saline is added to bupivacain in control group for Tap block."
1693283|NCT01516255|Drug|liraglutide|0.6 mg daily for 7 days followed by 1.2 mg daily for 7 days followed by 1.8 mg daily for 7 days. Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
1693284|NCT01516255|Drug|placebo|Injected subcutaneously. Subjects are randomly allocated to two treatment sequences
1693285|NCT01516255|Drug|moxifloxacin|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where a single dose of 400 mg moxifloxacin (tablets) is administered as positive control
1693286|NCT01516255|Drug|placebo|Following the double-blinded period and a wash-out period of 7 days, subjects are re-randomised to an open-label, parallel period where single dose of oral placebo is administered
1693287|NCT01516255|Procedure|electrocardiogram (ECG)|24 hours serial ECG is collected before initial dose of 0.6 mg liraglutide, on the last dosing day of 1.2 mg liraglutide and on the last dosing day of 1.8 mg liraglutide
1693288|NCT01516255|Procedure|electrocardiogram (ECG)|Six hours after moxifloxacin or placebo single dose, 1 hour serial ECG is collected
1693289|NCT01516242|Other|No treatment given|Collection of data about patients with type 1 diabetes or type 2 diabetes treated with insulin changing their insulin administration from syringe to a insulin delivery system based on completion of questionaire
1693290|NCT01516229|Drug|somatropin|Prescription of somatropin at the discretion of the physician
1693291|NCT01516216|Drug|FOLFOX + bevacizumab|Given intravenously on Day 1 of every cycle
1693292|NCT01516216|Dietary Supplement|Vitamin D|Standard Dose (400 IU once daily)
1693293|NCT01516216|Dietary Supplement|Vitamin D|Higher Dose (8000 IU once daily for 2 weeks, followed by 4000 IU once daily)
1693294|NCT01516203|Drug|AZD5847|Eligible subjects will be randomly assigned to receive monotherapy with one of four doses of oral AZD5847 for 14 days: 500 mg orally once daily, 500 mg orally twice daily, 1200 mg orally once daily, or 800 mg orally twice daily.
1693295|NCT01516203|Drug|Rifafour|Eligible subjects will be randomly assigned to receive treatment with standard 4 drug anti-tuberculosis regimen: Rifafour e-275 mg tablets (75 mg isoniazid/150 mg Rifampin/275 mg Ethambutol/400 mg Pyrazinamide) orally, dosed by body weight for 14 days.
1693296|NCT01516190|Behavioral|Exercise|Supervised exercise sessions and independent exercise
1693297|NCT01516190|Behavioral|Surgical preparation program|Book, tapes, CD
1693298|NCT01516164|Device|Laryngoscopy|After establishing full monitoring, inducing general anaesthesia and ensuring paralysis laryngoscopy is performed and the patient's trachea intubated.
1693299|NCT01516151|Dietary Supplement|CaPre™|1 capsule of 0.5g total CaPre™ for 4 weeks followed by one 1.0g capsule per day for an additional 4 weeks
1693300|NCT01516151|Dietary Supplement|CaPre™|1 capsule of 1.0g total CaPre™ for 4 weeks followed by two 1.0g capsules per day for an additional 4 weeks
1693301|NCT01516151|Dietary Supplement|CaPre™|2 capsules of 1.0g total CaPre™ for 4 weeks followed by 4 capsules of 1.0g total per day for an additional 4 weeks.
1693302|NCT01516151|Drug|Lipid Lowering Medication|Patient will be treated as per the Standard of care.
1693303|NCT01516151|Dietary Supplement|CaPre™|4 capsules of 1 g total per day for 8 weeks.
1693304|NCT01516138|Drug|GIK|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
1693305|NCT01516138|Drug|Control|Intravenous solution was started at about 10 minutes before general anesthesia, running at a rate of 1 mL/kg/h for 12.5 hours.
1693306|NCT01516099|Other|General Practitioners|The general practitioner can refer his patients to a physical activity counselor for an individual coaching (intake session with development of program and pretesting, follow up by e-mail or phone (max 4x), personal contact moments (max 3x) and exit session with evaluation and posttesting).
1693361|NCT01515696|Drug|Gastrografin|Patients will receive 3ml Gastrografin + 6ml sterile water/kg as a single dose via a nasogastric tube during the first 24 hours of life.
1693307|NCT01516099|Other|Social-cultural organizations|In the social-cultural organization, members can sign in for group sessions led by the physical activity counselor (intake session with development of program and pretesting, follow up by email or letters (max 4x), personal contact moments (max 4x) and exit session with evaluation and posttesting).
1693308|NCT01516086|Drug|Fluticasone Propionate (FP)|FP Inhalation BID
1693309|NCT01516073|Drug|Fluticasone Propionate|FP BID for 12 weeks
1693310|NCT01516060|Drug|Efavirenz|400mg qd; 2 x 200mg
1693311|NCT01516060|Drug|Efavirenz|600mg qd; 3 x 200mg qd
1693312|NCT01516047|Drug|Cohort 1|125 mg to 2000 mg abiraterone acetate suspension on Day 1
1693313|NCT01516047|Drug|Cohort 2|2000 mg abiraterone acetate suspension on Day 1
1693314|NCT01516034|Device|Cupola Tattoo Removal device|Up to 6 treatments with the device every 2-3 weeks to the tattoo area.
1693315|NCT01516021|Dietary Supplement|intake of high or low fat yoghurt|intake of 500 ml of a high fat yoghurt on one day and intake of 500 ml of a low fat yoghurt on the other day
1693316|NCT01516008|Drug|Tapentadol IR 50 mg|Type= exact number, unit= mg, number= 50, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
1693317|NCT01516008|Drug|Tapentadol IR 75 mg|Type= exact number, unit= mg, number= 75, form= tablet, route= oral use. Tapentadol IR will be administered as a single oral dose once every 4 to 6 hours (patients may take their next dose as early as 4 hours, but no later than 6 hours, after the previous dose), for a period of 72 hours.
1693318|NCT01516008|Drug|Placebo|Form= tablet, route= oral use. Placebo tablets will be administered as a single oral dose every 4 to 6 hours, for a period of 72 hours.
1693319|NCT01515995|Drug|Nebulized magnesium sulfate|"15 mg albuterol in 22 ml of magnesium sulfate solution (880 mg) via nebulizer over one hour
Versus
15 mg albuterol in 22 ml of normal saline via nebulizer over one hour"
1693320|NCT01515982|Behavioral|Aerobic Exercise|The training exercise intensity is established at 60% of VO2máx. This intensity was determined using exercise prescription guidelines established by the American College of Sports Medicine (ACSM). Each aerobic session began with a 10-minute warm-up period (40%VO2máx), followed by 20 minutes of continuous treadmill walking at an intensity established by 60% of VO2máx. The exercise session will be concluded with a 5 minutes of cool down. Heart hate (Polar® Sport Tester, Finland) and perceived exertion (Borg Scale) will be monitored and recorded at each five minutes during each exercise session by physical education instructors.
1693321|NCT01515982|Behavioral|Control Group|All participants were asked not to commence any new exercise regimen.
1693322|NCT01515969|Drug|Erlotinib hydrochloride|Given PO
1693323|NCT01515969|Drug|Dovitinib lactate|Given PO
1693324|NCT01515956|Drug|BMN 110|Patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/wk over a period of approximately 4 hours every week for up to 208 weeks.
1693325|NCT01515943|Other|Active home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed 15 minutes/day of active home-based computer therapy for 5 days/week during the 12 week treatment phase. Active home-based computer therapy will be provided the Home Therapy System (HTS) computer software and will include both fusional vergence and accommodative therapy. Subjects will perform the computer therapy while wearing red/blue glasses and accommodative therapy will be performed using the HTS accommodative flippers. Please refer to the procedures manual for further details.
1693326|NCT01515943|Procedure|Near target push-ups|At enrollment, subjects will be prescribed 15 minutes/day (3 sessions of 5 minutes each) of near target push-ups (NTP) for 5 days/week during the 12-week treatment phase. An alphabet pencil will be used as the target and an index card placed in the background will provide physiological diplopia control. With the pencil positioned at arm's length directly between the subject's eyes, the subject will slowly bring the pencil toward his/her nose while focusing on the small letter on the pencil. When the subject is no longer able to maintain a single image of the pencil, he/she will slowly move the target away from the nose until the pencil becomes single again. This procedure will be repeated several times. Please refer to the procedures manual for further details.
1693327|NCT01515943|Other|Placebo home-based computer vergence/accommodative therapy|At enrollment, subjects will be prescribed either 5 minutes/day (NTP group) or 15 minutes/day (Placebo group) of placebo home-based computer therapy for 5 days/week during the 12 week treatment phase. Placebo computer-based therapy will be provided by the Home Therapy System (HTS) computer software. The vergence procedures are similar to the active version, however, the tasks will be modified to ensure no demand on the vergence system and no accommodative therapy is included in the placebo version. Please refer to the procedures manual for further details.
1693328|NCT01515943|Procedure|Placebo yoked prism flippers|"Subjects will be prescribed 5 minutes/day of placebo yoked prism flipper therapy for 5 days/week during the 12 week treatment phase. This procedure utilizes a 4 pd base right/4 pd base left prism flipper and Accommodative Hopping Cards. Subjects view the text on the card through the prisms at 40 cm, perform the appropriate task and then flip the prism flipper to the other side after each word before proceeding to the next line. Please refer to the procedures manual for further details. The task remains constant, but the nature of the procedure changes with time:
Weeks 1-4: View the target through prism flippers
Weeks 5-8: Wear red-blue filter glasses while viewing the text through prism flippers
Weeks 9-12: Wear polaroid glasses while viewing the text through prism flippers"
1693329|NCT01515930|Behavioral|Parent Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring & resolving ambivalence, with a strong evidence for improving adolescent & adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from parental monitoring of diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation & goals they set regarding monitoring diabetes care.
1693362|NCT01515696|Drug|Sterile water|Patients will receive 9ml/kg sterile water as a single dose via a nasogastric tube during the first 24 hours of life.
1693363|NCT01515683|Behavioral|Only support from an anaesthetic nurse on the surgery ward|Additional staff are only present if required by law.
1693407|NCT01515397|Drug|Gelofusine balanced|Gelofusine balanced combined with Sterofundin ISO
1693330|NCT01515930|Behavioral|Parent & Child Computer-Delivered Motivational Intervention|Motivational Interviewing (MI) is a client-centered, directive method for enhancing intrinsic motivation to change by exploring & resolving ambivalence, with a strong evidence for improving adolescent & adult health behaviors. Three motivational sessions will be provided by an animated character who delivers the intervention with high fidelity to MI principles. Small amounts of psychoeducation about potential improvements illness management that can result from monitoring/completing diabetes care will be integrated with more purely motivational elements. Mailings will be sent to participants to remind them of the reasons they gave as motivation & goals they set regarding diabetes care.
1693331|NCT01515930|Behavioral|Computer-Delivered Information|Computer-Delivered Information about issues related to living with diabetes that do not directly impact completing diabetes care.
1693332|NCT01515917|Drug|Citicoline|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 1000 mg daily citicoline. These participants will receive a 14-day supply of citicoline at visit 1 and again at visit 2, making for a 28-day administration period.
1693333|NCT01515917|Drug|Omega-3|Participants randomly assigned to the experimental group, who, in addition to the research staff will be blind to such assignment, will be instructed to orally administer 2000 mg daily omega-3. These participants will receive a 14-day supply of omega-3 at visit 1 and again at visit 2, making for a 28-day administration period.
1693334|NCT01515917|Other|Rice bran oil|Rice bran oil will be one of two placebos administered to participants randomly assigned to the placebo arm. Rice bran oil will serve as the placebo for omega-3 fatty acids and will be orally administered daily in 500 mg doses.
1693335|NCT01515917|Other|Microcrystalline Cellulose|Microcrystalline Cellulose will be one of two placebos administered to participants randomly assigned to the placebo arm. Microcrystalline Cellulose will serve as the placebo for Citicoline and will be orally administered daily in 470 mg doses.
1693336|NCT01515904|Behavioral|STOMP Clinic|"A new interdisciplinary clinic (STOMP) was created to provide care for children and adolescents with severe 'complex' obesity. As part of the program, a subset of adolescents undergo bariatric surgery. The core elements include an interdisciplinary team, frequent visits, individualized care plans for medically-complex adolescents) and building on other aspects, such as increased psychosocial intervention; involvement of a key worker (nurse practitioner) to support families; provision of continuity of care with other health providers in all settings, community services and schools; a more diverse patient population; and group support sessions."
1693337|NCT01515891|Drug|BIA 9-1067|90 µCi (3.33 MBq) [14C]-labeled of 100 mg BIA 9-1067 (single-dose).
1693338|NCT01515878|Device|Hemocontrol|Blood Volume Tracking system using biofeedback
1693339|NCT01515865|Drug|Midodrine HCl|dose at subject's current dose level
1693340|NCT01515865|Drug|Placebo|single dose of matching placebo
1693341|NCT01515852|Procedure|general anesthesia in stereotactic biopsy|stereotactic biopsy
1693342|NCT01515852|Procedure|local anesthesia in stereotactic biopsy|stereotactic biopsy
1693343|NCT01515839|Dietary Supplement|Multivitamin Supplement intervention|"We recommend the following protocol:
2 tablets of a high quality multivitamin BID
2 capsules of omega 3 fish oil BID for a total of 3 grams daily
3 capsules of a brain and memory formula BID which contains Acetyl-L-Carnitine (HCL) 1000 mg, Ginkgo Biloba Extract 120 mg, Alpha-Lipoic Acid (ALA) 300 mg, Huperzine A (Huperzia serrata)150 mcg, N-Acetyl-L-Cysteine (NAC) 600mg, Phosphatidyl Serine (soy) 100 mg, Vinpocetine 15mg
Weight loss"
1693344|NCT01515826|Drug|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.075% Ophthalmic Gel (VIGADEXA Gel)|One ribbon (approximately 1-1.5 cm) administered topically in the conjunctival sac of the study eye three times daily (TID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
1693345|NCT01515826|Drug|Moxifloxacin 0.5%/Dexamethasone Phosphate 0.1% Ophthalmic Solution (VIGADEXA Solution)|One drop administered topically in the conjunctival sac of the study eye four times daily (QID), starting the day before surgery (Day -1) and continuing on the day of surgery and for 15 days following surgery.
1693346|NCT01515813|Drug|Pravastatin sodium|One 40 mg tablet of Pravastatin sodium taken orally once daily.
1693347|NCT01515813|Drug|Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate|Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily
1693348|NCT01515813|Drug|Pravastatin sodium|Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
1693349|NCT01515800|Behavioral|Text message reminder|Receive text message
1693355|NCT01515761|Procedure|Postero-lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or postero-lateral area of the LV based on pre-procedure randomization.
1693356|NCT01515761|Procedure|Antero-Lateral|A device implant procedure will be performed under the standard of care technique with the right ventricular lead at the right ventricular apex and the left ventricular lead targeting or antero-lateral area of the LV based on pre-procedure randomization.
1693357|NCT01515748|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form:solution for infusion Route of administration: intravenous
1693358|NCT01515748|Drug|OXALIPLATIN (SR96669)|Pharmaceutical form:solution for infusion Route of administration: intravenous
1693359|NCT01515748|Drug|S-1 (1-(2-tetrahydrofuryl)-5-fluorouracil + CDHP (Gemeracil) + Oxo (Oteracil)|Pharmaceutical form:Tablet Route of administration: Oral
1748550|NCT00171132|Drug|atenolol|
1693364|NCT01515683|Behavioral|Support: a theatre nurse + an anaesthetic nurse|Theatre nurse stay with the patient, follow her to the operating table and stays with her until she is anaesthetized
1693365|NCT01515683|Behavioral|Support: a nurse from the ward + an anaesthetic nurse|A nurse from the ward follows the patient to the operating table and stays with her until she is anaesthetized.
1693366|NCT01515683|Behavioral|Optional relative supports|Optional relative follows the patient to the operating table and stays with her until she is anaesthetized
1693367|NCT01515657|Drug|PL2200 Aspirin Capsules|325 mg aspirin; once per day for 3 days
1693368|NCT01515657|Drug|Immediate-Release Aspirin Tablets|325 mg aspirin; once per day for 3 days
1693369|NCT01515657|Drug|Enteric-coated aspirin caplets|325 mg aspirin; once per day for 3 days
1693370|NCT01515644|Other|Powder based infant formula|Powder based infant formula with Inulin I
1693371|NCT01515644|Other|Powder based infant formula|Powder based infant formula with Inulin II
1693372|NCT01515644|Other|Powder based infant formula|Powder based infant formula without Inulin
1693373|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. Dose is weekly incremented with 5 mcg/kg
1693374|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg the third week, and finally 20 mcg for 2 weeks
1693375|NCT01515592|Drug|liraglutide|One daily subcutaneous dose for 5 weeks. 5 mcg/kg the first week, then 10 mcg the second week followed by 15 mcg for 3 weeks
1693376|NCT01515592|Drug|placebo|Liraglutide placebo administered to subjects randomised at each dose level in the ratio of 3:1
1693377|NCT01515579|Drug|liraglutide|One single dose of 6.25 mg/mL administered subcutaneously
1693378|NCT01515579|Drug|liraglutide|One single dose of 6.0 mg/mL administered subcutaneously
1693379|NCT01515566|Drug|Fentanyl|Fentanyl SQ dose equivalent to 15-25% of the morphine equivalent daily dose (MEDD) 15 minutes before 6 minute walk test.
1693380|NCT01515566|Other|Placebo|Normal saline 0.9% preservative free SQ 15 minutes before walk test.
1693381|NCT01515566|Other|Walking Tests|6 minute walk test at baseline and 15 minutes after Fentanyl or Placebo.
1693382|NCT01515566|Behavioral|Questionnaires|Questionnaires completed at baseline (two) and after study visit (one) taking about 5 ot 10 minutes to complete.
1693383|NCT01515553|Drug|liraglutide|Two single doses of 0.72 mg liraglutide administered subcutaneously on two different dosing occasions separated by a wash-out period
1693384|NCT01515540|Drug|lidocaine|5% lidoderm patch
1693385|NCT01515540|Drug|placebo|placebo
1693386|NCT01515527|Drug|Cladribine|"Induction cycle: 5 mg/m2 by vein on days 1 - 5 for up to 2, 28 day cycles.
Consolidation cycle: 5 mg/m2 by vein on days 1 - 3 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
1693387|NCT01515527|Drug|Cytarabine|"Induction cycle: 20 mg subcutaneously twice daily on days 1-10 for up to 2, 28 day cycles.
Consolidation cycle: 20 mg subcutaneously twice daily on days 1 - 10 of cycles 2, 5, 6, 9, 10, 13, 14, 17, and 18."
1693388|NCT01515527|Drug|Decitabine|Consolidation cycle: 20 mg/m2 by vein over 1 to 2 hours on days 1-5 of cycles 3, 4, 7, 8, 11, 12, 15, and 16.
1693389|NCT01515501|Procedure|Endoscopic mucosal resection (EMR)|EMR uses an endoscope to take a tissue sample from the rectum. It is the same type of instrument used in a routine colonoscopy. It is hoped that this procedure will help diagnose Hirschsprung's Disease more often than by recal suction biopsy alone, which can often be unclear and result in more invasive surgery for diagnosis.
1693390|NCT01515488|Other|Nurse-initiated triage|Nurse-assisted triage for obtaining medical history and presenting problem(s)
1693391|NCT01515488|Other|Self-triage kiosk|Audio-assisted self-triage kiosk for obtaining medical history and presenting problem(s)
1693392|NCT01515475|Procedure|Glasses|For patients in the glasses group, glasses will be prescribed at enrollment with the sphere cut symmetrically by 1.00D and full cylinder correction. If a subject in the observation group has confirmed deterioration, glasses will be prescribed with amount of correction at investigator discretion.
1693393|NCT01515462|Genetic|Autologous CD34 positive cells transduced with WAS encoding lentiviral vector.|The Medicinal Product consists of autologous CD34+ cells collected from the bone marrow and/or peripheral blood and transduced with a lentiviral vector encoding WASP controlled by WAS promoter sequences (w1.6W). Dosage indications: a minimum dose of 2x10^6 CD34+ cells/Kg (maximum 20x10^6 CD34+ cells/Kg) and an optimal dose of 5-10x10^6 CD34+ cells/Kg will be infused i.v.
1693394|NCT01515436|Other|Mozart alternating with Beethoven|Study participants will listen to Mozart's Sonata for Two Pianos in D Major, K. 448 alternating with Beethoven's Fur Elise.
1693395|NCT01515436|Other|Beethoven alternating with Mozart|Study participants will listen to Beethoven's Fur Elise alternating with Mozart's Sonata for Two Pianos in D Major, K. 448.
1693396|NCT01515423|Drug|PP3M 175 mg eq.|Type= exact number, unit= mg eq., number= 175, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
1693397|NCT01515423|Drug|PP3M 263 mg eq.|Type= exact number, unit= mg eq., number= 263, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
1693398|NCT01515423|Drug|PP3M 350 mg eq.|Type= exact number, unit= mg eq., number= 350, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
1693399|NCT01515423|Drug|PP3M 525 mg eq.|Type= exact number, unit= mg eq., number= 525, form= injection, route= intramuscular use. One injection every third month for 48 weeks.
1693400|NCT01515423|Drug|Placebo (20% Intralipid)|Form= injection, route= intramuscular use. One injection monthly when not receiving active medication for 48 weeks.
1693401|NCT01515423|Drug|PP1M 50 mg eq.|Type= exact number, unit= mg eq., number= 50, form= injection, route= intramuscular use. One injection every month for 48 weeks.
1693402|NCT01515423|Drug|PP1M 75 mg eq.|Type= exact number, unit= mg eq., number= 75, form= injection, route= intramuscular use. One injection every month for 48 weeks.
1693403|NCT01515423|Drug|PP1M 100 mg eq.|Type= exact number, unit= mg eq., number= 100, form= injection, route= intramuscular use. One injection every month for 48 weeks.
1693404|NCT01515423|Drug|PP1M 150 mg eq.|Type= exact number, unit= mg eq., number= 150, form= injection, route= intramuscular use. One injection every month for 48 weeks.
1693405|NCT01515410|Drug|DM-1992|72.5mg carbidopa/230mg levodopa
1693406|NCT01515410|Drug|Sinemet IR|Immediate-release tablet containing 25mg carbidopa and 100mg levodopa
1693408|NCT01515397|Drug|Gelofusine 4%|Gelofusine 4% combined with NaCl 0.9%
1693409|NCT01515384|Drug|18F-AV-133|IV injection, 7.6 mCi (281.2 MBq)
1693410|NCT01515371|Drug|IncobotulinumtoxinA|"Subject to receive one injection of either 2.5U, 5U or 7.4U of IncobotulinumtoxinA.
For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per 50U vial, respectively, resulting in a concentration of 6.25 U/ml, 12.5 U/ml and 18.5 U/ml. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection."
1693411|NCT01515371|Drug|Placebo Comparator|For three dose stages: solution prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), reconstitution volume 8 ml, 4 ml and 2.7 ml per vial, respectively. Injection volume is 0.4 ml for all three dose stages. Mode of administration: unilateral soft palate injection.
1693412|NCT01515358|Drug|Placebo|Administered orally
1693413|NCT01515358|Drug|LY3000328|Administered orally
1693414|NCT01515345|Drug|prasugrel or ticagrelor|prasugrel 10mg od for 12 month ticagrelor 90mg td for 12 month
1693415|NCT01515345|Drug|Clopidogrel|clopidogrel 75mg od for 12 month
1693416|NCT01515319|Drug|Y242|Single ascending dose: subcutaneous injection of 2, 7.5, 15, 30, 60 and 120 mg Y242 (Part A) Multiple ascending doses at weekly intervals, doses to be determined (Part B)
1693417|NCT01515319|Drug|0.9% saline|Identical volume to that of Y242
1693418|NCT01515306|Biological|ramucirumab (IMC-1121B)|ramucirumab (IMC-1121B) 8 milligrams/kilogram (mg/kg) intravenous infusion, administered on Day 1and Day 15 of each 4-week cycle, unless otherwise specified.
1693419|NCT01515306|Drug|paclitaxel|paclitaxel 80 milligrams/square meter (mg/m²) intravenous infusion, administered on Days 1, 8 and 15 of each 4-week cycle, unless otherwise specified.
1693420|NCT01515293|Procedure|Single Incision Laparoscopic Appendectomy|
1693421|NCT01515293|Procedure|Conventional appendectomy|
1693422|NCT01515254|Behavioral|lifestyle counseling, parental feeding|Intervention group subjects will undergo a Feeding Dynamic Intervention (FDI). The intervention will be delivered in a closed group setting and will consist of 6 intervention sessions lasting 90 minutes each. Visits to physicians, WIC offices, nutrition program etc will be tracked. The subjects will undergo the energy regulation tests at baseline and 3 months. They will complete surveys and have their weight taken.
1693423|NCT01515241|Drug|CER-001|Weekly injection
1693424|NCT01515228|Device|Xience Prime|everolimus-eluting stent implantation
1693425|NCT01515228|Device|Cilotax stent|paclitaxel with cilostazol dual drug eluting stent implantation
1693426|NCT01515215|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specific brain regions. (MagPro X100)
1693427|NCT01515202|Drug|BMS-823778|Capsules, Oral, 2 mg, Once daily, 14 days
1693428|NCT01515202|Drug|BMS-823778|Capsules, Oral, 12 mg, Once daily, 14 days
1693429|NCT01515202|Drug|BMS-823778|Capsules, Oral, 25 mg, Once daily, 14 days
1693430|NCT01515202|Drug|BMS-823778|Capsules, Oral, 15 mg, Once daily, 14 days
1693431|NCT01515202|Drug|Placebo matching with BMS-823778|Capsules, Oral, 0 mg, Once daily, 14 days
1693437|NCT01515163|Behavioral|Exercise training|Aerobic exercise training, two times a week
1693438|NCT01515137|Drug|Erlotinib|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
1693439|NCT01515137|Drug|Erlotinib plus sulindac|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
1693440|NCT01515137|Drug|Placebo|Erlotinib (150 mg PO QD) plus sulindac (150 mg PO BID) (Arm A), Erlotinib (150 mg PO QD) (Arm B) or placebo (for Erlotinib) QD (Arm C).
1693441|NCT01515124|Behavioral|Exercise Intervention|The Exercise Intervention combines the twice-weekly weight-lifting intervention from PAL with the 180 minutes of weekly aerobic exercise from the recently completed WISER trial and the ongoing WISER Sister Trial. Women will be trained by certified fitness professionals in both the PAL weight-lifting intervention and in safely increasing their aerobic exercise activity over 6 weekly sessions, and then monitored through phone contact, and monthly in-person sessions.
1693442|NCT01515124|Behavioral|Weight Loss Intervention|The Weight Loss Intervention begins with a 24 week intensive phase that includes weekly meetings and provision of all meals and snacks from a commercial manufacturer (NutriSystem, Inc., Fort Washington, PA). Daily caloric intake will be strictly controlled during this first 24 weeks at 1200-1500 calories per day.
1693443|NCT01515098|Dietary Supplement|Freeze-dried blueberries|Wild blueberries, freeze-dried and pulverized
1693444|NCT01515098|Dietary Supplement|Dextrose Placebo|Placebo developed to closely match blueberry powder.
1693445|NCT01515085|Procedure|laser interstitial thermal therapy|residual gliomas either after debulking or biopsy evaluated for intervention with laser ablation prior to onset of adjuvant therapy
1693446|NCT01515072|Other|RIPC (Remote Ischemic Preconditioning)|Remote Ischemic Preconditioning (RIPC) by Inflation of Pneumatic Tourniquet. The intervention will consist of tourniquet inflation on the mid-thigh for 5 minutes, followed by a deflation period of 5 minutes for a total of 4 cycles. The intervention will take place at two time points: First, after determination of brain death and consent for organ donation and again upon incision for organ recovery. The second intervention will occur in a manner identical to the first intervention but in the opposite limb.
1693447|NCT01515046|Drug|Gemcitabine with escalating ascorbic acid|"Gemcitabine 1000 mg/m2 weekly for 3 weeks with one week off (this is 1 cycle)
Ascorbate dose is targeted to achieve plasma level of 350 mg/dL. Infusions are given twice weekly, each week of a cycle (4 weeks to a cycle)"
1693448|NCT01515033|Other|aerobic exercise training|"The continuous exercise training was performed on a treadmill with a 50-minutes duration and intensity at ventilatory anaerobic threshold.
The interval exercise training consisted of 7 sets of 3 minutes at respiratory compensation point and 7 sets of 3 minutes of exercise at moderate intensity corresponding to the ventilatory anaerobic threshold totaling 42 minutes"
1693449|NCT01515020|Drug|vancomycin monotherapy|intravenous therapy by vancomycin
1693450|NCT01515020|Drug|daptomycin monotherapy|intravenous therapy by daptomycin
1693451|NCT01515007|Drug|Ciprofloxacin|once daily for 28 days on and 28 days off for six cycles
1693452|NCT01514994|Device|AngioScore's Valvuloplasty Scoring Balloon|All patients will receive treatment for their aortic valve stenosis with the Valvuloplasty Scoring Balloon Catheter.
1693453|NCT01514981|Drug|AMG 761|Single dose of AMG 761 on study day 1.
1693454|NCT01514981|Drug|Placebo|Single dose of placebo on study day 1.
1693455|NCT01514968|Drug|cyclosporine|Single oral dose
1693456|NCT01514968|Drug|danoprevir|Single oral dose
1693457|NCT01514968|Drug|ritonavir|Single oral dose
1693458|NCT01514955|Radiation|Gold seeds insertion to detect movements at pelvis|
1693459|NCT01514955|Radiation|Image guided MRI based RT (IMRT+Brachytherapy)|
1693460|NCT01514942|Dietary Supplement|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
1693461|NCT01514942|Dietary Supplement|Myo-inositol + Folic acid|Myo-inositol (2g) Folic acid (200mcg) (2 per day)
1693462|NCT01514942|Dietary Supplement|D-chiro-inositol, manganese, folic acid, vit B12|D-Chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
1693463|NCT01514942|Dietary Supplement|D-chiro-inositol, manganese, folic acid, vit B12|D-chiro-inositol (500 mg), manganese (1 mg), folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
1693464|NCT01514942|Drug|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
1693465|NCT01514942|Drug|Folic acid, vit B12|Folic acid (200 mcg), vit B12 (1.25 mcg) (2 per day)
1693466|NCT01514929|Drug|ACHN-490 Injection|20mg/kg IV 30 minute infusion given once
1693467|NCT01514929|Drug|ACHN-490 Injection|15mg/kg IV 30 minute infusion given once
1693468|NCT01514929|Drug|Moxifloxacin|400mg oral pill given once
1693469|NCT01514929|Drug|Placebo|Placebo oral pill given once
1693470|NCT01514916|Device|mechanical anastomosis without suture|The Vascular Join device is intended to be used to create sutureless end-to-end anastomosis between an artery and a venous or synthetic graft conduit. Any type of e-PTFE and Dacron conduits can be used.
1693471|NCT01514903|Drug|HIP0908|SINGLE DOSE , CROSS OVER
1693472|NCT01514903|Drug|viagra|single dose, cross over
1693473|NCT01514877|Drug|Icotinib|Patients will receive whole brain radiotherapy therapy 30Gy over 10 fractions and icotinib will be administered at the beginning of whole brain radiotherapy in doses of 125 mg thrice per day until disease progression or undue toxicity.
1693474|NCT01514864|Drug|Dasatinib|Tablet, oral, 140 mg, once daily until unacceptable toxicity or disease progression
1693475|NCT01514851|Drug|Lanthanum carbonate (BAY77-1931)|
1693476|NCT01514851|Drug|Calcium carbonate|
1693477|NCT01514838|Drug|ASP1941|oral
1693478|NCT01514838|Drug|acarbose|oral
1693479|NCT01514838|Drug|Placebo|oral, used only during placebo run-in period
1693480|NCT01514825|Drug|YM150|oral
1693481|NCT01514825|Drug|Placebo|oral
1693482|NCT01514812|Drug|YM150|oral - modified release formulation of YM150
1693483|NCT01514812|Drug|placebo|oral
1693484|NCT01514812|Drug|digoxin|oral
1693485|NCT01514799|Procedure|gastric bypass|two techniques of gastric bypass for studying the effects of making a long BP-limb
1693486|NCT01514786|Behavioral|Colorectal Web|The intervention arm will allow participants on Colorectal Web to manipulate their preferences for CRCS
1693488|NCT01514734|Drug|Brinzolamide/timolol maleate fixed combination|Commercially marketed topical ocular agent for the treatment of open-angle glaucoma (OAG) or ocular hypertension.
1693489|NCT01514721|Drug|Travoprost/Timolol Maleate BAK-Free Fixed Combination|Commercially marketed Travoprost/Timolol BAK-free ophthalmic solution indicated for the treatment of patients with open angle glaucoma (OAG) or ocular hypertension (OH).
1693490|NCT01514708|Biological|AdimFlu-S Influenza Vaccine|Suspension for injection
1693491|NCT01514695|Drug|Midazolam|Starting with 1mg intravenously in all patients. More can be added at the discretion of the physician as needed for sedation.
1693492|NCT01514695|Drug|Fentanyl|100mcg intravenously given in 2mL syringe at start of procedure
1693493|NCT01514695|Other|Placebo|One dose of saline (2ml)
1693494|NCT01514682|Drug|Anti-inflammatory Combination Therapy|"salsalate: target dose 4 gm/day, administered in two divided doses of 2 gm in the morning and 2 gm in the evening
fluvastatin: target dose 40 mg/day, administered in a single evening dose
combined omega-3-fatty acid preparation of EPA and DHA; target dose EPA 2 gm/day and DHA 2 gm/day administered in a single evening dose"
1693495|NCT01514682|Drug|Placebo|Non-medication pills; To be taken in morning and evening intervals.
1693496|NCT01514656|Other|CPR Training using the Family and Friends CPR Anytime Video Self Instruction|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Program. The subject's will undergo training in-hospital then they will be encouraged to take the training materials home with them to practice CPR with their family members and friends.
1693497|NCT01514656|Other|Implementation of a Hospital-based CPR Training Model|Nurses and Volunteers will be trained in the hospital-based CPR Training Model, and be encouraged to implement the training program in their respective hospitals.
1693498|NCT01514656|Other|Follow-up prompting to encourage skill retention|Subjects will be contacted every two months and encouraged to practice the skills that they have learned. Means of contact include: a) email b) text blasts c) phone calls d) social media e) mail
1693499|NCT01514630|Drug|Creatine monohydrate|Five grams of creatine monohydrate will be administered for eight weeks.
1693575|NCT01513967|Drug|RPh201, botanical drug product|SC administration at varying doses
1693576|NCT01513967|Drug|Placebo|SC administration at varying doses
1748667|NCT00180622|Procedure|CT Scan|
1693500|NCT01514617|Procedure|Diffusion -and perfusion weighted MRI including iv contrast agent injection|"MRI is a technique based on magnetic fields and does not require the use of ionizing radiation. Although there are no known side effects associated with MRI, a few precautions should be taken because of the 3T magnetic field. This implicates that all metal and magnetized objects must be removed from the patients before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductors/prostheses are for reason not eligible for the study.
During the MRI examination, an intravenous contrast agent will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
1693501|NCT01514578|Drug|TRV130A|Intravenous infusion of 1 hour duration
1693502|NCT01514578|Drug|Dextrose in Water|Intravenous infusion of 1 hour duration
1693503|NCT01514552|Other|Strawberry gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this strawberry intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
1693504|NCT01514552|Other|Placebo control gummy|Randomized to consume 2 gummies (6 gram gummies each, total 12 grams/dose)four times daily for 7 days. Subjects will be randomized to either start with this a placebo gummy intervention during intervention days 0 to 7 or during the crossover intervention on days 21 to 28.
1693505|NCT01514539|Other|cross-sectional|"Monitoring two recently discovered appetite hormones called ghrelin and neuropeptide YY (PYY). This study evaluated whether fasting or postprandial ghrelin or PYY is different btween lactating and nonlactating postpartum women matched for age, body weight, and adiposity."
1693506|NCT01514526|Drug|Dovitinib|"Dovitinib (TKI-258), gelatin capsule of 100mg, developed and supplied by Novartis Inc. The study regimen consists of the administration of 500 mg / day (5 x 100mg) once daily, taken orally with a large amount of water, preferably one hour prior to a meal or at least two hours following a meal. This dose will be taken once daily according to 5 days on/2 days off schedule.
The patient will continue on treatment until disease progression,unacceptable toxicity, death or premature withdrawal."
1693507|NCT01514513|Drug|Licefreee Spray|Liquid applied to hair and left on for at least one hour once on day 1 and once on day 8 if live lice are present.
1693508|NCT01514513|Drug|1% permethrin creme rinse|Creme rinse applied to hair and rinsed off after 10 minutes once on day 1 and once on day 8 if live lice are present.
1693509|NCT01514500|Drug|NNC0195-0092|Single dose administered s.c. (subcutaneously, under the skin). Escalation to the next dose level will be based on safety evaluation
1693510|NCT01514500|Drug|placebo|Single placebo dose administered s.c. (subcutaneously, under the skin)
1693511|NCT01514500|Drug|NNC0195-0092|Multiple doses administered s.c. (subcutaneously, under the skin). All subjects will be dosed four times with a dosing frequency of once weekly. Escalation to the next dose level will be based on safety evaluation
1693512|NCT01514500|Drug|placebo|Multiple placebo doses administered s.c. (subcutaneously, under the skin)
1693513|NCT01514487|Drug|liraglutide|One single dose of 0.75 mg administered on three different dosing occasions with a 14-day wash-out period between each dosing. Injected subtaneously
1693514|NCT01514461|Drug|LCQ908|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
1693515|NCT01514461|Drug|Placebo|LCQ908 10 mg, LCQ908 20 mg, LCQ908 40 mg
1693516|NCT01514448|Drug|Everolimus (RAD001)|Everolimus was used as commercially available formulated tablets of 10 mg strength
1693517|NCT01514435|Device|Electroconvulsive therapy|treatment for major depression
1693518|NCT01514435|Device|18-Fluoro-desoxy-glucose positron emission tomography|"intravenous injection of 18-FDG, after 30 min PET-Scan of the brain for aprox. 40 min.
It´s a neuroimaging technique."
1693519|NCT01514422|Drug|Minocycline|Minocycline 100 to 300mg per day for 8 weeks
1693520|NCT01514409|Dietary Supplement|5-Hydroxytryptophan|"Thirty-three participants were randomly allocated in a double-blind manner to receive either 3x50mg capsules of 5-HTP or placebo (silica) for 14 days.
5-HTP is produced commercially by extraction from the seeds of the African plant griffonia simplicifolia."
1693521|NCT01514409|Dietary Supplement|Pharmaceutical grade silica|Pharmaceutical grade silica was utilized as placebo
1693529|NCT01514344|Drug|intralesional rituximab|10-20 mg (1-2 ml) rituximab once a week for 4 weeks; followed by 10-20 mg (1-2 ml) rituximab monthly per six months
1693530|NCT01514344|Biological|supplemental autologous serum|patients in PD or SD during or after administration of 6 doses monthly rituximab will be administered the same dose of intralesional rituximab supplemented by autologous serum
1693531|NCT01514331|Other|SIMV+VG mode of ventilation (synchronized intermittent mandatory ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with SIMV+VG mode
1693532|NCT01514331|Other|PSV+VG (pressure support ventilation+volume guarantee)|Neonates who need mechanical ventilation will be ventilated with PSV+VG
1693533|NCT01514318|Device|Revelation Hip Stem (Revelation)|Subjects who received the Revelation Hip Stem prior to 2002 and still maintain the original device.
1693534|NCT01514292|Device|Continuous Glucose Monitoring of glucose levels (Dexcom)|Manipulation of glucose levels during multiple clinic days. Achieved through diet, exercise and insulin regimen defined in protocol.Evaluation of CGM performance characteristics in reference to a laboratory standard.
1693535|NCT01514279|Behavioral|HealthyCHANGE|"Cognitive behavioral strategies to address diet, physical activity, sedentary behavior and sleep for children.
It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
1693610|NCT01513720|Drug|Lamictal®|Lamictal® 200 mg Tablets
1693536|NCT01514279|Behavioral|SystemCHANGE|"Intervention (based on systems improvement and choice architecture theories) System improvement and choice architecture theories seek to teach a set of skills using family self-designed experiments to redesign daily routines regarding eating, activity and sleep.
It involves an intensive series of group sessions, followed by rotating monthly face-to-face meetings or phone calls."
1693537|NCT01514266|Drug|Curcumin+Bioprine|The intervention arm is Curcumin+Bioprine at escalating doses of 1 gram of Curcumin and 5 mg of Bioprine bid for one month, then 1.5 grams of Curcumin and 5 mg of bioprine bid for one month, and finally 2 grams of curcumin with 5 mg of bioprine bid for additional one month.
1693538|NCT01514266|Drug|Placebo|
1693539|NCT01514253|Drug|Glucose 25%|1 ml glucose 25%, once
1693540|NCT01514253|Dietary Supplement|Materna RTF Stage 1|1ml Materna RTF Phase 1, 2-3 minutes prior red-reflex examination.
1693541|NCT01514253|Other|Water for Injection|1 ml Water for Injection (WFI), 2-3 minutes prior red-reflex examination
1693542|NCT01514240|Drug|D9421-C capsule 3 mg|Patients randomised to D9421-C 9 mg will take 3 capsules of D9421-C capsule 3 mg once daily before breakfast and 4 tablets of Mesalazine tablets placebo three times a day after each meal for 8 weeks.
1693543|NCT01514240|Drug|Mesalazine tablets|Patients randomised to Mesalazine 3 g will take 3 capsules of D9421-C capsule placebo once daily before breakfast and 4 tablets of Mesalazine tablets 250 mg three times a day after each meal for 8 weeks.
1693544|NCT01514227|Drug|Aspirin or thienopyridine|Subjects randomized 6 month DAPT will be prescribed either aspirin or thienopyridine (clopidogrel or ticlopidine) following 6 months DAPT for the duration of study, which is left on the physician's discretion.
1693545|NCT01514227|Drug|Aspirin and thienopyridine|Subjects randomized 18 month DAPT will be prescribed both aspirin and thienopyridine (clopidogrel or ticlopidine) for 18 month after stenting.
1693546|NCT01514214|Device|WInged perimeter biliary stent insertion (Viaduct)|Insertion of a winged perimeter stent. Size to be determined during the ERCP based on findings.
1693547|NCT01514214|Device|traditional polyethylene stent insertion (Cotton Huibregtse)|insertion of a traditional polyethylene stent during ERCP, size to be determined depending on findings during ERCP
1693548|NCT01514201|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
1693549|NCT01514201|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1693550|NCT01514201|Other|Laboratory Biomarker Analysis|Optional correlative studies
1693551|NCT01514201|Other|Pharmacological Study|Correlative studies
1693552|NCT01514201|Drug|Temozolomide|Given PO
1693553|NCT01514201|Drug|Veliparib|Given PO
1693554|NCT01514188|Drug|INNO-206|INNO-206 administered at 350 mg/m2 (260 mg/m2 doxorubicin equivalent) intravenously (IV) on Day 1 every 21 days for up to 6 consecutive cycles
1693555|NCT01514188|Drug|Doxorubicin|Doxorubicin administered at 75 mg/m2 for up to 6 consecutive cycles.
1693556|NCT01514175|Drug|IV Ibuprofen|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
1693557|NCT01514175|Drug|IV Ketorolac|Patients will be randomized to receive 800 mg intravenous ibuprofen or 30 mg ketorolac; each of the two treatment groups will consist of 25 patients.
1693558|NCT01514162|Device|Trifecta valve|surgical replacement of aortic valve
1693559|NCT01514149|Drug|CJC-1134-PC Injection|CJC-1134-PC administered weekly by subcutaneous injection
1693560|NCT01514149|Drug|Weekly placebo for CJC-1134-PC Injection|Weekly placebo for CJC-1134-PC administered weekly by subcutaneous injection
1693561|NCT01514136|Device|Ostomy appliance: convex 1-piece drainable|8 variations of an ostomy devices are tested
1693562|NCT01514123|Drug|VGX-100|VGX-100 will be administered by IV infusion once every week
1693563|NCT01514123|Drug|Bevacizumab|Bevacizumab will be administered by IV infusion once every 2 weeks
1693564|NCT01514110|Drug|RAD001|Pharmacology of RAD001 as a combination partner for conventional agents.
1693565|NCT01514071|Behavioral|Pop-up picture|"An animated picture depicting the key elements of the PECARN CT scan head injury rules will be explained. The picture will pop-up when a provider selects the order set for a CT scan due to head injury. Providers will need to select a box stating the patient either meets criteria or does not meet criteria in order to close the animated picture window."
1693566|NCT01514058|Procedure|EUS-FNA first, followed by CRCP with bilinary stenting|EUS-FNA first, followed by CRCP with bilinary stenting (using a plastic stent)
1693567|NCT01514058|Procedure|ERCP with stent placement, followed by EUS-FNA|ERCP with stent placement, followed by EUS-FNA
1693568|NCT01514032|Procedure|Extracorporal shockwave lithotripsy|Extracorporal shockwave lithotripsy
1693569|NCT01514032|Procedure|Retrograde intrarenal surgery|Retrograde intrarenal surgery
1693570|NCT01514019|Drug|Acebutolol|Acebutolol
1693571|NCT01514019|Drug|Placebo|Placebo capsule(Capsules filled up with lactose)
1693572|NCT01513993|Procedure|Telemonitoring for patients with Congestive Heart Failure|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device and digital weight scale for clinical parameters measuring and a gateway device for data transmission.
The patient can monitor a complete set of clinical parameters, such as pulse-oxymetry, heart rate, blood pressure, ECG and body weight, with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alerts the reference clinician in case of worsening of symptoms."
1693573|NCT01513980|Procedure|self-monitoring for patients with severe COPD|"Patients are equipped with a telemonitoring kit composed by a portable wrist-clinic device for clinical parameters measuring and a gateway device for data transmission.
The patient can monitor pulse-oxymetry and heart rate with a frequency set by the clinician in the personalised treatment plan. Data are transmitted to a regional eHealth centre where a group of operators keeps these information under control and alert the reference clinician in case of worsening of symptoms. CAT questionnaire is monthly administrated by phone to the patients"
1693574|NCT01513980|Procedure|nurse-monitoring for patients with severe COPD|A nurse is in charge of data collection during home visits with a frequency set by the lung specialist depending to the patient clinical conditions. The nurse uses portable biomedical devices to measure pulse-oxymetry, heart rate, spirometry and if scheduled an arterial blood gas test. Data are transmitted to the clinician who checks them on his laptop in the hospital and completes the visit with the medical report.
1693577|NCT01513967|Drug|RPh201, botanical extract product|3-month treatment schedule, consisting of bi-weekly SC administration of the study drug followed by a follow up period 3 months post end of the last treatment day
1693578|NCT01513967|Drug|Placebo|3-month treatment schedule, consisting of bi-weekly SC administration of the placebo followed by a follow up period 3 months post end of the last treatment day
1693579|NCT01513941|Drug|Telaprevir|Type=exact number, unit=mg, number=750 or 1125, form=tablet, route=oral. the patients will receive 2 oral tablets every 8 hours for 12 weeks except for patients on efavirenz who will receive 1125mg (3 oral tablets) every 8 hours for 12 weeks.
1693580|NCT01513941|Drug|Ribavirin|Type=exact number, unit=mg, number=400, form=tablet, route=oral. The patients will receive 2 oral ribavirin tablets twice daily for 24 or 48 weeks, based on the response guided therapy.
1693581|NCT01513941|Drug|Pegylated-Interferon-alfa-2a|Type=exact number, unit=microgram, number=180, form=injection, route=subcutaneous The patients will receive Peg-IFN-alfa-2a 180 microgram once a week for 24 or 48 weeks; based on the response guided therapy.
1693582|NCT01513928|Drug|Pf-04937319|Formulation A) Pf-04937319 50 mg - administered as tablet
1693583|NCT01513928|Drug|Pf-04937319|Formulation B) Pf-04937319 50 mg - administered as capsule
1693584|NCT01513928|Drug|Pf-04937319|Formulation C) Pf-04937319 50 mg - administered as capsule
1693585|NCT01513915|Other|Group cognitive behavioral intervention|A Group cognitive behavioral intervention _based on parent training component of FRIENDS program_ was performed.The program protocol was translated to Persian, using the back translation method.The intervention was delivered in 6 two-hour weekly sessions. Two intervention groups ran, each group included 10 parents.The therapy was provided by an attending board certified child and adolescent psychiatrist and co lead by a fellow of child and adolescent psychiatry who distributed psychometric procedures and completed treatment adherence ratings.
1693586|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children aged 12 to less than 18 years who are unable to swallow tablets will have the option of taking oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
1693587|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Oral solution will be used for children weighing <40 kg. Oral tablets will be used for children weighing ≥40 kg. Children less than 12 years of age with a body weight of ≥40 kg will have the option of taking oral solution or tablets. Body Weight (kg) Dose (mg) Volume (mL) 5-11 1 1; 12-18 1.5 1.5; 19-24 2 2; 25-31 2.5 2.5; 32-39 3 3; ≥40 5 5
1693588|NCT01513902|Drug|CP-690,550|CP-690,550 will be administered orally twice daily according to the dosing regimen provided below. Children with a body weight ≥30 kg will have the option of taking oral solution or tablets, and children weighing <30 kg will be dosed with the oral solution. Body Weight (kg) Dose (mg) Volume (mL) 5-6 1 1; 7-9 1.5 1.5; 10-12 2 2; 21-15 2.5 2.5; 16-19 3 3; 20-22 3.5 3.5; 23-26 4 4; 27-29 4.5 4.5; ≥30 5 5
1693589|NCT01513863|Drug|Metronidazole Topical Gel 1%|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
1693590|NCT01513863|Drug|Metronidazole Topical Gel 1% (Metrogel)|Metronidazole Topical Gel 1% applied to affected area once a day for 70 days
1693591|NCT01513863|Drug|Placebo|Placebo applied to affected area once a day for 70 days
1693592|NCT01513850|Drug|Hepabulin IV|I.V.
1693593|NCT01513824|Behavioral|pressure pain sensitivity measure followed bu acupressure|twice daily measure of pressure pain sensitivity on the chest bone followed by stress management of which acupressure is mandatory.
1693594|NCT01513811|Drug|Polyethylene glycol electrolyte solutions|Patients received 2 packets of polyethylene glycol electrolyte solutions(PEG-E) without itopride.PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours.6 hours later, the colonoscopy was performed.
1693595|NCT01513811|Drug|Itopride and Polyethylene glycol electrolyte solutions|Patients were assigned to itopride 150mg, then 30 min later they were given 2 packets of polyethylene glycol electrolyte solutions(PEG-E). PEG-E was dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopy was performed.
1693596|NCT01513811|Drug|itopride and polyethylene glycol electrolyte solutions|Patients received itopride 150mg t.i.d(7am、12am、8pm) 24 hours before the examination day and another 150mg 30min before administration of polyethylene glycol electrolyte solutions(PEG-E).Two packets of PEG-E were dissolved in 2 L of water. Patients were instructed to drink PEG solution 200ml every 10 min and consumed the total 2 L solution in 2 hours. 6 hours later, the colonoscopies were performed.
1693597|NCT01513798|Behavioral|Modified paleolithic diet and exercise under observation|Modified paleolithic diet and exercise 3 session/week under observation
1693598|NCT01513798|Behavioral|Modified paleolithic diet and general advice on exercise|Modified paleolithic diet and general advice on exercise
1693599|NCT01513785|Drug|Rabeprazole and Amoxicillin|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 10 mg b.i.d.for 14 days.
1693600|NCT01513785|Drug|Amoxicillin and Rabeprazole|Amoxicillin (Zhuhai United Laboratories Co., Zhuhai, China) 1 g t.i.d and Rabeprazole (Misato Plant of Eisai Co., Ltd. Japan) 20 mg b.i.d. for 14 days
1693601|NCT01513772|Drug|Dexmedetomidine|Dexmedetomidine(4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
1693602|NCT01513772|Drug|Normal saline 0.9%|Normal saline(guess as 4㎍/mL) : 0.4㎍/kg/hr infusion until extubation
1693603|NCT01513759|Drug|recombinant tissue plasminogen activator|Patients receive 24 mg of recombinant tissue plasminogen activator delivered via the EkoSonic Endovascular Device.
1693604|NCT01513759|Device|EKOS EkoSonic Endovascular System|24 mg of recombinant tissue plasminogen activator delivered through the EkoSonic Endovascular System.
1693605|NCT01513759|Drug|Alteplase|Patients receive 24 mg of alteplase delivered via the EkoSonic Endovascular Device
1693606|NCT01513733|Drug|tasquinimod|tasquinimod 0.25 mg continuously
1693607|NCT01513733|Drug|tasquinimod 0.25 mg; 0.5 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg continuously, if tolerated
1693608|NCT01513733|Drug|tasquinimod 0.25 mg; 0.5 mg; 1.0 mg|tasquinimod 0.25 mg for 3 weeks followed by 0.5 mg for 3 weeks followed by 1.0 mg continuously, if tolerated
1693609|NCT01513720|Drug|Lamotrigine|Lamotrigine Tablets 200 mg
1693611|NCT01513694|Procedure|Instrumented posterolateral arthrodesis|"Cell suspension of mesenchymal stem cells (MSCs) obtained from bone marrow aspirate from the patient and expanded in vitro in a specific medium enriched with platelet lysate without addition of animal products.
They used a minimum dose of 0.5 x106 CSM / kg and a maximum of 1, 5x106 CSM / kg of patient weight.
Dosage Form: Suspension cell support hydroxyapatite and calcium phosphate Route of administration: placement in the fusion bed during surgery."
1693612|NCT01513681|Drug|Lamotrigine|Lamotrigine Tablets 200 mg
1693613|NCT01513681|Drug|Lamictal®|Lamictal® 200 mg Tablets
1693614|NCT01513668|Drug|Acetaminophen|Extended release Gel tabs 650 mg
1693615|NCT01513655|Device|LTNIV|LTNIV with the ventilator and the settings and pressures which reversed the respiratory failure and the hypercapnic acidosis. We know the patients are able to tolerate these settings. The ventilators are Philips A30. The patients must use the ventilator for a minimum of six hours a night.
1693616|NCT01513642|Behavioral|Breath Stacking|To perform the BS maneuver, a silicone mask containing a one-way valve was attached to the patient's face. Once the mask was adjusted to allow only inspiration (the expiratory branch remained occluded), the patient was asked to make successive inspiratory efforts during 20 seconds.
1693617|NCT01513616|Other|Pulmonary rehabilitation|8-week program, 3 supervised session per week
1693618|NCT01513616|Other|Usual care|An 8-week control period (includes optimization of respiratory medications, instructions on how best to manage COPD, standard access to treatment in the event of an exacerbation, self-management education)
1693619|NCT01513603|Drug|CLAG-M|IV times 5 days
1693620|NCT01513603|Drug|CLAG-M|Chemotherapy
1693621|NCT01513590|Drug|insulin degludec/insulin aspart|Administered s.c. (under the skin) twice daily. Dose individually adjusted. Pre-trial metformin treatment to be continued.
1693622|NCT01513577|Other|Pedicle screws|The control group received posterior fixation with pedicle screws through a midline approach. Through the approach bone was harvested from the right posterior iliac crest. Before closure of the posterior approach an epidural catheter and a drain was placed.
1693623|NCT01513577|Other|Percutaneous stab incisions|The intervention group received posterior fixation through 6 percutaneous stab incisions with the use of the sextant system. Through a separate 3-4 cm long incision, bone was harvested from the right posterior iliac crest. After decorticating the transverse processes through the stab wounds, the bone graft was placed with a 10 ml cut syringe. An epidural catheter was placed at the end of the posterior procedure.
1693624|NCT01513564|Drug|Postoperative epidural morphine|The control group received postoperative epidural morphine 0.4 mg/ml four times a day, epidural bupivacaine 2.5 mg/ml, 3-4 ml on request for 75 hours and a 7 day rehabilitation program.
1693625|NCT01513564|Drug|Local anaesthesia|Preemptively and posteruptively, the intervention group received local anaesthesia with bupivacaine 2.5 mg/ml, 10 + 10 ml posteriorly and 10 + 10 anteriorly; preemptive epidural analgesia with 3 ml lidocaine 20 mg/ml, 3 ml, 10 ml morphine 0.4 mg/ml plus 5 ml bupivacaine; postoperative continuous epidural analgesia for 72 hours with 250 ml with bupivacaine 1 mg/ml + morphine 50 ug/ml, and 0.5 ml epinephrine 1 mg/ml, 4 ml/hour, and after wound closure ketorolac 30 mg intravenously.
1693626|NCT01513551|Biological|Pneumococcal Conjugate Vaccine (V114)|Single intramuscular injection of V114 (0.5 mL) on Day 1
1693627|NCT01513551|Biological|Pneumococcal Polysaccharide Vaccine|Single intramuscular injection of pneumococcal polysaccharide vaccine (0.5 mL) on Day 1
1693628|NCT01513551|Biological|Pneumococcal 13-Valent Conjugate Vaccine|Single intramuscular injection of pneumococcal 13-valent conjugate vaccine (0.5 mL) on Day 1
1693630|NCT01513525|Drug|liraglutide|Single dose of 0.60 mg administered subcutaneously in three different injection sites on three separate dosing visits
1693631|NCT01513499|Drug|Oxytocin|Intranasal oxytocin 24 IU single-dose administration
1693632|NCT01513499|Drug|Placebo|Intranasal Placebo single-dose administration
1693633|NCT01513486|Behavioral|immobilization|
1693634|NCT01513473|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
1693635|NCT01513473|Drug|insulin detemir|Injected subcutaneously (under the skin) once or twice daily. Dose individually adjusted.
1693636|NCT01513473|Drug|insulin aspart|Injected subcutaneously (under the skin) as mealtime bolus insulin. Dose individually adjusted.
1693637|NCT01513460|Drug|NVA237 50µg once daily|NVA237 50 μg o.d., delivered via single-dose dry-powder inhaler (SDDPI)
1693638|NCT01513460|Drug|Tiotropium 18µg once daily|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
1693639|NCT01513460|Drug|Flu/Sal|Flu/Sal 500/50 μg b.i.d. delivered via a proprietary inhalation device
1693640|NCT01513460|Drug|NVA237 placebo + Tiotropium placebo.|Tiotropium 18 μg o.d. delivered via a proprietary inhalation device
1693641|NCT01513447|Drug|Intracutaneous injections|Four intracutaneous injections: two sites lateral to the lumbosacral spine and two sites 2-3 centimeters below and 1- 2 centimeters medial to the original two injections sites. 0.1 millimeters of the study drug is injected between the dermal layers at each of the four sites. The injections are administered sequentially, with the series of four injections, performed two at a time, completed in 20-30 seconds.
1693642|NCT01513434|Procedure|transtibial technique|Femoral tunnel was made via tibial tunnel in anterior cruciate ligament reconstruction.
1693643|NCT01513434|Procedure|Transportal technique|Femoral tunnel was made via anteromedial portal in anterior cruciate ligament reconstruction.
1693644|NCT01513434|Procedure|anterior cruciate ligament reconstruction|femoral and tibial tunneling graft fixation on the femoral side with endobutton and on the tibial side with post-tie and interference screw
1693645|NCT01513421|Procedure|Percutaneous drainage of intra-abdominal collection|"Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.
Procedures perform by a board certified interventional radiologist"
1693673|NCT01513187|Drug|Pazopanib + interferon alpha 2A|"Five levels of pazopanib in different doses: 400, 600 and 800 mg / day and interferon alfa 2-A 3, 6 and 9 MIU three times a week, in cycles of 28 days.
Treatment will continue until disease progression, unacceptable toxicity, non-compliance or withdrawal of consent by the patient"
1693674|NCT01513174|Drug|Gefitinib|Gefitinib 250 mg once a day, continuously, in 28-day cycles, until progression
1694723|NCT01505413|Drug|Erlotinib|Erlotinib 100 mg po qd daily
1693648|NCT01513382|Procedure|Pilonidal sinus excision|The dyed portion of the excised pilonidal sinus and non-dyed cavity excision specimen will be studied histopathologically to detect any remnant of pilonidal sinus.
1693649|NCT01513369|Drug|ferric carboxymaltose|Dose:according to SmPC Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
1693650|NCT01513369|Drug|NaCl (0,9%)|Duration: 12 weeks; Frequency: at week 1 and again at week 5 (if again indicated according to principal inclusion criteria); Application: intravenous
1693651|NCT01513356|Drug|BKM120|BKM120 will be administered on a continuous once daily dosing schedule at a dose of 100 mg (p.o.)until progression of disease or unacceptable toxicity or a maximum of 4 weeks.
1693652|NCT01513343|Behavioral|Parent and child groups focused on self-regulation of eating|
1693653|NCT01513330|Device|SenSura Mio|Ostomy product - 1 piece closed bag
1693654|NCT01513330|Device|Standard Care|Ostomy product 1 piece closed bags. Either SenSura, Nova 1, Moderna/Moderna Flex, Esteem or Flexima/Softima.
1693655|NCT01513317|Drug|Siltuximab|15 mg/kg administered as a 1-hour intravenous infusion every 4 weeks
1693656|NCT01513317|Drug|Placebo|Administered as a 1-hour intravenous infusion every 4 weeks
1693657|NCT01513317|Drug|Best supportive care (BSC)|Best supportive care according to local standards and guidelines
1693658|NCT01513304|Procedure|Manual therapy|
1693659|NCT01513291|Drug|MK-6096|MK-6096, two 5 mg tablets (total 10 mg dose), orally, once daily
1693660|NCT01513291|Drug|Placebo|Placebo, 2 tablets, orally, once daily
1693661|NCT01513278|Drug|APN201|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
1693662|NCT01513278|Drug|Placebo|"All patients receive APN201 and placebo at the same time. The irradiated region is divided vertically into two symmetric areas (left and right). One area is treated with APN201 (recombinant human superoxide dismutase (rhSOD) encapsulated in liposomal vesicles formulated as a hydrophilic gel; 1.6 mg rhSOD per mL), the other area is treated with placebo (empty liposomes formulated as a hydrophilic gel) in a double-blind fashion.
Study treatment (APN201 and placebo) starts on the day of initiation of radiation therapy and continues until the end of radiation therapy to the whole breast (25 or 28 daily fractions to a total dose of 50.0 Gy or 50.4 Gy, respectively). Study treatment is applied as a thin film on the irradiated area ≥10 minutes each day before radiation therapy (approximately 1 mL APN201 per 100 cm2 of the radiation field size and approximately 1 ml placebo per 100 cm2 of the radiation field size)."
1693663|NCT01513265|Other|Pharmaceutical care plan, mostly based on the RASP|Drug use of subjects enrolled in this arm will be systematically evaluated by a clinical pharmacist, using the RASP list. Potentially inappropriate drug use will be pointed out to the treating physician. The pharmaceutical advice is not limited to the RASP list. Any actual change in drug prescription will be decided by the treating physician based upon comprehensive medical evaluations in each individual patient.
1693664|NCT01513252|Behavioral|Gröber and Buschke test|spontaneous delayed recall score after a 5 years follow-up
1693665|NCT01513239|Biological|MK-6072|Single IV infusion of MK-6072 (10 mg/kg of monoclonal antibody to C. difficile Toxin B)
1693666|NCT01513239|Biological|MK-3415A|Single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to C. difficile Toxin A and 10 mg/kg of monoclonal antibody to C. difficile Toxin B)
1693667|NCT01513239|Biological|Placebo|Single IV infusion of normal saline (0.9% sodium chloride)
1693668|NCT01513239|Drug|SOC|SOC for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metronidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
1693669|NCT01513226|Other|Cycled light|lights on at daytime, lights off at nighttime
1693670|NCT01513200|Drug|Unfractionated heparin (UFH)|UFH solution for infusion Initially 60U/kg bolus followed by intravenous infusion (12U/kg/hr) for approximately 11 hours
1693671|NCT01513200|Drug|Bendavia|Bendavia for infusion Constant intravenous infusion (Bendavia 0.25mg/kg/hr) for 4 hours
1693672|NCT01513200|Drug|Saline (0.9%, sterile, for infusion)|Saline (placebo) Constant IV infusion for 4 hours
1693675|NCT01513174|Drug|Gefitinib plus olaparib|Gefitinib 250 mg once a day, in combination with olaparib (at the recommended dose in the previous Phase Ib study) twice a day, continuously, in 28-day cycles.
1693676|NCT01513161|Drug|nalfurafine hydrochloride (TRK-820)|Soft capsule containing 2.5ug nalfurafine hydrochloride. Start with 2.5ug of oral administraion once daily, and can be increased up to 5ug if necessary.
1693677|NCT01513161|Drug|Placebo|
1693678|NCT01513148|Device|Superluminous light diode|900W, 880nm, 1.6 J/cm2 for 30sec
1693679|NCT01513135|Biological|Tat|Recombinant biologically active Tat 30 mcg in Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
1693680|NCT01513135|Biological|Placebo|Phosphate saline buffer, pH 7.4, 1% sucrose, 1% Human Serum Albumin
1693681|NCT01513122|Drug|Lopinavir / ritonavir + 2-3N(t)RTI|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + 2-3 N(t)RTI
1693682|NCT01513122|Drug|Lopinavir /ritonavir + raltegravir|LPV/r 200mg/50mg 4 tabs once daily or 2 tabs twice daily + raltegravir 400mg 1 tablet twice daily.
1693683|NCT01513109|Biological|Recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI)|i.m. administration
1693684|NCT01513096|Drug|itopride|itopride, 10mg, twice per day, for 1 day
1693685|NCT01513083|Drug|trastuzumab emtansine|Multiple intravenous doses
1693686|NCT01513070|Drug|Quick-Acting Heart Reliever|Quick-Acting Heart Reliever，200mg，tid，po. for six months
1693687|NCT01513070|Drug|Isosorbide Dinitrate|Isosorbide Dinitrate，10mg，tid，po. for six months
1693688|NCT01513070|Drug|Placebo of Isosorbide Dinitrate|Placebo of Isosorbide Dinitrate，10mg，tid，po. for six months
1693689|NCT01513070|Drug|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
1693690|NCT01513070|Drug|Placebo of Quick-Acting Heart Reliever|Placebo of Quick-Acting Heart Reliever，200mg，tid，po. for six months
1693691|NCT01513070|Drug|Aspirin Enteric-coated Tablets|Aspirin Enteric-coated Tablets，100mg，qd，po. for six months
1693692|NCT01513057|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
1693693|NCT01513057|Drug|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
1693694|NCT01513044|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 250 mg capsules of Dr. Reddy's Laboratories Limited
1693695|NCT01513044|Drug|Mycophenolate Mofetil|250 mg capsules of Roche Laboratories Inc.
1693696|NCT01513031|Other|Education and telephone follow-up|Education related to anti-arrhythmic therapy and monthly telephone follow-up to assess adherence to medication.
1693697|NCT01513018|Other|high tidal volumes|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.
Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
1693698|NCT01513018|Other|low tidal volume|"One-lung ventilation was started at skin incision using a volume-controlled square-wave flow pattern. Patients were randomly assigned to 30 minutes of ventilation with a tidal volume of 10 ml/kg tidal volume without external PEEP and respiratory rate of 10 breaths/minute (n=50) or to a tidal volume of 5 ml/kg with 5 cmH2O PEEP and a respiratory rate of 20 breaths/minute (n=50). Minute volume was thus kept constant during each experimental condition.
Randomization was based on computer-generated codes that were maintained in sequentially numbered sealed opaque envelopes until after induction of anesthesia. During the subsequent 30 minutes of one-lung ventilation, the alternative ventilatory management was used."
1693699|NCT01513005|Procedure|Laparoscopic Sleeve Gastrectomy|"the operative technique consists in few steps:
position of 4 trocars and insertion of a nasogastric tube
dissection and mobilization of the greater curvature of the stomach
preparation of the stomach for division
gastric partition
extraction of the gastric remnant
postoperative surveillance"
1693700|NCT01512992|Procedure|Home telehealth|"Patients receive tailored intervention according to their clinical complexity.
All patients in the intervention group receive:
Personalised care plan
Education on self-management
Access to a personalized online health folder
Access to Call center
Access to primary care and hospital specialists; follow-up visits for evaluation of clinical recovery and care plan adjustments (if needed).
Patients with LOW complexity additionally receive:
Daily videoconferences for the 1st week after discharge
Remote monitoring for respiratory parameters. Sensors are selected on an individual basis by the medical specialists.
Patients with HIGH complexity additionally receive:
Videoconferences for at least 1 month after discharge, scheduled on an individual basis.
Remote monitoring for respiratory parameters.
One monthly phone call from the call centre to promote and assess patient self-management."
1693701|NCT01512979|Drug|metformin|1000 mg to 2000 mg per day
1693702|NCT01512979|Drug|linagliptin|5 mg daily
1693703|NCT01512979|Drug|metformin placebo|0 to 2 tablets daily
1693704|NCT01512979|Drug|metformin placebo|4 tablets daily
1693705|NCT01512966|Biological|VEGF Trap-Eye (BAY86-5321)|Subjects in the VEGF Trap-Eye group will receive intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks. The overall treatment period is 48 weeks.
1693706|NCT01512953|Drug|Lansoprazole|Lansoprazole 30 mg once a day
1693707|NCT01512940|Procedure|Laparoscopic Greater Curvature Plication|"The greater curvature of the stomach is separated from the greater omentum. At least two rows of at least five continuous stitches will be placed about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure. The two tissue bites of an individual stitch will be centered about the intended fold line.
Subsequent stitches will be uniformly spaced distally along the length of the fold. The second row of sutures will be placed across the fold line created by the previous row of sutures in the same fashion as the first row. Up to 2 additional rows may be added as required to achieve this result (for a total of up to 4 rows). Upon completion of the procedure, the section of the stomach infolded by the sutures will be inspected using the endoscope."
1693708|NCT01512914|Drug|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and nebulization of saline 3 ml after surgery
1693709|NCT01512914|Drug|Ropivacaine 30 mg|preoperative instillation of saline 20 ml, preoperative nebulization of saline 3 ml and nebulization of ropivacaine 1% 3 ml (30 mg) after surgery
1748668|NCT00180622|Procedure|Blood test|
1693710|NCT01512914|Drug|Ropivacaine 100 mg|preoperative instillation of ropivacaine 0,5% 20 ml (100 mg) and nebulization of saline 3 ml before and after surgery
1693711|NCT01512914|Drug|saline|preoperative instillation of saline 20 ml and nebulization of saline before and after surgery
1693712|NCT01512901|Drug|Betamethasone Microsphere (DE-102） Low Dose|
1693713|NCT01512901|Drug|Betamethasone Microsphere (DE-102） High Dose|
1693714|NCT01512901|Drug|Sham|
1693715|NCT01512888|Genetic|CL20-4i-EF/a-hyc-OPT|Participants will undergo infusion with autologous CD34+ bone marrow cells transduced with a lentiviral vector that contains a normal copy of the human γc gene.
1693716|NCT01512888|Drug|Busulfan|Given intravenously (IV).
1693717|NCT01512888|Device|CliniMacs|Isolation and purification of CD34+ stem cells will be done after the unmodified frozen backup is obtained and in accordance with our FDA IND and in accordance with the CliniMacs manual of operations.
1693718|NCT01512862|Drug|Calcitriol|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
1693719|NCT01512862|Drug|Placebo|Dosage of 0.25 mcg administered orally once daily for 6 weeks and dose escalated to 0.5 mcg orally once daily up to 6 months
1693720|NCT01512849|Drug|TA-7284 Low|Low
1693721|NCT01512849|Drug|TA-7284 High|High
1693722|NCT01512836|Behavioral|Case Management|"Patients, who are randomized to the intervention group, will receive case management from a trained and experienced nurse. The case manager will carry out following tasks:
Formulation and implementation of care plans together with the patient
Monitoring of individual status and care plan effectuation
Overall coordination between health care providers
Support to the patient and their caregivers during times of transition related to health status and environmental changes (e.g. hospital to home)
Regular telephone consultations and home visits
Promote disease-self management through coaching"
1693723|NCT01512823|Behavioral|Education|"Interactive educational intervention:
4 hour education session (with notes and 'evidence packs'); presentations, small group discussion tasks and practice of particular skills - 2 hour session (1 week later)
Emailed notes from second session
Telephonic/email follow-up (reminders)
Didactic educational intervention:
- 4 hour education session (with notes and 'evidence packs'; questions answered but no discussion or application of skills"
1693725|NCT01512797|Drug|Sitagliptin phosphate|100 mg/day orally
1693726|NCT01512797|Other|Placebo|1 Placebo Pill per day
1693727|NCT01512784|Biological|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).
Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:
First dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.
Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:
Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
1693728|NCT01512784|Biological|Quadrivalent Human Papillomavirus (6, 11, 16 and 18) vaccine (Gardasil ®)|"Human Papillomavirus vaccine (types 6, 11, 16 and 18) (Recombinant, adsorbed).
Each dose of Gardasil suspension for injection contains 0,5 ml. The shot is usually given in the arm muscle, 3 shots are given on the following schedule:
first dose: at chosen date. Second dose: 2 months after dose 1. Third dose: 6 months after dose 1.
Ingredients: highly purified non-infectious protein for each of the Human Papillomavirus types (6, 11, 16 and 18). Each dose (0,5ml) contains approximately:
Human Papillomavirus type 6 L1 protein 20 micrograms. Human Papillomavirus type 11 L1 protein 40 micrograms. Human Papillomavirus type 16 L1 protein 40 micrograms. Human Papillomavirus type 18 L1 protein 20 micrograms."
1693729|NCT01512771|Other|CPAP|6 weeks of CPAP
1693730|NCT01512758|Drug|Alisertib|Alisertib will be given orally twice daily for 7 consecutive days followed by a 14-day rest period (cycle length = 21 days). If, at the end of 14 days of rest, all alisertib-related toxicities (except alopecia) have not resolved to less than Grade 2, the cycle will be extended to a maximum of 28 days (ie, additional 7-day rest period). Patients will continue to receive repeated cycles of alisertib treatment for as long as their disease has not progressed and they have not experienced unacceptable alisertib-related toxicity.
1693731|NCT01512745|Drug|apatinib|apatinib 850 mg qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
1693732|NCT01512745|Drug|placebo|placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
1693733|NCT01512719|Procedure|POEM|Per Oral Endoscopic Myotomy for achalasia
1693734|NCT01512706|Biological|160Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
1693735|NCT01512706|Biological|320Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 60 infants aged 6-11 months old on day 0, 28
1693736|NCT01512706|Biological|640Eu/0.5ml in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 6-11 months old on day 0, 28
1693737|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in infants (6-11 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 6-11 months old on day 0, 28
1693738|NCT01512706|Biological|0Eu/0.5ml in infants (6-11 months old)|0Eu/0.5ml placebo in 80 infants aged 6-11 months old on day 0, 28
1693739|NCT01512706|Biological|160Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
1693740|NCT01512706|Biological|320Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 infants aged 12-23 months old on day 0, 28
1693741|NCT01512706|Biological|640Eu/0.5ml in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 infants aged 12-23 months old on day 0, 28
1693742|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in infants (12-23 months old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 40 infants aged 12-23 months old on day 0, 28
1693743|NCT01512706|Biological|0Eu/0.5ml in infants (12-23 months old)|0Eu/0.5ml placebo in 50 infants aged 12-23 months old on day 0, 28
1694899|NCT01504126|Procedure|Surgery|Initial tumor reductive surgery.
1693744|NCT01512706|Biological|160Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
1693745|NCT01512706|Biological|320Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 30 children aged 24 months-5 years months old on day 0, 28
1693746|NCT01512706|Biological|640Eu/0.5ml in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
1693747|NCT01512706|Biological|1280Eu/0.5ml (without adjuvant) in children (24 months-5 years old)|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml in 40 children aged 24 months-5 years months old on day 0, 28
1693748|NCT01512706|Biological|0Eu/0.5ml in children (24 months-5 years old)|0Eu/0.5ml placebo in 50 children aged 24 months-5 years old on day 0, 28
1693750|NCT01512680|Behavioral|Education to Functional Insulin Therapy|"Intake of Continuous Glucose Monitor for 5 to 7 days
Functional Insulinotherapy training during 3 days, blood sampling, autoevaluation and QOL questionnary.
1 month after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes
3 months after the training: Blood sampling, vital signs and data on diabetes
6 months after the training: 2 sessions of training, blood sampling, autoevaluation and QOL questionnary, vital signs and data on diabetes, Intake of Continuous Glucose Monitor for 5 to 7 days
9 months after the training: Blood sampling, vital signs and data on diabetes
1 to 3 weeks before last visit: Intake of Continuous Glucose Monitor for 5 to 7 days
12 months after the training: Follow-up consultation, clinical exam, vital signs and data on diabetes, autoevaluation and QOL questionnary"
1955740|NCT03093480|Biological|rFVIIIFc|rFVIIIFc 200 IU/kg/day in ITI Period and 50 or 100 IU/kg (adjusted according to Investigator judgement) in tapering Period as powder for injection administered intravenously.
1693752|NCT01512654|Device|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will not be displayed. Patient will decide his need of insulin according to the results given by the HemoCue glucometer and CGM trends. He/She will inject insulin at mealtimes or program a bolus on his/her pump by him/herself and will adapt his/her basal insulin doses or pump delivery rates as usual. As needed or on request and more particularly if hypo or hyperglycaemia occurs, the subject will be advised and helped by nurses and physicians.
1693753|NCT01512654|Device|Personalized Glucose Predictive and Therapy Advisory System (DIAdvisor)|Glucose predictions and therapy advices will be displayed to the patient. Patients will be asked to follow the advices suggested by DIAdvisor system according to their own judgement. Patient will decide his need of insulin according to the results given by the HemoCue glucometer, CGM trends, glucose predictions as well as therapy advices. In case of any doubt with the predictions displayed or the advices suggested, the patients will be invited to ask study personal and/or the study physician for help.
1693754|NCT01512641|Other|Primary stage|Kiddie-Schedule for Affective Disorders and Schizophrenia
1693755|NCT01512641|Other|Secondary stage|children who are positive to the kiddie-SADS (primary stage), will take the tests: PANSS, Scale for the Assessment of Negative Symptoms (SANS), ADI-R, scale TLC and WISC IV
1693756|NCT01512628|Drug|Pentaspan, voluven, volulyte|Different colloids are administered during operation for replacement of blood loss before the transfusion of blood.
1693757|NCT01512615|Other|Integrated rehabilitation|Integrated Rehabilitation consisting of exercise training (minimum 3 times a week for a total of twelve weeks) and psychoeducational care (5 sessions over 6 months)
1693758|NCT01512615|Other|Usual follow-up|Standard follow-up at the participating heart center
1693759|NCT01512602|Behavioral|DBT|16 weeks DBT treatment
1693760|NCT01512602|Behavioral|CAMS|CAMS-informed psychotherapy
1693761|NCT01512589|Radiation|Proton Beam Therapy (PBT)|1.8 Gy (Relative Biologic Equivalence ((RBE)) to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
1693762|NCT01512589|Radiation|Intensity Modulated Radiation Therapy (IMRT)|1.8 Gy to be delivered to the periphery of the planning target volume (PTV) 1 time each day, 5 days a week (Monday through Friday) for up to 28 treatments.
1693763|NCT01512589|Behavioral|Questionnaires|Symptom and Quality of Life questionnaires completed at baseline, every week during radiation therapy, during break after radiation therapy, and during follow up phase.
1693764|NCT01512576|Other|acupuncture|one 30-minute treatment session using sterile 1-time-use needles (Euro-acupuncture needles) were used, but the therapist was allowed to chose the needle length and diameter
1693765|NCT01512576|Behavioral|relaxation|1 treatment session of 30 minutes
1693766|NCT01512563|Device|Biliary stent|palliative treatment for malignant patients
1693767|NCT01512550|Procedure|GF hip guide|Using GF hip guide to measure and control the peroperative positioning of the hip stem
1693768|NCT01512550|Procedure|Stryker Navigation System|Using Orthomap Modular Hip Software to navigate the operation
1693769|NCT01512550|Device|ABG II modular femoral component|A hip prosthesis made by Stryker. It has the same basic shape as the ABG II femoral component but has a modular neck system allowing it to better follow the patient specific hip anatomy regarding offset, varus-valgus angle and rotation in the anteroposterior plane.
1693770|NCT01512537|Radiation|Narrowband UVB|UVB 3 times a week
1693771|NCT01512537|Dietary Supplement|Vitamin D and calcium|1 daily tablet of 1600 IU vitamin D3 and 1000 mg calcium
1693772|NCT01512524|Other|MRI scan and endocrinology analysis|Endocrinology analysis including statique and dynamic exams, neuropsychologic evaluations and IRM scan.
1693773|NCT01512511|Procedure|nitrous oxide use for pneumoperitoneum creation|use nitrous oxide for create pneumoperitoneum in laparoscopic cholecystectomy
1693774|NCT01512485|Drug|Clopidogrel|Clopidogrel Tablets 75 mg
1693775|NCT01512472|Drug|degarelix|Starting dose of 240 mg (40 mg/mL; injection volume 2 x 3 mL; s.c.) degarelix one-month depot will be administered sc on Day 0, followed by a maintenance dose of 80 mg (20 mg/mL; injection volume 1 x 4 mL; s.c.) sc degarelix one-month depot will be administered into the anterior abdominal wall on Month 1, 2, 3, 4, 5, 6, 7, 8 and 9 for the 10 month arm and month 1, 2 and 3 for the 4 month arm.
1693776|NCT01512459|Drug|Venlafaxine|Venlafaxine MR Capsules 150 mg
1693777|NCT01512446|Drug|Alendronate|70 mg per week
1693778|NCT01512446|Drug|Placebo|1 pill per week
1693827|NCT01512108|Drug|liraglutide|0.9 mg/day liraglutide was injected once daily subcutaneously (s.c., under the skin).
1693779|NCT01512433|Procedure|Ture acupuncture|Ture acupuncture included shenmen point in the ear cartilage ridge area without electrical stimulation and Hegu (LI 4) and Zusanli (ST 36) on both hands and legs with electrical stimulation. The frequency of stimulation alternated between 20 and 100 Hz (dense and disperse, DD) at automatic 2-second intervals. The intensities of the stimulations were increased in 1 mA increments to maximal tolerable intensity.
1693780|NCT01512433|Procedure|Sham acupuncture|"The needles on the bilateral Hegu (LI 4) and Zusanli (ST 36) were then connected to the electro-acupuncture machine with zero frequencies and amplitude.DeQiwas avoided during needling."
1693781|NCT01512407|Procedure|Transarterial chemoembolisation using cisplatin-lipiodol mixture|Cisplatin-lipiodol mixture was infused through catheter placed at hepatic artery followed by gelfoam embolisation. This is performed 4 to 6 weeks after surgery
1693782|NCT01512394|Procedure|standard bowel prep|standard bowel prep
1693783|NCT01512394|Procedure|no bowel prep|no bowel prep
1693784|NCT01512381|Device|Implantation of CRT device|RV lead of CRT system is implanted into the middle part of interventricular septum
1693785|NCT01512381|Device|Implantation of conventional VVI(R) pacemaker|RV lead is implanted into the middle part of interventricular septum
1693786|NCT01512368|Other|Supervised Exercising|A treadmill exercise test (following the Bruce's protocol) was done five times per week (from Monday to Friday) for two weeks.
1693787|NCT01512355|Drug|Dexmedetomidine|After, induction of general anesthesia, dexmedetomidine 0.2 mcg/kg/hr continuous intravenous infused during the surgery
1693788|NCT01512355|Drug|placebo group|normal saline_02mcg/kg/hr
1693789|NCT01512342|Behavioral|Pacing|3 one-on-one sessions weekly for 3 consecutive weeks
1693790|NCT01512342|Behavioral|relaxation therapy|3 one-on-one sessions weekly for 3 consecutive weeks
1693791|NCT01512329|Behavioral|pacing|3 one-on-one sessions weekly for 3 consecutive weeks
1693792|NCT01512329|Behavioral|relaxation|3 one-on-one sessions weekly for 3 consecutive weeks
1693793|NCT01512316|Drug|d-Cycloserine|250mg, one dose, 2hrs prior to fMRI
1693794|NCT01512316|Drug|Lactose pill|one dose, 2hrs prior to fmri
1693795|NCT01512316|Genetic|Saliva sample|Buccal cell material will be sampled from all participants on day3
1693796|NCT01512316|Other|Functional neuroimaging (fMRI)|
1693797|NCT01512303|Behavioral|Sudarshan Kriya Yoga|SKY incorporates yoga, discussion periods and several types of breathing exercises for relaxation.
1693798|NCT01512303|Behavioral|Mindfulness-Based Stress Reduction|MBSR incorporates yoga, discussion periods, and several types of meditation, all involving attention to the present moment and acceptance of any feelings, sensations or thoughts
1693799|NCT01512290|Other|Theta Burst Transcranial Magnetic Stimulation|This rTMS paradigm consists of 5 pulses at 50Hz repeated at 5Hz for 60 seconds with a total of 900 pulses per treatment
1693800|NCT01512277|Biological|rSh28GST|subcutaneous route at Day 0, Day 28, and Day 150 for the third administration of 100µg for Arm 1
1693801|NCT01512264|Device|Magstim SuperRapid|This design will allow systematic evaluation of the efficacy of nerTMS and its most optimal dose for language recovery.
1693802|NCT01512251|Drug|BKM120 Combined with Vemurafenib (PLX4032)|"Phase I is 3+3 dose escalation study to identify the recommended phase 2 dose (RP2D)
Dose Level -1: BKM120 60 mg daily, Vemurafenib 480 mg bid
Dose Level 1: BKM120 60 mg daily, Vemurafenib 720 mg bid
Dose Level 2: BKM120 80 mg daiy, Vemurafenib 720 mg bid
Dose Level 3: BKM120 100 mg daiy, Vemurafenib 720 mg bid
Dose Level 4: BKM120 100 mg daiy, Vemurafenib 960 mg bid
Phase II is a single-stage, single arm prospective trial: patients will receive BKM120 and vemurafenib at the RP2D"
1693803|NCT01512238|Other|Pharmaceutical care|Information about medicine, sideeffect, adherence
1693804|NCT01512225|Drug|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 28 days
1693805|NCT01512225|Drug|Placebo Tablet|placebo tablet 10 mg orally three times daily for 14 days
1693806|NCT01512225|Drug|Domperidone maleate|domperidone maleate tablet 10 mg orally three times daily for 14 days
1693807|NCT01512212|Procedure|biopsy|fnab
1693815|NCT01512173|Drug|propranolol gel|Topical administration twice daily
1693816|NCT01512173|Drug|Placebo|Topical administration twice daily
1693817|NCT01512160|Drug|PF-04531083|2000 mg oral solution
1693818|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
1693819|NCT01512160|Drug|PF-04531083|1000 mg oral solution
1693820|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
1693821|NCT01512160|Drug|Ibuprofen|2 x 200 mg tablets
1693822|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
1693823|NCT01512160|Other|Placebo|Placebo solution for PF-04531083
1693824|NCT01512160|Other|Placebo|Placebo tablets for Ibuprofen
1693825|NCT01512147|Other|Isoflurane, Propofol, Dexmedetomidine|"We will include following general anesthesia techniques:
Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250 mcg/kg/min, Isoflurane 0.6% expiratory With this general anesthesia technique we will do our first SSEP/MEP measurements after 30 minutes.
After 30 minutes we will stop isoflurane and will wash out the inhalational anesthetic with high flow air/oxygen and provide:
Fentanyl 1 - 2 mcg/kg/hr, Propofol 150 - 250mcg/kg/min. This technique will be held for 30 minutes. SSEP/ MEP measurements will be done after 30 minutes.
After the measurements dexmedetomidine will be added with a loading dose of 0.5 mcg/kg over 10 minutes and continuous infusion of 0.5 mcg/kg/hr for 30 minutes.
Fentanyl 1 -2 mcg/kg/hr, Propofol 100 - 250mcg/kg/min, Dexmedetomidine 0.5 mcg/kg/hr."
1693826|NCT01512134|Device|Deep Brain Stimulation Device|Deep brain stimulation surgery
1693828|NCT01512108|Drug|oral anti-diabetic drug|An additional oral anti-diabetic drug (OAD) with a different mechanism of action than the pre-trial OAD. The type and dosage of the additional OAD should be chosen by the investigator within the Japanese labelled dose.
1693829|NCT01512095|Drug|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
1693830|NCT01512095|Drug|somatropin|A single dose administered subcutaneously (under the skin) on 2 separate dosing visits (treatment periods) separated by a wash-out period
1693831|NCT01512082|Device|Pulsed electromagnetic field devices|Every person received two active devices. The devices emitted 2-ms bursts of 27.12 MHz sinusoidal waves repeating at 2 bursts/s. Peak magnetic field intensity was 0.05 G which induced an average electric field of 10 mV in the tissue with an effect of 7.3 mW/cm3.
1693832|NCT01512082|Device|Pulsed electromagnetic field devices|Every persons received two sham pulsed electromagnetic field devices.
1693833|NCT01512069|Behavioral|Web-based Health Planner on diet and exercise|"URL is closed
The program is 12-week program, provides tailored information on the exercise and diet based on the stage of motivational readiness of TTM. The program is designed to allow to plan a regular exercise of 12.5 MET per week and to recommend to eat number of portions from six food groups for balanced diet tailored to individual's BMI, ideal body weight, and calories needed per day. The program provide the feedback based on the achievement of goals of the behaviors."
1693834|NCT01512069|Behavioral|Non-tailored booklet on exercise and diet|The active control group is provided non-tailored booklet on exercise and diet, whose information is same as web-based program except stage-matching.
1693835|NCT01512056|Drug|AdimFlu-S|All enrolled participants will be divided into 3 groups: participants refused to receive vaccination, those receive either one (week 0) or one more booster vaccination (week 0 and week 3). Each dose of vaccine contains 15μg antigen of each virus strain suggested by WHO (A/California/7/2009 (H1N1);A/Perth/16/2009 (H3N2);B/Brisbane/60/2008).
1693836|NCT01512043|Behavioral|Breathing control|Practice of device guided breathing control twice a day for four weeks.
1693837|NCT01512017|Device|Crystalline cellulose simple occlusive dressing|A natural biological film of vegetable origin. It is classified as skin semi occlusive dressing, as a temporary skin substitute in case of skin lesions or loss.
1693838|NCT01512017|Device|Vaseline|External use
1693839|NCT01512004|Drug|Propiverine Hydrochloride|drug of oral capsule
1693840|NCT01512004|Drug|Tolterodine Extended-release Tablet|4mg/tablet; oral; once per day
1693842|NCT01511978|Drug|Continuous 3,4-DAP|Subjects were maintained on their usual personal dose and schedule of 3,4-DAP base
1693843|NCT01511978|Drug|Taper 3,4-DAP to Placebo|Subjects were tapered over 3 days from their usual regimen of 3,4-DAP base to placebo with up to an additional 16 hours of placebo before resuming their usual pre-study regimen of 3,4-DAP base
1693844|NCT01511965|Other|autologous (cellular therapy)|The skin sample, the preparation and implementation of the epidermal cells, are conducted on one day. A review of selected lesions is performed and a photograph. Second, are performed successively in a single day the collection of thin skin, preparing the cell suspension, a desepidermisation laser Erbium: YAG lesions of vitiligo to be grafted, and applicated.
1693845|NCT01511952|Other|Music Intervention|Applied by randomization-live at bassinet in the AM or PM Gato Box, Ocean Disc or parent-selected lullabies
1693846|NCT01511952|Other|Music|Remo Ocean disc Gato box Music therapist's or Parent's preferred lullaby or 'Twinkle'
1693847|NCT01511939|Drug|Pennsaid|Administered 10 drops x 4 until 40 drops applied topically to index knee (and also non-index knee if osteoarthritis pain is present bilaterally) 4 times a day for a 4 week active treatment period.
1693848|NCT01511913|Other|Non-Interventional|Non-Interventional
1693849|NCT01511900|Drug|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 1-9 subjects will be treated with CAT-1004
1693850|NCT01511900|Drug|Placebo|Multiple dose oral administration of placebo daily for 14 days-3 subjects will be treated with placebo per cohort
1693851|NCT01511900|Drug|CAT 1004|Multiple dose oral administration once daily for 14 days of CAT 1004 at dose level 2 -9 subjects will be treated with CAT-1004
1693852|NCT01511900|Drug|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 3-9 subjects will be treated with CAT-1004
1693853|NCT01511900|Drug|CAT 1004|Multiple dose oral administration BID for 14 days of CAT 1004 at dose level 4-9 subjects will be treated with CAT-1004
1693854|NCT01511900|Drug|CAT 1004|Multiple dose oral administration daily for 14 days of CAT 1004 at dose level TBD-9 subjects will be treated with CAT-1004
1693855|NCT01511887|Drug|Oral Ibuprofen|10mg/kg oral ibuprofen followed by two 5mg/kg in 12 hours intervals. If there was no improvement after first cycle of treatment this treatment was repeated.
1693856|NCT01511874|Drug|ELIGARD 22.5mg|a subcutaneous injection of ELIGARD 22.5mg at 0 and 12weeks
1693857|NCT01511848|Drug|DFP (ferriprox) and deferasirox (ICL 670)|"Drug: Ferriprox It will be given orally in the morning Other Name: DFP Initial dose 25/mg/kg 3 times/d (better tolerated if started and then built up over 4 weeks).
Dose may be increased up to 100mg/kg/day guided by serum ferritin. Agranulocytosis risk 1-2%. Monitor TLC and granulocytic count / 2weeks. Patients need to be continually educated about this risk, know that they must stop DFP if they have a fever or infection.
Drug: Deferasirox will be orally administered at a dose of 20 mg/kg once daily at evening for 5 days.
Other Name: ICL670"
1693858|NCT01511848|Drug|DFP, DFO|"Drug: Deferoxamine It will be administered subcutaneously over 8 hours for 5 days at a dose of 40 mg/kg.
Other Name: Desferal, DFO Drug: DFP DFP: will be orally administered at a dose of 75mg/kg orally in 3 divided doses for 7 days"
1693859|NCT01511835|Dietary Supplement|inositol + folic acid|2000 mg of inositol+200mcg of folic acid; 2 per diem
1693860|NCT01511835|Dietary Supplement|inositol + folic acid|600 mg of inositol + 200mcg of folic acid; 2 cp per diem
1693861|NCT01511835|Drug|Folic Acid|Folic Acid 400mcg; 1 cp/die
1693862|NCT01511822|Drug|Drospirenone Ethinyl estradiol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/month for 6 months)
1693863|NCT01511822|Drug|Drospirenone Ethinyl estradiol Myo-inositol|Drospirenone 3mg/die Ethinyl estradiol 30 mg/die (21 days/months for 6 months) + Myo-inositol 6g /die for 6 months
1693865|NCT01511809|Drug|Atazanavir/ritonavir monotherapy|Monotherapy Simplification Strategy with Atazanavir/ritonavir 300/100 mg once daily for 96 weeks.
1693866|NCT01511796|Other|upper limb rehabiliation|3 months upper rehabilation (twice a week) and then 3 more months upper limb rehabitation ( twice a week)
1693867|NCT01511783|Drug|E2609|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
1693868|NCT01511783|Drug|Placebo|E2609 to be administered for 14 days, concurrently with placebo controls. Doses will be 25, 50, and 200 mg once daily by the oral route, each dose administered to a separate cohort (group) of subjects. After each dose has been administered to all subjects in a given cohort, safety and tolerability findings will be evaluated and a decision made by the sponsor and investigators as to whether or not to proceed to the next higher dose.
1693869|NCT01511770|Drug|Fluconazole|Fluconazole Tablets, 200 mg
1693870|NCT01511770|Drug|Fluconazole|Fluconazole 200 mg tablets
1693871|NCT01511757|Drug|Fluconazole|Fluconazole Tablets, 200 mg
1693872|NCT01511757|Drug|Fluconazole|fluconazole 200 mg
1693873|NCT01511744|Biological|Inactivated influenza split vaccine|3000 participants (750 of above 60,750 of age 19-60, 750 of age 13-18 and 750 of age 3-12) to receive influenza split vaccine of 15 μg HA; one dose regime
1693874|NCT01511731|Drug|Famotidine|Famotidine Tablets 40 mg
1693875|NCT01511731|Drug|Pepcid|40mg tablets
1693876|NCT01511718|Drug|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
1693877|NCT01511718|Drug|Ondansetron Hydrochloride|Zofran Tablets 8 mg
1693878|NCT01511705|Drug|Ondansetron Hydrochloride|Ondansetron Hydrochloride Tablets 8 mg
1693879|NCT01511705|Drug|Ondansetron Hydrochloride|Zofran Tablets 8 mg
1693880|NCT01511692|Drug|liraglutide|1.8 mg/day injected subcutaneously for 4 weeks
1693881|NCT01511692|Drug|placebo|Liraglutide placebo, injected subcutaneously for 4 weeks
1693882|NCT01511692|Drug|placebo|Glimepiride placebo, dose individually adjusted, administered orally for 4 weeks
1693883|NCT01511692|Drug|glimepiride|Dose individually adjusted, administered orally for 4 weeks
1693884|NCT01511666|Device|Prehospital mechanical compressions, intraarrest cooling and in hospital ECLS|ECLS states for extracorporeal life support.
1693885|NCT01511666|Other|Standard care|Standard care as per recent guidelines will be provided.
1693886|NCT01511640|Drug|Pregabalin|pregabalin 2x daily for duration of study
1693887|NCT01511640|Drug|Placebo|placebo 2x daily for duration of study
1693888|NCT01511627|Drug|General Anesthesia + Spinal anesthesia combined|"All patients will receive a preoperative multimodal analgesic regime:
Tylenol® 975mg per os
Naproxen® 500 mg per os
Patients will receive a spinal anesthetic with:
Bupivacaine 0.5% 10 mg
Fentanyl 10ug
Epidural Morphine 150ug
After the spinal, a general anesthetic will be induced using:
Midazolam 1 - 2 mg intravenously
Fentanyl 1 - 2 ug/kg intravenously
Propofol 1-3 mg/kg intravenously
Rocuronium 0.3 - 0.9mg/kg intravenously
followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.
Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg to maintain MAP and heart rate within 20% of baseline.
Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.
Dexamethasone 4mg and Ondansetron 4mg intravenously
Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously Patients will receive a Morphine PCA to be initiated in the Post Anesthetic Care Unit (PACU)."
1693889|NCT01511627|Drug|General Anesthesia (control group)|"All patients will receive a preoperative multimodal analgesic regime:
Tylenol® 975mg per os
Naproxen® 500 mg per os
Group I (General anesthetic) patients will receive a general anesthetic :
Midazolam 1 - 2 mg intravenously
Fentanyl 1 - 2 ug/kg intravenously
Propofol 1-3 mg/kg intravenously
Rocuronium 0.3 - 0.9mg/kg intravenously
followed by endotracheal intubation. Maintenance of anesthesia with sevoflurane, oxygen and air.
Intraoperative Morphine 0 - 0.3mg/kg or Fentanyl 0 - 7.5ug/kg. to maintain MAP and heart rate within 20% of baseline.
Phenylephrine and Ephedrine can be used to support blood pressure and heart rate within 20% of baseline.
Dexamethasone 4mg and Ondansetron 4mg intravenously
Neostigmine 3mg and Glycopyrrolate 0.6mg intravenously
Patients will receive a Morphine PCA as per protocol that will be initiated in the Post Anesthetic Care Unit (PACU)."
1693890|NCT01511575|Genetic|RNA analysis|
1693891|NCT01511575|Genetic|reverse transcriptase-polymerase chain reaction|
1693892|NCT01511575|Other|laboratory biomarker analysis|
1693893|NCT01511562|Drug|carmustine|Given IV
1693894|NCT01511562|Drug|cytarabine|Given IV
1693895|NCT01511562|Drug|etoposide|Given IV
1693896|NCT01511562|Drug|thiotepa|Given IV
1693897|NCT01511562|Procedure|stem cell transplant|
1693898|NCT01511562|Drug|G-CSF|
1693899|NCT01511549|Drug|placebo|"Pharmaceutical form:injection
Route of administration: intra-articular"
1693900|NCT01511549|Drug|SAR113945|"Pharmaceutical form:injection
Route of administration: intra-articular"
1693901|NCT01511536|Drug|Cabazitaxel XRP6258|Pharmaceutical form:solution Route of administration: injection
1693902|NCT01511536|Drug|Abiraterone acetate|Pharmaceutical form:tablets Route of administration: oral
1693903|NCT01511536|Drug|Prednisone 5 mg|Route of administration: oral
1693904|NCT01511523|Dietary Supplement|RGMA001|3 capsules administered BID once a day.
1693905|NCT01511523|Dietary Supplement|Sugar Pill|Placebo
1693906|NCT01511510|Drug|PF-04958242|PF-04958242 0.05 mg oral solution Q24 hours for 14 days
1693907|NCT01511510|Drug|PF-04958242|PF-04958242 0.10 mg oral solution Q24 hours for 14 days
1693908|NCT01511510|Drug|PF-04958242|PF-04958242 0.15 mg oral solution Q24 hours for 14 days
1693909|NCT01511510|Drug|PF-04958242|PF-04958242 0.25 mg oral solution Q24 hours for 14 days
1693910|NCT01511510|Drug|Placebo|Placebo oral solution Q24 hours for 14 days
1693911|NCT01511497|Biological|PF-04427429|Intravenous, single dose given over 1 hour with experimental dose. Subjects can receive one of four potential doses - 300, 1000, 1500 or 2000 mg.
1693912|NCT01511497|Other|Normal saline|Intravenous, normal saline
1694759|NCT01505114|Drug|Emtricitabine|200-mg capsule, once daily, from Week 0 through Week 48
1693913|NCT01511484|Behavioral|Information-only|"Selected pages from the British National Health Service (NHS) information booklets [5 A Day, Just Eat More (fruit & veg); pages i, ii, 12-15, 20 & 21] and [5 A Day, Just Eat More (fruit & veg): What's it all about?; pages i-ii)] were provided to all participants on completion of baseline questionnaires. The pages provided information on recommended portion sizes, meal planning, health benefits and answered frequently asked diet-related questions"
1693914|NCT01511484|Behavioral|Generic appearance intervention|"Participants in the generic appearance intervention group received images to illustrate the impact of fruit and vegetable consumption on skin appearance. Participants in this group were presented with gender congruent stimuli, constructed by averaging the facial shape and colour of four male/female faces.
Participants viewed the gender-congruent set of the resulting stimuli in two forms. Firstly, after completion of baseline questionnaires, images were displayed on a computer monitor. Participants were instructed to select what they perceived as the healthiest face colour, which was recorded by the computer program over two trials.
Participants in this group also received a take-home photo quality leaflet to further illustrate the effect of fruit and vegetable consumption on skin colour."
1693915|NCT01511484|Behavioral|Personalised appearance intervention|Participants in this group received stimuli manipulated in identical ways to that received by the generic appearance-intervention group, except the illustrations were performed upon images of the participant's own face.
1693916|NCT01511471|Drug|Ticagrelor|Ticagrelor 90mg twice a day for 15 days
1693917|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with PEEK Cage|Anterior cervical discectomy and fusion with the use of a PEEK plastic interbody spacer
1693918|NCT01511445|Device|Anterior cervical discectomy and fusion (ACDF) with a Valeo CSC Cage|Anterior cervical discectomy and fusion with a Valeo ceramic cage interbody spacer.
1693919|NCT01511432|Drug|telaprevir formulation A|A single 1125-mg dose administered orally
1693920|NCT01511432|Drug|telaprevir Formulation B|A single 1125-mg dose administered orally
1693921|NCT01511432|Drug|telaprevir Formulation C|A single 1125-mg dose administered orally
1693922|NCT01511432|Drug|telaprevir Formulation D|A single 1125-mg dose administered orally
1693923|NCT01511419|Biological|live attenuated monovalent A/17/mallard/Netherlands/00/95(H7N3) influenza vaccine|two doses given one month apart
1693924|NCT01511419|Biological|placebo|manufactured placebo based on allantoic fluid of chicken embryos not inoculated with influenza virus
1693925|NCT01511406|Behavioral|cognitive behavioral therapy|Patients allocated to the treatment arm will receive up to 26 sessions of cognitive behavioral therapy
1693926|NCT01511393|Other|No treatment given|None. Non-interventional study.
1693927|NCT01511380|Behavioral|Risk Reduction Therapy for Adolescents|This project integrates CM and a family systems intervention for sexual risk with evidence-based family engagement strategies, and tests this intervention in a juvenile drug court setting. Due to the individualized nature of the proposed intervention, the specific course of treatment will vary by youth and family. Based on our experience with clinic-based treatment models it is anticipated that most families will remain in active treatment for 4-6 months and that, during this time, they will attend approximately 1-2 sessions per week, for 1-2 hours per session.
1693928|NCT01511380|Behavioral|Usual services|In addition to the standard juvenile drug court requirements, youth randomly assigned to the usual services condition are also ordered to receive treatment services from the local state or privately-funded alcohol and drug treatment provider agencies. The service delivery model for agencies typically includes intensive outpatient, traditional outpatient, and home-based services, depending upon assessment of youth and family needs. Groups focus on risk reduction, peer influence, conflict resolution, and anger management. Additionally, youth might receive treatment pertaining to drug selling behavior, individual sessions and/or family group therapy. The theoretical orientations of the provider agencies are cognitive-behavioral and systems theory. Interventions are not usually manual driven, and selection of material is typically left to the therapists' discretion.
1693929|NCT01511367|Drug|Flutiform|50/5ug (fluticasone/formoterol) 2 puffs twice daily
1693930|NCT01511367|Drug|Seretide|50/25 ug (fluticasone/salmeterol) 2 puffs twice daily
1693931|NCT01511367|Drug|Flixotide|50ug 2 puffs twice daily
1693932|NCT01511341|Behavioral|Telenursing|The nurse-led intervention will consist of providing a monthly telephone call by a qualified and experienced nurse specialist in paediatric rheumatology and TN to ensure follow-up of the children and their family. The intervention will focus on providing affective support, health information, and aid to making decision.
1693933|NCT01511328|Other|HPV testing|Testing for Human Papilloma Virus
1693934|NCT01511315|Drug|Ustekinumab|Biologic agent: sub-cutaneous injection at Weeks 0, 4, and then every 12 weeks thereafter.
1693935|NCT01511302|Drug|RNS60|RNS60, 2ml, nebulized twice daily.
1693936|NCT01511302|Drug|Normal Saline|Normal Saline placebo, 2 ml, nebulized twice daily.
1693937|NCT01511302|Drug|Budesonide|Budesonide, in either 0.25 mg or 0.5 mg per 2 ml concentration in liquid suspension, nebulized once per day in combination with RNS60 or NS.
1693938|NCT01511289|Drug|Imatinib|400mg/Tab, QD
1693939|NCT01511289|Drug|Radotinib|100mg or 200mg/Capsule, 300mg or 400mg BID
1693940|NCT01511276|Behavioral|Diet|Energy restricted diet, according the national guidelines for healthy nutrition, creating a mean energy deficit of 500 kCal/day.
1693941|NCT01511276|Behavioral|Mainly exercise induced weight loss|"Exercise programme of 2 hours per week fitness containing endurance and resistance training. And 2 hours of Nordic Walking. Equivalent to an energy expenditure of 350 kCal/day.
Next to the exercise programme participants will follow an energy restricted diet according to the national guidelines of healthy nutrition creating an extra energy deficit of 250 kCal/day."
1693942|NCT01511263|Drug|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhithmias)|Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
1693943|NCT01511263|Drug|Diuretics (plus antiarrhythmic drugs, i.e. amiodarone, in case of complex ventricular arrhythmias) plus EGCG|"Antiarrhythmic drugs (i.e. amiodarone), angiotensins which transform inhibitor enzymes, and/or beta-blockers if tolerated.
EGCG, 675 mg/day, oral, for one year."
1693985|NCT01511016|Drug|"Human recombinant leptin (metreleptin)"|Metreleptin was administered at a dose of 0.02 mg / kg body weight for two months, followed by a dose of 0.04 mg / kg for two more months.
1694944|NCT01503736|Drug|ferric citrate|0g/day ferric citrate capsule, TID for 56 days
1693944|NCT01511250|Biological|TDV|TDV 0.5 mL, injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose) in participants aged:21 to 45 yrs, 12 to 20 yrs, 6 to 11 yrs, 1.5 to 5 yrs, and 1.5 to 11 yrs. TDV comprised of 4 recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4 containing 2*10^4 PFU, 5*10^4 PFU, 1*10^5 PFU, and 3*10^5 PFU respectively, total virus per dose: 4.7*10^5 PFU.
1693945|NCT01511250|Biological|Placebo|TDV placebo-matching 0.5 mL injection, subcutaneously, once on Day 0 (first dose) and Day 90 (second dose) in participants aged 21 to 45 yrs, 12 to 20 yrs, 6 to 11 yrs, 1.5 to 5 yrs, and 1.5 to 11 yrs.
1693946|NCT01511237|Drug|Nevirapine, zidovudine, lamivudine|"Mothers: One NVP 200 mg tablet at onset of labor with continuation of HAART for four weeks postpartum
Newborn: AZT+3TC+ NVP for 2 weeks, followed by AZT+3TC for 2 weeks:
NVP syrup 2 mg/kg every 24 hours for seven days, followed by NVP syrup 4 mg/kg every 24 hours for seven days. Newborns less than 2500 g will be administered 2mg/kg NVP syrup at each intake
AZT syrup 4 mg/ kg will be given every 12 hours for four weeks (preterm infants less than 30 weeks will be administered 2 mg/kg every 12 hours; preterm 30-35 weeks will receive 2 mg/kg every 12 hours for the first 2 weeks, increased to 3 mg/kg for the next 2 weeks).
3TC syrup 2 mg/kg every 12 hours for four weeks."
1693947|NCT01511211|Drug|Dexamethasone|2 cc of 4 mg/cc dexamethasone will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for a femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of normal saline will be added to the patient's IV to maintain blinding.
1693948|NCT01511211|Drug|Ropivacaine|2 cc of normal saline will be added to 38 cc of 0.5% ropivacaine solution. Of this combination, 15 cc will be used for the femoral nerve block, 20 cc for the popliteal nerve block, and 5 cc for the obturator nerve block. In addition, 2 cc of 4 mg/cc dexamethasone will be added to the patient's IV.
1693949|NCT01511198|Drug|liraglutide|Injected subcutaneously once daily
1693950|NCT01511198|Drug|metformin|1000 mg twice daily, administered orally
1693951|NCT01511185|Drug|liraglutide|A single dose of 7.5 mcg/kg administered subcutaneously in random order
1693952|NCT01511185|Drug|placebo|A single dose administered subcutaneously in random order
1693953|NCT01511172|Drug|liraglutide|Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
1693954|NCT01511172|Drug|metformin|1000 mg daily, administered orally
1693955|NCT01511172|Drug|placebo|Metformin placebo administered orally. 1000 mg daily
1693956|NCT01511172|Drug|placebo|NNC 90-1170 placebo. Individually adjusted dose, maximum 2.0 mg. Injected subcutaneously
1693957|NCT01511172|Drug|glimepiride|Individually adjusted dose, administered orally
1693958|NCT01511159|Drug|liraglutide|Single dose of 6 mcg/kg by inhalation. Progression to open-label trial part will be based on safety data
1693959|NCT01511159|Drug|placebo|Single dose by inhalation. Progression to open-label trial part will be based on safety data
1693960|NCT01511159|Drug|liraglutide|Single dose of 12 mcg/kg by inhalation. Subjects receive treatment in random order
1693961|NCT01511159|Drug|liraglutide|Single dose 6 mcg/kg injected subcutaneously. Subjects receive treatment in random order
1693962|NCT01511159|Drug|insulin human|Single dose 0.4 IU/kg by inhalation. Subjects receive treatment in random order
1693963|NCT01511159|Drug|insulin human|Single dose 0.08 IU/kg injected subcutaneously. Subjects receive treatment in random order
1693964|NCT01511159|Drug|liraglutide|24 mcg/kg by inhalation. Progression to dose level will be based on safety evaluation
1693965|NCT01511146|Drug|Oxaliplatin|oxaliplatin 85 mg/m2 in 10 minutes
1693966|NCT01511146|Drug|Mitomycin + Gemcitabine|Mitomycin 5 mg/m2 Gemcitabine 1000 mg/m2
1693967|NCT01511133|Procedure|Stool sample|Stool samples collected at pre-determined time points in previous studies will be analysed to detect the presence of PCV-1 DNA and pattern of detection.
1693968|NCT01511133|Procedure|Serum sample|Serum samples collected at pre and post vaccination time points in previous studies will be assessed for Anti-PCV-1 antibody.
1693969|NCT01511120|Drug|Tetraspan|
1693970|NCT01511120|Drug|acetated Ringer`s solution|
1693971|NCT01511107|Drug|Amoxicillin-Clavulanate, 10 days|Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-10
1693972|NCT01511107|Drug|Amoxicillin-Clavulanate, 5 days|"Amoxicillin-clavulanate (90/6.4mg/kg/day in 2 divided doses) Days 1-5
Plus
Placebo Days 6-10"
1693973|NCT01511094|Procedure|Goniocurettage|Ab interno surgery consisting on scraped away the trabecular tissue from the angle (goniocurettage) removing segments of pathologically altered trabecular meshwork from the scleral sulcus
1693976|NCT01511068|Drug|Leukine|Participants will receive inhaled rhGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg one time per week for 12 weeks. Following an interim safety evaluation, participants may be entered into a second 12 week treatment period where participants will receive either 250 mcg or 500 mcg once weekly. At the end of any treatment period, participants will be followed for 12 additional weeks in the absence of inhaled rhGM-CSF to evaluate safety and efficacy.
1693977|NCT01511055|Drug|EC-17|One-time dose of Folate-FITC (EC-17), 0.1mg/kg IV 2-3 hours prior to surgery.
1693978|NCT01511042|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
1693979|NCT01511042|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
1693980|NCT01511042|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
1693981|NCT01511029|Drug|Dexpramipexole|300 mg - Oral Tablets
1693982|NCT01511029|Drug|Dexpramipexole|600 mg Oral Tablets
1693983|NCT01511029|Drug|Dexpramipexole Placebo|Placebo - Oral Tablet
1693984|NCT01511029|Drug|Moxifloxacin|400 mg - Oral Tablet
1693986|NCT01511016|Drug|Placebo|Placebo was administered at a dose of 0.02 mg / kg body weight daily by subcutaneous injection for two months, followed by 0.04 mg / kg for two more months.
1693987|NCT01511003|Drug|Tacrolimus|oral
1693988|NCT01510990|Drug|Gefitinib|gefitinib 250mg/day daily
1693989|NCT01510977|Drug|polyethylene glycol, Bisacodyl|After failure of first colonoscopy, bowel preparation with polyethylene glycol and bisacodyl one week after
1693990|NCT01510977|Drug|polyethylene glycol|Immediately after first colonoscopy failure, polyethylene glycol 2L addition
1693991|NCT01510964|Behavioral|prompt-sheet|"Prompt sheet is a form on which to write the reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist and a written list of possible questions the patient (companion) would like to ask to the oncology."
1693992|NCT01510964|Behavioral|control group|"Patients and companions of the control group receive a form on which to write their reply to the following request: Please indicate the arguments which you want to discuss today with your oncologist"
1693993|NCT01510951|Drug|AMG 811 or Placebo|Single dose subcutaneous administration of AMG 811 or placebo to adult subjects with psoriasis.
1693994|NCT01510938|Dietary Supplement|L. acidophilus DDS-1, B. lactis UABLA-12|1 g of probiotic will be reconstituted in 25-50 ml tepid water, juice or age specific baby food and immediately fed once a day (5 billion CFU/daily) for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
1693995|NCT01510938|Dietary Supplement|Placebo|1 g in 25-50 ml of tepid water or juice fed once a day for 2-weeks trial period or to the end of acute respiratory infection depending on whatever is longer.
1693996|NCT01510912|Drug|Diclofenac|35 mg bid or tid Capsules
1693997|NCT01510899|Drug|RO4917838|Single dose of RO4917838
1693998|NCT01510899|Drug|RO4917838|Single dose of RO4917838
1693999|NCT01510873|Other|HRQOL evaluation|"Patients will be asked to complete a Questionnaire (i.e. HRQOL Survey Packet) that will cover a number of issues. These will include socio-demographic aspects, HRQOL information, symptom burden, clinical decision-making, social support and psychological wellbeing. Most of these information will be collected through well known psychometrically sound questionnaires. The copyright for using standardized questionnaires will be obtained, from the appropriate copyright holders, for the purpose of this research.
The Questionnaire properly formatted will be distributed to all participating Centers prior to study start."
1694000|NCT01510860|Drug|UDCA (Ursodeoxycholic acid)|250 mg
1694001|NCT01510860|Drug|UDCA (Ursodeoxycholic acid)|500 mg
1694002|NCT01510847|Drug|Andriol Testocaps|Oral, 40mg, Twice a day, 30days
1694003|NCT01510834|Behavioral|Multibehavioral, Computerized Tailored Intervention STR2IVE|All participants were provided with the same multibehavioral CTI system and chose two or three behavior programs to complete (smoking cessation, stress management, and/or depression prevention)monthly. They were asked to complete an assessments at baseline, 30-days, and 90-days. They were allowed to access the system workbook anytime but they must wait a minimum of 25 days between assessments and programs at time points 1 and 2, and 55 days between time points 2 and 3.
1694004|NCT01510821|Other|Use of Maquet Vasoshield Pressure-limiting syringe on SVG|Use of Maquet Vasoshield Pressure-limiting syringe on SVG
1694005|NCT01510821|Other|Use of non-regulated syringe on SVG|Use of non-regulated syringe on SVG
1694006|NCT01510808|Procedure|orthodontic treatment|Patients with Aggressive Periodontitis which are in the maintenance phase, had been treated for malocclusion.
1694007|NCT01510795|Drug|spironolactone|Spironolactone initiated at 3 months posttransplant at 25 mg qd and up-titrated to 50 mg qd after 14 days. Spironolactone therapy will be maintained for 9 months.
1694008|NCT01510782|Drug|Placebo to BI 655064|intravenous infusion of escalating doses
1694009|NCT01510782|Drug|Placebo to BI 655064|subcutaneous injection of escalating doses
1694010|NCT01510782|Drug|BI 655064|intravenous infusion of escalating doses
1694011|NCT01510782|Drug|BI 655064|subcutaneous injection of escalating doses
1694012|NCT01510769|Drug|Lesinurad|Tablets, 400 mg once daily (QD)
1694013|NCT01510769|Drug|Lesinurad|Tablets, 200 mg QD
1694014|NCT01510769|Drug|Placebo|Tablets, Placebo QD
1694015|NCT01510769|Drug|Febuxostat|80 mg
1694016|NCT01510756|Drug|Sorafenib|Sorafenib 400mg orally twice daily will be administered for three cycles (1 cycle = 28 days). Subjects without significant toxicity or progressive disease may elect to continue treatment for a total of twelve cycles.
1694017|NCT01510730|Drug|eradication treatment of Helicobacter pylori infection|Eradication group receive Omeprazole sodium 20mg, amoxicillin 1g, clarithromycin 500mg orally at the same time twice daily for 7 days.
1694018|NCT01510717|Device|AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
1694019|NCT01510717|Device|AcrySof® IQ Monofocal IOL Model SN60WF|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
1694020|NCT01510704|Drug|APD421|IV
1694021|NCT01510704|Drug|Placebo|IV
1694022|NCT01510678|Behavioral|Increase Fruits and Vegetables|Children will be encouraged to consume 1 cup/day and 1.5 cups/day of whole fruit, and 1.5 cups/day and 2 cups/day of vegetables for children aged 6 to 8 years and 9 to 12 years, respectively. Children will gradually work towards these goals. Parents will also work towards F&V goals, with 2 cups/day of whole fruit and 2.5 cups/day of vegetables. Both parent and child will self-monitor these behaviors. As one barrier to consuming F&Vs is perceived cost of these foods, information regarding lower-cost options for F&Vs will be included in the manual.
1694023|NCT01510678|Behavioral|Decrease Snack Foods|This condition will reduce intake of SFs (i.e., candy, cookies, cakes, ice cream, chips, nuts) to < 3 servings/week (for children aged 6 to 12 years, the solid fats and added sugar energy limit is 840 kcals/week and the DECREASE goal will help with meeting this limit). Children and parents will gradually work towards meeting these goals and self-monitor these behaviors.
1694024|NCT01510678|Behavioral|Increase Fruits and Vegetables and Decrease Snack Foods|Will combine the goals of the increase and decrease conditions.
1694025|NCT01510665|Dietary Supplement|Magnesium citrate|Magnesium citrate tablets 950 mg, two pills once daily (Total daily dose of 300 mg elemental magnesium)
1694026|NCT01510665|Dietary Supplement|Placebo|Identical appearing placebo with inactive ingredients, two pills once daily.
1750129|NCT00193440|Drug|CHOP|
1694027|NCT01510665|Behavioral|Dietary modification|Nutritionist counseling session and advice on following a magnesium rich diet
1694028|NCT01510652|Procedure|BiP Group|Implantation of standard Left Ventricular (LV) lead
1694029|NCT01510652|Device|Quad Group|Implantation of quadripolar Left ventricular (LV) lead Quartet
1694030|NCT01510639|Biological|Platelet Rich Plasma|The application of autologous thrombocyte concentrate (PRP). This is a concentrate with a high amount of thrombocytes (containing growth factors), obtained by centrifuging the patient's own blood. The concentrate is applied into the subacromial space after closure.
1694031|NCT01510626|Dietary Supplement|Food proteins|Food proteins
1694032|NCT01510626|Drug|Omalizumab|Drug
1694033|NCT01510613|Drug|Pomalidomide and Dexamethasone|Pomalidomide: 2-4mg/day, every day in cycles of 28 days until progression or unacceptable toxicity Dexamethasone: 20-40mg/week, on days 1, 8, 15, 22 in cycles of 28 days until progression or unacceptable toxicity
1694034|NCT01510600|Genetic|DNA analysis|
1694035|NCT01510600|Genetic|polymerase chain reaction|
1694036|NCT01510600|Other|laboratory biomarker analysis|
1694037|NCT01510600|Other|medical chart review|
1694038|NCT01510587|Behavioral|4-Health Educational curriculum|During the intervention, parents meet about every 3 weeks (90 min/session) in small groups with facilitators. During meetings classroom activities aim to integrate 3 areas: 1) parents' knowledge about healthy diets, physical activity and improved body image; 2) parents' understanding, skills and potential roles as positive change-agents (i.e., parenting and behavior management); and 3) parents' learning and practicing cognitive-behavioral exercises that encourage specific skills within the family/home setting. Between monthly meetings, participants explore a suggested online websites or facilitator-assigned questions and provide feedback. The majority of outside time/assignments for parents is spent doing take-home activities with their preteen child and family.
1694039|NCT01510587|Behavioral|Healthy Living Information|During the Healthy Living Information intervention, participants receive packets delivered to their homes by mail at intervals similar to the meeting intervals for the educational curriculum intervention. (10 total packets.) Approximately every three weeks between late September 2011 and April 2012, corresponding approximately to the meeting times for the 4-Health Educational Program, participants in the Healthy Living Information control group receive mailed packets of information.
1694040|NCT01510574|Drug|Misoprostol|3 x 200mcg tablets of oral misoprostol
1694041|NCT01510574|Drug|placebo|3 x placebo tablets resembling misoprostol taken orally
1694042|NCT01510561|Drug|90Y-hPAM4|90Y-hPAM4 will be administered weekly for 3 weeks in conjunction with gemcitabine which will be administered weekly x 4.
1694043|NCT01510561|Drug|90Y-hPAM4|
1694044|NCT01510561|Drug|90Y-hPAM4 + gemcitabine|
1694045|NCT01510548|Biological|Adalimumab injections for acute disc prolapse patients|see the study protocol. Three arms, which two of them included active medication and one will be placebo( NaCl solution) in controlled double blind setting.
1694046|NCT01510535|Drug|Placebo|First 2 weeks Placebo(2ml) once weekly in experimental group
1694047|NCT01510535|Drug|Hyruan Plus|Hyruan Plus Inj. (2ml)once weekly for 3 weeks in control group
1694048|NCT01510535|Drug|LBSA0103|at third week LBSA0103(60mg) once in experimental group
1694049|NCT01510522|Drug|Glucophage|Glucophage Powder for oral solution in sachets (metformin hydrochloride in 850mg strengths) Dosing schedule: > 1.700mg/day for 6 month
1694050|NCT01510522|Drug|Glucophage|"Glucophage tablets (metformin hydrochloride in 850mg strengths)
Dosing schedule: > 1.700mg/day for 6 month"
1694051|NCT01510509|Device|Titanium bare metal stent (Titan2®)|Titan2®, Hexacath, Paris, France
1694052|NCT01510509|Device|Everolimus Drug Eluting Stent (Xience-V®)|Xience-V®, Abbott Vascular, Santa Clara, California, USA
1694053|NCT01510496|Procedure|Inguinal herniorraphy.|Inguinal herniorraphy (non laparoscopic).
1694054|NCT01510496|Procedure|Hysterectomy.|Hysterectomy: Vaginal and abdominal.
1694055|NCT01510496|Procedure|Thoracotomy .|Thoracotomy (non laparoscopic).
1694056|NCT01510483|Behavioral|Obesity Prevention|Those in the experimental, obesity prevention, condition will be exposed to the office-wide intervention for diet and activity. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
1694057|NCT01510483|Behavioral|Tobacco Prevention|Those in the control, tobacco prevention, condition will be exposed to the office-wide intervention for avoidance of tobacco and second hand smoke. The intervention will consist of training of orthodontists and office staff to provide appropriate social prompts, reinforcement and counseling, and modification of the offices to provide supportive physical and social resources for their patients and parents.
1694058|NCT01510457|Drug|Milnacipran|Total target dose of 200 mg/day. Subjects will titrate-up according to the following schedule: 25 mg/d (2 pills, 2 days), 50mg mg/d (4 pills, 2 days), 100mg/d (2 pills, 3 days), 150 mg/d (3 pills, 4 days), and steady state is reached once the study participant ingests 200 mg/d(4 pills). The steady state is maintained for 44 days (approx. 6 weeks). If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 100 mg/day at the discretion of the PI. Subjects unable to tolerate 100 mg/day will be discontinued from the study. A 2-week down-titration will be used.
1694059|NCT01510457|Drug|Placebo|Subjects will receive identical placebo pills and dosing schedule as that of participants receiving active study medication.
1694060|NCT01510431|Drug|PROCHYMAL (remestemcel-L)|intravenous administration of 200 million cells on days 0, 3, 7, and 14, and then, at investigator discretion, periodically thereafter
1694061|NCT01510405|Other|Tissue Collection|Tissue sample collection
1694062|NCT01510392|Device|OCT imaging, the FDA Cleared iVue|The OCT system scans a beam of light across the eye to take a picture. OCT imaging does not touch the eye. This is a test that is performed using an FDA approved system, and is regularly used to take pictures of the back of the eye.
1694063|NCT01510379|Device|Reletex|Neurostimulation device for prevention/treatment of post-operative nausea and vomiting, Reletex arm.
1694064|NCT01510379|Drug|IV ondansetron 4 mg q 6 hours for a total of 4 doses|
1694065|NCT01510379|Drug|IV promethazine 25 mg q 6 hours prn|
1694066|NCT01510379|Drug|Elixir promethazine 25 mg q 6 hours prn after discharge|
1695204|NCT01501916|Dietary Supplement|Placebo|daily intake of placebo
1694067|NCT01510366|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) 3 x 0.5ml intramuscular injections, one month apart.
1694068|NCT01510366|Biological|Inactivated Poliomyelitis Vaccine (Salk strains)|Inactivated Poliomyelitis Vaccine (Salk strains)3 x 0.5ml intramuscular injections, one month apart.
1694069|NCT01510353|Device|Radiation monitoring device|Radiation monitoring device (Bleeper Sv, Vertec Scientific Ltd, Berkshire, UK) that provides real-time auditory feedback on radiation exposure during cardiac catheterization
1694070|NCT01510340|Behavioral|VIH-TAVIE|The tailored virtual intervention is composed of four interactive computer sessions hosted by a virtual nurse who engages the PLHIV in a medication-intake self-management skills-learning process.
1694071|NCT01510327|Device|PROMUS Element Everolimus-Eluting Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
1694072|NCT01510327|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
1694073|NCT01510327|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
1694074|NCT01510314|Biological|C-reactive protein and procalcitonin dosages|
1694075|NCT01510301|Device|Mobile phone-based self-report system, electronic Patient-Reported Outcomes Measure (e-PROM)|"To test an electronic Patient-Reported Outcomes Measure (e-PROM) intended to assess patients' daily perceptions of symptoms and wellbeing, as well as self-measured blood pressure, treatment side-effects and medicine intake;
Explore patient interactions (learning and understanding) with an internet-reporting system providing structured feedback of e-PROM results to examine if such feedback is useful in improving adherence;
Explore patient-physician/nurse interactions to examine if structured feedback of e-PROM results serves as a useful complement to support consultations regarding treatment monitoring and adherence."
1694076|NCT01510288|Drug|GVAX and ipilimumab|All patients receive a 500 million cell priming dose of granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) intradermally on day 1 followed by bi-weekly intradermal injections of 300 million cells for a 24 week period. The vaccinations are combined with monthly intravenous administrations of ipilimumab. The dose-escalation part of this study will be performed using the standard 3+3 phase-I trial design. Patients will be enrolled in cohorts of three; each cohort will receive an escalating dose of ipilimumab at 0•3, 1•0, 3•0 or 5•0 mg/kg. Sixteen patients will be treated in an expansion cohort with GVAX and 3•0 mg/kg ipilimumab.
1694077|NCT01510275|Device|Combined use of RESPIVOL® and RESPILIFT®|Active devices (combined) for 14 consecutive session, bid, for 15 minutes.
1694078|NCT01510275|Device|Combined use of RESPIVOL® and RESPILIFT®|Sham devices (combined) (without resistive load)for 14 consecutive session, bid, for 15 minutes.
1694081|NCT01510236|Behavioral|Self-help program|The program is available via an internet platform (www.carebase.se) and consists of two steps: interactive support (Step 1) and cognitive behavioral therapy (CBT) delivered via internet (2). Step 1 provides information about the cancer experience and psychoeducation about frequent reactions and distress and how to manage this. The information and education is provided via texts, audio files, and video-interviews with persons who have survived cancer during adolescence. Step 1 also capitalizes on interaction between participants via chat and forum. There is also a possibility to ask questions to an expert via the website. Twenty-eight weeks after start of Step 1 participants are offered access to Step 2 which lasts ten weeks and consists of a self-help CBT material consisting of modules and weekly contact with a psychologist. Each module is focused on one problem area, e.g. worry or depressive symptoms. Step 1 is available during Step 2. The whole program lasts for 34 weeks.
1694082|NCT01510223|Dietary Supplement|Olive oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).
The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.
High-fat milkshake supplements were consumed daily for five days before a test trial. 90 g olive oil added to the supplement for the purpose of the HF intervention phase."
1694116|NCT01509911|Drug|TL-118|TL-118 investigational product is supplied as an oral liquid for daily administration at a specific dosing regimen. Treatment protocol includes weekly therapy cycles.
1694117|NCT01509911|Drug|Gemcitabine|Monthly cycles of 3 weekly treatments a month and one week off of treatment
1694083|NCT01510223|Dietary Supplement|Olive oil and fish powder|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).
The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.
High-fat milkshake supplements were consumed daily for five days before a test trial. 86.67 g olive oil and 3.3 g of n-3 fish powder (500 mg EPA+DHA)added to the supplement for the purpose of the HF intervention phase."
1694084|NCT01510223|Dietary Supplement|Olive oil and macadamia oil|"Each volunteer will complete three test trials. The first (CONTROL) and second test trials (HF) were separated by 28 days. The third trial (LF) takes place on the 6th day following the second trial (5 days apart).
The CON and LF milkshake supplements are identical (272 kcal; 6 g fat). The basic control (CON) or LF milkshake (that the oil was added to) was: 275 g semi skimmed milk, 25 g chocolate milkshake mix, 15 g dried skimmed milk, 1 g xanthan gum. This was made up to 580 ml with still water.
High-fat milkshake supplements were consumed daily for five days before a test trial. 74.82 g olive oil and 15.18 g macadamia nut oil added to the supplement for the purpose of the HF intervention phase."
1694085|NCT01510223|Dietary Supplement|Deadaptation|A period of 5 days supplementation with the low-fat milkshake represents a de-adaptation period from high-fat intervention.
1694087|NCT01510171|Drug|Prasugrel|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
1694088|NCT01510171|Drug|Ticagrelor|25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
1694089|NCT01510158|Drug|Lesinurad|Tablets, 200 mg once daily (qd)
1694090|NCT01510158|Drug|Lesinurad|Tablets, 400 mg qd
1694091|NCT01510158|Drug|Placebo|Tablets, Placebo qd
1694092|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
1694093|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
1694094|NCT01510158|Drug|Allopurinol|Tablets, ≥ 300 mg QD (≥ 200 mg qd for subjects with moderate renal impairment)
1694095|NCT01510145|Drug|Travoprost 0.004% BAK-free|Containing Polyquad (PQ) preservative
1694096|NCT01510132|Drug|Travoprost/timolol fixed combination (Travacom)|Commercially-marketed drug for the treatment of open-angle glaucoma or ocular hypertension
1694097|NCT01510119|Drug|Hydroxychloroquine|
1694098|NCT01510119|Drug|RAD001|
1694099|NCT01510093|Drug|Insulin Aspart 100 IE/ml|1.5 IE/hour/subject/visit. Each vist takes 10 hours
1694100|NCT01510080|Behavioral|Computer-assisted live supervision|8 BITE sessions, 4 video-based sessions (each 50 minutes) during treatment of 2 patients
1694101|NCT01510080|Behavioral|Delayed video-based supervision|12 video-based sessions (each 50 minutes) during treatment of 2 patients
1694102|NCT01510041|Other|Inspiratory muscle training|A group will be associated with inspiratory muscle training (GTMI). The inspiratory muscle strength training will be done in the POWERbreathe ®, and the patient will breathe for two minutes, seven times with one minute rest between them, with 15% MIP, the first week, then, increased 5-10% to reach 60% of the initial MIP after four weeks. After the first month, every fifteen days the charge will be adjusted to 60% of the new value of MIP. The breathing pattern will remain free
1694103|NCT01510041|Other|Respiratory exercise|Specific exercise program for mobility and biomechanics of the rib cage, as exercises of the trunk and upper limbs, and stretching of large muscle groups of the trunk.
1694104|NCT01510028|Biological|Recombinant human arylsulfatase A|6 patients treated with HGT-1110 EOW by IT injection
1694105|NCT01510015|Drug|Risperidone|variable dose
1694106|NCT01510002|Procedure|Total thyroidectomy|Extracapsular total thyroidectomy
1694107|NCT01510002|Procedure|Total thyroidectomy + prophylactic central neck dissection|Extracapsular total thyroidectomy plus prophylactic central neck dissection
1694108|NCT01509976|Other|triclosan/triclocarban-containing personal care products|Subjects will be randomly assigned to one of two arms with either triclosan/triclocarban-containing personal care products or products without triclosan/triclocarban. After 5 months, each subject will cross over to the other arm.
1694109|NCT01509963|Other|no intervention : measure of score|To provide probability of non sentinel lymph node metastasis in case of metastatic lymph node according to MSKCC nomogram and Tenon score.
1694110|NCT01509950|Procedure|Staples|Staples for closure of cesarean section skin incision
1694111|NCT01509950|Procedure|Prolene non-absorbable sutures|Prolene non-absorbable sutures for closure of cesarean skin incision
1694112|NCT01509950|Procedure|Absorbable Sutures|Absorbable sutures for closure of cesarean skin incision
1694113|NCT01509937|Device|body bioimpedance spectroscopy device|Name of the device is BCM from Fresenius Medical Care D GmbH
1694114|NCT01509937|Device|Device|participants in control arm will not receive BCM measurement.
1694115|NCT01509924|Other|Physical activation on Prescription|The advice on physical activity is patient oriented and based on FYSS (FYSS is a information bank that summarizes the up-to-date scientific knowledge on how to prevent and treat various diseases and conditions using physical activity). An individual prescription on physical activity is issued. The prescription form reminds of an ordinary drug prescription and provides specified types of physical activities including intensity, frequency and duration of the respective activities. The prescribed physical activity could be either self-monitored or organized by public physical activity organizations.
1750130|NCT00193440|Drug|CVP|
1694121|NCT01509859|Device|PFNA proximal femur nail device (Synthes)|"synthes PFNA proximal femur nail device"
1694122|NCT01509859|Device|INTERTAN proximal femur nail device (Smith&Nephew)|"Smith&Nephew INTERTAN proximal femur nail device"
1694123|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^8 vp/mL Sf2aWC administered on Day 0
1694124|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^9 vp/mL administered on Days 0, 28, and 56
1694125|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^10 vp/mL administered on Days 0, 28, and 56
1694126|NCT01509846|Biological|Shigella flexneri 2a whole cell killed vaccine (Sf2aWC)|2.6±0.8 x 10^11 administered on Days 0, 28, and 56
1694127|NCT01509833|Drug|rFSH|Administration of rFSH for ovarian stimulation.
1694128|NCT01509833|Drug|hCG|Administration of late follicular low dose hCG(100IU) for ovarian stimulation.
1694129|NCT01509833|Drug|hCG|Administration of late follicular low dose hCG(200IU) for ovarian stimulation.
1694130|NCT01509807|Drug|IV morphine sulfate or Sponsor-approved equivalent|Patients enrolled in this group will receive IV morphine sulfate or Sponsor-approved equivalent via a patient-controlled analgesia (PCA) pump, as needed.
1694131|NCT01509807|Drug|EXPAREL|Patients enrolled in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
1694132|NCT01509794|Other|Low Valence|Participants in the low valence condition will participate in two photo-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
1694133|NCT01509794|Other|High Valence|Participants in the low valence condition will participate in two video-based simulations: first, an orientation to become familiar with the interface, and then a clinical simulation. Afterward, they will complete a written debriefing followed by an verbal debriefing with a study investigator. They will complete all activities while having their heart rate and galvanic skin response monitored using non-invasive methods.
1694134|NCT01509781|Procedure|Insertion of suction drain(s) following mastectomy|One suction drain (16 Ch Redon drain) following simple mastectomy and two following modified radical mastectomy.
1694135|NCT01509781|Procedure|Adaptive skin sutures.|Subcutis of skin flaps of the axilla and the wound edges are adapted to the chest wall and pectoralis major muscle by 8 to 24 stitches (depending on the wound surface of the breast and axilla) using 3.0 absorbable sutures, in a distance of 4-5 cm from each other in a chessboard pattern. The wound is then closed with 3.0 running subcutaneous sutures and 4.0 intracutaneous stitches. Compressive dressing is applied on the chest in the first 12-24 hours after surgery.
1694136|NCT01509755|Drug|placebo|Once daily injection, under the skin (s.c.) for 12 weeks
1694137|NCT01509755|Drug|liraglutide|Once daily injection, under the skin (s.c.) for 12 weeks
1694138|NCT01509755|Drug|glimepiride|Tablets administered orally according to current treatment guidelines. Dose adjusted according to the glycaemic response
1694139|NCT01509742|Drug|liraglutide|Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
1694140|NCT01509742|Drug|placebo|Single dose injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement
1694141|NCT01509729|Procedure|Sham operation|A randomized group of patients received a placebo patch. As a supplement, each patient was given a dose of morphine, as required.
1694142|NCT01509729|Procedure|Knee arthroscopic surgery|A randomized group of patients was given small patches with active 5% lidocaine.
1694143|NCT01509703|Procedure|High flow therapy|Each patient is treated with nasal high flow at different flow rates (15, 30, 45L/min). The order of flow rates is randomized. Each flow rate will be used for 15 minutes. A wash out time of ten minutes is planned after each phase, during which the patient uses his his individual oxygen flow.
1694144|NCT01509690|Other|Multidisciplinary, intensive and collaborative care|"No specific study drugs, devices or procedures are involved.
Subjects will be seen in a multidisciplinary, intensive management clinic involving a renal physician, a clinical pharmacist trained in renal pharmacotherapy and a renal coordinator. The main aim of this clinic is to provide multidisciplinary, intensive and consistent care in the first 3 to 4 months after HD initiation to streamline the management of the patients. Specific objectives of this clinic include providing patients with educational materials and information to enable a better understanding of their disease process, providing uniform anemia and renal bone disease management, increasing permanent HD access [arteriovenous (AV) fistula or graft] placement, increasing transplant referrals, providing suitable vaccinations to all patients, as well as reducing hospitalizations for fluid overload, uncontrolled hypertension and anemia-related complications."
1955745|NCT03091569|Other|Vitamin K Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
1955746|NCT03091569|Other|Placebo Cream|To be applied topically 3 times in 24 hours (approximately at 8 and 16 hours post initial application) from the appearance of the erythema.
1694147|NCT01509664|Behavioral|Discount intervention|50% discount on selected fruits and vegetables at participating supermarket
1694148|NCT01509651|Drug|Sugammadex|After the induction of anaesthesia, monitoring neuromuscular function is initiated and performed continuously using the TOF-Watch SX (Organon Ireland Ltd, Ireland) at the thumb. Repetitive train-of four (TOF) stimulation is applied every 15 s at the ulnar nerve until the end of anaesthesia, at least until recovery of the TOF ratio to 0.9 after administration of sugammadex. Each patient receives a single IV bolus dose of rocuronium 0.6 mg kg-1, after which tracheal intubation is performed. Maintenance doses of rocuronium 0.1 mg kg-1, are permitted as required and administered at the reappearance of the second twitch in the TOF. On reappearance of the second twitch at the end of surgery, patients receive a single IV bolus dose of sugammadex, 2.0 mg kg-1, for reversal.
1695205|NCT01501903|Procedure|Standard|FNA in a single plane
1694149|NCT01509638|Drug|Group 1 Standard of Care|Patients in this group will receive IV morphine sulfate or Sponsor-approved equivalent via PCA pump, as needed.
1694150|NCT01509638|Drug|Group 2 EXPAREL|Patients in this group will receive 266 mg EXPAREL diluted with preservative-free 0.9% normal saline to a total volume of 30cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
1694151|NCT01509625|Drug|Fulvestrant|It is an observacional retrospective study to asses the results of the administration of fulvestrant in the routine clinical practice.
1694152|NCT01509612|Drug|Additive classical homeopathy|Homeopathic remedies every 2 to 3 months
1694153|NCT01509612|Drug|Homeopathic Placebo globules|Homeopathic placebo globules every 2 to 3 months
1694154|NCT01509599|Procedure|Cryotherapy: Cooling gel wrap|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy: cooling gel wrap during the home-based intervention
1694155|NCT01509599|Procedure|Usual care|Patients will wear compression stockings (provided), elevate legs on an elevator pillow (provided) and apply the sham cyrotherapy wrap (sham) during the home-based intervention
1694156|NCT01509586|Drug|Potentially Reduced Exposure Product (PREP): a smokeless, spit-free tobacco product|The PREP Group will be given a sample supply of a PREP product that is already on the market. It is unclear if it is safer than cigarettes, and that is why it is classified as a Potentially Reduced Exposure Product. It provides both nicotine and tobacco in the form of a pouch that can be thrown away after used. Unlike chewing tobacco, there is no need for spitting with this product. There are multiple flavors and participants will have his/her choice of preferred flavor. This group will be asked to sample the product and use it in several ways, but whether a participant uses the product or not is up him/her.
1694157|NCT01509573|Behavioral|Family Strengthening Intervention in Rwanda (FSI-R)|"Core components of the FSI-R are derived from the FBPI theoretical framework, and were chosen to address key risk factors identified in qualitative data. The FSI-R holds separate preliminary meetings with caregivers and children to prepare for a larger family meeting. In these modules, the interventionist helps caregivers and children prioritize concerns or key messages that they most want to share with the other party. Role play and discussions are used to impart improved parenting and communication skills. In the family meetings, children and caregivers share their concerns with one another and develop a shared family narrative, which integrates past events into a singular story with shared goals and a future orientation. These family modules also discuss the services and supports (formal and non-formal resources) that the family can engage with in order to achieve their shared goals.
8-12 weeks for 1-2 hours per week, depending on each family's pace and coverage of the material."
1694158|NCT01509560|Drug|Everolimus|"Start therapy: 2x 0.75 mg/day (morning and evening) to receive a serum trough level of 3 - 5 ng/ml. First evaluation of Everolimus serum level 3-7 days after start of therapy, second 7 days later, subsequently on study weeks 4, 6, 9, 12 and 16. Dose has to be adapted if trough level exceeds 5 ng/ml. As soon as Everolimus trough level exceeds 3 ng/ml after start of therapy, calineurine inhibitors (e.g. cyclosporine) will be reduced: halve of the dose for the 3 consecutive days, withdrawal on day 4.
Prednisone will be reduced accordingly (a 22 weeks scheme is recommended) Everolimus will be used for 98 days or 14 weeks, as described above Everolimus therapy might be extended (independently of the study) if the patient suffering from milde chronic GvHD (according to NIH criteria) or milde PTOLD and lung function score is not reduced more than 25% since begin of Everolimus therapy Everolimus will be reduced to 50% of the dosage for 2 weeks before withdraw (normally weeks 15 and 16"
1694159|NCT01509547|Drug|Varenicline|participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
1694160|NCT01509547|Drug|placebo|participants >55 kg will take varenicline/placebo 0.5 mg once daily for 3 days, titrated to 0.5 mg twice daily for 4 days, titrated to 1 mg twice daily thereafter. Participants ≤55 kg will take varenicline/placebo 0.5 mg once daily for 7 days, titrated to 0.5 mg twice daily thereafter.
1694161|NCT01509521|Drug|Ephedrine|An infusion with a maximum of 3 mg/minute for maximum 60 minutes or if sideeffects develope.
1694162|NCT01509521|Drug|Phenylephrine|An infusion of maximum 4 mg/hour for maximum 60 minutes.
1694163|NCT01509508|Drug|Immediate ARV treatment initiation with TDF/FTC/EFV|"All HIV-infected adults will be offered ART regardless of their immunological and clinical staging.
The first line regimen proposed will be Atripla (R), a fixed dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(FTC/TDF/EFV). The dosing will be 1 tablet OD."
1694164|NCT01509508|Other|South African recommendation guided ARV (TDF/FTC/EFV) initiation|"HIV-infected adult participants will be eligible for ART as per the South African guidelines (August 2011) if:
CD4 count ≤ 350 cells/mm3 irrespective of clinical symptoms
WHO clinical stage 3 or 4 irrespective of CD4 count
MDR or XDR TB The first line regimen proposed will be Atripla (R), a fixes dose combination containing tenofovir disoproxil (245 mg)/emtricitabine (200 mg)/efavirenz (600 mg)(TDF/FTC/EFV). The dosing will be 1 tablet OD."
1694165|NCT01509495|Device|Akern BIA101 and Custom Device|Impedance Measurement every 4 hours
1694166|NCT01509482|Other|blood samples|blood samples to test for primary and secondary outcome measures
1694167|NCT01509482|Other|Blood samples|IR Cholesterol HDL LDL Fasting Glucose Triglycerides
1694168|NCT01509469|Dietary Supplement|Casein|Ileal infusion of low dose casein (5 gram)
1694169|NCT01509469|Dietary Supplement|Casein|Ileal infusion of high dose casein (15 gram)
1694170|NCT01509469|Dietary Supplement|Sucrose|Ileal infusion of low dose sucrose (4.3 gram)
1694171|NCT01509469|Dietary Supplement|Sucrose|Ileal infusion of high dose sucrose (12.9 gram)
1694172|NCT01509469|Other|Saline|Ileal infusion with saline (180mL in total)
1694173|NCT01509469|Dietary Supplement|Safflower oil|Ileal infusion with safflower oil (6gr safflower oil in water)
1694174|NCT01509456|Dietary Supplement|Potassium Bicarbonate|90 mmol daily, effervescent tablets 30 mmol diluted in 200 ml tab water supplemented three times a day together with the main meals for 21 days of HDT- bedrest
1694175|NCT01509443|Other|Exercise|Participants will perform 2-4 sessions of the prescribed exercise every day (One session: deep breathing 5-10 times; upper body stretching 5-10 times).
1694176|NCT01509430|Other|Progressive Resistance Exercise Training|12 weeks of Progressive Resistance Exercise Training followed by 12 weeks of self chosen training
1694177|NCT01509430|Other|Progressive Resistance Exercise Training|12 weeks of self chosen training followed by 12 weeks of progressive resistance exercise training
1694178|NCT01509417|Other|ad lib feedings after pyloromyotomy|ad lib feedings after pyloromyotomy
1694179|NCT01509417|Other|FLAP diet after pyloromyotomy|FLAP diet after pyloromyotomy
1694180|NCT01509404|Drug|Valganciclovir|Valcyte per package insert guidelines for 200 days post transplant
1694181|NCT01509404|Biological|CMV hyperimmune globulin|100 mg/kg administered at 90 days, 120 days, and 180 days post-transplant
1694182|NCT01509404|Drug|Valganciclovir|valganciclovir per package insert guidelines for prophylaxis against CMV infection for 200 days post-transplant
1694183|NCT01509391|Drug|keyhole-limpet hemocyanin|Subcutaneous administration keyhole-limpet hemocyanin
1694184|NCT01509365|Drug|clopidogrel|2 tablets of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
1694185|NCT01509365|Drug|clopidogrel|1 tablet of 75 mg clopidogrel for one month followed by standard 75 mg clopidogrel for 3 months to one year.
1694186|NCT01509352|Procedure|esophageal stitches during fundoplication|placement of esophageal stitches with fundoplication
1694187|NCT01509352|Procedure|no esophageal stitches placed during fundoplication|no esophageal stitches are placed during the fundoplication procedure
1694188|NCT01509339|Drug|Vancomycin|250 mg vancomycin in 5cc sterile water will be inhaled once. Patients will use a Pari Sprint nebulizer and Pari Vios compressor as the delivery system.
1694191|NCT01509313|Device|hysteroscopic morcellator (TruClear)|It can be used to treat uterine pathology with a mechanical cutting edge
1694192|NCT01509313|Device|Bipolar Electrical resectoscope (Versapoint)|It can be used to treat uterine pathology with an electrical cutting edge
1694193|NCT01509300|Biological|anti-thymocyte globulin|On days -10 to -9
1694194|NCT01509300|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
1694195|NCT01509300|Radiation|Total body irradiation|2Gy D-6 to D-4
1694196|NCT01509300|Drug|Fludarabine|30mg/M2 once daily IV on days -8 to -4
1694197|NCT01509300|Drug|cyclophosphamide|60 mg/kg IV on day-3 and -2
1694198|NCT01509300|Drug|Tacrolimus|begin on 0
1694199|NCT01509300|Drug|Mycophenolate mofetil|begin on 0
1694200|NCT01509300|Drug|Rituximab|375mg/m2 on day +21
1694201|NCT01509274|Biological|Plasma|3 ml plasma injected once into the plantar fascia
1694202|NCT01509274|Biological|Saline|3 ml of saline injected once into the plantar fascia
1694203|NCT01509274|Other|Physiotherapy + heel cap|Physiotherapy three times a day for 8 weeks. Heel caps until symptoms are gone
1694204|NCT01509261|Drug|Ilaprazole|20mg/Tap, QD
1694205|NCT01509261|Drug|Lansoprazole|30mg/Tap, QD
1694206|NCT01509235|Procedure|Chest physiotherapy|The whole exercise session consisted of three short period of exercise of 5 minutes each entirely done under the physiotherapists' supervision (FA).
1694207|NCT01509222|Behavioral|Personalized nutrition counseling|
1694208|NCT01509209|Drug|Pseudoephedrine / Levocetirizine|tablet, BID everyday
1694209|NCT01509196|Drug|HIP0901 / Lipidilsupra|HIP0901 capsule(Fenofibric acid, 135mg) / Lipidilsupra tablet(Fenofibrate, 160mg)
1694210|NCT01509183|Device|Asthmapolis System|The Asthmapolis system works through the provision of information to patients and their providers. With the Asthmapolis device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Asthmapolis where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
1694211|NCT01509157|Device|MDRS System (Remote & Safety diabetes management system)|Participants will be using the MDRS system combined with their regular Continuous Glucose Monitoring during nightime for 2 weeks. The MDRS will allow the supervising personal to get real time remote data of glucose level and to alarm the patients and intervene in cases such as pending hypoglycemia, long standing hyperglycemia or technical faults
1694212|NCT01509157|Procedure|Continuous Glucose Monitoring|Participants will be using their regular Continuous Glucose Monitoring during nightime for 2 weeks, without using the MDRS remote control system
1694213|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 1 Nasal vaccine - Low-dose (20 µg in 40 µL) IM vaccine (200 µg in 400 µL)
1694214|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 2 Nasal vaccine - Mid-dose (100 µg in 200 µL) IM vaccine (200 µg in 400 µL)
1694215|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 3 Nasal vaccine - Full-dose (200 µg in 400 µL) IM vaccine (200 µg in 400 µL)
1694216|NCT01509144|Biological|EN41-FPA2 HIV vaccine|Group 4 Nasal Placebo - 400 µL IM vaccine (200 µg in 400 µL)
1694217|NCT01509144|Biological|Na Cl Placebo vaccine|Group 5 Nasal placebo - 40 µL in Cohort 1 / 200 µL in Cohort 2 IM placebo (400 µL)
1694218|NCT01509131|Drug|2L PEG-CS plus bisacodyl|Patients will be asked to take 2L of Lovolesse and bisacodyl (10-20 mg according to patient bowel habit)
1694219|NCT01509131|Drug|2L PEG-ASC|Patients will asked to take PEG-ASC according to labeling instructions
1694220|NCT01509105|Biological|13-valent pneumococcal vaccine|0.5mL IM (Intramuscular administration) as per recommended schedule
1694221|NCT01509092|Procedure|vitrectomy surgery|"pars plana vitrectomy +internal limiting membrane peeling done immediately after the identification of the macular hole"
1694222|NCT01509079|Drug|Vitamin D3|Cholecalciferol capsule, 4000IU, daily for 6 months
1694223|NCT01509079|Drug|Vitamin D3|cholecalciferol capsule, 600 IU, daily for 6 months
1694224|NCT01509066|Other|Diet|Dietary approaches for PCOS
1694264|NCT01508858|Drug|levonorgestrel / ethinylestradiol|One single oral tablet after the liraglutide or placebo dose administration at the end of each treatment period
1694265|NCT01508845|Dietary Supplement|cholecalciferol|800 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
1694225|NCT01509053|Drug|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.
Number of injections: 6. Participants have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2014."
1694226|NCT01509053|Drug|Oral aripiprazole|Oral aripiprazole tablets 10-15 mg/day (up to 30 mg/day).
1694227|NCT01509040|Other|Standard Care|"Triple-lumen central venous catheter inserted for pressure monitoring. All patients to receive 500-mL bolus of intravenous crystalloid every 30 minutes to achieve central venous pressure of 8 to 12 mm Hg; vasopressors if mean arterial pressure less than 65 mm Hg; and vasodilators if mean arterial pressure is 90 mm Hg or above.
Initiation and maintenance of therapeutic hypothermia, target core temperature of below 34°C via standard external cooling techniques.
Percutaneous coronary intervention performed as soon as feasible in patients with ST elevation or left bundle branch block on initial ECG.
Serum biochemistry (including sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate) monitored every 6 hours."
1694228|NCT01509040|Device|Low Volume Hemofiltration|"Patients will receive isovolemic HF at a blood flow rate of 250 mL/min and ultrafiltration rate of 45 mL/kg/h for 48 hours. Initial replacement solution will be Prismasol BGK4/2.5. 3.1mg/dL phosphate (1.0 mmol/L) added to each bag. Replacement fluid adjusted as required based on chemistry values for sodium, potassium, bicarbonate, glucose, calcium, phosphate, magnesium and lactate.
Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution used. HF 1400 (i.e. polysulfone -based membrane) filters used throughout study. Hemofilter changed every 6 h after initiation of HF, and as required."
1694229|NCT01509040|Device|High Volume Hemofiltration|"Patients allocated to high volume HF will receive HF at 250 mL/h blood flow rate and 90 mL/kg/h ultrafiltration rate for 48 hours. All other care will be identical to that provided in the low volume HF group.
Vascular access for HF will be via an 11.5-F, double-lumen venous catheter in a central vein. The hemofiltrate will be replaced by fluid infused into the bloodstream before (i.e. predilution) and after (i.e. postdilution) the filter. A fixed ratio of 80:20 predilution:postdilution will be used. HF 1400 (i.e. polysulfone -based membrane) filters will be used throughout the study. The hemofilter will be changed every 6 h after initiation of HF, and otherwise as required."
1694230|NCT01509027|Behavioral|education by DVD|Information on detrimental conseqences of hyperphosphatemia is presented on DVD
1694231|NCT01509027|Behavioral|Standard care|standard care
1694232|NCT01509027|Behavioral|Education by DVD and dietician|Information on detrimental conseqences of hyperphosphatemia is presented on DVD and individual dietary counseling is given by dieticican
1694233|NCT01509014|Behavioral|CPATCH intervention to support statin adherence|Routine identification of new statin users (first year of therapy), consistent assessment of barriers to adherence at every dispensation for these patients, reassurance about efficacy and safety, and proactive response to identified adherence barriers.
1694234|NCT01509001|Drug|Metformin|750 to 2500 mg/day, two times a day during 4 months
1694235|NCT01509001|Drug|Glimepiride|1 to 8 mg/day , two times a dya, during 4 months.
1694236|NCT01508988|Drug|ONO-9054|Eye drops 0.3 µg/mL both eyes on Day one
1694237|NCT01508988|Drug|ONO-9054|Eye drops 1 µg/mL both eyes on Day one
1694238|NCT01508988|Drug|ONO-9054|Eye drops 3 µg/mL both eyes on Day one
1694239|NCT01508988|Drug|ONO-9054|Eye drops 10 µg/mL both eyes on Day one
1694240|NCT01508988|Drug|ONO-9054|Eye drops 20 µg/mL both eyes on Day one
1694241|NCT01508988|Drug|ONO-9054|Eye drops 30 µg/mL both eyes on Day one
1694242|NCT01508988|Drug|ONO-9054|Matched-placebo eye drops dosed in the same manner as ONO-9054 in both eyes on Day one
1694243|NCT01508975|Other|White Rice, Brown Rice, Glucose|white rice, brown rice, glucose
1694244|NCT01508949|Drug|liraglutide|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
1694245|NCT01508949|Drug|placebo|Once daily dosing of 0.6 mg for 8 weeks, injected subcutaneously
1694246|NCT01508936|Drug|Reslizumab|Reslizumab administered at a dosage of 3.0 mg/kg by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
1694247|NCT01508936|Drug|Placebo|Matching placebo administered by intravenous (iv) infusion by qualified study personnel every 4 weeks for 16 weeks (for a total of 4 doses).
1694248|NCT01508923|Drug|liraglutide|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
1694249|NCT01508923|Drug|placebo|6 mcg/kg injected subcutaneously daily in each treatment period in random order. In total, subjects are treated 9-10 days
1694253|NCT01508897|Drug|liraglutide|Single dose administered as subcutaneous injection
1694254|NCT01508897|Drug|liraglutide|Single dose administered as subcutaneous injection
1694255|NCT01508884|Biological|influenza vaccine|single dose of intradermal 15 mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
1694256|NCT01508884|Drug|Imiquimod|pretreatment with topical imiquimod cream to the injection site before vaccination
1694257|NCT01508884|Biological|influenza vaccine|single dose of intradermal 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
1694258|NCT01508884|Drug|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
1694259|NCT01508884|Biological|influenza vaccine|single dose of intramuscular 15mcg non-adjuvanted 2011/2012 trivalent influenza vaccine
1694260|NCT01508884|Drug|Aqueous cream|pretreatment with topical aqueous cream to the injection site before vaccination
1694261|NCT01508871|Other|Observational study, no intervention|No intervention
1694262|NCT01508858|Drug|liraglutide|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
1694263|NCT01508858|Drug|placebo|Administered with daily subcutaneous injections for approximately 3 weeks in each treatment period in random order
1751991|NCT00208169|Drug|Aripiprazole|
1694266|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
1694267|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU vitamin D3, 1 dose
1694268|NCT01508845|Dietary Supplement|cholecalciferol|50,000 IU vitamin D3, 1 dose; 800 IU deuterated vitamin D3, 1 dose
1694269|NCT01508832|Drug|Lidocaine Digital Nerve Block|Lidocaine 1% Digital Nerve Block (2 cc
1694270|NCT01508832|Drug|Bupivacaine Digital Block|Bupivacaine 0.25% Digital Block (2 cc)
1694271|NCT01508819|Other|recommendations to admit to ICU all the patients included|recommendations to emergency and ICU physicians to admit to ICU all the patients included in the trial
1694272|NCT01508806|Drug|liraglutide|Single dose of 0.75 mg, administered as a subcutaneous injection
1694273|NCT01508793|Behavioral|Optimize Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for the duration of the two month intervention
1694274|NCT01508780|Device|St Jude Medical C7 Dragonfly Optical Coherence Tomography (OCT)|All subjects will have OCT and IVUS imaging during their right heart catheterization.
1694275|NCT01508780|Device|Boston Scientific Intravascular Ultrasound|All subjects will have OCT and IVUS imaging during their right heart catheterization.
1694276|NCT01508767|Other|Removal of urethral catheter|All participants are to have a urethral catheter placed following successful placement of an epidural catheter for analgesia prior to undergoing colorectal resection. Following urethral catheter placement participants will be randomly assigned to either the experimental arm or the control arm. Participants assigned to the experimental arm will have their urethral catheters removed at 48 hours following surgery. Participants assigned to the control group will have their urethral catheters removed within 12 hours of withdrawal of the epidural infusion, as is standard practice in our institution.
1694277|NCT01508754|Procedure|Continuous positive airway pressure treatment|Treatment with CPAP for 6 months, pressure will be titrated during a second polysomnography.
1694278|NCT01508741|Dietary Supplement|5-Aminolevulinic Acid (5-ALA)|5-ALA 50 mg. p.o. daily capsules taken over 6 weeks.
1694279|NCT01508741|Dietary Supplement|Placebo|Daily p.o. capsule of similar shape and color to active ingredient 5-ALA capsule taken over 6 weeks.
1694280|NCT01508728|Device|ORTHOSENS orthosis|with active vibration
1694281|NCT01508728|Device|ORTHOSENS orthosis|with placebo vibration
1694282|NCT01508715|Other|Shoulder resistive exercise|"Both groups will perform the seated full can, sidelying internal rotation (IR), sidelying external rotation (ER) with towel roll, supine protraction at 120° of flexion, sidelying horizontal abduction, sidelying abduction, and seated pulley extension using resistance weights in the participant's pain-free shoulder motion. One group will complete only the eccentric portion of the exercise actively, the other will complete only the concentric portion actively. The treating physical therapist will reposition the weights to avoid active resistance occuring in the opposite direction of the desired intervention. Both groups will use 70% of their predicted one repetition maximum (1RM), progressing to 80% with 1RM reassessed and training weight adjusted every two weeks."
1694283|NCT01508702|Drug|lesinurad|Tablets, 400 mg QD
1694284|NCT01508702|Drug|Placebo|Tablets, Placebo QD
1694285|NCT01508689|Behavioral|Receive Kellogg's Nutri-Grain® cereal bars first|First three weeks of study: consume perceived usual diet; Second three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day; Third three weeks of study: consume perceived usual diet
1694286|NCT01508689|Behavioral|Receive Kellogg's Nutri-Grain® cereal bars second|First six weeks of study: consume perceived usual diet; Last three weeks of study: Receive 42 Kellogg's Nutri-Grain® cereal bars per person, consume 2 bars per day
1694287|NCT01508676|Drug|Pennsaid|
1694288|NCT01508676|Drug|Placebo (2.3% DMSO solution)|
1694289|NCT01508663|Device|Everolimus Eluting Stent or Zotalolimus Eluting Stent|Everolimus Eluting Stent(Xience V, Xience prime) Zotalolimus Eluting Stent(Endeavor-resolute, Resolute Integrity)
1694290|NCT01508663|Drug|ARB, CCB, ACE-inhibitor, statin, Nitrate, Antiplate etc.|one or two anti-platelet agents, beta-blockers, calcium channel blockers, nitrates, angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), and statin
1694291|NCT01508650|Behavioral|Usual care|Usual care control group
1694292|NCT01508650|Behavioral|Rehabilitation intervention|Multi-domain rehabilitation intervention
1694293|NCT01508637|Other|Diesel Exhaust|Freshly generated diesel exhaust, diluted to 300 micrograms/cubic meter. Exposures are two hours in duration.
1694294|NCT01508637|Other|Filtered Air|Sham exposure, identical to conditions of diesel exhaust exposure, but with only air filtered of particles and volatile organic compound gases
1694295|NCT01508637|Drug|Terazosin|2 mg by mouth, 90 minutes prior to exposure initiation
1694296|NCT01508637|Drug|placebo|capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
1694297|NCT01508624|Other|Interaction|Participants in this condition will interact with nurses during their surgery. The nurses will not touch the patient's hand during treatment as this intervention looks at interaction with another person, in the absence of tactile stimuli.
1694298|NCT01508624|Other|Music|Participants will be offered a choice of music to listen to from a selection at the clinic, they will also have the opportunity of bringing or selecting their own music which can be streamed from the internet. They will listen to the music through headphones
1694299|NCT01508624|Behavioral|Touch - stress balls|Participants will be provided with two stress balls which they will be encouraged to squeeze during their surgery and administration of the local anaesthetic
1694300|NCT01508624|Behavioral|DVD|participants will be given a choice of DVDs to watch during their procedure. A wall mounted screen will be positioned so that participants can comfortably view the screen during their procedure. they will listen to the accompanying audio through wireless headphones.
1694301|NCT01508611|Other|30% silver diammine fluoride|"The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
Anteroposterior toothbrushing technique will be explained to the children."
1694302|NCT01508611|Behavioral|Oral hygiene|With the patient's own brush, supervised brushing the erupting molar with fluoridated toothpaste will be guided using the cross-toothbrushing technique
1694303|NCT01508585|Behavioral|Telephone Based Cognitive Behavioral Therapy|6 sessions of Cognitive Behavioral Therapy (CBT), lasting approximately 60 minutes each.
1694305|NCT01508546|Procedure|axillary dissection|Conservative breast surgery with or without axillary dissection
1694306|NCT01508494|Drug|Galantamine|16 mg galantamine daily P/O
1694307|NCT01508494|Drug|placebo|placebo
1694308|NCT01508468|Drug|symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin)|Converting Enzyme inhibitor , Angiotensin II receptor antagonist, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin.
1694309|NCT01508468|Drug|experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab)|NIST and IV infusion of Rituximab 375mg/m² at day (1) and day (8)
1694310|NCT01508455|Drug|Dexmedetomidine|
1694311|NCT01508455|Drug|Midazolam|
1694312|NCT01508455|Drug|Fentanyl|
1694313|NCT01508455|Drug|Morphine|
1694314|NCT01508429|Other|placebo|4 placebo tablets (resembling misoprostol) administered sublingually
1694315|NCT01508429|Drug|Misoprostol|800mcg misoprostol (4 200mcg tablets administered sublingually)
1694316|NCT01508390|Radiation|CyberKnife Boost|21 Gy in 7 Gy per day, 3 fractions, Every other day
1694317|NCT01508377|Behavioral|Exposure for PTSD with cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003)
The long version of the PTSD treatment (including cognitive restructuring) can be divided into three phases.
First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.
Second phase - cognitive restructuring (4 essays) Again the participants write four texts, however, this time they go beyond mere descriptions and use their experiences to write a supportive letter to an imaginary friend who had been through the same experience.
Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
1694318|NCT01508377|Behavioral|Exposure for PTSD without cognitive restructuring|"The treatment lasts five weeks. During that time-frame, participants write ten texts for approximately 45 minutes, twice a week. Each time after having received two texts, the therapists provide feedback and further instructions, which are based upon the manual (Lange et al., 2003).
The short version of the PTSD treatment can be divided into only two phases. Compared to the long version the phase dealing with cognitive restructuring is excluded.
First phase - self-confrontation (4 essays) At the beginning the participants receive psychoeducation about the mechanisms of exposure before writing four essays about their emotionally most painful memories.
Third phase - parting (2 essays) In the third phase, two texts are written in the form of a letter to document the past in a worthy document."
1694319|NCT01508364|Drug|Sorafenib (Nexavar, BAY 43-9006)|Dosage according to label or at discretion of the attending physician
1694320|NCT01508338|Dietary Supplement|Placebo|An oral placebo capsule will be taken each morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
1694321|NCT01508338|Dietary Supplement|HMB|A placebo capsule will be taken each morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
1694322|NCT01508338|Dietary Supplement|Peak ATP and HMB|One capsule containing 400 mg of Peak ATP will be taken in the morning and three dosages of HMB gel, each providing 1 g of HMB, will be taken daily for a total of 3 g HMB per day for 12 weeks.
1694323|NCT01508338|Dietary Supplement|ATP|One capsule containing 400 mg of Peak ATP will be taken daily in the morning and three dosages of a placebo gel containing polydextrose will be taken 3 times daily for 12 weeks.
1694324|NCT01508325|Drug|Bisoprolol|Subjects will receive bisoprolol fumarate (Concor®) at a dose of 5 milligram (mg) once daily orally as sustained release (SR) tablets for a period of 4 weeks. The dose of bisoprolol will be escalated to 7.5 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 10 mg orally once daily for the next 4 weeks (Weeks 8 to 12), if clinic systolic blood pressure (SBP) was greater than or equal to (>=) 140 millimeters of mercury (mmHg) and/or diastolic blood pressure (DBP) was >=90 mmHg measured every 4 weeks.
1694325|NCT01508325|Drug|Metoprolol|Subjects will receive metoprolol succinate (Betaloc SR) at a dose of 47.5 mg once daily orally as SR tablets for a period of 4 weeks. The dose of metoprolol will be escalated to 71.25 mg orally once daily for next 4 weeks (Weeks 4 to 8) and to 95 mg orally once daily for the next 4 weeks (Weeks 8 to 12) if clinic SBP was >=140 mmHg and/or DBP was >=90 mmHg measured every 4 weeks.
1694326|NCT01508312|Drug|brentuximab vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with persistent abnormalities on FDG-PET/CT following 2 cycles of brentuximab vedotin will receive 2 cycles of augmented ICE. The first cycle of augmented ICE will be initiated 7-14 days after the last dose of SGN-35. FDG-PET/CT will be repeated within 7-14 days following the second cycle of augmented ICE. Stem cell mobilization can be performed following the first or second cycle of augmented ICE.
1694327|NCT01508312|Drug|Brentuximab Vedotin (SGN-35)|Patients will receive 2 cycles of weekly brentuximab vedotin, 1.2mg/kg on days 1, 8, and 15 of each 28 day cycle. FDG-PET/CT will be repeated after 2 cycles of treatment within 1 week of the last dose of cycle 2. Patients with pre-treatment positive bone marrow biopsies will have repeat bone marrow biopsies if the PET scan is negative. Patients with normalization of FDG-PET/CT and negative bone marrow biopsies following 2 cycles of brentuximab vedotin will undergo stem cell mobilization in preparation for ASCT.
1694328|NCT01508299|Procedure|skin test|skin test with the Suspected raw food
1694329|NCT01508286|Drug|Telaprevir + peginterferon alfa + ribavirin|During the first 12 weeks of the early access program, all eligible patients will receive telaprevir 750 mg every 8 hours in combination with peginterferon-alfa and ribavirin.
1694330|NCT01508286|Drug|peginterferon alfa + ribavirin|Patients with severe fibrosis who are treatment naïve or prior treatment relapsers will subsequently be treated with peginterferon-alfa and ribavirin alone for either an additional 12 or 36 weeks.
1751992|NCT00208182|Drug|Risperidone|
1694331|NCT01508286|Drug|peginterferon alfa + ribavirin|Previously treated patients with prior partial or null response, or who had viral breakthrough, with severe fibrosis and all subjects with cirrhosis will subsequently be treated with peginterferon-alfa and ribavirin alone for an additional 36 weeks.
1694332|NCT01508273|Behavioral|Exercise Program|Resistance training bands, guidebook, and pedometer given at baseline visit. Internet-based curriculum access given to teach goal-setting, overcoming barriers to physical activity, self-management strategies, and time-management skills. Access given website that will allow participant to track exercise behavior and help set goals.
1694333|NCT01508273|Behavioral|Website|Website access given that allows participant to track exercise behavior and help to set goals.
1694334|NCT01508273|Behavioral|Exercise DVD|Participants receive chair-based exercise DVD. Participants in this chair-based exercise program for a total of 8 weeks.
1694335|NCT01508273|Behavioral|Survey|"Exercise Intervention Program Group : Survey completion monthly about attitudes and beliefs about physical activity.
Sedentary Behavior and Dietary Intervention Group: Survey completion monthly attitudes and beliefs about sedentary behavior and dietary intake."
1694336|NCT01508273|Behavioral|Self-Report Assessments|Self-report assessments given about quality of life and physical assessments of balance and coordination.
1694337|NCT01508260|Procedure|Aquapheresis|Participant connected to aquapheresis pump through an intravenous (IV) catheter placed in forearm. Average treatment is about 24 hours but can extend up to 7 days.
1694338|NCT01508260|Drug|Furosemide|20-40 mg by vein every 8 hours as indicated for optimal diuresis to achieve negative fluid balance or 0.5 to 5 mg per hour by continuous infusion.
1694339|NCT01508247|Biological|inactivated vaccine (Vero Cell) against EV71|inactivated vaccine (vero cell) against EV71, 320U /0.5ml, two doses, on day0, 28
1694340|NCT01508247|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, on day0, 28
1694341|NCT01508221|Drug|Trental|400 mg tid starting first day after last radiosurgery treatment and continuing for 6 months
1694342|NCT01508221|Dietary Supplement|Vitamin E|400IU twice daily starting the first day after last radiosurgery treatment and continuing for 6 months
1694343|NCT01508208|Other|Hypertensive disorder of pregnancy|Collection of a random sample of urine for a spot test and a 24 hour urine collection for a 24 hour urine protein.
1694344|NCT01508195|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
1694345|NCT01508195|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
1694346|NCT01508195|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
1694347|NCT01508195|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
1694348|NCT01508195|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 100, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
1694349|NCT01508195|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
1694350|NCT01508182|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 1.
1694351|NCT01508182|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1.
1694352|NCT01508182|Drug|Canagliflozin/metformin IR FDC tablets|Type = exact number, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2.
1694353|NCT01508182|Drug|Canagliflozin tablets|Type = exact number, unit = mg, number = 300, form = tablet, route = oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period 2.
1694354|NCT01508182|Drug|Metformin IR tablets|Type = exact number, unit = mg, number = 500, form = tablet, route = oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
1694355|NCT01508182|Drug|Canagliflozin/metformin IR FDC tablets|Type = 2, unit = mg, number = 50/500, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1.
1694356|NCT01508169|Device|Foot orthosis (Orthotics Unit of the Clinical Hospital of UNICAMP)|Custom foot orthoses made of ethylene-vinyl acetate (EVA) with medial arch supports and metatarsal pads (supporting the diaphysis of the second to fourth metatarsals) that were manufactured by the Orthotics and Prostheses Unit of the Clinical Hospital of UNICAMP.
1694357|NCT01508156|Drug|IDX719|IDX719 liquid suspension (1 - 100 mg) taken by mouth.
1694358|NCT01508156|Drug|Placebo|Placebo liquid suspension matching IDX719 taken by mouth.
1694359|NCT01508143|Drug|Misoprostol 400 micrograms|Misoprostol 400 micrograms each 6 hours for 8 dose
1694360|NCT01508143|Drug|Misoprostol 800 micrograms|Misoprostol 800 micrograms each 12 hours for 4 doses
1694361|NCT01508117|Drug|Axitinib|5 mg twice daily starting 21 days after resection and continuing until progression or unacceptable toxicity
1694362|NCT01508117|Radiation|Radiation Therapy|45 Gy in 15 fractions starting after 28 days of Axitinib monotherapy
1694363|NCT01508104|Drug|BEZ235|dose escalation 400mg- 1000mg per day
1694364|NCT01508104|Drug|Everolimus|dose escalation 2.5 to 5 mg per day
1694407|NCT01507805|Device|EA preconditioning|EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)with electrical stimulation(5—30 Hz，2．34—6．24 mA，30 min)for 5 consecutive days before surgery
1694436|NCT01507584|Device|SENSIMED Triggerfish|Comparison of fluctuation of Intraocular pressures with different class of drugs
1695206|NCT01501903|Procedure|Fanning|FNA in multiple planes
1694367|NCT01508065|Device|Glucometer GM-205|The study procedure consists of two days trial. Each day consists of 4-6 hours, during which, hyper and hypoglycaemic clamp will be done. The first day will be used to calibrate the non-invasive Glucometer GM-205 for the specific patient.. The calibration will be done using the hexokinase assay (YSI 2300 STAT Plus) from the venous. During the second day, hyper and hypo glycemic clamp will be done and the results of blood glucose level reading from the non-invasive
1694368|NCT01508052|Device|sequential compression device|applying sequential compression device during the surgery
1694369|NCT01508052|Device|elastic stockings|applying elastic stockings during the surgery
1694370|NCT01508039|Other|Chitin Micro Particle|"The total spray volume for each application is 0.4 ml equivalent to a total single-dose for chitin of 2 mg (0.5 mg per 0.1 ml spray).
A total single-dose for LPS, of 2 mg of endotoxin from Enterobacter agglomerans (0.5 mg per 0.1 ml spray)"
1694371|NCT01508026|Drug|Nebivolol and Valsartan 1|Fixed Dose Combination Nebivolol 5 mg and Valsartan 80 mg, oral administration, then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration
1694372|NCT01508026|Drug|Nebivolol and Valsartan 2|Fixed Dose Combination Nebivolol 5 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 10 mg and Valsartan 320 mg, oral administration
1694373|NCT01508026|Drug|Nebivolol and Valsartan 3|Fixed Dose Combination Nebivolol 10 mg and Valsartan 160 mg, oral administration then dose doubled at Week 11 to Fixed Dose Combination Nebivolol 20 mg and Valsartan 320 mg, oral administration
1694374|NCT01508026|Drug|Nebivolol 1|Nebivolol Monotherapy 5 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 10 mg, oral administration
1694375|NCT01508026|Drug|Nebivolol 2|Nebivolol Monotherapy 20 mg, oral administration, then dose doubled to at Week 11 to Nebivolol Monotherapy 40mg, oral administration
1694376|NCT01508026|Drug|Valsartan 1|Valsartan Monotherapy 80 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 160 mg, oral administration
1694377|NCT01508026|Drug|Valsartan 2|Valsartan Monotherapy 160 mg, oral administration, then dose doubled to at Week 11 to Valsartan Monotherapy, 320 mg, oral administration
1694378|NCT01508026|Drug|Placebo|Dose matched placebo, oral administration
1694379|NCT01508013|Behavioral|Appearance-Focused Website Intervention|The intervention is a teen-friendly website with information concerning the health and appearance effects of indoor tanning.
1694380|NCT01508013|Behavioral|Control Website|The control website contains information about alcohol and drug abuse which is oriented for a teen audience.
1694381|NCT01508000|Drug|FOLFOX6|5-FU, folinic acid, oxaliplatin
1694382|NCT01508000|Biological|Bevacizumab|Targeted therapy
1694383|NCT01508000|Biological|Panitumumab|Targeted therapy
1694384|NCT01508000|Procedure|Surgery|
1694385|NCT01507974|Drug|Preventive antibiotic treatment- NITROFURANTOIN|P.O NITROFURANTOIN 100 mg per day for 6 weeks
1694386|NCT01507974|Drug|Preventive antibiotic treatment- CEPHALEXIN|P.O CEPHALEXIN 500 MG PER DAY FOR 6 WEEKS
1694387|NCT01507974|Drug|PREVENTIVE TREATMENT- AMOXICILLIN|P.O AMOXICILLIN 250 MG PER DAY FOR 6 WEEKS
1694388|NCT01507974|Drug|PREVENTIVE TREATMENT- AMOXICILLIN AND CLAVULANATE POTASSIUM|P.O AMOXICILLIN AND CLAVULANATE POTASSIUM, 875 MG PER DAY FOR 6 WEEKS
1694389|NCT01507974|Drug|PREVENTIVE TREATMENT- CEFUROXIME|P.O CEFUROXIME 250 MG PER DAY FOR 6 WEEKS
1694390|NCT01507974|Drug|PREVENTIVE TREATMENT SULFAMETHOXAZOLE AND TRIMETHOPRIM|P.O SULFAMETHOXAZOLE AND TRIMETHOPRIM 1 TAB PER DAY FOR 6 WEEKS
1694391|NCT01507948|Behavioral|Prolonged exposure|PE will be delivered in 9-12 90-minute sessions. Therapy will be delivered by PhD-level therapists at Stanford and Palo Alto VA. PE consists of four components: psychoeducation about PTSD symptoms and the behavioral or cognitive factors maintaining it, a brief breathing retraining that can be used as a stress management tool, prolonged imaginal exposure to the trauma memory both within-session and repeated as homework, and prolonged in vivo exposure to avoided scenarios in patients' day-to-day lives.
1694392|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture I
1694393|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with added prebiotic oligosaccharides mixture II
1694394|NCT01507935|Other|Regular non-hydrolysed cow's milk|Regular non-hydrolysed cow's milk with the same composition as the Investigational Formulas but without supplementation of prebiotic oligosaccharides
1694395|NCT01507922|Drug|Fenoverine|Fenoverine 100mg three times a day for 8 weeks
1694396|NCT01507922|Drug|Timebutine|Timebutine maleate 150mg three times a day for 8 weeks
1694398|NCT01507870|Procedure|onlay mesh placement|prophylactic onlay mesh in patients with median laparotomy
1694399|NCT01507857|Biological|400U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
1694400|NCT01507857|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
1694401|NCT01507844|Device|positive ventilation|10 minutes of increased 4,7,12 positive pressure ventilation
1694402|NCT01507831|Drug|Placebo (for alirocumab)|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
1694403|NCT01507831|Drug|Alirocumab|Solution for injection, one subcutaneous injection in the abdomen, thigh, or outer area of upper arm with a pre-filled syringe.
1694404|NCT01507831|Drug|Lipid-Modifying Therapy (LMT)|Statin (rosuvastatin, simvastatin or atorvastatin) at stable dose with or without other LMT as clinically indicated.
1694405|NCT01507818|Device|Ivivi Torino II|Emits a PRF generated specific electromagnetic signal consisting of a 27.12 MHz radio frequency carrier pulse-modulated with a burst duration of 3 milliseconds repeating at 2 times per second (2Hza0>
1694406|NCT01507818|Device|Inactive Sham device|The inactive control device (Sham) identical to the Active device with the exception that a PRF signal is not delivered.
1694637|NCT01505959|Device|CPAP treatment|CPAP treatment with telemedicine system
1694408|NCT01507805|Device|sham EA preconditioning|Patients in Sham EA preconditioning group was treated at bilateral Neiguan(PC 6)，Lieque(LU 7)and Yunmen(LU 2)without electrical stimulation(5—30 Hz，2．34—6．24 mA，30 min)for 5 consecutive days before surgery
1694409|NCT01507792|Drug|iron sulphate|1 or 2 330 mg/daily iron sulphate oral tablets
1694410|NCT01507792|Drug|antiH1-histamine, proton pump inhibitor|This is not an intervention of interest, but it is a selection criterion to define unexplained cough, as suggested by cough guidelines.
1694411|NCT01507779|Biological|IVACFLU|IVACFLU is formulated to contain 15 mcg hemagglutinin (HA) of influenza A/California/07/2009(H1N1)-like virus per 0.5 mL dose
1694412|NCT01507779|Other|PBS (Phosphate buffered saline)|Phosphate buffered saline (PBS), pH 7.2, in 0.5 ml single-dose vials.
1694413|NCT01507766|Drug|early enteral nutrition|The enteral nutrition was started within 48h after admission
1694414|NCT01507766|Drug|Delayed enteral nutrition|The enteral nutrition was started at the 8th day after admission
1694415|NCT01507753|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
1694416|NCT01507753|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
1694417|NCT01507753|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
1694418|NCT01507740|Drug|Avastin|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
1694419|NCT01507740|Drug|Suntent|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
1694420|NCT01507740|Drug|Nexavar|Dosage, duration, indications and contraindications of treatment rely on the sole responsibility of the treating physician and are not subject of the present study
1694421|NCT01507727|Drug|Tolvaptan|Tablet;15mg/tab; 30mg/tab; 15/30/60mg/day for 7 days Plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
1694422|NCT01507727|Drug|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as CHF, hepatic cirrhosis and SIADH or others.
1694423|NCT01507714|Procedure|Preventive transobturator tension free vaginal tape|during the vaginal wall repair surgery, a TVT-O procedure will be done
1694424|NCT01507701|Drug|Clonidine|50 micrograms twice a day for 14 days; thereafter 25 microgram clonidine twice a day for 7 days; thereafter discontinuation.
1694425|NCT01507688|Behavioral|Stroke Self-Management|Stroke self-management program- Participants randomized to this program will receive 6 bi-weekly telephone sessions during the first 3 months followed by 3 monthly reinforcement telephone sessions coupled with 3 monthly group sessions during months 4-6.
1694426|NCT01507662|Behavioral|Bone Mineral Density Result Letter and Bone Health Brochure|Letter mailed to patient to include - Date of DXA, T-score, impression, 10 year major fracture risk with visual depiction of risk, basic bone health guidelines, instructions to follow-up with their healthcare provider. The brochure will include information on osteoporosis, calcium, vitamin D, medicines, exercise, tobacco and alcohol cessation and where to find more information.
1694427|NCT01507649|Behavioral|telephone-based cognitive-behavioral intervention|The intervention is based on the cognitive-behavioral approach. It consists of five, 30-minutes sessions delivered weekly from postpartum week one to week five via telephone.
1694428|NCT01507636|Other|Occupational Therapy|Occupational therapy using a special arm function training.
1694429|NCT01507636|Other|Physical therapy|Physical therapy for arm force training.
1694430|NCT01507623|Device|Capnography (Phillips MP20 monitor)|"In the intervention group the NAPS nurse observed possible hypoxia and changes in capnography curves/values during the procedure and was instructed to decrease propofol and take actions against insufficient ventilation* if etCO2 ≥ 7kPa or ≤ 2 kPa for ≥ 1 minute, if respiratory frequency ≤ 8 or a loss of curve shape was registered.
*Suction, increase oxygen supply, tongue holder or nasal airway, bag-mask ventilation,paged anaesthesia Discontinued procedures"
1694431|NCT01507610|Drug|Sumatriptan|To compare the single-dose pharmacokinetics (PK) and relative bioavailability of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet, and 6 mg IMITREX® (sumatriptan) Subcutaneous Injection, in healthy subjects.
1694432|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.2 pmol/kg/min) for 210 minutes.
Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
1694433|NCT01507597|Drug|NaCl|Continuous iv. saline infusion (NaCl Isotonic) for 210 minutes. Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)
1694434|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.4 pmol/kg/min) for 210 minutes.
Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
1694435|NCT01507597|Drug|Native human Glucagon-like Peptide-1 ( GLP-1(7-36))|"Continuous iv. infusion of the native gut hormone GLP-1 (0.8 pmol/kg/min) for 210 minutes.
Combined with a step wise glucose clamp using 20% w/w glucose iv. infusion reaching plasma glucose value of 15 mM starting at fasting plasma glucose (30 min per step)"
1694713|NCT01505504|Drug|mirtazapine|30 mg at bedtime
1751993|NCT00208195|Drug|Divalproex ER|
1694437|NCT01507571|Other|Dignity Therapy|"Dignity Therapy is a brief psychotherapeutic intervention consisting of:
a tape-recorded session with the patient using the DT question protocol
Transcription of the interview, which is then edited
A session where the edited transcript is returned to the patient who can give it to family members or friends.
If needed, one or more sessions are added. Dt allows the patient to give voice to the matters of importance concerning himself and his loved ones. Its purpose is to enhance sense of meaning, purpose and worth. It also gives the opportunity to leave something behind to be remembered by."
1694438|NCT01507558|Procedure|Administration of dexamethasone to SFA/popliteal adventitia|Following a balloon angioplasty or atherectomy of a stenotic TASC II A, B, or C lesion in the superficial femoral or popliteal artery, a Bullfrog Micro-Infusion Catheter will be used to infuse 0.96 mg dexamethasone per cm arterial lesion.
1694439|NCT01507545|Drug|MORAb-004|MORAb-004 8mg IV per kg once a week
1694440|NCT01507545|Drug|Placebo|Placebo - normal saline IV once a week
1694441|NCT01507532|Other|pharmacokinetic monitoring|pharmacokinetic monitoring
1694442|NCT01507519|Device|Sirolimus Eluting Coronary Stent System (Biomime)|Coronary Artey PTCA
1694443|NCT01507506|Radiation|Radiotherapy|"Conventional arm: 3D conformational radiotherapy (arm A): 60 Gy per fractions of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with a linear accelerator equipped with a portal imaging.
Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :
during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,
post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
1694444|NCT01507506|Radiation|Experimental arm|"Conformational radiotherapy with simultaneous integrated boost by intensity modulation (Arm B): 60 Gy per fraction of 2 Gy in 30 sessions on the PTV1 (contrast enhancement + 2 cm) with concomitant daily superimposed boost on spectroscopic active region (PTV2) corresponding to the ratio Cho / NAA> 2 + 0.7 mm + contrast enhancement + 3mm. The PTV2 will receive a daily dose of 2.4 Gy for a cumulative dose of 72 Gy Only irradiation with simultaneous integrated boost are allowed
Chemotherapy (Drug) :treatment should be combined with temozolomide during and after radiotherapy in a conventional treatment Stupp (Stupp et al. 2005), ie :
during radiotherapy : Temozolomide 75 mg/m2/day by oral route every day,
post radiotherapy : 6 cycles of Temozolomide oral route : 150 mg/m2/day from D1 to D5 for the 1st cycle followed by 200 mg/m2/day from D28 to D32."
1694445|NCT01507480|Drug|Bevacizumab|There are five increasing doses of bevacizumab nasal spray (25mg/mL): 10 mg, 25 mg, 50 mg, 75, mg and 100 mg. Each test dose is a single dose divided into five fractions and administered into each nostril every 30 minutes for 2 hours:
1694446|NCT01507467|Radiation|Accl. RT|Accelerated Radiotherapy: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week
1694447|NCT01507467|Radiation|Accl. radiotherapy + Nimorazole|Radiation: Radiotherapy 66-70 Gy, 2Gy/fx, 6fx/week plus Nimorazole (tablets or powder) 1.2 g/m2 body surface in connection with the first daily radiation treatments
1694448|NCT01507454|Drug|estradiol, 25 mcg|Vaginal tablets for 6-12 weeks according to product labelling
1694449|NCT01507441|Genetic|gene mapping|
1694450|NCT01507441|Genetic|microarray analysis|
1694451|NCT01507441|Genetic|mutation analysis|
1694452|NCT01507441|Genetic|nucleic acid sequencing|
1694453|NCT01507441|Other|laboratory biomarker analysis|
1694454|NCT01507428|Drug|18F-Fluoromisonidazole|Undergo FMISO PET/CT (Correlative studies)
1694455|NCT01507428|Drug|Carboplatin|Given IV
1694456|NCT01507428|Procedure|Computed Tomography|Undergo FDG PET/CT
1694457|NCT01507428|Procedure|Computed Tomography|Undergo FMISO PET/CT (Correlative studies)
1694458|NCT01507428|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
1694459|NCT01507428|Drug|Fludeoxyglucose F-18|Undergo FDG PET/CT
1694460|NCT01507428|Radiation|Image-Guided Adaptive Radiation Therapy|Undergo individualized adaptive radiotherapy
1694461|NCT01507428|Other|Laboratory Biomarker Analysis|Correlative studies
1694462|NCT01507428|Drug|Paclitaxel|Given IV
1694463|NCT01507428|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
1694464|NCT01507428|Procedure|Positron Emission Tomography|Undergo FMISO PET/CT (Correlative studies)
1694465|NCT01507402|Drug|REGN1033(SAR391786)|Administration method A
1694466|NCT01507402|Drug|REGN1033(SAR391786)|Administration method B
1694467|NCT01507402|Drug|Placebo|(inactive substance)
1694468|NCT01507389|Drug|liraglutide|Single dose of 0.75 mg injected subcutaneously (under the skin)
1694469|NCT01507376|Drug|recombinant hCG|recombinant hCG(250 µg Ovitrell)
1694470|NCT01507376|Drug|recombinant hCG|recombinant hCG(500 µg Ovitrell)
1694471|NCT01507376|Drug|urinary hCG|10,000 IU urinary hCG
1694472|NCT01507363|Drug|Gabapentin|Tables with Gabapentin (1300 mg/ day) for 7 days, starting on the day of surgery
1694473|NCT01507363|Drug|Gabapentin|Tables with Gabapentin (900 mg/day) for 7 days, starting on the day of surgery
1694474|NCT01507363|Drug|Placebo|Placebo tablets for 7 days, starting on the day of surgery
1694475|NCT01507337|Drug|liraglutide|A single dose of 1 mg administered subcutaneously (under the skin)
1694476|NCT01507311|Drug|liraglutide|A single dose injected subcutaneously (under the skin)
1694477|NCT01507311|Drug|placebo|A single dose injected subcutaneously (under the skin)
1694478|NCT01507285|Drug|liraglutide|Initial single dose followed by subsequent multiple s.c. (under the skin) doses on several dose levels (1.25, 5, 7.5, 10 and 12.5 mcg/kg). Each subject will be allocated to one dose level only
1694479|NCT01507285|Drug|placebo|Initial single dose followed by subsequent multiple s.c. (under the skin) doses
1694480|NCT01507272|Drug|liraglutide|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
1694481|NCT01507272|Drug|liraglutide|Subjects receiving the dose level 5 mcg/kg s.c. will in addition receive, after a wash-out of at least 7 days, a single i.v. (into the vein) dose of 5 mcg/kg
1694482|NCT01507272|Drug|placebo|Administered s.c. After a wash-out of at least 7 days, a single i.v. (into the vein) dose is administered
1694483|NCT01507272|Drug|placebo|Administered as 5 single s.c. (under the skin) doses - 1.25, 2.5, 5, 10 and 20 mcg/kg once daily - in ascending order
1694484|NCT01507259|Other|cocoa|70% versus 34%
1694485|NCT01507246|Drug|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via PCA pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the PACU or immediately upon transfer to the floor if the stay in the PACU is less than one hour.
1694486|NCT01507246|Drug|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
All patients will be offered rescue analgesia, as needed."
1694487|NCT01507233|Drug|IV morphine sulfate|Patients in this group will receive IV morphine sulfate via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour.
1694488|NCT01507233|Drug|EXPAREL (bupivacaine liposome injectable suspension)|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac, a non-steroidal anti-inflammatory drug (NSAID), may be substituted per the site's standard of care.
All patients will be offered rescue analgesia, as needed."
1694489|NCT01507220|Drug|morphine sulfate|Patients in this group will receive IV morphine sulfate (or Sponsor-approved equivalent) via patient-controlled analgesia (PCA) pump, as needed. The PCA pump will be set up postsurgically as soon as possible and prior to the patient leaving the post-anesthesia care unit (PACU) or immediately upon transfer to the floor if the stay in the PACU is less than 1 hour. All morphine sulfate (Group 1) patients will receive the same opioid in their PCA pump.
1694490|NCT01507220|Drug|bupivacaine liposome extended-release injectable suspension|"Patients in this group will receive 266 mg EXPAREL diluted with preservative free 0.9% normal saline to a total volume of 30 cc and administered via wound infiltration prior to wound closure. When not contraindicated, 30 mg IV ketorolac will be given at the end of surgery. If not indicated, an IV non-steroidal anti-inflammatory drug (NSAID) may be substituted per the site's standard of care.
All patients will be offered rescue analgesia, as needed."
1694491|NCT01507207|Procedure|Injection laryngoplasty|Patients will undergo a direct microlaryngoscopy in the operating room for diagnostic purposes. In patients in whom laryngeal cleft is diagnosed, injection laryngoplasty will be carried out using sodium carboxymethylcellulose aqueous gel (commercial name Radiesse) injection material.
1694492|NCT01507194|Drug|Ondansetron|Single IV dose
1694493|NCT01507194|Drug|Vestipitant|Single IV dose
1694494|NCT01507181|Drug|Ketamine|single dose IV ketamine, .5mg/kg infused over 40 minutes
1694495|NCT01507181|Drug|Midazolam|single dose IV midazolam, .45mg/kg infused over 40 minutes
1694496|NCT01507168|Drug|Placebo|iv Days 1 and 8, and every 2 weeks thereafter
1694497|NCT01507168|Drug|RO5137382|1600 mg iv Day 1 and 8, and every 2 weeks thereafter
1694498|NCT01507155|Device|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
1694499|NCT01507116|Other|No treatment given|Three separate survey questionnaires, one for each of the three diabetes groups. Each questionnaire is composed of multiple items including pre-coded (multiple choice) questions, dichotomous (yes/no) questions and rating scales.
1694500|NCT01507103|Biological|Tecemotide (L-BLP25)|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8, which will be administered concomitantly with the chemoradiotherapy, followed by a 9th subcutaneous injection 7 to 11 days prior to surgery.
1694501|NCT01507103|Drug|cyclophosphamide (CPA)|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of CPA will be given 3 days before the first tecemotide (L-BLP25) administration.
1694502|NCT01507103|Other|Chemoradiotherapy|Radiotherapy of 45-52 grays (Gy) will be applied 5 times per week, over a minimum period of 5 weeks. Capecitabine at a dose of 825 mg/m^2, twice daily or equivalent dose of 5-fluorouracil (5-FU) will be given orally, starting at the first day of radiotherapy and given 5 to 7 days per week during the time of radiotherapy.
1694503|NCT01507090|Device|Mercy TAPE|2D Mercy TAPE and 3D Mercy TAPE
1694504|NCT01507077|Drug|ZGN-440|Subjects will receive ZGN-440 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
1694505|NCT01507077|Drug|ZGN-440 sterile diluent|Subjects will receive placebo twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
1694506|NCT01507064|Drug|Sorafenib|tablets 200mg dosage: 400mg bid duration: 4 weeks
1694507|NCT01507064|Procedure|laser ablation (LA)|"For LA, we use a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the tumor through four 21-gauge needles. The tips of the needles will be positioned at a distance of 15mm from each other.
When, after LA treatments, CT or MRI findings show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
1694508|NCT01507051|Drug|Warfarin (Coumadin)|Days -6 and -5: 10 mg warfarin (Coumadin) once daily, dosage lower if the INR is already high on day -5; Days -4 to -1 (could be prolonged by two days): 2.5, 5, 10, 12.5 or 15 mg warfarin (Coumadin) once daily, dosage depending on INR
1694509|NCT01507051|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Days 0 to 3: 20 mg rivaroxaban once daily
1694510|NCT01507051|Drug|Placebo|Days 0 to 3: 1 tablet placebo, identical to active tablet
1694511|NCT01507051|Drug|Vitamin K (Konakion)|Day 5: 10 mg vitamin K (Konakion) once daily
1694512|NCT01507038|Drug|YH14617|1mg once weekly
1694513|NCT01507038|Drug|YH14617|1.6mg once weekly
1694514|NCT01507038|Drug|YH14617|2mg once biweekly
1694515|NCT01507038|Drug|Placebo|Once weekly
1694516|NCT01507012|Dietary Supplement|Berry Polyphenols|
1694517|NCT01507012|Dietary Supplement|Placebo|Placebo control containing sugar and artificial flavouring.
1694518|NCT01506999|Biological|MULTIGENE SCREENING FOR SINGLE SNPS|DNA will be genotyped employing a multicolour assay system for SNPs based on TaqMan MGB (Minor Groove Binder) probes.
1751994|NCT00208208|Drug|Ziprasidone|
1694521|NCT01506973|Drug|Hydroxychloroquine (HCQ)|
1694522|NCT01506973|Drug|Gemcitabine|
1694523|NCT01506960|Device|InfraReDx Lipiscan IVUS|Near Infrared Spectroscopy/Intravascular Ultrasound will be performed following OCT imaging.
1694524|NCT01506947|Drug|Paricalcitol|"Paricalcitol was administered by intravenous bolus. The initial dose was calculated according to the following formula:
[Paricalcitol (µg) = iPTH (pg/mL) / 80]. Subsequent doses were determined based on iPTH, calcium and phosphorus levels."
1694525|NCT01506947|Drug|Darbepoetin alfa|Routine darbepoetin alfa use was allowed when transferrin saturation (TSAT) was ≥ 20% and ferritin ≥ 200 μg/L, and hemoglobin level < 11.5 g/dL. The initial dose was 0.25 to 0.75 µg/kg/week, and the maintenance dose was 0.13 to 0.35 µg/kg/week. Target hemoglobin level was between 10 to 11.5 g/dL.
1694526|NCT01506934|Drug|linifanib|"Single Dose on Day 1 of Periods 1, 2 and 3 (Bioavailability Portion)
Single Dose on Day 1 of Periods 1 and 2 (Food Effect Portion)"
1694527|NCT01506921|Drug|Racemic ketamine|0.6 mg/kg
1694528|NCT01506921|Drug|S-ketamine|0.3 mg/kg
1694529|NCT01506908|Drug|oral nicotine|oral nicotine replacement product
1694530|NCT01506908|Drug|Placebo|no active
1955747|NCT03090464|Other|Use of digital disease management tool|The purpose of the study is to evaluate if the provision of a digital disease management tool, in addition to SOC for T2DM, will improve glycemic control. The impact of the tool will be assessed in comparison to a Control group who will receive SOC alone. All participants will complete the PRO assessments. This is a real world study carried out at the point of care.
1955748|NCT03088930|Drug|Crizotinib|Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
1694533|NCT01506882|Drug|Levetiracetam (LEV)|"Active Substance: Levetiracetam
Pharmaceutical Form: Film-coated tablet
Concentration: LEV 250 mg, LEV 500 mg
Frequency: Twice daily
Route of Administration: Oral use"
1694534|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intravenous)|Paclitaxel(intravenous) + Carboplatin(intravenous) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IV infusion, Day1 A total of 6 to 8 cycles will be repeated.
1694535|NCT01506856|Drug|Paclitaxel(intravenous) + Carboplatin(intraperitoneal)|Paclitaxel(intravenous) + Carboplatin(intraperitoneal) Paclitaxel : 80mg/m2, IV infusion, Day1, 8, and 15 Carboplatin: AUC=6.0, IP injection, Day1 A total of 6 to 8 cycles will be repeated.
1955749|NCT03088800|Drug|Ibuprofen|Oral Ibuprofen at 10 mg/kg dose
1694537|NCT01506830|Procedure|Relative isolation with cotton rolls|Cotton roll group: Moisture control was provided using a labial retractor, cotton rolls and gingival retraction cord placed into the gingival sulcus
1694538|NCT01506830|Procedure|Absolute isolation with rubber dam|Rubber dam group: Moisture control was provided by a rubber dam and a gingival retraction clamp placed in the cervical area of the tooth.
1694539|NCT01506817|Procedure|Dynamic contrast-enhanced MRI of the hands|The hand and wrist will be examined in a 3T Siemens Verio® MR scanner with the patients and normal controls supine and the hand along the side of the body (3T Verio) using a semiflex 15 channel body coil. Total imaging time varies between 30-35 minutes.
1694540|NCT01506804|Other|methylprednisolone|Steroid injection X 2 and 10 weeks exercise program of painful shoulder vs exercise program of contralateral shoulder
1694541|NCT01506791|Drug|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
1694542|NCT01506778|Device|Tenaculum|Single tooth tenaculum are use to the cervix for steady the cervix, straighten the cervicouterine angle and provide countertraction. Most of gynecological office procedure such as endometrial sampling procedure, hysterosalpingography, hysteroscopy, insertion of contraceptive intrauterine device, difficult intrauterine insemination or embryo transfer procedures often require the application of a tenaculum.
1694543|NCT01506765|Drug|N-Acetyl-Cysteine (NAC)|Once included, the patients will be randomly placed in two groups: one group (1) will receive 2 g/day of NAC (2caps of 0.5g twice a day) and the other group (2) a placebo, for a duration of 8 weeks. At the end of the 8 weeks, group (2) will receive NAC and (1) the placebo for another 8 weeks
1694544|NCT01506752|Drug|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet without water.
1694545|NCT01506752|Drug|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet without water.
1694546|NCT01506752|Drug|Donepezil Hydrochloride|improved orally disintegrating E2020 10 mg tablet with water.
1694547|NCT01506752|Drug|Donepezil Hydrochloride|current orally disintegrating E2020 10 mg tablet with water
1694548|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 film-coated tablet: E2020 film-coated tablet (5mg) orally administered in a single dose with 200 mL water.
1694549|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form (suspended): E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose after suspended in 20 ml water.
1694550|NCT01506739|Drug|Donepezil Hydrochloride|Drug E2020 dry syrup 1% form: E2020 dry syrup 1% (0.5 g) will be orally administered in a single dose with 200 mL water.
1694551|NCT01506726|Drug|Salsalate|Salsalate 750mg tablet 1 pill bid for one month followed by Salsalate 750mg tablets 2 pills (1500mg) twice a day for a further 5 months (total duration of treatment will be 6 months)
1694552|NCT01506726|Drug|Placebo|Placebo tablet - one pill twice daily for one month, followed by 2 pills twice daily for a further 5 months. Total duration of treatment is 6 months
1694553|NCT01506713|Drug|Clopidogrel|Clopidogrel Tablets 75 mg
1694554|NCT01506700|Device|Optical Coherence Tomography|Optical coherence tomography will be used to image tissue structure on excised and in vivo specimens.
1694555|NCT01506687|Behavioral|Health counselling by nurse navigator|Information on colorectal cancer and screening, assistance in selection of screening option and obtaining kit or colonoscopy referral
1694556|NCT01506687|Behavioral|Usual primary care counselling|Usual care health counselling on colorectal cancer and screening options
1955750|NCT03088800|Drug|APAP|Oral APAP at 15mg/kg dose
1694557|NCT01506661|Drug|Zostavax (varicella zoster virus) vaccine|Standard vaccination protocol for Zostavax will be utilized. 0.65 ml (19,400 plaque forming units) Zostavax will be administered subcutaneously once at the baseline visit
1694558|NCT01506635|Drug|Timolol|
1694559|NCT01506635|Drug|Placebo|artificial tear twice a day
1694560|NCT01506622|Drug|Administration of propofol|Propofol 1 mg/kg will be administered to propofol group at the end of anesthesia.
1694561|NCT01506622|Drug|Administration of fentanyl|Fentanyl 1 mcg/kg will be administered to fentanyl group at the end of anesthesia.
1694562|NCT01506622|Drug|Administration of saline|Saline will be administered to control group at the end of anesthesia.
1694568|NCT01506596|Drug|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle. Study treatment may continue until disease progression or unacceptable toxicity.
1694569|NCT01506570|Biological|TetraVax-DV Vaccine - Admixture TV003|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV003 (10^3 plaque-forming unit [PFU] of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
1694570|NCT01506570|Biological|TetraVax-DV Vaccine - Admixture TV005|One SC injection at Day 0 and Day 180 of the TetraVax-DV Vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
1694571|NCT01506570|Biological|Placebo|One SC injection at Day 0 and Day 180 of placebo
1694572|NCT01506557|Dietary Supplement|cholecalciferol|dose 800 IU/day for 6 month
1694573|NCT01506557|Dietary Supplement|placebo|oil capsules
1694574|NCT01506544|Drug|Hydroxyurea|20mg/kg of Hydroxyurea or the patient's standard daily dose
1694575|NCT01506531|Procedure|silo for gastroschisis|silo placed around abdominal contents in gastroschisis patients
1694576|NCT01506531|Procedure|Primary closure of gastroschisis|Primary closure of gastroschisis, if possible
1694577|NCT01506505|Drug|Cardiovascular Agents|Acetylsalicylic acid 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorthiazide 12.5mg in individual agents or a combination pill
1694578|NCT01506492|Behavioral|CALM|Patients assigned to the intervention arm will receive 3-6 CALM therapy sessions over 3-6 months delivered by a trained therapist at our center.
1694582|NCT01506466|Other|blood test/ additional measurement|blood test (hormonal, inflammatory, lipid and growth factors); body composition measurements; energy balance evaluation
1694583|NCT01506453|Drug|gabapentin|Participants randomized to the active treatment arm will receive gabapentin 20mg/kg/day PO divided into 3 doses and rounded to the nearest 100 mg for capsules and 10 mg for liquid preparation.
1694584|NCT01506453|Drug|placebo|Participants randomized to the placebo treatment arm will receive look-alike capsules or liquid in a respective capsule size or liquid measure equivalent to the active treatment arm, but which contain no active treatment.
1694585|NCT01506440|Procedure|cognitive assessment|Given cognitive assessments
1694586|NCT01506440|Procedure|quality-of-life assessment|Ancillary studies
1694587|NCT01506427|Radiation|[F-18] HX4|A single dose of 10 mCi, injected intravenously.
1694588|NCT01506414|Drug|rhTPO in combination with Rituximab|Rituximab was given intravenously at a dose of 100 mg weekly for 4 consecutive weeks (Day 1, 8, 15, 22). Rh-TPO (TPIAOTM, a product of Sunshine Pharmaceutical Co Ltd, China, approved by China State Food and Drug Administration) was given subcutaneously at a dose of 1.0 μg/kg（300u/kg）for 14 days (Day 1-14).
1694589|NCT01506401|Device|SensorMedics 3100B High Frequency Oscillatory Ventilator|High Frequency Oscillation
1694590|NCT01506401|Procedure|Lung Protective Ventilation|Tidal Volume 6ml/kg; plateau pressure < or = 35cmH20; Prescribed PEEP/FiO2 chart
1694591|NCT01506388|Device|foley catheter|foley 14 catheter intracervical plus vaginal IMN 40 mg evry 6 hours
1694592|NCT01506388|Drug|Misoprostol|misoprostol 50 Ug , vaginally every 4-6 hours
1694593|NCT01506388|Drug|Vaginal IMN|IMN vaginal 40 mg every 4-6 hours
1694594|NCT01506375|Biological|gpASIT+TM|1 subcutaneous injection every 7 days during 29 days
1694595|NCT01506375|Biological|gpASIT+TM + adjuvant|1 subcutaneous injection every 7 days during 29 days
1694596|NCT01506362|Drug|BL-7040|"BL-7040 is an orally available new chemical entity for the treatment of IBD. BL-7040 is a synthetic oligonucleotide with dual activity on both the nervous and immune systems.
Study duration can last up to 8 weeks, including up to 9 days in the screening period, up to 5 weeks of treatment with BL-7040, and up to 2 weeks for follow up.
BL-7040 12 mg QD for 19-21 days followed by BL-7040 40 mg QD for 14 days."
1694597|NCT01506349|Dietary Supplement|gluten|4 grams of gluten.
1694598|NCT01506349|Dietary Supplement|Placebo|
1694599|NCT01506336|Drug|masitinib|masitinib 12 mg/kg/day
1694600|NCT01506336|Drug|sunitinib|sunitinib 50 mg/day
1694601|NCT01506323|Behavioral|Mantram Repetition Program (MRP)|The MRP teaches three portable, mindfulness strategies to train attention and manage symptoms: 1) Mantram (sacred word) Repetition, 2) Slowing Down, and 3) One-Pointed Attention. These tools are presented as working together synergistically and cumulatively, over time, to interrupt negative thoughts, behaviors, and emotional states such as anger, rage, irritability and impatience. Participants choose their own words or phrases and are encouraged to practice repeating a mantram at any time or place. In this study, MRP is delivered individually in eight weekly, 1-hour sessions, using a standardized manual, instructor guide, and homework assignments for experiential learning.
1694714|NCT01505491|Drug|adalimumab|40mg adalimumab single s.c. injection
1694602|NCT01506323|Behavioral|Present Centered Therapy (PCT)|The PCT is a form of individual therapy that is problem-oriented to improve current coping. It avoids details of traumatic experiences. In this study, it is delivered individually in 8 weekly, 1 hour sessions to serve as an active, attention control arm. Sessions are unstructured and managed so that there is some engagement of the participant's emotional concerns with an emphasis on strengths and process encouragement rather than skills training. Three components of PCT include 1) developing a therapeutic relationship for social support, 2) focusing on current problems and problem solving, 3) and setting goals.
1694603|NCT01506310|Behavioral|Behavioral therapy|General written dietary recommendations (about cooking, lowering sugar intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out. A brief written guide on behavior change.
1694604|NCT01506310|Other|Exercise|The exercise groups will be advised to walk at least 20-minute a day.
1694605|NCT01506310|Other|Behavioral therapy and exercise|"General written dietary recommendations (about cooking, lowering fat intake, reducing salt intake, reducing beverages and food with added sugars) and written options for dining out.
Written recommendations for physical activity A brief written guide on behavior change"
1694606|NCT01506284|Procedure|Forced oscillatory technique (FOT) and laser interferometry (LIR).|"FOT: The stimulating signal is generated by an A/D-D/A board and amplified by a power amplifier that drives a loudspeaker the output of which is connected to inspiratory line of the ventilator. Pressure and flow are measured at the inlet of the endotracheal tube by a piezoresistive pressure transducer and a mesh-type heated pneumotachograph coupled with a differential pressure transducer.
LIR: The scanner unit is made by three laser interferometers, the beams of which are deflected on the chest wall surface by a mirror moved by a stepper motor triggered on the respiratory pattern of patient."
1694607|NCT01506271|Drug|MK-7655 250 mg with imipenem/cilastatin|"Participants randomized to receive MK-7655 250 mg will be administered 250 mg doses of MK-7655 IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval.
A 500 mg dose of imipenem/cilastatin will be administered in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval."
1694608|NCT01506271|Drug|MK-7655 125 mg with imipenem/cilastatin|"Participants randomized to receive MK-7655 125 mg will be administered 125 mg doses of MK-7655 IV, in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval.
A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval."
1694609|NCT01506271|Drug|imipenem/cilastatin with placebo|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
1694610|NCT01506271|Drug|Matching placebo to MK-7655|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
1694611|NCT01506258|Procedure|Application of Stem Cells|IV infusion of autologous stem cells within the first 48 hours after birth.
1694612|NCT01506258|Procedure|Observation|Control group of patients that meet the inclusion criteria but that do not wish to have the intervention.
1694613|NCT01506245|Behavioral|Family-based behavioral therapy|The intervention consist of a 6-month family-based behavioural therapy either in group (1 session/week, with a dietician and a psychologist) or in individual setting (with a paediatrician or a dietician in alternance 1x/month). Both therapies include exercise training twice per week (60 minutes each). Parents, or at at least the mother, must participate to the behavioral treatment.
1694615|NCT01506193|Biological|PriorixTetra™|One dose administered subcutaneously
1694616|NCT01506193|Biological|Meningitec|One dose administered intramuscularly
1694617|NCT01506154|Drug|MRX-7EAT|Once daily application of a patch for 14 days
1694618|NCT01506141|Drug|Idursulfase-IT|Idursulfase-IT administered once monthly at the dose used in study HGT-HIT-045 via intrathecal drug delivery device (IDDD)
1694619|NCT01506128|Other|Collecting a Pad used at the first menstrual period after enrollment|Collecting a Pad used at the first menstrual period after enrollment
1694620|NCT01506115|Drug|Photofrin|Photodynamic therapy: Intravenous Photofrin at a dose of 2 mg/kg body weight, 48 hours before photoactivation by intraluminal light illumination
1694621|NCT01506102|Device|Thromboelastography|Thromboelastography during labor and after delivery
1694622|NCT01506089|Other|36 degrees Celsius|Embryos in this group will be cultured in incubators set to 36 degrees Celsius.
1694623|NCT01506076|Drug|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
1694624|NCT01506063|Drug|Levocetirizine DiHCl|Levocetirizine DiHCl Tablets 5 mg
1694625|NCT01506050|Drug|Desloratadine|Desloratadine ODT 5 mg
1694626|NCT01506037|Drug|Desloratadine|Desloratadine ODT 5 mg
1694627|NCT01506024|Procedure|Total hip arthroplasty direct lateral approach|
1694628|NCT01506024|Procedure|Total hip arthroplasty posterior approach|
1694629|NCT01506024|Procedure|Total hip arthroplasty, anterior approach|
1694630|NCT01506011|Drug|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
1694631|NCT01505998|Drug|Amlodipine Besylate/Benazepril HCl|Amlodipine Besylate/Benazepril HCl 10 mg/40 mg capsules
1694632|NCT01505985|Dietary Supplement|Oral nutritional Supplement|Specialized nutritional supplement for seniors
1694633|NCT01505985|Dietary Supplement|Placebo|placebo product with no specific nutrients
1694634|NCT01505972|Other|Six and three time schedule|Invitation letter sent 6 weeks and reminder 3 weeks before a pre-specified screening colonoscopy appointment date.
1694635|NCT01505972|Other|Four and two time schedule|Invitation letter and reminder sent 4 and 2 weeks before pre-specified screening colonoscopy appointment date.
1694636|NCT01505959|Device|CPAP treatment|Usual CPAP treatment
1694715|NCT01505491|Drug|BI695501|BI 695501 single s.c injection
1694638|NCT01505946|Other|TGA (Thrombin generation Assay)|"TGA will be performed on plasma in order to evaluate differences in the ability to stimulate the thrombin generation among the different class of FVIII concentrates and possibly identify the most effective. The TGA will be quarterly repeated in order to verify if it is also adequate to check the therapy effectiveness during the study period"
1694639|NCT01505933|Drug|Dexmedetomidine|"Administer dexmedetomidine at 1mcg/kg over 10min followed by an infusion of dexmedetomidine at 1mcg/kg/hr and image the upper airway.
After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of dexmedetomidine 2mcg/kg followed by increase in the infusion rate to 3mcg/kg/hr. Upper airway images will be repeated 5mins after increasing infusion Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
1694640|NCT01505933|Drug|propofol|"Administer propofol bolus at 2mg/kg,followed by an infusion of propofol at 100 mcg/kg/min. Upper airway images will be obtained 5 mins after the patient is stable on this infusion.
After the initial set of images is obtained, the depth of anesthesia will be increased by administering a bolus dose of 1mg/kg propofol and infusion increased to 240mcg/kg/min.
Image acquisitions will be repeated approximately 5 min after the increase in infusion rate."
1694641|NCT01505920|Procedure|Lidocaine spray|10% lidocaine spray 40 mg applied directly to the cervix, 3 minutes before starting cervical excision
1694642|NCT01505920|Procedure|Lidocaine submucosal injection|2% lidocaine with 1:100,000 adrenaline 2 ml injected submucosally into the four quadrant of the cervix, 3 minutes before starting cervical excision
1694643|NCT01505907|Drug|CXB909|CXB909
1694644|NCT01505894|Drug|BI 409306|High dose film-coated tablet
1694645|NCT01505894|Drug|BI 409306 Placebo|Placebo film-coated tablet
1694646|NCT01505894|Drug|BI 409306|Low dose film-coated tablet
1694647|NCT01505894|Drug|BI 409306|Medium dose film-coated tablet
1694648|NCT01505881|Drug|dabigatran etexilate low dose|active treatment (low)
1694649|NCT01505881|Drug|warfarin 5mg|comparator warfarin
1694650|NCT01505881|Drug|dabigatran etexilate intermediate dose|active treatment (medium)
1694651|NCT01505881|Drug|warfarin 1mg|comparator warfarin
1694652|NCT01505881|Drug|dabigatran etexilate high dose|active treatment (high)
1694653|NCT01505881|Drug|warfarin 3mg|comparator warfarin
1694654|NCT01505868|Drug|Cabazitaxel|"25 mg/m² intravenously on Day 1 of each 3 week cycle.
Phase I Starting Dose: 20 mg/m2 intravenously on Day 1 of each 3 week cycle.
Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
1694655|NCT01505868|Drug|Prednisone|5 mg by mouth twice a day on day 1 of a 3 week cycle.
1694656|NCT01505868|Drug|Carboplatin|"Phase I Starting Dose: AUC 3-4 intravenously on Day 1 of each 3 week cycle.
Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
1694657|NCT01505855|Drug|23-valent polysaccharide pneumococcal vaccine|23-valent polysaccharide pneumococcal vaccine (PSV-23 vaccine) 0.5mL single intramuscular injection
1694658|NCT01505842|Procedure|Colonoscopy with Indigo-Carmine chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in the whole colon and rectum plus 32 random biopsies plus biopsies from suspicious areas
1694659|NCT01505842|Procedure|Conventional white-light colonoscopy|White light colonoscopy plus 32 random biopsies plus biopsies from suspicious areas
1694660|NCT01505816|Device|Multifocal Intraocular Lens (RAYNER M-FLEX T TORIC IOL)|Multifocal IOL implantation
1694661|NCT01505803|Dietary Supplement|Zinc supplements|Participants will receive 40 mg of zinc each day for 12 weeks.
1694662|NCT01505803|Dietary Supplement|Omega 3 supplements|Participants will receive 2 g of omega 3 fatty acids each day for 12 weeks.
1694663|NCT01505803|Dietary Supplement|Placebo supplements|Participants will receive placebo supplements each day for 12 weeks.
1694664|NCT01505790|Drug|PRASUGREL|60 mg the first day then 10 mg per day during one month
1694665|NCT01505790|Drug|Clopidogrel|"600 mg clopidogrel will be administered during the first 6 to 12 hours then a measure of platelets reactivity will be done. An additional administration of clopidogrel (600 mg) could be done every 6 hours until to obtain a VASP <50%. No more than 3 * 600mg of clopidogrel will be authorized in this protocol.
Then for patient which have received more than one dose of clopidogrel 600mg , 150 mg per day of clopidogrel will be administrated, for which who have received only one dose of 600mg of clopidogrel , 75 mg per day will be administrated during one month at least."
1694666|NCT01505777|Drug|Probiotics (Medirac)|10/mosapride 10mg three times a day, P.O. 4week
1694667|NCT01505777|Drug|Probiotics (Medirac)|15/mosapride 10mg three times a day, P.O. 4week
1694668|NCT01505777|Drug|Probiotics (Medirac)|15/mosapride 15mg three times a day, P.O. 4week
1694669|NCT01505777|Drug|Probiotics (Medirac)|30/mosapride 15mg three times a day, P.O. 4week
1694670|NCT01505777|Drug|Probiotics (Medirac) placebo/mosapride placebo|three times a day, P.O. 4week
1694671|NCT01505764|Drug|Anamorelin HCl|100 mg tablets; oral administration every day for 84 days, at least 1 hour before the first meal of the day.
1694672|NCT01505764|Drug|Placebo|Placebo tablets identical in appearance to active tablets; oral administration once a day for 84 days, at least 1 hour before the first meal of the day.
1694673|NCT01505738|Other|bacterial samples|bacterial samples taken
1694674|NCT01505712|Genetic|gene expression analysis|
1694675|NCT01505712|Other|laboratory biomarker analysis|
1694676|NCT01505699|Genetic|RNA analysis|
1694677|NCT01505699|Genetic|cytogenetic analysis|
1694678|NCT01505699|Genetic|microarray analysis|
1694679|NCT01505699|Other|laboratory biomarker analysis|
1694680|NCT01505686|Procedure|MRI scan|MRI scan with a 1,5 T MRI scanner
1694716|NCT01505491|Drug|adalimumab|40mg adalimumab single s.c. injection
1694717|NCT01505465|Drug|Melatonin|5mg of melatonin will be taken by the subject for 3 nights prior and continuing 3 nights after surgery as tolerated.
1694718|NCT01505465|Drug|Placebo|5mg of placebo will be taken by the subject 3 nights prior to surgery and continuing 3 nights after surgery
1694719|NCT01505439|Drug|solifenacin|oral
1694720|NCT01505426|Drug|ASP1941|oral
1694683|NCT01505660|Behavioral|Care management|The intervention will include healthcare delivery team notification of patient reported outcomes (PROs) including medication adherence and adherence barriers such as depression symptoms along with intervention recommendations and targeted care management using a stepped care approach. Patients will receive structured calls from their care manager 2 and 6 weeks after enrollment. An assessment including depression, adherence, and substance use will be completed at the beginning of each call. After the 2nd call, a stepped care approach will be used where patients with a greater need based on adherence and depression will receive more intensive interventions based on the PEARL intervention. The components include: a) problem solving treatment, b) social and physical activation, c) pleasant events scheduling, d) patient support and education regarding medication use, and e) medical and psychiatric consultation. Patients will also receive follow-up calls at ~9 and 12 months after enrollment.
1694684|NCT01505647|Biological|Zoster Vaccine, Live (AMP)|One approximately 0.65-mL injection subcutaneously on Day 1
1694685|NCT01505647|Biological|Zoster Vaccine, Live|One approximately 0.65-mL injection subcutaneously on Day 1
1694686|NCT01505634|Drug|MK-7655 250 mg|Participants randomized to receive MK-7655 250 mg will be administered a 250 mg dose of MK-7655 IV in a blinded fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
1694687|NCT01505634|Drug|MK-7655 125 mg|Participants randomized to receive MK-7655 125 mg will be administered a 125 mg dose of MK-7655 IV in a blinded-treatment fashion once every 6 hours with each dose infused over a 30-minute interval. A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
1694688|NCT01505634|Drug|imipenem/cilastatin 500 mg|A 500 mg dose of imipenem/cilastatin will be administered IV in an open-label fashion once every 6 hours with each dose infused over a 30-minute interval.
1694689|NCT01505634|Drug|Placebo to MK-7655|Participants randomized to receive imipenem/cilastatin alone will receive a placebo-matching infusion of IV normal saline (0.9%) once every 6 hours.
1694690|NCT01505634|Drug|Ciprofloxacin|After at least 96 hours of IV treatment, participants may be switched, at the discretion of the investigator, to 500 mg ciprofloxacin, administered orally, twice daily
1694691|NCT01505621|Other|L[ring-13C6]phenylalanine|Oral drink composed of essential amino acids including L[ring-13C6]phenylalanine
1694692|NCT01505608|Drug|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 28-day cycle.
1694693|NCT01505608|Drug|Temozolomide|Oral (PO) Temozolomide at a dose of 100mg/m2 on days 1-5 of each 28 day cycle
1694694|NCT01505608|Drug|Irinotecan|Intravenous (IV) Irinotecan at a dose of 10mg/m2 on days 1-5 and 8-12 of each 28 day cycle.
1694695|NCT01505595|Other|Proprioceptive training|12 weeks
1694696|NCT01505595|Other|Sham proprioceptive training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
1694697|NCT01505582|Other|Inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 60% Pi,max
1694698|NCT01505582|Other|Sham inspiratory muscle training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of 10% Pi,max
1694699|NCT01505569|Drug|Ifosfamide|"Arms A&B: 1.8 g/m^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days before conditioning regimen
Arm C: 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles"
1694700|NCT01505569|Drug|Etoposide|"Arms A&B: 100 mg/m^2/day intravenously (IV) over 1 hour; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.
Arm C: 400 mg/m^2 daily on days -4, -3, and -2 every 21 days"
1694701|NCT01505569|Drug|Mesna|"Arms A&B: 1.8 g/m^2/day divided in every 6 hrs dosing; given in a window of 30-100 days before transplant for 5 days prior to conditioning regimen.
Arm C: 2000 mg/m^2 IV daily on Days 1-3 every 14 days for 2 cycles"
1694702|NCT01505569|Biological|G-CSF|"Arms A&B: Beginning 24 hours after treatment with ifosfamide, etoposide and mesna, administer 10 mcg/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophil count (ANC) is greater than (>) 1,000/mm^2. Starting that day, increase dose to 15 mcg/kg/day SQ or IV given as a single injection for 3 doses. All patients should receive G-CSF, 5 ug/kg/day IV as a bolus injection each evening beginning on day 0 until the ANC is >2500 x 10^9/L for 2 consecutive days. G-CSF will subsequently be restarted at 5 ug/kg/day SC or IV if the ANC falls below 1000/mm^3.
Arm C: 10 μg/kg subcutaneously daily beginning 6 hours after completion of ifosfamide on day 3 until adequate CD34+ cell collection or day 15, whichever occurs first."
1694703|NCT01505569|Drug|Busulfan|Arm A: 1.1 mg/kg IV every 6 hours on days -8 through -6
1694704|NCT01505569|Drug|Melphalan|Arm A: 50 mg/m^2 intravenously (IV) over 30 min on Days -4 and -5
1694705|NCT01505569|Drug|Thiotepa|Arm A: 250 mg/m^2 intravenously (IV) over 2 hrs on days -2 and -3 Arm B: 10 mg/kg/day or 300 mg/m^2 IV on days -3 and -2
1694706|NCT01505569|Biological|Autologous stem cell infusion|Arms A, B & C: On Day 0, stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
1694707|NCT01505569|Radiation|Radiation|"Arm A: If a patient is considered for post-transplant irradiation, a disease appropriate full tumor restaging should be done prior to starting.
Whole lung irradiation (1500cGy in 10 fractions) may be given in patients with prior lung metastasis. Areas of known metastatic disease or PET areas may receive spot irradiation using a dose and method determined to be tolerable by radiation oncology staff. Additional radiation will be given if primary disease has not been irradiated to maximum tolerated dose."
1694708|NCT01505569|Drug|Carboplatin|Arm B: depending on age and GFR 17mg/kg/day IV over 4 hours or 510 mg/m^2/day IV over 4 hours Arm C: AUC=8 daily on days -4, -3, and -2 every 21 days
1694709|NCT01505569|Drug|Paclitaxel|Arm C: 200 mg/m2 IV over 3 hours on Day 1 every 14 days for 2 cycles
1694710|NCT01505569|Procedure|Leukapheresis|Arm C: Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
1694711|NCT01505530|Drug|LY2495655|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
1694712|NCT01505530|Drug|Placebo|Intravenous (IV) treatment every 14 days while on study. Number of Cycles: until treatment options are exhausted or unacceptable toxicity develops.
1694724|NCT01505413|Drug|Gemcitabine|Gemcitabine 1000 mg/m² with 150mL of normal saline intravenously infusion over 100min on Day 1
1694725|NCT01505413|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 with 500mL of 5DW intravenously a 2-hour infusion on D2
1694726|NCT01505387|Dietary Supplement|Litramine|Fibre complex of plant origin in tablet form 2 tablets 3 times daily (oral consumption, after meal)
1694727|NCT01505387|Dietary Supplement|Placebo|Identical to Litramine tablets 2 tablets 3 times daily (oral consumption, after meal)
1694728|NCT01505374|Procedure|Study Technique|One leg will receive the saphenous nerve block, at the level of the adductor canal (study technique). The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
1694729|NCT01505374|Procedure|Control Technique|The other leg will receive the femoral nerve block (control technique). The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivacaine. All study patients, regardless of study arm will receive combined spinal epidural, with 3 ml of 0.5% bupivacaine as the spinal agent. Epidural local anesthetic, if needed, will consist of 2% lidocaine.
1694732|NCT01505348|Other|Overnight fast|Overnight fast from 21:00 h
1694734|NCT01505309|Device|Stent Graft (Medtronic, Microport, Ankura)|Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
1694735|NCT01505296|Drug|Antiarrhythmic drug|propafenone, flecainide, sotalol, dofetilide
1694736|NCT01505296|Procedure|Catheter ablation|Complete PVI
1694737|NCT01505283|Drug|NaCl 0.9%|epidural administration of 6 ml of NaCl 0.9%
1694738|NCT01505283|Drug|Sufentanil|epidural administration of sufentanil 10 µg
1694739|NCT01505283|Drug|lidocaine|epidural administration of lidocaine 50 mg
1694740|NCT01505270|Other|Retrospective case study|Retrospective case study
1694742|NCT01505244|Behavioral|Before-School Physical Activity|3 days/week of before-school moderate to vigorous physical activity
1694743|NCT01505231|Drug|Vasopressin|Blinded Vasopressin will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement.
1694744|NCT01505231|Drug|Norepinephrine|Blinded Norepinephrine will be started if there is persistent hypotension, characterized by mean arterial pressure <65 mmHg after fluid replacement
1694745|NCT01505218|Drug|Propofol sedation by nurse anaesthestist|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.
Patient-controlled sedation: self-administration of propofol boluses of 5 mg with zero lock-out time. Administration time for the pump was 12 sec, equivalent to maximum delivery of 25 mg of propofol per minute.
Propofol sedation by nurse anaesthetists:"
1694746|NCT01505218|Drug|Patient-controlled propofol sedation|"Propofol (10 mg/ml) is a short-acting, intravenously administered hypnotic agent used for light-moderate-deep sedation.
Self-administration of propofol via patient-controlled sedation pump (CME T-34L PCA). No programmed lock-out period, no dose limit or background infusion. 5 mg propofol/effectuated demand from the patients. Capacity of the pump was 6 possible doses per minute.
Before start of ERCP the patients were allowed to sedate themselves to a sense of heavy tiredness."
1694747|NCT01505192|Device|continuous Hb monitor|Pre and post partum non invasive continuous Hb monitor
1694748|NCT01505179|Drug|Ranolazine|Patients with be given 500 mg by mouth twice a day for three days, and then the dose will be increased to 1000 mg by mouth twice daily thereafter. (patients who concurrently take moderate CYP3A inhibitors including diltiazem, verapamil, aprepitant, erythromycin, and fluconazole will continue to 500 mg by mouth twice a day for the entire dosing period)
1694749|NCT01505179|Drug|Placebo|Patients will be given 1 tab twice a day for 3 days, then increasing to 2 tabs twice a day thereafter (patients who concurrently take moderate CYP3A inhibitors, will be given 1 tab twice daily for the entire dosing period)
1694750|NCT01505166|Biological|Vigil™ Vaccine|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
1694751|NCT01505166|Drug|Placebo|Patients will receive 1 x 10^7 cells (Group A) or placebo (Group B) via intradermal injection for a minimum of 5 doses and a maximum of 12 doses starting post-surgery Week 4-8 (C1W1D1) and continuing C1W3D1, C2W3D1, then every 28 days. Starting C1W4D1, all patients will receive modified FOLFOX6 (oxaliplatin 85 mg/m2 D1, l-leucovorin 200 mg/m2 D1, fluorouracil 400 mg/m2 IV bolus (or short infusion) D1, fluorouracil 2400 mg/m2 46 hours continuous infusion every 14 days x 6 cycles (1 cycle = 4 weeks).
1694752|NCT01505153|Biological|pbi-shRNA STMN1 LP|This is a Phase I safety trial of bifunctional shRNA-STMN1 (pbi-shRNA™STMN1) BIV (bilamellar invaginated vesicle) lipoplex (LP), pbi-shRNA™ STMN1 LP administered by a single intratumoral (IT) injection. Patients will accrue in 4-patient escalation cohorts using a modified Fibronacci escalation schema at a starting intratumoral dose of 0.010 mg/kg of DNA through a dose of 0.053 mg/kg DNA intratumoral / single dose.
1694753|NCT01505140|Other|Whole walnuts|75 gm whole walnuts per day will be consumed with usual Western style diet
1694754|NCT01505127|Drug|TAK-438|
1694755|NCT01505127|Drug|Lansoprazole|
1694756|NCT01505127|Drug|Amoxicillin|
1694757|NCT01505127|Drug|Clarithromycin|
1694758|NCT01505114|Drug|Maraviroc|300-mg tablet, once daily, from Week 0 through Week 48
1694760|NCT01505114|Drug|Tenofovir disoproxil fumarate|300-mg tablet, once daily, from Week 0 through Week 48
1694761|NCT01505114|Other|Maraviroc placebo|Once daily from Week 0 through Week 48
1694762|NCT01505114|Other|Emtricitabine placebo|Once daily from Week 0 through Week 48
1694763|NCT01505114|Other|Tenofovir disoproxil fumarate placebo|Once daily from Week 0 through Week 48
1694764|NCT01505101|Behavioral|Mindfulness-Oriented Recovery Enhancement|MORE is a multimodal, dual-process group intervention involving mindfulness training, cognitive restructuring, and positive emotion induction. MORE consists of eight, weekly, two-hour group sessions led by a trained therapist.
1694765|NCT01505101|Behavioral|Conventional Support Group (SG)|The control arm will participate in a time-matched, conventional SG led by a Master's level therapist, discussing topics pertinent to chronic pain and opioid misuse. The SG format is adapted from the support group detailed in the evidence-based, Matrix Intensive Outpatient Treatment manual. The SG consists of eight, weekly, two-hour sessions.
1694766|NCT01505088|Drug|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
1694767|NCT01505088|Drug|Prednisolone Acetate (1%) Eyedrops|Prednisolone acetate (1%) eyedrops
1694768|NCT01505088|Drug|100 mM sodium citrate buffer solution|Transscleral iontophoresis delivery of 100 mM Sodium citrate buffer solution
1694769|NCT01505088|Drug|Placebo Eyedrops|Placebo Eyedrops
1694770|NCT01505075|Radiation|Hypofractionated radiation|40 Gy in 5 fractions to prostate, 30 Gy in 5 fractions to seminal vesicles; total treatment duration 29 days
1694772|NCT01505049|Drug|quadrivalent HPV vaccine|For the group who have received two prior doses of vaccine, the third and final dose of vaccine will be given. For the unvaccinated cohort, women will receive all three doses of the vaccine. The second dose of the vaccine will be given two months after the first dose. The third and final dose of the vaccine will be given six months after the first dose.
1694773|NCT01505036|Other|SMARTCARE service|U-Healthcare service
1694774|NCT01505023|Dietary Supplement|Partial meal replacement|The PMR was designed to contain sufficient amounts of all vitamins and minerals. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
1694775|NCT01505023|Dietary Supplement|Partial meal replacement with inulin|The PMR was designed to contain sufficient amounts of all vitamins and minerals plus inulin. Women were instructed to consume 2 servings per day at breakfast and dinner, each consisting of 33 g of powder dissolved in 250 ml of skim milk.
1694776|NCT01505023|Dietary Supplement|Inulin|Women were asked to consume one 5g serving of inulin mixed with any drink at breakfast and same amount at dinner (10 g of inulin/d).
1694778|NCT01504997|Device|Robot assisted distal gastrectomy (DaVinci)|patients who received robot assisted distal gastrectomy
1694779|NCT01504984|Drug|SYO-1126|Imatinib 400mg/tablet, PO, 1 tablet once daily for I&II D1(crossover)
1694780|NCT01504984|Drug|Glivec film coated tab 4T(400mg)|Imatinib 100mg/tablet, PO, 4 tablets once daily for period I&II D1(crossover)
1694781|NCT01504971|Other|symptom questionaire|GerdQ questionaire
1694782|NCT01504971|Procedure|pH monitoring|24-hour pH monitoring
1694783|NCT01504971|Procedure|Tri-modal imaging endoscopy|To investigate WLI,NBI and AFI
1694784|NCT01504971|Drug|rabeprazole|10mg, bid, p.o.
1694785|NCT01504958|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Each subject will receive up to 1800 pulses of up to 20Hz per day to all simulated brain regions together. Treated brain areas will be alternated each day (only 3 a day).
Sham participants will receive the same study procedures as patients receiving active rTMS."
1694786|NCT01504958|Behavioral|NICE Cognitive Training|"12 levels of difficulty in tasks designed to relate to the region of the brain being stimulated (left and right parietal cortex, left and right DLPFC, left superior temporal gyrus, left inferior frontal gyrus).
A particular cognitive exercise will start 200msec after the termination of each TMS train.
Sham participants receive sham cognitive training that follows the same procedures as the active group."
1694787|NCT01504945|Other|RBC transfusion|1 bag of packed red blood cells
1694788|NCT01504945|Other|Normal saline infusion|500 mL of normal saline infusion
1694789|NCT01504932|Drug|lyophilized black raspberry lozenge|ARM I: Patients will be instructed to begin LBR administration and continue daily for 6 months.
1694790|NCT01504932|Other|survey administration|Patients will be asked to complete a baseline survey of family history of cancer and tobacco/alcohol and mouthwash usage, a Head and Neck Cancer Inventory Survey (HNCI), an Insomnia Severity Index (ISI) survey, and a Brief Fatigue Inventory (BFI) survey. They will then receive a logbook (specific for this trial)
1694791|NCT01504932|Other|laboratory biomarker analysis|Patients will be asked to do blood, urine, and saliva sample and a buccal scrape. These biological samples will be evaluated for the presence of LBR components (as a measure of compliance) and assessment of LBR responsive genes, respectively.
1694792|NCT01504932|Other|pharmacological study|Correlative studies
1694793|NCT01504919|Behavioral|Health Education|Brief counseling at baseline, at 6 months and again at 12 months, and self-help materials addressing smoking cessation, diet, physical activity, referrals to available resources, and a home-based exercise kit (e.g., pedometer, exercise ball, strength training cables).
1694794|NCT01504919|Behavioral|Questionnaires|Computer-based questionnaires completed at baseline, then every 6 months taking 60-90 minutes to complete.
1694795|NCT01504919|Behavioral|Telephone Counseling Sessions|9 proactive, telephone counseling sessions over 18 months. Each of these phone calls should last about 20-30 minutes.
1694796|NCT01504919|Drug|Nicotine Patches|6-week supply of nicotine patches given to participants ready to quit smoking.
1694797|NCT01504906|Drug|cyclosporine|Oral tablets, 600 mg , single dose
1694798|NCT01504906|Drug|ticagrelor|Oral tablets, 180 mg, single dose
1694799|NCT01504893|Procedure|protective ventilation|Low tidal volume, PEEP and recruitment maneuver
1694800|NCT01504867|Drug|Aspirin|325mg loading dose once on study day 1, followed by 81mg dose once daily on study days 2-7. Administered by mouth or down nasal gastric tube.
1695444|NCT01500213|Drug|Rolapitant|200 mg PO
1694801|NCT01504867|Drug|Lactose powder|Matching lactose powder filled capsules will be administered on days 1-7.
1694802|NCT01504854|Drug|Resveratrol|The dosage will begin at 500 mg taken once daily and increase at 13 week intervals to 1 gram taken by mouth twice daily, supplied as 500 mg capsules (two capsules twice daily).
1694803|NCT01504854|Drug|Placebo|The matching placebo will begin at a capsule taken once daily and increase at 13 week intervals to two capsules twice daily.
1694804|NCT01504841|Drug|Etravirine (ETR)|ETR will be administered as 25-mg scored tablets and/or 100-mg tablets swallowed whole or dispersed in an appropriate liquid vehicle following a meal. Children will take the specified dose orally twice daily within 30 minutes following a meal. Dose will be decided according to dosing tables in protocol.
1694805|NCT01504828|Drug|Ramipril|Ramipril in one dose to reduce vascular stiffness to determine effects of this on left ventricular function and energetics
1694806|NCT01504815|Drug|cisplatinum|i.v. 100 mg/m2 on days 1, 22 and 43 of radiotherapy
1694807|NCT01504815|Radiation|Conventional radiotherapy|conventional radiotherapy, 70Gy in 7 weeks
1694808|NCT01504815|Radiation|Adaptive radiotherapy|adaptive high dose radiotherapy up to 84 Gy max on 50% uptake GTV in 7 weeks
1694809|NCT01504789|Behavioral|Baseline Fitness Test|Complete fitness tests to measure strength, flexibility, balance, and aerobic capacity. All of the baseline fitness tests will be repeated at the end of the program (at about the 16th week) during a follow-up visit.
1694810|NCT01504789|Behavioral|Questionnaires|At the baseline visit, complete questionnaires about demographic information taking about 35 minutes to complete. At 6 months after the follow-up visit, a packet of follow-up questionnaires about physical activity and quality of life will be mailed or given over the phone. It should take about 10 minutes to complete these questionnaires. Patients also be asked to fill out a questionnaire every week that asks about level of physical activity. The questionnaire should take about 5 minutes to complete.
1694811|NCT01504789|Behavioral|Individualized Exercise Program|The exercise programs will be individualized based on results from baseline fitness assessments and individual medical history using ACSM guidelines. For resistance and flexibility exercises each patient will receive an exercise prescription and instructional session prior to beginning the program. Invitation extended to attend monthly Group Exercise sessions with a family member. Resistance tubes, pedometer, exercise book, and video issued for use at home.
1694812|NCT01504789|Behavioral|Written Materials|Either culturally adapted AI materials or non-culturally intervention materials will be mailed to patients every 2 weeks. The 7 themed sessions are: Getting Started;Goal Setting;Effective Energy Balance;Getting Confident;Uncovering Barriers;Lapsing, Relapsing, Collapsing;and Continuing to be Active.
1694813|NCT01504776|Drug|Panobinostat|Dose escalation study of oral panobinostat administered Monday-Wednesday-Friday (MWF) weekly x 4 weeks, utilizing 3+3 dosing scheme (15, 20, 25 mg) in combination with a fixed dose of bortezomib 1.3 mg/m2 administered as a short intravenous (IV)infusion of 3-5 seconds every week x 4 weeks, representing one cycle. Each week, bortezomib will be administered IV prior to the oral dose of panobinostat
1694814|NCT01504776|Drug|Bortezomib|
1694815|NCT01504763|Procedure|Chair massage|Chair massage for 15 minutes once a week for 10 weeks.
1694816|NCT01504750|Procedure|dynamic daylight and atmosphere lighting|In the ceiling, luminaires are installed that offer the basic lighting in the patient room that will automatically and gradually change in light level (100-300 lux) and color temperature (3000-4000 K). This so called daily rhythm light meets the EN12464-1 standard for patient rooms in hospitals. The system offers a light boost by bringing the illuminance to a level of maximal 2000 lux and 7000 K, during a period of two hours in the morning. Besides, a low intensity color cove as well as some white LED spots are added to create a pleasant ambience in the patient room. The illuminance is between 50 and 60 lux and, depending on the color choice, the color temperature is 2300 K (relax) or 3800 K (active). The lighting solution used is HealWell of Philips Lighting.
1694819|NCT01504724|Drug|bevacizumab|intravitreal bevacizumab injection (1.25 mg/0.05 mL) was done 4.0 mm posterior to the corneal limbus using a 30-gauge needle after topical anesthesia
1694820|NCT01504711|Drug|fosaprepitant dimeglumine|Given IV
1694821|NCT01504698|Procedure|Advice and exercise-based treatment plus joint manipulation|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment plus joint manipulation.The areas and frequency of manipulative treatment will be determined by the chiropractor and will consist of high-velocity, low-amplitude manipulation and/or mobilization to the spine and/or the extremities.
1694822|NCT01504698|Procedure|Advice and exercise-based treatment|The treatment can consist of advice, activation and exercise and/or manual soft-tissue treatment. However, assisted stretching is not allowed as this will approach mobilization.
1694823|NCT01504685|Procedure|Banded Laparoscopic Roux-en-Y gastric bypass|"A 6.5-cm polypropylene Marlex mesh was placed immediately cephalad to the gastrojejunostomy. The gastrojejunostomy was hand-sewn in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.
The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
1694824|NCT01504685|Procedure|Unbanded Laparoscopic Roux- en-Y gastric bypass|"A hand-sewn gastrojejunostomy in 2 layers using 3-0 Polyglactin for the internal and 3-0 silk for the external layer.
To ensure a diameter of 1-1.5 cm,a 32F bougie was used to calibrate the gastro jejunum anastomosis. The length of alimentary and biliopancreatic limbs was approximately 150 cm and 50 cm, respectively."
1694900|NCT01504126|Behavioral|Questionnaire|Completion of questionnaires at baseline and after cycles 3 and 6 of chemotherapy.
1694826|NCT01504659|Drug|Ketamine hydrochloride injection|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 10 mg ketamine(0.25-0.5mg/kg)and will not exceed a maximum dose of 40 mg ketamine. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 20 mg ketamine(0.20-0.5mg/kg) and will not exceed a maximum dose of 120mg. ketamine. There will be 4 administrations of the drug at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, subjective opinion. Doses will be held constant as long as a therapuetic response, as measure of 80% improvement on YBOCS and YMRS, is reached.
1694827|NCT01504659|Drug|Flat tonic water (e.g., Canada Dry Tonic Water)|Separate dosing regimens will be applied depending on the weight of the child. Group A with minimum-maximum weight of 20 kg-40 kg will receive a fixed initial dose of 0.1cc placebo and not exceed a maximum dose of 0.4cc placebo. Group B with minimum - maximum weight of 40.01kg-100kg will get a fixed initial dose of 0.2cc placebo and will not exceed a maximum dose of 1.2cc. placebo. There will be 4 administrations of the placebo at three day intervals. Titration upward will depend upon degree of side effects, improvement from baseline on primary measures, and subjective opinion. Doses will be held constant as long as a therapuetic response, as a measure of 80% improvement on YBOCS and YMRS, is reached.
1694828|NCT01504646|Dietary Supplement|Lyprinol|8 capsules (1 capsule=50mg n-PUFA, 100mg olive oil) per day for 3 weeks
1694829|NCT01504646|Dietary Supplement|Placebo (Olive Oil)|8 capsules (1 capsule = 100mg olive oil) per day for 3 weeks
1694830|NCT01504633|Dietary Supplement|DHA/EPA and iron supplementation|24-week supplementation consisting of daily dosage of DHA/EPA or placebo capsule and iron/placebo syrup Capsule: DHA/EPA (100mg DHA + 20mg per day) or placebo Syrup: Fe syrup (16mg elemental iron per day) or placebo
1694831|NCT01504620|Other|Sugar infusion|Infusion of glucose to achieve high blood glucose levels
1694832|NCT01504620|Drug|insulin infusion|i.v. infusion of insulin
1694833|NCT01504607|Procedure|Congenital Cataract Surgery|Congenital cataract surgery with IOL implantation
1694834|NCT01504594|Procedure|Intracoronary autologous stem cell infusion|Under sedation and under sterile conditions in a fluoroscopy operation room, cardiac catheterization will be performed through the femoral artery to infuse the stem cells directly into the heart´s coronary arteries.
1694835|NCT01504581|Biological|HM10660A|Single dose of HM10660A 1.5, 2.25, 3.0, or 4.0 ug/kg
1694836|NCT01504581|Biological|HM10660A placebo|Single dose of HM10660A Placebo
1694837|NCT01504581|Biological|Pegasys|Single dose of Pegasys 180ug
1694838|NCT01504568|Other|Treatment|Adults: ≥40 kg:250mg every eight hours Children: <40kg: 20mg/kg/day divided in three doses (up to 250mg) every eight hours Suspension form 250mg/ml
1694839|NCT01504542|Biological|HS110 vaccine|0.5ml to be administered twice weekly for 18 weeks (36 doses)
1694840|NCT01504542|Biological|Placebo|0.5ml buffered saline placebo to be administered twice weekly for 18 weeks (36 doses)
1694841|NCT01504542|Biological|HS110 vaccine|0.5 mls to be dosed twice weekly for 18 weeks (36 doses)
1694842|NCT01504516|Drug|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
1694843|NCT01504516|Drug|Aricept|Aricept 10 mg Tablets
1694844|NCT01504503|Drug|Donepezil Hydrochloride|Donepezil Hydrochloride Tablets 10 mg
1694845|NCT01504503|Drug|Aricept|Aricept 10 mg Tablets
1694846|NCT01504490|Drug|CS-7017 and Bexarotene|"CS-7017 will be administered orally, twice daily for 28 days of each 28-day cycle in escalating doses depending on cohort patient is assigned to.
Bexarotene will be administered orally once daily for 28 days of each 28-day cycle. The dose a patient receives will depend on which cohort the patient is assigned to."
1694847|NCT01504477|Drug|Panitumumab and bortezomib|"Panitumumab 6 mg/kg IV over 60 minutes on Day -14 (first cycle only), then Day 1 and 15 of each 28-day cycle.
Bortezomib will be administered in escalating doses until the maximum tolerated dose is determined and then at the maximum tolerated dose as an IV bolus injection over 3-5 seconds on Day 1, 8, and 15 of each 28-day cycle."
1694848|NCT01504464|Biological|mesenchymal stem cell|intra articular injection of mesenchymal stem cell
1694849|NCT01504464|Biological|Placebo|Patients with knee joint osteoarthritis who underwent intra articular placebo injection
1694850|NCT01504451|Device|ILR insertion|Insertion of implantable loop recorder
1694851|NCT01504451|Procedure|AF ablation|AF ablation
1694852|NCT01504438|Device|Salto-Talaris Total Ankle Replacement|Salto-Talaris Total ankle replacement surgery
1694853|NCT01504438|Device|STAR Total Ankle Replacement|STAR Total Ankle Replacement
1694854|NCT01504412|Drug|DS-5565|Oral tablets administered twice daily
1694855|NCT01504412|Drug|DS-5565|Oral tablets administered twice daily
1694856|NCT01504412|Drug|DS-5565|Oral tablets administered twice daily
1694857|NCT01504412|Drug|Placebo|DS-5565 placebo oral tablets and pregabalin placebo oral capsules administered 2 times per day
1694858|NCT01504412|Drug|Pregabalin capsules|Pregabalin oral capsules 150 mg administered twice a day
1694859|NCT01504386|Procedure|TAP block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0.5 %
1694860|NCT01504386|Procedure|Placebo TAP block|Bilateral placement of 20 ml of saline 0.9 % in the transversus abdominis plane
1694861|NCT01504373|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Subjects will be placed in the NAVA mode of ventilation.
1694862|NCT01504360|Genetic|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and localisation of the sarcoma secondary developed will be collected. 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
1694863|NCT01504360|Genetic|tumor genetic predisposition to develop sarcoma assessment|data concerning initial radiation and data demonstrating the lack of secondary sarcoma will be collected . 2 blood samples (2 x 5 ml)will be collected. One sample of 5 mm will be dedicated to study radiation induced apoptosis assessed by flow cytometry. The second sample will be used to study the polymorphism of the genes involved in reparation of DNA by using chip screening of single nucleotide polymorphisms (SNP). DNA will be extracted and controlled by flow cytometrical separation.
1751995|NCT00208221|Drug|ramipril|
1694867|NCT01504334|Drug|Pirfenidone|Pirfenidone（200mg）tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week.
1694868|NCT01504334|Drug|Placebo|Placebo（without active ingredient） tablets will be taken 3 times a day during the whole study process. For the first week, 1 tablet will be taken each time. For the second week, 2 tablets will be taken each time. From the third week to the 48th week, 3 tablets will be taken each time. Base drug Acetyl Cysteine Tablets（600mg）will be taken once a day, 1 tablet each time from the first to the 48th week for both groups.
1694869|NCT01504321|Drug|Moxonidine|0.2 mg/day moxonidine for 2 weeks 0.4 mg/day moxonidine for 3 months
1694870|NCT01504321|Drug|Placebo|Encapsulated lactose powder
1694871|NCT01504308|Device|MR-HIFU treatment|A treatment session with the Philips Sonalleve MR-HIFU device for thermal ablation of uterine fibroids with high-intensity focused ultrasound.
1694872|NCT01504308|Device|Sham treatment|A pretend treatment session with the Philips Sonalleve MR-HIFU system in which no therapeutic ultrasound doses are delivered.
1694873|NCT01504295|Drug|Metadoxine|Improve Liver Function and Reduce ALcohol Use
1694874|NCT01504282|Drug|mitomycin-C|
1694875|NCT01504282|Drug|Placebo|balanced salt solution (BSS)
1694876|NCT01504256|Drug|catumaxomab, Fluorouracil, leucovorin, oxaliplatin, docetaxel|"Catumaxomab: 4 intraperitoneal infusions of catumaxomab at an escalating dose of 10µg (d0), 20µg (d3), 50µg (d7), and 150µg (d10)
and 7 days after the last catumaxomab infusion
FLOT; 6 cycles q2w: Fluorouracil 2600 mg/m² as 24h infusion (d1) , leucovorin 200mg/m² (d1), oxaliplatin 85 mg{m² (d1), docetaxel 50 mg/m² (d1)"
1694877|NCT01504256|Drug|Fluorouracil, leucovorin, oxaliplatin, docetaxel|"FLOT; 6 cycles q2w:
Fluorouracil 2600 mg/m² as 24h infusion (d1) leucovorin 200mg/m² (d1) oxaliplatin 85 mg{m² (d1) docetaxel 50 mg/m² (d1)"
1694880|NCT01504191|Behavioral|Internet‐based CBT|"The participants read texts and do weekly homework assignments instructed from an Internet page. Additional resources like discussion forum, pictures, animations, videos and sounds will be a part of the treatment program.
A psychologist will communicate with the participants through internal text‐messages. The therapist will devote about 10 minutes to each participant each week via the Internet. The content of the intervention will be standard components from CBT, for example relaxation training, behavioral activation, exposure for fear related stimuli, cognitive restructuring, behavioral sleep treatment etc."
1694881|NCT01504178|Drug|duloxetine|administration during 28 days
1694882|NCT01504178|Drug|placebo of duloxetine|administration during 28 days
1694883|NCT01504178|Drug|injection of apomorphine|injection performed at D28
1694884|NCT01504178|Drug|injection of placebo of apomorphine|performed at D28
1694885|NCT01504178|Drug|L-Dopa|performed at D28
1694886|NCT01504178|Drug|injection of placebo of L-Dopa|performed at D28
1694887|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
1694888|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
1694889|NCT01504165|Drug|cilengitide 2000mg|A single dose of cilengitide 2000mg (250mL) will be administered as 1-hour i.v. infusion on Day 1
1694890|NCT01504165|Drug|cilengitide 1000mg|A single dose of cilengitide 1000mg (125mL) will be administered as 1-hour i.v. infusion on Day 1
1694891|NCT01504165|Drug|cilengitide > 1000mg and up to 2000mg|A single dose of cilengitide > 1000mg and up to 2000mg will be administered as 1-hour i.v. infusion on Day 1 if applicable, based on Safety Monitoring Committee decision
1694892|NCT01504152|Behavioral|questionnaire|The intervention is a self-administered questionnaire that is voluntarily completed by the subject. This questionnaire has been previously validated and demonstrated to be reproducible in English speaking travelers. The final version of the survey questionnaire consists of 49 questions.Patients who never traveled after HSCT will answer only eighteen questions related to their medical and HSCT history in addition to their demographics.
1694893|NCT01504139|Drug|hCG(r-hCG, Ovitrelle, Merck-Serono, Hellerup, Denmark) in the late follicular phase + luteal phase|when the follicles are over 12 mm FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) is replaced by hCG (r-hCG, Ovitrelle,Merck-Serono, Hellerup,Denmark).
1694894|NCT01504139|Drug|hCG(r-hCG, Ovitrelle,Merck-Serono, Hellerup, Denmark) in the follicular phase + luteal phase|hCG(r-hCG,Ovitrelle,Merck-Serono, Hellerup, Denmark) is given together with FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark) from the beginning of the FSH(r-hFSH; Gonal-F, Merck-Serono, Hellerup, Denmark)stimulation.
1694895|NCT01504139|Drug|LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase|LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
1694896|NCT01504139|Drug|vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol(Estrofem; Novo Nordisk, Copenhagen, Denmark) in the luteal phase|The usual dose of vaginal progesterone(Crinone; Merck-Serono, Hellerup, Denmark) and estradiol (Estrofem; Novo Nordisk, Copenhagen, Denmark) is given in the luteal phase-
1694897|NCT01504126|Drug|Propranolol|20 mg by mouth twice a day for 48-72 hours preoperatively. Resume when participant tolerating oral intake post-operatively until completion of chemotherapy.
1694898|NCT01504126|Drug|Chemotherapy|Within 3 weeks of surgery, standard intravenous platinum or taxane chemotherapy (without bevacizumab) over 3-week cycles.
1694901|NCT01504074|Behavioral|if needed (decided individually) either Acular eye drops, Ultracortenol eye drop or intravitreal triamcinolone injection|if prescribed: Ultracortenol/ Acular eye drops 3-4 times a day, if prescribed: singular intravitreal triamcinolone injection
1694902|NCT01504061|Other|Mederma N&I|Topical gel applied three times a day for eight weeks.
1694903|NCT01504061|Other|Mederma Ultra Gel|Topical gel applied once daily for eight weeks.
1694904|NCT01504048|Procedure|Colonoscopy with Indigo-Carmine Chromoendoscopy|Colonoscopy with chromoendoscopy using 0.2-0.5% Indigo-Carmine solution sprayed in five areas of the large intestine: Cecum, ascending colon, transverse colon, descending colon and rectum. Pictures are taken before and after dye-spraying and biopsies are collected from all segments of the large intestine and rectum.
1694905|NCT01504035|Device|Orthostat-L|Application of nx2g Lidocaine loaded hemostatic putty, i.e. Orthostat-L at the iliac crest bone graft harvest site
1694906|NCT01504035|Device|Orthostat|Application of nx2g hemostatic putty, i.e. Orthostat at the iliac crest bone graft harvest site
1694907|NCT01504022|Other|Telecare, selfmonitoring, lifestyl behaviour|Patients measure their own bloodpressure and the results are shown at a secured website after USB connection of the monitor to the computer. Patients receive medication adjustments and lifestyle advices via this secured website.
1694908|NCT01504009|Other|Muscle training|12 weeks of strength training 2-3 times/week
1694909|NCT01503996|Behavioral|alter drinking habits|if dehydration is apparent, more fluid intake is recommended
1694910|NCT01503983|Drug|Trastuzumab|Trastuzumab: 8 mg/kg day 1 followed by 6 mg/kg every 3 weeks (i.v.)
1694911|NCT01503983|Drug|Capecitabine|Capecitabine: 1000 mg/m2/12h/days 1 - 14 every 3 weeks (v.o.)
1694912|NCT01503983|Drug|Oxaliplatin|Oxaliplatin: 130 mg/m2 in 2 h, day 1 / (i.v.) /every 3 weeks
1694913|NCT01503970|Device|Arthroscopic matrix encapsulated chondrocyte implantation|Each implant of collagen scaffold contains approximately 6,000,000 autologous chondrocytes. This constructs of 10 mm diameter are implanted arthroscopically at the defect.
1694914|NCT01503957|Device|Nasya|Thixotropic nasal spray suspension, 2 sprays in each nostril
1694915|NCT01503957|Device|Saline solution|Nasal spray, 2 sprays in each nostril
1694916|NCT01503944|Drug|18F-AV-133|185 MBq
1694917|NCT01503944|Drug|18F-AV-45|185-370 MBq
1694918|NCT01503918|Drug|Valaciclovir/Aciclovir|2g valaciclovir, four times a day, enterally for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Those unable to receive enteral drugs will receive intravenous aciclovir 10mg/kg three times a day. Dosing modified in the presence of renal dysfunction.
1694919|NCT01503918|Drug|Valganciclovir/Ganciclovir|450mg valganciclovir, once a day, by enteral route. Treatment will continue for 28 days, or until discharge from the critical care unit, but for a minimum of 14 days unless discharged from hospital. Intravenous ganciclovir 2.5mg/kg once a day will be used if drugs cannot be given enterally. Treatment dosing will be modified for renal dysfunction
1694920|NCT01503905|Drug|Docetaxel|75mg/m2, iv injection, day1, every 21 days
1694921|NCT01503905|Drug|epirubicin|80mg/ m2, iv injection, day1, every 21 days
1694922|NCT01503905|Drug|cyclophosphamide|500 mg/m2, iv injection, day1, every 21 days
1694923|NCT01503905|Procedure|Modified radical mastectomy or breast-conserving Surgery|Two weeks after four cycles of neoadjuvant chemotherapy
1694924|NCT01503905|Drug|Docetaxel (post-operative)|Two weeks after surgery,75mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
1694925|NCT01503905|Drug|Epirubicin (post-operative)|Two weeks after surgery, 80mg/m2,iv injection, day1, every 21 days, 4 cycles totally
1694926|NCT01503905|Drug|Cyclophosphamide (post-operative)|Two weeks after surgery, 500mg/m2, iv injection, day1, every 21 days, 4 cycles totally.
1694927|NCT01503905|Radiation|Radiation therapy|Two weeks after post-operative chemotherapy, perform radiation therapy based on 2011 NCCN guideline.
1694928|NCT01503905|Drug|Herceptin （post-operative)|Perform herceptin therapy (one year) based on 2011 NCCN guideline if the pathological test of the operative tumor sample showed HER2 positive.
1694929|NCT01503905|Drug|Tamoxifen (post-operative)|After radiation therapy, totally five years. Perform hormone therapy based on 2011 NCCN guideline if the tumor is ER/PR positive.
1694930|NCT01503892|Dietary Supplement|Metanx|Metanx- one tablet twice daily for twelve months
1694931|NCT01503892|Drug|Placebo|Placebo- one tablet twice daily for twelve months.
1694932|NCT01503866|Drug|bardoxolone methyl|oral, single dose
1694933|NCT01503840|Drug|sugammadex|sugammadex 10 mg/ml diluted solution dosage: 1mg/kg i.v. (0,1 ml/kg)
1694934|NCT01503840|Drug|Sodium chloride solution|Sodium chloride solution 0,9% dosage: 0,1 ml/kg i.v.
1694935|NCT01503827|Radiation|WBRT|A minimum of 30 Gy in 10 fractions given as one fraction per day within 4 weeks of randomisation
1694936|NCT01503814|Other|Simplified cardiovascular disease management|"This study is a complex pragmatic trial.The intervention includes a package of 4 main established measures for cardiovascular prevention and management:
2 therapeutic lifestyle recommendations- smoking cessation (if applicable) and reduced salt consumption
2 drug therapies (if applicable)- hydrochlorothiazide, 25mg tab, 1/2 tab daily (12.5mg/day) and aspirin, 25mg tab, 3 tabs daily (75mg/day)"
1694937|NCT01503801|Drug|Nitric Oxide|The infants in experimental group will receive inhale nitric oxide initiated at 5 ppm for 24 h followed by 2 ppm for 6 days or until weaning off
1694938|NCT01503801|Device|respiratory support|Routine respiratory support.
1694939|NCT01503788|Drug|Midazolam|participants will be given Midazolam IV 10-5 minutes prior to diagnostic lumbar puncture
1694940|NCT01503762|Other|Mirror therapy|mirror therapy
1694941|NCT01503762|Other|Classical rehabilitation techniques|splinting, tendon gliding, active range of motion, activities of daliy living
1694942|NCT01503749|Drug|G-colony stimulating factor|G-colony stimulating factor (5ug/kg/day)will be administered subcutaneously to three patients with liver cirrhosis of this arm.
1694943|NCT01503749|Other|Infusion of the mobilized monocyte cells|G-colony stimulating factor (5ug/kg/day)will be administered twice subcutaneously for 3 days to three patients with liver cirrhosis of this arm. On the day 4th, leukapheresis will be done to collect peripheral blood mononucleated cells. And then we are going to infuse the collected peripheral blood mononucleated cells of their own through the portal vein of each patients under ultrasonographic guidance.
1752061|NCT00196079|Device|Coronary stent|
1694945|NCT01503736|Drug|ferric citrate|4g/day ferric citrate capsule, TID for 56 days
1694946|NCT01503736|Drug|ferric citrate|6 g/day ferric citrate capsule, TID for 56 days
1694947|NCT01503723|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
1694948|NCT01503684|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
1694949|NCT01503671|Drug|Atorvastatin|Atorvastatin 40 mg/day
1694950|NCT01503658|Drug|Clopidogrel+Aspirin|Clopidogrel 75 mg, Aspirin 100 mg
1694951|NCT01503632|Behavioral|behavioral intervention|Receive intervention program
1694952|NCT01503632|Drug|mercaptopurine|Given orally
1694953|NCT01503632|Procedure|standard follow-up care|Receive usual standard of care
1694954|NCT01503632|Behavioral|compliance monitoring|Correlative studies
1694955|NCT01503632|Other|questionnaire administration|Ancillary studies
1694956|NCT01503632|Other|laboratory biomarker analysis|Correlative studies
1694957|NCT01503619|Other|laboratory biomarker analysis|Correlative studies
1694958|NCT01503606|Drug|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization for one week
1694959|NCT01503606|Drug|Clarithromycin|clarithromycin 500mg po bid after randomization for one week
1694960|NCT01503606|Drug|Cefazolin|Cefazolin 1.0gm IVs q 12 hours after randomization until delivery
1694961|NCT01503606|Drug|Clarithromycin|clarithromycin 500mg po bid after randomization until delivery
1955760|NCT03084939|Biological|Trastuzumab Emtansine|Trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) was administered intravenously on Day 1 of each 21-day cycle.
1694963|NCT01503580|Drug|tolterodine, solifenacin|The enrolled women before March 2009 were treated with tolterodine 4 mg slow-release, and after March 2009 were treated with solifenacin 5 mg once a day for 12 weeks.
1694964|NCT01503567|Other|No treatment given|Subject will only fill out a questionaire
1694965|NCT01503554|Behavioral|Combined Social Worker and Pharmacist Program|"Physician or nurse performs a med rec during hospital stay Clinical pharmacist completes an additional med rec of home meds, assesses med-related risks, and provides education After discharge, a Master's prepared social worker contacts the patient and conducts an assessment from a psychosocial perspective to identify any unmet needs.
Pharmacist will be available to patients should they have any medication-related questions post-discharge"
1694966|NCT01503554|Behavioral|No Intervention: Usual Care|Patient receives usual care upon discharge from the hospital.
1694967|NCT01503541|Genetic|DNA analysis|
1694968|NCT01503541|Genetic|RNA analysis|
1694969|NCT01503541|Genetic|gene expression analysis|
1694970|NCT01503541|Genetic|mutation analysis|
1694971|NCT01503541|Genetic|polymerase chain reaction|
1694972|NCT01503541|Other|laboratory biomarker analysis|
1955761|NCT03084939|Drug|Lapatinib|Lapatinib 1250 mg was administered orally once per day of each 21-day cycle.
1955762|NCT03084939|Drug|Capecitabine|Capecitabine 1000 milligrams per square meter (mg/m^2) was administered orally twice daily on Days 1-14 of each 21-day cycle.
1694976|NCT01503515|Drug|caspofungin acetate|Given IV
1694977|NCT01503515|Drug|fluconazole|Given IV or PO
1694978|NCT01503515|Drug|voriconazole|Given IV or PO
1694979|NCT01503515|Other|laboratory biomarker analysis|Optional correlative studies
1694980|NCT01503502|Drug|flumatinib|Flumatinib was supplied as 100 and 200 mg film-coated tablets for oral administration. Storage condition: 25°C, light proof, sealed.
1694981|NCT01503502|Drug|imatinib|Imatinib was supplied as 100 mg film-coated tablets. Storage condition: 25°C (77°F). Protected from moisture.
1694982|NCT01503489|Drug|Selective Serotonin Reuptake Inhibitors (SSRI), Serotonin-Norepinephrine Reuptake Inhibitor( SNRI), and Tricyclics.|Risk for antidepressant-associated switch from depression to hypomania, mania, or mixed episode during the 8 weeks after the introduction of an antidepressant or after increasing the dosage of baseline antidepressant.
1694983|NCT01503476|Device|Bravo® pH Monitoring System|Bravo pH monitoring
1694984|NCT01503476|Device|Bravo® pH Monitoring System|Bravo pH monitoring
1694985|NCT01503463|Procedure|Home telemonitoring of patients with CHF|"Patients in the intervention group receive a personal 1-lead or 12-lead ECG recorder, a blood pressure monitor, a digital weight scale and appropriate education regarding the use of these devices. ThA trained nurse visits the patients weekly during the first month, and monthly thereafter, to confirm the appropriate use of the devices and services, to monitor symptoms, adherence to pharmacological and non-pharmacological treatment, and to complete the case record forms when necessary.
If there is deterioration in the monitored vital signs, or if symptoms are reported, the allocated cardiologist is informed via the telehealth platform and has to decide whether the patient has to visit the hospital as in- or outpatient and whether the therapy has to be modified."
1695445|NCT01500213|Drug|Granisetron|10 mcg/kg IV
1694986|NCT01503450|Drug|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
1694987|NCT01503437|Drug|Olanzapine OD Tablets 5 mg|Olanzapine OD Tablets 5 mg of Dr. Reddy's Laboratories Limited
1694988|NCT01503424|Drug|Olanzapine|Olanzapine Tablets, 5 mg
1694989|NCT01503398|Drug|Olanzapine|Olanzapine Tablets, 5 mg
1694990|NCT01503385|Drug|Celecoxib|400 mg by mouth twice daily for for 5-7 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 6 weeks).
1694991|NCT01503372|Drug|Pazopanib|Adding Pazopanib to a standard chemotherapy consisting of FLO. 800 mg (2x400mg or 4x200mg) Pazopanib per day should be taken orally without food at least one hour before or two hours after a meal. Pazopanib will be given d1-14 each cycle (2 weeks cycles) with 12 cycles of chemotherapy FLO (d 1, each cycle). After 12 cycles chemotherapy FLO will be discontinued and Pazopanib will be given alone until disease progression
1694992|NCT01503372|Drug|5-FU, Oxaliplatin, Leukovorin (FLO)|Oxaliplatin 85 mg/m2 2h iv Leucovorin 200mg/m2 2h - iv FU 2600mg/m2 24h iv q2w for 12 cycles
1694993|NCT01503359|Dietary Supplement|Sarcosine|"Sarcosine group patients will receive 2 grams of sarcosine once a day in the morning for 6 months.
Placebo group patients will receive 2 grams of placebo once a day in the morning for 6 months."
1694994|NCT01503346|Drug|DaHuang GanTsao Tang|"Intervention group
2 grams of DaHuang abstract powder and 0.5 grams GanTsao abstract powder are mixed and separated into four packages;
each package was given to each patient four times a day (three time after meal and one time before sleep);
each patient received the usual medication of the hospice ward at the same time;
record the patients' score of pre-test, mid-test and after-test of QIPCTP at the 1st day, the 3rd day and the 6th day;
record the patients' score of EORTC QLQ-C30 V3.0 and ECOG (Eastern Cooperative Oncology Group Performance Status) at the 1st day and the 6th day."
1694995|NCT01503333|Behavioral|Physical activity intervention|Receiving individual counseling with the school nurse, tailored feedback from computer program, and after-school physical activity club.
1694996|NCT01503320|Dietary Supplement|Enteral glutamine|Dosage of glutamine: 0.57g/kg, ~ 30g/day= 3sachets
1694997|NCT01503320|Dietary Supplement|Placebo|Similar appearing nutritional supplement without glutamine.
1694998|NCT01503281|Other|Circuit training|Aerobic and resistance training exercises + Mediterranean diet
1694999|NCT01503268|Device|Implantation of implantable loop recorder|An implantable loop recorder (ILR) will be used to assess atrial fibrillation(AF) before and after DCCV or ablation, unless there is a pre-existing ILR or permanent pacemaker capable of continuous monitoring for occurrence of AF.
1695000|NCT01503268|Procedure|Percutaneous ablation of atrial fibrillation|Catheter-based percutaneous ablation of atrial fibrillation
1695001|NCT01503268|Procedure|Surgical ablation of atrial fibrillation|Minimally-invasive thoracoscopic surgical ablation of atrial fibrillation
1695002|NCT01503255|Behavioral|cognitive behavioral group therapy|6 weekly 90-minute group sessions
1695003|NCT01503255|Behavioral|health education group|6 weekly 90-minute group sessions
1695004|NCT01503242|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
1695005|NCT01503242|Drug|Cyclosporine|Given PO
1695006|NCT01503242|Drug|Fludarabine Phosphate|Given IV
1695007|NCT01503242|Drug|Mycophenolate Mofetil|Given IV or PO
1695008|NCT01503242|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
1695009|NCT01503242|Radiation|Total-Body Irradiation|Undergo TBI
1695010|NCT01503242|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given IV
1695011|NCT01503229|Drug|Abiraterone Acetate|Given PO
1695012|NCT01503229|Other|Laboratory Biomarker Analysis|Correlative studies
1695013|NCT01503229|Other|Pharmacological Study|Correlative studies
1695014|NCT01503229|Drug|Prednisone|Given PO
1695015|NCT01503216|Dietary Supplement|cholecalciferol|cholecalciferol, 2000 IU per day, 8 weeks
1695016|NCT01503216|Dietary Supplement|ergocalciferol|vitamin d2, 2000 IU per day for 8 weeks
1695017|NCT01503216|Dietary Supplement|Placebo|Placebo
1695018|NCT01503203|Other|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
1695019|NCT01503203|Other|Core training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
1695020|NCT01503203|Other|Physical Virtual Training|The video game (Nintendo Wii and Wii Balance Board) will used for intervention. After strength and core training will be applied the physical virtual training during thirty minutes. Tho total time session for the Wii Group will be 110 minutes.
1695021|NCT01503203|Other|Strength Training|It will be does three times per week. The exercises are: squat, single leg squat, leg extension, leg curl, chair adductor, chair abductor and double plantar flexion.
1695022|NCT01503203|Other|Core Training|Exercises for trunk stabilization. Will be lateral, front and back bridges. It will be does three times per week with three sets between fifteen and third seconds.
1695023|NCT01503177|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|Given intrapleurally
1695024|NCT01503177|Other|laboratory biomarker analysis|Correlative studies
1695025|NCT01503177|Procedure|single photon emission computed tomography|Correlative studies
1695026|NCT01503177|Procedure|computed tomography|Correlative studies
1695029|NCT01503151|Behavioral|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
1695030|NCT01503151|Behavioral|Interpretation Bias Modification (IBM)|Interpretive Bias Modification Treatment (IBMT) using a computerized task modified to facilitate a more benign interpretation bias.
1695446|NCT01500213|Drug|Dexamethasone|20 mg PO and 8 mg PO
1955775|NCT03075670|Drug|N9-GP|A single dose of 50 IU/kg for intravenous (i.v.) injection
1955776|NCT03075670|Drug|ALPROLIX®|A single dose of 50 IU/kg for intravenous (i.v.) injection
1695031|NCT01503151|Behavioral|Control Condition|Attention and interpretation training using a computerized tasks not intended to alter threat-related biases patterns.
1695032|NCT01503151|Behavioral|Attention and Interpretive biases modification (CBM)|Attention and interpretation training via computerized tasks intended to direct attention away from threat stimuli and to facilitate a more benign interpretation bias.
1695033|NCT01503138|Behavioral|Purpose-built intervention|A purpose-built intervention consists of: (i) Empowerment; (ii) Parenting workshops; and (iii) Telephone social support and Peer support.
1695034|NCT01503112|Other|No intervention, observational study|
1695035|NCT01503086|Other|computer-assisted cognitive training|Receive computer-assisted cognitive training
1695036|NCT01503086|Other|questionnaire administration|Ancillary studies
1695037|NCT01503086|Procedure|cognitive assessment|Ancillary studies
1695038|NCT01503086|Procedure|psychosocial assessment and care|Ancillary studies
1695039|NCT01503086|Procedure|quality-of-life assessment|Ancillary studies
1695040|NCT01503073|Device|tdcs (ELDITH, Neuroconn, Ilmenau, Germany)|transcranial direct current stimulation
1695041|NCT01503060|Behavioral|Educational video - Active|The active video will instruct parents in techniques related to optimal infant soothing.
1695042|NCT01503060|Behavioral|Educational Video - Sham|The sham video will provide general information about immunization immunization pain management.
1695043|NCT01503060|Drug|Sucrose Placebo (water)|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
1695044|NCT01503060|Drug|Sucrose|Infants will receive 2mL of liquid on the tongue 2 minutes prior to vaccination
1695045|NCT01503060|Drug|Lidocaine Placebo|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
1695046|NCT01503060|Drug|Lidocaine|Infants will receive 1 g of cream to one or both injection site(s), as required, for 20-30 minutes prior to vaccination
1695047|NCT01503047|Dietary Supplement|Tonalin®|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g of a 1:1 mix of c9-t11 and t10-c12 (Tonalin®) (CLA group)
1695048|NCT01503047|Dietary Supplement|Placebo|Treatment consisted of exchanging the normal milk product consumed at breakfast for 200 ml of a skimmed milk with a lipid composition of 0.42 g saturated fatty acids (SFAs) and 0.72 g oleic acid, enriched with 3 g oleic acid (placebo)
1695049|NCT01503021|Drug|SFP|Dialysis with SFP administered via the liquid bicarbonate concentrate at a concentration of 2 µmoles (110 µg) iron/L of dialysate
1695050|NCT01503021|Other|Placebo|Dialysis with standard liquid bicarbonate concentrate without iron
1695051|NCT01503008|Device|Proteus Sustained Behavior Change system|The SBC system uses ingestible and wearable sensing devices and mobile phones to reinforce positive behaviors around medication usage, exercise and rest. Subjects will be taking their regularly prescribed oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors); glucometer
1695052|NCT01503008|Drug|Regularly prescribed diabetes medicines (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors)|Oral hypoglycemics (metformin, sulfonylureas, thiazolidinediones, DPP-IV inhibitors, alpha-glucosidase inhibitors) at subjects' regularly prescribed doses; glucometer
1695053|NCT01502995|Device|Laser light (U-Step Walking Stabilizer with laser light)|Use of a laser light on a rolling walker during episodes of freezing of gait.
1695054|NCT01502982|Drug|R-CHOEP14x6+HD-AraC+HD-Mtx|rituximab 375 mg/m2 day 1 cyclophosphamide 750 mg/m2 day 1 doxorubicin 50 mg/m2 day 1 vincristine 1.4 mg/m2 day 1 etoposide 100mg/m2 days 1,2,3 Prednison 100 mg days 1,2,3,4,5 cycle repeated six times every two weeks followed by HD-AraC 3g/m2x4 and HD-mtx 3 g/m2 HD-AraC 3g/m2x4 times every 12 h
1695055|NCT01502969|Biological|Rotavin-M1|liquid, 10e6ffu/dose, 2 doses, 2 month interval
1695056|NCT01502969|Biological|cell culture medium in absence of virus|Placebo
1695059|NCT01502943|Drug|Louxiangdan Tongxin granules|"TCM treatment:
Decoction: Louxiangdan Tongxin granules Herbs:Danshen 10g、Chenxiang 1g、Gualou10g、Xiebai 10g、Banxia6g、Chuanxiong 6g 、Dangshen 10g、Zhiqiao 6g、Taoren 10g、Guizhi 6g Therapeutic Principle:Invigorating Spleen to Remove Phlegm and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.
Usage:Once 100ml, twice per day after breakfast and supper."
1695060|NCT01502943|Drug|TCM granules placebo|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
1695061|NCT01502943|Drug|Chixiangshen Tongxin granules|"TCM treatment:
Decoction: Chixiangshen Tongxin granules Herbs: Chishao 10g, Chenxiang 1g, Danggui 10g, Jupi 10g, Yanhusuo 6g, Chuanxiong 6g, Dangshen 10g, Huangqi 6g, Taoren 10g, Honghua 10g Therapeutic Principle:Invigorating Spleen to Replenish Qi and activating blood and dissolving stasis, at least 6 kinds of TCM herbs can be chosen and their dosages be adjusted according to Syndrome Differentiation.
Usage:Once 100ml, twice per day after breakfast and supper."
1695062|NCT01502943|Drug|TCM granule placebo plus western basis treatment|Chinese medicine granules placebo: once 100ml, twice per day after breakfast and supper.
1695153|NCT01502241|Radiation|Radiotherapy of the partial brain.|60 Gy in 30 fractions à 2 Gy.
1695207|NCT01501890|Drug|dihydroxyprogesterone caproate|250mg once a week by intramuscular administration
1955781|NCT03073733|Biological|human retinal progenitor cells|live suspension of 3 or 4 x 10e6 human retinal progenitor cells (hRPC) suspended in clinical grade medium injected intravitreally under local anesthesia
1955782|NCT03073733|Other|Mock injection|pressing the hub of a syringe with no needle against the eye to mimic intravitreal injection
1958218|NCT01874353|Drug|Placebo to match olaparib 300mg|300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
1695063|NCT01502943|Drug|Western basis treatment|Aspirin: 100mg pd. P.O.( patients who have Aspirin resistance or Allergy can replaced with Piece clopidogrel 75mg pd. P.O.) Atorvastatin calcium (Lipitor): 10mg pd. P.O.( patients who have Atorvastatin calcium resistance or Allergy can replaced with Additive amount of pravastatin equal to 10mg Lipitor) Nitroglycerin: sublingual necessary.
1695064|NCT01502930|Behavioral|IRT|Internet-based IRT with therapist support during 6 weeks
1695065|NCT01502930|Behavioral|Stress Reduction|Internet-based stress reduction with therapist support during 6 weeks
1695066|NCT01502917|Radiation|Radioactive iodine-labeled monoclonal antibody 8H9|Prior to treatment, children will be pre-medicated with super-saturated potassium iodide (SSKI) & liothyronine to prevent thyroid uptake of the therapeutic radioisotopes. The proposed intervention is a surgical procedure using interstitial infusion of the radiolabeled monoclonal antibody 124I-8H9 into the brain stem tumor. This will be performed by stereotactic placement of a small caliber infusion cannula into the tumor followed by a slow infusion (CED) of 124I-8H9. Following treatment, these children will be monitored during inpatient hospitalization with clinical evaluations & PET/CT or PET/MRI scans of the brain & other organs. Clinical observations, intensive care unit monitoring, routine blood & interval imaging studies (MRI & PET/CT or PET/MRI scans) will be performed at predetermined time points. If the PET/CT scan happens to fall on a weekend or holiday, the scan may be done before or after at the discretion of the Study PI. This will not affect dosimetry interpretation.
1695067|NCT01502904|Device|Sirolimus-eluting stent|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
1695068|NCT01502904|Device|Biolimus-eluting stents|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
1695069|NCT01502904|Drug|pravastatin 20mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
1695070|NCT01502904|Drug|pitavastatin 2mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
1695071|NCT01502904|Drug|Non-ARB /day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
1695072|NCT01502904|Drug|Eposartan 600mg/day after DES implantation|2x2 randomization by the treatment of dyslipidemia and hypertension(In patients of dyslipidemia: pitavastatin 2mg/day vs. pravastatin 20mg/day, in patients of hypertension: eporsartan 600mg/day vs. Non-ARB) and the types of the implanted DES, SES vs BES.
1695073|NCT01502891|Other|Decision Aid|The decision aid, Depression Medication Choice, uses plain language and is designed to enhance patient understanding and satisfy the International Patient Decision Aid Standards (IPDAS) requirements for a safe and unbiased decision aid.
1695074|NCT01502878|Dietary Supplement|Nut challenge|Nut powder made from non-roasted nuts and roasted banana mixed with oats yoghurt or chocolate pudding
1695075|NCT01502878|Dietary Supplement|Nut challenge: Placebo|Dried banana mixed with oat yoghurt or chocolate pudding
1695076|NCT01502878|Dietary Supplement|Nut oral desensitization|Roasted peanut powder mixed with milk- and soy-free margarine
1695077|NCT01502839|Other|No Intervention|This retrospective data analysis will rely on data obtained from chart review.
1695078|NCT01502826|Dietary Supplement|standardized mixed meal|All participants will undergo a mixed meal test (300 kcal/m2 of body surface area, 53.8% carbohydrates, 29.5% lipids, 16.7% proteins) and will be monitored for 300 minutes thereafter.
1695079|NCT01502813|Drug|Citicoline, Omega-3 Fatty Acids and Creatine|Citicoline: 500 mg/day for 28 days Omega-3 Fatty Acids: 2 g/day for 28 days Creatine: 5 g/day for 28 days
1695080|NCT01502800|Drug|ARQ 761|ARQ 761 will be administered intravenously at a starting dose of 195 mg/m2 IV once weekly. Depending on toxicities observed, up to seven treatment cohorts will be enrolled with dose escalation occurring by doubling (first escalation) and 40% increments thereafter. If dosing is tolerated at all levels and pharmacokinetic data suggest continued escalation is warranted, additional dose levels will
1695081|NCT01502800|Drug|ARQ 761 Weekly Administration|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)
You will receive the same dose of ARQ761 each week for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.
The beginning dose level will be 390 mg/m2."
1695082|NCT01502800|Drug|Bi-Weekly Administration of ARQ 761|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein bi-weekly via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)
You will receive the same dose of ARQ761 bi-weekly for 8 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.
The beginning dose level will be 390 mg/m2."
1695083|NCT01502800|Drug|Two Consecutive Weeks Administration of ARQ 761 with one week of rest|"If you decide to participate in this study ARQ 761 (beta lapachone) will be given to you through your vein once a week via a Portacath or Hickman line (a device that will make it easier to access your central vein that will be placed under your skin in your upper chest)
You will receive the same dose of ARQ761 for 2 consecutive weeks followed by one week of rest for 6 weeks. The total infusion time will be determined by your physician, it may be either 2 or 3 hours.
The beginning dose level will be 390 mg/m2."
1695084|NCT01502787|Drug|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
1695208|NCT01501890|Drug|Placebo|0.9% NaCl
1695447|NCT01500213|Drug|Placebo|(4 X 0 mg capsules) o mg PO
1754105|NCT00226096|Drug|Esmolol|
1695085|NCT01502787|Drug|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
1695086|NCT01502787|Procedure|Forearm blood flow|Using high-resolution ultrasound, investigators will measure skeletal muscle blood flow in the forearm at rest, following handgrip exercise (described below), and following Angiotensin II infusion (described below).
1695087|NCT01502787|Procedure|Microneurography|Investigators will measure sympathetic nerve activity from the peroneal nerve by inserting a tiny needle directly into the nerve in the leg. Investigators will localize the nerve by electrical stimulation over the skin using a blunt probe. With this stimulation, subject will notice either involuntary twitching or a tingling sensation, which may be annoying but not painful. Investigators will then introduce a tiny, sterile wire needle (an electrode) through the skin at the same location. When the tip of the needle enters the nerve, subjects may again notice involuntary muscle twitches or tingling in the leg. Investigators will then turn the electrical stimulator off and make minor adjustments in the position of the needle until investigators begin to record the nerve signals. The recording needle will remain in position throughout the study.
1695088|NCT01502787|Procedure|Rhythmic handgrip exercise|Subjects will perform a rhythmic handgrip exercise at 30% of maximal voluntary contraction for 3 minutes. Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure, and sympathetic nerve activity (SNA) at baseline and following this handgrip exercise.
1695089|NCT01502787|Procedure|Lower body negative pressure|Lower body negative pressure increases sympathetic nerve activity. Therefore, investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and after rhythmic handgrip exercise plus lower body negative pressure (LBNP) for 2 minutes.
1695090|NCT01502787|Drug|Angiotensin II|Investigators will measure cardiac output (non-invasive impedance plethysmography), blood pressure and sympathetic nerve activity at baseline and during intravenous infusion of Angiotensin II at the dose of 1, 2, and 3 ng/kg/min for 15 minutes at each dose.
1695091|NCT01502774|Drug|Injection of Cyclosporin|one single intravenous bolus injection of 2.5 mg/Kg
1695092|NCT01502774|Drug|Placebo|One single intravenous bolus injection of Placebo
1695093|NCT01502774|Procedure|Echocardiography|1 year after AMI
1695094|NCT01502761|Drug|Magnesium Sulfate|Intra-arterial
1695095|NCT01502748|Other|endovascular sampling|Paired sampling from the distal arterial(endovascular catheter) and peripheral venous (femoral sheath) locations: withdrawal of 3ml of blood from vasculature distal to the occlusive thrombus
1695096|NCT01502735|Biological|DENV-1 PIV, 2.5 µg|2.5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
1695097|NCT01502735|Biological|DENV-1 PIV, 5 µg|5 µg Purified Inactivated Virus (PIV) in a volume of 0.5 mL administered via intramuscular injection on Study Days 0, and 28 (±4 days)
1695098|NCT01502722|Behavioral|Effect of ingestion sugary and sweetened drinks on thirst|The participants will drink Water (control group), Decarbonized Pineapple Soda (11% sugar)and Decarbonized Pineapple Diet Soda (1% Sugar and Sucralose). The beverages will be presented chilled but without ice in 500 ml portions in opaque plastic containers and participants will be asked to consume the entire amount within 15 min. The beverages will be tested previously in laboratory in order to obtain their pH and osmolality.
1695099|NCT01502709|Device|Caloric Vestibular Neurostimulation|1 treatments of caloric vestibular neurostimulation for 7.5 minutes in the right ear
1695100|NCT01502709|Device|placebo|Matching placebo device
1695101|NCT01502696|Biological|PEG IFN alfa-2b|3µg/kg weekly injections
1695102|NCT01502683|Procedure|No aortic clamping|No aortic clamp used in this group. The aortic clamp is a standard cardiac surgical instrument used during cardiac operations, not a specific device used for this study.
1695103|NCT01502683|Procedure|partial occluding clamp|The partial-occluding clamp is a standardized instrument used during coronary artery bypass surgery, it is not a specific device for this study.
1695104|NCT01502683|Procedure|single cross clamp|The proximal anastomoses performed under single clamp is an alternative method during coronary artery bypass surgery. The single clamp essentially means that whole operation is done using the cross clamp, which is a standard instrument during cardiac operations, not a specific device for this study.
1695105|NCT01502683|Procedure|cross clamp and partial occluding clamp|Both an aortic cross clamp and partial occluding clamp are used in this arm. Neither the cross clamp nor the partial clamp are specific devices for this study but are standard cardiac surgical instruments used during coronary artery bypass surgery and cardiac surgery.
1695106|NCT01502670|Drug|18F-FACBC Radiotracer|Test radiotracer uptake in lung nodule
1695107|NCT01502657|Device|Ultrasonography (EnVisor Philips Medical Systems)|Percutaneous tracheostomy is performed using the dilatational method with ultrasonography guidance;
1695108|NCT01502644|Drug|Oxycodone|Daily dosage up to 120 mg
1695109|NCT01502644|Drug|Morphine|Daily dosage up to 90 mg immediate release or 180 mg extended release
1695110|NCT01502644|Drug|Placebo|Placebo-matching oxycodone, placebo-matching morphine
1695111|NCT01502631|Drug|SUN13837 injection|SUN13837 injection, injection 1 x daily for 28 doses
1695112|NCT01502631|Drug|Placebo|Matching placebo, volume equivalent to injection 1 x daily for 28 doses
1695113|NCT01502618|Behavioral|Focus Group|N/A. Protocol is the focus group
1695114|NCT01502605|Drug|5-Aminolevulinic Acid|A one time, single-dose administration of ALA is planned 4 hours pre-operatively the day of surgery. ALA will be mixed in the minimum volume of sterile water or juice immediately before use and given as a single oral bolus. Once ALA has been administered, patients will be kept in subdued lighting away from sunlight.
1695115|NCT01502592|Procedure|Cryoablation|"OncCore Biopsy (+ Cryo) Date*
Pre- and post- cryo MRI
Core biopsy x ≥3
Cryoablation Optional pre-surgery MRI day prior or day of Mastectomy Date* Safety assessment 30 (+/-10) days after surgery research bloods 30 (+/-10) days after surgery.*"
1695154|NCT01502228|Drug|150-Water|Patients will be imaged immediately before, and between 14-28 days after initiation of Sunitinib therapy, in the single bed position using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 15O-water at 50 mCi/dose, IV.
1695268|NCT01501422|Drug|Placebo|Placebo patch for 8 weeks
1695116|NCT01502592|Biological|Ipilimumab|"Ipilimumab Appt. with Med Onc Ipilimumab administered Core Biopsy Date*
MRI
Core biopsy x ≥3 Optional pre-surgery MRI biopsy prior or day of Mastectomy Date* Safety assessment 2-3 weeks post-mastectomy (co-ordinated with off-study surgery follow-up appt if feasible) and then every 2-3 weeks thereafter until at least 12 weeks post ipilimumab date. # Research bloods 30 (+/-10) days after surgery."
1695117|NCT01502566|Behavioral|Education Intervention|Children/mothers allocated to this arm will receive an pamphlet with key information on dental caries prevention, together with oral instructions about how to avoid dental caries.
1695118|NCT01502553|Device|Comparison Test to Yuyue Medical BP Meter, YYBP-212|DUT: Transtek Blood Pressure Monitor, LS-802. Reference Device: Yuyue Medical Blood Pressure Meter, YYBP-212, accuracy: ±1mmHg and range: 0-300mmHg.
1695119|NCT01502527|Dietary Supplement|Femarelle|Twice daily oral treatment with Femarelle
1695120|NCT01502514|Procedure|Fat Harvesting and Implantation of Adipose Derived Stem Cells|Local Liposuction will be performed to harvest the fat. The Adipose Derived Stem Cells will be implanted via intramyocardial injection and intravenously.
1695121|NCT01502501|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells (ASCs)|Local liposuction procedure to harvest the fat tissue. Adipose Derived Stem Cells are then implanted via intramyocardial and intravenous injection.
1695122|NCT01502488|Procedure|Fat Harvesting and Stem Cell Injection|Cells will be harvested through a local liposuction and injected via IV delivery
1695123|NCT01502449|Behavioral|DESTRESS-T|Usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider, and care coordination
1695124|NCT01502449|Other|Optimized Usual Care (OUC)|Optimized Usual Care is usual primary care PTSD treatment, plus a telephone care management program that includes: four outreach calls, feedback to the treating primary care provider (PCP), and care coordination.
1695125|NCT01502423|Biological|Adalimumab|Subcutaneously 40 mg every other week (eow) or every week (ew) (as dosing requires)
1695126|NCT01502410|Drug|sorafenib tosylate|Given PO dosage 200 mg/m2/dose (max dose:400 mg/dose) given every 12 hours on days 1-28
1695127|NCT01502410|Other|pharmacological study|Optional correlative studies
1695128|NCT01502410|Other|laboratory biomarker analysis|Optional correlative studies
1695129|NCT01502384|Other|neurological examination|motor and cognitive functions
1695130|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg|MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
1695131|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg|MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
1695132|NCT01502371|Drug|Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg|MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
1695133|NCT01502371|Drug|Mometasone Furoate (MF) Dry Powder Inhaler (DPI), 100 mcg|MF DPI 100 mcg (per inhalation), 1 puff QD for 12 weeks
1695134|NCT01502371|Drug|Placebo Metered Dose Inhaler (MDI)|Placebo MDI, 2 puffs BID for 12 weeks
1695135|NCT01502371|Drug|Placebo Dry Powder Inhaler (DPI)|Placebo DPI, 1 puff QD for 12 weeks
1695136|NCT01502358|Biological|Tetravalent Dengue Vaccine (TVDV)|Low dose delivered intramuscularly on Study Days 0, 30 and 90
1695137|NCT01502358|Biological|Tetravalent Dengue Vaccine (TVDV) with Vaxfectin® (low-dose)|Low dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
1695138|NCT01502358|Biological|Tetravalent Dengue Vaccine TVDV with Vaxfectin® (High Dose)|High dose: TVDV formulated with Vaxfectin®; 1.0 mL volume delivered intramuscularly on Study Days 0, 30 and 90
1695139|NCT01502345|Biological|Vaccine/device combination for prevention of HFRS|PUUV DNA Vaccine, 2.0mg/ml TDS-IM injection HTNV DNA Vaccine, 2.0 mg/ml TDS-IM injection HTNV + PUUV Vaccine mixture, 1.0mg/mL + 1.0mg/ml TDS-IM injection
1695140|NCT01502332|Other|Intensive Alveolar Recruitment|Recruitment with opening pressures of 45 cmH2O in the airways, followed by ventilation with PEEP = 13 cmH2O, during 4 hours of protective mechanical ventilation with tidal volume (VT) = 6 mL/kg/pbw.
1695141|NCT01502332|Other|Moderate Alveolar Recruitment|Recruitment with opening pressures of 20 cmH2O in the airways, followed by ventilation with PEEP = 8 cmH2O, during 4 hours of protective mechanical ventilation with VT = 6 mL/kg/pbw.
1695143|NCT01502306|Behavioral|Telephone counseling|Telephone counseling is conducted in the appropriate language (Spanish and English) by counselors at the California Smokers' Helpline. Counselors use a structured protocol and there is a record for each call. Quantitative information that will be available for analysis include: timing, length, and frequency of counseling calls.
1695144|NCT01502306|Drug|Nicotine patches|Clients will be screened for contraindications to nicotine patch use, and a doctor's approval will be necessary before patches are sent if a contraindication exists.
1695145|NCT01502306|Behavioral|Incentive|They will be given their choice of gift cards from one of 4 major business chains: Wal-Mart, Target, Vons/Safeway, or Ralph's/Kroger card.
1695146|NCT01502293|Biological|Plasmid INTERLEUKIN-12|Patients will receive intratumoral injection(s) of pIL-12.
1695147|NCT01502293|Device|Intratumoral Electroporation|Immediately following intratumoral injection of pIL-12, electroporation will follow by electrical discharge around the tumor site using the OMS system.
1695148|NCT01502280|Drug|5-Aminolevulinic acid (ALA)|Following informed consent, within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] either (1) 5-ALA/Gliolan® mixed with sterile water (20mg/kg)
1695149|NCT01502280|Drug|Placebo - ascorbic acid|Within 3 hours prior to surgery, patient will orally ingest [or be given via Nasogastric (NG), Orogastric (OG), or Gastric tube (G-tube)] 1.5 Gm. placebo - ascorbic acid in 50 ml sterile water.
1695150|NCT01502267|Drug|High dose IVIG and B cell depleting agents|"IVIG(2g/kg two times on day 1, 30)
Rituximab(375mg/m2 on day 3)
Bortezomib(1.3mg/m2 four times on day 31, 34, 38, 41)"
1695151|NCT01502254|Other|audio recorded information|Access to the audio recorded information about the clinical trial the patient was information about and asked to consider. A copy of the audio recording is given to the patients directly after the clinical visit.
1695152|NCT01502241|Drug|Temozolomide|100 mg/m2 per day on seven out of fourteen days.
1695155|NCT01502228|Drug|62Cu-ethylglyoxal bis|Imaging with 62Cu-ETS will be done immediately following imaging with 150-water. Patients will be imaged immediately before, and between 14-28 days after, initiation of Sunitinib therapy using the Siemens Biograph 64 TruePoint system located in the clinical facilities of the I.U. Cancer Center. Administer 62Cu-ETS in the range of 20-25 mCi/Dose, IV.
1695156|NCT01502228|Procedure|Positron Emission Tomography|PET Scan
1695157|NCT01502228|Drug|Sunitinib|
1695158|NCT01502215|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hemoglobin fall below 9 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hemoglobin levels is performed;if a patient's hemoglobin is 9 g/dL or higher, no additional transfusion is necessary.
1695159|NCT01502215|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hemoglobin fall below 7 g/dL since ICU admission until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hemoglobin 7 g/dL or higher, no additional transfusion is necessary
1695160|NCT01502202|Drug|Gefitinib|Gefitinib 250mg, per PO. daily, D 5-18 (during 14 days)
1695161|NCT01502202|Drug|Placebo|Placebo 1 tablet, per PO, Daily on D 5-18 (during 14 days)
1695162|NCT01502202|Drug|Pemetrexed plusCIsplatin|Pemetrexed 500mg/m2 on D1 plus Cisplatin 75mg/m2 on D1 every 3 weeks maximum 9 cycles
1695163|NCT01502189|Other|Representational approach|The Representational approach as described in the detailed description. Each participating parent receives three rounds that consist of two meetings. Each round starts with a meeting where the parent identifies an area where he/she needs more information. The nurse and the parent jointly survey the parent's representation of the area and discusses consequences of knowledge gaps or misunderstandings. Then, new information is introduced and benefits from the new information is discussed. After some days, a follow-up meeting takes place.
1695164|NCT01502163|Device|Thermoflect [TM] passive insulation|passive insulation in the preoperative phase, befor induction of anesthesia
1695165|NCT01502163|Device|Active prewarming (Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL)|Prewarming Thermoflect™/Mistral Air™, TSCI, Amersfoort, NL before induction of anesthesia
1695166|NCT01502150|Other|Data Collection|Information collected from follow-up visits post proton radiation therapy yearly or more often, and test results for at least 10-15 years.
1695167|NCT01502150|Other|Dose Distribution Data Collection|Data collection of complete plan information, including dose distribution, beam configuration and images, computed tomography (CT) images acquired on multiple days and 4D CT's for respiratory correlated imaging.
1695168|NCT01502137|Drug|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, patients will receive 8 doses.
1695169|NCT01502137|Drug|somatropin|Injected subcutaneously, 50 mcg/kg/day (up to a maximum of 4 mg/day) once daily. Additional dose administered during dialysis. In total, subjects will receive 7 doses.
1695170|NCT01502124|Drug|somatropin|Injected subcutaneously 7 times per week after reconstitution with liquid buffer prior to use. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
1695171|NCT01502124|Drug|somatropin|Injected subcutaneously 7 times per week. Dose level of 0.024-0.050 mg/kg at the discretion of the practicing paediatric endocrinologists
1695172|NCT01502098|Procedure|Postoperative early passive motion|Shoulder exercises starting on the first postoperative day
1695173|NCT01502098|Other|Sling|Sling for 4 weeks
1695174|NCT01502085|Drug|Vorinostat, Lenalinomide and Dexamethasone|"Vorinostat: 400 mg po days 1-7 and 15-21 Lenalidomide: 25 mg po days 1-21
* Lenalidomide dose for patients with renal impairment (CrCL<50ml/min) has be dose adjusted according to package insert
Dexamethasone: 40mg po days 1, 8, 15 and 22 for patients aged less than 75 years, 20mg for those aged 75 years and above"
1695175|NCT01502072|Drug|Ribavirin|Modified schedule of 60 milligrams/milliliter for 3-hour period 3 times/day for at least 5 days by aerosolization via a SPAG-2 generator via a face mask.
1695176|NCT01502072|Drug|Ribavirin|One time loading dose of 10 mg/kg oral dose then 20 mg/kg orally (rounded to the nearest 200 mg dose) divided into three doses per day (max 1800 mg/day).
1695177|NCT01502059|Other|Pilates|Pilates training - twice a week (one hour per class) during 90 days
1695178|NCT01502046|Drug|delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD)|Sativex 2.7 mg delta-9-tetrahydrocannabinol/2.5 mg cannabidiol Oromucosal Spray. One spray per day, up to a maximum of 12 sprays per day.
1695179|NCT01502046|Drug|Placebo|Placebo, One spray per day, up to a maximum of 12 sprays per day.
1695180|NCT01502033|Device|Transcranial Magnetic Stimulation|30 daily treatments of (over 6-8 weeks) of 10 Hz rTMS at 120% motor threshold, applied to the left dorsolateral prefrontal cortex with 3,000 stimulations per treatment
1695181|NCT01502020|Drug|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
1695182|NCT01502020|Drug|Vehicle Cream|Dosage form: Topical Cream Dosage: Placebo Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
1695183|NCT01502020|Drug|imiquimod cream, 3.75%|Dosage form: Topical Cream Dosage: 3.75% Frequency: The assigned test article was to be applied once daily for two 2-week treatment cycles separated by a 2-week no treatment interval Duration of Treatment: Two 2-week treatment cycles separated by a 2-week no-treatment period and an 8-week follow-up period.
1695184|NCT01502007|Other|Accelerometer feedback and lifestyle counseling|Subjects will meet with the exercise counselor who will use accelerometer data to provide feedback and counseling to help the user increase their activity by at least 20% each day. In subjects who achieve an increase of 20%, the counseling will focus either on maintaining activity levels or increasing activity further depending on the desire of the subject. Counseling will be provided once weekly by phone and in person at least once a month. Following the 26th week the experimental subjects will continue to wear the Fitbit and receive feedback about their activity levels for an additional 24 weeks, but they will no longer receive counseling. The control group will receive no counseling for the first 26 weeks of the study and will then crossover to get accelerometry feedback and counseling for the last 24 weeks of the study.
1695185|NCT01502007|Other|Accelerometer without Feedback|The accelerometer, Fitbit, will be worn continuously. Fitbit can provide feedback to subjects about their physical activity. Subjects will wear the Fitbit for two weeks (without feedback) to obtain baseline activity data. The experimental group will then be instructed on use of the fitbit. This group will receive feedback from the accelerometer for the remainder of the study. The control group will wear the Fitbit but receive no feedback for the first 26 weeks of the study. For the last 24 weeks they will crossover and receive feedback from the Fitbit accelerometer.
1695186|NCT01501994|Other|GRUVE accelerometer (MUVE, inc.)|Physicians in the experimental group will be given an accelerometer for 2 weeks (without feedback) prior to starting the study and will continue to have their activity monitored for the duration of the study. The accelerometer monitors movement and accurately estimates physical activity energy expenditure. They will receive feedback about their activity for the remainder of the trial. Physicians in the control group will wear the accelerometer but not receive feedback for the first 14 weeks of the trial. They will receive feedback for the last 12 weeks of the trial as they crossover to the experimental group.
1695187|NCT01501994|Other|walking workstation|The physicians in the experimental group will be provided with a walking workstation. The walking workstation has a computer keyboard, computer monitor and telephone attached to an exercise treadmill (assembled by the investigators). This allows the user to walk at 1 mile per hour while dictating, typing, responding to e-mail, etc. The treadmill can be placed in an examining room if the physician wishes to use it while dictating notes or it can be placed in a separate office. For the last 12 weeks of the study the experimental group will not use the walking workstation while the control grop will use the workstation (crossover).
1695188|NCT01501994|Procedure|exercise counseling|After the first two weeks of baseline data collection, the experimental group will receive exercise counseling for the next 12 weeks. They will be advised to make use of the accelerometer and the walking workstation as well as how to increase their activity in other ways. This group will not receive exercise counseling for the last 12 weeks of the study while the control group will cross over and receive exercise counseling for the last 12 weeks of the study (the control group will not receive exercise counseling for the first 14 weeks of the study).
1695189|NCT01501968|Drug|Colistin|Colistimethate sodium 2.5-5mg/kg iv per day
1695190|NCT01501968|Drug|Colistin + Ascorbic acid|Colistimethate sodium 2.5-5mg/kg iv per day and ascorbic acid 2 grams iv q 12 hours
1695193|NCT01501942|Drug|AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide|AIM-102 is supplied as an oral solution. Dose is 15 mg of AIM-102 per kg of patient weight measured on Treatment Day 1 of each treatment phase The study drug will be administered for 4 consecutive days with at least a 2 week wash-out period prior to crossing over to the alternative treatment for 4 days.
1695194|NCT01501942|Drug|Buffered Saline|The matching placebo is an oral solution of phosphate buffered saline
1695195|NCT01501929|Drug|Metoprolol succinate|The subject will be started on metoprolol succinate (Toprol XL) 100-300mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
1695196|NCT01501929|Drug|Nebivolol|The subject will be started on nebivolol (Bystolic) 5-20mg daily, which he or she will continue for a period of 12 weeks. Following the 12-week treatment period, the procedures listed below will be performed. After completion of the study procedures, the medication will be discontinued.
1695197|NCT01501929|Drug|Hydrochlorothiazide|During the washout period between the two treatments, subjects will be followed after 2 weeks of drug withdrawal. Hydrochlorothiazide (HCTZ) 25 mg once daily will be started in subjects found to have BP > 140/90 mmHg and continued for a 2 week period. The subjects will return in 2 weeks, and at that time HCTZ will be stopped if started in the earlier visit. The subject will then be switched to the remaining treatment (Nebivolol or Metoprolol).
1695198|NCT01501929|Drug|DEFINITY®|The DEFINITY® vial contains components that upon activation yield perflutren lipid microspheres, a diagnostic drug that is intended to be used for contrast enhancement during echocardiographic procedures. The vial contains a clear, colorless, sterile, non-pyrogenic, hypertonic liquid, which upon activation with the aid of a Vialmix®, provides a homogeneous, opaque, milky white injectable suspension of perflutren lipid microspheres. The suspension of activated DEFINITY® will be infused intravenously at a rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit.
1695199|NCT01501929|Procedure|Non-invasive measurement of Cardiac Output (CO)|Cardiac Output (CO) will be measured non-invasively at rest and during exercise by thoracic electrical bioimpedance. Stroke volume will be derived from change in impedance/time measured during electrical systole. Cardiac output will be determined as the product of stroke volume and heart rate.
1695200|NCT01501929|Procedure|Flow mediated vasodilation|Flow mediated vasodilation (FMD), which is a non-invasive assessment of endothelial function, will be performed on the brachial artery using ultrasound. After a clear picture of the artery has been obtained, the cuff on the same arm will be inflated until it is tight for five minutes. During and following this, the subject's arm will continue to be imaged to monitor maximal increase in the brachial artery diameter.
1695201|NCT01501929|Procedure|Endothelial cell collection|We will collect endothelial cells from a superficial vein, usually in the arm. Following insertion of a peripheral intravenous (IV) catheter, we will collect cells from the inner lining of the vein using a thin, flexible J-tipped wire. The wire will be inserted through the IV into the vein and then removed, along with a sampling of endothelial cells. The cells collected will be processed and stained for several proteins involved in endothelial cell function, using immunofluorescent technique.
1695202|NCT01501929|Procedure|Microvascular perfusion assessment using Definity|Using high-resolution ultrasound, we will measure skeletal muscle blood flow during infusion of a solution containing the octafluoropropane microbubble contrast agent, Definity. The solution will be a dilution of 1 vial of Definity to 30 cc of normal saline. The ultrasound probe will be placed over the forearm to obtain images while octafluoropropane microbubbles (Definity) are infused intravenously at the rate of 0.20 to 0.27 ml/min, not to exceed a maximum dose of 2 vials per study subject per day or visit. The microvascular perfusion assessment using Definity be performed at rest as well as during slow and fast handgrip exercises.
1695203|NCT01501916|Dietary Supplement|Vitamin D3|daily dosage of 50 µg Vitamin D3 for 8 weeks
1754106|NCT00226096|Drug|Clonidine|
1695209|NCT01501877|Behavioral|Acceptance and Commitment Therapy|The intervention is based on Acceptance and Commitment Therapy and will be tailored to smokers with Type 2 diabetes.
1695210|NCT01501877|Behavioral|Standard smoking cessation intervention|Standard smoking cessation intervention based on clinical practice guidelines.
1695211|NCT01501864|Behavioral|School Support Intervention|Comprehensive school support is provided that includes payment of school fees, school uniform, and a nurse researcher who monitors attendance and addresses problems that may lead to school absence and dropout.
1695212|NCT01501825|Device|5 channels Multiway deep Transcranial Magnetic Stimulator|During the single channel treatment trial period the patients will receive the following dose of rTMS: 10 Hz - left DLPFC ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
1695213|NCT01501825|Device|five channels Multiway deep Transcranial Magnetic Stimulation|"During the four channels treatment trial period the patients will receive the following dose of rTMS: 10 Hz- left DLPFC, 1Hz - right DLPFC together, and than 10 Hz- left parietal cortex, 1Hz - right parietal cortex together.
10 Hz protocol: ( 10 Hz, at 120% MT, 3 sec pulse train, 20 second inter-train interval, 55 trains, i.e. a total of 1650 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 33,000pulses in 4 weeks)
1 Hz protocol:
1 Hz, at 120% MT, 5 min pulse train, 1 min inter-train interval, 6 trains, i.e. a total of 1800 pulses per session, a total of 20 sessions in the study and a cumulative exposure (total number of pulses) of 36,000 pulses in 4 weeks)"
1695214|NCT01501812|Behavioral|Generalization pattern|"During evaluation a conditioning of a tone (conditioning stimulus) and aversive sound (metal scratch) will conduct (another tone which will be un-conditioning stimulus for control). Generalization patterns will be evaluated, by measuring the differentiation capability between different tones (neutral and aversive) before and after the conditioning, and after extinction phase. The generalization will also be measured by the generalization curve that plotted from displaying tones, different from the original tones, and asked the subject whether the current tone is original or new"
1695215|NCT01501799|Drug|adapalene 0.1% and benzoyl peroxide 2.5% topical gel|Dosage form: topical gel Dosage: A pea-sized amount was applied to each affected area of the face Frequency: once daily in the evening Duration: 12 weeks
1695216|NCT01501799|Drug|EPIDUO|EPIDUO (adapalene 0.1% and benzoyl peroxide 2.5%) Gel
1695217|NCT01501799|Drug|Placebo (Vehicle Gel)|Vehicle Gel
1695218|NCT01501786|Drug|control|propofol 8mg/kg/h saline 0.24 ml/kg/h
1695219|NCT01501786|Drug|Ket10|propofol 6.4 mg/kg/h ketamine 10 microg/kg/min
1695220|NCT01501786|Drug|Ket20|propofol 4.8 mg/kg/h ketamine 20 microg/kg/min
1695221|NCT01501773|Biological|Autologous bone marrow stem cell|Autologous bone marrow stem cell have bone marrow aspiration and receive 30-500 million bone marrow mononuclear cells intravenously on the day of randomization.
1695222|NCT01501760|Drug|bevacizumab|Three subconjunctival injections of 0.5 ml of bevacizumab at: inclusion, 1 month, 2 month
1695223|NCT01501760|Drug|NaCl|Three subconjunctival injections 0.5 ml placebo (Balanced salt) solution at inclusion, 1 month, 2month
1695224|NCT01501747|Drug|Caffeine, paracetamol, cephalexin, or ibuprofen|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving the active drug.
1695225|NCT01501747|Drug|Placebo (caffeine, paracetamol, cephalexin, or ibuprofen)|The study has 4 sub-parts (one for each of 4 drugs), each sub-part has a crossover design. In this arm, the volunteer will be given one oral dose of 300 mg caffeine, 500 mg paracetamol, 500 mg cephalexin, or 400 mg ibuprofen and will be told that they are receiving a placebo.
1695226|NCT01501734|Device|watch-pat|"The Watch-PAT is a home sleep testing (HST) device. The Watch-PAT is a patient-worn, self-contained, non-invasive device used in the patient's home.
The Watch-PAT diagnoses obstructive sleep apnea (OSA) by measuring the PAT signal, heart rate, oxygen saturation, and actigraphy. The PAT signal is a validated surrogate measure of sympathetic activation that is associated with apneic events and respiratory effort related arousals (RERA). The Watch-PAT provides measures of all the OSA indices, i.e., Apnea Hypopnea Index (AHI), Respiratory Disturbances Index (RDI), and Oxygen Desaturation Index (ODI), which enable accurate assessment of the presence and severity of OSA and its effect on sleep architecture, sleep quality.
Based on the PAT and actigraphy signals, Watch-PAT differentiates between sleep and wake and detects sleep stages (light, deep, and REM) providing, the effect on additional specific conditions such as REM related apnea."
1695227|NCT01501721|Behavioral|Exercise|Home-based exercise program
1695228|NCT01501721|Behavioral|Diet|Nutritional counseling aiming to reduce suggar intake
1695229|NCT01501708|Drug|Caspofugin based combination therapy|"Caspofungin: 70 mg on the ﬁrst day of therapy, followed by 50 mg q.d.
All patients received azoles as prophylaxis (fluconazole as prophylaxis and itraconazole or voriconazole as secondary prophylaxis), combination with liposomal amphotericin B at a dosage 3mg/kg q.d will be given.
In case of renal function damage, combination with voriconazole 6mg/kg followed by 4 mg/kg b.i.d. will be given."
1695233|NCT01501669|Drug|Irinotecan, Capecitabine|"Irinotecan 80 mg/m2, day 1 and 8, every 3 weeks
+ capecitabine 1000 mg/m2, BID, day 1-14, every 3 weeks"
1695234|NCT01501643|Device|Non invasive positive pressure ventilation|At least one hour every four hour but may be maintained more if the patient chooses to or is asleep with the machine on.
1695235|NCT01501643|Device|Spirometry|Every two hours during the day with 10 maximum inspirations and at night if the patient is awake
1695236|NCT01501630|Device|performance of PET/CT and whole-body MRI|For PET/CT radiopharmaceuticals, both registered in France:Fluoride (18F)FLUOROCHOLINE (18F)No contrast agent scheduled for MRI in the study RadiopharmaceuticalsSingle use, 2-4 MBq/kg body weight, IV infusion
1754107|NCT00226096|Drug|Enalaprilat|
1695239|NCT01501604|Drug|BKM120|100 MG PO QD in cycles of 28 days
1695240|NCT01501591|Drug|Hydroxizine|25 mg orally, one time on two different days, 72 hours apart
1695241|NCT01501591|Other|Placebo|Matching placebo once on two different days, 72 hours apart.
1695242|NCT01501591|Drug|hydroxyzine/placebo|25 mg hydroxyzine or placebo once on two different days, 72 hours apart
1695243|NCT01501565|Procedure|Postoperative transverse abdominal plain (TAP) blockade|Bupivacaine 0.25%. Maximum 150 mg. A maximum of 75 mg bupivacaine is administered in each side (posterior and subcostal TAP) in a single puncture.
1695244|NCT01501552|Other|Training and support (T&S)|Two face-to-face educational meetings of at least one hour and a maximum of 2 hours, and one telephone support call of at least ten minutes and a maximum of 30 minutes. The telephone call will be offered to one of the GPs ('leader'). Depending on the needs of the PHCU, one additional face to face training (1 to 2 hours) may be offered. The time interval between meetings will be on average 2 weeks. The training sessions will address improving knowledge, skills, attitudes, and perceived barriers and facilitators by combining theory and practice-based training.
1695245|NCT01501552|Other|Financial incentive|Groups will receive a financial incentive depending on their screening and brief intervention activities. They will be paid for the performance, with the country dependent system of pay (fee for item or fee for achieving set rates) and based on normal practices and financial rates for financial incentives for clinical preventive activities.
1695246|NCT01501552|Other|E-SBI (online screening and brief intervention)|Referring identified at-risk patients to an approved e-SBI programme, which will be either country specific (where these exist) or based on the WHO e-SBI programme (Poland).
1695247|NCT01501539|Procedure|Standard Hydrocolloid Dressing|Treatment placed over insertion site.
1695248|NCT01501539|Procedure|Silver Hydrocolloid Dressing|Place dressing against skin under gastrostomy tube
1695249|NCT01501513|Drug|PEG-3350 based bowel preparation|solution for oral administration prior to colonoscopy
1695250|NCT01501513|Drug|BLI800 approved preparation regimen|solution for oral administration prior to colonoscopy
1695251|NCT01501513|Drug|BLI800 investigational preparation regimen|solution for oral administration prior to colonoscopy
1695252|NCT01501500|Drug|BOTOX|once injection of BTA 3oU into hallux oblique and transverse heads each
1695253|NCT01501500|Drug|Normal Saline (0.9% NaCl)|Normal saline 0.3ml to oblique and transverse heads each
1695254|NCT01501487|Drug|TAC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Doxorubicin 50 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
1695255|NCT01501487|Drug|TC chemotherapy|Docetaxel 75 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1; Cycled every 21 days for 6 cycles
1695256|NCT01501487|Drug|Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy|Doxorubicin 60 mg/m2 IV day 1, Cyclophosphamide 600 mg/m2 IV day 1, Cycled every 14 days for 4 cycles, OR 5-Fluorouracil 500 mg/m2 IV day 1, Epirubicin 100 mg/m2 IV day 1, Cyclophosphamide 500 mg/m2 IV day 1; Cycled every 21 days for 3 cycles Followed by Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 weeks, OR Docetaxel 100mg/m2 IV day 1 cycled every 21 days for 3 or 4 cycles
1695257|NCT01501487|Drug|TCH chemotherapy|Docetaxel 75 mg/m2 IV day 1, followed by Carboplatin AUC 6 IV day 1; Cycled every 21 days for 6 cycles Trastuzumab initial dose of 4 mg/kg over 90 minute IV infusion, then 2 mg/kg over 30 minute IV infusion weekly for 52 weeks, OR initial dose of 8 mg/kg over 90 minutes IV infusion, then 6 mg/kg over 30-90 minutes IV infusion every three weeks for 52 weeks.
1695258|NCT01501487|Drug|T + trastuzumab followed by CEF + trastuzumab|"Trastuzumab 4 mg/kg IV for one dose beginning just prior to first dose of paclitaxel.
Followed by trastuzumab 2 mk/kg IV weekly for 23 weeks Paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks Followed by 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles Trastuzumab 6mg/kg IV every 21 days for 9 cycles to complete 1yr"
1695259|NCT01501487|Drug|Dose dense AC followed by T + trastuzumab|"Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 (cycled every 14 days for 4 cycles) Followed by paclitaxel 80 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 2 mg/kg (4 mg/kg loading dose).
Following chemotherapy , trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week."
1695260|NCT01501487|Drug|Dose dense AC followed by T + trastuzumab + pertuzumab|Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles Followed by docetaxel 75-100 mg/m2 by 1 h IV infusion weekly for 12 wks All cycles are with filgrastim support with trastuzumab 6 mg/kg (8 mg/kg loading dose with C1) Pertuzumab 420 mg (840 mg loading dose with C1). Following chemotherapy, trastuzumab to continue every 3 weeks at 6 mg/kg for the duration of 1 week.
1695261|NCT01501487|Drug|PTH followed by dose dense AC of FEC|"Docetaxel 75-100 mg/m2 by 1 h IV infusion Cycled every 21 days for 4 cycles With Trastuzumab 6 mg/kg IV (8 mg/kg IV loading dose) q3W And Pertuzumab 420 mg IV (840 mg IV loading dose) q 3w +/- pegfilgrastim 6 mg sq on day 2-3,
Followed by 4 cycles of AC or FEC:
AC Doxorubicin 60 mg/m2 IV day 1 Cyclophosphamide 600 mg/m2 IV day 1 Cycled every 14 days for 4 cycles with pegfilgrastim 6 mg sq on day 2 FEC 5-Fluorouracil 500 mg/m2 IV on days 1 and 4 Epirubicin 75 mg/m2 IV on day 1 Cyclophosphamide 500 mg/m2 IV on day 1 cycled every 21 days for 4 cycles
In all of the above mentioned regimens docetaxel might be substituted with paclitaxel as paclitaxel is better tolerated but is expected to have the same efficacy as docetaxel."
1695262|NCT01501461|Procedure|Harvesting and implantation of stem cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable area using tumescent syringe liposuction. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for injection intravenously.
1695263|NCT01501448|Drug|Levonorgestrel and ethinylestradiol|30 microgram of ethinylestradiol plus levonorgestrel daily for 12 to 16 days
1695264|NCT01501448|Drug|Estradiol valerate|4mg estradiol valerate from cycle day 20 till the day before the initiation of the cycle
1695265|NCT01501435|Drug|CJ-30039|single dose
1695266|NCT01501435|Drug|fenofibric acid|single dose
1695267|NCT01501422|Drug|Estrogen patch|50 microgram estrogen patch weekly
1754108|NCT00226096|Drug|Nitroprusside|
1695269|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group I used SLS-free(a commercially available SLS-free dentifrice(Wiconi® dentifrice) and SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
1695270|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group II used SLS-A (a dentifrice containing 1.5%; Wiconi® dentifrice + 1.5% SLS) and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
1695271|NCT01501409|Other|sodium lauryl sulfate|The subjects were divided into three groups, each of which comprised 30 randomly assigned subjects: group III used SLS-free (a commercially available SLS-free dentifrice (Wiconi® dentifrice), and SLS-B (a commercially available 1.5% SLS-containing dentifrice). The subjects used one of the two assigned dentifrices for 8 weeks, and then the other for the following 8 weeks. The order of the dentifrices used was selected at random, and there was a 2-week washout period between the two phases, during which the subject used the same dentifrice as they used before participating in this study. The subjects were asked to brush their teeth using their usual toothbrushing method with the dentifrice and toothbrush supplied.
1695272|NCT01501396|Drug|Megestrol Acetate|
1695273|NCT01501396|Drug|Mirtazapine|
1695274|NCT01501383|Drug|VX-765 Part A|Tablets of VX-765 given at different doses based on treatment group in Part A
1695275|NCT01501383|Drug|Placebo|Matching placebo
1695276|NCT01501383|Drug|VX-765 Part B|Tablets of VX-765 given at different doses based on patients who meet the study eligibility criteria for Part B
1695277|NCT01501370|Drug|Vorinostat|Vorinostat orally at the dose of 400 mg/day on days 1-7 and 15- 21 on a 28-day cycle
1695278|NCT01501370|Drug|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
1695279|NCT01501370|Drug|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
1695280|NCT01501370|Drug|Lenalidomide|Lenalidomide orally at the dose of 25 mg/day for 21 days every 28 days
1695281|NCT01501370|Drug|Dexamethasone|Dexamethasone orally at the dose of 40 mg day 1,8, 15, 22 every 28 days.
1695282|NCT01501357|Behavioral|modified toothbrush with multilevel filaments|After the allocation of patients in this group they were instructed to brush their first molars erupt with the brushing technique anteroposterior.
1695283|NCT01501357|Behavioral|cross toothbrushing|Children allocated to the group multi-bristled brush will be modified compared to the results of the group cross toothbrushing technique
1695284|NCT01501344|Dietary Supplement|200 g yogurt with fortified calcium content and MBP 80 mg|Intake of one container of vanilla or strawberry yogurt in the morning on a daily basis during 12 weeks.
1695285|NCT01501331|Device|CRTD or ICD (Energen)|RRT measurement by cardiac resynchronization therapy devices and implantable cardioverter defibrillators
1695286|NCT01501318|Behavioral|Personalized feedback report|Participants receive the personalized feedback report but no additional education.
1695287|NCT01501318|Behavioral|Personalized feedback report plus education|Participants receive the personalized feedback report plus education. This is the currently implemented service approach.
1695288|NCT01501305|Dietary Supplement|Mineral solution|Rehydration mineral solution
1695289|NCT01501305|Dietary Supplement|Carob powder with probiotics|7 1/2 grams of carob powder and probiotic twice daily for one week or until diarrhea is gone
1695290|NCT01501292|Other|Fixation and staining|Fixation and staining by MitiTracker Green FM
1695291|NCT01501292|Other|Observation by laser microscopy|Observation with Laser scanning confocal microscopy
1695292|NCT01501279|Procedure|Pudendal nerve block|the pudendal nerve block is going to be performed to the medial of ischial tuberosity with USG guidance in lithotomy position
1695293|NCT01501253|Drug|CKD-828 2.5/40mg|fixed dose combination of S-Amlodipine 2.5mg and Telmisartan 40mg
1695294|NCT01501253|Drug|CKD-828 2.5/80mg|Fixed dose combination of S-Amlodipine 2.5 and Telmisartan 80mg
1695295|NCT01501253|Drug|S-Amlodipine 2.5mg|S-Amlodipine 2.5mg monotherapy
1695296|NCT01501227|Device|Taper Guard Endotracheal Tube|comparison of two different endotracheal tubes
1695297|NCT01501227|Other|Conventional endotracheal tube|Sham Comparator
1695298|NCT01501214|Drug|Atosiban|Patients in the atosiban group will receive intravenous atosiban 30 min before the transfer with a bolus dose of 6.75 mg, and the infusion will be continued with an infusion rate of 18 mg/h. After performing ET, the dose of atosiban will be reduced to 6 mg/h and the infusion will be continued for 2 hours (total administered dose: 37.5 mg). Those in the placebo group will receive normal saline only.
1695299|NCT01501214|Drug|Normal saline|Normal saline given
1695300|NCT01501201|Procedure|Gastric By-Pass|Bariatric surgery laparoscopic Roux-en-Y Gastric Bypass (RYGBP)
1695301|NCT01501201|Drug|optimized medical management|group receiving an optimized medical management, among patients with obesity and poorly controlled type 2 diabetes
1695302|NCT01501188|Other|Kinesio Taping|The participants were randomly assigned to an experimental group, to received Kinesio Taping application for gastrocnemius muscle enhancement and functional correction of the ankle.The treatment was performed three times a week during a 4-week period.
1695303|NCT01501188|Other|Placebo kinesio taping|Placebo-control group received treatment with a sham Kinesio Taping protocol to enhance gastrocnemius muscle function and dorsal ankle flexion.The strips used in this group did not follow the principles of tension and anatomic distribution of Kinesio technique.The treatment was performed three times a week during a 4-week period
1695439|NCT01500252|Device|Profix TKR with Patellar Retention|All subjects received a Profix TKR. Subjects in the Patellar Retention group retained their native patellar surface.
1695304|NCT01501175|Other|consultation with a vascular physician|As in usual practice, patient with suspected SVT will consult a vascular physician to diagnose SVT and eventually DVP/PE associated. Vascular physician will collect risk factors of SVT.
1695305|NCT01501162|Drug|hepatitis, alcohol, probiotics|7 days of probiotics (1500 mg/day)
1695306|NCT01501162|Drug|alcohol, hepatitis, Placebo|Placebos of the same shape and size were manufactured at Pharmaceutical Corporation.
1695307|NCT01501149|Drug|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
1695308|NCT01501149|Drug|Modified SMILE （MTX，DEX，IFO，L-ASP，Etoposide，Mesna）|MTX,2g/m2 (20% ivgtt（intravenously guttae）,2h;80% ivgtt,4h), d1;DEX,40mg,ivgtt,d2-4;IFO,1.5g/m2,ivgtt,d2-4;L-ASP,6000U/m2,ivgtt,d3-9;VP-16,100mg/m2,ivgtt,d2-4; Mesna,0、4、8h after IFO, 240mg/m2,iv,d2-4.Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
1695309|NCT01501136|Other|DDGP(cisplatin,dexamethasone,gemcitabine,pegaspargase)|DDP 20 mg/m2,ivgtt（intravenously guttae）, d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
1695310|NCT01501136|Other|VIPD（cisplatin，Etoposide，Ifosfamide， dexamethasone，Mesna）|DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required. Completion of chemotherapy is followed by radiotherapy 50Gy.Efficacy was evaluated every two cycles.
1695311|NCT01501136|Other|gemcitabine,pegaspargase,cisplatin,dexamethasone|Radiotherapy 50Gy is followed by chemotherapy(DDP 20 mg/m2,ivgtt（intravenously guttae）,d1-4;DEX 15mg/m2,ivgtt,d1-5;GEM 800mg/m2,ivgtt,30min,d1,8;Pegasparaginase,im,2500IU/m2 d1.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
1695312|NCT01501136|Other|cisplatin,Etoposide,Ifosfamide,dexamethasone,Mesna|Radiotherapy 50Gy is followed by chemotherapy(DDP,33mg/m2,ivgtt（intravenously guttae）,d1-3；VP-16,100mg/m2,ivgtt,d1-3；IFO,1.2g/m2,ivgtt,d1-3；DEX,40mg,ivgtt,d1-4；Mesna,0、4、8h after IFO,240mg/m2,iv,d1-3.Every 21 days for one cycle and three cycles are required ).Efficacy was evaluated every two cycles.
1695313|NCT01501136|Radiation|Radiotherapy|Suitable type intensity-modulated radiation therapy(IMRT)50Gy
1695314|NCT01501123|Drug|Haloperidol|5mg IM
1695315|NCT01501123|Drug|Midazolam|
1695316|NCT01501110|Drug|N-acetylcysteine|in infusion of 1200 mg of n-acetylcysteine twice a day for 48 hours
1695317|NCT01501097|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm :early HV-crrt(50ml/kg/h) or Control group
1695318|NCT01501084|Drug|Exenatide|10mcg sc (subcutaneous) injection once at one of the 2 MRI visits
1695319|NCT01501084|Drug|Normal saline .2cc subcutaneous injection|sterile saline injection
1695320|NCT01501071|Device|Esophageal calibration tube|An orogastric calibration tube is inserted during laparoscopic Nissen fundoplication in order to secure a certain esophageal lumen for reducing postoperative dysphagia
1695321|NCT01501058|Behavioral|parent-assisted social skills training program for adolescents with autism spectrum disorder|The subjects will participate in the treatment program weekly for a total of 14 weeks. The final visit will be made at the point three months after the completion of treatment to see mid- and long-term effects.
1695322|NCT01501058|Behavioral|Delayed intervention|Intervention is provided to Waitlist Control Group after waiting for 14 weeks
1695323|NCT01501045|Device|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS (rTMS)
1695324|NCT01501045|Device|TMS system MagPro x100, Tonica Elektronik A/S, Denmark|repeated TMS
1695325|NCT01501032|Device|MD-logic artificial pancreas system|The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
1695326|NCT01501019|Other|Exercise training|"Sjöegren arm: 30-60 minutes of combined aerobic and strength exercises, twice a week, moderate intensity.
Myositis arm: 30 minutes of resistance training combined partial blood flow restriction, twice a week, low intensity.
Takayasu's arteritis arm: 30-50 minutes of aerobic, twice a week, moderate intensity."
1695327|NCT01500993|Drug|Capecitabine|Capecitabine standard therapy (i.e. 2,500 mg/sqm) x 5 cycles plus 1 cycle of capecitabine based chemoradiotherapy (1.650 mg/sqm)
1695328|NCT01500993|Drug|5-FU|4 cycles of bolus 5-FU (500 mg/sqm) and 1 cylce of 5-Fu based chemoradiotherapy (either 1,000 mg/sqm/day infusional 5-Fu days 1-5 and 29-33 or 225 mg/sqm/day infusional 5-Fu throughout the time of chemoradiotherapy)
1695329|NCT01500980|Biological|P. falciparum infection|P. falciparum (NF54 strain) infection delivered by the bites of 12 - 15 infected A. stephensi mosquitos
1695330|NCT01500980|Drug|Chloroquine|Weekly chloroquine dosing (600 mg loading dose, 300 mg thereafter)
1695331|NCT01500980|Drug|Primaquine|Primaquine (45 mg) on day 2 or 3 post ITV infection
1695332|NCT01500980|Drug|Primaquine|Primaquine (45 mg) on day 2 or 3 (pending results of pilot study) post ITV infection
1695333|NCT01500967|Other|Shi-style cervical manipulations|Shi-style cervical manipulation is a spinal manipulation for cervical radiculopathy.It is a kind of traditional chinese massage and can dredge the meridian.Patients are treated every day for 30 minutes.Seven times at one course and totally there are two courses.3 times a week, once the other day（except the weekends）,30 minutes, 2 weeks.
1695334|NCT01500967|Other|Cervical Traction control|6kg to 10kg, 3 times a week, once the other day（except the weekends）,20 minutes, 2 weeks.
1695335|NCT01500941|Dietary Supplement|probiotics|a mixture of Lactobacillus LS01 DSM 2275 and Bifidobacterium BR03 DSM 16604 at a dose of 1 x 109 colony forming units (CFU)/g each in maltodextrin
1695336|NCT01500941|Other|maltodextrin|sachets
1695337|NCT01500928|Device|SOLO insulin pump|Use of the SOLO insulin pump for treatment of type 1 diabetes.
1695338|NCT01500915|Drug|Ranibizumab|0,5mg intravitreal ranibizumab
1695339|NCT01500902|Other|EndoPAT testing (non invasive device)|Using the EndoPAT device, we will assess endothelial function.
1695340|NCT01500902|Other|WatchPAT testing (non-invasive device)|Using the WATCHPAT device we will assess sleep apnea.
1754949|NCT00236626|Drug|topiramate|
1695341|NCT01500889|Procedure|Group I: Conventional Lateral internal sphincterotomy:|LIS was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy to the level of the dentate line. Figures 5, 6, 7 and 8 illustrate the procedure.
1695342|NCT01500889|Procedure|GroupII: V-Y advancement flap|"GroupII: V-Y advancement flap:
The V-Y advancement flap was performed by making a V-shaped incision from the edges of the fissure extending about 4 cm from the anal verge and away from the midline. The V-shaped flap formed of skin and subcutaneous fat was mobilized sufficiently to allow advancement into the anal canal to cover the fissure defect. Care was taken to preserve enough pedicles to ensure adequate blood supply. The base of flap was sutured to the lower anal mucosa with interrupted 000 Vicryl Rapide."
1695343|NCT01500889|Procedure|GroupIII: Tailored LIS with V-Y advancement flap|Tailored lateral sphincterotomy was performed in the lithotomy position by a standard open technique, briefly; a 5-mm incision was made into the perianal skin along the intersphinteric groove. The internal anal sphincter was then dissected and a segment withdrawn with a pair of artery forces and divided with diathermy, the extent of sphincterotomy was done to be more or less equal to the length of the fissure. Then the V-Y advancement flap was performed.
1695344|NCT01500876|Radiation|4D-CT pre-treatment scan|Undergo pre-treatment 4D-CT study for treatment planning External Beam Radiation: standard fractionation (2Gy per day) or stereotactic body radiation therapy Evaluation: Repeat 4D-CT study at 3 months and 6 months post-treatment
1695345|NCT01500863|Drug|hCG|single shot of 6500 IU hCG s.c. at the time of triggering
1695346|NCT01500863|Drug|triptorelin|single shot of 0.2mg triptorelin s.c. at the time of triggering
1695347|NCT01500863|Drug|Triptorelin, estradiol valerate, micronized vaginal progesterone|4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
1695348|NCT01500863|Drug|triptorelin, hCG|single shot of 1500 IU hCG s.c. the day of OPU plus 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
1695349|NCT01500863|Drug|triptorelin, hCG|Multiple doses of 500 IU hCG (OPU, +4 and +7) and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
1695350|NCT01500863|Drug|triptorelin, recombinant LH|300 IU recombinant LH every 48h and 4mg of estradiol valerate per os plus 400mg micronized vaginal progesterone daily starting the day after OPU
1695351|NCT01500850|Drug|nph insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
1695352|NCT01500850|Drug|human insulin|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
human insulin: bolus injections before each main meal"
1695353|NCT01500850|Drug|Insulin Glargine|Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
1695354|NCT01500850|Drug|Insulin glulisine|"Dosage will be pro re nata. Patients should aim an blood glucose level of ≤ 100 mg/dL.
Insulin glulisine: bolus injections before each main meal"
1695355|NCT01500837|Drug|association of RIFAMPIN + CLINDAMYCIN|association of RIFAMPIN + CLINDAMYCIN
1695356|NCT01500837|Drug|association of LEVOFLOXACIN+ CLINDAMYCIN|association of LEVOFLOXACIN+ CLINDAMYCIN
1695357|NCT01500824|Drug|Crizotinib|Crizotinib, 250 mg BID, will be administered orally at approximately the same time each day on a continuous daily dosing schedule
1695358|NCT01500811|Biological|cell injection|Intra articular injection of chondrocyte
1695359|NCT01500798|Drug|20 mg bardoxolone methyl|20 mg, oral, once daily
1695360|NCT01500798|Drug|Placebo|Oral, once daily
1695361|NCT01500785|Drug|levosimendan|infusion; levosimendan (12 μg/kg) The study drug will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient)
1695362|NCT01500785|Drug|Vitamin B 12|Infusion made of Glucos B.Braun 50 mg/ml infusion together with vitamin B12 which is used to colour the glucose infusion to look identical to Simdax infusion The placebo will be administered together with the induction of cardioplegia solution during five minutes (=once for each patient).
1695363|NCT01500772|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
1695364|NCT01500772|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
1695365|NCT01500772|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
1695366|NCT01500746|Procedure|Pulse lavage treatment|A pulse lavage machine will be used to irrigate the wound with a total of 4 liters of water, twice daily, for a total of 4 days (8 treatments).
1695367|NCT01500746|Other|Dressing changes|Wounds will be treated with moist gauze dressing changes twice daily for a total of 4 days (8 treatments).
1695369|NCT01500720|Drug|Cabazitaxel|Cabazitaxel 25 milligram per square meter (mg/m^2) intravenously (IV) on Day 1 every 3 weeks (21-day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
1695370|NCT01500720|Drug|Topotecan|Topotecan 1.5 mg/m^2 IV on Day 1 to Day 5 every 3 weeks (21-Day cycle) until unacceptable toxicity, disease progression or withdrawal consent.
1695371|NCT01500707|Drug|SCH 900800|SCH 900800, one 20 mg tablet, orally
1695372|NCT01500694|Drug|Extended-release Guanfacine HCl (Intuniv, SPD503)|Subjects will be dosed orally once-daily in the AM at 1, 2, 3, 4, 5, 6, or 7 mg according to subjects weight and age
1695373|NCT01500681|Procedure|Plasma exchange (PLEX)|Regular maintenance PLEX courses, typically 3 procedures monthly
1695374|NCT01500668|Drug|Botox|Injection of 200 units of Botulinum Toxin A (BOTOX) to a treated limb. Each limb will be divided to two levels - arterial arch and digital arteries (near MCP/MTP) levels. In each level 100 units of Botox will be injected in 6 injection points in the proximity of the arteries.
1695375|NCT01500668|Drug|Placebo|Injection of 0.5cc of normal saline (0.9% NaCl) to each injection site as in the Active drug arm.
1695376|NCT01500655|Procedure|Regional nerve block|a block of the lateral femoral cutaneous nerve is performed under ultrasound guidance. For LFCN block, ropivacaine 0.2% will be used. Dose will be 20 ml, unless patient weighs less than 20 kg, in which case volume will be equal to patient's weight in kilograms.
1695440|NCT01500226|Drug|Rolapitant|(4 X 50 mg capsule) 200 mg PO
1695441|NCT01500226|Drug|Granisetron|2 mg PO
1695377|NCT01500655|Procedure|Catheter|After an ultrasound guided nerve block is performed a catheter is placed under the fascia iliaca and an infusion of ropivacaine 0.2% running at 0.15 ml/kg/hour is administered for 48 hours.
1695378|NCT01500642|Biological|Slit One|slit one sublingual immunotherapy 200 stu
1695379|NCT01500642|Biological|Slit One|slit one vestibular immunotherapy 200 stu
1695380|NCT01500642|Biological|Slit One ragweed|slit one 400 stu dose ragweed (sublingual doubled immunotherapy)
1695381|NCT01500629|Device|C-1266-7|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Investigational Nasal Spray (C-1266-7) in each nostril, for a total of 200 uL per treatment.
1695382|NCT01500629|Device|C-1266-6 (placebo)|Each subject will receive two sprays (50 uL per spray for a total of 100 uL) of Sham Nasal Spray (C-1266-6, placebo) in each nostril, for a total of 200 uL per treatment.
1695383|NCT01500616|Drug|Telaprevir|type = exact number, unit = mg, number = 750, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with pegylated interferon alfa (Peg-IFN alfa) and ribavirin (RBV) during 48 weeks for eligible non treated HIV patients and for patients whose highly active antiretroviral therapy (HAART) regimen is the combination of ritonavir-boosted atazanavir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or the combination of raltegravir, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
1695384|NCT01500616|Drug|Telaprevir|type = exact number, unit = mg, number = 1125, form = tablet, route = oral use, every 8 hours for 12 weeks in combination with Peg-IFN alfa and RBV during 48 weeks when patient's HAART regimen is the combination of efavirenz, plus either TDF or abacavir, plus either emtricitabine or lamivudine, or etravirine, TDF, plus either emtricitabine or lamivudine, or etravirine, abacavir, plus either emtricitabine or lamivudine, or rilpivirine, TDF, plus either emtricitabine or lamivudine, or rilpivirine, abacavir, plus either emtricitabine or lamivudine.
1695385|NCT01500603|Device|AdvanceXP Male sling device|Patients will receive AdvanceXP retrourethral male sling (polypropylene mesh) implantation under general or loco-regional anaesthesia, by perineal approach. The sling is placed via transobturator route.
1695386|NCT01500603|Device|Pro-ACT balloon device|Patients will receive Pro-ACT balloons implantation under general or loco-regional anaesthesia, by perineal approach. The balloons are placed under X-ray control laterally to the urethra, under the bladder neck. The extremity of the device (titanium port), linked to the balloon, is located subcutaneously in the scrotum. During post-operative visits, readjustments of the volume of the balloons will be made under local anaesthesia. The volume will be increased or decreased according to the patients symptoms.
1695387|NCT01500590|Drug|Renin-angiotensin system blockers|ramipril 2.5mg to 10mg once daily if patient experience cough, we will use irbesartan 150 mg to 300mg once daily
1695388|NCT01500590|Drug|non-renin angiotensin system blockers|amlodipine 2.5 to 10 mg once daily nifedipine retard 20mg to 40mg twice daily indapamide 2.5mg once daily metoprolol 25mg to 100mg daily methyldopa 125 mg to 500mg twice daily
1695389|NCT01500577|Drug|nimesulide|Nimesulide 100 mg (capsules). 100mg/die every day for 1 year. Oral administration
1695390|NCT01500577|Drug|Simvastatin|Simvastatin 20 mg (capsules). 20mg/die every day for 1 year. Oral administration
1695391|NCT01500577|Other|Placebo|Placebo (capsules). 1 cps/die every day for 1 year. Oral administration
1695392|NCT01500564|Device|anodal tDCS (device) Eldith DC-Stimulator|tDCS applied to the motor cortex every day of two consecutive weeks (10 sessions) at 1 mA during 20 minutes. Conductive rubber covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 100 seconds.
1695393|NCT01500564|Device|Sham tDCS|Participants will receive sham tDCS over the primary motor cortex of the ipsilesional hemisphere during 20 minutes of motor training (10 consecutive sessions Monday-Friday during two weeks).
1695394|NCT01500551|Drug|Tofacitinib|"Tofacitinib will be administered orally BID (twice daily) approximately 12 hours (±2 hours) apart, once in the morning and once in the evening, based on body weight.
Body Weight (Dose in tablet [mg BID] or solution [ml BID]) 5 ‑ < 7 kg (2 mg or 2 ml) 7 - < 10 kg (2.5 mg or 2.5 ml) 10 - <15 kg (3 mg or 3 ml) 15 - <25 kg (3.5 mg or 3.5 ml) 25 - <40 kg (4 mg or 4 ml) >=40 kg (5 mg or 5 ml)
Oral solution (1 mg/mL concentration) will be used for subjects weighing <40 kg. Oral tablets (5 mg) will be used for subjects weighing >=40 kg; subjects who are unable to swallow tablets will have the option of taking oral solution.
Subjects will swallow study tablets whole and will not manipulate or chew tablets prior to swallowing."
1695395|NCT01500551|Drug|Tofacitinib|For subjects rolling over from study A3921103 and actively participating in this study at the time of Protocol Amendment 6 and receiving a dosage of tofacitinib in accordance with the dosing scheme specified in Protocol Amendment 5, investigators will have the option of maintaining the subject's current dosage regimen from index study A3921103 (if the desired clinical response has been attained with no safety concern) or adjusting the dosage regimen in accordance with the dosing scheme specified in this section.
1695396|NCT01500538|Drug|Eltrombopag and Vorinostat|4 week mono-therapy eltrombopag, commencing at 50mg/day, increasing to 200mg. Daily intake of 400mg vorinostat for minimum of 6 cycles, each cycle of 4 weeks, possibly in combination with daily intake eltrombopag commencing at 50mg/day at a maximum dose of 200md/day (150mg/day for subjects of East-Asian ancestry)
1695397|NCT01500512|Other|Clinical Observation|Undergo observation
1695398|NCT01500499|Genetic|gene expression analysis|
1695399|NCT01500499|Genetic|gene rearrangement analysis|
1695400|NCT01500499|Genetic|polymerase chain reaction|
1695401|NCT01500499|Genetic|protein analysis|
1695402|NCT01500499|Genetic|western blotting|
1695403|NCT01500499|Other|laboratory biomarker analysis|
1695404|NCT01500499|Other|mass spectrometry|
1695405|NCT01500486|Device|NordiFlex PenMate™|Subjects whom will be offered growth hormone (Norditropin NordiFlex®) on prescription as part of normal clinical practice will be asked to evaluate the NordiFlex PenMate™ device.
1695406|NCT01500473|Drug|Desogestrel|Reclipsen oral contraceptive pill with 0.03mg ethinyl estradiol and 0.15mg desogestrel
1695438|NCT01500252|Device|Patellar Replacement Prosthesis|The Profix™ Total Knee System, a posterior cruciate retaining prosthesis manufactured by Smith and Nephew, Inc. was utilized in all subjects. Subjects randomized to the Resurfaced group received an all polyethylene patellar implant
1695407|NCT01500434|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
1695408|NCT01500434|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
1695409|NCT01500434|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
1695410|NCT01500421|Device|TH - Endovascular alone (Alsius®, Zoll, USA)|Patients are cooled with an endovascular (Alsius®, Zoll, USA) groin catether (9,3 french).
1695411|NCT01500421|Device|TH - Endovascular + nasopharyngeal induction (Alsius®, Zoll, USA) (Rhinochill®, Benechill, USA)|Patient are cooled with a groin endovascular catheter (Alsius®, Zoll, USA) + a nasopharyngeal induction catheter (Rhinochill®, Benechill, USA) in the nostrils. The nasopharyngeal induction is designed to give a more quick and localised brain cooling.
1695412|NCT01500421|Device|Intravenous cold saline and surface cooling (Arctic Sun, Medivance, USA)|Infusion of ice cold saline of 4°C (25 mL/kg body weight)followed by surface cooling
1695413|NCT01500408|Drug|Interferon beta-1a (current approved manufacturing process invloving FBS)|Single dose of 60 mcg given Intramuscularly (IM)
1695414|NCT01500408|Drug|Interferon beta-1a (new process, manufactured without FBS)|Single dose of 60 mcg given Intramuscularly (IM)
1695415|NCT01500395|Procedure|Hybrid operation|Hybrid Operations including debranching technique+Thoracic Endovascular Aortic Repair (TEVAR), Frozen elephant trunk technique, aortic arch replacement with concommitant TEVAR, et al. Devices include Medtronic Stent Graft（Medtronic Medtronic, Inc., US） Microport Stent Graft（Microport Co.,LTD.，Shanghai, China） Ankura Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）.
1695416|NCT01500382|Drug|Vibegron|Tablet, 50 or 100 mg, once daily, for up to 10 days based on treatment assignments and treatment period.
1695417|NCT01500382|Drug|Tolterodine ER|Capsule, 4 mg, once daily, for up to 10 days based on treatment assignment and treatment period.
1695418|NCT01500382|Other|Placebo (vibegron)|Inactive agent in tablet form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
1695419|NCT01500382|Other|Placebo (tolterodine ER)|Inactive agent in capsule form, oral administration, once daily, up to 5 weeks, based on treatment assignment in each treatment period.
1695420|NCT01500382|Drug|Prophylactic Antibiotic|A pre-procedural prophylactic antibiotic (ie, levofloxacin 250 mg, cephalexin) administered orally, 30 minutes prior to each scheduled urodynamic study intervention. It is up to the discretion of the Investigator, based on study protocol recommendations, as to which type of antibiotic may be administered.
1958223|NCT01863745|Drug|nilotinib|Nilotinib can be provided as 200 mg and 150 mg hard gelatin capsules. The starting dose of nilotinib should be the same as the last dose that was given in the parent nilotinib study. After this, the dose of nilotinib is based on the investigator's judgment.
1695423|NCT01500356|Behavioral|Behavioral weight loss intervention|Weight loss intervention that focuses on reducing energy intake.
1695424|NCT01500356|Behavioral|Diet Plus Moderate Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 150 minutes per week of moderate-intensity exercise.
1695425|NCT01500356|Behavioral|Diet Plus High Exercise|Weight loss intervention that involve an energy restricted diet (identical to the Diet Alone arm) plus the inclusion of 250-300 minutes per week of moderate-intensity exercise.
1695426|NCT01500343|Drug|Saccharomyces boulardii|1 gram per day, during 3 months
1695427|NCT01500330|Procedure|cupping massage|the upper back is covered in massage oil the cupping glass is drawn along the back muscles
1695428|NCT01500330|Procedure|Progressive muscle relaxation|standardized programme on muscle relaxation according to Jacobson
1695429|NCT01500317|Drug|Tapentadol|Subjects received tapentadol immediate release formulation, 75 mg three times per day (tid) for 48 hours.
1695430|NCT01500317|Drug|Oxycodone|Subjects received oxycodone immediate release formulation, 5 mg three times per day (tid) for 48 hours.
1695431|NCT01500317|Drug|Placebo|Subjects received placebo three times per day (tid) for 48 hours.
1695432|NCT01500304|Procedure|Minimally invasive inguinal lymph node dissection|Operative intervention will be a minimally invasive inguinal lymphadenectomy, which is a three trocar technique to the inguinal dissection, that respects the same anatomic boundaries as the conventional open procedure
1695433|NCT01500291|Other|2 courseware databases.|All participant voluntarily response all items in the SST and SAST courseware database.
1695434|NCT01500278|Biological|Certolizumab Pegol (CZP)|"Active substance: an injectable volume of 1 ml solution for injection CZP
Pharmaceutical form: prefilled syringes CZP
Concentration: 200 mg/ml CZP
Route of Administration: injections will be given subcutaneously: loading dose of CZP 400 mg at Baseline, and Weeks 2 and 4, followed by a maintenance dose of 200 mg every 2 weeks through Week 102 or withdrawal."
1695435|NCT01500278|Biological|Adalimumab (ADA)|"Active substance: an injectable volume of 0.8 ml solution for injection ADA
Pharmaceutical form: prefilled syringes ADA
Concentration: 40 mg/0.8 ml ADA
Route of Administration: injections will be given subcutaneously. ADA 40 mg plus an injection with Placebo (to preserve blind) at Baseline, and Weeks 2 and 4, followed by ADA 40 mg every 2 weeks through Week 102 or withdrawal."
1695436|NCT01500278|Drug|Methotrexate (MTX)|"Active substance: Methotrexate
Pharmaceutical form: oral tablet
Concentration: 15-25 mg/week
Route of Administration: MTX orally"
1695437|NCT01500265|Biological|plasma and urine samples, sample with ADN|plasma and urine samples every three months Sample with ADN at baseline
1695442|NCT01500226|Drug|Dexamethasone|20 mg PO
1695443|NCT01500226|Drug|Placebo|(4 X 0 mg capsules) 0 mg PO
1695448|NCT01500200|Drug|ALKS 5461|Two active tablets, given daily
1695449|NCT01500200|Drug|Placebo|Two placebo tablets, given daily
1695450|NCT01500187|Device|Vanish varnish|5% sodium fluoride varnish with tricalcium phosphate
1695451|NCT01500187|Device|Oral B Minute-Gel|Fluoride gel
1695452|NCT01500174|Device|ultraviolet therapy UV254|three times per week until wound closure or patient discharge from hospital
1695453|NCT01500174|Device|Placebo ultraviolet therapy UV254|Three times per week irradiation of wound base and periwound skin
1695454|NCT01500161|Drug|Busulfan|Busulfan 3.2 mg/kg/day intravenously on days -7, -6, -5 and -4(for non-NHL patients patients who get Clofarabine regimen)
1695455|NCT01500161|Drug|Clofarabine|Clofarabine intravenously 40 mg/m2/day on days -7, -6, -5, -4 and -3(for non-NHL patients patients who get Busulfan regimen)
1695456|NCT01500161|Drug|Fludarabine|Fludarabine 30 mg/kg/day intravenously on days -7, -6, -5, -4 and -3 (for non-NHL patients who receive Melphalan containing regimen)
1695457|NCT01500161|Drug|Melphalan|Melphalan intravenously 140 mg/m2/day on day -3 (only for non-NHL patients who receive Fludarabine OR for all NHL regimens)
1695458|NCT01500161|Drug|Carmustine|BCNU(Carmustine)300 mg/m2 intravenously on day -7 (for NHL patients only)
1695459|NCT01500161|Drug|Etoposide|Etoposide 300 mg/m2/day intravenously on days -6, -5, -4 and -3 (for NHL patients only)
1695460|NCT01500161|Drug|Cytarabine|ARA-C(Cytarabine) 100 mg/m2/day on days -6, -5, -4 and -3 (for NHL patients only)
1695461|NCT01500148|Device|PMVr procedure (SJM Percutaneous Mitral Valve Repair (PMVr)|A maximum of ten (10) subjects will receive a percutaneous mitral valve clip procedure.
1695462|NCT01500135|Drug|TachoSil®|TachoSil® is a sterile, ready-to-use, absorbable patch for intra-operative topical application. It consists of an equine collagen patch coated with fibrin glue components: human fibrinogen and human thrombin.
1695463|NCT01500135|Drug|Surgicel® Original|Surgicel® Original is an absorbable hemostat (oxidized regenerated cellulose)
1695464|NCT01500122|Drug|RhuDex|"Part 1:
Regimen A: Rhudex Formulation in Labrafac/ Gelucire Regimen B: Rhudex Formulation in Labrafac/ Aerosil single dose
The formulation platform (A or B) that shows the best potential to achieve the target PK profile and shows acceptable safety and tolerability will be progressed into part 2 of the study. The purpose of part 2 is to optimize the selected formulation platform. This will be achieved by administrating up to four different formulation compositions."
1695465|NCT01500109|Drug|Oral acetaminophen|Oral acetaminophen administered as a cherry flavored elixir will be dosed preoperatively 15 mg/kg and redosed every 6 hours for 24 hours. Placebo oral acetaminophen will be administered to the other two arms of the study according to the same timetable. Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
1695466|NCT01500109|Drug|Ofirmev®|Intravenous acetaminophen is initiated after intravenous access is obtained intraoperatively and before surgical incision. Dosing is age based as follows: 5 months-2 years 12.5 mg/kg, 2-5 years 15 mg/kg. Redosing will be every 6 hours for 24 hours. The two other arms will receive a placebo in the form of normal saline given intravenously. Intraoperative opioids will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
1695467|NCT01500109|Drug|Opioid only|Intraoperative opioids (Fentanyl or Morphine) will be administered as deemed necessary by anesthesia care team. in the PACU, fentanyl 0.5-1 mcg/kg will be administered for moderate-severe pain. Once discharged from PACU, morphine 0.05 mg/kg will be given every 3 hours as needed.
1695470|NCT01500083|Drug|Bendamustine at a dose of 100 mg/m2|Bendamustine will be administered intravenously over 30 minutes.
1695471|NCT01500083|Drug|Bendamustine at a dose of 120 mg/m2|Bendamustine will be administered intravenous (i.v.) over 60 minutes.
1695472|NCT01500070|Device|Everolimus-Eluting Stent (PROMUS ELEMENT)|PROMUS ELEMENT Everolimus-Eluting Stent System (Boston Scientific) or PROMUS ELEMENT PLUS Everolimus-Eluting Stent System (Boston Scientific).
1695473|NCT01500057|Device|Greenlight XPS Laser|Treatment of BPH with Greenlight XPS laser
1695474|NCT01500057|Device|BiVAP Saline Vaporization of the prostate|treatment of BPH with BiVAP Saline Vaporization
1695475|NCT01500044|Procedure|Program targeting the opening of foramen|Rehabilitation intervention that specifically targets the opening of the intervertebral foramen
1695476|NCT01500044|Procedure|Conventional Rehabilitation Program|Program used in previous randomized clinical trials in this population
1695477|NCT01500031|Device|OffRoad Re-entry Catheter System|Facilitate the placement and positioning of guidewires within the peripheral vasculature.
1695478|NCT01500018|Drug|TC-5214|Single oral dose of 2 mg
1695479|NCT01500018|Drug|TC-5214 Placebo|Single oral dose
1695480|NCT01500018|Drug|Ketamine|Single oral dose of 100 mg
1695481|NCT01500018|Drug|Phentermine|Single oral dose of 45 mg
1695482|NCT01500018|Drug|TC-5214|Single oral dose of 8 mg
1695483|NCT01500018|Drug|TC-5214|Single oral dose of 16 mg
1695484|NCT01500018|Drug|Phentermine|Single oral dose of 90 mg
1695485|NCT01500005|Drug|Baby D3 drops|2000-4000 iu per day
1695515|NCT01499706|Behavioral|4-session telephone-administered motivational interviewing|Participants will receive four weekly sessions of telephone-delivered motivational interviewing to reduce sexual risk behavior.
1695516|NCT01499693|Drug|Magnesium Pantoprazole 20 mg|oral dose, twice a day
1695517|NCT01499693|Drug|Magnesium Pantoprazole 40 mg|oral dose, once a day (morning)
1695567|NCT01499277|Drug|Ceftaroline fosamil|IV ceftaroline 600mg every 8 hours
1695568|NCT01499277|Drug|Vancomycin|IV vancomycin 15mg/kg every 12 hours
1695486|NCT01499992|Procedure|Standard physical therapy program PLUS aquatic physical therapy|2. Standard physical therapy program PLUS aquatic physical therapy: The above PLUS a aquatic physical therapy program which will be conducted twice weekly for 10 weeks and will include a 40-50 minute hydrotherapy session emphasizing range of motion and light resistive exercises of the arm, primarily focusing on the shoulder. The program will start with general mobility of the other upper limb joints to allow time for preconditioning of the painful shoulder. Shoulder exercises will emphasize flexion, rotation and abduction and a slow transition from pain-free range to the restricted range of motion to maximize the effectiveness of the heat and buoyancy.
1695487|NCT01499992|Other|standard care|Total of 12 weeks; each exercise session will be 20 -30 minutes of direct contact and additional supervised exercise as defined by assignment and stage.
1695488|NCT01499979|Procedure|In situ hypothermic perfusion|In situ perfusion of the future remnant liver with chilled lactated Ringer's solution during liver resection.
1695489|NCT01499966|Procedure|Plaster of Paris/ Tubigrip|"After informed consent was obtained the patients were randomized such that each patient was allocated to use either a Tubigrip (Group A) or Plaster of Paris (Group B). The standardized treatment in the form of RICE (Rest, Ice, Compression and Elevation) protocol was given to all patients. The Patients were randomized using the Block randomization. One hundred and twenty six white papers were taken and TG for Tubigrip and POP for Plaster of Paris were written and the patients were allowed to pick the envelope of their choice. The authors were blinded till the opening of the envelope by the patients. Patient's usage of analgesia in form of Paracetamol was specifically noted. The patients in TG group receive the Tubigrip treatment and the patients in POP group were given a below knee plaster cast. Patients were instructed to follow up at 2 weeks and then at 6 weeks"
1695490|NCT01499953|Drug|Rivaroxaban|Dose: 10 mg Duration: 45 (±5) days Frequency: once daily Application: oral
1695491|NCT01499953|Drug|Fondaparinux|Fondaparinux Dose: 2.5 mg Duration: 45 (±5) days Frequency: once daily Application: subcutaneous
1695492|NCT01499940|Drug|Vitamin D3|Vitamin D3 will be administered at a dose of 2000 IU orally daily starting on day 1 of the first cycle of oxaliplatin. The vitamin will be continued at this dose and schedule for approximately 6 months if the patient is receiving oxaliplatin in the adjuvant setting and neither dosage nor interval has been modified for neurological toxicity. The duration of therapy if oxaliplatin is given for metastatic disease will vary. Nonetheless, the study vitamin will be continued using the same criteria as in the adjuvant setting.
1695493|NCT01499927|Other|electronic reminders|Behavioral: Early switching from intravenous to oral antiinfective agents due to electronic reminders
1695494|NCT01499914|Biological|influenza vaccination|Influenza vaccination in patients with cystic fibrosis
1695495|NCT01499901|Procedure|bilateral cochlear Implantation in sequential|bilateral cochlear Implantation in sequential
1695496|NCT01499901|Procedure|bilateral cochlear Implantation in simultaneous|bilateral cochlear Implantation in simultaneous
1695497|NCT01499888|Procedure|Allogeneic Non-Myeloablative Stem Cell Transplantation|"Alemtuzumab-based non-myeloablative allogeneic hematopoietic stem cell transplantation using immune-suppressive agents and low-dose total body irradiation (TBI) without standard chemotherapy.
Transplant regimen Day -7 to -3: Alemtuzumab (1mg/kg, total dose) divided over the 5 days, IVPB over 2 hours daily Day -3 until 100% chimerism obtained: Sirolimus dosed for target trough level of 10-15 ng/mL Day -2: Total body irradiation with 300cGy Day 0: Stem cell infusion"
1695498|NCT01499888|Drug|Alemtuzumab|In this protocol, patients will be given alemtuzumab 1mg/kg divided equally over five days with the maximum dose of 20mg per day.
1695499|NCT01499888|Drug|Sirolimus|On day -1, patients will receive a loading dose of 12 mg followed by 4 mg per day. Subsequent dosing will be based on clinical toxicity, GVHD concurrent medications, medical conditions, prior drug levels, drug-drug interactions, and blood levels with target of 3 to 12 ng/mL.
1695500|NCT01499875|Drug|Phenoxymethylpenicillin|mixture, 25 or 50 mg/kg taken once.
1695501|NCT01499862|Device|Tibion Bionic Leg|A programmable, carbon-fiber robotic leg orthosis (Tibion Bionic Leg, Tibion Corporation, Sunnyvale, CA) was used during therapy to actively supplement concentric and eccentric quadriceps function on the participant's impaired side. The device uses internal sensors at the foot and knee joint to detect intention of movement and, once a variable force threshold is passed, the devices provides appropriate assistive and resistive adjustments.
1695502|NCT01499849|Drug|Rolapitant|(4 X 50 mg capsules) 200 mg PO
1695503|NCT01499849|Drug|Granisetron|10 mcg/kg IV
1695504|NCT01499849|Drug|dexamethasone|20 mg PO and 8 mg PO
1695505|NCT01499849|Drug|Placebo|(4 X 0 mg capsules) 0 mg PO
1695506|NCT01499836|Other|PVB|paravertebral block
1695507|NCT01499810|Procedure|Bilateral radiofrequency sympathetic renal denervation|Bilateral radiofrequency sympathetic renal denervation is performed as percutaneous transluminal radiofrequency (RF) ablation of neural pathways in the renal artery walls and surrounding tissue using standard equipment for RF ablation of cardiac electrical pathways
1695508|NCT01499797|Other|The CareWell programme|"The CareWell programme contains the following components:
multidisciplinary primary care teams
working with proactive care plans integrating cure, care and welfare
advanced care planning (e.g. recording limitations of treatment, non-resuscitation decisions)
medication review
case-management
guidelines for consultation of in-hospital geriatric experts
guidelines for transfers from primary care to home-based facilities and hospital and back
practice guidelines for management of common geriatric conditions"
1695509|NCT01499784|Behavioral|pelvic floor muscle training|behavioral modification and pelvic floor muscle training
1695510|NCT01499771|Drug|Atorvastatin|80 Mg tablets
1695511|NCT01499758|Drug|Atorvastatin|80 Mg tablets
1695512|NCT01499745|Behavioral|Pulmonary Rehabilitation|"Exercise Training in Pulmonary Rehabilitation Program:
12 weeks of 60 min exercise bout, twice a week at pulmonary rehabilitation"
1695513|NCT01499719|Behavioral|Checklist introduction / Pause|Operating room staff will be introduced to a new checklist specifically designed to address concerns around protocols for endoscopic sinus surgery to raise awareness and attention to 11 specific areas of interest.
1695514|NCT01499706|Behavioral|1-session of telephone-administered motivational interviewing|Participants will receive a single session of telephone-delivered motivational interviewing to reduce sexual risk behavior.
1695565|NCT01499290|Drug|Metronidazole|500 mg of Metronidazole
1695566|NCT01499290|Drug|Meropenem|1 gram of Meropenem
1695518|NCT01499693|Drug|Placebo|"oral dose, once a day (night)
Placebo will be administered at night in the group with 40mg magnesium pantoprazole to keep the blinding (so treatment administration is comparable w/the 20mg group)."
1695519|NCT01499667|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration once daily
1695520|NCT01499667|Drug|Placebo|Matching placebo in capsules for oral administration once daily.
1695521|NCT01499654|Drug|Half-dose of the Tc99-m sestamibi (Cardiolite)|Researchers will administer half of the radiotracer (Cardiolite), obtain resting images, administer the remainder of the radiotracer and obtain a second set of resting images. Subjects will be given the same amount of radioactive material that would normally be given for this test; however, it will be administered in two ½ doses.
1695522|NCT01499641|Drug|Methylprednisolone|Epidural methylprednisolone 40 mg or none
1695523|NCT01499628|Behavioral|Supervised Reading|Participant attends once a week for three weeks for a 45 minute appointment of supervised reading using appropriate spectacles and/or glasses
1695524|NCT01499628|Behavioral|EVT at the PRL|Eccentric viewing training at the Preferred Retinal Locus (PRL), using reading/target cards. Three 45 minute sessions completed over three weeks.
1695525|NCT01499628|Behavioral|EVT at the TRL|Participant attends once a week for three weeks for a 45 minute appointment of TRL training using the MAIA microperimeter and then further reading using magnifiers and/or spectacles.
1695526|NCT01499615|Device|cardiac monitor|All children receive the same intervention which is the application of the 4 ekg electrodes
1695527|NCT01499602|Drug|LNG-IUS; Mirena; Bayer Schering Pharma Oy, Finland|Initial release rate of 20µg Levonorgestrel per day for one year follow up.
1695528|NCT01499602|Drug|Norethisterone Acetate tablets|Norethisterone Acetate tablets at a dose of 5 mg three times daily (15mg/day) for 3 weeks over three months.With persistence of endometrial hyperplasia, the treatment is repeated for another 3 months
1695529|NCT01499589|Procedure|regional anesthesia|regional anesthesia procedure
1695530|NCT01499576|Procedure|Acetic acid chromoendoscopy|Acetic acid chromoendoscopy Spraying 1.5% acetic acid(or vinegar), during screening gastroduodenoscopy
1695531|NCT01499563|Drug|ITI-007|Capsules containing ITI-007 for 28 days
1695532|NCT01499563|Drug|Placebo|Capsules containing inactive placebo for 28 days
1695533|NCT01499563|Drug|Risperidone|Capsules containing risperidone for 28 days
1695534|NCT01499550|Device|humidified transnasal insufflation (TNI20oxy)|The alternative breathing support with TNI supplies COPD patients with 20L/min of warm humidified air. This method may be applicable to wash out the dead space between glottis and nasal opening. Pre-investigations have shown that 45 minutes of TNI during daytime reduced PCO2 and respiratory rate compared to application of oxygen alone.Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
1695535|NCT01499550|Other|overnight oxygen treatment with individual flow rate|The patient is treated with his individual oxygene flow rate. Transcutaneous PCO2 is measured over night. A capillary blood gas analysis (BGA) is carried out at beginning and end of each measurement night.
1695536|NCT01499537|Device|biliary drainage|percutaneous transhepatic biliary drainage (PTBD)
1695537|NCT01499537|Device|EUS guided biliary drainage|endoscopic ultrasonography guided biliary drainage through the duodenal or the gastric wall
1695538|NCT01499498|Drug|Sildenafil and Boceprevir|25mg once/800mg three times a day
1695539|NCT01499485|Drug|Acetazolamide|"Daily morning ABGA:
If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of acetazolamide 500 mg .
If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of acetazolamide 500 mg.
If actual bicarbonate <= 26 mmol/L: omit treatment that day."
1695540|NCT01499485|Drug|Placebo|"Daily morning ABGA:
If actual bicarbonate > 26 mmol/L and pH > 7.35: administration of enteral capsule of placebo.
If actual bicarbonate > 26 mmol/L and pH <= 7.35, increase minute ventilation to reach pH > 7.35 and then administer enteral capsule of placebo.
If actual bicarbonate <= 26 mmol/L: omit treatment that day."
1695541|NCT01499472|Device|shock wave therapy|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
1695542|NCT01499472|Device|dermagold shockwave|shock wave therapy given in accordance to wound assessment every 2 weeks for 4 treatments.
1695543|NCT01499472|Procedure|standard of care|regular care including debridement and bandaging.
1695545|NCT01499446|Drug|GW685698X (fluticasone furoate) 100mcg Morning|GW685698X inhaled once daily in the morning plus placebo in the evening for 28 days
1695546|NCT01499446|Drug|GW685698X (fluticasone furoate) 100mcg Evening|GW685698X inhaled once daily in the evening fplus placebo in the morning for 28 days
1695547|NCT01499446|Drug|GW685698X (fluticasone furoate) 250mcg Evening|GW685698X inhaled once daily in the evening plus placebo in the morning for 28 days
1695548|NCT01499446|Drug|Placebo|Placebo inhaled twice daily (morning and evening) for 28 days
1695549|NCT01499433|Drug|caspofungin|Caspofungin injection, intravenously administered, loading dose at 70mg qd for the first 24hrs, maintenance dose at 50mg qd for the following 20 days
1695550|NCT01499420|Biological|CSL112 (reconstituted high density lipoprotein)|Single escalating intravenous doses of CSL112
1695551|NCT01499420|Biological|Placebo|Single intravenous doses of normal saline (0.9%)
1695552|NCT01499407|Device|ClearWay RX catheter|
1695553|NCT01499407|Drug|Abciximab|
1695554|NCT01499368|Drug|Lafutidine|Lafutidine 20mg/day
1695555|NCT01499368|Drug|Famotidine|Famotidine 40mg/day
1695556|NCT01499368|Drug|Omeprazole|Omeprazole 20mg/day
1695557|NCT01499355|Biological|BIIB023|
1695558|NCT01499355|Biological|Placebo|
1695559|NCT01499355|Drug|mycophenolate mofetil|titrated to a target daily dose of 2 g (1 g twice daily)
1695560|NCT01499355|Drug|oral corticosteroids|oral corticosteroids (prednisone or equivalent) at a target prednisone dose of 10 mg/day
1695561|NCT01499316|Procedure|High Flow oxygen|10 minute shigh flow oxygen
1695562|NCT01499316|Procedure|Room Air|Room air breathing
1695563|NCT01499303|Drug|Fostamatinib|Phase II Trial to evaluate the efficacy of 200mg fostamatinib
1695564|NCT01499290|Drug|CAZ-AVI|Ceftazidime 2000 mg and 500 mg of avibactam
1695569|NCT01499277|Drug|Aztreonam|IV aztreonam 1 g every 8 hours
1695570|NCT01499264|Device|MySkin patch|Hydrogel and polyurethane film
1695571|NCT01499264|Device|Traditional Dressing|Gauze and Patch
1695572|NCT01499251|Drug|Phase 1 Dose Escalation|Macitentan 30, 60, 90 mg or higher in 30 mg dose increments, given orally, up to 150 mg, then 225 mg, 300 mg and 375 mg, unless otherwise decided by the Safety Monitoring Committee. Dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
1695573|NCT01499251|Drug|Phase 1b|Macitentan given orally and daily at doses/schedule determined from the dose escalation period. Dose-dense temozolomide 150mg/m2 body surface area alternating 1 week on 1 week off.
1695574|NCT01499251|Drug|Ancillary Study|Macitentan dosed initially for 8-14 days prior to craniotomy, then treatment interrupted from time of craniotomy until 7 days before start of dose dense temozolomide therapy. dose-dense temozolomide 150 mg/m2 body surface area alternating 1 week on 1 week off.
1695575|NCT01499238|Device|Nasal SIMV|rate: 30-50/min, PIP: 16-20, PEEP: 4-6, FİO2: 40%
1695576|NCT01499238|Device|nasal CPAP|PEEP: 4-6 mmHg, FİO2: 40%
1695577|NCT01499225|Drug|YH14642 500mg Tab|YH14642 500mg per day(once a day)
1695578|NCT01499225|Drug|YH14642 500mg Tab|YH14642 1000mg per day(twice a day)
1695579|NCT01499225|Drug|YH14642 500mg Tab|YH14642 2000mg per day(three times a day)
1695580|NCT01499225|Drug|INSADOL[Zea mays L. extract] 35mg Tab|"[Initiation dose : 4weeks after administraion] INSADOL[Zea mays L. extract] 210mg TAB per day
[Maintain dose : Between 4weeks and 8weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day
[Maintain dose : Between 8weeks and 12weeks after administraion] INSADOL[Zea mays L. extract] 105mg TAB per day"
1695581|NCT01499225|Drug|DENTISTA[Doxycycline hyclate] 20mg Cap|DENTISTA[Doxycycline hyclate] Cap 40mg per day
1695582|NCT01499225|Drug|Placebo|Placebo
1695583|NCT01499212|Procedure|I:E ratio|I:E ratio 1:1 Volume controlled ventilation TV:8ml/kg EtCO2:35-40mmHg
1695584|NCT01499199|Drug|Dolutegravir|50mg Once Daily
1695585|NCT01499186|Other|Local Vibration|The subjects of the vibration group will be subjected to local vibration training by the use of custom-made cylindrical vibrators which will be placed on the hip and thigh. The subjects will apply the vibrations by themselves and they will learn how to follow the pre-programmed training program. Training sessions take place 5 times a week, during one year. The physiotherapist and the research assistant will attend the training session 1x/week. Training parameters will vary during the year to create a variable stimulus (frequency 40-80Hz and G-force 0.5-5g). The intervention group will perform all measurements.
1695586|NCT01499173|Behavioral|Stroke Preparedness Intervention|A faith-based, scientific theory-driven, peer-led behavioral intervention performed in a group setting in African American churches.
1695590|NCT01499147|Drug|fludarabine/busulfan|All patients below age 55, should receive fludarabine/busulfan, and ATG in case of unrelated or mismatched donor, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 <40%, DLCO<50%, LVEF<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl) and/or specific medical conditions such as preventing a standard myeloablative treatment, as per discussion with the PI.
1695591|NCT01499147|Drug|fludarabine/ melphalan|All patients above age 55 or below age 65, should receive fludarabine/melphalan, and ATG, unless there is significant pulmonary, hepatic or cardiac damage: (E.g FEV1 <40%, DLCO<50%, LVEF<40, Serum bilirubin >1.5 mg% or serum transaminases > 2x nl).
1695592|NCT01499147|Drug|ATG|Patients receiving a transplant from a matched unrelated or mismatched related/unrelated donor would receive ATG in the conditioning regimen.
1695593|NCT01499134|Drug|nebivolol|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at the study visits. Nebivolol is approved for hypertension treatment at a dose of 5-40 mg daily. Based on the study titration schedule, the maximum doses used will be 20 mg of nebivolol (each maximum dose being contained in 4 capsules for daily dosing).
1695594|NCT01499134|Drug|Metoprolol succinate|Study medication will initially be dispensed as one capsule daily and the dose will be titrated at study visits. Metoprolol succinate at 25-400 mg daily. Based on the study titration schedule, the maximum dose used will be 200 mg of metoprolol succinate (each maximum dose being contained in 4 capsules for daily dosing).
1695595|NCT01499121|Drug|Sunitinib|The starting dose will be 50 mg Sunitinib on the 28/14 schedule. In patients that develop ≥ grade-2 toxicity after 2 weeks, therapy will be held for 7 days or resolution before continuing therapy according to the 1st dose/schedule change. In patients that do not develop ≥ grade-2 toxicity, therapy will continue for 1-2 weeks or until ≥ grade-2 toxicity. In patients that develop > grade-2 toxicity after less than 4 weeks, therapy will be held for 7 days or before continued according to the 1st dose/schedule change. Patients that do develop grade-2 toxicity (but no more) on the 50 mg 28/14 schedule, will remain on schedule but the time off therapy will be reduced to 7 days if toxicity has resolved after a 7-day break. Patients that develop ≤ grade-1 toxicity on the 50 mg 28/14 schedule, will be dose escalated according to protocol.
1695596|NCT01499108|Drug|liraglutide|Subcutaneous injection of liraglutide at doses of 0.6, 1.2, and 1.8 mg once daily during the 49 days duration of the study
1695597|NCT01499095|Drug|Lantus (Insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
1695598|NCT01499095|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months in combination with oral antidiabetic drug(s). Dose titration seeking fasting plasma glucose 4.4 - 5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
1695711|NCT01498289|Drug|leucovorin calcium|400 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle.
1696367|NCT01493531|Drug|Allopurinol|Tablets
1695599|NCT01499082|Drug|HOE901-U300 (new formulation of insulin glargine)|HOE901-U300 (new insulin glargine 300 units per milliliter [U/mL]) subcutaneous (SC) injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 millimole per liter (mmol/L) (80 - 100 milligram per deciliter [mg/dL]). After 6 months participants were proposed to participate to the administration substudy and to receive either HOE901-U300 once daily at intervals of 24 +/- 3 hours (adaptable dosing intervals) or to continue once daily injections of HOE901-U300 every 24 hours (fixed dosing intervals) up to Month 9.
1695600|NCT01499082|Drug|Lantus (insulin glargine)|Lantus (HOE901-U100, insulin glargine 100 U/mL) SC injection once daily (evening) for 12 months on top of mealtime insulin analogue. Dose titration seeking fasting plasma glucose 4.4-5.6 mmol/L (80 - 100 mg/dL).
1695601|NCT01499069|Drug|Oxybutinin, Fesoterodine, Solifenacin, Propiverin, Trospium|"Dosage and frequency can be adjusted according to the patients' symptoms based on the instruction for administration .
Duration; 3 or 6 months"
1695602|NCT01499056|Biological|stem cell injection|intra articular inection of mesenchymal stem cell
1695603|NCT01499043|Drug|PLX3397|Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day.
1695604|NCT01499017|Drug|PF-06291874 or placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 3 mg to 100 mg. Correspondingly, placebo doses will be administered as suspension.
1695605|NCT01499017|Drug|PF-06291874 or Placebo|PF-06291874 will be administered as an extemporaneously prepared suspension for all doses within the initially planned range of 300 mg to 650 mg. Correspondingly, placebo doses will be administered as suspension.
1695606|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered with food.
1695607|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) MR-B1 formulation administered with food
1695608|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation A|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation A administered without food
1695609|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B1|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B1 administered without food
1695610|NCT01499004|Drug|tofacitinib (CP-690,550) modified-release formulation B2|A single dose of 22 mg tofacitinib (CP-690,550) modified-release formulation B2 administered without food
1695611|NCT01499004|Drug|tofacitinib (CP-690,550) immediate-release formulation|A single dose of 10 mg tofacitinib (CP-690,550) immediate-release formulation administered without food
1695612|NCT01498991|Device|AMES Treatment|The AMES device rotates the ankle over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the leg. Each participant will receive treatment of both lower extremities. Treatment of the 2 legs will be scheduled to run in the same session. The subject's task is to assist the motion of the device. The AMES treatment device couples assisted movement and tendon vibration (enhanced sensation) in 30 treatments which will each run approximately 40 minutes (20 minutes on the right leg and 20 minutes on the left leg).
1695615|NCT01498952|Drug|MEDI-573 (1 of 3 doses)|MEDI-573, a human immunoglobulin G2 lambda (IgG2λ) monoclonal antibody (MAb), is a dual-targeting human antibody that neutralizes insulin-like growth factor (IGF)-I and IGF-II ligands
1695616|NCT01498952|Drug|Sorafenib|Sorafenib is a tyrosine kinase inhibitor, anti-angiogenic, VEGF inhibitor
1695617|NCT01498939|Drug|insulin detemir|Each subject will be randomly allocated to an insulin detemir dosing sequence. Three doses of insulin detemir (0.2, 0.4 or 0.8 U/kg) will be administered on three inconsecutive days with a wash-out period between each dosing. Injected subcutaneously (s.c., under the skin)
1695618|NCT01498926|Drug|insulin detemir|Single dose containing mannitol as isotonic agent. Administered subcutaneously (s.c., under the skin)
1695619|NCT01498926|Drug|insulin detemir|Single dose containing glycerol as isotonic agent. Administered subcutaneously (s.c., under the skin)
1695620|NCT01498913|Drug|repaglinide|Prescription with NovoNorm® 0.5mg, 1mg or 2mg tablets according to product labelling in daily clinical practice at the discretion of the physician
1695621|NCT01498900|Drug|repaglinide|Prescription according to the product labelling at the physicians' discretion
1695623|NCT01498874|Drug|Placebo|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
1695624|NCT01498874|Drug|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
1695625|NCT01498874|Drug|gevokizumab|Sterile solution administered subcutaneously on Day 0, Day 28, and Day 56
1695626|NCT01498861|Drug|Ortho-Cyclen|Ortho-cyclen is an oral contraceptive.
1695627|NCT01498861|Drug|Dolutegravir|Dolutegravir is an experimental HIV drug
1695628|NCT01498861|Drug|Placebo|Placebo is a tablet with no drug in it
1695629|NCT01498848|Dietary Supplement|Cooking oils|Families were randomized to receive either soybean or sunflower oil for cooking during 4 weeks
1695630|NCT01498835|Drug|Sunitinib|"Patients will receive Sunitinib daily for 2 weeks prior to and then concurrently with irradiation as neoadjuvant treatment. Radiotherapy will be given as intensity modulated radiation therapy with a total dose of 50.4Gy in 28 fractions to each patient (5 1/2 weeks).
Sunitinib will be given in two dose levels. The first dose level will be 25mg Sunitinib per os daily. The second dose level will be 37.5mg sunitinib per os daily. A dose modification schedule according to a 3+3 design will be applied for patient accrual."
1695631|NCT01498822|Drug|Levetiracetam|250 mg and 500 mg Levetiracetam tablet, 1000 mg-3000 mg/day, maximum 50 weeks including initial up titration of 500 mg/day for 2 weeks
1695632|NCT01498822|Drug|Oxcarbazepine|150 mg and 300 mg Oxcarbazepine tablet, 900 mg-2400 mg/day, maximum 50 weeks including 2 weeks of up titration (300 mg/day 1week then 600 mg/day 1 week)
1695633|NCT01498809|Drug|Midodrine|Single 10 mg dose
1695634|NCT01498796|Drug|Ketorolac|
1695635|NCT01498796|Drug|Normal Saline|
1695712|NCT01498289|Drug|oxaliplatin|85 mg/m^2, IV over 2 hours on Day 1 of every 14 day cycle.
1696619|NCT01491282|Other|Enabling and disabling VNS|No intervention
1695636|NCT01498783|Drug|5-fluorouracil|5-fluorouracil, bolus dose of 500 mg/m^2 given weekly for 4 weeks followed by a two week rest period equals one cycle (6 weeks). Therapy may continue for up to 16 cycles (about 2 years).
1695637|NCT01498770|Drug|Asenapine|Asenapine prescribed as recorded in the CPRD in the UK
1695638|NCT01498770|Drug|Aripiprazole|Aripiprazole prescribed as recorded in the CPRD in the UK
1695639|NCT01498770|Drug|Quetiapine|Quetiapine prescribed as recorded in the CPRD in the UK
1695640|NCT01498770|Drug|Risperidone|Risperidone prescribed as recorded in the CPRD in the UK
1695641|NCT01498770|Drug|Olanzapine|Olanzapine prescribed as recorded in the CPRD in the UK
1695642|NCT01498770|Drug|Ziprasidone|Ziprasidone prescribed as recorded in the CPRD in the UK
1695643|NCT01498770|Drug|Iloperidone|Iloperidone prescribed as recorded in the CPRD in the UK
1695644|NCT01498770|Drug|Paliperidone|Paliperidone prescribed as recorded in the CPRD in the UK
1695645|NCT01498770|Drug|Lurasidone|Lurasidone prescribed as recorded in the CPRD in the UK
1695646|NCT01498770|Drug|Clozapine|Clozapine prescribed as recorded in the CPRD in the UK
1695647|NCT01498770|Drug|Amisulpride|Amisulpride prescribed as recorded in the CPRD in the UK
1695648|NCT01498770|Drug|Sertindole|Sertindole prescribed as recorded in the CPRD in the UK
1695649|NCT01498770|Drug|Zotepine|Zotepine prescribed as recorded in the CPRD in the UK
1695650|NCT01498744|Drug|Oral Clindamycin|Based on our preliminary susceptibility data, oral clindamycin (10mg/kg up to 300 mg, every 8 hours) is the first line of antibiotic. Patients allergic or intolerant to clindamycin will receive oral trimethoprim-sulfamethoxazole [bactrim] (5mg/kg trimethoprim up to 160 mg, every 12 hours).
1695651|NCT01498731|Behavioral|Discharge home|Patients who test negative for Copeptin at admission will be considered low-risk and will be discharged home. To secure the patients safety they will be transferred into our co-operating network of resident cardiologists preferably the next day (but latest within the next three days). In case of any findings suggestive of acute coronary syndrome or worsening of the patient's condition, the patient will immediately be re-admitted to our Emergency Room.
1695652|NCT01498718|Biological|DNA vaccine|VRC-FLUDNA061-00-VP is composed of 3 closed-circular DNA plasmids that encode for the hemagglutinin (HA) from the following 3 strains: A/California/04/2009 (H1N1); A/Perth/16/2009 (H3N2), and B/Brisbane/60/2008. DNA vaccine vials will be supplied at 4 mg/mL and each dose will be 1 mL.
1695653|NCT01498718|Biological|TIV|2012/13 Seasonal Influenza Trivalent Inactivated Vaccine (TIV)
1695654|NCT01498705|Other|Procalcitonin level|PCT level upon admission and on days 1, 3, and 5 following baseline level
1695655|NCT01498692|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating)
1695656|NCT01498679|Drug|GW685698/GW642444 (fluticasone furoate/vilanterol trifenatate)|ICS/LABA combination (100/25mcg) administered once daily in the evening via a Novel Dry Powder Inhaler (NDPI)
1695657|NCT01498679|Drug|Placebo|Placebo administered once daily in the evening via a NDPI
1695658|NCT01498666|Dietary Supplement|L. reuteri protectis|1 tablet once daily for 4 weeks
1695659|NCT01498666|Dietary Supplement|Placebo tablet|1 tablet once daily for 4 weeks
1695660|NCT01498653|Drug|GW685698/GW642444|ICS/LABA
1695661|NCT01498653|Drug|CCI18781|ICS
1695662|NCT01498640|Biological|Collagenase clostridium histolyticum|up to three 0.58 mg injections
1695663|NCT01498627|Biological|Cervarix|3 doses over a period of 6 months (Month 0 and ideally Month 1 and Month 6, with 1 month minimum between any two doses).
1695664|NCT01498627|Other|Data collection|PGRx information system
1695665|NCT01498614|Behavioral|Affect School and Basal body awareness|Affect School is an educational method based on SS Tomkins affect theory and Basal Body Awareness therapy is an educational stress reducing method
1695666|NCT01498601|Other|Enhanced oral care protocol|"Changing mouth suction equipment every 24 hours
Mouth assessment every 2-4 hours
Cleansing mouth with toothbrush every 12 hours
Cleansing oral mucosa with oral rinse solution every 2-4 hours
Moisturize mouth/lips with swab and standard mouth moisturizer every 4 hours
Suction mouth and throat as needed
Head of the bed elevated to a minimum of 30° during oral care"
1695667|NCT01498588|Drug|Eribulin|Patients will receive 4 cycles of neoadjuvant eribulin followed by 4 cycles of dose-dense doxorubicin and cyclophosphamide (AC).
1695668|NCT01498588|Drug|Doxorubicin|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
1695669|NCT01498588|Drug|Cyclophosphamide|Neoadjuvant eribulin followed by dose-dense doxorubicin and cyclophosphamide
1695670|NCT01498588|Drug|Pegfilgrastim|Growth factor support (pegfilgrastim) can be given at the discretion of the investigator. Administration of pegfilgrastim is required 24 to 48 hours following administration of dose-dense doxorubicin and cyclophosphamide.
1695671|NCT01498575|Behavioral|Teen driving plan|Web-based intervention designed to facilitate parent supervised practice driving with novice teen driver.
1695672|NCT01498562|Drug|Gefitinib and Nimotuzumab|Combination therapy group: Gefitinib(250mg daily) + Nimotuzumab (200mg weekly)
1695673|NCT01498562|Drug|Gefitinib|Mono-therapy group: Gefitinib(250mg daily)
1695674|NCT01498549|Drug|Atomoxetine|Atomoxetine 40mg and 80mg compared to the sugar pill
1695675|NCT01498549|Drug|Sugar Pill|Sugar pill compared to Atomoxetine 40mg and 80mg.
1695676|NCT01498536|Behavioral|aerobic exercise|3 times per week for 12-weeks
1695677|NCT01498523|Other|Camel milk|600ml of raw camel milk will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
1695678|NCT01498523|Other|camel milk powder solution|72g camel milk powder will be dissolved in 540ml water to make 600ml camel milk powder solution. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
1695755|NCT01497938|Device|Medtronic MMT-754 Veo Insulin pump testing Low Glucose Suspend (LGS) feature|Automatic suspension of insulin delivery when glucose is low.
1696673|NCT01490866|Drug|5-Fluorouracil|400 mg/m2 Days 1 and 15; IV
1695679|NCT01498523|Other|raw cow milk|50ml water will be added to 550ml raw cow milk to make 600ml cow milk. This will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
1695680|NCT01498523|Other|Glucose solution|25g glucose will be dissolved in 600ml water, and this will be consumed in 10 minutes. the blood glucose concentrations will be measured at 0, 15, 30, 45, 60 ,90 and 120 minutes by finger-prick blood samples. Also, blood insulin and amino acids concentration will be measured at 0, 30 and 75 minutes.
1695681|NCT01498510|Behavioral|Web-based CBT for chronic pain|An interactive, web-based intervention, based on principles of cognitive behavior therapy (CBT), that is designed to train chronic pain patients in self-management skills to reduce pain and aberrant behavior and improve functioning
1695682|NCT01498497|Drug|EUR-1100|
1695683|NCT01498497|Drug|Placebo|
1695684|NCT01498484|Biological|EBV-specific T cells|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
1695685|NCT01498458|Drug|Pazopanib plus capecitabine|"Patients will receive pazopanib tablets once daily at a dose according to the allocated dose level:
dose level I: 400 mg
dose level II: 600 mg
dose level III: 800 mg
In addition patients receive capecitabine at the same oral dose for all dose levels with 1600 mg/m2 on days 1 to 14 every 3 weeks.
Treatment will be given until disease progression or unacceptable toxicity of the study drug, or withdrawal of consent of the patient.
Six patients will be recruited in each dose level. If less than 2 out of 6 patients experience a DLT within the first 2 cycles (weeks 1 to 6), the next dose level is started. Once the MTD is established, additional 6 patients will be included into this dose level to further characterise the safety of the dose regimen.
If it is reported, that two patients had a DLT, all patients are informed about it and the dose level immediately reduced by one dose level."
1695689|NCT01498432|Drug|Heliox21|For Heliox21 the percentage of O2 will match the percentage of O2 prior to extubation, and Helium will make up the remainder (e.g. Helium 65% + O2 35%), and the O2 concentration will be titrated as their clinical condition indicates (as O2 increases Helium will decrease and vice versa).
1695690|NCT01498432|Drug|Air O2|For Air-O2 the percentage of O2 delivered will match the patient's percentage of O2 prior to extubation, and will be titrated as their clinical condition indicates.
1695691|NCT01498419|Drug|Moxifloxacin (M)|
1695692|NCT01498419|Drug|Pretomid (Pa)|
1695693|NCT01498419|Drug|Pyrazinamide (Z)|
1695694|NCT01498419|Drug|Rifafour|Rifafour e-275 once daily for 8 weeks. Daily dose dependent on weight as follows: 30-37kg: 2 tablets, 38-54 kg: 3 tablets, 55-70 kg: 4 tablets: 71 kg and over: 5 tablets
1695695|NCT01498406|Dietary Supplement|vitamin D|The investigators will carry out a two-armed prospective pilot study of the influence of vitD on cutaneous lupus (CLE) disease severity. Patients with CLE will be eligible for an observational or interventional arm based on their 25(OH)D levels and consent. Subjects with low vitD status (<30 ng/mL) will be eligible for the investigational arm involving participation in a randomized controlled trial of daily high dose (4000 IU) vs. low dose (400 IU) vitD supplementation for 8 months. Subjects who have sufficient vitD status (>30ng/mL) or those with low vitD who choose not to participate in the RCT are eligible for continued participation in the observational arm of the study. All subjects will be followed at 4, 8, and 12 months.
1695696|NCT01498393|Device|Laser treatment|Laser treatment to Improve the Appearance of Onychomycosis
1695697|NCT01498380|Drug|Dexmedetomidine|The bolus dose of dexmedetomidine given will range from 0.25-2.0 mcg/kg and will be based on the up-and-down method, such that subject 1 will receive 0.5 mcg/kg and if no significant hemodynamic changes occur (heart rate decrease < 20% or blood pressure decrease/increase < 20%) the does will be increased by 0.25 mcg/kg for the subsequent subject. If significant hemodynamic changes occur (HR decrease >/= 20% or SBP/DBP/MAP decrease or increase >/= 20%) the dose will be decreased by 0.25 mcg/kg for the subsequent subject. Each subject will be observed for 10 minutes following the dexmedetomidine bolus.
1695698|NCT01498367|Procedure|Telemonitoring of patients with diabetes type 2|Telemonitoring of the patients's blood glucose level measurements using a the tele-glucose meter
1695699|NCT01498354|Procedure|2-D high definition vision systems, transanal endoscopic operation (TEO)|Transanal endoscopic operation (TEO). Through its 2-D vision system using a rectoscope, this procedure allows access to rectal tumors located up to 20 cm from the anal verge
1695700|NCT01498354|Procedure|Transanal endoscopic microsurgery (TEM)|Transanal endoscopic microsurgery (TEM). 3-D vision system using a rectoscope, allowing access to rectal tumors located up to 20 cm from the anal verge
1695701|NCT01498328|Drug|Bevacizumab|A vascular endothelial growth factor (VEGF)-specific humanized monoclonal antibody angiogenesis inhibitor. Infusions of 10 mg/kg of bevacizumab will begin on day 1 and will be administered every two weeks until progression of disease or intolerance during the treatment period.
1695702|NCT01498328|Drug|Rindopepimut (CDX-110) with GM-CSF|Rindopepimut/GM-CSF will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM-CSF.
1695703|NCT01498328|Drug|KLH|KLH will initially be given three times, two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8 mL containing approximately 100 mcg of KLH.
1695704|NCT01498315|Other|Ultrasound examination|Ultrasound examination following hysterectomy
1695705|NCT01498302|Other|diagnostic laboratory biomarker analysis|
1695706|NCT01498302|Other|flow cytometry|
1695707|NCT01498289|Drug|FOLFOX regimen|Given IV. Fluorouracil, oxaliplatin, & leucovorin calcium.
1695708|NCT01498289|Drug|docetaxel|30 mg/m^2, IV over 30 minutes on Day 1,8 of each 21 day cycle.
1695709|NCT01498289|Drug|fluorouracil|400 mg/m^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
1695710|NCT01498289|Drug|irinotecan hydrochloride|65 mg/m^2, IV over 90 minutes on Days 1 & 8 of every 21 day cycle.
1695713|NCT01498237|Device|Photoacoustic endoprobe|The PAE assessment will be performed in the operating room following strict sterile technique. PAE is performed immediately prior to the planned surgery. Participants are prepped following standard protocol. Length of the endometrial cavity is determined by a uterine sound. Endocervix is dilated as needed to allow passage of the PAE probe. The PAE probe will be advanced to the uterine fundus. Images will be obtained during withdrawal of the PAE probe from fundus to the os. Recorded images will allow computer assisted image analysis and functional measurements to be performed. Duration and difficulty of the procedure will be recorded. Comments and complications will be specifically noted.
1695714|NCT01498237|Procedure|Photoacoustic endoscopy|Photoacoustic endoscopy probe will be inserted into the endometrial canal to the uterine fundus and images will be obtained during the withdrawal of the probe from the fundus to the endocervical os.
1695715|NCT01498224|Device|ReSure Sealant|Comparison of ReSure Sealant to suture(s)
1695716|NCT01498224|Procedure|Sutures|
1695717|NCT01498211|Procedure|Biopsy|3 mm punch biopsy of the skin at the distal leg.
1695718|NCT01498198|Procedure|Rotator Cuff Repair Surgery|Participants will have surgery within 3 months. They will be followed up at 6 weeks, 12 weeks, 6 months and 12 months pos operatively.
1695719|NCT01498198|Other|Non Operative Treatment|Participants will undergo a 6 week assessment, and if they are improving they will continue undergoing non operative care up until 12 months. If at any assessment point (6 weeks, 12 weeks, 6 months, 12 months) they are deemed to not be making any more progression, they will be referred back to the surgeon.
1695720|NCT01498185|Drug|Dapagliflozin|Tablets, Oral, 1 mg, Once daily, 14 days
1695721|NCT01498185|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, Once daily, 14 days
1695724|NCT01498159|Behavioral|Pharmacist disease/medication management|
1695725|NCT01498159|Behavioral|Pharmacist-patient encounters|
1695726|NCT01498159|Behavioral|Pharmacist medication intensification and adherence support|
1695727|NCT01498159|Behavioral|Pharmacist communication with primary care physicians|
1695728|NCT01498159|Behavioral|Pharmacist documentation in electronic medical record|
1695729|NCT01498159|Behavioral|Health promoter-patient encounters in-person or by phone|
1695730|NCT01498159|Behavioral|Health promoter medication and lifestyle support|
1695731|NCT01498159|Behavioral|Health promoter communication with pharmacists|
1695732|NCT01498133|Procedure|skin-to skin contact|Skin-to-skin contact consisted of placing the infant slightly worn (only diapers) in prone decubitus, upright against the mother's breast. The infant was restrained in position by a track that involved him with his/her mother. The mother sat in a chair positioned beside the infants' bed. A team member that accompanied the intervention monitored infants' temperature, heart rate and oxygen saturation.
1695733|NCT01498120|Drug|Rotigotine|"Optimal dose after titration period
0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2)
1 patch /day"
1695734|NCT01498107|Behavioral|SilverCloud Platform|The SilverCloud online intervention will be provided as an alternative choice to paper manuals to support guided self-help for depression in a primary care mental health service. Participants will receive up to eight progress reviews on a weekly or fortnightly basis as agreed with their therapist with the intervention running not more than three months.
1695735|NCT01498094|Procedure|High Flow Nasal Cannula Oxygen Therapy|Warm humidified oxygen will be delivered at 8 liters/minute via nasal cannulae, at a concentration that maintains saturations greater than 92%.
1695736|NCT01498094|Other|Standard low flow oxygen|Standard low flow oxygen will be given to patients to maintain saturations greater than 92%.
1695737|NCT01498081|Drug|AZD2115|AZD2115 administered via inhalation
1695738|NCT01498081|Drug|Placebo|Placebo administered via inhalation
1695739|NCT01498081|Drug|Indacaterol|Indacaterol administered via inhalation
1695740|NCT01498081|Drug|Indacaterol + Tiotropium|Indacaterol + Tiotropium administered inhalation
1695741|NCT01498068|Drug|Telaprevir|Telaprevir Type = exact number, unit = mg, number = 750, form = tablet, route = oral. Telaprevir 750 mg (2 oral tablets) is taken every 8 hours for 12 weeks
1695742|NCT01498068|Drug|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a type = exact number, unit = microgram, number = 180, form = injection, route = subcutaneous. 180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks
1695743|NCT01498068|Drug|Ribavirin|Ribavirin Type = exact, number = 1000 or 1200, unit = mg, form = tablet, route = oral. 1000mg (if participant's weight is < 75kg) or 1200mg (if participant's weight is >= 75kg) per day for 24 or 48 weeks.
1695744|NCT01498029|Procedure|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
1695745|NCT01498029|Device|Cartilage Autograft Implantation System (CAIS)|The Cartilage Autograft Implantation System (CAIS) is a kit of devices that utilizes morselized autologous hyaline cartilage harvested arthroscopically, affixed onto a synthetic, resorbable implant using a fibrin sealant and implanted in a single surgical procedure. The system is designed as a surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region.
1695746|NCT01498016|Drug|Busulfan|Iv busulfan 1.6mg/kg q12h D1- D4
1695747|NCT01498003|Drug|tirofiban|10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion for 12h
1695748|NCT01498003|Drug|normal saline solution|same use as tirofiban
1695749|NCT01497990|Drug|Ertapenem|The patient received two injections of ertapenem, at a dose of 1g.j-1 by intravenous injection of 30 minutes, separated by 24 h.
1695750|NCT01497977|Drug|phytoestrogens|The red clover capsule consisted of 4 isoflavones: biokain A (23mg), daidzein (1mg), formononetin (15mg) and genistein (1mg).
1695751|NCT01497977|Drug|phytoestrogens|The soya daily dose contained 2 isoflavones: genistein (39mg) and daidzein (1mg).
1695752|NCT01497964|Drug|cabazitaxel XRP6258|Pharmaceutical form: solution for infusion Route of administration: intravenous
1695753|NCT01497951|Other|Aminolaevulinic acid|Photodynamic therapy
1695754|NCT01497951|Other|Methylcellulose Placebo|Methylcellulose
1695756|NCT01497938|Device|Medtronic (NO LGS FEATURE ) using Paradigm® Revel™2.0 Pump|No Automatic suspension of insulin delivery when glucose is low.
1695757|NCT01497925|Drug|ADI-PEG 20|Dosage: 4.5, 9, 18 and 36 mg/m2. Frequency: weekly.
1695758|NCT01497912|Drug|Atorvastatin|Atorvastatin 80mg once daily for 8 weeks
1695759|NCT01497912|Drug|Placebo|Placebo tablet once daily for 8 weeks
1695760|NCT01497899|Drug|E/C/F/TDF|150/150/200/300 mg FDC tablet administered orally once daily
1695761|NCT01497899|Drug|E/C/F/TAF Placebo|Tablet administered orally once daily
1695762|NCT01497899|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily
1695763|NCT01497899|Drug|E/C/F/TDF Placebo|Tablet administered orally once daily
1695764|NCT01497886|Behavioral|Hip Hop Stroke educational program|Three one-hour sessions, conducted over three consecutive days
1695765|NCT01497886|Behavioral|Nutrition Education program|"The investigators will use what they will refer to as a usual care control. For this purpose the investigators have selected nutrition, physical activity, and obesity education. A trained facilitator will conduct the control program in the school auditorium. The investigators will use this control method to control for attention, i.e., having a facilitator come to the classroom for the same amount of time as in the intervention that is, 1-hour sessions on three consecutive days. The facilitator will provide focused lectures on relevant topics, and show two short, 4-minute animated films on nutrition, and physical activity. The investigator will conduct parallel pretests and post-tests on the children (same as intervention testing sequence)."
1695766|NCT01497873|Drug|Topotecan|1.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
1695767|NCT01497873|Drug|Belotecan|0.5 mg/m^2 IV days 1, 2, 3, 4, 5 of each 21-day cycle until 6 cycle or more
1695768|NCT01497860|Drug|Vinorelbine|IV Vinorelbine (6mg/m2) provided once a week for 6 weeks followed by a 2 week rest (6 of every 8 weeks) for one year. Progression free survival will be monitored for 60 months.
1695769|NCT01497834|Drug|BMS-790052 (Daclatasvir)|Tablets, Oral, 60mg, Once daily, 24 weeks
1695770|NCT01497834|Drug|BMS-650032 (Asunaprevir)|Capsules, Oral, 100mg, Twice daily, 24 weeks
1695771|NCT01497821|Drug|AMG 172|AMG 172 is an antibody drug conjugate
1695772|NCT01497808|Drug|Ipilimumab|
1695773|NCT01497808|Radiation|Stereotactic Body Radiation Therapy|
1695774|NCT01497782|Other|Instructor feedback|Intervention group who receives up to three sessions of instructor feedback during completion of a predefined proficiency level on a laparoscopic virtual reality simulator.
1695775|NCT01497769|Biological|Aerosol inhaled MVA85A|Aerosol inhaled MVA85A 1 x 10^7 pfu and intradermal saline placebo
1695776|NCT01497769|Biological|Intradermal MVA85A|Intradermal MVA85A 1 x 10^7 pfu and inhaled aerosol saline placebo
1695777|NCT01497756|Device|CAPP use|Any abdominal pelvic pressure
1695778|NCT01497743|Drug|Lactobacillus|All randomized subjects will receive probiotic or matching placebo: 1 capsule orally twice daily, with meals) for the first 4 weeks. There will be a 6-week washout period, followed by 4 weeks of the alternate treatment. The subject will not be on study medication during this washout period.
1695779|NCT01497730|Device|Total Knee Replacement|"Subjects will receive one of the following total knee implants:
PFC Sigma Fixed Bearing (FB) cruciate retaining (CR), posterior stabilized (PS) or Rotating Platform CR or PS devices. LCS Rotating platform or PS devices. Triathlon CR, PS or mobile bearing devices. NexGen CR, LPS, LPS Flex FB PS, LPS Flex Mobile bearing, or LPS Mobile bearing devices."
1695780|NCT01497717|Drug|Adalimumab (Humira)|"Open label pilot trial.
The study includes 3 phases :
Open label treatment period of 24 weeks.
Extension follow -up (3 years): Patients who responded well to study drug and their disease relapsed within the first 12 weeks following study drug interruption will be eligible to receive the study drug for 3 years in order to comply with the Israeli Ministry of Health requirements.
Safety follow-up: For patients who withdraw from either the open label treatment period or extension period, for another 24 weeks."
1695781|NCT01497704|Drug|YN968D1|Daily dosing of YN968D1 for treatment of solid tumors
1695782|NCT01497691|Device|NIPPV (PALMtop PTV)|PALMtop PTV Models 8/10 aka CareFusion EnVe The primary study device is the PALMtop PTV. It is the NIPPV/BiPAP device used in this study. It is FDA approved for use in children who weigh 5 kilograms or greater (#K070594).
1695783|NCT01497691|Device|Volumetric CO2 (NM3)|The NM3 is FDA approved (#K091459) for spirometric and carbon dioxide monitoring as well as continuous, non-invasive monitoring of arterial oxygen saturations and pulse rates in neonatal and pediatric patients in the emergency department.
1695784|NCT01497691|Device|USCOM|The USCOM a non-invasive ultrasonic device that is FDA approved for monitor beat-to-beat cardiac hemodynamics in adult and pediatric patients (#K043139). It will be used in an attempt to better understand the underlying physiology of NIPPV use.
1695785|NCT01497678|Device|Extracellular Matrix|Extracellular Matrix
1695786|NCT01497665|Drug|GRN1005|650 mg/m2 IV every 3 weeks
1695787|NCT01497652|Drug|Rasagiline/Placebo|Will receive placebo pills each day for the entire 14 weeks.
1695788|NCT01497652|Drug|Rasagiline|0.5 mg for two weeks, then 1 mg for 12 weeks.
1695789|NCT01497639|Device|Interleaving stimulation mode (Medtronic)|Interleaving stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Interleavingr stimulation mode (Medtronic)'
1695790|NCT01497639|Device|Double monopolar stimulation mode (Medtronic)|Double monopolar stimulation mode with constant frequency (125 Hz) and pulse-width (120us)parameters 'Double monopolar stimulation mode (Medtronic)'
1695791|NCT01497626|Drug|Lapatinib and bortezomib|"Lapatinib will be taken orally continuously for 28 days of each 28-day cycle, including a run-in of lapatinib alone day -7 to day 1 of cycle 1.
Bortezomib will be administered IV on days 1, 8, and 15 of each cycle. The exact doses of both drugs will be dependent on which cohort the subject is in and adverse events observed in previous cohorts."
1695794|NCT01497600|Drug|insulin detemir|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
1754950|NCT00236639|Drug|topiramate|
1695795|NCT01497600|Drug|insulin NPH|Each subject will be randomly allocated to three doses: 0.3, 0.6, and 1.2 U/kg. Administrated subcutaneously (s.c., under the skin)
1695796|NCT01497587|Drug|insulin detemir|Single dose, 0.5 U/kg, administered s.c. (under the skin)
1695797|NCT01497574|Drug|insulin detemir|On two dosing visits, 0.4 U/kg insulin detemir will be administered followed by 0.4 U/kg insulin glargine after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
1695798|NCT01497574|Drug|insulin glargine|On two dosing visits, 0.4 U/kg insulin glargine will be administered followed by 0.4 U/kg insulin detemir after a 24 hours' interval and repeated in opposite order at next dosing visit. Administrated subcutaneously (s.c., under the skin)
1695799|NCT01497561|Drug|insulin detemir|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
1695800|NCT01497561|Drug|insulin NPH|Each subject will be randomly allocated to two dose administrations out of four possible doses. Administrated subcutaneously (s.c., under the skin)
1695801|NCT01497548|Drug|Methylphenidate|Methylphenidate started at 5mg on morning (0800) and noon (1200) on day 1. Dose increased to 10mg on morning (0800) and noon (1200) on day 3; 15mg on morning and noon on day 6 depending on the clinical response. Similarly, the dose can be reduced to 5mg/day if patients are not able to tolerate a higher dose. The treatment continues until day 28.
1695802|NCT01497548|Drug|Placebo|Placebo given on morning (0800) and noon (1200)daily
1695803|NCT01497535|Drug|insulin detemir|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
1695804|NCT01497535|Drug|insulin glargine|On four different dosing days where subjects enter a 24-hour euglycaemic glucose clamp procedure, the subject will be allocated to one single dose of either 0.4 U/kg insulin detemir or 0.4 U/kg insulin glargine administered subcutaneously (s.c., under the skin)
1695805|NCT01497522|Drug|Vildagliptin|vildagliptin 50 mg twice daily
1695806|NCT01497522|Drug|Placebo|Matching Placebo of vildagliptin 50 mg twice daily
1695807|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine/ep 1:600,000; infusion 10mL/hour 0.25% bupivacaine and epi 1:800,000|
1695808|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine/ epinephrine 1:600,000;infusion 10mL/hour 0.25% bupivacaine, 2 mcg/mL fentanyl, and epinephrine 1:800,000|
1695809|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine, 10mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 2.5 mcg/mL fentanyl, and epi 1:800,000|
1695810|NCT01497509|Drug|Bolus 10mL 0.25% bupivacaine, 5 mcg/mL fentanyl, and epi 1:600,000; infusion 10mL/hour 0.25% bupivacaine, 3.5 mcg/mL fentanyl, and epi 1:800,000|
1695811|NCT01497509|Drug|No epidural fentanyl or bupivacaine|
1695812|NCT01497496|Drug|High Dose Methylprednisolone (HDMP)|1000 mg/m^2 on Cycle 1: Day 1, 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15
1695813|NCT01497496|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP. 300 mg on Cycle 1 Day 1. 2000 mg on Cycle 1: Day 8, 15, 22; Cycle 2: Day 1, 15; Cycle 3: Day 1, 15; Cycle 6: Day 1; Cycle 8: Day 1; Cycle 10: Day 1: Cycle 12: Day 1
1695814|NCT01497496|Drug|Lenalidomide|The lenalidomide treatment will start with cycle 4. 5-10 mg pd Days 1-28 as per Creatinine Clearance (CrCl)
1695815|NCT01497483|Drug|Pravastatin alone|Pravastatin 40 mg with placebo.
1695816|NCT01497483|Drug|Pravastatin and Cyclosporine|Pravastatin 40 mg co-administered with 200 mg of cyclosporine.
1695817|NCT01497470|Drug|Custirsen, paclitaxel and carboplatin|Custirsen (640 mg IV over 2 hours) will be administered weekly on Days 1, 8, and 15 of each 21 day cycle. Paclitaxel (200 mg/m2 IV over 3 hours) and carboplatin (AUC 6.0 mg/mL/min IV over 30 minutes) will be administered on Day 1 of each 21 day cycle
1695818|NCT01497457|Procedure|MR saline peritoneography|Ultrasound-guided Intraperitoneal injection of 250cc of steril saline solution with a 22G needle, followed by rectal MR imaging
1695819|NCT01497444|Drug|hypoxia-activated prodrug TH-302|
1695820|NCT01497444|Drug|sorafenib tosylate|
1695821|NCT01497431|Dietary Supplement|Selenium|Given PO
1695822|NCT01497431|Other|Placebo|Given PO
1695823|NCT01497431|Other|Laboratory Biomarker Analysis|Correlative studies
1695824|NCT01497431|Other|Pharmacological Study|Correlative studies
1695825|NCT01497431|Drug|Methylselenocysteine|Given PO
1695826|NCT01497405|Behavioral|Test, Treat, Retain(TTR) + Women's Health CoOp (WHC)|TTR +WHC: Participants in this group will be screened for HIV. HIV positive women, will be given post-test counseling and referrals for prompt medical evaluation and assessment.Both HIV negative and positive participants in this group will participate in 2 individual behavioral counseling sessions focusing on reducing HIV risk behaviours, alcohol and other drug use, and risk of violent victimization. It also adds case management to increase follow through with referrals and risk reduction plans and activities.This will also include case management sessions. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
1695827|NCT01497405|Biological|Test, Treat, Retain(TTR) only|TTR +only: Participants in this group will be screened for HIV. HIV positive women will be given post-test counseling and referrals for prompt medical evaluation.
1695828|NCT01497392|Drug|dovitinib lactate|Given PO
1695829|NCT01497392|Drug|gemcitabine hydrochloride|Given IV
1695830|NCT01497392|Drug|capecitabine|Given PO
1695831|NCT01497392|Other|laboratory biomarker analysis|Correlative studies
1695832|NCT01497392|Other|enzyme-linked immunosorbent assay|Correlative studies
1695833|NCT01497392|Other|pharmacological study|Correlative studies
1695834|NCT01497379|Procedure|surgical implantation of subretinal device|surgical implantation of subretinal device
1695835|NCT01497379|Procedure|surgical implantation of subretinal device|intra-individual implant OFF
1695836|NCT01497366|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
1695837|NCT01497366|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
1695838|NCT01497366|Drug|RBV|"Ribavirin (RBV) administered as 200 mg tablets up to 1200 mg in a divided daily dose
Dose of sofosbuvir+RBV group based on baseline weight: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg
Dose of PEG+RBV group: 800 mg"
1695839|NCT01497353|Procedure|Position at introitus level|After birth: Weigh at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec then another Weigh will be obtained after clamping
1695840|NCT01497353|Procedure|position at Maternal Abdomen|After birth: Weight at 10 + 2 sec then the baby will be placed at maternal abdomen and Cord clamping will be performed at 120 sec and new Weigh will be obtained after clamping
1695841|NCT01497340|Other|Position at introitus level|After birth: Weight at 10 + 2 sec then Held the baby at the level of introitus and Cord clamping will be performed at 120 sec Weight after clamping
1695842|NCT01497340|Other|Position at Maternal Abdomen|Newborns weight's difference between having them weighed immediately after birth and when cord is clamped in both positions(introitus and abdomen).
1695843|NCT01497327|Drug|PSI-352938|PSI-352938 300mg once daily (QD) for seven days
1695844|NCT01497327|Drug|PSI-7977|PSI-7977 400mg QD for seven days
1695845|NCT01497314|Other|Low Lactose Infant Formula|Low Lactose Infant Formula
1695846|NCT01497301|Behavioral|Group Visits|"During group visits, there will be discussions regarding the basic pathophysiology of diabetes, the ABCs to Better Diabetic Care as defined by the ACP Diabetes Care Guide, setting goals, nutrition, exercise, diabetic medications, and complications of diabetes. Patients will have blood drawn to measure hemoglobin A1C and lipids. They will be educated on self glucose monitoring so they will undergo finger sticks to measure their own glucose. BP measurements, monofilament foot exams, and urine collection for microalbumin will also occur during the study. They may also receive immunizations. A consent form for participation in the group visits, including undergoing the above procedures will be reviewed at our first group visit and signed by all participants."
1695847|NCT01497288|Drug|INFS (Intranasal Fentanyl Spray)|Intranasal Fentanyl Spray
1695848|NCT01497275|Drug|Rituximab, Bortezomib,Y90 ibritumomab tiuxetan|Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.
1695849|NCT01497262|Drug|Fingolimod|Fingolimod will be supplied as 0.5mg capsules in bottles of 35.
1695850|NCT01497249|Dietary Supplement|A dietary fiber (FCHO)|15 g twice per day in beverage
1695851|NCT01497249|Dietary Supplement|Placebo|Placebo drink
1695852|NCT01497236|Dietary Supplement|Dietary Supplement: Nutrition supplement with RUTF or MNP|"14 days nutritional supplementation with either
a fortified high quality food(RUTF), 1 sachet/day, 500 kcal and multi micronutrients
a multi micronutrient powder (MNP), 2 sachets per day, no calories, twice recommended daily intake
a placebo (to MNP), 2 sachets per day , no calories, no micronutrients, containing micronutrient carrier"
1695853|NCT01497223|Drug|MGCD290|1 Oral Dose Administration
1695854|NCT01497210|Device|EASH dressing|Apply study dressing for 4 weeks changing at least every 7 days followed by Aquacel for four weeks.
1695855|NCT01497197|Drug|GONAL-f®|GONAL f® 300 international units [IU] per day as subcutaneous injection using liquid pen.
1695856|NCT01497197|Drug|Luveris®|Luveris® 150 IU per day lyophilized powder for subcutaneous injection.
1695857|NCT01497197|Biological|Recombinant human chorionic gonadotropin (r-hCG)|A single injection of r-hCG (Ovidrel®/Ovitrelle®) 250 mcg to induce final oocyte maturation.
1695858|NCT01497184|Procedure|HSCT|Hematopoietic stem-cell transplant using cells from a matched family donor (matched related allogeneic HSCT) using a non-T cell depleted graft under standard of care procedures
1695859|NCT01497184|Genetic|DLI|Allogeneic donor lymphocyte infusion (DLI) starting dose not to exceed 10^6/m^2 intravenously between 6 weeks and 12 weeks following allogeneic HSCT.
1695860|NCT01497171|Procedure|Elevate Mesh|Transvaginal mesh repair of anterior vaginal prolapse
1695861|NCT01497171|Procedure|Anterior Colporrhaphy|Traditional suture repair of anterior vaginal prolapse
1695862|NCT01497158|Other|Self-help brochure|Self help brochure given at baseline visit.
1695863|NCT01497158|Other|Biomarker feedback|Biomarker feedback from urine of adult non-smoker in the home.
1695864|NCT01497145|Drug|KRN321|
1695865|NCT01497132|Drug|Vitamin D3|Oral drops 30000 IU weekly
1695866|NCT01497132|Drug|Placebo|Matching placebo
1695867|NCT01497119|Drug|JNJ-39758979, 300 mg|Type=exact number, unit=mg, number=300, form=tablet, route=oral use, once daily for 6 weeks.
1695868|NCT01497119|Drug|JNJ-39758979, 100 mg|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, once daily for 6 weeks.
1695869|NCT01497119|Drug|Placebo|Form=tablet, route=oral use, once daily for 6 weeks.
1695870|NCT01497106|Behavioral|Calorie Restriction|Participants will work with the CRU dietetics staff to plan a diet that will result in their losing 1-2 pounds per week over 16 weeks. They will wear an accelerometer to track there activity during these weeks.
1695871|NCT01497106|Behavioral|Control (normal living)|Participants will continue their normal living for entire time of the study. They will be asked to wear an accelerometer for the next 16 weeks and check in weekly at the CRU to exchange accelerometers.
1695872|NCT01497093|Drug|Pomalidomide|Pomalidomide 1, 2, 3, or 4 mg will be taken orally on Days 1-14 of a 21-day cycle
1695873|NCT01497093|Drug|Bortezomib|Bortezomib 1 or 1.3 mg/m2 will be administered intravenously or subcutaneously on Days 1, 4, 8 and 11 of 21 days for cycles 1 -8 and on days 1, 8 of 21 days for cycle 9 and onward until disease progression
1695874|NCT01497093|Drug|Dexamethasone|Dexamethasone 20 mg/day [≤ 75 years old] or 10 mg/day [> 75 years old] will be taken orally on days 1, 2, 4, 5, 8, 9, 11, 12 of 21 days for cycles 1-8 and on days 1, 2, 8, 9 of 21 days for cycles 9 and onward until disease progression
1695875|NCT01497041|Drug|Docetaxel|Docetaxel (diluted in 250 ml of 5% dextrose solution, over 60 minutes) 35 mg/m2 IV (D1, D8) every 3 weeks
1695876|NCT01497041|Drug|Oxaliplatin|Oxaliplatin (diluted in 500 ml of 5% dextrose solution, over 120 minutes) 60 mg/m2 IV D1 every 3 weeks
1695877|NCT01497028|Procedure|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.|PLAGB will be studied and compared to the standard LAGB procedure through a dual center, prospective clinical trial.
1695878|NCT01497015|Behavioral|memory training|10 1-hour sessions over 6-8 weeks
1695964|NCT01496326|Drug|placebo|2 grams of placebo cream for 14 days
1695879|NCT01497015|Behavioral|speed of processing training|10 1-hour sessions delivered over 6-8 weeks
1695880|NCT01497015|Behavioral|waitlist control|Breast cancer survivors will receive the speed of processing training compact disc in the mail after study completion.
1695881|NCT01497002|Drug|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 100 mg/m²/day i.v. 24h-infusion day 1-7 and Daunorubicin 60 mg/m² day 3+4+5. Consolidation chemotherapy (2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5.
1695882|NCT01497002|Drug|Cytarabine|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (2 courses): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8.
1695883|NCT01497002|Biological|human stem cells|Induction chemotherapy (1 or 2 courses): AraC 1 g/m² i.v. 3h-infusion a 12h day 1+3+5+7, Mitoxantrone 10 mg/m² day 1-3 and Pegfilgrastim 6 mg s.c. day 10. Consolidation chemotherapy (1 course): AraC 500 mg/m² i.v. 1h-infusion a 12h day 1+3+5, Mitoxantrone 10 mg/m² day 1+2 and Pegfilgrastim 6 mg s.c. day 8. Allogeneic stem cell transplantation using reduced intensity conditioning: Fludarabine 30 mg/m² day -4 - -2, TBI 200 cGy day 0; GvHD prophylaxis: cyclosporine A and mofetil mycofenolate
1695884|NCT01496989|Biological|HIV-MAG (3,000mcg)|Delivered intramuscularly by in vivo electroporation
1695885|NCT01496989|Biological|GENEVAX® IL-12 (100mcg)|Co-administered with HIV-MAG, delivered intramuscularly by in vivo electroporation
1695886|NCT01496989|Biological|GENEVAX® IL-12 (1000mcg)|Co-administered with HIV-MAG, delivered intramuscular by in vivo electroporation
1695887|NCT01496989|Biological|Ad35-GRIN/ENV|(2x10^10vp) Delivered intramuscularly by standard needle injection
1695888|NCT01496976|Drug|High Dose Methylprednisolone (HDMP)|HDMP will be administered at 1 gm/m^2 IV over 90 minutes daily with ofatumumab infusions 1-8.
1695889|NCT01496976|Drug|Ofatumumab|Ofatumumab infusion will be administered immediately after HDMP.
1695890|NCT01496976|Drug|Lenalidomide|The Lenalidomide Starting Dose (Cycle 4) Based on Renal Function Prior to Cycle 4 of Treatment.
1695891|NCT01496963|Other|Physician standard-of-care according to ESC/ERS Guidelines|Physician standard-of-care
1695892|NCT01496950|Device|10Hz active rTMS|10Hz active rTMS delivered to the left dorsolateral prefrontal cortex
1695893|NCT01496950|Device|Placebo|10Hz placebo rTMS delivered to the vertex
1695894|NCT01496937|Drug|GLPG0974|
1695895|NCT01496937|Drug|GLPG0974|
1695896|NCT01496924|Other|speech therapy|A single oral-motor technique will be used in a 10-times series intercalated with rest. Swallowing training techniques comprised indirect therapy (swallowing of saliva) and direct therapy (swallowing of food).
1695897|NCT01496911|Drug|Levocetirizine|a single oral dose of 5 mg
1695898|NCT01496911|Drug|Hydroxyzine|a single oral dose of 50 mg
1695899|NCT01496911|Drug|Placebo|a single oral dose
1695900|NCT01496859|Device|Placement and use of Baska mask|use of a supraglottic airway device as a standard part of a general anaesthetic
1695903|NCT01496833|Device|Ankura Branched/Fenestrated Stent Graft|Ankura Branched/Fenestrated Stent Graft（Lifetech Scientific Co.,LTD.，Shenzhen, China）
1695904|NCT01496820|Dietary Supplement|GO2KA1|GO2KA1(chitosan oligosaccharide)1500mg/day for 12weeks
1695905|NCT01496820|Dietary Supplement|Placebo|placebo 1500mg/day for 12weeks
1695906|NCT01496807|Drug|Sylatron|Sylatron - Once per week for 12 weeks, given as an injection under the skin.
1695907|NCT01496807|Drug|Yervoy|Yervoy - Once every 3 weeks for 12 weeks (4 times total), given over a 90-minute intravenous infusion (through the vein).
1695908|NCT01496781|Procedure|Hemoclip|Hemoclip application is a standard treatment option after endoscopic mucosal resection of colonic lesion to stop and prevent post-procedure bleeding.
1695909|NCT01496781|Procedure|EndoClot|EndoClot hemostat is applied immediately after EMR to achieve hemostasis.
1695910|NCT01496768|Dietary Supplement|Leucine|7,2 g/day during 3 months
1695911|NCT01496768|Dietary Supplement|Alanine|7,2 g/day during 3 months
1695912|NCT01496755|Drug|Placebo|Single/multiple doses
1695913|NCT01496755|Drug|RG7667|Single/multiple ascending doses
1695914|NCT01496742|Drug|Placebo|Matching RO5490258 (MetMAb) placebo iv, Day 1 of each 21-day cycle
1695915|NCT01496742|Drug|RO5490258|15 mg/kg iv, Day 1 of each 21-day cycle
1695916|NCT01496742|Drug|bevacizumab [Avastin]|15 mg/kg iv, Day 1 of each 21-day cycle
1695917|NCT01496742|Drug|cisplatin/carboplatin|standard dose iv, Day 1 of each 21-day cycle, 4 cycles
1695918|NCT01496742|Drug|paclitaxel|200 mg/m2 iv, Day 1 of each 21-day cycle, 4 cycles
1695919|NCT01496742|Drug|pemetrexed|500 mg/m2, Day 1 of each 21-day cycle
1695920|NCT01496729|Procedure|Transversus abdominis plane (TAP) block|A Transversus abdominis plane (TAP) block with ropivacaine, a local anesthetic, will be performed at the end of the surgical procedure.
1695921|NCT01496729|Procedure|Sham TAP block with normal saline|A sham TAP block with normal saline will be performed at the end of the surgical procedure.
1695922|NCT01496716|Procedure|Hip arthroplasty|The purpose of hip arthroplasties is to reduce pain and increase mobility.
1695923|NCT01496703|Other|no intervention, this is an observational retrospective trial|no intervention, this is an observational retrospective trial
1695924|NCT01496690|Drug|Pregabalin|Subjects are randomized 1:1 to either pregabalin treatment or placebo. The intervention period is 8 weeks. The daily pregabalin dose is 75 mg. during the first week followed by 7 weeks of flexible daily dosing (150, 300, 450 or 600 mg.) depending on tolerability and response. Doses above 150 mg. should be divided in two daily dosages.
1695925|NCT01496690|Drug|Pregabalin Placebo Capsules|Parallel to Active Comparator
1695926|NCT01496677|Drug|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to elderly subjects
1695927|NCT01496677|Drug|TR-701 FA 200 mg|Single oral tablet of TR-701 FA to younger group (18-45 years old)
1695928|NCT01496664|Procedure|Combined CABG and PCI|Coronary artery bypass grafting Percutaneous coronary intervention
1695929|NCT01496651|Procedure|Percutaneous coronary intervention|"PCI will be performed by the femoral or the transradial approach. In complex distal lesion anatomies, the use of 7-8F guiding catheters and the transfemoral approach may be recommended. Ostial and mid-shaft lesions will be treated with a single stent. For the treatment of distal bifurcation lesions crush, culotte, T-stenting, V-stenting or a single stent strategy may be used according the lesion morphology and the experience of the operator. However, based on the Nordic Bifurcation Studies the culotte technique seems to be associated with especially favorable angiographic and long-term clinical results in these large vessel size bifurcation lesions.
There should be a low threshold for the use of high pressure post dilatation balloons. Generally, final kissing balloon dilatations are encouraged and mandatory when two-stent techniques are used. Intravascular ultrasound (IVUS) in mandatory pre and post stent placement."
1695930|NCT01496651|Procedure|Coronary artery bypass graft operation|Patients randomized to the CABG group for the treatment of LMCA stenosis are treated according to current clinical practice. Both off-pump and on-pump techniques can be used and the selection between the used methods is operator dependent. The left internal mammary artery will be used for the revascularization of the left anterior descending coronary artery, whenever feasible. For other lesion location, saphenous venous grafts, free arterial grafts or the right internal mammary artery may be used.
1695931|NCT01496638|Procedure|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with no side branch treatment
1695932|NCT01496638|Procedure|Implantation of coronary stent in bifurcation lesion|Implantation of coronary stent in bifurcation lesion with stenting of main vessel and side branch
1695933|NCT01496612|Drug|Buspirone|
1695934|NCT01496573|Other|laboratory biomarker analysis|Correlative studies
1695935|NCT01496547|Drug|intensive chemo - RIC preparation|The intensive chemotherapy is composed of fludarabine 35mg/m2 + high-dose cytarabine 2g/m2 D1-5 + idarubicin (12mg/m2) D5-7. The reduced intensity preparation regimen will start 7 days after the chemotherapy with fludarabine 35mg/m2 for 5 days + iv busulfan 3.2mg/kg/day for 3 days followed by stem cell infusion 2 days later.
1695936|NCT01496534|Drug|Cisplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Cisplatin 70 mg/m2 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
1695937|NCT01496534|Drug|Carboplatin|Gemcitabine 1000 mg/m2 IV on days 1 + 8 Carboplatin AUC 5 IV day 1 Dovitinib given orally on days 1-5, 8-12 and 15-19. Treatment will be recycled every 21-days. The dose of dovitinib will be escalated in successive cohorts
1695938|NCT01496521|Drug|Aspirin|100mg qd for 6 months.
1695939|NCT01496521|Dietary Supplement|Tea Polyphenols|300mg bid for 6 months.
1695940|NCT01496508|Device|mechanical ventilation (SLE 5000, Servo-i-Maquet)|Ventilation strategies for both groups were to emphasize lung recruitment and avoid atelectasis and over distention. The optimum lung volume was determined as expansion to 8 to 9.5 ribs for most infants, and 7 to 8 ribs for infants with air leak. HFOV setting were as follows: initial frequency was set between 11 and 15Hz; pressure amplitude of oscillation was initially adjusted to provide adequate chest wall movement and was subsequently titrated to maintain the PaCO2 between 40 and 55 mmHg; The initial mean airway pressure (MAP) was set at 8-10 cmH2O. MAP and FIO2 were set to maintain arterial oxygen saturation between 88 to 95%, an arterial pH of at least 7.25. Extubation was considered when MAP was ≤7 cmH2O and the pressure amplitude of oscillation reach 10 to 15 cmH2O.
1695941|NCT01496495|Drug|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule
1695942|NCT01496482|Other|Only measurements done on subjects in both groups.|As study compared specific diagnostic procedures, no intervention was done or compared.
1695943|NCT01496469|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 6 weeks
1695944|NCT01496469|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 6 weeks.
1695945|NCT01496456|Device|Resin infiltration|Split-mouth design (at least two lesions per patient): Treatment of one caries lesion with resin infiltration therapy
1695946|NCT01496456|Behavioral|Caries management|Split-mouth design (at least two lesions per patient). Baseline preventative caries management: dietary and behavioral modification, and over-the-counter fluoride supplements
1695947|NCT01496443|Drug|TAK-875 and Glimepiride|
1695948|NCT01496430|Drug|Placebo|
1695949|NCT01496430|Drug|Azilsartan medoxomil|
1695950|NCT01496430|Drug|Azilsartan medoxomil|
1695951|NCT01496417|Drug|Belatacept|Belatacept infusion intravenous at 10 mg/kg on post-operative days 1, 5, and weeks 2, 4, 8, 12; 5mg/kg intravenous dose at weeks 16, 20, 24, 28, 32, 36, 40, 44, and 48.
1695952|NCT01496404|Procedure|Electrocautery|Electrocautery using cutting mode of epidermis and dermis of skin.
1695953|NCT01496404|Procedure|Scalpel|Incising skin (epidermis and dermis) with scalpel.
1695954|NCT01496378|Behavioral|Problem-Solving Skills Training|Parents will receive 8, 1-hour sessions of individual problem-solving therapy over 8 weeks. Caregivers will complete the first training session and at least 3 subsequent sessions in person. Remaining sessions will be completed via telephone. In session 1, parents will be introduced to the PSST program and a rationale and explanation for problem solving strategies will be provided. During sessions 2-8, parents will identify a problem that they wish to work on. The therapist will use the primary cognitive-behavioral strategies of modeling, behavioral rehearsal, performance feedback, and generalization of skills in the process of teaching problem solving skills to parents. Parents will complete homework assignments to practice using the problem-solving skills in real-life situations
1695955|NCT01496365|Drug|DS-5565 tablet|5mg and 10mg tablets
1695956|NCT01496365|Drug|pregabalin capsule|75mg and 150mg over-encapsulated
1695957|NCT01496365|Drug|Placebo tablet|
1695958|NCT01496365|Drug|placebo capsule|
1695959|NCT01496352|Drug|DFA-02|Modified release product containing gentamicin and vancomycin for application at the conclusion of surgery after closure of the fascia and prior to skin closure
1695960|NCT01496352|Drug|Placebo|DFA-02 placebo
1695961|NCT01496339|Biological|MenSCs transplantation|1×10^6/kg MenSCs are infused through pancreatic artery or intravenous infusion once a week by the 4 consecutive therapies.
1695962|NCT01496339|Drug|exogenous indulin injection daily|traditional therapy, such as insulin injection daily, monitoring random and postprandial blood glucose.
1695963|NCT01496326|Drug|Ibuprofen|10% ibuprofen cream formulation at a dose of 200mg
1695965|NCT01496313|Drug|300mg vandetanib|"Oral blinded tablets taken once daily.
At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment
Dosing with unblinded study treatment can continue until 24 months after patient was randomised.
At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (200mg/day). Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
1695966|NCT01496313|Drug|150mg vandetanib|"Oral blinded tablets taken once daily.
At objective disease progression or 14 months (whichever is earlier), patient may be unblinded to treatment. Patients who have not dose reduced at the time of unblinding may have their dose increased to 300mg
Dosing with unblinded study treatment can continue until 24 months after patient was randomised
At any time dosing may be interrupted for up to 6 weeks due to toxicity. Dosing may restart at a reduced dose (100mg/day) [OR 300 reduced to 200mg/day if dose was increased at unblinding.] Once reduced, dose increases are not permitted and dosing must stop if further toxicities occur."
1695967|NCT01496300|Procedure|Manual Intervention|Implantation of acetabular component without the use of the navigation system information
1695968|NCT01496300|Procedure|Navigated Intervention|Navigated implantation of acetabular component using OrthoPilot image free navigation system
1695969|NCT01496287|Device|Tube Delivery System (TDS)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system under local anesthesia in an office/clinic setting
1695970|NCT01496274|Biological|rIX-FP|Recombinant IX-FP (rIX-FP) is a fusion protein linking coagulation factor IX with albumin, and will be administered by intravenous administration
1695971|NCT01496261|Drug|Clopidogrel and Aspirin|Clopidogrel and Aspirin seperate combination, single dose
1695972|NCT01496261|Drug|Fixed dose combination of clopidogrel/aspirin|Fixed dose combination of clopidogrel/aspirin
1695973|NCT01496248|Dietary Supplement|Korean Red Ginseng|100% of the past psychiatric medication dose will be maintained during 8 week study period. Korean Red ginseng will be started with 2g/day and then maintained using flexible dosing of 2-3g/day during the study period.
1695974|NCT01496235|Dietary Supplement|Dark chocolate|Each chocolate bar provided 210 calories represented in 25 grams of carbohydrates, 3 g of proteins, 18 g of total fat and the presence of 70% cocoa solids
1695975|NCT01496235|Dietary Supplement|White chocolate|Each chocolate bar provided 230 calories represented in 28 grams of carbohydrates, 3 g of proteins, 18 g of total fat, without the presence of 70% cocoa solids
1695976|NCT01496209|Biological|Endomyocardial injections of allogeneic Human CSps|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of Allogeneic Human CSps.
1695977|NCT01496209|Biological|Endomyocardial injections of vehicle only.|NOGA electromechanical mapping and endomyocardial injections at 15 peri-infarct sites, via NOGA MYOSTAR catheter, of placebo.
1695978|NCT01496196|Drug|tranexamic acid|500 mg/5 ml 3-4 times a day
1695979|NCT01496196|Drug|tranexamic acid|500 mg/5 ml 3-4 times a day
1695980|NCT01496183|Drug|Olanzapine|Olanzapine 5mg capsule administered orally at bedtime for 7 days followed by Olanzapine 10 mg capsule administered orally at bedtime for 7 days.
1695981|NCT01496183|Drug|Placebo|Placebo capsule administered orally at bedtime for 14 days
1695982|NCT01496170|Drug|MK-8931|MK-8931, capsules, at a dose of 12 or 40 mg, orally, once per day for 7 days
1695983|NCT01496170|Drug|Placebo|Placebo capsules, orally, once per day for 7 days
1695985|NCT01496144|Procedure|Manual therapy and active exercises|"Spinal manipulation/mobilisation (5-10 minutes), consisting of passive accessory intervertebral movements, muscle-energy techniques and high velocity, low amplitude dynamic thrust.
Active exercises (20 minutes), consisting of mobility, stretching, strengthening and motor control exercises"
1695986|NCT01496144|Procedure|Detuned ultrasound and active exercises|Electrotherapy device inactivated and ineffective. Active exercises, consisting of mobility, stretching, strengthening and motor control exercises
1695987|NCT01496131|Radiation|Radiation therapy|Radiation therapy will be administered at a daily dose of 180 centigrays (cGy) 5 days a week for approximately 6 to 8 weeks.
1695988|NCT01496131|Drug|Goserelin|ADT (Goserelin) will be administered at a dose of 10.8 milligrams (mg) subcutaneously every 3 months for 24 months for the high risk group and for 6 months in the intermediate risk group, starting 2-3 months prior to radiation therapy.
1695989|NCT01496131|Drug|Cyclophosphamide|Cyclophosphamide will be administered at a single dose of 300 milligrams per square meter (mg/m^2) to a maximum of 600 mg, as an intravenous injection 3 days prior to the first administration of tecemotide (L-BLP25).
1695990|NCT01496131|Drug|Tecemotide (L-BLP25)|Tecemotide (L-BLP25) will be administered at a dose of 918 microgram (mcg) as subcutaneous injection every 2 weeks for 5 doses followed by every 6 weeks for an additional 4 doses, starting 2-3 months prior to radiation therapy and on the same day that ADT began.
1695991|NCT01496118|Drug|carfilzomib and panobinostat|"Cohort 1 (Dose Level 4): Carfilzomib Cycle 1: 20 mg/m2 IV D1, 2 / 45 mg/m2 IV D8, 9, 15, 16; Carfilzomib Cycle 2 to progression: 45 mg/m2 IV D 1, 2, 8, 9, 15, 16;
Panobinostat cycle 1: 30 mg D 1, 3, 5, 15, 17, 19; Panobinostat cycle 2 to progression: 30 mg D 1, 3, 5, 15, 17, 19
Cohort 2 (Dose Level 6): Carfilzomib Cycle 1: 20 mg/m2 IV D1, 2 / 56 mg/m2 IV D8, 9, 15, 16; Carfilzomib Cycle 2: 56 mg/m2 IV D 1, 2, 8, 9, 15, 16;
Panobinostat all cycles: 20 mg D 1, 3, 5, 15, 17, 19."
1695992|NCT01496105|Drug|Lidocaine|
1695993|NCT01496105|Drug|saline|
1695994|NCT01496092|Drug|Keto Acid|12 tablets per day
1695995|NCT01496053|Dietary Supplement|AndoSan|AndoSan 30 ml x 2 for 21 days
1695996|NCT01496053|Dietary Supplement|Sugar Extract|Sham comparator
1695997|NCT01496040|Drug|rAAV2/4.hRPE65|"One injection in on eye
Cohorte 1 : 3 patients will receive one injection of up to 400 microliters of the IMP
Cohorte 2 : 3 patients will receive one injection of up to 800 microliters of the IMP.
Cohorte 3 : 3 patients under age of eighteen will receive one injection up to 400 or 800 microliters of the IMP."
1695998|NCT01496001|Procedure|Lumpectomy, axillary block dissection, breast conserving surgery|Wide excision of primary tumor (using 1 cm surgical margins). Minimally invasive biopsy of the sentinel lymph node.
1695999|NCT01496001|Other|Radiotherapy|Adjuvant radiotherapy carried out by institutional protocols.
1696156|NCT01494974|Device|FP7 Ahmed Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP7
1696003|NCT01495975|Other|Diabetes Transitions Tool Kit|Access to a remote glucose monitoring and a web-based patient-provider communication portal, the Diabetes Transitions Toolkit (DTTK), for the month after discharge.
1696004|NCT01495962|Drug|Botulinum Toxin Type A|Six 25 cc injection of Botulinum Toxin A
1696005|NCT01495962|Drug|Placebo|Placebo (Normal Saline)
1696006|NCT01495949|Drug|etomidate|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 2-4 mg (1-2 ml) of etomidate will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious.
1696007|NCT01495949|Drug|thiopentone|During induction, after 3 mcg/kg of fentanyl and 0.05 mg/kg of midazolam given, small doses 25-50 mg (1-2 ml) of thiopentone will be given by titration (the syringe pump and extension and three way stopcock are covered to blind the study drug) until the patients are unconscious
1696008|NCT01495936|Procedure|RM + Positive End Expiratory Pressure|A recruitment maneuver (RM) will be applied to the ventilated lung by performing a valsalva maneuver for 5 seconds (holding the inspiratory pressure at 25cmH2O). Immediately after the RM, Positive End Expiratory Pressure (PEEP) will be applied to the ventilated lung at a pressure of 5cmH2O for 20 minutes. Both the RM and PEEP will be performed using the operating room ventilator.
1696009|NCT01495936|Procedure|Continuous Positive Airway Pressure|Continuous positive airway pressure, at a pressure of 5cmH2O will applied to the non-ventilated lung for 20 minutes by the Mallinckrodt Bronchocath Disposable CPAP system (a recognised anesthetic breathing system design for CPAP)
1696010|NCT01495923|Procedure|epidural steroid injection|Injection of steroids and local anesthetic into the epidural space
1696011|NCT01495923|Procedure|Sham epidural steroid injection|Injection of saline into the back muscles
1696012|NCT01495923|Drug|Gabapentin|Titration of gabapentin to effect
1696013|NCT01495923|Drug|Placebo gabapentin|Titration of placebo gabapentin
1696014|NCT01495910|Drug|Abiraterone acetate|Abiraterone acetate oral suspension administered daily from study Day 1 to study Day 6 of each treatment period: the first dose level is 100 mg with escalating doses of 250 mg and 500 mg in subsequent treatment periods.
1696015|NCT01495897|Device|Tracking eye movement|Device: studying Saccadic eye movements with a video eye tracker: The subjects are seated in darkness facing a screen located 60 cm before their eyes, their chin on a chin strap and their forehead placed against a frontal support. Eye position is sampled at 500 Hz with a video-based monocular eye tracker (SMI, Germany). Each recording session start with a calibration test in which the subjects looked at nine consecutive targets covering the entire visual field, as used during the oculomotor paradigms: four experimental conditions: a visually guided saccade task, a pre-test, a backward adaptation task, and a post-test. The pre-test and post-test (40 trials each) are performed before and immediately after the backward adaptation task, in the same conditions, except that the target was extinguished when the velocity threshold (150°/s for 10 ms) is reached, instead of jumping to a new location.
1696016|NCT01495897|Device|Tracking eye movement under deep brain stimulation|Device: studying Saccadic eye movements with a video eye tracker. If the patient has deep brain stimulation, recording will be made in the morning, before the usual morning start of the deep brain stimulation.
1696017|NCT01495884|Drug|non-pegylated liposomal doxorubicon (Myocet™)|
1696018|NCT01495884|Drug|Lapatinib (Tyverb™)|
1696019|NCT01495871|Dietary Supplement|Amino Acids|15 grams amino acids two times per day for 6 weeks
1696020|NCT01495871|Dietary Supplement|Placebo of inert compounds|Placebo two times per day for 6 weeks
1696021|NCT01495871|Dietary Supplement|Valine|2.5 grams valine supplementation two times a day for 6 weeks
1696022|NCT01495858|Drug|Naproxen Sodium 440 mg / DPH 25 mg (BAY98-7111)|Participants received one tablet of Naproxen Sodium 220 mg / Diphenhydramine hydrochloride (DPH) 25 mg and one tablet of Naproxen Sodium 220 mg, single dose, orally.
1696023|NCT01495858|Drug|Naproxen Sodium 440 mg (BAYH6689)|Participants received two tablets of Naproxen Sodium 220 mg, single dose, orally.
1696024|NCT01495858|Drug|DPH 50 mg|Participants received two tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
1696025|NCT01495845|Other|Pharmacogenomics testing for clopidogrel responsiveness|Patients must come to the pharmacy for all visits. At the 1st visit, the patient will provide consent, a complete list of medications, a complete pre-study questionnaire, a copy of their insurance card, and a buccal swab (collected by the pharmacist). The swab will be sent to the testing facility for genotypic testing of CYP2C19. Upon receipt of the results of the results, the pharmacist will propose an intervention to the prescriber based on the patient's indication for clopidogrel and the identification of certain genetic variations atCYP2C19. All patients will be asked to return to the pharmacy for explanation of the results and implementation of any changes approved by the prescriber and to complete a follow-up questionnaire. After the visit to explain the results of testing, the patient's insurance will be billed electronically for a medication therapy management visit; patients without insurance will not be billed. Patients may opt out of billing to insurance at any time.
1696026|NCT01495832|Other|Pulse Group|The pulse group will consume pulse-enriched foods designed to deliver ½ cup of pulses per day for 12 weeks.
1696027|NCT01495832|Other|Control Group|The control group will consume comparator foods for 12 weeks.
1696028|NCT01495819|Drug|Saline|5cc's of saline give at least once.
1696029|NCT01495819|Drug|Nicotine|(0.0125, 0.025, 0.0.5, 0.1 and 0.2 mg/70 kg or about 0.18, 0.36, 0.7, 1.4 and 2.8 µg/kg).
1696030|NCT01495806|Drug|Glucomannan|2 x 5g
1696031|NCT01495806|Drug|placebo|glucose 5 g
1696032|NCT01495793|Drug|Rotigotine|"Rotigotine transdermal patch:
Dose (size): 0.5 mg/24 h (2.5 cm^2)- 1 mg/24 h (5 cm^2)- 2 mg/24 h (10 cm^2)- 3 mg/24 h (15 cm^2) The patch has to be applied continuously for 24h. After 24h, the patch has to be removed and a new one applied."
1696157|NCT01494974|Device|FP8 Glaucoma Drainage Implant|Ahmed Glaucoma Valve model FP8
1696033|NCT01495780|Behavioral|Remote Health Monitoring|1 year of remote health monitoring of symptoms, medication use, breathing tests, physical activity, and healthcare utilization.
1696034|NCT01495767|Other|Filling in a psychometric questionnaire|Juvenile patients attending the uveitis are asked to fill in a psychometric questionnaire
1696035|NCT01495754|Other|coffee|Comparison of different amounts of coffee
1696036|NCT01495728|Procedure|Thrust Manipulation - Thoracic Spine|Mid and Upper Thoracic Spine
1696037|NCT01495728|Procedure|Sham Manipulation|Mid and Upper Thoracic Spine
1696038|NCT01495715|Drug|Idebenone|
1696039|NCT01495715|Drug|Placebo|
1696040|NCT01495702|Drug|NNRTI|NNRTI agents administered according to prescribing information; allowed NNRTIs include efavirenz (EFV), nevirapine, or rilpivirine.
1696041|NCT01495702|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
1696042|NCT01495702|Drug|Stribild|Stribild® (elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate; E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
1696043|NCT01495689|Behavioral|Ottawa Model with SmartCard|On-site counseling for Smoking Cessation along with the IVR automated telephone call follow-up and SmartCard worth $110 towards purchase of smoking cessation aids
1696044|NCT01495689|Behavioral|Usual care|Usual care or control arm will receive strong physician advice, brief counseling from clinic nurse +/- a prescription for smoking cessation aid if requested and willing
1696045|NCT01495676|Other|Radiation + cisplatin|"RT will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.
Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 if an additional treatment is decided.
A cystoscopy with a transurethral resection will be performed 3 weeks after the last day of the first part of radio-chemotherapy.
In the absence of tumor cells, the 2nd part will start on the 4th week or at latest on the 5th week after the last day of the 1st part of radio-chemotherapy.
In case of a microscopic tumor residue or of a local tumor progression, operability will be re-evaluated in view of a radical cystectomy and the patient will exit the study."
1696046|NCT01495676|Other|Radiation + cisplatin + gemcitabine|"Radiotherapy will encompass bilateral internal and external iliac lymph nodes at a dose of 45 Gy and the bladder up to 63 Gy. Fractionation will be 1.8 Gy per fraction.
Cisplatin: 20 mg/m2/day through continuous iv perfusion for 4 consecutive days, from D2 to D5 and from D23 to D26 for the first part of the treatment, then from D2 to D5 for the second part of the treatment if an additional treatment is decided.
Gemcitabine: iv injection for 30 minutes, twice a week at a dose of 25 mg/m2 on days 2, 5, 9, 12, 16, 19, 23, 26, 30, and 33 for the 1st part of treatment, then on days 2, 5, 9, and 12 for the 2nd part of treatment if an additional treatment is decided (cystoscopy with a transurethral resection). RT will be delivered between 2 and 6 hours after completion of the gemcitabine injection."
1696047|NCT01495663|Drug|I-131-CLR1404|"Description:
Dosimetry: IV, 5 mCi, single dose, 6-day duration
Therapy: IV, starting dose level of 12.5 mCi/m2, single dose, 56-day duration with follow up to one year"
1696048|NCT01495650|Behavioral|Tailored program of PA and nutritional counseling|Patients receive tailored program of physical exercises and nutritional counseling during the course of adjuvant treatments (CT followed by RT, 27 weeks).
1696049|NCT01495637|Drug|GM-CSF|GM-CSF is to be administered IV at one of four possible dosing regimens (three days at a dose of 30, 62, or 125 mcg/m2 per day, or an extended dosing regimen of 125 mcg/m2/day through post-trauma 6) if severe innate immune suppression is identified on post-trauma days 1, 2, or 3.
1696050|NCT01495624|Other|ropivacaine plus dexamethasone anesthetic|Subjects will receive interscalen block comprised of 30 ml 0.5% ropivacaine plus dexamethasone 8 mg (2 ml) mixed with the local anesthetic with 2 ml normal saline given intravenously (systemic placebo);
1696051|NCT01495624|Other|ropivacaine plus saline plus dexamethasone anesthetic|Subjects will receive interscalen block with 30 ml 0.5% ropivacaine for interscalene block mixed with 2 ml normal saline (perineural placebo) plus dexamethasone 8 mg (2 ml) administered systemically.
1696053|NCT01495585|Drug|Lonafarnib|Commercially approved products used to test the research hypothesis
1696054|NCT01495585|Other|Placebo|Placebo control
1696055|NCT01495572|Drug|Fludarabine|25 mg/m^2 IV (in the vein) for 5 days (day -5 to -1)
1696056|NCT01495572|Drug|Cyclophosphamide|60 mg/kg IV (in the vein) for days -7 and -6
1696057|NCT01495572|Drug|Aldesleukin|Only given to patients assigned to high dose (HD) Arm - 720,000 IU/kg intravenous (IV) over 15 minutes, every 8 hrs (+/- 1 hr) for up to 5 days (max 15 doses).-6
1696058|NCT01495572|Drug|MART-1 Reactive CD8+ PBL|Intravenous (IV) over 30 minutes on day 0
1696059|NCT01495546|Other|Early loading|Patients stepping down immediately after THA
1696060|NCT01495546|Other|Late loading|Patients stepping down after three weeks of HTA
1696061|NCT01495533|Device|uncoated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a AngioSculpt(R) scoring balloon (no drug coating)
1696062|NCT01495533|Device|Drug coated AngioSculpt(R)|Predilatation of coronary BMS-ISR with POBA followed by a drug coated AngioSculpt(R) scoring balloon (paclitaxel 3.0 µg/mm²)
1696063|NCT01495520|Drug|Ranolazine|os, pill, 750 mg, b.i.d., 30 days
1696064|NCT01495520|Drug|Placebo|os, pill, b.i.d., 30 days
1696065|NCT01495507|Procedure|MPFL- Reconstruction|
1696066|NCT01495494|Device|Marketed Nasal Strip|Breathe Right Nasal Strips - Clear small/medium strip
1696067|NCT01495494|Device|Prototype Nasal Dilator|Prototype Nasal Dilator AB2R11
1696068|NCT01495481|Drug|Dexmedetomidine|Dexmedetomidine 2 mcg/kg, Intravenous push
1696069|NCT01495481|Drug|Adenosine|Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful
1696070|NCT01495468|Biological|PEG-somatropin|drug:pegylated somatropin 0.2mg/(kg.w), once per week for 6 months drug: Jintropin AQ, 0.25mg/(kg.w), once per day for 6 months
1696071|NCT01495442|Device|modified Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
1754951|NCT00236652|Drug|levofloxacin|
1696072|NCT01495442|Device|standard Handihaler DPI|subjects randomized to receive 1 inhaled dose on 2 separate days, each dose delivered 2-3 days apart. The radiolabeled albuterol drug powder will be dispersed from either the DET bead-HandiHaler prototype or via the established HandiHaler device standard with the lactose-albuterol formulation provided to us by the sponsor.
1696073|NCT01495429|Procedure|Central venous catheter|Placement of a peripherally inserted central venous catheter
1696074|NCT01495429|Procedure|Central venous catheter|Placement of a centrally inserted central venous catheter
1696075|NCT01495403|Drug|Hydroxychloroquine|daily dosing
1696076|NCT01495377|Drug|Remifentanil|Powder for injection/ infusion fluid solution, 1 mg Infusion TCI 3 ng/ml 60 min ( 0,15 ug/kg/min)
1696077|NCT01495377|Drug|Placebo|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
1696078|NCT01495377|Drug|Technetium|37-40 MBq( effective dose 0,7 mSv) 99Tc albumin colloid in a volume of 6 ml, infusion velocity 0,1 ml/min via a transnasal catheter
1696079|NCT01495377|Device|Dynamometer (Jamar)|portable hydraulic hand dynamometer to assess grip strength.
1696080|NCT01495364|Biological|NBS10|dosage = 10 or more million CD34+ cells via intracoronary infusion
1696081|NCT01495364|Other|placebo|matching placebo
1696082|NCT01495351|Drug|ABT-888/Bortezomib|ABT-888 is given orally (PO) twice daily (every 12 hours) for 14 days in a 21 days cycle. First dose to be given within 1 hour of Bortezomib on day 1. Planned starting dose is 20 mg PO every 12 hours. Starting dose escalation is planned until an MTD is reached.
1696083|NCT01495338|Drug|AC-170 0.17%|1 drop in one eye at one timepoint
1696084|NCT01495338|Drug|AC-170 0.24% (Formulation 1)|1 drop in one eye at one timepoint
1696085|NCT01495338|Drug|AC-170 0.24% (Formulation 2)|1 drop in one eye at one timepoint
1696086|NCT01495338|Drug|Olopatadine hydrochloride 0.2%/Tears Naturale II|1 drop in one eye at one timepoint
1696087|NCT01495325|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 µg/min).
1696088|NCT01495325|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using the Badimon Chamber
1696089|NCT01495312|Device|SLT (selective laser trabeculoplasty ) SENSIMED Triggerfish|SLT (single session; 180 to 360 degrees of angle will be treated)
1696090|NCT01495299|Device|Phacoemulsification with implantation of intraocular lens (CE-IOL) SENSIMED Triggerfish|Phacoemulsification (standard cataract extraction surgery)
1696091|NCT01495286|Device|EMPI Select Transcutaneous Electrical Nerve Stimulation|Experimental: EMPI Select TENS unit For analgesia, StimCare electrodes will be placed on the baby's legs at specific acupuncture points and electrical stimulation will be administered via a standard EMPI Select TENS unit. For the main study, a low continuous current will be provided with voltage of 3.5 mA. The frequency will be delivered using a stimulation of 10 Hz for 10±1 minutes prior to the heelstick, with continued stimulation during and for 5±1 min after the heel stick. Two sub studies will precede the main safety study, with 6 infants in each, using electrical stimulation intensities that are a fraction of the planned intensity. Infants in sub study 1 will receive electrical stimulation at 1 mA and 2 Hz. Infants in sub study 2 will receive electrical stimulation at 2 mA and 10 Hz.
1696092|NCT01495273|Procedure|Transtracheal injection|Experimental group will undergo transtracheal injection using needle connected to a nerve stimulator device.
1696093|NCT01495273|Procedure|Transtracheal injection|Control group will undergo transtracheal injection with a standard needle/syringe assembly.
1696094|NCT01495260|Drug|N-acetylcysteine|N-acetylcysteine, 800-2400 mg daily for 2 months
1696095|NCT01495260|Drug|lipoic acid|lipoic acid, 300-600 mg daily for 2 months
1696096|NCT01495260|Drug|vitamin E|vitamin E, 150-300 mg daily for 2 months
1696097|NCT01495247|Drug|BEZ235 + Paclitaxel|"Doses of oral BEZ235 (BID), supplied as 200mg, 300mg or 400mg in SDS sachets, together with standard weekly paclitaxel at a fixed dose (80mg/m²) during 1h by i.v. in infusion.
The paclitaxel infusion will be given in the morning and directly thereafter the BEZ235 dose will be given.
BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established. The initial dose level for the first cohort will be 200mg (BID), and then based on the Bayesian model the dose may be escalated to 300mg, 400mg, 500mg or 600mg for the next cohorts."
1696098|NCT01495234|Device|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
1696099|NCT01495234|Device|rhBMP-2/BCP device|The rhBMP-2/BCP device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
1696101|NCT01495208|Drug|Aflibercept|intravitreal aflibercept injection 2mg
1696102|NCT01495195|Drug|High-dose donepezil|Donepezil titrated to 22.5 mg daily
1696103|NCT01495195|Drug|Low-dose donepezil|Donepezil titrated to 10 mg daily
1696104|NCT01495195|Drug|Selegiline|Transdermal selegiline, 6 mg daily
1696105|NCT01495195|Drug|Placebo|microcrystalline cellulose
1696106|NCT01495182|Other|Dietary fiber|A proprietary fiber will be given to subjects
1696107|NCT01495169|Drug|iloperidone (oral tablet)|iloperidone 12 to 24 mg/day followed by 26 weeks of flexible dosing (6 to 24 mg/day)
1696108|NCT01495156|Drug|Lithium treatment in combination with a SGA (Second Generation Antipsychotic)|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.
Subjects in the lithium /adjunctive SGA group will be started at 900 mg/day lithium in thrice daily dosing. The lithium dose will be increased to 1200mg/day on day 4 if lithium has been well-tolerated and symptoms of mania remain, as determined by a phone assessment done by a blinded study physician. The target serum level of lithium will be 1.2 mEq/L (range 0.8 to 1.4 mEq/L)."
1696359|NCT01493570|Drug|BI 409306|Medium dose film-coated tablet
1696360|NCT01493557|Drug|pantoprazole|40 mg q.a.m, p.o.
1754952|NCT00236665|Drug|topiramate|
1696109|NCT01495156|Drug|Placebo/Adjunctive SGA treatment|"All patients will be treated with aripiprazole with a target dose of 10 mg/day and a max daily dose of 30 mg. If aripiprazole is ineffective or not tolerated, it will be tapered and risperidone treatment will be started. If patient had an adequate aripiprazole trial in the past as described above, risperidone will be the initial treatment. Risperidone dosing will begin with 0.5 mg/day on day 1 with a target dose of 2.5 mg/day and a max daily dose of 6mg.
Subjects in the placebo /adjunctive SGA group will receive placebo for the entire trial in addition to the adjunctive SGA."
1696110|NCT01495143|Procedure|Posterolateral lumbar fusion surgery|Two MD catheters with 1% lidocaine 1-2 ml are placed in the paraspinal muscle.
1696111|NCT01495130|Procedure|ultrasound imaging|Undergo transrectal ultrasound
1696112|NCT01495130|Procedure|robot-assisted laparoscopic surgery|Undergo robotic-assisted laparoscopic prostatectomy
1696113|NCT01495117|Drug|Povidone-Iodine|7.5% povidone iodine soaping 10% povidone iodine painting
1696114|NCT01495117|Drug|Chlorhexidine gluconate|4% chlorhexidine gluconate soaping 2% chlorhexidine gluconate painting
1696115|NCT01495104|Drug|RO4917838|Multiple doses
1696116|NCT01495104|Drug|valproate|Multiple doses
1696117|NCT01495078|Procedure|Telemonitoring|"Is a computer system designed jointly by engineers and clinical personal of Parc Salut Mar) to be able daily automated selfreported symptom and weight, blood pressure and heart rate monitoring . The system allow weekly follow up throught videoconferences.
Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians and nurses."
1696118|NCT01495065|Drug|GSK2251052 750 mg|Treatment A: 750 mg IV GSK2251052 single dose
1696119|NCT01495065|Drug|GSK2251052 1500 mg|Treatment B: 1500 mg IV GSK2251052 single dose
1696120|NCT01495065|Drug|GSK2251052 1500 mg BID|Treatment C: 1500 mg IV GSK2251052 BID or placebo for 12 days
1696121|NCT01495065|Drug|GSK2251052 2250 mg|Treatment D: On Day 1 a single dose of GSK2251052 2250 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 2250 mg IV (for 9 days), fasted
1696122|NCT01495065|Drug|GSK2251052 3000 mg|Treatment E: On Day 1 a single dose of GSK2251052 3000 mg IV administered over 60 minutes; Days 4 - 12 BID doses of GSK2251052 3000mg IV (for 9 days), fasted
1696123|NCT01495065|Drug|GSK2251052 0.9% saline|Treatment P: On Day 1 a single dose of 0.9% saline IV administered over 60 minutes; On Days 4 - 12 BID doses of 0.9% saline (for 9 days), fasted
1955783|NCT03071523|Procedure|coronally advanced lingual flap|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.
1696125|NCT01495039|Drug|Nystatin|Systematic nystatin prophylaxis (2 x 106 U per day administered three times daily in the naso-gastric tube)
1696126|NCT01495026|Drug|Dutasteride (0.5mg, fasted state)|Open-label, randomized, single dose, multi-stage, cross-over study
1696127|NCT01495026|Drug|Dutasteride (0.5mg, fed state)|Commercial formulation of Dutasteride 0.5mg
1696128|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC with 85%, 65% and 0% of the dose as enteric-coated pellets and with X and/or Y% of the dose as enteric-coated pellets (X and Y to be determined from PK results from Stage 1)
1696129|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC containing faster-release enteric-coated pellets
1696130|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fasted state)|FDC bioequivalent to Harnal-D tablets
1696131|NCT01495026|Drug|Fixed dose combination capsule containing dutasteride 0.5mg and tamsulosin 0.2mg (fed state)|FDC bioequivalent to Harnal-D tablets
1696132|NCT01495026|Drug|Harnal-D Tablets with water (fasted state)|Commercial formulation of Harnal-D Tablets
1696133|NCT01495026|Drug|Harnal-D Tablets with water (fed state)|Commercial formulation of Harnal-D Tablets
1696134|NCT01495026|Drug|Harnal-D tablets without water (fasted state)|Commercial formulation of Harnal-D Tablets
1955784|NCT03071523|Procedure|periosteal releasing incision|Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
1958234|NCT01856686|Drug|BP22042013|This group of patients receive 2.000 kilo-calories diet (60 g. carbohydrates, 144 gr of fat and 107 gr of proteins), including 2 protein shakes.
1958235|NCT01856686|Dietary Supplement|Low carbohydrate diet|the second group of patients receive diet of 2.000 Kilo-calories without rapidly absorbed carbohydrates and without proteins supplements
1696149|NCT01495000|Drug|denosumab|60mg subcutaneous injection, single dose
1696150|NCT01495000|Drug|placebo|placebo subcutaneous injection, single dose
1696151|NCT01494987|Drug|Ranolazine|Ranolazine tablet(s) administered orally
1696152|NCT01494987|Drug|Placebo|Placebo to match ranolazine for the duration of the study
1696153|NCT01494987|Drug|Glimepiride|Glimepiride tablets (2 mg or 4 mg) administered orally once daily with the morning dose of study drug or placebo. The target dosing regimen for glimepiride is 4 mg once daily.
1696154|NCT01494987|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
1696155|NCT01494987|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
1754953|NCT00236678|Drug|Epoetin alfa|
1696158|NCT01494961|Behavioral|Couple-oriented post-test HIV counseling|COC is an individual behavioural intervention, strengthening standard post-test HIV counselling delivered to pregnant women after prenatal HIV testing. COC was based on the assumption that developing women's communication skills and self-efficacy during HIV counselling would enable them to discuss HIV and sexual issues with their partners, and yield tangible effects on partner HIV testing. The structure of the COC intervention was adapted from a WHO PMTCT counselling manual and was described in a COC manual, which was used to train the COC counsellors and could also be used during the counselling session. Tested during the pilot phase of the trial, COC was shown to be feasible and acceptable in the four study sites.
1696159|NCT01494948|Other|allergen challenge|nasal challenges with antigen to which they are sensitive to
1696160|NCT01494935|Behavioral|High Glycemic Diet|NORMAL FAT AND GLYCEMIC DIET CONSUMED High FAT AND Glycemic Diet consumed
1696161|NCT01494935|Behavioral|Control diet|Normal fat, normal fat diet
1696162|NCT01494922|Drug|EXC 001 (currently called PF-06473871)|Single dose administered by injection at four different times
1696163|NCT01494909|Dietary Supplement|Ensure plus|Ensure plus sip feeds every 20 min during 6 hours. After 2 hour pancreatic enzyme intake in CF
1696165|NCT01494870|Procedure|PCI|urgent PCI on admission
1696166|NCT01494857|Drug|Adalimumab|Adalimumab 40 mg from 4 to 1 injection once in two weeks. Total Treatment period - 10 weeks.
1696167|NCT01494844|Device|Respiratory monitor patient interface.|Wear each interface for 20 minutes
1696168|NCT01494831|Behavioral|TF-CBT|15 sessions of group-based, trauma-focused cognitive behavioral therapy
1696169|NCT01494818|Device|Hydrogen peroxide-based contact lens care system|
1696170|NCT01494818|Device|PHMB-containing contact lens solution|
1696171|NCT01494818|Device|Soft contact lenses|Contact lenses identical to habitual prescription worn per usual replacement regimen
1696172|NCT01494805|Biological|rAAV.sFlt-1|1 x 10^10 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
1696173|NCT01494805|Biological|rAAV.sFlt-1|1 x 10^11 vector genomes (vg) rAAV.sFlt-1, delivered by subretinal injection
1696174|NCT01494805|Other|Control (ranibizumab alone)|Patients will not receive rAAV.sFlt-1, but will be eligible for retreatment with ranibizumab (Lucentis).
1696175|NCT01494792|Device|In Vitro Diagnositc aid for diagnosis|
1696176|NCT01494779|Drug|Somatropin|single subcutaneous dose of 5mg
1696177|NCT01494779|Drug|Somatropin|single subcutaneous dose of 5mg
1696178|NCT01494766|Dietary Supplement|L-Tyrosine|L-Tyrosine 750 mg PO every day for 7 days, then increase to 1500 mg PO every day for 7 days, then increase to 2250 mg PO every day for 7 days, then increase to 3000 mg PO every day for remainder of the study.
1696179|NCT01494753|Drug|T2345|One drop at 8.00pm.
1696180|NCT01494753|Drug|Prostaglandin|One drop at 8.00pm.
1696181|NCT01494740|Biological|split-virion, non-adjuvanted vaccine of 7.5 μg|120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.
1696182|NCT01494740|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
1696183|NCT01494740|Biological|split-virion, non-adjuvanted vaccine of seasonal influenza|120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
1696184|NCT01494727|Drug|CJ Amlodipine/Valsartan 10/160mg|single dose
1696185|NCT01494727|Drug|Novartis Exforge 10/160mg|single dose
1696186|NCT01494714|Drug|JNJ 10229570-AAA 1.2% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
1696187|NCT01494714|Drug|JNJ 10229570-AAA 2.4% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
1696188|NCT01494714|Drug|JNJ 10229570-AAA 3.6% cream|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
1696189|NCT01494714|Drug|Color-matched vehicle in a cream formulation containing 0 mg of JNJ 10229570-AAA|A patch containing the cream will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
1696190|NCT01494714|Drug|Petroleum jelly|A patch containing the petroleum jelly will be applied on the back and left for 48 hours on the left side, and 24 hours on the right side.
1696191|NCT01494701|Drug|nusinersen|Administered by intrathecal (IT) injection
1696192|NCT01494688|Drug|Paclitaxel|Paclitaxel, at a dose of 80 mg/m^2 will be administered QW for up to 12 weeks.
1696193|NCT01494688|Drug|RO5509554|RO5509554 will be administered Q2W, Q3W or initial biweekly followed by monthly maintenance as intravenous (IV) infusion until disease progression, unacceptable toxicity, death or participant refusal, whichever occurs first.
1696194|NCT01494675|Other|procalcitonin measurement|"The patients assigned to the procalcitonin group had procalcitonin and C reactive protein levels measured at day 0 (bacteremia), 5 or 7 (if positive blood culture) and then every 48 hours until hosptital discharge, death or until the antibiotics were stopped. A predefined procalcitonin protocol was used together with the clinical outcome, to guide the physician´s decision to discontinue antibiotics.
The procalcitonin protocol encouraged the physician to discontinue the antibiotics when: 1)procalcitonin dropped more than 90% from the baseline peak level or 2)an absolute value below 0,5ng/mL was reached. Cases in which the antibiotic treatment was continued against what the PCT values indicated were categorized as  antibiotic discontinuation overruling"
1696195|NCT01494662|Drug|HKI-272|240 mg orally, once daily
1696196|NCT01494662|Procedure|Surgical Resection|Neratinib concentrations from craniotomy specimen, CSF, plasma Neratinib.
1696197|NCT01494662|Drug|Capecitabine|750 mg/m2 orally, twice daily (1,500 mg/m2 daily) for 14 days followed by 7 days off
1696198|NCT01494649|Drug|Test Toothpaste|0.454% stannous fluoride toothpaste
1696199|NCT01494649|Drug|Negative Control Toothpaste|0.76% sodium monofluorophosphate toothpaste
1696200|NCT01494636|Drug|GSK2339345 (solution)|3, 6, 15, 30, 60 and 120 micrograms (proposed doses). 2 alternating cohorts of 6 subjects. Each subject to receive 3 ascending doses with washout of at least 48 hours between doses. Rinse, Gargle and Spit.
1696361|NCT01493557|Drug|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
1696201|NCT01494636|Drug|GSK2339345 (nebulised)|25, 100, 250, 1000 and 2000 micrograms (proposed doses). Subjects randomised to receive three ascending doses (with each dose given on two consecutive days). Washout of at least 6 days between treatment periods. Nebulised.
1696202|NCT01494636|Drug|Placebo (0.9% sodium chloride solution)|Administered on Day 1 of one of the treatment periods in part B. Randomised. Nebulised.
1696203|NCT01494636|Drug|Lidocaine|40mg dose. Administered on Day 2 of one of the treatment periods in part B. Randomised. Nebulised.
1696204|NCT01494623|Device|repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain regions.
1696205|NCT01494610|Drug|SERETIDE Rotacaps|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods and a placebo delivered via a capsule-based inhaler (Rotacaps) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
1696206|NCT01494610|Drug|SERETIDE Diskus|The study consists of four treatment periods of 10 +/- 1 days each in a cross-over fashion. Each patient will be administered SERETIDE delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods and a placebo delivered via a multi-dose dry powder inhaler (Diskus) twice for two treatment periods in a randomised, double-blind, double-dummy fashion. Dosing is twice daily in the morning and evening over the duration of each treatment period.
1696207|NCT01494597|Drug|isavuconazole|oral
1696208|NCT01494597|Drug|cyclosporine|oral
1696209|NCT01494584|Drug|ezogabine/retigabine|ezogabine dose escalation
1696210|NCT01494558|Other|Chemoradiotherapy Regimen between PC and PE|etoposide 50mg/m2 d1-5, 29-33 and cisplatin 50mg/m2 d1,8,29 and 36 29-33 during radiotherapy paclitaxel 45mg/m2 weekly and carbplatin AUC =2mg/mL/min weekly during radiotherapy
1696211|NCT01494545|Device|Delefilcon A contact lens|Silicone hydrogel contact lens CE-marked for single use, daily disposable wear
1696212|NCT01494532|Drug|ropinirole/L-dopa|Ropinirole as adjunctive therapy with L-dopa
1696213|NCT01494532|Drug|placebo/L-dopa|Placebo as adjunctive therapy with L-dopa
1696214|NCT01494519|Procedure|Surgery with an external ring fixator|Modern ring external fixator is defined as any fixator that has at least 1 ring proximal and 1 ring distal to the fracture site. The rings may be connected to the tibia using any combination of external fixation pins or wires at the surgeon's discretion. There must be at least two pins or wires connected to each ring, and typically there will be at least three pins or wires. Any FDA approved ring fixator meeting this definition from any manufacturer is allowed.
1696215|NCT01494519|Procedure|Definitive fixation with a locked IM nail or plate|"Eligible patients with tibial diaphyseal fractures will typically receive a standard locked IM Nail. The nail must use at least one static interlock proximal to and one static interlock distal to the fracture site. The nail may be placed with either a reamed or unreamed technique.
Methaphyseal fractures, especially those with fracture lines extending into the joint may be more commonly treated with plate fixation. The plate may be applied in an open or percutaneous fashion. Any combination of locked and/or non-locked screws may be used."
1696216|NCT01494506|Drug|MM-398|"Arm A: MM-398 120 mg/m2 IV Q3W
Arm C: MM-398 80mg/m2 IV Q2W"
1696217|NCT01494506|Drug|5 Fluorouracil|"Arm B: 5 Fluorouracil 2000 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks
Arm C: 5 Fluorouracil 2400 mg/m2 IV every 2 weeks"
1696218|NCT01494506|Drug|Leucovorin|"Arm B: Leucovorin 200 mg/m2 IV for 4 weeks followed by 2 weeks of rest every 6 weeks
Arm C: Leucovorin 400 mg/m2 IV every 2 weeks"
1696219|NCT01494493|Device|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS used in conjunction with an allograft bone dowel.
1696220|NCT01494493|Procedure|Autogenous bone/allograft bone dowel|An allograft bone dowel containing autogenous bone taken from the patient's iliac crest.
1696221|NCT01494480|Procedure|stem cell transplantation|after stem cell prepared, the patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments. The patient would have to be in the bed at least 6 hours and removed the pillow.
1696222|NCT01494467|Drug|CD5024|CD5024 1% Cream, once daily
1696223|NCT01494467|Drug|Azelaic acid 15% Gel|Topical Gel applied twice daily
1696224|NCT01494454|Device|rhBMP-2/BCP/TSRH® or rhBMP-2/BCP/CD HORIZON® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, either the TSRH® Spinal System or CD HORIZON® Spinal System.
1696225|NCT01494454|Device|Autograft/TSRH® or autograft/CD HORIZON® Spinal System.|Either the TSRH® Spinal System or the CD HORIZON® Spinal System with autogenous bone taken from the patient's iliac crest.
1696226|NCT01494441|Procedure|rhBMP-2/BCP|The rhBMP-2/BCP device component consists of recombinant human Bone Morphogenetic Protein-2 ( rhBMP-2) and the biphasic calcium phosphate (BCP) carrier.
1696227|NCT01494441|Device|rhBMP-2/BCP/TSRH® Spinal System|rhBMP-2/BCP device will be used in conjunction with the posterior spinal fixation system, the TSRH® Spinal System.
1696228|NCT01494441|Device|Autograft/TSRH® Spinal System|The control device will be autogenous bone from the iliac crest of the patient used in conjunction with the TSRH® spinal System.
1696229|NCT01494428|Device|rhBMP-2/ACS/allograft bone dowel|The rhBMP-2/ACS will be used in conjunction with an allograft bone dowel.
1696230|NCT01494428|Device|Autogenous bone/allograft bone dowel|An allograft bone dowel contains autogenous bone taken from the patient's iliac crest.
1696231|NCT01494415|Drug|Paclitaxel for Injection（Albumin Bound）|concurrent: 60 mg/m2, IV, weekly; consolidation: 260 mg/m2, IV, every 3 weeks
1696232|NCT01494415|Drug|carboplatin|concurrent: AUC 2, IV, weekly; consolidation: AUC 6, IV, every 3 weeks
1696233|NCT01494415|Radiation|thoracic radiation therapy|66 Gy in 33 fractions,both three-dimensional conformal and intensity modulated radiation therapy are allowed
1696234|NCT01494402|Drug|D961S|Oral gelatine capsule
1696235|NCT01494402|Drug|Esomeprazole|Oral HPMC capsule
1696236|NCT01494402|Drug|Buffered acetylsalicylic acid|Tablet
1696237|NCT01493271|Drug|Placebo|Placebo to RO5093151
1696238|NCT01493271|Drug|RO5093151|oral doses twice daily for up to 28 days
1696362|NCT01493557|Drug|Pradaxa, within 30 minutes after a meal|Patients randomized to this intervention would be instructed to take their dabigatran 30 minutes after a meal
1696363|NCT01493557|Drug|Pradaxa (dabigatran etexilate)|150 mg or 75 mg b.i.d. (150 mg or 110 mg b.i.d. in Canada)
1696239|NCT01493258|Other|iCOPE Intervention group|The study participants in the intervention group will use iCOPE platform providing adapted CERSG content in an interactive and tailored way. The intervention provided by the iCOPE platform will be implemented with the understanding that it should be user-friendly and not time consuming. Initially, all participants will be asked to complete the computer-mediated interactive CERSG module via touch screen tablet PC provided at hospital, in a primary care office, and in senior centers. The total time to complete the curriculum is about 30 min, however the patients will be able to distribute this time throughout a day at their convenience. Once the educational curriculum is completed, the intervention subjects will receive access to other components of the iCOPE platform.
1696240|NCT01493245|Drug|JNS020QD|During weeks 1-3, initial doses of 0.84 mg, 1.7 mg, 3.4 mg, or 5 mg can be increased until individual optimal dose (up to maximum 20.1 mg) is determined. The optimal dose will be administered during the maintenance period (1 week), followed by a long-term treatment (48 weeks) period, where the dose will be adjusted (escalated or reduced) in consideration of the efficacy of the study, and the condition of adverse events. The patches are applied on the skin and exchanged daily (every 24 hours) for consecutive 52 weeks.
1696242|NCT01493206|Radiation|intraoperative radiotherapy|intraoperative radiotherapy
1696243|NCT01493193|Other|Endurance training with constant work load|Endurance training with constant work load(n=15): 31min at 65-75% HRmax
1696244|NCT01493193|Other|Pyramid-Training|Pyramid-Training (n=15): One Pyramid consists of 8 one-minute blocks. Those are grouped starting with one block of 70-75% HRmax, followed by one block at 75-80% HRmax and another one at 80-85% HRmax. The top of the pyramid are 2 blocks of 85-90% HRmax. Intensity is lowered afterwards with one block at 80-85% HRmax, followed by one block at 75-80% HRmax and last one at 70-75% HRmax. Two more pyramids follow, each divided by 2min of active recovery at 65-70% HRmax, making it a total of 28min.
1696245|NCT01493193|Other|High-intensity interval training|HIT (n=15): 4x4min intervals at 85-95% HRmax divided by 3x3min of active recovery at 60-70% HRmax, making it a total of 25min
1696246|NCT01493180|Drug|OPC-12759 ophthalmic suspension|OPC-12759 ophthalmic suspension 2%
1696247|NCT01493180|Drug|Sodium hyaluronate ophthalmic solution|Sodium hyaluronate ophthalmic solution 0.1%
1696248|NCT01494363|Drug|Fluorouracil|5-fluorouracil 2400 mg/m2 (diluted in 1000 ml of 5% dextrose solution) administered as a continuous intravenous infusion over 48 hours every 2 weeks
1696249|NCT01494363|Drug|Leucovorin|Leucovorin 400 mg/m2 (diluted in 250 ml of 5% dextrose solution) as a 2-hour intravenous infusion every 2 weeks
1696250|NCT01494363|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 (diluted in 250 ml of 5% dextrose solution) given as a 2-hour intravenous infusion every 2 weeks
1696251|NCT01494363|Drug|Irinotecan|Irinotecan 150 mg/m2 (diluted in 250 ml of 0.9% normal saline solution) given as a 90-minute intravenous infusion every 2 weeks
1696252|NCT01494350|Drug|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing paromomycin and gentamicin that will be applied to each lesion once a day for 20 days and covered with a sterile gauze and tape dressing.
1696253|NCT01494337|Procedure|HOLEP|USING HOLMIUM LASER, the prostate adenoma will be enucleated and removed into small pieces
1696254|NCT01494337|Procedure|PVEP-XPS|Greenlight laser will be used with high power setting for selective vaporization of the prostate adenoma, using 180 watt XPS laser machine
1696255|NCT01494324|Other|CT guided percutaneous ablation|Depending on tumor size and location, we will direct a core biopsy needle in the ablated tumor using post-ablation dynamic Liver CT guidance, preferably including liver triphasic examination. The obtained tissue will be detached, collected and submitted to our molecular cytology laboratory. All specimens will be submitted fresh to our molecular cytology laboratory for immediate analysis in order to classify them as viable tumor (V) or apoptotic cells/coagulation necrosis (CN). CT will be performed within 24 hours of the ablation to demonstrate the ablation defect, representing the area of coagulation necrosis. This CT will be used for targeting the ablated tumor for biopsy. All patients will undergo CT again, approximately within 4-8 weeks (+/- 2 weeks) of percutaneous ablation to evaluate for CN in the target tumor or any sign of residual tissue enhancement, representing incomplete treatment.
1696256|NCT01494311|Drug|Lidocaine/tetracaine patch|The lidocaine/tetracaine patch topical anesthetic patch contains 70 mg each of lidocaine and tetracaine. The central area of each patch consists of a Controlled Heat Assisted Drug Delivery pod which is designed to warm the skin to 26-34°C, theoretically enhancing drug absorption and allowing application just 20 minutes before percutaneous procedures. A active or placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
1696257|NCT01494311|Drug|Placebo Patch|A placebo patch was placed on each patient's wrist in the region of the maximum radial artery pulsation. After 20 minutes, the patch was removed.
1696258|NCT01494311|Drug|Subcutaneous injection of 0.5 ml Lidocain 1%|After removing the patch, a blinded investigator injected 0.5 ml of 1% lidocaine solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
1696259|NCT01494311|Drug|Subcutaneous injection of saline|After removing the patch, a blinded investigator injected 0.5 ml saline solution. Three minutes after injection, an attempt was made to cannulate the radial artery with a 20-gauge catheter.
1696260|NCT01494285|Drug|ARK-E021 5%|Topically applied once daily at bedtime
1696261|NCT01494285|Drug|ARK-E021 10%|Topically applied once daily at bedtime
1696262|NCT01494285|Drug|Placebo|Topically applied once daily at bedtime
1696263|NCT01494259|Drug|Bupivacaine|Up to 300cc of 0.5% bupivacaine administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
1696264|NCT01494259|Drug|Saline|Up to 300cc of normal saline administered to the mastectomy site via 2 catheters connected to the Symbios GOPump at a rate of 2 cc per hour per catheter over 3 days.
1696265|NCT01494246|Other|electronic mail|Some e-mail will be sent to participants who will be in the intervention group in order to intensify the brief advise received for stop smoking.
1696266|NCT01494233|Drug|250 mg LX1033 tablets|250 mg LX1033 tablets administered orally
1696267|NCT01494233|Drug|Placebo tablet|Matching placebo tablet administered orally
1696268|NCT01494220|Device|Bispectral index monitoring (BIS)|BIS recording electrodes (Aspect Medical Systems. Inc., One Upland Road, Norwood, MA 02062 USA) were applied to the forehead of each patient according to the manufacturer recommendations. The BIS monitor was masked with opaque sheet and BIS data was recorded prior to induction of general anesthesia then continued throughout the procedure. All information obtained from the BIS monitor was continuously downloaded to a computer for offline analysis. The patient's management was not guided by the changes in BIS readings.
1696269|NCT01494207|Behavioral|Wellness counseling|Each participant will receive up to six counseling sessions where the counselor will employ motivational interviewing techniques. The first and last session will be face-to-face with the remaining four sessions being telephonic.
1696270|NCT01494194|Other|Air Structuring Protein|A novel food protein preparation
1696271|NCT01494194|Other|Placebo sorbet|Placebo sorbet for double blind placebo controlled food challenge
1696272|NCT01494168|Procedure|Bariatric surgery (Roux-en-y bypass or sleeve gastrectomy)|Bariatric surgery
1696273|NCT01494155|Drug|Capecitabine|825 mg/m2 BID orally for a total of 10 days (M-F of weeks 2 and 3)
1696274|NCT01494155|Drug|Hydroxychloroquine|400 mg BID from study day 1 until surgery. Dosing resumed upon discharge from hospital
1696275|NCT01494155|Radiation|Proton or Photon Radiation Therapy|Daily, beginning Week 2 for 5 consecutive days
1696276|NCT01494116|Other|900 mL of 0.9% Normal Saline|"The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered."
1696277|NCT01494103|Biological|iCaspase9-transduced T cells|Patients will receive the T cells between 30 and 90 days following transplantation. The T cells will be infused through a catheter line.
1696278|NCT01494103|Drug|AP1903|"AP1903 will be administered if there is development of Grade 1 or greater GvHD.
Dose: 0.4 mg/kg by IV over 2 hours.
Up to 3 additional doses may be administered if the GvHD does not respond or gets worse."
1696279|NCT01494090|Drug|Rosuvastatin|5 or 20 mg per day during 6 months
1696280|NCT01494090|Drug|Placebo|5 or 20 mg per day during 6 months
1696281|NCT01494077|Other|Laboratory processing for results|There is no intervention. Extra fluid that is normally discarded will be processed.
1696282|NCT01494051|Behavioral|Diet counseling|Subjects counseled how to follow either the high carbohydrate diet or the high protein diet for 4 months at home.
1696283|NCT01494038|Drug|Isoniazid (INH)|300-mg tablet once daily by mouth, either from entry through Week 28 antepartum (Arm A) or from Week 12 postpartum through Week 40 postpartum (Arm B)
1696284|NCT01494038|Drug|Placebo for isoniazid (INH)|Placebo tablet once daily by mouth, either from Week 28 visit through Week 40 postpartum (Arm A) or from entry until Week 12 postpartum visit (Arm B)
1696285|NCT01494025|Behavioral|Diet and Exercise|Subjects underwent a diet regimen targeted to elicit a 10% weight loss. Diets were designed based on the US Dietary Guidelines with caloric deficits individualized for each subject. Aerobic exercise was monitored over approximately 14 weeks, several times per week, to elicit significantly increased VO2max.
1696286|NCT01494012|Radiation|stereotactic body radiation therapy|Undergo SBRT
1696287|NCT01494012|Procedure|positron emission tomography|Undergo FDG-PET/CT
1696288|NCT01494012|Procedure|computed tomography|Undergo FDG-PET/CT
1696289|NCT01494012|Other|questionnaire administration|Ancillary studies
1696290|NCT01494012|Drug|fludeoxyglucose F 18|Undergo FDG-PET/CT
1696291|NCT01493999|Drug|Clopidogrel reloading|Up to three times 600 mg clopidogrel
1696292|NCT01493999|Drug|Prasugrel|60 mg prasugrel in patients with HPR
1696293|NCT01493986|Drug|Ropivacaine|Dosage. Onset time
1696294|NCT01493973|Drug|Epoetin alfa|Epoetin alfa will be administered s.c. at 1200 IU/Kg every 12 weeks
1696295|NCT01493973|Drug|Placebo|Placebo
1696298|NCT01493947|Drug|Ivermectin 1% cream|Ivermectin 1% cream applied once daily on the face during 16-week plus 36-week extension period.
1696299|NCT01493947|Drug|Metronidazole 0.75% cream|Metronidazole 0.75% cream applied twice daily on the face during 16-week plus 36-week extension period.
1696300|NCT01493934|Drug|injection of 6-DIG|Unique injection dose of 92.5 MBq
1696301|NCT01493921|Drug|SR-T100 gel|Patient will be instructed to self-apply approximately 0.3~0.5g of SR-T100 gel on 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
1696302|NCT01493921|Drug|Vehicle gel|Patient wil be instructed to self-apply approximately 0.3~0.5g of vehicle gel (without active ingredient)per total of 25 cm squared treatment area (avoiding the periocular areas, lips, and nares) once daily with an occlusive dressing for 16 weeks treatment period.
1696303|NCT01493908|Drug|High price|Acetaminophen label as high price
1696304|NCT01493908|Drug|Low price|Acetaminophen label as low price
1696305|NCT01493908|Drug|Low price participants aware paying part|Acetaminophen label as low price; participants aware they are paying part of the full price
1696306|NCT01493908|Drug|No price|acetaminophen. No price - price issue not introduced to participants.
1696307|NCT01493908|Drug|Free of charge|Acetaminophen. participants aware the product is free of charge
1696308|NCT01493895|Device|standard hoem treatment|"All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.
Every treatment will consist of the following steps:
A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.
Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method."
1696364|NCT01493531|Drug|Lesinurad|Tablets, 200 mg QD
1696365|NCT01493531|Drug|Lesinurad|Tablets, 400 mg QD
1696366|NCT01493531|Drug|Placebo|Tablets, Placebo QD
1696309|NCT01493895|Device|LLLT-808 B-cure laser machine|"From the day of entering the study, ulcers will be treated twice daily regardless of the treatment that was used until then.
All treatments will be carried out by trained study caregivers that will give standard treatment to all the participants under their care.
Every treatment will consist of the following steps:
A thorough rinse with an antiseptic soap (Septal scrub) with a stream of warm water.
Drying of the foot with an absorbable disposable paper towel. Using clean latex gloves the caregiver will beam the ulcer with LLLT 808, B-cure laser machine in the following method.
The part of the laser machine from which the laser beam is radiating - the beam guard, will be cleaned with a disposable swab of 70% alcohol. The cleaning will be performed while the machine is pointing downwards."
1696310|NCT01493882|Drug|Placebo|Form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
1696311|NCT01493882|Drug|JNJ-39758979 30 mg/d|Unit = mg, number = 30, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
1696312|NCT01493882|Drug|JNJ-39758979 100 mg/d|Unit = mg, number = 100, form = tablet, route = oral administration, once daily from Week 0 to Week 24 only for Part 2
1696313|NCT01493882|Drug|JNJ-39758979 300 mg/d|Unit = mg, number = 300, form = tablet, route = oral administration, once daily from Week 0 to Week 24 for Part 1 and Part 2
1696314|NCT01493869|Drug|cabozantinib|3 25-mg strength capsules (75-mg dose) administered as a single oral dose on Day 1 of study participation
1696315|NCT01493856|Drug|Cresto|tablet, rosuvastatin 20mg
1696316|NCT01493856|Drug|Olmetec|tablet, olmesartan medoxomil(CS-866) 40mg
1696317|NCT01493856|Drug|DWJ1276|tablet, Rosuvastatin 20mg and olmesartan medoxomil 40mg
1696318|NCT01493843|Drug|pictilisib|Pictilisib, 260 milligrams (mg) or 340 mg, will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, pictilisib will be taken once daily continuously.
1696319|NCT01493843|Drug|Placebo|Placebo corresponding to 260 mg or 340 mg pictilisib will be taken orally once daily on Days 1-14 of a 21-day cycle for four cycles. Starting with Cycle 5, placebo will be taken once daily continuously.
1696320|NCT01493843|Drug|bevacizumab|Bevacizumab, 15 milligrams per kilogram (mg/kg) will be administered intravenously (IV) at Day 1 of each 21-day cycle for a maximum of 34 cycles.
1696321|NCT01493843|Drug|carboplatin|Carboplatin will be administered IV to achieve an initial target area under the concentration curve (AUC) of 6 milligrams per milliliter per minute (mg/mL per min) on Day 1 of each 21-day cycle for a maximum of four cycles.
1696322|NCT01493843|Drug|paclitaxel|Paclitaxel will be administered at 200 milligrams per square meter (mg/m^2) IV on Day 1 of each 21-day cycle for a maximum of four cycles.
1696323|NCT01493830|Genetic|fluorescence in situ hybridization|
1696324|NCT01493830|Genetic|gene expression analysis|
1696325|NCT01493830|Genetic|microarray analysis|
1696326|NCT01493830|Genetic|mutation analysis|
1696327|NCT01493830|Genetic|protein analysis|
1696328|NCT01493830|Other|immunohistochemistry staining method|
1696329|NCT01493830|Other|laboratory biomarker analysis|
1696330|NCT01493830|Other|microscopy|
1696331|NCT01493817|Other|laboratory biomarker analysis|Correlative studies
1696332|NCT01493791|Drug|CDB-2914|
1696333|NCT01493778|Drug|turoctocog alfa|Patients will be scheduled to receive treatment with turoctocog alfa for at least 100 exposure days. In most cases, treatment will be given at home with intravenous (i.v., into the vein) self-injection by the parent/caregiver/support person.
1696334|NCT01493765|Other|Simulator training with expert scoring|Residents will be trained using surgical simulation
1696335|NCT01493752|Dietary Supplement|beetroot juice|250mls daily beetroot juice
1696336|NCT01493726|Drug|ALKS 9072, Low dose|IM injection, given monthly
1696337|NCT01493726|Drug|ALKS 9072, Med dose|IM injection, given monthly
1696338|NCT01493726|Drug|ALKS 9072, High dose|IM injection, given monthly
1696339|NCT01493726|Drug|Placebo|Dosed matched placebo IM injection, given monthly
1696340|NCT01493713|Other|Evaluate the correlation of overall different objective response.|Evaluate the correlation of overall different objectives response. Chemotherapeutic agents: XELOX scheme (Xeloda; Oxaliplatin) Device: MDCT (MultiDetector Computed Tomography)
1696341|NCT01493700|Procedure|heated circuit|use electrically heated respiratory circuit (set at 37oC)during mechanical ventilation of anesthetic machine during shoulder arthroscopy
1696342|NCT01493700|Procedure|control|use routine respiratory circuit during mechanical ventilation of anesthetic machine during shoulder arthroscopy
1696343|NCT01493687|Drug|CD5024|CD5024 1% Cream, once daily
1696344|NCT01493687|Drug|Azelaic acid 15% Gel|Topical Gel applied twice daily
1696345|NCT01493674|Dietary Supplement|folic acid|two 5-mg tablets of folic acid
1696346|NCT01493661|Other|Chronic Sleep Restriction|All volunteers will undergo 25% of sleep restriction of their total sleep time at the beginning sleep for five consecutive days. The nights will be monitored by polysomnography.
1696347|NCT01493648|Drug|Vitamin D|Participants will receive weekly doses of 30,000 IU of vitamin D for 3 months.
1696348|NCT01493648|Drug|Placebo|Participants will receive placebo (lactose 100 mg) for 3 months.
1696349|NCT01493635|Other|analgesic ladder|Patients will be managed according to the standard 3 Step approach of the WHO analgesic ladder (Step 1 - Step 2 - Step 3).
1696350|NCT01493635|Other|analgesic ladder|Patients managed according to the WHO analgesic ladder bypassing Step 2, i.e. patients will move from Step 1 of the WHO analgesic ladder to Step 3.
1696351|NCT01493622|Drug|minocycline|variable dose SGA and minocycline,100mg per capsule po（take orally） bid，16 weeks；
1696352|NCT01493622|Drug|placebo|variable dose SGA and 100mg per capsule po（take orally） bid，16 weeks；
1696353|NCT01493609|Behavioral|Click-East app|Computer game, delivered as an iPad app, designed to provide an environment to practice basic social skills.
1696354|NCT01493596|Drug|CPP-115|Appropriate amount of drug substance will be dissolved in juice within 3 hours of dosing.
1696355|NCT01493596|Drug|Placebo|An equal volume of water mixed with juice will be administered.
1696356|NCT01493570|Drug|BI 409306|High dose film-coated tablet
1696357|NCT01493570|Drug|BI 409306|Low dose film-coated tablet
1696358|NCT01493570|Drug|BI 409306 Placebo|Film-coated tablet
1754954|NCT00236691|Drug|topiramate|
1696368|NCT01493518|Drug|AMG 557 or PLACEBO|Multiple subcutaneous doses of AMG 557 or Placebo on Days 1, 8, 15, 29, 43, 57 and 71.
1696369|NCT01493505|Drug|AMG 386|AMG 386 15mg/kg IV QW (until progression or unacceptable toxicity develops)
1696370|NCT01493505|Drug|Paclitaxel|Paclitaxel 175 mg/m2 3 hour IV Q3W (6 cycles)
1696371|NCT01493505|Drug|AMG 386 Placebo|AMG 386 Placebo IV QW (until progression or unacceptable toxicity develops)
1696372|NCT01493505|Drug|Carboplatin|Carboplatin AUC 5 or 6 IV Q3W (6 cycles)
1696373|NCT01493479|Drug|90Y Ibritumomab tiuxetan|2 x iv infusions of 11.1 MBq/kg. 1st infusion at week 1, 2nd during weeks 9-13. 2nd infusion may be reduced to 7.4MBq/kg in the case of grade 3 haematological toxicity following the 1st infusion.
1696374|NCT01493479|Drug|Rituximab|"All patients receive 2 x iv infusions of 250 mg/m2 Rituximab given 7-8 days apart prior to each zevalin infusion. The 2nd rituximab infusion is given immediately prior to Zevalin.
In addition patients with greater than 20% bone marrow involvement at screening receive rituximab pretreatment prior to entering the main treatment phase of the trial, consisting of 4 x weekly iv doses of rituximab(375 mg/m2). This is followed by a repeat bone marrow biopsy, bone marrow involvement must have fallen to <= 20% to enter the main treatment phase of the trial."
1696375|NCT01493453|Genetic|aCD19z cells, IL2, pre conditioning Cyclophosphamide & Fludarabine|aCD19z T cells IV Day 1. The dose of aCD19z T cells will be determined by dose escalation scheme, starting at 10*9 IL2 given as 15 minute IV infusion every eight hours for up to 12 doses Cyclophosphamide (C) 15mg/kg day -7 and day -6, Fludarabine (F) 25mg/m2 day -5 to day -1.
1696376|NCT01493440|Drug|atosiban|Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
1696377|NCT01493427|Drug|Travoprost 0.004%|Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
1696378|NCT01493414|Drug|INC424|All patients enrolled into the study receive INC424 (ruxolitinib). The study drug is provided as 5 mg tablets. Sixty tablets are packaged per bottle. Starting dose is based on baseline platelet counts: 15 mg BID PO with PC 100 - 200,000/μl or 20 mg BID PO with PC > 200,000 μl. After 4 weeks, dose can be increased by 5 mg BID (15 mg BID increased to 20 mg BID or 20 mg BID increased to 25 mg BID) if warranted. No INC424 dose will exceed 25 mg BID PO.
1696379|NCT01493401|Procedure|Midurethral slings (MUS)|Retropubic, Transobturator, and Single incision MUS can be used.
1696380|NCT01493388|Drug|insulin|Patients will be treated according to routine clinical practice at the discretion of the treating physician.
1696381|NCT01493336|Drug|capecitabine RTD|single oral dose
1696382|NCT01493336|Drug|capecitabine [Xeloda]|single oral dose
1696383|NCT01493336|Drug|capecitabine [Xeloda]|standard treatment
1696384|NCT01493323|Behavioral|Assessment of personality traits|suicide behaviour , psychic pain, social exclusion, decision making...
1696385|NCT01493323|Behavioral|Assessment of suicidal act|suicide behaviour , psychic pain, social exclusion, decision making...
1696386|NCT01493323|Behavioral|Assessment of depression|suicide behaviour , psychic pain, social exclusion, decision making...
1696387|NCT01493323|Procedure|Cyber ball game|functional neuroimaging
1696388|NCT01493323|Procedure|Iowa Gambling Task|functional neuroimaging
1696389|NCT01493323|Procedure|Microcomputer|functional neuroimaging
1696390|NCT01493323|Procedure|blood sample|blood sample
1696391|NCT01493310|Drug|mifepristone|"Given orally (by mouth)
Up to 4 doses of mifepristone will be studied (300 mg, 600 mg, 900 mg, 1200 mg)"
1696392|NCT01493310|Drug|placebo|Given orally
1696393|NCT01493310|Drug|nab-paclitaxel|"Given by intravenous infusion (IV)
Dose of 80 mg/m2"
1696394|NCT01493297|Other|Labeled iron solutions|Labeled iron as FeSO4 (4 mg/test meal)
1696396|NCT01493167|Other|limb casting/splinting|ankle and arm cast
1696397|NCT01493154|Biological|DNA Vaccine|Patients will receive intramuscular needle injections of pNGVL4a-CRT/E7 (detox) DNA vaccine using the TDS-IM device on Day 1, 22, and 43 for a total of three vaccinations per patient. One day prior to each DNA vaccination, the patient will receive a single low dose of 200 mg/m2 of cyclophosphamide intravenously. The DNA vaccine will be administered in a dose-escalating manner.
1696398|NCT01493154|Drug|Cyclophosphamide|A single low dose of 200 mg/m2 of cyclophosphamide (CTX) will be administered intravenously up to 24 hours (Day 0) prior to each DNA vaccination.
1696399|NCT01493115|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1696400|NCT01493115|Drug|Insulin glargine - New formulation HOE901|Pharmaceutical form:solution for injection Route of administration: subcutaneous
1696401|NCT01493102|Drug|Vasopressin|Vasopressin will be reduced first (0.01 U/hour)
1696402|NCT01493102|Drug|Norepinephrine|Norepinephrine will be reduced first (0.1 microgram/kg/hour)
1696403|NCT01493089|Drug|Zegerid|20 mg Zegerid suspension to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
1696404|NCT01493089|Drug|Losec|20 mg Losec capsule to be taken when heartburn occurs. Maximum one dose per day on 3 out of 14 days.
1696405|NCT01493076|Device|Primary cannulation/precut sphincterotomie with the Baby-S|"At the papilla the ankle for cannulation was optimized due to changes of the position of the sphincterotome, its lay in the working channel and the tension of the Albaran-lever and the cutting wire. After successful cannulation, the catheter with the sphincterotome inside was slightly pushed into the duct. If necessary, the baby-sphincterotome was replaced with a guide wire and than conventional endoscopic sphincterotomie was completed with a standard traction-type sphincterotome."
1696406|NCT01493063|Other|Physiopathology|Samples of breastmilk and infant serum
1696409|NCT01493037|Device|PICSO (Pressure-controlled Intermittent Coronary Occlusion|The PICSO catheter has a balloon which is placed in the coronary sinus via the femoral vein. The balloon is inflated and deflated at intervals calculated by an algorithm and adjusted according to the patient's own coronary sinus pressure plateau.
1696489|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.003 mg/kg, Once Weekly, 9 weeks
1696412|NCT01493011|Device|chemotherapy & WBH|standard first-line chemotherapy combined with whole-body hyperthemia to treat stage Ⅲb/Ⅳ NSCLC
1696413|NCT01492998|Other|guggulsterone, a natural FXR antagonist.|Gugulipid®, natural extract from Commiphora mukul tree, containing 2.5% guggulsterone
1696414|NCT01492985|Biological|Placebos of GTU-multiHIV B and LIPO-5 vaccines|Placebos corresponds respectively to 1X PBS pH = 7.2 and glucose 5%
1696415|NCT01492985|Biological|GTU-multHIV B vaccine and LIPO-5 vaccine|Vaccines are respectively an HIV-DNA plasmid and a mixture of 5 HIV-lipopeptides.
1696416|NCT01492972|Radiation|Radiation|"Consists of:
Conformal Proton Radiation Dose: 2.5 Gy (RBE) five days a week in 28 treatments over 5.5-6.5 weeks (total dose: 70 Gy (RBE))
High Dose Radiation with IMRT alone: 1.8 Gy five days a week in 45 treatments over 9-10 weeks (total dose: 81 Gy)
Intraoperative LDR Brachytherapy and IMRT: 100Gy Pad103 implant and IMRT 1.8 Gy five days a week in 25 treatments over 5-6 weeks (total dose: 45 Gy)"
1696417|NCT01492972|Drug|Androgen Suppression Therapy|Androgen suppression will begin 8 - 10 weeks prior to the start of RT for a total of 6 (+/- 2) months. Luteinizing Hormone-Releasing Hormone (LHRH) agonist therapy will consist of analogs approved by the FDA (or by Health Canada for Canadian institutions)
1696418|NCT01492959|Drug|insulin human|Insulin human delivered with the InnoLet® device was prescribed according to product labelling to subjects in need of insulin treatment
1696419|NCT01492920|Dietary Supplement|Acetyl-L-Carnitine Hydrochloride|Given orally
1696420|NCT01492920|Other|Placebo|Given orally
1696421|NCT01492920|Other|Questionnaire Administration|Ancillary studies
1696422|NCT01492920|Other|Quality-of-Life Assessment|Ancillary studies
1696423|NCT01492907|Radiation|MeIQx|On the day of administration, the subject will swallow a capsule with a dietary relevant dose of MeIQx, 21 µg, labeled with a very low level of 14-carbon. The radioactive dose for MeIQx, 0.002 mSv (4.3 µCi), or less than an average dental x-ray.
1696424|NCT01492907|Procedure|Pancreatectomy|Patients with operable pancreatic cancer scheduled for a pancreatectomy at the University of Minnesota Medical Center.
1696425|NCT01492894|Drug|Cyclosporins/Tacrolimus|Decrease the dose of calcineurin inhibitor by 1/2 and the drug level will be followed and adjusted to the target level of 50% of the previous levels
1696426|NCT01492894|Drug|Sirolimus|Change from current calcineurin inhibitor to Sirolumus
1696427|NCT01492881|Drug|Vorinostat|Oral, 400mg, taken days 4 through 11 of each cycle.
1696428|NCT01492881|Drug|Bortezomib|subcutaneous injection, 1.3mg/m2, Days 1, 4, 8, and 11 every cycle
1696429|NCT01492881|Drug|pegylated liposomal doxorubicin|Intravenous, 30mg/m2, Day 4
1696430|NCT01492855|Procedure|Arthroscopy|Arthroscopy is offered for the patients who do not benefit from conservative treatment.
1696431|NCT01492855|Behavioral|Non-invasive treatment|All patients will receive information and supervised exercises by a physiotherapist.
1696432|NCT01492829|Behavioral|individual and group-based, community health worker delivered|Pre-test will be individual, tablet-based; participants will receive correct information for incorrect HIV/STI knowledge responses and will watch a brief HIV/STI educational video. This will be followed by participants attending 6 weeks of group educational sessions focused on: HIV, STI, interpersonal relationships, communication and decision-making, mental health and coping, creating social change
1696433|NCT01492816|Behavioral|Community Mobilization|The proposed study seeks to continue C2P community mobilization efforts that have developed coalitions that plan for and bring about structural changes for purposes of reducing Human Immunodeficiency Virus (HIV) incidence and prevalence among youth in targeted communities at nine sites. Earlier phases of C2P have been outlined in ATN Protocols 016a, 016b, 040/040b. The C2P community mobilization model entails: determining a geographic area and population of focus for the coalitions to prioritize their planning and action (accomplished in an earlier phase of C2P); coalitions establishing a shared vision and mission; development of a strategic plan focused on structural changes to reduce risks associated with HIV; process documentation; and feedback as technical assistance to the coalitions.
1696434|NCT01492803|Dietary Supplement|Probiotics|"Probiotic is a live microorganism that when administered in adequate amounts confer a health benefit on the host. It is classified by the FDA as generally recognized as safe (GRAS)"
1696435|NCT01492803|Dietary Supplement|Placebo|The placebo sticks will contain approximately 1 g maltodextrin
1696436|NCT01492790|Procedure|Emergency cholecystectomy first|The intervention is an emergency cholecystectomy without prior common bile duct imaging
1696437|NCT01492790|Procedure|Sequential common bile duct imaging/cholecystectomy|This intervention is a common bile duct imaging modality and, if needed, ERCP first followed in the same hospital stay by a cholecystectomy
1696438|NCT01492751|Behavioral|Quality of life assessment and Clinical evaluation|"quality of life assessed by the Expanded Prostate Cancer Index Composite (EPIC), the Medical Outcomes Study 36-Item Short Form (SF-36) version 2, the Functional Assessment of cancer Therapy, General and Prostate specific (FACT-G and FACT-P, respectively), the International Prostate Symptom Score (IPSS), and the International Index of Erectile Function (IIES). Quality of Life questionnaires are administered centrally by telephone interview before treatment and during follow-up at 1, 3, 6, and 12 months after treatment the first year, then annually until 10 years, and every 5 years thereafter.
Demographic and clinical characteristics at baseline are recorded at clinical sites and include age, Prostate Specific Antigen (PSA), Gleason grading, prostate volume, risk group and use of neoadjuvant hormonal treatment. According tho the national health guidelines participants are visited every 6-12 months after treatment."
1696490|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.01 mg/kg, Once Weekly, 9 weeks
1696491|NCT01492374|Drug|BMS-241027|Intravenous (IV), 0.03 mg/kg, Once Weekly, 9 weeks
1696492|NCT01492374|Drug|Placebo matching BMS-241027|Intravenous (IV), 0.0 mg/kg, Once Weekly, 9 weeks
1696493|NCT01492361|Drug|AMR101|Parallel Assignment
1696494|NCT01492361|Drug|Placebo|Parallel Assignment
1696583|NCT01491594|Drug|Eltrombopag|Eltrombopag is taken by mouth daily beginning 5 days before the start of each chemotherapy cycle for 10 days. In the phase 1 part of the study the dose will be 100, 150, 225, or 300 mg.
1696439|NCT01492751|Procedure|Radical retropubic prostatectomy surgery|The surgery group underwent radical retropubic prostatectomy. The surgery is performed by a technique based on a modification of the radical retropubic prostatectomy described by Walsh. The prostatectomy is performed in retrograde way, preserving the neurovascular bundles if feasible, controlling the vessels with titanium clips, and avoiding any kind of coagulation to decrease the risk of neurovascular bundle damage. The bladder neck may be preserved on surgeon criteria. Lymph node dissection is rarely performed due to the extremely low risk of metastatic involvement in this subset of patients. The operative time is about 2 to 3 hours and required hospital stay. The patient has a urinary catheter placed for 1 to 3 weeks to facilitate bladder emptying.
1696440|NCT01492751|Radiation|External beam radiotherapy|External beam radiation is carried out with the 3D conformal technique. Patients are treated in a supine position by immobilizing feet and legs. Data from a computed tomography (CT) scan performed with the patient in the treatment position were entered into a 3D treatment-planning system to outline prostate, bladder, and rectum on each slice. Seminal vesicles and regional lymphatics are also contoured if a high risk of involvement was suspected. Applied margins are used to calculate prostate planning target volume (PTV). Custom blocking with Cerrobend blocks or multileaf collimators are designed using beam's eye view, and additional margins were adjusted to provide a minimum dose of 95% to the prostate PTV. Treatment is delivered in 1.8 to 2.0 Gy daily fractions, 5 days per week. Off-line setup control is assessed weekly by comparing orthogonal portal images with the corresponding digitally reconstructed radiographs.
1696441|NCT01492751|Radiation|Prostate Brachytherapy|Brachytherapy is performed by pre-planned procedure. Under epidural anaesthesia, the patient is placed in the lithotomy position (forced lithotomy position larger prostate volumes) and, after probing the patient, the best prostate spatial location is searched, proceeding then to prepare the sterile field and bladder catheterization. A prostate volumetry with a three-dimensional reconstruction is performed and automatically transferred to the scheduler, which processes the images and outlines the prostate, urethra and rectum in each of the sections. In LDR prostate brachytherapy, the prostate gland corresponds to the PTV. The standard dose for 100% isodose is 145 Gy according to the TG-T43 for I-125 sources. Dosimetry calculation of the automatically prescribed dosage is then estimated, with a final manual optimization.
1696442|NCT01492738|Procedure|Acupuncture|After completing questionnaires and anxiety survey, a licensed acupuncturist will insert needles according to Clean Needle Technique into specific acupuncture points. Procedure will last 20 minutes.Following acupuncture treatment, participants will complete anxiety survey and memory test.
1696443|NCT01492725|Device|Intra-arterial Clot Retrieval with Solitaire device|Intra-arterial mechanical clot retrieval with the Solitaire device after patients have received standard therapy with intravenous tissue plasminogen activator (tPA). Clot retrieval involves cerebral angiography and takes approximately 2 hours.
1696444|NCT01492725|Genetic|intravenous tissue plasminogen activator (tPA)|Standard care IV tPA therapy administered as per registered product information
1696445|NCT01492712|Drug|Propofol|Patients in the low-high-low group will receive an infusion of propofol with an initial blood target concentration of 2 mcg/ml. After 15 minutes the target will be increased to 5 mcg/ml and after a further 15 minutes the target will be reduced back to 2 mcg/ml for a further 15 to 30 minutes.
1696446|NCT01492712|Drug|Propofol|Patients in the high-low-high group will receive an infusion of propofol with an initial blood target concentration of 5 mcg/ml. After 15 minutes the target will be reduced to 2 mcg/ml and after a further 15 minutes the target will be increased back to 5 mcg/ml for a further 15 to 30 minutes.
1955788|NCT03067597|Drug|Dinoprostone|The DVI contains 10 mg dinoprostone
1696451|NCT01492673|Drug|Cyclophosphamide, Topotecan, and Bevacizumab|The treatment schedule for this study will consist of a 21-day cycle. Dose modification will only occur with administration of the investigational agent, bevacizumab. The schedule of administration is summarized as follows. Administration of bevacizumab will precede the administration of the cyclophosphamide and topotecan by 3 days (Day - 3) to allow for vascular stabilization prior to initiation of chemotherapy. The chemotherapy backbone will consist of cyclophosphamide and topotecan administered as follows: cyclophosphamide 250 mg/m2/day IV over 30 minutes ± 5 minutes on Days 0-4 followed by topotecan 0.75 mg/m2/day IV over 30 minutes ± 5 minutes on Day 0-4 of every cycle. The dosing of cyclophosphamide and topotecan will be fixed.
1696452|NCT01492660|Device|echogenic needle and catheter|Visibility of needle shaft and tip with engraved markers. Ultrasonographic Visibility of catheter tip
1696453|NCT01492660|Device|Neurostimulation to position needle and catheter|The non echogenic needle will be positioned using ultrasonography and neurostimulation and the catheter will be positioned using neurostimulation with plantar or dorsiflexion with 0.6-1.5mA current. 20mL of 2% mepivacaine will be injected via the catheter. Sensory motor block will be evaluated every 5 minutes for 30 mins
1696454|NCT01492647|Drug|JNJ 10229570-AAA 1.2%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
1696455|NCT01492647|Drug|JNJ 10229570-AAA 3.6%|One single application of 2.5 mL of the cream will be applied to the face, neck, shoulders, chest and to the upper back areas.
1696456|NCT01492647|Drug|Color-matched vehicle containing 0 mg of JNJ 10229570-AAA|One single application of 2.5 mL of the color-matched vehicle will be applied to the face, neck, shoulders, chest and to the upper back areas.
1696524|NCT01492114|Dietary Supplement|Resveratrol|"Subjects in the group resvetarol first will be submitted to: 30 days of treatment with Transmax (resveratrol, 500 mg, Biotivia Bioceuticals LLC), one tablet/day in the morning at fasting; then to 30 days of wash-out (no supplementation), and then to 30 days of treatment with placebo (one tablet/day in the morning at fasting)."
1696457|NCT01492634|Other|Prescription of post-dialytic weight based on BCM device|"Prescription of post-dialytic weight target: On a weekly base, the patients are pre-dialytically measured by BCM (body composition monitor).
The time average fluid overload (TAFO) determines the target range. TAFO is defined as the mean value of pre- and post-dialytic overhydration (TAFO = (OHpre+OHpost)/2). The target range is set asymmetrically around a TAFO of 0.8, from -1.0 L to +0.5, i.e. the TAFO target range will be from -0.2 L to 1.3 L.
Prescription steps will be calculated weekly for all study patients. TAFO < -0.2 L: Increase post-dialytic weight by Cw x 0.5 kg/week, TAFO between -0.2 to 1.3 L: No action, TAFO between 1.3 to 2.8 L Decrease post-dialytic weight by Cw x 0.5 kg/week, TAFO > 2.8 L: Decrease post-dialytic weight by Cw x 1.0 kg/week."
1696458|NCT01492621|Drug|Desvenlafaxine|Desvenlafaxine 50mg from week 1-8. At week 8 optional increase to 100mg if remission has not been attained.
1696459|NCT01492608|Drug|Magnesium sulphate|Magnesium sulphate will be given as a loading dose of 5 g infused for 20-30 minutes, followed by a maintenance dose of 1 g per hour. Placebo will be given in identical appearing doses. The maintenance infusion will be continued until delivery appears, or for 24 hours if delivery does not occur or no longer is considered imminent. The infusion will be resumed when delivery is considered imminent again. Another loading dose of 5 g will be given if at least 6 hours has passed after infusion was stopped. The doses that are used in this project are similar to those used for prevention of eclampsia among women with severe preeclampsia.
1696464|NCT01492569|Procedure|electroacupuncture therapy|Undergo TAPS at sham point
1696465|NCT01492569|Other|questionnaire administration|Ancillary studies
1696466|NCT01492569|Procedure|electroacupuncture therapy|Undergo TAPS
1696467|NCT01492556|Drug|Etoposide|Lastet (Etoposide Capsules, 25mg*40 capsules/box), manufactured by Nippon Kayaku Co., Ltd.
1696468|NCT01492543|Drug|Tegafur Gimeracil Oteracil Potassium Capsule|Aiyi® (Tegafur Gimeracil Oteracil Potassium Capsule; T25mg,G7.25mg,O24.5mg*42 capsules/box), manufactured by Jiangsu Hengrui Medicine Co., Ltd.,
1696469|NCT01492530|Behavioral|Men of African American Legacy Empowering Self|Small group intervention. 6 main sessions + 2 booster sessions. Each session lasts 2 hours. Main sessions held over 3 weeks.
1696470|NCT01492530|Behavioral|Standard HIV Education & Risk Reduction|Single, individual counseling and education session. Lasting 20-30 minutes.
1696471|NCT01492517|Other|Ozone exposure|Exposure to 0.3ppm ozone for 2 hours
1696472|NCT01492517|Other|Diesel exhaust|Diesel exhaust generated from a diesel generator delivered to the exposure at a target concentration of 300 μg/m3
1696473|NCT01492517|Other|Ozone18|Exposure to ozone generated using the heavy non-radioactive isotope of oxygen (18O).
1696474|NCT01492517|Other|Clean Air|Exposure to air which has been scrubbed to remove air pollutants including ozone and particles.
1696476|NCT01492491|Device|SUPRA-HFR|usual dialytic prescription for duration, frequency, acid buffer and anticoagulation regimen.
1696477|NCT01492465|Drug|AMG 876|Ascending single doses of study drug administered SC, with one cohort administered IV
1696478|NCT01492452|Other|standardized guidelines for nursing|Information was provided regarding the preoperative preparation of the child, the same conditions and in the postoperative period, as well as information relating to housing and food for the parents. The conventional orientation took about 15 minutes.
1696479|NCT01492439|Behavioral|Cognitive Remediation|The George Brown College Redirection Through Education (RTE) is a supported education program, offered at no fee to students, that facilitates entry into formal education and employment for persons with mental illness. In addition to the supports available to all RTE students, this group will receive a total of twenty 45 minute computer-based cognitive exercise sessions held twice a week using COGPACK (Ver 6.0,www.cogpack.de). This program facilitates practice across a range of cognitive functions, including attention,psychomotor speed,memory, and executive functions. Participants will also take part in 10 weekly group discussion sessions,approximately 60 minutes in duration, focusing on strategies for management of symptoms and other cognitive deficits in an academic setting.
1696480|NCT01492439|Behavioral|Supported Education|Students enroll in credit courses, such as communications, computer skills, and the psychology of human relations which can lead to eligibility for post-secondary programs. Remedial skills in English, supervised study skills classes and other non-credit courses are included. Vocational testing is offered to help students determine their interests and aptitudes and students try out possible careers as well as their readiness to return to work by engaging in volunteer and work placements. Counsellors are also available to assist students in areas such as learning difficulties and coping with the stresses of school. The overarching goal of this program is to help students explore valued non-illness identities, build confidence, and re-engage with their communities.
1696481|NCT01492426|Drug|Daclatasvir|Film-coated tablet, oral, 60 mg, once daily, 24 weeks
1696482|NCT01492426|Drug|Telaprevir|Film-coated tablet, oral, 750 mg, 3 times daily
1696483|NCT01492426|Drug|Peginterferon alfa-2a|Solution for injection, subcutaneous injection, 180 μg, weekly
1696484|NCT01492426|Drug|Ribavirin|Film-coated tablet, oral, in a body weight stratified dose range of 1000-1200 mg per day
1696485|NCT01492413|Behavioral|online lifestyle counseling and a fortified diet beverage|The fortified diet beverage contains green tea extract (total catechin 167 mg), soluble dextrin fiber (10 g), and caffeine (100 mg).
1696486|NCT01492400|Drug|dexamethasone Intravitreal Implant|Injection of 700 ug dexamethasone intravitreal implant into the study eye on Day 1, Month 5, and Month 10.
1696487|NCT01492400|Drug|ranibizumab|Injection of ranibizumab 0.5 mg into the study eye on Day 1. Patients may receive additional injections on a monthly basis, as needed, for disease progression.
1696488|NCT01492387|Other|Discontinuation of antibiotic therapy|Patients randomized in the Individualized Arm will be treated according to clinical response: antibiotic therapy will be discontinued 48 hours after the day that the patient reaches clinical stability, with at least 5 days of total antibiotic treatment.
1696495|NCT01492348|Behavioral|STEPS UP|"The STEPS UP intervention enhances RESPECT-Mil in several ways:
Adds care manager training in motivational enhancement, problem solving, and behavioral activation strategies to improve patient engagement.
Adds preference-based stepped care (i.e., order of steps determined by symptom severity, patient preference, & primary care recommendation) to existing options of pharmacotherapy that includes web-based self-management programs; flexible, modularized telephone-delivered CBT; and individual face to face psychotherapy by specialist.
Adds option for centralized, telephone-based care management to improve fidelity of intervention delivery, continuity of care, and access to care during off-hours.
Adds a centralized care team using an electronic symptom registry to provide staffing to care managers, track patients longitudinally, develop stepped-based treatment recommendations, and monitor intervention components."
1696496|NCT01492348|Behavioral|OUC|"Service members randomized to Optimized Usual Care (OUC) will get usual treatment at the site. OUC is RESPECT-Mil, a voluntary, primary care-based implementation program based on the three-component model where, with the assistance and collaboration of a psychiatrist and an on-site nurse-level care manager, service members with symptoms of PTSD and depression are screened, tracked, and treated within the primary care system. Components of the RESPECT-Mil program include (1) equipping and training primary care clinics to screen each visit and use symptom severity tools for diagnosis and assessment; (2) using nurse care managers to assist patients and primary care clinicians; and (3) increasing access to a mental health specialist, often using a clinic specialist."
1696497|NCT01492335|Behavioral|Cognitive Report|Physicians in the Cognitive Report group receive the results of their patients cognitive assessment which includes a clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia) and treatment recommendations
1696498|NCT01492335|Behavioral|Treatment As Usual|Physicians in the Treatment As Usual group do not receive the results of their patients cognitive assessments, they are not given treatment recommendations nor are they told of the patients clinical diagnosis (Normal, Mild Cognitive Impairment, Dementia).
1696499|NCT01492322|Radiation|TRODAT|Smoker will receive a TRODAT injection
1955789|NCT03068351|Drug|RO6870810|RO6870810 will be administered subcutaneously (SC) at ascending-dose levels (from 0.30 milligrams/kilogram [mg/kg] to 0.65 mg/kg). In Cycle 1, RO6870810 will be given on Day 1 (omitted on Day 2) and then every day from Day 3 through to Day 15. Starting at Cycle 2, it will be given every day from Day 1 to Day 14 of each 21-day cycle. In the first combination therapy cohort RO6870810 will be administered at one dose-level below the maximum tolerated dose (MTD).
1955790|NCT03068351|Biological|daratumumab|Daratumumab will be administered intravenously (IV) at a dose of 16 milligrams/kilogram (mg/kg) of body weight weekly for the first 8 weeks, every two weeks for the following 16 weeks, and every four weeks thereafter, until disease progression.
1696502|NCT01492296|Procedure|endoscopy after short fasting|patients were evaluated with endoscopy after fasting for two hours
1696503|NCT01492296|Procedure|conventional fasting|patients were evaluated after fasting for 8 hours
1696504|NCT01492283|Other|OGTT|50g waterfree glucose dissolved in 300 ml water consumed over 5 min.
1696505|NCT01492283|Other|IIGI|iso glycemic intravenous (iv) glucose infusion (IIGI) with 20% glucose
1696506|NCT01492270|Procedure|Prostate HistoScanning|Advanced Ultrasound assessment of the prostate
1696507|NCT01492270|Procedure|Multi-parametric MRI|Multi-sequence Magnetic resonance imaging of the prostate
1696508|NCT01492270|Procedure|Transperineal prostate mapping biopsy|Needle biopsy of the perineum via the transperineal route at 5mm intervals guided by the use of ultrasound.
1696509|NCT01492270|Procedure|Image guided biopsies|Biopsies targeted to lesions seen at a) Prostate HistoScanning and b) mp-MRI. In men with an MRI lesion further MRI/US registration biopsies will be obtained
1696510|NCT01492257|Other|Shared Decision Making Intervention|Digital video discs and booklets produced by the Foundation for Informed Medical Decision Making and Health Dialog; a question-prompting phone call with a trained health coach; audio-recordings of the patient-surgeon consultation; and a copy of the surgeon's dictated note.
1696511|NCT01492218|Drug|biphasic human insulin 30|Administered via the NovoLet® device and according to the instructions in the product insert or as instructed by the physician. Individually adjusted dosage as instructed by the physician.
1696512|NCT01492205|Drug|insulin human|All subjects were treated with human insulin administered either by using the NovoLet® pre-filled insulin system or the conventional vial and syringe method. Doctors and nurses must personally administer at least 10 insulin doses to each patient under their individual clinical supervision for assessment of the NovoLet® pre-filled insulin system
1696514|NCT01492179|Drug|Normal saline|Normal saline would be administered intravenously and intra-abdominally.
1696515|NCT01492179|Drug|Intravenous Lidocaine|Standardized infusion of lidocaine during 24 h. 100 mg bolus and 50 mg/h during 24 h would be administered.
1696516|NCT01492179|Drug|Intra-abdominal Lidocaine|Lidocaine 5 mg/ml; 100 mg would be administered intraoperatively intra-abdominally and subsequently 50 mg/h as intermittent injection intra-abdominally during 24 h
1696517|NCT01492166|Drug|biphasic human insulin 30|Dose and timing of dose for each subject was at the discretion of the attending physicians based on current clinical practice guidelines
1696518|NCT01492153|Drug|biphasic human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
1696519|NCT01492153|Drug|isophane human insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
1696520|NCT01492153|Drug|human soluble insulin|NovoLet® device delivering human insulin. Selection of drug and timing of dose for each patient was at the discretion of the investigator
1955791|NCT03067727|Drug|Dinoprostone|The DVI contains 10 mg Dinoprostone
1955792|NCT03067727|Drug|Placebo|The placebo product is identical with the active product except that it does not contain Dinoprostone.
1696523|NCT01492127|Biological|Blood test|Blood test
1696584|NCT01491581|Dietary Supplement|food bar|milk based food bar enriched with micronutrients
1696525|NCT01492114|Dietary Supplement|resveratrol|"Subjects in the group Placebo first will be submitted to: 30 days of treatment with placebo, one tablet/day in the morning at fasting; than to 30 days of wash-out (no supplementation), and then to 30 days of treatment with Transmax (resveratrol, 500 mg) (one tablet/day in the morning at fasting)."
1696526|NCT01492101|Drug|NKTR-102|145 mg/m2 NKTR-102 will be delivered q21day as a 90 minute intravenous (IV) infusion on day 1 of each treatment cycle.
1696527|NCT01492101|Drug|Treatment of Physician's Choice (TPC)|"One of the following Treatment of Physician Choice will be administered per standard of care:
eribulin ixabepilone vinorelbine gemcitabine paclitaxel docetaxel or nab-paclitaxel"
1696528|NCT01492088|Drug|Brentuximab vedotin|Brentuximab vedotin IV infusion
1696529|NCT01492075|Drug|PCRA (Intermittent injection)|Intermittent injection of LA intraabdominally
1696530|NCT01492062|Device|Multiple Model Predictive Controller|Use of closed loop algorithm in an inpatient environment while closely monitoring blood glucose levels.
1696531|NCT01492049|Behavioral|CRCS patient decision aid (PtDA) video|Participant views PtDA program video in same room as research assistant who offers instruction as needed.
1696532|NCT01492049|Behavioral|Questionnaires|Up to 3 questionnaires (baseline demographics, post-intervention evaluation, and follow up) taking from 5 to 25 minutes to complete each.
1696533|NCT01492049|Behavioral|Essential Hypertension video|Participant views Essential Hypertension video in same room as research assistant who offers instruction as needed.
1696534|NCT01492036|Other|Blood Tests|If participant received retroviral gene therapy, blood test performed to check for a type of infection called the replication-competent retrovirus (RCR). Blood (up to 4 tablespoons each time) drawn every 3 months for first year after gene transfer therapy and once a year after that.
1696535|NCT01492036|Behavioral|Questionnaires|"Once a year during Years 1-5, questionnaire completions that asks about medical history (general health, the status of any medical conditions, and any illnesses or hospitalizations that may have occurred). It should take about 15-30 minutes to complete.
Once a year during Years 6-15, completion of mailed questionnaire. Participant will be asked about medical history (including if participant has had any children since the infusion) and whether there have been any changes in contact information. The questionnaires should take about 15-30 minutes each time."
1696536|NCT01492023|Behavioral|neuropsychological rehabilitation|attention retraining and teaching compensatory strategies as well as offering psychological support to better cope with cognitive impairments (13 times 60 minutes, once per week during 13 weeks)
1696537|NCT01492010|Dietary Supplement|whey protein|25 g whey protein
1696538|NCT01492010|Dietary Supplement|whey protein supplemented with leucine|6.25 g whey protein supplemented with free form leucine
1696539|NCT01492010|Dietary Supplement|whey protein supplemeted with essential amino acids|6.25 g whey protein supplemented with essential amino acids devoid of leucine
1696540|NCT01491997|Behavioral|Mind/Body Medicine Course 1|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through experiences. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
1696541|NCT01491997|Behavioral|Mind/Body Medicine Course 2|The subject of the course is Mind/Body medicine. This course is learning about the mind and the body through lectures. The course will meet once every week, for a total of 8 weeks, for roughly 2 hours per class. You will be provided with a schedule of the weekly classes, which will occur on the same day every week, at the same time. Weekly sessions will be run by a teacher and will include other participants in the class. You will also be given homework assignments that are intended to reinforce what you learn in the program. The assignments will require up to 45 minutes, 6 days/week. Following the 6th class, and before the 7th class, there is a voluntary all day Saturday program. Participation in this program is optional. You are expected to continue to incorporate what you learned in the class in your daily routine after you are done with the classes.
1696542|NCT01491984|Device|Laryngoscopy order: 1) MAC, 2) Levitan|Laryngoscopy with MAC, then Levitan
1696543|NCT01491984|Device|Laryngoscopy order: 1) Levitan, 2) MAC|Laryngoscopy with Levitan, then MAC
1696544|NCT01491971|Drug|Degarelix|
1696548|NCT01491945|Device|Ventana Fenestrated Stent Graft System|"The Ventana Fenestrated Stent Graft System consists of the following:
bifurcated stent graft, Ventana fenestrated proximal extension stent graft, and Xpand renal stent grafts"
1696549|NCT01491932|Drug|AFQ056|AFQ056 will be supplied as oral capsules.
1696550|NCT01491919|Drug|Lisinopril|Subjects will be randomized to Low, Medium, or High dose of Lisinopril
1696551|NCT01491906|Behavioral|Text Messaging and Behavior Counseling|"Participants randomized to the intervention arm will receive a series of components, delivered over 6 months: personalized behavior change goals to be self-monitored via text messaging, group starter counseling sessions, and personalized individual counseling. Each participant will also receive a pedometer to facilitate self-monitoring."
1696552|NCT01491893|Biological|PVSRIPO|PVSRIPO will be delivered in a single infusion directly into the tumor via catheter placed at the time of biopsy. The current dose level is dose level minus one (5 x 10^7 TCID50 (tissue culture infectious dose)).
1696553|NCT01491880|Behavioral|Therapist-Assisted by Telephone|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
1696554|NCT01491880|Behavioral|Self-Help|Parents will receive educational workbooks to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries independently. Parents will have the option to access support over the phone from a child anxiety specialist.
1696555|NCT01491867|Drug|travoprost 0.003%|Instillation of travoprost 0.003% 1/die in both eyes for 3 months
1696556|NCT01491854|Other|Bloodsampling|Bloodsampling
1696558|NCT01491828|Device|Kai Strap|Medical device component that vibrates on a subject's neck.
1696559|NCT01491815|Drug|Non-biological DMARD's|Methotrexate: 25mg/week. SSZ: 2 g/day. HCQ: 35 mg/kg/week (Finland and Denmark) Methotrexate: 25mg/week. Prednisolone 20 mg/day tapered in 9 weeks to 5 mg/day, discontinued after 9 months. (Sweden, Norway, and Iceland)
1696560|NCT01491815|Biological|Cimzia|Certolizumab-pegol: 200 mg s.c. every other week. Methotrexate: 25mg/week
1696561|NCT01491815|Biological|Orencia|Abatacept: 125 mg s.c. every week. Methotrexate: 25mg/week
1696562|NCT01491815|Biological|RoActemra|"Tocilizumab is given as 4-weekly infusions at dosage 8 mg/kg or 162 mg in solution s.c. every week.
Methotrexate: 25mg/week"
1696563|NCT01491802|Drug|LAMA/LABA|GSK573719/GW642444 inhalation powder used in the Novel Dry Powder Inhaler (DPI): a long-acting beta2-agonist (GSK642444, 25mcg) with a long-acting muscarinic antagonist (GSK573719, 125mcg) combination therapy will be taken once daily for 4 weeks.
1696564|NCT01491802|Drug|LAMA|GSK573719 (125mcg) inhalation powder is a long-acting muscarinic antagonist that will be taken once daily for 4 weeks
1696565|NCT01491789|Device|The VSail-Access simulator|You will be transferred to the VSail cockpit and secured. Following the trainer's instruction, you will sail the simulator around virtual courses displayed on a computer screen, using a joystick to control the rudder angle and a mainsheet to control the set of the sail. You will do this for 1 hour.
1696566|NCT01491763|Drug|Imatinib|600 mg p.o. from day 1 until consolidation
1696567|NCT01491750|Behavioral|GUIDED IMAGERY|DAILY LISTENING TO A GUIDED IMAGERY CD FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
1696568|NCT01491750|Behavioral|PLACEBO|DAILY LISTENING TO AN AUDIO BOOK SEGMENT FOR 2 WEEKS BEFORE AND 3 WEEKS AFTER SURGERY
1696569|NCT01491737|Drug|Pertuzumab|Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.
1696570|NCT01491737|Drug|Trastuzumab|Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.
1696571|NCT01491737|Drug|Aromatase Inhibitor|Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.
1696572|NCT01491737|Drug|Induction Chemotherapy|Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.
1696573|NCT01491711|Drug|Methylaminolevulinate PDT in 2 sessions|The methylaminolevulinate creme is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm, 570-670 nm, 75 J/cm2). The light intensity at the lesion surface should not exceed 200 mW/cm2. During illumination a fan is used to cool the treatment site. After the first treatment the skin area is covered to prevent exposure to daylight during 48 hours. After one week (on day 8), the same procedure is repeated. After the treatment the skin area is covered to prevent exposure to daylight during 48 hours. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs.
1696574|NCT01491711|Drug|Fractionated 5-aminolevulinic acid hydrochloride 20% gel PDT|The 5-ALA HCl 20% gel is applied to the tumour with a margin of 1 cm, ± 1-2 mm thick. Tegaderm®, a gauze and tinfoil is placed over the area to prevent contact with UV light. After 4 hours the area is illuminated with Aktilite (632 nm). During illumination a fan is used to cool the treatment site. The treatment site is covered again with Tegaderm for 2 hours after first treatment, whereupon a second illumination with the same light takes place. A side-effect of the treatment is a burning pain during illumination and slight erythema afterwards lasting a few days. Sometimes blistering occurs. Patients are advised to avoid direct sunlight two days after treatment.
1696575|NCT01491698|Procedure|Roux-en-Y pouch reconstruction (RYP)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
1696576|NCT01491698|Procedure|conventional Roux-en-Y reconstruction (RYC)|Patients will be consented to the study and complete pre-surgical questionnaires. Final randomization will occur once the surgeon in the operating room has confirmed eligibility intraoperatively. The envelope will be opened, and the patient randomized to either receive RYP or RYC. There are no restrictions on how surgeons may create the RYC or RYP reconstruction, except that the pouch must be a minimum of 15 cm in length (from esophago-jejunal anastomosis to end of jejuno-jejunal anastomosis).
1696577|NCT01491672|Drug|RAD001|Study drug was supplied as 5 mg tablets in blister packs.
1696578|NCT01491659|Dietary Supplement|Idoform Plus|orally once daily
1696579|NCT01491659|Dietary Supplement|Placebo|orally once daily
1696580|NCT01491633|Drug|Dasatinib|140 mg orally, daily in 28 day cycles
1696581|NCT01491620|Device|532 nm KTP laser|Two laser treatment sessions, 6 weeks apart.
1696582|NCT01491607|Biological|BioThrax|BioThrax, 0.5 mL administered subcutaneously on days 0, 14, and 28.
1754955|NCT00236704|Drug|topiramate|
1955800|NCT03063892|Drug|Tranexamic Acid (TXA)|Tranexamic acid is an antifibrinolytic used to control bleeding
1696585|NCT01491568|Device|rhBMP-2/CRM/CD HORIZON® Spinal System|rhBMP-2/CRM with the CD HORIZON® SpinalSystem
1696586|NCT01491542|Device|INFUSE® Bone Graft/MASTERGRAFT® Granules/CD HORIZON®|The INFUSE® Bone Graft component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2(rhBMP-2) and an absorbable collagen sponge (ACS)carrier. The MASTERGRAFT® Granules will be used as a type of bulking agent to provide compression resistance.
1696587|NCT01491542|Device|Autogenous Bone / CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System.
1696588|NCT01491529|Drug|AFQ056|"AFQ056 will be supplied as oral modified release tablets in 25 mg, 50 mg, 100 mg, 150 mg, and 200 mg.
Patients will be randomized in two groups by amantadine status.
Group 1: Patients are not permitted to take amantadine within 2 weeks prior to the BL1 visit.
Group 2: Patients must be on a stable and well tolerated dose of amantadine for at least 4 weeks prior to BL1 and must maintain the stable dose of amantadine during the remainder of the study.)"
1696589|NCT01491529|Drug|Placebo|Placebo for AFQ056 will be supplied as oral tablets.
1696590|NCT01491516|Device|TELAMON P™ /INFUSE® Bone Graft/CD HORIZON® Spinal System|The TELAMON P™/INFUSE™ Bone Graft Implant in conjunction with the CD HORIZON® Spinal System for single level lumbar fusion from L1 to S1
1696591|NCT01491503|Drug|Levocetirizine|Levocetirizine dihydrochloride 5mg. PO. Single dose.
1696592|NCT01491503|Drug|montelukast sodium|Montelukast sodium 10mg. PO. Single dose.
1696593|NCT01491503|Drug|Montelukast & levocetirizine|Montelukast sodium 10mg & levocetirizine dihydrochloride 5mg PO. Single dose.
1696594|NCT01491490|Drug|GWP42003 : GWP42004 (40:1)|Capsules taken once a day for 6 weeks
1696595|NCT01491490|Drug|Placebo|Capsules taken once a day for 6 weeks
1696596|NCT01491477|Device|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
1696597|NCT01491477|Device|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
1696598|NCT01491464|Device|rhBMP-2/ACS/INTER FIX™|The INTER FIX™ device containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS).
1696599|NCT01491464|Device|Autogenous bone/INTER FIX™|The INTER FIX™ device containing autogenous bone taken from the patient's iliac crest.
1696600|NCT01491451|Device|rhBMP-2/ACS/INTERFIX™|INTERFIX™ device containing recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and the absorbable collagen sponge (ACS) carrier.
1696601|NCT01491451|Device|Autogenous bone/INTERFIX™|INTERFIX™ device containing autogenous bone taken from the patient's iliac crest.
1696602|NCT01491438|Procedure|PRGF+ Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|"PRGF once a week (day 1) and conventional treatment twice a week (days 1 and 4)during 12 weeks.
Types of dressing: enzyme cutting dressing (collagenase), hydrogel, polymeric foam, alginate dressing, hydrocolloid hydrofiber dressing, silver dressing, coal and silver dressing, argentum sulfadiazine dressing, polyurethane or caster hydrocolloid dressing"
1696603|NCT01491438|Procedure|Cleaning, debridement of the wound, application of the corresponding dressing and using of antibiotics if necessary|Twice a week (days 1 and 4) during 12 weeks
1696604|NCT01491425|Device|rhBMP-2/ACS//LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
1696605|NCT01491425|Device|Autogenous Bone//LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
1696606|NCT01491399|Device|INFUSE™ Bone Graft/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone containing recombinant human Bone Morphogenetic Protein (rhBMP-2) soaked into an absorbable collagen sponge (ACS) used in conjunction with ATLANTIS™ anterior cervical plate system.
1696607|NCT01491399|Device|Autogenous bone/CORNERSTONE-SR™ /ATLANTIS™|Cornerstone-SR™ allograft bone packed with autogenous iliac crest bone graft used in conjunction with ATLANTIS™ anterior cervical plate system.
1696608|NCT01491386|Device|rhBMP-2/ACS/LT-CAGE® Device|LT-CAGE® device with recombinant human bone morphogenetic protein-2 ( rhBMP-2) and the absorbable collagen sponge (ACS).
1696609|NCT01491386|Device|Autogenous Bone/LT-CAGE® Device|LT-CAGE® device with autogenous bone taken from the iliac crest.
1696610|NCT01491373|Device|rhBMP-2/ACS/LT-CAGE® Device|rhBMP-2/ACS inserted into Sofamor Danek's LT-CAGE® device.
1696611|NCT01491373|Device|Autograft/LT-CAGE® Device|LT-CAGE® device filled with autogenous bone taken from the patient's iliac crest
1696612|NCT01491360|Procedure|LaserACE(R)|Partial depth scleral micro-excisions with an Er:YAG laser in a predetermined pattern.
1696613|NCT01491321|Procedure|Bee Venom Acupuncture Therapy|"Bee Venom 1:20,000 under BVA Increment Protocol
Increment Protocol as
1st week : SC 0.2cc/day, 2days/week
2nd week : SC 0.4cc/day, 2days/week
3rd week : SC 0.8cc/day, 2days/week"
1696614|NCT01491321|Drug|Loxoprofen|60 mg/Tab, pers os 1Tab tid, for 3 weeks
1696615|NCT01491321|Procedure|Placebo|"Normal Saline (0.9% NaCl) under NS Increment Protocol
Increment Protocol as
1st week : SC 0.2cc/day, 2days/week
2nd week : SC 0.4cc/day, 2days/week
3rd week : SC 0.8cc/day, 2days/week"
1696616|NCT01491308|Other|Red blood cells transfusion|This transfusion policy holds to any time from the start of surgery until discharge. The physicians caring for the patient will be instructed to administer transfusion, one unit at a time, and to measure the patient's hemoglobin concentration after each unit is transfused. In both groups, no further units will be given if the goal hemoglobin was obtained (7.5 g per deciliter for the restrictive arm and 10.0 g per deciliter for the liberal one). All other management decisions are left to the discretion of the patients' physicians. Attending physicians can administer RBC transfusions outside the rules of the protocol (i.e more than 1 unit at a time, without determining pre-transfusion hemoglobin) if severe acute bleeding occurs or other forms of circulatory shock.
1696617|NCT01491295|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate 300mg QD for 36 months (adjust dosage according to renal function)
1696618|NCT01491295|Drug|Lamivudine plus adefovir|Lamivudine 100mg QD for 36 months (adjust dosage according to renal function) Adefovir 10mg QD for 36 months (adjust dosage according to renal function)
1696620|NCT01491269|Behavioral|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
1955801|NCT03063892|Drug|Saline solution|Saline solution is used as the placebo comparator
1696623|NCT01491243|Drug|Intensive treatment with sodium bicarbonate|i.v., sodium bicarbonate (3 ml/kg/h for 1 hour, then 1 ml/kg/h for 7 h) followed by i.v. saline for 48 h in case of abnormal NGAL findings
1696624|NCT01491243|Drug|Standard treatment with saline infusion|i.v. 1 ml/kg/h saline infusion for 48 h in case of abnormal NGAL findings
1696627|NCT01491191|Dietary Supplement|Palmitoylethanolamide|Before surgery: 600 mg cp twice a day After surgery: 600 mg microgranules twice a day for 10 days then 600 mg cps once a day for 20 days
1696628|NCT01491191|Dietary Supplement|Placebo|Before surgery: 1 sugar pill twice a day for 8 days After surgery: 1 sugar microgranules twice a day for 10 days then 1 sugar pill once a day for 20 days
1696630|NCT01491165|Procedure|stem cell transplantation through interventional procedures|one time interventional procedures
1696631|NCT01491152|Device|Galileo® tilt table for children|Two weeks of introduction and 12 weeks of training with side-alternating whole body vibration (WBV) (Galileo® tilt table)
1696632|NCT01491139|Drug|olaparib|Given twice daily. Exposure will escalate by daily dose and duration.
1696633|NCT01491139|Drug|cisplatin|Dose will be 35mg/m2 i.v. once weekly.
1696634|NCT01491139|Radiation|Intensity Modulated Radiotherapy|Total dose will be 70Gy in 35 fractions over 7 weeks.
1696635|NCT01491113|Drug|Levetiracetam 250 mg|Tablet containing Levetiracetam 250 mg
1696636|NCT01491113|Drug|Levetiracetam 500 mg|Tablet containing Levetiracetam 500 mg
1696637|NCT01491100|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose subcutaneously administered, according to the label and to clinical routine practice.
1696638|NCT01491087|Biological|DTacP IPV//PRP~T combined vaccine: PENTAXIM®|0.5 mL, Intramuscular
1696639|NCT01491074|Drug|Tocilizumab 280 mg|Intravenous administration of 280 mg Tocilizumab (14 ml), mixed with 86 ml 0.9% NaCl
1696640|NCT01491074|Drug|NaCl 0.9% 100 ml|Placebo
1696641|NCT01491061|Drug|Ranolazine|os, 1,000 mg twice 12 hours apart prior to PCI
1696642|NCT01491061|Drug|Placebo|os, two doses 12 hours apart prior to PCI
1696643|NCT01491048|Procedure|THA Physiotherapy|Patients will be randomized into two groups. The control group will receive care from the team of the THA Assistance Protocol already used by the HSG of HCPA without the intervention of physiotherapy. During hospitalization, the group of cases will be submitted to physical therapy associated with the intervention of the team of the THA Assistance Protocol.
1696644|NCT01491048|Procedure|No physiotherapy after THA|No physiotherapy after THA
1696645|NCT01491035|Drug|Vortioxetine|5 mg tablets for 14 days; orally; once daily
1696646|NCT01491035|Drug|Vortioxetine|10 mg tablets for 14 days (initial up-titration with 5 mg/day for 2 days); orally; once daily
1696647|NCT01491035|Drug|Vortioxetine|15 mg tablets for 14 days (initial up-titration with 5 and 10 mg/day for a total of 4 days); orally; once daily
1696648|NCT01491035|Drug|Vortioxetine|20 mg tablets for 14 days (initial up-titration with 5, 10, and 15 mg/day for a total of 6 days); orally; once daily
1696649|NCT01491022|Drug|Ampyra first, then Placebo|10 mg po bid for 4 weeks followed by placebo 4 weeks.
1696650|NCT01491022|Drug|placebo first, then Ampyra|placebo
1696651|NCT01491009|Drug|Remifentanil|IV infusion
1696652|NCT01491009|Drug|Midazolam|IV infusion
1696653|NCT01490996|Drug|Oral complex C3 curcumin + chemotherapy|Daily oral capsule(s)
1696654|NCT01490996|Drug|Chemotherapy only|Standard care chemotherapy
1696655|NCT01490983|Behavioral|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
1696656|NCT01490983|Behavioral|eMedonline access|patients will be given access to eMedonline use for 3 months
1696657|NCT01490970|Other|Database|Database
1696658|NCT01490957|Other|Database|Database
1696659|NCT01490944|Drug|Iron, Folic acid and Cyanocobalamin|"Total duration= 6 months Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 500 mcg weekly supplementation in the form of capsule for 6 weeks
Iron=100 mg, Folic acid= 500 mcg, Cyanocobalamin 15 mcg weekly supplementation in the form of capsule for next 20 weeks"
1696660|NCT01490944|Drug|Iron and Folic Acid|Iron= 100 mg, Folic acid= 500 mcg weekly supplementation in the form of capsule for 6 months
1696661|NCT01490931|Drug|Ketorolac Nasal Spray|15.75 mg nasal spray delivery to each nostril no more than every six hours
1696662|NCT01490918|Drug|Acarbose|The dose of Acarbose or its placebo should be 50mg b.i.d at first. At the 2nd week and the 4th week, it should be 50mg t.i.d and 100mg t.i.d respectively
1696663|NCT01490905|Other|Theramine (A medical food)|Theramine two capsules twice daily for 28 days.
1696664|NCT01490905|Drug|Theraprofen|Theramine two capsules twice daily and ibuprofen 400mg once daily for 28 days.
1696665|NCT01490905|Drug|Ibuprofen|Ibuprofen 400mg once daily for 28 days.
1696667|NCT01490879|Drug|Nexagon® Low Dose|Twice weekly, topical application of Nexagon® low dose in addition to a Removable Cast Walker
1696668|NCT01490879|Drug|Nexagon® Medium Dose|Twice weekly, topical application of Nexagon® medium dose in addition to a Removable Cast Walker
1696669|NCT01490879|Drug|Nexagon® High Dose|Twice weekly, topical application of Nexagon® high dose in addition to a Removable Cast Walker
1696670|NCT01490879|Drug|Nexagon® vehicle|Twice weekly, topical application of Nexagon® vehicle in addition to a Removable Cast Walker
1696671|NCT01490866|Drug|Axitinib|5-mg tablets PO BID
1696672|NCT01490866|Drug|Bevacizumab|5 mg/kg Days 1 and 15; IV
1696674|NCT01490866|Drug|5-Fluorouracil|2400 mg/m2 over 46-48 hours Days 1 and 15; Continuous Intravenous
1696675|NCT01490866|Drug|Leucovorin|400 mg/m2 Days 1 and 15; IV
1696676|NCT01490866|Drug|Oxaliplatin|85 mg/m2 Days 1 and 15; IV
1696677|NCT01490853|Drug|Interpheron alpha|Long term outcom after interferon alpha discontinuation or not
1696678|NCT01490840|Other|Physical exercise|Strength training exercises are performed against own body weight or with training aids like elastic rubber bands or gym balls. All exercises are home-based. To increase balance and core stability, a subset of exercises is performed on shaky ground and/or one-legged. Exercise intensity, duration and frequency are individually assigned by a sports therapist. For each muscle group, a set of exercises of increasing difficulty allows for individual and progressive training adaption. Therapists can choose from an exercise database of approximately 150 different strength exercises with different graduation.
1955807|NCT03061110|Biological|Stromal Vascular Fraction|Stromal Vascular Fraction will be produced from the subject's own adipose tissue by the Tissue Genesis Icellator device.
1696681|NCT01490801|Genetic|DNA analysis|
1696682|NCT01490801|Genetic|RNA analysis|
1696683|NCT01490801|Genetic|cytogenetic analysis|
1696684|NCT01490801|Genetic|in situ hybridization|
1696685|NCT01490801|Genetic|mutation analysis|
1696686|NCT01490801|Genetic|polymerase chain reaction|
1696687|NCT01490801|Genetic|western blotting|
1696688|NCT01490801|Other|flow cytometry|
1696689|NCT01490801|Other|immunohistochemistry staining method|
1696690|NCT01490801|Other|medical chart review|
1955808|NCT03061110|Other|Usual Care|Usual care will include over-the-counter and prescription methods to treat xerostomia.
1696694|NCT01490775|Behavioral|no access to eMedonline|patients will be followed for 3 months but will not use eMedonline
1696695|NCT01490775|Behavioral|eMedonline access|patients will be given access to eMedonline use for 3 months
1696696|NCT01490762|Drug|Technosphere Insulin Inhalation Powder using the Gen2C inhaler|Inhalation Powder
1696697|NCT01490762|Drug|Regular Human Insulin|Subcutaneous injection
1696698|NCT01490749|Drug|RAD001|Dose escalation for Phase I; dose for Phase II to be determined after Phase I is completed.
1696699|NCT01490749|Drug|XELOX|Patients will receive two cycles of XELOX.
1696700|NCT01490749|Drug|Carboplatin|Given on a 3 weeks on and 1 week off schedule.
1696701|NCT01490749|Radiation|Radiation|1.8 Gy to 36 Gy; 3 fields or laterals to 50.4 Gy.
1696702|NCT01490736|Drug|Lemuteporfin|lemuteporfin topical solution, 1%
1696703|NCT01490723|Drug|Rituximab|250 mg/m2 by vein preceding 111In Ibritumomab and (90Y) ibritumomab tiuxetan administration, respectively on Days -22 and -14.
1696704|NCT01490723|Drug|111In Ibritumomab|(5.0 mCi +/- 10% of 111In) by vein immediately following the infusion of rituximab on Day -22.
1696705|NCT01490723|Procedure|Planar Scintigraphy Imaging|Day -22, -21 to -16: Planar scintigraphy whole-body imaging started on Day -22 post 111In Ibritumomab infusion prior to voiding, and repeated 3-6 hours later (including Single Photon Emission-Computed Tomography/Computed Tomography (SPECT/CT) scan of the abdomen). Whole-body planar scintigraphy imaging will be repeated between 22-26 hours, then between 70-74 hours, and later between 142-146 hours post 111In Ibritumomab injection.
1696706|NCT01490723|Drug|90Y IbritumomabTiuxetan|Calculated to deliver not below 10 Gy to normal organs (liver, lungs, kidneys) by vein post rituximab on Day -14.
1696707|NCT01490723|Drug|Fludarabine|30 mg/m2 intravenously on Days -5, -4, and -3.
1696708|NCT01490723|Drug|Bendamustine|130 mg/m2 intravenously on D-5, -4 and -3.
1696709|NCT01490723|Drug|Thymoglobulin|1 mg/kg (based on actual body weight) on Days -2 and -1 will be administrated to patients receiving a cord blood (CB) and a matched unrelated donor (MUD).
1696710|NCT01490723|Drug|Tacrolimus|"Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus is changed to oral dosing when tolerated and can be tapered off after day +90 if no Graft versus Host Disease (GVHD) is present.
For patients receiving cord blood (CB) graft, the Graft versus Host Disease (GvHD) prophylaxis will be with Tacrolimus. Tacrolimus will start on D-2 administrated at starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on D -2 and will be tapered around Day +180 if no GvHD is present."
1696711|NCT01490723|Drug|Methotrexate|5 mg/m2 by vein on Day +1, +3 and +6. Patients receiving an unrelated graft will also be given methotrexate on Day +11 after the transplant.
1696712|NCT01490723|Drug|Mycophenolate|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth administered from Days -3 to +45 and then tapered to end by day 100 if there is no Graft versus Host Disease (GVHD).
1696713|NCT01490723|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning Day +7 for patients receiving related and matched unrelated donor (MUD) grafts and on Day 0 for patients receiving a cord blood (CB). G-CSF will continue until the absolute neutrophil count (ANC) is > 500 * 10/L for 3 consecutive days.
1696714|NCT01490723|Procedure|Stem Cell Transplantation|Stem Cell Transplantation on Day 0
1696715|NCT01490710|Other|collection of clinical and biological parameters|Investigation focal lies in hemodynamic monitoring during the last 10 minutes (Cardiac Index Assessment and clinico-biological parameters as: ventilatory and respiratory parameters, NIRS, GDS, Omega Score, heart rate, blood pressure, lactate, BNP, perfusion coefficient…)
1696716|NCT01490710|Other|assign optimal ventilatory mode|End of study: At the end of the second session, clinician will assign optimal ventilatory mode regarding patient clinical response.
1696863|NCT01489683|Drug|lidocaine|3 ml of 4% lidocaine was instilled to larynx and trachea
1955812|NCT03058627|Procedure|PCI|FFR guided PCI
1696717|NCT01490697|Drug|Mifepristone|1800 mg tablet, single dose 90 minutes prior to script preparation on Day 7.
1696718|NCT01490697|Drug|d-Cycloserine|100 mg capsule, single dose, taken 4 hours prior to to mifepristone on Day 7.
1696719|NCT01490697|Drug|Placebo-matching Mifepristone|Placebo-matching mifepristone tablets
1696720|NCT01490697|Drug|Placebo-matching d-Cycloserine (DCS)|Placebo-matching DCS capsules
1696721|NCT01490671|Drug|1% tenofovir gel|One applicator of 1% tenofovir gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
1696722|NCT01490671|Drug|Placebo gel|One applicator of placebo gel will be inserted by the participant into the vagina once each day for 28 days or until delivery, whichever comes first
1696723|NCT01490658|Drug|repaglinide|Single dose of 2 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with metformin as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
1696724|NCT01490658|Drug|metformin|Single dose of 500 mg tablets administered immediately prior to a standard high fat breakfast concomitantly with repaglinide as separate tablets. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
1696725|NCT01490658|Drug|repaglinide and metformin combination tablet|Single dose of 2 mg repaglinide/500 mg metformin (NN4440 2/500) or 1 mg repaglinide/500 mg metformin (NN4440 1/500)administered immediately prior to a standard high fat breakfast. Subjects will be randomised to receive trial drug on 3 separate dosing visits in varying order out of 6 possible treatment periods
1696726|NCT01490632|Drug|Placebo|Administered orally
1696727|NCT01490632|Drug|Baricitinib|Administered orally
1696728|NCT01490619|Behavioral|Healthy Thinking In Teens|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
1696729|NCT01490619|Other|Advanced Diabetes Education.|9 sessions. Manualized and group based program. Each session lasts 90 minutes. Sessions occur approximately every other week.
1696730|NCT01490606|Other|knee OA project|"physical therapy in OA Knee project, total of 12 sessions, 6 group therapies amd 6 one on one therapy."
1696731|NCT01490606|Other|conventional PT|12 SESSIONS OF CONVENTIONAL PHYSICAL THERAPY
1696732|NCT01490593|Behavioral|Public Health strategies|It is hoped that by recording of the data (i.e. locations and mechanisms of eye injuries), we may be able to develop public health strategies to prevent further injuries. For example, encouraging more visor wear in hockey games if we notice increased prevalence of hockey eye injuries with no visor.
1696733|NCT01490580|Drug|atropine+ propofol|Atropine bolus: 20 µg/kg Propofol injected over 60 seconds: 1 mg/kg for infants < 1000g - Renewable once 2.5 mg/kg for infants > 1000G - Possible additional dose of 1 mg/kg
1696734|NCT01490580|Drug|atropine + atracurium + sufentanil|Atropine bolus: 20 µg/kg Atracurium: 0.3 mg/kg- Possible additional dose of 0.1 mg/kg Sufentanil: 0.1 µg/kg for infants < 1000g 0.2 µg/kg for infants > 1000g
1696735|NCT01490567|Drug|Donepezil|5 mg/day
1696736|NCT01490567|Drug|placebo|placebo 5mg/d
1696737|NCT01490554|Procedure|autologous fibroblasts grafts|Autologous cultured fibroblasts will be grafted in facial skin
1696738|NCT01490515|Procedure|non-invasive metabolomic profiling|non-invasive metabolomic profiling of IVF human embryos
1696739|NCT01490515|Other|morphological evaluation|Simple microscopic observation of embryos and evaluation of morphological characteristics
1696740|NCT01490502|Drug|Vitamin D3|Patients will be assigned to low dose (600 IU/day) versus high-dose (5000 IU/day) of vitamin D3 as an add-on therapy to glatiramer acetate (Copaxone).
1696741|NCT01490489|Other|blood sample and doppler Ultrasound of uterine arteries|"36 ml of blood samples (serum and plasma) will be collected
After a bed rest supine for 15 minutes, ultrasound Doppler from each of the uterine arteries will be performed to search for Notch"
1696742|NCT01490476|Drug|RAD001|10 mg per os / day or 05mg per os / day with 12 month
1696743|NCT01490450|Biological|Placebo matching BMS-945429|Injection, Subcutaneous, 0 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
1696744|NCT01490450|Biological|BMS-945429|Injection, Subcutaneous, 25 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
1696745|NCT01490450|Biological|BMS-945429|Injection, Subcutaneous, 100 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
1696746|NCT01490450|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, every 4 weeks, Short term:24 weeks, Long term: After 24 Wk, selected dose, open-label
1696747|NCT01490437|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes on D1 every 3 weeks
1696748|NCT01490437|Drug|Cisplatin|Cisplatin 70 mg/m2 IV over 60 minutes on D1 every 21 days
1696749|NCT01490437|Drug|Dexamethasone|Dexamethasone 4 mg bid PO from D-1 to D2 every 3 weeks
1696750|NCT01490437|Drug|Vitamins|Folic acid 350 ug - 600 ug daily from D-7 daily vitamin B12 1,000 ug every 9 weeks from D-7
1696751|NCT01490411|Drug|Placebo|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
1696752|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
1696753|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
1696754|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
1696755|NCT01490411|Biological|rBet v1-FV|The drug tested in this study (rBet v1-FV) was given as a subcutaneous (just under the skin) injection. Patients received at least 10 injections of Placebo or rBet v1-FV, administered in increasing doses weekly for 10 weeks, up to one of the maximum concentrations.
1696969|NCT01488929|Drug|Placebo|
1696756|NCT01490398|Drug|Rosuvastatin|After baseline assessment, the starting dose of rosuvastatin 10 mg will be given to study patients. If tolerated and LDL-C is > 100mg/dL after 2-4 weeks, the dose will be increased to 20 mg. Rosuvastatin treatment is scheduled to continue for 1 year without no further dose titration, and each patient will be followed at 2 months, 6 months and 1 year.
1696757|NCT01490385|Device|LED Phototherapy|
1696760|NCT01490346|Drug|Initiation of anti-retroviral therapy|Subjects begin taking a preferred initial anti-retroviral regimens as determined by their primary care provider. Intracellular levels of those medications are measured.
1696761|NCT01490333|Dietary Supplement|Vitamin D3|The vitamin D3 will be taken daily.
1696762|NCT01490320|Behavioral|AAP Handout entitled, Pulling the Plug on Violence.|This handout is two pages and is part of the Connected Kids Program, American Academy of Pediatrics
1696763|NCT01490320|Behavioral|Play Nicely Program|Multimedia program available at www.playnicely.org.
1696764|NCT01490320|Other|Control Group|Standard care in primary care clinic.
1696765|NCT01490307|Behavioral|Family Check-Up|The Family Check-Up starts with a rapport-building session that allows therapists to gauge parents' concerns and motivation for change. This is followed by a thorough assessment of individual family strengths and weaknesses, utilizing parent and child questionnaires and family video observations. Parents then receive feedback on the results of the assessment using motivational interviewing techniques. Attention is focused on parents' and children's readiness to change, as well as the delineation of specific change options. Families may continued to receive tailored intervention services using the Everyday Parenting Curriculum.
1696766|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.01 mmol/kg BW (0.01 mL/kg) for stress MRI and 0.01 mmol/kg BW (0.01 mL/kg) for rest MRI (total dose 0.02 mmol/kg)
1696767|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.025 mmol/kg BW (0.025 mL/kg) for stress MRI and 0.025 mmol/kg BW (0.025 mL/kg) for rest MRI (total dose 0.05 mmol/kg)
1696768|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.05 mmol/kg BW (0.05 mL/kg) for stress MRI and 0.05 mmol/kg BW (0.05 mL/kg) for rest MRI (total dose 0.1 mmol/kg)
1696769|NCT01490294|Drug|Gadobutrol (Gadavist,Gadovist, BAY86-4875)|0.1 mmol/kg BW (0.1 mL/kg) for stress MRI and 0.1 mmol/kg BW (0.1 mL/kg) for rest MRI (total dose 0.2 mmol/kg)
1696770|NCT01490281|Behavioral|water-based exercise|Interventions will consist of aerobic, muscular strength and flexibility exercises in the water
1696771|NCT01490281|Behavioral|land-based exercise intervention|Interventions will consist of aerobic, muscular strength and flexibility exercises in the land
1696772|NCT01490268|Drug|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.4 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
1696773|NCT01490268|Drug|Sufentanil, Hydromorphone|Intraoperatively: Target controlled infusion with 0.8 ng/ml Sufentanil, Postoperatively: Patient-controlled analgesia with target-controlled infusion of Hydromorphone
1696774|NCT01490255|Drug|Ranolazine|os, 750 mg, twice per day, for 15 days
1696775|NCT01490255|Drug|Amlodipine|os, 10 mg, once daily, 15 days
1696776|NCT01490229|Drug|Ezetimibe|os, 10 mg, once daily, 1 year
1696777|NCT01490229|Drug|Nutraceuticals|os, 1 pill containing red yeast rice 200 mg, policosanol 10 mg, and berberine 500 mg, once daily, 1 year
1696778|NCT01490216|Drug|lisdexamfetamine|20mg q.d. to 70mg b.i.d
1696779|NCT01490203|Drug|Gd-EOB-DTPA|"Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.
Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
1696780|NCT01490203|Drug|Gd-EOB-DTPA|"Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.
Gd-EOB-DTPA will be administered intravenously with an amount of 0.1mL/kg, 1mL/sec injection rate, followed by saline infusion."
1696781|NCT01490203|Procedure|MRI|"Gd-EOB-DTPA enhanced MRI will be obtained within 1 week before, and within 3 to 5 days after surgical resection of the liver.
Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
1696782|NCT01490203|Procedure|MRI|"Gd-EOB-DTPA enhanced MRI will be performed within 3 days of obtaining ICG R15 test.
Multiphasic MRI including dynamic hepatocyte specific phase will be performed for evaluation of hepatic extraction fraction, with 25 phase dynamic MRI obtained until 30 minutes after contrast injection."
1696783|NCT01490190|Drug|Ethinylestradiol + Etonogestrel Vaginal Ring (NuvaRing)|Three cycles of NuvaRing use, each cycle consisting of etonogestrel 0.120 mg and ethinylestradiol 0.015 mg over a period of 21 days followed by 7 ring-free days.
1696784|NCT01490177|Drug|Food proteins|Oral ingestion of Food proteins
1696827|NCT01489982|Drug|Doxepin and Zopiclone|Zopiclone 3.75 mg at h.s., increasing to 7.5 mg after one week if insufficient clinical effects ( and no troublesome side effects) or Doxepin 5 mg at h.s. followed by increase up to 10 mg after the first week if insufficient clinical effect (and no troublesome side effects)
1696785|NCT01490151|Device|TTR controller (Medtronic)|Subjects will arrive in the morning and the TTR controller (Medtronic) will be initialized, and then they will give their usual premeal insulin bolus for breakfast. At lunch, they will either have a low glycemic index meal or a high glycemic index meal and the meal bolus will be omitted. The device will be turned off before dinner, they will have their usual insulin bolus for dinner, eat dinner, and then be discharged to home. On another admission, they will receive an insulin dose before lunch which will be 120% of their usual insulin bolus.
1696786|NCT01490125|Drug|QVA149|QVA149 110/50 μg hard non-gelatin capsule, inhalation/blister once a day via SDDPI
1696787|NCT01490125|Drug|Tiotropium|Tiotropium 18 ug hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
1696788|NCT01490125|Drug|Placebo to QVA149|Placebo 0 mg hard non-gelatin capsule, inhalation/ blister once a day via SDDPI
1696789|NCT01490125|Drug|Placebo to tiotropium|Placebo 0 mg hard gelatin capsule, inhalation/ blister once a day via HandiHaler® device
1696790|NCT01490125|Drug|Salbutamol/albuterol|salbutamol/albuterol (containing CFC-free propellant -HFA 134a) inhaler used as rescue medication when needed.
1696791|NCT01490112|Drug|insulin aspart|Subjects who had a first drug date on NovoRapid® were prescribed to inject insulin aspart using vial, FlexPen, NovoLet or Penfill devices. Injected subcutaneously (s.c., under the skin) immediately before meals for 24 weeks
1696792|NCT01490099|Drug|insulin detemir|One single dose of insulin detemir produced by current process and the NN729 process injected subcutaneously on two separate dosing visits in varying order
1696793|NCT01490086|Drug|RP5063|daily
1696794|NCT01490086|Drug|placebo|daily
1696795|NCT01490086|Drug|RP5063|daily
1696796|NCT01490086|Drug|RP5063|daily
1696797|NCT01490086|Drug|aripiprazole|daily
1696798|NCT01490073|Drug|Insertion of nitroglycerin ointment|Nitroglycerin ointment inserted into the vagina 30-45 minutes prior to IUD insertion
1696799|NCT01490073|Drug|Insertion of placebo ointment|Placebo ointment inserted into the vagina 30-45 minutes prior to IUD insertion
1696800|NCT01490060|Drug|Fosaprepitant|150 mg administered intravenously, delivered in either single dose or two doses, on Day 1 for single dose and on Days 1 and 4 for two doses, varying between Cycle 1 or Cycle 2 depending upon randomization to arm.
1696801|NCT01490060|Drug|Dexamethasone|Intravenous push (IVPB) daily for 5 days (12 mg on day 1, and 8 mg on days 2-5)
1696802|NCT01490060|Drug|5HT3 receptor antagonist|5HT3 receptor antagonist as standard of care 30 minutes prior to chemotherapy
1696803|NCT01490060|Drug|Ifosfamide-based chemotherapy (AI)|Doxorubicin + Mesna + + Ifosfamide + Vincristine, chemotherapy cycles repeated every 3-4 weeks for up to 6 cycles. Chemotherapy drugs listed separately, individual dosages, etc.
1696804|NCT01490060|Drug|Doxorubicin|25 mg/m^2/day IV continuous infusion for 72 hours on days 1, 2, and 3, completing infusion on day 4 (total dose: 75 mg/m^2) as part of AI Chemotherapy.
1696805|NCT01490060|Drug|Mesna|Prior to ifosfamide (Day 1) - 500 mg/m^2 (20% of ifosfamide dose) given simultaneously with ifosfamide and then daily continuous infusion (Days 1-4 completing infusion on day 4) - 1,500 mg/m^2/day (60% of daily ifosfamide dose) for a total of 6 gm/m^2. The mesna infusion complete 24 hours after last dose of ifosfamide.
1696806|NCT01490060|Drug|Ifosfamide|2.5 g/m^2 IV bolus over 3 hours on days 1, 2, 3, 4 (total dose: 10 g/m^2).
1696807|NCT01490060|Drug|Vincristine|2 mg IV by rapid infusion (Day 1) may be given to participants with sarcomas of small cell histology.
1696808|NCT01490047|Drug|Recombinant human TNF-α|Infusion will be done over 60 minutes, preferably via central venous catheter. Will immediately follow the infusion of Liposomal doxorubicin.
1696809|NCT01490047|Drug|Liposomal doxorubicin|Infusion over 60 minutes
1696810|NCT01490047|Drug|Caelyx|Administration of Caelyx® will be done first, as infusion in 250 ml D5W, followed immediately by infusion of rhTNF-α.
1696811|NCT01490047|Drug|Recombinant human TNF-α|Recombinant human TNF-α (Beromun) will be diluted in 250 mL of normal saline with albumin (2 mg/mL) to prevent adherence of the protein to the delivery apparatus. Infusion will be done over 60 minutes, preferably via central venous catheter, including PICC lines.
1696812|NCT01490034|Behavioral|Metabolic effects of consuming energy dense beverages|Consumption of energy dense beverages for 2 weeks and monitoring physiological responses
1696813|NCT01490034|Behavioral|energy dense solid food|Effects of consuming energy dense solid food for two weeks on physiological responses
1696814|NCT01490034|Behavioral|Energy dilute beverages|Effects of consuming energy dilute beverages for two weeks on physiological responses.
1696815|NCT01490034|Behavioral|Energy dilute solid food|Effects of consuming energy dilute solid food for two weeks on physiological responses
1696816|NCT01490021|Procedure|rTMS/Active TBS|A continuous Theta-Burst Stimulation (TBS) protocol will be applied over the left dorsolateral prefrontal cortex. Three stimuli at 50Hz, 80% of individual Motor Threshold will be repeated every 200ms for 40sec (Galea et al., 2010; Oberman and Pascual-Leone, 2009).
1696817|NCT01490021|Procedure|rTMS/Placebo TBS|rTMS/Placebo TBS
1696818|NCT01490008|Drug|Veregen|Patients in treatment arm 1 will apply Veregen® 15% ointment (approved commercial source in US) in a total of 750 mg/day for one week, corresponding to application of maximal about 106,9 mg catechins/d, thereof maximal 81 mg ECGg per day). Patients will be instructed to apply fix portions of 250 mg three times daily on the defined anogenital administration area.
1696819|NCT01490008|Other|Green Tea|"Healthy volunteers in treatment arm 2 will drink Lipton® Green Limone in a total of 1500 mL/d for one week, in portions of 500 mL three times daily after the meals"
1696820|NCT01489995|Drug|A (migalastat)|150 mg migalastat HCl in the fasting state (reference arm)
1696821|NCT01489995|Drug|B (migalastat)|150 mg migalastat HCl with simultaneous consumption of a glucose drink
1696822|NCT01489995|Drug|C (migalastat)|150 mg migalastat HCl 1 hour before consumption of a high fat meal
1696823|NCT01489995|Drug|D (migalastat)|150 mg migalastat HCl 1 hour before consumption of a light meal
1696824|NCT01489995|Drug|E (migalastat)|150 mg migalastat HCl 1 hour after consumption of a light meal
1696825|NCT01489982|Device|Light box (Litebook company)|Light therapy will be administered daily for a duration of 30 minutes, starting two hours (+/- 1 hour) prior to usual bedtime
1696826|NCT01489982|Behavioral|CBT and sleep hygiene|6 weekly sessions totalling 90 minutes
1696862|NCT01489696|Drug|tamsulosin|oral
1696828|NCT01489982|Device|Light box ( Litebook company)|The intervention will be 30 minutes of light therapy, using red light below the threshold required to entrain light cycles
1696829|NCT01489969|Drug|Neu-P11|1 tablet daily 1-2 before bed time for 28 days of double blind treatment
1696830|NCT01489956|Biological|Immucothel Alone (Part A)|100 ug at day 0 (priming dose) and day 9(booster dose)
1696831|NCT01489956|Biological|Immucothel+Montanide (Part A)|100 ug SQ Immucothel plus Montanide at day 0 (priming dose) and day 9 (booster dose)
1696832|NCT01489956|Biological|Immucothel Alone or Immucothel+Montanide (Part B)|50 mg of native KLH on days 0-4 and 10-14 (total of 500 mg). Immunization on days 26 and 35.
1696833|NCT01489943|Drug|GSK1605786 500 mg|Subjects will receive 500 milligram (mg) (2 doses of 250 mg) GSK1605786 hard gelatin capsules twice daily orally on Days 5 to 14. GSK1605786 will be administered with 240 milliliter (mL) of water.
1696834|NCT01489943|Drug|Midazolam 3 mg|Subjects will receive 3 mg oral syrup of Midazolam once daily on Day 1 and Day 11. Midazolam will be administered with 240 mL of water.
1696835|NCT01489943|Drug|Pioglitazone 15 mg|Subjects will receive 15 mg tablet of pioglitazone orally once daily on Day 2 and Day 12. Pioglitazone will be administered with 240 mL of water.
1696836|NCT01489943|Drug|Omeprazole 40 mg|Subjects will receive 40 mg hard gelatin capsules of Omeprazole once daily on Days 3 and 13. Omeprazole will be administered with 240 mL of water.
1696837|NCT01489943|Drug|Rosuvastatin 10 mg|Subjects will receive 10 mg tablet of Rosuvastatin orally once daily on Days 4 and 14. Rosuvastatin will be administered with 240 mL of water.
1696838|NCT01489930|Behavioral|Endurance exercise|Participants will perform 8-weeks of endurance exercise training. Participants will train 5 days per week for 60 min at 65% of VO2 peak.
1696839|NCT01489930|Behavioral|Resistance exercise|Participants will perform 8-weeks of resistance exercise training. Participants will train 4 days per week for ~60 min. Two days will focus on lower body resistance training and two days will focus on upper body.
1696840|NCT01489930|Behavioral|Control/Combined training|Participants will perform 8-weeks of no exercise (control), followed by 8-weeks of combined endurance and resistance training. Participants will endurance train 5 days per week for 30 min at 65% of VO2 peak and resistance train 4 days per week for 30 min.
1696841|NCT01489917|Other|Patent hemostasis and heparin|Radial artery patency is verified. If not maintained, then a bolus of heparin 50 U/kg or a maximum of 5000 units is administered and the compression (TR band) is left in place for 2 hours.
1696842|NCT01489904|Biological|BOTULINUM NEUROTOXIN TYPE-A|Botulinum toxin type A / First infiltration: 25U in each salivary gland=100 U in Parotid and submandibular glands. 24 weeks after first infiltration is a Second infiltration with 50U Botulinum toxin type -A 25 U in each salivary gland only in parotid glands.
1696843|NCT01489891|Drug|Lidocaine|Applying of 5 puff controlled released (50 mg) transoral spray of lidocaine (10 mg=1 puff).
1696844|NCT01489891|Drug|Placebo|Applying of 5 puff controlled released (50 mg) transoral spray of placebo (excipients of trade mark of lidocaine ensuring the patient masking).
1696845|NCT01489865|Drug|ABT-888 and mFOLFOX-6|ABT-888 in escalating doses twice a day for Days 1-7 of each 14-day cycle Oxaliplatin 85 mg/M2 IV on Day 1 Leucovorin 400 mg/m2 IV on Day 1 5-FU 400 mg/m2 IV bolus followed by 2400 mg/m2 IV continuous infusion over 46 hours Days 1-3
1696846|NCT01489852|Drug|17beta-estradiol|Pretreatment with 17beta-estradiol (Provames®, Aventis, Paris, France) was administered daily (2 mg twice a day) during the cycle preceding the IVF/ICSI cycle, starting 7 days before the predicted onset of menses and administered up until to the following Thursday after the occurrence of menses.
1696847|NCT01489839|Other|Periodontal therapy|All subjects will have professional dental prophylaxis and periodontal therapy withheld for 12 months during the disease progression and monitoring phase. After 12 months, subjects with periodontal disease will receive periodontal therapy to consist of scaling and root planing, and periodontally healthy subjects will receive professional dental prophylaxis. Subjects with periodontal disease will also receive Supportive Periodontal Therapy at the 3- and 6-month post-therapy visits. Subjects showing periodontal disease progression greater than a predetermined threshold during the monitoring or maintenance phases of the study will be given rescue therapy consisting of placement of a local antibiotic at the site of disease progression.
1696848|NCT01489826|Drug|Dexanabinol|Patients will (initially) be given a slow intravenous (i.v.) infusion of Dexanabinol over 3 hours on Days 1, 8 and 15 of a three weekly (21 day) cycle.
1696849|NCT01489826|Other|Cremophor|Drug vehicle.
1696852|NCT01489800|Behavioral|Clear liquid diet|clear liquid diet, the same for each arm, will be given 24 hours after extubation as the intervention in the experimental arm.
1696853|NCT01489787|Procedure|HIFU|"The shootings will concern the healthy liver to remove, distant to the important vascular structures and metastases. Two HIFU shootings will be made on each patient:
One hurt on the surface starting from the Glisson capsule and extending to subjacent hepatic parenchyma.
One hurt at given depth, at least 10 mm deeper than the hurt done on the surface NB: The shooting depth will determined for each patient at the beginning of the operation, considering preoperative exams (scans, etc.), size and location of the liver part to be resected and physical structure of the patient."
1696854|NCT01489787|Procedure|HIFU|The shootings will concern healthy liver to be resected, distant (step 1) then close (step 2) to the important vascular structures of the liver. Several shootings HIFU will be made on each patient (ideally 4 hurts, minimum 2 hurts)
1696855|NCT01489787|Procedure|HIFU|"Shootings will concern small metastases (≤ 20 mm) and peri lesional healthy liver. They will be juxtaposed on multiple plans in order to generate a large hurt containing the metastasis targeted and guaranteeing a sufficient safety margin in healthy liver.
Several metastases can be treated in the same patient"
1696856|NCT01489774|Drug|Placebo|single and multiple dose
1696857|NCT01489774|Drug|CJ-12406|single and multiple dose
1696858|NCT01489761|Device|percutaneous coronary intervention|drug eluting stent implantation
1696859|NCT01489722|Drug|AZD1208|Daily oral doses of AZD1208 for 28 day cycles until progression or unacceptable toxicity develops. Starting dose will be 120 mg and will be escalated in successive cohorts until an MTD is established.
1696860|NCT01489709|Drug|Vesicare|oral
1696861|NCT01489696|Drug|mirabegron|oral
1696864|NCT01489683|Drug|normal saline|3 ml of normal saline was instilled to larynx and trachea before endotracheal intubation
1696865|NCT01489670|Drug|bimatoprost 0.01% ophthalmic solution|Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.
1696866|NCT01489644|Drug|repaglinide|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
1696867|NCT01489644|Drug|metformin|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
1696868|NCT01489644|Drug|repaglinide and metformin combination tablet|Subjects will receive 850 mg metformin alone on a fasting state, 2 mg repaglinide alone on a fasting state, 2 mg repaglinide/850 mg metformin (NN4440 2/850) in the fasting state or 2 mg repaglinide/850 mg metformin (NN4440 2/850) immediately prior to a standardised high fat meal on 4 separate dosing visits in varying order
1696869|NCT01489631|Drug|naropin|ropivacaine 0,2%, 3x 50 ml during surgery
1696870|NCT01489631|Drug|marcaine|bupivacaine 0,125%
1696871|NCT01489631|Drug|sufentanil|sufentanil 1mcg/ml
1696872|NCT01489631|Drug|neurontin|gabapentin 600 mg pre-operative 3 dd 300 mg
1696873|NCT01489618|Biological|PPS|POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE
1696874|NCT01489618|Biological|PnCJ PPS|PRIMEBOOST CONJUGATED ANTI- PNEUMOCOCCAL VACCINE (Week 0) POLYSACCHARIDE ANTI- PNEUMOCOCCAL VACCINE (Week 4)
1696875|NCT01489605|Device|GlideScope Groove|Patients will be intubated using the GlideScope Groove device. (Verathon)
1696876|NCT01489605|Device|Control: Standard GlideScope|Patients will be intubated using the standard GlideScope. (Verathon)
1696877|NCT01489592|Drug|curcuma longa|oral administration of 6 grams of curcumin
1696880|NCT01489566|Drug|Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; Tyroserleutide for injection(30mg) ,through the micro infusion pump,every cycle,3-5 days
1696881|NCT01489566|Drug|the placebo ,chemotherapy(mitomycin, and Fluorouracil )|mitomycin(10mg)+Fluorouracil(1.0g),through the chemoradiative pump,every cycle,5-30 minites; the placebo(30mg) ,through the micro infusion pump,every cycle,3-5 days
1696882|NCT01489540|Device|laser Doppler imager (Moor)|The laser Doppler imager measures the blood flow of the skin/burn
1696883|NCT01489527|Biological|Gardasil Vaccine|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
1696884|NCT01489527|Other|Placebo|The study vaccine was blindly administered as supplied on Day 1, Month 2, and Month 6. All vaccines were injected intramuscularly into the deltoid muscle by a member of the clinical staff.
1696885|NCT01489514|Other|Epicutaneous skin prick testing|"Epicutaneous skin prick testing will be performed utilizing the following extracts:
Histamine control purchased from Greer.
Saline control purchased from Greer.
Standard Peanut Extract purchased from Greer.
Sterile extract prepared from Trypsin and Chymotrypsin treated peanuts. This is prepared by North Carolina A & T.
Sterile extract prepared from roasted & blanched but untreated peanuts. This is prepared by North Carolina A & T.
Sterile extract prepared from peanuts (no blanching, no enzyme). This is prepared by North Carolina A & T. This is not classified as a drug and is
Sterile extract containing peanuts treated with 0.2% inactivated a-chymotrypsin and trypsin as an enzyme negative control.
Sterile extracts containing peanuts that have been treated with alcalase"
1696886|NCT01489501|Procedure|Surgical transplantation of CAOMECS to the ocular surface|Surgical transplantation of oral mucosa derived CAOMECS sheet onto eye cornea.
1696887|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 2.4 milligram (mg) riociguat (BAY63-2521) as pediatric high-concentration suspension (0.15 mg per milliliter [mg/mL], i.e. 16 mL) under fasting conditions
1696888|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 2.4 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 16 mL) under fed conditions
1696889|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 0.3 mg riociguat as pediatric high-concentration suspension (0.15 mg/mL, i.e. 2 mL) under fasting conditions
1696890|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of 0.15 mg riociguat as pediatric low-concentration suspension (0.03 mg/mL, i.e. 5 mL) under fasting conditions
1696891|NCT01489488|Drug|Riociguat (BAY63-2521)|Single oral dose of riociguat immediate release (IR) tablet 1 mg under fasting conditions
1696892|NCT01489462|Behavioral|High Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants in this group are lifting 3 sets of each exercise at 75-90% of 1RM.
1696970|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
1697244|NCT01486563|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
1955827|NCT03053557|Behavioral|Social Skills Coach|Social Skills Coach is a multi-platform interactive device that engages users with information and skills learned in social skills training programs. The program includes a web application and provider dashboard and encourages users to practice skills on the app and use them in the real world and then report how the application of skills was experienced.
1696893|NCT01489462|Behavioral|Low Intensity Strength Training|The strength-training intervention will consist of 5-min warm-up, 40-min training, and 15-min cool-down. The 60-min sessions will be conducted 3 times/wk for 18 months. Every 2 weeks the load lifted will be adjusted so that the participants are lifting 3 sets of 15 repetitions at 30-40% of 1RM.
1696894|NCT01489462|Behavioral|Attention Control|Participants in the control group will attend 60-min organized workshops 2 times/month for the first 6 months and then 1 time/month for months 7-18. Over the 18 months interactive presentations will cover such topics as foot care, nutrition, managing medication, and sleep practices, and experts will give wide-ranging lectures.
1696895|NCT01489449|Device|Stent|bare metal stent implantation, any bare metal stent is allowed from different companies
1696896|NCT01489449|Device|SeQuent(R) Please coated balloon|Angioplasty with Drug coated balloon (DCB)
1696897|NCT01489436|Procedure|Single-port cholecystectomy|In brief, a flexible, multi-sleeve 15-mm trocar designed specifically for single-port cholecystectomy will be inserted at the umbilicus via a 15-mm single incision. This trocar permits simultaneous introduction of multiple instruments, including a 5-mm flexible-tip laparoscope. Standard 5-mm instruments will be used for retraction and dissection. An additional 2-mm grasping device may be introduced in the right upper quadrant for retraction if necessary. A 5-mm laparoscopic clip applier will be introduced through the periumbilical trocar to ligate the cystic artery and the cystic duct. The gallbladder will be removed through the umbilical port.
1696898|NCT01489436|Procedure|Four-port laparoscopic cholecystectomy|The control procedure for the research practicum is a four-trocar laparoscopic cholecystectomy, the current gold-standard operation. This approach utilizes a 10-mm trocar placed at the umbilicus via a 15-mm incision and three separate subcostal 5-mm trocars placed via separate 5-mm incisions. The gallbladder will be removed through the umbilical trocar site. On occasion, this incision needs to be enlarged to accommodate removal of the gallbladder.
1696899|NCT01489423|Genetic|RNA analysis|
1696900|NCT01489423|Genetic|in situ hybridization|
1696901|NCT01489423|Genetic|polymerase chain reaction|
1696902|NCT01489423|Other|enzyme-linked immunosorbent assay|
1696903|NCT01489423|Other|flow cytometry|
1696904|NCT01489423|Other|immunohistochemistry staining method|
1696905|NCT01489423|Other|laboratory biomarker analysis|
1696906|NCT01489410|Drug|Drug-Eluting Beads (DEB) with Doxorubicin|One treatment of Drug-Eluting Beads (DEB) with Doxorubicin administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
1696907|NCT01489410|Drug|Lipiodol Ethanol Mixture|One treatment of Lipiodol Ethanol Mixture (LEM) is administered to the liver through a groin puncture site and delivered through the vessels that feed the liver (per standard of care).
1696908|NCT01489397|Device|Confocol laser endomicroscopy|Confocal laser endomicroscopy was applied at suspected lesion and normal mucosa followed by biopsy for pathology.
1696909|NCT01489371|Other|Laboratory Biomarker Analysis|Correlative studies
1696910|NCT01489371|Biological|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given IP
1696911|NCT01489371|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
1696912|NCT01489358|Biological|VRC-CHKVLP059-00-VP|VRC-CHKVLP059-00-VP is a VLP vaccine that consists of the E1, E2 and capsid proteins of the Chikungunya Virus
1696913|NCT01489345|Drug|ONO-2952|30 mg to 100 mg QD at a multiple dose, and 21 days duration
1696914|NCT01489345|Drug|ONO-2952 Matching Placebo|30 mg to 100 mg QD at a multiple dose, and 21 days duration
1696915|NCT01489332|Drug|intensified preoperative chemotherapy|"capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days, 7 days rest for one cycle; radiotherapy: 50.4 Gy to the pelvis (25x 1.8 Gy on days 1-33, excluding weekends) plus 5.4 Gy on days 36-38 as a boost to the primary tumour (3 fractions of 1.8 Gy).Three- dimensional CT planing and a four field box technique with high energy photons (15 MV) will be used. capecitabine 825 mg/m² p.o. twice daily on days 1-38 (including weekends), One week after completion of radiochemotherapy patients receive 2 cycles of capecitabine based chemotherapy (1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks).
Radical surgery (TME): to be undertaken 8 weeks following completion of chemoradiation Postoperative treatment:capecitabine 1250 mg/m² p.o. twice daily for 14 consecutive days every three weeks; 3 cycles (R0 beginning 6-8 weeks after surgery"
1696916|NCT01489319|Drug|Salsalate|4 out of 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
1696917|NCT01489319|Drug|Salsalate|4 out of the 10 subjects will receive salsalate 2.0 gm twice a day for 12 weeks; 4 out of 10 subjects will receive PCE 200 mg containing 20% resveratrol twice a day for 12 weeks.
1696918|NCT01489306|Drug|MDT-637|Inhaled doses of MDT-637 over a 10 day period
1696919|NCT01489306|Drug|MDT-637|Inhaled doses of MDT-637 over a 10 day period
1696920|NCT01489267|Other|stem cell transplantation|The patients accepted 4 times stem cell transplantations through lumbar puncture, the time is 3-5days between two treatments and the dose is about 2 ml(including 1×10`7 cells).
1696921|NCT01489254|Drug|Glatiramer Acetate (GTR)|Glatiramer Acetate (GTR) 20 mg daily, for 9 months (Part 1) followed by additional 15 month treatment period (Part 2)
1696922|NCT01489254|Drug|Glatiramer Acetate (Copaxone®)|Glatiramer Acetate (Copaxone), 20 mg daily, for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
1696923|NCT01489254|Drug|Placebo|Placebo (daily) for 9 months followed by additional 15 month GTR 20 mg daily treatment period (Part 2)
1696924|NCT01489241|Procedure|Telemonitoring|Within 24 hours after patient's discharge, the telemedicine equipment is installed at the patient's home and patients are trained in the use of the equipment. Patients are followed by a dedicated telehealth centre. Patients at home are asked to fill out each morning the CAT questionnaire and to record extra use of COPD relief medications. Patients in stable conditions perform telespirometry and teleoximetry at 4 and 12 weeks. When a clinical worsening is detected (increase in CAT score by 5 points or higher on two consecutive days) the patient is contacted and asked to perform ad hoc telespirometry and teleoximetry and to send the data to the telehealth centre.
1696925|NCT01489228|Drug|E1224|100 mg tablets
1696926|NCT01489228|Drug|Benznidazole|100mg tablets
1696927|NCT01489228|Drug|Placebo|tablets
1696971|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
1696928|NCT01489215|Behavioral|"presence"|"constant presence of the parent in the child's room throughout the night during the first week of the intervention. In addition to sleeping near the child's crib, the parents repeat the same routines as in the checking method if the child is actively protesting or crying."
1696929|NCT01489215|Behavioral|"checking"|putting the child into the crib at bedtime and leaving the room with repeated quick visits every 5 minutes if the child is actively protesting or crying, providing brief reassurance, helping the child to resume a sleeping position.
1696930|NCT01489202|Device|platinum chromium everolimus-eluting stent|An everolimus-eluting stent with a platinum chromium platform
1696931|NCT01489202|Device|cobalt chromium everolimus-eluting stent|An everolimus-eluting stent with cobalt chromium platform
1696932|NCT01489189|Other|Prompt Panretinal Photocoagulation|Panretinal photocoagulation alone at baseline (full session completed within 56 days).
1696933|NCT01489189|Drug|0.5-mg Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline and up to every 4 weeks using defined retreatment criteria.
1696934|NCT01489189|Other|Deferred panretinal photocoagulation|PRP is deferred until failure/futility criteria for intravitreal injection are met.
1696935|NCT01489176|Drug|Regadenoson; Optison|A one-time intravenous bolus of Regadenoson 400 mcg; continuous intravenous infusion of Optison of 2-4 mL/minute.
1696936|NCT01489163|Behavioral|Lifestyle Counseling|The Phase I intervention will be delivered through 1 individual in-person session and 3 individual telephone counseling contacts. The Phase II intervention begins at 6-week postpartum and will be delivered through 3 individual in-person sessions and 13 telephone counseling contacts over a period of 6 months. The maintenance phase (Phase III) will begin at 8 months postpartum.
1696937|NCT01489137|Drug|remifentanil|"According to previous patient's response, the investigators will allocate the effect site concentration of remifentanil of next patient during head fixation. And, For this allocation of dose of remifentanil the investigators use biased coin design up-and-down method.
For the first patient, the dose of remifentanil would be fixed at 5.5ng/ml which we predict as EC90. And, step size of dose is 0.5ng/ml."
1696938|NCT01489124|Drug|Imipenem|0.5 g of imipenem every 6 hrs administrated by 0.5-hr infusion for 3 days
1696939|NCT01489124|Drug|Imipenem|0.5 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
1696940|NCT01489124|Drug|Imipenem|1 g of imipenem every 6 hrs administrated by 2-hr infusion for 3 days
1696941|NCT01489111|Drug|turoctocog alfa pegol|Bleeding preventive treatment administered i.v. before, during and after surgery. Individually adjusted doses.
1696942|NCT01489072|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
1696943|NCT01489072|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mcg/kg given once before emergence of general anesthesia
1696944|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 10,30,50 μg/kg, daily for 5 days every 3 weeks (daily x 5), 16-20 weeks depending on response
1696945|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, 30,100,150 μg/kg, weekly, 16-20 weeks depending on response
1696946|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, daily for 5 days every 3 weeks (daily x 5), 12-16 weeks depending on response
1696947|NCT01489059|Biological|BMS-982470 (recombinant interleukin-21)|Solution, Intravenous, Maximum tolerated dose from Part 1, Weekly, 12-16 weeks depending on response
1696948|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, 1,3,10 mg/kg, every 3 weeks, 16-20 weeks depending on response
1696949|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, Maximum tolerated dose from Part 1, every 3 weeks, 12-16 weeks depending on response
1696950|NCT01489059|Biological|Ipilimumab|Solution, Intravenous, 3mg/kg, Every 3 weeks, 12-16 weeks depending on response
1696951|NCT01489046|Drug|BMS-986001|Capsules, Oral, 100 mg, Once daily, At least 48 weeks
1696952|NCT01489046|Drug|BMS-986001|Capsules, Oral, 200 mg, Once daily, At least 48 weeks
1696953|NCT01489046|Drug|BMS-986001|Capsules, Oral, 400 mg, Once daily, At least 48 weeks
1696954|NCT01489046|Drug|Placebo matching with BMS-986001|Capsules, Oral, 0 mg, Once daily, At least 48 weeks
1696955|NCT01489046|Drug|Efavirenz|Tablets, Oral, 600 mg, Once daily, Entire Treatment Phase
1696956|NCT01489046|Drug|Lamivudine|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
1696957|NCT01489046|Drug|Tenofovir|Tablets, Oral, 300 mg, Once daily, Entire Treatment Phase
1696958|NCT01489033|Biological|Subcutaneous immunotherapy with Phleum pratense pollen extract|Increasing doses up to a maximum dose of 500 TSU
1696959|NCT01489020|Biological|subcutaneous immunotherapy with DPT extract|Increasing doses of subcutaneous immunotherapy in three different scales up to the maximum dose of 500 TSU (Treatment Standardized Units)
1696961|NCT01488981|Other|Upper Extremity Therapy without stimulation|Two 12 week phases of occupational therapy without electrical stimulation.
1696962|NCT01488981|Device|Upper Extremity Therapy with stimulation from the Radiofrequency Microstimulator (RFM) System (Alfred Mann Foundation, Santa Clarita, CA)|Two 12 week phases of occupational therapy that incorporates electrical stimulation from the RFM System.
1696963|NCT01488968|Radiation|Standard Radiation Treatment|39 radiation treatments
1696964|NCT01488968|Radiation|Hypofractionated radiation treatment|25 radiation treatments
1696965|NCT01488955|Drug|Ibuprofen|400 mg oral once a day from day 0 for 3 days
1696966|NCT01488955|Drug|Fosfomycin-Trometamol|8 g granulate with 3 g Fosfomycin-Trometamol oral once at day 0, placebo to Ibuprofen once a day oral from day 0 for 3 days
1696967|NCT01488942|Other|monetary reinforcer|The protocol will follow an escalating schedule of reinforcements tied to clinic visit attendance for the first 24 weeks, after which the reinforcers will take the form of an escalating variable reinforcement schedule in the form of fishbowl prize draws linked to maintenance of suppressed viral load for the remainder of the 52-week study period. In addition, a reset function will be incorporated by which the reinforcer will be rolled back to an initial lower value if clinic visits or viral load targets are not met. This will be rapidly scaled up again once targets are met.
1696968|NCT01488929|Drug|TC-5619|
1696972|NCT01488890|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL, Subcutaneous
1696973|NCT01488890|Biological|Yellow Fever|0.5 mL, Subcutaneous
1696974|NCT01488877|Drug|PF-03882845|3 mg tablet once daily
1696975|NCT01488877|Drug|PF-03882845|up to 10 mg tablet once daily
1696976|NCT01488877|Drug|PF-03882845|up to 30 mg once daily
1696977|NCT01488877|Drug|Spironolactone|spironolactone 25 mg once daily
1696978|NCT01488877|Other|placebo|placebo once daily
1696979|NCT01488864|Behavioral|Applied Relaxation (AR)|"AR is a technique influenced on cognitive behavioral therapy using coping mechanism and conditioning. AR focuses on muscle relaxation, where breathing is used for the conditioning of the relaxation. AR implies participation in 10 group sessions during a period of 12 weeks. A therapist will see the women assigned to AR in a group consisted of 6-8 women. The weekly sessions will last for 60 minutes each and are based on a scheme from Öst. The women will be told to practice each component daily.
During the first session a lecture about menopause and about theories of the mechanisms behind hot flashes will be given.
The aim of applying AR in view of coping with vasomotor symptoms will be discussed. The group is given a rationale of applying AR as a coping technique for handling sudden unanticipated symptoms by quick calming down, and thus gaining control over the situation."
1696980|NCT01488838|Drug|Cisplatin: 40 mg/m2 weekly during radiation|Cisplatin: 40 mg/m2 weekly during radiation for 7 doses
1696981|NCT01488838|Radiation|Radiation: 60-66 Gy in 2 Gy daily fractions|Radiation: 60-66 Gy in 2 Gy daily fractions
1696982|NCT01488825|Behavioral|Yoga Therapy|Therapeutically oriented style of yoga originated from Pancha Kosha philosophy of Vedanta was used throughout the trial. All the sessions emphasized on postures, breathing practices with the specific focus on relaxation, combination of chants and meditation. Once a week, Kunjal and Jalaneti (cleansing practices) were practiced in guidance of therapist. They all were instructed to eat light and rest on Kriya days.
1696983|NCT01488799|Behavioral|Motivational Interviewing and Cognitive Behavioural Therapy|Participants with a diagnosis of severe Generalized Anxiety Disorder will be randomly assigned to receive either 4 weekly sessions of MI followed by 11 weekly sessions of CBT (MI-CBT arm) or 15 weekly sessions of CBT (CBT alone arm). Both groups will also receive 2 follow-up CBT treatment sessions at 1 and 3 months post-treatment. In order to increase generalizability to clinical practice, in the CBT phase for the MI-CBT arm, therapists will shift to MI in the presence of empirically derived markers of resistance and shift back to CBT when resistance has diminished. In the CBT alone arm therapists will respond to resistance using manualized recommendations derived from leading CBT theorists for the management of resistance.
1696984|NCT01488786|Device|BrainPort Vision Device|2-3 days of training (10 hours) followed by minimum in-home use 300 minutes per month for 12 months.
1696985|NCT01488773|Drug|first prescription of montelukast|The index event (intervention) was defined as the first prescription for montekuast (leukotriene receptor antagonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
1696986|NCT01488773|Drug|first prescription of salmeterol|The index event (intervention) was defined as the first prescription for salmeterol (long-acting β2-agonist) occurring in patient's medical history that established a 12-month pre-index and three consecutive 12-month post-index periods.
1696987|NCT01488747|Dietary Supplement|Coromega Omega-3 Squeeze|660 mg EPA, 434 mg DHA
1696988|NCT01488747|Dietary Supplement|Coromega Nectar|660 mg EPA, 436 mg DHA
1696989|NCT01488747|Dietary Supplement|Barleans Swirl|660 mg EPA, 660 mg DHA
1696990|NCT01488747|Dietary Supplement|Nordic Omega-3 Softgel|660 mg EPA, 440 mg DHA
1696991|NCT01488734|Dietary Supplement|Mushroom with 600 IU vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 600 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
1696992|NCT01488734|Dietary Supplement|Mushroom with 4000 IU Vitamin D2|Subjects in this group will eat daily meals containing mushrooms fortified with 4000 IU of Vitamin D2. These subjects will also take one placebo tablet per day.
1696993|NCT01488734|Dietary Supplement|600 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 600 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
1696994|NCT01488734|Dietary Supplement|4000 IU Vitamin D3 and untreated mushroom|Subjects in this group will take one commercially available tablet of 4000 IU of Vitamin D3. These subjects will also eat one meal per day with untreated (inactive) mushrooms.
1696995|NCT01488734|Drug|Placebo|Placebo for the fortified mushroom arms
1696996|NCT01488708|Drug|LY2127399|120 mg LY2127399 administered via subcutaneous (SC) injection for 216 weeks Participants randomized to active treatment in the core studies will remain on the same active dose. In order to ensure that the original randomization arm from the preceding core studies are not unblinded, the first dose in BCDX will be blinded, with all participants receiving 2 injections of blinded study drug.
1696997|NCT01488708|Drug|Placebo|Placebo administered via SC injection at first dose to maintain blinding of previous study treatment.
1696998|NCT01488695|Device|GlideScope Groove|GlideScope Groove
1696999|NCT01488695|Device|Control: Macintosh blade|Control: Patients will be intubated using the Macintosh blade
1697000|NCT01488682|Procedure|Neck dissection with Harmonic scalpel|The Harmonic Focus® Curved Shears (Ethicon Endo-Surgery, Cincinnati, OH) was used for vascular control of the surgery regardless of vessel diameter, except when hand-tied or suture ligation was needed for IJV ligation or in case bleeding was not controlled with electrocoagulation
1697001|NCT01488682|Procedure|neck dissection with conventional hand-tie ligation|electrocautery was used to control the small vessels and conventional hand-tied ligation was used for large sized arterial, venous, or lymphatic vessels
1697002|NCT01488669|Procedure|robot assisted neck dissection via retroauricular approach|A modified face lift or retroauricular incision is made and subplatysmal skin flap is elevated.The marginal mandibular branch of the facial nerve and spinal accessory nerve is identified and lateral part of level II and III is dissected under direct vision using conventional technique. Then, the robotic arms are inserted and the remaining fibrofatty tissue of level I,II,III are dissected under 3D vision.
1697031|NCT01488409|Drug|Acipimox|250 mg by mouth (PO) three times daily
1697032|NCT01488409|Drug|Placebo|0 mg by mouth (PO) three times daily
1697033|NCT01488396|Drug|0.05%cyclosporin eye drop|use twice daily for 6 months
1697003|NCT01488669|Procedure|Conventional neck dissection|A transverse skin incision from the mastoid tip to the midline 2 finger below the mandible is made and subplatysmal skin flap is elevated. The fibrofatty tissue of level I,II,III is dissected while preserving the marginal branch of the facial nerve and the spinal accessory nerve. The vessels are ligated using the conventional tie technique and the Harmonic scalpel.
1697004|NCT01488656|Dietary Supplement|Placebo|7-pill placebo dietary packed visually identical to active dietary supplement
1697005|NCT01488656|Dietary Supplement|Antioxidant, anti-inflammatory dietary supplement|A combination of dietary supplements including: β-carotene, vitamin C, vitamin D3, vitamin E, vitamin K, thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, biotin, pantothenic acid, calcium, iodine, magnesium, zinc, selenium, copper, manganese, chromium, molybdenum, boron, silicon, vanadium, eicosapentaenoic acid, docosahexaenoic acid, olive extract, mixed tocopherols, bioflavonoids, inositol, choline, N-acetyl L-cysteine, bromelain, coenzyme Q10, turmeric extract, lutein, lycopene, broccoli concentrate, grape seed extract
1697006|NCT01488630|Other|STaRS|The intervention entails testing an automated substance abuse treatment referral system (STaRS) to be implemented in primary care practices through electronic health record systems to improve 1) referral rates to specialty care providers, 2) patient treatment initiation with the specialty care providers, and 3) revenues to the practices.
1697007|NCT01488604|Device|Polymeric Nasal Spray|Experimental nasal spray
1697008|NCT01488604|Device|Sham Nasal Spray|Sham nasal spray
1697009|NCT01488578|Drug|Tolterodine tartrate|Detrusitol Capsule 2mg and 4mg, depending on the Investigator prescription.Frequency and duration are according to Package Insert as follows.
1697010|NCT01488565|Drug|Azacitidine and eltrombopag|Standard: azacitidine D1-5, 8&9, until loss of clinical benefit. Experimental: eltrombopag at a dose ranging from 50-300mg for 6 months, continuing only in those deriving clinical benefit.
1697011|NCT01488552|Drug|Gemcitabine|1000 mg/m2 weekly on days 1,8, and 15 in a 28 day cycle. Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
1697012|NCT01488552|Drug|nab-paclitaxel|125 mg/m2 on days 1,8, and 15 of a 28 day cycle Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
1697013|NCT01488552|Drug|FOLFIRINOX|"The combination below will be given on days 1 and 15 of a 28 day cycle; 5-Fluorouracil 2400 mg/m2 with a 46-hour continuous IV infusion; Leucovorin 400 mg/m2 over a 2 hour IV infusion;
Oxaliplatin 85 mg/m2 as a 2 hour IV infusion; Irinotecan 180 mg/m2 over a 90 minute IV infusion Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients)."
1697014|NCT01488552|Genetic|Immunohistochemistry (IHC) Analysis|Immunohistochemistry (IHC) Analysis will be performed on a fresh tissue biopsy of the tumor after chemotherapy has been administered. A targeted-based regimen will be determined from the results of the IHC analysis for the next therapy given to the patient in the maintenance phase of the study.
1697015|NCT01488552|Drug|Metformin|Metformin 500 mg daily as a 24 hour extended release tablet will also be given as part of the maintenance phase of this study.
1697016|NCT01488552|Drug|mFOLFIRI|5-FU IV infusion, 2400 mg/m2 46h continuous infusion (no bolus 5-FU) treatments per month equaling 1 cycle Leucovorin 400 mg/m2 dl (over a 2 hour IV infusion) Irinotecan 180 mg/m2 dl (over a 90 minute IV infusion) Part A: nab-paclitaxel/Gem for 6 cycles, followed by FOLFIRINOX for 6 cycles (31 patients); Part B: Alternate nab-paclitaxel/Gem with mFOLFIRI every 2 months for up to 1 year or 6 cycles of each regimen (30 patients).
1697017|NCT01488539|Behavioral|STAIR/NT treatment|STAIR/NT is a two module, sequential treatment in which the first module emphasizes present-focused skills training in affective an interpersonal regulation (STAIR) for day-to-day life difficulties and the second module incorporates past-focused work on the processing of the trauma, using narrative therapy (NT). STAIR/NT is a cognitive behavioral treatment that can be flexibly applied allowing treatment tailored to the needs of the individual patient; may be as brief as 16 sessions and as long as 24.
1697018|NCT01488539|Behavioral|Treatment as Usual (TAU)|The Treatment as Usual intervention content varies from site to site and involve some combination of psychotherapy and pharmacotherapy. Treatment duration varies across sites and ranges from 30 to 45 sessions.
1697019|NCT01488526|Drug|TDF treatment|About 100 mothers treated with tenofovir from 30-32 weeks of pregnancy to the week 4 of postpartum, then observed to the end of the study at post-partum week 28, paired infants received standard HBV prophylaxis.
1697020|NCT01488513|Drug|sphingosine kinase-2 inhibitor ABC294640|Given PO Starting dose of ABC294640 250 mg once on day on Days 1-28 of each 28-day cycle. Subsequent cohort doses (if reached) are as follows: 250 BID, 500 BID, 750 BID, 1,000 BID, 1,500 BID, 2,000 BID, 2,500 BID
1697021|NCT01488500|Other|Bronchoscopy|24 hours after exposure, a bronchoscopy will be performed to allow analysis of cells and inflammatory markers in bronchial wash, bronchioalveolar lavage and lung biopsies.
1697022|NCT01488487|Drug|Everolimus|Everolimus 7.5 mg administered daily for 28 days per cycle until disease progression or unacceptable toxicity.
1697023|NCT01488487|Drug|Pasireotide|Monthly (every 28 days) intramuscular injection of long-acting pasireotide (pasireotide LAR 60 mg) repeated on day 1 of every 28 day cycle until disease progression or unacceptable toxicity.
1697024|NCT01488474|Procedure|peripheral nerve stimulation|defining the minimal current threshold for distal motor response
1697025|NCT01488461|Genetic|blood sample|Blood sample will be analysed in order to check presence or not of mutation in ABC7, SLC9A6, GPR56, ATCAY.
1697026|NCT01488448|Drug|3% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
1697027|NCT01488448|Drug|0.9% sodium chloride|4 milliliters delivered via nebulizer with 5 Liters O2 flow every 4 hours until discharge
1697028|NCT01488435|Dietary Supplement|Cow's milk|Powdered whole cow's milk
1697029|NCT01488435|Dietary Supplement|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
1697030|NCT01488422|Behavioral|Stress Reduction|We are comparing 2 well-studied approaches to stress reduction. All participants will receive stress reduction instructions that have already been proven to effectively reduce stress. Our goal is to compare the neural mechanisms associated with both approaches.
1697034|NCT01488383|Drug|Purified extract of Rebaudina Stevia-Stevioside|volunteers will take only one capsule of stevioside (one day), and then corresponding measurements will be performed.
1697035|NCT01488383|Drug|Sodium saccharin|Volunteers will take one capsule of saccharin 250mg (one day) and then, corresponding measurements will be performed
1697036|NCT01488370|Device|Endotracheal intubation|Endotracheal intubation
1697037|NCT01488344|Drug|triple kinase inhibitor BIBF1120|triple kinase inhibitor BIBF1120 is given in addition to low-dose cytarabine
1697038|NCT01488318|Drug|Cetuximab|Cetuximab 250 mg/m2 IV weekly after loading dose 400 mg/m2 on cycle 1, day 1
1697039|NCT01488318|Drug|Dasatinib|Dasatinib 150 mg po
1697040|NCT01488305|Dietary Supplement|MNP (micro-nutrient powders)|MNP is added to explore the additional value of MNP in existing AAMA program
1697041|NCT01488292|Behavioral|RECAP social skills and reading program|weekly individual and group sessions
1697043|NCT01488266|Drug|Aripiprazole|patients who are randomly assigned to adjunctive aripiprazole are treated with a starting dose of 2.5 (or 5) mg/day of aripiprazole, which can be increased weekly in 2.5~5mg/day increments to a maximum dose of 15 mg/day based on assessment of tolerability and clinical response. Doses can be decreased at any visit, based on tolerability; They continue to receive the same fixed-dose of the previously used antidepressant throughout the study period when patient is assigned to aripiprazole augmentation group.
1697044|NCT01488266|Drug|switching to different class of antidepressant|Patients randomly assigned to switching to different antidepressant have to discontinue the previously used antidepressant and receive different antidepressant within flexible therapeutic doses as indication label information (as based on clinicians' preference and experience). Dose increase is permitted until the first 2 weeks of the study.
1697045|NCT01488253|Drug|Sirolimus|Sirolimus will be administered as a 6-mg oral loading dose beginning on day -1, followed by 3 mg per day orally in a single morning dose with a target trough level of 5-12 ng/mL. Trough levels will be measured once a week. Sirolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
1697046|NCT01488253|Drug|Tacrolimus|Tacrolimus will be administered beginning on day -1 at 0.05 mg/kg intravenously by continuous infusion every 24 hours, with a target serum level of 5 to 10 ng/mL. Tacrolimus dosing is converted to oral capsules prior to discharge. Trough levels will be measured once a week. Tacrolimus will be gradually tapered beginning at day +100, and eliminated by day +180, unless the patient required continued treatment for GVHD or experienced toxicity related to drugs.
1697048|NCT01488227|Dietary Supplement|Vitamin D|4000 IU of Vitamin D daily for 6 months
1697049|NCT01488227|Dietary Supplement|Placebo|Acts as a control for the Vitamin D intervention
1697050|NCT01488214|Other|Magnetic resonance Imaging|Magnetic resonance Imaging Assessment
1697051|NCT01488201|Drug|Placebo|
1697052|NCT01488201|Drug|KHK4827|
1697053|NCT01488188|Biological|Influenza vaccine|Administration of 1 dose (0.2 ml) by nasal route
1697054|NCT01488188|Biological|Influenza vaccine|Administration of 1 dose (0.2 ml) by sublingual route
1697055|NCT01488175|Procedure|tourniquet|a tourniquet around the thigh is used during insertion of the TKA to achieve a bloodless environment
1697056|NCT01488175|Procedure|no tourniquet|a tourniquet around the thigh is not used during insertion of the TKA
1697059|NCT01488123|Behavioral|Individualized manualized Ayurvedic intervention|The manualized intervention will begin with an initial clinic visit (approximately 90 minutes) with the Ayurvedic practitioner in which the patient's diagnosis will be determined, an overview of Ayurveda will be given, and the initial treatment will be recommended based on the Ayurvedic diagnosis. Follow-up visits will range between 30 and 60 minutes in duration. The treatment modalities employed in the study will include nutrition, lifestyle, yoga, and marma (a treatment similar to acupressure).
1697060|NCT01488110|Device|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an active nasal probe.
1697061|NCT01488110|Device|In-house prototype invented by Jan-Erik Juto|30 minutes treatment with an inactive nasal probe.
1697062|NCT01488097|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose A of SBC-102 (sebelipase alfa) and bi-weekly infusions of Dose B or Dose C of SBC-102 (sebelipase alfa)
1697063|NCT01488097|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose B of SBC-102 (sebelipase alfa) and bi-weekly infusions of Dose B or Dose C of SBC-102 (sebelipase alfa)
1697064|NCT01488097|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose C of SBC-102 (sebelipase alfa) and bi-weekly infusions of Dose C of SBC-102 (sebelipase alfa)
1697065|NCT01488084|Procedure|Coronary Artery Bypass Graft Surgery|Comparison of two techniques of saphenous vein graft harvesting for coronary artery bypass graft surgery
1697066|NCT01488084|Procedure|Conventional open SVG harvesting|SVG harvested using conventional open technique and manually distended with crystalloid solution
1697067|NCT01488071|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
1697068|NCT01488071|Drug|Agomelatine|encapsulated tablets, daily, orally
1697069|NCT01488058|Other|OxIGen + iCBT|OxIGen is an Internet-based intervention taking place over 1 week followed by iCBT, an Internet-based treatment for depression taking place over 10 weeks.
1697070|NCT01488058|Other|Waitlist Control|Waitlist will receive iCBT at week 11
1697071|NCT01488045|Drug|Fentanyl|Fentanyl will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 50µg of Fentanyl. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Fentanyl in no more than 50µg increments. increments.
1697072|NCT01488045|Drug|Propofol|Propofol will be administered IV according to standard procedure for colonoscopy. The initial bolus of propofol will be up to 60 mg IV. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more sedation in 10-20 mg boluses.
1697145|NCT01487395|Drug|Placebo|the placebo will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
1697245|NCT01486563|Drug|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
1697073|NCT01488045|Drug|Midazolam|Midazolam will be administered IV according to standard procedure for colonoscopy. Initial dose will consist of no more than 2 mg of Midazolam. Patient response will be monitored for 30-60 seconds of observation before deciding to administer more Midazolam in no more than 2 mg increments.
1697074|NCT01488019|Drug|Perforomist-Placebo|Placebo vehicle, 2mL, twice daily for 52 weeks
1697075|NCT01488019|Drug|Perforomist, nebulization, COPD|Perforomist, 20 mcg/2 mL, twice daily for 52 weeks
1697076|NCT01488006|Device|Bigliani/Flatow Shoulder System|Primary Total Shoulder Arthroplasty with the Bigliani/Flatow prosthesis
1697077|NCT01487993|Drug|Metformin|Oral administration, 500 mg daily at week 1. Every week metformin dosage increases with 500 mg, to a maximum dose of 1000 mg bid. This maximum dose will be administered till the end of the study.
1697078|NCT01487993|Behavioral|Lifestyle intervention|Lifestyle intervention: 18 months physical therapy and dietary advice
1697079|NCT01487980|Procedure|Cord clamping|Early vs Delayed
1697080|NCT01487967|Other|Preference and Goal Instrument|Families in the intervention arm will receive culturally appropriate educational material, complete the Preference and Goal Instrument at the study start, use the results to inform decision making about ADHD treatment, have their preferences/goals tracked in the electronic health record, and have their progress toward their goals assessed at 3 months and 6 months (approximately).
1697081|NCT01487954|Dietary Supplement|alkaline water|Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.
1697082|NCT01487954|Dietary Supplement|distilled water|Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.
1697083|NCT01487954|Radiation|external beam radiation therapy (EBRT)|Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.
1697084|NCT01487928|Dietary Supplement|Human Milk Cream|If the caloric level of human milk (mother's own or donor) falls below 20 kcal/oz, then an appropriate amount of human milk cream will be added to the milk to bring the content as close as possible to 20 kcal/oz. For example, if the human milk is 19 kcal/oz, 2 mL of human milk cream will be added to 100mL of human milk.
1697085|NCT01487915|Drug|GCb|Gemcitabine 1000 mg/㎡ D1, D8 plus Carboplatin AUC=4.5 D1 every 3 weeks
1697086|NCT01487915|Drug|GemOx|Gemcitabine 1000 mg/㎡ D1 plus Oxaliplatin 100 mg/㎡ D1 every 2 weeks
1697087|NCT01487902|Drug|ADT|Luprolide 11.25 mg long-acting depo (Lucrin Depot PDS inj®) every 12 weeks SC wit Docetaxel-prednisolone (TAX327 regimen)
1697088|NCT01487902|Drug|No ADT|Docetaxel-prednisolone (TAX327 regimen) alone
1697089|NCT01487889|Other|Fatty acid composition of complementary food|Groups receive commercial vegetable-potato-meat-meals as part of complementary food which differs in the fatty acid composition
1697090|NCT01487876|Biological|HBV DNA vaccine|HBV DNA vaccine means that each volunteer received 4 injections of 4 mg DNA vaccine scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
1697091|NCT01487876|Other|Placebo|Placebo means the arm in which each volunteer received 4 injections of 4 mg placebo scheduled by a prime and 3 boosts at intervals of 4, 8, 12 weeks.
1697092|NCT01487863|Biological|sipuleucel-T|Sipuleucel-T is an autologous cell product consisting of antigen presenting cells (APCs) loaded with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
1697093|NCT01487863|Drug|abiraterone acetate|Abiraterone acetate (1000 mg po QD) was administered in combination with prednisone (5 mg po BID) for a total of 26 weeks.
1697094|NCT01487850|Biological|blood sample|blood sample in each musician to search for specific antibodies against molds isolated from instruments
1697095|NCT01487837|Drug|Human fibrinogen concentrate|Administration of human fibrinogen concentrate (30 mg / kg bw) over 15 min Repetition if hourly intraoperative ROTEM measurements revealed hypofibrinogenemia according to treatment group definition
1697096|NCT01487811|Drug|biphasic insulin aspart 30|Single dose administrated subcutaneously (s.c., under the skin)
1697097|NCT01487798|Drug|biphasic human insulin 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
1697098|NCT01487798|Drug|biphasic insulin aspart 30|Administrated s.c. (subcutaneously, under the skin) for 16 weeks in treatment period 1 followed by 16 weeks in treatment period 2
1697099|NCT01487785|Drug|LDE225+gemcitabine|Patients will receive increasing doses of LDE225 (from 400 mg), depending on the cohort they are assigned to, orally once daily and standard doses of gemcitabine (1000 mg/m2) on days 1, 8 and 15 of every 28-day cycle. Patients will receive the study treatment until they progressed, experience unacceptable toxicity, withdraw from the study, or the investigator decides it is in their best interest to discontinue the study treatment.
1697100|NCT01487759|Dietary Supplement|Oligofructose enriched inulin|
1697101|NCT01487759|Dietary Supplement|Maltodextrin|
1697102|NCT01487733|Genetic|gene expression analysis|
1697103|NCT01487733|Genetic|in situ hybridization|
1697104|NCT01487733|Other|immunohistochemistry staining method|
1697105|NCT01487733|Other|laboratory biomarker analysis|
1697106|NCT01487720|Drug|GEMOX|Gemcitabine 1000 mg/m2 IV on day 1 every 2 weeks (fixed-dose rate 10 mg/m2/min) Oxaliplatin 100 mg/m2 IV on day 1 every 2 weeks Prednisolone 5 mg twice a day orally daily
1697107|NCT01487707|Behavioral|Voluntary Health Worker (VHW) Program|Voluntary Health Workers will conduct door-to-door campaigns on maternal and child health, and will visit pregnant women regularly to to educate and to encourage use of antenatal care and facility-based deliveries.
1697108|NCT01487707|Behavioral|Safe Birth Kit|A safe birth kit, containing sterile materials to diminish infection risk will be given to pregnant women.
1697109|NCT01487707|Behavioral|Community Folk Media Campaigns|Community-wide media activities, including dramas, intended to address community norms regarding maternal and child health.
1697110|NCT01487694|Drug|cimicifuga racemosa|Cimicifuga racemosa (black cohosh) rhizome and root extract 40 mg once daily for 12 weeks (equivalent to triterpene glycosides 12.3 mg)
1697111|NCT01487694|Drug|placebo|matching placebo without active ingredient 1 tab daily for 12 weeks
1697146|NCT01487382|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice
1697246|NCT01486550|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg minimum
1697112|NCT01487668|Behavioral|Life Goals Collaborative Care|LGCC consists of 1) 10 self-management sessions that cover personal goal-setting and mental health symptom management reinforced through healthy lifestyles; 2) medical care management that includes identification of patient medical risk factors, monitoring of patient symptoms and medical needs via a registry over time; and 3) support for provider guidelines and community linkages.
1697113|NCT01487642|Device|Standard 15-minute telephone counselling|Subjects in arm 1 will benefit from a standard 15-minute telephone counselling session with a professional adviser which resembles a normal call to the national Quit-line. The telephone counselling will be reactive, thus the smoker initiates the call to a designated number to receive advice and information based on the needs and wishes of this particular smoker. Participants can receive self-help materials and information on other smoking cessation services if they wish.
1697114|NCT01487642|Device|Proactive telephone counselling|subjects in arm 2 will benefit from of five 15-minute calls from a professional adviser. Similar to the standard reactive telephone counselling, the proactive counselling will be a personal discussion and advice based on the needs and wishes of the particular participant. Together, the participant and adviser will determine a cessation date and schedule one call 3-7 days before the cessation date, one call immediately after the cessation date and three additional calls on days 3, 10 and 24, respectively, post-cessation.
1697115|NCT01487642|Device|Interactive web-based smoking cessation programme|Subjects in arm 3 will benefit from a tailored and interactive web-based smoking cessation programme. Besides interactive and personalised information generated on the webpage, the participant will receive by e-mail and SMS tailored feedback messages based on the particular profile of the participant on particular dates as well as topics during the cessation period depending on how well the cessation is proceeding.
1697116|NCT01487642|Device|Self-help material|Participants receives self-help materials and on request information on other smoking cessation services if they wish.
1697117|NCT01487629|Drug|Bevacizumab|Bevacizumab, 1.5 mg, intravitreal, throughout the study
1697118|NCT01487629|Drug|Ranibizumab|Ranibizumab, 0.5 mg, intravitreal, throughout the study
1697119|NCT01487590|Other|Acupuncture moxibustion|Six interventions with acupuncture moxibustion, stimulating point BL67, during 20 minutes each, 48 hours apart.
1697120|NCT01487590|Other|Placebo|Six interventions with placebo (inactivated laser), stimulating point BL67, during 20 minutes each, 48 hours apart
1697121|NCT01487577|Drug|Mycophenolate mofetil|Based on individual pharmacokinetics data, mycophenolate mofetil will be administered by continuous infusion to target a desired AUC exposure
1697122|NCT01487564|Drug|Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, format= tablet, route= oral use. One tablet of hydromorphone 16 mg.
1697123|NCT01487551|Drug|paquinimod|Hard gelatine capsules 3.0 mg/day for 8 weeks
1697124|NCT01487538|Behavioral|Videos|Provide information on physical activity, diet, calorie tracking to support weight maintenance in rural women.
1697125|NCT01487538|Behavioral|Action Plans|Online action plans will be used by subjects to set and evaluate physical activity goals
1697126|NCT01487538|Behavioral|Discussion Boards|forum to exchange information and experiences
1697127|NCT01487538|Behavioral|Health behavior tracking|online tracking of weight for both intervention and standard advice group. In addition, the intervention group will also track their calories in and out and their pedometer steps
1697128|NCT01487525|Device|Double leg press with partial blood flow restriction|double isotonic and isokinetic leg press extension with application of partial blood flow restriction to the upper leg
1697129|NCT01487525|Other|Double leg press without partial blood flow restriction|double isotonic and isokinetic leg press extension without application of partial blood flow restriction to the upper leg
1697130|NCT01487512|Drug|Treatment A: Hydromorphone 8 mg|type= exact number, unit= mg, number= 8, form= tablet, route= oral use. One tablet of Hydromorphone 8 mg in each of 4 treatment sequences.
1697131|NCT01487512|Drug|Treatment B: Hydromorphone 16 mg|type= exact number, unit= mg, number= 16, form= tablet, route= oral use. One tablet of Hydromorphone 16 mg in each of 4 treatment sequences.
1697132|NCT01487512|Drug|Treatment C: Hydromorphone 32 mg|type= exact number, unit= mg, number= 32, form= tablet, route= oral use. One tablet of Hydromorphone 32 mg in each of 4 treatment sequences.
1697133|NCT01487512|Drug|Treatment D: Hydromorphone 64 mg|type= exact number, unit= mg, number= 64, form= tablet, route= oral use. One tablet of Hydromorphone 64 mg in each of 4 treatment sequences.
1697134|NCT01487499|Drug|Cisplatin|40 mg in 40 mL of normal saline for each of 4 bronchoscopies
1697135|NCT01487486|Drug|IVF Antagonist Protocol|"Ovulation Induction: Achieved with recombinant FSH (Follistim®) with or without HMG (Menopur®) at total doses of 75-450 IU/day subcutaneous (SC) for 9-14 days.
Ovulation Suppression: GnRH Antagonist (Ganirelix® - 250microgram 0.5ml) will be initiated following ovulation induction when lead follicle >14mm diameter on ultrasound and continued through the day of hCG (Novirel® or Ovidrel ®) injection
hCG Injection: Once patient has met criteria for oocyte retrieval, she will inject either Novarel® (5,000-10,000 units Intramuscular) or Ovidrel® (250microgram - 500microgram SC) 35 hours prior to oocyte retrieval."
1697136|NCT01487473|Behavioral|Mindfulness-Based Stress Reduction|An 8-week structured group program that was developed to improve psychological and physical symptoms associated with pain. It incorporates a variety of mindfulness meditation exercises including mindful yoga, sitting meditation, and body scan to facilitate attention, acceptance, and awareness of one's experiences.
1697137|NCT01487460|Drug|TAP311|
1697138|NCT01487447|Other|Customized sound|treatment with customized sound therapy
1697139|NCT01487447|Other|Regular Masker|treatment with white noise
1697140|NCT01487434|Behavioral|Check & Connect|Structured mentoring and case management
1697141|NCT01487421|Drug|insulin aspart|Subjects were observed over a time period of 12 weeks after initiation of a supplementary insulin therapy regimen (SIT) with insulin aspart at mealtimes. Administrated subcutaneously (s.c., under the skin)
1697142|NCT01487421|Drug|insulin detemir|Insulin detemir were added to insulin aspart in the evening or at bedtime, if needed. Administrated subcutaneously (s.c., under the skin)
1697143|NCT01487408|Drug|insulin aspart|Adminstered subcutaneously (s.c., under the skin). Prescribed by physician as a results of normal clinical practice
1697144|NCT01487395|Drug|Donepezil .|Donepezil will be administered OS as of 5 mg- Orally Disintegrating Tablets one per day in the morning over 15 days.
1755267|NCT00239265|Drug|Tamuslosin|
1697147|NCT01487369|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin). Prescribed by physician as a result of normal clinical practice.
1697148|NCT01487356|Other|No intervention|Colonoscopies were conducted as per the endoscopist's usual practice. No change in protocol was expected.
1697149|NCT01487343|Behavioral|questionnaire and interview|Interviews will be conducted with the first 10 participants who agree to be interviewed (or until data saturation is reached). Self-report questionnaires assessing adherence, beliefs about medications, side effect experience, self-efficacy, and satisfaction with patient education; the qualitative portion is an interview guided by two open-ended questions. Data will be collected approximately 2 weeks - 6 months (2 - 24 weeks) after being prescribed capecitabine.
1697150|NCT01487330|Device|Transcatheter Aortic Valve Implantation (TAVI)|Placement of the SJM TAVI aortic valve with a transfemoral delivery system.
1697151|NCT01487317|Drug|Rivastigmine transdermal patch|One transdermal patch of Rivastigmine (equivalent to 4.6 mg/24h per os) per day from randomization to day 14 before day 14: end od treatment, if DRS R-98 severity < 10 during 2 consecutive days At day 14, if DRS R-98 severity ≥ 10: one transdermal patch of Rivastigmine 9.5 mg/24h per day from day 14 to day 30 if DRS R-98 severity < 10, the active treatment will be stopped
1697152|NCT01487317|Drug|placebo patch|One transdermal patch of placebo per day from randomization to day 14 Before day 14: end of treatment if DRS R-98 severity < 10 during 2 consecutive days, At day 14 if DRS R-98 severity ≥ 10: One transdermal patch of placebo per day from day 14 to day 30 if DRS R-98 severity < 10, the placebo treatment will be stopped
1697153|NCT01487304|Drug|Marketed low dose hormone replacement therapy|A low dose of marketed HRT products prescribed at the discretion of the treating physician
1697154|NCT01487278|Drug|misprostol|600 mcg misoprostol oral
1697155|NCT01487278|Device|UnijectTM|10 IU oxytocin delivered intramuscularly with UnijectTM
1955830|NCT03054402|Drug|BAY1834845|Escalating doses of BAY1834845 including comparison of solution and tablet in one dose group
1697157|NCT01487252|Behavioral|At home saliva sampling|Saliva samples taken every half an hour in evening before bedtime.
1697158|NCT01487239|Drug|[14C]-GDC-0980|100 uCi of [14C]-GDC-0980 in total dose of 10 mg GDC-0980
1697159|NCT01487226|Drug|paclitaxel|Paclitaxel 175 mg/m2 over 3 hr Repeat every 3 weeks * 6 cycles
1697160|NCT01487226|Drug|Cisplatin 50mg/m2|"Cisplatin 50mg/m2
Repeat every 3 weeks * 6 cycles"
1697161|NCT01487213|Other|Home self assessment of complete medical abortion|Self assessment of complete abortion using a home semiquantitative U-hCG test. Follow-up out patient review two-three weeks later by qualified practitioner to evaluate success of procedure using the clinic's standard routine. The patient charts will be reviewed after three months in order to control for possible extra visits related to abortion-related complications.
1697164|NCT01487187|Procedure|Milking the umbilical cord at birth|Infants in the cord-milked group will be placed at or below the level of the placenta, and about 20 cm of the umbilical cord (or the length of cord that is accessible if less than 20 cm) will be vigorously milked towards the umbilicus three times before clamping the cord
1697165|NCT01487187|Procedure|immediate umbilical cord clamping|immediate cord clamping without milking as per standard practice
1697166|NCT01487174|Drug|KD019|KD019 will be administered orally once daily at a dose of 300 mg. One dose reduction to 200 mg will be permitted.
1697167|NCT01487174|Drug|Erlotinib|Erlotinib will be administered orally once daily at a dose of 150 mg. One dose reduction to 100 mg daily will be permitted.
1697168|NCT01487161|Drug|FX006|Single intra-articular injection
1697169|NCT01487161|Drug|Commercially available triamcinolone acetonide|Single intra-articular injection
1697170|NCT01487135|Drug|EVP-6124|A single oral low dose of EVP-6124 in cranberry juice (180 mL) administered on Day 1 and a high dose of EVP-6124 in cranberry juice (180 mL) administered on Day 2.
1697171|NCT01487135|Drug|Placebo|Cranberry juice only (180 mL) administered orally on both Day 1 and Day 2.
1697172|NCT01487135|Drug|Moxifloxacin|A moxifloxacin 400 mg tablet administered orally on Day 1
1955831|NCT03054402|Drug|Placebo|Single dose of placebo
1697176|NCT01487109|Drug|CTP-499|600 mg tablet twice daily
1697177|NCT01487109|Drug|Placebo|Matching placebo tablet
1697178|NCT01487096|Drug|Teriflunomide|"film-coated tablet
oral administration"
1697179|NCT01487096|Drug|Placebo (placebo for teriflunomide)|"film-coated tablet
oral administration"
1697180|NCT01487083|Drug|Pomaglumetad methionil|Administered orally
1697181|NCT01487070|Drug|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.
Pegaptanib sodium is formulated at 0.3mg/90µl and presented in a USP Type I glass barrel syringe sealed with a bromobutyl rubber stopper. A 30-guage needle is fixed to the end of the syringe after removal of the rubber stopper. The syringe comes in a sealed foil pouch, and the 30-gauge needle is added to the sterile injection field separately. The drug product is preservative-free and intended for single use by intravitreous injection only."
1697210|NCT01486823|Drug|MLDL1278A|Single intravenous dose of 360 mg MLDL1278A followed by a single subcutaneous dose of 360 mg MLDL1278A.
1697211|NCT01486823|Drug|MLDL1278A|Single subcutaneous dose of 360 mg MLDL1278A.
1697212|NCT01486810|Drug|Lisdexamfetamine|Patients will be titrated to the tolerated dose over a two week period, with a maximum of 140mg daily, and then maintained on the highest tolerated dose for four weeks
1697247|NCT01486550|Drug|Sodium Chloride 9mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
1955834|NCT03051607|Drug|Tozadenant|1 Year Open Label, 120 mg BID tozadenant, with dose modification to 60 mg BID tozadenant permitted.
1697182|NCT01487044|Drug|Macugen (Pegaptanib Sodium)|"Pegaptanib sodium drug substance is a pegylated (40 kDa branched PEG molecule consisting of two 20 kDa PEG arms) anti-VEGF aptamer. It is formulated in phosphate buffered saline at pH 6-7. Sodium hydroxide or hydrochloric acid may be added for pH adjustment.
Pegaptanib sodium is formulated at 0.3mg/90µl and presented in USP Type I glass barrel syringes sealed with a bromobutyl rubber plunger stopper. The syringe has a needle attachment at allows for a 30-guage need to be fixed to the syringe prior to injection. The stoppered syringe is packaged in a foil pouch. The drug product is preservative-free and intended for single use by intravitreous injection only."
1697183|NCT01487031|Other|Music Therapy|Patients randomized to receive music therapy will receive 2 sessions of live music therapy, at least 48 hours apart, from a Music Therapist-Board Certified (MT-BC, certified through the Certification Board for Music Therapists) in their room
1697184|NCT01487031|Other|No music therapy|Those patients randomized to standard therapy (no music therapy) are allowed to listen to music; however they will not receive interactive music therapy from a certified therapist.
1697185|NCT01487018|Procedure|Navigation Surgery|To evaluate the feasibility and accuracy of a new method for planning and realizing zygomatic osteotomies in cases of established post-traumatic deformities using computer assisted navigation.
1697186|NCT01487018|Procedure|Traditional Surgery|To compare with the experamental group.
1697187|NCT01486992|Drug|mFOLFIRI+Nimotuzumab|irinotecan 180mg/m2，iv ，d1，LV 200 mg/m2 ，2h，d1，5-FU 400 mg/m2， iv，d1 5-FU 2400mg/m2，CIV，46h，q2w Nimotuzumab 200mg，iv，qw
1697188|NCT01486979|Drug|estradiol, 10 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
1697189|NCT01486979|Drug|estradiol, 25 mcg|One vaginal tablet once daily in the morning during the first two weeks of treatment followed by one vaginal tablet twice weekly in the morning for 10 weeks
1697190|NCT01486966|Drug|insulin detemir|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
1697191|NCT01486966|Drug|insulin aspart|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
1697192|NCT01486966|Drug|insulin NPH|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) once daily using NovoPen®4
1697193|NCT01486966|Drug|human soluble insulin|Dose individually adjusted. Administered subcutaneously/s.c. (under the skin) three times a day before a meal using NovoPen®4
1697194|NCT01486966|Drug|metformin|For subjects previously treated with metformin, the dosage and frequency will be kept unchanged
1697195|NCT01486953|Drug|Desflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received desflurane 6-7% for maintenance of anesthesia.
1697196|NCT01486953|Drug|Sevoflurane|Using random numbers, patients were divided into two groups to receive either sevoflurane or desflurane. After induction of anesthesia and intubation, the patient's lungs were ventilated in constant-flow VCV mode by an anesthetic Ventilator (Datex-Ohmeda, GE healthcare, Finland). Ventilator settings were tidal volume 10 ml/kg, inspiratory:expiratory (I:E) ratio 1:1.5, inspired oxygen concentration (FiO2) 0.5 with air, and 3 L/min of inspiratory fresh gas flow. End-inspiratory pause was set 20% of total breathing cycle. Positive end-expiratory pressure (PEEP) was not used. Respiratory rate was adjusted to maintain an end-tidal CO2 pressure of 33-35 mmHg. Patients received sevoflurane 2-2.5% for maintenance of anesthesia.
1697197|NCT01486940|Drug|insulin detemir|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
1697198|NCT01486940|Drug|insulin aspart|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
1697199|NCT01486940|Drug|insulin NPH|Individually adjusted dose administered subcutaneously (s.c., under the skin) twice daily
1697200|NCT01486940|Drug|human soluble insulin|Individually adjusted dose administered subcutaneously (s.c., under the skin) prior to meals
1697201|NCT01486927|Biological|rVIII-SingleChain|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg recombinant, single-chain coagulation factor VIII (rVIII-SingleChain) preceded by a 4-day washout period. In Parts 2 and 3 of the study, subjects received repeat injections of rVIII-SingleChain either as an on-demand or prophylaxis regimen at a dose and frequency determined by their study doctor. Subjects participating in the Part 3 PK analyses received a single infusion of 50 IU/kg rVIII-SingleChain and a repeat dose of the same strength of rVIII-SingleChain after 3 to 6 months. Subjects from Parts 2 and 3 participating in the surgical substudy received an individualized dose regimen of rVIII-SingleChain, based on the type of surgery and the clinical status of the subject.
1697202|NCT01486927|Biological|Octocog alfa|In Part 1 of the study, subjects received a single intravenous infusion of 50 IU/kg of octocog alfa preceded by a 4-day washout period. Octocog alfa is the international nonproprietary name (INN) for recombinant human coagulation factor VIII.
1697203|NCT01486914|Drug|insulin aspart|Single dose of each formulation administrated subcutaneously (s.c., under the skin) at two separate dosing visits
1697204|NCT01486901|Drug|isophane human insulin|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
1697205|NCT01486888|Drug|biphasic human insulin 30|Single dose of each formulation, administered subcutaneously (s.c., under the skin) on two separate dosing visits
1697206|NCT01486875|Drug|biphasic insulin aspart 30|Dose individually adjusted, and administered subcutaneously (under the skin) once or twice daily
1697207|NCT01486862|Drug|biphasic insulin aspart 30|Dose individually adjusted. Administered once daily for 16 weeks. If HbA1c after 16 weeks of treatment is above 7.0%, insulin is administered twice daily for additional 16 weeks.
1697213|NCT01486797|Drug|NOX-A12|"Pilot Group (NOX-A12 single agent, and combined with BR):
3 cohorts of 3 patients will receive treatment with NOX-A12 alone at a single dose of 1, 2 or 4 mg/kg i.v. 2 weeks before the combination treatment of NOX-A12 and BR begins.The combination of NOX-A12 and BR will follow a dose titration design beginning at 1 mg/kg NOX-A12 (cycle 1), proceeding to dose levels of 2 mg/kg (cycle 2) and 4 mg/kg (cycle 3) NOX-A12 in combination with BR. This is followed by consolidation in cycles 4-6 when NOX-A12 will be kept at the highest individually titrated dose.
Expansion Group (NOX-A12 in combination with BR):
Expansion patients will not receive single agent NOX-A12, but will receive combination treatment as for the pilot group."
1697214|NCT01486784|Drug|TL32711|
1697215|NCT01486771|Drug|Macugen ® (pegaptanib sodium)|"Patients assigned to either IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. The group will then receive an intravitreal injection every 12 weeks.
Patients assigned to IV Mac Q6Arm will receive a total of 3 intravitreal pegaptanib sodium injections administered at 6-week intervals beginning on Day 0 and ending at Week 12. After the third injection subjects in this group will receive Selective Laser Photocoagulation at Week 18.
Patients assigned to Panretinal Photocoagulation will act as the control group. Subjects in this group will receive standard Panretinal Photocoagulation using a modified ETDRS protocol.
All intravitreal study injections will consist of 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection."
1697216|NCT01486758|Drug|Azithromycin|Oral azithromycin 10 mg/kg once daily for 7 days followed by 5mg/kg once daily for additional 7 days.
1697217|NCT01486758|Drug|Placebo|
1697218|NCT01486732|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion intravenously or intraarterially under non-myeloablative immunosuppression.
1697219|NCT01486732|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They will receive two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 2.5 months.
1697220|NCT01486732|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood that resembles cord blood in appearance was designed : 1.5 to 3 ml of the subject's own blood was collected and mixed with 15 to 20 ml of albumin
1697221|NCT01486719|Procedure|Sensate Dorsal Digital Island Flap|This article reports repair of the finger pulp defect using the dorsal digital island flap. Both dorsal branches of the proper digital nerves (PDNs) were used for maximal sensory restoration.
1697222|NCT01486706|Drug|Gabapentin|100mg/capsule initially one capsule once a day then titrate according to the symptoms of the patient upto maximum dose of 1500mg/day
1697223|NCT01486706|Drug|Solifenacin Succinate|5mg/tablet initially 1 tablet once a day then titrate up to maximum dose of 10mg/tab
1697224|NCT01486706|Drug|Placebo drugs|will titrate medications similar to the active drug group
1697225|NCT01486680|Procedure|Laparoscopic Silastic Ring Roux-en-Y Gastric Bypass|An isolated lesser curve-based gastric pouch will be created, with an antecolic antegastric Roux limb fashioned measuring 100 cm in length. The biliopancreatic limb will measure 50cm for all patients. A 6.5cm silastic ring will be placed above the gastrojejunostomy to prevent long term stomal dilatation.
1697226|NCT01486680|Procedure|Laparoscopic Sleeve gastrectomy|Resection of the greater curvature of the stomach from the distal antrum (2cm proximal to pylorus) to the angle of His, using a laparoscopic stapling device over a 36Fr bougie, will be performed to create a lesser curve gastric sleeve
1697227|NCT01486667|Drug|levothyroxine|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of levothyroxine will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of levothyroxine. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
1697228|NCT01486667|Drug|sugar pill|Eligible patients will be randomized and be given 25 mcg of levothyroxine or identical placebo tablet at the beginning of the enrollment. The dosage of drug will subsequently be individualized for each patients according to Serum levels of TSH and FT4 which will be checked initially and then every 6 weeks until the end of the study. The investigators will attempt to maintain TSH levels between (0.25-2.5) mU/l which is the lower half of normal range by adding or reducing the dose of medication. Advice given to patient regarding whether to increase or decrease the dose of medications will be based on patient TSH level according to study protocol.
1697229|NCT01486654|Device|Transcranial Direct Current Stimulation - Cathodal stimulation|Cathodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
1697230|NCT01486654|Device|Transcranial Direct Current Stimulation - Anodal stimulation|Anodal transcranial direct stimulation (tDCS) to the left hemisphere, 1.0 mA for 13 minutes, is received five days a week, for six weeks, during the initial 13 minutes of 90 minutes of speech-language treatment.
1697231|NCT01486654|Device|Transcranial Direct Current Stimulation - Sham stimulation|Sham stimulation provided together with 90 minutes of speech language therapy, 5 days a week, for 6 weeks.
1697232|NCT01486641|Procedure|Anterolateral approach|Anterolateral approach acording to Gammer for hip arthroplasty.
1697233|NCT01486628|Drug|ND0612|levodopa and carbidopa solution for subcutaneous administration
1697234|NCT01486628|Drug|Placebo|Saline solution for SC continuous administration
1697235|NCT01486615|Drug|meloset (melatonin)|3 mg melatonin tablet 1-2 hour prior surgery
1697236|NCT01486615|Drug|stresnil ( melatonin and alprazolam)|3 mg melatonin and 0.5 mg alprazolam 1-2 hr before anesthesia
1697237|NCT01486615|Drug|(alprax) alprazolam|0.5 mg alprazolam
1697238|NCT01486615|Drug|placebo|similar looking placebo tablet
1697239|NCT01486602|Drug|carboplatin|IV
1697240|NCT01486602|Drug|paclitaxel|IV
1697241|NCT01486602|Radiation|radiation therapy|Defined per the protocol
1697242|NCT01486576|Drug|Voluven (Hydroxyethyl starch 130/0,4)|7,5 ml/kg in the first hour and then 5 ml/kg
1697243|NCT01486576|Drug|Sodium Chloride 9 mg/ml|7,5 ml/kg in the first hour and then 5 ml/kg
1697466|NCT01484561|Drug|Placebo|Placebo BID orally, approximately 72 days
1697250|NCT01486485|Drug|heparinized saline priming group|
1697251|NCT01486485|Drug|nafamostat infusion after heparinized saline priming|
1697252|NCT01486472|Drug|S-1|Adjuvant S-1 chemotherapy will be performed to GC patients receiving curative D2 gastric surgery
1697253|NCT01486459|Drug|Lithium|250 mg daily for 6 weeks, increased 250 - 500 mg depending on plasma levels.
1697254|NCT01486446|Drug|XPF-002|XEN402 8% w/w ointment for topical application, applied to the skin twice daily for 14 or 21 days
1697255|NCT01486446|Drug|Placebo|XEN402 0% w/w ointment for topical application. Identical content and appearance to the XPF-002 ointment but without the active medicine. Applied to the skin twice daily for 14 or 21 days.
1697256|NCT01486433|Drug|Simvastatin|40 mg (1 tablet) simvastatin once a day
1697257|NCT01486433|Drug|acetylsalicylic acid (ASA)|81 mg aspirin (1 tablet), once a day, co-administered with simvastatin
1697258|NCT01486433|Drug|omefas|4 g (4 capsules) Epanova once a day, co-administered with simvastatin and aspirin
1697259|NCT01486420|Procedure|Corticosteroid injections|Corticosteroid injections in and around A1-pulley.
1697260|NCT01486420|Procedure|Open surgery|Open A1-pulley release
1697261|NCT01486394|Other|Focused Sonography of the heart, lungs and deep veins|The patient is randomised to either a control group where usual treatment and diagnostic work-up is performed or to an intervention group where usual treatment and diagnostic workup are supplemented by a sonographic examination of the heart, lungs and deep veins are performed within one hour after the primary evaluation. The primary evaluation is defined as the first evaluation of the patient by a physician in the Acute Medical Admission Department.
1697262|NCT01486381|Drug|biphasic insulin aspart 30|Administered subcutaneously (s.c., under the skin)
1697263|NCT01486368|Drug|PF-03446962|PF-03446962 will be administered by IV infusion every 2 weeks (q2w). A cycle will be 2 weeks in duration and include one administration of PF-03446962.
1697264|NCT01486355|Biological|Measles vaccine|Edmonston-Zagreb measles vaccine
1697265|NCT01486342|Radiation|PET-CT scan|"PET-CT imaging with [18F]FDG will be performed within 24 hours of admission to the ICU. All patients imaged will be those remaining on mechanical ventilation at the time of PET imaging.
A low-dose CT scan (50 effective mAs) will be obtained with placement of the participant such that the lungs are centered within the field of view. After completing the transmission scan, 10 mCi of [18F]FDG will be injected intravenously at the start of a 60-minute dynamic scan acquisition and the intravenous (IV) catheter flushed with 10 ml saline. Imaging will be obtained with the following framing schedule: 24 5-sec, 6 3-minute and 8 5-minute frames."
1697266|NCT01486329|Biological|VXM01|Live anti-angiogenic cancer vaccine drink solution, escalating dose
1697267|NCT01486329|Biological|Placebo|Drink solution
1697270|NCT01486303|Procedure|Facial Cosmetic Acupuncture|Patients received five treatment sessions during 3 weeks. Facial cosmetic acupuncture was applied at muscles and acupoints on the face, head and neck
1697271|NCT01486290|Behavioral|Behavioral|the intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by an office based educator over a six month by phone calls. From six months to twelve months subjects did not have any contact with study staff.
1697272|NCT01486277|Drug|Quisinostat, 12 mg|Participants will receive quisinostat 12 mg capsule orally (by mouth) on Days 1, 3, and 5 of each week in a 21-day treatment cycle, until a reason for discontinuation is met (ie, disease progression, toxicity, availability of other effective medications that the participant may receive, or treating physician advice).
1697273|NCT01486264|Biological|Xeomin®|Xeomin is botulinum toxin type A produced from fermentation of Hall strain Clostridium botulinum serotype A
1697274|NCT01486251|Drug|axitinib|"Axitinib will be given BID orally. The 3 dose levels tested will be: 1st cycle: 5 mg BID; 2nd cycle: 7 mg BID; 3rd cycle: 10 mg BID.
One cycle is defined as a 14-day period (7 days ON / 7 days OFF). Patients will receive a first cycle of single agent axitinib at the starting dose with DCE-US assessment. If no study treatment-related adverse event (AE) of grade > 1 is observed during this cycle, intrapatient dose escalation will be performed for the second cycle. The same dose escalation method wil apply between the 2d and 3d cycles."
1697275|NCT01486238|Drug|Macugen® pegaptanib sodium|"Patients assigned to either arm (IVMac q4 and IVMac q6) will receive 0.3 milligrams (mg) of pegaptanib sodium delivered by intravitreal injection administered.
Patients assigned to IVMac q4 will receive a total of 6 intravitreal Macugen® injections administered at 4 week intervals beginning on Day 0 and ending at Week 20. Patients assigned to IVMac q6 will receive a total of 4 intravitreal Macugen® injections administered at 6 week intervals beginning on Day 0 and ending at Week 18. Each Macugen® injection will be administered as described in the package insert."
1697276|NCT01486225|Device|Innothera's brand Stockings|15 patients having used Innothera branded Stocking
1697277|NCT01486225|Other|Stockings other than Innothera's brand|15 patients having used any other brand than Innothera's brand stockings
1697278|NCT01486199|Other|Absorptive clearance scan|Subjects will inhale a nebulized mixture of the radiopharmaceuticals Indium 111-DTPA and Technetium 99m-sulfur colloid.
1697279|NCT01486186|Drug|Traditional Chinese Medicine|A herbal extract twice daily for 52 weeks for lower dosage, There are 3 Recipe for the 3 traditional Chinese syndrome, they are syndrome of lung-qi deficiency, syndrome of deficiency of pulmonosplenic qi, syndrome of insufficiency of QI of the lung and kidney.
1697280|NCT01486186|Drug|placebo chinese medicine|There are 3 placebo Recipe for the 3 traditional Chinese syndrome.
1697281|NCT01486147|Behavioral|Visual nutrient profiling tool|Shown color coded fiber and protein 2x2 plot, selected fiber and protein ratings from boxes on the plot.
1697282|NCT01486147|Behavioral|Nutrient ratings table|Showed nutrition information and had to match to fiber and protein ratings from a table.
1697283|NCT01486134|Procedure|Multipolar Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
1697284|NCT01486121|Other|Therapy strategy|Sedation & mechanical ventilation
1697285|NCT01486108|Procedure|dorsal column stimulator|test different settings of stimulation
1697286|NCT01486095|Device|AXXESS + Biomatrix Biolimus Eluting stent|NAP
1697287|NCT01486095|Device|Culotte technique with Xience V or Xience Prime stents|NAP
1697288|NCT01486082|Other|OCA 10|A group will be treated with omeprazole (20 mg / 12 h), amoxicillin (1 g/ 12 h)and clarithromycin (500 mg/12 h) for 10 days (as following current guides) without having a previous antibiogram, and the other group will be treated after antibiotic susceptibility.
1697289|NCT01486043|Drug|Metformin|All subjects will be started on metformin 500 mg orally twice daily. The dose will be increased by 500 mg weekly as tolerated until subjects' blood glucoses are well controlled or until the patient reaches metformin 1000 mg PO BID.
1697290|NCT01486017|Drug|ASP015K|oral
1697291|NCT01486004|Drug|TMC435|Type = exact number, unit = mg, number = 150, form = capsule, route = oral use. Capsule is taken once daily for 10 days (Day12 till and including Day21) in 2nd OC cycle.
1697292|NCT01486004|Drug|Ovysmen|Type = exact number, unit = mg, number = 35µg/1mg, form = tablet, route = oral use. 35 µg ethinylestradiol and 1 mg norethindrone once daily for first 21 days in each OC cycle (2 OC cycles in total)
1697293|NCT01485991|Drug|TMC435|TMC435 Type=exact number, unit=mg, number=150, form=capsule, route=oral use. TVR placebo Form=tablet, route=oral use. TMC435 capsule is taken once daily in addition to 2 TVR placebo tablets 3 times a day for 12 weeks, and peginterferon alfa-2a and ribavirin for 48 weeks.
1697294|NCT01485991|Drug|TVR|TVR Type=exact number, unit=mg, number=375, form=tablet, route=oral use. TMC435 placebo Form=capsule, route=oral use. 2 TVR tablets are taken 3 times a day together with 150 mg TMC435 placebo capsule once daily for 12 weeks, in addition to peginterferon alfa-2a and ribavirin for 48 weeks
1697298|NCT01485965|Drug|SEN0014196|100 mg, immediate release tablets, once daily administration
1697299|NCT01485952|Drug|SEN0014196 (Low Dose)|10 mg once daily administration (immediate release capsule)
1697300|NCT01485952|Drug|SEN0014196 (High Dose)|100 mg once daily administration (immediate release capsule)
1697301|NCT01485952|Drug|Placebo|Once daily administration (immediate release capsule)
1697302|NCT01485939|Other|placebo patch applied|Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.
1697303|NCT01485939|Other|5% lidocaine patch|Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
1697304|NCT01485926|Drug|Docetaxel, Carboplatin and Trastuzumab|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab 8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
1697305|NCT01485926|Drug|Docetaxel, Carboplatin, Trastuzumab and Lapatinib|6 cycles q3weekly Docetaxel (75mg/m²) + Carboplatin (AUC 6) + Trastuzumab (8 mg/kg on day 1 (loading dose) and 6mg/kg for subsequent cycles, q3weekly thereafter.) + Lapatinib (1000mg daily) until 1 week prior to surgery. Patients will be scheduled for surgery and will continue to receive Trastuzumab post-operatively 6 mg/kg for one year from 1st dose of Trastuzumab.
1697306|NCT01485913|Other|intensive education intervention using a network of involved diabetic patients (peer educators)|the purpose of this methodology is to set up coordinated training and education activities targeting populations with diabetes based on a pragmatic approach (the learning nests methodology) of appropriation and construction of knowledge that takes into account the individual, social, economic, cultural context. This work is being implemented on the basis of group modules specifically designed in their running: are studied the concrete elements of knowledge to mobilize, patients' actions, the role of health the educator, indicators of progress and monitoring during sessions and on the long term. Each patient is gotten to consider the elements involved in his/her disease, and the actions that can be achieved taking into account the feasibility in his/her own context. The education monitoring is envisaged through a data compendium present in the individual booklets that are given to patients at the end of each education session.
1697307|NCT01485900|Drug|SAR407899A|"Pharmaceutical form:capsule
Route of administration: oral"
1697308|NCT01485887|Drug|Venlafaxine ER|Treatment phase: 10 months (75-225 mg/day), oral administration Tapering phase: 1-3 weeks (stepwise dose reduction: 150-37.5 mg/day), oral administration
1697309|NCT01485874|Drug|Doxil (Pegylated Liposomal Doxorubicin)|Phases I and II: 40 mg/m2 IV over 60 min (+/- 15 min) on day 1 of 28-day cycle
1697310|NCT01485874|Drug|BIBF 1120|"Phase I: Escalating cohorts days -2 through +2, orally 100mg bid, 150mg bid, 200mg bid
Phase II: MTD orally, bid, day 2 of 28-day cycle"
1697311|NCT01485861|Drug|Abiraterone|Orally once daily
1697312|NCT01485861|Drug|GDC-0980|Orally once daily
1697313|NCT01485861|Drug|Ipatasertib|Orally once daily
1697314|NCT01485861|Drug|Placebo|Orally once daily
1697315|NCT01485861|Drug|Prednisone|Orally bid
1697316|NCT01485861|Drug|Prednisolone|Orally bid
1697317|NCT01485848|Drug|EP-100|Pharmaceutical form:Solution Route of administration: Intravenous
1697318|NCT01485848|Drug|Paclitaxel|Pharmaceutical form:Solution Route of administration: Intravenous
1697319|NCT01485835|Drug|Ganetespib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
1698179|NCT01479361|Drug|Atovaquone 1500 mg twice daily|
1697320|NCT01485835|Drug|Bortezomib|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
1697321|NCT01485835|Drug|Dexamethasone|Standard 3+3 design to determine the maximum tolerated dose (MTD) of ganetespib when given in combination with bortezomib and dexamethasone.
1697322|NCT01485822|Procedure|Trabecular Meshwork Tissue Collection|A minimum of two punches were used to remove tissue to form a sclerostomy. Tissue removed by the punch was collected for analysis. Alternatively, the tissue was collected by block excision of the meshwork with scissors at the time of sclerostomy.
1697323|NCT01485822|Drug|Travoprost 0.004% ophthalmic solution|
1697324|NCT01485809|Drug|Gefitinib|Gefitinib 250mg/day, oral daily q every 4 weeks
1697327|NCT01485770|Drug|ADX-N05|150 mg once a day for seven days followed by 300 mg once a day for seven days
1697328|NCT01485770|Drug|Placebo|Placebo to match ADX-N05 to be taken for 2 consecutive weeks during 4 week study treatment period
1697329|NCT01485757|Drug|L-arginine|All study subjects will be treated with a 12 week (11-13 week) course of oral L-arginine at a dose of 6 g per day, divided into morning and evening doses of 3 g (3 1000 mg capsules or caplets).
1697330|NCT01485744|Drug|LDE225; Fluorouracil; Leucovorin; Oxaliplatin; Irinotecan|LDE225 200-800 mg daily orally. Fluorouracil 2400 mg IV every other week. Irinotecan 180 mg/m2 IV every other week. Oxaliplatin 85 mg/m2 IV every other week. Leucovorin 400 mg/m2 IV every other week.
1697331|NCT01485731|Drug|Nelfinavir|Nelfinavir (NFV) will be prescribed orally twice daily for 7 days prior to initiation of cisplatin and pelvic radiation at the starting dose level, 875 mg BID
1697332|NCT01485731|Drug|Cisplatin|Cisplatin at 40 mg/m2 (maximum total dose of 70 mg per week), will be infused intravenously once per week on either Day 1, 2, 3, 4, or 5 of weeks 2 to 6, preferably approximately four hours prior to radiation therapy. One additional cycle of cisplatin will be given either week 7 or 8 for a total of 6 cycles of cisplatin. Patients are not to be dosed more than 70 mg/week.
1697333|NCT01485731|Radiation|Pelvic External Beam Radiation Therapy|Pelvic external beam radiation therapy (PEBRT) will be delivered in combination with weekly IV cisplatin (40mg/mg2) and twice daily oral NFV.PEBRT should be delivered once each day during the business week (Monday to Friday) according to the acceptable standards of care as prescribed by the treating radiation oncologist(s). The radiation therapy should consist of whole pelvic external beam radiation therapy (WPEBRT) with or without a parametrial boost (PB). PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
1697334|NCT01485731|Radiation|Brachytherapy|PEBRT will be interdigitated with one administration of intrauterine brachytherapy (BT) given on any business day of week 7 or 8.
1697335|NCT01485731|Procedure|Pharmacokinetic Sampling|Serum levels of Nelfinavir will be assayed at the following 3 time points: 5-8 days after initiation of NFV single agent (on Day 5, 6, or 7 of week 1 or day 1 of week 2), 1 week after combined NFV and cisplatin pelvic radiation (on day 15, 16, or 17 if start on Monday) for measurement of steady state, and at the completion of treatment (within the last 3 days of radiation in week 6). Blood samples will be taken before drug administration on the day of the sample to make sure the concentrations are actually at a minimum and before tumor biopsies.
1697336|NCT01485731|Procedure|Cervical Biopsy|Three punch biopsies of cervical tumor will be obtained during office visit at each time point (for PCR, IHC, and banked for future research). NFV serum levels will be obtained once NFV has been started (day 5-8 pre chemoradiation and at completion of chemoradiation) before each cervical biopsy
1697337|NCT01485731|Procedure|Pelvic Examination|Pre-Treatment, at the end of treatment +/- 1 week, every 3 months +/- 2 weeks after therapy (x 1 year)
1697338|NCT01485731|Procedure|Pap Smear|Recommended. Every 3 months +/- 2 weeks after therapy (x 1 year)
1697339|NCT01485731|Procedure|Audiogram|Required in patients with history of hearing loss; 28 days within starting treatment and every other cycle.
1697340|NCT01485731|Procedure|Proctoscopy|Optional. Pre-Treatment
1697341|NCT01485731|Procedure|Cytoscopy|Optional. Pre-Treatment
1697342|NCT01485731|Procedure|Renal Ultrasound|Optional. Pre-Treatment
1697343|NCT01485731|Procedure|CT Scan|CT Scan of Chest/Abdomen/Pelvis, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
1697344|NCT01485731|Procedure|Whole Body PET/CT Scan|In lieu of CT Scan, pre-treatment,Immediately at end of trial +/- 1 week, Every 3 months +/- 2 weeks after therapy (x 1 year)
1697347|NCT01485705|Other|Retrospective examination by experts whether care given fo child admitted at the ICU for suspicion of bacterial infection (not nosocomial) was optimal or not|"When child is admitted at Intensive Care Unit (ICU) for suspicion of bacterial infection that is not nosocomial, data on child's infection and cares received, is completed on an electronic Case Report Form (e-CRF) by Doctor of ICU. Characteristic optimal or not of initial medical care is then determined by the independent experts blinded from issue of the care."
1697348|NCT01485692|Drug|haloperidol+promethazine|haloperidol, 2,5mg plus promethazine,25mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, in the 90 minutes period of observation
1697349|NCT01485692|Drug|haloperidol + midazolam|haloperidol, 2,5mg plus midazolam, 7,5 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
1697350|NCT01485692|Drug|olanzapine|olanzapine, 10mg, intramuscular injection, after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes of observation
1697351|NCT01485692|Drug|Ziprasidone|ziprasidone, 10 mg, intramuscular injection after baseline measures of agitation, could be repeated twice, if necessary, between the 90 minutes period of observation
1697659|NCT01483118|Dietary Supplement|Placebo|Placebo capsules containing ground cereal.
1697352|NCT01485679|Other|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography|18 fluoro-deoxy-glucose positrons emission tomography combined with computed tomography
1697353|NCT01485666|Other|Percutaneous Lead Management Kit|A kit of commercially available components to be used for HeartMate II driveline exit site cleaning, dressing and stabilization
1697354|NCT01485653|Drug|Mepivacaine|Group 1) 20mL 1.5% mepivacaine, one dose Group 2) 30mL 1.5% mepivacaine, one dose
1697355|NCT01485640|Drug|Lurasidone|Lurasidone flexibly dosed; doses of 20, 40, 60 or 80 mg/day will be taken orally with food
1697356|NCT01485627|Behavioral|Communication training and coaching|Oncologists will receive communication training. Patients will be coached to make the most of the oncologist visit.
1697364|NCT01485601|Biological|MT10109|Single dose intramuscular injection MT10109 vs Botox®
1697365|NCT01485588|Drug|hI-con1™|Phase 1: 20µl, 50µl, or 100µl per injection (in the eye) on Day 1 only
1697366|NCT01485575|Procedure|Use of intraoperative filters in vitrectomy|During vitrectomy with xenon endoillumination, an orange, green and a yellow filter are applied sequentially to determine which one produces the best contrast behavior of vital dyes
1697367|NCT01485562|Drug|Misoprostol|4 tablets of 200 mcg misoprostol administered sublingually if the woman experiences a PPH after child birth
1697368|NCT01485562|Other|placebo|4 tablets, administered sublingually if the woman experiences a PPH
1697369|NCT01485536|Drug|AUY922|Starting Dose: 70 mg/m2 by vein on days 1, 8, 15, and 22 days of a 28 day cycle.
1697370|NCT01485523|Other|Nasal provocation test|"TPNC to dust mite has an interest in the diagnosis of allergic rhinitis to dust mites when there remains a doubt due to the poly sensitization of the patient, or the lack of specific symptoms and / or the variability of the allergic symptoms during the year. However, this test has not completely validated with a study including a significant number of patients. That's why we plan a prospective single-center comparative open study with the main objective is to determine the sensitivity and specificity of conventional nasal provocation test (TPNC) in 120 patients of 18 to 65 years old with allergic rhinitis sensitized to dust mites and patients with allergic rhinitis not sensitized to dust mites. Our secondary objective is to compare the TPNC a faster TPN-called minute (60 minutes) and which allow a wider use. If we demonstrate the validity of TPN then it would become the gold standard needed to decide on a desensitisation to mites."
1697371|NCT01485510|Behavioral|GIFT|An attachment-based assessment, then a tailored intervention aimed at maximising the chances of a maltreated child returning to the birth family.
1697372|NCT01485510|Behavioral|FACS|A social work assessment of family functioning that makes recommendations regarding future placement of a maltreated child.
1697373|NCT01485497|Device|3D endoscopic Fourier Domain OCT|Evaluation of Obstructive Sleep Apnea
1697374|NCT01485484|Device|Optic imaging use near-infrared trans-illumination methods|Optic imaging use near-infrared trans-illumination methods
1697375|NCT01485471|Device|Diffuse optical spectroscopy imaging|ear exam imaging
1697376|NCT01485458|Procedure|Early surgery|Surgery within 24 hours after admission
1697377|NCT01485458|Procedure|Delayed surgery|Surgery more than 2 weeks after injury
1697378|NCT01485445|Drug|Fluticasone Furoate (200mcg unit strength)|inhalation powder
1697379|NCT01485445|Drug|Fluticasone Furoate/Vilanterol (200/25mcg unit strength)|inhalation powder
1697380|NCT01485432|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measurements
1697381|NCT01485406|Biological|Pneumococcal vaccine GSK2830930A|1 dose administered intramuscularly
1697382|NCT01485406|Biological|Synflorix™|1 dose administered intramuscularly
1697383|NCT01485393|Drug|Dexmedetomidine|A dose of dexmedetomidine will be administered at 1mcg/kg over 10 minutes. Subjects will never receive active drugs (Zolpidem or dexmedetomidine concurrently).
1697384|NCT01485393|Drug|Zolpidem|12.5 mg of oral Ambien CR. Subjects will never receive active drugs (Zolpidem/Ambien or dexmedetomidine concurrently).
1697385|NCT01485380|Drug|dexmedetomidine|The dexmedetomidine infusion will be individualized to each study participant by a target plasma concentration where loss of consciousness is initially observed. Loss of consciousness will be assayed by specific auditory and verbal stimuli.
1697386|NCT01485367|Drug|adapalene gel 0.3%|A pea size drop of Adapalene gel 0.3% will be applied to the odd numbered subjects on the left dorsal hand & extensor forearm. A pea size drop of Adapalene gel 0.3% will be applied to the even numbered subjects on the right dorsal hand & extensor forearm. The randomized area will be cleansed with Cetaphil Gentle Cleanser before applying the study medication. All subjects will apply sunscreen with zinc oxide in the morning to both the right & left forearms.
1697387|NCT01485354|Device|Armeo Spring training|Upper-limb training using the Armeo system for a period of 6 weeks
1697388|NCT01485341|Dietary Supplement|gluten|gluten is administered once a day at 10g/day for 15 days
1697389|NCT01485341|Dietary Supplement|rice starch|rice starch is administered once a day at 10 g/day for 15 days
1697390|NCT01485328|Drug|AMARGOL®|per oral solution, 40 mL single dose
1755273|NCT00239304|Procedure|Radiotherapy|
1697391|NCT01485315|Biological|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin at 9.0 g/dl (5.6 mM) or less at point-of-care testing
1697392|NCT01485315|Biological|SAGM (Saline-Adenine-Glucose-Mannitol) blood transfusion|One unit prestorage, leuko-depleted SAGM blood at haemoglobin 7.0 g/dl (4.3 mM) or less at point-of-care testing
1697393|NCT01485302|Drug|SAR228810|"Pharmaceutical form:solution
Route of administration: intravenous"
1697394|NCT01485302|Drug|SAR228810|"Pharmaceutical form:solution
Route of administration: subcutaneous"
1697395|NCT01485276|Procedure|DBS Surgery|
1697396|NCT01485237|Other|We will compare the resources used by both groups|The main purpose of this study is to review the resource utilization. Secondary objectives include, comparison of resource utilization to other similar disorders (viral pneumonia, bacterial pneumonia, septic shock, ARDS). We will also look at the percentage of patients that required ICU care as compared to those who could be cared for on medical wards. We will determine the resources used by both groups and compare. Finally we will record the frequency of chronic comorbidities in hospitalized adult H1N1 patients.
1697397|NCT01485224|Drug|Thalidomide|"Eligible patients will receive thalidomide at a starting dose of 50 mg/day by mouth at bedtime for 4 weeks. In the event of unsatisfactory/no response, thalidomide dosage will be progressively increased by 50 mg/day every 4 weeks until complete or partial response, to a maximum dose of 200 mg/day.
Treatment will be continued until one of the following criteria is met:
8 additional weeks of treatment after the achievement of complete response
16 additional weeks of treatment after the achievement of partial response
24 weeks of treatment completed without response
unacceptable toxicity. Then, patients will be followed off of thalidomide for 24 weeks."
1697398|NCT01485211|Drug|cross-linking with hypo-osmolar riboflavin|Hipo-osmolar riboflavin was applied every 20 seconds until the TCT reached 400µm. UVA irradiation was performed for 30 min. Pachymetry was recorded at the thinnest point of the cornea preoperatively, after epithelial removal, after iso-osmolar riboflavin, after hypo-osmolar riboflavin, after UVA irradiation, and at 1, 6 and 12 months.
1697399|NCT01485198|Procedure|Bone Marrow Autologous Stem Cells Infusion|Extraction and knee infusion of Bone Marrow Autologous Stem Cells
1697400|NCT01485198|Drug|Acetaminophen|Acetaminophen (750mg orally TID) administration
1697401|NCT01485185|Drug|Gabapentin lower dose|Repeat, oral dose
1697402|NCT01485185|Drug|Donepezil|Repeat, oral dose
1697403|NCT01485185|Other|Placebo (Dop)|Placebo to donepezil, Repeat, oral dose
1697404|NCT01485185|Other|Placebo (Gaba)|Placebo to gabapentin, Repeat, oral dose
1697405|NCT01485185|Drug|Gabapentin higher dose|Repeat, oral dose
1697406|NCT01485172|Drug|ropinirole monotherapy|ropinirole as monotherapy in Parkinson's disease
1697407|NCT01485172|Drug|placebo monotherapy|placebo as monotherapy in Parkinson's disease
1697408|NCT01485159|Procedure|Spirometry|assessment of lung function by spirometry
1697409|NCT01485146|Drug|ETC-1002|escalating doses
1697411|NCT01485107|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin.
1697412|NCT01485094|Drug|GRT6010|Oral solution given once daily.
1697413|NCT01485094|Drug|Pregabalin|Over-encapsulated pregabalin capsules 75mg twice daily on Days 1 to 3, and 150mg twice daily on Days 4 to 7.
1697414|NCT01485094|Drug|Matching Placebo|"Matching Placebo capsules to the over-encapsulated Pregabalin capsules and Matching Placebo oral solution to the GRT6010 solution.
Capsules twice daily on Days 1 to 7. Solution once daily."
1697415|NCT01485081|Device|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in the side branch of a de novo bifurcation lesion.
1697416|NCT01485068|Device|Danubio paclitaxel-eluting balloon|Inflation of the Danubio Paclitaxel Eluting Balloon in in-stent restenosis lesions.
1697417|NCT01485055|Drug|Infliximab and Basiliximab|"Participants in this research study will receive combination therapy (2 drugs: Infliximab and Basiliximab)once a week for four weeks. Both drugs will be given through the participant's broviac, port or through a vein in the arm. It will take about 4-5 hours to complete the 2-drug combination therapy each week. Participants will be given pre-medications to help prevent reactions to the study drugs.
Infliximab will be given at a dose of 10mg per Kg per dose. Basiliximab will be given in 10mg doses to patients who weigh less than 35kg. Patients who weigh weigh more than 35kg will receive 20mg doses. Patients will receive both drugs weekly on days 1,8,15 and 22. Each drug will be given 4 times."
1697418|NCT01485042|Drug|Pazopanib and TH-302|Pazopanib 800 mg daily TH-302 IV on Days 1, 8, 15 at MTD Subjects will receive this regimen until disease progression.
1697419|NCT01485029|Procedure|Nasopharyngeal (NP) aspirate|Nasopharyngeal (NP) aspirate with a small flexible canule to obtain NP swabs
1697421|NCT01484990|Drug|Levodopa-Carbidopa|Intestinal Gel
1697422|NCT01484977|Drug|Lacosamide|"50 mg and 100 mg lacosamide tablets will be combined and taken in two equal doses per day to provide the required total daily dosage of 100 - 600 mg/day. Subjects were titrated to a minimum of 200 mg/ day during the Treatment Period.
Maximum duration of study drug administration is approximately 23 weeks."
1697423|NCT01484964|Drug|ASP015K|oral
1697424|NCT01484951|Drug|Brinzolamide 1% and timolol 0.5% fixed combination eye drops|
1697425|NCT01484938|Device|OPTI-FREE PureMoist|Commercially marketed multi-purpose contact lens solution for cleaning, rinsing, disinfecting/storing, and reinserting contact lenses
1697426|NCT01484912|Drug|STA-2|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of STA-2 was:
STA-2 250 mg capsule, each containing 100 mg green tea polyphenols, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
1697427|NCT01484912|Drug|Placebo|"After 1 week of screening and washout, patients who met the entry criteria were randomly assigned either to the treatment or control group. The regimen of Placebo was:
Placebo 250 mg capsule, 2 capsules t.i.d. (three times a day) for 6 weeks, to be administered in a non-fasting state."
1698493|NCT01477060|Drug|Lapatinib|1250 mg/ die, os
1697428|NCT01484886|Other|Red blood cell transfusion|10cc/kg weight RBC transfusion as needed according to hemoglobin level
1697429|NCT01484886|Other|Red blood cell transfusion|10cc/kg body weight RBC will be transfused for hemoglobin under 9.5 for biventricular repairs and under 12 for single ventricle palliations.
1697430|NCT01484873|Drug|Exenatide|Treatment with exenatide 5 mcg twice daily for 4 weeks, then 10 mcg twice daily for 46 weeks.
1697431|NCT01484860|Drug|AUY922|AUY922 is a solution for intravenous administration Dose: 70 mg/m2 over 1 hour, weekly
1697432|NCT01484847|Drug|PF-00299804|Tablet, single dose of 45 mg via gastrojejunostomy tube (G-Tube) on an empty stomach
1697433|NCT01484834|Behavioral|Exercise and Education|"Exercise were prescribed three times a week with duration of fifteen minutes for three months.
Educational Intervention were composed by a quality of life computer software and poster with tips on health behaviors"
1697434|NCT01484834|Behavioral|Exercise|Exercise were prescribed three times a week with duration of fifteen minutes for three months.
1697435|NCT01484834|Behavioral|Educational Intervention|This company received a quality of life software and poster intervention with tips on health lifestyle. The posters were printed in A3 paper and eight of them were put up per month in different parts of the companies (near water fountains, rest places, cafeterias, near the restrooms and change rooms). The used messages, both by the posters and the software were basedon scientific evidence related to quality of life and health
1697436|NCT01484834|Other|Control Company|No intervention was applied for the participants of this group
1697437|NCT01484821|Device|ARFI|Muscle sonoelastography using ARFI(Acoustic Radiation Force Impulse) imaging
1697438|NCT01484795|Device|BILEVEL (Respironics)|Bilevel was delivered by a Bipap® ventilator (Respironics Inc, Murrysville, PA), applied via facial mask, with inspiratory positive pressure (IPAP) of 20 cmH2O and expiratory positive airway pressure (EPAP) of 10 cmH2O.
1697439|NCT01484795|Device|Continuos positive airway pressure (Respironics)|CPAP was delivered by a ventilator (Respironics Inc, Murrysville, PA), applied via a facial mask, with expiratory positive airway pressure of 10 cmH2O.
1697440|NCT01484782|Behavioral|Interactive Voice Response (IVR) automated calls|Interactive Voice Response (IVR) is a type of automated telephone call. Weekly automated telephone assessment and behavior change calls focused on blood pressure management will be sent to the experimental group. They will receive a weekly 10-minute automated phone call to their telephone for disease assessment and self-care support for 6 weeks. In-home blood pressure cuffs were provided for measurement of blood pressure throughout the study.
1697441|NCT01484756|Dietary Supplement|daily multi micronutrient supplement|Multi micro-nutrient supplement tablet containing 40 mg elemental zinc (as gluconate, 120 mg ascorbic acid, 6 mg beta-carotene, 15 mg alpha-tocopherol (as d-alpha-tocopheryl acid succinate, 400 micrograms folic acid in experimental group given daily for six months
1697442|NCT01484756|Dietary Supplement|Placebo|calcium carbonate 500 mg
1697443|NCT01484743|Procedure|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
1697444|NCT01484730|Device|Multi-Spectral & Laser Speckle Imaging|Changes in skin tissue and blood flow.
1697445|NCT01484717|Behavioral|contingency management for smoking abstinence|Participants earn the chance to win prizes for breath samples that test negative for cigarette smoking.
1697446|NCT01484717|Drug|transdermal nicotine|Participants receive an 8 week supply of transdermal nicotine [21 mg patches (4 wks), 14 mg (2 wks), 7 mg (2 wks)].
1697447|NCT01484717|Behavioral|Telephone counseling|Participants receive brief twice weekly telephone counseling.
1697448|NCT01484691|Drug|Budesonide|Inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
1697449|NCT01484665|Other|PROCASE Decision-Aid|"VA health services researchers have developed a patient education pamphlet for prostate cancer screening. The pamphlet, titled The PSA test for prostate cancer: Is it Right for ME was created by members of the PROstate CAncer Screening Education (PROCASE) study team. A modified version of the PROCASE decision aid will be utilized in this study."
1697450|NCT01484652|Drug|COV795|2 tablets taken every 12 hours
1697451|NCT01484652|Drug|Placebo|2 tablets taken every 12 hours
1697452|NCT01484639|Other|Liberal transfusion triggers|"Patients allocated to a liberal transfusion strategy will receive red cell transfusion if their hemoglobin concentration is 95 g/L or less intraoperatively and postoperatively in the intensive care unit, and less than 85 g/L on the ward."
1697453|NCT01484639|Other|Restrictive transfusion triggers|"Patients allocated to a restrictive transfusion group will receive a red cell transfusion if their hemoglobin is 75 g/L or less intraoperatively and postoperatively."
1697454|NCT01484626|Drug|Bendamustine|The first group of 3 patients to enter the study will receive a 25 mg/m2 dose of Bendamustine. If this dose is found to be safe, the next 3 patients will receive 50 mg/m2. The dose will continue to increase until the highest safe dose of Bendamustine is found. Bendamustine and Bortezomib will be given through a catheter twice a week every 21 days. Dexamethasone and Lenalidomide will be given orally. In general, a cycle of chemotherapy will last 21 days.
1697455|NCT01484626|Drug|Bortezomib|Bortezomib will be given through a catheter twice a week every 21 days.
1697456|NCT01484626|Drug|Lenalidomide|Lenalidomide will be given orally taken as instructed by the physician.
1697457|NCT01484626|Drug|Dexamethasone|Dexamethasone will be given orally as instructed by the physician.
1697458|NCT01484613|Device|quadripolar LV lead (Quartet)|All participants will receive CRT-D system with a quadripolar lead. This lead offers 10 LV lead vectors to choose from
1697459|NCT01484600|Drug|REGN668: Injection Rate 1|Subjects will receive REGN668 via SC injection
1697460|NCT01484600|Drug|REGN668: Injection Rate 2|Subjects will receive study drug via alternate delivery (if necessary)
1697461|NCT01484587|Drug|CNTO 1959|CNTO 1959: type=range, unit=mg, number=10, 30, 100, 300, form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
1697462|NCT01484587|Drug|Placebo|Placebo: form=solution for injection, route=subcutaneous use, ascending dosing for 24 weeks
1697463|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of low dose of stem cells
1697464|NCT01484574|Biological|Allogeneic Mesenchymal Stem Cells|Single intramuscular administration of intermediate dose of stem cells
1697465|NCT01484561|Drug|CP-690,550 or Placebo|CP-690,550 10 mg twice a day (BID) orally or placebo BID orally, approximately 72 days
1755274|NCT00239317|Drug|Tamusulosin|
1697467|NCT01484548|Biological|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 2 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
1697468|NCT01484548|Biological|LEISH-F3 + GLA-SE|20 ug of LEISH-F3 and 5 ug of GLA-SE adjuvant. 3 injections at Days 0, 28, and 56.
1697469|NCT01484548|Biological|LEISH-F3 alone|20 ug of LEISH-F3 antigen alone. 3 injections at Days 0, 28, and 56.
1697470|NCT01484535|Procedure|Ankle Aspiration|Ankle aspiration will be performed through either a standard anterolateral or anteromedial approach, depending on the conditions of the soft tissue. The anterolateral approach will be the preferred method due to the higher reproducibility of intra-articular needle placement. The anteromedial approach will be reserved for patients whose soft tissues over the anterolateral portal are compromised. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18 gauge needle will be introduced into the ankle joint and a syringe will be used to aspirate the ankle until no more hemarthrosis is able to be removed. The amount of hemarthrosis aspirated will be recorded. Following the procedure, care will continue as per standard of care.
1697471|NCT01484535|Procedure|Ankle aspiration Standard Anterolateral|Placebo ankle aspiration will be performed through a standard anterolateral. Sterile preparation of the limb will be achieved with the use of chlorhexidine or Betadine. An 18-gauge needle will be introduced into the skin. The needle will be held in the skin for 5-10 seconds in an effort to simulate the pain and time-lag experienced with aspiration. The needle will not pass the fascia or ankle joint capsule. Following the procedure, care will continue as per standard of care.
1697472|NCT01484522|Biological|FluMist|Administered at the manufacture's recommended dose
1697473|NCT01484522|Biological|Fluvirin|Vaccine administered at the manufacturer's recommended dose.
1697474|NCT01484522|Biological|Fluzone|Vaccine administered at manufacturer's recommended dose
1697475|NCT01484496|Biological|Placebo|Placebo
1697476|NCT01484496|Biological|Belimumab 200 mg SC|Belimumab 200 mg SC
1697477|NCT01484496|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
1697478|NCT01484470|Biological|StemEx|"For patients allocated to StemEx® arm:
Day -20: Start small (or equal) portion expansion at processing site. (II) Conditioning Phase
Day -6 to -1: Subject receives a RIC regimen containing Fludarabine, Cyclophosphamide and Total Body Irradiation (TBI) (III) Transplantation and Follow-up Phase
Day 0: CBU unmanipulated portion transplantation (for StemEx® arm) or unmanipulated CBU transplantation.
Day 1: StemEx® transplantation.
Day 2 to 3 years: Post transplant follow-up."
1697479|NCT01484457|Device|Closed-loop session|"Subjects will arrive fasting at 7am unless needed for hypoglycemia (glucose < 70 mg/dL) and no extra bolus insulin after 3am. An IV catheter will be inserted for blood samples and for IV administration of glucose if necessary. Blood samples will be analyzed for glucose by YSI 2300Stat every 30 minutes.
Breakfast consisting of 25g of CHO will be eaten at 7:30 am and the subject will bolus for this amount of CHO. The controller is switched on on the down slope of the meal response, and the subject is brought to a basal steady-state by the controller. Target blood glucose is 110 ± 30-mg/dL.
After approximately 3 hours a small lunch will be eaten consisting of 25g of CHO (unannounced meal challenge). The subject will be monitored until blood glucose returns to euglycemia."
1697480|NCT01484431|Drug|Tadalafil- Tablet|"Tadalafil tablets: 2.5 mg and 5 mg, 10 mg, 20 mg and 40 mg (two 20 mg) administered orally, once daily in the heavy weight cohort >=40 kg and middle weight cohort >=25 kg to <40 kg
Drug: Tadalafil - Oral suspension
Tadalafil Oral suspension: 1 mg, 5 mg administered orally, once daily in the light weight cohort <25 kg"
1697481|NCT01484418|Behavioral|Exposure in vivo|5-10 sessions based on an individualized fear hierarchy
1697482|NCT01484418|Behavioral|Cognitive Behavioural Psychotherapy|graded activity, relaxation techniques and cognitive interventions
1697483|NCT01484405|Procedure|posterior approach|Surgical approach for Total Hip Arthroplasty
1697484|NCT01484405|Procedure|anterolateral approach|anterolateral surgical approach
1697485|NCT01484379|Procedure|unilateral neck exploration|All elderly patients with primary hyperparathyroidism suspected to have a single gland disease will have a unilateral neck exploration following the index gland identification.
1697486|NCT01484366|Procedure|intramedullary nailing and plating|Surgical intramedullary nailing of the ulna and plating of the radius
1697487|NCT01484366|Procedure|plating|Surgical plating of both bonforearm fractures
1697488|NCT01484353|Behavioral|Coronary Health Improvement Project Program|The Coronary Health Improvement Project' (CHIP; an intensive, community-based, lifestyle change program including a low saturated fat diet rich in whole, grown foods) has been shown to improve the health of diabetics through an intensive education taught over a 12 week period, but has not been studied in terms of its effect on HBAIC. Kaiser Permanente places significant resources into preventive medicine but does not have programs with the level of intensity of CHIP. This study aims to determine if Kaiser members with uncontrolled type 2 diabetes can achieve a significant improvement in their HBAIC after 12 weeks of participation in the CHIP program.
1697489|NCT01484340|Drug|Nicotine|"The nicotine patch be given in three phases:
2 weeks of patches at enrollment
6 weeks of patches at two-week follow-up visit
2 weeks of patches at two-month follow-up visit
This schedule will cover the entire 10-week course of therapy as per label instructions: 6 weeks at 21mg; 2 weeks at 14mg; and 2 weeks at 7mg."
1697490|NCT01484340|Behavioral|Intensive Counseling|"The advice to quit smoking message will follow NCI's 5A's model for smoking cessation counseling. This is a simple smoking cessation counseling strategy with 5 discrete components: (1) Ask about smoking at every opportunity; (2) Advise the patient to quit smoking; (3) Assess readiness to quit; (4) Assist the patient in quitting; and (5) Arrange follow-up.
Visit schedule:
Baseline
2-week follow-up (Quit Day)
1-month follow-up
2-month follow-up
3-month follow-up
6-month follow-up
Participants abstinent at 6-month follow-up will be next seen at 12-month follow-up.
Participants still smoking at 6-month follow-up will be offered group-assigned intervention again."
1697491|NCT01484327|Drug|Carvedilol|Minimum dosage 3.125 mg Χ 2, Maximum dosage 50 mg
1697492|NCT01484314|Drug|Eltrombopag|100mg (patients of East Asian descent will receive a dose of 50mg) orally dosed once daily starting 6 days prior to initiation of chemotherapy for a total of 11 days of treatment during two consecutive cycles of chemotherapy
1697493|NCT01484288|Device|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
1698494|NCT01477060|Drug|Metformin|1500 mg/die, os
1697494|NCT01484275|Drug|Siltuximab|Type=exact, unit=mg/kg, number=15, form=intravenous infusion, route=intravenous use, every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
1697495|NCT01484275|Drug|Placebo|Form=intravenous infusion, route=intravenous use route=intravenous, use every 4 weeks until progression to symptomatic multiple myeloma, unacceptable toxicity, withdrawal of consent, or the end of the study.
1697496|NCT01484262|Drug|liraglutide|Patients will be treated according to routine clinical practice at the discretion of the treating physician according to current labelling.
1697497|NCT01484262|Drug|insulin|Any insulin in any device available on the market may be used by patients as part of routine clinical practice according to current labelling.
1697498|NCT01484249|Device|CE Pro System|The CE Pro System consists of a delivery catheter with an integrated proximal filter intended to be deployed in the brachiocephalic artery. In addition, the device has an articulating distal tip and a through lumen to allow a commercial intravascular filter to be back-loaded into the CE Pro System and be deployed into and retrieved from the left carotid artery.
1697499|NCT01484223|Behavioral|Cognitive Behavioral Therapy|Four Cognitive behavioral group sessions. Each session will last two hours a week
1697500|NCT01484210|Drug|Elpenhaler active - Diskus placebo|randomized, double-blind, double-dummy, 2-way crossover, single dose study, comparing the efficacy and safety of the Fluticasone/Salmeterol (500/50 μg) combination administered with Elpenhaler® (Rolenium®) versus the innovative one (Seretide Diskus®) in patients with asthma.
1697501|NCT01484197|Drug|75 µg indacaterol maleate (LB)|75 µg indacaterol maleate lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
1697502|NCT01484197|Drug|75 µg indacaterol maleate (PoS)|75 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
1697503|NCT01484197|Drug|37.5 µg indacaterol maleate (PoS)|37.5 µg indacaterol maleate PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
1697504|NCT01484197|Drug|placebo to indacaterol (LB)|Placebo to indacaterol lactose blend (LB) delivered via the Concept1 device once daily in the morning for 7 days.
1697505|NCT01484197|Drug|placebo to indacaterol (PoS)|Placebo to indacaterol PulmoSphereTM (PoS) delivered via the Concept1 device once daily in the morning for 7 days.
1697506|NCT01484184|Drug|SPINALON (buspirone + levodopa + cardidopa)|The proposed study is a combination of 1 and 2-arm designs. First, a 2-arm design will be used, the first arm being composed of 3 subjects receiving the lowest dose of the study drug, and the second arm being composed of 1 subject receiving a placebo. This 2-arm design will be repeated consecutively (not simultaneously) with increasing doses of SPINALON, as long as the dose is well tolerated. Six (6) groups are expected to be tested with this 2-arm design.This will be followed by a 2-arm composed of 1 group with 1 subject receiving placebo and 1 larger group (10 subjects) who will receive SPINALON at MTD as identified in the previous 2-arm groups.
1697507|NCT01484171|Drug|idarubicin|idarubicin 10-12 mg/m2 for three days
1697508|NCT01484171|Biological|microtransplantation|idarubicin 10-12mg/m2 for four days. After chemotherapy infusion granulocyte colony-stimulating factor-mobilized HLA-mismatched donor peripheral blood stem cells following each of three cycles of high dose cytarabine chemotherapy
1697509|NCT01484145|Drug|Terbinafine HCl|4% w/w terbinafine HCL gel, single dose,
1697510|NCT01484132|Procedure|Restoration of dental caries with dental composite|Dental Restoration (bisphenol A diglycidyl ether methacrylate based composite)
1697511|NCT01484119|Drug|ACT-129968|daily tablets
1697512|NCT01484119|Drug|Placebo|matching placebo tablets and capsules
1697513|NCT01484119|Drug|Cetirizine|daily capsules
1697514|NCT01484106|Other|Fluid Resuscitation|"In the Treatment group, this information will be used in a specific 4-hour treatment algorithm to guide fluid administration that is summarized in Figure 1. The information provided by the NICOM in response to the fluid bolus will be used to assess whether the subject is fluid responsive (FR)."
1697515|NCT01484106|Other|Standard of Care|Standard of Care
1697516|NCT01484093|Other|R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.|INDUCTION: R-CHOP-14 CHEMOTHERAPY: 4 cycles every 2 weeks ± 1 day All patients in the study in both phases will undergo induction and consolidation with R-CHOP 14R-HIDAC, followed by RIT/HDT/ASCR. Patients will undergo restaging scans 12 to 14 days following completion of R-CHOP 14, with CT, and FDG-PET. Patients demonstrating at least a PR may proceed to consolidation with R-HIDAC. CONSOLIDATION: R- HIDAC CHEMOTHERAPY: 2 cycles every 3 weeks ± 2 days After R-HIDAC, restaging will occur 17-21 days post cycle 2 with CT scan (or FDG-PET, if this was positive following R-CHOP-14). Radioimmunotherapy Dosimetric dose is given approximately 4-5 weeks after completing cycle 2 of R-HIDAC. This is to be preferred 1 week post restaging scans 17-21 days post cycle 2 of RHIDAC, and up to 2 weeks post-scans will be acceptable only if required by 131 I Tositumomab availability.
1697517|NCT01484080|Drug|BIBF + Paclitaxel|"Priming Period:
Oral BIBF 1120 will be administered during 2 weeks at the dose determined during the phase-I part that can be combined safely with weekly paclitaxel, on a continuous schedule for 14 days.
One week washout is planned before starting the treatment phase.
Treatment Phase:
Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 + BIBF 1120 recommended dose bid po days 1-21 q 21 days. (BIBF 1120 morning dose is skipped on the paclitaxel administration days)."
1697518|NCT01484080|Drug|Paclitaxel|Paclitaxel 80 mg/m2 iv on days 1, 8 and 15 q 21 days. A total of 4 cycles will be administered in both arms.
1697519|NCT01484067|Device|Patch ( Compeed© Total CareTM Cold Sore Patch)|A cold sore patch containing zinc sulfate
1697520|NCT01484054|Device|etafilcon A with print and PVP for dark eyes (EAPVPDE)|A daily disposable contact lens
1697521|NCT01484054|Device|etafilcon A control lens (EADE)|A marketed daily disposable contact lens
1697522|NCT01484041|Drug|Dovitinib|Dovitinib at the recommended Phase 2 dose for 5 consecutive days followed by a 2-day rest
1697523|NCT01484041|Drug|Aromatase Inhibitors|Patients will receive one of the aromatase inhibitors either anastrozole 1 mg po daily, letrozole 2.5 mg po daily, or exemestane 25 mg po daily
1697524|NCT01484028|Device|etafilcon A control lens (1DM)|A marketed daily disposable contact lens
1697525|NCT01484028|Device|etafilcon A with print and PVP for light eyes (EALE)|A daily disposable contact lens
1697526|NCT01484028|Device|etafilcon A with print and PVP for dark eyes (EADE)|A daily disposable contact lens
1697527|NCT01484015|Drug|cefepime hydrochloride|Given IV
1697528|NCT01484002|Device|Total hip arthroplasty|Replacement of a patient's native hip with an artificial implant featuring a metal-on-polyethylene articulation
1697529|NCT01483989|Other|SYSTANE® Gel Drop lubricant eye gel|SYSTANE Gel Drops Lubricant Eye gel dosed (bilaterally) 3 times per day for the 28 day period.
1697530|NCT01483976|Other|Oral medical nutritional supplement|orally over a three hour period
1697531|NCT01483976|Other|Experimental oral medical nutritional supplement with AN777|orally over a three hour period
1697532|NCT01483963|Biological|AA4500 0.29 mg/1 mL|treatment of adhesive capsulitis
1697533|NCT01483963|Biological|AA4500 0.58 mg/2 mL|treatment of adhesive capsulitis
1697534|NCT01483963|Biological|AA4500 0.58 mg/1 mL|treatment of adhesive capsulitis
1697535|NCT01483963|Biological|AA4500 0.58 mg/0.5 mL|treatment of adhesive capsulitis
1697536|NCT01483963|Other|Shoulder exercises|Home shoulder exercises, minimum of 3 times per day
1697537|NCT01483937|Device|Usual care physical therapy plus SEMD|Patients will receive usual care physical therapy while wearing SEMD. SEMD protocols will also be provided to device subjects.
1697538|NCT01483937|Other|Usual care physical therapy only|Subjects will receive usual care physical therapy from vestibular and balance specialists.
1697539|NCT01483924|Drug|Apo805K1|Sequential parallel dose escalation.
1697540|NCT01483911|Biological|ALX-0171|Single or multiple ascending doses (2.1-210 mg), administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
1697541|NCT01483911|Biological|Placebo|Single or multiple doses, administered via pulmonary inhalation. Multiple dosing will consist of twice daily dosing on 5 consecutive days.
1697542|NCT01483898|Biological|Ixmyelocel-T|On Day 14, 20 intramuscular injections of either ixmyelocel-T or vehicle control on pre-identified index leg.
1697543|NCT01483898|Other|Placebo|On Day 14, 20 intramuscular injections of either ixmyelocel-T or vehicle control on pre-identified index leg.
1697544|NCT01483885|Device|Transcutaneous Electric Nerve Stimulation|Tens at 4Hz and 100 Hz will be delivered using TENS stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
1697545|NCT01483885|Device|Interferential Current|Interferential Current (IC) at 4Hz and 100 Hz will be delivered using IC stimulator (Ibramed/Neurodyn-São Paulo, Brazil)
1697546|NCT01483885|Procedure|Manual Acupuncture|Manual acupuncture will be delivered with sterile needles for each subject in the acupoint TA5 and CS6 localized in the dominant forearm.
1697547|NCT01483872|Drug|NAC/Tigecycline/Heparin combination lock solution|
1697548|NCT01483872|Drug|Standard anticoagulant (Heparin or Citrate)|
1697549|NCT01483859|Other|preoperative liver stiffness measurement|Liver stiffness measurement (LSM) using Fibroscan is a newly introduced noninvasive tool that generates an elastic wave using a vibrator applied to the thoracic wall at the level of the right lobe of the liver and measures the prolongation velocity of the wave, which is directly associated with liver stiffness (LS).
1697550|NCT01483846|Drug|AV-101|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
1697551|NCT01483846|Drug|Placebo|Placebo or AV-101 at 360 mg, 1080 mg, or 1440 mg will be dosed once daily for 14 consecutive days.
1697552|NCT01483833|Drug|Iferanserin|Iferanserin 0.5% ointment applied intra-anally twice daily for 14 days
1697553|NCT01483833|Drug|Placebo|Placebo ointment applied intra-anally twice daily for 14 days
1697554|NCT01483820|Drug|TPI 287|Subjects will receive six cycles of intravenous (IV) TPI 287 at a dose of 125 mg/m2 on Days 1, 8 and 15 of a 21-day cycle.
1697555|NCT01483807|Behavioral|Sound Production Treatment (SPT) - Blocked|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice
1697556|NCT01483807|Behavioral|SPT - Random|A treatment for acquired apraxia of speech. Combines therapist modeling, simultaneous production, articulatory instruction, feedback and repeated practice - stimuli are practiced in non predictable order
1697557|NCT01483781|Drug|Canagliflozin|Type = exact number, unit = mg, number = 300, form = capsule, route = oral use. One encapsulated tablet once daily for up to approximately 85 days (approximately 12 weeks)
1697558|NCT01483781|Drug|Placebo|Form = capsules, route = oral use. One capsule once daily for up to approximately 85 days (approximately 12 weeks)
1697559|NCT01483768|Procedure|Sleeve gastrectomy for morbid obesity|Sleeve gastrectomy or longitudinal gastrectomy for morbid obesity: is a partial gastrectomy without interruption of the gastric continuity. This procedure includes the resection of the great curvature of the stomach, the fundus , except the lesser curvature and the antrum.
1697560|NCT01483755|Procedure|Postconditioning|Postconditioning consists of four cycles of one minute balloon inflation followed by one minute of balloon deflation, with the initial inflation being started within the first minute after reopening of the culprit coronary artery.
1697561|NCT01483755|Procedure|Percutaneaous intervention|Conventional primary percutaneaous intervention
1697562|NCT01483742|Drug|RO5024048|1000 mg orally bid, 24 weeks
1697563|NCT01483742|Drug|danoprevir|100 mg orally bid, 24 weeks
1697564|NCT01483742|Drug|peginterferon alfa-2a [Pegasys]|180 mcg weekly, 24 weeks
1697565|NCT01483742|Drug|ribavirin|1000-1200 mg/kg/day orally in two divided doses, 24 weeks
1697566|NCT01483742|Drug|ritonavir|100 mg orally bid, 24 weeks
1697567|NCT01483729|Drug|danoprevir|Phase 3 Tablet Formulation 1, single oral dose
1697568|NCT01483729|Drug|danoprevir|Phase 3 Tablet Formulation 2, single oral dose
1697569|NCT01483729|Drug|danoprevir|Reference Phase 2 Tablet Formulation, single oral dose
1697570|NCT01483729|Drug|ritonavir|Test Formulation 1, single oral dose
1697571|NCT01483729|Drug|ritonavir|Test Formulation 2, single oral dose
1697572|NCT01483729|Drug|ritonavir|Reference Formulation, single oral dose
1697573|NCT01483716|Behavioral|Rehabilitation|
1697574|NCT01483703|Device|Laser Speckle Imaging|Laser Speckle Imaging of Critical Care Neonates
1697575|NCT01483690|Drug|Decitabine|10 mg/m2/day given IV over 1 hour on days 1 through 5 and days 15 through 19.
1697576|NCT01483690|Drug|Vorinostat|180 mg/m2/day (Max dose=400mg daily) given orally on days 2 through 7 and days 16 through 21.
1697577|NCT01483690|Drug|Vincristine|1.5 mg/m2/day (Max dose 2 mg) given IV push on days 10, 17, 24 and 31.
1697836|NCT01481779|Drug|Glargine|Administered by SC injection via a pen device.
1697578|NCT01483690|Drug|Dexamethasone|20 mg/m2/day divided BID given orally on days 8 through 12 and 22 through 26.
1697579|NCT01483690|Drug|Mitoxantrone|10 mg/m2/day given on days 8 and 9 as a short IV infusion over 5-15 minutes; do not infuse over less than 3 minutes
1697580|NCT01483690|Drug|Pegaspargase|2500 international units/m2/day IM or IV on days 10 and 24.
1697581|NCT01483690|Drug|Methotrexate|"Given intrathecally to all patients the dose defined by age below.
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients >9 years of age
CNS 1 or 2 patients get doses on day 8, 22 and 35 and CNS 3 patients should get doses on day 8, 15, 22, 29 and 35"
1697582|NCT01483677|Other|Nintendo Wii|Subjects played the game Boomblox for 30 continuous minutes on the Nintendo Wii.
1697583|NCT01483677|Other|Playstation 2|Subjects played the game Time Crisis2 on the Playstation2 for 30 continuous minutes.
1697584|NCT01483651|Drug|Glucagon|The first dose of glucagon will be delivered approximately one hour after infusion of IV insulin has started. The subsequent three doses will be delivered every two hours. The dosage will depend on the IV insulin infusion (50 units regular insulin in 499.5 mL 0.9% saline): Study 1) insulin 0.01 units/kg/hour and glucagon doses (ug): 10,25,45,70; Study 2) insulin 0.02 units/kg/hr and glucagon doses (ug): 25,45,70,100; Study 3) insulin 0.04 units/kg/hr and glucagon doses (ug): 45,70,100,135; Study 4) insulin 0.08 units/kg/hr and glucagon doses (ug): 70,100,135,175. Insulin levels and glucagon doses will be randomized. Glucagon will be reconstituted with 10 mL of sterile water and administered subcutaneously.
1697585|NCT01483651|Drug|Insulin|Insulin was administered at a low, medium or high infusion rate. The intervention sequence was randomly pre-determined for all participants.
1697586|NCT01483638|Drug|axitinib|5 mg BID taken orally with food continuously on Day 1 of the study. One cycle corresponds to 28 days.
1697587|NCT01483638|Drug|placebo|will be administered orally with the same schedule of axitinib
1697588|NCT01483625|Drug|tiotropium|18mcg
1697589|NCT01483625|Drug|Placebo|placebo
1697590|NCT01483612|Behavioral|Interdisciplinary lifestyle intervention|"Individual meetings with a dietitian and a kinesiologist at 0, 3, 6 weeks and then every 6 weeks for 18 months or until delivery. A reminder phone call/email will also take place once between each meeting.
The program also includes 12 group sessions discussing subjects about nutrition, psychology and demonstration of physical activity."
1697591|NCT01483599|Drug|CNTO 1959 (5 mg)|Subcutaneous (SC) injections
1697592|NCT01483599|Drug|CNTO 1959 (15 mg)|SC injections
1697593|NCT01483599|Drug|CNTO 1959 (50 mg)|SC injections
1697594|NCT01483599|Drug|CNTO 1959 (100 mg)|SC injections
1697595|NCT01483599|Drug|CNTO 1959 (200 mg)|SC injections
1697596|NCT01483599|Drug|Adalimumab|SC injections
1697597|NCT01483599|Drug|Placebo|SC injections
1697598|NCT01483586|Drug|kanglaite gelcap|3 KLTc gelcap capsules four times a day throughout the study (12 months). Each gelcap contains .45g KLT per capsule
1697599|NCT01483586|Drug|Kanglaite gelcap|6 KLTc gelcaps taken four times a day throughout the study (12 months). Each gelcap contains .45g KLT
1697600|NCT01483573|Other|neural mobilization|stretch the nerve
1697601|NCT01483573|Other|straight leg raise|stretch the hamstring
1697602|NCT01483560|Drug|Metformin|3 years treatment duration
1697603|NCT01483560|Drug|Placebo|3 years duration
1697604|NCT01483547|Device|Bispectral Index (BIS Vista, Covidien)|BIS values at LOC, PI, ROC.
1697605|NCT01483534|Device|TLD Therapy (IPS SystemTM)|Targeted Lung Denervation Therapy will be achieved bronchoscopically. As this is a single-arm, non-randomized study, it is anticipated that all patients who provide written informed consent and meet the protocol entry criteria will undergo treatment.
1697606|NCT01483521|Other|Clinical home visitation|Clinical Home visitation consisted of once a month visits to families on the experimental group. During those visits home visitors facilitated developmentally appropriate play guidance and co-construction tasks for the dyad.
1697607|NCT01483508|Other|Flavanol- and procyanidins-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols [monomer] and procyanidins [dimers to decamers]
1697608|NCT01483508|Other|Procyanidins-containing drink|Single oral intake of a ocoa-based dairy drink containing procyanidins [dimers to decamers]
1697609|NCT01483508|Other|Flavanol-containing drink|Single oral intake of a cocoa-based dairy drink containing flavanols [monomers]
1697610|NCT01483495|Device|Diffuse optical spectroscopy|Diffuse Optical Spectroscopy Imaging Cerebrovascular Reactivity
1697611|NCT01483482|Procedure|Conservative Treatment|Simple Sling
1697612|NCT01483482|Procedure|Surgical treatment|Superior Locking plate
1697613|NCT01483469|Drug|RO4917523|orally daily, 14 days
1697614|NCT01483469|Drug|RO5011232|[11C]-RO5011232 intravenously
1697615|NCT01483456|Other|"The multidisciplinary prevention program called IPR (in French Identifier, Prévenir, Relever)"|"The intervention is a multidisciplinary program of fall prevention including 3 complementary interventions which focus on several stages of elderly inpatient management:
Identification of patient's fall risk,
Multifactorial fall prevention program (integrated actions targeted on risk factors, exercise programs and review of the hospital environment),
Get up workshop and morbidity and mortality conferences related to fall cases"
1697616|NCT01483443|Procedure|Oophrectomy|Both oophrectomy
1697617|NCT01483430|Drug|Ginseol Kg1 (low dose)|1 capsule/day (100mg of Ginseol Kg1), Duration: 8 weeks
1697618|NCT01483430|Drug|Ginseol Kg1(high dose)|1 capsule/day (300mg of Ginseol Kg1), Duration: 8 weeks
1697619|NCT01483430|Drug|Placebo|1 capsule/day (starch), Duration: 8 weeks
1697620|NCT01483417|Procedure|Single incision Laparoscopic hysterectomy|SILS port
1697621|NCT01483417|Procedure|Conventional laparoscopic hysterectomy|3-4 conventional ports
1697622|NCT01483404|Procedure|Measurement with O2c|Intra-surgery measurement of the microcirculation with the O2c device
1697623|NCT01483391|Behavioral|Enhanced Care|The 3 family sessions involve the youth and all family members. These sessions will help the child and family members with mood charting and developing a mood management plan. Families will rehearse mood regulation strategies for current family, social or academic problems. Clinicians then meet with the child individually every month for the next 3 mos. to provide support, assist with problem-solving, and troubleshoot use of the mood management plan.
1699083|NCT01472835|Drug|Fentanyl|Used for analgesia and as a sedative
1697624|NCT01483391|Behavioral|Family-Focused Treatment|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. The goal of this intervention is to improve the child's ability to regulate moods and to reduce tension and conflict in the family.
1697625|NCT01483378|Other|Choosing to receive the vaccine|
1697626|NCT01483365|Drug|Vaginal tablet Endometrin twice a day|Endometrin 100 mg twice a day
1697627|NCT01483352|Device|Accu-Chek DiaPort|
1697628|NCT01483339|Behavioral|Metacognitive Therapy|Metacognitive Therapy for OCD according to Wells (1997)
1697629|NCT01483339|Behavioral|Exposure and Response Prevention|Exposure and Response Prevention for OCD according to Kozak & Foa (1997)
1697630|NCT01483300|Drug|lobaplatin|Gemcitabine 1000 mg/m2 d1, 8; Lobaplatin 30mg/m2 d1 q 3 weeks
1697631|NCT01483300|Drug|cisplatin|Gemcitabine 1000 mg/m2 d1, 8; Cisplatin 25 mg/m2 d1-3 q 3 weeks
1697632|NCT01483287|Dietary Supplement|Alpha-Galactosidase|"The study is conducted during a total of two days at two different occasions. Visit 1: The patients will be served breakfast and lunch at the gastro unit and dinner will be enclosed when the patient leave for home. At each meal (breakfast, lunch, and dinner) the participants will ingest three capsules with a total content of 1200 GaIU alpha-galactosidase-randomized to be either the enzyme (α-Galactosidase) or a non-active substance (placebo). Visit 2: The procedure from visit 1 will recur after at least two weeks has passed - except that the content of the capsules will be opposite from the first visit.
No other food or beverage are ingested from 1800 hours the evening before the intervention day until breakfast the day after intervention (no exact time)."
1697633|NCT01483274|Biological|Vaccine|Decitabine followed by donor lymphocyte infusing and Dendritic cells pulsed with MAGE-A1, MAGE-A3, and NEY-ESO-1 vaccine
1697634|NCT01483261|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|15 sessions of manualised, culturally modified trauma-focused cognitive behavior therapy
1697635|NCT01483248|Biological|conventional therapy plus MenSC transplantation|"patients will receive conventional treatment,such as antiviral drugs, lowering aminotransferase and jaundice medicine.
MenSCs transplantation: taken i.v., twice per week, at a dose of 1*10E6 MSC/kg body for 2 weeks."
1697636|NCT01483248|Drug|Conventional therapy plus placebo treatment|25 of the enrolled patients were assigned to receive comprehensive treatment including antiviral drugs, lowering aminotransferase and jaundice medicine.
1697637|NCT01483235|Behavioral|Reduced cardiac rehabilitation group intervention (rCRP).|The rCRP is a comprehensive intervention that will keep the same nature of therapies as the standard cardiac rehabilitation group (sCRP). The difference with the sCRP resides in the number of hospital based exercise sessions; instead of 32 sessions there will be 10 sessions spread throughout the 4 months of intervention (hence, not a shorter program). The rCRP intervention works within the sCRP. Hence, those randomized to the rCRP will be supervised in the same facility and by the same clinical staff as those in the sCRP. Patients from rCRP will receive individual exercise guidelines, an educational package with questions of the week and a diary to record their exercise sessions (logbook), that will serve as a self-monitoring system.
1697638|NCT01483235|Behavioral|Standard cardiac rehabilitation intervention|The standard cardiac rehabilitation is a multidisciplinary four-month intervention to modify ischemic heart disease risk factors and lifestyle behaviours. These programs aim to reduce morbidity and mortality by improving adherence to regular physical activity, a healthy diet and smoking cessation, as well as risk factor modification. Patients receive an initial intake evaluation by a cardiologist, nurse,exercise specialist and dietitian before starting the program. The program consists of 32, twice weekly in-hospital exercise sessions, educational sessions, nutritional counselling, medical care, psychological screening and smoking cessation if needed.
1697639|NCT01483222|Device|QUIKDRAW Pro, Aspen Medical Products|Wearing an inelastic lumbar support (QUIKDRAW Pro, Aspen Medical Products) for 6 months
1697640|NCT01483222|Device|MUELLER 4581, Mueller Sports Medicine|Wearing an elastic lumbar support (MUELLER 4581, Mueller Sports Medicine) for 6 months
1697641|NCT01483209|Drug|Injection of botulinum toxin A|One-time injection of 100 units of botulinum toxin into hand to perform full chemical digital sympathectomy
1697642|NCT01483196|Procedure|ultrasound imaging|Undergo TCD
1697643|NCT01483196|Other|questionnaire administration|Complete neurocognitive questionnaires
1697644|NCT01483196|Procedure|assessment of therapy complications|Undergo TCD
1697645|NCT01483196|Procedure|quality-of-life assessment|Ancillary studies
1697646|NCT01483196|Procedure|magnetic resonance imaging|Undergo MRI
1697647|NCT01483183|Drug|OPC-108459|"Part 1: single dose OPC-108459, 10-minute constant rate IV infusion to achieve specified Cmax target
Part 2: single dose OPC-108459, 10-minute constant rate IV infusion to achieve Cmax target concentration from Part 1; if failure to convert to sinus rhythm, second dose OPC-108459 administered, 10-minute constant rate IV infusion to achieve target concentration from Part 1"
1697648|NCT01483183|Drug|Placebo|Placebo dose, 10-minute constant rate IV infusion
1697649|NCT01483170|Drug|Tablets Fexinidazole|Administration of 3 or 4 tablets of 600mg per day during 4 days (loading dose) then administration of 2 tablets of 600mg for 6 days Dosing in fed condition.
1697650|NCT01483170|Drug|Placebo|Placebo fexinidazole
1697651|NCT01483157|Other|vascular occlusion with exercise trainig|twelve weeks of resistance training with vascular occlusion twice a week
1697652|NCT01483157|Other|high intensity resistance training|twelve weeks of resistance training twice a week
1697653|NCT01483144|Drug|Eflornithine plus Sulindac|Eflornithine [250 mg tablet, three tablets (750 mg) orally once a day] and Sulindac [150 mg tablet, one tablet orally once a day] for 24 months
1697654|NCT01483144|Drug|Eflornithine and Placebo|Eflornithine [250 mg, three tablets (750 mg) orally once a day] and Placebo [one tablet orally once a day] for 24 months
1697655|NCT01483144|Drug|Sulindac and Placebo|Sulindac [150 mg tablet, one tablet orally once a day] and Placebo [three tablets orally once a day] for 24 months
1697656|NCT01483131|Other|Exercise training|12 weeks of resistance training twice a week.
1697657|NCT01483131|Other|Resistance training with vascular occlusion|12 weeks of resistance training with vascular occlusion twice a week
1697658|NCT01483118|Drug|Cinnamon Extract|Purified aqueous abstract of cinnamon in 125mg capsules, which would be taken orally before each meal, for a total of 1,500mg/day for 6 months.
1755275|NCT00239330|Drug|Rosuvastatin|
1697660|NCT01483105|Behavioral|DVD Self-Hypnosis Training Program|The DVD training program contains instructional materials developed by an experienced psychiatrist and psychologist at the Department of Psychiatry at Stanford University School of Medicine. Parents will be instructed to review these materials, watch the DVD, and practice the self-hypnosis exercises every day for a week with their child prior to the upcoming procedure. Parents are encouraged to practice self-hypnosis during their child's VCUG procedure.
1697661|NCT01483092|Dietary Supplement|inulin|20g/day for 4 weeks
1697662|NCT01483092|Dietary Supplement|maltodextrin|20g/day for 4 weeks
1697664|NCT01483053|Drug|Agomelatine|Participants who are randomly assigned to the agomelatine group will be treated with agomelatine oral tablets for twelve weeks. Participants will begin their agomelatine treatment at 25mg/day dosage, increasing to 50mg/day as clinically indicated.
1697665|NCT01483053|Drug|Escitalopram|Participants who are randomly assigned to the escitalopram group will be treated with escitalopram oral tablets for twelve weeks. Participants will begin their escitalopram treatment at 10mg/day dosage, increasing to 20mg/day as clinically indicated.
1697666|NCT01483040|Device|colonoscopy system (PeerScope B System™)|Cancer of the colon and rectum is second only to lung cancer as the leading cause of cancer-related deaths in the United States.Each year, about 1.23 million new cases of bowel cancer are diagnosed worldwide, 333,000 in Europe alone. Colorectal cancer almost always starts in a benign growth called a polyp. Polyps originate in the inner lining of the colon, where they may be visible in a screening test known as colonoscopy. Recent research has shown that appropriate screening and treatment can alleviate much of the suffering associated with colorectal cancer and reduce the number of deaths caused by this malignancy
1697667|NCT01483027|Device|TheraSphere|yttrium 90 microspheres
1697668|NCT01483014|Drug|imatinib mesylate|
1697669|NCT01483001|Drug|Cancer Stem Cells Sensitivity Assay|To test in vitro sensitivity of cancer stem cells to several antineoplastic drugs in order to personalize treatment
1697670|NCT01482975|Other|Tailored computer based intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment.
1697671|NCT01482975|Other|Tailored computer intervention|Best practices for TTM tailored communication with two types of feedback: normative - compared to peer and ipsative - self compared to previous assessment
1697672|NCT01482962|Drug|Alisertib|Patients randomized to receive alisertib will be administered an enteric-coated tablet formulation 5×10-mg twice daily orally for 7 consecutive days (Cycle Days 1-7) in a 21-day cycle.
1697673|NCT01482962|Drug|Pralatrexate|"Patients randomized to single-agent comparator will be assigned by the investigator to receive ONE of either Pralatrexate,or Romidepsin, or Gemcitabine.
Patients randomized to receive Pralatrexate will be administered the drug at 30mg/m2 as an intravenous (IV) push over 3 to 5 min once weekly for 6 weeks in 7-week cycles with concurrent vitamin B12 and folic acid supplementation. Cycles should be repeated every 7 weeks"
1697674|NCT01482962|Drug|Gemcitabine|"Patients randomized to single-agent comparator will be assigned by the investigator to receive ONE of either Pralatrexate, or Romidepsin, or Gemcitabine.
Patients randomized to receive Gemcitabine will receive the drug intravenously at 1,000 mg/m2 over 30 minutes on Days 1, 8, and 15 of a 28-day cycle. Cycles should be repeated every 28 days in the absence of disease progression or unacceptable toxicity."
1697675|NCT01482962|Drug|Romidepsin|"Patients randomized to single-agent comparator will be assigned by the investigator to receive ONE of either Pralatrexate, or Romidepsin, or Gemcitabine.
Patients randomized to receive Romidepsin will be administered the drug intravenously at 14mg/m2 over a 4-hour period on Days 1,8,& 15 of a 28-cycle. Cycles should be repeated every 28 days."
1697676|NCT01482949|Drug|AGS-003|Autologous Dendritic Cell Immunotherapy
1697677|NCT01482936|Drug|Oxycodone (OxyNorm®) Injection|The subjects will be randomized to receive a single dose of OxyNorm® 2.5, 5, and 10mg.The plasma concentration will be analyzed to determine the following pharmacokinetic parameters:AUC0-t:ug•hr/L-Area under the plasma concentration-time curve frame: predose,0,2min,5min,10min,15min,30min,45min,1hr,1.5hr,2hr,3hr,4hr,6hr,8hr,12hr, 24hr post-dose.AUC0-inf:ug•hr/L-Area under the plasma concentration-time curve extrapolated to infinity. Cmax: ug/L-Maximum observed plasma concentration of oxycodone and noroxycodone.Tmax: hrs-time at which Cmax is first observed. t½: Apparent half life of oxycodone elimination.
1697678|NCT01482923|Behavioral|Treatment as usual|Participants in the Treatment as Usual study arm will be provided with the following: 1) brief smoking cessation counseling as recommended in the Public Health Service treatment guidelines; 2) direct referral to the NY/NJ State Quitline; 3) a brochure that describes the Quitline services and provides contact information via telephone or internet; 4) a NY State brochure on HIV and smoking that identifies the specific risks of smoking for PLWHA; and 5) referral assistance to participants who present with untreated co-morbid conditions.
1697679|NCT01482923|Behavioral|AIR (Aspirations, Inspiration, Respiration)|Participants in the Aspirations, Inspiration, and Respiration study arm will receive all of the components of Treatment as Usual along with these additional components: 1) a lung age test to determine the ability and functioning of their lungs; 2) a personal lung health report with their lung age, the CO level of their breath, and a summary of their respiratory symptom assessment; 3) a review of this personal lung health report with a study counselor, 4) motivational interviewing techniques guided by Self-Determination Theory concepts to explicitly elicit at least one life aspiration of the patient and encourage discussion of such aspirations using an autonomy-supportive approach.
1697680|NCT01482910|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Participants in the VEGF Trap-Eye group received intravitreal injections every 8 weeks following a loading phase with injections given every 4 weeks for an overall treatment period of 48 weeks. Additionally, sham PDT treatments was administered as needed.
1697681|NCT01482910|Drug|Visudyne|Participants in the PDT group (Visudyne group) received Visudyne as needed. Additionally, sham IVT injections was administered until week 28. Thereafter, subjects in the PDT group received active (= no sham) VEGF Trap-Eye treatment until week 48.
1697682|NCT01482897|Drug|Prednisolone acetate|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with corticoid (125mg in.5 ml)
1697730|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
1697683|NCT01482897|Drug|sham procedure|feigning of peridural infiltration : anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with placement of empty syringe in peridural.
1697684|NCT01482897|Drug|comparator : physiological solution|anesthetic bloc (10 ml of xylocaïne 1%) immediately followed with physiological solution (20 ml)
1697685|NCT01482884|Drug|tralokinumab|2 sc injections of every 2 weeks for 12 weeks.
1697686|NCT01482884|Drug|placebo|2 sc injections of every 2 weeks for 12 weeks.
1697687|NCT01482871|Drug|ALG-1001|1.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
1697688|NCT01482871|Drug|ALG-1001|2.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
1697689|NCT01482871|Drug|ALG-1001|5.0 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
1697690|NCT01482871|Drug|ALG-1001|7.5 mg per 100ul injected in the eye on day 0, day 30 and day 60 and followed for 180 days until unacceptable toxicity develops
1697691|NCT01482858|Dietary Supplement|Gastrolith|Gelatin capsules, each containing 500 mg of GASP (comprised of 125 ±5 mg elemental calcium) for oral use.
1697692|NCT01482858|Other|Placebo|Gelatin capsules, each containing 500 mg [comprised of 312.5 mg calcium carbonate (125 ±5 mg elemental calcium) and 187.5 mg of sucrose] for oral use as placebo
1697693|NCT01482845|Drug|ABT-126|Dose 1 is given to 8 subjects in Group 1. Dose 2 is given to 8 subjects in Group 2. All doses will be administered once daily in the morning for 10 days.
1697694|NCT01482845|Drug|Placebo|Placebo is given to 2 subjects each in Group 1 and Group 2. All doses will be administered once daily in the morning for 10 days.
1697695|NCT01482832|Behavioral|Interpersonal therapy-based treatment|Interpersonal therapy-based treatment Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. (5 weekly sessions with a booster session postpartum)
1697696|NCT01482819|Device|galyfilcon A|contact lenses worn bilaterally for 8-12 hours
1697697|NCT01482819|Device|galyfilcon A plus|contact lenses worn bilaterally for 8-12 hours
1697698|NCT01482819|Device|lotrafilcon A|contact lenses worn bilaterally for 8-12 hours
1697699|NCT01482819|Device|polymacon|contact lenses worn bilaterally for 8-12 hours
1697700|NCT01482819|Other|spectacles|habitual spectacles owned by subject, non-specific manufacturer
1697701|NCT01482806|Behavioral|CCBT+ISG/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program plus access to a moderated ISG where patients will be able to communicate confidentially to receive and provide advice and peer-support from other study participants
These interventions will be delivered as part of a collaborative care intervention provided in concert with their usual source of primary care.
Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
1697702|NCT01482806|Behavioral|CCBT/Collaborative Care|"Guided patient access to the Beating the Blues CCBT program.
This interventions will be provided as part of a collaborative care intervention provided in concert with their usual source of primary care.
Patients will also have the option of pharmacotherapy for their mood and/or anxiety disorder and referral to a community mental health specialist per their preference."
1697703|NCT01482793|Procedure|Vertebroplasty|AVAmax radiopaque bone cement is injected into the vertebral body using a 13 G or 11 G vertebroplasty needle.
1697704|NCT01482780|Device|PICSO|PICSO (pressure controlled intermittent coronary sinus occlusion) will be used in the pre ECC period. The procedure of PICSO will be performed in analogy to retrograde cardioplegia.
1697705|NCT01482767|Drug|Pegylated-Interferon Alfa 2b (PEG-IFN)|1.5 mcg/kg subcutaneously (SC) once a week (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
1697706|NCT01482767|Drug|Ribavirin (RBV)|800-1400 mg orally per day with food (based on participant's weight at entry) for up to 48 weeks depending on cirrhosis status and, in Group A, Week 8 HCV viral response.
1697707|NCT01482767|Drug|Boceprevir (BOC)|800 mg orally every 8 hours with food from Week 5 to up to Week 48 depending on cirrhosis status and, in Group A, Week 8 HCV viral response
1697708|NCT01482754|Drug|Rituximab (Mabthera®, Roche Pty Ltd, Basel, Switzerland)|Recommended and approved dosage of Rituximab is 375mg/m2. The recommended guideline for Rituximab infusion for first cycle is commencing at an infusion rate of 50mg/hr for the first 30 minutes. If tolerated well, the subsequent increments will step up to 50mg/hr every 30 minutes to a maximum dose of 400mg/hr. For second and subsequent infusions, the infusion rate commences at 100mg/hr with 30 minute increments of 100mg/hr to a maximum dose of 400mg/hr. The first and subsequent infusion generally completes between 5-6 and 3-4 hours respectively.
1697709|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
1697724|NCT01482650|Device|supraglottic airway placement and use|The investigators will place the device (Baska mask or LMA) according to a pre-defined protocol and monitor its performance intra and postoperatively.
1697725|NCT01482637|Other|CAS|All clients will be asked to complete the CAS instrument.
1697726|NCT01482624|Device|Hyaluronan (0.5%, 5 mg/10 ml)|Standard arthroscopic meniscal surgery and add-on treatment with VISCOSEAL® SYRINGE. Single injection of Hyaluronan directly after arthroscopic procedure.
1697727|NCT01482624|Procedure|Standard arthroscopic meniscal surgery|Standard arthroscopic meniscal surgery without add-on treatment.
1697728|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = 10, 75, 300, form = suspension, route = oral use.
1697710|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
1697711|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
1697712|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
1697713|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
1697714|NCT01482741|Behavioral|Focus Group Sessions|Participants will complete a pre-focus group demographic questionnaire. Focus group participants will be asked to report the following: current age; gender; race/ethnicity; income; highest education attained; occupation; and cancer stage if participant has a cancer history. Participants who are parents of pediatric patients will also report their child's current age, gender, and cancer stage. Ten questions will be developed by the investigators and posed to each group by the moderator to solicit the desired information. The objective for the focus groups will be to systematically explore three domains: 1) what participants know about radiation as it relates to medical imaging; 2) how what they know or believe about radiation shapes their attitudes about it; 3) and participant perceptions regarding the availability and adequacy of their sources, including risk-benefit communication with health care providers
1697715|NCT01482728|Drug|Dasatinib|100 mg dasatinib, the day before surgery and the day of surgery
1697716|NCT01482728|Drug|Dasatinib|200 mg dasatinib the day before surgery and the day of surgery
1697717|NCT01482715|Drug|Rucaparib|Oral tablets administered daily with 8 oz (240 mL) of water on an empty stomach or with food; 21-day cycles of treatment. In Part 1, the initial dose level is 40 mg/day (once a day); doses and dosing frequency(e.g. twice a day or three times a day) will be adjusted until Maximum Tolerated Dose (MTD) and the Recommended Phase 2 Dose (RP2D) are established. Patients enrolled in Part 2 and Part 3 will receive the RP2D for continuous 21-day treatment cycles until disease progression.
1697718|NCT01482702|Behavioral|weight loss intervention|Behavioral weight loss intervention
1697719|NCT01482702|Behavioral|Weight Loss|Behavioral weight loss intervention
1697720|NCT01482702|Behavioral|Weight Loss|Behavioral weight loss intervention
1697721|NCT01482689|Dietary Supplement|Fish oil capsule (specially manufactured for the study)|One capsule per day for 4 weeks (28 days). The fish oil group receives a daily supplement of one fish oil capsule, specially manufactured for the present study by Peter Möller (now Möller's, Nydalen, Norway). The fish oil capsules are aimed to contain a dose of cholecalciferol identical to the dose already found in the multivitamin tablets by analysis in an independent laboratory (AS Vitas, Oslo, Norway), and similar doses of vitamin A. In addition, the fish oil capsule contains vitamin E and n-3 fatty acids.
1697722|NCT01482689|Dietary Supplement|Multivitamin tablet of type: Vitaplex ABCD|One tablet per day for 4 weeks (28 days). The multivitamin group receives a daily supplement of one multivitamin tablet of type Vitaplex ABCD (Cederroth AS, Revetal, Norway), a common vitamin supplement sold in grocery stores in Norway. In addition to 10 micrograms (400 IU) of cholecalciferol,the multivitamin tablet contains vitamin A and the water-soluble vitamins: B1, B2, B6, Niacin, pantothenic acid, and vitamin C.
1697723|NCT01482663|Behavioral|Healthy Skin Clinic|"The intervention is founded upon three concurrent elements. Firstly, a SKIN-profile generated by data from a baseline questionnaire (S=Susceptibility, K=Competencies, I=Individual characteristics, N=Necessary precautions).
Secondly, a patient self-management book which includes a patient's log and is offered in both an online and a physical form. Also support to self-management is offered through possible asynchronous communication and networking.
Finally, a counselling consultation with a nurse, trained within dermatology."
1697729|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = 30, 150, 600, form = suspension, route = oral use.
1755276|NCT00239330|Drug|Atorvastatin|
1697731|NCT01482611|Drug|JNJ-47910382|Type = exact number, unit = mg, number = To be determined, form = suspension, route = oral use.
1697732|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent of 10, 75, 300, form = suspension, route = oral use.
1697733|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent of 30, 150, 600, form = suspension, route = oral use
1697734|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use.
1697735|NCT01482611|Drug|Placebo|Type = exact number, unit = mg, number = equivalent dose to be determined, form = suspension, route = oral use
1697736|NCT01482598|Device|Remote Care Follow up|Patient device is checked daily through remote transmitter (Merlin@Home) and every 6 month a complete transmission with all device data is performed
1697737|NCT01482585|Other|CT, PET, copy number alteration|Duel-energy CT, PET, copy number alteration
1697738|NCT01482572|Procedure|biopsy|percutaneous lung biopsy and aspiration
1697739|NCT01482559|Drug|Dopamine hydrochloride|Active drug substance 1.5 mg in 1 mL IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
1697740|NCT01482559|Drug|Dextrose 5%|IV Infusion Minimum dose = 5mcg/kg/min Maximum dose = 20mcg/kg/min
1697741|NCT01482468|Drug|continuous infusion of palonosetron added to prophylactic single injection of palonosetron|continuous infusion of palonosetron 0.00075 mg/hour after single injection of palonosetron 0.075mg
1697742|NCT01482468|Drug|continuous infusion of normal saline added to prophylactic single injection of palonosetron|continuous infusion of normal saline after single injection of palonosetron 0.075mg
1697743|NCT01482455|Other|Elevation of FFA during OGTT|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1"
1697744|NCT01482455|Other|Elevation of FFA during Clamp|"0-240 min: Intralipid® 20%, Pharmacia AB, Stockholm, Sweden, 90 ml/hr; Heparin Immuno®, Immuno AG, Vienna, Austria, bolus: 200IU, continuous infusion: 0.2 IU.kg-1.min-1."
1697745|NCT01482442|Drug|sorafenib|Patients will receive continuous oral treatment with 800 mg of sorafenib daily (Nexavar, Bayer HealthCare Pharmaceuticals-Onyx Pharmaceuticals). Treatment interruptions and dose reductions (to 400 mg once daily) will be permitted for drug-related adverse effects. At the discretion of the investigator, the dose may be re-escalated to after the resolution of the adverse event.
1697746|NCT01482442|Drug|SIR-Sphere|The first step will check patient eligibility and prepare conditioning by performing selective mesenteric and hepatic angiography (to document the arterial tumor supply and to occlude extrahepatic vessels) and 99mTc-macroaggregated albumin scintigraphy. The second step is RADIOEMBOLIZATION therapy. One to two weeks after patient eligibility and conditioning, treatment is performed with SIR-Sphere (SIRTEX Medical Ltd.,Lane Cove,Australia).
1697747|NCT01482429|Other|Multidisciplinary weaning-ventilator protocol|We implemented a multidisciplinary protocol for weaning from mechanical ventilation.This consist of a daily screening for readiness, performing a spontaneous breathing test, evaluation of signs of intolerance and decision on extubation.
1697748|NCT01482416|Drug|Estrogens, Conjugated (USP)|Experimental group will use 0.625mg/day during 30 days
1697749|NCT01482416|Drug|Placebo|Placebo group will use placebo once/day during 30 days
1697750|NCT01482403|Drug|Copegus|total daily dose of 1000 mg or 1200 mg for 24 weeks
1697751|NCT01482403|Drug|Copegus|total daily dose of 1000 mg or 1200 mg for 48 weeks
1697752|NCT01482403|Drug|Pegasys|180 microgram subcutaneous once a week for 24 weeks
1697753|NCT01482403|Drug|Pegasys|180 microgram subcutaneous once a week for 48 weeks
1697754|NCT01482403|Drug|boceprevir|800 mg three times a day for 24 weeks
1697755|NCT01482403|Drug|boceprevir|800 mg three times a day for 48 weeks
1697756|NCT01482403|Drug|mericitabine|1000 mg twice daily for 24 weeks
1697757|NCT01482403|Drug|mericitabine placebo|mericitabine placebo
1697758|NCT01482403|Drug|boceprevir placebo|boceprevir placebo
1697759|NCT01482403|Drug|boceprevir|800 mg three times a day for 44 weeks
1697760|NCT01482390|Drug|Ribavirin|Participants will receive a total daily dose of 1000 milligrams (mg) (for participants weighing less than [<] 75 kg) or 1200 mg (for participants weighing greater than or equal to [>=] 75 kg) orally for 24 or 48 weeks.
1697761|NCT01482390|Drug|Mericitabine|Participants will receive mericitabine 1000 mg orally twice daily.
1697762|NCT01482390|Drug|Peginterferon Alfa-2a|Participants will receive 180 micrograms (mcg) subcutaneous injection once weekly.
1697763|NCT01482390|Drug|Placebo|Participants will receive placebo matching to mericitabine orally twice daily.
1697764|NCT01482390|Drug|Telaprevir|Participants will receive telaprevir 750 mg orally three times daily.
1697765|NCT01482377|Drug|RO5479599|RO5479599 will be administered Q2W or Q3W (other regimen could be explored based on observations during dose escalation part).
1697766|NCT01482377|Drug|Cetuximab|Cetuximab will be administered via intravenous (IV) infusion at a starting dose of 400 mg/m^2 for the first infusion, followed by doses of 250 mg/m^2 for subsequent infusions.
1697767|NCT01482377|Drug|Erlotinib|Erlotinib, at a dose of 150 mg will be administered.
1697768|NCT01482377|Drug|zirconium-89-labeled RO5479599|Single dose of radiolabeled drug will be administered.
1697769|NCT01482364|Device|Integrated hemodynamic management (IHM) - HOTMAN System|Therapeutic approach according to HOTMAN System measurement(ICG)results .
1697770|NCT01482364|Device|Non Integrated Hemodynamic Management (Non-IHM) - HOTMAN System|Therapeutic approach according to 2007 ESH Guidelines, regardeless HOTMAN results.
1697772|NCT01482338|Drug|EE 20 microgram with desogestrel 150 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
1755277|NCT00239343|Drug|gefitinib|
1697773|NCT01482338|Drug|EE 20 microgram with drospirenone 3 mg|Comparison of 2 different low-dose oral contraceptive pill which one consists of 20 microgram ethinyl estradiol and 150 mg desogestrel and the other consists of 20 microgram ethinyl estradiol and 3 mg drospirenone. Both were taken orally by participants every day beginning Day1 to Day 3 of the first menstrual cycle until complete 24 days and continued with free-hormone pills for 4 days. The next cycle has to continue in the same way until complete 6 cycles.
1697774|NCT01482325|Device|Blood pressure monitoring with GE Healthcare DASH2500 Patient Monitor|10-20 Non-Invasive Blood Pressure readings on investigational software in the DASH2500 Patient Monitor
1697775|NCT01482312|Device|lotrafilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
1697776|NCT01482312|Device|comfilcon A contact lenses|Commercially marketed, silicone hydrogel, single-vision, soft contact lenses FDA-approved for daily and extended (overnight) wear for up to 30 nights of continuous wear.
1697777|NCT01482312|Other|Glasses|Glasses per habitual prescription
1697778|NCT01482299|Drug|RAD001|"RAD001 (everolimus) 10 mg daily, orally without interruption.
1 cycle is equal to 4-week treatment. Treatment will be continued unless disease progression or intolerability."
1697779|NCT01482286|Drug|Metformin|Subjects randomized to the metformin treatment group will receive 1000 mg extended release metformin hydrochloride tablets (Bristol Myers Squibb) twice per day with food approximately 8 hours apart.
1697780|NCT01482286|Behavioral|Dietary Restriction|Subjects randomized to the dietary restriction group will reduce their energy intake by 25% of their weight maintenance energy intake determined at baseline. Total energy expenditure as measured by a 14-day doubly labeled water (DLW) study will be used to determine the baseline energy intake of each subject. There will be no gradual ramping of dietary restriction. The 25% energy reduction goal will apply from the first day of the intervention for a period of 24 weeks. Subjects will be asked to not modify their normal level of physical activity.
1697781|NCT01482286|Behavioral|Exercise Training|"For the aerobic training component, subjects are required to meet a weekly energy expenditure target of 10 kcal per kg of body weight per week (KKW).
The resistance training program will be performed 2 days a week. The resistance program includes 9 exercises. The 9 primary exercises are seated chest press, seated row, shoulder press, lat pull down, double leg press, leg extension, leg curl, back extension and abdominal crunch."
1697782|NCT01482273|Procedure|CDT+US group|CDT using the EkoSonic Endovascular System with intravascular high-frequency, low-power ultrasound for 15 hours.
1697783|NCT01482273|Procedure|CDT-US group|CDT using the EkoSonic Endovascular System without intravascular high-frequency, low-power ultrasound for 15 hours.
1697784|NCT01482260|Procedure|Biopsy|Biopsy
1697785|NCT01482247|Dietary Supplement|L-Arginine|Dietary Supplement
1697786|NCT01482247|Dietary Supplement|Placebo Supplement|Dietary Supplement
1697787|NCT01482234|Behavioral|TXT Me|text messages, physical activity, self determination theory, extrinsic motivation, intrinsic motivation, pedometers, walking, prompts
1697788|NCT01482221|Drug|AZD6765 iv|50 mg (AZD6765 Solution for Infusion, 0.5 mg/mL) by iv infusion.
1697789|NCT01482221|Drug|AZD6765 iv|100 mg (AZD6765 Solution for Infusion, 1.0 mg/mL) by iv infusion.
1697790|NCT01482221|Drug|Placebo|0.9 sodium chloride [normal saline] solution for injection by iv infusion
1697793|NCT01482156|Drug|RAD001 + BEZ235|RAD001 is formulated as tablets of 2.5 mg and 5 mg strength, blistered in units of 10 tablets (for oral use) each. Blisters should be opened only at the time of dministration as the drug is both hygroscopic and light-sensitive. RAD001 should be administered immediately after a meal with a large glass of water. BEZ235 is supplied as 50-mg, 200-mg, 300-mg and 400-mg sachets (for oral use). BEZ235 is packaged in aluminum foil bags. Bags are packaged in a box. Patients will receive RAD001 in combination with BEZ235.
1697794|NCT01482143|Drug|AFQ056|
1697795|NCT01482130|Behavioral|Heavy, explosive strength training|All participants of the training group will pursue a 12 weeks of heavy, explosive strength training, 3 sessions a week for a total of 36 sessions. The training session will include one squat exercise only, which allows muscle contraction of the quadriceps from a 90° bend at the knees to straight legs.
1697796|NCT01482130|Behavioral|recommendations|"The control group will be encouraged to follow a training program according to recommended exercise guidelines:
Weight bearing activities (walking, jogging or strength training)
30 - 60 minutes, 3 - 5 times each week
A total of 2 - 3 hours each week should be achieved"
1697797|NCT01482117|Drug|Clopidogrel|single oral administration of 300mg of clopidogrel
1697798|NCT01482117|Drug|Cilostazol|single oral administration of 100mg cilostazol
1697799|NCT01482117|Drug|Clopidogrel/Cilostazol|single oral administration of 300mg clopidogrel and 100mg cilostazol
1697802|NCT01482091|Drug|Fentanyl Citrate|A single dose of fentanyl citrate (2 mcg/kg; max 100mcg) administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device
1697803|NCT01482091|Drug|Normal Saline|A single dose of equivalent volume of 0.9% Normal Saline will be administered intranasally. Half of the volume will be administered in each nare. The medication will be administered using a mucosal atomization device.
1697835|NCT01481818|Drug|EGCG|Apply about 0.05ml/cm2 EGCG with different concentration topically for 3 times a day during radiotherapy
1697804|NCT01482065|Device|CPAP (ResMed S9 autoset CPAP)|A ResMed S9 autoset CPAP device will be utilized throughout the study. Throughout the study intervention period, subjects (for AHI> 15) will be instructed to utilize their CPAP and adherence will be monitored using an automatic meter that is built into the CPAP device.
1697805|NCT01482052|Biological|meningococcal meningitis conjugate vaccine, quadrivalent|NmVac4-A/C/Y/W-135-DT™conjugate is a vaccine in liquid form composed of purified polysaccharides (PS) conjugated to diphtheria toxoid. Single intramuscular 0.5 mL dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 16 µg total diphtheria toxoid.
1697806|NCT01482052|Biological|meningococcal meningitis conjugate vaccine, quadrivalent|Meningococcal (Groups A,C,Y and W-135-DT) Polysaccharide Conjugate Vaccine 0.5 mL dose, intramuscular. Single dose contains 4 µg each Serogroup A, C, W-135, Y PS conjugated to approximately 48 µg total diphtheria toxoid.
1697809|NCT01482026|Other|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
1697810|NCT01482026|Other|ADHD Rating Scale-IV|ADHD Rating Scale-IV test
1697811|NCT01482013|Drug|HPP854|Oral, once a day for 28 days.
1697812|NCT01482013|Drug|Placebo|Oral, once a day for 28 days.
1697813|NCT01482000|Other|Pulmonary daoyin therapy of China|The intervention group will perform a 3 months pulmonary daoyin of China therapy program which consists of training and patient education. They will be evaluated with some tests for the study.
1697814|NCT01482000|Other|usual care|The control group will get the usual care with some additional tests for the study.
1697815|NCT01481987|Procedure|Epiretinal Membrane Surgical treatment|epiretinal membrane peeling
1697816|NCT01481974|Drug|Treprostinil|"The Treatment Phase will begin at the initiation of Treprostinil after induction of anesthesia for the transplant surgery and continues throughout the surgery and for approximately a total of 120 hours.
Treatment phase activities include:
• Initiation of Treprostinil after the patient is hemodynamically stable following transplant surgery. (Treprostinil dosing will follow a standard 3 + 3 phase 1 design."
1697817|NCT01481961|Procedure|repetitive Transcranial Magnetic Stimulation (rTMS)|After locating the left DLPFC, treatment with active rTMS will be directed by 20-minute session during which pulse trains of 5 seconds of 10 Hz spaced 25 seconds (2 trains of pulses per minute or 40 pulse trains per session). Treatment will occur 2 sessions per day during 5 days per week. Subjects will be monitored during rTMS for any side effects or adverse events.
1697818|NCT01481948|Behavioral|Food, Fun, & Fitness Internet Program for Girls|This is an 8 episode intervention, delivered entirely over the internet. Each episode, girls will view an interactive story in which 6 8-10 year old African American characters attempt to solve a mystery about their town. The online program will include information about healthy nutrition (i.e., consuming more fruit, vegetables, water) and physical activity. There will be two groups; one group (the experimental group) will view the interactive story and participate in key behavior change procedures, such as personal goal setting, problem solving, and self monitoring activities. The second group (the active comparator group) will view the online stories but will not engage in key behavior change procedures.
1697819|NCT01481935|Other|Enhanced cleaning of surfaces in ICU rooms|Using a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), the following surfaces will be wiped clean by a study investigator if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. Cleaning will occur once on the day of enrollment and follow-up.
1697820|NCT01481935|Other|Sham enhanced cleaning of surfaces in ICU rooms|While holding a paper towel pre-soaked with a commercially-available quaternary ammonium cleaning solution (Virex WetTask wipes, Kimberly-Clark, Irving, Texas), a study investigator will mime the action of wiping the following surfaces in the room clean if present: bed rail top bar, bed electronic control surfaces, moveable tray table top and control surfaces desktop and sides, IV poles, infusion pump control surfaces, nurse call button, patient telephone/remote control, sink console top, light switches and plates, supply cart top and drawer handles, ventilator control surfaces and desk, vital signs monitor control surfaces. The sham cleaning will occur once on the day of enrollment and follow-up.
1697821|NCT01481922|Device|whitacre 24 gauge|Whitacre 24 gauge spinal needle 3 inches 1/2. Manufactured by Becton Dickinson
1697822|NCT01481922|Device|whitacre 22 gauge|Whitacre 22 gauge spinal needle 3 inches 1/2 manufactured by Becton Dickinson
1697823|NCT01481909|Drug|Rupatadin|20 mg, 28 days over 60 days
1697824|NCT01481896|Device|Metal-on-metal primary total hip arthroplasty (DePuy )|Replacement of a patient's native hip with an artificial implant featuring a metal-on-metal articulation
1697825|NCT01481883|Drug|Raloxifene Hydrochloride|120mg daily - 1 capsule daily for 12 week trial
1697826|NCT01481883|Drug|Placebo|1 capsule daily for 12 week trial
1697827|NCT01481870|Drug|Sorafenib-sunitinib|sorafenib 400mg b.i.d. followed by sunitinib treatment when progression is observed
1697828|NCT01481870|Drug|Sunitinib-sorafenib|sunitinib 50mg q.d. 4 weeks on two weeks off followed by sorafenib treatment when progression is observed
1697829|NCT01481857|Other|Segmental trunk exercise associated with proprioception|Proprioceptive exercise
1697830|NCT01481857|Other|Segmental trunk exercise|Segmental trunk exercise
1697831|NCT01481844|Drug|Lansoprazole , Tab Amoxycillin , Tab Clarithromycin ,Tab Tinidazole|use of Sequential therapy as second line treatment for eradication H pylori currently Sequential therapy is indicated as first line treatment for H pylori eradication
1697832|NCT01481844|Drug|Lansoprazole, Bismuth Subsalicylate, Metronidazole, Tetracycline|this combination is standard of care as H pylori second line treatment
1697833|NCT01481831|Drug|Palonosetron Hydrochloride|0.25 mg IV*1 dose on day 1, 30 minutes prior to the administration of the major chemotherapeutic agent.
1697834|NCT01481831|Drug|Palonosetron Hydrochloride|0.25mg IV*3 doses on days 1,3 and 5,30 minutes prior to the administration of the major chemotherapeutic agent.
1699085|NCT01472822|Dietary Supplement|Placebo|Placebo 1.2g/day for 12weeks
1697837|NCT01481779|Drug|LY2605541|Administered by SC injection with a pen device.
1697838|NCT01481779|Drug|Insulin Lispro|Administered by SC injection with a pen device.
1697839|NCT01481766|Dietary Supplement|Ferrous Sulfate|6 mg elemental iron/kg/day (0.4 ml/kg/day) in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
1697840|NCT01481766|Dietary Supplement|Placebo|0.4 ml/kg/day in 2 or 3 divided doses (at the discretion of prescribing study doctor) for four months plus dietary counseling
1697841|NCT01481766|Behavioral|Dietary counseling|Dietary counseling will include written recommendations regarding maximum daily cow's milk intake, varied solid food intake including high iron containing foods, and avoidance of foods which reduce iron absorption.
1697842|NCT01481753|Procedure|pancreaticoduodenectomy without Braun enteroenterostomy|no Braun enteroenterostomy has been added to standard pancreaticoduodenectomy; pancreaticoduodenectomy without Braun enteroenterostomy
1697843|NCT01481753|Procedure|Braun enteroenterostomy|addition of Braun enteroenterostomy (side-to-side anastomosis between the afferent and efferent loops of the gastrojejunostomy) to standard PD reconstruction can decrease the rates of POPF and/or DGE, improving the perioperative outcome of patients undergoing PD.
1697844|NCT01481740|Drug|Phenylephrine bolus|10 ml of 100mcg/ml phenylephrine and placebo infusion
1697845|NCT01481740|Drug|phenylephrine infusion|60ml infusion of 100mcg/ml phenylephrine and placebo bolus
1697846|NCT01481727|Device|BiPAP Pro 2, Phillips Respironics|mechanical ventilation type bilevel at high intensity (>18mmHg) for at least six hours, nocturnal ventilation.
1697847|NCT01481727|Device|CPAP sham|CPAP sham maneuver (IPAP less or equal to 4cmH2O)
1958248|NCT01847885|Device|Smartpatch Peripheral Nerve Stimulation (PNS) System|"The Smartpatch System is an Investigation Device which delivers mild electrical stimulation to the muscles in the shoulder. The Smartpatch System includes a small wire (called a Lead) that is placed through the skin into the muscle of the shoulder. It also includes a device worn on the body that delivers stimulation (called the Smartpatch Stimulator)."
1697850|NCT01481701|Drug|Oxaliplatin|85 mg/m² / 14days
1697851|NCT01481701|Drug|oxaliplatin|oxaliplatin
1697854|NCT01481662|Device|Diffusion tensor magnetic resonance imaging of the brain|Diffusion tensor magnetic resonance imaging of the brain will be obtained to more carefully study the cerebral microvasculopathy of the disease.
1697855|NCT01481623|Other|Constitution of a biological bank|Blood samples for the constitution of a biobank (DNA, RNA, serum)
1697856|NCT01481623|Other|Metabolic studies|oral glucose tolerance test (OGTT) intravenous glucose tolerance test (IVGTT) hyperglycemic clamp staged glucose perfusion arginine test measure of body composition (BIPHOTONIC absorptiometry, DEXA)
1697857|NCT01481610|Drug|Lumiracoxib|Patients in this group will receive a standard fixed dose of lumiracoxib PO (200 mg/day), for a period no longer than 10 days, but no shorter than 7 days.
1697858|NCT01481610|Drug|Diclofenac|Patients in this group will receive a standard fixed dose of diclofenac PO (100 mg/day) for a period no longer than 10 days but no shorter than 7 days.
1697859|NCT01481597|Drug|deuteporfin|deuteporfin 1 mg/kg IV as a single dose
1697860|NCT01481597|Drug|deuteporfin|deuteporfin 2.5 mg/kg IV as a single dose
1697861|NCT01481597|Drug|deuteporfin|deuteporfin 5 mg/kg IV as a single dose
1697862|NCT01481597|Drug|deuteporfin|deuteporfin 7.5 mg/kg IV as a single dose
1697863|NCT01481597|Drug|placebo|Placebo for 2.5 mg/kg, 5 mg/kg and 7.5mg/kg of deuteporfin (single dose)
1697864|NCT01481584|Dietary Supplement|Protein drink - protein isolate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein isolate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
1697865|NCT01481584|Dietary Supplement|Protein drink - protein hydrolyzate|The subjects consumed 500 mL of a protein drink (tomato juice) containing 30 g protein (canola protein hydrolyzate or reference protein) after overnight fasting. After run-in period, each volunteer have to pass both protein-intervention days in different order with a four-week wash out period in between.
1697866|NCT01481571|Device|Vitrification medium oocyte, warming medium oocyte and Rapid-i|Media and device for vitrification of human oocytes
1697867|NCT01481558|Device|Transcranial direct current stimulation|tDCS 2 mA, dorsolateral pre-frontal cortex
1697868|NCT01481545|Radiation|Radiation therapy|Radiation therapy will be administered at the total dose of 45 Gy, given with five weekly fractions over a period of 5 weeks. The daily fraction dose will be 1.8 Gy
1697869|NCT01481545|Drug|Oxaliplatin|100 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
1697870|NCT01481545|Drug|Raltitrexed|2.5 mg/m2 on day 1 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1) , an additional 2 cycles of chemotherapy will be given after radiation therapy)
1697871|NCT01481545|Drug|levofolinic acid|250 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
1697872|NCT01481545|Drug|5-fluorouracil|800 mg/m2 on day 2 every 2 weeks for 3 cycles (for patients with resectable organ metastases (M1), an additional 2 cycles of chemotherapy will be given after radiation therapy)
1697912|NCT01481246|Behavioral|Categorization training|Behavioral intervention consisting of cognitive training exercises to improve categorization performance
1697913|NCT01481233|Drug|Colchicine|Colchicine 0.6 mg bid to a maximum of 1.2 mg bid
1697948|NCT01480908|Procedure|Echocardiography during exercise|TASM is measured during exercise along with pulse measurements to evaluate the force-frequency-relation.
1697873|NCT01481545|Drug|Bevacizumab|will be given by intravenous infusion at the dose of 5 mg/kg concurrent with chemotherapy and radiotherapy every 2 weeks for 4 cycles from -14 days to start chemo-radiotherapy (classical schedule) or 4 days before the concurrent administration of chemotherapy and radiation therapy for 2 cycles if the number of TRG1 was not reached in the first stage (statistical design) with the classical schedule (for patients with resectable organ metastases (M1), one additional administration of bevacizumab will be given after radiation therapy)
1697874|NCT01481532|Drug|Crotoxin|Intra patient dose escalation
1697875|NCT01481519|Drug|dexamethasone 0.1%/povidone-iodine 0.4%|dexamethasone 0.1%/povidone-iodine 0.4%
1697876|NCT01481519|Drug|Artificial Tears|artificial tears 1 drop, 4 times per day
1697877|NCT01481506|Procedure|Telemonitoring|Use of wearable sensors for heart rate, haemoglobin oxygen saturation, physical activity, respiratory rate with automatic transmission to the monitoring central.
1697878|NCT01481493|Biological|BT061|subcutaneous administration of the monoclonal antibody BT061
1697879|NCT01481493|Biological|Placebo|subcutaneous injection of placebo
1697880|NCT01481480|Procedure|Latissimus dorsi tendon transfer|Latissimus dorsi tendon transfer
1697881|NCT01481480|Procedure|Arthroscopic repair|Arthroscopic repair
1697882|NCT01481467|Behavioral|Influenza vaccination implementation strategy|A multi-faceted influenza vaccination implementation strategy
1697883|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
1697884|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
1697885|NCT01481454|Biological|Quadrivalent Influenza Vaccine (split virion, inactivated)|0.5 mL, Intramuscular
1697886|NCT01481454|Biological|2011 to 2012 Trivalent Influenza Vaccine|0.5 mL, Intramuscular
1697887|NCT01481441|Drug|SonoVue|2.4 ml Bolus Injection by intravenous canule. Multi-repeatable (up to 4 bolus) if necessary.
1697888|NCT01481428|Behavioral|Computer-facilitated HIV intervention|Individuals assigned to the experimental condition will complete the self-directed CARE HIV intervention during each of their first three sessions. The 20 minute intervention sessions involve several components including a brief risk assessment, review of identified risks, structured skill building videos, and the development of a risk prevention action plan. Because of the adaptive nature of the CARE program, the content of each session will be tailored to address the current risks of the participant. While the main focus of the intervention is on risk, individuals who report being HIV infected will receive a referral to treatment if they are not currently receiving medical care and their session will address, among other things, adherence to HIV care.
1697889|NCT01481428|Behavioral|Attention Control|Life skills training DVDs that match the duration of the anticipated experimental condition. The DVDs address topics such as positive listening skills, anger management, and stress reduction.
1697890|NCT01481402|Drug|Liothyronine|Liothyronine 40 microgram per day
1697891|NCT01481402|Drug|Liothyronine|3 months of placebo followed by 3 months of Liothyronine 40 microgram per day (oral)
1697892|NCT01481389|Dietary Supplement|Theobromine|200 ml drink with added theobromine (no cocoa added)
1697893|NCT01481389|Dietary Supplement|Cocoa|200 ml drink with cocoa (no theobromine added)
1697894|NCT01481389|Dietary Supplement|Cocoa and theobromine|200 ml drink with added cocoa and theobromine
1697895|NCT01481389|Dietary Supplement|Placebo|200 ml drink (no added theobromine or cocoa)
1697896|NCT01481363|Behavioral|The Talking Sense manual|Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.
1697897|NCT01481363|Behavioral|Treatment as usual - communication information and advice|Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
1697898|NCT01481350|Drug|sildenafil|The patients will receive a dose of 10 mg every 8 hours, for a maximum time of 72 hours.
1697899|NCT01481337|Procedure|Colonic polypectomy or endoscopic mucosal resection (EMR)|Resection of colonic polyps using polypectomy tehnique (with electrocoagulation) or mucosal resection (EMR or mucosectomy) with injection of physiological serum thus resection with electrocoagulation.
1697900|NCT01481311|Device|medical Body Composition Analyzer seca 514/515|Current of 100 µA
1697901|NCT01481311|Procedure|Deuterium and Sodium Bromide dilution methods|Orally administered to the subject in a solution with 100 ml tap water.
1697902|NCT01481272|Drug|Ofatumumab|1000 IV, according to detailed instruction included in the protocol, on day 1 of each 21-day cycle, maximum 6 cycles
1697903|NCT01481272|Drug|Etoposide|60mg/m2 IV, daily over 1 hour, on days 1-5 of 21-day cycle, maximum 6 cycles
1697904|NCT01481272|Drug|Ifosfamid|1500mg/m2 or 1000mg/m2 (patients >/=60 years), IV, daily over 1 hour, on 1-5 days of each 21-day cycle, maximum 6 cycles
1697905|NCT01481272|Drug|Mesna|300mg/m2 or 200mg/m2 (patients >/=60 years), IV, over 1 hour, mixed with ifosfamid then 900mg/m2 or 600mg/m2 (patients >/=60 years)over 12 hour or by local practice, on 1-5 days of each 21 day cycle, maximum 6 cycles
1697906|NCT01481272|Drug|Cytarabine|2g/m2 or 0,5-1g/m2 (patients >/= 60 years), IV, over 3 hours, 12 hourly (total of 4 doses), on days 1-2 of each 21 day cycle, maximum 6 cycles
1697907|NCT01481272|Drug|Methotrexate|12mg, it, on day 5 of each 21 days cycle, maximum 6 cycles
1697908|NCT01481272|Drug|Leukovorin|15mg, po 24 hours after methotrexate it
1697909|NCT01481272|Drug|Granulocyte-Colony Stimulating Factor|5 microgram/kg or 263 microgram ampoule, sc, daily, starting on day 7 of each 21 day cycle, until ANC>1.0x109/l
1697910|NCT01481259|Biological|Autologous cytokine-induced killer cell|Subjects receive autologous cytokine-induced killer cell infusion every 21 days in the absence of disease progression or unacceptable toxicity.
1697911|NCT01481259|Other|Pemetrexed|Subjects receive pemetrexed infusion at a dose of 500mg/m2 every 21 days in the absence of disease progression or unacceptable toxicity.
1697997|NCT01479465|Drug|Simtuzumab|Simtuzumab administered intravenously biweekly
1697914|NCT01481220|Drug|Eltrombopag|In this study 4 different doses of oral eltrombopag (50mg, 100mg, 200mg and 300mg) will be tested. A modified 3+3 patient cohorts design will be used so no new patients are accepted to start on a higher dose without prior tolerance at the previous dose. Patients will be given eltrombopag once daily starting one week before the start of azacitidine treatment and then continue throughout the study, which duration will be approximately 3 months (three Azacytidine cycles). Patients will be evaluated continuously by clinical and laboratory assessments as well as bone marrow examinations during the treatment period until 4 weeks after discontinuation of Eltrombopag. Response, AEs/SAEs and DLTs will be monitored throughout the study.
1697915|NCT01481194|Drug|Doxorubicin|50 mg/m2 IV on day 1 of a 21-day cycle
1697916|NCT01481194|Drug|Bortezomib|1.3 mg/m2 IV push on days 2 and 9 of a 21-day cycle
1697917|NCT01481194|Drug|Lenalidomide|15 mg orally on days 1-14 of a 21-day cycle
1697918|NCT01481194|Drug|Dexamethasone|20 mg orally on days 2, 3, 9, and 10 of a 21-day cycle
1697919|NCT01481194|Drug|Cyclophosphamide|750 mg/m2 IV on day 1 of a 21-day cycle
1697920|NCT01481181|Dietary Supplement|Zinc enriched water|3mg zinc/L of purified water from a filter installed in the households
1697921|NCT01481168|Device|Pacemaker implantation (Medtronic)|DDD+/-R pacing
1697922|NCT01481168|Device|Pacemaker implantation (Medtronic)|ODO pacing
1697923|NCT01481168|Device|Implantable Loop Recorder (Medtronic)|Loop recorder implantation
1697924|NCT01481155|Procedure|ablative CO2 laser therapy|CO2 laser therapy
1697925|NCT01481155|Procedure|photodynamic therapy|Treatment with 5-ALA cream, application time at least 4 h, red light radiation with 76 J/cm²
1697926|NCT01481142|Device|(GMA) Adsorptive Apheresis|Patients will be treated with once-weekly Adacolumn® apheresis over 5 consecutive weeks; treatment can be extended to up to 10 treatments administered once weekly over 10 weeks.
1697927|NCT01481129|Drug|Akt Inhibitor MK2206|Given PO
1697928|NCT01481129|Other|Laboratory Biomarker Analysis|Correlative studies
1697929|NCT01481129|Other|Pharmacological Study|Correlative studies
1697930|NCT01481116|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily and metformin ≥1500 mg or Maximum Tolerated Dose (MTD) for up to 104 weeks.
1697931|NCT01481116|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily and metformin ≥1500 mg or MTD for up to 104 weeks.
1697932|NCT01481116|Drug|Glimepiride|Glimepiride 1 mg, tablets, orally, once daily (up-titrated to 2 mg after 1 week of treatment. Up-titrated to a maximum of 6 mg in 2 mg increments/down titrated if recurrent (or severe) hypoglycemia occurs) and metformin ≥1500 mg or MTD for up to 104 weeks.
1697933|NCT01481103|Procedure|Acupuncture|participants will receive 8 weekly acupuncture sessions. Acupuncture will be performed by a licensed acupuncturist. Each session will last approximately 25 minutes.
1697934|NCT01481090|Procedure|Acupuncture, Electro-Acupuncture|Participants will receive 4 Electro-acupuncture stimulation applied to acupoints SP-6, Zi-Gong, CV-3 and CV-4acupuncture treatments during hormone treatment.
1697935|NCT01481077|Drug|Latanoprost-PPDS|Sustained release for 12 weeks
1697936|NCT01481064|Behavioral|Multifaceted approach|Audit and feedback, educational outreach visits, and patient-mediated interventions.
1697937|NCT01481051|Drug|Latanoprost-PPDS|Sustained delivery for 12 weeks
1697938|NCT01481025|Drug|Cimicifuga + Hiperico|"1 tablet, 80+450mg/tablet, twice a day for 1-3 months
1 tablet, 80+450mg/tablet, once a day for 3-6 months"
1697939|NCT01481025|Drug|Cimicifuga Herbarium|"2 caps, 80mg/caps, once a day for 1-3 months
1 caps, 80mg/caps, once a day for 3-6 months"
1697940|NCT01481025|Drug|Aplause®|4 tablets, 20mg/tablet, twice a day for 1-3 months 2 tablets, 20mg/tablet, twice a day for 3-6 months
1697941|NCT01480986|Drug|Irinotecan combined with cisplatin, octreotide lar|Phase 1 irinotecan 180mg/m^2，ivgtt，90min，D1 Cisplatin 50 mg/m^2，ivgtt，120min，D1（with hydration） Phase 2 Octreotide 0.1mg，ih，q8h，D1-14 Octreotide lar 20mg，deep i.m，D8，
1697942|NCT01480973|Radiation|Stereotactic Body Radiation Therapy|SBRT involves highly precise delivery of very high dose Radiotherapy (RT) over a very few fractions (hypofractionation) to accurately delineated, size-restricted malignant targets in which motion has been accounted for during the delivery process. SBRT administration achieves avoidance of normal tissue exposure to radiation during the planning process, by providing for sharp fall-off dose gradients outside the target.
1697943|NCT01480960|Other|Pulmonary rehabilitation + whole body vibration training|standard inpatient rehabilitation program including endurance and strength plus squats on a vibration plate for 4x2 minutes, 3 times per week
1697944|NCT01480947|Drug|Bio-three|oral Bio-three three times daily for 7 days, Bio-three dosage plan: 1) patients aged 6 years old, 1 tablet t.i.d.; 2) patients aged between 6 and 12 years old, 2 tablets t.i.d.; 3) patients aged 12 years old, 3 tablets t.i.d.
1697945|NCT01480921|Behavioral|Home-based exercise training|"Participants in the home-based group will be advised to exercise, a minimum of 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Prescriptions will include the same elements of those for the hospital group:
5-10 min warm-up
30 min aerobic interval training (walking or stationary bicycle)
10 min cool-down
Home-based participants will be asked to record their exercise in an exercise log book and will receive bi-weekly telephone calls from exercise personnel to monitor progress, assess and document adherence, revise the exercise prescription if necessary and provide support and education. Patient safety will be monitored during each call and serious health concerns will be relayed, with the patient's permission, to their primary health provider. Patients in this group will be encouraged to call the exercise specialist or kinesiologist with concerns or questions throughout the study."
1697946|NCT01480921|Behavioral|Supervised hospital-based exercise training|"Patients in the hospital-based group will participate in supervised, on-site, group exercise sessions 3 times per week, but will be encouraged to exercise a total of 5-7 days per week as per CACR and ACSM guidelines. Trained exercise personnel (kinesiologists and exercise specialists) will supervise these sessions. Exercise sessions will include:
5-10 min of warm-up
30 min of aerobic interval training using stationary cycles, treadmills and arm ergometers
10 min of cool down
Exercise will be tracked by the participant in exercise log books."
1697947|NCT01480908|Procedure|Echocardiography at rest|Dimensions of all 4 chambers, inspiratory collapse, and gradient over the tricuspid valve is measured. Tricuspid Annulus Plane Systolic Excursion(TAPSE) and Tricuspid Annular peak Systolic Motion(TASM) is measured as well.
1755391|NCT00232245|Drug|Fish oil|
1697949|NCT01480908|Procedure|MRI at rest|Dimensions of all 4 chambers are measured at end-systole and end-diastole. Blood flow measurements through the aortic and the pulmonary valve are made as well. No use of contrast.
1697950|NCT01480908|Procedure|Exercise testing|Maximal oxygen consumption is measured during on a bicycle. Prior to the test a spirometry is performed to rull out potential differences in pulmonary function between the cohorts. During the test pulse, blood pressure, saturation, and EKG are monitored. Ventilatory volume, oxygen consumption and carbon dioxide excretion are measured. Anaerobic threshold is calculated at the end of the test.
1697951|NCT01480895|Behavioral|Lifestyle instruction for Jews and Bedouin GDM women.|Every several months the women had instructions and checkups.
1697952|NCT01480882|Procedure|Conventional Chest Physiotherapy (CCPT)|Conventional chest percussion will be applied for a duration of 15 minutes.
1697953|NCT01480882|Device|Mechanical percussion (LEGA)|Mechanical chest percussion will be delivered by a device for 15 minutes.
1697954|NCT01480869|Drug|calcium and cholecalciferol|Tablet to suck: calcium 500 mg bid, cholecalciferol 200 IU bid
1697955|NCT01480869|Drug|calcium and cholecalciferol|"Tablet: calcium 500 mg bid + 2 ml drinkable solution cholecalciferol 100 000 IU whose schedule of administration depends on vitamin deficiency level:
100 000 IU of vitamin D3 at D1, D15, D28 and D43 if 25-OHD level < 10 ng/mL
100 000 IU of vitamin D3 at D1, D15, D28 if 10 ng/mL ≤ 25-OHD level < 20 ng/mL
100 000 IU of vitamin D3 at D1 if 20 ng/mL ≤ 25-OHD level < 30 ng/mL"
1697956|NCT01480856|Procedure|Cobedding|Newborn twins are settled in a singe bed: this is cobedding
1697957|NCT01480856|Procedure|Single-bedding|Newborn twins are settled in two single beds : this is single-bedding
1958253|NCT01840163|Other|Static version of CanSORT tool|
1697959|NCT01480830|Device|Magnetic Endoscopic Imaging (MEI) colonoscopy|Colonoscopy using the Scope Guide system (Olympus Canada Inc.) by
1697960|NCT01480817|Drug|Sorafenib|Sorafenib 400mg po bid
1697961|NCT01480817|Procedure|TACE for HCC with portal vein invasion|The volume of iodized oil ranged from 2 to 12 mL, and the amount of doxorubicin ranged from 10 to 60 mg. Gelatin sponge particles were mixed with mitomycin and contrast material.Cisplatin was infused at the tumor feeder vessels as a solution with a concentration of 0.5 mg/mL at a rate of 5-10 mL/min. The total amount of cisplatin used ranged from 50 to 100 mg depending on the patient's body weight and the level of infusion.
1697962|NCT01480804|Other|Intervention for age specific barriers to self care|The intervention included developing strategies to help patients cope with their barriers to self care. The intervention were implemented by care manager over 6 month period in person and by phone calls. During the six to twelve month period subjects did not have any contact with study staff or care manager.
1697963|NCT01480791|Drug|Aliskiren vs. hydrochlorothiazide|Aliskiren will be used at increasing doses from 150 to 300 mg per day for 6-12 months.
1697964|NCT01480791|Drug|Hydrochlorothiazide|Hydrochlorothiazide will be used at increasing doses from 12.5 to 25 mg per day for 6-12 months.
1697965|NCT01480778|Drug|LNG+EE2|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
1697966|NCT01480778|Drug|Nordette|Administration of one pill contained 0.15 mg of levonosgestrel and 0.03 mg of ethynil estradiol per day over 21 days.
1697967|NCT01480765|Drug|Pregabalin|150mg (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to 75mg twice daily for 2 days and finally to 50 mg twice daily for 2 days
1697968|NCT01480765|Drug|Ketamine infusion|0.1mg/kg/hr for 48 hours post operatively
1697969|NCT01480765|Drug|Placebo capsules|Single capsule (2hrs) pre operatively and twice daily post operatively for 10 days, followed by dose reduction to single capsule twice daily for 2 days and finally to single capsule twice daily for 2 days
1697970|NCT01480765|Drug|Placebo infusion|Normal saline placebo intravenous infusion for 48 hours
1697971|NCT01480752|Drug|Lornoxicam|PDL injection of 0/2 ml of lornoxicam (4mg/ml),before the root therapy and after the inferior alveolar injection
1697972|NCT01480752|Drug|normal saline|PDl injection of 0/2 ml normal saline before the root therapy and after inferior alveolar injection
1697973|NCT01480752|Drug|no injection|inject nothing after inferior alveolar injection and before root canal therapy
1697974|NCT01480739|Drug|100 mg (50 mg x 2) AZD5069|Twice daily for 7 days
1697975|NCT01480739|Drug|100 mg Placebo|Twice daily for 7 days
1697976|NCT01480726|Procedure|Surgery|
1697977|NCT01480713|Drug|Isentress® (Raltegravir, 400 mg every 12 hours)|Lopinavir/r 200/50 mg every 12 hours + Raltegravir 400 mg every 12 hours
1697978|NCT01480713|Drug|Isentress® (Raltegravir, 400 every 12 hours)|Darunavir/rit 800/100 mg every 24 hours + Raltegravir 400 mg every 12 hours
1697979|NCT01480700|Other|Nutritional study|subjects consume 2 eggs per day during 4 months
1697980|NCT01480687|Dietary Supplement|DHA-EPA|1800 mg/day
1697981|NCT01480687|Drug|Ciprofibrate|100 mg/day
1697982|NCT01480674|Drug|Trastuzumab|
1697983|NCT01480661|Drug|Roflumilast|Roflumilast 500 µg, once a day in the morning during 6 months
1697984|NCT01480661|Drug|Placebo of Roflumilast|Placebo 500 µg, once a day in the morning during 6 months
1697985|NCT01480661|Radiation|Functional Respiratory Imaging|CT scan of thorax, at baseline and after 6 months
1697986|NCT01480648|Drug|BI 144807 Placebo|Placebo that represents BI drug
1697987|NCT01480648|Drug|BI 144807|single dose (low to high dose)
1697988|NCT01480622|Drug|TDF tablets|"White, almond-shaped, film-coated tablets, one side with the markings GILEAD and 4331"
1697989|NCT01480609|Drug|Retigabine / Ezogabine|Retigabine / Ezogabine will be available as immediate release tablets of 50 milligrams strength. Subjects will be administered the tablet will 250 milliliters of water
1697990|NCT01480596|Biological|Belimumab|10mg/kg IV infusion
1697991|NCT01480596|Other|Placebo|placebo IV infusion
1697992|NCT01480583|Drug|GRN1005|550 mg/m2 IV every 3 weeks
1697993|NCT01480583|Drug|Trastuzumab|2 mg/kg IV every week or 6 mg/kg IV every 3 weeks per investigator choice
1697994|NCT01480583|Drug|18F-FLT|5 mCi of 18F-FLT IV during Screening and during Cycle 1
1697995|NCT01479478|Dietary Supplement|Placebo|One placebo capsule daily.
1697996|NCT01479478|Dietary Supplement|Probiotic dietary supplement|Dietary Supplement: Lactobacillus rhamnosus GR-1, Lactobacillus reuteri RC -14
1958254|NCT01840163|Other|CanSORT Online Tool|
1697998|NCT01479465|Drug|FOLFIRI|FOLFIRI administered intravenously biweekly
1697999|NCT01479465|Drug|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously biweekly
1698000|NCT01480557|Procedure|liquefaction|Cataract extraction surgery type
1698001|NCT01480557|Procedure|Torsional ip|A type cataract surgery using torsional ip technology
1698002|NCT01480544|Other|Experimental: Treatment 1|Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.
1698003|NCT01480544|Other|Experimental: Treatment 2|Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
1698004|NCT01480531|Drug|Clevidipine|"Clevidipine administration begins in the ER or ICU
Clevidipine is again administered post op when blood pressure control is required.
Clevidipine will be administered by an infusion pump via either a central line or a peripheral IV as follows:
Clevidipine will be initiated at an infusion rate of 0.4 μg•kg-1•min-1 and will be titrated as tolerated in doubling increments every 90 s up to 3.2 μg•kg-1•min-1.
Infusion rates above 3.2 μg•kg-1•min-1 will be guided by the patient's response and permitted in serial increments of 1.5 μg•kg-1•min-1.
Infusion rates between 4.4 and 8.0 μg•kg-1•min-1 will be administered for no longer than 2 h.
As blood pressure approaches goal, increase dose by less than double and lengthen time between does adjustments to every 5-10 minutes (a 1-2 mg/hr increase will generally result in a 2-4 mm Hg reduction in SBP)"
1698005|NCT01480518|Genetic|DNA analysis|
1698006|NCT01480518|Genetic|comparative genomic hybridization|
1698007|NCT01480518|Genetic|gene expression analysis|
1698008|NCT01480518|Genetic|mutation analysis|
1698009|NCT01480518|Genetic|polymerase chain reaction|
1698010|NCT01480518|Genetic|polymorphic microsatellite marker analysis|
1698011|NCT01480518|Other|laboratory biomarker analysis|
1698012|NCT01480505|Procedure|Pars plana vitrectomy with gas tamponade|"A standard three-port 20 Gauge vitrectomy under a wide-angle-viewing contact lens was performed. Peripheral vitreous shaving was completed under slit-lamp illumination without contact lens by gentle scleral indentation. Posterior hyaloid detachment was checked and completed if necessary without dye. The epiretinal membrane removal or internal limiting membrane (ILM) peeling was performed if necessary. In general this latter procedure was not conducted for RD secondary to peripheral retinal tears without any sign of PVR or ERM but was done in almost all cases related to posterior break.
Subretinal fluid was aspirated through the retinal tear, the MH, the PVT or through a retinotomy to obtain a complete peroperative retinal reattachment."
1698013|NCT01480492|Drug|Telbivudine|600mg,1/d,one year
1698014|NCT01480479|Drug|Rindopepimut (CDX-110) with GM-CSF|"Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance.
Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF."
1698015|NCT01480479|Drug|Temozolomide|150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, or until intolerance or progression.
1698016|NCT01480479|Drug|KLH|Two intradermal injections two weeks apart, followed by monthly injections until tumor progression or intolerance. Each dose will be 0.8mL containing approximately 100mcg of KLH.
1698017|NCT01480466|Other|Obesity tools in the electronic health record|The intervention is a set of new tools within the Partners electronic health record that are designed to assist primary care clinicians with the assessment and management of overweight and obesity in their patients.
1698018|NCT01480453|Device|Trabecular Metal Humeral Stem|Trabecular Metal Humeral Stem used in primary, total or hemi shoulder arthroplasty
1698019|NCT01480440|Device|Trabecular Metal Reverse Shoulder System|Trabecular Metal Reverse Shoulder System used in primary or revision total shoulder arthroplasty
1698020|NCT01480414|Biological|4times injection|bone marrow derived mono nuclear stem cell
1698021|NCT01480414|Biological|stem cell transplantation|Mono nuclear stem cell transplantation by intra muscular injection to the ischemic lower limb
1698022|NCT01480401|Other|low-sodium diet (1500 mg daily)|
1698023|NCT01480388|Drug|Placebo/JNJ-39758979 (300 mg/d)|Form = tablet, route = oral adminstration placebo once daily from Week 0 to Week 24 followed by JNJ-39758979 300 mg once daily from Week 24 to Week 48.
1698024|NCT01480388|Drug|JNJ-39758979 (10 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
1698025|NCT01480388|Drug|JNJ-39758979 (30 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
1698026|NCT01480388|Drug|JNJ-39758979 (100 mg)|Form = tablet, route = oral adminstration once daily up to 48 weeks
1698027|NCT01480388|Drug|JNJ-39758979 (300 mg)|Form = tablet, route = oral adminstration once daily for 48 weeks
1698028|NCT01480375|Device|Navigo system|"The NaviGo workstation is used as an adjunct to the ultrasound imaging and biopsy procedures of the prostate gland. When operated in conjunction with the standard equipment in a TRUS guided prostate biopsy procedure, the NaviGo™ software may be used for the following:
To assist the physician by transfer and display of ultrasound images on the workstation screen;
Build display and manipulate a 3D model of the prostate on screen;
Archiving the ultrasound images and the 3D model;
Providing data management solutions;
Tracking, displaying and recording of the biopsy needle trajectory location in real time."
1698029|NCT01480362|Device|Negative Pressure Wound Therapy|"Used therapy systems:
KCI. V.A.C. Freedom; Acti V.A.C.; INFO V.A.C. to be used with the V.A.C. Granufoam (black), V.A.C. Granufoam Silver and V.A.C. WhiteFoam Smith & Nephew: Renasys GO and Renasys EZ Plus to be used with the Renassys-F/P and Renassys-G Use of the medical devices and applicable consumption items according to manufacturers guidelines and FDA regulations."
1698030|NCT01480362|Other|Standard Wound Therapy|Standard wound therapy according to current evidence-based guideline(basic and advanced methods of wound treatment)
1698031|NCT01480336|Drug|Amiodarone Plus Ranolazine|Ranolazine 500mg by mouth twice daily
1698032|NCT01480336|Drug|Amiodarone with Placebo|stabel dose of amiodarone as prescribed by cardiologist
1698033|NCT01480323|Drug|Interleukin-2|intratumoral injections of 9 MIU/day on days 1, 4, 8, 11, 15, 18, 22 and 25. The administered dose will be distributed between all injectable soft-tissue metastases
1698034|NCT01480323|Drug|Ipilimumab|IV infusion, 3 mg/kg, day 2, 23, 44, 65
1698035|NCT01480310|Drug|MCAF5352A|may receive up to 3 subcutaneous doses of MCAF5352A
1755823|NCT00243087|Drug|BI 2536|
1698036|NCT01480310|Drug|Placebo|may receive up to 3 subcutaneous doses of placebo
1698037|NCT01480297|Drug|Salsalate|Salsalate 3 grams daily (1 gram TID with meals)
1698038|NCT01480284|Drug|GSK548470 300 mg tablet|Blue tablets, each tablet containing 300 mg of tenofovir disoproxil fumarate
1698039|NCT01480284|Drug|ETV 0.5 mg capsule|Brown capsules, each capsule containing 0.53 mg of entecavir hydrate
1698040|NCT01480271|Drug|2 ng GSK2445053|2ng GSK2445053 administered intranasally
1698041|NCT01480271|Drug|20ng GSK2445053|20ng GSK2445053 administered intranasally
1698042|NCT01480271|Drug|100ng GSK2445053|100ng GSK2445053 administered intranasally
1698043|NCT01480271|Drug|200ng GSK2445053|200ng GSK2445053 administered intranasally
1698044|NCT01480271|Drug|400ng GSK2445053|400ng GSK2445053 administered intranasally
1698045|NCT01480271|Drug|1000ng GSK2445053|1000ng GSK2445053 administered intranasally
1698046|NCT01480271|Drug|2000ng GSK2445053|2000ng GSK2445053 administered intranasally
1698047|NCT01480271|Drug|4000ng GSK2445053|4000ng GSK2445053 administered intranasally
1698048|NCT01480271|Drug|Placebo|Placebo administered intranasally
1698049|NCT01480258|Biological|V419|Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age
1698050|NCT01480258|Biological|Rotavirus vaccine|Rotarix 1.5 mL oral dose at 2 and 4 months of age (subset 1) or RotaTeq 2 mL oral dose at 2, 4 and 5 months of age (subset 2)
1698051|NCT01480258|Biological|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 4, and 11 to 12 months of age
1698052|NCT01480258|Biological|INFANRIX hexa|INFANRIX hexa 0.5 mL intramuscular injection at 2, 4 and 11 to 12 months of age
1698054|NCT01480232|Drug|EVP-6124|One EVP-6124 capsule ingested orally daily for 12 weeks (84 days)
1698055|NCT01480232|Drug|Placebo Capsule|One placebo capsule ingested orally daily for 12 weeks (84 days)
1698056|NCT01480232|Drug|NicoDerm Patch (Active)|One NicoDerm patch once daily for first 6 weeks (42 days). Dosage will taper from 21 mg (Weeks 1-3) to 14 mg (Weeks 4-5) to 7 mg (Week 6).
1698057|NCT01480232|Drug|NRT Patch (Placebo)|One NRT patch (Placebo) daily for first 6 weeks (42 days).
1698058|NCT01480232|Behavioral|Brief Supportive and Behavioral Treatment|Brief, standard, manualized individual cognitive behavioral therapy intervention will be based on the Freedom from Smoking curriculum from the American Lung Association.
1698059|NCT01480219|Drug|voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
1698060|NCT01480219|Other|no voriconazole (Vfend)|Voriconazole utilization was identified as any vs. none for the period 180 days before and 180 days after the date of transplant.
1698061|NCT01480206|Other|Endovascular Aortic Repair (EVAR)|Use of 3D interventional imaging tools in endovascular procedures in the surgical environment
1698062|NCT01480193|Other|Sound Based and Educational Therapies|The SBE program will consist of two hour-long individual counseling and sound therapy sessions based on the Department of Veterans Affairs Progressive Audiologic Tinnitus Management approach. SBE treatment incorporates the use of education, counseling, increased relaxation and decreased stress, along with the integration of sound therapy to better manage the impact of tinnitus.
1698063|NCT01480193|Other|Integrated Medicine Therapies and Sound Based Education Therapies|3 Cognitive Based Therapy Sessions, 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
1698064|NCT01480193|Other|Integrated Medicine Therapies and SBE|2 Sound Based and Educational Sessions 3 Cognitive Based Therapy Sessions 9 Telephonic Health Coaching Sessions 5 Acupuncture Sessions Group-Based 8 week Mindfulness Based Stress Reduction
1698065|NCT01480180|Drug|turoctocog alfa pegol|Administered i.v.
1698066|NCT01480167|Device|Vertebral Augmentation (STABILIT)|Vertebral Augmentation with the STABILIT Vertebral Augmentation System
1698067|NCT01480167|Other|Non-operative Management|Conservative Care
1698068|NCT01480154|Drug|Akt Inhibitor MK2206|Given PO
1698069|NCT01480154|Drug|Hydroxychloroquine|Given PO
1698070|NCT01480154|Other|Laboratory Biomarker Analysis|Correlative studies
1698071|NCT01480154|Other|Pharmacological Study|Correlative studies
1698072|NCT01480141|Drug|BIBW 2992 (Afatinib)|Patients will receive treatment with afatinib 40mg orally daily for a minimum of 2 weeks
1698073|NCT01480128|Procedure|Single-port|Single-port laparoscopic colon resection
1698074|NCT01480128|Procedure|Multi-port|Multi-port laparoscopic colon resection
1698075|NCT01480115|Other|ultrasound examination for AFC evaluation|Ultrasound examination three times during the menstrual cycle to measure the AFC.
1698076|NCT01480102|Drug|Group A-Paravertebral block|Bupivicaine 0.5% without epinephrine (100mg)20cc will be injected into the T10 paravertebral space. Active Group
1698077|NCT01480102|Other|Group B- No block|direct pressure for 5 minutes will be held at the site of the where the local anesthetic was applied to mimic the application of the block.
1698078|NCT01480089|Drug|Intraperitoneal Ropivacaine (AIR)|Ropivacaine 2 mg/kg per lean body mass up to no more than 200mg total dose will be atomized and delivered into the peritoneal cavity at the completion of surgery.
1698079|NCT01480089|Drug|Atomized Intraperitoneal Saline (AIS)|Atomized saline will be administered to the peritoneal cavity at the completion of surgery.
1698080|NCT01480076|Drug|Fampridine|Supplied as a 10 mg twice daily tablet and taken twice daily. Doses must be spaced at least 12 hours apart.
1698081|NCT01480063|Drug|Fampridine|Fampridine administered as prescribed in routine clinical practice. Biogen is not supplying drug for this study.
1698082|NCT01480050|Drug|temozolomide|
1698083|NCT01480050|Other|3'-deoxy-3'-[18F]fluorothymidine|tracer used for FLT PET CT
1698084|NCT01480050|Other|pharmacological study|
1698085|NCT01480050|Drug|Mibefradil|
1698086|NCT01480011|Drug|lactobacillus CD2 lozenges|The study drug contains not less than 2x109 (2 billion) viable cells of Lactobacillus CD2 as active ingredient
1698087|NCT01479998|Other|standard care|standard care plus nicotine replacement therapy
1699208|NCT01471886|Drug|Ketorolac Tromethamine|Every 8 hours for 4 days.
1698088|NCT01479998|Other|standard care plus contingency management|standard care is 4 counseling sessions and nicotine replacement therapy plus 3 weekly meetings with positive reinforcers
1698090|NCT01479972|Biological|VPM1002|Tuberculosis vaccine
1698091|NCT01479972|Biological|BCG|commercially available live vaccine BCG
1698092|NCT01479959|Device|Eole 3 ventilator - Resmed|positive end expiratory pressure is added to the ventilation mode and it is activated by a switch under patient's control
1698093|NCT01479946|Drug|Electrochemotherapy|bleomycin together with electroporation
1698094|NCT01479933|Dietary Supplement|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
1698095|NCT01479933|Dietary Supplement|Placebo|Inactive placebo
1698096|NCT01479933|Dietary Supplement|Vitamin D 80|Vitamin D3 80 micrograms (3200 IU) per day
1698097|NCT01479920|Drug|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
1698098|NCT01479920|Procedure|DCEAS (Hwato®/ Dongbang®)|"Six pairs of cranial acupoints are used: Baihui (Du-20) and Yintang (EX-HN3), left Sishencong (EX-HN1) and Toulinqi (GB15), right Sishencong (EX-HN1) and Toulinqi (GB15), bilateral Shuaigu (GB8), bilateral Taiyang (EX-HN5), and bilateral Touwei (ST8). All these acupoints are located on the forehead.
Disposable acupuncture needles (Hwato®/ Dongbang®, 0.30 mm in diameter and 25-40 mm in length) are inserted at a depth of 10-30 mm obliquely into acupoints, on which low- and high-frequency alternating electrical stimulation with continuous waves is conducted for 30 min. The intensity is adjusted to a level at which patients feel comfortable."
1698099|NCT01479920|Procedure|n-CEA (Strietberger®)|Streitberger's acupuncture needles will be applied on the same acupoints, with the same electrical stimulation parameters, except that the needles only adhere to the skin instead of insertion.
1698100|NCT01479907|Dietary Supplement|Synbiotics|12 gr in 250 cc of water once daily X 15 days
1698101|NCT01479907|Dietary Supplement|Placebo|12 gr in 250 cc of water once daily X 15 days
1698102|NCT01479881|Drug|tacrolimus|a single 2-mg dose of tacrolimus (on Day 1 in treatment C and on Day 7 in treatment D).
1698103|NCT01479881|Drug|TMC435|TMC435, 150 mg daily for 12 days (Days 1 to 12 in treatment D).
1698104|NCT01479881|Drug|cyclosporine|A single 100-mg dose of cyclosporine (on Day 1 of treatment A and on Day 7 of treatment B).
1698105|NCT01479881|Drug|TMC435|TMC435, 150 mg daily for 10 days (Day 1 - 10 in treatment B).
1698106|NCT01479868|Drug|TMC435|TMC435 150 mg will be administered once daily for 12 weeks along with peginterferon alpha-2a and ribavirin.
1698107|NCT01479868|Drug|Pegylated interferon alpha-2a|Pegylated interferon alpha-2a 180 microgram will be administered as subcutaneous injection of 0.5 mL until 24 to 48 weeks.
1698108|NCT01479868|Drug|Ribavirin|Ribavirin 1000 or 1200 mg twice daily will be administered each day until 24 to 48 weeks.
1698109|NCT01479842|Drug|BTK inhibitor PCI-32765|Given PO
1698110|NCT01479842|Biological|rituximab|Given IV
1698111|NCT01479842|Drug|bendamustine hydrochloride|Given IV
1698112|NCT01479842|Other|pharmacogenomic studies|Correlative studies
1698113|NCT01479842|Other|pharmacological study|Correlative studies
1698114|NCT01479842|Other|laboratory biomarker analysis|Correlative studies
1698115|NCT01479829|Drug|ESC + CBX|Escitalopram (ESC) 10 mg twice day given orally twice a day plus Celecoxib (CBX) 200 mg twice daily.
1698116|NCT01479829|Drug|ESC + PBO.|• Escitalopram (ESC) 10 mg twice per day plus Placebo (PBO)administered twice daily.
1698117|NCT01479829|Drug|ESC+CBX|• Escitalopram 10 mg given twice day plus Celecoxib 200 mg twice daily.
1698118|NCT01479803|Procedure|Puncture with fine needle aspiration under endoscopic ultrasonographic control|Puncture of the pancreatic solid mass with fine needle aspiration under endoscopic ultrasonographic control Passage in the same pancreatic mass of first EchoTip HD Procore then EchoTip 22 Gauge or vice versa according to the randomization
1698119|NCT01479790|Device|EyeGiene|The eye mask with a temperature of not more than 40 deg C (confirmed by thermometer) will be worn by the volunteer for 5 minutes.
1698120|NCT01479777|Device|FES Stepping (RT600 from Restorative Therapies, INC.)|You will be transferred to the RT600 device and secured in a support harness. We will place your legs onto the RT600 device and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs, buttock, stomach, and back. The pads will be connected to a stimulator box through a wire. We will then start the stepping motor and stimulate your muscles with electric current. This will cause your legs to step. You will do this for 1 hour.
1698121|NCT01479764|Drug|Sugammadex|sugammadex, intravenous (IV) bolus, 2 or 4 mg/kg depending on level of neuromuscular recovery
1698122|NCT01479764|Drug|Neostigmine|neostigmine, per usual practice
1698123|NCT01479764|Drug|Glycopyrrolate|glycopyrrolate per usual practice
1698124|NCT01479751|Drug|Magnesium Sulfate|Patients receive MgSO4 50 mg/kg for 10 min before injection of Roc 0.6 mg/kg.
1698125|NCT01479751|Drug|Ketamine|patients receive ketamine 0.5 mg/kg 2 min before Roc injection.
1698126|NCT01479751|Drug|rocuronium|Patients receive Roc 0.06 mg/ kg as a priming dose 3 min before injection of Roc 0.54 mg/kg.
1698127|NCT01479738|Procedure|Capitate bone grafting|Capitate bone graft transfer for PIP joint reconstruction
1698128|NCT01479725|Procedure|HBOT|HBOT
1698129|NCT01479712|Procedure|Normal Saline Irrigation|Irrigation with warm normal saline into the abdominal cavity. Approximately 500-1000cc.
1698130|NCT01479699|Dietary Supplement|Olive leaf extract capsules|Four capsules taken at baseline each containing 4mg oleuropein
1698131|NCT01479686|Procedure|iMRI|3.0TiMRI guided resection in adults with glioma
1698132|NCT01479686|Procedure|conventional neuronavigation|conventional neuronavigation guided resection in adults with glioma
1698176|NCT01479374|Drug|AL-4943A vehicle|Inactive ingredients used as placebo
1698177|NCT01479374|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2%|
1698133|NCT01479673|Dietary Supplement|Indirect Calorimetry measurement of Resting Energy Expenditure .|Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
1698134|NCT01479660|Other|Control|Placebo will be orally administered daily for a period of 12 weeks in high dose and low dose
1698135|NCT01479660|Drug|Probiotic|Probiotic Capsules (450 billion CFU) will be orally administered daily for a period of 12 weeks and Probiotic in higher dose of (3600 billion CFU) will be administered daily for a period of 12 weeks
1698136|NCT01479647|Drug|PH-797804|Tablet, 1 mg, single dose
1698137|NCT01479647|Drug|PH-797804|Tablet, 1 mg, single dose
1698138|NCT01479647|Drug|PH-797804|Tablet, 10 mg, single dose
1698139|NCT01479647|Drug|PH-797804|Tablet, 10 mg, single dose
1698140|NCT01479647|Drug|PH-797804|Tablet, 24 mg, single dose
1698141|NCT01479634|Drug|Standard ART|Standard Ugandan 3-drug antiretroviral therapy regimen consistent with current practices
1698142|NCT01479634|Drug|Study-Provided ART|"Study provided drugs:
Truvada® (one tablet PO daily of fixed dose combination consisting of tenofovir disoproxyl fumarate [TDF] and emtricitabine [FTC]) PLUS
Efavirenz [EFV]"
1698143|NCT01479621|Drug|Fp MDPI|"Fp MDPI is an inhalation-driven multidose dry powder inhaler (MDPI) containing fluticasone propionate (Fp) dispersed in a lactose monohydrate excipient and contained within a reservoir. A metered dose of drug is delivered to a dose cup via an air pulse activated when the cap is opened.
During the treatment period, participants were randomized to 12.5, 25, 50 or 100 mcg of Fp one inhalation twice a day for a total daily dose of 25, 50, 100 or 200 mcg. Study drug was administered in the morning and in the evening"
1698144|NCT01479621|Drug|Flovent Diskus|Flovent Diskus contains the active ingredient fluticasone propionate (Fp). Flovent Diskus 100 mcg was used twice a day, once in the morning and evening, for a total daily dose of 200 mcg of Fp. This therapy was not blinded as the inhaler device was different than the MDPI used in the other treatment arms.
1698145|NCT01479621|Drug|albuterol/salbutamol|A short-acting β2-adrenergic agonists (SABA), albuterol/salbutamol hydrofluoroalkane (HFA) metered dose inhaler (MDI), was provided to be used as needed for the relief of asthma symptoms during both the run-in and treatment periods (to replace the subject's current rescue medication).
1698146|NCT01479621|Drug|Placebo MDPI|Placebo multidose dry powder inhaler in the morning and evening. Placebo MDPI was provided in devices identical in appearance to Fp MDPI.
1698147|NCT01479608|Procedure|Liver transplantation and liver resection|
1698148|NCT01479595|Drug|QBX258|QBX258 infusion, a combination of VAK694 and QAX576, was supplied to the Investigator as open label bulk medication. The planned dose of VAK694 (lyophilisate in vial, 150 mg/vial), was 3 mg/kg. The planned dose of QAX576 (lyophilisate in vial, 150 mg/vial), was 6 mg/kg.
1698149|NCT01479595|Drug|Placebo|The placebo infusion was an equal volume of 5% dextrose for infusion and was provided by the clinical site.
1698150|NCT01479582|Drug|Access to unlicensed cord blood units|
1698151|NCT01479569|Procedure|Pericardiocentesis|
1698152|NCT01479556|Drug|Pregabalin|Pregabalin Alpha2-delta calcium channel blocker. 150mg BID p.o.
1698153|NCT01479556|Drug|Placebo|150mg BID p.o.
1698154|NCT01479543|Other|Probiotic CNCM I-4034|Probiotic CNCM I-4034 in a concentration of 9x10E9 cfu (colony forming unit) per day during 28 days.
1698155|NCT01479543|Other|Probiotic CNCM I-4035|9x10E9 cfu (colony forming unit) per day during 28 days.
1698156|NCT01479543|Other|Probiotic CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
1698157|NCT01479543|Other|Probiotics CNCM I-4035 and CNCM I-4036|9x10E9 cfu (colony forming unit) per day during 28 days.
1698158|NCT01479543|Other|Placebo|Placebo capsule for 28 days.
1698159|NCT01479530|Drug|Placebo|Once daily; tablet; orally; 16 weeks
1698160|NCT01479530|Drug|Azilect®|1 mg daily; tablet; orally; 16 weeks
1698161|NCT01479517|Drug|Kovacaine Mist 0.1 mL x 4 sprays|Dose = 4 intranasal sprays of study drug delivered at 4-minute intervals.
1698162|NCT01479517|Drug|Kovacaine Mist 0.2 mL x 2 sprays|Dose = 2 intranasal sprays of study drug delivered at 4-minute intervals.
1698163|NCT01479517|Drug|Kovacaine Mist 0.2 mL x 1 spray|Dose = 1 intranasal spray of study drug
1698164|NCT01479504|Drug|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
1698165|NCT01479504|Drug|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
1698166|NCT01479504|Drug|nedaplatin and docetaxel|"neoadjuvant chemotherapy: nedaplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: nedaplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
1698167|NCT01479504|Drug|cisplatin and docetaxel|"neoadjuvant chemotherapy: cisplatin 80mg/m2+docetaxel 65 mg/m2/day,every 21 days for 2 cycles before radiotherapy
concurrent chemotherapy: cisplatin 40mg/m2,weekly,for 6 cycles during radiotherapy"
1698168|NCT01479491|Other|Data collection|Data source will be the Japan Medical Data Centre Company Limited (JMDC) - JMDC Medical Data Bank (JMDC-MDB) database. Aggregated data (age in months and years and gender) for all subjects recorded in the database and subject-level data for IS cases will be extracted from the database. This database will be reviewed to extract data for the period between January 2005 and April 2011. Cases of IS will be identified using the International Classification of Diseases-10 (ICD-10) diagnostic codes, examination codes and procedural codes.
1698169|NCT01479452|Procedure|Bariatric surgery|Gastric banding, vertical banded gastroplasty, gastric bypass
1698170|NCT01479452|Other|Usual care|Non-surgical obesity treatment
1698171|NCT01479439|Drug|Losartan|Form: suspension, tablet. Dosage & frequency: age 6-16 = 0.7mg/kg once daily; age >16 = 50mg once daily. Duration: 6 months
1698174|NCT01479387|Drug|[111]In-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received In-111 Zevalin.
1698175|NCT01479374|Drug|AL-4943A ophthalmic solution|
1698178|NCT01479361|Drug|Atovaquone 750 mg twice daily|
1698181|NCT01479309|Drug|Sodium Stibogluconate|400 mg/m^2 IV daily on days 1-5.
1698182|NCT01479309|Drug|Interferon Alpha-2b|3x10^6 units subcutaneously three times weekly
1698183|NCT01479296|Biological|VRC rAd5 vaccine (rAd5 gag-pol/env A/B/C)|Given intramuscularly
1698184|NCT01479296|Biological|rAd5 env A|Given intramuscularly
1698185|NCT01479296|Biological|rAd5 env B|Given intramuscularly
1698186|NCT01479296|Biological|rAd5 env C|Given intramuscularly
1698187|NCT01479296|Biological|rAd5 gag-pol|Given intramuscularly
1698188|NCT01479296|Biological|Placebo Vaccine|Given intramuscularly
1698189|NCT01479283|Drug|24-Hour Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.
Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.
Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 24 hours followed by IV saline for 4 days. No other post-operative antibiotics will be administered."
1698190|NCT01479283|Drug|5-Days Prophylactic Cefazolin* Antibiotic Regimen|"Pre-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin within 60 minutes prior to the procedure. No other pre-operative antibiotics will be administered.
Intra-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 3-4 hours. No other intra-operative antibiotics will be administered.
Post-Operative Antibiotic Regimen: Patients will receive 2g (or a weight-based dose based on 100mg/kg/day with a maximum single dose of 2g if < 18 years old) of IV cefazolin every 8 hours for 5 days. No other post-operative antibiotics will be administered."
1698191|NCT01479270|Drug|TAP Block of 0.25% Ropivacaine with 1:200,000 Epinephrine|Bilateral transversus abdominal plane injection under ultrasound guidance, done at conclusion of hysterectomy procedure, prior to emergence from general anesthesia
1698195|NCT01479244|Biological|NeuVax™ vaccine|E75 peptide acetate (HER2/neu p366-379) in WFI (1.5 mg/mL) mixed with 250 micrograms Leukine® (sargramostim, GM-CSF), will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, NeuVax™ vaccine boosters will be given the same way once every six months for the next five times (totaling 36 months).
1698196|NCT01479244|Biological|Leukine® (sargramostim, GM-CSF) and water for injection|Leukine® 250 micrograms in water for injection, will be administered in intradermal injections, in four divided doses (4 sites on upper thigh) once a month, for six consecutive months. At the end of the six months, boosters inoculations will be given the same way once every six months for the next five times (totaling 36 months).
1698197|NCT01479231|Drug|dexlansoprazole|Dexlansoprazole 60 mg daily for 6 weeks
1698198|NCT01479218|Device|Occlutech PDA occluder|Four different sizes of Occluders will be evaluated based on pre-assessment of PDA size.
1698199|NCT01479192|Drug|Fenretinide|100mg (2cps/day) for 5 years
1698200|NCT01479192|Other|Placebo|2 cpr/day of matched placebo for 5 years
1698201|NCT01479179|Drug|AMG 479|"Phase I Starting Dose: 18 mg/kg by vein on Day 1 of a 21 day cycle.
Phase II Starting Dose: Maximum tolerated dose from Phase I."
1698202|NCT01479179|Drug|Trastuzumab|"Phase I and II Starting Dose: 8 mg/kg by vein on Day 1 of a 21 day cycle.
Phase I and II Maintenance Dose: 6 mg/kg by vein on Day 1 of a 21 day cycle."
1698203|NCT01479153|Procedure|Randomization of the site for catheterization|Ultra-sound guided insertion strongly recommended
1698204|NCT01479127|Drug|ABT-SLV187|
1698205|NCT01479127|Drug|Oral Levodopa/Carbidopa|Tablet; contains 100 mg levodopa and 10 mg carbidopa
1698206|NCT01479127|Device|Infusion Pump: CADD-Legacy® 1400 Pump|General infusion pump, manufactured by Smiths Medical (US)
1698207|NCT01479127|Device|NJ-Tube: Silicon ED Tube|Device used to deliver nutrition/drug to stomach/intestine or to aspirate stomach fluid, manufactured by Create Medic Co., Ltd. (Japan)
1698208|NCT01479127|Device|Adaptor: Hakko Adaptor|Accessory set for fluid infusion set, consisting of caps, connectors and adapters, etc, manufactured by Hakko Medical (Japan)
1698209|NCT01479114|Drug|rh-GCSF|10 ug/kg/day intravenously for 3 days
1698210|NCT01479101|Other|MammaPrint 70-gene expression profile|
1698211|NCT01479101|Other|BluePrint 80 gene expression profile|
1698212|NCT01479088|Drug|Cinacalcet HCl|The 6-month pre-treatment period will be followed by a run-in period with a baseline evaluation prior to the drug administration, followed by a 6-month cinacalcet dose titration period, during which the dose will be increased on monthly basis by 0.5 mg/kg or by 30 mg OD up to the achievement of target iPTH value <180 pg/mL as tolerated by the patient
1698213|NCT01479075|Drug|intransal insulin|4x 40mU intranasal insulin
1698214|NCT01479075|Drug|Placebo|
1698215|NCT01479075|Device|taVNS|
1698216|NCT01479075|Device|sham stimulation|
1698217|NCT01479062|Behavioral|Alive-PD|Weekly email/web goal-setting intervention to improve physical activity, diet and weight loss for pre-diabetics, with additional phone support
1698218|NCT01479062|Behavioral|Usual Care|Placebo Control
1756956|NCT00252876|Drug|tesaglitazar|
1698221|NCT01479036|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
1698222|NCT01479036|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 75 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
1698223|NCT01479023|Drug|64Cu-DOTA-U3-1287|
1698224|NCT01479023|Drug|U3-1287 (unlabeled)|
1698225|NCT01479010|Drug|Anakinra 100 mg subcutaneously daily|Anakinra 100 mg subcutaneously daily
1698226|NCT01478997|Dietary Supplement|Flexsure Capsules|Flexsure - 3 capsules once a day in the absence of meals (at least 30 min prior to meals) for 56 days
1698227|NCT01478997|Dietary Supplement|Placebo Capsules|Carboxy Methyl Cellulose
1698228|NCT01478984|Procedure|One-Stage group|Patients randomized to One-Stage group were completely revascularizated in one time PCI,
1698229|NCT01478984|Procedure|Multi-Staged group|patients randomized to Multi-Staged group were completely revascularizated in more time PCI, during the same hospitalization
1698230|NCT01478971|Drug|Epoetin|Commercially available epoetin alfa administered weekly, twice weekly, or thrice weekly at an initial starting dose, frequency of administration, and mode of administration (intravenous [IV] or subcutaneous [SC]) individually determined for each participant using the site's usual standard of care. Subsequent dose adjustments or dose holds may have been made in order to maintain a hemoglobin concentration of <11 g/dL.
1698231|NCT01478971|Drug|Peginesatide|Administered as a once monthly intravenous (IV) or subcutaneous (SC) injection. The initial dose of peginesatide injection was based on the final weekly dose of epoetin administered in the SCP; subsequent doses may have been adjusted in order to maintain hemoglobin concentrations at <11 g/dL.
1698232|NCT01478958|Dietary Supplement|SFA diet|Volunteers are following a high saturated fat diet for a 4-month period
1698233|NCT01478958|Dietary Supplement|MUFA diet|Volunteers are following a high monounsaturated fat diet for a 4-month period
1698234|NCT01478958|Dietary Supplement|n-6 PUFA diet|Volunteers are following a high n-6 polyunsaturated fat diet for a 4-month period
1698236|NCT01478932|Behavioral|diaphragmatic breathing retraining|Experimental group participates in an 8-week breathing retraining intervention that requires 30 minutes a day. Control group receives an 8-week health promotion attention control condition.
1698237|NCT01478893|Biological|SEL-068|Sub-cutaneous injection, multiple dose
1698238|NCT01478893|Biological|Saline|Sub-cutaneous injection, multiple dose
1698239|NCT01478880|Procedure|continuous theta burst stimulation (cTBS)|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4)
1698240|NCT01478880|Procedure|sham cTBS|bilateral continuous theta burst stimulation (bursts of 3 stimuli, 50Hz every 200ms for 40s, 80% active motor threshold) to the temporoparietal cortex (EEG 10/20: halfway T3/P3 and T4/P4) with the stimulation coil tilted 45°
1698241|NCT01478867|Other|Detection of gluten in feces|Detection of Gluten in Feces
1698242|NCT01478854|Radiation|Radiation|Patients will be treated to a total dose of 60 Gy with a once daily fractionation schedule of 2 Gy per fraction, administered five days per week. All patients will undergo CT simulation with intravenous contrast. In addition they will undergo MRI simulation with both T1 with gadolinium as well as FLAIR sequences. They will be treated in a supine position using an aquaplast mask system for immobilization. CT image data will be reconstructed in approximately 3 mm slice thickness and manually coregistered with T1 post-gadolinium and FLAIR sequence MRI.
1698243|NCT01478854|Drug|Chemotherapy|Temozolomide
1698244|NCT01478841|Drug|polyphenol|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
1698245|NCT01478841|Drug|placebo|2 capsules of 0.5 gram to be taken at the beginning of breakfast and dinner (2g/day) fructose : dose of 3 g/kg/day from D57 to D62 in the form of a 20% solution taken during the three main meals
1698246|NCT01478828|Drug|Lovastatin|oral qd varying dose escalations/de-escalations
1698247|NCT01478815|Behavioral|contingency management|Participants will receive the opportunity to win prizes for submitting cocaine negative urine samples.
1698248|NCT01478815|Other|Standard Care|Standard Care
1698249|NCT01478802|Device|Lung protective CMV|Low tidal volume-high positive end-expiratory pressure conventional mechanical ventilation (CMV) and recruitment maneuvers, as specified in detail in the Detailed Description Section.
1698250|NCT01478802|Device|HFO-RMs|Initial, 96-hour-lasting session (session duration modifiable according to oxygenation criteria) of High-frequency oscillation (HFO) combined with recruitment Maneuvers (RMs), followed by additional HFO-RMs sessions (if required according to the study protocol oxygenation criteria)during days 1-10. During the rest of the intervention period, patients will be treated with the same lung protective CMV strategy of the CMV arm. Additional details are provided in the Detailed Description Section.
1698251|NCT01478789|Dietary Supplement|WD-PS intervention phase|2g/d of free plant sterol in 100g yogurt
1698252|NCT01478789|Dietary Supplement|PS-Ester intervention phase|2g/d of free plant sterol in 100g yogurt
1698253|NCT01478789|Dietary Supplement|placebo|100g/d yogurt with no added plant sterol
1698256|NCT01478750|Dietary Supplement|administration of fat (sunflower oil), emulsified|40 ml sunflower oil, in the presence of the emulsifier tween-80.
1698257|NCT01478750|Procedure|Insertion of nasoduodenal tube|A nasoduodenal tube is inserted to enable collection of gastric and duodenal aspirates of 2 mL each, to determine gastrointestinal digestion of fat
1698258|NCT01478737|Drug|Intravitreal dexamethasone implant|Intravitreal Ozurdex after vitrectomy
1698259|NCT01478737|Procedure|Vitrectomy|Vitrectomy only
1698260|NCT01478724|Dietary Supplement|Milk proteins fraction|capsules, one per day, 24 months
1698261|NCT01478711|Other|Clinical Decision Support Tool|A clinical decision support tool embedded within Epic will appear for children with a history of prematurity at the intervention sites.
1698264|NCT01478685|Drug|CC-486|CC-486 will be administered orally at doses between 100-300 mg daily for either 14 or 21 days depending on tolerability
1698265|NCT01478685|Drug|Carboplatin|Carboplatin will be given by intravenous (IV) infusion once every 21 Days at a dosage of AUC x 4.
1698266|NCT01478685|Drug|ABI-007|ABI-007 will be administered by intravenous (IV) infusion on two of every three weeks at a dosage of 100 mg/m^2
1698267|NCT01478672|Procedure|Health Coaching and Life-long Monitoring|Participants receive tablet PCs with software that collects and transmit diagnostic measurements. Measurements are performed by the participants following indications of the health coaching team. Equipment used by all participants: • blood pressure meter, • pedometer • pulse watch• 2-channel electrocardiograph. Measured values are entered manually by the participants, unrealistic values are refused and values are provided with a time-stamp. Measurements is reviewed in a graphical display. Measured values are accessed by the health coaching team that develops an individualized measurement and medication scheme. Reminders are provided by the software and can be exported to personal calendars or mobile phones. Secure authentication of users is be provided
1698268|NCT01478659|Dietary Supplement|Control study food with no added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars without added fiber.
1698269|NCT01478659|Dietary Supplement|Study food with added fiber|Adults consuming their usual diet modified by incorporating yogurt and snack bars containing 16 g of chicory root fiber (Frutalose®).
1698270|NCT01478646|Other|conventional breathing therapy|duration: 60 minutes.
1698271|NCT01478646|Other|reflectory breathing therapy|duration: 60 minutes.
1698272|NCT01478633|Drug|Galantamine|8 mg/day (4 mg twice daily) for 4 weeks, followed by 16 mg/day (8 mg twice daily) for an additional 4 weeks, followed by dose at 16 mg or increased to 24 mg (with the option of decreasing back to 16 mg) for the remainder of the study (to week 24)
1698273|NCT01478620|Drug|Canephron® N|3x 2 coated tablets/day for 7 days p.o.
1698274|NCT01478607|Drug|QUTENZA|A Qutenza (8% capsaicin) patch will be applied to identified painful areas for 30 minutes (Arm 1) or 60 minutes (Arm 2).
1698275|NCT01478594|Drug|Tivozanib|Capsules for oral administration
1698276|NCT01478594|Drug|Bevacizumab|Solution for intravenous infusion
1698277|NCT01478594|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin 85 mg/m^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, leucovorin calcium 400 mg/m^2 administered as an intravenous bolus over 2 hours on Days 1 and 15, fluorouracil 400 mg/m^2 administered as an intravenous bolus over 5 to 15 minutes on Days 1 and 15, then 2400 mg/m^2 continuous intravenous infusion over 46 hours on Days 1 to 3 and 15 to 17.
1698278|NCT01478581|Drug|PCI-32765|
1698279|NCT01478581|Drug|Dexamethasone|
1698280|NCT01478568|Drug|mirabegron|oral
1698281|NCT01478568|Drug|desipramine|oral
1698282|NCT01478555|Drug|ISV 101|Bromfenac in DuraSite
1698283|NCT01478542|Drug|Conventional Vincristine|
1698284|NCT01478542|Drug|Liposomal Vincristine|
1698285|NCT01478542|Drug|Ricover-scheme rituximab|
1698286|NCT01478542|Drug|optimised rituximab-schedule|
1698287|NCT01478529|Drug|mirabegron OCAS|oral administration
1698288|NCT01478529|Drug|mirabegron|iv administration
1698289|NCT01478516|Procedure|Intravitreal injection|autologous plasmin was prepared in the operation department. Samples (3.5 mL) of autologous whole blood, collected by sterile vacuum blood collection tubes, were obtained from a peripheral vein. The blood was centrifuged at 4,000 rounds per minute for 15 minutes to obtain complete sedimentation of the cells; 1.5 mL of the plasma was aspirated and transferred under sterile conditions in a vial of urokinase(10,000 IU) that had been incubated for 15 minutes at 37°C. By gently moving the vial for 5 minutes, the solution was incubated for 15 minutes at 37°C; 0.2 mL of the obtained solution was used for intravitreal injection.
1698290|NCT01478503|Drug|mirabegron OCAS|oral
1698291|NCT01478503|Drug|Placebo|oral
1698292|NCT01478490|Drug|mirabegron|oral
1698293|NCT01478490|Drug|metoprolol|oral
1698294|NCT01478477|Dietary Supplement|omega-3 fatty acid supplement|6 capsules per day (4.3 g)x 6 months
1698295|NCT01478477|Other|Placebo|6 capsules per day (4.3 g)x 6 months. Supplement should be taken with food once per day. No specific food requirements are needed.
1698296|NCT01478477|Other|Clinical assessments|All three instruments will be administered at baseline, at 3 months, 6 months and at additional time intervals when there is a significant change in therapy (discontinuation/switch, pain medication administration) during routine medical oncology visits.
1698297|NCT01478477|Other|Assessment of therapy complications|Severity/grade of reaction according to the NCI Common Terminology Criteria for Adverse Events v4.0 (CTCAE).
1698298|NCT01478477|Procedure|Magnetic Resonance Imaging|Optional bilateral hand and wrist MRI imaging will be obtained at baseline and at 6 months to eligible patients who have no contraindications to MRI imaging.
1698299|NCT01478477|Procedure|Correlative/special studies|Plasma, RBC, and serum samples from the baseline blood draw will also be stored at -70C for fatty acid and biomarker analyses and repeated at 3 month and 6 month intervals. Samples will be analyzed in batches every 6 months.
1698300|NCT01478464|Other|Massage|"The hamstring muscle will be massaged with a massage roller for ten minutes."
1698301|NCT01478451|Behavioral|Exercise|Exercise will be performed for 10 minutes at the left or right trapezius (randomized)
1698302|NCT01478451|Other|Massage|massage will be provided for 10 minutes at the left or right trapezius (randomized)
1698303|NCT01478438|Device|Novilase Interstitial Laser Therapy|Image guided Interstitial Laser Ablation of breast tumors
1698304|NCT01478425|Device|Lipidic Microemulsion|Topical nasal, twice a day
1698305|NCT01478425|Device|Saline|Topical Nasal, twice a day
1698306|NCT01478412|Other|Polymer based fiducial placement|Fiducial marker placement with rectal ultrasound imaging.
1698307|NCT01478399|Drug|PB1023 Injection|90 mg Dose
1698308|NCT01478386|Other|Orthovisc|Subjects will receive a series of three Orthovisc injections into their affected knee
1698309|NCT01478386|Device|DonJoy HA lite knee brace|Subjects will be fitted and educated on using the DonJoy HA lite knee brace to treat their affected knee
1698310|NCT01478386|Device|Orthovisc injections and DonJoy HA lite knee brace|Subjects will receive a series of three Orthovisc injections and be fitted and educated on using a DonJoy HA lite knee brace
1698311|NCT01478373|Drug|Dovitinib (TKI258)|Oral Dovitinib (TKI258) as a gelatin capsule of 100 mg strength and dosed on a flat scale of 500 mg on a 5 days on /2 days off dosing schedule.
1698312|NCT01478360|Drug|AIN457 (secukinumab)|Secukinumab intravenous injection
1698313|NCT01478360|Drug|Placebo|Placebo intravenous injection
1698314|NCT01478347|Biological|Recombinant meningococcal B + OMV NZ|2 injections 2 months apart
1698315|NCT01478334|Behavioral|high intensity interval training|"First 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion.
Second 10 weeks participants are instructed not to change their dietary patterns or physical activity levels during the study period."
1698316|NCT01478334|Behavioral|Control|"First 10 weeks participants are instructed not to change their dietary patterns or physical activity levels, and to continue their habitually lifestyle.
Second 10 week of high intensity interval training, twice a week. The interval training session consists of 10 minutes warm up at 70 percent of maximal heart rate and continues with 4 times 4 minutes of high intensity intervals at 90 to 95 percent of maximal heart rate separated by 3 minutes of active brakes in between at 70 percent of maximal heart rate. Training will be performed by cycling. Training intensity will be supervised through the use of polar puls monitors and the BORG scale of subjective perceived exhaustion."
1698317|NCT01478321|Drug|Temozolomide|Given PO
1698318|NCT01478321|Radiation|hypofractionated radiation therapy|Undergo hypofractionated radiation therapy
1698319|NCT01478321|Biological|bevacizumab|Given IV
1698320|NCT01478321|Other|questionnaire administration|Ancillary studies
1698321|NCT01478308|Drug|Metformin hydrochloride|Metformin is administered orally, with food. Metformin tablets contain 500mg, 850mg, or 1000mg of metformin hydrochloride. Tablets contain inactive ingredients including pofidone and magnesium stearate. The coating for 500mg and 850mg tablets contains hypromellose. Metformin is an antihyperglycemic agent which decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization.In this study, Metformin will be given 850 mg orally, with food, once daily for 1 week starting the week before first docetaxel infusion, and thereafter 850 mg twice daily.
1698322|NCT01478308|Drug|Docetaxel|Docetaxel will be administered 75 mg/m2 as one hour infusion on day 1 every 21 days.
1698323|NCT01478308|Drug|Prednisone|Prednisone will be given 5mg orally twice daily which is the standard regimen with docetaxel
1698324|NCT01478295|Behavioral|CuidaCare Intervention|Nursing intervention address to Caregiver Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education
1698325|NCT01478295|Other|Control Group/Usual Care:|"Control Group/Usual Care:
Standardized care plan (PCE) Coping strategies promoting social support and empowerment through health education"
1698328|NCT01478256|Drug|Erythromycin|Topical erythromycin ointment twice a day
1698329|NCT01478256|Drug|Besifloxocin|Topical Besifloxocin twice a day
1698330|NCT01478230|Drug|Nicotine|Nicotine 5 mg Inhaler
1698331|NCT01478230|Drug|Nicotine|Nicotine 10 mg Inhaler
1698332|NCT01478178|Drug|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 1.5 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
1698333|NCT01478165|Drug|Total intravenous anesthesia|Total intravenous anesthesia plus normal saline 1.5 ml immediately before induction of anesthesia
1698334|NCT01478165|Drug|Total intravenous anesthesia plus palonosetron|Total intravenous anesthesia plus palonosetron 0.075 mg(1.5 ml)immediately before induction of anesthesia
1698335|NCT01478152|Other|Drug-like Medical Device: Ectoin Inhalation Solution|"After baseline visit subjects will receive 0.9% saline inhalation solution for placebo. Patients will be instructed to inhale once daily with the AKITA2® APIXNEB® inhalation system for 5 - 7 days.
The treatment phase with low dose of Ectoin® will follow subsequently without any washout phase. This treatment phase will be repeated for medium and a high Ectoin® dose. All doses of Ectoin® inhalation solution will be administered for 5 - 7 days without any washout phase. To minimize circadian variations Methacholine challenge tests will be performed always at the approximately same time. Sputum inductions will be conducted on the last but one day of placebo treatment phase and on the last but one day of treatment phase with the highest Ectoin® dose."
1698336|NCT01478139|Procedure|LIFT-plug|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track and plug (LIFT-plug) procedure
1698337|NCT01478139|Procedure|LIFT|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure
1698338|NCT01478126|Drug|N(2)-L-Alanine L-Glutamine dipeptide|Intravenous infusion of glutamine in total dose of 2 g/kg/day (rate=2*weight/24 ml/h). Infusion starts in operating room and ends next day after the surgery.
1698339|NCT01478126|Drug|Placebo|Intravenous infusion of 0,9% solution of NaCl, rate=2*weight/24. Infusion starts in operating room and ends next day after the surgery.
1698340|NCT01478113|Drug|Amphetamine/dextroamphetamine|The amphetamine/dextroamphetamine will be in a pill formulation. The dosage of the amphetamine/dextroamphetamine will be flexibly adjusted up or down by a study clinician based on the participant's response. Dose ranges will be 1-3 pills (placebo or 5 mg amphetamine) in the morning and 1-3 pills (placebo or 5 mg amphetamine) at noon.
1698341|NCT01478113|Drug|Placebo|The placebo will match the dextroamphetamine in form, dosage, frequency, and duration.
1698342|NCT01478113|Behavioral|Well-being therapy|Therapy sessions will last between 30-50 minutes. The sessions will take place at every visit after the screening visit.
1698343|NCT01478087|Device|Mysorba|Subjects will undergo one cycle of five immunoadsorption (IA) treatment sessions over two weeks.
1698344|NCT01478074|Drug|G-CSF|5 mcg/kg daily from day -7 until post-nadir ANC > 1000
1698345|NCT01478074|Drug|Cytarabine|2 g/m2 daily from day -6 through -2
1698346|NCT01478074|Drug|Fludarabine|30 mg/m2 daily from day -6 through -2
1698347|NCT01478074|Biological|Donor Natural Killer (NK) cells|Infused once on day 0. Four cohorts of escalating doses receiving 0, 1, 10, or 20 x 10^6 cells/Kg
1698348|NCT01478074|Biological|ALT-801|0.04 mg/kg IV thrice weekly for 8 doses beginning day +2
1698349|NCT01478061|Device|Anastomosis (C-Port® )|creation of anastomoses in blood vessels and grafts, including use in coronary artery bypass grafting procedures
1698350|NCT01478048|Biological|Elotuzumab|Solution; Intravenous (IV); 10 mg/kg; (Cycles 1 & 2: Days 1, 8 & 15; Cycles 3-8: Days 1 & 11; Cycle 9+: Days 1 & 15); Until subject meets criteria for discontinuation of study drug
1698351|NCT01478048|Drug|Bortezomib|Solution; IV; 1.3 mg/m2; (Cycles 1 - 8: Days 1, 4, 8, 11; Cycles 9+: Days 1, 8, 15); Until subject meets criteria for discontinuation of study drug
1698352|NCT01478048|Drug|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1& 2: once daily on Days 2, 4, 5, 8, 9, 11; Cycles 3-8: once daily on Days 2, 4, 5, 9, 12; Cycles 9+: once daily on Days 2, 8, 9, 16); Until subject meets criteria for discontinuation of study drug
1698353|NCT01478048|Drug|Dexamethasone|Tablets; Oral; 8 mg; (Cycles 1& 2: Days 1, 8, 15; Cycles 3-8: Days 1 &11; Cycles 9+; Days 1 & 15); Until subject meets criteria for discontinuation of study drug
1698354|NCT01478048|Drug|Dexamethasone|Solution; IV; 8 mg; (Cycles 1& 2: Days 1, 8, 15; Cycles 3-8: Days 1 &11; Cycles 9+; Days 1 & 15); Until subject meets criteria for discontinuation of study drug
1698355|NCT01478048|Drug|Dexamethasone|Tablets; Oral; 20 mg; (Cycles 1-8 once daily on Days 1, 2, 4, 5, 8, 9, 11, 12; Cycles 9+ once daily on Days 1, 2, 8, 9, 15, 16); Until subject meets criteria for discontinuation of study drug
1698356|NCT01478035|Drug|Phenytoin|Phenytoin 18 mg /Kg/day iv as loading dose. 24 hours later phenytoin 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
1698357|NCT01478035|Drug|placebo|Placebo 18 mg /Kg/day iv as loading dose. 24 hours later placebo 6 mg/Kg/d in 3 divided doses iv shifting to oral route at the same dose when the patient is able to use oral route.
1698358|NCT01478022|Drug|Isosorbide Dinitrate|Isosorbide Dinitrate 10 mgx2, daily, capsules
1698359|NCT01478022|Drug|Ibuprofen|Ibuprofen 200 mg daily, capsules
1698360|NCT01478022|Other|Ibuprofen and Isosorbide Dinitrate combination|Ibuprofen 200 mg and Isosorbide Dinitrate 20 mg combination daily dose
1698361|NCT01478009|Dietary Supplement|Korean red ginseng|Korean red ginseng(3.0g/day) for 12 weeks
1698362|NCT01478009|Dietary Supplement|Placebo|Placebo (3.0g/day) for 12 weeks
1698363|NCT01477996|Procedure|27-gauge|27-gauge needle for IVT
1698364|NCT01477996|Procedure|30-gauge|30-gauge needle for IVT
1698365|NCT01477983|Procedure|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
1698366|NCT01477983|Drug|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
1698367|NCT01477983|Procedure|ATP guide additional ablation.|Following successful PV isolation, intravenous ATP of 0.4 mg/body-weight-kg is rapidly is injected, and dormant LA-PV conduction is evaluated. If dormant LA-PV conduction is unmasked, then additional radiofrequency energy applications are delivered to the conduction gaps until disappearance of dormant LA-PV conduction.
1698368|NCT01477983|Drug|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
1698369|NCT01477983|Procedure|Control|Following successful PV isolation, intravenous ATP is not administered.
1698370|NCT01477983|Drug|Antiarrhythmic drug (AAD)|Following successful ablation, AAD (Vaughan Williams class I or III) is administered for 90 days. The recommended drugs are flecainide, propafenone, sotalol and amiodarone, but the final choice of drug and dosage is left to the discretion of the attending physician.
1698371|NCT01477983|Procedure|Control|Following successful PV isolation, intravenous ATP is not administered.
1698372|NCT01477983|Drug|Control|Following successful ablation, AAD (Vaughan Williams class I or III) including flecainide, propafenone, sotalol and amiodarone is not used during the period of 0 - 90 days.
1698373|NCT01477957|Procedure|surgery|biliopancreatic diversion, gastric banding, gastric sleeve resection
1698374|NCT01477931|Drug|Bupropion extended release|300mg once a daily, PO, 8weeks
1698375|NCT01477905|Device|Remi50 with prime|for using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was performed using 50 μg/ml (Remi50) of remifentanil, with PRIMING
1698376|NCT01477905|Device|Remi20 with prime|For using experimental TCIs, targeting an effect-site concentration (Ceff) of 4.0 ng/ml, was 20 μg/ml (Remi20) of remifentanil, and with PRIMING
1698377|NCT01477892|Drug|low dose remifentanil|non-inferiority test for low dose remifentanil 0.1mcg/kg/min compared with high dose remifentanil 0.25mcg/kg/min in pain control
1698378|NCT01477879|Other|Versabase gel with sarracenia purpurea 20% liquid extract|Topical application of gel/plant mix to lesions
1698379|NCT01477879|Other|placebo (versabase gel only)|versabase gel only
1698380|NCT01477866|Dietary Supplement|citogenex|CITOGENEX is a dietary supplement of insoluble polysaccharides, of Lactobacillus Casei (specific type) and of Bifidobacterium Lactis (specific type).
1698381|NCT01477866|Other|conventional therapy|conventional therapy for colon-rectal cancer
1698382|NCT01477853|Drug|Sitagliptin|Sitagliptin 100 mg tablet orally daily
1698383|NCT01477853|Drug|Atorvastatin|Atorvastatin 80 mg tablet orally daily
1698384|NCT01477853|Other|Placebo to sitagliptin|Placebo to sitagliptin tablet orally daily
1698385|NCT01477853|Other|Placebo to atorvastatin|Placebo to atorvastatin tablet orally daily.
1698386|NCT01477853|Drug|Metformin (open-label)|Participant will remain on prestudy dose of metformin tablets (at least 1500 mg daily) throughout entire study.
1698387|NCT01477853|Drug|Glimepiride (open-label)|Phase A: Glimepiride 1 or 2 mg tablet once daily with breakfast or the first main meal of the day (titrated up to 6 mg/day) for 16 weeks as rescue therapy for randomized participants not meeting specific glycemic goals.
1698388|NCT01477853|Drug|Glimepiride (double-blind)|Phase B: glimepiride up to 6 mg daily for participants not rescued with open-label glimepiride during Phase A.
1698389|NCT01477853|Drug|Placebo to glimepiride|Phase B: placebo to glimepiride tablet orally daily.
1698390|NCT01477840|Drug|Misoprostol|Sublingual Misoprostol 200 Micrograms After Spinal Anesthesia
1698391|NCT01477827|Other|None - observational study|
1698392|NCT01477814|Behavioral|Physician chart reminder|Subjects randomized to this intervention will have paper or electronic chart reminders placed on their medical records alerting their physicians to the need for colorectal cancer screening
1698393|NCT01477814|Behavioral|chart reminder, educational mat'ls, FIT|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet
1698394|NCT01477814|Behavioral|CR,ed mat'ls, FIT, phone call|Subjects randomized to this group will have a physician chart reminder, mailed educational packet which includes the CDC Screen for Life materials, a FIT with return envelope, a magnet to remind the subject about CRC screening and a CRC screening preference sheet. Subjects will also receive a telephone call from project staff to assess barriers to screening and to encourage CRC screening
1698395|NCT01477801|Drug|CHOLECALCIFEROL|"Standard guideline based therapy plus cholecalciferol:
Loading dose 300.000 U then 50.000 U every month for six months"
1698396|NCT01477801|Drug|PLACEBO|Standard guideline based therapy plus placebo
1698397|NCT01477775|Drug|Oral P2Y12 receptor blocker|Free choice among clopidogrel, prasugrel or ticagrelor
1698398|NCT01477775|Drug|Customized choice for the oral P2Y12 receptor blocker|one drug among clopidogrel, prasugrel or ticagrelor based on an algorithm integrating phenotype information.
1698399|NCT01477762|Drug|Dexamethasone|One tablet of 0.5 mg dexamethasone will be taken ten hours prior to completing study assessments.
1698400|NCT01477762|Drug|Placebo|One placebo tablet will be taken ten hours prior to completing study assessments.
1698401|NCT01477749|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
1698402|NCT01477736|Drug|Oxybutynin|5 mg of immediate-release oxybutynin orally 3 times daily
1698403|NCT01477736|Drug|Botulinum toxin A|300 U intradetrusor injection
1698404|NCT01477723|Other|Experimental Oral Nutritional Supplement|Experimental ONS orally Two 8 fl oz servings/day
1698405|NCT01477710|Procedure|Hold mask|The clinician will connect a SAVe ventilator to a face mask and hold the mask in place on the mannequin with two hands while maintaining the airway on the correct position for 10 minutes.
1698406|NCT01477710|Procedure|Strap Mask|The clinician will attach the face mask to the mannequin using the mask and mask strap included in the ventilator kit for 10 minutes
1698407|NCT01477710|Procedure|Airway|The clinician will blindly insert a supralaryngeal airway (the King lT) and connect the SAVe ventilator to the connector and provide ventilation for 10 minutes.
1698408|NCT01477697|Dietary Supplement|Omega-3|50 mg/kg per day of omega-3 fatty acids
1698409|NCT01477697|Dietary Supplement|Placebo|50 mg/kg per day of placebo equivalent
1698410|NCT01477632|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
1698411|NCT01477632|Drug|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|A single oral dose of 2 tablets under fasting conditions
1698412|NCT01477632|Drug|1.0 mg estradiol / 0.5 mg norethisterone acetate (NETA)|A single oral dose of 1 tablet under fasting conditions
1698413|NCT01477619|Drug|Tasimelteon|20mg single dose on Day 1
1698414|NCT01477606|Drug|Midostaurin|"Induction therapy: 50 mg, oral, twice daily, starting on day 8, thereafter continuous dosing until 48h before start of subsequent chemotherapy cycle.
Consolidation therapy: 50 mg, oral twice daily, starting on day 6, thereafter continuous dosing until 48h before start of conditioning therapy for allogeneic HSCT or 48h before start of subsequent consolidation chemotherapy.
Maintenance therapy:
50 mg oral twice daily over one year."
1698415|NCT01477606|Drug|Cytarabine|"Induction therapy:
200 mg/m2/day by continuous i.v. infusion on days 1-7 (total dose 1400 mg/m²)
Consolidation therapy:
Younger adult patients (18 to 65 yrs): 3 g/m2 by i.v infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 18 g/m2).
Older patients (>65 yrs): 1 g/m2 by i.v. infusion over 3 hours every 12 hours on days 1, 3, and 5 (total dose 6 g/m2)."
1698416|NCT01477606|Drug|Daunorubicin|"Induction therapy:
60 mg/m², by 1-hour i.v. infusion, day 1-3 (total dose 180 mg/m²)"
1698417|NCT01477593|Procedure|circumcision with Shenghuan in Yan's method|The foreskin is first separated from the glans.Then the inner ring is placed between them and over the glans. After adjusting the position of inner ring to retain 0.5cm inner foreskin, the operator install the outer ring over the foreskin and combine them together. Removal of excess foreskin is then performed upon the device.
1698484|NCT01477112|Dietary Supplement|Betacarotene|6 mg betacarotene in caplets for 45 days (daily)and reevaluate parameters 30 days after finishing supplementation
1698485|NCT01477112|Dietary Supplement|Controls. No treatment|Evaluate at time 0, 45 days and 75 days, but without receiving betacarotene supplements
1698486|NCT01477099|Device|Toothbrushing with a manual brush|Toothbrushing with a manual brush
1698487|NCT01477073|Drug|FSH-GEX™|
1698418|NCT01477593|Procedure|circumcision with Shenghuan in Peng's method|The foreskin is first separated from the glans. Then the inner ring is placed on the outer layer of foreskin. Next, the rim of the foreskin is clamped with blood vessel forceps at the 3, 6, 9 and 12 o'clock points. An urologist and an assistant each hold two clamps to widen the opening of the foreskin, and pull it over the inner ring. After the inner and outer layers of the foreskin and the frenulum are symmetrically positioned, the assistant install the outer ring over the foreskin and gently combine it together. Removal of excess foreskin is then performed below the device.
1698419|NCT01477593|Procedure|conventional method with incision|The procedure of conventional circumcision involve transection of the excess foreskin with reservation of 0.5cm inner foreskin, haemostasis by electrocautery and suture of skin edges with 4-0 absorption sutures.
1698420|NCT01477580|Biological|Low-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
1698421|NCT01477580|Biological|Low-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
1698422|NCT01477580|Biological|Medium-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of medium-dose V180 with no adjuvant at Months 0, 1, and 2
1698423|NCT01477580|Biological|Medium-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
1698424|NCT01477580|Biological|Medium-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
1698425|NCT01477580|Biological|Medium-dose V180 with Alhydrogel™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing Alhydrogel™ adjuvant at Months 0, 1, and 2
1698426|NCT01477580|Biological|High-dose V180 (non-adjuvanted)|Three 0.5-mL intramuscular doses of high-dose V180 with no adjuvant at Months 0, 1, and 2
1698427|NCT01477580|Biological|High-dose V180 with low-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing low-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
1698428|NCT01477580|Biological|High-dose V180 with medium-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing medium-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
1698429|NCT01477580|Biological|Low-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of low-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
1698430|NCT01477580|Biological|Medium-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of medium-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
1698431|NCT01477580|Biological|High-dose V180 with high-dose ISCOMATRIX™ adjuvant|Three 0.5-mL intramuscular doses of high-dose V180 containing high-dose ISCOMATRIX™ adjuvant at Months 0, 1, and 2
1698432|NCT01477580|Biological|Placebo|Three 0.5-mL intramuscular doses of phosphate-buffered saline at Months 0, 1, and 2
1698433|NCT01477567|Drug|LY3009385|
1698434|NCT01477567|Drug|Placebo|
1698435|NCT01477554|Other|PRONTO training|PRONTO is an intervention consisting of two training modules for medical professionals. Module 1 is delivered over 2-3 days, takes place in the hospital, and consists of high-fidelity, low-tech simulations. The curriculum employs elements of the Team STEPPS program to strengthen teamwork and leadership skills, and the use of effective communication techniques. The activities and simulations have clear objectives and use evidenced-based medical concepts. Module 2, the follow-up training, uses the same teaching methodology as Module 1 to reinforce teamwork, communication, and emergency response skills, and incorporates new topics such as preeclampsia /eclampsia, shoulder dystocia and pelvic presentation.
1698436|NCT01477541|Other|PM/ON integration|Professional midwives or obstetric nurses are integrated into clinic staff and delivering services.
1698437|NCT01477502|Other|individual homeopathic treatment|participants are diagnosed by a trained homeopath and receive individualized homeopathic treatment in addition to standard UTI prophylaxis
1698438|NCT01477502|Other|standard treatment without homeopathy|participants receive standard UTI prophylaxis
1698441|NCT01477476|Drug|Anakinra|Anakinra treatment will be given I.V. as a bolus of 2 mg/kg infused intravenously over 30 minutes followed by infusion of 2 mg/kg/hour for 4 hours.
1698442|NCT01477476|Other|Placebo Comparator|A placebo will be given to 7 subjects.
1698443|NCT01477463|Drug|Vitamin D3|4,000 IU oral vitamin D3
1698444|NCT01477463|Drug|placebo and vitamin D|
1698445|NCT01477450|Device|Pulse-dose oxygen|Pulsed-dose oxygen delivery from an oxygen concentrator
1698446|NCT01477450|Device|Cylinder oxygen delivery|Oxygen delivery from an oxygen cylinder
1698447|NCT01477437|Other|Teens Taking Charge: Managing Hemophilia Online- Online self-management intervention|"The content will be delivered on a password-protected website, as part of the About Kids Health interface developed and maintained at the Hospital for Sick Children, Toronto, Canada. The website has been developed as eight discrete educational modules for adolescents. Each module takes approximately 30 to 45 minutes to complete. Content has been written and reviewed by experts from comprehensive hemophilia care clinics across Canada (physicians, nurses, physiotherapists and social workers) and edited by a medical writer to ensure that it is written at the suggested grade 6 reading level for patient education materials. Content has been written in English and will be translated into French prior to program launch. The format is geared towards adolescents and includes narratives with video components and interactive illustrations. In addition, each module will have quiz questions with real-time feedback to promote interactivity and knowledge retention."
1698448|NCT01477424|Drug|PA21|The maximum dose of PA21 will be 15.0 g/day.
1698449|NCT01477424|Drug|Warfarin|The maximum dosage of Warfarin will be 10 mg/day
1698450|NCT01477411|Drug|PA21|The maximum dose of PA21 will be 15.0 g/day.
1698451|NCT01477411|Drug|Digoxin|The maximum dosage of Digoxin will be 0.5 mg/day
1698452|NCT01477398|Device|QED-100|Use of the QED-100 results in mild hypercapnia during emergence
1698488|NCT01477073|Drug|Drug: Comparator 1|
1698489|NCT01477073|Drug|Drug: Comparator 2|
1698490|NCT01477073|Drug|Drug: Placebo|
1698453|NCT01477385|Procedure|Resin Infiltration|After cleaning the proximal surface with caries lesion, it will be performed the local infiltration anesthesia and adaptation of the rubber dam. The adjacent tooth will be protected by plastic or metal strip. Hydrochloric acid 15% will be applied on the lesion, which will be washed and dried. The surface should be dried by applying 95% ethanol and air-way syringe. The resin infiltration (Icon, DMG) will be applied on the lesion. The resin will be polymerized and applied again and polymerized.
1698454|NCT01477385|Procedure|30% Silver Diammine Fluoride|It will be cleaned like group I. Soft tissues will be protected with petroleum jelly. The 30% silver diamine fluoride (Cariestop, Biodinamica) will be applied with a disposable microbrush for 3m. Then the surface will be washed for 30s.
1698455|NCT01477385|Procedure|Dental Flossing|In this group, the patient will perform only mechanical removal of biofilm to floss daily.
1698456|NCT01477385|Procedure|Resin Infiltration Placebo|In this group, the patient will be held only inserting the rubber dam and applied sterile water as a substitute for acid, ethanol and resin infiltration.
1698457|NCT01477385|Procedure|30% Silver Diammine Fluoride Placebo|Soft tissues will be protected with petroleum jelly. The patient will receive sterile water application with a disposable microbrush for 3m. Then the surface will be washed for 30s.
1698458|NCT01477372|Behavioral|Supervised exercise program|Intervention group participated in Blooming Exercise Program as from week 10-12 of gestation. At least 56 sessions through 22 weeks. 3 sessions per week
1698459|NCT01477346|Other|Nurse intervention|Complex package of care involving patient information and advice concerning lifestyle modification and recommended drug therapy.
1698460|NCT01477346|Other|Standard care|Continuing standard General Practitioner led care.
1698461|NCT01477333|Drug|UT-15C SR|Initiated at 0.125 mg BID, titrated as clinically indicated.
1698462|NCT01477333|Drug|Tyvaso Inhalation Solution|Administered as at least 9 breaths 4 times daily for at least 4 weeks prior to Baseline
1698466|NCT01477294|Drug|Caffeine|5 mg/ kg of body weight (capsules), twice a day (morning and afternoon), during 4 days.
1698467|NCT01477294|Drug|Placebo|Malt dextrin (5 mg/kg body mass) twice a day during 4 days
1698468|NCT01477281|Drug|Daflon|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
1698469|NCT01477281|Drug|Venaflon (Diosmin and Hesperidin)|Administer one tablet 2 times daily (oral), the main meals (lunch and dinner).
1698470|NCT01477268|Drug|Zoloft (antidepressant)|Zoloft 50-200 mg po od x 12 weeks
1698471|NCT01477255|Behavioral|iPad|The proposed investigation is a prospective case-control pilot study. The major goal of this pilot study is to assess the feasibility of a daily diary methodology for monitoring the experiences of recently diagnosed pediatric cancer patients and healthy-matched peers. The investigation will also examine the relationships among individual and contextual factors that influence the daily psychosocial functioning of youth with cancer in comparison to youth without cancer.
1698472|NCT01477242|Drug|Ondansetron|2mg (5mL) in < 15 kg and 4mg (10mL) in 15kg to 30kg
1698473|NCT01477216|Other|ELSA 1-9|Measuring GI and II values for Finnish foods
1698474|NCT01477203|Drug|Escitalopram|2-4 weeks, 5-10mg, max 20mg
1698475|NCT01477190|Drug|Spinal analgesia|isobaric bupivacaine 0.5% 10 mg together with preservative-free morphine was injected. The dose of morphine was based on patient's age, with 200 μg in patients aged ≤ 75 years and 150 μg in patients aged > 75 years.
1698476|NCT01477190|Drug|Patient Control Analgesia (PCA) Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
1698477|NCT01477177|Device|Polar Wand carbon dioxide cryotherapy|Patients with Barrett's esophagus dysplasia will be treated with the Polar Wand device at 0 month, 2 and 4 months,6 months (with four quadrant surveillance biopsies), 8 and 10 months (treatment as necessary), and, at 12 months for final surveillance with biopsies throughout entire initial Barrett's segment length.
1698478|NCT01477164|Behavioral|High intensity aerobic exercise|Participants will perform 12-weeks of high intensity aerobic training. Training will be 5-days per week. Three days (e.g. Monday, Wednesday and Friday) will include repeated bouts of cycling for 4-minutes at ~90% maximal effort followed by 3 minutes of active rest. The other two days (e.g. Tuesday and Thursday) will be treadmill exercise for 45 minutes at 70% of maximal effort.
1698479|NCT01477164|Behavioral|Resistance exercise training|Participants will perform 12-weeks of resistance exercise training. Training will be 5-days per week of daily sessions of 60 minutes that include resistance exercise for all major muscle groups.
1698480|NCT01477164|Behavioral|Combined|The combined group will be assessed before and after 12 weeks of no exercise training, then again following 12 weeks of combined aerobic and resistance exercise training.
1698481|NCT01477151|Drug|Volatile anesthetic|"The intervention in this trial is randomization to either maintenance of anesthesia with sevoflurane or maintenance of anesthesia with isoflurane. The designated volatile anesthetic will be given at a strict minimal amount throughout the entire cardiac surgery (including cardiopulmonary bypass). This regimen (administration throughout the entire operation) has proved to have the greatest efficacy. Apart from this intervention, the anesthetic for patients participating in this trial will not be substantially different from normal practice, as the intention is to allow normal practice (with the exception of the choice of volatile anesthetic agent) to maximize the applicability and external validity of the trial. The management of anticoagulation, cardiac surgical techniques, and other aspects of the procedure will be managed in an unaltered fashion.
No IV drug infusions will be permitted until after protamine administration."
1698482|NCT01477138|Procedure|pacemaker implantation, AAI(R)-DDD(R) versus DDD(R)|Indication for pacemaker implantation: sick sinus syndrome in conformity with the current guidelines. Only market-released CE certified 2-chamber cardiac pacemakers and electrodes are used. The implantation is done according to the applicable standards. Active RV-lead is positioned on the right ventricular septum.
1698483|NCT01477125|Behavioral|Flex working memory training|30-40 minutes of working memory training, 5 days a week for 5 weeks
1698491|NCT01477073|Drug|FSH-GEX|
1698495|NCT01477034|Dietary Supplement|Vitamin D3|2,000 or 4,000 IU/day vitamin D3 for 3 or 6 months.
1698496|NCT01477021|Drug|cyclophosphamide|Given IV
1698497|NCT01477021|Biological|NY-ESO-1-specific T cells|Given IV
1698498|NCT01477021|Other|laboratory biomarker analysis|Correlative studies
1698499|NCT01477008|Device|BiPhasic Cartilage Repair Implant|1 or 2 BiCRI devices, depending on lesion size
1698500|NCT01477008|Procedure|Marrow Stimulation|Microfracture or Subchondral Drilling
1698501|NCT01476982|Device|ClearView Scan|Assessment with ClearView device
1698502|NCT01476969|Device|Remote ischemic postconditioning|the treatment group consisted of three 4-minute cycles left lower limb ischemia,induced by inflating a blood pressure cuff on the lower limb to 600 mmHg with an intervening 4 minutes of reperfusion ,during which time the cuff was deflate;the control group consisted of placing an uninflated cuff on the left lower limb for 24 minutes.The postconditioning protocol was applied after the aortic cross-clamping.
1698503|NCT01476956|Other|Observational study|RA patients on standard DMARD therapy
1698504|NCT01476930|Procedure|cupping and serkangabin syrup|wet cupping serkangabin syrup
1698505|NCT01476930|Drug|conventional migraine drug treatment|nortriptyline ,propranolol ,ergotamine , sumatriptan tablets
1698506|NCT01476917|Device|Attune Sleep Apnea System|Observation of Attune Sleep Apnea System for use during sleep.
1698507|NCT01476904|Drug|Placebo|0 mcg/inhalation, 2 inhalations QID
1698508|NCT01476904|Drug|Primatene Mist|220 mcg/inhalation, 2 inhalations QID
1698509|NCT01476904|Drug|Epinephrine inhalation|125 mcg/inhalation, 2 inhalations QID
1698510|NCT01476891|Other|Immediate MBSR|Immediate Online MBSR Group. Participation in a standardized manual-based 8-week online MBSR program.
1698511|NCT01476891|Other|Wait-list Control Group.|Wait-list Control Group. The control group will receive the next available online MBSR program.
1698512|NCT01476878|Device|Frameless Stereotactic Radiosurgery with radiation mask|Linac-based radiosurgery using a thermoplastic mask (single treatment)
1698513|NCT01476839|Biological|basiliximab|Given IV
1698514|NCT01476839|Drug|carmustine|Given IV
1698515|NCT01476839|Drug|etoposide|Given IV
1698516|NCT01476839|Drug|cytarabine|Given IV
1698517|NCT01476839|Drug|melphalan|Given IV
1698518|NCT01476839|Other|pharmacological study|Correlative studies
1698519|NCT01476839|Other|laboratory biomarker analysis|Correlative studies
1698520|NCT01476839|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic progenitor cell infusion
1698521|NCT01476839|Biological|yttrium Y 90-labeled basiliximab|Given IV
1698522|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
1698523|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
1698524|NCT01476813|Drug|Glycopyrrolate|comparison of different dosages of drug
1698525|NCT01476813|Drug|Comparator|comparison of different dosages of drug versus comparator
1698526|NCT01476800|Drug|YM178 OCAS|oral
1698527|NCT01476800|Drug|Ketoconazole|oral
1698528|NCT01476787|Drug|Rituximab|375 mg/m2 on days 1, 8, 15 and 22 of cycle 1, day 1 of cycles 2 to 6; 8 weeks later responding patients continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
1698529|NCT01476787|Drug|Lenalidomide|20-mg on days 2-22 every 28 days x 6 cycles, if CR then 10-mg on days 2-22 every 28 days for 12 cycles. PR after 6 cycles, continue 20 mg for 3~6 cycles and then 10 mg on days 2-22 every 28-day cycles for upto 18 cycles
1698530|NCT01476787|Drug|Rituximab-CHOP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
1698531|NCT01476787|Drug|Rituximab-CVP|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
1698532|NCT01476787|Drug|Rituximab-Bendamustine|7 to 8 weeks later responding patients will continue with 375 mg/m2 rituximab every 8 weeks for 12 cycles.
1698533|NCT01476774|Drug|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.
maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
1698534|NCT01476774|Drug|Buprenorphine Transdermal System|"Titration period（21 days）:BTDS 5 mg or oral tramadol CR 100 mg bid, and will then be titrated, if necessary, a maximum of BTDS 20 mg or oral tramadol CR 200 mg bid will be given.
maintenance period(5 week):Patients will continue at a dosage level that provided acceptable pain control ."
1698535|NCT01476761|Device|Microcutter XPRESS and Microcutter XCHANGE|Surgical stapling devices
1698536|NCT01476748|Device|LaproStop|One of the subject's trocars will be randomized to be used with a LaproStop device.
1698537|NCT01476735|Other|individual preparation for colonoscopy|The volume of polyethylene glycol solution depends on risk factors presented in each patient. Time of administration of second dose will be confirmed according to the time of colonoscopy. In case of constipation an enema before colonoscopy will be administered. All patients will give educational booklet of preparation before colonoscopy
1698538|NCT01476722|Device|OPTI-FREE PureMoist multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used as indicated for cleaning, rinsing, reconditioning, disinfecting, and storing silicone hydrogel and soft contact lenses on a daily wear basis for 30 days
1698539|NCT01476696|Drug|Prasugrel|Administered orally
1698540|NCT01476683|Drug|Racecadotril|Film-coated tablet
1698541|NCT01476683|Drug|Racecadotril|Racecadotril Powder Blend
1698542|NCT01476683|Drug|Racecadotril|Marketed Capsule
1698543|NCT01476683|Drug|Racecadotril|Marketed Film-coated Tablet
1698544|NCT01476670|Other|Monitoring|Transcranial Doppler will be used to assess the cerebral autoregulation and carbon dioxide reactivity of patients with posterior fossa tumor
1698545|NCT01476657|Drug|IPI-145 (duvelisib)|Oral Twice A Day (BID) Dosing
1698581|NCT01476397|Other|Test infant formula|partially hydrolyzed whey formula with probiotic
1698582|NCT01476384|Dietary Supplement|Glucose|Glucose drink: 75 gram dextrose monohydrate, dissolved in 250 ml water
1698583|NCT01476384|Dietary Supplement|Placebo|250 ml water
1698793|NCT01474915|Drug|Dexamethasone|Subject will receive 10 mg of Dexamethasone IV around anesthesia induction
1757151|NCT00254163|Drug|Rituximab|
1698546|NCT01476631|Behavioral|Walking|"7 days prior to baseline participants must wear a blinded pedometer
At baseline information on the blinded pedometer will downloaded to the computer for analysis as well as number of days worn and hours of wear. Sociodemographic, cancer risk factors, height/weight, fast blood draw to check levels on insulin, C-peptide, IL-6 and PEG-2 and questionnaires PPAQ, Exercise Confident Survey and Sallis Social Support Scale, Day/night; Home/Work, neighborhood safety, HINTS, IPAPS, CES-D, Brief COPE, Urban and Life Stress Scale."
1698547|NCT01476618|Other|No Intervention|No Intervention
1698548|NCT01476605|Procedure|Dextrose prolotherapy|PrT-D solution is 4 mL 50% dextrose, 3 mL normal saline, and 2 mL 2% lidocaine
1698549|NCT01476605|Procedure|PrT-DMS|PrT-DMS. 1.0 mL 5% morrhuate sodium + 1.5 mL 50% dextrose, 1 mL 2% lidocaine and 3.5 mL normal saline.
1698550|NCT01476605|Procedure|Platelet Rich Plasma injection|Platelet rich plasma injection therapy (PRP) uses components of autologous blood to promote healing in chronically diseased joint tissues.
1698551|NCT01476592|Dietary Supplement|Resveratrol|5 gm/day of resveratrol orally, in two divided doses of 2.5 gm each without a break in therapy for a total of three cycles.
1698552|NCT01476579|Device|Cardiac Computer Tomography|Compare Cardiac CT with reference standard wich is conventional invasive coronary angiography.
1698553|NCT01476566|Behavioral|Educational intervention|Peer continuous medical education (CME) groups in general practice will be recruited to a cluster randomised educational intervention study. Participating groups will be randomised either to an intervention- or a control group. A multifaceted intervention has been tailored where key components are educational outreach visits (EOV) to the CME-groups, audit, and feedback. Trained GPs will conduct the EOVs during which evidence-based recommendations for diagnosis and treatment of HF will be presented. A software will be handed out for installation on participants' practice computers, enabling collection of diagnosis- and prescription-data. The captured data will subsequently be linked to corresponding data from the Norwegian Prescription Database (NorPD).
1698554|NCT01476553|Procedure|Extensive Intraperitoneal Lavage (EIPL)|"EIPL is performed after completing resection and lymphadenectomy: the abdominal cavity has to be washed ten times with one liter Ringer's solution. Each liter has to be well dispersed manually in the abdominal cavity, and removed and disposed completely. 100 ml of the last liter of lavage fluid will be harvested and sent for analysis.
Contrary to the Japanese trial, Ringer's solution will be used instead of normal saline solution because of a presumed higher likelihood of peritoneal adhesions when employing the latter (7). Ringer's solution is the standard used for all intraperitoneal lavage procedures at the study centre. To avoid hypothermia, the lavage fluid will be warmed to body temperature (37° Celsius)."
1698555|NCT01476540|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone.
1698556|NCT01476527|Procedure|Deep Brain Stimulation|Deep Brain Stimulation (DBS) is a neurosurgical procedure involving the implantation of deep brain electrodes, connected via a subcutaneous extension wire, to an implantable pulse generator (IPG, or 'battery') that is implanted below the collarbone
1698557|NCT01476514|Other|No intervention|The testing will be the same for healthy volunteers and patients with a mutations in the glycine channel.
1698558|NCT01476501|Drug|Vitamin D3|Randomized into 1 of 2 oral vitamin D3 softgel capsule supplementation strategies: 1) 2,000 IU/day (2 x 1,000IU/capsule each day) or 2) 40,000 IU/month (4 x 10,000IU/capsule last day of each month), for 6 months each.
1698559|NCT01476488|Drug|tacrolimus|
1698560|NCT01476475|Drug|Insulin glargine /lixisenatide Fixed Ratio Combination|FRC was self-administered by subcutaneous (SC) injection within 1 hour before breakfast using pen-type injector (Tactipen®): 100 U/ml insulin glargine and 50 mcg Lixisenatide (ratio of 2 U/1 mcg). The initial dose was 10 U/5 mcg and then dose was adjusted weekly to reach and maintain fasting self-monitored plasma glucose (SMPG) of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L.
1698561|NCT01476475|Drug|Insulin glargine|Insulin glargine (100 U/ml) was self-administered by SC injection before breakfast using pen-type injector (Lantus® Solostar®). The initial daily dose of insulin glargine was 10 U and then dose was adjusted weekly to reach and maintain fasting SMPG of 80 mg/dL to 100 mg/dL (4.4 mmol/L to 5.6 mmol/L).
1698562|NCT01476475|Drug|Metformin (Background drug)|Pharmaceutical form: Tablet; Route of administration: oral administration. To be kept at stable dose (≥1.5 g/day) throughout the study.
1698563|NCT01476449|Drug|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
1698564|NCT01476449|Drug|Ranibizumab|Pars plana injection of ranibizumab 0.5mg into the vitreous cavity.
1698565|NCT01476436|Other|Low carbohydrate dietary advice|Dietary advice
1698566|NCT01476436|Other|Continue usual diet|Blood and urine samples every 3 weeks. Participants continue to eat usual diet with no change in level of physical activity
1698567|NCT01476423|Drug|activated recombinant human factor VII|A prospective, observational multi-national registry collecting data and evaluating the efficacy and safety of rFVIIa in patients with GT with past or present refractoriness to platelet transfusions. The registry will also collect data from a broader range of GT patients treated with systemic haemostatic treatment (with or without antifibrinolytic drugs or other agents) used in the clinics. Data collection will continue for a maximum of six years. Baseline data as well as data obtained during either bleeding episodes or invasive procedures/surgeries will be recorded in the registry.
1698568|NCT01476410|Drug|brentuximab vedotin|Given IV
1698569|NCT01476410|Drug|doxorubicin hydrochloride|Given IV
1698570|NCT01476410|Drug|vinblastine|Given IV
1698571|NCT01476410|Drug|dacarbazine|Given IV
1698572|NCT01476410|Procedure|quality-of-life assessment|Ancillary studies
1698573|NCT01476410|Genetic|DNA analysis|Optional correlative studies
1698574|NCT01476410|Genetic|RNA analysis|Optional correlative studies
1698575|NCT01476410|Radiation|fludeoxyglucose F 18|Correlative studies
1698576|NCT01476410|Procedure|positron emission tomography|Correlative studies
1698577|NCT01476410|Other|laboratory biomarker analysis|Optional correlative studies
1698578|NCT01476410|Other|immunohistochemistry staining method|Optional correlative studies
1698579|NCT01476410|Genetic|polymorphism analysis|Optional correlative studies
1698580|NCT01476397|Other|Control infant formula|partially hydrolyzed whey infant formula consumed ad libitum throughout study
1698584|NCT01476371|Behavioral|Mindfulness-based group treatment|An 8-week course of mindfulness-based group treatment (one 2-hour session per week; 10 patients per group). Each group session will be led by two mindfulness instructors, who will lead the patients through the Here & Now mindfulness program. Between sessions, patients will perform additional mindfulness practice at home via the Internet.
1698585|NCT01476358|Dietary Supplement|Vitamin A (retinyl palmitate).|"Active Comparator (Vitamin A): 1 capsule containing oil carrier and 50,000IU Vitamin A, within 48hs of birth
Placebo Comparator: 1 capsule containing oil carrier and 0IU Vitamin A, within 48hs of birth"
1698586|NCT01476345|Drug|LY2963016|Administered subcutaneously
1698587|NCT01476345|Drug|Lantus|Administered subcutaneously
1698588|NCT01476332|Drug|cis-urocanic acid 0,5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
1698589|NCT01476332|Drug|cis-urocanic acid 2.5% eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
1698590|NCT01476332|Drug|Placebo for cis-UCA, eye drops|one drop three times a day, applied on one eye at Part 1 and on both eyes at Part 2
1698591|NCT01476319|Other|video|The intervention group includes patients who obtain information about percutaneous cholecystostomy from a video will view at their bedside on a laptop.
1698592|NCT01476306|Other|Telemedicine|Patient will receive care using HIPAA-compliant web-based videoconferencing rather than their usual in-patient care.
1698593|NCT01476306|Other|Usual care|Patients in this group will receive care as they usually do with the physician.
1698594|NCT01476280|Drug|palonosetron|0.075mg immediately before induction of anesthesia
1698595|NCT01476280|Drug|Ramosetron|0.3mg immediately before induction of anesthesia
1698596|NCT01476267|Drug|dalcetrapib|Single oral radiolabeled dose
1698597|NCT01476241|Procedure|PEG tube placement|Percutaneous endoscopic gastrostomy
1698598|NCT01476228|Device|EEG recording|EEG recording
1698599|NCT01476215|Drug|Paracetamol fast dissolution suspension|
1698600|NCT01476215|Drug|Paracetamol medium dissolution suspension|
1698601|NCT01476215|Drug|Paracetamol slow dissolution suspension|
1698602|NCT01476215|Drug|Paracetamol|
1698603|NCT01476202|Drug|nicotine|nicotine in the form of a mouth strip, lozenge and gum
1698604|NCT01476189|Drug|Experimental paracetamol formulation|experimental
1698605|NCT01476189|Drug|Marketed paracetamol|Marketed paracetamol
1698606|NCT01476189|Drug|Higher dose marketed paracetamol|Higher dose marketed paracetamol
1698607|NCT01476176|Drug|Experimental paracetamol|experimental paracetamol with caffeine
1698608|NCT01476176|Drug|Paracetamol marketed formulation|marketed formulation containing caffeine
1698609|NCT01476163|Drug|migalastat HCl|150 mg capsule taken every other day by mouth. An inactive reminder capsule may be provided to take on the days in between migalastat HCl
1698610|NCT01476137|Drug|GSK1120212|MEK inhibitor
1698611|NCT01476137|Drug|GSK2110183|AKT inhibitor
1698612|NCT01476124|Drug|morphine Placebo|Morphine Placebo
1698613|NCT01476124|Drug|GEn 600 mg|Gabapentin enacarbil 600 mg
1698614|NCT01476124|Drug|Morphine|morphine extended release 60 mg
1698615|NCT01476124|Drug|GEn Placebo|Gabapentin enacarbil placebo
1698618|NCT01476085|Radiation|ML10|[18F]ML10 radioligand apoptosis biomarker
1698619|NCT01476072|Other|MRI scan|MRI scan only, methodology study with no other intervention
1698620|NCT01476059|Other|Telephone follow-up|Asthmatic children being treated, who will be given medical guidance and therapeutic guidance through telephone calls at every fifteen days to the parents or guardians, performed by trained professionals.
1698621|NCT01476059|Other|No telephone follow-up|Asthmatic children being treated, who will be given medical guidance without telephone follow-up calls to parents or guardians.
1698622|NCT01476046|Drug|GSK1995057 single dose|Single intravenous dose
1698623|NCT01476046|Drug|Placebo|Single intravenous dose
1698624|NCT01476033|Dietary Supplement|nutraceutical group|6 capsules of supplement or placebo for 8wk
1698627|NCT01475994|Other|Grass pollen : Dactylis glomerata|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with either 4000 pollen grains/m3 of dactylis glomerata pollen.
1698628|NCT01475994|Other|Challenge with clean air|The subjects will be challenged for 4 hours on two consecutive days (Day 1 and Day 2) with clean air.
1698629|NCT01475981|Drug|JTK-853 or Placebo|Tablets, single dose, fasted, fed or high-fat fed condition
1698630|NCT01475968|Other|Ultrafine Air Pollution Particulate Matter|Ultrafine (particle diameter less than 2.5 microns) Air Pollution Particulate Matter, concentrated from the ambient air outside of the Chapel Hill EPA Human Studies Facility
1698631|NCT01475968|Other|Filtered Air|Filtered Air
1698632|NCT01475955|Drug|Broad Area ALA 1-hour incubation|20% ALA, broad area, 1 hour incubation
1698633|NCT01475955|Drug|Broad Area ALA 2 hour incubation|20% ALA broad area 2-hour incubation
1698634|NCT01475955|Drug|broad area ALA 3-hour incubation|20% ALA broad area 3 hour incubation
1698635|NCT01475955|Drug|Spot ALA 2 hour incubation|20% ALA spot 2 hour incubation
1698636|NCT01475955|Drug|Vehicle PDT|Levulan Kerastick containing vehicle ingredients only.VEH group will be randomized (1:1:1:1) to be balanced for the four active groups; broad area application for 1, 2 or 3 hours or spot application for 2 hours prior to BLUE light treatment. Subjects receiving VEH will be considered a single treatment group.
1698637|NCT01475955|Device|Blue Light Treatment|10 J/cm2 blue light delivered at 10 mW/cm2
1698638|NCT01475942|Dietary Supplement|Probiotic|4 month probiotic intervention with 1 month run-in and 1 month wash-out. Probiotic given once a day.
1698639|NCT01475929|Dietary Supplement|Probiotic supplement|A single strain probiotic supplement given at two doses
1698640|NCT01475916|Behavioral|Educational program: consultation with paediatric pulmonologist|Longitudinal prospective study
1757152|NCT00254163|Drug|Pentostatin|
1698641|NCT01475903|Procedure|Longitudinal sleeve gastrectomy|The main objective of this study is to assess during a 2-year prospective follow-up, the prevalence of nutrient deficiencies in patients undergoing a longitudinal sleeve gastrectomy for morbid obesity
1698642|NCT01475890|Dietary Supplement|Vitamin D3|7000IU per day of vitamin D3 for 12 months.
1698643|NCT01475890|Dietary Supplement|Placebo|Once a day for 12 months.
1698644|NCT01475877|Drug|Bromfenac|Bromfenac 0.09% 1 drop in study eyes q day
1698645|NCT01475864|Procedure|ERCP with metal stent|ERCP will be used so that a metal stent can be placed to facilitate the removal of the biliary stone
1698646|NCT01475851|Drug|GSK548470 300 mg tablet|Blue tablets containing 300 mg of tenofovir disoproxil fumarate
1698647|NCT01475838|Drug|PI|PI administered according to prescribing information; allowed PIs include atazanavir (ATV), darunavir (DRV), fosamprenavir (FPV), lopinavir (LPV), or saquinavir (SQV)
1698648|NCT01475838|Drug|RTV|RTV administered according to prescribing information FTC/TDF administered according to prescribing information
1698649|NCT01475838|Drug|FTC/TDF|FTC/TDF (200/300 mg) administered according to prescribing information
1698650|NCT01475838|Drug|Stribild|Stribild (E/C/F/TDF) (150/150/200/300 mg) STR administered orally once daily with food
1698651|NCT01475825|Drug|mipomersen sodium 200 mg|200 mg (200 mg/mL in a volume of 1 mL), subcutaneous injections
1698652|NCT01475825|Drug|Placebo|Placebo vehicle for subcutaneous injection.
1698653|NCT01475825|Drug|mipomersen sodium 70 mg|70 mg (140 mg/mL in a volume of 0.5 mL), subcutaneous injections
1698654|NCT01475812|Other|Hyperinflation and ADL|Assessment of dynamic pulmonary hyperinflation during activities of daily living in COPD patients.
1698655|NCT01475799|Device|Replacement of the Aortic Stenotic Valve|Treatment for patients with Severe Aortic Stenosis.
1698656|NCT01475786|Genetic|Low Dose: 16 mg VM202|"Subjects in the Low Dose Group (8mg VM202 / leg) will receive the following intramuscular injections in each calf:
Day 0 - 32 injections / calf:
• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)
Day 14 - 32 injections / calf:
• 16 injections of 0.5mL of VM202 / calf - (4 mg of VM202 / calf)"
1698657|NCT01475786|Genetic|High Dose: 32 mg VM202|"Subjects in the High Dose Group (16 mg VM202 / leg) will receive the following intramuscular injections in each calf:
Day 0
• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)
Day 14
• 32 injections of 0.5mL of VM202 / calf (8 mg of VM202 / calf)"
1698658|NCT01475786|Genetic|Control- Placebo (normal saline)|subjects will receive thirty-two (32) 0.5 mL injections of normal saline on Day 0 and Day 14.
1698659|NCT01475760|Other|K2CG chewing gum (20mg chitosan)|All participating subjects will chew gum TID for 14 days beginning on Day 1 through Day 14
1698660|NCT01475760|Other|K2CG chewing gum (60mg chitosan)|"Subjects will be randomized in a 1:1 fashion to either chew gum or continue with Standard of Care (no intervention)if they have a change in serum phosphorus of greater than or equal to -0.2 mg/dL from:
Baseline (defined as the mean of values from Visit 2, 3, and 4) to the end of active treatment (defined as the mean of Visit 6 and 7) AND/OR Baseline (defined as the mean of values from Visit 2, 3, and 4) and end of wash out (defined as Visit 7 (Day 22).
If randomized: Chew gum TID for 14 days beginning on Day 29 through Day 42"
1698661|NCT01475734|Biological|albiglutide|subcutaneous injection
1698662|NCT01475734|Biological|placebo|subcutaneous injection
1698663|NCT01475721|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
1698664|NCT01475721|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
1698665|NCT01475721|Drug|ADVAIR 500/50mcg|fluticasone propionate/salmeterol combination (500/50mcg) twice daily (AM and PM) for 6 months
1698666|NCT01475721|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
1698667|NCT01475721|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
1698668|NCT01475721|Drug|FLOVENT 500mcg|fluticasone propionate (500mcg) twice daily (AM and PM) for 6 months
1698669|NCT01475708|Drug|Doxycycline|100 mg PO bid, 14 days
1698670|NCT01475695|Drug|14C GSK2251052|1500 mg iv dose GSK2251052
1698671|NCT01475669|Biological|Fibrinogen Concentrate (Human) (FCH)|Single dose infused intravenously within 5 minutes of the completion of the measurement of the 5-minute bleeding mass; the dose is determined individually based on the measured maximum clot firmness (MCF) and subject body weight
1698672|NCT01475669|Biological|Placebo|Single dose of sodium chloride solution infused intravenously within 5 minutes at a volume equivalent to that needed for FCH
1698673|NCT01475656|Drug|levetiracetam|Infants in the both groups will receive 50 mg/kg IV levetiracetam after (continued) seizures are EEG confirmed.
1698674|NCT01475643|Drug|Loteprednol etabonate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
1698675|NCT01475643|Drug|Prednisolones acetate|1-2 Ophthalmic drops administered to study eye four times daily (QID) for 14 days post surgery. Tapered to twice daily (BID) for 7 days. Then once daily (QD) for 7 days.
1698676|NCT01475630|Procedure|physical therapy|mobilisation of the jaw, exercises, boostering information on avoiding parafunctions
1698677|NCT01475630|Procedure|control|relaxation
1698678|NCT01475617|Dietary Supplement|AquaVanta Chewable Tablet|AquaVanta Chewable Tablet (proprietary formulation of vitamin and minerals) 2 times a day for 6 months
1698679|NCT01475617|Dietary Supplement|Flinstones Complete|Flinstones Complete Multivitamin 2 times a day for 6 months
1698680|NCT01475617|Dietary Supplement|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
1698681|NCT01475617|Dietary Supplement|Nature Made Calcium Softgels|Nature Made Calcium Softgels (Calcium Carbonate 600 mg and Vitamin D 200 mg) three times a day for 6 months
1698682|NCT01475617|Dietary Supplement|Twin Labs Iron Caps|Twin Labs Iron Caps (Ferrous Fumarate) 18 mg per day for menstruating women for 6 months
1698683|NCT01475617|Dietary Supplement|Rexall Vitamin B12 Tablet|Rexall Vitamin B12 Tablet (Cyanocobalamin 500 mcg)per day for 6 months
1698684|NCT01475604|Device|Ivivi Torino II|Targeted pulsed electromagnetic field treatment for 4 weeks post-surgery
1698685|NCT01475604|Device|Ivivi Torino II|Sham treatment for 4 weeks post-surgery
1757323|NCT00248144|Drug|Famciclovir|
1698686|NCT01475591|Behavioral|Web-based multimodal rehabilitation based on cognitive based principles|The patient will be randomized to either the interventions group (multimodal pain rehabilitation with an added web-based multimodal rehabilitation with CBT-influences) or a control group (multimodal pain rehabilitation).
1698687|NCT01475578|Drug|STA-1|STA-1 capsule (manufactured by Sinphar Tian-Li (Hangzhou) Pharm. Co., Ltd.; Batch number: 020121), 2 capsules/time, 3 times/day, orally
1698688|NCT01475578|Drug|Ergoloid Mesylates tablet|Ergoloid Mesylates tablet (manufactured by Tianjin Huajin Pharmaceutical Factory; Batch number: 011230), 2 tablets/time, 3 times/day, orally before meal
1698689|NCT01475552|Drug|Abciximab|Patients, who showed PRU >270 unit and were randomized to abciximab group,were treated with abciximab in addition to conventional antiplatelet treatment (aspirin+clopidogrel).
1698690|NCT01475552|Drug|control|"Patients,who showed PRU >270 unit and were randomized to control group,were treated with conventional antiplatelet therapy (aspirin+clopidogrel) during PCI and follow up periods.
Aspirin : D-1 300mg, D0-30 100mg qd Clopidogrel : D-1 300mg, D0-30 75mg qd"
1698691|NCT01475539|Biological|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
1698692|NCT01475539|Biological|Injectable inactivated types 1, 2 and 3 poliovirus + Live oral Polio|0.5 mL, Intramuscular + 1g dragee candy oral dose
1698693|NCT01475539|Biological|Live oral poliovirus type 1, 2 and 3|1g dragee candy, oral
1698694|NCT01475526|Other|El Valor de Nuestra Salud Store Intervention|Changes to physical and social environment of grocery stores through implementation of the El Valor de Nuestra Salud intervention.
1698695|NCT01475513|Drug|Ortho Cyclen®|Ethinyl estradiol 35 mcg and norgestimate 0.25 mg (oral) will be taken as one tablet daily for 21 days per month followed by a 7-day pill-free period per cycle. Duration of the study is for 6 cycles of this birth control pill.
1698696|NCT01475500|Procedure|Sputum sample|This is a collection of sputum (mucous) you cough up. Three morning samples will be collected at one time. Sputum will be collected at baseline, year 1, year 2 and year 5.
1698697|NCT01475500|Procedure|Pulmonary function tests|A series of different breathing tests designed to measure lung function and to determine the presence or absence of chronic obstructive pulmonary disease will be performed at baseline.
1698698|NCT01475500|Radiation|Computerized tomography (CT) scan of the chest|A CT scan uses x-rays to take detailed pictures of the chest. Performed at baseline, year 2 and year 5. If nodules are present, CT scans will be performed every 3 months for the first year of the study.
1698699|NCT01475500|Other|Buccal epithelium collection|Collect cells from the inside of the cheek. Samples will be collected at baseline and yearly to year 5.
1698700|NCT01475500|Procedure|Nasal brushings|A cytobrush is used to remove cells on the surface of the inside of the nose. Samples will be collected at baseline and yearly to year 5.
1698701|NCT01475500|Procedure|Bronchoscopy|A flexible tube with a light and a camera will be inserted through the nose or mouth, and into the lungs to look at the airway. Bronchial tissue will be obtained.
1698702|NCT01475500|Procedure|Bronchoalveolar lavage|During a bronchoscopy, a flexible tube with a light and a camera is passed through the mouth or nose into the lungs and fluid is squirted into a small part of the lung and collected for examination. Bronchoscopies will be performed at baseline and at year 5.
1698703|NCT01475500|Procedure|Blood sample collection|A venous blood sample will be collected for testing of biomarkers and other relevant tests. Blood will be taken at baseline and yearly to year 5.
1698704|NCT01475500|Procedure|Urine sample|Urine will be collected for routine urine tests at baseline and yearly to year 5.
1698705|NCT01475500|Procedure|Questionnaire-data collection|A questionnaire about the patient's health, medical, and smoking history. Administered at baseline and yearly to year 5. Data will be taken from patient interviews and from the medical record.
1698706|NCT01475487|Procedure|Utrasound guided cricothyrotomy|Utrasound guided cricothyrotomy
1698707|NCT01475474|Device|Renew Insert|The Renew Insert is indicated for the management of accidental bowel leakage due to bowel incontinence. The Renew Insert is designed for self-insertion to seal and help prevent the involuntary leakage of stool from the rectum.
1698708|NCT01475461|Drug|Placebo|double-dummy placebo tablets administered once-daily for 84-days
1698709|NCT01475461|Drug|PF-04937319 - 3mg|PF-04937319 3mg administered as tablets once-daily for 84-days
1698710|NCT01475461|Drug|PF-04937319 - 20mg|PF-04937319 20mg administered as tablets once-daily for 84-days
1698711|NCT01475461|Drug|PF-04937319 - 50mg|PF-04937319 50mg administered as tablets once-daily for 84-days
1698712|NCT01475461|Drug|PF-04937319 - 100mg|PF-04937319 100mg administered as tablets once-daily for 84-days
1698713|NCT01475461|Drug|Sitagliptin - 100mg|Sitagliptin 100mg administered as tablets once-daily for 84-days
1698714|NCT01475448|Other|Long distance training|Long distance training during four months, 3 times per week
1698715|NCT01475448|Other|Walking training|Walking training during four months, three times per week
1698716|NCT01475435|Procedure|non- surgical periodontal treatment|scaling and root planning
1698717|NCT01475435|Procedure|Prophylaxis|Periodontally healthy patients will receive oral hygiene instructions and prophylaxis.
1698718|NCT01475422|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) how the body and diabetes works, 2) healthy eating and physical activity, 3) treatment with medication and monitoring blood glucose, and 4) reaching the targets with insulin (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program. Participants will be followed for an expected average of 12 weeks.
1698719|NCT01475422|Behavioral|Usual Care|Patients are followed in the medical appointments for evaluation and treatment of diabetes mellitus, according to service routine. Participants will be followed for an expected average of 12 weeks.
1698720|NCT01475409|Biological|QuantiFERON-TB Gold In-Tube (QFT-GIT)|Patients were randomized to undergo, on the same day, TST and QFT-GIT by means of a randomization list to generate the order by which the 2 tests had to be executed. QFT-GIT was repeated after 3 and 6 months since TNF antagonist onset
1698721|NCT01475396|Behavioral|exercise|
1698887|NCT01474187|Radiation|Radiotherapy|50Gy for whole pelvis
1698722|NCT01475383|Drug|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
1698723|NCT01475383|Drug|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1.
1698724|NCT01475383|Drug|Placebo|once daily dosing of placebo capsules following the dosing scheme described in 1.1
1698725|NCT01475383|Drug|PF-03654746|20-day dose titration phase: all dosages in capsules starting at 0.25 mg qd x 5 d, then 0.5 mg qd x 5 d, then 1.0 mg qd x 5 d, then 2.0 mg qd x 5 d. If a subject has intolerable, severe, or serious AEs after taking 2 mg qd for 1 to 5 days of dosing, the dose will be decreased by the investigator to 1 mg qd. If, in the investigator's opinion, the subject is determined to be unlikely to tolerate continued dosing at a dose of 1 mg qd, the subject should be discontinued from the study. Subjects remaining in the study will proceed to the 3-week Stable Dosing Phase; doses will be 2 mg daily x 21 days or 1 mg daily x 21 days.
1698727|NCT01475357|Other|Arm 1: NPO by mouth pre-operative|Current treatment for infants born with cardiac defects awaiting surgery is to keep them NPO pre-operatively. Arm 1 will make no changes to this current policy.
1698728|NCT01475357|Other|Arm 2: Fresh Breast Milk pre-operative|Infants randomized to Arm 2 of the study will receive their mother's own breast milk pre-operatively.
1698729|NCT01475344|Drug|Human Fibrinogen Concentrate|"intravenous infusion over 5 min/vial:
Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg
No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)
Fibrinogen Concentrate: 1.5 g / 3 g / 4.5 g / 6 g
Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
1698730|NCT01475344|Drug|Placebo|"intravenous infusion over 5 min/vial:
Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg
No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)
Placebo: 1.5 g / 3 g / 4.5 g / 6 g
Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8)."
1698731|NCT01475331|Drug|Ethanol|Cysts will be lavaged for 3-5 minutes with 80% EtOH
1698732|NCT01475331|Drug|Normal Saline|Cysts will be lavaged for 3-5 minutes with normal saline
1698733|NCT01475331|Drug|Chemotherapy|Following lavage with either 80% ethanol (control group) or normal saline (study group), cysts will be injected with a cocktail of 3mg/ml paclitaxel and 19mg/ml gemcitabine.
1698734|NCT01475318|Drug|mifepristone|200 mg mifepristone on day 1
1698735|NCT01475318|Drug|Letrozole|Letrozole 10mg PO on day 1, day 2, and day 3
1698736|NCT01475318|Drug|Misoprostol|misoprostol 800mcg PV on day 3
1698737|NCT01475305|Drug|Placebo|Participants received single intravenous (IV) dose of placebo matched to MEDI-557 on Day 1 and were inoculated with respiratory syncytial virus (RSV-A) (Memphis-37 strain) as intranasal drops on Day 3.
1698738|NCT01475305|Drug|MEDI-557|Participants received single IV dose of 30 milligram per kilogram (mg/kg) MEDI-557 on Day 1 and were inoculated with RSV-A (Memphis-37 strain) as intranasal drops on Day 3.
1698739|NCT01475292|Drug|RV568|RV568 50 ug administered via a nebuliser once daily for 14 days
1698740|NCT01475292|Drug|RV568|RV568 100 ug administered via a nebuliser once daily for 14 days
1698741|NCT01475292|Drug|Placebo|Placebo administered via a nebuliser once daily for 14 days
1698742|NCT01475279|Drug|Warfarin; Dantonic|Individual warfarin dose during the study; 225mg Dantonic b.i.d for one week
1698743|NCT01475266|Drug|EO9 (Apaziquone)|4 mg/40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
1698744|NCT01475266|Drug|Placebo|40 mL, Intravesical instillation, Single dose within 6 hours after TURBT
1698745|NCT01475253|Drug|Lidocaine Releasing Intravesical System - LiRIS®|Lidocaine Releasing Intravesical System (LiRIS®) is inserted into the bladder via cystoscopy on Study Day 0 and removed on Study Day 14. LiRIS releases lidocaine gradually during the 14 day indwelling period.
1698746|NCT01475253|Other|LiRIS Placebo|LiRIS Placebo contains inactive substance only; LiRIS Placebo is inserted into the bladder via cystoscopy on study Day 0 and removed via cystoscopy on study Day 14.
1698747|NCT01475253|Procedure|Sham Cystoscopy Procedure|Cystoscopy procedure only; no investigational product is inserted/removed from the bladder.
1698748|NCT01475227|Drug|1 Solvazinc tablet, day 2 to day 15|Zinc sulphate 125mg, day 2 to day 15
1698749|NCT01475227|Drug|1 Solvazinc tablet, day 15 to day 28|Zinc sulphate 125mg, day 15 to day 28
1698750|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.0 mmol/kg per day, given in three even daily doses after meals with a full glass of water
1698751|NCT01475214|Dietary Supplement|potassium bicarbonate|potassium bicarbonate in dose of 1.5 mmol/kg per day, given in three even daily doses after meals with a full glass of water
1698752|NCT01475214|Other|Inactive placebo capsule|microcrystalline cellulose
1698789|NCT01474928|Behavioral|knowledge video|Group one viewed a physician-led knowledge video
1698790|NCT01474915|Drug|Aprepitant|Subject will receive 40 mg of Aprepitant versus placebo PO before anesthesia induction
1698791|NCT01474915|Drug|Ondansetron|Subject will receive 4 mg of Ondansetron IV versus placebo around anesthesia induction
1698792|NCT01474915|Drug|Promethazine|Subject will receive 25 mg of Promethazine IV around anesthesia induction
1698888|NCT01474174|Biological|trivalent influenza vaccine|Given IM
1698753|NCT01475201|Behavioral|Step count prescription|Treating physicians will provide a pedometer, pedometer log, and step count prescription. The aim is a net increase of at least 3,000 steps/day over one year. The time frame for this increase will be 10 months for sedentary participants (<5,000 steps/day), 7 months for low active participants (5,000-7,499 steps/day), and 5 months for somewhat active participants (7,500-9,999 steps/day). If goals are not met, the doctor and participant will review barriers and facilitators, and a more individualized prescription will be formulated (e.g. lower incremental step count targets or slower rate of dose escalation). For participants who meet goals, the doctor and participant will together decide whether to aim for a further increase.
1698754|NCT01475201|Behavioral|Usual care|The control trial arm will receive usual care alone, over a one-year period (i.e. no step count prescription but, in accordance with guidelines, including advice to engage in 30-60 minutes of activity on most days of the week).
1698755|NCT01475188|Drug|Allergovit|commercially available grass pollen allergoid (100%), concentration A (1000 TU/ml, therapeutic units/ml)concentration B (10000 TU/ml).Patients were given subcutaneous injections with initial dose of 0.1 ml (concentration A) was increased once a 7 (+7) days until the highest tolerated dose (0.6, concentration B) was reached and SIT was continued with injections once every 4 - 6 weeks up to two years.
1698756|NCT01475188|Other|placebo|placebo administered with the same scheme and doses as specific subcutaneous immunotherapy
1698757|NCT01475175|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D) Medtronic Vision 3D™|Market approved Medtronic Vision 3D™ CRT-D implantable device.
1698758|NCT01475175|Other|Adaptive CRT (aCRT) Pacing|Adaptive CRT pacing software adjusts how the device paces the heart based on the patient's current heart status.
1698759|NCT01475162|Drug|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg once every three weeks for three doses. After Day 56 doses may be decreased to 4mg/kg once every three weeks depending on GVHD response.
1698760|NCT01475149|Other|Phlebotomy|Subjects will have blood drawn at each of the 3 study visits.
1698761|NCT01475136|Drug|LY2140023|Administered orally
1698762|NCT01475123|Drug|Nicorandil|15mg per day
1698763|NCT01475110|Drug|Imatinib|Observation of Imatinib resistant patients treated with Nilotinib.
1698764|NCT01475097|Drug|Iodixanol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
1698765|NCT01475097|Drug|Iopamidol|Iodixanol 320 mg I/mL given by intra-arterial administration. Comparator agent Isovue (iopamidol) 370 mg I/mL given as intra-arterial administration.
1698766|NCT01475084|Device|cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps|"The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
Forceps biopsy will be performed on usual way."
1698767|NCT01475071|Drug|Metvix and natural daylight PDT|Methyl aminolevulinate, cream 160mg/g.One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
1698768|NCT01475071|Drug|Metvix and conventional PDT|Methyl aminolevulinate, cream, 160mg/g. One session at baseline and a second session administration at week 12 for lesions showing non-complete response and new lesions on target area.
1698769|NCT01475058|Biological|allogeneic cytomegalovirus-specific cytotoxic T lymphocytes|Allogeneic CD19-specific chimeric antigen receptor-modified CD8+ central memory derived virus-specific T cells. Allogeneic CD19CAR-TCM cells given IV
1698770|NCT01475032|Drug|CHF 1535|CHF 1535 (BDP/FF) for 12 weeks
1698771|NCT01475032|Drug|Beclomethasone (BDP)|Beclomethasone (BDP) for 12 weeks
1698772|NCT01475032|Drug|Beclomethasone (BDP) + Formoterol Fumarate (FF)|free combo Beclomethasone (BDP) + FF for 12 weeks
1698773|NCT01475019|Drug|Orlistat|Tablet, 120 mg, three times daily, for six months
1698774|NCT01475019|Drug|Sibutramine|Tablet, 10 mg, once daily, for six months
1698775|NCT01475019|Behavioral|Diet and physical exercise|Hypocaloric diet and regular physical exercise
1698776|NCT01475006|Drug|AMG 595|AMG 595 is an antibody drug conjugate that binds to EGFRvIII.
1698777|NCT01474993|Drug|Sulforaphane-rich Broccoli Sprout Extract|"30 subjects will be randomly selected to receive sulforaphane-rich Broccoli Sprout Extract. The medication will be supplied and dispensed as No.1 size gelcaps (each gelcap containing ~ 250 mg sulforaphane rich Broccoli Sprout Extract, equivalent to ~ 50 µmol of sulforaphane). The dosage of sulforaphane will depend on subject's body weight:
Subjects with body weight less than 101 lbs will receive ~ 50 micromol sulforaphane per day (1 gelcap to be taken once a day)
Subjects with body weight 101 lbs to 199 lbs will receive ~ 100 micromol sulforaphane per day (2 gelcaps to be taken once a day)
Subjects with bidy weight > 199 lbs will receive ~ 150 micromol sulforaphane per day (3 gelcaps to be taken once a day)"
1698778|NCT01474993|Drug|Placebo|15 subjects will be randomly selected to receive inactive placebo (Gelcaps identical in appearance to that of active medication and containing microcrystalline cellulose)
1698779|NCT01474967|Drug|Metformin|500 mg metformin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 1 week 500 mg metformin with breakfast and 1000 mg with dinner for 22 weeks
1698780|NCT01474967|Drug|Metformin|500 mg metfomin daily with breakfast for 1 week 500 mg metformin per 12 hours with breakfast and dinner for 23 weeks
1698781|NCT01474941|Drug|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo once daily for 2 weeks
1698782|NCT01474941|Drug|PF-04620110 or Placebo|Multiple oral doses of 5 mg PF-04620110 as a modified-release formulation or placebo twice daily for 2 weeks
1698783|NCT01474941|Drug|PF-04620110 or Placebo|Repeat Arm 1 or Arm 2
1698784|NCT01474928|Behavioral|patient role played community video|Group two viewed the patient role played community video
1698785|NCT01474928|Behavioral|both videos group|Group three viewed both the knowledge and community videos
1698786|NCT01474928|Behavioral|Pamphlet group|Group four read an educational pamphlet only
1698787|NCT01474928|Behavioral|physician-led knowledge video|Group one viewed a physician-led knowledge video
1698788|NCT01474928|Behavioral|Community video group|Group two viewed the patient role played community video
1698794|NCT01474902|Drug|Enoxaparin|Lovenox- Enoxaparin; Sanofi-Aventis Canada Inc.
1698795|NCT01474889|Device|RT-CGM|Each device is approximately the size of a pager and transmits with a subcutaneously placed sensor consisting of a 21 - 26 gauge needle 5 - 12 mm in length. Sensors are placed using sterile precautions and changed every 3 - 7 days depending on the manufacturers' instructions. All devices are approved as adjunctive tools to blood glucose monitoring that will be continued at least 4 times daily, before each meal and at bedtime.
1698796|NCT01474863|Drug|High Dose Citrulline|Initial intravenous bolus of 20mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 9mg/kg (max 700mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days
1698797|NCT01474863|Drug|Placebo|D5W IV fluids at isovolumetric rate (about 15ml/hr)
1698798|NCT01474863|Drug|Low Dose Citrulline|Initial intravenous bolus of 10mg/kg (to a maximum of 1500mg) L-citrulline over 10 minutes. Immediately after the initial bolus, a continuous intravenous infusion of L-citrulline at 4.5mg/kg (max 350mg) per hour will be administered through a dedicated intravenous line or port of a multilumen catheter for 4 days.
1698799|NCT01474850|Procedure|lung recruitment maneuver|RM: peak inspiratory pressure 30 cmH2O, PEEP 15 cm H20 FiO2 0,4 (from end of surgery till extubation)
1698800|NCT01474837|Behavioral|Intervention: Exercise and motivational interviewing|12 sessions of exercise with MI
1698801|NCT01474798|Drug|RA-18C3|"For subjects weighing 27-53 kg: 100 mg (1 ml) administered every three weeks by subcutaneous injection.
For subjects weighing > 53 kg: 200 mg (2 ml) administered every three weeks by subcutaneous injection."
1698802|NCT01474785|Drug|human ghrelin|0.5-1 pmol/kg.min of human ghrelin administered by IV two times
1698803|NCT01474785|Other|very low calorie diet|standard very low calorie diet that is prescribed for all RYGB patients after their operation
1698804|NCT01474785|Procedure|Hyperinsulinemic/Euglycemic Clamp|Insulin and glucose infusions to measure glucose kinetics.
1698805|NCT01474772|Drug|Pregabalin|150-300 mg/day given in 3 divided doses as capsules
1698806|NCT01474772|Other|placebo|matching placebo capsules given in 3 divided doses
1698807|NCT01474759|Behavioral|Advice on diet, physical activity, and behavior change|Individuals will participate in individual sessions with Registered Dietitians providing basic instruction in principles of weight loss. The program will instruct individuals on the principles of healthy eating and nutrition during calorie restriction. These materials include one module with general information on the importance of limiting portion sizes. The program will also include instruction on physical activity and behavioral strategies for weight loss.
1698808|NCT01474759|Behavioral|Instruction in food portion size|Individuals assigned to this program will participate in individual instructional sessions with specialized materials and tools that address food selection and choosing appropriate portion sizes of various foods.
1698809|NCT01474759|Other|Provision of pre-portioned foods|Individuals assigned to this program will be provided with commercially available pre-portioned foods and will be taught effective ways to incorporate them into their daily diet.
1698810|NCT01474759|Behavioral|Advice on healthy eating for weight loss|Individuals assigned to this program will participate in individual instructional sessions that address principles of healthy eating while on a calorie-restricted diet.
1698811|NCT01474746|Drug|Sertraline|Liquid sertraline (20 mg/mL) will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid sertraline once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid sertraline once per day for a period of six months.
1698812|NCT01474746|Drug|Placebo|The placebo will be dosed in an age-dependent manner. Participants aged 2-3 years of age will be given 2.5 mg (0.125 mL) of liquid placebo once per day for a period of six months. Participants aged 4 years to 5 years 8 months will be given 5 mg (0.25 mL) of liquid placebo once per day for a period of six months.
1698813|NCT01474733|Other|educational intervention|series of lectures and workshops on health literacy
1698814|NCT01474720|Drug|Zostavax vaccine|Commercially available Zostavax vaccine will be administered subcutaneously according to package insert guidelines. Each 0.65-mL dose contains a minimum of 19,400 PFU (plaque-forming units) of Oka/Merck strain of VZV.
1698815|NCT01474707|Behavioral|Group one|Group 1 will view the knowledge-based video only
1698816|NCT01474707|Behavioral|Group two|Group two will view the motivational video only
1698817|NCT01474707|Behavioral|Group three|Group three will view both knowledge-based and motivational videos
1698818|NCT01474707|Behavioral|Group four|Group four will view the printed educational pamphlet and will not view either video
1698819|NCT01474694|Other|Abdominal surgery|The patient is placed in a supine position and standard laparotomy (either via subcostal, midline or inverted hockey-stick incision) is performed. After mobilization of the liver, surgical swabs are packed around the organ to prevent unnecessary movement of the liver during the acquisition of the landmarks and the subsequent surgical procedure
1698820|NCT01474681|Biological|HSC835|
1698821|NCT01474668|Drug|GDC-0941|Single oral dose\n \n\n\n\n
1698822|NCT01474655|Procedure|Pars plana vitrectomy and removal of epiretinal membrane|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. Visualization of the fundus was achieved using a wide-angle viewing system. After core vitrectomy, induction of a posterior vitreous detachment was conducted using a 23-gauge angulated dissecting needle in cases without presence of a posterior vitreous detachment. The epiretinal membrane and internal limiting membrane was removed in all eyes. In most cases, internal limiting membrane was removed without the assistance of staining dye. Indocyanine green dye was used to facilitate the removal of internal limiting membrane in some of the cases.
1698823|NCT01474642|Drug|Capecitabine/Cisplatin(XP)|Capecitabine/Cisplatin(XP) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1 Cisplatin 75mg/m2 iv q 3 weeks
1698824|NCT01474642|Drug|Capecitabine/Paditaxel(XG)|Capecitabine/Paditaxel(XG) D1-D14 Capecitabine 2000mg/m2 D#2 PO D1,D8 Paditaxel(genexol) 80mg/m2 iv q 3 weeks
1698825|NCT01474629|Dietary Supplement|probiotic-based dietary supplement|24 trained men receive a probiotic-based dietary supplement for 16 weeks. Dosage 3x 10-9 per day
1698889|NCT01474174|Other|laboratory biomarker analysis|Correlative studies
1698826|NCT01474629|Dietary Supplement|placebo|24 trained men receive a placebo for 16 weeks with same dosage compared to active group
1698827|NCT01474616|Other|Sit-to-Stand Activity|Health care aides will be expected to prompt residents to repeatedly stand up and sit down on four occasions throughout the day (twice on each of the day and evening shifts). The number of repetitions on each occasion will vary according to residents' ability and fatigue. The sit-to-stand activity is to be integrated into usual care routines such as when entering the dining room at mealtimes, while toileting, and on other occasions of regular activity. The timing and location will be at the discretion of the health care aide.
1698828|NCT01474603|Dietary Supplement|n-3 PUFA in protein-enriched low-GI diet|3 g per day n-3 polyunsaturated fatty acids in a protein-enriched low-GI diet
1698829|NCT01474590|Drug|Epiduo/Tactuo|topical to the face, once daily in the evening
1698830|NCT01474590|Other|vehicle gel|topical to the face, once daily in the evening
1698831|NCT01474590|Drug|doxycycline 200mg|oral, 2 capsules once daily in the morning with aglass of water and with food
1698832|NCT01474590|Drug|Isotretinoin|oral, 0.5mg/kg/day for a period of four weeks, adjusted to 1 mg/kg/day for the four following months.
1698833|NCT01474577|Other|questionnaire|Patients will complete one questionnaire over the phone. We will ask patients to describe their cardiac history since Rb-82 PET (chest pain, shortness of breath, cardiac catheterization, and heart attack). This information will be correlated to the scan results and other relevant information in the patient's medical record.
1698834|NCT01474564|Other|Blood draw|Patients with pancreatic adenocarcinoma will be enrolled. Venous blood is collected in a standard 10 ml heparin blood collection tube. We may ask for blood samples at different times during the course of the study, specifically, before you start treatment and when your treatment changes. During the one year of the study, the physician anticipates blood samples will be collected a minimum of one and a maximum of four times. The amount of blood collected at any of these times will be 10 mL, about 1 tablespoon.
1698835|NCT01474551|Drug|vemurafenib|All patients would be treated with vemurafenib given orally at 960 mg twice a day, which was the phase III dose. One cycle is 4 weeks long.
1698836|NCT01474538|Drug|Insulin Lispro|Insulin lispro (100 U/mL) administered by CSII pump
1698837|NCT01474538|Drug|Insulin Aspart|Insulin aspart (100 U/mL) administered by CSII pump
1698838|NCT01474525|Device|Home Blood Glucose Telemonitoring System|"The system is designed to send the measured blood glucose values directly to a hospital server. Values recorded by the glucometer are sent to the Blackberry® cell phone. A special removable Bluetooth® adapter unit is required for data transmission from the glucometer to the Blackberry®. The patient must then select on the Blackberry® the meal period the last measurement corresponds. The cellular phone serves as the platform for data-transmission to the central server. The threshold number of readings can be set for each patient individually through the web-interface. The system can be accessed by both the patients and the care providers through a secure web-interface.
Apart from collecting values the system generates automated adherence reminders to patients and high/low blood glucose alert messages to both patients and their care providers."
1698839|NCT01474512|Drug|80 mg Ixekizumab Dosing Regimens 1, 2, and 3|Administered SC
1698840|NCT01474512|Drug|Placebo|Administered SC
1698841|NCT01474499|Drug|Glycerine|
1698842|NCT01474499|Drug|Docusate sodium and sorbitol rectal solution|
1698843|NCT01474486|Drug|Micronutrients|Thiamin one tablet daily provides 50 milligrams(mg) of thiamin, Vitamin B-50 one tablet daily: provides an additional 50 mg of thiamin, riboflavin, niacin, pantothenic acid and pyridoxine, 100 microgram(mcg folic acid, and 50 mcg cyanocobalamin (B12) and biotin; Vitamin D one 50,000 International Units(IU) tablet of ergocalciferol per week for two months followed by one tablet every other week for four months, and Zinc Sulfate (Zn SO4) one tablet daily at bedtime which provides 50 mg elemental zinc (220 mg Zn SO4)
1698844|NCT01474473|Device|CACIPLIQ20 and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of CACIPLIQ20 treatment and is maintained during the treatment.
CACIPLIQ20 is applied on the wound for 10 minutes every 3 to 4 days"
1698845|NCT01474473|Device|Placebo and Nonremovable, Windowed, Fiberglass Cast Boot|"The Nonremovable, Windowed, Fiberglass Cast Boot is implemented before the beginning of placebo treatment and is maintained during the treatment.
Placebo is applied on the wound for 10 minutes every 3 to 4 days"
1698846|NCT01474460|Dietary Supplement|phytonadione|Phytonadione 200mcg PO daily for 6 months + normal dose of warfarin and standard of care treatment
1698847|NCT01474447|Behavioral|Grinberg Method|The GM is a methodology of attention that teaches through expanding and focusing body attention to create a change and an improvement in pain and in quality of life. The method focuses on the way in which we experience pain, and offers an approach that trains people to use their attention and will in order to turn an unwanted experience that causes suffering, into a controlled experience in which they can take responsibility on the way they react to an existing pain. The method uses attention in order to learn the fixed ways in which we respond to pain in our body: where we focus our attention, what is the level of tension in our muscles, how we breathe and relax and more. It gives simple and effective tools to control all these, in order to create optimal conditions in the body to utilize its natural potential to recover and recuperate
1698848|NCT01474434|Drug|pradigastat (LCQ908)|pradigastat tablets were supplied to the investigators at dose strengths of 10 mg and 20 mg as individual patient packs.
1698849|NCT01474434|Drug|Placebo|matching placebo tablets
1698850|NCT01474421|Drug|AQW051|Patients will receive AQW051 in a high dose once daily orally for 28 days.
1698851|NCT01474421|Drug|AQW051|Patients will receive AQW051 in a low dose once daily orally for 28 days.
1698852|NCT01474421|Drug|Placebo|Patients will receive placebo once daily orally for 28 days.
1698853|NCT01474408|Behavioral|interval training day 1|
1698854|NCT01474408|Behavioral|Moderate exercise day 2|
1698855|NCT01474408|Behavioral|Control day 3|
1698890|NCT01474161|Drug|GFT505 120mg - old formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study part I), 6 capsules with 250mL of water.
1698891|NCT01474161|Drug|GFT505 120mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part I) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 2 capsules with 250mL of water.
1699084|NCT01472822|Dietary Supplement|Omija extract.|Omija extract 1.2g/day for 12weeks
1758475|NCT00258271|Drug|cladribine|
1955873|NCT03041415|Behavioral|ALED Alone Physical Activity Program|• 12-week class focused on teaching self-regulatory skills to increase regular PA
1955874|NCT03041415|Behavioral|ALED + Our Voice PA Program|"12-week class focused on teaching self-regulatory skills to increase regular PA
Neighborhood assessment, consensus-building, & advocacy program in which participants are taught skills to promote neighborhood-level changes in support of regular Physical activity"
1698861|NCT01474369|Drug|TAK-438|TAK-438 10 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
1698862|NCT01474369|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for 4 weeks. Thereafter, TAK-438 placebo tablets, orally, once daily for 1 week.
1698863|NCT01474369|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 5 weeks.
1698864|NCT01474356|Other|hyperthermia|45 minutes of interstitial heating 42.5-49°C during the interstitial brachytherapy
1698865|NCT01474343|Genetic|SAF-301|The treatment plan consists on a direct injection of the investigational medicinal product SAF-301 to both sides of the brain through 6 image-guided tracks, with 2 deposits per track, in a single neurosurgical session.
1698866|NCT01474330|Drug|Pomalidomide|0.5-mg, 1-mg, or 2-mg capsule administered once daily for 5 days under fasted conditions
1698867|NCT01474330|Drug|Placebo|Placebo capsule
1698868|NCT01474317|Device|G3 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and AST of the palm using the G3 meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects utilize some additional features of the meter using the User Guide and provide feedback.
1698869|NCT01474304|Drug|Acetaminophen|1000 mg dose intravenous acetaminophen before craniotomy incision and a second 1000 mg dose intravenous acetaminophen 6 hours after surgery
1698870|NCT01474291|Biological|Tocilizumab|Tocilizumab administered according to prescribing information and normal clinical practice.
1698871|NCT01474278|Drug|Placebo|Single dose
1698872|NCT01474278|Drug|RO5028442|Single dose
1698876|NCT01474252|Drug|RSI|"All medications are administered only one dose before intubation
Anesthetics:
Propofol 2-2.5 mg/kg Thiopental 3-5mg/kg Etomidate 1-2mg/kg
Neuromuscular blocking agents:
Succinylcholine 1-1.5mg/kg Rocuronium 0.9mg/kg
Opioid:
Fentanyl 1-2ug/kg"
1698877|NCT01474239|Drug|bevacizumab [Avastin]|10 mg/kg every 2 weeks intravenously until disease progression or unacceptable toxicity
1698878|NCT01474239|Drug|fotemustine|75 mg/m2 intravenously on days 1, 8 and 15 followed by, after a 5 weeks interval, 100 mg/m2 on day 1 of a 3-weeks cycle. Until disease progression or unacceptable toxicity
1698879|NCT01474226|Dietary Supplement|Amino Acid Crystalline Lysine Amino Acid Mix|crystalline lysine from AA MIX (20, 40, and 60% of the mean lysine requirement of 35 mg/kg/d) Lysine will be given in the form of L-Lysine-HCl, Sigma-Aldrich Brand.
1698880|NCT01474226|Dietary Supplement|Cooked Rice containing Lysine|Lysine (20,40 and 60 % of the mean lysine requirement) from Cooked Rice
1698881|NCT01474213|Drug|dexmedetomidine group|1-1.5cmg/kg dexmedetomidine infusion within 10 minutes, while followed by maintainly infusing 0.7cmg/kg/min dexmedetomidine
1698882|NCT01474213|Drug|remifentanil group|target controlled 3.5-4ng/ml remifentanil infused(blood plasma concentration)
1698883|NCT01474200|Device|Isolated veno-venous ultrafiltration (AQ)|Aquapheresis treatment (isolated veno-venous ultrafiltration) using the Aquadex FlexFlow System during index hospitalization until the patient's signs and symptoms of fluid overload have improved to the satisfaction of the treating physician. Ultrafiltration rates, duration and frequency of treatment are dependent on the amount of patient fluid excess and on the rate of fluid movement from the interstitial spaces into the vascular compartment during Aquapheresis (Plasma Refill Rate, or PRR)
1698884|NCT01474200|Drug|IV Loop Diuretics (LD)|"IV Loop Diuretics treatment using only FDA approved IV loop diuretics indicated for the treatment of patients with fluid overload. This includes furosemide or other IV loop diuretics administered at equivalent doses to furosemide. Patients will receive either a twice daily IV bolus or continuous IV LD infusions according to the high dose protocol of theDiuretic strategies in patients wth acute decompensated heart failure (DOSE) trial."
1698885|NCT01474187|Drug|Irinotecan|initial from 50mg/m2/week and increased by 15mg/m2/week
1698886|NCT01474187|Drug|Capecitabine|625mg/m2,bid,d1-5,qw
1955883|NCT03039686|Biological|BMS-986089|Take BMS-986089 subcutaneously on specified days over a 48 week blinded period
1955884|NCT03039686|Biological|Placebo for BMS-986089|Take placebo subcutaneously on specified days over a 48 week blinded period
1698892|NCT01474161|Drug|GFT505 180mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III and IV), 3 capsules with 250mL of water.
1698893|NCT01474161|Drug|GFT505 240mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II) or multiple dose administration from Day 1 to Day 14 (Study Part III), 4 capsules with 250mL of water.
1698894|NCT01474161|Drug|GFT505 300mg - new formulation|hard gelatin capsules dosed at 60mg, one single oral administration (Study Part II), 5 capsules with 250mL of water.
1698895|NCT01474161|Drug|Placebo|hard gelatin capsules, one single oral administration (3 to 5 capsules with 250mL of water for Study Part II) or multiple dose administration from Day 1 to Day 14 (2 to 4 capsules with 250mL of water for Study Part III).
1698896|NCT01474148|Device|IRS-8 (8-Channel implanted stimulator-telemeter)|Surgical implantation of the 8-channel neuroprosthesis
1698897|NCT01474135|Drug|0.25% AR-12286 / 0.004% travoprost|
1698898|NCT01474135|Drug|0.5% AR-12286, 0.004% travoprost|
1698899|NCT01474135|Drug|0.004% Travoprost|
1698900|NCT01474122|Drug|Macitentan 3 mg|Macitentan 3-mg tablet once daily
1698901|NCT01474122|Drug|Macitentan 10 mg|Macitentan 10-mg tablet once daily
1698902|NCT01474122|Drug|Placebo|Placebo tablet matching macitentan tablet, once daily
1698903|NCT01474109|Drug|macitentan 3mg|macitentan 3mg tablet once daily
1698904|NCT01474109|Drug|macitentan 10mg|macitentan 10mg tablet once daily
1698905|NCT01474109|Drug|placebo|matching placebo once daily
1698906|NCT01474096|Other|implementation strategy of Breastfeeding|implementation strategy (including training session, information distribution, an opinion leader) of Breastfeeding
1698907|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment A: GK1-399 200 mg. Oral administration, twice per day.
1698908|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment B: GK1-399 800 mg. Oral administration, once per day.
1698909|NCT01474083|Drug|GK1-399 (formerly TTP399)|Treatment C: GK1-399 800 mg. Oral administration, twice per day.
1698910|NCT01474083|Drug|Placebo|Dose-matched placebo. Oral administration.
1698911|NCT01474070|Device|Intraocular Pressure Measurement|Intraocular pressure is measured with GAT and with DCT
1698912|NCT01474057|Behavioral|DESTRESS-PC|"An online nurse-assisted, self-management intervention designed for primary care treatment of war-related PTSD, this intervention will consist of 3 weekly logins to a secure website for a period of 6 weeks. A DESTRESS Nurse will train the participant to use the website and will monitor their progress and report key information back to the primary care physician."
1698913|NCT01474057|Other|Optimized Usual Primary Care PTSD treatment|Participants receive usual Primary Care treatment that is administered by the primary care physician; the DESTRESS Nurse monitors the participants' progress throughout the study.
1698914|NCT01474044|Drug|Gastropylor Complex Capsules|3 pills, three times a day, after meal
1698915|NCT01474044|Other|Placebo Comparator|Placebo that is same as gastropyloric complex capsules
1698916|NCT01474031|Other|biomechanics|"Time interval: pre-op - 3m - 6m - 12m
Assessment of all subjects:
XR with magnification marker
Biodex force measurement in flexion and extension and mid flexion (with EMG if possible)
Gait analysis with surface EMG and trunk markers:
Unipodal standing: 3 trials Right and 3 trials Left on FP
Level walking: 3 trials Right and 3 trials Left on FP
Chair rise: 3 trials, both legs on FP
Stair ascent: 3 trials Right and 3 trials Left on first FP
Stair descent: 3 trials Right and 3 trials Left on first FP
Squat: 3 trials, both legs on FP
Bipodal squat: 3 trials Right and 3 trials Left on FP
Functional scores (HHS, UCLA, HOOS, SF-36)
Assessment of final 5 subjects per group:
CT pre and post at 6w (pre: pelvis-knee and post: hip)
MRI pre and 1 y post
Accelerometer 1 week"
1698917|NCT01474018|Drug|QR-bromocriptine|The study drug is added-on to patients on existing type 2 diabetes treatment with insulin +metformin+exercise/nutritional counseling. The study drug is titrated up starting at one 0.8mg tab daily for 1 week, then 2 (0.8mg) tablets for week 2, then 3 tablets for week 3, then 4 tablets for week 4, then 5 tablets for week 5, then six tablets for week 6 (total 4.8). The limiting factor is nausea at which point the patients will back down the highest tolerated dose and continue on that dose for the remainder of the 6 months of the study.
1698918|NCT01474005|Device|PROTIP MEDICAL ( Artificial larynx prosthesis)|establishment of an artificial larynx prosthesis
1698919|NCT01473992|Device|Otto Bock C-Leg|Amputees' preferred prosthetic knee.
1698920|NCT01473992|Device|Otto Bock Genium|Study knee.
1698921|NCT01473979|Procedure|Surgical closure of the poststernotomy wound infection|"Arm A) Secondary closure with the vacuum-assisted system (VAC); The initial surgical revision is done within 24 hours. The first revision with second look and debridement is usually made in 72 hours Subsequently in the following days the wound is stepwise revised during VAC changes.The patients are obtained 5 to 7 times to the surgical procedures in time intervals of 72 hours. Subsequently when the last three bacteriology samples are negative a delayed primary closure or rectus abdominal muscle flap may be done.
Arm B) Surgical procedure by delayed primary closure; The patients will receive treatment delivered through the VAC system in the first 48 hours following the first surgical intervention, subsequently the wound is closed. after the sternum is closed by using metallic wires, pectoral muscle on both chest parts is mobilized and closed directly over the bone."
1698922|NCT01473966|Dietary Supplement|coffee|patients will receive a cup of coffee at room temperature orally twice daily
1698923|NCT01473966|Dietary Supplement|coffee rectally|patients receive an enema of two cups of coffee at room temperature once daily
1698924|NCT01473953|Drug|liraglutide-depot|Subjects will be randomised to receive a single dose of liraglutide-depot, at increasing dose levels, injected s.c./subcutaneously (under the skin). Progression to next dose level (max. 8) will be based on safety evaluation.
1698925|NCT01473953|Drug|placebo|Subjects will be randomised to receive a single dose of liraglutide-depot placebo, at increasing dose levels, injected s.c./subcutaneously (under the skin).
1698926|NCT01473940|Biological|ipilimumab|Given IV
1698927|NCT01473940|Drug|gemcitabine hydrochloride|Given IV
1698928|NCT01473940|Other|laboratory biomarker analysis|Correlative studies
1698990|NCT01473459|Procedure|IVM (In Vitro Maturation) Treatment|There will be no gonadotropin stimulation. There will be ovum pickup from antral follicles of immature oocyte which will be matured in the lab and fertilized by intracytoplasmic sperm injection (ICSI). Embryo transfer will take place on days 2 or 3.
1698929|NCT01473927|Other|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
1698930|NCT01473927|Other|Endoscopy|Only patients undergoing endoscopy for clinical reasons will be included in the study, i.e. no endoscopies will be performed solely for study reasons. For the purposes of our study, endoscopy serves to determine the degree of inflammation and no additional biopsies are taken. Blood for CRP and ficolin-2 analysis will be taken through the Venflon® installed for endoscopy.
1698931|NCT01473914|Dietary Supplement|Low dose: supplemental zinc, selenium and vitamin E|"ZINC 25mg (AS ZINC SULFATE)
SELENIUM 50 mcg (AS SODIUM SELENITE)
VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
1698932|NCT01473914|Dietary Supplement|Standard renal vitamin: B and C renal vitamin|"BIOTIN 300 MCG
D-PANTOTHENIC ACID (CALCIUM D-PANTOTHENATE) 10 MG
FOLIC ACID 1 MG
NIACINAMIDE 20 MG
VITAMIN B1 (THIAMINE MONONITRATE) 1.5 MG
VITAMIN B12(CYANOCOBALAMIN) 6 MCG
VITAMIN B2 (RIBOFLAVIN) 1.7 MG
VITAMIN B6 (PYRIDOXINE HYDROCHLORIDE) 10 MG
VITAMIN C (ASCORBIC ACID) 100 MG
INERT FILLER (CORNSTARCH)"
1698933|NCT01473914|Dietary Supplement|Medium dose: supplemental zinc, selenium and vitamin E|"ZINC 50 mg (AS ZINC SULFATE)
SELENIUM 75 mcg (AS SODIUM SELENITE)
VITAMIN E (D-ALPHA-TOCOPHEROL) (AS SUCCINATE) 250 IU"
1698934|NCT01473901|Drug|BKM120 + temozolomide|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
1698935|NCT01473901|Drug|BKM120 +temozolomide with/without radiotherapy|The investigational drug, BKM120, will be supplied as 10-mg and 50-mg hard gelatin capsules. BKM120 will be administered on a continuous once daily dosing schedule at a dose of 40 mg, or 60 mg, or 80 mg, or 100 mg (p.o.), in combination with the approved dosing of temozolomide and SoC delivery of cranial irradiation for GBM. The patient will be dosed with BKM120 on a flat scale of mg/day and the dose of BKM120 will not be adjusted to body weight or body surface area. Patients should not eat for 2 hours after the administration of BKM120. Temozolomide in 5 mg, 20 mg, 100 mg, 140 mg, 180 mg or 250 mg capsules will be administered in combination with the investigational drug BKM120.
1698936|NCT01473888|Drug|T89(Dantonic)|capsule, 225mg B.I.D.
1698937|NCT01473875|Drug|SBC-102|SBC-102 is a recombinant human lysosomal acid lipase (rhLAL). The investigational medicinal product is an enzyme replacement therapy intended for treatment of patients with LAL Deficiency.
1698938|NCT01473836|Drug|Metronidazole|Metronidazole will be administered at a dose of 500 mg TID (or QID for refractory or severe infection) for 3 to 14 days, in principle. Treatment duration can be prolonged up to 21 days based on subject's condition.
1698939|NCT01473836|Drug|Ceftriaxone sodium|Ceftriaxone sodium will be administered at a daily dose of 2 g (strength) when metronidazole is administered TID or at a daily dose of 4 g (strength) when metronidazole is administered QID.
1698940|NCT01473823|Dietary Supplement|Omega-3 LCPUFA|Dosage is 5 ml daily until age 3 years.
1698941|NCT01473810|Biological|Vacc-4x low dose|80 µg Vacc-4x (20 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
1698942|NCT01473810|Biological|Vacc-4x medium dose|400 µg Vacc-4x (100 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
1698943|NCT01473810|Biological|Vacc-4x high dose|1200 µg Vacc-4x (300 µg pr. peptide) in 300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
1698944|NCT01473810|Biological|Zero dose|300 µl Endocine divided into two administrations, one for each nose cavity, administrated once weekly for four weeks
1698945|NCT01473797|Drug|Cladribine|Subcutaneous injections, 0,1 mg/kg/day for 5 days, one course per month for 4 months
1698946|NCT01473784|Procedure|transoral robotic surgery|Undergo TORS using the Da Vinci Robotic Surgical System
1698947|NCT01473784|Procedure|quality of life assessment|After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
1698948|NCT01473771|Behavioral|Caring Letter (email)|"Participants will be emailed letters for two years. The first letter will be sent one week afer discharge from the inpatient psychiatric unit. There will be four subsequent email letters sent every month starting from the day of discharge, then another four every two months. The last four email letters will be sent every three months for the remainder of the two year period."
1698949|NCT01473758|Drug|Roflumilast|500 µg tablet, od, oral administration in the morning after breakfast
1698950|NCT01473758|Drug|Placebo|tablet, od, oral administration in the morning after breakfast
1698951|NCT01473745|Procedure|conventional alar base cinch|The conventional suture began from the bilateral alar part of the nasalis muscle and passed through a hole drilled on the anterior nasal spine.
1698952|NCT01473745|Procedure|modified alar base cinch|The modified suture began from the bilateral alar part of the nasalis muscle and dermis tissue over the alar base, and then passed through a hole drilled on the anterior nasal spine.
1698953|NCT01473732|Drug|Everolimus|Starting dose 1.5 mg bid, target trough level 6-10 ng/ml. Myfortic Min. dose 360 mg bid and Max dose 720 mg bid. Both for one year.
1698954|NCT01473732|Drug|Tacrolimus|Target trough level of Tacrolimus 3-5 ng/ml. Myfortic Min. 360 mg bid and Max. 720 mg bid Both for one year.
1698955|NCT01473719|Behavioral|motivational intervention|7-session individual motivationally-based intervention
1698956|NCT01473719|Behavioral|health education|7 individual sessions focusing on health education
1699028|NCT01473238|Other|Evaluation form|A validated user experience evaluation questionnaire will be completed by each participant in the beginning, at the interim period, and at the end of the trial
1758476|NCT00258271|Drug|cytarabine|
1698957|NCT01473706|Other|Consumer Mini Nutritional Assessment|A 11 question, self administered nutrition screening tool. The consumer and their caregiver will complete the consumer version of the Mini Nutritional Assessment. A healthcare professional will then meet with the consumer and complete a nutrition screening with utilizing a validated nutrition screening tool.
1698958|NCT01473693|Other|MRI Screening Form, MRI, Demographic / Medical Data form|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits. Administration time: 5 minutes. MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.
Demographic / Medical Data: Administration time: 5 minutes."
1698959|NCT01473693|Other|MRI Screening Form, MRI. Demographic / Medical Data|"MRI Screening Form: MRI screening form will be administered twice at baseline and follow up visits Administration time: 5 minutes.
MRI data: at both time points (pre- and post-treatment only) Administration time: 30 minutes.
Demographic / Medical Data: Administration time: 5 minutes"
1698960|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
1698961|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
1698962|NCT01473680|Other|EEG, Neuropsychological Evaluation, Psychological Questionnaires, Medical Questionnaire|Participants will complete a medical/psychiatric history questionnaire, and a standardized battery of neuropsychological (NP) tests and psychological instruments. EEG recording will be made as participants engage in tasks of basic perceptual or pre-attentive processes and selective attention. Following chemotherapy (and a matched interval for the no-chemotherapy and healthy control groups), the standardized battery of NP tests, psychological instruments, and EEG will be repeated.
1698963|NCT01473667|Procedure|Superficial Cervical Plexus Block (SCP) block|SCP block using 10-15ml of 1% Ropivacaine
1698964|NCT01473667|Procedure|Local site infiltration|Local site infiltration using 2% lidocaine
1698965|NCT01473654|Behavioral|ADAPT tool|Use of ADAPT shared goal setting tool in EMR
1698966|NCT01473628|Drug|Rituximab|"375 mg/m^2 by vein every week for four consecutive weeks during the radiation treatment.
Maintenance: 375 mg/m2 by vein every 3 months for a total of 2 years."
1698967|NCT01473628|Radiation|Radiation|Total dose of 24 to 30 Gy over 12 to 15 treatments.
1698968|NCT01473615|Behavioral|Mindfulness Based Cognitive Therapy|A manualized 8-week MBCT group skills program with weekly sessions that each last 2 hours. The MBCT sessions combine elements of cognitive therapy with a mindful approach to thoughts and feelings, including a significant meditation component. The program is specifically tailored to a population that suffers from active depressive symptoms and chronic pain. The program also includes daily homework exercises.
1698969|NCT01473602|Drug|Teriparatide|Administered by SC injection
1698970|NCT01473602|Drug|Placebo|Administered by SC injection
1698971|NCT01473602|Dietary Supplement|Calcium supplementation|Administered orally
1698972|NCT01473602|Dietary Supplement|Vitamin D supplementation|Administered orally
1698973|NCT01473589|Drug|Teriparatide|Administered by SC injection
1698974|NCT01473589|Drug|Placebo|Administered by SC injection
1698975|NCT01473589|Dietary Supplement|Calcium supplementation|Administered orally
1698976|NCT01473589|Dietary Supplement|Vitamin D supplementation|Administered orally
1698977|NCT01473576|Dietary Supplement|Nitrate|0.15 mmol/kg body weight sodium nitrate (dissolved in 250 mL water)
1698978|NCT01473576|Dietary Supplement|Sodium chloride|0.15 mmol sodium chloride dissolved in 250 mL water.
1698979|NCT01473563|Drug|Pemetrexed|Administered intravenously
1698980|NCT01473550|Behavioral|Access to TELUS Health Space and Smart Phone|Participants will be given their own TELUS Health Space and Smart Phone in order to have access to their personal health records. Specific procedures using the smart phone will depend on the individual care plan for each participant. Prompts and assessments will vary depending on participant needs.
1698981|NCT01473537|Drug|calcium lactate solution|Calcium lactate solution 75 mM, 150 mM, 175 mM and placebo
1698982|NCT01473524|Drug|Obeticholic Acid (OCA)|
1698983|NCT01473524|Drug|Placebo|
1698984|NCT01473511|Behavioral|Strongest Families Intervention (formerly Family Help)|Distance HEALTH education intervention focussed on skill learning for parents
1698985|NCT01473498|Other|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.
In the first group (study group, n=30), mean arterial pressure will be increased to 85 mm Hg for 72 hours by increasing the dose of norepinephrine in patients."
1698986|NCT01473498|Other|Haemodynamic management|"Patients will be treated with fluid and norepinephrine to achieve and maintain a mean arterial pressure of 65 mm Hg. Then they will be randomized in two groups.
In this group (control group, n=30), mean arterial pressure will be maintained at 65 mm Hg."
1698987|NCT01473485|Device|ExAblate Transcranial System|MR Guided Focused Ultrasound
1698988|NCT01473472|Drug|Truvada|2 tablets of truvada within 24 hours before first sexual relations, then 1 tablet of Truvada during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of Truvada approximately 24 hours later
1698989|NCT01473472|Drug|Placebo|2 tablets of placebo within 24 hours before first sexual relations, then 1 tablet of placebo every 24 hours during the period of sexual activity including the last sexual intercourse, finally, a last dose of 1 tablet of placebo approximatively 24 hours later
1699029|NCT01473225|Other|Calorie information|Nutrition label featuring calorie information will be provided.
1699030|NCT01473225|Other|No calorie information|No nutrition label will be provided in this condition.
1698991|NCT01473459|Procedure|IVF (In Vitro Fertilization) Antagonist Protocol|The first stage of the treatment will be stimulation with gonadotropins. Next GNRH Antagonist will be added. Ovulation induction will be performed with GNRH agonist. After ovulation there will be ovum pickup and fertilization in the lab. Embryo transfer will take place on days 2 or 3.
1698992|NCT01473446|Procedure|Goal directed fluid therapy guided by LiDCOrapid|"Standard monitoring. The patient is connected to the LiDCOrapid monitor via an arterial line placed in a.radialis. A bolus of 500 ml Ringer acetate is given before anesthesia. If the stroke volume (SV) increases more than 10%, repeat the procedure until the SV is not increasing. After that, induction of anesthesia.
Maintenance fluid is given as Ringer acetate 2ml/kg/t. Continuous monitoring of stroke volume variation (SVV). If SVV> 10%, give a fluid bolus 6ml/kg Ringer acetate. Repeat until SVV <10%. Bleeding is being replaced 1:1 with hydroxyethyl starch. SAG by bleeding >1000ml. By fall in blood pressure and SVV <10%, start vasoactive treatment with epinephrine. Postoperative is given Glucose 5% 80ml/h."
1698993|NCT01473433|Procedure|Pericardial adipose pedicle (adiFLAP) transposition.|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be covered by the adiFLAP and the revascularizable area will be treated with the normal procedure. A non-revascularizable area will be considered whenever a transmural necrosis is detected by means of gadolinium contrast using MRI.
1698994|NCT01473433|Other|Control|Patients with a established transmural necrosis, candidates for revascularization of other myocardial areas, will be enrolled. The non-revascularizable area will be left untouched and the revascularizable area will be treated normally (by-pass).
1698995|NCT01473420|Biological|Epoetin Hospira|Variable dose
1698996|NCT01473420|Biological|Epogen Amgen|Variable dose
1698997|NCT01473407|Biological|Epoetin Hospira|Variable dose
1698998|NCT01473407|Biological|Epogen (Amgen)|Variable dose
1698999|NCT01473394|Drug|Dose-matched placebo|Dose-matched placebo was supplied as tablets.
1699000|NCT01473394|Drug|Vilazodone|Vilazodone was supplied as tablets.
1699001|NCT01473381|Drug|Vilazodone|Vilazodone was supplied as film-coated tablets.
1699002|NCT01473381|Drug|Placebo to citalopram|Placebo to citalopram was supplied as a capsule.
1699003|NCT01473381|Drug|Placebo to vilazodone|Placebo to vilazodone was supplied as film-coated tablets.
1699004|NCT01473381|Drug|Citalopram|Citalopram was supplied as encapsulated tablets.
1699005|NCT01473368|Dietary Supplement|Saccharomyces boulardii|500 mg, 2 times daily for 14 days
1699006|NCT01473368|Drug|Amoxicillin Clavulanate|875/125 mg 2 times daily at least 1 hour before meals for 7 days
1699007|NCT01473355|Device|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
1699008|NCT01473342|Behavioral|Mila Blooms|Behavioral intervention will be administered to 30 adolescent childhood cancer survivors & their parents (3 blocks of 10 survivor-parent(s) groups) who serve as their own controls. The intervention phase begins at Week 9 (immediately following the 8-week control phase) and runs for 9 weeks (Weeks 9 - 17). Adolescents are assigned a smartphone installed with the Mila Blooms app to use for the first 8 weeks (Weeks 9 - 16) of the intervention. The app integrates (1) tools for tracking health behaviors (e.g., diet, physical activity, etc.); (2) an avatar system to provide virtual rewards, and (3) a social network of users for support. As part of the intervention, adolescents will also receive weekly coaching phone calls from study staff to discuss areas of concern and to encourage goal-setting & participation. During the 9th week (Week 17), participants complete one final survey & accelerometer wear.
1699009|NCT01473329|Other|Structured Diabetes Education|The intervention group received a structured DSME course adapted from 15. The course was composed by weekly 2 hour meetings for five weeks total hours group of 10 patient and reinforcement meetings every 4 months, for one year
1699010|NCT01473316|Drug|GDC-0980|Single oral dose
1699011|NCT01473316|Drug|Ketoconazole|Repeating Oral Dose
1699012|NCT01473303|Biological|ganitumab|Given IV
1699013|NCT01473303|Drug|fluorouracil|Given IV
1699014|NCT01473303|Drug|irinotecan hydrochloride|Given IV
1699015|NCT01473303|Drug|leucovorin calcium|Given IV
1699016|NCT01473303|Drug|oxaliplatin|Given IV
1699017|NCT01473303|Other|placebo|Given IV
1699018|NCT01473303|Other|questionnaire administration|Completed on paper
1699019|NCT01473290|Dietary Supplement|live freeze-dried lactic acid bacteria probiotic|Given orally (PO)
1699020|NCT01473290|Other|placebo|Given PO
1699021|NCT01473277|Drug|BT-A (Dysport 500U), Triamcinolone acetonide|"All patients will be randomize to receive an intra-articular injection of BT-A (Dysport 500U) or triamcinolone acetonide (40 mg). Both drugs will be reconstituted with 2.0 ml of saline. Both drugs will be injected in the glenohumeral joint with a standard posterior approach. The time of the intra-articular injection od BT-A or steroid will be considered the time zero for each patient. The primary and secondary efficacy variables will be evaluated in all patients at 1 week, 2 weeks, 4 weeks, 3 months and 6 months after the treatment."
1699022|NCT01473264|Drug|recombinant human CC10 (rhCC10)|5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
1699023|NCT01473264|Drug|recombinant human CC10 (rhCC10)|1.5 mg/kg rhCC10, single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg
1699024|NCT01473264|Drug|placebo|Half normal saline solution; single dose delivered intratracheally (IT). Treatment was delivered within four hours after surfactant treatment. Dose was delivered IT in two (2) equal aliquots via a premeasured feeding tube placed in the distal third of the endotracheal tube with the patient in the right and then left lateral decubitus position and 30 degrees of Trendelenburg.
1699025|NCT01473251|Drug|Avastin|1.25 mg monthly for 4 months
1699026|NCT01473251|Drug|Avastin|1.25 mg monthly for 4 months
1699027|NCT01473251|Drug|Lucentis|0.5 mg monthly for 4 months
1699082|NCT01472835|Drug|Midazolam|Used for anxiolysis
1758477|NCT00258271|Drug|imatinib mesylate|
1699031|NCT01473199|Device|BioPoly RS Partial Resurfacing Knee Implant|A long term, surgically invasive device for replacement of focal osteochondral defects in the weight bearing region of the femoral condyles.
1699032|NCT01473173|Drug|CJ-12420|
1699033|NCT01473173|Drug|Esomeprazole 40mg|
1699034|NCT01473160|Device|delefilcon A contact lens|CE-marked, silicone hydrogel, single vision, soft contact lens for daily disposable wear
1699035|NCT01473160|Device|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single vision, soft contact lens for daily disposable wear.
1699036|NCT01473147|Drug|Exenatide|Exenatide 5 microgram bid sc.
1699037|NCT01473147|Drug|Normal saline|Normal saline 2 u bid sc.
1699038|NCT01473121|Other|No Intervention|All treatment options (inc. surgery, TACE, drugs) will be registered.
1699039|NCT01473108|Drug|Finerenone (BAY 94-8862) PEG solution|2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862
1699040|NCT01473108|Drug|Finerenone (BAY 94-8862) immediate release tablet|20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets
1699041|NCT01473108|Drug|Eplerenone (Inspra®)|Single oral dose of 50 mg eplerenone
1699042|NCT01473108|Drug|Placebo|Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
1699044|NCT01473082|Device|PFNA Augmentation (Synthes)|Proximal Femoral Nail Antirotation (PFNA) Augmentation (with Traumacem V+)
1699045|NCT01473082|Device|PFNA (Synthes)|Proximal Femoral Nail Antirotation (PFNA)
1699046|NCT01473069|Drug|JTK-853, ketoconazole|JTK-853 Tablets or Placebo, twice a day for 14 days, JTK-853 and ketoconazole Tablets, 1 each on Day 15
1699047|NCT01473069|Drug|JTK-853 or Placebo|JTK-853 Tablets or Placebo, twice a day for 14 days
1699048|NCT01473056|Drug|JTK-853|Tablets, twice a day for 3 days
1699049|NCT01473056|Drug|Dose 2 JTK-853|Tablets, twice a day for 3 days
1699050|NCT01473056|Drug|Dose 3 JTK-853|Tablets, three times a day for 3 days
1699051|NCT01473056|Drug|Dose 4 JTK-853|Tablets, twice a day for 3 days
1699052|NCT01473056|Drug|Placebo|Tablets, twice a day or three times a day for 3 days
1699053|NCT01473043|Drug|Axitinib|5mg twice daily [BD] daily dosing until progression or prohibitive toxicity Dose titration by 2 levels upwards (7mg and 10mg) and downwards (3mg and 2mg) allowed per protocol
1699054|NCT01473017|Behavioral|CBT-based Guided Self-Help|CBT-based booklet tailored to anxiety and/or depression in Type 2 Diabetes to enhance mood and Diabetes self-care
1699055|NCT01473004|Device|Sir-Spheres®|Sir-Spheres® Yttrium-90 microspheres given intra-hepatic; once for each lobe involved separated by 4 weeks.
1699056|NCT01472991|Drug|TC-5619-238 5mg|TC-5619-238 5mg capsule taken once daily for 4 weeks
1699057|NCT01472991|Drug|TC-5619-238 25mg|TC-5619-238 25mg capsules taken once daily for 4 weeks
1699058|NCT01472991|Drug|Placebo|Placebo capsules will be taken once daily for 4 weeks
1699059|NCT01472978|Drug|metronidazole|Metronidazole, 500 mg three times a for 10 days
1699062|NCT01472939|Drug|SSP-002358 (0.1 mg) + PPI|0.1 mg tablet three times daily (t.i.d.) taken in addition to a PPI
1699063|NCT01472939|Drug|SSP-002358 (0.5 mg) + PPI|0.5 mg tablet t.i.d. taken in addition to a PPI
1699064|NCT01472939|Drug|SSP-002358 (2.0 mg) + PPI|2.0 mg tablet t.i.d. taken in addition to a PPI
1699065|NCT01472939|Drug|Placebo + PPI|Placebo t.i.d. taken in addition to a PPI
1699066|NCT01472926|Drug|Tenecteplase|Intravenous (IV) tenecteplase 0.25 mg/kg (single bolus; maximum dose 25 mg)
1699067|NCT01472926|Drug|alteplase|Intravenous alteplase 0.9mg/kg to maximum of 90mg, given as 10% bolus and 90% of dose over 1 hour infusion
1699068|NCT01472913|Drug|Fibrin sealant|Fibrin sealant is applied on the surfaces of bone and soft tissue of surgery after placement of the prothesis due to the randomised knee.
1699069|NCT01472913|Drug|Saline water|Same procedure to the opposite knee (the same patient) performed with sprayed saline water (placebo).
1699070|NCT01472900|Device|2940 nm Er:YAG laser (DualisXS M002-2A, Fotona®, Fotona d.d, Ljubljana, Slovenia)|2 passes of 2940nm Er:YAG laser
1699071|NCT01472900|Drug|Benzoyl Peroxide gel|2.5% benzoyl peroxide gel apply twice daily on inflammatory acne on the control side of face
1699072|NCT01472887|Drug|SAR3419|"Pharmaceutical form:concentrate for solution for infusion
Route of administration: intravenous"
1699073|NCT01472874|Drug|Once a day Trientine|Trientine at a dosage of ~15 mg/kg rounded upwards to the nearest 250 or 300 mg in a single daily dosage. The entire daily dosage will be taken at once in the AM an hour before any meal. Duration of the study is 1 year.
1699074|NCT01472861|Procedure|AECC (Autologous endometrial coculture)|endometrial biopsy with autologous endometrial coculture
1699075|NCT01472861|Other|no endometrial biopsy or Autologous endometrial coculture (AECC) performed|routine procedures with out biopsy
1699076|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
1699077|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses ranging from low to high dose.
1699078|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
1699079|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
1699080|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
1699081|NCT01472848|Drug|PF 05212389 or placebo|QD SC administration of PF 05212389 (12 subjects) or matching placebo (3 subjects); doses to be determined from the results of previous cohorts
1758839|NCT00270062|Drug|epoetin alfa|
1699086|NCT01472809|Drug|ZYGK1|"ZYGK1 Tablets: 0.125, 0.25, 0.5, 1, 2, .... mg.
Dose escalation will continue till single AE occurs in any block of 3 volunteers on ZYGK1 or pharmacokinetic (dose linearity) saturation is reached or desired PK/PD effect is achieved"
1699087|NCT01472809|Drug|Placebo|Placebo Tablets: 0.125, 0.25, 0.5, 1, 2, ... mg
1699088|NCT01472796|Dietary Supplement|Vitamin D (cholecalciferol)|Tekturna (Aliskirin) 300 mg per day supplemented with 50,000 IU Vitamin D every other week x 8 weeks
1699089|NCT01472796|Drug|Tekturna(Aliskiren) plus placebo|Aliskiren 300 mg per day supplemented with placebo
1699090|NCT01472783|Drug|Veliparib|Veliparib (tablet) 300 mg twice daily on days 1-28 of 28 days cycles until progression, unacceptable toxicity or patient refusal.
1699091|NCT01472770|Drug|Gemcitabine + Capecitabine|Gemcitabine: 1000 mg/m2 intravenously over 30 min. on day 1 in 2-weeks cycles. Capecitabine: Peroral tablet 2000 mg/m2 daily on days 1-7 in 2-weeks cycles.
1699092|NCT01472757|Drug|VR506|VR506 inhalation powder delivered via a new dry powder inhaler
1699093|NCT01472757|Drug|Placebo|Placebo delivered via a new dry powder inhaler
1699094|NCT01472744|Behavioral|Dance Group|Participants will be instructed and learn various forms of dance (i.e. English country, folk, ballroom) and will be led by trained dance instructors and exercise specialists. Participants will for one-hour sessions and meet three times per week for six months.
1699095|NCT01472744|Behavioral|Strength, Stretching, Stability|Exercises focusing on strength, flexibility and balance will be performed at one-hour sessions held three times per week for six months. Classes are led by trained exercise specialists.
1699096|NCT01472744|Behavioral|Walking|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists.
1699097|NCT01472744|Behavioral|Walking + Nutrition|Participants in this moderate aerobic conditioning exercise program will be instructed in a walking program that focuses on having them walk within their target heart rate. They will be provided with heart rate monitors and pedometers for accurate record keeping. They will meet three times per week for one hour for six months. Warm up and cool down stretches will be a part of each walking session and sessions will be monitored and led by trained exercise specialists. These participants will also be provided with a daily nutritionally balanced liquid, milk-based supplement formula.
1699098|NCT01472731|Other|89Zr-GC1008|radioactive labeled GC1008, intravenous use, 37 MBq total
1699099|NCT01472731|Drug|GC1008|5 mg/kg intravenous use
1699100|NCT01472718|Device|coronary thrombectomy|coronary thrombectomy with either Angiojet device (rhelytic thrombectomy) or Export device (manual aspiration)
1699101|NCT01472718|Device|standard primary PCI (with stenting, as required)|standard primary PCI (usually with stenting) for STEMI, without use of thrombectomy or distal protection devices
1699102|NCT01472692|Drug|Febuxostat|80mg PO daily for 8 weeks
1699103|NCT01472666|Dietary Supplement|High content of MC-SFA|12 weeks dietary intervention
1699104|NCT01472666|Dietary Supplement|Whey|12 weeks dietary intervention
1699105|NCT01472666|Dietary Supplement|Low content of MC-SFA|12 weeks dietary intervention
1699106|NCT01472666|Dietary Supplement|Casein|12 weeks dietary intervention
1699107|NCT01472653|Drug|cisplatin|cisplatin 30 mg/m2/week I.V. during radiotherapy
1699108|NCT01472653|Radiation|radiotherapy|3-dimensional conformal radiotherapy planning and delivery, 35x2 Gy/day over 7 weeks
1699109|NCT01472653|Drug|cetuximab|cetuximab 400 mg/m2 I.V. 1 week before the start of radiotherapy, cetuximab 250 mg2/week I.V. during radiotherapy
1699110|NCT01472640|Drug|liraglutide|1.8 mg sc QOD
1699111|NCT01472640|Drug|placebo|1 U sc QOD
1699112|NCT01472627|Procedure|Blood draws|Blood draws
1699113|NCT01472614|Drug|DLBS3233|Study treatment will be DLBS3233 at a dose of 100 mg once daily (for 12 weeks) in addition to current anti-diabetic treatment used by respective study subjects and treatment intensification (lifestyle modification)
1699114|NCT01472588|Behavioral|DPP lifestyle intervention-Community Health Coach (CHWs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by CHWs in group format in community settings.
1699115|NCT01472588|Behavioral|DPP Lifestyle intervention--health professionals/(PHCs)|Lifestyle counseling. During a 16 month period, the behavioral weight loss program (n=24 sessions of the DPP lifestyle intervention) is delivered by PHCs in group format in community settings.
1699116|NCT01472588|Other|Self Help|Public education/information booklet on weight management.
1699117|NCT01472562|Drug|lenalidomide|"Induction phase: 20 mg/day for days 1-21 of a 28-day cycle for 12 cycles. If no excess toxicity is observed the dose will be increased to 25 mg/day.
Maintenance phase: Lenalidomide will be given at 15 mg/day for days 1-21 of a 28-day cycle."
1699118|NCT01472562|Biological|rituximab|"Induction phase: Rituximab will be administered at 375 mg/m2 per dose for a total of 9 doses. The first 4 doses will be administered weekly starting on day 1 of lenalidomide (e.g. days 1, 8, 15 and 22). Subsequent rituximab doses will be administered for one dose each at weeks 12, 20, 28, 36 and 44.
Maintenance phase: Rituximab at 375 mg/m2 per dose will be administered for one dose every 8 weeks, starting at week 52."
1699119|NCT01472549|Drug|Iodine-alcohol|Skin preparation with 8.3% povidone-iodine with 72.5% alcohol (Prevail-FX, Cardinal Health) preoperative skin preparation.
1699120|NCT01472549|Drug|Chlorhexidine-alcohol|Skin preparation with 2% chlorhexidine gluconate with 70% alcohol (ChloraPrep, Cardinal Health) preoperative skin preparation
1699121|NCT01472536|Behavioral|Sequestration|Students will be sequestered within their residence hall room for 3 days following influenza like illness symptoms.
1699122|NCT01472510|Drug|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 6 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
1699123|NCT01472510|Drug|Ranibizumab|A 0.5mg intravitreal injection of Ranibizumab will be administered to subjects. Subjects will receive 12 monthly consecutive ranibizumab injections. Study visits will be scheduled to occur every 28 days relative to the date of the first injection
1758840|NCT00270075|Drug|epoetin alfa|
1699124|NCT01472497|Drug|Pioglitazone|pioglitazone (15mg) once a day for 24 weeks
1699125|NCT01472484|Other|586/8x87 white|2 x 50 g
1699126|NCT01472484|Other|586/8x87 brown|2 x 50 g
1699127|NCT01472484|Other|BAT 881|2 x 50 g
1699128|NCT01472484|Other|586/8|2 x 50 g
1699129|NCT01472458|Behavioral|Quality improvement|The primary intervention in this project will be a multi-faceted quality improvement plan targeting improved predictions of neurological outcome and survival after cardiac arrest.
1699132|NCT01472432|Drug|Placebo|Placebo is added to the standard good medical practice. Plus Metformin and/or Sulfonylurea
1699133|NCT01472432|Drug|vildagliptin|50 mg per os b.i.d. for 4 months of treatment, added to the standard good medical practice.Plus Metformin and/or Sulfonylurea
1699134|NCT01472406|Device|Sansum Closed-Loop Artificial Pancreas|The Sansum Closed-loop Artificial Pancreas Device is the infrastructure that allows communication between the insulin pump, the CGM, the zone-MPC, and the HMS.
1699135|NCT01472406|Device|Insulin infusion pump|The insulin pump, which has received 510k clearance (K080639), delivers insulin subcutaneously through an infusion set.
1699136|NCT01472406|Device|Continuous Glucose Monitor|The CGM, which is an approved device (P050012), measures interstitial glucose.
1699137|NCT01472406|Device|zone-Model Predictive Control algorithm|The zone-MPC predicts future glucose values, based on CGM data, to regulate blood glucose level by increasing, decreasing, or stopping insulin infusion via an insulin infusion pump.
1699138|NCT01472406|Device|Safety Health Monitoring System|The HMS predicts future glucose values, based on CGM data, to warn the Sansum Closed-loop Artificial Pancreas Device of values below 70 mg/dL.
1699139|NCT01472393|Dietary Supplement|Creatine supplementation|The CR group will receive either 1g or 3g of Cr monohydrate (Creapure®) per day throughout the trial. The dose of creatine will be formulated in a tablet.
1699140|NCT01472393|Dietary Supplement|dextrose (placebo)|The placebo group will be given the same dose of dextrose formulated in a tablet to be consumed under the same conditions. The two types of tablets will not be distinguishable from each other having the same appearance, taste and smell.
1699141|NCT01472380|Drug|efavirenz|600 mg
1699142|NCT01472380|Drug|fenofibric acid 105 mg|fenofibric acid 105 mg
1699143|NCT01472367|Drug|Metformin|Metformin oral tablets twice daily. Participants on a metformin daily dose of 1000, 1250, or 1275 mg at screening will be switched to a metformin daily dose of 1000 mg (500 mg twice a day); 1500, 1700, or 1750 mg will be switched to a metformin daily dose of 1700 mg (850 mg twice a day); 2000 mg or more will be switched to a metformin daily dose of 2000 mg (1000 mg twice a day).
1699144|NCT01472367|Drug|Sitagliptin + Metformin FDC|Sitagliptin + metformin FDC oral tablet 50/500, 50/850, or 50/1000 mg dosed twice daily.
1699145|NCT01472367|Drug|Placebo to Metformin|Matching placebo to metformin administered twice daily.
1699146|NCT01472367|Drug|Placebo to Sitagliptin + Metformin FDC|Matching placebo to sitagliptin + metformin FDC oral tablet administered twice daily.
1699147|NCT01472367|Biological|Insulin|Participants who enter the study on background insulin will continue on the same dose and formulation of insulin throughout the study. If rescue therapy is necessary, participants who are not on background insulin will intiate insulin and those that entered the study on insulin will uptitrate their background insulin dose.
1699148|NCT01472367|Biological|Insulin glargine|Participants who are not on background insulin therapy during the base study may initiate insulin glargine during the extension period if their fasting fingerstick glucose is >130 mg/dL and their fasting state A1C is greater than 7.5%.
1699149|NCT01472354|Behavioral|Leap-c group intervention|4-week group intervention to help HIV/HCV co-infected patients reframe negative appraisals associated with hCV treatment, increase HCV knowledge, increase skills related to working with health care providers
1699150|NCT01472328|Procedure|HBO therapy|Effect of 2 hrs HBO therapy on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
1699151|NCT01472328|Procedure|Hyperbaric room air|Effect of 2 hrs hyperbaric room air on muscular insulin sensitivity and resistance in obesity and type 2 diabetes mellitus
1699152|NCT01472315|Drug|medroxyprogesterone acetate|MPA hormone therapy 30mg two hours before bedtime and 30mg right before going to bed every night for two weeks period
1699153|NCT01472315|Drug|Placebo|Placebo pills were taken in same way as active comparator
1699154|NCT01472302|Device|Adaptive Support Ventilation|Ventilation protocol according to the patients ideal body weight
1699155|NCT01472302|Device|Pressure Controlled Ventilation|Ventilation protocol (6-8 ml/kg tidal volume) according to our ICU
1699156|NCT01472289|Other|Autologous Bone Marrow Mononuclear cells (BMMNCs)|Multiple intramuscular injections of concentrated bone marrow derived mononuclear cells (0.5 cc/injection) into the ischemic muscle of the affected limb.
1699157|NCT01472276|Behavioral|Web-based program|Provided with the web-based program
1699158|NCT01472263|Drug|Pentoxifylline|Pentoxifylline 400mg 3 times a day on a total dose o 1200mg, oral capsules
1699159|NCT01472263|Drug|Placebo|Placebo capsules 3 times a day. The capsules have the same shape, color and form as the treatment group, and are identified by envelope numbers.
1699160|NCT01472250|Drug|Clinical chemo-drugs|"Clinical drugs will be selected by the investigator according to recommendations in Chinese and foreign guidelines and depending on clinical experience and the patient's individual conditions, including but not limited to the drugs listed below:
Platinum products: oxaliplatin, cisplatin Fluorouracil products: 5-fluorouracil, capecitabine, TS-1 Taxanes: paclitaxel, docetaxel"
1699161|NCT01472237|Other|Nutritional intervention|Modification of diet
1699162|NCT01472211|Device|zinc enriching filter (LifeStrawFamily)|filter purifies water and enriches it with zinc at 1-4 mg/l.
1699163|NCT01472211|Device|placebo filter|filter purifies water
1699164|NCT01472211|Other|disinfection tablets|government promoted tablets disinfect water
1699165|NCT01472198|Drug|Simtuzumab|Simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
1699166|NCT01472198|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 administered intravenously on Days 1, 8, and 15 of each 28-day cycle
1699167|NCT01472198|Drug|Placebo to match simtuzumab|Placebo to match simtuzumab administered intravenously every 2 weeks for a total of 2 infusions (Days 1 and 15)
1699168|NCT01472185|Drug|Ranolazine|Ranolazine tablets administered orally twice daily.
1699169|NCT01472185|Drug|Placebo|Placebo to match ranolazine administered orally twice daily.
1699170|NCT01472185|Behavioral|Diet|Participants are instructed to continue the diet regimen prescribed by their physician.
1699171|NCT01472185|Behavioral|Exercise|Participants are instructed to continue the exercise regimen prescribed by their physician.
1699172|NCT01472172|Device|Cryobiopsy (Autoclavable cryoprobe 20416-032)|The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline.
1699173|NCT01472159|Behavioral|CGM Family Teamwork Intervention|The family-focused behavioral intervention targets barriers associated with sustained CGM use in youth with type 1 diabetes. During months 1-18, families in the intervention group will participate in the intervention at each study visit for about an additional 30 minutes.
1699174|NCT01472146|Drug|Zo-Nantax|"Experimental:
AC,Docetaxel,Trastuzumab,Zolendronate
Drug: AC Adriamycin 60mg/m2 IV plus cyclophosphamide 600mg/m2 every 21 days for 4 cycles
Drug: Docetaxel
Docetaxel 100 mg/m2 every 21 days for 4 cycles.
Drug: Trastuzumab
Trastuzumab 8mg/kg [loading dose] once then 6mg/kg IV every 21 days for 3 cycles plus docetaxel.
Drug: zolendronic acid
Zolendronic acid 4mg IV every 21 days for 8 cycles combine with chemotherapy"
1699175|NCT01472133|Other|Recording of 12 lead ECG|Recording of 12 lead ECG
1699176|NCT01472133|Other|Recording of lying and standing blood pressure|Recording of lying and standing blood pressure
1699177|NCT01472133|Other|Recording of chest wall movement|Recording of chest wall movement
1699178|NCT01472133|Other|Recording of heart rate variability|Done during deep breathing and a valsalva manoeuvre
1699179|NCT01472133|Other|Recording of ECG and Pulse oximeter waveform at rest|For 10 mins
1699180|NCT01472133|Other|Recording of ECG and Pulse oximeter waveform during exercise|Recording of ECG and Pulse oximeter waveform during exercise
1699181|NCT01472081|Biological|Nivolumab|
1699182|NCT01472081|Biological|Pazopanib|
1699183|NCT01472081|Drug|Sunitinib|
1699184|NCT01472081|Biological|Ipilimumab|
1699185|NCT01472068|Device|Inko RS Device|30 minute pre-programmed treatment for 5 days out of 7. Treatment to be carried out while standing.
1699186|NCT01472055|Drug|Fludarabine|"Fludarabine 40 mg/m^2 once a day intravenous administration over 30 min
Development of sampling-minimized analysis method through individualized pharmacokinetics Sampling time: 0hr (pre-dose), 30 min (post-dose), 1hr, 3hr, 5hr, 8hr, 24hr
Population pharmacokinetics analysis
Comparative analysis of population pharmacokinetics in pediatric and adult patients
Analysis of population pharmacokinetics, toxicity, engraftment rate, survival rate"
1699187|NCT01472042|Other|Banyan Biomarkers|Biomarkers to detect specific proteins.
1699188|NCT01472029|Drug|5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab|"Pre-operative treatment 4 cycles and post-operative treatment 4 cycles:
Trastuzumab 4 mg/kg BW (6 mg loading dose at 1st administration), iv over 1 h on day 1 of each 14 day cycle
Docetaxel 50 mg/m², iv over 2 h on day 1 of each 14 day cycle
Oxaliplatin 85 mg/m² in 500 ml G5%, iv over 2h on day 1 of each 14 day cycle
Leucovorin 200 mg/m² in 250 ml NaCl 0,9%, iv over 1 h on day 1 of each cycle
5-FU 2600 mg/m², iv over 24 h on day 1 of each 14 day cycle"
1699189|NCT01472029|Drug|Post-operative treatment trastuzumab mono therapy|"Trastuzumab mono therapy for 9 cycles:
Trastuzumab 6 mg/kg BW, iv over 1 h on day 1 of each 21 day cycle"
1699190|NCT01472016|Drug|ABT-700|ABT-700 will be administered by intravenous infusion at escalating dose levels on day 1 in 21-day dosing cycles. Additional subjects will be enrolled in an dose expansion cohort that will further evaluate ABT-700.
1699191|NCT01472016|Drug|docetaxel|Docetaxel will be administered by intravenous infusion on Day 1 in 21-day dosing cycles.
1699192|NCT01472016|Drug|FOLFIRI|5-fluorouracil, Folinic acid and Irinotecan will be administered by intravenous infusion on Day 1 and 15 in 28-day dosing cycles.
1699193|NCT01472016|Drug|cetuximab|Cetuximab will be administered by intravenous infusion weekly.
1699194|NCT01472016|Drug|erlotinib|Erlotinib will be taken orally daily.
1699195|NCT01472016|Drug|ABT-700|ABT-700 will be administered by intravenous infusion on Day 1 and Day 15 in 28-day dosing cycles.
1699196|NCT01472003|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
1699197|NCT01472003|Drug|ABT-806i|ABT-806i will be administered by intravenous infusion.
1699198|NCT01471990|Drug|Pituitary Adenylate Cyclase-Activating Polypeptide-38|10 pmol/kg/min over 20 mins
1699199|NCT01471990|Drug|Vasoactive Intestinal Peptide|8 pmol/kg/min over 20 mins
1699200|NCT01471977|Other|education,counseling, default tracers,quality of care|these interventions were administered along with standard treatment i.e. DOTS at the time of standard follow up of patients at clinic
1699201|NCT01471964|Drug|MLN8237 and Erlotinib|Erlotinib pills once every day and MLN8237 pills twice every day, day 1-7 of every 21 days
1699202|NCT01471951|Other|Single embryo transfer in women at risk of multiple pregnancies|Prospective study of single embryo transfers in selected women with good reproductive prognosis and high risk of multiple pregnancies in an IVF-ICSI program.. The day of the embryo transfer, the patients will be randomized by a computer application for morphological and morphometric embryo selection.
1699203|NCT01471925|Drug|Nexium®|
1699204|NCT01471925|Drug|Esomeprazol (40mg) + Sdium Bicarbonate (721mg)|
1699205|NCT01471912|Procedure|pars plana vitrectomy and fluid gas exchange|A three-port standard pars plana vitrectomy was performed by a single surgeon using a 23-gauge vitrectomy system, either Associate®(Dutch Ophthalmic Research Center. Inc., Zuidland, The Netherlands) or Accurus®(Alcon Laboratories Inc., Fort Worth, USA), with one step scleral tunnel incision. In all cases, the peeling of the internal limiting membrane, approximately 1 disc diameter area from center of MH was conducted without assistance of dyes followed by complete fluid-gas exchange using 25% sulfur hexafluoride gas. Combined cataract surgery was performed in patients with visually significant cataracts or with incipient cataract in the subjects older than 60 years. All patients were instructed to maintain a face-down position for at least 7 days postoperatively.
1699206|NCT01471899|Drug|Ketorolac Tromethamine|10 drops each 8 hours for 4 days.
1699207|NCT01471899|Drug|Naproxen|2 tablets every 8 hours for 4 days
1758841|NCT00270088|Drug|epoetin alfa|
1699209|NCT01471886|Drug|Naproxen|Every 8 hours for 4 days.
1699210|NCT01471873|Procedure|Corneal Collagen Cross-linking (CXL)|"The same surgical procedure was applied to all CXLG patients that included:
Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation. In details, an 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2.The UVA radiation source that was used is the UV-XTM (IROC AG, Zurich, Switzerland). Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation, as well."
1699211|NCT01471860|Device|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
1699212|NCT01471847|Drug|BEZ235 + Trastuzumab Phase l/Phase ll)|"Phase l: Patients will receive increasing doses of oral BEZ235 (BID) together with standard weekly trastuzumab at a fixed dose. BEZ235 doses will be escalated in cohorts of 3 to 6 patients guided by an adaptive Bayesian logistic regression model with overdose control until MTD/RP2D has been established.
Phase ll: If randomized to the trastuzumab + BEZ235 arm, patients will receive standard weekly trastuzumab in combination with oral BEZ235 (BID) at the MTD or RP2D and will continue on study treatment until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met. They will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy)."
1699213|NCT01471847|Drug|Lapatinib + Capecitabine (Phase II)|"If randomized to the lapatinib + capecitabine treatment arm, patients will receive standard lapatinib plus capecitabine until PD, unacceptable toxicity or until other pre-defined discontinuation criteria are met.
Patients will have regular safety assessments and will be evaluated for response to treatment according to RECIST every 2 cycles for the first 36 weeks then every 12 weeks until disease progression (or start of new anti-neoplastic therapy). After progression, survival f-up will continue.
All patients participating in the Phase II part of the study will be required to have available archival or fresh tumor tissue for biomarker analysis prior to treatment start"
1699214|NCT01471834|Device|Barostim Neo System|Baroreflex Activation Therapy using the Barostim Neo System
1699215|NCT01471821|Drug|antiretroviral treatment|antiretroviral treatment
1699216|NCT01471808|Drug|CSII|continuous subcutaneous insulin infusion for 2~4 weeks
1699217|NCT01471808|Drug|CSII, Metformin, Pioglitazone|CSII for 2~4 weeks combined with metformin 1.5g/d and pioglitazone 30mg/d for 3 months.
1699218|NCT01471808|Drug|CSII, Sitagliptin|CSII for 2~4 weeks combined with sitagliptin 100mg/d for 3 months
1699219|NCT01471782|Biological|Blinatumomab|Administered by continuous intravenous infusion
1699220|NCT01471769|Behavioral|Pain management video|6-minute video
1699221|NCT01471769|Behavioral|Falls Prevention Video|6-minute video
1699222|NCT01471756|Procedure|Standard of Care Procedure as described in ARM|Standard of Care Procedure as described in ARM
1699223|NCT01471743|Dietary Supplement|Impact Advance Recovery (R)|
1699224|NCT01471743|Dietary Supplement|Ensure Plus (R)|
1699225|NCT01471730|Drug|Fibrinogen|All the patients randomized and not withdrawn will be tested 20 minutes before removal of aortic cross clamping with a Thromboelastometric fibrinogen test FIBTEM (Rotem) . They will all receive either human fibrinogen concentrate (according to the formula: (22 [mm] − MCF [mm]) * body weight [kg] / 140 [m] = whole g fibrinogen to be dosed as HFC) (treatment group) or placebo (control group). Study drug or placebo has to be administered after protamine.
1699226|NCT01471730|Drug|Saline solution|Normal saline will be administered to control patients.
1699227|NCT01471730|Drug|Prothrombin complex|After 15min from study drug administration and in presence of ongoing microvascular bleeding, we run a CT EXTEM. In case of prolonged CT time at EXTEM as long as 80 seconds [M1] , they will receive coagulation factors concentrates (Confidex) at a weight-based dose of 7 U/kg b.w. (treatment group) or placebo.
1699228|NCT01471717|Drug|INX-08189 50 mg QD X 5 days|Cohort 1: Subjects will begin administration of INX-08189 50 mg QD on Study Day 0. Dosing will occur each morning for 5 days after a fast of at least 8 hours prior to each dose on Study Days 0 through 4. INX-08189 will be administered with water, and subjects will remain fasting for 2 hours following each dose.
1699229|NCT01471717|Drug|INX-08189 / Victrelis 800 mg TID X three days|Cohort 1: INX-08189 50 mg QD will be administered concurrently with Victrelis 800 mg TID for 3 additional days (Study Days 5 through 7)
1699230|NCT01471717|Drug|Victrelis 800 mg TID x 3 days|In Cohort 2, subjects will begin administration of Victrelis 800 mg TID on the morning of Study Day 0. Victrelis will be administered with water and food with doses at least 7 hours apart. Victrelis 800 mg TID will be administered for a total of 3 days (Study Days 0 through 2).
1699231|NCT01471717|Drug|Victrelis 800 mg TID with INX-08189 50 mg QD|Victrelis 800 mg TID will be administered concurrently with INX-08189 50 mg QD for 5 additional days (Study Days 3 through 7).
1699232|NCT01471717|Drug|Placebo with Victrelis 800 mg|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
1699233|NCT01471717|Drug|Cohort 2: Victrelis 800 mg with Placebo|During combination dosing with INX-08189 and Victrelis, each morning dose will start with INX-08189 or placebo after at least an 8 hour fast, followed by a 2 hour fast with the first Victrelis dose of the day then administered with food.
1699234|NCT01471704|Drug|INX-08189 50 mg|Study Day 0: Single 50 mg dose of INX-08189 in the morning
1699235|NCT01471704|Drug|240 mg verapamil HCL ER|Study Days 6 to 11: 240 mg verapamil HCL ER once daily (QD) in the morning
1699236|NCT01471704|Drug|50 mg dose of INX-08189 and 240 mg verapamil HCL ER|Study Day 12: Co-administration of single 50 mg dose of INX-08189 and 240 mg verapamil HCL ER in the morning
1699237|NCT01471691|Drug|ranibizumab 0.5mg|Standard dose
1699238|NCT01471691|Drug|ranibizumab 1.0mg|High dose
1699239|NCT01471678|Drug|Dutasteride (0.5mg)|This study is an open-label, randomized, single dose, four-period cross-over study.
1699240|NCT01471678|Drug|FDC product of dutasteride (0.5mg) and tamsulosin HCl (0.2mg)|FDC (with 10% enteric coated tamsulosin pellets); (2): FDC (with 15% enteric coated tamsulosin pellets);
1758842|NCT00270101|Drug|epoetin alfa|
1699241|NCT01471678|Drug|Harnal D Tablets and Harnal Capsules (both comprising 0.2 mg tamsulosin HCl)|a commercial formulation of dutasteride plus tamsulosin HCl (Harnal-D Tablet); (4): a commercial formulation of dutasteride plus tamsulosin HCl(Harnal Capsule). Each dosing session will be separated by a wash-out period of 5 to 10 days
1699244|NCT01471652|Drug|Nutraceutical supplements|"CoEnzyme Q10: oral gel capsule bid
Acetyl L-carnitine: oral capsule bid
Alpha Lipoic Acid: oral tablet qd
Docosahexaenoic acid: oral gel capsule bid"
1699245|NCT01471652|Drug|Placebo|"Capsule form to imitate the following nutraceuticals:
Placebo 1: oral gel capsule bid
Placebo 2: oral capsule bid
Placebo 3: oral tablet qd
Placebo 4: oral gel capsule bid"
1699246|NCT01471639|Drug|intranasal ketorolac|15 mg
1699247|NCT01471626|Device|polysomnograph Dream and Sleep Box|Portable polysomnograph will be placed at home around 7:00PM. The Sleep Box (wireless monitoring device) will be left near the patient, to allow real-time GPRS transmission of recorded sleep parameters to the sleep lab.
1699248|NCT01471613|Procedure|Conventional Treatment|Conventional treatment includes surgeries such as laminectomy, spinal decompression etc. and the medicine generally adapted to treat spinal cord injury
1699249|NCT01471613|Drug|Lithium Carbonate Tablet|250mg/tablet, administrated orally for 6 weeks.
1699250|NCT01471613|Biological|Cord Blood Cell|Cord blood mononuclear cell, 6.4 million viable cells, are transplanted into spinal cord at upper and lower edges of the injured site
1699251|NCT01471613|Other|Placebo|Placebo tablet, orally administration of placebo for 6 weeks
1699252|NCT01471600|Procedure|group drink|group glucose drink : 200 ml of fruit juice without pulp, ± 200ml coffee or tea, 2 at 4 hours before induction of anaesthesia
1699253|NCT01471574|Drug|Daclatasvir|Tablets; oral; 30, 60, or 90 mg; once daily; up to 24 weeks
1699254|NCT01471574|Drug|Ribavirin|Tablets; oral; for patients weighing <75 kg, the total dose is 1000 mg per day (2 200-mg tablets in the morning and 3 200-mg tablets in the evening); for patients weighing >75 kg, the total dose is 1200 mg per day (3 200-mg tablets in morning and 3 200-mg tablets in evening); twice daily with food; 24 or 48 weeks depending on response
1699255|NCT01471574|Drug|PEG-Interferon alfa 2a|Syringe, subcutaneous injection, 180 μg, once weekly, 24 or 48 weeks depending on response
1699256|NCT01471548|Drug|TKI258|
1699257|NCT01471535|Drug|Pegylated interferon alfa-2a|patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland)180 µg by subcutaneous injection once weekly for 120 weeks
1699263|NCT01471509|Other|water, glucose with or without amino acid|240 ml water, 50 g glucose ± 1 mmol amino acid/kg lean body mass
1699264|NCT01471496|Procedure|prophylactic injection therapy|Standard application of endoscopic injection therapy as it is used for actively bleeding ulcers, 10 ml of serum saline with 1/10000 epinephrine is submucosally injected to the four quadrants of the ulcer margins.
1699265|NCT01471483|Behavioral|geriatric assessment and telephone call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. The patient will receive a phone call once a week by a nurse who is an expert in caring for older patients. He/she will be asking questions about symptoms, medications and support at home. Each call is designed to last less than 30 minutes.
1699266|NCT01471483|Other|geriatric assessment and no call from nurse|The geriatric assessment will be completed at four time points: 1) on the day the patient receives a new chemotherapy regimen or within 30 days prior, 2) within 30 days of completion of the chemotherapy regimen (or at 12 months from study entry +/-30 days if the chemotherapy regimen is still being continued), 3) within 30 days prior to surgical debulking, and 4) 30 days after surgical debulking. They will not receive the phone calls, questions and symptoms will be addressed directly by the doctors and nurses on the medical and surgical teams.
1699267|NCT01471470|Drug|Docetaxel, Capecitabine, Cisplatin, Bevacizumab|Bevacizumab 7.5mg/kg IV (D1) Docetaxel 60 mg/m2 IV (D1) Cisplatin 60 mg/m2 IV (D1) Xeloda 1,875 mg/m2/day/bid PO (D1-D14)
1699268|NCT01471457|Drug|Trimo-San gel|Pessary wearers are instructed to apply one fingertip (approx 1 tablespoon) of Trimo-San gel inside the vagina or to the pessary (for women removing and cleaning pessary before reinsertion after cleaning) once nightly
1699269|NCT01471444|Drug|Fludarabine|"Flu + Bu Group: 40 mg/m2 by vein on Days -6 through -3.
Flu +Clo + Bu Group: 10 mg/m2 by vein on Days -6 through -3."
1699270|NCT01471444|Drug|Clofarabine|30 mg/m2 diluted in normal saline to produce a final concentration of 0.4 mg/mL, and infused on Days -6 through -3.
1699271|NCT01471444|Drug|Busulfan|Busulfan systemic exposure dose of 6000 µMol-min in normal saline over three (3) hours by vein every twenty-four (24) hours for four (4) consecutive days (days -6 to -3), starting immediately after the completion of Clofarabine. The dose on day -6 to -3 based on pharmacokinetic analysis of target AUC of 4,000 µMol-min ± 5% for 61-70 years of age (without Pharmacokinetics alternate dose 130 mg/m2).
1699272|NCT01471444|Drug|Thymoglobulin|"Both groups who receive a graft from an unrelated donor:
0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.0 mg/kg on day -1. On day -3, administered after the chemotherapy is complete."
1699273|NCT01471444|Procedure|Stem Cell Infusion|Cryopreserved bone marrow or peripheral blood progenitor cells infused on day 0.
1699274|NCT01471444|Drug|Tacrolimus|Starting dose: 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Changed to oral dosing when tolerated and can be tapered off after day +90 if no graft versus host disease (GVHD) present.
1699275|NCT01471444|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3, 6 and 11 post transplant.
1699276|NCT01471431|Other|spontaneous breathing trial|"The SBT is performed daily on rounds if an infant is on conventional ventilation and meets all predetermined ventilator criteria (set ventilator rate ≤30, peak inspiratory pressure (PIP) delivered on mandatory breaths ≤20 cm H2O, pressure support (PS) ≤8 cm H2O, positive end-expiratory pressure (PEEP) ≤6 cm H2O, inspired fractional oxygen (FiO2) ≤0.40).
During the SBT, the ventilator rate and pressure support are set to zero, and the infant is maintained on continuous positive airway pressure (CPAP) alone via the endotracheal tube. The trial duration is 3 minutes, unless an infant fails before the trial is complete. Failure is defined as bradycardia <100 for >15 seconds or oxygen saturation by pulse oximetry <85% despite a 15% increase in FiO2. If an infant passes the SBT, they are extubated within 3 hours. If an infant fails the SBT, they remain intubated and the daily application of the SBT continues as long as the minimum ventilator criteria are met."
1699277|NCT01471418|Drug|PET/CT with 18-FDG|FDG uptake
1699278|NCT01471392|Device|STD Diagnostic Kit (Identigene)|The Identigene STD Test Collection Kit is an at-home kit that allows individuals to utilize the Gen-Probe technology to test for CT and NG in privacy and in a more convenient manner. The primary technology is the approved Gen-Probe APTIMA Combo 2 assay, which is repackaged into the Identigene kit for use by consumers. As such, the laboratory technology and testing method is identical to that of the Gen-Probe APTIMA Combo 2 assay, which has been cleared for in vitro diagnostic use.
1699279|NCT01471379|Drug|Milnacipran|50mg Milnacipran PO, BID, for 6 weeks.
1699280|NCT01471379|Drug|Milnacipran|Milnacipran, 100mg PO, BID, for six weeks
1699281|NCT01471379|Drug|Milnacipran|Milnacipran, 50mg PO BID for 12 weeks
1699282|NCT01471379|Drug|Placebo|Inactive pill, identical in shape, size, and appearance to active drug, PO, BID.
1699283|NCT01471366|Dietary Supplement|Frozen capsule|Two frozen fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water without food or dairy products.
1699284|NCT01471366|Dietary Supplement|Capsule with food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with food but no dairy products
1699285|NCT01471366|Dietary Supplement|Capsule without food|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of water with no food or dairy products
1699286|NCT01471366|Dietary Supplement|Capsule with milk|Two room temperature fish oil capsules (300 mg EPA/DHA per capsule) by mouth three times daily with 8 ounces of milk with no food or additional dairy products
1699287|NCT01471353|Drug|Sorafenib Plus Capecitabine (SorCape)|Sorafenib 200-400 mg PO twice daily on days 1-21 (dose escalation schema) plus Capecitabine 1000 mg/m2 PO twice daily on days 1-14 repeated every 21 days
1699288|NCT01471340|Drug|Mometasone Furoate/Formoterol MDI 100/5 mcg|two inhalations twice daily (BID)
1699289|NCT01471340|Drug|Mometasone Furoate/Formoterol MDI 200/5 mcg|two inhalations BID
1699290|NCT01471340|Drug|Mometasone Furoate MDI 100 mcg|two inhalations BID
1699291|NCT01471340|Drug|Mometasone Furoate MDI 200 mcg|two inhalations BID
1699292|NCT01471340|Drug|Albuterol 90 mcg /salbutamol 100 mcg HFA MDI|use as needed for asthma symptoms
1699293|NCT01471340|Drug|Prednisone/prednisolone|Oral prednisone/prednisolone used only as an emergency rescue medication at the discretion of the investigator
1699294|NCT01471327|Biological|SB-240563|10mg, 75mg, 250mg and 750mg IV, single dose on Day 1
1699295|NCT01471327|Other|Placebo|Saline IV, single dose at Day 1
1699296|NCT01471314|Behavioral|Headache day versus non-headache day|
1699297|NCT01471288|Drug|Carum Cravi|40mg/kg of body weight
1699298|NCT01471288|Drug|Placebo|Placebo
1699299|NCT01471275|Drug|Metformin|250 mg or 500mg three times a day
1699300|NCT01471275|Drug|Jiangtangtiaozhi decoction|15 grams each time, twice a day, with boiled water
1699301|NCT01471262|Procedure|Right hepatectomy|Right liver resection
1699302|NCT01471262|Procedure|Extended right hepatectomy|Right hepatectomy involving 5 or more segments
1699303|NCT01471236|Device|Agili-C Bi-phasic Implant|"The implantation site should be created in perpendicular manner to the articular cartilage. The surrounding tissue will be cleaned and scraped to prepare a clean site. The implant will be placed in the correct orientation (drilled channels pointing towards the joint side and chamfer towards the bone).
The implant will be inserted gently in a pressed fit manner."
1699304|NCT01471236|Procedure|mini-arthrotomy|"The procedure will be conducted according to hospital practice. The implants will be positioned via open incision, depending on lesion location, and Investigator`s final decision. Related treatments during the procedure should be recorded.
Device positioning details medications and adverse events during the procedure will be recorded. MOCART (off-site), X-ray evaluation (off-site), ICRS Cartilage injury mapping system, Articular cartilage injury Classification and the Osteochondritis Dissecans classification will be recorded."
1699305|NCT01471210|Drug|Urelumab (BMS-663513)|
1699306|NCT01471197|Biological|Ipilimumab|Intravenous (IV) solution, IV, 10mg/kg, Once every 3 weeks for 4 doses, then once every 12 weeks during Treatment Phase, 90 minute infusion
1699307|NCT01471197|Biological|Pemetrexed|IV solution, IV, 500 mg/m2, Once every 3 weeks during Treatment Phase, 10 minute infusion.
1699308|NCT01471184|Device|Ectoin® Allergy Nasal Spray and Ectoin® Allergy Eye Drops|
1699309|NCT01471184|Device|Placebo|Placebo Eye Drops/Nasal Spray
1699310|NCT01471171|Drug|Aclidinium Bromide|1 puff of 400 micro grams in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
1699311|NCT01471171|Drug|Placebo|1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h)
1699371|NCT01470742|Drug|XELOX|D1-14 Capecitabine 1000mg/m2 bid D1 Oxaliplatin 110mg/m2 + D5W 250ml over 2hr every 3weeks
1699312|NCT01471158|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|Brinzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
1699313|NCT01471158|Drug|Dorzolamide/timolol Maleate Fixed Combination (COSOPT)|Dorzolamide/timolol maleate fixed combination, one drop instilled in one eye at baseline, followed by one drop instilled in each eye once in either first intervention period or second intervention period.
1699314|NCT01471145|Drug|Naltrexone|naltrexone for extended-release injectable suspension, 380 mg/vial, every 4 weeks or once a month
1699315|NCT01471132|Drug|Oxaliplatin|Oxaliplatin 345mg/m2,43℃，30mins
1699316|NCT01471132|Drug|Paclitaxel|Paclitaxel 260mg/m2,43℃，30mins
1699317|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 1|Dermatophagoides Farinae Drops Group 1 is the group with maintenance dose of 2 drops of grade 5 Dermatophagoides Farinae and 1 drop of placebo.
1699318|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 2|Dermatophagoides Farinae Drops Group 2 is the group with maintenance dose of one drop of grade 5 Dermatophagoides Farinae and 2 drop of placebo.
1699319|NCT01471119|Biological|Dermatophagoides Farinae Drops Group 3|Dermatophagoides Farinae Drops Group 3 is the group with maintenance dose of 3 drops of grade 4 Dermatophagoides Farinae.
1699320|NCT01471119|Biological|Placebo|Placebo Group is the group with maintenance dose of 3 drops of placebo.
1699322|NCT01471093|Drug|OPC-12759 Ophthalmic solution|2％ OPC-12759 Ophthalmic solution
1699323|NCT01471093|Drug|OPC-12759 Ophthalmic suspension|2％ OPC-12759 Ophthalmic suspension
1699324|NCT01471080|Procedure|RFA|using RFA to treat cavernous hemangiomas
1699325|NCT01471080|Procedure|hepatectomy|using hepatectomy to treat cavernous hemangiomas
1699326|NCT01471067|Drug|Melphalan|140 mg/m2 by vein on Day -2 only for Fludarabine + Melphalan group.
1699327|NCT01471067|Drug|Fludarabine|10 mg/m2 by vein on Days -7 to -4 for Melphalan + Thiotepa + Fludarabine group, or 40 mg on Days -5 to -2 for Fludarabine + Melphalan group.
1699328|NCT01471067|Drug|Mycophenolate mofetil|15 mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or by mouth twice a day from Days -3 to +100 in the absence of Graft vs Host Disease (GvHD).
1699329|NCT01471067|Drug|Tacrolimus|Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no Graft vs Host Disease (GvHD) is present.
1699330|NCT01471067|Procedure|Cord Blood Infusion|Cord blood infusion on Day 0. Each participant will receive cells from one unexpanded cord blood sample plus cells from a second cord blood sample that has undergone fucosylation.
1699331|NCT01471067|Drug|Rituximab|375 mg/m^2 by vein on Day -10 for B cell malignancy.
1699332|NCT01471067|Drug|ATG|"1.25 mg/Kg by vein on Day -4.
1.75 mg/Kg by vein on Day -3."
1699333|NCT01471067|Drug|Busulfan|Busulfan per standard of care, test dose either as an outpatient prior to admission or as an inpatient on Day -9. Busulfan pharmacokinetics performed with test dose and the first dose on Day -7 per standard of care. Doses of Days -5 and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1.
1699334|NCT01471067|Drug|Clofarabine|30 mg/m^2 IV Day -7 to Day -4;
1699335|NCT01471067|Radiation|Total Body Irradiation (TBI)|2 Gy in AM of Day -3.
1699336|NCT01471054|Drug|Ozurdex|"Eyes in the Ozurdex group can have a maximum total of three Ozurdex insertions in the first 12 months after enrolling into the study. The criteria for retreatment with Ozurdex are:
i.The study eye must have shown initial favorable response to prior Ozurdex implant (>10% decrease in central macular thickness with maintenance [change in BCVA of <=1 line] or improvement of visual acuity [increase of BCVA of >1 line]) ii. Interval since last Ozurdex implant should be > 4 and < 12 months. iii. The study eye must show definite evidence of recurrence of macular edema."
1699337|NCT01471054|Drug|Bevacizumab|Eyes in the Bevacizumab group can have a maximum total of twelve bevacizumab injections in the first year after enrolling into the study. All patients will receive 6 monthly injections after entering the study. After the sixth injection (at month 5) the interval between injections will be extended to 6 weeks if the study eye has shown initial favorable response to prior intravitreal bevacizumab.
1699338|NCT01471041|Device|Venous Window Needle Guide|Subcutaneous, extravascular needle guide made of medical-grade titanium
1699339|NCT01471028|Biological|ELAD treatment|ELAD treatment consists of treatment with an extracorporeal liver assist system.
1699340|NCT01471028|Other|Standard of care (Control)|Control receives standard medical treatment.
1699341|NCT01471015|Drug|Darbepoetin alfa|10 mcg/kg/dose x2, with the first dose given as IV within 12 hours of delivery and the second dose given as IV or SQ at 7 days old.
1699342|NCT01471015|Drug|Darbepoetin alfa|2 mcg/kg/dose x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old.
1699343|NCT01471015|Drug|Placebo|Placebo given x2, with the first dose given IV within 12 hours of delivery and the second dose given IV or SQ at 7 days old
1699344|NCT01471002|Device|Galil Medical patented 17G Cryoablation Needles|
1699345|NCT01470989|Drug|ACZ885|canakinumab 150 mg s.c., given on demand upon new flares
1699346|NCT01470976|Other|Goal-directed Resuscitation Therapy (GDT)|"A target value of a cardiac index (CI) greater than 3.0 L/min/m2 will be sought.
The first step will be fluid resuscitation with 250ml aliquots of Lactated Ringer's solution whenever the CI is lower than 3,0 L/min/m2 and systolic volume index (SVI) is lower than 35ml/m2. The fluid challenge will be stopped if the CVP rises by more than 4 mmHg during the infusion period.
When the CI is lower than or equal to 3,0L/min/m2 and SVI higher than or equal to 35 ml/m2, dobutamine will be initiated with increasing doses up to 20mcg/kg/min.
The final step will be red blood transfusion to reach a hematocrit higher than 28%."
1699347|NCT01470976|Other|Standard protocol|The control group will be managed by the anesthetic team in the operative room and by the surgical ICU staff in the postoperative period according to institutional protocol of hemodynamic monitoring.
1699348|NCT01470963|Other|Implementation of referral template|Implementation of referral template at the GP office
1699349|NCT01470950|Procedure|Motionmaker|3 times per week, FES Training on the Motionmaker device, for 6 months
1699350|NCT01470937|Drug|Acarbose|acarbose 100 mg PO once daily
1699351|NCT01470937|Drug|Placebo|acarbose placebo
1699352|NCT01470911|Drug|SB010|"Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
Dose level (DL) 1: 0.4 mg hgd40/2 mL; DL 2: 2 mg hgd40/2 mL; DL 3: 5 mg hgd40/2 mL; DL 4: 10 mg hgd40/2 mL; DL 5: 20 mg hgd40/2 mL; DL 6: 40 mg hgd40/2 mL."
1699353|NCT01470911|Drug|Placebo|Six ascending dose groups (DG) are planned, with a total of 48 subjects. DG 1 and 2 will consist of n=6 subjects (n=3 receiving SB010, n=3 placebo). The following DG will consist of n=9 subjects (n=6 receiving SB010, n=3 placebo). The number of subjects to be exposed to active compound will be limited on a particular study day. Subjects of a particular DG will be divided into subgroups and exposed to the drug on different days. In DG 1 and 2, the time interval between the two administrations of the first subgroup will be at least 2 hours. In DG 3-6, the time interval between two subsequent administrations will be at least 1 hour.
1699354|NCT01470898|Device|bispectral index monitoring|A BIS sensor was applied to patient's forehead before induction of anesthesia and connected to A-2000 BIS monitor (Aspect Medical Systems, Newton, MA, USA). It records the electroencephalogram from 4 electrodes and after processing it with mathematic algorithms it generates a number from 0 to 100. When the BIS value is lower than 40, the patient is in deep anesthesia state, when the value is over 80, the patient is under light sedation.At the induction of anesthesia, and every 15 minutes during operation following parameters were recorded: heart rate (HR), systolic blood pressure (BP), end-tidal CO2 (etCO2) and BIS level. Also, operation time and extubation time were recorded. Finally, all patients were visited on the first postoperative day and interviewed about intraoperative recall.
1699355|NCT01470859|Drug|pramipexole|tablets, 0.375mg-4.5mg/day divided by 3 times according to the optimal improvement of motor dysfunction in PD patients. duration is 1 year.
1699356|NCT01470859|Drug|Sinemet CR|tablet of Sinemet CR, dosage of levodopa ranging from 200mg-600mg/day divided by 2 or 3 times, Duration is 1 year
1699357|NCT01470846|Procedure|epidural analgesia|thoracic position (T8-T9 or T11-T12) depending on the site of surgery
1699358|NCT01470846|Procedure|PCA|Morphine 2 mg / 10 min (no max dose) + droperidol 2.5 mg / 50 mL.
1699359|NCT01470833|Procedure|Early weight-bearing|"The group allowed early weight-bearing is instructed as follows:
Week 1 to 2 Weight-bearing is allowed with in pain limit. Crutches are recommended.
Week 3 to 4 Full weight-bearing is allowed. Week 5 to 8 Full weight-bearing is allowed. Crutches should be avoided.
Dynamic rehabilitation From day 15 patients of both groups must do ankle exercises. Minimum 5 times a day the patient must take of the orthosis. Sitting at a table with the leg hanging freely over the edge a series of 25 active dorsal flexion and passive plantar flexion exercises must be made."
1699360|NCT01470820|Other|Phototherapy with blue light|The infants were placed in a bassinet with the phototherapy device placed above them. All infants were exposed naked (apart from eye pads and diaper) to continuously phototherapy for 24 hours, interrupted only for feeding and nursing for 30 minutes every three hours. TsB was determined before phototherapy and after 24 hours of treatment. The phototherapy apparatus used was neoBLUE LED phototherapy device (Natus Medical Inc., San Carlos, CA, USA) emitting blue light with an emission peak at 460 nm and a bandwidth of 450-470 nm. The irradiance was measured by use of the neoBLUE LED phototherapy radiometer (Natus Medical Inc.) every 8th hour at the infants head, trunk and knees and the average was calculated. The radiometer measures spectral irradiance in the range 420-500 nm with maximum sensitivity in the spectrum 440-480 nm.
1699361|NCT01470807|Device|portable artificial pancreas system with CTR algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
1699362|NCT01470794|Biological|Toca 511|All subjects will receive Toca 511, a retroviral replicating vector that expresses the cytosine deaminase (CD) gene. CD converts the antibiotic 5-FC to the anti-cancer drug 5-FU in cells that have been infected by the Toca 511 vector. Beginning approximately 6 weeks after administration of Toca 511, subjects will take a course of oral 5-FC. These courses of 5-FC will be repeated cyclically during the 6-month study.
1699363|NCT01470781|Behavioral|BrainWorks|"13 programs targeting cognition in 4 separate domains: Auditory processing, visual processing, social cognition, and executive functioning. Games are imbedded in a format that is engaging and interactive. Animated characters serve as directors for each program, explaining the tasks in both verbal and written formats and providing feedback on each trial and overall after each activity. Users move systematically through the programs and can track their progress as the go. Each session includes activities from several different games to maintain interest and train a variety of skills; however, games are presented in the order of domains listed above (i.e. auditory, then visual, then social, and finally executive) to avoid stimulus interference during the training."
1699364|NCT01470781|Behavioral|Computer Control|"Sessions will involve generic computer games administered via the game interface Sporcle. Sporcle is a game site that offers a collection of quiz-type activities available on line. The activities include typing, basic timed arithmetic (e.g. simple addition); picture identification (e.g. name the corporate logo; name the sitcom), and subject-based quizzes in areas like history (e.g. name the US presidents), geography (e.g. name the state capitals), and literature (e.g. book title fill-in-the-blank). An administrator can track the activity of subjects including when they logged in, which games they played and for how long, and what their accuracy was on each game. We will use a pre-developed game schedule that includes a mix of each type of game in each session, and ensures that subjects are playing the same games in the same order. This format was developed to mirror the treatment condition, as subjects are given a variety of specific games to play at each session."
1699365|NCT01470768|Other|Amino Acid-based Formula with high DHA and ARA|
1699366|NCT01470768|Other|Amino Acid-based Formula with lower DHA and ARA|
1699367|NCT01470755|Drug|salbutamol|Metered dose inhaler, 100µg+300µg per puff, administered one day
1699368|NCT01470755|Drug|Salbutamol - dose2|Metered dose inhaler, 100µg+500µg per puff, administered one day
1699369|NCT01470755|Drug|Salbutamol -dose3|Metered dose inhaler, 200µg+600µg per puff, administered one day
1699370|NCT01470755|Drug|salbutamol -dose4|Metered dose inhaler, 200µg+200µg per puff, administered one day
1699859|NCT01466881|Other|Pharmacological Study|Correlative studies
1699372|NCT01470742|Drug|XELODA|Capecitabine 1000mg/m2 bid D1-14 every 3weeks
1699373|NCT01470729|Other|metabolic and imaging biomarkers in SCA1,2,3 and 7 patients|MRI, a bone mineral density and a resting metabolic rate assessments, as well as donating fasted blood samples
1699374|NCT01470716|Drug|Erlotinib|Neo-adjuvant Erlotinib treatment during maximum 8 weeks.
1699375|NCT01470703|Device|ECMO (Quadrox®, Jostra®, Maquet®)|ECMO will be initiated as rapidly as possible by venovenous access. The material to be used consists of pre-heparinized cannulae and tubing, a centrifuge pump (CardioHelp®) and a heparinized membrane oxygenator (Quadrox®, Jostra®, Maquet®). To minimize the trauma induced by mechanical ventilation, the following ventilator settings will be used: volume-assist control mode, FiO2 30-60%, PEEP ≥10 cm H2O, VT lowered to obtain a plateau pressure <25 cm H2O, respiration rate (RR) 10-30/minute or APRV mode with high pressure level <25 cm H2O and low pressure level ≥10 cm H2O
1699376|NCT01470703|Other|conventional care|Standard management of ARDS, according to the modalities applied by the 'maximal pulmonary recruitment' group in the EXPRESS trial (1): assist-controlled ventilatory mode, VT set at 6 ml/kg of ideal body weight and PEEP set so as not to exceed a plateau pressure of 28-30 cm H2O. In the case of refractory hypoxemia, the usual adjunctive therapeutics can be used: NO, prone position, HFO ventilation, almitrine infusion. A cross-over option to ECMO will be possible in the case of refractory hypoxemia defined as blood arterial saturation SaO2 <80% for >6 hours, despite mandatory use of recruitment maneuvers, and inhaled NO/prostacyclin and if technically possible a test of prone position, and only if the patient has no irreversible multiple organ failure and if the physician in charge of the patient believes that this could actually change the outcome
1699377|NCT01470690|Drug|boceprevir|Boceprevir 800 mg TID for 4 consecutive days + a single dose of 800 mg on Day 5
1699378|NCT01470690|Drug|Omeprazole|Omeprazole 40 mg QD for 5 consecutive days
1699379|NCT01470677|Drug|Tachosil fibrin patch|A Tachosil® patch of 4.8x4.8cm will be attached to the obturator fossa and a Tachosil® patch of 4.8x4.8cm will be attached to the femoral canal of each side of surgery in the intervention group. In the control group, no Tachosil® patch will be used. No specific drainage of the retroperitoneum will be performed.
1699380|NCT01470664|Drug|FST-100|FST-100
1699381|NCT01470664|Drug|FST-100 (Component #1)|FST-100 (Component #1)
1699382|NCT01470664|Drug|FST-100 Vehicle|FST-100 Vehicle
1699383|NCT01470651|Drug|Armodafinil|50mg - 250mg pills, taken each morning, for 14 weeks
1699384|NCT01470651|Drug|Sugar Pill|Inactive pill, matched to look like active medication
1699385|NCT01470625|Other|LCP Program|The LCP Program is continuous quality improvement program of end-of-life care implemented in hospice
1699390|NCT01470586|Procedure|Surgery for colorectal cancer|Surgical resection of colorectal cancer
1699391|NCT01470573|Procedure|biological replacement corneal surface|the expanded tissue will be applied to patient to replace the damaged ocular surface
1699392|NCT01470560|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|Mindfulness-Based Stress Reduction (MBSR) was developed by Jon Kabat-Zinn in 1979. MBSR is a group-based intervention, typically provided to up to 30 participants, in a class-based format of eight weekly two hour sessions.
1699393|NCT01470560|Behavioral|Sham Yoga Group|Emphasis will be placed on healthy alignment and ways to pace and adjust poses to make them safe and productive for the body.
1699394|NCT01470534|Dietary Supplement|carbohydrate drink|carbohydrate drink
1699395|NCT01470534|Procedure|Muscle biopsy|Open muscle biopsy
1699396|NCT01470534|Procedure|Blood sampling|Venopuncture
1699397|NCT01470534|Dietary Supplement|Placebo|
1699398|NCT01470521|Biological|Hookworm larvae|Hookworm larvae solution is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
1699399|NCT01470521|Biological|Placebo|Pharmacopoeial grade water is pipetted onto a plaster dressing which is then placed on the upper forearm for 24 hours. This is administered only once.
1699400|NCT01470508|Behavioral|Cognitive Behavioral Therapy|Individuals meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy is manualized and is the standard form of care at the UNC Eating Disorders Program.
1699401|NCT01470508|Behavioral|Cognitive Behavioral Therapy with Family Enhancement|Individuals will meet with a therapist once a week for 25 sessions, 50 minutes in length, for a period of 27 weeks for therapy. Cognitive Behavioral Therapy with Family Enhancement is manualized and will involve the participation of family members during six (6) weeks of treatment.
1699402|NCT01470495|Other|RFA + Sorafenib|combined RFA and Sorafenib to treat recurrent HCC
1699403|NCT01470495|Other|RFA|treat Recurrent HCC with RFA
1699404|NCT01470482|Procedure|No use of tourniquet|Tourniquet is not applied i 25 pts
1699405|NCT01470482|Procedure|Tourniquet|Use of tourniquet
1699406|NCT01470469|Drug|SPD503 (extended-release Guanfacine hydrochloride)|Once-daily oral dosing of SPD503 in the evening ranging from 1-6 mg for 12 weeks (6 week dose optimization and 6 week dose maintenance).
1699407|NCT01470469|Drug|Placebo|Once-daily oral dosing in the evening for 12 weeks.
1699408|NCT01470456|Drug|SAR3419|Pharmaceutical form:solution for infusion Route of administration: Intravenous
1699409|NCT01470456|Drug|rituximab|Pharmaceutical form:solution for infusion Route of administration: intravenous
1699410|NCT01470443|Drug|Oxaliplatin|Oxaliplatin 130mg/㎡, day 1, every 3 weeks
1699411|NCT01470443|Drug|Oxaliplatin|Oxaliplatin 100 mg/㎡, day 1, every 3 weeks
1699412|NCT01470417|Drug|Chemotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with low risk disease will have an additional two cycles of therapy (4 total cycles) prior to resection.
1699413|NCT01470417|Drug|Chemotherapy + ChemoRadiotherapy|Nab-paclitaxel 100 mg/m2 IV over 30 minutes on days 1, 8, and 15 along with gemcitabine 1000 mg/m2 IV over 30 minutes on days 1, 8, and 15 in an every 28 day cycle for two cycles. Subjects with high-risk or borderline resectable disease will receive additional chemotherapy with radiation therapy prior to resection.
1699414|NCT01470391|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with Ropivacaine
1699415|NCT01470391|Procedure|Femoral Nerve Block|US-guided Femoral Nerve Block with Ropivacaine
1699416|NCT01470378|Procedure|Thigh Surgery|Circumferential thigh surgery post bariatric surgery
1699417|NCT01470365|Procedure|quality-of-life assessment|Ancillary studies
1699418|NCT01470365|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1699419|NCT01470365|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional CRT
1699420|NCT01470352|Drug|Doluxetine|30 mg/d
1699421|NCT01470352|Drug|Placebo|suger pill 30mg/d
1699422|NCT01470339|Drug|duloxetine|duloxetine 60mg once a day for 5 weeks
1699424|NCT01470313|Drug|PD-0360324|Subjects will receive PD-0360324 intravenously in 3 different cohorts. The cohorts will be evaluated in ascending fashion. The doses planned are 100 mg every other week for 3 months, 150 mg every other week for 3 months, and 200 mg every 4 weeks for 3 months.
1699425|NCT01470313|Drug|Placebo|Placebo is normal saline. The timing of placebo administration will depend of the dosing frequency of the cohort (either every other week for 3 months or every 4 weeks for 3 months).
1699426|NCT01470300|Other|Energy density feeding study|In a crossover design, adults are served breakfast, lunch, and dinner, 1 day a week for 4 weeks. Meal entrees will vary in energy density (100% and 80%) and the method used to reduce the energy density (added fruit & vegetables, decreased fat, added plain water).
1699427|NCT01470287|Biological|DTwP-HepB-Hib Vaccine|Open label, Single arm study to evaluate immunogenicity, safety and tolerability of a fully liquid pentavalent (DTwP-HepB-Hib) vaccine in infants of 6-8 weeks of age.
1699428|NCT01470248|Drug|Arsenic Trioxide|Drug will be given as a loading dose of 0.32mg/kg/day for 4 days in Week 1, followed by 0.25mg/kg/day twice per week for 5 weeks, followed by 2 weeks of rest, at which time response assessment will be performed. Patients will be restaged prior to the beginning of a new cycle, every 2 months on average. Maximum of 6 cycles of therapy will be administered in the absence of tumor progression or excessive side effects
1699429|NCT01470222|Other|Weight loss intervention|Menu-based recommendations to consume a high fiber, low glycemic load diet with education on nutrition and behavior change.
1699430|NCT01470209|Drug|BKM120|BKM120 (20mg to 100mg) will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. BKM120 will be administered on a continuous once daily dosing schedule. Patients should be instructed to take the dose of BKM120 daily in the morning, one hour after a light breakfast (morning meal) at approximately the same time each day. BKM120 should be taken with a glass of water and consumed over as short a time as possible. Patients should swallow the capsules as a whole and not chew them. Patients should continue to fast for 2 hours after the administration of each BKM120 dose.
1699431|NCT01470209|Drug|Everolimus|RAD001 will be self-administered (by the patients themselves). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. RAD001 will be administered orally as once daily dose of 5mg or 10 mg (based on the dose cohort) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day.
1699432|NCT01470196|Drug|Dexamethasone|20 mg IV on Days 1, 2, 8, 9, of 21 day cycle for cycles 1-6 20 mg IV on Days 1, 2 of 21 day cycles q 2 months for cycles 1-8
1699433|NCT01470196|Drug|Carfilzomib|20 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycle 1 36 mg/m2 IV on Days 1, 2, 8, 9 of 21 day cycles for Cycles 2-6 36 mg/m2 IV on Days 1, 2 of 21 day cycles q 2 months for Cycles 1-8
1699434|NCT01470196|Drug|Rituximab|375 mg/m2 IV on Days 2, 9 of 21 day cycles for Cycles 1-6 375 mg/m2 IV on Day 2 of 21 day cycles q 2 months for Cycles 1-8
1699435|NCT01470170|Drug|Alfentanil|Give Alfentanil before TCI Propofol sedative bronchoscope
1699436|NCT01470170|Drug|Normal saline|Normal Saline (placebo comparator) was given in equivalent amount of alfentanil dosage in each arm, for double blinded purpose.
1699437|NCT01470170|Device|Targeted controlled infusion|The Propofol dosage was according to the effect site concentration to reach OAAS-3 ( loss of conscious), using Schneider model
1699438|NCT01470170|Drug|Propofol|The Propofol dosage is according to the effect site concentration to reach OAAS-3 ( loss of conscious), using TCI Schneider model during the whole procedure of bronchoscope
1699439|NCT01470157|Drug|Ketamine|5mg/kg as oral suspension
1699440|NCT01470157|Drug|Normal Saline|Normal Saline (placebo) in addition to Midazolam 0.5mg/kg as oral suspension
1699441|NCT01470144|Drug|Epoprostenol|Administered by continuous intravenous infusion via a central venous catheter; using an ambulatory infusion pump. The dose and infusion rate of EFI may be adjusted throughout the study in order to balance tolerability and maximum clinical benefit
1699442|NCT01470131|Drug|masitinib 6 mg/kg/day|masitinib 6 mg/kg/day
1699443|NCT01470131|Drug|placebo|matching placebo
1699444|NCT01470118|Drug|alcaftadine 0.25% ophthalmic solution|One drop of alcaftadine 0.25% ophthalmic solution instilled in each eye at Day 0 and Day 14.
1699445|NCT01470118|Drug|olopatadine 0.2% ophthalmic solution|One drop of olopatadine 0.2% ophthalmic solution instilled in each eye at Day 0 and Day 14.
1699446|NCT01470118|Drug|dextran 70 0.1%/hydroxypropyl methylcellulose 0.3%|One drop of placebo instilled in each eye at Day 0 and Day 14.
1699447|NCT01470105|Other|blood sampling, the SF-36 questionnaire|"The patient be asked to fill out a questionnaire. The questionnaire asks about their quality of life and will take approximately 15 minutes to complete. It will be completed at a regularly scheduled clinic visit.
At the scheduled pre-operative testing, an extra sample of your blood (equal to about 4 teaspoons) will be collected for research tests. The research tests will measure levels of inflammation in your body. These tests are not part of routine care. A physical examination of the operative site will be done by the Orthopaedic Surgeon. The patient will complete the same questionnaire at the regularly scheduled three and six month follow-up visit"
1699448|NCT01470092|Drug|Tibolone|Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
1699449|NCT01470053|Drug|mometasone furoate plus azelastine HCl|
1699450|NCT01470053|Drug|mometasone furoate|
1699451|NCT01470053|Drug|azelastine HCl|
1700066|NCT01465438|Drug|Adalimumab|Adalimumab 40 mg every other week
1699452|NCT01470040|Drug|discontinuation of aspirin therapy|discontinuation of aspirin therapy
1699453|NCT01470040|Drug|continuation of aspirin therapy|continuation of pre-injury low dose aspirin therapy as per previous medical indication
1699454|NCT01470027|Drug|N-acetylcysteine|900mg NAC effervescent tablets
1699455|NCT01470027|Drug|Placebo|effervescent tablets
1699456|NCT01470001|Drug|solifenacin|patient will receive solifenacin 5mg daily or placebo daily
1699457|NCT01469988|Drug|Testosterone|Patients will be dosed accordingly: Female: 0.3g once daily (or matching placebo) gel;Males: 5g once daily (or matching placebo) gel.
1699458|NCT01469975|Drug|OTSA101-DTPA-90Y level 1|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 370MBq of 90Y will be administered IV as a single injection on Day 0.
1699459|NCT01469975|Drug|OTSA101-DTPA-90Y level 2|Part 2 of the study 1.5 mg of OTSA101-DTPA radiolabelled with 1110 MBq of 90Y will be administered IV as a single injection on Day 0.
1699460|NCT01469975|Drug|OTSA101-DTPA-90Y level 3|"Part 2 of the study 3 mg of OTSA101-DTPA radiolabelled with 2220 MBq of 90Y will be administered IV as a single injection on Day 0.
This third dose level evaluation will be based on safety and preliminary efficacy data."
1699461|NCT01469949|Other|Watching or imagining movement|Mental imagery are administered in two forms : kinesthetic when subjects imagine the movement of flexion and extension of the lumbar spine and Visual when subjects watch a video of a third person doing the flexion and extension movement
1699462|NCT01469936|Dietary Supplement|PERMEAPROTECT|"Composition : glutamine, curcuma, zinc, chitosan, beta carotene, Green Tea polyphenols, thiamine and folic acid.
Duration : 5 weeks +/- 1 week.
Dosage :
First Week of intervention : 1/2 stick per day
Second to 5th Week : 1 stick per day"
1699463|NCT01469936|Dietary Supplement|PLACEBO|"Duration : 5 weeks +/- 1 week.
Dosage:
First Week : 1/2 stick per day
Second to 5th Week : 1 stick per day"
1699464|NCT01469923|Drug|AZD2820|Ascending subcutaneous injections of AZD2820 once daily for 14 days in the abdomen
1699465|NCT01469923|Drug|Placebo|Ascending subcutaneous injections of placebo for AZD2820 once daily for 14 days in the abdomen
1699466|NCT01469910|Drug|Simotinib Hydrochloride|Single ascending doses: 25 mg、50 mg、100 mg、150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
1699467|NCT01469910|Drug|Placebo|Single ascending doses: 150 mg、225 mg、300 mg、400 mg、500 mg、600 mg、750 mg
1699468|NCT01469884|Drug|Everolimus|The conversion will be performed abruptly for all patients. Calcineurin inhibitor will be discontinued one day before the day of conversion (Day 1). Everolimus will be introduced on day 1 at dose of 3 mg/d (1,5mg bid), and then everolimus trough levels will be adjusted to achieve 6-10 ng/ml.
1699469|NCT01469884|Drug|Cyclosporine|Trough level should be between 100 and 200ng/ml.
1699470|NCT01469884|Drug|Tacrolimus|Trough level should be between 5 and 10ng/ml.
1699471|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Hypafix Transparent dressing after hip surgery.
1699472|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Mepore Pro dressing after hip surgery.
1699473|NCT01469871|Device|Dressing of wound|The wound will be dressed using the Mepilex Border dressing after hip surgery.
1699474|NCT01469858|Device|Siemens magnetom avanto1.5 Tesla, Siemens magnetom trio A Tim system 3 Tesla|functional magnetic resonance imaging
1699475|NCT01469845|Device|3% hypertonic saline|4 ml dose to be administered every 6 hours
1699476|NCT01469832|Biological|MA09-hRPE|"Cohort 1 50,000 cells
Cohort 2 100,000 cells
Cohort 2a Better Vision 100,000 cells
Cohort 3 150,000 cells
Cohort 4 200,000 cells"
1699477|NCT01469819|Drug|Lubiprostone|24 mcg twice a day (BID) for 2 weeks.
1699478|NCT01469806|Device|Zimmer Gender Solutions PFJ Knee Prosthesis|Partial knee arthroplasty of the patello-femoral joint
1699479|NCT01469793|Drug|DMOT4039A|DMOT4093A will be administered by intravenous infusion on either a Q3W or a Q1W dosing schedule, in 21-day cycles.
1699480|NCT01469767|Drug|Fluocinonide cream|Fluocinonide cream 0.1% applied twice daily for 5 days.
1699481|NCT01469741|Behavioral|Prospective Memory Strategy|Prospective memory is central to performance in everyday life as it serves to bind together goal-directed actions and enables people to carry out their plans and wishes meaningfully and appropriately. Everyday prospective memory tasks include remembering to run errands, keep appointments, and turn off the stove after using it.
1699482|NCT01469728|Procedure|Non-awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed through sole general anesthesia and one-lung ventilation
1699483|NCT01469728|Procedure|Awake VATS talc pleurodesis|Thoracoscopic talc pleurodesis performed in awake patients through sole thoracic epidural anesthesia.
1699484|NCT01469715|Device|GBP CGM|Visit 1: Screening visit to determine if subject qualifies for the study. Visit 2: Inpatient admission requiring a 25.5-hour hospital stay. Each subject will wear one active & one mock device simultaneously during hyperglycemic & hypoglycemic challenge conditions to observe a wide range of glucose values. Visit 3 & 4: Subjects will return to the research center approximately 24 & 48 hours after sensor removal, respectively, for evaluation of the postimplantation sensor site. Visit 5: Subjects will return to the research center approximately 28 days post inpatient admission. Blood samples for future testing of GBP and polyethylene Glycol neutralizing antibodies will be taken at Visit 1 & 5.
1699485|NCT01469702|Drug|prednison and azithromycin|Patients with typical cat-scratch disease will be treated with a 5-day course of prednison and azithromycin.
1699486|NCT01469702|Drug|prednison, azithromycin|Cap Azithromycin 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day, qd, for 5 days.
1699487|NCT01469702|Drug|prednison, Azenil|Cap Azenil 500 mg qd (first day), then 250 mg qd for 4 days and Tab prednison 1 mg/kg/day, not exceeding 60 mg/day qd, for 5 days.
1699488|NCT01469689|Other|Google Adwords|The investigators will display Google Adwords advertising the investigators' website offering online help for depression
1699489|NCT01469689|Other|Local organisation websites|The investigators will place adverts on local organization websites with links to the investigators' project website offering online help for depression
1699490|NCT01469676|Device|Filtering group LG-6, Pall Biomedical Products|In Filtering group, a Leukocyte filter (LG-6, Pall Biomedical Products) was placed on the CPB arterial line circuit, trying to filter the white blood cells.
1699491|NCT01469650|Dietary Supplement|cholecalciferal|400 IU/day
1699492|NCT01469650|Dietary Supplement|cholecalciferol|800 IU/day D3
1699493|NCT01469637|Drug|sulfamethoxazole + MMX placebo|800 mg sulfamethoxazole/160 mg trimethoprim twice daily (BID) + MMX Mesalazine/mesalamine placebo once daily (QD) orally for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + single does of MMX Mesalazine/mesalamine placebo orally on Day 4.
1699494|NCT01469637|Drug|Sulfamethoxazole + MMX Mesalazine/mesalamine|800 mg sulfamethoxazole/160 mg trimethoprim BID + 4.8 g MMX Mesalazine/mesalamine QD for 3 days, then a single dose of 800 mg sulfamethoxazole/160 mg trimethoprim + a single dose of 4.8 g MMX Mesalazine/mesalamine on Day 4
1699495|NCT01469624|Drug|Pentoxifylline|pentoxifylline 400 mg PO three times a day for 24 hours before and 24 hours after PCI
1699496|NCT01469611|Biological|JX-594|Infusion Procedure:JX-594 will be administered on the designated treatment days at a dose of either 1 x 106, 1 x 107 or 3 x 107 pfu per kg. Virus infusion should occur over 60 minutes (+/- 5 minutes). The final infusion volume of virus plus diluent will be approximately 250 mL.
1699497|NCT01469598|Drug|Gemcitabine/Docetaxel|Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min Docetaxel 35 mg/m2 IV over 1hr every 21 days
1699498|NCT01469585|Drug|Doxycycline|40 mg orally at the start of cycle 3 (study day 57) for 28 days.
1699499|NCT01469572|Drug|Pasireotide|Pasireotide is given as an injection.
1699500|NCT01469572|Procedure|Sir-sphere Radioembolization|A catheter will be placed in a branch of the hepatic artery (liver) that supplies the tumor with blood. Radioactive beads will be injected into the tumor through the catheter.
1699501|NCT01469572|Drug|Everolimus|Given orally every day for the duration of the study
1699502|NCT01469559|Drug|Novolin Toronto insulin|Subjects randomized to active drug are provided with 20 IU BID of Novolin Toronto at randomization (week 5). The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast) and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. Dose escalations occur every 2 weeks with the insulin increasing to 40 IU BID at week 7, then 80 IU BID at week 9. The study completes at week 11. The total treatment period is 6 weeks. The insulin is diluted with an amount of normal saline to provide a total volume in the study treatment vial to equal 1.1 milliliters.
1699503|NCT01469559|Drug|Normal saline|Subjects randomized to placebo are provided with 1.1 milliliters of normal saline at randomization (week 5). The study completes at week 11. The total treatment period is 6 weeks. The dosing is prescribed to be taken 30 minutes after the morning meal (breakfast)and 30 minutes after the evening meal (supper). Subjects are asked to consume their meals and take their doses of study treatment within the same time frame each day. The amount of normal saline in the study treatment vial (1.1 milliliters) is identical in volume to the active insulin being used in the study .
1699504|NCT01469546|Drug|Axitinib (AG-013736)|The subjects will be started on treatment with 5 mg of Axitinib twice a day continuously, with subsequent dose escalation to 7 mg and then 10 mg twice a day in the absence of grade 2 or worse toxicities. This will be followed by clinical and/or radiologic response assessment after 8 weeks and subsequently every 2 months until disease progression (defined per RECIST [Response Evaluation Criteria In Solid Tumors] criteria, or obvious progression on clinical or laryngoscopic/endoscopic exam) or intolerable toxicity (defined as below). During treatment on this protocol, all patients will be evaluated for safety. Correlative biomarker analysis will also be conducted.
1699505|NCT01469533|Other|Spinal mechanical manipulation intervention|Subjects in experimental group are assessed through use of the Activator Methods (AM) assessment protocol. Spinal adjustment of the indicated pelvis, sacrum and lumbar spine is performed through the use of spinal mechanical manipulation. In this study leg length analysis only uses Position #1 and Position #2. Mechanical manipulation is delivered with the Activator Ⅳ Adjusting Instrument (AAI Ⅳ; Activator Methods International, Ltd, Phoenix, AZ) set in the maximal force setting 4, as it is used in routine clinical practice. The Activator Ⅳ delivers a very short duration (<5 ms) force-time impulse with a peak force magnitude of approximately 176N.
1699506|NCT01469533|Other|Sham manipulation intervention|Subjects in the control group receive a protocol identical to that described above, with the following exception: a sham mechanical thrust is delivered during the AM protocol. The sham procedure is accomplished by setting the expansion control knob on the Activator Ⅱ to the zero (off) position. The expansion control is used to adjust the spring compression and thus the amount of excursion of the instruments' stylus. In the zero position, no excursion of the stylus occurs, although the same clicking sound that the instrument produces during normal use is heard after manual activation of the mechanical trigger.
1699507|NCT01469520|Drug|Epivir®, Retrovir® and Viramune®|12 mL of Epivir® (lamivudine) 10 mg/mL solution plus 24 ml of Retrovir® (zidovudine) 10 mg/mL syrup plus and 20 mL of Viramune® (nevirapine) of 10 mg/mL
1699508|NCT01469520|Drug|Lamivudine, Zidovudine and nevirapine|20 mL of reconstituted granules for suspension containing lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per 5 mL of suspension
1699509|NCT01469520|Drug|Lamivudine, zidovudine, nevirapine|Lamivudine 30mg/zidovudine 60 mg/nevirapine 50 mg per tablet.
1699510|NCT01469507|Device|Chondroitin sulfate and sodium hyaluronate|3 weekly injections
1699511|NCT01469507|Drug|Hyaluronan|3 weekly injections
1699512|NCT01469494|Procedure|DIEP flap breast reconstruction|DIEP stands for deep inferior epigastric perforator. This is the name of the main blood vessel that runs through the abdominal tissue that will be used to reconstruct the breast. In DIEP flap reconstruction, only skin, fat, and blood vessels are removed from the lower belly (the abdomen between the waist and hips). No muscle is removed.
1699513|NCT01469494|Procedure|SIEA flap breast reconstruction|"The SIEA flap is very similar to the DIEP flap procedure. Both techniques use the lower abdominal skin and fatty tissue to reconstruct a natural, soft breast following mastectomy.
The main difference between the SIEA flap and the DIEP flap is the artery used to supply blood flow to the new breast. The SIEA blood vessels are found in the fatty tissue just below skin whereas the DIEP blood vessels run below and within the abdominal muscle (making the surgery more technically challenging). While the surgical preparation is slightly different, both procedures spare the abdominal muscle and only use the patient's skin and fat to reconstruct the breast."
1699514|NCT01469481|Drug|PF-04991532|a single oral dose of [14C]PF-04991532 (450 mg/100 uCi suspension)
1699515|NCT01469468|Drug|Simvastatin|Day 1: Single dose of simvastatin 20 mg Day 8: single dose of simvastatin 20 mg (with PF-05175157)
1699516|NCT01469468|Drug|PF-05175157|Days 2-9 inclusive: daily dosing of PF-05175157 200 mg
1699563|NCT01469104|Other|3 day CHO-free diet|Subjects will receive a carbohydrate-free diet for 72 hours
1699517|NCT01469455|Drug|DT01|"DT01 starting dose will be 16 mg and it is planned to be increased to 32, 48 mg and 64 mg, or higher.
DT01 will be administered 3 times a week (e.g., Mondays, Wednesdays and Fridays) over 2 weeks (6 administrations of DT01 in total) at least 3 hours prior to the radiotherapy sessions."
1699518|NCT01469442|Procedure|External Biliary duct stent in the bile duct by cystic way|The size of the external biliary duct stent depending of cystic duct size
1699519|NCT01469429|Other|placebo|Receive lozenge placebo PO
1699520|NCT01469429|Other|laboratory biomarker analysis|Correlative studies
1699521|NCT01469429|Other|questionnaire administration|Ancillary studies
1699522|NCT01469429|Drug|chemoprevention|Receive LBR lozenge PO
1699523|NCT01469429|Drug|chemoprevention|Receive LBR Saliva Substitute PO
1699524|NCT01469429|Other|placebo|Receive Saliva Substitute placebo PO
1699525|NCT01469416|Drug|Rosuvastatin|Rosuvastatin 20 mg PO x 1
1699526|NCT01469416|Drug|Clopidogrel|Clopidogrel 300 mg PO x 1 (30 minutes prior to rosuvastatin dose); Clopidogrel 75 mg PO x 1 (24 hours post-rosuvastatin dose)
1699527|NCT01469403|Behavioral|8 weeks weight loss program, Cambridge.|Fast weight losses improve the prognosis for the sustained weight loss. During the first week a dietitian will tutor the participants in formula food diet (The Cambridge Health and Weight plan UK.), followed by seven weeks with control guidance and instruction in healthy eating habits once a week. The guidance by the dietitian will be carried out both on an individual basis and in groups. The goal of the intervention is to achieve a preoperative weight loss of at least 5 to 10% of the patient's body weight, thus improving patient's health before surgery.
1699528|NCT01469377|Drug|cariprazine|cariprazine (2-4.5 mg/day) given orally, in capsule form, once daily for 8 weeks
1699529|NCT01469377|Drug|cariprazine|cariprazine (1-2 mg/day) given orally, in capsule form, once daily for 8 weeks
1699530|NCT01469377|Drug|placebo|Matched placebo given orally, in capsule form, once daily for 8 weeks
1699531|NCT01469364|Drug|Aztreonam Lysine for Inhalation (AZLI)|The intervention will involve open label treatment with AZLI inhaled 75mg TID self-administered intermittently for 28 days on study drug and 28 days off study drug over a study period of 5 consecutive months (on/off/on/off/on AZLI)
1699532|NCT01469364|Procedure|Status Post Lung Transplant|Bronchoscopy, pulmonary function testing, and laboratory testing will be performed on a regular basis during study enrollment consistent with each center's usual standard clinical care.
1699533|NCT01469351|Drug|Liraglutide|"Liraglutide (Victoza ®), human GLP-1 analog produced using recombinant DNA technology in saccharomyces cerevisiae. Victoza ® is registered and approved for the treatment of type 2 diabetes.
Victoza ® stimulates glucose-dependent insulin secretion from β-cells and inhibits glucagon secretion, slows ventricle emptying and reduces body weight and body fat mass by affecting appetite regulation.
Form of administration: Liraglutide is a clear injection fluid, which comes in a prefilled disposable pen.
1 ml contains 6 mg of liraglutide in sterile water. There is added disodium phosphate and propylene glycol and the preservative phenol. A filled pen contains 18mg liraglutide in 3ml. NovoFine® needles are used."
1699534|NCT01469351|Drug|non-active study drug|placebo
1699535|NCT01469338|Drug|cabazitaxel|Given IV
1699536|NCT01469338|Drug|prednisone|Given PO
1699537|NCT01469338|Drug|octreotide pamoate|Given IM
1699538|NCT01469338|Other|questionnaire administration|Ancillary studies
1699539|NCT01469338|Drug|octreotide acetate|Given SC
1699540|NCT01469325|Other|Repetitive Transcranial Magnetic Stimulation|We deliver rTMS to the left prefrontal cortex at 120% motor threshold (10 Hz, 4-second train duration, and 26-second intertrain interval) for 37.5 minutes (3000 pulses per session) using a figure-eight solid-core coil
1699541|NCT01469325|Other|Sham rTMS|Sham rTMS using a similar coil with a metal insert blocking the magnetic field and scalp electrodes that delivered matched somatosensory sensations.
1699542|NCT01469312|Other|modified pasta|50 grams carbohydrate as a single breakfast meal
1699543|NCT01469286|Device|TEA|Electroacupuncture at ST36
1699544|NCT01469286|Device|Sham-TEA|Electroacupuncture at sham-points
1699545|NCT01469273|Drug|Mutaflor® Suspension|Application of Mutaflor-Suspension on 10 consecutive days.
1699546|NCT01469260|Other|Pedometer|Pedometer provided, counseling on pedometer use and step recommendations of 10,000 steps per day, handouts given every 4 weeks to encourage exercise
1699547|NCT01469247|Radiation|Radiation Therapy|Starting Dose 24 Gy in 2 Gy fractions.
1699548|NCT01469234|Drug|loratadine|loratadine, one 10 mg tablet, orally
1699549|NCT01469234|Drug|fexofenadine|fexofenadine, one 180 mg tablet, orally
1699550|NCT01469234|Drug|placebo to loratadine|one tablet, orally
1699551|NCT01469234|Drug|placebo to fexofenadine|one tablet, orally
1699554|NCT01469182|Biological|SCH 39641|Rapidly dissolving tablet sublingually once daily
1699555|NCT01469182|Drug|Placebo for SCH 39641|Rapidly dissolving tablet sublingually once daily
1699556|NCT01469169|Drug|Iloprost (Ventavis inhaled, BAYQ6256)|2.5 μg or 5.0 μg BAYQ6256 per inhalation session (Inhalation session is to be conducted 6 to 9 times per day with dosing intervals of at least 2 hours.)
1699557|NCT01469156|Drug|ranibizumab 0.5 or 2.0 mg/0.05 cc|ranibizumab (3:1 ratio of 2mg:0.5 mg ranibizumab) administered in three initial monthly doses followed by a 9 month period of criteria-based, as-needed retreatment and 12 month off drug safety follow up.
1699558|NCT01469143|Drug|Faster-acting insulin aspart|Each subject will randomly be allocated to a treatment sequence consisting of 9 dosing visits during which the subject will receive 8 single doses of different formulations. For all investigational medicinal products the dose levels will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
1699559|NCT01469143|Drug|insulin aspart|At one of the scheduled visits, the subject will receive a single dose of insulin aspart. The dose level will be 0.2 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
1699560|NCT01469130|Drug|MEK162|MEK162 in an oral formulation. It is a film-coated capsule-shape tablets (i.e. caplets).
1699561|NCT01469117|Other|enteral formula|Complete feeding of study enteral formula, route and regimen prescribed by the physician
1699562|NCT01469104|Other|3 day fast|Subjects will fast for 72 hours
1699564|NCT01469091|Behavioral|Smoking intervention.|Nicotine replacement therapy and meetings with nurse specialized in smoking intervention.
1699565|NCT01469078|Drug|Monofer®|Single Bolus Injections
1699566|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 25 mg given twice a day (BID) for 14 days
1699567|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 75 mg given twice a day (BID) for 14 days
1699568|NCT01469065|Drug|PF-04991532|Oral administration of PF-04991532; 150 mg given twice a day (BID) for 14 days
1699569|NCT01469065|Drug|PF-0499132|Oral administration of PF-04991532; 300 mg given twice a day (BID) for 14 days
1699570|NCT01469065|Drug|Placebo|Oral administration of PF-04991532 Matching Placebo; given twice a day (BID) for 14 days
1699571|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (10 mg once a day, 10 mg twice a day, 20 mg twice a day or 30 mg twice day) in the fed state
1699572|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (20 mg twice a day) in the fed state
1699573|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fed state
1699574|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (15 mg once a day) in the fed state
1699575|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (5 mg twice a day) in the fasted state
1699576|NCT01469052|Drug|AG-013736|Axitinib continuous oral dosing (2 mg twice a day on the first day of dosing, followed by 5 mg twice a day) in the fasted state
1699577|NCT01469039|Drug|ALKS 9072|Intramuscular (IM) injection, 441 mg or 882 mg given monthly
1699578|NCT01469039|Drug|Placebo|Placebo for IM injection, given monthly
1699579|NCT01469026|Radiation|PET/CT or Conventional diagnostics including CT|"Radiation:
PET/CT. 4 MBq/kg (max. 400 MBq) 18F-flour-deoxyglucosegiven iv. 60 min. before PET/CT scan.
CT. iv.contrast medium (Ultravist 370 mg I/ml)."
1699584|NCT01469000|Drug|Gefitinib|250 mg orally once per day. Number of cycles until disease progression or unacceptable toxicity develops.
1699585|NCT01469000|Drug|Pemetrexed|500 mg/m² IV on day 1 of each 21 day cycle. Number of cycles until disease progression or unacceptable toxicity develops.
1699586|NCT01468987|Drug|LY2605541|- Administered by subcutaneous injection
1699587|NCT01468987|Drug|Insulin Glargine|- Administered by subcutaneous injection
1699588|NCT01468987|Drug|Insulin Lispro|- Administered subcutaneously
1699589|NCT01468974|Device|ESPRIT BVS|Subjects receiving ESPRIT BVS for the treatment of symptomatic claudication from occlusive vascular disease of the superficial femoral (SFA) or common or external iliac arteries
1699590|NCT01468961|Behavioral|Internet-based CBT|10 weeks of internet-based CBT with online therapist contact
1699591|NCT01468948|Drug|Octanoic Acid|
1699594|NCT01468909|Other|Laboratory Biomarker Analysis|Correlative studies
1699595|NCT01468909|Drug|Paclitaxel|Given IV
1699596|NCT01468909|Drug|Pazopanib Hydrochloride|Given PO
1699597|NCT01468909|Other|Placebo|Given PO
1699601|NCT01468883|Procedure|M|Modified radical mastectomy
1699602|NCT01468883|Radiation|X|Excisional biopsy plus radiation
1699605|NCT01468818|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
1699606|NCT01468818|Drug|Fludarabine|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
1699607|NCT01468818|Biological|Young Tumor Infiltrating Lymphocytes (TIL)|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of young TIL. On day 0, cells (1x10e9 to 2x10e11) will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
1699608|NCT01468805|Procedure|Cockroach mitigation/extermination|
1699609|NCT01468779|Dietary Supplement|Probiotics|The probiotics pills are given orally in the amount of two pills twice a day as early as two days before surgery until ten days after surgery.
1699610|NCT01468779|Dietary Supplement|Sugar pill|
1699611|NCT01468766|Other|Supervised progressive resistance training|2x60 minutes per week for 12 weeks
1699612|NCT01468766|Other|Supervised progressive muscle relaxation training (Jacobson method)|2x60 minutes per week for 12 weeks
1699613|NCT01468753|Procedure|Vaginal Insemination|Women will perform vaginal insemination during the fertile period with semen within one hour of collection. Vaginal insemination will occur within one hour of collection 2 days prior to ovulation, on the day of ovulation and 2 days after ovulation for up to 6 months or until conception occurs. For example, if ovulation were on day 14 of a 28 day menstrual cycle, vaginal insemination will occur on days 12, 14 and 16 of the cycle.
1699614|NCT01468740|Drug|Doxorubicin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain doxorubicin.
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
1699644|NCT01468545|Other|Iloprost (Ventavis inhaled, BAYQ6256)|No extra educational reinforcement.
1699645|NCT01468532|Drug|docetaxel|Given IV
1699646|NCT01468532|Drug|pasireotide|Given IM
1699647|NCT01468532|Drug|prednisone|Given PO
1699615|NCT01468740|Drug|Bleomycin|"The four-drug ABVD chemotherapy regimen and the seven-drug BEACOPP-baseline chemotherapy regimen contain bleomycin.
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation or 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
1699616|NCT01468740|Drug|Vinblastine|"The four-drug ABVD chemotherapy regimen contains vinblastine
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
1699617|NCT01468740|Drug|Dacarbazine|"The four-drug ABVD chemotherapy regimen contains dacarbazine
Early stage favorable Hodgkin Lymphoma: 2 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) + 30 Gy involved field (IF) radiation
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of ABVD + 30 Gy involved field (IF) radiation"
1699618|NCT01468740|Drug|Etoposide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains etoposide.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
1699619|NCT01468740|Drug|Cyclophosphamide|"The seven-drug BEACOPP-baseline chemotherapy regimen contains cyclophosphamide.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
1699620|NCT01468740|Drug|Vincristine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains vincristine.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
1699621|NCT01468740|Drug|Procarbazine|"The seven-drug BEACOPP-baseline chemotherapy regimen contains procarbazine.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
1699622|NCT01468740|Drug|Prednisone|"The seven-drug BEACOPP-baseline chemotherapy regimen contains prednisone.
Early stage unfavorable Hodgkin Lymphoma: 4 cycles of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone (BEACOPP)-baseline + 30 Gy IF radiation
Advanced Hodgkin Lymphoma: 8 cycles of BEACOPP-baseline. After the completion of chemotherapy sites of initial bulky disease (those at least 5 cm in diameter) and residual tumor larger than 2.5 cm in diameter receive 30 Gy of irradiation."
1699623|NCT01468727|Dietary Supplement|xylitol wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
1699624|NCT01468727|Dietary Supplement|placebo wipe|Parents were instructed to wipe their infants' teeth and gums three times per day with two wipes each time after feeding in addition to their daily tooth brushing.
1699625|NCT01468714|Drug|PF-04937319 / ketoconazole|Single 20 mg dose of PF-04937319 on day 1, multiple dose of ketoconazole 200 mg twice daily from day 3 to 7, single 20 mg dose of PF-04937319 on day 6
1699626|NCT01468688|Drug|STI571|
1699627|NCT01468688|Drug|BKM120|BKM120 combination therapy
1699628|NCT01468675|Other|Intervention|risk assessment survey; decision support for providers for prevention based on risk
1699629|NCT01468649|Device|NIR Imaging with FLARE and Mini-FLARE Imaging System|A custom-designed imaging platform that utilizes NIR fluorescence optics will be employed to identify the injected dye and its path through the lymphatic track, and its eventual highlighting of the SLN. Both color images and NIR images will be merged to give the operating surgeon a clear picture of the ICG track superimposed over anatomical landmarks. This technique will identify the SLN and provide an accurate video image of its location.
1699630|NCT01468636|Drug|Oral Zinc|200 mg BID of oral zinc gluconate x 8 weeks
1699631|NCT01468636|Drug|Placebo|200mg BID x 8 weeks
1699632|NCT01468623|Other|Pharmacokinetic 5-FU dose adjustment using OnDose® assay|OnDose is a commercially available assay to measure concentration of 5-FU exposure.
1699633|NCT01468623|Other|Standard of care|Patients' dose of 5-FU will be based on Body Surface Area (BSA).
1699634|NCT01468610|Drug|desvenlafaxine|50-100 mg daily for 8 weeks
1699635|NCT01468584|Drug|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
1699636|NCT01468584|Drug|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
1699637|NCT01468584|Drug|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
1699638|NCT01468571|Drug|Spironolactone|50 mg po daily of spironolactone for 8 weeks. A cross-over study where each subject will receive spironolactone or placebo in a random order for 8 weeks each.
1699639|NCT01468571|Drug|Placebo|"Each subject will receive placebo or spironolactone for 8 weeks. At the end of week 8, treatment arm for each subject will be blindly switched.
So if a study patient received placebo for the first 8 weeks then he/she will be switched to receive active drug (spironolactone) for the next 8 weeks."
1699640|NCT01468558|Drug|MAP0004|MAP0004 1.0mg via inhalation on Day 1 and Day 6 of Visit 2
1699641|NCT01468558|Drug|IV DHE|IV DHE (Intravenous Dihydroergotamine Mesylate) administered at Visit 3
1699642|NCT01468558|Drug|Ketoconazole|Ketoconazole 400 mg administered once a day on days 3-6 of Visit 2
1699643|NCT01468545|Other|Iloprost (Ventavis inhaled, BAYQ6256)|An extra educational reinforcement at baseline and at 6 months will be given to a group of patients
1699648|NCT01468519|Drug|Insulin|Insulin via continuous subcutaneous insulin infusion
1699649|NCT01468519|Drug|Insulin|insulin via multiple daily injections
1699650|NCT01468480|Drug|Pro Root MTA|application of MTA in second group and 24 hour interval before restoration
1699651|NCT01468480|Drug|Pro Root MTA- single visit|application of MTA in third group and 15 minute interval before restoration
1699652|NCT01468480|Drug|MultiCal|application of Multical in forth group as a pulp dressing agent
1699653|NCT01468480|Drug|Dycal|application of Dycal in first group as a pulp dressing agent
1699654|NCT01468467|Drug|AC220|Oral Liquid
1699655|NCT01468454|Drug|18 F-DOPA|one time injection of 0.08 - 0.16 mCurie/kg of 18F-DOPA
1699656|NCT01468441|Drug|Triptorelin|Triptorelin (0.1 mg, Gonapeptyl® Daily; Ferring, Kiel, Germany) in alternate-days from Day 1 of the menstrual cycle until the day of hCG administration.
1699657|NCT01468441|Drug|Cetrorelix|When patients presented at least two follicles ≥ 14mm upon scan on days 7- 9, GnRH antagonist (cetrorelix, 0.25 mg/day, Cetrotide®; EMD Serono, Inc, Rockland, MA, USA) administration is started and continued until hCG administration.
1699658|NCT01468415|Drug|phenol|1 cc of 8% phenol dissolved in water or 20cc of 8o mg Methylprednisolone diluted in 0.25% marcaine.
1699660|NCT01468389|Drug|Capecitabine|900-1000mg/m2 bid, days 1-14, every 3 weeks
1699661|NCT01468389|Drug|capecitabine|Dosing schedule: 900-1000mg/m2 bid, days 1-14, every 3 weeks Maintenance dosing schedule: 1000-1250mg/m2 bid, days 1-14, every 3 weeks
1699662|NCT01468376|Dietary Supplement|GLU-01|14 day dosing
1699663|NCT01468376|Dietary Supplement|GLU-02|14 day dosing
1699664|NCT01468376|Dietary Supplement|GLU-03|14 day dosing
1699665|NCT01468376|Dietary Supplement|GLU-04|14 day dosing
1699666|NCT01468376|Dietary Supplement|GLU-05|14 day dosing
1699667|NCT01468376|Dietary Supplement|GLU-06|14 day dosing
1699668|NCT01468363|Device|Dry weight adjustment|Dry weight adjustment according to BCM results
1699669|NCT01468350|Drug|dalfampridine-ER 10mg|
1699670|NCT01468350|Other|Placebo|
1699671|NCT01468337|Drug|Interferon gamma-1b|"Participant 1: 2 drops of topical interferon gamma-1b three times daily in the study eye for a daily dose of 42 μg
Participant 2: 3 drops 3 times daily in the study eye for a daily dose of 63 μg, if the 1st participant's dose is deemed well-tolerated by the investigator at Weeks 1, 2 and 4.
Participant 3: 3 drops 4 times daily in the study eye for a daily dose of 84 μg, if the 2nd tolerates the daily dose of 63 μg at Weeks 1, 2 and 4.
Participants 4 and 5: 4 drops 4 times daily in the study eye for a daily dose of 112 μg, if the 3rd tolerates the daily dose of 84 μg at Weeks 1, 2 and 4.
If the 63, 84 or 112 μg doses are not well-tolerated, subsequent participants will be enrolled at the prior dose level (42, 63 or 84 μg). Well-tolerated is defined as no corneal irritation (e.g., punctuate epithelial keratitis), no coexisting conjunctival erythema and edema, and no signs of more serious toxicities (e.g., intraocular inflammation or lens changes)."
1699672|NCT01468324|Drug|AZD7451|Depending on dose level, AZD7451 will be given once daily for 28 day cycles.
1699673|NCT01468311|Procedure|Auto stem cell transplant|Auto stem cell transplant (ASCT) is given after 90Y-daclizumab
1699674|NCT01468311|Drug|BEAM|BCNU, etoposide, cytarabine and melphalan (BEAM) chemotherapy are given after 90Y-daclizumab
1699675|NCT01468311|Radiation|111In-daclizumab|111In-daclizumab will be administered to patients with each therapeutic infusion of 90Y-daclizumab in order to define the distribution of radiolabeled daclizumab, and to allow visualization by scans.
1699676|NCT01468311|Radiation|90Y-daclizumab|90Y-daclizumab administered with a fixed dose of pentetate calcium trisodium (Ca-DTPA) followed by BEAM Chemo and Auto stem cell transplant
1699677|NCT01468298|Other|Isostretching|All of patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week. The Isostretching method includes therapeutic different postures, lying, sitting or standing, and the positions were selected according to the postural changes of each patient, identified in the assessment. The Isostretching protocol involves nine positions held for a period of nine breaths, and every three cycles, the patient should rest for a period. The physical therapist used verbal commands to emphasize pursed lip breathing, self growth, curvatures correction and isometric of abdominal, paravertebral, quadriceps and gluteal muscles with the aim of optimizing the stretching and discouraging compensatory movements.
1699678|NCT01468298|Other|Global Posture Reeducation|All patients were accompanied by an individual treatment program composed by 12 sessions of 45 minutes, twice a week, involving a series of active gentle movements and postures aimed at realigning joints, stretching shortened muscles and enhancing the contraction of antagonist muscles, thus avoiding postural asymmetry. The positions were selected according to the postural changes of each patient, identified in the assessment and these therapeutic postures imply an active involvement of the patient. The protocol includes three therapeutic postures, lying, sitting or standing, to be held for 15 minutes each. The physical therapist used verbal commands and manual contact to maintain the alignment and make the necessary postural corrections, with the aim of discouraging compensatory movements.
1699681|NCT01468272|Drug|free comb. beclomethasone DPI and formoterol DPI|free combination of beclomethasone dipropionate 100 ug/unit DPI (two inhalations, total dose 200 ug), and formoterol fumarate 6 ug/unit DPI (four inhalations, total dose 24 ug).
1699682|NCT01468272|Drug|CHF 1535 50/6 NEXT DPI|four inhalations of CHF 1535 50/6 NEXT DPI, a fixed combination of beclomethasone dipropionate 50 ug plus formoterol fumarate 6 ug (TOTAL DOSE:BDP/FF 200/24 ug)
1699683|NCT01468259|Drug|Droxidopa|The dose to be used is a single 600 mg dose (2 x 300 mg capsules) of droxidopa.
1699684|NCT01468233|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
1699685|NCT01468233|Biological|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
1699686|NCT01468220|Other|Endurance training|Endurance training three times per week over six weeks
1758843|NCT00270114|Drug|epoetin alfa|
1699687|NCT01468207|Biological|adalimumab|Adalimumab pre-filled syringe, administered by subcutaneous injection
1699688|NCT01468207|Biological|placebo|Placebo pre-filled syringe, administered by subcutaneous injection
1699689|NCT01468194|Other|Breathing procedure 1|inhalation during one step, exhalation during the next step
1699690|NCT01468194|Other|Breathing procedure 2|inhalation and exhalation during one step
1699691|NCT01468181|Drug|LY2189265|
1699692|NCT01468181|Drug|Sulfonylureas (SU)|SU is a pre-study prescribed dose and is not being provided as part of the trial.
1699693|NCT01468181|Drug|Biguanides (BG)|Biguanides is a pre-study prescribed dose and is not being provided as part of the trial.
1699694|NCT01468181|Drug|alpha-glucosidase inhibitor (a-GI)|a-GI is a pre-study prescribed dose and is not being provided as part of the trial.
1699695|NCT01468181|Drug|Thiazolidinedione (TZD)|TZD is a pre-study prescribed dose and is not being provided as part of the trial.
1699696|NCT01468181|Drug|Glinides|Glinides is a pre-study prescribed dose and is not being provided as part of the trial.
1699700|NCT01468155|Drug|dabigatran|30 days pre ablation and 90 days post ablation
1699701|NCT01468129|Other|Cell Saver|
1699702|NCT01468103|Procedure|Surgical Iridectomy|Surgical Iridectomy is now widely used in our clinical.
1699703|NCT01468103|Procedure|Laser Iridotomy|alternative choice to surgical iridectomy
1699704|NCT01468077|Drug|Tocilizumab|8 mg/kg infusion
1699705|NCT01468064|Genetic|Autologous BMSCs transplantation|"The first transplantation: 2.5 million cells per kg autologous BMSCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.
The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
1699706|NCT01468064|Genetic|Autologous EPCs transplantation|"The first transplantation: 2.5 million cells per kg autologous EPCs suspended in 100 ml saline plus 5% autologous serum are infused intravenously approximately 4 weeks after bone marrow aspiration.
The second transplantation: the same amount of cells are again transplanted approximately 1 weeks after initial boosting."
1699707|NCT01468064|Genetic|IV infusion of placebo|IV infusion of saline plus 5% autologous serum.
1699710|NCT01468038|Drug|Trazodone|active trazodone and sentra pm-like placebo
1699711|NCT01468038|Other|Sentra PM|Active Sentra PM and trazodone-like placebo
1699712|NCT01468038|Drug|Sentra PM and Trazodone (CoPack Kit Trazamine)|A CoPack Kit - Trazamine, consisting of the co-administration of Sentra PM and trazodone.
1699713|NCT01468038|Drug|Placebo trazodone and placebo Sentra PM|Trazodone-like placebo and Sentra PM-like placebo co-administered as placebo of Trazamine CoPack Kit.
1699714|NCT01468025|Drug|Active Theramine and Active Naproxen|Co-administration of Theramine and Naproxen, CoPack Kit Theraproxen
1699715|NCT01468025|Other|Theramine and naproxen-like placebo|Theramine, a medical food, co-administered with naproxen-like placebo
1699716|NCT01468025|Drug|Naproxen and Theramine-like placebo|naproxen co-administered with Theramine-like placebo.
1699717|NCT01468012|Drug|levodopa carbidopa and entacapone (LCE)|400mg/100mg/200mg, twice daily
1699718|NCT01468012|Drug|Placebo|matched placebo for LCE condition dosed twice daily
1699719|NCT01467999|Drug|Guanfacine|Guanfacine, 4mg given once daily
1699720|NCT01467986|Drug|Dasatinib|Pharmacotherapeutic Group: protein kinase inhibitor ATC-Code: L01XE06 Excipients: Tablet core: Lactose monohydrate, Cellulose, microcrystalline, Croscarmellose sodium, Hydroxypropyl cellulose, Magnesium stearate. Film-coating: Hypromellose, Titanium dioxide, Macrogol 400 Formulation: film coated tablet Route of Administration: orally. Patients should be instructed to swallow the tablets as a whole and not to split, chew, or crush them.
1699721|NCT01467986|Drug|Rapamycin|Pharmacotherapeutic Group: Immunosuppressive agents - mTOR Inhibitors ATC-Code: L04A A10 Excipients: Polysorbat 80, Phosal 50 PG ((3-sn-Phosphatidyl)cholin from Soy beans, Propylenglycol, lipid acid mono- and -diglyzeride from Soy oil, Ethanol (1,5% bis 2,5%), Soy liid acid and Palmitoyl ascorbic acid) Formulation: Oral solution Route of Administration:orally
1699722|NCT01467986|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
1699723|NCT01467986|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).
Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
1699724|NCT01467986|Drug|Irinotecan|Pharmacotherapeutic Group: cytostatic topoisomerase-I-inhibitor ATC-Code: L01XX19 Excipients: Sorbitol (E420), lactic acid, sodium hydroxid (to adjust the pH to 3.5), water for injection Formulation: concentrate for solution for infusion Route of Administration: intravenously
1699725|NCT01467986|Drug|Temozolomide|"Pharmacotherapeutic Group: Antineoplastic agents - Other alkylating agents, ATC-Code: L01A X03 Excipients: Capsule content: Anhydrous lactose, Sodium starch glycolate Type A, Colloida anhydrous silica, Tartaric acid, Stearic acid. Capsule shell: Gelatine, Titanium dioxide (E171).
Printing ink: Shellac Propylene glycol, Titanium dioxide (E171), Sunset yellow FCF Aluminium Lake (E110) Formulation: capsule, hard Route of Administration: orally; Temomedac hard capsules should be administered in the fasting state. The capsules must be swallowed whole with a glass of water and must not be opened or chewed"
1699833|NCT01467089|Other|Two way video assessment|Participants will be assessed extrapyramidal symptoms and tardive dyskinesia
1700069|NCT01465399|Procedure|Conventional closure of the lesion|
1699726|NCT01467947|Biological|Berinert, lyophilizate for IV application containing 500 IU C1-INH to be reconstituted with 10 mL water for injection|Individual treatment duration per subject is 9 months, irrespective of the number of treated attacks. Each attack that occurs in this time frame will be treated with 20 IU Berinert/kg body weight.
1699727|NCT01467921|Drug|oxaliplatin|oxaliplatin 85 mg/m2 will be given intravenously on day 1 for over 2 h
1699728|NCT01467908|Device|Navigated transcranial magnetic brain stimulation|Standard NBS motor mapping using the Eximia TMS stimulator, Nexstim Ltd., Finland.
1699729|NCT01467882|Drug|Triptorelin|Powder and solution for solution for injection
1699730|NCT01467856|Procedure|PAP Device Procedure|"Following titration, subjects will be issued a PAP machine programmed at this optimum pressure and instructed to use the device nightly for the ensuing three months. Compliance checks will be conducted at months 1 and 3 by having the subjects present the PAP Smartcard for download and interpretation.
Daily compliance will be reported as the total number of hours of PAP use per 24 hour period. Patients who use PAP > 4 hours/ night for more than 50% of the nights at one month and 3 month follow-up will be classified as 'compliant' with PAP. Non-compliance will be addressed by a clinical problem-solving approach normally utilized by sleep laboratory personnel in the UM PAP clinic."
1699733|NCT01467830|Procedure|Open Inguinal Hernia Repair With Mesh,the Use of Absorbable Versus Non Absorbable Fixation Sutures|use of absorbable sutures to fixate mesh inguinal hernia repair.
1699734|NCT01467817|Behavioral|Lifestyle Intervention|The intervention incorporates 6 months of active structured lifestyle intervention containing participant education, exercise, dietary intervention, and behavioral support
1699735|NCT01467817|Behavioral|Exercise Control|The control group intervention will test benefits of exercise alone while controlling for investigator contact.
1699736|NCT01467804|Drug|Sertraline plus placebo of JWXYJN|oral sertraline (start with 50 mg/day for one week then continue with 100 mg/day plus placebo of JWXYJN
1699737|NCT01467804|Drug|JWXYJN plus placebo of Sertraline|JWXYJN 3.6g/d plus placebo of sertraline
1699738|NCT01467791|Other|Observation|Observe patients
1699739|NCT01467778|Device|ELAPR|ELAPR implant product is under development for mid to deep dermal implantation for the treatment of the symptoms of skin aging including the correction of moderate to sever facial wrinkles and folds, such as nasolabial folds and skin abnormalities such as scars.
1699740|NCT01467778|Device|ELAPR|Implant area of the medial aspect of the upper arm along the posterior line of the bicep is to be selected where there are no pigmentations or moles. Injections will be marked with a tattoo and placed at 2 cm intervals. The order is to be from proximal to distal control, ELAPR001, ELAPR002, ELAPR003
1699741|NCT01467765|Other|Elental|200Kcal/200mL of liquid nutrient for 15 min at 7:30 am is administered in PEG patients
1699742|NCT01467752|Procedure|MCP joint|reconstruction of metacarpophalangeal (MCP) joint using a bone graft
1699745|NCT01467726|Drug|Velusetrag|Capsules
1699746|NCT01467726|Drug|Velusetrag|Capsules
1699747|NCT01467726|Drug|Placebo|Capsules
1699748|NCT01467713|Drug|Ramelteon SL|Ramelteon sublingual (SL) tablets
1699749|NCT01467713|Drug|Placebo|Ramelteon sublingual (SL) placebo-matching tablets
1699750|NCT01467700|Drug|Ramelteon SL|Ramelteon SL tablets
1699751|NCT01467700|Drug|Placebo|Ramelteon placebo-matching tablets
1699752|NCT01467687|Drug|verapamil controlled release|verapamil 300 mg controlled release capsule as a single dose
1699753|NCT01467661|Drug|SPD422 (anagrelide hydrochloride)|Subjects will be continued on the dose of anagrelide that controlled their platelet levels in Study 308 and titrated if necessary.
1699754|NCT01467648|Drug|Doripenem|"(i) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.
Blood samples (approximately 2 ml)will be obtained by direct venepuncture at the following time: 0, 0.5, 1, 2, 3, 4, 4.5, 5, 6, 7 and 8 h after 7th dose of doripenem."
1699755|NCT01467648|Drug|Doripenem|"(ii) 0.5 g in 100 ml of normal saline solution and administered via an infusion pump at a constant flow rate over 1 h every 8 h.
Blood samples (approximately 2 ml) will be obtained by direct venepuncture at the following time: 1, 1.5, 2, 4, 5, 6, 7 and 8 h after 7th dose of doripenem."
1699756|NCT01467635|Device|Endobronchial ultrasound guided lymph node sampling|Patients with enlarged mediastinal or hilar lymph nodes have these sampled under endobronchial ultrasound guidance using either the EBUS-TBNA needle or the EBUS-TBNB biopsy forceps.
1699757|NCT01467622|Procedure|Chest tube removal|Chest tube removal on the basis of local recommendations for postoperative chest tube management
1699758|NCT01467596|Device|Elderly population, Middle aged population|The study method is a step-up/step-down sequence model where the dose of local anesthetic for the following patient is determined by the outcome of the preceding block. The starting dose of 50:50 mixture of 0.5% levobupivacaine and 2% lidocaine is 30 mL. In the case of block failure, the dose will be increased by 5 mL. Conversely, block success will result in a reduction in dose by 5 mL. A blinded assistant will assess sensory and motor blockade in each nerve territory ( the median, radial, ulnar and musculocutaneous) at 5-min intervals up to 30 min after completion of US-SCB. Effective US-SCB will be defined as complete sensory blockade in the distribution of the radial, ulnar, median and musculocutaneous nerve.
1699759|NCT01467583|Drug|Fondaparinux|2.5 mg every 48 hours
1699760|NCT01467570|Dietary Supplement|oral rehydration solution Hipp ORS Apple 200|"Volume of the solution calculated by weight:
fast oral rehydration in 3-4 hours by mouth
ORS given for ongoing losses until diarrhea stops (maintenance phase)"
1699761|NCT01467570|Dietary Supplement|ESPGHAN ORS|"Volume of the solution calculated by weight:
fast oral rehydration in 3-4 hours by mouth
ORS given for ongoing losses until diarrhea stops (maintenance phase)"
1699762|NCT01467557|Device|narafilcon B daily disposable soft contact lenses|daily disposable soft contact lenses
1699763|NCT01467557|Device|etafilcon A daily disposable soft contact lenses|daily disposable soft contact lenses
1699764|NCT01467544|Other|Tai Chi class|The 8-week tai chi group intervention will be lead by Project PI. A focused short form of tai chi involving 12 movements will be used in this project. Each of 8 weekly 60-minute sessions will begin with a 10-minute guided meditation session. Movements learned the previous week will be reviewed prior to introducing new movements. Training DVDs will be produced and provided to participants for weekly and ongoing practice of the techniques.
1699765|NCT01467531|Drug|Dolutegravir|50mg q 24h
1699766|NCT01467531|Drug|Rlipivirine|25mg q24h
1699767|NCT01467531|Drug|GSK1265744|30mg q24h
1699768|NCT01467518|Drug|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV. Dose of 50mg every 12 hours for 5 days.
1699769|NCT01467518|Drug|Methadone|Methadone is a synthetic opioid used in the treatment of opioid dependence. Subjects will be on individualize stabe dose for 8 days.
1699770|NCT01467505|Drug|Telaprevir|Tablet
1699771|NCT01467505|Drug|Ribavirin|Tablet
1699772|NCT01467505|Drug|Pegylated Interferon Alfa-2a|Subcutaneous Injection
1699773|NCT01467505|Drug|Immunosuppressant Regimen|Cyclosporine (CsA) based immunosuppressant regimen or Tacrolimus (TAC) based immunosuppressant regimen, as per standard practice. Immunosuppressant regimen were not considered study drugs.
1699774|NCT01467492|Drug|Telaprevir|Tablet
1699775|NCT01467492|Drug|Ribavirin|Tablet
1699776|NCT01467492|Biological|Pegylated Interferon Alfa-2a|Subcutaneous Injection
1699777|NCT01467479|Drug|Telaprevir|Tablet
1699778|NCT01467479|Drug|Ribavirin|Tablet
1699779|NCT01467479|Biological|Pegylated Interferon Alfa-2a|Subcutaneous Injection
1699780|NCT01467479|Drug|Highly Active Antiretroviral Therapy (HAART)|Atazanavir/ritonavir (ATV/r) based HAART, Efavirenz (EFV) based HAART, or Raltegravir (RAL) based HAART, as per standard practice. HAART medications were not considered study drugs.
1699781|NCT01467466|Drug|IV isotonic saline|The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
1699782|NCT01467466|Drug|IV isotonic bicarbonate|The investigators will administer 3 ml/kg of isotonic bicarbonate over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic bicarbonate over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic bicarbonate (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
1699783|NCT01467466|Drug|N-acetylcysteine|NAC will be administered at a dose of 1200mg orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
1699784|NCT01467466|Drug|Placebo|A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
1699785|NCT01467453|Device|Triggerfish|The Triggerfish is a contact lens with an embedded sensor to track changes in intraocular pressure during a period of 24 hours.
1699786|NCT01467440|Device|Selective Laser Trabeculoplasty|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
1699788|NCT01467414|Drug|insulin degludec|Injected s.c. (under the skin) once daily for 6 days
1699789|NCT01467401|Drug|biphasic insulin aspart|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
1699790|NCT01467401|Drug|biphasic human insulin|Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily
1699791|NCT01467388|Procedure|selective laser trabeculoplasty (SLT)|trabeculoplasty with an SLT-Laser to reduce intraocular pressure
1699792|NCT01467375|Drug|biphasic insulin aspart|Individually adjusted dose, injected s.c. (under the skin) before breakfast and dinner
1699793|NCT01467362|Drug|V0034CR01B|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 91 days
1699794|NCT01467362|Drug|Vehicle cream|Cream Out of flares: 1 application bid (morning and evening) During flares: 1 application once a day (in the morning) Maximum 28 days
1699795|NCT01467362|Drug|desonide 0.1% cream|cream, once a day (in the evening) during flares
1699796|NCT01467362|Other|Foaming gel|for the washing and cleaning
1699797|NCT01467336|Procedure|Arthroscopic rotator cuff repair|Arthroscopic rotator cuff repair for all groups
1699798|NCT01467323|Drug|biphasic insulin aspart|Injected subcutaneously (under the skin) twice daily
1699799|NCT01467323|Drug|biphasic human insulin|Injected subcutaneously (under the skin) twice daily
1699800|NCT01467310|Drug|GSK1120212|1.5 to 2.0 mg taken orally every day for seven days.
1699803|NCT01467284|Behavioral|Step Ahead|Promotion of weight gain prevention among teachers and staff in public high schools through Step Ahead, a comprehensive intervention targeting three levels suggested by the ecological framework health behavior change: organizational school level, interpersonal level, and individual level.
1699804|NCT01467284|Behavioral|Basic Intervention|Promotion of weight gain prevention among teachers and staff in public high schools through receipt of the workbook print materials and access to website similar to the enhanced intervention.
1699805|NCT01467258|Drug|Amantadine|Single dose
1699806|NCT01467245|Procedure|Hypercapnia during thoracoscopy|keyhole surgery through the chest for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
1699807|NCT01467245|Procedure|Open surgery|open surgery for repair of oesophageal atresia with tracheo-oesophageal fistula or congenital diaphragmatic hernia in neonates
1699858|NCT01466881|Other|Laboratory Biomarker Analysis|Correlative studies
1699808|NCT01467232|Biological|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium.
1699809|NCT01467232|Biological|Injection of autologous CD133+ stem cells at the time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells, or placebo (saline solution containing autologous plasma without CD133+) will be injected into the myocardium
1699810|NCT01467219|Procedure|lymphadenectomy|bilateral pelvic and para-aortic lymph node dissection
1699811|NCT01467219|Procedure|therapeutic conventional therapy|hysterectomy, bilateral salpingo-oophorectomy,bilateral pelvic and para-aortic lymph node dissection +/- omentectomy via laparotomy, laparoscopy or robotic-assisted
1699812|NCT01467219|Procedure|Positron Emission Tomography/ Computed Tomography|Pre-operative PET/CT scan
1699813|NCT01467219|Radiation|fludeoxyglucose F 18|5 MBq/kg body weight of FDG (up to 550 MBq)
1699814|NCT01467206|Behavioral|Long term follow up by a coordinating physiotherapist|Monthly meetings with an coordinating physiotherapist who motivate and encourage the patient to do 60 minutes of weekly exercise and 30 minutes of daily physical activity
1699815|NCT01467206|Behavioral|Standard care|Standard care as it is given to all stoke patients after stroke
1699816|NCT01467193|Dietary Supplement|Fat diet|Instructions for a high fat diet will be given at the end of visit 2. This consists of the usual food intake with a supplementary fat intake of 0.75g fat/kg BW, administered as 3 additional snacks. These snacks will be distributed in pre-packed bags. A food diary will be kept. All arms will receive this diet during the 3 days preceding the clamp.
1699817|NCT01467193|Other|2h standardized aerobic exercise|Aerobic (50-60% of Vo2 max) standardized exercise on a bicycle during 2 hours
1699818|NCT01467180|Device|septeX|continuous veno-venose hemodialysis (CVVHD) with dialysate flow rate (Qd)of 35ml/kg/h for 48h
1699819|NCT01467180|Device|HF CVVH|continuous veno-venose hemofiltration (CVVH) with 35ml/kg/h UF-rate for 48h
1699820|NCT01467141|Drug|insulin aspart|Injected s.c. (under the skin) three times a day
1699821|NCT01467141|Drug|human insulin|Injected s.c. (under the skin) 30 minutes before the meals
1699822|NCT01467141|Drug|isophane human insulin|May be administered s.c. (under the skin) in both treatment groups thrice daily
1699823|NCT01467128|Other|Structured expert pharmacist review|The researcher will apply the pharmacist intervention to the cases randomised to this arm of the study. This consists of an expert pharmacist review of the patients prescribed medications at the time of recruitment into the study. Recommendations following the intervention will be communicated both verbally and in writing to the medical team with primary responsibility for the patient. Recommendations arising from the intervention will be printed out and inserted into the patients' notes, in addition to the relevant registrar being informed in person or via the telephone.
1699824|NCT01467128|Other|No Intervention|Normal hospital pharmaceutical care
1955905|NCT03032536|Drug|AL-3778|AL-3778 tablets or capsules
1955906|NCT03032536|Drug|Entecavir|Entecavir once daily for 14 days
1955907|NCT03032536|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate once daily for 14 days
1955910|NCT03029884|Device|Active DBS|Pain-related pathway regions will be implanted, recorded from and stimulated in patients. Recorded neural data will inform stimulation parameters that may decrease pain states.
1955911|NCT03029884|Device|Inactive DBS|Pain-related pathway regions will be implanted, recorded from but not stimulated in patients. Recorded neural data will inform stimulation parameters that may decrease pain states.
1699834|NCT01467076|Drug|Aerosolized Normal Saline|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. Placebo will be administered over a maximum duration of 72 hours.
1699835|NCT01467076|Drug|Inhaled PGE1|Two initial doses of IPGE1 will be tested - 150 and 300 ng/kg/min. Thus, there will be three arms to the study - IPGE1 [150], IPGE1 [300], and placebo (normal saline). This design will allow comparison of the two doses of IPGE1 with each other and controls; and also allow comparison of any IPGE1 with controls. In this Pilot RCT, two doses of IPGE1 (300 and 150 ng/kg/min) will be administered over a maximum duration of 72 hours to determine the optimal dose and duration of therapy.
1699836|NCT01467063|Dietary Supplement|Glutamine|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a drink containing Glutamine (0.25 g/kg/dose). Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
1699837|NCT01467063|Dietary Supplement|Placebo|Participants will keep a diary of food intake and activity as well as wear an accelerometer (to measure overall movement) for 2-3 days prior to the admission. Subject will come to the Clinical Research Center for approximately 24 hours. They will receive a PLACEBO drink. Afterwards they will have an afternoon exercise session consisting of 15-min bouts of exercise, interspersed with 5-min rest periods in between for a total of 75min. Blood glucose will be checked during rest intervals. They will be served a controlled dinner. Before bedtime another dose of the same drink will be given. Overnight blood glucose will be monitored closely. In the morning, another dose of the same drink will be given. Subjects will have two isotope infusions (non-radioactive) running concomitantly and a hyperinsulinemic-euglycemic clamp will be performed. Afterwards lunch will be served and subject discharged home.
1699840|NCT01467037|Other|No intervention done|Not applicable because no intervention was done.
1699842|NCT01467011|Drug|Enteric-coated Mycophenolate Sodium|1440mg/day for 6 months posttransplant
1699843|NCT01466998|Other|Paced Respiration|Practice paced respiration 15 minutes per day for a total of 12 weeks.
1699844|NCT01466998|Other|Music Therapy|Practice music therapy for 15 minutes per day for a total of 12 weeks.
1699845|NCT01466985|Drug|Doravirine|Doravirine tablets, orally, once daily for 7 days at a dose of 25 mg in Panel A and 200 mg in Panel B; dose in Panel C to be determined (≤200 mg).
1699846|NCT01466985|Drug|Placebo|Placebo tablets once daily for 7 days.
1699847|NCT01466972|Drug|Pazopanib|Oral, 800mg tablet daily per cycle
1699848|NCT01466959|Other|citrate dialysate (CD)|Citrasate (CD) is substituted as the dialysate during the patients regular dialysis run 4hours three times weekly for a period of 2 weeks. The only difference between citrasate and the regular dialysate is the lack of acetic acid.
1699849|NCT01466959|Other|acetic-acid based dialysate (AD)|Acetate based dialysate; AD is the standard dialysate used in hemodialysis runs 4 hours three times weekly. For the study it will be used for a period of 2 weeks and compared to the CD study time period.
1699850|NCT01466946|Behavioral|semi-structured interviews|Use semi-structured interview methods to gather narrative data from research participants, as more open-ended interviews allow participants to share information that is most relevant to their own experiences (Patton, 2002; Rubin & Rubin, 2005; Kvale, 1996). Semi-structured interviewing can generate a rich understanding of a participant's life routines, experiences, and attitudes related to a topic of inquiry, and can yield a nuanced and thorough description of a research participant's life story and belief systems.
1699851|NCT01466933|Behavioral|Responsive parenting|On a monthly basis, mothers meet with the peer educator to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development. Mothers practice with their child and are coached by the peer educator.
1699852|NCT01466933|Behavioral|Child Development|On a monthly basis, mothers meet with the government worker to learn about ways to provide a hygienic environment (hand-washing), proper diverse diet (family foods, breast milk), play materials and conversation to stimulation their child's cognitive and language development.
1699853|NCT01466907|Other|Secondary prevention, supportive counselling|Patients' self-reports on Mobility, Self Care, Usual activities, Pain/Discomfort, Anxiety/Depression, Health Outcome were registered. Health problems were assessed. Secondary prevention was controlled by measuring blood pressure, Cholesterol levels, HbA1c, Weight to estimate nutritional status. Functional status was assessed. Supportive counselling was provided. Referral was sent to physician if medical interventions were needed.
1699854|NCT01466907|Other|Standard care until one year follow-up|No intervention three months after stroke. Assessment one year after stroke and comparison with the intervention group.
1699855|NCT01466894|Biological|IMM 124-E|Tablets orally twice a day for 24 weeks
1699856|NCT01466894|Biological|Placebo|Tablets orally twice daily for 24 weeks
1699857|NCT01466881|Drug|Alisertib|Given PO
1699860|NCT01466868|Drug|MK2206|"Treatment will be administered orally once weekly, 2 hours before or after a meal, at day 1, 8, 15, 22 over a 28 day cycle period.
The starting dose level is 200 mg. 2 dose reduction are allowed (135 mg and 90 mg)in case of documented toxicity according to the specific algorithms."
1699861|NCT01466855|Drug|Intra-Ophthalmic Artery Topotecan Infusion|Topotecan via intra-ophthalmic artery delivery infused over 30 minutes on Day 1 of every 21-day cycle.
1699862|NCT01466842|Procedure|Catheter ablation using cryothermia|Three months before the catheter ablation procedure, a subcutaneous loop recorder will be implanted. The ablation procedure will be performed using cryothermia.
1699863|NCT01466829|Drug|Parathyroid hormone|100 microgram daily. S.c
1699864|NCT01466829|Drug|Placebo|Placebo; saline injection.
1699865|NCT01466816|Dietary Supplement|test meals with various fatty acid compositions|Three different milkshakes with a U13C palmitate tracer added
1699866|NCT01466803|Drug|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
1699867|NCT01466803|Drug|Vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
1699868|NCT01466790|Drug|TMC435|TMC435 will be administered as one oral capsule of 150 mg once a day.
1699869|NCT01466790|Drug|PSI-7977 (GS7977)|PSI-7977 (GS7977) will be administered as oral tablets (2 tablets of 200 mg for Cohort 1 and 1 tablet of 400 mg for Cohort 2) once a day.
1699870|NCT01466790|Drug|Ribavirin|Ribavirin will be administered according to body weight. For patients with body weight less than 75 kg daily dose (1000 mg) will be administered as 400 mg (2 oral tablets of 200 mg) in the morning and 600 mg (3 oral tablets of 200 mg) in the evening. Body weight more than or equal to 75 kg daily dose (1200 mg) will be administered as 600 mg twice a day (3 tablets of 200 mg per intake, morning and evening).
1699871|NCT01466777|Procedure|Traditional surgery type|Traditional laparoscopic surgery for endometrial cancer
1699872|NCT01466777|Procedure|Robotic assisted laparoscopic surgery|Robotic assisted laparoscopic surgery for endometrial cancer
1699873|NCT01466764|Drug|Anakinra|An injection of 100 mg Anakinra was administered 1 hour prior to surgery and again 24 hours following surgery.
1699874|NCT01466764|Other|Normal Saline|An injection of normal saline was administered 1 hour prior to surgery and again 24 hours following surgery.
1699876|NCT01466738|Biological|HRV-16 (100 TCID50)|Each volunteer will receive a single administration of 100 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
1699877|NCT01466738|Biological|HRV-16 (1000 TCID50)|Each volunteer will receive a single administration of 1000 TCID50 of HRV-16 in a total volume of approximately 1.0 mL administered via 4 intranasal instillations.
1699878|NCT01466725|Drug|CC-930|
1699879|NCT01466725|Drug|Placebo|Placebo
1699880|NCT01466712|Drug|Tiotropium + formoterol/beclometasone|Tiotropium 18 µg/dose once daily (handihaler device) + formoterol, fumarate 6µg + beclometasone, dipropionate 100µg / dose (Pressurised inhaler): 2 puffs bid, for one month.
1699881|NCT01466712|Drug|tiotropium + placebo|Tiotropium 18 µg/dose once daily (handihaler device) + placebo (Pressurised inhaler): 2 puffs bid, for one month.
1699882|NCT01466686|Radiation|Low Dose Fractionated Radiation Therapy (LDFRT)|All patients will receive 0.5 Gy of radiation therapy twice daily. This study will include a safety run-in component. If > 33% of patients in the initial cohort of 6 experience grade 3 or greater hematologic toxicity according to the NCI Common Toxicity Criteria version 4, then a dose reduction will occur following the schedule listed below. Otherwise, following a 1 month waiting period after the first cycle of adjuvant LDFRT plus temozolomide for the first cohort of patients, the phase 2 study will open for full accrual. Patients will receive radiation with the first six 28-day cycles of temozolomide.
1699883|NCT01466686|Drug|Temozolomide|All patients will receive temozolomide (150 to 200 mg per square meter for 5 days during each 28 day cycle) for a total of 1 year or until the time of disease progression.
1699884|NCT01466673|Drug|Ethinyl estradiol/Norgestimate (EE/NGM)|Ethinyl estradiol/Norgestimate encapsulated oral tablet will be administered once daily at bed time as 0.035/0.18 milligram (mg) for Days 1-7, 0.035/0.215 mg for Days 8-14, and 0.035/0.250 mg for Days 15-21 of EE/NGM, respectively up to 6 consecutive menstrual cycles consisting of 21 days each.
1699885|NCT01466673|Drug|Ethinyl estradiol/Desogestrel (EE/DSG)|Ethinyl estradiol/Desogestrel oral formulation will be administered once daily at bed time as 0.040/0.025 mg for Days 1-7, 0.030/0.125 mg for Days 8-22 of EE/DSG, respectively up to 6 consecutive menstrual cycles consisting of 22 days each.
1699886|NCT01466660|Drug|Afatinib|afatinib once daily
1699887|NCT01466660|Drug|gefitinib|Gefitinib once daily
1699888|NCT01466647|Drug|AXL1717|A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
1699889|NCT01466634|Procedure|percutaneous coronary intervention with stent|patients with coronary artery disease treated by percutaneous coronary intervention with BP-DES are compared with patients with coronary artery disease treated by percutaneous coronary intervention with PP-DES
1699890|NCT01466608|Drug|Rosuvastatin|Oral administration of rosuvastatin 20 mg once daily for 21 days.
1699891|NCT01466595|Drug|Rifaximin|Participant were administered one 550 mg tablet of rifaximin to be taken orally two times a day for 4 weeks.
1699892|NCT01466569|Drug|AbGn-7|Phase 1a: dose escalation; Drug: AbGn-7 weekly iv infusion Duration: 6 weeks
1699893|NCT01466569|Drug|AbGn-7|Phase 1b: two doses (one dose below MTD/MAD and MTD/MAD as determined in phase 1a) Drug: AbGn-7 weekly iv infusion combined with FOLFOX7 Duration: 6 weeks
1699894|NCT01466556|Other|Routine laboratory tests|Laboratory tests to determine metabolic syndrome
1699895|NCT01466543|Drug|Zydena (Udenafil)|Zydena (Udenafil) 100 mg, one time
1699896|NCT01466543|Drug|Placebo|Placebo
1699897|NCT01466530|Drug|Placebo|received sublingual two moistened white coated placebo tablets which looked identical in size, colour, and packing to misoprostol tablet.
1699898|NCT01466530|Drug|Misoprostol|sublingual misoprostol was given by putting two moistened tablets of misoprostol (400 µg) under the tongue and allowing them to dissolve (Misotac®, Sigma Pharmaceutical Industries, Egypt) (200 µg/tablet).
1700070|NCT01465386|Drug|bortezomib|Given SC
1699899|NCT01466517|Drug|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
1699900|NCT01466517|Drug|Ibuprofen|400mg of Ibuprofen equivalent to 10mL (40mg/mL) oral suspension of the Test Drug
1699901|NCT01466504|Procedure|skin punch biopsy|Skin biopsy prior to sorafenib or regorafenib treatment and when rash appears or 12 weeks into treatment.
1699902|NCT01466491|Drug|Paracervical block technique with lidocaine|The PCB will consist of a total of 20 mL local anesthetic (18 mL of 1% lidocaine buffered with 2 mL sodium bicarbonate) injected with the following technique: 2 mL are injected at the tenaculum site, 12 o'clock, superficially into the cervix. The tenaculum is placed at 12 o'clock. The remaining 18 mL are injected paracervically (vaginal fornices) over sixty seconds. The injection, occurring in either two or four sites, is continuous from superficial to deep (3 cm) to superficial (injecting with insertion and withdrawal). It will be followed with either no wait or a three-minute wait period.
1699903|NCT01466478|Drug|Ointment A: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
1699904|NCT01466478|Drug|Ointment B: LEO 29102 2.5 mg/g ointment|once daily application, 4 weeks
1699905|NCT01466478|Drug|Ointment C: Calcipotriol 50 µg/g ointment|once daily application, 4 weeks
1699906|NCT01466478|Drug|Ointment D: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
1699907|NCT01466478|Drug|Ointment G: LEO 29102 2.5 mg/g plus calcipotriol 50 µg/g ointment|once daily application, 4 weeks
1699908|NCT01466478|Drug|Daivonex® ointment|once daily application, 4 weeks
1699909|NCT01466478|Drug|Diprosone® ointment|once daily application, 4 weeks
1699910|NCT01466465|Drug|Cholecalciferol|given orally, once daily, before grass pollen season
1699911|NCT01466465|Other|middle-chain fatty acids (carrier)|given orally, once daily, before grass pollen season
1699912|NCT01466452|Drug|Aspirin|single-dose aspirin in 100 mg 1 tablet every 24 hours
1699913|NCT01466452|Drug|Aspirin|single-dose aspirin 200 mg 1 tablet every 24 hours
1699914|NCT01466452|Drug|Aspirin|double-dose aspirin 100 mg 1 tablet every 12 hours
1699915|NCT01466439|Procedure|high-frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 20 Hz
1699916|NCT01466439|Procedure|low frequency of repetitive transcranial magnetic stimulation (rTMS)|frequency of stimulation of 1 Hz
1699917|NCT01466413|Device|Tropoelastin|"Multiple intradermal implants comprising of three treatments, 3 weeks apart, each consisting of 16 injections in total, each 10mm apart in a grid formation over a 3cm x 3cm area of the mid to deep dermis of the medial aspect of the upper arm. Each injection will consist of 20-30ul of product delivered using a 30Gx¼ needle. Each subject will also receive Restylane® Vital Light (control) to the opposite arm following the same treatment regimen and using the same technique. The treatment will be administered on Day 1, 22 and 43."
1699923|NCT01466374|Drug|Placebo|Normal Saline, Intravenous (IV), 0 mg, Once a week for the first week and every other week thereafter, 11 weeks
1699924|NCT01466374|Drug|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 337days
1699925|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 10 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
1699926|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 20 mg/kg, Once a week for the first week and every other week thereafter, 11 weeks
1699927|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 7.5 mg/kg, Every other week, Up to 337 days
1699928|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg, Every other week, Up to 337 days
1699929|NCT01466374|Drug|BMS-936557 (Anti-IP-10 Antibody)|Solution for IV administration, Intravenous, 15 mg/kg or optimal dose, Every other week, Open
1699930|NCT01466361|Drug|Nicotine lower dose|lower dose nicotine lozenge
1699931|NCT01466361|Drug|Nicotine higher dose|higher dose nicotine lozenge
1699932|NCT01466361|Drug|Placebo|placebo
1699933|NCT01466348|Drug|Paracetamol and Caffeine|Paracetamol 1000 mg and caffeine 130 mg
1699934|NCT01466348|Drug|Paracetamol|Paracetamol 1000 mg
1699935|NCT01466335|Drug|Ronacaleret (100mg tablet)|100mg tablet
1699936|NCT01466335|Drug|Placebo|matching placebo tablet
1699937|NCT01466322|Drug|GSK2018682 CD2 Capsule; GSK2018682 CD3 non-micronised Tablet; GSK2018682 CD3 micronised Tablet; GSK2018682 CD3 non-micronised Tablet in fed state|Four single dosing sessions where each regimen A,B C or D will be administered orally in a randomised, cross-over manner. At each dosing session, pharmacokinetic sampling time-points will be the same.
1699938|NCT01466309|Device|Somnoguard oral appliances|wearing somnogaurd daily at bedtime
1699939|NCT01466296|Device|Chaotic Perturbation|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the random shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will impose perturbations in the range tolerated by the subject. The therapist will make a written report of each session."
1699940|NCT01466296|Device|Dummy not active shoes|"Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will perform basic stretching and muscle strengthening, then wear the dummy shoes and perform a set of exercises following specific verbal tasks, e.g., Walk 5 strides forward, or, Walk to the right side until I ask you to stop. During this stage of walking the device will not impose perturbations. The therapist will make a written report of each session."
1700067|NCT01465412|Drug|Preladenant|After at least an 8 hours overnight fast, one 5-mg preladenant tablet, is administered orally, on Day 1.
1699941|NCT01466296|Device|Treadmill training|Each subject will undergo 36 intervention sessions, 3 times per week over 12 weeks. Each session will last up to 45 minuets, depending on the subject's endurance. During each session the subject will exercise basic stretching and muscle strengthening, then walk on the treadmill. A physiotherapist according the subject's rate of improvement will determine the increase in treadmill velocity and slope. The therapist will make a written report after each session.
1699942|NCT01466283|Genetic|DNA methylation analysis|
1699943|NCT01466283|Genetic|fluorescence in situ hybridization|
1699944|NCT01466283|Genetic|gene expression analysis|
1699945|NCT01466283|Genetic|reverse transcriptase-polymerase chain reaction|
1699946|NCT01466283|Other|laboratory biomarker analysis|
1699947|NCT01466270|Drug|donepezil hydrochloride|Given PO
1699948|NCT01466270|Drug|Placebo|Given PO
1699949|NCT01466257|Biological|cetuximab|
1699950|NCT01466257|Drug|cisplatin|
1699951|NCT01466257|Genetic|DNA analysis|
1699952|NCT01466257|Genetic|gene expression analysis|
1699953|NCT01466257|Genetic|mutation analysis|
1699954|NCT01466257|Other|laboratory biomarker analysis|
1699955|NCT01466244|Biological|cetuximab|
1699956|NCT01466244|Drug|cisplatin|
1699957|NCT01466244|Genetic|gene expression analysis|
1699958|NCT01466244|Genetic|microarray analysis|
1699959|NCT01466244|Other|immunohistochemistry staining method|
1699960|NCT01466244|Other|laboratory biomarker analysis|
1699961|NCT01466231|Drug|Everolimus|Tablets p.o. 10 mg daily until progression, unacceptable toxicity, complete response or inability of the subject to comply with study requirements.
1699962|NCT01466205|Drug|DAR-0100A|DAR-0100A will be administered intravenously in a dose of 15mg in 150mls of saline over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
1699963|NCT01466205|Drug|Placebo|150mls of saline is administered over 30 minutes at approximately 11:00AM on each of three consecutive days of administration. Additional saline will be co-administered to ensure hydration.
1699964|NCT01466192|Drug|MP-424 (generic name:Telaprevir)|750mg q8h for 12 weeks
1699965|NCT01466192|Drug|Ribavirin|400 - 1000 mg/day based on body weight for 24 weeks
1699966|NCT01466192|Drug|Peginterferon alfa-2b|1.5mcg/kg/week for 24 weeks
1699967|NCT01466179|Biological|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
1699968|NCT01466166|Biological|pegloticase|pegloticase 8mg intravenous every 2 weeks
1699969|NCT01466153|Drug|Rituximab|Rituximab was administered by IV infusion as a dose of 375 mg/m^2 on Day 2 of Cycle 1 and then at 500 mg/m^2 on Day 1 of up to 5 subsequent 28-day cycles
1699970|NCT01466153|Drug|Bendamustine|Bendamustine was administered by IV infusion as a dose of 70 mg/m^2 on Day 1 and Day 2 of each 5 subsequent 28-day cycle.
1699971|NCT01466153|Drug|MEDI-551|MEDI-551 was administered at 2 mg/kg or 4 mg/kg by IV infusion on Days 2 and 8 of Cycle 1 and then on Day 1 of up to 5 subsequent 28-day cycles.
1699972|NCT01466140|Other|Writing down request for help|Patients in the intervention group could write down their request for help on a request card (with a maximum of 2 questions).
1699973|NCT01466127|Drug|Oxytocin|Liquid metered-dose nasal spray, 30 IUs, administered once.
1699974|NCT01466127|Drug|Placebo|Matched nasal spray placebo
1699975|NCT01466114|Drug|estriol|4 capsules of 2 mg (total of 8 mg) PO QD
1699976|NCT01466114|Other|Placebo|4 capsules PO QD
1699977|NCT01466114|Drug|Norethindrone|Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
1699978|NCT01466114|Other|Progestin Placebo|Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
1699979|NCT01466101|Drug|Placebo administration|Administration of placebo
1699980|NCT01466101|Drug|Pregabalin administration|Administration of pregabalin
1699981|NCT01466088|Drug|Donepezil|Subjects taking donepezil will take 1-2 capsules of 5 mg donepezil and a placebo for AZD3480 (to maintain blind) orally once a day.
1699982|NCT01466088|Drug|AZD3480|Subjects taking 30 mg AZD3480 will take one capsule of AZD3480 and two capsules of placebo for donepezil (to maintain blind) orally once a day.
1699983|NCT01466075|Device|Apollo Evolution Investigational BG Monitoring System|Untrained subjects with diabetes perform self Blood Glucose (BG) tests with capillary fingerstick blood and Alternative Site Testing (AST) of the palm using the Apollo Evolution meter and an investigational sensor. Study staff test subject venous blood and all BG results are compared to a reference laboratory glucose method. Untrained subjects complete basic tasks using the User Guide and provide feedback.
1699984|NCT01466062|Drug|Palivizumab|
1699985|NCT01466036|Drug|Cabozantinib|60 mg QD orally in cycles of 28 days
1699986|NCT01466010|Procedure|surgical removal of osteoid osteoma|surgery for osteoid osteoma: this may include curettage or en-bloc resection of the lesion
1699989|NCT01465984|Drug|Paracetamol|paracetamol , 1 gram Iv infusion Morphine Sulfate0.1 Mg/Kg Iv
1699990|NCT01465958|Biological|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Intravenous Administration: 200-600 mg/kg per intravenous infusion every 3-4 weeks
1699991|NCT01465958|Biological|GAMUNEX-C|GAMUNEX-C Immune Globulin Injection (Human), 10%, Caprylate/Chromatography Purified, Subcutaneous Administration: weekly subcutaneous infusion at a mg/kg dose based on subject's intravenous dose and dosing interval x 1.37 conversion factor
1699992|NCT01465945|Procedure|Defect Unsutured|The defect is not sutured after the rectal tumor is removed by TEM.
1699993|NCT01465945|Procedure|Defect Sutured|Defect is sutured after the rectal tumor has been removed by TEM.
1700068|NCT01465399|Biological|Plasma Rich in Growth Factors PRGF-Endoret|
1758844|NCT00270127|Drug|Epoetin alfa|
1699994|NCT01465932|Other|Control, no Proprioception|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 1 (control group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff and cryotherapy.
1699995|NCT01465932|Other|Experimental, Proprioceptive exercises|The period of data collection period was from June 2010 to August 2011. All subjects who met the inclusion criteria, were randomly allocated to group 1 (control) or group 2 (experimental). Both groups consisted of 12 physical therapy sessions, taking place 2 times a week for 6 weeks. After randomization, subjects were allocated to group 2 (experimental group) underwent cervical stretching exercises, strengthening the scapular muscles and rotator cuff exercises and cryotherapy as well as proprioceptive sensory-motor
1699996|NCT01465919|Drug|Mirtazapine|Mirtazapine will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week, dosing between 7.5mg/day and 45mg/day, in patients with interferon induced depression.
1699997|NCT01465919|Other|Supportive psychotherapy|Supportive psychotherapy will be administered at baseline, 1-week, 2-week, 4-week, 6-week, and 8-week in patients with interferon induced depression.
1699998|NCT01465906|Drug|tulobuterol|patch, 2mg, qN, 3 months
1699999|NCT01465906|Drug|Tiotropium Bromide|18ug, inhale, qD, 3 months
1700000|NCT01465906|Drug|tiotropium bromide|18ug, inhale, qD, 3 months
1700001|NCT01465893|Drug|Vitamin D|vitamin D ,50000 unit /week
1700002|NCT01465893|Drug|Vitamin D withheld|do not receive anything
1700003|NCT01465880|Other|Part A|Smoking abstinence, smoking 2 and 4 cigarettes
1700004|NCT01465867|Dietary Supplement|Selenium|83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
1700005|NCT01465867|Other|Sugar Pill Placebo|Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour.
1700006|NCT01465867|Other|Selenium + L-Thyroxine (LT4)|"83 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for all the length of pregnancy and for 3-6th month after labour
+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
1700007|NCT01465867|Other|Sugar Pill Placebo + L-Thyroxine (LT4)|"Placebo supplements in the same capsule as selenium. 1 tablet daily for all the length of pregnancy and for 3-6th month after labour
+ LT4 taken orally daily according to the dose required(in women already receiving it or needing of start it)"
1700008|NCT01465841|Device|PC 400 coils (Penumbra )|The Penumbra Embolization Coil is indicated for the endovascular embolization of aneurysms. The Embolization Coil functions to selectively embolize aneurysms by packing a sufficient quantity of soft platinum coils to achieve occlusion. The Coil Implant is constructed of 92% Platinum and 8% Tungsten round wire with a diameter approximately 0.0015in ± 0.0001in. The maximum primary diameter is 0.022in and the coil implant will have a semi-spherical atraumatic distal tip.
1700011|NCT01465815|Drug|erlotinib hydrochloride|Given PO
1700012|NCT01465815|Drug|linsitinib|Given PO
1700013|NCT01465815|Drug|placebo|Given PO
1700014|NCT01465815|Radiation|radiation therapy|Undergo radiation therapy
1700015|NCT01465815|Procedure|therapeutic conventional surgery|Undergo planned surgery
1700016|NCT01465815|Other|laboratory biomarker analysis|Correlative studies
1700017|NCT01465802|Drug|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule until disease progression, toxicity, death or withdrawal of consent
1700018|NCT01465802|Drug|Dacomitinib|Dacomitinib 45 mg orally daily on a continuous schedule for the first 10 days in Cycle 1, followed by 4 days off treatment, followed by continuous daily dosing until disease progression, toxicity, death or withdrawal of consent
1700019|NCT01465802|Drug|Doxycycline|Doxycycline or Doxycycline placebo BID for 4 weeks
1700020|NCT01465802|Drug|Probiotic|VSL#3 probiotic 4 capsules orally daily or 1 sachet orally daily for up to 5 weeks (starting between Day minus 7 to Day minus 4 and continuing through Day 28)
1700021|NCT01465802|Drug|Alclometasone cream|Topical alclometasone diproprionate cream 0.05% applied to face, hands, feet, neck, back and chest at bedtime for 4 weeks
1700022|NCT01465776|Other|laboratory biomarker analysis|Correlative studies
1700023|NCT01465776|Other|preventative dietary intervention|lyophilized black raspberries(LBR) administration: 3 LBR troche lozenges (dissolved in mouth), 4 times/day beginning at minimum of 24 hrs following biopsy until night before surgery
1700024|NCT01465763|Drug|tofacitinib|10 mg oral BID
1700025|NCT01465763|Drug|Placebo|Plabebo oral BID
1700026|NCT01465737|Other|Histologic types|evaluate survival among different histologic types
1700027|NCT01465724|Procedure|Renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system.
1700028|NCT01465711|Procedure|All abdominal surgical procedures|Laparotomy, Laparoscopy
1700029|NCT01465711|Procedure|Intubation|Ventilatory support
1700030|NCT01465711|Radiation|Imaging|Abdominal ultrasound Computer Tomography Magnetic Resonance Imaging
1700031|NCT01465698|Behavioral|Exercise|"The main target for exercise intervention is to restore impairments in movement control. First, the participants need to learn the proper technique of each exercise, second to achieve movement control of lumbar neutral zone in each exercise, and finally to increase the challenge of exercises for balance, coordination, muscular endurance and strength. Target dose for exercise is twice a week, 60 minutes per session for six months.
The neuromuscular exercise program is progressive including three different performance levels. During the first eight weeks, the supervised exercise sessions will take place twice a week. The next 16 weeks the participants have one instructed weekly session, and they exercise once a week at home with help of a DVD or booklet produced for the study"
1758845|NCT00270140|Drug|epoetin alfa|
1700032|NCT01465698|Behavioral|Counseling|Counseling is conducted according cognitive-behavioral principles. Fear-avoidance model is implemented using problem based learning. The objective is to change participants' understanding of LBP towards less fearful and negative beliefs, and to provide encouragement for usual daily activities, including physical activity. Advice on nursing tasks that are strenuous for low back is aimed to improve awareness of injury risk and provide examples of proper postures and movements. The target is that participants in counseling groups attend 10 sessions each lasting 45 minutes. During the first four weeks the groups meet every second week, and after that once a month up to six months. Participants will receive workbooks to enhance problem-based learning.
1700033|NCT01465698|Behavioral|Exercise and counseling|Participants take part in both exercise and counseling as described in the separate interventions.
1700034|NCT01465698|Other|Control group|Participants in the control group take part only in measurements of NURSE-RCT.
1700035|NCT01465685|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
1700036|NCT01465685|Drug|Methylphenidate|1 hour before MDMA/placebo 60 mg methylphenidate per os, single dose
1700037|NCT01465685|Drug|Placebo|capsules identical to MDMA or methylphenidate
1700040|NCT01465646|Drug|levothyroxine|
1700041|NCT01465646|Drug|levothyroxine|
1700042|NCT01465633|Drug|levothyroxine|
1700043|NCT01465633|Drug|levothyroxine|
1700044|NCT01465620|Behavioral|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by a 5 minutes phone call per week during 3 months
1700045|NCT01465620|Behavioral|hygienic-dietetic measures|Therapeutic education about hygienic-dietetic measures followed by only one phone call
1700046|NCT01465607|Behavioral|Mujer Segura|Brief (35-minute) counseling intervention using techniques from Motivational Interviewing and principles of social cognitive theory (SCT) and theory of reasoned action (TRA).
1700047|NCT01465607|Behavioral|CENSIDA counseling program|Didactic HIV and STI counseling involving some personal risk assessment and presenting appropriate information on methods of transmission and for avoiding or reducing the risk of infection. Based on a counseling manual disseminated by CENSIDA, Mexico's federal HIV-AIDS prevention agency.
1700048|NCT01465594|Procedure|transurethral catheter after EERPE/ RALP|transurethral catheter after EERPE/ RALP
1700049|NCT01465594|Procedure|suprapubic catheter after EERPE /RALP|suprapubic catheter after EERPE /RALP
1700050|NCT01465581|Procedure|Division of the filum terminal|Division of the filum is performed through a 6cm incision over the lumbosacral junction that can be oriented either longitudinally or transversely - to be hidden beneath underclothes or swim wear. A single level laminectomy provides sufficient exposure. The dural opening can be as short as 1cm. Under the microscope the filum is identified visually and separated from lower sacral rootlets with the aid of microelectrode stimulation. When a segment of the filum has been excised and sent for laboratory examination, the dura is closed and reinforced with fibrin glue. The wound is closed in layers, and the patient is kept at bed rest horizontal for 2 nights to discourage CSF fistulization of the wound.
1700051|NCT01465568|Drug|Denosumab|60mg subcutaneous injection 6 monthly for 2 doses
1700052|NCT01465568|Drug|bisphosphonates|continue present bisphosphonate treatment
1700053|NCT01465555|Behavioral|Cognitive Behavioral Intervention|Counselors in this condition will work with the modified RecoveryTrack tested in the pilot study which has been altered to provide automated Clinical Alerts at either the intake, Month 1, or Month 2 CRM interview for High Risk patients. In addition, High Risk patients will be flagged in the counselor's caseload for discussion with clinical supervisors. Counselors in this condition will receive the Clinical Alert + Cognitive Behavioral Intervention (CBI) training, as well as monthly feedback from the Principal Investigator on their delivery of the CBI Months 1-3, with a booster session at Month 6.
1700054|NCT01465529|Drug|OligoG CF-5/20|6% OligoG CF-5/20 in water
1700055|NCT01465529|Drug|Saline|0.9% NaCl in water
1700057|NCT01465503|Drug|Bivalirudin|Patients randomized to Bivalirudin group will be treated by bivalirudin before and during the procedure. Bivalirudin will be given as bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.The infusion will be lowered to 1.0 mg/kg per hour in patients with eGFR <30 ml/min/1.73 m2.
1700058|NCT01465503|Drug|Unfractionated Heparin|Patients randomized to the Control group will receive unfractionated heparn (UFH) before and during the procedure. UFH bolus will be of 70 UI/kg. If the activated clotting time measured 5 minutes after the study drug administration is lower than 270 seconds, an additional bolus of the randomised drug (UFH 20 U/kg) will be given.
1700059|NCT01465490|Behavioral|Monitoring and Feedback Intervention|Clients participate in standard treatment and complete the MMI weekly with their counselors at the beginning of each individual counseling session. Counselors have been trained to administer the MMI and will have access to the data to use during sessions.
1700060|NCT01465477|Biological|Inactivated split virion Influenza vaccine|WHO recommended 2011 Influenza vaccine
1700061|NCT01465477|Biological|WHO recommended 2011 Influenza vacccine|WHO recommended 2011 Influenza vacccine
1700062|NCT01465464|Drug|Orantinib (TSU-68)|200 mg (1 tablet) of Orantinib was administered orally twice per day after meals, morning and evening.
1700063|NCT01465464|Drug|Placebo|1 tablet was administered orally twice per day after meals, morning and evening.
1700064|NCT01465451|Procedure|curative resection for colorectal cancer|right hemicolectomy for right colon cancer, transverse colectomy for transverse colon cancer, left hemicolectomy for left colon cancer, sigmoid colectomy for sigmoid colon cancer, and anterior resection or abdominal-perineal resection for rectal cancer.
1700065|NCT01465451|Drug|intra-operative 5-FU chemotherapy|"5-FU, 1000 mg/m2, injection into bowel lumen at the beginning of resection 5-FU, 200 mg/m2, injection into portal vein via mesentery vein at the end of tumor removal and bowel reconstruction.
5-FU, 300 mg/m2, left in abdominal cavity before incision closure. surgical procedures will be the same as described in ARM A."
1700071|NCT01465373|Drug|Endometrin|100 mg per vagina TID
1700072|NCT01465373|Drug|Progesterone in Oil|50 mg IM injection daily
1700073|NCT01465347|Drug|Trans Sodium Crocetinate (TSC)|TSC administered intravenously as a bolus injection prior to radiation therapy sessions during 6 weeks of radiotherapy.
1700074|NCT01465334|Drug|Ofatumumab|1000 mg IV
1700075|NCT01465334|Drug|High-Dose Methylprednisolone|1000 mg/m2 IV
1700076|NCT01465334|Drug|Alemtuzumab|30 mg subcutaneously
1700077|NCT01465308|Dietary Supplement|Honey mouthwash|The patients in the intervention group will receive honey mouthwash 15 minutes before the radiotherapy session, 15 minutes after and 6 hours after the radiotherapy session
1700078|NCT01465308|Other|Normal Saline|Saline rinses 15 minutes before radiotherapy, 15 minutes after, and 6 hours after radiotherapy
1700079|NCT01465295|Device|Mechanical hemiepiphysiodesis using the HemiBridge System|Surgical application of mechanical hemiepiphysiodesis using the HemiBridge device.
1700080|NCT01465282|Drug|CT327 0.05%|0.05% CT327 (w/w) ointment
1700081|NCT01465282|Drug|CT327 0.1%|0.1% CT327 (w/w) ointment
1700082|NCT01465282|Drug|CT327 0.5%|0.5% CT327 (w/w) ointment
1700083|NCT01465282|Drug|Placebo|Placebo
1700084|NCT01465269|Behavioral|Group Interactive Structured Treatment|GIST groups consist of 8 group participants and two group therapists. Group members receive the workbook and are asked to bring it to each session. During each of the 13, 1.5 hour sessions, key concepts from the previous session are reviewed, a new topic is discussed, strategies and skills are practiced interactively, and real-life social problems are addressed. Previously covered topics are integrated into each session through discussion and problem solving to provide repetition and reinforcement of information.
1700085|NCT01465269|Behavioral|Alternative Intervention|Participants in the alternative treatment will attend 13 weekly classroom sessions, where they will view video presentations of the same curriculum topics covered in the GIST workbook. The group therapists will serve as moderators and will meet with participants individually. Group interaction will not be encouraged. Homework exercises will be offered but participants will not be asked to return their homework and will not receive any feedback.
1700086|NCT01465256|Drug|Aspirin|Aspirin hold for a certain period of time in the patients who take aspirin for the primary prevention of vascular disease,
1700087|NCT01465243|Drug|Icotinib|125 mg Tid (375 mg per day) 250 mg Tid (750 mg per day)
1700088|NCT01465230|Drug|Maintenance lenalidomide|Daily maintenance treatment, oral lenalidomide
1700089|NCT01465217|Behavioral|text message medication reminders|daily medication reminders for one month
1700090|NCT01465204|Behavioral|Total Sanitation and Sanitation Marketing|"Total Sanitation and Sanitation Marketing (TSSM) program is designed to promote demand for and supply of improved sanitation. On the demand side, it includes Community-Led Total Sanitation (CLTS). On the supply side, TSSM incorporates sanitation marketing interventions. Both CLTS and sanitation marketing draw heavily on the behavior-change communication and social marketing approaches that have been well developed in other sectors. The basic TSSM approach also builds sustainability and scalability through the strengthening of the national level sanitation sector enabling environment."
1700091|NCT01465204|Behavioral|Scaling Up Handwashing Behavior Change|The Handwashing with soap (HWWS) behavior change program expands and improves existing hygiene behavior change efforts with new and innovative promotional approaches in order to generate widespread and sustained improvement in handwashing with soap practices. These approaches include social marketing to deliver handwashing messages; broad and inclusive partnerships with government, private commercial marketing channels, and concerned consumer groups and NGOs.
1700092|NCT01465191|Drug|Morphine|Morphine will be given via spinal injection at doses of 50, 100, 150 micrograms as part of a spinal anesthetic for cesarean section
1700093|NCT01465178|Dietary Supplement|cholecalciferol|2000 IU cholecalciferol gelcaps by mouth daily
1700094|NCT01465178|Dietary Supplement|Placebo|matching placebo
1700095|NCT01465152|Drug|metformin|Adminstered orally during the three main meals for 24 weeks
1700096|NCT01465152|Drug|repaglinide|Administered orally before the three main meals for 24 weeks
1700097|NCT01465139|Drug|CDX-301|"CDX-301, administered in multiple dosages and frequencies depending on arm:
n=3-6 at between 1-75 μg/kg over 5 days
n=3-6 at 25 μg/kg over 7 days
n=3-6 at 25 μg/kg over 10 days"
1700098|NCT01465113|Drug|Omeprazole|28-day run-in phase during which subjects are treated with a proton pump inhibitor (omeprazole 20 mg po q day or an equivalent dose of another proton pump inhibitor).
1700099|NCT01465113|Drug|Vitamin D3|These patients (indefinite for dysplasia, LGD, or no dysplasia) will take vitamin D3 50,000 IU once a week for 12 weeks following the upper endoscopy.
1700100|NCT01465113|Drug|Vitamin D3|Due to the risk of progression, subjects with Barrett's esophagus with high grade dysplasia will take vitamin D3 50,000 IU once a week for 2 weeks.
1700101|NCT01465113|Procedure|upper endoscopy|After the run-in phase subjects will undergo an upper endoscopy for Barrett's surveillance or Barrett's mapping as part of routine clinical care. At the time of endoscopy, in addition to large cup forceps biopsies obtained for surveillance or mapping as part of standard care, research biopsies will be obtained for the study. Following vitamin D3 supplementation, all subjects will undergo a repeat upper endoscopy for additional large cup forceps biopsies for measurement of post-treatment mucosal levels.
1700102|NCT01465113|Drug|Metformin|500mg for the first week, 1000mg during the second week, 1500mg during the third week, maximum dose of 2000mg in the fourth week
1700103|NCT01465100|Radiation|Preparative Radiation Therapy|Subjects will undergo CT-based simulation and treatment planning for radiation therapy. Once a suitable hepatocyte donor is found and the cell count and viability is acceptable for transplantation, patients will receive Intensity-Modulated Radiation Therapy (IMRT) in one fraction(10 Gy)to the right lobe of the liver (but not exceeding 50% of the liver mass).
1700104|NCT01465100|Procedure|Hepatocyte Transplant|Within a maximum of two days after hepatic irradiation,the right or main portal vein will be occluded transiently (60-90 min)to provide a compensatory mitotic signal to donor hepatocytes. Directly following this transient occlusion of the portal vein, donor hepatocytes will be transplanted into the irradiated portion of the recipient's liver. If at 6 months we see an improvement in PHE tolerance but not normalization (i.e. PHE levels from 6 mg/dl to 10 mg/dl) on an unrestricted PHE diet, we will recommend re-transplantation with a goal of complete correction of PKU. Subjects will be re-evaluated every 6 months for re-transplantation.
1700105|NCT01465100|Drug|Immunosuppression|Following transplantation, patients will be treated with conventional immune suppression, as is used following whole organ liver transplantation. Patients will be followed as routinely performed following organ transplantation and also followed as would normally be performed for their PKU.
1700106|NCT01465100|Other|Liver Evaluation|Prior to the hepatocyte transplant subjects will undergo a liver evaluation which is standard for all patients who have whole organ transplants at Children's Hospital of Pittsburgh of UPMC. The evaluation includes immunosuppression medication education, psychological assessment, bloodwork to assess blood count, blood and tissue type, blood chemistries, immune system function and certain infectious diseases and abdominal ultrasound to assess blood flow to the blood vessels in the liver.
1700107|NCT01465100|Behavioral|Psychological Assessment|Subjects may undergo a psychological assessment at least 6 months post-transplant which will include a semi-structure open ended interview as well as the Adaptive Behavior Assessment System-II assessment and Beck Depression Inventory. If subjects undergo these assessments, they will be compared to those obtained pre-transplant to determine whether an improvement is associated with the transplant procedure. In addition, if subjects are experiencing depression, they will be referred for further care.
1700108|NCT01465087|Other|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
1700109|NCT01465074|Drug|Nicotine polacrilex|4 mg
1700110|NCT01465074|Drug|Regular chewing gum; Dentyne Ice, Wrigely´s Mint Gum|30 min chewing, one dose
1700111|NCT01465061|Behavioral|Online support group|Joining online support group
1700112|NCT01465048|Biological|Plasmodium falciparum sporozoites 2sites|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intradermal injection sites
1700113|NCT01465048|Biological|Plasmodium falciparum sporozoites 1 site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 2,500 sporozoites, 50ulx2, 2 intramuscular injection sites
1700114|NCT01465048|Biological|Plasmodium falciparum sporozoites 1site|Aseptic, purified, cryopreserved Plasmodium falciparum sporozoites, 25,000 sporozoites, 50ulx2, 2 intramuscular injection sites
1700115|NCT01465035|Biological|TIV and MVA-NP+M1|1.5 x 108 pfu MVA-NP+M1, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
1700116|NCT01465035|Biological|Saline placebo and seasonal influenza vaccine TIV|Saline placebo, intramuscular injection into the thigh. Inactivated Influenza Vaccine (Split Virion) 0.5ml (containing 15 micrograms of haemagglutinin, intramuscular injection into the thigh
1700117|NCT01465022|Drug|Combined estrogen-progestin pill|1 mg norethindrone and .035 mg ethinyl estradiol orally for 21 days followed by 7 days of placebo
1700118|NCT01465022|Drug|Progestin-only pill|.35 mg norethindrone once a day orally
1700119|NCT01465009|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Single Administration of 2 tablets Acetylsalicylic acid (500 mg each); in addition, 2 tablets matching placebo to Paracetamol
1700120|NCT01465009|Drug|Paracetamol|Single Administration of 2 tablets Paracetamol (500 mg each); in addition, 2 tablets matching placebo to Acetylsalicylic Acid
1700121|NCT01465009|Drug|Placebo|Single Administration of 2 tablets matching Placebo to Acetylsalicylic Acid together with 2 tablets matching placebo to Paracetamol
1700122|NCT01464996|Procedure|Adhesive: OptiBond XTR; Composite: Herculite Ultra|The intervention in Arm 1 (Adhesive: OptiBond XTR; Composite: Herculite Ultra) is a 2-step, self-etching adhesive.
1700123|NCT01464996|Procedure|Adhesive: OptiBond FL; Composite: Herculite Ultra|Arm 2 (Adhesive: OptiBond FL; Composite: Herculite Ultra) is a 3-step, etch-and-rinse adhesive.
1700124|NCT01464983|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
1700125|NCT01464983|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
1700126|NCT01464983|Drug|Ibuprofen|Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
1700127|NCT01464983|Drug|Ibuprofen|Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
1700128|NCT01464983|Drug|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
1700129|NCT01464970|Procedure|Both Superficial Inferior Artery and Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are clamped
1700130|NCT01464970|Procedure|Superficial Inferior Epigastric Vessels both unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst both the contralateral Superficial Inferior Epigastric Artery and Vein are unclamped
1700131|NCT01464970|Procedure|SIE Artery Unclamped, Vein Clamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is unclamped and the Vein is clamped
1700132|NCT01464970|Procedure|SIE Artery clamped, Vein unclamped|Perfusion assessed in Zone IV of the DIEP flap whilst the contralateral Superficial Inferior Epigastric Artery is clamped and the Vein is unclamped
1700133|NCT01464957|Behavioral|Semi-tailored newsletter|Delivered over 3 consecutive years, in the spring
1700134|NCT01464944|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Paracetamol
1700135|NCT01464944|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Paracetamol
1700136|NCT01464944|Drug|Paracetamol|Paracetamol 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Paracetamol, and 2 Placebo tablets of Acetylsalicylic Acid
1700137|NCT01464944|Drug|Paracetamol|Paracetamol 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
1700138|NCT01464944|Drug|Placebo|2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Paracetamol, orally, single dose
1700139|NCT01464931|Drug|Denosumab|Adminstered by subcutaneous injection
1700189|NCT01464567|Procedure|Pressure Support Ventilation|Pressure-Support Ventilation for 30 minutes
1955931|NCT03024827|Drug|CanniMed® 1:20|A cannabidiol (CBD): tetrahydrocannabinol (Δ9 THC) 20:1 ratio product will be provided as an oil-based suspension.
1700141|NCT01464905|Biological|NU100|0.25 mg SQ, every other day for 12 months
1700142|NCT01464905|Biological|Placebo|1 mL SQ, every other day for 4 months
1700143|NCT01464905|Biological|rhIFN beta-1b|0.25 mg SQ, every other day for 12 months
1700144|NCT01464892|Behavioral|Imagery Rescripting and Reprocessing Therapy|This intervention is comprised of 16 sessions (twice a week) of trauma-focused imagery rescripting
1700145|NCT01464892|Behavioral|STAIR + Imagery Rescripting|A two-phased treatment. Phase 1 is comprised of 8 (weekly) sessions of Skills Training in Affective and Interpersonal Skills (STAIR). Phase 2 consists of 16 sessions (twice weekly) of trauma-focused imagery rescripting.
1700146|NCT01464879|Drug|Testosterone Gel (FE 999303)|
1700147|NCT01464866|Other|Nutritional Supplement|Liquid, pediatric nutritional supplement. 1-2 bottles/day for up to 28 days.
1700148|NCT01464866|Other|Hospital food|Typical hospital food given daily at meals
1700149|NCT01464853|Other|Enteral nutrition with fatty acids|Enteral Feeding to provide 25 kcal/Kg/day
1700150|NCT01464853|Other|Standard Enteral Nutrition|Enteral Feeding to provide 25 kcal/Kg/day
1700151|NCT01464840|Drug|Azithromycin|500 mg intravenous infused over 1 hour
1700152|NCT01464827|Drug|ABT-450|ABT-450 tablets
1700153|NCT01464827|Drug|ABT-333|ABT-333 tablets
1700154|NCT01464827|Drug|ABT-267|ABT-267 tablets
1700155|NCT01464827|Drug|Ribavirin|Ribavirin tablets administered at a weight-based dose, between 1,000 to 1,200 mg daily (divided).
1700156|NCT01464827|Drug|Ritonavir|Ritonavir capsules
1700157|NCT01464814|Dietary Supplement|probiotic plus fish oil capsule|Lactobacillus casei (4B CFU) plus fish oil capsule, T.I.D., for seven (7) days.
1700158|NCT01464814|Dietary Supplement|Fish oil capsule|Fish oil capsule, T.I.D., for seven (7) days
1700159|NCT01464801|Dietary Supplement|Resveratrol|Tablet Resveratrol 500 mg 3 times daily for 6 months
1700160|NCT01464801|Dietary Supplement|Placebo|Tablet Placebo 3 times daily for 6 months
1700161|NCT01464788|Drug|Low Dose Argatroban|100 micrograms/kilogram bolus, followed by 1 microgram/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
1700162|NCT01464788|Drug|High Dose Argatroban|100 micrograms/kilogram bolus, followed by 3 micrograms/kilogram/minute IV infusion for 48 hours and rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
1700163|NCT01464788|Drug|rt-PA (alteplase)|rt-PA (alteplase) 0.9mg/kg (max dose 90mg) - 10% bolus, then 90% over 1-hour
1700166|NCT01464762|Drug|TMC207|400mg once daily by mouth for 2 weeks followed by 200mg by mouth three times per week for 22 weeks + individualized background of antibacterial drugs
1700167|NCT01464749|Behavioral|Task-oriented circuit class training|5 sessions/week over 2 weeks (10 sessions) 120 minutes/each
1700168|NCT01464749|Behavioral|usual care|no specific rehabilitation
1700169|NCT01464736|Other|physical training|For both groups, the approximately hour-long sessions occurred three times a week on alternate days for six consecutive weeks (18 sessions). Each session began with five minutes of stretching that included the cervical muscles and the upper and lower limbs, which was followed by five minutes of warm-up on a treadmill at 2Km/h and 30 minutes of aerobic physical training at a constant 3% incline.
1700170|NCT01464723|Drug|Ranibizumab|Intravitreal injections of 0.5 mg ranibizumab administered monthly for the first 4 months, and then as needed for a total duration of 12 months.
1700171|NCT01464697|Drug|Oral micronized progesterone|300 mg as 3-100 mg capsules taken orally at bedtime daily for 12 weeks
1700172|NCT01464697|Drug|placebo|placebo comparator, taken as 3 round capsules at bedtime daily for 12 weeks
1700173|NCT01464671|Drug|Bivalirudin|Anticoagulation during percutaneous coronary intervention
1700174|NCT01464671|Drug|Heparin|Anticoagulation during percutaneous coronary intervention
1700175|NCT01464658|Procedure|panniculectomy|surgery
1700176|NCT01464645|Device|Modular Revision Hip System|Hip System that is indicated for patients whose bone stock is of poor quality or inadequate for other reconstruction techniques as indicated by deficiencies of the femoral head, neck or portions of the proximal femur.
1700177|NCT01464632|Device|EPIK™ uni-compartmental knee|This device is intended for partial replacement of the articulating surfaces of the knee when only one side of the joint is affected due to compartmental primary degenerative or post-traumatic degenerative disease, previous tibial condyle or plateau fractures, deformity, or revision of previous arthroplasty.
1700178|NCT01464619|Other|The Incredible Years Parenting Intervention|The Incredible Years Parents, Babies, and Toddlers Program is a validated group parenting education program, which has been adapted for use with depressed caregivers by inclusion of psychoeducational depression materials.
1700179|NCT01464619|Other|Delayed Intervention|Caregivers assigned to delayed intervention will be assigned to the Incredible Years parenting intervention 3-4 months after enrollment.
1700180|NCT01464606|Drug|Vincristine|≥ 3 years: 1.5 mg/m2 IV x 1 (maximum dose 2 mg)
1700181|NCT01464606|Drug|Dactinomycin|≥ 3 years: 0.045 mg/kg (maximum dose 2.5 mg) IV X 1
1700182|NCT01464606|Drug|Cyclophosphamide|≥ 3 year: 1.2 gm/m2/dose IV as 1 hr infusion with IV fluids
1700183|NCT01464606|Drug|Ifosfamide|≥ 3 years: 3 g/m2/dose IV over 3 hours on Days 1, 2, (6 g/m2/cycle)
1700184|NCT01464606|Drug|Doxorubicin|≥ 3 years: 30 mg/m2/dose IV over 30 min, Days 1, 2 (60 mg/m2/cycle)
1700188|NCT01464567|Procedure|"T Tube Spontaneous Breathing Trial"|"T Tube ventilation for 30 minutes"
1700190|NCT01464554|Behavioral|Usual care|alcohol and drug education
1700191|NCT01464554|Behavioral|Project Free Talk|motivational interviewing alcohol and drug program
1700192|NCT01464541|Procedure|operative fracture size vs CT fracture size|comparing actual intraoperative fracture size to the CT fracture size
1700193|NCT01464541|Procedure|orbital fracture intraoperative measurement|comparing intraoperative fracture size to the CT orbital fracture size
1700194|NCT01464528|Drug|Hyaluronan|single use of 10 mL of the hyalobarrier gel intrauterine immediately following hysteroscopic surgery
1700195|NCT01464515|Device|H-Coil Deep TMS|this group will receive high frequency treatment of deep TMS with 10Hz
1700196|NCT01464515|Device|SHAM Coil TMS|this group will receive SHAM treatment of deep TMS
1700197|NCT01464502|Procedure|Standard CRT Implant|
1700198|NCT01464502|Procedure|Pressure-wire guided CRT implant|A pressure wire will be sited in the left ventricle to measure dP/dT max. The LV lead position that gives the highest dP/dT max will be the final position used.
1700199|NCT01464489|Drug|Atropine|"Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1.
Atropine(atropine sulphate) 10 μg.kg-1, intravenous injection during induction After 120 sec of atropine injection, record intubating condition"
1700200|NCT01464489|Drug|Normal saline|Anaesthesia was induced with alfentanil 10 μg.kg-1, propofol 2.5 mg.kg-1 and rocuronium 0.3 mg.kg-1 Normal saline intravenous injection during anesthetic induction After 120 sec of normal saline injection, record intubating condition
1700201|NCT01464476|Drug|Azimilide Dihydrochloride|Azimilide 75 mg. Once daily, oral administration
1700202|NCT01464476|Drug|Placebo|Dose-matched placebo. Once daily, oral administration
1700203|NCT01464463|Behavioral|CBT - active|Patients get CBT treatment combined with moderate physical exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
1700204|NCT01464463|Behavioral|CBT - euthymic|Patients get the same common CBT treatment as group I, but instead of physical exercise they receive an enjoyment training Patients get CBT treatment combined with euthymic exercise (4x40min/week for 4 weeks, week 5, 6, 7 and 8).
1700205|NCT01464463|Behavioral|CBASP|"Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, psychodynamic and interpersonal strategies.
Foci of the CBASP-therapy are situation analysis and subsequent behavioral trainings as well as interpersonal strategies to create a therapeutic relationship."
1700206|NCT01464450|Drug|Rivaroxaban|Single 20 mg-dose
1700207|NCT01464437|Drug|AMG 151|Drug: AMG 151 50 mg BID
1700208|NCT01464437|Drug|Placebo|Placebo
1700209|NCT01464437|Drug|Metformin|Subjects will remain on their metformin regimen throughout the study. The metformin dose must be ≥ 850 mg/day for at least 2 months immediately prior to randomization.
1700210|NCT01464437|Drug|AMG 151|Drug: AMG 151 100 mg BID
1700211|NCT01464437|Drug|AMG 151|Drug: AMG 151 200 mg BID
1700212|NCT01464437|Drug|AMG 151|Drug: AMG 151 100 mg QD
1700213|NCT01464437|Drug|AMG 151|Drug: AMG 151 200 mg QD
1700214|NCT01464437|Drug|AMG 151|Drug: AMG 151 400 mg QD
1700215|NCT01464424|Drug|Travoprost 0.004% ophthalmic solution|
1700216|NCT01464424|Drug|Bimatoprost 0.01% ophthalmic solution|
1700217|NCT01464398|Behavioral|Stress reduction|8 weekly sessions
1700218|NCT01464398|Behavioral|Stress reduction with Health education|8 weekly sessions
1700219|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237mL
1700220|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237 mL
1700221|NCT01464385|Other|Nutritional Beverage|Nutritional Beverage Oral 237mL
1700222|NCT01464372|Device|Electrical Field Stimulation Device|Treatment with Electrical Field Stimulation Device
1700223|NCT01464372|Device|Sham Nerve Stimulation Device|Use of the sham device
1700224|NCT01464359|Drug|Allopurinol|On Day 8 pre-transplant, start hydration with allopurinol per standard of care.
1700225|NCT01464359|Drug|Fludarabine|On Days 7, 6 and 5 pre-transplant, 25 mg/m^2 intravenously over 1 hour.
1700226|NCT01464359|Radiation|Total body irradiation|On Days 5, 4, 3, and 2 pre-transplant, 165 cGy times 2 (330 cGy daily, 1320 total dose) according to the University Of Minnesota Blood and Marrow Transplant Program total body irradiation (TBI) guidelines.
1700227|NCT01464359|Drug|Cyclophosphamide|"On Days 7 and 6 pre-transplant, 60 mg/kg intravenously (IV) over 2 hours with a high volume fluid flush and mesna per institutional guidelines.
Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 5, 4, 3 and 2 pre-transplant; 50 mg/kg/day IV over 2 hours."
1700228|NCT01464359|Drug|Levetiracetam|Alternate Preparative Therapy for Patients Not Able to Receive Total Body Irradiation (TBI): Hydration therapy on Day 10 pre-transplant.
1700229|NCT01464359|Drug|Busulfan|Alternate Preparative Therapy For Patients Not Able To Receive TBI: Days 9, 8, 7 and 6 pre-transplant; 0.8 mg/kg (1.1 mg/kg if <12 kg) intravenously every 6 hours
1700230|NCT01464359|Biological|Umbilical Cord Blood Transplantation|Day 0: Two UCB units will compose the graft. The infusion of the first UCB unit should begin within 15 minutes, and no later than 30 minutes after arrival on the Unit. The UCB unit without IL-2 activation will be infused first, followed by the IL-2 activated unit. Both cords will be infused within 30-60 minutes of each other as deemed clinically safe by the BMT attending.
1700231|NCT01464359|Biological|Interleukin-2|"First Course of IL-2 (begin day +3) post-transplant: For patients ≥ 45 kg, IL-2 will be given at 9 million units every other day for a total of 6 doses subcutaneously. Patients weighing less than 45 kilograms, the IL-2 will be dosed at 5 million units/m^2 every other day for a total of 6 doses.
Second Course of IL-2 (day +60):
Patients will receive a second course of IL-2 beginning on Day +60 post transplant to expand and educate the NK cells derived from the UCB graft source."
1700233|NCT01464320|Drug|ABT-614|Active
1700234|NCT01464320|Drug|Placebo Comparator|Placebo
1700235|NCT01464307|Drug|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection.
1700236|NCT01464307|Drug|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
1700237|NCT01464294|Device|Milled ceramic restorations|Restoration of back teeth with milled ceramic crowns or onlays
1700238|NCT01464294|Device|Milled nano-composite restorations|Restoration of back teeth with milled crowns or onlays
1700239|NCT01464281|Drug|Peginterferon alfa 2a|Group 1 : 48-week standard treatment by Peginterferon alfa 2a 180µg/week Group 2 : 96-week prolonged treatment by Peginterferon alfa 2a 180µg/week.
1700240|NCT01464268|Drug|Riboflavin|Administration of riboflavin every 2 minutes for the duration of UV exposure.
1700241|NCT01464268|Drug|Riboflavin|Administration of riboflavin every 1 minute for the duration of UV exposure.
1700242|NCT01464255|Device|ocufilcon D|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
1700243|NCT01464255|Device|ocufilcon B|Participants wear a first pair of lenses for one week and then crossover and wear an alternate second pair of lenses for one week.
1700244|NCT01464242|Drug|Meglumine antimonate|Glucantime® 20mg/kg/day IM daily for 20 days
1700245|NCT01464242|Drug|Placebo|Placebo 400mg orally 3 times a day for 20 days
1700246|NCT01464242|Drug|Pentoxifylline|Pentoxifylline 400mg orally 3 times a day for 20 days
1700247|NCT01464229|Drug|Iloperidone|Iloperidone 1-8 mg for 4 weeks
1700248|NCT01464229|Drug|Placebo|Placebo
1700249|NCT01464203|Other|CT coronary angiography|"CT coronary angiography:
This allows two distinct assessments of the coronary arteries to be made:
coronary calcium scan, which is a 30 second, low-radiation scan that allows reproducible quantification of the amount of calcium in the coronary arteries to be made.
contrast enhanced CT coronary angiogram. This is a quick, non-invasive scan to assess the patency of coronary arteries."
1700250|NCT01464203|Other|Standard of Care|The management of patients in this group is according to the NHS protocol and is not altered by their participation in the trial. The choice of diagnostic investigation for CAD is determined by the patient's clinical scenario and the availability of different diagnostic modalities in the recruiting hospital.
1700251|NCT01464190|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
1700252|NCT01464190|Drug|Sevelamer carbonate|Film coated, compressed tablets. Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day).
1700253|NCT01464177|Radiation|Stereotactic hypofractionated RT 5x5Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:
Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
Planning tumor volume (PTV) equals GTV plus 3mm margin.
The dose of radiation will be 25Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
RT to begin in a maximum of 2 weeks after randomization"
1700254|NCT01464177|Radiation|Stereotactic hypofractionated RT 5x7Gy|"Stereotactic hypofractionated radiation therapy delivered as follows:
Gross tumor volume (GTV) equals enhancement area in T1 contrast enhanced MRI.
Planning tumor volume (PTV) equals GTV plus 3mm margin.
The dose of radiation will be 35Gy delivered in 5 fractions.1 fraction per day, non consecutive days in a maximum period of 10 working days.
RT to begin in a maximum of 2 weeks after randomization."
1700255|NCT01464164|Drug|Sotatercept|"Cohort 4a: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks. If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:
Cohort 5a: 3 patients on Sotatercept 1 mg/kg every 3 weeks"
1700256|NCT01464164|Drug|Sotatercept with prednisone boost|"Cohort 4b: 3 patients on Sotatercept 0.75 mg/kg every 3 weeks with a three week prednisone boost of 1 mg/kg/day (max 60 mg). If the patients have no untoward events in the Patients in Dose Level 4 by the end of 3 of the 6 doses, then additional patients (Dose Level 5) will be enrolled at the next dose level:
Cohort 5b: 3 patients on Sotatercept 1 mg/kg every 3 weeks with a 3 week prednisone boost of 1 mg/kg/day (max 60 mg)."
1700257|NCT01464138|Drug|Fosmidomycin and Clindamycin co-administration|Fosmidomycin sodium syrup at a concentration of 250mg/5ml and clindamycin hydrochloride syrup at a concentration of 75mg/5ml. Administered in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg)
1700258|NCT01464125|Drug|Fosmidomycin|Fosmidomycin sodium capsules 450 mg x 4 twelve-hourly for three days
1700259|NCT01464125|Drug|Azithromycin|Azithromycin capsules 250 mg x 3 twelve-hourly for three days
1700260|NCT01464112|Drug|JNJ-2641585 / VELCADE / Dexamethasone|JNJ-26481585: type=range, unit=mg, number=6 to 12, form=capsules, route=oral use, on Days 1, 3, and 5 of each week. VELCADE: type=exact, unit=mg/m2, number=1.3, form=powder for solution for injection, route=subcutaneous use, on Days 1, 4, 8, and 11 of each 21-day cycle (Cycles 1 to 8) and on Days 1, 8, 15, and 22 of each 35-day cycle (Cycles 9-11). Dexamethasone: type=exact, unit=mg, number=20, form=tablets, route=oral use, on the day of and after VELCADE.
1700261|NCT01464099|Drug|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
1700262|NCT01464099|Drug|insulin aspart|An initial priming dose of insulin aspart is administered, then a continuous subcutaneous insulin aspart infusion followed by a bolus of insulin aspart on top of the continuous insulin aspart infusion
1700263|NCT01464086|Other|whole body MRI|whole body MRI at inclusion, one and two years
1700264|NCT01464073|Behavioral|LIPOXmax|Arm 1: LIPOXmax arm. Subjects will perform a physical activity 4x1 hour per week at the optimal intensity for fat oxidation (LIPOXmax) measured by indirect calorimeter.
1700265|NCT01464073|Behavioral|60% VO2peak|Arm 2: physical activity standard arm (60% of VO2max measured by cardio respiratory exercise test). Subjects will realize 4 sessions per week and duration of sessions will be adjusted so that arms 1 and 2 have the same total energy expenditure by session.
1700266|NCT01464073|Behavioral|Good Medical Practices|"Arm 3: The subjects initially receive the recommendations of good medical practice for physical activity (achieving at least 30min per day of moderate exercise)."
1700267|NCT01464073|Dietary Supplement|supplementation in fruits and vegetables|all groups will be supplemented in fruits and vegetables (5 per day) during all the study
1700273|NCT01464008|Drug|Pegylated interferon alfa-2a and ribavirin|all patients were given peginterferon alfa-2a (40KD) (Pegasys®; Roche, Basel, Switzerland) 135 or 180 µg by subcutaneous injection once weekly, and received twice daily oral ribavirin at a target total daily dose of 13 mg/kg/day. .
1700274|NCT01463982|Drug|Oratecan and Capecitabine|"Oratecan in combination with Capecitabine
Irinotecan HCl Tablet - Initial dose 10 mg/m2 (may be increased up to 20 mg/m2), Day1~Day5
HM30181AK Tablet - Fixed dose 15 mg, Day1~Day5
Capecitabine Tablet - Initial dose 800 mg/m2 (may be increased up to 1000 mg/m2), Day1~Day14"
1700275|NCT01463956|Drug|Boceprevir|Boceprevir 200 mg capsules at 2400mg/day (800mg 3 times a day) from week 4 until week 48 or until liver transplant (can be performed from week 16)
1700276|NCT01463956|Biological|Peg-Interferon α-2b or Peg-Interferon α-2a|Peg-Interferon α-2b by subcutaneous injection, 1.5µg/kg/week, from day 0 until week 48 or until liver transplantation, or Peg-Interferon α-2a by subcutaneous injection, 180 µg, once weekly, from day 0 until week 48 or until liver transplantation
1700277|NCT01463956|Drug|Ribavirin|Ribavirin: capsules 200 mg (weight-based daily dose: <65kg, 800 mg; 65-80kg, 1000mg; 81-105kg: 1200mg; >105kg: 1400mg), from day 0 until week 48 or until liver transplantation or, Ribavirin: Tablet Oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, from day 0 until week 48 or until liver transplantation
1700278|NCT01463943|Other|Probiotic|
1700279|NCT01463943|Other|Probiotic|
1700280|NCT01463943|Other|Probiotic|
1700281|NCT01463930|Behavioral|Educational audiovisual videodisc and medical verbal information|General and specific medical verbal information and ten-minute DVD where the process from admission to the surgical intervention, recovery room, immediate postoperative care, and outpatient care at two, six, and twelve months after surgery was shown. The video included experiences of patients with respect to pain and function and examples of functionality during daily life activities such as stairs, kneeling or squatting. The video also demonstrated the facilities and rehabilitation techniques employed in the Physical Medicine and Rehabilitation Service.
1700282|NCT01463930|Behavioral|Medical verbal information|General and specific verbal information provided by both the surgeon and a specialized nurse including basics of surgical technique, potential complications, and rehabilitation.
1700283|NCT01463917|Drug|Hypertonic solution|Use of Hypertonic solution 4 ml/Kg during left marginal branch CABG surgery.
1700284|NCT01463917|Drug|Isotonic|Use of Isotonic solution 4 ml/Kg during left marginal branch CABG surgery.
1700285|NCT01463904|Procedure|SADI-S 250|Single-Anastomosis Duodeno-Ileal bypass with Sleeve gastrectomy
1700286|NCT01463891|Drug|Eribulin Mesylate|The usual adult dose of eribulin mesylate is 1.4 mg/m^2 (body surface area) administered intravenously over 2 to 5 minutes, once daily once a week. Treatment shall be continued for 2 consecutive weeks followed by a third week of drug cessation. With each cycle lasting 3 weeks, the treatment shall be repeated. The dose may be reduced, depending on the condition of the individual patient.
1700287|NCT01463878|Dietary Supplement|Glycerna|Diabetes specific formula
1700288|NCT01463878|Dietary Supplement|Jevity - Control Diet|Control Diet
1700289|NCT01463865|Drug|ropivacaine|Single shot nerve block with ropivacaine 10-20 ml; 7,5 mg/ml
1700290|NCT01463865|Drug|Sodium chloride|Single shot nerve block with isotonic sodiumchloride 10-20 ml; 0.9%
1700291|NCT01463852|Drug|vincristine|Vincristine 2mg will be administered one time to participants. Blood samples will be collected pre and post dose.
1700292|NCT01463813|Dietary Supplement|Vitamin D3|Vitamin D3 40 micrograms (1600 IU) per day
1700293|NCT01463813|Dietary Supplement|Vitamin D3|Vitamin D3 80 micrograms (3200 IU) per day
1700294|NCT01463813|Dietary Supplement|Placebo|Inactive placebo
1700295|NCT01463800|Behavioral|Structured exercise training|12 weeks low level ambulatory structured exercise training
1700296|NCT01463787|Procedure|microsurgical varicocelectomy in inguinal approach|In inguinal approach, the incision, which was about 3cm, was made two fingers up the pubic symphysis, from external inguinal rings parallel to the inguinal ligament.
1700297|NCT01463787|Procedure|microsurgical varicocelectomy in subinguinal approach|In subinguinal approach, the incision was about 3 cm horizontal and 1 cm below the external inguinal ring.
1700298|NCT01463774|Drug|Treatment A: Canagliflozin tablet|Type=exact number, unit=mg, number=100, form=tablet, route=oral use. One canagliflozin tablet taken orally (by mouth) on Day 1 of Treatment Period A.
1700299|NCT01463774|Drug|Treatment A: Metformin IR tablets|Type=exact number, unit=mg, number=850, form=tablet, route=oral use. Two metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period A.
1700300|NCT01463774|Drug|Treatment B: Canagliflozin/metformin fixed dose combination tablets|Type=exact number, unit=mg, number=50/850, form=tablet, route=oral use. Two canagliflozin/metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period B.
1700301|NCT01463761|Device|ANS activity|This ANS activity is measured by nocturnal heart rates records with Holter ECG.
1700302|NCT01463748|Other|Graptopetalum paraguayense E. Walther|Graptopetalum paraguayense E. Walther
1700303|NCT01463748|Other|Placebo|starch
1700304|NCT01463735|Dietary Supplement|Vitamin E supplement (tocofersolan)|700 mg per day per os (i.e. 350 mg twice a day with meals)
1700305|NCT01463722|Other|Amniotic fluid Lamellar Body Counting|fluid samples were obtained by amniocentesis during normal delivery or before rupturing the membrane in cesarean. The samples were sent to the lab as soon as possible and after centrifuging with 500 round per minute for 3 minutes, they were placed in the cell counter machine (STKR coulter).
1700306|NCT01463709|Device|PulseCure pulse generator and Derm-pulse electrode|"PulseCure 100 ns pulse generator: generates 30 kV/cm electric pulses 100 ns long to trigger apoptosis in cells between the electrodes.
NanoBlate: Delivery device to treat 5 mm wide skin lesions with 100 ns pulses from PulseCure"
1700307|NCT01463696|Drug|MK-8242|10 mg, 100 mg and 150 mg capsules
1700308|NCT01463683|Biological|2XP HEPTAVAX™-II SC|
1700309|NCT01463683|Biological|1XP HEPTAVAX™-II SC|
1700310|NCT01463683|Biological|2XP HEPTAVAX™-II IM|
1758912|NCT00261612|Drug|dexamethasone|
1700311|NCT01463670|Drug|lenalidomide|patients will begin therapy with lenalidomide 25 mg daily, 21 days out of a 28 day schedule. All patients will be evaluated monthly after every cycle. The dose will be adjusted downward in response to side effects and according to specific guidelines. Symptomatic POD occurring at any time during the study will result in removal of the patient from the study. After 2 cycles of lenalidomide, patients with at least stable disease (SD) will continue lenalidomide indefinitely until asymptomatic POD, at which time dexamethasone will be added at a dose of 40mg weekly. On the other hand, patient with asymptomatic POD after 2 cycles of lenalidomide will have dexamethasone added at a dose of 40 mg weekly. Patients with any type of POD after any cycle that includes dexamethasone will be taken off study. Patients can remain on study on lenalidomide or lenalidomide/dexamethasone indefinitely as long as they do not have POD as stated above and they tolerate the treatment.
1700312|NCT01463657|Device|Juvéderm® Ultra Plus|Patients will receive either ELAPR002b or ELAPR002d for the treatment of one NLF, and Juvéderm® Ultra Plus for the treatment of the second, opposite NLF. Treatments will be provided on Day 1 and repeated on Day 29 (if required at the discretion of the investigator) Day 57 (if required at the discretion of the investigator)to achieve OCR.
1700313|NCT01463657|Device|ELAPR002|Each treatment will consist of up 15 injections in total, each consisting of up to 0.1 ml of product, delivered to the mid to deep dermis of the skin of each NLF using a 27G needle. The needle will be inserted at an approximate angle of 30o parallel to the skin, and the product may be injected by a retrograde injection or by deposition of a bolus. ELAPR and the control may be implanted parallel or perpendicular to the NLF. Exactly the same technique will be used for the treatment of both NLFs for each patient.
1700317|NCT01463605|Drug|Nimotuzumab|Nimotuzumab 200mg,once per week,for 5 to 6 weeks
1700318|NCT01463592|Biological|RENESSANS , INTERFERON ALPHA 2b, Ribavirin|ORAL RENESSANS 5gm. Twice Daily +INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
1700319|NCT01463592|Drug|Interferon Alfa-2b AND RIBAVIRIN|INTERFERON ALPHA 2b 3 Million Units s/c +RIBAVIRIN 15mg/kg
1700320|NCT01463592|Biological|RENESSANS|ORAL RENESSANS 5gm. Thrice Daily{active iodine 300mg} for 6months
1700321|NCT01463579|Other|Exercise Programme|"Patients will complete three exercise sessions per week (2 supervised and 1 unsupervised) for 6 weeks. They will receive a written exercise manual which facilitates completion of their exercise programme. The exercise programme will consist of a warm-up, an exercise circuit, a period of aerobic exercise, and a cool down. The programme will be tailored to each patient's ability and needs.
At the end of the 6 weeks patients will receive a short consultation to set goals relating to continuing exercise at home."
1700322|NCT01463579|Other|Standard Care|Following ICU admission patients are discharged to hospital wards to the care of a consultant, and the patients are no longer under the care of the ICU team. They are provided with appropriate medical and nursing care, and with referral to other disciplines as necessary. One mobile and able to return home to a carer or another facility they are discharged from hospital. There is usually no support to address potential problems specific to critical illness for patients after ICU discharge.
1700323|NCT01463566|Device|Zimmer Gender(R) Solutions(TM) Natural-Knee(R) Flex System|Gender Solutions Natural Knee Flex System in total knee arthroplasty
1700324|NCT01463553|Procedure|VATS pleurodesis|Based on the findings, establish selection standards for the timing of surgery to treat PSP by VATS and establish technical specifications for performing operations on different types of lung bullae. The goal is to improve the diagnosis and treatment of PSP so as to reduce the recurrence rate of pneumothorax, reduce the trauma of operation, shorten hospital stays and postoperative recovery time, and provide better services for returning to everyday life and improving the quality of life for patients.
1700325|NCT01463540|Device|A 20 Fr gastrostomy tube, placed using push/pull techniques.|In this group a 20 Fr gastrostomy tube will be placed, of the type in use at each centre, using the push or the pull method. Positioning of the gastrostomy tube will be carried out endoscopically in sedated patients, after antibiotic prophylaxis. Single dose ampicillin/sulbactam 1g/500 mg will be infused intravenously 30 minutes before positioning. In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis with ampicillin/sulbactam will be not given.
1700326|NCT01463540|Device|A 20 Fr balloon type tube, placed after gastropexy.|In this group a 20 Fr balloon type gastrostomy tube will be placed endoscopically, after gastropexy performed using the Kimberly Clarke MIC Introducer kit, according to the instructions suggested by the manufacturer. The kit includes 4 T-fasteners (only 3 are usually placed in clinical use) and a serial 24 Fr dilator with a pell-away sheath. All commercially available brands of balloon type gastrostomy tubes will be allowed for use in the study. Positioning of the gastrostomy tube will be carried out in sedated patients, after antibiotic prophylaxis (Single dose ampicillin/sulbactam 1g/500 mg ev.). In patients just receiving antibiotic therapy, as treatment of concomitant disease, the current therapy will be continued and antibiotic prophylaxis will be not given.
1700328|NCT01463514|Procedure|Right heart catheterization|Oxygenation and hemodynamic parameters will be assessed during RHC according to standard procedures. All measurements will be noted as usual for PH assessment including: at rest breathing room air, during an oxygen challenge, under vasodilator testing with NO and/or during exercise. Room air, supplemental oxygen and NO will be applied over common breathing mask while patient is in a supine position. Oxygen will be taken as usual from the common adjustable hospital wall access, NO will be taken according to usual clinical practice during RHC from a gas cylinder connected to a reservoir, where adequate ppm concentration can be regulated. A dose of 40 ppm NO will be used according to common practise. Oxygen delivery to maintain the peripheral oxygen saturation between 88% and 90% will be adjusted over a 3 minute period of time.
1700329|NCT01463514|Procedure|Near-infrared spectroscopy|For study purpose, patients will have additional non-invasive NIRS assessment. The measurement will take place during right heart catheterization.
1700330|NCT01463501|Other|Neoadjuvant chemoradiotherapy|Paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f) followed by surgery, consolidate paclitaxel/carboplatin 2 cycles.
1700331|NCT01463501|Other|Adjuvant chemoradiotherapy|Surgery followed by paclitaxel/carboplatin and concurrent radiation (50.4Gy/28f), consolidate paclitaxel/carboplatin 2 cycles.
1700332|NCT01463488|Drug|SAR113945|"Pharmaceutical form:Injection
Route of administration: Intra-articular"
1700333|NCT01463488|Drug|placebo|"Pharmaceutical form:Injection
Route of administration: Intra-articular"
1700334|NCT01463475|Procedure|Bone marrow aspirate|A single bone marrow aspirate procedure is planned.
1700335|NCT01463449|Procedure|gastric bypass|Low grade inflammation in adipose tissue before and after gastric bypass
1700336|NCT01463436|Dietary Supplement|soy isoflavone|100 mg soy isoflavone tablet containing genistein 55%, daidzein 39% and glycitein 6% and calcium carbonate 500 mg in the experimental group for 6 months and 12 months
1700337|NCT01463436|Dietary Supplement|control group|the control group receiving tablet contain calcium carbonate 500 mg/day for 6 months and 12 months
1700338|NCT01463423|Diagnostic Test|PET Scan|Standard of Care
1700339|NCT01463423|Diagnostic Test|CT Scan|Standard of Care
1700340|NCT01463423|Radiation|SABR|Standard of Care
1700341|NCT01463397|Drug|SAR292833|"Pharmaceutical form: capsule
Route of administration: oral"
1700342|NCT01463397|Drug|placebo|"Pharmaceutical form:capsule
Route of administration: oral"
1700343|NCT01463384|Drug|Minocycline|50mg, twice daily for 6 months.
1700344|NCT01463371|Drug|Azithromycin|250 mg three times a week during three months
1700345|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDD60 is supposed to prevent events of syncope, presyncope of cardioinhibitory origin and symptom associated to av block
1700346|NCT01463358|Device|DDD60 (INSIGNIA® pacing systems Guidant (Boston Scientific)|pacing in DDDI30 is supposed to act as a safety backup upfront to episodes of syncope, presyncope or AV block, but not supposed to reduce symptoms.
1700347|NCT01463345|Other|Blood transfusion|Conservative transfusion arm: Subjects randomized to the conservative transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 7.5 g/dl. Blood products should be given to maintain Hgb levels >7.5 g/dl.
1700348|NCT01463345|Other|Blood transfusion|Liberal transfusion arm: Subjects randomized to the liberal transfusion arm will receive transfusions of PRBCs post-surgery only when their Hgb level measures < 9.0 g/dl. Blood products should be given to maintain Hgb levels > 9.0 g/dl.
1700349|NCT01463332|Drug|I.V injection of 10 ml normal saline|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group NS were injected intravenously with 10 ml of normal saline before injection of propofol.
1700350|NCT01463332|Drug|I.V injection with 0.25mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D25 were injected intravenously with 0.25mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
1700351|NCT01463332|Drug|I.V injection of 0.50mic/kg of dexmedetomidine|Patients were randomly assigned in to three groups of 50 each using a computer-generated table of random numbers. Patients Group D50 were injected intravenously with 0.50mic/kg of dexmedetomidine diluted with normal saline into 10ml before injection of propofol.
1700352|NCT01463319|Other|air insufflation|air insufflation during insertion phase colonoscopy
1700353|NCT01463319|Other|warm water irrigation|warm water irrigation during insertion phase colonoscopy
1955943|NCT03023800|Procedure|Macular buckling|Surgical procedures of macular buckling, drainage of aqueous fluid (0.1-0.2 ml) through limbal paracentesis, and inject gas ( C3F8 100%, 0.2ml-0.3ml) into vitreous body through pars plana, under systemic anesthesia.
1700355|NCT01463293|Dietary Supplement|B. lactis HN019|Capsule containing 10 billion cfu B. lactis HN019 once a day
1700356|NCT01463293|Dietary Supplement|B. lactis HN019|Capsule containing 1 billion cfu B. lactis HN019 once a day
1700357|NCT01463293|Dietary Supplement|Placebo|Capsule containing no probiotic once a day
1700358|NCT01463280|Drug|tumescent lidocaine infiltration|Tumescent local anesthesia containing dilute lidocaine is infiltrated into subcutaneous tissue prior to liposuction
1700359|NCT01463267|Device|iPhone or pillbox|People will be reminded to take their medications by a device that alerts the patient to the need to take a medication.
1700360|NCT01463267|Behavioral|Non-reminding|As a comparison, the devices will collect medication taking information without providing reminders.
1700361|NCT01463241|Behavioral|Behavioral and Affective Skills in Coping (BASIC)|The investigator's seek to develop a treatment protocol that integrates five core intervention principles that are common to evidence-based treatments for youth depression, anxiety, and disruptive behavior problems. The protocol will be designed for implementation in everyday community practice settings by practitioners. The BASIC protocol will include (a) a therapist manual guiding the use of five BASIC skills [Belief Repair, Action, Solving Problems, Incentives, and Calming]; (b) child and parent materials to facilitate learning skills, practicing them in-session, and using them outside sessions; and (c) a decision tree to guide judgments about which skills to use and when to switch skills or treatment focus.
1700362|NCT01463228|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
1700363|NCT01463228|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 150/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
1700501|NCT01462331|Other|Sucrose|12g/dose, three times a day
1955944|NCT03023800|Procedure|Vitrectomy|Surgical procedures of small gauge vitrectomy, internal limiting membrane peeling, and gas (C3F8, 14%) tamponage, under local or systemic anesthesia
1700364|NCT01463215|Drug|Ambroxol|Ambroxol at a dose level of 187.5 or 225 mg/day will be given once daily by mouth for 2 months.
1700365|NCT01463202|Drug|Depot medroxyprogesterone acetate|Postpartum administration of DMPA (prior to hospital discharge)
1700366|NCT01463202|Drug|Depot medroxyprogesterone acetate|Delayed administration of DMPA (4-6 weeks postpartum)
1700367|NCT01463189|Behavioral|painACTION: Arthritis|"Participants will be asked to complete eight 20-minute sessions on the site over a four-week intervention period (two site visits per week), and complete five 20-minute booster sessions (one site visit per month) during the follow up period. Each session will have a minimum set of requirements. Specific details about the requirements for each session will be provided in the session logs."
1700368|NCT01463176|Behavioral|Music Therapy|Live music therapy is interactive and incorporates behavioral cues for coping techniques during the procedure, using patient-preferred music.
1700369|NCT01463163|Drug|Prasugrel|Prasugrel 60mg LD followed by 10mg x1 MD starting post 24 hours
1700370|NCT01463163|Drug|Ticagrelor|Ticagrelor 180mg LD followed by 90mg x2 MD starting after 12±6 hours
1700371|NCT01463150|Drug|Clopidogrel|Clopidogrel 150mg per day for 15 days
1700372|NCT01463150|Drug|Prasugrel|Prasugrel 5mg per day for 15 days
1700373|NCT01463137|Behavioral|Attention bias modification|All arms will consist of 10 minutes of training in front of a computer screen (192 trials) once a day for 14 days.
1700374|NCT01463124|Behavioral|Lookin' Good Feelin' Good|Six 30-minute individual student-centered counseling sessions delivered by school nurses during the first two months followed by weekly weigh-ins and monthly visits over the subsequent 6 months, plus an exercise program in the school 3 times a week for the full eight months of the intervention.
1700375|NCT01463124|Behavioral|Information attention-control|Six individual sessions with school nurse over the first two months followed by monthly visits over the remaining 6 months to check weight and behavior changes and provide a series of pamphlets on weight and weight management.
1700376|NCT01463111|Drug|Lithium|Open label treatment per standard of care for bipolar disorder for six weeks.
1700377|NCT01463111|Drug|Valproate|Open label treatment per standard of care for bipolar disorder for six weeks.
1700378|NCT01463111|Drug|Lamotrigine|Open label treatment per standard of care for bipolar disorder for six weeks.
1700379|NCT01463098|Drug|E2006 1.0 mg|1.0 mg, or placebo
1700380|NCT01463098|Drug|E2006 2.5 mg|2.5 mg or placebo
1700381|NCT01463098|Drug|E2006 5.0 mg|5.0 mg or placebo
1700382|NCT01463098|Drug|E2006 10.0 mg|10.0 mg or placebo
1700383|NCT01463098|Drug|E2006 25.0 mg|25.0 mg or placebo
1700384|NCT01463098|Drug|E2006 50.0 mg|50.0 mg or placebo
1700385|NCT01463098|Drug|E2006 100 mg|100mg or placebo
1700386|NCT01463098|Drug|E2006 200 mg|200 mg or placebo
1700387|NCT01463098|Drug|zolpidem 10 mg|10 mg
1700388|NCT01463098|Drug|zolpidem - matched placebo|Part B only
1700389|NCT01463098|Drug|E2006 - matched placebo|(Part A and Part B)
1700390|NCT01463085|Other|Low-fat dairy|Dietary Intervention of 3 servings per day of low-fat dairy
1700391|NCT01463072|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1700392|NCT01463072|Other|questionnaire administration|Ancillary studies
1700393|NCT01463059|Biological|Placebo|Placebo solution for injection, administered as subcutaneous injections
1700394|NCT01463059|Biological|Olokizumab 60 mg|Olokizumab 60 mg solution for injection, administered as subcutaneous injections
1700395|NCT01463059|Biological|Olokizumab 120 mg|Olokizumab 120 mg solution for injection, administered as subcutaneous injections
1700396|NCT01463059|Biological|Olokizumab 240 mg|Olokizumab 240 mg solution for injection, administered as subcutaneous injections
1700397|NCT01463046|Drug|Panobinostat|"Induction - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8
Second induction - 20-60 mg (1-3 20 mg capsules) PO days 1,3 and 5
Consolidation - 20-60 mg (1-3 20 mg capsules) PO on days 1,3,5 and 8"
1700398|NCT01463046|Drug|Cytarabine|"Induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-9.
Second induction - 100 mg/m2 continuous IV daily for 7 doses on day 3-7.
Dosing for consolidation - 100 mg/m2 continuous IV daily for 7 doses on day 3-9."
1700399|NCT01463046|Drug|Daunorubicin|"Induction - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5.
Second induction - 60 mg/m2 IV over 15-30 minutes daily for 2 doses on day 3 and 4.
Dosing for consolidation - 60 mg/m2 IV over 15-30 minutes daily for 3 doses on day 3-5."
1700400|NCT01463033|Drug|Levetiracetam|55 mg/kg/day given in 2 divided doses 12 hours apart
1700401|NCT01463020|Behavioral|Smartphone delivered BA|A 8 week behavioural activation therapy delivered through smartphone
1700402|NCT01463020|Other|Smartphone delivered mindfulness|A 8 week mindfulness intervention delivered through smartphone
1700403|NCT01463007|Radiation|Accelerated partial breast irradiation|Accuboost APBI 34.0 Gy in 10 fractions
1700404|NCT01463007|Other|Extended Follow up|This arm extends follow up at the Rhode Island Hospital location to 5 years. Annual mammograms and additional documentation is required to be submitted only if completed.
1700405|NCT01462994|Other|Blood will be withdrawn at baseline and in intervals of 3 months for a total period of 2 years|
1700406|NCT01462968|Device|Activated clotting time versus blood-heparin concentration|Activated clotting time used for heparinization strategy during cardiag surgery versus blood-heparin concentration
1700407|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol Fixed Dose Combination (FDC) low dose (400/6 μg), twice per day
1700408|NCT01462942|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC high dose (400/12 μg), twice per day
1700409|NCT01462942|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
1700410|NCT01462942|Drug|Placebo|Inhaled dose-matched placebo, twice per day
1700411|NCT01462942|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
1700412|NCT01462929|Drug|Aclidinium bromide|Dosage form: Dry powder. Route of administration: Oral inhalation by Genuair multidose dry powder inhaler Dose and regimen: 1 puff of 400 micrograms in the morning (09:00 ± 1h) and in the evening (21:00 ± 1h)
1700413|NCT01462929|Drug|Tiotropium|Dosage form: Dry powder hard gelatin capsule. Route of administration: Oral inhalation by HandiHaler single-dose dry powder inhaler Dose and regimen: 1 capsule (18 μg) in the morning (09:00 ± 1h)
1700414|NCT01462929|Drug|Placebo|Dosage form: Dry powder Route of administration: Oral inhalation by Genuair multidose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h) and 1 puff in the evening (21:00 ± 1h) AND Oral inhalation by HandiHaler single-dose dry powder inhaler. 1 puff of placebo in the morning (09:00 ± 1h).
1700415|NCT01462916|Dietary Supplement|honey|A crossover design (two 12-weeks intervention periods) will be used to measure treatment effects. The subjects will be randomized into two groups (intervention to control [I/C] and control to intervention [C/I] groups). Each study group will have 15 subjects. The subjects in the I/C group will consume 2 ml honey/kg/dose (maximum 50 ml/dose), twice weekly in the first 12-week period (period 1) while the subjects in the C/I group will not receive honey as a Control in period 1. After period 1 the subjects of each group will exchange their protocol for the following 12-week period (period 2).
1700416|NCT01462903|Biological|tumor infiltrating lymphocytes, IL-2|Biological: Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells) by iv in 30 Minutes. Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
1700417|NCT01462890|Biological|Bevacizumab|15 mg/kg, iv on day 1 every 3 weeks up to and including cycle 22 vs cycle 44
1700418|NCT01462890|Drug|Paclitaxel|175 mg/m², iv on day 1 every 3 weeks for 6 cycles
1700419|NCT01462890|Drug|Carboplatin|AUC 5, iv on day 1 every 3 weeks for 6 cycles
1700420|NCT01462890|Other|specialized pathology review (Germany only)|before randomization
1700421|NCT01462877|Drug|fenofibrate|Fenofibrate Capsule 200mg qd orally
1700422|NCT01462864|Behavioral|Structured Lifestyle Education|A 3-4 hours group education delivered in a patient group composed of 4-8 patients and delivered by two healthcare professionals.
1700423|NCT01462851|Drug|PF-05297909 25 mg|Single oral (PO) dose, PF-05297909 25 mg
1700424|NCT01462851|Drug|PF-05297909 100 mg|Single oral (PO) dose, PF-05297909 100 mg
1700425|NCT01462851|Drug|PF-05297909 250 mg|Single oral (PO) dose, PF-05297909 250 mg
1700426|NCT01462851|Drug|PF-05297909 525 mg|Single oral (PO) dose, PF-05297909 525 mg
1700427|NCT01462851|Drug|PF-05297909 525 mg|Single oral (PO) dose, 525 mg
1700428|NCT01462838|Biological|P16_37-63|100 ug per application subcutaneously, mixed with 0.3 ml Montanide ISA-51 VG; once a week for four weeks, followed by a 4 week rest period (1 cycle), up to 3 cycles
1700429|NCT01462825|Dietary Supplement|tomato ketchup meal|A single intake of 200 g tomato ketchup together with 200 g white cooked rice.
1700430|NCT01462825|Dietary Supplement|Placebo meal|Self-prepared vinaigrette matching the qualitative and quantitative macronutrient composition of the tomato ketchup together with 200 g cooked rice resulting in a meal that is isocaloric to the tomato-ketchup meal
1700431|NCT01462812|Drug|Sumatriptan|Sumatriptan 20mg
1700432|NCT01462812|Drug|Placebo|Matching placebo
1700433|NCT01462799|Behavioral|PBL in patient education|The experiment group will enter a PBL patient education that is characterised by autonomous learning. The patients work together in small groups. Focus is on lifestyle changes. Starting point of learning is the patient's individual life style goals. Thirteen meetings during 1 year for 2 hours; weekly for the first month, every second week next two months and the last meetings 16, 20 and 26, 39 and 52 weeks after start. The programme shall be completed 1 year after start. The patients work with starting triggers such as pictures, texts, or concrete materials. Nurses work as tutors (after completion of a tutorial education) during the meetings using a problem based model to support patients formulate issues and goals to work with during the year. When the patients do not solve question the possibility of inviting e.g. a GP, dietician, pharmacist or physiotherapist is possible.
1700434|NCT01462799|Behavioral|Mailed patient information|During the study year patients in this control group will receive mailed patient information about life style changes.
1700435|NCT01462786|Drug|ATX-101|2 mg/cm2 ATX-101
1700436|NCT01462773|Drug|Bortezomib|VELCADE (1.0 mg/m2, 1.3 mg/m2, or 1.6 mg/m2 IV based on patient cohort). After three patients have received 5 weeks of therapy (1 cycle) at the initial dose of VELCADE (1.0 mg/m2, Cohort 1) with no dose limiting toxicity, the dose will be raised to 1.3 mg/m2 for the next cohort of three patients. If this dose level is well-tolerated in three consecutive patients, the dose of VELCADE will be raised to 1.6 mg/m2.
1700437|NCT01462773|Drug|Interferon Alfa-2b|I = IFN-α-2b (INTRON A): 5 million units (MU)/m2 SC. INTRON A (5MU/m2) will be administered subcutaneously on Days 1, 3 and 5 of Week 0. During Cycle I, INTRON A will be administered on Days 1, 3 and 5 of Weeks 1-3 of and on Days 1 and 3 of Week 4 to allow for surgical biopsy on Day 5. During Cycles II-V, IFN-α will be administered on Days 1, 3 and 5 of Weeks 1-4. To assess the toxicity profile of IFN-α-2b alone, no VELCADE will be administered during Week 0.
1700438|NCT01462760|Device|Assessment with inclinometer|joint assessment with inclinometer. The inclinometer used in this trial is Baseline® Bubble Inclinometer
1700439|NCT01462760|Device|Assessment with actigraph|joint assessment with actigraph The actigraph used in this trial is the Motion Pod. It's an analysis and reeducation systems by biofeedback. The manufacturer is Movea.
1700440|NCT01462747|Device|KULIST|Twice daily dosing for 8 weeks
1700441|NCT01462734|Procedure|human vitreous and blood serum sampling, PCR|1ml of human vitreous and 3ml of human blood serum
1700442|NCT01462721|Device|eSVS® Mesh|Patients with multi-vessel coronary artery disease who require saphenous vein graft (SVG) coronary artery bypass graft (CABG) surgery of the Right coronary Artery (RCA) and the Circumflex Artery (Cx) due to atherosclerotic coronary artery disease will serve as their own control. They will be randomized to either an SVG+eSVS Mesh to the RCA and an SVG to the Cx or an SVG to the RCA and an SVG+eSVS Mesh to the Cx.
1700443|NCT01462708|Drug|[18F]MK-9470|Subjects will be injected with 10 mCi, and not to exceed 11 mCi (not >10% of 10 mCi limit)of [18F]MK-9470, followed by PET imaging.
1700444|NCT01462695|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1700445|NCT01462695|Other|Pharmacological Study|Correlative studies
1700446|NCT01462695|Drug|Sunitinib Malate|Given PO
1700447|NCT01462669|Drug|50mg Ezogabine/retigabine|A single 50mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
1700448|NCT01462669|Drug|100mg Ezogabine/retigabine|A single 100mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
1700449|NCT01462669|Drug|200mg Ezogabine/retigabine|A single 200mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
1700502|NCT01462318|Drug|Midazolam|5 mg
1700503|NCT01462318|Other|Caffeine|200 mg
1700450|NCT01462669|Drug|400mg Ezogabine/retigabine|A single 400mg ezogabine/retigabine tablet will be administered orally with the subject in the fasted state
1700451|NCT01462656|Drug|Non-EZG containing AED polytherapy|AED polytherapy without EZG
1700452|NCT01462656|Drug|EZG containing AED polytherapy|AED polytherapy including EZG
1700453|NCT01462656|Drug|Non-EZG AED monotherapy|AED monotherapy without EZG
1700454|NCT01462656|Drug|EZG AED monotherapy|Any off-label use of EZG as monotherapy
1700455|NCT01462643|Drug|LAS41004|once daily, topical ointment, 100 microgram per day
1700456|NCT01462630|Drug|pazopanib hydrochloride|Given PO
1700457|NCT01462630|Other|laboratory biomarker analysis|Correlative studies
1700458|NCT01462630|Procedure|positron emission tomography|Correlative studies
1700459|NCT01462630|Procedure|computed tomography|Correlative studies
1700460|NCT01462630|Radiation|fludeoxyglucose F 18|Correlative studies
1700461|NCT01462617|Drug|GSK2269557|Study Drug
1700462|NCT01462617|Drug|GSK2269557 matching placebo|Study Drug
1700463|NCT01462604|Other|non-drug intervention educational programme|educational programme
1700464|NCT01462591|Dietary Supplement|L-citrulline|2 weeks of L-citrulline supplementation (100mg/kg of body weight).
1700465|NCT01462578|Drug|Azacitidine|Azacytidine injection: 75 mg/m²/d, subcutaneous; initial minimum 6 cycles; another 6 or 12 cycles according to MRD niveau; maximum 24 cycles
1700468|NCT01462552|Drug|Lapatanib|Prescription of lapatinib (Tykerb)
1700469|NCT01462513|Biological|L-BLP25|Treatment: 930µg per treatment once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
1700470|NCT01462513|Biological|Placebo|Treatment: Placebo 930µg per treatment, once weekly for 8 weeks, then at 6-week intervals during years 1 and 2.
1700471|NCT01462500|Drug|Miltefosine|Children (2-12 years of age) and adults (18-60 years of age) will receive Miltefosine PO at a dose of 1.8-2.5 mg/kg/day for 28 days.
1700472|NCT01462487|Drug|Treatment with zanamivir|Subjects treated with zanamivir
1700473|NCT01462474|Drug|Famitinib|Either at 12.5 mg, 16.5 mg、20 mg or 25 mg qd p.o., 2 weeks before concurrent chemoradiotherapy and D1-D49, exception D1, D22, and D43.
1700474|NCT01462474|Drug|Cisplatin|100 mg/m2, D1, D22, and D43(q3w)
1700475|NCT01462474|Radiation|radiation（IMRT）|IMRT (Intensity-Modulated Radiation Therapy). Radiation is delivered to GTV at 70 Gy in 32-33 fractions, CTV1 at 60 Gy in 32-33 fractions and CTV2 at 54 Gy in 32-33 fractions
1700476|NCT01462448|Procedure|Blood Draw|Single blood draw of 30 ml
1700477|NCT01462435|Drug|Diclofenac Test (lower dose)|Capsules
1700478|NCT01462435|Drug|Diclofenac Test (upper dose)|Capsules
1700479|NCT01462435|Drug|Celecoxib|200 mg Capsules
1700480|NCT01462435|Drug|Placebo|Capsules
1700481|NCT01462422|Drug|Misoprostol|Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery
1700482|NCT01462422|Drug|Misoprostol|Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby
1700483|NCT01462409|Device|RESMed S9 with humidifier H5i and heated tube Climate Line|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Controlled heated humidification with heated tubing (Climate Line).
1700484|NCT01462409|Device|CPAP without humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. Without any humidification.
1700485|NCT01462409|Device|CPAP with heated humidification|At stable ambient room temperature and different CPAP pressure levels, 8 and 12 cmH2O, with and without additional leakage, humidity and temperature is measured inside of a patients nasal mask. With controlled heated humidification and standard tubing.
1700486|NCT01462396|Device|CD34+ cells selected with the Miltenyi Clinimacs machine|Haploidentical allogeneic stem cell transplant following sub-myeloablative conditioning and cell selection using the Miltenyi Clinimacs device
1700487|NCT01462370|Drug|Etoricoxib|Etoricoxib 120 mg tablet given orally for one dose.
1700488|NCT01462370|Drug|Ibuprofen|Ibuprofen 600 mg (three 200-mg capsules) given orally up to four times a day as needed, for a maximum of 2400 mg/day.
1700489|NCT01462370|Drug|Placebo to etoricoxib|Placebo to etoricoxib, one tablet.
1700490|NCT01462370|Drug|Placebo to ibuprofen|Placebo to ibuprofen, up to four 3-capsule doses.
1700491|NCT01462370|Drug|Acetaminophen 250 mg, isopropylantipyrine 150 mg and anhydrous caffeine 50 mg|Provided to participants as rescue medication. Participants may take 2 tablets at a time and up to 3 doses within 24 hours for rescue purposes.
1700492|NCT01462357|Biological|Cervarix|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6
1700493|NCT01462357|Biological|Gardasil|2 or 3 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes or vials to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Day 0 and Month 6 (Gard_2D) or at Day 0, Month 2 and Month 6 (Gard_3D), respectively.
1700494|NCT01462357|Drug|placebo|2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding
1700495|NCT01462344|Drug|ADVAIR 100/50mcg|fluticasone propionate/salmeterol combination (100/50mcg) twice daily (AM and PM) for 6 months
1700496|NCT01462344|Drug|ADVAIR 250/50mcg|fluticasone propionate/salmeterol combination (250/50mcg) twice daily (AM and PM) for 6 months
1700497|NCT01462344|Drug|FLOVENT 100mcg|fluticasone propionate (100) twice daily (AM and PM) for 6 months
1700498|NCT01462344|Drug|FLOVENT 250mcg|fluticasone propionate (250mcg) twice daily (AM and PM) for 6 months
1700499|NCT01462331|Other|Isomaltooligosaccharide (digestion-resistant carbohydrates)|12g/dose; three times a day
1700500|NCT01462331|Other|Isomaltooligosaccharide (digestion-resistant carbohydrates)|18g/dose, three times a day
1700504|NCT01462318|Drug|S-warfarin|10 mg
1700507|NCT01462318|Drug|Dextromethorphan|30 mg
1700508|NCT01462318|Biological|BIIB019 (Daclizumab)|150 mg in 1 ml PFS
1700509|NCT01462305|Device|goLITE|goLITE at 30 minutes per day, within 30 minutes of waking in the morning
1700510|NCT01462305|Device|Control|light therapy using 580nm LED source within 30 minutes of waking in the morning every day for 6 weeks
1955947|NCT03021304|Drug|Mepolizumab|It is a clear to opalescent, colorless to pale yellow sterile solution for SC injection, supplied in a single-use, prefilled syringe containing 100 mg/mL mepolizumab with sodium phosphate, citric acid, sucrose EDTA and polysorbate 80 within a safety syringe.
1700515|NCT01462279|Drug|Thiamine|200mg of intravenous thiamine in 50ml of D5W will be infused over 30 minutes once
1700516|NCT01462266|Drug|Sitagliptin|Sitagliptin 100 mg tablet once daily for 24 weeks
1700517|NCT01462266|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 24 weeks
1700518|NCT01462266|Biological|Insulin Glargine|Participants on insulin glargine or another insulin regimen for at least 10 weeks prior to screening will continue or switch to open-label insulin glargine once-daily in the evening for the duration of the study.
1700519|NCT01462266|Drug|Metformin|Participants on metformin oral tablet(s) at a dose of at least 1500 mg/day for at least 10 weeks prior to screening will continue receiving metformin at their current dose for the duration of the study.
1700521|NCT01462240|Device|LPS Flex Porous Femoral Components|Porous femoral components in total knee arthroplasty
1700522|NCT01462227|Drug|Naltrexone High Dose|Naltrexone 100mg for two administrations.
1700523|NCT01462227|Drug|Naltrexone Low Dose|Naltrexone 50mg for two administrations.
1700524|NCT01462214|Drug|Everolimus|Patients will be treated with low-dose oral cyclophosphamide (8 different dose levels and schedules) in combination with fixed dose (10 mg) everolimus in patients with mRCC.
1700525|NCT01462201|Device|Non Invasive Ultrasound|Each treatment session is estimated to take approximately 60 minutes and will be performed on a bi-weekly basis.
1700526|NCT01462188|Procedure|Immediate stenting|Primary coronary stenting
1700527|NCT01462188|Procedure|Delayed stenting|Coronary stenting 3 to 7 days after having reopened the vessel in the acute phase
1700528|NCT01462175|Drug|RO5503781|
1700529|NCT01462162|Drug|Tocilizumab|
1700530|NCT01462149|Drug|Neoadjuvant chemotherapy|Docetaxel 75mg/m2BAS, q 3 weeks, 3 cycles
1700531|NCT01462149|Drug|Carboplatin|Carboplatin AUC 5, q 3 weeks, 3 cycles
1700532|NCT01462136|Drug|ACHN-490 Injection|7.5 mg/kg single dose administered intravenously over 30 minutes
1700533|NCT01462123|Other|endoscopic assessment of colonic polyps|
1700534|NCT01462097|Behavioral|Aerobic exercise training|12 months of aerobic exercise
1700535|NCT01462097|Behavioral|Health Education|12 months of health education sessions
1700536|NCT01462084|Device|Adaptive servo-ventilation (ASV)|Adaptive servo-ventilation (ASV) is a form of positive airway pressure (PAP) that is delivered based on the needs of the individual.
1700537|NCT01462084|Device|Bi-Level PAP|Bi-Level PAP delivers therapy at 2 pressures IPAP and EPAP that are fixed.
1700538|NCT01462058|Dietary Supplement|Vitamin D3|70µg Vitamin D3, daily, 12 weeks
1700539|NCT01462058|Drug|Placebo|Placebo, daily, 12 weeks
1700540|NCT01462045|Behavioral|Mindfulness-based exercise|8-week program of mindfulness-based stretching and breathing exercises
1700541|NCT01462032|Behavioral|Training Executive, Attention and Motor Skills (TEAMS)|Children will be taught games targeting these skills and parents will be encouraged to play these games with children at home
1700542|NCT01462032|Behavioral|Parent support and education|Parents will participate in groups designed to provide information about ADHD and support for working with their child.
1700543|NCT01462019|Device|Photobiomodulation|"the participants of this group will receive, in addition to guidance on the breast care and proper techniques for feeding, phototherapy applications through photobiomodulador a device developed specifically for the treatment of nipple injuries. The parameters for applications are: continuous mode of emission, power output 10 mW, wavelength infrared (scanning from 880 to 904 nm) fluence of 4 J / cm ² and total application time of 10 minutes.
The application of the device will be three times per week on alternate days for seven consecutive weeks, totaling 21 sessions."
1700544|NCT01462006|Drug|sirolimus|randomized to drug or placebo, followed by washout, followed by crossover
1700545|NCT01462006|Other|Placebo|randomized to drug or placebo, followed by washout, followed by crossover
1700546|NCT01461993|Biological|rLP2086 and Gardasil|Gardasil vaccine and rLP2086 injection will be given to the subject concomitantly in Group 1 at Months 0, 2 and 6.
1700547|NCT01461993|Biological|rLP2086|Injections of rLP2086 and saline will be given to the subject concomitantly in Group 2 at Months 0, 2 and 6.
1700548|NCT01461993|Biological|Gardasil|Injections of saline and Gardasil vaccine will be given to the subject concomitantly in Group 3 at Months 0, 2 and 6.
1700549|NCT01461980|Biological|rLP2086 + MCV4 + Tdap|At visit 1, group 1 will receive MCV4 + Tdap vaccines concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 1 will receive an injection of rLP2086.
1700550|NCT01461980|Biological|MCV4 + Tdap + saline|At visit 1, group 2 will receive MCV4 + Tdap vaccines concomitantly with an injection of saline. At visits 3 and 5 (months 2 and 6), this group will receive a saline injection only.
1700626|NCT01461512|Drug|heme arginate administration|heme arginate 1 mg/kg body weight 24 hours prior to ischemia
1700627|NCT01461512|Drug|Placebo administration|NaCl isotonic
1701275|NCT01456312|Drug|Entecavir|combination
1700551|NCT01461980|Biological|rLP2086 + saline|At visit 1, group 3 will receive 2 injections of saline concomitantly with an injection of rLP2086. At visits 3 and 5 (Months 2 and 6), group 3 will receive an injection of rLP2086. Subjects randomized to this group will receive MCV4 and Tdap following their final visit blood draw (Visit 6).
1700552|NCT01461967|Drug|Placebo|Single ascending doses
1700553|NCT01461967|Drug|RO5508887|Single ascending doses
1700554|NCT01461967|Drug|RO5508887|Single doses
1700555|NCT01461954|Drug|FST-100|FST-100
1700556|NCT01461954|Drug|FST-100 Vehicle|FST-100 Vehicle
1700557|NCT01461941|Drug|E6005|0.0% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
1700558|NCT01461941|Drug|E6005 ointment (vehicle)|0.2% E6005 ointment applied twice daily for 4 weeks (vehicle-controlled phase), and then, following 8-week is extension phase which all subjects receive 0.2% E6005 ointment twice daily. Subjects are randomized to either 0.2% E6005 ointment group or vehicle group at a ratio of 2:1.
1700559|NCT01461928|Drug|Chemotherapy (Induction Period)|Participants will receive standard combination chemotherapy every 3-4 weeks for 6 to 8 months. The chemotherapy regimen will be selected at Investigator's discretion, for individual participant. Study protocol does not enforce any particular chemotherapy regimen.
1700560|NCT01461928|Drug|Rituximab|Participants will receive rituximab according to the regimen specified in individual arm.
1700561|NCT01461915|Drug|Abraxane ( Nab-paclitaxel)|Nab-paclitaxel 125 mg/m2 administered IV over 30 minutes. Given weekly for 3 weeks followed by one week of rest.
1700562|NCT01461915|Drug|Abraxane ( Nab-paclitaxel)|Nab-paclitaxel 125 mg/m2 administered IV over 30 minutes. Nab-paclitaxel to be given weekly for 3 weeks followed by one week of rest.
1700563|NCT01461915|Drug|Gemcitabine|Gemcitabine at 1000 mg/m2 over 30 minutes to be administered after the completion of Abraxane administration. Gemcitabine will be given weekly for 3 weeks followed by one week of rest.
1700564|NCT01461915|Drug|Gemcitabine|Gemcitabine at 1000 mg/m2 administered IV over 30 minutes (after the nab-paclitaxel IV administration is complete). Gemcitabine to be administered weekly for 3 weeks followed by one week of rest.
1700565|NCT01461915|Drug|ODSH ( 2-O, 3-O Desulfated Heparin)|"ODSH IV bolus at 4 mg/kg to be administered in 5 minutes immediately after completion of gemcitabine administration.
ODSH 48-h IV continuous infusion at 0.375 mg/kg/h should be started immediately after the ODSH IV bolus has been administered."
1700566|NCT01461915|Drug|ODSH ( 2-O, 3-O Desulfated Heparin)|"ODSH IV bolus at 4 mg/kg will be administered in 5 minutes immediately after completion of gemcitabine administration.
ODSH 48-h IV continuous infusion at 0.375 mg/kg/h should be started immediately after the ODSH IV bolus has been administered."
1700567|NCT01461915|Drug|Abraxane ( nab-paclitaxel)|Nab-paclitaxel 125 mg/m2 administered IV over 30 minutes will be given weekly for 3 weeks followed by one week of rest.
1700568|NCT01461915|Drug|Gemcitabine|Gemcitabine to be administered IV at 1000 mg/m2 over 30 minutes given weekly for 3 weeks followed by one week of rest
1700569|NCT01461889|Other|Transfuse plasma to High INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (2.5) while patient is actively bleeding or 48 hours whichever comes first
1700570|NCT01461889|Other|Transfuse plasma to Low INR target|Using a dosing algorithm we will bolus plasma to reach an INR target (1.8) while patient is actively bleeding or 48 hours whichever comes first
1700571|NCT01461876|Drug|antiretroviral therapy|Standard of care antiretroviral therapy
1700572|NCT01461863|Dietary Supplement|Porridge protein calorie supplement|250 gm of fortified flour to make porridge containing 1062 kcal and 42 gm protein
1700573|NCT01461863|Dietary Supplement|multivitamin|Standard multivitamin
1700574|NCT01461850|Procedure|Laparoscopy|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo only to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. After neoadjuvant chemotherapy interval debulking surgery will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
1700575|NCT01461850|Procedure|Cytoreduction|Patients with suspected advanced ovarian cancer (FIGO stage IIIC) will undergo to diagnostic laparoscopy. Omental cake, diaphragmatic or peritoneal extensive carcinomatosis, tumor diffusion to the small and large curvature of the stomach, large and/or small bowel mesentery disease, spleen and/or liver metastases will be investigated in order to obtain a laparoscopic score. Then, an attempt of laparotomic cytoreduction will be performed: total hysterectomy, bilateral salpingo-oophorectomy, radical omentectomy, appendectomy, pelvic and paraaortic lymphadenectomy, eventual bowel resection, eventual bladder resection, eventual splenectomy, eventual parietal and diaphragmatic peritonectomy, eventual gastric resection, eventual hepatic resection, eventual pancreas resection, eventual cholecystectomy.
1700576|NCT01461837|Drug|CD34 selected T-cell depleted allogeneic SCT|Hydroxyurea (60 mg/kg/day) and azathioprine (3 mg/kg/day) day -59 to day -11; fludarabine (30 mg/m2) Days -17, -16, -15, -14, -13; busulfan (3.2 mg/kg/day) Days -12, -11, -10, -9; thiotepa (10 mg/kg IV) day -8; cyclophosphamide (50 mg/kg) Days -7, -6, -5, -4; TLI on day -3; rabbit ATG (2.0 mg/kg/day) day -5,-4,-3, and -2; Stem Cell infusion day 0
1700578|NCT01461811|Device|Nelfilcon A toric contact lenses (with comfort additives)|
1700579|NCT01461811|Device|Nelfilcon A toric contact lenses|
1700580|NCT01461798|Dietary Supplement|assessment of efficacy of Benecol yogurt|Benecol Yogurt and Yogurt placebo for 4 weeks each, at a dose of 100 ml (200 ml in total) of yogurt twice a day with main meals
1700581|NCT01461798|Dietary Supplement|Placebo Yogurt|Yogurt without the active principle
1700582|NCT01461798|Dietary Supplement|yogurt|yogurt without plant stanols
1700705|NCT01460836|Drug|Aztreonam lysine for inhalation|
1700822|NCT01459796|Drug|Rilonacept|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 52 weeks.
1700585|NCT01461772|Radiation|Radiation therapy|pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
1700586|NCT01461772|Drug|Carboplatin|carboplatin 130mg/m2BSA on day 1,8,15,22,29,and 36
1700587|NCT01461772|Drug|Cisplatin|Cisplatin 40mg/m2BSA on day 1,8,15,22,29,and 36
1700588|NCT01461759|Drug|Doctaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 8 cycles
1700589|NCT01461759|Drug|Cisplatin|Cisplatin 60mg/m2BAS, q 3 weeks, 8 cycles
1700590|NCT01461746|Drug|Docetaxel|Docetaxel 70mg/m2BSA, q 3 weeks, 3 cycles
1700591|NCT01461746|Drug|Cisplatin|Cisplatin 60mg/m2BSA, q 3 weeks, 3 cycles
1700592|NCT01461746|Radiation|Radiation therapy|Pelvic radiation therapy (Extended filed radiation therapy and addition of brachytherapy is allowed)
1700593|NCT01461733|Drug|amiodarone|standard dose amiodarone
1700594|NCT01461733|Drug|Placebo|placebo delivered blinded
1700595|NCT01461720|Other|Standard medical care|Standard medical care includes treatment to prevent recurrence, optimal control of risk factors and post stroke follow-up rehabilitative treatment.
1700596|NCT01461720|Biological|Autologous bone marrow-derived mesenchymal stem cells|Single intravenous infusion of autologous bone marrow-derived mesenchymal stem cells concurrently with standard medical care.
1700597|NCT01461707|Behavioral|Mobile phone-based physical activity|Participants will receive the mobile phone-based physical activity program using the trial app.
1700598|NCT01461707|Behavioral|Activity monitor|Participants will receive an activity monitor
1700599|NCT01461694|Device|Intense Pulsed Light (IPL)|Half Face Treated with IPL
1700600|NCT01461694|Device|Alexandrite Laser|Half face treated with Alexandrite Laser
1700601|NCT01461681|Procedure|Symptom Management Service for Heart failure|The symptom management service for heart failure (SMS-HF) will begin in the hospital where the patient will be seen daily until discharge and continue with at least 6 contacts over the next 6 months with the first outpatient contact occurring in person in the HF clinic within a month of discharge. Of the subsequent 5 monthly contacts, at least 2 will be in person with the remainder by telephone. Additional contacts between the SMS-HF team and patient will be scheduled as needed. Patients discharged to a site other than home will have monthly contacts by telephone until they are able to attend the clinic. We will assess changes in depression, pain, dyspnea, and quality of life from baseline to 6 month follow-up.
1700602|NCT01461668|Drug|Retapamulin|Two times a day for 5 days
1700603|NCT01461668|Drug|Placebo|Two times a day for 5 days
1700604|NCT01461655|Drug|marketed topical retinoid|once daily application, 4 weeks
1700605|NCT01461655|Drug|marketed topical NSAID|once daily application, 4 weeks
1700606|NCT01461655|Drug|vehicle gel|once daily application, 4 weeks
1700607|NCT01461655|Drug|marketed topical retinoid|once daily application, 4 weeks
1700608|NCT01461642|Other|Self management asthma plan indorsment.|Subjects adherence to asthma self management plan will be monitored through web-based support.
1700609|NCT01461616|Drug|NPH|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
1700610|NCT01461616|Drug|Detemir|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
1700611|NCT01461616|Drug|Glargine|equal doses of NPH insulin, insulin Detemir and insulin glargine injection
1700612|NCT01461603|Dietary Supplement|Vamin (Fresenius Kabi)|Vamin 18gN 1ml/min infusion in 6 hours
1700613|NCT01461603|Dietary Supplement|3hydroxybutyrate|Goldbio, FFA-3OHB, dry powder mixed with sterile water at Aarhus University hospital pharmacy.
1700614|NCT01461590|Other|Whole blood|30mls/kg transfused over fours hours
1700615|NCT01461590|Other|Whole blood|20mls/kg transfused over four hours
1700616|NCT01461577|Drug|INSULIN GLARGINE HOE 901|Pharmaceutical form:solution Route of administration: subcutaneous
1700617|NCT01461564|Procedure|Colonoscopy|Screening colonoscopy
1700618|NCT01461551|Drug|Sevoflurane|anesthesia was maintained with sevoflurane (end-tidal concentration 1.0-1.5 minimum alveolar concentration)
1700619|NCT01461551|Drug|Propofol|anesthesia was maintained with propofol (2-4 μg/ml via target-controlled infusion)
1700620|NCT01461551|Drug|combine of sevoflurane and propofol|anesthesia was maintained with a combine of propofol (1 μg/ml via target-controlled infusion) and sevoflurane (end-tidal concentration 0.7-1.0 minimum alveolar concentration)
1700621|NCT01461538|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous (IV) infusion
1700622|NCT01461538|Drug|brentuximab vedotin|2.4 mg/kg every 3 weeks by intravenous (IV) infusion
1700623|NCT01461538|Drug|brentuximab vedotin|1.2 mg/kg weekly, 3 out of 4 weeks, by intravenous (IV) infusion
1700624|NCT01461525|Procedure|Abdominoperineal resection|After high ligation of IMA, TME with autonomic nerve preservation, proctectomy with sphincter sacrifice and permanent colostomy.
1700625|NCT01461525|Procedure|Sphincter preservation surgery|After high ligation of IMA, TME with autonomic nerve preservation, sphincter preservation and proctectomy with distal margin of more than 0.5cm in length and temporary ileostomy
1760241|NCT00282347|Drug|Methylprednisolone|
1700630|NCT01461486|Device|Continuous Positive Airway Pressure (CPAP)|The device is a flow generator used to open the airway during sleep.
1700631|NCT01461486|Device|Oral Appliance (BRD)|The device increases the volume of the airway by mandibular traction.
1700632|NCT01461473|Device|Positive Airway Pressure (PAP)|Participants randomized to the Positive Airway Pressure treatment group received adequate Positive Airway Pressure (PAP) pressure therapy by a PAP titration study and used the device for 6 months.
1700633|NCT01461473|Device|Oral Appliance (OA)|Participants randomized to the Oral Appliance treatment group received a dental evaluation to determine the optimal setting for the Oral Appliance (OA), and used the appliance for 6 months.
1700634|NCT01461460|Drug|TR-701 FA 1200 mg|6 tablet of T-701 FA
1700635|NCT01461460|Drug|Moxifloxacin 400 mg|1 tablet 400 mg Moxifloxacin
1700636|NCT01461460|Drug|TR-701 FA 200 mg plus Placebo|1 tablet of TR-701 FA with 5 tablet placebo
1700637|NCT01461460|Drug|Placebo|6 placebo tablets
1700638|NCT01461447|Biological|Modified Vaccinia Ankara|Healthy volunteers will receive intramuscularly 1 injection of MVA-CMDR 1ml (Total 10 power 8 pfu) boost injection in the left deltoid muscle.
1700639|NCT01461434|Device|Medtronic Reveal XT implantable loop recorder|subcutaneous implantation
1700640|NCT01461421|Behavioral|Nutrition Education|Participants are taught about energy balance, caloric intake, the nutrition content of foods, and diet.
1700641|NCT01461421|Behavioral|Behavioral Weight Loss Strategies|Participants are taught self-monitoring and goal setting techniques.
1700642|NCT01461421|Behavioral|Standard Cognitive Techniques|Participants are taught how to modify, get rid of, or distract from thoughts and also how to regulate emotions.
1700643|NCT01461421|Behavioral|Acceptance Based Techniques|Participants are taught how to accept and change their perception of their thoughts and emotions.
1700644|NCT01461408|Behavioral|Health Education Session|"The educational messages during the education session will engage individual women, their peer group, their family members and community influencers in a way that is authentic and share-able. Involving women in give-and-take discussions with people they trust and respect—their hairdressers—will be essential to increasing the number of them who consider the HPV vaccine for themselves and for those they care about.
The investigators plan to recruit eight (8) predominantly African American beauty salons in Philadelphia and train multiple stylists in each salon to act as in-salon educators and facilitators for client recruitment to sexual health education sessions. These education sessions will be run by trained health educators (also African American females) and take place during down times in each of the salons, on a rotating basis. There will be two types of sessions offered, one for mothers of females ages 9-18 and one for females ages 18-26."
1700645|NCT01461382|Other|Treadmill Desks|Treadmill Desk were installed in subjects personal workspace.
1700646|NCT01461382|Other|Treadmill Desks|Treadmill desks were installed in subjects personal workspace six months after phase I started.
1700647|NCT01461369|Drug|Diclofenac|35 mg bid Capsules
1700648|NCT01461369|Drug|Diclofenac|35 mg tid Capsules
1700649|NCT01461369|Drug|Placebo|Capsules
1700650|NCT01461356|Procedure|Minimally invasive total knee replacement|A cemented tricompartmental total knee replacement will be performed using a minimally invasive surgical approach.
1700651|NCT01461356|Procedure|Standard approach total knee replacement|A cemented tricompartmental total knee replacement will be performed using a traditional medial parapatellar surgical approach.
1700652|NCT01461343|Other|CT imaging, functional PET imaging|Physiology study using CT and functional PET imaging with 13NN and 11CO as radiotracers; images obtained before and after administration of inhaled nitric oxide and balance 80% oxygen as pulmonary vasodilators
1700653|NCT01461330|Other|DASH diet plus exercise|"DASH diet adapted to the usual diet of Brazilian type 2 diabetic patients = prescription of a normocaloric diet including fruits, vegetables, grain products, low fat dairy foods, legumes, without sugar, and with limited fat
Exercises: the recommended physical activity will consist of using a pedometer during the experimental period."
1700654|NCT01461330|Other|ADA diet|Adoption of ADA diet.
1700655|NCT01461317|Drug|Etrolizumab|Participants will receive etrolizumab at a dose of 100 mg.
1700656|NCT01461304|Drug|triheptanoin|subjects will receive a modified diet containing triheptanoin (up to 2 grams/kg/24 hours), or continued on their previously established triheptanoin dose; not to exceed RDA for fat, substituted for their MCT oil and/or natural fat. Study subjects will continue the triheptanoin-supplemented diet for a period of 12 months and then be able to continue into an indefinite extension phase in this compassionate use study. Laboratory evaluations will take place at two, six, and twelve months as well as every 12 months in the extension phase.
1700657|NCT01461291|Device|iStent inject|Implantation of two GTS400 stents using G2-M-IS iStent inject
1700658|NCT01461291|Procedure|Cataract surgery|Cataract surgery alone
1700659|NCT01461278|Device|iStent supra|Cataract surgery and implantation of one iStent supra
1700660|NCT01461278|Procedure|Cataract surgery|Cataract surgery alone
1700661|NCT01461265|Procedure|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
1700662|NCT01461252|Procedure|Cryoablation|For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study and are at the discretion of the investigator.
1700663|NCT01461252|Procedure|Radiation|Radiation therapy is usually performed with 6-18 Megavolt photons from a linear accelerator. The proposed dose and frequency of radiation for this protocol are: 8 Gray in 1 fraction, 30 Gray in 10 fractions, or 37.5 Gray in 15 fractions. These proposed doses or other doses will be prescribed at the discretion of the investigator. It is anticipated that subjects will begin the radiation therapy approximately within one to three weeks after the cryoablation procedure. The doses and frequency of the radiation treatment will be collected as well as toxicities.
1700664|NCT01461239|Procedure|fiber post and resin core - self-adhesive cement|pre-fabricated glass fiber posts, cemented with self-adhesive resinous cement
1700665|NCT01461239|Procedure|cast post and core|Ni-Cr alloy cast post and core luted with self-adhesive resin cement
1700666|NCT01461239|Procedure|fiber post luted with conventional resin cement|fiber post luted with conventional etch-and-rinse adhesive system and conventional resin cement, followed by core construction with composite resin
1700667|NCT01461226|Behavioral|Exercise training|Individualized and progressively increased supervised aerobic exercise program on a daily base (3-4hours per day, hypocaloric diet and psychological guidance
1700668|NCT01461226|Behavioral|Usual care|Nutritional assessment and dietary advice by general practitioner, promotion of sports activities
1700669|NCT01461213|Drug|rAAV2.REP1|Single subretinal injection of rAAV2.REP1 vector suspension containing 10e12 genome particles per ml. Dose 1 = dose containing approximately 10e10 rAAV2.REP1 genome particles. Dose 2 = dose containing approximately 10e11 rAAV2.REP1 genome particles.
1700670|NCT01461200|Other|Swab of vestibule and middle meatus of nose|Swabs of vestibule and middle meatus of nose will be taken prior to and during the grass/tree allergy season
1700671|NCT01461187|Other|exercise during pregnancy|supervised aerobic physical exercises twice a week.
1700672|NCT01461174|Drug|Modafinil|200 mg tablet, single dose
1700673|NCT01461174|Drug|Donepezil|Donepezil or placebo, 5 mg tablet one per day, 15 days
1700674|NCT01461174|Drug|Memantine|Memantine or placebo, 10 mg tablet one per day, 15 days
1700675|NCT01461161|Drug|bardoxolone methyl|oral, single dose
1700676|NCT01461148|Biological|FSP peptides|100 ug of each FSP (TAF1B(-1), HT001(-1) and AIM2(-1), weekly for 4 consecutive weeks and repeated every four weeks up to a total of 3 cycles.
1700677|NCT01461109|Drug|[18F] CFPyPB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
1700678|NCT01461096|Biological|Quadrivalent HPV Vaccine|Participants were prescribed one intramuscular (IM) injection of the quadrivalent HPV vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
1700679|NCT01461096|Biological|Placebo Vaccine for Male Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
1700680|NCT01461096|Biological|Placebo Vaccine for Female Participants Only|Participants were prescribed one IM injection of the placebo vaccine in the upper arm or thigh at baseline and Weeks 8 and 24.
1700681|NCT01461083|Drug|[18F]MPPF|Subjects will be dosed by intravenous bolus injection of [18F]MPPF targeted to be 5.0 mCi, and not to exceed 5.5 mCi (not >10% of 5.0 mCi limit) and not to exceed 5 µg of MPPF
1700682|NCT01461057|Drug|Capecitabine|1000 mg/m2 twice daily, from the evening of Day 1 to the morning of Day 15 of each cycle
1700683|NCT01461057|Drug|Cisplatin|80 mg/m2 on Day 1 of each cycle
1700684|NCT01461057|Drug|Pertuzumab|loading dose of 840 mg, then 420 mg once every three weeks
1700685|NCT01461057|Drug|Pertuzumab|840 mg once every three weeks
1700686|NCT01461057|Drug|Trastuzumab|loading dose of 8 mg/kg for Cycle 1 and a dose of 6 mg/kg for subsequent cycles
1700687|NCT01461031|Drug|nefopam|nefopam infusion for postoperative 24 hours
1700688|NCT01461031|Drug|normal saline (control)|normal saline infusion for postoperative 24 hours
1700689|NCT01461018|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use.
1700690|NCT01461005|Device|Dynamic Stabilization System (DSS)|Dynamic Stabilization System
1700691|NCT01460992|Procedure|Evia/Entovis pacemaker system under Magnetic Resonance Imaging (MRI) conditions|patients will undergo an MRI scan for 30 minutes.
1700692|NCT01460979|Drug|Temsirolimus|25mg weekly intravenous until progression
1700693|NCT01460966|Procedure|Filtrap™ + Thrombus aspiration catheter|Combination of distal protection device (Filtrap™ )and thrombus aspiration catheter
1700694|NCT01460966|Procedure|Thrombus aspiration catheter|Thrombus aspiration catheter only
1700695|NCT01460953|Behavioral|health literacy training video|participants will watch a training video
1700696|NCT01460940|Drug|panobinostat|Administered orally Monday, Wednesday, Friday of every week for 4 weeks. A cycle is define as 28 days.
1700697|NCT01460940|Drug|lenalidomide|Lenalidomide will be administered orally daily on days 1-21. Lenalidomide will not be given on days 22-28. A cycle is define as 28 days.
1700698|NCT01460927|Device|TriActive+ RF|"Radio frequency handpiece uses a multi-polar technology with a particular electrical frequency of 1MHz. The handpiece has a special skin contact identification system which delivers energy only when electrodes are adherent to the skin surface in order to avoid the prickling sensation when the treatment starts."
1700699|NCT01460901|Biological|Tri-virus specific cytotoxic t-cells|Infusion of donor derived tri-virus specific cytotoxic t-cell post allogeneic stem cell transplantation
1700700|NCT01460888|Drug|Olaparib|25mg tablets, oral. Commenced 3 days prior to radiotherapy and continuing until the last day of radiotherapy (36 days in total).
1700701|NCT01460888|Radiation|Radical external beam radiotherapy, 50Gy in 25 fractions|Radiotherapy to the oesophageal carcinoma. For patients receiving olaparib this is delivered as 50Gy in 25 daily fractions for 5 weeks (Monday-Friday only). For patients in the comparator arm (RT only) other total doses/ fractionation are permitted, according to local policy/ best standard care.
1700702|NCT01460875|Biological|recombinant interferon alfa-2b|Given SC
1700703|NCT01460875|Other|laboratory biomarker analysis|Blood for use in correlative studies approximately 30 ml 30 x 106 peripheral blood mononuclear cell (PBMCs) will be drawn on day 1 every other week during the first 12 weeks just prior to treatment and at 1 and 4 hours post therapy.
1700704|NCT01460836|Drug|Tobramycin solution for inhalation|
1760242|NCT00282347|Drug|Diphenhydramine|
1700706|NCT01460823|Procedure|Percutaneous Cochlear Implantation using image guided surgical techniques|Percutaneous Cochlear Implantation using image guided surgical techniques.
1700707|NCT01460810|Other|1000CsK Silicon Oil Tamponade|Details covered in arm description
1700708|NCT01460797|Other|Glycemic Index Diets and Metformin hydrochloride|1g of Metformin hydrochloride a day in High Glycemic Index Diet
1700711|NCT01460758|Device|Medial Frontal rTMS Double-Cone-Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option) applied over medial superior frontal cortex (supplementary motor cortex) (Brodmann area 6/8),Double-Cone-water-cooled-Coil (2000 Stimuli of 10 Hz each session), 110% motor threshold.
1700712|NCT01460758|Device|Left DLPFC Butterfly Coil|High frequency rTMS ( Alpine Biomed Mag Pro Option): 2000 stimuli of 10 Hz over the left DLPFC (each session), Butterfly-water-cooled-Coil, 110% motor threshold.
1700713|NCT01460758|Device|Placebo Stimulation|Sham Stimulation (conventional butterfly-coil, angled 45°): left DLPFC continuous rTMS, 10 Hz, 2000 Stimuli each session, 110% motor threshold
1700714|NCT01460732|Device|Blood Pressure Monitoring|Home Blood pressure Monitoring Nocturnal-Home Blood Pressure Monitoring Ambulatory Blood Pressure Monitoring
1700715|NCT01460719|Biological|V212|V212 viral antigen for HZ, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
1700716|NCT01460706|Drug|[68Ga]DOTATOC|120MBq 68Ga-DOTATOC intravenously and PET/CT imaging. Performed once to a patient before the surgery.
1700717|NCT01460693|Drug|Imatinib|Oral Imatinib 100mg daily
1700718|NCT01460693|Drug|Dasatinib|Oral Dasatinib 100mg daily
1700721|NCT01460654|Drug|Testosterone|Testosterone Gel (Fortesta) 40mg daily.
1700722|NCT01460654|Drug|Alendronate|Alendronate (Fosamax) 70mg every week.
1700723|NCT01460654|Drug|Placebo Alendronate|A placebo alendronate tablet will be taken every week by subjects in the Testosterone and Placebo Alendronate Group.
1700724|NCT01460654|Drug|Placebo Testosterone|Placebo testosterone gel will be applied daily by subjects in the Alendronate and Placebo Testosterone group.
1700725|NCT01460628|Drug|Armodafinil|Women who are eligible will receive 4 weeks of treatment with armodafinil. Armodafinil will be titrated from 50-mg/day up to 150-mg/day. For exploratory reasons only, at the end of the 4-week treatment period, participants will enter a discontinuation phase in which they will be randomized to double-blind treatment with armodafinil 150-mg/day or matching placebo for 2 weeks in a 1-to-1 ratio. No primary outcomes were studied in the discontinuation phase.
1700726|NCT01460615|Drug|Hydrocortisone|
1700727|NCT01460602|Drug|MTD of Velcade, Nipent and Rituxan established in Part 1|"One of the following dose levels will be chosen and used in Part 2:
(VAN1) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
(VAN2) VA= 1.3 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
(VBN1) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 2 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1
(VBN2) VA= 1.5 mg/m2 IV Days 1, 4, 8, 11 N1= 4 mg/mg2 IV Days 1, 8 375 mg/m2 IV Day 1"
1700728|NCT01460589|Procedure|timing to initiate the adjuvant chemotherapy|Chemotherapy regimen: FOLFOX-6, every 2weeks, total 12 cycles treatment day1: Oxaliplatin 85mg/m2 day1: Leucovorin 200mg/m2 day1: 5-FU 400mg/m2 IV bolus and 2,400mg/m2 over 46 hours
1700729|NCT01460563|Drug|Magnesium Sulfate|MgSO4 infusion: 50mg/kg bolus followed by continuous infusion
1700730|NCT01460563|Drug|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
1700731|NCT01460563|Drug|0.9% saline|0.9% saline as same dose as MgSO4 as placebo
1700732|NCT01460550|Procedure|Retrocolic gastro- or duodeno- jejunostomy in hte pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the retrocolic reconstruction, the jejunal loop was anastomosed to the duodenum or stomach through a separate mesocolic window on the left of the middle colic vessels.
1700733|NCT01460550|Procedure|Antecolic gastro- or duodeno- jejunostomy in the pancreaticoduodenectomy|The duodenojejunostomy or gastrojejunostomy was constructed in two layers or single layer. For the antecolic reconstruction, the jejunal loop about 30 cm distal to the hepaticojejunostomy, was brought up anterior to the transverse colon and anastomosed to the duodenum or stomach.
1700734|NCT01460537|Drug|Gemcitabine|Gemcitabine 1000mg/m2 as 30-minutes IV infusion
1700735|NCT01460537|Drug|BAY80-6946|Escalated dose starting from 0.6 mg/kg in 100 mL of 0.9% NaCl as 60-minutes IV infusion
1700736|NCT01460537|Drug|Cisplatin|1 liter of 0.9% NaCl including 25 mg/m2 cisplatin, 20 mmol of potassium chloride, and 8 nmol of magnesium sulfate over 60 minutes
1700737|NCT01460537|Drug|NaCl|Infusion of 500 ml of 0.9% NaCl over 30-minutes
1700738|NCT01460537|Drug|BAY80-6964 fixed dose|BAY80-6946 IV infusion at the maximum tolerated dose determined in Treatment A over 60 min. [If Treatment A MTD is not tolerable, further subject enrollment will begin at one BAY80-6946 Dose Level lower with the cisplatin-gemcitabine doses remaining constant.]
1700739|NCT01460511|Drug|Epinephrine Inhalation Aerosol|250 mcg (2 inhalations), 4 times daily
1700743|NCT01460472|Biological|Racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), intradermally, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and further onco-specific therapy is indicated, the patient will be able to continue in the study and vaccination will not be interrupted unless criteria for vaccine discontinuation are met.
1700744|NCT01460472|Other|Best Support Treatment|Patients will receive best support treatment for advanced NSCLC as per each institution's standards, including onco-specific therapies when disease progresses.
1700820|NCT01459809|Drug|GLIMEPIRIDE|"Pharmaceutical form: oral
Route of administration: oral"
1700745|NCT01460459|Behavioral|a specific frequency of SMBG|"Patients are instructed to measure their blood glucose concentrations 4 times per day (pre-prandial and before bedtime:
high frequency: one day weekly middle frequency:one day per two weeks low frequency:one day monthly"
1700746|NCT01460446|Device|Aviva Expert blood glucose meter|
1700747|NCT01460446|Device|Aviva Nano blood glucose meter|
1700748|NCT01460433|Procedure|Genital and rectal swabbing|Subjects swabs their genitals and rectum daily. The amount of HSV shed over the previous 24 hours is measured and the daily HSV shed rate is calculated.
1700749|NCT01460420|Drug|Bz (Bortezomib)|Bz 1.3 mg/m2 on days +1, +4 and +7. Maintenance therapy and dose reduction pre-specified.
1700750|NCT01460420|Drug|Len (lenalidomide)|"Len at a dose of 6 mg po on day -5 and then 4 mg per day in order to maintain serum levels in the range of 6-12 ng /mL.
Maintenance therapy and dose reduction pre-specified."
1700751|NCT01460407|Drug|LY2216684|Administered orally
1700752|NCT01460407|Drug|Clarithromycin|Administered orally
1700753|NCT01460381|Drug|LY2216684|Administered orally
1700754|NCT01460381|Drug|Quinidine|Administered orally
1700755|NCT01460368|Drug|LY2409021|Administered orally
1700756|NCT01460368|Drug|Placebo|Administered orally
1700757|NCT01460368|Drug|Moxifloxacin|Administered orally
1700758|NCT01460355|Drug|Botulinum Toxin Type A|injection of 5U in 0.1ml of saline solution will be given to the recessed muscle
1700759|NCT01460355|Drug|saline solution|injection of 0,1ml of saline solution will be given to the recessed muscle
1700760|NCT01460342|Drug|Tadalafil|5 mg (2 x 2.5-mg tablets), given once daily as oral tablet
1700761|NCT01460342|Drug|Placebo|2 tablets (identical to 2.5-mg tadalafil tablets) given orally once daily.
1700762|NCT01460329|Device|Ultrasonic Cardiac Output Monitor (USCOM).|This device is FDA approved and based on the principles of ECHO using continuous-wave Doppler ultrasound to measure cardiac output.
1700763|NCT01460316|Biological|Bood sampling for biochemicals and genetic analysis|There will be one blood sampling for the nutritionnal, metabolic and genetic parameters studied in the protocol
1700764|NCT01460303|Device|Bladder catheter: OPTION-vf patient controlled catheter vs. indwelling transurethral catheter with leg bag|"OPTION-vf patient controlled catheter (transurethral catheter with external drainage valve to provide on-demand drainage of urine stored directly from the bladder), worn maximum of 30 days post-op until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
1700765|NCT01460303|Device|Transurethral catheter with leg bag|"Transurethral catheter w/leg bag urine storage, worn maximum of 30 days post-up until bladder challenge is passed. Bladder challenge is considered passed when a patient is able to void adequately and spontaneously (without the assistance of a catheter)."
1700766|NCT01460290|Drug|Asenapine|Asenapine will be administered open-label in pill form. Asenapine will be initiated at 5 mg twice a day and increased as tolerated to a maximum of 20 mg/day. It is anticipated that maximum stable dosing will be achieved by 4 weeks of treatment, although dosage may be reduced due to tolerability concerns at the discretion of the treating research psychiatrist.
1700767|NCT01460277|Procedure|Hydrokinesiotherapy Intervention|The hydrotherapy exercise intervention consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (water walking, running, side stepping), 5 minutes of a light cool down (marching on the spot), and 10 minutes of gentle stretching in the water.
1700768|NCT01460277|Procedure|Land-based exercise intervention|The conventional exercise intervention used no water-based exercises but land-based exercises. The exercise program consisted of 5 minutes of warm-up, 10 minutes of lower-extremity stretching exercises, 10 minutes of lower-extremity strengthening exercises, 20 minutes balance and gait training (walking, side stepping), 5 minutes of a light cool down, and 10 minutes of gentle stretching out of the water.
1700769|NCT01460251|Drug|DiaPep277|1.0 mg DiaPep277® administered every 3 months.For patients who just completed the 2-year 901 study, a 3-year extended treatment will be offered with 13 administrations; patients who completed the 2-year 910 extension study will be offered a 3rd year of treatment with 5 additional administrations.
1700770|NCT01460225|Drug|lubiprostone|24 micrograms twice daily for 1 week
1700771|NCT01460212|Drug|SSRI antidepressants|SSRI antidepressants are Selective serotonin reuptake inhibitors. They include fluoxetine (Prozac); sertraline (Zoloft); paroxetine (Paxil); citalopram (Celexa) ;escitalopram (Lexapro) and fluvoxamine (Luvox). It will be chosen according to special condition of every patient.
1700772|NCT01460212|Behavioral|Cognitive-Behavior Therapy|The essence of CBT is a learning process through which an appropriate pattern in cognitive and behavioral could be learn and stored as memory
1700773|NCT01460199|Drug|CTP-499|"3 X 200 mg tablets (QD for 2 weeks)
3 x 200 mg tablets (BID for 2 weeks)"
1700774|NCT01460199|Drug|placebo|tablets
1700775|NCT01460186|Other|Blood sample for genetic analysis (Identification of germ line genetic factors that influence the risk of metastatic breast cancer)|Blood samples will be collected in one 6 ml EDTA and one 6 ml ACD tube after informed consent and inclusion in the study.
1700776|NCT01460173|Other|Divided Attention Steering Simulator (DASS)|Half-hour divided attention test with steering wheel after 5 to 10 minutes of practice. Completion of three questionnaires (ESS, Young, Berlin Questionnaire).
1700779|NCT01460134|Drug|CDX-1127|"Patients will initially receive a single dose of CDX-1127, followed by a 28-day observation period and a Multi-Dose Phase (one cycle of 4 weekly doses of CDX-1127). All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression.
The dose of CDX-1127 given for the Dose Escalation phase will depend on the cohort each patient is assigned to, and will range between 0.1 and 10.0 mg/kg of CDX-1127."
1700821|NCT01459809|Drug|METFORMIN|"Pharmaceutical form: oral
Route of administration: oral"
1700780|NCT01460134|Drug|CDX-1127|"Patients will receive 4 weekly doses of CDX-1127 followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
1700781|NCT01460134|Drug|CDX-1127|"Patients will receive four doses of CDX-1127 administered every three weeks followed by an observation period. All patients with stable disease who do not experience a DLT or start alternate anti-cancer treatments may then be eligible for a Retreatment Phase (up to 4 additional cycles). Patients with confirmed partial response or complete response will be followed for response duration and may be eligible for additional cycles of treatment at the time of relapse/progression."
1700782|NCT01460121|Device|SpotOn's corrective elements for dizziness|Eyeglasses with dizziness correction elements (real SpotOn eyeglasses) or eyeglasses with placebo (sham eyeglasses) elements will be worn during the whole four weeks study period.
1700783|NCT01460121|Device|Placebo|
1700784|NCT01460108|Device|AeriSeal System|20 mL
1700785|NCT01460095|Other|HbA1c measurement and education|three-monthly point of care measurement of HbA1c with immediate feedback to patients and provision of interpretation and targeted one-to-one education
1700786|NCT01460069|Drug|liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylenglycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
1700787|NCT01460069|Drug|Placebo|The placebo pens contain saline and are administered in the same way and volume as (liraglutide) Victoza. The placebo pens are specially prepared for this study and will be used in the study only.
1700788|NCT01460043|Drug|Homeopathy|Each homeopathic medication was given as 1 g dose of homeopathic preparation in 30c potency. The dose is prepared as lactose globules on which the homeopathic preparation.
1700789|NCT01460043|Drug|placebo|corresponding placebo was identical in appearance of homeopathic globule prepared in alcohol.
1700790|NCT01460030|Drug|Cinacalcet HCl|Oral administration
1700793|NCT01460004|Device|patella knee strap|infra patella strap 100% cotton pressure is exerted immediately under the patella
1700794|NCT01459991|Other|Walnut|Participants will consume 1 ounce walnuts daily and follow a Mediterranean style diet.
1700795|NCT01459991|Other|MyPyramid|Participants will follow a USDA MyPyramid style diet for lactating moms.
1700796|NCT01459978|Other|CUmulative SUM (CUSUM) Chart|"Intervention is described as follows:
Step 1: Implementation of the CUmulative SUM (CUSUM)control chart using available medical data Step 2: Submission of monthly results to the coordinator of each participating center (if CUmulative SUM (CUSUM) results period).
Step 3: When an alarm is generated, the steering committee will meet with maternity staff to find the causes of these alerts and propose"
1700797|NCT01459965|Procedure|ERCP with 10 French biliary plastic stent placement|Stent placement of a 10 French biliary plastic stent
1700798|NCT01459965|Procedure|ERCP with 11.5 French biliary plastic stent|biliary plastic stent placement
1700799|NCT01459952|Dietary Supplement|Rose hip Liquid|Rose hip Liquid, 20 ml BID
1700800|NCT01459939|Dietary Supplement|Rose-hip powder capsules|5 x 0,5 g rose-hip powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
1700801|NCT01459939|Dietary Supplement|Placebo|5 x 0,5 g placebo powder capsules BID the first 3 weeks and decreasing to 5 x 0,5 g QD the following 9 weeks
1700802|NCT01459926|Drug|TD-1211|once daily
1700803|NCT01459926|Drug|TD-1211|Once daily
1700804|NCT01459926|Drug|TD-1211|Once daily
1700805|NCT01459926|Drug|Placebo|Once daily
1700806|NCT01459913|Drug|Telaprevir|Tablet
1700807|NCT01459913|Drug|Pegylated Interferon Alfa-2a|Subcutaneous Injection
1700808|NCT01459913|Drug|Ribavirin|Tablet
1700809|NCT01459900|Procedure|Renal artery ablation|Catheter based renal denervation by applying low power radiofrequency to the renal artery using the Ardian Medtronic Simplicity Catheter, introduced by femoral artery access.
1700810|NCT01459900|Procedure|Renal angiography|Renal angiography by femoral access.
1700811|NCT01459887|Drug|CHOP combined with CMAB304|Patients treated with CHOP-304 undergo 1 cycle every 3 weeks, received CMAB304 at a dose of 375 mg/m2 on day 1 and CHOP on day 2 of each of the 6 cycles.
1700812|NCT01459887|Drug|CHOP, CMAB304|First standard CHOP, then sequential CMAB304 in patients who reached a complete response or undocumented complete response at the end of treatment of 6 cycles.
1700813|NCT01459874|Behavioral|Organizational model for remote monitoring|An organizational model defining roles and behaviors of subjects involved in the remote monitoring of pacemaker and defibrillator recipients
1700814|NCT01459861|Procedure|Canal Block and Capsular Injection|Continuous Adductor canal block with 15ml of ropivacaine 0.2% with epinephrine 1:400,000 followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days post operatively. This is combined with ultrasound guided posterior capsular knee injection with 30ml ropivacaine 0.2% with epinephrine 1:400,000.
1700815|NCT01459861|Procedure|Femoral Nerve Block with Tibial Nerve Block|Continuous femoral nerve block with 15ml of ropivacaine 0.2% followed by an infusion of ropivacaine 0.2% at 6ml per hour for 2 days after surgery combined with tibial nerve block in the popliteal fossa with ropivacaine 0.5% up to 15ml.
1700816|NCT01459848|Behavioral|block play|30 minutes of block play
1700817|NCT01459848|Behavioral|baby dvd|30 minutes of dvd viewing
1700818|NCT01459835|Behavioral|media diet|advice and tips and tools for healthy non violent TV viewing
1700819|NCT01459835|Behavioral|nutritional intervention|advice on healthy eating
1700823|NCT01459796|Drug|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 52 weeks.
1700824|NCT01459796|Drug|Allopurinol|Allopurinol 50 or 100 mg, orally daily for 52 weeks as background treatment.
1700825|NCT01459783|Behavioral|Dementia care management|Care management is initiated via a structured assessment, to identify prevalent caregiving problems: unmet need for assistance, lack of social support, educational needs, difficulty with managing behavioral issues and safety concerns, need for respite, establishing advance care planning, depression of the person with dementia as well as the caregiver, management of other chronic medical issues, and need for diagnostic information and assistance with acute medical issues. Collaboration between the caregiver and the care manager results in problem prioritization and subsequent counseling, education, referrals as needed, and proactive follow-up to achieve resolution of these problems. An electronic tracking tool and resource manual guide delivery of the care management protocols.
1700826|NCT01459770|Other|Medication Information Transfer Intervention|A pharmacist will visit participants randomized to the intervention group in their homes within 5 days of hospital discharge to administer the 5As Medication Self-Management intervention: Assessment, Advise, Agreement, Assistance, Arrangements.
1700827|NCT01459770|Other|Usual care for hospital discharge|Patients will receive medication information according to standard practice for discharge of hospitalized patients.
1700828|NCT01459757|Other|non-interventional|Non-interventional; Mutational status data analyzed previously but not collected in the A6181036 study, will be correlated wth A6181036 clinical outcomes data collected during the A6181036 study.
1700829|NCT01459744|Behavioral|Communication training for cardiologists.|"Communication training: a 90 minute workshop to discuss ways to improve communication in patients with serious illness.
Reminders to Cardiologists. Cardiologists will receive reminders to prompt them to have conversations relating to ICD management with patients enrolled in the study.
Audit and feedback. Cardiologists will receive feedback on their rates of conversation as well as data on patient/family satisfaction with their communication skills."
1700830|NCT01459744|Other|Control arm|Cardiology grand rounds will be held at usual care sites on the importance of advance care planning.
1700833|NCT01459705|Behavioral|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
1700834|NCT01459705|Behavioral|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
1700835|NCT01459705|Behavioral|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
1700836|NCT01459692|Other|Music Exposure|Twenty-seven subjects were randomly assigned to receive nightly exposure to music at periodic intervals between the hours of 9:00 PM and 8:00 AM.
1700837|NCT01459679|Device|KXL System (15 mW/cm2)|UVA irradiation for 8 minutes at 15 mW/cm2
1700838|NCT01459679|Device|KXL System (30 mW/cm2)|UVA irradiation for 4 minutes at 30 mW/cm2
1700839|NCT01459679|Device|KXL System (45 mW/cm2)|UVA irradiation for 2 minutes 40 seconds at 45 mW/cm2
1700840|NCT01459679|Drug|riboflavin ophthalmic solution|Drops of riboflavin ophthalmic solution will be applied in the eye every two minutes for 20 minutes
1700841|NCT01459666|Drug|Dysport (abobotulinumtoxinA)|Intramuscular injection effects lasting up to 3 months
1700842|NCT01459666|Drug|Bacteriostatic 0.9% Sodium Chloride (vehicle)|Intramuscular injection
1700843|NCT01459640|Drug|Hyaluronic Acid|Intra-articular injection; 30mg/2ml; three-weekly injection regimen
1700844|NCT01459640|Biological|Autologous bone marrow-derived mesenchymal stem cells|"Single intra-articular implantation of autologous bone marrow-derived mesenchymal stem cells in hyaluronic acid Orthovisc (3rd injection in a three-weekly injection regimen)"
1700845|NCT01459627|Other|6 months DAPT|Dual antiplatelet therapy will be stopped at randomisation to the 6 months DAPT group. Patients will be treated from 6 months onwards only with ASA.
1700846|NCT01459627|Other|12 months DAPT|Dual antiplatelet therapy will be continued till 12 months after enrollment in the study
1700847|NCT01459614|Drug|Gemcitabine|IV at 10mg/m2/min (50 minutes for 500mg/m2) on Days 4 and 11
1700848|NCT01459614|Drug|Taxotere|IV on Days 4 and 11
1700849|NCT01459614|Drug|Xeloda|orally, twice a day Days 1-14
1700850|NCT01459614|Drug|Cisplatin|IV Days 4 and 11
1700851|NCT01459601|Drug|Cabergoline|0,5mg per week
1700852|NCT01459588|Drug|Carboxymethylcellulose Based Eye Drop Formulation A|Carboxymethylcellulose Based Eye Drop Formulation A (Refresh Optive® Advanced Sensitive Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
1700853|NCT01459588|Drug|Carboxymethylcellulose Based Eye Drop Formulation B|Carboxymethylcellulose Based Eye Drop Formulation B (Refresh Optive® Advanced Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
1700854|NCT01459588|Drug|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops|Carboxymethylcellulose Based Preservative-Free Lubricant Eye Drops (Optive® Sensitive Preservative-Free Lubricant Eye Drops) 1-2 drops in each eye as needed at least 2 times daily for 30 days.
1700855|NCT01459588|Drug|Carboxymethylcellulose Based Lubricant Eye Drops|Carboxymethylcellulose Based Lubricant Eye Drops (Optive® Lubricant Eye Drops) 1-2 drops in each eye as needed, at least 2 times daily for 30 days.
1700856|NCT01459562|Drug|NI-0501|
1700857|NCT01459562|Drug|Placebo|
1700858|NCT01459549|Procedure|Roux-en-Y choledochojejunostomy|Roux-en-Y choledochojejunostomy must be operated
1700859|NCT01459523|Procedure|Proximal placement|Subjects assigned to this group will have their perineural catheter placed in a proximal position (higher up in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
1700924|NCT01458964|Drug|Quetiapine|100 mg (peach colored oblong tablet) and 200 mg (yellow colored oblong tablet)
1700860|NCT01459523|Procedure|Short axis ultrasound|Subjects assigned to this group will have the target nerve or plexus identified in short axis (cross-section) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
1700861|NCT01459523|Procedure|Long axis|Subjects assigned to this group will have the target nerve or plexus identified in long axis (longitudinal) using ultrasound. Perineural catheter insertion will be performed in-plane. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
1700862|NCT01459523|Procedure|Distal placement|Subjects assigned to this group will have their perineural catheter placed in a distal position (further down in the arm or leg) with ultrasound guidance. The onset time of sensory anesthesia will be measured following local anesthetic bolus via the catheter.
1700863|NCT01459510|Behavioral|Play Nicely Program|Multi media educational intervention
1700864|NCT01459497|Radiation|Radiation Therapy|Image-Guided Radiation Therapy (IGRT)60 Gy in 15 fractions in 3 weeks
1700865|NCT01459497|Radiation|Conventional radiation|Conventional radiation 60-66 Gy in 30-33 fractions in 6-7 weeks
1700866|NCT01459484|Drug|Mifamurtide arm|"PRE SUGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
POST SURGERY TREATMENT for good responder patients with positive P-GLYCOPROTEIN
Methotrexate 12g/m2 (10 Cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)
POST SURGERY TREATMENT for poor responder patients with positive P-GLYCOPROTEIN
Methotrexate 12g/m2; Cisplatinum 120mg/m2; Doxorubicin 90mg/m2 ifosfamide 15g/m2 MEPACT 2 mg/m2 twice a week for the first 3 months the weekly for the next 6 months (total lenght treatment 44 weeks)
All the product are used as commercial formulation"
1700867|NCT01459484|Other|3 drugs arm|"High grade osteosarcoma who do not over express ABCB1/P-glycoprotein will be treated with a standard 3-drugs regimen
PRE-SUGERY TREATMENT:
Methotrexate: 12g/m2 (3 cycles) Cisplatinum: 120mg/m2 (3 cycles) Doxorubicin: ADM 75mg/m2 (3 cycles)
POST SURGERY TREATMENT:
Methotrexate 12g/m2 (10 cycles) Cisplatinum 120mg/m2; Doxorubicin 90mg/m2
Total lenght 34 weeks
All the product are used as commercial formulation"
1700868|NCT01459471|Procedure|Bariatric surgery|Staple line reinforcement during sleeve gastrectomy
1700869|NCT01459458|Behavioral|Family Planning-based Partner Violence Intervention|"The intervention includes three major components:
Enhanced Screening and Education: scripted questions to assess for reproductive coercion and pregnancy risk combined with intimate partner violence (IPV) assessment and education regarding how IPV may affect women's reproductive health with the assistance of a safety/educational card created for this intervention.
Harm Reduction Counseling: assisting clients in identifying and planning strategies to reduce their risk for future unintended pregnancies and IPV.
Supported Referral: educating all clients regarding local resources for victims of IPV and problem-solving regarding barriers to acquisition of these resources as needed."
1700870|NCT01459445|Drug|Metformin, Ethinylestradiol 30µg-Drospirenone|Metformin: 1700 mg /day (twice per day)-6 months; EE30µg-drospirenone: 1 tb/day, 21 days/month, 6 months
1700871|NCT01459432|Other|Venepuncture and blood sample collection.|Venepuncture and blood sample collection.
1700872|NCT01459419|Drug|anti-CD3 monoclonal antibody|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
1700873|NCT01459419|Drug|Sodium Chloride placebo|Sodium chloride will be administered orally every day for 30 days. Up to 9 subjects will be treated at each dosage level. One 20mg tablet of Omeprazole (a proton pump inhibitor) will be taken concomitantly orally
1700874|NCT01459406|Dietary Supplement|Glucose|500 ml water drink containing 40g glucose
1700875|NCT01459406|Dietary Supplement|Fructose|500 ml water drink containing 40g fructose
1700876|NCT01459406|Dietary Supplement|Fructan|500 ml water drink containing 40g fructan
1700877|NCT01459406|Dietary Supplement|Fructose and glucose|500 ml water drink containing 40g fructose and 40g glucose
1700878|NCT01459393|Drug|5-ALA Photodynamic Therapy|
1700879|NCT01459393|Drug|Cryotherapy with liquid nitrogen|Topical application of liquid nitrogen spray (500ml Cry-ac ® bottle) over the actinic keratosis lesion and over a 0,5 cm margin around it during sufficient time to freeze both the lesion and margin.
1700880|NCT01459380|Biological|Bevacizumab|Given IV
1700881|NCT01459380|Drug|Carboplatin|Given IV
1700882|NCT01459380|Other|Laboratory Biomarker Analysis|Correlative studies
1700883|NCT01459380|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
1700884|NCT01459380|Drug|Veliparib|Given PO
1700885|NCT01459367|Drug|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
In the maintenance treatment period, the participants will receive treatment of TAK-438 10 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
1700886|NCT01459367|Drug|TAK-438|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
In the maintenance treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily and lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks."
1700887|NCT01459367|Drug|Lansoprazole|"In the treatment period, the participants will receive treatment of TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
In the maintenance treatment period, the participants will receive treatment of TAK-438 placebo-matching tablets, orally, once daily and lansoprazole 15 mg, capsules, orally, once daily for up to 24 weeks."
1700888|NCT01459328|Radiation|Radiotherapy|"Short course radiotherapy: 25Gy in 5 daily fractions over 1 week Chemotherapy: - Bolus 5 Fluorouracil 450 mg/m2/day
Injected Leucovorin 20 mg/m2/day for 5 days"
1700889|NCT01459328|Radiation|Radiotherapy|"Conventional long course chemo-radiation:
Radiation 50Gy in 25 daily fractions over 5 weeks
Bolus 5 Fluorouracil 350mg/m2/d for 5 days
Injected Leucovorin 20mg in both the first and last (5th) week of radiation
Oral Capecitabine (CAPE) 825mg/m2 b.i.d. during the entire radiotherapy course over 5 weeks."
1700925|NCT01458951|Drug|tofacitinib|10 mg oral BID
1700926|NCT01458951|Drug|Placebo|Placebo oral BID
1700927|NCT01458938|Other|treatment plan|Data Collection Study
1701088|NCT01457846|Drug|paclitaxel|Infusion administered once a week, 3 weeks on and 1 week off
1760243|NCT00282347|Drug|Acetaminophen|
1700890|NCT01459315|Drug|dolutegravir|Subjects will take a GSK1349572 (dolutegravir) 50mg tablet by mouth once daily for 8 days. GSK1349572 concentrations will be measured in blood plasma, seminal fluid, rectal fluid, and rectal tissue over 24 hours after a single dose and over two 24 hour periods once steady state is reached. Blood plasma will be collected pre-dose and 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24 hours after dosing. Each subject will also provide a total of 9 seminal and rectal fluid samples and have 2 rectal tissue biopsies performed pre-dose or at 1, 3, 6, 12, 18, or 24 hours after receiving single or multiple doses.
1700891|NCT01459289|Other|leaflet|
1700892|NCT01459289|Other|counseling and leaflet|
1700893|NCT01459276|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
1700894|NCT01459276|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
1700896|NCT01459250|Drug|AGO178C|
1700898|NCT01459211|Drug|Lenalidomide & Dexamethasone|"Subjects with relapsed or refractory CLL will receive twelve 28-day cycles of treatment. Each cycle will consist of:
Oral Dexamethasone (20mg daily, days 1-4),
Oral Lenalidomide on days 1-28 of each cycle, starting at 5mg per day in cycle 1 in patients with creatinine clearance ≥ 60ml/min calculated by Cockcroft-Gault. The dose will be increased to 10mg per day with cycles 2-12 unless there is evidence of disease progression or unacceptable drug toxicity"
1700899|NCT01459198|Biological|RSV MEDI ΔM2-2 vaccine|Given intranasally once at a baseline study visit, at a dose of 10^5 or 10^6 plaque-forming units (PFU), depending on study arm.
1700900|NCT01459198|Biological|Placebo vaccine|Given intranasally once at a baseline study visit
1700901|NCT01459185|Drug|S-1|Chemotherapy comprised eight courses (4-week administration, 2-week withdrawal; total 1 year) of S-1 at 80-120 mg/body/day according to body surface area (BSA)
1700902|NCT01459172|Other|limonene containing massage oil|daily massage application to the breast for 4 weeks
1700903|NCT01459159|Drug|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
1700904|NCT01459146|Drug|Artemether-lumefantrine combination plus albendazole|AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat
1700905|NCT01459146|Drug|Artemether-lumefantrine plus Praziquantel plus Albendazole|Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral
1700906|NCT01459146|Drug|Albendazole plus Praziquantel|Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
1700907|NCT01459133|Drug|Technosphere® Insulin Inhalation System|Single Site, Single Subject use of Technosphere® Insulin Inhalation System
1700908|NCT01459120|Other|Door-to-door|Health workers propose the integrated service package including VCT at the peoples' homes (home-based testing).
1700909|NCT01459120|Other|Pitso|"Health care workers propose the integrated service package including VCT through community gatherings (Pitso)."
1700910|NCT01459107|Procedure|Deceased donor hand transplantation|Deceased donor hand is surgically attached to recipient arm's stump.
1700911|NCT01459107|Drug|Bone marrow cell-based therapy & single-drug immunosuppression.|This protocol uses a novel bone marrow cell-based therapy for composite tissue allotransplantation (CTA) rather than conventional triple-drug immunosuppression to facilitate long-term graft survival of deceased donor human upper extremities under low-dose maintenance immunosuppression. Initial T-cell depletion with alemtuzumab is followed by upper extremity transplantation and tacrolimus maintenance therapy. Donor bone marrow cells are infused on Day 10 (±4 days) post-transplantation to elicit a host alloimmune response triggering exhaustion and deletion of the respective host (anti-donor) lymphocyte clones. Subsequently, tacrolimus therapy is given for at least 6 months before spaced weaning is considered in stable recipients.
1700912|NCT01459094|Drug|A (CANA/MET IR FDC tablet - fasting state) / B (CANA/MET IR FDC tablet - fed state)|Treatment A: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally (by mouth) in a fasting state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 2.
1700913|NCT01459094|Drug|B (CANA/MET IR FDC tablet - fed state) / A (CANA/MET IR FDC tablet - fasting state)|Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fed state on Day 1 of Treatment Period 1 followed 10-14 days later by Treatment B: Type = 1, unit = mg, number = 150/1000, form = tablet, route = oral use. One CANA/MET IR FDC tablet taken orally in a fasting state on Day 1 of Treatment Period 2.
1700914|NCT01459081|Drug|Zanamivir|10 mg inhaled by mouth, twice daily, for 5 days
1700915|NCT01459081|Drug|Placebo|inhaled by mouth, twice daily, for 5 days
1700916|NCT01459068|Behavioral|Common Elements Treatment Approach|"CETA components include:
Engagement (encouraging participation)
Psychoeducation (introduction)
Anxiety Management Strategies (relaxation)
Behavioral Activation (getting active)
Cognitive Coping/Restructuring (thinking in a different way, part I and part II)
Imaginal Gradual Exposure (talking about difficult memories)
In Vivo Exposure (Live exposure)
Suicide/Homicide/Danger Assessment and Planning (safety)
Screening and Brief Intervention for Alcohol (alcohol intervention)"
1700917|NCT01459029|Drug|D-serine|Adjuvant treatment with D-serine up to 6000 mg/day vs. placebo
1700918|NCT01459016|Other|PET scan using florbetapir|A single intravenous microdose of 260 MBq (7 mCi) 18F-AV-45 (florbetapir F 18) will be administered.
1700919|NCT01459016|Other|MRI Scan|Three different measurements will be taken: volumetric MRI (vMRI), diffusion tensor imaging (DTI), and resting state functional MRI (rsfMRI). In addition, radiological MRI scans will be taken to monitor vasogenic edema and microhemorrhages.
1700920|NCT01459003|Other|beauty care|beauty care performed before each chemo cycle
1700921|NCT01458990|Drug|Omeprazole|20mg PO BID for 20 days
1700922|NCT01458977|Drug|Truvada® (300 mg tenofovir disoproxil fumarato/200 mg emtricitabine)|TDF/FTC 300/200mg daily during 3 months + Placebo during 6 months
1700923|NCT01458977|Drug|Placebo|Placebo during 3 months + TDF/FTC 300/200mg daily during 3 months + Placebo during 3 months
1701391|NCT01455441|Other|Training and liraglutide|
1700928|NCT01458925|Device|The P1 Check-Cap capsule|The P1 Check-Cap capsule will be ingested by all participants. After the Capsule test, they will be referred for optical colonoscopy as part of the study
1700929|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
1700930|NCT01458912|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
1700931|NCT01458912|Drug|BI 54903 MD|2 puffs MD b.i.d. via Respimat inhaler
1700932|NCT01458912|Drug|BI 54903 HD|2 puffs HD p.m. via Respimat inhaler
1700933|NCT01458899|Drug|TC-5214|Oral tablets, single 4mg dose
1700934|NCT01458886|Drug|BI 54903 MD|2 puffs b.i.d. via Respimat inhaler
1700935|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
1700936|NCT01458886|Drug|Placebo matching Respimat|2 puffs a.m. via Respimat inhaler
1700937|NCT01458886|Drug|BI 54903|2 puffs LD b.i.d. via Respimat inhaler
1700938|NCT01458873|Drug|sodium bicarbonate 4.2%|diluted sodium bicarbonate 50 ml
1700939|NCT01458873|Drug|diluted sodium bicarbonate 2.1%|50ml
1700940|NCT01458873|Drug|normal saline|50ml
1700941|NCT01458847|Drug|cis-UCA solution|Cohort I: 2% cis-UCA solution (50 ml); min 3, max 12 patients
1700942|NCT01458847|Drug|cis-UCA solution|Cohort II: 4% cis-UCA solution (50 ml); min 0, max 12 patients
1700943|NCT01458847|Drug|cis-UCA solution|Cohort III: 6% cis-UCA solution (50 ml); min 0, max 12 patients
1700944|NCT01458834|Behavioral|Attention bias modification task|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the active training task, the arrow will replace the neutral pictures 80% of the time.
1700945|NCT01458834|Behavioral|Control Condition|Participants will complete a computerized probe-discrimination task from their home computer or handheld electronic device 3 times per day for one week. Each training session will consist of 160 trials. In each trial, two pictures (smoking-related or neutral) will appear on the screen simultaneously and then disappear. An arrow will appear in the location of one of the pictures (< or >). Participants are asked to quickly identify the direction of the arrow by pressing a button. In the control training task, the arrow will replace the neutral and smoking-related pictures with equal frequency.
1700946|NCT01458821|Behavioral|Brain Fitness Program - Tinnitus|Brain Fitness Program-Tinnitus was developed to improve cognitive function by engaging the brain's neuroplasticity; the program is novel, non-invasive, and inexpensive.
1700947|NCT01458808|Other|Dietary sodium restriction|Restriction of 2 grams on daily sodium diet intake.
1700948|NCT01458808|Other|Dialysate sodium concentration reduction|Reduction of dialysate sodium concentration from 138 to 135 mEq/L
1700949|NCT01458795|Procedure|Endovenous laser ablation|
1700950|NCT01458782|Procedure|Treatment of cartilage defects in the knee|Two groups, either ACI or AMIC. ACI includes an arthroscopy for harvesting of cartilage 3-4 weeks prior to the open cartilage surgery. AMIC includes only open surgery at one setting.
1700951|NCT01458769|Drug|C-10276|C-10276 200 mg, C-10276 400 mg, Reyataz 400 mg oral, single dose
1700952|NCT01458769|Drug|C-10276|C-10276 300 mg, CTP-518 100 mg with C-10276 300 mg, C-10276 400 mg oral, single dose
1700953|NCT01458769|Drug|C-10297|C-10297 200 mg, oral, single dose
1700954|NCT01458769|Drug|C-10299|C-10299 200 mg, oral, single dose
1700955|NCT01458769|Drug|C-10297|C-10297 400 mg, Reyataz 400 mg, C-10297 600 mg, oral, single dose
1700956|NCT01458769|Drug|C-10299|C-10299 400 mg, Reyataz 400 mg, C-10299 600 mg, oral, single dose
1700957|NCT01458769|Drug|C-10276|C-10276 600 mg, Reyataz 400 mg, Reyataz 600 mg, oral, single dose
1700958|NCT01458769|Drug|Reyataz®|Reyataz 400 mg, oral, single dose Reyataz 600 mg, oral, single dose
1700959|NCT01458743|Drug|Ceftaroline|60-minute single intravenous dose of 600 mg of Ceftaroline on Days 1 and 8; 60-minute intravenous dose of 600 mg of Ceftaroline twice per day on Days 3-7.
1700960|NCT01458743|Drug|Ceftaroline|Single intravenous dose on Days 1 and 9. Intravenous three times per day on Days 2-8.
1700961|NCT01458730|Drug|Immunochemotherapy|Rituximab, HD-MTX, HD-Ara C, Cyclophosphamide, Iphosphamide, Vincristin, Vindesin, Temozolomide, Depocyte
1700962|NCT01458717|Drug|Neoadjuvant chemoradiation|"Neoadjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡
4 weeks rest, re-evaluation for resectability
operation
start maintenance chemotherapy within 4~6 weeks after operation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
1700963|NCT01458717|Procedure|Upfront surgery|"Operation at time of diagnosis
Adjuvant chemoradiation; 45Gy/25fx + 9Gy/5fx of radiation over 6 weeks with Gemcitabine 400mg/㎡
start maintenance chemotherapy within 4~6 weeks after completion of adjuvant chemoradiation with Gemcitabine 1000mg/㎡ (D1, 8, 15) every 4 weeks, for 4 cycle"
1700964|NCT01458704|Other|next generation sequencing|next generation sequencing (including targeted gene sequencing, exome sequencing, transcriptome sequenicing)
1700965|NCT01458691|Procedure|Steroid injection into the glenohumeral joint|"Group: Steroid
Total volume of injection drugs: 4ml(1ml of triamcinolone acetonide 40mg/ml + 3ml of 2% lidocaine)
The number of injections : only once during the study period
Injection site : glenohumeral joint
Material : 25-gauze spinal needle
The intra-articular injections were performed using ultrasonographic guidance."
1700966|NCT01458691|Procedure|Allogeneic PRP injection into the glenohumeral joint|"Group: Allogeneic PRP
Total volume of injection drugs: 4ml
The number of injections : only once during the study period
Injection site : glenohumeral joint
Material : 25-gauze spinal needle
The intra-articular injections were performed using ultrasonographic guidance."
1700967|NCT01458678|Other|Volume of colloid infusion|Colloid infusion is primarily given as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
1700968|NCT01458678|Other|Volume of colloid infusion|Colloid infusion is given primarily as hydroxyethyl starch 60 mg/ml. If more than 30 ml/kg hydroxyethyl starch 60 mg/ml is given, colloid solution is changed to albumin 4% or plasma.
1701038|NCT01458275|Drug|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
1700969|NCT01458665|Procedure|Conventional arthroscopic rotator cuff repair|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4-5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repair of full thickness rotator cuff tear was done with suture anchors.
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound."
1700970|NCT01458665|Procedure|Arthroscopic rotator cuff repair with PRP|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4-5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repair of full thickness rotator cuff tear was done with suture anchors.
After tying sutures of the medial row, PRP gels were applied on the repair site.
The lateral row was secured using suture anchors.
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound."
1700971|NCT01458652|Drug|Kremezin|Kremezin is an oral adsorbent, 9g/day in treatment arm
1700972|NCT01458639|Drug|Technegas V SPECT imaging|Technegas V SPECT imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
1700973|NCT01458639|Drug|Xenon-133 Ventilation Planar imaging|Xenon-133 Ventilation Planar imaging and Technetium 99m MAA Perfusion imaging for the diagnosis pf pulmonary embolism.
1700974|NCT01458626|Drug|mirtazapine|mirtazapine 30mg QD
1700975|NCT01458626|Drug|paroxetine 20mg QD|paroxetine 20mg QD
1700976|NCT01458600|Drug|Diclofenac|T Diclofenac 50 mg twice daily for 12 months
1700977|NCT01458600|Drug|Methimazole|T Methimazole 5 mg 3x2 for 18 months
1700978|NCT01458600|Drug|L-thyroxin|L-thyroxin approximately 100 to 200 micrograms/day. The dose is adjusted to reach euthyroidism during concomitant treatment with methimazole for 18 months
1700979|NCT01458600|Drug|Propranolol|T Propronalol 40mg 1x1-3 during during 1-3 weeks until the patient has responded to thyrostatics
1700980|NCT01458600|Drug|Metoprolol|T Metoprolol 50 mg 1x3 for 1-3 weeks until the patient has responded to thyrostatics
1700981|NCT01458587|Drug|Aminolevulinic Acid PDT (ALA)|20% ALA applied to upper extremities for 3 hours prior to 10 J/cm2 blue light
1700982|NCT01458587|Drug|Vehicle PDT (VEH)|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to upper extremities 3 hours prior to 10 J/cm2 blue light
1700983|NCT01458574|Drug|Placebo|Placebo 10 mg orally (PO) twice a day (BID)
1700984|NCT01458574|Drug|CP690,550|CP-690,550 5 mg orally (PO) twice a day (BID)
1700985|NCT01458574|Drug|CP-690,550|CP-690,550 10 mg orally (PO) twice a day (BID)
1700986|NCT01458561|Device|BioFoam Surgical Matrix|Surgical adjunct to control bleeding in open liver surgery
1700987|NCT01458561|Device|Gelfoam Plus|Surgical adjunct in control of bleeding in open liver surgery
1700988|NCT01458548|Drug|Rituximab|Rituximab 375 mg/m2 IV on days 1, 8, 15 and 22.
1700989|NCT01458548|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV, adriamycine 50 mg/m2 IV, vincristine 1.4mg/m2 IV, and prednisone 50mg/m2 PO every 3 weeks at days 50, 72, 94 and 116.
1700990|NCT01458535|Drug|ABT-450|tablets
1700991|NCT01458535|Drug|ABT-267|tablets
1700992|NCT01458535|Drug|ribavirin|tablets
1700993|NCT01458535|Drug|ritonavir|capsules
1700996|NCT01458509|Behavioral|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. The intervention will be an email alert to study personnel (EASP). Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
1700997|NCT01458509|Behavioral|surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. Patients randomized to EASP will receive a phone call if their bowel function by the clinical office nurse if the study personnel determine that the patient's BFI, as reported on the monthly survey, is less than 53 (lowest quartile scores). Interventions that may occur include dietary and/or medication advice at the discretion of the office staff.
1701039|NCT01458275|Drug|Placebo|Placebo - one actuation per nostril
1701040|NCT01458262|Other|systemic and cerebral oxymetry|oxymetry measurement using near infrared spectroscopy
1760244|NCT00282347|Drug|Prednisone|
1700998|NCT01458509|Behavioral|surveys|IVRS: An interactive voice response system (IVRS) is an automated telephone platform. The IVRS system will allow the participant to complete the survey when they receive the call and/or to call the system within the survey window to complete the survey. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not get a phone call.
1700999|NCT01458509|Behavioral|Surveys|Web: Study participants will be sent an email containing a link to the web survey. The participants will click on the link and complete the survey. Study participants may also login to the web survey independent of the link received via email. In each group, administration of a survey including the BFI, PRO-CTCAE sexual function items, and QOL LASA and in each group, the survey will be conducted once a month over a six-month period. This group will not receive a phone call.
1701000|NCT01458496|Behavioral|Health Coaching|The intervention will take approximately six months to complete. A combination of group and individual face-to-face meetings will be used. Participants will be divided into groups of 20 for group meetings. Groups will be brought together for a group coaching session at the beginning and the end of the coaching process (i.e., intervention). Each participant will also receive four individual coaching sessions with the health coach and will be able to avail of three one-hour telephone coaching sessions during the six month intervention. Participants will be encouraged to utilize telephone coaching for key support periods.
1701001|NCT01458483|Device|Baroreceptor Stimulation|The stimulation catheter may be placed in different locations within the IJV at the level of the cervical spine vertebrae. Stimulation amplitudes will be varied from 0.1 mA to 20 mA.
1701002|NCT01458470|Drug|Memantine|oral tablet, 1 BID, 24 weeks
1701003|NCT01458470|Other|Placebo|oral tablet, 1 BID, 24 weeks
1701004|NCT01458457|Other|Individualized complementary medicine treatment|An individual treatment plan will be made for each patient that includes one to all of the following treatments: acupuncture, traditional Chinese herbal medicine, enzyme therapy, nutrition advise, Healing Touch, homoeopathy, hyperthermia treatment, infusions, laser therapy, lymphatic drainage, manual therapy, mistel therapy, neural therapy, orthomolecular therapy, osteopathy, phytotherapy, shiatsu
1701005|NCT01458457|Other|Individualized usual care|Patients get usual care from their general practitioners/specialized physicians
1701006|NCT01458444|Device|Non invasive ventilation (VNI)|BIPAP® vision
1701007|NCT01458444|Device|Non invasive ventilation|OPTIFLOW system
1701008|NCT01458431|Drug|Levobupivacaine|continuous levobupivacaine subfascial infusion
1701009|NCT01458431|Drug|NaCl|continuous NaCl subfascial infusion
1701010|NCT01458418|Drug|Montelukast|Those in Montelukast 10mg/day group will receive two 5mg tablets of Montelukast.
1701011|NCT01458418|Other|placebo|Those in the placebo group will receive 2 placebo tablets per day. Those in the Montelukast 5mg/day will receive 1 placebo tablet per day.
1701012|NCT01458418|Drug|5 mg Montelukast|Subject will receive one 5mg tablet of Montelukast and one placebo tablet per day.
1701013|NCT01458405|Biological|CAP-1002 Allogeneic Cardiosphere-Derived Cells|Single dose, intracoronary infusion of 25 Million cardiosphere-derived cells or placebo
1701014|NCT01458392|Biological|Dalantercept|Subcutaneous dose of dalantercept once every 3 weeks.
1955974|NCT03011372|Drug|INCB054828|INCB054828 at the protocol-defined once-daily dose.
1701022|NCT01458353|Procedure|Stapled anastomosis|Stapled anastomosis after ileocolonic resection
1701023|NCT01458353|Procedure|Handsewn anastomosis|Handsewn anastomosis after ileocolonic resection
1701024|NCT01458340|Drug|TD-9855|Once daily
1701025|NCT01458340|Drug|TD-9855|Once daily
1701026|NCT01458340|Drug|Placebo|Once daily
1701027|NCT01458327|Drug|3,4-methylenedioxymethamphetmine (MDMA)|125 mg MDMA followed by 62.5 mg 1.5 to 2.5 hours later
1701028|NCT01458327|Behavioral|Psychotherapy|Psychotherapy in combination with MDMA
1701029|NCT01458314|Other|Daily NIV during rehabilitation|Addition of non invasive mechanical ventilation (NIV) during daily rehabilitation in patients using nocturnal NIV
1701030|NCT01458314|Other|Rehabilitation without NIV|Training in patients without NIV adoption
1701031|NCT01458301|Drug|Placebo|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
1701032|NCT01458301|Drug|TAK-385|TAK-385 10 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
1701033|NCT01458301|Drug|TAK-385|TAK-385 20 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
1701034|NCT01458301|Drug|TAK-385|TAK-385 40 mg, tablets, orally, once daily and Leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks
1701035|NCT01458301|Drug|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and Leuprorelin acetate injection, subcutaneously, once every 4 weeks for up to 12 weeks
1701036|NCT01458288|Drug|TG-0054|3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of four leukapheresis sessions)
1701037|NCT01458275|Drug|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37 mcg
1701041|NCT01458249|Drug|eribulin mesylate|Administration of eribulin mesylate at a dose of 1.4 mg/m^2 as an IV bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
1701042|NCT01458236|Drug|Beraprost Sodium 314d Modified Release Tablets|Available as 15 μg and 60 μg tablets for oral, twice daily (BID) administration
1701043|NCT01458236|Drug|Placebo|Placebo tablets, which are identical in size and appearance to those containing BPS-314d-MR and are for oral, BID administration, will be utilized in subjects assigned to the placebo study drug treatment group
1701044|NCT01458223|Drug|Antibiotic|Ancef or Vancomycin
1701045|NCT01458223|Drug|Antibiotic|Ancef or Vancomycin
1701046|NCT01458210|Drug|Ortho-Cyclen|Administered orally
1701047|NCT01458210|Biological|Dulaglutide|Administered subcutaneously
1701048|NCT01458197|Drug|Tarafenacin 0.2 mg|Capsule, qd, 12 weeks
1701049|NCT01458197|Drug|Placebo|Capsule, qd, 12 weeks
1701050|NCT01458197|Drug|Tarafenacin 0.4 mg|Capsule, qd, 12 weeks
1701051|NCT01458184|Behavioral|PhoneCare system|"The aim of this study is to assess the effectiveness of Telephone-Linked Care for Complex Patients (TLC-C) in the care of patients with complex health care needs. TLC-C uses conversational computer telephony to monitor patients' multiple diseases between their ambulatory care visits. The system monitors patients through virtual visits and detects and notifies clinicians about important clinical problems to attend to. It also promotes patient self-care (e.g., medication adherence and appointment preparation)."
1701052|NCT01458171|Biological|Immune globulin subcutaneous (Human)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human immunoglobulin for subcutaneous (SC) use. Subjects will receive weekly infusions of IgPro20 for a total of 24 weeks at a dose based on the subject's IgPro20 dose in the pivotal study ZLB06_002CR (NCT01199705).
1701053|NCT01458145|Behavioral|Minding the Baby Home Visiting Program|Weekly home visits for one year followed by bi-weekly home visits until child is 24 months of age provided to young at risk families by a team of nurse practitioner and social worker home visitors
1701055|NCT01458119|Drug|migalastat HCl 150mg|Provided in 14-day supply blister packs. Migalastat HCl is taken every other day by mouth. An inactive reminder capsule is taken taken on the days between migalastat HCl.
1701056|NCT01458106|Drug|BIIB031 (rFVIIIFc)|Vials of rFVIIIFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
1701057|NCT01458106|Drug|FVIII (PK subgroup only)|Baseline prestudy FVIII dosing in participants who enter the PK subgroup. Vials of prestudy FVIII were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
1701058|NCT01458093|Other|colonoscopy|evaluation of surveillance timing adequacy as compared to the guidelines
1701059|NCT01458080|Drug|eltrombopag|eltrombopag
1701060|NCT01458067|Drug|GSK2636771|Oral capsules
1701061|NCT01458054|Drug|Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)|GSK2336805 and Omeprazole
1701062|NCT01458054|Drug|Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)|GSK2336805 and Ritonavir
1701063|NCT01458041|Drug|Iloprost (Ilomedin, BAYQ6256)|Prescription and treatment of Iloprost will be decided by physicians
1701064|NCT01458028|Drug|BAY85-3934|Single doses of 20 mg BAY85-3934 as tablet
1701065|NCT01458028|Drug|Placebo|Single dose of placebo tablet matching the 20 mg BAY85-3934 tablet
1701066|NCT01458015|Drug|tapentadol, oxycodone|tapentadol pr 100-500 mg oxycodone cr 20-120mg
1701067|NCT01458002|Other|Tailored Internet Communication with Relational Agent|"The Tailored Internet Intervention will include a relational agent component, which is an animated conversational agent that builds a working relationship with subjects over time and uses this alliance to boost intervention effectiveness and retention to the Tailored Internet Communications web site."
1701068|NCT01458002|Other|Tailored Internet Communications|Best practices for TTM tailored communications with two types of feedback: normative - compared to peers and ipsative - self compared to previous assessment.
1701069|NCT01457989|Drug|retigabine/ezogabine|dose range up to 1200 mg/day
1701070|NCT01457950|Drug|denosumab|double-blind phase: 60mg subcutaneous injection, single dose
1701071|NCT01457950|Drug|placebo|double-blind phase: placebo subcutaneous injection, single dose
1701072|NCT01457950|Drug|open-label denosumab|open-label phase: 60mg subcutaneous injection, single dose
1701073|NCT01457937|Drug|Pegylated Interferon, Ribavirin, Boceprevir|"PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day)
or
PEG IFN alfa 2b 1,5 ug/kg once weekly; Ribavirin (800-1400 mg / day); Boceprevir (1.5 mcg / kg QW)"
1701078|NCT01457911|Drug|Glimepiride and Metformin hydrochloride combination (HOE490)|Pharmaceutical form:tablet Route of administration: oral
1701079|NCT01457911|Drug|Glimepiride (HOE490)|Pharmaceutical form:tablet Route of administration: oral
1701080|NCT01457898|Device|VPAP II®|VPAP group:inspiratory pressure to generate 6ml/kg of weight and expiratory pressure of 7cmH2O plus oxygen therapy (FIO2=40%) during three hours.
1701081|NCT01457885|Drug|Clofarabine/Busulfan x 4|"Clofarabine IV dose level: 40 mg/m2/day x 5 days
Busulfan IV dose level: 3.2 mg/kg daily x 4 days"
1701082|NCT01457885|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
1701083|NCT01457872|Behavioral|Strength-based case management|Strength-based case management
1701084|NCT01457872|Behavioral|Control condition - referral only|Referral only
1701085|NCT01457859|Drug|Triclosan|Triclosan coated surgical sewing threads (VICRYL+ and MONOCRYL+) applied for leg wound closure after CABG
1701086|NCT01457859|Other|Conventional non-coated surgical sutures|Conventional non-coated surgical sewing threads (POLYSORB and BIOSYN) will be applied after CABG for leg wound closure
1701087|NCT01457846|Drug|AZD4547|Tablets taken, oral, twice daily, commencing with a 2 week on AZD4547, 1 week off AZD4547 schedule.
1701089|NCT01457833|Device|EBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
1701090|NCT01457833|Device|IBV implantation|In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. The most advanced technique is the implantation of valves. The one-way mechanism of these valves allows air to be expelled during exspiration without any influx of air during inspiration.
1701091|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 800mg, then 400mg BD for 5 days
1701092|NCT01457820|Drug|Allopurinol|Stat dose Allopurinol 400mg, then 300mg BD for 5 days
1701093|NCT01457820|Drug|Placebo|Matched placebo, stat dose, then 5 days of matched placebo BD.
1701094|NCT01457807|Drug|AZD3241 ER formulation 1|Oral tablets, 100mg bd on Day 1 to Day 2, 200mg bd on Day3, 300mg bd on Day 4 to Day7 and 300mg Once daily on Day 8 with High Fat Breakfast
1701095|NCT01457807|Drug|Placebo|Placebo will be administered with the same intervention scheme as intervention 1 and 2
1701096|NCT01457807|Drug|AZD3241 Alternative titration scheme with formulation 1 or 2|50 mg oral dose bd on Day 1, 100 mg oral dose bd on Day 2 and 3, 200 mg oral dose bd on Day 4, 300 mg oral dose bd on Day 5 to 7 and 300 mg once in the morning on Day 8
1701097|NCT01457794|Other|School meals based on the principles of the New Nordic Diet|The study participants are provided with three daily school meals for 3 month
1701098|NCT01457781|Drug|Nitric Oxide|0.025 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours)
1701099|NCT01457781|Other|Placebo|Placebo 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (Nitrogen N2, 99.999%)
1701100|NCT01457781|Drug|Nitric Oxide|Cohort 2: 0.075 mg/kg IBW/hr for up to 24 hours/day x 16 weeks (3.0 mg/L [2440 ppm] NO mini-cylinder; change q 24 hours)
1701101|NCT01457742|Device|Ivivi SofPulse|15 minute Pulsed Radio Frequency (PRF) treatment twice per day
1701102|NCT01457742|Device|Ivivi SofPulse|15 minute simulated treatment using Sham Device twice per day
1701103|NCT01457729|Behavioral|Motivation by Telephone Call|Telephone call not exceeding 10 minutes according to a protocol
1701104|NCT01457716|Drug|Budesonide|Single inhalation
1701105|NCT01457716|Drug|Formoterol|Single inhalation
1701106|NCT01457716|Device|Easyhaler|Inhaler device
1701107|NCT01457716|Device|Turbohaler Forte|Inhaler device
1701108|NCT01457703|Drug|Cetrorelix|Abolishes pituitary sensitivity to GnRH.
1701109|NCT01457703|Drug|Gonadorelin-GnRH|GnRH is used to stimulate the pituitary gland to produce LH and FSH.
1701110|NCT01457703|Drug|Recombinant LH|Used to stimulate ovarian function in women.
1701111|NCT01457703|Drug|Letrozole|An aromatase inhibitor.
1701112|NCT01457690|Drug|Tocofersolan|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
1701113|NCT01457690|Drug|tocopherol alpha|Administration of a daily dose of vitamin E for 4 months:50 IU/kg
1701114|NCT01457690|Drug|Tocofersolan and tocopherol alpha|Administration of a single dose of vitamin E (Vitamin E water-soluble then Vitamin E conventional fat-soluble form)
1701115|NCT01457677|Drug|Placebo|matching placebo to RO4995819 oral once daily for 6 weeks
1701116|NCT01457677|Drug|RO4995819|5 mg oral once daily for 6 weeks
1701117|NCT01457677|Drug|RO4995819|15 mg oral once daily for 6 weeks
1701118|NCT01457677|Drug|RO4995819|30 mg oral once daily for 6 weeks
1701119|NCT01457664|Drug|Placebo|Placebo to RO4995819 once daily for 14 days
1701120|NCT01457664|Drug|RO4995819|RO4995819 doses once daily for 14 days
1701121|NCT01457651|Procedure|Alveolar recruitment|"Four approaches:
CPAP 40 cm H2O
Peak pressure 40 cm H2O
PEEP 15 cm H2O for 300 sec
no intervention (controls)"
1701122|NCT01457638|Procedure|Inferior turbinate surgery|During rhinoseptoplasty inferior turbinate submucosal cauterization is performed.
1701123|NCT01457638|Procedure|No iInferior turbinate surgery|During rhinoseptoplasty no intervention is done in inferior turbinates
1701124|NCT01457612|Dietary Supplement|Strawberry|20g twice per day (BID) in beverage
1701125|NCT01457612|Dietary Supplement|Placebo1|Placebo Beverage 1 without fiber
1701126|NCT01457612|Dietary Supplement|Placebo2|Placebo Beverage 2 with Fiber
1701127|NCT01457599|Procedure|Computertomography-guided marking of colorectal liver metastases|Computertomography-guided marking of colorectal liver metastases
1701128|NCT01457586|Biological|Blood transfusion|Blood transfusion in perioperative period.
1701129|NCT01457586|Biological|No blood transfusion|No transfusion in the perioperative period.
1701131|NCT01457560|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
1701132|NCT01457560|Biological|OPV|One dose administered orally
1701133|NCT01457547|Biological|DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)|Three doses administered intramuscularly
1701134|NCT01457547|Biological|DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)|Three doses administered intramuscularly
1701135|NCT01457521|Drug|Ibuprofen|Ibuprofen
1701136|NCT01457508|Biological|DTPa-HBV-IPV/Hib (Infanrix hexa™)|Three doses administered intramuscularly
1701137|NCT01457508|Biological|DTPa-HBV-IPV (Infanrix penta™)|Three doses administered intramuscularly
1701138|NCT01457508|Biological|Hib (Hiberix™)|Three doses administered intramuscularly
1701392|NCT01455441|Other|Training and placebo|
1701139|NCT01457495|Biological|DTPa-HBV-IPV/Hib (Infanrix-hexa™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
1701140|NCT01457495|Biological|DTPa-IPV/Hib (Infanrix-IPV/Hib™)|3 doses administered intramuscularly into the right thigh at study month 0, 2 and 8
1701141|NCT01457495|Biological|HBV (Engerix™-B)|3 doses administered intramuscularly into the left thigh at study month 0, 2 and 8
1701142|NCT01457482|Other|Art Therapy and therapeutic conversations|Treatment consists of five sessions of Art Therapy given by an authorised Art Therapist and therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
1701143|NCT01457482|Other|Therapeutic conversations|Therapeutic conversations with specialist midwives. Number of conversations is determined by the participant.
1701144|NCT01457469|Other|questionnaire administration|Ancillary studies
1701145|NCT01457469|Procedure|quality-of-life assessment|Ancillary studies
1701146|NCT01457469|Other|counseling intervention|Undergo counseling session
1701147|NCT01457469|Other|internet-based intervention|Receive enhanced quitline intervention
1701148|NCT01457469|Behavioral|telephone-based intervention|Receive enhanced quitline intervention
1701149|NCT01457469|Other|educational intervention|Receive usual care plus
1701150|NCT01457469|Drug|nicotine replacement therapy|Receive nicotine replacement patches
1701151|NCT01457469|Other|educational intervention|Receive enhanced quitline intervention
1701152|NCT01457430|Drug|Icatibant|30 mg subcutaneous dose of Icatibant
1701153|NCT01457417|Drug|DKN-01|DKN-01 will be administered intravenously (IV) once a week over 30 minutes (min) and 2 hours (max) for 75, 150 and 300 mg. At 600 mg, DKN-01 will be administered by IV on days 1 and 15 of each cycle. PART A - Dose Escalation: 3 participants will be treated with a 28 day cycle of DKN-01 at an assigned dose level until disease progression. Dose escalation will occur sequentially over the doses of 75, 150, 300, and 600 mg until the criteria for reaching maximum tolerated dose (MTD) are met (or highest planned dose study group is completed). Cycle 1 will define the dose limiting toxicity (DLT) that governs dose escalation. PART B - Dose Confirmation: Once the MTD is established (or the highest planned dose level), 300 mg of DKN-01 will be administered IV on days 1 and 15 of every 28 day cycle.
1701154|NCT01457404|Behavioral|Integrated Cognitive Behavioral Therapy|Individual or group ICBT, approx. 12 sessions, one session per week
1701155|NCT01457404|Behavioral|Treatment-as-usual|Individual or group therapy as usual within the SATP or PTSD clinics at the PVAMC
1701156|NCT01457391|Behavioral|Cognitive Behavioral Therapy|Individual CBT, approx. 12 sessions, one session per week
1701157|NCT01457391|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
1701158|NCT01457391|Behavioral|Treatment-as-usual|Individual or group therapy, approx. 9-12 hours per week, multiple times a week for 2 months
1701159|NCT01457352|Drug|SPARC0921|
1701160|NCT01457352|Drug|Placebo0921|
1701161|NCT01457339|Drug|SPD489 (Lisdexamfetamine dimesylate)|SPD489 administered orally in ascending doses (50mg, 70mg, 100mg, 150mg, 200mg, 250mg). Each of these doses will be administered once daily for 5 days. Total number of days dosed is 30 days.
1701162|NCT01457339|Drug|Placebo|Placebo Capsule(s) for oral use taken once daily for 30 days
1701163|NCT01457300|Other|Rehabilitation|Model 1: Regular Assessment of Rehabilitation Goal, Rehabilitation Plan, Weekly Multi-Disciplinary Evaluation and Adjustment of Plan, Regular use of Measurement Scales, Regular Dialog between Personnel, Patient and Relatives. Model 2: More Occasional use of the Listed Activities. Model 1 and Model 2: Physical Training and Functional ADL Training, in Groups, One by One or Self-Training.
1701164|NCT01457274|Other|Sedation depth|"The intervention is the depth of sedation targeted in this study.
Patients enrolled in this study will be sedated with the same medications (fentanyl bolus and propofol target controlled infusion), and at the same starting doses, in each study arm. However, the depth of sedation targeted will differ between the arms, and this depth will be guided by the BIS monitor.
It is expected that those patients randomised to deep sedation will require a higher dose of sedative medication to achieve their target BIS value (<60) than those in the light sedation group (BIS 70-80)."
1701165|NCT01457261|Drug|Salbutamol|Radiolabelled salbutamol to be administered as a monodisperse particle via a spinning top aerosol generator or else as a polydisperse mist via a nebuliser or metered dose inhaler.
1701166|NCT01457248|Device|Endotracheal tube TaperGuard|Patients are intubated by endotracheal tube with taper-shaped cuff (TaperGuard, Mallinckrodt)
1701167|NCT01457248|Device|Endotracheal tube Hi-Contour Brandt|Patients are intubated by endotracheal tube with cylindrical-shaped cuff (Hi-Contour Brandt, Mallinckrodt)
1701168|NCT01457235|Other|Cognitive Remediation|All subjects will complete an MR brain scan, blood test, saliva test, and a neuropsychological battery of manual and computerised tests at baseline, at week 12 (end of active treatment) and week 26 (follow-up). Subjects randomly allocated to an active group will participate in a 12-week group-based cognitive remediation programme once a week for two hours. The waiting list group continues treatment as usual.
1701169|NCT01457222|Behavioral|Mindfulness intervention|Web-based guided mindfulness meditation 10 minutes daily
1701170|NCT01457222|Behavioral|Music relaxation|Music relaxation 10 minutes daily
1701171|NCT01457209|Other|Acupuncture|"Needle placement in abdominal muscles, in m. vastus lateralis, lower leg and hands.
Stimulation: Manual rotation of the needles and electrical stimulation of the needles in the abdominal muscles and m. vastus lateralis will be stimulated electrically with low burst frequency Duration: 30 min Treatment: 3 times/wk during 5 weeks."
1701172|NCT01457196|Diagnostic Test|Tumor Genetic Sequencing|This study will look at genetic material from a sample of the subjects tumor, look at certain changes in the genetic material, and see if these changes are related to the subjects cancer.
1701173|NCT01457183|Device|Pulsed lavage (Stryker Pulsavac Plus)|Healthy subjects with intact skin will be lavaged through the device for 1 minute on 3 different sites. The stryker pulsavac plus will be used for the lavage.
1701174|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
1701175|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
1701176|NCT01457170|Drug|Saline (Placebo)|During right heart catheterisation, saline will be infused for 15 minutes while the subject rest and for a further 15 minutes while the subject exercises using a supine ergometer.
1701177|NCT01457170|Drug|Apelin|During right heart catheterisation, Apelin will be infused at 30, 100 and 300 nanomol/min for 5 minutes. Apelin will then be infused at 300 nanomol/min for a further 15 minutes while the subject exercises using a supine ergometer.
1701178|NCT01457144|Drug|RiBVD|"Every cycle:
Rituximab intravenous infusion dosage 375 mg/m² day 1 Bendamustine direct intervenous 90 mg/m² day 1 and day 2 Velcade®subcutaneous 1,3 mg/m² day 1,4, 8 and 11 dexamethasone 40 mg IVD on day 2"
1701179|NCT01457131|Drug|Fludarabine|50 mg/m2, IV(in the vein)on day 5 of each 25 day cycle
1701180|NCT01457131|Drug|Cyclophosphamide|60 mg/kg/day X 2 days IV in 250 ml D5W with mesna 15 mg/kg/day X 2 days
1701181|NCT01457131|Other|IL-12 &amp; Anti-NY ESO1 TCR PBL|10(7) cells to 3 X 10(10) cells
1701182|NCT01457118|Drug|NKTR-102|A 90 minute IV infusion of 145 mg/m2 or less of NKTR-102 on Day 1 of each 21-day treatment cycle. Patients who previously received a dose of NKTR-102 < 145 mg/m2 will continue at the lower dose on this study.
1701183|NCT01457105|Device|Endoscopic retrograde cholangiography (ERC) (ComVi biliary stent)|Metal stents placement in the main biliary duct during ERC
1701184|NCT01457092|Device|FC Nitinol SEMS (Niti-S, TaeWoong Medical Co., Korea)|Placement of self-expandable metal stents
1701185|NCT01457066|Behavioral|Peer Navigator Intervention|Peer navigators will teach HIV retention and linkage skills and knowledge using group-based as well as one-on-one, peer-based learning approaches.
1701186|NCT01457053|Drug|Loop diuretics (furosemide, torsemide, bumetanide)|"Patients with ADHF and hypervolemia will be enrolled in a prospective, randomized fashion.
Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization for the management of fluid overload.
Patients randomized to diuretic therapy will be treated with intravenous loop diuretics (e.g. furosemide, bumetanide, torsemide). The selection of diuretic, dose and frequency of diuretic administration will be determined by the treating physicians based upon clinical assessment of volume status, response to medication, and perceived safety."
1701187|NCT01457053|Other|Ultrafiltration|"Subjects will be randomized with a computer generated random number function to either ultrafiltration or diuretic therapy within 24 hours of hospitalization or outpatient heart failure clinic for the management of fluid overload. If randomized to the ultrafiltration arm, on admission to the hospital patients will be initiated on ultrafiltration therapy for 2-5 days.
Patients randomized to UF will be treated using the Aquadex System 100 ultrafiltration device (CHF Solutions, Minneapolis, MN). The selection of ultrafiltration rate (fluid removal rate)will be determined by the treating physicians based upon clinical assessment of volume status and perceived safety."
1701190|NCT01457027|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2011-2012 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus
15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
1701191|NCT01457014|Device|servo ventilation auto|Expiratory pressure automatically adjusted to stabilize the upper airway. Inspiratory pressure automatically adjusted to deliver consistent peak flow.
1701192|NCT01457014|Device|Continuous positive airway pressure|continuous positive airway pressure
1701193|NCT01457014|Device|servo ventilation manual|servo ventilation titrated in manual mode
1701194|NCT01457001|Drug|25-OH-D vitamin|
1701195|NCT01456975|Procedure|Aortic valve reimplantation using Valsalva prosthesis|Aortic valve reimplantation (David procedure)using Valsalva prosthesis
1701196|NCT01456949|Device|Medtronic Arctic Front® Cardiac CryoAblation System|Cardiac cryoablation to isolate the pulmonary veins using the Arctic Front® CryoAblation System, with point ablation using the Freezor® Max as needed.
1701197|NCT01456936|Drug|Placebo|Triple dummy placebo for each treatment arm
1701198|NCT01456936|Drug|varenicline tartrate|Subjects will be titrated to the full dose during the first week in the following manner: 0.5 mg (tablet form) once a day for 3 days, 0.5 mg twice a day for 4 days, then 1 mg twice a day for 11 weeks
1701199|NCT01456936|Drug|bupropion hydrochloride|Subjects will receive 150 mg (tablet form) once a day for 3 days and then will take 150 mg twice a day for the remainder of the treatment period (11 weeks and 4 days).
1701200|NCT01456936|Drug|Nicotine Replacement Therapy Patch|Subjects will start active dosing the morning of the Week 1 visit and will receive a 21 mg transdermal patch per day x 7 weeks, followed by a 14 mg transdermal patch per day x 2 weeks, and then a 7 mg transdermal patch x 2 weeks for a total of 11 weeks of treatment.
1701201|NCT01456923|Other|Treatment with chemotherapy|
1701202|NCT01456923|Other|Only chemotherapy treatment for study cohort|Control patients were treated both with surgery and chemotherapy. Study patients were treated only with chemotherapy
1701203|NCT01456923|Procedure|surgery|
1701204|NCT01456910|Behavioral|Resistance Training Program|Frequency, volume, repetitions, load, interval
1701205|NCT01456897|Drug|OPC-34712|orally administered once daily
1701206|NCT01456884|Behavioral|Live guitar and vocal music therapy|Live guitar and vocal music therapy. Subject is passive recipient for 30 minutes.
1701207|NCT01456884|Behavioral|Vibroacoustic Music Therapy|30 minutes using vibroacoustic mat.
1701208|NCT01456871|Procedure|Guided insertion of electrodes|Fine-wire needle electrodes (30mm x 27gauge needle with a pairs of 0.051mm, insulated, hooked wires, Motion Lab Systems, Baton Rouge, LA) guided by sonographic evaluation of the pulley system using a Philips iU22 Ultrasound Machine (Philips Ultrasound Systems, Bothell, WA), a 17-5 MHz linear array transducer, and standard ultrasound gel.
1701209|NCT01456871|Procedure|Electromyographic (EMG) recording|EMG signal recording, performed with an MA 300 EMG system (Motion Lab Systems, Baton Rouge, LA).
1701271|NCT01456325|Drug|Erlotinib|Participants will receive erlotinib 150 mg tablet orally once daily from Day 1, Cycle 1.
1760245|NCT00282360|Drug|Trimetazidine|
1701210|NCT01456858|Other|Insecticide Treated Polyethylene Sheeting|Insecticide Treated Polyethylene Sheeting is based on the standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. During manufacture the pyrethroid insecticide, deltamethrin, is extruded with the polyethylene into three-ply laminated sheets, comprising an inner low-density laminate and two, outer high-density laminates. The insecticide release characteristics enable the deltamethrin to diffuse slowly to the outer surfaces and to become available for pick-up by any insect that lands on the surface.
1701211|NCT01456858|Other|Untreated Plastic Sheeting|Standard polyethylene sheeting that is issued routinely as temporary shelter for people affected by emergencies. Standard untreated plastic sheeting is Identical to ITPS but without the incorporation of insecticide.
1701212|NCT01456819|Biological|Mononuclear and mesenchymal stem cells|Intramuscular administration into the ischemic limb
1701213|NCT01456819|Biological|Mononuclear cells|Intramuscular administration into the ischemic limb
1701214|NCT01456806|Other|Education|Structured group education programmes were delivered to provider and/or people with type 2 diabetes by trained professionals; identical system interventions were applied to all four groups.
1701215|NCT01456793|Behavioral|Teen Options to Prevent Pregnancy (T.O.P.P.)|Telephone-based care coordination and mobile contraceptive services
1701216|NCT01456780|Drug|Loteprednol/tobramycin|Zylet (loteprednol/tobramycin) drops, 1 drop twice a day for 4 weeks.
1701217|NCT01456780|Drug|Loteprednol|Eye drops, 1 drop twice a day for 4 weeks
1701218|NCT01456780|Drug|B+L Advanced Eye Relief Lubricant Drop|Bausch + Lomb (B+L) Advanced Eye Relief Lubricant Drop (Artificial Tears), 1 drop twice a day for 4 weeks.
1701219|NCT01456767|Dietary Supplement|Probiotics|"Bacterial supplements (Lactobacillus plantarum WCFS1, Lactobacillus plantarum CIP104448, and Lactobacillus plantarum CIP104450) will be prepared in the food-grade pilot plant of NIZO food research. Exactly 1x10^11 life bacteria are consumed by each participant.
Consumption of this amount of life bacteria is in line with earlier human studies and routinely reached by the consumption of dairy. As a placebo, the same drink will be used without addition of bacterial cells."
1701220|NCT01456754|Dietary Supplement|low feeding frequency (3x)|3 meals a day
1701221|NCT01456754|Dietary Supplement|High feeding frequency (14x)|14 meals a day
1701222|NCT01456741|Procedure|EBNA with ROSE|"The patients in this arm will undergo:
A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence with rapid on-site evaluation
B) if A will be negative transthoracic needle aspiration or surgical biopsy will be performed
C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
1701223|NCT01456741|Procedure|standard EBNA|"The patients in this arm will undergo:
A) bronchoscopy, endobronchial needle aspiration (EBNA) with a cytologic needle (21 gauge), at least three forceps biopsies, bronchial brushing and bronchial washing in this procedural sequence.
B)if A will be negative transthoracic needle aspiration or surgical biopsy will be performed
C) if A and B will be negative follow-up with computed tomography or positron emission tomography and computed tomography"
1701224|NCT01456728|Dietary Supplement|Progastria|"All subjects will receive 2 x 20 mg omeprazole per day for 28 days.
L. reuteri ProGastria will be delivered at a dose of 1x108 CFU of 2 strains of L. reuteri giving a final dose of L. reuteri of 2x108 CFU. One chewable tablet is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. This dose of L. reuteri has been shown to be effective in a series of conditions earlier, including inhibition of H. pylori in humans, and is considered the optimal dose. The study products will be taken daily for 28 consecutive days."
1701225|NCT01456728|Dietary Supplement|Placebo|The placebo will have identical in appearance and taste with the active study product only lacking the bacteria. It will be prescribed the same way as ProGastria: omeprazole 2x20mg and Placebo 1 tablet per day for 28 consecutive days
1701226|NCT01456715|Biological|Gardasil vaccine, Immunogenicity, Booster dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Gardasil given 42 months later.
1701227|NCT01456715|Biological|Cervarix Vaccine, Immunogenicity, Booster Dose.|Gardasil vaccine given according to the 0,6 months schedule and a booster dose of Cervarix given 42 months later.
1701228|NCT01456702|Procedure|risk stratification group|goal-directed volume therapy due to svv measurement or volume therapy via standard operated procedures in dependence of cardiac risk factores
1701229|NCT01456689|Drug|LGH447|
1701230|NCT01456689|Drug|midazolam|
1701231|NCT01456676|Drug|Nilotinib + LDE225|Nilotinib is an aminopyrimidine ATP-competitive inhibitor of the protein tyrosine kinaseactivity of BCR-ABL.
1701232|NCT01456663|Drug|AFQ056|
1701233|NCT01456650|Drug|Glyburide|"Patients in which the fasting glucose persisted above the treatment goal ( fasting plasma glucose above 126 mg/dl) will receive glyburide. The dose of the medication will be adjusted based on the result of blood glucose using the following table:
Fasting glucose 126 to 140 mg/dl: 2.5 mg/day (half tablet in the morning) 141 to 180 mg/dl: 5 mg/day (a tablet in the morning) 181 220 mg/dl: 7.5 mg/day (a tablet in the morning and half tablet per night) 221 to 250 mg/dl: 10 mg/day (a tablet in the morning) and a tablet in the evening."
1701234|NCT01456637|Behavioral|CBT for insomnia|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
1701235|NCT01456624|Drug|Megace|800mg
1701236|NCT01456624|Drug|DW-ES(B)|625mg
1701237|NCT01456611|Drug|Diclofenac|Diclofenac Sodium Gel 1%
1701238|NCT01456611|Drug|Placebo|Placebo Topical Gel
1701272|NCT01456325|Drug|Onartuzumab (MetMab)|Participants will receive onartuzumab 15 mg/kg IV infusion on Day 1 of every 3-week cycle.
1701273|NCT01456325|Drug|Placebo|Participants will receive onartuzumab matching placebo on Day 1 of every 3-week cycle.
1701274|NCT01456312|Drug|Peginterferon alfa-2a|Duration and combination
1701239|NCT01456598|Procedure|Laparoscopic gastrectomy|"After laparoscopic observation, the possibility of surgery can be considered by examining inside of abdomen.
The surgeon undergoes laparoscopic subtotal gastrectomy and D2 lymph node dissection
After lymph node dissection, it is possible to undergo gastrectomy on appropriate part and reconstruction under small incision or laparoscopic view.
As the reconstruction, one of the techniques among Billroth type I, Billroth type II and Roux en Y is applied and there is no limitation on use of appliance."
1701240|NCT01456598|Procedure|Open gastrectomy|"After laparotomy, the possibility of surgery can be considered by examining inside of abdomen.
The surgeon undergoes open subtotal gastrectomy and D2 lymph node dissection
After lymph node dissection, one of the techniques among Billroth type I, Billroth type II and Roux en Y is applied and there is no limitation on use of appliance."
1701241|NCT01456585|Other|Gemcitabine|
1701242|NCT01456585|Drug|CP-870,893|
1701243|NCT01456572|Dietary Supplement|ensure plus|17 % protein, 30 % fat and 53 % carbohydrate; 1 kcal/mL
1701244|NCT01456572|Dietary Supplement|standardized test meal|scrambled eggs, two slices of whole wheat bread, 200 mL of milk and labeled with 13C-octanoic acid
1701245|NCT01456559|Other|Lower body negative pressure (LBNP)|"The purpose with the planned study is to study pleth variability index (PVI) as a non invasive indicator for mild hypovolemia during spontaneous breathing in healthy subjects. Lower body negative pressure (LBNP), a well established technique, is used to create defined levels of hypovolemia.
Baseline data are recorded with the subjects in the supine position breathing with normal tidal volume without PEEP and without LBNP applied. Data are then recorded with LBNP applied in two steps (40 and 15 mmHg). Recordings are continued 5 minutes after releasing the negative pressure. Data are collected in total in four different series; normal tidal volume without PEEP; normal tidal volume with PEEP 5cm H2O; three doubled tidal volume without PEEP; three doubled tidal volume with PEEP 5 cm H20."
1701246|NCT01456546|Drug|Proguanil|2x350 mg Malarone followed by 3 days of blood- and urine sampling
1701247|NCT01456546|Drug|Clopidogrel|2x300 mg Plavix followed by 7 hours days of blood sampling
1701248|NCT01456520|Drug|Vycavert|single dose Vycavert containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
1701249|NCT01456520|Drug|Norco|single dose Norco containing 10 mg hydrocodone bitartrate/325 mg acetaminophen
1701250|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fasting condition
1701251|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|single dose of ALO-02 capsule under fed condition
1701252|NCT01456507|Drug|ALO-02 (Oxycodone Naltrexone)|ALO-02 with the ALO-02 pellets sprinkled on applesauce, and administered under fasting conditions.
1701253|NCT01456494|Other|Brief Intervention|A brief educational strategy that employs verbal and written instructions, without demonstration or repeated rounds of instruction, to teach patients how to use their inhalers.
1701254|NCT01456494|Other|Teach-to-Goal Education|Teach-to-goal (TTG) is a method of patient instruction that employs repeated rounds of teaching (demonstration, verbal, written instructions) and assessments (teach-back) of patient comprehension.
1701255|NCT01456481|Drug|midodrine hydrochloride|Target dose is midodrine hydrochloride or placebo pills 10 mg three times a day for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
1701256|NCT01456481|Drug|matching placebo|The target dose in this study is 10mg q4h x3 for 12 months. The starting dose is 5mg q4h x3, and if tolerated a forced titration up to 10mg/dose. If there is an intolerance, then the dose can be reduced to 2.5mg/dose.
1701257|NCT01456468|Drug|Oral all-trans retinoic acid (ATRA)|"The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.
The specific intervention is the addition of daily oral ATRA (45 mg/m^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process."
1701258|NCT01456442|Device|anorectal manometry|High-resolution anorectal manometry is done under standard clinical conditions with a 10 cm catheter inserted into the rectum loaded with pressure transducers at a distance of 6 mm in the sphincter area and an attached latex balloon at the catheter tip. It will measure the length of the anal sphincter, the static pressure and the clamping pressure during at least 3 over 40 seconds sustained maneuvers according to a standardized protocol. Mean and maximum pressure increase over the resting pressure during the first 30 seconds of the squeeze and the maximum possible squeeze time will be documented. Moreover, the initial anorectal perception threshold, the perception of urge to defecate and maximum tolerable volume balloon will be documented.
1701259|NCT01456442|Device|barostat|For the barostat study a balloon will be attached to the catheter. Instead of a barostat machine a 60ml syringe and a sphygmomanometer will be connected to the catheter and the catheter will be positioned in the rectum. The balloon is then dilated gradually to assess perception, urge and discomfort threshold in relation to rectal volume.
1701260|NCT01456429|Procedure|Thoracic endosonography|Endobronchial-ultrasound controlled transbronchial needle aspiration (EBUS-TBNA) in combination with a transoesophageal-ultrasound controlled needle aspiration of mediastinal lymph nodes
1701261|NCT01456403|Other|Histological validation|3D ultrasound, PET/CT, MRI, contrast ultrasound
1701262|NCT01456390|Device|iStent and iStent supra|Implantation of two iStent devices and one iStent supra device
1701263|NCT01456377|Drug|predinose oral|1 mg for kg for 3 wekees
1701264|NCT01456377|Drug|placebo group|use a oral placebo
1701265|NCT01456364|Drug|Ticagrelor|A loading dose of 180 mg of ticagrelor is administered followed by 90 mg maintenance doses twice daily
1701266|NCT01456364|Drug|Prasugrel|A prasugrel loading dose of 60 mg is administered followed by a 10 mg per day maintenance dose for patients < 75 years or a 5 mg maintenance dose per day for patients >= 75 years
1701267|NCT01456351|Drug|Bendamustine plus Rituximab|Bendamustine 90 mg/m² d 1+2 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
1701268|NCT01456351|Drug|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w|Fludarabine 25 mg/m² d 1-3 + Rituximab 375 mg/m² d 1 q4w for maximum 6 cycles
1701269|NCT01456338|Behavioral|Cognitive Behavioral Therapy for PTSD|Individual CBT, approx. 12 sessions, one session per week
1701270|NCT01456338|Behavioral|Individual Addiction Counseling|Individual therapy, approx. 12 sessions, one session per week
1701276|NCT01456299|Drug|Remifentanil 1|"Remifentanil 1: The R1 group, which received a target effect-site remifentanil concentration of 1 ng/ml."
1701277|NCT01456299|Drug|Control|The control group, which received an infusion of normal saline
1701278|NCT01456299|Drug|Remifentanil 2|"Remifentanil 2: The R2group, which received a target effect-site remifentanil concentration of 2 ng/ml."
1701279|NCT01456286|Drug|sapropterin|two weeks of treatment: 5 mg/kg per day during first week 10 mg/kg per day during second week
1701280|NCT01456273|Procedure|Traditional Medical Consultation|Group A will be divided into 2 subgroups : A1- Traditional medical consultation + placebo, and A2- traditional medical consultation plus omeprazole
1701281|NCT01456273|Procedure|Therapeutic Encounter|"Group B (who receive care Therapeutic Encounter) will be divided in subgroup B1, which will receive the Drug Therapy Classic and 2 in group B who received placebo."
1701282|NCT01456260|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
1701283|NCT01456260|Drug|Placebo|Lansoprazole placebo matching capsules, orally, once daily for 28-80 weeks.
1701284|NCT01456260|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
1701285|NCT01456260|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
1701286|NCT01456260|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
1701287|NCT01456260|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
1701288|NCT01456247|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for 28-80 weeks.
1701289|NCT01456247|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
1701290|NCT01456247|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for 28-80 weeks.
1701291|NCT01456247|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for 28-80 weeks.
1701292|NCT01456247|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for 28-80 weeks.
1701293|NCT01456247|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for 28-80 weeks.
1701294|NCT01456234|Drug|Oseltamivir|Oseltamivir 75 mg BID
1701295|NCT01456221|Dietary Supplement|Omega3 and an hypocaloric diet.|Thirty caps with the supplement will be provided every mo during three mo. Supplement will be administered as gel caps containing 1.1 g of DHA and EPA (®MaxEpa, Merck Laboratory) Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
1701296|NCT01456221|Dietary Supplement|Sunflower oil with an hypocaloric diet.|Thirty caps with the placebo will be provided every mo during three mo. Placebo will be administered as gel caps containing 1g of sunflower oil, which is omega-3 free, and is not expected to produce anti-inflammatory or insulin sensitivity effects. Hypocaloric diet will start at admission and will continue during the six months of follow-up. It will consist in providing a personalized diet including: a) reduction of 700 Kcal from the usual diet considering lipids and carbohydrates, b) increasing fruits and vegetables intake up to six portions daily each, and c) incrementing the intake of fiber to 30 g a day through the inclusion of whole grains.
1701297|NCT01456208|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
1701298|NCT01456208|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
1701299|NCT01456208|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
1701300|NCT01456195|Drug|Placebo|Fasiglifam placebo-matching tablets
1701301|NCT01456195|Drug|Fasiglifam|Fasiglifam tablets
1701302|NCT01456182|Drug|AFX-2|Dose level 1
1701303|NCT01456182|Drug|AFX-2|Dose level 2
1701304|NCT01456182|Drug|AFX-2|Dose level 3
1701305|NCT01456182|Drug|AFX-2|Dose level 4
1701306|NCT01456182|Drug|AFX-2|Dose level 5
1701307|NCT01456169|Drug|Azilsartan medoxomil/placebo|Azilsartan medoxomil and placebo to chlorthalidone combination tablets
1701308|NCT01456169|Drug|Azilsartan medoxomil - chlorthalidone|Azilsartan medoxomil and chlorthalidone fixed dose combination tablets
1701309|NCT01456156|Radiation|postoperative radiotherapy|IMRT or 3DCRT, 50-60Gy to the tumor bed
1701310|NCT01456143|Device|High Resolution Microendoscopy (HRME)|High Resolution Microendoscopy imaging device that operates as a fluorescence microscope with a fiber optic imaging probe. The probe is placed against the mucosa to obtain images relayed to a tablet computer.
1701311|NCT01456143|Other|Proflavine hemisulfate|0.01% Proflavine hemisulfate used as a fluorescent contrast agent applied topically to mucosa
1701312|NCT01456130|Drug|Alogliptin|Alogliptin tablets
1701313|NCT01456130|Drug|Rapid-acting insulin secretagogue|Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
1701314|NCT01456117|Drug|Pioglitazone|Pioglitazone once daily for up to 14 days.
1701315|NCT01456117|Drug|Pioglitazone|Pioglitazone once daily for up to 14 days.
1701316|NCT01456117|Drug|Pioglitazone|Pioglitazone once daily for up to 14 days.
1701317|NCT01456117|Drug|Placebo|Pioglitazone matching placebo once daily for up to 14 days.
1701318|NCT01456104|Biological|Langerhans-type dendritic cells (a.k.a. Langerhans cells or LCs)|Patients will receive a total of 5 vaccinations, comprising a primary immunization followed by four boosters at 3 week intervals with a window of ± 4 days. Vaccines will be dosed at 10x106 LCs per vaccine x 5.
1701319|NCT01456091|Behavioral|AIM 4 Teen Moms|The AIM (Adult Identity Mentoring) 4 Teen Moms program is a combination of individual and small group sessions intervention that encourages parenting young women ages 15-19 years old to delay rapid repeat pregnancies for 24 months or later.
1701393|NCT01455428|Drug|Lyrica (pregabalin)|Capsule, 300 mg/d, BID, 8 weeks treatment
1701320|NCT01456078|Drug|177Lu-DOTA-TATE|"177Lu-DOTA-TATE given as intravenous infusion given during 3-5 treatments. Evaluation is performed after every single cycle. Further more, evaluation is made after last cycle, and delivered cumulative dose to kidneys should be 27 Gy.
Patients with stable disease or partial response, and without pronounced toxicity will continue treatment to a step 2, where additional 3-5 treatment cycles are given, with a cumulative dose to kidneys to 40 Gy."
1701321|NCT01456065|Biological|Procure|The IMP (Investigational Medical Product) consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO (Dimethyl sulfoxide), solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial. 8 vial will be injected on weekly administration basis to the patient.
1701322|NCT01456065|Biological|Procure|The IMP consists of 1.3*107 autologous, fully mature DCs, double loaded with TERT-mRNA and Survivin-peptide, diluted in 0.5 mL of a standard freezing solution, made up of 10% DMSO, solved in a physiologic water solution of 5% glucose; provided in a 2 mL cryovial, 8 vials will be injected into the patient on biweekly basis.
1701323|NCT01456052|Drug|500 mg LX1606 QD|500 mg LX1606 administered orally once daily (QD)
1701324|NCT01456052|Drug|500 mg LX1606 TID|500 mg LX1606 administered orally three times daily (TID)
1701325|NCT01456052|Drug|Placebo|Matching placebo administered orally
1701326|NCT01456039|Drug|Romidepsin|Intravenous dosing for 4 hours on Days 1, 8, and 15 of each 28-day cycle
1701327|NCT01456026|Dietary Supplement|Glycated beta-lactoglobulins.|oral, 20 g, single administration
1701328|NCT01456026|Dietary Supplement|Non-glycated beta-lactoglobulins|20 g, oral, single administration,
1701331|NCT01456000|Device|EAS-AC (HeartLight)|Pulmonary vien isolation
1701332|NCT01456000|Procedure|Control Arm Ablation|Treatment with standard ablation.
1701333|NCT01455974|Other|Decreasing dialysate sodium from 138 mmol/L to 136 mmol/L|After 1-month period of dialysis with standard dialysate sodium concentration 138mmol/L, patients were followed up over a 1-year period with dialysate sodium set at 136mmol/L, without changes in instructions to patients about dietary sodium.
1701334|NCT01455948|Device|Relieva Balloon Sinuplasty™ System|Catheter-based devices used to dilate blocked paranasal sinus ostia (openings).
1701335|NCT01455948|Procedure|Functional Endoscopic Sinus Surgery|Specialized probes are used to cannulate closed ostia (openings), and small forceps are used to resect periostial bone and tissue to enlarge the sinus ostia.
1701336|NCT01455935|Drug|Anti-platelets and statin|
1701337|NCT01455935|Drug|alteplase|"Full dose Intravenous thrombolysis
0.9 mg/kg
Maximum dose is 90 mg
10% of the dose will be given over one minute
90% of the dose will be infused over 1 hour
Admission to Neuro Intensive Care Unit(NICU) for 24 hours if no complications
Neuro checks every 5 minutes during the infusion
Neuro checks every hour after the infusion for 24 hours"
1701338|NCT01455935|Procedure|intra arterial intervention|"Intra arterial Activase (Maximum dose of 22 mg)
MERCI device (Maximum of 3 tries per device, no standard time frame for how long the procedure takes)
PENUMBRA device (no standard time frame for how long the procedure takes)"
1701339|NCT01455922|Drug|ITCA 650|ITCA 650 is exenatide in DUROS
1701340|NCT01455922|Drug|glimepiride|glimepiride will be up-titrated to 8 mg/day over first 13 weeks
1701341|NCT01455909|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
1701342|NCT01455909|Drug|sitagliptin|sitagliptin oral 100 mg/day
1701343|NCT01455896|Drug|ITCA 650|ITCA 650
1701344|NCT01455896|Other|ITCA placebo|ITCA placebo
1701345|NCT01455883|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
1701346|NCT01455883|Drug|glimepiride|oral glimepiride does-escalated,if tolerated, to 8 mg/day
1701347|NCT01455870|Drug|ITCA 650 60 mcg/day|exenatide in DUROS
1701348|NCT01455870|Drug|sitagliptin|oral sitagliptin 100 mg/day
1701349|NCT01455857|Drug|ITCA 650|ITCA 650 is exenatide in DUROS
1701350|NCT01455857|Other|ITCA placebo|Formulation in DUROS (no exenatide)
1701351|NCT01455844|Drug|CaPre (TM)|CaPre™ 1.0g + Placebo 1.0g daily for 12 weeks.
1701352|NCT01455844|Other|Placebo|2.0g Placebo (Microcrystalline cellulose) daily for 12 weeks
1701353|NCT01455844|Drug|CaPre (TM)|CaPre™ 2.0g daily for 12 weeks
1701354|NCT01455831|Drug|Tinzaparin|The experimental arm will receive a subcutaneous injection of 4,500 IU of tinzaparin daily beginning at randomization and continued for 56 days following resection. There will be a minimum of one dose of pre-operative LMWH since it is not reasonable to delay surgery for the purpose of administering LMWH. The maximum duration of pre-operative LMWH will be 6 weeks.
1701355|NCT01455831|Drug|Tinzaparin|The control arm will receive a daily subcutaneous injection of 4,500 IU of tinzaparin beginning with the first post-operative dose and continued for the duration of hospitalization.
1701356|NCT01455805|Device|Minuteman Fusion Implant|The Minuteman™ interspinous interlaminar fusion device consists of a central threaded portion that has a two-part wing plate hinged near its proximal end, with spikes on the extended distal end of the wing plate, and a multi-spiked end cap plate that is located at the distal end of the device and is retained and tightened in place with a locking hex nut. Compression between the spiked wing plate and the spiked end cap plate serves to fix the spinous processes in place and to facilitate fusion, together with bone graft fusion material placed within the device. The threaded external body has been designed to provide ease of distraction and insertion via a minimally invasive surgical procedure.
1701357|NCT01455805|Procedure|surgical decompression|Surgical decompression refers to the following operations Laminectomy, Foraminotomy, Discectomy or any other surgical procedure that the clinician feels is relevant for the decompression of lumbar spinal stenosis
1701358|NCT01455792|Procedure|Biopsies using image fusion|MRI and soft image fusion guided biopsy
1701359|NCT01455792|Procedure|Gold standard biopsy|Gold standard TRUS biopsy
1701394|NCT01455428|Drug|Placebo|Capsule, 300 mg/d, BID, 8 weeks treatment
1701395|NCT01455415|Drug|pregabalin|150 - 300 mg/day in divided dose (3 time a day) for 6 weeks
1701396|NCT01455415|Drug|placebo|matching placebo 3 time a day
1701397|NCT01455389|Drug|DOTAP:Chol-fus1|Starting Dose 0.045 mg/kg by vein on day 1 of each 21 day cycle; Phase II is Maximum Tolerated Dose from Phase I.
1701361|NCT01455753|Other|The effect of proximity on flu shot participation|The investigators will move the location of the flu shot clinic to a high traffic area in our partner company's second headquarters building. After that clinic is complete, the investigators will then host a flu shot clinic in our partner company's first headquarters building, also in a high traffic area, which will not be publicized until the first flu shot clinic is complete.
1701362|NCT01455740|Other|Medication Adherence among HIV/AIDS Patients|"If patients are interested and available, they will be scheduled for a first study visit (study visit 1) involving enrollment and baseline data collection. The second (study visit 2), third (3), fourth (4), and fifth (5) study visits will be used to implement the intervention with financial incentives and will involve data collection. The sixth (6) will involve only data collection; there should be time during the sixth to complete chart extraction—for hospital, pharmacy, and clinical records.
Subjects will be told that study visit 5 is the end of the study, although we may follow up later. Study visit 6 will be an unanticipated meeting."
1701363|NCT01455727|Other|Pharmaceutical care|The Pharmacist provided Pharmaceutical care on the ambulatory elderly Diabetes patients, provided recommendation to the physician and reffered the patients to other diabetes-care-team members, including the CDEs and dietitians.
1701364|NCT01455727|Other|Usual care|Control patients received usual care directed by their physician.
1701365|NCT01455701|Drug|Tocilizumab|Tocilizumab will be administered as indicated in the arm description.
1701366|NCT01455688|Drug|early HAART|Initiation of HAART within 5 days of ICU admission
1701367|NCT01455688|Drug|Late HAART|Initiation of HAART after ICU discharge
1701368|NCT01455675|Drug|IgY|Avian polyclonal anti-pseudomonas antibodies (IgY)
1701369|NCT01455675|Drug|Placebo|Placebo, 70 ml gargling solution, once daily
1701370|NCT01455649|Drug|Everolimus|Group will switch calcineurin inhibitor to everolimus within 1 day (overnight).
1701371|NCT01455649|Drug|calcineurin inhibitor|Group will maintain their initial immunosuppression therapy with calcineurin inhibitor
1701372|NCT01455636|Other|Hand Sanitizer|The water-based hand sanitizer to be used in the current project will be produced in India by Hexagon Inc. It will be dispensed via a foam dispenser, since it has been established that foam is preferable to gel because of the natural tendency to rub foam more thoroughly into one's hands.
1701373|NCT01455636|Dietary Supplement|Improved Micronutrient Powder|A modified and improved formulation of MNPs will be used. The composition is specially designed to enhance appetite and growth with 17 essential micronutrients; including calcium and magnesium, as well as an increased amount of zinc (10 mg). Previously MNP formulations (including the UNICEF formulation) contained only 5 mg of zinc and did not contain magnesium and calcium, which are essential nutrients for bone formation.
1701374|NCT01455636|Other|No hand sanitizer|"All family members will receive hand-hygiene education with Information, Education and Communication (IEC) materials including pictorial messages describing critical points for hand-hygiene.
No placebo for the hand sanitizers will be provided to families in Groups 3 and 4 because it would be unethical if families were to use an inactive hand-hygiene product as a substitute for routine hand-washing. Nevertheless, all groups will be instructed"
1701375|NCT01455636|Dietary Supplement|No Micronutrient Powder|I-MNP and placebo will be procured from a local pharmaceutical company in Dhaka, Bangladesh (Renata Pharma Ltd.). The outer-packaging of the sachets of 'I-MNP' and 'placebo-MNP' will be identical except for a different numeric code for each.
1701376|NCT01455597|Drug|Estradiol Vaginal Gel|Estradiol vaginal gel containing 0.017 mg estradiol per gram, 3X weekly for 40 weeks
1701379|NCT01455558|Drug|Pletaal|"Part 1: a single dose of the SR (200mg x 1 tablet, QD) and IR (100mg x 2 tablets, BID) formulation of cilostazol orally 7 days apart in a fasted state
Part 2: a single dose of the SR (200mg x 1 tablet, QD) formulation of cilostazol 7 days apart in a fasted and a fed state
Part 3: multiple doses of the two formulations for eight consecutive days 21 days apart"
1701380|NCT01455532|Drug|Iniparib (SAR240550-BSI-201)|"Pharmaceutical form:Solution for infusion
Route of administration: Intravenous"
1701381|NCT01455532|Drug|Gemcitabine|"Pharmaceutical form:Solution for infusion
Route of administration: Intravenous"
1701382|NCT01455532|Drug|Carboplatin|"Pharmaceutical form:Solution for infusion
Route of administration: Intravenous"
1701383|NCT01455532|Drug|Placlitaxel|"Pharmaceutical form:Solution for infusion
Route of administration: Intravenous"
1701384|NCT01455532|Drug|Pegylated liposomal doxorubicin|"Pharmaceutical form:Solution for infusion
Route of administration: Intravenous"
1701386|NCT01455506|Drug|Decitabine plus Fludarabine and Busulfan|"Decitabine will be administered at a dose of 60 mg/m2 IV daily based on adjusted body weight for patient >20% above ideal body weight
Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 5 days starting on transplant day -7.
Busulfan will be administered at a dose of 130 mg/m2 IV daily for 2 days on transplant days -4 and -3.
Patients will also receive rabbit antithymocyte globulin (Thymoglobulin) at a dose of 2 mg/kg IV daily for 3 days on transplant days -4, -3, and -2.
Hematopoietic cells will be infused on day 0."
1701387|NCT01455493|Drug|GDC-0980|Oral daily dose
1701388|NCT01455480|Drug|RPh201, botanical drug product|topical
1701389|NCT01455467|Device|One iStent|Implantation of one iStent in conjunction with cataract surgery
1701390|NCT01455467|Device|Two iStent|Implantation of two iStent in conjunction with cataract surgery
1701398|NCT01455389|Drug|Erlotinib|Starting Dose 100 mg by mouth each day of a 21 day cycle (except for first week of Cycle 1, if enrolled in Phase II delayed-schedule group). Phase II is Maximum Tolerated Dose from Phase I.
1701399|NCT01455389|Drug|Dexamethasone|8 mg orally 24 and 12 hours and 20 mg by vein 30 minutes before DOTAP:Chol-fus1 treatment followed by 8 mg orally at 12, 24 and 36 hours after treatment (total number doses = 5).
1701400|NCT01455389|Drug|Diphenhydramine|50 mg by mouth or by vein 30 minutes prior to treatment with DOTAP:Chol FUS1
1701401|NCT01455376|Drug|hyperosmolar sodium lactate|Patients in this group received intravenous infusion of hyperosmolar sodium lactate at 1.5 ml.KgBW-1 within 15 minutes before neurosurgery
1701402|NCT01455363|Procedure|BCC surgery|This clinical trial will use skin flap model for trunk and facial BCC, with respect the classical excision margin of BCC surgery (3-4mm): after local anesthesia, a little random pattern skin flap will be raised around the BCC, then the cutaneous pedicle will be clamped with surgical clamp for 3 minutes and clamp released.
1701403|NCT01455363|Other|Tourniquet ischemia|In case of limb BCC, limb tourniquet will be used, and occluded during 3 minutes upstream to the BCC location.
1701404|NCT01455363|Other|Laser speckle imaging|During all steps of experimentation, laser speckle imaging will be used to measure continuously the peri-tumoral and tumoral perfusion, start from tumor excision, up to10 minutes after tumor pedicle clamp or tourniquet release.
1701405|NCT01455350|Procedure|Multimodal physiotherapy|10 weeks of weekly physiotherapy treatments including relaxation techniques, stretching and pelvic floor muscle control exercises.
1701406|NCT01455350|Drug|lidocaine|10 weeks of daily topical 5% lidocaine application
1955981|NCT03007576|Biological|RegStem|RegStem, 1.5 ml, one injection
1701409|NCT01455324|Device|Novel conformable woven inner socket|Prosthetic socket liner fabricated from novel materials to allow passive conformability for the user
1701410|NCT01455311|Procedure|EUS Guided Fine Needle Aspiration|EUS-guided fine needle aspiration of the cyst fluid
1701411|NCT01455311|Procedure|EUS Guided EchoBrush Sampling|EUS-guided brushing of the cyst wall
1701412|NCT01455298|Other|Transient Elastography and fibrotest|a Transient Elastography and an ultrasound are performed.
1701413|NCT01455285|Device|transcutaneous electrical nerve stimulation|
1701414|NCT01455272|Procedure|prophylactic GPBPCI|A G-CSF-primed PBPCI was planned within day 60 post-transplantation before hematologic relapse was diagnosed
1701415|NCT01455259|Biological|AdCD40L|Adenoviral serotype 5 vector, E1/E3 deleted. Human CD40L gene insert driven by RSV promoter. Vector diluted in infusion solution, 500uL solution containing 2.5x10e11 VP is intratumorally injected/treatment.
1701416|NCT01455246|Drug|Daptomycin + Meropenem|Daptomycin will be administered at the dose of 6 mg/kg every 24 hours and 6 mg/kg every 48 hours for an estimated creatinine clearance (CKD-EPI) of > 30 ml/min and < 30 ml/min respectively. Meropenem will be administered at the dose of 1 g t.i.d., 1 g b.i.d., 0.5 g every 24 hours for an estimated creatinine clearance of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours will be added a rescue therapy with fluconazole. In patients in which cultures shown a bacterial species resistant to therapy, daptomycin and meropenem will be discontinued and replaced by a therapy based on antibiotic susceptibility of isolated species.
1701417|NCT01455246|Drug|Ceftazidime|Ceftazidime will be administered at the dose of 2 g t.i.d, 2 g b.i.d and 2 g at every 24 hours by intravenous infusion for an estimated creatinine clearance (CKD-EPI) of >50 ml/min, 10-50 ml/min, and < 10 ml/min respectively. The treatment will go on for 7 days. In the patients without response to treatment after 48 hours, or in which cultures shown a bacterial species resistant to therapy, ceftazidime will be discontinued and replaced by a rescue therapy with meropenem and daptomycin as provided for the experimental arm
1701420|NCT01455220|Drug|Tysabri ® (Natalizumab)|IV, monthly
1701421|NCT01455207|Behavioral|Neuropsychological testing|assessment of memory, executive functions and ataxia
1701422|NCT01455207|Biological|blood draw|hepatic markers, red blood markers and vitamin markers
1701423|NCT01455207|Genetic|genetic testing|genes coding for thiamine enzymes (α-ketoglutarate dehydrogenase complex, transketolase et pyruvate dehydrogenase)
1701424|NCT01455207|Other|Brain imaging examination|MRI, DTI and PET examinations
1701425|NCT01455194|Drug|Ciclesonide|During the treatment period subjects will inhale two puffs of either 40, 80 or 160 μg ciclesonide in the morning and the evening (corresponding to a total daily dose of 160, 320 or 640 μg)
1701426|NCT01455181|Drug|NPSP558|50, 75, 100 μg
1701429|NCT01455142|Drug|insulin degludec/insulin aspart|Single injection of each formulation. The dose level will be 0.5 U/kg body weight (BW). The trial products will be administered subcutaneously (under the skin).
1701430|NCT01455129|Drug|Tiotropium|18 mcg tiotropium capsule, once daily, inhaled by HandiHaler, for 24 months
1701431|NCT01455129|Drug|placebo|placebo, once daily, inhaled by HandiHaler
1701432|NCT01455116|Procedure|Mild Induced Hypothermia|Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
1701433|NCT01455103|Biological|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 1 mg/kg, Every 2 weeks, Up to 2 years, depending on response
1701434|NCT01455103|Biological|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 3 mg/kg, Every 2 weeks, Up to 2 years, depending on response
1701435|NCT01455103|Biological|BMS-936559 (Anti-PD-L1)|Solution, Intravenous infusion, 10 mg/kg, Every 2 weeks, Up to 2 years, depending on response
1701436|NCT01455090|Drug|BMS-650032|
1701437|NCT01455090|Drug|BMS-790052|
1701438|NCT01455090|Drug|BMS-791325|
1701440|NCT01455064|Device|FreeStyle Navigator II Continuous Glucose Monitoring System|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration
1701441|NCT01455051|Drug|Ofatumumab|We plan to add five doses of ofatumumab to the standard conditioning regimen (fludarabine + melphalan). Ofatumumab will be administered on days -20 (300 mg), -13 (2000 mg), -6 (2000 mg), +1 (1000 mg) and +8 (1000 mg) of the transplantation (day 0 being the day of the hematopoietic cell infusion). If the patient requires donor lymphocyte infusions within 3 years after the procedure, these infusions will also include one administration of 300 mg of ofatumumab, followed by a 1000 mg dose, 7 days later).
1701442|NCT01455025|Drug|Plerixafor granulocyte-colony stimulating factor|"Induction phase Plerixafor IV from D1 to D3 and from D8 to D10, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D10, Intravenous daunorubicin 60 mg/m2/day from D1 to D3 Cytarabine 500 mg/m2/day continuous infusion over 24h from D1 to D3 followed by cytarabine 2-hour bolus of 1000 mg/m2/12h from D8 to D10.
Consolidation phase Plerixafor at D1, D3 and D5, granulocyte-colony stimulating factor IV 5 μg/kg/day from D1 to D5, Cytarabine continuous infusion of 3-h bolus of 3000 mg/m2/12h D1, D3 and D5"
1701443|NCT01455012|Drug|Rotigotine|Rotigotine 1 mg/24 h, 2 mg/24 h, and 3 mg/24 h. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
1701444|NCT01455012|Drug|Placebo|Matching Placebo. Subjects will be titrated to their optimal/maximal dose in weekly increments of 1 mg/24 h during a Titration Period. During Maintenance Period the subjects will continue on their optimal/maximal dose for 28 days. Following the Maintenance Period, subjects will be de-escalated over 7 days, depending on their optimal/maximal dose.
1701445|NCT01454999|Behavioral|CTI|Web-based computerized, tailored intervention (CTI) for smoking cessation, based on the transtheoretical model of change.
1701446|NCT01454986|Drug|ALXN1007|Single dose, IV
1701447|NCT01454986|Other|Placebo|Single dose, IV
1701448|NCT01454960|Behavioral|Clinical Decision Support: Accountable Justification|Accountable Justification is triggered by discordant prescriptions that populate the EHR note with provider's rationale for guideline exceptions (AJ).
1701449|NCT01454960|Behavioral|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
1701450|NCT01454960|Behavioral|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
1701451|NCT01454947|Behavioral|Clinical Decision Support (CDS): Accountable Justifications|Accountable Justifications triggered by discordant prescriptions that populate the electronic health record (EHR) note with provider's rationale for guideline exceptions (AJ).
1701452|NCT01454947|Behavioral|Audit and Feedback: Peer Comparison|Performance feedback that benchmarks providers' own performance to that of their peers (PC, for Peer Comparison).
1701453|NCT01454947|Behavioral|CDS Order Sets: Suggested Alternatives|Order Sets that are triggered by EHR workflow containing exclusively guideline concordant choices (SA, for Suggested Alternatives).
1701454|NCT01454934|Drug|Eribulin|Administration of eribulin mesylate at a dose of 1.4 mg/m2 i.v. over 2 to 5 minutes on Days 1 and Day 8 of every cycle, where the duration of each cycle is 21 days.
1701455|NCT01454934|Drug|TPC -Vinorelbine,Gemcitabine,Docetaxel, and Pemetrexed|"Vinorelbine 30 mg/m2 i.v. on Day 1, every 7 days
Gemcitabine 1250 mg/m2 i.v. on Days 1 and 8, every 21 days
Docetaxel 75 mg/m2 i.v. on Day 1 every 21 days
Pemetrexed 500 mg/m2 i.v. on Day 1 every 21 days (nonsquamous histology only)."
1701456|NCT01454921|Behavioral|Evolution: Young Women Taking Charge and Growing Stronger|The intervention aims to address the following concerns: 1) reducing the risk of young women infected with HIV transmitting the virus to their sexual partners, and 2) preventing young women infected with HIV from re-infection with a new viral strain or co-infection with another sexually transmitted disease (STD).
1701458|NCT01454895|Behavioral|Sampler of hearing protection devices|In a pilot study, hearing protection devices were mailed to farmers, resulting in a significant increase in use. These results suggested that overall, HPDs were acceptable to farmers, and that access to HPDs may be an important contributor to frequency of use. The study will build on this earlier work by providing an assortment of hearing protection devices to a sub-sample of each group of farmers receiving the Interactive and Static Web Interventions. The assortment includes the most commonly used types of devices (i.e., muffs, foam plugs, pre-molded plugs, and semi-aurals). The sampler is delivered, together with manufacturers' standard written instructions for use, via mail at the designated time according study design.
1701459|NCT01454895|Behavioral|Static Web-based information|The standard information promoting HPD use delivered via Internet will be based on an informational brochure previously developed for use by farmers (i.e., Have You Heard? and They're Your Ears Protect Them). These brochures, including color graphics and text, are available on the Internet (as PDF files). Although they have been printed and distributed by NIOSH, most farmers will not have been exposed to copies. There are important differences between the SWI and IWI interventions, including interactivity, animation, explication of farmer-generated tips and techniques for addressing common barriers to hearing protector use, use of color, audio, and video, hotlinks, and farmer testimonials.
1701460|NCT01454895|Behavioral|Interactive Web-based information|This intervention includes a number of features/techniques designed to promote behavior change. Messages focus on farmer-friendly techniques for adopting use of HPDs. The factors found to be significant predictors of HPD use (Barriers to Use and Situational Factors Influencing HPD Use) are particularly relevant to farmers' learning needs, and are especially emphasized in this model-based intervention to increase hearing protector use among farmers. Participants will select the sequence of features they visit, as well as the time spent in each feature and number of visits to the site. Their patterns of use will be tracked by the enrollment and data collection systems and used in analysis.
1701461|NCT01454882|Behavioral|Effects of Clothing|There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
1701792|NCT01452607|Drug|Placebo|0 mg Ebselen oral capsules (SPI-1000), single dose
1701462|NCT01454882|Behavioral|Effects of Temperature|There will be two temperature conditions; warm temperature [WT, 75°F (24°C)] and cool temperature [CT, 60°F (16°C)]. During each condition, subjects will vary the amount of clothing they are wearing at specified times
1701463|NCT01454882|Behavioral|Low Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
1701464|NCT01454882|Behavioral|High Physical Activity|This will be a randomized study with two within subject conditions (high and low physical activity levels)
1701465|NCT01454882|Behavioral|Direct calorimetry and doubly labeled water|TDEE will be measured simultaneously for 14 days using direct calorimetry and doubly labeled water. A heterogeneous sample of adult men and women in stable health will be studied.
1701466|NCT01454869|Drug|standard care|Standard care treatment consist of chest physiotherapy ,early ambulation, airway suctioning, bronchial hygiene therapy , salbutamol nebulization(100-200 µgQ4h)/N-acetyl cysteine20% nebulization(3cc Q4h) and if needed mechanical ventilation support.
1701467|NCT01454869|Drug|Heparin|Study group would consist of 85 burn patients with documented smoke inhalation injury who will be randomized to receive standard care plus heparin nebulization(5000U every 4 hours for 7 days) in combination with intravenously administrated fresh frozen plasma(10 cc/Kg daily for 7 days).
1701468|NCT01454843|Procedure|Wavefront-guided LASIK - Allegretto|Wavefront-guided LASIK using the Allegretto excimer laser for myopia.
1701469|NCT01454843|Procedure|Wavefront-guided LASIK - AMO|Wavefront-guided LASIK using the AMO CustomVue excimer laser for myopia.
1701470|NCT01454830|Behavioral|Tailored|Individualized on critical indicator (Self-efficacy measure in Sleep Apnea) measured at each intervention delivery period (pre-diagnosis, immediately post-diagnosis, post-CPAP titration, and during week 1 of home CPAP treatment. Intervention components include patient education, preparatory skills training, modification of inaccurate/unrealistic cognitive perceptions of risk, outcome expectations, and treatment self-efficacy
1701471|NCT01454830|Other|Usual care|Usual care comparison group will proceed from initial clinical evaluation for OSA, diagnosis by polysomnography, CPAP titration polysomnography, and home CPAP treatment initiation as per current standard of care
1701472|NCT01454817|Behavioral|Quality of life|Improving Quality of Life
1701473|NCT01454804|Drug|Pazopanib|Starting dose: 200 mg by mouth every other day starting on day 1 for 28 days.
1701474|NCT01454804|Drug|Lapatinib|Starting dose 500 mg by mouth every day for 28 days.
1701475|NCT01454804|Drug|Trastuzumab (Herceptin®)|"4 mg/kg loading dose as a 90 minute infusion by vein on day 1 of cycle 1.
Maintenance dose of 2 mg/kg every week as 30 minute infusion by vein.
Dose Expansion Phase: Maximum tolerated dose (MTD) from Dose Escalation Phase"
1701476|NCT01454804|Drug|Pazopanib|Starting dose 200 mg by mouth every day for 28 days.
1701477|NCT01454791|Drug|diclofenac sodium topical gel|diclofenac sodium topical gel 1% applied 1-4 times per day for two weeks either preceded by or followed by two weeks of placebo
1701478|NCT01454791|Other|Placebo|a placebo gel is applied 1-4 times per day for two weeks.
1701479|NCT01454778|Drug|Paclitaxel|"Paclitaxel in addition to angioplasty, stenting or atherectomy Dosing will be based on the lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3
Paclitaxel Dosage:
Superficial Femoral/Common Femoral: 2.4 mg/inflation of balloon* Popliteal: 1.8 mg/inflation of balloon* Tibial: 1.4 mg/inflation of balloon*
not to exceed 10mg total dose"
1701480|NCT01454765|Other|generation of stem cells|Collected germ cells will be cultured in medium. The germ cell cultures will be infected with reprograming factors. Rare colonies with characteristic stem cell morphologies will be expanded.
1701481|NCT01454752|Drug|Intermittent parasite clearance|Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days
1701482|NCT01454752|Other|Placebo|Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
1701484|NCT01454726|Other|Diaoshi Jifa therapy plus the Western medical treatment.|Diaoshi Jifa treatment
1701485|NCT01454726|Other|drug|the Western medical treatment alone.
1701486|NCT01454700|Device|Insulin pump therapy (CSII) plus continuous glucose monitoring (CGM)|Randomization to 12 months with CSII plus CGM
1701487|NCT01454700|Other|Multiple daily insulin injections (MDI)|Randomization12 months therapy with MDI
1701488|NCT01454687|Procedure|Grafting of Autologous Cultured Revertant Keratinocytes|Grafting of two to four epidermal sheets 40cm2 - 50cm2 onto wounded areas
1701489|NCT01454674|Other|2, 5 & 10 Vegetable doses|2,5 & 10 serving dose/day combination of fresh lettuce mix, baby carrots, red bell peppers & tomatoes consumed for 3 week intervals
1701490|NCT01454661|Dietary Supplement|LGG|Lactobacillus rhamnosus GG 10E9 cfu / day
1701491|NCT01454661|Dietary Supplement|LGG+Bb-12|A combination of the probiotics Lactobacillus rhamnosus GG and Bifidobacterium lactis Bb-12 administered 10E9 cfu / day each.
1701492|NCT01454661|Dietary Supplement|Placebo|Microcrystalline cellulose is used as placebo.
1701494|NCT01454622|Drug|A (canagliflozin and metformin IR individual tablets) / B (canagliflozin/metformin IR FDC tablets)|Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 2
1701495|NCT01454622|Drug|B (canagliflozin/metformin IR FDC tablets / A (canagliflozin and metformin IR individual tablets)|Treatment B (canagliflozin/metformin IR FDC): Type = 2, unit = mg, number = 50/1000, form = tablet, route = oral use. Two Canagliflozin/metformin IR FDC tablets taken orally on Day 1 of Treatment Period 1 followed 10-15 days later by Treatment A: Canagliflozin: Type = 1, unit = mg, number = 100, form = tablet, route = oral use + Metformin IR: Type = 2, unit = mg, number = 1000, form = tablet, route = oral use. One canagliflozin tablet and 2 metformin IR tablets taken orally (by mouth) on Day 1 of Treatment Period 2.
1701496|NCT01454609|Drug|0.9% Normal saline|Saline
1701793|NCT01452594|Drug|Diphenylcyclopropenone|Topical administration
1701794|NCT01452594|Drug|Placebo|Placebo
1701497|NCT01454609|Drug|Bupivacaine|Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
1701498|NCT01454609|Device|Bupivacaine with clonidine (combination)|"Bupivacaine - amide local anesthetic, maximum recommended dose is 2 mg/kg duration 2 - 4 hours of sensory anesthesia up to 24 hours
Clonidine - 0.5 - 1 microgram/ kg"
1701503|NCT01454583|Drug|Aliskiren|Aliskiren (Rasilez®, Novartis) is the first clinically available substance with direct renin inhibition (DRI) which effectively lowers blood pressure.
1701504|NCT01454583|Drug|ACE-I/ARB|
1701505|NCT01454583|Drug|No RAS-inhibition|
1701506|NCT01454557|Other|Auditory Stimuli|Auditory Stimuli during rest and during physical activity
1701507|NCT01454544|Biological|AIT Tablet|1 tablet per day in 12 months
1701508|NCT01454531|Drug|AVANZ Phleum pratense|AVANZ Phleum pratense up-dosing phase (300, 600, 3000, 6000 and 15,000 SQ+) + one 15,000 SQ+ maintenance injection
1701509|NCT01454518|Procedure|Infiltration of local anesthetic|30 ml of ropivacaine 0.5% infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
1701510|NCT01454518|Procedure|Normal Saline Injection|injection of 30ml normal saline infiltrated around lateral anterior and medial aspect of hip joint with ultrasound guidance.
1701511|NCT01454505|Drug|AL-53817 nasal spray solution|Active ingredients administered in 1 of 3 concentrations during Stage A to determine maximum tolerated dose (MTD), and administered at maximum tolerated dose during Stage B.
1701512|NCT01454505|Other|Vehicle nasal spray|Inactive ingredients used as placebo comparator during Stage A and Stage B.
1701513|NCT01454479|Drug|Lapatinib and ixempra|Ixabepilone 40 mg/m2 Lapatinib 250 mg
1701514|NCT01454466|Procedure|Partial posterior hyaloidectomy (a modified procedure of vitrectomy)|The core vitrectomy entails more extensive removal of vitreous gel, in contrast to the conventional core vitrectomy. IPVD was conducted by engaging the attached posterior cortical vitreous with a 23-gauge needle with angulated tip in the area adjacent to the optic disc followed by gently moving the tip to approximately 3 disc diameters away from the margin of the optic disc. After then, slightly elevating the tip in a posteroanterior direction with slowly proceeding it to the extent that we planned. With IPVD, the surgeon was able to visualize a floating Weiss ring in all of the cases. Active suction to initiate IPVD was not used in any of the cases. In the temporal direction, the extension of a PVD was restricted to approximately 2 disc diameters distance beyond the margin of temporal major vascular arcade
1701515|NCT01454453|Drug|Patients- dose titration|dose titration (patients) - 4-10 weeks
1701516|NCT01454440|Drug|Eptifibatide|Intravenous eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure) vs placebo.
1701517|NCT01454414|Other|Permethrin Impregnated Uniforms|Uniforms treated with permethrin according to proprietary process used by Insect Shield, Inc.
1701518|NCT01454401|Device|LeucoPatch treatment|weekly
1701519|NCT01454388|Other|breakfast|
1701520|NCT01454375|Behavioral|Referral to QuitNow Services|QuitNow Services is a telephone counseling program supported by the Ministry of Health Living and Sport that counsels individuals to stop smoking
1701522|NCT01454349|Drug|PRX302|Single intraprostatic injection with an ascending dose per cohort of 0.75, 1.5, 3.0, and 6.0 µg/mL
1701523|NCT01454349|Drug|Placebo|Single intraprostatic injection of matching placebo
1701524|NCT01454336|Biological|Cell injection|MSCs introduced into portal vein
1701525|NCT01454323|Other|Bone marrow mononuclear cells|Intracoronary infusion of autologous bone marrow-derived mononuclear cells
1701526|NCT01454310|Device|Wound coverage by acellular skin substitute|Burn wounds are covered by an acellular skin substitute and remains 10-14 days that peals away in line with re-epithelialisation
1701527|NCT01454310|Device|Autologous skin|Matched burn wound is covered by autologous skin after tangential excision.
1701528|NCT01454284|Drug|Glargine|Administered by subcutaneous injection
1701529|NCT01454284|Drug|LY2605541|Administered by subcutaneous injection.
1701530|NCT01454284|Drug|Insulin Lispro|Administered subcutaneously
1701531|NCT01454271|Procedure|Total Hip Arthroplasty Replacement|Total Hip Arthroplasty Replacement
1701532|NCT01454245|Drug|JNJ-39439335|Part 2:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules taken (25 mg/day) once on Day 1 in 2 treatment periods.
1701533|NCT01454245|Drug|JNJ-39439335|"Part 1:Type=1, unit=mg, number=25, form=capsule, route=oral use. One capsule (25 mg/day) taken once on Day 1 in 3 treatment periods.
or Part 1:Type=2, unit=mg, number=12.5, form=capsule, route=oral use. Two capsules (25 mg/day) taken once on Day 1 in 3 treatment periods."
1701534|NCT01454232|Other|stools sampling|stools sampling at baseline, 1, 3 and 12 months
1701535|NCT01454232|Other|adipose tissue biopsy|surgical adipose tissue biopsy during surgery, 1, 3 and 12 months
1701536|NCT01454219|Other|Bakery and confectionary products|Control product: Glucose solution, Test products: 11 bakery and confectionary products
1701537|NCT01454206|Behavioral|iSBIRT|"Participants will be screened for substance use, view information about the health effects of substance use on the computer, and receive advice from the primary care provider regarding the health effects of substance use. Those found to be at high risk will complete an internet-based program encouraging them to change their substance use."
1701616|NCT01453777|Procedure|harvesting and implantation of adipose derived stem cells|Adipose-Derived Stem cells will be derived from the patient's fat tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the internal carotid artery and intravenously.
1760246|NCT00282373|Device|mild hypothermia|
1701538|NCT01454180|Drug|gemcitabine, or gemcitabine and capecitabine, or gemcitabine and erlotinib, or FOLFIRINOX, or FOLFOX, or FOLFIRI.|"Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.
Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.
Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily
FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.
FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.
FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
1701539|NCT01454180|Drug|Gemcitabine, Gemcitabine-Capecitabine, Gemcitabine-Erlotinib, FOLFOXIRI, FOLFOX, FOLFIRI|"Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks.
Gemcitabine - Capecitabine (GEM-CAP):Gemcitabine 1000 mg/m2 weekly for 3 weeks, Capecitabine 830 mg/m2 orally every 12 hours daily for 3 weeks; every 4 weeks.
Gemcitabine-Erlotinib: Gemcitabine 1000 mg/m2 weekly for 7 weeks, then weekly regimen of 3 weeks every 4 weeks, Erlotinib 100 mg orally daily
FOLFOXIRI: Oxaliplatin 85 mg/m2,irinotecan 180 mg/m2, folinic acid 400 mg/m2, 5'Fluouracilo 400 mg / m2, 5 'fluorouracil 2400 mg/m2 continuous intravenous infusion of 46 hours. Repeated every 14 days.
FOLFOX: Oxaliplatin 85 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo, 2400 mg/m2 5'Fluouracilo continuous intravenous infusion of 46 hours. Repeated every 14 days.
FOLFIRI: Irinotecan 180 mg/m2, folinic acid 400 mg/m2, 400 mg/m2 5'Fluouracilo intravenous bolus, 5'Fluouracilo 2400 mg / m2 continuous intravenous infusion for 46 hours. Repeated every 14 days."
1701540|NCT01454154|Drug|Glyburide|RP-1127 (Glyburide for Injection) delivered as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
1701541|NCT01454154|Drug|Placebo|Placebo delivered as an approximately 2 minute loading dose followed by 72 hours of continuous infusion.
1701542|NCT01454141|Other|Cognitive Control Training|Three sessions of CCT.
1701543|NCT01454141|Other|Peripheral Vision Task|Three sessions of PVT.
1701544|NCT01454128|Behavioral|exercise|36 session supervised exercise intervention
1701545|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 0.3 mg, Once daily, once
1701546|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 1.5 mg, Once daily, once
1701547|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 5.0 mg, Once daily, once
1701548|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 15.0 mg, Once daily, once
1701549|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 50 mg, Once daily, once
1701550|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 100 mg, Once daily, once
1701551|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 200 mg, Once daily, once
1701552|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 400 mg, Once daily, once
1701553|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Capsule, Oral, 50 mg, Once daily, once
1701554|NCT01454115|Drug|BMS-708163 (Gamma-Secretase Inhibitor)|Oral Solution, Oral, 800 mg, Once daily, once
1701555|NCT01454115|Drug|Placebo matching BMS-708163|Oral Solution, Oral, 0 mg, Once daily, once
1701556|NCT01454115|Drug|Placebo matching BMS-708163|Capsule, Oral, 0 mg, Once daily, once
1701566|NCT01454089|Drug|OGX-427 600 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (600 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
1701567|NCT01454089|Drug|OGX-427 1000 mg|Patients will receive three loading doses of 600 mg Study Drug within a 9-day period. Following the loading dose period, patients will receive weekly Study Drug infusions (1000 mg IV) on Days 1, 8 and 15 of each 21-day cycle.
1701568|NCT01454089|Drug|Placebo|Patients will receive three loading doses of placebo within a 9-day period. Following the loading dose period, patients will receive weekly placebo infusions (IV) on Days 1, 8 and 15 of each 21-day cycle.
1701569|NCT01454089|Drug|Gemcitabine|Patients will receive gemcitabine (1000 mg/m^2) for up to 6 cycles administered IV on Days 1 and 8 of each 21-day cycle following Study Drug infusion. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
1701570|NCT01454089|Drug|Cisplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m^2) will be administered IV for up to 6 cycles. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
1701571|NCT01454089|Drug|Carboplatin|Following the administration of gemcitabine on Day 1, cisplatin (70 mg/m^2) is to be administered IV for up to 6 cycles; however, carboplatin could be substituted for cisplatin for some unacceptable toxicities. The Cycle 1, Day 1 administration of chemotherapy must occur within 5 days of the third loading dose of Study Drug.
1701789|NCT01452633|Drug|Saline will be in injected into the port site prior to closure|Saline will be injected into the port site prior to the closure without any preincisional intervention
1701577|NCT01454063|Drug|OMS302|OMS302 drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 60.75 millimolar (mM) phenylephrine hydrochloride (HCl) and 11.25 mM ketorolac tromethamine formulated in a 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available balanced salt solution (BSS) through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
1701578|NCT01454063|Drug|Placebo|Placebo drug product will be supplied as a sterile, clear colorless liquid, free from particulates of foreign matter. Each vial contains a nominal 4.5 mL solution containing 20 mM sodium citrate buffer (pH 6.3 +/- 0.5). For administration to patients, 4.4 mL of the drug product is added to a 500 mL bottle of commercially available BSS through a syringe filter. This will achieve 4.0 mL of the drug product in a 500 mL bottle of BSS.
1701579|NCT01454037|Procedure|Prostate cryotherapy|cryoablate the prostate
1701580|NCT01454037|Procedure|Radical prostatectomy|Remove prostate
1701581|NCT01454037|Procedure|Radiation|Radiate prostate
1701582|NCT01454024|Device|FlexPen®|Prescribed insulin treatment delivered by FlexPen® as part of routine clinical practice
1701583|NCT01454024|Device|NovoPen® 3|Prescribed insulin treatment delivered by NovoPen® 3 as part of routine clinical practice
1701584|NCT01454011|Drug|Testosteron 250mg injection|The combination of 4 different testosterone esthers (30 mg testosterone propionate, 60 mg testosterone phenylpropionate, 60 mg testosterone isocaproate and 100 mg testosterone decanoate) injected in 3 weeks intervals.
1701585|NCT01454011|Drug|Testosterone 50mg transdermal application|Application of testosterone 50mg transdermal gel in every night
1701586|NCT01453998|Biological|Infanrix hexa™|Single dose, licensed formulation, intramuscular into right thigh
1701587|NCT01453998|Biological|Prevenar 13®|Single co-administered dose, intramuscular into left thigh
1701588|NCT01453998|Biological|GSK217744|Single dose, investigational formulation A or B, intramuscular into right thigh
1701589|NCT01453985|Procedure|Full-Thickness-Gastroplication|
1701590|NCT01453972|Behavioral|Long distanse moderate training|Moderate exercise
1701591|NCT01453972|Behavioral|Long interval training|High-intensity exercise, long duration
1701592|NCT01453972|Behavioral|Short interval training|High intensity exercise, short duration
1701595|NCT01453946|Drug|Entocort|Entocort capsules, taken orally, 6 mg daily.
1701596|NCT01453933|Drug|raltegravir|Switch of lopinavir/ritonavir to raltegravir 400 mg BID (duration 8 weeks)
1701597|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
1701598|NCT01453920|Drug|Ranibizumab|Intravitreal Ranibizumab 0.05cc (10mg/ml)
1701599|NCT01453907|Drug|"ETI-204, Anthim"|intravenously, single dose
1701600|NCT01453907|Drug|placebo|intravenously, single dose
1701601|NCT01453894|Behavioral|Reminder and Outreach Intervention|This intervention includes (1) phone calls and text messages to remind participants that they are due for colorectal cancer (CRC) screening (2) mailed fecal occult blood test (FOBT) to participants so they can perform the test conveniently at home and mail them to the clinic, avoiding the need for a visit (3) plain language information and instructions to support understanding of CRC and FOBT use (4) a CRC screening coordinator to contact those still failing to complete testing by telephone or text (5) a feedback loop to patients regarding test results.
1701602|NCT01453881|Device|Spacer|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day with the aid of a Valved Holding Chamber - VORTEX
1701603|NCT01453881|Device|Comparator|Beclomethasone/Formoterol 100/6mcg pMDI 2 puffs two times/day without the aid of a Valved Holding Chamber - VORTEX
1701604|NCT01453868|Other|Non Impact Aerobics|a 12 week, twice a week class in non impact aerobics
1701605|NCT01453868|Other|Passive : lecture series|a 12 week, once a week for one hour lecture series with no exercise. Topics will cover symptom management in Multiple Sclerosis
1701606|NCT01453855|Drug|Travoprost ophthalmic solution, 0.003%|
1701607|NCT01453855|Drug|Travoprost ophthalmic solution, 0.004%|
1701608|NCT01453842|Dietary Supplement|Diet oil|Carrot and diet oil (containing 2-OG) and 1½ g of paracetamol
1701609|NCT01453842|Dietary Supplement|Olive oil|Carrot and olive oil and 1½ g of paracetamol
1701610|NCT01453842|Dietary Supplement|Carrot|Carrot and 1½ g of paracetamol
1701611|NCT01453829|Procedure|Harvesting and Isolation of Stem Cells|This will be an open-label, non-randomized multi-center patient sponsored study of ASC implantation using a catheter delivery system. ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be implanted into the Internal Carotid Artery and intravenously.
1701612|NCT01453816|Procedure|Harvesting and Isolation of Stem cells|Adipose-Derived Stem Cells (ASCs) will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells. The cells will be delivered via catheter into the renal artery and intravenously.
1701613|NCT01453803|Procedure|Harvesting and Implantation of Adipose-Derived Stem Cells|The adipose tissue specimen will be collected from the patient's abdomen or applicable region using a liposuction cannula. The adipose tissue is transferred to the laboratory for separation of the adipose tissue-derived stem cells, which are then transferred for catheter injection.
1701614|NCT01453790|Behavioral|Parent-Specific Depression Education and Motivation|Parent-specific written and verbal depression messages garnered from previous research were consolidated into a pamphlet and script, respectively. These are dispensed after randomization in the pediatric office. At two days, mothers in the experimental group receive a motivational telephone call.
1701615|NCT01453790|Behavioral|General Depression Education-Motivation|General depression education messages were compiled and are delivered verbally (scripted) and written (JAMA Depression Patient Page) after randomization in the pediatric office. At 2 days, mothers in the comparison group receive an attention control telephone call.
1760301|NCT00282945|Drug|Metformin|
1955996|NCT03006068|Drug|ABT-494|ABT-494 will be administered orally.
1701617|NCT01453764|Procedure|Harvesting and Implantation of SVF|The cell therapy in this study is composed of stem cells derived from a patient's own adipose tissue that are harvested by liposuction using tumescent technique and isolated in the laboratory. The Adipose SVF will be delivered via intravenous injection.
1701618|NCT01453751|Procedure|Harvesting and Implantation of Adipose-Derived Stromal Vascular Fraction (AD-SVF)|ASCs will be derived from the patient's adipose-derived tissue. Liposuction using local anesthesia and syringe collection will be performed to collect the adipose tissue specimen for subsequent processing to isolate the stem cells.
1701619|NCT01453738|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
1701620|NCT01453738|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
1701621|NCT01453725|Biological|Golimumab|Golimumab 50 mg SC injection every 4 weeks
1701622|NCT01453725|Biological|Placebo|Placebo SC injection every 4 weeks
1701623|NCT01453712|Radiation|Control group|Conventional coronary CT angiography using standard reconstruction technique (filtered back projection).
1701624|NCT01453712|Radiation|Intervention group|Using the new scan protocol with 30 % less tube current and iterative image reconstruction algorithm.
1701625|NCT01453686|Drug|Hydrocortisone 1%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
1701626|NCT01453686|Drug|Clobetasol Propionate 0.05%|Topical cream, used twice daily for 6 weeks on affected area, followed by 6 weeks of no treatment, followed by an additional 6 weeks of the same intervention.
1701627|NCT01453660|Other|Endo-PAT2000 testing|Endo-PAT2000 testing is done six times during the study. Baseline Assessment Time 1 Cycle 1, Day 1 (Pre-chemotherapy)Time 2 Cycle 1, Day 1 (After 1st dose of cisplatin), Time 3 Cycle 1, Day 2 (Before second cisplatin dose of cycle 1), Time 4 Cycle 1, Day 5 (After last cisplatin dose of cycle 1), End-of-Study Assessment Time 5 (14-34 weeks from Time 1; e.g., 1-12 weeks following completion of the last cycle of first-line chemotherapy) Long-Term Follow Up Assessment Time 6 (24-30 months from Time 1)
1701628|NCT01453660|Other|Endo-PAT2000 testing|Time 1: A baseline assessment will be performed in the fasting state including Endo-PAT2000, vital signs, waist circumference, fasting blood draw, & urine sample. This will be considered Day 1 of the study for this group of patients. Time 2 (2-5 hours from Time 1): Two to five hours after Time 1, patients will undergo assessment of blood pressure & heart rate, including orthostatics & Endo-PAT2000 testing. Time 5 -- End of Study visit (14-34 weeks from Time 1): At a time point 14 to 34 weeks later than Time 1 patients will undergo study testing in the fasting state. This includes Endo-PAT2000 testing, vital signs including orthostatics, waist circumference, fasting blood draw, & urine sample. The Surgery-Only Group will not have any assessment at Time 3 (Day 2) or Time 4 (Day 5) due to logistical concerns. Long-Term Follow Up Assessment Time 6 (24-30 months following Time 1)
1701629|NCT01453647|Other|Guided Imagery|The intervention consists of three audio-recorded guided imagery scripts formatted as three separate tracks on one CD. Each track is 30 minutes in length and is to be used in a recommended order for the first 6 weeks of the intervention and then used in any order for the follow-up weeks, 7 through 10. Project participants will be instructed to use each CD track, as prescribed, a minimum of once daily. CD Track 1 is a basic relaxation entrainment script; CD track 2 is a pleasant scene imagery script; CD track 3 is a well body imagery script.
1701630|NCT01453634|Drug|Lunacalcipol 180|4 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
1701631|NCT01453634|Drug|Lunicalcipol 270|8 subjects are planned to receive a total of 11 doses of the study drug given three times per week (tiw) over 24 days (day 1 to day 24), administered not more often than every other day.
1701632|NCT01453621|Other|Computerized clinical decision support|Intervention sites will receive decision support regarding whether patient meets very low risk criteria for clinically-important traumatic brain injury based on the PECARN prediction rules.
1701633|NCT01453608|Drug|Ferinject (ferric carboxymaltose)|Subjects will receive Ferinject (ferric carboxymaltose) intravenously on Day 0
1701634|NCT01453608|Drug|Placebo (saline)|Subjects will receive Placebo (saline) intravenously on Day 0
1701635|NCT01453595|Drug|BEZ235|"BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.
Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily"
1701636|NCT01453582|Drug|Total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
1701637|NCT01453582|Drug|total Flavonoids of Propolis dropping pill|One pack contains 30 pills, weight 33g. One pack each time, three times a day, 14 days a course.
1701638|NCT01453569|Drug|Sodium oligo-mannurarate 600mg|sodium oligo-mannurarate capsule 600mg twice a day for 24 weeks
1701639|NCT01453569|Drug|Sodium oligo-mannurarate 900mg|sodium oligo-mannurarate capsule 900mg twice a day for 24 weeks
1701640|NCT01453569|Drug|Placebo|simulant of sodium oligo-mannurarate capsule
1701641|NCT01453556|Procedure|Laparoscopic right colectomy|Laparoscopic right colectomy with mechanical ileo-colon anastomosis L-L
1701642|NCT01453543|Other|deep transverse friction massage|For the application of the deep transverse friction massage, the participants were positioned supine with the ankle in 90 ° of dorsiflexion, in order to bring some tension on the tendon. The treating clinician stabilized the subject's foot with one hand while applying the DTF with the other hand. The deep friction massage is a pinching technique with thumb and index finger, reinforced by the middle finger.
1701646|NCT01453517|Behavioral|Behavioral intervention for regain after bariatric surgery|6 week intervention targeting dietary behavioral adherence, stress management, and distress tolerance skills to prevent weight regain
1701647|NCT01453504|Drug|DHAP|Dexamethasone, Cytarabine, Cisplatin
1701648|NCT01453504|Drug|Everolimus|
1701649|NCT01453491|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 25mg or 250 mg of micronized SRT2104 powder with no additional additives into a size 00 opaque, hard gelatin capsule. All subjects will be provided with one dosing bottle per day that contains two 25 mg or 250 mg SRT2104 capsules for oral ingestion.
1701650|NCT01453478|Drug|GSK1325756|CXCR2 antagonist
1701651|NCT01453465|Genetic|RNA analysis|
1701652|NCT01453465|Genetic|gene expression analysis|
1701653|NCT01453465|Genetic|polymerase chain reaction|
1701654|NCT01453465|Genetic|protein expression analysis|
1701655|NCT01453465|Other|laboratory biomarker analysis|
1701656|NCT01453452|Behavioral|behavioral dietary intervention|Reduce caloric intake by 500 kcal/day, increase fruit and vegetable intake to 5 or more servings per day, and limit daily calories from fat to be < 30%. Diet will be measured using 3 repeated 24-hr diet recalls. Participants will receive information on the recommended dietary modifications via mailed materials and telephone counseling sessions.
1701657|NCT01453452|Behavioral|exercise intervention|150 min/wk of moderate exercise through use of the Curves® centers, engage in physical activity outside of Curves®, and use pedometers to track activity.
1701658|NCT01453452|Other|counseling intervention|14 40-min behavioral counseling sessions via telephone with the goal of increasing intervention adherence and increasing participant retention.
1701659|NCT01453452|Procedure|quality-of-life assessment|PROMIS-43 - online questionnaire to assess quality of life.
1701660|NCT01453439|Behavioral|Cognitive Behavioral Therapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based CBT. During the sessions, participants will receive education about BDD and CBT, learn to develop more helpful thoughts and beliefs, gradually enter anxiety provoking situations while reducing compulsions (repetitive behaviors), and learn relapse prevention techniques.
1701661|NCT01453439|Behavioral|Supportive Psychotherapy|Participants will receive a total of 22 sessions (over 24 weeks) of individual, manual-based SPT. During the sessions, participants will receive education about BDD and SPT, learn about factors that may affect their symptoms (for example, relationships, work, stress), and learn to cope with challenges in their life by improving self-esteem and positive coping skills.
1701662|NCT01453426|Drug|BG00012 Dose 1|
1701663|NCT01453426|Drug|BG00012 Dose 2|
1701664|NCT01453413|Other|Blood Glucose meter|Staff tested subject Blood Glucose using a Blood Glucose meter.
1701665|NCT01453400|Drug|Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo|Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
1701666|NCT01453400|Drug|Acetaminophen + placebo|Single dose, 2 x 500 mg Acetaminophen caplets (1000 mg) + 2 x placebo fast release Aspirin tablets
1701667|NCT01453400|Drug|Placebo|Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
1701668|NCT01453387|Drug|MSC2015103B|Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
1701669|NCT01453387|Drug|MSC2015103B|Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
1701670|NCT01453374|Drug|VIVITROL 380mg|380 mg IM injection given once monthly
1701671|NCT01453361|Biological|Vigil™ Vaccine|
1701676|NCT01453309|Procedure|Cell Saver|Cell Savers are used intraoperatively to decrease the risk of transfusion due to surgical blood loss. Blood collected from the operative field is anticoagulated, filtered, and stored in a reservoir. Once a set volume of blood has been collected in the reservoir, the blood is separated into its red blood cell and plasma components by use of a centrifuge. Red blood cells are washed with a crystalloid solution and then reinfused into the patient.
1701677|NCT01453309|Procedure|No Cell Saver|Cell Saver will not be available during surgery
1701678|NCT01453296|Drug|GW642444|GW642444 25 μg; Novel dry powder inhaler
1701679|NCT01453296|Drug|Placebo|Matching placebo; Novel dry powder inhaler
1701680|NCT01453283|Drug|Trabectedin (ecteinascidin-743, ET-743, YONDELIS [R])|
1701681|NCT01453270|Device|NICOM|Assessment of fluid responsiveness will be done using the non-invasive cardiac output monitor (NICOM) and passive leg-raising (PLR) maneuver to target mean arterial pressure of between 65mmHg and 90mmHg; and change in stroke volume index (SVI) less than 10%, prior to administration of fluid boluses.
1701682|NCT01453270|Other|Usual care|Usual care is given at the clinician's discretion in accordance with current best practice. Standard treatment may involve treatment with intravenous fluids, and medications to support the blood pressure and heart.
1701683|NCT01453257|Drug|Tailored Chemotherapy|"Patients will be treated with Folfox, Folfiri, Xelox or Xeliri and Cetuximab or Bevacizumab at usual doses tailored by:
K-ras native: Cetuximab. K-ras mutated: Bevacizumab Topoisomera 1 positive ( Topo-1): Irinotecan Topo-1 positive and ERCC-1 negative: oxaliplatin Topo-1 1 negative and ERCC-1 positive: investigator option Thimidylate synthase (TS) positive: No Fluoropyrimidines (FLP) TS negative: FLP Thimidylate phosphorylasa (TP) positive: Capecitabine TP negative: 5-FU"
1701684|NCT01453231|Procedure|thighplasty|Plastic surgery of thigh
1701685|NCT01453218|Drug|ATeGe-Fresenius|Administered at 1 , 3, 5 and 7 day post-transplant at 2-3mg/kg with dose adjustment according to CD2/CD3 levels
1701790|NCT01452633|Drug|0.25% bupivicaine will be injected into the port site prior to closure|0.25% bupivicaine will be injected into the port site at closure without any preincisional intervention
1760472|NCT00284271|Drug|Bleomycin|
1701686|NCT01453205|Drug|MEDI-551|MEDI-551 at the assigned dose will be administered via Intravenous (IV) infusion. Subjects will receive 3 cycles of M-ICE or M-DHAP unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
1701687|NCT01453205|Drug|Rituximab|Rituximab at 375 mg/m2 will be administered via IV infusion 2 days before the start of Cycle 1 and on Day 1 of each cycle. The infusion time for rituximab will be 50 400 mg/hr, depending on subject's tolerance. Subjects will receive 3 cycles of Rituximab with Ice (R ICE) or Rituximab with DHAP (R-DHAP) unless CR is achieved at the end of Cycle 2, disease progression is noted at the end of Cycle 2, or a significant/serious drug related toxicity occurs (as per the opinion of the investigator).
1701688|NCT01453205|Drug|ICE|ICE will be administered via IV infusion as follows: ifosfamide 5 g/m2 continuously for 24 hours with mesna on Days 2 and 3; carboplatin AUC=5 mg/mL x min [800 mg maximum) on Day 2; etoposide 100 mg/m2 on Days 1, 2, and 3) in 21-day cycles.
1701689|NCT01453205|Drug|DHAP|DHAP will be administered via IV infusion as follows: dexamethasone 40 mg on Days 1, 2, 3, and 4; cisplatin 100 mg/m2 continuously for 24 hours on Day 1 of dosing cycle; cytarabine 2 g/m2 in 3-hour infusion repeated after 12 hours (2 doses) on Day 2 in 21-day cycles.
1701690|NCT01453205|Procedure|Autologous Stem Cell Transplant (ASCT)|Subjects who achieve CR or PR will undergo stem cell harvest and autologous stem cell transplantation (ASCT) following standard institutional protocols.
1701691|NCT01453192|Drug|Raltegravir|Introduction of Raltegravir 2 days after renal transplantation within an antiretroviral regimen without ritonavir boosted antiprotease
1701692|NCT01453179|Drug|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
1701693|NCT01453179|Drug|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
1701694|NCT01453166|Other|Brazilian heart-prevent meal|Nutrient profile of the diets used was based on the Brazilian guidelines to cardiovascular disease treatment.The main difference between this group involves a Brazilian version of accessible and energy density concept dietary therapy to cardiovascular diseases. Furthermore, it explores a set of tools and educational materials that help the patient understand and follow the principles of balanced and healthy diet weekly session with the dietitians which could be in person, by phone or in a gourmet shop. During attendances at the gourmet shop, patients received tips for eating in restaurants, instruction on label reading and a list of typical foods. The menus were based on typical foods consumed in Brazil, all foods included in the menu were low-cost and widely available at local markets
1701695|NCT01453166|Other|Heart prevent control meal weekly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts). The difference between groups B and C was the number of sessions with the dietician. Group B received weekly sessions, which could be in person or by phone, and group C had monthly in person sessions
1701696|NCT01453166|Other|Heart prevent control Meal monthly|received the usual dietary therapy to patients with cardiovascular diseases, which had the same nutrient profile as presented in Group A and B, but customized by the integration of mediterranean typical foods (e.g. olive oil and nuts) at the same of group B. The difference of group C was the number of sessions with the dietician. That happen monthly in person sessions.
1701697|NCT01453153|Drug|Gemcitabine|1000 mg/m2 given IV one time a week (Cycle 1: 7 weeks on treatment, 1 week off treatment; Cycle 2+: 3 Weeks on treatment, 1 week off treatment)
1701698|NCT01453153|Drug|PEGPH20+ gemcitabine|(Cycle 1: 7 weeks on treatment/1 week off treatment; Cycle 2+: 3 Weeks on treatment/1 week off treatment). Doses start at 1.0 mcg/kg and modified until recommended Phase 2 dose is determined. Gemcitabine given at 1000mg/m2. Treatment continues until occurrence of significant treatment-related toxicity, progressive disease, or discontinuation criteria are met
1701702|NCT01453127|Drug|I-123 Ioflupane solution injection prior to SPECT scan (DaTscan)|I-123 Ioflupane solution for injection into a living test subject. The iodine introduced during manufacture is a radioactive isotope, I-123, and it is the properties of this isotope that makes the solution visible to a gamma camera on SPECT imaging. I-123 has a half-life of approximately 13 hours and a gamma photon energy of 159 keV making it an good radionuclide for medical imaging. DaTscan is administered by intravenous cannula. The scan is carried out 3-6 hours post injection.
1701703|NCT01453127|Device|Single photon emission computed tomography (SPECT) scan|Single-photon emission computed tomography(SPECT)is a nuclear medicine tomographic imaging technique using gamma rays. It is very similar to conventional nuclear medicine planar imaging using a gamma camera. However, it is able to provide true 3D information. This information is typically presented as cross-sectional slices through the patient, but can be freely reformatted or manipulated as required.
1701704|NCT01453114|Behavioral|Cognitive Behavioral Therapy|CBT is administered for 12 sessions over the period of 16 weeks, followed by optional monthly sessions.
1701705|NCT01453101|Drug|Fludarabine monophosphate, melphalan, Bortezomib|"Fludarabine will be administered at a dose of 30/mg/m2 IV daily for 4 days starting on transplant day -5.
Melphalan will be administered at a dose of 140 mg/m2 on transplant day-2
Bortezomib will be administered by rapid IV push at a dose of 1.6mg/m2 on days-4 and -1. The bortezomib should be given at least 20 hours after the melphalan."
1701706|NCT01453088|Drug|Melphalan|"Melphalan is administered at a dose of 200mg/m2 by rapid intravenous infusion via a central or peripheral vein over 30 minutes to one hour.
Melphalan will be given as a single dose (not split over 2 or more days) and given on day-1.
Dosing will be based on body surface area calculated using actual body weight
Stem cell infusion:
Stem cell infusion will occur on day 0 and will be at least 20 hours after the infusion of melphalan. The infusion of peripheral blood stem cells will be done in accordance with the Blood and Marrow Transplant program standard operating procedures.
Filgrastim will be administered at a dose of 5 mcg/kg (rounded to vial size) every other day starting on day+3 then daily starting on day 9 until engraftment (at least)."
1701707|NCT01453088|Drug|Bortezomib|"Bortezomib:
Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line. Bortezomib will be administered any time on day -4 and at least 20 hrs after the start of the melphalan infusion on day -1."
1701708|NCT01453075|Drug|Valacyclovir|Valacyclovir 1.5 mg po bid
1701709|NCT01453075|Drug|Placebo|Matching placebo twice daily
1701710|NCT01453062|Drug|Arzerra|Treatment with Arzerra
1701711|NCT01453049|Drug|rosiglitazone/glimepiride fix dose combination|oral, once daily, dosage is titrated according to FPG and hypoglycemia events
1701712|NCT01453049|Drug|glimepiride|oral, once daily, dosage is titrated according to FPG and hypoglycemia
1701713|NCT01453036|Procedure|23S rRNA point mutation test of Helicobacter pylori|mutation test group>> Helicobacter pylori polymerase chain reaction kit by dual-priming oligonucleotide-based multiplex polymerase chain reaction system before eradication of Helicobacter pylori at mutation test groupConventional Conventional AOC group, Conventional AOM group >> no intervention
1701714|NCT01453036|Procedure|UBT test & Gastroenterology with biopsy c silver stain|UBT test & Gastroenterology with biopsy c silver stain due to indentify H. pylori infection Conventional AOM group, Conventional AOC group, Mutation test group >> intervention
1701715|NCT01453023|Drug|Fluticasone Furoate|100mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
1701716|NCT01453023|Drug|Fluticasone Furoate/Vilanterol|100/25 mcg delivered via a novel dry powder inhaler on days 1-14 of one study treatment period.
1701718|NCT01452997|Drug|NSAI treatment|Ibuprofen 5% gel
1701719|NCT01452997|Drug|Steroid treatment|Steroid intervention with 0.05% w/w clobetasone butyrate.
1701720|NCT01452958|Biological|TNF-alpha|Study protocol 1: 6 ng/kg/h intraarterial Study protocol 2: 18 ng/kg/h intravenous
1701721|NCT01452958|Biological|Endotoxin|Study protocol 2:0,075 ng/kg/h intravenous
1701722|NCT01452932|Other|Physiotherapy|"The physiotherapeutic intervention was based on the Kabat (PNF) technique. Thirty-three sessions were planed. Each session lasted between thirty and fifty minutes.
The experimental group was guided by a physiotherapist or a physiotherapy student and each session took place in a hospital auditorium provided with oxygen cylinders, chairs and water.
Each session consisted of a warm up and stretch period, a period of resistance training of the upper limbs with their rest periods in which diaphragmatic breathing exercises and finally a cooling period.
The instructions and instruments given to each participant such as weights and elastic bands were the same for all of them."
1701723|NCT01452932|Other|Yoga|"The intervention for the other group was the Yoga technique. Thirty-six sessions were planed. Each session was based on breathing, relaxation, and stretching exercises. Each session lasted between thirthy and forty minutes.
The group was led by a Yoga Instructor and each sessions took place in a hospital auditorium provided by oxygen cylinders, chairs and water.
No instruments were needed for this intervention."
1701724|NCT01452919|Drug|LY2140023|Administered orally
1701725|NCT01452919|Drug|Placebo|Administered orally
1701726|NCT01452906|Drug|PA21 and Omeprazole with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day
1701727|NCT01452906|Drug|No PA21; Omeprazole with food|The maximum dosage of Omeprazole will be 40 mg/day
1701728|NCT01452906|Drug|PA21 with food, Omeprazole 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day
1701729|NCT01452893|Procedure|Spiroergometry|"At visit 1 determination of the individual VO2max (maximal oxygen uptake) by spiroergometry after first testing of cognitive function.
At visit 2: Spiroergometry with 3 min warm up followed by 5 min 50% VO2max and 15 min at the individual respiratory compensation point (RCP)."
1701730|NCT01452880|Drug|Remifentanil|Remifentanil is an ultra-short-acting oppioid, which is quickly metabolized by unspecific blood and tissue esterases
1701731|NCT01452880|Drug|Remifentanil|GROUP A (N = 114): patients assigned to this group received Remifentanil at infusion rate of 0.05 mcg / kg / min I.V. ; GROUP B (N = 114): in this group Remifentanil was administered at infusion rate of 0,1 mcg / kg / min I.V. Remifentanil was administered intravenously throughout ESWL procedure.
1701732|NCT01452867|Device|Bag-Valve-Mask-Ventilation (Ambu Facemask)|Bag-Valve Mask-Ventilation
1701733|NCT01452867|Device|Laryngeal Mask (Laryngeal Mask Airway Supreme)|Ventilation
1701734|NCT01452867|Device|Laryngeal Tube (Laryngeal Tube LT-S-D (VBM))|Ventilation
1701735|NCT01452841|Other|Grapefruit|1.5 Rio Red Grapefruit consumed daily for 6 weeks
1701736|NCT01452841|Other|Control|Participants followed a diet low in bioactive rich fruits and vegetables and avoided citrus for six weeks
1701737|NCT01452828|Drug|TR-701 FA single infusion|Single IV infusion, 200 mg daily for 7 days
1701738|NCT01452828|Drug|TR-701 FA|Two separate infusions of 200 mg
1701739|NCT01452828|Drug|TR-701 FA|Single IV infusion, 200 mg daily for 7 days
1701740|NCT01452815|Drug|Placebo|Two #2 oval shaped,opaque-white, hard gelatin shell capsules containing inactive ingredients taken orally once daily for 12 weeks.
1701741|NCT01452815|Drug|10mg TZP-102|One 10mg #2 oval shaped, opaque-white, hard gelatin shell capsule containing active ingredients and one placebo capsule each taken orally once daily for 12 Weeks
1701742|NCT01452815|Drug|20mg TZP-102|Two 10mg #2 oval shaped, opaque-white, hard gelatin shell capsules containing active ingredients
1701791|NCT01452607|Drug|SPI-1005|200 mg Ebselen oral capsules (SPI-1005), single dose
1760701|NCT00275366|Device|Robotic Therapy|
1701743|NCT01452802|Device|HM II (HeartMate II LVAD)|The HM II pump contains a single moving component, the rotor. The pump is implanted just below the left hemidiaphragm with the inflow attached to the apex of the left ventricle and the outflow graft anastomosed to the ascending aorta. Blood is pumped continuously throughout the cardiac cycle from the left ventricle to the aorta.
1701744|NCT01452802|Drug|OMM (Optimal Medical Management)|Optimal medical management per established heart failure guidelines for this subject population including ACE inhibitors, beta blockers and aldosterone antagonists 45 out of the last 60 days or an inability to tolerate neurohormonal antagonists.
1701745|NCT01452789|Drug|sublingual buprenorphine|Initial daily dose: 15.9 mcg/kg/day; Initial unit dose: 5.3 mcg/kg q8 hours; Maximum daily dose: 60 mcg/kg/day; Up-titration rate: 25%; Weaning rate: 10%; Cessation Dose: Within 10 or 20% of starting dose
1701746|NCT01452789|Drug|oral morphine|Initial daily dose: 0.4 mg/kg/day; Initial unit dose: 0.07 mg/kg q 4 hours; Maximum daily dose: 1.25 mg/kg/day; Up-titration rate: 20%; Weaning rate: 10%; Cessation Dose: 0.025 mg/kg q 4 hours
1701747|NCT01452776|Drug|TAK-438|TAK-438 10 mg, tablets, orally, once daily for up to 52 weeks.
1701748|NCT01452776|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 52 weeks.
1701749|NCT01452763|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
1701750|NCT01452763|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
1701751|NCT01452763|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
1701752|NCT01452763|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
1701753|NCT01452763|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
1701754|NCT01452763|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
1701755|NCT01452750|Drug|TAK-438|TAK-438 10 mg tablets, orally, once daily for up to 24 weeks.
1701756|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
1701757|NCT01452750|Drug|TAK-438|TAK-438 20 mg tablets, orally, once daily for up to 24 weeks.
1701758|NCT01452750|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 24 weeks.
1701759|NCT01452750|Drug|Lansoprazole|Lansoprazole 15 mg capsules, orally, once daily for up to 24 weeks.
1701760|NCT01452750|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 24 weeks.
1701761|NCT01452737|Drug|Standard Bowel Prep|Subjects will be asked to take 4L of Golytely the day prior to procedure.
1701762|NCT01452737|Drug|2L Golytely/bisacodyl|Subjects will be asked to take 2L Golytely and 15mg bisacodyl the day prior to procedure.
1701763|NCT01452724|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 6 weeks.
1701764|NCT01452724|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 6 weeks.
1701765|NCT01452724|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 6 weeks.
1701766|NCT01452724|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 6 weeks.
1701767|NCT01452711|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
1701768|NCT01452711|Drug|Placebo|Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
1701769|NCT01452711|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
1701770|NCT01452711|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
1701771|NCT01452698|Drug|TAK-438|TAK-438 20 mg, tablets, orally, once daily for up to 8 weeks.
1701772|NCT01452698|Drug|Placebo|"Lansoprazole placebo-matching capsules, orally, once daily for up to 8 weeks.
For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
1701773|NCT01452698|Drug|Lansoprazole|"Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
For participants whose EE is not endoscopically healed at Week 8, the participants will receive additional treatment of TAK-438 40 mg, tablets, orally, once daily for up to an additional 8 weeks."
1701774|NCT01452698|Drug|Placebo|TAK-438 placebo-matching tablets, orally, once daily for up to 8 weeks.
1701775|NCT01452685|Drug|Placebo|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
1701776|NCT01452685|Drug|TAK-385|TAK-385 10 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
1701777|NCT01452685|Drug|TAK-385|TAK-385 20 mg, tablets orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
1701778|NCT01452685|Drug|TAK-385|TAK-385 40 mg, tablets, orally, once daily and leuprorelin acetate placebo injection, subcutaneously, once every 4 weeks for up to 12 weeks.
1701779|NCT01452685|Drug|Leuprorelin acetate|TAK-385 placebo-matching tablets, orally, once daily and leuprorelin acetate 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks
1701780|NCT01452672|Radiation|Radiotherapy|RT 40 Gy in 15 fractions
1701781|NCT01452672|Radiation|Irradiation of the chest-wall and supraclavicular fossa|RT 40Gy in 15 fractions
1701782|NCT01452659|Drug|TAK-385|TAK-385 10 mg, tablets, orally, once daily for up to 12 weeks.
1701783|NCT01452659|Drug|TAK-385|TAK-385 20 mg, tablets, orally, once daily for up to 12 weeks.
1701784|NCT01452659|Drug|TAK-385|TAK-385 40 mg, tablets, orally, once daily for up to 12 weeks.
1701785|NCT01452659|Drug|Placebo|TAK-385 placebo-matching tablets, orally, once daily for up to 12 weeks.
1701787|NCT01452633|Drug|0.25% bupivicaine will be injected at the study port site prior to incision|Injection will precede the incision
1701788|NCT01452633|Drug|Saline will be injected at the study port site prior to incision|Injection will precede incision
1701795|NCT01452581|Other|Red blood cell transfusion|Maximal 2 units of packed red blood cells given one at a time on the first postoperative day. Evaluation of primary outcome is done after administration of each unit.
1701796|NCT01452581|Drug|Voluven|Infusion of up to 2 x 280 ml colloid (6% Hydroxyethyl Starch 130/0.4 in 0.9% Sodium Chloride). 280 ml at a time. Evaluation of primary outcome after each intervention.
1701797|NCT01452568|Drug|Aspirin|150mg/daily for three months, starting day after surgery
1701798|NCT01452568|Drug|Warfarin|Warfarin daily dosage to obtain an INR in between 2,0 to 3,0. Started the day after surgery and continued for three months.
1701799|NCT01452555|Behavioral|Video or In-Person Presentation|Participants will be randomly assigned to an in person counseling session or will watch a HIV and HIV testing video
1701800|NCT01452542|Drug|Eliglustat, common blend proposed commercial formulation|All participants will receive a single oral 150-mg dose of the common blend proposed commercial formulation of eliglustat, administered as one 150-mg strength capsule (Treatment T), on 2 separate dosing occasions.
1701801|NCT01452542|Drug|Eliglustat, Phase 3 capsule formulation|All participants will receive a single oral 150-mg dose of the Phase 3 capsule formulation of eliglustat, administered as three 50-mg strength capsules (Treatment R), on 2 separate dosing occasions.
1701806|NCT01452503|Device|Path Women's Condom|comparison between 3 types of female condoms
1701807|NCT01452503|Device|FC2 female condom|comparison between 3 types of female condoms
1701808|NCT01452503|Device|Reddy 6 female condom (V-Amour)|comparison between 3 types of female condoms
1701809|NCT01452490|Device|Diode Laser Treatment|Laser treatment once every 6 weeks, for a total of 4 treatment sessions
1701810|NCT01452477|Drug|tanshinone|tanshinone 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
1701811|NCT01452477|Drug|tanshinone placebo|placebo 1.0g / time, 3 times / day orally, continuous treatment for 12 weeks.
1701812|NCT01452464|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
1701813|NCT01452451|Drug|HM11260C|1, 2, and 4 mg for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. 8, 12 and 16 mg for 3 monthly subcutaneous injections for cohorts M1, M2 and M3
1701814|NCT01452451|Drug|Placebo|Placebo for 8 weekly subcutaneous injections for cohorts W1, W2 and W3. Placebo for 3 monthly subcutaneous injections for for cohorts M1, M2 and M3
1701815|NCT01452438|Biological|MenACWY-CRM|MenACYW-CRM vaccination received as part of routine clinical care and as registered in the vaccine records.
1701816|NCT01452425|Device|Tourniquet|Inflation of a tourniquet (pressure equal to the mean arterial pressure) obtaining a model of slight venous congestion and arterial hypoperfusion
1701817|NCT01452425|Device|INVOS assessment|Near Infraread spectroscopy, non invasive
1701818|NCT01452425|Device|EMG assessment|Electromyography, non invasive
1701819|NCT01452412|Drug|Sodium bicarbonate|0.4 mEq/kg/day ideal body weight to be taken once a day
1701820|NCT01452412|Drug|Placebo|To be taken on the same schedule as the active arm
1701823|NCT01452373|Drug|Placebo|Placebo DHEA capsules (2) + placebo acolbifene capsule (1); daily oral dosing for 12 weeks.
1701824|NCT01452373|Drug|DHEA and Acolbifene|DHEA capsules (2 x 50 mg) + acolbifene capsule (1 x 20 mg); daily oral dosing for 12 weeks.
1701825|NCT01452347|Drug|warfarin 1mg|comparator warfarin
1701826|NCT01452347|Drug|dabigatran etexilate intermediate dose|active treatment (medium)
1701827|NCT01452347|Drug|dabigatran etexilate low dose|active treatment (low)
1701828|NCT01452347|Drug|warfarin 5mg|comparator warfarin
1701829|NCT01452347|Drug|dabigatran etexilate high dose|active treatment (high)
1701830|NCT01452347|Drug|warfarin 3mg|comparator warfarin
1701831|NCT01452334|Biological|BMS-936559 (Anti PD-L1)|Injection for infusion, Intravenous (IV), 1, 3 or 10 mg/kg, Every 2 weeks, 48-96 weeks depending on response
1701832|NCT01452321|Procedure|repetitive transcranial magnetic stimulation (rTMS)|"20 daily sessions: each with 25 trains of 10 seconds at 5Hz, with a 20 second inter-train interval, at an intensity of 120% of motor threshold.
Site: Left Dorsolateral Prefrontal Cortex"
1701833|NCT01452308|Biological|Simtuzumab|
1701834|NCT01452295|Drug|ELAD (Extracorporeal Liver Assist System)|ELAD (Extracorporeal Liver Assist System)
1701835|NCT01452269|Behavioral|Deaf Weight Wise program|"Groups will consist of approximately 13 subjects who meet for 2 hours a week for 16 weeks. Group sessions will be offered at a variety of times and days of the week. A trained, deaf, ASL-fluent counselor will lead the sessions.
Subjects will be asked to complete a food and physical activity diary. Each intervention session will include a weigh-in, group sharing/problem solving, discussion of a weight management topic, and goal setting/action planning for the next week. Periodically, each subject will receive a Personal Feedback Report. Subjects will be able to earn points for complying with various aspects of the program. Points can be redeemed for small prizes (i.e. water bottles).
The maintenance phase consists of two meetings at the beginning of the 6-month maintenance period and three months later. This will consist of a weigh-in, review of self-monitored diet and physical activity, problem solving and goal setting/action planning for their long-term program."
1701836|NCT01452256|Drug|Desflurane|4-6 Vol %
1701837|NCT01452256|Drug|Propofol|TIVA to achieve BIS value of 40-60
1701838|NCT01452243|Drug|Vitamin D and calcium suplementation|The pharmacological intervention will be the daily administration of chewable tablets containing 800 IU of vitamin D and 1200 mg of calcium. They will be administered over 2 years during the months of November to April in order to avoid the influence of sunlight.
1702335|NCT01448395|Drug|[14C]NXL104|500mg/100mL intravenous solution
1701840|NCT01452217|Drug|Secretin|Secretin 1 IU/kg over 3 min
1701841|NCT01452204|Other|Pulsed Electromagnetical Field and Exercise|G1: MT, three times per week lasting 30' each session. G2: placebo MT, 3 X week lasting 30'each session. After 3 weeks of application of MT, will begin a program of exercises.
1701842|NCT01452191|Behavioral|Injury Prevention Briefing Plus facilitation|Injury Prevention Briefing (IPB) to provide best evidence on what works to reduce house fire injuries, and activities to get the evidence into practice. This arm will receive facilitation to support the implementation of the information in the IPB
1701843|NCT01452191|Behavioral|Injury Prevention Briefing|Children's centres will receive the Injury Prevention Briefing only.
1701844|NCT01452152|Drug|clopidogrel|clopidogrel 75 mg/day plus aspirin 81-162 mg/day for one year
1701845|NCT01452152|Drug|prasugrel|Prasugrel 5-10 mg/day plus aspirin 81-162 mg/day for one year
1701846|NCT01452139|Genetic|Point-of-Care Genetic Testing|Point-of-Care Genetic Testing for Genetic Variants Linked to Adverse Outcomes with Clopidogrel (CYP2C19*2 & ABCB1 3435 TT)
1701847|NCT01452139|Drug|Prasugrel|Treatment of STEMI patients carrying at least one high risk genetic variant with prasugrel 10mg daily.
1701848|NCT01452126|Drug|Ropivacaine concentration|Single shot preoperative perineural injection of ropivacaine to achieve surgical anesthesia. The concentration of ropivacaine is lowered by 0.05% after every successful surgical anesthesia specific to that block and raised by 0.05% after every unsuccessful surgical anesthesia specific to that block
1701849|NCT01452113|Drug|Vildagliptin|one 50 mg tablet per os
1701850|NCT01452100|Drug|prednisone|Patients enrolled into the study will be treated with prednisone, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
1701851|NCT01452100|Other|placebo|• Patients enrolled into the study will be treated with placebo, 20 mg/day (if body weight <70 kg ; or 25mg/d if body weight >70 kg) for 1 month, then tapered to 12.5 mg/d (month 2) and 7.5 mg/d (month 3) and stop. In both groups, patients will be treated according to expert advice including use of statins (according to French Health Agency recommendation), a RAS inhibitor and supportive treatment (including nutrition, treatment of heart failure, and dialysis).
1701852|NCT01452087|Other|Exercise|Subjects will exercise on a treadmill for 1 hour at moderate intensity (i.e., 90% of the exercise intensity found to elicit their ventilatory threshold during the preliminary testing, which is equivalent to approximately 60% of their maximal predicted heart rate).
1701853|NCT01452074|Other|Exercise Training|During the first 12 weeks of the study, subjects will adhere to an exercise training program while maintaining their original body weight. The exercise training program will entail the following: 40min/session, ~50% of their maximal aerobic capacity (approximately 100-110 beats per min), 5-6 days/week
1701854|NCT01452074|Other|Weight Loss with continued Exercise Training|After the first 12 weeks in the study, subjects will continue with the same exercise program, but then they will be placed on a reduced calorie diet until they lose exactly 10% of their original body weight
1701855|NCT01452035|Other|Exercise|single session of exercise
1701856|NCT01452022|Device|Inductigraft|Synthetic bone graft
1701857|NCT01452009|Drug|Travoprost Ophthalmic Solution, 0.004% (New Formulation)|Travoprost Ophthalmic Solution, 0.004% given one drop once daily
1701858|NCT01452009|Drug|TRAVATAN®|TRAVATAN® administered one drop once daily
1701859|NCT01451996|Drug|Claritin|Subject will be given 10mg Claritin tablet.
1701860|NCT01451970|Other|High Fat Diet|Subjects will adhere to their specific diet for four weeks. For both diet treatments, the diet will be a weight-maintaining diet, and the target nutrient composition for diets will be 55% carbohydrate, 30% fat, 15% protein. For the monounsaturated fat treatment (M diet) approximately 10% of all lipids ingested will be saturated. For the saturated fat treatment (S diet) approximately 40% of all lipids ingested will be saturated.
1701861|NCT01451957|Other|Exercise - caloric balance|90 min exercise on Day 1 with meals afterward resulting in caloric balance for the day (i.e.; extra kcals provided to account for energy expended during exercise)]
1701862|NCT01451957|Other|No Exercise - hyper-caloric diet|Subjects remain sedentary on Day 1 and they ingest meals that are identical to those ingested on the day they performed exercise (i.e.; more calories ingested than expended because no exercise performed).
1701863|NCT01451957|Other|No exercise - caloric balance|Subjects remain sedentary on Day 1 and they ingest a similar proportion of macronutrients however, the total calories ingested will be lower than the other two trials, resulting in caloric balance for the day.
1701864|NCT01451944|Behavioral|education|home asthma case management and education
1701865|NCT01451931|Other|Point-of-care Ultrasound|Perform ultrasonography in the ED (physician).
1701866|NCT01451931|Radiation|Radiology Ultrasound|Diagnostic ultrasound completed in the radiology department at time 0.
1701867|NCT01451931|Other|Radiology CT|Computed tomography of abdomen completed in the radiology department at time 0.
1701868|NCT01451918|Drug|Resveratrol|500mg bid for one week followed by 1 gram bid for one week prior to lipoprotein study.
1701869|NCT01451905|Drug|Liraglutide|Victoza® is supplied in pens for injection containing 18 mg of the GLP-1 agonist liraglutide in 3 mL sterile water with disodiumphosphate and propylene glycol, and phenol for conservation (pH 8.15). Commercial pens will be used and the information given in the packaging will be applicable. The initial daily dose will be 0.6 mg for one week, 1.2 mg the following week and then 1.8 mg for the remaining treatment period. The injection is administered once daily in the morning. The maximal plasma concentration is reached 8-12 hours after subcutaneous injection. The half-life in plasma is approximately 13 hours. The duration of effect is 24 hours.
1701870|NCT01451905|Drug|Placebo|The placebo pens contain saline and are administered in the same way and volume as Victoza. The placebo pens are specially prepared for this study and will be used in the study only
1701871|NCT01451892|Other|Dance Therapy|overweight individuals participating in a patient education program for obese people combined with specific dance-therapy
1701872|NCT01451892|Other|patient education|overweight individuals participating in a patient education program
1760702|NCT00275379|Drug|ERB-041|
1701873|NCT01451879|Drug|Rituximab|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
1701874|NCT01451879|Drug|Miglustat|Clinically prescribed immune modulation regimen dosage determined by local medical provider.
1701875|NCT01451866|Other|resistance training|hypertrophic resistance training
1701876|NCT01451866|Other|complex resistance training|complex resistance training with speed, excentric and power-endurance elements
1701877|NCT01451853|Drug|SPI-1005 Low Dose|"Oral capsules, 200 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
Arms: Low Dose
Other Names:
200 mg Ebselen"
1701878|NCT01451853|Drug|SPI-1005 Middle Dose|Oral capsules, 400 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
1701879|NCT01451853|Drug|SPI-1005 High Dose|Oral capsules, 600 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
1701880|NCT01451853|Drug|Placebo|Oral capsules, 0 mg ebselen, twice daily, 3 days for each cycle of chemotherapy
1701881|NCT01451840|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.25 mcg/kg given once before emergence of general anesthesia
1701882|NCT01451840|Drug|Alkalinized lidocaine|Administration of alkalinized lidocaine in the endotracheal tube cuff
1701883|NCT01451827|Drug|Tolvaptan MR|50/80 mg capsules
1701884|NCT01451827|Drug|Tolvaptan IR|60/30 mg capsules
1701885|NCT01451827|Drug|Placebo|tablet
1701886|NCT01451814|Behavioral|Positive Psychotherapy for smoking cessation|6 sessions of individual behavioral smoking cessation counseling that incorporates techniques from Positive Psychotherapy to increase positive affect and reduce negative affect prior to and after quitting smoking. Intervention includes 8 weeks of transdermal nicotine patch.
1701887|NCT01451814|Drug|Nicotine polacrilex|8 weeks of nicotine patch
1701888|NCT01451814|Behavioral|Relaxation training|Instructions in progressive muscle relaxation
1701889|NCT01451814|Behavioral|Behavioral smoking cessation treatment|Counseling on techniques to manage triggers and avoid smoking
1701890|NCT01451801|Biological|Twinrix|"A total of 400 healthy volunteers receive a standard course of immunization with a combined hepatitis A and B vaccine (Twinrix®) at 0, 1, and 6 months.
Twinrix ® Adult suspension for injection. 1 ml contains 720 ELISA units of hepatitis A virus antigen adsorbed to aluminum hydroxide and 20 micrograms hepatitis B surface antigen (HBsAg) adsorbed to aluminum phosphate in sterile water. Excipient: sodium chloride. Contains traces of neomycin."
1701891|NCT01451788|Device|Gelatin matrix with human derived thrombin (Floseal, Baxter)|Floseal will be used to stop cancellous bone bleeding, pedicle channel bleeding or epidural space bleeding by injecting suitable amount of this matrix and irrigating it away after few minutes.
1701892|NCT01451775|Drug|Empagliflozin|high dose of empagliflozin after overnight fasting for at least 10 h
1701893|NCT01451775|Drug|Empagliflozin|low dose empagliflozin after overnight fasting for at least 10 h
1701894|NCT01451775|Drug|Empagliflozin|high dose of empagliflozin after a standardised high fat breakfast
1701895|NCT01451762|Drug|.9 normal saline|.9 normal saline administered before surgery.
1701896|NCT01451762|Drug|25 mg diphenhydramine IV|25 mg diphenhydramine IV administered before surgery
1701897|NCT01451762|Drug|50 mg diphenhydramine IV|50 mg diphenhydramine administered IV before surgery
1701898|NCT01451749|Drug|Shenwu Capsule|"1 shenwu capsule contains 451 mg extract from herbs.5 capsules/time, 3 times/day for 6 months.
Placebo identified to donepezil: 1 tablet per time, 1 time per day for 6 months."
1701899|NCT01451749|Drug|Donepezil|"This active drug is donepezil 5 mg tablet. 1 tablet/time, 1 time/day for 6 months.
Placebo identical to shenwu capsules,5 capsules/time,3times/day for 6months."
1701900|NCT01451736|Drug|paliperidone palmitate|long-acting injectable
1701901|NCT01451736|Drug|risperidone|oral
1701902|NCT01451723|Drug|Polyphenon E|Polyphenon E is a standardized green tea extract. For this study we will use capsules of Polyphenon E containing 200 mg of EGCG per capsule. Subjects will take two capsules twice a day with food.
1701903|NCT01451723|Other|Placebo|Matching placebo capsules
1701904|NCT01451710|Drug|Prednisone or Prednisolone|daily single dose of 1mg/kg (maximum 80mg) or alternate day single dose of 2mg/kg (maximum 120mg),maintained for a minimum period of 6 weeks and maximum period of 12 weeks. After achieving complete remission., corticosteroids should be tapered slowly, 10mg every two weeks tapered to reach 0.15mg/kg/d, then 2.5mg every two to four weeks tapered to reach the minimum dosage 10mg/ alternate day
1701905|NCT01451697|Behavioral|Cognitive Remediation|A computerized cognitive remediation program focused on attentional training will be used.
1701906|NCT01451697|Behavioral|Control (Placebo)|The control condition will involve relaxation training.
1701907|NCT01451658|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
1701908|NCT01451645|Drug|Colchicine (Colcrys®)|daily 0.6 mg colchicine dosing for 16 weeks
1701909|NCT01451645|Drug|placebo|daily placebo dosing for 16 weeks
1701910|NCT01451645|Drug|allopurinol|background therapy
1701911|NCT01451632|Drug|MM-121|escalating doses MM-121 IV QW
1701912|NCT01451632|Drug|Irinotecan|180 mg/m2 IV Q2W
1701913|NCT01451632|Drug|Cetuximab|escalating doses cetuximab IV QW
1701914|NCT01451619|Drug|Laropiprant|One 100-mg tablet orally once daily for 4 weeks
1701915|NCT01451619|Drug|Placebo for Laropiprant|One tablet orally once daily for 4 weeks
1701916|NCT01451606|Drug|Duloxetine|30 mg dose once daily, administered orally for 1 week, 60 mg dose once daily, administered orally for 5 weeks, 30 mg dose once daily, administered orally for 1 week
1701917|NCT01451606|Drug|Placebo|To serve as placebo for duloxetine. Administration schedule same as for active drug.
1701918|NCT01451593|Drug|Phenytoin|Phenytoin will be loaded using at total dose of 15mg/kg (rounded to the nearest 100mg) divided into three equal doses given once daily for 3 days.This will be followed by a daily maintenance dose of 4mg/kg once a day (rounded up to the nearest 50mg, with a maximum dose of 300mg)for 13 weeks.Phenytoin levels will be taken at 1 and 3 months.
1701919|NCT01451593|Drug|Placebo|placebo identical in appearance to active IMP (phenytoin)
1701920|NCT01451580|Drug|Lipo-Dox|
1701921|NCT01451567|Behavioral|Ergonomic plan|participants in the intervention group were evaluated by the REBA and received an overall coaching that stretched over four meetings Each session paid special attention to, and included explanations about, the anatomy and physiology of body regions
1701922|NCT01451554|Behavioral|portion control plate|Individuals are provided with a portion control plate to use while eating and dietary counseling by dietician
1701923|NCT01451554|Behavioral|Usual Care|self-help booklets
1701924|NCT01451541|Drug|Ciclesonide nasal aerosol 37 mcg|ciclesonide nasal aerosol 37mcg - the dose is administered as 1 actuation per nostril to give a total dose of 37
1701925|NCT01451541|Drug|ciclesonide nasal aerosol 74 mcg|ciclesonide nasal aerosol 74 mcg - the dose is administered as 1 actuation per nostril to give a total dose of 74 mcg
1701926|NCT01451541|Drug|Placebo|Placebo - one dose per nostril
1701927|NCT01451528|Biological|Allogeneic Umbilical Cord Blood|Allogeneic Umbilical Cord Blood Transplantation via Intravenous or Intraarterial route
1701928|NCT01451515|Drug|Prednisone|Given orally (PO).
1701929|NCT01451515|Drug|Vincristine|Given intravenously (IV).
1701930|NCT01451515|Drug|Daunorubicin|Given IV.
1701931|NCT01451515|Drug|PEG-asparaginase|Given intramuscularly (IM) or IV.
1701932|NCT01451515|Drug|Erwinia asparaginase|Given IM or IV if allergy occurs with the first or second PEG-asparaginase dose.
1701933|NCT01451515|Drug|Doxorubicin|Given IV.
1701934|NCT01451515|Drug|Cyclophosphamide|Given IV.
1701935|NCT01451515|Drug|Cytarabine|Given IV or IT.
1701936|NCT01451515|Drug|Thioguanine|Given PO.
1701937|NCT01451515|Drug|Clofarabine|Given IV.
1701938|NCT01451515|Drug|Methotrexate|Given IV or IT.
1701939|NCT01451515|Drug|Mercaptopurine|Given PO.
1701940|NCT01451515|Drug|Dexamethasone|Given PO or IV.
1701941|NCT01451515|Drug|Hydrocortisone|Given IT.
1701942|NCT01451515|Drug|Etoposide|Given IV.
1701943|NCT01451502|Biological|Umbilical Cord Blood (UCB)|Infusion of Minimally Manipulated UCB Units - the UCB unit will be infused through a central line according to institutional guidelines.
1701944|NCT01451489|Drug|FK506|FK506:0.05-0.1mg/kg/d
1701945|NCT01451489|Drug|Cyclophosphamide|CTX 750mg/m2 per month in the induction phase,then 750mg/m2 every 2 month for 3 times,then 750mg/m2 every 3 months.
1701946|NCT01451450|Drug|QGE031|QGE031 liquid for subcutaneous injection.
1701947|NCT01451450|Drug|Placebo|Placebo liquid for subcutaneous injection.
1701948|NCT01451437|Drug|MK-8242|MK-8242 capsules, orally, once per day on Days 1-7 and Days 15-21 of each 28-day cycle (except Cycle 1 Day 7) up to a maximum of 12 cycles. Starting dose will be 30 mg and will be escalated in successive cohorts until maximum tolerated dose (MTD) is established. Beginning at a dose level of ≥120 mg total daily dose (TDD), the dosing regimen will switch to twice daily (BID). Amendment 4 added a 21-day dosing cycle in which MK-8242 would be given BID on Days 1-7 of each cycle, at the assigned dose level.
1701949|NCT01451424|Drug|Proellex|vaginal suppository, daily, for 12 weeks
1701950|NCT01451411|Drug|Conivaptan hydrochloride|Intravenous
1701951|NCT01451411|Drug|Placebo|Intravenous
1701952|NCT01451398|Drug|Technosphere® Insulin|Technosphere® Insulin Inhalation Powder
1701953|NCT01451398|Drug|Technosphere Powder|Placebo Comparator
1701954|NCT01451385|Drug|COV795|2 tablets COV795 taken every 12 hours
1701955|NCT01451359|Device|EndoBronchial Valve|The implantable IBV™ device is a one-way valve, designed for placement in selected regions of the bronchial tree using a flexible bronchoscope.
1701956|NCT01451346|Dietary Supplement|B. Infantis 35624|One sachet daily for 12 weeks
1701957|NCT01451333|Drug|Efavirenz|600mg qd; 3 x 200mg qd
1701958|NCT01451333|Drug|Efavirenz|400mg qd; 2 x 200mg
1701959|NCT01451320|Drug|Streptokinase|3-hour infusion of 1.5 million units of streptokinase (16 patients, 16 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units)
1701960|NCT01451320|Drug|Streptokinase|24-hour infusion of 1.5 million units of streptokinase (41 patients, 41 episodes), repeat once 24 hours later if needed (maximum total dose 3 million units).
1701961|NCT01451320|Drug|Tissue plasminogen activator|5-hour infusion of 90 mg t-PA (Tissue plasminogen activator) after 10 mg bolus (10 patients, 12 episodes), repeat once 24 hours later if needed (maximum total dose 200 mg)
1701962|NCT01451320|Drug|Tissue Plasminogen Activator|6-hour infusion of 50 mg t-PA (Tissue plasminogen activator) without bolus (27 patients, 27 episodes), repeat once 24 hours later up to 3 times if needed (maximum total dose 150 mg).
1701963|NCT01451320|Drug|Tissue Plasminogen Activator|6-hour infusion of 25 mg t-PA (Tissue plasminogen activator) without bolus (108 patients, 124 episodes), repeat once 24 hours later up to 6 times if needed (maximum total dose 150 mg).
1701964|NCT01451294|Drug|Administration of phenylephrine|Phenylephrine: 50-100µg
1701965|NCT01451294|Drug|Administration of ephedrine|Ephedrine: 5- 10 mg
1701966|NCT01451268|Drug|Panobinostat|10mg upto 40mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every week; duration: one year
1701967|NCT01451268|Drug|Panobinostat|Start of Arm B after completion of Arm A; initial dose-level: one level below MTD of Arm A; 10mg upto 60mg Panobinostat dose escalation in consequent cohorts; frequency: three times a week, every other week; duration: one year
1701968|NCT01451242|Other|no intervention is made|no intervention is made
1701969|NCT01451229|Drug|higenamine|infused intravenously with higenamine at the escalating doses from 0.5 ug/kg/min through 1.0 ug/kg/min and 2.0 ug/kg/min to 4.0 ug/kg/min, each dose being given for 3 minutes
1701970|NCT01451203|Drug|Placebo|Subcutaneous (SC)
1701971|NCT01451203|Drug|CZP|SC
1701972|NCT01451203|Drug|methotrexate (MTX)|oral
1701973|NCT01451190|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
1702087|NCT01450241|Other|Usual practice|Continued antibiotic treatment as accepted by guidelines for febrile neutropenia
1702088|NCT01450228|Drug|KI1001|Prolonged release melatonin 2mg
1702089|NCT01450228|Drug|Placebo KI1001|Placebo KI1001 tablets
1701974|NCT01451177|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp, plucked of hairs prior to excision, is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. The cells are then injected into the balding area of the scalp of the original subject.
1701975|NCT01451164|Drug|OPC-34712|orally administered once daily
1701976|NCT01451164|Drug|OPC-34712|orally administered once daily
1701977|NCT01451164|Drug|OPC-34712|orally administered once daily
1701978|NCT01451164|Drug|Placebo|orally administered once daily
1701979|NCT01451151|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. A mixed population of dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
1701980|NCT01451138|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
1701981|NCT01451125|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
1701982|NCT01451112|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
1701983|NCT01451099|Biological|Autologous cultured dermal cells|A piece of occipital scalp is taken from the subject. The dermal cells from this tissue are expanded in culture. The cells are then harvested. These cells are then injected into the balding area of the scalp of the original subject.
1701984|NCT01451086|Biological|vaccine made by Beijing Minhai Biotechnology Co., Ltd|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
1701985|NCT01451086|Biological|vaccine made by Chengdu Institute of Biological Products|Subjects receive 0.5 mL/dose of 23-valent pneumococcal polysaccharide vaccine by intramuscular (deltoid) injection on Day 0.
1701986|NCT01451073|Biological|Autologous cultured dermal and epidermal cells|Two pieces of occipital scalp are taken from the subject, three weeks apart. The dermal and epidermal cells from these tissues are expanded in culture. The cells are then harvested and, for certain types of product, combined. On the day the cells are harvested after manufacture, they are then injected into the balding area of the scalp of the original subject within a certain time period.
1701987|NCT01451060|Drug|Metaraminol|It will be used a dose of 0.5 mg to any fall in blood pressure of the fetus until birth
1701988|NCT01451060|Drug|Ephedrine|It will be used at any one dose de1mg fall in blood pressure of the fetus until birth
1701989|NCT01451047|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
1701990|NCT01451034|Procedure|WHYX cancer group|WHYX cancer diagnosed by pathologic report
1701991|NCT01451021|Biological|Autologous cultured dermal and epidermal cells|A piece of occipital scalp is taken from the subject. The epidermal and dermal cells from this tissue are expanded in culture. The cells are then harvested and, for certain types of product, combined. These cells are then injected into the balding area of the scalp of the original subject.
1701992|NCT01451008|Device|Compression anastomotic ring-locking procedure (CARP)|The Compression anastomotic ring-locking procedure (CARP) device is based on a set of rings to make a compression anastomosis between the intestinal ends.
1701993|NCT01450995|Drug|Treximet|Tablet form, one tablet dose, one tablet at migraine onset with second tablet for persistent or recurring migraine two hours after first dose.
1701994|NCT01450995|Drug|Imitrex and two Aleve|Imitrex tablet, one tablet dose, Aleve tablets, 2 220 mg tablet dose. Three tablets taken concurrently with migraine onset. Second dose of tablets may be taken if migraine persists for two hours
1701995|NCT01450982|Drug|JNJ-38518168 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose
1956022|NCT02993146|Other|Laboratory Biomarker Analysis|Correlative studies
1702002|NCT01450930|Drug|Hydrocortisone intramuscular first|Hydrocortisone intramuscular first
1702003|NCT01450930|Drug|Hydrocortisone subcutaneously first|Hydrocortisone subcutaneously first
1702004|NCT01450904|Procedure|Quadriceps incision < 2 cm|MIS-TKA was performed with less than 2 cm Quadriceps incision length
1702005|NCT01450904|Procedure|Quadriceps incision 2-4 cm|MIS-TKA was performed with 2 to 4 cm Quadriceps incision length
1702006|NCT01450904|Procedure|Quadriceps incision > 4 cm|MIS-TKA was performed with more than 4 cm Quadriceps incision length
1702007|NCT01450878|Drug|beta-epoietin|100 000UI beta-epoietin injection one hour before organ retrieval
1702008|NCT01450865|Drug|flupirtine|Potassium channel opener (SNEPCO)
1702009|NCT01450852|Behavioral|Strength Training|Each Member of this group completed 12 weeks of progressive, periodized resistance training for 3d/wk.
1702084|NCT01450254|Device|AposTherapy Biomechanical System|The system is a rehabilitation program implementing a device comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center of pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
1702412|NCT01447706|Drug|MM-121|MM-121 (SAR256212) (IV)
1702010|NCT01450839|Drug|E2022|The treatment period consists of 2 periods, Period I and Period II. In Period I, one 5 mg E2020 tablet will be administered in a single dose. In Period II, the tape containing 16 mg E2022 (which corresponds to one 5 mg E2020 tablet) will be applied repeatedly for 17 days. A washout period of at least 8 days will be allowed between the day of single dose administration in Period I and the first day of repeated application in Period II. A post-treatment examination will be performed at least 21 days after the last removal of the investigational product in Period II.
1702011|NCT01450839|Drug|Placebo|Matching Placebo tablets and tape
1702012|NCT01450826|Drug|Aprepitant|On day 1, eligible patients will receive a single oral dose of Aprepitant 125 mg p.o, 1 hour before first dose of the 5-day oral temozolomide regimen. This will be followed by Aprepitant 80 mg p.o. on days 2 -5 (1 hour prior to temozolomide).
1702013|NCT01450826|Drug|Ondansetron|On Days 1-5, eligible patients will receive a single oral dose of Ondansetron, 30 minutes before first dose of the 5 -day oral temozolomide regimen.
1702014|NCT01450813|Drug|Saline 0.06 ml/kg|IV Infusion x1 prior to laryngoscopy
1702015|NCT01450813|Drug|Rocuronium 0.2 mg/kg|IV Infusion x1 prior to laryngoscopy
1702016|NCT01450813|Drug|Rocuronium 0.4 mg/kg|IV Infusion x1 prior to laryngoscopy
1702017|NCT01450813|Drug|Rocuronium 0.6 mg/kg|IV Infusion x1 prior to laryngoscopy
1702018|NCT01450800|Drug|Nitrofurantoin|Nitrofurantoin 100mg po daily to be taken every day the patient uses a catheter for up to one week post-operatively
1702019|NCT01450800|Drug|Placebo|Participants randomized to placebo will be instructed to take placebo one tablet by mouth daily starting on postoperative day 1 for up to 7 days during catheterization
1702020|NCT01450774|Drug|CHF 1535 50/6µg|fixed combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
1702021|NCT01450774|Drug|beclomethasone dipropionate 50µg + formoterol fumarate 6µg|free combination of beclomethasone dipropionate 50µg + formoterol fumarate 6µg
1702022|NCT01450761|Biological|Ipilimumab|
1702023|NCT01450761|Biological|Placebo matching Ipilimumab|
1702024|NCT01450761|Drug|Etoposide|
1702025|NCT01450761|Drug|Cisplatin|
1702026|NCT01450761|Drug|Carboplatin|
1702027|NCT01450748|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
1702028|NCT01450748|Drug|Placebo|matching placebo oral suspension, 50 mg/ml, 20 ml three times daily, 8 weeks
1702029|NCT01450735|Device|MANOS CTR™|The MANOS device is a carpal tunnel blade used to release the transverse carpal ligament in order to provide relief for Carpal Tunnel Syndrome.
1702030|NCT01450722|Procedure|bypass surgery, stent placement|bypass surgery, stent placement
1702031|NCT01450722|Procedure|stent placement|placement of paclitaxel eluting stent in long superficial femoral artery obstruction
1702032|NCT01450709|Dietary Supplement|Kibow Biotics|6 month, double-blind, cross-over, wash-out, placebo controlled study in an outpatient setting. Each patient takes two capsules, three times a day (180 CFU/day).
1702033|NCT01450696|Drug|Capecitabine|Capecitabine will be administered at a dose of 800 mg/m^2 orally twice daily for 14 days q3w for up to 6 cycles (Cycles 1 to 6).
1702034|NCT01450696|Drug|Cisplatin|Cisplatin will be administered at a dose of 80 mg/m^2 intravenously q3w on Day 1 of each 3-week cycle for up to 6 cycles (Cycles 1 to 6).
1702035|NCT01450696|Drug|Herceptin|Herceptin will be administered at a loading dose of 8 mg/kg on Day 1 of Cycle 1 followed by 6 or 10 mg/kg (depending upon treatment assignment) q3w from Day 1 of Cycle 2 until disease progression, occurrence of unacceptable toxicity, or withdrawal from the study for another reason.
1702036|NCT01450683|Drug|Itraconazole|"600 mg/day oral (PO)
IUPAC name: (2R,4S)-rel-1-(Butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one"
1702037|NCT01450670|Dietary Supplement|Kibow Biotics|Month 1, one capsule three times daily (90 Colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3, three capsules three times daily (270 CFU's). Continued on tolerated maintenance dosage for an additional 6 months. Once tolerated dosage is identified the patient will be continued on that maintenance dosage for an additional 6 months. All medical, physical, clinical, QOL and other parameters will be monitored as well.
1702038|NCT01450657|Dietary Supplement|Kibow Biotics/Renadyl|Month 1, one capsule three times daily (90 colony forming units); Month 2, two capsules three times daily (180 CFU's); Month 3 & 4, three capsules three times daily (270 CFU's). Months 5 & 6 are washout periods, in which the patient receives no product. All parameters are still monitored by the study site during months 5 & 6. All medical, physical, clinical, QOL and other parameters will be monitored as well.
1702039|NCT01450644|Other|The Hospital2Home Service|This intervention is a new multiprofessional, patient case conference that is organised for people nearing the end-of-life. Evidenced based guidelines for the management of the physical, psychological, spiritual and end of life-planning needs for these patients will be used in the H2H case conference. A case conference will be organised in their home (or place of their choice). The patient, informal caregiver, H2H CNS, GP, district nurse, social worker and community palliative care nurse are invited to attend. Current and anticipated care needs are discussed, and an action plan is agreed allocating a responsible health care professional for each item. During the case conference, individualised care plans will be made. This is then communicated with local services, primary and specialist teams resulting in streamlining of transfer of data and codifying responsibility for the patient, hospital and community care professionals.
1702040|NCT01450631|Device|Prevena™ Incision Management System (PIMS)|PIMS is a non-significant-risk, FDA Class II, medical device commercially available in the USA, Canada and Europe. The prospective, post-marketing clinical study described in this protocol will assess the effectiveness and functional performance of the system. The PIMS unit is a single patient use, battery-powered, disposable unit that can provide continuous -125 mmHg negative pressure over a 7-day therapy period. It is an easy to use device that also provides audible and visual alerts for low battery, maximum canister volume, and leak conditions. Additional alerts include system error and device life-cycle expiration (8 days). It is contained in a water-resistant housing, which allows the Subject to lightly shower with the device. Wound fluids are contained within the 45 mL canister.
1702085|NCT01450254|Other|Control|No intervention will be prescribed to the control group during participation in the study.
1702086|NCT01450241|Other|Early antibiotic discontinuation|Antibiotic treatment for unexplained febrile neutropenia stopped after 72 hours, regardless of fever
1702041|NCT01450631|Device|Standard-of-care Dressing|The standard-of-care is consistent with the national standard for dressing Cesarean section incisions and includes, but not limited to, coverage of the sutured incision with sterile gauze and non-penetrable barrier (e.g., Tegaderm™). The non-penetrable barrier may be left in place for a minimum of 1 day and no longer than 2 days (± 4 hours) to promote epithelialization of the surgical incision edges. After the dressing is removed, the surgical site is left exposed to air to promote further healing. Other therapies include traditional gauze dressings with or without advanced therapies such as hydrocolloids, growth factors, and Negative Pressure Wound Therapy.
1702042|NCT01450605|Drug|No Intervention|Patients are previously on Reyataz® treatment or initiated Reyataz® for the first time
1702043|NCT01450592|Other|No drug|Diabetic Population
1702044|NCT01450592|Other|No drug|Non-Diabetic Population
1702045|NCT01450579|Biological|ASP7373|Intermuscular administration
1702046|NCT01450579|Biological|Placebo|Intramuscular administration
1702047|NCT01450566|Drug|Lidocaine|Use of lidocaine
1702048|NCT01450566|Drug|Saline|Saline
1702049|NCT01450514|Drug|Pipamperone|15 mg PIP once daily per os on top of continued stable treatment with RIS or PAL
1702050|NCT01450514|Drug|Placebo|matching placebo sugar pill once daily per os on top of continued stable treatment with RIS or PAL
1702051|NCT01450488|Drug|masitinib|masitinib 3 mg/kg/day
1702052|NCT01450488|Drug|masitinib|masitinib 6 mg/kg/day
1702053|NCT01450475|Procedure|Remote ischemic postconditioning|At the time of reperfusion, remote ischaemic postconditioning will be induced by inflating a cuff around leg to 100 mmHg for 5 mins followed by 5 mins of reperfusion. This cycle will be repeated 3 times.
1702054|NCT01450462|Dietary Supplement|Vitamin D3 (cholecalciferol)|Women in the vitamin D arm take 50,000 international units (IU) of vitamin D3 (cholecalciferol) weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
1702055|NCT01450462|Dietary Supplement|Placebo|Women in the placebo arm will take their matching supplement weekly for four weeks (end of week 1, week 2, week 3 and week 4), then every 4 weeks through 24 weeks of follow-up (end of week 8, week 12, week 16, week 20 and week 24) for a total of 9 treatments
1702056|NCT01450449|Radiation|Radiotherapy|25 Gy in 5 daily fractions over 1 week
1702057|NCT01450449|Radiation|Radiotherapy|40 Gy in 15 daily fractions over 3 weeks
1702058|NCT01450436|Other|Peapod assessment|"EPIPOD consists in a Non-Interventional Research according to French regulations. Actually, Peapod examination at discharge takes part of current clinical practice and patient management in Nantes Neonatal Intensive Care Unit since 2008.
After checking inclusion and non-inclusion criteria and obtaining oral informed consent from newborn legal authority or parents, PEAPOD assessment was leaded in the last week of hospitalization. Consisting in 2 repeated measurement, body composition estimation was completed by clinical and demographic data as neonatal nutrition (Parenteral nutrition pattern at Day 5, 10 and 21, and ASQ/BLR Neurodevelopmental assessment at 2 years old)."
1702059|NCT01450423|Behavioral|Physical activity|Participation in a 10-week supervised cardio exercise program two-three times a week. Each training session consists of 10 minutes of warm-up, 20 minutes treadmill run/walk and 30 minutes cycling. Heart rate (HR) is monitored during each session. Week 1-5: at least 15 minutes above 75% of HRmax in each session. Week 6-10: at least one session above 75% HRmax.
1702060|NCT01450410|Drug|Nicotinic acid|Nicotinic acid / laropiprant (Tredaptive 1000 mg/20 mg modified-release tablets). Patients treated with nicotinic acid 1g/day receive one dose of one month and 2 g / day thereafter. Nicotinic acid treatment will last for 12 weeks.
1702061|NCT01450410|Drug|Placebo|Placebo treatment will last for 12 weeks.
1702062|NCT01450397|Biological|XIAFLEX|One Injection of 0.58 mg of Xiaflex into the affected area of the hand.
1702063|NCT01450384|Drug|sorafenib tosylate|Given PO
1702064|NCT01450384|Drug|pemetrexed disodium|Given IV
1702065|NCT01450384|Other|laboratory biomarker analysis|Correlative studies
1702066|NCT01450384|Procedure|biopsy|Optional correlative studies
1702067|NCT01450371|Device|Interferential|The individuals are treated acutely with IES during 30 min, providing a continuous flow of symmetrical rectangular interferential current biphasic pulses using bipolar electrodes with two channels and a slope of 1/5/1. The fixed current is adjusted to 4000 Hz, with the current AMF at 100 Hz and an AMF variation of 25 Hz (25% of AMF).
1702068|NCT01450371|Device|Interferential Placebo|The same instructions and electrode positions were provided to the placebo, although the equipment did not provide any stimulation current
1702069|NCT01450358|Other|Antibiotic regimen|The medical researcher will change the antibiotic regimen (De-escalation) immediately as a result of Multiplex PCR (6-12 h).
1702070|NCT01450345|Drug|Pregabalin|The patient under Group P will be serving with 150 mg of oral Pregabalin 1 to 2 hours prior to induction.
1702071|NCT01450332|Device|Knee-T-Nol|The ACL prosthesis is intended for the treatment of ruptured ACL. It will be used as an implant to replace the native, torn ACL. Implantation will be done using arthroscopy
1702072|NCT01450319|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m^2) every 2 weeks until disease progression, death, or consent withdrawal.
1702073|NCT01450306|Drug|D-cycloserine|50 mg d-cycloserine, oral, 1 dose
1702074|NCT01450306|Behavioral|Exposure therapy|Single session graded in vivo exposure therapy, 60-180 minutes
1702075|NCT01450306|Drug|Placebo|Single capsule of oral placebo, administered once 1 hr prior to exposure therapy
1702076|NCT01450293|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|1x10^10 vp AdCH63 ME-TRAP followed by 1x10^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
1702077|NCT01450293|Biological|AdCH63 ME-TRAP, MVA ME-TRAP|5x10^10 vp AdCH63 ME-TRAP followed by 1x10^8 pfu MVA ME-TRAP 8 weeks later. Intramuscular needle injection into the anterolateral thigh.
1702078|NCT01450280|Biological|ChAd63 CS|ChAd63 CS 5x10^9 vp intra-muscularly Day 0
1702079|NCT01450280|Biological|ChAd63 CS, MVA CS|ChAd63 CS 5x10^9 vp intra-muscularly Day 0; MVA CS 2x10^8 pfu intra-muscularly Day 56
1702080|NCT01450280|Biological|ChAd63 CS|ChAd63 CS 5x10^10 vp intra-muscularly Day 0
1702081|NCT01450280|Biological|ChAd63, MVA CS|ChAd63 CS 5x10^10 vp intra-muscularly Day 0; MVA CS 2x10^8 pfu intra-muscularly Day 56
1760829|NCT00285844|Behavioral|weight loss|
1702090|NCT01450215|Drug|Revlimid|Group R:25 mg lenalidomide 21 of 28 days will be given orally as maintenance .
1702091|NCT01450202|Other|bowel insufflation gas|air insufflation, during colonoscopy and esophagogastroduodenoscopy
1702092|NCT01450202|Other|bowel insufflation gas|CO2 insufflation, during colonoscopy and esophagogastroduodenoscopy
1702093|NCT01450189|Behavioral|Standard HIV prevention messages|A single session of standard HIV prevention messages during HIV post-test counseling with supplemental information regarding the acute stage of their infection.
1702094|NCT01450189|Behavioral|BI: Information-Motivation-Behavioral Skills Model|The behavioral intervention consists of five counselor-delivered sessions based on the Information-Motivation-Behavioral Skills (IMB) Model. The sessions are designed to provide participants with the information, motivation, and skills needed to abstain or practice protected sex during the brief acute HIV period, as well as plan for long-term behavioral risk reduction.
1702095|NCT01450189|Drug|Raltegravir|raltegravir (400 mg) administered orally twice daily for 12 weeks
1702096|NCT01450189|Drug|emtricitabine/tenofovir disoproxil fumarate|emtricitabine/tenofovir (200/300 mg daily) in a fixed dose combination administered orally for 12 weeks
1702097|NCT01450176|Drug|Olopatadine hydrochloride 0.2%|1 drop in each eye once daily for 2 weeks
1702098|NCT01450176|Drug|Bepotastine besilate ophthalmic solution 1.5%|1 drop in each eye twice daily for 2 weeks
1702099|NCT01450163|Drug|Pregabalin, Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Pregabalin will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
1702100|NCT01450163|Drug|Placebo , Oxaliplatin|Oxaliplatin will be infused according to the FLOX treatment strategy, as a regular six-month-long adjuvant treatment to colorectal cancer. Placebo will be administered P.O. three days before and three days after each of the nine Ox infusions. The dose will be titrated during the first Ox infusion to the highest level tolerated by the patient. The dose used in this first session will be used in the eight following sessions.
1702101|NCT01450150|Device|Transcranial Direct Current Stimulation|20-minute daily sessions of 2 mA tDCS for 15 days (Monday to Friday on three consecutive weeks)
1702102|NCT01450150|Device|Transcranial Direct Current Stimulation|The tDCS stimulator will be turned on for 30 seconds only, after which it will be gradually decreased and then turned off for the remainder of the 20-minute daily sessions for 15 days (Monday to Friday on three consecutive weeks).
1956023|NCT02993146|Other|Pharmacological Study|Correlative studies
1956024|NCT02993146|Other|Quality-of-Life Assessment|Ancillary studies
1702105|NCT01450124|Drug|Boswellic acids (BOSWELAN)|8 months of treatment at a t.i.d. (Ter In Die (Latin: Three Times A Day) dose of between 400-1600 mg Boswelan
1702106|NCT01450111|Drug|Lacosamide|Lacosamide 50 mg, tablet, once in the morning on Day 1
1702107|NCT01450111|Drug|Lacosamide|Lacosamide 100 mg, tablet, once in the morning on Day 1 Lacosamide 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
1702108|NCT01450111|Drug|Lacosamide|Lacosamide 200 mg, tablet, once in the morning on Day 1 Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
1702109|NCT01450111|Other|Placebo|Placebo matched with Lacosamide 50 mg tablet once in the morning on day 1.
1702110|NCT01450111|Other|Placebo|Placebo matched with Lacosamide 100 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamode 100 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
1702111|NCT01450111|Other|Placebo|Placebo matched with Lacosamide 200 mg, tablet, once in the morning on Day 1 Placebo matched with Lacosamide 200 mg, tablet, twice daily Day 5 to Day 8 and once in the morning on Day 9
1702112|NCT01450098|Drug|LY2484595 Reference Formulation (RF)|Administered orally
1702113|NCT01450098|Drug|LY2484595 spray-dried solid dispersion-propyl gallate (SDSD-PG)|Administered orally
1702114|NCT01450085|Other|GeneXpert|Point of care GeneXpert
1702115|NCT01450085|Other|LED Microscopy|Point of care LED Microscopy
1702116|NCT01450072|Device|Selective Venography followed by therapeutic balloon angioplasty|Venography followed by therapeutic balloon angioplasty
1702117|NCT01450072|Other|Control arm|Venography and sham angioplasty
1702118|NCT01450046|Drug|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol will be administered orally as a single agent twice daily for 14 consecutive days. Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The first cohort will be dosed with δ-tocotrienol at 100 mg twice daily for 14 consecutive days. A minimum of 3 subjects is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety and available PK data from prior cohorts. At the MTD or MAD, 18 subjects will be enrolled.
1702119|NCT01450033|Behavioral|Peer Mentoring|Subjects will be assigned a peer mentor who will provide social support primarily via e-communication. They will also meet in-person at study entry, 6 months and 1-year.
1702120|NCT01450033|Behavioral|e-Communication with mentor|Subjects will interact on a mutually agreeable basis via their choice of text messaging, Facebook, phone calls, emails, and other formats
1702121|NCT01450020|Other|educational intervention|Receive ACS material
1702122|NCT01450020|Other|questionnaire administration|Ancillary studies
1702123|NCT01450020|Other|counseling intervention|Undergo PN session
1702124|NCT01450020|Other|survey administration|Ancillary studies
1702125|NCT01450020|Procedure|quality-of-life assessment|Ancillary studies
1702126|NCT01450007|Drug|Ropivacaine|25 ml ropivacaine 0.5%
1702127|NCT01450007|Drug|Dexamethasone|8 mg dexamethasone (perineural)
1702128|NCT01450007|Drug|Dexamethasone|8 mg dexamethasone (0.8 ml dexamethasone, 4.2 ml saline) to total volume of 5 ml (intravenous)
1702129|NCT01450007|Drug|Normal saline|5 ml normal saline (intravenous)
1702130|NCT01450007|Drug|Normal saline|0.8 ml normal saline (perineural)
1702131|NCT01449994|Device|Activator IV (Activator Methods Int. Phoenix, Arizona)|Instruments gives a defined impulse on specified areas of the body
1702213|NCT01449396|Procedure|Acupuncture|Acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
1956025|NCT02993146|Drug|Ropidoxuridine|Given PO
1702132|NCT01449981|Behavioral|Integrated Twelve-Step Facilitation|The iTSF condition will include review of treatment goals and overall review of progress, coping skills, real life practices, emotions/mood management, how to make changes in one's social network and discussions about how 12-step meetings can be helpful in one's recovery efforts. In addition, speakers from 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA) will be invited to share their experiences and discuss myths and facts related to attendance at 12-step meetings as well as answer any questions participants have about these fellowships.
1702133|NCT01449981|Behavioral|Cognitive Behavioral Therapy|The CBT condition will include review of progress, coping skills, group exercises, real life practice, and emotions/mood management.
1702134|NCT01449968|Other|home visit|home visit of UMG
1702135|NCT01449968|Other|telephone management|telephone management of the situation reported by the patient's GP
1702136|NCT01449955|Drug|Rapamycin|"Sirolimus is an FDA approved immunosuppressant drug used to prevent rejection in organ transplantation, and is especially useful in kidney transplants. It is non-toxic to kidneys, unlike other immunosuppressants. In this study, the medication will be administered once to see if it interferes with emotional memory reconsolidation. This is based on the fact that it inhibits the mammalian target of Rapamycin (mTOR) through directly binding the mTOR Complex1 (mTORC1). mTOR is a serine/threonine protein kinase that regulates cell growth, cell proliferation, cell motility, cell survival, protein synthesis and transcription.
a single dosage of 15mg will be administered during this study."
1702137|NCT01449955|Drug|Placebo|Inactive
1702138|NCT01449942|Biological|DNAzyme targeting EBV-LMP1 (DZ1)|"DZ1 in saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday. Dosage for each injection is 12 mg in 0.1 mL (200 micrograms per kilogram body weight.
The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
1702139|NCT01449942|Other|Saline|"0.1 mL of saline is administrated by intratumoral injection two hours prior to radiation therapy from week 1 to week 7 on Monday and Thursday.
The radical radiotherapy is given to patients 5 times per week with 2 Gy of each treatment. The entire procedure lasts seven weeks."
1956026|NCT02993146|Radiation|Whole-Brain Radiotherapy|Undergo WBRT
1702144|NCT01449890|Behavioral|E-mail follow up care|After having terminated inpatient CBT patients receive follow up care by email for 12 weeks (on average one contact per week). The follow up care aims at supporting the patients in continuing exercises in order to cope with depression.
1702145|NCT01449877|Drug|Trimethoprim-Sulfamethoxazole|Sulfamethoxazole 800mg + Trimethoprim 160mg / tablet. In treatment of acute phase, 1 tablet 12/12h 45 days. After acute phase, 1 tablet every other day, morning, 311 days. Placebo tablet - Composition: starch. After acute phase, 1 tablet every other day, morning, 311 days.
1702146|NCT01449864|Radiation|Proton therapy|The goal of radiation therapy is to deposit the majority of the radiation dose to the target while minimizing the dose to the surrounding normal tissues.
1702147|NCT01449838|Drug|Colistimethate sodium|active
1702148|NCT01449838|Drug|Saline|placebo
1702149|NCT01449825|Drug|Pazopanib use|Treatment with pazopanib
1702150|NCT01449825|Drug|Use of sunitinib, bevacizumab, or sorafenib|Treatment with any of the three other marketed anti-VEGF drugs: sunitinib, bevacizumab, and sorafenib
1702151|NCT01449812|Biological|Infanrix+Hib™|Intramuscular, one dose
1702152|NCT01449812|Biological|Poliorix™|Intramuscular, one dose
1702153|NCT01449799|Drug|GSK961081 800 microgram dose|To be provided via a combination of 4 inhalers - one 400 micrograms GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation and one inhalation each from two separate placebo Diskus inhalers
1702154|NCT01449799|Drug|Fluticasone Propionate 500 microgram dose|To be provided via a combination of 4 inhalers - one 250 microgram fluticasone propionate Diskus inhalation, a second 250 microgram fluticasone proopionate Diskus inhalation, and one inhalation each from two separate placebo Diskus inhalers
1702155|NCT01449799|Drug|GSK961081 800 microgram and Fluticasone Propionate 500 microgram separately|To be provided via a combination of 4 inhalers - one 400 microgram GSK961081 Diskus inhalation, a second 400 microgram GSK961081 Diskus inhalation, one 250 microgram fluticasone propionate Diskus inhalation, and a second fluticasone propionate 250 microgram Diskus inhalation
1702156|NCT01449799|Drug|GSK961081 800 microgram Fluticasone Propionate 500 microgram in a blend|To be provided via a combination of 4 inhalers - one inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, a second inhalation of a Diskus inhaler containing a blend of 400 microgram of GSK961081 and 250 microgram of fluticasone propionate per inhalation, and one inhalation each from two separate placebo inhalers
1702157|NCT01449786|Drug|rMal d 1|25 µg daily as sublingually administered drops, 16 weeks
1702158|NCT01449786|Drug|rBet v 1|25 µg daily administered sublingually as drops over 16 weeks
1702159|NCT01449786|Other|placebo drops|25 µg of placebo Drops daily administered sublingually over 16 weeks
1702160|NCT01449773|Dietary Supplement|n-3 PUFAs|5 capsules/day in order to provide 3 g/day of n-3 PUFAs.
1702161|NCT01449773|Dietary Supplement|Placebo|5 capsules/day containing corn and soybean oil
1702162|NCT01449760|Other|Physical Therapy|These patients have a standardized conventional therapy (i.e. 9 sessions of physical therapy over 6 weeks)
1702163|NCT01449760|Other|Wii Balance Board|These patients get an instruction about how to install and use the Wii Balance Board ®. After the instruction they get the equipment for 6 weeks.
1702164|NCT01449747|Drug|Sitagliptin|Sitagliptin (100mg, per oral) once a day.
1702165|NCT01449721|Drug|Intravenous fluid|0.9% Sodium chloride intravenous fluid
1702166|NCT01449708|Drug|TIVA NoNarc|"patients in both groups receive antiemetic prophylaxis
patients in the TIVA NoNarc group will receive propofol, dexmedetomidine, ketamine, ketorolac and acetaminophen intraoperatively
postop management in both groups is similar in both groups"
1702214|NCT01449383|Dietary Supplement|low meat high fibre|less than 30g red meat and at least 40g dietary fibre per day
1956027|NCT02994394|Drug|OPC-41061|
1702167|NCT01449695|Behavioral|Life style counseling|A nurse-based intervention with face-to-face contacts based on motivational interviewing techniques and influence on behavioral determinants. Well-trained nurses in our hospital will apply these behavioral change interventions. An individual contact will take about twenty minutes.
1702168|NCT01449695|Behavioral|an individualized web portal|This website shows patient's lab results, life style issues, blood pressure and weight in various risk monitors. These lab results and lifestyle changes will be visualized in risk monitors and provide structural feedback to the patient. The results of the screening and the two additional visits can be seen by the patient.
1702169|NCT01449695|Behavioral|individual and group consultations|group consultations with peers and a nurse individual consultation with a nurse
1702170|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit, then PRN if evidence of macular edema on OCT studies
1702171|NCT01449682|Drug|Ozurdex|0.7 mg intravitreal DEX implant on first visit then every 16 weeks
1702172|NCT01449656|Device|LMA Proseal: control device|LMA Proseal will be placed in children weighing 10-20kg based on a computer generated randomization
1702173|NCT01449656|Device|LMA Supreme: comparison device|LMA Supreme will be placed in children weighing 10-20kg based on a computer generated randomization
1702176|NCT01449630|Drug|LY3031207|Administered orally
1702177|NCT01449630|Drug|Placebo|Administered orally
1702178|NCT01449630|Drug|Celecoxib|Administered orally
1702179|NCT01449617|Drug|Aspirin plus clopidogrel|"Clopidogrel, will be started 48 hours before the procedure with a loading dose of of 300mg and continued at 75mg/day.
Aspirin will be given at the dose of 100-325mg/day."
1702180|NCT01449604|Radiation|stereotactic radiotherapy|Stereotactic radiotherapy, hypofraction using 18 Gray in 3 fractions
1702181|NCT01449604|Radiation|stereotactic radiosurgery|Radio surgery 12 Gy
1702182|NCT01449591|Drug|BFH772 1% ointment|
1702183|NCT01449591|Drug|Vehicle ointment|
1702184|NCT01449591|Drug|Noritate® 1% cream|
1702185|NCT01449578|Drug|Dexpramipexole|Oral Tablet at varying doses
1702186|NCT01449578|Drug|Dexpramipexole Placebo|Oral tablet at varying doses
1702187|NCT01449565|Drug|Naltrexone|3 monthly intramuscular injections of naltrexone 380 mg (extended release)
1702188|NCT01449565|Drug|Placebo|3 monthly intramuscular injections of placebo, matched to naltrexone 380 mg (extended release)
1702189|NCT01449552|Drug|Tranexamic acid|the drain was not clamped and the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
1702190|NCT01449552|Procedure|Drain clamping|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
1702191|NCT01449552|Other|Drain clamping and tranexamic acid|the drain was clamped for three hours, released for three hours, then clamped for another three hours, and then released free for 48 hours. the patient received tranexamic acid 10mg/kg intravenous 10 minutes before inflating the tourniquet and 10mg/kg intravenous three hours post-operative, and then tranexamic acid 250mg/capsule 2X3 orally for five days.
1702192|NCT01449552|Other|No clamp and placebo|The drain was not clamped. The patient received placebo (saline 10 minutes before surgery and three hours post-operative, and then an oral form of placebo 2X3 capsules for five days).
1702193|NCT01449539|Drug|Hyperbaric Oxygen Therapy|Treatment Monday through Friday in a monoplace hyoerbaric chamber 100% oxygen at 2.0 atmospheres (14.7 PSI or the equivalent of being under 33 feet of sea water) for 90 minutes at pressure. Treatment lasts 2 hours as time is allowed for gradual pressurization and depressurization. Each subject will be treated for two weeks for a total of 10 HBOT treatments
1702194|NCT01449526|Device|B&L Investigational Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
1702195|NCT01449526|Device|B&L PureVision Contact Lens|Lenses will be worn on a daily wear basis for 3 months, new lenses dispensed monthly.
1702196|NCT01449513|Drug|Ingenol mebutate|0.05% Ingenol mebutate Gel once daily for 2 consecutive days
1702197|NCT01449513|Drug|Placebo Gel|Gel vehicle of PEP005
1702198|NCT01449500|Dietary Supplement|L. reuteri|Chewable tablet, one tablet/day for 28 days
1702199|NCT01449500|Dietary Supplement|Placebo|Chewable tablet, one tablet per day for 28 days
1702200|NCT01449487|Drug|PPC-5650|Solution for administration in the rectum Single dose of 25µg/ml at a volume of 50ml
1702201|NCT01449487|Drug|Placebo|Solution for administration in the rectum Identical tp active solution but without active drug
1702202|NCT01449474|Device|Patient matched instruments|The patients undergo TKA with using patient matched instruments
1702203|NCT01449474|Device|Jig based instruments|The patients undergo TKA with using jig based instruments
1702204|NCT01449461|Drug|Brigatinib|Brigatinib tablets and capsules
1702205|NCT01449448|Drug|Ketorolac|Subacromial injection
1702206|NCT01449448|Drug|Triamcinolone|Subacromial Injection
1702207|NCT01449435|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
1702208|NCT01449422|Device|Dressing|the dressing should be changed on average every 1 to 2 days, then as often as required (up to 7 days) depending on the exudate volume and the clinical condition of the wound (evaluated by the investigating doctor).
1702209|NCT01449422|Device|Dressing|the hydrofibre dressing should be changed when it is saturated, or depending on the clinical appreciation of the situation. The dressing can remain in place for up to 7 days.
1702210|NCT01449409|Other|Real-time asthma care outreach|Real-time asthma care identification of uncontrolled asthma and real-time notification of patients and their physicians of uncontrolled asthma and directions to improve care. Patients without an asthma specialist visit in the prior 3 years are offered an expedited allergy department referral.
1702211|NCT01449396|Other|Bed Rest|Bed rest during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
1702212|NCT01449396|Procedure|Acupuncture|Sham acupuncture during 25 minutes on day 1, 4 and 6 of ovarian stimulation, before and after embryo transfer
1702215|NCT01449383|Dietary Supplement|high meat low fibre|at least 200g red meat (pork, beef or other mammals) and not more than 20g dietary fibre per day
1702216|NCT01449370|Drug|TAK-117|oral administration of TAK-117, daily and intermittent schedules.
1702217|NCT01449357|Drug|zalutumumab|IV infusion, 16mg/kg on weekly basis until DP
1702218|NCT01449344|Drug|Rituximab|Rituximab 375mg/m² IV , day 1
1702219|NCT01449344|Drug|High dose Ara-C|Ara-C 2000 mg/m² (patients >65 years or s/p myeloablative treatment: 1000 mg/m²) IV, d 2 and 3
1702220|NCT01449344|Drug|Dexamethasone|Dexamethasone 40 mg PO, day 1-4
1702221|NCT01449344|Drug|Bortezomib|Bortezomib 1.5 mg/m² IV, day 1 and 4
1702222|NCT01449318|Device|Thermal Sensory Analyzer (Senselab)|"Thermal stimuli will be administered to the ventral surface of the dominant forearm and then to the lower abdomen (surgical site)using the Thermal Sensory Analyser. Each thermal testing trial will be separated by approximately 2 min and at a separate site.
To measure the thermal pain threshold temperature, The thermode will be applied to the ventral surface of the dominant forearm and the temperature will be increased at 1°C/s from 35 to 50°C.
To measure the Suprathreshold Thermal Pain Intensity and unpleasantness, Stimulus responses for noxious heat stimuli will be performed by applying phasic heat stimuli at 8 different temperatures (35, 43, 44, 45, 46, 47, 48, and 49°C)."
1702223|NCT01449305|Device|Nanoone Woman Underwear|Chen Yi Enterprise, Co., Ltd. design a kind of negative ion materials can supply delocalized electron, and add fiber inside, make clothes to wear in the body, no external power or battery, only depend on infrared body photon hit of thermoelectric effect or heart compression pulse, blood flow of piezoelectric, therefore can sustained sufficient amount of effective negative ion, to eliminate positive ions in vivo, or make oxygen free radical to obtain the lack electrons. Decrease active free radical and get non toxic effect in short time.
1702224|NCT01449292|Device|Treatment plus Optimal Medical Therapy|Patients will be treated with the AeriSeal System in 2 subsegments in the upper lobes of each lung (4 subsegments total). 20mL of foam sealant will be injected via catheter into each subsegment selected for treatment. Patients will also receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
1702225|NCT01449292|Other|Optimal Medical Therapy|Patients will receive Optimal Medical Therapy. Guidelines for prescribing medical treatment for emphysema have been published by the American Thoracic Society (ATS) and the National Heart Lung and Blood Institute/World Health Organization (NHLBI/WHO GOLD workshop summary).
1702226|NCT01449279|Drug|Ipilimumab|Ipilimumab will be administered as a single agent standard of care with base dose of 3 mg/kg iv over approximately 90 minutes every 3 weeks for a total of 4 treatments.
1702227|NCT01449279|Radiation|Radiation Therapy|Standard of care palliative radiation therapy will start within 5 days of the first ipilimumab dose. Dose is dependent upon lesion size and is determined by the radiation oncologist.
1702228|NCT01449266|Drug|Dotarem® IV injection at 0.1 mmol/kg|Dotarem® was IV administered at a dose of 0.1 mmoL/kg (0.2 mL/kg).
1702229|NCT01449253|Drug|Sildenafil|20 mg initially and then increased to 20 mg TDS if there is no fall in BP
1702230|NCT01449253|Drug|Bosentan|Bosentan 62.5 mg BD initially for 1 month and then increased to 125 mg BD
1702231|NCT01449240|Other|No treatment|
1702232|NCT01449214|Procedure|Ultrasound|Ultrasound-guided technique
1702233|NCT01449214|Procedure|Landmarking|Landmark-guided technique
1702234|NCT01449201|Drug|PF-00299804|45 mg P.O. Daily (28-day treatment as one treatment cycle)
1702235|NCT01449188|Drug|ondansetron|FDA approved drug used to treat nausea and vomiting
1702236|NCT01449188|Drug|moxifloxacin|FDA approved antibiotic commonly used as a positive control in thorough QT studies
1702237|NCT01449188|Other|saline|USP saline IV solution used as placebo for ondansetron IV.
1702238|NCT01449162|Drug|masitinib 6 mg/kg/day|6 mg/kg/day
1702239|NCT01449162|Drug|placebo|placebo matching masitinib 6 mg/kg/day
1702240|NCT01449149|Radiation|Proton Therapy|
1702241|NCT01449136|Other|Antibacterial cement|Glass ionomer cement containing 1% each of metronidazole, ciprofloxacin, and cefaclor
1702242|NCT01449123|Drug|Mannitol challenge test & reversibility test|"Patients perform an asthma control test (ACT) to establish if they are well controlled or symptomatic. All patients will perform then perform the mannitol challenge test. Aridol™ is an indirect osmotic bronchial challenge test which can be used to identify bronchial hyperresponsiveness"
1702243|NCT01449110|Dietary Supplement|Placebo in primary cardiovascular prevention (PP)|"12 months follow-up:
capsule/day of placebo (350 mg maltodextrin) for 6 months
capsules/day of placebo (350 mg + 350 mg maltodextrin) for 6 months"
1702244|NCT01449110|Dietary Supplement|Placebo in secondary prevention|"12 months follow-up:
capsule/day (350 mg maltodextrin) for 6 months
capsules/day (350 mg + 350 mg maltodextrin) for 6 months"
1702245|NCT01449110|Dietary Supplement|Grape extract in primary prevention (PP)|"12 months follow-up:
capsule/day (350 mg grape extract) for 6 months
capsules/day (350 mg + 350 mg grape extract) for 6 months"
1702246|NCT01449110|Dietary Supplement|Grape extract in SP|"12 months follow-up:
capsule/day (350 mg grape extract) for 6 months
capsules/day (350 mg + 350 mg grape extract) for 6 months"
1702247|NCT01449110|Dietary Supplement|Resveratrol-enriched grape extract in PP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.
12 months follow-up:
capsule/day (350 mg resveratrol-enriched grape extract) for 6 months
capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
1702248|NCT01449110|Dietary Supplement|Resveratrol-enriched grape extract in SP|"Resveratrol-enriched grape extract (Stilvid) is obtained from grapes treated with UVC illumination. Similar polyphenolic content to conventional grape extract used in the arms 'Grape extract in PP' and 'Grape extract in SP' but containing 8 mg resveratrol.
12 months follow-up:
capsule/day (350 mg resveratrol-enriched grape extract) for 6 months
capsules/day (350 mg + 350 mg resveratrol-enriched grape extract) for 6 months"
1702249|NCT01449097|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-blockade with Ropivacaine
1702250|NCT01449097|Procedure|The femoral nerve block|US-guided femoral nerve block with ropivacaine
1702251|NCT01449097|Procedure|Placebo|US-guided Adductor-Canal-Blockade/femoral nerve block with saline
1702252|NCT01449084|Procedure|immediate stent removal|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.
THE STENT WAS REMOVED AT THE END OF THE ERCP PROCEDURE"
1702253|NCT01449084|Other|Leaving the stent in place|"The stent used was a 5-Fr polyethylene duodenal pigtail pancreatic stent without an inner flange. The stent length was 4 or 5 cm (Zimmon stent, Cook Endoscopy, Winston-Salem, NC, USA): selection was based on the degree of flexion and the length of the Wirsung duct in the head of the pancreas.
THE STENT WAS LEFT IN PLACE AT THE END OF THE ERCP PROCEDURE"
1702254|NCT01449071|Biological|Placebo|Placebo infusions at study weeks 0, 1, 2, and 3.
1702255|NCT01449071|Biological|Epratuzumab 400 mg|Epratuzumab 400 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
1702256|NCT01449071|Biological|Epratuzumab 1200 mg|Epratuzumab 1200 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
1702257|NCT01449071|Biological|Epratuzumab 100 mg|Epratuzumab 100 mg infusions at study weeks 0, and 2, and placebo infusion at study weeks 1 and 3.
1702258|NCT01449071|Biological|Epratuzumab 600 mg|Epratuzumab 600 mg infusions at study weeks 0, 1, 2, and 3.
1702259|NCT01449058|Drug|BYL719|taken orally
1702260|NCT01449058|Drug|MEK162|taken orally
1702261|NCT01449045|Drug|IPTc+CCM|Monthly administration of sulfadoxine-pyrimethamine plus amodiaquine, combined with community case management
1702262|NCT01449045|Drug|Community Case Management with artemether-lumefantrine (AL)|Malaria diagnosis with Rapid Diagnostic Test and treatment with AL if the test is positive
1702263|NCT01449032|Biological|MSC|No of cells after culture expansion
1702264|NCT01449032|Biological|Saline|3 cc saline
1702265|NCT01449019|Drug|exendin(9-39)amide|intravenous infusion of exendin(9-39)
1702266|NCT01449019|Drug|saline|intravenous infusion of saline
1702267|NCT01449019|Other|duodenal meal|duodenal perfusion of a meal
1702268|NCT01449019|Other|duodenal saline|duodenal perfusion of saline
1702269|NCT01449006|Drug|Maraviroc|Maraviroc oral tablet. Dosage: 150 mg twice daily, 300 mg twice daily, or 600 mg twice daily. Dosing will be dependent on the participant's background HAART therapy, and will be in accordance with the product information sheet.
1702270|NCT01448993|Drug|Azithromycin|Taking 250mg azithromycin 3 times per week in alternate days.
1702271|NCT01448993|Drug|Placebo|
1702272|NCT01448980|Procedure|Thai Traditional Massage (TTM)|Thai Traditional Massage will receive massage 2 time per week for 6 weeks
1702273|NCT01448980|Procedure|Physical therapy program|Physical therapy program 2 times per week for 6 weeks.
1702274|NCT01448954|Drug|ADC3680B oral|Once daily for 28 days
1702275|NCT01448954|Drug|Placebo oral|Once daily for 28 days
1702276|NCT01448941|Procedure|Temporary extraarticular plate fixation|Arm 1: arthrodesis TMT 1 Arm: 2 temporary extraarticular plate fixation TMT 1
1702277|NCT01448928|Drug|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Patients who have received Zevalin for relapsed or refractory, CD20+, low grade B-cell non-Hodgkin's lymphoma and Mantle cell lymphoma.
1702278|NCT01448902|Drug|OC000459|OC000459 200mg bid for 8 days
1702279|NCT01448902|Drug|Placebo|Placebo bid for 8 days
1702280|NCT01448889|Drug|100% oxigen|patients will recive 100% oxigen in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
1702281|NCT01448889|Drug|placebo|patients will recive 21% oxigen (room air) in a mask with reservoir from the begginind of the procedure to 4 hours after its termination
1702282|NCT01448863|Other|Culture medium metabolomic analysis|"During the embryo transfer at day 3, the investigators keep and freeze a small drop of the culture medium of each embryo transferred. Each drop of culture medium will have a volume of 40-50 microliters, before freezing is spun at 10.000 rps to avoid any possible contamination.
The frozen media culture is analyzed for the metabolomic profile."
1702283|NCT01448850|Biological|MEDI8968 600 mg IV, 300 mg SC|MEDI8968 600 mg as IV infusion on Day 1 followed by 300 mg injection SC every 4 weeks up to Week 53.
1702284|NCT01448850|Other|Placebo|Placebo matched to MEDI8968 as IV infusion on Day 1 followed by SC injection every 4 weeks up to Week 53.
1702285|NCT01448837|Drug|Bimatoprost/Timolol, 24-hour intraocular pressure monitoring|Administered once in the evening
1702286|NCT01448837|Drug|Latanoprost, 24-hour intraocular pressure monitoring|assessment of 24-hour efficacy for the two drugs after 3 months of chronic dosing
1702287|NCT01448824|Drug|LY2484595|Administered orally
1702288|NCT01448824|Drug|Placebo|Administered orally
1702289|NCT01448824|Drug|Ketoconazole|Administered orally
1702290|NCT01448811|Device|AEP monitor|In AEP monitoring group, nurses adjusted propofol dose according to AAI values. If AAI＞40, titrate up propofol dosage, AAI＜25, titrated down propofol dosage.
1702291|NCT01448811|Procedure|Ramsay Sedation Scale|During bronchoscopy, nurses adjusted propofol dose according to Ramsay Sedation Scale.
1702292|NCT01448798|Procedure|Application of a hemostatic gelatin-thrombin matrix|Hemostatic gelatin-thrombin matrix is used for hemostasis during nerve-sparing dissection of the prostate.
1702293|NCT01448798|Procedure|Use of mono- and bipolar electrocautery and surgical clips|Mono- and bipolar electrocautery and surgical clips are used for hemostasis during nerve-sparing dissection of the prostate.
1702294|NCT01448785|Device|abiliti system implant|Subjects will receive implanted abiliti System.
1702295|NCT01448785|Device|Laparoscopic adjustable gastric band (Allergan Lap Band)|Subjects will receive an implanted laparoscopic adjustable gastric band. Specific brand is at the investigator's discretion.
1702296|NCT01448772|Drug|Dronabinol Capsules, 5 mg|Comparison of different routes of administration of a drug using the approved Abbott 5 mg capsule product under fasting conditions; two treatment periods with a washout period separating the study periods
1702297|NCT01448772|Drug|Dronabinol Oral Solution|Comparison of different routes of administration of a drug using a proposed oral solution formulation under fasting conditions; two treatment periods with a washout period separating the study periods
1702298|NCT01448759|Other|blood sampling|Other: Blood sampling 10mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
1702299|NCT01448746|Drug|low molecular weight heparin|40mg 12 hours before surgery and 12 hours later surgery
1702300|NCT01448733|Drug|Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning with with tretinoin 0.05% gel in the evening|Green pea sized amount of Benzoyl peroxide 2.5%/clindamycin phosphate 1.2% in the morning in combination with a green pea sized amount of tretinoin 0.05% gel in the evening
1702301|NCT01448720|Drug|Paliperidone palmitate|Type=exact number, unit=mg, number=150, 100, 75 mg equivalent (eq), form=suspension for injection, route=intramuscular use. One IM injection of 150 mq on Day 1, 100 mg eq. on Day 8 (+/- 4 days), and 75 mg eq. is recommended on Days 36, 64, and 92.
1702302|NCT01448707|Drug|Darunavir|Darunavir (DRV): type = exact number, unit = mg, number = 800, form = tablet, route = oral use
1702303|NCT01448707|Drug|Ritonavir|ritonavir (rtv): type = exact number, unit = mg, number = 100, form = tablet, route = oral use
1702304|NCT01448694|Other|No treatment|No treatment, only collecting observational data.
1702305|NCT01448681|Other|No Interventions|
1702308|NCT01448629|Device|Standard Care|"Participants are using their own product and this procedure is called Standard Care.
Standard Care are the participants own products and may consist of several manufacturer and brand names."
1702309|NCT01448629|Device|River|River is a new developed product with Coloplast as manufacturer
1702310|NCT01448616|Drug|TDF|Oral tenofovir will be administered as tablets. TDF (Viread®) tablets contain 300 mg of tenofovir disoproxil fumarate, which is equivalent to 245 mg of tenofovir disoproxil. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
1702311|NCT01448616|Drug|Placebo Vaginal Gel|"Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
The placebo gel (known as the 'universal' placebo gel) is formulated to minimize any possible effects — negative or positive — on study endpoints."
1702312|NCT01448616|Drug|Vaginal TFV Gel|Tenofovir 1% gel (w/w) is a gel formulation of tenofovir. Study participants are instructed to insert one dose (the entire contents of one applicator) of product into the vagina once each day. They are instructed to insert their gel as close to the same time each day as possible.
1702313|NCT01448616|Drug|Placebo Tablets|TDF placebo tablets are film-coated and contain denatonium benzoate, a bittering agent, in addition to other inactive ingredients. Study participants are instructed to take the one tablet, by mouth, once each day without regard to meals.
1702314|NCT01448603|Biological|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
1702315|NCT01448603|Biological|ToleroMune Ragweed|No further medication to be administered in this study. Intervention refers to treatment received in Study TR002.
1702318|NCT01448551|Behavioral|Tailored Mobile Messages to Enhance Weight Loss for Teens|For this trial adolescents will be allowed to use their own phone (with reimbursement for any study-related costs), or will be provided with a mobile phone, if requested. Participants will receive messages delivered daily over the course of 20 weeks. The content of the messages will be tailored on participants' responses to the MPOWER enrollment survey and the initial tailoring questionnaire. On school days, all messages will be sent after 3 pm (which is after school hours for most Michigan middle and high schools). Therefore, patients will not need to carry cell phones to school. The tailored messages will utilize various degrees of personalization, adaptation and feedback - including momentary assessments with feedback requiring a text reply from the adolescents.
1702319|NCT01448538|Drug|Anti-VEGF injections|All Anti-VEGF injections approved for the German market, dosages as defined by doctors
1702320|NCT01448525|Drug|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
1702321|NCT01448525|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied to the upper eyelid margin of both eyes once daily in the evenings for 16 weeks.
1702322|NCT01448512|Behavioral|PartnerPlus Intervention|The intervention employs a closed, structured, group intervention limited to 10 participants (women or men). Four weekly, 11/2-2 hour sessions are led by a trained gender-congruent counselor and a peer facilitator and emphasize group participation, cognitive-behavioral skill building, sexual negotiation and experimentation with products.
1702323|NCT01448512|Other|Usual Care|4 time matched sessions focused on health education
1702324|NCT01448499|Drug|Clozapine|escalating dose of clozapine up to 900 mg/day
1702325|NCT01448499|Drug|Amisulpride|escalating dose of amisulpride up to 800 mg/day
1702326|NCT01448499|Drug|Clozapine+Amisulpride|augmentation of clozapine with amisulpride
1702327|NCT01448486|Drug|Raltegravir|Oral raltegravir, 400 mg tablet, twice daily for one year.
1702328|NCT01448473|Other|4-views series|The 4-film series will include the following views: anterior-posterior; one lateral; Waters, and Townes views.
1702329|NCT01448473|Other|2-views serie|The 2-film series will include the following views: anterior-posterior and one lateral.
1702330|NCT01448447|Device|Mammosite ML|34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days
1702331|NCT01448447|Device|Mammosite ML|5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)
1702332|NCT01448434|Biological|Ex- vivo cultured adult allogeneic MSCs|Single intraarticular dose of allogeneic MSCs suspended in 2ml Plasmalyte followed by 2ml of Hyaluronan
1702333|NCT01448434|Biological|Plasmalyte-A|Single intraarticular dose of 2ml Plasmalyte followed by 2ml Hyaluronan
1702334|NCT01448421|Device|SMT Embolic Deflection Device|The SMT Embolic Deflection Device is used in the aortic arch to deflect and to reduce embolic material (debris/thrombus) to the cerebral/carotid arteries during endovascular procedures.
1702336|NCT01448382|Device|PillCam® capsule with Given PillCam® Platform|capsule endoscopy
1702337|NCT01448369|Device|Blephasteam|10 minute treatment twice daily
1702338|NCT01448369|Device|EyeGiene|10 minute treatment, twice daily
1702339|NCT01448369|Device|Hot compresses|10 minute treatment, twice daily
1702340|NCT01448356|Procedure|temperature and humidity|"The volunteer is exposed to a controlled environment with a chamber setting of:
25°C and 45% humidity;
25°C and 65% humidity;
30°C and 45% humidity;
30°C and 65% humidity
After an adaptation period of at least 20 minutes, participants underwent measurements of tear evaporation and tear film break up time. After collection of data, the chamber settings were adjusted to the next condition."
1702341|NCT01448343|Device|Fluid management system 2000 (FMS)|The FMS has an integrated large volume (about 3000 ml) reservoir and delivers a blood mixture (4 unit RBC, 4 unit FFP and 800 ml normal saline) put in the reservoir at a maximum rate of 750 ml/min.
1702342|NCT01448330|Drug|HCP0911 / clopidogrel, aspirin|combination tablet vs coadministration
1702343|NCT01448317|Drug|Alirocumab (Solution)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1702344|NCT01448317|Drug|Alirocumab (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation
Route of administration: subcutaneous"
1702345|NCT01448317|Drug|Placebo (Solution)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1702346|NCT01448317|Drug|Placebo (Lyophilized formulation)|"Pharmaceutical form: lyophilized formulation
Route of administration: Subcutaneous"
1702347|NCT01448304|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
1702348|NCT01448291|Drug|Etonogestrel /Ethinyl Estradiol Contraceptive Vaginal Ring|Etonogestrel 0.12mg/Ethinyl Estradiol 0.015mg Vaginal Ring (NuvaRing®) for 3 months
1702349|NCT01448278|Procedure|"All-inside"|"The All-inside technique is a new minimally invasive procedure for anterior cruciate ligament reconstruction (ACL). It consists of incomplete bone tunnels drilling and cortical fixation."
1702350|NCT01448278|Procedure|Classical technique|The Classical technique is a usual procedure for anterior cruciate ligament reconstruction (ACL). The fixation is achieved with interference screws.
1702351|NCT01448265|Procedure|Cryoballoon ablation.|Cryoballoon ablation using a novel circular mapping catheter.
1702352|NCT01448252|Biological|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides)|multiple (4 autologous subcutaneous T cell vaccinations with T cell lines reactive to nine myelin peptides at days 1, 30,90,180
1702353|NCT01448252|Biological|T cell vaccination|Multiple injections of autologous T cell lines reactive to 9 myelin peptides.
1702354|NCT01448239|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
1702355|NCT01448239|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:Solution Route of administration: Subcutaneous
1702356|NCT01448213|Drug|Prednisolone acetate|Subjects assigned to Treatment Regimen A will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for 3 months, then 3 times a day for one month, then twice a day for one month, then once a day until the subject exits the study.
1702357|NCT01448213|Drug|Fluorometholone|Subjects assigned to Treatment Regimen B will instill 1 drop of prednisolone acetate 1% four times a day in the transplant eye for one month. Then they will instill one drop of fluorometholone four times a day in the transplant eye for 2 months, then 3 times a day for 1 month, then twice a day for 1 month, then once a day until the subject exits the study.
1702358|NCT01448200|Drug|PPI-668|capsules
1702359|NCT01448200|Drug|Placebo|capsules
1702360|NCT01448174|Drug|Atorvastatin|"Atorvastatin (10 - 80 mg/day) will be administered orally in the one evening dose in the case of strict indications for such a treatment. Before starting atorvastatin, serum lipid profile will be examined two times, and when both results are abnormal the treatment is started. Duration of administration:
atorvastatin 12 weeks, 6 weeks washout, placebo 12 weeks or
placebo 12 weeks,6 weeks washout,atorvastatin 12 weeks."
1702361|NCT01448148|Other|Cognitive intervention|Different strategies will be included to improve episodic memory. Training on imagery will be provided prior to episodic training.Particular attention will be paid to memory self-efficacy and the negative perception that elderly individuals entertain about memory tasks. The issue of generalization is of major importance in cognitive therapy.
1702362|NCT01448148|Other|Psychosocial intervention|Based on a cognitive-behavioural approach, the psychosocial intervention will aim at improving general psychological well-being or preventing psychological distress in persons with MCI.
1702363|NCT01448135|Other|VITAL AF|Semi-elemental, high protein, and high omega-3 fish oil enteral formula
1702364|NCT01448135|Other|Osmolite 1.2|High protein enteral formula
1702365|NCT01448122|Other|Avene Compact Honey SPF 50|Patients will have part of their back covered with 2 mg/mL of Avene Compact Honey SPF 50.
1702366|NCT01448109|Drug|Hydrocortisone|Hydrocortisone 100mg vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion at rate of 200mg/per day for 7 days.
1702367|NCT01448109|Drug|Sterile air filled vial|"the sterile air filled vial (blinded) is reconstituted with 2ml of water for Injection, agitated for 20 seconds, rested for 3 minutes, contents of vial aspirated and added to 100ml bag of normal saline or 5% dextrose and given intravenously as a continuous infusion. 2 sterile air filled vials per day for 7 days"
1702368|NCT01448096|Drug|Rituximab|R-CHOP21 consist of rituximab (375 mg/m2), cyclophosphamide (750 mg/m2), doxorubicin (50 mg/m2), and vincristine (1.4 mg/m2, a maximum of 2mg), administered intravenously on day 1 and 100 mg oral prednisone on days 1 through 5.
1702369|NCT01448096|Procedure|Prophylactic intrathecal chemotherapy|Prophylactic intrathecal chemotherapy using methotrexate (12mg total dose) will be performed
1702370|NCT01448083|Other|Standard of care diagnostic MIBG scan for neuroendocrine tumor diagnosis.|Each subject will receive a 370 MBq (10 mCi ) (±10%) injection of I- 123 MIBG. Myocardial I-123 MIBG uptake will be quantitatively measured over time via planar imaging acquired at 15 minutes, one, two, four, and at 24 hours (the standard of care time point for NET patient imaging) post I-123MIBG injection.
1702371|NCT01448070|Drug|human insulin|Single dose of 0.2 IU/kg, administered subcutaneously (under the skin)
1702413|NCT01447706|Drug|Paclitaxel|Standard dosing Paclitaxel (IV)
1760830|NCT00285844|Drug|thiazolidinedione|
1702372|NCT01448057|Drug|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets|Paracetamol (500 mg)/dimethindene maleate (1 mg)/ phenylephrine hydrochloride (10 mg) tablets
1702373|NCT01448057|Drug|Paracetamol (500 mg) tablets|Paracetamol (500 mg) tablets
1702374|NCT01448044|Drug|BMS-790052 (NS5A Replication Complex Inhibitor)|
1702375|NCT01448044|Drug|Placebo matching BMS-790052|
1702376|NCT01448044|Drug|Pegylated-interferon alfa 2a|
1702377|NCT01448044|Drug|Ribavirin|
1702378|NCT01448031|Drug|Capsule ASA 81mg/esomeprazole 20mg|Multiple doses administered on Day 1 to 5
1702379|NCT01448031|Drug|Acetylsalicylzuur Apotex Cardio|Multiple doses administered on Day 1 to 5
1702380|NCT01448018|Drug|ranibizumab|3 monthly intravitreous injection as soon as possible after the inclusion
1702381|NCT01448018|Procedure|hemodilution|hemodilution using erythrocytapheresis - target hematocrit: 35% - as soon as possible after the inclusion
1702382|NCT01448005|Device|wearable defibrillator (LifeVest)|A wearable defibrillator automatically detects and treats ventricular tachycardia and ventricular fibrillation without the need for bystander intervention.
1702383|NCT01447992|Device|Portable artificial pancreas system with Control-To-Range|We will test the new portable Control-To-Range system in clinical research center conditions for 10 hours followed by 18 hours of Control-To-Range in a hotel.
1702384|NCT01447979|Device|portable artificial pancreas system with Control-To-Range algorithms|The investigators will test the new portable CTR system in CRC conditions for 10h followed by 18h of CTR in a hotel.
1702385|NCT01447966|Behavioral|Cognitive Behavioral Therapy|Family based cognitive behavioral therapy with exposure and response prevention. Twice weekly for 45-60 minute visits.
1702386|NCT01447953|Other|Activity targeted pain rehabilitation|An activity and life-role targeting rehabilitation programme (ALAR) provided by one of the care givers in the multi-professional rehabilitation teams at each of the eight participating primary health care centres, by ten weekly 1-hour treatment sessions.
1702387|NCT01447953|Other|Treatment as usual|Usual treatment with type of treatment modalities, number, frequency and duration of visits according to the judgement of the muli-professional teams at each primary health care centre.
1702388|NCT01447940|Device|Meos ePortal use|Patients will use Meos ePortal + 2 standard visits (inclusion and 12 months) + additional visits if necessary + HbA1c measure at 6 months
1702389|NCT01447927|Drug|metformin hydrochloride|Given PO QD and BID
1702390|NCT01447927|Other|placebo|Given PO QD and BID
1702391|NCT01447914|Drug|Tivantinib|Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.
1702392|NCT01447914|Other|Diagnostic laboratory biomarker analysis|Correlative studies
1702393|NCT01447914|Other|Questionnaire administration|Ancillary studies
1702394|NCT01447914|Procedure|Quality-of-life assessment|Ancillary studies
1702395|NCT01447888|Drug|150% Oral Morphine Equivalent (OME)|Patients will receive 150% of their oral morphine equivalent (OME) utilizing the drugs Dilaudid and Fentanyl.
1702396|NCT01447888|Other|Clinical Judgment|This method of perioperative parenteral opioid dosing has been used on spine surgery patients, based on clinical decision of the anesthesiologist.
1702397|NCT01447875|Other|Passive Leg Raising|elevation of both legs to a 45 degrees for about 1-2 minute before sedation
1702398|NCT01447875|Drug|propofol or mexmedetomidine|
1702399|NCT01447862|Drug|Brinavess (Vernakalant)|3mg/kg Brinavess (Vernakalant) in 100ml normal saline over 10min. If atrial fibrillation continues after another 15 minutes of observation, patients will receive a second infusion of 2mg/kg Brinavess (Vernakalant) over 10 minutes
1702400|NCT01447862|Drug|Corvert (Ibutilide)|Patients will be given 1mg of Corvert (Ibutilide) in 100ml normal saline intravenously over 10min. If atrial fibrillation continues after another 10 minutes of observation, patients will receive a second infusion of 1mg ibutilide over 10min.
1702401|NCT01447849|Drug|lubiprostone|24mcg twice a day (BID) 1 week
1702402|NCT01447849|Drug|placebo|Placebo pills twice a day for one week.
1702403|NCT01447810|Other|Focused rigidity bi-valve long arm cast|Two focused rigidity bi-valve long arm (upper arm to finger tips) casts will be fabricated for each participant on day one of the constraint-induced therapy (CIT) program. Focused rigidity casting materials are water proof and latex/fiberglass free. Focused rigidity casting does not require use of a cast saw for removal thus decreasing potential for anxiety during the casting process. Casts will be fabricated by therapist trained in the casting technique.
1702404|NCT01447797|Drug|HCP0912 / Irbesartan and Atorvastatin|Irbesartan and Atorvastatin combination tablet / coadministration of Irbesartan and Atorvastatin
1702405|NCT01447784|Biological|ToleroMune HDM|Intradermal injection 1 x 11 administrations 4 weeks apart
1702406|NCT01447784|Biological|Placebo|Intradermal injection 1 x 11 administrations 4 weeks apart
1702407|NCT01447771|Behavioral|Decision control preference scale|At time 1, participants in the intervention group will be asked to complete the Decision Control Preference Scale.The range of decision control is measured by the Decision Control Preference (DCP) Scale. The scale is used to measure the preferred or actual role in decision making using five response statements: two represent an active or patient-controlled role, one a shared or collaborative role, and two represent a passive or provider-controlled role. The preferred level of decision making control will be known by the participant in the intervention group and the information given to the oncologist prior to the consultation regarding adjuvant therapy
1702408|NCT01447758|Drug|LEO 29102|Cream, 1,7mg/cm2 BSA, BID, 7 days In Cohort I, II and III, 6 weeks in Cohort IV
1702409|NCT01447758|Drug|LEO 29102 Cream Vehicle|Cream, 1,7mg/cm2 BSA, BID, 7 days in Cohort I and II, 6 weeks in Cohort IV
1702410|NCT01447732|Drug|CEP-37250/KHK2804|"Part 1 is based on the CEP-37250/KHK2804 tolerability and safety data from three subjects enrolled in a cohort, enrollment at the next dose level or additional subjects into the ongoing cohort will occur based upon the number subjects with DLT at a given dose level. Dose depends on subject's body weight. Part 1 includes intervention of CEP-37250/KHK2804.
Part 2 will receive CEP-37250/KHK2804 at a dose to be determined following completion of Part 1."
1702411|NCT01447719|Drug|florbetapir F 18|No study drug administered in this trial. Study subjects previously dosed with 18F-AV-45 in study 18F-AV-45-A07 (NCT00857415) are followed to autopsy in this extension study.
1702414|NCT01447693|Procedure|application of ointment (olive-omega 3 ointment)|
1956030|NCT02993731|Drug|Napabucasin|Napabucasin will be administered orally, twice daily, with doses separated by approximately 12 hours.
1702416|NCT01447654|Drug|Losartan|100 mg for 12 months.
1702417|NCT01447654|Drug|Placebo|100 mg for 12 months.
1702418|NCT01447641|Other|Polysomnography|Overnight physiological recording of sleep
1702419|NCT01447641|Other|Actigraphy|Wristwatch activity to measure basic rest activity cycle and sleep efficiency
1702420|NCT01447628|Drug|Saline|intravenous, no active drug
1702421|NCT01447628|Drug|Ferinject or CosmoFer|Intravenous, 1000 mg iron
1702422|NCT01447615|Behavioral|Bridges|Each child participant in the Bridges Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 1:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges and their families.
1702423|NCT01447615|Behavioral|Bridges PLUS|Each child participant in the Bridges PLUS Arm will receive the usual care in addition to a Child Development Account (CDA) to be used for secondary education by the AIDS-orphaned child. The CDA will be a matched savings account held in the child's name in a financial institution registered by the Central Bank (Bank of Uganda). The account will be matched with money from the program at a match rate of 2:1. Additionally, participants will receive: 1) twelve 1-2 hour workshops focused on asset building, future planning, and protection from risks; 2) mentorship sessions to reinforce learning and build optimism; and 3) a family income-generating /micro-enterprise promotion component for children enrolled in Bridges PLUS and their families.
1702424|NCT01447615|Other|Usual Care|Participants in the usual care condition will receive usual care for AIDS-orphaned children in the study area. This includes: counseling, school lunches, and scholastic materials (textbooks and notebooks). Counseling will be provided by priests in the community (as is currently done).
1702425|NCT01447602|Behavioral|IPT-A|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy as an intervention for adolescent depression
1702426|NCT01447589|Drug|nelfinavir|Nelfinavir tablets BD 7 days per week from D-7 of starting radiotherapy until completion of radiotherapy on D47. 3 dose levels: 750 mg bd; 1000 mg bd; and 1250 mg bd.
1702427|NCT01447589|Radiation|Radical Radiotherapy|Total dose of 66 Gy delivered in 33 fractions (2.0 Gy/fraction) to the primary tumour plus a margin.
1702428|NCT01447576|Drug|ADT|Once daily dosing during the duration of the study.
1702429|NCT01447576|Drug|OPC-34712|OPC-34712, Oral Tablets, 0.25 - 3 mg
1702430|NCT01447563|Drug|Clopidogrel bisulfate|subjects received a single 75 mg tablet of the reference formulation, given with 250 mL water
1702431|NCT01447563|Drug|Clopidogrel|subjects received a single 75 mg tablet of the test formulation, given with 250 mL water
1702432|NCT01447550|Drug|Bosentan|Bosentan therapy consisted of a month's treatment with 62.5 mg bid orally administered. Dose doubled to 125 mg bid after the first month. The full-dose regimen (125 mg/12h) was maintained for the following months or until total healing fo the ulcers.
1702433|NCT01447537|Other|Exercise + relaxation|Exercise + relaxation
1702434|NCT01447537|Other|Relaxation|Relaxation without exercise Patients will receive only relaxation for 3 months
1702435|NCT01447524|Behavioral|Very Low Calorie Diet|Very Low Calorie Diet consisted of a 400 kcal/day diet, with percentage distribution of lipids, proteins and carbohydrates, according to Italian Standards of Care.
1702436|NCT01447511|Drug|Control - Warfarin only|A single 10 mg warfarin dose taken at the start of the study period. No other medications taken during this study period.
1702437|NCT01447511|Drug|Fluconazole - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 400 mg fluconazole taken every morning starting a week before the start of the study period and continuing throughout the study period.
1702438|NCT01447511|Drug|Rifampin - Warfarin|A single 10 mg warfarin dose taken at the start of the study period. 300 mg rifampin taken every morning starting a week before the start of the study period and continuing throughout the study period.
1702439|NCT01447498|Other|Screening for risk factors for ulcer bleeding|"Following PCI the patients fill out a questionnaire to assess the risk factors for ulcer bleeding.We randomise between:
screening and risk assessment
control group
All screened patients, who fulfil the criteria for having a moderate to high risk of ulcer bleeding will be sent written information about risk factors and the purpose of the PPI prophylaxis. They will be recommended PPI prophylaxis (Pantoprazole), as long as they are being treated with low-dose aspirin and clopidogrel.
Patients in the screening group, who are already on PPI treatment is recommended to change to Pantoprazole.
Definition of risk of ulcer bleeding: The table below will be used for screening. Patients scoring ≥ 2 points will receive PPI prophylaxis.
points: Age: < 60: 0; 60-69: 1; 70-79: 2; >=80: 3 ___ Dyspepsia: 1 ___ Uncomplicated ulcer: 2 ___ Complicated ulcer 3 ___ NSAID 2 ___ Steroids 2 ___ SSRI 2 ___ Anticoagulant Tx 2 ___"
1702440|NCT01447485|Drug|Valsartan (VAL489)|
1702441|NCT01447472|Drug|MDMA|One single dose of MDMA ( 1.5 mg/kg; range: 75-100 mg)
1702442|NCT01447459|Behavioral|Reinforced Asthma Education|"Before beginning the actual study, a board-certified Asthma Educator (AE) will prepare and administer an asthma education training session for the study personnel, including the PI, the co-investigators, and the study coordinator. The AE will also make herself available via pager for assistance with questions from the study personnel regarding asthma education.
At the end of the administration of the phone surveys (i.e. at 2 weeks, 1 month and 3 months following enrollment), the study coordinator will provide reinforced asthma education to the caregiver via telephone for the subjects enrolled in Group A (the intervention group). The reinforced asthma education will be consistent with the asthma education training session delivered by the AE before the beginning of the study."
1702443|NCT01447446|Drug|Peg-IFN Alfa-2a|Peg-IFN Alfa-2a according to standard of care and in line with local labeling.
1702444|NCT01447446|Drug|Peg-IFN Alfa-2b|Peg-IFN Alfa-2b according to standard of care and in line with local labeling.
1702445|NCT01447446|Drug|Ribavirin|Ribavirin according to standard of care and in line with local labeling.
1702446|NCT01447446|Drug|Boceprevir|Boceprevir according to standard of care and in line with local labeling.
1702447|NCT01447446|Drug|Telaprevir|Telaprevir according to standard of care and in line with local labeling.
1702448|NCT01447433|Drug|Calcium Carbonate|tablet, 600mg elemental calcium and 125IU vitamin D, once daily, for 12 weeks
1702449|NCT01447433|Behavioral|Energy restriction|A balanced diet contains 500kcal of caloric deficit based on daily energy expenditure.
1702450|NCT01447420|Drug|peginterferon alfa-2a|180 mcg sc weekly, 48 weeks
1702451|NCT01447420|Drug|ribavirin [Copegus]|1'000 or 1'200 mg orally daily, 48 weeks
1702452|NCT01447407|Biological|NDV-3 vaccine with alum administered IM|One dose administered IM
1702453|NCT01447407|Biological|NDV-3 vaccine without alum administered IM|One dose administered IM
1702454|NCT01447407|Biological|Placebo administered ID|One dose saline placebo administered ID
1702455|NCT01447407|Biological|NDV-3 vaccine without alum administered ID|One dose administered ID
1702456|NCT01447394|Biological|Pegylated Interferon Lambda|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
1702457|NCT01447394|Biological|Pegylated Interferon Alfa-2a|Syringe, Subcutaneous, 180 μg, Once weekly, 48 weeks
1702458|NCT01447394|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
1702459|NCT01447368|Drug|Cinacalcet|oral cinacalcet 25mg once daily as a start and up titrated by 25mg daily according to response in lowering PTH and maximum oral dose allowed is 100mg daily
1702460|NCT01447368|Procedure|Surgical total parathyroidectomy with forearm autografting|Surgical total parathyroidectomy with forearm autografting will be performed
1702461|NCT01447355|Drug|cholecalciferol|Given PO
1702462|NCT01447342|Device|Cryo-Touch II|Percutaneous treatment with the device
1702463|NCT01447329|Other|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The subject will receive five needles intra-operatively on each ear.
1702464|NCT01447329|Drug|Standard Treatment|
1702465|NCT01447316|Other|Subject outcomes following bariatric surgery|Subject outcomes (body composition, gait analysis, lower extremity joint pain and perceived quality of life) measured at per-op, 2, 4 weeks and 3 months.
1702466|NCT01447303|Other|Subject outcomes following viscosupplementation of the knee|The study subject outcomes (WOMAC, VAS, SF-36, Chair rise, Stair climb, Six minute walk and Gait analysis) measured at 1, 3, 6 and 12 months following viscosupplementation of the knee
1956031|NCT02993731|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
1702469|NCT01447264|Procedure|Land exercises|3 times a week. 50 minutes in every session. Performed by educational professor
1702470|NCT01447264|Procedure|Water exercises|3 times a week. 50 minutes in every session. Performed by educational professor
1702471|NCT01447251|Behavioral|PreDx Diabetes Risk Score|The PreDx DRS measures 7 predictive biomarkers -Adiponectin, C-reactive protein (CRP), Ferritin, Glucose, Insulin, IL-2 and HbA1c, using a proprietary algorithm a risk score in order to calculate a risk score. There are three risk strata, with low risk defined as PreDx DRS <4.5, moderate risk as PreDx DRS ≥4.5 and <8.0, and high risk as PreDx DRS ≥8.0.
1702472|NCT01447238|Device|Direct visualization and needle based confocal laser-induced endomicroscopy miniprobe|"Patients will undergo the EUS-FNA procedure, as per standard of care, plus an additional direct visualization (fiber optic probe) and nCLE procedure with the prototype probes, which will add 10 minutes maximum to the EUS-FNA procedure.
The probes will be positioned against the lining of the pancreatic cyst, and images will be acquired. After imaging, fine needle aspiration of the lesion will be performed, as usual."
1702473|NCT01447225|Drug|MM-121|MM-121 administered at 20 mg/kg IV loading dose followed by12mg/kg/week IV or 40 mg/kg IV loading dose followed by 20mg/kg/week IV
1702474|NCT01447225|Drug|Carboplatin|administered at AUC 6
1702475|NCT01447225|Drug|Pemetrexed|administered IV at 500 mg/m2
1702476|NCT01447225|Drug|Cabazitaxel|administered IV at 20 mg/m2 or 25 mg/m2
1702477|NCT01447225|Drug|Gemcitabine|administered IV at 1000 mg/m2 or 1250 mg/m2
1702478|NCT01447212|Drug|Hydromorphone, Injectable|Phase I: 3x daily, up to 500mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable hydromorphone; 2) switch to oral hydromorphone, for another 6 months.
1702479|NCT01447212|Drug|Diacetylmorphine, injectable|Phase I: 3x daily, up to 1,000mg per day, for 6 months. Phase II: At 6 months, participants are randomized to either: 1) stay on injectable diacetylmorphine; 2) switch to oral diacetylmorphine, for another 6 months.
1702480|NCT01447212|Drug|Hydromorphone, liquid oral|Study Phase II: After 6 months of receiving Hydromorphone injectable , participants will be randomized to stay on injectable hydromorphone or switch to oral hydromorphone, for another six months. Oral = experimental; injectable = active comparator
1702481|NCT01447212|Drug|Diacetylmorphine, liquid oral|Study Phase II: After 6 months of receiving Diacetylmorphine injectable, participants will be randomized to stay on injectable Diacetylmorphine or switch to oral Diacetylmorphine, for another six months. Oral = experimental; injectable = active comparator
1702482|NCT01447199|Behavioral|Health and Diet Questionnaire|Mailed questionnaires asking about foods eaten, cooking methods as well as overall health, and vitamin/medication use, taking several hours to complete.
1702483|NCT01447186|Behavioral|Post-Test Questionnaire|Questionnaire following Demographic questionnaire, Pre-Test Knowledge Questionnaire and slide set review.
1702484|NCT01447186|Behavioral|Interviews|Using draft slide set, participants engage in think-aloud exercises, where each slide is reviewed and described.
1702485|NCT01447186|Behavioral|Focus Groups|Up to 40 subjects will participate in the formative focus groups. Each group will be scheduled with 6 to 10 participants to explore Hispanic men's beliefs and concerns about prostate cancer and early detection.
1702486|NCT01447173|Drug|Vitamin D|Vitamin D 2000 IU daily pill Vitamin D 400 IU daily pill
1702487|NCT01447160|Drug|Cortisone|intraarticular infiltration with 1ml of triamcinolone hexacetonide versus intramuscular injection with 1 ml of triamcinolone acetonide
1702488|NCT01447147|Drug|Placebo|Placebo capsules once daily
1702489|NCT01447147|Drug|CCX140-B|CCX140-B capsules once daily (Group B)
1702490|NCT01447147|Drug|CCX140-B|CCX140-B capsules once daily (Group C)
1702491|NCT01447121|Device|Tatsu/Tradewind Investigational BG Monitoring System|Tradewind is a Bayer investigational meter that used an investigational sensor.
1702492|NCT01447108|Device|Low Intensity Low Frequency Surface Acoustic Wave Ultrasound (PainShield™)|"All subjects will be treated four weeks with a placebo PainShield™ while continuing with their current pharmaco- analgesic regimen. Aferterwards all subjects will be crossed over to active Painshield™ therapy for the next four weeks.
The Painshield™ device is a patch, which will be applied to their forehead for six-eight hours during night while sleeping."
1702493|NCT01447095|Drug|Prostacyclin 1 ng/kg/min|Continuous i.v. infusion of epoprostenol 1 ng/kg/min day 5-10 after SAH
1702494|NCT01447095|Drug|Prostacyclin 2 ng/kg/min|Continuous i.v. infusion of epoprostenol 2 ng/kg/min day 5-10 after SAH
1702495|NCT01447095|Drug|Placebo|Continuous i.v. infusion with placebo day 5-10 after SAH
1702496|NCT01447069|Drug|Salbutamol|The initial dose will be 0.5mg bid, with acceleration of the dose every two weeks by 1mg, up to a maximal dose of 2mg bid or an increase in heart rate by 50% above the baseline heart rate, as long as it remains <100 bpm
1702497|NCT01447056|Biological|LMP specific T cells|"Three dose levels will be evaluated:
Dose Level 1: 2×10^7 cells/m2; Dose Level 2: 1×10^8 cells/m2; Dose Level 3: 2×10^8 cells/m2
If patients have a partial response or have stable disease they will be eligible to receive up to 5 further doses of CTLs, each of which will consist of the same number as their first injection."
1702498|NCT01447043|Drug|Ranibizumab|Patients with wet AMD treated with ranibizumab as prescribed by physician
1702499|NCT01447017|Drug|DPK-060|DPK-060 2% ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
1702500|NCT01447017|Drug|Placebo for DPK-060 ear drops|Placebo for DPK-060 ear drops were administered as 3 applications per day into the outer ear by use of a single-dose pipette (0.3 mL/pipette) for 7 days. In case clinical symptoms remained after 7 days of treatment, the treatment period was extended by another 3 days with 3 applications per day.
1702501|NCT01446991|Drug|Degarelix|240 mg loading dose followed by monthly 80 mg maintenance dose for 2-3 months
1702502|NCT01446991|Drug|Degarelix|240 mg loading dose of Degarelix followed by 80 mg maintenance doses every month for a total duration of 6 months.
1702503|NCT01446978|Biological|hepatitis A vaccine|3 doses of hepatitis A vaccine, given at 0+1+6 months
1702504|NCT01446978|Biological|hepatitis A vaccine|Two doses of hepatitis A vaccine given at day 0, one in each M deltoids. An additional dose will be given at 6 months later
1702506|NCT01446952|Drug|Vitamin E δ-Tocotrienol|The first cohort will be dosed with δ-tocotrienol at 200 mg. A minimum of 3 participants is planned for each dosing cohort with Vitamin E δ-Tocotrienol dose escalation dependent on safety from prior cohorts.
1702507|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
1702508|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
1702509|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
1702510|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
1702511|NCT01446926|Biological|Pneumococcal Vaccine Low Dose (Formulation 2)|0.5 mL, Intramuscular
1702512|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
1702513|NCT01446926|Biological|Pneumococcal Vaccine Middle Dose (Formulation 3)|0.5 mL, Intramuscular
1702514|NCT01446926|Biological|Pneumococcal Vaccine Middle Dose (Formulation 4)|0.5 mL, Intramuscular
1702515|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
1702516|NCT01446926|Biological|Pneumococcal Vaccine High Dose (Formulation 1)|0.5 mL, Intramuscular
1702517|NCT01446926|Biological|Tris buffered saline (Placebo)|0.5 mL, Intramuscular
1956032|NCT02993731|Drug|Gemcitabine|Nab-paclitaxel 125 mg/m^2 immediately followed by gemcitabine 1000 mg/m^2 will be administered on Days 1, 8 and 15 of every 28-day cycle via intravenous infusion.
1702520|NCT01446900|Drug|Rituximab|375mg/mq, IV on day 1 of each 28 day cycle for 4 cycles. 375 mg/mq IV every 2 months for a total of 8 administrations as additional infusions for patients, who achieve a partial response or complete response after the therapy with R- 2-CdA.
1702521|NCT01446900|Drug|Cladribine|0,1 mg/Kg, SC from day 1 to day 5 of each 28 day cycle for 4 cycles.
1702522|NCT01446887|Other|prophylactic anticoagulation|prophylactic anticoagulation by rivaroxaban
1702523|NCT01446874|Procedure|Intensive Brushing Regimen|"Toothbrushing 3 times/day for at least 5 days preoperatively using a 0.12% chlorhexidine solution Intubation with tapered polyurethane cuff endotracheal tube with subglottic drainage (Mallinckrodt™ Sealguard™ Evac Endotracheal Tube, Covidien, Mansfield, MA) intraoperatively and postoperatively as indicated, based upon standard clinical practice.
The intensive toothbrushing regimen and chlorhexidine mouthwash will be continued for the duration of the hospitalization or a minimum of 5 days postoperatively in the study group."
1702524|NCT01446848|Dietary Supplement|iron supplement|325 mg tablets by mouth once a day for 1 week, then twice a day for 1 week, then three times daily for the remainder of the 3-month study period.
1702525|NCT01446835|Device|nelfilcon A contact lens with print|Investigational spherical contact lens
1702526|NCT01446835|Device|etafilcon A contact lens with print|Commercially marketed (Singapore) spherical contact lens
1702527|NCT01446822|Device|Bipolar transurethral resection of the urinary bladder (PlasmaKinetic, Gyrus, Fresenius)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection not possible because of adductor muscle contraction, patients undergo relaxation.
1702528|NCT01446822|Device|Monopolar transurethral resection of the urinary bladder (Storz GmbH &Co., Erbotom, Purisole)|Lateral wall urinary bladder tumors are resected transurethrally without obturator nerve block or relaxation under general anesthesia. If resection is not possible because of adductor muscle contraction, patients are treated by bipolar resection. If this is still not possible, they undergo relaxation.
1702537|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to AAI 90
1702538|NCT01446796|Device|Implantable Cardioverter-Defibrillator (subject's pre-existing ICD)|Pacing parameters set to DDD 90-100
1702539|NCT01446783|Drug|mecasermin|0,1 ml mecasermin (10 mg/ml) is injected intratendinous into the patella tendon with ultrasound guidance.
1702540|NCT01446783|Drug|Saline|0,1 ml saline is injected intratendinous into the patella tendon with ultrasound guidance.
1702541|NCT01446770|Device|Hydrogel scaffold (MF-4181)|Following surgical removal of the ear keloid, the incision will be treated with MF-4181.
1702542|NCT01446757|Procedure|The intervention group|Medical assessment (co-morbid condition, physical and neurological examination, medication review, nutrition, and blood-tests to identify anaemia, diabetes, metabolism and liver- and kidney function); assessment of functioning (ADL/IADL, fall risk), psychological assessment (cognitive decline and depression) and assessment of social and environmental conditions. The care plan is based on the CGA and will be individualised and carried out in discussion with the patient and his/her caregivers. The care will be carried out by an inter-professional Geriatric Team with employees from both the county council and the municipality. The team consists of a core team (including geriatrician and nurse) and a support team (including a social worker, occupational therapist, dietician, pharmacist, physiotherapist, and dental hygienist). The care will involve treatment for unstable medical conditions and support of patients and their caregivers. The team will have regular team conferences.
1702543|NCT01446757|Procedure|control group|No intervention
1702544|NCT01446744|Radiation|Stereotactic ablative radiotherapy|Total dose and number of fractions will depend on the site of disease. Treatment will be given daily, or every other day, over 1 -3 weeks.
1702545|NCT01446744|Radiation|palliative radiotherapy|"Investigators should follow the principles of palliative radiotherapy as per the individual institution. Treatment recommendations are as follows:
Brain: Whole brain radiotherapy i.e. 20 Gy in 5 fractions, 30 Gy in 10 fractions
Lung: Palliative radiotherapy as per 2011 consensus guidelines.15 i.e. 8 Gy in 1 fraction, 20 Gy in 5 fractions, 30 Gy in 10 fractions
Bone: Palliative radiotherapy as per 2011 consensus guidelines.16 i.e. 8 Gy in 1 fraction (most common), 20 Gy in 5 fractions, 30 Gy in 10 fractions
Liver: 20 Gy in 5 fractions if standard institutional practice"
1702546|NCT01446731|Biological|mRNA transfected dendritic cell|"Autologues monocytes are matured into dendritic cells which are then transfected with mRNA from PSA, PAP, survivin and hTERT.
5x 10e6 DCs are given as intradermal injections in the groin Day 8 and Day 15 in a 3 week period repeated 4 times and thereafter Day 8 in a 3 week period until progression (no maximum duration)."
1702547|NCT01446731|Drug|Docetaxel|Docetaxel 75 mg/m2 is given as an intravenous injection Day 1 every three weeks in a maximum of 12 cycles (1 cycle = 3 weeks).
1702548|NCT01446718|Biological|Gardasil vaccine|0.5ml of intramuscular vaccine in three doses
1702549|NCT01446705|Other|Active Health Information Exchange|Patients selected to share data between the VA & external healthcare agencies.
1702550|NCT01446705|Other|Non-Active Health Information exchange|Patients not selecting to share data
1702551|NCT01446679|Drug|atrovastatin|oral
1702552|NCT01446653|Behavioral|Motivational Interviewing plus feedback|Provides an MI + feedback intervention supplemented with video and brochures-based information
1702553|NCT01446653|Behavioral|Video|Video arm will provide information via documentary video
1702554|NCT01446653|Behavioral|Informational Brochure|Informational Brochures are given to participants following baseline assessment.
1702555|NCT01446640|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 1x10^6 MSCs per kg; intrathecal administration of up to 1x10^6 MSCs per kg.
1702556|NCT01446627|Other|There is no intervention for this study|None, no intervention made.
1702557|NCT01446614|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks
1702558|NCT01446601|Device|Hypoglossal Nerve Stimulation (HGNS) System (Apnex Medical )|The HGNS System in an investigational device that includes three implantable components: a neurostimulator, a stimulation lead, and a respiration sensing lead. The HGNS System is designed to activate the muscles in the upper airway to help keep the airway open during sleep. The HGNS System is intended for the treatment of moderate to severe OSA in individuals that have failed or do not tolerate positive airway pressure (PAP) therapy.
1702559|NCT01446588|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
1702560|NCT01446562|Biological|Y90 Ibritumomab Tiuxetan RIT|40 mCi/kg
1702561|NCT01446549|Other|High intensive antigravity locomotor exercise|High intensive antigravity locomotor exercise, 3 sessions/week, for 8 weeks.
1702562|NCT01446549|Procedure|Deep Brain Stimulation|Deep Brain Stimulation implantation
1702563|NCT01446536|Other|Checklist cohort|CHF discharge checklist was used arbitrarily by their treating physicians in addition to the standard therapy
1702564|NCT01446523|Drug|placebo|Syrup, 30 ml BD for 3 months in Gr. NL
1702565|NCT01446523|Drug|Lactulose|Syrup 30 ml BD for 12 weeks
1702566|NCT01446510|Other|Application of VTE Risk Assessment|Use of a method to assess a patient's risk of VTE, and then appropriate prophylaxis for the assigned level of risk
1702567|NCT01446497|Drug|Brimonidine/Timolol mixed combination|Twice per day, 1 drop at each time
1702568|NCT01446497|Drug|Timolol|Twice per day, 1 drop at each time
1702569|NCT01446484|Biological|CD4+CD25+CD127lowFoxP3+ T regulatory cells injection|Blood samples from patients in the experimental group will be collected twice with weekly interval in the amount of 70 ml/1,73 m2. T cells CD4+ will be separated from blood samples and frozen in liquid nitrogen. At day 30 after transplantation patients will undergo subcutaneous injection of approximately 2x 10^8 autologous T regs, expanded from previously frozen CD4+ T cells. Levels of T reg cells in patient's blood will be estimated by flow cytometry in a week after injection. That cell injection procedure will be repeated at 6 months after transplantation
1702613|NCT01446133|Drug|Lenalidomide|10 mg/day by mouth daily beginning on Day 9 of cycle 1.
1702570|NCT01446484|Drug|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous infusion on Days 14 - 21 before Tx and on Day 0 after Tx
1702571|NCT01446484|Drug|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 2-3 until withdrawal or end of the study
1702572|NCT01446484|Drug|Sirolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
1702573|NCT01446484|Drug|Tacrolimus|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
1702574|NCT01446484|Drug|Cyclosporine|Immunosuppressant; daily dose starting Day 0 until withdrawal or end of the study
1702575|NCT01446484|Drug|Everolimus|Immunosuppressant; oral daily dose starting no earlier then after Month 1 post-transplant until withdrawal or end of the study
1702576|NCT01446484|Procedure|Kidney transplantation|Living related kidney transplantation
1702577|NCT01446458|Drug|Modified FOLFIRINOX|Patients receive modified FOLFIRINOX Chemotherapy for 4 cycles (1 cycle = 15 days). Modified FOLFIRINOX: Oxaliplatin 85 mg/m2 intravenous infusion on day 1; Irinotecan 180 mg/m2 intravenous infusion on day 1; 5-Fluorouracil 2400 mg/m2 continuous intravenous infusion on days 1 to 3; pegylated filgrastim (neulasta) 6 mg subcutaneous injection on day 3.
1702578|NCT01446458|Radiation|Stereotactic Body Radiotherapy (SBRT)|Patients will receive Stereotactic Body Radiotherapy (SBRT) to pancreas tumor 2 weeks following chemotherapy. SBRT is given in 3 daily fractions at designated doses per treatment cohort. Starting dose level-Dose level 1: 10 Gy SBRT to primary tumor volume (PTV) / 2 Gy SBRT to the retroperitoneal margin daily for a total Gy to Gross tumor volume (GTV) of 36 Gy. There are weekly toxicity assessments for 4 weeks. This is a standard 3 + 3 design with 4 dose levels.
1702579|NCT01446445|Drug|Ganciclovir/ Valganciclovir according to SPC|Doses according to Summaries of Product Characteristics (SPC)
1702580|NCT01446445|Drug|Ganciclovir/ Valganciclovir according to PK model|Doses according to population pharmacokinetic model
1702581|NCT01446419|Device|Intracept Treatment|Percutaneous transpedicular RF ablation of an intraosseous nerve within the lumbar vertebral body to treat chronic axial low back.
1702582|NCT01446419|Device|Sham Treatment|Percutaneous transpedicular access to the lumbar vertebra, no RF ablation delivered.
1702583|NCT01446406|Device|MONARCA|Monitoring affective symptoms entered by the patient every day.
1702584|NCT01446406|Device|NON-MONARCA|A mobile phone for communication purposes only. No application has been installed.
1702585|NCT01446341|Procedure|Below knee plaster casting|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
1702586|NCT01446341|Procedure|Functional rehabilitation|Subjects will be randomly assigned to either immobilization of their lateral ankle sprain with a below knee cast or to enter a functional rehabilitation program
1702587|NCT01446328|Drug|Amisulpride|Tablets, dose range 50-1200 mg/ day
1702588|NCT01446328|Drug|Aripiprazole|Tablets, dose range 5-30 mg/ day
1702589|NCT01446328|Drug|Olanzapine|Tablets, dose range 2.5-20 mg/ day
1702590|NCT01446315|Behavioral|Use of Asthma APGAR system and tools|Practices will use the Asthma APGAR control questionnaire and the care algorithm.
1702591|NCT01446315|Behavioral|Asthma APGAR tools|Usual care
1702592|NCT01446302|Dietary Supplement|Double meal|A standardized meal is served 1 h after start of HD and 1 h after end of HD.
1702593|NCT01446289|Biological|Group B Streptococcus Trivalent Vaccine|Pregnant women who received one injection of Group B Streptococcus Trivalent Vaccine administered intramuscularly.
1702594|NCT01446289|Biological|Placebo|Pregnant women who received one injection of saline solution administered intramuscularly.
1702595|NCT01446276|Dietary Supplement|Resveratrol|500 mg 3 times daily for six month
1702596|NCT01446276|Other|Placebo|1 placebo tablet 3 times daily for six month
1702597|NCT01446263|Procedure|Radial access versus femoral access for coronary angiography and intervention|Radial access or femoral access for coronary angiography and intervention in patients with prior coronary artery bypass grafts
1702598|NCT01446250|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
1702599|NCT01446250|Drug|Boceprevir|BOC 800 mg (4 x 200 mg soft gel capsules) administered orally
1702600|NCT01446250|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
1702601|NCT01446250|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
1702602|NCT01446237|Other|acne system - benzoyl peroxide 2.5%, Salicyclic Acid 0.5%|over the counter acne system
1702603|NCT01446224|Drug|Pazopanib|Patients treated with pazopanib
1702604|NCT01446224|Drug|Other anti-VEGFs|Patients treated with other anti-VEGFs including Bevacizumab, Sorafenib, and Sunitinib
1702605|NCT01446211|Drug|Gusperimus + glucocorticoids|Both severity subgroups will be treated with gusperimus + glucocorticoids up to 12 months.
1702606|NCT01446211|Drug|cyclophosphamide followed by methotrexate (azathioprine) + glucocorticoids or methotrexate (azathioprine) + glucocorticoids|"Severe subgroup: will receive intravenous cyclophosphamide pulses for at least 13 weeks and 22 weeks at maximum, followed by methotrexate + glucocorticoids after achieving a response with BVAS ≤ 2. Patients intolerant to methotrexate and patients with impaired renal function will receive azathioprine + glucocorticoids .
Non-severe subgroup: will receive methotrexate + glucocorticoids (or azathioprine + glucocorticoids for those previously intolerant to methotrexate or with impaired renal function)."
1702607|NCT01446185|Device|Oncotype DX breast cancer test|The Oncotype DX breast cancer test measures the expression of 21 genes of an individual tumor to generate an Recurrence Score result that quantifies the magnitude of chemotherapy benefit and the likelihood of recurrence for early-stage breast cancer patients.
1702608|NCT01446159|Drug|MEDI-573|MEDI-573
1702609|NCT01446159|Drug|Aromatase Inhibitor|aromatase inhibitor
1702610|NCT01446146|Behavioral|Informed decision making|40 minute session with a clinician. Participants will learn about the available PTSD treatment options and will be given a decision aid with more information.
1702611|NCT01446146|Behavioral|Placebo session|Participant will complete clinician-administered measures in a 40-minute session.
1702612|NCT01446133|Drug|Rituximab|375 mg/m2 by vein on Day 1, Day 8, Day 15 and Day 22 and then continued once every 4 weeks during cycles 3-12 (+ 7 days). Rituximab will not be given in Cycle 2.
1702614|NCT01446120|Drug|NPH-Insulin Injection|
1702615|NCT01446120|Drug|Insulin loaded Orally Dissolved Films (insulin-ODF|
1702616|NCT01446107|Other|placement of fissure sealant|placement of resin-based fissure sealant at baseline without replacement
1702617|NCT01446107|Other|fluoride varnish|topical applications of a 5% sodium fluoride (NaF) varnish onto tooth surface every 6 months
1702618|NCT01446107|Other|silver fluoride|topical applications of a 38% silver diamine fluoride (SDF) solution onto tooth surface every year
1702619|NCT01446107|Other|placebo control|application of water onto tooth surface every year
1702620|NCT01446094|Drug|regadenoson|Intravenous administration of 0.4 mg dose of Regadenoson using per routine CMR, as indicated in the package insert.
1702621|NCT01446081|Behavioral|Exercise|Patients will receive an individualized, supervised mixed-modality exercise program created by a CSEP-Certified Exercise Physiologist (CEP). They will perform 30 minutes of light to moderate intensity exercise 4-5 times/week tailored to ability. Aerobic exercise will primarily consist of walking and/or stationary cycling. Resistance exercises will target large muscle groups using dumbbells, resistance bands, and stability balls. The CEP will monitor and document details of each exercise session as well as patient tolerance and symptoms, and make appropriate adaptations to ensure program safety and progression. Exercise intensity and duration will vary based on patient tolerance, symptoms and blood parameters. Exercise equipment will be carefully sanitized between each use.
1702622|NCT01446068|Dietary Supplement|High-fat meal|Three caloric doses of high-fat meal (500, 1000, 1500 kcal)
1702623|NCT01446055|Device|ResQ processed bone marrow sample|Autologous bone marrow is processed with ResQ at point of care, prior to the transplantation
1702624|NCT01446055|Device|Ficoll conventional cell processing method|Comparison of different cell processing methods
1702625|NCT01446042|Drug|Testosterone|Intranasal testosterone
1702626|NCT01446042|Drug|Testosterone|Intranasal testosterone
1702627|NCT01446029|Device|Video Telemonitoring Device with Clinical Care Modules|Telemonitoring of vital signs; videoconferencing, remote titration of diabetes, blood pressure, and lipid medications using evidence based treatment algorithm, and cooperative goal setting using education modules to enhance lifestyle changes
1702628|NCT01446016|Drug|Taxane|Chloroquine 250mg po daily together with Paclitaxel (Taxane) 175 mg/m2 three hours infusion every three weeks.
1702629|NCT01446016|Drug|Taxotere|Chloroquine 250mg po daily together with Taxotere 75 mg/m2 administered intravenously over one hour every three weeks
1702630|NCT01446016|Drug|Abraxane|Chloroquine 250mg po daily together with Abraxane 260 mg/m2 administered intravenously over 30 minutes every three weeks.
1702631|NCT01446016|Drug|Ixabepilone|Chloroquine 250mg po daily together with Ixabepilone is 40 mg/m2 administered intravenously over three hours every three weeks.
1702632|NCT01446003|Drug|MK-8457|10 x 10-mg capsule BID for 10 days
1702633|NCT01446003|Drug|Placebo for MK-8457|10 x 10-mg capsule BID for 10 days
1702634|NCT01445990|Device|Lactate-meter: LactatePro (ARKRAY Inc)|Capillary glucose and lactate measurement. Every hours for the first 24 hours, and every 4 hours for the next 4 days.
1702635|NCT01445964|Drug|Atenolol|Atenolol oral administration
1702636|NCT01445964|Drug|Atenolol with apple juice 1200 mL|Atenolol oral administration with apple juice 1200 mL
1702637|NCT01445964|Drug|Atenolol with apple juice 600 mL|Atenolol oral administration with apple juice 600 mL
1702638|NCT01445951|Drug|Technosphere® Insulin with MedTone C Inhaler|Inhalation Powder and injectable insulin
1702639|NCT01445951|Drug|Technosphere ®Insulin with Gen2 Inhaler|Inhalation Powder and injectable insulin
1702640|NCT01445951|Drug|Insulin Aspart in combination with a basal insulin|Injectable insulin
1702641|NCT01445938|Drug|SAR97276A|"Pharmaceutical form:solution for injection
Route of administration: intramuscular"
1702642|NCT01445938|Drug|arthemeter + lumefantrine (ACTs)|"Pharmaceutical form:tablet
Route of administration: oral"
1702646|NCT01445899|Drug|PF-04523655 (Stratum I)|PF-04523655 (a small interfering RNA) - a single IVT injection
1702647|NCT01445899|Drug|ranibizumab|6 monthly IVT injections of ranibizumab (Stratum II)
1702648|NCT01445899|Drug|PF-04523655 (Stratum II)|6 monthly IVT injections of PF-04523655 (a small interfering RNA)
1702651|NCT01445873|Drug|Sitaxentan sodium|Sitaxentan sodium 100 mg / day
1702652|NCT01445860|Drug|Simvastatin/PF-03882845|Single dose 20 mg simvastatin on Day 1, 30 mg PF-03882845 once daily from Days 2 to 13, the single dose 20 mg simvastatin on Day 12.
1702721|NCT01445275|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
1956046|NCT02988440|Drug|PDR001|PDR001 will be administered intravenously
1956047|NCT02988440|Drug|Sorafenib|Sorafenib is formulated as a tablet.
1702653|NCT01445847|Drug|Lidocaine|1 mg/kg or 1 mL/10 kg prior to extubation period. Injection of Lidocaine will be immediately when inhalational agent (Desflurane) is discontinued.
1702654|NCT01445847|Other|Placebo|1 mL/10 kg prior to extubation period. Injection of placebo will be immediately when inhalational agent (Desflurane) is discontinued.
1702655|NCT01445821|Procedure|Cytoxan rATG/Fludarabine/HSCT|The conditioning regimen will be 120 mg/kg of intravenous cyclophosphamide given in 2 equal fractions on days -3 and -2 with intravenous mesna. Rabbit anti-thymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Fludarabine 30 g/m2 will be given IV on days -5, -4, and -3. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. PBSC will be infused intravenously on day 0. Filgrastrim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
1702656|NCT01445821|Procedure|Cytoxan rATG/HSCT|The control arm will have the same conditioning regimen used in ASSIST study. The conditioning regimen will be 200 mg/kg of intravenous cyclophosphamide given in 4 equal fractions on days -5 through -2 with intravenous mesna. Rabbit antithymocyte globulin (rATG) (Thymoglobulin®) will be dosed at 0.5 mg/kg on day-5 and then 1.5 mg/kg from day-4 thru day -1. Methylprednisolone 1000 mg will be used infused intravenously before each dose of rATG. PBSC will be infused intravenously on day 0. Filgrastrim 5-10 mcg/kg will be started on day + 5 and continued until neutrophil engraftment.
1702657|NCT01445808|Behavioral|Psychodynamic Motivation and Training Program (PMT)|The Psychodynamic Motivation and Training Program (PMT) is a psychodynamic stepped care approach. Depending on the individual needs PMT consists of 3 to 8 sessions of individual psychodynamic psychotherapy. If appropriate session 4 - 8 may be conducted by a nurse. PMT targets the mental and external barriers to improve physical activity by focusing on affects, interpersonal relations and maladaptive self- and other representations. PMT will be offered in addition to +Ex.
1702658|NCT01445808|Behavioral|Advice in Exercise Training (+Ex)|Advice in Exercise Training consists of one individual session of advice in exercise training based on the results of the spiroergometry.
1702659|NCT01445808|Other|Treatment as usual (TAU)|Usual care by family doctor, cardiologist
1702660|NCT01445795|Drug|200 mg INX-08189 Fasted|200 mg capsule INX-08189 fasted x7 days
1702661|NCT01445795|Drug|Placebo QD Fasted|Placebo capsule QD fasted x7 days
1702662|NCT01445795|Drug|100 mg INX-08189 QD|100 mg INX-08189 capsule QD x 7 days
1702663|NCT01445795|Drug|Placebo QD|Placebo capsule Placebo QD dosed with ribavirin x7 days (ribavirin will be dosed in a weight-based fashion as labeled BID)
1702664|NCT01445795|Drug|100 mg INX-08189 with low-fat meal|INX-08189 100 mg capsule, with low-fat meal QD for seven days
1702665|NCT01445795|Drug|Placebo with low-fat meal|Placebo capsule administered with a low-fat meal QD for seven days
1702666|NCT01445795|Drug|100 mg INX-08189 BID Fasted|100 mg INX-08189 BID fasted x7 days
1702667|NCT01445795|Drug|Placebo BID Fasted|Placebo BID fasted x7 days
1702668|NCT01445795|Drug|ribavirin|
1702669|NCT01445782|Drug|AZD2115|Multiple dose, oral inhalation (nebuliser solution)
1702670|NCT01445782|Drug|Placebo|Multiple dose, oral inhalation (nebuliser solution)
1702671|NCT01445769|Drug|Ruxolitinib|Ruxolitinib was provided as 5 mg tablets. Dose increases were only permitted at wks 12 & 18 for lack of efficacy. Increases were restricted to patients who didn't meet criteria for a dose hold over the prior 6 wks, had a platelet count ≥ 100 x 10^9/L at wk 12 or ≥ 150 x 10^9/L at wk 18, and had a self-reported PGIC score of 3 (minimally improved) to 7 (very much worse) OR the subject's palpable spleen length below the costal margin was reduced by less than 40% relative to Baseline. Dose increases were elective and not required. Subjects were permitted a dose increase of 5 mg BID to 15 mg BID at wk 12 and to a maximum of 20 mg BID at wk 18. The protocol required dose decreases for thrombocytopenia (platelets <100 x 10^9/L) or protocol-defined anemia (decline in hemoglobin of at least 2 g/dL to a level < 8 g/dL, development of transfusion dependence, or a 50% increase in transfusion requirements for transfusion dependent subjects).
1702672|NCT01445756|Drug|Lidocaine|During the procedure (placement of the IUD), 1ml of gel will be applied to the anterior lip of the cervix. After 1 minute of waiting, a tenaculum will be placed to steady the cervix. The catheter will be introduced into the cervical canal, past the external os and 1-1.5ml of gel will be placed into the canal. After another minute, the IUD will be placed in the standard fashion.
1702673|NCT01445756|Drug|Placebo|Placebo; no topical lidocaine administered
1702674|NCT01445743|Biological|Biological/Vaccine: Tdap Vaccine|Biological: Tdap Intervention comprises 104 randomly assigned pregnant women who will receive a blinded dose of Tdap vaccine (ADACEL) containing 2.5 ug of detoxified pertussis toxin (PT), filamentous haemagglutinin 5 ug, 3 ug Pertactina; 5 ug Fimbriae type 2 and 3, (in addition to Tetanus Toxoid (5 Lf) and diphtheria toxoid (2Lf) as a single 0.5 mL intramuscular injection into the deltoid.
1702675|NCT01445730|Dietary Supplement|Fructose|fructose drink 75 g/day per day while consuming a self-selected ad libitum diet
1702676|NCT01445730|Dietary Supplement|Fructose|3 month fructose diet 75 g/day while consuming isocaloric diet
1702677|NCT01445704|Dietary Supplement|Probiotics|"The probiotic supplementation will use lactic acid bacteria in the ProbioMax DF™ supplement from Xymogen, Inc. This preparation consists of a four-strain probiotic with 100 billion CFU per vegetable capsule. The strains included are Lactobacillus acidophilus La-14, Bifidobacterium lactis HN019, Lactobacillus planarum Lp-115, and Bifidobacterium longum B1-05."
1702678|NCT01445704|Dietary Supplement|Placebo|The placebo supplementation is identical-looking to the capsule of the probiotic supplementation.
1702679|NCT01445691|Drug|5-ALA (Gliolan)|20 mg/kg administered once 3-5 hours prior to surgery
1702680|NCT01445678|Drug|CXA-201 and metronidazole|CXA-201 IV infusion (1500mg q8h) and metronidazole IV infusion (500mg q 8h) for 4-14 days
1702681|NCT01445678|Drug|Meropenem|Meropenem IV infusion (1000mg q8h) for 4-14 days
1702682|NCT01445652|Device|nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
1702683|NCT01445652|Other|Spectacles|Spectacles per current prescription
1702684|NCT01445639|Drug|Dexmedetomidine|Intravenous infusion at rate of 0.4μg/kg/h, during the first 24 hours postoperatively
1702685|NCT01445639|Drug|Normal saline|as placebo
1702686|NCT01445626|Drug|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
1760925|NCT00286689|Drug|Growth Hormone|
1702687|NCT01445613|Device|RX Acculink Carotid Stent System (RX Acculink)|Those patients receiving the RX Acculink used with an Embolic Protection System (EPS) approved for use with RX Acculink.
1702688|NCT01445600|Drug|ALTARGO(retapamulin)|Basically there is no treatment allocation. Subjects who would be administered of ALTARGO(retapamulin) at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
1702689|NCT01445587|Drug|Part 1; Cohort 1|On Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 125mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 125mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the dose will be escalated to 150mg GSK2110183 for the subject enrolled to Cohort 2. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
1702690|NCT01445587|Drug|Part 1; Cohort 2|For Cohort 2, on Cycle 0, Day -3, three subjects will be enrolled to receive a single oral dose of 150mg GSK2110183. After the 72 hour PK sampling is completed, the subjects will continue the 150mg GSK2110183 dose daily for 21 day cycles. If none of the 3 subjects experience one of the DLTs listed in the protocol during Cycle 1, the MTD will be determined unless the PK and Pharmacodynamic data indicates another dose level should be evaluated. Alternately, if 1 subject reports a DLT, then 3 more subjects will be enrolled at the same dose. If 2 of 6 subjects report a DLT, then the MTD has been exceeded. Subjects will remain on study until they meet one of the Treatment Discontinuation Criteria.
1702691|NCT01445587|Drug|Part 2; Stage 1|Following the completion of PK sampling and the determination of a Recommended Phase 2 Dose (RP2D) of GSK2110183 in Cohorts 1 and 2, subjects will be enrolled into Part 2, Stage 1 of the study. Twenty subjects will be enrolled in Stage 1. If no subject responds, the study will be stopped; otherwise, the study will continue enrollment of Stage 2.
1702692|NCT01445587|Drug|Part 2, Stage 2|Twenty subjects will be enrolled in Part 2, Stage 2. If 4 or fewer of the 40 subjects (Stages 1 and 2) respond, the study will not be deemed as a success for GSK2110183 monotherapy. However, those subjects meeting the criteria for progression (as defined by IMWC Panel 1) who also meet the additional eligibility criteria for salvage therapy may proceed to GSK2110183 + bortezomib salvage therapy. GSK2110183 + bortezomib salvage therapy will be continued until one of the Treatment Discontinuation Criteria is met
1702695|NCT01445548|Drug|Sirolimus|
1702699|NCT01445522|Drug|ABT-888|
1702700|NCT01445522|Drug|Cyclophosphamide|
1702703|NCT01445444|Behavioral|Habit Reversal Training|"8 weekly therapy sessions lasting 50 minutes based on the protocol outlined by Woods (2001).
The overall focus of treatment is to provide patients with tools to help them manage and reduce hair-pulling.
components:
Session 1. (a) to develop an understanding of the subject's hair-pulling through an initial interview; and (b) to establish a protocol for ongoing assessment.
Session 2. implement habit reversal, including awareness training, competing response training, and social support.
Sessions 3-8. For subjects with a single hair-pulling site, Session 3 will review and practice HRT procedures and name solutions to problems that may have arisen. For those with multiple hair-pulling sites, treatment will be reviewed for the first site in the hierarchy."
1702704|NCT01445431|Other|Virgin Coconut Oil|Virgin coconut oil applied to the test site twice daily for four weeks
1702705|NCT01445431|Other|Mineral Oil|Mineral oil applied to the test site twice daily for four weeks
1702707|NCT01445405|Drug|Bortezomib (Velcade, PS-341)|
1702708|NCT01445405|Drug|Cetuximab|
1702709|NCT01445405|Drug|Cisplatin|
1702710|NCT01445405|Procedure|Radiation Therapy|
1702715|NCT01445379|Drug|Ipilimumab|Dose Level Escalation: 1mg/kg, 3mg/kg, 5mg/kg, 10mg/kg
1702716|NCT01445366|Device|High volume post dilution hemodiafiltration|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
1702717|NCT01445366|Device|high flux hemodialysis|The midweek dialysis sessions of the patients is changed once to a 4 hours high volume post dilution hemodiafiltration (HDF) session, and once to an 8 hours high flux hemodialysis (HD) session.
1702718|NCT01445340|Drug|Romidepsin (FR901228)|
1761471|NCT00288652|Drug|[S,S]-Reboxetine|
1956053|NCT02984878|Device|Revanesse Ultra|Nasolabial Fold correction
1956061|NCT02979431|Biological|ALX-0171 Dose 1|
1956062|NCT02979431|Biological|ALX-0171 Dose 2|
1702722|NCT01445275|Other|Medical Chart Review|Ancillary study
1702723|NCT01445275|Other|Study of Socioeconomic and Demographic Variables|Ancillary studies
1702724|NCT01445262|Drug|Levocetirizine|
1702725|NCT01445249|Procedure|Landmark guided ankle block.|25-30mls 0.5% levobupivacaine will be infiltrated to provide a landmark guided ankle block.
1702726|NCT01445249|Procedure|PNS guided block.|This group will have 25-30mls of 0.5% levobupivacaine infiltrated as directed by peripheral nerve stimulation.
1702727|NCT01445236|Other|Immunosuppresion withdrawal|Gradual discontinuation of all immunosuppressive drugs.
1702728|NCT01445223|Drug|Lopinavir ritonavir|400mg BD 100mg BD
1702729|NCT01445223|Drug|Atazanavir ritonavir|300mg QD 100mg QD
1702730|NCT01445223|Drug|Efavirenz|600mg QD
1702731|NCT01445210|Procedure|Continuous saphenous nerve block|0,2% Ropivacaine by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
1702732|NCT01445210|Procedure|Placebo|Isoton saline by elastomeric infusion pump at 5 ml/h for 48 postoperative hours
1702733|NCT01445197|Biological|Biostate|200 IU/kg administered daily
1702734|NCT01445171|Device|Aortic Valve Replacement with EDWARDS INTUITY Valve System|Aortic Valve bioprosthesis
1702735|NCT01445132|Drug|Allogeneic Cell Therapy w/ Tumor-derived Lypho|
1702736|NCT01445119|Drug|Enzastaurin (LY317615)|
1702737|NCT01445119|Drug|Carboplatin|
1702738|NCT01445106|Drug|Nelfinavir|
1702739|NCT01445106|Drug|Nelfinavir Mesylate|
1702740|NCT01445080|Drug|Sorafenib|Administered orally BID continuously. 28 days will be considered a cycle
1702741|NCT01445067|Drug|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 300 mg, Once, One day
1702742|NCT01445067|Drug|BMS-927711 (CGRP Antagonist)|Capsule, Oral, 600 mg, Once, One day
1702744|NCT01445041|Biological|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 1 infusion of their own volume reduced cord blood cells. The dose for each infusion is 5x10e7 cells/kg.
1702745|NCT01445041|Biological|Autologous Umbilical Cord Blood|Infants who meet study enrollment criteria for hypoplastic left heart syndrome in the neonatal period will receive 3 infusions of their own volume reduced cord blood cells. The first infusion will be a fresh, volume-reduced infusion and the subsequent infusions will be thawed and washed infusions. The dose for each infusion is 5x10e7 cells/kg.
1702746|NCT01445028|Drug|Isotretinoin|Isotretinoin 20mg daily for 12 weeks
1702747|NCT01445015|Behavioral|Stress management program|10 session intervention utilizing a cognitive behavorial program with a goal of stress reduction
1702748|NCT01445015|Other|Peer viewed movies|PG rated movies to be viewed over 10 sessions in peer setting
1702749|NCT01445002|Biological|BM32|Subcutaneous injection of 10 micrograms each of the BM32 components adsorbed on 0.3 mg of aluminum hydroxide every 4 week for a total of 3 injections
1702750|NCT01445002|Biological|BM32|Subcutaneous injection of 20 micrograms of each of the BM32 components adsorbed on 0.6 mg of aluminum hydroxide every 4 weeks for a total of 3 injections
1702751|NCT01445002|Biological|BM32|Subcutaneous injection of 40 micrograms of each of the BM32 components adsorbed on 1.2 mg of aluminum hydroxide every 4 weeks until a total of 3 injections
1702752|NCT01445002|Biological|Placebo|Subcutaneous injection of 1.2 mg of aluminum hydroxide suspension every 4 weeks until 3 injections
1702753|NCT01444989|Other|AKRQ questionnaire|The AKRQ is an experimental instrument composed of 10 questions that assess quality of life and risk factors
1702754|NCT01444989|Other|Skindex-16, DLQI, Skin Health Calculator|These are all previously validated questionnaires
1702755|NCT01444976|Drug|local anesthesia|patients will receive only topical anesthesia with 1% lidocaine
1702756|NCT01444976|Behavioral|hypnosis|Hypnosis will be performed by the same anesthesiologist according to indirect Erickson's method
1702757|NCT01444976|Drug|Midazolam|Before insertion of the probe, the patients will be sedated with midazolam at a dose of 0,.05 mg/kg iv (to achieve a Ramsay Sedation Score of 2-3). If needed, additional iv doses (0.005 mg/kg) were given during the procedure.
1702758|NCT01444924|Drug|Bupivicaine|The TAP block will be placed using a standardized ultrasound-guided approach. Subjects assigned to the study group will have an injection of 30 mL 0.25% bupivacaine, a local anesthetic with 3 mcg/mL of epinephrine, placed into the plane between the internal oblique and the transversus abdominis
1702759|NCT01444924|Drug|Placebo|The placebo block will be placed in a similar manner, using a standardized ultrasound-guided approach. The placebo injection will consist of 30 mL sterile, preservative-free saline.
1702760|NCT01444911|Device|Vaginal Renewal Program|The Vaginal Renewal™ Program (VRP) consists of instructions on the use of a vibrating vaginal wand along with a particular water based lubricant.
1702761|NCT01444911|Device|Vaginal Dilator|Still vaginal dilator with lubricant.
1702762|NCT01444898|Drug|Exenatide|The investigators will give patients naive to GLP-1 agonists exenatide per manufacturer dosing recommendations for 6 months. The investigators will begin by giving 5 mcg subcutaneously twice a day for 1 month and then increase the dose to 10 mcg subcutaneously twice a day for the remainder of the study (5 months).
1702763|NCT01444885|Drug|Placebo|2 weeks treatment of Cilostazol 100mg, or placebo oral tablets bid after 2 weeks treatment of Cilostazol 50mg, or placebo oral tablets bid (Total 4 weeks)
1702764|NCT01444872|Drug|TRV120027|IV infusion
1702765|NCT01444872|Drug|Normal Saline|IV infusion
1702766|NCT01444859|Dietary Supplement|Trenev Trio®/Healthy Trinity®|Trenev Trio®/Healthy Trinity® (1 capsule, 2x/day for 10 weeks), which offers a daily dose of: a) Lactobacillus acidophilus NAS strain (10 billion CFU), b) Bifidobacterium bifidum Malyoth strain (40 billion CFU), and c) Lactobacillus delbrueckii subspecies bulgaricus LB-51 strain (10 billion CFU)
1702767|NCT01444859|Dietary Supplement|Placebo|Daily placebo for 10 weeks
1956063|NCT02979431|Biological|ALX-0171 Dose 3|
1956064|NCT02979431|Other|Placebo|
1761850|NCT00284791|Drug|Lamotrigine (drug)|
1702772|NCT01444833|Drug|Candesartan|32 mg per day duration 6 months
1702773|NCT01444820|Radiation|hypofractionation|Centres using IMRT will use the dose painting technique to treat the prostate + proximal 1-cm SV to 6800 cGy in 25 fractions while the pelvic lymph nodes will receive 4500 cGy in 25 fractions. For patients with T3b, the whole SV is to be treated to 6800 cGy. Institutions using 3D-CRT will deliver the required dose to the pelvic volume (including pelvic lymph nodes and boost volume) - 4500 cGy - and a concomitant boost to the prostate and proximal 1-cm (or the whole SV if involved) SV to 6800 cGy.
1702774|NCT01444820|Radiation|conventional|"The first phase: whole pelvis including the prostate and regional lymph nodes treated with 4400 cGy in 22 fractions.
The second phase: prostate + proximal 1-cm SV treated with 3200 cGy in 16 fractions.
For patients with T3b, the whole SV is to be treated to 7600 cGy."
1702775|NCT01444807|Drug|sorafenib|sorafenib 400 mg bid
1702776|NCT01444781|Biological|DTaP-IPV-Hep B-PRP~T combined vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
1702777|NCT01444781|Biological|DTaP-Hep B-IPV // Hib Vaccine + Pneumococcal polysaccharide|0.5 mL, Intramuscular each into the right and left deltoid muscle
1702778|NCT01444781|Biological|DTaP-IPV-Hep B-PRP~T + Pneumococcal polysaccharide vaccine|0.5 mL (each), Intramuscular each into the right and left deltoid muscle
1702779|NCT01444768|Other|Computerized Physician Order Entry|Computer ordering system allowing emergency department physicians to order medications, laboratory tests, radiology studies, and nursing interventions
1702780|NCT01444742|Drug|Clofarabine|"Induction:
10 mg/m2 by vein over 1-2 hours daily for 5 days (days 1-5)
Consolidation:
10 mg/m2 by vein over 1-2 hours daily for 3 days (days 1-3)"
1702781|NCT01444742|Drug|Cytarabine|"Induction:
20 mg subcutaneously twice daily for 7 days (days 1-7)
Consolidation:
20 mg subcutaneously twice daily for 5 days (days 1-5)"
1702784|NCT01444716|Drug|Ofatumumab|Starting dose: 300 mg by vein during week 1, then 2000 mg in weeks 2, 3 and 4, then monthly during months 2-12.
1702785|NCT01444703|Other|licorice solution|licorice (0.5 g)
1702786|NCT01444703|Other|sugar solution|sugar (5 g).
1702787|NCT01444690|Drug|Dimiracetam|Capsules for oral administration twice daily
1702788|NCT01444690|Drug|Dimiracetam 25 mg|Inactive dose level in capsules administered orally twice daily
1702789|NCT01444677|Drug|MB12066|MB12066 300mg
1702790|NCT01444677|Drug|MB12066|MB12066 400mg
1702791|NCT01444677|Drug|MB12066|MB12066 100mg
1702792|NCT01444677|Drug|MB12066|MB12066 200mg
1702793|NCT01444677|Drug|Placebo|Placebo 300mg (single dose), 400mg (single dose), 100mg (multiple dose), 200mg (multiple dose)
1702794|NCT01444664|Procedure|Surgical Clipping of Aneurysm|Surgical clipping of intracranial aneurysm
1702795|NCT01444651|Drug|Tadalafil|20 mg Tadalafil taken once a day for 3 months
1702796|NCT01444651|Drug|Placebo|Placebo tablet taken by mouth once a day for 3 months
1702797|NCT01444638|Device|Ultrasound examination|Trainees will receive pre-procedure U/S guided examination of the parturient's back.
1702798|NCT01444625|Other|Flavanol-rich chocolate|High-flavanol chocolate, 12 weeks.
1702799|NCT01444625|Other|Flavanol-free chocolate|Flavanol-free chocolate, 12 weeks
1702800|NCT01444612|Drug|dalteparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received dalteparin during one day prior to or two days after cancer-related surgery during the hospitalization.
1702801|NCT01444612|Drug|enoxaparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received enoxaparin during one day prior to or two days after cancer-related surgery during the hospitalization.
1702802|NCT01444612|Drug|fondaparinux|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients received fondaparinux during one day prior to or two days after cancer-related surgery during the hospitalization.
1702803|NCT01444612|Drug|unfractionated heparin|An injectable anticoagulant medication for the prevention of VTE related to cancer surgery. Patients unfractionated heparin received during one day prior to or two days after cancer-related surgery during the hospitalization.
1702804|NCT01444586|Drug|Rivaroxaban (Xarelto, BAY59-7939)|The patients will be treated according to the routine practice. All the patients meeting the criteria of inclusion and exclusion to whom administration of Xarelto is indicated are fit for participation in this non-interventional study.
1702805|NCT01444573|Device|implantable continuous monitor|The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check.
1702806|NCT01444547|Drug|paclitaxel and cisplatin|"Paclitaxel 150 mg/m2 will be administered as an intravenous (IV) infusion over 3 hour on Days 1; Cisplatin 50 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.
14 days as a cycle, up to 8 cycles."
1702807|NCT01444534|Device|Dbees; diabetes mobile phone application|Participants randomized to the intervention group (G2) were asked to stop using their paper logbook and start using an electronic logbook on their computer and mobile phone using an application of Dbees. The Dbees software enables the mobile phone to be used as a small computer to record the blood glucose values, dose of insulin injection, daily carbohydrate intake, amount of physical activity, and blood pressure.
1702808|NCT01444534|Device|control group|Participants in the control group (G1) continued using their paper logbook (usual care) and had no electronic logbook. Patients in the control group were requested not to use another mobile phone application instead of or besides their paper logbook.
1702809|NCT01444521|Drug|irinotecan and cisplatin|"irinotecan 125 mg/m2 will be administered as an intravenous (IV) infusion over half a hour on Days 1; Cisplatin 60 mg/m2 will be administered as an intravenous (IV) infusion on Days 2, and to take enough hydration in the day and the next day.
14 days as a cycle, up to 8 cycles."
1702900|NCT01443845|Drug|Roflumilast|Roflumilast 500 µg, oral administration, once per day
1702901|NCT01443845|Drug|Placebo|Dose-matched placebo, oral administration, once per day.
1702812|NCT01444495|Radiation|Preoperative radiotherapy|Preoperative radiotherapy 5x5 Gy (total dose of 25 Gy)
1702813|NCT01444495|Procedure|Surgery|Total mesorectal excision of rectal cancer
1702814|NCT01444482|Biological|Matrix M|1 human dose of seasonal influenza vaccine formulated with 50 µg Matrix M, total dosage volume 0.55 mL injected intramuscularly in the upper arm once at day 0.
1702815|NCT01444482|Biological|Seasonal influenza vaccine|1 human dose of seasonal influenza vaccine
1702816|NCT01444469|Drug|Zithromax|250mg * 2 capsules once daily for three days
1702817|NCT01444469|Drug|Placebo|Lactose powder
1702818|NCT01444443|Device|Closed-loop control|Blood glucose controlled by algorithm
1702819|NCT01444443|Other|Open-loop control|Blood glucose controlled by patient
1702820|NCT01444430|Drug|Symbicort pMDI|Patients were randomized to Symbicort and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): Symbicort pMDI 80/4.5 μg x 2 actuations bid (morning and evening) or Symbicort pMDI 160/4.5 μg x 2 actuations bid (morning and evening), for oral inhalation.
1702821|NCT01444430|Drug|budesonide pMDI|Patients were randomized to budesonide and assigned to one of the following treatments (based upon ACQ at baseline and prior asthma therapy): budesonide pMDI 80 μg x 2 actuations bid (morning and evening) or budesonide pMDI 160 μg x 2 actuations bid (morning and evening), for oral inhalation.
1702822|NCT01444417|Drug|Romiplostim|The starting dose of romiplostim is 1 µg/kg administered weekly by subcutaneous injection. Participants will return to the clinic weekly to provide platelet counts and undergo dose titrations under the supervision of the treating physician. Weekly dose increases will continue in increments of 1 µg/kg up to a maximum dose of 10 µg/kg in an attempt to reach a target platelet count of ≥ 50 x 10^9/L. Dose adjustment will be allowed during the treatment period to maintain a platelet count between ≥ 50 x 10^9/L and ≤ 200 x 10^9/L.
1702823|NCT01444417|Drug|Placebo|Matching placebo administered by subcutaneous injection
1702824|NCT01444404|Drug|AMG 820|AMG 820 is a fully human IgG2 c-fms antagonistic antibody and will be given every two weeks until progression or unacceptable toxicity develops.
1702825|NCT01444391|Device|Tympanostomy tube placement (Acclarent iontophoresis device)|Placement of tympanostomy tube by the Acclarent tympanostomy tube delivery system following delivery of anesthetic with Acclarent iontophoresis device
1702826|NCT01444378|Device|Stenting using Absolute Pro® and Pro LL® Peripheral Stent Systems|Stenting of the Superficial Femoral Artery (SFA) and/or proximal popliteal artery using either of these devices.
1702827|NCT01444365|Drug|ABT-652 NSAID|ABT-652 capsules - 2 ABT-652 capsules twice daily (add-on) NSAID- as prescribed
1702828|NCT01444365|Drug|Placebo NSAID|Placebo - 2 placebo capsules twice daily NSAID- as prescribed
1702829|NCT01444352|Biological|Pneumococcal vaccine Formulation 1|0.5 mL, Intramuscular (Low dose)
1702830|NCT01444352|Biological|Pneumococcal vaccine Formulation 2|0.5 mL, Intramuscular (Middle dose)
1702831|NCT01444352|Biological|Pneumococcal vaccine Formulation 3|0.5 mL, Intramuscular (High dose)
1702832|NCT01444352|Biological|Placebo|0.5 mL, Intramuscular
1702833|NCT01444339|Biological|Pneumococcal Vaccine Formulation 1|0.5 mL, intramuscular (1 middle dose)
1702834|NCT01444339|Biological|Pneumococcal Vaccine Formulation 2|0.5 mL, intramuscular (2 low doses)
1702835|NCT01444339|Biological|Pneumococcal Vaccine Formulation 3|0.5 mL, intramuscular (2 middle doses)
1702836|NCT01444339|Biological|Pneumococcal Vaccine Formulation 4|0.5 mL, intramuscular (2 middle doses)
1702837|NCT01444339|Biological|Pneumococcal Vaccine Formulation 5|0.5 mL, intramuscular (2 high doses)
1702838|NCT01444339|Biological|Placebo|0.5 mL, intramuscular
1702839|NCT01444326|Other|Dairy|"During the DAIRY diet, subjects will be asked to incorporate 3 servings of dairy (375 ml of milk, 175 g of yogurt, 30 g of cheese) into their every day diet.
During the CONTROL arm of the study, participants will be asked to consume energy equivalent replacement products (375 ml of fruit juice, 1 homemade cookie, 20 g of cashew)."
1702840|NCT01444313|Device|narafilcon A contact lens|Soft contact lenses with UV protection
1702841|NCT01444313|Device|nelfilcon A soft contact lenses|Soft contact lenses without UV protection
1702842|NCT01444300|Drug|Dalfampridine|10mg, bid, pill taken by mouth for 12 weeks
1702843|NCT01444300|Drug|Placebo|placebo pill, bid for 12 weeks
1702844|NCT01444287|Device|narafilcon B|test product
1702845|NCT01444287|Device|Polymacon|marketed product
1702846|NCT01444287|Device|Lotrafilcon A|marketed product
1702847|NCT01444287|Other|Spectacles|None - subject used own spectacles
1702848|NCT01444274|Device|Obalon Gastric Balloon(s)|One or two balloons administered per patient
1702849|NCT01444261|Dietary Supplement|Fer-in-Sol|Fer-in-Sol drops providing 7.5 mg iron in 0.3 ml per day given from 84 to 168 d of age and iron-fortified cereal
1702850|NCT01444261|Other|control|No dietary supplements
1702851|NCT01444248|Drug|Glimepiride/ Metformin|4/1000mg once daily
1702852|NCT01444248|Drug|Glimepiride/ Metformin|4/1000mg bid
1702853|NCT01444235|Drug|Custodiol-N|Route of administration: by infusion Dosage: will be infused antegrade into the root of the aorta until 1500-2000 mL of solution have been infused Duration: infusion technique will be continued for seven minutes
1702854|NCT01444235|Drug|Custodiol|Route of administration: by infusion duration: infusion technique will be continued for seven minutes dosage: until 1500-2000 mL of solution have been infused
1702855|NCT01444209|Radiation|Iodine Implants|Interstitial Radioactive Iodine Implants
1702856|NCT01444196|Drug|Desloratadine|Every day,per mouth,in the evening, for 14 +- 2 days.
1702973|NCT01443169|Drug|Sequence 1 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
1956073|NCT02976467|Drug|BAY1142524|25 mg BAY 1142524 are given twice daily over a treatment period of 6 months
1702857|NCT01444183|Behavioral|Focused Attention A|"The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.
Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
1702858|NCT01444183|Behavioral|Focused Attention B|"The focused attention practices will consist of one or more of the following components: movement of body parts, breathing exercises, and writing exercises.
Both groups will practice twice daily, one 15 minute practice in the AM and a 5 minute practice in the PM. An additional 5 minute mid-day practice will occur only when e-diary entries from experience sampling meet specific predetermined criteria."
1702859|NCT01444170|Dietary Supplement|dicreatinol sulfate|nutritional supplement
1702860|NCT01444170|Drug|placebo sugar pill|
1702861|NCT01444157|Other|Palliative homecare nursing|The nurse helps the family assess the identified problems. Written coping strategies according to each problem is produced including actions of the patient, family member, nurse or others. At the same time the nurse keeps attention to the family members specific needs of knowledge and support when handling direct or indirect care, understanding and coping with the disease, treatment, physical, psychosocial and economical problems and the family members own physical and mental health. The nurse provides knowledge to the family on how to prevent and/or cope with problems that may occur or re-occur and/or accepts or adapt to unsolvable problems.
1702862|NCT01444144|Other|Fracture union|Retrospective records review post-operatively until fracture resolved.
1702863|NCT01444131|Drug|Varenicline, Nicotine Patch|active nicotine patches added to varenicline.
1702864|NCT01444131|Drug|Varenicline and Placebo Patch|placebo nicotine patches added to varenicline.
1702865|NCT01444118|Biological|Therapeutic EGF Vaccine (Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine)|Patients in this arm will receive a low dose of Cyclophosphamide and the recombinant human rEGF-P64K/Montanide ISA 51 vaccine in addition to Best Supportive Care.
1702866|NCT01444105|Device|iStent|Implantation of two iStent devices
1702867|NCT01444105|Other|SLT|Laser treatment
1702868|NCT01444092|Drug|Entocort|Entocort capsules, oral
1702869|NCT01444066|Procedure|Dilation of the esophagus|Esophagus will be dilated with a Savory dilator.
1702870|NCT01444053|Device|No Intervention|No Intervention
1702871|NCT01444040|Device|iStent inject|Implantation of two iStent inject devices
1702872|NCT01444040|Drug|Travoprost|Travoprost drops
1702874|NCT01444014|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response.
1702875|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
1702876|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
1702877|NCT01444001|Biological|Pneumococcal Vaccine|0.5 mL, intramuscular
1702878|NCT01443988|Device|iStent|Implantation of two iStent devices
1702879|NCT01443988|Drug|Travoprost|Travoprost drops
1702880|NCT01443975|Procedure|x-pander|Measurement of the size and quality of the bony acetabulum before mounting the artificial hip socket.
1702881|NCT01443962|Other|PEEP|applying PEEP 0 cmH2O during pneumoperitoneum continuously
1702882|NCT01443962|Other|ZEEP|applying PEEP 10 cmH2O during pneumoperitoneum continuously
1702885|NCT01443923|Drug|Boceprevir|
1702886|NCT01443923|Drug|Peg-Interferon-alfa 2B|
1702887|NCT01443923|Drug|Ribavirin|
1702888|NCT01443897|Dietary Supplement|1,000 IU vitamin D2|capsule containing 1,000 IU vitamin D2
1702889|NCT01443897|Dietary Supplement|placebo capsule|0 IU vitamin D2
1702890|NCT01443897|Other|mushrooms|untreated button mushrooms, obtained from Monterey Mushrooms, Monterey, CA
1702891|NCT01443897|Other|UVB-treated mushrooms, 400 IU vitamin D2|UVB-treated button mushrooms, 400 IU vitamin D2 per 1/2 cup serving, obtained from Monterey Mushrooms, Monterey, CA
1702892|NCT01443897|Other|UVB-treated mushrooms, 1,000 IU vitamin D2|UVB-treated button mushrooms, 1,000 IU vitamin D2 per 1/c serving, obtained from Monterey Mushrooms, Monterey, CA
1702893|NCT01443884|Dietary Supplement|Grape powder, followed by placebo powder|For three weeks, twice per day, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) stirred into water. Following a two week washout, volunteers will consume one packet of placebo powder twice per day for three weeks.
1702894|NCT01443884|Dietary Supplement|Placebo powder followed by grape powder|For three weeks, twice per day, volunteers will consume one packet of placebo powder stirred into water. Following a two week washout, volunteers will consume one packet of freeze-dried grape powder containing the equivalent of approximately 2 servings of fresh grapes (46 grams of powder) twice per day for three weeks.
1702895|NCT01443871|Other|Aromatherapy|Subject will assigned inhale aromatherapy
1702896|NCT01443871|Other|Pure water|Subject will assigned inhale Pure water
1702897|NCT01443858|Drug|Meclizine|Pre-Quit Period: In this group, participants will take meclizine daily during the three week pre-quit period. The meclizine will be taken in two doses daily, one capsule with breakfast and one with dinner.
1702898|NCT01443858|Drug|Nicotine Patch|"Pre-Quit Period: During weeks two and three, participants will apply active 21mg/24h nicotine patches daily.
Post-Quit Period: Following the quit-day these participants will apply active nicotine patches daily using the following dose schedule: 21mg/24h for four weeks, 14mg/24h for one week, and 7mg/24h for one week."
1702899|NCT01443858|Drug|Placebo|Pre-Quit Period: In this group, participants will take placebo capsules daily during the three week pre-quit period. The placebo will be taken in two doses daily, one capsule with breakfast and one with dinner.
1702902|NCT01443832|Dietary Supplement|Fe57 and Fe58-FeSO4 stable isotopes|[57Fe] and [58Fe]- FeSO4 prepared from isotopically enriched 57Fe and 58Fe respectively, by dilution of each compound in 0.1 mol H2SO4/L.
1702903|NCT01443819|Other|Lumbar Transforaminal Epidural Corticosteroid Injection|"Injection: Anesthetic/corticosteroid (per randomization); repeat 1-3 times if clinically indicated.
The following drugs will be used for this procedure: 80mg Depo-Medrol and 1% lidocaine. These drugs used for the epidural injections are local anesthetic numbing medicines and cortisone/steroid anti-inflammatory medicines."
1702904|NCT01443819|Other|Physical Therapy|"Physical therapy carried out per protocol; 2-3 times per week for a total of 12 treatment sessions (excluding initial evaluation, including exit evaluation, minimum attendance 8/12) to be completed by 6 weeks from initiation of care (within study).
Please note: There will be another PT evaluation at the end of 6 weeks."
1702905|NCT01443819|Other|Observation|If subject declines then inquire about enrolment in the observational cohort. Participants in this group (Cohort) will chose their treatment (per-protocol physical therapy, injections, or both) after consulting with their physicians.
1702906|NCT01443806|Drug|Oseltamivir|75 mg, one time
1702907|NCT01443780|Dietary Supplement|Selenium and ubiquinon (Q10) combined|A combination of 200 mg/day of coenzyme Q10 (Bio-Quinon 100 mg B.I.D, Pharma Nord, Vejle, Denmark) and 200 µg/day of organic selenium (SelenoPrecise 200 µg, Pharma Nord), or placebo
1702908|NCT01443754|Procedure|LIMA-LAD surgical revascularization|"Off-pump coronary artery bypass (OPCAB) in which coronary revascularization is performed on the beating heart will be followed, the choice of the technical solutions being left at the discretion of the cardiac surgeon:
use of a left anterior small thoracotomy (LAST), LIMA harvesting using thoracoscopic methods and manual anastomosis of the LIMA-LAD using a stabilization device;
minimally invasive direct coronary bypass surgery (MIDCAB). The procedures can be performed alone or in combination with one another."
1702909|NCT01443754|Procedure|PCI|"State of the art drug eluting stent (DES)-based percutaneous coronary intervention will be used by each participating site, according to current international guidelines.
Zotarolimus, everolimus or sirolimus drug-eluting stents will be used in all sites."
1702910|NCT01443741|Other|Therapeutic education|Specific program for FIT Therapy and specific program for traditional way
1702911|NCT01443728|Drug|Vitamin D3|Vitamin D3 100,000 IU orally once a month
1702912|NCT01443728|Drug|Vitamin D3|Vitamin D3 12,000 IU orally once a month
1702913|NCT01443715|Behavioral|Stepped Care IPT-A (SCIPT-A)|Interpersonal Psychotherapy for adolescents (IPT-A) is a guideline based treatment with established efficacy focusing on reducing depression symptoms and current interpersonal problems associated with depression.
1702914|NCT01443715|Behavioral|Treatment as Usual|Standard treatment in the community
1702915|NCT01443702|Drug|Lapis Judaicus|2 g capsule per day.
1702916|NCT01443702|Drug|Placebo|2 g capsule per day.
1702917|NCT01443689|Biological|human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus hUCMSCs transplantation.
1702918|NCT01443689|Biological|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given conventional therapy plus and hCBMNCs and hUCMSCs transplantation.
1702919|NCT01443689|Drug|Conventional therapy|Participants will be given conventional therapy only.
1702920|NCT01443676|Drug|Bevacizumab|Bevacizumab will be added to radiotherapy
1702921|NCT01443676|Radiation|Radiation therapy|Radiation therapy
1702922|NCT01443663|Biological|H5N1 Vaccine|Vaccine will be administered intramuscularly (IM) in the deltoid muscle at baseline for participants in Groups 1-4 and at baseline and Day 28 for participants in Group 5.
1702923|NCT01443650|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
1702924|NCT01443624|Drug|critical care patients venofer|100mg IV in one hour (in critically ill patients the injection could be repeated on day 2 (200mg) and 4 (100mg) depending on treatment
1702925|NCT01443585|Device|Progressive Addition Lens (Shamir PrimeIITM) Spectacles|A pair of progressive addition lenses manufactured according to the subject's personal prescription.
1702926|NCT01443572|Drug|desflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
1702927|NCT01443572|Drug|sevoflurane anesthetics|40 patients are randomly allocated into two groups : desflurane group (n=20) and sevoflurane group (n=20). And anesthesia is maintained with desflurane (desflurane group) or sevoflurane (sevoflurane group).
1702928|NCT01443559|Genetic|Xenogenic cornea|lamellar acellular xenogenic corneas were sterilised by radiation
1702929|NCT01443559|Genetic|homogenic cornea|homogenic corneas were sterilised by radiation
1702930|NCT01443546|Drug|HCG|hCG Trigger
1702931|NCT01443546|Drug|Lupron Trigger|leuprolide acetate 2 mg SQ
1702932|NCT01443546|Drug|Dual Trigger|a combination of the two drugs in low dosage (leuprolide acetate 2 mg and hCG 1500 IU).
1702933|NCT01443533|Behavioral|LARC Script|The LARC Script is a one-minute educational script that describes long-acting reversible contraceptive methods.
1702934|NCT01443520|Drug|Placebo|The subjects will be given orally placebo twice a day for 8 days prior to the study.
1702935|NCT01443520|Drug|Duloxetine|The subjects will be given orally duloxetine 30mg twice a day for 8 days prior to the study.
1702936|NCT01443520|Drug|Venlafaxine|The subjects will be given orally venlafaxine 37,5mg twice a day for 8 days prior to the study.
1702937|NCT01443507|Other|endurance exercise of different duration and intensity|Two interventions are compared with aerobic capacity as the main outcome. one group exercise at 70% of maximal heart rate for 90 minutes 3 times per week. group two exercise performe10 minutes warm up at 70% of maximal heart rate 4 x 4 minutes intervals at 90-95% of maximal heart rate with 3 minutes active pause at 70% of maximal heart rate in between, and finally 5 minutes cooling down at 70 % of maximal heart rate.
1702938|NCT01443494|Other|NE|norepinephine
1702939|NCT01443481|Drug|Dovitinib|Starting dose to be determined based on the study outcome of the mild and moderate hepatic impairment groups
1702974|NCT01443169|Drug|Sequence 1 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
1703100|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 10 mcg/kg up to a maximum total dose of 0.75 mg
1761851|NCT00284791|Drug|Fluoxetine (drug)|
1702940|NCT01443455|Behavioral|videodance|Using a commercially available product called Dance Dance Revolution (DDR) this video-game based dancing system uses a game player, force sensing pad and software. The step sequences are set to a wide range of music and become more complex and frequent as the dancer gains skill. Participants are oriented over 2 weeks. For the rest of the first 3 months, the participant attends at least one supervised session per week. Participants may use the center for additional, unsupervised sessions and/or they can take a dance system home. They also receive brief behavioral intervention sessions for safety orientation, exercise education and adherence promotion. For the following 3 months, the participant enters the transition phase in which she is encouraged to continue to exercise but no formal supervision is provided.
1702941|NCT01443455|Behavioral|Brisk Walking|The overall goal is to increase the duration and speed of walking, using structure and supervision for the first three months, followed by reduced support in the second three months. For the first two weeks, each participant comes to the center at least twice a week to walk.They are encouraged to gradually increase effort and duration to a target of 150 minutes per week of brisk walking.Participants are taught to use Borg's ratings of perceived exertion and self-monitored heart rate to target their level of activity. The next 10 weeks include once weekly supervised sessions and additional sessions either at the center or in preferred community settings. The recommended goal is a minimum of 150 minutes per week of exercise in sessions of at least 10 -15 minutes duration.Participants are given pedometers in order to help them monitor their progress. After 12 weeks, the participant enters a transition phase for a further 3 months.
1702942|NCT01443455|Behavioral|delayed entry control|Participants who are randomized to the delayed entry non-exercise control group receive the American Heart Association pamphlet, but no direct support for exercise implementation. After they have completed six months of follow up, they are invited to select any combination of dancing and walking that they prefer and then receive support and instruction according to the protocols described above.
1956074|NCT02976467|Drug|Placebo|Matching placebo tablets are given twice daily over a treatment period of 6 months
1702945|NCT01443429|Drug|beraprost sodium(BPS)|
1702946|NCT01443416|Biological|13-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age
1702947|NCT01443416|Biological|10-valent pneumococcal conjugate vaccine|The vaccine will be given to 12 month old children who have had 2 doses of Prevenar at 2 and 4 months of age.
1702948|NCT01443403|Drug|Placebo|Matching placebo tablets administered orally once a day.
1702949|NCT01443403|Drug|Naldemedine|Naldemedine tablets administered orally once a day.
1702950|NCT01443377|Biological|Panitumumab|Intravenous (IV), Panitumumab 6 mg/kg BW q2w d1-d57 (5 times total); begin on day 1 (run-in-phase) and subsequent application on days 15, 29 43 and 57.
1702951|NCT01443364|Biological|Certolizumab pegol|Prefilled syringes containing an injectable volume of 1ml of liquid Certolizumab Pegol (CZP) for single use at a dosage strength of 200 mg/ml. Injections will be given subcutaneously. CZP 400 mg at Week 0, 2 and 4, then continued as maintenance dose of 200 mg every 2 weeks until Week 50.
1702952|NCT01443338|Drug|Triptergium Wilfordii|Tablet,10mg/Tab,20mg Tid,No more than 8 Weeks
1702953|NCT01443338|Drug|Acitretin|Capsule,10mg/Cap,30mg Qd,no more than 8 weeks
1702954|NCT01443325|Drug|lidocaine patch|1 patch for 12 hours within each 24 hours period
1702955|NCT01443312|Genetic|Laboratory analysis.|The blood transfusions given to the patients are in accord to physician decision and not related to the study
1702956|NCT01443273|Other|Medical Records study|No interventions will be done related to the study besides summary of the Medical Files.
1702957|NCT01443260|Biological|GL-ONC1|A genetically-engineered vaccinia virus administered via intraperitoneal infusion through an indwelling catheter every 4 weeks for 4 cycles.
1702958|NCT01443247|Drug|anti-d|intervention group received injection anti-d in dose of 50 µg/kg (250IU/kg) along with platelet concentrate while control ( non intervention ) group received platelet support only
1702959|NCT01443234|Other|OxIGen|Internet-based intervention with 12 sessions over 4 weeks
1702960|NCT01443234|Other|OxIGen: control version|A control version of the OxIGen internet-based intervention (i.e. identical but with putative active components removed)
1702961|NCT01443221|Drug|mitiglinide and metformin|Free combination of Mitiglinide 10mg and Metformin 500mg
1702962|NCT01443221|Drug|mitiglinide and metformin|Fixed-dose combination of Mitiglinide 10mg and Metformin 500mg
1702963|NCT01443208|Drug|desvenlafaxine|one 50 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
1702964|NCT01443208|Drug|desvenlafaxine|one 100 mg desvenlafaxine succinate sustained-release tablet or matching placebo, single dose and once daily dose for 5 days
1702965|NCT01443208|Drug|desvenlafaxine|two 100 mg desvenlafaxine succinate sustained-release tablets or matching placebo, single dose and once daily dose for 5 days
1702966|NCT01443195|Drug|Iron preparation|"Iron supplementation with IPC in a dose of 4 mg/kg/day of elemental iron started not before 4 weeks of age and as soon as 120 ml/kg/day of enteral feedings is tolerated given together with the first morning meal. Serum samples will be obtained at 3 different times:
Before starting iron supplementation (maximum one week before).
At the beginning of iron supplementation in order to assess early signs of erythropoiesis, iron overload or free iron (day 4 - 7 days of supplementation).
Before discharge from hospitalization in order to asses the iron metabolism and sings of iron deficiency (At least more than 2 weeks of supplementation)."
1702967|NCT01443182|Behavioral|STAIR|Skills Training in Affective and Interpersonal Regulation
1702968|NCT01443182|Behavioral|MPE|Modified prolonged exposure (MPE)
1702969|NCT01443182|Behavioral|EMDR|Eye movement desensitization and reprocessing
1702970|NCT01443169|Drug|Sequence 1 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702971|NCT01443169|Drug|Sequence 1 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702972|NCT01443169|Drug|Sequence 1 - Treatment C:Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702975|NCT01443169|Drug|Sequence 2 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702976|NCT01443169|Drug|Sequence 2 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
1702977|NCT01443169|Drug|Sequence 2 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702978|NCT01443169|Drug|Sequence 2 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702979|NCT01443169|Drug|Sequence 2 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
1702980|NCT01443169|Drug|Sequence 3 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702981|NCT01443169|Drug|Sequence 3 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702982|NCT01443169|Drug|Sequence 3 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
1702983|NCT01443169|Drug|Sequence 3 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702984|NCT01443169|Drug|Sequence 3 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
1702985|NCT01443169|Drug|Sequence 4 - Treatment D: Controlled Release Pregabalin|330 mg CR reference tablet administered after a 600 to 750 calorie medium-fat evening meal.
1702986|NCT01443169|Drug|Sequence 4 - Treatment C: Controlled Release Pregabalin|330 mg CR tablet (slow dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702987|NCT01443169|Drug|Sequence 4 - Treatment B: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, lighter tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702988|NCT01443169|Drug|Sequence 4 - Treatment A: Controlled Release Pregabalin|330 mg CR tablet (fast dissolution, heavier tablet) administered after a 600 to 750 calorie medium-fat evening meal.
1702989|NCT01443169|Drug|Sequence 4 - Treatment E: Immediate Release Pregabalin|300 mg IR capsule administered in the evening in the fasted state.
1702990|NCT01443143|Other|Portion-controlled diet|During this diet period, participants will consume portion-controlled products from the Nutrisystem-D program for three entrees and one (women) or two (men) snacks per day. These pre-packaged portion-controlled items will be supplemented with grocery additions (fruits, vegetables, and low-fat dairy items) to provide approximately 1300 (women) to 1500 (men) calories per day. The Nutrisystem-D program (i.e., provided foods plus grocery additions) provides approximately 53% of calories from carbohydrate, 22% of calories from fat (6% from saturated fat and 0% from trans fat), and 25% of calories from protein. Women and men on the program consume approximately 1800 and 2000 mg/d, respectively, of sodium, and 31 and 35 g/d, respectively, of fiber.
1702991|NCT01443143|Dietary Supplement|Usual Diet|"During the usual diet period, participants will not be given any specific instructions about what they should or should not consume. Instead, they will be told to Eat how you would normally eat if you were not in this study."
1702992|NCT01443130|Drug|Chloroquine|Chloroquine tablets contain 300 mg chloroquine base per tablet. Dosages: Chloroquine 1,500 mg base over 3 days twice during pregnancy or Chloroquine 600 mg loading dose followed by 300 mg orally once per week. Intermittant preventative treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34 gestation, 4 weeks apart. Participants randomized to IPTp with chloroquine will require their second and third doses of chloroquine after the initial dose given in the clinic and those assigned to chloroquine chemoprophylaxis will require weekly doses.
1702993|NCT01443130|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine 3 tablets (1,500 mg sulfadoxine and 75 mg pyrimethamine) twice during pregnancy. Intermittant preventive treatment in pregnancy (IPTp) doses will be administered between weeks 20-28 and weeks 28-34, 4 weeks apart.
1702994|NCT01443117|Biological|PPV-23 Vaccine|Administered as a 0.5 mL IM dose
1702995|NCT01443117|Biological|PCV-13 Vaccine|Administered as a 0.5 mL IM dose
1702996|NCT01443117|Biological|Placebo Vaccine|Administered as a 0.5 mL IM dose
1702997|NCT01443104|Device|Sirolimus-eluting stent with a bioresorbable polymer (Orsiro)|Percutaneous coronary intervention with implantation of a sirolimus-eluting stent with a bioresorbable polymer for coronary artery disease
1702998|NCT01443104|Device|Everolimus-eluting stent with a durable polymer|Percutaneous coronary intervention with implantation of an everolimus-eluting stent with a durable polymer for coronary artery disease
1702999|NCT01443091|Other|application of mother's own colostrum|application of 0.2mL of mother's own colostrum to the infant's oropharyngeal mucosa every 3 hours for 5 days (day of life 2 until day of life 7)
1703000|NCT01443091|Other|application of sterile water|application of 0.2mL sterile water to the infant's oropharyngeal mucosa every 3 hours for 5 days (from day of life 2 until day of life 7)
1703001|NCT01443078|Drug|pemetrexed|
1703002|NCT01443078|Drug|cisplatin|
1703003|NCT01443078|Drug|Carboplatin|
1703004|NCT01443078|Drug|Gemcitabine Hydrochloride|
1703005|NCT01443078|Drug|Vinorelbine Tartrate|
1703006|NCT01443078|Drug|Docetaxel|
1703007|NCT01443065|Drug|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
1703008|NCT01443065|Drug|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
1703009|NCT01443065|Drug|5-fluoro-uracil|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
1703010|NCT01443065|Drug|panitumumab|6mg/kg over 60-90 mn every 2 weeks up to progression or toxicity
1703011|NCT01443065|Drug|AMG102|10mg/kg over 60 mn every 2 weeks up to progression or toxicity
1703012|NCT01443052|Other|Gait analysis|walking on an electronic walkway GAITRite® at self-selected speed
1703061|NCT01442675|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
1703062|NCT01442662|Drug|pazopanib + gemcitabine|pazopanib tablets (200mg) per os, 800mg/day continuously gemcitabine IV, 2 injection per cycle
1703013|NCT01443039|Drug|phenotypical approach|each visit : CAFEINE : (solution orale) 2 ampoules de 2 ml = 100 mg de CAFEINE DEXTROMETHORPHANE : 15 ml de sirop contains 20 mg =>22,5 ml = 30mg Midazolam : (solution injectable, ampoule 1 ml = 1 mg) : deux ampoules = 2 mg Digoxine nativelle (solution injectable, ampoule de 0.5mg) : 1 ampoule per os = 0.5 mg Losartan 50 mg : 1cp de 50mg
1703014|NCT01443026|Drug|Lycopene 30mg|Lycopene 30 mg.
1703015|NCT01443026|Drug|Placebo|Placebo
1703016|NCT01443013|Other|Renal Transplant|urinary sample at month 3, 6 and 12
1703017|NCT01442987|Drug|Irbesartan/Atorvastatin A|once daily, P.O. 8week
1703018|NCT01442987|Drug|Irbesartan|once daily, P.O. 8week
1703019|NCT01442987|Drug|Atorvastatin A|once daily, P.O. 8week
1703020|NCT01442987|Drug|Placebo|once daily, P.O. 8week
1703021|NCT01442987|Drug|Irbesartan/Atorvastatin B|once daily, P.O. 8week
1703022|NCT01442987|Drug|Atorvastatin B|once daily, P.O. 8week
1703023|NCT01442974|Drug|Gemcitabine plus nab-paclitaxel|Gemcitabine 1000mg/mq on d1,8,15 over 28 days of cycle nab-paclitaxel 125mg/mq on d1,8,15 over 28 days cycle Treatment will be administered for two cycles
1703024|NCT01442961|Procedure|laparoscopy, laparoscopic hysterectomy|laparoscopic hysterectomy
1703025|NCT01442961|Procedure|vaginal : vaginal hysterectomy|Vaginal hysterectomy
1703026|NCT01442935|Drug|Oxaliplatin|85mg/m² over 120 mn every 2 weeks up to progression or toxicity
1703027|NCT01442935|Drug|Folinic Acid|400mg/m² over 120 mn every 2 weeks up to progression or toxicity
1703028|NCT01442935|Drug|5-FU|400mg/m² in bolus, then 2400mg/m² over 46 h every 2 weeks up to progression or toxicity
1703029|NCT01442935|Drug|Irinotecan|180mg/m² over 90 mn every 2 weeks up to progression or toxicity
1703030|NCT01442935|Drug|Irinotecan|150mg/m² over 30-90 mn every 2 weeks up to progression or toxicity
1703031|NCT01442935|Drug|Bevacizumab|5mg/kg over 90 mn every 2 weeks up to progression or toxicity
1703032|NCT01442935|Drug|Cetuximab|500mg/m² over 90 mn every 2 weeks up to progression or toxicity
1703033|NCT01442922|Other|completion of the (VAS) for level of back pain|Patients will complete the (VAS) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
1703034|NCT01442922|Other|completion of the (OLBPQ) for assessment of function|Patients will complete the (OLBPQ) pre-operatively and post-operatively at 6 wks, and 3, 6, 12, and 24 mos.
1703035|NCT01442909|Drug|Docetaxel and pemetrexed|docetaxel 60mg/m2 every 3 weeks for 4 cycles followed by pemetrexed 500mg/m2 every 3 weeks for 4 cycles; or in reverse sequence.
1703036|NCT01442883|Device|Simplicity Catheter|percutaneous selective renal sympathetic nerve ablation with the use of the Simplicity Catheter system
1703037|NCT01442870|Drug|Metformin|Metformin
1703038|NCT01442857|Radiation|MRI|High resolution MRI of the brachial plexus
1703039|NCT01442844|Device|Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile dressing that will be placed on the surgical wound.
1703040|NCT01442831|Drug|Human ADME|Oral single dose
1956078|NCT02974036|Other|Patient education for osteoarthritis|Group sessions and optional supervised exercise.
1703043|NCT01442805|Behavioral|Virtual Reality Exposure Therapy|Participants are exposed to the feared situation (flying) through the virtual reality technology
1703044|NCT01442805|Behavioral|Exposure Therapy through Imagination|Participants are exposed to the feared situation (flying) through exposure technique of imagination.
1703045|NCT01442792|Drug|UFH|Unfractionated Heparin: 70-100 IU/Kg bolus and adjusted upon activated coagulation time (ACT) 250 300 seconds
1703046|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg single dose Rivaroxaban (per os)
1703047|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg single dose Rivaroxaban (per os)
1703048|NCT01442792|Drug|Rivaroxaban (Xarelto, BAY59-7939) and UFH|10 mg single dose Rivaroxaban (per os) followed by bolus 50 IU/Kg unfractionated heparin (UFH)
1703049|NCT01442779|Drug|Interferon alpha oral lozenge|dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year
1703050|NCT01442766|Drug|Donepezil|5mg for 4 weeks, 10mg for 8 weeks if tolerated, or lower dose to continue
1703051|NCT01442766|Drug|Placebo|Inert pill that appears identical to donepezil pill. 1 pill for first 4 weeks, followed by 2 pills until end of study.
1703052|NCT01442753|Behavioral|Family-Skills Training|Sessions will be divided between self-reflection, didactics, and skill-building exercises all aimed at developing strong parenting practices and facilitating relationship building between parents and youth.
1703053|NCT01442740|Procedure|Reverse Trendelenburg Position|Patients will be placed on the operating table in a head up, feet down, tilt position (15 degree tilt to the horizontal). This is in contrast to the standard of care, 0-degree supine position.
1703054|NCT01442727|Drug|sodium selenite|200 micrograms (µg) of selenium in the form of sodium selenite; capsule form consumed once daily with breakfast.
1703055|NCT01442727|Drug|placebo|dicalcium phosphate capsule matching the selenium capsule in appearance; consumed once daily with breakfast
1703058|NCT01442701|Other|Removal of triclosan-containing cleaning products from household.|An intervention is nested within the observational cohort study as a secondary outcome. Commercially available household and personal cleaning products that either do not contain triclosan or that may contain triclosan will be delivered to the household every 4 months for the duration of the study. All cleaning products will be formulated, packaged and labeled by the original manufacturer with no modification for this study. Use of these products will be as per each individual product's label and at the discretion of the participant.
1703059|NCT01442688|Drug|Amoxicillin + MMX placebo|MMX placebo administered once a day (QD) orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX placebo on Day 4.
1703060|NCT01442688|Drug|Amoxicillin + MMX mesalazine/mesalamine|MMX mesalazine/mesalamine (4.8 g) administered QD orally on Days 1-3, then a single oral dose of Amoxicillin (500 mg) + MMX mesalazine/mesalamine (4.8 g) on Day 4.
1703751|NCT01437527|Behavioral|therapy as usual|Body image therapy as usual
1703069|NCT01442636|Device|stent|Implantation of one or more Everolimus-eluting XIENCE PRIME™ Everolimus Eluting Coronary Stent Systems.
1991027|NCT01599520|Behavioral|Spanish-Language Self-Administered Training Plus Usual Care (SL-SAT)|"Patients will receive usual care. In addition, a Spanish-speaking intervention associate will spend an extra 10 minutes on the day usual care is initiated reviewing the self-administered training materials in Spanish titled Cómo tratar el estrés durante la quimioterapia. Materials consist of an 18-minute DVD (also available as a videocassette (VC)), a 28-minute CD (also available as an audiocassette (AC)), a 16-page booklet, and a workbook to record practice and use of stress management techniques. Participants are instructed to first view the DVD/VC and then follow directions in the booklet and on the CD/AC about training, practice, and use of stress management techniques."
1703071|NCT01442610|Drug|Rasagiline|Rasagiline tablets 1mg once daily for 8 weeks
1703072|NCT01442610|Drug|Placebo|Placebo 1tablet once daily for 8 weeks
1703073|NCT01442597|Behavioral|Standard Treatment As Usual (TAU)|Treatment normally offered at this clinic which could include individual or group drug counseling sessions one time per week last one hour each time.
1703074|NCT01442597|Behavioral|Individual clinician-provided CBT|Individual drug counseling sessions with trained clinicians using CBT one time per week last one hour per session.
1703075|NCT01442597|Behavioral|CBT4CBT|Subjects work with a computerized program that teaches skills for stopping drug use and increasing coping skills. Computerized sessions are one time per week and last about one hour per session.
1703076|NCT01442584|Procedure|ovarian transplantation|ovarian transplantation
1703077|NCT01442571|Device|Hyaluronic Acid Injection|
1703078|NCT01442571|Drug|Saline Injection|
1703079|NCT01442558|Drug|Bupivacaine|Bupivacaine 5 mg/cc with adrenaline 5 mcg/cc will be injected with complete spread of the drug around nerves.
1703080|NCT01442545|Drug|JNJ-39758979 / MTX|Day 1: MTX: Route=oral use, single dose of participant's weekly MTX dose; Days 3-15: MTX: Route=oral use, single dose of participant's weekly MTX dose and JNJ 39758979: Type=exact, unit=mg, number=300, form=tablet, route=oral use, administered daily.
1703081|NCT01442532|Drug|JNJ-38518168 (30 mg)|Type=range, unit=mg, number=30, form=tablet, route=oral use, in single and multiple doses for 14 days
1703082|NCT01442532|Drug|JNJ-38518168 (10 mg)|Type=range, unit=mg, number=10, form=tablet, route=oral use, in single and multiple doses for 14 days
1703083|NCT01442532|Drug|JNJ-38518168 (3 mg)|Type=range, unit=mg, number=3, form=tablet, route=oral use, in single and multiple doses for 14 days
1703084|NCT01442532|Drug|Placebo|Form=tablet, route=oral use, for 14 days
1703085|NCT01442532|Drug|Midazolam and JNJ-38518168|Midazolam: Type=exact, unit=mg, number=2.5, form=oral solution; route=oral use, on Days 1 and 15; JNJ-38518168: Type=exact, unit=mg, number=30, form=tablet, route=oral use, once daily from Day 2 through Day 15
1703086|NCT01442519|Biological|bacillus Calmette-Guerin|The BCG instillation consisted of 81 mg wet weight (10•2±9•0_108 colony-forming units) BCG Connaught substrain (ImmuCyst®, Alfa Wassermann SpA, Bologna, Italy). Lyophilised (ie, freeze-dried) BCG is suspended in 50 mL bacteriostatic-free solution of 0•9% sodium chloride. After draining of the bladder, the suspension is infused intravesically through a Foley catheter. The solution is retained in the bladder for 120 min, followed by emptying of the bladder and removal of the catheter. The BCG-alone group is assigned one course of intravesical treatment per week for 6 weeks. Patients in the BCG-alone group who are disease-free 3 months after treatment are scheduled to receive monthly infusions of BCG for 10 months
1703087|NCT01442519|Drug|electromotive mitomycin|BCG instillation of 81 mg BCG Connaught-substrain, suspended in 50 mL bacteriostatic-free saline solution, retained for 120 min. Electromotive instillation: 40 mg mitomycin in 100 mL water infused intravesically and retained in the bladder for 30 min, while 20 mA for 30 min pulsed electric current is given externally. Patients assigned sequential BCG and EMDA MMC are assigned 1 course of treatment/week for 9 weeks: one cycle consisted of two BCG infusions and one mitomycin infusion (three cycles in total). Patients in the BCG-and-mitomycin group who are disease-free 3 months after treatment are scheduled to receive one infusion a month for 9 months: three cycles of mitomycin, mitomycin, and BCG (ie, six infusions of MMC and three of BCG).
1703088|NCT01442506|Other|biopsies|taking biopsies
1703089|NCT01442506|Other|biopsy|biopsy
1703090|NCT01442493|Other|Patient-Centered Methadone Treatment|Unlike in treatment as usual, counseling will be encouraged but not required and counselors will be responsible for enforcing the clinic's rules. The rules will be enforced by the Clinical Director. Clinic rules will be modified such that involuntary discharge from treatment will be a rare event.
1703091|NCT01442493|Other|Methadone Treatment as usual|Counseling will be required and counselors will enforce the usual clinic rules. Involuntary discharge may occur for ongoing drug use or rule infractions as usually occurs in the clinic.
1703092|NCT01442480|Dietary Supplement|Fish oil|Subjects (ages 50 to 75 years), were randomly assigned to receive 3 g/d of fish oil (1.2 g eicosapentaenoic acid and 0.82 g docosahexaenoic acid) for 28 d.
1703093|NCT01442480|Dietary Supplement|Olive oil|Subjects (ages 50 to 75 years) were randomly assigned to receive 3 g/d of olive oil for 28 d.
1703094|NCT01442454|Other|chronic pancreatitis|No intervention, subjects followed through surgery
1703095|NCT01442428|Drug|Dexamethasone|Dexamethasone: 4 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
1703096|NCT01442428|Drug|Atorvastatin|Atorvastatin: 80 mg once daily (equivalent to 30mg ± 10mg with rifamycin co-administration in this TB population)
1703097|NCT01442428|Drug|Naproxen|Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
1703098|NCT01442428|Drug|Placebo|Atorvastatin placebo
1703099|NCT01442415|Behavioral|Lifestyle modification|Weekly lifestyle modification sessions including dietary counseling and physical activity
1703101|NCT01442376|Drug|Palonosetron|Single dose Palonosetron IV 20 mcg/kg up to a maximum total dose of 1.5 mg
1703102|NCT01442376|Drug|Ondansetron|Single three (every 4 hours) Ondansetron IV doses 0.15 mg/kg up to a maximum total dose of 32 mg
1703103|NCT01442376|Drug|Placebo to Ondansetron|
1703104|NCT01442376|Drug|Placebo to Ondansetron|
1703105|NCT01442376|Drug|Placebo to Palonosetron|
1703106|NCT01442363|Drug|BLI-1300 low dose|topical ointment
1703107|NCT01442363|Drug|BLI-1300 high dose|topical ointment
1703108|NCT01442363|Drug|placebo|topical ointment
1703109|NCT01442337|Drug|ASP8597|one time IV dose
1703110|NCT01442337|Drug|Placebo|one time IV dose
1703111|NCT01442324|Procedure|Irreversible electroporation (IRE)|Needle-like electrodes are inserted through the liver and in the lesion without exceeding its deepest margin, at which point the IRE NanoKnife™ System (AngioDynamics) is started.
1703112|NCT01442311|Other|enhanced DOT (both pegylated interferon alfa-2a and ribavirin)|Subjects randomized to the PEG/RBV-DOT arm receive weekly provider-administered pegylated interferon alfa-2a injections plus modified directly observed ribavirin therapy. We describe this as modified because ribavirin ingestion is observed at the methadone window three to six days per week based on the participants' methadone pick-up schedule, and only one of two daily doses is observed.
1703113|NCT01442311|Other|standard DOT (PEG-DOT control arm)|Subjects randomized to the Peg-DOT arm receive standard on-site treatment (weekly provider-administered pegylated interferon alfa-2a injections) and self-administered twice-daily oral ribavirin. Subjects in the PEG-DOT arm are dispensed monthly medication bottles of ribavirin, and ingest the ribavirin at home.
1703114|NCT01442298|Procedure|Limb occlusion pressure (LOP)|The tourniquet cuff pressure were decided by measurement of limb occlusion pressure (LOP) using an automated photo plethysmographic sensor connected to a ATS 3000 tourniquet apparatus (Zimmer Sweden Inc®).
1703115|NCT01442298|Procedure|conventional measurement method|Standard method at our department, the tourniquet cuff pressure was based on the patient's systolic blood pressure and a margin that were decided by the surgeon.
1703116|NCT01442285|Behavioral|personalized, motivational messages|A Healthcare Provider Report will be printed after each assessment and reviewed by the subject's oncologist. If any mental health functioning scale scores fall in the elevated or high range, a treatment plan will be constructed. Subjects will receive a personalized Patient Feedback Report after each assessment which will include motivationally tailored messages and suggestions for action.
1703117|NCT01442272|Drug|Hidroferol®|Hidroferol® drinkable ampoule in oral solution, 266 mcg (1 drinkable ampoule) each 15 days during 12 months
1703118|NCT01442272|Drug|Paricalcitol: Zemplar®|Paricalcitol (Zemplar®) oral capsule , 1 mcg (1 capsule)each 24 hours during 12 months
1703119|NCT01442272|Drug|Habitual medication|Habitual medication
1703120|NCT01442259|Drug|AFQ056|
1703121|NCT01442246|Drug|Leuprorelin Acetate|Leuprorelin Acetate 45mg, one injection every 6 months for 24 months
1703122|NCT01442233|Procedure|plasma exchange|6 plasma exchange each 48 hours during 2 weeks after randomization
1703123|NCT01442233|Procedure|sham exchanges procedure|6 sham exchanges each 48 hours during 2 weeks after randomization
1703124|NCT01442207|Procedure|Placement of a Cervical Cerclage|Surgical placement of a cervical cerclage
1703125|NCT01442207|Procedure|Standard Expectant Management|"Participants assigned to the expectant management group will be followed by their doctor and managed per standard management which includes:
Standard management for placenta previa.
Hospital admission for vaginal bleeding/hemorrhage
Antenatal corticosteroids > 24w0d of gestation
Tocolytic therapy per physician's discretion
Magnesium sulfate for neuroprotection
Fetal Heart Rate Monitoring
Avoidance of digital examinations of the cervix
Elective delivery no earlier than 36w0d gestation unless indicated (uncontrolled hemorrhage, imminent delivery, PROM > 34 wks, worsening maternal or fetal condition )
Fetal Fibronectin (fFN) test collected at the time of transvaginal Ultrasound."
1703126|NCT01442194|Drug|other disease-modifying therapy|
1703127|NCT01442194|Drug|Fingolimod|
1703128|NCT01442181|Procedure|Minimally Invasive Surgery|Small thumb sized incisions are made on each side of the chest wall where instruments are inserted for the purpose of completing the surgery.
1703129|NCT01442181|Other|Medical therapy|Patients are treated with rhythm and rate control medications.
1703130|NCT01442168|Drug|Sevuparin sodium + atovaquone/proquanil|Sevuparin 4 times per day and malanil according to label
1703131|NCT01442168|Drug|atovaquone/proquanil|malanil according to label
1703132|NCT01442155|Drug|Capecitabine|Administered according to the Summary of Product Characteristics.
1703133|NCT01442155|Biological|Oxaliplatin|Administered according to the Summary of Product Characteristics.
1703134|NCT01442142|Behavioral|CAAT: Appetite Awareness|"Participants in this Children's Appetite Awareness Training (CAAT) group learn to get in touch with the internal cues of hunger - aka the hunger meter - and practice skills to get back in touch with these internal cues of true hunger and fullness. Sessions occur once a week for 8 weeks."
1703135|NCT01442142|Behavioral|CRST: Volcravo|"Participants in this Cue Reactivity and Sensitivity Training (CRST) group learn about how external cues can affect when and how much we eat (aka volcravo - the craving volcano). Over 8 weekly sessions, they practice skills to ride out the cravings external cues can cause."
1703136|NCT01442142|Behavioral|Combined CAAT and CRST program|Participants meet weekly for 14 weeks to learn about both Children's Appetite Awareness Training (CAAT) and Cue Reactivity and Sensitivity Training (CRST) - i.e. appetite awareness and external cues that affect food intake.
1703137|NCT01442129|Biological|MPC Intramyocardial injection|Intramyocardial injection of 25 million mesenchymal precursor cells at the time of LVAD implantation
1703138|NCT01442129|Biological|Control Solution|Injection of control solution during the LVAD implantation.
1703139|NCT01442116|Procedure|stress echocardiography|safety and efficacy of stress echocardiography
1703140|NCT01442103|Device|Normlgel Ag|Normlgel Ag dressing will be changed together with planned investigation visits. Dressing changes between visits will be performed at home on Day 3 or 4 of each week by subject or caregiver and documented in a dressing log.
1703141|NCT01442090|Drug|Everolimus|Everolimus will be administered orally at a 10 mg daily dose.
1703142|NCT01442090|Drug|GDC-0980|GDC-0980 will be administered orally at a 40 mg daily dose.
1761852|NCT00284791|Drug|sertraline (drug)|
1703143|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 3 weeks (6 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for 3 weeks (6 treatments).
1703144|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 12 treatments, in which the subject will be treated twice a week for 6 consecutive weeks, without intermission.
1703145|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 8 treatments, in which the subject will be treated twice a week for two weeks (4 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated twice a week for two weeks (4 treatments).
1703146|NCT01442077|Device|Extracorporeal Shockwave Therapy Generator (Omnispec ED1000)|Series of 6 treatments, in which the subject will be treated once a week for 3 weeks (3 treatments), then would be discontinuation of the study for 3 weeks, and at the end of this period will be treated once a week for 3 weeks (3 treatments).
1703147|NCT01442064|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year).
1703148|NCT01442051|Procedure|Acute Normovolemic Hemodilution|A predetermined volume of whole blood will be removed from these patients based on an established protocol. Crystalloid and colloid will then be infused to replace intravascular volume based on this protocol. Patients will be closely monitored intraoperatively with serum arterial hemoglobin (HgB) levels drawn hourly. Patients will be transfused with autologous blood if HgB < 7.0 g/dL. If the volume of autologous blood has not been transfused within eight hours or by the completion of the procedure, the remainder will be transfused at that time. If the volume of autologous blood has been transfused and the patients require additional blood transfusions (HgB <7g.dL), allogenic blood will be transfused thereafter. These transfusion triggers are based on common intraoperative practice patterns. Patients may also be transfused intraoperatively at any time for a HgB ≥ 7.0 g/dL based on the judgment of the attending anesthesiologist or surgeon but the reason will be recorded.
1703149|NCT01442038|Drug|Ranolazine|"Subjects will receive ranolazine 500 milligrams (mg) twice daily for 7 days, followed by 1000 mg administered orally twice daily for the duration of the study.
Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
1703150|NCT01442038|Drug|Placebo|"Subjects will receive one tablet of matching placebo twice daily for 7 days, followed by two tablets of matching placebo twice daily for the duration of the study.
Subjects receiving a moderate CYP3A4 inhibitor will receive ranolazine 500 mg or placebo administered orally twice a day for the duration of the concomitant therapy."
1703151|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg to be increased to 10 mg/kg based on clinical symptoms
1703152|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg or 10 mg/kg if dose increase criteria are met (biological)
1703153|NCT01442025|Drug|Infliximab|Perfusion of IFX 5mg/kg or 7,5 mg/kg if dose increase criteria are met (biological)and 10mg/kg if dose increase criteria are met for a second time
1703154|NCT01442012|Other|Ear seeds|The investigators will use ear seeds to stimulate acupuncture points. The seeds will be applied when the patients are in the preoperative room. After the patients have been discharged, they will need to stimulate these points every eight hours for five minutes, and every time they have nausea and/or vomiting during the first three postoperative days.
1703155|NCT01441999|Device|Less rigid rod|Titanium rod with semi rigid end
1703156|NCT01441999|Device|Rigid Rod|Rigid Titanium rods
1703157|NCT01441986|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide•1 H2O; 30 mg; hard capsules; single, oral dose.
1703158|NCT01441986|Drug|Amantadine|Amantadine hydrochloride 100 mg; tablets; single, oral dose.
1703159|NCT01441986|Drug|Pacebo 1 (placebo for Amantadine)|Talets for oral use; single dose.
1703160|NCT01441986|Drug|Placebo 2 (fo Dextromethorphan)|Capsles for oral administration; single dose.
1703161|NCT01441973|Biological|Elotuzumab (BMS-901608; HuLuc63)|
1703162|NCT01441960|Drug|Succinylcholine|Succinylcholine will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments. The investigators will switch to the second compound as soon as the patient has received one neuromuscular blocking agent dose that resulted in 'acceptable muscle relaxation', and another dose that resulted in 'unacceptable' conditions'.
1703163|NCT01441960|Drug|Rocuronium|Rocuronium will be given during the series of ECT treatments. The initial dose will be defined by the anesthesiologist in charge for clinical care. The Dixon's up and down method will be used in consecutive treatments.
1703164|NCT01441947|Drug|Cabozantinib|Part of combination arm
1703165|NCT01441947|Drug|Fulvestrant|part of combination arm
1703166|NCT01441934|Drug|Sildenafil citrate|sildenafil 20 mg t.i.d. compared to placebo 20 mg t.i.d - 16 weeks treatment
1703167|NCT01441934|Drug|Sugar pills|placebo t.i.d.
1703168|NCT01441921|Dietary Supplement|Pistachios|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.
Total duration of intervention and follow-up is nine months."
1703169|NCT01441921|Other|control diet|"Participants are randomised crossover clinical trial of 4-months trials separated by a 2-week washout period.
Total duration of intervention and follow-up is nine months."
1703170|NCT01441908|Drug|Pravastatin|40mg or 80mg dose 28 days for 6 month period
1703174|NCT01441869|Drug|Onglyza (saxagliptin)|Oral tablets, 5 mg , single dose
1703175|NCT01441869|Drug|Diabex|Extended release oral tablets, 1000 mg, single dose
1703176|NCT01441869|Drug|5-mg saxagliptin/1000 mg metformin|Extended release fixed dose combination tablet, single dose
1703177|NCT01441869|Drug|Diabex|Extended release oral tablets, 500 mg, single dose
1703178|NCT01441869|Drug|5-mg saxagliptin/500 mg metformin|Extended release fixed dose combination tablet, single dose
1703179|NCT01441856|Procedure|Open or Laparoscopic left hemihepatectomy|Patients in this arm will undergo a left hemihepatectomy within an Enhanced Recovery After Surgery Program.
1703180|NCT01441856|Procedure|Open or Laparoscopic right hemihepatectomy|Patients in this arm will undergo a right hemihepatectomy within an Enhanced Recovery After Surgery Program.
1703181|NCT01441843|Drug|Lorazepam|Once 1mg <75kg body weight, 1.5mg 75kg and >75kg body weight, IV, before surgery
1703182|NCT01441843|Drug|NaCl 0.9% (Sodium Chloride)|Once 1ml <75kg body weight, 1.5ml 75kg or >75kg body weight, IV, before surgery
1703183|NCT01441830|Device|Radial extracorporeal shock wave therapy|The shockwave treatment will be administered once a week for four weeks on one to three specific points (supraspinatus, infraspinatus or subscapular tendon)and with a pressure between 1,5-3 Bar
1703184|NCT01441817|Procedure|Internal fixation|Internal fixation of the medial malleolus following open reduction and internal fixation of the lateral and, if required, posterior malleolus.
1703185|NCT01441804|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
1703186|NCT01441804|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
1703187|NCT01441804|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
1703188|NCT01441804|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
1703189|NCT01441791|Procedure|Lung protective strategy ventilation|Patients are randomized and intra-operatively ventilated with a lung protective strategy (PEEP at 12 cmH2O with recruitment maneuvers)
1703190|NCT01441778|Drug|NSS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
1703191|NCT01441778|Drug|BHS nasal irrigation salt|nasal irrigation twice daily for 4 weeks period
1703192|NCT01441765|Drug|CT-011|CT-011 at 3 mg/kg IV for 4 cycles of 6 weeks
1703193|NCT01441765|Biological|DC/RCC fusion vaccine|Vaccination once per cycle on Day 8 of treatment cycles 2-4
1703194|NCT01441752|Drug|TCM|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe.
1703195|NCT01441752|Drug|placebo|three types with functions such as benefiting Qi recipe, benefiting Yin recipe and detoxication and resolving masses recipe，with the same color, smell ，taste weight and package
1703197|NCT01441687|Other|laboratory biomarker analysis|Correlative studies
1703198|NCT01441687|Procedure|transrectal prostate biopsy|Undergo prostate biopsy
1703199|NCT01441674|Behavioral|Animal Assisted Therapy|There will be a therapy dog and dog trainer present working with the patient for the AAT arm.
1703200|NCT01441648|Other|contact lens wear|tinted contact lens wear
1703201|NCT01441635|Other|Placebo|Placebo
1703202|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 1
1703203|NCT01441635|Other|Placebo|Placebo
1703204|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 2
1703205|NCT01441635|Drug|Elagolix Dose 1 plus estradiol/norethindrone acetate|Elagolix Dose 1 plus estradiol/norethindrone acetate
1703206|NCT01441635|Other|Placebo|Placebo
1703207|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 3
1703208|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 4
1703209|NCT01441635|Drug|Elagolix, elagolix sodium|Elagolix Dose 5
1703210|NCT01441635|Drug|Elagolix Dose 2 plus estradiol|Elagolix Dose 2 plus estradiol
1703211|NCT01441635|Drug|Elagolix Dose 2 plus cyclical progesterone|Elagolix Dose 2 plus cyclical progesterone
1703212|NCT01441622|Device|AL539 (SRETT)|recording data with AL539 (SRETT)
1703213|NCT01441596|Drug|Vinorelbine|Vinorelbine 25 mg/mÂ² on days 1, 8, 15 in a 3-weekly course
1703214|NCT01441596|Drug|Investigator's choice of treatment|Patients will receive, at the investigator's discretion, the most appropriate medical treatment consisting of single agent or combination regimen approved for the treatment of metastatic breast cancer, and according to patient status and local guidelines.
1703215|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
1703216|NCT01441596|Drug|afatinib|Afatinib monotherapy:once daily, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.
1703217|NCT01441583|Device|RAAT|For Pacemaker and CRT-P: Right Atrial Automatic Threshold (RAAT)
1703218|NCT01441583|Device|RYTHMIQ|For pacemakers only: RYTHMIQ RYTHMIQ randomized to on at pre-discharge or at 1-month, depending on assignment
1703219|NCT01441570|Drug|Nebivolol|Subject will take nebivolol daily for 12 weeks.
1703220|NCT01441570|Drug|Metoprolol succinate|Subject will take metoprolol succinate daily for 12 weeks.
1703221|NCT01441557|Drug|3,4-diaminopyridine|test dose 10 mg then 20 mg, then depending on tolerance and efficacy full-dose administration(from 10mg /8h to 20 mg /8h)
1703222|NCT01441544|Behavioral|Variety of Active Videogames|Thirty men and women, aged 18- to 35- years, recruited from the local area, with a normal body mass index (BMI) between 18.5 and 29.9 kg/m, will participate in two experimental sessions, VARIETY (playing the same active video game over 4 sessions) and NON-VARIETY (playing 4 different active video games over 4 sessions), with order of experimental sessions counterbalanced across participants.
1703223|NCT01441531|Drug|gabapentin 600 mg po|Given one hour before surgery
1703224|NCT01441531|Drug|Placebo pill given one hour before surgery|Placebo pill given
1703256|NCT01441349|Drug|IP chemotherapy plus simvastatin|"Cisplatin(30mg/m2)diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 &8
Irinotecan( 65 mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1& 8.
Every 21days.
Simvastatin 40 mg per day orally D1of cycle 1"
1703225|NCT01441518|Other|Home care|"Home care, sometimes called ambulatory care or outpatient, was defined as the blood-glucose self-monitored by the pregnant women at home. This project will provide glucometers to all those who are randomized to home care. The women will receive training for glucose control in pre-defined days, with the glucometer to obtain the mean glucose. According to blood-glucose levels in glycemic profile, insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia ."
1703226|NCT01441518|Other|Hospital care|"Hospital care, sometimes called acute care, was defined as control of maternal diabetes made at hospitals by admission to hospital. The blood-glucose and metabolic control are done in gestational diabetes and mild gestational hyperglycemia treated conventionally.
The hospitalized patients will have their glycemic control done in the hospital. . According to blood-glucose levels in glycemic profile , insulin dose will be maintained or altered both in gestational diabetes as in mild gestational hyperglycemia.
All the women of the study will be accompanied by a team of obstetricians specializing in high-risk pregnancies; residents; dietitians; nurses and neonatologists."
1703227|NCT01441505|Drug|Ketamine|Ketamine IV, IM, or SC will be administered in Phase I and II
1703228|NCT01441505|Drug|Saline or Midazolam (active placebo)|Saline, or midazolam 0.01mg/kg will be administered in Phase I
1703229|NCT01441492|Procedure|No Drains|A closed-suction drain will not be placed near the transection margin at the time of surgery in the experimental group.
1703230|NCT01441492|Procedure|Drains|A drain will be placed near the pancreatic transection margin at the time of surgery (standard of care).
1703231|NCT01441479|Device|In Vitro Diagnostic Device aid in diagnosing|
1703232|NCT01441466|Other|Isolation|Patients in this arm are nursed together (in the same room) independent of viral agent
1703233|NCT01441453|Procedure|FibroScan (Transient Elastography measurement)|Preoperative evaluation of liver stiffness through FibroScan
1703234|NCT01441440|Drug|venlafaxine ER 75 mg/day (fixed dose)|Treatment phase: 8 weeks (37.5 mg/day for 1st week and 75 mg/day for 7 weeks), oral administration Tapering phase: 2 weeks (37.5 mg/day for the 1st week and placebo for the 2nd week), oral administration
1703235|NCT01441440|Drug|venlafaxine ER 75 mg/day to 225 mg/day (flexible dose)|Treatment phase: 8 weeks (37.5 mg/day for the 1st week, 75 mg/day for the 2nd weeks, 75-150 mg for the 3rd week, 75-225 mg/day for the rest of 5 weeks), oral administration Tapering phase: 2 weeks (75/37.5 mg/day for the 1st week and 37.5 mg/day/placebo for the 2nd week), oral administration
1703236|NCT01441440|Drug|Placebo|Treatment phase: 8 weeks (placebo), oral administration Tapering phase: 2 weeks (placebo), oral administration
1703237|NCT01441427|Drug|recombinant human G-CSF, and rhEPO|G-CSF 4.5 microgram /kg/day enteral EPO 88 mIU/kg/day enteral
1703238|NCT01441427|Drug|rh G-CSF|Dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
1703239|NCT01441427|Drug|rh EPO|Dosage: 88 IU/ kg once daily (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
1703240|NCT01441427|Drug|rh G-GSF and rh EPO together|EPO dosage: 88 IU/ kg once daily i.e 88000 mU/kg/day (diluted into 1 ml distilled water) administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.G-CSF dosage: 4.5 µg/ kg (diluted into 1 ml distilled water) administered once daily by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
1703241|NCT01441427|Drug|Placebo|distilled water :1 ml distilled water administered by an orogastric tube till the enteral intake reached 100 mL/kg of milk, or after a maximum of seven days.
1703242|NCT01441414|Biological|PF-04856884|15 mg/kg/week intravenously [IV] until toxicity or disease progression
1703243|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
1703244|NCT01441414|Drug|Axitinib (AG-013736)|5 mg PO BID
1703245|NCT01441401|Drug|gabapentin|According to Japanese Package Insert: For infants and children aged 3 to 12 years, a daily dosage of 10 mg/kg of gabapentin should be administered orally in 3 divided doses on the first day of treatment, and an effective dosage of 20 mg/kg should be administered to them in 3 divided doses on day 2. From day 3 on, infants aged 3 to 4 years should be maintained on the dosage of 40 mg/kg, and children aged 5 to 12 years on the dosage of 25 to 35 mg/kg administered orally in 3 divided doses, respectively (the maximum daily dosage: 1800 mg). Though the maintenance dosage may be adjusted depending on the patient's condition, the maximum daily dosage should be 50 mg/kg. At any time point, dosage should not exceed that the dosage for adults and children aged 13 years.As for children aged 13 years or over is as same as administration for adult.
1703246|NCT01441388|Drug|Crizotinib plus VEGF inhibitor combinations|Three combinations will be prioritized, namely crizotinib plus axitinib, crizotinib plus sunitinib and crizotinib plus bevacizumab, with a fourth combination, crizotinib plus sorafenib to be tested only if crizotinib does not combine with either axitinib and/or sunitinib. All study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
1703247|NCT01441388|Drug|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
1703248|NCT01441388|Drug|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
1703249|NCT01441388|Drug|Crizotinib plus axitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
1703250|NCT01441388|Drug|Crizotinib plus sunitinib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
1703251|NCT01441388|Drug|Crizotinib plus bevacizumab|Study drugs are tablets or capsules except for bevacizumab which is parenteral (intravenous). Dosage, frequency and duration to be determined.
1703252|NCT01441388|Drug|Crizotinib plus sorafenib|Study drugs are tablets or capsules; dosage, frequency and duration to be determined.
1703253|NCT01441362|Procedure|90 degrees rotation|Double-lumen tube intubation with 90 degrees rotation
1703254|NCT01441362|Procedure|180 degrees rotation|Double-lumen tube intubation with 180 degrees rotation
1703255|NCT01441349|Drug|IP chemotherapy|"Irinotecan/cisplatin (IP) chemotherapy
Cisplatin(30 mg/m2) diluted into 150 ml of 0.9% NS for IV over 30 min on day 1 &8.
Irinotecan(65mg/m2) diluted into 200ml of 5DW IV over 90 min on day 1 & 8
Every 21 days"
1703399|NCT01440257|Drug|Placebo|Placebo capsules once daily
1703400|NCT01440257|Drug|CCX140-B|CCX140-B capsules once daily (Group B)
1703257|NCT01441336|Procedure|Laparoscopic gastrectomy|Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
1703258|NCT01441323|Behavioral|Nutrition|Nutrition classes for 1 hour & 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
1703259|NCT01441323|Behavioral|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
1703260|NCT01441310|Procedure|Laparoscopic sentinel node navigation surgery|Laparoscopic SNNS using simultaneous indocyanine green (ICG) and 99mTc-antimony sulfur colloid (ASC) injections
1703261|NCT01441297|Drug|BIBF 1120|BIBF 1120 200mg bid, PO, daily until PD
1703262|NCT01441284|Drug|pramipexole|pramipexole extended release, 2.1 mg pramipexole base (3.0mg pramipexole salt) once daily
1703263|NCT01441284|Drug|placebo|placebo
1703264|NCT01441271|Procedure|Ileal diversion and lavage|The surgical approach involves an attempted laparoscopic creation of a loop ileostomy after visually assessing the colon to assure viability. If the loop is unable to be safely performed laparoscopically an open loop ileostomy will be performed. Intraoperatively, 8 liters of warmed polyethylene glycol 3350/electrolyte solution [GoLytely®; Braintree Laboratories] will be infused into the colon via the ileostomy and collected via a rectal drainage tube. Post-operatively, the patients will receive antegrade vancomycin flushes [500 mg in 500 ml of Lactated Ringers; q8 hours for duration of 10 days] via a Malecot catheter [24 French] left in the efferent limb of the ileostomy (Figure 1). Additionally patients will be continued on intravenous metronidazole [500mg q8 hours] for 10 days.
1703265|NCT01441271|Procedure|total abdominal colectomy|The surgical approach of the colon in a total abdominal colectomy involves a midline incision. The complete colon in the abdomen (from ileum to rectum) will be removed and an end ileostomy is performed.
1703266|NCT01441258|Behavioral|Dialectical Behavior Therapy Skills (DBT-S) Groups|The intervention will be delivered within an 18-week, once-weekly, one-and-half-hour skill group (8 participants per group) comprised of the same four modules administered in standard DBT skills training groups: (1) mindfulness, (2) interpersonal effectiveness, (3) emotion regulation, and (4) distress tolerance. There will be four sessions for each module totaling 16 sessions. There will be two booster sessions reviewing mindfulness and the concept of dialectics in-between each of the modules (i.e., between modules 2 and 3 and 3 and 4).
1703267|NCT01441258|Behavioral|Wait List-Treatment as Usual|Participants will be seen by their standard treaters for 18 weeks as usual.
1703268|NCT01441258|Behavioral|No intervention-treatment as usual|Participants will receive the intervention after 18 weeks in the treatment as usual group.
1703269|NCT01441245|Drug|furosemide infusion|Patients were randomized in a 1:1 ratio to receive furosemide dose divided into twice-daily bolus injection (group 0) or continuous infusion (group 1)(mixed as a 1:1 ratio in 5% dextrose in water) for a time period ranging from 72 to 120 hours. The mean daily diuretic dosage was similar in the two groups. The median time from presentation to randomization was 16 hours, and the median duration of study-drug administration was 112± 24 hours
1703270|NCT01441232|Drug|LX4211|400 mg of LX4211 administered as two 200 mg tablets
1703271|NCT01441232|Drug|Januvia®|100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
1703272|NCT01441219|Device|Colon 2|Ingest one colon 2 capsule
1703273|NCT01441206|Drug|rifampin|"Infants who will be receiving up to 4 doses of rifampin per protocol(Cohort 1)
Cohort 1:
Dosing will be as follows:
GA at birth < 32 weeks - PNA < 14 days: 10 mg/kg QD GA at birth < 32 weeks - PNA ≥ 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA < 14 days: 15 mg/kg QD GA at birth ≥ 32 weeks - PNA ≥ 14 days: 20 mg/kg QD"
1703274|NCT01441193|Biological|HIV-1 Tat/delta-V2 Env combined vaccine|
1703275|NCT01441193|Biological|HIV-1 delta-V2 Env vaccine|
1703276|NCT01441193|Biological|HIV-1 Tat vaccine 7.5 microg|
1703277|NCT01441193|Biological|HIV-1 Tat vaccine 30 microg|
1703278|NCT01441180|Drug|GS7977|drug intervention
1703279|NCT01441180|Drug|RBV|drug intervention
1703280|NCT01441167|Biological|PfSPZ|
1703281|NCT01441128|Drug|PF-02341066/PF-00299804|Combined PF-02341066 and PF-00299804
1703282|NCT01441128|Drug|PF-02341066/PF-00299804|Single Agent PF-00299804 followed by Combined PF-02341066 and PF-00299804
1703283|NCT01441115|Procedure|Radiation Therapy|
1703284|NCT01441115|Drug|ECI301|
1703285|NCT01441102|Drug|Dextromethorphan hydrobromide|Participants instructed to take 60 mg dextromethorphan capsules orally two times a day for 24 months.
1703286|NCT01441076|Drug|Anakinra|Anakinra/Kineret[registered] is a recombinant, non-glycosylated form of the human interleukin-1 receptor antagonist (IL-1Ra)
1703291|NCT01441024|Drug|DAS181|20 mg per day of DAS181-FO3 for 5 days
1703292|NCT01441024|Other|Placebo|20 mg per day of Lactose for 5 days
1703293|NCT01441011|Behavioral|Group phone counseling|Bi-weekly phone counseling sessions from 6 - 18 months
1703294|NCT01441011|Behavioral|Newsletter|Bi-weekly newsletter mailings from 6 - 18 months
1703295|NCT01440998|Drug|Carboplatin|Given IV
1703296|NCT01440998|Drug|Dasatinib|Given PO
1703297|NCT01440998|Other|Laboratory Biomarker Analysis|Correlative studies
1703298|NCT01440998|Drug|Paclitaxel|Given IV
1703299|NCT01440985|Drug|Nicotine|Nicotine Gum 2 mg, Lot number GD922A
1703300|NCT01440985|Drug|Nicotine|Nicotine gum 4 mg, Lot number GC962A
1703301|NCT01440985|Drug|Nicotine|Nicotine Microtab 2 mg, Lot number GB196G
1703302|NCT01440972|Other|partial blood flow restriction (PBFR)|low intensity resistance training with partial blood flow restriction 3 times/week for 4 weeks.
1703303|NCT01440972|Other|low intensity resistance training|low intensity resistance training without partial blood flow restriction
1703304|NCT01440959|Drug|dovitinib|TKI258 at 500 mg/day on a 5 days on/2 days off dosing schedule
1703441|NCT01439958|Drug|Inhalation|Twice daily inhalation for a maximum of three years.
1703305|NCT01440946|Drug|rFIXFc|Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.
1703306|NCT01440946|Drug|FIX|Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
1703307|NCT01440933|Drug|Magnesium Sulfate|1ml/kg of the study solution containing 60 mg/ml of magnesium sulphate are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
1703308|NCT01440933|Drug|Placebo comparator|1ml/kg of the study solution containing physiologic saline are given intravenously over 15 minutes in the conscious patient. After anaesthesia induction and calibration of neuromuscular monitoring (TOF Watch SX - acceleromyography) 0,6 mg/kg of rocuronium is given intravenously. After recovery of the neuromuscular block to a posttetanic count of 2 (deep neuromuscular block) (PTC 2) or reappearance of 2 twitches of the Train of four (superficial neuromuscular block) 4 mg/kg (deep neuromuscular block) or 2 mg/kg (superficial neuromuscular block) of Sugammadex are given intravenously.
1703309|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 0.3 mg
1703310|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 1 mg
1703311|NCT01440920|Drug|OCV-501|subcutaneously administered once a week, 4 times at the dose of 3 mg
1703312|NCT01440907|Other|Care Coordination Program|The Care Coordination Program includes: (1) access to a secure online personal health record (PHR) that people can logon and manage their health information, as well as receive alerts and reminders about action items for them to take on their healthcare; and (2) depending on the patient's health care needs, nursing support (either in-person or by phone).
1703313|NCT01440894|Device|Comparison test|"Reference Device: Transtek Glass Body Analyzer, GBF-950, accuracy: ±0.1kg and range: 0-180kg.
DUT(Device Under Test): Transtek Glass Body Fat Analyzer, Model: GBF-733-W1, GBF-1012, BF-1039, BF-1041-A, and GBF-950-D."
1703314|NCT01440881|Drug|Nesiritide|infuses at 0.01MCG/KG/min for 48 hours
1703315|NCT01440881|Drug|Placebo|infuses at 0.01MCG/KG/min for 48 hours
1703316|NCT01440868|Procedure|Sustained lung inflation|Sustained lung inflation (SLI) will be performed with mask using a pressure control system (Neopuff, Fisher & Paykel, Inc). Peak inflation pressure (PIP) of 25 cm H2O will be delivered for 15 seconds and then reduced to a PEEP of 5 cm H2O. A second SLI manoeuvre will be repeated in case of persistent hearth failure (HR <100 bpm ).
1703317|NCT01440855|Other|CIS (Cancer Information Service) Information Sheet|CIS Fact Sheet, available on the Cancer Information Service website. Used to control for attention. 5-page document provides information about the CIS:What is it, How can CIS information specialists help me, How can I use CIS's services. Also includes definitions of glossary terms and a table of email and website addresses.
1703318|NCT01440855|Other|Facing Forward booklet|NCI's (NCI: National Cancer Institute) Facing Forward 61-page booklet, which describes common feelings and reactions that cancer survivors experience during the re-entry phase and offers behavioral recommendations to help them through this period, i.e., ways of dealing with common problems and guidelines for managing physical, social, and emotional health. Booklet sections: Congratulations on Finishing Your Cancer Treatment, Getting Follow-up Medical Care, Ways to Manage Physical Changes, Body Changes and Intimacy, Your Feelings, Social and Work Relationships, Reflection, 6-page Appendix, which provides information on Financial and Legal Matters, and Resource Organizations.
1703319|NCT01440842|Other|Closed-loop insulin delivery|Intravenous infusion delivery of Actrapid insulin and dextrose, dose calculated by Model Predictive Control (MPC) algorithm, based on continuous glucose sensor readings.
1703320|NCT01440842|Other|Standard IV insulin infusion sliding scale|Standard intravenous insulin infusion sliding scale as per intensive care unit protocol.
1703321|NCT01440829|Drug|L-ornithine-L-aspartate|The patients will be treated with LOLA (30g per day) for a week after TIPS procedure.
1703322|NCT01440816|Biological|interleukin-12 gene|Given IT
1703323|NCT01440816|Biological|electroporation-mediated plasmid DNA vaccine therapy|Undergo electroporation-mediated plasmid DNA vaccine therapy
1703324|NCT01440803|Drug|Teriparatide|Daily injection of 20 mcg teriparatide for the treatment of idiopathic osteoporosis for 24 months.
1703325|NCT01440803|Drug|Saline Placebo|Daily injection of saline placebo for 6 months, followed by teriparatide treatment for 24 months.
1703326|NCT01440790|Dietary Supplement|glucose bolus|50g anhydrous glucose dissolved in 300ml water consumed within 10min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
1703327|NCT01440790|Dietary Supplement|Glucose sipping|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min followed by a lunch (cheese sandwich, fruit and milk) at 4h.
1703328|NCT01440790|Dietary Supplement|Glucose bolus plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed within 10min with 1g vitamin C followed by a lunch (cheese sandwich, fruit and milk) at 4h.
1703329|NCT01440790|Dietary Supplement|Glucose sipping plus 1g vitamin C|50g anhydrous glucose dissolved in 300ml water consumed at rate of 25ml per 15min. 1g vitamin C taken with first 25ml. Followed by a lunch (cheese sandwich, fruit and milk) at 4h.
1703330|NCT01440777|Behavioral|Go! to Sleep|"The online program provides various tools for the delivery of the intervention including:
Daily articles
Daily activities to help get the sleep you need
Daily sleep improvement recommendations
Audio recorded relaxation exercises
Daily e-mails from your program coach
Personal progress charts
An online sleep log and daily sleep score"
1703331|NCT01440764|Drug|Furosemide|
1703332|NCT01440764|Drug|Saline|
1703442|NCT01439945|Drug|magnesium oxide|Given PO
1703335|NCT01440738|Behavioral|health workshops|health workshops in relation to: Increase knowledge of healthy habits (physical activity, diet), incorporate and maintain a balanced diet. Incorporate and maintain regular physical activity
1703336|NCT01440725|Biological|Autologous Platelet-rich plasma (PRP)|4-8cc, a single dose
1703337|NCT01440725|Procedure|Evacuation of haematoma|Evacuation of the haematoma, a single procedure
1703338|NCT01440712|Drug|Gastrografin|Administration of 100 ml of gastrografin by the nasogastric tube, only once.
1703339|NCT01440712|Drug|physiological serum|Administration of 100 ml of physiological serum 0,9% by the nasogastric tube, only once.
1703340|NCT01440699|Biological|Allogenic human adipose-derived stem cells|ALLO-ASC 1xE7 cells/mL is injected once along the fistula. If there is no safety issue for 4 weeks, 3 more people could be enrolled who are subject to ALLO-ASC 3xE7 cells/mL.
1703341|NCT01440686|Drug|Somatropin|A single dose 5.0mg administered subcutaneously(under the skin) via Genotropin
1703342|NCT01440686|Drug|Placebo|Tablets, oral administrations
1703343|NCT01440673|Drug|Aprepitant|Aprepitant 80 mg, Aprepitant 125 mg
1703344|NCT01440647|Procedure|Extubation to NIPPV|After extubation infants were placed on NIPPV as soon as all the extubation criteria were met
1703345|NCT01440647|Procedure|Extubation to CPAP|After extubation infants were placed on CPAP
1703346|NCT01440634|Other|Supervised exercise Program|Supervised exercise Program consist of six months of supervised, intermittent track walking. Walking duration will begin at 20 - 30 minutes per session for the first month of the program, and increased by 5 minutes per session per month until a total of 45 minutes of walking per session is reached by the third month. During each exercise session, individuals will be encouraged to walk at a speed of approximately 2 mph until they achieve leg pain or discomfort on walking of moderate severity.Individuals are then allowed to have a brief period of standing or sitting rest to permit symptoms to resolve before they resume exercise.
1703347|NCT01440621|Drug|Modafinil|Tablet Modafinil 100mg (Generic) to be given in 100mg once a day dose, at 8AM daily in the morning, and to be given from Day 1 of Radiation Therapy till the first post treatment follow-up
1703348|NCT01440621|Drug|Pyridoxine|Tablet Pyridoxine 10mg once a day at 8AM daily, from Day one of RT till first post-treatment followup. Tab Pyridoxine 10mg has been chosen as placebo as it resembles Tab Modafinil 100mg in physical appearance, size and shape. Tab Pyridoxine is unlikely to affect Cancer Related Fatigue on its own as all patients on RT are already on multivitamin supplements as per our institutional guidelines.
1703349|NCT01440608|Drug|Albendazole|Pill form, to be given once, 200 mg dosage for children 1-2 years of age, 400 mg dosage for children 2-3 years of age
1703350|NCT01440608|Drug|Placebo|Pill form, 400 mg dose to be given once per day for 14 days in Placebo arm and 13 days in Albendazole arm following one dose of Albendazole.
1703351|NCT01440608|Dietary Supplement|High-dose Zinc|Pill form, equivalent to 20 mg elemental zinc, to be given once per day for 14 days
1703352|NCT01440595|Drug|Grazoprevir|Grazoprevir 100 mg tablets once daily for 12 weeks.
1703353|NCT01440595|Drug|Placebo to Grazoprevir|Placebo to Grazoprevir once daily for 12 weeks
1703354|NCT01440595|Drug|Peginterferon alfa-2b (Peg-IFN)|Peg-IFN weekly subcutaneous injection at 1.5 mcg/kg/week for 12 or 24 weeks
1703355|NCT01440595|Drug|Ribavirin (RBV)|Ribavirin 200 mg capsules twice daily at a dose of 600 mg to 1400 mg based on weight for 12 or 24 weeks
1703356|NCT01440582|Drug|Panobinostat|"Induction Therapy (Part A, 21-day cycles): 10 mg by mouth on Days 1, 3, 5, 8, 10, and 12 for 2 weeks with 1 week of rest at the end of each cycle.
Induction Therapy (Part B, 28-day cycles): 10 mg by mouth on Days 1, 3, 5, 15, 17, and 19 of every cycle.
Maintenance dose (Part A, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 8, 10, and 12 of each cycle.
Maintenance dose (Part B, 28-day cycles): Maximum tolerated dose (MTD) from Induction phase on Days 1, 3, 5, 15, 17, 19 of each cycle."
1703357|NCT01440582|Drug|Bortezomib|"Induction Therapy (Part A, 21-day cycles): 1.3 mg/m^2 by vein daily on days 1, 4, 8 and 11 of Cycles 1 - 8.
Induction Therapy (Part B, 28-day cycles): 1.3 mg/m^2 by vein daily on days 1, 8 and 15 of Cycles 1 - 8."
1703358|NCT01440582|Drug|Lenalidomide|"Induction Therapy (Part A, 21-day cycles): 25 mg by mouth daily on days 1-14 of every cycle.
Induction Therapy (Part B, 28-day cycles): 25 mg by mouth daily on days 1-21 of every cycle.
Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1 - 21 of each cycle."
1703359|NCT01440582|Drug|Dexamethasone|"Induction Therapy (Part A, 21-day cycles): 20 mg by mouth daily on Days 1, 2, 4, 5, 8, 9, 11 and 12 of Cycles 1 - 8.
Induction Therapy (Part B, 28-day cycles): 20 mg by mouth daily on Days 1, 2, 8, 9, 15 and 16 of Cycles 1-8.
Maintenance dose (Parts A and B, 28-day cycles): Last tolerated dose from Induction Phase on Days 1, 8, 15, 21 of each cycle."
1703360|NCT01440582|Behavioral|Symptom Questionnaire|Completed on day 1 of each cycle.
1703361|NCT01440569|Drug|COBI|150 mg tablet administered orally with food once daily
1703362|NCT01440569|Drug|DRV|800 mg (2 x 400 mg tablets) administered orally with food once daily
1703363|NCT01440569|Drug|NRTIs|Participants will receive 2 nucleoside analogue reverse transcriptase inhibitors (NRTIs) selected by the investigator after resistance testing at screening and administered according to prescribing information. NRTIs may include emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF), zidovudine+FTC/TDF, abacavir (ABC)+TDF, ABC+FTC/TDF, ABC+lamivudine (3TC), or didanosine (DDI)+FTC.
1703364|NCT01440543|Procedure|Water immersion insertion AND CO2 insufflation|"room temperature water infused by water pump into the colon just to facilitate scope insertion
CO2 insufflation by CO2 insufflation system during colonoscope withdrawal and mucosal inspection"
1703365|NCT01440543|Procedure|Water immersion insertion|"room temperature water infused by water pump into the colon just to facilitate scope insertion
standard room air insufflation during colonoscope withdrawal and mucosal inspection"
1703366|NCT01440543|Procedure|CO2 insufflation|- CO2 insufflation by CO2 insufflation system during both colonoscope insertion and withdrawal
1703443|NCT01439945|Other|placebo|Given PO
1703367|NCT01440530|Behavioral|Educational Intervention|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
1703368|NCT01440530|Other|Usual Care|Following randomization to TIDES (N=117) or usual care (N=49), TIDES group was oriented to the multimedia online intervention including a dosed sequence of learning via email, video, slideshows, food solutions, expert questions and answers, and quizzes.
1703369|NCT01440517|Drug|Tc99m-Maraciclatide|Freeze-dried powder Kit for the preparation of Maraciclatide (99mTc) Injection
1703370|NCT01440504|Other|culture ex vivo with exposure to different therapeutic agents alone or in combination.|When tumor resection, tumor specimens of ovarian cancer will be made towards a culture ex vivo with exposure to different therapeutic agents alone or in combination.
1703371|NCT01440491|Other|Physiotherapy exercise|once a day, during 15 minutes, for 12 weeks
1703372|NCT01440478|Drug|LY2140023|Administered orally
1703373|NCT01440478|Drug|Ammonium chloride|Administered orally
1703374|NCT01440478|Drug|Sodium bicarbonate|Administered orally
1703375|NCT01440452|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
1703376|NCT01440452|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
1703377|NCT01440452|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
1703378|NCT01440452|Behavioral|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
1703379|NCT01440439|Drug|Insulin glargine|Use of insulin glargine as basal insulin for treatment of Type 1 Diabetes Mellitus
1703380|NCT01440439|Drug|Insulin detemir|Use of insulin detemir as basal insulin for treatment of Type 1 Diabetes Mellitus
1703381|NCT01440426|Procedure|Autologous connective tissue graft with rotated papilla flap|Subepithelial connective tissue graft harvested from hard palate
1703382|NCT01440426|Device|Collagen matrix construct (Mucograft)|Mucograft Collagen Matrix combined with rotated papilla flap
1703383|NCT01440413|Biological|Blood and tumor sample|"Blood samples will be collected on the first day of the first cycle of chemotherapy (before injection of chemotherapy), on the first day of the third cycle (before injection of chemotherapy), on day of surgery and 6 months after surgery and in case of relapse.
Tumor samples will be collected on diagnosis, on surgery and on the first day of the third chemotherapy course (optional)."
1703384|NCT01440400|Procedure|Ultrasound guided spinal anesthesia|Using the ultrasound to identify the spinal puncture level, mid-line and the depth of the dura.
1703385|NCT01440387|Biological|FLULAVAL® QUADRIVALENT|Intramuscular injection, 1 dose each in FLULAVAL QUADRIVALENT Adults and FLULAVAL QUADRIVALENT Elderly Groups
1703386|NCT01440374|Drug|eltrombopag|100 mg daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg (150 mg for subjects of East Asian heritage)
1703387|NCT01440374|Drug|placebo|100 mg matching placebo daily (50 mg for subjects of East Asian heritage), intra-subject dose escalations to a maximum dose of 300 mg matching placebo (150 mg for subjects of East Asian heritage)
1703388|NCT01440361|Drug|Belimumab|10 mg /kg given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
1703389|NCT01440361|Drug|Normal saline placebo|Placebo given as an intravenous infusion every 4 weeks for 24 weeks (with an additional dose at Week 2)
1703390|NCT01440348|Procedure|cruciate ligament reconstruction|Multiple cruciate ligament reconstructions with a single Achilles allograft with was divided into two or three strips according to the thickness and length of the allograft.
1703391|NCT01440335|Drug|Oral R,R'-Fenoterol|
1703392|NCT01440335|Drug|Oral Racemic Fenoterol|
1703393|NCT01440322|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
1703394|NCT01440322|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
1703395|NCT01440309|Biological|Biological: mesenchymal stem cell|Mesenchymal stem cells,5-50 million/kg, Intravenous infusion, One dosage，whether to give another dosage depending on patients' condition
1703396|NCT01440309|Drug|ursodeoxycholic acid|13-15 mg/kg/day, to the end of the study
1703397|NCT01440283|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT delivery will follow current conventional volume-targeting guidelines, however, appropriate application within the abdomen will be determined by ascertaining intra-abdominal organ motion and the potential for reducing normal tissue dose, while simultaneously increasing dose delivered to target tissues, particularly when dose escalation for gross residual disease is required. Concurrent neuro-hormonal tests, cytokine analyses, functional and morphologic imaging will generate novel data describing the acute and chronic effects of radiotherapy within the abdomen.
1703398|NCT01440270|Drug|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency & treatment mode: Weekly Duration: 6 weeks
Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)
Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)
Arms: Neo-adjuvant Erbitux-based chemotherapy"
1703401|NCT01440244|Procedure|Cervical mediastinoscopy|minimally invasive technique to perform pleural evaluation, pleural biopsy and pleurodesis
1703402|NCT01440231|Drug|Placebo|Matching placebo administered by subcutaneous injection, once weekly
1703403|NCT01440231|Drug|Atacicept|Atacicept 5 mg administered by subcutaneous injection, once weekly
1703404|NCT01440231|Drug|Atacicept|Atacicept 25 mg administered by subcutaneous injection, once weekly
1703405|NCT01440231|Drug|Atacicept|Atacicept 75 mg administered by subcutaneous injection, once weekly
1703406|NCT01440231|Drug|Atacicept|Atacicept 115 mg administered by subcutaneous injection, once weekly
1703407|NCT01440205|Behavioral|Easy list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly easy."
1703408|NCT01440205|Behavioral|Challenging list of healthy habits|"The recipient will be prompted to check off yes or no to healthy habits that most people will find fairly difficult."
1703409|NCT01440205|Behavioral|Control|No check box element
1703410|NCT01440192|Biological|PDA001 (cenplacel-L)|1 unit PDA001 (approximately 200 x 106 cells) IV on Days 1 & 8
1703411|NCT01440179|Drug|SAR3419|Pharmaceutical form: concentrate solution for infusion Route of administration: intravenous
1703412|NCT01440166|Drug|Drug|Single dose oral administration of CAT1004 or placebo-6 to 8 subjects will be treated with CAT-1004 per cohort.
1703413|NCT01440166|Other|Placebo|Single dose oral administration of CAT1004 or placebo- 2 subjects treated with placebo per cohort.
1703414|NCT01440153|Other|Exercise Intervention|Participants from group A receive an active program aiming at improving their cardiovascular endurance, muscular strength and motor control. The level for cardiovascular training is based on the results of the maximal exercise test performed during baseline assessment. The level of training is determined at a level of 70% of the predicted maximal heart rate and was increased every 6 weeks with 5%, ending at 85%. Heart rate will be monitored during the training.
1703415|NCT01440153|Other|Passive Intervention|Participants from group B will receive an alternative program, in which all active parts are replaced by passive interventions. Several education sessions will be given regarding different topics, such as stress management, nutrition, injuries, etc. In addition, also practical sessions well be held to practice massage, passive stretching, taping.
1703416|NCT01440140|Other|Closed-loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings.
1703417|NCT01440140|Other|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
1703418|NCT01440127|Drug|Metformin|Pills will be taken for one week prior to the scheduled surgery or biopsy procedure.
1703419|NCT01440114|Drug|fentanyl|In intervention group patient received fentanyl 1 mcg/kg intravenous 15 minutes before the end of surgery.
1703420|NCT01440114|Drug|NSS|Patient in this group received NSS (0.1ml/kg)intravenous route 15 minutes before the end of surgery.
1703421|NCT01440101|Drug|Natalizumab (BG00002)|
1703422|NCT01440101|Drug|Placebo|
1703425|NCT01440075|Other|Cardiac evaluation|"complete cardiac evaluation with :
Electrocardiogram Echodoppler Echodoppler with dobutamine stress Carotid Echodoppler Coronary scan Positron emission tomography with adenosine stress Blood test (search for early atherosclerosis marker Genotyping"
1703426|NCT01440062|Drug|Verum arm receiving Vitamin D oil|oil: 20000 IU/g tablet: 400 IU/g every second day
1703427|NCT01440062|Drug|low dose arm receiving neutral oil and 400 IU/g of Vitamin D every second day|neutral oil and a low dose of vitamin D
1703428|NCT01440049|Other|Prospective Observational|this is an observational study non interventional
1703429|NCT01440036|Procedure|Carotid endarterectomy|The removal of atherosclerotic plaque from the carotid artery, by surgery
1703430|NCT01440023|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|CBIT is an 8 session treatment protocol held over 10 weeks. Its core components are implemented across the various therapy sessions. These core components include habit reversal training (HRT), functional assessment/function-based interventions, and a behavioral reward program for the child.
1703431|NCT01440023|Behavioral|Computerized Response Inhibition Training|Twice-weekly 45 minute computerized sessions for cognitive training focused on enhancing response inhibition capabilities.
1703432|NCT01440023|Behavioral|Computerized Placebo Cognitive Training|Twice-weekly 45 minute computerized sessions for placebo cognitive training, which has been designed to be irrelevant for response inhibition capabilities.
1703434|NCT01439997|Drug|Desmopressin|Administration of minirin melt 60 µg: desmopressin (acetate) 60 µg oral lyophilisate.
1703435|NCT01439984|Drug|Clomipramine|Clomipramine 15 mg tablet or placebo tablet on demand for 12 weeks
1703436|NCT01439971|Biological|PF-05280602|0.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
1703437|NCT01439971|Biological|PF-05280602|4.5 micrograms per kilogram of PF-05280602, IV infusion, single dose
1703438|NCT01439971|Biological|PF-05280602|9.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
1703439|NCT01439971|Biological|PF-05280602|18.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
1703440|NCT01439971|Biological|PF-05280602|30.0 micrograms per kilogram of PF-05280602, IV infusion, single dose
1703444|NCT01439932|Device|algometer|"Pressure algometer (Algometry) - This is an instrument that measures pain threshold (the minimum pressure required to produce pain). The instrument consists of a flat disk size centimeter square attached to pressure transducer and measuring electrodes. The disk is placed vertically on the point of pain and therapist increases the intensity of the pressure until initial pain appears (when sense of pressure becomes sense of pain.) Score is determined by average of three repeated measurements with 30 seconds break between each.
The algometer allows an objective assessment of pain in addition to LEFS score which is a subjective tool. The algometer test was found to be valid and reliable in repeated measurements (interrater, intrarater) by Andrew A. Fischerin 1987 with healthy people [Andrew 1987]. In another study high reliability was found for averaging between three repeated tests: ICC = 0.91 (CI 0.82; 0.97 95%). [Linda et al 2007]"
1703445|NCT01439919|Drug|SSR411298|"Form: tablet
Route: oral administration with food"
1703446|NCT01439919|Drug|Placebo (for SSR411298)|"Form: tablet
Route: oral administration with food"
1703447|NCT01439906|Procedure|Surgical correction of the deformity|"Three different surgical techniques are used:
lumbar fusion vs thoraco-lumbar fusion
iliac fixation vs fixation to the sacrum
posterior + interbody fusion vs posterior interbody fusion"
1703448|NCT01439893|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
1703449|NCT01439893|Drug|Placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
1703450|NCT01439880|Biological|Evolocumab (AMG 145) and standard of care|Evolocumab (AMG 145) is a fully human monoclonal antibody against PCSK9. Standard of care therapy is per local practice; this could include prescribed therapies and/or dietary/exercise regimes
1703451|NCT01439880|Other|Standard of care|Standard of care therapy as per local practices. This could include prescribed therapies and/or dietary/exercise regimes
1703452|NCT01439867|Drug|Cinacalcet hydrochloride|Cinacalcet was provided as 5 mg capsules that were opened, and the contents were either sprinkled on soft food or suspended into a sucrose syrup to create a liquid suspension for administration. All doses were administered with food or shortly after a meal at the same time daily.
1703453|NCT01439867|Drug|Standard of Care|Standard of care may have included vitamin D sterols (25 OH vitamin D and/or 1-25 OH vitamin D and its analogs) at the discretion of the investigator.
1703454|NCT01439854|Drug|Dapagliflozin|Treatment arm, 10 mg per day for 2 weeks
1703455|NCT01439854|Drug|Placebo|Patients are treated with placebo
1703456|NCT01439841|Dietary Supplement|Multi-strain probiotic|The product consists of Lactobacillus rhamnosus GG, Lactobacillus acidophilus La-5 and Bifidobacterium animalis subsp. lactis Bb-12 added to fermented skimmed milk
1703457|NCT01439841|Dietary Supplement|Placebo|Fermented and subsequently heat-treated, sterile skimmed milk
1703458|NCT01439828|Drug|N-acetylcystein|Visit 1: Consent signed. Blood and urine analysis. Questionnaires assessing cannabis and tobacco's craving.N-acetylcystein and placebo doses will be increased if craving decreases <25% compared to previous visit.The doses start at 200 mg x 4/24h to 800 mg x 4/24h.Visit 2 to 5: Medication safety and cannabis craving and withdrawal assessment during 4 weeks.
1703459|NCT01439815|Drug|Fluticasone Propionate Nasal Spray|50 mcg QD
1703460|NCT01439815|Drug|Saline Nasal Spray|two sprays in each nostril once daily
1703461|NCT01439802|Device|Copper IUD placement at time Cesarean Delivery (Copper T 380A)|Placement of Paragard IUD at time of Cesarean Delivery
1703462|NCT01439789|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
1703463|NCT01439789|Drug|Placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion
1703464|NCT01439776|Dietary Supplement|Vit D|800IU/day
1703465|NCT01439750|Drug|Rituximab|375 mg/m2 on day 5, 12, 19, 26 of Cycle1; and day 5 of Cycles 2-6; then every 2 months as maintenenace dose
1703466|NCT01439750|Drug|bortezomib|1.6 mg/m2 day 12, 19, 26 for 3 cycles (28 days). Then beginning with Cycle 4, 1.6/mg/m2 every two weeks (Days 5 and 19; maintenance every other week until toxicity or proression of disease).
1703467|NCT01439750|Drug|Cladribine|Phase I will use 3 dose levels Level 1: caldribine (2-CdA) 3mg/m2 days 1-5; Level 2 caldribine 4mg/m2 days 1-5; Level 3: cladribine 5mg/m2 days 1-5
1703468|NCT01439724|Device|Low Level Laser Therapy- (DMC, São Paulo, Brazil)|Diode laser (DMC,São Paulo, Brazil) InGaAlP (indium phosphide, gallium and aluminum), with 100 mW, 4J/cm ², with an area of 0.24 cm ². The laser was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.
1703469|NCT01439724|Device|Placebo (DMC, São Paulo, Brazil)|The placebo (DMC, São Paulo, Brazil) was daily applied by a dentist and touched the mucosa of the lips, right and left buccal mucosa, left and right lateral tongue border, buccal floor and ventral tongue, totaling nine points per region.Patients in the placebo group received the same treatment during the same time, but in this case the laser tip produced no light.
1703470|NCT01439711|Drug|letrozole|
1703471|NCT01439711|Procedure|MRI|
1703472|NCT01439711|Procedure|conventional surgery|
1703473|NCT01439698|Device|Radio Frequency ablation Probe|Any probe that can conduct radiofrequency ablation within biliary ducts.
1703474|NCT01439672|Dietary Supplement|Mixed meal and insulin challenge|The subject will undergo a mixed meal and insulin challenge as follows: an insulin bolus will be administered and a mixed meal nutrition drink will be consumed over 1-5 minutes. The mixed meal nutrition drink will be selected for that individual to be most likely to raise the glucose levels by 100mg/dl and then return to baseline within a four-hour time period. The nutrition drink will selected from the following types of product lines: Boost products (Nestle Nutrition), Ensure products (Abbott Nutrition), Carnation Instant Breakfast (Nestle Nutrition) or Glucerna (Abbott Nutrition).The pre-meal insulin bolus will be calculated to bring the subject to ~100mg/dl at 1100.
1703475|NCT01439659|Behavioral|Nutritional Counseling|Initial interview and subsequent telephone contact once per week for two months, once every other week for the following two months, and once per month for the remaining two months.
1703476|NCT01439659|Dietary Supplement|Daily Supplements|Two capsules daily in the morning and two capsules daily in the evening of Juice Plus+ in addition to regular meal. Also a beverage, Juice Plus+ Complete (a powder mixture to be added to one cup of fluid) daily in the evening.
1703477|NCT01439646|Other|it is a retrospective study, hence no active intervention|since it is an observational restrospective study hence no active intervention is planned
1704159|NCT01434472|Drug|Mycophenolate Mofetil|Given PO
1703478|NCT01439633|Device|MGH OFDI marking|Imaging of esophagus with OFDI system
1703479|NCT01439620|Device|MGH Optical Frequency Domain Imaging (OFDI)|Imaging of biliary tract with OFDI system using MGH Optical Frequency Domain Imaging (OFDI) System
1703480|NCT01439607|Other|Bone marrow and blood sampling|Bone marrow and blood sampling
1703481|NCT01439594|Device|MGH OFDI Imaging|Imaging of Esophagus with OFDI system
1703483|NCT01439568|Drug|LY2510924|Administered subcutaneous injection
1703484|NCT01439568|Drug|Carboplatin|Administered intravenously
1703485|NCT01439568|Drug|Etoposide|Administered intravenously
1703486|NCT01439555|Drug|Simvastatin + L-Arginine + Tetrahydrobiopterin|Simvastatin, 40 mg per day orally; L-Arginine, 2 Gm four times per day orally; Tetrahydrobiopterin 20 mg/kg/day orally
1703487|NCT01439542|Radiation|Stereotactic Body Radiation|"Clinical Target Volume 1 (CTV1): 25 Gy to nodes in 5 fractions, 1 fraction per week
Clinical Target Volume 2 (CTV2): 40 Gy to prostate and seminal vesicles in 5 fractions, 1 fraction per week"
1703488|NCT01439542|Drug|Luteinizing Hormone Releasing Hormone (LHRH) Agonist|12 months (2x6 month depot) of androgen suppression with LHRH agonist
1703489|NCT01439529|Other|Device programming: nominal|CRT device is programmed to nominal values
1703490|NCT01439529|Other|Programming optimization by QRS|CRT device is programmed by QRS optimization
1703491|NCT01439516|Behavioral|Information|Receipt of PREPARED educational book and video about treatments for end stage renal disease (ESRD)
1703493|NCT01439490|Other|FES-PET|Patients undergo FES-PET prior to obtaining histology
1703494|NCT01439464|Device|4 CIS one-touch titanium cage|4 CIS one-touch titanium cage(Solco Biomedical Co. Ltd)
1703495|NCT01439464|Device|Bonglass-SS SSLPB|Bonglass-SS SSLPB(BioAlpha Inc.)
1703496|NCT01439451|Procedure|perturbation training|The experimental and control groups will participate in 3 month training program twice a week 20 minutes each training session
1703497|NCT01439438|Drug|Topiramate coated tablet|Test formulation
1703498|NCT01439438|Drug|Topamax® coated tablet|Reference formulation
1703499|NCT01439425|Behavioral|Weight Loss|The low-calorie diet was designed to achieve a loss of 5-10% of initial body weight. The caloric restriction was 500 kcal below the resting energy expenditure, as evaluated by the Harris-Benedict equation. Intervention group patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range: 1200-1500 kcal/d for women, 1300-1600 kcal/d for men).
1703500|NCT01439412|Procedure|Acupuncture and standard treatment|"This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
In addition they also will receive one treatment of standardized acupuncture procedure during the consultation.
The acupuncture treatment starts with distal points in the right hand: Lumbar Pain Points (Yaotongxue), strong stimulation for one minute. With the needles still positioned, the patient is instructed to make cautious back and hip movements in 2 minutes. Then the patient lies down on a bench to treat the local points Huatuojiaji (Jiaji) bilaterally in the segments of the L2-L4 for 5 minutes."
1703501|NCT01439412|Other|Standard treatment in general practice|This group will get standard treatment in general practice in accordance with national guidelines, i.e. general advice about activity, prescription of pain relievers (paracetamol, eventually ibuprofen and eventually tramadol), and eventually sick leave.
1703502|NCT01439399|Drug|Lidocaine,|Lidocaine group received an IV bolus of 1.5 mg.kg-1 followed by a continuous infusion of 2 mg.kg-1.h-1 intraoperative and 1.33 mg.kg-1.h-1 for 48 h postoperative.
1703503|NCT01439399|Drug|Ketamine|Ketamine group received a bolus of 0.5 mg.kg-1, then 0.25 mg.kg-1.h-1 followed by 0.1 mg.kg-1.h-1 for the first 24 h, then 0.05 mg.kg-1.h-1 for the next 24 h.
1703504|NCT01439399|Drug|association ketamine-lidocaine|Ketamine-lidocaine group received a bolus of 1.5 mg.kg-1 of lidocaine and 0.5 mg.kg-1 of ketamine, a continuous infusion of 1.3 mg.kg-1.h-1 of lidocaine and 0.17 mg.kg-1.h-1 of ketamine was delivered followed by 0.9 mg.kg-1 of lidocaine with 0.08 mg.kg-1.h-1 of ketamine during 48 h, the dose of ketamine being reduced to 0.04 mg.kg-1.h-1 after the first 24 hours.
1703505|NCT01439399|Drug|Placebo|The control group (C) received an equal volume of saline 0.9 % during 48 h.
1956094|NCT02967653|Drug|Atorvastatin|Member of drug class called statins, primarily used as a lipid-lowering agent and the prevention of events associated with cardiovascular disease
1703517|NCT01439347|Drug|Vincristine Sulfate Liposomes Injection (VSLI)|2.25 mg/m2 (without any dose cap) as an IV infusion over 60 minutes
1703518|NCT01439347|Drug|Vincristine Sulfate Injection (VSI)|1.4 mg/m2 with a 2 mg dose cap as an intravenous (IV) infusion over 10 minutes
1703519|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Brief|Online prevention program using positive images
1703520|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Online Program Extended Length|Online Program Extended Length
1703521|NCT01439334|Behavioral|MB-SBIRT (multiple behavior screening, brief intervention and referral to treatment) Control|Control
1703522|NCT01439321|Biological|Eltrombopag|Switched to Eltrombopag
1703523|NCT01439321|Biological|Romiplostim|Switched to Romiplostim
1956095|NCT02967692|Biological|PDR001|PDR001 will be supplied in vial in liquid or lyophilized pharmaceutical form. PDR001 will be administered via intravenous infusion over 30 minutes (up to 2 hours) once every 4 or 8 weeks.
1956096|NCT02967692|Other|Placebo|Placebo will be a Dextrose 5% in water (D5W) infusion supplied by the site.
1703526|NCT01439282|Drug|eribulin mesylate|Cohort I & II: eribulin mesylate (E7389) 1.4 mg/m2 intravenously over 2 - 5 minutes on Day 1 and Day 8 for 4 cycles
1703527|NCT01439282|Drug|capecitabine|Cohort 1: capecitabine 900 mg/m2 orally twice daily on Days 1 - 14 of a 21-day cycle for 4 cycles Cohort II: fixed dose of 1500 mg oral capecitabine twice daily, 7 days on then 7 days off for 4 cycles
1703528|NCT01439269|Behavioral|Family Nurture Intervention|Family Nurture Intervention is facilitated by specially trained Nurture Specialists. The intervention involves calming interactions between mother and infant in the isolette via odor exchange, firm sustained touch and vocal soothing, through calming interactions during holding and feeding via the Calming Cycle and through family sessions designed to engage the help and support of family members for the mother.
1703529|NCT01439256|Behavioral|Computer Controlled Telephone Counseling|The subjects in the intervention arm receive medication adherence counseling through a computer controlled telephone counseling program
1703530|NCT01439256|Other|Physician information and management recommendations|Treating physicians for those subjects in the intervention arm receive through the medical record system a summary of blood pressure values and adherence data and recommendations.
1703531|NCT01439243|Drug|Donepezil|10 mg Tablet
1703532|NCT01439243|Drug|Aricept®|10 mg Tablet
1703533|NCT01439230|Drug|Donepezil|10 mg Tablet
1703534|NCT01439230|Drug|Aricept®|10 mg Tablet
1703535|NCT01439204|Biological|Abatacept (BMS-188667)|Solution for injection, Intravenous, 750 mg, Single dose, 1 day,
1703536|NCT01439191|Drug|humanized anti-HER2 antibody|Initial dose of 4 mg/kg as an intravenous infusion over 90 minutes then at 2 mg/kg as an intravenous infusion over 30 minutes weekly for 12 weeks. For single agent group, patients with complete response, partial response or stable disease could be treated for 24 weeks.
1703537|NCT01439191|Drug|Vinorelbine|Vinorelbine was administered weekly at a dose of 25 mg/m2 on day 1, 8 and 21 every 4 weeks
1703538|NCT01439178|Drug|Intravitreal Avastin injection|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA) will be injected through the pars plana at 3.5 mm from the limbus, using 30 gauge needle.
1956097|NCT02967692|Drug|Dabrafenib|Dabrafenib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Dabrafenib will be administered orally twice daily (150 mg BID) for Days 1-28 of a 28-day cycle.
1703541|NCT01439152|Drug|BAY94-9343|BAY94-9343 will be administered intravenously in this study. The starting dose for this first-in-man study is 0.15 mg/kg administered as a 1 hour infusion every 21 days.
1703542|NCT01439152|Drug|BAY94-9343 (Expansion)|BAY94-9343 will be administered intravenously in this study. The dose for this expansion cohort is 5.5mg/kg administered as a 1 hour infusion every 21 days
1703543|NCT01439152|Drug|BAY94-9343 (1.8 mg/kg)|BAY94-9343 will be administered intravenously in this study. The dose for this cohort is 1.8 mg/kg administered as a 1 hour infusion every week for 3 weeks.
1703544|NCT01439152|Drug|BAY94-9343 (2.2 mg/kg)|BAY94-9343 will be administered intravenously in this study. The dose for this cohort is 2.2 mg/kg administered as a 1 hour infusion every week for 3 weeks.
1703545|NCT01439126|Drug|clonidine hydrochloride|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, 0.3 mg, or 0.4 mg from Weeks 11-36
1703546|NCT01439126|Drug|Placebo|KAPVAY™ (clonidine hydrochloride) 0.1 mg, 0.2 mg, or 0.3 mg at Week 11; KAPVAY™ 0.1 mg, KAPVAY™ 0.2 mg, or placebo at Week 12; KAPVAY™ 0.1 mg or placebo at Week 13; placebo from Weeks 14-36
1703547|NCT01439113|Procedure|Ultrasound guided IV placement|The nurse will use the emergency department's ultrasound machine to locate peripheral veins and then cannulate the vessel under ultrasound guidance.
1703548|NCT01439100|Drug|Oxycodone/Naloxone Prolonged Release tablets|
1703549|NCT01439100|Drug|Placebo|Dummy tablet
1703550|NCT01439087|Device|MGH Optical Frequency Domain Imaging (OFDI) System|Imaging of Colonic Polyps with OFDI system
1703551|NCT01439074|Device|Mepilex Ag|Dressing
1703552|NCT01439074|Drug|Silver sulphadiazine|Cream
1703553|NCT01439061|Device|Device: easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
1703554|NCT01439035|Device|MGH OFDI Imaging|Imaging of Duodenum with OFDI system
1703555|NCT01439022|Behavioral|Exercise Programme|6 months 2 x a week aerobic and anaerobic exercise delivered in community facilities by an exercise professional and supported by a physiotherapist
1703556|NCT01439022|Behavioral|Hand Writing programme|6 months 2 x a week hand writing practice. Performed in the home supported by a physiotherapist (5 support sessions)
1703559|NCT01438996|Biological|NVGH Vi-CRM197|Vi-CRM197 glycoconjugated vaccine
1703560|NCT01438970|Device|ALFApump system|The device described above will be implanted using general anaesthesia. The device will be programmed according to each patient's individual requirements, setting the daily loss of ascitic fluid needed to maintain a stable body weight.
1703561|NCT01438957|Drug|Dexmedetomidine hydrochloride|Dexmedetomidine 0.2 to 0.7 mcg/kg/hr
1703562|NCT01438957|Drug|Placebo|
1703563|NCT01438944|Drug|Nicabate 21mg transdermal NRT|Nicabate 21mg Transdermal NRT Patch applied daily for 14 days Testing at Baseline, Day 4, Day 14 and 14 days post.
1703564|NCT01438931|Drug|DA-9501|Dexmedetomidine hydrochloride variable dose
1703565|NCT01438931|Drug|placebo|
1703566|NCT01438918|Drug|SD-6010|200 mg tablets once a day for 2 years
1703567|NCT01438918|Drug|SD-6010|50 mg tablets once a day for 2 years
1703568|NCT01438918|Drug|Placebo|Placebo tablets once a day for 2 years
1703602|NCT01438697|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material addressing the behaviors and symptoms of insomnia.
1704160|NCT01434472|Other|Pharmacological Study|Correlative studies
1703569|NCT01438905|Other|Small amplitude (Grade IV) mobilization|The subject will be in a seated position and the therapist will stabilize the distal tibia with one hand and make contact the anterior talus with the opposite hand. Three 60-second anterior to posterior joint mobilizations of the talus (small amplitude at end range; Grade IV) will be applied by the therapist with one minute rest in between sets.
1703570|NCT01438905|Other|High velocity, low amplitude (Grade V) mobilization|The subject will be in a seated position and the therapist will grasp the dorsum of the foot with their fingers. The ankle will be dorsiflexed until the restrictive barrier is reached. A small amplitude, quick thrust at end of range (High velocity, low amplitude; Grade V mobilization/manipulation) will be applied. If joint cavitation is not felt or heard by the therapist or subject the technique will be repeated one additional time.
1703571|NCT01438892|Drug|tDMARDs|Traditional DMARDs for RA
1703572|NCT01438892|Drug|biodmards|Biologic DMARDs
1956098|NCT02967692|Drug|Trametinib|Trametinib will be provided by the sponsor to the investigative site or supplied locally as commercially available. Trametinib will be administered orally once daily (2 mg QD) for Days 1-28 of a 28-day cycle.
1703575|NCT01438853|Biological|TNX-832|Single intravenous dose of TNX-832 at 0.06, 0.08 or 0.10 mg/kg
1703576|NCT01438853|Drug|Placebo|Single intravenous dose of saline control
1703577|NCT01438840|Drug|Avatrombopag|
1703578|NCT01438840|Drug|Placebo|
1703579|NCT01438840|Drug|Standard of care|"Permitted ITP concomitant background therapies are as follows:
Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization;
Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization;
Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport [P-gp] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization.
At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen.
Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization."
1703580|NCT01438827|Drug|Avanz Phleum pratense|Suspension for Injection, Every 6 weeks for one year
1703581|NCT01438827|Drug|Placebo|Suspension for Injection, Every 6 weeks for one year
1703582|NCT01438814|Drug|metformin placebo|metformin placebo tablets 500mg
1703583|NCT01438814|Drug|linagliptin placebo|linagliptin placebo tablets 5mg
1703584|NCT01438814|Drug|metformin|metformin tablets 500mg
1703585|NCT01438814|Drug|metformin|metformin tablets 500 mg
1703586|NCT01438814|Drug|linagliptin|linagliptin tablets 5mg
1703587|NCT01438801|Drug|Nutropin [Somatropin (rDNA origin) for injection]|Doses in the diagnostic protocol are 0.7 and 1.4 mg/m2/day, injected by subcutaneous injection at bedtime for 2 weeks, divided by washout periods of preferably 4 weeks (accepted range 4-6 weeks). An additional period of 2 weeks on 2.8 mg/m2/day (after a washout period of 4-6 weeks) will be added if the IGF-I response on either dosage is insufficient (serum IGF-I SDS <0).
1703588|NCT01438788|Other|Low protein diet|Patients will receive a diet with 0.6-0.8 grams of protein/kilogram body weight/day for one year. Bread, biscuits and pasta will be in part substituted with aproteic food.
1703589|NCT01438775|Drug|NX-1207|2.5 mg NX-1207 in 10 mL saline vehicle
1703590|NCT01438762|Behavioral|Patient information and education|All subjects will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form. This information is expected to take approximately 45minutes per patient.
1703591|NCT01438762|Other|Information, education and physiotherapy|"Patients will receive one-to-one patient education delivered by a physiotherapist. The information will be standardized and cover the topics of: why does it hurt: pain management; information of how to reduce physical activity if necessary; how to return slowly to sports; how to cope with knee pain and information of how to increase knee alignment during walking and stair walking. The patients will also receive this information in written form.
In addition the patients will receive supervised multimodal physiotherapy carried out by a physiotherapist with previous experience in treating adolescents and PFPS and has more than two years of practical experience in these areas. The multimodal physiotherapy intervention will be carried out at school premises right after the end of class."
1703592|NCT01438749|Drug|Placebo|Single dose
1703593|NCT01438749|Drug|RO4917838|Single doses (3 dose levels)
1703594|NCT01438749|Drug|diazepam|Single dose
1703595|NCT01438736|Drug|Desogestrel 75 micrograms POP (Cerazette), Etonogestrel 68 mg implant (Nexplanon)|Desogestrel 75 micrograms POP daily for 3 monts, followed by etonogestrel 68 mg subdermal implant for following 6 months
1703596|NCT01438736|Drug|Etonogestrel 68 mg subdermal implant|Etonogestrel 68 mg subdermal implant for 6 months
1703597|NCT01438723|Drug|Metformin|prior to CAGB surgery 3 day treatment with metformin 500 mg three times a day
1703598|NCT01438723|Drug|Placebo|prior to CABG surgery 3 day treatment with placebo capsules three times a day
1703599|NCT01438710|Drug|Prograf|Oral Prograf or generic tacrolimus doses will be taken b,i,d, consistently in 2 divided doses, once in the morning and once in the evening, to maintain trough level in the range of 3 to 12 ng/mL. Target trough level for the subject will be determined per clinical practice.
1703600|NCT01438710|Drug|LCP-Tacro|LCP-Tacro will be administered orally q.d. in the morning based on a conversion factor from Prograf or generic tacrolimus to LCP-Tacro of 0.7 for non-African American subjects and 0.85 for African American subjects to maintain target trough level of 3 to 12 ng/mL.
1703601|NCT01438697|Behavioral|Internet Intervention|Participants will spend 1-2 hours each week for 9 weeks using the Internet intervention. Users will complete daily sleep diaries as well as interactive tutorials covering the topics of sleep behaviors, sleep thoughts, sleep education, and relapse prevention. As users progress through the program they will receive tailored instructions for how to improve their sleep.
1703603|NCT01438684|Drug|RPh201|400 microliter s.c. twice a week for 3 months
1703604|NCT01438684|Drug|Saline|400 microliter Saline solution s.c. twice a week for 3 months
1703605|NCT01438671|Procedure|Nintendo Wii Fit|The Nintendo Wii Fit is an accessory for the Nintendo Wii video game system that utilizes a balance board peripheral. The subject stands on the balance board and engages in video games that require weight shifting and balancing in order to interact with the game. This intervention will be administered for 30 minutes, 3 to 5 times per week (as tolerated by subject), for a two week period.
1703606|NCT01438671|Procedure|Traditional balance training|This physical therapy intervention involves gait training, balance education on various surfaces, activities involving limited and changing bases of support, and dynamic interaction with the subject's environment. This intervention will be administered 30 minutes per day, 3 to 5 days per week (by subject's tolerance), for a two week period.
1703607|NCT01438645|Device|Olympus ScopeGuide|ScopeGuide-assisted colonoscopy using Olympus CF-H180DL variable-stiffness colonoscopes equipped with ScopeGuide capabilities. ScopeGuide will provide the endoscopist with a 3-dimensional image on the monitor depicting the shape of the colonoscope inside the patient's body as it moves through the colon.
1703608|NCT01438632|Device|jet injection device|Rapid-acting insulin analogue aspart (Novorapid®) administration by means of a jet injector or a conventional insulin pen in the subcutaneous tissue. Dosage of insulin will be determined by the normal dosage of insulin used by the patient before breakfast.
1703609|NCT01438606|Biological|VSV-Indiana HIV gag vaccine|Administered IM in both deltoids at baseline and Week 8. Dose will vary depending on which group the participant is enrolled in.
1703610|NCT01438606|Biological|Placebo injection (normal saline)|Administered IM in both deltoids at baseline and Week 8.
1703611|NCT01438593|Procedure|Intercerebral implantation of allogenic CD34+ stem cell|Each patient will receive brain implant of approximately 5 million allogenic Umbilical cord blood CD34+ Stem Cell
1703612|NCT01438580|Drug|Warfarin|Patients randomised to receive warfarin were initiated on treatment at the baseline dose of 1.25mg daily and then gradually increase the amount to the target INR range.
1703613|NCT01438580|Drug|aspirin|100mg aspirin was administrated every day
1703614|NCT01438567|Drug|oxycodone/naloxone prolonged release (OXN PR) tablets|Drug: Oxycodone/naloxone prolonged release tablets Arms: OXN PR Dosage: 2x50/25mg daily or 2x60/30mg daily or 2x70/35mg daily or 2x80/40mg daily
1703615|NCT01438567|Drug|oxycodone prolonged release (OxyPR) tablets|Drug: Oxycodone prolonged release tablets Arms: OxyPR Dosage: 2x50mg daily or 2x60mg daily or 2x70mg daily or 2x80mg daily
1703616|NCT01438554|Drug|Pazopanib|
1703617|NCT01438554|Drug|GSK1120212|
1703618|NCT01438541|Device|Window|Dressing
1703619|NCT01438528|Device|easypod ™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
1703620|NCT01438515|Drug|Rifampin|600mg po once daily x 7 days
1703621|NCT01438515|Drug|Doxycycline|100mg po twice daily x 7 days
1703622|NCT01438515|Other|2% mupirocin ointment|~ 1cm applied to the anterior nares twice daily for 7 days
1703623|NCT01438515|Other|4% chlorhexidine gluconate|Daily full body wash (including hair) for 7 days
1703624|NCT01438502|Drug|HyperHAES® (hypertonic saline/HES)|After arrival to the operating theatre both study groups will receive an infusion of acetated Ringers solution 4 ml/kg/hour. Additionally both groups for 4 hours will receive 1 ml/kg/hour of a blinded solution. This solution will be either acetated Ringers solution or HyperHAES® (7.2 % NaCl/ 6 % hydroxyethyl-starch (200/0.5)).
1703625|NCT01438489|Biological|Anifrolumab 300 mg|Participants will receive 300 milligram (mg) anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
1703626|NCT01438489|Biological|Anifrolumab 1000 mg|Participants will receive 1000 mg anifrolumab as an intravenous infusion every 4 weeks for 48 weeks.
1703627|NCT01438489|Other|Placebo|Participants will receive placebo matched to anifrolumab intravenous (IV) infusion every 4 weeks for 48 weeks.
1703628|NCT01438476|Procedure|Intravenous Patient-Controlled Analgesia (IVPCA)|Intravenous analgesia delivered prior to surgery, then patient-controlled following surgical procedures.
1703629|NCT01438476|Procedure|Thoracic Epidural Analgesia (TEA)|Thoracic epidurals (needle inserted into the space between the covering of spinal cord and the cord itself) placed preoperatively in either the holding area or in the operating room.
1703630|NCT01438476|Behavioral|Questionnaires|Questions measure how quickly participant recovers from sedation Day 1 through Day 5 after surgery; approximately 20-40 minutes.
1703631|NCT01438476|Behavioral|Pain Assessment|Hourly post surgery rating level of pain on a scale of 0-10.
1703632|NCT01438463|Biological|Placebo|Increasing volumes of placebo, will be administered by subcutaneous injection (starting with 0.05 ml) at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of placebo, are given at 4-weekly intervals.
1703633|NCT01438463|Biological|PURETHAL Mites 6,667 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
1703634|NCT01438463|Biological|PURETHAL Mites 20,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
1703635|NCT01438463|Biological|PURETHAL Mites 50,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
1703636|NCT01438463|Biological|PURETHAL Mites 100,000 AU/ml|Increasing dosages, corresponding to increasing volumes of drug solution (starting with 0.05 ml), will be administered by subcutaneous injection at weekly intervals till the maintenance dose (0.5 ml) is reached. Subsequently, maintenance dosages, corresponding to 0.5 ml of drug solution, are given at 4-weekly intervals.
1703709|NCT01437826|Drug|antioxidants|tablets composed of 200 mcg selenium [as l-selenomethionine], 30 mg zinc, 2 mg vitamin A [retinol], 180 mg vitamin C [ascorbic acid] and 30 mg vitamin E [D-α-tocopherol acetate]
1761974|NCT00295035|Drug|CELECOXIB|
1703637|NCT01438450|Drug|Oral|"Capecitabine : 500 mg OD x 1 week 500 mg BD x 1 week 500 mg (2 morning, 1 evening) x 1 week After attaining the max dose of 1500 mg, a cycle of Capecitabine 1500mg every day for 2 weeks and 1 week off to be maintained.
Thalidomide: 50 mg OD x 1 week 100 mg OD x 1 week 200 mg OD x 1 week, 300 mg OD x 1 week"
1703638|NCT01438450|Other|Supportive|No specific therapy will be given
1703639|NCT01438437|Procedure|PAI|Under local anaesthesia, taking proper aseptic precautions, 40% acetic acid (total dose not exceeding 3 times the diameter of the mass, (not more than 2ml in one sitting), will be injected into the mass through the percutaneous route
1703640|NCT01438437|Procedure|RFA|Under aseptic conditions and local anesthesia, the needle electrode would be introduced percutaneously into the tumor under ultrasound guidance.
1703641|NCT01438424|Drug|Entecavir|Tablets, Oral, 1.0 mg, once daily
1703642|NCT01438424|Drug|Lamivudine|Oral, 100 mg, daily
1703643|NCT01438411|Drug|Cholic Acid|10-15 mg/kg body weight/day supplied in 50 or 250 mg Cholic Acid Capsules
1703644|NCT01438398|Procedure|Submucosal endoscopic myotomy with mucosal flap technique|Submucosal Endoscopy with Mucosal Flap (SEMF) technique involves the following: (1) injecting 0.9 % normal saline solution to create a submucosal cushion, (2) tiny cut is made into the cushion, (3) Balloon will be used to dilate the opening and allow passage of endoscope in the submucosal space, (4) Upon direct visualization of the muscle fibers, the doctor will cut the circular layers of the diseased muscles, and (5) Tiny clips will be used to close the tiny cut made earlier.
1703645|NCT01438398|Procedure|Submucosal Endoscopic Mucosal Flap (SEMF) technique|
1703646|NCT01438385|Procedure|Interventional Endoscopy|Advanced imaging endoscopic or therapeutic endoscopy
1703647|NCT01438372|Drug|Intravenous iron sucrose|Intravenous iron sucrose will be administered on days 1, 7, 14, and 21 using the formula: Total dose: (normal Hb for age - initial Hb)/100 x blood volume (ml) x 3.4 x 1.5. First dose will be infused over 30 minutes, with subsequent doses administered over 15 minutes if no reactions encountered.
1703648|NCT01438372|Drug|Oral ferrous sulfate|Oral ferrous sulfate will be administered at 3 mg/kg/day divided into 2 doses for 28 days. A tablet form of ferrous sulfate (325 mg with 65 mg of elemental iron per tablet) will be used.
1703649|NCT01438359|Drug|PA21 and Furosemide with food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Furosemide will be 40 mg/day
1703650|NCT01438359|Drug|No PA21; Furosemide with food|The maximum dosage of Furosemide will be 40 mg/day
1703651|NCT01438359|Drug|PA21 with food and Furosemide 2hrs later|The maximum dose of PA21 will be 15 g/day. The maximum dose of Furosemide will be 40 mg/day
1703652|NCT01438346|Behavioral|Substance Abuse Education|10 weeks of usual care for substance abuse.
1703653|NCT01438346|Behavioral|Mind-body Bridging|Two sessions per week for 10 weeks, besides usual care treatment for substance abuse.
1703654|NCT01438333|Dietary Supplement|lactobacillus brevis tablets|5 tablets a day for 6 weeks
1703655|NCT01438333|Dietary Supplement|PLACEBO|5 tablets a day for 6 weeks
1703656|NCT01438320|Dietary Supplement|Quercetin|Bioflavonoid
1703657|NCT01438307|Drug|Cabazitaxel-XRP6258 (3-week cycle)|Subjects in Schedule A will begin with an initial dose of 20 mg/m2 every 3 weeks as a 1 hour IV infusion. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 25 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
1703658|NCT01438307|Drug|Cabazitaxel-XRP6258 (5-week cycle)|Subjects in Schedule B will begin with an initial dose of 8.4 mg/m2 as a 1 hour IV infusion on days 1, 8, 15, and 22 of a 5-week cycle. If no dose limiting toxicities are experienced after cycle 1, then the dose will be escalated to 10 mg/m2. Treatment with Cabazitaxel-XRP6258 will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity or withdrawal of consent. Further treatment after 6 cycles of treatment in patients who achieved an objective response or stable disease, and no significant toxicity will be an individual decision from the investigator.
1703659|NCT01438294|Other|Video game group|The training with video game will be done with heart rate monitors with intensity required to achieve 70% of maximum heart rate reached the maximum test for thirty minutes.Will be used Kinect games ( adventure- reflex ridge).
1703660|NCT01438294|Other|Aerobic exercise group|A 10 minutes warm up period was performed on a treadmill at 2 km/h prior to each session. After that, exercise training was performed during 30 minutes beginning at 70% of the maximum effort determined in the maximal exercise testing. Before and after each session, 3 measures of the peak flow were performed in the standing position (AssessTM, USA). There was progression in the training intensity throughout the study: if the patient maintained 2 consecutive exercise sessions without symptoms, exercise intensity was increased by 5% of cardiac frequency by using either treadmill speed or grade as previously described (Mendes et al.2011).
1703661|NCT01438281|Drug|SYL1001|SYL1001 eye drops. topical administration
1703662|NCT01438242|Device|Genecept Assay|Genetic test which analyzes seven pharmacodynamic and three pharmacokinetic genes important in psychiatric disorders
1703663|NCT01438229|Device|St. Jude Medical renal artery ablation system: RF ablation generator (IBI 1500T11.5) and Renal artery ablation catheter (DS3D001, DS3D002)|Catheter-based RF ablation in renal artery
1703664|NCT01438203|Procedure|Thrust manipulation|Thrust manipulation is a passive procedure which involves a high velocity low amplitude thrust to the spinal region
1703665|NCT01438203|Procedure|Non-thrust manipulation|Non-thrust manipulation involves a low amplitude, low speed mobilization to the targeted region while adjusting the procedure based on patient feedback
1703666|NCT01438190|Drug|Metformin, gonadotropins in step-down regimen|Metformin 850 mg cps, two cps daily for 12 weeks. gonadotropins 75IU f, step-down regimen, starting dose of 225 IU daily.
1703667|NCT01438190|Drug|Placebo, gonadotropins in step-up regimen|Placebo cps, two cps daily. Gonadotropins 75IU f, step-up regimen, starting dose of 75 IU daily.
1703668|NCT01438177|Drug|Velcade|
1703669|NCT01438177|Drug|Cyclophosphamide|
1703670|NCT01438177|Drug|Chloroquine|
1703710|NCT01437826|Drug|placebo|placebo had an identical appearance as intervention
1703826|NCT01436903|Device|Thermal Balloon Endometrial Ablation|Thermal Balloon Endometrial Ablation for 10 minutes after curettage
1703671|NCT01438151|Drug|Remicade|The first potential for dose augmentation will be at infusion #3 (visit 1 and 2 patients will receive 5 mg/kg). Patients will be assessed at each infusion visit for response defined as a reduction in HBI score by 2 or more points from prior visit (unless in remission; HBI score of 4 or less). Patients with a response will be maintained at the dose where response was achieved. If there is no response to treatment, or flare at any visit (beginning at visit #3), infliximab dose or dosing frequency will be increased in a gradual fashion, up to a maximum of 15 mg/kg every 6 weeks, until response is achieved.
1703672|NCT01438138|Other|diagnostic laboratory biomarker analysis|Correlative studies
1703673|NCT01438125|Other|MF-4181|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
1703674|NCT01438125|Other|Standard surgical wound closure|Surgical procedure will be performed as per the standard of care. Scar halves randomized to treatment with device (MF-4181), opposite side treated per standard of care.
1703675|NCT01438112|Biological|CG0070 adenovirus vector|CG0070 adenoviral vector with GM-CSF expression given intravesically 1x10e12 viral particles for each instillations, weekly times six
1703676|NCT01438112|Other|Control Arm: Quadruple Choice|"Quadruple Choice Treatment Options:
I. Mitomycin C II. Interferon III. Valrubicin IV. Gemcitabine"
1703680|NCT01438073|Drug|kisspeptin 112-121|24-h continuous intravenous infusion of kisspeptin 112-121 (12.5-40 mcg/kg/h), single intravenous dose of kisspeptin 112-121 (0.313-13.19 mcg/kg)
1703681|NCT01438073|Drug|GnRH|Single intravenous dose of GnRH (2.5-250 ng/kg)
1703682|NCT01438060|Drug|Aripiprazole (BMS-337039)|"Acute Phase: Oral, Tablets (1 and 5 mg), Week 1-2: 2 mg, Week 3-4: 2 - 5 mg, Week 5-6: 2 - 10 mg, Weeks 7-10: 2 - 15 mg, Once daily, 10 weeks
Extension Phase: Oral, Tablets (1 and 5 mg), Week 11: 2 mg, Weeks 12-13: 2 - 5 mg, Weeks 14-15: 2 - 10 mg, Weeks 16-140: 2 - 15 mg, Once daily, 130 weeks"
1703683|NCT01438060|Drug|Placebo|Acute Phase: Oral, Tablets, 0 mg, Once daily, 10 Weeks
1703684|NCT01438034|Drug|kisspeptin 112-121|0.24 nmol/kg
1703685|NCT01438021|Other|pharmacological study|Correlative studies
1703686|NCT01438021|Drug|methotrexate|Given intraventricularly
1703687|NCT01438008|Drug|24% sucrose po solution|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of a 24% sucrose solution. The maximum amount of the study solution will be administered according to the infant's gestational age and according to the hospital's Sucrose policy. The total amount of the study solution will be divided into a maximum of 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure."
1703688|NCT01438008|Drug|Placebo po|"CHEO pharmacy department will provide syringes labeled NICU Pain Relief Study containing a maximum of 1 ml dose of water (almost identical in color, consistency and odor placebo to the sucrose solution in identical packaging) The total amount of the study solution will be divided into 5 aliquots and administered throughout the procedure at two minutes prior to the heel lance, immediately prior to the heel lance, and two-minutely intervals until completion of the procedure"
1703689|NCT01437995|Drug|Fluticasone/Salmeterol Diskus|Continuation of Fluticasone/Salmeterol Diskus 250/50 ug twice daily
1703690|NCT01437995|Drug|Fluticasone/Salmeterol Diskus|Reduced dose Fluticasone/Salmeterol Diskus 100/50 ug twice daily
1703691|NCT01437995|Drug|Fluticasone Diskus|Fluticasone Diskus alone 250 ug twice daily without Salmeterol
1703692|NCT01437982|Drug|Loteprednol Etabonate|Ocular administration of study drug. at least once within any indication of the label.
1703693|NCT01437982|Drug|Prednisolone Acetate 1% Oph Susp|Ocular administration of study drug. at least once within any indication of the label.
1703694|NCT01437969|Genetic|genotyping and/or sequencing|genotyping and/or sequencing DNA for IL28
1703695|NCT01437943|Drug|Aliskiren|Take 1 tablet (150 mg) by mouth daily for 180 days
1703696|NCT01437943|Drug|Placebo|Take 1 tablet (0 mg) daily for 180 days.
1703697|NCT01437930|Dietary Supplement|n-3 PUFA|"products (sausage, bread rolls, milk beverage, wafers) enriched with Intervention a-c): n-3 rich plant oils/powder
linseed oil (20g/d)(PPM, Magdeburg)
echium oil (20g/d) (HARKE Nutrition)
microalgae powder(12g/d)(HARKE Nutrition)"
1703698|NCT01437917|Other|20% amylose bread|20% amylose bread
1703699|NCT01437917|Dietary Supplement|10% amylose bread|10% amylose bread
1703700|NCT01437917|Dietary Supplement|Carbohydrates|50g of carbohydrates ingested with 400 ml of water
1703701|NCT01437904|Procedure|Outpatient Recovery|Patients go home following Percutaneous nephrolithotomy
1703702|NCT01437904|Procedure|In hospital recovery|Patients are hospitalized following Percutaneous nephrolithotomy
1703703|NCT01437878|Drug|Iloprost|5ug dose of inhaled iloprost (20ug/mL solution) administered 6 to 9 times per day for 4 weeks
1703704|NCT01437878|Drug|Placebo|matching placebo
1703705|NCT01437865|Drug|Gadofosveset contrast agent enhanced MRI Axilla|A MRI of the Axilla will be performed before and after administration of a single IV bolus injection of gadofosveset of an equivalent of 0.03 mmol Gd/kg body weight at an injection speed of 1.5 mL/sec., followed by a saline flush of 25 mL at an injection speed of 1.5 mL/sec.
1703707|NCT01437839|Drug|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fasting state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fed state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
1703708|NCT01437839|Drug|Apixaban|Period I: 1 x 5 mg Commercial Image Tablet in fed state(single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: 1 x 5 mg Commercial Image Tablet in fasting state (single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period)
1703750|NCT01437527|Behavioral|Anamorphic Micro software|Body image therapy with Anamorphic Micro software
1761975|NCT00295035|Drug|CURCUMIN|
1703711|NCT01437813|Drug|Glimepiride/extended release Metformin|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose. Patients received a high fat diet 30 min before administration.
1703712|NCT01437800|Drug|Glimepiride/extended release Metformin (4/850 mg).|One tablet of Glimepiride/metformin extended release (4/850 mg) was administered as a single oral dose, to all patient in fasting.
1703713|NCT01437787|Drug|SAR302503|"Pharmaceutical form:capsule
Route of administration: oral"
1703714|NCT01437787|Drug|Placebo|"Pharmaceutical form:capsule
Route of administration: oral"
1703715|NCT01437774|Device|thrombectomy (ReStore or Merci)|Each arm will use either ReStore or Merci as the primary thrombectomy device
1703716|NCT01437761|Device|2008 Sorbent System|2008 Sorbent System with dialysate flow rates (Qd) of 400 and 500 ml/min while maintaining a constant blood flow rate (Qb) and constant dialyzer (KoA).
1703717|NCT01437748|Drug|Indacaterol maleate|Dry powder, 300 mcg, only one inhalation with 24 hours duration
1703718|NCT01437748|Drug|Tiotropium bromide|Dry powder, 18 mcg, only one inhalation with 24 hours duration
1703719|NCT01437735|Drug|QAW039|QAW039 po
1703720|NCT01437735|Drug|Comparator leukotriene receptor antagonist (LRTA)|leukotriene receptor antagonist (LRTA)
1703721|NCT01437735|Drug|Placebo|Placebo
1703722|NCT01437722|Drug|1% SPL7013 Gel|vaginal gel
1703723|NCT01437722|Drug|3% SPL7013 Gel|vaginal gel
1703724|NCT01437722|Drug|placebo gel|vaginal gel
1703725|NCT01437709|Biological|Ofatumumab (This arm is closed)|Ofatumumab Day 1 Week 1: 1000 mg, Day 2 week 1: 1000mg. Patients who exhibit a baseline leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose Ofatumumab Day 1, Weeks 2-4: 1000 mg Will reassess 8-10 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
1703726|NCT01437709|Other|Ofatumumab + Bendamustine|Ofatumumab day 1 + Bendamustine 90 mg/m2 days 1 & 2 x 6 cycles q 28 days Cycle 1, day 1: Ofatumumab 1000 mg followed by Bendamustine 90 mg/m2. Patients who exhibit a leukocytosis ≥ 20,000 will receive 300 mg of ofatumumab on day 1, week 1. Thereafter, they can receive the 1000 mg dose. Cycle 1, day 2: Ofatumumab 1000mg followed by Bendamustine 90 mg/m2 Cycles 2-6: Ofatumumab 1000 mg day 1, Bendamustine 90 mg/m2 days 1 and 2 Will reassess 4-6 weeks after conclusion of treatment with CT CAP, and following this q 12 wks for 2 yrs, then q 6mo until POD or for a maximum of 5 years
1703727|NCT01437696|Dietary Supplement|Vitamin D|A liquid cholecalciferol at a dosage of 500IU will be added to a specific food and provided to the participants once a day for 24 weeks.
1703728|NCT01437696|Dietary Supplement|Vitamin D|A liquid cholecalciferol at a dosage of 1000IU will be added to a specific food and provided to the participants once a day for 24 weeks.
1703729|NCT01437696|Other|placebo|No liquid cholecalciferol will be added to the food.
1703730|NCT01437670|Drug|solifenacin 5mg, 10mg|solifenacin 5mg, 10mg
1703731|NCT01437657|Drug|Placebo|Matching RO4917523 placebo orally daily, 6 weeks
1703732|NCT01437657|Drug|RO4917523 0.5 mg|0.5 mg orally daily, 6 weeks
1703733|NCT01437657|Drug|RO4917523 1.5 mg|1.5 mg orally daily, 6 weeks
1703734|NCT01437644|Drug|botulinum toxin intramuscular injection|"A single dose of active drug or placebo will be administered immediately prior to surgery.
The injections will be given to the anaesthetised child before the surgical procedure begins. The surgeon will perform the injections at three muscle groups around each hip: the adductors, hamstrings and iliopsoas muscles. Two units per kilogram will be given at each site. The maximum dose will be 12 units per kilogram or 500 units in total (whichever is the lesser), divided equally between six or three sites. Each active drug vial will contain 100 iu of the Botox preparation. The volume injected will be dependent on the weight of the child. Injections of normal saline will be administered in those children randomised to the placebo."
1703735|NCT01437631|Procedure|prophylactic clip application|prophylactic clip application after colonoscopic polypectomy
1703736|NCT01437618|Drug|FOLFOXIRI plus bevacizumab|"BEVACIZUMAB 5 mg/Kg i.v. over 30', day 1 followed by
IRINOTECAN 165 mg/sqm i.v. over 1-h, day 1 followed by
OXALIPLATIN 85 mg/sqm i.v. over 2-h, day 1 concomitantly with
l-LV 200 mg/sqm i.v. over 2-h, day 1 followed by
5-FLUOROURACIL 3200 mg/sqm i.v. 48-h continuous infusion, starting on day 1 Cycles repeated every 2 weeks"
1703737|NCT01437605|Drug|MAGE-A3 ASCI injections without Poly IC:LC|MAGE-A3 ASCI injections without Poly IC:LC as outlined in Detailed Description
1703738|NCT01437605|Drug|MAGE-A3 ASCI injections with Poly IC:LC|MAGE-A3 ASCI injections with Poly IC:LC as outlined in Detailed Description
1703739|NCT01437592|Drug|insulin degludec|For each subject, a single dose of NN1250 will be administered subcutaneously (under the skin)
1703740|NCT01437579|Procedure|intratrigonal injection of botulinum toxin|Bladder intratrigonal injection of botulinum toxin during cystoscopy under general anesthesia
1703741|NCT01437579|Procedure|cystoscopy|cystoscopy under general anesthesia
1703742|NCT01437566|Drug|Fulvestrant|Participants will receive fulvestrant 500 mg as 2 IM injections of 250 mg on Days 1 and 15 of Cycle 1 and on Day 1 of each subsequent cycle, each cycle of 28 days until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
1703743|NCT01437566|Drug|GDC-0941|Participants will receive GDC-0941 260 mg (Part II) or 340 mg (Part I) QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
1703744|NCT01437566|Drug|GDC-0941 Matching Placebo|Participants will receive GDC-0941 matching placebo QD orally from Day 1 or Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
1703745|NCT01437566|Drug|GDC-0980|Participants will receive GDC-0980 30 mg (Part I) QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
1703746|NCT01437566|Drug|GDC-0980 Matching Placebo|Participants will receive GDC-0980 matching placebo QD orally from Day 15 of Cycle 1 until disease progression, intolerable toxicity, elective withdrawal from the study, study completion or termination.
1703747|NCT01437553|Device|iMAP|IVUS and iMAP analysis for acute coronary syndromes
1703748|NCT01437540|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled aclidinium bromide 400 μg/formoterol fumarate 12 μg, high dose twice per day
1703749|NCT01437540|Drug|Formoterol Fumarate|Inhaled formoterol fumarate 12 μg, twice per day
1703752|NCT01437514|Radiation|preoperative short-course radiotherapy|preoperative RT received a total dose of 25 Gy in five fractions during five consecutive days. The clinical target volume included the primary tumor and the mesentery with vascular supply containing the perirectal, presacral, and internal iliac nodes(up to the S1/S2 junction).The recommended upper border was at the level of the promontory. Radiation treatment was delivered with a three-portal technique.
1703753|NCT01437501|Drug|Broccoli Sprout Extract Beverage|Broccoli Sprout Extract Beverage: 600 micromole glucoraphanin and 40 micromole sulforaphane dissolved in 100 mL dilute pineapple and lime juice daily for 84 days.
1703754|NCT01437501|Drug|placebo beverage|100 mL of dilute pineapple and lime juice daily for 84 days.
1703755|NCT01437488|Drug|Cabazitaxel|"Cycle 1: 20 mg/m2 in 250cc NS via IV on Day 1 every 21 days
Following cycles: 20 mg/m2 or escalated to 25 mg/m2 or reduced by 5 mg/m2 in 250cc NS via IV on Day 1 every 21 days at investigator's discretion
Treatment continues until disease progression, intercurrent illness preventing further treatment, unacceptable adverse event(s), patient withdraws from the study, or changes in the patient's condition which render further treatment unacceptable in the judgment of the investigator"
1703756|NCT01437488|Drug|Neulasta|6 mg via SQ on Day 2 (24-48 hours post-cabazitaxel) every 21 days
1703757|NCT01437488|Procedure|CT Scan|CT scan of chest, abdomen, and pelvis to assess disease following every 3rd cycle of treatment (approximately every 9 weeks)
1703758|NCT01437488|Biological|Blood Draw|Approximately 2 tablespoons of blood will be taken to test complete blood count, glucose, hematology, electrolytes, liver function, creatinine clearance, and a chemistry profile. This week be done weekly during the first cycle of treatment
1703759|NCT01437475|Biological|Sci-B-Vac|10 microgram/ml hepatitis B surface antigen, 1 ml given intramuscularly
1703760|NCT01437462|Drug|Sevoflurane|Sevoflurane inhalation anesthesia, sufficient amount to maintain adequate general anesthesia for surgery
1703761|NCT01437462|Drug|Propofol|Propofol intravenous anesthesia, sufficient amount to maintain adequate anesthesia during surgery
1703762|NCT01437449|Drug|Docetaxel|30 mg/m2 iv
1703763|NCT01437449|Drug|Cisplatin|30 mg/m2 iv
1703764|NCT01437449|Drug|Cetuximab|C1: 400 mg/m2, thereafter 250 iv
1703765|NCT01437449|Drug|Carboplatin|AUC 2 iv
1703766|NCT01437436|Procedure|ventilation tube|ventilation tube insertion
1703767|NCT01437423|Biological|TETRAXIM™: Combined adsorbed diphtheria, tetanus, acellular pertussis and enhanced inactivated polio|0.5 mL, Intramuscular at 2, 4, 6 months (Primary) or at 4 to 6 years (Booster) vaccination
1703768|NCT01437410|Procedure|EUS-FNA|tissue samples were harvested from 116 patients undergoing EUS-FNA of solid masses for cytologic smear and histological analysis.
1703769|NCT01437397|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/12μg, twice per day
1703770|NCT01437397|Drug|Aclidinium Bromide/Formoterol Fumarate|Inhaled Aclidinium/formoterol FDC 400/6μg, twice per day
1703771|NCT01437397|Drug|Aclidinium Bromide|Inhaled Aclidinium 400 μg, twice per day
1703772|NCT01437397|Drug|Formoterol Fumarate|Inhaled Formoterol 12 μg, twice per day
1703773|NCT01437397|Drug|Placebo|Inhaled dose-matched placebo, twice per day
1703774|NCT01437384|Drug|E5501|20 mg oral dose of E5501; 240 mg once daily oral dose of sustained release verapamil; 400 mg oral dose of cyclosporine
1703775|NCT01437371|Drug|- Angiotensin conversing enzyme inhibitors: enalapril, captopril, lisinopril, ramipril, trandolapril.|The purpose of this study is to determine if there is an interest to optimize HF management in patients over 80 years old. The primary objective is to assess the effect of HF optimized management (guidelines of the European society of Cardiology (ESC) on QOL in aged over 80 year's old at 6 months
1703776|NCT01437358|Other|Epidural analgesia|The purpose of this observational prospective study is to describe the safety and feasibility of this analgesia technique in ICU patients
1703777|NCT01437319|Device|lotrafilcon A|To be used during run-in phase only.
1703778|NCT01437319|Device|comfilcon A|To be assigned at randomization at phase 2 only.
1703779|NCT01437319|Device|balafilcon A|To be assigned at randomization during phase 2 only.
1703780|NCT01437319|Other|etafilcon A|Assigned to Neophytes during Phase I for a 2-week period
1703782|NCT01437293|Drug|L-dopa / carbidopa / entacapone (LCE)|For this trial we propose a target dosage of L-dopa / carbidopa / entacapone of 400 mg L-dopa / 100mg carbidopa / 200 mg entacapone, twice daily.
1703783|NCT01437280|Biological|CGTG-102|"VP=virus particle
Dose Level 1: 3x10^10 VP/injection
Dose Level 2: 1x10^11 VP/injection
Dose Level 3: 3x10^11 VP/injection
Patients will receive 4 administrations of CGTG-102 (on days 1, 4, 8, 15).
Escalation to the next dose level will occur when the safety of all 4 administrations has been evaluated at day 43 on all patients in the preceding dose level.
The total dose will be injected into up to 10 tumors injectable by either direct visualization/palpitation and/or ultrasound. Typically, the largest safely injectable tumors are chosen.
Injections will be performed by a radiologist or other trained physician. Injections will be planned based on the baseline PET-CT: only PET-positive tumors or tumor regions should be injected. Injection needles designed for percutaneous insertion into tissues will be used."
1703784|NCT01437267|Biological|Vi-CRM197 vaccine|
1703785|NCT01437267|Biological|Pneumococcal conjugate vaccine|
1703786|NCT01437267|Biological|Vi Polysaccharide (PS) vaccine|
1703787|NCT01437254|Drug|CPERT|Single 340 MBq CPERT scan in first 10 subjects
1703788|NCT01437254|Drug|GPERT|Single 340 MBq GPERT scan in up to 20 case-matched controls
1703789|NCT01437228|Drug|povidone- iodine solution.|%10 Polivinilpirolidon iyot (Polividon- iyot
1703790|NCT01437228|Drug|placebo|NO İNTERVENTİON
1703791|NCT01437215|Device|Ventana Fenestrated Stent Graft System|Endovascular repair of juxtarenal or pararenal aortic aneurysm
1703792|NCT01437189|Drug|Sertraline|Starting dose 25mg/day for 1 week, then increasing to 50mg/day, add on 50mg each time when the depressive symptoms are not improved, at 2-week intervals. Maximum: 200mg/day. Maintenance: lowest effective dose.
1703793|NCT01437176|Device|new type of intramedullary nail|This is a new fixation treat for intertrochanteric fracture.
1703794|NCT01437176|Device|The intramedullary nail of PFNA|It was used very common in treat with intertrochanteric fracture.
1763617|NCT00312104|Drug|insulin detemir|
1703795|NCT01437163|Device|TopHat 655 rejuvenation system|TopHat 655 system is to be applied every other day for 16 weeks for a pre-programmed time period
1703796|NCT01437163|Device|Laser and/or Light Hair Rejuvenation System|A red incandescent light source replaces all lasers and light emitting diodes.
1703797|NCT01437150|Device|Anatomical locking plate|This is a new fixation treat for acetabular posterior wall fracture.
1703798|NCT01437150|Procedure|The Reconstructive Plate|Reconstructive plate was used very common in treatment of acetabular fracture.
1703799|NCT01437137|Device|classic-laryngeal mask airway (c-LMA)|Insertion of c-LMA
1703800|NCT01437137|Device|i-gel™|Insertion of I-gel
1703801|NCT01437111|Drug|MK-217A/Alendronate Sodium 70-mg/Vitamin D3 5600 IU Combination Tablet|One combination tablet orally once a week
1703803|NCT01437072|Other|No treatment given|The screening test includes a combination of a risk assessment questionnaire and biochemical tests.
1703804|NCT01437059|Drug|ALN-PCS02|Dose levels between 15 and 400 μg/kg by intravenous (IV) infusion
1703805|NCT01437059|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
1703808|NCT01437020|Drug|SCH708980 Anti-IL-10 monoclonal|Participants in Part 1 of the study will receive varying doses (0.3 mg/kg, 1.0 mg/kg, 3.0 mg/kg, or 10.0 mg/kg) of a single IV infusion of SCH708980. Participants in Part 2 of the study will receive a single IV infusion of SCH708980 on Day 1.
1703809|NCT01437020|Drug|AmBisome|Participants in Part 1 of the study will receive a single IV infusion of AmBisome (10 mg/kg) 7 days after they receive SCH708980. Participants in Part 2 of the study will receive varying doses (3.75 mg/kg, 5 mg/kg, or 10 mg/kg) of a single IV infusion of AmBisome on Day 8.
1703810|NCT01437007|Drug|TKM-080301|
1703811|NCT01436994|Procedure|Block and Replace|The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range. Carbimazole is commenced in a dose of 0.75 mg/kg/day (propylthiouracil - for dose see below) with the aim being to completely preventing endogenous thyroxine production. Thyroxine is then added in a low replacement dose as the thyroid hormone levels fall into the lower half of the laboratory normal range. The principle measure of control during the first 6 months will be thyroid hormone levels rather than TSH. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil.
1703812|NCT01436994|Procedure|Dose Titration|"The primary objective of treatment is to maintain a euthyroid state with TSH and thyroid hormone levels in the local laboratory normal range.
Carbimazole is commenced in a dose of 0.75 mg/kg/day until thyroid hormone levels fall into the local laboratory normal range. The dose is then reduced to 0.25 mg/kg/day with the intention of maintaining a euthyroid state as reflected by a free thyroxine and TSH within the normal range.
Most paediatricians in the UK commence thyrotoxic children on carbimazole rather than propylthiouracil. Carbimazole is the preferred treatment because of the increased risk of hepatotoxicity with propylthiouracil but patients who are treated with propylthiouracil can also be recruited and randomised. The guidelines detailed above can be used in the knowledge that 1mg of carbimazole is approximately equivalent to 10 mg of propylthiouracil."
1703813|NCT01436994|Drug|carbimazole|Carbimazole 5mg and 20 mg tablets Administered as a once or twice daily regimen with total daily dose adjusted according to prevailing biochemistry
1703814|NCT01436994|Drug|propylthiouracil|50 mg tablets administered once daily with the dose adjusted according to the prevailing biochemistry
1703815|NCT01436994|Drug|thyroxine|25mcg, 50mcg and 100mcg tabletes administered once daily with the dose adjusted according to the prevailing biochemistry
1703816|NCT01436981|Procedure|CABG|Preparation of artery mammaria interna
1703819|NCT01436955|Drug|Placebo|multiple oral doses
1703820|NCT01436955|Drug|RG1662|Cohorts receiving multiple oral doses
1703821|NCT01436942|Behavioral|Exercise|"The exercise intervention will be carried out at a fitness center with supervision from a physiotherapist.
A cardiorespiratory and muscle strengthening exercise program following the American College of Sports Medicine (ACSM) recommendations for maintenance and improvement of physical fitness. Cardiorespiratory fitness: two interval sessions (4 x 4 min), one continuous moderate exercise session (40 min) on a treadmill. The muscle strength exercises will consist of: 15-20 repetitions, large muscle groups as thighs, back and abdomen.
Dose: 12 weeks. Three times a week, 60 minutes."
1703822|NCT01436929|Drug|Silymarin|Silymarin 140mg 1tab bid for 8 weeks
1703823|NCT01436929|Drug|Placebo|Placebo 1tab bid
1703824|NCT01436916|Drug|oral cholecalciferol + life style counselling|oral cholecalciferol 600000 units loading then 60000 units fortnightly for 6months
1703825|NCT01436916|Drug|placebo + life style counselling|Will provide placebo 10 sachets loading and then single sachet fortnightly for 6 months
1703827|NCT01436890|Drug|Revamilast|Tablet. Low dose, Once daily for 12 weeks
1703828|NCT01436890|Drug|Revamilast|Medium dose, Once daily for 12 weeks
1703829|NCT01436890|Drug|Revamilast|High dose, Once daily for 12 weeks
1703830|NCT01436890|Drug|Placebo|Placebo tablet in triple dummy format, Once daily for 12 weeks
1703831|NCT01436877|Device|Insertion of Temporary Implantable Nitinol Device (TIND)|Subjects will be inserted with the Temporary Implantable Nitinol Device (TIND) to the bladder neck and urethral prostate for 5 days and thereafter the TIND will be withdrawn in the doctor office.
1703832|NCT01436864|Biological|Recombinant Human VEGF Receptor-Fc Fusion Protein|Intravitreal injection of KH902 once per month
1703833|NCT01436851|Biological|Storage mite allergen extracts|Nasal provocation with increasing doses of storage mite allergen extracts
1703834|NCT01436838|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|All patients will be prescribed with Betaseron and be instructed on treatment by their phisicians
1703835|NCT01436825|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylactic treatment : 20-40 UI /Kg administered all 2 in 3 days .
1703836|NCT01436812|Procedure|zero end-expiratory pressure|positive end expiratory pressure 0 cm H2O during peumoperitoneum
1703837|NCT01436812|Procedure|positive end expiratory pressure|PEEP 0 cmH2O
1703838|NCT01436799|Drug|propofol|anaesthesia was induced with the effect-site concentration of propofol 5.0 μg ml-1 mainly.
1703839|NCT01436799|Drug|Desflurane|anaesthesia was maintained by desflurane 4-7vol%
1703840|NCT01436799|Drug|alfentanil|administration of alfentanil 10 μg kg-1 for anesthetic induction
1703841|NCT01436799|Drug|Rocuronium|administration of rocuronium 0.6 mg kg-1 for anesthetic induction
1703842|NCT01436786|Other|Guided Imagery|The 12 week intervention consists of a set of 4 GI compact discs (CDs), each 20 minutes in length. Participants will be instructed to listen to the CD once a day in a recommended order for weeks 1-4 and used in any order for weeks 5-12.
1703843|NCT01436747|Drug|Paricalcitol|2 micrograms daily, peroral, 24 weeks
1703844|NCT01436747|Drug|Placebo|2 micrograms daily, peroral, 24 weeks
1703845|NCT01436734|Other|Fasting glycemia|no intervention
1703846|NCT01436734|Other|Hypoglycemia|Insulin induced hypoglycemia
1703847|NCT01436721|Device|Surgicel® absorbable Haemostat|The raw cut surface was covered with Surgicel® absorbable Haemostat or none but was dried by using fine sutures and an argon beam to achieve complete haemostasis.
1703848|NCT01436695|Device|Epicall|The Epicall system is intended for early detection of seizure by monitoring pre-seizure biomarkers.
1703849|NCT01436656|Drug|LGX818|
1703850|NCT01436643|Drug|Venlafaxine|Venlafaxine starting dose was 75 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 150 Mg
1703851|NCT01436643|Drug|Fluoxetine|Fluoxetine starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
1703852|NCT01436643|Drug|Citalopram|Citalopram starting dose was 20 mg and given once daily for at least 7 days and a maximum of 28 days. Dosage was increased afterwards to the individual final dose given once daily, i.e. after at least 7 days and a maximum of 28 days, patients were titrated to their maximum dose of 40 Mg
1703853|NCT01436643|Drug|Fingolimod|Dosage of 0.5 mg per capsule (hard gelatin capsules) was taken p.o. once daily. Fingolimod was supplied in bottles containing 35 capsules each.
1703854|NCT01436630|Other|Step Test and Six Minute Walk.|The 6 Minute Walk Test (6MWT) was conducted in a level corridor 30 meters long and 5 meters wide. Before and after testing were measured O2 saturation (SatO2) and heart rate (HR), respiratory rate (RR), blood pressure (BP), the Double Product (DP), a measure of myocardial oxygen consumption, was calculated as the product of HR and systolic BP, and the sensation of dyspnea and fatigue of the lower limbs using the Borg scale, and performing the record turns traveled, each 30 meters is considered a covered back. To calculate the predicted distance, the investigators use the formula described by American Thoracic Society (ATS) knowing the weight, age and height of participants. The Step Test (ST) was conducted in six minutes for it to be compared to the 6MWT.
1703855|NCT01436617|Other|blood sample|The IgE anti cetuximab test will then be conducted by an ELISA test
1703856|NCT01436604|Other|Cardiac MRI|"The examinations will be conducted on an MRI with a dedicated antenna heart, by a physician with expertise in cardiac MRI.
After establishing a good quality ECG synchronization, the following sequences are carried out successively:
Sequences locating anatomical
T2 black blood (such as ESF)
rapid sequence of cine-MRI (such as balanced FFE) vertical and horizontal long axis and short axis of the base to the apex
T1-weighted sequence with inversion recovery for the assessment of possible consequences of cell damage."
1703857|NCT01436578|Drug|Posaconazole oral suspension 40 mg/mL|Posaconazole oral suspension prescribed according to the current local label
1703858|NCT01436565|Drug|MM-121 (SAR256212)|"Pharmaceutical form:solution
Route of administration: Intravenous"
1703859|NCT01436565|Drug|SAR245408|"Pharmaceutical form:tablet
Route of administration: oral"
1703860|NCT01436539|Drug|Adefovir Dipivoxil and polyene phosphatidylcholine|Adefovir Dipivoxil 10 mg once daily for 48 weeks plus Polyene phosphatidylcholine (PPC) 456 mg three times per day for 48 weeks
1703861|NCT01436539|Drug|Adefovir Dipivoxil|Adefovir Dipivoxil 10 mg once daily for 48 weeks
1703862|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 2*5 mg tablet in first intervention period and 1*10 mg tablet in second intervention period (after washout period)
1703863|NCT01436526|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Single oral dose of rivaroxaban administered under fasting conditions 1*10 mg tablet in first intervention period and 2*5 mg tablet in second intervention period (after washout period)
1703864|NCT01436513|Drug|Premarin reference tablet (fasted)|Premarin reference tablet, single dose, fasted conditions
1703865|NCT01436513|Drug|Premarin new tablet (fasted)|Premarin new tablet, single dose, fasted conditions
1703866|NCT01436513|Drug|Premarin reference tablet (fed)|Premarin reference tablet, single dose, fed conditions
1703867|NCT01436513|Drug|Premarin new tablet (fed)|Premarin new tablet, single dose, fed conditions
1703868|NCT01436500|Drug|Ifetroban Injection|Ifetroban sodium injectable, diluted in sterile water with 5% dextrose
1703869|NCT01436500|Drug|Placebo|Sterile water with 5% Dextrose
1703870|NCT01436487|Biological|MultiStem|single infusion 1-2 days following ischemic stroke
1703871|NCT01436487|Biological|Placebo|single infusion 1-2 days following ischemic stroke
1703872|NCT01436474|Drug|Varenicline|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
1703873|NCT01436474|Drug|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 45 days. Patients assigned to varenicline and are current smokers will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to varenicline and are non-smokers will receive 0.5mg by the oral route once a day for 6 days, followed by 0.5mg twice a day for 6 days. After the first 12 days the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline.
1703874|NCT01436448|Drug|Probiotics Lactobacillus Rhamnosus|Probiotics Lactobacillus Rhamnosus (1010 Colony forming Units (CFU)/day)
1703875|NCT01436435|Device|Jetstream Atherectomy System|Atherectomy
1703876|NCT01436422|Biological|TetraVax-DV Vaccine - Admixture TV003|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV003 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
1703877|NCT01436422|Biological|TetraVax-DV Vaccine - Admixture TV005|One subcutaneous injection at Day 0 and Day 180 of a live attenuated recombinant TetraVax-DV vaccine, Admixture TV005 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
1703878|NCT01436422|Biological|Placebo|One subcutaneous injection at Day 0 and Day 180 of placebo
1703879|NCT01436409|Other|echography|echography during labor
1703880|NCT01436396|Biological|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 12, 18, and 24 months
1703881|NCT01436396|Biological|Yellow fever vaccine|0.5 mL subcutaneous in the deltoid at age 12 to 13 months.
1703882|NCT01436396|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 12 to 13 months.
1703883|NCT01436396|Biological|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
1703884|NCT01436396|Biological|Hepatitis A Pediatric Vaccine|0.5 mL, intramuscular at age 13 to 14 months
1703885|NCT01436396|Biological|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
1703886|NCT01436396|Biological|Live, attenuated dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 18 to 19 and 24 to 25 months
1703887|NCT01436396|Biological|Yellow Fever Vaccine|0.5 mL, subcutaneous at age 12 to 13 months
1703888|NCT01436396|Biological|Placebo (NaCl)|0.5 mL, subcutaneous at age 12 to 13 months
1703889|NCT01436396|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous at age 13 to 14 months
1703890|NCT01436396|Biological|Pneumococcal Conjugated Vaccine|0.5 mL, intramuscular at age 13 to 14 months
1703891|NCT01436396|Biological|Diphtheria, tetanus, pertussis, polio, and Haemophilus influenzae vaccine|0.5 mL, intramuscular at age 19 to 20 months
1703892|NCT01436383|Other|Hypoxic exposure|Hypoxic exposure
1703893|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® High Dose [60 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
1703894|NCT01436370|Biological|Trivalent inactivated influenza vaccine|Inactivated trivalent influenza virus vaccine (Sanofi Pasteur Fluzone® [15 mcg x 3 strains]), as a single intramuscular dose. 80 and up to 100 subjects. Subjects enrolling between October 2011 and February 2012 will receive the 2011-2012 vaccine and subjects enrolling after July 2012 will receive the 2012-2013 vaccine.
1703895|NCT01436357|Biological|AdCh3NSmut1|Stages I and II: Receive AdCh3NSmut1 at 2.5 x 10^10 total virus particles (vp)/dose, intramuscularly on day 0.
1703896|NCT01436357|Biological|MVA-NSmut|Stages I and II: 1 dose of MVA-NSmut at the dosage 1.8 x10^8 plaque forming units (pfu) intramuscularly on day 56.
1703897|NCT01436357|Other|Placebo|Stages I and II: Two doses of placebo intramuscularly, 1 at day 0 and 1 at day 56.
1703898|NCT01436331|Other|Treatment As Usual (TAU)|Services participating in the trial are routine public Community Mental Health Centres (CMHCs), which operate within the Italian National Health Service. Multi-disciplinary teams operating these CMHCs provide a wide range of integrated programmes, including inpatient care, day care, rehabilitation, outpatient care, home visits, 24-hour emergency services, and residential facilities. Standard care for FEP patients generally consists of personalized outpatient psychopharmacological treatment, combined with non-specific supportive clinical management at the CMHC level. Family interventions generally consist of non-specific informal support/educational sessions. Both specialized individual psychotherapeutic interventions for patients (included CBT) and specialized psycho-educational or cognitive-oriented family interventions are usually not provided, due to lack of trained professionals.
1703930|NCT01436136|Other|Intervention Group|Patients randomised to the intervention group will follow an intensive 52 week period using a clinical protocol aimed to manage CVD risk in HIV individuals with the use of regular visits to a nurse led CVD risk management clinic, within a multi disciplinary approach to care with the involvement of treating physicians, nurses, dieticians, smoking cessation advisors and an exercise physiologist or personal trainer with the aim to reach their individualised CVD risk target.
1704397|NCT01432535|Drug|PegIFN-2b (Sylatron®)|Single 4.5 μg/kg dose
1703899|NCT01436331|Behavioral|TAU+CBT for pts+Family Intervention+CM.|The experimental treatment package is administered by the CMHC staff, after training and with ongoing supervision by experts. Cognitive-behavioural therapy (CBT) is based on the model developed by Kuipers in 1998 and Garety in 2008. A total of 20-30 CBT sessions per patient will be delivered, with weekly sessions during months 1-3 and fortnightly over the following 6 months. Family Intervention is based on the model proposed by Leff in 1982 and further developed by Kuipers in 2002. It includes a total of 10-15 sessions with each individual family: 6 in months 1-3, and at least 1 session/month in the 6 months afterwards. Every patient/family will have a dedicated Case Manager, who will coordinate all planned interventions. Specific training programs have been developed, with assessment of the staff competence. Detailed Manuals based on international standards have been developed and will be used. Fidelity will be measured at the end of the trial.
1703900|NCT01436305|Drug|Alemtuzumab|Induction therapy. Group 1 and 2 study therapy regimens include induction with alemtuzumab, administered as a single intravenous dose intra-operatively over a period of 2 hours.
1703901|NCT01436305|Drug|MMF|"All treatment groups (e.g., Group 1, 2 and 3): Administered at a target dose of 1000 mg by mouth twice daily beginning on the day of surgery or post operative day 1 and adjusted as clinically warranted.
Note: Myfortic® (mycophenolate sodium) may be used as a replacement for MMF, at a dose of 720 mg taken by mouth twice daily."
1703902|NCT01436305|Biological|Basiliximab|Induction therapy. Group 3 study therapy regimen includes induction with basiliximab, administered in two doses: 1 dose administered within 2 hours prior to transplantation surgery and the 2nd dose 4 days after transplantation (unless held due to contraindication[s])
1703903|NCT01436305|Drug|Short-term Tac|Short-term (3 months)
1703904|NCT01436305|Drug|tacrolimus|maintenance
1703905|NCT01436305|Biological|Belatacept|maintenance
1703906|NCT01436305|Drug|methylprednisolone|All study treatment groups: administration started on the day of transplant and tapered over a 4 day course.
1703907|NCT01436292|Drug|5% human albumin solution (HAS)|"Patient will receive 5% HAS daily for the first 7 days of stay in ICU according to their albumin level:
≥ 30 gr/L: albumin will not be administered; 25 - 29.9 gr/L: 25 g of 5% HAS; 20 - 24.9 gr/L: 50 g 5% HAS; 15 - 19.9 gr/L: 75 g of 5% HAS; 10 - 14.9 gr/L: 100 g of 5% HAS; < 10 gr/L: 150 g of 5% HAS."
1703908|NCT01436279|Drug|Mifepristone|200 mg po 20-24 hours prior to the procedure
1703909|NCT01436279|Device|osmotic dilators|osmotic dilators placed in the cervix 20-24 hours prior to the procedure
1703910|NCT01436266|Drug|Misoprostol|400 mcg buccally 2 hours prior to procedure
1703911|NCT01436266|Other|Folic acid|2mg buccally 2 hours prior to procedure
1703912|NCT01436253|Behavioral|Lifestyle Changes|Diet, increased physical activity, and weight reduction as per European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology were encouraged in addition to pharmacological measures at the discretion of the treating physician.
1703913|NCT01436253|Drug|Hypolipemics|Pharmacological measures at the discretion of the treating physician and in accordance with the respective authorized label and European Guidelines on the Management of Hypercholesterolemia accepted by the Croatian Society of Cardiology.
1703914|NCT01436240|Behavioral|questionnaire administration followed by cognitive interviews|Each cognitive interviewing procedure will include two parts. Participants will first be asked to independently complete a series of PRO-CTCAE symptom items in a Patient Questionnaire. Following completion by the participant of the Patient Questionnaire containing PRO-CTCAE items, the bilingual interviewer will query participants regarding item comprehension, relevance, inclusiveness, cultural appropriateness, and cognitive processes used to generate responses, via a semi-scripted cognitive debriefing interview developed to assure consistency across interviews.
1703915|NCT01436227|Drug|Pazopanib|800 mg by mouth once daily for up to six, four week cycles.
1703916|NCT01436214|Drug|APC-100|Daily oral, dose escalation, 28-day cycle(s)
1703917|NCT01436201|Drug|Digoxin|Administered orally
1703918|NCT01436201|Biological|Dulaglutide|Administered as subcutaneous injection
1703919|NCT01436188|Procedure|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours
1703920|NCT01436188|Procedure|Alternate frequency CSR sampling procedure|an alternative frequency of CSF sampling procedure for 36 hours
1703921|NCT01436188|Procedure|Standard frequent CSR sampling procedure with 800 mg ibuprofen|standard frequent CSF sampling procedure on Day 1 for 36 hours with 800 mg Ibuprofen administered on Day 1
1703922|NCT01436188|Procedure|Standard CSR sampling procedure|standard frequent CSF sampling procedure for 36 hours.
1703923|NCT01436188|Procedure|Alternative lower frequency CSR sampling procedure|an alternative lower frequency of CSF sampling procedure in comparison to Cohort 1 for 36 hours
1703924|NCT01436175|Drug|SPD489 (Lisdexamfetamine dimesylate) + Antidepressant|SPD489 20mg, 30mg, 50mg, or 70mg + Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily for 52 weeks
1703925|NCT01436162|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
1703926|NCT01436162|Drug|Antidepressant + Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
1703927|NCT01436149|Drug|SPD489 (Lisdexamfetamine dimesylate )|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
1703928|NCT01436149|Drug|Placebo|Antidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
1703929|NCT01436136|Other|Control|GPs managing matched control patients allocated usual care will be unaware of the details of the intervention arm and asked to apply their usual pattern of patient visits and treatment strategies to achieve optimal reduction of CVD risk.
1703971|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 3: Darinaparsin 300 mg/m2 for 5 consecutive days every 21 days (5 days therapy, 16 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
1703931|NCT01436123|Other|Stenting and micro-infusion of NP|Step 1 - IVUS, OCT-guided put in everolimus-eluting (drug-eluting-DES) stent + intravascular ultrasound (IVUS) mapping + harvesting stem cells with mesenchymal phenotype; Step 2 - culturing of stem cells in medium by gold nanoparticles with silica-iron oxide shells; Step 3 - micro-infusion of stem cells bearing NP into the lesion; Step 4 - detonation of nanoshells after migration of stem cells with NPs inside (until 7-10 days after transplantation). We expect 'melting' and 'burning' effects of PPTT, beneficial effects of bioactive products of stem cells lysis + benefits from further migration of stem cells from patch into the plaque
1703932|NCT01436123|Device|Implantation of everolimus-eluting stent|Put stent in ischemia-related coronary artery by indications for PCI
1703933|NCT01436110|Drug|Fluticasone furoate 50mcg|Once daily inhalation powder via Novel Dry Powder Inhaler
1703934|NCT01436110|Drug|Fluticasone propionate 100mcg|Twice daily inhalation powder via DISKUS/ACCUHALER
1703935|NCT01436110|Drug|Placebo|Inhalation powder via Novel Dry Powder Inhaler and DISKUS?ACCUHALER
1703936|NCT01436097|Behavioral|Information provision intervention|Participant will have access to weekly data showing how much produce they are purchasing. No incentives will be given under this arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
1703937|NCT01436097|Behavioral|information provision + flat incentive|Participants will earn back 15% of what they spent on groceries for the week if they spend at least 15% of their total grocery budget on fresh produce in addition to receiving the same treatment as the IP arm. They will also receiving information on weekly purchases, online resources, and weekly reminders on eating healthy.
1703938|NCT01436097|Behavioral|Information provision + tiered incentive|In addition to receiving information on weekly purchases, online resources, and weekly reminders on eating healthy the participants assigned to the IP + tiered incentive group would earn back increasing percentages of their grocery spending for meeting increasing targets of produce consumption.
1703939|NCT01436097|Behavioral|Usual Care|Participants will have access through the Way to Health portal to web-based educational materials and recipes related to healthy eating. They will be informed they will receive up to $50 in reimbursements for completing the surveys that are part of the Way To Eat program as follows: $20 for completing the intake questionnaire and weigh-in and $30 reimbursements for completing the exit questionnaire and weigh-in.
1703940|NCT01436084|Drug|SB1518|400 mg taken orally, once daily without regard of food, 28 day cycle.
1703941|NCT01436071|Drug|Fluticasone furoate 50mcg|Inhalation powder delivered by Novel Dry Powder Inhaler
1703942|NCT01436071|Drug|Placebo|Inhalation powder delivered by Novel Dry Powder Inhaler
1703943|NCT01436058|Biological|mesenchymal stem cell|intraarticular injection of mesenchymal stem cell in patients with ankle joint osteoarthritis
1703944|NCT01436045|Drug|Insulin glulisine|Single treatment, 20 IU/Intranasal (.1ml/10 units Intranasally in each nostril)
1703945|NCT01436045|Drug|Saline|Single treatment,(saline) 20 IU/Intranasal (.1ml/10units intranasally in each nostril)
1703946|NCT01436032|Drug|N1539|IV
1703947|NCT01436032|Drug|N1539|IV
1703948|NCT01436032|Drug|N1539|IV
1703949|NCT01436032|Drug|Ketorolac Tromethamine|IV
1703950|NCT01436032|Drug|Placebo|IV
1703951|NCT01435993|Drug|GSK1223249|Intravenous infusion
1703952|NCT01435993|Other|Saline placebo|placebo intravenous infusion
1703953|NCT01435980|Procedure|Gastric Bypass|basal treatment and Gastric Bypass
1703954|NCT01435980|Drug|Exenatide|basal treatment and Exenatide
1703955|NCT01435967|Other|Data collection|Data collected when only the lyophilised formulation of Rotarix was in use (which is considered as baseline) will be specifically compared to data collected post the introduction of the liquid formulation. The results will also be compared to available vaccine coverage data for those rotavirus vaccines being used in Belgium.
1703956|NCT01435954|Drug|Early combination therapy|If index drug was an alpha-blocker (AB) (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claims for a 5-alpha reductase inhibitor (5ARI) (dutasteride, finasteride) on or within 30 days after the index date or if index drug was 5ARI, fill for an AB on or within 30 days after the index date
1703957|NCT01435954|Drug|Delayed combination therapy|If index drug was an AB (alfuzosin, doxazosin, tamsulosin, or terazosin), a pharmacy claim for a 5ARI (dutasteride, finasteride) more than 30 days but less than or equal to 180 days of the index date
1703958|NCT01435941|Drug|Non-steroidal anti-inflammatory drug (NSAID)|Participants who self-report that they have treated headaches with any drug in the non-steroidal anti-inflammatory drug (NSAID) class
1703959|NCT01435941|Drug|Triptan|Participants who self-report that they have treated headaches with any drug in the NSAID class and any drug in the triptan class including naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, and zolmitriptan
1703960|NCT01435928|Drug|Lurasidone|Lurasidone 40 and 80 mg, once daily in the evening with a meal or 30 minutes after eating
1703961|NCT01435928|Drug|Matching Placebo|Matching placebo once daily in the evening with a meal or 30 minutes after eating
1703962|NCT01435915|Drug|Ropinirole|"Ropinirole 2 milligrams once daily prolonged release tablet will be given at 24-hour intervals in the morning.
Single and repeat dose treatment periods will be separated by 7 days of washout period."
1703963|NCT01435902|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 4 weeks
1703964|NCT01435902|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 4 weeks
1703965|NCT01435876|Procedure|Post exercise Surgery|ORTHOPTICS/MINUS LENS THERAPY
1703966|NCT01435876|Procedure|Orthoptics|MINUS LENS THERAPY/ ORTHOPTICS
1703967|NCT01435876|Procedure|Postop orthoptics|ORTHOPTICS/MINUS LENS THERAPY
1703968|NCT01435876|Procedure|Post exercises surgery|UNIOCULAR/BINOCULAR RECESSION/RESECTION
1703969|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 1: Darinaparsin 200 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
1703970|NCT01435863|Drug|SP-02L (darinaparsin for injection)|Cohort 2: Darinaparsin 300 mg/m2 for 5 consecutive days every 28 days (5 days therapy, 23 days no therapy is one cycle). Subjects may start from Cycle 1 and continue to a maximum of 4 cycles of treatment.
1763618|NCT00312104|Drug|insulin glargine|
1703972|NCT01435850|Procedure|primary total hip arthroplasty|All patients eligible to the study criteria will be included. A total hip arthroplasty unilateral will be performed.
1703973|NCT01435837|Drug|C2 (200mg of caffeine; 1/2 L of water)|200mg of caffeine (tablet); 1/2 of water
1703974|NCT01435837|Drug|C3(200mg of caffeine; 1 L of water)|Ingestion of 200 mg of caffeine and 1 Liter of water after between pretest and posttest.
1703975|NCT01435837|Drug|C1 (200mg of caffeine, no water)|Ingestion of 200mg of caffeine (tablet); no water ingestion.
1703976|NCT01435837|Drug|Placebo (no caffeine, no water).|No ingestion of caffeine; no ingestion of water between pretest and posttest.
1703977|NCT01435824|Drug|Human milk-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of breast milk to have 100mL of a 50mg/mL suspension.
1703978|NCT01435824|Drug|Water-dissolved amoxicillin|An amoxicillin suspension bottle containing 5 grams of amoxicillin (powder) will be resuspended in 60 ml of water to have 100mL of a 50mg/mL suspension.
1703979|NCT01435811|Biological|Norovirus challenge pool (GII.4, CIN-1)|Norovirus challenge pool (GII.4, CIN-1)
1703980|NCT01435798|Drug|Dextromethorphan|0, 25, 50 and 100% of maximum tolerated dose, each administered over a 4 week period
1703982|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mg|Antidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
1703983|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mg|Antidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
1703984|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mg|Antidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
1703985|NCT01435759|Drug|Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mg|Antidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
1703986|NCT01435759|Drug|Antidepressant + Placebo|oral, once daily for 8 weeks
1703987|NCT01435746|Behavioral|Red blood cell transfusion|The intervention of this trial is the regime of red blood cell transfusion. The control group will receive red blood cell transfusions according to a conservative regime, whereas the experimental group will receive red blood cell transfusion according to a liberal transfusion regime.
1703988|NCT01435720|Biological|SNS01-T|0.05 mg/kg twice weekly x 6 weeks
1703989|NCT01435720|Biological|SNS01-T|0.2 mg/kg twice weekly x 6 weeks
1703990|NCT01435720|Biological|SNS01-T|0.375 mg/kg twice weekly x 6 weeks
1703991|NCT01435720|Biological|SNS01-T|0.0125 mg/kg twice weekly x 6 weeks
1703992|NCT01435707|Other|epidural steroid injection with Triamcinolone 40mg|epidural steroid injection with Triamcinolone 40mg
1703993|NCT01435707|Other|Selective transforaminal epidural block with triamcinolone 20 mg|Selective transforaminal epidural block with triamcinolone 20 mg
1703994|NCT01435707|Other|caudal epidural steroid injection with Triamcinolone 20mg|caudal epidural steroid injection with Triamcinolone 20mg
1703995|NCT01435707|Other|Selective transforaminal epidural block with triamcinolone 40 mg|Selective transforaminal epidural block with triamcinolone 40 mg
1703996|NCT01435694|Behavioral|Lokomat (Hocoma, Switzerland)|
1703997|NCT01435694|Behavioral|Conventional Therapy|
1703998|NCT01435668|Behavioral|Brief Motivational Intervention (BMI)|Patients receive an information leaflet plus a referral to a psychologiste. BMI is provided by the psychologist. BMI consists in a first face-to-face interview (35-45 minutes) plus a telephone interview, at 1 and 2 months. Minors' parents are also invited to attend the BMI session.
1703999|NCT01435668|Behavioral|Simple written advice|Patients receive an information leaflet.
1704000|NCT01435655|Drug|tafamidis|tafamidis meglumine 20 mg QD
1704001|NCT01435642|Other|No treatment given|Subject will fill out a questionnaire when entering the non-interventional study
1704002|NCT01435629|Drug|somatropin|Dosage and administration to be prescribed by the physician as a result of a normal clinical practice.
1704003|NCT01435616|Drug|Glargine|Administered by subcutaneous injection
1704004|NCT01435616|Drug|LY2605541|Administered by subcutaneous injection
1704005|NCT01435603|Behavioral|Standard Lifestyle Advice|Standard clinical education is offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits and are provided with clinical recommendations for lifestyle and cardiovascular risk factor management. Brief lifestyle advice is delivered by a study Research Assistant at baseline, 6, 12, and 24 months.
1704006|NCT01435603|Behavioral|Advice Plus Lifestyle Intervention|Standard clinical education offered routinely by the participant's usual primary care team. Primary care teams receive educational outreach visits for lifestyle and cardiovascular risk factor management. Brief lifestyle advice delivered by a study research assistant at baseline, 6, 12, and 24 months. AND, participant offered free of charge access to an intensive lifestyle intervention offered in a community setting. Lifestyle interventions are delivered in community settings by lay instructors from community organizations who are centrally trained by the study team.
1704007|NCT01435590|Procedure|Curette v/s endocervical brush|
1704008|NCT01435577|Drug|Tapentadol|30 mg per administration, maximum 12 administrations over 48 hours
1704009|NCT01435577|Drug|Matching Placebo|Maximum 12 administrations over 48 hours
1704010|NCT01435564|Behavioral|Mobile phone|Participants in this group will receive both the pedometer and the mobile-phone based physical activity intervention fot three months.
1704011|NCT01435564|Behavioral|pedometer only|Participants in this group will receive only a pedometer.
1704012|NCT01435551|Other|Hypnotherapy|1 year study,1 hour session per month for 9 months, 3 remaining months evaluation
1704015|NCT01435499|Biological|melanoma GVAX|Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.
1704472|NCT01431963|Drug|Lamictal|No comparison.
1704016|NCT01435499|Drug|Cyclophosphamide|200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
1704017|NCT01435486|Drug|Caffeine citrate|Single stat dose (25 mg per kilogram of body weight) of intravenous caffeine citrate (25mg caffeine citrate equal to 12.5mg caffeine base).
1704018|NCT01435486|Drug|Normal saline|Placebo with an equivalent volume of normal saline.
1704019|NCT01435473|Procedure|Cardiac Surgery|
1704020|NCT01435460|Drug|Loteprednol etabonate 0.2%|1 drop of Alrex 4 times daily (QID) in both eyes at approximately 4 hour intervals for 2 weeks.
1704021|NCT01435460|Drug|Olopatadine 0.1%|1 drop of Patanol 2 times daily (BID)at intervals of 6-8 hours or more for 2 weeks.
1704022|NCT01435447|Drug|FLu-Bu-Cy|Fludarabine at 30mg/m2 daily followed by iv-Busulfan at 3.2mg/kg daily for a total of 4 days from Day-6 to -3 and cyclophosphamide as 60mg/kg daily for 2 days on Day +3 and +4, CSA 3mg/kg starting after D+5.
1704023|NCT01435434|Device|the Sepax is a tool to standardize adult stem cell. Ignite ®ICS injectable scaffold manufactured by Wright Medical Technology.|
1704024|NCT01435408|Other|Conventional primary PCI|Conventional primary PCI in STEMI with implantation of DES.
1704025|NCT01435408|Other|Ischemic postconditioning.|Primary PCI in STEMI with implantation of DES. Following re-opening of the culprit artery mechanical postconditioning with 4 cycles of 30/30 sec. reperfusion/re-occlusion i performed.
1704026|NCT01435408|Other|Deferred stenting in primary PCI.|In STEMI re-opening of the artery with guidewire/thrombectomy/small size balloon inflation DES stenting is postponed for 48 hours.
1704027|NCT01435395|Drug|Temozolomide, bevacizumab and bortezomib|Escalating temozolomide with standard dose bevacizumab and bortezomib
1704033|NCT01435356|Biological|recMAGE-A3 + AS15 ASCI|5 doses will be administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
1704034|NCT01435356|Biological|Placebo|5 doses will be administered (intramuscular) at 3-week intervals followed by 8 doses administered at 3-month intervals for a total maximum duration of study treatment administration of 27 months
1704035|NCT01435343|Drug|fludarabine|30 mg/m2/day intravenously on days 1 to 4
1704036|NCT01435343|Drug|Idarubicin|10 mg/m2/day intravenously on days 1 to 3
1704037|NCT01435343|Drug|cytarabine|2 g/m2/day intravenously on days 1 to 4
1704038|NCT01435343|Drug|G-CSF|5 μg/kg/day subcutaneously from days 1 to 4
1704039|NCT01435343|Drug|plerixafor|intravenously from days 1 to 4
1704040|NCT01435330|Drug|BVS857|
1704041|NCT01435330|Drug|Placebo|
1704042|NCT01435317|Device|ANM T30 CR®-System|Stimulation for 4-6h/day for a time of 1 year
1704043|NCT01435304|Device|method of returning residual CPB blood ( Hemobag®)|The Hemobag® is a collection reservoir used to facilitate ultrafiltration of the CPB circuit after the patient has been disconnected from CPB).
1704044|NCT01435291|Drug|Advagraf Capsule|"Other Names:
FK506E
MR4
tacrolimus modified/prolonged release Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
1704045|NCT01435291|Drug|Prograf Capsule|"Other Names:
FK506E
MR4
tacrolimus Drug: MPA Solution for infusion and per os Other Name: Mycophenolate Mofetil or Mycophenolic Acid Drug: Basiliximab IV infusion Other Name: Simulect Drug: Corticosteroids per os Other Name: Methylprednisolone or equivalent"
1704046|NCT01435278|Device|Glucosanol|2 tablets taken 3 times a day.
1704047|NCT01435265|Behavioral|Standard nurse education|Standard-of-care education from a dermatology nurse on the proper use of adalimumab
1704048|NCT01435265|Behavioral|Additional nurse education|Additional education from a nurse on the use of adalimumab. This will include discussion of the pre-study evaluation with the subject, design of an Individual Educational Plan based on the pre-study evaluation, and a 30-60 minute educational session with the nurse educator at each study visit. Additional information concerning the benefits of the local support group and National Psoriasis Foundation will be provided. Additional education on self-injection and the opportunity to practice self-injection under the supervision of a nurse will also be provided. Subjects will also receive reminder phone calls to take each scheduled dose.
1704049|NCT01435252|Drug|Cetuximab|Arm A: chemoradiation in combination with concurrent cetuximab Arm B: chemoradiation in combination with concurrent and consolidation cetuximab
1704050|NCT01435239|Device|The cuff inflation by the resting volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
1704051|NCT01435239|Device|The cuff inflation by the maximum volume|80 patients are randomly allocated into two groups : resting volume group (n=40), half the maximum volume group (n=40). In the resting volume group, the pilot balloon valve is connected to syringe without piston for keeping the valve open to the atmosphere and allowing the pressure within the cuff of LMA to equalize with atmospheric pressure. In the half the maximum volume group, the cuff of LMA is completely emptied and then the cuff is filled with the half the maximum volume.
1704052|NCT01435226|Drug|GS-5885|"Drug: GS-5885 tablet
GS-5885 tablet, 90 mg, QD"
1704053|NCT01435226|Drug|GS-9451|"Drug: GS-9451 tablet
GS-9451 tablet, 200 mg QD"
1704054|NCT01435226|Drug|tegobuvir|tegobuvir 30 mg BID
1704055|NCT01435226|Drug|placebo to match tegobuvir|tegobuvir placebo BID
1704056|NCT01435226|Drug|placebo to match RBV|Ribovirin placebo BID
1704473|NCT01431950|Drug|fluticasone furoate|Inhaled corticosteroid
1704057|NCT01435226|Drug|Ribavirin|Ribavirin (Copegus®) BID (1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg) divided BID
1704058|NCT01435213|Drug|Atipamezole|Administration of a single dose of 5-150 micrograms of atipamezole as an intravenous infusion
1704059|NCT01435213|Drug|Atomoxetine|A single dose of 1.2 mg/kg of atomoxetine administered orally
1704060|NCT01435213|Drug|Ketamine|A single dose of ketamine (approximately 60 mg) administered as an intravenous infusion
1704061|NCT01435213|Other|Cold pressor test|30-45 min cold pressor test of the foot
1704062|NCT01435213|Drug|Insulin|Insulin administered as an intravenous infusion to induce hypoglycemia
1704063|NCT01435213|Drug|Placebo|A single dose of placebo (capsules) administered orally
1704064|NCT01435200|Drug|Intravenous iron|Intravenous iron 200 mg add in 0.9% Normal saline 100 ml infused within 15 minutes after every cycles of chemotherapy
1704068|NCT01435161|Drug|Nifedipine,|Nifedipine 30-60mg/day
1704069|NCT01435161|Drug|Telmisartan|Telmisartan 80-160mg/day
1704070|NCT01435148|Procedure|Deep Brain Stimulation, implanted|Deep brain stimulator implanted during neurosurgery. Specific stimulation parameters programmed after surgery as required. After blinded study arms open stimulation of either or both targets.
1704075|NCT01435122|Drug|Axitinib|Axitinib Administration as outlined in Arm description
1704076|NCT01435109|Behavioral|Patient Behavioral Intervention for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
1704077|NCT01435109|Behavioral|Provider Intervention for OA|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
1704078|NCT01435109|Behavioral|Combined Patient and Provider Interventions for OA|Patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management; primary care providers receive patient-specific osteoarthritis information and treatment recommendations at the point of clinical care.
1704079|NCT01435096|Drug|BN80927|Administered over 30 minutes in the vein with a fixed infusion rate once every 3 weeks. Each patient could participate in a maximum of 10 continuous cycles, equivalent to 30 weeks treatment.
1704080|NCT01435083|Drug|Desmopressin|120 µg, oral lyophilisate, sublingual use
1704081|NCT01435070|Procedure|Kirschner wire fixation|"The wires are passed through the skin over the dorsal aspect of the distal radius and into the bone in order to hold the fracture in the correct (anatomical) position. The size and number of wires, the insertion technique and the configuration of wires will be left entirely to the discretion of the surgeon.
A plaster cast will be applied at the end of the procedure to supplement the wire fixation as per standard surgical practice. This cast holds the wrist still and is left on until the wires are removed at the follow-up appointment."
1704082|NCT01435070|Procedure|Volar Locking Plate fixation|The locking-plate is applied through an incision over the volar (palm) aspect of the wrist. The surgical approach, the type of plate and the number and configuration of screws will be left to the discretion of the surgeon. The screws in the distal portion of the bone will be fixed-angle, i.e. screwed into the plate, but this is standard technique for use of these plates. The type of proximal screw will be left to the discretion of the surgeon; these may be locking or non-locking screws. The use of a cast will left to the discretion of the surgeon.
1704083|NCT01435057|Procedure|exercise training|comparison of strength versus endurance training (two or three times a week, 60 minutes per training session) over 24 months
1704084|NCT01435044|Drug|Sofosbuvir|Sofosbuvir 400 mg (2 × 200 mg tablets) administered orally once daily
1704085|NCT01435044|Drug|GS-0938|GS-0938 300 mg (3 × 100 mg tablets) administered orally once daily
1704086|NCT01435044|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1704087|NCT01435044|Drug|Placebo to match sofosbuvir|Placebo to match sofosbuvir administered orally once daily
1704088|NCT01435044|Drug|Placebo to match GS-0938|Placebo to match GS-0938 administered orally once daily
1704089|NCT01435031|Device|CTO Treatment Device|"Subjects receiving at least 1 of the following for the treatment of CTO:
XIENCE V® and/or XIENCE nano™ and/or XIENCE PRIME™ LL Everolimus Eluting Coronary Stent
HT PROGRESS and/or HT PILOT guide wires in recanalization
MINI-TREK Coronary Dilatation Catheter in predilatation"
1704155|NCT01434472|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT (infusion of donor stem cells via central catheter)
1704094|NCT01435005|Other|Moderate Volume|Moderate volume (150 minutes per week) aerobic exercise
1704095|NCT01435005|Other|High Volume|Participate in one-year high volume (300 minutes per week)aerobic exercise.
1704096|NCT01434966|Other|Lumbopelvic Manipulation|The lumbopelvic joint manipulation (Grade V mobilization) will be performed on the ipsilateral side of the test limb. The participant will be passively side-bent towards and rotated away from the selected lumbopelvic region which is followed by the delivery of a posterior/inferior force through the opposite anterior superior iliac spine. If a cavitation is not heard or felt by the patient or clinician, the technique will be repeated. If the second attempt does not produce cavitation the procedure will be repeated on the contralateral side using similar methods. If cavitation is not heard or felt by the participant or clinician following the second attempt on the contralateral side, the participant will proceed with the assessment of quadriceps strength and activation as usual.
1704097|NCT01434966|Other|TENS- Spine|The TENS electrodes will be applied lateral to L1 and L2 and lateral to S5 and S1. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
1704098|NCT01434966|Other|TENS- Knee|The TENS electrodes will be applied on the medial and lateral superior, as well as the medial and lateral inferior, borders of the patella. Care will be taken not to place TENS electrodes on the quadriceps muscles or muscles of the anterior leg. The TENS unit will be set to deliver a continuous TENS biphasic pulsatile current at 150 Hz, with a phase duration of 150 microseconds. The TENS unit will be worn during all exercise testing and for the first 30 minutes of quadriceps force output and activation testing. After the 30 minute post-intervention measures (Post30) are obtained, the TENS unit will be turned off.
1704099|NCT01434953|Behavioral|Labeled prehypertension|A study physician informs subjects of their blood pressure level. Subjects are told they have prehypertension and are informed of the associated health risks.
1704100|NCT01434953|Behavioral|Unlabeled prehypertension|"A study physician informs subjects of their blood pressure level. The term prehypertension is not used and associated health risks are not discussed."
1704101|NCT01434940|Other|Eye movements will be recorded using video-oculography techniques based on both the corneal reflection principle and an infra-red light beam|. The system named H6-HSCN by Applied Science Laboratories (ASL®) helps keep the patient's head fixed on a support, important for the elderly population. This system allows to capture data with good temporal resolution (sampling at 360Hz) and good spatial resolution (accuracy of 0.1° of visual angle) at a distance of about 70 cm from the screen test with a visual angle of 32.6°. Results will be processed with ASL Result Software.
1704102|NCT01434927|Procedure|Unsedated colonoscopy|Patients were offered to undergo colonoscopy without routine premedication
1704103|NCT01434927|Procedure|Unsedated colonoscopy|Patients were offered to undergo unsedated procedure. Their demographics and clinical data were recorded
1704104|NCT01434914|Drug|octenisept®|Cutaneous solution
1704105|NCT01434914|Drug|Placebo|Cutaneous use
1704106|NCT01434901|Drug|Placebo|A placebo will be taken by mouth 1 hour before ingestion of a mixed meal.
1704107|NCT01434901|Drug|Bethanechol (25 mg)|25 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
1704108|NCT01434901|Drug|Bethanechol (50 mg)|50 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
1704109|NCT01434901|Drug|Bethanechol (100 mg)|100 mg of Bethanechol will be taken by mouth 1 hour before ingestion of a mixed meal
1704110|NCT01434888|Drug|Preservative free tafluprost 0.0015% eye drops|Preservative free tafluprost eye drops will be administered once daily at 09:00 into both eyes for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
1704111|NCT01434888|Drug|Preservative free timolol 0.5% eye drops|Preservative free timolol eye drops will be administered into both eyes twice daily at 9:00 and 21:00 for seven days
1704112|NCT01434888|Drug|Preservative free FDC of tafluprost 0.0015% and timolol 0.5% eye drops|Preservative free fixed-dose combination eye drops will be administered into both eyes once daily at 9:00 for seven days. For masking purposes vehicle eye drops will be administered in the evening at 21:00.
1704113|NCT01434862|Drug|Closed loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
1704114|NCT01434862|Device|Closed loop without pramlintide|This visit will assess how well the closed loop system works without the pramlintide.
1704115|NCT01434862|Drug|Open loop with pramlintide|Dose of pramlintide will be titrated based on subject's current prescribed dose. The target dose is 60 mcq three times daily.
1704116|NCT01434849|Drug|topical 0.5% Timolol maleate|topical 0.5% Timolol aqueous solution, 1-2 drops to cover the hemangioma, twice daily
1704117|NCT01434849|Drug|Control (placebo) group|Aqueous placebo, 1-2 drops to cover the hemangioma, twice daily
1704118|NCT01434836|Other|active tDCS and working memory training|This group will receive 2.0 mA anodal DC stimulation over the left DLPFC and cathodal stimulation over the right DLPFC. During the stimulation, this group will be trained on working memory processes. Sessions will be scheduled daily for two consecutive weeks.
1704119|NCT01434836|Other|sham tDCS and working memory training|This group will receive sham stimulation (e.g., identical stimulation set-up but no electric current is sent through the electrodes). Patients however receive the real working memory training, daily, for two weeks.
1704156|NCT01434472|Drug|Cyclosporine|Given PO
1704157|NCT01434472|Drug|Fludarabine Phosphate|Given IV
1704120|NCT01434823|Other|Nocturnal coverage|"The investigators will randomize, by week, nocturnal coverage. During the intervention weeks, intensivists will be in the MICU from 7pm until 7am.
For the Intensivist Sleep and Work sub-study:
Measurements of Daytime Intensivist work hours, sleep, and attention will be measured with actigraphy, PVT, Sleep and Work Diaries, and Surveys. Results will be compared between periods with standard staffing to periods with overnight intensivist coverage."
1704123|NCT01434745|Drug|Simvastatin|Simvastatin will be administered as a powder mixed with lactose at the dose of 0.5mg/kg/day
1704124|NCT01434745|Dietary Supplement|Lactose|Lactose will be administered in a capsule formula.
1704127|NCT01434706|Other|Nucleic Acid Amplification Testing|The Gen-Probe Transcription-Mediated Amplification (TMA) technology exponentially amplifies captured HIV-1 and HCV RNA in blood samples. The Gen-Probe system is available in two commercially available FDA approved products; 1) the Procleix assay is a multiplex system that is used to screen the blood supply for HIV and HCV. This assay will allow the simultaneous detection of all known HIV-1 subtypes with sensitivities designed to reduce the window period of false negative results from standard HIV antibody testing (EIA), while maintaining the ability to discriminate positive from negative specimens, even at very low copy numbers (Giachetti, Linnen et al., 2002).
1704128|NCT01434693|Biological|Trichuris suis ova|single dose
1704129|NCT01434693|Other|Placebo|
1704130|NCT01434680|Biological|MenC-CRM LIQ|One dose of MenC-CRM vaccine, liquid formulation
1704131|NCT01434680|Biological|MenC-CRM ROS|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Rosia, Italy.
1704132|NCT01434680|Biological|MenC-CRM EMV|One dose of MenC-CRM vaccine, lyophilized formulation produced with drug substance manufactured at Emeryville, USA.
1704133|NCT01434667|Behavioral|APOE genotype disclosure and Alzheimer's disease risk disclosure|Subjects with MCI will learn their own APOE genotype and a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
1704134|NCT01434667|Behavioral|Alzheimer's disease risk disclosure|Subjects with MCI will learn a three-year numerical risk estimate for the chance of progressing to dementia of the Alzheimer's type.
1704135|NCT01434641|Other|low-dose stress MPI SPECT|novel low-dose rest/high-dose Tc-99m sestamibi SPECT protocol with wide beam reconstruction SPECT processing
1704136|NCT01434628|Device|PrePex™ device|PrePex™ device for adult male circumcision. The PrePex™ device facilitates adult male circumcision that is bloodless with no anesthesia and no sutures
1704137|NCT01434615|Device|CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) and receive CRT-P or CRT-D device
1704138|NCT01434615|Other|No-CRT|Patients who meet CRT device implantation guidelines (i.e., meet CRT indication and on optimal medical therapy) but who do not get a CRT-P or CRT-D device implanted
1956116|NCT02960022|Drug|enzalutamide|Subjects will receive enzalutamide orally once daily at the same time each day.
1704142|NCT01434576|Biological|HGS1025|2 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
1704143|NCT01434576|Biological|HGS1025|10 mg/kg of HGS1025 administered by IV infusion on Day 0, 14, 28 and 56, and then every 28 days thereafter if patient achieves clinical response
1704144|NCT01434576|Drug|Placebo|Placebo administered by IV infusion on Day 0, 14, 28 and 56. Subjects receiving placebo during the first 8 weeks of treatment will be given the option to receive HGS1025 10 mg/kg in the continuation phase of the study.
1704145|NCT01434550|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Everyone who takes part in this study will receive SBRT. After making an individual radiation plan for each participant, they will receive 5 days of radiation to the pancreas. Participants will have follow-up visits with blood tests one month after the end of SBRT and then every 3 months for 3 years. They will also have CT scans (chest and pancreas) and FDG PET/CT (body) at 1 month and then at 3, 6, 9 and 12 months.
1704146|NCT01434550|Radiation|Tissue, Blood, Research Imaging (TBRI)|"Post-SBRT procedures (day 1, 3, 5 of SBRT, and 4 weeks after) A) Endoscopic or CT guided biopsy of treated pancreatic cancer to assess
Necrosis/apoptosis
Lymphocyte infiltrate and antigen presenting cells B) Imaging to evaluate cell death (day 1, 3, 5 of SBRT, and 4 weeks after)
1. Aposense-PET imaging"
1704148|NCT01434511|Biological|OBI-1|intravenous infusion, up to every 2-3 hours for the first 24 hours of treatment
1704149|NCT01434498|Drug|GS-5885 tablet|GS-5885 tablet, 90 mg, QD
1704150|NCT01434498|Drug|GS-9451 tablet|GS-9451 tablet, 200 mg QD
1704151|NCT01434498|Drug|tegobuvir capsule|tegobuvir capsule, 30 mg BID
1704152|NCT01434498|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
1704153|NCT01434498|Drug|placebo matching ribavirin tablet|placebo matching ribavirin tablet, BID
1704154|NCT01434498|Device|placebo matching tegobuvir capsule|placebo matching tegobuvir capsule, BID
1704158|NCT01434472|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
1763619|NCT00312104|Drug|insulin aspart|
1704161|NCT01434472|Biological|Rituximab|Given IV prior to yttrium Y 90 ibritumomab tiuxetan
1704162|NCT01434472|Radiation|Total-Body Irradiation|Undergo TBI
1704163|NCT01434472|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
1704164|NCT01434459|Drug|Gemcitabine with TheraSphere|Gemcitabine dose will be escalated and combined with therasphere.
1704165|NCT01434446|Behavioral|Sound stimulation|Listening to sound stimuli at the lowest audible level.
1704166|NCT01434420|Genetic|BRCA1 BRCA2 PTEN PALB2 mutation|detection of BRCA1 BRCA2 PTEN PALB2 mutation
1704167|NCT01434407|Other|Dietary meal intervention|Test meals with different AGE content made by different cooking methods
1704168|NCT01434394|Drug|Neo-adjuvant Erbitux-based chemotherapy|"Name/Substance: Erbitux Formulation: 2 mg/ml or 5 mg/ml Dose: 400 mg/m^2 initial, and then 250 mg/m^2 weekly Route: Intravenous infusion Frequency & treatment mode: Weekly Duration: 6 weeks
Name/Substance: Docetaxel Formulation: Liquid (20 mg/2 ml) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)
Name/Substance: Cisplatin Formulation: Powder (30 mg) Dose: 75 mg/m^2 Route: Intravenous infusion Frequency & treatment mode: Day 1, every 3 weeks Duration: 2 cycles (6 weeks)"
1704169|NCT01434381|Biological|Pfs25-EPA/Alhydrogel|
1956117|NCT02960022|Drug|abiraterone acetate|Subjects enrolling from study 9785-CL-0011 will receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
1956118|NCT02960022|Drug|prednisone|Subjects enrolling from study 9785-CL-0011 will receive abiraterone acetate once daily and prednisone twice daily, in addition to enzalutamide
1704172|NCT01434342|Drug|Nicotine Replacement Patch|Study participants will receive a baseline assessment after they consent to participate and before randomization. The intervention period will last 12 weeks (approximately 1 week for the in-office intervention and 12 weeks for all components of the Quitline intervention- telephone counseling and habitrol patches). Follow-up assessments will be administered at 3, 6, 12, & 24 weeks after the date of the in-person intervention (for Quitline Intervention group) or the provision of the physician letter (for the Usual Care Plus group).
1704173|NCT01434329|Genetic|DNA methylation analysis|
1704174|NCT01434329|Genetic|gene expression analysis|
1704175|NCT01434329|Genetic|microarray analysis|
1704176|NCT01434329|Other|laboratory biomarker analysis|
1704177|NCT01434329|Other|medical chart review|
1704178|NCT01434316|Drug|Dinaciclib|Given IV
1704179|NCT01434316|Other|Laboratory Biomarker Analysis|Correlative studies
1704180|NCT01434316|Other|Pharmacological Study|Correlative studies
1704181|NCT01434316|Drug|Veliparib|Given PO
1704187|NCT01434277|Other|Eye Drops with Experimental Preservative|Glycerin, Hypromellose, Polyethylene glycol 400 with experimental preservative PQ-42
1704188|NCT01434264|Procedure|Energy healing|"Healer-Ringen, a Danish national association of healers, selects healers with an educational background as required by the Registry of Alternative Practitioners (RAB) and have rooms reserved for the healing practice. The treatment takes place in the clinic of the healer and is not restricted in respect to what form of energy healing that shall be used, provided that it is based on the idea of the healer providing some kind of energy by the hands to the participant. Conversation as usual is accepted, but no other form of therapy may be provided. The intervention consists of four sessions over a period of two months, distributed as decided by each participant-healer pair."
1704189|NCT01434251|Other|Anti-hypotensive treatment|Hypotension is managed using a variety of treatment options. Options include: fluid bolus(es), dopamine, dobutamine, hydrocortisone and epinephrine.
1704190|NCT01434238|Other|Counseling and nutrition supplement|24-week intervention that includes a) a daily ration of fortified lipid-based nutrient supplement and b) nutrition counseling delivered through biweekly group and individualized sessions. Dietary supplement is a locally- produced lipid-based nutrient spread (Meds and Foods for Kid, Cap Haitian, Haiti) that in a 65g daily ration provides 345 kcal energy and single allowance of key micronutrients for the 6-12 month age group.
1704191|NCT01434225|Drug|Bumetanide|Bumetanide - Standard Phenobarbital plus either 0.05 mg/kg,0.1 mg/kg, 0.2 mg/kg, or 0.3 mg/kg of bumetanide as determined by the the dose escalation design Maximum dose allowed is 0.3mg/kg given up to 4 times at 12 hourly intervals (total of 1.2mg/kg).
1704192|NCT01434212|Drug|Interferon Alfa-2b, Ribavirin|"Interferon:dosage,5 million units/person;frequency,every other day (qod);duration,48 weeks;Subcutaneous injection.
Ribavirin: dosage,15mg/kg/day;frequency,three times a day (t.i.d);duration,48 weeks;take orally."
1704193|NCT01434199|Procedure|UPD guidance|A real time, three-dimensional image and position of the colonoscope would be provided to the endoscopist during the procedure.
1704194|NCT01434186|Drug|Placebo matching with Saxagliptin|Tablet, Oral, 0.0 mg, Daily, Day 1 through week 52
1704195|NCT01434186|Drug|Metformin IR|Tablet, Oral, 1000 mg -2000 mg, Daily , Day 1 through week 52
1704196|NCT01434186|Drug|Metformin XR|Tablet, Oral, 1000 mg -2000 mg, Daily, Day 1 through week 52
1704197|NCT01434186|Drug|Saxagliptin|Saxagliptin Tablet, 2.5 mg, or Saxagliptin Tablet, 5 mg, (based on subject's weight)
1704198|NCT01434173|Drug|Moxifloxacin (Avelox, BAY12-8039)|Eligible patients who are new users of moxifloxacin during the study period. A new user is defined as a person who has a first recorded dispensing of moxifloxacin during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days
1704199|NCT01434173|Drug|Amoxicillin, Amoxicillin plus clavulanic acid, Cefuroxime, Clarithromycin, Doxycycline, Levofloxacin, Telithromycin|Eligible patients who are new users of one of the other study antimicrobials (amoxicillin, amoxicillin plus clavulanic acid, cefuroxime, clarithromycin, doxycycline, levofloxacin, or telithromycin) during the study period. A new user is defined as a person who has a first recorded dispensing of a study a study antimicrobial during the study period and who has not had a previous recorded dispensing for any of the study antimicrobials during the previous 180 days.
1704200|NCT01434160|Drug|Skyla (Levonorgestrel, BAY86-5028)|Levonorgestrel intrauterine contraceptive system (LCS12) insertion into the uterus at insertion visit 2 with the study treatment of 12 months. An optional follow up phase up to 3 years will be offered for all subjects completing 12 month treatment time.
1763620|NCT00312117|Drug|Sodium bicarbonate|
1704201|NCT01434147|Drug|preoperative induction chemotherapy in combination with bevacizumab followed by combined radiochemotherapy with capecitabine|Therapy start: Capecitabine 1000mg/ m² bid during 14 days(d1-14), oxaliplatin 130mg/m² and Bevacizumab 7.5mg/kg body weight d1, repetition day 22 and 43 (3 cycles) Radiotherapy: Followed by 5 x 5 days 1.8 Gy after 1 week of concluded 3rd cycle of induction chemotherapy Chemotherapy: Capecitabine 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
1704202|NCT01434134|Drug|Metoprolol|Tablet, target dose 100 mg once daily
1704203|NCT01434134|Drug|Placebo|Tablet, target dose 100 mg once daily
1704204|NCT01434134|Drug|Candesartan|Tablet, target dose 32 mg once daily
1704205|NCT01434134|Drug|Placebo|Tablet, 32 mg once daily
1704206|NCT01434121|Drug|Ascorbic Acid|The infusion of either a high dose of ascorbic acid, low dose ascorbic acid, or placebo
1704207|NCT01434121|Drug|Placebo|
1704208|NCT01434108|Drug|Ornithine-phenylacetate|"Phase A: Open-label scalating dose of OP. Treatment will be initiated at 1/3 of the final dose and will be scalated every 12 hours up to the full dose, except if there are problems of tolerance. Duration of the infusion 5 days.
Phase B: Comparative study of experimental drug vs placebo for 5 days OP (OCR-002) at a dose of 10 g diluted in 150 ml of water for injection administered as a continuous i.v. infusion for 24 hours (8.3 ml/h)during 5 days."
1704209|NCT01434095|Procedure|half-dose photodynamic therapy|photodynamic therapy (PDT) was performed using 3 mg/m2 body surface area of verteporfin (Visudyne, Novartis AG, Bülach, Switzerland) which is one-half the conventional dose of verteporfin. The verteporfin was infused over a 10 minute period followed by the delivery of 50 J/cm2 from a 689-nm laser system (Carl Zeiss, Dublin, CA) over an 83-second exposure time.
1704210|NCT01434082|Behavioral|comparison of types of sleep disordered breathing|comparison of types of sleep disordered breathing (primary snoring, upper airway resistance syndrome, obstructive sleep apnea) in children with and without arthritis.
1704211|NCT01434069|Drug|SOM230C LAR|Participants will be given one LAR dose injected into the muscle of the buttocks by a study nurse about once every 28 days until unacceptable toxicity or progression of the disease.
1704212|NCT01434069|Drug|FOLFIRI Infusion|Standard therapy of FOLFIRI
1704213|NCT01434030|Behavioral|Focus Group|Focus group methodology was chosen to obtain qualitative and quantitative data on participants' desire to use glucose advisory systems to manage their diabetes, their concerns about and desired features and functions of these systems, and their perceived confidence with behavioral event recording. At the outset of each interview, the personalized glucose advisory system (PGASystem) was described to participants as a system composed of a continuous glucose monitor (CGM) device and insulin pump, into which they would input daily information about their insulin, food, and physical activity. The system would then use their data to create personalized algorithms and advice about various aspects of their diabetes management, such as suggestions regarding bolus and basal rate dosing. The interview consisted of open-ended, multiple choice, and dichotomous questions.
1704214|NCT01434017|Drug|Dexamethasone|Patients will receive dexamethasone 250 mcg/kg just after induction of anesthesia.
1704215|NCT01434017|Drug|Dexamethasone and droperidol|Patients will receive dexamethasone 250 mcg/kg + droperidol 10 mcg/kg just after induction of anesthesia.
1704216|NCT01434017|Drug|Dexamethasone and Ondansetron|Patients will receive dexamethasone 250 mcg/kg + ondansetron 150 mcg/kg just after induction of anesthesia.
1704217|NCT01434004|Behavioral|Lifestyle counseling|"Diet component: focus on increasing intake of whole grains, soybeans, soybean products, other beans, and vegetables.
Physical Activity: encourage completion of morning exercise sessions. Mindfulness Stress Reduction: training in mindfulness meditation, including dealing with intensive physical symptoms and difficult emotional situations."
1704218|NCT01433991|Drug|E7050 plus lenvatinib|Dose escalation will begin at low doses of both E7050 and lenvatinib, then gradually increase in future cohorts until a recommended combination dose is identified. This recommended dose will be used to treat patients with Glioblastoma and Melanoma in later groups in this study.
1704219|NCT01433991|Drug|lenvatinib plus E7050|The recommended dose for the combination of E7050 plus lenvatinib determined from the Dose escalation phase will be given to subjects to confirm it as the MTD. This recommended dose will be used to treat patients with Glioblastoma and Melanoma in later groups in this study.
1704220|NCT01433991|Drug|E7050 plus lenvatinib or lenvatinib alone plus E7050 add-on therapy|Phase 2 Cohort 1 Arm A: E7050 will be taken once daily for 28 day cycles starting C1D1 in combination with lenvatinib at Recommended phase 2 (RP2) dose Arm B: E7050 at RP2 dose will be added on to single agent lenvatinib at time of disease progression.
1704221|NCT01433991|Drug|E7050 plus lenvatinib|"Phase 2 Cohort 2:
Arm C: E7050 will be taken once daily for 28 day cycles starting C1D1 in combination with lenvatinib at Recommended phase 2 (RP2) dose"
1704222|NCT01433991|Drug|E7050|Phase 2 Cohort 2: Arm D: E7050 will be taken alone at 400 mg daily for 28 day cycles.
1704223|NCT01433978|Drug|Eltrombopag|
1704224|NCT01433978|Drug|Avatrombopag|
1704225|NCT01433965|Drug|Lenalidomide|Lenalidomide will be taken orally once a day for 21 days continuously in 28 day cycles. The dose of the lenalidomide administered to each patient will be based on the group that the patient is enrolled. The dose cycles will be 21 days of a 28 day cycle.
1704226|NCT01433952|Dietary Supplement|Thiamine|Vitamin B1
1704227|NCT01433952|Dietary Supplement|Placebo|Placebo
1704228|NCT01433913|Drug|metformin hydrochloride|Given PO
1704229|NCT01433913|Other|placebo|Given PO
1704230|NCT01433913|Other|laboratory biomarker analysis|Correlative studies
1704231|NCT01433900|Drug|Tafluprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
1704232|NCT01433900|Drug|Latanoprost|1 drop of tafluprost to eligible eye(s) once daily (at 9 pm)
1704233|NCT01433887|Drug|48-weeks course|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
1704234|NCT01433887|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
1704235|NCT01433887|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
1704236|NCT01433887|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
1704301|NCT01433380|Drug|PF-05175157|One single dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM.
1704474|NCT01431950|Drug|albuterol/salbutamol|Provided as rescue relief of asthma symptoms
1704237|NCT01433874|Procedure|Pulmonary recruitment maneuver|A pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cmH2O. The anesthesiologist held the fifth positive pressure inflation for approximately 5 seconds.
1704238|NCT01433874|Procedure|Intraperitoneal normal saline infusion|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. We will leave the fluid in the abdominal cavity
1704239|NCT01433874|Procedure|combined group|The upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500cc. Later, a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure oof 60 cmH2O.
1704240|NCT01433874|Procedure|Control group|Co2 was removed by passive exsufflation through the port site.
1704241|NCT01433861|Procedure|Laparoscopy-assisted gastrectomy|Laparoscopy-assisted proximal gastrectomy versus Laparoscopy-assisted total gastrectomy
1704242|NCT01433835|Drug|MBX-400|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
1704243|NCT01433835|Other|Placebo|Capsule(s) for oral administration as a single dose. Planned doses include: 35, 100, 350, 700, 1000 and 1350 mg.
1704244|NCT01433770|Drug|Amevive|Alefacept 15mg subcutaneous; once a week for 12 weeks
1704245|NCT01433757|Drug|Ampicillin|Ampicillin will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of Ampicillin will be given to the patient, to be taken in the same manner as described above.
1704246|NCT01433757|Drug|Sugar pill|The sugar pill will be given in capsule form. Dosage will be 2 mg daily for adults and 1 mg daily for children. One capsule will be taken each day for 28 consecutive days. After the first 28 days, there will be a 7 day 'washout' period during which no capsules are taken. Following the 'washout' period, another 28-day supply of the sugar pill will be given to the patient, to be taken in the same manner as described above.
1704247|NCT01433744|Procedure|Non-surgical periodontal treatment|Patients included in the test group were submitted to a non-surgical periodontal treatment protocol, which consisted of oral hygiene orientation and motivation followed by mechanical plaque control involving scaling and root planning using Gracey curets (Hu-Friedy Manufacturing, Chicago, IL, USA) and ultrasonic instrumentation (Cavitron Ultrasonics, Long Island City, NY, USA), under local anesthesia (Mepivacaine 2% with epinephrine 1:100000). The treatment was performed in one or two sessions depending on the extension of the patient's periodontal condition. Patients that presented teeth unreasonable to treat due to advanced periodontitis, or any other condition were extracted under local anesthesia.
1704248|NCT01433731|Drug|placebo for SHAPE (SHP-141)|topical gelled solution
1704249|NCT01433731|Drug|SHAPE (SHP-141) 0.1% BID|topical gelled solution
1704250|NCT01433731|Drug|SHAPE (SHP-141) 0.5% BID|topical gelled solution
1704251|NCT01433731|Drug|SHAPE (SHP-141) 1.0% BID|topical gelled solution
1704252|NCT01433718|Procedure|Neuromuscular and Resistance Training|1 hour/session, 3 sessions/week, 6 weeks
1704253|NCT01433705|Other|Rb-82 Pet scans|Intravenous administration of Rb-82. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For Rb-82 images, 40 mCi (millicuries are a measurement of radioactivity) will be used. Acquisition time for both rest and stress studies should take about 30 min.
1704254|NCT01433705|Other|F-18 FDG Pet scans|"Volunteers undergoing the F-18 FDG protocols will undergo: (1) glucose loading protocol for viability protocol imaging with the hyperinsulinemic euglycemic clamp according to standard procedures in our laboratory, and (2) inflammation protocol imaging using a high fat preparatory diet and three sub-therapeutic heparin doses (10 units / kg each) according to standard laboratory procedure. When metabolically prepared with the viability protocol and the inflammation protocol (two separate days), 10 mCi (millicuries) of F-18 FDG will be administered IV per FDG protocols, via heparin lock. 40-60 minutes after FDG injections PET imaging will be performed according to standard clinical imaging protocol."
1704255|NCT01433705|Other|N-13 ammonia Pet scans|Intravenous administration of N-13. Images will be taken according to standard clinical imaging protocol and reviewed. Patient will be connected to an EKG machine to monitor the heart. Blood pressure will be monitored as well. For N-13 ammonia images, 20 mCi (millicuries) will be used. Acquisition time for both rest and stress studies should take about 30 min.
1704256|NCT01433705|Drug|Regadenoson|Regadenoson is used as a stressor; but not to study its effects.
1704257|NCT01433692|Behavioral|Brief Intervention|CANABIC is a quantitative study to validate use of BI with cannabis users: a randomized controlled trial, clustered study, comparing an intervention group (IG) and a control group (CG). The intervention is the achievement of the IB during a specific consultation. The outcome is the consumption of cannabic (Number of joints / month).
1704258|NCT01433679|Behavioral|Zamzee Intervention|The Zamzee intervention is designed to motivate middle school-aged children to increase their rates of moderate to vigorous physical activity (MVPA) by providing rewards based on amount and duration of physical activity. Rewards include gift cards to retail stores, donations to charity, small tangible goods, and customization of their cartoon-like avatars on the website.
1704259|NCT01433666|Drug|roflumilast (EU: Daxas, USA: Daliresp)|Acute intervention: 1 time each dose on different days. Capsulated
1704260|NCT01433666|Drug|Placebo|Acute intervention: single administration, capsulated form.
1704261|NCT01433666|Drug|roflumilast|Acute intervention: 1 time each dose (100ug, 300ug, 1000ug, placebo). Capsulated.
1704262|NCT01433653|Behavioral|Cognitive Behavioral Therapy for Complicated Grief|Manualized CBT with 25 sessions, once a week. Key elements are exposition and cognitive restructuring.
1704263|NCT01433627|Other|trans-radial and short-term bivalirudin|trans-radial intervention followed by Bivalirudin given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be stopped.
1704293|NCT01433432|Drug|80 mg DR-6MP|All subjects from the original study, Protocol C2/13/DR-6MP-02, whether they received test drug for 12 weeks or Purinethol for 12 weeks, will now receive an additional 12 weeks of 80 mg DR-6MP drug to be administered as 2 x 40 mg DR-6MP test tablets, once nightly, before bedtime.
1704264|NCT01433627|Other|trans-radial and long-term bivalirudin infusion|"Trans-radial intervention: will be performed according to institutional guidelines and established local practice.
Bivalirudin: given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
1704265|NCT01433627|Other|trans-radial and standard of care pharmacology|Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
1704266|NCT01433627|Other|Trans-femoral and Short-term bivalirudin|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.
Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI."
1704267|NCT01433627|Other|trans-femoral and long-term bivalirudin infusion|"Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice.
Bivalirudin will be given immediately upon enrolment as bolus of 0.75 mg/kg followed immediately by an infusion of 1.75 mg/kg/h. This infusion should be run continuously until completion of PCI at which time the infusion should be reduced to a dose of 0.25 mg/kg/h for at least 6 hours. An optional higher-dose infusion of 1.75 mg/kg/h is also permitted for up to 4 hours in the prolonged infusion arm but prohibited in the short bivalirudin group."
1704268|NCT01433627|Other|trans-femoral and standard of care pharmacology|Trans-femoral intervention: will be performed according to institutional guidelines and established local practice. Access closure devices are allowed as per local practice. Unfractionated heparin (UFH) (100 IU/kg with no glycoprotein IIb/IIIa inhibitor (GPI) and 60 IU/kg with a GPI); +/- routine or bail out eptifibatide (two 180 μg /kg boluses with a 10 minute interval followed by an infusion of 2.0 μg /kg/min for 72-96 hours) or tirofiban (25 μg/kg followed by an infusion of 0.15 μg/kg/min for 18 to 24 hours) or abciximab (bolus of 0.25 mg/kg followed by an infusion of 0.125 μg/kg/min for 12-24 hours (maximum dose, 10 μg/min).
1704272|NCT01433601|Behavioral|Enhanced Treatment Support (ETS)|"An internal supporter - family member or other person trusted by the patient is trained to fill in a checklist whether the drugs has been taken and if this was observed. Anexternal supporter - a peer selected PLWHA visit the patient twice weekly the first two months. The external supporter follows a checklist and ask about general well being, psychological problems or adverse drugs reactions as well as go through the adherence since last visit, using the internal supporter checklist. If the adherence is good, the number of visits are decreased to once weekly after two months, if not, the number of visits are intensified. If there are any symptoms of opportunistic infections, immunological reconstruction syndrome or adverse drug reactions the patient are refered for medical checkup."
1704273|NCT01433588|Device|The Calmer|This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.
1704274|NCT01433588|Other|Standard of Care|Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
1704275|NCT01433575|Drug|RO4917838|10 mg single oral dose
1704276|NCT01433575|Drug|RO4917838|20 mg single oral dose
1704277|NCT01433562|Drug|DLBS1425|DLBS1425 capsule 150 mg thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
1704278|NCT01433562|Drug|Placebo DLBS1425|Placebo DLBS1425 capsule thrice daily for 3 cycles @ 21 days. CAF (Cyclophosphamide (500 mg/m2 iv), Doxorubicin 50 mg/m2 iv, Fluorouracil 500 mg/m2 iv) or CEF (Cyclophosphamide 500 mg/m2 iv, Epirubicin 70 mg/m2 iv, Fluorouracil 500 mg/m2 iv) regimens on Day-1 of every cycle for the total of 3 cycles.
1704279|NCT01433549|Device|Lotrafilcon B|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
1704280|NCT01433549|Device|Senofilcon A|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily wear and extended (overnight) wear up to 6 nights.
1704281|NCT01433523|Drug|ALK HDM AIT Placebo|Oral lyophilisate, Placebo, to be administered sublingually once daily
1704282|NCT01433523|Drug|ALK HDM AIT 6 DU|Oral lyophilisate, 6 DU, to be administered sublingually once daily for 14-18 months.
1704283|NCT01433523|Drug|ALK HDM AIT 12 DU|Oral lyophilisate, 12 DU, to be administered sublingually once daily for 14-18 months.
1704284|NCT01433510|Drug|Grazax|1 tablet/day - pre and co-seasonal
1704285|NCT01433497|Drug|masitinib|6 mg/kg/day
1704286|NCT01433497|Drug|placebo|masitinib matching placebo
1704287|NCT01433484|Behavioral|Maintenance of Weight Loss--Control|As the maintenance of weight loss randomized trial does not begin until a year after the start of this study, the intervention and control conditions are not yet specified. This will occur before randomization and this section will be updated before the first participant is randomized.
1704288|NCT01433484|Behavioral|Maintenance of Weight Loss--Experimental|
1704289|NCT01433471|Drug|Trichuris suis ova|2,500 eggs by mouth every two weeks for 12 weeks
1704290|NCT01433458|Drug|RLX030A|RLX030 is administered as a continuous 24 hour infusion
1704294|NCT01433419|Drug|TAK-875|
1704295|NCT01433419|Drug|TAK-875|
1704296|NCT01433406|Drug|TAK-875|
1704297|NCT01433406|Drug|TAK-875|
1704302|NCT01433380|Drug|Placebo|One single dose of placebo will be administered as a powder-in-capsule in the fasting state in the AM.
1704303|NCT01433367|Device|CerPass® Total Disc Replacement|Single level cervical disc disease
1704304|NCT01433354|Drug|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths,25mg and 100 mg, identical in appearance, will be used.
1704305|NCT01433328|Drug|Lidocaine|Lidocaine
1704306|NCT01433328|Drug|Placebo|Placebo
1704307|NCT01433315|Behavioral|sleep restriction|restricted sleep
1704308|NCT01433302|Procedure|Punch Biopsy|5 mm punch biopsy specimens from the affected, lymphedematous limb will be obtained just prior to lymphatico-venular bypass and six (6) months after lymphatico-venular bypass. Punch biopsies will be obtained from the radial (lateral) aspect of the upper arm approximately 10cm above the olecranon process. Biopsy specimens will be collected from the contralateral (normal) arm at the exact same location.
1704309|NCT01433289|Drug|Polyphenon E|There will be three treatment arms, each consisting of 8 participants. Two participants in each study arm will be randomized to receive placebo. Dosing will be escalated sequentially contingent on the safety profile of previous doses. Safety data from all participants receiving Polyphenon® E in the preceding arm will be evaluated and considered acceptable prior to escalation to the next higher dose. PK analyses will be also performed as each arm is completed. It is necessary to confirm EGCG pharmacokinetics in the event that the primary outcome measure of virologic response is not observed for each arm. For each PK visit on Study Days 1 and 14, a total of 10 blood samples will be obtained per subject.
1704310|NCT01433276|Drug|Hyperosmolar sodium lactate|1st loading : Upto 2 liters of Ringer's lactate, followed by Totilac which was given 5 mL/kgBW/15 minutes, followed by maintenance 2 mL/kgBW/hour for 3 hours
1704311|NCT01433276|Drug|Ringer's lactate|1st loading : Upto 2 litres of Ringer's lactate, followed by 5 mL/kgBW/15 minutes,followed by maintenance : 2 mL/kgBW/hour for 3 hours
1704312|NCT01433263|Drug|BYM338 active drug|
1704313|NCT01433263|Drug|Placebo|
1704314|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
1704315|NCT01433250|Drug|AIN457|(10mg/kg i.v.).
1704316|NCT01433237|Genetic|RNA analysis|
1704317|NCT01433237|Genetic|gene expression analysis|
1704318|NCT01433237|Other|laboratory biomarker analysis|
1704319|NCT01433224|Genetic|DNA methylation analysis|
1704320|NCT01433224|Genetic|RNA analysis|
1704321|NCT01433224|Genetic|mutation analysis|
1704322|NCT01433224|Genetic|nucleic acid sequencing|
1704323|NCT01433224|Genetic|polymerase chain reaction|
1704324|NCT01433224|Genetic|polymorphism analysis|
1704325|NCT01433224|Other|laboratory biomarker analysis|
1704326|NCT01433224|Other|medical chart review|
1704327|NCT01433198|Other|Aquatic training|Aquatic training during a 6 weeks program (15 to 18 sessions of 1 hour)
1704328|NCT01433185|Other|Text message|Text messages sent to women before and after delivery
1704329|NCT01433172|Biological|Phase I - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.
Phase I: Participants receive the GM.CD40L.CCL21 vaccine in a standard 3+3 design."
1704330|NCT01433172|Biological|Phase II - GM.CD40L cells Vaccinations|Patients randomized to Arm A will receive vaccinations on 3 occasions, at 2 week intervals. 7.5 X 10^6 irradiated H1944 tumor cells, 7.5 X 10^6 irradiated H2122 cells, and containing 15 X 10^6 GM.CD40L cells (1.1 mL) will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2 weeks after vaccine 3. If patients show no sign of disease progression, patients will then be vaccinated at 4-week intervals.
1704331|NCT01433172|Biological|Phase II - GM.CD40L.CCL21 Vaccinations|"This is a dual-agent, Phase I study with an expansion of each group at the recommended Phase II dose. Participants are entered in cohorts of 3 at the first dose level. Doses are not escalated over the course of treatment of an individual patient.
Phase II: Participants are randomized to one of the 2 arms (ratio 1:1): GM.CD40L versus GM.CD40L.CCL21. Patients in Arm B will receive vaccines at the same dose and schedule as described for patients in Arm A. In addition, their vaccine will include H1944 cells expressing CCL21. Note for patients on Arms A and B: the use of steroid medication is to be avoided for 4 weeks before to the initiation of vaccine therapy and during the vaccine treatment period."
1704332|NCT01433159|Drug|HP011-101 (Xenaderm Ointment)|The test article will be applied at approximately the thickness of a dime twice daily, or more often if removed incidental to cleansing for 14 days treatment with HP011 101.
1704333|NCT01433159|Drug|Standard Care|No restrictions are placed on the nature of this care, except that it conform to the typical practices in place during the prior 3 months and that the regimen does not include the use of a BCT ointment (ointments containing Balsam Peru, castor oil and trypsin).
1704334|NCT01433133|Biological|implantation|subcutaneous implantation of autologous dermis implant treated ex vivo with genetic vector carrying the gene for interferon alfa 2b
1704335|NCT01433120|Dietary Supplement|Lactobacillus paracasei ssp paracasei F19|10^10 CFU of Lactobacillus paracasei F19 (dissolved in a glass of water once per day)
1704336|NCT01433120|Dietary Supplement|Flax seed fibres|10 grams of flax seed fibres per day (baked into two breakfast buns)
1704337|NCT01433120|Dietary Supplement|Maltodextrin (Placebo)|Maltodextrin is dissolved in a glas of water once per day
1704338|NCT01433107|Drug|Terbinafine|1% single application
1704339|NCT01433107|Drug|Terbinafine Placebo|single application
1704340|NCT01433094|Behavioral|Falloon et al. Psychoeducation Program|The intervention aims to improve communication and problem-solving abilities in patients and their families by sessions focused on: assessment of the individual's and the family's strengths, weaknesses, and goals; education about schizophrenia and treatment; communication skills training; problem-solving training; and special problems (Falloon et al. 1985). Treatment sessions are provided on a weekly basis for months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
1704395|NCT01432561|Drug|Cysteamine bitartrate|500 mg total, single dose taken orally on visits 2, 3 & 4 which must occur within a 14 day period.
1704475|NCT01431937|Drug|GSK2018682|Active Drug
1704341|NCT01433094|Behavioral|Generic Treatment|The comparator is a treatment with generic informative prospect on the disorders and with the same frequencies as the Intervention. Treatment sessions are provided on a weekly basis for 6 months (1 hour for each session) (groups of about 8-9 persons - patients and caregivers).
1704342|NCT01433081|Drug|Placebo infusion of .9 normal saline|administration of .9 normal saline
1704343|NCT01433081|Drug|administration of magnesium sulfate|administration of magnesium sulfate
1704344|NCT01433068|Device|NBTXR3|One intratumor implantation by injection
1704345|NCT01433055|Drug|Minocycline|"Minocycline Dosing:
Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day (minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
1704346|NCT01433055|Drug|Placebo|"Placebo Dosing:
Minocycline (Dynacin® or generic) will be available in 50, 75 and 100 mg capsules. There will be matched placebo-minocycline capsules for each minocycline capsule strength. During the first week subjects will receive one 50 mg capsule twice per day(minocycline 100 mg total or matching placebo) and during weeks 2-10 subjects will receive 2- 50 mg capsules twice per day If a subject should complain of any side effect, then the blind psychiatrist will be allowed to omit the next dose of study medication and then continue the subject on the optimal treatment dose. If, despite this intervention, the subject is still unable to tolerate the 200 mg/day dose, then the dose may be lowered to 150 mg to alleviate side effects and minimize attrition."
1704347|NCT01433042|Device|capsule endoscopy|capsule endoscopy procedure
1704348|NCT01433029|Other|Surgical Video Assessments|Rate performance of the surgeon/trainee in each CAB video performance (5 recorded procedures) using two rating scales, a checklist and the Global Rating Scale. Up to 38 different recorded procedures rated while on the study, each procedure lasting about 15 minutes.
1704349|NCT01433029|Other|Video Recording of CAB|Each video begins when dissection of a coronary artery has begun and ends when all manipulation of anastomosis is complete. At least 6 separate anastomoses will be recorded, or at least 2-3 procedures. A ProXennon Surgical Headlight Camera System (a small camera that is mounted in place directly over a high-intensity light that is worn on the head) records the performance of the coronary artery bypass (CAB) procedures.
1704350|NCT01433016|Drug|13C Sodium Octanoate|13C labeled Sodium Octanoate Substrate is provided in powder form in doses of 100mg for single breath test, and is dissolved in 150cc of tap water before ingestion. Duration of the observation after the drug ingestion is one hour.
1704351|NCT01433003|Procedure|Plasma Exchange|Plasma exchange is a blood purification technique that removes plasma from the blood and replaces it with donor plasma.
1704352|NCT01432990|Device|Robot gait training|Robotic gait training for 20 minute include preparing and rest time for 10 minute plus conventional physical therapy program for 30 minute, totally 60 minute per day for 5 working day per week.
1704353|NCT01432990|Other|control|Conventional physical therapy program for 60 minute per day for 5 working day per week.
1704354|NCT01432977|Drug|paracetamol /droperidol|
1704355|NCT01432977|Drug|paracetamol / ondansetron|
1704356|NCT01432964|Procedure|Orbital revision surgery|Surgical revisions were performed under general anaesthesia. The orbital floor was routinely exposed via a transconjunctival incision. In patients with involvement of the medial wall, a combined transconjunctival-transcaruncular approach was used. Herniated or incarcerated tissue was then complete repositioned. Stable borders around the bony defect in the orbital floor were exposed. The aluminium template was pre-bend and controlled in situ. Type and size of mesh were chosen and adjustments performed, as needed. Following the bending of the titanium mesh according to the template, it was inserted and fixed with 1.5mm screws. Alternatively the mesh could be preformed, using a sterilized skull model to shape and contour it to a normal orbit. Finally the eye bulb mobility was controlled using fine forceps (forced duction test) and the wound closed (Vicryl 5/0 rapid; optional).
1704357|NCT01432951|Drug|Enzastaurin|Administered orally
1704358|NCT01432938|Biological|dulaglutide|Administered subcutaneously
1704359|NCT01432938|Drug|Warfarin|Administered orally
1704360|NCT01432925|Procedure|surgical intervention on Buruli ulcer|Can the need for surgical intervention be avoided by delay of the decision on surgical intervention, comparing the need on surgical intervention from time points of week 8 and week 14 (number of weeks after start of antibiotic treatment with streptomycin/rifampicin).
1704361|NCT01432912|Behavioral|Physician Educational Seminar|Participating Physicians will attend an hour long seminar on smoking cessation counselling.
1704362|NCT01432886|Drug|E7389|Eribulin mesylate (iv) will be administered on Day 1 and Day 8 of each cycle (3 weeks as 1 cycle). Trastuzumab (iv) will be administered as weekly use or tri-weekly use. Trastuzumab will be administered immediately after eribulin mesylate administration when used concomitantly.
1704363|NCT01432873|Drug|Oral selenium|Drug: selenium tablet Oral selenium 1 Tab bid from day -6/-7 until discharge
1704364|NCT01432873|Drug|Oral placebo|Drug: Placebo Oral placebo 1 Tab bid from day -6/-7 until discharge
1704365|NCT01432860|Behavioral|In-person counseling|The design is a 3 [in-person training of patients and partners (PARTNER) vs. workbook training of patients and partners (WORKBOOK) vs. an assessment only group that receives education and treatment as usual care] X 7 [baseline, 4, 8, 12, 16, 20, and 24 month follow-up] study. Standard education of melanoma patients, which are to be performed with the study partner, includes a recommendation to check moles and mark ones to remember on a body map. All participants receive the same measures and will be recruited using the same procedures, thus, yielding equivalence across conditions. Pairs will observe how to use their skin check tools and be asked to demonstrate their competence in using them.
1704366|NCT01432860|Behavioral|Workbook|Participants will read a workbook and perform skills training exercises.
1704367|NCT01432860|Behavioral|Tablet Computer-Based Education|Participants will receive their education from an interactive app designed for a tablet computer.
1704396|NCT01432548|Procedure|ischemic preconditioning|Surgery with ischemic preconditioning in liver resection
1704476|NCT01431937|Drug|Placebo|Placebo
1704368|NCT01432834|Other|Laser in situ keratomileusis (LASIK)|"During LASIK treatments the Carriazo-Pendular microkeratome (SCHWIND eye-tech-solutions GmbH & Co.KG, Kleinostheim, Germany) with 130μm cutting head was used for the creation of the flap. The normal value of the negative pressure of the suction ring was between 600-620 mmHg and the velocity of the head movement was constant (3mm/sec). The hinge was created at the 12 o'clock position. The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol."
1704369|NCT01432834|Other|Photorefractive keratectomy (PRK)|"The same surgical procedure was applied to all PG participants that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 20-30 seconds and subsequent de-epithelialization by means of a hockey knife.The Allegretto Wave excimer laser (software version: 2.020 / WaveLight AG, Erlangen, Germany) was used for all ablations. Attempted ablations were modified according to the S001 Wellington nomogram for the wavefront optimised protocol. A soft therapeutic lens was applied until complete re-epithelialization of the cornea was detected."
1704370|NCT01432821|Other|Apomorphine (Experimental product)|"Dosage Form: Injection Dosage: 1 or 5 mg / kg
Route of administration: Subcutaneous
Duration of treatment: two injections of apomorphine followed by two injections of a placebo one week after or vice versa.
Two injections will be made by visiting during visits 2 and 3.
The study was conducted cross-over with two visits EEG recording, the order will be randomized injections:
Sequence A during visit 2 followed by sequence B during visit 3
or sequence B during visit 2"
1704371|NCT01432795|Device|Gliding aids for medical compression stockings|"Each subject tests devices:
3 gliding aids for stockings with closed tips
3 gliding aids for stockings with open tips
2 stocking butlers using
3 medical compression stockings with open tip, compression class 3 (36-46mmHg)
3 medical compression stockings w. closed tip, compression class 3 (36-46mmHg)
2 superimposed compression stockings class 1 (18 - 21 mmHg)"
1704372|NCT01432782|Drug|Placebo|Saline 4 ml
1704373|NCT01432782|Drug|Botulinum Toxin Type A|per-endoscopic injection of 100 U of botulinum toxin dissolved in 4 ml of saline
1704374|NCT01432769|Dietary Supplement|dietary supplement high in energy and protein|"patients in the standardized diet will receive extra 500 kcal from the dietary supplement"
1704375|NCT01432756|Behavioral|Let's Talk Worksite Parenting Program|The Let's Talk Worksite Parenting Program is designed for Xhosa-speaking and Afrikaans speaking parents (separate sessions) with 11- to 15-year-old children. The 5-session program meets weekly for 2 hours. The program will include instruction on parenting skills and will cover topics relevant to promoting adolescent sexual health, such as; parental involvement; adolescent sexual behavior; HIV; violence; and alcohol/substance use. Parent participants will receive weekly exercises to help them practice their new skills at home with their child.
1704376|NCT01432743|Procedure|NavX Fusion|Using NavX Fusion to guide catheter ablation
1704377|NCT01432743|Procedure|Cartomerge|Guidance of catheter ablation using Cartomerge guidance
1704378|NCT01432730|Drug|Gefapixant|Oral tablets, BID
1704379|NCT01432730|Drug|Placebo|Oral tablets, BID
1704380|NCT01432717|Biological|ACE-536|Subjects receive a total of 2 subcutaneous doses of ACE-536 on Day 1 and Day 15.
1704381|NCT01432717|Other|Placebo|Subjects receive a total of 2 subcutaneous doses of placebo on Day 1 and Day 15.
1704382|NCT01432704|Drug|colecalciferol|Once weekly peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) that contain 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D3 for a duration of 12 months
1704383|NCT01432691|Procedure|Hemi (hemialloplastik)|THA vs hemi
1704384|NCT01432665|Drug|Placebo|Solid Oral Dosage. Maximum every other day (on an as needed basis)
1704385|NCT01432665|Drug|Sildenafil|Solid Oral Dosage. Maximum every other day (on an as needed basis)
1704386|NCT01432665|Drug|Testosterone|Solid Oral Dosage. Maximum every other day (on an as needed basis)
1704387|NCT01432639|Other|Exercise-based cardiac rehabilitation program|The intervention consists of usual medical care (i.e., medicine prescription and counseling of lifestyle modifications) and an supervised outpatient aerobic exercise training, which will be performed 3 days per week for 8 weeks. Each exercise session include 10 min of warm up, 35 min of aerobic exercise (i.e., cycloergometer or treadmill) and 10 min of cool down. The exercise intensity will be calculated as 65- 75% of maximal heart rate achieved in the treadmill exercise testing. Individualized exercise prescription will be periodically adjusted. A perceived exertion scale will be used as an adjunctive intensity modulator. In addition, each patient will be encouraged to daily exercise outside the formal exercise program.
1704388|NCT01432626|Drug|I-123 radiolabeled metaiodobenzylguanidine cardiac imaging|All subjects will receive an intravenous injection of 10 mCi (370 MBq) of 123I-mIBG. A ±10% tolerance of the nominal dose will be allowed, thus yielding an acceptable dose range of 9 to 11 mCi (333 to 407 MBq). The investigational medicinal product will be administered in a volume of 5 mL (diluted using 0.9% sodium chloride as needed) and injected over 1 to 2 minutes. The patient will have planar and SPECT imaging performed after the dose is administered. This dosing and imaging procedure will be performed during the acute phase and after the patient has recovered cardiac function, approximately 6 weeks later. This means that each study subject will receive a total of 2 doses of I123-mIBG at 2 different time points.
1704389|NCT01432613|Procedure|MRI-oriented muscle biopsy|Orientation of muscle biopsy according to the MRI results
1704390|NCT01432600|Drug|Pomalidomide|Pomalidomide at 4 mg by mouth (PO) as outlined in the treatment arms.
1704391|NCT01432600|Drug|Dexamethasone|Dexamethasone at 40 mg (20 mg) PO as outlined in the treatment arms.
1704392|NCT01432600|Drug|Cyclophosphamide|"The dose escalation uses a standard 3x3 design: Ex: If none of the first 3 participants have a DLT, enter 3 participants at the next higher dose level. Once the maximum tolerated dose (MTD) of oral weekly cyclophosphamide in combination with pomalidomide and dexamethasone was determined, investigators proceeded with the second phase of the trial, a randomized phase II study comparing pomalidomide and dexamethasone with pomalidomide, dexamethasone and oral weekly cyclophosphamide delivered at the MTD determined in the phase I study."
1704393|NCT01432587|Drug|Diflunisal|Film-coated tablet, 250 mg twice daily, orally for approximately 2 years
1704394|NCT01432574|Biological|Gardasil|The First Shot: Given on the day participants joined the study (Visit 1). The Second Shot: Given about 2 months later (Visit 2). The Third Shot: Given about 6 months after the first (Visit 3).
1704398|NCT01432522|Drug|Epinephrine|"Intranasal epinephrine 5 mg /spray
Intramuscular epinephrine 0.3 mg
Intranasal saline spray"
1704399|NCT01432509|Other|Prediabetes screening and prospective follow-up over 5 years|"The study period per patient is 5 years. The planned schedule of the study is as follows :
Enrollment at visit V0 of subjects at high metabolic risk, based on a biological value (within the past 2 months) of moderate fasting hyperglycaemia (blood glucose ≥ 1,10 g/l and < 1,26 g/l) or fasting blood glucose ≥ 1 g/l and < 1,10 g/l with HbA1c ≥ 6,5%.
First biological sample (B0) within 1 month following V0 (measuring fasting blood glucose + glycated hemoglobin HbA1c + lipid profile + creatinemia + liver function; and establishment of a biological sample collection to identify biomarkers).
Annual follow-up for five years consisting in one blood sample (B1 to B5) measuring the same parameters as V0 + biological sample collection, and questionnaire on major health events or health events related to study procedures.
End of study phone call"
1704400|NCT01432496|Drug|Ropivacaine 150 mg|Nebulization of Ropivacaine 150 mg in the peritoneal cavity
1704401|NCT01432496|Drug|saline 15 ml|Nebulization of saline 15 ml in the peritoneal cavity
1704402|NCT01432483|Drug|Denileukin diftitox (ONTAK)|Given at a dose of 9 or 18mcg/kg/day by intravenous infusion over 30 to 60 minutes for 5 consecutive days every 21 days for 8 cycles.
1704403|NCT01432470|Drug|Oxytocin|Gel for intravaginal use, 600 IU once per day for 2 weeks followed by 600 IU twice a week for ten weeks
1704404|NCT01432470|Drug|Placebo|Gel for intravaginal use of identical appearance as active substance, once per day for two weeks followed by twice a week for ten weeks
1704405|NCT01432457|Drug|desvenlafaxine succinate sustained-release 50 mg/day|50 mg tablets of DVS SR taken orally once daily for 8 weeks; 1 week of placebo taper
1704406|NCT01432457|Drug|desvenlafaxine succinate sustained-release 100 mg/day|100 mg tablets of DVS SR taken orally once daily for 8 weeks (which includes 1 week of titration at 50 mg/day); 1 week of taper at 50 mg/day
1704407|NCT01432457|Drug|placebo|50 mg and 100 mg placebo matching tablets taken orally once daily for 8 weeks; 1 week of placebo taper
1704408|NCT01432444|Drug|Aripiprazole (Abilify®) IM Depot Injection|"400 mg IM depot injection every 26-30 days. Dosage may be adjusted at the investigator's discretion to 300 mg.
Number of injections: 6. Subjects have the option of entering the extension phase of the study and continuing with injections every 26-30 days until the drug is either commercially available, or December 2013."
1704409|NCT01432431|Procedure|spiritual therapy|Undergo palliative spiritual care
1704410|NCT01432431|Other|questionnaire administration|Ancillary studies
1704411|NCT01432431|Other|survey administration|Ancillary studies
1704412|NCT01432431|Other|counseling intervention|Undergo palliative spiritual care
1704413|NCT01432431|Other|psychosocial support for caregiver|Undergo palliative spiritual care
1704414|NCT01432431|Procedure|psychosocial assessment and care|Undergo palliative spiritual care
1704415|NCT01432418|Other|Wheelchair skills training program|A training program that uses methods based on the rehabilitation, wheelchair, and motor skills literature to teach wheelchair skills.
1704416|NCT01432405|Drug|Exenatide|Type 2 diabetic subjects will be randomized to receive exenatide 10 micrograms injected subcutaneously twice daily for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
1704417|NCT01432405|Drug|Pioglitazone|Type 2 diabetic subjects will be randomized to receive pioglitazone 45 mg daily orally for 12 months. Prior to randomization, all subjects will receive baseline measurements of fasting plasma glucose, plasma adipocytokines, Free Fatty Acids, insulin, plasma lipids, and HbA1c as well as measurement of liver fat content with magnetic resonance spectroscopy. All subjects will undergo repeat measurements of fasting plasma glucose, Free Fatty Acids, insulin and adipocytokines as well as hepatic fat content determination at the end of the 12 month treatment period.
1704418|NCT01432379|Biological|botulinum toxin Type A|155-195 U of botulinum toxin Type A administered intramuscularly in the face, head, and neck areas as directed by physician (approximately every 12 weeks) for 1 year.
1704419|NCT01432366|Other|SC anti-TNF|Subcutaneous (SC) anti-TNF
1704420|NCT01432353|Drug|DFRF4539A|multiple ascending doses
1704421|NCT01432340|Biological|Seasonal influenza vaccine|annual recommended Southern Hemisphere vaccine
1704422|NCT01432327|Device|SenseWear display|"Participants use the self-monitoring device (display) to aid behavior change via real-time lifestyle feedback targeting physical activity.
The display has a versatile design that allows it to be clipped to a shirt, bag or belt loop. The Display can help participants stay in sync with their daily goals."
1704423|NCT01432327|Device|Pedometer|Participants receive a pedometer to determine their daily amount of steps. Every day they write down their amount of steps in a step diary.
1704424|NCT01432327|Device|SenseWear Armband|Participants wear the SenseWear Armband for 4 weeks
1704425|NCT01432327|Behavioral|Personal Coaching|A weekly meeting with a Personal Coach to evaluate the physical activity patterns in daily life
1704426|NCT01432314|Other|Radiation therapy|"A. Started 1 week after entry. B. Equipment: linear accelerator using 6-15 MV photons (external beam equipment). Computerized treatment planning system will be used to determine the radiation fields and 3D dose distribution.
C. Target volume: include only the portal vein tumor thrombus and 2 cm margin into the contiguous HCC. Respiratory movement will be tracked (4D-CT).
D. Dose:
i) Dose for fraction: 3 Gy, at 5 fractions/week ii) Total dose: 45 Gy E. Criteria for stopping RT i) Development of grade 3 or 4 hepatotoxicity or gastrointestinal complications, as defined by CTCAE ver 4.0. Restart of RT should be within 2 weeks after stopping RT."
1704427|NCT01432314|Other|Transarterial chemoembolization|"A. Start at 2 weeks after completion of RT. B. TACE procedure: cisplatin 2 mg/kg infusion with 5-20 mL of lipiodol emulsion through the target artery of HCC. Gelfoam embolization will be used until to no tumor staining on re-angiography.
C. At an interval of 8 weeks twice, and then every 3 months until contraindications or complete response develop."
1704428|NCT01432301|Drug|uridine triacetate|uridine triacetate granules, 10gms, q6H x 20 doses
1704429|NCT01432275|Device|ADC blood glucose meter|Subjects used the FreeStyle InsuLinx with the insulin calculator not activated. Subjects had not previously used the FreeStyle InsuLinx meter.
1704430|NCT01432275|Device|Comparator blood glucose meter|Subjects were randomly assigned one of the comparator meters. Subjects had not previously used the assigned comparator meter.
1704431|NCT01432275|Device|ADC blood glucose meter with insulin calculator active|Subjects used the FreeStyle InsuLinx with the insulin calculator activated.
1704432|NCT01432262|Biological|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
1704433|NCT01432262|Biological|vaccine-13vPnC|Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
1704434|NCT01432249|Drug|Enbrel group|will be decided by treating physicians
1704435|NCT01432236|Drug|Pregabalin|Pregabalin 300 or 450 mg/day dosed BID ( twice a day) for 14 weeks; 150 mg/day starting dose
1704436|NCT01432236|Drug|placebo|placebo capsules twice a day for 14 weeks
1704437|NCT01432223|Drug|Nab-paclitaxel|Nab-paclitaxel 260mg/m2 q3w
1704438|NCT01432210|Other|Post-prandial Feeding Study|
1704439|NCT01432197|Other|ADL intervention|1) ADL training, 2) home modifications, 3) delivery and supervision in adaptive equipments, and 4) instruction in self-training programs.
1704440|NCT01432184|Procedure|strategies to reverse decrease in rSO2|an alarm threshold at a value of 90% of the resting baseline cerebral saturation value (baseline - 10%) will be established. To minimize the probability of patients reaching significant decreases rSO2 values, interventions to improve cerebral oxygenation will be initiated according to the strategies described in the algorithm. The success and failure of these interventions will be noted. As in the Control group, the screen will remain blinded in the ICU and the intensivist will not see the values.
1704441|NCT01432171|Drug|Lacosamide|Starting dose: 50 mg by mouth twice a day.
1704442|NCT01432171|Other|Placebo|To be taken by mouth twice daily.
1704443|NCT01432158|Biological|Prevenar 13|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
1704444|NCT01432158|Biological|Pneumovax II|This vaccine will be given to healthy adults without prior pneumococcal vaccination.
1704445|NCT01432145|Drug|6-Mercaptopurine|The dose of 6MP will be 75mg/m2 body surface area, administered orally (PO) once a day (od) in the morning 1 hour after eating, on a continuous schedule. Tablets should be taken at roughly the same time each day. One cycle is 28 days. Treatment is given continuously (see table below) until disease progression.
1704446|NCT01432145|Drug|Methotrexate|Methotrexate (20 mg/m2) will be taken orally, once a week, in the morning. One cycle is 28 days. Treatment is given continuously (see table below) until disease progression.
1704447|NCT01432132|Behavioral|Interview|Face-to-face audio recorded interview. It should take about 1 hour to complete.
1704448|NCT01432132|Behavioral|Questionnaire|Questionnaire about demographic information such as age and ethnicity.
1704449|NCT01432119|Device|SIR-Spheres|100% full dose SIR-Spheres on Day 1 of Cycle 1. SIR-Spheres with yttrium-90 microspheres will be given through a catheter in a vein in the groin.
1704450|NCT01432119|Drug|Cetuximab|Starting Dose: 200 mg/m2 by vein weekly. During Cycle 1, patients will receive cetuximab during Weeks 2-4. In Cycles 2 and beyond, patients will receive cetuximab weekly.
1704451|NCT01432119|Drug|Erlotinib|Starting dose: 100 mg by mouth daily. Erlotinib will be given starting with Cycle 2 at 100 mg by mouth daily. If tolerated, the dose will be increased to 150 mg by mouth daily in Cycle 3.
1704452|NCT01432119|Procedure|Break-Through Scan|"Nuclear medicine break-through scan performed within 29 days before receiving SIR-Spheres. The results of this test will be used to determine if a full or partial dose of SIR-Spheres with yttrium-90 microspheres will be delivered."
1704453|NCT01432106|Drug|Aliskerin/Valsartan and Rampiril|"Patients will start on low dose Ramipril 10 mg or Valturna 150/160 at visit 2, and up-titrate to target dose of Ramipril 20 mg or Valturna 300/320 at visit 3. At visit 5, the addition of Hydrochlorothiazide (HCTZ) or amlodipine will be allowed to achieve the SBP target of < 140 mmHg. High dose will then be maintained throughout the remainder of the study. In case of symptoms of low blood pressures, the study medication may be decreased to the low dose.
(However, all non-study medication will be manipulated, initially.)"
1704454|NCT01432093|Other|Intensive glycemic management|Intravenous insulin infusion, strict dietary intervention, carbohydrate matched subcutaneous insulin therapy. This is a multifaceted approach to achieve strict glucose goals of 90 to 120 mg/dL in the ICU and hospital wards.
1704455|NCT01432093|Other|Conventional management|Conventional treatment to control hyperglycemia with a target glucose goal of 120 to 150 mg/dL in the ICU and 140 to 180 mg/dL on the hospital floors.
1704456|NCT01432080|Drug|Prednisone|Prednisone 0.75 mg/kg actual body weight/day PO for 7 days followed by a 7 day taper.
1704457|NCT01432080|Drug|Azithromycin|Azithromycin 250 mg PO daily for 2 weeks, then 3 times per week until 3 months
1704458|NCT01432080|Drug|Montelukast|Montelukast 10 mg PO qhs for 3 months
1704459|NCT01432080|Drug|Symbicort|Symbicort 200/6 mcg, 2 inhalations every 12 hours for 3 months
1704460|NCT01432067|Other|Adapted physical activity|Physical activity advices according to a program adapted to physical status of the patient.
1704461|NCT01432067|Other|Classic physical activities|Daily physical activities based on a standard guide
1704462|NCT01432041|Behavioral|tailored health education|Health Information via a computer kiosk in the pediatric emergency department
1704463|NCT01432028|Drug|Estradiol and Progesterone|3 mg/day intranasal estradiol daily or 1,5 mg/day transdermal estradiol and 200 mg/day vaginal micronized progesterone for 14 days/month
1704464|NCT01432028|Drug|Estradiol and Drospirenone|oral estradiol 1mg and drospirenone 2 mg/day
1704465|NCT01432015|Drug|fosaprepitant|Fosaprepitant for Injection 150 mg is administered intravenously on Day 1 only as an infusion over 20-30 minutes initiated approximately 30 minutes prior to chemotherapy. Patient will receive standard pre-medications
1704466|NCT01432015|Drug|aprepitant|Aprepitant 125 mg orally 1 hour prior to chemotherapy treatment (Day 1) and 80 mg orally once daily in the morning on Days 2 and 3. patient will receive standard pre-medications
1704467|NCT01432015|Other|Oral Placebo|One pill administered on days 1-3 in conjunction with Fosaprepitant.
1704468|NCT01432015|Other|IV placebo|100 cc of IV placebo administered on day in conjunction with Aprepitant
1704469|NCT01431989|Drug|Amoxicillin powder for oral suspension (Clamoxyl®) 500mg/5mL|Test formulation
1704470|NCT01431989|Drug|Amoxil® 500mg/5mL powder for oral suspension|Reference formulation
1704471|NCT01431976|Drug|Lamictal|No comparison
1704477|NCT01431924|Drug|Higher-dose inhaled corticosteroids|fluticasone propionate 110 or 220 mcg
1704478|NCT01431924|Drug|Low-dose fixed dose fluticasone propionate/salmeterol xinafoate combination|Low dose inhaled corticosteroids/salmeterol xinafoate (100mcg/50mcg or 250 mcg/50mcg)
1704479|NCT01431911|Drug|Early maintenance treatment|Various classes of COPD maintenance treatment initiated within 30 days post index COPD exacerbation (hospitalization/ED visit)
1704480|NCT01431911|Drug|Delayed Maintenance treatment|Various classes of COPD maintenance treatment initiated after 30 days post index COPD exacerbation (hospitalization/ED visit)
1704481|NCT01431898|Drug|GS-9669 tablets|
1704482|NCT01431898|Drug|Placebo to Match GS-9669 tablet|
1704483|NCT01431885|Procedure|Diagnosis by cervical length and fibronectin|Diagnosis will be made by MOD Algorithm B
1704484|NCT01431885|Procedure|Cervical change|Diagnosis will be made by digital examination of cervical change
1704485|NCT01431859|Biological|Allergovit Birch pollen|Birch pollen specific immunotherapy. Once weekly injection for 7 weeks prior to birch pollen season for 2 consecutive seasons
1704486|NCT01431859|Other|Placebo|Placebo injection to be given subcutaneously once weekly for 7 weeks prior to birch pollen season for 2 consecutive years.
1704487|NCT01431846|Behavioral|Intervention|Informed by the interviews and best practices from the literature, pilot test the transitions of care intervention that targets patients and providers to evaluate the feasibility of the intervention to improve process of care measures, including: 1) PCP follow-up within 2-4 weeks of hospital discharge; 2) medications reconciled between pre and post-hospital discharge; 3) discharge summary available to PCP at time of visit; and 4) patient awareness of symptoms that require medical attention
1704488|NCT01431833|Drug|TR-701 FA|Oral single dose 200 mg
1704489|NCT01431820|Drug|Luliconazole Solution, 10%|Topical
1704490|NCT01431820|Drug|Vehicle Solution|Topical
1704491|NCT01431807|Drug|SYR-472|oral, for up to 52 weeks.
1704492|NCT01431794|Drug|LDE-225|"Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 600 mg daily.
Phase II:
Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days."
1704493|NCT01431794|Drug|Gemcitabine|"Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 600 mg daily.
Phase II:
Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days."
1704494|NCT01431794|Drug|nab-paclitaxel|"Phase I:
Four cycles of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/ m2on days 1, 8, and 15 every 28 days cycle in combination with oral LDE225 600 mg daily.
Phase II:
Arm A: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15 in combination with LDE-225 at the recommended phase 2 dose. Cycles repeated every 28 days.
Arm B: Four cycles of gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8 and 15. Cycles repeated every 28 days."
1704495|NCT01431781|Drug|Stilamin+common daily treatment|"dose:250 micrograms bolus intravenous in 3 minutes when ERCP starts and continuous infusion for 11 hours after ERCP.
Common daily treatment: fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory."
1704496|NCT01431781|Other|Common daily practice|Fasted for 6h after ERCP, Fluid replacement, Gastric acid inhibition, Antiinflammatory
1704497|NCT01431768|Device|Respirio Flu Test|The Respirio Flu Test (RFT) is a rapid test for identifying whether a patient is infected with the Influenza A or B virus. The test separates the Influenza virus from the patient's nose blow sample and utilizes the same underlying technology as a pregnancy test (lateral flow/immuno-chromatography) to deliver a positive or negative result in less than 10 minutes. The RFT is easy to use, designed with a 3 step process similar to that of the home pregnancy test. Results are presented to the patient as a combination of different coloured lines, depending on whether the patient has Influenza A or B.
1704498|NCT01431755|Device|Restylane SubQ|Treatment with up to 2 ml of the product
1704499|NCT01431755|Device|Restylane SubQ Lidocaine|Treatment with up to 2 ml of the product
1704500|NCT01431742|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
1704501|NCT01431729|Other|honey, hope,mucositis|Eligible patients were randomly allocated by a computer-generated list of random numbers to be assigned into one of three treatment groups; Group (1) received an empirical dose of 15 gm honey applied topically to the affected oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (2) received an empirical dose of 5 gm of a 4:2:1 mixture of honey, olive oil-propolis extract and beeswax (HOPE) applied topically to the oral mucosa three times daily until healing or for 10 days, which ever comes first. Group (3) served as controls and received benzocaine 7.5% gel applied topically to areas of ulcers three times daily.
1704502|NCT01431716|Drug|EFI/ACT-385781A|
1704503|NCT01431690|Drug|warfarin|A single 25 mg dose of warfarin
1704504|NCT01431690|Drug|omefas|4 x 1 g capsule dose of Epanova®
1704505|NCT01431690|Drug|omega-3-acid ethyl esters|4 x 1 g capsule dose of Lovaza®
1704506|NCT01431677|Procedure|Muscle Biopsy|
1704507|NCT01431664|Drug|multikinase inhibitor AT9283|
1704508|NCT01431664|Other|laboratory biomarker analysis|
1704509|NCT01431664|Other|pharmacological study|
1704510|NCT01431651|Dietary Supplement|probiotics,digestive enzyme|patients was randomized into 3 groups: clostridium butyricum MIYAIRI group (80 mg daily) bifidobacterium Longum BB536 group (2 packs daily) biotase:4 tables per day
1704511|NCT01431638|Drug|Canakinumab 150mg in prefilled syringe|Canakinumab 150mg in prefilled syringe will be given in a single dose subcutaneously upon demand for gouty arthritis flares
1704551|NCT01431339|Drug|IV Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
1704552|NCT01431339|Drug|Vancomycin/Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg every 12 hours). Total duration of therapy is 10-14 days
1704553|NCT01431326|Drug|The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:|
1763621|NCT00312130|Drug|Vildagliptin|
1704512|NCT01431625|Other|Combined Training (endurance and strength exercises)|"All patients underwent a training program to be held for 12 weeks in sessions of 60 minutes:
.- 20 minutes of bicycle ergometer with an initial load level of about 70% of baseline peak oxygen consumption, increasing the load every two weeks as tolerated.
- Weightlifting in 2 sets of 6 reps of 5 simple exercises. These are held at a station multigimnastyc (CLASSIC Fitness Center, KETTLER) and are as follows: pulls Chest, Shoulder press, Butterfly, Leg extension and Leg curls. The resistance will be increased gradually from 70% of the maximum weight you can lift the patient in a single maneuver (Test 1RM). Every two weeks the maximum weight is re-evaluated to adjust the training load in each patient."
1704513|NCT01431612|Drug|Esmolol administration|50 µg/kg/min of the ß1-receptor-blocker esmolol was infused intravenous over 3 hours
1704514|NCT01431612|Drug|Phenylephrine infusion|0.01 µg/kg/min of the alpha-1-adrenergic receptor agonist phenylephrine
1704515|NCT01431612|Drug|Lactated Ringer´s solution|Intravenous Infusion of 10 ml/h lactated Ringer's solution that contained no drug
1704517|NCT01431586|Drug|JDtic|"The planned JDTic dose levels to be evaluated are 1 mg, 3 mg, and 10 mg; however, the actual dose levels evaluated may be different, and/or additional dose levels may be added by protocol amendment, depending on the safety and PK results of the lower doses.
Subjects will be admitted to the clinic the day before dosing and will be confined to the clinic for 6 nights, with safety and PK evaluations and assessments lasting approximately 125 hours following administration of study drug."
1704518|NCT01431573|Behavioral|Wake Therapy|Maintaining wakefulness on alternating nights over 7 days, with continued sleep deprivation the next day.
1704519|NCT01431573|Device|light box|use of a lightbox titrated between 15-60 minutes (typically 30 minutes), timed according to chronotype score on the Morningness-Eveningness Questionnaire
1704520|NCT01431573|Drug|Lithium|For patients not already taking lithium, dose will start at 600 mg daily (all in the evening) and be adjusted in 300 mg/d increments according to weekly blood levels (i.e., lithium dose may be changed once a week if most recent blood level is too low; if too high, it will be decreased or temporarily discontinued as clinically indicated; 150 mg increments will be utilized if multiples of 300 mg result in intolerance or blood levels outside the target range (0.6 - 1.0 mEq/L)
1704521|NCT01431560|Device|fixation of the ankle fracture (Solco )|fixation with metallic implant
1704522|NCT01431560|Device|fixation of the ankle fracture (Freedom)|fixation with biodegradable implant
1704523|NCT01431547|Drug|dalotuzumab|For Part 1: dalotuzumab, intravenously (IV) over 60 minutes every three weeks, dose based on participant body surface area (BSA), starting dose of 900 mg/m^2, and escalated for successive cohorts of participants until MTD is found
1704524|NCT01431547|Drug|dalotuzumab|For Part 2: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, starting at the lowest tolerated dose that met PK target levels in Part 1. For Part 3: dalotuzumab IV over 60 minutes every three weeks, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
1704525|NCT01431547|Drug|ridaforolimus|For Part 2: ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at 1 dose level lower than the MTD or highest dose level used in the companion study MK-8669-056. For Part 3:ridaforolimus 10 mg enteric coated tablets, orally, on 5 consecutive days each week, dose based on participant BSA, at the dose level identified for combination therapy in Part 2
1704527|NCT01431521|Drug|MK-4074 200 mg|2 x 100-mg capsules, orally, twice-daily (BID) for 4 weeks
1704528|NCT01431521|Drug|Placebo for MK-4074|2 x 100-mg capsules, orally, BID for 4 weeks.
1704529|NCT01431521|Drug|Pioglitazone hydrochloride 30 mg|1 x 30-mg tablet, orally, once daily for 4 weeks
1704530|NCT01431521|Drug|Placebo for pioglitazone hydrochloride|1 x 30-mg tablet, orally, once daily for 4 weeks
1704531|NCT01431508|Drug|Losartan 50 mg / HCTZ 12.5 mg|Losartan 50 mg / HCTZ 12.5 mg tablet once daily for 12 weeks
1704532|NCT01431495|Drug|Pidogrel|Pidogrel(R)75 mg/day for period ranging from 1 to 6 months.
1704533|NCT01431495|Drug|Plavix|Plavix(R) 75 mg/day for period ranging from 1 to 6 months.
1704534|NCT01431469|Dietary Supplement|Cow's milk|Powdered Whole Cow's Milk
1704535|NCT01431469|Dietary Supplement|Follow-On Formula|Powdered Follow-On Formula with added long-chain Polyunsaturated fatty acid, prebiotics, and polysaccharide
1704536|NCT01431456|Drug|Dabigatran|
1704537|NCT01431456|Drug|Rivaroxaban|
1704538|NCT01431456|Drug|Nadroparin|
1704539|NCT01431443|Other|Flavanol-rich chocolate|The aim of this study is to evaluate the beneficial effect of dark chocolate consumption through the activity of flavanols on the endothelial function and blood pressure regulation, in acute (after 3 hours) and chronic effect (12 weeks), among pregnant women at high risk for preeclampsia.
1704540|NCT01431443|Other|Placebo Chocolate|Placebo intervention
1704541|NCT01431430|Drug|Cholecalciferol 100 000 UI|Cholecalciferol 100 000 UI FORTHIGHTLY for 2 months then monthly for 22 months
1704542|NCT01431430|Drug|Cholecalciferol 12 000 UI|Cholecalciferol 12 000 UI FORTHIGHTLY for 2 months then monthly for 22 months.
1704543|NCT01431404|Biological|Etanercept (Enbrel)|prefilled syringe, SC
1704544|NCT01431404|Biological|HD203|HD203, prefilled syringe, SC injection
1704545|NCT01431391|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
1704546|NCT01431391|Drug|leuprolide acetate|45.0 mg depot injection, 2 doses 6 months apart
1704547|NCT01431365|Behavioral|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
1704548|NCT01431365|Behavioral|Passive Sitting Group|Participants will be required to sit passively for 10 minutes on a chair.
1704549|NCT01431352|Drug|Letrozole|2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
1704550|NCT01431352|Drug|Chinese herbal medicine granules or Chinese herbal medicine granules placebo|twice a day for 6 month
1704554|NCT01431313|Drug|Inhaled Nitrite|Each patient will receive a starting dose of 45 mg of inhaled nitrite, with one planned subsequent planned dose of 90 mg of inhaled nitrite
1704555|NCT01431300|Drug|gadofosveset|Intravenous administration of the specified dosage of gadolinium contrast agent
1704556|NCT01431287|Drug|tiotropium + olodaterol|fixed dose combination
1704557|NCT01431287|Drug|tiotropium + olodaterol|fixed dose combination
1704558|NCT01431287|Drug|tiotropium|low dose or high dose
1704559|NCT01431287|Drug|tiotropium|low dose or high dose
1704560|NCT01431287|Drug|olodaterol|one dose only
1704561|NCT01431287|Device|Respimat|Respimat inhaler
1704562|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
1704563|NCT01431274|Drug|tiotropium|low dose
1704564|NCT01431274|Drug|olodaterol|one dose only
1704565|NCT01431274|Drug|tiotropium|high dose
1704566|NCT01431274|Drug|tiotropium + olodaterol|fixed dose combination
1704567|NCT01431274|Device|Respimat|Respimat inhaler
1704568|NCT01431261|Other|Education and training|Educational sessions in pain management 4 times and treatment sessions including instructions in training and specific exercises 8 times
1704569|NCT01431261|Behavioral|Pain management|Educational sessions in pain management 4 times
1704570|NCT01431235|Behavioral|cognitive behavioral therapy for treating ADHD symptoms|5 sessions of one hour CBT for treating ADHD symptoms by a trained health care worker
1704571|NCT01431222|Device|percutaneous treatment by implanting a Mitra Clip device|With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.
1704572|NCT01431209|Other|Laboratory Biomarker Analysis|Correlative studies
1704573|NCT01431209|Drug|Ruxolitinib Phosphate|Given PO
1704574|NCT01431196|Biological|Autologous dendritic cell vaccination|Autologous dendritic cell vaccination. Dendritic cells are pulsed with their own tumor antigens
1704575|NCT01431183|Behavioral|Mailed influenza vaccination reminder notice|Influenza vaccination reminder sent by postal mail
1704576|NCT01431170|Drug|Besivance Treatment Group|Subjects Receive Besivance™ ophthalmic suspension, 0.6% one drop in the study eye three times daily (TID) for 10 days.
1704577|NCT01431170|Drug|Polytrim Treatment Group|Subjects receive Polytrim ophthalmic solution one drop in the study eye three times daily (TID) for 10 days.
1704578|NCT01431157|Procedure|Nocturnal nasal oxygen|Nasal oxygen at 2 l/min will be given at night
1704579|NCT01431157|Other|No nasal oxygen|Patients will have no intervention for sleep apnea
1704580|NCT01431144|Procedure|connective tissue autograft|A connective tissue autograft is harvested from the palate and grafted at the site of implant placement on the facial surface.
1704581|NCT01431144|Procedure|connective tissue allograft|An acellular dermal matrix allograft (Alloderm, BioHorizons, Inc, Birmingham, AL, USA) is grafted at the site of implant placement on the facial surface.
1704582|NCT01431131|Procedure|Intrasocket graft|Intrasocket mineralized cancellous allograft
1704583|NCT01431131|Procedure|Intrasocket plus facial overlay graft|Intrasocket mineralized cancellous allograft plus a facial overlay graft of bovine xenograft
1704584|NCT01431118|Other|specific dragon boating training intervention|male athletes of the german national dragon boat team performing three specific training units at one day
1704585|NCT01431118|Other|specific dragon boat intervention|women athletes of the german national dragon boat team performing two specific training units and one weight lifting test at one day
1704586|NCT01431105|Drug|Atorvastatin|Atorvastatin dose titration to maximum tolerated dose (once daily for 6 weeks)
1704587|NCT01431092|Drug|Placebo|Both Circadin and placebo are encapsulated in lactose containing gelatin capsules to optimize the blinding.
1704588|NCT01431092|Drug|Melatonin|Prolonged-release melatonin (Circadin®) 2 mg, once daily, 1-2 hours before bedtime.
1704589|NCT01431079|Behavioral|HPV vaccine acceptability|One arm will receive health belief model based educational intervention and other arm will receive knowledge-based educational intervention.
1704590|NCT01431066|Device|Sham pulsed radio-frequency electromagnetic device|Disabled PRFE device
1704591|NCT01431066|Device|ActiPatch PRFE Device|Actipatch PRFE device
1704592|NCT01431053|Drug|aspirin|Aspirin 50mg po daily
1704593|NCT01431053|Drug|Exemestane|Exemestane 25mg po daily
1704594|NCT01431040|Other|No bowel prep|Participants in this group will have a regular diet and no bowel prep the day prior surgery up until midnight.
1704595|NCT01431040|Other|Clear liquid diet and 2 Fleet's enemas|Participants in this group will receive a clear liquid diet and 2 Fleets enemas in the late afternoon prior to surgery.
1704596|NCT01431014|Drug|"Dexamethasonelow-dose"|5mg
1704597|NCT01431014|Drug|"Dexamethasonehigh-dose"|15 mg
1704598|NCT01431001|Device|Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator (DSF-rTMS)|The Cervel Neurotech Deep Shaped-Field repetitive transcranial magnetic stimulator is an investigational rTMS device
1704599|NCT01430975|Drug|CardioGen-82|CardioGen-82 was not administered as part of this trial but the patients enrolled had to have received CardioGen-82 previously
1704600|NCT01430975|Drug|CardioGen-82|Patients do not received CardioGen-82 as part of this study. To be in the study they would have had to receive CardioGen-82 previously.
1704601|NCT01430949|Procedure|Catheter Ablation of Paroxysmal Atrial Fibrillation|Catheter ablation for the treatment of paroxysmal atrial fibrillation. A pulmonary vein isolation procedure will be performed using the OTW MAS and radiofrequency ablation.
1704602|NCT01430923|Drug|refrigeration free latanoprost|latanoprost Eye drops 0.005% once daily, 3 months
1704603|NCT01430923|Drug|latanoprost eye drops|latanoprost eye drops 0.005% w/v, once daily, 3 months
1704604|NCT01430910|Drug|CAZ104|IV infusion
1704605|NCT01430910|Drug|Avibactam|IV infusion
1704606|NCT01430910|Drug|Ceftazidime|IV infusion
1704607|NCT01430884|Other|Aspirated Coronary Blood|Coronary arterial blood is taken distal to the lesion before stent implantation and serve as control and coronary aspirate blood is obtained during stent implantation.
1704608|NCT01430858|Device|Strain Gauge|The study participants will each undergo sterile surgical implantation of a tibial bone strain gauge in the right leg (dominance will recorded and determined by handedness). A single stacked, 45°, rosette strain gauge (FRA-2-11 Tokyo Sokki Kenkyujo Co., Japan) will be unilaterally bonded to the medial tibial cortex and carefully aligned with the long axis of the tibia. The gauge will be attached at the mid-shaft region, to determine the transmission of the vibrations through the bone and quantification of the microstructural effect.
1704609|NCT01430858|Other|Vibration therapy|"Galileo 900 platform. Study subjects will be asked to stand on the device for a series of 36 tests, with vibrations applied at various frequencies and amplitudes. A 20-second duration of videomotion & strain gauge readings will be captured.
Juvent 1000 platform The volunteers will stand on the platform for one minute during which a 20-second duration of videomotion & strain gauge readings will be captured.
Power Plate Pro5 Two amplitude settings will be tested, described as low & high. The subject will stand on each platform test for up to 1 minute, during which a 20-second duration of videomotion & strain gauge readings will be captured."
1704610|NCT01430819|Biological|Influenza Virus Vaccine: Fluzone® 2011-2012 Formulation|0.5 mL, Intramuscular
1704611|NCT01430819|Biological|Influenza Virus Vaccine: Fluzone® High-Dose 2011-2012 Formulation|0.5 mL, Intramuscular
1704612|NCT01430806|Drug|Dronedarone arm|PO Dronedarone 400 mg BID
1704613|NCT01430806|Drug|Dronedarone|Dronedarone PO 400 MG BID
1704614|NCT01430793|Drug|Vitamin D3 600,000 units IM|Vitamin D3 600,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
1704615|NCT01430793|Drug|Vitamin D3 600,000 Orally|Vitamin D3 600,000 units will be given orally and then will be repeated every 2 monthly for 2 times if vitamin D levels remain < 30 ng/ml
1704616|NCT01430793|Drug|Vitamin D3 200,000 units IM|Vitamin D3 200,000 units will be given by Intramuscular injection and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
1704617|NCT01430793|Drug|Vitamin D3 200,000 Orally|Vitamin D3 200,000 units will be given by orally and then will be repeated every 2 monthly for 2 times if level of vitamin D remain < 30 ng/ml
1704618|NCT01430780|Drug|nitrate group|Isosorbide Mononitrate orally 20mg twice per day.
1704619|NCT01430780|Drug|control group|placebo
1704620|NCT01430754|Drug|tasimelteon|20 mg tasimelteon capsules, daily
1704621|NCT01430754|Drug|Placebo|Placebo capsules, daily
1704622|NCT01430741|Other|Getting To Outcomes|"GTO strengthens the knowledge, attitudes, and skills practitioners need to carry out evidence based programs. GTO consists of a series of steps practitioners should follow in order to obtain positive results and then provides them with the guidance necessary to complete those steps with quality. According to GTO, carrying out an evidence based program includes a series of steps corresponding to three general areas: (1) planning - e.g., developing goals and performance targets, ensuring staff are trained in the evidence based program; (2) implementation - e.g., monitoring program activities, maintaining adherence to an evidence based program model, supervision; and (3) self-evaluation - e.g., tracking patient outcomes, using data to improve program operations."
1704623|NCT01430741|Behavioral|Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking (Veterans Edition)|MISSION-Vet has been developed to target mental health, substance abuse and related issues facing homeless Veterans through assertive outreach, psychoeducation, and linkages to community-based resources
1704624|NCT01430715|Other|Active vido games and outdoor play|Fifteen children, aged 5- to 8- years, attending a nearby preschool, with a normal body mass index (BMI)-for-age percentile between, > 5th % to < 85th %.BMI, will participate in unstructured, outdoor play and one AVGs in a randomized order. Activity type, duration and intensity will be measured via accelerometery and direct observation. The energy expenditure (EE) will be calculated from Metabolic Equivalent (MET) values and the percent of time each activity meets MVPA intensity will be calculated. A MET is the energy cost of the activity expressed as kilocalories expended per kilogram of body weight per hour of activity. If EE and intensity in AVG play is similar to EE and intensity in outdoor play, then AVG play could be a great supplement to efforts aimed at increasing PA in children.
1704625|NCT01430702|Device|Computerized medication delivery unit (Electronic Medication Management Assistant (EMMA)|The patient's prescriptions and refills are packaged in standard-sized blister cards and loaded into EMMA units. The EMMMA identifies each medication automatically - no patient input is required. When activated by the patient, the medications are selected from the blister cards and released into the delivery tray. The EMMA will remain in the patient's home for a period of 30-days immediately following hospitalization. After 30 days, the EMMA MDU will become available for the next eligible patient. This maximizes the number of patients that can benefit from the MDU, while addressing the transition period when medication-reconciliation problems are most common.
1704628|NCT01430676|Procedure|differences in surgical techniques|follow the risk for morbidity after incisional hernia repair
1704629|NCT01430650|Drug|Oral strogen|2 mg of estradiol every day beginning the second day of the cycle until day 7. 4 mg of estradiol every day beginning 8th day of the cycle until day 10. 6 mg of estradiol every day beginning 11th day of the cycle until day 16.
1704630|NCT01430650|Drug|Transdermal strogen|One patch of 75 mcg of estradiol hemimydrate every 48 h from 2 to day 6. Two patches of 75 mcg of estradiol hemimydrate every 48 h from 6 to day 12. Three patches of 75 mcg of estradiol hemimydrate every 48 h from 12 to day 16.
1704631|NCT01430637|Genetic|DNA analysis|
1704632|NCT01430637|Genetic|RNA analysis|
1704633|NCT01430637|Genetic|gene expression analysis|
1704634|NCT01430637|Genetic|mutation analysis|
1704635|NCT01430637|Genetic|nucleic acid sequencing|
1704636|NCT01430637|Genetic|polymerase chain reaction|
1704637|NCT01430637|Other|laboratory biomarker analysis|
1704638|NCT01430637|Other|pharmacogenomic studies|
1704639|NCT01430624|Behavioral|PPRS|Video including information psychoeducation and modeling of adaptive behavioral coping strategies for use post-assault. Shown at time of post assault medical exam.
1704640|NCT01430624|Behavioral|PIRI|Video containing pleasant imagery and relaxation instruction information. Shown at time of post assault medical exam.
1704641|NCT01430611|Biological|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
1704642|NCT01430611|Biological|Meningococcal (Groups A and C) Polysaccharide Vaccine|0.5 mL, Subcutaneous
1704643|NCT01430598|Procedure|Rotator Cuff Repair and Subacromial Decompression|Arthroscopic decompression and rotator cuff repair will be completed during the same surgical date.
1704644|NCT01430598|Other|Questionnaire|Patients will be asked to complete two separate questionnaires prior to the surgical intervention. Patients will be asked to complete the same two questionnaires at 12 weeks post surgery.
1704645|NCT01430585|Drug|PF-04691502|PF-04691502 administered as single agent for 2 weeks. After this period, patients in this arm will take PF-04691502 in combination with Letrozole until Week 6. Beyond Week 6, if considered appropriate, patients can be treated with the combination for up to 10 additional weeks until breast surgery.
1704646|NCT01430585|Drug|PF-04691502 in combination with Letrozole|PF-04691502 in combination with Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
1704647|NCT01430585|Drug|Letrozole|Letrozole will be administered for 6 weeks. Beyond Week 6, if considered appropriate, patients can be treated for up to 10 additional weeks until breast surgery.
1704648|NCT01430572|Drug|Pazopanib|Starting Dose: 200 mg by mouth on Days 1 - 5 of Cycle 1 only. On Day 6 and every cycle-day with an even number, only pazopanib administered.
1704649|NCT01430572|Drug|Everolimus|"Starting dose: 5.0 mg by mouth on Days 1 - 5 of Cycle 1. On Day 7 and every cycle-day with an odd number, only everolimus will be administered.
Dose Expansion Phase: Maximum tolerated dose (MTD) from lead in phase."
1704650|NCT01430559|Drug|Meloxicam|7.5mg x2 once a day for 12 weeks
1704651|NCT01430559|Drug|Placebo|Study subjects will be randomized to two treatment groups: one with Meloxicam 7.5 mgx2 once a day and another one with placebo. The duration of the interventional treatment is 12 weeks.
1704652|NCT01430533|Drug|azelaic acid pre foam formulation|
1704653|NCT01430533|Drug|Vehicle pre foam formulation|
1704654|NCT01430533|Drug|Water|
1704655|NCT01430520|Drug|Escitalopram|Tables with Escitalopram (10 mg), 1 tablet a day for 7 days, starting on the day of surgery
1704656|NCT01430520|Drug|Placebo|Placebo tablets, 1 tablet a day for 7 days, starting on the day of surgery
1704657|NCT01430507|Drug|Revamilast|Tablet, Low dose, Once daily for 12 weeks
1704658|NCT01430507|Drug|Revamilast|Tablet, Medium dose, Once daily for 12 weeks
1704659|NCT01430507|Drug|Revamilast|Tablet, High dose, Once daily for 12 weeks
1704660|NCT01430507|Drug|Placebo Comparator|Matching Placebo in triple dummy format, Tablet, Once daily for 12 weeks
1704661|NCT01430481|Dietary Supplement|Rosehip powder|The trial is a patient and physician blinded, 12-week, randomized controlled trial (1:1:1). Participants will be randomized into one of 3 groups: 'Standard rosehip powder' (A), 'New rosehip formulation' (B), or 'New rosehip formulation in half dose' (C). Personnel responsible for data collection will be blinded to group assignment. The patients will report on their symptoms every four weeks.
1704662|NCT01430468|Procedure|Glenoid Positioning System|Design and fabrication of patient specific instrument for placement of a guide pin to be used to aid in bone preparation for placement of a metaglene and its fixation screws or anatomic glenoid component
1704664|NCT01430442|Drug|Placebo matching BMS-927711|Capsule, Oral, 0mg, One time, One dose
1704665|NCT01430442|Drug|BMS-927711|Capsule, Oral, 10mg, One time, One dose
1704666|NCT01430442|Drug|BMS-927711|Capsule, Oral, 25mg, One time, One dose
1704667|NCT01430442|Drug|BMS-927711|Capsule, Oral, 75mg, One time, One dose
1704668|NCT01430442|Drug|BMS-927711|Capsule, Oral, 150mg, One time, One dose
1704669|NCT01430442|Drug|BMS-927711|Capsule, Oral, 300mg, One time, One dose
1704670|NCT01430442|Drug|BMS-927711|Capsule, Oral, 600mg, One time, One dose
1704671|NCT01430442|Drug|Sumatriptan|Capsule, Oral, 100mg, One time, One dose
1704672|NCT01430429|Drug|NI-0801|
1704673|NCT01430416|Drug|AEB071|
1704674|NCT01430403|Biological|Omalizumab|Participants received active omalizumab (Xolair(R)) injections and a placebo inhaler. Each participant received omalizumab (Xolair(R)) subcutaneous injections at minimum dose of 0.016 mg/kg/IgE (immunoglobulin E) [IU/mL] every 2 or 4 weeks during the 4-5 months treatment period. All participants received standardized specialist asthma care.
1704675|NCT01430403|Drug|Inhaled Corticosteroid Boost Therapy (ICS)|Self-administered fluticasone (Flovent ® Diskus®) inhalers sufficient to deliver the required 200 mcg or 500 mcg daily boost of fluticasone. All participants will receive standardized specialist asthma care.
1704676|NCT01430403|Biological|Placebo omalizumab|Placebo was administered subcutaneously every 2 or 4 weeks over a period of 4 to 5 months. Doses (mg) and dosing frequency were determined by serum total immunoglobulin E (IgE) level (IU/mL) and body weight (kg). Also, participants continued with their conventional asthma therapy according to the National Asthma Education and Prevention Program (NAEPP, 2007) guidelines, under the management of an asthma specialist health care provider.
1704677|NCT01430403|Biological|Placebo fluticasone|Self-administered placebo fluticasone (placebo Flovent ® Diskus®) inhalers identical in dose and guidance as active fluticasone. All participants will receive standardized specialist asthma care.
1704678|NCT01430390|Biological|Biological/Genetically Modified T cells|Following completion of the chemotherapy, genetically modified T cells will be given intravenously at one of 3 dose levels. After the infusion patients will be monitored clinically and with serial blood and marrow evaluations to assess toxicity, therapeutic effects, and the in-vivo survival of the genetically modified T-cells.
1704679|NCT01430377|Procedure|SB predilatation|Initial SB [predilatation.
1704680|NCT01430377|Procedure|No SB predilatation|Without SB predilatation
1704681|NCT01430364|Device|BIOSS LIM implantation|BIOSS LIM is a dedicated bifurcation stent system with sirolymus elution.
1704682|NCT01430364|Device|BIOSS Lim|
1704683|NCT01430364|Device|CarloS|
1704684|NCT01430351|Drug|Temozolomide|150 m/m2 by mouth 1 time each day on alternate weeks on Days 1-7 and Days 15-21 of every 28 day cycle.
1704685|NCT01430351|Drug|Memantine|30 mg by mouth twice a day for a 28 day cycle.
1704686|NCT01430351|Drug|Mefloquine|250 mg by mouth 1 time a day on Days 1-3 of the first week, then on Monday, Wednesday, and Friday of every week after that for a 28 day cycle.
1704687|NCT01430351|Drug|Metformin|1000 mg by mouth twice a day for a 28 day cycle.
1704688|NCT01430325|Drug|Hyperbaric Oxygen (1.5 atm abs)|Hyperbaric oxygen (100% oxygen) delivered at a chamber pressure of 1.5 atm abs.
1704689|NCT01430325|Drug|Sham Chamber Session|Sham control chamber session: regular air delivered at a chamber pressure of 1.2 atm abs
1704690|NCT01430312|Drug|azelaic acid pre-foam formulation|
1704691|NCT01430312|Drug|Vehicle pre-foam formulation|
1704692|NCT01430312|Drug|Water|
1704693|NCT01430312|Drug|Sodium lauryl sulfate|
1704694|NCT01430299|Device|Integra Accell Evo3|Prospective use Integra Accell Evo3
1704695|NCT01430286|Behavioral|psycho-social intervention based on a web-based psycho-educational program, called Diapason.|This group will be trained for a 3 month period by a web-based psycho-educational program, Lifestyle Counseling, etc.
1704696|NCT01430286|Behavioral|Consultation in memory clinic|This group will receive treatment as usual (consultation in memory clinic every 6 months)
1704697|NCT01430260|Drug|Ciclesonide|200 ㎍ once daily
1704698|NCT01430260|Drug|Levocetirizine|5mg once daily
1704699|NCT01430260|Drug|Ciclesonide & Levocetirizine|"Omnaris (ciclesonide) 200 ㎍ once daily
Levocetirizine 5mg once daily"
1704700|NCT01430247|Other|Amblyopia screening|Monocular vision testing at near (40cm) and distance (3m)
1704701|NCT01430234|Drug|Panzytrat 25.000 FIP-E units of Lipase|patients will experiment with Panzytrat (containing 25.000 units of lipase) to a maximum of 16 capsules a day according to general guidelines.
1704702|NCT01430221|Behavioral|Mindfulness-based Personalized Health Planning|
1704703|NCT01430221|Other|Structured & Guided Education|
1704704|NCT01430208|Procedure|resectoscopy|hysteroscopy for myomas G0 and/or polyps
1704705|NCT01430195|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation Other Name: CUV1647
1704706|NCT01430195|Procedure|Narrow-Band UVB Light Treatment|To be administered 3 times/week for 6 months. 72 treatments in total.
1704707|NCT01430182|Drug|Methadone|0.2 mg*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
1704708|NCT01430182|Drug|Morphine|0.2 mg*kg-1 by actual body weight, administered over 10 minutes, once induction of anesthesia and endotracheal intubation are complete.
1704709|NCT01430169|Biological|AA4500|Two injections of AA4500 0.58 mg 24 hours apart
1704710|NCT01430156|Drug|Heme arginate (Normosang)|3mg/kg as a single IV infusion prior to transplant over 30 mins and same dose repeated on day 2 post-transplantation. Each drug infusion will be followed by 100ml saline IV to flush the line.
1704711|NCT01430156|Drug|0.9% sodium chloride|Solution for infusion, this will be given prior to transplantation and again on day 2; the same as active drug.
1704712|NCT01430143|Behavioral|Exercise|Daily exercise for 12 weeks.
1704713|NCT01430130|Device|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
1704714|NCT01430117|Biological|Four different concentrations of Poa pratensis allergen extract, positive control and negative control|Four concentrations of Poa pratensis allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
1704715|NCT01430104|Drug|Teriparatide|Administered subcutaneously during the Treatment Period
1704716|NCT01430104|Drug|Aspara-CA 600 mg|Administered orally throughout the study
1704717|NCT01430104|Drug|Alfarol 1.0 µg|Administered orally throughout the study
1704718|NCT01430091|Drug|Prasugrel (clinical formulation)|Administered orally
1704719|NCT01430091|Drug|Prasugrel (Orally Disintegrating Tablet [ODT])|Administered orally
1704720|NCT01430078|Drug|ASP015K|oral tablet
1704721|NCT01430078|Drug|ASP015K|solution via oral capsule
1704722|NCT01430065|Drug|ASP015K|oral
1704723|NCT01430065|Drug|Tacrolimus|oral
1704724|NCT01430052|Drug|Drug: gemcitabine, S-1|Gemcitabine 1,000mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks.
1704725|NCT01430052|Drug|gemcitabine, S-1, radiotherapy|Gemcitabine 600mg/㎡ is administered with 30 min intravenous infusion on day 1 and 8 every 3 weeks. S-1 60mg/㎡/day is administered orally for 2 consecutive weeks every 3 weeks. Concurrent radiotherapy (a total dose of 50.4Gy) was delivered in 28 fractions.
1704726|NCT01430039|Procedure|blood sample|Blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
1704727|NCT01430039|Procedure|Blood sample - venous blood 10 ml.|venous blood sample from a peripheral vein, 10ml total for blood count, total serum : protein, albumin, LDH, C-reactive protein,syndecan-1
1704728|NCT01430013|Drug|Endostar and CHOPT|Endostar 7.5mg/m2, for iv for continuous 14 days cyclophosphamide, pirarubicin, vincristine, teniposide, prednisone
1704729|NCT01430000|Biological|Subcutan implantation of autologus skin graft after ex-vivo treatment|Subcutan implantation of autologus skin graft after ex-vivo treatment
1704731|NCT01429974|Other|amniometer model po1|"The detection of Meconium, is based on recognizing a characteristic fluoroscopic spectral pattern emitted by Meconium under light excitation at a specific wavelength.
The diagnostic test does not require penetration into the amniotic sac and is safe, painless and simple to perform."
1704732|NCT01429961|Drug|SOX|TS-1, Oxaliplatin regimen (3week) Oxaliplatin 130 mg/m2 IV Day 1 S-1 40 mg/m2 b.i.d. Day1~14
1704736|NCT01429909|Device|MAGNETOM Avanto (MRI device)|The primary purpose is to optimize the fMRI by a quantitative measurement of the T2* in the cortex and the basal ganglia using MRI. The secondary purpose is to study the effect of age and Parkinson's disease on T2*.
1704737|NCT01429896|Other|Food challenge|Double blind placebo controlled peanut challenge. Each challenge given with or without extrinsic factors exercise or sleep restriction.
1704738|NCT01429870|Drug|Steroid active treatment|Triamcinolone in unguentum leniens 0.1%
1704739|NCT01429844|Drug|Tacrolimus|Tacrolimus therapy was started immediately after transplantation with a continuous intravenous infusion of 0.01-0.03 mg/kg/d. After extubation, the mode of delivery was switched to oral administration (b.i.d.) with doses of 0.05-0.3 mg/kg/d. Tacrolimus doses were adjusted to trough levels. Target C0 (trough) levels were 10-15 ng/ml for the first 3 months after transplantation and 8-12 ng/ml thereafter with dose adjustments according to patient outcome.
1704740|NCT01429844|Drug|Cyclosporine|Cyclosporine therapy was started immediately after transplantation with a continuous intravenous infusion of 1-3 mg/kg/d. After extubation the mode of delivery was switched to oral administration (b.i.d. or t.i.d.) with doses of 4-18 mg/kg/d. Cyclosporine doses were adjusted to C0 or C2 levels according to local practice. Target trough levels were 200 - 300 ng/ml for the first 3 months after transplantation and 150 - 200 ng/ml thereafter.
1704741|NCT01429831|Drug|Aripiprazole|starting aripiprazole dose from 2-5mg/day, dose adjustment by every week, and maximum dose can up to 15mg/day. The duration is 6 weeks.
1704742|NCT01429818|Drug|Glimepiride/metformin|4/1000 mg tablets once a day foe eight weeks
1704743|NCT01429818|Drug|Metformin|1000 mg tablets once daily for eight weeks
1704744|NCT01429805|Device|HipJack Balloon Spacer|Use of the HipJack Kit to maintain distraction of the joint during hip arthroscopy.
1704747|NCT01429779|Drug|Movicol|Movicol® in sachets of 13,81 gram each. One sachet consists of 13,125 gr Macrogol 3350, 178,5 mg Sodium bicarbonate, 350,7 mg Sodium chloride and 46,6 mg Potassium chloride. Administration of 1 sachet of Movicol® daily during one week preoperatively and 2 sachets of Movicol® daily postoperatively.
1704749|NCT01429753|Other|Advanced Imaging Guided LV lead placement|Use of MRI to identify scar and latest activating LV segment as well as CS anatomy. This will be used to guide LV lead placement real-time.
1704750|NCT01429753|Device|Standard LV lead placement|Standard LV lead placement not guided by advanced imaging
1704751|NCT01429740|Drug|PF-05180999|Ascending single oral doses of 0.1, 0.3, 1.0, 3, 10, 30, 100, and 250 mg oral solution or capsules
1704752|NCT01429740|Drug|Placebo|Placebo oral solution or capsules
1704753|NCT01429714|Device|Individually tailored duration of elastic compression therapy|Individually tailored duration of elastic compression therapy,based on signs and symptoms according to the Villalta scale, following an initial therapeutic period of 6 months
1704754|NCT01429714|Device|Elastic compression therapy with a standard duration of 24 months|Elastic compression therapy with a standard duration of 24 months
1704755|NCT01429701|Drug|polymyxin B sulphate + prednisolone + benzocaine + clioquinol|applied 3 times / day at lesion
1704756|NCT01429701|Drug|betamethasone + gentamicin + tolnaftato + cleoquinol|applied 3 times / day at lesion
1704757|NCT01429688|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day for 3 days
1704758|NCT01429675|Drug|bonviva|150mg Ibandronate once a month
1704759|NCT01429662|Behavioral|Modified Relaxation (MR)|Modified Relaxation (MR) This technique intend to train participants in a group of 8-10 in only 1 session that lasts 60 minutes. After completing the training, participants will be given a hand-out on MR. They will be asked to practice MR at home once a day for 15-20 minutes during their leisure times, for at least 5 days a week during the whole 16 weeks of the study period.
1704760|NCT01429662|Behavioral|Lifestyle Education (LE)|Participants in this group will receive conventional care and lifestyle education on dietary choice and exercise.
1704761|NCT01429649|Procedure|cryotherapy or radiofrequency ablation|Cryoablation or Radiofrequency ablation is performed under CT image guidance.
1704762|NCT01429636|Behavioral|Modified Relaxation (MR)|The MR technique is modified from the AR technique that will require participants to attend only 1 session, lasting 60 minutes. After the training session, participants will be given a hand-out on MR. They will continue to practice MR at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
1704763|NCT01429636|Behavioral|Applied Relaxation (AR)|Participants will receive 12 sessions AR training. After that they will asked to practice at home once a day for 15-20 minutes during their leisure times, at least 5 days a week for the whole 12 weeks of the follow-up period.
1704764|NCT01429623|Drug|ladostigil hemitartrate|10mg ladostigil base administered once daily as hard gelatin capsule
1704765|NCT01429623|Drug|Placebo|Placebo comparator
1704797|NCT01429376|Other|Questionnaires|"Minnesota Living with Heart Failure Questionnaire (MLHFQ), modified Medical Research Council (MRC) dyspnoea scale, 10-point Borg dyspnoea score.
All questionnaires were completed on the day of initial pulmonary function tests and three months later."
1704798|NCT01429376|Other|Chest radiograph|Standard posteroanterior and lateral chest radiographs were performed and evaluated on the presence or absence of congestion and other conditions that belonged to the exclusion criteria.
1704872|NCT01428674|Other|Interpersonal Mindful Compassion with Touch|A practitioner lightly touches the participant on the hands, arms, shoulders, lower legs and feet while extending loving kindness to the participant.
1704766|NCT01429610|Drug|Rituximab+mVPDL|"Induction:
Dauno 90 mg/m2/d by civ (d1-3)
Vinc 2 mg iv (d1, 8)
Pred 60 mg/m2/d po (d1-14)
for Ph(-): L-asp 4,000 units/m2/day im/sc (d17-28) for Ph(+): Imatinib 600mg/d po qd (d8-continue till the end of maintenance or just before alloHCT)
Rituximab 375mg/m2/d (d8)
Consolidation A (cycle1)
D 45 mg/m2/day by continuous iv (d1, 2)
V 2 mg iv (d1, 8)
P 60 mg/m2/day po (d1-14)
for Ph(-): L-asp (d1-14) for Ph(+): Imatinib
Rituximab 375mg/m2/d (d8)
Consolidation B (cycles2&4)
Cyt 2,000 mg/m2/d iv over 2 hr (d1-4)
Eto 150 mg/m2/d iv over 3 hr (d1-4)
Rituximab 375mg/m2/d d8
Consolidation C (cycles 3&5)
Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hr (d1-2, 15-16)
Leucovorin 50 mg/m2 iv every 6hr for 3 doses,
Rituximab 375mg/m2/d (d8&22)
Maintenance (for 2 years)
- for Ph(-): 6- Mercaptopurine 60 mg/m2 po qd Methotrexate 20 mg/m2 po qw for Ph(+): imatinib 600mg/d po qd
Consider alloHCT"
1704767|NCT01429584|Drug|interscalene nerve block with 0.25% bupivacaine|interscalene nerve block performed with 20 ml of 0.25% bupivacaine
1704768|NCT01429584|Drug|interscalene block with 0.125% bupivacaine|interscalene block with 20 ml of 0.125% bupivacaine
1704769|NCT01429571|Other|No intervention|No intervention
1704770|NCT01429545|Drug|Atosiban|Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.
1704771|NCT01429545|Drug|Atosiban and nifedipine|This group were given simultaneously as follows:Atosiban was given as a bolus (6.7 mg. IV) over 1 min then an infusion of 18 mg/hr for 3 hrs followed by 6 mg/hr for 48 hrs.Nifedipine was given in the dose of 10 mg orally every 15 min till uterine quiescence was achieved (<4 contractions/hr). Maximum dose was 40 mg in the first hour then maintenance dose of 10 mg every 4-6 h for 48 hrs was given.
1704772|NCT01429532|Procedure|phacoemulsification|Cataract surgery performed with three incision-size-dependent phacoemulsification systems (1.8, 2.2 and 3.0 mm)
1704773|NCT01429519|Drug|RPh201, botanical drug product|topical, three times per week for a period of 4 consecutive weeks, followed by a single follow up visit 3 months post end of the last treatment day
1704774|NCT01429506|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
1704775|NCT01429506|Drug|Intensive medical management|Exenatide 10 mcg BD, Metformin 2-3 gm/day, 800 Kcal diet
1704776|NCT01429493|Radiation|Conventional Radiotherapy|Conventional radiotherapy will be used (8 Gy/ 1 fraction).
1704777|NCT01429493|Radiation|Biological image-guided radiotherapy with conventional dose.|Biological image-guided radiotherapy on the positron emitting tomography (PET) positive lesion with conventional dose (8Gy/ 1 fraction) will be used.
1704778|NCT01429493|Radiation|Biological image-guided SBRT with dose-escalation.|Biological image-guided stereotactic body radiotherapy (SBRT) with dose-escalation on the PET positive lesion will be used.
1704779|NCT01429480|Procedure|Preoperative Ultrasound Guided Ilioinguinal/Iliohypogastric Block|
1704780|NCT01429480|Procedure|Preoperative Ultrasound Guided Posterior TAP Block|
1704781|NCT01429480|Drug|Patient controlled analgesia|
1704782|NCT01429467|Device|Continuous Glucose Monitor (CGM) and Telemedicine (Enlite Guardian real-time system Medtronic®)|Phase 2 patients will receive 6 weeks of CGM (Enlite Guardian real-time system- Medtronic®). Optimisation of glycaemic control will be through a telemedicine system to deliver a standardised protocol to instruct changes in pump settings and insulin delivery rate. This has been devised in our department and used successfully in a clinical trial comparing MDI v. CSII in young people, sponsored by Diabetes UK. 2008-2010). Subjects will be contacted at 1, 3 and 5 weeks after starting the CGM
1704783|NCT01429454|Drug|Omega-3 Long Chain Fatty Acid|: The Omega-3FA compound will be manufactured by Ocean Nutrition Canada and contain an 2:1 proportion of EPA to DHA in which each capsule includes 370 mg EPA and 200 mg DHA as well as 2 mg/g Tocopherol. The dose will be two capsules per day for a total of 740 mg of EPA and 400 mg of DHA.
1704784|NCT01429454|Drug|Placebo|The placebo is a soybean/corn blend. Both the Omega-3FA and placebo are colored with carob (so shell is brown) and flavored with natural lemon-lime, to mask them. The dose will be 2 capsules per day.
1704785|NCT01429441|Drug|Ocriplasmin|0.125 mg single intravitreal injection
1704786|NCT01429441|Other|Sham injection|Sham injection
1704787|NCT01429428|Other|Far-IR compression stockings|The far-IR side of compression stocking will be used by subjects, during the day, for six hours a day, during 90 days.
1704788|NCT01429428|Other|No far-IR compression stockings|This side of compression stocking without far-IR radiation will be used by subjects, during the day, for six hours a day, during 90 days.
1704789|NCT01429415|Drug|Magnesium Sulfate Sandoz|Each treatment will utilize 600 mg (1.2 mL) of Magnesium Sulfate Sandoz
1704790|NCT01429415|Drug|Sodium Chloride , USP PPC|Intervention: The control group will receive Sodium Chloride , USP PPC (1.2 mL hypertonic 5.5% saline with 5 mg Salbutamol - GlaxoSmithKline/Pharmascience
1704791|NCT01429402|Drug|Botulinum Toxin Type A|1-2U/kg, at 25U/mL, into the bilateral aberrant oriented orbicularis ocuris muscle via 4 superficial injection site; only once after surgery. No additional injection is needed
1704792|NCT01429402|Drug|Botulinum Type A|b. Study group II: For revision lip surgery, immediately after revision lip surgery 3 injection of 2.5U of botulinum toxin with a distance of 0.5 cm from each injection and operative wound are injected over both sides of upper lip in a adult on the operation room just after surgery. (total dosage injected 15U)
1704793|NCT01429402|Drug|Normal Saline|Similar amount (in C.C.) of normal saline as group I will be injected after primary lip surgery at 3 months of age.
1704794|NCT01429402|Drug|Normal Saline|Similar amount (in C.C.) of normal saline as study group II will be injected after revision lip surgery (secondary cleft lip repair).
1704795|NCT01429376|Other|Pulmonary function tests|Patients underwent several pulmonary function tests (spirometry, diffusion measurement, body plethysmography) according to the study protocol 1 month after the first blood sample. COPD was diagnosed post-bronchodilation according to GOLD guidelines. Patients with newly diagnosed COPD received standard treatment for COPD. Spirometry was repeated after 3 months of standard treatment for COPD in patients with newly diagnosed COPD to confirm persistent airway obstruction (COPD) and thus exclude asthma.
1704796|NCT01429376|Other|Blood tests|"First blood sample (day 1): NT-pro-BNP, sodium, potassium, urea, creatinin, glomerular filtration rate (GFR).
Second blood sample (after 1 month): NT-pro-BNP, sodium, potassium, urea, creatinin, GFR, haemoglobin, and arterial blood gas analysis in patients with GOLD III COPD. For systemic inflammation substudy also high sensitivity CRP, leukocytes, and platelets.
Third blood sample (after 3 months from second blood sample): NT-pro-BNP, sodium, potassium, urea, creatinin, and GFR."
1704799|NCT01429363|Procedure|Targeted disc decompression|The Targeted disc catheter is connected to Neurotherm TDD unit and heating protocol is started.In this heating protocol temperature gradually increases from 65C to 90C during a time period of 12 minutes;
1704800|NCT01429350|Drug|intravenous (IV) recombinant human tissue plasminogen activator (rtPA)|0.9mg/kg to a maximum of 90mg
1704801|NCT01429350|Device|Penumbra System|The Penumbra System is an aspiration based mechanical thrombectomy device
1704802|NCT01429337|Drug|Midostaurin|Midostaurin 25 mg soft gelatin capsules. The midostaurin capsules will be administered orally with 240 mL of non-carbonated water in the morning (between 8-10 AM), and in the evening (after a 12 hour-break), from Day 1 to Day 6. On day 7, midostaurine will be administered only in the morning.
1704803|NCT01429298|Drug|2 mg IV hydromorphone|2 mg IV hydromorphone
1704804|NCT01429298|Drug|Usual care|Attending administers IV opioid of his choosing
1704805|NCT01429285|Drug|Hydromorphone|0.5 mg IV hydromorphone followed by an optional 0.5 mg IV dose
1704806|NCT01429285|Drug|Usual care|Attending administers any IV opioid in any dose he chooses
1704810|NCT01429259|Drug|meropenem|meropenem 40mg/kg total body weight will be administered every 8 hours. Each infusion will be infused as a 3 hour infusion.
1704811|NCT01429246|Dietary Supplement|Regular Salt|Estimated Household Individual Consumption of 30 grams per day
1704812|NCT01429246|Dietary Supplement|Salt Substitute|Estimated 30 grams per day per household member
1704813|NCT01429194|Procedure|ACE Stapler|The ACE Stapler is used endoscopically, and incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
1704814|NCT01429181|Drug|Non-racemic mixture of methadone HCl|Non-racemic mixture of methadone HCl capsules, 5 mg
1704815|NCT01429168|Drug|Etoricoxib|One 60-mg tablet orally daily
1704816|NCT01429168|Drug|Placebo for etoricoxib|One 60-mg tablet orally daily
1704817|NCT01429155|Genetic|Interleukin 28B genotype|Interleukin 28B genotype will be obtained from a tissue block of the liver explant (liver transplanted patients) Interleukin 28B genotype will be obtained from a blood sample drawn (liver donors)
1704818|NCT01429142|Behavioral|Treatment as usual|In this multi-center trial, the content of usual adherence care is not known prior to the study, but it is part of our data collection to examine the content and variability between clinics and professionals afterwards.
1704819|NCT01429142|Behavioral|AIMS intervention|"The AIMS-intervention is counseling intervention, using MEMS-data printed in simple plots. The following intervention steps will be followed:
-Discussion of practical, tailored information about adherence -Identification of desired adherence level and motivations -Print of patients' MEMS-report and comparison with desired level -ID causes of non-adherence and how to deal with problems -Designing a tailored action plan. -Follow-up: evaluation of accomplishments, remaining problems and solutions, until desired level of adherence has been accomplished. -Formulation of goals for behavioral maintenance.
Among patients starting treatment, the same elements will be delivered but MEMS-feedback can only be incorporated in the second session (after medication has been used). Moreover, a readiness element is added at treatment initiation, where patients discuss the necessity and concerns of initiating medication and are offered the possibility to practice intake for 2 weeks with placebo."
1704820|NCT01429129|Drug|Nicotine replacement therapy|Nicotine transdermal patches as per product monograph
1704821|NCT01429116|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 24 months + 12 month optional extension
1704822|NCT01429090|Procedure|blood sampling|blood sampling before and 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 10, 12, 16 hours after administration of study medication
1704823|NCT01429090|Drug|Vagantin®|administration of 2 coated tablets Vagantin® (coated tablets of 50 mg methantheline bromide)
1704824|NCT01429090|Drug|methantheline solution|administration 100 ml methantheline solution (100 mg methantheline bromide)
1704825|NCT01429090|Procedure|Measurement of salivation|"Volume of salivary gland secretion was measured by chewing a 5 x 5 cm piece of PARAFILM M® (American Can Company, UK) for 5 min. Saliva was collected in glass tubes and the amount of the stimulated saliva was measured by weighing"
1704826|NCT01429090|Procedure|Measurement of accommodation|Accommodation was measured with the optometer according to Schober (Velhagen 1972)
1704827|NCT01429090|Procedure|Pupillometry|Pupil function was assessed with the pupillograph (Compact Integrated Pupillograph, AMTech, Weinheim, Germany). The following data were obtained: pupil diameter, response to defined flash stimuli
1704828|NCT01429077|Drug|levodopa/carbidopa|The study drug (100 mg levodopa / 25 mg carbidopa), is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
1704829|NCT01429077|Drug|Placebo comparator|The placebo comparator (inactive pill) is received orally 30-45 minutes before 1 hour of speech-language treatment, five days a week, for six weeks.
1704830|NCT01429064|Drug|ODM-201|ODM-201 administered orally daily
1704831|NCT01429051|Drug|Intranasal Fentanyl Spray (INFS)|Applied as 1 puff (= 1 dose) in one nostril, or applied as two puffs (= 2 doses, 1 in each nostril) with ten minutes apart.
1704832|NCT01429051|Drug|Placebo|Matching intranasal placebo spray
1704833|NCT01429038|Biological|Mesenchymal Stem Cells|Third party MSC 1,5-3,010E6/kg. No HLA matching between MSC donor and the recipient or the liver/kidney donor. One infusion at day 3+/-2.
1704834|NCT01429025|Biological|rituximab|IV
1704835|NCT01429025|Drug|bendamustine|IV
1704836|NCT01429025|Drug|lenalidomide|PO
1704837|NCT01429012|Biological|Mesenchymal Stem Cells|Mesenchymal Stem Cells. Dose= 40 X 10E6 in 2 ml. Frequency = one injection. If no evidence of a callus after 6 months a second injection can be proposed.
1704838|NCT01429012|Other|Culture medium without MSC.|2 ml of culture medium.
1704839|NCT01428999|Dietary Supplement|probiotics|probiotics 1 pack (2g) bid for three weeks
1704840|NCT01428986|Drug|Maraviroc|Maraviroc, 300mg BID for 72 weeks, except for cases with Efavirenz or Etravirine, 600mg BID for 72 weeks
1704841|NCT01428973|Drug|Mycophenolate mofetil|Tablets. For HLA-identical sibling donors:15 mg/kg t.i.d from day 0 to day 28. For alternative donor: 15 mg/kg, from day 0 to day 42.
1705020|NCT01427816|Drug|KCT-0809|
1704842|NCT01428973|Drug|Sirolimus|Tablets. 6 mg loading dose on day −3, followed by (1)-2 mg daily to a target trough level of 5 to 10 ng/mL. Full doses will be given until day 100 (sibling recipients) or 180 (alternative donor recipients). Doses will then be progressively tapered to be definitely discontinued by day 180 (sibling donors) or 365 (alternative donor recipients) in the absence of GVHD.
1704843|NCT01428960|Dietary Supplement|Palm Mid Fraction, Shea Butter, High Oleic Sunflower Oil|Acute effect of sn-1 and sn-3 palmitic acid-rich or stearic acid-rich fats on postprandial lipemia, haemostatic and inflammatory markers, gut hormone concentrations, satiety, and insulinemic response in human volunteers ; 6 wk each with 2 week wash out in between
1704844|NCT01428947|Procedure|Arterial approach|Randomization to right radial or femoral approach
1704845|NCT01428921|Behavioral|Theory based education and brief motivation interview|"Standard education programme as described above,
Plus
Face-to-face session (Part 1: Knowledge Enhancement Session, Part 2: Brief Motivation Interview Session) after the morning of CPAP titration
Follow-up phone call would be arranged within 1 week after using CPAP.
Video, slides and booklets would be used as education media."
1704846|NCT01428908|Biological|A+C+hib Conjugate Vaccine|The group A, C polysaccharide meningococcal and type b haemophilus influenzal conjugate vaccine (Wuxi Royal Biological Co., LTD, 20110101) will be administered intramuscularly on one arm, per 0.5ml dose
1704847|NCT01428908|Biological|Placebo|Placebo will be administered intramuscularly on the other arm, per 0.5ml dose
1704848|NCT01428908|Biological|A+C Vaccine|The group A, C polysaccharide meningococcal vaccine (Wuxi Royal Biological Co., LTD, 20101202) will be administered intramuscularly on one arm, per 0.5ml dose
1704849|NCT01428908|Biological|Hib vaccine|The type b haemophilus influenzal vaccine (Sanofi Pasteur Limited) will be administered intramuscularly on the other arm, per 0.5ml dose
1704850|NCT01428895|Procedure|Surgery Alone|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
1704851|NCT01428895|Other|Combined Surgery and Radiation therapy|Although we are looking at two groups, this intervention is not protocol specific but is part of the patient's standard management plan. The protocol specific part of the study is completely observational. This involves data being recorded by the attending physician during assessment and patient accounts recorded in the form of questionnaires.
1704852|NCT01428882|Drug|Midazolam|Midazolam (5 mg/5 mL) 2 mg before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
1704853|NCT01428882|Drug|Propofol|Placebo (normal saline 2 ml) before standard propofol induction (0.5-1.5 mg/Kg) and boluses-based sedation during colonoscopy, targeted to a moderate sedation level
1704854|NCT01428843|Drug|FERRISAT|A single infusion of 50 mg/ml of Ferrisat during inclusion visit.
1704855|NCT01428843|Drug|PLACEBO|A single infusion of Glucose 5% solution during inclusion visit
1704856|NCT01428830|Procedure|7-day catheterization following fistula repair surgery|This group will have an indwelling urethral catheter for 7 days following fistula repair surgery.
1704857|NCT01428830|Procedure|14 day catheterization|This group will have an indwelling urethral catheter for 14 days following fistula repair surgery.
1704858|NCT01428817|Drug|Carbetocin|20mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
1704859|NCT01428817|Drug|Carbetocin|40mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
1704860|NCT01428817|Drug|Carbetocin|60mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
1704861|NCT01428817|Drug|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
1704862|NCT01428817|Drug|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
1704863|NCT01428804|Device|transcranial Direct Current Stimulation (tDCS)|Device: Eldith DC-Stimulator real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system) Other Name: Eldith DC - Stimulator (neuroConn GmbH, Ilmenau, Germany)
1704864|NCT01428791|Behavioral|Generations older adult membership program|"Rush Generations is a membership program for older adults emphasizing chronic disease prevention and management through a wide range of health and aging-related programs. Participants assigned to the Generations intervention are actively encouraged to participate in activities, including:
• RUSH-based lectures by experts in the fields of health and aging providing practical information and resources on physical and mental health, functional status, and social support. • Individual and family consultations with social work staff. • Health fairs with a variety of assessment services and information about community-based social service and health agencies. • Assistance with referral to community programs such as physical activity, driver safety events, and mind-body connection workshops."
1704865|NCT01428791|Behavioral|BRIGHTEN Heart Virtual Team intervention|"BRIGHTEN Heart provides an interdisciplinary team evaluation of physical and mental health and on-going support for mental health & health behavior change for 6 - 12 months, including:
• Comprehensive health risk assessment by a licensed social worker, including physical, mental, and functional status. • Virtual team case review and recommendations by interdisciplinary team including psychologist, social worker, occupational therapist, pharmacist, chaplain, dietitian, geriatric psychiatrist, and patient's primary care physician. • Development of Patient Centered Action Plan, in which the social worker assists the patient in prioritizing recommendations. • Monthly telephone calls by the social worker to support implementation of Action Plan and Case Management. • Evidence Based Psychotherapy, as needed, delivered by supervised geriatric psychology and social work fellows."
1704866|NCT01428739|Device|MRS|Procedure
1704867|NCT01428726|Drug|NT-KO-003|NT-KO-003 is a coated tablet, administered once a day
1704868|NCT01428713|Drug|Oral tranexamic acid|Group A received oral tranexamic acid at 1300 mg (two 650mg tablets), three times each day on days 1 to 5 of menstrual cycle for 3 cycles.
1704869|NCT01428713|Drug|Oral Contraceptive Pills|Group B received combined oral contraceptive pills with 3 weeks of hormonal pills and 1 week of placebo for 3 cycles.
1704870|NCT01428687|Behavioral|Sleep Duration|Subjects are taught sleep hygiene strategies to increase their sleep; they record their sleep in a diary and wear an actigraph and call in their sleep to the office each day.
1704871|NCT01428687|Behavioral|No change in sleep|This group is taught to maintain their current sleep habits.
1704873|NCT01428674|Other|Reading while extending loving kindness|The practitioner sits in a room with the participant, pretending to read, while extending loving kindness to the participant.
1704874|NCT01428661|Drug|tasimelteon|20 mg once daily
1704875|NCT01428661|Drug|placebo|once daily
1704876|NCT01428648|Behavioral|Ballroom Dancing Classes|bi-weekly, 12-Week ballroom dance classes
1704878|NCT01428622|Device|Respimat|aqueous and ethanolic solution
1704879|NCT01428622|Device|Respimat|aqueous and ethanolic solution
1704880|NCT01428622|Device|Respimat|aqueous and ethanolic solution
1704881|NCT01428622|Device|Respimat|aqueous and ethanolic solution
1704882|NCT01428622|Device|Respimat|aqueous and ethanolic solution
1704883|NCT01428622|Device|Respimat|aqueous and ethanolic solution
1704884|NCT01428622|Device|Respimat|aqueous and ethanolic solution
1704885|NCT01428622|Drug|Olodaterol|aqueous solution
1704886|NCT01428622|Drug|Olodaterol|aqueous solution
1704887|NCT01428622|Drug|Olodaterol|aqueous solution
1704888|NCT01428622|Drug|Olodaterol|aqueous solution
1704889|NCT01428622|Drug|Olodaterol|aqueous solution
1704890|NCT01428622|Drug|Olodaterol|aqueous solution
1704891|NCT01428622|Drug|Olodaterol|aqueous solution
1704892|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
1704893|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
1704894|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
1704895|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
1704896|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
1704897|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
1704898|NCT01428622|Drug|Olodaterol & BI54903|ethanolic solution
1704899|NCT01428622|Drug|BI54903|ethanolic solution
1704900|NCT01428622|Drug|BI54903|ethanolic solution
1704901|NCT01428622|Drug|BI54903|ethanolic solution
1704902|NCT01428622|Drug|BI54903|ethanolic solution
1704903|NCT01428622|Drug|BI54903|ethanolic solution
1704904|NCT01428622|Drug|BI54903|ethanolic solution
1704905|NCT01428622|Drug|BI54903|ethanolic solution
1704906|NCT01428609|Procedure|Amalgam|In all surgical intervention a zinc free amalgam (Tytin. Kerr Sybron Crop., Romulus, MI) was used in the root end prepared spaces as root end filling material. Blood samples were collected in three period of time immediately before and immediately after each surgery and also one week later.
1704907|NCT01428596|Biological|HIVAX|Vaccine 1.0 ml SQ lower dose (10^8 TU) at weeks 0, 8 and 16.
1704908|NCT01428596|Biological|saline solution|Saline solution 1.0 ml SQ at weeks 0, 8 and 16.
1704909|NCT01428596|Biological|HIVAX|Vaccine 1.0 ml SQ higher dose (10^9 TU) at weeks 0, 8 and 16.
1704910|NCT01428583|Drug|oxycodone HCl and naltrexone HCl extended-release capsules|Daily dose range of 20 mg to 160 mg of the oxycodone component in a 24 hour time interval, administered twice daily approximately 12 hours apart (At the discretion of the Investigator, oxycodone HCl and naltrexone HCl extended-release capsules may be administered once daily, at 24 hour intervals.)
1704911|NCT01428570|Device|Pentax-AWS (AWS; Pentax Corporation, Tokyo, Japan)|Each group of patients will be intubated using the Macintosh laryngoscope or Pentax-AWS.
1704912|NCT01428544|Drug|Fondaparinux sodium|For patients whose body weight is 100 kg or more, fondaparinux is injected 10 mg subcutaneously once daily for treatment of acute pulmonary thromboembolism or acute deep venous thrombosis.
1704913|NCT01428531|Drug|Fondaparinux Sodium|
1704914|NCT01428518|Drug|Lamotrigine tablets|Administered according to the prescribing information in the locally approved label by the authorities.
1704915|NCT01428505|Radiation|[18F]PBR111|radioligand to assess binding to TSPO
1704916|NCT01428492|Drug|GSK2110183|The oral, once daily dose of GSK2110183 will be dependent on the cohort to which a subject is assigned. Subjects enrolled in Cohort 1 will receive 75 mg GSK2110183 once daily. Dose escalation in Schedule A and Schedule B will follow 25 mg increments in a 3+3 dose escalation procedure up to a maximum of 150mg daily or until MTD is reached, whichever comes first, for each schedule. GSK2110183 will continue at daily dosing until treatment discontinuation criteria is met.
1704917|NCT01428492|Drug|Bortezomib|Bortezomib (1.0 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for cohort 1 for up to 8 cycles. Bortezomib (1.3 mg/m2) will be administered on days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles. Bortezomib (1.5 mg/m2) will be administered on days 1, 8, and 15 of each 21-day cycle for up to 8 cycles.
1704918|NCT01428492|Drug|Dexamethasone|Dexamethasone will be given orally at a fixed dose of 20 mg only on days of bortezomib dosing in both Schedule A and Schedule B.
1704919|NCT01428479|Drug|GR121167 Solution|GR121167 solution will be administered intravenously. For 100 mg subject will receive 10 milliliter (mL) of solution, 30 mL for 300 mg and 60 mL for 600 mg
1704920|NCT01428479|Drug|Placebo|Placebo solution will be administered intravenously.
1704921|NCT01428466|Drug|GSK2585823|CLDM1%/BPO3%
1704922|NCT01428466|Drug|Benzoyl peroxide 3%|Benzoyl peroxide 3%
1704923|NCT01428466|Drug|Benzoyl peroxide 5%|Benzoyl peroxide 5%
1704924|NCT01428466|Other|Vehicle|placebo
1704928|NCT01428427|Drug|GSK1120212|Continuous daily oral dosing while on study or disease progression (cycle = 28 days).
1704929|NCT01428427|Drug|Gemcitabine|Dosing once weekly for 3 weeks in a 28 day cycle until disease progression.
1704930|NCT01428414|Drug|Trastuzumab|2 mg/kg, iv, d1,8,15(loading dose 4mg/kg wk1), qw
1704931|NCT01428414|Drug|Paclitaxel|75mg/m2, iv d1, 8,15. qw; 4-6 cycles
1704932|NCT01428414|Drug|Epirubicin|75mg/m2, iv d1, q3w, 4-6 cycles
1704933|NCT01428414|Drug|Carboplatin|AUC 2, qw, iv d1, 8,15. 4-6 cycles
1705021|NCT01427816|Drug|KCT-0809|
1704934|NCT01428401|Drug|Chinese Herb Astragalus membranaceus|Astragalus membranaceus ( AM) at a rate of 3 g three times per day
1704935|NCT01428401|Other|Placebo|at a rate of 3 g three times per day
1704938|NCT01428375|Drug|(1) Paracetamol injection|Drugs: (1) Bottle containing 1000 mg Paracetamol in 100 ml solution for intravenous infusion
1704939|NCT01428375|Other|Sterile water|Drugs: (2) Bottle containing 100 ml sterile water for intravenous infusion
1704940|NCT01428362|Drug|VI-1121|
1704941|NCT01428362|Drug|Placebo|
1704942|NCT01428349|Other|Cognitive Remediation|Computer training on 3 tasks that targets the attention to context deficits associated with psychopathic offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
1704943|NCT01428349|Other|Cognitive Remediation|Computer training on 3 tasks that targets the affective cognitive control deficits associated with externalizing offenders. Participants complete 6 training sessions, that include the tasks, feedback and real-world translational examples.
1704944|NCT01428336|Procedure|1 ug ACTH stimulation test|1 ug cortrosyn dose
1704945|NCT01428336|Procedure|250 ug ACTH stimulation test|ACTH stimulation test will be done using 250 ug cortrosyn dose
1704946|NCT01428336|Procedure|25 ug Cortrosyn stimulation test|ACTH stimulation test using a 25 ug cortrosyn dose
1704947|NCT01428336|Procedure|Insulin tolerance test|subjects will undergo an insulin tolerance test
1704948|NCT01428323|Device|Vented and Unvented Jet Nebulizer|Nebulizers used with 500mg aminoglycosides in 4ml until One minute after the sputerring point.
1704949|NCT01428310|Dietary Supplement|Anatabloc(TM)|one dissolvable bit, one time, after a period of abstinence from smoking
1704950|NCT01428310|Dietary Supplement|CigRx(R)|one dissolvable bit, one time, after a period of abstinence from smoking
1704951|NCT01428297|Drug|BPR277 ointment (controlled application)|
1704952|NCT01428297|Drug|Placebo (Vehicle)|
1704953|NCT01428297|Drug|BPR277 ointment|
1704954|NCT01428297|Drug|Placebo (Vehicle)|
1704955|NCT01428297|Drug|BPR277|
1704956|NCT01428297|Drug|Placebo (Vehicle)|
1704957|NCT01428284|Drug|Canagliflozin/Probenecid|Canagliflozin: Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Probenicid: Type = 1, unit = mg, number = 500, form = tablet, route = oral use. One 300-mg canagliflozin tablet taken orally once daily on Days 1 to 14 (administration of canagliflozin alone) and on Days 15 to 17 (administration of canagliflozin + twice-daily administration of probenecid).
1704958|NCT01428271|Other|Ultrasonography|The confirmation of the real site of the sacral hiatus by ultrasonography
1704959|NCT01428258|Other|GMP Diet/GMP Medical Foods|The intervention consists of a low-phenylalanine (Phe) diet in combination with medical foods made with the peptide GMP supplemented with limiting indispensable amino acids, as provided by Cambrooke Therapeutics, LLC. The diet is formulated to replace the protein equivalents provided by AA medical foods with GMP medical foods, keeping other dietary components constant. The GMP dietary treatment period consists of all subjects following the GMP diet for 3-wks at home. The GMP diet intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
1704960|NCT01428258|Other|AA Diet/AA Medical Foods|The intervention consists of a low-Phe diet in combination with commercial AA medical foods as consumed in each subject's usual diet. A total of 15 different commercial AA medical foods were consumed by subjects in the study. The diet is formulated to provide each subject with their typical daily intake of protein equivalents from AA medical foods. The AA dietary treatment period consists of all subjects following the AA diet for 3-wks at home. The AA Diet comparator intervention is administered in differing orders, GMP Diet/AA Diet or AA diet/GMP Diet.
1704961|NCT01428245|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
1704962|NCT01428245|Drug|Estrace (estrogen)|oral estrace, 0.5-1 mg once a day for seven days
1704963|NCT01428232|Other|implementation of the Baby-Friendly Hospital Initiative|Implementation of BFHI steps 1-9 in maternities
1704964|NCT01428232|Other|BFHI steps 1-9 +well-child clinic|Implementation of BFHI steps 1-9 in maternities and provision of breastfeeding support including culturally appropriate educational messages and metaphors as the ongoing aspect of step 10 in well-child clinic
1704965|NCT01428219|Drug|Cabozantinib|Cabozantinib is available in capsule form. The dose is 60 mg daily by mouth. Subjects with disease progression at 6 weeks who do not have significant toxicities may remain on therapy for an additional six weeks until a progression is confirmed. Further study drug administration beyond 12 weeks will be at the discretion of the investigator provided that the subject does not have disease progression, does not have unacceptable side effects, does not withdraw from study, or does not have a medical condition or illness that renders the subject unacceptable to receive further study drug.
1704966|NCT01428206|Other|Liverpool care pathway|Liverpool care pathway is started tha last day in life for elderly at nursing homes
1704970|NCT01428180|Drug|Indomethacin|3 doses of 0,2mg/kg every 12h (first week of life) or every 8h (after first week of life)
1704971|NCT01428180|Procedure|Surgical Ligation|In nonresponders to medical treatment with persistent hemodynamically relevant patent ductus arteriosus surgical ligation is performed.
1704972|NCT01428180|Drug|Ibuprofen|3 doses every 24h; first dose 10mg/kg, second and third dose 5mg/kg
1704973|NCT01428154|Drug|Darbepoetin alfa|A single 1.5 μg/kg subcutaneous (SC) dose administration on day 1
1705022|NCT01427816|Drug|Placebo|
1705023|NCT01427803|Drug|Naproxen Sodium ER (BAYH6689)|BAYH6689; oral tablet used as needed upon incidence of pain
1705058|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Parent Letter
1705687|NCT01422707|Drug|Hydrocortisone|10 mg/m2/per day PO at bedtime (X4 weeks)
1704974|NCT01428141|Drug|E7050|Drug: E7050 The starting dose of E7050 will be 400 mg given orally, once-daily, in patients with advanced tumor that have progressed following effective therapy. The study consists of 2 parts: a Tolerability Confirmation Component to confirm the tolerable dose in subjects with solid tumor and an Expansion Component to confirm the safety and to preliminarily assess the anti-tumor activity in subjects with gastric cancer.
1704975|NCT01428128|Drug|Arsenic Trioxide|IV; 0.005mg/kg. Infusion on Days -3, -2 and -1 of Chemo Cycles 2, 4, and 6 (if more than 4 cycles received).
1704976|NCT01428089|Drug|Progesterone|Subjects will take 5-25 mg oral micronized P (based on body weight, to achieve mean plasma P 1-2 ng/ml) or placebo at 1100, 1500, and 1900 h.
1704977|NCT01428089|Drug|Placebo|Placebo
1704978|NCT01428076|Drug|Polidocanol Endovenous Microfoam (PEM)|Pharmacokinetic comparison of different doses of drug
1704979|NCT01428063|Drug|Daclatasvir|
1704980|NCT01428063|Drug|Asunaprevir|
1704981|NCT01428063|Drug|Pegylated interferon alfa-2a|
1704982|NCT01428063|Drug|Ribavirin|
1704983|NCT01428050|Drug|3% NaCl Solution|1cc/kg/hr of 3%NaCl + 9cc/kg/hr of lactated ringers solution
1704984|NCT01428050|Drug|Lactated Ringers Solution|15cc/kg/hr for intraoperative fluids
1704985|NCT01428037|Drug|Placebo|One tablet vaginal inserted at 4 hrly interval with maximum of three doses
1704986|NCT01428037|Drug|Misoprostol vaginal Tablet 25 mcg|One tablet vaginal insert at 4 hrly interval with maximum of three doses
1956127|NCT02956798|Radiation|Radiation|treatment regimens including ≥25Gy x1 fraction, ≥12Gy x 3 fractions, or ≥8Gy x 5 fractions
1956128|NCT02956798|Drug|Pazopanib|800mg, PO, daily until progression
1704989|NCT01427998|Dietary Supplement|olive leaf extract|olive leaf extract, 1 pill daily, 500 mg, for a duration of 14 wks
1704990|NCT01427998|Other|placebo|placebo
1704991|NCT01427985|Drug|Atropine, Fentanyl, Mivacurium|"Atropin 10µg/kg
Mivacurium 200µg/kg immediately followed by
Fentanyl 2µg/kg"
1704992|NCT01427985|Drug|Atropine, Fentanyl, Mivacurium|"Atropin 10µg/kg
Fentanyl 2µg/kg, repeat max. two times
Mivacurium 200µg/kg"
1704995|NCT01427946|Drug|IPI-504|
1704996|NCT01427946|Drug|Everolimus|
1704997|NCT01427933|Biological|Ramucirumab (IMC-1121B)|Administered intravenously
1704998|NCT01427933|Drug|Eribulin|Administered intravenously
1704999|NCT01427920|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) using FlexPen® twice daily for 20 weeks. Directions for use were given to each subject at each dispensing visit. Subjects continued on their pre-trial metformin dose. Any previous basal insulin analogue and OAD (oral anti-diabetes drug) treatments (except for metformin) were discontinued.
1705000|NCT01427907|Drug|Calcium acetate oral solution (COS)|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
1705001|NCT01427907|Drug|Sevelamer carbonate|Each subject will undergo two separate treatment periods. Subjects will ingest either COS or sevelamer for 28 days (Treatment Period 1) and then switch to the other binder for 28 days (Treatment Period 2).
1705002|NCT01427894|Other|Maternal singing with Kangaroo Care|Maternal singing with Kangaroo Care
1705003|NCT01427881|Drug|cyclophosphamide|Given IV
1705004|NCT01427881|Drug|cyclosporine|Given IV
1705005|NCT01427881|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSCT
1705006|NCT01427881|Radiation|total-body irradiation|Undergo TBI
1705007|NCT01427881|Drug|fludarabine phosphate|Given IV
1705008|NCT01427881|Drug|busulfan|Given IV
1705009|NCT01427881|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
1705010|NCT01427868|Drug|LB80380 maleate salt|183 mg (150 mg as a free base)
1705011|NCT01427868|Drug|LB80380 free base|150 mg
1705012|NCT01427855|Other|High saturated fat red meat diet|4 weeks of a high saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (15% kcal from saturated fat))
1705013|NCT01427855|Other|High saturated fat non-meat diet|4 weeks of a high saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (15% kcal from saturated fat))
1705014|NCT01427855|Other|High saturated fat white meat diet|4 weeks of a high saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (15% kcal from saturated fat))
1705015|NCT01427855|Other|Low saturated fat red meat diet|4 weeks of a low saturated fat red meat diet (38% carbohydrate; 25% protein (12% kcal from red meat protein); 37% fat (7% kcal from saturated fat))
1705016|NCT01427855|Other|Low saturated fat white meat diet|4 weeks of a low saturated fat white meat diet (38% carbohydrate; 25% protein (12% kcal from white meat protein); 37% fat (7% kcal from saturated fat))
1705017|NCT01427855|Other|Low saturated fat non meat diet|4 weeks of a low saturated fat non-meat diet (38% carbohydrate; 25% protein (16% kcal from non-meat protein); 37% fat (7% kcal from saturated fat))
1705018|NCT01427842|Drug|DEVINE vancomycin regimen|The dosing regimen varies by weight and height and by initial or ongoing dose prescribed. The loading dose is based on actual volume of distribution of vancomycin whilst the ongoing doses are based on creatinine clearance.
1705019|NCT01427829|Behavioral|Computer-assisted Psychosocial Risk Assessment (CaPRA)|The study intervention was a touch-screen self-assessment survey which eligible patients completed on a touch-screen iPad in Dari/Farsi language while waiting to see their medical practitioner. The Computer-assisted Psychosocial Risk Assessment (CaPRA) survey had questions on psychosocial risks (e.g., alcohol, tobacco and street drug use, sexual health, personal violence, post-traumatic stress disorder, depression, and food insecurity), cardiovascular risks (e.g., physical activity, weight, diabetes, and hypertension), road and home safety, stress buffers (e.g., coping and social support) and sociodemographics. The tool generated two tailored print-outs at the point of care. The recommendation sheet for patients summarized their disclosed risks in simple Dari/Farsi language along with contacts of relevant services. The risk-report for medical practitioner summarized patients' risks with possible referrals. This was attached to the medical chart prior to the consult.
1705024|NCT01427764|Device|manual and ultrasonic instruments|"The individuals were instructed regarding causes and consequences of periodontal disease as well as prevention techniques, including the sulcular brushing technique and flossing. The retention factors of plaque (caries cavities, excess supragingival restorations and calculus) were removed during the initial visits. Clinical parameters were initially assessed 30 days after initial therapy.
The quadrants were randomly assigned and a total of 28 teeth were examined and treated. One side was treated with Gracey curettes (Hu-Friedy™ - Chicago, IL, USA) - control group and the other side with ultrasonic instruments (Profi II Ceramic™, Dabi Atlante - Ribeirão Preto, São Paulo, Brazil) - the test group, using the tip for subgingival instrumentation Perio Sub (Dabi Atlante ®)."
1705025|NCT01427751|Drug|dexamethasone intravitreal implant|Injection of Ozurdex® (dexamethasone intravitreal implant) into the study eye on Day 1 and Month 5. Patients may receive up to one additional treatment, thereafter.
1705026|NCT01427751|Biological|ranibizumab|Injection of Lucentis® (ranibizumab) into the study eye on Day 1 and monthly for five months. Patients will receive additional treatment thereafter based on re-treatment criteria.
1705027|NCT01427738|Drug|Gentian Violet|Participants were administered topical Gentian violet solution, orally, twice daily for 14 days.
1705028|NCT01427738|Drug|Nystatin oral suspension|Participants were administered Nystatin oral suspension 4 times a day for 14 days.
1705029|NCT01427699|Drug|T2-18C3 therapeutic antibody|1.25 mg/kg Intravenous infusion every 2 weeks for a total of 4 doses.
1705030|NCT01427686|Drug|Dobutamine|Start Dobutamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dopamine.
1705031|NCT01427686|Drug|Dopamine|Start Dopamine with 5µg/kg/min. Increase as needed until mean arterial pressure is in normal range (defined by responsible neonatologist, usually between gestational age in weeks and 10mmHg above this threshold) or until a maximum dose of 15µg/kg/min is reached. Only in the latter case switch to Dobutamine.
1705032|NCT01427673|Procedure|Bipap procedure|Overlap patients randomized to Bipap titrated per AASM guidleines with an IPAP to EPAP diffrence of at least 8 cm H2O.
1705033|NCT01427660|Behavioral|Community Health Worker Diabetes Education: Print media|Providing information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
1705034|NCT01427660|Behavioral|CHW Diabetes Education: tailored web site|Providing tailored and interactive information to patients about potential benefits, harms, costs, and burdens of medications and discussing patients' treatment preferences.
1705035|NCT01427647|Procedure|Laparoscopic technique and thoracic epidural anesthesia|We have compared colorectal cancer surgery under two types of surgical(laparoscopic versus open) and anesthesia (thoracic epidural versus general) techniques
1705036|NCT01427634|Behavioral|Palliative Care|Receive ongoing counseling and symptom assessment as well as clarification and documentation of goals of care, starting before implantation and continuing throughout the course of the study. Intervention patients will also be followed by the inpatient palliative care consultation service when hospitalized for their initial VAD implantation and during any subsequent hospitalizations as needed
1705037|NCT01427634|Other|Usual Care|Receive usual care as provided by the VAD clinical team.
1705038|NCT01427621|Procedure|remote ischemic pre and postconditioning (RIPC)|RIPCcom group: combined intervention of remote ischemic pre- and postconditioning consisted of three 10-minute cycles of right lower limb ischemia, which was induced with an automated cuff-inflator placed on the right upper leg and inflated to 250 mmHg, with an intervening 10 minute of reperfusion during which the cuff was deflated. This intervention were performed at 10 minutes after induction of anesthesia and then 10 min after weaning from CPB.
1705039|NCT01427608|Drug|Olanzapine|Olanzapine 15mg/day. Adjustment of dose to 5mg/day to a maximum of 20mg/day will be permitted if necessitated by significant side-effects or clinical worsening
1705040|NCT01427608|Drug|Placebo|Taper from current dose of olanzapine to placebo over 4 weeks. Continue placebo for remainder of 36 week study.
1705041|NCT01427595|Drug|Metformin|500-2000 mg PO BID (X12 weeks)
1705042|NCT01427595|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days (X2)
1705043|NCT01427595|Drug|estrace|oral estrogen (estrace, 0.5-1 mg once a day for seven days)- X2
1705044|NCT01427582|Drug|Trabectedin|Trabectedin i.v. formulation at a dose of 1.5 mg/m2 i.v. over 24 hours on Day 1 every 21 days
1705045|NCT01427569|Drug|IZN-6D4 Gel|Standard wound therapy plus twice weekly topical application of hydrogel containing botanical extracts.
1705046|NCT01427569|Other|Placebo hydrogel|Standard wound therapy plus twice weekly topical application of color-matched placebo hydrogel
1705047|NCT01427543|Behavioral|MILE intervention|Participants will be asked to attend 6 - 2 hour group sessions over the course of 3 weeks. The intervention aims to reduce HIV risk taking related to sex risk and alcohol and drug use.
1705048|NCT01427530|Device|Deep Brain Stimulation|Deep Brain Stimulation
1705049|NCT01427517|Drug|N-acetylcysteine|Single, intravenous administration of N-acetylcysteine
1705050|NCT01427504|Drug|boceprevir; etravirine|boceprevir tablets 800 mg, every 8 hours x 11-14 days. etravirine tablets 200 mg, every 12 hours x 11-14 days.
1705051|NCT01427491|Device|Aquacel® Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
1705052|NCT01427491|Device|Mepilex® Border Ag|Dressing will be changed during the clinic visit on day 3, 7 and 14. In between the clinic visits the dressing should be changed when needed depending on the clinical condition of the wound and the volume of exudate.
1705053|NCT01427478|Drug|AFATINIB|AFATINIBat the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
1705054|NCT01427478|Drug|Placebo of AFATINIB|placebo of Afatinib at the dose of 40 mg/during the 1st month and then 50 mg/d during the 11 following months
1705055|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Consult
1705056|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Control - Standard of Care
1705057|NCT01427465|Behavioral|Brief Prevention Program Using Positive Image|Newsletter
1706370|NCT01417013|Other|Systane Ultra|Lubricant Eye Drops
1705059|NCT01427426|Dietary Supplement|All Greens|All Greens is a mixture of organic alfalfa powder, barley, wheat grass juice powder, lycopene, cranberry juice extract, rosehips, grapeseed phytosomes, soya extract, Acidophilus, bromelain, apple pectin, and other ingredients. All Greens is approved by Health Canada and available to the public for purchase.
1705060|NCT01427426|Other|Control Formulation|The Control Formulation is a rice-flour based product that has been designed to mimic the All Greens in appearance and taste.
1705061|NCT01427400|Drug|Botulinum Toxin-A|100 Units diluted in 25cc saline
1705062|NCT01427400|Drug|Saline|Dispensed in a 25cc syringe
1705063|NCT01427387|Drug|ASP0456|oral
1705064|NCT01427387|Drug|Placebo|oral
1705065|NCT01427348|Procedure|with assistant|head extension by an assistant during direct laryngoscopy
1705066|NCT01427348|Procedure|without assistant|without head extension by an assistant during direct laryngoscopy
1705067|NCT01427335|Drug|calcium|"intravenous infusion of 10 % calcium gluconate 10 mL in 200 mL of physiologic saline on the day of ovum pickup, day 1,day 2, and day 3 after ovum pickup were administered in study group.
Intravenous infusion was performed within 30 minutes"
1705068|NCT01427335|Drug|0.9 % saline|0.9 % saline intravenous infusion
1705069|NCT01427322|Drug|Lapatinib|given orally 2-4 hours before first fraction of radiation therapy
1705070|NCT01427322|Radiation|Radiation therapy|Standard radiation therapy
1705071|NCT01427309|Biological|High Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
1705072|NCT01427309|Biological|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
1705073|NCT01427296|Drug|Polyethylene glycol|HalfLytely and Bisacodyl Tablet Bowel Prep Kit, administered as 1 bisacodyl tablet followed by HalfLytely oral solution in a total liquid volume of approximately 2 L
1705074|NCT01427296|Drug|Oral sodium phosphate solution|OsmoPrep tablets (48 g), administered as 32 total tablets in a total liquid volume of approximately 2 L
1705075|NCT01427283|Drug|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
1705076|NCT01427283|Drug|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
1705077|NCT01427283|Drug|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
1705078|NCT01427270|Drug|Oxycodone/Naloxone controlled-release|Oxycodone/Naloxone controlled-release tablets (10/5 - 40/20 mg) taken orally every 12 hours
1705079|NCT01427270|Drug|Oxycodone HCl controlled-release|Oxycodone HCl controlled-release tablets (10 - 40 mg) taken orally every 12 hours
1705080|NCT01427270|Drug|Placebo|Placebo tablets to match OXN or OXY taken orally every 12 hours
1705081|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation A
1705082|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation B
1705083|NCT01427257|Drug|Single Dose PB1023|Single Dose PB1023 Formulation B
1705084|NCT01427244|Drug|trastuzumab|monoclonal antibody
1705085|NCT01427231|Dietary Supplement|glucose|The effect of a glucose solution on cognitive performance will be measured.
1705086|NCT01427231|Dietary Supplement|sacharose|The effect of a sacharose solution on cognitive performance will be measured.
1705087|NCT01427231|Dietary Supplement|Placebo|The effect of a placebo drink with sweeteners on cognitive performance will be measured.
1705088|NCT01427218|Other|Titration of medications|Titration of medications for cholesterol, blood pressure, heart failure, and angina will occur. Cholesterol medications will be titrated according to labs at intervals nor more frequently than every 6 weeks until target LDL reached. Blood pressure (BP) medications will be titrated no more frequently than every 1-2 weeks until target BP reached. Heart failure medications will be titrated no more frequently than every 1-2 weeks until target doses reached or clinical status goals achieved. Anginal (chest pain) medications will be titrated no more frequently than every 1-2 weeks until control of chest pain occurs. Some patients will require more titrations than other patients (titration is patient specific).
1705089|NCT01427218|Behavioral|Lifestyle Counseling|The pharmacist will provide counseling on diet modification, smoking cessation, and physical activity
1705090|NCT01427218|Behavioral|Medication Counseling|The pharmacist will counsel the patient on adherence aids and medication safety and efficacy self and clinical monitoring.
1705091|NCT01427218|Other|Usual Care with Medication Reconciliation|A medication history and assessment of adherence will be completed by the pharmacist.
1705092|NCT01427205|Drug|Cetuximab|Loading dose 400 mg/m2 by vein once followed by 250 mg/m2 weekly (+/- 7 days).
1705093|NCT01427205|Drug|OSI-906|150 mg by mouth twice a day.
1705094|NCT01427205|Other|Placebo|Placebo taken by mouth twice daily.
1705095|NCT01427192|Drug|acetazolamide|250 mg bid
1705096|NCT01427192|Other|Supplemental oxygen|Oxygen deliverded by nasal cannula
1705097|NCT01427192|Procedure|Non-invasive ventilation|Bi-level non-invasive ventilation via nasal mask
1705098|NCT01427192|Other|Room air|Room air applied via sham oxygen concentrator
1705099|NCT01427192|Drug|Placebo tablet|Placebo tablet (Mannitol) similar to acetazolamide
1705100|NCT01427166|Other|Non invasive venous ultrasound|Subjects will undergo a venous duplex ultrasound, on a General Electric LOGIQ-9 unit with a Phillips-IU-22 probe
1705101|NCT01427153|Procedure|Orthopaedic manual physical therapy|OMPT consists of joint and soft-tissue mobilizations and the exercises that reinforce the manual techniques.
1705102|NCT01427153|Procedure|Corticosteroid Injection|Corticosteroid injection to the tibiofemoral joint
1705103|NCT01427140|Other|Polyunsaturated fatty acid group|Addition of polyunsaturated fatty acids to the diet in the form of pastries
1705104|NCT01427140|Other|Saturated fatty acid group|Addition of saturated fatty acids to the diet in the form of pastries
1705105|NCT01427127|Drug|Ramosetron|Patients received intravenous ramosetron 0.3 mg at end of surgery and 24hr after surgery.
1705106|NCT01427114|Drug|rituximab, cyclophosphamide, vincristine, and prednisolone|6 cycles of R-CVP followed by 2 cycles of rituximab
1705107|NCT01427088|Device|CR Technology, TAMAS for repetitive TMS|repetitive TMS, lef DLPFC, 20Hz, 100% of MEP, 2weeks
1705108|NCT01427075|Procedure|LATERAL PHARYNGOPLASTY|tonsilectomy and lateral pharyngoplasty
1705263|NCT01425814|Drug|Reference|Dry powder inhalation (capsule),single dose
1765219|NCT00322660|Drug|Adrenaline|
1705111|NCT01427049|Device|renal denervation|percutaneous selective renal sympathetic denervation with the use of the Symplicity Catheter system
1705112|NCT01427036|Procedure|MISS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.
Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.
skin incision 6 to 8 cm in the axis of the proximal femur, beginning a little above trochanteric crest in, then incised longitudinally extensive externe1 cm under the sub trochanteric crest, on a length of 3 cm. Passage of the raspatory along thefemoral shaft under the muscle on the entire length of the plate."
1705113|NCT01427036|Procedure|PHS|"Installation of the patient in the operating room (same technique for MISS and PHS) operated supine on a fracture table, a fluoroscope (C Arm) authorizing a control AP and lateral.
Reduction of the fracture before incision (same technique for MISS and PHS): it is essential for minimally invasive surgery and inclusion in the study. One checked on the AP and the lateral view the absence of a fracture gap greater than the thickness of the the cortical.
Surgical approach for PHS : Longitudinal external starting on trochanteric crest, long 15-20 cm depending on morphotype of the patient. Incision of the fascia latta like a  L  detaching the vastus lateralis to expose the external surface of the femur on the length of the plate."
1705114|NCT01427023|Device|APTIMA Trichomonas vaginalis (ATV) Assay|APTIMA Trichomonas vaginalis (ATV) Assay
1705115|NCT01427010|Radiation|[18F]FDG-PET-voxel intensity-based IMRT|Non-controlled, non-randomized, prospective study on 18F-Fluorodeoxyglucose-Positron Emission Tomography ([18F]FDG-PET)-voxel intensity-based intensity-modulated radiotherapy (IMRT) (dose painting) adapted to the anatomical and biological changes as detected by per-treatment FDG-PET/Computertomography (CT) acquired at the end of the 2nd and the 4th week of treatment.
1705116|NCT01426984|Drug|methylphenidate|a capsule containing 20 mg
1705117|NCT01426971|Drug|IBUPROFEN + CAFFEINE|Pharmaceutical form: capsule Route of administration: oral
1705118|NCT01426971|Drug|IBUPROFEN|Pharmaceutical form: capsule Route of administration: oral
1705119|NCT01426958|Drug|afatinib|standard therapeutic dose
1705120|NCT01426958|Drug|ritonavir + afatinib|simultaneous intake of ritonavir and afatinib on second treatment day
1705121|NCT01426958|Drug|ritonavir + afatinib|on the second treatment day the first ritonavir tablet will be taken 6 hours after the afatinib tablet
1705122|NCT01426945|Genetic|protein expression analysis|
1705123|NCT01426945|Other|immunohistochemistry staining method|
1705124|NCT01426945|Other|laboratory biomarker analysis|
1705125|NCT01426932|Other|Video recording of Head Impulse Test|Video recording of Head Impulse Test
1705126|NCT01426919|Other|Head CT scan and blood draw within 12 hours of injury|
1705127|NCT01426906|Drug|Ketoconazole|Period 1 : LC15-0444 Period 2 : LC15-0444 with ketoconazole
1705128|NCT01426906|Drug|rifampicin|Period 1 : LC15-0444 Period 2 : LC15-0444 with rifampicin
1705129|NCT01426880|Drug|Carboplatin|Carboplatin, AUC, 2 min/mL weekly, infusion
1705130|NCT01426880|Drug|background treatment|"background treatment according to standards fpr triple negative and Her2pos breast cancer patients Paclitaxel: 80 mg/m² i.v. given weekly on day 1 q day 8 for 18 weeks. NPLD (Myocet®): 20 mg/m² weekly on day 1 q day 8 for 18 weeks Trastuzumab (only for HER2-positive patients): Loading dose: 8 mg/kg, Maintenance dose: 6 mg/kg, day 1 q day 22 for 6 cycles. Post-surgery: up to a total duration of 1 year according to current AGO guidelines Lapatinib 750 mg/day p.o. continuously for 18 weeks; in case of good tolerability (no CTC grade II toxicity except alopecia and nausea/vomiting) during the first cycle the dose may be escalated to 1000 mg.
Bevacizumab: 15 mg/kg i.v., day 1 q day 22 for 6 cycles (only in TNBC patients)."
1705131|NCT01426867|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
1705132|NCT01426867|Drug|Brinzolamide ophthalmic suspension, 1%|
1705133|NCT01426867|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
1705134|NCT01426854|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Topical ocular administration
1705135|NCT01426854|Other|Nepafenac Vehicle Ophthalmic Solution|Inactive ingredients used as placebo; topical ocular administration
1705136|NCT01426841|Radiation|Adaptive Radiation|Thoracic Radiotherapy which is adapted or adjusted during its course to account for tumor volume shrinkage which occurs during treatment
1705137|NCT01426828|Biological|CD3/CD28|CD3/CD28 activated autologous lymphocytes intravenously
1705138|NCT01426815|Drug|Placebo|The prefilled syringe with placebo will be administrated subcutaneously every 4 weeks during a study period of 24 weeks.
1705139|NCT01426815|Drug|Golimumab|The prefilled syringe with golimumab 50mg (Simponi ®) will be administrated subcutaneously every 4 weeks during a study period of 48 weeks.
1705140|NCT01426802|Drug|vildagliptin|Drug 50mg vildagliptin bid
1705141|NCT01426789|Drug|Placebo|Matching placebo to secukinumab I.V.
1705142|NCT01426789|Drug|Secukinumab|In part 1 (blinded period), participants randomized to secukinumab received 10 mg/kg I.V.. Participants, enrolled in part 2 (open label), received secukinumab 300 mg subcutaneous.
1705143|NCT01426776|Procedure|heart valve replacement|The patients with heart valve disease and CSR will be received heart valve replacement
1705144|NCT01426763|Biological|CINRYZE with rHuPH20|
1705145|NCT01426750|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
1705146|NCT01426737|Drug|Vildagliptin|Vildagliptin 50mg twice/d as add-on to metformin alone over 18 months compared to an add-on therapy with gliclazide 30mg max 4x/d(metformin - gliclazide).
1705147|NCT01426724|Drug|Contrast Enhanced Ultrasonography|Definity microbubbles will be infused intravenously at a rate of 2mL/min. contrast enhanced images of the kidneys will be obtained during the infusion and following the destruction of microbubbles within the kidney tissue with ultrasound to measure renal blood flow two times within a 90 day (plus or minus 10 day) window
1705148|NCT01426698|Procedure|delayed cord clamping|at birth, the obstetrical provider delays the cord clamping for 45 seconds while lowering the infant. At 45 seconds the cord is milked once and then clamped and cut.
1705149|NCT01426672|Other|Monovision Correction (with the help of glasses or contact lenses)|
1705150|NCT01426659|Behavioral|parental stimulation according to protocol|"verbal stimulation every day image of the Protocol Dire et Faire"
1705151|NCT01426646|Drug|S-1|S-1 was administered at 40mg/m2 orally twice daily (days 1-28) every 42 days. Patients received a maximum of eight cycles.
1705152|NCT01426646|Drug|S-1 plus cisplatin|"S-1 plus cisplatin every 3 weeks, a total of eight cycles
S-1: 40mg/m2 orally twice daily (days 1-14)
Cisplatin: 60mg/m2 IV on day 1"
1705153|NCT01426633|Drug|Gemcitabine + Trabectedin|Combination therapy of gemcitabine and trabectedin
1705154|NCT01426620|Dietary Supplement|Blueberry powder|The intervention consists of 2-3 packages (15 grams per package) of lyophilized blueberry powder, taken daily after mixing with natural yogurt, milk, water, or juice in combination with set dosage of docetaxel (35 milligrams per meter squared) administered intravenously every week for 4 cycles, 21-day cycles.
1705155|NCT01426607|Device|AMO|
1705156|NCT01426581|Behavioral|Teach-To-Goal|"Participants observe a demonstration on the use of each inhaler, with corresponding verbal step-by-step instructions (demonstration, verbal instruction), then participants 'teachback or re-demonstrate the steps; cycles are repeated are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)"
1705157|NCT01426581|Behavioral|Brief Intervention|Participants are read step-by-step instructions (verbal instructions) for each respective inhaler (Metered Dose Inhaler +/- Diskus), and receive a copy of these instructions with images depicting the steps (written instructions)
1705158|NCT01426568|Behavioral|Multi-Convergent Therapy|Cognitive Behavioural Therapy Relaxation Techniques Meditation Stress Management
1705159|NCT01426555|Other|FES-Rowing|FES- Rowing Exercise
1705160|NCT01426555|Drug|Zoledronic acid|5 mg IV single dose
1705161|NCT01426542|Drug|Topiramate|Topiramate 5 mg/kg by mouth (or by feeding tube) once a day for one week before and one week after heart surgery.
1705162|NCT01426542|Other|No medication, but routine heart surgery|No medication, but routine heart surgery
1705163|NCT01426529|Drug|Para-aminohippuric Acid|"Aminohippurate sodium is an agent to measure effective renal plasma flow (ERPF). It is the sodium salt of para-aminohippuric acid, commonly abbreviated PAH."
1705164|NCT01426529|Drug|Angiotensin II|Angiotensin II (Ang II) is a naturally occurring hormone whose primary purpose is to regulate the body's internal volume. It accomplishes this task by influencing the function of a variety of organs and tissues. It increases aldosterone secretion from the adrenal gland. It causes blood vessels to contract, particularly renal blood vessels, and it modifies the way the heart works.
1705165|NCT01426529|Drug|Norepinephrine|A hormone that is normally present in your body, which regulates your blood pressure.
1705166|NCT01426516|Device|Genecept Assay|Genetic test which analyzes five pharmacodynamic and two pharmacokinetic genes important in psychiatric disorders
1705167|NCT01426490|Dietary Supplement|Vitamin C|Vitamin C, 100 mg/d
1705168|NCT01426490|Dietary Supplement|Vitamin B6|Vitamin B6, 50mg/d
1705169|NCT01426490|Dietary Supplement|Folic acid|Folic acid 400 microgram/d
1705170|NCT01426490|Dietary Supplement|Vitamin B6 plus folic acid|Vitamin B6, 50 mg; folic acid, 400 microgram
1705171|NCT01426464|Drug|0.005% Latanoprost dosed once.|0.005% Latanoprost dosed once. Placebo lotion dosed once.
1705172|NCT01426451|Other|Group tutoring program|Academic in-class intervention that focuses on differentiated academic instruction and improved overall academic adjustment. In each classroom assigned to the tutorship intervention, two academic resource assistants will provide weekly in-class support to students for the same length of time than the drama workshop (75 minutes, once a week), with the teacher present in the classroom.
1705173|NCT01426451|Other|Theatre workshops|The theatre expression workshops will run for 12 weeks, with one 75-minute workshop per week. They will be incorporated into the regular class timetable and will be run by the two members of the intervention team who have training in theatre and psychology, and the homeroom teacher, whose level of direct involvement will increase gradually as he or she becomes familiar with the workshops.
1705174|NCT01426438|Drug|Niacin|Extended-release niacin will be given with aspirin 325 mg by mouth in the evening and dose-escalated as follows: 500 mg once daily for 4 weeks, 1000 mg once daily for 4 weeks, then 1500 mg once daily for 16 weeks (through week 24)
1705175|NCT01426438|Drug|Aspirin|Aspirin 325 mg will be given by mouth in the evening with extended-release niacin through week 24.
1705176|NCT01426438|Drug|Fenofibrate|Fenofibrate will be administered as 200 mg by mouth once daily for 24 weeks.
1705177|NCT01426425|Device|Freezor Xtra Cryoablation Catheter|Freezor® Xtra Cardiac CryoAblation applied for cryoablation of the conducting tissues of the heart in the treatment of patients with atrioventricular nodal reentrant tachycardia using an endocardial approach.
1705178|NCT01426412|Drug|LY3015014 (intravenously)|Administered intravenously over 30-90 minutes
1705179|NCT01426412|Drug|Placebo (intravenously)|Administered intravenously only over 30-90 minutes
1705180|NCT01426412|Drug|LY3015014 (subcutaneously)|Administered subcutaneously
1705181|NCT01426412|Drug|Placebo (subcutaneously)|Administered subcutaneously
1705182|NCT01426399|Drug|LC15-0444|LC15-0444 50mg qd (8 days once daily)
1705183|NCT01426399|Drug|Metformin|Metformin 1000 mg bid (8 days twice daily)
1705184|NCT01426399|Drug|LC15-0444+Metformin|LC15-0444 50mg qd (8 days once daily) + Metformin 1000 mg bid (8 days twice daily)
1705185|NCT01426386|Drug|FE 999049|
1705186|NCT01426386|Drug|Gonal - F|
1706371|NCT01417013|Other|Optive|Lubricant eye drops
1705187|NCT01426373|Drug|Deoxycholic acid injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
1705188|NCT01426360|Other|control dentifrice|use the dentifrice to brush teeth twice a day for one minute for 3 days
1705189|NCT01426360|Other|strontium chloride/potassium nitrate dentifrice|use the dentifrice to brush teeth twice daily for 3 days
1705190|NCT01426347|Drug|Placebo sugar pill|Intervention includes 1 sugar pill once a week for 16 weeks dispensed as a capsule.
1705191|NCT01426347|Drug|Ergocalciferol|Ergocalciferol 50,000 IU per week for 16 weeks
1705192|NCT01426334|Drug|dasatinib|Given PO
1705193|NCT01426334|Other|diagnostic laboratory biomarker analysis|Correlative studies
1705194|NCT01426334|Other|pharmacological study|Correlative studies
1705195|NCT01426334|Drug|cyclosporine|Given PO
1705196|NCT01426321|Other|Imaging guided LV lead positioning|"LV lead positioning guided by echocardiography (mechanical strain evaluation by speckle tracking) in combination with cardiac CT. A viable segment with the latest mechanical activation is targeted, and an appropriate optimal cardiac vein segment is then chosen using the CT images."
1705197|NCT01426295|Device|Caphosol|"The Caphosol ™ is a recently launched medical in France (2009). (source: laboratory EUSA Pharma ®)
The product is an aqueous solution for mouthwash that comes in the form of a hyper-saturated mixture of calcium phosphate at neutral pH to reconstitute immediately before use.
Each patient randomized to the treatment arms in the study will receive daily at least 4 (maximum 10) mouthwash Caphosol ™.
The treatments are to begin preventive J1 to chemotherapy and continued until out of aplasia (ANC> 500/mm3), and / or mucositis grade 0."
1705198|NCT01426295|Drug|Bicarbonate de sodium|"Treatment of the early start on the day of conditioning and stop when the ANC> 500/mm3 and / or mucositis grade zero, provisional date of bone exceeded.
Versylène: Method of administration: gargle made with a minute from 15 to 30 mL, 2-5 times a day, alternating with PAROEX ®."
1705199|NCT01426282|Other|no intervention|no intervention
1705200|NCT01426282|Other|health education|"15 minutes health education given by nurse according to  The Chinese Resident Meals Guide  , National Revision Committee of the Guidelines of Hypertension Prevention and Control in 2005 ,  Guidelines on Prevention and Treatment of Blood Lipid Abnormality in Chinese Adults  ,  Guideline for diagnosis and treatment of patients with chronic stable angina , Guideline for prevention and treatment overweight and obesity in chinese adults "
1705201|NCT01426269|Drug|Doxycycline|During phase 1 (baseline - week 12): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads)), oral, one capsule daily in the morning During phase 1 (baseline - week 12) and phase 2 (week 12 - week 52): Oracea (doxycycline 40 mg USP (30 mg immediate release & 10 mg delayed release beads), oral, one capsule daily in the morning
1705202|NCT01426269|Drug|Metronidazole|During Phase 1: MetroGel 1% (metronidazole 1% gel), topical, apply a thin layer once daily to the affected area
1705203|NCT01426269|Drug|Placebo|During phase 2 (week 12 - week 52): placebo, oral, one capsule daily in the morning
1705204|NCT01426256|Dietary Supplement|Cholecalciferol|Bolus dose of 250,000 IU during hospitalization + maintenance dose of 50,000 IU vitamin D every other week to be initiated 3 months after bolus dose
1705205|NCT01426243|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
1705206|NCT01426243|Biological|Yellow fever vaccination (STAMARIL)|Yellow fever vaccination (STAMARIL)
1705207|NCT01426191|Drug|xinzhijun|"durg:Cefotaxime sodium and sulbactam sodium for injection(2:1)
1.5-3.0g,iv,bid or tid for 5-12 days;
Serious infections:1.0-1.5g,iv,tid or qid for 5-12 days"
1705208|NCT01426178|Device|Neurally Adjusted Ventilatory Assist in Non Invasive Ventilation (Device)|"After written information and consent, patients are randomised in two groups: NAVA first or PSV first.
They receive a NAVA catheter, which has exactly the same appearance as a standard naso-gastric catheter."
1705209|NCT01426165|Drug|Magnesium Sulfate|8 grams over 4 or 8 hours depending on randomization
1705210|NCT01426139|Device|Percutaneous Coronary Intervention Biotronik Orsiro DES|Stenting
1705211|NCT01426126|Drug|Genexol PM|Genexol-PM at a dose of 240 mg/㎡ was diluted in 500 ml of 5% dextrose solution and infused i.v. for 3 hours on day 1. Specialized i.v. infusion sets or in-line filter was not required for the administration. The dose of Genexol-PM was escalated to 300 mg/㎡ from the second cycle when pre-specified criteria were fulfilled (nadir ANC ≥ 1,000/ mm3, nadir platelet count ≥ 100,000/ mm3, and no grade 2 or worse non-hematologic toxicities with the exception of alopecia)
1705212|NCT01426113|Drug|bimatoprost ophthalmic solution formulation A|1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the evening for 6 weeks, followed by 1 drop of bimatoprost ophthalmic solution formulation A in the affected eye(s) in the morning for 6 weeks.
1705213|NCT01426113|Drug|timolol ophthalmic solution|1 drop timolol ophthalmic solution in the affected eye(s) in the morning and evening for 12 weeks.
1705214|NCT01426113|Drug|bimatoprost vehicle|1 drop of bimatoprost vehicle in the affected eye(s) in the morning for 6 weeks, followed by 1 drop of bimatoprost vehicle in the affected eye(s) in the evening for 6 weeks.
1705215|NCT01426100|Drug|CKD-828 40/2.5mg|Fixed dose combination of Telmisartan 40mg and S-Amlodipine 2.5mg
1705216|NCT01426100|Drug|CKD-828 40/5mg|Fixed dose combination of Telmisartan 40mg and S-Amlidioine 5mg
1705217|NCT01426100|Drug|Telmisartan 80mg|Telmisartan 80mg monotherapy
1705218|NCT01426087|Drug|Somatostatin|giving stilamin 250ug/h after endoscopic therapy for 5 days
1705219|NCT01426087|Procedure|endoscopic therapy|gastroscope plus EIS/EVL/HI
1705220|NCT01426074|Drug|Bevacizumab 5 mg/kg|Intravenously every two weeks
1705221|NCT01426061|Other|Reflexology plus conventional treatment|Patients in the reflexology group received reflexology treatment in addition to usual care of asthma.Patients received treatments weekly for four to six weeks, followed by two treatments for one month. Treatments were then given monthly until the end of the study.
1705222|NCT01426061|Other|Homeopathy plus conventional treatment|Patients in the homeopathy group received homeopathic treatment in addition to usual care of asthma.Homeopathic treatment was decided on an individual basis by the homeopath and prescribed as an oral treatment. Patients received homeopathic product with potency between C30 (dilution by a factor 10030 =1060) and M10 (dilution by a factor 100010 =1030). The number of homeopathy sessions attended was six to twelve during one year.
1705311|NCT01425463|Other|Placebo to Polyferose|Administered orally with water.
1705223|NCT01426061|Other|Conventional treatment|Patients in the conventional treatment group received usual care of asthma. This treatment was monitored and adjusted as usual by the patient's general practitioner.
1705224|NCT01426048|Other|Gynaecological examination and a supine stress test, questionnaires|Gynaecological examination and a supine stress test, questionnaires
1705225|NCT01426035|Drug|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE CREAM 5MG/G|APLIED 4 TIMES/DAY AT LESION
1705226|NCT01426022|Other|Nutrition|Moderate alcohol consumption with dinner (3 glasses of sparkling white wine, containing ca. 30 g alcohol)
1705227|NCT01426022|Behavioral|mood manipulation|Mood will be manipulated by changing the ambiance in either a pleasant or unpleasant way.
1705228|NCT01426009|Drug|EP-101 via nebulizer (eFlow®)|EP-101 Dose 1 administered once daily for 7 days
1705229|NCT01426009|Drug|EP-101 via nebulizer (eFlow®)|EP-101 administered once daily for 7 days
1705230|NCT01426009|Drug|Placebo EP-101|Placebo EP-101 administered once daily for 7 days
1705231|NCT01426009|Drug|Tiotropium bromide via (Spiriva® Handihaler®)|Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
1705232|NCT01426009|Drug|Ipratropium bromide Inhalation Solution via Handihaler® DPI|Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
1705233|NCT01425996|Drug|Lipotecan® (TLC388)|"Cohort A1: TLC388 15 mg/m2 x 6 dose + 3DCRT
Cohort A2: TLC388 30 mg/m2 x 6 dose + 3DCRT
Cohort A3: TLC388 40 mg/m2 x 6 dose + 3DCRT
Cohort A4: TLC388 50 mg/m2 x 6 dose + 3DCRT (dose-escalation)
Cohort Ax: TLC388 MTD x 6 dose + 3DCRT"
1705234|NCT01425983|Dietary Supplement|amino acid composition (asn01)|"Amino acid composition with micronutrients, once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.
Duration: 12 weeks"
1705235|NCT01425983|Other|Placebo|"Placebo; once a day (in the evening, 2 hours after dinner) content of a sachet mixed with 200 ml water.
Placebo contains no amino acids and micronutrients and is identical in appearance and solution properties.
Duration: 12 weeks"
1705236|NCT01425970|Drug|INX-08189|Tablet, Oral, 25 mg, Once daily (QD), 12 weeks
1705237|NCT01425970|Drug|INX-08189|Tablet, Oral, 50 mg, Once daily (QD), 12 weeks
1705238|NCT01425970|Drug|INX-08189|Tablet, Oral, 100 mg, Once daily (QD), 12 weeks
1705239|NCT01425970|Drug|Placebo matching with INX-08189|Tablet, Oral, 0 mg, Once daily (QD), 12 weeks
1705240|NCT01425970|Biological|Pegylated interferon alfa-2a|Syringe, Subcutaneous injection, 180 μg, Once per week, 12 weeks
1705241|NCT01425970|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg weight dependent, Twice daily (BID), 12 weeks
1705242|NCT01425970|Drug|INX-08189|Tablet, Oral, 200 mg, QD, 12 weeks
1705243|NCT01425970|Drug|Daclatasvir|Tablet, Oral, 60 mg, QD, 12 weeks
1705244|NCT01425957|Procedure|Lumbar puncture|"All the patients will be divided in two groups based on their Aβ 1-42 levels measured in the cerebro-spinal fluid obtained form a lumbar puncture: in low Aβ1-42 (positive aMCI patients CSFP) and high Aβ1-42 (Negative aMCI patients CSFN). The threshold of Aβ1-42 used to divide the patient will be 500 (ng/L) based on Sjogren criteria (2001).
Timeframe of lumbar punctures: every 18 months during 2 years (T0 and T18) or 3 years (T0, T18 and T36)."
1705245|NCT01425931|Procedure|Heart Lung machine|measurement of microcirculation with O2C device
1705246|NCT01425918|Behavioral|Social Enhancement Intervention|The intervention will be conducted at our center and focuses on providing an invigorating learning environment in which emerging social skills/knowledge are the focus of intervention with the aim of bringing them to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children robust learning experiences. Parent training sessions will focus on strategies aimed at improving child social engagement and communication.
1705247|NCT01425918|Behavioral|Parent Education|Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources. The curriculum provides parents with information about child development and autism as well as instructional strategies (e.g., responsive teaching strategies, principles of applied behavior analysis) for use at home to enhance their children's communication, engagement, and play development. Concrete examples for home-based implementation are presented. Each week, homework will be given and parents will be encouraged to practice the strategies daily at home. No direct coaching to parents during interaction with their children or direct intervention with the child will be provided.
1705248|NCT01425905|Other|The Blues Program|
1705249|NCT01425905|Other|Hey Durham|
1705250|NCT01425879|Drug|Akt Inhibitor MK2206|Given PO
1705251|NCT01425879|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1705252|NCT01425879|Other|Pharmacological Study|Correlative studies
1705253|NCT01425866|Behavioral|Structured self-management group education during 2 years|After an initial intensive group education, four-monthly follow-up self-management group education sessions for 2 years. Each session is based on empowerment, socio-constructivism, social learning theory: personalized assessment (BG and risk factors, actions: realized, planned, achieved (or not), cognitive work, analysis of individual and social context and environment (facilitators, obstacles) then action planning. Specific additional sessions can be scheduled (food management, diabetes treatment and hypoglycemia, exercise, self monitoring of BG, insulin dosage, foot care). Sessions are framed, and structured, with patient booklet support. Sessions are delivered at the community level, by trained registered nurses, under the coordination of the health management network Reucare.
1705254|NCT01425853|Drug|Chondroitin/Glucosamine (Droglican)|Experimental
1705255|NCT01425853|Drug|Celecoxib|Active comparator
1705256|NCT01425840|Drug|Lidocaine|100 mg of the following formulations: Liposome-encapsulated 2,5% and 5% lidocaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
1705257|NCT01425827|Drug|duloxetine HCL|60 mg/day duloxetine for 16 weeks
1705258|NCT01425827|Drug|placebo|similar looking tablets to the active agent for 16 weeks
1705259|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
1705260|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
1705261|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
1705262|NCT01425814|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
1705264|NCT01425814|Drug|Placebo|Dry powder inhalation or Dry powder inhalation (capsule),Once daily, single dose
1956133|NCT02955394|Drug|Enzalutamide|160mg of Enzalutamide will be given daily in conjunction with Fulvestrant.
1956134|NCT02955394|Drug|Fulvestrant|500mg Fulvestrant will be given IM on days 1, 15, 28, then every 4 weeks as per standard of care (SOC)
1705268|NCT01425788|Biological|Osiris Phleum pratense|
1705269|NCT01425788|Biological|Osiris Phleum pratense|
1705270|NCT01425788|Biological|Osiris Phleum pratense|
1705271|NCT01425775|Drug|vitamin D 25(OH)D|2000IU/day for 12 months
1705272|NCT01425775|Other|Placebo|2000IU/day of vitamin D will be compared to similar looking tablets of placebo for 12 months
1705273|NCT01425762|Other|Drug Dose|100 versus 200 mcg IT morphine
1705274|NCT01425749|Biological|recMAGE-A3 + AS15 ASCI|Injections of recMAGE-A3 + AS15 ASCI will be given 5 times at 3-week intervals. This will either be administered cutaneously or intramuscularly depending on the study group. The injected doses will be administered in alternating extremities at each visit.
1705275|NCT01425736|Drug|Chemotherapy|Chemotherapy :Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)
1705276|NCT01425736|Drug|Nimotuzumab and Chemotherapy|"Nimotuzumab treatment:(200mg/w,18weeks );
Chemotherapy treatment:(Docetaxel(75mg/m²,1 time/21d, 6times);Cisplatin(75mg/m²,1 time/21d, 6 times);Fluorouracil(750mg/m²/d,5times/21d, 30times)Nimotuzumab treatment:(200mg/w,18weeks );"
1705278|NCT01425697|Other|2% Chlorhexidine Gluconate cloths|2% chlorhexidine Gluconate wipes will bw used 12 hours prior to cardiac surgery and then again 3 hours prior to cardiac surgery. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
1705279|NCT01425697|Other|Standard of Care preoperative preparation.|Preoperative standard of care preparation utilized at the clinical site will be used. Subjects will be randomized to either receive a preoperative phone call reminder or no phone call reminder.
1705280|NCT01425658|Drug|distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
1705281|NCT01425658|Drug|Clonidine|The clonidine group (group C) received bupivacaine 10mg combined with 75 microgram clonidine intrathecally .
1705282|NCT01425658|Drug|Fentanyl|The Fentanyl group (group F) received bupivacaine 10mg combined with 25 microgram fentanyl intrathecally .
1705283|NCT01425645|Other|FDD program|FDD is a 12 month lifestyle intervention and behavioural support program delivered in the context of the surrounding family
1705284|NCT01425632|Drug|TAU-284|TAU-284 Low
1705285|NCT01425632|Drug|TAU-284|TAU-284 High
1705286|NCT01425632|Drug|Placebo|Placebo
1705287|NCT01425619|Biological|Cream of Macrogol cetostearyl ethers|The cream will be applied on the volar aspect of both arms for 1 hour
1705288|NCT01425619|Drug|Cream of Lidocaine 2.5 %.and Prilocaine 2.5 %|1-2 gr. of the cream will be applied on the volar aspect of the second arm; for 1 hour
1705289|NCT01425619|Behavioral|Care and treatment from a medical clown|Medical clown will entertain the children before, during and after performing the skin test. Placebo cream will be applied on both arms.
1705290|NCT01425619|Behavioral|Care and treatment from a medical clown|Medical clown will entertain the children, placebo cream will be applied on one arm and anesthetic cream on the second arm
1705291|NCT01425606|Other|blood test|blood test to measure levels of: sodium, albumin and acid - base status in venous blood.
1705292|NCT01425580|Drug|liraglutide|1.8 mg s.c. (QD)
1705293|NCT01425580|Drug|glimepiride|4 mg p.o. (QD)
1705294|NCT01425580|Drug|Metformin|500 mg p.o. (BID)
1705295|NCT01425567|Drug|Intravenous Lipid Emulsion Comprised of Fish Oil|IV lipid provided for parenteral nutrition when enteral feeds are not tolerated due to intestinal disease
1705296|NCT01425554|Other|Doppler sonography of internal jugular veins|Doppler sonography of internal jugular veins
1705297|NCT01425554|Other|Magnetic resonance venography of internal jugular veins|Magnetic resonance venography of internal jugular veins
1705298|NCT01425554|Other|Air-plethysmography of the neck|Air-plethysmography of the neck
1705299|NCT01425554|Other|Catheter venography of internal jugular veins|Catheter venography of internal jugular veins
1705300|NCT01425541|Drug|estrace|0.5-1 mg once a day PO for 7 days
1705301|NCT01425541|Drug|Progesterone|20 mg/ml, 25-100 mg, Three times a day at 0700, 1500, and 2300 hr for 7 days
1705302|NCT01425528|Drug|Sapropterin|Sapropterin will be taken daily for 12 or 24 weeks. Starting dose will be 20mg/kg/day and will increase at the 8 week visit to 30 mg/kg/day. Dosing may be further increased to as high as 40 mg/kg/day in attempt to normalize BH4 levels in CSF. Starting dose for Cohort 2 will be determined from data analysis in Cohort 1.
1705303|NCT01425515|Behavioral|Complex quality improvement intervention|We are implementing a complex quality improvement intervention that includes changes in practice processes to enhance hypertension care, provision of home blood pressure monitors to patients, and telephone coaching around hypertension self-management.
1705304|NCT01425502|Behavioral|DQIP Intervention|"The DQIP intervention comprises of:
Educational outreach
Information technology application
Financial incentives"
1705305|NCT01425476|Drug|Celecoxib|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
1705306|NCT01425476|Drug|Placebo|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
1705307|NCT01425476|Drug|Cholecalciferol|Take one tablet from each bottle (one bottle containing either placebo/celecoxib and one bottle containing either cholecalciferol 400 IU or 2,000 IU) daily for 30 days.
1705308|NCT01425463|Drug|Ferrous (II) Glycine Sulphate Complex|"Oral dose of 567.7 mg Ferrous (II) Glycine Sulphate Complex three times a day (t.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).
Administered orally with water."
1705309|NCT01425463|Drug|Polyferose|"Oral dose of 150 mg Polyferose Capsules twice daily (b.i.d) for 12 weeks (equivalent to 300 mg iron element per day for 12 weeks).
Administered orally with water."
1705310|NCT01425463|Other|Placebo to Ferrous (II) Glycine Sulphate Complex|Administered orally with water.
1705312|NCT01425450|Drug|HF1020|Single doses at 0.5 mg capsules, 2.5 mg capsules, 10 mg capsules, and 25 mg capsules in each of cohorts 1, 2, 3 and 4 respectively.
1705313|NCT01425450|Drug|HF1020 placebo|Single dose: HF1020 placebo capsule
1705314|NCT01425424|Other|Vitamin D supplementation|Vitamin D
1705315|NCT01425411|Drug|valsartan|80/160 mg dosage of valsartan or 160+12,5 mg valsartan+hydrochlorothiazide combination, once a day, for six months
1705316|NCT01425398|Drug|Rosuvastatin|Rosuvastatin 40 mg PO qd x 5 days before surgery and then from post-op day 0 to 5.
1705317|NCT01425398|Drug|Placebo|Placebo 1 tab qd x 5d before operation and then from post-op day 0 to 5.
1705318|NCT01425385|Other|Near infrared spectroscopy monitoring|This is an observational study without interventions
1705319|NCT01425385|Other|Autoregulation monitoring|There are no interventions in this observational study
1705320|NCT01425359|Drug|Ranolazine|
1705321|NCT01425359|Drug|Ranolazine placebo|
1705322|NCT01425333|Procedure|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
1705323|NCT01425333|Procedure|Surgery for ovarian endometrioma|Patients undergoing surgery for ovarian endometrioma
1705324|NCT01425320|Drug|Fixed Combination dapsone/adapalene Formulation A Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
1705325|NCT01425320|Drug|Fixed Combination dapsone/adapalene Formulation B Gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
1705326|NCT01425320|Drug|dapsone 5% gel|Study medication will be applied twice daily for 14 days to the face, upper chest, upper back, and shoulders.
1705327|NCT01425320|Drug|adapalene 0.3% gel|Study medication will be applied once daily for 14 days to the face, upper chest, upper back, and shoulders.
1705328|NCT01425307|Drug|Hydroxyurea|Capsules (300 mg, 400 mg, or 500 mg) taken once daily liquid formulation (100 mg/mL)
1705331|NCT01425268|Device|AeroForm Tissue Expansion|The AeroForm Patient Controlled Tissue Expander is a breast tissue expander implanted following mastectomy and activated by remote control to release small doses of carbon dioxide from an internal reservoir to fill and inflate the expander.
1705332|NCT01425268|Procedure|Saline Tissue Expansion|A saline tissue expander is a breast tissue expander which is implanted following mastectomy and inflated over time using needle injections to fill and inflate the expander with saline.
1705333|NCT01425242|Drug|Aliskiren|Starting dose: Aliskiren 150 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of Aliskiren to 300 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
1705334|NCT01425242|Drug|Amlodipine|Starting dose: amlodipine 5 mg p.o, if hypertension is insufficiently treated Hydrochlorothiazide 12.5 mg p.o. tablet once daily for maximally 12 months can be added, the next step is to add increase the dosage of amlodipine to 10 mg p.o. tablet once daily until maximally 12 months after baseline, the final step to take in case hypertension is still present is to increase Hydrochlorothiazide to 25 mg p.o. tablet once daily until maximally 12 months after baseline.
1705335|NCT01425229|Drug|Bosentan|"Administration of bosentan: 1 x 125 mg p.o. on day 1, 2 x 125 mg p.o. on day 2-14
Administration of clarithromycin: 2 x 500 mg p.o. on day 11-14"
1705336|NCT01425216|Drug|Sorafenib|Treatment will be administered on an outpatient basis. All patients will keep a drug diary in order to record compliance with their drug regime. Sorafenib will be taken orally. Maximum length of treatment is 6 months. Starting dose of sorafenib is 200 mg three times per week for one month. In absence of Grade 2 toxicity, the dose will be increased on a monthly basis and will stop at 400 mg twice daily.
1705337|NCT01425203|Drug|Boceprevir|boceprevir 200-mg capsules, 800 mg 3 times a day (TID), orally (PO)
1705338|NCT01425203|Drug|Placebo|boceprevir-matched placebo four 200-mg capsules PO TID.
1705339|NCT01425203|Biological|peginterferon alfa-2b|peginterferon alfa-2b 1.5 μg/kg/wk subcutaneously (SC)
1705340|NCT01425203|Drug|Ribavirin|ribavirin (weight-based dosing) 800 to 1400 mg/day PO divided twice daily dose (BID).
1705341|NCT01425190|Drug|Boceprevir|Single dose of boceprevir powder prior to breakfast in a dosing vehicle of chocolate pudding (i.e., a mousse or custard), apple sauce, Nutella, fruit pudding such as strawberry, cherry, or raspberry pudding, or yogurt or a similar semi-solid product into which the boceprevir powder can be evenly stirred
1705342|NCT01425177|Procedure|Normal Saline Irrigation|After removing CBD stones with the ERCP, 200ml of the normal saline solution was irrigated into the common bile duct.
1705343|NCT01425164|Drug|Ivabradine|ivabradine tablets, 5 to 7.5 mg bis-in-die.
1705344|NCT01425164|Drug|Carvedilol|carvedilol tablets, 12.5 to 25 mg bis-in-die.
1705345|NCT01425151|Device|i-Gel|Oropharyngeal leak pressure Insertion success
1705346|NCT01425151|Device|ProSeal|Oropharyngeal leak pressure Insertion success
1705347|NCT01425125|Drug|Tolvaptan in euvolemic hyponatremia|This arm will test the effectiveness of tolvaptan in treating the hyponatremia of patients with euvolemic hyponatremia.
1705348|NCT01425112|Procedure|Phacoemulsification|Surgery for complications of trabeculectomy
1705349|NCT01425099|Drug|Dolutegravir|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
1705350|NCT01425099|Drug|Prednisone|Prednisone is a commonly used corticosteroid used for a variety of medical condiitons
1705352|NCT01425073|Other|Discontinue TMP/SMZ prophylaxis|Subjects in the intervention arm will discontinue use of daily TMP/SMZ for the duration of the study
1705353|NCT01425060|Behavioral|Contraceptive management program|The contraceptive management program will consist of two components: (1) the World Health Organization's contraception protocol and (2) reinforced follow-up visits.
1705354|NCT01425060|Other|Usual care|The usual care condition will be given general information about contraceptive options and contact information for clinics and providers that provide contraceptive services.
1705355|NCT01425034|Other|casts for the thumb|The 'Cast' group will be placed in a thumb spica short arm cast with the thumb IP joint free. They will be allowed digit, thumb IP and elbow range of motion.
1705356|NCT01425034|Other|Motion group|The 'Motion' group will be placed in a forearm based thumb spica splint with the thumb IP free. They will be allowed digit, thumb IP and elbow range of motion.
1705357|NCT01425008|Drug|MLN2480|Dose Escalation Phase: patients will receive MLN2480 orally in escalating doses every other day or once weekly for three weeks of a 28-day cycle. Patients may continue treatment for additional cycles (up to 12 months) until disease progression, unacceptable toxicity, or the patient discontinues for any other reason. If it is determined that a patient would derive benefit from continued therapy beyond 12 months treatment may continue. Dose Expansion Phase: Patients will take MLN2480 at the maximum tolerated dose orally every other day or once weekly for three weeks of a 28-day cycle until disease progression, unacceptable toxicity, or the patient discontinues for any other reason. The maximum duration of treatment is 1 year unless determined that a patient would derive benefit from continued therapy beyond 12 months.
1705358|NCT01424982|Drug|Cyclophosphamide|300 mg/m^2 by vein over 3 hours every 12 hrs for 6 doses days 1,2,3 (total dose 1800mg/m2) for Odd Courses 1,3,5,7.
1705359|NCT01424982|Drug|Mesna|600 mg/m^2 by vein continuous infusion daily for 24 hours for Odd Courses 1,3,5,7.
1705360|NCT01424982|Drug|Doxorubicin|50 mg/m2 by vein over 24 hrs via central venous catheter on Day 4 of Odd Courses 1,3,5,7.
1705361|NCT01424982|Drug|Vincristine|"2 mg by vein on day 1 and day 11 of Odd Courses 1,3,5,7.
Maintenance Therapy Starting Dose: 2 mg by vein on day 1 approximately every 28 days for 24 months."
1705362|NCT01424982|Drug|Dexamethasone|40 mg by vein or by mouth daily on days 1-4 and days 11-14 of Odd Courses 1,3,5,7.
1705363|NCT01424982|Drug|Ponatinib|"Odd Courses 1,3,5,7: 45 mg by mouth daily days 1-14 for Course 1. For subsequent courses 3, 5, and 7, 30 mg by mouth daily.
Even Courses 2,4,6,8: 30 mg by mouth daily.
Maintenance Therapy Starting Dose: 30 mg by mouth daily and 15 mg by mouth daily in patients who have achieved complete molecular response."
1705364|NCT01424982|Drug|G-CSF (Filgrastim)|Even and Odd Courses: 10 mcg/kg subcutaneously daily (or 5mcg/kg twice daily) until post-nadir granulocytes >1.0 x 109/L.
1705365|NCT01424982|Drug|Rituximab|"Odd Courses: 375 mg/m2 by vein on days 1 and 11 of Cycles 1 and 3 for patients with CD20 expression (>20% by flow cytometry).
Even Courses: 375 mg/m2 by vein on days 1 and 8 of cycles 2 and 4 for patients with CD20 expression (>20% by flow cytometry)."
1705366|NCT01424982|Drug|Methotrexate|"12 mg intrathecally (6mg via Ommaya reservoir) on day 2 for Odd Courses.
200 mg/m2 by vein over 2 hours (+ 1 hr) followed by 800 mg/m2 over 22 hours on day 1 for Even Courses."
1705367|NCT01424982|Drug|Cytarabine|"CNS prophylaxis: 100 mg intrathecally day 7 for Even and Odd Courses.
Even Course 2,4,6,8: 3g/m2 by vein over 3 hours every 12 hours for 4 doses on days 2, 3."
1705368|NCT01424982|Drug|Solu-medrol ( Methyl Prednisolone)|50 mg by vein every 12 hours for 6 doses days 1-3 of Even Course 2,4,6,8.
1705369|NCT01424982|Drug|Citrovorum (Leucovorin)|Even Courses 2,4,6,8 on Days 2 - 5: Rescue 50 mg by vein or mouth followed by 15 mg by vein or by mouth every 6 hours for 8 doses beginning 12 hours post Methotrexate completion, i.e. approximately 36 hours from start of Methotrexate.
1705370|NCT01424982|Drug|Prednisone|Maintenance Therapy Starting Dose: 200 mg by mouth daily days 1-5 approximately every 28 days with vincristine for 24 months.
1705371|NCT01424982|Drug|Pegfilgrastim (Neulasta)|"Even Courses: Neulasta may replace G-CSF at a dose of 6 mg subcutaneously on Day 5.
Odd Courses: Neulasta may replace G-CSF at 6 mg subcutaneously on Day 4."
1705372|NCT01424956|Device|Automated Breast Ultrasound (ABUS)|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography.
1705373|NCT01424943|Behavioral|Stepping Stones Triple P|10-12 session manualized intervention delivered in client homes
1705374|NCT01424943|Other|BabyNet Services As usual|BabyNet services as usual based on IFSP
1705375|NCT01424930|Drug|Abiraterone|Participants will receive abiraterone acetate at a starting dose of 1,000 mg once daily for 7 days post 30-minutes of a standardized low-fat meal and high-fat meal from Cycle 1 Day 8 to Cycle 1 Day 14.
1705376|NCT01424930|Drug|Prednisone|Prednisone will be administered as 5 mg oral tablet twice daily during Cycle 1 Day 8 to Cycle 1 Day 14.
1705377|NCT01424904|Dietary Supplement|DGB-01 Supplementation|"Approximately one-half of the subjects will initially receive DGB-01. The other half of the subjects will receive casein. Investigators and subjects are blinded to the product the subject is receiving. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks.
Subsequently, all subjects will undergo a supplement-free washout period of at least four weeks duration. Following the washout period, the subjects who originally received DGB-01 will receive casein and the subjects who originally received casein will receive DGB-01. Subjects will be asked to consume one pouch of their assigned study product twice daily for four weeks."
1705378|NCT01424891|Drug|Simvastatin 80 mg|treatment with 80 mg of simvastatin over a period of 8 weeks
1705379|NCT01424891|Drug|Sim10/Eze10|treatment with combination of simvastatin 10 mg and ezetimibe 10 mg
1705380|NCT01424891|Drug|Placebo|treatment with placebo over 8 weeks
1705381|NCT01424865|Genetic|fluorescence in situ hybridization|
1705382|NCT01424865|Other|immunohistochemistry staining method|
1705383|NCT01424865|Other|immunologic technique|
1705384|NCT01424865|Other|laboratory biomarker analysis|
1705385|NCT01424852|Dietary Supplement|Probiotics in infant milk formula|Probiotic infgant milk formula administered during the forst year of life
1705386|NCT01424839|Radiation|craniospinal irradiation|"Metastatic or incompletely staged pure germinoma 24 Gy (15 fractions) to craniospinal axis with a 16 Gy (10 fraction) boost to tumour bed and any intracra-nial metastases and spinal deposits (total tumour dose 40 Gy)
Metastatic germinoma plus teratoma (incompletely resected) 24 Gy (15 fractions) to craniospinal axis ; 30.4 Gy (19 fraction) boost to tumour bed and 16 Gy (10 frac-tion) boost to metastases (total tumour dose 54.4 Gy)
Patients with metastastic non-germinomatous disease at diagnosis After Chemotherapy: 30 Gy (20 fractions) to cranio-spinal axis with 24 Gy (15 fraction) boosts to tumour site and any intracranial metastases (total tumour dose 54 Gy) and 20.8 Gy (13 fraction) boosts to spinal deposits (total dose 50.8 Gy)"
1765983|NCT00327002|Drug|LY518674|
1705387|NCT01424839|Drug|Carboplatin, Etoposide, Ifosfamide|• Non-metastatic fully staged germinoma (± teratoma) Two courses (1 and 3) of Etoposide and Carboplatin, alternating with two courses (2 and 4) of Etoposide and Ifosfamide
1705388|NCT01424839|Radiation|ventricular irradiation|"Non-metastatic pure germinoma in PR/SD After Chemotherapy: 24 Gy (15 fractions) to whole ventricles with a 16 Gy (10 fraction) boost to tumour bed (total tumour dose 40 Gy)
Non-metastatic germinoma in CR After Chemotherapy: 24 Gy (15 fractions) to whole ventricles
Non-metastatic germinoma plus teratoma (incompletely resected) After Chemotherapy: 24 Gy (15 fractions) to whole ventricles; 30.4 Gy (19 fraction) boost to tumour bed (total tumour dose 54.4 Gy)"
1705389|NCT01424839|Drug|Cisplatin, etoposide, Ifosfamide (standard)|Four courses of Etoposide, Cisplatin and Ifosfamide (standard treatment )
1705390|NCT01424839|Drug|Cisplatin, Etoposide, Ifosfamide (high dose)|Two courses of standard Etoposide, Cisplatin and Ifosfamide, followed by two dose intensified courses of Etoposide, Cisplatin and Ifosfamide with stem cell support
1705391|NCT01424839|Radiation|focal irradiation|• Patients with localised non-germinomatous disease at diagnosis After Chemotherapy: 54 Gy focal radiotherapy in 30 fractions
1705392|NCT01424826|Drug|Raltegravir|400 mg bd for minimum of 28 days and maximum 35 days
1705393|NCT01424826|Drug|Rifampicin|< 50 kg 600 mg 3 times/week for a minimum of 27 days and maximum of 34 days > 50 kg 900 mg 3 times/week for a minimum of 27 days and maximum of 34 days
1705394|NCT01424826|Drug|Raltegravir|800 mg bd for 4 days
1705395|NCT01424813|Drug|Placebo MDPI|Placebo MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
1705396|NCT01424813|Drug|Albuterol MDPI|Albuterol MDPI administered as 2 inhalations 4 times a day (QID) (at approximately 7:00 AM, 12 noon, 5:00 PM, and bedtime) for 12 weeks.
1705397|NCT01424800|Device|A disposable NIRS (near-infrared spectroscopy) sensor will be applied on the patient's forehead for continuous registration of the cerebral oxygen saturation.|When the patient is on CPB, pressure and/or flow will be changed while continuously measuring ScO2. Temperature, CO2 , arterial oxygen content, hematocrit and anesthesia will be kept constant during the measurements. First, baseline MAP (mean arterial pressure), baseline ScO2 and baseline central venous oxygen saturation (SvO2) are determined. With the interventions, we will induce a change of 20% in MAP and/or flow. This is within the normal range during operations. Changes in blood pressure will be obtained by the use of vasoactive agents (sodiumnitroprusside for blood pressure decrease and phenylephrine for blood pressure increase). Flow is regulated by manual control of the pump flow. Values of the different variables will be obtained after a 5 min stabilisation period. Flow/pressure interventions will be randomized.
1705398|NCT01424774|Drug|CardioGen-82|CardioGen-82 is not administered to patients in this study, however to be able to qualify for enrollment, the patients must have received CardioGen previously
1705399|NCT01424761|Dietary Supplement|Coenzyme Q10|Coenzyme Q10 300 mg/d (150 mg/bid)
1705400|NCT01424761|Other|Placebo|Placebo :starch
1705401|NCT01424748|Dietary Supplement|Tahitian Noni Juice|noni fruit juice
1705402|NCT01424748|Dietary Supplement|Placebo|Placebo juice
1705403|NCT01424735|Drug|Mycobacterium w.(Mw)-freeze dried extract 0.5ml|0.5 ml of Mw in 500ml 0.9% normal saline administered over two hours as an infusion. 2ml(4mg/ml) of dexamethasone administered two hours prior to Mw administration
1705404|NCT01424722|Device|Fortify® ST, Fortify Assura® ST, Ellipse® ST family of devices|Algorithm for detecting ST changes that may be indicative of an acute coronary syndrome.
1705405|NCT01424709|Drug|Gemcitabine, Docetaxel, CPT-11,Cisplatin|Based on expression levels of RRM1 and BRCA1 mRNA，one of the four regimens will be given to each patient: Gemcitabine/cisplatin, Docetaxel/gemcitabine, CPT-11/Cisplatin, docetaxel monotherapy. The chemotherapy will be repeated every 3 week. Dose reduction or interruption for toxicity could take place at any time.
1705406|NCT01424709|Drug|gemcitabine/cisplatin|gemcitabine/cisplatin up to 6 cycles or disease progression or intolerable toxicity.
1956141|NCT02953938|Biological|Ranibizumab|Ranibizumab is a biologic and known anti-VEGF (vascular endothelial growth factor) medication approved for treatment of ME (Macular Edema) due to RVO (Retinal Vein occlusion)
1956142|NCT02953938|Radiation|Grid&Direct short pulse laser photocoagulation|Grid&Direct short pulse laser photocoagulation is a kind of laser treatment to retina within vascular arcades and used to suppress macular edema
1705411|NCT01424657|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography
1705412|NCT01424657|Procedure|MRCP|magnetic resonance cholangiopancreatography
1705413|NCT01424644|Biological|Placebo + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.
Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine(Tdap) is Boostrix®."
1705414|NCT01424644|Biological|MenACWY-CRM Conjugate Vaccine + Combined Tetanus, Reduced Diphtheria Toxoid, Acellular Pertussis Vaccine + Quadrivalent Human Papillomavirus Vaccine|"All three vaccines were administered concomitantly. MenACWY-CRM contains diphtheria-like toxoid as carrier for the capsular polysaccharides. Quadrivalent Human Papillomavirus [Types 6, 11, 16, 18] Recombinant Vaccine is GARDASIL®.
Reduced Diphtheria Toxoid,Acellular Pertussis Vaccine(Tdap) is Boostrix®."
1705415|NCT01423656|Drug|LEO 29102|
1705416|NCT01423656|Drug|Placebo|Placebo Comparator: LEO 29102 vehicle
1705418|NCT01423617|Dietary Supplement|Zenoctil|3 tablets 2 times daily
1705419|NCT01423617|Other|Placebo|3 tablets 2 times daily
1705420|NCT01424631|Procedure|single incision laparoscopic appendectomy|
1705421|NCT01424631|Procedure|conventional laparoscopic appendectomy|
1705422|NCT01424618|Drug|Leuprolide|leuprolide 10 units daily, decreased to 5 units daily once suppression achieved for a total of approximately 4 weeks. Once suppression achieved, estradiol and progesterone administered to mature uterine lining.
1705547|NCT01423747|Drug|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
1705423|NCT01424618|Drug|Ganirelix|Ganirelix 250 mcg daily will be used to suppress pituitary-ovarian function and is administered concurrently with estradiol and progesterone for approximately two weeks.
1705424|NCT01424605|Procedure|DLT intubation|Using a video-assisted laryngoscope to facilitate endotracheal tube intubation
1705425|NCT01424592|Device|Testing with a portable sleep apnea monitor .|Portable sleep apnea testing will performed on referred patients.
1705426|NCT01424579|Other|Actual Diacutaneous Fibrolysis|Diacutaneous Fibrolysis is a non-invasive physiotherapeutic technique applied by means of a set of metallic hooks ending in a spatula with bevelled edges that allow a deeper and more precise application, which could not be achieved manually. Appropriate hook is applied following the intermuscular septum between the muscles with an anatomical or functional relationship with the painful structure, in a centripetal direction towards the pain location, in order to release adherences between musculoskeletal structures.
1705427|NCT01424579|Other|Placebo Diactuaneous Fibrolysis|Placebo Diacutaneous Fibrolysis was applied at a superficial level and, instead of fibrolysis, a pinch of skin was held with the thumb of the palpatory hand and the tip of the spatula, without any action taking place on the deep tissular levels.
1705428|NCT01424579|Other|Protocolized physiotherapeutic Treatment|Tree weeks of daily therapeutic exercises, analgesic electrotherapy and cryotherapy.
1705429|NCT01424566|Drug|Sativex®|100 μl oromucosal spray administered twice daily up to a maximum of 10 sprays per day
1705430|NCT01424566|Drug|Placebo (product code GA0034)|Matching placebo: oromucosal spray, containing excipients, peppermint flavored
1705431|NCT01424553|Other|Prevention and follow-up of the patients pulmonary parameters|Respiratory symptoms and lung function will be evaluated in very low birth weight and term infants, born in 1997 and included in the French EPIPAGE cohort.
1705432|NCT01424540|Drug|GSK2336805 150mg|Single Dose
1705433|NCT01424540|Other|Placebo|Single Dose
1705436|NCT01424501|Biological|GSK Biologicals' investigational TB vaccine GSK 692342|Intramuscular injection, 2 doses
1705437|NCT01424501|Biological|Placebo|Intramuscular injection, 2 doses
1705438|NCT01424488|Drug|sugammadex|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2 Sugammadex in the dose of 4 mg/kg is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
1705439|NCT01424488|Drug|placebo|Anesthetised patients will receive a single intubation dose of succinylcholine (1.0 mg/kg) and maintenance bolus dose of pipecuronium (0.08 mg/kg) to maintain the level of neuromuscular blockade at reappearance of T2. 3,0 ml of saline (placebo) is to be administered as an intravenous bolus dose at the level of neuromuscular blockade of reappearance of T2 (moderate blockade) by means of TOF-Watch SX after the last dose of pipecuronium according to randomization
1705440|NCT01424475|Genetic|Healthy|Healthy Volunteers
1705441|NCT01424475|Genetic|PKD Patients|PKS Patients
1705442|NCT01424462|Drug|A|Single dose treatment IR formulation
1705443|NCT01424462|Drug|B|Low Extended release single dose
1705444|NCT01424462|Drug|C|Medium extended release formulation
1705445|NCT01424462|Drug|D|High extended release rate single dose
1705446|NCT01424449|Radiation|[11C]PHNO|examine the effects of [11C]PHNO mass carry-over and displaceable binding
1705447|NCT01424449|Drug|Aripiprazole|A 4th scan will follow a 15mg dose of aripiprazole (a D2/D3 compound which allows the highest clinically acceptable blockade of central D2/D3 receptors)
1705448|NCT01424436|Biological|GSK933776|1mg/kg dose group
1705449|NCT01424436|Biological|GSK933776|3mg/kg dose group
1705450|NCT01424436|Biological|GSK933776|6mg/kg dose group
1705451|NCT01424423|Drug|Placebo|Placebo
1705452|NCT01424423|Drug|GSK1223249|I.V. Infusion
1705456|NCT01424384|Drug|Citalopram|Neurophysiological testing.
1705457|NCT01424384|Drug|GSK424887|Neurophysiological testing
1705458|NCT01424384|Drug|Plactebo To Match|Neurophysiological testing
1705459|NCT01424358|Other|Web-based Educational Intervention|The intervention group will be invited to participate in the web-based educational program. PCPs in the intervention group will be asked to view the educational module which will be followed by an assessment. This group will be tested on the following knowledge outcomes: Index of knowledge of risk factor for oral cancer and Index of knowledge of diagnostic procedures for oral cancer.
1705460|NCT01424345|Drug|adjustment of immunosuppressant dosages|adjustment of immunosuppressant dosages according to the results of ImmuKnow results and routine post-transplant lab results
1705461|NCT01424345|Drug|adjustment of the dosages of immunosuppressants|adjustment of the dosages of immunosuppressants will be done according to the results of conventional post-transplant follow-up lab
1705462|NCT01424332|Drug|Darexaban|oral
1705463|NCT01424332|Drug|Acetyl Salicylic Acid (ASA)|oral
1705464|NCT01424319|Drug|Atrasentan low dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
1705465|NCT01424319|Drug|Atrasentan high dose group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
1705466|NCT01424319|Drug|Atrasentan placebo group|Subjects will take two tablets daily of one of those which are atrasentan low dose, atrasentan high dose or atrasentan placebo for 12 weeks during the treatment period.
1705467|NCT01424306|Other|Fructose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a fructose-sweetened beverage for 8 days. The amount of fructose consumed will be 25% of the subject's estimated daily calorie requirement.
1705548|NCT01423747|Radiation|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
1705721|NCT01422434|Drug|Rinderon® - DP = betamethasone dipropionate|Applied once daily for 4 weeks.
1705468|NCT01424306|Other|Glucose-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a glucose-sweetened beverage for 8 days. The amount of glucose consumed will be 25% of the subject's estimated daily calorie requirement.
1705469|NCT01424306|Other|High-fructose corn syrup-sweetened beverages|In addition to consuming a standardized diet, subjects will be asked to consume 4 servings per day of a high-fructose corn syrup-sweetened beverage for 8 days. The amount of high-fructose corn syrup consumed will be 25% of the subject's estimated daily calorie requirement.
1705470|NCT01424293|Device|Indocyanine Green|1ml of intravenous ICG and imaging transanally using the Spyscope system
1705471|NCT01424293|Device|The SPY® Intraoperative Imaging System|
1705472|NCT01424280|Drug|1440115|Single dose of either 750 mg or 500 mg administered as 250 mg tablets.
1705473|NCT01424280|Drug|Placebo|Single dose of matching placebo tablets
1705474|NCT01424267|Device|Zenith® Low Profile AAA Endovascular Graft|Treatment of an abdominal aortic or aorto-iliac aneurysm with the CE-marked Zenith(R) Low Profile AAA Endovascular Graft.
1705475|NCT01424254|Device|Capsule GIVEN IMAGING|Injection of Capsule Endoscopy
1705476|NCT01424254|Procedure|Push-Enteroscopy|currently recommended standard
1705478|NCT01424228|Drug|placebo|Placebo matching tablet 2 mg once daily before breakfast for 24 weeks
1705479|NCT01424228|Drug|prucalopride|"Prucalopride 2 mg daily before breakfast
1 mg for subjects >65 years; in case of insufficient response 2 mg at week 2 or week 4"
1705480|NCT01424215|Drug|Indocyanine Green (ICG)|Injection of ICG intravenously then intraoperative imaging of the biliary anatomy during laparoscopic cholecystectomy using a near infrared (NIRF) imaging camera(Spy scope, Novadaq Canada)
1705481|NCT01424202|Device|Mechanical Insufflation Exsufflation|"After passing the SBT and randomized to group B, before extubation, all patients were submitted to a treatment of MI-E (3 sessions) through the endotracheal tube with pressures set at 40 cm H2O for insufflation and -40 cm H2O for exsufflation pressure. An insufflation/exsufflation time ratio of 3secs/2 secs and a pause of 3 sec between each cycle was used. Eight cycles were applied in every session with an abdominal thrust timed to the exsufflation cycle.
On top of the standard medical therapy, during the first 48 hours post extubation, each patient received 3 daily treatments by means of a light-weight, elastic oronasal mask. Treatments (3 sessions each) were divided between morning, afternoon and night, making a total of 9 daily sessions.
The daily treatment frequency and its outcomes were recorded in a diary by the nursing staff. All MI-E treatments were administered by a trained respiratory therapist, ICU physician or nurse."
1705482|NCT01424189|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
1705483|NCT01424189|Device|AcrySof® ReSTOR® Multifocal IOL Model SA60D3|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
1705484|NCT01424176|Drug|Dexpramipexole (dose 1)|
1705485|NCT01424176|Drug|Dexpramipexole (dose 2)|
1705486|NCT01424163|Drug|Single dose reduced|Treatment 1 (Part A)
1705487|NCT01424163|Drug|Single dose standard|Treatment 2 (Part A)
1705488|NCT01424163|Drug|Multiple Dose|Treatment 3 (Part A)
1705489|NCT01424163|Drug|Multiple Dose|Part B
1705490|NCT01424150|Other|Liberal fluid therapy|Liberal protocol group is designed to provide approximately 6.0L per day.
1705491|NCT01424150|Other|Restrictive fluid therapy|Restrictive protocol group is designed to provide less than 2.0 L water and 120 mmol sodium per day.
1705492|NCT01424137|Device|Easyhaler type A|Easyhaler type A inhaler, 3 consecutive inhalations
1705493|NCT01424137|Device|Easyhaler type B|Easyhaler type B inhaler, 3 consecutive inhalations
1705494|NCT01424137|Device|Diskus inhaler|Diskus inhaler, 3 consecutive inhalations
1705495|NCT01424124|Drug|YHD001 dose level 1|Tablet, three times daily / 8 weeks
1705496|NCT01424124|Drug|YHD001 dose level 2|Tablet, three times daily / 8 weeks
1705497|NCT01424124|Drug|Singulair|Tablet, one times daily / 8 weeks
1705498|NCT01424124|Drug|Placebo|Tablet, one times daily / 7 days
1705499|NCT01424111|Drug|Escitalopram|An open-label, 10-20 mg/day, flexible-dose of escitalopram will be administered to all subjects included in this study in the form of tablets. The treatment period is 8 weeks long.
1705500|NCT01424111|Other|Healthy Control|No Treatment
1705501|NCT01424098|Behavioral|Balance training program|Training will consist of 30 minute sessions 3 times/week for 6 weeks in keeping with best practice guidelines for older adults. Sessions will be supervised by physical therapists, using a circuit training approach with different stations designed to target specific areas of impairment. Participants will work through stations in a group setting; however, will receive individualized exercise prescription regarding level of difficulty and exercise progression.
1705502|NCT01424072|Other|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
1705503|NCT01424072|Other|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
1705504|NCT01424059|Other|WEDQ-B (questionnaire)|Questionnaires are answered after delivery; within 48 hours and after five weeks
1705505|NCT01424046|Drug|basal insulin glargine|Individuals assigned to this arm will initially receive a basal insulin injection daily and gradually be introduced to meal time coverage of blood sugar with additional short acting insulin. Education will like wise proceed in a stepwise manner.
1705506|NCT01424046|Drug|standard therapy|Participants will continue with current mixed insulin treatment using NPH , or lente, and regular insulin .
1705507|NCT01424033|Drug|N-Acetylcysteine|600mg by mouth, three times daily for 12 months
1705508|NCT01424020|Other|Questionnaire|Self completed questionnaire, Supervised by the physician Ankle brachial index (ABI) calculation Maximal walking distance (MWD) on treadmill or over the 6 minutes walking test (when available)
1705596|NCT01423305|Drug|Budesonide/formoterol capsule.|Oral administration with concomitant charcoal.
1705509|NCT01424007|Behavioral|Weight loss|Participants would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
1705510|NCT01423994|Procedure|pacemaker|"A single or dual chamber pacemaker will be implanted according to the manufacturer's instructions for use with standard techniques.
Either a single or dual chamber pacemaker will be permitted according to local practice unless the patient is in chronic or persistent atrial fibrillation, in which case a single chamber pacemaker will be used. The pacemaker configuration will be at the discretion of the investigator.
Single chamber ventricular pacemakers will be programmed to activity responsiveness off in VVI mode, rates 50-120 bpm.
Dual chamber pacemaker programming will be to DDD mode (50-120) with mode switch on."
1705511|NCT01423994|Procedure|implantable loop recorder|The implantable loop recorder will be programmed for automatic detection using settings of Low Heart Rate <50 bpm, High Heart Rate >165 bpm, and Pause > 3 seconds.
1705512|NCT01423968|Biological|Lipopolysaccharide infusion|Lipopolysaccharide 4 nanogram/kg body weight
1705513|NCT01423968|Other|saline|
1705514|NCT01423955|Drug|Erythropoietin zeta|The active drug will be given only once after the anesthesia induction and before the start of surgery. The active drug will be diluted to 2000U/kg and given as a single dose of 400U/kg. The dose will be prepared prior to surgery by a independent nurse.
1705515|NCT01423955|Drug|Placebo|Placebo arm will receive NaCl 9mg/ml with a dose of 0.2 ml/kg. The placebo dose will be prepared prior to the surgery by a independent nurse. The calculated volume will match the volume of the active durg.
1705516|NCT01423929|Drug|Oxygen|Fitting of Oxymask TM and treatment with 10 L O2/min
1705517|NCT01423929|Device|Room air|Fitting of Oxymask TM
1705518|NCT01423916|Drug|OPC-34712 (4mg)|Arms assigned to this intervention receive 4mg.
1705519|NCT01423916|Drug|Moxifloxacin|Arms assigned to this intervention will receive 400mg.
1705520|NCT01423916|Drug|OPC-34712 (12mg)|Arms assigned to this intervention receive 12mg.
1705521|NCT01423916|Drug|Placebo|OPC-34712 placebo
1705522|NCT01423903|Drug|OPB-51602|A cycle will consist of 28 days of OPB-51602 be taken by study subjects daily by mouth for every day of each 28 day cycle.
1705523|NCT01423890|Genetic|ONCOTYPEDX Test|Gene signature test containing 21 genes (16 cancer-related genes, e.g., invasion, proliferation, ER, Her 2 and five reference genes) and generates an individualized recurrence score.
1705524|NCT01423864|Drug|conventional ECMO with intravenous steroid|refractory acute respiratory distress syndrome and multi-organ dysfunction syndrome treated with intravenous steroid, Solu-Cortef 50mg q6h taper down when hemodynamic stable
1705525|NCT01423864|Drug|solumedrol|Initially, intrapleural steroid administration was performed using 40 mg solumedrol q6h (for both the pleural cavities). If chest radiography showed an improvement in consolidation, i.e., 0.8 > FiO2 ≥ 0.5 and 5 ≤ PEEP ≤ 10, the dosage of solumedrol was reduced to 40 mg q12h. When FiO2 was below 0.5 and the PEEP was below 10, the dosage of solumedrol was lowered to 40 mg qd for 3 days and then its administration was discontinued.
1705526|NCT01423851|Drug|NS-018|Treatment will be administered continuously as oral daily therapy in cycles of 4 weeks in duration (28 day treatment cycles).
1705527|NCT01423838|Drug|Solifenacin|5 mg, oral, once in a day
1705528|NCT01423838|Drug|Oxybutynin|5 mg, oral, three times in a day
1705529|NCT01423825|Biological|Sub C gp140 Vaccine|100 mcg of Sub C gp140 vaccine admixed with MF59C.1 adjuvant administered as one 0.5 mL injection intramuscularly (IM) in either deltoid
1705530|NCT01423825|Biological|MF59C.1 Adjuvant|MF59C.1 adjuvant admixed with 100 mcg of Sub C gp140 vaccine administered as one 0.5 mL injection intramuscularly (IM) in either deltoid. MF59C.1 adjuvant contains no biologicals.
1705531|NCT01423825|Other|Sodium chloride|Sodium chloride as 0.5 mL IM injection in either deltoid to act as placebo
1705534|NCT01423799|Dietary Supplement|Nutritional supplements containing arginine, n-3 and nucleotides|Nutritional intervention with immuno-nutrients
1705535|NCT01423799|Dietary Supplement|Isocaloric control|Isocaloric and isonitrogenous control without immuno nutrients
1705536|NCT01423786|Dietary Supplement|Early Oral Nutrition|Once enrolled in the study, patients will be allowed a oral diet that is low in fat.
1705537|NCT01423773|Device|Lotrafilcon A test contact lens|Silicone hydrogel single vision, soft contact lens with alternate parameters
1705538|NCT01423773|Device|Lotrafilcon A control contact lens|Silicone hydrogel single vision, soft contact lens
1705539|NCT01423773|Device|Ultra-High Resolution Optical Coherence Tomographer (OCT)|Investigational, nonsignificant risk device for measuring post lens clearance and ocular tissue compression during contact lens wear
1705540|NCT01423760|Biological|Tecemotide|Subjects who received tecemotide (L-BLP25) for the treatment of non-small cell lung cancer (NSCLC) or multiple myeloma in a feeder trial will continue to be treated with tecemotide (L-BLP25) and have safety assessments performed until the discontinuation criteria in the respective feeder trial protocol are met.
1705541|NCT01423760|Other|No intervention|Subjects who had not received tecemotide in the feeder study, or who had discontinued treatment with tecemotide (L-BLP25), will only be observed for progressive disease (PD) (if applicable) and survival in 6-month intervals and will not be provided treatment with tecemotide (L-BLP25).
1705542|NCT01423747|Drug|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
1705543|NCT01423747|Radiation|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
1705544|NCT01423747|Drug|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
1705545|NCT01423747|Radiation|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
1705546|NCT01423747|Drug|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG 20mg/kd/d on day -3 to day -1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
1766325|NCT00321191|Drug|No nitrous oxide|
1705549|NCT01423734|Other|magnetic resonance imaging (MRI)|"Each patient will undergo clinical and research MRI examinations. Before any MRI examination, the patient will answer a standard radiology MR department questionnaire form, with specific questions addressing contra-indications to MRI. The questionnaire form will be reviewed by radiology personnel as per standard practice.
During the research MRI, the patient will be monitored visually and communication will be maintained between the patient and the MR technologists via a speaker system. At the termination of the study, the patient will be evaluated by the MR department radiology personnel as done routinely. Two breath hold DWI sequences will be performed for each patient. Since this is a reproducibility study, identical scan parameters will be used for the clinical and research MRI. The multiple b value DWI will be performed using the enhanced DW sequence that have been recently made available on our 3.0 Tesla MR 750 scanners at the Breast and Imaging Center."
1705550|NCT01423721|Drug|Bromihexine hydrochloride syrup|syrup
1705551|NCT01423721|Drug|Bromihexine hydrochloride granules|granules
1705552|NCT01423708|Drug|Everolimus|Administration of Everolimus within 24 hours from the time of randomization (7 days from the time of transplantation) in association with Tacrolimus and steroids. The first dose level of the trough will be performed at day 7 after initiation of therapy. After the reaching an Everolimus trough level of >5ng/ml (final target 6-12 ng/ml), there will be a gradual weaning of tacrolimus (bringing Tacrolimus blood levels <5 ng/ml) with discontinuation of Tacrolimus within 30 days after transplantation when possible.
1705553|NCT01423695|Drug|paclitaxel plus trastuzumab|Weekly paclitaxel (90 mg/m² iv, 12 courses) plus weekly trastuzumab (4mg/kg body weight iv as loading dose, 2 mg/kg iv from week 2 onwards; continued until disease progression)
1705554|NCT01423682|Behavioral|Eccentric exercise|Patients and healthy subjects will perform an eccentric exercise during which a weight is lifted along the body and lowered with an extended arm at a slow speed. Weight is determined, based on pain in patients and based on force in healthy subjects.
1705555|NCT01423604|Drug|Capecitabine|Capecitabine starting dose - 2000 mg/m^2 (1000 mg/m^2 twice a day (BID)) (NOTE: Frequency of administration may be adjusted during the study.)
1705556|NCT01423604|Drug|Ruxolitinib|Ruxolitinib starting dose - 15 mg BID (NOTE: Starting dose of randomized study drug may be 10 mg BID based on results from safety run-in study. Dose of ruxolitinib may be increased during randomized study.)
1705557|NCT01423604|Drug|Placebo|Placebo matching ruxolitinib
1705558|NCT01423591|Drug|infliximab|Infliximab 5 mg/kg. i.v. at week 0, 2, 6, 14 y 22.
1705559|NCT01423591|Drug|inactive powder|Inactive powder. i.v. at week 0, 2, 6, 14 y 22.
1705560|NCT01423578|Behavioral|Hatha Yoga (HY)|3 Sessions of yoga instruction
1705561|NCT01423578|Behavioral|Cardiovascular Exercise (CE)|3 sessions of cardiovascular exercise
1705562|NCT01423578|Behavioral|Smoking Cessation Counseling|4 smoking cessation counseling visits.
1705563|NCT01423565|Device|Deep Brain Stimulation (Medtronic, Activa PC)|"Following subthalamic nucleus deep brain stimulation patients will be randomized to receive either constant current or constant voltage stimulation and subsequently crossed over to receive the other type of stimulation"
1705564|NCT01423539|Drug|bendamustine|Intravenous repeating dose\n
1705565|NCT01423539|Drug|navitoclax|Oral repeating dose\n
1705566|NCT01423539|Drug|rituximab|Intravenous repeating dose\n
1705567|NCT01423526|Drug|DWP10292|Drug: DWP10292 tablets, oral administration, single administration
1705568|NCT01423526|Drug|Placebo|Placebo tablets, oral administration, single administrations
1705569|NCT01423513|Other|Fibular Taping|Tape with be applied with tension.
1705570|NCT01423513|Other|Sham Taping|Tape will be applied without tension
1705571|NCT01423500|Drug|VP16|patients with MSD receive as conditioning VP16 60mg/kg/d on day -3
1705572|NCT01423500|Radiation|TBI|patients with a MSD receive TBI (12Gy in 6 fractions) as conditioning
1705573|NCT01423500|Drug|VP16, ATG|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive VP16 60mg/kg/d on day -3 and ATG fresenius 20mg/kg/d on day -3,-2,-1
1705574|NCT01423500|Radiation|TBI|patients with a HLA matched unrelated Donor (9/10 oder 10/10) receive TBI (12Gy in 6 fractions)
1705575|NCT01423500|Drug|Fludarabine, OKT3, Treosulfan, Thiotepa|patients with a MMD (haploidentical or cord blood) receive Fludarabine 30mg/m²/d on day -9 to -5, ATG fresenius 20mg/kg/d on day -3,-2,-1, Treosulfan 14g/m²/d on day -7 to -5 and Thiotepa 2x5mg/kg/d on day -4
1705576|NCT01423500|Drug|VP16, ATG|patients with MMD-transplantation (8/10)receive VP16 60mg/kg/d on day -4, ATG from day -3 to day-1 20mg/kg/d
1705577|NCT01423500|Radiation|TBI|patients with a MMD-transplantation (8/10) receive 12 Gy in 6 fractions
1705578|NCT01423487|Drug|Metformin|0.5g bid 26 weeks
1705579|NCT01423487|Other|Starch tablets|0.5g bid 26 weeks
1705580|NCT01423474|Radiation|Image-guided radiotherapy|40 Gy / 5 fractions / 11 days
1705581|NCT01423474|Radiation|Image-guided radiotherapy|40 Gy / 5 fractions / 29 days
1705582|NCT01423448|Other|bulletin board|An asynchronous online bulletin board for people with experience of depression
1705583|NCT01423435|Drug|TRK-100STP|oral
1705584|NCT01423409|Device|pictorial VAS|Pictorial VAS includes elements which promote understanding of Deaf people: colours and 6 detailed expressive faces.
1705585|NCT01423409|Device|usual VAS|usual visual analog scale (VAS) of pain (line from 0: no pain to 10:worst pain)
1705586|NCT01423396|Other|optimal care of VRF|VRF of AD patients will be treated optimally in strict compliance with the French HAS guidelines concerning targets for blood pressure, glycaemia and blood lipid levels, in accordance with standardized therapeutic regimens.
1705587|NCT01423396|Other|standard care|AD patients will be followed with the city doctor and the letter t will be send for remember French HAS guidelines
1705588|NCT01423370|Drug|YHD1023|5g oral once daily
1705589|NCT01423370|Drug|YHD1023|5g oral twice a day
1705590|NCT01423370|Drug|YHD1023|10g oral once daily
1705591|NCT01423370|Drug|Cialis|5mg oral once daily
1705592|NCT01423370|Drug|Placebo|Oral
1705593|NCT01423357|Other|Condom distribution and peer education|Condom distribution and condom demonstrations by youth peer educators at least twice a week
1705594|NCT01423318|Drug|lebrikizumab|Dose-level cohorts receiving single subcutaneous dose
1705595|NCT01423318|Drug|placebo|single dose subcutaneously
1767046|NCT00333281|Drug|tadalafil|
1705597|NCT01423305|Drug|Budesonide/formoterol capsule for oral adm.|Oral administration without concomitant charcoal.
1705598|NCT01423292|Procedure|Ultrasound Guided Transversus Abdominis Plane (TAP) Block|Ultrasound Guided Transversus Abdominis Plane (TAP) Block
1705599|NCT01423292|Drug|bupivacaine|0.25 bupivacaine 30ml (15ml on each side)
1705600|NCT01423292|Drug|Placebo|placebo
1705601|NCT01423266|Procedure|12-week supervised weight loss intervention|Patients in the 2 study arms will participate in an intensive 12-week supervised weight loss intervention and will be seen by the same dietician at regular intervals: baseline, 2 weeks, 4 weeks, 8 weeks, and 12 weeks. Participants will receive personalized nutrition counseling and support during each of these visits. Participants will be randomized to either the HP or SP diet and assigned to receive one of two standard structured energy-restricted meal plans (1200, 1500 Kcal/day) based on the computed calorie deficit
1705603|NCT01423240|Drug|Lurasidone 20 mg|Lurasidone 20 mg once daily orally in the evening
1705604|NCT01423240|Drug|Lurasidone 60 mg|Lurasidone 60 mg once daily orally in the evening
1705605|NCT01423240|Drug|Placebo|Placebo once daily orally in the evening
1705606|NCT01423227|Behavioral|Home-based pulmonary rehabilitation|One home visit plus weekly telephone calls for 8 weeks
1705607|NCT01423227|Behavioral|Hospital-based pulmonary rehabilitation|Standard twice-weekly 8-week outpatient pulmonary rehabilitation program
1705608|NCT01423214|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
1705609|NCT01423214|Procedure|Laparoscopic surgery|Conventional laparoscopic procedures
1705610|NCT01423188|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 24 weeks
1705611|NCT01423188|Drug|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 24 weeks
1705612|NCT01423175|Drug|Clofarabine, ara-C|
1705613|NCT01423175|Drug|FLAMSA|
1705614|NCT01423162|Other|Dietary Intervention (with Vit C then without Vit C)|Fortified oat drink with vitamin C followed by fortified oat drink without vitamin C
1705615|NCT01423162|Other|Dietary Intervention (without Vit C followed by with Vit C)|Fortified oat drink without vitamin C followed by fortified oat drink with vitamin C
1705616|NCT01423149|Drug|Combretastatin A-4 Phosphate|Combretastatin A-4 Phosphate is administered on Day 0 and Day 7 (+/- 2 days). If the treating ophthalmologist notes any leakage from CNV in the study eye on a fluorescein angiography during the study or an increase in subretinal fluid on an optical coherence tomography measurement, retreatment with Combretastatin A-4 Phosphate is recommended with up to 3 additional treatments. The retreatment visit(s) could occur during a scheduled visit or at an additional visit 1 week after a regular study visit. A post-retreatment follow-up visit is necessary.
1705617|NCT01423136|Device|Remote ECG monitoring Spacelab SL 1050|If ischemia noted, Sx will be notified and currently accepted treatments of myocardial ischemia will be recommended.
1705618|NCT01423123|Drug|Paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days until disease progression.
1705619|NCT01423123|Biological|trastuzumab|4 mg/kg IV loading dose, then 2 mg/kg IV weekly until disease progression.
1705620|NCT01423123|Drug|Neratinib|Dose level 1: 120 mg/day orally; Dose level 2: 160 mg/day orally; Dose level 3: 240 mg/day orally; Dose level 4: 200 mg/day orally.
1705621|NCT01423110|Biological|BYM338|
1705622|NCT01423110|Biological|Placebo|
1705623|NCT01423084|Biological|Serogroup B meningococcal vaccine|"All subjects will receive two rMenB+OMV NZ vaccinations one month apart and will be followed for a total of 2 months. Subjects will be randomized to 1 of 2 treatment arms to receive either two doses of rMenB+OMV NZ vaccine Lot 1 or two doses of rMenB+OMV NZ Lot 2.
A total of 2 blood samples will be collected (at the first vaccination and 1 month after the 2nd vaccination). An additional blood draw will be collected in a subset of approximately 160 subjects (approximately 80 subjects in Group 1 and approximately 80 subjects in Group 2) at 2 weeks after the second vaccination"
1705624|NCT01423058|Drug|Momelotinib|"In the Part I dose-escalation phase of the study, subjects will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 200 mg BID (twice daily with doses taken approximately 12 hours apart. Doses will be escalated by 50 mg BID in successive cohorts of 3 subjects per dose level. Subjects will be evaluated weekly for the first cycle, every 2 weeks during cycle 2, then monthly for 4 cycles for a total of 6 cycles.
In the dose confirmation phase of the study (Part 2), subjects will be evaluated every 2 weeks during the first treatment cycle, and then monthly for 5 cycles for a total of 6 cycles."
1705625|NCT01423032|Drug|bendamustine|100 mg/m² iv, day 1+2, q4w
1705626|NCT01423032|Drug|Fludarabine|25 mg/m² iv, days 1-5, q4w
1705627|NCT01423019|Dietary Supplement|Advantra Z|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine.
1705628|NCT01423019|Dietary Supplement|Advantra Z + Naringin + Hesperiden|Two capsules are taken twice daily, 20-30 minutes before breakfast and evening meals. Two capsules contain a total of 50 mg p-synephrine, 600 mg naringin, and 100 mg hesperiden.
1705629|NCT01423019|Other|Sugar pill|Two capsules containing inert ingredients are taken twice daily, 20-30 minutes before breakfast and evening meals.
1705630|NCT01423006|Procedure|Radio-Frequency Ablation (RFA) ENCAGE™|RFA is a minimally invasive procedure. It is an image-guided technique that heats and destroys cancer cells. In RFA, imaging techniques such as ultrasound or magnetic resonance imaging (MRI) are used to help guide a needle electrode into a cancerous tumor. High-frequency electrical currents are then passed through the electrode, destroying the cancer cells.
1705631|NCT01422993|Other|12 Week Exercise Program|Participants will be asked to take part in a one hour exercise program twice a week for 12 weeks. They will also be asked to answer questionnaires and participate in an evaluation of their strength, balance, and physical function every 4 weeks immediately following the exercise program. This evaluation will take an additional hour every 4 weeks.
1705632|NCT01422980|Other|1- Test dairy product containing specific ingredients|
1705633|NCT01422980|Other|2- Control dairy product without specific ingredients|
1705634|NCT01422967|Behavioral|Balance and muscle strength|Balance test: bi and unipodal balance in the place force Muscle strength: bilateral test of knee in dynamometer isokinetic
1767047|NCT00333294|Drug|Gefitinib|
1705635|NCT01422954|Drug|Chloroquine prophylaxis|Standard prophylactic regime: a loading dose of 300 mg on day 14 and day 17 and then 300 mg once a week, starting on day 21, for a total duration of 13 weeks. On day 0, day 3, day 7 and day 10, this group will receive a placebo.
1705636|NCT01422954|Drug|Mefloquine prophylaxis|Mefloquine prophylaxis, starting with a loading regime of split doses during the first three weeks: 125 mg on day 0, day 3, day 7, day 10, day 14 and day 17 and 250 mg once a week from day 21 onwards for a total duration of 13 weeks.
1705637|NCT01422954|Biological|Immunization|Group 1 and 2 will receive three immunizations with Plasmodium falciparum infected mosquito-bites. Group 3 will receive an equal number of uninfected mosquito-bites.
1705638|NCT01422954|Biological|Controlled Human Malaria Infection|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
1705639|NCT01422954|Drug|Malarone|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
1705640|NCT01422941|Device|CAVU Attune Device|The CAVU Attune device is used with LAGB.
1705641|NCT01422928|Procedure|Medical Acupuncture|"Subjects will be asked to report symptom concerns. Subjects are requested to wear loose clothing as most acupoints lie at or distal to the elbow and knee.
Sterile single use steel needles (ITO Adiquip 0.25 x 4.0 cm) will be inserted to a depth of 1 - 2 cm at acupoints thought to impact positively on the immune system. An ITO ES-160 Electrostimulator will be used to mimic the pecking technique of manual stimulation. Following needle insertion by the acupuncturist, a nurse or acupuncture student may assist by attaching electrodes to provide electrical stimulation. A 0.3 ms duration, 4 HZ, alternating current will be delivered with voltage set just below the pain threshold of the patient. After 20 minutes, the needles will be removed. Acupoints will include:
GV.14
LI.11 (bilateral)
SP.6 (bilateral)
SP.10 (bilateral)
ST.36 (bilateral)
Additional points may be added based on the symptom concerns reported."
1705642|NCT01422915|Drug|Colestipol|2 grams morning and bedtime for 90 days.
1705643|NCT01422902|Other|Plasticity-based Cognitive Training|
1705644|NCT01422902|Other|Non-plasticity-based Training|Computer games
1705645|NCT01422889|Device|ION™ Coronary Stent System|This study is intended to evaluate the ION™ Paclitaxel-Eluting Platinum Chromium Coronary Stent System across a range of institutions and physician users to observe and assess subject outcomes and technology performance in a real-world setting.
1705646|NCT01422876|Drug|high dose FDC|once daily
1705647|NCT01422876|Drug|BI 10773 high dose|once daily
1705648|NCT01422876|Drug|high dose FDC placebo|once daily
1705649|NCT01422876|Drug|low dose FDC placebo|once daily
1705650|NCT01422876|Drug|high dose FDC placebo|once daily
1705651|NCT01422876|Drug|high dose FDC placebo|once daily
1705652|NCT01422876|Drug|low dose FDC placebo|once daily
1705653|NCT01422876|Drug|low dose FDC placebo|once daily
1705654|NCT01422876|Drug|high dose BI 10773 placebo|once daily
1705655|NCT01422876|Drug|low dose FDC|once daily
1705656|NCT01422876|Drug|high dose FDC placebo|once daily
1705657|NCT01422876|Drug|BI 10773 low dose|low dose once daily
1705658|NCT01422876|Drug|high dose BI 10773 placebo|once daily
1705659|NCT01422876|Drug|high dose BI 10773 placebo|once daily
1705660|NCT01422876|Drug|linagliptin|once daily
1705661|NCT01422876|Drug|low dose FDC placebo|once daily
1705662|NCT01422876|Drug|linagliptin placebo|once daily
1705663|NCT01422876|Drug|BI 10773 low dose placebo|once daily
1705664|NCT01422876|Drug|linagliptin placebo|once daily
1705665|NCT01422876|Drug|low dose BI 10773 placebo|once daily
1705666|NCT01422876|Drug|linagliptin placebo|once daily
1705667|NCT01422876|Drug|high dose BI 10773 placebo|once daily
1705668|NCT01422876|Drug|BI 10773 low dose placebo|once daily
1705669|NCT01422876|Drug|low dose BI 10773 placebo|once daily
1705670|NCT01422876|Drug|linagliptin placebo|once daily
1705671|NCT01422863|Behavioral|Lifestyle Intervention|Participants undergo 3 months of monitored exercise, consisting of aerobic and resistance training (3 days per week for 1 hour). Participants will also meet with a registered dietician, who will prescribe an American Heart Association low fat diet. The goal is to achieve a 1-2 lb weight loss per week.
1705672|NCT01422850|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as three intravenous injections interspaced by 5 weeks.
1705673|NCT01422811|Behavioral|Multicomponent strategy to reduce avoidable length of stay|"The strategy comprises two integrated components:
Distribution of two monthly reports, one consisting in the list of patients who, through data collection performed, are classified to be present on the ward although their clinical status is considered compatible with discharge; the other featuring individual length of stay profiles for each physician operating in the intervention arm (information taken from administrative data), allowing comparisons with the rest of the medical staff;
Audits performed by professionals of each ward of the intervention arm designed to discuss cases judged to be compatible with discharge. The organization of this work are left to the wards, without any interference from the project team."
1705674|NCT01422811|Other|No intervention|No interventions (reporting, auditing) are planned; nevertheless control ward physicians know study aims and are informed about their patient's data collection.
1705675|NCT01422785|Drug|clindamycin phosphate 1.2%/tretinoin 0.025% gel alone|Once daily application of the clindamycin phosphate 1.2%/tretinoin 0.025% gel in the evening
1705676|NCT01422785|Drug|clindamycin phosphate 1.2%/tretinoin 0.025% gel plus benzoyl peroxide 6% foaming cloths|wash face with the benzoyl peroxide foaming cloth then rinse. then apply clindamycin phosphate 1.2%/tretinoin 0.025% gel. both done in the evening.
1705677|NCT01422772|Biological|VM202RY|0.5mg intramuscular injection
1705678|NCT01422772|Biological|VM202RY|1mg intramuscular injection
1705679|NCT01422772|Biological|VM202RY|2mg intramuscular injection
1705680|NCT01422759|Drug|Spironolactone|50-100 mg PO BID (X 12 weeks)
1705681|NCT01422746|Drug|Metformin|500-1000 mg PO BID (X12 weeks)
1705682|NCT01422733|Drug|Hydrocortisone|10mg/m2/per day PO at bedtime (X12 weeks)
1705683|NCT01422733|Drug|dexamethasone|1 mg PO twice
1705684|NCT01422733|Drug|Cosyntropin|250 micrograms IV twice
1705685|NCT01422733|Drug|rhCG|25 mcg IV twice
1705686|NCT01422720|Drug|Eslicarbazepine Acetate|ESL tablets (800 mg) QD
1705688|NCT01422681|Device|minimally invasive extracorporeal carbon dioxide removal|"The application of the extracorporeal carbon dioxide removal will be initiated by using a modified continuous veno-venous hemofiltration system equipped with a membrane lung with a total membrane surface of 1,35 m2 (Decap® Smart).
Femoral vein is accessed via a double lumen catheter (14 F) inserted with the Seldinger technique and connected with the extracorporeal circuit. Blood flow is driven through the circuit by a roller nonocclusive low-flow pump (0- 450 ml/min) through a membrane lung (Euroset) that is connected to a fresh gas flow source delivering 100% oxygen at a constant rate of 8 l/min. Exiting the membrane lung, blood is driven to a hemofilter (Medica D250). The resulting plasmatic water is recirculated through the membrane lung by a peristaltic pump (0-155 ml/min)."
1705690|NCT01422642|Device|legacy posterior stabilized high-flexion (NexGen LPS-Flex)|NexGen legacy posterior stabilized high-flexion (NexGen LPS-Flex) total knee system
1705691|NCT01422642|Device|legacy posterior stabilized standard (NexGen LPS)|NexGen legacy posterior stabilized standard (NexGen LPS) total knee system
1705692|NCT01422629|Device|Ultrasonic ablation device|High Intensity focused ultrasound treatment
1705693|NCT01422616|Drug|Low-dose rtPA|Patients allocated to low-dose will receive 0.6 mg/kg (maximum of 60 mg) i.v. (15% bolus [maximum bolus dose of 9mg] and 85% infusion over 60 mins) recombinant tissue plasminogen activator (rtPA).
1705694|NCT01422616|Drug|Standard-dose rtPA|Patients allocated to standard-dose will receive 0.9 mg/kg (maximum of 90 mg) i.v. (10% bolus and 90% infusion over 60 mins) rtPA.
1705695|NCT01422616|Other|Intensive blood pressure (BP) lowering|"Intensive blood pressure (BP) lowering to a target systolic BP range 130-140 mmHg within one hour and to maintain this level for at least 72 hours (or until hospital discharge or death if this should occur earlier). A standardised i.v. BP lowering regimen using locally available and approved i.v. BP lowering agents will be used, commenced in the emergency department and later in a high dependency area (e.g. acute stroke or neurointensive care unit) as is usual for patients receiving rtPA.
The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
1705696|NCT01422616|Other|BP management policies|"Patients allocated to the control group will receive management of BP that is based on a standard guideline, as published by the AHA. For this group, the attending clinician may consider commencing BP treatment if the systolic level is greater than 180 mmHg, however and the first line treatment will be oral (including nasogastric if required) and/or transdermal routes. Should control of systolic BP not be achieved via these routes, i.v. treatment may be started until the target systolic BP of 180 mmHg is achieved.
The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets."
1705697|NCT01422603|Drug|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to full intensity allogeneic stem cell transplant
1705698|NCT01422603|Drug|Clofarabine|Clofarabine preconditioning (40mg/m2 daily for 5 days) prior to reduced intensity allogeneic stem cell transplant
1705699|NCT01422590|Drug|Sitagliptin|Single oral administration of sitagliptin 100 mg
1705700|NCT01422590|Drug|Mitiglinide|Single oral administration of mitiglinide 10 mg
1705701|NCT01422590|Drug|Sitagliptin, Mitiglinide|Concomitant administration of sitagliptin 100 mg and mitiglinide 10 mg
1705702|NCT01422577|Device|Bright Narrow Band Imaging|It is a High Definition system with narrow band imaging option in th endoscope.
1705703|NCT01422577|Device|White light Endoscopy|White light Endoscopy
1705704|NCT01422564|Device|Metal on Metal Hip System|Total hip arthroplasty with a metal on metal component system
1705705|NCT01422564|Device|Highly Cross Linked Polyethylene cup System|Total hip arthroplasty with Highly Cross Linked Polyethylene cup System
1705706|NCT01422551|Behavioral|Cognitive Behavioral Stress Management|10 weekly 2-hour sessions of group-based cognitive behavioral stress management
1705707|NCT01422551|Behavioral|a psycho-educational control|a single-day psycho-educational seminar
1705708|NCT01422538|Device|Ulthera® System|Focused ultrasound energy delivered below the surface of the skin on the lower face.
1705709|NCT01422538|Drug|Sculptra®|Injectable filler reconstituted prior to use. Injections are administered to the lower face in a combination of cross-hatching and fanning techniques. The Sculptra is injected in two treatment sessions 6 weeks apart.
1705710|NCT01422538|Other|Sculptra® treatment followed by Ultherapy™ treatment|Sculptra® administered in 2 injection sessions 6 weeks apart, then Ultherapy™ treatment 4 months following Sculptra.
1705711|NCT01422525|Procedure|spectral domain optical coherence tomography|RNFL thickness measurement using spectral domain optical coherence tomography at baseline, 1, 3 and 6 months postoperatively.
1705712|NCT01422512|Biological|seasonal influenza vaccine|Subjects received one single IM dose of trivalent Surface, Antigen, Inactivated, Influenza Vaccine Produced in Mammalian Cell Culture during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
1705713|NCT01422499|Drug|zolinza/vorinostat|orally once per day (suspension of 50mg/ml or capsules of 100 mg vorinostat); starting dose will be 180 mg/m²/d; escalated with increments of 50 mg/m²/d every two weeks until dose limiting toxicity (grade 3 or 4 toxicity according to CTC) occurs or up to a maximum dose of 580 mg/m²/d; This dose will then be applied for 3 months. Patients without progression at first response evaluation will continue treatment for a maximum of 9 months.
1705714|NCT01422486|Drug|ezatiostat hydrochloride (Telintra®)|Three weeks of treatment with ezatiostat at 2000 mg per day in divided doses followed by a one week rest period in four-week treatment cycles.
1705715|NCT01422473|Device|EnSeal Trio Tissue Sealing Device|For surgery in ligating and dividing vascular tissue during abdominal surgery.
1705716|NCT01422460|Biological|Platelet Rich Plasma|"Platelet Rich Plasma (Preparation Rich in Growth Factors)
intra articular injection 2ml
Arms: Platelet Rich Plasma (Preparation Rich in Growth Factors)"
1705717|NCT01422447|Other|regular intervention|the subjects in the control group live in the used model
1705718|NCT01422447|Other|community intervention|in addition to regular intervention, those subjects in the intervention group will be given education intervention.
1705719|NCT01422434|Drug|LEO 90105 = calcipotriol + betamethasone dipropionate|Applied once daily for 4 weeks.
1705720|NCT01422434|Drug|Dovonex® = calcipotriol|Applied twice daily for 4 weeks.
1705722|NCT01422421|Other|intensive control|use any medication to achieve systolic blood pressure less than 120mmHg and LDL cholesterol within 70-85mg/dl
1705723|NCT01422421|Other|standard control|use any medication to achieve systolic blood pressure less than 130mmHg and LDL cholesterol less than 100mg/dl
1705727|NCT01422395|Procedure|Freezing|Vitrification
1705728|NCT01422382|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
1705729|NCT01422382|Drug|Diltiazem (Cardizem LA) 240 mg QD|Diltiazem (Cardizem LA) 240 mg QD
1705730|NCT01422369|Drug|Pitavastatin (NK-104)|Pitavastatin (NK-104) 4mg once daily (QD)
1705731|NCT01422369|Drug|Darunavir/Ritonavir (Prezista)|Darunavir/Ritonavir (Prezista) 800 mg/100 mg
1705732|NCT01422343|Procedure|percutaneous transluminal angioplasty femoro-popliteal|percutaneous transluminal angioplasty femoro-popliteal
1705733|NCT01422330|Drug|Etravirine|Type=exact number, unit=mg, number=100, form=tablet, route=oral use, 2 tablets. Type=exact number, unit=mg, number=200, form=tablet, route=oral use, 1 tablet. The drug is taken twice a day, after meals.
1705734|NCT01422317|Drug|EPA / DHA / Alpha-Tocopherol|Two gelatine capsules of Omacor-R (Pronova AS, Oslo) twice a day, each containing 850-882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethylesters in the average ratio of EPA to DHA of 1:2. Alpha-Tocopherol (4 mg) was added to each capsule.
1705735|NCT01422317|Drug|Corn Oil / Alpha-Tocopherol (4 mg)|Two gelatine capsules twice a day. Each capsule contains 1g Corn Oil and 4 mg Alpha-Tocopherol
1705736|NCT01422304|Drug|Sugammadex|Sugammadex 4 mg/kg intravenously
1705737|NCT01422304|Drug|neostigmine and glycopyrrolate or atropine|Neostigmine and glycopyrrolate or neostigmine and atropine administered intravenously per usual practice and per the product labels
1705738|NCT01422304|Drug|Placebo to neostigmine|Normal saline (NaCl 0.9%)
1705739|NCT01422304|Drug|Placebo to sugammadex|Normal saline (NaCl 0.9%)
1705740|NCT01422291|Drug|paracetamol|1 gr
1705741|NCT01422291|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
1705742|NCT01422291|Drug|Dexketoprofen|50 mg
1705743|NCT01422291|Drug|Paracetamole|1 gr
1705744|NCT01422278|Other|Rehabilitation|Three weeks of rehabilitation in Hospital.
1705745|NCT01422252|Device|Vigi'Fall®|Precocious fall detection device
1705746|NCT01422239|Behavioral|Tailored treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes tailored to the perceived risks of quitting most strongly held by each participant. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
1705747|NCT01422239|Behavioral|Standard Treatment|8 sessions of individual behavioral counseling. The first 3 sessions will be 45 minutes long and include 30 minutes focused on the benefits of quitting smoking. The final 5 sessions will be 30 minutes long and include material from the Mayo Clinic's smoking cessation manual.
1705748|NCT01422226|Drug|Misoprostol|Experimental: 400 mcg taken sublingually 2 hours prior to IUD insertion
1705749|NCT01422226|Other|Placebo|Pill identical to study drug in appearance, taste, smell. Taken sublingually 2 hours prior to IUD insertion
1705750|NCT01422213|Drug|Placebo|capsules; daily; orally
1705751|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
1705752|NCT01422213|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
1705753|NCT01422200|Biological|2011-2012 seasonal flu vaccine|The 2011-2012 seasonal flu vaccine will be given by subcutaneous injection.
1705754|NCT01422200|Biological|2011-2012 seasonal flu vaccine|the 2011-2012 seasonal flu vaccine will be given by intramuscular injection
1705755|NCT01422187|Drug|Taliglucerase alfa|Taliglucerase infusion every two weeks for 21 months
1705756|NCT01422174|Procedure|Implantable Cardio Defibrillator (ICD),|Standard ICD implantation (as per clinical decision)
1956148|NCT02947347|Drug|ibrutinib|ibrutinib 560mg administered orally
1705758|NCT01422148|Drug|Amiodarone|oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
1705759|NCT01422148|Drug|Minocycline|intravenous minocycline 100 mg daily x 5 days starting intra-operatively combined with oral amiodarone (400 mg twice daily for 7 days, then 200 mg twice daily for the next 7 days
1956149|NCT02947347|Drug|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
1705761|NCT01422122|Drug|Vitamin D3|4000 mg per day, one tablespoon syrup per day
1705762|NCT01422122|Drug|Placebo|one table spoon Syrup per day
1705763|NCT01422109|Drug|YH14659|YH14659 capsule by oral
1705764|NCT01422109|Drug|clopidogrel & aspirin|clopidogrel tablet(75mg) + aspirin capsules(100mg) by oral
1705765|NCT01422096|Drug|Leuprolide|depot leuprolide 11.25 mg if less than or equal to 37.5 kg or 15 mg if > 37.5 kg im once
1705766|NCT01422083|Procedure|home stretching program|A home stretching program (sleeper's stretch): 3 x 30 seconds, once a day for 6 weeks.
1705767|NCT01422018|Drug|Avastin (bevacizumab)|Bevacizumab (1.25 mg in 0.05 ml) (Avastin; Genentech Inc., San Francisco, CA, USA)
1956150|NCT02947347|Drug|rituximab|rituximab 375mg/m^2 IV
1956151|NCT02947347|Drug|ibrutinib|ibrutinib 560mg administered orally
1705770|NCT01421992|Drug|Methylphenidate|One Tablet of methylphenidate, 20 mg per day during 3 weeks
1705771|NCT01421992|Drug|Placebo|one tablet placebo per day during 3 weeks
1705772|NCT01421979|Dietary Supplement|Energy Drink, Taurine, Caffeine|
1705773|NCT01421966|Biological|CureXcell®|CureXcell® injection will be administered about every 4 weeks for up to 4 treatments, or until until ulcer closure, whichever occurs first.
1705774|NCT01421966|Biological|Sham injection|The sham injections will be made by pressing on the ulcer with a needle connected to an empty syringe, at each cm of the ulcer bed
1705775|NCT01421953|Device|CT-simulation and 4D PET-CT|Patients will do a CT-simulation and 4D PET-CT in radiotherapy treatment position. The target volumes and the dosimetries obtained with both modalities will be compared.
1705776|NCT01421940|Drug|Placebo drug|After total mesorectal excision for rectal cancer, patients take placebo drug five time per week for 12 weeks.
1705777|NCT01421940|Drug|Udenafil|After total mesorectal excision, patients take 50mg udenafil five times per week for 12 weeks.
1705778|NCT01421927|Drug|Lenalidomide|"Start between Day+100 and Day+120 post-transplant
- Initial dose: 5 mg/day every day
In the absence of thrombocytopenia < 75000/mm3 or neutropenia < 1000/mm3 (with or without G-CSF), increase to the upper level than the ongoing one every third month up to the maximal dose of 15 mg/day every day.
- Duration
until persistent stringent complete response for 3 months
or progression defined by IMWG criteria12
or unacceptable toxicity
or one year after transplant"
1705779|NCT01421914|Other|Bupivacaine 0,5%|The study method was a step-up/step-down sequence model where the dose for following patients was determined by the outcome of the preceding block. The starting dose of bupivacaine was 5 mL per nerve. In the case of block failure, the dose was increased by 0.5 mL per nerve. Conversely, block success resulted in a reduction in dose by 0.5 mL per nerve. Each of the three nerves was treated as a separate entity. Dose adjustments were made to each nerve individually. The volume dose was increased in 0.5 mL at every 5 consecutive cases regardless of the result of the previous block in order to minimize bias occurence. A blinded assistant assessed sensory and motor blockade at 5-min intervals up to 30 min.
1705780|NCT01421901|Drug|Ertapenem|Ertapenem i.v,m 1g, once a day, 3 days
1705781|NCT01421901|Procedure|appendectomy|
1705782|NCT01421875|Genetic|DNA methylation analysis|
1705783|NCT01421875|Genetic|RNA analysis|
1705784|NCT01421875|Genetic|gene expression analysis|
1705785|NCT01421875|Genetic|microarray analysis|
1705786|NCT01421875|Genetic|nucleic acid sequencing|
1705787|NCT01421875|Other|laboratory biomarker analysis|
1705788|NCT01421862|Genetic|DNA methylation analysis|
1705789|NCT01421862|Genetic|RNA analysis|
1705790|NCT01421862|Genetic|gene expression analysis|
1705791|NCT01421862|Genetic|microarray analysis|
1705792|NCT01421862|Genetic|mutation analysis|
1705793|NCT01421862|Genetic|nucleic acid sequencing|
1705794|NCT01421862|Other|laboratory biomarker analysis|
1705795|NCT01421849|Procedure|Denture implantation|"In a preliminary phase, a new denture is made according to standardized prosthodontic protocol or the old denture is adapted to provide a well-fitting denture.
Eight weeks after insertion of the new denture an implant is placed under local anaesthetics in the centre of the mandibula.If primary stability is good, the implant is immediately loaded by the denture. If not, the implant is loaded after 6 to 12 weeks. Before, during and after the treatment patient satisfaction is evaluated by a 20 item questionnaire. Afterwards questionnaires are compared. After the insertion of the implant clinical evaluations take place at several moments.
The total duration of the study will be 12 to 18 months."
1705796|NCT01421836|Procedure|ERCP-guided stent insertion|ERCP guided stent insertion for malignant biliary obstruction
1705797|NCT01421836|Procedure|EUS guided stent insertion|EUS-guided stent insertion for malignant biliary obstruction
1705798|NCT01421823|Drug|alpha agonist ointment|2 weeks local treatment with alpha agonist ointment
1705799|NCT01421823|Drug|Placebo|2 weeks local treatment with placebo ointment
1705800|NCT01421810|Drug|Dexamethasone|1 mg PO
1705801|NCT01421810|Drug|rhCG|25 mcg IV
1705802|NCT01421797|Drug|Dexamethasone|1 mg PO
1705803|NCT01421797|Drug|Cortrosyn|single IV bolus of 0.25 mg will be administered
1705804|NCT01421784|Other|cine MRI|Rapid Cine-MRI for Monitoring Moving and Deforming Tumors
1705805|NCT01421771|Drug|Antihypertensive Agents|"Study formulary consists of ACE/ARB, Beta Adrenergic Blocker, Calcium Channel Blocker, vasodilators, peripheral alpha antagonist and central alpha agonist.
ACE I or ARB is first line, the order of addition of subsequent medications is per the discretion of the investigator"
1705806|NCT01421771|Other|Dry weight Challenge|Reduce the estimated dry weight of the patient's progressively over 2 -week intervals until the dry weight challenge is no longer tolerated or the patient is at BP goal
1705807|NCT01421771|Dietary Supplement|Extend dialysis treatment time and re-challenge estimated dry weight|Extend dialysis treatment time and re-challenge estimated dry weight
1705808|NCT01421758|Behavioral|online social network enrollment plus education and self monitoring|Participants are enrolled in an online social network designed to increase social support for physical activity and will self monitor physical activity and receive educational materials at a dedicated study website.
1705809|NCT01421758|Behavioral|Web education control|Participants will receive access to a dedicated study website where they can view educational materials related to physical activity
1705810|NCT01421745|Other|Cultural Competence Education module|A four hour cultural competence education module including lecture, case studies, and discussion of cultural competence.
1705811|NCT01421719|Drug|Cystoscopic injection of Botox into the urinary bladder|100 U of Botox A injected transurethrally into the urinary bladder muscle and submucosa.
1705812|NCT01421706|Drug|Sibutramine-clopidogrel|Sibutramine-clopidogrel
1705813|NCT01421706|Drug|sibutramine-Clarithromycin|sibutramine-Clarithromycin
1705814|NCT01421693|Drug|Ceftriaxone|"≥2-<14 years - 60mg/kg/ once daily for 7 days
14 years and older - 2g once daily for 7 days
Intravenous infusion. Vials of crystalline powder."
1705815|NCT01421693|Drug|Gatifloxacin|Gatifloxacin 10 mg/kg/day for 7 days. Tablets for oral administration.
1705816|NCT01421680|Dietary Supplement|Ensure powder|Ensure powder(500kcal) per day for 7 weeks
1705817|NCT01421667|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
1705818|NCT01421667|Drug|rituximab|375 mg/m2 every 3 weeks by IV infusion
1705819|NCT01421654|Device|S9 Elite with Acclimate|S9 Elite Flow Generator with Acclimate feature activated
1705820|NCT01421654|Device|S9 Elite|S9 Elite Flow Generator
1705821|NCT01421641|Drug|Intracervical Lidocaine Injection|Injection of 2 cc of 1% lidocaine solution at the anterior lip of the cervix using a standard 22 gauge spinal needle
1705822|NCT01421641|Drug|Topical Lidocaine Gel|Application of 1cc of 2% lidocaine gel to the anterior lip of the cervix with a Q-tip
1705823|NCT01421628|Other|Fitness exercise program|Exercise program, daily frequency, duration of 6 weeks.
1705824|NCT01421615|Drug|Vaginal capsules of lactobacilli|The patients in one-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they would NOT receive any treatment but would be followed up to the 4th-7th days of postpartum.
1705825|NCT01421615|Drug|Vaginal capsules of lactobacilli|The patients in two-course group who were BV positive would receive the first course treatment of vaginal lactobacillus capsule and be repeatedly evaluated BV status after treatment. If their BV test result were still positive after one-course treatment, they will receive the second course treatment of Lactobacilli preparation.
1705826|NCT01421589|Drug|Growth hormone treatment|Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.
1705827|NCT01421576|Dietary Supplement|High fat meal|offer high fat-meal in the morning before drug intake.
1705828|NCT01421563|Drug|Anplag|Sarpogrelate HCl 300mg once a day or 100mg three times a day
1705829|NCT01421550|Procedure|Conservative treatment|Patients that randomize for conservative management of their umbilical hernia will be followed routinely at the polyclinical ward.
1705830|NCT01421550|Procedure|Surgical repair|Patients that randomize for surgical repair of their umbilical hernia will be operated in an elective setting after a careful preoperative work-up.
1705831|NCT01421524|Drug|CC-122|CC-122 dose in both arms will increase by 1 mg increments starting with 3 mg 5/7 days using the 3+3 design in dose escalation phase. A dose-level -1, with a starting dose of 2mg, may also be evaluated if the opening dose level is not tolerated. At all dose levels in MM-2b arm, DEX will be combined with CC-122 at a starting dose dependent on the subject's age: for subjects who are ≤ 75 years of age, DEX 40 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle and for subjects who are > 75 years of age, DEX 20 mg/day will be given on Days 1, 8, 15 and 22 of a 28-day cycle. Approximately 33 subjects will be enrolled in the dose escalation phase (15 in each treatment arm). An additional intermittent schedule of 21/28 days may be evaluated per Safety Review Committee (SRC) decision. Following dose escalation, one or two arms will be expanded at or below the MTD in up to 28 subjects (14 subjects in each arm).
1705832|NCT01421524|Drug|CC-122|One or more intermittent schedules of CC-122 either given 5 continuous days out of 7 per week (5/7 days) or 21 continuous days out of 28 days per cycle (21/28 days). Following dose escalation, one or more of these intermittent schedules will be evaluated at a starting dose of 4 mg.
1705833|NCT01421524|Drug|CC-122|Dose escalation on a continous schedule will be evaluated at a starting dose of 4 mg. Specifically, dose levels with 1 mg increments (eg 4mg, 5mg, 6mg etc.) will be evaluated using a 3+3 design as detailed in Part A of the protocol .
1705834|NCT01421524|Drug|CC-122|Up to 10 subjects with relapsed or refractory PCNSL will be enrolled to a PCNSL cohort to evaluate intermittent schedules of CC-122 and to further explore preliminary signals of efficacy and biomarker hypotheses.
1705835|NCT01421511|Drug|TR-701 FA|"TR-701 FA 200 mg once daily in 250 mL sterile saline for injection as a 60 minute IV infusion
TR-701 FA Tablets, 200 mg, orally once daily"
1705836|NCT01421511|Drug|Linezolid|"Linezolid 600 mg IV Injection twice daily in 300 mL sterile saline for injection as a 60 minute IV infusion
Linezolid Tablets, 600 mg, orally every 12 hours"
1705837|NCT01421498|Drug|Lifitegrast|Dosage Form: Ophthalmic Solution Dosage: 5.0% Frequency: BID Duration: 12 weeks
1705838|NCT01421498|Drug|Placebo|Dosage Form: Ophthalmic Solution Frequency: BID Duration: 12 weeks
1705839|NCT01421485|Behavioral|Integrated treatment program|CBT, psychopharmacological treatment, family treatment, HIV prevention, case management
1705840|NCT01421485|Behavioral|Treatment as Usual|Treatment in community, case management
1705841|NCT01421472|Drug|MM-121|MM-121 IV at 40 mg/mg loading dose on Cycle 1, Week 1 followed by 20 mg/mg weekly for all subsequent doses
1705842|NCT01421472|Drug|Paclitaxel|Standard dosing of paclitaxel IV, followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.
1705843|NCT01421459|Drug|LY2963016|Administered subcutaneously
1705844|NCT01421459|Drug|Lantus|Administered subcutaneously
1705845|NCT01421459|Drug|OAMs|Administered orally
1705846|NCT01421433|Drug|Tandrilax|Tandrilax (caffeine, carisoprodol, sodium diclofenac, paracetamol). Tablets, administered 3 times a day, for 7 consecutive days.
1705847|NCT01421433|Drug|Dolamin Flex|Dolamin Flex (lysine clonixinate and cyclobenzaprine). Tablets, administered 3 times a day, for 7 consecutive days.
1705848|NCT01421407|Device|Ultrasonic ablation device|High Intensity Focused Ultrasound treatment
1705849|NCT01421368|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5
1705850|NCT01421368|Drug|Depo-medroxyprogesterone acetate (DMPA)|DMPA is an intramuscular injectable contraceptive containing 150 mg of medroxyprogesterone acetate. It is FDA approved for 12 weeks of use per injection.
1705851|NCT01421368|Drug|Oral contraceptive: LNG 150 mcg and EE 30 mcg|Each pill contains LNG 150 mcg (the active levorotatory enantiomer of norgestrel) and EE 30 mcg. Each pack contains 21 active pills and 7 placebo pills
1705852|NCT01421355|Drug|Atazanavir|The study design is a single arm, open label trial. Treatment is atazanavir 300 mg BID per day for 4 days. The Brigham and Women's Hospital Investigational Drug Service (IDS) will dispense study drug.
1705853|NCT01421342|Drug|Augmenting: Antidepressant + Aripiprazole|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment or adjust depending on response or side effect profile for up to 36 weeks.
And
Aripiprazole (Dose: 2 mg - 15 mg taken orally once per day for up to 36 weeks): Initiating with aripiprazole dose of 2 mg for one week, then increasing dose per protocol up to 15 mg, maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
1705891|NCT01421121|Biological|200U EV71 vaccine without adjuvant|inactivated vaccine (vero cell) against EV71 without adjuvant of 200U /0.5ml, two doses, 28 days interval
1767049|NCT00333294|Drug|Cisplatin|
1705854|NCT01421342|Drug|Augmenting: Antidepressant + Bupropion-SR|"Current antidepressant (either a SSRI or a SNRI or mirtazapine): Continue the dose prescribed at time of enrollment, or adjust depending on response or side effect profile for up to 36 weeks.
And
Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases."
1705855|NCT01421342|Drug|Switching: Bupropion-SR|Bupropion-SR (Dose: 150 mg - 400 mg taken per day orally for up to 36 weeks): Initiating with bupropion-SR dose of 150 mg, then increasing dose per protocol up to 400 mg (200 mg BID), maintaining or decreasing dose for up to 36 weeks depending on response and side effect profile through the acute and continuation phases.
1956152|NCT02947347|Drug|placebo to match ibrutinib|placebo capsules to match ibrutinib administered orally
1705857|NCT01421316|Radiation|Whole brain radiotherapy with volumetric arc therapy|Whole brain radiotherapy with volumetric arc therapy is used.
1705858|NCT01421303|Drug|Enbrel|Enbrel
1705859|NCT01421290|Procedure|Surgery|Knee surgery
1705860|NCT01421290|Other|Conservative comparator|Kinesitherapy, intra-articular injection, wearing a brace, thermotherapy, intake of supplements.
1705861|NCT01421277|Drug|Statin Therapy|Investigator's choice of any statin.
1705862|NCT01421264|Drug|Gabapentin|300mg capsules by mouth
1705863|NCT01421238|Behavioral|Survey|Participants were randomized to one of two survey groups. In one arm (resuscitation default arm), resuscitation was presented as the course of action that would be followed unless the participant objected. In the other arm (comfort care default arm), comfort care was presented as the course of action that would be followed unless the participant objected.
1705866|NCT01421212|Biological|Hepatitis B Immune Globulin (Boca HBVIg)|"Phase I (12 weeks): Intravenous Boca HBVIg 10,000 IU administered intraoperatively during the anhepatic phase, following reperfusion, daily on days 1-7, once during week 4 and once during week 8 (total of 11 doses).
Phase II (24 weeks): Starting at 12 weeks post liver transplantation, Boca HBVIg will be reduced to 5,000 IU given intravenously on a monthly basis for patients who had an anti-HBs trough titer greater than or equal to 500 IU/L at 8 weeks without the need for additional Boca HBVIg doses. Patients with an 8 week trough level less than 500 IU/L will receive 10,000 IU Boca HBVIg every 4 weeks for the remainder of the study."
1705867|NCT01421199|Procedure|Myringotomy|tube placement for children with multiple ear infections
1705868|NCT01421186|Drug|MOR03087 phase 1 dose escalation|"Treatment cycles will be 28 days. Initial MOR03087 doses will be 0.01 mg/kg in part A, 4 mg/kg in parts B and C and 8 mg/kg in parts D and E; in all parts MOR03087 doses will be escalated to a maximum of 16 mg/kg. In part A, patients will receive a biweekly intravenous infusion of MOR03087 which will be administered on days 1 and 15 of the cycle. In parts B to E patients will receive a weekly intravenous infusion of MOR03087 which will be administered on days 1, 8, 15, and 22 of the cycle.
In all parts a loading dose of MOR03087 will be additionally administered on day 4 of cycle 1."
1705869|NCT01421186|Drug|MOR03087|MOR03087 will be administered according to the MTD or recommended dose and dosing regimen for MOR03087 from parts A-E of the phase I dose escalation. The biweekly MOR03087 regimen as described in part A; the weekly regimen as described for parts B-E.
1705870|NCT01421186|Drug|Dexamethasone|Dexamethasone will be administered to patients orally; 40 mg (≤ 75 years old) or 20 mg (> 75 years old) on days 1, 8, 15, and 22 of the 28-day cycle. An additional dose will be administered in cycle 1 on day 4.
1705871|NCT01421186|Drug|Pomalidomide|Pomalidomide will be administered to patients orally 4 mg on days 1-21 of the 28-day cycle.
1705872|NCT01421186|Drug|Lenalidomide|Lenalidomide will be administered to patients orally 25 mg on days 1-21 of the 28-day cycle.
1705873|NCT01421173|Drug|Vorinostat|Starting dose: 200 mg by mouth on Days -8 to -2.
1705874|NCT01421173|Drug|Gemcitabine|Starting dose: 2175 mg/m2 by vein on Days -8 and -3. This includes the gemcitabine 75 mg/m2 loading dose.
1705875|NCT01421173|Drug|Busulfan|"AUC: 4,000 micrometer (microM).min/day, or 105 mg/m2/day) on Days -8 to -5.
Pharmacokinetics will be performed with the first dose of 32 mg/m2 by vein on Day -8. The doses on Days -6 and -5 will be subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible, a dose of busulfan of 105 mg/m2 will be administered on days -6 and -5."
1705876|NCT01421173|Drug|Melphalan|60 mg/m2 by vein on Days -3 and -2.
1705877|NCT01421173|Procedure|Stem Cell Infusion|Infusion of stem cells by vein on Day 0.
1705878|NCT01421173|Drug|Rituximab|375 mg/m2 on days +1 and +8 for patients with CD20+ tumors.
1705879|NCT01421173|Drug|G-CSF|5 mcg/kg/day (rounded up the nearest vial) subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
1705880|NCT01421173|Drug|Palifermin|60 mcg/kg by vein daily for 6 doses. Three doses administrated prior to start chemo (24 hours must elapse between the last dose and first therapeutic dose of chemo) and three doses after the last chemo starting on day 0.
1705881|NCT01421173|Drug|Dexamethasone acetate|8 mg by vein twice a day from day -8 AM to day -2 PM.
1705882|NCT01421160|Drug|sodium citrate and citric acid|sodium citrate and citric acid equivalent to 1 mEq/ml bicarbonate (usual dose 10-30 mls/day diluted with water)
1705883|NCT01421147|Drug|LY2963016|Administered subcutaneously
1705884|NCT01421147|Drug|Lantus|Administered subcutaneously
1705885|NCT01421147|Drug|Insulin Lispro|Administered subcutaneously
1705886|NCT01421134|Drug|Lurasidone|20, 40, 60 mg, flexible dose, once daily PM 6 weeks
1705887|NCT01421134|Drug|Placebo|Placebo
1705888|NCT01421121|Biological|100U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 100U /0.5ml, two doses, 28 days interval
1705889|NCT01421121|Biological|200 U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 200U /0.5ml, two doses, 28 days interval
1705890|NCT01421121|Biological|400U EV71 vaccine with adjuvant|inactivated vaccine (vero cell) against EV71 of 400U /0.5ml, two doses, 28 days interval
1706372|NCT01417000|Biological|GVAX Pancreas|
1705892|NCT01421121|Biological|Placebo|0.5ml placebo, two doses, 28 days interval
1705893|NCT01421108|Behavioral|Framing (Gain-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message and loss- framed message. Each group of adolescents will read the respective pamphlets with the exception of the control group. The gain-framed pamphlet contains six positive messages with three related full-color images(6.1 X 4.5). The gain-framed pamphlet, entitled The Benefits of good oral hygiene, emphasizes the benefits of brushing, and flossing."
1705894|NCT01421108|Behavioral|Framing (Loss-framed messages)|"The adolescents will randomly assign to three groups: gain-framed message , loss- framed message and a control group. Each group of adolescents will read the respective pamphlets with the exception of the control group.
The loss-framed pamphlet contains six negative messages with three related full-color images (6.1 X 4.5). The loss-framed pamphlet, entitled The disadvantages of poor oral hygiene, emphasizes the costs of not brushing and flossing."
1705895|NCT01421095|Drug|recombinant FSH|Each participant will recieve recombinant FSH (150 IU) intravenously
1705896|NCT01421082|Device|Lung Volume Reduction Coil (LVRC) (PneumRx, Inc.)|Lung Volume Reduction Coil (LVRC)
1705897|NCT01421069|Drug|etanercept|"Subjects aged <18 years and less than or equal to 62 kg will receive etanercept SC at a dose of 0.8 mg/kg QW (up to a maximum dose of 50 mg QW).
Subjects aged greater than or equal to 18 years or >62 kg will receive etanercept SC at a dose of 50 mg QW."
1705901|NCT01421043|Drug|triazolam liquid oral drops|0.25 mg single dose oral drops
1705902|NCT01421043|Drug|triazolam tablets|0.25 mg single oral dose
1705903|NCT01421030|Procedure|Percutaneous pulmonary valve implantation or open heart surgery|Outcomes before percutaneous pulmonary valve implantation or open heart surgery before, 1, 3, 6 and 12 months after the treatment
1705904|NCT01421017|Radiation|Radiation|
1705905|NCT01421017|Drug|Imiquimod|
1705906|NCT01421017|Drug|Cyclophosphamide|
1705907|NCT01421004|Drug|TKI258|
1705908|NCT01420978|Procedure|CSF Diversion|CSF drainage
1705909|NCT01420965|Drug|CT-011 (Anti-PD1 Antibody)|Immune Enhancer
1705910|NCT01420965|Other|Sipuleucel-T (Provenge)|Vaccine
1705911|NCT01420965|Drug|Cyclophosphamide|Low dose- Immune Enhancer
1705912|NCT01420952|Drug|[11C]LY2428703|
1705919|NCT01420913|Drug|Pregabalin|Pregabalin 300mg a day
1705920|NCT01420900|Device|THA with ABG II / Trident|Surgery with total hip arthroplasty in the form of ABG II / Trident
1705921|NCT01420900|Device|THA with CLS / Trilogy|Surgery with total hip arthroplasty in the form of CLS / Trilogy
1705922|NCT01420887|Procedure|Continuous Passive Motion|Continuous passive motion.
1705923|NCT01420887|Procedure|Physical Therapy|Physical therapy.
1705924|NCT01420874|Drug|FOLFOX6|IV administration of 85 mb/m(2) oxaliplatin and 400 mg/m(2) leucovorin over 120 mins, followed by 400 mg/m(2) 5-fluorouracil (FU) bolus then 2400 mg/m(2) 5-FU as a 46 hr infusion. All patients must have central intravenous acess (e.g. mediport, PICC line) for continuous infusion of 5-FU. Adv. colorectal and pancreatic pts. w/no other standard chemo available, & in pts who cannot receive FOLFOX chemo, immunotherapy may be given w/o antecedent chemo.
1705925|NCT01420874|Biological|EGFRBi armed ATC Infusions|Armed ATC will be infused intravenously (IV) with the rate of infusion based on the endotoxin content of the product. All patients will be observed for at least 4 hours after an infusion. Armed ATC infusions will begin 3 weeks after chemotherapy and subsequent doses will be administered once weekly, for 3 weeks, then 12 weeks post aATC#1. Dose escalation level(per infusion): Level 0-5 billion; Level 1-10 billion; Level 2-20 billion; Level 3-40 billion
1705926|NCT01420861|Drug|GTx-758|two GTx 758 tablets per day
1705927|NCT01420848|Other|Auriculotherapy|Auriculotherapy stimulates points to achieve better emotional balance, mental and physiological.
1705928|NCT01420848|Other|Placebo Group|They were evaluated at the baseline,twelve sessions and 15-day follow-up and received 12 sessions through the Fist and Outer ear points.
1705929|NCT01420835|Other|Auriculotherapy (protocol group)|The auriculotherapy points of the protocol group will be 5 points (Liver yang1, Liver yang2, Shenmen, Kidney, Brainstem), during 45 days, twice per week, 12 sessions and assessment of the follow-up (30 days) after finishing the treatment.
1705930|NCT01420835|Other|without protocol group|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion. Five points will be chosen to treat stress according to the symptoms and the Chinese diagnosis.
1705931|NCT01420822|Drug|Fluticasone|Collection of safety data
1705932|NCT01420796|Other|Swallowing exercise|"Patients will perform oral motor exercises for swallowing muscles for five weeks, four days a week.
This exercises aim to increase strength and range of motion of mouth, larynx and pharynx structures. All patients will make sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side."
1705933|NCT01420796|Other|Breathing Exercises|Patients will perform expiratory muscle training. Initial load will be 30% of maximal expiratory pressure which will increase until 75%. This load will be keep until end of training. Patients will made the exercises for 30 minutes with three minutes of training and two of rest.
1706056|NCT01419834|Biological|Humanized 3F8 Monoclonal Antibody (Hu3F8)|Hu3F8 is infused IV over ~30 minutes
1705934|NCT01420796|Other|Swallowing and breathing exercises|For five weeks, patients will perform swallowing and breathing exercises that follow: expiratory muscle training and sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side.
1705935|NCT01420783|Drug|SAR302503|"Pharmaceutical form:capsule
Route of administration: oral"
1705936|NCT01420770|Drug|SAR302503|"Pharmaceutical form:capsule
Route of administration: oral"
1705937|NCT01420757|Procedure|incisional hernia repair|Tension-free open or laparoscopic incisional hernia repair
1705938|NCT01420744|Drug|BT086|"BT086 will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day and is calculated by the mean Immunoglobulin M (IgM) content of BT086 which is 23%.
Infusion rate:
Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate) Treatment will be administered over a 5-day period."
1705939|NCT01420744|Drug|1% Human Albumin infusion|"1% Albumin will be administered per intravenous infusion (IV). The dose to be administered is 3.65 mL /kg bw/day.
Infusion rate:Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate). Rate is to be raised in steps of 0.1 mL every 10 min until the target infusion rate is reached.
Treatment will be administered over a 5-day period.
Starting rate is 0.1 mL/min. Maximum infusion rate is 0.5 mL/min (target infusion rate)"
1705940|NCT01420718|Drug|MTA|partial pulpotomy using White ProRoot MTA. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material.
1705941|NCT01420718|Drug|iRoot BP|Partial pulpotomy using iRoot BP. Partial pulpotomy includes removal of 1mm of coronal pulp and covering the remaining tissue with a suitable material. Bioaggregate is the first nano particle, water based root end filling material. This product includes calcium silicate, calcium hydroxide, hydroxy apatite and Tantalum oxide. Compared to MTA,this material lacks Bismuth oxide and calcium aluminate. iRoot BP is the injectable for of Bioaggregate (Injectable Root Bioaggregate Paste).
1705942|NCT01420692|Drug|Gliclazide MR|Doses between 30 mg to 120 mg/day p.o. Gliclazide MR will be arranged according to the target glycemic levels.
1705943|NCT01420692|Drug|Insulin Detemir|Early initiation of s.c. insulin detemir in contrast to Gliclazide MR. Insulin detemir treatment will be exchanged to Gliclazide MR after 12 weeks.
1705945|NCT01420666|Drug|Acetaminophen|Acetaminophen 325 mg, three tablets four times a day, orally, with food
1705946|NCT01420666|Drug|Maxigesic 325|Maxigesic 325 (Acetaminophen 325 mg+ ibuprofen 97.5mg), three tablets four times a day, orally, with food
1705947|NCT01420666|Drug|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, orally, with food
1705948|NCT01420666|Drug|Placebo|placebo, three tablets four times a day, orally, with food
1705949|NCT01420653|Drug|Maxigesic 325|Maxigesic USA (acetaminophen 325 mg + ibuprofen 97.5mg), three tablets four times a day with food for 48 hours
1705950|NCT01420653|Drug|Acetaminophen|Acetaminophen 325 mg, 3 tablets four times a day, with food for 48 hours
1705951|NCT01420653|Drug|Ibuprofen|Ibuprofen 97.5mg, three tablets four times a day, with food for 48 hours.
1705952|NCT01420653|Drug|Placebo|placebo, three tablets four times a day, with food for 48 hours
1705953|NCT01420640|Behavioral|Lower frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 1x/week
1705954|NCT01420640|Behavioral|Higher frequency, shorter period of Tai Chi|12 weeks of supervised Tai Chi classes, 2x/week
1705955|NCT01420640|Behavioral|Shorter frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 1x/week
1705956|NCT01420640|Behavioral|Higher frequency, longer period of Tai Chi|24 weeks of supervised Tai Chi classes, 2x/week
1705957|NCT01420640|Behavioral|Aerobic Exercise Training|24 weeks of supervised aerobic exercise training, 2x/week
1705962|NCT01420601|Drug|Temsirolimus|The usual adult dosage of this drug is 25 mg as temsirolimus once weekly by intravenous drip infusion for 30 to 60 minutes. The dosage may be appropriately reduced, depending on patient condition.
1705963|NCT01420575|Behavioral|Visual Decision Aid and Shared Decision Making Model|Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
1705964|NCT01420575|Behavioral|Usual Care|Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
1705965|NCT01420562|Procedure|blood sampling|During posaconazole treatment, blood sampling will occur on day 0 (=day of transplantation), day 7 and 14 to correlate posaconazole exposure to severity of mucositis.
1705966|NCT01420549|Drug|Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according with titration.|Tables containing: Rosuvastatin 10 mg + Ezetimibe 10 mg and Rosuvastatin 20 mg + Ezetimibe 10 mg, according with titration.
1705967|NCT01420549|Drug|Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according with titration.|Tables containing: Simvastatin 20 mg + Ezetimibe 10 mg and Simvastatin 40 mg + Ezetimibe 10 mg, according with titration.
1706007|NCT01420211|Drug|Primovist® 0,25 mmol/ml solution for injection|intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist® and blood sampling before (serum blank) and 6, 11, 21, 31, 45, 65, 95, 125 min and 3, 4, 6, 8, 12, 24 and 48 h after drug administration
1706109|NCT01419340|Drug|Torrent's Donepezil Hydrochloride Tablets 10mg|
1956162|NCT02941042|Drug|NNC9204-1177|A single dose administered subcutaneously ( s.c. under the skin)
1705969|NCT01420523|Drug|Raltegravir-Maraviroc|Raltegravir 400 mg twice a day + Maraviroc 300 mg twice a day
1705970|NCT01420510|Drug|Adelmidrol vaginal gel|Application of a Adelmidrol vaginal gel
1705971|NCT01420510|Drug|Placebo vaginal gel|Application of a placebo vaginal gel
1705972|NCT01420497|Drug|intra-articular infiltration|intra articular infiltration
1705973|NCT01420497|Drug|epidural infiltration|epidural infiltration
1705974|NCT01420484|Other|different blood pressure intervals|In differnent blood presure intervals the IAP and CNAP measurement differences will be observed.
1705975|NCT01420471|Drug|Triamcinolone|Spacer will be impregnated with 2mL of Triamcinolone. The triamcinolone-impregnated spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6 days following surgery.
1705976|NCT01420471|Other|Saline-impregnated spacer|Spacer will be impregnated with 2mL of Saline solution. The saline-impregnated spacer will be inserted into the middle meatal space intraoperatively. The spacer will be left in the middle meatus for a period of 6 days following surgery.
1705977|NCT01420458|Drug|Experimental|Bioequivalence of two drug formulations
1705978|NCT01420445|Drug|YHD001 dose level 1|three times daily / 7 days
1705979|NCT01420445|Drug|YHD001 dose level 2|three times daily / 7 days
1705980|NCT01420445|Drug|Pelargonium sidoides extract|6-9mL three times daily / 7 days
1705981|NCT01420445|Drug|placebo|three times daily / 7 days
1705982|NCT01420432|Biological|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat repeated after three months
1705983|NCT01420419|Other|Lanolin|Pea-sized amount of lanolin applied to each nipple after every breastfeeding session (approximately 8-12 times daily) until complete resolution of nipple pain and damage for a maximum of 7 days.
1705984|NCT01420419|Other|Standard (usual) in-hospital and community postpartum care|Women randomized to standard care will not receive lanolin or information regarding how to use lanolin. In-hospital standard care may include any of the following pain management measures at the recommendation / discretion of the participant's health care provider, or based on the patient's personal preference: analgesics (such as ibuprofen or acetaminophen); application of cold or warm compresses; application of ice packs; use of breast shields; air drying the nipples; or applying expressed breast milk.
1705985|NCT01420406|Other|0 mg retinol activity equivalents|0 mg retinol activity equivalents (RAE) as white-fleshed sweet potatoes and a corn oil capsule
1705986|NCT01420406|Other|12 mg of BC|12 mg of BC as orange-fleshed sweet potatoes and a corn oil capsule
1705987|NCT01420406|Other|6 mg of CX|6 mg of CX as tangerines and a corn oil capsule
1705988|NCT01420406|Other|1.0 mg RAE|1.0 mg RAE vitamin A as retinyl palmitate in corn oil, and white-fleshed sweet potatoes
1705989|NCT01420393|Procedure|Rhythm control|Patients randomized to catheter ablation-based AF rhythm control group will receive optimal HF therapy and one or more aggressive catheter ablation, which include PV antral ablation and LA substrate ablation with or without adjunctive antiarrhythmic drug
1705990|NCT01420393|Other|Rate Control|Patients in the rate control group will receive optimal HF therapy and rate control measures to achieve a resting HR < 80 bpm and 6-minute walk HR < 110 bpm.
1705991|NCT01420367|Drug|metronidazole and cephalzolin|IV doses of metronidazole (12.5mg/kg up to 500mg) and cefazolin (25mg/kg up to 1g). One dose for study arm, two for comparative arm.
1705992|NCT01420341|Drug|Co-trimoxazole 12|Receive treatment with co-trimoxazole for 12 weeks.
1705993|NCT01420341|Drug|Co-trimoxazole 20|Receive treatment with co-trimoxazole for 20 weeks.
1705994|NCT01420328|Drug|Vytorin|Simvastatin 40 mg and Ezetimibe 10 mg daily combination pill (Vytorin
1956163|NCT02941042|Drug|Placebo|A single dose administered subcutaneously ( s.c. under the skin)
1705997|NCT01420289|Device|High pressure intermittent pneumatic compression (HPIPC)|Apply therapy for 45 minutes twice daily
1705998|NCT01420289|Behavioral|Excercise|Treadmill walking 45 minutes once daily
1705999|NCT01420263|Procedure|Re-feeding residuals|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be re-fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
1706000|NCT01420263|Procedure|Fresh Feeding Breastmilk or Formula only|In the presence of significant gastric residuals (more than 1/3 of previous feed or > 2ml), residual volumes will be discarded and fresh breastmilk or formula will be fed if the physician decision is to continue feeds as scheduled in the absence of other clinical signs and symptoms of feeding intolerance. This practice will be continued until full enteral feeding is achieved and maintained for a minimum of 48 hours.
1706005|NCT01420237|Device|Restoration ADM X3 Device|Restoration ADM X3 Device in total hip replacement.
1706006|NCT01420224|Other|Commercial airline flight|Normal scheduled passenger flight
1706008|NCT01420211|Device|MRI|lmaging of 20 slices (thickness: 3 mm; max. time of imaging 10 s) before and 0.25, 1, 2, 3, 4, 5, 7, 8, 9, 10, 20, 30, 40, 50, 60, 90 and 120 min after intravenous bolus injection of 25 µmol/kg (=0,1 ml/kg) body weight Primovist®
1706009|NCT01420198|Behavioral|Lifestyle intervention|Increased physical activity and improved food habits
1706010|NCT01420185|Genetic|RNA analysis|
1706011|NCT01420185|Genetic|gene expression analysis|
1706012|NCT01420185|Genetic|microarray analysis|
1706013|NCT01420185|Genetic|reverse transcriptase-polymerase chain reaction|
1706014|NCT01420185|Other|laboratory biomarker analysis|
1706015|NCT01420172|Other|Data Collection|Collection of data on patients who were seen at OSUMC at any time between 01Jan2000 and 30Jun2011 post hematopoietic stem cell transplantation
1706016|NCT01420159|Drug|Methoxyflurane|Patients will have access to two 3 mL methoxyflurane (Penthrox) Inhalers or two 5mL placebo Inhalers to be self-administered.
1706017|NCT01420146|Drug|Zr89-trastuzumab|trastuzumab labelled with zirconium 89 for PET/CT
1706018|NCT01420133|Other|Regimen|regimen normal in salt and sugar
1706019|NCT01420133|Other|Standard regimen|with diet low in salt and sugar
1706020|NCT01420094|Drug|Acetylsalicyclic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablet 1000 mg (2 x 500 mg) and 2 placebo-matching acetaminophen caplets with a full glass of water (240 milliliter [mL]) between 1-4 hours post dental surgery.
1706021|NCT01420094|Drug|Acetaminophen (Tylenol extra strength)|Single oral dose of acetaminophen (Tylenol extra strength) caplet 1000 mg (2 x 500 mg) and 2 placebo matching aspirin tablets with a full glass of water (240 mL) between 1-4 hours post dental surgery.
1706022|NCT01420094|Drug|Placebo|Single oral dose of placebo (2 placebo aspirin tablets and 2 placebo acetaminophen caplets) with a full glass of water (240 mL) between 1-4 hours post dental surgery.
1706023|NCT01420081|Drug|PF-05212384|154mg IV weekly
1706024|NCT01420081|Drug|PF-05212384|154mg IV weekly
1706025|NCT01420081|Drug|PF-05212384|154mg IV weekly
1706026|NCT01420068|Drug|SPP100|
1706027|NCT01420055|Drug|fingolimod|
1706028|NCT01420042|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with lemon flavoured cordial and Water for Injection.
1706029|NCT01420042|Drug|Placebo|Lemon flavoured cordial and Water for Injection
1706031|NCT01420003|Procedure|Bone Marrow Aspiration|3 per study
1706032|NCT01420003|Procedure|Tonsil Biopsy|Optional upon completion of study
1706033|NCT01419990|Drug|GLPG0634|GLPG0634 300 mg oral capsules, qd, 10 days
1706034|NCT01419990|Drug|GLPG0634|GLPG0634 450 mg oral capsules, qd, 10 days
1706035|NCT01419990|Drug|Placebo|Placebo oral capsules, qd, 10 days
1706036|NCT01419977|Drug|Placebo|Normal saline solution, administered by nursing staff once daily
1706037|NCT01419977|Drug|Dalteparin|Low molecular weight heparin (LMWH), 5000 unites subcutaneously, administered by nursing staff once daily, Other Name: Fragmin
1706038|NCT01419964|Drug|Group 01|ACH24
1706039|NCT01419964|Drug|Group 02|Placebo
1706040|NCT01419951|Behavioral|Clinic + Home Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 12 weekly sessions that alternate between a group-based clinic session (concurrent parent and child groups) and individual home visits. Phase II Maintenance is 12 weeks of every other week visits alternating between clinic and home. Treatment targets 3 components: Dietary education, physical activity and parenting training.
1706041|NCT01419951|Other|Pediatrician Counseling|A one-time 45 minute visit with a board certified pediatrician that focuses on the AAP guidelines for eating and physical activity for preschool aged children.
1706042|NCT01419951|Behavioral|Clinic Only Behavioral Intervention|A 6 month intervention consisting of two phases: Phase I Intensive intervention is 6 sessions delivered in a group-based format in clinic (concurrent parent and child groups) every other week. Phase II Maintenance is 3 monthly clinic visits. Treatment targets 3 components: Dietary education, physical activity and parenting training.
1706043|NCT01419938|Device|Light therapy and Cognitive behaviour therapy|Light therapy every morning during 30 minutes for two weeks. CBT for 90 to 120 minutes weekly during four weeks.
1706044|NCT01419938|Device|Light therapy|Light therapy every morning during 30-45 minutes for two weeks.
1706049|NCT01419912|Dietary Supplement|soy milk|
1706050|NCT01419912|Dietary Supplement|cow's milk|
1706051|NCT01419899|Behavioral|Brief motivational intervention|A 20-30 minute motivational based discussion
1706052|NCT01419873|Drug|Actrapid Human Insulin|Actrapid Insulin is a drug used in routine neonatal practice to treat hyperglycaemia. The intervention in this study was to base dosing on insulin by a computer based-model approach as opposed to sliding scales, fixed protocols or clinician intuition
1706053|NCT01419860|Procedure|Elective colon resection|In our scientific experiment, we evaluate microcirculation in colon wall and anastomosis with laser induced fluorescence videoangiography of ICG. By implementing this technique we can measure average pixel intensity of fluorescence signal in area of interest on bowel, which represents tissue perfusion in this respective part of intestinal wall.
1706054|NCT01419847|Drug|Ciclopirox|
1706055|NCT01419847|Drug|Placebo|
1706057|NCT01419821|Drug|Vitamin D|800IU (4gtt/d) once a day for 2 years once a day.
1706058|NCT01419821|Other|Placebo (for Vitamin D)|4gtt/d for the placebo for two years.
1706059|NCT01419808|Procedure|Vascularized Bone Graft|Vascularized bone graft in the treatment of Scaphoid Non-Union
1706060|NCT01419808|Procedure|Non-Vascularized Bone Graft|Non-Vascularized Bone Graft in the treatment of Scaphoid Non-unions
1706061|NCT01419795|Drug|lenalidomide|Given PO
1706062|NCT01419795|Biological|rituximab|Given IV
1706063|NCT01419795|Other|pharmacological study|Correlative studies
1706064|NCT01419795|Other|laboratory biomarker analysis|Correlative studies
1706065|NCT01419782|Other|Whole-body vibration|Frequency: 40 Hz, vibration amplitude: 2 mm, duration: 60 sec
1706066|NCT01419769|Device|AXIOS Stent & Delivery System|"The AXIOS Stent & Delivery System study is a prospective, multi-center, non-blinded, single-arm(nonrandomized) study that will be conducted at up to 10 sites in the United States, European Community and/or Japan will enroll a total of 24 patients. A majority of the patients will be enrolled in the United States.
Patients between the age of 18 and 75 scheduled for endoscopic drainage of symptomatic pancreatic pseudocysts that are equal or greater than 6 cm in diameter, adherent to the bowel wall, and have ≥ 70% fluid contents are potential study candidates.
Study patients will undergo the following clinical follow-up evaluations of study endpoints conducted at 30 days, 60 days, 1 week post stent removal and possibly at 3 and 6 months post stent removal."
1706067|NCT01419756|Device|VentriPoint Medical System|The Knowledge Based Reconstruction (KBR) method generates a 3D reconstruction of the RV based on the Piecwise smooth subdivision surface method but without requiring manual border tracing. Instead KBR reconstructs a new patient's ventricular surface from the placement of anatomic landmark points on a 2D ultrasound image
1706068|NCT01419730|Drug|Vitamin D3|Vitamin D3 50,000 IU
1706069|NCT01419730|Behavioral|Physical Activity|Progressive walking and resistance band exercise prescription for a period of 24 weeks
1706070|NCT01419717|Drug|denosumab|120 milligrams of denosumab injected subcutaneously every 4 weeks until denosumab is approved and available for sale (expected to be approximately 1 year of treatment per subject)
1706071|NCT01419704|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
1706072|NCT01419691|Drug|auranofin|6 mg twice a day for a total of 12 mg total daily dose
1706073|NCT01419678|Other|collection of blood samples for PK testing|PK samples collected around dosing of posaconazole
1706074|NCT01419665|Biological|GP2013|Type: Biological/Vaccine
1706075|NCT01419665|Biological|rituximab|Type: Biological/Vaccine
1706076|NCT01419652|Other|hold hypoglycemic meds|continue versus hold hypoglycemic medications
1706077|NCT01419639|Drug|Everolimus (RAD001) , Afinitor®|Everolimus will be provided by Novartis. Everolimus is formulated as tablets for oral administration of 2.5 mg, 5 mg, 10 mg strength. Everolimus will be self-administered (by the patients themselves) or administered by the patient's parent or guardian (for minors). The investigator will instruct the patient to take the study drug exactly as specified in the protocol. Depending the age-based dosing schedule, everolimus should be administered orally once (or twice) daily, preferably in the morning (and evening), at the same time every day with our without food. Everolimus tablets should be swallowed whole with a glass of water. The tablets must not be chewed or crushed. In cases where tablets can not be swallowed, the tablets should be disintegrated in water just prior to being taken. Everolimus will be administered orally as per the age-based dosing schedule continuously from study day 1 until progression of disease or unacceptable toxicity.
1706078|NCT01419613|Behavioral|Motivational Interviewing|Breast cancer survivors will receive general information on how to adopt healthy lifestyle behaviors.
1706079|NCT01419613|Behavioral|Counseling|The control group of breast cancer survivors will receive counseling on how to increase their level of physical activity.
1706080|NCT01419600|Drug|AZD8683|Single Dose Inhaled IMP via Turbuhaler
1706081|NCT01419600|Drug|Placebo to match|Single dose Inhaled Placebo via Turbuhaler
1706083|NCT01419548|Drug|ABT-888|
1706084|NCT01419548|Drug|Carboplatin|
1706085|NCT01419548|Drug|Paclitaxel|
1706087|NCT01419522|Other|Gait Training Method|Treadmill training at constant velocity
1706088|NCT01419509|Genetic|DNA methylation analysis|
1706089|NCT01419509|Genetic|microarray analysis|
1706090|NCT01419509|Genetic|polymerase chain reaction|
1706091|NCT01419509|Other|laboratory biomarker analysis|
1706092|NCT01419496|Genetic|protein expression analysis|
1706093|NCT01419496|Other|flow cytometry|
1706094|NCT01419496|Other|laboratory biomarker analysis|
1706096|NCT01419470|Drug|dapoxetine|"multiple dosing
12 subjects will be administered YHD1044 (I, III, V) or active/placebo comparators;dapoxetine"
1706097|NCT01419457|Drug|Favipiravir|1200 mg BID for Day 1 + 800 mg BID for Day 2-5
1706098|NCT01419457|Drug|Favipiravir|800 mg BID for Day 1 + 400 mg BID for Day 2-3
1706099|NCT01419457|Drug|Favipiravir|800 mg Single Dose
1706100|NCT01419444|Behavioral|Airflow Exercises for Voicing|Gargling, Cup Bubble Blowing, and Stretch and Flow Exercises will be taught to reduce laryngeal closure and improve airflow through the glottis during voicing.
1706101|NCT01419431|Procedure|Laparoscopic resection|Inflammatory response in laparoscopic surgery
1706102|NCT01419405|Drug|Pregabalin|hard capsule, 150 mg, 2 times, 2 days
1706103|NCT01419405|Drug|Remifentanil|50-90 min: TCI 0.6 ng/mL, 100-140 min: 1.2 ng/mL, 150-190 min: TCI 2.4 ng/mL
1706104|NCT01419405|Drug|sugar pill, saline infusion|hard capsule, 150 mg, 2 times, 2 days, saline infusion
1706105|NCT01419392|Drug|Sildenafil citrate|25 mg orally, 4 times per day for 21 days
1706106|NCT01419392|Drug|matching placebo|orally, 4 times per day for 21 days
1706107|NCT01419366|Drug|Torrent's Donepezil Hydrochloride Tablets 10mg|
1706108|NCT01419353|Drug|estradiol valerate|2 mg P.O / day for 1-6 days.
1706373|NCT01417000|Biological|CRS-207|
1706110|NCT01419327|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.
1706111|NCT01419314|Device|Splinting application to the lower extremities|Walkabout™ splints (Don Joy Orthopedics, Vista, CA, USA) will used in the splinting treatment. The Walkabout splint is a one-piece injection molded walking boot fitted with a rocker bottom allowing for ambulation. The participants will be fitted and instructed to wear the bilateral LE splints to sleep for the duration of the study (6 weeks).
1706112|NCT01419314|Device|Splint liner application|The liner or protective sheath from the Walkabout™ splint will be applied to the LEs, with the structural frame of the splint removed by the researcher in advance, patients will be blinded to this arm of the study (6 weeks).
1706113|NCT01419301|Behavioral|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is program based on daily meditation practice that guides an individual towards increased awareness and self-regulation of thoughts and actions. MBSR is easier to implement and may be shown to be more effective than cognitive-behavioral stress reduction, and is more applicable to patients with chronic illness.
1706114|NCT01419288|Other|Treadmill Training|The program requires volunteer participants to attend 15 sessions over 10 to 12 weeks with a total time commitment of 13.5 hours. There is an initial testing session that includes an assessment of the participant's legs, balance, and walking abilities. The entire program includes 12 treadmill training visits that take place three times per week for four weeks, a post-training testing session one week after completion of the training, and a follow-up testing session four weeks after completion of the training.
1706115|NCT01419275|Drug|Xenon contrast agent|
1706116|NCT01419275|Device|Magnetic Resonance Imaging|Arterial spin label sequence for the purpose of measuring collateral flow
1706117|NCT01419262|Drug|Vitamin D - Cholecalciferol 400 IU|One drop per day (liquid), 400 IU, 4 to 9 months depending on date of enrollment and date of follow-up
1706118|NCT01419262|Drug|Vitamin D3 - Cholecalciferol 2000 IU|One drop per day (liquid), 2000 IU, 4 to 9 months depending on date of enrollment and date of follow-up
1706119|NCT01419249|Other|Blood sampling|Subjects with pre-established diagnosis of IGHD and TS and were treated with r-hGH therapy for 1 year, will be observed in this retrospective cohort study wherein blood sampling will performed for genotyping of the various genetic markers along with collection of retrospective data relative to the r-hGH treatment.
1706120|NCT01419236|Drug|Testosterone Solution 2%|Administered topically
1706121|NCT01419236|Drug|Placebo Solution|Administered topically
1706122|NCT01419210|Other|Pre-study Questionnaire|Assess the interest level for various CAM topics through feedback received from the study participants
1706123|NCT01419210|Other|Educational Presentations|Attend a two-hour presentation each week for four weeks
1706124|NCT01419210|Other|CAM Therapies|Integrate the CAM topics of highest interest into participant's regular care
1706125|NCT01419210|Other|Post-study Questionnaire|Examine the data to see if it supports recommending a larger, multi-site, integrative CAM program for other women with ovarian cancer
1706126|NCT01419197|Drug|Trastuzumab emtansine|The dose was calculated based on the patient's Baseline weight on Day 1 of each 3-week treatment cycle. The same dose was administered in subsequent cycles if the patient's weight stayed within 10% of the Baseline weight. If there was a weight change > 10%, the dose was adjusted accordingly and the recorded weight became the new Baseline weight. Trastuzumab emtansine was provided as a single-use lyophilized formulation.
1706127|NCT01419197|Drug|Treatment of physician's choice|"The treatment of physician's choice (TPC) was a protocol-specified approved or standard of care therapy or combination of therapies, based on frequently used regimens for late-line HER2-positive metastatic breast cancer treatment after receipt of both trastuzumab- and lapatinib-containing regimens. The therapies included single-agent chemotherapy, single-agent (e.g., tamoxifen or aromatase inhibitor) or dual-agent (e.g., aromatase inhibitor with luteinizing hormone releasing hormone [LHRH] agonist) hormonal therapy for hormone receptor positive-disease, and HER2-directed therapy.
Participants who had documented progressive disease (PD) were eligible to switch treatment to receive trastuzumab emtansine 3.6 mg/kg. Participants who switched treatment remained on trastuzumab emtansine treatment until another PD event or unmanageable toxicity.
The formulation, storage, and preparation of all TPC were as per the appropriate package insert or national prescribing information."
1706128|NCT01419184|Drug|Daptomycin|
1706129|NCT01419184|Drug|Vancomycin|
1706130|NCT01419171|Device|OMEGA™ Monorail Coronary Stent System|All enrolled patients are treated with the OMEGA™ Monorail Bare Metal Coronary Stent System and followed for 12 months post-procedure.
1706131|NCT01419145|Other|Multimodal intervention|Nutritional supplements aimed at optimal energy balance and protein intake (2 cartons of ProSure per day), nutritional advice, home-based self-assisted exercise program and anti-inflammatory treatment (300 mg celecoxib) for 6 weeks. The aerobic exercise program is performed as self-administered daily walking sessions, aiming for a minimum of two sessions 30 minutes on a weekly basis. Other aerobic activities could be used instead of walking. The resistance exercise program should be performed 3 times weekly and lasts about 20 minutes. The program is targeting major muscle groups in the upper body and legs with use of weights. The intensity of the exercise and performance of the exercises are adapted to the individual patient's disease burden and physical performance.
1706132|NCT01419145|Other|Standard care|Standard cancer care
1706133|NCT01419132|Drug|Furosemide|125-250 mg furosemide bid
1706134|NCT01419132|Drug|Furosemide|125-250 mf furosemide bid
1706135|NCT01419119|Drug|Cholecalciferol|10 000 IU daily i.e. 15 drops orally once daily for 12 weeks
1706136|NCT01419119|Drug|Cholecalciferol|2000 IU daily i.e. 3 drops orally once a day for 12 weeks,
1706137|NCT01419119|Drug|Cholecalciferol|2000 IU once a week i.e. 3 drops orally once a week (the same day every week) for 12 weeks,
1706138|NCT01419119|Drug|Cholecalciferol|2000 IU daily i.e. 3 drops orally once daily for 12 weeks
1706139|NCT01419106|Device|Ultrasound (A point of care ultrasound protocol)|Bedside ultrasound will be used to view any intraperitoneal bleeding, pleural fluid, cardiac abnormalities, or structural abnormalities of major blood vessels. The results of this test will then be used to determine the best course of treatment for the patient.
1706168|NCT01418742|Drug|Panitumumab, Doxycycline/Placebo|comparison of Doxycyline/Placebo and Panitumumab regarding efficacy of the therapy of panitumumab induced skin toxicity
1706374|NCT01417000|Drug|Cyclophosphamide|
1706140|NCT01419093|Other|5 A communication intervention|This study will examine the effect of primary care clinicians' communication intervention linked to a community-based exercise program. We will use the 5As in discussion of physical activity in 371 office visits in an ethnically diverse, primarily low income patient population. Secondary and exploratory aims are to provide pilot information on [feasibility and sustainability of the intervention from the patients' and clinicians' perspective and derive effect sizes on the intervention's effect on objective changes in physical activity in a subset of participants.
1706141|NCT01419067|Procedure|Radical Surgery or Limited Surgery|Patients will be selected for radical surgery based on the neurosurgeon's assessment that a Gross-Total Resection may be achieved with acceptable post-operative morbidity. The goal of surgical intervention in this study should be to facilitate tumor control, keeping surgical morbidity to a minimum. Common indications for surgical intervention directed at the tumor will include establishing a tissue diagnosis, tumor control by radical resection, relieving tumor mass effect to reduce symptoms and decreasing the target volume for proton therapy by planned volume reduction surgery. These indications can be achieved through radical or limited surgery.
1706142|NCT01419067|Device|Proton Therapy|Proton therapy will be started once a final treatment plan has been developed and approved. There is no time limit for the interval from enrollment to when proton therapy commences. The total prescribed dose will be 54CGE administered at 1.8CGE per fraction. The time course of administration will be one fraction per day, 5 days per week, for a period of 6 weeks. Radiation will be prescribed to the planning target volume which will include the tumor bed encompassed by an anatomically defined margin meant to include subclinical microscopic disease, and an additional geometric margin that is meant to account for the technical limitations associated with planning and administering daily fractionated treatment. Making radiation therapy safer through the use of proton therapy.
1706143|NCT01419067|Drug|^1^8F-fluorodeoxyglucose|This is a contrast media that will be given intravenously to aid in tumor visualization.
1706144|NCT01419067|Drug|^1^1C-methionine|This is a contrast media that will be given intravenously to aid in tumor visualization.
1706145|NCT01419041|Drug|crizotinib|Single-dose oral 250 mg crizotinib in subjects with normal renal function (CLcr =>90 mL/min)
1706146|NCT01419041|Drug|crizotinib|Single-dose oral 250 mg crizotinib in subjects with severe renal impairment (CLcr <30 mL/min)
1706147|NCT01419015|Device|SAPIEN XT NovaFlex delivery system|Transcatheter aortic valve implantation via transfemoral approach.
1706148|NCT01419002|Radiation|neoadjuvant RTx|Neoadjuvant radiotherapy with external intensity modulated beam radiation followed by duodenopancreatectomy and adjuvant chemotherapy according to German S3 guidelines.
1706149|NCT01419002|Procedure|Surgery|Surgery and adjuvant chemotherapy according to German S3-guidelines
1706150|NCT01418989|Drug|tocilizumab [RoActemra/Actemra] Syringe|Single dose administration with pre-filled syringe
1706151|NCT01418989|Drug|tocilizumab [RoActemra/Actemra] auto-injector|Single dose administration with auto-injector
1706152|NCT01418976|Behavioral|Intensive Mobility Training (IMT)|Intensive Mobility Training will be used as an intensive physical therapy intervention. Participants will receive 3 hours per day for a 10 day session, be post-tested, and receive another 10 day session followed by two more testing sessions.
1706153|NCT01418963|Drug|RO5285119|single and multiple ascending oral doses
1706154|NCT01418963|Drug|placebo|single and multiple oral doses
1706155|NCT01418950|Other|Written information and verbal counseling|control group will only receive verbal counseling. Study group will receive written information before verbal counseling
1706156|NCT01418937|Biological|CervarixTM (GSK580299)|Three intramuscular injections
1706157|NCT01418911|Other|questionnaire|questionnaire only
1706158|NCT01418898|Other|Dietary Intervention|Nutrient fortified oat beverage
1706159|NCT01418872|Other|Didactic Concerts|"The activity we are going to test consists in a communication and spreading strategy.
The activity will take place in the auditorium of the school, scheduling 1 hour for concert, within the school hours, and having maximum 50 children per turn.
Preparation of the auditorium for the activity 5 classic musical pieces and a story as a conducting thread. Children will be asked to clap and raise hands to participate in the mission of becoming a heart-savers: Ideal number of daily meals, Importance of daily breakfast for the activity, Time for breakfast, Basic components for a healthy breakfast, The role of cereals at breakfast, dairy products in breakfast, fruits at breakfast, Importance of exercise for cardiovascular health, The role of sedentary lifestyle.
Students will be invited to take the playbill as a bookmark format and a cup is inscribed: I am a heart-saver, so that they take them home and serve as a reminder of the activity. A NAOS strategy pamphlet will also be delivered."
1706160|NCT01418820|Device|Verum stimulation|10 days (2x 5 working days), daily transorbital alternating current stimulation (rtACS) is applied with a device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 µA. Current intensity is individually adjusted according to how well patients perceived phosphenes, e.g. any sensation of flickering light in response to the rtACS stimulation. Stimulation frequencies were between the individual alpha frequency peak and below flicker fusion.
1706161|NCT01418820|Device|Placebo stimulation|10 days (2x 5 working days), daily sham-stimulation with the same electrode montage set-up that is used for verum transorbital alternating current stimulation (rtACS). Minimal sham-stimulation was performed with single bursts (approx. one per min) of electrical currents at a given frequency of 5Hz and individually adjusted current amplitude.
1706162|NCT01418807|Procedure|TRANSVAGINAL SPECIMEN EXTRACTION|Transvaginal specimen retrieval following posterior colpotomy
1706163|NCT01418807|Procedure|TRANSUMBILICAL SPECIMEN EXTRACTION|Transumbilical specimen retrieval following enlargement of the umbilical port
1706164|NCT01418794|Device|High dose rapamycin stent|Concentration of rapamycin is 2.5%
1706165|NCT01418794|Device|Low dose rapamycin stent|Concentration of rapamycin is 1.5%
1706166|NCT01418768|Other|inpatient rehabiliation|inpatient, multimodal, individual workout including endurance training, strength training, coordination training etc. for three weeks.
1706167|NCT01418755|Biological|platelet rich plasma injection|The approximate 2.0 to 2.5-fold platelet concentration (taking into consideration the mean human blood platelet count of 200 000 /μl) was achieved in all specimens. Mean platelet concentration in PRP was 459 000 /μl (range, 407 000 /μl to 513 000 /μl).
1706169|NCT01418742|Drug|Panitumumab|mCRC patients receiving panitumumab as EGFR inhibitor.
1706170|NCT01418729|Drug|Pravastatin|"Treatment:
Patients will be randomized in two groups, A and B:
Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.
Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h."
1706171|NCT01418716|Other|Facilitation|Facilitation is a change management process. In the TRANSIT study, the change consist in implementing the TRANSIT program in primary care clinics. In the facilitation group, external facilitators accompany, support, and empower clinical teams so they quickly develop a sense of ownership regarding new clinical practices and sustainably implement them with lower costs. External facilitators offer counseling, coaching, and various tools to an internal facilitation team composed of clinicians of the clinical team to support their efforts in implementing change in their practices. Facilitation activities are structured in a cycle of 4 steps, the Plan-Do-Study-Act cycle (PDSA cycle).
1706172|NCT01418716|Other|Passive diffusion|Clinical teams in primary care clinics implement the TRANSIT program without the help of facilitators.
1706173|NCT01418703|Device|Closed Loop Control (CLC)|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This Control to Range System uses two DexCom Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer used CGM values to make recommendations of insulin treatment based on the algorithms.
1706174|NCT01418703|Device|Open Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects use their own pump. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
1706175|NCT01418677|Drug|E7389|Severe renal impairment-the dose to be administered will be based on the interim analyses of safety and pharmacokinetics in subjects with moderate renal impairment (Cohort 1).
1706176|NCT01418677|Drug|E7389|Moderate renal impairment-HALAVEN will be dosed at 1.4 mg/m2.
1706177|NCT01418677|Drug|E7389|Normal renal function-HALAVEN will be dosed at 1.4 mg/m2.
1706178|NCT01418664|Dietary Supplement|D Max drops|Women in study arm will be cases, and will recieve ferrous sulphate and calcium lactate, along with 4000IU D Max drops
1706179|NCT01418651|Drug|Savella|milnacipran 25 to 200 mg daily, divided into two doses (morning and evening)
1706180|NCT01418625|Drug|Venlafaxine Hydrochloride Extended-Release Capsules 150mg (Test formulation, Torrent Pharmaceutical Limited., India)|
1706181|NCT01418612|Drug|Venlafaxine Hydrochloride Extended-Release Capsules of Torrent Pharmaceuticals Limited|
1706182|NCT01418599|Drug|Torrent's Alfuzosin Extended Release Tablet|
1706183|NCT01418586|Drug|Torrent's Alfuzosin Extended Release Tablet|
1706184|NCT01418573|Other|Palaeolithic meal 1|Based on estimated ratios for protein, fat and carbohydrates that are typical of Hunter-Gatherers and does not contain ingredients that were not available in pre-neolithic times
1706185|NCT01418573|Other|Palaeolithic meal 2|Based on WHO dietary guidelines for protein, fat and carbohydrate but does not contain ingredients that were not available in pre neolithic times
1706186|NCT01418573|Other|Reference meal|Based on WHO dietary guidelines for protein, fat and carbohydrate.
1706187|NCT01418560|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
1706188|NCT01418547|Drug|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
1706189|NCT01418534|Drug|Torrent's Isosorbide Mononitrate 120 mg ER Tablets|
1706190|NCT01418521|Drug|Balanced hydroxyethyl starch solution|Patients receiving Tetraspan 6% ( a balanced 3rd generation Hydroxyethyl starch)for volume replacement after elective cardiac surgery as needed.
1706191|NCT01418521|Drug|Ringer- albumin|Patients receiving lactated ringer-albumin solution for volume replacement after cardiac surgery
1706192|NCT01418508|Behavioral|low protein diet plus α-keto acid|low protein diet plus α-keto acid 0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
1706193|NCT01418508|Behavioral|very low protein diet plus α-keto acid|very low protein diet plus α-keto acid 0.3g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
1706194|NCT01418495|Other|Cytology Specimen Collection Procedure|Correlative studies
1706195|NCT01418495|Other|Pharmacological Study|Correlative studies
1706196|NCT01418482|Device|Mepilex Border Ag|a silver dressing
1706197|NCT01418469|Dietary Supplement|Caseinate|18 mg protein/kg body weight caseinate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
1706198|NCT01418469|Dietary Supplement|Whey protein isolate|18 mg protein/kg body weight whey protein isolate and 46 mg maltodextrin / kg body weight per 20 min sip feeding
1706199|NCT01418469|Dietary Supplement|Soy|18 mg protein/kg body weight soy and 46 mg maltodextrin / kg body weight per 20 min sip feeding
1706200|NCT01418469|Dietary Supplement|soy+BCAA|18 mg protein/kg body weight soy+BCAA and 46 mg maltodextrin / kg body weight per 20 min sip feeding
1706201|NCT01418456|Drug|antibiotics|A variety of antibiotics may be used, according to microbiology results, for up to 20 weeks
1706202|NCT01418443|Drug|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
1706203|NCT01418430|Drug|CHOP-daclizumab|
1706204|NCT01418417|Drug|Torrent's Pantoprazole Sodium Delayed - Release Tablets|
1706205|NCT01418404|Other|Noxious TS|hot, cold alternately, noxious TS in study A
1706206|NCT01418404|Other|Innocuous TS|warm, cool alternately, Innocuious TS in study A
1706207|NCT01418404|Other|High Frequency of Noxious TS|High Frequency of Noxious TS in study B
1706208|NCT01418404|Other|Low Frequency of Noxious TS|Low Frequency of Noxious TS in study B
1706209|NCT01418404|Other|High Intensity of Noxious TS|High Intensity of Noxious TS in study C
1706210|NCT01418404|Other|Low Intensity of Noxious TS|Low Intensity of Noxious TS in study C
1706211|NCT01418391|Procedure|Transversus Abdominis Plane block|"TAP BLOCK:
dosage form: 0.5% bupivacaine 75mg with 2% xylocaine 300 mg mixed dosage: total 30 ml frequency: single shot duration: 12~18 hours upon to the regional anesthetics choose"
1707101|NCT01411189|Drug|Menthol|20 mL NPO-11 in prefilled syringe
1706214|NCT01418365|Drug|Metronidazole + MMX Mesalazine/mesalamine placebo|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine placebo once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine placebo single dose on Day 4 orally
1706215|NCT01418365|Drug|Metronidazole + MMX Mesalazine/mesalamine|Metronidazole 750 mg twice daily + MMX Mesalazine/mesalamine 4.8 g once daily for 3 days orally, then Metronidazole 750 mg single dose + MMX Mesalazine/mesalamine 4.8 g single dose on Day 4 orally
1706216|NCT01418352|Drug|aripiprazole 52.5 mg|Fixed dose of once-weekly aripiprazole tablets for 8 weeks
1706217|NCT01418352|Drug|Matching Placebo|Matching Placebo once-weekly for 8 weeks
1706218|NCT01418352|Drug|Aripiprazole 77.5 mg|Fixed dose of once-weekly aripiprazole tablets for 8 weeks
1706219|NCT01418352|Drug|Aripiprazole 110 mg|Fixed dose of once-weekly aripiprazole tablets for 8 weeks
1706220|NCT01418339|Drug|aripiprazole|Flexible dose of once-weekly aripiprazole tablets
1706221|NCT01418339|Drug|Placebo|Dose of matching placebo tablets for 8 weeks
1706222|NCT01418300|Drug|sequential versus triple|sequential: lansoprazole 30mg bid+amoxicillin 100mg bid for first five day lansoprazole 30mg bid+clarithromycin 500mg bid+metronidazole 500mg for 5day conventional tripe lansoprazole 30mg bid+clarithromycin 500mg bid+amoxicillin 1000mg bid
1706223|NCT01418274|Drug|danoprevir|oral doses of danoprevir
1706224|NCT01418274|Drug|escitalopram|oral doses of escitalopram
1706225|NCT01418274|Drug|ritonavir|oral doses of ritonavir
1706226|NCT01418261|Device|Renal denervation (Symplicity Catheter System)|
1706227|NCT01418261|Diagnostic Test|Renal angiogram|
1706228|NCT01418235|Biological|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Month 1; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6.
Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
1706229|NCT01418235|Biological|MVA-C + gp140/MF59|"SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, at Months 0, 3; placebo in right deltoid at Month 1; placebo in each deltoid at Month 6
Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
1706230|NCT01418235|Biological|DNA-C2 + MVA-C|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid, with placebo in left deltoid, at Months 3, 6
Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
1706231|NCT01418235|Biological|DNA-C2 + MVA-C + gp140/MF59|"SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid, with placebo in left deltoid, at Month 0; SAAVI DNA-C2 administered as 1 ml intramuscularly in right deltoid at Month 1; SAAVI MVA-C administered as 0.5 ml intramuscularly in right deltoid at Months 3, 6; Novartis subtype C gp140 admixed with Novartis MF59 adjuvant administered as 0.5 ml intramuscularly in left deltoid, with placebo in right deltoid, at Months 3, 6
Placebo comparator: Placebo administered at Months 0, 1, 3, 6"
1706232|NCT01418222|Drug|5-FU|Intravenous repeating dose
1706233|NCT01418222|Drug|FOLFOX regimen|Intravenous repeating dose
1706234|NCT01418222|Drug|Placebo|Intravenous repeating dose
1706235|NCT01418222|Drug|bevacizumab [Avastin]|Intravenous repeating dose
1706236|NCT01418222|Drug|leucovorin|Intravenous repeating dose
1706237|NCT01418222|Drug|onartuzumab [MetMAb]|Intravenous repeating dose
1706238|NCT01418209|Drug|Low-dose 17-ß-estradiol with progesterone taper|Low-dose 17-ß-estradiol oral (by mouth), 0.5 mg once per day for 8 (eight) weeks. 17-ß-estradiol is approved by the US Food and Drug Administration (FDA) and is indicated for the treatment of menopausal symptoms. ß is the Greek symbol for beta; the symbol and the word are used interchangeably. The 8 week estradiol treatment is followed by 14 days (2 weeks) of progesterone taper (as medroxy-progesterone 10 mg/day).
1706239|NCT01418209|Drug|Venlafaxine XR|Venlafaxine oral (by mouth) 37.5 mg once per day for 1 (one) week, then 75 mg once per day for 7 (seven) weeks. Venlafaxine XR should not be taken while also taking monoamine oxidase inhibitors (MAOIs). Venlafaxine XR is approved by the US Food and Drug Administration (FDA) for treatment of depression, generalized anxiety disorder, social anxiety disorder, and panic disorder, and is available by prescription. Venlafaxine XR is not FDA-approved for the treatment of hot flashes, although prior studies have indicated that it is useful for treating hot flashes and vasomotor symptoms. After the 8-week venlafaxine XR study treatment period, women will receive a tapering dose of venlafaxine XR 37.5 mg once per day for 14 days (2 weeks).
1706240|NCT01418209|Drug|Placebo|The placebo is an inactive pill that looks like the active medication.
1706241|NCT01418183|Procedure|Trigeminal nerve block|5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
1706242|NCT01418183|Procedure|Trigeminal nerve block|2.5ml of long-effective local analgesics (5% levobupivacaine) will be delivered to maxillary and mandibular branches of trigeminal nerve.
1706243|NCT01418183|Procedure|Trigeminal nerve block|5ml Normal saline will be delivered to maxillary and mandibular branches of trigeminal nerve.
1706281|NCT01417845|Behavioral|Moderate Intensity Exercise Training|"Moderate intensity resistance and aerobic training
Resistance training is performed on 2 days per week for 3 months.
Aerobic training is performed on the same days as resistance training and 1 additional day per week."
1956172|NCT02933060|Other|Normal saline (1000 mL)|
1956173|NCT02933060|Other|Control|
1956174|NCT02934191|Drug|Celecoxib|Dosing will be 6mg/kg twice a day with a maximum dose of 300mg twice a day. All ages will be given the suspension (concentration 100mg/5mL) orally
1956175|NCT02934191|Other|Placebo|Placebo will have the same appearance, taste and consistency as celecoxib. Placebo will consist of calcium carbonate powder suspended in the same syrup as celecoxib. Dose of elemental calcium is 3 mg/kg/day.
1706244|NCT01418170|Other|cervical spinal manipulative therapy|A real cervical spine manipulation will be used for the intervention vs a sham cervical spine manipulation. For the rcSMT the subject's head will be supported by the clinician's forearm. The contact hand of the clinician will contact the C5-C6 spinal segment. A thrust maneuver will be given by the contact hand of the clinician with the supportive hand resting on the subject's zygoma. A rotational inferior drop thrust maneuver will be completed. For the scSMT the subject's head will be rotated to 45 degrees and will be supported by the clinician's forearm, which will lie on top if the headpiece. A thrust maneuver will then be given by the contact hand of the treating clinician to the drop piece with the hand beside the paraspinal musculature simulating a real thrust, the supportive hand will be resting on the subject's zygoma. A inferior drop thrust will be applied to the drop piece (no thrust is made by the contact hand on the cervical spine).
1706245|NCT01418157|Drug|Acetazolamide|125 mg twice daily until 4380 meters altitude
1706246|NCT01418157|Drug|Placebo|Twice daily
1706247|NCT01418144|Procedure|Transversus abdominis plane (TAP) block|Bilateral UL-guided TAP block with 20 ml of ropivacaine 0,5%
1706248|NCT01418144|Procedure|Placebo TAP block|Bilateral placement of 20 ml of saline 0,9% in the transversus abdominis plane
1706249|NCT01418131|Drug|Rectal tacrolimus|Rectal tacrolimus made as an ointment at a concentration of 0.5mg/ml with 3 mls will be applied rectally twice a day
1706250|NCT01418131|Drug|Placebo|Placebo
1706251|NCT01418118|Drug|Epinephrine|0.2mcg/kg/min maximum infusion; to increase mean arterial pressure by 30mmHg
1706252|NCT01418118|Drug|Norepinephrine|Maximum infusion of 0.2mcg/kg/min, to increase mean arterial pressure by 30mmHg
1706253|NCT01418118|Drug|Dobutamine|Maximum infusion rate of 8mcg/kg/min to increase mean arterial pressure by 30mmHg
1706254|NCT01418118|Drug|Dopexamine|Maximum infusion rate of 5mcg/kg/min to increase mean arterial pressure by 30mmHg
1706255|NCT01418105|Procedure|Videofluroscopic swallow study (VFSS)|Barium, radiation
1706256|NCT01418105|Procedure|cervical spine isometric exercises|patients with cervical scoliosis will execute isometric exercises of the cervical spine
1706257|NCT01418105|Procedure|Fiberoptic endoscopic esophageal study (FEES)|food for swallowing
1706258|NCT01418092|Drug|ALKS 37|Capsules for oral administration
1706259|NCT01418092|Drug|Placebo|Capsules for oral administration
1706260|NCT01418079|Device|O2 MedTech cerebral oximeter (Oxygen desaturation)|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
1706261|NCT01418066|Drug|Ayurvedic Herbs|A tea made of Murraya koenigii leaves, Punica granatum and Curcuma as powder. Decoction of 12ml powder in 100ml hot water is taken twice daily at least 30 minutes before a meal.
1706262|NCT01418066|Drug|Placebo tea|Graminis Flores and Maidis stigmata as a powder. Decoction made of 12ml in 100ml hot water. To drink twice daily at least 30 Minutes before a meal.
1706263|NCT01418053|Drug|caraway oil|essential oil, Carum carvi, 2% dissolved in olive oil, 1 teaspoon with caraway oil used externally as inunction together with a hot cataplasm
1706264|NCT01418053|Drug|Olive oil|1 teaspoon with caraway oil used externally as inunction together with a hot or cold cataplasm as assigned
1706265|NCT01418027|Other|Intensive exercise|Subjects conduct an aerobic exercise at 65-80% maximum oxygen consumption for 30 minutes each day, five days a week, totally for 6 months.Subsequently, moderate physical activity(3.0-6.0 MET s) at 150 min/wk for 6 months.
1706266|NCT01418027|Other|Conventional exercise|Subjects receive moderate physical activity(3.0-6.0 MET s) at 150 min/wk(30 min per day, five days a week) for 12 months.
1706267|NCT01418001|Drug|Gemcitabine and Docetaxel in Combination with Pazopanib|"Patients who meet the eligibility criteria above will be treated with the combination therapy of Gemcitabine, Docetaxel, and Pazopanib for two cycles and subsequently re-evaluated for treatment effect. If no progression of the tumor is seen, patients will continue with two more cycles of treatment (total four cycles). Those patients who have progression of disease will proceed directly to surgical resection.
Following completion of neoadjuvant treatment, all patients will have definitive surgical resection. Following recovery from surgery, patients will proceed with adjuvant radiation therapy. Patients will then be followed for 2 years or until January 1st 2015, whichever comes first ."
1706268|NCT01417988|Drug|Experimental: Empiric TB treatment|Initiation of 4 drug TB treatment (8 weeks of 4 drug, 16 weeks of 2 drug therapy) followed by ART (efavirenz-based) within 2 weeks
1706269|NCT01417988|Drug|ART only arm|ART (efavirenz-based) only (+ pyridoxine 50mg) given within 2 weeks after enrolment
1706270|NCT01417975|Behavioral|Moderate Exercise Group|Participants will be required to walk briskly (equivalent to moderate intensity) on a treadmill for 10 minutes.
1706271|NCT01417975|Behavioral|Passive Sitting Group|Participants will be required to sit passively on a chair for 10 minutes.
1706272|NCT01417949|Other|Time of starting antiretroviral therapy|"Within 24 hours after sending the screening form, the site investigator will receive a randomization sheet with the decision when to start ART (immediate or deferred). The day of receiving the randomization sheet will be defined as baseline visit."
1706273|NCT01417936|Drug|Sym004|Sym004 will be administered at the dose of 12 milligram per kilogram (mg/kg) as an intravenous infusion every week up to disease progression or withdrawal from treatment.
1706274|NCT01417923|Drug|vitamin D|P.O.4000 units Vit D per day for 6 weeks
1706275|NCT01417897|Drug|Insulin glulisine|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
1706276|NCT01417897|Drug|Insulin aspart|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
1706277|NCT01417897|Drug|Regular human insulin|Dosage will be pro re nata. Patients should aim an blood glucose level of 2h ppBG ≤ 135 mg/dL.
1706278|NCT01417858|Procedure|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
1706279|NCT01417858|Procedure|YAG laser peripheral iridotomy|1 drop 30 minutes before yag laser iridotomy
1706280|NCT01417845|Behavioral|High Intensity Exercise Training|"High intensity resistance and aerobic training
Resistance training is performed 2 days per week for 3 months
Aerobic training is performed on the same days as resistance training and 1 additional day per week."
1706284|NCT01417819|Other|Mobile short message service|Mobile short message service reminder for appointments of parents of cataract children
1706285|NCT01417806|Drug|Topotecan and Pasireotide|Topotecan 1.5mg/m2 dailyx5 days and Pasireotide 60 mg IM every 28 days
1706286|NCT01417793|Behavioral|Smoking Cessation Program|Comparison of smoking cessation rate among different smoking cessation program
1706287|NCT01417780|Drug|AB103 0.25 mg/kg|Active
1706288|NCT01417780|Drug|AB103 0.5 mg/kg|Active
1706289|NCT01417780|Drug|NaCl 0.9%|Placebo
1706290|NCT01417767|Drug|CHG regimen|cytarabine (25mg/d, days1-14) and homoharringtonine (1mg/d, days1-14) by intravenous continuous infusion, G-CSF (300 μg/d) by subcutaneous injection from day 0 until neutrophil count recovery to 2.0× 109/L.
1706291|NCT01417767|Drug|5-aza-deoxycytidine|Decitabine (5-aza-deoxycytidine)for injection, 20mg/m2/day, IV (in the vein) on days 1-5 of each 28 day cycle, Number of Cycles: 2.
1706292|NCT01417754|Drug|Toremifene|20mg toremifene per day in tablet form starting from the cycle day 15 and continued to premenstrual period. Medication using about 10 days per volunteer
1706293|NCT01417741|Device|Acupuncture Needle|A small 1.8 mm needle to be placed in the P6 acupuncture point on the wrist
1706294|NCT01417715|Device|Endomicroscopy|Patients will undergo advanced endoscopic imaging using endomicroscopy. Findings will be compared to histopathological and clinical results.
1706295|NCT01417702|Device|High-definition white light endoscopy and i-Scan|Patients will undergo advanced endoscopic imaging. Findings will be compared to histopathological and clinical results.
1706296|NCT01417689|Other|Encouragement to attempt eye drop instillation with a specific technique|Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
1706297|NCT01417676|Radiation|Radiation: pelvic lymph nodes with boost to prostate|78(74)Gy/39(37) fractions to prostate, 56(55)GY /39(37) fractions to pelvic lymph nodes, 5 fractions per week.
1956176|NCT02934191|Drug|Acetaminophen|Acetaminophen syrup at a dose of 15mg/kg/dose will be given every 4 hours for the first 5 days after surgery. After that point, is given as needed.
1706300|NCT01417650|Radiation|Low level laser therapy|In this group, the 890 nm diode laser (Mustang 2000+, Russia) will be applied with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the joint area and painful muscles if any.
1706301|NCT01417650|Radiation|Low level laser therapy|In this group, the low level laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects.
1706302|NCT01417637|Radiation|Low level laser therapy|Ga As diode laser (890 nm) Mustang 2000+, Russia), with frequency of 1500 Hz, and dose of 2 J/cm2 per point in the painful muscles. Laser therapy will be applied on all painful muscles three times a week for four weeks.
1706303|NCT01417637|Radiation|Placebo group|In this group, the low power laser will be applied with a minimal dose that is very lower than the threshold necessary for therapeutic effects. Laser therapy will be applied on all painful muscles three times a week for four weeks.
1706304|NCT01417624|Other|CMR Guidance in terms of guiding LV lead implantation|"Following randomisation, the optimal position of the LV lead will be determined either according to current standard criteria (as proposed by the primary operator) or with CMR guidance.
The CRT device will be implanted using established conventional techniques. The CMR study will be performed pre-implantation only. The distribution of myocardial scar and fibrosis will be derived from this study. A CMR venogram will also be generated and the suggested optimal venous tributaries of the great cardiac vein will be identified from discussion between the principal investigator and senior CMR physician. This information will be used for those in the active arm only."
1706305|NCT01417611|Procedure|i-scan CE, SE, TE mode|I-scan technology is the newly developed image enhanced endoscopy technology, classified as a digital contrast method among endoscopic imaging techniques. I-scan has three modes of image enhancement, i.e. surface enhancement (SE); contrast enhancement (CE); and tone enhancement (TE). The three modes (SE, CE and TE) are arranged in series, therefore, it is possible to apply two or more of these three modes at one time. Switching the levels or modes of enhancements can be done on a real-time basis, without any time lag by pushing a relevant button, thus enabling efficient endoscopic observation.
1706306|NCT01417598|Other|Gait and balance group training|The balance-training program is based on scientifically well-established principles of exercise training and postural control as well as current research on training in elderly and PD. For the PD group it has been modified based on the current knowledge of the neurophysiology and the inevitable constraints on mobility and postural control resulting from basal ganglia degeneration. The training will be conducted as a progressive individually adjusted group program, led by experienced physiotherapists and researchers in order to challenge the specific balance disorder of every participant and endorse progression. It is progressive and specific balance program including dual- and multitasks. The program is performed 3 times/week for 10-12 weeks.
1706307|NCT01417598|Other|Nordic walking (only osteoporosis group)|To further test the hypothesis that physical activity may enhance the results from the balance training program pole striding will be added to the balance training program, at least 30-45 minutes three times per week during leisure time. Each individual in this group will be provided with individually adjusted poles, a pedometer and a diary to enter when and for how long time they have been walking.
1706308|NCT01417585|Behavioral|Client-centered ADL intervention|Client-centered ADL refers to rehabilitation of activities of daily living specifically guided by the needs as expressed by the client/patient and her/his significant others, a process that specifically aims to support the client by taking the client's goals and views as the guide for the rehabilitation process.
1706309|NCT01417585|Behavioral|Usual ADL intervention|The variation of strategies and ways to conduct usual ADL rehabilitation according to the routines and praxis of the participating rehabilitation units randomized to supply the control condition.
1706310|NCT01417572|Drug|lidocaine|to evaluate the effect of lidocaine on oculocardiac reflex during the surgery
1706312|NCT01417507|Procedure|cognitive assessment|Undergo neurocognitive assessment
1706313|NCT01417507|Procedure|magnetic resonance imaging|Undergo MRI
1706314|NCT01417507|Other|laboratory biomarker analysis|Correlative studies
1706315|NCT01417507|Other|questionnaire administration|Ancillary studies
1706316|NCT01417507|Procedure|quality-of-life assessment|Ancillary studies
1706317|NCT01417494|Drug|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen)|
1706318|NCT01417494|Drug|Chemotherapy ( FOLFIRI regimen, FOLFOX regimen or LV5FU2 regimen) + bevacizumab|
1706319|NCT01417481|Dietary Supplement|Glycine|Daily oral supplement of glycine at a dose of 0.5 g/kg divided in three doses during 8 weeks
1706320|NCT01417481|Dietary Supplement|Placebo|Daily oral administration of placebo (sugar glass) at a dose of 0.5 g/kg divided in three doses during 8 weeks
1706321|NCT01417468|Behavioral|CLSI, MI, CR|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
1706322|NCT01417468|Behavioral|CLSI - Unknown|(CLSI) Canfield Learning Styles Inventory (MI) Multiple Intelligences (CR) Cognitive Rehabilitation
1706323|NCT01417442|Genetic|BRAF V600E POSITIVITY|BRAF V600E mutation analysis will be made using the tumor tissues of the patients with papillary thyroid cancer (3 sections of 7 mm from he paraffin blocks). And mutation positives and negatives will be identified.
1706324|NCT01417429|Drug|Galantamine|8mg/a day or placebo
1706325|NCT01417429|Drug|IV Nicotine|1.0 mg/70 kg of nicotine against saline
1706326|NCT01417403|Drug|hydroxychloroquine|Given PO
1706327|NCT01417403|Radiation|radiation therapy|Undergo radiotherapy
1706328|NCT01417390|Drug|Drug: Gemcitabine and cisplatin|Patients receive Gemcitabine (1000mg/m2 on day 1,8) and cisplatin (20mg/m2 on day 1-4) every three weeks for two cycles before the radiotherapy, then receive radical radiotherapy with IMRT and cisplatin (40mg/m2) every week for six cycles during radiotherapy.
1706329|NCT01417390|Drug|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2) every week for six cycles during radiotherapy
1706330|NCT01417377|Drug|Mircera|Participants with chronic kidney disease receiving methoxy polyethylene glycol-epoetin beta (Mircera) and previously on treatment with short-acting epoetin alpha will be observed for a period of 6 months.
1706331|NCT01417364|Drug|Testosterone enanthate|100 mg. IM weekly throughout study
1706332|NCT01417364|Drug|Testosterone enanthate|100 mg IM weekly for one month alternating with placebo injections for one month throughout the study
1706333|NCT01417364|Drug|Placebo|Injected IM weekly throughout study
1706334|NCT01417351|Dietary Supplement|400 IU vitamin D3|Women in this study arm receive 400 IU of vitamin D3 per day, or what is in a standard prenatal multivitamin. They also receive a placebo study supplement.
1706335|NCT01417351|Dietary Supplement|2,000 IU Vitamin D3|Women in this arm receive 2,000 IU vitamin D per day: 400 IU from a standard prenatal multivitamin plus an additional 1,600 IU vitamin D3 in the study supplement.
1706336|NCT01417312|Dietary Supplement|Capsules with 160 mg Teavigo (at least 94% EGCG)|Daily intake of 600 mg EGCG for 3 months
1706337|NCT01417312|Dietary Supplement|Placebo|Daily intake of placebo capsules for 3 months
1706338|NCT01417299|Dietary Supplement|RPh201|Patients will receive 400 microliter s.c., of RPh201 twice a week for 3 months
1706339|NCT01417299|Dietary Supplement|saline|Patients will receive 400 microliter s.c., of saline twice a week for 3 months
1706340|NCT01417286|Radiation|External beam radiation therapy|Hypofractionated accelerated radiation therapy over 11 days
1706341|NCT01417273|Dietary Supplement|vitamin A|1 cap vitamin A 25000 IU/day for 6 months and 10000 IU/day for next 6 months
1706342|NCT01417273|Drug|Drug: placebo|1 cap placebo/day for 12 month
1706343|NCT01417247|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
1706344|NCT01417234|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
1706345|NCT01417221|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
1706346|NCT01417208|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
1706347|NCT01417195|Drug|Bravelle|
1706348|NCT01417195|Drug|Menopur|
1706349|NCT01417182|Drug|18F-DCFBC|A bolus of 10 mCi (370 MBq) of 18F-DCFBC will be injected once into the IV line by slow push IV push.
1706350|NCT01417169|Drug|micafungin|Eligible patients who provided informed consent form will be administered micafungin at 50 mg/day (1mg/kg/day for patients weighting <50kg) as 1-h infusion. Infusion of Micafungin will be started on the day -2 of the conditioning course of autologous stem cell transplantation
1706351|NCT01417156|Drug|Nintedanib|150 mg bid
1706352|NCT01417156|Drug|Pirfenidoneone|Existing treatment
1706353|NCT01417143|Drug|TKI258 (Dovitinib):|TKI258 (Dovitinib): 500 mg daily po medication with 5 days on/2 days off schedule. TKI258 (Dovitinib) will be provided by Norvatis for the study purpose. One cycle consists of 4 weeks
1706354|NCT01417104|Drug|Aliskiren|150 mg/300mg
1706355|NCT01417104|Drug|Placebo|150mg/300mg
1706356|NCT01417091|Drug|BPS804|
1706357|NCT01417078|Drug|Diazepam|single-dose; dosage in mg, based on patient body weight
1706358|NCT01417065|Drug|Temsirolimus|Starting dose will be 0.02 mg intravenous administered once on Day 1 over 60 minutes.
1706359|NCT01417052|Drug|50 mg LX3305 QD|50 mg LX3305 once daily in capsule form
1706360|NCT01417052|Drug|100 mg LX3305 QD|100 mg LX3305 once daily in capsule form
1706361|NCT01417052|Drug|150 mg LX3305 QD|150 mg LX3305 once daily in capsule form
1706362|NCT01417052|Drug|200 mg LX3305 QD|200 mg LX3305 once daily in capsule form
1706363|NCT01417052|Drug|250 mg LX3305 QD|250 mg LX3305 once daily in capsule form
1706364|NCT01417052|Drug|300 mg LX3305 QD|300 mg LX3305 once daily in capsule form
1706365|NCT01417052|Drug|400 mg LX3305 QD|400 mg LX3305 once daily in capsule form
1706366|NCT01417052|Drug|250 mg LX3305 BID|250 mg LX3305 twice daily in capsule form
1706367|NCT01417052|Drug|500 mg LX3305 QD|500 mg LX3305 once daily in capsule form
1706368|NCT01417052|Drug|Placebo|Matching placebo dosing in capsule form
1706369|NCT01417026|Drug|Intranasal Oxytocin (Trade name: Syntocinon)|This is a double-blind placebo-controlled trial of intranasal oxytocin in children and adolescents with ASD. Subjects will be randomized to 24 IU intranasal oxytocin or placebo for a 5 day period with concomitant game play of computer games, which are designed to enhance face perception skills. Measures of social function and cognition will be administered before and after the intervention period.
1706375|NCT01416974|Drug|cyclophosphamide|Patients will first receive a single infusion of therapy conditioning with cyclophosphamide.
1706376|NCT01416974|Biological|modified T cells|followed by consolidative therapy with the modified T cells in 3 planned cohorts.
1706377|NCT01416961|Radiation|Radiation Therapy|Concurrent chemo and photon radiation therapy will start within 7 days of completing neutron therapy. There will be a Day 1 of neutron therapy and a Day 1 of concurrent therapy.Photon radiation therapy will begin within 24 hours of the first cycle of chemotherapy and will be delivered 5 days per week, one fraction per day, in 1.8 Gy per fraction. High LET radiotherapy will be delivered in 1 NGy per fraction five days per week. High LET radiotherapy will be delivered first followed by combined chemoradiotherapy.
1706378|NCT01416961|Drug|Chemotherapy - Squamous Cell Histologies|Cisplatin 50 mg/m2 administered on days 1,8, 29, 36; Etoposide 50 mg/m2 administered on days 1-5 and then again days 29-33
1706379|NCT01416961|Drug|Chemotherapy - NSCLC other than squamous cell|Cisplatin 75 mg/m2 days 1,22,43; Pemetrexed 500 mg/m2 days 1,22,43
1706380|NCT01416948|Drug|Methylphenidate Hydrochloride 20 mg|For patients assigned to the MPH arm of the study, the drug will be initiated at 5 mg bid at week 0, and increased to 10 mg bid at week 4, and finally increased to 20 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (5 mg bid) will be withdrawn from the study.
1706381|NCT01416948|Drug|Placebo Capsule|For patients randomly assigned to the placebo arm of the study, placebo will be administered BID at Week 0 through Week 12. Matching placebo will be administered to match the taper period.
1706382|NCT01416948|Drug|Galantamine 12 mg|For patients randomly assigned to the GAL arm of the study, the drug will be initiated at 4 mg bid at week 0, increased to 8 mg bid at week 4, and finally increased to 12 mg bid at week 8 and then held constant until the major outcome assessment at week 12. The drug will be gradually tapered during weeks 12-14. If adverse events ensue, the subject's dose can be held at the current dose (rather than proceeding with scheduled dose increases) or reduced to the previous dose. Subjects who cannot tolerate the minimum dose (4 mg bid) will be withdrawn from the study.
1706383|NCT01416935|Other|No Amiodarone|This is a randomized study whereby patients who would routinely/usually be scheduled to receive Amiodarone as their anti-arrhythmic medication post surgical ablation will be randomly assigned to receive Amiodarone or no Amiodarone, but all other medications would remain as prescribed for patients following surgical ablation which will include beta blockade therapy unless contraindicated which is an American Heart Associated and Heart Rhythm Society recognized treatment.
1706384|NCT01416909|Other|Laxative Treatment|Participants will be taken off any laxative preparation they may already be on. Patients will be put on laxative treatment based on the Constipation Treatment Protocol.
1706385|NCT01416909|Other|Standard of Care|Participants will receive their usual care at Moffitt while participating in weekly assessments. After participation in the study is complete, participants will be offered the same protocol that is given to patients in the treatment groups.
1706386|NCT01416909|Other|Assessment Questionnaires|Constipation Assessment Scale (CAS), Laxative Interview (based on Laxative Diary completed by patients), Memorial Symptom Assessment Scale (MSAS), Functional Assessment of Cancer Therapy-General (FACT-G).
1706387|NCT01416896|Procedure|Hemodialysis using the standard venous needle|Hemodialysis using the standard venous dialysis needle
1706388|NCT01416896|Procedure|"Hemodialysis using a new venous needle, the BME needle"|"Hemodialysis using a new venous dialysis needle or the BME needle"
1706389|NCT01416896|Procedure|"Hemodialysis using a new venous needle, the BME needle"|"One hemodialysis using a new venous needle, the BME needle"
1706390|NCT01416896|Procedure|Hemodialysis using the standard venous needle|One hemodialysis using the standard venous needle
1706391|NCT01416883|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
1706392|NCT01416870|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
1706393|NCT01416870|Drug|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
1706394|NCT01416857|Other|RDDT|
1706395|NCT01416844|Biological|anti-OX40|Patients with metastatic melanoma will be given 0.4 mg/kg anti-OX40 on days 1, 3 and 5 of a single treatment cycle.
1706396|NCT01416831|Other|Radiation therapy and high-dose IL-2|Patients 1 - 20 will receive a single fraction of radiation. Patients 21 through the completion of the study will receive two fractions. The dose for all patients will be 20 Gy per fraction to the prescription line at the edge of the planning treatment volume (PTV) with the last dose delivered on a Friday before IL-2 administration. For patients receiving two radiation doses, the doses can be administered on the Wednesday and Friday before IL-2 starts. Patients who are assigned to IL-2 monotherapy and have progressive disease after two IL-2 cycles are then eligible to receive SBRT before cycle 3 of IL-2 commences, single fraction for patients 1-20 and two fractions for patients 21- end of study.
1706397|NCT01416831|Drug|High-dose IL-2|IL-2 will be given on a Monday at a dose of 600,000 IU per kilogram IV every 8 hours for up to 14 doses each cycle. The second cycle is planned 16 days after cycle 1 but may be delayed up to one week to allow toxicity to resolve. The maximum number of doses that can be given during two cycles will be 28 doses. Patients who respond after two cycles can receive 4 more cycles of IL-2. Patients with disease progression after 2 cycles may elect to receive radiation before a 3rd cycle of IL-2. If patients crossover, IL-2 will be given on the Monday following the last dose of radiation, at a dose of 600,000 IU per kilogram IV every 8 hours for a maximum of 14 doses each cycle. Another cycle is planned 16 days after cycle 3 but may be delayed up to one week to allow toxicity to resolve.
1956177|NCT02934191|Drug|Oxycodone|Oxycodone may be used every 4 hours post-operatively to treat breakthrough pain. The most commonly prescribed dose is 0.075mg/kg/dose (suspension) every 4 hours as needed.
1706430|NCT01416519|Procedure|Assisted deep inspiration technique|After extubation, starting early supplemental oxygen with Venturi (FiO2 50%) with gradual weaning, applying assisted deep inspiration technique with Voldyne(R) with four sets of 10 repetitions and assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
1706431|NCT01416506|Other|No Drug|It's a surveillance
1706403|NCT01416792|Procedure|Centrifugation|
1706404|NCT01416792|Procedure|Multiple-pass hemofiltration|The residual volume from the CPB circuit is pumped though a hemofilter for multiple passes removing the crystalloid component thereby concentrating the plasma.
1706405|NCT01416779|Behavioral|Writing Intervention|Finding Balance Writing Intervention
1706406|NCT01416766|Other|Self-monitoring-nurse-primary care provider feedback loop|Intervention participants will receive an Omron BP monitor and assistance in setting it up to upload BP data to Reliant Medical Group from a home/work or clinic-based computer. They will be encouraged to upload readings at least once/month. Diabetes management nurses will receive the readings and, if a participant's mean BP is not at target, will follow protocols to address this, contacting PCPs as indicated by protocols.
1706407|NCT01416753|Device|UCR|BVM-based regulation of ultrafiltration and conductivity
1706408|NCT01416753|Device|UTR|BVM-based regulation of ultrafiltration; regulation of temperature
1706409|NCT01416740|Procedure|Indirect MRA of shoulder|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
1706410|NCT01416740|Drug|Gadopentetate Dimeglumine|Patient will be weighed and the correct dose of 0.1 mmol/kg calculated. An IV will be inserted into patient's arm. The gadopentetate dimeglumine will be injected into the IV and the patient is asked to gently exercise the shoulder (small windmills and flexion/extension) for 5 minutes. The patients then undergo MRI imaging 15-30 minutes after the injection. Contraindications include known allergy to gadopentetate dimeglumine, and renal failure with creatinine clearance of less than 30ml/min.
1706411|NCT01416727|Other|Emergency Psychiatry Immersion Course|A two-day simulation-based training course covering assessment of self-harm, capacity, managing aggression, working with the emergency team and medical emergencies in the psychiatric hospital
1706412|NCT01416727|Other|Observed SKills in the Emergency Room|For four weeks, participants will be accompanied by a senior psychiatric registrar or consultant psychiatrist, who has received training in giving feedback, during their on-call duties. Each participant will receive between 8-12 hours of 1:1 training.
1706413|NCT01416701|Dietary Supplement|Vitamin D (D3, cholecalciferol)|Week 0-4: 152 mcg/daily (4 tablets) Week 5-52: 76 mcg/daily (2 tablets)
1706414|NCT01416701|Dietary Supplement|Placebo (cellulose)|Week 0-4: 4 tablets daily Week 4-52: 2 tablets daily
1706415|NCT01416688|Procedure|assessment of therapy complications|Will be given by questionnaire
1706416|NCT01416688|Procedure|psychosocial assessment and care|Will be given by questionnaire
1706417|NCT01416688|Procedure|quality-of-life assessment|Will be given by questionnaire
1706418|NCT01416662|Drug|gemcitabine hydrochloride|
1706419|NCT01416649|Drug|Exenatide|Exenatide is started for the treatment of type 2 diabetes as determined by the patients regular physician. The dose will be 5-10 micrograms twice daily which is the standard dose. The medication is given by self-administered subcutaneous injection. The medication may continue for the treatment of the type 2 diabetes after the study is completed after 3 months.
1706420|NCT01416636|Drug|Treprostinil sodium|
1706421|NCT01416623|Drug|henatinib|Henatinib Maleate Tablets
1706422|NCT01416597|Biological|Vaccines|Unadjuvanted, monovalent, and trivalent vaccines, and vaccines delivered intramuscularly, intradermally, or intranasally, depending on what is found in the included studies.
1706425|NCT01416571|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Intramuscular (IM), two doses
1706426|NCT01416558|Drug|Nab-Paclitaxel|"Nab-Paclitaxel 125 mg/m2 i.v. over 30 min. weekly in 5 out of 6 weeks
Given until progression, unacceptable toxicity, patient's request or withdrawal from Study"
1706427|NCT01416545|Behavioral|Educational program in cardiovascular prevention|a weekly educational program in cardiovascular prevention with a multidisciplinary heath team during the year 2010. This intervention tried to teach to these children, in different manners appropriate for their age, concepts of healthy nutrition, avoidance of tobacco and physical activity. Both at the inclusion in the study and one year later we collect data of parents and their children of the two groups, in a single weekend, including nutritional and exercise survey, measures of weigh, height, waist circumference, arterial blood pressure, and laboratorial exams.
1706428|NCT01416545|Behavioral|Lifestyle counseling|The control group received written educational material directed for their parents and related to healthy lifestyle (nutrition, exercise and smoke quitting).
1706429|NCT01416519|Procedure|Continuous Positive Airway Pressure (CPAP) facial mask|After extubation, starting non-invasive ventilation with face mask (1 hour) followed by assisted cough maneuver. Total of 18 calls in 72 hours distributed as long the patient was extubated.
1706710|NCT01414426|Other|pharmacological study|Correlative studies
1706432|NCT01416493|Drug|s.c. injections of bovine intestinal Alkaline Phosphatase|daily subcutaneous treatment with two injections of 2000IU bIAP for three days
1706433|NCT01416480|Drug|Theobromine 300mg|Capsule, b.i.d.
1706434|NCT01416480|Drug|Levodropropizine 10mg|Syrup, t.i.d.
1706435|NCT01416441|Drug|aripiprazole|Open-label Once-weekly formulation of aripiprazole as a flexible-dose regimen
1706436|NCT01416428|Drug|oprozomib|Patients enrolled will receive Oprozomib Tablets once daily either on Days 1-5 (QDx5 schedule) or on Days 1, 2, 8, and 9 (QDx2 weekly schedule) of the 14-day treatment cycle.
1706437|NCT01416415|Other|Video education on proper eye drop instillation technique|The video is approximately seven minutes long and teaches the Robert Ritch method of instilling eye drops.
1706438|NCT01416415|Other|Placebo video education on healthy eating tips|The video is approximately seven minutes long and teaches tips to promote healthy eating.
1706439|NCT01416402|Drug|Arhalofenate|400 mg once daily orally for two weeks then up-titrated to 600 mg once daily orally for an additional two weeks
1706440|NCT01416402|Drug|Febuxostat|80 mg once daily orally for 5 weeks
1706441|NCT01416402|Drug|Colchicine|Colchicine 0.6 mg daily as prophylaxis to prevent gout flares
1706446|NCT01416376|Drug|SRT2379|SRT2379 is supplied as hard gelatin capsules containing either 25mg or 250mg free-base equivalent of SRT23790 drug substance as its succinate salt.
1706447|NCT01416376|Drug|Placebo|For the placebo capsules, the SRT2379 drug substance will be replaced by microcrystalline cellulose (Avicel PH200) to visually match the SRT2379 investigational product.
1706448|NCT01416363|Drug|Firategrast immediate release tablet|Firategrast immediate release tablet is white to pale cream colored 300 mg unit dose and subjects will administer it with 240 milliliter (mL) of water.
1706449|NCT01416363|Drug|Firategrast modified release tablet|Firategrast modified release tablet is white to slightly colored 600 mg unit dose and subjects will administer it with 240 mL of water.
1706450|NCT01416363|Drug|Firategrast gastro-retentive solution|Firategrast solution is clear colorless solution and subject will administer it via nasogastric route.
1706451|NCT01416350|Drug|Azithromycin - 250 mg|Part A - A single azithromycin dose of 250 mg.
1706452|NCT01416350|Drug|Azithromycin - 1000 mg|Part A - A single azithromycin dose of 1000 mg.
1706453|NCT01416350|Drug|Azithromycin - 250 mg every other day for 3 weeks|Part B - Repeat dose study treating subjects with Azithromycin (250 mg every other day for 3 weeks), the dose approximates that used in the treatment of chronic neutrophil-related inflammatory conditions.
1706454|NCT01416337|Drug|GSK1120212|2 mg single dose tablet on Day 1 of study
1706455|NCT01416337|Drug|GSK1120212B|A single administration of a slow 1 minute IV push on Day 1.
1706456|NCT01416324|Drug|placebo|Vehicle used to dilute the powder for oral administration.
1706457|NCT01416324|Drug|0.1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
1706458|NCT01416324|Drug|0.3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
1706459|NCT01416324|Drug|1 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
1706460|NCT01416324|Drug|3 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
1706461|NCT01416324|Drug|10 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
1706462|NCT01416324|Drug|30 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
1706463|NCT01416324|Drug|60 mg GSK2330672|GSK2330672 is available as a white to almost white solid powder diluted in vehicle for oral administration.
1706464|NCT01416311|Drug|Eltrombopag|
1706465|NCT01416298|Other|Continuous Renal Replacement Therapy|The investigators will use the NGAL data daily to 1) drive initiation of CRRT in children with elevated NGAL and > 10-20% fluid overload and 2) drive CRRT discontinuation in patients with decreasing NGAL concentrations. All members of the Critical Care Medicine and Nephrology divisions have agreed that initiation of CRRT within 24-48 hours of a patient reaching >10% fluid overload is clinically acceptable, and that often the decision to start CRRT has been arbitrary in the past, based on physician bias or preference. All members agree that the current standard of 24-48 hours after >10% is achieved is acceptable and now will be put into standard clinical practice.
1706466|NCT01416272|Device|KeraSoft IC Soft Contact Lenses|Lenses will be worn between 8 and 16 hrs each day, for 12 months
1706467|NCT01416259|Drug|Withdraw treatment|
1706468|NCT01416246|Procedure|Fractionated Stem Cell Infusions|Following enrollment patients will be treated with melphalan intravenously (IV) through a central venous catheter (CVC) over 30 minutes at 200mg/m2 or 140mg/m2 (if creatinine clearance is < or = to 50 and/or age > 70 years) on day -2. Following 24 hours of rest, the first dose of CD34+ stem cell will be administered on day 0 (2.5-5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg), followed by 3 additional doses of CD 34+ stem cells (1.5-2.5 x 106 CD 34+ stem cells/kg)+/- 0.5 x 106 CD34+ stem cells/kg) on days +2, +4, and +6. Pegfilgrastim 6μg will be administered on day +1. Filgrastim 5μg/kg will be 12-24 hours after the 2nd-4th stem cell infusions. There will be a +/- 1 day window for the Day +2, +4, and +6 infusions to accommodate infusions that occur over the weekend or on holidays.
1706469|NCT01416233|Procedure|autologous fat grafting to the orbit|subjects will undergo fat harvesting followed by autologous fat grafting into the orbit into their anophthalmic orbit
1706470|NCT01416220|Drug|Lithium|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.
Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Lithium carbonate will be commenced at 600mgs hs, with increase to 900mgs at day 7. Dose will be flexibly titrated to give a serum level between 0.5 and 1.1mmol/l. At visit 4, the dose of lithium may be adjusted (within the range of 0.6 and 1.1 mmol/l."
1706471|NCT01416220|Drug|Paroxetine|"Study drug will be packaged and supplied in an open-label fashion. There will be a washout period of all active psychotropic medication. Psychotropics will be withdrawn over 5 half-lives with the exception of drugs known to cause withdrawal symptoms (primarily antidepressants), which will be tapered over 10 days.
Following the enrollment period, subjects will enter a six-week randomized treatment period with either lithium or paroxetine. Paroxetine will be commenced at 10mgs and increased to 20mgs on day 7. At visit 4, the dose of paroxetine may be increased to 40mgs, if there is no response (less than 20% reduction in MADRS score) as per current Canadian guidelines."
1706472|NCT01416207|Drug|Avonex|4 weekly injections of Avonex (IM)
1706473|NCT01416194|Drug|Bazedoxifene|Patients receiving Bazedoxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
1706474|NCT01416194|Drug|Bisphosphonate|Patients receiving Bisphosphonates in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
1706475|NCT01416194|Drug|Raloxifene|Patients receiving Raloxifene in usual clinical care. In this non-interventional study there is no protocol mandated drug assignment or dosing schedule.
1706476|NCT01416181|Drug|natalizumab|Administered as specified in the treatment arm
1706477|NCT01416181|Drug|Placebo|Matched placebo in part 1
1706478|NCT01416168|Other|McCorkle Model Intervention|The intervention will consist each week in a home visit and a phone call. The GNP conducting the home visit will identify current problems using a comprehensive geriatric assessment (CGA) and record problems on the Intervention and Recommendation Data Sheet. In addition, the cases will be reviewed at a weekly Intervention Team meeting between the intervention GNP (VM, CV), the geriatrician (VP), and the intervention PI (JO). That team meeting will also record how intervention goals for the various problems are met, using the instruments and criteria developed during our pilot study5. To ensure optimal consistency and an up-to-date evidence-based approach over the 4 years of the intervention, treatment recommendations will be offered according to national evidence-based treatment guidelines.
1706479|NCT01416155|Drug|natalizumab|
1706480|NCT01416142|Device|PureVision2 HD contact lenses|Lenses to be worn through 1/2 of an HD movie. Following the movie, all subjects were to wear the dispensed contact lenses on a daily wear basis for approximately one week.
1706481|NCT01416142|Device|Spectacles|Spectacles to be worn throughout 1/2 of an HD movie.
1706482|NCT01416129|Device|Standard of care socket|Amputees' preferred socket.
1706483|NCT01416129|Device|Prosthetic brimless socket|Study socket
1706484|NCT01416116|Drug|QUTENZA|topical
1706485|NCT01416116|Drug|Lidocaine|topical
1706486|NCT01416116|Drug|Tramadol|oral
1706487|NCT01416103|Other|Intervention group|Alcohol treatment paralleling welfare-to-work participation: The participants are referred to the municipalities' outpatient alcohol treatment programmes and at the same time referred to an ordinary welfare-to-work programme.
1706488|NCT01416103|Other|Control group|The participants will as usual be referred to the welfare-to-work schemes deemed most appropriate by the caseworker. The intervention is no different than what the municipality would have offered if the participant was not part of the study.
1706489|NCT01416077|Other|fluid optimisation|"Stroke Volume and Cardiac Index are measured with the Flotrac/Vigileo system and circulation is optimised
Crystalloid infusion (2,5 ml/kg/t) throughout surgery
3 ml/kg Volulyte (artifical colloid) is infused during 5 minutes and SV is measured directly before and 5 minutes after. If SV increases more than 10% the dose is repeated until no increase > 10% is observed. A new dose is given if SV decreases more than 10% from the last value.
If despite optimal filling Cardiac Index (CI) is below 2,5 l/min/m2 infusion with dobutamin is started to attain CI > 2,5.
If despite CI > 2,5 Mean Arterial Pressure <65 mmHg vasopressor (phenylephrine / norepinephrine) is started until MAP equals or is over 65."
1706490|NCT01416064|Drug|Molindone|The populations will be comprised of male and female pediatric subjects from the 810P202 study. Subject will be converted to a total daily dose of 18 or 36mg of molindone (depending on weight), following enrollment into 810P203. The dosage level may be adjusted at the investigators discretion.
1706491|NCT01416051|Dietary Supplement|Olibra|Fractionated palm oil and fractionated oat oil in the proportion of 95:5
1706492|NCT01416051|Other|Placebo|100% milk fat
1706493|NCT01416038|Biological|DPX-Survivac|Vaccine targeting survivin antigen will be administered subcutaneously.
1706494|NCT01416038|Drug|low dose cyclophosphamide (oral)|Low dose cyclophosphamide will be taken by mouth.
1706495|NCT01416025|Drug|Prospective TDM Arm|Voriconazole dose will be adjusted based on per protocol obtained TDM levels
1706496|NCT01416012|Behavioral|Physical Therapy (standard)|This group consists of the usual physical therapy rehabilitation with a special emphasis on lower and upper limb and balance reinforcement.
1706497|NCT01416012|Behavioral|Balance and Gait training in Individualized sessions|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement.
1706498|NCT01416012|Behavioral|Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
1706499|NCT01416012|Behavioral|Group Xbox Kinect|The NW group consists of the use of Nintendo Wii games that targeted upper and lower limbs as well as balance reinforcement
1706500|NCT01415986|Drug|Temoporfin|A single dose of 0.15 mg of Temoporfin per kilogram of body weight will be administered by slow intravenous injection into a deep vein (such as the antecubital vein) in not less than 6 minutes.
1706501|NCT01415986|Device|Medical diode laser emitting light at a wavelength of 652 nm. (Ceralas PDT 652, CeramOptec GmbH)|Light dose of 20 J/cm, at a rate of 100 mW/cm, will be delivered to the target tumor and margins, within 200 seconds.
1706502|NCT01415973|Dietary Supplement|3 ounces of cooked, 85% lean ground beef|Consumed once per subject.
1706503|NCT01415973|Dietary Supplement|20 grams beef protein isolate|Subjects would drink 200 ml water mixed with 20 grams of beef protein isolate one time.
1706504|NCT01415960|Drug|Leuprolide acetate 22.5 mg depot, GP-Pharm SA|Administered by im injection, twice during the study, three months apart
1706505|NCT01415947|Device|V Chordal|"V-Chordal system, consists in the ability to adjust (elongate or shorten) the neochordae off-pump . The adjustment mechanism allows overcoming the main problem of chordal replacement by enabling accurate sizing of the chords."
1707102|NCT01411176|Drug|Menthol|20 mL NPO-11 in a prefilled plastic syringe
1706506|NCT01415934|Other|discontinue statins|patients will be randomized to either continue taking statins or discontinue.
1706507|NCT01415921|Drug|Pyridostigmine Bromide|15, 30, and 60 mg tabs, 1 tab every 8 hours for 10 weeks. Forced titration protocol increases dose at 2 week intervals from 15 to 30 to 60 mg as tolerated. Continue maximally tolerated dose for 4 weeks and then downtitrate at weekly intervals (60 to 30 to 15) and then discontinue.
1706508|NCT01415908|Device|INFUSE Bone Graft|Subjects enrolled in the investigational treatment group will receive surgical treatment with INFUSE® Bone Graft, the CAPSTONE® Spinal System, and posterior supplemental fixation (in this study the CD HORIZON® Spinal System). The investigational treatment will be implanted using a TLIF surgical approach.
1706509|NCT01415908|Other|Iliac Crest Bone Graft|Subjects enrolled in the control group will receive the same surgical treatment as the investigational group, including the CAPSTONE® Spinal System and posterior supplemental fixation system (CD HORIZON® Spinal System), except for the use of autogenous bone graft (from the iliac crest) instead of INFUSE® Bone Graft. A TLIF surgical approach will also be used for implanting the control treatment.
1706510|NCT01415895|Drug|ATNC05 - a study drug capsule|subjects will receive 1 study drug capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
1706511|NCT01415895|Drug|placebo|subjects will receive 1 placebo capsule by mouth twice daily for 3 weeks, followed by 1 capsule in the morning for 3 days.
1706512|NCT01415882|Drug|Cyclophosphamide|Given PO
1706513|NCT01415882|Drug|Dexamethasone|Given PO
1706514|NCT01415882|Drug|Ixazomib Citrate|Given PO
1706515|NCT01415882|Other|Laboratory Biomarker Analysis|Correlative studies
1706516|NCT01415856|Device|Active Device (Torino II)|Device is giving treatment for 15 minutes every 2 hours for a total of two weeks.
1706517|NCT01415856|Device|Sham Device (Torino II)|Device is designed to appear to be giving treatment when it is not actually giving treatment. Patients will wear this for a duration of two weeks.
1706518|NCT01415830|Biological|Anti-scorpion venom serum Birmex|the dose may be required for the patient according to clinical manifestations and evolution
1706519|NCT01415830|Biological|Anti-scorpion venom serum Alacramyn|The dose may be required fot the patient according to clinical manifestations and evolution
1706520|NCT01415817|Other|Training session|Series of two training sessions after the first phase of study followed by monthly feedback.
1706521|NCT01415804|Device|endoprosthesis|Thoracic aortic stentgraft
1706522|NCT01415791|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
1706523|NCT01415778|Drug|ICI176,334-1|Subject will receive single dose of ICI176,334-1
1706524|NCT01415778|Drug|Casodex 80 mg tablet|Subject will receive single dose of Casodex 80 mg tablet
1706525|NCT01415765|Drug|MLN4924|Part A: 150mg/m2 IV (in the vein) on days 1,4,7,11 of each 21 day cycle Part B: variable dose levels IV on days 1,5 each 21 day cycle
1706526|NCT01415765|Drug|Etoposide|CIV(continuous intravenous infusion) on days 1-4 of every 21 day cycle
1706527|NCT01415765|Drug|Prednisone|PO (by mouth) twice daily on days 1-5 of every 21 day cycle
1706528|NCT01415765|Drug|Vincristine|CIV on days 1-4 of every 21 day cycle
1706529|NCT01415765|Drug|Cyclophosphamide|IV on day 5 of each 21 day cycle
1706530|NCT01415765|Drug|Doxorubicin|CIV on days 1-4 of each 21 day cycle
1706531|NCT01415765|Drug|Rituximab|IV on day 1 of each 21 day cycle
1706532|NCT01415765|Drug|Filgrastim|Subcutaneously beginning Day 6 of each 21 day cycle
1706533|NCT01415752|Biological|rituximab|Given IV
1706534|NCT01415752|Drug|bendamustine hydrochloride|Given IV
1706535|NCT01415752|Drug|bortezomib|Given IV or SC
1706536|NCT01415752|Drug|lenalidomide|Given PO
1706537|NCT01415739|Other|laboratory biomarker analysis|Correlative studies
1706538|NCT01415726|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 6 ~ 7 hrs.
1706539|NCT01415713|Drug|S-1,Leucovorin,Oxaliplatin,Gemcitabine|Biweekly S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma
1706540|NCT01415700|Device|Functional electrical stimulator|The stimulator is surgically implanted
1706541|NCT01415700|Device|feet orthosis|feet orthosis specifically mold
1706542|NCT01415687|Drug|Polyethylene Glycol-Based Lavage|"Split dose Polyethylene Glycol-Based Lavage (2L + 2L)
If arrival for colonoscopy is prior to 10AM: at 12 noon on the day before your colonoscopy drink 2L of PEG within two hours. At 8PM that day, drink the remaining 2L of PEG within two hours.
If arrival for colonoscopy is at or after 10AM: at 8PM on the day before your colonoscopy, drink 2L of PEG within two hours. Starting five hours before your arrival time at the Centre on the day of your colonoscopy, drink the remaining 2L of PEG within two hours."
1706543|NCT01415687|Drug|Pico-Salax (Magnesium Citrate) plus Bisacodyl|"If arrival for colonoscopy is prior to 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 12 noon, drink the first packet of Pico-Salax in 8oz water, and the second packet of Pico-Salax in 8oz of water at 8PM. Day of colonoscopy, drink clear fluids.
If arrival for colonoscopy is at or after 10AM: 2 tablets Dulcolax at 8PM three days before colonoscopy, 2 tablets Dulcolax at 8PM two days before colonoscopy, and on the day before colonoscopy at 8PM, drink the first packet of Pico-Salax in 8oz water. Day of colonoscopy, drink the second packet of Pico-Salax in 8oz water five hours before you are to arrive at the Centre."
1706544|NCT01415674|Drug|Afatinib|Afatinib 40mg per os daily for 14 to 28 days, depending on the date of the surgery
1706545|NCT01415661|Other|cricoid pressure|The current study test by direct visual evidence the occlusion of esophageal entrance during application CP. The closure of the lumen was further demonstrated by the inability to introduce a GT into the esophagus during CP.
1706546|NCT01415648|Other|cerebral oximetry monitoring using INVOS™ and hemodynamic optimisation|continuous per operative cerebral oximetry monitoring associated with hemodynamic optimisation algorithm (excluding norepinephrine) if cerebral oximetry decrease more than 15% under the preoperative baseline
1706547|NCT01415648|Other|standard cerebral monitoring and hemodynamic optimisation|the patient is continously monitored with cerebral oximeter but this latter is blinded to the medical team, the alarm switch off , and patients are managed with the standard care of the centre.
1706548|NCT01415635|Dietary Supplement|Nutritional intervention using|"The study is af 12 week randomized clinical trail with inclusion of 96 patients at nutritional risk, according to the NRS-2002 system. The intervention group is is given a tailored nutritional care(the possibility to order small energy and protein-enriched dishes called Delights of Herlev Hospital)."
1706549|NCT01415622|Device|PlasmaDerm|plasma treatment 3 times a week for 8 weeks, 45 sec / cm² of Ulcus cruris size, in addition to standard care.
1706550|NCT01415622|Procedure|standard care of Ulcera crurum|standard care of Ulcera crurum: Mepithel gaze for non-exsudative wounds, Mepilex for exsudative wounds, followed by surgical hose treatment. Additionally, a standardized compression therapy with Ulcer X is applied.
1706551|NCT01415596|Drug|salbutamol|
1706552|NCT01415596|Drug|Placebo|
1706553|NCT01415583|Drug|Dexamethasone|0.5mg/kg (max dose 20mg)
1706554|NCT01415557|Other|Non-Fortified Control Product|Non-Fortified Control Beverage
1706555|NCT01415557|Other|Micronutrient Fortified Test Product|Micronutrient Fortified Test Beverage
1706556|NCT01415531|Drug|Nebivolol|Nebivolol (non-trade 5, 10 or 20 mg tablet), oral administration
1706557|NCT01415531|Drug|Placebo|Dose-match placebo
1706558|NCT01415518|Drug|Drug: Budesonide/formoterol (Symbicort Turbuhaler|budesonide/formoterol (Symbicort Turbuhaler 160/4.5µg/inhalation, 2 inhalations twice daily)
1706559|NCT01415518|Drug|Drug: ipratropium (AtroventTM)|ipratropium (AtroventTM 20 µg/inhalation, 2 inhalations four times daily)
1706560|NCT01415518|Drug|theophylline SR|theophylline SR (0.1g/tablet, 1 tablet p.o. twice daily)
1706561|NCT01415505|Drug|Nebivolol, Valsartan and Hydrochlorothiazide|Nebivolol 5 mg (tablet), oral administration Nebivolol 10 mg (tablet), oral administration Nebivolol 20 mg (tablet), oral administration Valsartan 160 mg (tablet), oral administration Valsartan 320 mg (tablet), oral administration Hydrochlorothiazide 12.5 mg rescue medication (capsules), oral administration. Hydrochlorothiazide 25 mg rescue medication (capsules), oral administration
1706562|NCT01415492|Behavioral|HD2|The intervention was delivered via either print materials or access to a HD2 Web Site. ADDITIONAL NOTE: A sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
1706563|NCT01415492|Behavioral|HD2+|The intervention was delivered via either print materials or access to a HD2 Web Site. In addition participants received two coaching calls from Health Coaches. ADDITIONAL NOTE: as noted above, a sub-set of these participants was randomly selected to receive the Electronic Reminders through the intervention. Those who were selected could choose to receive the Electronic Reminders either as text messages or as automated phone reminders.
1706564|NCT01415479|Behavioral|Control|Computer-based presentation regarding colorectal cancer (CRC) and screening for CRC with colonoscopy, sigmoidoscopy, or stool testing. Includes a video from the American Cancer Society.
1706565|NCT01415479|Behavioral|Quantitative|Computer-based presentation providing quantitative information regarding (a) the lifetime average probability of getting CRC or dying from it, (b) the reduction in mortality provided by undergoing regular screening with colonoscopy, and (c) the reduction in mortality provided by undergoing regular screening with fecal immunochemical testing (FIT)
1706566|NCT01415479|Behavioral|Default|"Computer-based presentation that encourages subjects who are unwilling to undergo colonoscopy or are unsure about whether to undergo screening to get tested with Fecal Immunochemical Testing (FIT). This is labeled the Default intervention since it attempts to shift the default choice from no screening to FIT."
1706567|NCT01415466|Drug|Cresto|tablet, 20mg
1706568|NCT01415466|Drug|Olmetec|tablet, 40mg
1706569|NCT01415466|Drug|Cresto, Olmetec|tablet, 20mg and 40mg
1706570|NCT01415453|Procedure|Ultrasound Stimulus|Short pulses of focused ultrasound will be directed at spots on the retinal surface.
1706571|NCT01415440|Drug|Lisdexamfetamine|During the first 4 weeks of treatment, the dosage of Lisdexamfetamine will be adjusted based on the patient's response to the medication. The patient will then be maintained at the lowest effective dose for the remaining 8 weeks of treatment.
1706572|NCT01415440|Drug|Placebo|Placebo dosing will parallel that of Lisdexamfetamine.
1706573|NCT01415427|Drug|BMN 110 - Weekly|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg/qw administered over a period of approximately 4 hours once a week.
In Part 2, patients will continue to receive 2.0 mg/kg of BMN 110 every week, with no placebo."
1706574|NCT01415427|Drug|BMN 110 - Every Other Week|"In Part 1, patients will receive intravenous (IV) infusions of study drug at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week. Patients randomized to the 2.0 mg/kg/qow arm will receive infusions of placebo on alternating weeks, to mask active drug weeks.
In Part 2, patients will receive 2.0 mg/kg of BMN 110 every week, with no placebo."
1706575|NCT01415414|Drug|Iopromide (Ultravist, BAY86-4877)|CT enhancement for abdominal or pelvic scan. Generally doses of up to 1.5 g iodine per kg body weight are well tolerated
1706576|NCT01415401|Drug|Brinzolamide 1% / timolol 0.5% maleate fixed combination|
1706577|NCT01415388|Dietary Supplement|Krill Oil|4 Capsules twice daily providing 0 (placebo), 0.5, 1.0, 2.0, or 4.0 g krill oil/day for a period of 12 weeks
1706578|NCT01415375|Behavioral|Prostate Cancer Screening Education|tailored telephone education on prostate cancer testing
1706579|NCT01415375|Behavioral|Fruit and Vegetable Intake Education|tailored telephone education about fruit and vegetable consumption
1706580|NCT01415362|Device|Transcranial Direct Current Stimulation|"For both active and sham tDCS, the device will be hooked up to the closed loop system, using electrodes of 35cm^2. During active tDCS, the subject will receive 2mA for 5 min. During sham tDCS, the current will only be active for 30 seconds (current ramping up and then down) to simulate the sensations of active tDCS.
The subject will undergo either active or sham stimulation for their first 24-hour EEG monitoring visit, and the opposite intervention on the second 24-hour EEG monitoring visit."
1706581|NCT01415349|Drug|SSP-002358|1 mg, oral, once
1706582|NCT01415349|Drug|SSP-002358 + omeprazole|SSP-002358 (1 mg) + omeprazole (40 mg) given orally, once
1767050|NCT00333294|Drug|Vinorelbine|
1706583|NCT01415336|Drug|Doxorubicin, Cyclophosphamide|doxorubicin 60 mg/m², iv, day 1; Cyclophosphamide 600 mg/m², iv, day 1; every 3 weeks for 4 cycles
1706584|NCT01415336|Drug|doxorubicin, Capecitabine|doxorubicin 60 mg/m², iv, day 1; capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14; every 3 weeks for 4 cycles
1706585|NCT01415297|Drug|NKP-1339|NKP-1339 is administered as a 30-90 minute IV infusion (based on volume to be infused) on days 1, 8, and 15 of a 28 day cycle.
1706586|NCT01415284|Drug|Hydroxyethylstarch 130/0.4|first patient : 500 mL. Following volumes according to up-down sequential allocation, with increments or decrements of 100 mL. An absence of hypotension will lead to an decrement while a presence of hypotension will result in an increment.
1706587|NCT01415271|Other|Internet Communication|bi-weekly communication of blood sugars using an internet platform between patients with type 2 diabetes and an endocrinologist
1706588|NCT01415245|Device|Fluent (VGS Fluent external support device)|Fluent external support device applied to saphenous vein graft
1706590|NCT01415219|Other|Active rehabilitation|A program of 12 individual exercise sessions (3 per week during 4 weeks)
1706591|NCT01415206|Behavioral|Extended Staging Health Risk Intervention (S-HRI)|The S-HRI provides feedback on participants' stages of change for each risk and the single most important step they can take to begin progressing. A counselor will review the report with participants and provide motivational interviewing (MI) coaching and referrals to relevant behavior change services. Repeated computer and individual counseling contacts at baseline, 3, 6 and 12 months follow-up are designed to support participants through the process of changing multiple risk behaviors.
1706592|NCT01415206|Behavioral|Usual Care|Participants in the usual care condition will complete the core assessments and the S-HRA online at baseline, 3, 6, 12,and 18 months follow-up but will not meet with the study MI coach and will NOT receive any feedback or printed report until the 18-month follow-up.
1706593|NCT01415193|Procedure|Selective Tibial Nerve block|Use of selective pain block.
1706594|NCT01415193|Procedure|Sciatic Nerve Block|Use of Sciatic Nerve Block
1706595|NCT01415154|Device|NeuroStar TMS|NeuroStar TMS treatmant - 120% of Observed MT, 10 pulses per second, 4 second on-time, 26 second off-time, 75 trains, 3,000 total pulses/sessions for 6 days. 3 treatments in taper week 1, 2 treatments in taper week 2 and 1 treatment in taper week 3.
1706596|NCT01415141|Drug|Peginterferon alfa-2a|180ug subcutaneously, weekly
1706597|NCT01415141|Drug|Ribavirin|"Administered orally twice a day as follows:
weight < 75kg - 1000mg weight ≥ 75kg - 1200mg"
1706598|NCT01415141|Drug|telaprevir|750mg every 8 hours, orally
1706599|NCT01415128|Drug|Omeprazole|Once a day dosing of Omeprazole (40 mg) for 8 days
1706600|NCT01415128|Drug|Rosiglitazone|Single dose of Rosiglitazone (8 mg) for 1 day
1706601|NCT01415128|Drug|Desipramine|Single dose of Desipramine (50 mg) for 1 day
1706602|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 1: 50 ug
1706603|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 2 - Dose to be selected based upon safety/tolerability/PK at preceding dose
1706604|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 3 - Dose to be selected based upon safety/tolerability/PK at preceding dose
1706605|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 4 - Dose to be selected based upon safety/tolerability/PK at preceding dose
1706606|NCT01415102|Drug|Placebo|Inhaled
1706607|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 5 - Dose to be selected based upon safety/tolerability/PK at preceding dose
1706608|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 6 - Dose to be selected based upon safety/tolerability/PK at preceding dose
1706609|NCT01415102|Drug|PF-05212372|Inhaled. Dose Level 7 - Dose to be selected based upon safety/tolerability/PK at preceding dose
1706610|NCT01415102|Drug|Placebo|Inhaled
1706611|NCT01415089|Behavioral|FOCUS-Web|A 3-session individually tailored, interactive, web-based program providing support and education for cancer patients and one of their family caregivers.
1706612|NCT01415076|Procedure|Insufflation with CO2|Patients were randomly allocated to receive whole procedure or extubation-only CO2 insufflation, using a randomized computer-generated list.
1706613|NCT01415063|Procedure|RFA|For RFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores.
1706614|NCT01415063|Procedure|TACE-RFA|TACE first, then RFA within 2 weeks
1706615|NCT01415050|Device|Whole body vibration|15 times WBV
1706616|NCT01415037|Procedure|annular array ultrasound exam|For this research study you will be asked to sit in a chair. You will be given 2 drops of a numbing solution. The ultrasound camera will be enclosed in a sterile membrane and will be placed gently upon your eye. You may be asked to gaze at a light source while measurements are being made. The procedure will last about 10-15 minutes from start to finish.
1706617|NCT01415024|Procedure|second LV lead in CRT|second LV lead in CRT
1706618|NCT01415011|Drug|Afatinib (BIBW 2992)|All patients will be given daily oral afatinib (BIBW 2992) administered every 28 days until disease progression/toxicity/clinician decision to stop. Starting dose is 40mg. 30mg and 20mg will be administered according to protocol dose modification requirements following toxicity.
1706619|NCT01414998|Behavioral|Stress Ball vs Nicotine-free E-Cigarette|"In a cross over design, participants will be randomly allocated to:
use a stress ball for 5 minutes during a 1 hour controlled experiment. They will also use the stress ball for one day outside of the study centre.
use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.
One week later participants will complete the other arm."
1706620|NCT01414998|Behavioral|Nicotine-free E-Cigarette vs De-nicotinised Cigarette|"In a cross over design, participants will be randomly allocated to:
use a nicotine-free EC for 5 minutes during a 1 hour controlled experiment. They will also use the EC ad-libitum for one day outside of the study centre.
smoke 1 de-nicotinised cigarette during a 1 hour controlled experiment. They will also be given a pack to smoke ad-libitum for one day outside of the study centre.
One week later participants will complete the other arm."
1707103|NCT01411176|Drug|Placebo|The placebo is included same additives as active comparator.
1706621|NCT01414985|Biological|AAVrh.10CUCLN2|There will be 2 dose cohorts in this study. Group A consists of 2 subjects who have received 9.0x10^11 genome copies (900,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2. Group B will consist of 6 subjects who will receive a lower dose of 2.85x10^11 genome copies (285,000,000,000 molecules) of the study drug, AAVrh.10CUCLN2.
1706622|NCT01414972|Drug|Vitamin A|1 cap vitamin A 25000 IU/day for 3 month
1706623|NCT01414972|Drug|placebo|1 cap placebo/day for 3 month
1706624|NCT01414946|Other|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient`s measured resting energy expenditure.
1706625|NCT01414946|Other|Intravenous nutrition with amino acids|Amino acids intravenously starting 20 hours before the operation until the second postoperative day. Amino acids providing 20% of each patient`s measured resting energy expenditure.
1706626|NCT01414933|Other|Biopsy|Breast metastases biopsy
1706627|NCT01414920|Drug|Placebo|TAK-875 and sitagliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
1706628|NCT01414920|Drug|TAK-875|TAK-875 25 mg, tablets, orally, once daily for up to 12 weeks.
1706629|NCT01414920|Drug|TAK-875|TAK-875 50 mg, tablets, orally, once daily for up to 12 weeks.
1706630|NCT01414920|Drug|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
1706631|NCT01414920|Drug|TAK-875 and Sitagliptin|TAK-875 25 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
1706632|NCT01414920|Drug|TAK-875 and Sitagliptin|TAK-875 50 mg, tablets, orally, once daily and sitagliptin 100 mg tablets, orally, once daily for up to 12 weeks.
1706633|NCT01414907|Behavioral|Health promotion activities|Counselled activities on tobacco smoking secession, diet correlation and physical activities
1706634|NCT01414894|Other|Fluid manipulation|Patients are treated with conventional fluid replacement (Normovolemia) or increased the fluid replacement (Hypervolemia) for 10 days.
1706635|NCT01414894|Other|Blood Pressure Manipulation|Patients are treated with maintenance of blood pressure in a normal range (Conventional Blood Pressure) or increased the blood pressure (Augmented Blood Pressure) for 10 days.
1706636|NCT01414881|Drug|mipomersen|mipomersen 200mg subcutaneously (SC) once weekly
1706637|NCT01414881|Drug|Placebo|Placebo administered subcutaneously (SC) once weekly
1706638|NCT01414868|Drug|leukotriene receptor antagonist (montelukast)|montelukast (10 mg, once per night)
1706639|NCT01414855|Drug|obinutuzumab|1000 mg intravenously on Day 1 of each 21-day cycle, 8 cycles; during Cycle 1 administration also on Days 8 and 15.
1706640|NCT01414855|Drug|cyclophosphamide|750 mg/m^2 intravenous (IV), Day 1 of each 21-day cycle, 6 cycles.
1706641|NCT01414855|Drug|doxorubicin|50 mg/m^2 IV, Day 1 of each 21-cycle, 6 cycles.
1706642|NCT01414855|Drug|prednisone|100 mg/day, Days 1 through 5 of each 21-day cycle, 6 cycles.
1706643|NCT01414855|Drug|vincristine|1.4 mg/m^2 IV, Day 1 of each 21-day cycle, 6 cycles.
1706644|NCT01414842|Device|Automated sodium profiling in endogenous hemodiafiltration|Automated sodium profiling during endogenous reinfusion hemodiafiltration technique. The device processes the dialysate sodium and ultrafiltration rate during dialysis to achieve a preset sodium target at the end of the treatment. Sodium dialysate and maximal ultrafiltration rate are constraint within safety limits during dialysis.
1706645|NCT01414842|Device|Standard sodium dialysate|Standard constant (no profiled) sodium dialysate used during endogenous hemodiafiltration
1706646|NCT01414829|Procedure|Gastroscopy|The reason for gastroscopy will be not related to the study
1706647|NCT01414816|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|EOD, dosage frequency and duration will be decide by physicians.
1706648|NCT01414803|Drug|Lipid modification|rosuvastatin 10 mg/fenofibrate 160 mg per day
1706649|NCT01414803|Drug|Lipid modification|rosuvastatin 10 mg per day
1706650|NCT01414790|Procedure|ADM|29 patients (ADM group) had a total parotidectomy with a simultaneous ADM implantation
1706651|NCT01414777|Drug|ondansetron|Ondansetron 8mg IV or placebo will be administered prior to placement of the spinal anesthetic
1706652|NCT01414777|Drug|placebo|placebo or ondansetron 8mg IV will be administered prior to placement of the spinal anesthetic
1706653|NCT01414764|Other|Autologous conditioned plasma (ACP)|"10ml of patient's own venous blood is aspirated. ACP (1ml) (extracted from centrifuged venous sample), with additional calcium chloride is then injected into the tendon-bone junction and adjacent area under guided ultrasound.
First injection at approximately 10 days post-operatively
Second Injection at approximately 21 days post-operatively"
1706654|NCT01414764|Drug|Placebo|"10ml of patient's own venous blood is aspirated. The syringe is centrifuged in a proprietary closed unit (Arthrex Medical Company) for 5 minutes. The venous blood sample will be discarded and a placebo (1ml saline + local anaesthetic) is injected to the surrounding tissue, but not into the tendon, under guided ultrasound.
First injection at approximately 10 days post-operatively
Second Injection at approximately 21 days post-operatively"
1706655|NCT01414751|Behavioral|Absolute risk reduction|Patients receive effectiveness information concerning cholesterol lowering therapy by means of absolute risk reduction
1706656|NCT01414751|Behavioral|Prolongation of life|Patients receive effectiveness information concerning cholesterol lowering therapy by means of prolongation of life/life extension.
1706657|NCT01414738|Radiation|Radiotherapy|Hippocampal-Avoiding Whole Brain Irradiation with Simultaneous Integrated Boost
1956178|NCT02933567|Other|CSC OnDemand|CSC OnDemand is a multifaceted online learning product that includes four levels: 1) an online readiness tool and CSC Learning Hub; 2) dynamic multimedia core curriculum on first episode psychosis and CSC; 3) live faculty-led online courses; and 4) ongoing support, including an online community of practice to support peer-to-peer learning.
1706711|NCT01414413|Other|Home assessment and initiation of ART|Home-based ART eligibility assessment (WHO staging, CD4 count measurement and educational treatment preparation) and initiation.
1706762|NCT01414205|Drug|Corticosteroids|Participants were administered corticosteroids IV prior to the initial dose.
1706661|NCT01414712|Other|Blood Drawing|Blood Drawing to measure circulating tumor cells counts.
1706662|NCT01414699|Behavioral|Variety|These conditions will have snack served with an increase of fruit variety.
1706663|NCT01414699|Behavioral|Non-Variety|These conditions will receive a snack without a variety of fruit.
1706664|NCT01414686|Other|Commercially-Available Interactive Video Games|"Two commercially available gaming platforms were used in this study, the Nintendo Wii and the Sony PS 2. The Wii games included Wii Sports and Wii Fit; PS games included the EyeToy Play 2 and Kinetic. Each of these games provides multiple mini games which pose different movement challenges, including dynamic balance, speed, accuracy, general mobility, and weight shifts.
Game play was performed 1 hour/day, 4 days/ week, for a period of 5 weeks, totaling 20 hours."
1706665|NCT01414673|Drug|HCG|5000 IU
1706666|NCT01414660|Procedure|transplantation|transplantation of islet, kidney or liver
1706667|NCT01414647|Dietary Supplement|300 g of strawberry, raspberry and cloudberry|100 g of strawberry puree, 100 g of frozen raspberries and 100 g frozen cloudberries were concumed daily for 8 weeks. Bilberry consumption was restricted.
1706668|NCT01414647|Dietary Supplement|400 g of bilberry|Equivalent amount to 400 g of fresh bilberries were consumed as 40 g of dried bilberries and as 200 g of frozen bilberries. Restriction of use of strawberries, raspberries and cloudberries were set.
1706669|NCT01414647|Other|Control diet|Control diet, ie. habitual diet with restriction of berry consumption was consumed for eight weeks
1706670|NCT01414634|Biological|ETIMS|injection of peptide-coupled PBMC by i.v. infusion
1706671|NCT01414621|Other|atrial tissue sample|atrial tissue sample from CABG patient
1706672|NCT01414608|Drug|Carboplatin|Given IV
1706673|NCT01414608|Drug|Cisplatin|Given IV
1706674|NCT01414608|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
1706675|NCT01414608|Radiation|Internal Radiation Therapy|Undergo brachytherapy
1706676|NCT01414608|Drug|Paclitaxel|Given IV
1706677|NCT01414608|Other|Quality-of-Life Assessment|Ancillary studies
1706678|NCT01414595|Genetic|DNA analysis|
1706679|NCT01414595|Genetic|DNA methylation analysis|
1706680|NCT01414595|Genetic|RNA analysis|
1706681|NCT01414595|Genetic|gene expression analysis|
1706682|NCT01414595|Genetic|polymorphism analysis|
1706683|NCT01414595|Other|laboratory biomarker analysis|
1706684|NCT01414595|Other|medical chart review|
1706685|NCT01414582|Device|Anodal tDCS|Participants will receive anodal tDCS over the primary motor cortex of the ipsilesional hemisphere. The following parameters will be used: stimulation intensity of 1mA for the first 20 minutes of motor training (9 consecutive sessions Monday-Friday).
1706686|NCT01414582|Other|Motor Training|All participants will receive a standardised motor training intervention for the upper paretic limb
1706687|NCT01414569|Drug|Dexamethasone|Singe dose preoperatively in 100 ml saline intravenously
1706688|NCT01414556|Other|Glucose-dependent Insulinotropic polypeptide|infusion 4 pmol x kg x min first 15 min, thereafter 2 pmol x kg x min
1706689|NCT01414556|Other|saline|
1706690|NCT01414543|Other|Information Sheet|Providing the Participant with information regarding the aim of the experiment
1706691|NCT01414543|Other|Consent|Providing a consent form for participants. The participant is aware of his or her rights
1706692|NCT01414543|Other|interview|participants will interviewed by fardin jussab for approximately one hour regarding their experience of client violence
1706693|NCT01414543|Other|Debrief|at the end of each interview the researcher will ask participants whether the emotions aroused in the interview require further discussions. Interviewees will be also advised that should they wish to talk further about any topics covered the in the interview, they could telephone the researcher at a later time. There will also be leaflets of supporting agencies.
1706694|NCT01414530|Drug|oral contraceptive|ethinyl estradiol 0.03mg/levonorgestrel 0.15mg daily for 8 weeks
1706695|NCT01414530|Drug|NSAID|ibuprofen 200mg/arginine 185mg twice per day for 8 weeks
1706696|NCT01414517|Dietary Supplement|FructoOligoSaccharide|A mixture of 70% oligofructose and 30% inulin.
1706697|NCT01414517|Dietary Supplement|Maltodextrin|a non-prebiotic carbohydrate
1706702|NCT01414478|Other|Protein Shake|Protein shake contains 30 grams of protein in 11 fluid ounces.
1706703|NCT01414465|Drug|Orlistat|Obese women were treated with orlistat 120mg 3 times a day for 4 months, compared with basal data and with normal weight women that didn´t receive orlistat
1706704|NCT01414439|Behavioral|Existential Group Therapy|The treatment will be given in two groups of eight to ten participants each one and will consist of one hour weekly sessions over a period of seven weeks. Dividing the subjects into small groups allows reference to all members of the group. The group facilitators will be two psychologists who work in co therapy.
1706705|NCT01414426|Drug|vandetanib|Given PO
1706706|NCT01414426|Other|placebo|Given PO
1706707|NCT01414426|Other|immunohistochemistry staining method|Correlative studies
1706708|NCT01414426|Other|laboratory biomarker analysis|Correlative studies
1706709|NCT01414426|Procedure|biopsy|Correlative studies
1706712|NCT01414413|Other|Clinic-based ART assessment and initiation|Participants who meet eligibility criteria and reside in a cluster that has been allocated to the control arm of this study will receive supported access to ART care through the primary care system for confirmation of HIV status and entry into HIV following disclosure to the resident community counsellor.
1706713|NCT01414400|Other|Blood draw for culture|Blood will be drawn and sent for culture.
1706714|NCT01414387|Procedure|Carotid filter|"Patients randomized to this group will receive filter devices to prevent cerebral embolization during carotid stenting, assessed by intraoperative transcranial Doppler and postoperative cerebral DW-MRI.
The filter used for this trial is the RX accunet embolic protection system manufactured by abbott."
1706715|NCT01414387|Procedure|Carotid reversal of flow|On the flow reversal arm two type of devices will be used. The first is the Gore flow reversal system, manufactured by LW Gore and the second device is the IVANTEC MoMa Ultra Embolic protection device, manufatured by IVANTEC.
1706716|NCT01414374|Drug|Herbal medicine|Patients will receive a combination of Hibiscus sabdariffa (powdered dry plant), 200 mg, BID, and Centella asiatica tincture, 40 drops, BID, for 6 weeks.
1706717|NCT01414374|Drug|Iron|Patients will receive iron sulphate, 500 mg, BID, plus orange juice, for 6 weeks.
1706718|NCT01414348|Behavioral|Conventional rehabilitation.|1 hour / 2x / week for up to 15 sessions
1706719|NCT01414348|Behavioral|Novel rehabilitation approach|1 hr, 2x/week for up to 15 sessions
1706720|NCT01414335|Dietary Supplement|amino acid composition|one single pouch (13g) of amino acid mixture and vitamins diluted into 200 ml of still water. This solution was daily oral taken after a meal.
1706721|NCT01414335|Other|Placebo|placebo contained no amino acids and vitamins and was identical in appearance and solution properties.
1706722|NCT01414296|Drug|PSMA ADC|PSMA ADC administered IV
1706723|NCT01414283|Drug|PSMA ADC|PSMA ADC administered IV
1706724|NCT01413113|Drug|pazopanib hydrochloride|Given PO
1706725|NCT01413113|Radiation|iodine I 131|Given IM
1706726|NCT01413100|Biological|Anti-Thymocyte Globulin|Given IV
1706727|NCT01413100|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
1706728|NCT01413100|Drug|Cyclophosphamide|Given IV
1706729|NCT01413100|Biological|Filgrastim|Given SC
1706730|NCT01413100|Other|Laboratory Biomarker Analysis|Correlative studies
1706731|NCT01413100|Drug|Mycophenolate Mofetil|Given PO
1706732|NCT01413100|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
1706733|NCT01413100|Drug|Plerixafor|Given SC
1706734|NCT01413100|Other|Quality-of-Life Assessment|Ancillary studies
1706735|NCT01413100|Other|Questionnaire Administration|Ancillary studies
1706736|NCT01413087|Biological|Biological/Vaccine: BC-819|"Post screening and prior to randomization, all patients will receive gemcitabine by IV infusion at a dose of 1000mg/m2 once weekly for four weeks. They may also enter the study if they received up to 4 doses of gemcitabine before entering the study. In this case, they will be randomized immediately provided there is no evidence of disease progression.
After randomization patients will receive gemcitabine at a dose of 1000mg/m2 + 8 mg doses of BC-819 or gemcitabine at a dose of 1000mg/m2 + 12 mg doses of BC-819"
1706737|NCT01413074|Other|Peritoneal Dialysis treatment|PD treatment
1706738|NCT01413074|Other|Hemodialysis treatment|HD treatment
1706739|NCT01413061|Procedure|Subtalar Arthrodesis|
1706740|NCT01413048|Drug|Carvedilol 25mg|Tablet, q.d.
1706741|NCT01413048|Drug|AGSCT101 12.5mg|Tablet, q.d.
1706742|NCT01413035|Biological|MSC|1.0E+6 MSC/kg, IV drop in Day 0 and repeat to apply in Day 90 if the effect of MSC is better.
1706743|NCT01413022|Drug|Oxaliplatin|
1706744|NCT01413022|Drug|Irinotecan|
1706745|NCT01413022|Drug|Leucovorin|
1706746|NCT01413022|Drug|Fluorouracil|
1706747|NCT01413022|Other|laboratory biomarker analysis|Correlative studies
1706748|NCT01413022|Other|flow cytometry|Correlative studies
1706749|NCT01413022|Other|immunohistochemistry staining method|Correlative studies
1706750|NCT01413022|Other|pharmacological study|Correlative studies
1706751|NCT01413022|Drug|PF-04136309|
1706752|NCT01412996|Procedure|surgery|single ACCESS laparoscopic cholecystectomy
1706753|NCT01412996|Other|SURGERY|CONVENTIONAL LAPAROSCOPIC CGOLECYSTECTOMY
1706754|NCT01412983|Device|Bausch & Lomb Test lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
1706755|NCT01412983|Device|Ciba Vision soft contact lens|Lens to be worn on a daily wear basis for one week. Participants will be provided with Bausch + Lomb renu® fresh™ multi-purpose solution for daily rinsing, cleaning, and disinfecting of their lenses.
1706756|NCT01412970|Other|volume loading|volume loading according to functional parameters of cardiac preload, i.e. stroke volume variations measured by arterial pulse contour analysis
1706758|NCT01414244|Drug|Glutamine|Drug
1706759|NCT01414231|Drug|Cytarabine|Intermediate dose against low dose; IDA 12 mg/m2 iv days 1 - 3 and AraC 2 x 1 g/m2 bid on days 1+3+5+7 vs. AraC 100 mg/m2/day i.v.-for 7 days and Daunorubicin 60 mg/m2/Tag on days 3, 4 und 5.
1706760|NCT01414218|Behavioral|Humor as a Way of Life Seminar|One session per week lasting 2-3 hours per session for 4 months. Sessions will include the videotaping of humorous stories or situations and instruction related to strategies to incorporate humor into everyday life.
1706761|NCT01414205|Drug|Obinutuzumab|Participants were administered obinutuzumab either at 1000 mg or 2000 mg on Day 1, 8, 15 of Cycle 1 and then on Day 1 of each 21 day cycles for up to 8 cycles.
1706763|NCT01414166|Drug|ERN/LRPT|ERN/LRPT combination tablets (each containing 1 g of extended release niacin and 20 mg of laropiprant), orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
1706764|NCT01414166|Drug|placebo|ERN/LRPT-matched placebo, orally, one tablet once per day for 4 weeks, then 2 tablets once per day for 12 weeks
1706765|NCT01414153|Drug|4.0 mg iSONEP|4.0 mg iSONEP given monthly intravitreously for 4 months
1706766|NCT01414153|Drug|0.5 mg iSONEP|0.5 mg iSONEP given monthly intravitreously for 4 months
1706767|NCT01414153|Drug|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea|0.5 mg Lucentis or 1.25 mg Avastin or 2 mg Eylea given monthly intravitreously for 4 months
1706768|NCT01414153|Drug|sham injection|administered monthly for 4 months
1706769|NCT01414140|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Women inserted Mirena for intrauterine contraception.
1706770|NCT01414114|Drug|Etelcalcetide|Administered 3 times a week by bolus injection into the venous line of the dialysis circuit after the end of hemodialysis.
1706771|NCT01414101|Drug|ISIS CRP Rx or Placebo|
1706772|NCT01414088|Other|isotonic saline 0,9 mg/ml|infusion, 23 ml/kg, during 50 minutes
1706773|NCT01414088|Other|hypertonic saline 2,9 mg/ml|infusion, 7 ml/kg, during 50 minutes
1706774|NCT01414088|Other|glucose 5%|infusion, 23 ml/kg, during 50 minutes
1706775|NCT01414075|Drug|FG-4592|Tiered, weight-based dosing with or without oral or intravenous iron supplementation
1706776|NCT01414062|Behavioral|Cocinar Para Su Salud Program|A series of 9 Cocinar Para Su Salud intervention sessions held over a 12-week period. The 12-week intervention period will be divided into 3 groups: motivation, action, and environment. Each topic will use a nutrition roundtable, food shopping field trip, and a cooking class to teach pertinent points, in order to enable participants to progress from the precontemplation, contemplation, and preparation stages of change to the action and maintenance stages.
1706777|NCT01414062|Behavioral|Written dietary recommendations|Standard of care: one on one meetings with study staff to receive compiled written information on dietary recommendations for breast cancer survivors produced by the NYC-based not-for-profit, God's Love We Deliver
1706780|NCT01414036|Other|Enhanced Traditional Care control|Educational brochure, list of hospital and community resources
1706781|NCT01414036|Behavioral|Patient navigation|Patients will receive up to 4 hours of patient navigation, in person or over the phone, over a 3-month period.
1706782|NCT01414023|Behavioral|Cognitive Control Training|Pace Auditory Serial Addition Task (PASAT;(Gronwall, 1977): A computer version of the PASAT will be used to measure sustained attention and working memory. Participants are asked to add serially presented numbers. Attention Control Intervention (Wells, 2000): This task involves training individuals to attend differentially to multiple auditory sources (e.g., by counting tones, discriminating the location of tones, and moving their attention between auditory sources for a prolonged period).
1706783|NCT01414023|Behavioral|Peripheral Vision Task|Peripheral Vision Task (PVT; C. Moore, personal communication): This task serves as a non-active control condition which does not target the brain regions influenced by the Wells and PASAT tasks. Participants focus on the placement of dots on a computer screen in this task while listening to a tone.
1706784|NCT01414010|Dietary Supplement|Trametes versicolor extract|1,200 mg, 3 times daily on an empty stomach for 14 days
1706785|NCT01414010|Dietary Supplement|Saccharomyces boulardii|250 mg, 3 times daily on an empty stomach for 14 days
1706786|NCT01414010|Drug|Amoxicillin|250 mg 3 times daily at least 1 hour before meals for 7 days
1706787|NCT01413984|Behavioral|Helping Women Recover/Beyond Trauma|Four treatment rounds will be conducted, and a goal of 20 women (10 from each group) will be recruited to participate in each round. A new treatment group will start every four months. Sessions are approximately 2 hours each, 3-4 times per week over four months in a group format. This treatment program will focus on the integrated treatment of trauma and substance abuse in women. Versions of the curriculum exist both for community and corrections populations. In this intervention the corrections version will be used.
1706788|NCT01413958|Drug|Phenylephrine|Phenylephrine hydrochloride 30-mg extended-release tablets, one tablet every 12 hours for 7 days
1706789|NCT01413958|Drug|Placebo|Placebo to phenylephrine hydrochloride 30-mg extended release tablets, one tablet every 12 hours for 7 days
1706790|NCT01413958|Drug|Loratadine|Loratadine, 10 mg, once daily as rescue medication, only if needed for intolerable allergic rhinitis symptoms
1706791|NCT01413932|Drug|HT-2157|QD oral dosing
1706792|NCT01413932|Drug|Placebo|QD oral dosing
1706793|NCT01413906|Drug|BMS-833923 (XL139)|Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
1706794|NCT01413893|Drug|linifanib|QD daily
1706795|NCT01413867|Procedure|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the EEA stapler Covidien
1706796|NCT01413867|Procedure|stapled hemorrhoidopexy|stapled hemorrhoidopexy will be performed using the PPH01/03 Ethicon EndoSurgery
1706797|NCT01413854|Drug|sugar pill|One tablet two times daily during four weeks
1706798|NCT01413854|Drug|Diclofenac|50 mg, two times daily (oral adm.) during four weeks
1706799|NCT01413841|Drug|Nasal oxygen|3 l oxygen
1706800|NCT01413841|Drug|Regular nasal air|3 l nasal air
1706801|NCT01413828|Drug|concurrent|Trastuzumab will be administered concurrently with any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
1706802|NCT01413828|Drug|sequential|Trastuzumab will be administered sequentially to any anthracycline-containing regimen for breast cancer adjuvant chemotherapy. Trastuzumab will be given intravenously 8mg/kg loading dose, followed by 6mg/kg every 3 weeks for one year.
1706803|NCT01413815|Dietary Supplement|L-arginine|3.3 g of L-arginine capsules, oral,b.i.d for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine).
1706893|NCT01412879|Drug|cytarabine|Given IV
1706894|NCT01412879|Drug|dexamethasone|Given PO or IV
1706804|NCT01413815|Other|Placebo|3.3 g of placebo capsules/ b.i.d.; for a period of three days (a variability ±2 days is accepted to enable scheduling of surgery according to requirements of clinical routine)
1706805|NCT01413802|Procedure|Continuous nerve monitoring|Continuous nerve monitoring is performed during thyroid surgery.
1706806|NCT01413789|Drug|Dermatix|1 application of Dermatix
1706807|NCT01413789|Drug|Kelocote|1 application of Kelocote
1706808|NCT01413789|Drug|BAP scar gel|1 application of BAP scar gel
1706809|NCT01413789|Drug|Alhydran|1 application of Alhydran
1706810|NCT01413789|Drug|Bap Scar Care T|1 application of BAP Scar Care T
1706811|NCT01413789|Drug|Bap Scar Care S|1 Application of Bap Scar Care S
1706812|NCT01413789|Drug|Mepiform|1 application of Mepiform
1706813|NCT01413789|Drug|Scar Ban Elastic|1 application of Scar Ban Elastic
1706814|NCT01413776|Dietary Supplement|Corn Soya Blend+|A blended food consisting of corn (75-80%) and soybeans (20-25%) that has been fortified with a premix of 19 vitamins and minerals.
1706815|NCT01413763|Drug|Imiquimod cream 3.75%|3.75% cream, applied daily for 2 weeks
1706816|NCT01413763|Drug|Placebo cream|placebo cream applied daily for 2 weeks
1706817|NCT01413750|Drug|Paclitaxel|Given IV
1706818|NCT01413750|Drug|Carboplatin|Given IV
1706819|NCT01413750|Drug|Vorinostat|Given PO
1706820|NCT01413750|Other|Placebo|Given PO
1706821|NCT01413750|Other|Laboratory Biomarker Analysis|Correlative studies
1706822|NCT01413711|Drug|Vigabatrin|Oral vigabatrin as a single 25 mg/kg dose on Days 1 and 5, 25 mg/kg twice a day (50 mg/kg daily dose, orally) on Days 2-4
1706823|NCT01413685|Other|Pharmacokinetics/dynamics|Determination of tacrolimus concentrations in whole blood and of calcineurin activities in lymphocytes at D8, D15, D21 (pharmacokinetics on 4 times samples), D28, M2 and M3 (residual measurement)
1706824|NCT01413672|Device|Use of CASTLE barrier|Test barrier to be used in place of normal barrier. Otherwise normal routine is followed
1706825|NCT01413659|Biological|Symbiotic|Oral symbiotic every 8 h since 2 days before operation; Symbiotic resumes postoperatively on day +2 until day +4 for a total of 4 d of treatment (12 doses).
1706826|NCT01413646|Dietary Supplement|Walnut Supplementation|Eight weeks of walnut supplementation
1706827|NCT01413646|Dietary Supplement|No walnut supplementation|Eight weeks without walnut supplementation
1706828|NCT01413633|Procedure|cholecystectomy|single incision laparoscopic cholecystectomy
1706829|NCT01413620|Drug|dl-alpha-tocopheryl acetate|Ages 6 months-1 year will receive 75 IU/day of dl-alpha-tocopheryl acetate, while ages 2-5 years will receive 150 IU/day. Ages 6-8 will receive 300 IU/day, while ages 9-13 will receive 600 IU/day, ages 14-17 will receive 800 IU/day, and ages 18-70 will receive 1200 IU/day. Vitamin E will be administered in a liquid or pill form. The dose of aqueous vitamin E (Aqueous Vitamin E Oral Drops, Silarx, No. 54838-0005-30, Spring Valley, NY) will be given orally. When/If the patient is able to eat independently, the dose of vitamin E may be given in a pill form (Novatol 5-57, No. 410217, Archer Daniels Midland Company, Decatur, IL). Depending on the subject's group, the supplement of vitamin E either will be given on days 1-15 of the study or days 16-30 of the study.
1706830|NCT01413607|Device|Quill knotless tissue-closure device|The Quill knotless tissue-closure device is a barbed suture that allows the surgeon to keep tissue approximation without maintaining tension on the suture.
1706831|NCT01413607|Device|2-0 absorbable vicryl suture|In the control group a traditional 2-0 absorbable vicryl suture (Ethicon) will be used to close the central defect in the kidney.
1706832|NCT01413594|Behavioral|HABIT|90 hours of bimanual training over 3 weeks in a day camp environment
1706833|NCT01413581|Drug|rhBSSL (recombinant human bile-salt-stimulated lipase)|rhBSSL added to infant formula/pasteurized breast milk during a 4 week treatment period.
1706834|NCT01413581|Drug|Placebo|Placebo added to infant formula/pasteurized breast milk during a 4 week treatment period.
1706835|NCT01413568|Drug|POL6326|
1706836|NCT01413568|Procedure|Leukapheresis|
1706837|NCT01413568|Procedure|PBSC Transplant|
1706838|NCT01413555|Other|Blood Culture QI Program|The Blood Culture QI Program contains four components:(1) education: content knowledge and standardized experiential training on sterile technique designed for ED nurses; (2) process redesign: conversion of blood culture collection from a clean to a sterile technique using the Blood Culture Sterile Kit; (3) a checklist outlining optimal use of the Kit; (4) feedback of blood culture contamination rates to ED nurses who collect them.
1706839|NCT01413542|Drug|Sitagliptin (DPP4 inhibitor)|Sitagliptin 200 mg (DPP4 inhibitor) or matching placebo will be given one hour prior to intra-arterial infusions
1706840|NCT01413542|Drug|Substance P,|Substance P intra-brachial artery (2,4,8 pmol/min)
1706841|NCT01413542|Drug|bradykinin|bradykinin intra-brachial artery (23.6, 47.2, and 94.3 pmol/min)
1706842|NCT01413542|Drug|enalaprilat (ACE inhibitor)|intra-brachial artery(0.33 µg/min per 100 mL forearm volume)
1706843|NCT01413542|Drug|Glucagon-like peptide 1|intra-brachial artery (0.45-3.60 pmol/min)
1706844|NCT01413542|Drug|brain natriuretic peptide|Intra-brachial artery (0.90, 1.80 and 3.6 pmol/min)
1706845|NCT01413529|Behavioral|HEART to HAART|The HEART to HAART intervention is designed to enhance ongoing adherence counseling by providing (1) real time information about medication adherence (using Wisepill device); (2) periodic assessment of medication side effects, depressive symptoms and drug use frequency (as these are linked to poor adherence among drug users) using ecological momentary assessment and (3) tailored education, recommendation and encouragement based on assessments. The participant (using their phone) and their adherence team (using a clinician interface) can jointly track real time changes in adherence increasing the potential for shared decision-making.
1706846|NCT01413529|Behavioral|adherence counseling with the addition of smartphone control|Participants will receive adherence counseling with the addition of smartphone control.
1706847|NCT01413516|Behavioral|Smoking cessation counseling|Counseling sessions provided by a trained smoking counselor
1706848|NCT01413516|Drug|Placebo|Sugar pill without any active medication
1706849|NCT01413516|Drug|Varenicline|Varenicline (an approved medication for smoking cessation)
1706895|NCT01412879|Drug|doxorubicin hydrochloride|Given IV
1706896|NCT01412879|Drug|leucovorin calcium|Given PO or IV
1706897|NCT01412879|Drug|methotrexate|Given IV
1706898|NCT01412879|Drug|vincristine sulfate|Given IV
1706850|NCT01413503|Radiation|131I-MIBG|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 1200 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
1706851|NCT01413490|Drug|rimantadine|12 weeks of rimantadine therapy in addition to standard combination therapy with interferon and ribavirin
1706852|NCT01413477|Drug|Calcipotriol, Betamethasone, Calcipotriol & Betamethasone|All study patients will be randomized to receive one of four topical ointments (calcipotriol, betamethasone dipropionate, combination of both calcipotriol/betamethasone dipropionate, or Vaseline petroleum jelly). Each subject will receive one unlabelled 5g tube for application to be dispensed by pharmacist, Rudy Chin. We expect approximately 2g of TOTAL use (0.125g applied twice daily over a 5 cm x 5 cm area on one forearm for 7 days). Typically, topical steroids such as betamethasone dipropionate have been used for treating a number of inflammatory skin conditions, including eczema. In addition, vitamin D analogues such as calcipotriol are used to treat psoriasis. Both agents, in our study, will be used on a small area of normal skin for a short 7 day course.
1706853|NCT01413451|Drug|Amatuximab (MORab-009)|
1706854|NCT01413438|Procedure|Craniotomy|
1706855|NCT01413412|Procedure|Ventral hernia repair using full thickness skin graft|25 patients
1706856|NCT01413412|Procedure|Ventral hernia repair using mesh|25 patients
1706857|NCT01413399|Drug|4 degree chilled saline|4 degree chilled saline up to 2L in the prehospital setting
1706858|NCT01413386|Device|biliary stent|palliative treatment for malignant patients
1706859|NCT01413373|Radiation|cone beam computed tomography|A CBCT is performed for all patients in this study
1706860|NCT01413373|Radiation|computer tomography|One computer tomography examination before surgery
1706861|NCT01413360|Drug|High dose vitamin C|Vitamin C, 3g per day (tid), with meal, per oral with water 100mL
1706862|NCT01413347|Procedure|pillow|bronchoscopic confirmation of double-lumen tube position with a head on a pillow
1706863|NCT01413347|Procedure|neutral|bronchoscopic confirmation of double-lumen tube position in neutral position of a head
1706864|NCT01413295|Drug|Dendritic Cell Vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
1706865|NCT01413295|Other|Supportive treatment|Supportive treatment after progression of the illness after 2 lines of chemotherapy
1706866|NCT01413282|Radiation|Cardiac CT|Calcium scan and CT coronary angiography
1706867|NCT01413269|Radiation|radiotherapy|"one group receives radiation to the whole breast to a total dose of 43.5Gy,at 2.9Gy per fraction, 5 fractions a week, followed by tumor bed boost of 8.7Gy, at 2.9Gy per fraction 5 fractions a week.
the other group receives radiation to the whole breast to a total dose of 50Gy,at 2.0Gy per fraction, 5 fractions a week, followed by tumor bed boost of 10Gy, at 2.0Gy per fraction 5 fractions a week."
1706868|NCT01413243|Drug|Trichuris suis ova|Trichuris suis ova 2500 eggs every 2 weeks
1706869|NCT01413230|Drug|cholecalciferol|100 000 UI of cholecalciferol per week during 4 then 100 000 UI of cholecalciferol per month for 6 months
1706870|NCT01413204|Drug|TA-7284 Low|The patients will receive TA-7284-Low orally for 24 weeks.
1706871|NCT01413204|Drug|TA-7284 High|The patients will receive TA-7284-High orally for 24 weeks.
1706872|NCT01413204|Drug|Placebo|The patients will receive Placebo orally for 24 weeks.
1706873|NCT01413191|Biological|Cixutumumab|10 mg/kg IV infusion over 1 hour every 2 weeks with treatment cycle defined as 4 weeks
1706874|NCT01413191|Other|Laboratory biomarker analysis|Correlative studies
1706875|NCT01413178|Drug|Busulfan|Test dose (32 mg/m^2) on day -9 then 130 mg/m^2 by vein or adjusted dose on Days -7, -6, -5, and -4.
1706876|NCT01413178|Drug|Melphalan|70 mg/m2 by vein over 30 minutes minutes on Days -2 and -1.
1706877|NCT01413178|Other|Questionnaire|Quality of Life (QOL) questionnaire before starting the study drugs and then once every 4 weeks after the stem cell transplant, taking about 15 minutes to complete.
1706878|NCT01413178|Drug|G-CSF|Approximately 5 mcg/kg/day subcutaneously beginning on Day +5.
1706879|NCT01413178|Drug|High Dose Melphalan|200 mg/m2 by vein over 30 minutes on Day -2.
1706880|NCT01413178|Procedure|Stem cell transplant|Stem cell infusion on Day 0.
1706881|NCT01413152|Biological|blood and semen sampling, specific biological exams and biobank and self administered questionnaires|blood and semen sampling, specific biological exams and biobank and self administered questionnaires
1706882|NCT01413139|Device|4F portfolio products from Biotronik|4F portfolio products from Biotronik: Astron pulsar / Astron Pulsar-18, Fortress, Passeo-18, Cruiser-18
1706883|NCT01413126|Dietary Supplement|Whole peanuts without skins, Peanut butter, or no peanuts (control)|In accordance with the Food and Drug Administration qualified health claim regarding daily nut intake, 42.5 g of whole peanuts or peanut butter were added to a 75g available carbohydrate-matched breakfast meal each test session.
1706884|NCT01412957|Other|Best Supportive Care (BSC)|BSC was defined as the best palliative care available as judged appropriate by the investigator and according to institutional guidelines and could include antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy as clinically indicated.
1706885|NCT01412957|Drug|Panitumumab|Administered intravenously
1706886|NCT01412944|Drug|secukinumab 150mg|secukinumab 150mg (2 injections per dose)
1706887|NCT01412944|Drug|secukinumab 10mg/kg i.v. regimen|secukinumab 10mg/kg i.v. regimen
1706888|NCT01412918|Device|The Inhibitor™ Tinnitus Masking Device|The Inhibitor™ Tinnitus Masking Device
1706889|NCT01412892|Drug|RAD001: Everolimus|10 mg of RAD001 will be self-administered orally once daily continuously for one year or until unacceptable toxicity or discontinuation from the study from any other reason.
1706890|NCT01412879|Biological|rituximab|Given IV
1706891|NCT01412879|Drug|bendamustine hydrochloride|Given IV
1706892|NCT01412879|Drug|cyclophosphamide|Given IV
1706901|NCT01412853|Other|MR-Spectroscopy|response to standard radiotherapy treatment will be estimated for each patient every 3 months up to one year from the end of the radiotherapy
1706902|NCT01412840|Other|Diclofenac and sterile water injections|The patients in the intervention group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac. Patients in this group will also be given four subcutaneous injections of 0.5 ml sterile water at the same segmental level, i. e. the area in which the patient reports the pain.
1706903|NCT01412840|Other|Diclofenac and isotonic saline|The patients in this group will be given standard treatment, i.e. intramuscular injection of 50 mg diclofenac They will also be given four subcutaneous injections of isotonic saline at the same segmental level, i. e. the area in which the patient reports the pain.
1706904|NCT01412827|Radiation|1/2 dose of 99mTc OR 201Tl tracers|"Rest: Imaging will occur 30 to 60 minutes after injection of tracer.
Stress: All patients will undergo a symptom-limited Bruce protocol treadmill exercise test. At peak stress, the radiotracer will be injected intravenously, and exercise will continue for an additional 60 s. The patients who are unable to achieve the targeted heart rate or exercise will be stressed pharmacologically. Dipyridamole (0.142 mg/kg/min) will be infused intravenously for 5 minutes, and 99mTc radiotracer will be injected at 2 min after infusion completion (7 min into the study). Aminophylline (100-200 mg) will be given intravenously 2 min after injection of the radiotracer."
1706905|NCT01412814|Device|AposTherapy Biomechanical System|The device is comprised of four adjustable modular elements attached to foot-worn platforms that are capable of manipulating the foot's center-of-pressure and applying perturbation training throughout the gait cycle. The device allows for neuromuscular training during dynamic loading.
1706906|NCT01412814|Other|Physical Therapy Program|Their therapy program will be similar to the experimental group, but without the treatment device (placebo walking shoe).
1706907|NCT01412801|Biological|Group B streptococcus vaccine|Subjects receive one dose of 5 μg of each of the 3 glycoconjugates present in the Group B streptococcus vaccine.
1706908|NCT01412788|Procedure|peri-areolar incision|peri-areolar incision was used to carry out lumpectomy in breast-conserving surgery.
1706909|NCT01412788|Procedure|traditional incision|Traditional incision above tumor was used to carry out breast-conserving surgery.
1706910|NCT01412775|Behavioral|short-term group intervention program|"The intervention will include three aspects: Psycho-educational intervention: attending a lecture about stress and exhaustion; Techniques for decreasing stress: experiencing relaxation techniques and guided imagery and a BALINT style group:analyzing actual work cases and cognitive-behavioral focusing for reframing thoughts and making them more adaptive, expressing emotions and training for more appropriate behaviors.
The study includes three weekly sessions, Each session will be 90 minutes in duration."
1706911|NCT01412762|Behavioral|patient interviews|The pre-operative interview will be within 4 weeks of planned surgery and the postoperative interview within 8 weeks of surgery completion. This initial study is designed to develop an instrument to measure patient preoperative expectations in this patient population.
1706912|NCT01412762|Behavioral|CITSAV survey|Individual semi-structured qualitative interviews will be conducted with a total of 10 patients and 5 clinicians during this phase to identify and discuss levels of satisfaction, level of burden, potential obstacles to implementation, as well as suggestions for improving the intervention
1706913|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
1706914|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
1706915|NCT01412736|Drug|KHK4563|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
1706916|NCT01412736|Drug|Placebo|every 4 weeks for the first 3 doses on Weeks 0 (Day 1), 4, and 8 and then every 8 weeks thereafter for the last 4 doses on Weeks 16, 24, 32, and 40.
1706917|NCT01412723|Other|Ferrous sulfate as dietary supplementation|Ferrous sulfate as dietary supplementation
1706918|NCT01412723|Other|Iron amino acid chelated as dietary supplementation|Iron amino acid chelated as dietary supplementation
1706920|NCT01412697|Behavioral|Fruit and vegetable intake in rural youth|A theory based health behavior intervention, developed for youth is presented to seventh grade youth over 8 weeks to test their improvement in their intake of fruits and vegetables.
1706921|NCT01412684|Procedure|Distal pancreatectomy with partial splenectomy|Distal pancreatectomy with partial splenectomy
1706922|NCT01412671|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
1706923|NCT01412658|Dietary Supplement|Hydrolyzed milk protein mixture|Take twice a day, dosage 6 ml-21 ml based on weight, mix with 1/2 cup of milk.
1706924|NCT01412658|Dietary Supplement|Glycerol placebo|"Participants ingested 6ml-21ml of placebo mixed with 1/2 cup milk twice daily. The supplements were prepared in liquid form and packaged in generic bottles for double blind administration. The placebo was a starch-based placebo matched for color, texture, and taste to the active supplement.
A food diary is maintained daily."
1706925|NCT01412645|Dietary Supplement|Resveratrol|"500mg resveratrol 2 times daily for 4 months (High-dose Resveratrol), 75mg resveratrol 2 times daily for 4 months (Low-dose Resveratrol) or
1 placebo 2 times daily for 4 months"
1706927|NCT01412606|Procedure|scratching|scratching endometrium on day 21-26 of a spontaneous menstrual cycle
1706928|NCT01412593|Biological|Stem cell transplant|Patients randomized to the intervention arm will be admitted to the Liver Care Unit. Granulocyte colony-stimulating factor (G-CSF; 300mcg/mL) will be administered for 1 day as a single daily subcutaneous dose. This dose is sufficient to induce 10 folds enrichment for bone marrow cells.
1706929|NCT01412580|Other|observational follow-up|observational follow-up
1707262|NCT01409811|Drug|zoledronic acid|Given IV
1706930|NCT01412567|Drug|Vaccine+HBIG|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
1706931|NCT01412567|Drug|Vaccine+Placebo|Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth
1706932|NCT01412541|Procedure|Standard Uncoated Angioplasty Balloon|Subjects will be randomized 2:1 to the Moxy Drug Coated Balloon or Standard Angioplasty Balloon
1706933|NCT01412541|Device|Moxy Drug Coated Balloon|Subjects will be randomized 2:1 to the drug coated or standard angioplasty balloon
1706934|NCT01412528|Other|Allergen extracts|
1706935|NCT01412515|Drug|everolimus|everolimus per os 10mg per day
1706936|NCT01412502|Other|IES-R and HDAS scores|The Impact of Event Scale and Hospital Depression and Anxiety Score questionnaires are administered to participants.
1706937|NCT01412489|Device|HYALOBARRIER Gel|For each patient, the HYALOBARRIER Gel was introduced into the uterine cavity with the canula after hysteroscopic myomectomy procedure
1706938|NCT01412463|Device|stent placement|"pre-dilation of the study lesion is mandatory
stent placement with 1 Protégé Everflex+ stent
only 1 stent is allowed within the study protocol
post-dilation may be performed but is not mandatory"
1706939|NCT01412450|Device|nitinol stent|implantation of one Protégé EverFlex stent
1706940|NCT01412437|Dietary Supplement|diet|12 participants will be randomized to diet. Phe levels will be followed by blood levels. A dietician will analyze diet for phe content and advise
1706941|NCT01412437|Drug|sapropterin dihydrochloride|20 mg/kg for 4 months
1706942|NCT01412437|Drug|sapropterin dihydrochloride|
1706943|NCT01412424|Drug|Octreotide capsules|Octreotide was provided in hard gelatin capsules.
1706944|NCT01412411|Behavioral|Nutritionl Education|to assess the change in behaviour
1706945|NCT01412411|Dietary Supplement|Oral Iron Supplementation along with Nturition Eductaion|
1706946|NCT01412411|Dietary Supplement|Multiple micronutrient fortification plus Nutrition Education|
1706947|NCT01412398|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet|Patients in CCPD who have received Fosrenol for hyperphosphatemia
1706951|NCT01412372|Drug|Mesalamine|2 1.2g tablets once daily for 8 weeks. Patients randomized 50/50 to either Mesalamine or the Placebo
1706952|NCT01412372|Drug|Placebo|This is an inactive pill
1706953|NCT01412359|Drug|Omegaven®|Omegaven® 10% fat emulsion 1g/kg/day to infuse via IV over a period of 12 -24 hours every day until patient no longer requires intravenous lipid emulsion, is determined ineffective, or the patient stops participating in the study for any reason.
1706954|NCT01412346|Other|Effects of a Nordic diet rich in plant-based foods and fish|The intervention lasts for 20 weeks and it includes dietary counseling concerning salt restriction. Key foods are provided to the subjects.
1706955|NCT01412333|Drug|Interferon beta-1a|
1706956|NCT01412333|Drug|Ocrelizumab-matching placebo|
1706957|NCT01412333|Drug|Ocrelizumab|
1706958|NCT01412333|Drug|Interferon beta-1a-matching placebo|
1706959|NCT01412320|Other|Cocoa|dissolved in water twice daily
1706960|NCT01412320|Other|Cocoa|dissolved in water twice daily
1706961|NCT01412307|Drug|Lenalidomide|10, 15, 20 or 25 mg orally per cohort day 1-28 in a 28 days cycle
1706962|NCT01412307|Drug|Bendamustine|intravenous on days 1, 8 and 15 of each 28-days cycle at fixed dose of 60 mg/m2, as a 30-60 min i.v. infusion
1706963|NCT01412307|Other|Bio-specimen Retention|Samples with DNA and without DNA
1706964|NCT01412294|Drug|Capecitabine, Cisplatin|"Drug: Capecitabine Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
Drug: Cisplatin Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
1706965|NCT01412281|Biological|Virosomal influenza vaccine (AdImmune HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA Antigen) 2011/2012, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
1706966|NCT01412281|Biological|Virosomal influenza vaccine (CSL HA Antigen)|Virosomal influenza vaccine (surface antigen, inactivated, virosome, using CSL HA antigen) 2011/2012 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
1706967|NCT01412242|Other|Extensive search for isolated calf DVT|Extensive search for isolated calf DVT in patients with negative CUS of the proximal veins who have a high PTP and a positive D-dimer
1706968|NCT01412229|Drug|Cetuximab|Weekly cetuximab given intravenously for 6 weeks during induction chemotherapy and continue during the 2-3 week break prior to definitive chemoradiotherapy.
1706969|NCT01412229|Drug|Nab-paclitaxel|Weekly nab-paclitaxel given intravenously following cetuximab infusion for 6 weeks.
1706970|NCT01412229|Drug|Carboplatin|Weekly carboplatin given intravenously following nab-paclitaxel infusion for 6 weeks.
1706971|NCT01412216|Dietary Supplement|Fish Oil (Omega-3 Fatty Acids)|fish oil-4.4gm/day x 5 days
1706972|NCT01412216|Dietary Supplement|Fish Oil (Omega-3 Fatty Acids)|
1707083|NCT01411267|Drug|Methotrexate|"IT methotrexate given intrathecally to patients with ALL on day 0 of course 1 and 2. Dose defined by age
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients >9 years of age"
1707084|NCT01411254|Drug|Betamethasone Microsphere (DE-102） Low Dose|
1707085|NCT01411254|Drug|Betamethasone Microsphere (DE-102） High Dose|
1707086|NCT01411254|Drug|Sham|
1707104|NCT01411163|Drug|Creatine monohydrate|Up to 30 grams daily creatine monohydrate
1706973|NCT01412203|Behavioral|Action Schools! BC|AS! BC applies a socioecological, whole school approach to promote healthy living within the elementary school context. Schools are provided with the tools and support needed to create customized action plans that promote physical activity (PA) and healthy living across six Action Zones (School Environment, Scheduled Physical Education (PE), Classroom Action, Family and Community, Extra-curricular, School Spirit). Generalist teachers receive training and resources to implement their Action Plan with the ultimate goal of providing students with 150 minutes of PA/week. The model is choice-based; teachers are asked to provide 15 additional minutes of PA/day within the Classroom Action Zone. The activities require minimal equipment and can be performed in the classroom, hallway or on the school playground.
1706974|NCT01412190|Device|Restylane Vital Light|Treatment of up to 4 ml for one side of the face, one hand and one side of the décolletage dispensed by 10ul doses 0.5-1 cm apart. 3 treatment sessions 4 weeks apart.
1706975|NCT01412190|Other|No treatment|One side of face, one hand and one side of the décolletage is left untreated as a control.
1706976|NCT01412177|Drug|OTO-104|Single intratympanic injection of 12 mg OTO-104
1706977|NCT01412177|Drug|Placebo|Single intratympanic injection of placebo
1706978|NCT01412164|Device|FIREHAWK biodegradable polymer rapamycin-eluting stent|DES PCI for CAD
1706979|NCT01412151|Drug|Creatine monohydrate|Creatine taken twice daily for a total of 30 grams daily dosage or subject's highest tolerated dose
1706980|NCT01412138|Other|genetic analysis|"To identify by flow cytometry through technique of Side Population the population of somatic stem cells present in both human endometrial eutopic and ectopic endometrium of women with ovarian endometriosis, peritoneal and recto-vaginal.
In vitro culture conditions for cell proliferation.
To characterize the somatic stem cell population using techniques of endometriotic cell and molecular biology.
Compare the results obtained from patients with endometriosis with control patients (without endometriosis) earlier work by our group."
1706981|NCT01412125|Other|Huntington patient evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
1706982|NCT01412125|Other|Healthy subject evaluation|Neurological, neuropsychological, neuroimaging evaluation and biological sample
1706983|NCT01412099|Behavioral|peer counseling|Participants receive 3 phone calls from a peer counselor to deliver counseling using motivational interviewing techniques focused on diet and physical activity behaviors over a 6 week period.
1706984|NCT01412099|Behavioral|Feedback report|Participants receive a one-page printed feedback report displaying their current levels of nutrition and physical activity behaviors and tips for meeting recommended guidelines.
1706985|NCT01412086|Drug|No Intervention|No Intervention.
1706986|NCT01412073|Drug|oxytocin|group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
1706987|NCT01412073|Drug|Misoprostol|misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby & the placenta
1706988|NCT01412060|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of 3.0 to 9.0 mg cariprazine during the open-label phase and then randomized when they will receive cariprazine or placebo
1706989|NCT01412060|Drug|Placebo|Dose-matched placebo, once daily oral administration
1706990|NCT01412034|Drug|CER-001|Biweekly infusion
1706991|NCT01412008|Drug|Botox (botulinum toxin)|A series of three injections will be made simultaneously to the gastroc-soleus muscles of the affected lower limb; this will be the only drug intervention/injection session throughout the study, and occurs at baseline. The top injection site, closest to the knee, consists of 25 units of Botox and 0.25 cc saline. The bottom injection site, closest to the ankle, also consists of 25 units of Botox and 0.25 cc saline. The middle injection site will be considered the placebo injection, as it will not contain any Botox (0 units Botox) and 0.25 cc saline.
1956192|NCT02928029|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Sequential dose escalation in Intravenous (IV) injection
1956193|NCT02928029|Drug|Placebo|Matching placebo
1706994|NCT01411969|Drug|External Nasal Dilator Strip; 0.05% oxymetazoline chloride|External Nasal Dilator Strip placed above the upper lateral cartilage; 20 minutes after decongestion with 0.05% oxymetazoline chloride applied as an aerosol spray (two times); after decongestion with ENDS.
1706995|NCT01411956|Other|"24-minute video episode of patient education TV sitcom White Coats"|The series features a fictional married couple of Family Medicine physicians who work in the same practice, located in our community. In both their professional and private lives and, in moments both humorous and serious, these doctors teach patients about a wide variety of health topics. The intervention episode addressing hypertension will focus on three different patient-physician plot lines, which were developed to specifically address each of the beliefs about hypertension highlighted in the theoretical model (susceptibility, seriousness, barriers, self-efficacy and outcome efficacy.).
1706996|NCT01411956|Other|Placebo video|The control group watched a 25-minute patient education video on depression.
1706997|NCT01411930|Drug|Intramuscular olanzapine, aripiprazole|"1st clamp: single intramuscular 10.0 mg dose of olanzapine
2nd clamp: single intramuscular 9.75 mg dose of aripiprazole"
1706998|NCT01411930|Drug|Intramuscular aripiprazole, olanzapine|"1st clamp: single intramuscular 9.75 mg dose of aripiprazole
2nd clamp: single intramuscular 10.0 mg dose of olanzapine"
1706999|NCT01411917|Procedure|Transversus abdominis plane block|Ultrasound guidance will be utilized to inject 30ml of 0.375% bupivacaine into the muscular plane between the internal oblique and transversus abdominis muscles.
1707000|NCT01411904|Device|MagProbe (TM)|CD34 nanoparticles incubated in bone marrow and then extracted with the magnetic needle done at time of bone marrow biopsy
1707001|NCT01411891|Device|Chlorhexidine impregnated patch (Biopatch)|Patients assigned to the intervention group will have a chlorhexidine impregnated patch placed at the femoral nerve catheter insertion site.
1707087|NCT01411241|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 15 to 18 and 21 to 24 months.
1707088|NCT01411241|Biological|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
1707089|NCT01411241|Biological|Placebo|0.5 mL, subcutaneous
1707090|NCT01411241|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
1956194|NCT02928029|Drug|Bortezomib|Bortezomib is administered subcutaneous (SC) (per Investigator choice ) at 1.3 mg/m2/dose
1707002|NCT01411878|Behavioral|Reducing the Risk|Reducing the Risk: Building Skills to Prevent Pregnancy, STD and HIV (RtR) was developed by Richard Barth, MSW, Ph.D. in California. The training manual is in its 5th Edition and was last published in 2011. This curriculum is one of the first that was evaluated using an experimental design, with a longitudinal follow up (6 months and 18 months) and tested on a large group of high school students (N = 758). It is also one of the first programs to show an impact on beliefs of adolescent sexual behavior prevalence and actual behavior as well as increasing parent-child communication about abstinence and contraception (Kirby, Barth, Leland, and Fetro, 1991).
1707003|NCT01411878|Behavioral|Love Notes|The second healthy relationships program for high-risk youth, Love Notes, was developed to educate participants about healthy relationships, including issues of decision-making, communication and conflict resolution, and overall safety, including the prevention of pregnancy and sexually transmitted disease (Pearson, 2009). Love Notes is a derivative of the Prevention and Relationship Enhancement Program (PREP; Stanley, Markman, & Jenkins, 2009), which is relationship marriage education program listed as an evidence-based practice (EBP) by SAMSHA (www.samhsa.gov). This curriculum builds on social exchange theory and meets the needs of youth who are alienated and in need of loving personal relationships.
1707004|NCT01411865|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
1707005|NCT01411865|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed with the May 2010 issue of the newsletter.
1956195|NCT02928029|Drug|Dexamethasone|Dexamethasone is administered orally at 40 mg
1707008|NCT01411839|Behavioral|Cognitive-Behavioral Therapy AD|Therapeutic intervention, one-on-one and face-to-fact, over multiple sessions
1707009|NCT01411826|Behavioral|Information + Narratives + Support Group|Information from CDC website Narratives about CRCS written by others Peer social support among study participants
1707010|NCT01411826|Behavioral|Information Only|Information from CDC website on colon cancer screening.
1707011|NCT01411800|Drug|250 mg capsule|Two 250 mg capsules will be administered for 500 mg dose
1707012|NCT01411800|Drug|250 mg tablets|Two 250 mg tablets will be administered for a 500 mg dose
1707013|NCT01411787|Behavioral|Exercise|Five woman undergoing neoadjuvant chemotherapy for breast cancer will be randomized to an exercise protocol supervised by an experienced personal trainer. The exercise will be administered three times a week for the 4-6 months of neoadjuvant chemotherapy. The exercise protocol will consist of activities including walking/running up to a mile, calisthenics, and light weightlifting.
1707017|NCT01411761|Dietary Supplement|Reflor|5 million unit/day, first 15 day of life
1707018|NCT01411761|Other|serum physiologic|1 cc added to one feeding in a day
1707019|NCT01411748|Dietary Supplement|Reflor|5 million unit/day, orally, beginning on the second day of life, until discharge from hospital
1707020|NCT01411748|Drug|mikostatin|50000 unit/3 times a day, both for orally and by orogastric route
1707021|NCT01411735|Drug|Enalapril|2.5mg titrated up to 10mg twice daily
1707022|NCT01411735|Drug|placebo|2.5mg titrated up to 10mg twice daily.
1707091|NCT01411241|Biological|Pneumococcal vaccine|0.5 mL, intramuscular
1707092|NCT01411241|Biological|Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus|0.5 mL, subcutaneous at age 9 to 12, 16 to 19 and 21 to 24 months
1707093|NCT01411241|Biological|DTaP IPV//Hib vaccine|0.5 mL, intramuscular
1707094|NCT01411241|Biological|Placebo|0.5 mL, subcutaneously
1707095|NCT01411241|Biological|Measles, mumps, and rubella vaccine|0.5 mL, subcutaneous
1707023|NCT01411722|Device|Neurally adjust ventilatory assist (NAVA) and a nasogastric tube to measure the electrical activity of the diaphragm (EAdi catheter)|Nava is a new ventilatory mode which delivers pressure in proportion of the the Electrical activity of the diaphragm (EAdi), a reflection of the neural respiratory output. EAdi will be obtained through a nasogastric tube with a multiple array of electrodes placed at its distal end. Correct positioning of the EAdi catheter is assured by means of a specific function of the ventilator (''EAdi catheter positioning''). The EAdi signal is processed according to the American Thoracic Society (ATS) recommendations and filtered by algorithms designed to provide the highest possible signal-to-noise ratio
1707024|NCT01411709|Drug|Vitano|two 200mg tablets per day for 14 days
1707025|NCT01411696|Drug|dexamethasone intravitreal implant 0.7 mg|Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.
1707026|NCT01411683|Device|Implant-retained mandibular overdenture|Insertion of implants in the lower arch in order to retain existing complete dentures. Tested implants are approved by the Brazilian National Health Surveillance Agency for clinical use.
1707027|NCT01411670|Drug|Human protein C concentrate|Continuous infusion of human protein C concentrate at the dose of 3 UI/Kg/Hr to reach a protein C plasma activity of 70-120%
1707028|NCT01411670|Drug|Activated protein C|Continuous infusion of activated protein C at the dose of 24 micrograms/Kg/Hr for 96 hours
1707029|NCT01411670|Drug|Placebo comparator|Standard treatment
1707030|NCT01411657|Drug|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
1707031|NCT01411631|Dietary Supplement|Grape juice polyphenols|Participants will consume grape juice polyphenols for 12 weeks and a control juice for 12 weeks.
1707032|NCT01411618|Other|free alcohol essential oil mouthwash|All subjects were instructed to rinse twice a day, in the morning and in the evening, with 20 ml solution for 60 seconds, after which they expectorated. Subsequent rinsing with water was not allowed.
1707033|NCT01411605|Behavioral|Exercise training|"12-week supervised exercise-training (ET) program consisting of two 60-min and one 120-min exercise sessions per week which focus mainly on aerobic exercises (cycling, treadmill, rower).
Initial aerobic exercise intensity is set at 60 % of HR peak and will reach 80 % at the end of the ET protocol."
1707034|NCT01411592|Other|Multilink|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using an adhesive bonding system with a phosphonic acid acrylate primer for the zirconia ceramic (Multilink-Automix bonding system with Metal/Zirconia primer)
1707035|NCT01411592|Other|Panavia 21 TC|After air-abrasion of the retainer wings (50 µm alumina particles at 0.25 MPa) and etching the enamel with 36% phosphoric acid for 30 sec, the RBFDPs were inserted using a phosphate monomer containing resin (Panavia 21 TC) without any primer
1707036|NCT01411566|Behavioral|Skills trainig for patients with dual diagnosis|Skills trainig for patients with dual diagnosis
1707037|NCT01411566|Behavioral|regular treatment|regular treatment
1707038|NCT01411553|Other|Disposable ECG-LW|Disposable ECG leadwires used in ICU and telemetry monitoring; 5 lead sets for ICU and 6-lead sets for telemetry
1707039|NCT01411540|Dietary Supplement|Whole grains|Comparison of a diet containing whole grain compared to an energy matched diet based on similar foods, but using refined grains.
1707040|NCT01411514|Drug|Prednisone|Tablets, 60 mg od p.o. for 5 days, followed by 40 mg o.d. p.o. for 5 days, 20 mg o.d. p.o. for 5 days, 10 mg o.d. p.o. for 5 days, 5 mg o.d. p.o. for 5 days
1707041|NCT01411514|Drug|Placebo|Placebo tablets. They will be administered during 25 days
1707042|NCT01411501|Other|acupuncture|"Thrust and lift the needle to achieve De Qi. After being needled, the points will be punctured again using auxiliary needles 2 mm lateral to the first needle, and to a depth of 2 mm without manual stimulation. Put the electric stimulator on the pair of needles with a continuous wave, 20Hz. The current intensity is increased to the patients' maximum tolerance and then slightly reduced to a bearable level (0.1-1.0 mA).
Huatuo Brand needle (φ0.30×25mm,φ0.30×40mm,φ0.30×50mm, produced by Suzhou Medical Appliance Factory) and G6805-1A electro-acupuncture apparatus(produced by Shanghai Huayi Medical Instrument Co. Ltd.) will be used.
Five sessions/week in the first 2 weeks, three sessions/week for in the last 2 weeks."
1707043|NCT01411501|Drug|mosapride citrate|4-week oral use of mosapride citrate, 5mg, three times daily 0.5 hour before meal
1707044|NCT01411488|Device|Fecal management system|rectal tubes/fecal management systems: we compared products to determine if there is a difference in the incidence of anal erosions
1707045|NCT01411475|Other|Bifurcation restenosis classification|Classification of restenosis involving coronary bifurcation according to their pattern
1707046|NCT01411462|Device|VIBE + drug-eluting balloon|VIBE before and after durg-eluting balloon angioplasty
1707047|NCT01411449|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Patients who will need to undergo contrast enhanced MRI with Primovist
1707048|NCT01411436|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable HCC
1707049|NCT01411423|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients who have received Nexavar for unresectable or advanced RCC.
1707052|NCT01411397|Other|SURGERY|REPAIR OF STRANGULATED HERNIA with intestinal resection
1707053|NCT01411397|Other|mesh repair|mesh repair of strangulated hernia without resection
1707096|NCT01411241|Biological|Pneumococcal vaccine|0.5 mL, intramuscular
1707097|NCT01411228|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 24 months
1707098|NCT01411215|Drug|Enbrel|25mg biweekly or 50mg per week, subcutaneous injection
1707099|NCT01411202|Drug|Doxycycline|One time injection 500mg of powdered doxycycline reconstituted with 50cc of normal saline via Pleurx catheter
1707263|NCT01409811|Other|laboratory biomarker analysis|Correlative studies
1707054|NCT01411384|Procedure|Corneal collagen cross-linking|The same surgical procedure was applied to all keratoconus patients that included: Instillation of proparacaine hydrochloride 0.5% drops for topical anaesthesia, application of a sponge saturated with 10% alcohol to the central cornea for 30 seconds and subsequent de-epithelialization. Following de-epithelialization, a mixture of 0.1% riboflavin in 20% Dextran solution was instilled to the cornea for 30 minutes (2 drops every 2 minutes) prior to the irradiation, until the stroma was completely penetrated and aqueous was stained yellow. An 8.0mm diameter of central cornea was irradiated for 30 minutes by UVA light with a wavelength of 370nm and an irradiance of 3mW/cm2. Instillation of riboflavin drops (1 drop every 2 minutes) was continued during irradiation. Balanced salt solution (BSS) was applied every 6 minutes to moisten the cornea.
1707055|NCT01411384|Device|Ocular Response Analyzer (ORA)|An air puff is released by a non-contact probe, which scanned the central area of the eye and send a signal to the ORA device. The air puff causes the cornea to move inward, past applanation, and into slight concavity. After milliseconds, the air pumps shut off, the pressure decreases, and the cornea begins to return in its normal state. The system monitors the entire process and measures two pressure values, which are determined from the inward and outward applanation processes. The aforementioned measuring procedure enables the determination of Corneal Hysteresis and Corneal Resistance Factor.
1707058|NCT01411358|Biological|non-elderly aged between 18 and 60|one dose of 0.5mL AdimFlu-S
1707059|NCT01411358|Biological|elderly aged over 60|one dose of 0.5mL AdimFlu-S
1707060|NCT01411345|Radiation|Standard Salvage Radiation Treatment (SSRT)|A total dose of 68 Gy will be delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.
1707061|NCT01411345|Radiation|Mapped Tumor Salvage RT (MTSRT)|Dose escalation to the Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.
1707062|NCT01411345|Behavioral|Expanded Prostate Cancer Index Composite-SF12|Expanded Prostate Cancer Index Composite-Sf12 (EPIC SF12) quality of life questionnaire to be administered to study participants at protocol-defined intervals.
1707063|NCT01411345|Behavioral|Memory Anxiety Scale for Prostate Cancer patients|Memory Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire to be administered to study participants at protocol-defined intervals.
1707064|NCT01411345|Behavioral|International Prostate Symptom Score (IPSS)|International Prostate Symptom Score (IPSS) quality of life questionnaire to be administered to study participants at protocol-defined intervals.
1707065|NCT01411332|Radiation|SIMRT|A total dose of 80 Gy will be delivered in 40 fractions to the Clinical Target Volume (CTV).
1707066|NCT01411332|Radiation|HTIMRT|Dose escalation to the Multiparametric MRI (MP-MRI) by dose painting at 2.35-2.40 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 76 Gy. The hypofractionated targeted (HT) boost region will receive an absolute dose of 89.3-91.2 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 95.5 Gy in 2.0 Gy fractions.
1707067|NCT01411332|Behavioral|EPIC SF-12 Questionnaire|Expanded Prostate Cancer Index Composite-Short Form 12 (SF12) (EPICSF-SF12) quality of life questionnaire prior to, during and post radiation therapy per protocol.
1707068|NCT01411332|Behavioral|MAX-PC Questionnaire|Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) questionnaire prior to, during and post radiation therapy per protocol.
1707069|NCT01411332|Behavioral|IPSS Questionnaire|International Prostate Symptom Score (IPSS) questionnaire prior to, during and post radiation therapy per protocol.
1707070|NCT01411319|Radiation|Lattice Extreme Ablative Dose Radiation Therapy|12 - 14 Gy dose pipes in 1 fraction to the multiparametric MRI defined gross tumor volumes (GTV) on Day 1.
1707071|NCT01411319|Radiation|Standard IMRT|76 Gy in 38 fractions (2 Gy daily) of Standard Intensity-modulated radiation therapy (IMRT) starting on Day 2 for 7.5 weeks.
1707072|NCT01411319|Behavioral|EPIC SF-12 Questionnaire|Expanded Prostate Cancer Index Composite-Short Form 12 (EPIC-SF12) quality of life questionnaire at various time points per study protocol.
1707073|NCT01411319|Behavioral|MAX-PC Questionnaire|Memorial Anxiety Scale for Prostate Cancer patients (MAX-PC) quality of life questionnaire at various time points per study protocol.
1707074|NCT01411319|Behavioral|IPSS Questionnaire|International Prostate Symptom Score (IPSS) quality of life questionnaire at various time points per study protocol.
1707075|NCT01411306|Other|Toronto Bedside Swallowing Screening Test (TOR-BSST©)|All enrolled patients will be screened for dysphagia by two blinded screeners using the TOR-BSST©.
1707076|NCT01411306|Procedure|Videofluoroscopic Swallow Study|All enrolled patients will undergo a videofluoroscopic assessment of swallowing within 24 hours of being screened with the TOR-BSST©.
1707077|NCT01411293|Other|Low-Fat Milk|Participants will ingest 2 cups of low-fat milk on 1 occasion.
1707078|NCT01411293|Other|Rice Milk|Participants will ingest 2 cups of rice milk on 1 occasion.
1707079|NCT01411280|Drug|methylphenidate|Ritalin 10mg, Ritalin 20mg
1707080|NCT01411267|Drug|AC220|Dose assigned at study entry. AC220 will be given orally once daily on days 7-28.
1707081|NCT01411267|Drug|Cytarabine|"1000 mg/m2/day IV given every 12 hours on days 1 through 5.
IT cytarabine given intrathecally to patients with AML on day 0 of course 1 and 2. Dose defined by age
30 mg for patients age 1-1.99 years of age
50 mg for patients age 2-2.99 years of age
70 mg for patients >3 years of age"
1707082|NCT01411267|Drug|Etoposide|150 mg/m2/day IV on days 1 through 5.
1707100|NCT01411202|Other|normal saline|One time injection of normal saline (placebo) into Pleurx catheter
1767249|NCT00334815|Drug|etoposide|Given IV
1956209|NCT02926430|Biological|Ad26.RSV.preF 5*10^10 vp|Ad26.RSV.preF will be given at a concentration of 5*10^10 vp/0.5 milliliter (mL).
1956210|NCT02926430|Biological|Ad26.RSV.preF 1*10^11 vp|Ad26.RSV.preF will be given at a concentration of 1*10^11 vp/0.5 milliliter (mL).
1956211|NCT02926430|Drug|Placebo|Participants will receive placebo as formulation buffer.
1707105|NCT01411150|Drug|Creatine Monohydrate|Up to 30 grams daily creatine monohydrate
1707106|NCT01411137|Drug|IPX066|"Subjects were converted from their current treatment to IPX066 over a 6-week period.
Experimental Drug Product: IPX066 (carbidopa-levodopa) extended-release capsules"
1707107|NCT01411124|Drug|gabapentin enacarbil|600 mg investigational compound
1707108|NCT01411124|Drug|diphenhydramine|50 mg active comparator
1707109|NCT01411124|Drug|placebo|placebo
1707110|NCT01411111|Drug|Rosuvastatin 10 mg|days 1-14
1707111|NCT01411111|Drug|GSK2190915 30mg|1x30mg tablet, days 8-14
1707112|NCT01411111|Drug|GSK2190915 100mg|1x100mg tablet, days 8-14
1707113|NCT01411098|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
1707114|NCT01411098|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1707115|NCT01411098|Drug|cisplatin|Given IV
1707116|NCT01411098|Drug|etoposide|Given IV
1996765|NCT02384109|Behavioral|Shared decision-making with pharmacists|Pharmacist will engage patient using Healthwise (TM) Decision Tool to help match their personal preferences and values with treatment options, specifically lifestyle change with a goal of 7% weight loss or metformin. Patients interested in lifestyle change will be referred to a CDC (Center for Disease Control and Prevention)-approved diabetes prevention program, and pharmacists will coordinate with primary care providers to prescribe metformin for patients interested in this treatment.
1707118|NCT01411072|Drug|gemcitabine|Gem 1000 mg/m2 IV weekly for 3 weeks then one week off of each 28 day cycle
1707119|NCT01411072|Drug|5-fluorouracil|5-FU 425 mg/m2 and Leucovorin 20 mg/m2 IV day 1, 2, 3, 4, and 5 of each 28 day cycle
1707120|NCT01411059|Behavioral|yoga|yoga classes 2 times per week for 32 weeks
1707121|NCT01411046|Diagnostic Test|Synacthen test|250 microg Synacthen test, performed fasting, in the morning, starting between 08·00 and 10·30 h, after an overnight fast and a prednisolone pause of approximately 48 hours (depending on normal dose administration time).
1707122|NCT01411020|Procedure|endotracheal intubation|to perform endotracheal intubation if number of bispectral index (BIS) is 40-60,
1707123|NCT01410968|Drug|vacc. w/ Poly-ICLC & peptide-pulsed dendritic cells|Intradermal injection of 1x107 peptide-pulsed dendritic cells followed by intramuscular injection of 30 micrograms per kilogram Poly-ICLC on days 0, 14, 28 and 42. Additional dose of 30 micrograms per kilogram Poly-ICLC on days 3, 17, 31 and 45. Treatment given via one 56-day cycle. Leukapheresis performed at baseline for dendritic cell generation.
1707124|NCT01410955|Dietary Supplement|Probiotic formula|Probiotic formula Colon DophilusTM , will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
1707125|NCT01410955|Dietary Supplement|Placebo|Placebo capsules will be administered at a dose of 3x1 cps per day orally for 12 weeks. In the first cycle the starting dose is 3x1 cps per day. In other cycles the starting dose is 3x1 cps per day, or the dose according to dose adjustments from the previous treatment cycle.
1707126|NCT01410942|Other|Placebo|Capsules by mouth twice daily.
1707127|NCT01410942|Drug|Methylphenidate|Starting dose 5 mg by mouth twice daily.
1707128|NCT01410942|Behavioral|Counseling Sessions|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each.
1707129|NCT01410942|Other|Sham Exercise|Participants in placebo/sham exercise intervention meet with exercise physiologist in person on first visit to learn stretching exercises and receive written instructions same as those receiving exercise therapy.
1707130|NCT01410942|Other|Standardized Exercise Intervention Program|Resistance exercise sessions completed 3 days a week allowing at least 48 hours between each session, and walk minimum of 5 days a week at intensity and duration established by exercise physiologist.
1707131|NCT01410942|Other|Cognitive Behavioral Therapy (CBT)|8 weekly sessions (1 in person and 7 by telephone) lasting 45 minutes each, during which review learned relaxation skills and taught new cognitive and/or behavioral skill.
1707132|NCT01410929|Procedure|Kyphoplasty/Vertebral Augmentation (Device-StabiliT)|Targeted Vertebral Augmentation for the treatment of pathological fractures of the spine caused by multiple myeloma
1707133|NCT01410916|Drug|Eculizumab (Soliris®)|Eculizumab 300 mg, 600 mg, 900 mg or 1200 mg will be administered intravenously
1707134|NCT01410903|Device|TheraSorb Ig|1,5 plasma volume per treatment venovenous immunoadsorption frequency: three times weekly in week 1 and 2, two times weekly in week 3-6, two times two-weekly in week 7-12 duration: 12 months
1707135|NCT01410890|Biological|alglucosidase alfa|Intravenous (IV) infusion of 20mg/kg body weight every other week (qow)
1707136|NCT01410864|Device|DuraSeal Exact Spine Sealant System|DuraSeal Exact Spine Sealant System will be administered to those eligible patients, to treat a dural opening.
1707137|NCT01410864|Other|Control|Devices or drugs used to seal the dura (other than DuraSeal)
1707138|NCT01410851|Other|dietary treatment|A within-subject, balanced repeated-measures design was followed where subjects received 4 treatments or control over 5 weeks approximately 1 week apart. The pulse treatments contained: (1) chickpeas (Primo, Toronto, ON), (2) lentils (Primo, Toronto, ON), (3) navy beans (Ferma, Toronto, ON) or (4) yellow peas (Nupak, Toronto, ON).
1707139|NCT01410838|Other|Broth|200 mL of sodium chloride containing broth, consumed three times per day
1707140|NCT01410838|Other|Broth|200 mL of MSG containing broth consumed three times per day
1707141|NCT01410825|Biological|Retrovirus-mediated gene transfer|Two procedures: 1) Bone marrow harvest from the patient's posterior iliac crests or collection of peripheral blood stem cells via apheresis procedure. 2) One time infusion of patient's transduced bone marrow cells.
1707145|NCT01410799|Drug|Growth Hormone Releasing Hormone (GHRH )|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 PM, 1:00 AM, 3:00 AM, and 5:00 AM for 12 weeks
1707146|NCT01410786|Procedure|Conventional Instrumentation|Standard Oxford surgical instruments
1707147|NCT01410786|Procedure|Signature Custom Guides|Signature Custom Guides used with Instruments in surgical technique
1707148|NCT01410773|Device|Ninja 2 Investigational Blood Glucose Monitoring System|The Ninja 2 meter is a Bayer investigational meter that uses an investigational sensor.
1707264|NCT01409811|Procedure|therapeutic conventional surgery|Undergo definitive lumpectomy or mastectomy
1707265|NCT01409772|Drug|Ethanol Lock|Ethanol Lock
1707149|NCT01410760|Other|Perfusion CT scan|Patients in this imaging substudy of the FOXFIRE clinical trial will undergo a perfusion CT prior to FOXFIRE protocol therapy( Ox/MDG chemo alone for 12 cycles in arm A or OX+MDG chemo for 12 cycles with Yttrium 90 SIRshpheres liver radioembolisaton in arm B cycle 2) on Day 1/2 cycle 2, Day 1/2 cycle 3 and Day 1/2 cycle 5 chemotherapy.
1707150|NCT01410747|Drug|Tacrolimus|oral
1707151|NCT01410734|Drug|Indocyanine green (ICG)|2.5mg indocyanine green (ICG) will be administerly (IV injection) 30 minutes before surgery
1707152|NCT01410721|Behavioral|Cognitive Rehabilitation Intervention|Baseline training and follow-up at two months and four months.
1707153|NCT01410721|Behavioral|Cognitive Rehabilitation Control Intervention|Baseline training and follow-up at two months and four months.
1707154|NCT01410708|Drug|Dasatinib|
1707155|NCT01410695|Drug|masitinib|
1707156|NCT01410695|Drug|masitinib|
1707157|NCT01410695|Drug|methotrexate|
1707158|NCT01410682|Other|0,12% digluconate chlorhexidine|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
1707159|NCT01410682|Other|toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posterior to anterior movements.
1707160|NCT01410669|Behavioral|Motivational interviewing (MI)|"MI is a client-centered counseling approach developed to deliver stage-tailored intervention messages using non-confrontational, supportive communication strategies. The client is encouraged to explore the barriers and facilitating factors associated with the behavior change. The interviewer's role is to guide the conversation and avoid use of conventional directive approaches (e.g., persuasion, providing information).
In this trial, a trained motivational interviewer meets individually with patients randomized to the intervention for one-hour at baseline, followed by four MI telephone follow up contacts at 1-, 2-, and 4-months post baseline."
1707161|NCT01410656|Behavioral|Telephone Implementation Intention|Telephone implementation intention counseling
1707162|NCT01410656|Behavioral|Self-completed implementation intention|Self-administered implementation intention intervention
1707163|NCT01410643|Other|Macronutrient Modification|reduced carbohydrate versus standard carbohydrate diet
1996766|NCT02384109|Other|Standard care from primary care providers|Primary care providers address pre-diabetes as part of usual care, which may involve no action, referrals, or treatment with medications.
1996767|NCT02383316|Other|Oral Glucose tolerance test|Oral glucose tolerance test (OGTT): glucose and insulin levels will be measured at time points 0, 90 and 120 min or 30, 60, 90 and 120 after 1.75 g/Kg (max 75 g) glucose administration depending of the patient weight.
1707167|NCT01410617|Procedure|hemodialysis|3 sessions hemodialysis before CABG
1707168|NCT01410604|Drug|Metformin|Tablet of 500 mg metformin, oral every 12 hours (total metformin dose of 1 g/day) for 3 months.
1707169|NCT01410604|Drug|Placebo|Tablet of 500 mg oral placebo every 12 hours for 3 months.
1707170|NCT01410591|Device|8-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
1707171|NCT01410591|Device|10-mm covered stent group|Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
1707172|NCT01410565|Drug|Apaziquone|Apaziquone 4 mg in 40 mL diluent
1707173|NCT01410565|Drug|Placebo|Placebo for Double Blind Phase
1707174|NCT01410552|Device|PARADYM DR model 8550; PARADYM CRT model 8750; PARADYM RF DR model 9550; PARADYM RF CRT model 9750; PARADYM RF CRT SonR model 9770|PARADYM ICD and CRT-d with PARAD+ algorithm available
1707175|NCT01410539|Device|OCT guided PCI|OCT guided PCI. Only thrombectomy in case of negative OCT findings (other than uncovered struts).
1707176|NCT01410539|Drug|OCT guided medical therapy|OCT guided medical therapy. Tailored antiplatelet therapy.
1707177|NCT01410513|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
1707178|NCT01410500|Drug|Carfilzomib|Carfilzomib was administered as an intravenous (IV) infusion over approximately 10 minutes on Days 1, 2, 8, 9, 15, and 16 of repeated 28-day cycles at a dose of 20 mg/m² on Days 1 and 2 of Cycle 1 and 27 mg/m² for all infusions thereafter until Cycle 12. For Cycle 13 and higher for those still receiving carfilzomib, the carfilzomib infusion schedule was abridged to Days 1, 2, 15, and 16 of each subsequent 28-day cycle. Carfilzomib treatment was continued until disease progression, diagnosis of a new malignancy, unacceptable toxicity, withdrawal of consent, or the study was terminated
1707179|NCT01410474|Biological|Meningococcal ACWY conjugate vaccine|All subjects received a single dose of Meningococcal ACWY conjugate vaccine and had blood draw at day 1 and day 29.
1707180|NCT01410461|Device|quantitive sensory testing|Mechanical pain threshold: Threshold will be assessed, by using the von Frey filaments. The lowest gram weight capable of inducing pain in two of three trials will be considered as a pain threshold Heat pain threshold (HPT): HPT will be measured using thermal sensory analyzer
1707181|NCT01410461|Device|Ultrasound testing|Morphological measures of the pelvic muscles: Using a 3D 4-8MHz abdominal probe ultrasound testing will be performed. The following parameters will be measured: (1) anteroposterior hiatal diameter; (2) lateral hiatal diameter; (3) levator ani thickness and length at 3 o'clock and 9 o'clock; (4) length of the obturator (5) length of the pubococcygeus muscle; (6) obturator thickness.
1707182|NCT01410448|Drug|Everolimus|Everolimus was provided in blisters containing 0.25 and 0.75 mg tablets and was taken orally.
1707183|NCT01410448|Drug|Mycophenolate sodium|Two 360 mg tablets were administered twice daily at 12-hour intervals. The tablets were swallowed whole in order to maintain the integrity of the enteric coating.
1707184|NCT01410448|Drug|Cyclosporine|Cyclosporine was supplied as blisters containing 100 mg, 50 mg, 25 mg and 10 mg soft-gelatin capsules and was administered orally.
1707185|NCT01410448|Drug|Steroids|Steroids were administered according to local clinical practice.
1707186|NCT01410435|Drug|Monofer|Infusion according to current HB level
1707688|NCT01406535|Drug|Vardenafil|5 mg vardenafil per os twice daily
1707195|NCT01410383|Drug|Placebo|Tablets taken daily
1707196|NCT01410383|Drug|Eprotirome|Tablets taken daily
1707197|NCT01410383|Drug|Eprotirome|Tablets taken daily
1707198|NCT01410370|Radiation|6MV-X ray|3Gy/time, 5 times/week, a total of 10 times
1707199|NCT01410370|Drug|Endostar|7.5mg/m2/d, continuous infusion, in parallel with radiotherapy
1707200|NCT01410357|Behavioral|Targeted Training in Illness Management (TTIM)|This intervention blends psychoeducation, problem identification/goal-setting, behavioral modeling and reinforcement via use of Peer Educators, and health care linkage, has been adapted to the primary care setting and targeted for SMI-DM participants. Generalizability is enhanced with relatively brief in-person participation requirements and by utilizing professional staff typically found in primary care. TTIM will stress information sharing that is accessible to participants, and through a collaborative process, foster motivation for SMI-DM self-management.
1707201|NCT01410344|Drug|Fludarabine and Busulfan|"RIC Regimen (Flu/Bu): Fludarabine total dose: 120-180 mg/m^2, Busulfan: ≤ 8 mg/kg PO or 6.4 mg/kg IV). Recommended regimen:
Days -6 to -2: Flu (30 mg/m^2/day, total dose of 150 mg/m^2)
Days -5 to -4: Busulfan (4mg/kg/day PO or 3.2 mg/kg IV, 130 mg/m^2/day, total dose of 8 mg/kg PO or 6.4 mg/kg IV, or 260 mg/m^2 IV, respectively)
Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.
Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
1707202|NCT01410344|Drug|Fludarabine and Melphalan|"RIC Regimen (Flu/Mel): Fludarabine total dose: 120-180 mg/m^2, Melphalan total dose: less than or equal to 150 mg/m^2. Recommended regimen:
Days -5 to -2: Flu (30mg/m^2/day, total dose of 120 mg/m^2)
Day -1: Mel (140mg/m^2)
Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage."
1707203|NCT01410344|Drug|Busulfan and Fludarabine|"MAC Regimen (Bu/Flu): Fludarabine total dose: 120-180mg/m^2 Busulfan total dose less than or equal to 16mg/kg PO or 12.8 mg/kg IV. Recommended regimen:
Days -5 to -2: Busulfan (4 mg/kg/day PO with Bu Css 900 plus/equal to 100 ng/mL (or per institutional standard), 3.2 mg/kg/day IV or 130 mg/m^2/day IV; total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively)
Days -5 to -2: Flu (30 mg/m^2/day, total dose of 120 mg/m^2)
Patients with a creatinine clearance of 40-70 ml/min (measured or calculated) should have a 20 percent dose reduction in Fludarabine dosage.
Busulfan will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs more than 125 percent of IBW, in which case the drug will be dosed according to the adjusted IBW."
1707204|NCT01410344|Drug|Cyclophosphamide and Total Body Irradiation|"MAC Regimen (Cy/TBI): Cyclophosphamide total dose: 120 mg/kg, Fractionated TBI total dose: 1200-1420 cGy Recommended regimen:
Days -7 to -4: TBI (total dose of 1200-1420 cGy)
Days -3 to -2: Cy (60 mg/kg/day, total dose of 120 mg/kg)
Cyclophosphamide will be dosed according to the recipient's ideal body weight (IBW), unless the patient weighs less than IBW, in which case the drug will be dosed according to the actual body weight."
1707205|NCT01410331|Biological|JVS-100(4 mg) or placebo/8 injections|4 mg of JVS-100 or placebo delivered in 8 injections
1707206|NCT01410331|Biological|JVS-100(8 mg) or placebo/8 injections|8 mg of JVS-100 or placebo delivered in 8 injections
1707207|NCT01410331|Biological|JVS-100(8 mg) or placebo/16 injections|8 mg of JVS-100 or placebo delivered in 16 injections
1707208|NCT01410331|Biological|JVS-100(16 mg) or placebo/16 injections|16 mg of JVS-100 or placebo delivered in 16 injections
1707209|NCT01410292|Other|GI and fiber meals|meals with different fiber content and glycemic index
1707210|NCT01410292|Other|meals|four different meal regarding GI and fiber content
1707211|NCT01410279|Other|Inspiratory muscle training|The load is adjusted weekly in thirty percent of maximal inspiratory pressure of the subject.
1707212|NCT01410266|Other|Alternative follow-up|Alternative follow-up consists of a self-administered semi-quantitative pregnancy test designed to measure urine beta-hCG levels, and a self-administered questionnaire consisting of 7 questions. Results of both are reviewed by the provider to determine if in-clinic follow-up is needed.
1707213|NCT01410253|Other|Combination of four techniques of physiotherapy|The patients receive conventional physiotherapy, expiratory positive airway pressure, inspiratory muscle training and physical exercise. Twice daily for seven days
1707214|NCT01410253|Other|Combination of three techniques of physiotherapy|Patients receive conventional physiotherapy, expiratory positive airway pressure and physical exercise. Twice daily for seven days
1707215|NCT01410253|Other|Combination of two techniques of physiotherapy|Patients receive conventional physiotherapy,expiratory positive airway pressure respiratory muscle training. Twice daily for seven days
1707216|NCT01410253|Other|standard therapy|Patients receive conventional physiotherapy and expiratory positive airway pressure. Twice daily for seven days
1707217|NCT01410240|Procedure|Standard of Care|Conventional hemostatic techniques, such as cautery and manual compression, will be used.
1707260|NCT01409837|Drug|Lisinopril|"The two groups of patients, A and B, were randomly allocated treatments in a double-blind fashion. Group A was started on the coded drug DY1 while group B was started on the coded drug DZ2. Both DY1 and DZ2 were very identical in appearance. At week 96 the drugs were swopped between the groups such that group A changed to drug DZ2 while group B changed to drug DY1. There was no intervening washout period. The codes were concealed until after the data analysis."
1769214|NCT00353340|Drug|sodium bicarbonate|
1707218|NCT01410240|Drug|FLOSEAL Hemostatic Matrix + Standard of care|"FLOSEAL will be applied topically to areas of the knee where bleeding is observed (e.g. cut bone surfaces, subcutaneous tissue, posterior joint capsule, synovial tissue, medial and lateral gutters, branches of the genicular vessels, and suprapatellar pouch) and will occur intraoperatively. Sufficient amounts of FLOSEAL will be applied quickly using the provided applicators, followed by immediate approximation with a damp gauze, lap pad or sponge for approximately 2 minutes.
+ Standard of care: conventional hemostatic techniques, such as cautery and manual compression, will be used"
1707219|NCT01410227|Biological|Recombinant von Willebrand factor (rVWF)|Intravenous administration
1707220|NCT01410227|Drug|Placebo|Syringe supplied with physiologic saline solution for infusion
1707221|NCT01410227|Biological|Recombinant factor VIIII (rFVIII)|Intravenous administration
1707222|NCT01410214|Drug|Erlotinib|In the adjuvant treatment phase, erlotinib 150 mg/day taken orally for 2 years or till disease progression or unacceptable toxicity.
1707223|NCT01410214|Drug|vinorelbine/cisplatin|In the adjuvant treatment phase, patient will receive vinorelbine 25mg/m2 IV on day 1 and day 8, and cisplatin 25mg/m2 on day 1 and day 2 and day 3, of a 3-week schedule for 4 cycles or till disease progression or unacceptable toxicity.
1707224|NCT01410201|Drug|Dexamethasone Intravitreal Implant|Half of the study participants (15 out of 30) will receive one - Dexamethasone Intravitreal Implant 0.7 mg.
1707225|NCT01410188|Drug|OPA-6566|OPA-6566, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
1707226|NCT01410188|Drug|Placebo|Placebo, 2 dosing schedules (one drop once per day for 2 weeks and twice per day for 2 weeks)
1707227|NCT01410188|Drug|Latanoprost|Latanoprost (one drop once per day for 4 weeks)
1707228|NCT01410175|Device|Conventional scalpel|Use of conventional scalpel to incise the skin and subcutaneous layers.
1707229|NCT01410162|Drug|Tacrolimus|tacrolimus extended release capsules vs Prograf
1707230|NCT01410149|Other|PAV|Proportional Assist Ventilation will be used to ventilate the patient for a 24 hour period
1707231|NCT01410149|Other|PSV|Pressure Support Ventilation will be used to ventilate the patient for a 24 hour period
1707232|NCT01410149|Other|ACV|Assist Control Ventilation will be used to ventilate the patient for a 24 hour period
1707233|NCT01410136|Procedure|Chondrofix Osteochondral Allograft|Allogeneic, cylindrical, decellularized, osteochondral graft composed of hyaline cartilage and bone
1707234|NCT01410123|Other|Integrated Stepped Care (ISC)|"At risk drinking:
Step 1: Brief negotiated interview (BNI) + booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction Physician Management + Alcohol pharmacotherapy
Alcohol abuse/dependence:
Step 1: Addiction Physician Management + Alcohol Pharmacotherapy; Step 2: Motivational Enhancement Therapy; Step 3: Detoxification and aftercare
Moderate Alcohol + Liver Disease:
Step 1: Brief Negotiated Interview (BNI)+ booster; Step 2: Motivational Enhancement Therapy; Step 3: Addiction physician management + alcohol pharmacotherapy."
1707235|NCT01410123|Other|Treatment as Usual|The TAU arm will receive a handout with alcohol information embedded within general health-related information (exercise, smoking cessation, and flu vaccination) and standard care as provided by their treating physician. All patients will have access to a NIAAA informational website.
1707236|NCT01410110|Behavioral|Cognitive Training + Work Therapy|Cognitive training for 5 hours per week for 13 weeks and 15 hours of work therapy
1707237|NCT01410110|Behavioral|Work Therapy|20 hours per week of work therapy
1996768|NCT02382003|Behavioral|Positive Cognitive Bias Modification - Interpretation|Training involves presenting participants with brief scenarios that introduce an ambiguous potential threat. Critically, the ambiguity regarding how the situation is resolved remains until the last word of the scenario, which is presented as a word fragment that the participant must solve, which will then assign a benign (rather than threatening) meaning to the scenario.
1707240|NCT01410084|Dietary Supplement|Vitamin D3|100,000 IU vitamin D3 once monthly for 5 months
1707241|NCT01410084|Dietary Supplement|Vitamin E|400 IU vitamin E once monthly for 5 months
1707243|NCT01410045|Procedure|Ovariectomy|Ovarian cryopreservation has been used in an effort to preserve fertility in patients undergoing treatments which lead to premature and severe ovarian insufficiency.
1707244|NCT01410032|Procedure|Plate fixation|Reconstruction plate
1707245|NCT01410032|Procedure|ESIN|ESIN (Elastic Stable Intramedullary Nailing)
1707246|NCT01410019|Other|Gene transfer|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) GAMMARETROVIRAL vector pSRS11.EFS.IL2RG.pre
1707247|NCT01409993|Drug|Sildenafil|Sildenafil 25 mg by mouth three times a day for three months
1707248|NCT01409993|Drug|Placebo|Matching placebo three times a day for three months
1707249|NCT01409993|Diagnostic Test|Hyperglycemic clamp|Subjects with prediabetes will have a baseline hyperglycemic clamp (Aim 1) and then receive sildenafil or placebo for 3 months. Another hyperglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
1707250|NCT01409993|Diagnostic Test|Euglycemic clamp|Subjects with prediabetes will have a baseline euglycemic clamp (Aim 2) and then receive sildenafil or placebo for 3 months. Another euglycemic clamp will be performed followed by another 3 months off drug and an oral glucose tolerance test.
1707251|NCT01409928|Device|LAP-BAND (Allergan, Inc.)|Laparoscopic placement of adjustable gastric banding system for the treatment of severe obesity.
1707252|NCT01409915|Drug|Sagramostim|5 subjects 250 mcg /m2/day Leukine subcutaneously for 5 days/week for three weeks. Data and Safety Monitoring Board will then review data and recommend whether to continue at the same current recommended dose for additional subjects or to reduce the dose by half if excessive leukocytosis occurs
1707253|NCT01409915|Drug|Saline -- placebo comparator|subcutaneous injection
1707254|NCT01409889|Behavioral|Diabetes Prevention Program|
1707255|NCT01409889|Behavioral|Healthy Living Program|
1707256|NCT01409876|Radiation|brachytherapy|interstitial image- guided PDR/HDR brachytherapy
1707257|NCT01409863|Procedure|laser and standard diamond fraise dermabrasion|standard dermabrasion, CO2 laser resurfacing
1707258|NCT01409850|Device|Aqualizer|The Aqualizer is a soft splint with water-filled pads.
1707259|NCT01409850|Device|Soft splint|
1707261|NCT01409824|Other|CDSS|Clinical Decision Support System
1707266|NCT01409759|Procedure|Perforator based interposition flap|The flap is designed based on a selected perforator and locally available, preferably normal skin adjacent to the burn scar contracture. The flap consists of skin and underlying subcutaneous tissue. Based on the pre-operative defined perforator, the required length and width and the available preferable normal skin, a design for the perforator flap is made.
1707267|NCT01409733|Device|TACE using Drug Eluting Beads loaded with Doxorubicin|100-300 microns DC Beads loaded with Doxorubicin (75mg of Doxorubixcin per vial)
1707268|NCT01409720|Other|exercise|tailored isometric physical exercise
1707269|NCT01409707|Behavioral|Trauma-focused exposure therapy|cognitive behavioral therapy for PTSD
1707270|NCT01409707|Behavioral|Motivational enhancement + trauma-focused exposure therapy|Cognitive behavioral therapy for PTSD
1707271|NCT01409707|Behavioral|Healthy lifestyles sessions|
1707272|NCT01409694|Drug|Memantine|Memantine is administered to all participants according to the usual strategy, with upward titration of 5 mg per week during the first three weeks to reduce the risk of side effects. The final dosage is 20 mg per day, with no subsequent modification of dosage or specialty during the trial.
1707273|NCT01409694|Drug|Vitamin D|Subjects receive Vitamin D supplementation (cholecalciferol 100,000 IU, drinking solution, 2 mL vial) at a rate of 1 drinking vial of 100,000 IU cholecalciferol every month. In brief, the total dose is 600,000 IU over the duration of the study starting with one vial at the time of inclusion, then at week(W) 4, W8, W12, W16 and W20. The dose of vitamin D supplementation will not be adjusted except in case of an adverse event such as hypercalcemia. In this case, vitamin D supplementation is stopped and the participant is released prematurely from the study.
1707274|NCT01409694|Drug|Vitamin D placebo|Subjects receive Vitamin D placebo (drinking solution, 2mL vial) at a rate of 1 drinking vial every month. In brief, the subjects start with one vial at the time of inclusion, then at week(W)4, W8, W12, W16 and W20. The placebo drinking solution contains all the excipients present in the Vitamin D vial.
1707275|NCT01409668|Dietary Supplement|L. Amylovorus|L. Amylovorus
1707276|NCT01409668|Dietary Supplement|L. Fermentum|L. Fermentum
1707277|NCT01409655|Behavioral|cognitive-behavioral therapy|. Reinforcement for medication-taking will be wired to debit cards that patients will be given to receive the payments. This contingent reinforcement of medication-taking will be coupled with twelve sessions of cognitive-behavioral therapy (CBT) conducted by phone, also assisted by the website which will generate CBT-related text messages, reminders and scheduling information from a menu of choices negotiated by the patient and therapist.
1707278|NCT01409642|Behavioral|Individual Child CBT|12 sessions of individual child focused cognitive behavior therapy with a parent component
1707279|NCT01409642|Behavioral|Positive Family Interaction Therapy|Six sessions of family-focused treatment for childhood OCD administered as an adjunct to 12 sessions of child CBT
1707280|NCT01409642|Behavioral|Positive Family Interaction Therapy|Positive Family Interaction Therapy (PFIT) is a 6-session treatment designed to be used as an adjunct to standard child CBT in cases where OCD is complicated by challenging family dynamics.
1707281|NCT01409629|Behavioral|Computer game|Participants will play a computer game
1707282|NCT01409616|Drug|darexaban|oral
1707283|NCT01409616|Drug|darexaban (double dose)|oral
1707284|NCT01409616|Drug|Acetyl Salicylic Acid|oral
1707285|NCT01409616|Drug|clopidogrel|oral
1707286|NCT01409603|Drug|darexaban|oral
1707287|NCT01409603|Drug|Naproxen|oral
1707288|NCT01409590|Behavioral|Exercise program|Homogenous exercise program in local fitness centers
1707289|NCT01409590|Behavioral|Diet|Weigh loss diet program prescribed by a professional nutritionist
1707290|NCT01409564|Drug|Cilostazol|Cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, cilostazol 50mg bid per day will be administered orally.
1707291|NCT01409564|Drug|Placebo|Placebo with similar shape and color to cilostazol 100mg bid per day will be administered orally and the period is total 24 weeks. The first week is a period for increasing the quantity, and during this period, placebo 50mg bid per day will be administered orally.
1707292|NCT01409551|Procedure|VATS hyperthermic chemoperfusion|VATS, adhesiolysis, hyperthermic chemoperfusion (with a pump machine)
1707293|NCT01409551|Procedure|Bedside talc slurry pleurodesis|Bedside tube thoracostomy under local anesthesia. Bedside talc slurry pleurodesis.
1707294|NCT01409538|Other|Placebo Instructions|There is no intervention in this study. It is not a Clinical Trial. The study is an investigation of the neural basis of placebo analgesia.
1707295|NCT01409538|Other|Control condition|"This protocol represents an investigation of the neural mechanisms of placebo analgesia. As such, it does not represent the traditional clinical trial design. Instead the active intervention is a placebo, and the comparison condition is a no-intervention control."
1707296|NCT01409512|Procedure|ECG recording|At baseline and following 3 months on anticholinergic medications patients, ECG recording will be conducted.
1707297|NCT01409499|Procedure|hepatic resection|palliative hepatectomy followed by sorafenib
1707298|NCT01409499|Procedure|transcatheter hepatic arterial chemoembolization|TACE followed by sorafenib
1707299|NCT01409499|Drug|sorafenib|sorafenib monotherapy, 400mg Bid, continuously
1707300|NCT01409486|Other|Drawing blood spots from Newborns|Dry blood spots would be taken for determination of Alpha Glucosidase activity using LC-MS-MS
1707301|NCT01409473|Radiation|Prostate SBRT with concurrent boost to intraprostatic lesion(s)|40 Gy in 5 fractions to prostate for low-risk and 45 Gy in 5 fractions to prostate for intermediate-risk patients, and 50 Gy in 5 fractions to intraprostatic lesion(s), delivered over 10-14 days on preferably every other day.
1707302|NCT01409460|Procedure|Oburator Nerve block|Use of selective pain block.
1707303|NCT01409460|Procedure|Sham Injection in pectineus muscle.|Five minutes after the sham block pain was assessed in these patients. If pain score was 5 or greater a true obturator nerve block was performed on these patients.
1707304|NCT01409447|Device|Biphasic osteochondral composite|We had previously developed a biphasic osteochondral composite as the construct for chondrocyte implantation. We further conducted this feasibility study of such device to treat patients with osteochondral lesion of the knee joints.
1707305|NCT01409434|Drug|Oral Glucose Tolerance Test|Administration of 75 gram oral glucose load and three plasma glucose measurements (including baseline).
1707306|NCT01409421|Behavioral|motivational interviewing|counseling intervention
1707307|NCT01409421|Behavioral|three phone calls to remind patients to take their eye drops|reminder phone calls
1707308|NCT01409408|Drug|Aliskiren|300 mg of aliskiren daily for 8 weeks.
1707309|NCT01409408|Drug|Amlodipine|Amlodipine 5 mg daily for 8 weeks.
1707310|NCT01409395|Drug|Metformin and nizatidine|Subjects will be given a single oral dose of 850 mg of metformin and a single oral dose of 600 mg of nizatidine
1707311|NCT01409395|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
1707312|NCT01409382|Behavioral|Daily brisk walking plus a carbohydrate-restricted diet|Daily brisk walking at moderate speed (4 km/h) for at least 40 minutes per day, 7 days a week. Patients will be recommended to avoid high-glycemic index meals (such as snacks, candies, fiber-free juices and sugar-sweetened beverages), and to eat at least two daily servings of meat, poultry, fish (e.g. 2 g/kg) or other protein-rich food, starting when they decided to get pregnant and continuing until delivery. Recommendations will be emphasised at every appointment. Antidepressants will not be discontinued in both groups, but patients on paroxetine and sertraline, will be switched to fluoxetine.
1707313|NCT01409369|Drug|RO4995819|single oral dose
1707314|NCT01409369|Drug|activated charcoal|orally 3 times daily, Days 1-7
1707315|NCT01409356|Behavioral|Diet + exercise|Program of dietary counselling by dietists, who will periodically follow-up the patient to achieve weight loss; moreover a fitness professional will instruct and train the patients twice a week to enhance their physical activity. A step counter will be also given to all participants and daily step count will be recorded. The duration of diet+exercise is 4 months from baseline HVPG measurement.
1707316|NCT01409343|Drug|TrasGEX™|
1707317|NCT01409330|Dietary Supplement|diet intervention|8-week diet lacking red meat, but containing increased fibers and coffee (verum) versus standard recommendation (control) eating red meat.
1707318|NCT01409317|Device|Deep Transcranial Magnetic Stimulation|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold
1707319|NCT01409317|Device|Repetitive Transcranial Magnetic Stimulation|rTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
1707320|NCT01409304|Device|Deep Transcranial Magnetic Stimulation (DTMS)|DTMS will be administered according to the following parameters: 18 Hz in 84 trains of 2 seconds duration, with 20 seconds inter-train interval (3,024 pulses per session) at 120% of the resting motor threshold.
1707321|NCT01409278|Procedure|Ropivacaine infiltration and saline infusion.|50ml ropivacaine 0.2% with keterolac 15mg infiltration followed by normal saline infusion at 5ml per hour
1707322|NCT01409278|Procedure|Ropivacaine infiltration and infusion.|50 ml infiltration of ropivacaine 0.2% and ketorolac 15mg admixture followed by ropivacaine 0.2 % at 5ml per hour infusion for 48 hours.
1707323|NCT01409278|Procedure|Normal Saline|50ml of normal saline infiltration followed by normal saline infusion at 5ml per hour
1707324|NCT01409239|Drug|Intravenous insulin|24 hr IV insulin administered according to hospital guideline
1707325|NCT01409239|Drug|Subcutaneous Insulin|basal bolus insulin using carb counting technique and insulin analogues
1707326|NCT01409226|Device|3.0-T MRI|Participants undergo MRI prior to biopsy.
1707327|NCT01409226|Procedure|biopsy|Participants undergo breast biopsy after 3.0-T MRI.
1707331|NCT01409187|Drug|Ipilimumab|Starting dose 2 mg/kg by vein on day 1 of each of the four 3-week cycles (Phase II is maximum tolerated dose (MTD) from Phase I). During Consolidation and Maintenance phases one dose every 12 weeks.
1707332|NCT01409187|Drug|Interferon|5 million U/m2 subcutaneously daily for 5 days starting day 1 of each Induction and Consolidation cycle.
1707333|NCT01409187|Drug|Interleukin-2 (Aldesleukin)|9 million IU/m^2 daily by vein by continuous infusion for 4 days (total of 96 hours, days 2-5) starting day 2 of each Induction and Consolidation cycle.
1707334|NCT01409174|Drug|Ipilimumab|"Phase I Starting dose: 1 mg/kg by vein over 90 minutes on Day 1 of each 3 week cycle for Induction 12 weeks, then Day 1 of Cycle 1 for Consolidation 12 weeks and Day 1 of each 12 week cycle in Maintenance.
Phase II dose: Maximum tolerated dose (MTD) from Phase I."
1707335|NCT01409174|Drug|Temozolomide|200 mg/m^2 by mouth 1 time a day on Days 2-5 of each Induction cycle (four 3 week cycles).
1707336|NCT01409174|Drug|Cisplatin|25 mg/m^2 by vein over 1 hour on Days 2-4 of each Induction cycle (four 3 week cycles).
1707337|NCT01409174|Drug|Interferon Alfa-2b|5 million U/m2 subcutaneously on Days 2-6 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
1707338|NCT01409174|Drug|Interleukin-2|9 million IU/m^2 by vein as a continuous infusion on Days 2-5 of each 3 week Induction cycle (four 3 week cycles) and each 4 week Consolidation cycle (three 4 week cycles).
1707339|NCT01409161|Drug|ATRA|45 mg/m2 daily by mouth beginning Day 1 (in 2 divided doses approximately 12 hours apart) for Course 1 (Induction) and during Weeks 1-2 and 5-6 of Courses 2-5 (Consolidation).
1707340|NCT01409161|Drug|ATO|0.15 mg/kg by vein over 1 hour (+/- 10 minutes) daily beginning on day 1, Course 1 (Induction) then over 1-2 hours for 5 days total during Weeks 1-4 of Courses 2-5 (Consolidation). Each course is about 8 weeks.
1707341|NCT01409161|Drug|GO (Gemtuzumab ozogamicin)|9 mg/m2 by vein may be given one time during weeks 1-4 (Induction).
1707342|NCT01409161|Drug|Methylprednisolone|50 mg by vein daily for 5 days followed by rapid taper starting on day 6 (Induction).
1707343|NCT01409148|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2mCi (1 mg)
1707344|NCT01409135|Drug|AGS-22M6E|IV Infusion
1707345|NCT01409135|Drug|ASG-22CE|IV Infusion
1707346|NCT01409122|Drug|15 mg sodium nitrite inhalation solution|15 mg sodium nitrite inhalation solution Q8H
1769215|NCT00353340|Drug|sodium chloride|
1707347|NCT01409122|Drug|90 mg sodium nitrite inhalation solution|90 mg sodium nitrite inhalation solution Q8H
1707348|NCT01409122|Drug|45 mg sodium nitrite inhalation solution|45 mg sodium nitrite inhalation solution Q8H
1707349|NCT01409122|Drug|120 mg sodium nitrite inhalation solution|120 mg sodium nitrite inhalation solution or placebo Q8H
1707350|NCT01409122|Drug|25% MTD sodium nitrite inhalation solution|Multiple oral doses of 20 mg sildenafil will be administered open-label Q8H to a single cohort of eight subjects on Days 1 to 6. A single dose of sodium nitrite inhalation solution equal to 25% of the maximum tolerated dose (MTD) identified in Part A (or placebo) will be administered on Day 4, a single dose equal to 50% of the MTD (or placebo) will be administered on Day 5, and a single dose equal to 100% of the MTD (or placebo) will be administered on Day 6.
1707353|NCT01409083|Device|intravenous sodium bicarbonate|Dilted sodium bicarbonate 2.1%
1707354|NCT01409044|Other|Music|"Music listening for the treatment group. Music is from MusicCure selection Dreams. Outocmes are compared to control group who receives no music. Subjects are randomized Post-operatively."
1707355|NCT01409031|Drug|Intravenous Sildenafil|0.4 mg/kg bolus, followed by a continuous infusion of 1.6 mg/kg/day or an equivalent volume of placebo (D5W); infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
1707356|NCT01409031|Other|Placebo|An equivalent volume of placebo (D5W)infusion will be initiated as a bolus over 3 hours, followed by a controlled continuous infusion for up to 7 days.
1707357|NCT01409018|Drug|Itraconazole|pharmacokinetics
1707358|NCT01409005|Drug|Gemcitabine and UFTE chemotherapy|"Gemcitabine : 800 mg/m2 mix with 150mL of normal saline (i.v.) over 30 min on Days 1, 8 and 15
UFTE : 200mg/m2 PO q 8 hr, Days 1~21
Interval: every 4 weeks"
1707359|NCT01408992|Procedure|Audiometry|Standard hearing test performed by audiologists
1707360|NCT01408992|Other|Thai-Five Minute Hearing Test|All subjects will be interviewed with Thai-Five Minute Hearing Test
1707361|NCT01408979|Drug|Magnesium sulfate 12 hours|Magnesium sulfate, 1g/h, (10% solution), for 12 hours
1707362|NCT01408979|Drug|Magnesium sulfate 24 hours|Magnesium sulfate, 1g/h, (10% solution), for 24 hours
1707363|NCT01408966|Dietary Supplement|DarkChocolate|Dark chocolatee 0.55 g/kg of body weight was given together with the test meal in sitting position after the baseline measurement of HVPG. The meal + chocolate was ingested in 8 minutes.
1707364|NCT01408966|Dietary Supplement|WhiteChocolate|White chocolate 0.63 g/kg white chocolate (Lindt Excellence Natural Vanilla, Lindt & Sprüngli España) in an iso-caloric and iso-volumetric proportion adjusted to body weight was used as a control
1707365|NCT01408953|Biological|bevacizumab|"Bevacizumab will be diluted with 0.9% Sodium Chloride to achieve a concentration of 1 mg/0.3 ml. Bevacizumab will be injected inside ONE keloid tissue to result in a visual expansion of the keloid. Only 1 mg of bevacizumab is injected inside ONE keloid. The injections will be repeated every 14 days. Patients will receive maximum of 12 injections only.
A log will be kept for each patient indicating the date and the dose of bevacizumab that was delivered to each patient."
1707366|NCT01408927|Other|Thienopyridine resistance testing|Thienopyridine resistance will be measured by flow cytometry of vasodilator-stimulated phosphoprotein (VASP) phosphorylation, and/or VerifyNow P2Y12 assay, and/or the Chrono-Log Lumi-Aggregometer, and/or the PlaCor PRT 7000 platelet reactivity assay.
1707367|NCT01408927|Other|Aspirin resistance testing|Aspirin resistance will be measured by the VerifyNow aspirin resistance assay.
1707368|NCT01408927|Other|Genetic polymorphism assessment|The presence of minor alleles in selected single nucleotide polymorphisms (SNPs) as measured by the Applied Biosystems Open Array system.
1707369|NCT01408914|Drug|Higher-Dose Rifampin|The intervention phase of this trial will last 8 weeks. During that time, subjects will receive the following companion drugs: isoniazid (INH, 5 mg/kg/day), ethambutol (EMB, 20 mg/kg/day), and pyrazinamide (PZA, 25 mg/kg/day), pyridoxine (50 mg), the standard doses used in treatment. Subjects will also be randomized to receive one of the following weight-based doses of the study drug, rifampin (RIF): 10 mg/kg/day (standard dose, control), 15 mg/kg/day (intervention 1), 20 mg/kg/day (intervention 2). All patients will receive at least standard dose of RIF, the efficacy of which in multidrug-treatment for TB is well established. Placebo will be used to control only the additional RIF capsules provided in the intervention arms.
1707370|NCT01408901|Behavioral|Supervised Treadmill Exercise Therapy|Exercise intervention will be delivered three times weekly for 26 weeks. In the first week, participants will be asked to exercise 15 minutes per session (excluding rest periods). Walking exercise duration will be increased to 25 minutes minutes per session during week 2. Week 3 and 4 sessions will also be 25 minutes long, but the intensity will be increased either to produce leg symptoms or at a target rate of perceived exertion (RPE)of 12-14 on the Borg's 6-20 scale. For weeks 5-8, walking duration will be increased to 40 to 50 minutes while maintaining intensity. For weeks 9-26, exercise duration will continue to be 40 to 50 minutes but we will increase intensity up to a maximum of 4.0 miles per hour at 10% grade.
1707371|NCT01408901|Other|Health education sessions (Control)|Participants randomized to the attention control group will attend weekly one-hour educational sessions at Northwestern University for six months. These educational sessions are on topics of interest to the typical PAD patient and are led by physicians and other health care workers. Topics include Medicare Part D, nutritional supplements, C-reactive protein, and hypertension. Sessions do not include information about exercise.
1707372|NCT01408901|Drug|granulocyte macrophage colony stimulating factor (GM-CSF)|The dose of GM-CSF will be 250 ug/M^2 subcutaneously three times weekly for two weeks.
1707373|NCT01408888|Biological|LY2189265|Administered subcutaneously
1707374|NCT01408888|Drug|Sitagliptin|Administered orally
1707375|NCT01408875|Device|Low electrical myostimulation|The group of patients randomized for additional EMS will have 20 sessions of 1 hour electrical quadricipital myostimulation.
1707376|NCT01408862|Other|venous puncture|Blood for in vitro studies will be drawn
1707377|NCT01408849|Drug|Maytenus ilicifolia leaves infusion|2 g of powdered leaves in 150 mL of boiling water, 3 times a day, for 8 weeks
1707378|NCT01408849|Drug|Omeprazole|Standard therapy
1707379|NCT01408836|Procedure|Plasma exchange|Plasma exchange
1707380|NCT01408836|Drug|Intravenous methyl prednisolone|Intravenous methyl prednisolone
1707381|NCT01408836|Drug|Methyl prednisolone|methyl prednisolone
1707382|NCT01408810|Drug|Infliximab|5 mg/Kg, I.V. at weeks 0, 2, 6 and every 8 weeks thereafter
1707383|NCT01408797|Procedure|donor specific transfusion|before transplantation,200mL of donor whole blood will be transfused to the recipient
1707384|NCT01408797|Drug|MMF, Bortezomib|MMF and Bortezomib will be administered after donor specific transfusion
1707385|NCT01408797|Procedure|drugs added according to the immuno condition of the recipients|drugs (corticosteroid, MMF and/or CNI) will be added according to the recipients immuno event and donor specific antibody
1707386|NCT01408758|Other|Virtual Clinician Research Tool (VCRT)|The Virtual Clinician Research Tool (VCRT) will use Self-Determination Theory (SDT) to guide the process or style of how two national guidelines (one for hyperlipidemia, 1 for tobacco dependence)will be operationalized into a virtual format that patients can access online using any internet connected personal computer to develop their plan for change (in this project regarding tobacco or nutrition).
1707387|NCT01408758|Other|No VCRT, only physician counseling at visits|No intervention
1707388|NCT01408745|Device|Sternumfix|sternotomy closure with Sternumfix
1707389|NCT01408745|Procedure|steel wire|sternotomy closure with steel wire
1956212|NCT02926378|Procedure|Acupuncture Treatments|Every participant will receive six acupuncture treatments across a three to four-week period. The treatments will last a total of about one hour, including a 10 minute initial assessment, needling, and 45 min of lying down with the needles. Two treatments a week will be performed by Dr. Siminovich-Blok, the PI of this study and a NYS licensed acupuncturist at NYU Langone Medical Center (NYULMC) Ambulatory Care Center. Each acupuncture treatment will consist of 1) a combination of a fixed set of points suggested by the literature, and 2) an individualized set of points based on the evaluation by the licensed acupuncturist. The first set of points will consist of 4 acupoints used consistently in the treatment of stroke through the literature.
1707391|NCT01408719|Dietary Supplement|Control|Minimal beta-glucan
1707392|NCT01408719|Dietary Supplement|3g LMW beta-glucan|3grams beta-glucan
1707393|NCT01408719|Dietary Supplement|5g LMW beta-glucan|5 grams beta-glucan
1707394|NCT01408719|Dietary Supplement|3g HMW beta-glucan|3 grams of high molecular weight beta-glucan
1707395|NCT01408706|Device|Miller Air tip|Miller Enema Air Tip is inserted into rectum prior to simulation and each radiation treatment.
1707396|NCT01408706|Device|Radiadyne Immobilizer|Radiadyne Immobilizer is inserted into rectum prior to simulation and each radiation treatment
1707399|NCT01408680|Dietary Supplement|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 600 mg.
1707400|NCT01408680|Dietary Supplement|Coenzyme Q10|Wafer taken daily by mouth for duration of study, containing Coenzyme Q10 at 1200 mg.
1707401|NCT01408680|Dietary Supplement|Placebo|Wafer taken daily by mouth for duration of study, containing inactive ingredients. Wafer is indistinguishable from those wafers containing CoQ10.
1707402|NCT01408667|Drug|TRC150094|50 mg Tablets once a day
1707403|NCT01408667|Other|Placebo|Tablets once daily
1707404|NCT01408654|Behavioral|Peer Companionship|Peer companionship is provided at least four times per month over two years in the form of friendly visiting, supportive phone calls, and some instrumental support.
1707405|NCT01408641|Drug|Topiramate|Topiramate titrated over 6 weeks to 400mg or highest tolerated dose.
1707406|NCT01408641|Drug|Placebo|Placebo capsules without topiramate
1707407|NCT01408628|Behavioral|Internet Insulin Education|"Offer and assess the safety and effectiveness of a synchronous (live) interactive 4-week Internet course designed to teach groups of type 2 diabetic patients to safely administer basal insulin without significant support from their usual source of diabetic management and to self-adjust the dose to achieve an HbA1c of < 7.0% using an established treat-to-target algorithm."
1707408|NCT01408615|Drug|corifollitropin alfa|100 or 150 microgram single subcutaneous injection
1707409|NCT01408602|Drug|MRC375|MRC 375 (enteric coated Tetracycline) 75mg 3 times a day for 24 weeks.
1707410|NCT01408602|Drug|Matching Placebo|Matching Placebo 3 times a day for 24 weeks. Early escape at week 16,20.
1707411|NCT01408602|Drug|MRC375 150mg|MRC375 (enteric coated Tetracycline) 150mg 3 times a day for 24 weeks
1707412|NCT01408589|Drug|Atomoxetine, Strattera|Atomoxetine at 0, 40, 60, 80 mg/day was given for 5 days, all subjects took two capsules per day for 5 days; all active dose groups received 40 mg/day for first 3 days and where then dose escalated to dosage group assigned.
1707413|NCT01408576|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 consecutive weeks (cumulative dose 2400 mg) over eight 12-week treatment cycles
1707414|NCT01408576|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over eight 12 week treatment cycles
1707415|NCT01408563|Drug|Fludarabine|30 mg/m2/day IV x 6 days
1707416|NCT01408563|Drug|Melphalan|100 mg/m2/day IV x 1 day
1707417|NCT01408563|Radiation|Total Body Radiation|200 cGy on Day 0
1707418|NCT01408563|Biological|Cord Blood|2 cord blood units IV
1707419|NCT01408550|Drug|NPB-01|Intravenous immunoglobulin
1707420|NCT01408550|Drug|Placebo|Physiological saline
1707421|NCT01408537|Biological|JEVAC|Each subject will receive 3 doses of JEVAC subcutaneously on Day 0, 1-4 weeks and a booster vaccination at one year. Each dose of JEVAC contains 0.5 mL. of inactivated Vero cell derived JE vaccine (Beijing P-3 strain).
1707422|NCT01408524|Drug|Diltiazem|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
1707423|NCT01408524|Drug|Labetalol|2.5 mg iv q 2-5 min for keeping SBP below 140 mmHg during the emergence
1707424|NCT01408511|Drug|Mapracorat|Application of the investigational product on the affected skin areas
1707689|NCT01406535|Other|Placebo|5 mg placebo per os twice daily
1707426|NCT01408485|Device|Therapy™ Cool Flex™ Irrigated Ablation System|"The investigational components of the Therapy™ Cool Flex™ Irrigated Ablation System consist of:
Therapy™ Cool Flex™ 4mm Irrigated Ablation Catheter
IBI 1500T9 V1.43 RF Generator"
1707427|NCT01408472|Drug|NT-501 CNTF Implant|Single implantation of CNTF-secreting NT-501 device into one eye
1707430|NCT01408446|Drug|Menthol|Capsule 48mg three times a day after meals 8 weeks
1707431|NCT01408446|Drug|Placebo|Capsule 48mg three times a day after meals 8 weeks
1707432|NCT01408433|Other|Single Embryo Transfer|single embryo transfer of a chromosomally normal embryo
1707433|NCT01408433|Other|Double embryo transfer|two (2) embryo transfer of untested embryos
1707434|NCT01408420|Procedure|MAP > 60 mmHg|During heart surgery a blood pressure with a MAP > 60 mmHg during extracorporeal circulation is used.
1707435|NCT01408407|Other|Aveeno cream|Apply cream on irradiated area twice a day
1707436|NCT01408407|Other|Alkagin paste|Apply Alkagin paste three times a day.
1707437|NCT01408394|Drug|Ecopipam immediate release form|Tablet containing 100 mg of the immediate release form of ecopipam
1707438|NCT01408394|Drug|90 mg controlled release form|This is the 90 mg controlled release form
1707439|NCT01408394|Drug|180 mg controlled release form|This is the 180 mg controlled release capsule
1707440|NCT01408381|Other|Intraarterial Infusion of Autologous Bone Marrow Mononuclear Cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x108, 5x108 and 1x109 low, intermediate and high dose in the arms respectively.
1707441|NCT01408368|Procedure|Bilateral subtotal thyroidectomy|The intervention consisted of bilateral subtotal thyroidectomy (leaving on both sides of the neck thyroid stumps of approximately 2 g of normal remnant tissue each).
1707442|NCT01408368|Procedure|Total thyroidectomy|The intervention consisted of total extracapsular thyroidectomy.
1707443|NCT01408355|Drug|PF-06273588|Intravenous, 50 microgram, single dose
1707444|NCT01408355|Drug|PF-06273588|Oral solution, 50 microgram, single dose
1707445|NCT01408342|Drug|Alemtuzumab and Rituximab|"Alemtuzumab 10 mg (5 mg/m2 in patients under 30 kg weight) subcutaneous days 1,2 and 3
Rituximab 100 mg (50 mg/m2 in patients under 30 kg weight)intravenous days 4,11,18,25
Cyclosporine 3 mg/kg starting day 21"
1707446|NCT01408329|Device|CVAC Device (Cyclic Variations in Altitude Conditioning)|A hypobaric hypoxia chamber
1707447|NCT01408316|Drug|PX-866|Volunteers in part 1 of the study will receive two single dose 8 mg treatments of PX-866 (one each of crystalline PX-866 tablets and amorphous PX-866 capsules) in Periods A and B, separated by at least seven days. Volunteers in part 2 of the study will receive two single dose 6 mg treatments of PX-866 (crystalline PX-866 tablets administered in either fed or fasted state), in Periods C and D, separated by at least seven days.
1707448|NCT01408303|Drug|Olive oil, 4g|Olive oil: 4 x 1 g capsule daily for 6 weeks + prescription statin
1707449|NCT01408303|Drug|omega-3-carboxylic acids, 2g|Epanova: 2 x 1 g capsule + olive oil 2 x 1 g capsule daily for 6 weeks + prescription statin
1707450|NCT01408303|Drug|omega-3-carboxylic acids, 4g|Epanova: 4 x 1 g capsule daily for 6 weeks + prescription statin
1707451|NCT01408290|Biological|Vaccination with FAB-3511|One 0.5 mL injection of FAB-3511 trivalent influenza vaccine containing 3.5μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
1707452|NCT01408290|Biological|Vaccination with FAB-6011|One 0.5 mL injection of FAB-6011 trivalent influenza vaccine containing 6μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
1707453|NCT01408290|Biological|Vaccination with FAB-9011|One 0.5 mL injection of FAB-9011 trivalent influenza vaccine containing 9μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
1707454|NCT01408290|Biological|Vaccination with FluvalAB|One 0.5 mL injection of FLUVAL AB trivalent influenza vaccine containing 15μgHA of seasonal A/H1N1, A/H3N2 and B influenza antigens.
1707455|NCT01408277|Biological|Santyl|2 mm Santyl applied once daily
1707456|NCT01408277|Procedure|Control|Standard Care
1707457|NCT01408264|Device|Conventional 0.035 guidewire|0.035 guidewire
1707458|NCT01408264|Device|Olympus Visiglide 0.025 guidewire|0.025 guidewire
1707459|NCT01408238|Biological|Four different concentrations of Secale cereale allergen extract, positive control and negative control|4 concentrations of Secale cereale allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm
1707460|NCT01408225|Procedure|tissue banking|tissue procurement for this protocol will occur at the time of initial diagnosis, during routine follow-up, or at the time of relapse.
1707461|NCT01408212|Procedure|Acupuncture treatment|"Acupuncture treatment will be performed by licensed doctors in Korean Medicine using 0.20 mm (diameter) X 0.30 mm (length) sized disposable acupuncture on seven to ten consecutive days after admission to the Korean Medicine Hospital of Pusan National University. At least two sessions and a maximum of five sessions of acupuncture therapy will be administered per day. Acupuncture points consist of common points and additional points selected for typical complaints common in patients under chemotherapy. These points are as follows.
Common points: LI4 (bilateral), LU5 (bilateral), LU7 (bilateral), BL13 (bilateral), BL23 (bilateral), SP3 (bilateral), LU9 (bilateral), ST36 (bilateral) and CV22
Additional points Nausea/vomiting PC6 (bilateral) Dyspepsia: CV12, LU6 (bilateral) Insomnia: Yintang, KI5 (bilateral) Pain: Ashi points (tender spots)"
1707462|NCT01408199|Drug|Lenalidomide|5 mg daily will be administered until the achievement of complete response, and then tapered progressively according to clinical response
1707463|NCT01408186|Drug|Rabeprazole|Rabeprazole 20 mg daily
1707464|NCT01408186|Drug|Famotidine|Famotidine 40mg daily
1707465|NCT01408173|Drug|NPC-11 for intravenous or oral administration.|NPC-11, Each vial (3mL) contains 60 mg caffeine citrate (equivalent to 30mg caffeine).
1707466|NCT01408160|Drug|Cytarabine|Given IV
1707467|NCT01408160|Biological|Deglycosylated Ricin A Chain-Conjugated Anti-CD19/Anti-CD22 Immunotoxins|Given IV
1707468|NCT01408160|Other|Laboratory Biomarker Analysis|Correlative studies
1707469|NCT01408160|Other|Pharmacological Study|Correlative studies
1707878|NCT01405157|Drug|methylprednisolone|tablets 16 mg single dose
1707470|NCT01408147|Behavioral|Online postpartum weight control|The intervention group will be given access to an online weight loss program supplemented by monthly group meetings.
1707471|NCT01408134|Other|DE CT|Delayed scan (per VIVA protocol): The delayed scan will be performed 10 minutes after contrast second contrast bolus complete using axial acquisition at 100 kVp. Scan length will be limited to the cardiac structures.
1707472|NCT01408121|Other|Genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay|All patients will undergo genotyping and platelet reactivity testing with the VerifyNow P2Y12 assay, at least 6 hours after receiving a thienopyridine loading dose but before hospital discharge.
1956213|NCT02923908|Other|Noldus Facereader 7|A video recording of a subject's facial expressions while tasting a sweet, bitter, and neutral flavored liquid will be analyzed using Noldus Facereader 7 software.
1956214|NCT02923908|Other|Voice Recording|A voice recording will be made for the duration of the tasting period.
1707475|NCT01408095|Drug|LY2608204|Administered orally
1707476|NCT01408095|Drug|Glimepiride|Administered orally
1707477|NCT01408082|Drug|ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined)|Azithromycin and Dexamethasone twice daily for 2 weeks
1707478|NCT01408082|Drug|Azasite|Azasite twice daily for 2 weeks
1707479|NCT01408082|Drug|Dexamethasone|Dexamethasone twice daily for 2 weeks
1707480|NCT01408082|Other|Vehicle|Vehicle twice daily for 2 weeks
1707481|NCT01408069|Drug|MIGRANE|1 to 2 tablets(ergotamine 1mg + caffeine 100mg + acetylsalicylic 350 mg + homatropine 1,2 mg)
1707482|NCT01408069|Drug|PARCEL|1 to 2 tablets(ergotamine 1mg + paracetamol 450 mg + caffeine 40 mg)
1707483|NCT01408056|Drug|Timolol 0.5% Gel Forming Solution (GFS)|"Dose-based escalation schedule for topical application:
4-8 kg: Day 0-7: 1 drop every other day; Day 7-14: 1 drop daily; Day 14 - Day 60: 1 drop twice per day
8-12 kg: Day 07: 1 drop daily; Day 7-14: 1 drop twice per day; Day 14 - Day 60: 2 drops twice per day"
1707484|NCT01408056|Drug|Mupirocin 2% Ointment|Topical application twice per day for 60 days
1707485|NCT01408043|Drug|plerixafor|Given SC
1707486|NCT01408043|Biological|filgrastim|Given SC
1707487|NCT01408043|Drug|etoposide|Given IV
1707488|NCT01408043|Procedure|leukapheresis|Undergo apheresis
1707489|NCT01408030|Drug|Sterile saline|0.9%, 0.1 ml spray in each nostril bid
1707490|NCT01408030|Drug|Bevacizumab|1% solution in saline, 0.1 ml spray in each nostril bid
1707491|NCT01408030|Drug|Estriol|0.1% suspension in methylcellulose, 0.1 ml spray in each nostril bid
1707492|NCT01408030|Drug|Tranexamic Acid|10% solution in saline, 0.1 ml spray in each nostril bid
1707493|NCT01408004|Drug|Pazopanib|Tablet 800mg qd til progression
1707494|NCT01408004|Drug|Everolimus|tablet 10 mg qd til progression
1707495|NCT01408004|Drug|Pazopanib|tablet 800mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
1707496|NCT01408004|Drug|Everolimus|tablet 10mg qd, alternating schedule: 8 weeks Pazopanib, 8 weeks Everolimus
1707497|NCT01408004|Drug|Everolimus|Everolimus 10mg qd monotherapy until second progression (PD per RECIST 1.1)when first progression after 8 weeks of Pazopanib in alternating regimen
1707498|NCT01408004|Drug|Pazopanib|Pazopanib 800mg qd monotherapy until second progression (PD per RECIST 1.1) when first progression after 8 weeks of Everolimus in alternating regimen
1707499|NCT01407991|Other|enteral tube placement accuracy|The graph method is based on the infants' length determined by measurement using a length board and plotted on a graph derived from a formula to determine the depth for tube insertion (graph method). The graph method has been tested in the pediatric population but not in infants under six months of age (Klazner, Luke and Scalso, 2002). Using a graph method might reduce some of the variability in placement. We propose to extend the Klazner, Luke and Scalso (2002) study in the infant population.
1707500|NCT01407991|Other|NEM method for NG/OG tube placement|measure distance from the mouth to the ear and then the ear to mid abdomen and mark the tube to insert to that length
1707501|NCT01407978|Biological|Vaccination with Fluval P monovalent influenza vaccine|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.
Dose: 0.25 ml /total 3 μg HA/ in age group 3-12 years, and 0.5 ml /total 6 μg HA/ in age group 12-18 years, single dose."
1707502|NCT01407978|Biological|Vaccination with Fluval AB|"Vaccination with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.
Dose: 0.25 ml /total 3x7.5 μg HA/ in age group 3-12 years, 0.5 ml /total 3x15 μg HA/ in age group 12-18 years, single dose."
1707503|NCT01407978|Biological|Vaccination with Fluval AB Novo|"Vaccination with Fluval AB Novo trivalent influenza vaccine with 6 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant.
Dose: 0.25 ml /total 3x3 μg HA/ in age group 3-12 years, 0.5 ml /total 3x6 μg HA/ in age group 12-18 years, single dose."
1707504|NCT01407965|Procedure|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
1707505|NCT01407965|Procedure|microdialysis catheter|Placing of microdialysis catheter in fatty tissue and in the peritoneal cavity
1707506|NCT01407952|Device|HydroCoil Embolic System|HydroCoil Embolic System
1707507|NCT01407952|Device|Control (bare platinum coils)|bare platinum coils
1956215|NCT02923908|Other|5-Point Facial Hedonic Scale|A 5-point facial hedonic scale will be given to the participant to complete prior to the administration of any test substances and about 5, 10, and 30 minutes after the administration of each test substance.
1707509|NCT01407913|Procedure|caudal epidural steroid injection|injecting steroids in the epidural space via caudal route
1708085|NCT01403493|Behavioral|Patient education|
1956216|NCT02923908|Other|Follow-Up Questionnaire|Participants will be asked a few questions about each test agent after tastings.
1956217|NCT02925442|Procedure|t-RFA|standard thermal genicular radiofrequency ablation
1956218|NCT02925442|Procedure|C-RFA|Cooled radiofrequency ablation
1956219|NCT02925442|Procedure|Control|Simulated radiofrequency ablation for placebo controlled group
1707510|NCT01407900|Drug|CD-NP|CD-NP as a four hour infusion at 10 ng/kg/min IV
1707511|NCT01407900|Drug|5% Dextrose in Water|four hour infusion IV
1707512|NCT01407887|Drug|artesunate (AS) - amodiaquine (AQ) - methylene blue (MB)|The group AS-AQ-MB will receive once daily a fixed dose AS-AQ formulation combined with once daily MB over a three days period.
1707513|NCT01407874|Drug|Placebo|Oral dose administered daily for 84 days.
1707514|NCT01407874|Drug|Ulodesine (BCX4208) 5 mg|Oral dose administered daily for 84 days.
1707515|NCT01407874|Drug|Ulodesine (BCX4208) 10 mg|Oral dose administered daily for 84 days.
1707516|NCT01407861|Other|Relaxation Training|Patients participate in a relaxation training program under expert guidance at least three times a week over 12 weeks.
1707517|NCT01407861|Other|Aerobic endurance Training|Patients participate in a moderate aerobic endurance training program under expert guidance three times a week over 12 weeks.
1707518|NCT01407848|Drug|Furosemide|Patients received nebulised Furosemide iv solution 1 mg/kg (4x/d) for max.3 consecutive days.
1707519|NCT01407848|Drug|Saline 0,9%|nebulised 0,9% saline 4x/d for max.3 days
1707520|NCT01407835|Biological|Four different concentrations of Dactylis glomerata allergen extract, positive control and negative control|Four concentrations of Dactylis glomerata allergen extract, together with a positive and negative control will be tested in every patient in duplicate on the volar surface of the forearm.
1707521|NCT01407822|Drug|Erlotinib|In the neo-adjuvant treatment phase, erlotinib 150 mg/day taken orally for 6 weeks(42 days).In the post-surgery phase, erlotinib 150mg/day taken orally for 1 year or till disease progression or unacceptable toxicity.
1707522|NCT01407822|Drug|Gemcitabine/cisplatin|In the neo-adjuvant treatment phase, patient will receive gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles. In the post-surgery phase, Gemcitabine 1250mg/m2 IV on day 1 and day 8, and cisplatin 75mg/m2 on day 1 of a 3-week schedule for 2 cycles or till disease progression or unacceptable toxicity.
1707523|NCT01407809|Device|Venous Sinus Stenting|Venous sinus stenting consists of placing a stent into the narrowed veins of the brain.
1707524|NCT01407796|Drug|Endotoxin (E. coli O:113, Reference Endotoxin)|
1707525|NCT01407796|Drug|[18F](+/-)NOS|
1707526|NCT01407783|Behavioral|Problem Solving Tools (PST)|The problem solving tools was chosen as the depression treatment because it is well suited for use by non-mental health professionals and for in-home treatment. It is also a brief treatment (4-8 sessions) that takes a non-pathologizing approach.
1707527|NCT01407770|Genetic|DNA analysis|Genetic
1707528|NCT01407770|Genetic|gene expression analysis|Genetic
1707529|NCT01407770|Other|enzyme-linked immunosorbent assay|Genetic
1707530|NCT01407770|Other|flow cytometry|Genetic
1707531|NCT01407770|Other|laboratory biomarker analysis|Genetic
1707532|NCT01407770|Other|questionnaire administration|Genetic
1707533|NCT01407770|Procedure|adjuvant therapy|Genetic
1707534|NCT01407770|Procedure|assessment of therapy complications|Genetic
1707535|NCT01407770|Procedure|quality-of-life assessment|Genetic
1707536|NCT01407770|Radiation|3-dimensional conformal radiation therapy|Genetic
1707537|NCT01407770|Radiation|breast irradiation|Genetic
1707538|NCT01407770|Radiation|external beam radiation therapy|Genetic
1707539|NCT01407770|Radiation|hypofractionated radiation therapy|Genetic
1707540|NCT01407770|Radiation|intensity-modulated radiation therapy|Genetic
1707541|NCT01407770|Radiation|whole breast irradiation|Genetic
1707542|NCT01407757|Genetic|DNA analysis|
1707543|NCT01407757|Genetic|gene expression analysis|
1707544|NCT01407757|Other|laboratory biomarker analysis|
1707545|NCT01407757|Other|pharmacogenomic studies|
1707546|NCT01407744|Other|laboratory biomarker analysis|Correlative studies
1707547|NCT01407731|Genetic|protein expression analysis|
1707548|NCT01407731|Genetic|western blotting|
1707549|NCT01407731|Other|laboratory biomarker analysis|
1707550|NCT01407679|Drug|Alitretinoin|1 capsule Alitretinoin 30 mg per day; optional reduction to 10 mg per day in case unacceptable adverse reactions to the higher dose occur
1707551|NCT01407666|Procedure|paravertebral blocks|use bilateral thoracic paravertebral blocks for pain control
1707552|NCT01407653|Procedure|Virtual reality|3 sessions of immersion in a virtual reality 3D environment of 17 minutes per week for 4 consecutive weeks
1707553|NCT01407653|Procedure|Usual care|Classical care
1707554|NCT01407640|Procedure|Allergy tests|1/ to validate a diagnostic algorithm for patients presenting with possible allergy. 2/ to investigate immunogenetic profiles of patient with insulin allergy 3/ cellular mechanisms of IA
1707555|NCT01407627|Dietary Supplement|Fructose|"Subjects will be randomized to one of 2 sequences:
Sequence 1: Fructose (intervention) 200g daily x 14d followed by Dextrose (control) 200g daily x 14d Sequence 2: Dextrose (control) 200g daily x 14d followed by Fructose (intervention) 200g daily x 14d"
1707556|NCT01407614|Procedure|external lumbar drainage (ELD) of cerebrospinal fluid|Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
1707557|NCT01407601|Dietary Supplement|daily supplementation of MK-7 over 6 weeks|once daily intake of MK-7 prior to dialysis over 6 weeks
1707558|NCT01407588|Procedure|Magnetic navigation|Ablation with use of the magnetic navigation system
1707559|NCT01407588|Procedure|Ablation performed with manual navigation|Atrial fibrillation ablation performed with manual navigation
1707560|NCT01407575|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 1.6 mg/day)
1707561|NCT01407575|Drug|Placebo|matched placebo
1707562|NCT01407562|Drug|Pazopanib|Starting dose is 400 given on Days 2-5, 9-12, and 16-26 of each 28 day cycle
1707563|NCT01407562|Drug|Paclitaxel|Starting dose is 60 mg/m2 IV on days 1, 8, and 15 of each 28 day cycle
1707564|NCT01407562|Drug|Carboplatin|Starting dose of carboplatin that corresponds to an AUC of 2, IV on days 1, 8, and 15 of each 28 day cycle
1707638|NCT01406873|Drug|Mexiletine|150 mg/kg Mexiletine capsules taken by mouth, three times daily for 6 months
1708086|NCT01403467|Device|Continuous positive airway pressure|CPAP 8 cmH2O
1707565|NCT01407549|Behavioral|mindfulness group meetings with psychologist|The Mindfulness Program consists of one 2-hour session each week for 6 consecutive weeks plus a half day retreat near the end of the intervention. Participants will attend weekly group meetings (15-20 individuals per group) in which they will be guided through a progressive experiential exploration of mindfulness. Participants will be asked to develop a daily meditation practice of 30-45 minutes with audio-recordings for guidance, and will report the amount and type of practice in a daily dairy. . A psychologist with rich personal experience in mindfulness who is trained in mindfulness based therapy will be responsible for administering the program.
1707566|NCT01407536|Device|Thermal stimulation system|The subjects meeting our criteria will be randomly assigned to either the experimental group (EXP) or the control group (COT). The EXP and COT received upper extremity thermal stimulation protocol for 30 minutes a day for 20 days. The TS temperature of EXP for noxious stimulation was set at 46-47°C for heat and 7-8°C for cold stimulation; the temperature of COT for innoxious stimulation was set at 40°C for warm and 20°C for cold stimulation.
1707567|NCT01407523|Drug|Levetiracetam|"Formulation: concentrate for solution for infusion
Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)
Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day
Frequency: twice daily"
1707568|NCT01407510|Drug|Mapracorat|Application of the investigational product on the affected skin areas
1707569|NCT01407497|Biological|DNA HIVIS and MVA-CMDR|600 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12; 108 pfu i.m. MVA boosting at weeks 24 and 36
1707570|NCT01407497|Biological|DNA HIVIS and MVA-CMDR|1200 µg i.d. (separate plasmids pools) of DNA priming at weeks 0, 4 and 12 ; 108 pfu i.m. MVA boosting at weeks 24 and 36
1707571|NCT01407497|Biological|Saline solution|2 x 0.1 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
1707572|NCT01407497|Biological|Saline solution|2 x 0.2 ml of saline solution i.d at weeks 0, 4 and 12 ; saline solution i.m at weeks 24 and 36
1707573|NCT01407484|Drug|Prednisone|0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week.
1707574|NCT01407484|Drug|Placebo|Placebo 0,2 mg/kg/day for 3 weeks and 0,1mg/kg/day for 1 week
1707575|NCT01407471|Drug|Clobetasol + Spironolactone|One application 6 days a week during 4 weeks
1707576|NCT01407471|Drug|Clobetasol + Placebo|One application 6 days a week during 4 weeks
1707577|NCT01407471|Drug|Placebo + Spironolactone|One application 6 days a week during 7 weeks
1707578|NCT01407471|Drug|Placebo + Placebo|One application 6 days a week during 7 weeks
1707579|NCT01407458|Other|Upper Limb Exercises|Upper limb exercises
1707580|NCT01407458|Other|Normal physical exercises|Exercises usually done by children in physical education classes
1707581|NCT01407445|Drug|Placebo|1 tablet/ oral/ 3 times a day for 90 days
1707582|NCT01407445|Drug|Tribulus terrestris|1 tablet of 250mg/ oral/ 3 times a day for 90 days
1707583|NCT01407432|Drug|Folic acid|Taking of folic acid 15 mg per day by hanging oral route during 3 at 4 months
1707584|NCT01407432|Drug|placebo of folic acid|Taking of placebo of folic acid by hanging oral route during 3 at 4 months
1707585|NCT01407419|Other|Treatment Acceleration|"Subjects in the intervention group will be seen as frequently as monthly for subjects not achieving low disease activity (LDA) as defined as CDAI ≤10. Treatment acceleration will be expected to occur as frequently as monthly and at least every 3 months in these subjects, unless contraindicated.
Treatment acceleration for the purposes of this trial include the following options: Change in prescribed treatment or dosage of traditional or biologic Disease Modifying Anti Rheumatic Drugs (DMARDs) or a change in the route of Methotrexate administration (from oral to subcutaneous)"
1707586|NCT01407419|Other|Monthly Assessment|Monthly disease assessments are expected to be scheduled until the subject has achieved a CDAI of 10 or less (low disease activity).
1707587|NCT01407406|Drug|BIIB023 - low dose IV Dose|
1707588|NCT01407406|Drug|BIIB023 - high dose IV Dose|
1707589|NCT01407393|Device|Glucosanol|2 tablets 3x daily for 12 weeks
1707590|NCT01407393|Device|Placebo|2 tablets 3x daily for 12 weeks
1707591|NCT01407380|Drug|PWT33597 mesylate|PWT33597 taken orally daily for 28 consecutive days in 28 day cycle
1707592|NCT01407354|Device|Lokomat treadmill training|Lokomat treadmill training: 12 wks, 3x/wk, 45 mins@session
1707593|NCT01407354|Other|Aquatic exercise therapy|Aquatic exercise training: 12 wks, 3x/wk, 45 mins@session
1707594|NCT01407341|Procedure|musculoskeletal complications management/prevention|Receive beta tricalcium-phosphate bone graft
1707595|NCT01407341|Procedure|bone graft|Receive beta tricalcium-phosphate bone graft
1707596|NCT01407341|Procedure|quality-of-life assessment|Ancillary studies
1707597|NCT01407341|Other|questionnaire administration|Ancillary studies
1707598|NCT01407315|Device|GlucoMenDay|"Subjects will receive a standardized lunch (100 g of CHO), administration of insulin will be performed by the subject based on insulin to carbohydrate ratio.
An intravenous catheter will be inserted in one forearm and venous sampling will start 1 hour after lunch ingestion. Arterialized-venous blood sampling will be performed every 15 minutes for a period of two hours. Samples will be analyzed for glucose using the Super GL; concomitantly capillary measurements using the GlucoCard G Meter will be performed.
This procedure can be performed on days 3-4 of monitoring; each subject randomized to Procedure A undergoes this procedure once."
1707599|NCT01407315|Device|GlucoMenDay|"Subjects will receive a standard breakfast (75g CHO), the usual morning insulin dose will be post-poned. An increased dose of rapid-acting insulin analogue aiming to produce minor hypoglycaemia based on insulin to carbohydrate ratio will be injected subcutaneously. Arterialized-venous sampling will be performed every 10 minutes for a period of two hours.
Samples will be analyzed for glucose using the Super GL; concomitantly, capillary measurements using the GlucoCard G Meter will be performed.
This procedure will be performed on days 2 and 4 of monitoring; each subject randomized to Procedure B undergoes this procedure twice."
1707600|NCT01407302|Other|Head rotation|Repeated ultrasonographic examination according to the degree of head rotation (examination of overlap index of internal jugular vein and common carotid artery, and accuracy of external landmark of jugular cannulation)
1707601|NCT01407289|Drug|Insulin Aspart, Insulin Glargine|The Intervention is a paper based protocol, which provides suggestions for new insulin doses (basal-bolus regime).
1707602|NCT01407276|Drug|Omarigliptin|Single oral dose of 3 mg (3 x 1-mg capsules)
1707603|NCT01407263|Procedure|Lymph node template|Inclusion of the external iliac, hypogastric and obturator fossa nodal groups in the template undergoing a Radical Prostatectomy. Modifying the template for lymph node dissection may lead to removal of additional affected nodes, reducing the chance of recurrence.
1707604|NCT01407263|Procedure|Transverse versus vertical closure|Transverse versus vertical closure of the port site incision
1707605|NCT01407263|Drug|antibiotic prophylaxis|One vs. three days of antibiotic prophylaxis at catheter removal
1707606|NCT01407237|Drug|Angiotensin II Infusion|Angiotensin II (Bachem) will be infused at 0.3 ng/kg/min for 30 minutes, then 1.0 ng/kg/min for 30 minutes, then 3.0 ng/kg/min for 30 minutes; at baseline and at each infusion concentration, serum aldosterone will be measured. BP and heart rate will be monitored at baseline and every 2 minutes during the infusion.
1707607|NCT01407224|Behavioral|Improve Early Breastfeeding|One arm got only training, another arm training and supervision and third arm without any intervention as control.
1707608|NCT01407211|Dietary Supplement|vitamin A|"25000 IU/day vitamin A 6 months
1 Cap/Day
1 cap placebo/day for 6 month"
1707609|NCT01407198|Drug|Nilotinib|Orally, daily 200 - 400 mg BID
1707610|NCT01407198|Radiation|Radiation therapy|External beam radiation will be delivered at 1.8 Gy per day, 5 days per week (excluding holidays)for a total of 28 fractions over a 6 weeks period.
1707611|NCT01407185|Other|Resistive Exercise Training|Resistive Exercises (between 8 and 12 exercises for both upper and lower body) at 30 to 60% of 1 RM for 2x per week for 12 months.
1707612|NCT01407133|Device|transcranial magnetic stimulator (class 2b) Medtronic © MagPro X100 (with MagOption) stimulator and Butterfly Coil MCF-B65 (figure-8 coil with fluid cooling)|"The study is based on a dual procedure consisting of comparisons between active and sham rTMS on the one hand and between four increasing levels of magnetic pseudo-dose on the other hand. Each level comprises 16 patients randomly assigned to active rTMS group (12 patients) or sham rTMS group (4 patients). The transition from one level to another is authorized by an independent oversight committee charged with checking the tolerability of rTMS sessions for the tested level. The neuronavigated rTMS use either active or sham figure-eight coil and is centered over the primary auditory cortex contralateral to the perceived predominant side of tinnitus. This target is located through anatomical brain MRI and neuronavigated brain system. According to the stimulation parameters, each rTMS session can last from 5 to 112 minutes and the whole rTMS intervention from 1 to 20 weeks. The follow-up is spread over twelve months."
1707613|NCT01407133|Device|Sham transcranial magnetic stimulator Medtronic © MagPro X100 (shielded figure-8 coil with fluid cooling)|Same sound level as active rTMS, but magnetic field strongly attenuated
1707614|NCT01407120|Behavioral|New Beginnings Program|A preventive intervention for divorced families.
1707615|NCT01407107|Drug|nitroglycerin|0.2mg/hr nitroglycerin transdermal patch daily
1707616|NCT01407094|Drug|Sertraline|50-200mg/day
1707617|NCT01407094|Drug|Placebo|1-4 pills per day
1707618|NCT01407094|Drug|BupropionXL|150-450 mg/day
1707619|NCT01407081|Behavioral|Telerehabilitation Cognitive Strategy Training|The strategy intervention is a 16-week program during which a trained rehabilitation coach speaks by telephone to the stroke participant and their caregiver twice a week (one approximately 45-minute 'training' call and one approximately 15-minute 'update' call). Rehabilitation discussions during the training calls will follow a detailed protocol and focus each week on the stroke education and cognitive strategy training information provided in each section of the manual provided to the participants.
1707620|NCT01407068|Biological|AA4500 collagenase clostridium histolyticum|2 concurrent injections (0.58 mg) into 2 cords on the same hand
1707621|NCT01407055|Behavioral|Expectation Manipulation Intervention|The Expectation Manipulation Intervention targets patients' expectations prior to surgery (2 individual sessions, 2 phone calls). Main goal is to enhance positive outcome expectancies, as well as to improve patients' control expectations about possible side effects of the surgery and about their personal management of their coronary heart disease. Further EMI tries to correct dysfunctional beliefs about the coronary heart disease and tries to minimize fears about expected negative consequences.
1707622|NCT01407055|Behavioral|Supportive Therapy|Supportive therapy employs common factors such as elicitation of affect, reflective listening, feeling understood, but provides no explicit theoretical formulation to the patient. Supportive therapy thus provides a control condition for common factors and therapist attention but lacks the specific intervention part. It will be delivered in the same frequency and at the same time points as the Expectation Manipulation Intervention (2 individual sessions, 2 phone calls).
1707623|NCT01407042|Procedure|mobile-bearing unicondylar knee arthroplasty|mobile-bearing unicondylar knee arthroplasty
1707624|NCT01407016|Drug|metronidazole IV 500 mg|On Day 1, subjects will receive a single dose of 500 mg metronidazole by intravenous infusion over 20 minutes. On Day 3 to Day 7, subjects will receive multiple doses of 500 mg metronidazole by intravenous infusion over 20 minutes 4 times a day (every 6 hours) for 5 days.
1707625|NCT01407003|Drug|LIK066|Participants will receive a single or multiple doses of LIK066
1707626|NCT01407003|Drug|Placebo|Participants will receive a single or multiple doses of a matching placebo
1707627|NCT01406977|Drug|BPS804|
1707628|NCT01406964|Other|CAT test|A CAT test is performed in order to diagnose tubal factor causes
1707629|NCT01406964|Other|Histerosalpingography|A Histerosalpingography is performed.
1707630|NCT01406938|Drug|AIN457 150mg|(1 injection per dose) and placebo to secukinumab 150 mg
1707631|NCT01406938|Drug|AIN457 300mg|secukinumab 150 mg (2 injections per dose)
1707632|NCT01406925|Drug|Placebo control|Placebo cream
1707633|NCT01406925|Drug|NRL001 cream|Cream for single-dose intra-anal application
1707634|NCT01406912|Other|Recreational Activity|Recreational activities (playing cards, arts and crafts, dominoes, jenga or a ball game) and conventional rehabilitation.
1707635|NCT01406912|Other|Wii Gaming System Arm|Virtual reality Wii games (tennis and bowling from Wii® Sports, and bean bag, bocce ball, ping cup, darts or shuffleboard from Wii® Game Party 3) and conventional rehabilitation.
1707636|NCT01406899|Behavioral|Computer Based Treatment|Standard treatment as usual (TAU) plus coping skills computer program. In addition to the individual and group therapy sessions (TAU), individuals will work with a computerized program that teaches skills for stopping substance use and increasing coping skills twice weekly for 8 weeks.
1707639|NCT01406873|Drug|Placebo|150 mg/kg placebo capsules taken by mouth, three times daily for 6 months
1707643|NCT01406847|Other|Spinal Manipulation|High velocity low amplitude joint-biased intervention
1707644|NCT01406847|Other|Spinal Mobilization|Low velocity, large amplitude oscillating joint biased technique
1707645|NCT01406847|Other|Static Touch|The investigators maintains hand contact with both hands over the lumbar area of the participant
1707646|NCT01406834|Behavioral|Impact of Killing CBT Treatment|Treatment will include six, one hours sessions with a licensed clinical psychologist or an advanced postdoctoral fellow under the close supervision of a licensed psychologist.
1707647|NCT01406821|Procedure|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and platelet-rich plasma will be injected into the tendon under ultrasound guidance.
1707648|NCT01406821|Procedure|Ultrasound-guided dry needling|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Nothing will be injected into the tendon.
1707649|NCT01406808|Behavioral|genetic risk score for coronary risk factors|genetic risk score based on coronary artery disease genetic risk variants (SNPs)
1707650|NCT01406795|Device|Gore Viabahn Heparin Coated Stent|For subjects deemed to be suffering from chronic venous insufficiency of the femoral or popliteal veins, a Gore Viabahn stent will be implanted during a venoplasty procedure to determine whether the vein will stay open.
1707651|NCT01406782|Biological|rituximab|
1707652|NCT01406782|Genetic|DNA analysis|
1707653|NCT01406782|Genetic|gene expression analysis|
1707654|NCT01406782|Genetic|polymerase chain reaction|
1707655|NCT01406782|Other|laboratory biomarker analysis|
1707656|NCT01406769|Procedure|Bioelectric Impedance Analysis|Undergo preoperative and postoperative lower-extremity lymphedema assessment
1707657|NCT01406769|Procedure|Lymphadenectomy|Undergo lymphadenectomy
1707658|NCT01406769|Procedure|Therapeutic Conventional Surgery|Undergo radical vulvectomy or radical local excision
1707659|NCT01406743|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
1707660|NCT01406730|Other|exercise|16 week of periodized progressive running exercise 2-4 times/week
1707661|NCT01406717|Drug|SPIL1033, Placebo|5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
1707662|NCT01406704|Drug|Rosiglitazone|Rosiglitazone (8 mg/day)
1707663|NCT01406704|Drug|alpha-lipoic acid|alpha-lipoic acid (1800 mg/day)
1707664|NCT01406704|Drug|Rosiglitazone/alpha-lipoic acid|combination of Rosiglitazone (8 mg/day) and Thioctic acid (1800 mg/day)
1707665|NCT01406691|Device|Flashes|three hours of a sequence of light flashes (4000 lux, 3 msec, every 30 seconds); occurs during three hours immediately prior to desired waketime
1707666|NCT01406678|Procedure|RIPC|3 cycles of 5 min left upper arm ischemia by inflation of a blood pressure cuff to 200 mmHg and 5 min reperfusion
1707667|NCT01406678|Procedure|Control|Coronary artery bypass surgery without remote ischemic preconditioning protocol
1707668|NCT01406678|Drug|isoflurane+sufentanil anesthesia|Anaesthesia is maintained by inhaled isoflurane in concentrations 0.7-0.8 % end-tidal with additional sufentanil injected during surgery, as required. During extracorporal circulation patients receive isoflurane via a vaporizer incorporated in the extracorporeal gas supply in the same concentrations.
1707670|NCT01406639|Drug|Ranibizumab|Patients will be treated with a total of 4 applications of ranibizumab in a fine mist spray. This will be done with 2 mgs in 0.2cc; 0.1cc sprayed into each nostril a day; therefore 8 mgs will require 4 days of application. If, following the first treatments, they experience recurrent bleeding (equal to or less than a 75% reduction in their ESS number as compared to pre treatment), they will be offered the opportunity to be prescribed a second administration, to be completed in the same way (4 applications of 4 mg in 0.4 cc with 0.2cc per nostril).
1707671|NCT01406626|Behavioral|Health Navigator|Health navigation intervention to improve linkage to and retention in HIV care and suppress viral load for underserved HIV+ persons in Los Angeles
1707672|NCT01406613|Other|Observation|In this study we will examine the changes in bone density by DXA and QUS and bone turnover after stopping Bisphosphonate treatment. As we wish to measure the speed of offset of effects of treatment we have scheduled visits at 24 week intervals in order to fully assess this effect.
1707673|NCT01406600|Drug|recombinant hCG (Ovidrel®)|Recombinant hCG (Ovidrel®)will be administrated for final oocyte maturation triggering in poor responders with different two doses (250mcg vs. 500mcg). Usually rhCG is administrated after 24~48 hours from optimal ovarian stimulation status.
1707674|NCT01406587|Drug|PP4001|50 mg, 1 dose every 12 hours x 4 doses
1707675|NCT01406587|Drug|PP4001|100 mg, 1 dose every 12 hours x 4 doses
1707676|NCT01406587|Drug|PP4001|200 mg, 1 dose every 12 hours x 4 doses
1707677|NCT01406587|Drug|Placebo|Placebo, 1 dose every 12 hours x 4 doses
1707678|NCT01406574|Drug|OPB-31121|Oral administration, 400 mg/day or 600 mg once daily after breakfast during the treatment period (1 month)
1707679|NCT01406574|Drug|OPB-31121 phase2|Oral administration, recommended dose from Phase1 once daily after breakfast during the treatment period (6 months)
1707680|NCT01406561|Drug|OMS103HP-S|Proprietary concentration and formulation of OMS103HP in solution (OMS103HP-S) for injection into each 3 liter vehicle irrigation solution bag for use during meniscectomy surgery
1707681|NCT01406561|Drug|Vehicle|3 Liter bags of vehicle irrigation solution for use during meniscectomy surgery
1707682|NCT01406548|Drug|BPS804|
1707683|NCT01406548|Drug|Placebo|
1707684|NCT01406548|Drug|BPS804|
1707685|NCT01406548|Drug|Placebo|
1707686|NCT01406548|Drug|BPS804|
1707687|NCT01406548|Drug|Placebo|
1707690|NCT01406522|Drug|Oral tacrine|Tacrine, 160 mg per day, four times daily
1707691|NCT01406522|Drug|Oral placebo|Microcrystalline cellulose
1707692|NCT01406509|Biological|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0
1707693|NCT01406509|Biological|0.5ml/dose for a person|group A, C polysaccharide meningococcal and type b haemophilus Influenzal Conjugate vaccine of 0.5ml/dose for a person, on day0, 28
1707694|NCT01406496|Drug|insulin|Three different timings of insulin delivered by a pump
1707695|NCT01406483|Other|Platelet reactivity assessment|Platelet reactivity, as measured by the Chrono-log Lumi-Aggregometer, VerifyNow P2Y12 assay, and Vasodilator Stimulated Phosphoprotein (VASP) flow cytometry assay.
1707696|NCT01406470|Drug|Immune Globulin Intravenous (Human) 5% Liquid, IVIG-SN™|IVIG-SN™ 10g/200mL, dose is 300-900 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with IVIG-SN™ will be 12 months with a 3 month follow-up.
1707697|NCT01406444|Drug|rhIGF-1|Study participants will be started at a dose of 30 mcg/kg BID and will be titrated.
1707698|NCT01406444|Drug|Risedronate|Risedronate 35mg PO one time weekly
1707699|NCT01406444|Drug|Placebo|Placebo injections 30 mcg/kg BID, Placebo tablet PO once weekly
1707700|NCT01406431|Drug|Pitavastatin, Valsartan|Pitavastatin 4mg(2 tablets), Valsartan 160mg(1 tablet)
1707701|NCT01406431|Drug|Livalo® fixed combination drug|Livalo® fixed combination drug(1 tablet)
1707702|NCT01406418|Biological|CR6261 2 mg/kg|Administered as a single 2-hour intravenous infusion
1707703|NCT01406418|Biological|CR6261 5 mg/kg|Administered as a single 2-hour intravenous infusion
1707704|NCT01406418|Biological|CR6261 15 mg/kg|Administered as a single 2-hour intravenous infusion
1707705|NCT01406418|Biological|CR6261 30 mg/kg|Administered as a single 2-hour intravenous infusion
1707706|NCT01406418|Biological|CR6261 50 mg/kg|Administered as a single 2-hour intravenous infusion
1707707|NCT01406418|Biological|Placebo|Administered as a single 2-hour intravenous infusion
1707708|NCT01406405|Procedure|Posterior/Transforaminal Lumbar Interbody Fusion (P/TLIF), Anterior Cervical Discectomy and Fusion (ACDF)|Lumbar or cervical fusion
1707709|NCT01406392|Drug|Misoprostol 25mcg|Vaginal misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 200mcg or eight tablets.
1707710|NCT01406392|Drug|Sublingual Misoprostol|Sublingual misoprostol or placebo tablets will be administered for each six hours until the maximum dose of 100mcg or eight tablets
1707711|NCT01406379|Procedure|Prophylactic clip|Before conventional snare polypectomy, hemoclips were applied on the base of stalk in the prophylactic clip group
1707712|NCT01406379|Procedure|Detachable snare|In the detachable snare group, detachable snare was positioned at the base of stalk and followed by conventional snare polypectomy
1707713|NCT01406366|Behavioral|Group 1: Bright Futures Oral Health Curriculum|Residents who are randomized to Group 1 will receive a resident curriculum that exposes them to Bright Futures concepts of health promotion, including partnership building, communication and oral health. Group 1 residents will complete 7 modules, 3 on Bright Futures concepts (health, partnership building and communication), and 4 on oral health promotion. These modules have been developed in collaboration with the Pediatrics in Practice workgroup and the Open Wide modules endorsed by the American Academy of Pediatrics and the Maternal and Child Health Bureau. The oral health modules address dental caries development and prevention, importance of identifying maternal oral health status, duration of bottle-feeding or breastfeeding and discouraging both during sleep.
1707714|NCT01406366|Behavioral|Group 2: Iron Deficiency Training Module|Our study team opted to include a single 1-hour educational module addressing the identification and prevention of iron deficiency created by the AAP on Pedialink® to the active control group. This educational module addresses screening for and assessing risk for iron deficiency.
1707715|NCT01406353|Procedure|Percutaneous Mitral Commissurotomy|Percutaneous mitral commissurotomy is performed by experienced interventional cardiologists using the Inoue balloon technique. During the procedure, conventional hemodynamic parameters are monitored. A successful immediate result is defined as a mitral valve area > 1.5 square cm with less than moderate to severe mitral regurgitation.
1707716|NCT01406340|Drug|5 mg GSK1278863|5 mg per day administered orally for 14 days for normal subjects and subjects with Stage 3/4 renal function; 5 mg per day administered orally for 15 days for subjects with Stage 5 renal function
1707717|NCT01406327|Drug|Ambrisentan|Ambrisentan
1707718|NCT01406314|Drug|GSK2315698|Intravenous infusion for approximately 48hours followed by subcutaneous injection
1707719|NCT01406301|Drug|fondaparinux|fondaparinux
1707720|NCT01406288|Other|HUS standard coverage care (including in ICU)|HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption
1707721|NCT01406275|Drug|Amoxicillin and clavulanate|
1707722|NCT01406262|Biological|Albiglutide|once weekly subcutaneous injection
1707723|NCT01406262|Drug|Moxifloxacin|oral tablet
1707724|NCT01406249|Drug|SP|"Drug: S-1:
S-1 will be administered at 40 mg/m2 orally, twice daily (80 mg/m2 total daily dose) on Days 1 through 21 of each 35-day treatment cycle.
Drug: Cisplatin:
Cisplatin will be administered at 60 mg/m2 by intravenous infusion on Day 8 of each 35-day treatment cycle."
1707725|NCT01406249|Drug|XP|"Drug: Capecitabine:
Capecitabine will be administered at 1,000 mg/m2 orally, twice daily (2,000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
Drug: Cisplatin:
Cisplatin will be administered at 80 mg/m2 by intravenous infusion on Day 1 of each 21-day treatment cycle."
1707726|NCT01406236|Procedure|Transradial PCI|Transradial PCI
1707727|NCT01406236|Procedure|Transfemoral PCI|Transfemoral PCI
1707734|NCT01406197|Drug|Experimental: Vaginal progesterone|Vaginal progesterone formulation (150 mg micronized progesterone daily)
1707735|NCT01406197|Drug|Experimental: Topical progesterone|Progesterone will be applied daily (150 mg micronized progesterone)by topical application
1707783|NCT01405885|Biological|INO-3401|0.9mg of 3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
1707736|NCT01406197|Drug|Experimental: Intramuscular progesterone|Preterm labor patients will be injected IM with micronized progesterone (50 mg/day).
1707737|NCT01406184|Other|Durham Connects|The program consists of 4-7 intervention contacts, including 1) a hospital birthing visit when a staff member schedules an initial home visit; 2) 1-3 nurse home visits between 3-12 weeks of infant age to provide physical assessments for infant and mother, intervention and education, assessment of family-specific needs, and connections to matched community resources, as needed, to provide longer-term support; 3) 1-2 nurse contacts with community service providers to facilitate successful connections; and 4) a telephone follow-up one month after case closure to review community connection outcomes. With family consent, letters from the program reporting on the visit are also provided to also connect families to maternal and infant healthcare providers for ongoing support.
1707738|NCT01406171|Drug|Isavuconazole|oral
1707739|NCT01406171|Drug|Midazolam|Oral
1707740|NCT01406158|Drug|Solifenacin Succinate Formulation A|oral suspension
1707741|NCT01406158|Drug|Solifenacin Succinate Formulation B|oral suspension
1707742|NCT01406158|Drug|Solifenacin Succinate|oral tablet
1707743|NCT01406145|Drug|ASP0777|oral tablet
1707744|NCT01406145|Drug|Placebo|oral tablet
1707745|NCT01406132|Drug|ASP015K|oral
1707746|NCT01406119|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
1707747|NCT01406106|Dietary Supplement|Plant stanol esters|The administration of a dairy product in the form of liquid yoghurt, marketed in Spain, that contains 2 g per container of plant stanol esters: sitostanol and campestanol (AHA recommended dose - 1.5 to 3 g). The enriched product and the placebo will have the same characteristics (composition and outward appearance), but the placebo will not contain stanol esters. The dose will be one container a day, after the main meal, for 24 months. The participants may continue with their previously prescribed lipid-lowering treatment and new treatment needed for this disease or for other diseases. Composition per container: proteins 1.8 g, carbohydrates 9.8 g, fat (except stanol) 1.4 g, plant stanol 2 g, vitamin B6 0.6 mg, folic acid 60 mg. The control group will receive one unit a day of yoghurt not supplemented with stanol esters that has a similar appearance to the enriched yoghurt.
1707748|NCT01406080|Drug|Adapalene|Apply approximately 1 gram of Differin 0.3% every night on the entire face, except near the eye region.
1707749|NCT01406080|Drug|Tretinoin|Apply approximately 1 gram of Tretinoin emollient cream 0.05% every night on the entire face, except near the eye region.
1707750|NCT01406067|Behavioral|Treatment Program for Children with Aggressive Behavior|24 sessions with the child aiming at the reduction of peer related aggressive behavior via social skills training. Additionally up to 10 sessions with relatives of the child in most cases with the parents.
1707751|NCT01406067|Behavioral|Play group|12 double sessions (totally 24 treatment hours) in groups with up to 5 children. Different play activities were presented including techniques to activate resources of the child. These interventions give the children the opportunity to train pro-social interactions. Additionally up to 3 parent sessions were also included.
1707752|NCT01406054|Other|neuromuscular exercises|neuromuscular exercises delivered as a pre-practice and pre-game warm-up including dynamic stretching, strengthening, and plyometrics.
1707753|NCT01406041|Biological|Chemical and physical detection|CVP, Urine volume per day, Blood electrolytes, Urine sodium per day, Pituitrin
1707754|NCT01406028|Behavioral|Phone calls|Phone calls to offer emotional support
1707755|NCT01406015|Drug|Spironolactone|50 mg once daily for 6 weeks.
1707756|NCT01406015|Drug|Placebo|Placebo-matching spironolactone once daily for 6 weeks.
1707757|NCT01406002|Drug|darexaban|oral
1707758|NCT01406002|Drug|Rifampicin|oral
1707759|NCT01405989|Drug|darexaban|oral
1707760|NCT01405989|Drug|ketoconazole|oral
1707761|NCT01405976|Device|life style modification, noninvasive ventilation, CPAP|life style modification, noninvasive ventilation, CPAP
1707762|NCT01405963|Drug|AMG 157 Matching Placebo|Matching placebo administered as multiple IV doses in subjects with mild atopic asthma
1707763|NCT01405963|Drug|AMG 157|One dose level of AMG 157 administered as multiple IV doses in subjects with mild atopic asthma.
1707764|NCT01405950|Drug|Zanaflex Capsules|0.025 mg/kg
1707765|NCT01405950|Drug|Zanaflex Capsules|0.05 mg/kg
1707766|NCT01405950|Drug|Zanaflex Capsules|0.075 mg/kg
1707767|NCT01405950|Drug|Zanaflex Capsules|0.1 mg/kg
1707768|NCT01405937|Drug|vaniprevir|vaniprevir capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
1707769|NCT01405937|Biological|peg-IFN|peg-IFN 1.5 µg/kg once per week, subcutaneously (SC) for 24 weeks
1707770|NCT01405937|Drug|ribavirin|Capsules containing 200 mg ribavirin, orally, 3 to 5 capsules, dosage based on participant weight (600 mg/day to 1000 mg/day), for 24 weeks
1707771|NCT01405924|Drug|Fosaprepitant dimeglumine|Fosaprepitant 150 mg, IV on Day 1 of chemotherapy in Cycle 2
1707772|NCT01405924|Drug|5-HT3 RA|5-HT3 RA will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
1707773|NCT01405924|Drug|Dexamethasone|Dexamethasone will be administered at the same dosage in Cycle 2 of chemotherapy as was used for each particpant in Cycle 1 of chemotherapy.
1707774|NCT01405924|Drug|Rescue medication|Rescue medication is defined as any medication used to relieve the symptoms of established nausea or vomiting. Multiple medications are permitted by the protocol and may be taken by the participant, including 5-HT3 antagonists, phenothiazines and benzodiazepines.
1707775|NCT01405911|Drug|Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
1707776|NCT01405911|Drug|Sitagliptin 50 mg|1 tablet orally once daily before breakfast for 8 weeks
1707777|NCT01405911|Drug|Placebo for Sitagliptin 25 mg|1 tablet orally once daily before breakfast for 8 weeks
1707778|NCT01405911|Drug|Placebo for Sitagliptin 50 mg|1 tablet orally once daily for 8 weeks
1707779|NCT01405898|Dietary Supplement|beetroot juice|Beetroot juice 4 weeks 250ml daily
1707780|NCT01405898|Dietary Supplement|Nitrate-free beetroot juice|Nitrate-free beetroot juice 4 weeks 250ml daily
1707781|NCT01405885|Biological|INO-3605|0.9mg of INO-3605 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
1707782|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
1707784|NCT01405885|Biological|INO-3609|0.3mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
1707785|NCT01405885|Biological|INO-3605 AND INO-3609|0.45mg each of INO-3605 AND INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
1707786|NCT01405885|Biological|INO-3510|0.3mg each of INO-3605, INO-3609 AND INO-3401 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
1707787|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 16 and 24.
1707788|NCT01405885|Biological|INO-3609|0.9mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0 and Week 8
1707789|NCT01405885|Biological|Seasonal Influenza vaccine|0.5ml of vaccine delivered IM
1707790|NCT01405885|Biological|INO-3609|1.8mg of INO-3609 vaccine delivered ID followed by electroporation on Day 0, Week 8 and 24.
1707791|NCT01405872|Other|AVONEX PEN|Participants receive Avonex PEN commercially prescribed according to the local prescribing information.
1707792|NCT01405846|Drug|Gefitinib|250mg od for 6 months
1707793|NCT01405833|Drug|BG00010 (Neublastin)|Multiple doses, weight-based IV administration
1707794|NCT01405833|Drug|Placebo|Single dose IV matched placebo
1707795|NCT01405820|Drug|natalizumab IV|natalizumab for IV Infusion
1707796|NCT01405820|Drug|natalizumab SC|natalizumab for Subcutaneous Injection
1707797|NCT01405820|Drug|IV Placebo|Intravenous placebo to natalizumab
1707798|NCT01405820|Drug|SC Placebo|Subcutaneous placebo to natalizumab
1707799|NCT01405807|Drug|Alemtuzumab|Alemtuzumab will be administered on Day 1 and Day 2 at 0 and 6 months
1707800|NCT01405794|Drug|32ppm Silver Particle|Oral silver dose of 32ppm
1707801|NCT01405794|Drug|Placebo|Sterile Water No Silver
1707802|NCT01405768|Drug|sodium bicarbonate buffered lidocaine|8.4% sodium bicarbonate will be mixed with lidocaine in a 1:10 ratio prior to mixing with epinephrine and injecting into the cervix.
1707803|NCT01405768|Drug|Non-buffered lidocaine|
1707804|NCT01405755|Behavioral|Appropriate complementary feeding messages|Messages delivered through National Vaccine Program and radio
1707805|NCT01405742|Drug|rF.VIII|40 IU/kg recombinant factor VIII will be given once-weekly or thrice-weekly by intravenous injection for 26 weeks. At 26 weeks after a 72 hour washout period, 40 IU/kg recombinant factor VIII will be given thrice-weekly or once-weekly, respectively, by intravenous injection until week 52, with up to two rescue doses per week for bleeds
1707806|NCT01405716|Behavioral|Mindfulness Meditation|8-week mindfulness based program will be compared to and education control group
1707807|NCT01405716|Behavioral|Health Education|8-week health education program
1707808|NCT01405703|Other|xrays|xrays from 2 week postop to 5 year postop
1707809|NCT01405677|Biological|Epaxal 0.25 mL|12 IU hepatitis A antigen coupled to immunopotentiating reconstituted Influenza virosome (IRIV)
1707810|NCT01405677|Biological|Epaxal 0.5 mL|24 IU hepatitis A antigen coupled to IRIV
1707811|NCT01405677|Biological|Havrix Junior 0.5 mL|720 EU hepatitis A antigen absorbed onto aluminum hydroxide
1707812|NCT01405664|Other|Weight-Bearing as Tolerated|WBAT immediately after surgery
1707813|NCT01405651|Drug|ONO-6950|30 mg, 100 mg, 300 mg at multiple doses
1707814|NCT01405651|Drug|ONO-6950|Placebo to match ONO-6950 tablets dosed in a similar manner to ONO-6950
1707815|NCT01405638|Behavioral|Motivational Interviewing|One-on-one client-centered counseling for lifestyle changes related to blood pressure control
1707816|NCT01405638|Behavioral|Patient Navigation|One-on-one navigation to guide participants through the process of being screened for colorectal cancer.
1707817|NCT01405625|Other|Pictogram-based asthma action plan|Asthma action plan using plain language, pictograms, and photographs
1707818|NCT01405625|Other|AAAAI standard of care written action plan|
1707819|NCT01405612|Drug|Midazolam|Single oral administration on Day 1 or Day 5
1707820|NCT01405612|Drug|Ulimorelin|Intravenous infusion of 480 micrograms/kg on Days 1 to 5
1707821|NCT01405599|Drug|Ulimorelin|Single dose of 480 micrograms/kg administered as a 30 minute intravenous infusion
1707822|NCT01405586|Drug|Gemcitabine|1000mg/m2 days 1 and 8 every 3 weeks for 6 cycles
1707823|NCT01405586|Drug|Gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for 6 cycles
1707824|NCT01405586|Drug|Cisplatin|60 mg/m2 day 1 every 3 weeks for 6 cycles
1707825|NCT01405573|Other|Best Supportive Care|Therapy given according to clinical practices at participating centres. Experimental therapies not permitted.
1707826|NCT01405573|Drug|sorafenib|400 mg twice a day
1707827|NCT01405560|Drug|Vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 24 weeks
1707828|NCT01405560|Biological|peg-IFN|Open-label peg-IFN alfa-2b at 1.5 μg/kg once per week, administered subcutaneously (SC) for 24 weeks
1707829|NCT01405560|Drug|ribavirin|Capsules containing 200 mg RBV, orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 weeks
1707830|NCT01405521|Biological|Vaccine placebo (excipients only)|single oral dose,
1707831|NCT01405521|Biological|Ty21a|3 oral doses, alternate days
1707832|NCT01405521|Biological|M10ZH09 vaccine|single oral dose
1707833|NCT01405508|Drug|Brivaracetam tablets|100 mg, intake twice daily (BID) for 7 days during Run-In Period
1707834|NCT01405508|Drug|Brivaracetam bolus|10 mL (= 100 mg) of Brivaracetam administered intravenously over 2 minutes twice daily (BID) during Evaluation Period
1707835|NCT01405508|Drug|Brivaracetam infusion|10 mL (= 100 mg) of Brivaracetam diluted in 90 mL 0.9 % isotonic saline sterile solution for intravenous administration infused over 15 minutes twice daily (BID) during Evaluation Period
1707836|NCT01405508|Other|Placebo|100 mg twice daily (BID) for 7 days during Run-In Period
1707837|NCT01405495|Procedure|MRI-based techniques (sMRI, fMRI, DTI, ASL)|no drugs include
1707838|NCT01405482|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A 100 units injected under EMG guidance one time into the anterior,middle scalenes and pectoralis minor muscle
1707839|NCT01405482|Other|Normal Saline injection|10 cc of Normal Saline will be injected under EMG guidance into the Anterior and Middle Scalenes and Pectoralis Minor muscle of individual diagnosed with Thoracic Outlet Syndrome.
1769284|NCT00353886|Procedure|WISC-3|
1707840|NCT01405469|Other|Peroral Endoscopic Myotomy|A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. An electric generator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips
1707841|NCT01405456|Drug|Eplerenone and lifestyle|eplerenone 50mg by mouth daily as well as lifestyle counseling
1707842|NCT01405456|Other|placebo and lifestyle|placebo pill daily and lifestyle counseling
1707843|NCT01405430|Biological|Bevacizumab + blood samples|"Bevacizumab will be administered according to investigators appreciation.
Blood samples will be collected at enrollment, at second bevacizumab's administration and every 10 weeks until progression, or until patients stop bevacizumab because of toxicity or until one year at most in case that patients still receive bevacizumab."
1707844|NCT01405417|Procedure|Endoscopic Peroral Myotomy|Endoscopic peroral myotomy: A forward-viewing upper endoscope is used with a transparent distal cap attachment. Carbon dioxide gas is necessary for insufflation during the procedures. An endoscopic knife is used to access the submucosa, dissect the submucosal tunnel and also to divide circular muscle bundles over a length of approximately 10cm, extending 2-3cm onto the cardia. A electrogenerator is used with spray coagulation mode. A coagulating forceps is used for hemostasis as needed. Closure of the mucosal entry site is performed using standard endoscopic clips.
1707845|NCT01405404|Behavioral|Parent Training and childcare discount|12-session parent training intervention called the Chicago Parent Program; Childcare discount given in one arm to examine its effect on attendance rate
1707846|NCT01405404|Other|Parent Training|12-session group on parenting skills and child behavior management
1707847|NCT01405391|Drug|PM01183|PM01183 drug product (DP) is presented as a lyophilized powder for concentrate for solution for infusion with two strengths, 1 mg and 4 mg vials. Before use, the 1 mg and 4 mg vials should be reconstituted with 2 ml and 8 ml of water for injection respectively, to give a solution containing 0.5 mg/ml PM01183. For administration to patients as an i.v. infusion, reconstituted vials are diluted with glucose 50 mg/ml (5%) solution for infusion or sodium chloride 9 mg/ml (0.9%) solution for infusion.
1707848|NCT01405378|Device|Robot therapy and transcranial direct current stimulation|"Administration of Robot Therapy:
Therapy will be administered by making use of the Armeo Robot. Sessions will involve high-intensity, repetitive, task-oriented movements directed by video screens. Administration of tDCS:
Anodal tDCS will be administered using a CE marked transcranial Direct Current Stimulator (Newronika Italy). Direct current will be transferred by a saline-soaked pair of surface sponge electrodes (35 cm2)."
1707849|NCT01405365|Drug|Metronidazole|Metronidazole 400mg TID for 10 days
1707850|NCT01405365|Drug|Placebo|Placebo pill TID for 10 days
1707851|NCT01405365|Procedure|Scaling and root planning|Scaling and root planning performed with curettes and ultrasonic scalers under local anesthesia
1707852|NCT01405352|Dietary Supplement|Vitamin A|"25000 IU/day vitamin A 4 months
1 Cap/Day
1 cap placebo/day for 4 month"
1707853|NCT01405339|Device|Mucosal Atomization Device (MAD)|The use of pulmicort via MAD once a day for a total of 30 days.
1707854|NCT01405339|Device|Budesonide via Nasal Syringe|The use of budesonide via Sinus Irrigation Bottle will be once a day for 30 days.
1707855|NCT01405326|Biological|adalimumab|40mg sc. every two weeks for six months
1707856|NCT01405313|Device|Modified Adaptive Servoventilation Device|The modified ASV has a greater adaptive response to meet a target ventilation level that is constantly being assessed.
1707857|NCT01405313|Device|Conventional Adaptive Servoventilation device|Pressure support ventilation adapts to meet a target ventilation level that is constantly being assessed.
1707858|NCT01405300|Dietary Supplement|Control|34.8 g dextrose, 150 g heavy whipping cream, 39g chocolate syrup, 15 g sunflower oil, 22 g safflower oil, 27 g powdered egg whites, 9.6 g of fiber supplement, water and crushed ice. It will deliver ~1200 kcal.
1707859|NCT01405300|Dietary Supplement|Peanut|34.8 g dextrose. 137 g heavy whipping cream, 39g chocolate syrup + 3 oz peanuts with skin. It will deliver ~1200 kcal.
1707860|NCT01405287|Device|PTCA with stent placement|PTCA with stent placement (Drug Eluting Stent)
1707861|NCT01405274|Other|Physiotherapy|Physiotherapy treatment bi-weekly, delivered at the child's home
1707862|NCT01405261|Drug|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
1707863|NCT01405261|Drug|oral NNC 0113-0987|Subjects will be randomised to receive a single dose of NNC 0113-0987 at escalating dose levels. Progression to next dose will be based on safety evaluation.
1707864|NCT01405261|Drug|I.v. NNC 0113-0987|Subjects will be administered a single i.v (into the vein) dose. The treatment with NNC 0113-0987 will be open-label, and will not be randomised.
1707865|NCT01405261|Drug|oral placebo|Subjects will be randomised to receive a single dose of placebo.
1707866|NCT01405248|Drug|Butylphthalide|20 mg/time per os three times a day. 180days
1707867|NCT01405248|Drug|Placebo|20 mg/time per os three times a day. 180days
1707868|NCT01405235|Drug|Paclitaxel|Paclitaxel 70 mg/m2/d i.v. on Days 1, 8, and 15 in combination with Topotecan 1.75 mg/m2/d i.v. on Days 1, 8, and 15, q 28 d
1707869|NCT01405235|Drug|Cisplatin/Paclitaxel|Topotecan 0.75 mg/m2/d i.v. on Days 1- 3 in combination with Cisplatin 50 mg/m2 i.v. on Day 1, q 21 d
1707874|NCT01405183|Other|Hepatitis C testing|Hepatitis C antibody, Hepatitis C RNA quantitative and for those who test positive Hepatitis C genotype
1707875|NCT01405170|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
1707876|NCT01405170|Drug|methylprednisolone|tablets 32 mg single dose
1707877|NCT01405157|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 16 mg
1771307|NCT00363051|Drug|Octreotide Depot|
1707881|NCT01405131|Drug|methylprednisolone|constituted powder for oral suspension 4 mg/mL single dose at 32 mg
1707882|NCT01405131|Drug|methylprednisolone|tablets 32 mg single dose
1707883|NCT01405118|Drug|Metformin/CP-690,550|Single oral 500 mg dose of metformin on Days 1 and 4 and multiple oral 30 mg doses of CP-690,550 every 12 hours on Days 2-4.
1707884|NCT01405092|Device|use of continuous renal replacement machine for renal replacement|usual care with volume removal during continuous renal replacement therapy
1707885|NCT01405092|Device|use of blood volume monitoring device in conjunction with machine used for continuous renal replacement to assess and determine volume removal|blood volume monitoring device, Critline, Hemametric, USA, will be used in conjunction with continuous renal replacement to determine rate of volume removal
1707886|NCT01405079|Drug|Gefitinib|Gefitinib 250 mg/day oral daily
1707887|NCT01405079|Drug|Vinorelbine+Cisplatin|Vinorelbine 25 mg/m2 intravenous infusion on day 1 and day 8, Cisplatin 75 mg/m2 on day 1 for 4 cycles
1707888|NCT01405066|Behavioral|Radiation Dose Audit Reports|Audit reports by CT technologist, with graphs of radiation dose levels of 20 exams from each of the 4 most common CT exams. Reports show the distribution of radiation dose levels by each exam type, and compares the technologist's dose levels to the overall levels from the clinic where they work and to the United Kingdom's 2003 Reference Dose. Prior to the graphs, the reports include an introductory page explaining the organization of the report and defining the dosimetry metrics. The final page of the report lists exams meriting individual review because their doses are higher than that of the clinic averages.
1707889|NCT01405066|Behavioral|Educational Seminar: Radiation Dose Reduction|Seminar led by a Radiologic Physicist and Radiologist. Discussion of the parameters associated with radiation dosage from CT exams and methods for changing these parameters to lower radiation dose.
1707890|NCT01405053|Drug|Rufinamide|rufinamide up to 45 mg/kg/day, in 2 divided doses, administered as oral suspension (40 mg/mL) as an add-on to the subject's existing regimen of 1-3 antiepileptic drugs (AEDs)
1707891|NCT01405053|Drug|Any other approved AED|Any other approved AED: any other approved AED of the investigator's choice as an add-on to the subject's existing regimen of 1-3 anti-epileptic drugs (AEDs)
1707892|NCT01405027|Procedure|Educational Intervention|Receive patient education and management skills training from Hepatology Centers of Educational Expertise (HCEE) during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
1707893|NCT01405027|Other|Patient education and management skills training|Community sites received patient education and management skills training by HCEE investigators during four (4) educational interventions.The CLDF (Sponsor) intends to evaluate the effectiveness of the HCEE led educational interventions in improving a community site's HCV therapeutic management skills and patient outcomes.
1707894|NCT01405014|Behavioral|Hold Me Tight|Relationship enhancement group
1707895|NCT01404988|Behavioral|Telephone-Delivered BI|Behavioral Intervention will be delivered over the phone.
1707896|NCT01404988|Behavioral|Telephone-Delivered BEI|Behavioral and Environmental Intervention will be delivered over the phone
1707897|NCT01404988|Other|Telephone-Delivered API|Attention Placebo Intervention will be delivered over the phone
1707898|NCT01404975|Other|Thoracic paravertebral block (PVB)|"We are planning to replace the standard intravenous opioid analgesia with a continuous paravertebral block using local anesthetic after trans-apical aortic valve replacement.
Anesthesia management will be standardized to minimize any impact that anesthetic type may have on neurological outcomes.
Adjuvant supplemental analgesia will be provided to both groups according to the standardized institutional guidelines."
1707899|NCT01404962|Biological|Haemophilus influenza type b conjugate vaccine|Primary series is 3 doses given to infants beginning at 2 months of age with an interval of 2 months apart (i.e. 2, 4 and 6 months of age). Booster vaccination consists of 1 dose and is given to toddlers 16 to 20 months of age. In this study, subjects will receive vaccination from routine primary care.
1707901|NCT01404936|Drug|Interferon-2A|4 (x106 IU/m^2) subcutaneously on days 1-4.
1707902|NCT01404936|Drug|Adriamycin|25 mg/m^2 by vein on day 4.
1707903|NCT01404936|Drug|Bleomycin|10 mg/m^2 by vein on day 4.
1707904|NCT01404936|Drug|Velban|6 mg/m^2 by vein on day 4.
1707905|NCT01404936|Drug|Dacarbazine|375 mg/m^2 by vein on day 4.
1707906|NCT01404923|Drug|anti spasmodic agents|best standard of care prescriptions
1707907|NCT01404923|Drug|alverine citrate, simeticone|on-demand therapy
1707908|NCT01404910|Device|Apheresis using Liposorber LA-15 System|The Liposorber LA-15 Device is a dextran sulfate cellulose column, one of several currently approved in Europe and United States for pheresis of lipoproteins in the treatment of familial hypercholesterolemia. Such devices have been in use for over 30 years. Published experience in pregnant women with familial hypercholesterolemia suggests that lipoprotein pheresis can be safely used in pregnancy after appropriate individual benefit/risk assessment for both mother and fetus is considered. The Liposorber LA-15 system selected for this trial has been evaluated for its ability to efficiently and selectively remove sFlt-1 in vitro.
1707909|NCT01404897|Other|Dietary Intervention|3 weeks of a typical Western diet pattern. 48% carbohydrate, 15% protein, 37% fat.
1707910|NCT01404897|Other|Dietary Intervention|3 weeks of a diet based on the Dietary Approaches to Stop Hypertension (DASH) diet plan. 57% carbohydrate, 18% protein, 25% fat.
1707911|NCT01404897|Other|Dietary Intervention|3 weeks of a reduced carbohydrate, higher fat modification of the DASH diet plan. 42% carbohydrate, 18% protein, 40% fat.
1707912|NCT01404884|Procedure|SUPRACOR|The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. In addition to the treatment for the distance vision an additional central ablation component will be added to address the near vision.
1707913|NCT01404871|Drug|clomipramine|oral tablets, starting at 50mg/daily for 12 weeks including > 8 weeks at 250 mg/daily
1708339|NCT01401413|Drug|ramelteon|8 mg nightly for 30 nights
1707914|NCT01404871|Drug|escitalopram|oral tablet, starting 10mg/daily 12 week treatment including >8 weeks at max dose 50mg daily
1707915|NCT01404871|Drug|duloxetine|oral tablets, starting dose 30mg daily 12 week treatment including >8weeks at 120mg daily
1707916|NCT01404858|Behavioral|There is no intervention; this is a survey only study|There is no intervention; this is a survey only study
1707917|NCT01404845|Dietary Supplement|Nutrof Total|Nutrof Total : 2 capsules per day,during 8 months (5 mg Lutéine + 1 mg Zéaxanthine / capsule).
1707918|NCT01404845|Dietary Supplement|food supplement without Lutein and Zeaxanthin|food supplement without Lutein and Zeaxanthin : 2 capsules per day, during 8 months.
1707919|NCT01404832|Drug|Treat with lansoprazole 30 mg BID for 2 weeks, endoscopic examination with esophageal biopsy for patients with persistent symptoms|Treat with lansoprazole 30 mg BID for 2 weeks, perform endoscopic examination with esophageal biopsy
1707920|NCT01404819|Drug|Anesthesia with Xenon|Patients undergo anesthesia with xenon (remifentanil with xenon).
1707921|NCT01404819|Drug|Standard anesthesia|Patients undergo standard anesthesia (remifentanil with propofol)
1707922|NCT01404806|Drug|GSK1349572 (dolutegravir)|Subjects will take an oral daily 50mg dose of GSK1349572 for 5-7 days. GSK1349572 in the CVF and BP will be measured over 24 hours after both the initial dose, and once steady state is reached 5-7 days later at the following time points: 0 (pre-dose) 1, 2, 3, 4, 5, 6, 8, 12, 18, and 24h. Cervical and vaginal biopsies will be collected once at initial dose at either 3, 6, 12 or 24 hours post dose, and again at steady state at the same single time point. Samples will be collected from 2 subjects per time point. BP and CVF samples will be obtained at 48 and 72 hours following the final GSK1349572 dose.
1707923|NCT01404793|Drug|Rocuronium|After insertion of the new liver and restoration of portal venous flow, 0.6 mg kg-1 rocuronium will be administered
1707924|NCT01404780|Device|GlideScope (GVL)|The Glidescope (GVL) has not been extensively studied for double lumen tube intubation. The GVL may be particularly useful for patients with difficult airways as it has a camera attached to the blade.
1707925|NCT01404780|Device|Macintosh Direct Laryngoscope (MDL)|Current standard of care at UHN for 50 years
1707926|NCT01404767|Drug|Esmolol|Baseline treatment consists of a bolus of 500ug/kg/min followed by an infusion of 50ug/kg/min for 4 minutes and titrating in increment of 50ug/kg/min up to a maximum of 300ug/kg/min to maintain a HR within 10% of the target HR (≤ 70 bpm), which is 70± 7 bpm.
1707927|NCT01404767|Drug|Metoprolol|The night and morning before surgery, the patients in the metoprolol arm will receive their standard dose of beta blocker metoprolol.These patients will receive their daily beta blockers orally or via nasogastric tube postoperatively if they are NPO (Group A).
1707930|NCT01404741|Procedure|allogeneic stem cell transplantation|donor available, after 4 cycles 5-azacytidine allogeneic stem cell transplantation after reduced conditioning
1707931|NCT01404741|Procedure|5-azacytidine until progress|if no donor available 5-azacytidine until progress or toxicities
1707932|NCT01404715|Drug|Metformin|Subjects will be given an oral dose of 1000 mg of metformin followed by an oral dose of 850 mg for a grand total of 1850 mg in both study Arm 1 and study Arm 2.
1707933|NCT01404715|Drug|Imatinib|A single oral dose of 600 mg of imatinib
1707934|NCT01404702|Drug|Zoledronic Acid|4 mg/m2/dose given iv on day 0 of every 28 day cycle
1707935|NCT01404702|Biological|Aldesleukin|"Dose Level 1: 3 x 10^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle
Dose Level 2: 6 x 10^6 IU/m2/day given subcutaneously on days 0 through 4 and 14 through 18 every 28 day cycle"
1707936|NCT01404689|Drug|Dexmedetomidine|dexmedetomidine 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
1707937|NCT01404689|Other|normal saline|0.9% NaCl 1μg/Kg•hr IV continuous infusion, initiated 15 min before the procedure (ERCP) till complete procedure
1707938|NCT01404676|Drug|Vildagliptin and metformin|Effects on glycemic variability, oxidative stress, and endothelial cell function.
1707939|NCT01404676|Drug|Glimepiride and metformin|Effects on glycemic variability, oxidative stress,and endothelial cell function.
1707940|NCT01404663|Biological|CD133 stem cell injection|Bone marrow derived CD133 stem cell witch are transplanted by intrathecal injection
1707941|NCT01404650|Drug|AUY922|AUY922: 70 mg/m2 IV over 60 minutes on Days 1, 8, and 15 of each cycle. Treatment cycles will be repeated every 21 days. Patients will be evaluated for response at 6 and 12 weeks and then every 9 weeks (i.e., every 3 cycles) thereafter. Patients may continue treatment until evidence of disease progression.
1707942|NCT01404637|Drug|Tamsulosin 0.4mg|Treatment: tamsulosin 0.2mg (2T) /day Posology: two 0.2 mg tablet to be taken after an evening meal.
1707943|NCT01404637|Drug|Tamsulosin 0.2mg|tamsulosin 0.2mg (1T) /day Posology: one tablet to be taken after an evening meal.
1707944|NCT01404611|Drug|DF289|Ear drops
1707945|NCT01404611|Drug|DF277|Ear drops
1707946|NCT01404611|Drug|DF289 plus DF277|Ear drops
1707947|NCT01404598|Drug|naproxcinod 750 bid|naproxcinod 750 bid
1707948|NCT01404598|Drug|naproxcinod 3000 mg od|naproxcinod 3000 mg od
1707949|NCT01404598|Drug|naproxen 500 mg bid|naproxen 500 mg bid
1707950|NCT01404585|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 12 weeks
1707951|NCT01404585|Drug|BMS-817399|Tablets, Oral, 200 mg, twice daily, 12 weeks
1707952|NCT01404585|Drug|BMS-817399|Tablets, Oral, 400mg, twice daily, 12 weeks
1707953|NCT01404572|Drug|Atazanavir (current formulation)|Solution, oral, atazanavir 15 mg/5 mL with 10% aspartame, single dose
1707954|NCT01404572|Drug|Atazanavir, powder for oral use 1 (POU1)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame, single dose
1707955|NCT01404572|Drug|Atazanavir (POU2)|Solution, oral, atazanavir 15 mg/5 mL with 4.2% aspartame and sucralose, single dose
1707956|NCT01404559|Device|Ossur Variflex prosthetic foot|Lightweight energy-storing prosthetic foot
1707957|NCT01404559|Device|Ossur Ceterus prosthetic foot|Shock-absorbing prosthetic foot
1707958|NCT01404559|Device|Endolite Elite Blade prosthetic foot|Multi-axial prosthetic foot
1707959|NCT01404546|Other|cost free pharmacotherapy|Participants assigned to the CF group received a starter kit (4-week supply) of cost-free quit smoking medication (nicotine replacement therapy, bupropion, or varenicline) and a pre-printed prescription to be filled by the patient at the end of the 4-weeks.
1707960|NCT01404546|Other|usual care|Participants assigned to the prescription only usual care group received a prescription for smoking cessation pharmacotherapy to be filled at their own cost at their local community pharmacy.
1707961|NCT01404533|Dietary Supplement|Ferrous sulfate|60 mg Ferrous sulfate
1707962|NCT01404533|Dietary Supplement|Ferrous sulfate|60 mg ferrous sulfate
1707963|NCT01404533|Dietary Supplement|Ferrous sulfate|6 mg ferrous sulfate
1707964|NCT01404520|Other|Exercise based multimodal intervention|The intervention is initiated early, during treatment (consolidation) in the intra-hospital setting and continues for two successive treatment series (12 weeks). The intervention is a three hour/wk supervised in-hospital programme of aerobic (stationary cycle) and functional muscle training, progressive relaxation training, nutrition supplement (protein and carbohydrate) immediately after training and health-promoting consultation combined with an unsupervised in-home walking and progressive relaxation programme.
1707965|NCT01404507|Drug|Gp 2b 3a inhibitor|bolus injection of abciximab via intracoronary route single injection during primary PCI dosage : 0.25mg/kg
1707966|NCT01404507|Device|aspiration thrombectomy|Aspiration thrombectomy via aspiration catheter
1707967|NCT01404507|Other|Both use|Both use of intracoronary abciximab and aspiration thrombectomy
1707968|NCT01404481|Device|clean intermittent self catheterisation single use vs re use|Over the 16 week period all patient will participate in 8 weeks of single use cathetersation and 8 weeks of re use catheterisation. The study is a randomised control crossover trial
1707969|NCT01404468|Device|pulsed ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (pulsed ultrasound)
1707970|NCT01404468|Other|off device|off device with Lidocaine (approximately 2 cc) was administered transdermally
1707971|NCT01404468|Device|continuous ultrasound device with lidocaine|Lidocaine (approximately 2 cc) was administered transdermally using a transducer (continuous ultrasound )
1707972|NCT01404455|Other|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading|HES 130/0.4 (VoluvenⓇ, Fresenius Kabi, Graz, Austria) 500mL loading during 15 minutes after induction of anesthesia
1707973|NCT01404442|Drug|placebo(distilled water|The placebo group (group P) received bupivacaine 10mg combined with 0.5ml distilled water intrathecally .
1707974|NCT01404442|Drug|Ketamine|The ketamine group (groupK) received bupivacaine 10mg combined with 0.1 mg/kg ketamine preservative free intrathecally
1707975|NCT01404442|Drug|Midazolam|The midazolam group (group M) received bupivacaine 10mg combined with0.02 mg/ kg midazolam intrathecally
1707976|NCT01404429|Drug|Methotrexate|Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
1707977|NCT01404403|Device|Rapid System|
1707978|NCT01404390|Drug|BAY80-6946|0.4mg/ kg, iv, day 1,8 and 15, every 28 days
1707979|NCT01404390|Drug|BAY80-6946|0.8mg/ kg, iv, day 1,8 and 15, every 28 days
1707980|NCT01404377|Procedure|infiltration with ropivacaine solution|Patients are allocated randomly into two arms on the morning of surgery, using random numbers and sealed envelopes. In the treated group infiltration is performed with a ropivacaine 7.5 mg.ml-1 solution and in the control group with an isotonic saline solution. In the two groups patients are operated under and nitrous oxide for maintenance. Dexamethasone 4 mg was given intravenously after anaesthetic induction for prevention of postoperative nausea and vomiting. Twenty milliliters of the allocated solution were used at the end of the surgical procedure to infiltrate the subcutaneous and deep layers at the level of the breast and axilla surgical incision.
1707981|NCT01404364|Drug|Triamcinolone|0,3mL intravitreal injection of Triamcinolone, single dose
1707982|NCT01404364|Drug|Chlorpromazine|2,5mL Chlorpromazine retrobulbar injection, single dose
1707983|NCT01404351|Device|PEAK PlasmaBlade|
1707984|NCT01404351|Procedure|Scalpel and Traditional Electrosurgery|
1707985|NCT01404338|Drug|Halobetasol 0.05% ointment|
1707986|NCT01404338|Drug|Placebo Ointment|
1707987|NCT01404325|Drug|standard therapy|centre specific CNI-based triple drug immunosuppression
1707988|NCT01404325|Drug|Everolimus (RAD001) as add-on|quadruple immunosuppressive regimen consisting of everolimus, CNI, MPA and steroids
1707989|NCT01404325|Drug|RAD001|
1707990|NCT01404312|Drug|Rifapentine (RPT)|"RPT dosing will be based on participants' weight:
Participants who weigh 30 kg to less than 35 kg will receive 300 mg once daily (administered as two 150-mg tablets).
Participants who weigh 35 kg to less than 45 kg will receive 450 mg once daily (administered as three 150-mg tablets).
Participants who weigh greater than 45 kg will receive 600 mg once daily (administered as four 150-mg tablets)."
1707991|NCT01404312|Drug|Isoniazid (INH)|Participants will receive one 300-mg tablet or three 100-mg tablets of INH once daily.
1707992|NCT01404312|Dietary Supplement|Pyridoxine (Vitamin B6)|"Participants will receive 25 mg or 50 mg of pyridoxine, based on the current local, national, or international dosing guidelines.
Participants receiving 25 mg of pyridoxine will take one 25-mg tablet once daily with INH.
Participants receiving 50 mg of pyridoxine will take two 25-mg tablets once daily with INH."
1707993|NCT01404299|Dietary Supplement|Nutritional Supplementation|- Providing two 200mL per day of commercial liquid formula cans for 12 weeks (additional 400kal of energy, 25g of protein, 9.4g of essential amino acids (60.2% leucine), 400mL of water, and micronutrients per day)
1707994|NCT01404299|Other|Control|- No intervention, except monthly home visits
1707995|NCT01404286|Behavioral|Physical exercise|After the adaptation sessions, volunteers underwent a session of resistance training at 60% of 1 RM organized as follows: 3 sets of 10 to 12 repetitions on each exercise machine with a 1 minute and 30 second interval between each set and an interval of 2 minutes between each exercise machine, giving a total duration of training between 50 and 60 minutes. The sequence of exercise machines used was alternated by body segment. The sessions were performed at the same time of day (morning) under controlled temperature conditions (24 ± 21C).
1707996|NCT01404273|Behavioral|Meditation/Relaxation Response Training|1 hour weekly sessions with 20 min daily home practice for 6 weeks
1773920|NCT00383851|Drug|ATN-224|
1707997|NCT01404260|Drug|Gefitinib|Gefitinib 250mg/d every cycle d15-25,and Gefitinib 250mg/d from d15 of last cycle until disease progression
1707998|NCT01404260|Drug|Gemcitabine +Carboplatin|Gemcitabine 1250mg/m2+Carboplatin AUC=5, every 4 weeks, maximum 4 cycles
1707999|NCT01404247|Other|Observational: to better characterize the retina and optic nerve in newborns using spectral domain optical coherence tomography (s-oct).|The OCT technician will attempt to image the eyes of neonates. The neonate may be given Cyclomydril ophthalmic solution, if needed for dilation. Cyclomydril dosing for this study is 1 drop every 5 minutes times 2.
1708000|NCT01404247|Procedure|OCT imaging.|All newborns meeting eligibility requirements will undergo spectral domain optical coherence tomography imaging in order to better characterize the retina and optic nerve in newborns
1708001|NCT01404234|Drug|AZLI|AZLI 75 mg was administered 3 times daily via the investigational nebulizer.
1708002|NCT01404208|Drug|D-Cycloserine|25mg dose for children weighing between 22.5kg and 45kg (dose = approx. .7mg/kg) 50mg dose for children weighing greater than 46kg (dose = approx. .7mg/kg) Dose given 7 times, every seven days, except for the third dose, which will be given three days after the second dose. All doses given 1 hour prior to therapy session.
1708003|NCT01404208|Drug|Placebo|Sugar pill
1708004|NCT01404195|Dietary Supplement|Ensure Plus Advance|Participating patients will be dispensed two small bottles daily, one at breakfast and one in the evening, seven days a week
1708005|NCT01404182|Biological|Vaccination with Fluval AB influenza vaccine|Vaccination with a single dose of Fluval AB influenza vaccine (trivalent, seasonal, active ingredient content: 15 μg HA/0.5mL of seasonal H1N1, H3N2 and B influenza antigens each) and aluminium phosphate gel adjuvant.
1708006|NCT01404169|Drug|E2020|In titration period, donepezil 5-mg tablet will be taken orally once daily for 6 weeks, following donepezil 10 mg tablets taken orally once daily for 18 weeks in the maintenance period.
1708007|NCT01404169|Drug|Placebo|Placebo matched to donepezil 5 mg or 10 mg tablets taken orally once daily for 24 weeks.
1708008|NCT01404156|Drug|Epirubicin cisplatin 5-Fluorouracil|"Three 21-day cycles ECF preoperatively:
Epirubicin (50 mg per square meter of body-surface area) by intravenous bolus on day 1 Cisplatin: 60 mg per square meter intravenously with hydration on day 1 5-Fluorouracil: 200 mg per square meter daily for 21 days by continuous intravenous infusion"
1708009|NCT01404156|Other|Carboplatin paclitaxel plus concurrent radiotherapy|"5 cycles carboplatin and paclitaxel given on days 1, 8, 15, 22 and 29 preoperatively:
paclitaxel: 50 mg / m2 IV over 1 hour
carboplatin: dosed to an area under the curve of 2, by Calvert formula, as a 1 hour IV infusion Radiation Therapy Concurrent radiation therapy will begin within 24 hours of initiation of chemotherapy for patients randomized to chemoradiation treatment.
Dose specifications:
Phase 1: Total radiation prescription dose 45 Gy given in 25 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment / day, starting on the first day of first cycle of chemotherapy. This total radiation dose option is acceptable if boost dose is not possible due to clinical reasons or dosimetric constraints.
Phase 2: (GTV only) Boost is not mandatory and up to the discretion of radiation oncologist. Total radiation prescription dose 5.4 Gy given in 3 fractions of 1.8 Gy per fraction, 5 fractions / week, one treatment ."
1708010|NCT01404143|Procedure|Subscapularis Tenotomy|After the deltopectoral approach is completed, the subscapularis tendon will be tenotomized one centimeter medial to its insertion on the lesser tuberosity. The tendon will be tagged for later repair. Repair will take place with a combination of transosseous sutures (3) placed in a mattress configuration through the area of exposed lesser tuberosity. In addition, a soft tissue tendon to tendon repair will be carried out using figure-8 stitches using #2 (heavy) non-absorbable suture (Ticron).
1708011|NCT01404143|Procedure|subscapularis peel|The subscapularis will be elevated from the lesser tuberosity. The tendon will be tagged with stay sutures for later reattachment (3 sutures in mattress configuration). Reapproximation will take place with three non-absorbable mattress sutures placed in a trans-osseous fashion through the bicipital groove, exiting the greater tuberosity and tied over a 4-hole mini-fragment plate.
1708012|NCT01404130|Drug|Isotretinoin|0.5-1mg/kg daily for 4-6 months
1708013|NCT01404117|Drug|Laquinimod 0.6|Laquinimod 0.6 capsule
1708014|NCT01404117|Drug|Laquinimod 1.2|Placebo
1708015|NCT01404117|Other|Glatiramer Acetate or interferon-beta+ Placebo|GA 20 mg/1mL or IFN-B (Avonex®, Betaseron®/Betaferon®, Rebif® or Extavia®) + oral daily placebo
1708016|NCT01404104|Drug|Temsirolimus (pre surgery)|Temsirolimus will be given to patients 12 weeks prior to surgery (with a one week off period right before the surgery date).
1708017|NCT01404091|Drug|LY2940094|Administered orally
1708018|NCT01404078|Drug|Single Dose Polycap|Low strength polycap contains Ace inhibitor; betablocker; thiazide diuretic; statin; aspirin
1708019|NCT01404078|Drug|Double dose Polycap|2 Capsules of low strength polycap with 30mEq of Potassium
1708020|NCT01404065|Procedure|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2, at an intensity of 2mA. For active tDCS, the subject will undergo stimulation for 20 minutes. For sham stimulation, the current will be ramped up and then down again (for 30 seconds total) to simulate the feeling of active stimulation.
1708021|NCT01404052|Device|Transcranial Direct Current Stimulation|Subjects will be randomized to undergo either 5 sessions of active tDCS stimulation, or 5 sessions of sham tDCS stimulation. For both active and sham stimulation, we will use electrodes of 35cm^2 and an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex contralateral to the most painful side, and the cathodal electrode will be placed over the contralateral supraorbital area. Active stimulation will last for 20 minutes, while sham stimulation will only last for 30 seconds, mimicking the sensations during active stimulation.
1708022|NCT01404039|Behavioral|Motor Learning|Subject will have to draw a set of shapes and words during 20 minutes.
1708023|NCT01404039|Behavioral|Somatosensory Learning|Subjects will perform a learning task involving sensory activation of the hand. The task will consist of learning letters of Braille.
1708024|NCT01404039|Behavioral|Observational Task|Subjects will watch a 10 second video of a right-handed person performing movements of their left index finger. Subjects will be instructed to watch the video without any other specific instruction.
1708025|NCT01404039|Behavioral|Mental Imagery|Subjects will be asked to perform mental imagery of motor practice - finger movements of the left hand for 10 minutes.
1708087|NCT01403454|Behavioral|Interactive Health Communication Application|web-based application
1708026|NCT01404039|Device|transcranial direct current stimulation|Subjects will undergo active and sham tDCS stimulation in a randomized and counterbalanced order. During both active and sham stimulation, we will use electrodes of 35cm^2, intensity of 2mA for a duration of 20 minutes. The anode electrode will be placed over the right primary motor cortex (M1) and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be on for the duration of 20 minutes. For sham stimulation, the current will ramp up, and then down again for 30 seconds to simulate the sensation of active tDCS.
1708027|NCT01404026|Device|Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo tDCS stimulation. For both active and sham stimulation we will use electrodes at 35cm^2, with an intensity of 2mA. The anodal electrode will be placed over the primary motor cortex, and the cathode will be placed over the contralateral supraorbital area. For active stimulation, the current will be active for the duration of 20 minutes. For sham stimulation, the current will only be active for 30 seconds, simulating the sensations of active stimulation.
1708032|NCT01403987|Behavioral|Residency Program Teaching|The residency program provides education surrounding the management of ascites to all house-staff in the training program. This consists of lectures, case-based or bedside discussions, and board review. All arms will receive the standard teaching provided by the residency program.
1708033|NCT01403987|Behavioral|Lecture|During resident rotations on inpatient wards there are typically several dedicated, one-hour discussions facilitated by the team's supervising attending, addressing a variety of internal medicine topics. In place of or in addition to one of these discussions, a gastroenterology fellow will meet with the team for one hour to discuss a standardized case of a patient with ascites and the management issues. At this time they will review the consensus guidelines for management, and be provided with a pocket card with key points.
1708034|NCT01403987|Other|Pocket Card Reference|A 4x6 inch laminated card will be administered to both intervention arms at the beginning of the study. The card will contain a brief summary of AASLD guidelines, indications for and contraindications to paracentesis, and key studies to order for fluid analysis. The organization of residency rotations is such that members of one randomization group do not typically work with members of other groups, however in the event that there is crossover, they will be free to share information as they see fit in order to optimize patient care.
1708035|NCT01403987|Behavioral|Pager|"The intensive education arm will be given a pager number at their initial meeting that they can use to call for personal assistance with performing paracentesis. Since a paracentesis is frequently referred to by housestaff as a tap, the pager number will correlate with the letters, TAPS, or #8277. The goal of the pager is to provide supervision and individual teaching so that the care provider can become proficient in the procedure."
1708036|NCT01403974|Drug|BI 836845|Intravenous infusion once every week
1708037|NCT01403948|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion
1708038|NCT01403922|Drug|TC-5214|Tablet oral bid days 1 to 7
1708039|NCT01403922|Drug|TC-5214|Tablet oral bid days 8 to 14
1708040|NCT01403909|Device|Intermittent pneumatic compression|Intermittent pneumatic venous compression is applied to the lower limbs of patients during surgery.
1708041|NCT01403909|Procedure|Standard care|Intermittent pneumatic venous compression is not applied to the lower limbs of patients during surgery.
1708042|NCT01403896|Drug|Plerixafor (Mozobil)|They will receive Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
1708043|NCT01403896|Drug|Plerixafor + G-CSF|They will receive G-CSF (5 µg/kg/day) for 4 days (Days -4,-3,-2,-1 at 8 am) followed by Plerixafor (240 µg/kg/day subcutaneously for 1 dose) on Day 0 at 8 am
1708044|NCT01403883|Behavioral|Standard Care|Psychological & enterostomal therapy clinics on demand only
1708045|NCT01403883|Behavioral|Optimal care (Psychological and enterostomal therapy clinics)|Psychological clinics at D-45, D0, D45, D60, D90 enterostomal therapy clinics at D-45, D0, D45, D60
1708046|NCT01403870|Other|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
1708047|NCT01403857|Other|Whole grain foods|Eight commonly consumed whole grain products that meet the consumers Dietary Guidelines recommendations for a period of six weeks.
1708048|NCT01403857|Other|Refined grains|Eight commonly consumed refined grain products given in amounts that fulfill the consumer's Dietary Guidelines for Americans recommendation over the course of six weeks.
1708049|NCT01403844|Other|Carotenoid Depletion|Depletion of carotenoids using a restricted food list
1708050|NCT01403844|Other|Carotenoid Repletion|Carotenoid repletion with provided diet based on dietary guidelines.
1708051|NCT01403844|Other|Carotenoid Depletion|Carotenoid depletion using a restricted food list.
1708052|NCT01403844|Other|Natural Repletion|Resumption of usual personal diet regimen. No restrictions.
1708053|NCT01403831|Other|Daily text messages|2-3 times daily text messages regarding diabetes care and healthy lifestyle choices
1708054|NCT01403818|Drug|ASP1941|oral
1708055|NCT01403818|Drug|Mitiglinide calcium hydrate|oral
1708056|NCT01403805|Biological|Pneumococcal vaccination (Pneumovax NP, 21800AMY10131000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
1708057|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
1708058|NCT01403805|Biological|Influenza vaccination (Flubik HA, 16100EZZ01207000)|Injection,subcutaneous,0.5ml,ones,Planned duration of intervention:a day
1708088|NCT01403441|Device|Radiosurgical Neuromodulation using the Cyberknife|our team has selected 60 Gray (Gy) as the dose to the target margin to be used for radiosurgical neuromodulation in patients with intractable bipolar disorder; the target being the anterior cingulate (Cg) that correlates with Brodmann area 25 (Cg25).
1708458|NCT01400516|Drug|calcium citrate|1000 mg of calcium citrate
1708059|NCT01403805|Other|Specific frequency of oral care|1 dentist and 2 dental hygienists visited the nursing home once a week. After the residents agreed our receive oral care, the dentist/dental hygienist spent 15 minutes with brushing of teeth, scaling, oral wiping, gargling and cleaning of dentures, to reduce dental plaque which is oral bacteria mechanically by using cleaning tools, including toothbrush, interdental brush, dental scaler, tongue brush, and sponge brush to treatment of periodontal disease at the washstand in their private room primary care physicians. At the same time, they taught and recorded to the nursing care workers the methods of administering responsible oral care to dye for dental plaque by using plaque disclosing agent material.
1708060|NCT01403792|Drug|P2G12|A single intravaginal administration of 1ml P2G12/placebo.
1708061|NCT01403779|Radiation|intensity modulated radiotherapy (IMRT) for breast cancer|right sided breast cancer patients are stratified to receive a hypofractionated treatment course (40.05 / 2.67Gy in 15 fractions) and the left sided breast cancer patients a normofractionated irradiation (50/2Gy in 25 fractions). In both arms, patients between 60-69 years are to receive a boost (16 Gy / 2Gy).
1708062|NCT01403740|Drug|rFVIIIa, aPCC, FVIII, DDAVP, Azathioprine, Rituximab, Cyclosporin|According to local clinical standards
1708063|NCT01403714|Procedure|Renal Artery Stenting|If the patient has a hemodynamically significant renal artery stenosis, and they are randomized to renal artery stenting, they will undergo renal artery stenting
1708064|NCT01403701|Behavioral|Physical therapy|pelvic floor physical therapy
1708065|NCT01403688|Procedure|RPFNA|"Baseline RPFNA within 3 month prior to the initial COH cycle or within the first 10 days of the treatment cycle (delete this).
Repeat RPFNA if pregnancy is not achieved: 6 to 18 months following baseline assessment
Repeat RPFNA if pregnancy is achieved: approximately 12 months after discontinuation of breast feeding"
1708066|NCT01403675|Procedure|Ovarian autotransplantation|There are two ways to transplant the thawed ovarian tissue back into a woman's body. It can be put back inside the abdomen, close to the natural location of the ovaries, or the tissue can be put under the skin of the abdomen. After you have had the transplant, your hormone function will be tested every month. Each month, you will have a blood draw to measure hormones and an ultrasound to see how the tissue is growing. These monthly visits will continue until you have normal hormone levels. If the transplant is successful, it is expected that your hormones would return to normal in 3 - 7 months. If your hormone levels return and stay regular for three months, then Dr. Kim will talk to you about trying to get pregnant. The method of getting pregnant will depend on the type of transplantation surgery you had and your current medical condition. You will have weekly blood tests and other tests to determine the best way to get pregnant.
1708067|NCT01403662|Drug|Minocycline|Minocycline (100 mg bid) will be administered as an adjunctive agent to conventional Health Canada-approved, or first-line CANMAT bipolar guideline-recommended, agents for bipolar disorder.
1708068|NCT01403649|Behavioral|Private/public collaboration to increase flu vaccination|Intervention practices will develop office-based interventions including methods to identify high-risk patients within their practices and methods of maximizing the immunization of these children within the practice, use of patient reminders, after-hours influenza clinics, walk-in provision of influenza vaccine and increased focus on education regarding the need for immunization. The practices will also collaborate with their county public health departments and visiting nursing associations to develop private-public collaborative interventions that may include large clinics for school-aged children for multiple practices and tracking of influenza supplies and redistribution of influenza vaccine between practices when supplies are delayed or inadequate.
1708069|NCT01403649|Other|Usual care|This group will continue administering influenza vaccine to their patients in their practice as they normally do.
1708070|NCT01403636|Drug|SAR245409|Pharmaceutical form:capsule Route of administration: oral
1708071|NCT01403623|Procedure|Resuscitation and post resuscitation care with plastic bag|Infant will be resuscitated and placed in a plastic bag up to his/her neck and around the back of his head (not covering the face) in the delivery room and taken to the nursery. The infant will remain in the plastic bag until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
1708072|NCT01403623|Procedure|Resuscitation- no plastic bag for temperature regulation|Infant will be resuscitated in the delivery room and taken to the nursery. The infant will be observed per unit standard until first axillary temperature remains stable at 36.5-37.5 degrees Celsius. Expected length of time approximately one hour.
1708073|NCT01403610|Drug|TH-302|TH-302 single dose at 575 mg/m2 administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
1708074|NCT01403610|Drug|Placebo|Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
1708075|NCT01403597|Device|Refirme ST Applicator and Matrix RF Applicator|5 treatments with combination of devices every 4 weeks to the facial (or sub facial regions).
1708076|NCT01403571|Dietary Supplement|Salba (Salvia hispanica L.)|30g/1000kcal/day over 24 wks
1708077|NCT01403571|Dietary Supplement|Oat-based Control|Placebo: 36g/1000kcal/day over 24 weeks
1708078|NCT01403558|Behavioral|Cognitive behavioral therapy with motivational interwiewing|CBT combined With MI
1708079|NCT01403545|Drug|Liposomal Curcumin|Single dose intravenous infusion of liposomal Curcumin at 10, 20, 40, 80, 120, 180 mg/m² over 120 minutes
1708080|NCT01403545|Other|Placebo|5% glucose infusion over 120 minutes
1708081|NCT01403532|Drug|Traditional intervention for HH using HCG and FSH|Human chorionic gonadotropin(HCG),2000U,im,2 times/week, one year and a half; Follicle stimulating hormone(FSH),75U, im, 3 times/week, one year;
1708082|NCT01403532|Drug|Sequential intervention for HH using HCG and FSH|Human chorionic gonadotropin,2000U,im, 2 times/week, one and half a year Follicle stimulating hormone,75U,im,3 times/week, every other three months
1708083|NCT01403532|Drug|Sequential intervention for HH using HCG and FSH plus zinc|Human chorionic gonadotropin,2000U,im,2 times/week, one year and a half Follicle stimulating hormone,75U, im, 3 times/week, every other three months Zinc gluconate 20mg,P.O, twice daily
1708084|NCT01403506|Drug|N-acetyl Cysteine|600 mg N-acetyl Cysteine 6 hrs before renal transplantation, and 12 hrs and 18 hrs after renal transplantation.
1708089|NCT01403428|Other|Noninvasive positive pressure ventilation|Noninvasive positive pressure ventilation (NPPV) will deliver pressurized gas through a nasal or oronasal mask, connected to a pressure targeted ventilator. NPPV provides ventilator support without the use of an endotracheal tube. Standard of care includes use of corticosteroids, oxygen, short acting β-agonist and inhaled ipratropium bromide.
1708090|NCT01403415|Drug|Dexamethasone|Given PO or IV
1708091|NCT01403415|Other|Laboratory Biomarker Analysis|Correlative studies
1708092|NCT01403415|Drug|Methotrexate|Given IT
1708093|NCT01403415|Drug|Mitoxantrone Hydrochloride|Given IV
1708094|NCT01403415|Drug|Pegaspargase|Given IV
1708095|NCT01403415|Other|Pharmacological Study|Correlative studies
1708096|NCT01403415|Drug|Temsirolimus|Given IV
1708097|NCT01403415|Drug|Vincristine Sulfate|Given IV
1708098|NCT01403389|Drug|Eculizumab|1200 milligrams Eculizumab diluted in 0.9% NaCl to 5mg/mL for a total volume of 240 mL administered by IV infusion over 35 minutes in the operating room prior to organ reperfusion
1708099|NCT01403389|Drug|Placebo|240 mL of 0.9% Sodium Chloride IV fluid given as placebo in the operating room prior to organ reperfusion
1708100|NCT01403376|Drug|teriflunomide|"Film-coated tablet
Oral administration"
1708101|NCT01403376|Drug|Interferon-β-1|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
1708102|NCT01403376|Biological|Influenza vaccine|"Inactivated, split-virion influenza vaccine 2011-2012
One administration by intramuscular or intradermal route as per product specification"
1708103|NCT01403363|Drug|use of fentanyl patch that was halved|A sample of 95 patients will be recruited. Once consent form is signed, blood samples will be collected twice: 1. At the time of the visit; 2. After 144 hours (about 6 days) from the first sample, and at least 36 hours after replacing the cut patch. Pain management will be evaluated at both visits using the Brief Pain Inventory (Hebrew version) - BPI questionnaire, and rescue doses used before and after the cutting of the patch. The blood samples will be transferred to the laboratory for testing of fentanyl concentration levels.
1708104|NCT01403350|Device|Malaria Rapid Diagnostic test|Study Phase I: RDT used under the standard programme of training and support; Study Phase II: RDTs deployed with additional programme components including improved training and supportive interventions
1708105|NCT01403337|Other|Ischemic preconditioning|The RIPC protocol will consist of three cycles of the following: 5-minute inflation of a blood pressure cuff around the right upper arm to 200 mmHg (or 20 above the systolic blood pressure if baseline BP > 200 mmHg) to allow for external compression of the brachial artery resulting in transient arm ischemia, followed by a 5-minute interval of cuff deflation to allow for reperfusion. The total duration of the protocol is 30 minutes equally divided between ischemia and reperfusion. The protocol is to be applied in the patient room the morning of the operation.
1708106|NCT01403337|Other|Control|A Blood Pressure cuff inflated to 40-50 mmHg
1708107|NCT01403324|Drug|TSH stimulation|rh TSH stimulation followed by thyroid hormon withdrawal
1708108|NCT01403311|Drug|5-Aminolevuline Acid|5-Aminolevuline Acid (ALA) at 30 mg/kg given orally 4 hours before surgery
1708109|NCT01403298|Behavioral|Family-Based HIV prevention|This individual, family-based intervention provides sex and HIV/AIDS education as part of a family-based general health education program that focuses on safe decision-making and how to control emotions to stay safe and improve parenting skills.
1708110|NCT01403298|Other|Adolescent Only Health Promotion|An individual, adolescent-only health education program that focuses on risk behaviors related to HIV/AIDS, smoking, diet and exercise
1708111|NCT01403285|Drug|Cyclophosphamide|One single low-dose i.v. infusion of cyclophosphamide (300mg/m2) prior to the first vaccination as pre-treatment
1708112|NCT01403285|Biological|IMA950 plus GM-CSF|Six vaccinations with IMA950 plus GM-CSF as adjuvant on 8 pre-defined days from Day 1 to Day 78
1708113|NCT01403285|Biological|IMA950|After Day 78, vaccinations with IMA950 (no GM-CSF) will be given on a monthly basis for up to one year from start of vaccination or until disease progression
1708114|NCT01403285|Drug|Imiquimod|Imiquimod will be topically applied 10-20 minutes after each vaccination. After the third vaccination onward patients will apply additional imiquimod 24 hours after each vaccination at home on their own
1708115|NCT01403272|Device|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.
Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
1708116|NCT01403259|Drug|S-1 plus oxaliplatin|S-1 60 mg BID at day 1-14 Oxaliplatin 100 mg/m2 at day 1 Frequence of cycles: every 3 weeks
1708118|NCT01403233|Dietary Supplement|cogniVida 50mg/day|2 capsules 25 mg (total 50 mg) cogniVida™ once a day
1708119|NCT01403233|Dietary Supplement|cogniVida100mg/day|4 capsules 25 mg (total 100 mg) cogniVida™ once a day
1708120|NCT01403233|Dietary Supplement|Rebaudioside-A 303.7mg/day|4 capsules 75.92 mg (total 303.68 mg) rebaudioside A once a day
1708121|NCT01403220|Procedure|Hemodiafiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemodiafiltration.
1708122|NCT01403220|Procedure|Hemofiltration first|Patients will alternate consecutive dialysis sequences between hemodiafiltration and hemofiltration, but starting with hemofiltration.
1708123|NCT01403207|Other|musculoskeletal|Many musculoskeletal conditions are impacted by the chromosomal sex of the patient. While osteoarthritis (OA) is predominant in men younger than 50 years of age, after age 50 the condition is more prevalent in women, particularly post-menopause. This has implications for diagnosis and treatment of OA, as well as for joint replacement.
1708124|NCT01403194|Device|CPAP/BiPAP|Subjects will be treated with either CPAP or Bi-PAP for three months.
1708164|NCT01402947|Drug|Ciprofloxacin XR + MMX Placebo|MMX Mesalazine/mesalamine placebo dosed once-a-day (QD) orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose of MMX Mesalazine/mesalamine placebo on day 4
1708165|NCT01402947|Drug|MMX Mesalazine/mesalamine + Ciprofloxacin XR|MMX Mesalazine/mesalamine 4.8 g QD orally for 3 days, then a single oral 500 mg dose of ciprofloxacin XR + a single oral dose 4.8 g of MMX Mesalazine/mesalamine on day 4
1773921|NCT00383851|Drug|Temozolomide|
1708125|NCT01403181|Drug|Boceprevir|"In the experimental arm boceprevir (800 mg orally three times daily), PEG-IFN and ribavirin will be given for 24 weeks after the lead-in; the patients who will have undetectable HCV-RNA at week 8 will stop treatment at week 28; those who will be HCV-RNA positive at any visit between week 8 and 24 will receive an additional 20 weeks of PEG + RBV. Treatment will be discontinued if HCV-RNA is positive at week 24.
Immunological analysis will be performed longitudinally at the following time points: week -4, 0, 4 (end of lead-in), 8, 12, 24, 48, week 24 of follow-up. HCV-RNA will be quantified at the same time points and viremia will be correlated with immunological data."
1708126|NCT01403168|Other|OSTEOPATHY + conventional analgesic treatments|"5 sessions for osteopathy are planned and will start in the 15 days following the enrollment.
The conventional analgesic treatments will be administered in the 15 days following the enrollment."
1708127|NCT01403168|Other|Conventional analgesic treatments|These treatments will be administered in the 15 days following the enrollment. Dose and frequence will depend on patients.
1708128|NCT01403155|Biological|INO-3401 + EP|All subjects will receive 0.9mg/mL of study vaccine (INO-3401 DNA plasmid vaccine)at Day 0 and Month 3.
1708129|NCT01403129|Procedure|Artemis Ultrasound Exam|Ultrasound exam of both eyes using an Artemis-2 device. Exam will be performed once. Exam duration is 20 minutes per eye.
1708130|NCT01403129|Procedure|ARFI Ultrasound exam|Acoustic radiation force (ARFI) ultrasound exam. Corneal tissue displacements at the epithelial surface, at Bowman's membrane, and at the posterior corneal surface will be measured, pre and post toneburst. Measurements will be taken in both eyes.
1708133|NCT01403103|Dietary Supplement|cholecalciferol|Given PO
1708134|NCT01403103|Procedure|biopsy|Correlative studies
1708135|NCT01403103|Genetic|protein expression analysis|Correlative studies
1708136|NCT01403103|Other|enzyme-linked immunosorbent assay|Correlative studies
1708137|NCT01403103|Other|laboratory biomarker analysis|Correlative studies
1708138|NCT01403103|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
1708139|NCT01403090|Device|Angel Catheter|The Angel Catheter will be inserted in the femoral vein following standard central line placement techniques. Once the catheter is on the Inferior Vena Cava, the filter will be deployed following the manufacturer instructions and secured to the skin.
1708140|NCT01403077|Device|480 Biomedical Bioresorbable Scaffold System|480 Biomedical Bioresorbable Scaffold System
1708141|NCT01403064|Biological|ALD518|IV
1708142|NCT01403064|Drug|0.9% saline|IV Infusion
1708143|NCT01403051|Drug|EFV/FTC/TDF|FDC efavirenz/emtricitabine/tenofovir disoproxil fumarate (Atripla) 600 mg/200 mg/ 300 mg tablet taken orally once daily at bedtime on an empty stomach.
1708144|NCT01403051|Drug|Calcium Carbonate|Calcium carbonate 500 mg tablet taken orally twice daily with food for 48 weeks.
1708145|NCT01403051|Drug|Vitamin D3|One Vitamin D3 4000 IU capsule taken orally once daily with food for 48 weeks.
1708146|NCT01403051|Drug|Placebo for calcium carbonate|A placebo for calcium carbonate twice daily taken orally as one x 0 mg tablets with food for 48 weeks
1708147|NCT01403051|Drug|Placebo for vitamin D3|A placebo for vitamin D3 once daily taken orally as one capsule with food for 48 weeks.
1708148|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 1 for 84 days
1708149|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 2 for 84 days
1708150|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 3 for 84 days
1708151|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 4 for 84 days Other interventions may be added
1708152|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 5 for 84 days
1708153|NCT01403038|Drug|Elagolix|Elagolix Dose Regimen 6 for 84 days
1708154|NCT01403038|Drug|elagolix|Elagolix plus Activella Dose Regimen 7 for 84 days
1708155|NCT01403025|Drug|liraglutide|Once daily at a fixed timing, and subcutaneously (under the skin) in the abdomen, in the thigh or in the upper arm
1708156|NCT01403012|Other|Withdrawal of venous blood samples|"Withdrawal of venous blood samples (approx. 20 ml) and 2 skin biopsies (5 mm)
Laboratory measurements:
Fasting serum concentrations of 200 metabolites covering a biologically relevant panel of amino acids, sugars, acylcarnitines and phospholipids Genome-wide expression profiles generated from RNA derived from peripheral leukocytes"
1708157|NCT01402999|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
1708158|NCT01402986|Other|Placebo Q2W|Participants who received matching placebo subcutaneous injection every 2 weeks (Q2W) for a total of 26 doses up to 50 weeks.
1708159|NCT01402986|Biological|Tralokinumab 300 mg, Q2W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for a total of 26 doses up to 50 weeks.
1708160|NCT01402986|Other|Placebo, Q2/4W|Participants received matching placebo subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
1708161|NCT01402986|Biological|Tralokinumab 300 mg, Q2/4W|Participants received tralokinumab 300 mg subcutaneous injection Q2W for 12 weeks followed by Q4W for 38 weeks (Q2/4W) for a total of 16 doses.
1708162|NCT01402973|Other|Dietary|The diets will each consist of 3 meals/day and 1 snack/day which are either high or low in AGEs.
1708163|NCT01402960|Device|High Definition Transcranial Direct Current Stimulation (HD-tDCS)|"Subject will receive active anodal/cathodal and sham HD-tDCS in a randomized, counterbalanced order. Each stimulation session will be separated by at least one week to avoid carryover effects. For both active and sham HD-tDCS the electrodes will be placed over the primary motor cortex, at an intensity of 2mA.
For active anodal stimulation, the anode will be over the primary motor cortex, and the cathodal electrodes (4) will surround the anode in a 3 inch square, duration will be 20 minutes.
For active cathodal stimulation, the cathode will be over the primary motor cortex, and the anodal electrodes (4) will surround the cathode in a 3 inch square, duration will be 20 minutes.
For sham stimulation, the same procedure will be used, however, current will only be active for 30 seconds (current ramping up, then ramping down)"
1708166|NCT01402934|Procedure|Hydroxyethyl starch solution (Voluven) infusion|fluid loading will be performed by hydroxyethyl starch solution (Voluven), at 6 mL/kg
1708167|NCT01402921|Device|V0322 BC|"Stocking Elastic MCT is a widely recognized and the consensus-approved treatment for chronic venous insufficiency (CVI).Efficacy evidence level is often insufficient (grade B or C), or based on studies carried prior to CEAP classification (2004).
The medical device is defined by the following parameters: ankle pressure(10 mmHg)and calf pressure (23 mmHg)
3 months duration daily treatment"
1708168|NCT01402908|Drug|PI-88|Lyophilized powder reconstituted to provide 160 mg of PI-88
1708169|NCT01402908|Other|Placebo|Lactose lyophilized powder
1708170|NCT01402895|Other|Exercise|Transversus abdominus exercise
1708171|NCT01402895|Other|Mobilizations|The physiotherapist will perform mobilizations to the L-spine and SI joints with the participant in a specific position.
1708172|NCT01402882|Drug|Tranexamic Acid|2 grams (1 gram over 10 minutes and 1 gram over 8 hours)
1708173|NCT01402869|Drug|4% prilocaine plain|5mg/kg via infiltration into multiple sites of the buccal mucosa of mouth 1 time prior to start of restorative dental treatment
1708174|NCT01402869|Drug|2% Lidocaine with 1:100,000 epinephrine|2.5mg/kg via infiltration into multiple sites of buccal mucosa of mouth 1 time prior to restorative dental treatment
1708175|NCT01402856|Other|Education|An educational program targeting HS students on the risks of distracted driving that was 60-min long & utilized: a 5-10 min DVD on a teenager's real-life experience of the devastating effects of distracted driving, other videos placing the viewer in the driver's seat, power point presentations of state and national statistics related to seat belt usage, mortality, and substance use, overview of state laws, demonstrations of the physics of an accident, & interactive games simulating distracted driving.
1708176|NCT01402843|Drug|pitavastatin, valsartan, placebo|pitavastatin 4mg/day 8 week valsartan 320mg/day 8 week
1708177|NCT01402830|Other|Visual analogue scales (EVAs)|This scale measures the pain intensity.
1708178|NCT01402817|Drug|Sutent®/Sunitinib|Upon enrollment, subjects will receive Sutent® orally. Adults (Age >18) will receive 25mg. Children will receive 10mg/m2/day. All subjects will take the daily dose for 28 days followed by a 14 day rest period. If subjects tolerate the initial dose, adults will be increased to 37.5mg and children will be increased to 15mg/m2/day. Again, subjects will take that dose for 28 days followed by a rest period of 14 days. Adults who tolerate the increase will go up to the maximum dose of 50mg. The maximum dose for children is 15mg/m2/day.
1708179|NCT01402791|Other|Questionnaires|All included couples (women and their partners) are required to fill out several questionnaires: 1. Questionnaire for women; 2. Self-questionnaire for women; 3. SFQ for women; 4. Questionnaire for men; 5. Self-questionnaire for men; 6. IIEF for men.
1708180|NCT01402765|Device|Summit first|Pressure measurements are first taken on the Summit mattress. The patient is then transferred to a Nimbus 3 mattress, and the measures are repeated.
1708181|NCT01402765|Device|Nimbus 3 first|Pressure measurements are first taken on the Nimbus 3 mattress. The patient is then transferred to a Summit mattress, and the measures are repeated.
1708182|NCT01402752|Biological|Blood flow to the tracheo-bronchial mucosa|Measurement of blood flow to the tracheo-bronchial mucosa via differential absorption of diluted dimethyl ether tracer gas.
1708183|NCT01402739|Other|Point of Care Coagulation Monitoring Guided Transfusion Algorithm|(thromboelastometry, aggregometry, blood gas analysis)
1708184|NCT01402739|Other|standard coagulation monitoring guided transfusion algorithm|aPTT, ACT, platelet count, hemoglobin, fibrinogen
1708185|NCT01402726|Procedure|renal sympathetic modification|Device: THERMOCOOL® Catheter Renal sympathetic modification with a catheter-based procedure
1708186|NCT01402713|Biological|GC1107|GC1107-T5.0: low dose, GC1107-T7.5: high dose
1708187|NCT01402713|Biological|TD_PUR INJ / SK Td vaccine|step 1(phase 2)-TD_PUR INJ step 2(phase 3)-SK Td vaccine
1708188|NCT01402700|Device|Visi-Pro™ Balloon Expandable Stent System|Implantation of one or more study devices in the common and/or external iliac artery.
1708189|NCT01402674|Drug|Abrupt cessation of phentermine pharmacotherapy|Patients will be asked to cease taking phentermine, then to complete psychometric scales 24 and 48 hours later. Patients will be examined at 48 hours by physician who will determine if phentermine should be continued or discontinued.
1708190|NCT01402648|Dietary Supplement|Eviendep (CM&D Pharma Limited, UK)|175 mg milk thistle (fruit dry extract, 70% in silymarin)+ 20 mg flaxseed (dry extract, 40% in secoisolariciresinoldiglucoside)+750 mg non-starch, insoluble and indigestible fiber (6% in lignin). Provided in 5 g sachets, to be dissolved in half glass water, administered twice a day for 60 days on top of the common diet.
1708191|NCT01402648|Dietary Supplement|Maltodextrins|900 mg maltodextrin+excipient as per the active comparator eviendep, up to 5 g/sachet
1708192|NCT01402635|Device|point-of-care chemistry test(POCT) (Piccolo)|comprehensive chemistry POCT including ALB, ALP, ALT, AST, BUN, Ca, Cl-, Cre, Glu, K+, Na+, TBil, TCO2, TP It takes 12minutes to perform analyze.
1708193|NCT01402622|Drug|Propofol anesthesia|In the TIVA and TIVA-P group, propofol and remifentanil were used for induction and maintenance of anaesthesia. In the control group, propofol and remifentanil were used for induction and anaesthesia was maintained with desflurane and remifentanil. In the control and TIVA-P group, ramosetron 0.3mg was administered at the end of surgery. In all patients, postoperative pain was controlled with fentanyl-based intravenous patient-controlled analgesia. he depth of anaesthesia was monitored with a bispectral index score monitor and maintained at 40-60.
1708194|NCT01402609|Device|electronic discharge communication tool|The intervention will consist of discharges being conducted with the use of the electronic discharge communication tool.For the intervention group, the care team will record the information that they collect directly into the computerized tool during the hospital stay.
1708195|NCT01402609|Device|Usual care|Control group will receive usual care. This usual care typically involves paper-based handwritten discharge communications, with subsequent provision of a dictated discharge summary produced some time after hospital discharge, with unpredictable success of delivery, and with unstructured and sometimes haphazard content.
1708196|NCT01402596|Drug|Midazolam|0,4 mg per kg - intranasal midazolam - once
1708197|NCT01402596|Drug|Chloral Hydrate|50 mg per kg, rectal
1708198|NCT01402583|Drug|PEG IFN/Ribavirin|PEG IFN/Ribavirin
1708269|NCT01402076|Drug|Tasimelteon|20mg daily dosing, Days 4-20
1708270|NCT01402076|Drug|Rosiglitazone|4mg, single dose, Days 3 and 20
1708199|NCT01402570|Dietary Supplement|Glutathione|glutathione is a dietary supplement and an antioxidant. Subjects will take 1000 mg per day for three month. Each capsule contains 500 mg glutathione.
1708200|NCT01402557|Behavioral|Weight Loss Church Program|An initial 12-week weight loss program held in churches to ensure adequate participation, competence in performing exercises, and development of social relationships among participants. All participants attend the church programs prior to the weight maintenance phase.
1708201|NCT01402557|Behavioral|Telephone Counseling|Following completion of the weight loss program, participants will receive monthly telephone counseling.
1708202|NCT01402557|Behavioral|Telehealth Support|After the weight loss program, women will access the home weight maintenance telehealth program through Internet enabled digital video recorders connected to their television sets. The telehealth program includes three components: (1) Weekly Video: home access to weekly video programs including problem solving and relapse prevention strategies, as well as motivational stories; (2) Teleexercise: home access to updated video exercise programs; and (3) Electronic Communication: social support through online communication with other participants, and with an exercise and nutrition interventionist.
1708203|NCT01402544|Drug|ranibizumab|0.5mg intravitreal injection, monthly for 12 months, or until BCVA returns to pre-wet AMD baseline.
1708204|NCT01402531|Drug|Submucosal Bevacizumab|200 mg Bevacizumab, injected submucosally- 100 mg per nostril
1708205|NCT01402518|Procedure|Per-oral enodscopic myotomy|
1708206|NCT01402505|Procedure|Transvaginal NOTES sleeve gastrectomy|transvaginal NOTES sleeve gastrectomy
1708209|NCT01402479|Drug|Ramipril|ramipril 2.5mg twice a day
1708210|NCT01402466|Behavioral|Standard Referral|Participants randomized to this arm will be referred to local HIV care resources
1708211|NCT01402466|Behavioral|Project Bridge|Arm 2
1708212|NCT01402453|Behavioral|Monetary Incentives|Subjects will receive a payment of $2 per mm. drop in BP from the baseline value at each follow-up visit. If a subject reaches their target BP, they will receive a minimum of $30 each time to motivate continued participation in the study and reinforce continued improvement relative to baseline BP. Lottery incentives will be added to motivate attainment of intermediate goals. For remembering to do certain actions that assist in the management of their BP, the subject will receive one entry into a lottery with an expected value of $3 per ticket. For the lottery payment, the subject will be given 3 chances to randomly select a card that may or may not show a winning monetary prize.
1708213|NCT01402453|Behavioral|Intrinsic Motivation|A)Subjects will complete an additional component to the baseline questionnaire that probes systematically for areas of experience that currently are of importance to them. Their answers will help to identify patients' intrinsic motivations for controlling their BP. B)Answers to this component will be analyzed to characterize a role self-identity that will be used by study personnel to frame their interactions with the subject for the remainder of the study. C) Role identity will be kept highly salient throughout the study by using identity primes that remind the individual that improving blood pressure levels is an important responsibility associated with that role.
1708214|NCT01402440|Drug|AEB071|
1708215|NCT01402427|Drug|Verapamil|Intraarterial administration of 5 mg verapamil diluted with saline to 10 mL.
1708216|NCT01402427|Drug|Placebo|Intraarterial administration of 10 mL saline.
1708217|NCT01402414|Radiation|NB-UVB|The SB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the SB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
1708218|NCT01402414|Radiation|Bath-PUVA|Bath PUVA is performed with 8-Methoxypsoralen baths (concentration of ultimately 0.5 mg / l ) at 37 ° C with a bath time of 20 minutes and subsequent UVA irradiation (Waldmann cabine, 320-400 nm). The first dose is 70% of MPD, followed by 20% increase. The latter takes place at the earliest after 72 hours. The UV irradiations are carried out four times a week over a period of 4 weeks.
1708219|NCT01402414|Radiation|NB-UVB plus salt water baths|First, a 20-minute bath in 3% salt water (Dead Sea salt, 37 ° C) is taken. Thereafter, a NB-UVB irradiation is performed. The UV radiation can be administered according to established protocols. The NB-UVB irradiations (Cosmedico, Villingen-Schwenningen) are adapted to the NB-MED-UVB (70%) started and increased by 10-20% per session. The UV irradiations are carried out four times a week over a period of 4 weeks.
1708220|NCT01402401|Drug|AUY922 + Trastuzumab|
1708221|NCT01402388|Behavioral|Group lifestyle programme|
1708222|NCT01402375|Drug|Oral Opioid Pain Medicine|"In the first trial, patients will take 1 dose of either Hydrocodone or Codeine combined with Acetaminophen every 4 hours as needed for pain.
In the second trial, patients will take 1 dose of either oxycodone or Codeine combined with Acetaminophen every 4 hours as needed for pain."
1708225|NCT01402323|Other|time point of tooth extraction|
1708226|NCT01402310|Other|Ultrasound and digital cervical examination|Cervical length by transvaginal ultrasound Bishop score by digital examination Take cervicovaginal samples
1708271|NCT01402076|Drug|Midazolam|10mg, single dose, Days 1 and 18
1708338|NCT01401426|Procedure|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy
1774586|NCT00387959|Biological|filgrastim|
1708227|NCT01402297|Drug|Apocynin and placebo nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) and 0,9% NaCl as placebo, has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
1708228|NCT01402284|Drug|Carfilzomib|Cycle 1: 20 mg/m(2) intravenous (IV) infusion over 30 minutes on days 1 and 2, then 36 mg/m(2) IV on days 8, 9, 15, and 16 Cycle 2-8: 36mg/ m(2) IV infusion over 30 minutes on days 1, 2, 8, 9, 15, and 16
1708229|NCT01402284|Drug|Lenalidomide|Cycle 1: 25 mg oral days 2-21 of 28-day cycle; Cycle 2 - 8: 25 mg oral days 1-21 of 28-day cycle; After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles; After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
1708230|NCT01402284|Drug|Dexamethasone|Cycle 1: 20 mg oral or IV on days 2, 8, 9, 15, 16, 22, and 23 Cycle 2-4: 20 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23 Cycle 5-8: 10 mg oral or IV on days 1, 2, 8, 9, 15, 16, 22, and 23
1708231|NCT01402284|Drug|Lenalidomide|After 8 cycles of combination carfilzomib, lenalidomide, and dexamethasone (CRd), patients may continue Lenalidomide for 12 cycles
1708232|NCT01402284|Drug|Lenalidomide|After 12 cycles of extended dosing of Lenalidomide, patients may continue Lenalidomide for one year
1708233|NCT01402271|Drug|carboplatin|
1708234|NCT01402271|Drug|paclitaxel|
1708235|NCT01402271|Drug|pazopanib hydrochloride|
1708236|NCT01402271|Other|laboratory biomarker analysis|
1708237|NCT01402271|Other|pharmacological study|
1708238|NCT01402258|Behavioral|Tailored Internet-administrated CBT-Treatment|This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things.
1708239|NCT01402245|Biological|Pneumococcal polysaccharide vaccine|Pneumococcal polysaccharide vaccine 0.5 ml i.m.
1708240|NCT01402245|Biological|pneumococcal conjugate vaccine|pneumococcal conjugate vaccine 0.5 ml i.m.
1708241|NCT01402219|Drug|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
1708242|NCT01402219|Drug|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
1708243|NCT01402206|Behavioral|Structured patient-centered follow up of depression|"All patients who agree to participate in the study are diagnosed by their GP with a diagnostic assessment instrument called PRIME-MD. Participants in the intervention group visit their GPs at baseline and 4, 8, and 12 weeks. At each visit, participants complete MADRS-s for the assessment of depression severity and discuss the results with their GP in a patient-centered consultation. We have chosen to use the MADRS/MADRS-S depression rating scale in this study because it is a easy to use standard instrument especially suitable for measuring change in depressive symptoms.
The control group receives treatment as usual (no intervention)."
1708244|NCT01402193|Drug|Pre-radiotherapy commencement of Arimidex|Arimidex:1mg P.O. daily will be prescribed for 8 weeks in post-mastectomy patients and 9 weeks in BCT patients within the study period. Arimidex starts 3 weeks before adjuvant radiotherapy and throughout the course of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
1708245|NCT01402193|Drug|Post radiotherapy commencement of Arimidex|Arimidex：1mg P.O. daily will be prescribed at 2 weeks after the end of radiotherapy.Total duration of adjuvant hormonotherapy is prescribed by the investigators at the completion of study, 5 years in principle.
1708246|NCT01402193|Radiation|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
1708247|NCT01402193|Radiation|Radiotherapy|Radiotherapy is delivered to the whole breast/chest wall +/- regional lymph nodes to a total dose of 50Gy/25 fractions/5weeks, an additional tumor bed boost of 10Gy/5 fractions/1week is delivered to patients with breast conservative surgery
1708248|NCT01402180|Biological|Nimotuzumab|
1708249|NCT01402180|Radiation|Radiation therapy|
1708250|NCT01402180|Radiation|radiation therapy|
1708251|NCT01402180|Drug|chemotherapy|
1708252|NCT01402180|Drug|chemotherapy|
1708253|NCT01402167|Procedure|Kyphoplasty|Patients will be treated via a balloon kyphoplasty surgical procedure
1708254|NCT01402167|Procedure|Vertebroplasty|Patients will be treated via a transcutaneous vertebroplasty procedure.
1708255|NCT01402154|Biological|EPISPOT detection of the number of circulating cells|EPISPOT detection of the number of circulating, functional, prostate cells per unit blood
1708256|NCT01402154|Biological|CellSearch detection of the number of circulating, functional, prostate cells|CellSearch detection of the number of circulating, functional, prostate cells per unit blood
1708257|NCT01402141|Dietary Supplement|Chungkookjang|Chungkookjang(35g/say)for 12 weeks
1708258|NCT01402141|Dietary Supplement|Placebo|Placebo(35g/day) for 12 weeks
1708259|NCT01402128|Dietary Supplement|Barley beta-glucan(3.0g)|Barley beta-glucan(3.0g/day) for 12 weeks
1708260|NCT01402128|Dietary Supplement|Placebo|Placebo for 12 weeks
1708261|NCT01402115|Dietary Supplement|Polycan|polycan 150 mg/d for 12 weeks
1708262|NCT01402115|Dietary Supplement|Placebo|Placebo 150mg/d for 12 weeks
1708263|NCT01402102|Dietary Supplement|Aged garlic powder|Aged garlic powder(6.0g/day)
1708264|NCT01402102|Dietary Supplement|Placebo powder|Placebo powder(6.0g/day)
1708265|NCT01402089|Drug|Sunitinib|Patients with renal-cell cancer or GIST are receiving conventional treatment with sunitinib (50mg/day for 4 out of 6 weeks)
1708266|NCT01402089|Drug|Erlotinib|Patients with non small-cell lung cancer receive conventional treatment with erlotinib 150mg/day.
1708267|NCT01402089|Drug|Midazolam|For phenotyping of CYP3A4, all patients receive one-time midazolam 2mg as a drinking solution at the start of study treatment.
1708268|NCT01402089|Drug|Caffeine|For phenotyping of CYP1A2, patients with non small-cell lung cancer receive additionally one-time caffeine 100mg as a tablet.
1708272|NCT01402063|Drug|PPX (CT2103)|XRT: 60 Gy at 2 Gy/fraction x 30 fractions PPX: 50 mg/m2/week x 6 weeks during radiation Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum.
1708273|NCT01402063|Drug|Temozolomide|XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide, 75 mg/m2/day, 7 days per week, from the first to the last day of radiotherapy Temozolomide maintenance: Beginning 4 weeks after completion of chemoradiation, temozolomide d1-5 of 28 day cycle for 12 cycle maximum
1708274|NCT01402050|Drug|CERVIDIL (Dinoprostone)|INDUCTION OF LABOR
1708275|NCT01402050|Device|FOLEY BALLOON|INDUCTION OF LABOR
1708276|NCT01402037|Drug|Glucose|Glucose 20% intravenous
1708277|NCT01402037|Device|Continuous glucose monitoring|Blood glucose profiles: during 5 days glucose profiles will be determined by seven-point self-monitoring of blood glucose (SMBG) (pre-breakfast: assumed time 7 am, post-breakfast: 8.30 am, pre-lunch: 12 am, post-lunch: 1.30 pm, pre-supper: 6 am, post-supper: 7.30 pm, bedtime: 10 pm) and by continuous glucose monitoring (CGM). Participants will be blinded for the CGM results.
1708278|NCT01402024|Drug|Aprepitant|"The patient on study group with weight category of 15-40 kg will receive:
D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg and
The patient with weight category of 41-65 kg in study group will receive:
D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant 80 mg"
1708279|NCT01402024|Drug|Placebo|"Patient on control group with weight category of 15-40 kg will receive:
D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; and
The patient on control group with weight category of 41-65 kg will receive:
D1- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 125 mg; D2- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg; D3- Dexamethasone 0.15 mg/kg, ondansetron (0.15 mg/kg, single dose), Aprepitant placebo 80 mg (all are injectable except Aprepitant oral capsule)."
1708281|NCT01401985|Drug|TD-1211|Capsules once daily
1708282|NCT01401959|Drug|eribulin mesylate|1.4 mg/m2 IV Days 1 and 8, every 21 days
1708283|NCT01401959|Drug|Trastuzumab|6 mg/kg IV Day 1 every 21 days
1708284|NCT01401946|Drug|soy isoflavones|
1708285|NCT01401946|Drug|Placebo|
1708286|NCT01401933|Drug|Linifanib|QD on Days 1 and 13
1708287|NCT01401933|Drug|Rifampin|QD on Days 5-16
1708288|NCT01401920|Other|leg elevation|bilateral passive leg elevation for 30 seconds
1708289|NCT01401920|Other|Trendelenburg position|Trendelenburg position (15 degrees) for 30 seconds
1708290|NCT01401920|Other|Trendelenburg position + passive leg elevation|Trendelenburg position + passive leg elevation
1708291|NCT01401920|Other|control group|supine position without passive leg elevation or trendelenburg position
1708292|NCT01401907|Other|early palliative care|patient assigned to the intervention will receive early palliative care along with standard oncology care.
1708293|NCT01401868|Drug|ME-143|"experimental drug, dose escalation with 4 dose cohorts of 2.5 mg/kg, 5 mg/kg, 10 mg/kg, 20 mg/kg; Cycle 1 is 3 weekly IV infusions on Days 1, 8 and 15. If either the 10 mg/kg or 20 mg/kg dose levels are not tolerable, a 7.5 mg/kg or a 15 mg/kg dose level will be evaluated. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal.
Once the highest tolerated dose has been determined, patients will be enrolled to receive IV infusions 2-days per week. Cycle 1 at the highest dose level is 3 weekly IV infusions on Days 1, 2, 8, 9, 15 and 16. After safety assessment, if there is clinical benefit, weekly dosing may continue until withdrawal."
1708294|NCT01401842|Other|Lumbar ext. high intensity progressive resistance exercise|1 active set of 1 exercise, 1x/week, 11 weeks
1708295|NCT01401842|Other|Low intensity core stabilization exercise|1 set of 5 exercises, 1x/week, 11 weeks
1708296|NCT01401829|Behavioral|150 weekly minutes walking|12 week physical activity intervention group with a goal of 150 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
1708297|NCT01401829|Behavioral|75 weekly minutes walking|12 week physical activity intervention group with a goal of 75 minutes of moderate intensity exercise (walking) per week on a treadmill while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
1708298|NCT01401829|Behavioral|Stretching/Flexibility exercise|12 week stretching intervention group with a goal of 3 sessions per week while supervised by exercise specialists who are certified by ACSM and trained and monitored for quality control and safety
1708299|NCT01401816|Other|Text Message|Subjects will receive a text message on their personal cell phone on Days 1, 3 and 5 after enrollment reminding them to fill their prescription.
1708300|NCT01401803|Drug|Dysport|Patients entering will be based on gender and assessment of the glabella region (including the corrugators, procerus, and medial frontalis muscles). Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large). Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ and female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region. On (Day0) patients will be treated with Dysport™ 10 to 20 units bilaterally to the depressor component of the orbicularis. The dosing for patients will be based on assessment of orbicularis muscle mass. Patients will receive .05 mL to 0.1 mL (10 or 20 units) in two equally divided doses of Dysport™. Muscle mass will not be graded based upon gender for this region.
1708337|NCT01401426|Procedure|Laparoscopic vertical sleeve gastrectomy|Laparoscopic vertical sleeve gastrectomy for the treatment of morbid obesity.
1708301|NCT01401790|Device|Telehomecare (Intelligent Distance Patient Monitoring)|"Randomized patients were to be taugth and to use for 3 months a telehomecare program designed for
Automatic download of blood glucose levels
Automatic alerts indicating hypoglycemias, hyperglycemias and ketones to the medical team
Changes in treatment plan by the diabetes professionals
E mail exchanges between families and health care professionals
Reinforcement of teaching program"
1708302|NCT01401790|Other|Standard education and follow up at diabetes clinic|Patients allocated to the control branch receive standard diabetes teaching and care.
1708303|NCT01401764|Other|Formulation buffers|Platform II: Histidine, Polysorbate-80 PASS: Phosphate, Arginine, NaCl ARG 100: Phosphate, 100 mM Arginine
1708304|NCT01401751|Device|Hypoglycemia-Hyperglycemia Minimizer System|Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
1708305|NCT01401725|Behavioral|Electronic Order Entry System + CDSS|Physicians at this hospital will use an Electronic Order Entry System plus a computerized decision support system (CDSS) to support VTE prophylaxis decisions.
1708306|NCT01401725|Behavioral|Electronic Order Entry System Only|Physicians at this hospital will use an Electronic Order Entry System
1708307|NCT01401725|Other|Usual Care|Physicians at this hospital will practice usual care (no Electronic Order Entry System and no CDSS for VTE prophylaxis decisions)
1708308|NCT01401712|Procedure|ON-Q® Pain Relief System|Identify insertion site lateral to paraspinous muscles and posteromedial to the rib fractures. Then, incise skin and soft tissue down to the level of the rib. Advance tunneler perpendicular to chest wall until it contacts the rib, then, advance superiorly at 45° angle in the extrathoracic space. Remove tunneler and advance catheter in space created. Attach catheter to pump filled with 0.2% ropivacaine at infusion rate of 2-12ml/hr.
1708309|NCT01401712|Procedure|Thoracic epidural catheter|Introduce needle into the interspinous space of the vertebral column and advance into the epidural space. Advance the epidural catheter about 3-5 cm into the epidural space and remove the needle.
1708310|NCT01401699|Device|Optical Frequency Domain Imaging (OFDI) System|OFDI Imaging of esophagus
1708311|NCT01401673|Drug|Indantadol|Titration
1708312|NCT01401660|Other|Physical Therapy|The physician will complete a physical exam as well as analyze a completed CERSR® scan study to determine the root cause of the low back pain. The physician will then prescribe a targeted physical therapy regime to address the cause of the low back pain.
1708313|NCT01401647|Drug|amiodarone|300 mg will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 150 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 150 mg, followed by a second dose of 150 mg if the VF/pulseless VT persists.
1708314|NCT01401647|Drug|Lidocaine|120 mg will be given IV/IO push with reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 60 mg will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 60 mg, followed by a second dose of 60 mg if the VF/pulseless VT persists.
1708315|NCT01401647|Other|Normal saline|6 cc of normal saline (NS) will be given IV/IO push for reoccurrence of ventricular fibrillation or pulseless ventricular tachycardia after 1 or more shocks. A second dose of 3 cc will be given if VF/pulseless VT reoccurs after initial dose and a subsequent shock. The initial dose for patients estimated to be less than 100 pounds will be 3 cc, followed by a second dose of 3 cc if the VF/pulseless VT persists.
1708316|NCT01401634|Other|Oral water|2 Liters of water given orally
1708317|NCT01401634|Other|Intravenous normal saline|2 Liters Intravenous normal saline
1708318|NCT01401621|Behavioral|Scratchoff Prompt: Name of Test|A prompt will have the recipient scratch off the message that reveals the name of the test that the recipient needs
1708319|NCT01401621|Behavioral|Scratchoff Prompt: Call to Action|A prompt will have the recipient scratch off the message to find out how to follow the recommendation that the test be received.
1708320|NCT01401621|Behavioral|Control|No scratch-off element
1708321|NCT01401608|Device|RF Ablation|Ablation of arrhythmogenic ventricular tissue
1708322|NCT01401595|Drug|escitalopram oxalate|The purpose of this study is to determine the effectiveness of the anti-depressant Lexapro in the treatment of the Night Eating Syndrome. An ADAM SPECT-CT study of SERT binding will be conducted which will compare SERT binding in 31 night eaters with that of 10 control subjects. The first procedure will be to assess SPECT-CT images of night eaters and controls following up our pilot SPECT study of night eaters and controls. Medication will be administered starting at 10 mg daily, with increase up to 20 mg, as indicated and tolerated, for up to three months. Visits will occur at baseline and weeks 1, 2, 4, 6, 8, 10, and 12.
1708323|NCT01401582|Other|Implementation of Dementia Care Manager|"Home-visits of trained Dementia Care Manager (DCM) at least monthly for 6 months. The DCM will, in close cooperation with the general practitioner, establish and include a subsidiary support system for subjects and their caregivers."
1708324|NCT01401569|Behavioral|Exercise and counseling (for smoking cessation and physical activity)|Exercise and counseling (for smoking cessation and physical activity)
1708325|NCT01401556|Other|case management|
1708326|NCT01401556|Other|Multifaceted quality improvement intervention|
1708327|NCT01401543|Drug|LY2452473|Administered orally
1708328|NCT01401543|Drug|Tadalafil|Administered orally
1708329|NCT01401543|Drug|LY900010|Administered orally
1708330|NCT01401530|Biological|denileukin diftitox (E7777)|E7777 will be administered by intravenous (IV) infusion for 5 days from Day 1 through 5 of each cycle (21 days/cycle) with 8 cycles in maximum for E7777 alone therapy. E7777 dose will be escalated from 6 micro-g/kg/day to 12, 15 and then to 18 in a stepwise fashion.
1708331|NCT01401517|Drug|sodium nitrite|0, 40 or 80 mg twice each day for 10 weeks followed by a 1 week escalation of 2 times the dose.
1708332|NCT01401504|Drug|ASP3026|oral
1708333|NCT01401491|Drug|clozapine plus fluvoxamine|clozapine 100 mg/day plus fluvoxamine 50 mg/day
1708334|NCT01401491|Drug|clozapine plus placebo|clozapine 300 mg/day plus placebo
1708335|NCT01401465|Drug|ciclesonide|74 mcg ciclesonide nasal aerosol once daily
1708336|NCT01401465|Drug|mometasone|200 mcg mometasone aqueous nasal spray once daily
1774587|NCT00387959|Biological|rituximab|
1708340|NCT01401413|Drug|placebo|placebo control i pill nightly for 30 nights
1708341|NCT01401387|Other|Timing of start treatment with pancreatic enzymes|Patients who are randomised to standard treatment will start taking pancreatic enzymes only if they develop steatorrhea-related symptoms in combination with at least a 10% decrease in body weight (index weight at the time of randomisation).
1708342|NCT01401387|Other|Timing of start treatment with pancreatic enzymes|Patients who are allocated to the anticipative group will start enzyme suppletion immediately and receive dietary consultation after randomization, regardless of symptoms.
1708343|NCT01401361|Device|Treatment Arm|The investigational parts of the system consists of Contact Therapy Cool Path ablation catheter, 1500 T9 V1.43 RF Generator, Model 1611 connection cable, EnSite Velocity Contact™ Kit, and EnSite Velocity Contact software controlled via entitlement .
1708344|NCT01401335|Behavioral|Questionnaires|questionnaires at entry, month 4, 8 and 12
1708345|NCT01401322|Drug|Lenalidomide|50 mg; po
1708346|NCT01401296|Behavioral|Deprexis|Behavioral: Deprexis (10 sessions) delivered online versus wait-list control group
1708347|NCT01401296|Behavioral|Wait-list|Behavioral: the wait-list group receives Deprexis after 8 weeks
1708348|NCT01401283|Device|measurement of cardiac output and pulse pressure variation|hemodynamic optimization according to cardiac index and pulse pressure variation
1708350|NCT01401257|Drug|PXT3003 Low dose|Liquid,5 ml, twice a day, 12-month treatment
1708351|NCT01401257|Drug|PXT3003 Intermediate Dose|Liquid,5 ml, twice a day, 12-month treatment
1708352|NCT01401257|Drug|PXT3003 High Dose|Liquid,5 ml, twice a day, 12-month treatment
1708353|NCT01401257|Other|Placebo|Liquid,5 ml, twice a day, 12-month treatment
1708354|NCT01401244|Drug|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Norditropin® FlexPro® pen
1708355|NCT01401244|Drug|somatropin|A single dose 4.0 mg administered subcutaneously (under the skin) via Genotropin® Pen 12
1708358|NCT01401218|Other|Electronic Medical Record (EMR) Review|"measurements of potential risk factors of acute kidney injury through the patients' previous medical record review.
potential risk factors include previous history of hypertension, diabetes, cerebrovascular events, peripheral arterial disease, chronic obstructive pulmonary disease, recent myocardial infarction, coronary artery disease; preoperative glomerular filtration rate, preoperative creatinine level, preoperative cardiac ejection fraction reported on echocardiography, use of preoperative inotropics, use of deep hypothermic cardiac arrest, intraoperative colloid use, intraoperative blood product transfusion, total time of cardiopulmonary bypass,"
1708359|NCT01401205|Other|upper airway ultrasonographic examination|upper airway ultrasonographic examination and cuff leak test
1708360|NCT01401192|Drug|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 & cisplatin 70mg/m2 D1 every 3 weeks
1708361|NCT01401192|Drug|pemetrexed plus cisplatin|Pemetrexed 500mg/m2 & cisplatin 70mg/m2 D1 every 3 weeks
1708362|NCT01401192|Drug|pemetrexed plus cisplatin|pemetrexed 500mg/m2 & cisplatin 70mg/m2 every 3 weeks
1708363|NCT01401192|Drug|Gemcitabine plus cisplatin|Gemcitabine 1000mg/m2 D1, D8 & cisplatin 70mg/m2 D1 every 3 weeks
1708364|NCT01401179|Drug|cefazolin, erythromycin, clarithromycin|Antibiotics regimen was one of cefazolin or cefazolin plus erythromycin or cefazolin plus clarithromycin. Intravenous 1g cefazolin was given every 6 hours after negative result skin test for allergic reaction. With cefazolin plus erythromycin group or cefazolin plus clarithromycin, cefazolin was given with same protocol and 250mg oral erythromycin every 6 hours or 500mg oral clarithromycin every 12 hours was added. All antibiotics were given for 7 days or until delivery.
1708365|NCT01401166|Drug|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 milligrams per kilogram (mg/kg) for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 milligrams (mg) for both the SID and vial formulations for all cycles where SC Herceptin is given.
1708366|NCT01401166|Drug|Herceptin|Herceptin will be given on Day 1 of each 3-week cycle for a total of 18 cycles. If study treatment for Cycle 1 is IV Herceptin, the initial dose will be a loading dose of 8 mg/kg for de novo participants who start Herceptin treatment in the study. For all other cycles where IV Herceptin is given and for non-de novo participants, the dose will be 6 mg/kg. The SC dose will be 600 mg for both the SID and vial formulations for all cycles where SC Herceptin is given.
1708367|NCT01401166|Device|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 milliliters (mL).
1708368|NCT01401166|Device|Single-Use Injection Device|The SID will be used, containing Herceptin 600 mg per 5 mL.
1708369|NCT01401153|Other|Skipping lunch|Just water.
1708370|NCT01401140|Drug|St Thomas|Once the upper aorta has been clamped, the cardioplegic solution St Thomas will be administered directly into it via an anterograde approach. St Thomas will be infused every 30 minutes at a dosage of 10ml/kg bodyweight (infusion takes about three minutes). If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
1708371|NCT01401140|Drug|Custodiol|Once the upper aorta has been clamped, the cardioplegic solution Custodiol will be administered directly into it via an anterograde approach. Custodiol will be injected in one bolus (20 ml/kg), which takes eight minutes. If the heart appears to be starting again (ventricular fibrillation) for more than three minutes, infusion will be resumed at the same rate until the heart is effectively stopped.
1708372|NCT01401114|Drug|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara for postmenopausal osteoporosis
1708373|NCT01401101|Other|PCM|Care Manager (CM) intervention
1708374|NCT01401101|Other|MEU|The MEU condition consists of only the clinician education and patient screening without written feedback.
1708375|NCT01401088|Device|Artificial drainage implant|Artificial drainage implant is used for intra ocular pressure reduction in patient with refractory glaucoma
1708376|NCT01401075|Drug|mistletoe extract|subcutaneous injections thrice weekly with 1 ml in 4 increasing doses
1708377|NCT01401075|Drug|doxifluridine|600 - 900 mg per day orally, depending on weight and status of the patient
1708378|NCT01401062|Drug|Fresolimumab|
1708379|NCT01401062|Radiation|Radiation Therapy|
1708380|NCT01401049|Drug|Fospropofol|To compare the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion) versus the test drug fospropofol. A third arm will also be included using a current standard (propofol plus lidocaine) as a methodological control.
1708381|NCT01401049|Drug|Propofol/Lidocaine|We plan to assess the incidence and intensity of pain on injection that is caused by propofol (lipid emulsion).
1708382|NCT01401036|Device|Biolimus A9 eluting stents|implantation of Biolimus A9 eluting stents
1708383|NCT01401036|Procedure|uncoated stent|implantation of any uncoated bare metal stents currently available in Japan
1708384|NCT01401023|Drug|Tigecycline|: Standard treatment doses of oral antibiotics (vancomycin or metronidazole) for CDAD along with IV tigecycline (100 milligram loading dose followed by 50 milligrams every 12 hours) will be given to patients during their hospitalization (usually 7-14 days). Patients well enough to go home will receive only oral therapy.
1708385|NCT01401010|Drug|Doripenem|500 mg every 8 hours
1708386|NCT01401010|Drug|doripenem|1000 mg every 8 hours
1708387|NCT01400997|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
1708388|NCT01400984|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
1708389|NCT01400958|Drug|Nuvigil®|Nuvigil® 150 mg/day x 42 days THEN, No More Drug
1708390|NCT01400958|Drug|Placebo|Placebo x 42 days; THEN, No More Placebo
1708391|NCT01400945|Drug|AGSPT201 Tab contains S-pantoprazole|comparison of Pantoloc Tab 40mg
1708392|NCT01400932|Drug|GI148512|GI148512, Topical gel in 1 g containing benzoyl peroxide 30 mg
1708393|NCT01400932|Drug|vehicle gel|Matching vehicle gel of GI148512, not containing active ingredient (benzoyl peroxide)
1708394|NCT01400919|Device|Protégé® EverFlex™ Self-Expanding Stent System, and Protégé® GPS™ Self-Expanding Stent System.|Implantation of one or more study devices in the common and/or external iliac artery.
1708395|NCT01400906|Drug|100 micrograms Fluticasone propionate|100 micrograms micronized drug blended with lactose in dry powder inhalator
1708396|NCT01400906|Drug|500 micrograms Fluticasone propionate|500 micrograms micronized drug blended with lactose in dry powder inhalator
1708397|NCT01400906|Drug|lactose powder|lactose powder in dry powder device : placebo comparator
1708398|NCT01400893|Device|SCD|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
1708399|NCT01400867|Drug|Ceftaroline fosamil|"Subjects ≥ 6 months old: 12 mg/kg IV for subjects weighing ≤ 33 kg and 400 mg for subjects weighing > 33 kg will be infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)
Subjects < 6 months old: 8mg/kg infused over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour)"
1708400|NCT01400867|Drug|Vancomycin +/- Aztreonam or Cefazolin +/- Aztreonam|"Vancomycin 15mg/kg IV over 60 minutes (or a maximum of 10mg/min whichever is longer) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed)
Cefazolin 75mg/kg IV divided every 8 hours over 60 minutes (for sites that do not empirically cover for MRSA) +/- Aztreonam 30 mg/kg IV every 8 hours over 60 minutes (for infections involving gram negative pathogen suspected or confirmed"
1708401|NCT01400867|Drug|Cephalexin or Clindamycin or Linezolid|"Possible oral switch on or after study day 4.
Cephalexin: 25 mg/kg q6h PO or Clindamycin: 10 mg/kg q8h PO or Linezolid 600mg q12h (cohort 1) or 10 mg/kg q8h (cohorts 2,3 and 4) PO."
1708402|NCT01400854|Drug|Effentora®|prescribed as per local Summary of Product Characteristics (SmPC) for 4 weeks duration
1708403|NCT01400841|Device|HAART 300 Annuloplasty Device|Implantation of device for aortic valve repair
1708404|NCT01400828|Drug|Bilastine|20 mg (encapsulated) tablets QD/14 days
1708405|NCT01400828|Drug|Desloratadine|5 mg (encapsulated) tablets QD/14 days
1708406|NCT01400828|Drug|Placebo|(encapsulated) Tablets QD/14 days
1708407|NCT01400815|Drug|X-22 Smoking Cessation Product|"The X-22 Smoking Cessation Product is a tobacco-based (botanical) medical product consisting of very low nicotine (VLN) cigarettes.
Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
1708408|NCT01400815|Drug|Active Control Cigarettes|"The Active Control cigarette is identical to the X-22 cigarette except for the tobacco, which has a nicotine content similar to that of a conventional light cigarette.
Subjects will be allowed to smoke as much as desired throughout the 6-week treatment period."
1708409|NCT01400802|Biological|Insulin Lispro|Dosage form- Subcutaneous Injection
1708410|NCT01400789|Biological|Insulin Lispro|Dosage form- Subcutaneous Injection
1708411|NCT01400776|Drug|WC3011 Vaginal Gel|WC3011 Vaginal Gel administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks
1708412|NCT01400776|Drug|Vehicle|Vehicle Vaginal Gel administered once daily for 2 weeks followed by 2X/week or 3X/week for 10 weeks, total treatment duration 12 weeks.
1708413|NCT01400763|Dietary Supplement|Fresh lutein-enriched egg-yolk beverage|Fresh lutein-enriched egg-yolk beverage
1708414|NCT01400763|Dietary Supplement|Dried-1 lutein-enriched egg-yolk beverage|Dried-1 lutein-enriched egg-yolk beverage
1708415|NCT01400763|Dietary Supplement|Dried-2 lutein-enriched egg-yolk beverage|Dried-2 lutein-enriched egg-yolk beverage
1708416|NCT01400763|Dietary Supplement|Placebo beverage|Placebo beverage
1708417|NCT01400750|Drug|oral ciprofloxacin plus inhaled colistin|oral ciprofloxacin (30mg/kg/day divided in 2 doses) for 3 months (CC) plus inhaled colistimethate sodium(Colistineb® 2x2 mill U daily)
1708418|NCT01400750|Drug|TOBI|tobramycin inhalation solution (TOBI® 2x300 mg) for 28 days
1708459|NCT01400516|Drug|Vitamin D|800 IU of Vitamin D
1708568|NCT01399619|Drug|Bi 201335|BI 201335 for 24 w
1708419|NCT01400737|Drug|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively.
1708420|NCT01400737|Drug|ibuprofen|The prophylaxis group received ibuprofen suspension at a dosage of 10 mg/kg via an orogastric tube, followed by 0.5 ml of distilled water. The first dose was given within the first 24 hours of life. The second and third doses were given within 24 and 48 hours after the first dose respectively
1708421|NCT01400724|Dietary Supplement|Inofolic NRT|Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
1708422|NCT01400711|Other|ERAS perioperative care|Patient's education before surgery, early mobilization and oral feeding after surgery, no opioids analgesics.
1708423|NCT01400711|Other|Traditional|Nasogastric tube until bowel function, late oral eating, opioid analgesics.
1708424|NCT01400698|Drug|Saizen® A|Continuous or intermittent treatment with recombinant human Growth Hormone (r-hGH) 0.067 milligram/kilogram/day (mg/kg/day) subcutaneously (sc).
1708425|NCT01400698|Drug|Saizen® B|Observed until the first signs of puberty and then continuous treatment with r-hGH 0.067 mg/kg/day sc or observed without treatment.
1708426|NCT01400698|Other|Observation only|Subjects were only observed.
1708427|NCT01400685|Drug|Lenalidomide|Lenalidomide will be dose escalated until the maximum tolerated dose is reached. The starting dose is 2.5mg, followed by 5mg, followed by 10mg.
1708428|NCT01400685|Drug|Bendamustine|90 mg/m^2 IV days 1-2 of each cycle for 6 cycles
1708429|NCT01400685|Drug|Rituximab|375 mg/m^2 IV day 1 (cycle 1), 500 mg/m^2 day 1 (cycles 2-6)
1708430|NCT01400672|Biological|Tumor Lysate Vaccine|Vaccination is injected intradermally every 2 weeks for 4 doses, then every 4 weeks for up to 1 year. Patients will receive 1 mg protein divided into 2 doses at two separate subinguinal sites.
1708431|NCT01400672|Drug|Imiquimod|Marketed as 5% Aldara cream topically applied; total of 12.5 mg divided between the two vaccination sites and reapplied at the vaccination sites 24 hours later.
1708432|NCT01400672|Radiation|Radiation therapy|"Initial course of radiation therapy is given over 6-7 weeks, 5580 cGy. At the time of the 3rd vaccination, an additional 180 cGy fractions will be delivered in single doses in a novel effort to induce NKG2D ligand upregulation (thereby sensitizing residual tumor to lymphocyte attack). The total radiation dose for each patient will be 5760 cGy."
1708433|NCT01400659|Procedure|CFP counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CFP counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
1708434|NCT01400659|Procedure|CARB counting|Patients receive a standardized test meal at lunch time. The required insulin dose is calculated by CARB counting. Insulin is given as bolus and basal rate using an insulin pump. Continuous glucose monitoring is performed by sensor-augmented pump system for 6 hours after the meal. The intervention is taking part under in-patient clinical conditions.
1708435|NCT01400646|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One tablet once daily for 5 days (Treatment Period 1, Days 1-7).
1708436|NCT01400646|Drug|Warfarin|Type=exact number, unit mg, number=10, form=tablet , route=oral use. One tablet for 2-4 days (Treatment Period 1, Day 6 up to Day 11).
1708437|NCT01400646|Drug|Vitamin K|Type=exact number, unit=mg, number=1, form=oral solution, route=oral use. 1 mg dose for 1 day (Treatment Period 1, Day 12).
1708438|NCT01400646|Drug|Vitamin K|Type=exact number, unit=mg, number=5, form=oral solution, route=oral use. 5 mg dose for 1 day (Treatment Period 2, Day 7).
1708439|NCT01400646|Drug|Warfarin|Type-exact number, unit=mg, number=10, form=tablet, route=oral use. Tablet(s) administered once daily for 2-4 days (Treatment Period 2, Day 1 up to Day 6)
1708440|NCT01400646|Drug|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 1).
1708441|NCT01400646|Drug|Warfarin|Type=range, unit=mg, number=0-15, form=tablet, route=oral use. Tablet(s) taken once daily for up to 4 days after Warfarin 10 mg administered as monotherapy for 2-4 days (Treatment Period 2).
1708442|NCT01400633|Drug|decitabine injection|decitabine intravenous injection 20mg/m2 once a day for 5 consecutive days every 4 weeks
1708443|NCT01400620|Drug|IZN-6N4|Oral rinse containing 1% botanical extracts, 15 cc rinse 3 times per day, for up to 9 weeks
1708444|NCT01400607|Biological|Neocartilage Implant/DeNovo® ET (Engineered Tissue Graft)|The Neocartilage Implant is a cartilage repair technology cultured from juvenile human cartilage cells.
1708445|NCT01400607|Other|Microfracture|Marrow stimulation using the microfracture technique; performed arthroscopically
1708446|NCT01400594|Drug|HTU-520 Patch|Terbinafine hydrochloride patch
1708447|NCT01400594|Other|Placebo Patch|Treatment with Placebo Patch
1708449|NCT01400568|Drug|LPS challenge with nebulized LPS|20,000 EU of Clinical Center Reference Endotoxine (CCRE) will be applied by an AKITA® Jet Nebulizer under the constant supervision of the site staff.
1708450|NCT01400568|Drug|fluticasone propionate (FP)|The dosage of FP will be 2 mg. This dosage will be inhaled by 4 puffs of Flutide® forte 500 Diskus® 500 µg / dose according to the package insert.
1708451|NCT01400555|Drug|Cohort 4|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 750 mg/day + prednisone 10 mg/day
1708452|NCT01400555|Drug|Cohort 3|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 1000 mg/day + prednisone 10 mg/day
1708453|NCT01400555|Drug|Cohort 2|Docetaxel 75 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
1708454|NCT01400555|Drug|Cohort 1|Docetaxel 60 mg/m2 administered once every 3 weeks + abiraterone acetate 500 mg/day + prednisone 10 mg/day
1708455|NCT01400542|Device|CPAP Treatment|Patients with obstructive sleep apnea syndrome will be treated by Continuous Positive Airway Pressure (CPAP) at home during all 4 months all nights.
1708456|NCT01400542|Device|No treatment|no treatment
1708457|NCT01400516|Drug|Teriparatide|20 μg, subcutaneous injection, 1 injection per day
1708460|NCT01400516|Drug|TNF antagonist|TNF antagonist as prescribed in clinical practice (such as etanercept or adalimumab)
1708461|NCT01400503|Drug|Siltuximab|Type=exact number, unit=mg/kg, number=11, form=intravenous solution, route=intravenous. Siltuximab given as a 1-hour infusion every 3 weeks.
1708462|NCT01400490|Dietary Supplement|EPA-DHA Study|6 weeks of dietary supplementation
1956245|NCT02923570|Radiation|Photon intensity modulated radiation therapy (IMRT)|
1956246|NCT02923570|Radiation|Proton beam radiotherapy (PBRT)|
1708465|NCT01400464|Drug|Prednisone therapy and pharmacokinetic|Prednisone therapy delivered in accordance with a 10 to 18 month pre-defined schedule. Pharmacokinetic and pharmacogenetic tests at 14 or 28 days. Monthly visit for the first 6 month, then every 8 weeks months thereafter for the remainder of the study with standard biologic monitoring , physical exam and medical and medication history .Also, participants will be asked to complete several questionnaires to assess quality of life and observance to therapy. Participants may have additional study visits if a disease flare or disease-related complications occur during the study.
1708466|NCT01400451|Drug|Ipilimumab (BMS-734016)|Injection, intravenous (i.v.), cohort 1: 3 mg/kg, Escalate to cohort 2: 10 mg/kg, Escalate to cohort 3: at Recommended Phase 2 Dose (RP2D), De-escalate cohort 1A: 3 mg/kg, De-escalate cohort -1B: 10 mg/kg, (every three week) Q3wk, upto 2 yrs
1708467|NCT01400451|Drug|Vemurafenib|tablets, oral, cohort 1: 960 mg Twice daily (BID) x 28 days after date, cohort 2: 960 mg BID x 28 days after date, cohort 3: at Recommended Phase 2 Dose (RP2D) x 14 days after date, De-escalate cohort 1A: 720 mg BID x 28 days after date, De-escalate cohort -1B: 720 mg BID x 28 days after date , Up to 2 yrs
1708468|NCT01400438|Other|questionnaires|delivery of questionnaires and self-psychological interview
1708469|NCT01400438|Other|questionnaires|delivery of questionnaires and self-psychological interview
1708470|NCT01400425|Drug|florbetapir F 18|IV injection, 370 megabecquerel (MBq) (10 millicurie [mCi]), single dose
1708471|NCT01400412|Drug|Darunavir|Darunavir was administered orally once a day as two 400 mg tablets with food. When the 800 mg formulation tablet became available, it was substituted for the two 400 mg tablet.
1708472|NCT01400412|Drug|Ritonavir|Ritonavir was administered orally together with darunavir as one 100 mg tablet once daily with food.
1708473|NCT01400412|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate was administered orally as one 300 mg tablet once a day.
1708474|NCT01400412|Drug|Emtricitabine|Emtricitabine was administered orally once a day as one 200 mg capsule.
1708475|NCT01400412|Drug|Placebo for Tenofovir disoproxil fumarate|Placebo for tenofovir disoproxil fumarate was administered orally once a day as one tablet.
1708476|NCT01400412|Drug|Placebo for Maraviroc|Placebo for maraviroc was administered orally once a day as one tablet.
1708477|NCT01400412|Drug|Maraviroc|Maraviroc was administered orally once a day as one 150 mg tablet.
1708478|NCT01400386|Other|Coffee bioavailability trial|Coffee bioavailability trial
1708479|NCT01400373|Device|Prehospital intra-nasal cooling with RhinoChill|Patients in the intervention group will receive prehospital intra-nasal cooling with RhinoChill as soon as possible during the resuscitation (i.e. intra-arrest). Intra-nasal cooling will be ongoing until systemic hypothermia is started at the intensive care unit.
1708480|NCT01400360|Other|Combination of TBA and intraarterial application of vasodilators|In the invasive arm CVS should be treated by intraarterial therapy and efficacy controlled by CT or MRI after 48 hours and if necessary repeated.
1708481|NCT01400334|Radiation|Positron Emission Tomography|Quantification of cardiac function using positron emission tomography and: a)11C-meta-hydroxyephedrine [HED, 20 mCi (740 MBq)] to quantify sympathetic nerve function, b) 13N-ammonia [NH3, 20 mCi (740 MBq)] for regional perfusion, and c) 18F-2-deoxyglucose [FDG; 6.5 mCi (241 MBq)] administered during a hyperinsulinemic-euglycemic clamp to assess viability.
1708484|NCT01400282|Device|High frequency spinal cord stimulation|
1708485|NCT01400269|Behavioral|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention|Pacific Autism Center for Education (PACE ) developmentally based parent delivered intervention
1708486|NCT01400256|Drug|Valsartan|After the initial MRI, patients will be given a 160 mg dose of valsartan or placebo, in a double-blinded fashion. A sustained MAP reduction of 15-20% will be the goal. If the MAP remains within 15% of the initial value (prior to the first MRI scan) 24 hours after the first dose of valsartan (or placebo), the patients will be given a 320 mg dose of valsartan (or placebo) and will remain on valsartan 320 mg (or placebo) daily until day 7, or hospital discharge (whichever is sooner). If the MAP is falls by more than 20% after the 160 mg (or placebo) dose, the patient will be switched to 80 mg of valsartan (or placebo) until day 7, or hospital discharge (whichever is sooner). If the blood pressure is lowered by 15-20% (the goal), the patients will remain on valsartan 160 mg (or placebo) daily for the duration of the study.
1708487|NCT01400243|Drug|Nicotine|Nicotine patch 7mg
1708488|NCT01400243|Drug|Placebo Patch|Placebo patch
1708489|NCT01400230|Procedure|diagnostic procedures CCTA, CAG, IVUS and FFR|Diagnostic procedures including computed tomography, coronary angiography, intravascular ultrasound, fractional flow reserve were performed in the patients suspected ischemic heart disease.
1708490|NCT01400217|Drug|extra fine particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
1708491|NCT01400217|Drug|standard particle particle hydrofluoroalkane beclomethasone dipropionate via metered dose inhaler|IPDI cohort intervention = initiation of intervention drug; IPDS cohort intervention = switching from baseline inhaled corticosteroid therapy to intervention drug without a change in baseline inhaled corticosteroid dose; IPDA cohort intervention = increase in baseline inhaled corticosteroid drug as intervention drug
1774588|NCT00387959|Drug|cyclophosphamide|
1708492|NCT01400191|Drug|Metformin|The study was designed as a randomized, cross-over trial with a washout period of at least 4 weeks between the phases. In both phases, the volunteers fasted for 42 h. This was done in order to include an evaluation of the pharmacodynamic effect of metformin on the glucose production in fasting healthy volunteers.
1708493|NCT01400165|Drug|Trazodone|each subject will be taken 1 tablet of Trazodone 150mg of each group (brand/generic)
1708494|NCT01400165|Drug|Quetiapine|each subject will be taken 1 tablet of Quetiapine 100mg of each group (brand/generic)
1708495|NCT01400165|Drug|Pindolol|each subject will be taken 1 tablet of Pindolol 10mg of each group (brand/generic)
1708496|NCT01400165|Procedure|Blood Collection|Blood Samples will be collected at a predefined time-frame to study the plasma level of each medication.
1708497|NCT01400152|Device|Additional active warming|Chemical heat pad applied to the upper torso
1708499|NCT01400113|Drug|Asenapine|Asenapine Sublingual Tablet 10mg, single-dose
1708500|NCT01400113|Drug|Placebo|Placebo Sublingual Tablet, single-dose
1708501|NCT01400100|Drug|Intraarterial application of Octreotide|500 µg / 5 ml Octreotide is given as a single bolus injection in the gastroduodenal artery intraoperatively.
1708502|NCT01400100|Drug|sterile NaCl (sodium chloride) 0,9% solution|a single intraarterial shot of 5 ml saline solution in the gastroduodenal artery
1708503|NCT01400087|Device|Cap-attached Colonoscopy Versus Regular Colonoscopy|Trainees were divided into two group; Cap-attached Colonoscopy group or Regular Colonoscopy group. Trainees allocated to the former group undergo colonoscopy with cap for all cases, the latter without cap.
1708504|NCT01400074|Drug|Nilotinib, Imatinib|Nilotinib: 400 mg twice daily Imatinib: 400 mg twice daily
1708505|NCT01400048|Dietary Supplement|Aloe vera effervescent tablet (AVH200)|250 mg aloe vera and 60 mg ascorbic acid, Aloe Life®
1708506|NCT01400048|Dietary Supplement|Placebo control|60mg Ascorbic acid
1708507|NCT01400022|Other|UVA1 phototherapy|The UVA1-phototherapy is conducted 4 times per week over a period of 3 months. A UVA1-irradiation device of the company Sellamed, Gevelsberg (Germany) is used. The radiation intensity is 24 mW/cm ². The distance between radiation source and irradiation area is approximately 25 cm. Over five sessions, the UVA1 dose is increased slowly, starting with 10 J/cm ² in the first, 20 J/cm ² in the second and 30 J/cm ² in the third, 40 J/cm ² in the fourth, and from the fifth session 50 J/cm ². Additionally, a topical treatment with vaseline album once daily can be applied after irradiation (not before irradiation).
1708508|NCT01400022|Other|Cortisone|Clobetasol propionate (0.05%) in white vaseline is applied thinly once daily. The duration of treatment is 3 months.
1708509|NCT01400009|Drug|Vitamin D (Cholecalciferol )|10,000 IU tablets. 50,000 initial dose, followed by weekly doses of 10,000 IU
1708510|NCT01400009|Drug|Placebo|Standard Placebo made of Lactose 100 mg
1708511|NCT01399996|Dietary Supplement|Yogurt smoothie without probiotic|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
1708512|NCT01399996|Dietary Supplement|Yogurt smoothie with probiotic added post fermentation|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
1708513|NCT01399996|Dietary Supplement|Yogurt smoothie with probiotic added pre-fermentation|A daily 8 oz (240 mg) serving will provide 10x^y5 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
1708514|NCT01399996|Dietary Supplement|A capsule containing the probiotic|A capsule taken daily will provide between 10x^y9 and 10x^y10 cfu/ml of the probiotic (Bifidobacterium animalis subsp. lactis BB12).
1708515|NCT01399970|Other|Mobile Teleconsultation Arm (MTA)|"In addition to a face-to-face visit at baseline, patients will conduct mobile visits at home every two weeks. The general practitioner of choice will perform examinations, such as laboratory or occasionally pregnancy tests every 4 weeks according to the treatment guidelines."
1708516|NCT01399970|Other|Outpatient Consultation Arm (OCA)|Patients will receive routine outpatient care at the clinic according to the treatment guidelines, and will be scheduled for outpatient visits every 4 weeks.
1708517|NCT01399918|Drug|everolimus and bevacizumab|Cycle length will be defined as 28 days. Treatment will include everolimus 10mg, self administered orally once daily on a continuous schedule (days 1-28), and bevacizumab 10mg/kg, administered intravenously on days 1 and 15 of each cycle. Treatment will be continued until disease progression, major toxicity, or withdrawal from the study for any reason. Dose modification will be permitted based on toxicity. Patients that come off study before 6 months before documented progression/death will be treated as events for the 6 month PFS endpoint.
1708518|NCT01399905|Drug|carbidopa|75 mg of carbidopa per day versus 450 mg of carbidopa per day
1708519|NCT01399892|Dietary Supplement|soluble fiber in the form of benefiber|Benefiber, sugar free in an amount to total 20gms/1000kcal/day of fiber
1708520|NCT01399879|Other|Faraday cage, movement stabilization|The Faraday cage is a copper-mesh cage that surrounds the device and test site. It helps eliminate surrounding electrical noise. Movement stabilization will be achieved by placing a velcro strap over the arm to minimize random movements.
1708521|NCT01399866|Drug|D-cycloserine|2 single weekly doses, 50 mg capsule
1708522|NCT01399866|Drug|Placebo|
1708523|NCT01399853|Biological|160U /0.5ml EV71 Vaccine|inactivated vaccine (vero cell) against EV71 of 160U /0.5ml, two doses, 28 days interval
1708524|NCT01399853|Biological|320U /0.5ml EV71 vaccine|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 28 days interval
1708525|NCT01399853|Biological|640U /0.5ml EV71 vaccine|inactivated vaccine (vero cell) against EV71 of 640U /0.5ml, two doses, 28 days interval
1708526|NCT01399853|Biological|(without adjuvant) 640U /0.5ml|inactivated vaccine (vero cell) against EV71 of (without adjuvant) 640U /0.5ml, two doses, 28 days interval
1708527|NCT01399853|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, 28 days interval
1708528|NCT01399840|Drug|BMN 673|Oral capsule with multiple dosage forms given once daily
1708529|NCT01399827|Drug|ADHD Medication|For those subjects not on stable ADHD treatment (defined as a stable, effective dose for at least one month, determined by the study clinician, of a medication that is FDA approved to treat ADHD), OROS-Methylphenidate will be openly prescribed. Subjects on a stable dose of medication for ADHD will be instructed to continue on their current dose of medication.
1774589|NCT00387959|Drug|cyclosporine|
1708530|NCT01399827|Drug|Omega-3 Fatty Acids|Omega-3 Fatty Acids prescribed to participants randomized to active medication. They may be randomized to receive 1060mg of EPA (2 capsules containing 530mg EPA and 137mg DHA). Dosage will remain constant throughout study.
1708531|NCT01399814|Behavioral|perioperative fluid management|No preloading of epidural analgesia,7ml/kg lactated ringer's solution was administered in first hour,and 5ml/kg.h during the following hours,and 1000ml of glucose 5% was administered on the rest of the day during operation.1000~1500ml crystalloid was administered on the days following operation
1708532|NCT01399814|Behavioral|perioperative fluid treatment|500 mL HAES 6% was accepted as preloading of epidural analgesia,12ml/kg.h lactated ringer's solution was administered during the operation ,and 1000ml of glucose 5% was administered on the rest of the day during operation.2000~2500ml crystalloid was administered on the days following operation
1708533|NCT01399801|Procedure|Doppler flow measurement|use of doppler wire to measure change in flow that corresponds to changes in stroke volume to guide LV lead placement
1708534|NCT01399801|Procedure|standard implantation of the LV lead|Standard implantation of the LV lead with measurements of flow
1708535|NCT01399788|Drug|Myrin P Forte|Tablet containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide, given once daily, single dose
1708536|NCT01399788|Drug|Single drug references|containing Rifampicin, Isoniazid, Ethambutol and Pyrazinamide as single agents
1708537|NCT01399775|Procedure|immediate implantation|Immediately after tooth extraction, a dental implant is inserted
1708538|NCT01399775|Procedure|Delayed implantation|Four months after extraction, a dental implant is inserted and measurements are recorded.
1708539|NCT01399762|Device|mechanical recanalization|Endovascular thrombus extraction by mechanical recanalization devices
1708540|NCT01399749|Other|Implantation of autologous cells|Implantation of autologous ASC or chondrocytes, 1 million per cm² lesion, covered by autologous periosteal membrane
1708541|NCT01399736|Procedure|FFR-guided revascularisation strategy|FFR-guided revascularisation strategy
1708542|NCT01399736|Procedure|randomised to guidelines group|Staged revascularisation by proven ischemia or persistence of symptoms of angina
1708543|NCT01399723|Drug|Amoxicillin|Oral 45mg/kg 12 hourly
1708544|NCT01399723|Drug|Benzyl penicillin|Intravenous 50,000IU/kg 6 hourly
1708545|NCT01399710|Procedure|CT colonography|Participants were placed on a CT table and a small flexible rectal catheter was positioned. N-butyl-scopolamine was administered intravenously if this was common practice in the participating center. Immediately before scanning, pneumocolon was obtained through insufflation of room air or carbon dioxide, either manually by means of a balloon pump or with an automatic device, until maximum tolerance was reached. CT colonography was performed with the participant in supine and prone positions with the following scanning protocol: 120 kilovolt peak (kVp), 50 or fewer effective mA per second, and a section thickness not greater than 1.25 mm.
1708546|NCT01399710|Procedure|colonoscopy|Colonoscopy was performed at least 3 hours after CT colonography. The endoscope was advanced to the cecum and the entire length of the bowel was examined during endoscope withdrawal. The endoscopist was initially blinded to the result of CT colonography; at the end of each bowel segment evaluation, CT colonography results for that segment were disclosed (segmental unblinding). If a lesion measuring 6 mm or larger was detected at CT colonography but not at colonoscopy, the segment was reexamined to resolve the discrepancy
1708547|NCT01399710|Device|CT Colonography with computer assisted diagnosis (CAD),CADCOLON -im3D SpA., Torino Italy|Each CT colonography study was read in two phases. In the first phase the radiologist interpreted the examination without activating the CAD algorithm. This phase of reporting was defined as unassisted reading. Then the radiologist activated the CAD algorithm which pinpointed a series of colorectal lesion-like structures (i.e. lesion candidates) on both the prone and supine acquisition. All lesion candidates were examined. The second phase of reporting was defined as CAD-assisted reading.
1708548|NCT01399697|Drug|methotrexate|orally, Week 1 - 16
1708549|NCT01399697|Drug|methotrexate|orally, Week 17-28
1708550|NCT01399697|Drug|placebo|methotrexate placebo orally, Week 17-28
1708551|NCT01399697|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 28 weeks
1708552|NCT01399684|Drug|5-Fluorouracil|Participants will receive 5-fluorouracil 400 milligrams per squared meter (mg/m^2) intravenous (IV) bolus and then 2400 mg/m^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
1708553|NCT01399684|Drug|Bevacizumab|Participants will be administered bevacizumab at a dose of 5 milligrams per kilogram (mg/kg) every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
1708554|NCT01399684|Drug|Folinic acid|Participants will receive folinic acid 400 mg/m^2 IV infusion over 2 hours on Day 1 of every cycle until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
1708555|NCT01399684|Drug|MEGF0444A|Participants will be administered MEGF0444A at a fixed dose of 400 milligrams (mg) IV on Day 1 of Cycle 1, followed by subsequent doses of 400 mg every 14 days until disease progression or unacceptable toxicity, for a maximum of 52 cycles, whichever occurs first.
1708556|NCT01399684|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV infusion over 90 minutes on Day 1 of every cycle for a maximum of 8 cycles.
1708557|NCT01399684|Drug|Placebo|Participants will be administered MEGF0444A matching placebo every 14 days until disease progression, unacceptable toxicity or at the maximum of 52 cycles, whichever occurs first.
1708558|NCT01399671|Other|vestibular stimulation|vestibular stimulation
1708559|NCT01399658|Procedure|Image-guided brachytherapy|MRI-guided application of brachytherapy
1708560|NCT01399645|Drug|Liraglutide-metformin vs insulin-metformin|"Liraglutide (Victoza, Novo Nordisk) at a dose of 0.6 - 1.8 mg subcutaneous per day.
Insulin glargine (Lantus, Sanofi-Aventis) with an initial bedtime starting dose of 10 IU."
1708561|NCT01399632|Behavioral|Low Fat and High Carbohydrate Diet|Low Fat and High Carbohydrate Diet
1708562|NCT01399632|Behavioral|High Fat and Low Carbohydrate Diet|High Fat and Low Carbohydrate Diet
1708563|NCT01399619|Drug|PegIFN/RBV|PegIFN/RBV for 24 or 48w
1708564|NCT01399619|Drug|PegIFN/RBV|PegIFN/RBV for 24 or 48w
1708565|NCT01399619|Drug|BI201335|BI201335 for 12w
1708566|NCT01399619|Drug|BI201335 24W|BI201335 for 24w
1708567|NCT01399619|Drug|PegIFN/RBV|PegIFN/RBV for 24 or 48w
1708569|NCT01399606|Drug|BF2.649|5,10,20,or 40 mg per day, in a once daily scheme
1708570|NCT01399593|Drug|Eculizumab|
1708571|NCT01399580|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 8 weeks during the treatment period.
1708572|NCT01399580|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 8 weeks during the treatment period.
1708573|NCT01399567|Behavioral|Algorithm|The NH pain management algorithm is a series of decision-making tools that begin with regular, comprehensive pain assessment matched to residents' cognitive status and proceed through analgesic therapy appropriate to the character, severity, and pattern of pain.
1708574|NCT01399554|Behavioral|Motivational Enhancement Therapy plus Contingency Management|A combination of two motivational enhancement therapy (MET) sessions focused on increasing exercise spaced two months apart and four months of weekly contingency management (CM) for adhering to specific exercise activities. MET is a client-centered, directive method of enhancing intrinsic motivation to change by exploring and resolving ambivalence, and CM is a behavioral treatment offering individuals tangible reinforcers such as prizes for completion of specific target behaviors.
1708575|NCT01399515|Drug|Valproic Acid|One 500mg tablet by mouth daily
1708576|NCT01399502|Behavioral|Mood Memo emails|Participants will receive 12 emails over 6 weeks.
1708577|NCT01399489|Behavioral|Exercise training|Participants receive 16 weeks of moderate intensity aerobic training under the supervision of personal trainers. Each session lasts from 15 to 55 minutes depending upon patient tolerance
1708578|NCT01399476|Procedure|Endoscopic Myotomy|Patients will receive the surgical procedure described in the summary (POEM).
1708579|NCT01399476|Procedure|Endoscopic Myotomy for treatment of achalasia|Surgical procedure
1708580|NCT01399463|Device|Angioplasty performed via Paclitaxel Eluting Balloon catheter|
1708581|NCT01399463|Device|Angioplasty via DES|Angioplasty performed via commonly used Drug Eluting Stents
1708582|NCT01399450|Drug|paliperidone|paliperidone augmenting on ongoing medication
1708583|NCT01399424|Drug|CP|Immunization
1708584|NCT01399398|Procedure|Brain Scan-PET|
1708585|NCT01399398|Procedure|Brain Scan-MRI|
1708586|NCT01399398|Procedure|Arterial Line|
1708587|NCT01399398|Procedure|Venous Line|
1708588|NCT01399398|Procedure|Blood Sampling|
1708589|NCT01399372|Biological|rituximab|Given IV
1708590|NCT01399372|Drug|cytarabine|Given IV
1708591|NCT01399372|Drug|methotrexate|Given IV
1708592|NCT01399372|Drug|procarbazine hydrochloride|Given PO
1708593|NCT01399372|Drug|vincristine sulfate|Given IV
1708594|NCT01399372|Radiation|whole-brain radiation therapy|Undergo radiotherapy
1708595|NCT01399359|Behavioral|Counseling session|
1708596|NCT01399359|Other|Questionnaire 1|Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.
1708597|NCT01399359|Other|Questionnaire 2|Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.
1708598|NCT01399359|Other|online questionnaire|
1708599|NCT01399346|Drug|Insulin aspart|Application of 18 IU insulin aspart as one bolus at one injection site
1708600|NCT01399346|Drug|Insulin aspart|Application of 18 IU insulin aspart as 9 bolus of 2 IU each at nine injection sites
1708601|NCT01399333|Dietary Supplement|Group 1 Meal Replacement|4 weeks of utilizing Group 1 Meal Replacement 3-4 times daily, supplementing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
1708602|NCT01399333|Dietary Supplement|Group 2 Protein Supplement|4 weeks of utilizing Group 2 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
1708603|NCT01399333|Dietary Supplement|Group 3|4 weeks of utilizing Group 3 protein supplement 3-4 times daily, replacing this protein product at each meal. As standard of care for the bariatric patient, they are required to get in 60-80 gms of protein daily
1708604|NCT01399320|Procedure|cyanoacrylate|excision of the sinus under local anesthesia the packing of the wound by cyanoacrylate dressing
1708605|NCT01399307|Procedure|Liposuction|Elective Liposuction
1708606|NCT01399268|Drug|Hydrocortisone|Prepared by pharmacy, 100 mg, IV, every 8 hours, 3 times
1708607|NCT01399268|Drug|Saline|Prepared by pharmacy same volume as study drug, IV, every 8 hours 3 times
1708608|NCT01399255|Biological|Insulin lispro|Dosage form- Subcutaneous Injection
1708609|NCT01399242|Drug|Certican|Patients' therapy will be replaced from tacrolimus-based to everolimus-based immunosuppression. Everolimus will be introduced on day 1 at dose of 2 mg/day (1mg bid), and then everolimus trough levels will be obtained from day 3 onwards until C0 reaches the target for three consecutive days. Through levels will be adjusted to achieve 6-10ng/ml. Thereafter, if the target level was reached, the measurement will be performed weekly for 4 weeks and every 2 weeks until 8 weeks after conversion.In parallel, the tacrolimus dose will be reduced by 50% on day 1 and another 25% on day 7. The Tacrolimus will be withdrawn on day 14 if the target levels of everolimus are obtained.EC-MPS will be unchanged until day 14 after conversion.
1708610|NCT01399216|Dietary Supplement|Supplement containing fucoidan, EPA, and DHA|75 mg fucoidan per day, for 8 weeks
1708611|NCT01399216|Dietary Supplement|Placebo|for 8 weeks
1708612|NCT01399190|Biological|Bevacizumab|Bevacizumab administered according to prescribing information and normal clinical practice.
1708613|NCT01399190|Biological|Capecitabine|Capecitabine administered according to prescribing information and normal clinical practice.
1708614|NCT01399190|Drug|Oxaliplatin|Capecitabine administered according to prescribing information and normal clinical practice.
1708615|NCT01399164|Other|14C-B12 fortified bread|A single serving of 14C-B12 fortified bread
1708616|NCT01399151|Dietary Supplement|Vitamin D - Treatment 1|Volunteers will take a 400 IU/day dose of Vitamin D for 12 weeks.
1708617|NCT01399151|Dietary Supplement|Vitamin D - Treatment 2|Volunteers will take a 2,000 IU/day dose of Vitamin D for 12 weeks.
1708618|NCT01399151|Dietary Supplement|Vitamin D - Treatment 3|Volunteers will take a 5,000 IU/day dose of Vitamin D for 12 weeks.
1776174|NCT00400075|Drug|azathioprine|
1708619|NCT01399138|Dietary Supplement|Blueberry Powder|The groups will be randomized to receive 45g of blueberry powder or control (i.e., placebo) per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The second smoothie will be consumed at least 6 hours from the first smoothie. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients
1708620|NCT01399125|Drug|Rivastigmine Patch|Once-daily target patch size 10 cm²
1708621|NCT01399125|Drug|Rivastigmine Capsules|Twice-daily target dose of 6 mg oral capsule
1708622|NCT01399125|Drug|Placebo to Rivastigmine patch|Matching placebo to Rivastigmine patch
1708623|NCT01399125|Drug|Placebo to Rivastigmine capsules|matching Placebo to Rivastigmine capsules
1708624|NCT01399112|Behavioral|Web-based computer program|Web-based computer programs will be used to help education people with a recent first episode of a mental illness learn about smoking. The programs are designed to help young smokers become motivated to being a smoking cessation program.
1708625|NCT01399099|Device|embrace device|Adhesive bandage/dressing intended to minimize scar formation.
1708626|NCT01399086|Drug|Fulvestrant|250mg on d1,15,29 or 250mg on d1 q28days
1708627|NCT01399073|Behavioral|virtual reality setup|testing for neglect in a virtual reality setup
1708628|NCT01399073|Behavioral|paper and pencil tests|testing for neglect with the classical paper-and-pencil tests
1708629|NCT01399073|Other|c-mri|structural and functional (resting state) imaging
1708630|NCT01399047|Drug|Mycophenolate mofetil|The liquid dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (Omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
1708631|NCT01399047|Drug|Liquid Placebo|The dosage will be individualized, contingent upon the subject's weight. Subjects will receive 50% of the target dose (300mg/m2/dose BID) during Week 0-Week 2, then increase to the full dose (600mg/m2/dose BID) in Week 3, continuing at this dose through Week 8. Additionally, due to the risk of gastrointestinal disturbance (hemorrhage, ulcer), children will also receive prophylactic Prilosec (omeprazole) for the duration of the study, during both the mycophenolate and placebo arms.
1708632|NCT01399021|Other|Early Drain Removal|Drain will be removed prior to patient's discharge on the day of the surgery
1708633|NCT01399021|Other|Late Drain Removal|Patient will be seen on the day following the surgery to have the drain removed
1708634|NCT01399008|Drug|Arhalofenate|Arhalofenate 400 and 600 mgs over-encapsulated tablets once daily for 4 weeks or Allopurinol 300 mg once daily for 4 weeks
1708635|NCT01399008|Drug|Allopurinol|Allopurinol 300 mg as active comparator
1708636|NCT01399008|Drug|Colchicine|0.6 mg colchicine daily as flare prophylaxis
1708637|NCT01399008|Drug|Placebo|Placebo
1708638|NCT01398995|Other|Reduction of basal insulin infusion to 50% of normal|Each participant in this cross-over trial will participate in the 4 arms of the trial. They will be presented with the four conditions in randomised order - reducing their basal insulin infusion rate to 50% of normal at the four time points specified. A comparison will be made between the conditions.
1708639|NCT01398982|Drug|Bupivacaine (study group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of 0.25% Bupivacaine will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of 0.25% Bupivacaine will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
1708640|NCT01398982|Drug|Isotonic saline (control group)|At the conclusion of the surgery, a 0.2 mL/kg bolus of Saline will be injected through each catheter in the OR. At midnight following the OR, 0.2mL/Kg of Saline will be injected through each catheter every 8 hours for the next 2 postoperative days by a MD member of the pain team. At 8am on postoperative day 3, the TAP catheters were removed by the pain team. Our rationale for decreasing the frequency of intermittent boluses from every 12 hours to 8 hours in this study design was based on our finding in the pilot study that patients frequently used more PCA between 8-12 hours following Bupivacaine bolus as the effect of the anaesthetic agent weaned off.
1708641|NCT01398969|Procedure|Fresh Human Biotherapy|Patients will receive fresh fecal enema (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat HBT will be performed
1708642|NCT01398969|Procedure|Frozen-and-Thawed Human Biotherapy|Patients will receive frozen-and-thawed fecal enema (supernatant of fecal specimen mixed with water) on day 1. If cure is not reached at day 5 (+3) a repeat HBT will be performed
1708643|NCT01398956|Drug|Levetiracetam|"formulation: tablet or dry syrup
strength: 250 mg tablet, 500 mg tablet, dry syrup 50%
dosage: Sb ≥16 years and ≥4 and <16 years (≥50 kg): 1000 mg/day, 2000 mg/day or 3000 mg/day; Sb ≥4 and <16 years (<50kg): 20 mg/kg/day, 40 mg/kg/day, or 60 mg/kg/day
frequency: twice daily"
1708644|NCT01398943|Drug|Tetrahydrobiopterin (BH4)|single dose = 5 mg/kg
1708645|NCT01398943|Dietary Supplement|Antioxidant Cocktail|1g of vitamin C, 600 IU of vitamin E, and 600 mg of alpha-lipoic acid
1708646|NCT01398930|Other|acupuncture|This is a 3-armed single-blinded randomized sham-controlled trial, comparing acupuncture along with pharmacological treatment, sham acupuncture including pharmacological treatment, and pharmacological treatment alone.
1708647|NCT01398917|Procedure|plastic endoprosthesis|one 10 Fr Plastic endoprosthesis or 2 7 Fr plastic endoprosthesis inserted through dominant stricture(s), to be extracted after 1-2 weeks
1708648|NCT01398917|Procedure|balloon dilatation|4 cm 6 mm biliary dilatation balloon to be inflated for 2 minutes in dominant stricture(s)
1708690|NCT01398423|Drug|Active Control|Losartan potassium (50 mg) plus placebo to match alpha lipoic acid (600 mg)
1708691|NCT01398423|Drug|INV-144|INV-144 is a combination drug product consisting of losartan potassium (50mg) and alpha lipoic acid (600 mg)
1709509|NCT01391754|Behavioral|Services As Usual|Home based services not using the SafeCare model
1708649|NCT01398891|Other|Positive Psychology Exercises|At each session, the interventionalist will prepare the subject to complete a randomly-selected positive psychology exercise, lasting approximately 20 minutes, within the next 24 hours. He or she will describe the rationale for the exercise and the details of the exercise, and will answer any questions. A sheet with written instructions (matching the verbal instructions) for the exercise will be provided, with space for recording the exercise and an area to provide ratings on the exercise. On the following day, the interventionalist will review the prior day's exercise (and record whether it was completed). The exercises will be completed daily on weekdays for a maximum of 8 days.
1708650|NCT01398878|Behavioral|Intervention work shift|Shiftwork schedule with elimination of shifts greater than 16 hours in length and at least 8 hours off between shifts for all residents in the Intensive Care Unit
1708651|NCT01398865|Procedure|PET scan and MRI scan|"PET: The PET Scan is manufactured by Siemens and the model is the Exact HR+ .rCMRglu data will be gathered over a 30 minute resting period using a Siemens HR+ PET camera (4.5 mm in-plane and axial resolution). The total time for an individual PET session, will thus be one hour and a half (30 minutes for serum pregnancy test and 30 minute uptake period followed by 30 minutes of scanning).
MRI: High-resolution scans will be acquired using a Seimens (manufacturer) 1.5T Avonta system at MGH, to be coregistered with subsequently acquired PET images, and used for A) delineation of regions of interest (ROIs), and B) facilitation of optimal transformation to MNI space."
1708652|NCT01398852|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
1708653|NCT01398852|Device|VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
1708654|NCT01398839|Device|VEGA UV-A Illumination System|Only subjects assigned to the treatment group will receive treatment with the UV Light
1708655|NCT01398839|Drug|Riboflavin|Both treatment and sham groups will receive riboflavin
1708656|NCT01398787|Device|Lotrafilcon B contact lens with color|Plano (-0.00 diopter) silicone hydrogel contact lens in 1 of 4 colors: gray, blue, green, pure hazel
1708657|NCT01398787|Device|Phemfilcon A contact lens with color|Plano (-0.00 diopter) hydrogel contact lens in 1 of 4 colors: ColorBlends gray, Colorblends blue, Colorblends green, Colorblends pure hazel
1708658|NCT01398761|Other|Signout tool|Electronic signout tool
1708659|NCT01398748|Drug|Intranasal glutathione - (in)GSH|Intranasal glutathione-Tripeptide glutathione 100 mg/ml. 1 ml 3x per day TID X 12 weeks at 2100mg in 15 participants
1708660|NCT01398748|Drug|Intranasal glutathione - (in)GSH|Intranasal Glutathione-Tripeptide glutathione - 200mg/ml. 1 ml 3x per day TID X 12 weeks at 4200mg in 15 participants
1708661|NCT01398748|Drug|Saline Intranasal Delivery|Saline administration 1ml 3x/day 12 weeks in 15 participants
1708662|NCT01398722|Other|Intensive insulin therapy|Titration of the IV insulin rate for glucose goal 110-150 mg/dL
1708663|NCT01398722|Other|Conventional insulin therapy|Titration of the IV insulin rate for glucose goal 150-180 mg/dl
1708664|NCT01398709|Other|Slow rewarming strategy|Rewarming rate:0.24 degrees C/min.
1708665|NCT01398709|Other|Fast rewarming strategy|Rewarming rate:0.5 degrees C/min.
1708666|NCT01398696|Procedure|Patient Information Leaflets|Patient Information Leaflets (PIL) about adult gastroenteritis, children gastroenteritis, adult pharyngitis or either children pharyngitis in consultation room
1708667|NCT01398696|Procedure|usual consultation|No particular intervention during consultation for the Patient. No Information Leaflets (PIL) is given
1708668|NCT01398670|Biological|Insulin Lispro|"a. Lispro and Lispro Mix® 75/25 / Lispro Mix 50/50
The drugs would be administered subcutaneously"
1708669|NCT01398670|Biological|Insulin Lispro|"Humalog® and Humalog® Mix75/25 /Humalog® Mix 50/50
The drugs would be administered subcutaneously"
1708670|NCT01398657|Drug|Adjuvant Androgen-Deprivation Therapy|Short-term adjuvant androgen-deprivation therapy
1708672|NCT01398618|Drug|4-month rifampin vs. 9-month isoniazid|In the 4M-RMP group, enrolled subjects received 600 mg rifampin daily for 4 months. In the 9M-INH group, enrolled subjects received 300 mg isoniazid daily for 9 months.
1708673|NCT01398605|Other|Exercise training|Different dose of exercise training
1708674|NCT01398592|Drug|Vildagliptin|50mg vildagliptin bid
1708675|NCT01398592|Drug|Sitagliptin|100mg sitagliptin po qd
1708676|NCT01398579|Procedure|Gastroscopy|"20 patients will be randomized into two groups. All of them will be examined using four different endoscopy imaging technologies by one trained specialist. 10 patients will be in group A and another 10 patients will be in group B.
Group A: WLE followed by AFI followed by NBI followed by pCLE. Group B: WLE followed by NBI followed by AFI followed by pCLE."
1708678|NCT01398553|Device|Armeo Spring|30min Armeo Spring + 15min task oriented therapy over 6 weeks Frequency: 3 x/week
1708679|NCT01398553|Other|conventional physiotherapy|30min occupational therapy(15min ADL-training, 15min repetitive training) + 15min task oriented therapy over 6 weeks Frequency: 3x/week
1708680|NCT01398540|Biological|IXIARO|2 immunizations (0,5ml) with a 28 day interval
1708681|NCT01398527|Other|Educ sessions & LTC Osteoporosis toolkit|Three points of contact to be made. The first being a 1-hour personal visit at each intervention LTC home from an osteoporosis expert with the homes professional or health advisory committee (PAC or HAC). The second and third contact points will be made through webinars between the osteoporosis expert and the group from the first meeting.
1708682|NCT01398514|Drug|Escitalopram|Escitalopram 10mg/day or matched pill placebo
1708683|NCT01398501|Drug|Sorafenib|Oral, 200 to 400 mg QD or BID
1708684|NCT01398488|Behavioral|Patient education|Patient education by health care professional compared to education via tablet PC
1708685|NCT01398475|Drug|LY3009104|Administered orally
1708686|NCT01398462|Drug|CWP232291|IV Infusion
1708687|NCT01398449|Radiation|Elective nodal irradiation (ENI)|
1708688|NCT01398449|Other|Adjuvant chemotherapy only|
1708689|NCT01398436|Procedure|central venous catheter positioning in right atrium|A central venous catheter will be advanced for its entire length unless arrhythmias develop. Catheter position will be controlled by transesophageal echocardiography and/or by chest radiography
1708692|NCT01398410|Drug|Rabeprazole|Participants received rabeprazole 5 mg tablets and rabeprazole 10 mg matched placebo tablets orally, once daily
1708693|NCT01398410|Drug|Rabeprazole|Participants received rabeprazole 10 mg tablets and rabeprazole 5 mg matched placebo tablets orally, once daily
1708694|NCT01398384|Drug|Nitric Oxide|MI size at 48-72 hours
1708695|NCT01398384|Drug|MI size at 48-72 hours|Placebo gas
1708696|NCT01398371|Drug|Withdrawal of digoxin|Participants currently receiving digoxin for heart failure will have their digoxin stopped for 12 weeks.
1708697|NCT01398371|Drug|Digoxin|Stable digoxin therapy which produces a digoxin plasma level of 0.4-0.8.
1708700|NCT01398345|Behavioral|Exercise and Respiratory Training|Patients in the interventional group will participate in an exercise program 7 days a week at low workloads (10 to 60 W) that will be supervised by physical therapists and physicians.
1708701|NCT01398332|Device|Stent graft (EXCLUDER)|Endovascular repair
1708702|NCT01398319|Behavioral|Group Brief Alcohol Intervention|Intervention includes identifying reasons for joining the military, roadblocks to successful completion of training, information about alcohol, two anonymous self-assessments, information on quantity-based alcohol consumption in order to reduce the risk of incidents.
1708703|NCT01398306|Other|Blood sampling by vena punction.|We obtain 10mL blood of the patients. The blood is obtained twice: once with angiogenesis inhibitors or mTOR inhibitors, and once without.
1708704|NCT01398293|Drug|danoprevir|100 mg single dose orally
1708705|NCT01398293|Drug|danoprevir|400 mg single dose orally
1708706|NCT01398293|Drug|danoprevir placebo|single oral dose
1708707|NCT01398293|Drug|moxifloxacin|400 mg single dose orally
1708708|NCT01398293|Drug|moxifloxacin placebo|single oral dose
1708709|NCT01398293|Drug|ritonavir|100 mg single dose orally
1708710|NCT01398293|Drug|ritonavir placebo|single oral dose
1708711|NCT01398280|Drug|Topical aminocaproic acid (ACA) mixed with Vanicream|25% Aminocaproic acid cream twice daily for up to 12 weeks.
1708712|NCT01398280|Drug|Vehicle cream|Vehicle cream moisturizer twice daily for up to 12 weeks
1708713|NCT01398267|Drug|aleglitazar|150 mcg orally daily, 4 weeks (Day 15 to Day 43)
1708714|NCT01398267|Drug|lisinopril|20 mg orally daily, 6 weeks (Day 1 to Day 43)
1708715|NCT01398267|Drug|placebo|aleglitazar matching placebo orally daily, 4 weeks (Day 15 to Day 43)
1708716|NCT01398254|Procedure|Primary Percutaneous Coronary Intervention (PPCI)|Participants will be randomly assigned an access site, radial or femoral, for PPCI.
1708717|NCT01398241|Drug|RO5267683|Multiple ascending doses
1708718|NCT01398241|Drug|placebo|Multiple ascending doses
1708719|NCT01398228|Behavioral|quality improvement initiatives|A six component quality improvement intervention will be implemented. These components include: establishment of a quality improvement team, hospital performance audit and feedback, implementation of a clinical pathway, training of physicians and nurses, online technical support and patient education.
1708720|NCT01398215|Procedure|transvaginal NOTES ventral hernia repair|ventral hernia repair via the transvaginal approach
1708721|NCT01398202|Dietary Supplement|vitamin D3|20 micrograms per day for 10 weeks
1708722|NCT01398202|Dietary Supplement|25-hydroxyvitamin D3|7 microgram/day for 10 weeks
1708723|NCT01398202|Dietary Supplement|25-hydroxyvitamin D (20 microgram/day)|20 microgramday for 10 weeks
1708724|NCT01398202|Dietary Supplement|Placebo|0 ug vitamin D3/25-hydroxyvitamin D3/day for 10 weeks
1708725|NCT01398189|Drug|clozapine|C-11 clozapine
1708726|NCT01398176|Dietary Supplement|3 ounces of mushrooms|3 ounces of mushrooms consumed daily for 4 weeks
1708727|NCT01398176|Dietary Supplement|6 ounces of mushrooms|6 ounces of mushrooms consumed daily for 4 weeks
1708728|NCT01398163|Other|1-Fermented Dairy Product (test)|Arm 1 - Intervention 1 (probiotics)
1708729|NCT01398163|Other|2-Milk-based non-fermented dairy product(control)|Arm 2 - Intervention 2 (control)
1708730|NCT01398150|Dietary Supplement|Beverage made to look like the cranberry beverage|one 15 ounce bottle of beverage consumed daily
1708731|NCT01398150|Dietary Supplement|Beverage made from cranberry compounds|one 15 ounce bottle consumed daily for 70 days
1708732|NCT01398124|Biological|Cyclin B1 Peptide|vaccine
1708733|NCT01398111|Drug|Glycopyrrolate + Formoterol|glycopyrrolate pMDI + formoterol pMDI
1708734|NCT01398111|Drug|Glycopyrrolate|glycopyrrolate pMDI
1708735|NCT01398111|Drug|Formoterol|formoterol pMDI
1708736|NCT01398111|Drug|Placebo|placebo pMDI
1708737|NCT01398098|Drug|Sodium phosphate|32 tablets
1708738|NCT01398085|Radiation|I131 1.1 GBq|Radio-iodine
1708739|NCT01398072|Drug|Moxifloxacin|An oral dose of 400 mg once daily for 5 consecutive days every 4 weeks.
1708740|NCT01398072|Drug|Azithromycin|An oral dose of 250 mg once daily three times a week (every other day).
1708741|NCT01398072|Drug|Doxycycline|An oral dose of 100 mg once daily.
1708742|NCT01398072|Drug|Placebo|Oral dose of one table once daily.
1991083|NCT01541436|Device|Remote Ischemic Preconditioning, Capsaicin, UV-B|The participants will have one disposable tourniquet applied to the left mid thigh by research personnel. The participants will then be randomized to the treatment group or sham group. The treatment group will receive 3 cycles of RIPC to the left lower leg by occluding blood flow at the thigh with a pneumatic cuff. Each cycle will consist of 5 minutes of ischemia by inflating the cuff to 300 mmHg followed by 5 minutes of reperfusion. The sham group will have the cuff inflated to no more than 15mmHg for three cycles as described above. Areas of hypersensitivity and allodynia will be obtained every 40 min for 280 min following the end of capsaicin application.
1708743|NCT01398059|Other|Sedentary|In this condition, participants will engage in 8 hours of uninterrupted sedentary behaviour.
1708744|NCT01398059|Other|Sedentary With Breaks|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak.
1708745|NCT01398059|Other|Sedentary With Breaks and Physical Activity|In this condition participants will engage in 8 hours of sitting, although the sitting will be interrupted every 20 minutes. During these interruptions participants will spend 2 minutes walking at an intensity equivalent to 30% of VO2peak. Participants will also engage in 20 minutes of structured physical activity at an intensity of 60% of VO2peak in both the morning and afternoon.
1708746|NCT01398046|Drug|Dasatinib|dasatinib (100mg) PO x1
1708747|NCT01398046|Drug|Dasatinib plus Rabeprazole|Rabeprazole (20mg) PO twice daily (Days 1-3); Dasatinib (100mg) PO x1 (Day 4)
1708748|NCT01398046|Drug|Dasatinib plus Rabeprazole AND Betaine Hydrochloride|Rabeprazole (20mg) PO twice daily (Days 1-3); Betaine Hydrochloride (1500mg) PO x1 AND Dasatinib (100mg) PO x1 on Day 4
1708749|NCT01398033|Device|paclitaxel-coated balloon|Balloon is coated with paclitaxel in a concentration of 3µg/mm2.
1708750|NCT01398033|Device|non-coated balloon|percutaneous transluminal angioplasty with a non-coated balloon
1708751|NCT01398020|Drug|Standard Bowel Prep|Subjects will be asked to take 4L of Peglyte the day prior to procedure.
1708752|NCT01398020|Drug|2L Bi-Peglyte Bowel Prep|Subjects will be asked to take 2L Bi-Peglyte and 15mg bisacodyl the day prior to procedure.
1708753|NCT01398007|Procedure|Camouflage syringe|Dental anesthesia is administered using the camouflaged syringe.
1708754|NCT01397994|Drug|Nicorandil|Patients would be advised 10mg bd nicorandil for the first seven days. Drug will be titrated to 20 mg bd after one week, atenolol 50 mg will be given along with nicorandil from day 1
1708755|NCT01397994|Drug|Atenolol|Patients in the control arm would be advised atenolol 50 mg od
1708756|NCT01397981|Behavioral|Gait retraining|Changing the kinematics of walking
1708757|NCT01397968|Drug|YKP3089|Capsule, dose to be titrated
1708758|NCT01397968|Drug|Placebo|Placebo capsule
1708759|NCT01397955|Drug|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
1708760|NCT01397942|Other|Diet intervention|The participants in the two experimental arms will each have to consume 500 g of vegetables and cabbages daily.
1708761|NCT01397929|Drug|BAL101553|Intravenous administration
1708762|NCT01397890|Drug|Budesonide/formoterol (Symbicort® Turbuhaler®)|Budesonide/formoterol (Symbicort® Turbuhaler®) 160/4.5μg/inhalation, 2 inhalations twice daily
1708763|NCT01397890|Drug|Tiotropium (SpirivaTM)|Tiotropium (SpirivaTM) 18 μg/inhalation, 1 inhalation once daily
1708764|NCT01397877|Drug|BKM120|per os, 60mg/j, until progression or unacceptable toxicity
1708765|NCT01397864|Drug|rhC1INH or pdC1INH|C1 inhibitor, either plasma-derived (pdC1INH) or the recombinant human form (Ruconest)
1708766|NCT01397851|Device|Insecticide-treated net (BASF Incerceptor)|One per farmer, once during the 2010-2011 season
1708767|NCT01397838|Drug|Pro-Bone|500 mg Capsules of Pro-Bone twice daily
1708768|NCT01397825|Drug|Alisertib (MLN8237) + Rituximab + Vincristine|"Phase 1, Part 1: Safety lead-in cohort combining alisertib (MLN8237) as an enteric coated tablet (ECT) orally twice/day Days 1-7 & rituximab as an intravenous (IV) infusion on Day 1 in a 21 Day cycle for up to 8 cycles
Phase 1, Part 2: Alisertib (MLN8237) as an ECT orally twice/day Days 1-7 & rituximab as an IV infusion on Day 1 & vincristine IV Days 1 & 8 in a 21 Day cycle for up to 8 cycles
Phase 2: Alisertib (MLN8237) as an ECT orally twice/day Days 1-7 & rituximab as an IV infusion on Day 1 & vincristine IV Days 1 & 8 in a 21 Day cycle for up to 8 cycles
Following 8 cycles of treatment (or early discontinuation of rituximab) all patients with documented disease response or stabilization may continue with alisertib (MLN8237) single-agent therapy up to 2 years"
1708769|NCT01397812|Device|BreathScanner 1.0|For the HeartsBreath test, breath is collected using BreathScanner 1.0 and sent to central laboratory for analysis for markers of transplant rejection.
1708770|NCT01397812|Device|BreathLink|The BreathLink point-of-care system detects and quantifies the breath VOC's determined to be biomarkers during the development of the Heartsbreath test.
1708771|NCT01397799|Drug|KX2-391|Oral dose solution, once-daily dosing for 28-days. Subjects may continue beyond the first 28-days until disease progression or unacceptable toxicity develops.
1708772|NCT01397786|Drug|OPC-34712|"Phase A: 1-2 mgs/day by mouth, max of 4 wks.
Phase B: 1-4 mgs/day by mouth, up to 52 weeks"
1708773|NCT01397734|Drug|Arsenic trioxide|0.15mg/kg/day Arsenic trioxide given IV on days 1-5 of the cycle.
1708774|NCT01397708|Biological|INXN-2001|"approximately 1.0 x 1012 viral particles (vp) per injection
one intratumoral injection of INXN-2001 per study cycle
maximum of 6 study cycles"
1708775|NCT01397708|Drug|INXN-1001|"4 dose cohorts (5mg/day, 20mg/day, 100mg/day, and 160mg/day)
7 oral daily doses of INXN-1001 per study cycle
maximum of 6 study cycles
1 Expansion cohort at a single dose level at or below MTD (160mg/day)"
1708776|NCT01397695|Drug|Bevacizumab|The bevacizumab will then be sprayed by the treating physician in the clinic, under direct observation. Spray will be achieved by administering the bevacizumab through a mucosal atomization device. 0.1cc will be sprayed into both nares. Patients will then sit for 5 minutes, the application will be repeated for a total of 40 applications, thereby administering 50mgs into each nostril, a total of 100mgs into each patient. The 5 minute spacing has been arbitrarily chosen as sufficient time for 0.1cc of solution to be absorbed by the nasal mucosa. That will complete the treatment.
1708777|NCT01397682|Other|blood sample collection|A blood sample will be drawn within 24 hours from admission for determination of biomarkers and genetic analyses
1708778|NCT01397669|Procedure|Colon biopsy, lymph node biopsy, lumbar puncture|Eligible subjects will undergo a flexible sigmoidoscopy and biopsy, lumbar puncture, lymph node biopsy at Chulalongkorn University Hospital.
1708780|NCT01397643|Other|Non-operative|Patients in the non-operative arm will be managed conservatively using a sling, or an above elbow lightweight cast if problems with pain, for 10-14 days post injury. Patients will then be allowed to mobilise as able.
1776175|NCT00400075|Drug|cyclophosphamide|
1708781|NCT01397643|Other|Operative|For those patients in the operative group, tension band wire of plate fixation will be employed depending on the choice of their supervising consultant. Following surgery, the post-operative assessment and course will be as per normal protocol for patients who are not in this study. Patients in the operative group will be immobilised depending on fracture fixation during surgery and the decision will be made by the treating surgeon. Physiotherapy will be arranged when required.
1708782|NCT01397630|Drug|Oxytocin|Accelerated Oxytocin Titration
1708783|NCT01397617|Device|NobelActive Internal implant|Dental implant
1708784|NCT01397617|Device|NobelActive External implant|Dental implant
1708785|NCT01397617|Device|NobelReplace Tapered Groovy implant|Dental implant
1708786|NCT01397604|Drug|GLA-AF|GLA-AF contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-AF contains GLA in an aqueous solution. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
1708787|NCT01397604|Drug|GLA-SE|GLA-SE contains GLA, a new synthetic lipid A molecule that combines 6 acyl chains with a single phosphorylation site. GLA-SE contains GLA in a squalene oil emulsion. One 2 mcg injection will be given per patient in the upper arm, each randomized to either subcutaneous or intramuscular routes.
1708788|NCT01397604|Other|Squalene|Squalene is a natural organic compound obtained from shark liver oil. In this study, it is used to solubilize GLA in the GLA-SE formulation. Patients randomized to receive the squalene will be given one 2mcg injection of the squalene oil in the upper arm, each patient randomized further to either subcutaneous or intramuscular routes.
1708789|NCT01397591|Biological|Ofatumumab|Given intravenously
1708790|NCT01397591|Drug|Bortezomib|Given intravenously
1708791|NCT01397578|Drug|MABT5102A|Repeating subcutaneous injection
1708792|NCT01397578|Drug|MABT5102A|Repeating intravenous infusion
1708793|NCT01397578|Drug|placebo|Repeating subcutaneous injection
1708794|NCT01397578|Drug|placebo|Repeating intravenous infusion
1708795|NCT01397565|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
1708796|NCT01397565|Procedure|Minilaparoscopic cholecystectomy|Laparoscopic cholecystectomy performed using minilaparoscopic instruments
1708797|NCT01397552|Drug|Dexamethasone|10 mg/mL injected into lumbar spine, one level, one injection
1708798|NCT01397552|Drug|methylprednisolone acetate|80 mg of methylprednisolone acetate will be given in the lumbar spine, one level, one time
1708799|NCT01397539|Drug|BIIB037|Participants receive a single dose of BIIB037 by intravenous (IV) infusion in cohorts assigned to the following ascending doses: .03 mg/kg, 1 mg/kg, 3 mg/kg, 10 mg/kg, 20 mg/kg, 30 mg/kg, and 60 mg/kg.
1708800|NCT01397539|Other|Placebo|Participants receive a single dose of matching BIIB037 placebo by intravenous (IV) infusion.
1708801|NCT01397513|Drug|Aspirin|Tablets, 75 or 320mg once daily for 4 weeks. A 4-week wash-out period separated the two treatment periods.
1708802|NCT01397500|Drug|Genotropin|Genotropin administered sc once a day by patient or caregiver.
1708803|NCT01397500|Drug|Testosterone undecannoate|Testosterone undecannoate administered twice (6 week Interval) im by investigator.
1708804|NCT01397487|Procedure|Blastomere biopsy|The blastomere biopsy will be done after 72 hours of embryo culture. An inverted microscope Olympus IX70 with a heated stage will be used to perform the biopsy. The micromanipulation for the blastomere extraction will be made with a micropipette MBB-FP-M-30 (Humagen).
1708805|NCT01397474|Other|PPTFM|Peripheral Perfusion Targeted Fluid Management
1708806|NCT01397461|Drug|ozenoxacin placebo|cream
1708807|NCT01397461|Drug|retapamulin 1% ointment|ointment
1708808|NCT01397461|Drug|ozenoxacin 1% cream|1% cream
1708809|NCT01397448|Drug|E3810|E3810 5 mg/day Group: Orally administered E3810 5 mg tablets and E3810 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
1708810|NCT01397448|Drug|E3810|E3810 10 mg Group: Orally administered E3810 5 mg placebo tablets and 10 mg tablets once daily after breakfast; and orally administered Teprenone 50 mg placebo capsules three times daily after each meal.
1708811|NCT01397448|Drug|Teprenone|Teprenone 150 mg/day Group: Orally administered E3810 5 mg placebo tablets and 10 mg placebo tablets once daily after breakfast; and orally administered Teprenone 50 mg capsules three times daily after each meal.
1708813|NCT01397409|Drug|AGN-150998|AGN-150998 Intravitreal injection.
1708814|NCT01397409|Drug|ranibizumab|Ranibizumab 0.5 mg given by intravitreal injection.
1708815|NCT01397409|Other|Sham Injection|Stage 3: Sham injection at Weeks 12 and 16.
1708816|NCT01397396|Procedure|Inspiratory Muscle Training|Three times daily inspiratory muscle training (2x30 breaths) at an intensity of >50% Pi,max
1708817|NCT01397370|Drug|GLPG0492|Oral solution
1708818|NCT01397370|Drug|Placebo|Oral solution
1708819|NCT01397357|Other|Cardiac magnetic resonance - CINE MRI stress test.|Cardiac magnetic resonance - dipyridamole or dobutamine MRI stress test.
1708820|NCT01397331|Drug|Isoflurane|Anesthesia based on inhalation of 1-1.5 Minimal Alveolar Concentration of Isoflurane with the addition of infusion of remifentanil
1708821|NCT01397331|Drug|Propofol|Anesthesia based on the infusion of 2-5 mg/kg/h of propofol with the addition of infusion of remifentanil
1708822|NCT01397305|Drug|[6R] 5,10-methylenetetrahydrofolate|10, 50, 100, 200, and 500 mg/m2 IV on day 1, day 8 day and day 15 of each 21-day cycle. 3 cycles.
1708823|NCT01397305|Drug|Pemetrexed|500 mg/m2 IV on day 1 of each 21-day cycle. 3 cycles.
1708824|NCT01397279|Biological|intravenous glucose tolerance test|Administration of a 30% weight-adapted glucose bolus intravenously.
1708825|NCT01397279|Biological|hyperinsulinemic euglycemic clamp|Intravenous administration of 20% glucose and insulin over 3 hours
1708826|NCT01397266|Procedure|Transcranial Magnetic Stimulation|ACTIVE rTMS delivered to the left dorsolateral prefrontal cortex
1708827|NCT01397266|Procedure|Placebo TMS|PLACEBO rTMS delivered to the left dorsolateral prefrontal cortex
1708871|NCT01397032|Behavioral|Attention Bias Modification Treatment (ABMT)|Behavioral: Attention Bias Modification Treatment (ABMT) Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
1708828|NCT01397253|Other|Automated communication tools|"Automated communication tools will include:
PCP notification of patient admission and location
Data on medications begun on admission
Automated alerts on changes in patient status and location while the patient is hospitalized
Links to the EMR and to hospital physician contact information on all email alerts
Real-time delivery of discharge information (medications, instructions, and follow-up) to the PCP
Automatic reporting to PCPs of test results pending at discharge
Electronic delivery of final discharge summaries"
1708829|NCT01397240|Drug|Albis Tab|2 Tab, twice a day, 12 weeks
1708830|NCT01397240|Drug|Placebo|2 Tab, twice a day, 12 weeks
1708831|NCT01397227|Biological|Ad35.CS.01/Ad26.CS.01 low dose (1 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
1708832|NCT01397227|Biological|Ad 35.CS.01/Ad 26.CS.01 high dose (5 x 10^10 vp)|Prime-boost schedule: Each subject receives two injections of Ad35.CS.01 (on Days 0 and 28) followed by one injection of Ad26.CS.01 (on either Day 55 or 59).
1708833|NCT01397227|Biological|Placebo|Each placebo subject receives in total three injections of placebo: Day 0, Day 28, and either Day 55 or 59
1708834|NCT01397214|Drug|Megace F|Megace F oral suspension
1708835|NCT01397214|Drug|Megace OS|Megace oral suspension
1708836|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
1708837|NCT01397201|Drug|BI 54903|2 puffs b.i.d. BI54903 medium range via Respimat inhaler
1708838|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo BI54903
1708839|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
1708840|NCT01397201|Drug|Fluticasone|2 puffs b.i.d. 110mcg Fluticasone propionate HFA MDI
1708841|NCT01397201|Drug|BI 54903|2 puffs BI54903 via Respimat inhaler
1708842|NCT01397201|Drug|BI 54903|2 puffs b.i.d. BI54903 via Respimat inhaler
1708843|NCT01397201|Drug|Placebo|2 puffs placebo BI54903 via Respimat inhaler
1708844|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
1708845|NCT01397201|Drug|Placebo|2 puffs b.i.d. placebo HFA MDI
1708846|NCT01397188|Device|PiCCO|transpulmonary thermodilution technique
1708847|NCT01397188|Other|sham, no intervention|no intervention
1708848|NCT01397175|Device|Biolimus-eluting stent|Biolimus-eluting stent (BES, BioMatrix or BioMatrix Flex, Biosensors, USA) has bio-degradable polymer which is consisted with poly-lactic acid (PLA) and degraded into H2O and CO2 while releasing the biolimus. BES would be expected to reduce the stent thrombosis comparing with the DES with durable polymer.
1708849|NCT01397175|Device|Everolimus-eluting stent|Everolimus-eluting stent (EES, Xience V or Xience Prime, Abbott, USA) use the MULTILINK VISION stent platform and durable polymer containing everolimus. It has the thinnest strut thickness among the available DES in Korea.
1708850|NCT01397175|Device|Zotarolimus-eluting stent|Zotarolimus-eluting stent with biolinx polymer (ZES, Endeavor Resolute or Endeavor Resolute Intergrity, Medtronic, USA) has DRIVER stent platform. The durable polymer in this DES has changed from phosphorylcholine (PC) polymer which was used in Endeavor to Biolinx polymer which has more biocompatible features.
1708851|NCT01397162|Drug|Fluticasone propionate|2 puffs b.i.d. via HFA MDI matching placebo inhaler
1708852|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
1708853|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
1708854|NCT01397162|Drug|BI 54903|2 puffs b.i.d. via Respimat inhaler
1708855|NCT01397162|Drug|BI 54903|2 puffs b.i.d. via Respimat inhaler
1708856|NCT01397162|Drug|Placebo|2 puffs b.i.d. via placebo Respimat inhaler
1708857|NCT01397162|Drug|Placebo|2 puffs b.i.d. via placebo Respimat inhaler
1708858|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
1708859|NCT01397162|Drug|Placebo|2 puffs b.i.d. via HFA MDI matching placebo inhaler
1708860|NCT01397162|Drug|BI 54903|2 puffs b.i.d. via Respimat inhaler
1708861|NCT01397149|Drug|Placebo|Dosage form, frequency and duration exactly as experimental arm.
1708862|NCT01397149|Drug|Eltrombopag|"Phase I:
Single arm dose-escalation trial part, to test 4 doses of eltrombopag (75mg, 150mg, 225mg, 300mg) to find the appropriate, feasible dose to achieve a durable increase in platelet count (≥100,000/µl). Eltrombopag will be administered once daily at the respective dose level for 2 weeks (unless platelet counts rise to > 400,000/µl).
Phase II:
Patients will be randomized (2:1 eltrombopag : placebo) to explore the efficacy and confirm the safety of the identified dose level from Phase I. Eltrombopag/placebo will be administered before starting each cycle (and possibly following chemotherapy treatment depending on data from phase I), and will continue during all cycles of treatment until subjects finish chemotherapy (alkylating agents and/or purine analogue-based therapy). The schedule and days of eltrombopag dosing in Phase II will be determined based on data analyzed from Phase I."
1708863|NCT01397123|Other|Training teachers on healthier lifestyles|During 2007/2008 seven out of eighty public elementary public schools from Guimarães (Portugal) were invited to participate in this study. The number of schools involved was according to constraints of personnel for the assessment and intervention. Schools were the unit of randomization and three were assigned into intervention, and four into control group. Data was collected prior to intervention and immediately after, during the year 2009 (post-intervention). Prior to participation on data collection, parents provided informed consent, and children provided oral assent.
1708864|NCT01397110|Other|respiratory and exercise therapy|Conventional therapy with specific respiratory and physical therapy plus mental walking training
1708865|NCT01397097|Drug|LNG-IUS (BAY 86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months with an follow-up extension for up to 3 years
1708866|NCT01397097|Drug|68 mg etonorgestrel implant for subdermal use (Nexplanon)|Implant insertion will occur at randomization visit (Visit 2). Duration of study treatment is 12 months, may be continued up to 3 years under standard care.
1708867|NCT01397084|Drug|esomeprazole 20 mg|esomeprazole 20 mg once daily for 8 weeks
1708868|NCT01397071|Other|Avocado|Fresh Avocado
1708869|NCT01397045|Other|VATS|Video-assisted lung segmentectomy
1708870|NCT01397045|Procedure|Mini thoracotomy|Mini muscle sparing thoracotomy for lung segmentectomy
1708872|NCT01397032|Behavioral|Attention Control Condition|Attention training using a computerized spatial attention task (dot-probe) not intended to alter threat-related attention patterns.
1708873|NCT01397019|Drug|Oxaliplatin, irinotecan, 5-FU & leucovorin|FOLFIRINOX followed by 50 gy/27 F in combination with capecitabine in patients with borderline resectable tumors
1708874|NCT01397006|Drug|Pregabalin|Pregabalin dose escalating every 2 weeks. Starting dose is 75 mg. Titrated up to maximum of 450mg
1708875|NCT01396993|Procedure|Breast Surgery|breast conserving surgery AND immediate defect filling using local flaps (level I) or reduction plastics (level II) as well as mastectomy and immediate reconstruction using free flaps
1708876|NCT01396993|Procedure|Breast Surgery|Breast conserving therapy without defect correction
1708877|NCT01396967|Device|surgery|cataract surgery
1708878|NCT01396941|Behavioral|Sleep restriction|Sleep restriction will consist of 5 nights, sleeping 4 hours per night Normal sleep will consist of 5 nights, sleeping 9 hours per night
1708879|NCT01396928|Procedure|Colonic reservoir|Type of reservoir to be performed
1708880|NCT01396915|Dietary Supplement|Dietary Protein Intake|Dietary Protein Intake This is a 12-week randomized,prospective study incorporating a dietary intervention in which subjects will consume either higher protein(HP:1.4g protein•kg-1•d-1) or normal protein diet (NP:.8g protein•kg-1•d-1)
1708881|NCT01396902|Behavioral|Standard of care|You will receive an immunization handout and verbal instructions regarding your child's next apt. Your child's immuniztion records will also be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
1708882|NCT01396902|Behavioral|Text Messaging|You will receive text message reminders prior to your child's two, four and six month immunization due dates. You will be asked to take part in a phone interview and your child's immuniztion records will be checked through KSWebIZ an internet based system that tracks immunizations for kids in Kansas.
1708883|NCT01396889|Drug|Echinacea|0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old
1708884|NCT01396889|Drug|Placebo|Placebo (0.5ml daily for children 1-2 years old and 2ml daily for children 2-5 years old) for 3 months
1708885|NCT01396876|Behavioral|clown|a distraction technique is performed by a clown during venipuncture
1708886|NCT01396863|Procedure|HDF during the first examination|"The patient will receive treatment with pre-dilution hemodiafiltration during the first examination.
During the second examination the patient will receive treatment with low flux hemodialysis.
MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
1708887|NCT01396863|Procedure|HD during the first examination|"The patient will receive treatment with low flux hemodialysis during the first examination.
During the second examination the patient will receive treatment with pre-dilution hemodiafiltration.
MRI of the brain will be performed before and after the treatment. The MRI-data will later be processed to determine the degree of brain volume change due to the treatment."
1708888|NCT01396837|Device|RedDress Wound Care System (RD1)|Weekly application. A blood based wound care treatment
1708889|NCT01396824|Other|No intervention|No intervention
1708890|NCT01396811|Drug|33525|Daily for 14 days
1708891|NCT01396811|Drug|Placebo|Daily for 14 days
1708892|NCT01396785|Drug|33525|Daily for 14 days
1708893|NCT01396785|Drug|Placebo|Daily for 14 days
1708894|NCT01396772|Behavioral|PREPARE education program|"PREPARE stands for Prediabetes Research and Education Promoting Activity and Responsible Eating and is a 6-month community-based prediabetes lifestyle and behaviour change intervention program. It includes a series of six interactive education sessions of two hours each on healthy eating and physical activity."
1708895|NCT01396772|Other|standard of care presentation|A one-time 2-hour group prediabetes education session, offered as the standard for individuals referred for prediabetes in London, Ontario (Canada)
1708896|NCT01396759|Procedure|Bubble continuous positive airway pressure|All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
1708897|NCT01396759|Procedure|Humidified high flow air / O2 mix at 2 l/kg/min|Humidified high flow air / O2 mix at 2 l/kg/min through nasal canula. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
1708898|NCT01396759|Procedure|Standard O2 supplementation by nasal cannula at 0.5 - 2 l/min|Standard O2 supplementation will be given by nasal cannula at 0.5 - 2 l/min. All children will be monitored for by pulse oximetry for arterial O2 saturation, respiratory rate, lower chest wall in-drawing, intercostal retraction, head nodding, cyanosis, tracheal tug, heart failure (defined by the presence of tachypnea, tachycardia, gallop rhythm, hepatomegaly, pedal oedema, basal crackles). Arterial or capillary blood gas analyses will be done for children failing to maintain saturation (>90% with allocated treatment), or if there is concern about hypercarbia or acidosis.
1708899|NCT01396733|Drug|alpha-lipoic acids|alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
1708900|NCT01396720|Drug|fluvoxamine|Fluvoxamine 100mg daily, 7 days
1708901|NCT01396720|Drug|citalopharm|Citalopharm 20mg daily, 7 days
1708902|NCT01396707|Drug|Herceptin+XELOX|"Each 3-weekly cycle, with chemotherapy given for 6 cycles, and trastuzumab continued even after completion of the combination chemotherapy until disease progression
Trastuzumab: 8 mg/kg i.v. loading dose on day 1, followed by 6 mg/kg i.v.infusion every 3 weeks
Capecitabine: 1000 mg/m2 oral twice daily for 14 days every 3 weeks (from evening on day 1 to morning on day 15)
Oxaliplatin 130 mg/m2 i.v. on day 1"
1708903|NCT01396694|Other|Questionnaire|Questionnaire
1708978|NCT01396174|Behavioral|Standard Online Support Group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will focus on encouraging self-expression.
1709510|NCT01391754|Other|Uncoached|No in vivo coached quality control or fidelity monitoring
1708904|NCT01396681|Drug|gemcitabine and cisplatin|The study consists of three phases; Induction chemotherapy phase:Starting 4~8 weeks after R0 resection of pancreatic cancer. Gemcitabine: 1200mg/㎡ (Day 1, 8), cisplatin 60mg/㎡ (Day 1) every 3 weeks for 2 cycles. Chemoradiotherapy phase: Starting 1-2 weeks after completion of induction chemotherapy (within 5 weeks after D1 of 2nd cycle of induction chemotherapy), no later than 16 weeks after operation. Gemcitabine 300mg/㎡ weekly for 5 weeks throughout RT period. Radiotherapy: 50.4Gy at 1.8Gy/Fx, for 28 Fx (Field reduction at 45Gy) for 5.5 pweeks. Maintenance chemotherapy phase: Within 4 weeks after completion of chemoradiotheray, no later than 6 weeks after completion of chemoradiotherapy Gemcitabine: 1200mg/㎡ (Day 1, 8) every 3 weeks, for 4 cycles
1708905|NCT01396668|Drug|gemcitabine, cisplatin, capecitabine|Gemcitabine: 1000mg/㎡ (day 1, 8), cisplatin 60mg/㎡ (day 1) Capecitabine: 650mg/㎡ twice a day, during radiotherapy Gemcitabine: 1000mg/㎡ (day 1, 8)
1708906|NCT01396655|Drug|docetaxel (75 mg/m2) and doxorubicin (50 mg/m2)|The chemotherapeutic regimen consisted of docetaxel (75 mg/m2) and doxorubicin (50 mg/m2) by intravenous infusion every 3 weeks. After three cycles of neoadjuvant chemotherapy, the patients were re-evaluated for response and underwent curative surgery. Radiologic response was evaluated using breast magnetic resonance imaging (MRI) for the primary breast tumor and chest computed tomography (CT) for axillary, supraclavicular, internal mammary lymph nodes with RECIST criteria. Both breast MRI and chest CT were performed in all the 78 patients. Subsequently, the patients received three more cycles of docetaxel and doxorubicin as an adjuvant chemotherapy, followed by hormonal or radiation therapy, if indicated.
1708907|NCT01396642|Other|Topical Emollient|Neonates in this group will receive topical emollient application with coconut oil twice a day till 28th day of life
1708908|NCT01396629|Procedure|cartridge|IOL cartridge coated with polymer material may ensure smooth delivery of IOL during cataract surgery
1708910|NCT01396590|Drug|Perampanel|6 x 2 mg perampanel once per day
1708911|NCT01396590|Drug|Perampanel|12 mg perampanel once per day
1708912|NCT01396577|Drug|perampanel|3 x 2 mg perampanel once per day
1708913|NCT01396577|Drug|perampanel|6 mg perampanel once per day
1708914|NCT01396564|Drug|Metformin|850 mg of Metformin daily, increased to 1700 mg after 12 weeks, for the duration of the trial.
1708915|NCT01396564|Drug|Pioglitazone|15 mg of pioglitazone daily, increased to 60 mg after 12 weeks.
1708916|NCT01396551|Device|Implantation of anchored Beacon transponder in the lung|Anchored Beacon transponder has an anchoring feature to secure it in the small airways of the lung.
1708917|NCT01396525|Device|Omnilink Elite™ Peripheral Balloon-Expandable Stent System|Patients with treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
1708918|NCT01396512|Biological|Live attenuated Japanese encephalitis chimeric virus vaccine|0.5 mL, Subcutaneous
1708919|NCT01396512|Biological|Japanese encephalitis live attenuated vaccine (SA14 14 2 vaccine)|0.5 mL, Subcutaneous
1708920|NCT01396499|Drug|BKM120|Starting dose 80 mg tablets by mouth daily for a 28 day cycle.
1708921|NCT01396486|Drug|Omega-3|Children with bipolar spectrum disorders ages 6-12 will receive treatment with omega-3 fatty acids. Study subjects may be randomized to receive 3000mg (6 500mg capsules) of omega-3 fatty acids for the duration of the study. Omega-3 fatty acid capsules are in the form of Nordic Naturals brand, ProOmega Junior, which contains 325mg EPA and 225mg DHA per two capsules.
1708922|NCT01396486|Drug|Inositol|Children with bipolar spectrum disorders ages 6-12 will receive treatment with inositol, omega-3 fatty acids, or both weekly for 12 weeks. Subjects weighing 25kg or more may be randomized to receive 2000mg (4 500mg capsules) of inositol (80mg/kg for a 25kg child). Children weighing less than 25kg will be dosed at 80mg/kg rounded down to the nearest thousand mg dose. Dosage will remain constant throughout the study.
1708923|NCT01396473|Behavioral|Policy and Environmental Change|Afterschool programs participate in an assessment of physical activity and nutrition practices and policies. Study staff work with teams of afterschool programs in a participatory manner to identify areas in which programs would like to take practice, policy and communication efforts to meet physical activity and nutrition goals. Teams share progress and barriers during ongoing collaborative meetings.
1708924|NCT01396460|Other|breakfast (a chicken sandwich with juice)|patients received a breakfast after de initial measurement
1708925|NCT01396447|Drug|Placebo|Placebo was supplied in capsules.
1708926|NCT01396447|Drug|Cariprazine|Cariprazine was supplied in capsules.
1708927|NCT01396434|Biological|Prevenar 13|Prevenar 13 vaccine as prescribed by the physician based on approved product indication
1708928|NCT01396421|Drug|OPC-34712 [Brexpiprazole] High Dose|Higher dose, tablet, once daily, for six weeks
1708929|NCT01396421|Drug|Experimental: OPC-34712 [Brexpiprazole] Middle Dose|Middle dose, tablet, once daily, for six weeks
1708930|NCT01396421|Drug|Experimental: OPC-34712 [Brexpiprazole] Low Dose|Lower dose, tablet, once daily, for six weeks
1708931|NCT01396421|Drug|Placebo|Placebo, once daily, for six weeks
1708932|NCT01396408|Drug|Sunitinib|50 mg PO daily for 28 days, q 6 weeks (1 cycle=6 weeks or 42 days)
1708933|NCT01396408|Drug|Temsirolimus|25 mg IV weekly (Days 1, 8, 15, 22, 29, 36), q 6 weeks (1 cycle=6 weeks or 42 days)
1708934|NCT01396395|Drug|Nicorandil|The subjects will receive Nicorandil 5 mg tablet orally three times daily for a period of 12 weeks along with the standard treatment.
1708935|NCT01396395|Drug|Standard Treatment|The subjects will receive one of the standard anti-anginal therapies which included but not limited to aspirin, ACEI, lipid lowering statins and beta blockers according to the recommendation of guidelines. If the subject's condition permitted, they should take all these medicines. However, the dose, route, frequency and duration were determined by investigators according to subject's specific condition.
1708979|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
1708980|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
1709508|NCT01391754|Other|In vivo coached quality control|Live observation of practice with expert coaching, feedback and fidelity monitoring
1708936|NCT01396382|Radiation|68Ga-DOTATATE PET scan|68Ga-DOTATATE will be given in tracer doses and injected intravenously to image tumors by Positron Emission Tomography (PET). Efficacy of the 68Ga-DOTATATE PET scan was assessed and compared to 111In-Pentetreotide scan and to scans with CT and/or MRI. Safety and toxicity were also assessed with pre-injection and post-imaging vital signs, pulse oximetry on room air, 12 lead ECGs, and blood laboratory tests, including tumor markers, liver and renal functions and blood counts, and direct patient questioning. Late delayed tumor markers, liver and renal functions and blood counts were assessed when available.
1708937|NCT01396369|Drug|Birth control|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
1708938|NCT01396369|Drug|Birth control plus Brevail|In the initial visit, History and Physical Exam,menstrual history, pregnancy history, documentation of hirsutism using Ferriman-Gallwey scoring,body weight, height, and body mass index.The baseline ultrasound blood tests. After the lab tests, the patients in the control group will be started on OC (standard clinical practice) and those in the treatment group will be started on OC with Brevail (2 pills once a day). The patients will return to the clinic for a follow up visit after 3 months. If no side effects, Brevail and OC will be continued for 3 more months. The control group will also have a follow up after 3 months of OC. Six months after the initiation of the study, the patients in the both groups will have another H&P as well as repeat ultrasound and blood tests.
1708939|NCT01396356|Procedure|GI procedures|If you agree to participate in the study, you will undergo a series of tests about a week before the expected ablation procedure. The same tests will be repeated 24-48 hours after the ablation. These tests include esophageal manometry, gastric emptying scan, sham feeding test and completing a symptoms questionnaire.
1708940|NCT01396330|Behavioral|stress|3 professional safe drive training courses each lasting 30 minutes
1708942|NCT01396304|Device|Restore Calcium Alginate Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
1708943|NCT01396304|Device|AquaCel Ag Wound Dressing|Wound dressing appropriate for venous leg ulcers. Dressing to be changed minimally once per week.
1708944|NCT01396291|Drug|asenapine|asenapine, sublingual tablets, 5 to 10 mg twice per day (BID)
1708945|NCT01396291|Drug|placebo|asenapine-matched placebo, sublingual tablets, BID
1708946|NCT01396278|Drug|Placebo|2 puffs BID placebo matching fluticasone propionate HFA MDI
1708947|NCT01396278|Drug|Placebo|2 puffs BID placebo matching BI54903 Respimat
1708948|NCT01396278|Drug|Fluticasone propionate|2 puffs BID 88 mcg Fluticasone propionate HFA MDI
1708949|NCT01396278|Drug|BI 54903|2 puffs BID BI 54903 via Respimat inhaler
1708950|NCT01396278|Drug|Fluticasone propionate|2 puffs BID 220 mcg Fluticasone propionate HFA MDI
1708951|NCT01396278|Drug|Placebo|2 puffs BID placebo matching BI54903 Respimat
1708952|NCT01396278|Drug|BI 54903|2 puffs BID BI 54903 via Respimat inhaler
1708953|NCT01396278|Drug|BI 54903|2 puffs BID BI 54903 via Respimat inhaler
1708954|NCT01396278|Drug|Placebo|2 puffs BID placebo matching fluticasone propionate HFA MDI
1708955|NCT01396278|Drug|Placebo|2 puffs BID placebo matching fluticasone propionate HFA MDI
1708956|NCT01396265|Drug|Afatinib|single dose
1708957|NCT01396265|Drug|Afatinib|single dose
1708958|NCT01396265|Drug|Rifampicin|multiple doses
1708959|NCT01396252|Drug|BMS-820836|Tablets, Oral, 0.5 mg, Once daily, 14 days
1708960|NCT01396252|Drug|BMS-820836|Tablets, Oral, 1 mg, Once daily, 14 days
1708961|NCT01396252|Drug|BMS-820836|Tablets, Oral, 2 mg, Once daily, 14 days
1708962|NCT01396252|Drug|Placebo matching BMS-820836|Tablets, Oral, 0 mg, Once daily, 14 days
1708963|NCT01396252|Drug|BMS-820836|Tablets, Oral, (initiated at 1 mg and dose escalated to the target dose of 2 mg), Once daily, 14 days
1708964|NCT01396239|Drug|AVI-4658 (Eteplirsen)|Treatment group 1 (n=4): 50.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 2 (n=4): 30.0 mg/kg eteplirsen once weekly x 24 weeks via a 60-minute i.v. infusion Treatment group 3 (n=4): matching placebo once weekly x 24 weeks via a 60-minute i.v. infusion; treatment group 3a will match two placebo subjects to 50.0 mg/kg eteplirsen; treatment group 3b will match two placebo subjects to 30.0 mg/kg eteplirsen
1708965|NCT01396239|Other|Placebo|sterile, isotonic, clear, colorless phosphate buffered saline solution of eteplirsen at a concentration of 100 mg/mL in single-use vials containing a nominal volume of 1.0 mL without preservatives.
1708966|NCT01396226|Drug|AZD2927|A single dose of AZD2927 administered as an iv infusion
1708967|NCT01396226|Drug|Placebo|A single dose of placebo administered as an iv infusion
1708968|NCT01396213|Drug|Larazotide Acetate|gelatin capsule
1708969|NCT01396213|Drug|placebo|gelatin capsule
1708970|NCT01396200|Drug|Hydroxychloroquine|Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
1708971|NCT01396200|Drug|Rapamycin|Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
1708972|NCT01396187|Drug|PF-05231023|5 mg IV twice a week for 4 weeks
1708973|NCT01396187|Drug|PF-05231023|25 mg IV twice a week for 4 weeks
1708974|NCT01396187|Drug|PF-05231023|100 mg IV twice a week for 4 weeks
1708975|NCT01396187|Drug|PF-05231023|200 mg IV twice a week for 4 weeks
1708976|NCT01396187|Other|Placebo|0.9% w/v sodium chloride injection, United States Pharmacopeia (USP), twice a week IV for 4 weeks
1708977|NCT01396174|Behavioral|prosocial online support group|Six weekly 1.5 hour online support group meetings facilitated by a Cancer Support Community staff member. This online support group will maximize opportunities to provide help to others.
1708981|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once daily for 14 days immediately before breakfast, in healthy volunteers.
1708982|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule twice daily for 14 days, immediately before breakfast and dinner, in healthy volunteers.
1708983|NCT01396161|Drug|PF-05175157 or Placebo|One oral dose of PF-05175157 or placebo is administered as a powder-in-capsule once (or twice) daily for 14 days, immediately before breakfast (and dinner), in patients with type 2 diabetes.
1708984|NCT01396148|Drug|sunitinib malate dose escalation|sunitinib starting dose will be 15mg/m^2 daily on a 4 weeks on/2 weeks off schedule (Schedule 4/2).
1708985|NCT01396148|Drug|sunitinib malate|sunitinib 50mg daily on Schedule 4/2
1708986|NCT01396135|Drug|CP-601,927|Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
1708987|NCT01396135|Drug|CP-601,927|Single dose of 2 mg CP-601,927 given as oral 1 mg tablets
1708988|NCT01396135|Drug|CP-601,927|Single dose of 3 mg CP-601,927 given as oral 1 mg tablets
1708989|NCT01396135|Drug|Placebo|Single dose of placebo given as a matching number of oral tablets
1708990|NCT01396135|Drug|CP-601,927|Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
1708991|NCT01396135|Drug|Placebo|Multiple doses of placebo given as a matching number of oral tablets
1708992|NCT01396122|Procedure|Procedure: GYNECARE PROSIMA* Pelvic Floor Repair System|Perform surgery with GYNECARE PROSIMA* Pelvic Floor Repair System. Vaginal hysterectomy or mid-urethral sling procedure for incontinence could be performed concurrently.
1708993|NCT01396109|Procedure|Procedure: TVH and GYNECARE PROSIMA* Pelvic Floor Repair System|Subjects of this group were submitted to surgical treatment with GYNECARE PROSIMA* Pelvic Floor Repair System concurrently with transvaginal hysterectomy.
1708994|NCT01396109|Procedure|Procedure: TVH and Modified Pelvic Floor Reconstruction Surgery with mesh|Subjects of this group were submitted to surgical treatment of Modified Pelvic Floor Reconstruction Surgery with mesh concurrently with transvaginal hysterectomy.
1708995|NCT01396083|Drug|Ranibizumab|
1708996|NCT01396083|Drug|Dexamethasone implant and sham injections|
1708997|NCT01396070|Drug|Brentuximab vedotin|"1.8 mg/kg by IV every 3 weeks for a maximum of 16 doses (8 cycles).
Brentuximab vedotin is an antibody conjugate, consisting of the chimeric IgG1 anti-CD30 antibody cAC10; the microtubule disrupting agent monomethyl auristatin E (MMAE); a protease-cleavable linker that covalently attaches MMAE to cAC10."
1708998|NCT01396057|Drug|Ranibizumab|Injections consisted of 0.5 mg/0.05 ml solution to be injected intravitreally. Ranibizumab was formulated as a sterile solution aseptically filled in a sterile glass vial. It was suitable for single use only and the content of the vial was not allowed to be split
1708999|NCT01396057|Other|Dexamethasone Implant|Comparator Ozurdex® (dexamethasone) was formulated as a rod shaped implant to be inserted into the eye by an applicator. The implant as well as the respective applicator were suitable for single use only.
1709000|NCT01396057|Other|Sham injection|Sham injection: Empty sterile syringes were provided so that masking could be maintained. Either empty syringes in the case of sham injections or pre-filled syringes in the case of ranibizumab injections were visible to the patient in the room of study drug administration
1709001|NCT01396044|Other|Electronic checklist|Electronic checklist for process of care issues implemented in our institution. Training on a regular basis of the electronic checklist arm to use the electronic checklist. Process of care issues on the electronic checklist include several that are under investigation: antibiotics and mechanical ventilation.
1709002|NCT01396044|Other|Verbal prompting|Prompting by study investigators of physicians on the verbal prompting arm. Prompting will include questions related to antibiotic utilization and mechanical ventilation weaning.
1709003|NCT01396031|Behavioral|Physical Therapy|Standard of care
1709004|NCT01396005|Drug|boceprevir|boceprevir 800 mg (4 x 200 mg capsules), orally, every 8 hours, Day 2 through Day 7
1709005|NCT01396005|Drug|methadone|methadone, 20-150 mg tablets, liquid, or disket, orally, once per day, Day 1 through Day 8
1709006|NCT01396005|Drug|buprenorphine/naloxone|buprenorphine/naloxone 8/2-24/6 mg, tablets, sublingual, once per day, Day 1 through Day 8
1709007|NCT01395992|Drug|asenapine|asenapine 5 mg tablet, sublingually (SL) twice daily (BID) for 182 days
1709008|NCT01395992|Drug|asenapine|asenapine 10 mg tablet, SL BID for 182 days
1709009|NCT01395979|Behavioral|Cognitive Processing Therapy for Sexual Risk|Eight weekly sessions, 4 modules.
1709010|NCT01395979|Behavioral|Supportive Psychotherapy|Eight weekly sessions
1709011|NCT01395979|Behavioral|Sexual Risk Reduction Intervention|Two weekly sessions.
1709012|NCT01395966|Drug|DF289|Ear drops
1709013|NCT01395966|Drug|DF277|Ear drops
1709014|NCT01395966|Drug|DF289 plus DF277|Ear drops
1709015|NCT01395953|Drug|Buspirone|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
1709016|NCT01395953|Drug|Placebo|Children with Autism Spectrum Disorders will receive buspirone or matched placebo. Buspirone will be titrated to the maximum daily dose during the first four weeks of the trial (dose titration phase). Week 4 onwards subjects will be maintained on maximum achieved dose till the end of the trial (dose maintenance phase). During the titration phase total dose of buspirone will be increased at each visit by 5mg and on the 4th day after each visit by 5mg.
1709017|NCT01395940|Drug|KLH-2109|
1709018|NCT01395940|Drug|KLH-2109|
1709019|NCT01395927|Drug|Rifampin|Type=2, unit=mg, number=300, Form=capsule, route=oral use. Two 300-mg capsules once daily on days Days 4 through 12.
1709020|NCT01395927|Drug|Canagliflozin|Type=1, unit=mg, number=300, form=tablet. Single dose of one 300-mg tablet on Day 1 and Day 10
1709021|NCT01395914|Drug|Anamorelin HCl|
1709022|NCT01395914|Drug|Placebo|
1709023|NCT01395901|Drug|Palonosetron|Single dose Palonosetron IV 1 mcg/kg (up to a maximum total dose of 0.075 mg)
1709071|NCT01395485|Drug|AMG 827 or Placebo|A single dose of AMG 827 or matching placebo is to be administered subcutaneously (SC).
1709024|NCT01395901|Drug|Ondansetron|"Single dose Ondansetron IV:
0 months to 12 years dose: 0.1 mg/kg for ≤ 40 kg and 4 mg for >40 kg;
13 years to less than 17 years dose: 4 mg"
1709025|NCT01395901|Drug|Placebo to Ondansetron|
1709026|NCT01395901|Drug|Placebo to Palonosetron|
1709027|NCT01395888|Drug|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI)|fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Inhalation Powder delivered once daily via a Novel Dry Powder Inhaler (NDPI)
1709028|NCT01395888|Drug|Tiotropium|• Tiotropium (18 mcg) administered QD via a HandiHaler
1709029|NCT01395875|Drug|Fluticasone Propionate / Salmeterol Xinafoate Combination (FSC)|COPD patients receiving fluticasone propionate/salmeterol xinafoate combination (FSC) 250/50mcg
1709030|NCT01395875|Drug|Anticholinergics (AC)|COPD patients receiving anticholinergics (ACs) including tiotropium (TIO) and ipratropium or combination ipratropium-albuterol (collectively referred to as ipratropium [IPR]).
1709031|NCT01395862|Drug|Salmeterol and Fluticasone|
1709032|NCT01395849|Drug|Salmeterol and Fluticasone|
1709033|NCT01395823|Dietary Supplement|ergocalciferol supplementation|50,000 IU given either weekly; weekly for 3 months then monthly for 3 months; monthly
1709034|NCT01395823|Other|placebo|placebo pill given weekly, weekly for 3 months then monthly for 3 months; monthly
1709035|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
1709036|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
1709037|NCT01395810|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
1709038|NCT01395797|Drug|PIO|0, 15, and 45 mg per day.
1709039|NCT01395797|Drug|Placebo|Placebo
1709040|NCT01395784|Drug|pioglitazone|A PPARγ agonist, also marketed as Actos. Participants will be maintained on ascending doses of Placebo, pioglitazone 15 mg and 45 mg, prior to completing a lab session at the end of each dosing period.
1709041|NCT01395771|Behavioral|Phone call intervention, no phone call intervention|Biweekly phone call intervention +routine service will be assigned to intervention group of new cases and old cases. Only routine service will be assigned to the control group of abovementioned two kind of cases.
1709042|NCT01395758|Drug|ARQ 197 plus erlotinib|Eligible subjects will be randomly assigned to receive erlotinib plus ARQ 197.
1709043|NCT01395758|Drug|Pemetrexed, docetaxel or gemcitabine|A single agent chemotherapy (pemetrexed, docetaxel, or gemcitabine) administered according to approved labeling.
1709044|NCT01395745|Drug|blisibimod|blisibimod administered via subcutaneous injection every week for 52 weeks
1709045|NCT01395745|Drug|Placebo|Placebo will be administered weekly via subcutaneous injection for 52 weeks
1709046|NCT01395732|Drug|Bosentan|2 tablets of 62.5 mg a day from baseline to week 4, then 2 tablets of 125 mg per day to week 12.
1709047|NCT01395719|Other|Remote ischemic conditioning|Patients receiving kidney transplantation from a deceased donor. Remote ischemic conditioning (rIC) is done by inflating a tourniquet (250mmHg) on the patients leg before reperfusion of the kidney. The tourniquet stays on the leg on the opposite site of were the kidney is placed. rIC is done 4 x 5 min with 5 min intervals between with free blood flow.
1709048|NCT01395706|Procedure|ICG Fluorescence technique|"This is an uncontrolled, non-randomised, open-label, monocenter clinical trial.
A total of n=125 subjects will participate in this clinical trial. No clinical trial participant will be allowed to be included in this trial more than once.
10 mg (5mg/ml)per injection are applicated"
1709049|NCT01395693|Device|Salt Lake mask system|Study participants will Salt Lake mask system for 1 week in place of their current mask system.
1709050|NCT01395667|Other|CCRT|Combined IMRT with three escalated dose levels (45 Gy, 50 Gy, and 55 Gy in 25 fractions) and Bevacizumab-fluorouracil/ leucovorin/oxaliplatin (FOLFOX) regimens
1709051|NCT01395654|Drug|isoniazid, rifampin, pyrazinamide|rechallenge of isoniazid (INH), rifampin (RIF), and pyrazinamide (PZA) aftr recovery from hepatitis
1709053|NCT01395628|Drug|in vitro sensitivity-directed chemotherapy|
1709054|NCT01395628|Other|cell proliferation assay|
1709055|NCT01395628|Other|fluorescence activated cell sorting|
1709056|NCT01395628|Other|laboratory biomarker analysis|
1709057|NCT01395628|Other|microscopy|
1709058|NCT01395602|Drug|Cabergoline|cabergoline 0.5 mg twice weekly
1709059|NCT01395602|Other|placebo|1 pill twice weekly
1709060|NCT01395589|Drug|Vitamin D|Children with moderate-to-severe asthma exacerbations and vitamin D levels < 25 ng/mL underwent masked randomization, and then open dosing to either IM+oral (the latter daily) therapy or daily oral-only therapy, and were followed for 12 months.
1709061|NCT01395576|Device|Genu Neurexa orthosis|Knee orthosis for the prevention of knee hyper extension
1709062|NCT01395563|Behavioral|strength training|strength training, high intensity, twice up to 3 times per week
1709063|NCT01395537|Drug|Carboplatin AUC|Carboplatin AUC 6 IV over 30 minutes on day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
1709064|NCT01395537|Drug|Paclitaxel|Paclitaxel 175 mg/m2 IV over 3 hours day one of a three week cycle. This will be continued for 6 cycles or until progression of disease or intolerable side effects.
1709065|NCT01395537|Drug|lapatinib|Lapatinib should be taken once daily, at the same time daily, on an empty stomach, either 1 hour before, or 1 hour after meals.
1709066|NCT01395524|Drug|NKTR-118|12.5 mg oral tablet once daily
1709067|NCT01395524|Drug|NKTR-118|25 mg oral tablet once daily
1709068|NCT01395524|Drug|Placebo|Oral tablet intake once daily
1709069|NCT01395511|Device|Acupuncture|"Tool : Acupuncture Seirin SJ 0.16 * 40 (mm) / SJ 0.18 * 50 (mm) L-type needles were used for the study.
Made from stainless steel needle SEIRIN JAPAN"
1709070|NCT01395498|Other|laboratory testing of PCP and CMV genetic material|laboratory testing of PCP and CMV DNA in bronchoalveolar lavage fluid, CMV PCR in blood+ serology in patients with positive BAL.
1709072|NCT01395472|Behavioral|Acute Physical Exercise|Patients and healthy volunteers will be submitted to a protocol of progressive maximal exercise until voluntary exhaustion and one weak later to 30 minutes of physical exercise in ventilatory threshold I, both in the same cycloergometer.
1709073|NCT01395472|Behavioral|Stretching protocol|TBI patients will be submitted to 30 minutes of stretching exercises composed of 15 exercises that prioritize back, legs and hip.
1709074|NCT01395459|Behavioral|IVR only|As noted, patients in this arm receive consistent, but spaced out calls generated by an interactive voice response system reminding them of breast, cervical and colon cancer screenings needed, as applicable.
1709075|NCT01395459|Behavioral|IVR+PCC|Interactive voice response calls followed up by prevention care coordinator calls for those who do not respond to IVR
1709076|NCT01395433|Drug|Escitalopram|2 x 10 mg, single dose
1709077|NCT01395433|Drug|Escitalopram|2 x 10 mg, single dose
1709078|NCT01395433|Drug|Escitalopram|1 x 20 mg, single dose
1709079|NCT01395420|Drug|CAZ104|IV Infusion
1709080|NCT01395420|Drug|CAZ104|IV Infusion
1709081|NCT01395407|Radiation|Radiosurgery dose escalation|"Cohort A: resection cavity volume up to 4.2 cc (corresponds to 0 - 2 cm diameter).
Cohort B: resection cavity volume > 4.2 cc and ≤ 14.1 cc (2 - 3 cm diameter) Cohort C: resection cavity volume > 14.1 cc and ≤ 35 cc (3 - 4 cm diameter)
Dose level Cohort A (Gy) Cohort B (Gy) Cohort C (Gy)
21 18 15
23 20 17
25 22 19"
1709082|NCT01395394|Drug|Kuvan|Participants in the BH4 Non-Responder group will be given a 20 mg/kg body weight/day dose of Kuvan to take on a daily basis for two weeks. The last dose will be administered at the participant's study visit 2.
1709083|NCT01395394|Other|Meal Challenge|At each study visit, patients will receive a meal high in polyunsaturated fats that will promote a transitory increase in oxidative stress measures and endothelial dysfunction
1709084|NCT01395381|Drug|Placebo|placebo given once
1709085|NCT01395381|Drug|Albendazole|single dose albendazole given at the time of enrollment
1709086|NCT01395355|Behavioral|Linking Individuals Being Emotionally Real (LIBER8)|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of cognitive behavior and dialectical behavior therapy techniques.
1709087|NCT01395355|Behavioral|Weight Management Control|Participants will attend a 8-12 week, 1-2 hours long intervention comprised of behavioral techniques.
1709088|NCT01395342|Other|Exercise using stationary bicycle|"Before exercise, blood pressure and heart rate are measured in the sitting position.
Exercise is realized using stationary bicycle (horizontal bench mode) once at week, during 20 minutes under physiotherapist supervision.
The heart rate was maintained at 20% above resting heart rate and up to 140 bpm.
After exercise is performed a leg stretching and a low back stretching. The blood pressure and heart rate are measured in the sitting position."
1709089|NCT01395329|Drug|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
1709090|NCT01395329|Drug|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
1709091|NCT01395329|Drug|Placebo|gelatin capsule to be taken by mouth once per day for 12 weeks
1709092|NCT01395316|Drug|Alemtuzumab|10 mg/ml alemtuzumab intravenous infusion, sterile clear, colorless solution. dosage: 2 cycles. Month 0 dosed over 5 consecutive days: month 12 dosed over 3 consecutive days.
1709093|NCT01395290|Drug|cholecalciferol|20.000 IU per week, oral
1709094|NCT01395277|Dietary Supplement|High Flavanol first then Low Flavanol|The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
1709095|NCT01395277|Dietary Supplement|Low Flavanol first then High Flavanol|The low flavanol trial will be performed following consumption of a beverage containing 0 mg of Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption. The high flavanol trial will be performed following consumption of a beverage containing 1,050 mg of commercially available Cocoa Flavanols which will be mixed into 250 ml of distilled water. The subjects will consume this beverage and measurements will be performed 2 hours after consumption.
1709096|NCT01395251|Drug|Prednisolone|prednisolone 20 mg once a day per os for 3 subsequent days
1709097|NCT01395238|Behavioral|Fathers Supporting Success in preschoolers|Group-based, 8 weekly session for 2.0 hours/week.
1709098|NCT01395199|Drug|Amlodipine|5mg PO initially; may be reduced to 2.5mg PO if side effects
1709099|NCT01395186|Procedure|varicocelectomy|varicocelectomy for painful varicocele
1709100|NCT01395173|Procedure|Position change|Patients will be randomly assigned to two groups: Control group (those who will receive standard colonoscopy without position changes) and Position change group (those who will undergo position changes during colonoscope withdrawal during colonoscopy). Subjects in position change group will be asked to shift into three different positions during colonoscope withdrawal.
1709101|NCT01395173|Procedure|Standard|Subjects will undergo standard colonoscopy without position changes during scope withdrawal.
1709102|NCT01395147|Drug|Lu AA21004|Lu AA21004 10 mg, tablets, orally, once daily for 2 weeks; reduced to 5 mg or increased to 20 mg, once daily if necessary according to the responses and symptoms of participants for up to 50 weeks.
1709103|NCT01395134|Device|Neuromonitoring|Electrical stimulation of the nerve: 1 mA, 4 Hz with surface electromyography of the vocalis muscles.
1709104|NCT01395121|Drug|nilotinib|nilotinib 400 mgs orally twice daily until disease progression or withdrawal from treatment
1709105|NCT01395108|Drug|Nemonoxacin|oral once daily
1709106|NCT01395095|Other|rehabilitation+telephonic coaching|intervention starts 2 weeks after ending standard CR and is based on five phonebased coaching sessions at 6 weeks intervals up to 6 months. Each coaching session includes 5 stages: (1) Asking questions to establish patient's knowledge, attitude and beliefs about their risk factors; (2) Explanation and rationale; (3) Assertiveness training; (4) Goal setting; (5) Reassessment.
1709148|NCT01394783|Device|Miller laryngoscope|Phase 1 and 2: Endotracheal intubation using the Miller laryngoscope with blade 0 or 1 according to weight of infant.
1710512|NCT01383668|Genetic|polymerase chain reaction|Correlative studies
1709107|NCT01395095|Other|OPTICARE-B|standard CR according to the guidelines consisting of (a) 2 times a week exercise program of 1.5 hours during 12 weeks, (b) upon request of the patient: participation in multifactorial lifestyle and risk factor sessions (medical information, dietary advises and emotional advises, information about risk factors, smoking cessation program and stress management sessions).
1709108|NCT01395095|Other|OPTICARE-C|(a) standard CR consisting of 2 times a week exercise program of 1.5 hours during 12 weeks. (b) (mandatory) participation in multifactorial lifestyle and risk factor sessions: i.e. 4 sessions of 2 hours each (medical information, dietary advises, risk factors and emotional advises). If applicable, patients will participate in smoking cessation, dietary and stress management programs . (c) Individual sessions and a personalized home-based program to promote an active life style upon instruction of a physiotherapist and physical activity counselor during and after completion of rehabilitation. Activity monitors will be used to provide feedback. (d) Additional compulsory supervised multifactorial lifestyle and risk management training sessions of each 2 hours provided at 4, 6 and 12 months.
1709109|NCT01395069|Drug|Nepafenac 0.1%|1 drop QID for 1 month
1709110|NCT01395069|Drug|Ketorolac 0.5%|1 drop QID for 1 month
1709111|NCT01395069|Other|Placebo (sterile saline drops)|1 drop QID for 1 month
1709112|NCT01395043|Procedure|Placing bilateral TAP-catheters preoperatively|Place bilateral TAP-catheters preoperatively and give repeated boluses of local analgetics in order to treat postoperative pain after colon-surgery.
1709113|NCT01395043|Drug|Bupivacain 2.5 mg/ml with epinephrine bolus in TAP-catheters|Intermittent boluses of Bupivacain 2.5 mg/ml with epinephrine, 20 ml in each catheter every 12 hours for the first 2 postoperative days.
1709114|NCT01395030|Drug|Fluoromethylcholine (FCH) PET/CT Imaging|Investigational New Drug Radiopharmaceutical Imaging Agent - Single Dose Administration
1709115|NCT01395017|Drug|dasatinib|GEM 1000 mg/m2 by intravenous [IV] infusion weekly for 3 weeks of a 4-week cycle plus dasatinib 100 mg (or matched placebo) by mouth once daily (QD). Subjects will continue to receive study treatment until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
1709116|NCT01395017|Drug|Placebo|Matching Placebo
1709118|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week|450 IU/kg once a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
1709119|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week|150 IU/kg 3 times a week by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
1709120|NCT01394991|Drug|Epoetin alfa 450 IU/kg once a week (QW)|450 IU/kg once a week (QW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks
1709121|NCT01394991|Drug|Epoetin alfa 150 IU/kg 3 times a week (TIW)|150 IU/kg 3 times a week (TIW) by subcutaneous injection preferably in the abdomen for up to 4 weeks after the last dose of chemotherapy for a maximum of 26 weeks.
1709122|NCT01394978|Other|Control|Standard surgical techniques including staples and sutures.
1709123|NCT01394978|Device|ProGEL Pleural Air Leak Sealant|ProGEL is a single-use medical device that is formed as a result of mixing two components: (1) a solution of human serum albumin (HSA) and (2) a synthetic cross-linking component of polyethylene glycol (PEG).
1709124|NCT01394965|Procedure|ECG electrodes|Cardiac mapping of patients before and after ablation to develop future treatment/diagnostic options for cardiac patients.
1709125|NCT01394952|Drug|Dulaglutide|Administered subcutaneously
1709126|NCT01394952|Drug|Placebo|Administered subcutaneously
1709127|NCT01394939|Biological|JX-594|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
1709128|NCT01394939|Drug|Irinotecan|180 mg/m2 IV every 2 weeks.
1709129|NCT01394926|Drug|Optison|Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
1709130|NCT01394913|Drug|Reumatocept (etanercept)|50mg each week for 30 weeks
1709131|NCT01394913|Drug|Enbrel (etanercept)|50mg each week for 30 weeks
1709132|NCT01394900|Behavioral|CNU Intervention|Notions that strengthen the closeness with one's partner, connect with similar couples, and visibly strengthen a community as key to combating dynamics that cause poor communication, isolation, fragmentation of the Black MSM community.
1709133|NCT01394900|Behavioral|WP Intervention|Attention control condition - WP focuses on nutrition, fitness, healthcare, and stress management. Given the prevalence of health problems among the target population, WP emphasizes adherence to medical guidance and medication regimens.
1709134|NCT01394887|Drug|Metformin|850 mg of metformin twice daily over 12 weeks
1709135|NCT01394887|Drug|placebo|850 mg gel capsules with starch (6.8 calories)as placebo
1709136|NCT01394874|Behavioral|TLC|Computer-based telephone linked communication will be used to counsel subjects to adhere to their exercise program over time.
1709137|NCT01394861|Device|ESD using Master Slave Robotic System|Endoscopic submucosal dissection of early gastric cancer or broad sessile polyp using Master Slave Robotic System
1709138|NCT01394848|Device|Endothelial cell capture stent with 1 month clopidogrel|75mg PO clopidogrel per day for 1 months
1709139|NCT01394848|Device|Everolimus eluting stent with 12 month clopidogrel|75mg PO clopidogrel per day for over 12 months
1709140|NCT01394848|Drug|Atorvastatin 20mg loading|Atorvastatin 20mg loading before index percutaneous coronary intervention
1709141|NCT01394848|Drug|Atorvastatin 80mg loading|Atorvastatin 80mg loading before index percutaneous coronary intervention
1709142|NCT01394835|Drug|Alpha -1 Antitrypsin|Inhalation twice daily of 160mg
1709143|NCT01394835|Drug|Alpha-1 Antitrypsin|Inhalation twice daily .Dosage 160mg
1709144|NCT01394835|Drug|AAT|Inhalation twice daily' 160mg
1709145|NCT01394809|Behavioral|motor cognitive therapies|pre-test; 6 weeks intervention: week 1-3: 5 times per week 60 minutes a day. Week 4-6: 3 times per week 60 minutes a day; post-test; follow-up)
1777480|NCT00416468|Drug|Valsartan|
1709149|NCT01394783|Device|Storz videolaryngoscope|Phase 1: Endotracheal intubation using the videolaryngoscope with blade 0 or 1 according to weight of infant. Videolaryngoscope will be used to proceed to endotracheal intubation indirectly with the use of the video monitor for guidance. Phase 2: Endotracheal intubation using the classic laryngoscope with Miller blade 0 or 1 according to weight of infant.
1709150|NCT01394770|Drug|Aliskiren|Aliskiren 150 mg for 1 month with forced uptitration to 300 mg compared in parallel group with amlodipine 5 mg with forced uptitration to 10 mg
1709151|NCT01394757|Drug|Esketamine hydrochloride|Bolus: 15 mg/kg over 1 minute, followed by a maintenance infusion of 0.25 mg/kg/h for 19 minutes.
1709152|NCT01394731|Drug|Acetaminophen|
1709153|NCT01394731|Drug|Meperidine|
1709154|NCT01394718|Drug|Intravenous Acetaminophen|Scheduled doses of 15 mg/kg of IV acetaminophen will be administered to the treatment arm of the study for a total of 8 doses over a 48 hour period post-operatively.
1709155|NCT01394718|Other|Placebo|Saline placebo will be given at the time of skin closure intra-operatively and will continue to receive IV saline for 44 hours post-operatively. Doses will be administered every 6 hours (total of 8 doses).
1709156|NCT01394705|Device|BodyMedia|Accelerometer
1709157|NCT01394692|Procedure|intraoperative MRI-guided tumor resection|tumor resection with the use of an intraoperative MRI
1709158|NCT01394692|Procedure|standard microsurgery|microsurgical tumor resection
1709159|NCT01394679|Drug|(99m Tc) ECDG (Ethylenedicysteine-Deoxyglucose)|One injection of Technetium-99m Ethylenedicysteine-Deoxyglucose to yield a target dose of 25 mCi (range of 20-30 mCi)by IV push and less than 1 mg of EC-DG
1709160|NCT01394679|Drug|18 F FDG followed by PET/CT imaging|Single injection of 18 F FDG range of 10-20 mCi
1709161|NCT01394653|Drug|YM060|oral, with water
1709162|NCT01394640|Biological|Reassortant vaccine virus NYMC X-179A (New York Medical College, New York) derived form the A/california/7/2009 (H1N1) virus|The vaccine was administered intramuscularly as a single dose of 7.5 ug of hemagglutinin antigen.
1709164|NCT01394614|Biological|A/H1N1 vaccine|Verify if exposure to Arepanrix vaccine increase risk of developing narcolepsy in 16 weeks post-vaccination.
1709165|NCT01394588|Device|Use of continuous glucose monitor during surgery. ( Medtronic Minimed Guardian REALTime Continuous Glucose Monitor)|Use of continuous glucose monitor during surgery.
1709166|NCT01394575|Radiation|IMRT with an simultaneous integrated boost|IMRT in 25 fractions delivering 45Gy to the whole breast and 60Gy to the tumor bed
1709167|NCT01394562|Drug|Ferinject (ferric carboxymaltose)|Subjects will receive ferric carboxymaltose intravenously on Day 0, Week 6, and Week 12
1709168|NCT01394562|Other|Standard of Care|Subjects randomised to Standard of Care may receive oral iron at Investigator's discretion however patients will not be permitted to receive IV iron
1709169|NCT01394536|Device|Battery-operated electroacustimulation device (Inactive)|In the sham arm, this device will not be turned on. The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
1709170|NCT01394536|Device|Battery-operated electroacustimulation device (Active)|The device to be used is the ReliefBand (Aeromedix, Jackson, Wy), an FDA-approved, reusable, battery-operated electroacustimulation device. The ReilefBand is a portable battery powered (lithium coin cells) device that is worn on the wrist like a watch. Two electrodes contact the skin with the aid of the application of electroconductive gel, and an electrical current of 25 mHz is transmitted through the skin. The device is applied at the Neiguan (P6) point, which is located on the inside of the wrist and is thought, in traditional Chinese medicine, to relieve nausea and vomiting (NV).
1709171|NCT01394523|Drug|Bupivacaine|0.25% or 0.5%
1709172|NCT01394510|Drug|N-acetylcysteine|600 mg N-acetylcysteine (NAC) twice daily by mouth for 2 weeks followed by 1200 mg NAC twice daily by mouth for 2 additional weeks.
1709173|NCT01394497|Drug|N-acetylcystein|15 min systemic NAC infusion of the donor (30 mg/kg, maximum dose 3000 mg) diluted into 500 ml 5 % glucose solution, 30 min before initiating the liver harvesting procedure, and a loco‑regional infusion (150 mg/kg of estimated liver weight, maximum dose 300 mg) into the portal vein 5 min before cross‑clamping.
1709174|NCT01394484|Other|Intervention I|Four servings of dairy foods (milk and yogurt) per day for 42 days.
1709175|NCT01394484|Dietary Supplement|Intervention II|1200 mg of supplemental calcium and 400 IU of vitamin D3 for 42 days
1709176|NCT01394471|Drug|Intranasal Oxytocin Spray|6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
1709177|NCT01394458|Other|30 % ethanol / 4% sodium citrate catheter locking solution|This solution is locked into the lumens of hemodialysis catheters between treatments to prevent infection and thrombosis. Before each dialysis session, the solution should be removed and discarded.
1709178|NCT01394458|Drug|Heparin 1000 u / ml|In the control group, heparin 1000 u / ml will be locking into the hemodialysis catheters between treatments to prevent thrombosis. The heparin solution should be removed and discarded before each dialysis session.
1709179|NCT01394445|Drug|Physostigmine|continuous intravenous infusion per syringe pump (13 vials of 2 mg/5 ml --> 26 mg/65 ml; 1 ml = 0.4 mg Physostigmine) at rate of 1 mg/h (2.5ml/h) for 24 hours
1709180|NCT01394445|Drug|Placebo|"continuous intravenous infusion of 65 ml NaCl 0.9% with syringe pump at rate of 2.5 ml/h for 24 hours
PCA: Patient-controlled analgesia with hydromorphone 0.2 mg/ml, on demand: bolus of 0.2 mg, maximum 5 boli per hour; 4-hour-maximum 4 mg"
1709181|NCT01394432|Procedure|PCI and Stem Cells or Placebo injections|Conventional percutaneous coronary intervention after acute myocardial infarction. Harvest of bone marrow from iliac crest. Mesenchymal autologous stem cells preparation (7-10 days after PCI). LV mapping with Noga system (7-10 days after PCI). Randomization 1:1. Stem Cells or placebo implantation.
1709182|NCT01394419|Drug|N-acetylcysteine|N-acetylcysteine 150 mg/kg bolus over 15 min after induction of anesthesia, followed by an infusion of 150 mg/kg/day for 24 hrs
1709183|NCT01394419|Drug|Saline|Equal volume of normal saline
1709263|NCT01393717|Genetic|protein expression analysis|Correlative studies
1709184|NCT01394406|Drug|Ketamine|ketamine 3 mg/kg mixed to intravenous patient controlled analgesia device (fentanyl 20 mcg/kg. total volume 180 ml, basal infusion 2 ml, bolus 2ml, lock-out 15 min)
1709185|NCT01394406|Drug|Saline|equal volume of normal saline mixed to intravenous patient controlled analgesia device
1709186|NCT01394393|Behavioral|Experiential-Cognitive Therapy for Obesity|Is a relatively short-term, integrated, patient oriented approach that focuses on individual discovery (Riva, Bacchetta, Baruffi, Rinaldi, & Molinari, 1998, 1999; Riva et al., 2000). It shares with the cognitive-behavioral approach proposed by Cooper and colleagues the use of a combination of cognitive and behavioral procedures to help the patient identify and change the maintaining mechanisms (Cooper et al., 2003). However, it considers morbid obesity as a peculiar form of addiction. So, as in the cognitive-behavioral treatment of addictions (Carroll et al., 1994) the two main goals are the functional analysis of the maintaining mechanisms and the required skill training (relapse prevention).
1709187|NCT01394393|Behavioral|Behavioral cognitive Treatment|Therapists will follow a detailed manual that outlined the content of each session. This manual was based on the cognitive—behavioral treatment approach described by Cooper and colleagues (Cooper & Fairburn, 2002; Cooper et al., 2003). It was developed during a year of intensive pilot work and adapted to the in-patient setting. Patients will be taught to self-monitor their food intake and eating patterns and thoughts, as well as the circumstances and environment surrounding eating (e.g. whether eating alone or with others, speed of eating, and place of eating). Patients will also be taught to identify problems in eating, mood, and thinking patterns and to gradually develop alternative patterns.
1709188|NCT01394393|Dietary Supplement|Nutritional groups (NT)|5 weekly nutritional treatment based on the LEARN manual (Brownell, 1985), whose goal will be to provide practical guidelines for the self-monitoring of eating and lessons on nutrition (e.g stressing gradual weight loss with the caloric restriction achieved largely by reductions in fat intake), plus a low-calorie diet (1,200 kcal/day) and physical training (30 min of walking two times a week as a minimum).
1709189|NCT01394380|Other|artificially sweetened sodas|subjects will be allowed unlimited consumption of calorie-free, artificially-sweetened sodas, water, tea or coffee
1709190|NCT01394367|Other|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
1709191|NCT01394354|Drug|Vorinostat|"Vorinostat 100 mg/d p.o., on day 1-4, 8-11, and 15-18 /28 day treatment cycle in combination with BDD.
The dose level of Vorinostat will be escalated in each new cohort:
if no dose limiting toxicity (DLT) has been observed in the previous dose level in 3 patient, the second cohort of 3 new patients will be treated with Vorinostat 200 mg/d p.o. and the third cohort will be given Vorinostat with 300 mg/d p.o."
1709192|NCT01394354|Drug|Bortezomib|1.3mg/m2 (days 1,8,15)/28 day treatment cycle, i.v., for max. 6 treatment cycles
1709193|NCT01394354|Drug|Doxorubicin|18mg/m2 i.v. (days 1 and 8)/ 28 day treatment cycle, max. 6 treatment cycles
1709194|NCT01394354|Drug|Dexamethasone|40mg abs. p.o. (days 1,8,15,22) 1st treatment cycle, 20mg abs. p.o.(days 1,8,15,22) 2-6 treatment cycles
1709195|NCT01394341|Drug|Liraglutide|Daily sc. injection, individual dosage
1709196|NCT01394289|Biological|Lolium allergen extract|"This is an open, unblinded and non randomized biological as proposed by the Nordic Guidelines.
Four concentrations of Lolium perenne allergen extract, together with a positive and negative control, using 10 mg/ml histamine dihydrochloride solution and a glycerinated phenol saline solution, respectively, will be tested in every patient in duplicate on the volar surface of the forearm. This test will be referred to as the Titrated Skin Prick test."
1709197|NCT01394263|Drug|Histrelin hydrogel implant|50 mg histrelin acetate in hyrogel implant
1709198|NCT01394263|Drug|Zoladex goserelin implant|goserelin implant injection.
1709199|NCT01394250|Device|Buzzy|Cold, Vibrational Device
1709200|NCT01394250|Drug|Topical Lidocaine 4% Cream|Applied to anticipated IV site at least 30 minutes prior to cannulation.
1709201|NCT01394237|Other|Examination|Examination of recurrences of vaginal vault prolapse measured as objective anatomical results using the pelvic organ prolapse quantification (POP-Q) system
1709202|NCT01394224|Drug|Levetiracetam|Strength: 100 mg/mL Form: Concentrate for solution for infusion Frequency: Single dose
1709203|NCT01394224|Drug|Levetiracetam|Levetiracetam tablets Strength: 500 mg Form: Tablet Frequency: Single dose
1709204|NCT01394211|Drug|anastrozole|Given PO
1709205|NCT01394211|Drug|pazopanib hydrochloride|Given PO
1709206|NCT01394211|Procedure|therapeutic conventional surgery|Undergo definitive surgery
1709207|NCT01394185|Drug|Dronabinol 120mg/day|Participants receive 40mg dronabinol 3 times daily
1709208|NCT01394185|Drug|Placebo|Participants receive placebo
1709209|NCT01394185|Drug|Dronabinol 240mg/day|Participants receive 80mg dronabinol 3 times daily
1709210|NCT01394159|Procedure|22G Procore biopsy needle|Acquire tissue with the 22G Procore biopsy needle
1709211|NCT01394159|Procedure|22G FNA needle|Acquire tissue with the 22G FNA needle
1709212|NCT01394146|Other|Research diet|Participants will be provided specially prepared meals to eat at home for two weeks. During the first week, participants will eat foods that do not have any phosphorus-based food additives in them (this is called the control diet). During the second week, participants will eat foods that all have phosphorus-based food additives in them (called the intervention diet).
1709213|NCT01394133|Drug|Tenofovir, Emtricitabine, Atazanavir, Ritonavir|Women will be receiving Tenofovir 300mg, Emtricitabine 200mg, Atazanavir 300mg, Ritonavir 100mg, one dose on 2 separate visits. These medications will not be prescribed from the physician and not provided by the study.
1709214|NCT01394120|Drug|Targeted Therapy Tailored Treatment|"Targeted therapy tailored treatment, based on molecular determination in pancreas cancer specimen
Tim Synthase (TS) (neg), ERCC-1 (neg), Topoisomerase I (Topo I) (pos) : FOLFIRINOX
TS (neg), ERCC-1 (neg), Topo I (neg): FOLFOX
TS (neg), ERCC-1 (pos), Topo I (pos): FOLFIRI
TS (neg), ERCC-1 (pos), Topo I (neg): Capecitabine/Gemcitabine
TS (pos), EGFR Not Amplificate, K-Ras Mutation (pos) : Gemcitabine single agent
TS (pos), EGFR Ampl or K-Ras mut (neg): Gemcitabine plus Erlotinib"
1709215|NCT01394120|Drug|Standard Chemotherapy|Patients treated based on investigator´s criteria: : FOLFIRINOX, FOLFOX, FOLFIRI, Capecitabine-Gemcitabine, Erlotinib-Gemcitabine or Gemcitabine single agent
1709264|NCT01393704|Drug|Vasopressin|Dilute vasopressin solution will be injected subserosally into myoma at time of minimally invasive myomectomy.
1709216|NCT01394094|Behavioral|Gum chewing|Gum chewing(30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in the addition to conventional postoperative feeding schedule
1709220|NCT01394055|Drug|RM-131|100 μg subcutaneously once
1709221|NCT01394055|Drug|Placebo|Matching placebo volume subcutaneously once
1709222|NCT01394042|Device|Proxiscan device|All patients will be imaged with the device
1709223|NCT01394029|Drug|deferasirox|
1709224|NCT01394016|Drug|LY2835219|Administered orally, daily for 28-day cycles for two planned cycles. For Part G only in addition to LY2835219 as above, fulvestrant is administered as specified in the label. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criteria is met.
1709225|NCT01394016|Drug|Fulvestrant|Fulvestrant is administered intramuscularly into the buttocks as specified in the label in Part G only.
1709227|NCT01393990|Drug|LY2228820|Administered orally
1709230|NCT01393964|Drug|Lenalidomide|Capsules, Oral, 15 mg, One capsule every 48 hours through Days 1-21 (Repeat every 28 days until subject meets criteria for discontinuation of study drug
1709231|NCT01393964|Drug|Dexamethasone|Tablets, Oral, 28 mg weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
1709232|NCT01393964|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on days 8, 15 & 22 (cycle 1); days 8 &22 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
1709233|NCT01393964|Drug|Dexamethasone|Solution, Intravenous, 8 mg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond) Repeat every 28 days until subject meets criteria for discontinuation of study drug
1709234|NCT01393964|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous, 10 mg/kg, weekly, on day 1 (cycle 1); days 1, 8, 15, 22 (cycles 2-3; days 1 &15 (cycle 4 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
1709235|NCT01393951|Biological|ASP7374|subcutaneous and intramuscular
1709236|NCT01393938|Other|Three-dimensional ultrasound|Immediately following the standard of care 2D-US, for approximately 15 min.
1709237|NCT01393925|Drug|parecoxib|parecoxib 40mg at 30min before the end of surgery, at 8h and 20h after the surgery, intravenously
1709238|NCT01393912|Drug|Crenolanib|Crenolanib orally administered as whole or crushed tablets once per day with concurrent Radiation Therapy. Crenolanib will continue at the same dose level post Radiation Therapy
1709239|NCT01393899|Drug|Placebo|oral tablets twice daily
1709240|NCT01393899|Drug|CP-690,550|oral tablets twice daily
1709241|NCT01393899|Drug|CP-690,550|oral tablets twice daily
1709242|NCT01393886|Procedure|Laparoscopic Greater Curvature Plication (LGCP)|This procedure creates a small sized stomach by folding the stomach twice into itself vertically. The functional capacity of the stomach is decreased by 80% of its normal(At least two rows of five continuous stitches are placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum).
1709243|NCT01393834|Procedure|Delayed cord clamping|Delay cord clamping for 30 seconds after birth
1709244|NCT01393834|Procedure|Milking of the cord|Milking of the cord 4 times in 10 seconds
1709245|NCT01393821|Drug|menadione topical lotion|Given topically
1709246|NCT01393821|Other|placebo|Given topically
1709247|NCT01393821|Other|questionnaire administration|Ancillary studies
1709248|NCT01393821|Procedure|management of therapy complications|Given menadione topical lotion
1709249|NCT01393808|Drug|Paricalcitol|1-month Paricalcitol 2mcg/day
1709250|NCT01393808|Other|placebo|1-month Placebo Treatment
1709251|NCT01393795|Drug|Qutenza|8% patch
1709252|NCT01393795|Drug|Tegaderm|No active drug
1709253|NCT01393782|Drug|Angiotensin II|All patients will have their vasopressors titrated to a mean arterial pressure (MAP) of 65 mm of Hg (standard MAP goal in the ICU for patients suffering from shock). Patients will then be randomized to control or IV AII. In the interventional arm, AII will start at a dose of 20ng/kg/min; the dose can then be titrated up to 30ng/kg/min, and then to 40ng/kg/min. The intervention will last for 6 hours. Each patient will start with the assigned starting dose indicated above. After the first hour, if the patient is still requiring standing norepinephrine (the standard vasopressor for the treatment of shock in the GW ICU), the dose of the control/interventional drug can be increased 50%. After the second hour, if the patient is still requiring a standing dose of norepinephrine, the control/interventional can be increased again to twice the initial dose. At the end of 6 hours, the study drug will be titrated off.
1709254|NCT01393769|Drug|Melphalan|The usual number of chemotherapy cycles will be 3. First treatment with Melphalan will be initiated as soon as possible, once the patients are selected for the study. Once the first treatment has been completed, day 0, successive treatments will be considered, second and third (days 21 and 42). In those cases in which some patients could be considered for an additional treatments after the third cycle, these will be administrated in intervals at least of 21 days.Dosage range from 3 to 5 mg, depending of patient's weight and estimated tumour volume.
1709255|NCT01393756|Drug|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
1709256|NCT01393743|Drug|Perampanel|
1709257|NCT01393743|Drug|Placebo comparator|
1709258|NCT01393730|Drug|Abiraterone acetate|
1709259|NCT01393730|Drug|Dutasteride|
1709260|NCT01393730|Drug|Prednisone|
1709261|NCT01393717|Drug|brentuximab vedotin|Given IV
1709262|NCT01393717|Other|laboratory biomarker analysis|Correlative studies
1778312|NCT00425022|Procedure|thoracoscopy|
1709265|NCT01393691|Behavioral|CBT with parent involved play|This is a CBT adaptation designed for preschool children, which includes multiple standard cognitive-behavioral techniques, namely psycho-education, problem solving via play, gradual exposure and reinforcement management.
1709266|NCT01393691|Behavioral|Triadic expressive play therapy|Based on expressive play therapy guidelines, children and their parents will express themes concerning bedtime routines and fears via play.
1709267|NCT01393678|Drug|NISSEL|Biphenyl Dimethyl Dicarboxylate 25mg ............. 1 cap
1709268|NCT01393678|Drug|PENNEL|Biphenyl Dimethyl Dicarboxylate 25mg & garlic oil 50mg ............. 1cap
1709269|NCT01393665|Drug|PENNEL capsule|"hard capsule DDB 25mg & GO 50mg in cap .......... 1 capsule
1 or 2 capsule, T.I.D"
1709270|NCT01393665|Drug|Placebo|Placebo
1709271|NCT01393652|Drug|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
1709272|NCT01393652|Drug|PF-05105679|Subjects will receive single ascending doses of PF-05105679 or placebo to investigate safety/tolerability and pharmacokinetics of PF-05105679
1709273|NCT01393652|Drug|PF-05105679|Subject will be randomized to a treatment sequence, and assigned to placebo, 2 separate single doses of PF-05105679 in the fasted state and to controlled-release Oxycodone 20 mg (positive control) , with at least one week wash-out between doses.
1709274|NCT01393639|Drug|PF-04171327|1 mg tablet once daily (QD) for 8 weeks
1709275|NCT01393639|Drug|PF-04171327|5 mg tablet once daily (QD) for 8 weeks
1709276|NCT01393639|Drug|PF-04171327|10 mg tablet once daily (QD) for 8 weeks
1709277|NCT01393639|Drug|PF-04171327|15 mg tablet once daily (QD) for 8 weeks
1709278|NCT01393639|Drug|prednisone|5 mg capsule once daily for 8 weeks
1709279|NCT01393639|Other|prednisone|10 mg capsule once daily for 8 weeks
1709280|NCT01393639|Other|placebo|placebo (tablet or capsule) once daily (QD) for 8 weeks
1709281|NCT01393626|Drug|Placebo|oral tablets twice daily
1709282|NCT01393626|Drug|CP-690,550|oral tablets twice daily
1709283|NCT01393626|Drug|CP-690,550|oral tablets twice daily
1709284|NCT01393613|Drug|OPC-34712|Higher dose tablet, once daily, for six weeks,
1709285|NCT01393613|Drug|OPC-34712|Middle dose tablet, once daily, for six weeks
1709286|NCT01393613|Drug|OPC-34712|Lower dose tablet, once daily, for six weeks
1709287|NCT01393613|Drug|Placebo|Placebo, once daily, for six weeks
1709288|NCT01393600|Drug|NBI-98854|12.5 mg powder in bottle once daily for 14 days
1709289|NCT01393600|Drug|NBI-98854|50 mg powder in bottle once daily for 14 days
1709290|NCT01393600|Drug|Placebo|Solution containing no active substance
1709291|NCT01393587|Procedure|Taking blood samples|
1709292|NCT01393574|Drug|Melatonin|3 mg for body weight <40kg, 6 mg for body weight >40kg, once a day 30-60 minutes before sleep
1709293|NCT01393574|Drug|Methylphenidate|Drug formulary and dose will be decided by the treating neurologist from the available options in Israel (as would be given if not participating in the trial)
1709294|NCT01393561|Drug|Group 1|Brompheniramine + phenylephrine
1709295|NCT01393561|Drug|Group 2|Placebo
1709296|NCT01393548|Drug|brompheniramine + phenylephrine|"Oral solution: brompheniramine (2mg/mL) and phenylephrine (2,5 mg/mL), t.i.d., according weight of patient.
OR Syrup: brompheniramine (2mg/5mL) and phenylephrine(5 mg/5mL), t.i.d., according weight of patient."
1709297|NCT01393548|Drug|Brompheniramine + pseudoephedrine|Elixir: Brompheniramine (0,2mg/mL) and pseudoephedrine (3,0 mg/mL), t.i.d., according weight of patient
1709300|NCT01393509|Drug|PU-H71|PU-H71 will be administered as an intravenous infusion over 1 hour two times a week on a 2 week on and 1 week off (Q21 day) schedule with a starting dose of 10 mg/m2. A Cycle on study will be defined as 21 days. The same schedule of administration will be used for all patients in this Phase I trial, and a MCRM (modified continual reassessment method)design will be employed. The MPN expansion may explore different dosing schedules.
1709301|NCT01393496|Other|red blood cell transfusion|"Implementation of liberal guidelines for red blood cell transfusions in extremely low birth weight infants"
1709302|NCT01393496|Other|red blood cell transfusion|"Implementation of restrictive guidelines for red blood cell transfusions in extremely low birth weight infants"
1709303|NCT01393483|Other|serum and tissue mesothelin|"Tissue mesothelin staining at the time of the initial endoscopy, and of any subsequent biopsy specimen during the endoscopic screening period.
Serum mesothelin level at the time of initial endoscopy, and at each subsequent endoscopy for two years or until disease recurs."
1709304|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining on the surgically resected esophageal specimen. Serum mesothelin level at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
1709305|NCT01393483|Other|serum and tissue mesothelin|Tissue mesothelin staining on the initial endoscopic specimen (typically obtained when an EUS is done) and on the surgically resected esophageal specimen Serum mesothelin level prior to initiation of induction chemotherapy, at the time of the post-induction PET, at the time of surgical resection, and at each follow-up clinic visit for two years or until disease recurs.
1709306|NCT01393470|Procedure|Screening for cervical cancer|Organized screening for cervical cancer start for all cohorts at the age of 25 years with 5 year interval.
1709307|NCT01393457|Drug|levodopa/carbidopa|800/200 mg/d
1709308|NCT01393457|Drug|Ropinirole|2 or 4 mg/d
1709309|NCT01393457|Drug|Placebo|sugar pill
1709310|NCT01393444|Device|Implantation of ECoG sensors on the brain surface|One ECoG sensor will be implanted over the motor cortex of study participants
1709311|NCT01393418|Other|Cardiac Surgery|
1709312|NCT01393405|Drug|Methotrexate|"Induction period (week 1-16) (Open label):
25 mg MTX sq once weekly + Steroid taper + 1 mg folic acid daily
Maintenance period (week 17-48) (Randomization):
25 mg MTX sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine
or
Placebo sq once weekly + 1 mg folic acid daily + 2.4 g mesalamine"
1778782|NCT00419835|Drug|losartan|
1709313|NCT01393392|Behavioral|Intensive, tailored intervention|Eight, 45 minute counseling sessions, tailored to the individual and based on the Information-Motivation-Behavioral Skills model of behavior change. Incorporates motivational interviewing, education, cognitive-behavioral skills training. 12 week course of nicotine replacement patches provided. Nicotine lozenges also provided.
1709314|NCT01393392|Behavioral|NJ Quitline Referral|Participants will receive a facilitated referral to the NJ Quitline (i.e. fax to quit).
1709315|NCT01393366|Other|Telephone Intervention|Only for arm AMA, patient will have one phone every week to evaluate physical conditions.
1709316|NCT01393366|Other|Usual Practice|None, only usual practice.
1709317|NCT01393353|Other|Cognitive Training|
1709318|NCT01393353|Other|computer game|
1709319|NCT01393340|Drug|Omalizumab|"Omalizumab (Xolair(R)) is a recombinant DNA-derived humanized IgG1 monoclonal antibody that selectively binds to human IgE. Molecular weight is approximately 149 kilodaltons. Xolair(R) is a sterile, white, preservative-free, lyophilized powder contained in a single-use vial, reconstituted with Sterile Water For Injection (SWFI), and administered as subcutaneous (SC) injection.
Xolair(R) will be administered subcutaneously in a dose of 75 to 375mg every 2 to 4 weeks. Doses (mg) and dosing frequency are determined by total serum IgE level (IU/ml) measured at the start of treatment and body weight (kg). During this 20-week during trial patients will receive 4 or 8 doses of omalizumab."
1709320|NCT01393340|Drug|Placebo|Placebo
1709321|NCT01393327|Behavioral|respiratory and exercise therapy|Conventional therapy with diet, massage, relaxation baths, plus easy strolls specific respiratory and physical therapy plus mental walking training
1709322|NCT01393314|Device|Honeywell HomMed Telemonitor|telemonitoring post hospitalization
1709323|NCT01393301|Behavioral|Integrated cognitive-behavioral therapy for smoking cessation and anxiety|Standard smoking cessation treatment and nicotine replacement therapy (NRT) plus a cognitive-behavioral therapy for anxiety, depression, or other symptoms of distress.
1709324|NCT01393301|Behavioral|Control|Enhanced standard smoking cessation treatment and NRT.
1709325|NCT01393288|Drug|Ondansetron|8 mg ondansetron ODT or placebo, 1 hour pre-operatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch POD 1, evening POD 1, and morning of POD 2
1709326|NCT01393288|Drug|Lorazepam|1 mg Lorazepam or placebo 1 hour preoperatively, before discharge, evening of day of surgery, morning of postoperative day (POD) 1, lunch of POD 1, evening of POD 1, and morning of POD 2.
1709327|NCT01393288|Drug|Aprepitant|40 mg Aprepitant or placebo 1 hour preoperatively and before discharge (placebo for postoperative days 1-2)
1709328|NCT01393275|Other|rehabilitation exercise intervention|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 60 minutes rehabilitation exercise training - once a week
15 minutes warm up, 30 minutes strength endurance training - once a week"
1709329|NCT01393275|Other|placebo control group|"exercise intervention: 15 minutes warm up, 30 minutes strength endurance training, 5 minutes walking 55 minutes conversation in the group- once a week
15 minutes warm up, 30 minutes strength endurance training - once a week"
1709330|NCT01393223|Drug|LP-08 80mg|
1709331|NCT01393223|Drug|Normal Saline Placebo|
1709332|NCT01393223|Drug|LP-08 20mg|
1709333|NCT01393210|Dietary Supplement|low calorie diet plus beta-glucan|beta-glucan 1.3D-1.6D, together with a low calorie diet, 500 mg once daily for 12 weeks
1709334|NCT01393210|Other|low-calorie diet|low-calorie diet only for 12 weeks.
1709335|NCT01393197|Other|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
1709336|NCT01393184|Drug|Nimotuzumab and Radiotherapy|Nimotuzumab (Nimo)： Nimotuzumab weekly Nimo (200 mg) × 8, started 1 w before RT
1709337|NCT01393171|Device|Polypropylene mesh (Polyform by Boston Scientific)|Site-specific cystocele repair with polypropylene mesh augmentation
1709338|NCT01393171|Procedure|Porcine Dermis (Pelvicol by CRBard)|Site-specific cystocele repair with porcine dermis augmentation
1709339|NCT01393171|Procedure|Anterior Colporrhaphy|Anterior vaginal prolapse repair with suture.
1709341|NCT01393145|Drug|Combination Fluticasone /Formoterol 12/250 μg|Capsules containing Fumarate formoterol 12 µg + fluticasone propionate 250 µg dry powder for inhalation with aerocaps®
1709342|NCT01393145|Drug|Seretide Diskus (salmeterol/fluticasone) 50/250 μg|Capsules containing salmeterol xinafoate 72.5 µg (equivalent to 50 µg of salmeterol) presented as powder for aspiration, packed in a plastic device in disk format, containing 60 doses
1709343|NCT01393132|Drug|Thymosin Beta 4 eye drops|Patients will be randomized and will receive the same eye drops the Thymosin Beta 4.
1709344|NCT01393132|Drug|Vehicle Control|Patients will be randomized and will receive the same eye drops without the Thymosin Beta 4.
1709345|NCT01393119|Drug|GTx-758|
1709346|NCT01393119|Drug|GTx-758|
1709347|NCT01393119|Drug|GTx-758|
1709348|NCT01393119|Drug|GTx-758|
1709349|NCT01393106|Drug|Idelalisib|Idelalisib tablets administered orally
1709350|NCT01393093|Procedure|Therapeutic Chemoembolization|Transcatheter Arterial Chemoembolization
1709351|NCT01393080|Drug|Nimotuzumab and TP regimen|"TP Regims：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle, for 4 cycles.
Nimotuzumab: 200mg/w, weekly, for 6 weeks; Consolidation treatment， 200mg every 2 weeks, until the end of 4 cycles of chemotherapy or the disease progression."
1709352|NCT01393080|Drug|TP regimen|TP Regimen：Paclitaxel Liposome,135mg/m2,d1;Carbopatin（AUC=5） d2, 3 weeks/cycle,for 4 cycles.
1709353|NCT01393067|Device|Non-expandable plastic stent (plastic endoprosthesis)|plastic stent (plastic endoprosthesis)
1709354|NCT01393067|Device|Covered self-expandable metal stent (cSEMS)|Removable, covered self-expandable metal stent (cSEMS)
1709355|NCT01393054|Drug|Nigella sativa|Drug name: Nigella sativa seed extract in capsule Dosage 300 mg Frequency: twice daily Duration: 4 weeks
1709356|NCT01393041|Device|Angio-Seal VIP|Vascular Closure Device
1709357|NCT01393028|Other|Cardiac CT|Cardiac CT: calcium scan and CT coronary angiography
1709358|NCT01393028|Other|Standard care|Standard care according to international guidelines
1709359|NCT01393015|Device|Automated settings on the oxygen delivery device|FreeO2 automatically adjusts the oxygen flow delivered to patients based on the SpO2 signal. Patients keep using the same device for duration of hospitalization.
1709360|NCT01393015|Device|Manual settings with FreeO2 system in collection mode|Oxygen flow delivery is adjust by nurse and respiratory therapists. Standard medical treatment. Patients keep using the same device for duration of hospitalization.
1709361|NCT01392989|Drug|CIK cells|Standard of care
1709362|NCT01392989|Drug|Cyclosporine|5 mg/kg, po
1709363|NCT01392989|Drug|Mycophenolate Mofetil|15 mg/kg, oral
1709364|NCT01392989|Drug|Thymoglobulin|7.5 mg/kg, IV
1709365|NCT01392976|Drug|CO-1.01 Formulation A (Aqueous suspension containing 15 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 1 and Day 8 for Treatment Sequence 2.
1709366|NCT01392976|Drug|CO-1.01 Formulation B (Aqueous suspension containing 30 mg/mL of drug solubilized in purified phospholipids)|1250 mg/m2 intravenous infusion on Day 1 for Treatment Sequence 2 and Day 8 for Treatment Sequence 1.
1709369|NCT01392950|Device|Air Optix Aqua|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
1709370|NCT01392950|Device|Clariti|Lenses will be worn on a daily wear basis (ie. removed at night and stored in solution) and worn in the normal way. Lenses will be replaced each month. Lenses should be worn for a minimum of six hours a day, four days a week. The lenses are also to be worn for a minimum of two hours before attending all follow-up visits.
1709371|NCT01392937|Device|All-in-One Light multipurpose|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
1709372|NCT01392937|Device|Aquify care|The study was conducted over two months of wear. Subjects were examined initially, and at three follow-up visits after two weeks, one month and two months.
1709373|NCT01392924|Drug|SAR245408|Pharmaceutical form: tablet Route of administration: oral
1709374|NCT01392911|Drug|Rifampicin|High dose rifampicin
1709375|NCT01392898|Drug|liraglutide|liraglutide 1.8 mg q.d.
1709376|NCT01392898|Drug|Insulin|insulin dosed according titration scheme
1709377|NCT01392872|Other|Neuropsychological assessment|This study will evaluate the impact of these treatments on cognitive disabilities, tiredness state, emotion and quality of life in general, on a lengthened period.
1709378|NCT01392859|Drug|levocetirizine|5mg liquid or capsule, daily, five days
1709379|NCT01392859|Other|placebo|placebo will be given in liquid or capsule form to match levocetirizine, for five days
1709380|NCT01392833|Drug|methylprednisolone|intravenous methylprednisolone 1 g for three consecutive days at the beginning of months 1, 3 and 5
1709381|NCT01392833|Drug|azathioprine|azathioprine 1.5 mg/kg/day for six months followed by azathioprine 50 mg/day for a further six months.
1709382|NCT01392833|Drug|prednisone|prednisone 0.5 mg/kg every other day followed by prednisone 0.2 mg/kg every other day for a further six months.
1709383|NCT01392820|Drug|TC-5214|Tablet, Oral, twice daily
1709384|NCT01392820|Drug|Placebo|Tablet, Oral, twice daily
1709385|NCT01392807|Drug|NKTR-118|25 mg Oral tablets, single dose
1709386|NCT01392794|Drug|YM060|oral, without water
1709387|NCT01392768|Drug|Levetiracetam|Oral solution (Each mL contains 100mg of levetiracetam) or immediate-release tablets (Tablets containing 500mg or 1000mg of levetiracetam)
1709388|NCT01392768|Drug|Placebo|Placebo, properly standardized to suit the characteristics of each dosage form (oral solution and tablets) of levetiracetam
1709389|NCT01392755|Drug|danoprevir|oral doses of danoprevir
1709390|NCT01392755|Drug|omeprazole|oral doses of omeprazole
1709391|NCT01392755|Drug|ranitidine|oral dose of ranitidine
1709392|NCT01392755|Drug|ritonavir|oral doses of ritonavir
1709393|NCT01392716|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
1709394|NCT01392703|Drug|Dasatinib as tablets|2 50-mg tablets plus 240 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
1709395|NCT01392703|Drug|Dasatinib as liquid|100 mg administered as 10 mL of liquid drug (10 mg/mL) plus 230 mL noncarbonated, nonrefrigerated water. Oral, single dose, 1 day
1709396|NCT01392703|Drug|Dasatinib as dispersed tablets|2 50-mg dispersed tablets in 30 mL of 100% orange juice followed by 15 mL of orange juice plus 195 mL noncarbonated, nonrefrigerated water. Liquid (oral solution), single dose, 1 day.
1709397|NCT01392690|Behavioral|Dominique's Handy Tricks|Children assisted to 10 workshops where they learned exercises to control their stress and anxiety.
1709398|NCT01392677|Drug|dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 28- week extension period
1709399|NCT01392677|Drug|placebo|matching placebo tablet, oral, once daily, 24- week treatment and 28- week extension period
1709400|NCT01392638|Other|sugar pill|Sugar pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
1709401|NCT01392638|Drug|sildenafil|Sildenafil pills: 37.5, 50.0, and 100.0 mg each 30 minutes.
1709404|NCT01392612|Drug|erythropoietin|Subjects received one single intravenous injection of epoetin alpha (Erypo®, rhEPO, Ortho Biotech/Division of Janssen-Cilag Ag, Bridgewater, New Jersey, US) at a dose of 300 Units per kg bodyweight. Blood was sampled at baseline and 4, 24, 48 and 72 hours after administration of rhEPO during a biosimilarity trial.
1709441|NCT01392326|Drug|Placebo Comparator|Placebo Comparator
1709442|NCT01392313|Dietary Supplement|Carnitine|Carnitine Ingestion
1779225|NCT00423202|Drug|ambrisentan|
1709405|NCT01392599|Procedure|SUBCUTANEOUS VENOUS SYMPATHECTOMY (RSVS)|After incision of the skin a subcutaneous area of approximately 16 cm² (2.5 square inches) will be en block removed between dermis and muscle fascia. All prior detected and marked veins in the operating field will be ligated or coagulated precisely.The tissue defect generated by this operation will be closed by a full thickness or a meshed skin graft which arises during the preparation.
1709406|NCT01392586|Procedure|upfront breast surgery|surgery of primary tumor, lumpectomy or mastectomy
1709407|NCT01392586|Other|systemic therapy|chemotherapy, immunotherapy or endocrine therapy (possibly followed by local surgery of the breast)
1709410|NCT01392560|Drug|BI 10773|Oral once daily
1709411|NCT01392547|Drug|vatreptacog alfa (activated)|1-3 doses per bleeding episode
1709412|NCT01392547|Drug|eptacog alfa (activated)|1-3 doses per bleeding episode
1709413|NCT01392534|Drug|Telmisartan/hydrochlorothiazide (Pritor Plus, BAY98-7103)|Patients treated with telmisartan/hydrochlorothiazide tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
1709414|NCT01392521|Drug|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly for 3 weeks in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 4 of Cycle 1.
1709415|NCT01392521|Drug|Copanlisib + Refametinib (BAY86-9766)|Copanlisib will be administered as an IV infusion weekly in combination with Refametinib (BAY86-9766) at varying dose levels. Refametinib (BAY86-9766) is administered orally twice a day starting at Day 6 of Cycle 1 on a 4 day on, 3 day off schedule.
1709416|NCT01392495|Drug|Imatinib|200 mg or 400 mg qd
1709417|NCT01392469|Drug|Imatinib|
1709418|NCT01392456|Procedure|Insertion of two screw type dental implants|Each patient (of the 69 recruited) will receive 2 screw-type Straumann (Institute Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, in a 1-stage non-submerged procedure according to a strict protocol (Weingart D and ten Bruggenkate 2000).
1709420|NCT01392430|Other|Discontinuation of prophylactic drugs i.e. co-trimoxazole, dapsone, fluconazole, itraconazole, azithromycin|Discontinuation of prophylaxis for opportunistic infections
1709421|NCT01392391|Procedure|Task Oriented Exercise Training|"Treadmill training with safety harnesses begin at 6 to 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 30 minutes for 6 months.
Group dynamic balance exercise immediately follow the treadmill training 3 times a week. Participants also receive Best Stroke Care according to Get with the Guidelines"
1709422|NCT01392391|Procedure|"Stroke Care Get with the Guidelines"|"Post-stroke care is applied according to the recommendations of the American Stroke Association Get with the Guidelines adapted for Jamaica"
1709423|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
1709424|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
1709425|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
1709426|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
1709427|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
1709428|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given 6-8 hours after each vaccination, the second dose to be given 6-8 hours after the first.
1709429|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
1709430|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
1709431|NCT01392378|Drug|Paracetamol|Paracetamol suspension for oral administration will be given at a weight adjusted dose of 15mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
1709432|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
1709433|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
1709434|NCT01392378|Drug|Ibuprofen|Ibuprofen suspension for oral administration will be given at a weight adjusted dose of 10mg/kg/dose. The first dose will be given at the time of each vaccination, the second dose to be given 6-8 hours after the first, and the third dose to be given 6-8 hours after the second.
1709435|NCT01392378|Biological|13-valent pneumococcal conjugate vaccine|13vPnC will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
1709436|NCT01392378|Biological|INFANRIX hexa|INFANRIX hexa will be administered by intramuscular injection at 2, 3, 4 and 12 months of age.
1709437|NCT01392352|Drug|Pazopanib|2 x 400mg pazopanib tablets taken once daily for 12 weeks
1709439|NCT01392326|Drug|Secukinumab (75 mg)|Secukinumab (75 mg)
1709440|NCT01392326|Drug|Secukinumab (150 mg)|Secukinumab (150 mg)
1709443|NCT01392300|Drug|IncobotulinumtoxinA (400 Units)|Main period: One injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), 400 units, total volume 8.0 mL; Mode of administration: intramuscular injection
1709444|NCT01392300|Drug|Placebo Comparator|Main period: one injection session of solution, prepared by reconstitution of powder with 0.9% NaCl, corresponding total placebo volume 8.0 mL; Mode of administration: intramuscular injection
1709445|NCT01392287|Drug|Memantine|"Dosing Form: Tablet
Dosage: 5mg, 10 mg
Description:
Memantine hydrochloride (Namenda®), a low to moderate affinity uncompetitive (open-channel) NMDA antagonist, is manufactured and supplied by Forest Laboratories, Incorporated. Only the subjects in the depression group will receive the study drug memantine HCl. Per psychiatrist's instructions, subjects may remain on the maximum dosage of memantine HCl allowed by the study protocol for a given week, or reduce the dosage if concerns regarding tolerability arise. The dosage of memantine HCl cannot be increased more rapidly than the dosing schedule listed below.
Memantine HCl Dosing Schedule:
5 mg qAM week 1 5 mg qAM and 5 mg qHS for week 2 10 mg qAM and 5 mg qHS for week 3 10 mg BID for week 4, 5, 6, 7, and 8"
1709446|NCT01391325|Drug|Allopurinol|Commercially available allopurinol 100 mg and 300 mg oral tablets will be prescribed by the Investigator according to the approved product label.
1709447|NCT01391312|Biological|botulinum toxin Type A|botulinum toxin Type A 20U (total dose) injected into the glabellar region on Day 0.
1709448|NCT01391312|Drug|normal saline (placebo)|Normal saline (placebo) injected into the glabellar region on Day 0.
1709449|NCT01391299|Biological|botulinum toxin Type A|Botulinum toxin Type A (total dose 30 Units or 40 Units) injected into bilateral forehead and frown line areas on Day 1.
1709450|NCT01391299|Drug|Normal Saline|Normal Saline (placebo) injected into bilateral forehead and frown line areas on Day 1.
1709451|NCT01391286|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
1709452|NCT01391286|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
1709453|NCT01391273|Drug|bimatoprost solution 0.03%|One drop of bimatoprost solution 0.03% applied along each upper eyelid margin once daily in the evening for 4 months.
1709454|NCT01391273|Drug|bimatoprost vehicle solution|One drop of bimatoprost vehicle solution applied along each upper eyelid margin once daily in the evening for 4 months.
1709455|NCT01392235|Drug|Famitinib|25 mg qd p.o. and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
1709456|NCT01392222|Behavioral|Focus groups|"The focus groups will cover the following issues
Perceptions of thyroid cancer and disease status
Sources of information used in papillary microcarcinoma treatment decision-making
Treatment decision-making processes and influential factors
Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)
Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)
Views about how to improve acceptability of active surveillance as a disease management option"
1709457|NCT01392222|Behavioral|Focus groups|"The focus groups will cover the following issues:
Perceptions of thyroid cancer and disease status
Sources of information used in papillary microcarcinoma treatment decision-making
Treatment decision-making processes and influential factors
Perceived barriers to active surveillance to treat papillary microcarcinoma (for the immediate surgery sub-sample)
Perceived facilitators to active surveillance to treat papillary microcarcinoma (for the non-immediate surgery sub-sample)
Views about how to improve acceptability of active surveillance as a disease management option"
1709458|NCT01392209|Other|Bevacizumab & Stereotactic Radiotherapy|Treatment: (until treatment failure): bevacizumab 10 mg/kg IV once every two weeks on days 1 (+/- 3 days) and 15 (+/- 3 days) of every cycle (Cycle defined as 28 days). On day 28 (or up to 2 days before) of cycles 1 and 2 (and for every other cycle thereafter) patients will undergo a physical and radiological re-evaluation (MRI). Patients will begin stereotactic radiotherapy beginning anywhere from day 7 to day 10 of cycle 2 with escalating fraction sizes (interpatient - there is no intrapatient escalation). Assessment of response will be performed following cycles 1 and 2 then following every two cycles.
1709459|NCT01392196|Procedure|Renal Denervation|Renal Denervation using the Symplicity Catheter in Heart Failure Population
1709460|NCT01392183|Drug|Pazopanib|800 mg by mouth daily in 4 week study cycle.
1709461|NCT01392183|Drug|Temsirolimus|25 mg by vein infused over 30-60 minutes every week in 4 week study cycle.
1709462|NCT01392183|Behavioral|Quality of Life Assessment|Completion of full assessment battery at baseline, prior to treatment then every 8 weeks at clinical evaluation.
1709463|NCT01392183|Drug|Benadryl|25 to 50 mg by vein approximately 30 minutes before the start of each dose of temsirolimus.
1709464|NCT01392170|Drug|PEG-IFNá-2a|45 mcg given subcutaneously as a single weekly dose for 24 months.
1709465|NCT01392157|Device|copper-releasing intrauterine device|100 women received a 380 mm2 of copper releasing intrauterine device
1709466|NCT01392157|Device|ENG-releasing implant|60 mcg/day releasing etonogestrel implant
1709467|NCT01392157|Device|LNG-releasing intrauterine system|a LNG-IUS releasing 20 mcd/day of LNG
1709468|NCT01392157|Device|LNG-IUS|100 women will receive an LNG-IUS
1709469|NCT01392144|Procedure|Nitric oxide breath test|Breathe out into a device (nitric oxide breath analyzer) for 10 seconds; repeated 3 times. Done prior to start of radiation therapy, 1 week before completion of radiation therapy, at completion of radiation therapy, then at each follow-up visit for 6 months.
1709470|NCT01392144|Behavioral|Questionnaires|On day of each breathing test, completion of a breathing and symptom questionnaire, approximately 10 minutes.
1709471|NCT01392131|Dietary Supplement|Oncoxin|20 patients with hepatocellular carcinoma will receive syrup Oncoxin 25 ml bd and capsule Oncoxin 1 cap bd for 24 weeks
1709472|NCT01392131|Other|Supportive treatment|patients will receive only supportive treatment. No chemotherapy, radiotherapy, tumor ablation or surgery will be performed
1709473|NCT01392105|Drug|Mesenchymal stem cell|Route : intracoronary injection Frequency : single dose of autologous bone-marrow derived mesenchymal stem cells Dosage : 1x1000000 cells/kg Duration : mean injection duration approximately 4 weeks after primary percutaneous coronary intervention
1709474|NCT01392105|Drug|Control group|No additional treatment of mesenchymal stem cells
1709475|NCT01392079|Drug|Alemtuzumab|Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.)
1709476|NCT01392066|Behavioral|questionnaire|"Both the patient and the partner/spouse fill out a questionnaire that assesses their psychosocial adjustment. Time for completion is ca. 30 minutes.
The questionnaire is administered at baseline and 5- and 12-months follow up."
1709477|NCT01392053|Other|Lumbosacral Massage|Massage Group (GM) will receive lumbosacral massage for 30 minutes, during uterine contractions between 4-5 cm of cervical dilation.
1709478|NCT01392027|Procedure|Blood Draw|Blood draw for research specimens only
1709479|NCT01392014|Drug|dihydroartemisinin-piperaquine|This study used fixed-dose tablets of 40 mg dihydroartemisinin and 320 mg piperaquine for each tablet (D-ARTEPP®, Guilin Pharmaceutical Co., Ltd, China. The regimen is based on weight for 3 days (D0, D1 and D2) with maximal dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg.
1709480|NCT01392014|Drug|dihydroartemisinin-piperaquine + primaquine|For DHP, treatment was as for Arm dihydroartemisinin piperaquine. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets (local product by PT Pharos Indonesia, batch no 15306002, produced on 30/05/2008 and expiring on May 2012). The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
1709481|NCT01391988|Procedure|Electric scalpel|Radical mastectomy with electric scalpel. Electric scalpels were calibrated at 40 watts of cutting and coagulation power.
1709482|NCT01391988|Procedure|Harmonic scalpel|Radical mastectomy with harmonic scalpel. Harmonic GEN04 generator calibrated at power leve 3 and 5, using the HP054 handpiece and HF 105 curved blade
1709483|NCT01391975|Procedure|Active ultrasound surveillance of fistula and proactive treatment of stenosis|Regular duplex ultrasound assessment of fistula from time of creation until 6 months post procedure with referral of all haemodynamically significant stenoses to further imaging and treatment
1709486|NCT01391949|Behavioral|Detailed feedback|Once a week subjects will receive feedback about the total time spent cycling and walking in the previous week. Subjects in this intervention group will also receive feedback about average cycling speed, distance pedaled, average walking speed, and distance walked in the previous week.
1709487|NCT01391949|Behavioral|Basic feedback|Once a week subjects will receive feedback about total time spent cycling and walking in the previous week.
1709488|NCT01391936|Procedure|Tension Band Wiring|AO technique of TBW for fixation of fracture.
1709489|NCT01391936|Procedure|Plate fixation|Patients in this arm will receive plate and screw fixation of their olecranon fracture.
1709490|NCT01391923|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1709491|NCT01391897|Behavioral|psychotherapy|"multimodal complex psychotherapy"
1709492|NCT01391871|Device|OCT|Optical coherence tomography
1709493|NCT01391871|Device|Transthoracic echocardiography CFR measurement|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
1709494|NCT01391858|Drug|lyrica|150mg of pregabalin/placebo
1709495|NCT01391845|Drug|ulipristal acetate|30mg of ulipristal acetate orally the day of hCG injection in a unique dose
1709496|NCT01391845|Drug|placebo|placebo orally in a unique dose the day of hCG injection
1709497|NCT01391845|Drug|ulipristal acetate|ulipristal acetate 30mg orally in a unique dose the day of hCG administration
1709498|NCT01391845|Drug|placebo|placebo orally in a unique dose the day of hCG injection
1709499|NCT01391832|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|For the sham rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the sham mode so that all conditions are similar to the active delivery mode except that transcranial magnetic stimulation is not administered to the scalp and does not down modulate the right frontal lobe.
1709500|NCT01391832|Behavioral|Cognitive Processing Therapy|Cognitive Processing Therapy (CPT) is a 12 session evidenced based, trauma-focused treatment for PTSD. CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the combat related trauma.
1709501|NCT01391832|Device|Repetitive Transcranial Magnet Stimulation (rTMS)|For the active rTMS with CPT group, the rTMS coil will be placed over the right prefrontal scalp region with the MagStim Rapid Stimulator set to the active mode. After motor threshold determination, the stimulator coil is positioned over the dorsolateral prefrontal cortex - DLPFC (Brodmann Area 9/46). The right frontal rTMS will safely, reversibly, and temporarily down modulate the right frontal lobe. The conducting coil is placed over the scalp while electrical current pulses pass through the coil. This alternating current turned on and off rapidly produces magnetic pulses (1.5-2.0 Tesla strength) that last for 100 - 300 microseconds. The time-varying magnetic pulses induce an electrical field that will result in current flow in neural tissue, thereby activating or deactivating cortex subjacent to the coil.
1709502|NCT01391819|Other|Data collection|Socio-demographic information, medical history, yellow fever vaccination history and dengue suspicion data collection.
1709503|NCT01391819|Procedure|Blood sample collection|A blood sample will be collected at each of the three scheduled study visits and any time during the study that dengue is suspected. Samples collected at scheduled visits will be tested for anti-dengue antibodies. Samples collected at visits for dengue suspicion will be tested for dengue diagnosis.
1709504|NCT01391793|Drug|Placebo|Twice daily for 3 days
1709505|NCT01391793|Drug|Dexamethasone|0.15 mg/kg/dose twice daily for 3 days
1709506|NCT01391767|Device|NuOss XC|NuOss XC is a bone grafting material that will be placed in extraction socket site.
1709507|NCT01391754|Behavioral|SafeCare|Behavioral home based family preservation. Weekly visits X six months.
1710513|NCT01383655|Drug|Magnesium Sulfate|i.v. magnesium 40mg/kg in 20 min
1709511|NCT01391741|Other|Visual Cues|Walking with visual cues for 30 minutes, 4 times a week for 4 weeks
1709512|NCT01391741|Other|Walking without visual cues|Walking without visual cues, but verbal encouragement twice a week to take longer steps, for 30 minutes, 4
1709513|NCT01391728|Behavioral|Active Lifestyle all your Life|"Intervention After the first data collection the participants are randomised in an intervention and control group. The control group receives the normal treatment that may be given after a radius fracture and may vary from one care unit to another (but there is no preventive programme within the normal activity as far as we know). In groups of 6-8 participants the intervention group starts the programme Active lifestyle all your life with group meetings around every other week (10-12 times) and with 2 individual meetings directed at discussing fall risks in the participant's own home environment. After a summer break, Christmas and New Year three follow-up meetings take place, one of which is an individual meeting. The intervention is then terminated, but the participants are encouraged to continue the activity themselves."
1709514|NCT01391715|Drug|rabeprazole|rabeprazole 20mg bid per day for 2 weeks
1709515|NCT01391715|Drug|standard dose rabeprazole|rabeprazole 20mg qd per day for 2 weeks
1709516|NCT01391689|Dietary Supplement|diindolylmethane|Given PO
1709517|NCT01391689|Dietary Supplement|placebo|Given PO
1709518|NCT01391676|Procedure|trabeculectomy|postoperative imaging of trabeculectomy blebs with the spectral domain optical coherence tomography
1709519|NCT01391663|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 7 days.
1709520|NCT01391663|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 7 days.
1709521|NCT01391663|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, two tablets taken once daily for up to 7 days.
1709522|NCT01391650|Procedure|'biomechanic of the knee'|20 patients had their ACL replaced by SB reconstruction from hamstrings, 20 patients double - bundle technique with AM bundle being reconstructed first, and 20 patients with the PL bundle first.
1709523|NCT01391637|Biological|HuCNS-SC transplant in the lead-in phase|Long-term safety follow-up study
1709524|NCT01391624|Drug|Flaxseed oil|3 g (3 capsules/day) of flax oil for a period of 8 weeks
1709525|NCT01391624|Drug|Paraffin + # 2 dye|3 capsules of mineral oil (ineffective) for 8 weeks.
1709526|NCT01391611|Drug|Pazopanib|800 mg; PO
1709527|NCT01391598|Drug|Lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At lidocaine group 20 pacients will receive lidocaine at a dose of 4 mg / kg, not exceeding a dose of 240 mg diluted in 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study..:Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
1709528|NCT01391598|Drug|lidocaine|After completion of the inclusion criteria all patients receive a dose of amitriptyline 12.5 mg in the first week, and 25 mg in the eight subsequent weeks, orally, once daily at night. At saline group 20 pacients will receive 125ml of solution 0.9% saline.The solutions will be infused in 1 hour once a week in the four weeks following the start of the study. Patients may use as additional analgesics up to 4g/day acetaminophen, and if necessary, they can use tramadol, recording the dose
1709529|NCT01391585|Other|Text Message prompts|In this single armed intervention, patients will receive text message prompts
1709530|NCT01391572|Radiation|enlarge irradiation volume|In Arm A, postsurgical radiation target volume includes tumor bed and elective nodes area
1709531|NCT01391572|Radiation|Small volume radiation|In Arm B, postsurgical radiation target volume includes tumor bed only
1709532|NCT01391572|Drug|cisplatin|
1709533|NCT01391572|Drug|fluorouracil|
1709534|NCT01391559|Drug|arformoterol|15 mcg administered via nebulizer
1709535|NCT01391559|Drug|salmeterol|50 mcg delivered vis Diskus
1709537|NCT01391533|Drug|SAR125844|"Pharmaceutical form:solution
Route of administration: intravenous"
1709538|NCT01391520|Drug|deferiprone|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
1709539|NCT01391520|Drug|Placebo|3 tablets (treatment arm assigned in double-blind, randomized manner) will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
1709540|NCT01391507|Drug|0.9 % sodium chloride|Monthly intravenous injection for 6 months
1709541|NCT01391507|Drug|COR-1|Monthly intravenous injection for 6 months
1709542|NCT01391507|Drug|Standard therapy for heart failure|All patients will continue to receive standard therapy for heart failure (ie, in accordance with guidelines) throughout the study.
1709543|NCT01391494|Biological|160Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
1709544|NCT01391494|Biological|320Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
1709545|NCT01391494|Biological|640Eu/0.5ml in adults|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 adults aged 18-49 years old on day 0, 14.
1709546|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in 12 adults|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 adults aged 18-49 years old on day 0, 14.
1709547|NCT01391494|Biological|0Eu/0.5ml in adults|0Eu/0.5ml placebo in 24 adults aged 18-49 years old on day 0, 14.
1709548|NCT01391494|Biological|160Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
1709549|NCT01391494|Biological|320Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
1709550|NCT01391494|Biological|640Eu/0.5ml in children|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 12 children aged 3-11 years old on day 0, 14.
1709551|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in children|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 12 children aged 3-11 years old on day 0, 14.
1709552|NCT01391494|Biological|0Eu/0.5ml in children|0Eu/0.5ml placebo in 24 children aged 3-11 years old on day 0, 14.
1709553|NCT01391494|Biological|160Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 160Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
1710514|NCT01383655|Drug|Placebo|NaCl
1709554|NCT01391494|Biological|320Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 320Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
1709555|NCT01391494|Biological|640Eu/0.5ml in infants|inactivated EV71 vaccine (KMB-17) of 640Eu/0.5ml in 24 infants aged 6-35 months old on day 0, 28.
1709556|NCT01391494|Biological|1280Eu/0.5ml (without adjuvant) in infants|inactivated EV71 vaccine (KMB-17) of 1280Eu/0.5ml (without adjuvant) in 24 infants aged 6-35 months old on day 0, 28.
1709557|NCT01391494|Biological|0Eu/0.5ml in infants|0Eu/0.5ml placebo in 48 infants aged 6-35 months old on day 0, 28.
1709558|NCT01391481|Drug|Perfluorocarbon|Vaporized PFC Inhalation 100ml/8h for 5 days
1709559|NCT01391481|Drug|Sterile Water for Injection|Inhalation of Sterile Water for Injection, 100ml/8h for 5 days
1709560|NCT01391468|Dietary Supplement|Probiotics|intervention group receives probiotics containing 10E9 CFU B. bifidum, B. catenulatum, B. longgim, and L. plantarm in 6 months observations
1709561|NCT01391468|Dietary Supplement|Cornstarch|placebo will be given in 6 months
1709562|NCT01391455|Procedure|Isolation of the spermatic cord from mesh|The spermatic cord is isolated from the mesh employed to repair an inguinal hernia following standard open repair.
1709563|NCT01391442|Biological|blood and urine samples|58 ml of blood 120 ml of urine
1709564|NCT01391442|Genetic|blood sample|11 ml of blood
1709565|NCT01391442|Other|cardiovascular assessment|echography, echodoppler, measure of blood pressure...
1709566|NCT01391442|Other|Stanislas ancillary study : MRI examination with GRICS technique|
1709567|NCT01391429|Behavioral|Video Decision Support Tool|Six minute digital video illustrating specific treatments for three different levels of medical care: life-prolonging care, basic care and comfort oriented care.
1709568|NCT01391403|Drug|Artemisinin|400 mg/day
1709569|NCT01391403|Other|Placebo|400mg/day
1709570|NCT01391390|Drug|Melatonin|10mg/day, 12-week treatment
1709571|NCT01391390|Drug|Placebo|10mg/day, 12-week treatment for TD
1709572|NCT01391377|Drug|Niacin/Laropiprant combination|Niacin 1g / Laropiprant 20mg for 4 weeks followed by Niacin 2g / Laropiprant 20mg for 4 weeks
1709573|NCT01391377|Drug|Sugar pill|Placebo
1709574|NCT01391351|Other|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy :
On Day 1 of the first course of chemotherapy
On Day 1 of the second course of chemotherapy
Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy
At the end of chemotherapy"
1709575|NCT01391351|Other|blood samples|"blood samples in patients receiving Taxol and carboplatin chemotherapy with avastin:
On Day 1 of the first course of chemotherapy
On Day 1 of the second course of chemotherapy
Before the surgery, if programmed via J1 or the fourth cycle of chemotherapy
At the end of chemotherapy"
1709576|NCT01391338|Drug|ASP3652|Oral
1709577|NCT01391338|Drug|Placebo|Oral
1709578|NCT01391260|Other|Gefitinib|Radiation Therapy: 3D-CRT/IMRT 95%PTV 60-66Gy, 1.8-2.0Gy/f,5f/w; Gefitinib: 250 mg, Qd, p.o;
1709579|NCT01391234|Radiation|STAT RT planning and delivery workflow|"Patients will receive simulation, planning, quality assurance, and their first treatment in a single day using the STAT RT workflow.
Patients will receive a total of 1-5 fractions of high dose palliative radiation therapy via TomoTherapy consisting of 5-10 Gray per fraction.
Data will be collected to evaluate the effectiveness of our novel image co-registration techniques, CT-detector-based exit dose calculations, and infrared patient position monitoring. These novel techniques for image co-registration, radiation dose calculations, and patient position monitoring will not alter or replace standard of care techniques."
1709580|NCT01391221|Drug|Duloxetine|Subjects with major depression will be entered into the trial and treated with duloxetine 30 mg for one week, followed by 60 mg for 8 weeks. The option of increasing the dose as clinically indicated to 120mg is possible for the last 4 weeks of the study intervention
1709581|NCT01391208|Drug|GI heptapeptide|GI heptapeptide, Linear, 7 amino acid peptide sequence ASYNYDA with a 5-FITC tag and NH2 terminus. Chemical Formula: Ala1-Ser2-Tyr3-Asn4-Tyr5-Asp6-Ala7-Gly8- Gly9-Gly10-Ser11-Lys12 (5-FITC) -NH213.Investigational Agent Manufacturer: CPC Scientific, 1245 Reamwood Ave, Sunnyvale, CA 94089 Investigational Agent information: Lot Number: 10031701, M.W. 1577.6, 97.2% pure. Stored at -20C Yellow, lyophilized powder in single use amber vials. 5-FITC is light-sensitive, therefore stored protected from light. Manufactured under cGMP with Certificate of Analysis (COA) provided.
1709582|NCT01391195|Device|Phototherapy by low level laser therapy|Phototherapy by low level laser therapy during 9 weeks
1709583|NCT01391182|Other|EACA|EACA 5 grams IV (mixed in NS) given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
1709584|NCT01391182|Other|Placebo arm|Placebo (NS) IV given in two doses: prior to incision (total hip arthroplasty) and repeated 4 hours later.
1709585|NCT01391169|Other|seromuscular flap enforcement|seromuscular flap enforcement
1709586|NCT01391156|Drug|3%Minoxidil lotion|3% Minoxidil lotion apply two times a day
1709587|NCT01391156|Drug|3% Minoxidil with 0.1% Finasteride lotion|3% Minoxidil with 0.1% Finasteride lotion apply two times a day.
1709588|NCT01391143|Biological|MGA271|"Up to 9 dose escalation cohorts will be enrolled to determine the maximum tolerated dose of MGA271. Patients with evidence of clinical benefit will be allowed to continue therapy at the same dose once per week for 3 weeks out of every 4-week cycle until documented progression.
Patients treated in the Expansion Segment at the maximum administered dose will receive weekly, uninterrupted infusions of MGA271 in 8 week cycles for up to 12 cycles."
1709589|NCT01391130|Drug|LY2510924|Administered subcutaneously
1709590|NCT01391130|Drug|Sunitinib|Administered orally
1709591|NCT01391117|Drug|placebo.|panel 1: 2 participants receive placebo at a q24h regimen.
1709592|NCT01391117|Drug|placebo.|panel 3: 2 participants receive placebo. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
1709593|NCT01391117|Drug|TMC649128.|panel 2, arm 1: 8 participants receive a q12h regimen of TMC649128 at a selected dose based on results of panel 1.
1709594|NCT01391117|Drug|placebo.|panel 2, arm 2: 2 participants receive placebo at a q24h regimen.
1709595|NCT01391117|Drug|placebo|panel 4, arm 1: 10 participants receive PegIFN a-2a/RBV in combination with placebo, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
1709687|NCT01390441|Drug|Methotrexate|Methotrexate 10-25 mg administered orally, SC, or IM as a weekly stable dose
1709596|NCT01391117|Drug|TMC649128|panel 4, arm 2: 10 participants receive PegIFN a-2a/RBV in combination with TMC649128, administered q12h or q24h, for 14 days. Actual dose and dose regimen (12h or 24h) is to be selected based on panels 1, 2 and 3.
1709597|NCT01391117|Drug|TMC649128.|panel 2, arm 2: 8 participants receive a q24h regimen TMC649128 at a dose based on results of panel 1.
1709598|NCT01391117|Drug|TMC649128|panel 3: 8 participants receive TMC649128. Actual dose and dose regimen (q12h or q24h) to be selected based on the results of the panels 1 and 2.
1709599|NCT01391117|Drug|TMC649128.|panel 1: 8 participants receive a q24h regimen at 1000 mg of TMC649128.
1709600|NCT01391117|Drug|placebo.|panel 2, arm 1: 2 participants receive placebo at a q12h regimen.
1709601|NCT01391104|Drug|Sildenafil|Sildenafil citrate is a phosphodiesterase type-5 inhibitor. Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
1709602|NCT01391104|Drug|Sugar Pill|Patients will be assigned to sildenafil (20 mg tid) or placebo per os for 28 days in a randomized, double-blind manner. After a four-week wash-out period, patients will then be crossed over to the alternate therapy for the next 28 days.
1709603|NCT01391091|Procedure|Radiofrequency catheter ablation|PVAI
1709604|NCT01391091|Procedure|Radiofrequency catheter ablation|PVAI
1709605|NCT01391078|Device|Sensimed Triggerfish Sensor|IOP will be monitored for 24 hours
1709606|NCT01391078|Device|Goldmann Applanation Tonometry, Perkins Tonometry|IOP will be measured every two hours within 24 hours
1709607|NCT01391065|Radiation|MR PET Guided Brachytherapy|
1709608|NCT01391052|Drug|Norethindrone acetate pretreatment|5 mg tablets, three times a day for 21 days for 2 menstrual cycles.
1709609|NCT01391052|Other|No pretreatment|LVN IUS is placed withour Norethindrone acetate pretreatment.
1709610|NCT01391039|Drug|Perflutren lipid microsphere|Intravenous injection of 10 microL/kg once prior to ultrasound examination
1709611|NCT01391026|Behavioral|Enhanced patient-centered care|The experimental arm will be referred to a multi-disciplinary clinic
1709612|NCT01391013|Drug|Darunavir(DRV)|Oral administration of tablet DRV 800 mg (2 tablets of 400 mg) once daily at the same time, within 30 minutes after food for 48 weeks
1709613|NCT01391013|Drug|Ritonavir|Oral administration of tablet ritonavir 100 mg once daily at the same time, within 30 minutes after food for 48 weeks
1709614|NCT01391013|Drug|2 nucleoside reverse transcriptase inhibitors (NRTIs)|2 NRTIs will be administered as per the package inserts.
1709615|NCT01391000|Procedure|LASER CO2|The therapy is performed with the patient sitting, place the unit high above the shoulder with the following indicators: through a pulsed 40 Hz, distance between device and patient 60 cm, 10x15 cm area of application, power 2W; energy between 10 and 15 J/cm2
1709616|NCT01391000|Procedure|TENS|"Transcutaneous Electrical Nerve Application of Stimulation occurs through the use of No. 3 channels (long head of biceps area (CLB), the supraspinatus muscle area, the area medial border of the scapula.
Duration: Twenty (20) minutes, mpulsi: 70 microsec, frequency: 100 Hz, intensity: between 20 and 40 mA."
1709617|NCT01390961|Drug|alacaftadine and naphazoline HCl & pheniramine maleate|once a day
1956262|NCT02917187|Drug|BIIB074|Administered as specified in the treatment arm
1956263|NCT02917187|Drug|Placebo|Matched placebo
1956264|NCT02916056|Drug|Azeliragon 5mg|
1709621|NCT01390935|Other|guideline adherence|guideline adherence of physician
1709622|NCT01390922|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
1709623|NCT01390909|Drug|Anti-epileptic drug (AED)|Prescription claim for at least one AED including lamotrigine, tiagabine, pregabalin, ethosuximide, lacosamide, phenytoin, carbamazepine, valproic acid, felbamate, levetiracetam, zonisamide, primidone, oxcarbazepine, vigabatrin, phenobarbital, gabapentin, topiramate.
1709624|NCT01390896|Drug|Fondaparinux Sodium|
1709625|NCT01390883|Drug|Fondaparinux Sodium|
1709626|NCT01390870|Drug|5ARI or AB or Combination Therapy (5ARI + AB)|5ARI: Dutasteride or Finasteride; AB: Doxazosin, Silodosin, Tamsulosin, Terazosin, or Alfuzosin
1709627|NCT01390857|Drug|Valaciclovir|
1709628|NCT01390844|Drug|Boceprevir (BOC)|200 mg capsules, 800 mg three times daily by mouth
1709629|NCT01390844|Drug|Placebo to boceprevir|200 mg placebo capsules, 800 mg three times daily by mouth
1709630|NCT01390844|Drug|Peginterferon alfa-2b (PEG)|1.5 mcg/kg/week subcutaneously
1709631|NCT01390844|Drug|Ribavirin (RBV)|200 mg capsules, weight-based dosing 800 to 1400 mg/day by mouth divided twice daily
1709632|NCT01390844|Drug|Cross-Over Boceprevir Treatment|At Treatment Week 14, participants in the Placebo group with detectable HCV-RNA at Treatment Week 12 have the option to add boceprevir 800 mg three times daily to the PEG + RBV regimen for up to 32 weeks.
1709633|NCT01390831|Device|THERMOCOOL® Catheter|Catheter-based renal denervation
1709634|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) single dose capsule was administered at dose of 15 milligram (mg), 30 mg, 60 mg, 90 mg orally in successive 21-day cycles.Dose escalation was proceeded until Maximum Tolerated Dose (MTD) was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohorts enrolled subjects with Breast Cancer, Non-Small Cell Lung Cancer (NSCLC), Melanoma, and Colorectal Cancer.
1709635|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) capsule was administered orally at a dose of 30 mg, 50 mg, 70 mg and 90 mg in successive 21-day cycles. Dose escalation was proceeded until MTD was reached. Once the MTD was reached, enrollment began in four disease-specific expansion cohorts at either the MTD or a lower dose recommended by the Safety Monitoring Committee. The four expansion cohort enrolled subjects with Breast Cancer, NSCLC, Melanoma, and Colorectal Cancer.
1710515|NCT01383642|Other|No intervention, observational study|
1956265|NCT02916771|Drug|Ixazomib|Oral, proteasome inhibitor
1956266|NCT02916771|Drug|Lenalidomide|Oral, immunomodulatory agent
1956267|NCT02916771|Drug|Dexamethasone|Oral, steroid
1956269|NCT02915224|Drug|Chlorambucil|Participants will receive chlorambucil as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
1709636|NCT01390818|Drug|MSC1936369B (pimasertib)|MSC1936369B (pimasertib) capsule was administered twice daily orally at a dose of 60 mg and 45 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of MSC1936369B (pimasertib) was combined with a lower dose of SAR245409 (PI3K and mTOR inhibitor).
1709637|NCT01390818|Drug|SAR245409 (PI3K and mTOR inhibitor)|SAR245409 (PI3K and mTOR inhibitor) was administered twice daily orally at a dose of 30 mg and 50 mg in successive 21-day cycles. Dose escalation proceeded until MTD was reached. The maximum tolerated dose of SAR245409 (PI3K and mTOR inhibitor) was combined with a lower dose of MSC1936369B (pimasertib).
1709638|NCT01390805|Drug|Valaciclovir Hydrochloride.|
1709639|NCT01390792|Drug|Zanamivir hydrate|
1709640|NCT01390779|Device|SENSIMED Triggerfish|Contact lens-based device intended to continuously record the timing of relative changes in IOP for up to 24 hours
1709641|NCT01390766|Drug|Azathioprine|
1709642|NCT01390753|Dietary Supplement|Human donor milk|
1709643|NCT01390727|Device|Device-guided breathing (Resperate - InterCure, Israel)|After randomization, the patients allocated in this arm will be instructed to use a device-guided breathing, for 15 minutes per day during 8 weeks, with the aim to reduce the respiratory frequency to less than 10 breaths/min
1709644|NCT01390727|Other|Listen music|After randomization, the patients allocated in this arm will be instructed to listen to calm music for 15 minutes per day during 8 weeks
1709645|NCT01390714|Drug|E3710|"Arm A:
E3710 40 mg→RPZ 10 mg→E3710 20 mg
RPZ 10 mg→E3710 20 mg→E3710 40 mg
E3710 20 mg→E3710 40 mg→RPZ 10 mg
Crossover study of E3710 40 mg, E3710 20 mg, and PRZ 10 mg, once daily, for 5 days, oral administration."
1709646|NCT01390714|Drug|E3710|"Arm B:
E3710 40 mg→E3710 80 mg→EPZ 40 mg
E3710 80 mg→EPZ 40 mg →E3710 40 mg
EPZ 40 mg→E3710 40 mg→E3710 80 mg
Crossover study of E3710 40 mg, E3710 80 mg, and EPZ 40 mg, once daily, for 5 days, oral administration."
1709647|NCT01390701|Device|transcutaneous electrical nerve stimulation|30 min of bi-daily low-frequency transcutaneous electrical nerve stimulation on the upper extremities. Duration: 28+-4 days.
1709648|NCT01390701|Drug|felodipin|2,5mg of felodipin once daily. Duration: 28+-4 days.
1709649|NCT01390662|Dietary Supplement|Vitamin D3|one tablet of vitamin D3 70 µg pr. day, for 24 weeks.
1709650|NCT01390662|Dietary Supplement|placebo|one tablet of sugar pill pr. day, for 24 weeks.
1709651|NCT01390649|Biological|IgPro10|IgPro10 will be administrated by IV infusion either a single dose of 1 g/kg bw on 1 day or 2 doses of 1 g/kg bw on 2 days (2 g/kg bw total dose) dependent on the response to the first treatment.
1709652|NCT01390623|Drug|Ceftriaxone|"Patients will be included by investigators or coinvestigateurs, the day of consultation in the emergency adult department in Clermont-Ferrand city.
The diagnosis of acute uncomplicated pyelonephritis is established in the emergency department based on the clinical, laboratory and imaging criteria."
1709653|NCT01390597|Genetic|DNA analysis|
1709654|NCT01390597|Genetic|cytogenetic analysis|
1709655|NCT01390597|Genetic|gene mapping|
1709656|NCT01390597|Genetic|mutation analysis|
1709657|NCT01390597|Genetic|polymerase chain reaction|
1709658|NCT01390597|Other|laboratory biomarker analysis|
1709659|NCT01390584|Drug|ABVD Induction|Step 1 Induction (Arm I) - ABVD Treatment : (Cycle Length: 28 days)
1709660|NCT01390584|Drug|Escalated BEACOPP|Escalated BEACOPP (Cycle Length: 21 days)
1709661|NCT01390584|Drug|Standard BEACOPP|Standard BEACOPP (Cycle Length: 21 days)
1709662|NCT01390584|Diagnostic Test|PET|fludeoxyglucose F 18 Imaging exam
1709663|NCT01390584|Radiation|INRT|selective external radiation therapy
1709664|NCT01390571|Drug|olaparib|
1709665|NCT01390571|Drug|temozolomide|
1709666|NCT01390571|Genetic|gene expression analysis|
1709667|NCT01390571|Genetic|protein expression analysis|
1709668|NCT01390571|Other|laboratory biomarker analysis|
1709669|NCT01390571|Other|pharmacological study|
1709670|NCT01390571|Procedure|diffusion-weighted magnetic resonance imaging|
1709671|NCT01390571|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1709672|NCT01390571|Procedure|therapeutic conventional surgery|
1709673|NCT01390558|Procedure|custom orthotics|Orthotics are fabricated uniquely for each patient and use molds or casts of their foot as the template. They are fabricated by a licensed orthotist. There is no device or brand name other than custom orthotics.
1709674|NCT01390545|Drug|Veltuzumab|administered once weekly (days 1, 8, 15 and 22) by subcutaneous injection
1709675|NCT01390532|Device|3D Blood-Pool Gated SPECT (BPGS) with a new designed cardiac imaging camera (DSPECT, Spectrum Dynamics®, Ceasaria, Israel)|"Sequential 5 min Gated blood pool D-SPECT acquisition at rest and during last stage of dobutamine and atropin infusion (>85% PHR).
Rest and stress left ventricular ejection fraction, phase standard deviation and entropy will be determined using a fully automatic commercial software (QBS, Cedars-Sinai, Los Angeles, CA)."
1709676|NCT01390519|Other|everolimis|
1709677|NCT01390506|Drug|Sodium-selenite|Di-sodium-selenite-pentahydrate (Na 2SeO3.5H2O) in 0,9% sodium chloride is administered intravenously at a does of 3000µg on day 0, 2000µg on day 1 and 2 and at a dose of 1000µg per day on day 3-6.
1709678|NCT01390506|Drug|Placebo|0,9% sodium chloride is administered intravenously
1709679|NCT01390493|Behavioral|neurofeedback training|training of individual alpha frequency, 10 sessions, each 15 min
1709680|NCT01390480|Drug|Cholecalciferol|weekly dose (based on 70 IU/kg bodyweight/day) orally
1709681|NCT01390467|Drug|Cantab®|Randomized study, double-blind, crossover, controlled versus placebo.
1709682|NCT01390454|Procedure|Ultrasound of the elbow 1, days 7 to 15|The primary endpoint is evaluated a first time via an ultrasound exam.
1709683|NCT01390454|Procedure|Ultrasound of the elbow 2, days 7 to 15|The primary endpoint is evaluated a second time by a second practitioner.
1709684|NCT01390454|Procedure|Ultrasound of the elbow 3, days 45 to 90|A third ultrasound is performed only on tennis elbow patients between days 45 and 90.
1709685|NCT01390441|Biological|MK-8808|MK-8808 500 mg/m^2 administered by IV on Day 1 and Day 15 or MK-8808 1000 mg administered by IV at Week 54 and Week 56
1709686|NCT01390441|Biological|MabThera® (rituximab)|MabThera® 500 mg/m^2 or 1000 mg administered by IV on Day 1 and Day 15
1710516|NCT01383629|Behavioral|Counselling|Preoperative counselling
1709688|NCT01390441|Biological|Rituxan® (rituximab)|Rituxan® 1000 mg administered by IV on Day 1 and Day 15
1709689|NCT01390441|Drug|Methylprednisolone|Methylprednisolone 100 mg administered IV before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
1709690|NCT01390441|Drug|Acetaminophen|Acetaminophen 1000 to 1350 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
1709691|NCT01390441|Drug|Loratadine|Loratidine 10 mg administered orally before initiation of each infusion as pre-medication to reduce the incidence and severity of infusion reactions
1709692|NCT01390428|Drug|Grazoprevir|Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
1709693|NCT01390402|Drug|Fludarabine|40 mg/m2 intravenous over one (1) hour on each of four (4) consecutive days, Days -13 to -10.
1709694|NCT01390402|Drug|Busulfan|130 mg/ m2 by vein for 2 doses on Days -11 to -10.
1709695|NCT01390402|Procedure|NK cell infusion:|Natural killer cell infusion will be administered by vein on Day -8.
1709696|NCT01390402|Drug|Interleukin-2|0.5 million units subcutaneously daily for 5 days on Day -8 to day -4.
1709697|NCT01390402|Drug|Anti-Thymocyte Globulin|2.5 mg/kg by vein for 3 doses on Days -3 to -1.
1709698|NCT01390402|Procedure|Allogeneic related Stem Cell Transplant|Allogeneic related stem cell transplant by vein on day 0.
1709699|NCT01390402|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml.
1709700|NCT01390402|Drug|Methotrexate|5 mg/m2 by vein Days 1, 3 and 6 post transplant.
1709701|NCT01390402|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day + 7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
1709703|NCT01390376|Drug|DAAOI-1|DAAOI-1 1g
1709704|NCT01390376|Drug|DAAOI-1|DAAOI-1 2g
1709705|NCT01390376|Drug|placebo|starch pill
1709706|NCT01390363|Other|Parent Only Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites.
1709707|NCT01390363|Other|Parent and Adolescent Phone Call|A telephone call will be made to the parent/guardian informing them that the adolescent has not received one or more vaccines (Td/Tdap in the past 5 years, the MCV4 vaccine, or the 2nd VZV vaccine). The phone call will include a brief informational statement about the vaccine(s) that the adolescent has not yet received. Up to 4 telephone calls will be attempted. As part of the phone call, we will offer to schedule an appointment for the adolescent to receive the missing immunization(s). We will also ask them to mail or fax to the Adolescent/Young Adult Medicine clinic records of immunizations given at other sites. We will also ask permission to speak with the adolescent as well, and if granted, will make up to 4 phone calls to the adolescent to convey the same message.
1709708|NCT01390350|Drug|Canakinumab|150mg subcutaneous injections on day 0
1709709|NCT01390350|Drug|Placebo|150mg subcutaneous injections on day 0
1709710|NCT01390337|Drug|AC220|Oral Liquid
1709711|NCT01390337|Drug|daunorubicin|Intravenous Infusion
1709712|NCT01390337|Drug|cytarabine|Intravenous Infusion
1709713|NCT01390324|Drug|Fixed-dose combination of naratriptan+naproxen|Tablets containing naratriptan 2,5 mg + naproxen 500 mg
1709714|NCT01390324|Drug|Naratriptan|Tablets containing naratriptan 2,5 mg
1709715|NCT01390324|Drug|Naproxen|Tablets containing naproxen 500 mg
1709716|NCT01390311|Drug|Azacitidine|
1709717|NCT01390311|Drug|Pre-DLI Salvage Chemotherapy|At the discretion of the treating physician
1709718|NCT01390311|Biological|Donor Leukocyte Infusion (DLI)|
1956270|NCT02915224|Drug|Obinutuzumab|Participants will receive obinutuzumab as per summary of product characteristics in daily practice. Protocol does not specify any dosage.
1709720|NCT01390285|Device|Transcutaneous electric nerve stimulation|The subjects that enter the TENS-group will be asked to apply the TENS therapy for at least 40 minutes continuously per day. The parameters of the current will not be changed during the study (pulse: 250 µsec; internal frequency: 100Hz; burst frequency 3 Hz; intensity: until an unpleasant but not painful sensation is acquired).
1709721|NCT01390285|Device|sham transcutaneous electrical nerve stimulation|The patients that are assigned to the sham TENS will receive an inactive placebo TENS therapy using a nonfunctional unit that appears to work but provides no stimulus.
1709722|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
1709723|NCT01390272|Behavioral|Booster/ low resource|A LPN will provide behavioral support telephone calls that do not include goal setting and directed problem solving every two months.
1709724|NCT01390272|Behavioral|Medium/Level 1 resource intensity|Monthly tailored RN delivered calls + home BP monitoring.
1709725|NCT01390272|Behavioral|High/Level 2 resource intensity|Pharmacist delivered telephone behavioral self-management support + Home BP monitoring with feedback to pharmacist + Algorithmic medication changes directed by pharmacist (with physician backup).
1709726|NCT01390259|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, exercise, etc...).
1956271|NCT02914600|Drug|Filgotinib|Tablet(s) administered orally once daily
1709727|NCT01390259|Device|Closed-Loop|In this study, the researchers compared the management of diabetes during physical activity and meals with the closed-loop system developed at the University of Virginia. This system uses two DexComTM Seven Continuous Glucose Monitor, a computer containing an investigational control algorithm (well-defined instructions that are expressed in mathematical equations), and an OmniPod Insulin Management System, a portable subcutaneous (under the skin) insulin pump. During the closed-loop admission, the computer based algorithm used CGM values to make recommendations of insulin treatment. The study included a challenge to the insulin management system with meals and mild exercise, so as to demonstrate its capacity to avoid large glucose excursion with changing metabolic state.
1709728|NCT01390246|Drug|bupropion SR 150 mg tablets or matched placebo|Bupropion SR tablets or matched placebo. We will administer a 12-week course of therapy, 150 mg bid/placebo x 12 weeks. Subjects will be dispensed a 30 day supply at a time. They will be instructed to begin using study medication (bupropion SR 150 mg/matched placebo orally for 3 days, then BID for 4 days) on study visit day 1, which will be approximately 1 week prior to their quit date. Thereafter, they will continue to dose BID for 12 full weeks of therapy.
1709729|NCT01390246|Behavioral|Smoking Cessation Counseling|The behavioral counseling will include 35-minute counseling sessions at each of the first 2 visits and 10 minutes of smoking cessation counseling at subsequent visits, provided by the study nurse.
1709730|NCT01390233|Drug|Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel in the vagina.
1709731|NCT01390233|Device|Urinary Balloon Catheter|Pre-induction cervical ripening using a urinary balloon catheter device.
1709732|NCT01390233|Other|Combined Urinary Catheter & Prepidil Gel|Pre-induction cervical ripening using dinoprostone gel injected through a urinary balloon catheter placed in the lower uterine segment.
1709733|NCT01390220|Drug|USL261|
1709734|NCT01390220|Drug|Placebo|
1709735|NCT01390207|Other|16mm triggering|"Final oocyte maturation will be achieved by administration of 10.000 IU of hCG (Pregnyl®). Randomization will be into 2 groups:
• Group A (early hCG group): hCG will be administrated as soon as ≥ 3 follicles ≥ 16mm were present on ultrasound."
1709736|NCT01390181|Drug|Cozaar|Angiotensin II Receptor Blocker
1709737|NCT01390168|Behavioral|Tailored Internet-administrated CBT-Treatment|"This intervention contains up to 6-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
1709738|NCT01390168|Behavioral|Waitlist|active waitlist
1709739|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left anterior descending coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
1709740|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal left circumflex artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
1709741|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the proximal right coronary artery inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
1709742|NCT01390155|Procedure|Measurement of coronary collateral flow index|One-minute balloon occlusion of the target vessel (the vessel which shows a significant stenosis and accordingly requires a therapeutical intervention by balloon angioplasty and stenting) inducing a controlled short-time ischemic condition of a part of the myocardium and simultaneous evaluation of collateral flow.
1709743|NCT01390142|Procedure|Control|Deflated blood pressure cuff placed on upper arm for 30min
1709744|NCT01390142|Procedure|RIPer|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total.
1709745|NCT01390142|Procedure|RIPer + IPost|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated as soon as possible after patient admission in the cathlab and repeated 3 times in total. Within the first minute of re-established coronary flow by primo-stenting, the same balloon is re-inflated for 1 min and then deflated for 1min. This procedure of balloon inflation/deflation is repeated 4 times in total.
1709746|NCT01390129|Procedure|Control|Deflated blood pressure cuff placed on upper arm for 30min
1709747|NCT01390129|Procedure|Remote ischemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200 mmHg for 5 min and then deflated for 5 min. This cycle is initiated before aortic clamping and repeated 3 times in total
1709748|NCT01390116|Dietary Supplement|Aged garlic extract|2 aged garlic extract capsules taken twice daily
1709749|NCT01390116|Dietary Supplement|AGE|encapsulated aged garlic extract, 4 capsules per day, 2.56g/day
1709750|NCT01390103|Other|Assessment following hip injection|Assessment to evaluate the effect of the hip injection on biomechanics.
1709751|NCT01390077|Drug|Nitisinone|Taken orally. Supplied as a 2mg tablet. The starting dose is 2 mg once daily.
1709752|NCT01390064|Biological|Vaccination with Mimotope P10s-PADRE/MONTANIDE ISA 51 VG|All research participants will receive the Mimotope P10s-PADRE/MONTANIDE ISA 51 VG vaccine via subcutaneous (SC) injection following the schedule
1709753|NCT01390051|Drug|Innohep (Tinzaparin)|Dose: 4,500 IU daily in half of the study populationrandomised to treatment
1709754|NCT01390051|Drug|tinzaparin|Dose 4,500 IE daily
1709755|NCT01390038|Device|Simpliciti™ Shoulder System|Total shoulder arthroplasty system
1709756|NCT01390025|Biological|TCN-032|TCN-032 is a human monoclonal antibody that specifically binds to a conserved epitope of the amino-terminal extracellular domain (M2e) of the influenza virus matrix protein 2 (M2). The drug is intended for use as an antiviral agent for the treatment of disease caused by type A influenza viruses. Treatments within the study will consist of single ascending dose-escalation ranging from 1 to 40 mg/kg.
1709757|NCT01390025|Biological|Placebo|Placebo - 0.9% Sodium Chloride for Injection, USP
1709758|NCT01390012|Drug|Dexamethasone tablet 6 mg|Dexamethasone tablet 6 mg
1709759|NCT01390012|Drug|Dexamethasone injection 4 mg|Dexamethasone injection 4 mg
1710223|NCT01386008|Device|senfilcon A contact lens|senofilcon A spherical contact lens worn in a daily wear modality
1709760|NCT01389999|Other|Questionnaires|Each patient is asked to fill out several questionnaires: a french version of the BBQ, as well as the FABQ, the TAMPA score, and the Québec questionnaire, the Dallas score, the HAD score and a visual analog scale for pain.
1709761|NCT01389986|Behavioral|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
1709762|NCT01389973|Drug|ustekinumab 90 mg|Subcutaneous injections of ustekinumb 90 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
1709763|NCT01389973|Drug|ustekinumab 45 mg|Subcutaneous injections of ustekinumb 45 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
1709764|NCT01389973|Drug|ustekinumab 180 mg|Subcutaneous injections of ustekinumb 180 mg at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
1709765|NCT01389973|Drug|Placebo|Subcutaneous injections of placebo at Weeks 0 and 4 and every 8 weeks until the dose for the Long-Term Extension has been selected then every 8 weeks through Week 196 with the selected dose.
1709766|NCT01389934|Drug|levo-bupicaine|Women of this group will be infused L-bupivacaine 0.50% 2 ml / h for 48h after intervention
1709767|NCT01389934|Drug|Placebo|Women of this group be infused saline 2 ml / h for 48h.
1709768|NCT01389921|Other|Electroencephalography|Standard electroencephalography investigation according to the ICS standard Current recording of latency and amplitude of evoked potentials
1709769|NCT01389908|Drug|olanzapine|Patients will receive doses within the range of 280 mg to 405mg OP Depot, according the physician's judgment, on a 3-week interval.
1709770|NCT01389895|Drug|AMG 557|AMG 557 (210 mg) or (140 mg ) will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive AMG 557. Beginning on Day 1, subjects will receive either 210 mg AMG 557 or 140 mg AMG 557 once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of AMG 557 every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
1709771|NCT01389895|Drug|AMG 557 Placebo|AMG 557 Placebo (210 mg) or (140 mg )will be administered as subcutaneous injections in the anterior abdomen of the subjects. Twelve subjects will be randomized to receive placebo. Beginning on Day 1, subjects will receive placebo once weekly for 3 weeks on Day 1, Day 8, and Day 15 and following with 6 additional doses of placebo every other week on Day 29, Day 43, Day 57, Day 71, Day 85, and Day 99. Subjects will be followed out to Day 253 for safety, efficacy, pharmacokinetic (PK) and pharmacodynamic (PD) assessments.
1709772|NCT01389882|Procedure|neurally adjusted ventilatory assist (NAVA) ventilator mode|Neurally adjusted ventilatory assist (NAVA) utilizes the electrical activity of the diaphragm (EAdi) to trigger and cycle-off breaths, and therefore presents a means of bypassing the ventilator circuit, and the inherent delays with pneumatic triggering. This is a processed signal, which is not artificially influenced by changes in muscle length, chest wall configuration, and/or lung volume. It represents the summation of muscle motor unit recruitment and/or firing rate, and correlates with phrenic nerve activity. In this mode, the amount of support pressure is coupled with the magnitude of the EAdi. The proportion of support pressure to EAdi (NAVA level) is adjustable.
1709773|NCT01389869|Biological|Sniffing emotional tears|A band-aid soaked 100μl of emotional tears will be applied just below nostrils.
1709774|NCT01389869|Biological|Sniffing trickled saline|A band-aid soaked 100μl of trickled saline will be applied just below nostrils.
1709775|NCT01389869|Biological|Sniffing fasting plasma|A band-aid soaked 100μl of own fasting plasma will be applied just below nostrils.
1709776|NCT01389869|Biological|Sniffing postprandial plasma|A band-aid soaked 100μl of own postprandial plasma will be applied just below nostrils.
1709777|NCT01389856|Drug|Bosentan|2 mg/kg of weight at birth twice daily (b.i.d); quadrisectable 32 mg tablet of bosentan dispersed in sterile water and administered by nasogastric or orogastric tube.
1709778|NCT01389856|Drug|Matching placebo|twice daily (b.i.d); quadrisectable 32 mg tablet of matching placebo dispersed in sterile water and administered by nasogastric or orogastric tube.
1709779|NCT01389830|Behavioral|Telephone Survey|Telephone interviews (survey) at baseline taking approximately 30-40 minutes to complete; follow-up monthly surveys for cancer patients take 20-30 minutes to complete, follow ups until 12 months or death.
1709780|NCT01389817|Device|Near-infrared light-emitting diode (NIR-LED) therapy (Med Light 630 PRO (Medical Devices Inc.))|Subjects will be exposed to light emitted from a Med Light 630 PRO (Medical Devices Inc.) at a wavelength of 630 nm (+/-15nm) with an exposure of 4 J/cm2. This is accomplished by applying the 50 mW/cm2 LED-generated light to the closed study eye for 80 seconds. Treatments involve application of the LED-generated light for 80 seconds, twice daily.
1709781|NCT01389791|Drug|magnesium sulfate|Patients in this group receive intravenous MgSO4 50mg/kg before administration of rocuronium (induction dose).
1709782|NCT01389791|Drug|priming|Patients in this group receive 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
1709783|NCT01389791|Drug|magnesium sulfate and priming|Patients in this group receive MgSO4 50mg/kg and 0.06mg/kg of rocuronium before administration of 0.54mg/kg of rocuronium.
1709784|NCT01389778|Drug|Metformin ER|Metformin ER 1500 mg for 12 weeks
1709785|NCT01389778|Drug|Metformin|
1709786|NCT01389765|Drug|LY2216684|Administered orally
1709787|NCT01389752|Drug|LY2216684|Administered orally
1709788|NCT01389752|Drug|Activated Charcoal|Administered orally
1709789|NCT01389739|Other|Multi-faceted intervention to improve continuity of care|Periodic exchange of information between FP and oncology team and systematic appointments with FP at 3-month interval
1709790|NCT01389726|Behavioral|Behavioral Parent Training|Triple-P program involves 11 weeks of ongoing group support with contact one time per week with trained group leaders
1709791|NCT01389726|Behavioral|Cognitive Behavioral Therapy|Support group based intervention involving sessions one time per week for 11 weeks with 9-12 grandmothers, 1 trained professional group leader, and 1 trained peer leader
1710016|NCT01387867|Procedure|Unsupervised home based exercise|Unsupervised home based exercise as recommended by the Danish Arthritis Association 1 hour 3 x weekly for 4 months
1709792|NCT01389726|Behavioral|Psychosocial-Informational support|Standard of care normally provided to custodial grandparents. Involves providing information and support in the context of a weekly group meeting with 9-12 grandparents, 1 professional group leader & 1 peer leader over the course of 11 weeks.
1709793|NCT01389713|Drug|Clomifene Citrate|3x50 mg die for 5 days from day 3 to day 7 of the menstrual cycle
1709794|NCT01389713|Drug|GnRH analog and recombinant human FSH|daily subcutaneous 0.1 mg decapeptyl from day 1-2 of the menstrual cycle and recombinant human FSH 450 IU/die from day 3.
1709795|NCT01389700|Drug|SAR279356|"Pharmaceutical form: solution for infusion
Route of administration: intravenous infusion"
1709796|NCT01389700|Drug|placebo|"Pharmaceutical form: solution for infusion
Route of administration: intravenous infusion"
1709797|NCT01389687|Biological|Inactive Poliovirus Vaccine|0.5 mL, Subcutaneous
1709798|NCT01389674|Procedure|2D-strain echo|"2D-strain-analysis with elevation of the radial and circumferential strain and strain rate parameter(systolic and diastolic)occurs through the echocardiography.
Comparison of the echocardiography and the MRI-vitality data, calculation of a cut out of vision value of a vitality diagnosis with the help of 2D-strain-analysis."
1709799|NCT01389661|Biological|MSV treatment|Autologous maxillary bone marrow mesenchymal stem cells (MSV-H) collected from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV)
1709800|NCT01389648|Other|Pre Operative|Pre operative chest physiotherapy treatment
1709801|NCT01389622|Other|acupuncture|National Acupuncture Detoxification Association (NADA) points + digital pressure
1709802|NCT01389622|Other|acupuncture|random points + digital pressure
1709803|NCT01389609|Drug|Doxazosin 4 mg Japanese marketed IR tablet|Immediate release tablet, 4 mg, single dose
1709804|NCT01389609|Drug|Doxazosin 4 mg ODT with water|Orally-disintegrating Tablet , 4 mg, single dose with water
1709805|NCT01389609|Drug|Doxazosin 4 mg ODT without water|Orally-disintegrating Tablet , 4 mg, single dose without water
1709806|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
1709807|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
1709808|NCT01389596|Drug|Pregabalin add-on therapy|Subjects will be randomized to receive a fixed dose of either placebo, pregabalin Level 1 (maximum 150 mg/day) or pregabalin Level 2 (maximum 600 mg/day) in a 1:1:1 ratio, in addition to the subjects current AED medication regimen. Either capsules or oral liquid form will be administered, depending on subjects preference and ability to swallow capsules, in two equally divided daily doses. The study will have an 8 week baseline period; a 2 week dose escalation period; a 9 week dose maintenance period; and a 1 week dose taper period.
1709809|NCT01389583|Drug|AUY922|70 mg/m2 60-min i.v. infusion weekly
1709810|NCT01389570|Procedure|Acupressure wrist band|Use of acupressure wristband during surgery Manufacturer; Pinnacle Ind Ltd, Rm 831 Thriving Ind Ctr, 26-38 Sha Tsui Rd, Tsuen Wan, Hong Kong
1709811|NCT01389557|Drug|Dihydroartemisinin-piperaquine with primaquine|"P. falciparum : Treated with fixed doses of 40 mg dihydroartemisinin and 320 mg piperaquine based on weight for 3 days (D0, D1 and D2) with max dose of 1 x 3 tablets for patients weighing ≥ 41 kg; 1 x 2 tablets for patients weighing 31 - 40 kg, 1 x 1.5 tablets for patients weighing 18 - 30 kg, and 1 X 1 tablet for patients with body weight of 11 - 17 kg. A single dose PQ of 0.75 mg/kg BW was provided on Day-3 using 15 mg base PQ tablets. The maximal dose was 3 tablets for subjects weighing ≥ 60 kg. The dose range for subjects weighing 10 - 13 kg was 0.5 tablet; 14 - 18 kg was 0.75 tablet; 19 - 23 kg was 1 tablet, 24 -30 kg was 1.5 tablet; 31 - 40 kg was 2 tablets; 41- 49 kg was 2.25 tablet; 50 - 59 kg was 2.5 tablet and ≥ 60 kg was 3 tablets.
P. vivax: DHP (3 days) + primaquine (14 days)"
1709812|NCT01389544|Drug|danoprevir|200 mg daily (100 mg q12h) orally, Days 1-10
1709813|NCT01389544|Drug|methadone|stable maintenance therapy: 20-120 mg daily single oral morning dose
1709814|NCT01389544|Drug|ritonavir|200 mg daily (100 mg q12h) orally, Days 1-10
1709815|NCT01389531|Procedure|Rigid bronchoscopy|The HCPA-1 silicone stent available in the following dimensions (diameter x length in mm): 9x30, 9x50, 11x30, 11x50, 13x30, 13x50, 14x30, 14x50, 16x50, 16x70, 18x50 and 18x70 will be inserted through rigid bronchoscopy in patients who presented the criteria to participate in the study.
1709816|NCT01389518|Drug|Active|1 capsule de active (fixed combination of acetaminophen, chlorpheniramine and phenylephrine) administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
1709817|NCT01389518|Drug|Placebo|1 capsule administered in four 4-hour period of wakefulness in between at 07:00 and 23:00 (five daily doses) for two or three consecutive days
1709818|NCT01389505|Procedure|Panretinal photocoagulation|Three episodes of panretinal photocoagulation with one week of interval
1709819|NCT01389505|Procedure|Procedure: Panretinal Photocoagulation (PRP) Drug: Intravitreous injection of Bevacizumab|Intravitreous injection of Bevacizumab 1 week before and the other at the same day of the third episode of PRP
1709820|NCT01389492|Other|frozen meat cutlets meal|250 g of meat cutlets
1709821|NCT01389492|Other|meat meals|250 g of meat meal for 4 days
1709822|NCT01389479|Biological|Fluviral™|Intramuscular, single dose
1709823|NCT01389479|Biological|Fluzone®|Intramuscular, single dose
1709824|NCT01389466|Biological|Step 1|Investigational Product : MG1109 Dose : Cohort 1 : 0.125 mL Cohort 2 :0.25 mL Cohort 3 :0.5 mL Cohort 4 :1.0 mL intramuscularly injection, twice at an interval of 21 days
1709825|NCT01389466|Biological|Step 2|Investigational Product : MG1109 Dose : Cohort 1 :0.5 mL Cohort 2 :1.0 mL intramuscularly injection, twice at an interval of 21 days
1709826|NCT01389453|Procedure|stem cell transplantation|Patients accept a treatment course stem cell transplantation, including one time stem cell transplantation through intravenous injection way at the 10-21th day of cerebral hemorrhage, and the 7—14th day of cerebral infarction incidence; the second time transplantation through lumbar puncture way at the 7th day after the First time transplantation.
1709827|NCT01389440|Drug|Gemcitabine and Erlotinib|Administration of gemcitabine (300mg/m2/weekly)with Erlotinib (100 mg/daily) and radiotherapy (45 Gy/daily) after a period of infusion with a full dose of Gemcitabine (1.000mg/m2/weekly) and Erlotinib (100 mg/daily)
1709828|NCT01389427|Drug|Torisel dose 15 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709829|NCT01389427|Drug|Torisel dose 15 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709830|NCT01389427|Drug|Torisel dose 15 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709831|NCT01389427|Drug|Torisel dose 25 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709832|NCT01389427|Drug|Torisel dose 50 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709833|NCT01389427|Drug|Torisel dose 75 mg and R-CHOP|Torisel in association with Rituximab-Cyclophosphamide-Doxorubicin-Vincristine-Prednisone (R-CHOP) administered every 3 weeks (21 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709834|NCT01389427|Drug|Torisel dose 25 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709835|NCT01389427|Drug|Torisel dose 50 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709836|NCT01389427|Drug|Torisel dose 75 mg and R-FC|Torisel in association with Rituximab-Fludarabine-Cyclophosphamide (R-FC) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709837|NCT01389427|Drug|Torisel dose 25 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709838|NCT01389427|Drug|Torisel dose 50 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709839|NCT01389427|Drug|Torisel 75 mg and R-DHA|Torisel in association with Rituximab-Aracytine (high dose)-Dexamethasone (R-DHA) administered every 4 weeks (28 days) for 6 cycles for patients in relapsed/refractory Mantle Cell Lymphoma (MCL).
1709840|NCT01389414|Drug|Panitumumab plus GEMOX chemotherapy|panitumumab 6 mg/kg will be administered over 60 minute +/- 15 minutes on day 1 followed by Gemcitabine 1000mg/sqm administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
1709841|NCT01389414|Drug|GEMOX chemotherapy|Gemcitabine 1000mg/sqm will be administered by intravenous infusion as 1-hour infusion on day 1 of each cycle. Oxaliplatin 100mg/sqm will be administered by intravenous infusion as 2-hour infusion on day 2 of each cycle.
1709842|NCT01389401|Drug|omeprazole|omeprazole 40 mg twice a day for 16 weeks; dietary and lifestyle changes
1709843|NCT01389388|Drug|Rosuvastatin|All the patients who have signed the informed consent will after they have had performed a MCT and possibly SCC with an IVUS, will be give Rosuvastatinuntill their LDL level has reached 1.6-1.8 mmol/l. The objective is that all the participants should have reached 1.6-1.8 mmol/l 3 months after the start of the study. The participants will remain on Rosuvastatin medication for a total of 18 months.
1709844|NCT01389375|Device|FemoSeal®|Closure device for femoral artery access closure
1709845|NCT01389375|Device|ExoSeal®|Closure device for femoral artery access closure
1709846|NCT01389375|Other|Manual compression|Conventional manual compression
1956272|NCT02914600|Drug|Placebo|Tablet(s) administered orally once daily
1709849|NCT01389349|Other|Acupuncture|Battlefield acupuncture protocol
1709850|NCT01389349|Other|Sham Control|Sham control acupuncture
1709851|NCT01389323|Drug|Daclatasvir|Tablet, Oral, 60 mg, once daily, 24 weeks
1709852|NCT01389323|Drug|Peg-Interferon Alfa-2a|Syringe, Subcutaneous Injection, 180 μg, Once weekly, 24 or 48 weeks depending on response
1709853|NCT01389323|Drug|Ribavirin|Tablet, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 or 48 weeks depending on response
1709854|NCT01389297|Behavioral|SMART Recovery face-to-face meetings|Attending these meetings at least weekly in frequency
1709855|NCT01389297|Behavioral|Overcoming Addictions web application|Logging into and using the web application at least weekly during the course of the study
1709856|NCT01389284|Drug|Naproxen Sodium ER (BAYH6689)|660 mg Naproxen Sodium extended release tablet, orally administered once daily for 24 hours
1709857|NCT01389284|Drug|Naproxen Sodium IR (Aleve, BAYH6689)|220 mg Naproxen Sodium instant release tablet, orally administered 3 times daily (TID) for 24 hours
1709858|NCT01389284|Drug|Naproxen Sodium ER Placebo|Matching placebo of 660 mg Naproxen Sodium ER for 24 hours
1709859|NCT01389284|Drug|Naproxen Sodium IR Placebo|Matching placebo of 220 mg Naproxen Sodium IR (Aleve) for 24 hours
1709860|NCT01389271|Drug|Ventavis inhaled (Iloprost, BAYQ6256)|Since this study is an observational, inhaled iloprost dosage and frequency for each patient will be prescribed by physicians as medically required.
1709861|NCT01389258|Device|OsseoSpeed™ TX|OsseoSpeed™ TX narrow implants (diameter 3 mm) of lengths 11-15 mm
1709862|NCT01389245|Device|OsseoSpeed™ TX|OsseoSpeed™ TX implants of lengths 8-17 mm
1709864|NCT01389219|Other|Intervention|"A comprehensive package of intervention will be developed for the mothers and newborn infants which will be comprised of;
Provision of postpartum maternal and immediate newborn care, including postpartum visit, maternal nutrition supplementation (iron & vitamin A), cord care, eye care, Kangaroo Care, delayed bathing, colostrum administration and linkages to immunization services), complications/illness management through stabilization/referral of cases.
Provision of Information on family planning, birth spacing, LAM counseling, hygiene, danger signs recognition and complications readiness.
Nutrition counseling regarding immediate and exclusive breastfeeding and optimum postpartum diets.
5. Danger signs of newborn illnesses and maternal complications associated with labor and the postpartum period, care seeking. Early referral for subsequent maternal and newborn morbidities, such as anemia, postpartum depression, fistulas, prolapsed uterus and infections."
1709865|NCT01389193|Drug|Ibudilast|Ibudilast 40 mg twice daily oral capsules for a duration of 8 weeks
1709866|NCT01389193|Drug|Placebo|Placebo 40 mg twice daily oral capsules for a duration of 8 weeks
1709867|NCT01389180|Behavioral|Behavioral Drug and HIV Risk Reduction Counseling|BDRC is a highly individualized, structured, and prescriptive behavioral treatment designed to be provided by nursing or other available personnel in China who generally do not have advanced training or experience in psychotherapy or counseling techniques. BDRC provides education about HIV, Hepatitis C, and other bloodborne or infectious diseases, heroin addiction and MMT, incorporates coping skills training components of CBT, and makes use of explicit and detailed short-term behavioral contracts (either verbal or written), aimed at small, easily achievable, and measurable objectives linked to reduction of HIV risk behaviors and heroin use and improvements in daily functioning supporting sustained recovery
1709868|NCT01389180|Behavioral|Educational Counseling|EC uses a didactic lecture-discussion format, incorporating charts, slides, and audiovisual materials and handouts, to educate the patient about core recovery topics, including HIV and other infectious diseases transmission and effective protection strategies, heroin addiction and treatment with methadone maintenance, the importance of taking the methadone regularly, staying away from drugs, and improving social, family and vocational functioning.
1709869|NCT01389180|Behavioral|Treatment as Usual|TAU group will receive manual-guided minimal counseling approximating the current standard of care provided in MMTs in China, consisting of an initial introductory session (introduction to MMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month
1709870|NCT01389167|Drug|Vivitrol|An extended release naltrexone formulation for intramuscular injection
1709871|NCT01389167|Drug|Naltrexone (oral)|Naltrexone 50 mg pills, daily
1709872|NCT01389167|Behavioral|BDRC|Manual-guided BDRC is a highly structured, educational, prescriptive, and individualized treatment that focuses on the patient's current problem areas that are immediately related to marinating abstinence in order to achieve sustained recovery from drugs. The primary goals of BDRC include education about the disease of opiate dependence and effective treatment approaches, skills and strategies to maintain drug abstinence following detoxification, reduction/cessation of drug and sexual behaviors associated with HIV transmission, and increased engagement in non-drug-related social interactions and pleasurable activities.
1709873|NCT01389167|Behavioral|Medical Management|Patient assigned to MM will receive manual-guided medically oriented counseling approximating the current standard of care provided in with NTM the Russian Federation, consisting of an initial introductory session (introduction to NMT and basic education about HIV risks) and subsequent, brief (up to 20 minutes) support and advice sessions once per month.
1709874|NCT01389154|Procedure|Lung biopsy using Always On EM Tip Tracked Device|Patients screened by CT to have a subsegmental, less than 3.0 centimeter lung lesion will be assigned to outpatient bronchoscopy. The patient will have a chest CT with the Always on Patient vPad. Access to the lesion will be achieved using Electromagnetic Tip Tracked devices. Once accessed the operator will use the Electromagnetic Tip Tracked devices or standard devices to obtain a biopsy sample to then be to pathology for diagnosis and reporting. Once completed the patient will be moved to recovery and discharged. If the biopsy is negative the patient will be advised by the pulmonologist about other interventions, watchful waiting, or no further treatment. If the biopsy is positive, the patient will be referred to their physician for further treatment.
1709876|NCT01389102|Drug|Estradiol transdermal one 90 μL spray|Estradiol transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
1709877|NCT01389102|Drug|Estradiol transdermal spray, two 90 μL sprays|Estradiol transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
1709878|NCT01389102|Drug|Estradiol transdermal three 90 μL sprays|Estradiol transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
1709879|NCT01389102|Drug|Placebo transdermal two 90 μL sprays|Placebo transdermal spray, two 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
1709880|NCT01389102|Drug|Placebo transdermal three 90 μL sprays|Placebo transdermal spray, three 90 μL spray applied to adjacent non-overlapping areas on 1 inner forearm daily for 12 weeks using a blinded applicator
1709881|NCT01389102|Drug|Placebo transdermal one 90 μL spray|Placebo transdermal spray, one 90 μL spray applied to 1 inner forearm daily for 12 weeks using a blinded applicator
1709882|NCT01389089|Other|ice gel pack|ice gel pack combined with elevation
1709883|NCT01389089|Other|Multi-layer compression bandage|Application of a multi-layer compression bandage to the foot and lower limb (two layers of wool followed by several layers of a short stretch bandage).
1709884|NCT01389089|Device|A-V Impulse compression|A-V Impulse compression dosage: 130mmHg exerted to the sole of the foot for one second, every twenty second.
1709885|NCT01389076|Drug|Bexxar|"Iodine I 131 tositumomab (Bexxar) is a radioimmunotherapy (RIT) drug. RIT is a treatment strategy designed to target radiation specifically to cancer cells by attaching a radioactive atom to a monoclonal antibody, an immune system protein that binds to a particular protein. The Iodine I 131 tositumomab (Bexxar) therapeutic regimen is delivered in two sets of intravenous infusions given about 7 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body."
1709886|NCT01389076|Drug|Low Dose Methotrexate|Methotrexate is an antifolate drug. It interferes with cells' ability to copy their DNA. This mainly affects cells that are dividing frequently, such as immune system cells and cancer cells. Methotrexate will be used in this study to try to prevent the occurrence of HAMA by limiting your body's ability to produce anti mouse antibodies.
1709887|NCT01389063|Drug|Maraviroc|HAART of subjects enrolled in arm A will be intensified with maraviroc during week 1-8.
1709888|NCT01389050|Radiation|Intensity-Modulated Radiotherapy|Radiotherapy for the treatment of retroperitoneal sarcoma. IMRT will be 50.4 Gy given in 28 fractions.
1709889|NCT01389050|Radiation|Daily Cone Beam CT|Images and information from the daily CT will be used for the repositioning of the patient prior to their treatments as per standard procedures.
1709890|NCT01389037|Behavioral|Health Literacy-focused Self-help|Weekly 2-hour sessions over 6 weeks followed by 12 month follow-up with home blood pressure self monitoring with telephone counseling by community health workers.
1709891|NCT01389037|Behavioral|Delayed Intervention Control|Given pamphlets on the importance of high blood pressure control and offered weekly workshops. This group will be offered the intervention at the conclusion of data collection.
1709892|NCT01389024|Drug|Hydroxyurea|Hydroxyurea solution 100 mg/ml with a starting dose of 20 mg/kg/day by mouth once daily and escalation by 5 mg/kg/day every 8 weeks until hematological toxicity, an absolute neutrophil count of 2000 to 4000/ul, or a maximum dose of 35 mg/kg/day.
1709893|NCT01389024|Drug|Placebo|Sucrose solution 0.2 ml/kg/day by mouth once a day with blinded dose escalation of 0.05 ml/kg/day to match the frequency of dose escalation in the hydroxyurea arm.
1709894|NCT01388998|Other|Changes of difference in pulse pressure and plethysmography after applying various pressure levels on the caval vein|Following hepatic resection, a fitting area for pressure application on the caval vein will be identified by the attending surgeon. Baseline assessments of hemodynamic and heart-lung interaction parameters will be taken. Thereafter the surgeon will apply three different pressure levels (2 N, 5 N, 10 N) at random with a force gauge (Fa. ATP Messtechnik, Ettenheim, Germany). Assessment of the parameters will be performed after 2 minutes of pressure application by an investigator, unaware of the pressure applied. After each pressure application 5 minutes will be waited to assure hemodynamic recovery.
1709895|NCT01388985|Biological|Human Diploid Cell Vaccine (HDCV) rabies vaccine|Human Diploid Cell Vaccine (HDCV) rabies Merieux 1 ml vaccine for rabies, provided by Sanofi-Pasteur, administered zvia ID route at two sites
1709896|NCT01388959|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously once a week for 4 weeks
1709897|NCT01388946|Drug|Ropivacaine 0.75|
1709898|NCT01388946|Drug|Normal saline|
1709899|NCT01388933|Drug|TU-100|15g daily, orally as 5g three times daily for 8 consecutive weeks
1709900|NCT01388933|Drug|Matching Placebo|15g as 5g three times daily, orally for 8 consecutive weeks
1709901|NCT01388920|Drug|Tesamorelin|
1709902|NCT01388907|Other|Ringer lactate solution|Ringer lactate solution was applied directly onto the uterine surgical sites at the end of the myomectomy surgery, to prevent post-surgical adhesion formation.
1709903|NCT01388907|Device|Prevadh film|Prevadh film was applied directly onto the uterine surgical sites at the end of the myomectomy surgery to prevent post-surgical adhesion formation.
1709904|NCT01388881|Other|Music Education|"The intervention - music classes - will be methodologically and educationally based on the National Curriculum Parameters that were developed in Brazilian in the 80s; the focus here is centered on a modern approach to music education where the traditional process of musical learning is not restricted to the domain of the musical reading (sheet music), but also includes musical improvisation, composition and interpretation. Children will be encouraged to create their own music; perception and identification of the elements of musical language in production activities will be explained to them by means of voice, body, sound materials and tools available. Song lyrics, rhymes and rap will be created using elements of musical language not focused purely on the classical elements/music."
1709905|NCT01388868|Other|TOF count guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by No. of response to TOF stimulation displayed by NMT module.
1709906|NCT01388868|Other|T1/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T1 twitch height as compared with baseline (T0) displayed by NMT module.
1709907|NCT01388868|Other|T2/ T0 guided adjustment|adjustment of vecuronium infusion dose every 15 minutes as guided by T2 twitch height as compared with baseline (T0)displayed by NMT module.
1709908|NCT01388855|Drug|Cholecalciferol|Subjects receive cholecalciferol 20,000 IU daily for 30 days followed by 20,000 IU once weekly for 8 weeks.
1709909|NCT01388855|Drug|Placebo|Pills made to look like vitamin D but have no medication in them
1709910|NCT01388842|Drug|inhaled nitric oxide|Study drug will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the intervention arm will receive a dose equivalent to 80 ppm iNO in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
1709911|NCT01388842|Drug|Placebo|The placebo will be administered using an INOpulse delivery system that delivers small pulses of study drug to the patient via a nasal cannula. Subjects randomized to the placebo arm will receive nitrogen in air for 24 hours per day for a minimum of two days and until clinical improvement (coma recovery), death or a maximum of 5 days.
1709912|NCT01388829|Drug|Treatment A|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R3 lot
1709913|NCT01388829|Drug|Treatment B|150 mg single dose of PF 04991532 tablets (1x150 mg) manufactured from the R4 lot
1709914|NCT01388816|Drug|DRL-17822 or placebo|DRL-17822 50, 150 or 300 mg or matching placebo once daily after breakfast
1709915|NCT01388790|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously followed by once weekly subsequent intravenous infusion of cetuximab 250 mg/m^2 in each 5-week treatment cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
1709916|NCT01388790|Drug|Cisplatin|Cisplatin 60 mg/m^2 will administered as intravenous infusion on Day 8 of each 5-week cycle maximum up to 8 cycles until disease progression, unacceptable toxicity, or withdrawal of consent
1710017|NCT01387841|Behavioral|yoga|Postures,relaxation techniques
1710018|NCT01387841|Behavioral|Jacobsons PMRT group|jacobsons Progressive muscle relaxation training involving 16 muscle groups
1709917|NCT01388790|Drug|S-1|S-1, a combination of tegafur, gimeracil, and oteracil will be administered intravenously at a dose of 40 to 60 mg/m^2 orally twice daily for first three consecutive weeks of 5-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.
1709918|NCT01388777|Device|Visica 2™ Treatment System|The Visica 2™ Treatment System uses a closed system to circulate liquid nitrogen within the probe tip creating sub-freezing temperatures that result in precision cryoablation of the intended target tissue.
1709919|NCT01388777|Procedure|Cryoablation|Cryoablation procedure uses a hollow, thin tube called a cryoprobe to freeze and destroy cancer tissue. The cryoprobe needle insertion is done using ultrasound guide to reach target, procedure lasts about 20 minutes.
1709920|NCT01388777|Procedure|Surgical Resection|Complete surgical resection of the primary tumor following cryoablation therapy.
1709921|NCT01388764|Drug|L-arginine|Subjects will receive oral L-Arginine (0.3 grams/kg/day, divided 2 times per day, not to exceed 14 grams/day)
1709922|NCT01388751|Procedure|night splinting|splint finger at night for 4 weeks
1709923|NCT01388738|Drug|citicoline|citicoline IV 2000 mg, then citicoline 900 mg/day (300mg*3 times per day) per os
1709924|NCT01388738|Drug|L-Alpha glycerylphosphorylcholine|choline alfoscerate IV 1000mg daily 10 days
1709925|NCT01388738|Drug|cerebrolysin|Cerebrolysin IV 10 ml daily 10 days
1709928|NCT01388673|Procedure|BaroSense ACE Stapler for plication of dilated post-surgical gastric anatomy|The ACE Stapler is used endoscopically, an incorporates a unique tissue capture mechanism to produce large, permanent serosa to serosa plications in a completely trans-oral approach.
1709929|NCT01388660|Drug|Cloas|A tablet containing 75 mg of Clopidogrel and 100 mg of Aspirin, PO, 2 tablet once daily for Period I & II Day 1 (crossover manner)
1709930|NCT01388660|Drug|Plavix/Astrix|Simultaneous Administration of Plavix (75 mg of Clopidogrel) and Astrix (100 mg of Aspirin), 2 tablets once daily for Period I & II Day 1 (crossover manner)
1709931|NCT01388647|Drug|eribulin|During Phase I, the eribulin dose will be assigned upon study enrollment. The maximum tolerated dose (MTD) determined in Phase I will be the dose used for Phase II. Eribulin will be administered intravenously (IV) over 2 to 5 minutes on Days 1 and 8 of each cycle.
1709932|NCT01388647|Drug|carboplatin|Carboplatin area under the curve (AUC) 6 will be administered IV over 15 to 30 minutes on Day 1 of each cycle.
1709933|NCT01388647|Drug|trastuzumab|Trastuzumab will be administered as an IV infusion on Day 1 of each cycle. A loading dose of 8 mg/kg of trastuzumab will be administered over 90 minutes on Cycle 1 Day 1. Then, a maintenance dose of 6 mg/kg of trastuzumab will be administered over 30 to 90 minutes on Day 1 of Cycles 2 - 6.
1709934|NCT01388621|Drug|Panitumumab|Panitumumab 6 mg/kg/BW d1 + 15 q4w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
1709935|NCT01388621|Drug|pegylated liposomal doxorubicin (PLD)|pegylated liposomal doxorubicin (PLD) 30 mg/m² d1 q4w until progressive disease or for a max. of 6 cycles
1709936|NCT01388621|Drug|Carboplatin|Carboplatin AUC 5 d1 q4w until progressive disease or for a max. of 6 cycles
1709937|NCT01388621|Drug|Gemcitabine|gemcitabine 1000 mg/m² d1 + 8 q3w until progressive disease or for a max. of 6 cycles
1709938|NCT01388621|Drug|Carboplatin|Carboplatin AUC 4 d1 q3w until progressive disease or for a max. of 6 cycles
1709939|NCT01388621|Drug|Panitumumab|Panitumumab 9 mg/kg/BW d1 q3w until progressive disease or for a max. of 6 cycles In case of CR, PR or SD at the end of the combination treatment in experimental arm, panitumumab monotherapy is to be continued with 9 mg/kg/BW d1 q3w until time of tumor progression or up to a maximum of 6 months.
1709940|NCT01388595|Drug|FLUTICASONE PROPRIONATE|1. Fluticasone Propionate (FP) Product name: Flixotide Evohaler® Manufacturer: Allan and Hanbury's Active ingredients: Fluticasone Propionate Propellant: HFA 134a Dose: 250μg per actuation giving a total dose of 500µg per day through the spacer device with the customised nasal adaptor.
1709941|NCT01388595|Drug|Salmeterol|Salmeterol Product Name: Serevent® Manufacturer: Allan and Hanbury's Active ingredients: Salmetrol Xinafoate Propellant: HFA 134a Dose: 25μg per actuation giving a total dose of 50µg per day through the spacer device with the customised nasal adaptor
1709942|NCT01388595|Drug|PLACEBO|4. Placebo inhaler to SM, FP, SM+FP Manufacturer: Cipla Ltd Active ingredients: None Propellants: HFA 134a Imported & QP release tested in UK : DHP Clinical supplies, Powys, UK
1709943|NCT01388582|Device|LNG-IUS|10 women will receive the LNG-IUS during breastfeeding
1709944|NCT01388582|Device|Implanon|60 mcg/day contraceptive implant
1709945|NCT01388582|Drug|30 mcg EE and 150 LNG oral contraceptive (Microvlar)|10 women will receive oral contraceptive during breastfeeding
1709946|NCT01388582|Device|TCu380A copper-intrauterine device|Tcu380A copper-intrauterine device will be inserted on 10 women during breastfeeding as non-hormonal comparator group
1709947|NCT01388582|Device|TCu380A intrauterine device|10 women will receive a TCu380A intrauterine device as non hormonal contraceptive method during breastfeeding
1709948|NCT01388569|Other|flow cytometry|
1709949|NCT01388569|Other|immunologic technique|
1709950|NCT01388569|Other|laboratory biomarker analysis|
1709951|NCT01388556|Behavioral|Tango dancing|Twice weekly tango dance classes
1709952|NCT01388543|Drug|Atazanavir|Atazanavir 400mg once daily for 7 days followed by atazanavir 300mg plus ritonavir 100mg for 7 days
1709953|NCT01388530|Device|EMS 7500 Digital Muscle Stimulator|A standard FDA approved transcutaneous electrical nerve stimulation (TENS) unit will be used to apply low intensity stimulation to the trigeminal nerves during sleep.
1709954|NCT01388517|Drug|Tacrolimus|0.1% tacrolimus ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
1709955|NCT01388517|Drug|Calcitriol|0.0003% calcitriol ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
1709956|NCT01388517|Drug|Petrolatum|Petrolatum ointment to apply twice a day for 9 weeks on pytiriasis alba plaques.
1779278|NCT00423514|Drug|melphalan|
1709957|NCT01388504|Drug|sodium nitrite|sterile solution containing low dose sodium nitrite dissolved in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to opening of the infarct related artery using Percutaneous Coronary Intervention
1709958|NCT01388504|Other|Placebo|sterile solution containing 0.9%w/v sodium chloride in 5ml water injected intravenously over a period of 2½ - 5 minutes immediately prior to Percutaneous Coronary Intervention
1709959|NCT01388491|Drug|desogestrel/ethinyl estradiol and ethinyl estradiol|
1709960|NCT01388491|Drug|desogestrel/ethinyl estradiol|
1709961|NCT01388478|Drug|R-pramipexole|R-pramipexole will be taken as a liquid and start at one teaspoon (5 ml) twice a day for a total dose of 100 mg/day. After 4 weeks, the dose will double (two teaspoons twice a day, or a total of 200mg/day). Four weeks later the dose will be increased again to 2 1/2 teaspoons twice a day (total of 300mg/day) where it will remain for the remaining 16 weeks of study treatment. Prior to each increase, participants and their study partners will be interviewed regarding any possible side effects or problems. These findings will be discussed with Dr. Burns prior to increasing the study drug dose. The dose will only increase if the participant is not having side effects.
1709962|NCT01388465|Behavioral|Mobile phone text messaging|Daily assessment followed by feedback
1709963|NCT01388452|Device|Point of care HIV RNA PCR|The intervention is a HIV RNA PCR test for which UNC Project laboratory personnel will process samples in 48 hours so that patients can receive results prior to hospital discharge.
1709964|NCT01388439|Drug|Oseltamivir|Treatment dose was oseltamivir 3 mg/kg/dose by mouth (PO) twice daily. Prophylactic dose was oseltamivir 1 mg/kg/dose PO once daily to infants < 28 weeks postmenstrual age (PMA), 1 mg/kg/dose PO twice daily to infants 28 - 38 weeks PMA, and 3 mg/kg/dose PO once daily to infants > 38 weeks PMA. Dosing in infants < 28 weeks PMA was chosen based on unpublished data from Acosta et al. This data was obtained from phone contact with Dr. Peter Gal, co-author of the study. Dosing in infants 28 - 38 weeks PMA was chosen based on published data from Acosta et al.1 Dosing in infants > 38 weeks PMA and less than 3 months postnatal age was chosen based on data from Kimberlin et al. Dosing in infants > 38 weeks PMA and greater than 3 months postnatal age was per the recommendations of the Advisory Committee on Immunization Practices of the United States Department of Health and Human Services.
1709965|NCT01388426|Device|7eye( Panoptx)™ moisture chamber glasses|moisture chamber glasses
1709966|NCT01388413|Drug|Weekly Oral Cyclic Antibiotic programme|The Weekly Oral Cyclic Antibiotic Programme consisted of the alternate administration of an antibiotic once per week. The antibiotics that were chosen (efficient for urinary tract infection, well tolerated, low selection pressure) included : Amoxicillin 6000 mg, Amoxicillin/clavulanic acid 3000 mg, Cefixime 400 mg, Fosfomycin trometamol 6000 mg, Trimethoprim/sulfamethoxazole 2400 mg. During week A,the patient received a single antibiotic (A), and the following week B the patient was given another antibiotic (B). For each patient, antibiotics were specifically chosen according to the results of urine cultures.
1709967|NCT01388400|Other|conventional occupational therapy|upper limb exercises
1709968|NCT01388400|Device|video capture virtual reality|virtual reality delivered uppe limb exercises
1709969|NCT01388387|Other|Tacrolimus pharmacokinetics|tacrolimus pharmacokinetics over 12 hours
1709970|NCT01388374|Other|Other, care provided by Nurse Practitioners|Patients will receive care at the Primary Out of Hours Emergency Service by a Nurse Practitioner instead of a General Practitioner (substitution of care from physicians to nurses).
1709971|NCT01388361|Drug|insulin degludec|Injected s.c. (under the skin) once daily. The doses will be individually adjusted
1709972|NCT01388361|Drug|insulin aspart|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
1709973|NCT01388361|Drug|liraglutide|Injected s.c. (under the skin) once daily. The doses will be individually adjusted.
1709974|NCT01388348|Device|"Dynamic Urine Vibration Holter"|"each subject will undergo intervention for the diagnosis of bladder outlet obstruction first using the Dynamic Urine Vibration Holter and then urodynamically by pressure flow study"
1709975|NCT01388335|Drug|warfarin|Administered orally
1709976|NCT01388335|Drug|enzastaurin|Administered orally
1709977|NCT01388322|Drug|Enoxaparin|40 mg (4000 IU) women <80 kg at the time of randomization or 60 mg (6000 IU) women> 80 kg at the time of randomization One dose daily. Subcutaneous administration. Treatment periods: the same day of the Initiation visit (from 9 to 13.6 weeks of gestation) until 36 weeks gestation.
1709978|NCT01388270|Device|a pre-heparin-coated hemodialysis filter; Hepran|Use of the pre-heparin-coated filter compared to the conventional filter in a cross over design
1709979|NCT01388257|Procedure|All types of surgery procedures|All types of surgery procedures used for anoperineal fistula repair. Surgery procedures include fistulotomy, biological glue, rectal advancement flap and plug.
1709980|NCT01388257|Procedure|Simple seton drain removal|Patients are simply followed after seton drain removal.
1709981|NCT01388244|Other|Screening|Screening by risk factor assessment (FRAX) followed by DXA
1709982|NCT01388244|Other|Control|Observation by use of register data
1709983|NCT01388231|Behavioral|CBT-Manualized Intervention|Cognitive-behavioral therapy (CBT) for social phobia following the Clark and Wells (1995) model of social phobia.
1709984|NCT01388231|Behavioral|CBT-Treatment as Usual|Cognitive-behavioral therapy for social phobia following no specific model.
1709985|NCT01388205|Behavioral|Family-based Outdoor program|2 to 3 hour outdoor activities organized in conjunction with National Parks, Singapore
1709986|NCT01388179|Device|Transcranial Magnetic Stimulation|low-frequency rTMS to the left DLPFC prior to high-frequency deep rTMS to the FFA through the STS.
1709987|NCT01388166|Procedure|Education|Education
1709988|NCT01388153|Drug|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken without water
1709989|NCT01388153|Drug|Acarbose (Glucobay ODT, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay ODT; Day 2: oral sucrose load plus Glucobay ODT taken with water
1709990|NCT01388153|Drug|Acarbose (Glucobay, BAYG5421)|Day 1: oral sucrose load (75 g sucrose dissolved in 225 mL water) without Glucobay standard tablet; Day 2: oral sucrose load plus Glucobay standard tablet taken with water
1710019|NCT01387828|Procedure|Laparoscopic splenic aneurysm repair, eventual splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparoscopic approach
1709991|NCT01388114|Device|Electrosensing Antibody Probe System (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-procalcitonin antibody and procalcitonin in the serum of the patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds procalcitonin polypeptide target molecules in the test specimen
1709992|NCT01388101|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between specific anti- LECT2 and its antigen (LECT2 with liver cancer) present in the specimens of patients with liver cancer. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (i.e. specific LECT2) in the test specimens.
1709993|NCT01388088|Drug|Spironolactone|25 mg twice a day
1709994|NCT01388088|Drug|Amiloride|5 mg twice a day
1709995|NCT01388088|Drug|Placebo|twice a day
1709996|NCT01388075|Drug|Rifampicin|oral, 450 mg/day , 7 days
1709997|NCT01388062|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti- influenza virus antibody and its antigen (influenza virus) present in patients. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (influenza virus) in the test specimens. From assessment of the electric signature of semiconductive anti- influenza virus antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
1709998|NCT01388049|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-EV71 antibody and its antigen (EV71) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (EV71) in the test specimens. From assessment of the electric signature of semiconductive anti-EV71 antibodies, the eABprobe could offer sensitive detection and precise quantification of EV71.
1709999|NCT01388036|Drug|esmolol|consecutive infusions of esmolol and normal saline (placebo)
1710000|NCT01388023|Dietary Supplement|herbal formula for fresh breath|composition of herbal ingridients in a palatal mucoadhesive patch to remove volatile solfur compounds and reducequantity of vsc creating bacteria
1710001|NCT01388010|Other|1-Fermented Probiotic Dairy Product (test)|
1710002|NCT01388010|Other|2-Milk-based non-fermented dairy product(control)|
1710003|NCT01387997|Device|Electrosensing antibody probing system (e- Ab sensor)|Electrosensing antibody probing system (e- Ab sensor), which was developed for the rapid and sensitive detection of hapten, proteins, or viral antigen in medical samples, will be used for analyzing the interaction kinetics between anti-high risk HPV and its antigen (high-risk HPV) present in patients. The system incorporates the use of engineered semiconducive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe, which specifically and selectively binds targeted molecules (high-risk HPV) in the test specimens. From assessment of the electric signature of semiconductive anti- high-risk HPV antibodies, the eABprobe could offer sensitive detection and precise quantification of high-risk HPV.
1710004|NCT01387958|Drug|LCQ908|
1710005|NCT01387958|Drug|Placebo|
1710006|NCT01387945|Behavioral|HBPM+website+patient navigator|In addition to home blood pressure monitor, patient receives access to BP web portal and trained patient navigator.
1710007|NCT01387932|Device|HepaSphere/QuadraSphere Microspheres|HepaSphere/QuadraSphere Microspheres loaded with doxorubicin
1710008|NCT01387932|Procedure|PVA, lipiodol, doxorubicin|Conventional TACE procedure using PVA, lipiodol and doxorubicin
1710009|NCT01387919|Behavioral|Prolonged fasting|48 hours of fasting
1710010|NCT01387906|Drug|topical bimatoprost|topical bimatoprost will be applied one drop to each eyebrow each night.
1710011|NCT01387893|Behavioral|the Digital Repetitive Infrapubic Pressure maneuver|The Digital Repetitive Infrapubic Pressure maneuver is performed by exerting moderate inwards pressure with the index and middle fingers, spread slightly apart, palm-side up, pushing into the fold of skin at the base of the penis, where it comes forward beneath the pubic bones, one fingertip on each side of the penis' suspensory ligament. By repeatedly pushing inwards and slightly upwards, at a rate of about once per second, to a distance of about two centimeters, at times of significant urinary hesitancy it is often possible either to initiate spontaneous flow, or to pass a small quantity of urine with each push, such that after a minute or two one can empty the bladder to a satisfactory degree. While a few men find it useful when voiding in a standing position, for the majority, the maneuver requires a forward-leaning seated posture for optimal results.
1710012|NCT01387880|Drug|Everolimus|"Patients with KRAS mutant tumours are treated with cetuximab, everolimus and irinotecan as third line.
Patients with KRAS wildtype tumours that have progressed on therapy with cetuximab and irinotecan are treated with cetuximab, everolimus and Irinotecan."
1710013|NCT01387880|Drug|Everolimus|1.66 mg per day up to 7½ mg per day
1710014|NCT01387867|Procedure|Strength training|Supervised strength training in groups 2 x 1 hour weekly and un-supervised strength training 1 hour weekly for 4 months
1710015|NCT01387867|Procedure|Nordic Walking|Supervised Nordic Walking in groups 2 x 1 hour weekly and un-supervised Nordic Walking 1 hour weekly for 4 months
1710105|NCT01387087|Drug|Placebo|oral
1710020|NCT01387828|Procedure|Laparotomic splenic artery aneurysm repair, eventual artery reconstruction or splenectomy|Aneurysmectomy and eventual artery reconstruction or splenectomy performed with a laparotomic approach
1710021|NCT01387763|Drug|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
1710022|NCT01387763|Drug|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
1710023|NCT01387763|Drug|PegIntron|PegIntron, prefilled syringe 50 micrograms/0.5 ml. 30 micrograms subcutaneously once weekly.
1710024|NCT01387763|Drug|Pegasys|Pegasys, prefilled syringe 180 micrograms/0.5 ml 45 micrograms subcutaneously once weekly
1710025|NCT01387763|Drug|Hydrea|Capsule Hydrea 500-2000 mg orally QD or BID
1710026|NCT01387750|Other|Mentholated Cream|A topical cream containing menthol without the addition of the oxygenated glycerol triesters.
1710027|NCT01387750|Other|Mentholated Cream with OGT|A Topical Cream that contained both menthol and oxygenated glycerol triesters.
1710028|NCT01387737|Drug|TA-7284-Low|TA-7284-Low
1710029|NCT01387737|Drug|TA-7284-High|TA-7284-High
1710030|NCT01387724|Genetic|RNA analysis|
1710031|NCT01387724|Genetic|polymerase chain reaction|
1710032|NCT01387724|Genetic|protein expression analysis|
1710033|NCT01387724|Genetic|proteomic profiling|
1710034|NCT01387724|Genetic|western blotting|
1710035|NCT01387724|Other|enzyme-linked immunosorbent assay|
1710036|NCT01387724|Other|immunohistochemistry staining method|
1710037|NCT01387724|Other|laboratory biomarker analysis|
1710038|NCT01387724|Other|liquid chromatography|
1710039|NCT01387724|Other|mass spectrometry|
1710040|NCT01387711|Drug|PEP005 (Ingenol mebutat Gel, 0.05 %)|All eligible patients will receive PEP005 Gel, 0.05 %, on two consecutive days to both the AK Treatment Area and the Normal Skin Treatment Area
1710041|NCT01387672|Drug|Nitrates (NABT Main trial)|nitroglycerin; isosorbide mononitrate
1710042|NCT01387672|Other|Placebo|Placebo ointment
1710043|NCT01387659|Procedure|Gastric emptying test|Gastric emptying tests will be performed at baseline, 6 months and 12 months
1710044|NCT01387646|Behavioral|Project IMAGE|Participants in the intervention arm will be interviewed at baseline, given a targeted physical exam including a STI/HIV screen, pap smear and contraception counseling and enrolled in the intervention. The intervention will include 2 workshops, 5 support groups sessions and 2 individual counseling sessions. They will be interviewed and examined again after completing the intervention, to establish a post-intervention baseline.
1710047|NCT01387620|Drug|Hyaluronic Acid and hydroxypropylmethylcellulose|Hyaluronic Acid 1.6% was used to performed phacoemulsification in one eye and hydroxypropylmethylcellulose 2% was used in the fellow eye.
1710050|NCT01387594|Procedure|lumbar puncture|2 lumbar punctures prior to treatment; study drug 225mg SC once a month X 3 doses.
1710051|NCT01387594|Drug|lumbar puncture|1 lumbar puncture before and after 3 doses; study drug 225mg SC once a month X 3 doses.
1710052|NCT01387568|Drug|Lidocaine Infusion|children in group L received i.v. lidocaine 1.5 mg/kg followed by infusion at 1.5 mg. kg−1.h−1. and were continued up to 6 hours postoperatively
1710053|NCT01387568|Drug|saline Infusion|children in group P received i.v. saline 0.9% 1 ml/kg followed by infusion at 0.1 ml. kg−1.h−1,and were continued up to 6 hours postoperatively
1710054|NCT01387555|Biological|JX-594 recombinant vaccina GM-CSF|Patients will be randomised 2:1 to Arm A or Arm B and will receive 6 treatments on days 1, 8, 22, week 6, week 12, and week 18 plus best supportive care as needed.
1710055|NCT01387555|Other|Best Supportive Care|Patients will be randomised 2:1 to Arm A or Arm B and will receive best supportive care as needed.
1710056|NCT01387542|Drug|Paliperidone extended release (ER)|Paliperidone ER 3 milligram (mg) or 6 mg or 9 mg or 12 mg oral tablets depending on investigator's discretion once daily for 10 weeks
1710057|NCT01387516|Behavioral|Motivational Intervention|The MI session will be 60-90 minutes in length.The focus is on establishing rapport and building motivation. The counselor explores teen's reasons for entering treatment, prior treatment experience, previous attempts to change use, possible goals for treatment, substance effect expectancies, and perceptions of self-efficacy.A personalized feedback report outlines assessment results, highlights any problems or concerns related to cigarette use expressed by teen, and compares tobacco use levels with national norms for same age and gender peers.
1710058|NCT01387516|Behavioral|Relaxation Therapy|The Relaxation Therapy intervention encompasses several techniques, including Progressive Muscle Relaxation and Visualization-Imagination, and meditation to reduce stress; which may lead to substance use.
1956279|NCT02913105|Drug|LMB763|Hard Gelatin Capsules
1956280|NCT02913105|Drug|Placebo|Hard Gelatin Capsule
1710059|NCT01387516|Behavioral|Cognitive Behavioral Therapy|The Cognitive-Behavioral Therapy (CBT) Intervention focuses on the interrelationship between thoughts, feelings, and behaviors. It addresses specific deficits, such as improving problem solving skills and developing social supports, and behaviors such as substance abuse and smoking.
1710060|NCT01387516|Behavioral|Self-Help Programming|"The Self-Help Programming intervention combines elements of Nicotine anonymous (NicA) to provide someone who uses nicotine but wants a nicotine-free life, with a community of people that has also experienced nicotine addiction and strives to be nicotine free. It incorporate the 12 Steps and the NicA tools (i.e., meetings, phone list, literature, sponsorship, and service) to facilitate and maintain abstinence from nicotine."
1710061|NCT01387503|Procedure|Liver transplantation|Once randomized to Group 1, patients will be enlisted for liver transplantation at the recruiting Center. Prioritization is encouraged as a waiting time of more than 8 months could cause patients' drop-out from the study
1710062|NCT01387490|Behavioral|Individualized Scheduled Telephone Support (ISTS)|ISTS is a telephone intervention that provides injury-related education, training in problem solving, and focused behavioral strategies for problems (e.g., anxiety, depression) that commonly co-occur with Mild Traumatic Brain Injury (MTBI). ISTS also includes access to usual care and web-based and printed educational material. The 12 phone calls included in ISTS will be administered over a 6-month period.
1710063|NCT01387490|Other|Usual Care (UC)|UC is the usual care provided to service members attending the Traumatic Brain Injury (TBI) Clinics at Madigan Army Medical Center and Womack Army Medical Center, plus web-based education and 12 mailings of educational materials over a 6-month period.
1710064|NCT01387477|Drug|Lactate|Infusion of 66 mmol of lactate
1710065|NCT01387477|Drug|Glucose|Infusion of 33 mmol of glucose
1710066|NCT01387464|Drug|ISV-303|0.075% bromfenac in DuraSite dosed QD
1710067|NCT01387464|Drug|Bromday™|0.09% bromfenac dosed QD
1710068|NCT01387425|Drug|varenicline|varenicline at a dose of 1 mg twice a day for 12 week
1710069|NCT01387425|Drug|placebo tablet is made of lactose|placebo at a dose of 1 mg twice for 12 week
1710070|NCT01387399|Procedure|Cisplatin administered intraoperatively as hyperthermic intraperitoneal chemoperfusion|"Classical 3+3 dose escalation study of cisplatin administered as HIPEC (60mg/m², 80mg/m² and 100mg/m²)"
1710071|NCT01387373|Drug|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine + trastuzumab systemic
1710072|NCT01387360|Device|Supracor|"The presbyopic treatment consists of a standard treatment for distance vision and the procedure known as SUPRACOR addition to correct near vision.
The SUPRACOR addition provides a multifocal ablation with a central near addition with an aberration controlled transition zone towards the periphery, thereby allowing good focus over a range of object distances."
1710073|NCT01387347|Drug|Thymosin beta 4|A preservative-free, sterile eye drop solution containing 0.1% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
1710074|NCT01387347|Drug|Placebo|A preservative-free, sterile eye drop solution containing 0.0% (w/w) Tβ4 for direct instillation into each eye, twice a day (BID) for 28 days.
1710075|NCT01387334|Behavioral|Resistance Exercise Training Program With Rubber Bands|Resistive exercise consist of 5-min warm up, at least 30 min resistive exercise using rubber band as recommendation (8-12 times per set, at least 3 sets per day and at least 3 days per week) and 5-min cool down
1710076|NCT01387321|Drug|BYL719|
1710077|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
1710078|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 3, single dose
1710079|NCT01387308|Drug|Fostamatinib|Oral tablets, 100 mg, single dose
1710080|NCT01387308|Drug|Fostamatinib|Oral tablets, 150 mg, single dose
1710081|NCT01387308|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
1710082|NCT01387295|Drug|oxaliplatin, capecitabine, trastuzumab|Oxaliplatin intrahepatic capecitabine and trastuzumab systemic
1710087|NCT01387256|Drug|medical abortion|pregnancy termination with drugs
1710088|NCT01387243|Drug|Orlistat|60 mg
1710089|NCT01387230|Drug|GSK573719|62.5 mcg
1710090|NCT01387230|Drug|GSK573719|125mcg
1710091|NCT01387230|Other|Placebo|Placebo
1710092|NCT01387217|Drug|GSK2018682|GSK2018682
1710093|NCT01387217|Drug|Placebo|Matched Placebo
1710094|NCT01387204|Drug|GSK1120212|The 2 mg dose is based on clinical data from the ongoing FTIH study in which subjects have been dosed daily for greater than 21 days, as well as preclinical toxicity data.
1710095|NCT01387191|Drug|Epoprostenol|
1710096|NCT01387178|Drug|fluticasone propionate/salmeterol 250µg/50µg (FSC)|Patient records with evidence of COPD and prescription claims for FSC
1710097|NCT01387178|Drug|tiotropium bromide (TIO)|Patient records with evidence of COPD and prescription claims for TIO
1710098|NCT01387165|Drug|Treatment|were receiving an oral hypoglycemic agent (OHA) or insulin
1710099|NCT01387139|Drug|Ketamine|1.0 milligrams/kilogram (mg/kg) ketamine with additional doses of 0.5 mg/kg ketamine as needed (maximum single dose based on 100 kilogram (kg) person)
1710100|NCT01387139|Drug|Ketamine Co-administered with Propofol|0.5 mg/kg ketamine and 0.5 mg/kg propofol with additional doses of 0.25 mg/kg ketamine and 0.25 mg/kg propofol as needed (maximum single dose based on 100 kg person)
1710101|NCT01387126|Dietary Supplement|Novel fibre supplement|The full dose of the study intervention is 15 grams per day.
1710102|NCT01387113|Other|Computed tomography perfusion imaging|As per standard of care at CPMC
1710103|NCT01387100|Behavioral|Vocational Rehabilitation Intervention|Physical or occupational therapist will deliver a vocational rehabilitation intervention using the Work Experience Survey for Persons with Rheumatic Conditions (WES-RC) assessment tool to assess subject's health and vocational background as well as work barriers.
1710104|NCT01387087|Drug|ASP015K|oral
1710106|NCT01387074|Biological|botulinum toxin Type A|Botulinum toxin Type A treatment at a dose determined by the physician at Baseline followed by a second botulinum toxin Type A treatment approximately 12 weeks later if applicable.
1710107|NCT01387061|Procedure|hepatic resection|surgical resection of the liver for multiple HCC
1710108|NCT01387048|Drug|skinoren|gel 15%, twice daily, 36 weeks
1710109|NCT01387048|Drug|differin|0.1% gel, once daily in the evening
1710110|NCT01387048|Drug|skinoren|12 weeks treatment, the following 24 months only observation
1710111|NCT01387022|Drug|Tenofovir, lamivudine and efavirenz|Tenofovir, 300mg daily, lifelong Lamivudine, 300mg daily, lifelong Efavirenz, 600mg daily, lifelong
1710112|NCT01386996|Drug|Budesonide/formoterol Easyhaler 320/9 microg|2 inhalations as a single dose
1710113|NCT01386996|Drug|Symbicort Turbuhaler forte|2 inhalations as a single dose
1710114|NCT01386983|Drug|5ARI|Dutasteride or Finasteride
1710115|NCT01386983|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
1710116|NCT01386970|Drug|zidovudine 300mg and lamivudine 150mg as Combivir|twice daily for 12 days in the HIV-negative group and indefinitely for their care in the HIV-positive group
1710117|NCT01386931|Procedure|EUS-guided FNA performed with on-site Cytopathologist|Patients assigned to the on-site cytopathologist arm will have the cytopathologist dictate the number of FNA passes performed by the endosonographer. This number will be based on the adequacy of specimen and the ability to provide a preliminary diagnosis.
1710118|NCT01386931|Procedure|EUS-guided FNA performed without on-site Cytopathologist|In the absence of an on-site cytopathologist, the endosonographer will perform a predetermined number of 7 passes (standard of care in the absence of an on-site cytopathologist).
1710119|NCT01386918|Device|repetitive Transcranial Magnetic Stimulation|The treatment involves the administration of a magnetic field applied to a specific area of the brain.
1710120|NCT01386905|Device|BAROnova™ TransPyloric Shuttle™ (TPS™)|Subjects will undergo an endoscopic procedure to deliver the TPS™ into the stomach. The TPS™ moves freely without any physical attachment or invasive anchoring to tissue to reduce gastric outflow.
1710121|NCT01386892|Other|No intervention|There is no intervention for this study
1710122|NCT01386879|Drug|methylene blue|A dilute solution of methylene blue (5 ml of 1 % methylene blue solution in saline, 1:1 dilution) will be gently delivered into the hypopharynx using a flexible suction catheter approximately once per hour until trachea is extubated.
1710123|NCT01386866|Drug|AMG 706|Single oral dose of 125 mg AMG 706 (motesanib) containing 100 μCi of [14C]-AMG 706 followed by option to continue onto a treatment extension phase for potential treatment benefit. Subjects will be administered motesanib 125 mg (5 x 25 mg tablets) on a daily basis until subjects experience a dose-limiting toxicity (DLT), an unacceptable AE, disease progression, or voluntary withdrawal.
1710124|NCT01386853|Drug|Pitavastatin|2 mg QD
1710125|NCT01386853|Drug|Atorvastatin|10 mg QD
1710126|NCT01386840|Other|Severe Pneumonia - Home Management|"For those randomized to home management, first dose will be administered by the mother/caretaker under supervision at health facility. The health personnel will assess the parameters like temperature, Respiratory rate, Lower chest indrawing, Pulse rate, clinical deterioration, Other signs eg. co-morbid conditions, Assessment of adherence, Adverse event when they visit the home after 24 hours, 72 hours and on day 8th.
Mothers will be advised to return to the healthcare facility at their scheduled times and any time during the study period if there is clinical deterioration. The symptoms and signs of clinical deterioration will be discussed with the mother as described in the patient discharge counselling checklist. Mothers will be given a study patient data card with contact Numbers."
1710127|NCT01386827|Biological|Mouse brain derived japanese encephalitis vaccine (MB-JEV)|a) 2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 immunization and one booster dose of Ixiaro 0.5 ml > 2 years later
1710128|NCT01386827|Biological|Primary and booster immunizations with MB-JEV|2-3 doses of MB-JEV vaccine 0.5ml given on day 0, 7, 30 as primary immunization and one booster dose of 0.5 ml > 2 years later
1710129|NCT01386827|Biological|C) primary immunizations with Ixiaro|2 0.5 ml doses of Ixiaro 28 days apart
1710130|NCT01386827|Biological|S) Ixiaro booster to MBJEV primed|0.5ml Ixiaro to volunteers previously primed with 2-3 doses of MB-JEV
1710131|NCT01386788|Other|There is no intervention planned (observational)|No intervention foreseen
1710132|NCT01386762|Other|Exercise training|6 months of intense multi-modal exercise consisting of vibration exercise, gait training, electrical stimulation, etc.
1710133|NCT01386749|Procedure|vibration platform provide low magnitude and high frequency vibration treatment, which is self-developed by our research team|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5days/week
1710134|NCT01386736|Drug|Vitamin D drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
1710135|NCT01386736|Drug|Placebo drops|Subjects will be randomly assigned to Vitamin D 3,000 Units per day or Placebo drops.
1710136|NCT01386723|Drug|Discontinuation of eltrombopag|Observation of subjects as they discontinue the use of eltrombopag
1710137|NCT01386710|Drug|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier
Day 28: Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until disease progression on MRI scan.
If progression occurs, repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) plus Carboplatin (AUG5) every two weeks thereafter until progression on MRI scan.
Repeat Cycle"
1710138|NCT01386710|Drug|Bevacizumab and Carboplatin|"Day 0: Intraarterial Bevacizumab single dose (15mg/kg) plus Intraarterial Carboplatin (150mg/m2) after Mannitol to open the blood brain barrier
Day 28: No biweekly IV Bevacizumab plus Carboplatin treatment
If MRI shows progression then repeat intraarterial Bevacizumab single dose (15mg/kg) plus intraarterial Carboplatin (150mg/m2) to area of progression Repeat Cycle"
1710139|NCT01386671|Drug|Metformin glycinate|Drug: Metformin glycinate 12 months: 1 month,one tablet 1050.6 mg once daily + 11 months, one tablet 1050.6 mg twice daily
1710140|NCT01386671|Drug|Metformin hydrochloride|12 months: 1 month, once daily dose of 850 mg (before dinner) and 11 months, twice daily dose 850 mg (before breakfast) + 850 mg (before dinner).
1710141|NCT01386658|Drug|icatibant|Single dose of icatibant 0.4 mg/kg subcutaneous(SC) up to a maximal dose of 30 mg
1710142|NCT01386645|Other|low glycemic index diet|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable low glycemic index diet (glycemic index <35) for 4 weeks with all food provided by the Human Nutrition Lab
1710143|NCT01386645|Other|high glycemic index diet plus placebo|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take placebo capsules (matching for active N-acetylcysteine (NAC) in arm 3) twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
1710144|NCT01386645|Drug|high glycemic index diet plus N-acetylcysteine|Following a 2 week medium glycemic index control diet (glycemic index 50-55), subjects will be provided with a weight stable high glycemic index diet (glycemic index >70) for 4 weeks, all food provided by the Human Nutrition Lab. They will take N-acetylcysteine (NAC) two 600 mg capsules twice daily for the 4 weeks on the high GI diet. The NAC vs. placebo arms (arms 2 and 3) will be double-blinded.
1710145|NCT01386632|Drug|DCA (dichloroacetate)|DCA orally 12.5mg/kg PO or per G-tube BID daily for 8 weeks in conjunction with Cisplatin 100 mg/m^2 IV over 30-60minutes every 3wks X 3(Days 1, 22, and 43 of RT)and RT 70 Gy/35 -200 cGy/d x 7 weeks (35 Fractions)
1710146|NCT01386632|Drug|Placebo|Placebo PO or per G-tube twice a day for 8 weeks given in combination with Cisplatin.
1710147|NCT01386619|Biological|CD3-depleted/CD56+ selected natural killer cells collected from apheresis products|NK DLI products containing >1 10e7 NK cells/kg bodyweight (BW) and < 1 x 10e5 T-cells/kg BW are administered at days +4 (Frankfurt only), and on days +40 and +100 (both centers)
1710148|NCT01386606|Drug|Androxal (enclomiphene citrate)|"capsule oral
1X a day 6 weeks"
1710149|NCT01386606|Drug|Testosterone|"topical gel
1X a day 6 weeks"
1710150|NCT01386593|Drug|Basel cocktail+(Fluconazole, Ciprofloxacin, Paroxetine)|
1710151|NCT01386593|Drug|"Basel Cocktail"|
1710152|NCT01386593|Drug|Basel cocktail + Rifampicin|
1710153|NCT01386580|Drug|2B3-101|IV every 21 days
1710154|NCT01386580|Drug|Trastuzumab|IV every 21 days
1710155|NCT01386580|Drug|2B3-101 60 mg/m2 every 4 weeks|IV every 28 days
1710156|NCT01386580|Drug|2B3-101 50 mg/m2 every 3 weeks|IV every 21 days
1710157|NCT01386567|Drug|Androxal (enclomiphene citrate)|"capsules oral 1x a day
1 year"
1710158|NCT01386567|Drug|Testim (topical testosterone)|"topical
1 tube
1x a day
1 year"
1710159|NCT01386554|Drug|Repository Corticotropin Injection|Acthar (80 U two times per week) given SC for 6 months
1710160|NCT01386554|Drug|Placebo|"Placebo contains the same inactive ingredients as that used for H.P. Acthar Gel without the API.
Placebo given SC for 6 months (80 U two times a week)."
1710161|NCT01386541|Drug|BYK324677|capsules, administered orally
1710162|NCT01386528|Drug|nonacog beta pegol|The patients will receive nonacog beta pegol at screening just prior to and during surgical intervention, administered intravenously (into the vein).
1710163|NCT01386502|Biological|p53: 264-272 peptide|
1710164|NCT01386502|Drug|CT-011|
1710165|NCT01386489|Biological|VRC-HIVDNA016-00-VP|
1710166|NCT01386489|Biological|VRC-HIVADV014-00-VP|
1710167|NCT01386411|Genetic|BRCA testing and questionnaire assessments|If they consent to enroll, they will complete an instrument evaluating their beliefs regarding the value of genetic testing (Assessment 1). After that, they will decide whether they wish to attend an information session on genetic predisposition. If they do, after completing that information session they will complete a follow-up instrument (Assessment 2), and will then decide to either immediately donate a sample for immediate testing, or to defer the decision until after surgery. Women will be given the results of their genetic testing in the context of a standard results counseling session, after which they will continue with clinical care. They will be followed for clinical decision, especially whether or not they undergo CPM.
1710168|NCT01386398|Drug|bortezomib|
1710169|NCT01386398|Drug|vorinostat|
1710170|NCT01386398|Other|laboratory biomarker analysis|
1710177|NCT01386372|Drug|Tolvaptan|Patients will receive full-dose oral tolvaptan therapy up to 1 month after randomization. During the initial 4 days of therapy, the dose of the study drug will be increased from 15 to 30 mg or from 30 to 60 mg according to a regimen designed for slow correction of serum sodium concentrations to 135 mEq/L or more Depending on the serum sodium concentration the dose will be increased or decreased. Patients will then be continued on their maintenance therapy with adjustments allowed to prevent hyponatremia and avoiding hypernatremia. As soon as normal serum sodium levels are achieved in at least two consecutive measurements the dose of the study drug will be progressively tapered according to an individually tailored weaning program
1710178|NCT01386372|Other|Standard therapy|Fluid restriction, normal or hypertonic saline, furosemide.
1710180|NCT01386346|Drug|Azacitidine|Dose level -1: 50 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 1: 75 mg/m2 subcutaneous injection on Day 1-3 of a 21 day cycle. Repeat for a total of 3 cycles. Dose level 2: 75 mg/m2 subcutaneous injection on Day 1-5 of a 21 day cycle. Repeat for a total of 3 cycles.
1710181|NCT01386346|Drug|Oxaliplatin|130 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
1710182|NCT01386346|Drug|Epirubicin|50 mg/m2 IV on Day 3 or 5 of each 21 day cycle. Repeat for a total of 3 cycles.
1710183|NCT01386346|Drug|Capecitabine|625 mg/m2 orally twice daily beginning on Day 3 or 5 and will be taken without interruption for each 21-day cycle.
1710184|NCT01386333|Drug|oxytocin|Patients will be randomized to receive intranasal oxytocin or placebo in a dose escalation paradigm with three dose cohorts: 24IU, 48IU and 72IU of intranasal oxytocin twice daily for 1 week
1710185|NCT01386333|Drug|Saline Nasal Mist|Placebo arm wil receive saline nasal mist sprays matched in number to oxytocin dose cohorts
1711399|NCT01376284|Drug|Dutasteride|Collection of safety data
1710186|NCT01386320|Procedure|Ultrasound guided ankle block|Under ultrasound guidance, block of the tibial nerve, superficial and deep branches of the common peroneal nerve and saphenous nerves will be carried out using 12 mls 0.5% levobupivacaine and 12 mls 0.75% levobupivacaine.
1710187|NCT01386320|Procedure|Medial forefoot block|Using peripheral nerve stimulator guidance, the tibial and common peroneal nerves will be blocked ( plus the saphenous nerve ), using a total of 12 mls 0.75% levobupivacaine and 12 mls 0.5% levobupivacaine.
1710188|NCT01386294|Drug|Tenofovir gel|Tenofovir gel is a clear, transparent, viscous gel at concentrations of 1% formulated in purified water with edentate disodium, citric acid, glycerin, methylparaben, propylparaben, HEC, and pH adjusted to 4-5. Tenofovir gel will be supplies in a 4 ml single use applicator containing approximately 4 grams of gel, equivalent to approximately 40mg of tenofovir.
1710189|NCT01386294|Drug|Universal placebo gel|The placebo gel is an inert gel containing HEC as the gelling agent, purified water, sodium chloride, sorbic acid and sodium hydroxide. Each applicator contains approximately 4ml of placebo gel
1710190|NCT01386281|Drug|E2 transdermal (Julina, BAY86-5435)|Patients in daily life treatment receiving Julina for postmenopausal osteoporosis
1710191|NCT01386268|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients with diagnosis of hemophilia A, treated with KOGENATE FS as their only source of FVIII, decision taken by the investigator to administer KOGENATE FS
1710192|NCT01386255|Drug|Baclofen|The final baclofen dose will be 0.7 mg/kg (to a maximum of 40 mg/day) divided in three doses.
1710193|NCT01386255|Drug|placebo|placebo. No other names
1710194|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection,10μg,im,twice per week for first 2 weeks, followed by 20μg, im, twice per week after 2 weeks
1710195|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg/1mL,im,three times per week for first 2 weeks, followed by 20μg,im, three times per week after 2 weeks.
1710196|NCT01386242|Other|Saline Injection|Saline Injection, 1mL, im,three times per week
1710197|NCT01386242|Drug|Recombinant anti-tumor and anti-virus protein for injection|Recombinant anti-tumor and anti-virus protein for injection, 10μg, im, three times per week for first week, followed by 20μg for two weeks, and followed by 30μg for a week, and followed a maintenance dose of 40μg, the frequency of administration is three times per week.
1710198|NCT01386229|Drug|Ketamine|During standard anesthesia induction with fentanyl and midazolam, ketamine 2 mg/kg IV will be administered
1710199|NCT01386229|Drug|Etomidate|During standard anesthesia induction with fentanyl and midazolam, etomidate 3 mg/kg IV will be administered
1710200|NCT01386216|Device|Magellan®|Autologous Bone Marrow Cell Concentrate Prepared Using the Magellan System to be injected into the ischemic muscle tissue at 0.5 cc/injection for a total of 12-20 cc.
1710201|NCT01386190|Other|Exercise/Social Behavioral|Both the control and the intervention groups will be guided in implementing structured social interaction. In the intervention group, the structured interaction will incorporate augmented physical activities, while in the control group, the structured interaction will consist of predominantly social activities such as the caregiver reading or singing to the baby. The duration of the structured activities for both groups will be the same.
1710202|NCT01386177|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
1710203|NCT01386177|Drug|Doxazosin|"3 days (-64h) before MDMA: 4 mg doxazosin per os. 2 days (-40h) before MDMA: 8 mg doxazosin per os.
1 day (-16h) before MDMA: 8 mg doxazosin per os."
1710204|NCT01386177|Drug|placebo|capsules identical to MDMA or doxazosin
1710205|NCT01386164|Biological|Gardasil|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
1710206|NCT01386164|Biological|Cervarix|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
1710207|NCT01386151|Drug|Keratinocyte Growth factor|KGF will be administered intravenously in a 'collapsed dose' regime of 180ug/kg on day 0 and day 11
1710208|NCT01386151|Drug|Saline placebo|Normal (0.9%) saline will be used as a placebo.
1710209|NCT01386138|Behavioral|Psycho-education|Receive RBT education and peer-support in a group format.
1710210|NCT01386138|Behavioral|Experimental|Receive RBT education and a pro-active counseling method
1710211|NCT01386125|Drug|Mometasone Furoate Nasal Spray (MFNS)|MFNS, 200 mcg BID administered as two 50 mcg sprays in each nostril BID for up to 16 weeks
1710212|NCT01386125|Drug|Placebo for MFNS|Two sprays in each nostril BID for up to 16 weeks
1710213|NCT01386112|Drug|EUR-1100|Active oral medication
1710214|NCT01386112|Drug|placebo|matching placebo
1710215|NCT01386099|Drug|PSN821|Three PSN821 dose groups: PSN821 75mg twice a day, 250mg twice a day and 625mg twice a day for 12 weeks.
1710216|NCT01386099|Drug|Placebo|Placebo twice a day for 12 weeks.
1710217|NCT01386086|Drug|aripiprazole|The starting dose of aripiprazole will be 2 mg and the dose adjusted to a maximum of 15 daily
1710218|NCT01386073|Drug|FreshKote|Three times a day for three months
1710219|NCT01386073|Drug|Systane|three times a day for three months
1710220|NCT01386060|Other|Mindfulness Meditation Training|One-on-one mindfulness meditation training, 6 weeks, 1 1/2 hour training once per week, 30-45 min at-home practice per day.
1710221|NCT01386047|Other|Integrated Clinical Prediction Rule (iCPR)|Integrated clinical prediction rule for Strep Pharyngitis based on Walsh clinical prediction rule (CPR) criteria and rule for Pneumonia based on Hecklering CPR criteria.
1710222|NCT01386034|Drug|Citrulline and placebo|After receiving a 7-day oral supplementation with either citrulline or placebo, each subject will be admitted for a half day, after an overnight fast, and will receive a 5-h intravenous infusion of L-[1-13C]leucine. At regular intervals throughout the isotope infusion, blood will be obtained to measure 13C-enrichment in plasma a-keto-isocaproate, using gas chromatography-mass spectrometry. Simultaneously, 13C-enrichment will be measured in aliquots of expired air CO2 using isotope ratio mass spectrometry, and total CO2 production (VCO2) will be measured using direct calorimetry, respectively. Then the subject take no treatment for 13 days. The study will then be repeated a second time in an identical fashion, after a second 7-day period of oral supplementation with either citrulline or placebo.
1711400|NCT01376271|Drug|Paroxetine|
1710224|NCT01386008|Device|investigational enfilcon A|investigational enfilcon A, worn daily wear modality
1710225|NCT01385995|Device|Continuous Positive Airway Pressure (CPAP) (Philips-Respironics RemStar Pro® CPAP)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
1710226|NCT01385995|Device|Sham-Continuous Positive Airway Pressure (CPAP) (Philips-Respironics)|Subjects will be randomized to 8 weeks of CPAP or sham-CPAP, followed by the alternate therapy after a one month wash-out.
1710227|NCT01385982|Other|Actionable Test Result Management/Standardization|The intervention includes enterprise-wide standardization of actionable test result (ATR) definitions with stratification of significant results into alert levels, expected timeframes for clinician responses, a set of policies for ATR follow-up, metrics to measure ATR management and performance feedback.
1710228|NCT01385969|Device|Standard inflation of LMA cuff|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by manual palpation of the cuff per standard practice.
1710229|NCT01385969|Device|Pressure check with syringe recoil|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by syringe recoil
1710230|NCT01385969|Device|Pressure check by pressure transducer|LMA cuff will be inflated per standard practice with a syringe and resulting cuff pressure will be measured by pressure transducer.
1710231|NCT01385956|Drug|SOM 230 LAR|We will attempt dose escalation starting at a lower level 1 of 40 mg since we are using SOM 230 LAR in combination with gemcitabine for the first time.
1710232|NCT01385956|Drug|Gemcitabine|Fixed dose: 1000mg/m^2 weekly x3 then 1 week off
1710233|NCT01385930|Behavioral|Lifestyle counseling|Lifestyle counseling
1710234|NCT01385891|Drug|Clofarabine VP 16 ciclophospahamide|Clofarabine intravenously 2-hour infusion,dose 40 mg/m2, followed by Etoposide (VP 16)100 mg/m2 i.v. over 2 hours and Cyclophosphamide 440 mg/m2 i.v. over 1 hour
1710239|NCT01385865|Dietary Supplement|Mulberry leaf extract|18 tablets/day (6 tablets/serving x 3servings/day, mulberry leaf extract 336mg/1 tablet (800mg), 1-Deoxynojirimycin 4.3mg/1 g mulberry leaf extract), Duration: 4 weeks
1710240|NCT01385865|Dietary Supplement|Placebo|18 tablets/day (6 tablets/serving x 3servings/day, lactose 511mg/1 tablet (650mg)), Duration: 4 weeks
1710241|NCT01385852|Procedure|microcoaxial phacoemulsification|conventional longitudinal ultrasound
1710242|NCT01385839|Procedure|Hair transplantation|Hair transplantation is a procedure in which donor hair follicles are harvested from a section of a patient's scalp, and transplanted in another bald recipient area, at which time it will take root and continue to grow. Hairs generally continue to grow indefinitely.Hair transplant involves mild sedation with Valium, followed by local anesthesia of the donor and recipient areas. Donor hair is harvested using a scalpel to cut narrow strips of hair bearing areas. Follicular units are obtained by slicing the donor tissue into naturally occurring groupings. The follicular units are placed into holes made by a hypodermic needle in the alopecia areata affected areas of the subject. Grafts are held in place by coagulated blood. A bandage is applied after the procedure and left in place over night. The following day, the patient returns for follow up, bandage removal, cleansing, hair washing, and a check up.
1710243|NCT01385839|Procedure|Hypodermic needle irritation|In the areas which are simply treated with irritation with the hypodermic needle, the procedure is the same, except no follicular units are placed into the holes.
1710244|NCT01385826|Drug|Anti-tumor necrosis factor alpha monoclonal antibody|The dose of adalimumab will be 40 mg for children age 13 and over and for children younger than 13 adalimumab 24 mg per m2 BSA (up to a maximum total body dose of 40 mg).
1710245|NCT01385826|Drug|placebo|Patients will receive 4 injections of placebo on D0, D14, D28, and D42 with assessment of the primary endpoint at M2
1710246|NCT01385800|Biological|ToleroMune Grass|Intradermal injection 1 x 8 administrations 2 weeks apart
1710247|NCT01385800|Biological|Placebo|Intradermal injection 1 x 8 administrations 2 weeks apart
1710248|NCT01385774|Procedure|Percutaneous Transluminal Angioplasty|The Percutaneous Transluminal Angioplasty (PTA) procedure will be performed by an experienced interventional radiologist using a conventional guide wire and balloon catheter technique. A stent will be placed in cases in which the residual mean pressure gradient is greater than 10 mmHg across the treated site or when more than 30% stenosis after the procedure is detected. All PTA patients are encouraged perform at least three walking sessions every day.
1710249|NCT01385774|Other|Supervised Exercise Therapy|Supervised Exercise Therapy (SET) will take place in the hospital or community based according to the guidelines of the Dutch Society for Physiotherapists. The duration of the treatment will be at least 6 months and with a frequency of 2 times a week for at least 60 minutes and an intensity near maximum pain barrier (defined as pain of which it is not possible to be distracted). The frequency of the training will decrease after 3 months and the patients will receive homework, make a plan and keep a log of their exercise activities. Furthermore the program consists of walking pattern improvement and enhancement of endurance and strength. All SET patients are encouraged to perform at least three walking sessions every day on their own.
1710250|NCT01385761|Device|Laryngeal Mask Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
1710251|NCT01385761|Device|air-QTM Intubating Laryngeal Airway|Each child will be randomized to either receiving the LMA or air-Q ILA-SP as their supraglottic airway device for primary airway maintenance.
1710252|NCT01385748|Drug|Clonidine Lauriad® 50µg|50µg muco-adhesive buccal tablet once day every day up to 8 weeks
1710253|NCT01385748|Drug|Clonidine Lauriad® 100µg|100µg muco-adhesive buccal tablets, once a day, every day up to 8 weeks
1710254|NCT01385748|Drug|Placebo Lauriad®|placebo muco-adhesive buccal tablets, once a day, every day up to 8 weeks
1710255|NCT01385735|Drug|Rasagiline|Azilect Group: Dose: 1 mg per day, 12 week (84 days) duration
1710256|NCT01385735|Drug|Placebo|Placebo 1 Tbl per day, 12 week (84 days) duration
1781789|NCT00453050|Drug|imiquimod|
1710257|NCT01385696|Device|Genuair® (Almirall S.A.)|Inhaler with only placebo, once daily, 14 days
1710258|NCT01385696|Device|HandiHaler® (Boehringer Ingelheim's)|Inhaler with only placebo, once daily, 14 days
1710259|NCT01385683|Drug|Dabigatran then dabigatran and clarithromycin|D4 : dabigatran 300 mg (4 tablets) one time. D8 to D10 : Clarithromycin 500mg (1 tablet) twice daily. D11 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets)
1710260|NCT01385683|Drug|Clarithromycin and dabigatran then dabigatran|D1 to D3 : Clarithromycin 500mg (1 tablet) twice daily. D4 : Clarithromycin 500mg (1 tablet) + 300mg dabigatran (4 tablets). D11 : dabigatran 300 mg (4 tablets) one time.
1710261|NCT01385670|Device|Transcatheter PFO closure with the SeptRx Intrapocket PFO Occluder (IPO)|Transcatheter PFO closure
1710262|NCT01385657|Drug|REGN668 (SAR231893)|Dose 1 or placebo
1710263|NCT01385657|Drug|REGN668 (SAR231893)|Dose 2 or placebo
1710264|NCT01385644|Other|Placental MSC|MSC will be derived from mothers donating their term placenta for clinical trial research purposes at Mater Mothers Hospital, Brisbane. The donation, isolation and expansion of placental-derived MSC for research purposes has been approved by the Mater Health Services (MHS) Human Research Ethics Committee (Reference No. 1292A). These volunteer donor mothers are unrelated to and will be HLA-unmatched with the IPF recipients.
1710265|NCT01385631|Drug|Ezetimibe|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
1710266|NCT01385631|Drug|Placebo|100 patients with ST elevation myocardial infarction are randomized 1:1 to either placebo or Ezetimibe 10 mg per day in addition to treatment with Atorvastatin 80 mg in both arms.
1710267|NCT01385592|Drug|AFQ056|
1710268|NCT01385592|Drug|Placebo|
1710269|NCT01385579|Other|Care manager outreach|Patients assigned to the intervention arm are mailed a letter informing them that they are due for colorectal cancer screening, educational information about colorectal cancer screening, a fecal occult blood testing (FOBT) kit, and directions on how to complete and return the FOBT kit. Patients who do not respond to the mail outreach received up to 3 attempts at telephone outreach by the care manager.
1710270|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous|One 0.65 mL injection subcutaneously on Day 1
1710271|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous|One approximately 0.22 mL injection subcutaneously on Day 1
1710272|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal|Two intradermal injections of approximately 0.15 mL each on Day 1
1710273|NCT01385566|Biological|ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal|One intradermal injection of approximately 0.1 mL on Day 1
1710274|NCT01385566|Biological|Full Dose Intradermal Placebo|Two intradermal placebo injections of approximately 0.15 mL each on Day 1
1710275|NCT01385566|Biological|Intradermal Placebo|One intradermal placebo injection of approximately 0.1 mL on Day 1
1710276|NCT01385553|Behavioral|Fathers for Change|FATHERS FOR CHANGE comprises 16, 60 minute sessions of treatment utilizing components of three evidence based practices: SADV-Cognitive Behavioral Therapy, Behavioral Couple Therapy and Child-Parent Psychotherapy. The goals of the intervention are: 1) decreased substance abuse and IPV by teaching coping and anger management skills, 2) improved communication and increased problem solving around shared parenting 3) parenting education including child development and the impact of violence on children, 4) discussion of discipline practices and development of behavior modification or positive reinforcement plans, and 5) attachment focused parent-child play sessions to coach fathers in play with their children and process traumatic experiences.
1710277|NCT01385553|Behavioral|Individual Drug Counseling|Individual drug counseling focuses on the symptoms of drug addiction and related areas of impaired functioning and the content and structure of the patient's ongoing recovery program. This model of counseling is time limited and emphasizes behavioral change. It gives the patient coping strategies and tools for recovery and promotes 12-step ideology and participation. The primary goal of addiction counseling is to assist the addict in achieving and maintaining abstinence from addictive chemicals and behaviors. The secondary goal is to help the addict recover from the damage the addiction has caused in his or her life.
1710278|NCT01385540|Behavioral|Task-Based Functional Magnetic Resonance Imaging (fMRI)|Individuals will be shown a target, which is randomly selected from 12 objects designated as targets, before each scan. The target for a scan will never appear as a non-target object in another scan. Per established protocol, individuals will fixate on a central cross prior to imaging. Individuals will press a MR-compatible button when they detect the target. Target objects only appear in the cued stream. Cues, a filled red square, are programmed to occur, on average, every 2.06, 4.12, or 6.18 seconds within a temporal window of ± 400 milliseconds centered on those values.
1710281|NCT01385501|Other|Video intervention along with educational hand out|The interventional group will be shown an 8 minute video addressing common concerns of vaccine hesitant parents. Then, they will be provided with a handout describing how to find accurate vaccine information on the internet and a handout on more common questions from vaccine hesitant parents.
1710282|NCT01385488|Behavioral|self-monitor arm volume|bioelectrical impedance
1710283|NCT01385475|Behavioral|RT|8 week RT Intervention
1710284|NCT01385449|Procedure|interscalene catheter|interscalene catheter
1710285|NCT01385449|Procedure|interscalene block|interscalene block
1710286|NCT01385423|Drug|Preparative Regimen|Fludarabine 25 mg/m^2 x 5 days start day -6, Cyclophosphamide 60 mg/kg x 2 days on day -5 and -4 (*if < 4 months from prior transplant, omit day -4 dose)
1710287|NCT01385423|Biological|Intravenous Recombinant Human IL-15 (rhIL-15)|IL-15 at assigned dose (0.25, 0.5, 0.75 1, 2 and 3 mcg/kg for 3 to 6 patients) intravenously (IV) over 30 minutes once a day beginning day +1 and continuing for 12 doses
1710288|NCT01385410|Behavioral|Peer mother support for continued exclusive breastfeeding|Peer counselling on breastfeeding beginning in third trimester and continuing until 3 months postpartum
1710289|NCT01385397|Other|Preceptorship and virtual community|
1710376|NCT01384812|Drug|isoton sodium chloride|intravenous injection for 25 min
1710642|NCT01382589|Device|NB-UVB|NB-UVB light therapy 3-times per week, for total of 72 treatments
1710290|NCT01385384|Device|NeuRx RA/4 diaphragmatic pacemaker|"Patients will be implanted with 4 intramuscular electrodes, 2 in each hemi-diaphragm, using laparoscopic techniques.
The abdominal cavity is inflated with CO2 and 4 ports are inserted: one for optics, 2 for a probe containing a temporary electrode for mapping the diaphragm and the electrode insertion tool, and a smaller one for the output wires of the electrodes of the abdominal cavity. The intra-abdominal pressure variation during the stimulation test (mapping) will be measured externally by one of the ports.
Sites that provide the optimal response (greater region and magnitude) are noted.
Once the optimal site for electrode placement is identified two intramuscular electrodes are deployed in each hemi-diaphragm. The guide wires will come out of the peritoneum through the port placed in the xiphoid region. An additional electrode is placed subcutaneously in the upper abdomen. The instruments and ports are then removed and the incision sites closed."
1710291|NCT01385371|Biological|Grass (Phleum pratense) pollen allergen extract|One dissolving tablet sublingually once daily
1710292|NCT01385371|Biological|Placebo for SCH 697243|One dissolving tablet sublingually once daily
1710293|NCT01385358|Procedure|Thoracoscopically Assisted Surgical Ablation|Surgical AF ablation including pulmonary vein isolation, gananglionated plexi ablation +/- LAA excision/exclusion.
1710294|NCT01385358|Procedure|Catheter Ablation|In this arm, study subjects will undergo conventional catheter ablation as their index procedure. This will include pulmonary vein isolation, linear and electrogram based ablation.
1710295|NCT01385345|Drug|Vitamin D3 cholecalciferol|High dose Vitamin D3 (200,000 units followed by 100,000 units x 3 over 6 months) plus daily 1,000 units Vitamin D3 per day vs only daily 1,000 units Vitamin D3 per day
1710296|NCT01385332|Procedure|Early luteal phase|We will administer in the tenth day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
1710297|NCT01385332|Procedure|Late follicular phase -COH-|We will administer in the 20th day of the cycle 0.25mg/day of ganirelix until the estradiol levels will be less than 60pgr/mL. Then, we'll start a standard protocol of controlled ovarian hyperstimulation beginning with 150 UI/day. At 6th day of stimulation we'll begin with the antagonist.
1710298|NCT01385319|Device|Bare metal stent implantation|"After BMS implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient as follows:
Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.
Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.
Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
1710299|NCT01385319|Device|zotarolimus eluting stent|"After ZES implantation the duration of dual anti-platelet therapy is a function of the clinical presentation and the bleeding risk a given patient (i.e. identical to criteria set out for BMS patients) as follows:
Clopidogrel will be given for 1 month after PCI if indication to the procedure is stable coronary artery disease or for at least 6 month if indication to the procedure is ACS, including STEMI or NSTEACS. At discretion of the treating physician, prasugrel or ticagrelor may replace clopidogrel in ACS patients.
Patients recruited in the study due to high bleeding risk will receive clopidogrel for at least 30 days.
Patients recruited in the study due to high thrombosis risk will receive clopidogrel monotherapy life long or DAPT for at least 1 month."
1710300|NCT01385306|Device|AlphaCore System|Non-invasive neurostimulation of the vagus nerve
1710301|NCT01385293|Drug|BKM120|BKM120 at the maximum tolerated dose (MTD) of 100mg orally daily
1710302|NCT01385280|Biological|therapeutic estradiol|Given orally (PO)
1710303|NCT01385280|Drug|exemestane|Given PO
1710304|NCT01385280|Other|laboratory biomarker analysis|Correlative studies
1710305|NCT01385280|Other|enzyme-linked immunosorbent assay|Correlative studies
1710306|NCT01385267|Procedure|aspiration of amniotic fluid|a sample of amniotic fluid will be drawn from the amniotic sac of Twin A and Twin B. Each amniotic sac will be aspirated by the obstetrician and sent to the laboratory for determination of fetal lung maturity index and lamellar body count.
1710307|NCT01385241|Behavioral|Ipod video|This group will be asked to watch the video on their Ipod Touch in its entirety at least once per week during the first four weeks of the study, and as often as desired in weeks 5-12. The participants will be asked to record the times viewed and their feelings/comments in a viewing log, and will be given surveys at 30 and 90 days.
1710308|NCT01385228|Drug|Pazopanib|"Dose Level Xa - daily administration of pazopanib on days 1 through 21 starting at 400mg with a maximum dose of 1000mg."
1710309|NCT01385228|Drug|Docetaxel|Docetaxel given IV on Day 1 starting dose 60mg/m2 increase to 75mg/m2
1710310|NCT01385228|Drug|Pazopanib|"Dose Level Xb - daily administration of pazopanib on days 3 through 19 starting at 400mg with a maximum dose of 1000mg."
1710311|NCT01385228|Drug|Prednisone|5mg Prednisone given twice daily days 1-21.
1710312|NCT01385228|Drug|Pegfilgrastim|
1710313|NCT01385215|Drug|Fluzone|0.5 ml/15 micrograms
1710314|NCT01385215|Drug|Fluzone|0.5 ml/60 micrograms
1710315|NCT01385202|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
1710316|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
1710317|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
1710318|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
1710319|NCT01385189|Biological|10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses 10 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
1710320|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg)|3 doses of 30 μg Na-GST-1/Alhydrogel/GLA-AF (1 μg) administered at 56 day intervals
1710321|NCT01385189|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
1710322|NCT01385189|Biological|100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg)|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF (5 μg) administered at 56 day intervals
1710451|NCT01384188|Drug|ONO-5334|150 mg for 5 days administered in the morning or in the evening
1710324|NCT01385163|Behavioral|Treatment as usual|Standard psychosocial counseling
1710325|NCT01385163|Behavioral|Voluntary Savings/Loans Assoc|economic intervention for group savings and loans
1710326|NCT01385163|Behavioral|Cognitive Processing Therapy|group 12 session intervention
1710327|NCT01385150|Genetic|mutation analysis|
1710328|NCT01385150|Genetic|protein analysis|
1710329|NCT01385150|Other|laboratory biomarker analysis|
1710330|NCT01385150|Other|liquid chromatography|
1710331|NCT01385150|Other|mass spectrometry|
1710332|NCT01385137|Dietary Supplement|omega-3 fatty acid|Given orally
1710333|NCT01385137|Other|placebo|Given orally
1710334|NCT01385124|Drug|Oral Cannabidiol|Cannabidiol will be dissolved in oil to a predefined concentration. Patients will be given oral cannabidiol 10 mg twice daily from conditioning starting day and until day +30 after allogeneic transplantation.
1710335|NCT01385111|Procedure|EUS-B-FNA followed by EBUS-TBNA|EUS-B-FNA will be performed followed by EBUS-TBNA when additional needle aspiration is necessary after EBUS-TBNA.
1710336|NCT01385111|Procedure|EBUS-TBNA followed by EUS-B-FNA|EBUS-TBNA will be performed followed by EUS-B-FNA when additional needle aspiration is necessary after EUS-B-FNA
1710338|NCT01385072|Biological|Double matched sibling transplantation|"Patients with poor risk active acute leukemia and who have 2 matched sibling donors can be included. Patients' conditioning may be myeloablative or non-myeloablative. Both matched donors will be mobilized with G-CSF and their peripheral blood stem cells will be collected on day 0.Equal numbers of CD34+ cells from both donors will be transfused to the patient.
Patients will be followed for engraftment kinetics, chimerism, GVHD rate, severity and response to treatment, relapse rates, DFS and OS."
1710339|NCT01385059|Drug|axitinib|Given PO
1710340|NCT01385059|Procedure|therapeutic conventional surgery|Undergo prostatectomy and pelvic lymph node dissection
1710341|NCT01385059|Other|enzyme-linked immunosorbent assay|Correlative studies
1710342|NCT01385059|Other|laboratory biomarker analysis|Correlative studies
1710343|NCT01385046|Behavioral|Project Fit|physical activity and nutrition education
1710344|NCT01385033|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
1710345|NCT01385020|Drug|Gemfibrozil & red yeast rice (LipoCol)|The effect of gemfibrozil on the pharmacokinetics of red yeast rice capsule (LipoCol) after administering single-dose combination in healthy subjects.
1710346|NCT01385007|Behavioral|Preventing Aggression in Veterans with Dementia (PAVeD)|PAVeD-Telephone consists of three components: pain-management strategies, improvement of patient-collateral communication skills, and behavioral activation through increased pleasant activity planning. The intervention will be primarily geared toward the caregiver; but patients may be involved in some modules, depending on their dementia severity and willingness. The goal of the sessions is to prevent aggression in veterans with dementia. The sessions will include didactics, skill-building, and discussion. Participants will also be provided a copy of the book, Pain Management for Older Adults: A Self-help Guide, as an additional resource for optional reading on the topics covered in the intervention. The intervention is proposed to include six to eight sessions of weekly treatments, lasting 30 minutes to 45 minutes, specifically developed to address the recognition and management of pain in persons with dementia.
1710347|NCT01384994|Drug|Folic Acid|400 mg/m2, 2h infusion, d1, q2w
1710348|NCT01384994|Drug|5-FU|400 mg/m2 bolus iv, d1, q2w
1710349|NCT01384994|Drug|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
1710350|NCT01384994|Drug|Oxaliplatin|85 mg/m2 d1, q2w
1710351|NCT01384994|Drug|Panitumumab|6 mg/kg BW every 2 weeks
1710352|NCT01384994|Drug|Panitumumab|Panitumumab maintenance phase (3 months) 9mg/kg BW every 3 weeks
1710353|NCT01384994|Drug|Folic Acid|400 mg/m2, 2-h infusion, d1, q2w
1710354|NCT01384994|Drug|5-FU|400 mg/m2 bolus iv, d1, q2w
1710355|NCT01384994|Drug|5-FU|2400 mg/m2 46-h infusion, d1-2, q2w
1710356|NCT01384994|Drug|Oxaliplatin|85 mg/m2 d1, q2w
1710357|NCT01384981|Procedure|pulmonary rehabilitation|
1710358|NCT01384968|Dietary Supplement|beetroot juice|170 mL beetroot juice (Beet It, James White drinks Ltd).
1710359|NCT01384942|Behavioral|Meaning-Based Bereavement Group|A 12 week bereavement counselling group with tasks and themes that focus on re-constructing meaning following death.
1710360|NCT01384942|Behavioral|Conventional Bereavement Group|An 8 week traditional bereavement group that follows a more conventional approach to grief support.
1710361|NCT01384916|Behavioral|Yoga|2x weekly
1710362|NCT01384916|Behavioral|Healthy Living Workshop|2x weekly
1710363|NCT01384903|Drug|KW-3357|Intravenous infusion once a day
1710364|NCT01384903|Drug|Plasma-derived antithrombin|Intravenous infusion once a day
1710365|NCT01384890|Radiation|VMAT with CBCT|volumetric modulated arc therapy (VMAT) with cone-beam computed tomography (CBCT) position verification
1710366|NCT01384890|Radiation|VMAT with kV-ray|Volumetric modulated arc therapy (VMAT) with kV-ray position verification
1710367|NCT01384877|Drug|Lidocaine|10mg/kg by subcutaneous infusion over 5.5 hours
1710368|NCT01384877|Drug|Placebo (normal saline)|Same volume as for lidocaine infusion, identical clear liquid in appearance, given in same device over same time period (5.5 hrs)
1710369|NCT01384864|Drug|proflavine|2-6 ml of 0.01% proflavine
1710370|NCT01384851|Drug|Next Generation Emulsion|One drop both eyes 4 times daily for two weeks
1710371|NCT01384851|Drug|Refresh Dry Eye Therapy|One drop both eyes four times daily for two weeks
1710372|NCT01384851|Drug|Refresh Contacts|One drop both eyes four times daily for two weeks
1710373|NCT01384838|Behavioral|Counseling|Nutritional, lifestyle and sports counseling
1710374|NCT01384838|Behavioral|physical activity|counseling and controlled physical activity
1710375|NCT01384812|Drug|dinoprostone|intravenous injection 0.4 μgr/kg/min for 25 min
1710510|NCT01383668|Other|pharmacological study|Correlative studies
1956294|NCT02909426|Device|Ultrasonography|Radiologists' hand-held bilateral breast ultrasonography for each participant for one time
1956295|NCT02909426|Device|Digital mammography|Full-field digital mammography using one of the equipments from General Electric (GE), Hologic, and Medi-future companies for each participant for one time
1956296|NCT02906748|Procedure|injection with a syringe in new-site for parathyroid autografting|new-site for parathyroid autografting, close to the antecubital vein
1710380|NCT01384773|Other|Riboflavin Solution|This solution is used to saturate the corneal stroma prior to its photochemical activation by the IROC UV-X illuminator.
1710381|NCT01384773|Device|UV-X Illumination System|IROC UV-X irradiation system creates a uniform 11 mm circle of UVA light that is focused onto the corneal surface. This system is designed to irradiate the riboflavin saturated cornea with a uniform field of UVA light centered at 365 nm.
1710382|NCT01384760|Behavioral|Lifestyle modification|During the first 4 months, subjects will come for a counseling session weekly and then monthly for the following months. During each counseling session (15 to 20 minutes), the registered dietitian will review the seven-day food diaries and offer recommendations for controlling caloric intake. A varied balanced diet with an emphasis on fruit and vegetables, and low-fat and low calorific products in appropriate portions were encouraged. The registered dietitian will also review the daily activity log sheet to check the exercise adherence and progression set by exercise instructor. Subjects will be encouraged to do 30 minutes aerobic exercise two to three times a week.
1710383|NCT01384760|Behavioral|Simple lifestyle advice|Subjects in control group will receive simple lifestyle advice from a clinician at baseline and month 6. This will be a brief discussion about the general health risk associated with OSA and importance of balanced diet. Subjects are encouraged to perform regular 30-minute exercise 2 to 3 times per week. This is to resemble routine clinical practice.
1710384|NCT01384747|Drug|Fimasartan|60-120mg/day (target dose) of Fimasartan will be administered for the study period (till the follow-up angiography)
1710385|NCT01384747|Drug|Placebo|60-120mg/day (target dose) of Placebo will be administered for the study period (till the follow-up angiography)
1710386|NCT01384734|Drug|BMS-663068 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
1710387|NCT01384734|Drug|BMS-663068 800 mg|Tablets, Oral, 800 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
1710388|NCT01384734|Drug|BMS-663068 600 mg|Tablets, Oral, 600 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
1710389|NCT01384734|Drug|BMS-663068 1200 mg|Tablets, Oral, 1200 mg, once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
1710390|NCT01384734|Drug|Raltegravir 400 mg|Tablets, Oral, 400 mg, twice daily (BID), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
1710391|NCT01384734|Drug|Tenofovir 300 mg|Tablets, Oral, 300 mg, Once daily (QD), 24+ weeks until optimal dose is selected, or 96 weeks if optimal dose
1710392|NCT01384734|Drug|Ritonavir 100 mg|Tablets, Oral, 100 mg, Once daily, 96 weeks
1710393|NCT01384734|Drug|Atazanavir 300 mg|Capsules, Oral, 300 mg, Once daily, 96 weeks
1710394|NCT01384708|Drug|proflavine|1-10 ml of proflavine (derived form dissolving 10mg proflavine hemisulfate USP in 100 ml sterile water)
1710395|NCT01384695|Drug|Fluorescein|fluorescent contrast agent, Fluorescein 5ml
1710396|NCT01384695|Drug|Proflavine hemisulfate|3 ml of 0.01% proflavine (derived from dissolving 10mg proflavine hemisulfate USP in 100ml sterile water)
1710397|NCT01384682|Drug|Maraviroc|Maraviroc is a marketed drug for the treatment of HIV-infection. Maraviroc will be supplied in two different oral dose forms, 150mg and 300mg given twice a day. The drug will be dosed according to the recommendations in the product label i.e. with PI/r the dose is 150mg bid except, Maraviroc 300mg bid can be used at the discretion of the investigator if the PI/r is fosamprenavir/r; those randomised to the 2N(t)RTI arm, will receive Maraviroc 300mg bid. Patients randomised to receive Maraviroc will be provided with bottles of Maraviroc which contain a 30-day supply.
1710398|NCT01384656|Drug|GIK solution|Patients receive 0.3 ml/kg/hr GIK solution or the same volume of normal saline depending on the group during off-pump coronary bypass surgery. GIK solution consist of 50% glucose, potassium 80 mEq, and regular insulin 325 IU/500ml.
1710399|NCT01384643|Drug|Propofol|Induction of anesthesia: Propofol 1 mg/kg, sufentanil 1.0-3.0 µg/kg and rocuronium 50 mg IV Maintenance of anesthesia (pre CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Maintenance of anesthesia (during CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 IV infusion Weaning from CPB: Sufentanil 50 µg IV Maintenance of anesthesia (post CPB): Propofol 120-600 µg ∙ kg-1 ∙ h-1 , sufentanil 0.15-0.3 µg ∙ kg-1 ∙ h-1, vecuronium 8-10 mg/h IV infusion Propofol infusion rate is titrated using bispectral index (40-60).
1710400|NCT01384630|Drug|RA-18C3|200 mg subcutaneous injection
1710401|NCT01384617|Procedure|Stapling closure of the pancreatic stump|Echelon 60 with a gold cartridge provide provides precise and uniform wide compression throughout the entire 60mm length with compressible thickness to 1.8mm, which can attach two triple-staggered rows of titanium staples.
1710402|NCT01384617|Procedure|Roux-en-Y anastomosis of the pancreatic stump|end-to-side pancreaticojejunostomy into a retrocolic Roux-en-Y reconstruction. The pancreaticojejunostomy anastomosis is performed in duct-to-mucosa.
1710403|NCT01384591|Drug|N-acetylcysteine|50 mg/kg/dose. They get this the night before with dinner, at 6am when fasted and at 11am with a meal.
1710404|NCT01384591|Drug|Losartan|25mg/dose. They get this the night before with dinner, at 6am when fasted and at 11am with a meal.
1710405|NCT01384591|Other|PLacebo losartan and placebo NAC|Placebo losartan and placebo NAC is administered 3 times.
1710406|NCT01384578|Drug|pentoxiphylline and Vitamin E|Patients in cases group (Group 1) will receive pentoxiphylline (PTX) 400 mg thrice daily and vitamin E 800 IU/day.
1710407|NCT01384578|Drug|Vitamin E|Patients in control group will receive vitamin E 800 IU/day
1710511|NCT01383668|Genetic|RNA analysis|Correlative studies
1783060|NCT00451945|Procedure|biopsy|
1956297|NCT02906748|Procedure|injection with a syringe in traditional site for parathyroid autografting|traditional-site for parathyroid autografting,not intensively close to the antecubital vein
1710408|NCT01384565|Drug|G-CSF+EPO|"Drug: Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)
G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
Arms: G-CSF+EPO Drug: Placebo
Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses)."
1710409|NCT01384565|Drug|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
1710410|NCT01384552|Other|Package Unit Size - Single Serving|Participants will receive a box of twenty-two, 0.9-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
1710411|NCT01384552|Other|Package Unit Size - Standard|Participants will receive a box of two, 10-oz. packages of pretzels. Participants will receive the box of pretzels in the lab on a Thursday or Friday and will take the box of pretzels home for a period of four days. Participants will bring back the box of pretzels to the lab on the following Monday or Tuesday (depending on the day of the initial receipt of pretzels).
1710412|NCT01384539|Drug|Cholecalciferol|
1710413|NCT01384539|Drug|Calcitriol|
1710423|NCT01384500|Other|Saline in tube cuff|Use of sterile saline, instead of air, to inflate tracheal tube cuff. Tracheal tube cuffs to be inflated to 22-25 cm H2O.
1710424|NCT01384474|Other|Diffusion of a surgical safety checklist|"Assistance by a local caregiver investigator (i.e., surgeon, anaesthetist, nurse,...) responsible for the implementation of surgical safety checklist within the operatory rooms of his department ;
A two-step CRM training of surgical teams (i.e., surgeons, anaesthetists, nurses,...) conducted by advisors from the world of air company using video support:
First month following randomization: a course about the implementation of surgical safety checklist (using online-available WHO short movies and other videos of surgical teams) and core concepts of CRM adapted to the operating room;
Sixth month following randomization: a feedback to surgical teams aiming at identifying and solving barriers related to the checklist implementation and interpersonal communication
Written reminders including the systematic presence of an unfilled surgical safety checklist in the patient's medical report, stickers and wall posters in operatory rooms"
1710425|NCT01384448|Procedure|Stress Echocardiography|Stress echocardiography will be performed once. Treadmill stress is default. Patients that cannot exercise will receive dobutamine stress with or without atropine. Definity intravenous contrast will be given when needed.
1710426|NCT01384448|Procedure|Coronary CT Angiography|64-detector, resting EKG-gated coronary CT angiography will be performed once. Patients with elevated heart rates will be given oral and/or intravenous metoprolol. Prospective gating with reduced tube current will be default. Retrospective gating with tube current modulation will be used in patients with higher heart rates.
1710427|NCT01384435|Drug|KPS-0373|
1710428|NCT01384435|Drug|KPS-0373|
1710429|NCT01384435|Drug|KPS-0373|
1710430|NCT01384435|Drug|KPS-0373|
1710431|NCT01384435|Drug|Placebo|
1710432|NCT01384422|Drug|GLPG0634|
1710433|NCT01384409|Drug|KW-3357|Intravenous infusion once a day
1710434|NCT01384396|Drug|KW-3357|Intravenous infusion once a day
1710435|NCT01384383|Drug|GS-5885|GS-5885 30 mg tablet administered orally once daily
1710436|NCT01384383|Drug|GS-9451|GS-9451 200 mg tablet administered orally once daily
1710437|NCT01384383|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1710438|NCT01384383|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
1710439|NCT01384344|Other|observational|Observation during a physical exercise
1710440|NCT01384331|Drug|Marvelon|"7 days daily intake of oral capsule containing containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms followed by 14 days oral placebo capsules
21 days daily intake of oral capsules containing ethinyl oestradiol 30micrograms plus desogestrel 150 micrograms
21 days NuvaRing contraceptive vaginal ring releasing ethinyl oestradiol 15micrograms plus etonorgestrel 120 micrograms dailyleft in situ for 21 days
21 days daily oral placebo capsules Treatment will be for one cycle of 21 days"
1710441|NCT01384318|Other|Manometer|Measuring cuff pressure
1710442|NCT01384292|Drug|NKTR-118|12.5 mg oral tablet once daily
1710443|NCT01384292|Drug|NKTR-118|25 mg oral tablet once daily
1710444|NCT01384292|Drug|Placebo|Oral treatment
1710445|NCT01384279|Drug|metformin, topiramate|metformin 250 mg/d is gradually increased to 1000 mg/d over four weeks, and topiramate 50 mg/d is gradually increased to 200 mg/d over four weeks
1710446|NCT01384253|Other|²¹²Pb-TCMC-Trastuzumab|The starting dose level will be 200 μCi/m² of ²¹²Pb-TCMC-Trastuzumab. Three to six patients will be treated at each dose level, and dose escalation will proceed if no more than 1 out of 6 patients in a cohort experiences dose limiting toxicity. Six patients will be treated at the maximum tolerated dose.
1710447|NCT01384253|Biological|trastuzumab|4 mg/kg.
1710448|NCT01384240|Drug|Proflavine Hemisulfate|3-ml of 0.01% proflavine(derived from dissolving 10 mg proflavine hemisulfate USP in 100 ml sterile water)
1710449|NCT01384227|Drug|Proflavine Hemisulfate|Proflavine hemisulfate 0.01% (derived from dissolving 10 mg Proflavine Hemisulfate USP in 100 ml of sterile water)
1710450|NCT01384214|Biological|botulinum toxin Type A|750 U at Visit 1
1710452|NCT01384188|Drug|ONO-5334|150 mg QD for one day. Administered either in the fasted state or after the standard meal or high fat meal.
1710453|NCT01384175|Procedure|intravenous analgesia|Patients received postoperative analgesia with intravenous infusion of fentanyl 10 µg/ml 3-8 mL/h
1710454|NCT01384175|Procedure|epidural infusion|Postoperative analgesia was performed using continuous epidural infusion of ropivacaine 0.2% 3-8 mL/h and fentanyl 2 µg/mL
1710455|NCT01384175|Procedure|patient-controlled epidural analgesia|Postoperative analgesia was performed by continuous epidural infusion of ropivacaine/fentanyl mixture combined with patient-controlled epidural analgesia with ropivacaine/fentanyl bolus 1 mL, lock-out interval 12 min.
1710456|NCT01384162|Drug|sNN0029|ICV infusion
1710457|NCT01384149|Device|external slt|Nd:YAG LASER SLT perilimbal above trabecular meshwork 180 degrees ,100 lasering dots
1710458|NCT01384149|Device|standard slt|Nd:YAG LASER SLT gonioscopic laser treatment
1710459|NCT01384110|Dietary Supplement|Reduction of glycemic index of ingested foods|Oral administration of the experimental lemon tea powder(56.1 g) and the placebo lemon tea powder (55.6 g) dissolved in water. Each participant will receive both treatment in a cross-over protocol design during 2 visits separated by a 2-weeks period. The day before both intervention, participants will consume a standardised meal for the supper.
1710460|NCT01384084|Procedure|POP repair plus mini-sling|"For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.
A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh."
1710461|NCT01384084|Procedure|POP repair|For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
1710462|NCT01384071|Device|Unstable shoes (MBT)|Wearing unstable (MBT) shoes during 6 weeks
1710463|NCT01384071|Device|Sham intervention (Adidas shoes)|Normal stable shoes (Adidas Bigroar2)
1710464|NCT01384058|Drug|ezetimibe|ezetimibe 10 mg per day for six weeks
1710465|NCT01384058|Drug|simvastatin|Simvastatin 20 mg per day for six weeks
1710466|NCT01384058|Drug|Ezetimibe 10/Simvastatin 20|Ezetimibe 10mg/Simvastatin 20mg per day for six weeks
1710467|NCT01384045|Other|Health promotion outreach|Calling patients who are due for diabetes related services, sending them an interventional letter and assisting them in getting over due serves.
1710468|NCT01384032|Dietary Supplement|Low fat diet|Subjects were asked to consume a low fat diet for 8 weeks. Composition: 28% energy from fat, 8% energy from saturated fat, 55% energy from carbohydrate. Subjects were provided with low fat spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume two extra portions of carbohydrate per day (e.g. two slices of bread, equivalent to 35g carbohydrate) and to consume low fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
1710469|NCT01384032|Dietary Supplement|Hgih saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 2g control oil per day during this period. Control oil comprised palm olein and soybean oil.
1710470|NCT01384032|Dietary Supplement|High saturated fat diet|Subjects were asked to consume a high saturated fat diet for 8 weeks. Composition: 38% energy from fat, 18% energy from saturated fat, 45% energy from carbohydrate. Subjects were provided with spread, cooking oil and snacks and asked to consume these in place of normally eaten equivalent foods. Subjects were asked to consume one less portion of carbohydrate per day (e.g. one slice of bread and to consume full fat dairy products. Subjects also consumed 6g DHA-rich oil per day during this period providing 3g DHA.
1710471|NCT01384019|Device|distal protection and thrombus aspiration (The GuardWire Plus (Medtronic Inc.))|The GuardWire Plus (Medtronic Inc.): distal balloon occlusion and proximal thrombus aspiration
1710472|NCT01384019|Procedure|c-PCI|conventional PCI without Guard wire
1710473|NCT01383993|Drug|Voriconazole|"Study Days 1: IV voriconazole 9 mg/kg q12h. Study Days 2 to 7: IV voriconazole 8 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 9 mg/kg q12h with a maximum of 350 mg q12 h.
Notes:
If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.
Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.
(IV = Intravenous; POS = Powder for oral suspension)"
1710474|NCT01383993|Drug|Voriconazole|"Study Days 1: IV voriconazole 6 mg/kg q12h. Study Days 2 to 7: IV voriconazole 4 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h.
Notes:
If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.
Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.
(IV = Intravenous; POS = Powder for oral suspension)"
1710475|NCT01383980|Dietary Supplement|Continuous Tube Feedings|Tube feeds continued up until elective surgery.
1710476|NCT01383967|Drug|LY2979165|Administered orally
1710477|NCT01383967|Drug|placebo|Administered orally
1710478|NCT01383954|Drug|Diclofenac Gel|Diclofenac gel 4 grams (g) applied topically 4 times daily (QID) to the affected knee(s) for up to 4 weeks. Participants took a maximum dosage of 32 g/day.
1710479|NCT01383941|Drug|Guidelines-based asthma and rhinitis/rhinosinusitis therapy|All participants receive standardized asthma and rhinitis treatment. Asthma and rhinitis medication regimens were based on 1.) the National Asthma Education and Prevention Program (NAEPP) Expert Panel Report -3 (EPR-3) and 2.) the Rhinitis and its Impact on Asthma (ARIA) 2008 guidelines-derived treatment algorithms. References: 1.) J Allergy Clin Immunol 2007; Volume 120, Issue 5, Supplement s93-140. 2.) Allergy 2008; Volume 63, Issue Supplement s86, pages 7-160.
1956300|NCT02908035|Drug|Temsirolimus|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
1710481|NCT01383902|Other|Food type|1ml, 1ml, 5ml, 50ml, 6ml, 20ml, 60ml and 200ml of chocolate dessert or 1 g, 1 segment (5 segments to a bar) repeated 6 times, 2 bars repeated twice of chocolate bars
1710482|NCT01383889|Other|Physical exercise|Two modalities of exercise will be compared: treading mill and stationary bicycle. Pregnant women enrolled in the study will perform exercise during 20 minutes and will be monitored 20 minutes before, during and 20 minutes after exercise.
1710483|NCT01383876|Behavioral|Collar|Have a hard cervical collar placed in the operating room after surgery. The collar will be removed/exchanged for bathing, grooming, and dressing changes only. It will remain in place for 12 weeks.
1710484|NCT01383876|Behavioral|No Collar|Have a hard cervical collar placed in the operating room after surgery. This will remain in place for 1 to 2 days and be discontinued prior to discharge.
1710485|NCT01383850|Other|NCPAP + standard air|NCAP (SiPAP, Vyasis) was used to administer standard air
1710486|NCT01383850|Other|NCPAP + Heliox|Heliox21 (mixture of Helium 80%- Oxygen 20%) (BOC Medical UK- The Linde group) was stored in 10 liter cylinders and administrated through NCPAP for 12 hours (study period) starting from randomization.
1710487|NCT01383837|Behavioral|STYLEnS|Multifamily group HIV/STI Prevention Intervention or Single Family Dyad (youth and a parent)
1710488|NCT01383837|Behavioral|Health Promotion|Health Promotion Intervention
1710489|NCT01383824|Device|Silent™ Hip|A short cementless, femoral component for use in total hip arthroplasty
1710490|NCT01383811|Other|Moderate Intensity Aerobic Exercise|Individuals in this group will receive moderate intensity exercise in addition to their usual care (Medications+/-Psychotherapy). The moderate intensity exercise program will involve gradual progression in exercise intensity and duration. During the first 4 weeks, participants will attend 3 supervised sessions/week and will be asked to complete at least 2 unsupervised aerobic exercise sessions/week. From weeks 5-8 the number of supervised sessions will be 2/week with at least 3 unsupervised aerobic exercise sessions/week. From weeks 9-12, the participants will have only 1 supervised session/week and will be asked to complete at least 4 unsupervised aerobic exercise sessions/week. In total, the participants will be required to complete 150 minutes of moderate physical activity/week.
1710491|NCT01383811|Other|Wait-list|The wait list/usual care group will continue with their usual standard treatment (Medications +/- Psychotherapy) as before.
1710492|NCT01383798|Dietary Supplement|Placebo|100 mg lactose per day for 6 weeks
1710493|NCT01383798|Dietary Supplement|Ferrous sulfate|100 mg per day of ferrous sulfate for 6 weeks
1710494|NCT01383785|Other|Intracoronary direct injection|"Abciximab bolus dosage: 0,125 mg/kg.
Group A: Intracoronary full bolus dose of abciximab proximal to thrombus occlusion. The investigators inject the bolus of abciximab by catheter guide before cross the occlusion. This in the normal way in study' laboratory."
1710495|NCT01383785|Other|Intracoronary and distal injection by aspiration device|"Abciximab bolus dosage: 0,125 mg/kg.
Group B: Half bolus of intracoronary abciximab proximal to thrombus occlusion and the other half distal by aspiration catheter. The investigators inject half of the dose like group A and the other half like group C."
1710496|NCT01383785|Other|Intracoronary distal injection by aspiration catheter device|"Abciximab bolus dosage: 0,125 mg/kg.
Group C: Distal injection to thrombus occlusion of total bolus dose of abciximab by aspiration catheter. The investigators inject the bolus after cross the occlusion using an aspiration catheter."
1710497|NCT01383772|Procedure|Pan retinal Photocoagulation|All patients with bilateral proliferative diabetic retinopathy requiring bilateral pan retinal photocoagulation will undergo baseline visual field tests prior to commencing laser treatment. These fields will be repeated at 6 months following completion of laser treatment.
1710498|NCT01383759|Drug|Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone|"The treatment has three phases:
1) Initial treatment phase: This phase consists of 1-3 21-day-cycles of a combination regimen that includes bortezomib 1.3 mg/m2, IV or Subcutaneous Injection (SQ), on days 1, 4, 8, and 11; and dexamethasone 40 mg PO or IV, on days 1, 4, 8, and 11. Stem cell mobilization and HDM/ASCT. Post-ASCT consolidation/maintenance treatment phase: This phase consists of six cycles of bortezomib 1.3 mg/m2, IV or (SQ) with dexamethasone 20 mg PO or IV administered on days 1, 8, 15, and 22 every 12 weeks +/- 2 weeks."
1710499|NCT01383746|Device|Yttrium microsphere injection|Radiation therapy
1710500|NCT01383733|Drug|RO5458640|Multiple ascending doses intravenously, weekly or every 2 weeks or every 3 weeks
1710501|NCT01383720|Device|Lotus Valve System|The Lotus Valve System includes the Lotus Valve, a bovine tissue tri-leaflet bioprosthetic aortic valve, and the Lotus Delivery Catheter for guidance and placement.
1710502|NCT01383707|Drug|5-Fluorouracil (5-FU)|Participants will receive 5-FU 400 mg per meter-squared (mg/m^2) IV dose on Day 1 of each 2 weeks' cycle followed by 2400 mg/m^2, continuous infusion over 46 hours up to 12 cycles.
1710503|NCT01383707|Drug|Bevacizumab|Participants will receive 5 mg/kg bevacizumab IV dose on Day 1 of each 2 weeks' cycle up to Cycle 5 and thereafter cycles 7 to 12; followed by maintenance therapy of 5 mg/kg IV every 2 weeks up to 52 weeks (26 cycles).
1710504|NCT01383707|Drug|Levofolinic acid|Participants will receive levofolinic acid 200 mg/m^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
1710505|NCT01383707|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 mg/m^2 IV infusion over 2 hours on Day 1 of each 2 weeks' cycle up to 12 cycles.
1710506|NCT01383694|Drug|Piperine|
1710507|NCT01383681|Other|No treatment|There was no treatment in this study.
1710508|NCT01383668|Drug|sirolimus|Given PO
1710509|NCT01383668|Drug|gold sodium thiomalate|Given IM
1956301|NCT02908035|Drug|Saline|After completion of revascularization therapy and any decision to place stents, patients will be qualified for final enrollment in the study and will be treated with the investigational drug or saline. Investigators will be blinded to assignment.
1710517|NCT01383616|Device|Kyphon® Balloon Kyphoplasty (Kyphon Inc; Sunnydale, CA)|A Jamshidi Crown Bone Biopsy Needle (Cardinal Health; Dublin, OH) was then introduced through the incision into the pedicle, and advanced through the pedicle into the center of the vertebral body using a mallet at a 30 to 45 degree angle relative to the AP axis. A guidewire was then placed through the Jamshidi needle, and the needle removed. A series of dilating cannulae were then advanced over the guidewire until a working cannula was in place. A 15 millimeter (mm) or 20 mm bone tamp (Kyphon Inc; Sunnydale, CA) was then introduced into the vertebral body via the cannula and inflated until the balloon was in contact with the subchondral plate, lateral vertebral body wall, or anterior cortex of the vertebral body. The balloon was then deflated and removed. Subsequently, cement was injected into the cavity and allowed to harden.
1710518|NCT01383603|Biological|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart
1710519|NCT01383590|Biological|Cat-PAD|Intradermal injection 1 x 4 administrations 4 weeks apart.
1710520|NCT01383577|Procedure|Single hemorrhoidal ligation|Effective ligation of one hemorrhoidal group and sham ligation of the two other major hemorrhoidal groups is performed in each of three sessions of treatment. Final revision is performed 90 days after first session of hemorrhoidal ligation.
1710521|NCT01383577|Procedure|Triple hemorrhoidal ligation|The three major hemorrhoidal groups are ligated in the first session of ligation. Sham triple hemorrhoidal ligations are performed 30 and 60 days after the first session. Final revision is done 90 days after first ligation session.
1710522|NCT01383564|Procedure|CPAP group|Patients will be given a CPAP education program by our respiratory nurse supplemented by education brochure and a video. Attended overnight CPAP titration will be performed with the auto-titrating device. The CPAP level for each patient in the therapeutic CPAP arm is set at the minimum pressure needed to abolish snoring, obstructive respiratory events and airflow limitation for 95% of the night as determined by the overnight CPAP titration study. Patients in the CPAP therapy will be provided careful mask-fitting, chin strap to prevent mouth leak, regular review by our nurses, a basic CPAP device with intrinsic time clock to monitor CPAP usage and standard stroke rehabilitation programme. Patients on conservative treatment will only be offered standard treatment for asthma
1710523|NCT01383564|Procedure|non CPAP group|Patients who are randomised to non CPAP group will receive general health advice and no CPAP therapy will be arranged for them during the study period.
1710524|NCT01383551|Behavioral|"Becoming Parents intervention"|"A Becoming Parents programme consists of: (i) 3 antenatal workshops conducted over a period of 10-14 weeks in prenatal period; and (ii) support provided by trained volunteers for up to 3 months post-delivery; in addition to the usual prenatal education."
1710525|NCT01383538|Drug|FOLFIRINOX, IPI-926|"Oxaliplatin: intravenous, 50 to 85 mg/m2, over 2 hrs, once per cycle.
Leucovorin: intravenous, 400 mg/m2, over 2 hrs, once per cycle.
Irinotecan: intravenous, 120 to 180 mg/m2, over 90 minutes, once per cycle.
5-FU: intravenous, 1600 to 2400mg/m2, over 46hr continuous infusion, once per cycle.
IPI-926: oral, 130 to 160 mg/day, daily, 14 days per cycle."
1710526|NCT01383525|Device|Automated Direct Selective Trabeculoplasty device|Patients will be treated with a Direct Selective Trabeculoplasty (DLTP) laser. Placement of the spots is on the sclera around the limbus.
1710529|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
1710530|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
1710531|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
1710532|NCT01383499|Drug|Tiotropium bromide|inhalation solution administered via Respimat in 3 different doses
1710533|NCT01383486|Drug|Naproxen sodium ER (BAYH6689)|Naproxen Sodium ER (BAYH6689): oral tablet upon incidence of pain
1710534|NCT01383486|Drug|Advil|Commercially available Advil; oral caplet upon incidence of pain
1710535|NCT01383460|Drug|Granulocyte Colony-stimulating Factor (G-CSF) and Erythropoetin (EPO)|G-CSF (in prefilled syringe) at a dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Darbopoetin alpha 100 mcg/ week (in prefilled syringe) for 4 weeks (total 4 doses).
1710536|NCT01383460|Drug|Placebo|Placebo 1 (in prefilled syringe) s/c at days 1, 2, 3, 4, 5 and then every 3rd day till day 28 (total 12 doses), along with Placebo 2 every week (in prefilled syringe) for 4 weeks (total 4 doses).
1710537|NCT01383447|Drug|entinostat|Given PO
1710538|NCT01383447|Drug|imatinib mesylate|Given PO
1710539|NCT01383447|Other|laboratory biomarker analysis|Correlative studies
1710540|NCT01383447|Other|pharmacological study|Correlative studies
1710541|NCT01383447|Genetic|western blotting|Correlative studies
1710542|NCT01383447|Other|immunohistochemistry staining method|Correlative studies
1710543|NCT01383447|Other|flow cytometry|Correlative studies
1710544|NCT01383447|Genetic|polymerase chain reaction|Correlative studies
1710545|NCT01383447|Other|high performance liquid chromatography|Correlative studies
1710546|NCT01383447|Other|mass spectrometry|Correlative studies
1710547|NCT01383434|Procedure|Bone Marrow Transplant|Matched sibling, haploidentical or matched unrelated donor bone marrow transplant following chemotherapy
1710548|NCT01383408|Other|exhalation analysis of breath sample|study participants exhale 5 times into a test tube; test tube is presented to sniffer dogs for analysis
1710549|NCT01383395|Drug|simvastatin/cilostazol|
1710550|NCT01383356|Drug|Metformin Single Tablet|Metformin medium doseTablet
1710551|NCT01383356|Drug|Linagliptin/Metformin Combo|Fixed dose combination
1710552|NCT01383356|Drug|Linagliptin Single Tablet|Linagliptin Single medium dose Tablet
1710553|NCT01383343|Biological|Bevacizumab|Given IV
1710554|NCT01383343|Drug|Fluorouracil|Given IV
1710555|NCT01383343|Drug|Irinotecan Hydrochloride|Given IV
1710556|NCT01383343|Drug|Leucovorin Calcium|Given IV
1710557|NCT01383343|Drug|Sorafenib Tosylate|Given PO
1710558|NCT01383330|Drug|megace|800mg
1710559|NCT01383330|Drug|DW-ES(A)|625mg
1710560|NCT01383330|Drug|DW-ES(B)|625mg
1783994|NCT00459420|Drug|placebo|placebo
1710561|NCT01383317|Device|Thigh Tourniquet (VBM Single Use Tourniquet Cuff Items 20-34-722SLZ-1)|Disposable sterile thigh tourniquet
1710562|NCT01383317|Device|Sham RIPC|Disposable sterile thigh tourniquet
1710563|NCT01383278|Behavioral|Computer-directed 5 A's intervention for smoking|Computer-directed 5 A's intervention for smoking
1710564|NCT01383278|Behavioral|Screening and resource provision|Screening and resource provision
1710565|NCT01383265|Procedure|Water method and chromoendoscopy|Study method will employ a 0.008% IC solution used with the water method for screening colonoscopy
1710566|NCT01383265|Procedure|Water method|Control method will use plain water with water method for screening colonoscopy
1710567|NCT01383252|Procedure|Water infusion in lieu of air insufflation|Air pump is turned off, water is infused using a peristaltic pump to aid colonoscope insertion until the cecum is reached. Air pockets and dirty water are suctioned before clean water is infused (exchange) to facilitate scope insertion.
1710568|NCT01383252|Procedure|Air method|Conventional air method with minimal insufflation of air to aid scope insertion until the cecum is reached. Water in aliquots will be used for irrigation and cleansing.
1710569|NCT01383239|Other|Immediate Postoperative Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The Immediate group will began physical therapy 3-7 days postoperatively.
1710570|NCT01383239|Other|Delayed Physical Therapy|All patients will undergo a 16 week postoperative therapy program (a formal physical therapy program, a home exercise program or a combination of both). Immediate and delayed therapy are the current standard of care for postoperative physical therapy. The delayed group will began physical therapy 6 weeks postoperatively
1710571|NCT01383226|Procedure|Thoracic endosonography|Thoracic endosonography is a minimal invasive diagnostic intervention
1710572|NCT01383213|Other|Oxygen therapy|patient in group oxygen therapy by Venturi Mask will be treated with oxygen until reaching clinical stability, or criteria of endotracheal intubation
1710573|NCT01383213|Other|Helmet CPAP|patient in group CPAP will be treated with CPAP until reaching clinical stability, or criteria of endotracheal intubation
1710574|NCT01383200|Drug|Tetracaine drop|0.5% Tetracaine Right eye / 2% Lidocaine Left eye
1710575|NCT01383200|Drug|Lidocaine gel|0.5% Tetracaine Left eye / 2% Lidocaine Right eye
1710576|NCT01383187|Procedure|DE graft and PRP concentrate|Application of DE graft together with PRP concentrate
1710577|NCT01383187|Procedure|DE graft|DE grafting presents a standard treatment method in patients with deep-burn trauma.
1710578|NCT01383174|Behavioral|Peer Support Program|"Work with a trained counselor who is a breast cancer survivor
Meet 8 times in-person over the 8 week program with the counselor
Counselor helps participant develop a personalized support program to help her improve her quality of life
Receives information on breast cancer, its treatments, and stress management"
1710579|NCT01383161|Drug|Curcumin|Six 465 milligram capsules (containing 30 mg of curcumin each) per day for 18 months.
1710580|NCT01383161|Other|Placebo|Six 465 milligram capsules per day for 18 months.
1710581|NCT01383148|Biological|TG4010|"TG4010 • TG4010 will be administered starting on Day 1 (D1) of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by subcutaneous (SC) injections and then once every 3 weeks until progression or discontinuation due to any reason.
Chemotherapy (and bevacizumab if prescribed), will be given as 21-day cycles for a minimum of 4 cycles and up to 6 cycles.
First line therapy:
Non-squamous carcinoma: pemetrexed + cisplatin or paclitaxel + carboplatin +/- bevacizumab
Squamous carcinoma: gemcitabine + cisplatin or paclitaxel + carboplatin
Maintenance therapy:
• Pemetrexed or erlotinib for eligible patients and according to labeling."
1710582|NCT01383148|Drug|placebo|"Placebo will be administered starting on D1 of Cycle 1 of chemotherapy and will be administered weekly for 6 weeks by SC injections and then once every 3 weeks until progression or discontinuation due to any reason.
First line therapy: as in Arm 1
Maintenance therapy: as in Arm 1"
1710584|NCT01383122|Device|Pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
1710585|NCT01383122|Device|Inactive pulsed electromagnetic field device (ActiPatch TM)|Wire loop of pulsed electromagnetic field device is taped around the wound for 48 hours.
1710586|NCT01383109|Drug|14C-labeled Pyronaridine|Single dose of 720 mg Pyronaridine together with 14C-Pyronaridine (approx. 100 µg, 800 nCi).
1710587|NCT01383096|Drug|OZ439 mesylate 800mg Powder in Bottle for Oral Suspension|OZ439 800 mg (as free base) as powder in a bottle for reconstitution in a suspension prior to oral administration
1710588|NCT01383096|Drug|OZ439 mesylate 400mg Prototype Solution Formula 1|OZ439 400 mg (as free base) as a prototype solution formulation 1
1710589|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 1|OZ439 800 mg (as free base) as a prototype solution formulation 1
1710590|NCT01383096|Drug|OZ439 mesylate 800mg Prototype Solution Formula 2|OZ439 800 mg (as free base) as a prototype solution formulation 2
1710591|NCT01383070|Behavioral|Lactational Counseling by Cell phone|The approach to promoting TIBF, EBF and TICF will be through cell phone counseling in addition to counseling in the hospitals during scheduled ante natal visits. Mother in the intervention group (beneficiaries) would be provided handsets and included in a subsidized calling plan.
1710592|NCT01383057|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
1710593|NCT01383044|Procedure|EVL + carvedilol|EVL is performed for 2-3 times carvedilol 6.25mg-12.5 mg per day
1710594|NCT01383044|Drug|carvedilol|carvedilol 6.25mg-12.5 mg per day
1710595|NCT01383031|Procedure|CLC|CLC（4 ports or 3 ports）will be performed in a routine fashion by one full time faculty member with fellowship training in laparoscopy.
1710596|NCT01383031|Procedure|TU-LESSC|TU-LESSC will be performed in a routine fashion which is same to CLC by one full time faculty member with fellowship training in laparoscopy through the conventional laparoscopic instruments.
1710598|NCT01382979|Behavioral|AlcoholEdu for College|Online course for college freshmen.
1784348|NCT00462982|Drug|sunitinib malate|
1710599|NCT01382953|Device|Standard Holter/Investigational patch|The standard Holter and Investigational patch will be worn simultaneously for 24 hours. A single follow-up visit will follow in 2 days to remove both systems which will be sent away for analysis with the results of the standard system used, if pertinent, for patient management.
1710600|NCT01382940|Drug|rituximab|1000 mg in 250 mL intravenous infusion
1710601|NCT01382940|Drug|methotrexate|10 to 25 mg/week (oral or parenteral)
1710602|NCT01382940|Drug|methylprednisolone|100 mg methylprednisolone administered by slow intravenous infusion at least 30 minutes prior to the start of each study drug infusion
1710603|NCT01382940|Drug|acetaminophen|1 gram acetaminophen administered orally 30 to 60 minutes prior to the start of each study drug infusion
1710604|NCT01382940|Drug|antihistamine|50 mg diphenhydramine hydrochloride or equivalent dose of alternate antihistamine administered orally 30 to 60 minutes prior to the start of each study drug infusion
1710605|NCT01382914|Other|chlorhexidine 0.12%|twice daily, 10 ml, topical
1710606|NCT01382901|Drug|Ferric Carboxymaltose (FCM)|
1710607|NCT01382901|Drug|Placebo|
1710608|NCT01382888|Drug|Heparin 2,400 IU /ml Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication twice daily. Patients will get adequate training before first administration.
1710609|NCT01382888|Drug|Placebo Cutaneous Spray|Randomization will be performed 2 - 14 days post fistula creation surgery following confirmation that the fistula is patent by physical examination. Patients that are randomized to this study arm, will be asked to administer the study medication (placebo) twice daily. Patients will get adequate training before first administration.
1710610|NCT01382875|Other|Multi-disciplinary management program|conventional healthcare program for fragility fracture patients plus vibration treatment, exercise class and educational talk
1710611|NCT01382862|Other|Stroke Emergency Mobile Unit (STEMO)|Patients treated in the STEMO may receive a CT-scan and point-of-care laboratory work up. This depends on the results of the neurological examination including assessment of medical history and the indication for scanning by the radiologist on call. In case of no contraindications patients with acute ischemic stroke will receive intravenous tissue Plasminogen Activator (0.9 mg/kg BW) according to the routine use of tissue Plasminogen Activator in Germany within 4.5 hours of symptom onset but with no formal upper age limit. (In other words, patients older than 80 years will not be excluded.) In case of increased INR and intracerebral hemorrhage patients will receive Prothrombin Complex Concentrate (PCC). All other indications will be treated according to national guidelines or as considered appropriate by the neurologist.
1710612|NCT01382823|Procedure|Femtosecond Laser|Using the Femtosecond Laser to make a clear corneal incision.
1710613|NCT01382810|Drug|Altaire Gel forming solution|Three times a day for two months
1710614|NCT01382810|Drug|Refresh Tears|Three times a day for two months
1710615|NCT01382797|Drug|ALKS 37|Capsules for oral administration
1710616|NCT01382797|Drug|Placebo|Capsules for oral administration
1710617|NCT01382771|Drug|Intra-articular corticosteroid injection|Intra-articular injection of 0.5 cc triamcinolone acetonide (40 mg/cc) within each joint
1710618|NCT01382771|Drug|Intra-articular saline injection|Intra-articular injection of 0.5 cc normal saline in each joint
1710619|NCT01382745|Drug|Nimotuzumab|200mg Nimotuzumab once a week for 12 weeks
1710620|NCT01382745|Radiation|Intensity Modulated Radiation Therapy (IMRT)|IMRT radiation therapy with doses varying from 45Gy-54Gy in 25-30 fractions
1710621|NCT01382732|Drug|Carbetocin|Protocol A (carbetocin + placebo) Carbetocin: 100ug (1mL) + Ringer's Lactate 10mL directly into the vein in no less than two minutes.
1710622|NCT01382732|Drug|Oxytocin|Oxytocin 20 U (4mL) diluted in a bag with 1000mL of Ringer's Lactate to be passed intravenously at a rate of 125mL/hr
1710623|NCT01382719|Drug|bremelanotide|"Subjects will administer drug on an as needed basis, prior to anticipated sexual activity.
Investigational product: Bremelanotide aqueous solution for subcutaneous (SC) injection, provided as pre-filled syringes containing 0.75, 1.25, or 1.75 mg in 0.3 mL volume. Subjects will self-administer bremelanotide by SC injection into the anterior thigh or abdomen.
Placebo: Same formulation as the investigation product but without the active ingredient, provided as pre-filled syringes containing 0.3 mL volume. Subjects will self-administer the placebo by SC injection in the same manner as the investigational product."
1710624|NCT01382706|Drug|docetaxel|Given IV
1710625|NCT01382706|Drug|lapatinib ditosylate|Given PO
1710626|NCT01382706|Other|immunohistochemistry staining method|Correlative studies
1710627|NCT01382706|Genetic|fluorescence in situ hybridization|Correlative studies
1710628|NCT01382706|Other|laboratory biomarker analysis|Correlative studies
1710629|NCT01382693|Behavioral|TimeSlips|TimeSlips is a group-based creative storytelling program for people with dementia. The intervention will be held twice a week for six weeks, in hour-long sessions.
1710630|NCT01382693|Behavioral|Standard care activity program|Standard-of-care activities for the study site's skilled-nursing dementia Special Care Units.
1710632|NCT01382654|Drug|epinastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
1710633|NCT01382654|Drug|epinastine 0.1% with taste masking agent|nasal spray 2 sprays to each nostril for a total for a 3 doses
1710634|NCT01382654|Drug|epinastine 0.2%|nasal spray 2 sprays to each nostril for a total of 3 doses
1710635|NCT01382654|Drug|epinastine 0.2% with taste masking agent|nasal spray 2 sprays to each nostril for a total of 3 doses
1710636|NCT01382654|Drug|azelastine 0.1%|nasal spray 2 sprays to each nostril for a total of 3 doses
1710637|NCT01382641|Device|Hoya AF-1 IOL|The patients will be assessed for three months
1710638|NCT01382641|Device|Revital vision|The patients will be assessed for three months.
1710639|NCT01382602|Biological|AMDC|Cell Treatment
1710640|NCT01382602|Biological|Placebo Control|Placebo treatment
1710641|NCT01382589|Drug|Afamelanotide|NB-UVB phototherapy with or without subcutaneous, bioresorbable Afamelanotide 16 mg implants, contained in a poly(D,L-lactide-co-glycolide) implant core released over 7-10 days following implantation
1710643|NCT01382550|Drug|long-lasting OAT or 12-month OAT|"The antithrombotic treatment will be decided according to usual practice of enrolling Centers. The duration of the initial treatment with parenteral anticoagulation (Low Molecular Weight Heparin or Fondaparinux), the beginning of oral anticoagulation (OAT) with Vit K inhibitors and the International Normalized Ratio (PT-INR) target will be recorded.
According to Center indications the OAT duration (6 months, 12 months or long-lasting) will be recorded and population will be stratified accordingly. The length of therapy will be counted from the date when a stable PT-INR is achieved.
The occurrence of surgery, trauma, prolonged immobilization (>7 days), pregnancy (VTE risk periods) during the follow-up and the use of adequate anti-thrombotic prophylaxis will be recorded."
1710644|NCT01382537|Device|InterX 5000|A computer driven electrical stimulation unit that contains a cutaneous impedance sensor.
1710645|NCT01382537|Device|InterX 5000|Placebo treatment
1710646|NCT01382511|Drug|Simvastatine|80 mg
1710647|NCT01382498|Drug|Calcium dobesilate (Doxium)|500 mg, Tablet, Daily, 3 months
1710648|NCT01382498|Drug|Placebo drug|Similar to the that of the Experimental arm, Daily, Three months
1710649|NCT01382485|Other|RIA harvesting group|Subjects allocated to the RIA group will have the graft harvested in a standardized fashion using the technique described by Quintero et al. Briefly, the RIA device is a single-pass reamer that is connected to an aspirator and irrigator, allowing simultaneous reaming, irrigation, and aspiration of the contents of the femoral canal. RIA head size and tube length will be chosen based on preoperative templating of anteroposterior and lateral radiographs of the donor femur (a head size of 2mm larger than the inner cortical diameter at the isthmus of the femur will be selected). Fluoroscopic imaging will be used to confirm guidewire positioning and avoid eccentric reaming. Bone graft will be harvested from the central femoral canal and from each femoral condyle in 3 separate passes.
1710650|NCT01382485|Other|AICBG harvesting group|Iliac crest bone graft will be harvested from the anterior iliac crest through an incision beginning 2cm posterior to the anterior superior iliac spine and carried posteriorly. A window will be made in the iliac crest and a curette will subsequently be used to harvest the cancellous bone. The incision will be closed in 3 layers. The infiltration of local anaesthetic will be at the discretion of the surgeon.
1710651|NCT01382472|Drug|Rosuvastatin|40 mg per operative in PPCI, the 40 daily during hospital stay
1710652|NCT01382472|Drug|Simvastatin|No statin acutely. Simvastatin 20 mg from day 2.
1710653|NCT01382446|Drug|Chlorhexidine gluconate|0.12% Chlorhexidine Gluconate 15ml Twice Daily, administered via toothbrushing and swabbing teeth, tongue, gingiva, and oral mucosa.
1710654|NCT01382446|Other|Toothpaste|Brushing the teeth, tongue, gingiva, and oral mucosa twice daily with toothbrush and toothpaste.
1710655|NCT01382433|Procedure|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
1710656|NCT01382433|Behavioral|Cambridge Neuropsychological Test Automated Battery (CANTAB).|the CANTAB is sensitive to cognitive changes caused by a wide range of Central Nervous System disorders and medication side-effects . The CANTAB uses a computer with a touch screen, and affords a rapid and non-invasive assessment of cognitive functions.
1710657|NCT01382433|Behavioral|Experimental: Scale for the Assessment of Negative Symptoms (SANS) and the Positive and Negative Syndrome Scale (PANSS)|The SANS and PANSS scales asses the presence and severity of Positive and Negative of Schizophrenia
1710658|NCT01382420|Procedure|surgery|adrenalectomy
1710659|NCT01382407|Drug|Cetuximab|Once a week:Loading dose-400 mg/m2;subsequent-250 mg/m2 on days 8,15, 22,29,36 if administered as a single agent, or together with Irinotecan 125 mg/m2 on days 1,8,15,29 followed by administration every 42 days.
1710660|NCT01382368|Drug|Sildenafil|Acute single dose of 100 mg of sildenafil. Oral intake in tablet form.
1710661|NCT01382342|Drug|Rasagiline|1 mg daily
1710662|NCT01382342|Drug|Placebo|1 mg daily
1710663|NCT01382329|Biological|H5N1 (pre-)pandemic influenza vaccine (whole virion, Vero Cell derived, inactivated)|Intramuscular injection into the musculus deltoideus or subcutaneous injection in the upper arm
1710664|NCT01382316|Behavioral|Making Alcoholics Anonymous Easier (MAAEZ)|6-week, 90-minute, manualized, 12-step facilitation intervention consisting of 6 weekly session. First session is introduction. Four following core sessions attended in any order: sponsorship, principles not personalities, spirituality, living Sober. Last session, return to intro session as graduate.
1710665|NCT01382316|Behavioral|Usual care|Group format, six weekly education sessions about alcohol and drugs
1710666|NCT01382303|Drug|Pentoxifylline|Pentoxifylline 400mg three times a day
1710667|NCT01382303|Drug|Placebo|placebo tablet three times a day
1710668|NCT01382290|Procedure|MRI|
1710669|NCT01382277|Drug|Rosuvastatin|Rosuvastatin 20 mg per day for 76 weeks
1710670|NCT01382264|Other|Computer Assisted Decision Support|Program to provide recommendations for achieving glycemic control in poorly controlled patients with T2 diabetes.
1710671|NCT01382238|Drug|Dolutegravir 50 mg tablet|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
1710672|NCT01382238|Drug|Dolutegravir 50 mg oral granules|Dolutegravir is an experimental drug in the integrase inhibitor class for the treatment of HIV.
1710673|NCT01382225|Drug|Sodium Hyaluronate Ophthalmic Solution, 0.18%|
1710674|NCT01382225|Other|Vehicle|Inactive ingredients used as run-in and placebo comparator
1710675|NCT01382212|Drug|paricalcitol|Paricalcitol soft capsule. Starting dose of paricalcitol was determined by the intact parathyroid hormone (iPTH) value (iPTH/120) from prior to Day 1, rounded down to the nearest whole number, not to exceed 16 µg 3 times weekly, no more frequently than every other day. Decisions to hold, maintain, increase, or decrease a dose were based on the iPTH, phosphorus, and calcium results generated from the most recent visit and within target Kidney Dialysis Outcomes Quality Initiatives (KDOQI) levels.
1710676|NCT01382199|Drug|Lactoferrin|
1710677|NCT01382160|Biological|adalimumab|40 mg every two weeks, by subcutaneous way
1710678|NCT01382147|Drug|Ara-C, Mitoxantrone, Daunorubicin, Thioguanin|Chemotherapy
1710679|NCT01382134|Drug|Aspirin, desmopressin|Aspirin 100mg daily for 3 days Desmopressin 15 microgram subcutaneously once only
1710680|NCT01382134|Drug|Placebo, desmopressin|Placebo 1 tab daily for 3 days Desmopressin 15 microgram subcutaneously once only
1710715|NCT01381874|Drug|Abiraterone acetate + Prednisone or Prednisolone|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
1710681|NCT01382121|Behavioral|Peer Modeling|Participants watch a video of an adolescent completing the fitness test and explaining coping mechanisms to preform the test well.
1710682|NCT01382121|Behavioral|Control|watching a video unrelated to the fitness test and self-efficacy
1710683|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|10 ug on study days 0, 21 and 42
1710684|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|50 ug on study days 0, 21 and 42
1710685|NCT01382095|Biological|Recombinant fimbrial adhesin dscCfaE|250 ug on study days 0, 21 and 42
1710686|NCT01382095|Biological|Modified E. coli heat labile enterotoxin LTR192G|50 ug on study days 0, 21 and 42
1710687|NCT01382069|Drug|Dimethandrolone Undecanoate|Daily doses of 100, 200 and 400mg of dimethandrolone undecanoate
1710688|NCT01382069|Drug|Placebo|Placebo with capsules that look like the DMAU capsules but with no active ingredients
1710689|NCT01382056|Other|control foods|pulse-free control foods consumed daily, 5 days per week for 8 weeks
1710690|NCT01382056|Other|Mixed bean (higher amount)|0.6 cup of mixed beans consumed 5 days per week for 8 weeks
1710691|NCT01382056|Other|Mixed beans (lower amount)|0.3 cup of mixed beans consumed daily, 5 days per week for 5 weeks
1710692|NCT01382030|Drug|EIA chemotherapy|ifosfamide 1500 mg/m² iv days 1 - 4, etoposide 125 mg/m² iv days 1 and 4, and adriamycin 50 mg/m² iv day 1
1710693|NCT01382017|Drug|Lacosamide|Lacosamide 200 or 400 mg
1710694|NCT01382017|Drug|Placebo|Placebo
1710695|NCT01382017|Drug|Carbamazepine|Carbamazepine 600 mg
1710696|NCT01382004|Drug|Penicillin-G-benzathine|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.
Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
1710697|NCT01382004|Drug|Azithromycin|"Screening examination: Medical history (emphasis on skin lesions and bone signs) Physical examination.Blood samples for VDRL and TPHA. Clinical safety. Laboratory evaluations: haemoglobin, total WBC count, differential WBC count, platelet count, ALT, AST, urea and creatinine.
Routine assessments: General clinical assessment and physical examination on Days 0 (treatment administered) and 14. Adverse events and concomitant medications (at baseline, Day 14 and in any unscheduled visit). Photograph documentation of skin lesions (at 14 days follow up visit). Follow-up visits performed on 3 and 6 will have a ± 14 days allowable window"
1710698|NCT01381991|Device|i-scan|For all the study procedures, Pentax EPKi processor and high-resolution adult video endoscopes (EG-2890i; Pentax, Japan) with push button switch from WL to i-scan were used. I-scan consist of three modes of image enhancement including SE, CE, ant TE. For SE and CE, switching among three enhancement levels (2+,3+,4+) is possible. Although SE and CE modes can allow detailed observation of subtle mucosal irregularities, noise increases as enhancement becomes more intense. In addition, TE is possible to switch p (pit pattern), v (vessel), b (Barrett), e (esophagus), g (stomach) and c (colo-rectum) mode.
1710699|NCT01381965|Procedure|Vitreous surgery for macular hole|Vitreous surgery for macular hole
1710700|NCT01381952|Radiation|Low dose DSA (75% reduction compared to normal dose) with novel X-ray imaging technology.|Digital substraction angiography (DSA) with reduced dose settings (75% reduction expected) in combination with conventional X-ray imaging technology.
1710701|NCT01381952|Radiation|Normal dose DSA with conventional X-ray technology|Digital substraction angiography (DSA) with normal dose settings in combination with conventional X-ray imaging technology.
1710702|NCT01381926|Drug|exenatide|exenatide 5mcg sq twice daily for one month and exenatide 10mcg twice daily for month 2. The 3rd month is a washout period. Month 4 and 5 saline placebo is given as 5mcg and 10mcg respectively.
1710703|NCT01381926|Drug|Saline|Month 1 and 2 saline placebo is given as a low and high dose respectively. The 3rd month is a washout period. Month 4 exenatide 5mcg sq twice daily and for month 5 exenatide 10mcg twice daily is administered.
1710704|NCT01381900|Drug|Placebo|Form=capsule, route=oral administration. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
1710705|NCT01381900|Drug|Canagliflozin 100mg|Type=1, unit=mg, number=100, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
1710706|NCT01381900|Drug|Canagliflozin 300mg|Type=1, unit=mg, number=300, form=capsule, route=oral use. One capsule once daily for up to 18 weeks after completing a single-blind placebo run-in period (1 placebo capsule once daily for up to 2 weeks).
1710707|NCT01381900|Drug|Metformin|The participant's stable dose of background therapy of metformin should be continued throughout the study.
1710708|NCT01381900|Drug|Sulphonylurea|The participant's stable dose of background therapy of metformin plus sulphonylurea should be continued throughout the study.
1710709|NCT01381887|Drug|Placebo|Treatment A: Form=capsule, route=oral administration. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
1710710|NCT01381887|Drug|Canagliflozin 300mg/Placebo|"Treatment B: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.
Form=capsule, route=oral administration. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
1710711|NCT01381887|Drug|Canagliflozin 300mg/Canagliflozin 150mg|"Treatment D: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once on Day 1 in 1 of 4 treatment periods.
Type=1, unit=mg, number=150, form=capsule, route=oral use. Capsule is taken once on Day 2 in 1 of 4 treatment periods."
1710712|NCT01381887|Drug|Canagliflozin 300mg|Treatment C: Type=1, unit=mg, number=300, form=capsule, route=oral use. Capsule is taken once daily on Day 1 and Day 2 in 1 of 4 treatment periods.
1710713|NCT01381874|Drug|Exemestane|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets
1710714|NCT01381874|Drug|Abiraterone acetate + Prednisone/ Prednisolone + Exemestane|Prednisone or Prednisolone, type=equal, unit=mg, number=5, form=tablet, route=oral use. All drugs are taken once daily.
1710891|NCT01380613|Behavioral|Workshop|10 session intervention
1790002|NCT00510406|Drug|Placebo|Placebo
1710716|NCT01381861|Biological|Chimeric monoclonal antibody (TRC105) to CD105|10 mg/kg weekly by intravenous administration on Days 1, 8, 15 and 22 of each 28-day cycle
1710717|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=5, form=solution for injection, route=intravenous use, once on Day 1 for patients <8 weeks CA.
1710718|NCT01381848|Drug|Doripenem|Type=exact number, unit=mg/kg, number=8, form=solution for injection, route=intravenous use, once on Day 1 for patients >=8 weeks CA.
1710719|NCT01381835|Drug|TMC435|150 mg capsule once daily for 7 days
1992237|NCT03322865|Drug|Obinutuzumab|"Induction:
Cycle 1 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1,8,15*
*In the case of suspected increased risk of severe IRR, the dose of obinutuzumab may be 100 mg intravenously on day 1 in cycle 1, 900 mg on day 2.
Cycle 2-6 (28 days cycle): Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 Maintenance
Start 8 weeks after the last induction cycle for patients at least achieving a partial response after induction:
Obinutuzumab (OBINUTUZUMAB) 1000mg i.v. fixed dose day 1 every 8 weeks for a maximum of 12 infusions unless progression or study drug - related intolerable toxicity"
1710721|NCT01381809|Drug|Group 2: Placebo|form= solution for injection, route= subcutaneous use, weekly injections for 24 to 48 weeks
1710722|NCT01381809|Drug|Group 1: Epoetin alfa|type = range, unit= IU/Kg, number= 337.5 to 1050 IU/Kg, form= solution for injection, route= subcutaneous use, weekly injections (max 40,000 IU per week for first 8 weeks of treatment, max 80,000 IU per week later) using pre-filled 1mL 40,000 IU syringes for 24 to 48 weeks
1710725|NCT01381783|Procedure|Phacoemulsification|Phacoemulsification under topical anesthesia
1710726|NCT01381770|Biological|platelet-derived repairing factors|autologous platelet lysate injection within 24 hours from lesion
1710727|NCT01381744|Biological|Flagellin/F1/V|Flagellin/F1/V recombinant fusion protein vaccine administered by the intramuscular route on Days 0 and 28 at a dose of 1, 3, 6, or 10 micrograms (mcg). It is a clear, colorless solution.
1710728|NCT01381744|Other|Placebo|Phosphate buffered saline (PBS) used as diluent and placebo.
1710729|NCT01381731|Drug|diquafosol tetrasodium ophthalmic solution 2%|opthalmic solution 2 drops in each eye QID
1710730|NCT01381731|Drug|placebo|opthalmic solution 2 drops in each eye QID
1710733|NCT01381705|Biological|rituximab|
1710734|NCT01381705|Genetic|DNA analysis|
1710735|NCT01381705|Genetic|gene expression analysis|
1710736|NCT01381705|Genetic|polymorphism analysis|
1710737|NCT01381705|Other|laboratory biomarker analysis|
1710738|NCT01381705|Other|medical chart review|
1710745|NCT01381679|Drug|Ezetimibe|Ezetimibe was not mandatory and was prescribed as per routine prescription by physician.
1710746|NCT01381666|Drug|INS316 solution for inhalation|inhalation via nebulizer given for 2 doses for 60 minutes each
1710747|NCT01381666|Drug|hypertonic saline 3% sodium chloride solution|inhalation via nebulizer given for 2 doses for 60 minutes each
1710748|NCT01381653|Other|Behavioral: HIV prevention intervention|Substance using HIV-negative young men who have sex with men who engage in sexual risk and use social networking (Facebook) will be recruited and enrolled in a brief intervention utilizing Motivational Interviewing over chat window to reduce their substance use and sexual risk. They will also evaluate their intervention experience at the end of their eight sessions and post-assessment.
1710749|NCT01381640|Drug|Marketed paracetamol|marketed formulation
1710750|NCT01381640|Drug|Experimental paracetamol formulation|Experimental formulation
1710751|NCT01381627|Drug|Remifentanil|Remifentanil IV bolus 0.5 mcg/kg bolus in 10 minutes. Initial bolus followed by infusion 0.05-0.25 mcg/kg/min for OAA/S 2-3. Remifentanil IV bolus 0.3 mcg/kg PRN for time-limited painful stimuli.
1710752|NCT01381627|Drug|Dexmedetomidine|Dexmedetomidine 0.4 mcg/kg IV bolus in 10 minutes. Dexmedetomidine 0.5-1.0 mcgg/kg/h for OAA/S 2-3. Midazolam 0.015 mg/kg bolus IV PRN.
1710753|NCT01381614|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
1710754|NCT01381601|Drug|Targeted agents indicated in management of advanced/metastatic RCC (sunitinib, sorafenib, bevacizumab, and pazopanib)|Metastatic RCC patients on either sunitinib or sorafenib or bevacizumab or pazopanib (identified based on claims) will be evaluated for presence or absence of common severe adverse events. These common severe adverse events will be identified from agent's product labels.
1710755|NCT01381588|Other|Fracture evaluation|DEXA(Dual-energy X-ray absorptiometry), X-ray
1710756|NCT01381575|Biological|GSK Biologicals' HPV vaccine 580299|Subjects will receive 2 or 3 doses of HPV vaccine administered intramuscularly
1710760|NCT01381549|Drug|GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
1710761|NCT01381549|Drug|imipenem-cilastatin|Prepare as per prescribing information instructions in 100 mL bag of 0.9% NaCl and administered via IV infusion
1710762|NCT01381549|Other|Placebo|saline placebo
1710763|NCT01381536|Drug|GSK1550188 1mg/kg or 10mg/kg|IV one shot
1710764|NCT01381523|Drug|Combination therapy with sumatriptan and naproxen sodium (SumaRT/Nap)|Patients with new pharmacy claims for SumaRT/Nap with separate analyses for patients with at least one triptan pharmacy claim in the 6-month, pre-index period and those who are triptan-naive based on 6 months of data
1710765|NCT01381523|Drug|Single-entity oral triptans|Patients are propensity score matched to patients in the SumaRT/Nap groups and analyzed separately if patient has a pharmacy claim for a different type of triptan in the previous 6 months or is triptan treatment naive. Triptans included almotriptan, naratriptan, rizatriptan, eletriptan, zolmitriptan, frovatriptan, sumatriptan.
1710766|NCT01381510|Drug|5-alpha Reductase Inhibitor (5ARI)|A 5ARI: Either dutasteride or finisteride
1710767|NCT01381497|Drug|Combination therapy of sumatriptan and naproxen sodium (SumaRT/Nap)|This is an observational study and patients were prescribed this medication before study start
1710768|NCT01381497|Drug|Triptan monotherapy|This is an observational study and patients reported a previous triptan monotherapy prescription. Drugs of interested included naratriptan, sumatriptan, rizatriptan, frovatriptan, almotriptan, eletriptan, zolmitriptan
1710769|NCT01381484|Drug|10% Argireline|10% Argireline (La jolie gel®, Pacific health care, Thailand) were instructed to apply the gel over the face and periorbital area twice daily for a period of 3 months.
1710770|NCT01381471|Drug|fluticasone propionate/salmeterol xinafoate combination|fluticasone propionate/salmeterol xinafoate combination
1710771|NCT01381458|Drug|FSC|fluticasone propionate / salmeterol xinofoate combination
1710772|NCT01381458|Drug|ACs|tiotropium alone, ipratropium alone, or in combination with albuterol
1710773|NCT01381445|Drug|GW870086 0.2%|White to slightly coloured opaque cream
1710774|NCT01381445|Drug|GW870086 2%|White to slightly coloured opaque cream
1710775|NCT01381445|Drug|Clobetasol Propionate|White cream
1710776|NCT01381445|Drug|Placebo|White to slightly coloured opaque cream
1710777|NCT01381432|Drug|Azathioprine|At the start of treatment, 2 to 3 mg per kg of body weight each day. For the rest of treatment, 1 to 2 mg per kg of body weight each day.
1710778|NCT01381419|Drug|GSK1144814|Single dose.
1710779|NCT01381419|Drug|GSK1144814|Single dose which may be split in up to three divided doses given 2 to 3 hours apart.
1710780|NCT01381419|Drug|GSK1144814|Single dose that may be split in up to three divided doses given 2 to 3 hours apart.
1710781|NCT01381406|Drug|TIO|Patients receiving tiotropium bromide at index within the study period.
1710782|NCT01381406|Drug|TIO+FSC|Patients receiving tiotropium bromide plus fluticasone propionate-salmeterol xinafoate combination at time of index within the study period.
1710783|NCT01381393|Drug|Ibandronate|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
1710784|NCT01381380|Procedure|Manual therapy|Manual therapy, once a week for 8 weeks
1710785|NCT01381367|Biological|PPSV23 pneumococcal vaccine (Pneumovax®)|The adult anti-pneumococcal vaccine was a 23-polyvalent pneumococcal vaccine (Pneumovax®, Aventis Pastuer MSD), 0.5 ml of which was given subcutaneously. Duration of the efficacy is about 4-5 years.
1710786|NCT01381367|Drug|Normal Saline|normal saline, 0.5ml given subcutaneously
1710787|NCT01381354|Other|Progressive exercise|Progressive strengthening exercises designed to improve core muscles and muscles of ambulation.
1710788|NCT01381354|Device|Neuromuscular electrical stimulation delivered using the electrical therapy device EMPI 300 PV|Neuromuscular electrical stimulation to train core muscles and ambulation muscles. Device is Empi 300 manufactured by DJO Inc.
1710789|NCT01381354|Other|Modified paleolithic diet|Diet based upon a Paleolithic diet and structured to increase the consumption of greens, sulfur rich vegetables, bright colors, seaweed and omega 3 fatty acid rich foods.
1710790|NCT01381354|Dietary Supplement|Omega 3 fatty acids|4 grams daily by mouth.
1710791|NCT01381354|Dietary Supplement|Full Spectrum vitamin|Two capsules daily.
1710792|NCT01381354|Dietary Supplement|Essential - hydroxytyrosol|Two capsules twice daily.
1710793|NCT01381354|Dietary Supplement|Maltodextrin fiber supplement|One scoop daily.
1710794|NCT01381354|Dietary Supplement|Mineral boost (magnesium)|Two capsules daily
1710795|NCT01381354|Dietary Supplement|Niacinamide|500 mg daily
1710796|NCT01381354|Dietary Supplement|Methyl B12|Methyl B12 1000 mcg daily
1710797|NCT01381354|Dietary Supplement|Taurine|one gram daily
1710798|NCT01381354|Dietary Supplement|creatine|one teaspoon daily
1710799|NCT01381354|Dietary Supplement|thiamine|100 mg daily
1710800|NCT01381354|Dietary Supplement|riboflavin|200 mg daily
1710801|NCT01381354|Dietary Supplement|N acetylcysteine|1 gram daily
1710802|NCT01381354|Dietary Supplement|alpha lipoic acid|300 mg twice daily
1710803|NCT01381354|Dietary Supplement|L acetyl carnitine|500 mg twice daily
1710804|NCT01381354|Dietary Supplement|methyl folate|1000 mcg one pill four times a week
1710805|NCT01381354|Dietary Supplement|coenzyme Q|100 mg daily
1710806|NCT01381354|Behavioral|meditation|meditation 15 minutes daily
1710807|NCT01381354|Behavioral|self massage|self massage of hands, feet, ears 15 minutes daily
1710808|NCT01381354|Behavioral|learning|completing puzzles or learning 15 minutes daily
1710809|NCT01381354|Dietary Supplement|Coconut oil|If excessive weight loss occurs, the subject will add 1-2 tablespoons of coconut oil daily to smoothies or foods eaten.
1710810|NCT01381341|Drug|linifanib|QD on Day 1 of Periods 1 and 2
1710811|NCT01381315|Procedure|Injection of isotope|On the day of surgery, if the radioactive SLN cannot be located using the gamma probe prior to incision, lymphazurin or methylene blue dye will be used in the breast in the subareolar plexus at the discretion of the surgeon for assistance in identifying the sentinel nodes. This contingency, expected to occur <3% of the time, will be used since locating the SLN for staging is of greater importance than the study. If radioactive isotope is sufficient to identify the sentinel node draining from the breast, then the blue dye will be injected dermally in the upper inner arm along the bicipital groove of the ipsilateral arm in order to locate the draining lymphatics from the arm. No more than 5cc of blue dye will be injected in any of the above mentioned scenarios.
1710812|NCT01381315|Procedure|Axillary lymph node dissection|The one-year lymphedema rate among subjects undergoing axillary lymph node dissection with or without sentinel lymph node biopsy is ≥ 0.13. With our sample size of 58 subjects undergoing ALND, we will reject that hypothesis in favor of the alternative—that the lymphedema rate is <0.13 for subjects undergoing ALND—if lymphedema is confirmed in three or fewer (ie, 0, 1, 2, or 3) subjects.
1710813|NCT01381289|Drug|VX-770|150 mg tablet, oral use, twice daily every 12 hours (q12h)
1710814|NCT01381276|Other|Beta-Carotene bio-fortified cassava porridge without oil|300 g of porridge (11 ounces) containing 100 g drained mashed cassava and approximately 1 mg beta-carotene.
1710892|NCT01380613|Behavioral|Workshop control|1 session intervention on standard HIV/STD information
1710815|NCT01381276|Other|Beta-Carotene bio-fortified cassava porridge with oil|300g porridge (11 ounces) containing 100 g drained mashed cassava, 15 g peanut oil, and approximately 1 mg beta-carotene.
1710816|NCT01381276|Other|White cassava porridge with retinyl palmitate reference dose|300 g porridge containing 15 mL peanut oil, 100 g drained mashed cassava, and a tracer of approximately .3 mg pure food-grade retinyl palmitate.
1710817|NCT01381263|Behavioral|Behavioural medicine treatment|The behavioural medicine treatment program will include muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis and age appropriate interventions aimed to address the emotional and behavioural processes of pain.
1710818|NCT01381263|Other|Standard treatment|Standard treatment includes muscle strengthening, stretching, posture training, training of relaxation techniques and information about pain according to the best empirical praxis
1710819|NCT01381250|Behavioral|cognitive behavior therapy|The treatment was based on established cognitive behavior therapy methods, as described in self-help books (Hodgins, 2002; Ladouceur & Lachance, 2006). The text was divided into eight modules and was adapted for Internet use. The first four modules had a motivational interviewing focus and included building motivation for change by letting the participant answer open-ended questions that would evoke talk of change. The participants were encouraged to ask for input from their relatives on different aspects of their gambling. In addition, the first four modules included time line follow-back and mapping of the reasons for gambling. The remaining four modules were based on CBT. Each module included information and exercises and ended with three to eight essay-style questions. Feedback on homework assignments was usually given within 24 hr after participants had sent their answers via e-mail. Once weekly, a telephone call was made by the therapists to each participant.
1710820|NCT01381237|Behavioral|game-based balance exercises|16 sessions, scheduled two per week, each lasting 45 minutes.
1710821|NCT01381224|Other|Observation of biomechanical effects post injection|Observation of effects on gait, lumbar spine range of motion and pain symptoms immediately following injection and at two weeks post injection
1710822|NCT01381211|Drug|TACE-DEB|Transcatheter arterial chemoembolization (TACE) is performed with drug eluting beads (DEB), polyvinyl alcohol-based microspheres loaded with the chemotherapeutic agent doxorubicin.
1710823|NCT01381211|Drug|90Y-RE|Glass Yttrium-90 microspheres (TheraSphere®; MDS Nordion Inc.) will be used
1710824|NCT01381198|Procedure|Distal rectus femoris transfer|Transfer of the distal rectus femoris tendon to the semitendinosus tendon.
1710825|NCT01381185|Drug|Aspirin 200mg qd, Clopidogrel 2x75mg qd|According to 2 platelet monitoring assays HPR confirmation aspirin will be increased to 200mg qd, clopidogrel to 2x75mg qd. This treatment will be given for 30 days from index event (myocardial infarction)
1710826|NCT01381172|Device|Optimizer System|The OPTIMIZER System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
1710827|NCT01381172|Other|No intervention: Optimal medical therapy|The control group receives optimal medical therapy only.
1710828|NCT01381159|Behavioral|Motivational Communication|Brief MC sessions focused on medication adherence within 4-6 week period
1710829|NCT01381159|Behavioral|Control|Standard medical care
1710830|NCT01381146|Behavioral|Impact of Crime Modules|5 session/1 week modules of a restorative justice inspired victim impact group intervention
1710831|NCT01381146|Behavioral|TAU|have access to other jail programs and services
1710832|NCT01381133|Behavioral|Chestnut Bloomington Outpatient (CBOP)|CBOP is an evidence-informed intervention that has developed over 20 years and been shaped by treatment research. The underlying theory of change is that the combination of multiple evidence-based and best-practice treatment components will increase the adolescent's desire to change, provide the necessary skills, and create an environment supportive for this change. The intervention is based on a manual and is primarily delivered through skill and therapy groups, combined with a limited number of family and individual sessions for treatment planning and progress reviews.
1710833|NCT01381133|Behavioral|Motivational Enhancement Therapy/Cognitive Behavior Treatment (MET/CBT 7)|A manual-based 5-session MET/CBT model was supplemented with 2 family sessions. First was a family session to provide parents with an overview. Next was an individual adolescent MET session that focused on building rapport, explaining treatment, building motivation, and reviewing personalized feedback. In the third session, the therapist helped the adolescent complete a functional analysis of substance use and a personal goal worksheet. During sessions 4-6, the adolescent joined a closed group of 6 for 90-min CBT skills groups focusing on substance refusal skills, enhancing social support, planning for high-risk situations, and coping with relapse. The last session was a family session to review progress, relapse signs, and continuing care plans. Treatment lasted about 12 weeks.
1710834|NCT01381133|Behavioral|Assertive Continuing Care (ACC)|ACC is a home-based continuing care approach that takes place over a 12-14 week period and has shown promise in a randomized clinical trial of adolescents discharged from residential treatment. Following an operant reinforcement and skills training model, ACC combines the Adolescent Community Reinforcement Approach and case management services to help adolescents and their caregivers engage in prosocial activities, skills, and needed community services during weekly home visits.
1710835|NCT01381120|Drug|Solifenacin succinate treatment|Dosage form: tablet, film coated Dosage: 5 mg Frequency: daily Duration: three months
1710836|NCT01381120|Drug|Oxycodone and acetaminophen combination treatment|Dosage form: tablet, film coated Dosage: 10 mg Frequency: every 6 hours Duration: 5 - 8 days (stent inserted)
1710837|NCT01381107|Drug|ALKS 5461|Sublingual administration once daily for 7 consecutive days.
1710838|NCT01381107|Drug|Placebo|Sublingual administration once daily for 7 consecutive days.
1710839|NCT01381094|Drug|AKB-6548|oral dose administered once daily for 42 days
1710840|NCT01381094|Drug|Placebo|oral placebo administered once daily for 42 days
1710841|NCT01381081|Biological|platelet-rich plasma|a single intra-articular injection
1710842|NCT01381081|Drug|Corticosteroid|A single betamethasone and bupivacaine intra-articular injection
1710843|NCT01381068|Device|End tidal CO2 monitor|The sensor is placed in the respiratory circuit in both arms of the trial but the display is visible to the resuscitation team in the monitored arm and is covered in the control arm. The end tidal CO2 data is collected in both arms.
1711401|NCT01376258|Drug|5ARI|dutasteride or finasteride
1710844|NCT01381055|Drug|Pentoxifylline|Patients with cutaneous leishmaniasis treated with pentavalent antimony/Meglumine antimoniate 20mg/kg/day during 20 days and pentoxifylline pills 400mg three times a day during 20 days.
1710845|NCT01381055|Drug|Placebo|Patients with cutaneous leishmaniasis treated with pentavalent antimony/metilglucamine 20mg/kg/day during 20 days and placebo pills three times a day during 20 days.
1710846|NCT01381016|Drug|Estradiol|Subjects were instructed to apply 0.1 mg/d transdermal estrogen for one month.
1710847|NCT01381016|Drug|Gonadotropin-releasing hormone (GnRH)|Pituitary response was assessed to determine how estradiol administration alters pituitary sensitivity to GnRH.
1710848|NCT01381016|Drug|Progesterone|Subjects who failed to initiate a menstrual period following 40 days on the patch were instructed to take 200 mg daily of progesterone for 10 days or as long as deemed necessary.
1710849|NCT01381003|Genetic|pCCLchimGp91s lentiviral vector transduced CD34+ cells infusion|pCCLchimGp91s lentiviral vector transduced CD34+ cells will be infused in a volume of 50-100 mls intravenously over 30-45 minutes
1710850|NCT01380990|Genetic|EF1αS-ADA lentiviral vector transduced patient Cd34+ cells|EF1αS-ADA lentiviral vector transduced patient Cd34+ cells will be infused in a volume of ~10-20 mls/kg intravenously over 30-45 minutes.
1710851|NCT01380977|Behavioral|Impact of Crime group intervention|A group intervention for 16 1.5 hr sessions held twice a week
1710852|NCT01380951|Drug|telbivudine|telbivudine 600mg/d 96 weeks
1710853|NCT01380938|Drug|Peginterferon alpha-2a + Ribavirin|"Administration of ribavirin at a dosage of 1000 or 1200 mg per day based on body weight < or > 75 kg for 24 weeks (Arm A).
Treatment duration of 48 weeks with standard fixed dose of ribavirin (800 mg/day) (Arm B).
These schedules will be compared with diagram of standard therapy with 800 mg daily of ribavirin for 24 weeks (Arm C)"
1710854|NCT01380912|Drug|methylprednisoloneacetate|Either methylprednisoloneacetate 80 mg or saline solution will be injected first day after operation, when the drain is removed.
1710855|NCT01380899|Procedure|Biopsy of skin|Under local anesthesia with 1% xylocaine, 4-mm punch biopsies with 3-mm depth, including the dermis and subcutaneous fat tissue, will undergone from two regions, neck and lower back.
1710856|NCT01380886|Other|experimental infant formula with alternate protein source|experimental infant formula to be fed ad libitum
1710857|NCT01380886|Other|Infant formula powder|powdered infant formula to be fed ad libitum
1710858|NCT01380873|Drug|Period I : HKB0701, Period II : HKB0701 and SLM0807, Period III : CJ30001|
1710859|NCT01380873|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001, Period III : HKB0701|
1710860|NCT01380873|Drug|Period I : CJ30001, Period II : HKB0701, Period III : HKB0701 and SLM0807|
1710861|NCT01380860|Procedure|Colostomy with mesh implantation|Colostomy with mesh implantation
1710862|NCT01380860|Procedure|Simple colostomy|Colostomy with no mesh implantation.
1710863|NCT01380847|Genetic|mRNAs encoding genes|investigate whether the levels of 21 mRNAs encoding genes involved in EMT/fibrogenesis and the alloimmune response are a sensitive and specific non-invasive diagnostic test for CAN in renal allografts
1710864|NCT01380834|Drug|control group|Group 2(control group): 42 patients will have placebo/normal saline in paravertebral space, same amount, and injection at incision sites for all four insufflation ports with ropivacaine 0.5%.
1710865|NCT01380834|Drug|treatment group|Group 1( treatment group ): 42 patients will have six paravertebral nerve blocks with ropivacaine 0.5 %, and incisional administration of placebo / normal saline at all four laparoscopic ports.
1710866|NCT01380821|Radiation|Myocardial SPECT|Myocardial SPECT according to clinical standards for patients with a clinical indication to undergo this imaging test.
1710867|NCT01380808|Drug|capecitabine and pseudomonas aeruginosa combination|capecitabine 1000mg/m2 bid, po. pseudomonas aeruginosa 0.5ml loading dose,1ml qod ih.
1710868|NCT01380795|Biological|CTC|every two cures of a standard chemotherapy patients will be taken sample of blood to monitor CTC presence and EGFR/ K-ras status of that CTC
1710869|NCT01380782|Drug|BIBF 1120|200 mg BID oral for 28 day cycle
1710870|NCT01380769|Drug|CRLX101|CRLX101 is administered at 15mg/m2 IV every other week
1710871|NCT01380769|Other|Best Supportive Care|best supportive care
1710872|NCT01380756|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule aurora kinase inhibitor. AMG 900 will be administered daily for 4 days every 2 weeks or daily 7 days every 2 weeks (ie.g., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
1710873|NCT01380756|Drug|Arm 2- Dose Expansion|AMG 900 is a small molecule aurora kinases inhibitor. The dose expansion phase would be conducted to gain further clinical experience with AMG 900 in AML at the optimal dose schedule.
1710874|NCT01380743|Drug|duvoglustat hydrochloride|Single oral dose
1710875|NCT01380730|Biological|Evolocumab|Administered by subcutaneous injection
1710876|NCT01380730|Other|Placebo to Evolocumab|Administered by subcutaneous injection
1710877|NCT01380717|Drug|Beta-blocker, ACE-inhibitor|Beta-blocker: 50- 100 mg 1-2 times a day. ACEi: 5-10 mg once a day
1710878|NCT01380717|Drug|Calcium Channel Blockers, ACE-Inhibitor|Calcium Channel Blockers: 5-10 mg a day. ACEi: 5-10 mg a day
1710879|NCT01380704|Drug|ABT-436|QD Days 1-7
1710880|NCT01380704|Drug|Matching Placebo|QD Days 1-7
1710881|NCT01380691|Drug|LY2216684|Administered orally
1710882|NCT01380691|Drug|LY2216684 Placebo|Administered orally
1710883|NCT01380691|Drug|Alcohol Placebo containing beverage|Administered orally
1710884|NCT01380691|Drug|Alcohol containing beverage|Administered orally
1710885|NCT01380678|Drug|Intralesional injection of bevacizumab|single dose of 2 mg of bevacizumab intralesional injection on pterygium Combination of topical antazoline and tetrahydrozoline four times a day
1710886|NCT01380678|Drug|Topical antihistamine and vasoconstrictor|combination of topical antazoline HCl 0.05% and tetrahydrozoline HCl 0.04%
1710887|NCT01380665|Device|Prevena Incisional Management System|All evaluable patients will utilize the Prevena Incisional Management System
1710888|NCT01380652|Procedure|whole body vibration training|pulmonary rehabilitation with strength and endurance training and additionally vibration training
1710889|NCT01380639|Other|whole body vibration training|performing squats for 3x3 minutes while using vibration platform three times a week
1710890|NCT01380626|Procedure|exercise training|strength and endurance training, 5 time per week.
1710893|NCT01380600|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dose Range: 1x10^6 pfu/kg, 1x10^7 pfu/kg, 3x10^7 pfu/kg Up to 4 intravenous infusions administered over 60 minutes every 2 weeks.
1710894|NCT01380561|Drug|asimadoline|10mg [14]C labelled asimadoline Day 1 then 7 doses 0.5 mg asimadoline bid beginning on Day 2 and ending on Day 5.
1710895|NCT01380548|Dietary Supplement|Placebo|Placebo; once/day; for 12 weeks
1710896|NCT01380548|Dietary Supplement|Iron alone|Iron (3 mg); once/day; for 12 weeks
1710897|NCT01380548|Dietary Supplement|Low-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (12.5 mg) and iron (3 mg); once/day; for 12 weeks
1710898|NCT01380548|Dietary Supplement|Medium-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (25 mg) and iron (3 mg); once/day; for 12 weeks
1710899|NCT01380548|Dietary Supplement|High-dose 5-aminolevulinic acid with iron|5-Aminolevulinic acid (50 mg) and iron (3 mg); once/day; for 12 weeks
1710900|NCT01380535|Drug|ECP(Methoxsalen)+Corticosteroids+Cyclosporine or Tacrolimus|ECP UVADEX dose (TBD) administered during Wks 2-10 (2x/wk), Wks 11-18 (2x/wk every 2 wks), and Wks 19-26 (2x/wk every 4 wks) along with corticosteroids at a dose of 1.0 mg/kg prednisone, or equivalent, daily, tapered to 0.125 mg/kg daily by Wk 24 and maintained at that dose until Wk 28.
1710901|NCT01380535|Drug|Corticosteroids/Cyclosporine/Tacrolimus|1.0 mg/kg prednisone, or equivalent, daily, tapered to 0.125 mg/kg daily by Wk 24 and maintained at that dose until Wk 28 administered with cyclosporine or Tacrolimus (dose of cyclosporine/Tacrolimus should be consistent with local institutional practice).
1710902|NCT01380522|Drug|Metronidazole|Capsules, single-dose, fed
1710903|NCT01380522|Drug|Flagyl|Capsules, single-dose, fed
1710904|NCT01380509|Drug|Metronidazole|Capsules, single-dose, fasting
1710905|NCT01380509|Drug|Flagyl|Capsules, single-dose, fasting
1710906|NCT01380496|Drug|doxycycline monohydrate|tablet, 100 mg, single, oral dose
1710907|NCT01380496|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
1710908|NCT01380496|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
1710909|NCT01380483|Drug|doxycycline monohydrate|Tablets, 100 mg, single, oral dose
1710910|NCT01380483|Drug|doxycycline monohydrate|Capsule, 100 mg, single, oral dose
1710911|NCT01380457|Drug|Dronabinol|Capsules, 10 mg, single dose, fasting conditions
1710912|NCT01380457|Drug|Marinol|Capsules, 10 mg, single-dose, fasting conditions
1710913|NCT01380444|Procedure|Gamma3 Intramedullary Nails (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
1710914|NCT01380444|Procedure|Sliding Hip Screws|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
1710915|NCT01380431|Drug|Lisinopril|Tablets, 40 mg, single oral dose
1710916|NCT01380431|Drug|lisinopril|Tablets, 40 mg, single, oral dose
1710917|NCT01380431|Drug|Lisinopril|50% of subjects received the Par formulated product.
1710918|NCT01380405|Behavioral|education intervention|"Individual or collective education interventions about the correct use of inhalers.
session in the management of inhalers in the collective or individual programmed.
Session individual: 2 session. 15 min for session. Session collective: 2 session. 30-40 min for session. Maximum 4 persons."
1710919|NCT01380379|Behavioral|Life skills and self-defense training|8 week class which meets once per week for 2.5 hours. Each class contains the following components: 1) life skills/education training. This includes basic education about physical and sexual assaults, assault risks, dating and communication, assertiveness training and boundary setting, 2) physical self-defense training, 3) supportive therapy/debriefing.
1710920|NCT01380366|Drug|Somatropin|Patients are given somatropin (growth hormone) for their short bowel syndrome for 28 days at a dose of 0.1 mg/kg subcutaneously daily to a maximum of 8 mg daily.
1710921|NCT01380366|Procedure|Seven Day Food Diary|Subjects are asked to fill out a seven day food diary the week prior to their inpatient appointment, prior to receiving rHGH treatment for their short bowel syndrome. Subjects will be asked to repeat the use of a food diary after completing the administration of the growth hormone.
1710922|NCT01380366|Procedure|Blood Tests (standard of care)|Blood tests are taken (standard of care) to evaluate the potential hepato-protective effects of improving intestinal barrier function on those receiving human growth hormone for short bowel syndrome. Per clinical protocol to test liver function i.e. Alanine Aminotransferase (ALT), Aspartate Aminotransferase (AST), Alkaline phosphatase (ALP), Gamma-glutamyl transpeptidase (GGT), Total Bilirubin). A complete blood count (CBC) with platelets (PLTS) and white-count differential (WBC with diff) is performed to check for anemia and infection. These tests will be taken at baseline (before fasting) and repeated again on the 28th day (last dose) of the growth hormone. Blood is also taken at clinical visit over the next two years (approximately every two months).
1710923|NCT01380366|Other|Fasting|Eight hour overnight fast prior to being given sucralose, mannitol, lactulose, and sucrose. This is done at baseline (day one) and repeated again after the last dose of growth hormone and prior to sugar permeability urine tests.
1710924|NCT01380366|Other|Sugar Permeability Test|Subject will be given 4 capsules of sucralose (250mg per capsule), 2.0 grams of mannitol, 7.5 grams of lactulose, and 40 grams of sucrose in 150 mL of water. This will be given on the second day of the study after an 8-hour overnight fast and repeated within 72 hours of the last dose of growth hormone.
1710925|NCT01380366|Other|Urine Collection|Urine will be collected for the following five hours after subject has been given combination of sucralose, mannitol, lactulose, and sucrose to complete the intestinal sugar permeability test looking at urine ratio of lactulose to mannitol (L/M ratio). Tests include urinalysis (UA) and a blood urea nitrogen (BUN)/creatinine (Cr).
1710926|NCT01380353|Other|Diclofenac epolamine patch|Patch (10cm X 14cm) is comprised of an adhesive material containing 1.3% diclofenac epolamine which is applied to a non-woven polyester felt backing and covered with a polypropylene film release liner [B].
1710956|NCT01380132|Procedure|Anal injection of Nasha Dx|Submucous injection of Nasha Dx 5-10 mm above dentate line
1711459|NCT01375816|Drug|fluorouracil|
1710927|NCT01380340|Other|Seniors Early Intervention Planning and Discussion.|The seniors early intervention driving group is for seniors who have been identified by professionals as having to face changes to their driving status. It involves activities such as change strategies, positive psychology approaches and topic based discussion designed to mitigate the health and quality of life effects of driving regulation and cessation.
1710928|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - Low Dose|Participants are randomized to receive daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to three escalating doses, or until the maximum study dose (420 microliters, 1:20 w/v) was achieved.
1710929|NCT01380327|Other|Placebo|Participants are randomized to receive either daily (low dose) or twice-daily (high dose) placebo treatment placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The placebo was also administered during the preliminary dosing visits, up to three or seven escalating doses, or until the maximum study dose (420 or 840 microliters, 1:20 weight per volume [w/v]) was achieved.
1710930|NCT01380327|Biological|Cockroach Sublingual Immunotherapy (SLIT) - High Dose|Participants are randomized to receive twice-daily doses of glycerinated German cockroach (Blattella germanica) allergenic extract formulated in 50% glycerin at a concentration of 1:20 weight per volume [w/v] placed under the tongue (sublingual route) to dissolve. The treatment course and study duration was 3 months. Note: The extract was also administered during the preliminary dosing visits, up to seven escalating doses, or until the maximum study dose (840 microliters, 1:20 w/v) was achieved.
1710931|NCT01380314|Drug|Miltefosine + Imiquimod|150 mg x d during 28 days and cream applied every other day during 3 weeks
1710932|NCT01380314|Drug|Miltefosine 150 mg x day + Placebo|150 mg x d during 28 days and cream applied every other day during 3 weeks
1710933|NCT01380301|Drug|Miltefosine and antimony|Short course (half of each drug) administered simultaneously
1710934|NCT01380301|Drug|Miltefosine alone|short course (half)
1710935|NCT01380288|Drug|rivastigmine patch|rivastigmine patch 5cm2 for 4 weeks and then augmented to 10cm2 for 20 weeks
1710938|NCT01380249|Drug|PDM08|To assess the tolerability and safety of increasing multiple doses administration of PDM08: 560 μg, 1.12, 2.24, 3.5, 14, 28 and 56 mg administered twice a week for four weeks in patients with advanced solid tumours for which there is no standard therapy or they are refractory to it.
1710939|NCT01380236|Drug|ASM8|
1710940|NCT01380223|Drug|placebo|I.V. infusion of placebo for 8 hr
1710941|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.005 mg/kg/hr
1710942|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.015 mg/kg/hr
1710943|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.025 mg/kg/hr
1710944|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.0625 mg/kg/hr
1710945|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.125 mg/kg/hr
1710946|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.25 mg/kg/hr
1710947|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.5 mg/kg/hr
1710948|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 1.0 mg/kg/hr
1710949|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.75 mg/kg/hr (dose reduced)
1710950|NCT01380223|Drug|omecamtiv mecarbil|I.V. infusion of placebo for 2 hr followed by 6 hr infusion of omecamtiv mecarbil at 0.625 mg/kg/hr (dose reduced)
1710951|NCT01380197|Drug|Morphine|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
1710952|NCT01380197|Drug|Nubain|"Loading Dose: 0.1mg/kg. May repeat every 15 min up to a maximum of 3 total doses until pain controlled.
Continuous rate: 0.01-0.04mg/kg/hr (titrated to comfort level) PCA dose 0.01-0.03 mg/kg maximum 1.6 mg/dose 4 hour dose limit 0.24-0.3 mg/kg (Maximum dosing will not exceed 25 mg/4 hrs)."
1710953|NCT01380184|Drug|ridaforolimus|4 enteric coated tablets (ECT), each containing 10 mg ridaforolimus, orally (total 40 mg), on Day 1 and Days 8-12 of Cycle 1, and then once daily for 5 consecutive days in all subsequent cycles
1710954|NCT01380158|Device|Cup pessary (Bioteque America, Inc)|Placement of cup pessary in the vagina after randomization
1710955|NCT01380145|Biological|recMAGE-A3 Protein + AS15 Adjuvant|recMAGE-A3 + AS15 was administered intramuscularly at a dose of 300 µg recMAGE-A3, with no dose adjustments permitted. The first immunization was administered 6 to 15 week prior to auto-SCT, with subsequent immunizations administered on Days 10, 31, 52, 73, and 94 (± 3 days) and Days 180 and 270 (± 7 days) after auto-SCT.
1790931|NCT00519675|Drug|alitretinoin|
1710959|NCT01380106|Drug|Lenalidomide 15mg|Subjects will receive oral lenalidomide 15 mg once daily for 1-21 of a 28 day cycle.
1710960|NCT01380106|Drug|Lenalidomide 25mg|Subjects will receive oral lenalidomide 25mg once daily for days 1-21 out of a 28 cycle
1710961|NCT01380093|Drug|Placebo|Single-dose, 2 x microcrystalline cellulose (weighed to equal weights of average tablet/capsule of active comparator) mixed with 150 ml artificially sweetened, non-carbonated beverage
1710962|NCT01380093|Drug|MS Contin (morphine sulfate, controlled release)|Single-dose, 2 x 60 mg morphine sulfate whole tablets manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
1710963|NCT01380093|Drug|EMBEDA (morphine sulfate / naltrexone hydrochloride)|Single-dose, solution 2 x 60 mg morphine sulfate with sequestered 2.4 mg Naltrexone hydrochloride whole capsules manually crushed and mixed with 150 ml artificially sweetened, non-carbonated beverage
1710964|NCT01380080|Drug|Atripla (r)|Patients are administered one tablet of Efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (EFV/FTC/TDF, Atripla) to taken be taken orally once daily at bedtime without food.
1710965|NCT01380080|Drug|Efavirenz|Participants will take one 600 mg tablet administered orally once daily without food.
1710966|NCT01380080|Drug|Truvada|Participants will take one tablet of Emtricitabine 200mg/tenofovir disoproxil fumarate 300mg (FTC/TDF, Truvada) administered orally once daily with or without food.
1710967|NCT01380080|Drug|Rifampin/isoniazid/pyrazinamide/ethambutol FDC|Participants will be administered Rifampin/isoniazid/pyrazinamide/ethambutol FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 of the protocol, for the first 8 weeks.
1710968|NCT01380080|Drug|Rifampin/isoniazid FDC|Participants will be administered rifampin/isoniazid FDC tablets orally, once daily; dose by weight as determined in Table 5.1-1 in the protocol, for 16 weeks following the first 8 weeks.
1710969|NCT01380080|Drug|Isoniazid|INH 300 mg orally once daily
1710970|NCT01380054|Behavioral|Evaluation of quality of life|-Psychological interviews-Questionaires : HAD, STAI, CHIP, MHLC, WCC, SSQ scales-Quality of life : SF-36
1710971|NCT01380028|Drug|oral corticosteroids|Active treatment is prednisone establishment within 72 hours after the end of surgery at the dose of 1 mg / kg (rounded to the nearest 10 mg) once daily orally for one week . The daily dose then decreases in increments of 10 mg weekly, by the second week. Once the level of 10 mg / day reached the daily dose by one level lower than 5 mg weekly. Treatment is stopped after this week to 5 mg / day (average 2 months of treatment)
1710972|NCT01380028|Drug|placebo|placebo
1710973|NCT01380015|Other|Commercially spearmint tea|Commercially available, non-selectively bred spearmint tea.
1710974|NCT01380015|Other|High Rosmarinic Acid Spearmint Tea|The investigational product will be a high rosmarinic acid spearmint tea (700B) developed by the Department of Plant Agriculture, University of Guelph. Clone 700B has been selectively bred to contain a rosmarinic acid content 15-20 times greater than that of typical mint.
1710975|NCT01379989|Drug|Carboplatin|Carboplatin AUC 5
1710976|NCT01379989|Drug|Pegylated Lipoxomal Doxorubicin (PLD)|PLD 30 mg/m² i.v.
1710977|NCT01379989|Drug|Trabectedin|trabectedin 1.1 mg/m2 3-hour i.v. infusion on Day 1 every 3 weeks. The use of central venous access is strongly recommended.
1710978|NCT01379976|Drug|Acetylcarnitine|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).
Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
1710979|NCT01379976|Drug|Placebo|"ALC or placebo will be administered concurrently with CHT at 1000 mg sachet three times every day (before meals).
Treatment should be administered for a maximum of 6 cycles for both arms unless progression or unacceptable toxicity, or treatment refusal."
1710980|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 1|Intramuscular injection, two doses each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 1 - Havrix / Havrix Jr Group
1710981|NCT01379937|Biological|Influenza vaccine GSK1562902A Formulation 2|Intramuscular injection, one dose each in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and GSK1562902A Formulation 2 - Havrix / Havrix Jr Group
1710982|NCT01379937|Biological|Havrix™|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group, GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
1710983|NCT01379937|Biological|Havrix™ Junior|Intramuscular injection, one dose in GSK1562902A Formulation 1 and 2 - Havrix / Havrix Jr Group and two doses each in GSK1562902A Formulation 1 - Havrix / Havrix Jr Group,GSK1562902A Formulation 2 - Havrix / Havrix Jr Group and Havrix / Havrix Jr Group
1710987|NCT01379911|Other|Yogurt|
1710990|NCT01379885|Behavioral|Standard technique|Children in the ST group will receive vapocoolant spray and arm gripping adjacent to the injection site performed by MA 1(immunizer). A second MA (MA 2) will perform the visual distraction by descending contralateral arm vibration using the massage instrument (buzzer).
1710991|NCT01379885|Behavioral|Parent participation technique|The children in the PPT group will receive the same sequence, except that the parent/caregiver will administer the visual distraction rather than by MA2
1710992|NCT01379872|Other|Non-Interventional Study|This is a non-interventional study
1710993|NCT01379846|Biological|TAK-816+ DPT-TAKEDA|TAK-816 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
1710994|NCT01379846|Biological|ActHIB+ DPT-TAKEDA|ActHIB 0.5 mL and DPT-TAKEDA 0.5.mL, subcutaneous injections, three doses administered at 4-week intervals over 8 weeks, followed by a fourth dose 52 weeks after third dose.
1793547|NCT00538291|Drug|capecitabine|
1710995|NCT01379820|Device|OROTRACHEAL cpap WITH COMPENSATION BAG ( GREGORY CPAP)|USE OF OROTRACHEAL CPAP FOR RESPIRATORY DISTRESS SYNDROME IN NEWBORNS .
1710996|NCT01379807|Drug|panitumumab + docetaxel + cisplatino|Panitumumab, docetaxel and cisplatin combination treatment will be administered for 6 months or until disease progression (PD) according to investigator's criteria unacceptable toxicity or consent withdrawal.
1710997|NCT01379781|Behavioral|Behavioral Intervention for PPD|We will select a sample of pregnant women at risk for PPD, teach parenting skills to increase infant nocturnal sleep and reduce fuss/cry behavior to half of the sample during 3 perinatal visits.
1710998|NCT01379768|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily and extended (overnight) wear for up to 30 nights.
1710999|NCT01379768|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens FDA-approved for daily or extended (overnight) wear up to 6 nights.
1711000|NCT01379768|Device|Clear Care Cleaning and Disinfection Solution|Hydrogen peroxide-based contact lens care system for nightly cleaning and disinfection of study lenses
1711001|NCT01379742|Device|RapidStrand seeds for use with 18g needle|Rapidstrand seeds are standard size and are used with 20 g needles
1711002|NCT01379742|Device|ThinStrand|ThinStrand seeds are smaller in diameter and used with 20g needles
1711003|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
1711004|NCT01379729|Other|Transplantation of encapsulated beta cells.|Implantation of a therapeutical dose of encapsulated beta cells.
1711005|NCT01379716|Other|skin biopsy|Using a punch biopsy, the study doctor will take a small sample of skin (3mm diameter) from a pre-defined site of the subject. For PHN patients, 4 biopsies will be obtained: 2 in an area of PHN and 2 in a contralateral control site. Biopsy sites for each PHN control subject will be matched anatomically to the corresponding PHN patient with two biopsies each from symmetrical sites in a left and right dermatome. One biopsy from each site in each subject will be fixed in a left and right dermatome. One biopsy from each site in each subject will fixed yb immersion in 4% paraformaldehyde for immunocytochemical analysis, and the second biopsy form each site will be flash frozen for assessments of mRNA expression.
1711006|NCT01379690|Other|HBA1C|Used level of HBA1C as a reflection of glycaemic control of the cases and controls
1711007|NCT01379677|Drug|Rubidium-82|Maximum dose allowed per injection: 2200 MBq Maximum cumulated dose allowed per examination: 4400 MBq Intravenous Use
1711008|NCT01379677|Drug|Sestamibi. reconstitution with sodium pertechnetate (99mTc)|Maximum dose allowed per injection: 1000 MBq Intravenous Use
1711009|NCT01379664|Drug|Isoflurane|Isoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
1711010|NCT01379664|Drug|Sevoflurane|Sevoflurane is administered to patient during surgery as it would normally be administered by the attending anesthesiologist
1711011|NCT01379651|Other|Specific oral tolerance induction|Specific oral tolerance induction consisted in the administration of increasing amounts of raw emulsion egg
1711012|NCT01379625|Drug|Triheptanoin|Triglyceride with three heptanoin or 7 carbon fatty acids esterified to a glycerol backbone
1711013|NCT01379612|Other|Ultrasonic Elastography|Non-invasive
1711014|NCT01379599|Behavioral|brief motivation intervention|Brief motivation intervention consisting of brief psychosocial counseling (20 minutes at the time of an ER visit)
1711015|NCT01379586|Drug|ONO-4053|Part A: ONO-4053 doses proposed are 1 mg, 3 mg, 10 mg, 30 mg, 100 mg, 300 mg, 600 mg as a single dose administered by mouth once daily
1711016|NCT01379586|Drug|Placebo|Placebo to match ONO-4053 tablets dosed in a similar manner to ONO-4053
1711018|NCT01379560|Drug|unoprostone isopropyl|"unoprostone isopropyl (2 drops)
placebo (2 drops)"
1711019|NCT01379560|Drug|unoprostone isopropyl|"unoprostone isopropyl (3 drops)
placebo (3 drops)"
1711020|NCT01379547|Behavioral|Procalcitonin guided antibiotics treatment algorithm|Patients who will be randomized to arm 2 will receive antibiotics therapy with a duration based on procalcitonin measurement on day 5, 7 and 9.
1711021|NCT01379547|Behavioral|Conventional treatment|Patients who will be randomized to arm 1 will receive antibiotic therapy with a duration based on conventional practice.
1711022|NCT01379534|Drug|TKI258|
1711023|NCT01379521|Drug|everolimus|
1711024|NCT01379521|Drug|everolimus placebo|
1956307|NCT02905383|Other|Exercise|A multi-component exercise program that consists of endurance training, progressive strength exercises and balance exercises.
1956308|NCT02903381|Drug|Nivolumab|Intravenous, predetermined dosage, Days 1 and 15 during cycles 1-12 and
1711027|NCT01379495|Behavioral|educational program+telephone follow up|burns victims will participate in an educative program including telephone follow-up during six months after hospital discharge
1711028|NCT01379482|Drug|Multimodal treatment|"3 months (range 2-4.5) with neoadjuvant systemic chemotherapy. Four weeks after receiving the last course of chemotherapy, patients will undergo laparotomy with the objective of performing cytoreduction + hyperthermic intraperitoneal chemotherapy.
Early peritoneal chemotherapy though intrabdominal drains for the first five postoperative days.
Neo-adjuvant chemotherapy:
Irinotecan+Nordic FLv (6 pat.) EOX (6 pat.) FLOX (3 pat.) Docetaxel+Irinotecan+5-FU+LV (1 pat.) FOLFIRI (1 pat.) ECF (1 pat.)
Hyperthermic intraoperative chemotherapy:
Cisplatin+doxorubicin (5 pat.). Oxaliplatin +concomitant i.v. 5-FU+ i.v. LV (3 pat.)
Early postoperative chemotherapy:
5-FU + i.v. LV (5 pat.) Paclitaxel (1 pat.)"
1711029|NCT01379469|Drug|Drug-Carbamazepine (Tegretol XR)|To reduce the likelihood of hypersensitivity reactions the subjects will be started on 400 mg/day in 2 doses and the dose will be increased weekly by 200mg/day until reaching a stable therapeutic concentration with a dose not exceeding 1200mg/day(or 1000mg/day in subjects less than 15 years of age). The CBZ tablets will be encapsulated, and the placebo group will receive encapsulated tablets without CBZ.
1711030|NCT01379469|Drug|Carbamazepine (Tegretol XR) Placebo|Carbamazepine (Tegretol XR)Placebo-the subjects will be started on 400mg/day in 2 doses and the dose will be increased weekly by 200 mg/day until reaching a dose not exceeding 1200 mg/day (or 1000 mg/day in subjects less than 15 years of age). The placebo group will receive encapsulated tables without Carbamazepine.
1711031|NCT01379456|Procedure|physiotherapy|exercises, 20 sessions over 10 weeks
1711032|NCT01379443|Other|CTN model of care for children and their families|Parental reports on the quality of life of their children and service needs
1711033|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 1x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intramuscularly
1711034|NCT01379430|Biological|AdCh63 ME-TRAP followed by MVA ME-TRAP|AdCh63 ME-TRAP 5x10^10 vp intramuscularly, MVA ME-TRAP 2x10^8 pfu intradermal
1711035|NCT01379417|Dietary Supplement|Probiotic supplementation|1 capsule per day, from inclusion to 4 or 6 weeks after inclusion
1711036|NCT01379404|Device|Bioelectric Impedance Analysis|Bioimpedance devices are compact, portable, easy to use, relatively inexpensive and can be used to make repeated non-invasive measurements. Bioimpedance measures the impedance to the flow of an electric current through body fluids and consists of two components, resistance and reactance. Resistance is a measure of electrical current a substance will oppose and is inversely related to tissue fluid content. Reactance is the capacitative component of impedance and indicates energy stored by cell membranes and organelles; due to this property, reactance is associated with tissue cell mass. These raw measures provide a measure of volume as determined by vector length and the RXc graph method.
1711037|NCT01379391|Drug|Recombinant Human Thrombopoietin (rHTPO)|"Patients received allogeneic myeloablative hematopoietic stem cell transplantation with platelet count lower than 20G/L on +14 days after Allo-HSCT, met the above enrollment criteria and signed the informed consent forms are eligible subjects.
Administration method of rHuTPO: 300U/kg/d by percutaneous injection; Timing: d14 to d28 after Allo-HSCT."
1711038|NCT01379378|Device|Artificial urinary sphincter|Standard of care
1711039|NCT01379378|Device|InVance Sling|Standard of care
1711040|NCT01379378|Device|AdVance Sling|Standard of care
1711041|NCT01379378|Device|Virtue Sling|Standard of care
1711042|NCT01379378|Drug|Contigen|2.5-10 cc
1711043|NCT01379365|Device|Cryo-Touch III|Percutaneous treatment with the device
1711044|NCT01379339|Drug|Cabazitaxel 10mg/m2|"Cabazitaxel on D1 Dose: 10mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
1711045|NCT01379339|Drug|Cabazitaxel 12.5mg/m2|"Cabazitaxel on D1 Dose: 12.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
1711046|NCT01379339|Drug|Cabazitaxel 15mg/m2|"Cabazitaxel on D1 Dose: 15mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
1711047|NCT01379339|Drug|Cabazitaxel 17.5mg/m2|"Cabazitaxel on D1 Dose: 17.5mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
1711048|NCT01379339|Drug|Cabazitaxel 20mg/m2|"Cabazitaxel on D1 Dose: 20mg/m2 IV x 1 Route: Intravenous infusion over 60 minutes, mixed as described in protocol over 1 hour Schedule: Day 1, every 21 days (+ 2 days)
Cisplatin on D1 Dose: 100 mg/m2 Route: Intravenous infusion over 60 minutes to 3 hours, mixed in 1000 ml of normal saline Schedule: Day 1, every 21 days (+ 2 days)
5 Fluorouracil on D1-D4 Dose: 800 mg/m2/day Route: 24-hour continuous infusion over 4 days Schedule: Days 1, 2, 3 and 4 of Cycles 1, 2 and 3 (every 21 days) + 2 days)"
1711049|NCT01379326|Drug|Mebendazole|All children providing stool samples will be treated with mebendazole single table of 500mg under supervision (chewing + water).
1711050|NCT01379313|Procedure|conventional I:E ratio|conventional I:E ratio of 1:2 is applied.
1711051|NCT01379313|Procedure|1:1 ratio|I:E ratio of 1:1 is applied.
1711052|NCT01379313|Procedure|2:1 group|Inverse I:E ratio of 2:1 is applied.
1711053|NCT01379313|Procedure|external PEEP|external positive end-expiratory pressure of 5 cmH2O is applied.
1711054|NCT01379300|Drug|dabigatran etexilate|dabigatran etexilate, orally, as 2 x 75-mg capsules (150 mg), single administration
1711055|NCT01379300|Drug|rivaroxaban|rivaroxaban, orally, as 2 x 10-mg tablets (20 mg), single administration
1711056|NCT01379287|Drug|Iso-Fludelone|Iso-fludelone will be administered IV over 6 hours (+/- 30 mins) on Day 1 of every 3 week cycle.
1711057|NCT01379274|Drug|Lenalidomide and azacitidine combination|"lenalidomide 10 mg will be administered orally on Days 1-28 of each 28-day cycle. Patients who fail to achieve an erythroid response per 2006 IWG criteria after 3 cycles of monotherapy will receive lenalidomide at the same dose administered in cycle 3 and low-dose azacitidine25 mg/m2 subcutaneously (SC) or intravenously (IV) for 5 days (on Days 1-5) of every 28-day cycle.
Patients who fail to respond (2006 IWG criteria) after receiving two cycles of combination therapy will receive lenalidomide at the same dose administered in Cycle 3 and azacitidine 50 mg/m2 SC or IV given daily on Days 1-5 of each 28-day cycle, if no grade 4 toxicity developed or no delay greater than 2 weeks in starting a new cycle was experienced during the first 2 cycles of combination therapy."
1711058|NCT01379261|Procedure|Cooling|1-2 liters of cold saline and central venous catheter cooling with Philips InnerCool RTx Endovascular System prior to PCI
1711059|NCT01379248|Device|manual thrombus aspiration (Export catheter, Medtronic Inc. Minneapolis, Minnesota, USA)|manual thrombus aspiration catheter to be used during percutaneous coronary intervention
1711060|NCT01379235|Other|Pilatis exercise|12 weeks of pilatis exercise 3 times a week.
1711086|NCT01379014|Other|Treatment as Usual|The control group does not receive a copy of the decision aid tool booklet, instead received treatment as usual from vocational specialist
1711061|NCT01379222|Device|Endurant Stent Graft System|The Endurant Stent Graft System is designed to treat infrarenal abdominal aortic aneurysms using an endovascular approach. When placed within the aneurysm, the Endurant Stent Graft is designed to provide a permanent, alternative conduit for blood flow within the patient's vasculature by excluding the aneurysmal sac from blood flow and pressure.
1711062|NCT01379209|Drug|RGI-2001|RGI-2001 is a liposomal formulation of the α-galactosylceramide class of compound [(2S,3S,4R)-1-o-(alpha-D-galactopyranosyl)-2-(N-hexacosanoylamino)-1,3,4-octadecanetriol]. RGI-2001 is provided as an intravenous administration after AHSCT is complete. A single administration of RGI-2001 will be used in this trial. The study will last for 101 days in total; 29 days for safety and 101 days for evaluation of GvHD.
1711063|NCT01379196|Drug|Azithromycin|Tab. Azithromycin 500 mg PO three times weekly for 3 months
1711064|NCT01379183|Drug|Erythromycin|200 mg suspension
1711065|NCT01379183|Drug|Placebo|200 mg suspension
1711066|NCT01379183|Procedure|Magnetic Resonance Imaging|An MR enterography procedure uses magnetic resonance imaging (MRI) technology to obtain detailed images of the small bowel.
1711067|NCT01379183|Other|Barium Sulfate Solution|Participants will be given a low concentration of barium sulfate solution (1350 mL) prior to the MRI procedure. Barium sulfate is a radiopaque agent. Radiopaque agents are used to help diagnose certain medical problems. Since radiopaque agents are opaque to (block) x-rays, the areas of the body in which they are localized will appear white on the x-ray film. This creates the needed distinction, or contrast, between one organ and other tissues. The contrast will help the doctor see any special conditions that may exist in that organ or part of the body.
1711068|NCT01379170|Drug|Euthyrox (levothyroxine)|A dose of 25 μg per day of Euthyrox® will be administered orally during the first week and will be increased to 50 μg per day during the second week and to 75-100 μg per day in the third week depending on TSH, free T4 and T3 concentrations monitored throughout the treatment period. Patients will be instructed to take Euthyrox® after an overnight fast, 30 min before breakfast in the morning daily. After 3 months, free T4 and total T3 concentration must be in the normal range (free T4: 8.0-26 pmol/l, T4: 60-140 nmol/l and T3 1.2 - 3.4 nmol/l) and TSH 0.4-2.5 mU/l.
1711069|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 0.5 hr infusion of 0.5 g every 6 hr of imipenem at room temperature
1711070|NCT01379157|Drug|Imipenem|Each patient will receive a loading dose of 0.5 g 3 min infusion followed by 4 hr infusion of 1 g every 8 hr of imipenem at room temperature
1711071|NCT01379144|Drug|latanoprost 75 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).
Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
1711072|NCT01379144|Drug|latanoprost 100 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).
Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
1711073|NCT01379144|Drug|latanoprost 125 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).
Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
1711074|NCT01379144|Drug|latanoprost 50 ug|"Eligible patients were randomized to receive 1 of 4 different doses of latanoprost (50, 75, 100 or 125 ug/mL).
Study medication was supplied in clear bottles. Patients were instructed to instill one drop of study medication in one or both eyes (as instructed by their investigator) once daily in the evening between 7 PM and 9 PM during the entire treatment period. The first dose of study medication was instilled in the evening of the baseline visit and the last dose was instilled in the evening before the Week 4 (Day 28) visit."
1711075|NCT01379105|Other|neural mobilization|In the neural mobilization group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and performed 30 oscillations of plantar-to-dorsal flexion for one minute
1711076|NCT01379105|Other|Static Stretching|In the static stretching group, the subject was positioned in dorsal decubitus, and the researcher performed hip flexion with the knee extended passively and held for 30 seconds; this type of stretching corresponds to the maintenance of increased amplitude posture, without surpassing the maximum movement limit, three times with an interval of 10 seconds between the repetitions.
1711077|NCT01379092|Device|Trident Specimen Radiography System|MIBB images will be acquired on the standard of care device and the Trident System in the Breast Center at Hoag Hospital. BSS images will be acquired on standard of care device in the Operating Room and/or the Breast Center at Hoag Hospital and then on the Trident System. Image quality will be compared and system operation will be evaluated. Feedback will be provided to manufacturer and the Trident System further refined.
1711078|NCT01379092|Device|Bioptics, Faxitron, and Full Field Digital Mammography (FFDM) Selenia|All the above devices are used for SOC BSS imaging at Hoag Hospital. The images captured from these devices will be compared to the images captured from the Trident Specimen Radiography device.
1711079|NCT01379079|Drug|Acetylsalicylic acid|aspirin intake at bedtime
1711080|NCT01379079|Drug|Acetylsalicylic acid lysinate|aspirin intake on awakening
1711081|NCT01379040|Other|Cystic Fibrosis patients|
1711082|NCT01379027|Behavioral|Pure self-help Internet CBT for depression|Internet, CBT, Depression
1711083|NCT01379027|Behavioral|Guided self-help Internet CBT|CBT, Depression, Website intervention, coaching
1711084|NCT01379027|Behavioral|Stepped-Care Internet CBT condition|Depression CBT, Internet intervention
1711085|NCT01379014|Behavioral|Decision Aid Tool|A booklet which outlines to pros and cons of different decision outcomes, and is designed to assist the user in making a decision according to their own specific circumstances
1797610|NCT00568880|Drug|hydroxychloroquine|
1711087|NCT01379001|Drug|Scopolamine|Scopolamine 0.4mg IM x 1 dose; adjustment in older group for weight (0.4mg/70kg)
1711088|NCT01379001|Drug|Placebo|IM or PO placebo
1711089|NCT01379001|Drug|Donepezil|donepezil 5mg PO x 1
1711090|NCT01378988|Drug|Dexmedetomidine|For sedation according to protocol
1711091|NCT01378975|Drug|Vemurafenib|960 mg oral doses twice daily until disease progression, unacceptable toxicity or consent withdrawal.
1711092|NCT01378962|Drug|erlotinib [Tarceva]|150 mg orally once a day for 12 months
1711093|NCT01378949|Drug|Bupivacaine|Bupivacaine 0.5% with adrenaline 5 mcg/cc
1711094|NCT01378949|Drug|Morphine|Morphine 1 mg/cc
1711095|NCT01378936|Behavioral|MI plus IOC group intervention|45 minute Motivational Interview plus 16 session IOC intervention
1711096|NCT01378936|Behavioral|Motivational Interview only|45 minute Motivational Interview session
1956309|NCT02903381|Drug|Lenalidomide|Oral, predetermined dosage, Days 1-21 of cycle 1-12
1956310|NCT02903381|Drug|Dexamethasone|Oral, Days 1, 8, 15 of cycle 1-6
1711099|NCT01378910|Drug|Unique|Change of PI, NNRTI or integrase inhibitor to CCR5 antagonist (maraviroc)
1711100|NCT01378897|Device|MedSignals®pillbox,Omron pedometer,VitalSignals®weight scale|Participants will use three home monitoring devices (i.e., weight scale, pedometer, pillbox) for two months. In addition, participants will receive weekly phone calls from the study's bariatric dietician during weeks 1-4 of the study and then receive biweekly calls during the second month. The structured phone calls (approximately 10-15 minutes each call) will focus on discussing the patient's adherence data, discussing any barriers to adherence, and providing tailored patient education.
1711101|NCT01378884|Drug|Domperidone|Patient to receive treatment with Domperidone
1711102|NCT01378871|Drug|IMTOX-25|This agent is supplied as a sterile solution at 0.5 mg/ml. Thus a vial with 5 mls contains 2.5 mg IMTOX-25 15 mg/m²/cycle IV; The calculated total dose for the cycle will be divided by four and given on Days 1, 3, 5 and 7.
1711103|NCT01378871|Other|IMTOX-25|Imtox-25 is an immunotoxin. It is an antibody that is bound to a piece of the poison ricin. This antibody have been shown to bind to leukemia cells and kill them because of the ricin.
1711104|NCT01378858|Behavioral|Varenicline treatment as usual or directly observed therapy|Varenicline, titrated to 1 mg twice daily, will be given to participants in both study arms for 12 weeks.
1711105|NCT01378845|Drug|Tracleer|14 days 62,5 mg Bosentan p.o 140 days 125 mg Bosentan p.o
1711106|NCT01378845|Drug|Prostavasin|Prostavasin 60 µg i.v, 5 days per week for 2 weeks
1711107|NCT01378832|Procedure|Intra-peritoneal antibiotic lavage|The lavage was performed immediately prior to closure of the abdominal wall. Prior to the lavage, a microbiological sample from the peritoneal surface (parietal and visceral) was obtained with a swab (sample 1), followed by a lavage with 500 ml normal saline, similar to the one performed in Group 1. After this lavage, a new microbiological sample was obtained from the peritoneal surface (sample 2), and a second lavage with an antibiotic solution, including gentamicin (240 mg) and clindamycin (600 mg) dissolved in 500 ml normal saline was performed. During this lavage, the solution was allowed to sit in the abdominal cavity for 3 minutes. After aspirating the lavage, a third microbiological sample was obtained in the same way as the two previous ones (sample 3).
1711108|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|The laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
1711109|NCT01378819|Procedure|3-midline-ports laparoscopic cholecystectomy|Laparoscopic cholecystectomy will be performed through 3 ports placed in the line alba.
1711110|NCT01378806|Behavioral|Nutrition and exercise education and coping skills training|A 12-week intensive intervention on nutrition and exercise education and coping skills (Phase I), 9 months of continued monthly contact (Phase II), and then 6 months on their own.
1711111|NCT01378793|Behavioral|Relaxation Acupressure|Apply pressure (stimulate) to the 9 acupoints for 3 minutes per point giving a total treatment time of 27 minutes done once daily for a period of 6 weeks.
1711112|NCT01378793|Behavioral|Stimulating Acupressure|Apply pressure (stimulate) to the 10 excitatory acupoints for 3 minutes per point giving a total treatment time of 30 minutes done once daily for a period of 6 weeks.
1711113|NCT01378780|Behavioral|Educational intervention for diet and physical activity|The proposed project, SHARE, is a culturally-tailored, primary stroke prevention intervention for MAs and EAs that targets a number of health-related behaviors related to stroke risk. Using a combination of self-help materials, social support, peer counseling based on Motivational interviewing, tailored newsletters, and social environmental changes in Catholic Churches, the SHARE intervention will lead to increases in moderate and vigorous intensity physical activity, decreases in salt intake, and increases in fruit and vegetable intake. Additional targets include decreases in BMI for those overweight or obese, reduction of dietary fat (trans, saturated and total fat), and increases in low-fat dairy products, changes that will serve to reduce blood pressure and stroke risk. Additionally, SHARE will seek to improve hypertension medication adherence in participants with previously diagnosed high blood pressure at baseline screening.
1711114|NCT01378780|Behavioral|Educational message on skin cancer awareness|Control group will get the diet and physical activity intervention after the crossover but no outcomes will be measured after the crossover
1711115|NCT01378767|Dietary Supplement|Krill oil supplementation|During a 21-day Daniel Fast, group one supplemented with krill oil capsules (two grams per day) while group two supplemented with a placebo (coconut oil capsules at two grams per day).
1711116|NCT01378754|Drug|Fospropofol (Lusedra®) 6.5|Group 1 will receive 6.5 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
1711117|NCT01378754|Drug|Fospropofol (Lusedra®) 10|Group 2 will receive 10 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
1711118|NCT01378754|Drug|Fospropofol (Lusedra®) 12|Group 3 will receive 12 milligram per kilogram of Fospropofol (Lusedra®) injection (IV).
1711119|NCT01378741|Drug|Propofol|Upon arrival to ICU patients will receive a propofol 2-6mg/kg infusion until tracheal extubation
1711120|NCT01378741|Drug|Dexmedetomidine|Upon arrival to ICU patients will receive dexmedetomidine bolus of 0.4mcg/kg followed by an infusion of 0.2-0.7mcg/kg per hour for a maximum period of 24 hours.
1711121|NCT01378715|Drug|Rosuvastatin|Patients with coronary artery disease referred for coronary angiography and subsequently PCI will be enrolled and randomized to pre-treatment with rosuvastatin (20mg 12 hours prior + 20mg immediately prior PCI).
1711122|NCT01378702|Drug|mistletoe preparations|1 ampoule (1ml) twice per week subcutaneously
1711123|NCT01378689|Other|Storytelling online video|patients with a history of chronic glucocorticoids use tell their experiences of side effects resulting from chronic use and provide advice on ways to prevent side effects
1711128|NCT01378650|Drug|Cilostazol|Administration of Cilostazol 100mg twice a day for 4 weeks
1711129|NCT01378650|Drug|Placebo|placebo one tablet matching for cilostazol twice a day for 4 weeks.
1711130|NCT01378637|Device|AMES- Leg treatment|30 minutes of treatment of the leg consisting of the AMES device passively moving the ankle between plantarflexion and dorsiflexion with vibration of the tendons being stretched, while the participant tries to assist in the movement as much as possible.
1711131|NCT01378624|Other|Bronchoscopy|"In brief, during the first bronchoscopy a baseline BAL and baseline endobronchial brush and forceps biopsies will be obtained and allergen as well as saline (control segment) will be instilled.
The subjects will undergo a second bronchoscopy in order to obtain BAL from the allergen challenged segments and the saline challenged segment, and endobronchial forceps biopsies."
1711132|NCT01378611|Device|Vagus Nerve Stimulator: Neurocybernetic prothesis NCP, Cyberonics Inc., Webster, TX, USA|The study group is stimulated with the following parameters: Output current 0.25 milliampere (to be ramped up to max. 1.75 milliampere), Pulse width 0.5 milliseconds, Frequency 30 Hz, Duty cycle: 30 sec on 5 min off (duty cycle 10%).
1711133|NCT01378598|Other|Nursing Educational Intervention|Four educational sessions with the direct care nurse (DCN)
1711134|NCT01378585|Drug|DLBS1033|3 x 490 mg DLBS1033 daily
1711135|NCT01378585|Drug|Placebo|3 x 1 tablet daily
1711136|NCT01378559|Other|Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) Questionnaire|A questionnaire accessing satisfaction with a penis prosthesis
1711137|NCT01378546|Drug|3,4-diaminopyridine|Treatment will begin with 5mg three times a day or less.
1711138|NCT01378533|Drug|epirubicin, cyclophosphamide, paclitaxel, carboplatin, G-CSF|epirubicin 80mg/m2 iv d1 or divide in two days cyclophosphamide 600mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 175mg/m2 iv d1 G-CSF 3ug/kg ih d5-9 q14d*4cycles paclitaxel 150mg/m2 iv d1 carboplatin AUC=3 iv d2 G-CSF 3ug/kg ih d5-9 q14d*8cycles
1711139|NCT01378520|Drug|ketoconazole|600 mg capsule oral once
1711140|NCT01378520|Drug|inert powder|oral once
1711141|NCT01378507|Behavioral|endoscopic submucosal dissection|ESD was carried out by using a single-channel upper gastrointestinal endoscope with a water-jet system (Q260J; Olympus Optical Co, Tokyo, Japan) and a high-frequency generator with an automatically controlled system (ENDOCUT mode) (Erbotom ICC 200; ERBE Elektromedizin GmbH, Tübingen, Germany). The transparent attachment was fitted on the tip of the endoscope mainly to obtain a constant endoscopic view and to create tension on the connective tissue for the submucosal dissection.
1711142|NCT01378481|Drug|Vorinostat|Given PO
1711143|NCT01378481|Radiation|Stereotactic Radiosurgery|Undergo fractionated stereotactic radiation therapy
1711144|NCT01378481|Other|Laboratory Biomarker Analysis|Correlative studies
1711145|NCT01378481|Other|Pharmacological Study|Correlative studies
1711146|NCT01378481|Procedure|Therapeutic Conventional Surgery|Undergo neurosurgery
1711147|NCT01378468|Other|"oral triglyceride tolerance test (not a therapeutic intervention as such but a new diagnostic test)"|see Ebinger et al., IJS, 2010
1711148|NCT01378455|Other|interactive computerized handwriting training program|In ICHTP group, they received the training of visual-perception .visual-motor integration skill of children and modulate muscle strength of grasp through ICHTP software. The training program costs 45 min/once, three times/one week, and sustains four weeks.In traditional group, they received the training of paper-pencil activities with visual-perception and visual-motor integration skills. The training duration is as long as ICHTP group.
1711149|NCT01378455|Other|traditional handwriting training program|The THTP group ,they received the training of paper-pencil activities with visual-perception and visual-motor integration skills
1711150|NCT01378442|Other|fitness training program|"Experimental: high level training group. The experimental group received training for 40 min per day 3 times a week for 12 weeks. The hVCT program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, cycling for 20 min, and a cool-down exercise for 5 min.
Experimental: low level training group. The experimental group received training for 40 min per day 1-2 times a week for 12 weeks. The program consisted of a 5-min warm-up exercise, twenty repetitions of sitting-to-standing movements, fitness training for 20 min, and a cool-down exercise for 5 min.
Control:The control group will not receive fitness training program but maintain the usual life style."
1711151|NCT01378429|Drug|ciclesonide nasal aerosol|ciclesonide nasal aerosol (74 mcg)
1711152|NCT01378429|Drug|Placebo|Placebo
1711153|NCT01378416|Drug|Decitabine (Dacogen)|Intravenous injection; total dose-per-cycle was 135 mg/m^2 of decitabine.
1711154|NCT01378390|Drug|Expanded autologous adipose-derived adult stem cells (eASCs)|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgey standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell susupension will be placed into the fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure) at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
1711185|NCT01378156|Biological|JS7 plasmid DNA and MVA62B vaccine|JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25)
1805581|NCT00629577|Procedure|colposcopy|
1711155|NCT01378390|Drug|Placebo|Administration will be preceded by localization and closure of the internal opening following Major Ambulatory Surgey standards. Subjects will be receiving one treatment cycle with placebo consisting of intralesional instillation of 5 ml saline solution. Patients without healing (complete fistula closure) following week 12 assessment will continue to receive standard of care until the primary assessment of fistula closure at week 24. Patients with incomplete fistula closure at week 24 will be offered the possibility of participating in a separate open-label, single arm study using the ASCs derived from the liposuction procedure.
1956319|NCT02896296|Drug|Low dose RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose can be adjusted to high dose based on the medical judgment of the investigator.
1711157|NCT01378364|Drug|AbGn-168H|single very low dose of AbGn-168H i.v.
1711158|NCT01378364|Drug|AbGn-168H|single low dose of AbGn-168H i.v.
1711159|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
1711160|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
1711161|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
1711162|NCT01378364|Drug|Placebo|single dose of Placebo i.v.
1711163|NCT01378364|Drug|AbGn-168H|single medium dose of AbGn-168H i.v.
1711164|NCT01378364|Drug|AbGn-168H|single high dose of AbGn-168H i.v.
1711165|NCT01378364|Drug|AbGn-168H|single low dose of AbGn-168H s.c.
1711166|NCT01378364|Drug|Placebo|single dose of Placebo s.c.
1711167|NCT01378364|Drug|Placebo|single dose of Placebo s.c.
1711168|NCT01378364|Drug|AbGn-168H|single medium dose of AbGn-168H s.c.
1711169|NCT01378351|Other|Questionnaire survey|Mailed questionnaire investigating response to empiric treatment trials, further investigations by otolarygology and possible alternative diagnoses.
1711170|NCT01378325|Drug|Phenylephrine|Prophylactic variable rate of phenylephrine infusion started at 0.75 µg/kg/min vs saline
1711171|NCT01378325|Drug|saline|Prophylactic variable rate of saline infusion where we adjusted the pump at a starting rate of 0.75 µg/kg/min, equivalent to 0.0075 mL/kg/min of saline
1711172|NCT01378312|Biological|AERAS 402|0.5 mL IM injection of 3 x 1010vp AERAS-402 on Study Days 0 and 28
1711173|NCT01378312|Biological|Placebo|0.5 mL IM injection of 0vp (Placebo) on Study Days 0 and 28
1711174|NCT01378299|Drug|Testosterone Cypionate|"DEPo-Testosterone Injection, for intramuscular injection, contains testosterone cypionate which is the oil-soluble 17 (beta)-cyclopentylpropionate ester of the androgenic hormone testosterone.
Testosterone cypionate is a white or creamy white crystalline powder, odorless or nearly so and stable in air. It is insoluble in water, freely soluble in alcohol, chloroform, dioxane, ether, and soluble in vegetable oils. The chemical name for testosterone cypionate is androst-4-en-3-one,17-(3-cyclopentyl-1oxopropoxy)-,
(178)-. Its molecular formula is CvH400a, and the mole"
1711175|NCT01378286|Drug|ARTESUNATE + AMODIAQUINE|"Pharmaceutical form:
Route of administration:"
1711176|NCT01378286|Drug|Chloroquine|Pharmaceutical form:tablet Route of administration: oral
1711179|NCT01378247|Behavioral|Family Focused Nursing|All patients receive treatment as usual. Additionally, patients in the intervention arm receives family focused nursing consultations which are structured as outpatient sessions focusing on change, improvement and/or maintenance of family function within cognitive, affective and behavioral knowledge. Each session is organized and individualized according to the wishes and needs for education and counseling of the families within a period of six months.
1711180|NCT01378234|Behavioral|Enhanced Discharge Planning Program transitional care|"Enhanced Discharge Planning Program (EDPP) provides telephonic short-term post-discharge social work services that assess and intervene from a biopsychosocial perspective for at-risk older adults returning home after an inpatient hospitalization. EDPP follows a four-step process to with three guiding tasks to reach the goal of preventing avoidable adverse events post-discharge:
Ensure patients understand the discharge plan of care and receive recommended services while screening for unidentified medical or social needs
Connect patients to outpatient health services (ex: home health, in-home services, dialysis, radiology, laboratory services, specialty care) with particular emphasis on the first physician follow-up appointment
Supporting caregivers to reduce stress and burden"
1711181|NCT01378208|Behavioral|Intermittent fasting - the effect on glucose metabolism, body composition and cognitive function|"Each of the 10 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.
DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)
28 days of dietary monitoring
28 days measurement by pedometer DAY 1, DAY 28 & DAY 56: Test 1
Oral glucose tolerance test with stable isotopes
Fat and muscle biopsies DAY 2, DAY 29 & DAY 57: Test 2
DXA scanning
Resting Metabolic Rate Measurement
VO2max test on bicycle
Cognitive testing
MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 & DAY 48: Test 3
Actiheart for 3 days
72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION
Fasting from 7am - 9pm
28 days of dietary monitoring
28 days measurement by pedometer"
1711182|NCT01378195|Behavioral|CBT-based program for dementia caregivers|Participants will receive a CBT-based program [Cognitive Behavioral Therapy], containing videos, workbook, and website.
1711183|NCT01378195|Behavioral|Educational/Resources program|Participants will receive a traditional educational/resources program, containing videos, workbook, and website.
1711184|NCT01378182|Genetic|allogeneic mesenchymal stem cell transplantation|1.000.000(one million) cells/kg, IV (1/2 of dose in the Peripheral vein and 1/2 of dose into the right hepatic artery)
1956320|NCT02896296|Drug|High dose RBP-6000|Monthly injections subcutaneously on alternate sides of participant's abdomen. Dose can be adjusted to low dose based on the medical judgment of the investigator.
1711186|NCT01378143|Drug|OCZ103-OS [pentamidine bis(2-hydroxyethanesulfonate)], mFOLFOX6 or FOLFIRI|OCZ103-OS is given in combination with Chemotherapy each cycle
1711187|NCT01378117|Drug|Sitagliptin|Sitagliptin 50-100mg po once daily
1711188|NCT01378117|Drug|glargine|glargine once daily
1711189|NCT01378117|Drug|lispro|lispro before meals
1711190|NCT01378104|Drug|peginterferon alfa 2a (pegasys)|dosage form; 180ug/week during first 12 weeks and then 135 ug/week during 36 weeks otherwise unremarkable
1711191|NCT01378104|Drug|peginterferon alfa-2a (pegasys)|These patients would be treated with standard dose 180ug /week for 48 weeks. In general, the patient with CHC genotype 1is guided with treatment with pegasys 180ug /week and ribavirin 1000-1200 mg/day for 48 weeks. We do not make intervention of ribavirin dose.
1711192|NCT01378091|Drug|Lenalidomide|"Supplied as 5 mg and 25 mg capsules.
The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."
1711193|NCT01378091|Drug|Docetaxel|"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.
Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."
1711194|NCT01378091|Drug|Prednisone|"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.
5 mg BID daily."
1711195|NCT01378078|Device|eldith DC-stimulator (neuroconn, Ilmenau, Germany)|daily tDCS treatment over left DLPFC, 20 min, 2 mA
1711196|NCT01378078|Device|eldith DC-stimulator (Neuroconn, Ilmenau, Germany)|same as sham stimulation
1711197|NCT01378065|Device|Restorelle Direct Fix A&P|Restorelle Direct Fix A&P is a permanently implantable synthetic mesh for reconstruction of the pelvic floor secondary to the prolapse or protrusion of the pelvic organs into or out of the vaginal canal.
1711198|NCT01378039|Drug|comparison of treatment effect on different markers|inhaled budesonide (400 µg BD) or placebo BD
1711199|NCT01377987|Drug|Acetazolamide|4 mg/kg, once daily before bed, for 7 days
1711200|NCT01377987|Drug|Placebo|4 mg/kg, once daily before bed, for 7 days
1711201|NCT01377974|Drug|Miltefosine|1 Capsule of 50mg, taken orally 2 times a day for 28 days
1711202|NCT01377974|Drug|Standard Treatment Meglumine antimoniate|20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
1711203|NCT01377961|Drug|Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks|"After the screening and OGTT, the treatment group each subject will be in is decided by randomization. Neither subject nor the researchers will be allowed to choose which group a subject is assigned to. A single patient/subject cannot be assigned more than 1 allocation number. Each subject will be assigned randomly (like drawing straws) to receive either on the pills containing the combination of 6mg lycopene and 50mg isoflavones or placebo. Each subject has a 1 in 2 chance of receiving one of these treatments.
The subject are advised to take one capsule of Laflavon/Placebo by mouth daily for 12 weeks."
1711204|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
1711205|NCT01377961|Other|OGTT|OGTT will be done after the screening at Baseline and at the completion of the 12 weeks of taking the supplements by the subject.
1711206|NCT01377961|Other|Anthropometrics and Blood pressure|Measurements of height, weight, hip, waist and Blood Pressure are done before and after 12 weeks of taking the supplements.
1711207|NCT01377961|Other|Screening|Volunteer will be screened as an out patient with a history, physical examination, baseline fasting plasma glucose or A1C, creatinine, AST/ALT, TSH. We may utilize the lab results of the subject available upto 3months prior to the consent date. Pregnancy tests will be performed for female candidates. Information of the level of physical activity, diet, supplements and medications will be obtained.
1711208|NCT01377961|Other|Blood Drawing|The blood will be drawn at the baseline and at the completion of the 12 weeks of taking the capsules of laflavon /placebo.
1711209|NCT01377948|Behavioral|ACT with RAGE-Control|This is an open trial of ACT with RAGE-Control which is a behavioral intervention. The therapy involves five psychotherapy sessions taking place over five consecutive days.
1711212|NCT01377909|Drug|statin|daily statin orally for 48 weeks
1711213|NCT01377883|Other|standard|"Preparation and information regarding the BTX procedure: placing EMG electrodes, wiping the area with an alcohol swab, cooling with ethyl chloride, needle insertion into the muscle and the importance of EMG noise.
Injection performed under EMG guidance. Two sites of injection per muscle were used to enhance diffusion. The child could often see the procedure when the upper limb was treated but not during lower limb injections.
Memory change and positive reinforcement: Following the BTX injection, the medical staff present spoke to the child positively and offered prizes Volunteer attendance: In the daycare unit there are young volunteers routinely present, assisting with technical aspects of the procedure."
1711214|NCT01377883|Behavioral|clown care|Cognitive coping Imagery Empowerment Reflecting emotions
1711215|NCT01377870|Biological|intravenous injection of mesenchymal stem cells|15 patients with relapsing remitting multiple sclerosis underwent intravenous injection of mesenchymal stem cell
1711216|NCT01377870|Biological|injection of cell free media|Patients who are in control group underwent media injection but after 6 months they will be transplanted by stem cell.
1711217|NCT01377857|Behavioral|Monetary Incentive|$1, $5, or $10 incentive
1711218|NCT01377857|Behavioral|Questionnaire Timing|Timing of the questionnaire--either before or after testing is offered.
1711219|NCT01377857|Behavioral|HIV Test Offering|HIV Test will be offered as opt-in, opt-out, or active choice.
1711220|NCT01377844|Drug|EGT0001442|
1711221|NCT01377844|Drug|Placebo|
1711277|NCT01377285|Drug|ARB|"Angiotensin II receptor antagonists ,these medicines have names that end in sartan.For examples:losartan,candesartan,irbesartan,olmesartan,telmisartan,valsartan"
1711278|NCT01377285|Drug|Pentoxifylline|This medication is used to improve the symptoms of a certain blood flow problem in the legs/arms (intermittent claudication due to occlusive artery disease)
1711222|NCT01377818|Procedure|ventilation|"positive-pressure breathing bilevel (BiPAP ® Respironics, Inc.) Parameters initially programmed be: IPAP 10 cm H2O, EPAP 4 cmH2O, method ST setting yourself respirations 12 breaths minute. The IPAP was progressively increased to a maximum of 20 cm H2O, depending on patient tolerability, clinical response and arterial oxygen saturation was continuously monitored by pulse oximetry, trying to avoid possible leaks through the mask. It can also supply oxygen through a cannula connected to the mask at a flow rate of 2-4 liters per minute to maintain oxygen saturation at around 85-90%.
Patients aired uninterruptedly during nighttime (minimal between 6-8 hours night)."
1711223|NCT01377818|Procedure|excecise training|"The training program (trained group) was carried out for 12 weeks and sessions of 40 minutes duration:
20 minutes of bicycle ergometer with an initial charge of about 70% of initial maximal oxygen consumption, increasing the load every two weeks as tolerated.
Weightlifting in 2 sets of 6 replicates of 5 simple exercises. These are held at a station multigimnástica (CLASSIC Fitness Center, KETTLER)"
1711224|NCT01377818|Procedure|Both|both types of intervention
1711225|NCT01377792|Drug|Hypertonic saline|comparison of different dosages of drug
1711226|NCT01377779|Drug|Oxiplex/AP gel|Intrauterine application of Intercoat following hysteroscopy
1711227|NCT01377779|Drug|Normal Saline|No intrauterine application of Intercoat following hysteroscopy
1711229|NCT01377740|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1711230|NCT01377675|Other|Education|The third year internal medicine residents completed the usual curriculum for COPD and took one pretest and two posttests to validate the questions.
1711231|NCT01377662|Drug|OND-PR002 and MPh-IR|"Drug: OND-PR002
Single daily oral doses of 8 mg Ond-PR002
Drug: MPh-IR
Single daily oral doses of 20 mg MPh-IR"
1711232|NCT01377662|Other|Placebo: Two dextrose capsules for Ond-PR002 and MPh-IR|Single daily oral doses
1711233|NCT01377636|Drug|Isoproterenol|patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
1711234|NCT01377623|Drug|Dexmedetomidine group|Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
1711235|NCT01377623|Drug|Placebo group|Fifty six subjects (28 in each arm) will be enrolled. Subjects undergoing one or two level spinal fusion surgery will be screened for eligibility to participate in the study. Subject will be screened, recruited and randomized during the preadmission visit or the day of surgery. Eligible subjects will be randomized to one of the two treatment group in1:1 ratio to receive either DEX or matching placebo (PBO, LR).
1711236|NCT01377610|Drug|oral naltrexone|Following detoxification with buprenorphine (one dy of 8 mg) followed by oral naltrexone (ascending taper to 25 mg), participants will receive Vivitrol injection on Day 8. Behavioral therapy sessions will be offered for five weeks.
1711237|NCT01377610|Drug|Buprenorphine|Following detoxification with buprenorphine [8-mg buprenorphine (Day 1) tapering to 0 mg (Day 7)] participants will receive Vivitrol injection on Day 15. Behavioral therapy sessions will be offered for five weeks.
1711238|NCT01377610|Drug|Vivitrol|dose of long-acting injectable naltrexone (Vivitrol 380 mg i.m. Injection)
1711239|NCT01377597|Drug|ranibizumab|
1711240|NCT01377584|Behavioral|Couple-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately 2 hours. This session will provide the couple with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately one and a half hours. The second session will provide the couple with information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The individual telephone follow-up sessions will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
1711241|NCT01377584|Behavioral|Patient-oriented intervention|The first session will occur before the patient receives his/her CPAP and will last approximately one and a half hours. This session will provide the patient with education on sleep apnea and CPAP and information on different types of PAP therapy and cleaning procedures, explore patient's concerns about starting CPAP treatment, and provide a goal setting exercise. The second face to face session will occur one week after the patient receives his/her CPAP and will last approximately 45 minutes. The second session will provide information on CPAP usage and pre- and post-treatment AHI, explore barriers to CPAP use and benefits of CPAP use, and provide a goal setting exercise. The telephone follow-up session will occur two weeks after the patient has received his/her CPAP and will last approximately 20 minutes. This session will review CPAP usage and explore barriers and facilitators of CPAP use.
1711242|NCT01377584|Device|Continuous positive airway pressure (CPAP)|CPAP is treatment for obstructive sleep apnea. CPAP therapy keeps the airway open during the night by providing a stream of air through a mask that is worn while sleeping.
1711243|NCT01377584|Other|No intervention|No intervention will be received.
1711244|NCT01377571|Biological|Rotarix|2 doses of Rotarix vaccine, 106.5CID/dose, 1-month interval between doses
1711245|NCT01377558|Other|Aerobic endurance training intervention|"The aerobic endurance training group will use cardiovascular training devices
week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT two times per week
week 5-13: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT two times per week
week 14-26: 15 minutes warm up (group) 45 minutes intervention at 95-110% vAT two times per week"
1711279|NCT01377285|Drug|Placebo (for Pentoxifylline)|Sugar pill manufactured to mimic Pentoxifylline 400mg tablet
1711280|NCT01377259|Other|tissue oxygen saturation, spinal anesthesia|regional tissue oxygen saturation(rSO2)detected over upper and lower extremities before and after spinal anesthesia
1711281|NCT01377246|Drug|Octreotide-LAR|40 mg every 28 days (in two intragluteal 20 mg injections) for three years
1808327|NCT00646542|Drug|Placebo|
1711246|NCT01377558|Other|Strength endurance training intervention|"The strength endurance training intervention group will perform eight exercises on weight machines (Milon circuit training- 60 seconds activity, 30 seconds break)
week 1-4: 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) two times per week
week 5-13: 15 minutes warm up (group) 2 sessions resistance training intensity 5 (Buskies) two times per week
week 14-26: 15 minutes warm up (group) 3 sessions resistance training intensity 5 (Buskies) two times per week"
1711247|NCT01377558|Other|Combined aerobic endurance and strength endurance training|"week 1-4: 15 minutes warm up (group) 15 minutes intervention at 80-100% vAT once per week and 15 minutes warm up (group) 1 session resistance training intensity 3 (Buskies) once per week
week 5-13: 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) two times per week
week 14-26: 15 minutes warm up (group) 30 minutes intervention at 95-110% vAT and 1 session resistance training intensity 5 (Buskies) once a week and 15 minutes warm up (group) 15 minutes intervention at 95-110% vAT and 2 sessions resistance training intensity 5 (Buskies) once a week"
1711248|NCT01377545|Procedure|Local Anesthetic given via perineural catheter for infraclavicular nerve block.|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
1711249|NCT01377545|Procedure|Local Anesthetic given via needle for infraclavicular nerve block|Patients will be randomized to receive 30mL of Lidocaine via Catheter for an infraclavicular nerve block on one side (right or left) and via needle on the other side. Sensory and strength will be tested following local anesthetic administration.
1711250|NCT01377532|Drug|131 I-Metaiodobenzylguanidine (131 I-MIBG)|Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose: 8-12 mCi/kg (maximum 500 mCi ± 10% at investigator's discretion) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's peripheral or central line over 120 minutes. The patient will remain in a radiation protected isolation room until radiation emissions are ≤ 2 mr/hr at a 1 meter distance or meets institutional and state guidelines. This usually takes 4-6 days. In all cases, special shielding will be equipped in the room to minimize exposure to the outside environment and personnel will observe institutional radiation safety precautions.
1711251|NCT01377519|Procedure|MR Guided Focused Ultrasound|This is an FDA approved noninvasive treatment for fibroids that uses highly focused ultrasound waves to damage fibroid tissue.
1711252|NCT01377519|Procedure|Placebo MR Guided Focused Ultrasound|This is a placebo treatment that requires a participant to undergo identical procedures as those of the actual MR Guided Focused Ultrasound procedure, but higly focused ultrasound waves are not directed at the uterine fibroid.
1711253|NCT01377506|Behavioral|lifestyle counseling|21 session group-based behavioral weight management program delivered in senior center over 12 months by lay health educators
1711254|NCT01377506|Behavioral|Cognitive Training|21 session group-based cognitive training program delivered in senior center over 12 months by lay health educators
1711255|NCT01377493|Dietary Supplement|chewing gum|chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
1711256|NCT01377480|Drug|Posaconazole|POS 40 mg/mL oral suspension
1711257|NCT01377480|Drug|Placebo for posaconazole|Placebo oral suspension
1711258|NCT01377480|Drug|Benznidazole|BNZ 100 mg oral tablet
1711259|NCT01377467|Drug|Denosumab (Prolia)|60 mg s.c. injection at baseline and after 6 months
1711260|NCT01377441|Drug|Ibuprofen|Patients will receive either 800mg IV ibuprofen or placebo pre-operatively. Post-operatively, patients will receive either 800mg IV ibuprofen or placebo 6 hours after the first dose.
1711261|NCT01377441|Drug|Placebo/Saline solution|Patients will receive placebo pre-operatively. Post-operatively, patients will receive placebo at least 6 hours after the initial dose.
1711262|NCT01377428|Drug|Indacaterol|Indacaterol 150 µg once daily (od) via single-dose dry powder inhaler (SDDPI)
1711263|NCT01377428|Drug|Formoterol|Formoterol 12 µg twice daily (bid) via single-dose dry powder inhaler (SDDPI)
1711264|NCT01377415|Drug|bupivacaine|bupivacaine 5 mg/ml infusion 2 ml/h 48 h
1711265|NCT01377389|Drug|Ipilimumab|10 mg/kg by vein over 90 minutes once every 4 weeks, for 4 weeks.
1711266|NCT01377389|Drug|Leuprolide|7.5 mg intramuscular once a month for 8 months
1711267|NCT01377389|Drug|Goserelin|3.6 mg subcutaneous once a month for 8 months
1711268|NCT01377389|Drug|Degarelix|80 mg subcutaneous once a month for 8 months
1711269|NCT01377376|Drug|ARQ 197 and Erlotinib|Oral twice daily administration of ARQ197 and oral once daily administration of erlotinib
1711270|NCT01377376|Drug|Placebo and Erlotinib|Oral twice daily administration of placebo and oral once daily administration of erlotinib
1711271|NCT01377350|Device|"Pneumedicares monitoring system."|50 patients hospitalized due to the decompensated HF are considered for entry. 3 patches will be attached to the patients' thorax that include motion sensors. The system will be attached to the patients at the start of treatment. Patient's signals will be recorded during the entire treatment in the hospital, to the point that there is an improvement in their health condition.
1711272|NCT01377350|Device|"Pneumedicares monitoring system"|Non invasive clinical follow-up of patients with HF deterioration and improvement, by a device-based algorithm. The system comprises of patches attached to the patients' thorax that include motion sensors (Accelerometers) that measure the chest wall dynamics and the mechanics of lung inflation and deflation.
1711273|NCT01377337|Drug|sodium bicarbonate|"1 mEq/kg sodium bicarbonate administered intravenously immediately following the administration of the first epinephrine dose during advanced CPR. Dose may be repeated every 5-10 minutes up to 3 doses.
Note: The Placebo Arm receives 1 ml/Kg of 0.9% NaCl (in a blinded fashion)."
1711274|NCT01377324|Other|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|A FES-PET/(CT) will be performed thrice during protocol execution. Patients will be injected with ~200MBq 18F-FES
1711275|NCT01377311|Procedure|Transplant of cultured limbal stem cells on cornea|Remove the abnormal surface tissue on the lesion cornea, transplant the amniotic membrane with cultured limbal stem cells on the denuded cornea. Cover with contact lens after operation, and apply topical antibiotics and steroids.
1711276|NCT01377298|Drug|Pazopanib|200mg/tablet, 800mg/day PO.
1711460|NCT01375816|Drug|irinotecan hydrochloride|
1711282|NCT01377246|Other|Saline solution.|At the same volume of study drug every 28 days (in two intragluteal injections) for three years.
1711283|NCT01377233|Drug|Zicronapine open-label lead-in 10 mg daily|Encapsulated tablet ,10 mg, once daily, open-label
1711284|NCT01377233|Drug|Zicronapine 10 mg daily|Encapsulated tablet, 10 mg, once daily, double-blind
1711285|NCT01377233|Drug|Zicronapine 20 mg once weekly|Encapsulated tablet, 20 mg, once weekly (on day 1 of each 7 day cycle), double-blind
1711286|NCT01377233|Drug|Zicronapine 30 mg once weekly|Encapsulated tablet, 30 mg, once weekly (on day 1 of each 7 day cycle), double-blind
1711287|NCT01377233|Drug|Zicronapine 45 mg once weekly|Encapsulated tablet, 45 mg, once weekly (on day 1 of each 7 day cycle), double-blind
1711288|NCT01377220|Drug|11C-Choline|11C-Choline : 6MBq/kg on direct intravenous on one minute.
1711289|NCT01377207|Procedure|Primary PCI|Thrombus aspiration and hystopathological analysis, Optical Coherence Tomography assessment of STEMI culprit vessel, Primary PCI with Drug Eluting Stent implantation; Repeat OCT assessment of culprit vessel at 9 monts follow-up
1711290|NCT01377194|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER 40mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
1711291|NCT01377194|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER 80mg/day Study drug is to be given orally, in capsule form, once daily, for 8 weeks
1711292|NCT01377194|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
1711293|NCT01377168|Drug|oral naltrexone|
1711294|NCT01377168|Drug|Placebo pill|
1711295|NCT01377155|Drug|Insulin detemir|Subjects will be randomized to weight based method of 0.1 U/kg for basal insulin or a starting dose based upon an insulin challenge. Subject will record morning fasting blood sugar daily. Using a three day average, the subject will titrate the dose of basal insulin either increasing or lowering by three units based upon target blood glucose of 110 mg/dl.
1711296|NCT01377142|Device|Laparoscopic sacral hysteropexy|Laparoscopic sacral hysteropexy is performed laparoscopically with or without robotic assistance
1711297|NCT01377142|Device|Vaginal mesh hysteropexy|Uphold device used which includes sacrospinous ligament fixation
1711298|NCT01377129|Procedure|Single bundle anterior cruciate ligament reconstruction|Single bundle anterior cruciate ligamentoplasty
1711299|NCT01377129|Procedure|Double bundle anterior cruciate ligament reconstruction|Double bundle anterior cruciate ligamentoplasty
1711300|NCT01377103|Drug|testerone gel|5g daily for 4 weeks then 7.5 or 10g daily for 8 weeks; transdermal testosterone gel
1711301|NCT01377103|Drug|Placebo|
1711302|NCT01377077|Procedure|punchgrafting|autologous skin transplantation of small skinbiopsies taken from the hip and replaced in the depigmented lesions
1711303|NCT01377077|Procedure|punchgrafting|autologous skingrafting of small skin biopsies taken from the hip en placed in the depigmented lesions
1711304|NCT01377064|Behavioral|Physical Activity Group|9 months of home based physical activity meeting HHS recommendations for physical activity for all americans
1711305|NCT01377064|Other|Standard Care Group|No intervention, the group will be followed under their standard medical care.
1711306|NCT01377051|Drug|Indacaterol maleate|Dry powered, 300 mcg, only one inhalation with 24 hours duration
1711307|NCT01377051|Drug|Placebo|Dry powered, same to study drug, only one inhalation
1711308|NCT01377038|Other|Phenotype assessment|Quantitative sensory testing and patient reported outcome measures used to assess patient pain phenotype
1711309|NCT01377025|Drug|Placebo|two tablets in the morning and two in the evening.
1711310|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was PR or CR
1711311|NCT01377025|Drug|Sorafenib|400 mg Sorafenib bid until PD if staging after Run-In was SD
1711312|NCT01377012|Biological|Secukinumab (AIN457)|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL- 17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
1711313|NCT01377012|Biological|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
1711314|NCT01376999|Drug|FSH-r (Follicule stimulate hormone)|Step-Up: 75 IU FSH-r Step-Down: 150 FSH-r
1711315|NCT01376986|Behavioral|physical, psychological and social activation|
1711316|NCT01376960|Procedure|elective forefoot surgery|Includes both soft-tissue and osseous procedures.
1711317|NCT01376934|Procedure|procedure hysteroscopy|office hysteroscopy with gas or saline solution
1711318|NCT01376921|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics (SmPC) administered by easypod™
1711319|NCT01376908|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) tablets will be administered orally at the dose of 10 mg/kg/day and will be escalated to 20 mg/kg/day if after 4 weeks a subject's Phe tolerance is not increased by at least 20% versus baseline.
1711320|NCT01376908|Other|Phenylalanine (Phe)-restricted diet|Phe intake will be adjusted every 2 weeks, based on the mean Phe levels of the previous 2 weeks using pre-defined Phe adjustment criteria.
1711321|NCT01376895|Behavioral|PROJECT POWER|POWER is a three session intervention to help Black men who have sex with men and women lead healthier lives, make informed sexual choices and reduce their chances of getting or giving HIV to their sex partners. Interventions are designed to be delivered via the internet in real time by a trained health educator. Each session will last between 1 and 2 hours. The sessions are grounded on the social learning theory and use cognitive behavioral approaches. Participants learn the multiple influences on their behavior, how to identify their triggers and then use problem solving skills to develop a safer strategy for life. The sessions use videos and games to teach the lessons; participants are also given work that they must complete between the sessions.
1711322|NCT01376895|Behavioral|Power Health|Power Health is a one session intervention designed to help Black men who have sex with men and women improve their general health. It focuses on health issues (including HIV) that affect Black men. The program consists of 1 session delivered via the internet in real time by a trained health educator and last approximately 2 hours
1711323|NCT01376882|Dietary Supplement|Placebo|Inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH. 1 Size 0 capsule 3 times a day for 14 days and 1 size 0 capsule on day 15.
1711389|NCT01376310|Drug|Erlotinib + GSK1120212|dose as defined in the dose escalation protocol.
1711324|NCT01376882|Dietary Supplement|Caffeine and Placebo|100 mg Caffeine capsules 3 times per day for 14 days and 1 size 0 capsule of inert placebo containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH on day 15.
1711325|NCT01376882|Dietary Supplement|Placebo and Caffeine|Inert placebo capsules containing silica powder CAB-O-SIL-M-5Pharma (Pharmaceutical grade)CABOT GmbH, 1 Size 0 capsule 3 times a day for 14 days and a 100mg caffeine capsule on day 15.
1711326|NCT01376882|Dietary Supplement|Caffeine|Capsule containing 100 mg caffeine, one 3 times a day for 14 days and then one capsule on day 15.
1711327|NCT01376869|Dietary Supplement|Hops Extract|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers will be used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
1711328|NCT01376869|Other|Placebo (silica)|All 150 participants will complete 1 study visit; receiving either of the 4 hops doses or placebo (silica). Computer generated random numbers were used to allocate treatments to participant identification numbers. Treatment will be administered in capsule form and in a double blind manner.
1711329|NCT01376817|Drug|Fat emulsion with MCT, LCT, olive oil and omega 3 fatty acids|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
1711330|NCT01376817|Drug|Fat emulsion with MCT and LCT|40% of non-protein calories (25-30 kcal/kg/day) of total parenteral nutrition, IV (in the vein), from day 1 to day 10
1711331|NCT01376804|Drug|valganciclovir [Valcyte]|Oral, daily for up to 200 days.
1711332|NCT01376778|Drug|CMV hyperimmune globulin|The study's active drug is Cytogam® which is an immunoglobulin G (IgG) containing a standardized amount of antibody to CMV. This drug contains pooled adult human plasma selected for high titers of antibody for CMV, and is administered intravenously at a dose of 100 mg/kg body weight.
1711333|NCT01376778|Other|Placebo|The matching placebo consists of AlbuRx® 5% diluted 1:9 with D5W. AlbuRx® 5% contains pooled adult human plasma.
1711334|NCT01376765|Drug|Aluminum hydroxide adjuvant (Alhydrogel®)|Aluminum hydroxide adjuvant (Alhydrogel®);given with SARS vaccine; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine with adjuvant at 45 micrograms per dose
1711335|NCT01376765|Other|Phosphate buffered saline Placebo|Phosphate buffered saline Placebo; 2 intramuscular doses, 28 days apart. Cohort 1: 4 subjects given placebo at 5 micrograms per dose; Cohort 2: 4 subjects given placebo at 15 micrograms per dose; Cohort 3: 4 subjects given placebo at 45 micrograms per dose
1711336|NCT01376765|Biological|Recombinant S protein SARS vaccine|Recombinant S protein severe acute respiratory syndrome (SARS) vaccine given with adjuvant or without adjuvant; 2 intramuscular doses, 28 days apart, Cohort 1: 12 subjects given vaccine only or vaccine with adjuvant at 5 micrograms per dose; Cohort 2: 12 subjects given vaccine only or vaccine with adjuvant at 15 micrograms per dose; Cohort 3: 12 subjects given vaccine only or vaccine with adjuvant at 45 micrograms per dose
1711338|NCT01376739|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients who will need to undergo contrast enhanced MR angiography with Magnevist (a dosage of more than 0.2 mg/kg)
1711339|NCT01376726|Biological|Sub C gp140 Vaccine|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.
Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
1711340|NCT01376726|Biological|MF59C.1 Adjuvant|"Sub C gp140 100 mcg will be combined with MF59C.1 and administered as one injection (0.5 mL) IM in either deltoid at baseline and Month 6.
Participants in the study extension will receive an additional injection of the study vaccine approximately 14 to 20 months after their second (Month 6) vaccination."
1711341|NCT01376713|Biological|Ofatumumab|Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks
1711342|NCT01376713|Biological|Ofatumumab plus Dacarbazine|"Ofatumumab will be administered at a dose of 1000mg iv weekly for 8 weeks and q4w for another 16 weeks.
Dacarbazine administered q4w at a dose of 1000mg/m2, 4 days before next administration of Ofatumumab for 24 weeks."
1711343|NCT01376700|Biological|Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)|Intravenous infusion at a dose of 25 ± 5 IU/kg once per week. After 20 exposure days, the weekly infusions should be continued for as long as possible following the early prophylaxis period. If required by the clinical situation, dosing may be increased to twice weekly or even three times weekly after 20 exposure days, while keeping the low dose.
1711344|NCT01376596|Behavioral|Cognitive-Behavioral Therapy based intervention immediately|This intervention will include: i) Psychoeducation on social anxiety disorder; ii) Cognitive Restructuring: Identify negative thoughts that occur before, during, or after anxiety-provoking situations; Evaluate the accuracy of their thoughts in the light of data derived from Socratic questioning or as a result of so-called behavioral experiments; and derive rational alternative thoughts based on the acquired information; iii) Exposure component, which focuses on the collection of information that will allow patients to revise their judgments about the degree of risk to which they are exposed in feared situations, challenge their dysfunctional beliefs about the self relative to the illness and their self-efficacy (social status related), and iv) Use of Thought Records to identify, explore and dispute negative thoughts about dysfunctional self-identity and core beliefs related to the onset and presence of diagnosis of schizophrenia.
1711345|NCT01376596|Behavioral|Wait list|The group receiving treatment as usual (TAU) will be put on a wait list to receive the CBT intervention at the end of the experimental group, the one receiving the intervention immediately
1711390|NCT01376310|Drug|Pemetrexed + GSK1120212|dose as defined in the dose escalation protocol
1711391|NCT01376310|Drug|Carboplatin + GSK1120212|dose as defined in the dose escalation protocol
1711392|NCT01376310|Drug|Nab-paclitaxel + GSK1120212|dose as defined in the dose escalation protocol
1711393|NCT01376310|Drug|Gemcitabine + GSK1120212|dose as defined in the dose escalation protocol
1711394|NCT01376310|Drug|Everolimus + GSK1120212|dose as defined in the dose escalation protocol
1711395|NCT01376297|Drug|Netupitant and Palonosetron|
1711396|NCT01376297|Drug|Aprepitant|
1711346|NCT01376570|Behavioral|Abstinence-reinforcing contingency management intervention|The contingency management intervention consists of participants receiving vouchers exchangeable for goods and services contingent on achieving abstinence. When participants are abstinent (urine is free of cocaine, oxycodone and opiates), they will receive a voucher. If participants are not abstinent (cocaine or oxycodone or opiates are in the urine), they will not receive a voucher. The value of vouchers increases with continued evidence of abstinence. The voucher for the first drug-free urine is worth $2.50, and with each subsequent drug-free urine, the voucher increases by $2.50. When participants have urines with opiates or cocaine, the value of the voucher is reset back to baseline ($2.50). The maximum possible earnings for achieving continued abstinence over the intervention period is $1320. The vouchers are part of the intervention, they are not participant compensation.
1711347|NCT01376570|Behavioral|Performance Feedback intervention|Participants will receive performance feedback about their drug use. The research team will provide informational slips of paper indicating results of urine tests and will congratulate participants when urines are drug-free or encourage participants to stop using cocaine and/or opiates when urines are not drug-free.
1711348|NCT01376557|Drug|75 mg LX4211|Subjects will receive 75 mg LX4211 once daily
1711349|NCT01376557|Drug|200 mg LX4211|Subjects will receive 200 mg LX4211 once daily.
1711350|NCT01376557|Drug|400 mg LX4211|Subjects will receive 400 mg LX4211 once daily.
1711351|NCT01376557|Drug|200 mg LX4211|Subjects will receive 200 mg LX4211 twice daily.
1711352|NCT01376557|Drug|Placebo|Subjects will receive placebo once daily.
1711353|NCT01376544|Device|Treatment protocol designed to evaluate (SLE 5000 ventilator)|Assist control ventilation and pressure support ventilation
1711354|NCT01376531|Procedure|continuous veno-venous hemodialysis|continuous veno-venous hemodialysis
1711355|NCT01376518|Procedure|positive end-expiratory pressure|Elevation of positive end-expiratory failure for recruitment
1711356|NCT01376505|Biological|HER-2 vaccine|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. Increasing doses of the combined vaccine preparation emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Starting at dose level 1, 1.0mg of each peptide will be used for vaccination. In increasing dosing cohorts 1.5mg, 2.0mg and 2.5mg will be used. Patients may also receive 6 months booster shots.
1711357|NCT01376505|Biological|Extension HER-2 vaccine trial at OBD|Three intramuscular (IM) injections (separated by 21 days) of a mixture of two peptides {MVF-HER-2(597-626) and MVF-HER-2 (266-296)} vaccine emulsified with nor-MDP in ISA 720 vehicle. The dose level has been determined to be cohort 2. The combined vaccine preparation consists of 1.5mg of each of the HER-2 vaccine emulsified with nor-MDP (0.025) mg and Montanide ISA 720 will be administered in a final volume of 1.0 ml. Patients may also receive 6 months booster shots.
1711358|NCT01376492|Other|Functioning assessment|The functioning will be assessed with 2 scales, (Personal and Social Performance Scale (PSP) and Brief Psychiatric Rating Scale)
1711359|NCT01376492|Other|Quality of sleep assessment|The quality of sleep will be assessed with 2 scales, (Pittsburgh Sleep Quality Index (PSQI) and Epworth scale)
1711360|NCT01376479|Biological|INV21 Low Dose|Inactivated EV71 vaccine containing whole viral particles of EV71 formulated with aluminum hydroxide.
1711361|NCT01376479|Biological|INV21 High Dose|Inactivated EV71 vaccine consisting of whole viral particles of EV71 formulated with aluminum hydroxide.
1711362|NCT01376479|Biological|Placebo|Phosphate Buffered Saline (PBS)
1711363|NCT01376466|Other|CT scanning|CT image of the abdomen included the area between the 3rd. lumber vertebra and the top of acetabulum. A liter of contrast mixed with normal salin will be given by rectal catheter 20 minutes before CT image is taken.
1711364|NCT01376453|Drug|Sorafenib|In addition to radiation and 5-FU, sorafenib will be taken by mouth daily every day until the last day of radiation. The dose of sorafenib will be one of the following: 200 mg every other day, 200 mg daily, 400 mg daily, or 800 mg daily
1711365|NCT01376453|Drug|5-Fluorouracil (5-FU)|5-FU will be delivered at a dose of 225 mg/m^2 daily through a catheter in a large vein continuously until the last day of radiation.
1711366|NCT01376453|Radiation|Radiation|Radiation sessions will be daily, Monday through Friday, except for holidays.
1711367|NCT01376440|Other|household water treatment|household water treatment with 1.25% sodium hypochlorite
1711368|NCT01376427|Drug|Dexamethasone|Dexamethasone
1711369|NCT01376427|Drug|Methotrexate|Methotrexate
1711370|NCT01376427|Drug|Vincristine|Vincristine
1711371|NCT01376414|Other|Urea Breath Test (UBT) for H. pylori infection|13C UBT to detect H. pylori infection. Single bedside test that determines infection in about ten minutes. Test machine is a product of Exalenz bioscience.
1711372|NCT01376401|Drug|Bendamustine|
1711373|NCT01376401|Drug|Velcade|
1711374|NCT01376401|Drug|Prednisone|
1711375|NCT01376388|Drug|GSK573719/GW642444 Inhalation Powder|GSK573719/GW642444 inhalation powder inhaled orally once daily for 52 weeks.
1711376|NCT01376375|Procedure|Acupuncture|
1711377|NCT01376362|Drug|Interferon Gamma-1b|Interferon gamma-1b (Actimmune®, InterMune, Inc, Brisbane, CA 94005) was supplied to participants in single-use dropperettes. Each dropperette contained approximately 0.2 mL of interferon gamma-1b (Actimmune®). Participants received 28 dropperettes at the baseline visit and were instructed to place four drops (approximately 7 μg per drop) topically on the cornea of the study eye four times per day for seven days.
1711378|NCT01376349|Drug|prasterone|Applied vaginally
1711379|NCT01376349|Other|placebo|Applied vaginally
1711380|NCT01376336|Device|Safe storage device|This device is a specially designed water storage container that is intended to reduce the likelihood of re-contamination of household stored drinking water.
1996769|NCT02382003|Behavioral|50/50 Cognitive Bias Modification - Interpretation|This condition follows the same design and content as the Positive Training conditions, except the word fragments differ; rather than consistently resolving the scenario in a positive direction, half of the scenarios will end with a negative (anxiety-congruent) word fragment, and half will end with a positive word fragment.
1711387|NCT01376310|Drug|GSK1120212|up to 2 mg/day
1711388|NCT01376310|Drug|Docetaxel + GSK1120212|dose as defined in the dose escalation protocol.
1711402|NCT01376245|Drug|fluticasone furoate/vilanterol|Inhaled corticosteroid/long acting beta-agonist
1711403|NCT01376245|Drug|Placebo|matching placebo
1711404|NCT01376232|Drug|GSK1278863|GSk1278863 100mg
1711405|NCT01376232|Drug|GSK1278863 + food|High Fat meal + 100 mg GSK1278863
1711406|NCT01376232|Drug|Gemfibrozil|600 mg Gemfibrozil
1711407|NCT01376219|Other|asthma control test|results of asthma control testing collected
1711408|NCT01376206|Drug|Fluticasone|Collection of safety data
1711409|NCT01376193|Drug|Naratriptan|Collection of safety data
1711410|NCT01376180|Drug|Lamotrigine|Administered according to the prescribing information in the locally approved label by the authorities
1711422|NCT01376154|Drug|Lamivudine|
1711423|NCT01376141|Drug|Sumatriptan|
1711424|NCT01376128|Drug|Paroxetine|
1711426|NCT01376102|Drug|BONVIVA(ibandronate) injection|Basically there is no treatment allocation. Subjects who would be administered of ibandronate at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
1711427|NCT01376089|Drug|Iodixanol|Iodixanol 320 mg I/mL as a single iv. administration.
1711428|NCT01376089|Drug|Iopamidol|Comparator agent iopamidol (Isovue) 370 mg I/mL as a single iv. administration.
1711429|NCT01376076|Drug|Cariprazine|Patients meeting all study eligibility criteria will be randomized to receive cariprazine (Group 1) 1.5 to 18 mg once daily, administered orally.
1711430|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2A will receive double blind placebo for Days 1-5, Moxifloxacin (400mg) on Day 6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-35.
1711431|NCT01376076|Drug|Risperidone/Moxifloxacin|Patients randomized to Group 2B will receive double blind placebo for Days 1-6, Risperidone 4mg once daily Days 7-15, placebo Days 16-20, Risperidone Days 21-29, placebo Days 30-34, Moxifloxacin (400mg) on Day 35.
1711432|NCT01376063|Drug|FG-4592|"FG-4592 on days 3,5,7,9
Rosiglitazone maleate on days 1 and 9"
1711433|NCT01376050|Device|Erchonia ML Scanner (MLS)|Erchonia MLS comprises three 17.5 mW 635 nm diodes. The center diode is fixed at 6 inches above the venous stasis ulcer center and the other 2 diodes rotate about this center fixed diode for 20 minutes. Total dosage delivered to the skin is 2.95 J/cm squared.
1711434|NCT01376050|Device|Placebo Laser|Placebo Laser has no therapeutic output emitted.
1711435|NCT01376037|Device|Erchonia(r) ML Scanner (MLS)|The Erchonia ML Scanner (MLS) low level laser light therapy device is administered to both arms for 20 minutes each, 6 times across 2 weeks.
1711436|NCT01376037|Device|inactive placebo laser device|non-therapeutic light application
1711437|NCT01376011|Dietary Supplement|quercetin/placebo|Quercetin 500mg once per day versus placebo
1711438|NCT01375998|Drug|EE20/DRSP(YAZ, BAY86-5300)|Patients in daily life treatment receiving YAZ for dysmenorrhea.
1711439|NCT01375985|Drug|AVI-7100|Single intravenous administration
1711440|NCT01375985|Drug|Placebo|Single intravenous administration
1711441|NCT01375972|Drug|S-1 plus cisplatin|S-1 40 mg/m2 D1-D14 Cisplatin 60 mg/m2 D1 every 3 weeks
1711442|NCT01375972|Drug|Gemcitabine plus Cisplatin|Gemcitabine 1000 mg/m2 IV D1, D8 Cisplatin 60 mg/m2 IV D1 Every 3 weeks
1711443|NCT01375959|Dietary Supplement|resveratrol|resveratrol 500 mg capsules, 3 capsules (1500 mg) orally twice a day for 6 weeks
1711444|NCT01375959|Drug|Placebo|3 placebo capsules orally twice a day for 6 weeks
1711446|NCT01375933|Biological|NicVAX Vaccine|NicVAX Vaccine given 6 times over 6 months
1711447|NCT01375920|Drug|Metyrapone|500 milligrams to be taken twice a day orally
1711448|NCT01375920|Drug|placebo|a matched placebo will be administered to patients to take twice a day for 3 weeks
1711449|NCT01375907|Drug|Rotavin|Rotavin-M1, 10e6.3FFU/dose, 2 doses, 1-month between doses
1711450|NCT01375894|Device|"imitation assessment using the 5-dt data glove."|measuring the speed of the hand during imitation
1711451|NCT01375881|Drug|darunavir/ritonavir plus background regimen|darunavir/ritonavir, oral use, in naive and experienced patients at approved dosages
1711452|NCT01375868|Biological|Silgard|vaccination with tetravalent antiviral vaccine
1711453|NCT01375855|Procedure|Percutaneous transluminal Coronary Angioplasty|Coronary artery stent implantation
1711454|NCT01375842|Drug|Atezolizumab|Atezolizumab will be administered as IV infusion at eight dose levels (0.01, 0.03, 0.1, 0.3, 1, 3, 10, 20 mg/kg) in dose escalation cohort and at a dose which result in total drug exposure </= exposures achieved at the MTD or MAD, will be selected for expansion cohort.
1711455|NCT01375829|Drug|Ixabepilone|Given IV
1711456|NCT01375829|Other|Pharmacological Study|Correlative studies
1711457|NCT01375829|Drug|Temsirolimus|Given IV
1711458|NCT01375816|Drug|FOLFIRI 1-Bevacizumab|
1711462|NCT01375816|Drug|liposome-encapsulated irinotecan hydrochloride PEP02|
1711463|NCT01375816|Drug|Bevacizumab|
1711464|NCT01375803|Dietary Supplement|Novel dietary fiber|oral consumption in beverage
1711465|NCT01375803|Dietary Supplement|Novel dietary fiber|Oral consumption in beverage
1711466|NCT01375803|Other|Placebo|Oral consumption in beverage
1711467|NCT01375790|Device|Exercise with Whole-body vibration platform|The participants will perform static/dynamic exercises (balance and resistance training) on a vibratory platform (Frequency: 30-35 Hz; Amplitude: 2-4 mm).
1711468|NCT01375790|Other|Exercise|The participants will perform the same static/dynamic exercises (balance and resistance training) like WBV group but without the vibration stimuli.
1711469|NCT01375777|Biological|Evolocumab|Administered by subcutaneous injection
1711470|NCT01375777|Drug|Ezetimibe|Administered orally once a day
1711471|NCT01375777|Other|Placebo to Evolocumab|Administered by subcutaneous injection
1711472|NCT01375764|Biological|Evolocumab|Administered by subcutaneous injection
1711473|NCT01375764|Drug|Ezetimibe|Administered orally once a day
1711474|NCT01375764|Other|Placebo to Evolocumab|Administered by subcutaneous injection
1711475|NCT01375751|Biological|Evolocumab|Administered by subcutaneous injection
1711476|NCT01375751|Biological|Placebo|d by subcutaneous injection
1711477|NCT01375738|Procedure|Roux-en Y gastrojejunostomy|After subtotal gastrectomy with lymph node dissection, the jejunum is transected 25~30cm distal to the ligament of Treitz. Distal jejunum is drawn up and sutured to the gastric remnant and the proximal jejunum is anastomosed to the distal jejunum at 30~40cm from the new gastric-jejunal junction.
1711478|NCT01375738|Procedure|Gastroduodenostomy|After subtotal gastrectomy with lymph node dissection, the gastric remnant is anastomosed to duodenum 1st portion with circular or linear staplers and the artificial lesser curvature is repaired with linear stapler.
1711479|NCT01375712|Dietary Supplement|Fermented milk containing Lactobacillus casei strain Shirota|A fermented milk containing Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; 0.9 g of protein; and at least 6.5 x 10^9 colony-forming units of Lactobacillus casei strain Shirota.
1711480|NCT01375712|Dietary Supplement|Placebo|Non-fermented milk without Lactobacillus casei strain Shirota, 65 ml for oral administration, 1 bottle per day for 8 weeks (56 days). One bottle of the drink contains: 42.9 kcal/182 kJ; less than 0.1 g of fat; 9.6 g of carbohydrate; 0.01 g of sodium; and 0.9 g of protein.
1711483|NCT01375673|Other|Exercise|Walking Strength Training Bicycling
1711484|NCT01375660|Drug|Placebo|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
1711485|NCT01375660|Drug|50K vitamin D2|Supplement of vitamin D 400 units provided to all subjects, in addition Arm 1 will get placebo and Arm 2 will get D2 50K
1711486|NCT01375647|Biological|IPV|Administered per protocol
1711487|NCT01375647|Biological|Rotarix|Administered per protocol
1996770|NCT02382003|Behavioral|Anxious Imagery Prime|We will test whether priming anxious concerns and feared negative outcomes on the web via the addition of a guided anxious imagery prime at the start of each session will enhance effects.
1711489|NCT01375608|Drug|Decitabine|0.2mg/kg (range, 0.05-0.3 mg/kg) 1-2X/wk for a period of 48 weeks. Dose and frequency will be determined by hematologic toxicity and the achievement of an HbF level of greater the or equal to 20 percent.
1711490|NCT01375582|Drug|B & L Soothe Lubricant Eye Drops|Eye Drop
1711491|NCT01375582|Drug|Liposic EDO|Eye Drop
1711492|NCT01375582|Drug|OcuFresh Eye Wash|Saline drop
1711493|NCT01375569|Drug|TRC105|
1711494|NCT01375556|Drug|Ethanol|
1711495|NCT01375504|Behavioral|Dietary Counseling|The control group will receive two sessions of dietary counseling (with instruction to follow a weight loss program) provided by a clinical dietician, consistent with current routine care for adults with obesity.
1711496|NCT01375504|Behavioral|Mindfulness Training Program|The mindfulness program will be administered over three 90-minute sessions by a physician and clinical dietician with expertise in mind-body medicine and nutrition.
1711497|NCT01375491|Drug|Doxycycline|generic doxycycline 100mg twice daily
1711498|NCT01375491|Other|Placebo|Placebo comparator to doxycycline
1711499|NCT01375465|Device|DIOR drug-eluting PTCA balloon|Treatment for 45 seconds with the DIOR balloon (3 µg/mm2 Paclitaxel concentration on balloon surface)
1711500|NCT01375452|Drug|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
1711501|NCT01375439|Other|Active search of lower genital tract infections|Two groups (G1 and G2) will be part of study, each one composed of 140 pregnant women with a history of premature birth, G1 will have the active search and etiologic diagnosis of lower genital tract infections and G2 do not search of these infections, keeping for this group, the protocol of routine care of basic health units in the city of Botucatu. Workup care of pregnant women (G1) will include the completion of direct examination of vaginal contents stained by Gram's method, culture in the medium of Diamonds and polymerase chain reaction (PCR) of endocervical secretions, collected by health services in primary care the municipality in two moments: before 20th pregnancy week (M1) and in 36th pregnancy week (M2). The moment M3 will be after the birth, to evaluate the perinatal outcome.
1711502|NCT01375426|Drug|Oral amoxicillin|
1711503|NCT01375413|Behavioral|physical therapy|Physical therapy consisting of gait training 3 times a week for 6 weeks
1996771|NCT02382003|Behavioral|Neutral Imagery Prime|At the start of each session, participants will complete a neutral control imagery exercise where they do a guided imagery exercise imagining upcoming mundane tasks, like brushing one's teeth.
1711506|NCT01375387|Drug|Lacosamide|100 mg oral tablet, single dose
1711507|NCT01375387|Drug|Lacosamide|Lacosamide 2 X 100 mg tablet
1711508|NCT01375387|Drug|Lacosamide|Lacosamide 4 X 100mg tablet
1711509|NCT01375387|Other|Placebo 3|Placebo - 3 tablets
1711510|NCT01375387|Other|Placebo 4|Placebo - 4 tablets
1711511|NCT01375387|Other|Placebo 2|Placebo - 2 tablets
1711682|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
1808329|NCT00646581|Drug|Placebo|Placebo
1711514|NCT01375361|Drug|Albuterol|2.5mg Albuterol inhaled on enrollment and at 4 hours in the emergency department.
1711515|NCT01375361|Drug|Normal Saline|2.5mg Normal Saline inhaled on enrollment and at 4 hours in emergency department.
1711516|NCT01375348|Drug|Ultiva (remifentanil) or placebo|0.1microg/kg/min remifentanil administered as infusion Max infusion time is 20min
1711517|NCT01375335|Drug|Dobutamine|90 minutes of infusion 5 ug/kg/minute followed by isotonic saline for the same duration. The sequence of the above is randomized
1711518|NCT01375322|Drug|Amlodipine+Benazepril|Amlodipine besylate 5 mg + Benazepril hydrochloride 10 mg, daily use and forced titrate till 16-week end
1711519|NCT01375322|Drug|Valsartan+Hydrochlorothiazide|Valsartan 80 mg + Hydrochlorothiazide 12.5 mg, daily use and forced titrate till 16-week end
1711520|NCT01375309|Dietary Supplement|Bifidobacterium bifidum supplementation|Bifidobacterium bifidum supplementation wiht approximately 2.5*10to9th bacteria per day
1711521|NCT01375309|Dietary Supplement|Placebo contains dextrin|0.5 of dextrin
1711522|NCT01375296|Device|China-made SES (Firebird 2 and Excel)|patients with coronary 50-70% narrowing treated with China-made SES stent,i.e. Firebird 2 (cobalt-alloy platform with durable polymer coating sirolimus-eluting stent) and Excel (stainless steel platform with biodegradable polymer coating sirolimus-eluting stent).
1711523|NCT01375296|Other|routine medicine|patients with coronary 50-70% narrowing treated with routine medicine
1711524|NCT01375270|Procedure|Glucotoxicity|Glucose will be infused intravenously for a 24 hour period to raise blood glucose concentrations 5 mM above basal.
1711525|NCT01375270|Procedure|Lipotoxicity|Intralipid and heparin will be infused intravenously for a 24 hour period to raise blood free fatty acid concentrations to approximately 1 mM.
1711526|NCT01375257|Drug|Oral treatment with antibiotics for endocarditis|
1711527|NCT01375257|Drug|Guideline treatment with parenteral antibiotics|
1711528|NCT01375244|Drug|Lisinopril|Tablets, 10 mg, single dose
1711529|NCT01375244|Drug|Zestril|Tablets, 10 mg, single dose
1711530|NCT01375231|Procedure|Measured Resection of patellofemoral joint|The goal is to remove an amount of bone from the patella so that when reconstructed, the composite thickness of the entire prosthetic patellofemoral joint is recreated
1711531|NCT01375231|Procedure|Measured resection of patella|The thickness of the anterior condyle is not considered in this measurement. The goal is to restore the composite thickness of the patella only.
1711532|NCT01375218|Other|Pavlik Brace|Pavlik Brace
1711533|NCT01375218|Other|Plastizote Brace|Plastizote Brace
1711534|NCT01375205|Other|Cetaphil Restoraderm|Subjects will apply Cetaphil Restoraderm moisturizer once daily to infant's skin. They will bathe their infant with Cetaphil Restoraderm cleanser.
1711535|NCT01375205|Other|Standard of Care|Subjects will apply Johnson&Johnson moisturizer to their infant's skin as often as they wish. They will also use the Johnson&Johnson cleanser.
1711536|NCT01375179|Drug|KRP203|
1711537|NCT01375179|Drug|Placebo matching KRP203|
1711538|NCT01375153|Drug|BNP|3.0 pmol/kg/min human active BNP administered as a continuous intravenous infusion during four hours
1711539|NCT01375153|Drug|0.9% NaCl|0.9% NaCl administered as a continuous intravenous infusion during four hours
1711540|NCT01375140|Drug|Ruxolitinib|15 mg by mouth twice daily (BID), continuously in 28-day cycles.
1711541|NCT01375140|Drug|Lenalidomide|5 mg by mouth each day on days 1-21, followed by 7 days of no therapy of each 28 day cycle.
1711542|NCT01375140|Drug|Prednisone|"Prednisone will be added for patients who have not responded after 3 cycles of therapy.
30 mg by mouth a day during cycle 4, 15 mg/day during cycle 5, and 15 mg every other day during cycle 6, and then it will be discontinued."
1711543|NCT01375127|Drug|Tofacitinib|Subjects who previously took 15 mg BID or 30 mg BID
1711544|NCT01375127|Drug|Tofacitinib|Subjects who previously took 15 mg BID for 3 months then 10 mg BID, or 15 mg BID for 6 months then 10 mg BID
1711545|NCT01375114|Drug|Panax Ginseng|400 mg by mouth twice daily from Day 1-29.
1711546|NCT01375114|Dietary Supplement|Placebo|Placebo by mouth twice daily for 4 weeks.
1711547|NCT01375114|Behavioral|Questionnaires|Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
1711548|NCT01375101|Drug|placebo|The patient is directed to use placebo capsule two times a day, ,until the one mouth
1711549|NCT01375101|Drug|Quercetin|The patient is directed to digest quercetin hydrate capsule two times a day,until one mouth
1711550|NCT01375088|Drug|propolis|15 ml mouth wash 3 times a day for the whole period of radiotherapy for 5 min swish and then swallow
1711551|NCT01375075|Drug|LY2484595|Administered orally
1711552|NCT01375075|Drug|Placebo|Administered orally
1711553|NCT01375075|Drug|Atorvastatin|Administered orally
1711554|NCT01375062|Other|analyse and proliferate the cells|"Obtention of excess tissue from testicular biopsies and maintained in 4ºC until procedures.
Digestion of the biopsies through controlled enzymes
Replication of the cells
Selection undifferentiated cells
Expansion of the purification cells population
Characterization of the cell population
Assessment of pluripotent and germinal cell potential.
Possible maturation of the cells."
1711555|NCT01375049|Drug|Aztreonam for Inhalation Solution (AZLI)|AZLI 75 mg administered 3 times daily via the investigational eFlow® nebulizer
1711556|NCT01375023|Radiation|Radiotherapy|daily radiation therapy for 10 days, total dose of 80 cGY
1711557|NCT01375023|Biological|Anti-Thymocyte Globulin|1.5 mg/kg/day, IV from day -11 through day -7 before transplantation
1809144|NCT00645632|Drug|methotrexate|
1711561|NCT01374997|Other|micromethod from samples taken from blood spots on filter paper|a blood test to measure the level of alpha-galactosidase A activity by micromethod from samples taken from blood spots on filter paper
1711562|NCT01374984|Biological|VIGIV|VIGIV is licensed in US, by the FDA, for the treatment of complications of smallpox vaccinations and is available to eligible patients regardless of participation in this study.
1711563|NCT01374971|Drug|Certolizumab Pegol (CZP)|CZP is an anti-TNF, humanized antibody Fab' fragment/polyethylene glycol(PEG)conjugate. CZP liquid formulation 200 mg sc -(initial loading dose of 400 mg sc at 0 (Baseline), 2, and 4 weeks), then 200 mg sc every 2 weeks at 6, 8, and 10 weeks.
1711564|NCT01374971|Procedure|Arthroscopic synovial tissue biopsy|Subjects will undergo arthroscopy Pre and Post Treatment. The arthroscopy will be performed on a clinically inflamed joint. A single arthroscopy procedure using a small bore arthroscope will be conducted to obtain synovial tissue in each joint in all subjects. Local anesthesia will be used only. Two small incisions will be made to accommodate the arthroscope and other instruments. Synovial biopsies will be obtained using a motorized shaver.
1711565|NCT01373411|Drug|ticagrelor|ticagrelor 90 mg BID for 90 days
1711566|NCT01373411|Drug|Placebo|Placebo 1 pill BID for 90 days
1711567|NCT01373398|Drug|EO9(Apaziquone)|immediate instillation after TURBT + 6 weekly instillation 4mg/mL Apaziquone
1711568|NCT01373372|Drug|Acthrel|Powder for reconstitution, 1.0 mcg/kg body weight to a maximum of 100 mcg, delivered one time via IV over one minute.
1711569|NCT01374945|Device|Clearpath Lower GI|Clearpath device for cleaning of colon by irrigation and evacuation
1711571|NCT01374919|Drug|ferumoxytol|IV administration of 1020 mg of ferumoxytol in 15 minutes
1711572|NCT01374906|Drug|SOM230 LAR 30 mg|starting dose of 30 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of starting dose.
1711573|NCT01374906|Drug|SOM230 LAR 10 mg|starting does of SOM230 LAR 10 mg i.m. administered once every 28 days for 4 months, followed by dose up-titration or continuation of the starting dose.
1711574|NCT01374893|Behavioral|Exercise|The intervention group will perform the multi-session per day training program
1711575|NCT01374893|Behavioral|Control|Usual care
1711576|NCT01374854|Biological|Umbilical mesenchymal stem cell (UC-MSCs) infusion|1×10^6/kg UC-MSCs is infused through pancreatic artery along with mononuclear cells by interventional therapy and another same dose of UC-MSCs is administered one week post-intervention.
1711577|NCT01374854|Drug|traditional therapy|exogenous insulin injection daily
1711578|NCT01374841|Drug|Cyclophosphamide|14.5 mg/kg, IV qd on day -6 and -5 and 50 mg/kg, IV on day +3 and +4
1711579|NCT01374841|Other|Hematopoietic Stem Cell Transplantation,|Hematopoietic Stem Cell Transplantation,
1711580|NCT01374828|Drug|Ketolorac|Ketorolac 30 mg in 10 ml saline will be injected at the incision sites at the conclusion of the procedure.
1711581|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based social problems screening and referral tool developed at Children's Hospital.
1711582|NCT01374815|Other|The Online Advocate|The Online Advocate is a Web-based screening and referral tool for health-related social problems
1711583|NCT01374802|Drug|Darunavir|400 mg tablet for oral administration
1711584|NCT01374802|Drug|Ritonavir|tablet for oral administration
1711585|NCT01374802|Drug|BI 201335|
1711586|NCT01374789|Drug|GemCis + Panitumumab|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3 Panitumumab 9 mg/kg/body weight, i.v., day 1,q3
1711587|NCT01374789|Drug|GemCis|Gemcitabine: 1250 mg/m², day 1 and 8, i.v., q3 Cisplatin: 70 mg/m², day 2, i.v., q3
1711588|NCT01374776|Drug|Double blind, randomized, placebo controlled inter|The patients will be randomized to one of the 2 treatment groups (12 patients in each group): Group I: intravenous iron carboxymaltose; Group II: intravenous placebo. Group I (intravenous iron): Ferinject will be applied via a short infusion. Patients will receive 15mg/kg of iron as iron carboxymaltose Ferinject® in 250 ml 0.9% NaCl intravenously (time of infusion 20 mins), in a single dose. The maximum dose is limited to 1000mg iron. Group II (intravenous placebo): Intravenous placebo (250 ml 0.9 % NaCl will be administrated in the same manner and time schedule than group I.
1711589|NCT01374763|Drug|Oxycodone|Prolonged-release oxycodone 10-30 mg twice daily
1711590|NCT01374763|Drug|Prolonged-release oxycodone/naloxone|Prolonged-release oxycodone/naloxone 10-30 mg twice daily
1711591|NCT01374750|Drug|Sirolimus|Sirolimus
1711592|NCT01374750|Drug|m-TOR inhibitor free|calcineurin inhibitors
1711593|NCT01374737|Drug|Dexmedetomidine|dexmedetomidine, 0.1ug/kg up or down
1711594|NCT01374724|Behavioral|Tobacco Use Ban|Airmen are restricted from use tobacco products during Basic Military Training which lasts for 8.5 weeks.
1711595|NCT01374724|Behavioral|Tailored Pamphlet|A tailored relapse prevention pamphlet inspired by Forever Free and tailored for use in the United States Air Force.
1711596|NCT01374724|Behavioral|Informational Pamphlet|"The National Cancer Institute Pamphlet Clearing the Air was provided to subjects."
1711597|NCT01374724|Behavioral|Relapse Prevention Intervention|A 15 - 30 minute relapse prevention intervention designed to increase motivation to remain tobacco free.
1711598|NCT01374711|Drug|GM-CSF|GM-CSF (4microgram/kg/day subcutaneously) on days 2, 4 and 6.
1711599|NCT01374711|Drug|IFN-Y|IFN-Y (100 microgram/day, subcutaneously) on days 2, 4 and 6.
1711600|NCT01374711|Other|E.coli endotoxin|2 ng/kg E.coli reference endotoxin 11:H 10:K negative intravenously
1711601|NCT01374698|Drug|Aspirin|Aspirin 325 mg
1711602|NCT01374672|Other|laboratory biomarker analysis|Correlative studies
1711603|NCT01374646|Behavioral|JOIN Intervention|Behavioral group treatment for overweight and obese children and teens, that focuses on decreasing energy dense foods and sedentary behaviors.
1711683|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
1711684|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
1711604|NCT01374633|Drug|1: Sevoflurane|"Mean sevoflurane infusion rate will be around 6 ml/h or 72 ml for 12 hours. Maximal infusion rate will be around 12 ml/h, or 144 ml for 12 hours. Packaging: bottle containing 250 ml of liquid sevoflurane for evaporation. Administration mode: anaesthetic conserving device for volatile anaesthetics."
1711605|NCT01374620|Drug|Paclitaxel dose escalation|"Paclitaxel will be administered intravenously over 60 minutes, at D1, D8 and D15, at a given dose.
The Paclitaxel dose (mg/infusion) levels are as follows:
40
60
70
75
80
85
90"
1711606|NCT01374620|Drug|Paclitaxel|Patients will be treated at the recommended dose in order to confirm the recommended paclitaxel dose in association with metronomic cyclophosphamide
1711607|NCT01374620|Drug|Cyclophosphamide|"D1 to D28: 50 mg x 2/day/cycle
1 cycle = 28 days"
1711608|NCT01374620|Biological|Blood collection|At D1, D8, D15 and D21 of cycle 1 and cycle 2:2 blood samples for the correlation between clinical response and biological parameters
1711609|NCT01374581|Drug|Artemether/Lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).
Weight in kg Number of tablet per dose Age 5 to < 15 kg 1 tablet per dose 15 to < 25 kg 2 tablets per dose 25 to < 35 kg 3 tablets per dose"
1711610|NCT01374581|Drug|Artesunate/Amodiaquine|"Age (Weight in Kg) Dose Treatment duration 2 to 11 months (= 4,5 to < 9kg):1 tablet (25 mg/675mg) for 3 days
1 to 5 years (= 9 kg to < 18 kg)1 tablet(25mg/67,5mg)for 3 days"
1711611|NCT01374581|Drug|Quinine + Clindamycin|"this arm consist to 7 days treatment of 60 patients with quinine tablet 125mg + clindamycin syrup as follow;
Quinine:
9 to < 11 kg: ½ tablets 12 to < 19 kg: 1 tablets per dose 20 to < 27 kg: 1½ tablets per dose 28 to < 35 kg: 2 tablets per dose
Clindamycin syrup:
10 mg/kg twice daily"
1711612|NCT01374568|Drug|sitagliptin|sitagliptin 100mg daily
1711613|NCT01374568|Other|Placebo|1 pill daily
1711614|NCT01374542|Procedure|Respiratory endoscopy|Bronchoscopy, thoracoscopy, endobronchial ultrasound
1711617|NCT01374503|Biological|ALX-0651|single or multiple (once daily for maximum 3 consecutive days) i.v. administration, 0.003-12 mg/kg
1711618|NCT01374503|Biological|Placebo|single or multiple i.v. administration
1711619|NCT01374490|Drug|Crofelemer|Crofelemer will be administered orally as 1 tablet(125 mg)BID for a total daily dose of 250mg crofelemer.
1711620|NCT01374464|Other|Interscalene brachial plexus block|"4 different administrations of levobupivicaine will be applied:
High Volume, High Concentration = 15mls of 0.75% levobupivicaine
High Volume, Low Concentration = 15mls of 0.5% levobupivicaine
Low Volume, High Concentration = 5mls of 0.75% levobupivicaine
Low Volume, Low Concentration = 5mls of 0.5% levobupivicaine"
1711621|NCT01374451|Drug|Everolimus|Everolimus was supplied as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets
1711622|NCT01374451|Drug|Pasireotide LAR|Pasireotide LAR intra-muscular depot injections were supplied as a powder in vials containing 20 mg and 40 mg with ampoules containing 2 mL of vehicle (for reconstitution).
1711623|NCT01374438|Drug|MSDC-0160|MSDC-0160 150 mg capsules given once daily for 90 days
1711624|NCT01374438|Drug|Placebo|Placebo capsules given once daily for 90 days
1711625|NCT01374425|Drug|5-Fluorouracil|5-Fluorouracil 400 milligrams per meter-squared (mg/m^2) by IV bolus and subsequent 2400 mg/m^2 by IV infusion over 46 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
1711626|NCT01374425|Drug|Bevacizumab|Bevacizumab 5 milligrams per kilogram (mg/kg) of body weight via IV infusion will be administered every 2 weeks until disease progression or unacceptable toxicity. If participants are discontinued from oxaliplatin or irinotecan due to unacceptable toxicity, bevacizumab may be given in 3-week cycles with capecitabine.
1711627|NCT01374425|Drug|Irinotecan|Irinotecan 180 mg/m^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
1711628|NCT01374425|Drug|Leucovorin|Leucovorin 400 mg/m^2 or dose deemed appropriate by Investigator via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
1711629|NCT01374425|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 via IV infusion over 2 hours will be administered every 2 weeks until disease progression or unacceptable toxicity.
1711630|NCT01374425|Drug|Capecitabine|Capecitabine 850 or 1000 mg/m^2 may be offered in the event of unacceptable toxicity to oxaliplatin or irinotecan, to be given orally twice a day on Days 1 to 14 in 3-week cycles.
1711631|NCT01374399|Behavioral|exercise and relaxation|resistance and endurance exercise, 3-5 times per week
1711632|NCT01374386|Other|Exergaming|Exergaming equipment will be available for use at the YMCA daily. Exergames include a mixture of aerobic and resistance exercise activities. The Exergames include: WaterRowers, GameCyle System, Gamercize Pro Steppers, Expresso Bikes, Dogfight Simulators, and Dance Dance Revolution
1711633|NCT01374373|Biological|Epoetin alfa|Epoetin alfa 40.000-60.000 IU/week subcutaneously that will be controlled and up or down titrated every 2 weeks according to the currently approved prescription guidance for a total of 12 weeks of treatment with Co administration of oral ferrous sulfate 200mg BID and oral folic acid 5mg QD
1711634|NCT01374321|Drug|TRO40303|6 mg/kg, peripheral IV, single dose just before balloon inflation, slow bolus (35ml/min)
1711635|NCT01374321|Drug|Placebo|single dose just before balloon inflation by slow bolus (35ml/min, peripheral IV)
1711636|NCT01374308|Biological|NASVAC|NASVAC will be administered every 2 weekly intra-nasally at a dose of 100 micro grams for 5 times followed by every 2 weekly administration of 100 micro grams intra-nasally plus 100 micro grams subcutaneously.
1711637|NCT01374308|Drug|Pegylated interferon alpha 2b|Injection Pegylated interferon alpha 2b will be administered once weekly subcutaneously at a dose of 180 micro grams for 48 weeks
1711638|NCT01374295|Other|video|watch a 3 minute video
1711639|NCT01374295|Other|standard education|Receives standard verbal education from healthcare provider
1711640|NCT01374282|Drug|Cuprimine (penicillamine)|Dosage determined by the physician based on indication for treatment
1711641|NCT01374269|Other|Exercise program|Standardize the intervention programs Exercise program includes: physical agents, massage of myofascial points, stretching and strengthening exercises, cycloergometer or band aerobic exercises. 12 sessions, 3 per week.
1711642|NCT01374269|Drug|NSAID (Nonsteroidal anti-inflammatory drugs)|The second group was treated for 10 days with NSAIDs (naproxen 500 mg/d or celecoxib 200 mg/d) according to the indications and contraindications. The patients kept a journal stating whether they had taken the drug and any adverse reactions. If the pain intensity of any participant increased, acetaminophen (1.5 - 2.0 g/d) was proposed as a rescue procedure.
1711643|NCT01374230|Procedure|Total knee arthroplasty|Surgical implantation of total knee components for the treatment of osteoarthritis.
1711644|NCT01374217|Drug|Tadalafil, Cialis|Tadalafil will be administered at a dose of 20 mg orally daily starting with day 1 of the first cycle. Each cycle will last for 28 days
1711645|NCT01374191|Drug|onabotulinum toxin type-A|1 injection of Btx-A
1711646|NCT01374191|Other|placebo|1 injection of saline solution
1711647|NCT01374191|Drug|2nd phase - onabotulinum toxin type-A|2 - 3 injections of Btx-A, specific to patient pain recurrence
1711648|NCT01374178|Drug|LY2963016|Administered subcutaneously
1711649|NCT01374178|Drug|Lantus|Administered subcutaneously
1711650|NCT01374152|Other|cognitive sensory motor training therapy|training method that emphasis on cognition/ sensation/ and motor movement together train every working day 45 minutes per day for 4 weeks.
1711651|NCT01374139|Drug|Bosutinib|5 clinical 100 mg tablets and 100 mg capsules, 500 mg, single dose, 2x2 crossover under fed condition
1711652|NCT01374139|Drug|Bosutinib|4 commercial 100 mg tablets, 400 mg, single dose, 2x2 crossover under fed/fast condition
1711653|NCT01374126|Drug|Artesunate|Artesunate alone
1711654|NCT01374126|Drug|Azithromycin + Artesunate|Combination of azithromycin + artesunate
1711655|NCT01374113|Drug|50mg safinamide|50 mg safinamide on Day 1
1711656|NCT01374100|Behavioral|Standard Exercise|The standard exercise therapy program will include 12 treatments of approximately 45 minutes duration, twice a week for a period of six weeks by the same instructor and at the same location as for Qigong therapy. This exercise program is supervised and consists of cardio-vascular and resistance training exercises. Participants are asked to refrain from practicing Qigong during this 6 week period.
1711657|NCT01374100|Behavioral|Qigong Exercise|Qigong therapy will be led by a trained Qigong instructor and will occur for 45 minutes sessions, twice a week for a period of six weeks. Qigong is a self-directed walking exercise program that involves arm movements that are coordinated with slight movements of the waist, while in a state of deep relaxation or meditation. Patients will be asked to refrain from independent resistance or cardiovascular training during this 6 week period.
1711658|NCT01374087|Other|Brachytherapy + Triptorelin 22.5 mg|Brachytherapy: Low or high dose rate. Triptorelin: A single, intramuscular injection (22.5 mg), preferably 2 months before brachytherapy.
1711659|NCT01374087|Radiation|Brachytherapy|Brachytherapy: Low or high dose rate.
1711660|NCT01374061|Device|Classical intubation|Classical intubation
1711661|NCT01374061|Device|GLIDESCOPE|GLIDESCOPE intubation
1711662|NCT01374035|Other|Quality improvement intervention|A complex intervention will be implemented within the group of GPs in the intervention group. It includes participation in defining criteria for good referral letters, information about the correlation between information in the referral letters and outcome, introduction to the guideline, and consecutive feedback on own preformance regarding content of referral letter and outcome for the patient.
1711663|NCT01374022|Other|ART Strategy|Maximum alveolar recruitment maneuver in association with PEEP titrated by the static compliance of respiratory system.
1711664|NCT01374022|Other|ARDSNet Strategy|Conventional mechanical ventilation strategy.
1711665|NCT01373996|Device|Wireless invasive blood pressure monitoring (Hybymed® Wireless IBPM System)|"The readings of invasive arterial pressure were obtained from 2 identical pressure transducers, connected to a common arterial line via a Y connector. Data was collected from one transducer via a direct cable connection and from the second transducer via wireless transmission of the signal to the patient's bedside monitor using the HMW 10 Wireless System.
A comparison of data received by patient's bedside monitor from the two transducers was done (standard connection vs. wireless connection), as well as a comparison of data collected by the transmitter and data received by the receiver of the HMW 10 Wireless System."
1711666|NCT01373983|Drug|Ziconotide|1.25 or 2.5 mcg or 3.75 mcg i.t. according to an algorithm
1711667|NCT01373970|Drug|Placebo|Placebo, one tablet daily for 12 weeks
1711668|NCT01373970|Drug|Pantoprazole + Placebo|Pantoprazole 40 mg, one tablet daily in eight weeks followed by a blinded cross over to placebo, one tablet daily for four weeks
1711669|NCT01373931|Drug|LY2216684|Administered orally
1711670|NCT01373931|Drug|Ortho Cyclen|35 mcg ethinyl estradiol and 250 mcg norgestimate administered orally
1711671|NCT01373931|Drug|Placebo|Administered orally
1711672|NCT01373918|Drug|Intralipid|The subject will receive 1 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
1711673|NCT01373918|Drug|Intralipid|The subject will receive 3 g/kg/d of the standard intravenous fat emulsion while receiving Parenteral Nutrition until discharge from the hospital, death or 100 days of life, whichever comes first.
1711674|NCT01373905|Procedure|Recruitment maneuver|group I: Recruitment by CPAP 30 cm/H2o for 30 seconds group II: Using pressure controlled ventilation with end-inspiratory minus end-expiratory pressure of 15 cmH2O, respiratory rate of 10-15 C / min. PEEP was increased by 5 cm/ H2O every 2 minutes till Maximum of 40 cmH2O, patient was considered recruited if PaO2 of 250 mmHg was achieved. Then progressive decreases of PEEP in steps of 2 cmH2O every 2 minutes till PaO2 dropped by a 10% or more (alveolar collapsing pressure)
1711675|NCT01373905|Procedure|recruitment maneuver|recruitment as done by CPAP 30 cm/ H2o for 30 seconds or by stepwise elevation of PEEP by 5 cm/ H20 till 40 Cm/ H2o
1711676|NCT01373892|Procedure|Bariatric surgery|
1711677|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
1711678|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 5 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
1711679|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 1 x 10^8 pfu IM 8 weeks later
1711680|NCT01373879|Biological|AdCh63 ME-TRAP, MVA ME-TRAP|AdCh63 ME-TRAP 1 x 10^10vp IM followed by MVA ME-TRAP 2 x 10^8 pfu IM 8 weeks later
1711681|NCT01373879|Biological|HDCRV|HDCRV 1ml IM followed by HDCRV 1ml IM 8 weeks later
1711685|NCT01373866|Device|MagPro X100 repetitive Transcranial Magnetic Stimulation|"Target defined using both fMRI during hallucinations occurence and tractography.
Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session"
1711686|NCT01373866|Device|MagPro X100 repetitive Transcranial Magnetic Stimulation|Target: T3-P3 (10-20 EEG international System). Parameters: 1 Hz/ 100% of the Motor Threshold/ 10 sessions (2/ day over 5 days)/ 1200 pulses/ session
1711687|NCT01373853|Procedure|Lens Fragmentation by means of a femtosecondlaser|In Group A the anterior capsulotomy and a pre-fragmentation of the ocular lens will be performed by means of femtosecond laser surgery.
1711688|NCT01373853|Procedure|Manual Phacoemulsification|Group B acts as a control group where the capsulotomy and lens fragmentation are performed manually
1711689|NCT01373827|Device|VASERShape MC1|Use of the VASERShape MC1 device as part of routine practice
1711690|NCT01373801|Device|The HemCon GuardaCare|The HemCon GuardaCare (HemCon Medical Technologies Inc., Portland, OR) is a hemostatic dressing made of chitosan, a complex carbohydrate derived from chitin from shellfish and is designed as a hemostatic dressing, and a topical antimicrobial dressing. GuardaCare contains no pro-clotting agents, providing a safe and localized hemostatic solution and is latex free and sterile.
1711691|NCT01373801|Device|Control|Standard packing gauze roll bandage.
1711692|NCT01373775|Other|Patient charts reviewing|Reviewing chart and identifying risk factors
1711693|NCT01373762|Behavioral|Exercise Videogame Bikes|The intervention group will receive an exercise videogame bike that will be linked into their Sony Playstation 2® (Sony Computer Entertainment America Inc, Foster City, California). The Active Cycle® system reads the participant's cycling cadence which, in combination with a handlebar-mounted game controller, allows each participant to play a variety of Sony Playstation 2 and 3® videogames while exercising. The control-distraction group will receive a traditional stationary bike (i.e., same bike as the Active Cycle, but without the videogame controllers), which will be placed in front of their television. The recommended exercise training regime for both conditions will be activity of moderate intensity exercise (i.e., 60 to 75% of heart rate reserve), 3 days/week for 30 minutes/day.
1711694|NCT01373749|Drug|NO inhalation|NO inhalation was performed as the only treatment for PPHN during the whole course.
1711695|NCT01373749|Drug|NO inhalation continued with sildenafil|NO inhalation was performed as the primary treatment for PPHN in the first 48 hours, NO inhalation will be replaced by sildenafil after 48 hours of therapy.
1711696|NCT01373736|Drug|123I-meta-iodobenzylguanidine|
1711697|NCT01373723|Other|Different alternatives to improve the coverage of the populational screening programmes of cervical cancer|Cost-effectiveness analysis of 3 strategies to increase the recruitment of population screening for cervical cancer. These interventions will be compared to the current opportunistic screening strategy
1711698|NCT01373710|Drug|Trastuzumab|One injection per week during 8 weeks by lumbar puncture or Ommaya Reservoir. 4 levels of doses are expected from 30 mg to 150 mg
1711699|NCT01373697|Drug|Ibuprofen|Apply the gel at the site of pain or injury, massaging gently to promote penetration of 8 in 8 hours for 5 days. Leave the gel on the premises at least 4 hours before removal
1711700|NCT01373697|Drug|Profenid|Apply the gel on the spot of pain or injury, massaging slightly to facilitate the penetration of 8 in 8 hours during 5 days. Leave the gel on the the site at least 4 hours before removal
1711701|NCT01373684|Drug|Peginterferon alfa-2a|180 μg per week s.c. for a total duration of 48 weeks.
1711702|NCT01373684|Drug|Nucleos(t)ide analogue|All patients are all currently being treated with long-term NA treatment and will continue using these during the study. Dosage depends on which Nucleos(t)ide analogue they are using.
1711703|NCT01373671|Device|SIEMENS INSPIRATION DIGITAL BREAST TOMOSYNTHESIS (DBT) SYSTEM|DBT scan
1711704|NCT01373658|Device|Yinyi stent|subjects with Yinyi stent implantation
1711705|NCT01373645|Device|Yinyi stent|subjects with Yinyi stent implantation
1711706|NCT01373632|Device|Firebird 2 sirolimus-eluting stent|the Firebird 2 sirolimus-eluting stent is a SES with durable polymer based on Co-Cr stent platform
1711707|NCT01373632|Device|Excel sirolimus-eluting stent|the Excel sirolimus-eluting stent is a stent with biodegradable polymer (PLA) based on stainless steel (316L) stent platform
1711708|NCT01373619|Drug|Ivabradine|ivabradine titrated to 7.5 mg BID
1711709|NCT01373606|Drug|Terlipressin|
1711710|NCT01373593|Drug|lidocaine|
1711711|NCT01373593|Drug|Placebo|
1711713|NCT01373567|Drug|TINEFCON|Two 700 mg tablets of Tinefcon in the morning and evening to be taken orally.
1711714|NCT01373554|Drug|Placebo|30mig/bid or 60mg/bid P.O
1711715|NCT01373554|Drug|Oltipraz|30mig/bid or 60mg/bid P.O
1711716|NCT01373541|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
1711717|NCT01373541|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
1711718|NCT01373528|Drug|Budesonide irrigation|A budesonide (1 mg) in saline (240 mL) irrigation solution is applied to the sinonasal cavities twice daily. 120 mL of the solution is applied via irrigation in the AM, and 120 mL again in the PM.
1711719|NCT01373515|Biological|DCP-001|4 bi-weekly vaccinations
1711720|NCT01373502|Device|DES Limus Carbostent|DES Limus Carbostent Carbofilm Coated Coronary Stent
1711721|NCT01373502|Device|Taxus Liberté Stent|Taxus Liberté Coronary Stent
1711722|NCT01373489|Device|Technology-Assisted Case Management (TACM with the FORA 2-in-1 Telehealth System)|The TACM intervention uses the FORA 2-in-1 Telehealth System for diabetes to link a case manager to poorly controlled diabetics in real time. Patients will be assigned the FORA 2-in-1 Telehealth System and provided glucose test strips to allow testing at least once a day. They will be asked to perform glucose testing and blood pressure measurement using the FORA system once daily. They will be asked to upload the measurements daily as soon as possible after the test is performed. The nurse case manager will have access to a secure server to which the uploaded measurements are stored in real time.
1711723|NCT01373476|Drug|Qideng Mingmu capsule|High dosage group (4 Qideng Mingmu capsules each time): 4#, po, tid,24 weeks; Middle dosage group (2 Qideng Mingmu capsules plus 2 placebos each time):4#, po, tid,24 weeks;Low dosage group (1 Qideng Mingmu capsule plus 2 placebos each time):3#, po, tid,24 weeks.
1711724|NCT01373476|Drug|Placebo Comparator|Placebo group (4 placebos each time):4#, po, tid,24 weeks.
1711725|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
1711726|NCT01373463|Drug|Carboplatin|Carboplatin by vein Every 21 days for 3 cycles
1711727|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
1711728|NCT01373463|Drug|Pemetrexed|Pemetrexed by vein every 21 days for 3 cycles
1711729|NCT01373463|Drug|Cisplatin|Cisplatin by vein every 21 days for 3 cycles
1711730|NCT01373463|Radiation|Radiation Therapy|Radiation treatment 5 days a week for 5-6 weeks.
1711731|NCT01373463|Procedure|Lobectomy|Surgery
1711732|NCT01373463|Procedure|Lobectomy|Surgery to remove a portion of the lung where the tumor is located.
1711733|NCT01373450|Drug|Oxyntomodulin|3.0 pmol/kg/min as an intravenous (IV) infusion in the morning of the day of graded glucose infusion (GGI) (Day 1)
1711734|NCT01373450|Drug|Liraglutide 0.6 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
1711735|NCT01373450|Drug|Liraglutide 1.2 mg|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
1711736|NCT01373450|Drug|Placebo for Oxyntomodulin|IV infusion in the morning of the day of GGI (Day 1)
1711737|NCT01373450|Drug|Placebo for Liraglutide|Single subcutaneous dose in the evening of the day before the GGI (Day-1)
1711738|NCT01373437|Device|Ultrasonography (Sonosite )|Sonosite MICROMAXXTM with linear probe L38e/10-5 MHz
1711739|NCT01373359|Drug|Misoprostol|400 µg sublingual misoprostol
1711740|NCT01373359|Drug|Oxytocin|10 IU IM
1711741|NCT01373346|Procedure|Long limb Roux-en Y reconstruction|After radical gastrectomy, the gastrointestinal tract was reconstructed by Roux-en-Y gastrojejunostomy or esophagojejunostomy. The jejunum was divided at approximately 100-120 cm distal to the ligament of Treitz and the distal limb of the jejunum was then anastomosed along the proximal gastric greater curvature or esophagus. The jejuno-jejunostomy was performed approximately 100 to 120 cm distal from the gastrojejunal or esophagojejunal anastomosis
1711742|NCT01373333|Drug|3,4 DAP|Recommended maximum dosage: 20mg four times daily and if needed an additional 20 mg per day for a total of 100 mg per day. Drug must be kept refrigerated at all times.
1711743|NCT01373320|Behavioral|Lay health advisor interactions|"For smoking cessation: Cooper-Clayton group sessions plus motivational interviewing, both delivered by local lay health advisor.
For all cancer screenings: lay health advisor home visits incorporating motivational interviewing and focused on decreasing participant-identified barriers to screening."
1711744|NCT01373307|Behavioral|LHA-delivered energy balance classes/activities|4-6 sessions delivered by local LHA to age-appropriate groups (i.e., children/adolescents and adults), based on We Can! And Media Smart Youth curricula.
1711745|NCT01373294|Drug|Bacille Calmette-Guerrin (BCG)|Participants will receive BCG instillations once per week for the first 6 weeks. At 3 months and 6 months, participants will receive BCG instillations once per week for three weeks.
1711746|NCT01373294|Drug|Lenalidomide|Participants may also receive capsules of lenalidomide 10 mg to swallow once per day for 7 months. The study doctor will tell participants if they will be taking lenalidomide.
1711747|NCT01373281|Biological|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
1711748|NCT01373281|Biological|Placebo: NaCl 0.9%|0.5 mL, Subcutaneous
1711749|NCT01373255|Procedure|internal iliac catheterization|Women in this arm will undergo internal iliac artery catheterization prior to the cesarean delivery
1711750|NCT01373242|Drug|Liquid peanut extract (Peanut SLIT)|Liquid peanut extract will be administered under the tongue
1711752|NCT01373216|Drug|Exenatide|Perioperative continuous i.v. administration of exenatide lasting for 72 hours - 40 ng/min for initial 30 min, 20 ng/min for remaining 71.5 hours
1711753|NCT01373164|Drug|LY2157299|"Administered orally twice daily for 14 days followed by 14 days of rest. Dose escalation will proceed if none of the first 3 participants experience a dose limiting toxicity (DLT) during the first cycle of treatment. If 1 of 3 participants experiences a DLT, the cohort will be expanded to include an additional 3 participants. If 2 or more participants experience a DLT, then the sponsor and investigator will jointly decide whether to reduce the dose to 20 mg BID for Cohort 1 or recruit into an additional cohort at an intermediate dose for Cohorts 2 and 3.
Phase 2 recommended dose will be based on review of overall toxicity, dose reductions, omissions, and pharmacokinetic information from Phase 1b Cohorts. Dose will be administered orally twice daily for 14 days followed by 14 days of rest."
1711754|NCT01373164|Drug|Gemcitabine|Administered intravenously once per week for 7 weeks followed by a week of rest and then once per week for 3 weeks of every 4 weeks.
1711755|NCT01373164|Drug|Placebo|Administered orally twice daily for 14 days followed by 14 days of rest.
1711756|NCT01373151|Drug|BMS-945429 Placebo|Injection, Subcutaneous, 0 mg, Every 4 weeks, Day 1 - Week 24 only
1711757|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 25 mg, Every 4 weeks, Day 1 - Week 24 only
1711758|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 100 mg, Every 4 weeks, 48 weeks
1711759|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, Week 25 - Week 48
1711760|NCT01373151|Biological|BMS-945429|Injection, Subcutaneous, 200 mg, Every 4 weeks, 48 weeks
1711761|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, Day 1 - Week 24 only
1711762|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, 48 weeks
1711763|NCT01373151|Drug|Methotrexate Placebo|Tablets, Oral, 0 mg, Weekly, Day 1 - Week 24 only
1711764|NCT01373151|Drug|Methotrexate|Tablets, Oral, 15 mg, Weekly, Week 25 - Week 48 only
1711765|NCT01373151|Drug|Adalimumab Placebo|Injection, Subcutaneous, 0 mg, Every 2 weeks, 48 weeks
1711766|NCT01373151|Drug|Adalimumab|Injection, Subcutaneous, 40 mg, Every 2 weeks, 48 weeks
1711767|NCT01373138|Drug|Desloratadine and pseudoephedrine|Desloratadine and pseudoephedrine 5/240 mg
1711768|NCT01373112|Procedure|Static Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made to fit the femoral and tibial exposed metaphyses as a solid block with associated antibiotic cement coated tibial and femoral intramedullary rod, such that knee motion will be minimized.
1711769|NCT01373112|Procedure|Articulating Spacer|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or a static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of the infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed of 3 g of Vancomycin and 1 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic impregnated cement using the Stage One system (Biomet, Warsaw, IN).
1711770|NCT01373099|Procedure|Implantation of a static, non-articulating cement spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Static spacers will be hand-made with a rod of antibiotic-impregnated cement and cement beads of sufficient quantity to fill the acetabulum.
1711771|NCT01373099|Procedure|Implantation of an articulating spacer.|After diagnosis of infection and informed consent, patients will be taken to the operating room. After anesthetization, patients will be randomized to either an articulating spacer or static spacer. Randomization will be performed by prepared opaque envelopes administered by a nonparticipant in the study. After a complete debridement of devitalized tissue, explantation of infected components and any associated cement, either an articulating or static spacer will be placed. All spacers will be formed using 3.0 g of Vancomycin and 1.0 g of Tobramycin for each 40 g packet of cement. Articulating spacers will be formed of antibiotic-impregnated cement using the Stage One system (Biomet, Warsaw, IN) sized to fit the endosteal and acetabular bone defect.
1711772|NCT01373086|Drug|LFF269|
1711773|NCT01373086|Drug|Eplerenone|
1711774|NCT01373086|Drug|Placebo|
1711775|NCT01373073|Other|Experimental human milk fortifier|Human milk fortifier to be added to human milk feedings
1711776|NCT01373073|Other|Control human milk fortifier|Control human milk fortifier to be added to human milk
1711777|NCT01373060|Drug|ASP1941|oral
1711778|NCT01373060|Drug|Placebo|oral
1711779|NCT01373047|Biological|anti-CEA 2nd generation designer T cells|Three infusions of gene-modified T cells over the course of 6 weeks into the hepatic artery via a percutaneous approach.
1711780|NCT01373034|Dietary Supplement|Soy Dietary Fiber|Soy Dietary Fiber, Once a day, before meal, 1 pack(20g), per oral with water 90mL
1711781|NCT01373034|Dietary Supplement|Rice powder|Rice powder, Once a day, before meal, 1 pack(20g), per oral with water 90mL
1711782|NCT01373021|Drug|Fentanyl|Fentanyl 2500mcg+NS50ml
1711783|NCT01373021|Drug|Dexmedetomidine|Fentanyl 2500mcg+Dexmedetomidine 500mcg + NS 45ml
1711784|NCT01373008|Drug|Inhaled extra-fine hydrofluoalkane-beclomethasone (QVAR)|Infants will be randomized for Inhaled QVAR 100 microgram or placebo twice daily with spontaneous tidal breathing for 30 seconds via aerochamber with face mask for the study period.
1711785|NCT01372995|Drug|Enteral Vitamin D3 50,000 IU|Enteral Vitamin D3 50,000IU x 5 days (total dose 250,000IU)
1711786|NCT01372995|Drug|Enteral Vitamin D3 100,000IU|Enteral Vitamin D3 100,000IU over 5 days (total 500,000IU)
1711787|NCT01372995|Other|Inactive substance|Inactive substance given enterally for 5 days.
1711788|NCT01372982|Drug|Letrozole|Letrozole Tablets 2.5 mg of Dr.Reddy's Laboratories Limited
1711789|NCT01372969|Drug|Cx601|Suspension of adult expanded allogenic adipose-derived stem cells (eASCs) at a doses of 20 million cells and 40 million cells.
1711790|NCT01372943|Biological|"synthetic stool or pure cultures of probiotic intestinal bacteria"|"synthetic stool or pure cultures of probiotic intestinal bacteria from healthy donor stool that can be used as an enema to replace the use of stool transplant, for treatment of recurrent and refractory CDI"
1711791|NCT01372930|Drug|Etanercept|Etanercept 25mg in 1ml(subcutaneous injection)at 2h and 72h after PCI
1711792|NCT01372930|Drug|saline|saline 1ml(subcutaneous injection) at 2h and 72h after PCI
1711793|NCT01372904|Drug|Dexamethasone Phosphate|"0.7ml of Dexamethasone Phosphate 10mg/ml would be injected unilaterally to the middle ear using 25 gauge spinal needle.
The trans-tympanic membrane injection would take place at the posterior inferior quadrant of the ear drum facing the round window niche. The patient would be instructed to lie down for 20 minutes after the injection with the treated side up and to avoid swallowing or coughing. Intratympanic Dexamethasone would be delivered immediately prior to each cisplatin treatment as maximal level."
1711794|NCT01372878|Device|PillCam® COLON 2 procedure|Subjects will undergo a PillCam® COLON 2 procedure which includes ingestion of the PillCam® COLON 2 capsule. PillCam® COLON 2 is a disposable, ingestible capsule that takes video images throughout the digestive system.
1711795|NCT01372878|Procedure|Colonoscopy|"Subjects will undergo standard Colonoscopy procedure 4-6 weeks after PillCam® COLON 2 procedure.
Standard colonoscopy involves placement of a standard endoscope (a thin, flexible plastic tube) into the anus and into the colon, a tiny camera in the endoscope allows the study doctor to see the surface of the colon."
1711796|NCT01372865|Drug|Mometasone furoate|
1711797|NCT01372865|Drug|Mometasone furoate|
1711798|NCT01372839|Drug|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
1711799|NCT01372839|Drug|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
1711800|NCT01372826|Drug|NKTR118 Group1|Oral dose, 25 mg
1711801|NCT01372826|Drug|NKTR118 Group 2|Oral dose, 25 mg
1711802|NCT01372826|Drug|NKTR118 Group3|Oral dose, 25 mg
1711803|NCT01372826|Drug|NKTR118|Oral dose, 25 mg
1711804|NCT01372813|Drug|vandetanib|Daily dose 300mg/day by mouth, 28 day cycle
1711805|NCT01372787|Procedure|Assessment of Therapy Complications|Ancillary studies
1711806|NCT01372787|Other|Medical Chart Review|Ancillary studies
1711807|NCT01372787|Other|Quality-of-Life Assessment|Ancillary studies
1711808|NCT01372787|Other|Questionnaire Administration|Ancillary studies
1711811|NCT01372761|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
1711812|NCT01372761|Drug|Normal Saline|Subjects will receive placebo or ZGN-433 twice-weekly over a 4-week treatment period for a total of 8 doses. A range of doses will be evaluated.
1711813|NCT01372748|Other|Standard CPR|30:2 CPR consists of 3 cycles of standard CPR with each cycle consisting of 30 chest compressions with a pause for 2 ventilations at a compression:ventilation ratio of 30:2. CCC consists of a series of three cycles of continuous chest compressions without pauses for ventilation. In either group, each cycle will be followed by rhythm analysis until three cycles are completed or restoration of spontaneous circulation (ROSC), whichever occurs first.
1711814|NCT01372748|Other|Continuous chest compressions|Continuous chest compressions during the first 6 minutes of the resuscitation.
1711815|NCT01372735|Radiation|neoadjuvant short course IMRT|neoadjuvant short course intensity-modulated radiotherapy, single dose 5 Gy, total dose 25 Gy (5x5 schedule) to primary tumor and regional lymph nodes
1711816|NCT01372735|Radiation|IORT|intraoperative radiation therapy during resection, 15 Gy (to 90% isodose) to tumor bed
1711817|NCT01372722|Device|DBS Activa PC systems Medtronic|130Hz, 90us pulsewidth, 4V Amplitude
1711818|NCT01372722|Device|DBS, Activa PC systems Medtronic|30Hz, 90us pulsewidth, 4V Amplitude
1711819|NCT01372709|Device|Ovation™ or Ovation Prime™ Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
1711820|NCT01372696|Other|Sample of polyp|A small sample of the colonic polyp will be obtained for molecular testing. The remaining polyp will be sent for regular histological testing
1711822|NCT01372670|Drug|Hydroxyzine|"Study medications (hydroxyzine/placebo) will be dosed based on participant's weight. Dosing will be according to the following body weight ranges:
15-29 Kg 10 mg TID 30-44 Kg 20 mg TID
≥ 45 Kg 30 mg TID"
1711823|NCT01372670|Drug|hydroxyzine HCL|hydroxyzine HCL dosed on weight given 3x per day
1711824|NCT01372670|Other|Placebo|Placebo given 3 times per day
1711825|NCT01372657|Other|biometry calculation|
1711826|NCT01372644|Drug|SOM 230 / Pasireotide|
1711827|NCT01372631|Device|miniature spectral imaging system|Use of miniature spectral imaging system
1711828|NCT01372631|Device|Bench-top optical spectrometer|Use of bench-top optical spectrometer
1711829|NCT01372631|Device|High resolution microendoscope|Use of high resolution microendoscope
1711831|NCT01372605|Other|Measurement-Based Care collaborative depression management|Depression Care Manager collects metrics on depressive severity and side effects and provides decision support regarding antidepressant initiation and modification to HIV providers who prescribe medications
1711832|NCT01372605|Other|Enhanced Usual Care|
1711833|NCT01372592|Procedure|Surgery|Patients will receive standard of care surgical treatment dependent on his/her spinal condition.
1711834|NCT01372579|Drug|eribulin mesylate|Given IV
1711835|NCT01372579|Drug|carboplatin|Given IV
1711836|NCT01372579|Procedure|biopsy|Correlative studies
1711837|NCT01372566|Device|Harvest PRP Separation System|Platelet-rich plasma (PRP) is a blood-derived therapy that consists of platelets and growth factors. PRP can be formed by drawing blood from a vein and spinning it at a high speed in a specialized device called a centrifuge.
1711838|NCT01372566|Other|Sterile Saline injection|Sterile Saline will be injected multiple times in a different area of the arm (Part 1) or on the opposite side of the face from where the platelet rich plasma is injected.
1711839|NCT01372540|Drug|Arry-520|Part 1A Starting Dose: .75 mg/m^2 by vein on Days 1, 2, 15 and 16.
1711840|NCT01372540|Drug|Carfilzomib|"Part 1A Starting Dose: 20/27 mg/m^2 by vein on Days 1,2 8,9 and 15,16.
Part 1B Staring Dose: 20 mg/m2 dosing will be only on cycle 1 days 1 and 2, then starting 20/36 mg/m2 by vein on Days 1,2 8,9 and 15,16.
Dose Expansion Group: MTD of Part A and Part B."
1711841|NCT01372540|Drug|Dexamethasone|Part 1A and 1B, Part 2A and 2B: 4 mg by mouth or by vein on Days 1, 2, 8, 9 and 15, 16.
1711842|NCT01372540|Drug|Filgrastim|under the skin beginning on Day 3 or 4, and Day 17 or 18 of every cycle, and continue 1 time each day for 5-7 days.
1711843|NCT01372527|Other|TopCare: Use of provider knowledge vs. automated system|We will be evaluating the system in practices where providers are involved in determining to contact a patient, including the most appropriate outreach method, compared with practices where the system is fully automated without provider input.
1711844|NCT01372501|Device|Endobarrier Liner|Medical device placed endoscopically in the duodenum
1711845|NCT01372488|Procedure|Suture self removal|Suture self removal
1711846|NCT01372488|Procedure|Suture removal by family doctor or clinic|As above
1711847|NCT01372475|Device|Hymovis Intra-articular Injection|Hymovis Intra-articular injection
1711848|NCT01372475|Procedure|Phosphate Buffered Saline Injection|Placebo Intra-articular injection
1711849|NCT01372462|Device|NIOV - Room Air|Noninvasive ventilation with device powered by compressed room air.
1711850|NCT01372462|Device|NIOV - Oxygen|Noninvasive ventilation with device powered by compressed medical (100%) oxygen.
1711851|NCT01372462|Device|Nasal Cannula Oxygen|Supplemental oxygen delivered using a standard nasal cannula connected to 100% medical oxygen.
1711852|NCT01372449|Drug|Memantine|Memantine will be initiated at 3 mg. The dose will be increased every week by 3 mg for a maximum of 12mg for subjects weighing ≥ 60kg, 9mg for subjects weighing ≥ 40 kg but <60 kg, and 6 mg for subjects weighing ≥ 20 kg but < 40kg.
1711853|NCT01372449|Drug|Placebo|
1711854|NCT01372423|Drug|Lubiprostone|24 mcg capsules
1711855|NCT01372423|Drug|Placebo|24 mcg capsules
1711856|NCT01372410|Drug|GSK573719|125 mcg once daily
1711857|NCT01372410|Drug|GSK573719|62.5 mcg once daily
1711858|NCT01372410|Drug|GSK573719|31.25 mcg once daily
1711859|NCT01372410|Drug|GSK573719|15.6 mcg once daily
1711860|NCT01372410|Drug|GSK573719|31.25 mcg twice daily
1711861|NCT01372410|Drug|GSK573719|15.6 mcg twice daily
1711862|NCT01372410|Drug|Tiotropium|18 mcg once daily
1711863|NCT01372410|Drug|Placebo|once or twice daily
1711864|NCT01372384|Drug|erlotinib [Tarceva]|150 mg orally daily
1711865|NCT01372371|Biological|Vancomycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) + 500 mg of vancomycin instilled on surgical site before closure
1711866|NCT01372371|Biological|Vancomycin and Gentamycin|1 pre-operative dose of intravenous Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg) and 500 mg of vancomycin powder on surgical site before closure with gentamycin bone cement for joint replacement cases.
1711867|NCT01372371|Biological|Cefuroxime|1 pre-operative dose of Cefuroxime (1.5 gm) and 2 post-operative doses of Cefuroxime (750 mg)
1711868|NCT01372358|Drug|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
1711869|NCT01372345|Drug|CIPRO®XR|Ciprofloxacin 1000 mg Tablets Dr. Reddy's Laboratories Limited
1711870|NCT01372306|Drug|Reminyl|Galantamine Hydrobromide Tablets of Dr. Reddy's Laboratories Limited
1711871|NCT01372293|Drug|oral contraceptive pill|ethinyl oestradiol 20ug plus gestodene 75ug during 6 cycles
1711872|NCT01372280|Drug|Reminyl|Galantamine Hydrobromide Tablets 4 mg
1711873|NCT01372267|Behavioral|Psychoeducation for substance abuse|This active control provides detailed educational information about substance use and chronic pain to those enrolled.
1711874|NCT01372267|Behavioral|CBT for pain in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and pain.
1711875|NCT01372254|Behavioral|Standard Treatment|Participants will receive a standard, individual smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 5, 90-minute group sessions over an 4-5 week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BAD-AS condition.
1711876|NCT01372254|Behavioral|BAD-AS|BAD-AS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 5, 90-minute individual sessions over a 4-5 week period.
1711877|NCT01372254|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
1711878|NCT01372241|Behavioral|Lay health advisor visits and newsletter|The focus of the intervention was on reducing participants' self-identified barriers to obtaining Pap tests.
1711879|NCT01372228|Biological|hematopoietic stem cell infusion|Enriched hematopoetic stem cell infusion
1711880|NCT01372202|Drug|Paclitaxel|Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
1711881|NCT01372202|Drug|Cisplatin|"Paclitaxel and cisplatin:
Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29.
Cisplatin 30 mg/m² days 1, 8, 15, 22, 29.
Cisplatin and 5-fluorouracil:
5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1- 4 and 29 - 32.
Cisplatin 75 mg/m² days 1, 29."
1711882|NCT01372202|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 days 1, 15, 29.
1711883|NCT01372202|Drug|5-Fluorouracil|"Oxaliplatin and 5-fluorouracil:
Oxaliplatin 85 mg/m2 days 1, 15, 29.
5-Fluorouracil 180 mg/m2 prolonged infusion starting day 1 of radiation and completing on the final day of radiation (up to 40 days)
Cisplatin and 5-fluorouracil:
5-Fluorouracil 1000 mg/m2 per day over 24 hours days 1-4 and 29-32.
Cisplatin 75 mg/m² days 1, 29."
1711884|NCT01372202|Radiation|Radiotherapy|Patients will be treated 5 days/week at 1.8 Gy/day to a total dose of 45Gy.
1711885|NCT01372202|Procedure|Esophagectomy|The type of resection (Ivor-Lewis, Transhiatal, etc.) will be left to the discretion of the operating surgeon. Resection will be completed between 5 and 8 weeks starting from the completion of chemotherapy and radiation (days 36 - 56).
1711886|NCT01372176|Other|Early Goal-Directed Nutrition|"Initiation of early supplementary parenteral nutrition (≤ 24 hours of admission).
Measurement of requirements (indirect calorimetry, 24-hour urinary urea) leading to patient-specific, individualised and goal-directed nutritional therapy.
Intervention goal: delivering 100% of patient-specific requirements, measured or calculated throughout entire admission (EN+PN)."
1711887|NCT01372176|Other|ASPEN-guidelines|EN will be the preferred route of nutrition, and will be initiated within the first 24 hours of ICU admission, in accordance with best evidence. The amount is gradually increased over the first days of admission as tolerated by the patient (assessed from gastric aspirates). If EN fails to reach calculated goals at day 7, supplementary PN will be initiated at admission day 8 to reach goals. Protein and energy goals will be calculated as 25 kcal/kg/day and 1.2 g protein/kg/day.
1711888|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
1711889|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
1711890|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
1711891|NCT01372163|Drug|PF-05190457 or Placebo|Twice daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast and dinner in healthy volunteers.
1711892|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
1711893|NCT01372163|Drug|PF-05190457 or Placebo|Once daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast in healthy volunteers.
1711894|NCT01372163|Drug|PF-05190457 or Placebo|Once (or twice) daily oral doses of PF-05190457 or placebo is administered as a suspension for 14 days immediately before breakfast (and dinner if twice) in Type 2 Diabetic patients.
1711895|NCT01372150|Drug|desvenlafaxine succinate sustained release|Subjects randomized to DVS SR group receive 25, 35 or 50 mg/day based on subject weight at the Baseline visit. DVS SR provided as oral tablets.
1711896|NCT01372150|Drug|fluoxetine|Subjects randomized to the fluoxetine group receive 20 mg/day. Fluoxetine provided as oral capsules
1711897|NCT01372150|Drug|placebo|Subjects randomized to the placebo group receive corresponding placebo tablets and/capsules
1711898|NCT01372137|Drug|NOX-H94|Dosage form: NOX-H94 25 mg (oligonucleotide basis) Solution for Injection Strength: 14.6 mg NOX-H94 / mL Dose: 0.3 - 4.8 mg/kg single dose Route: IV infusion over 15 minutes / SC administration
1711899|NCT01372137|Other|Glucose 5%|Placebo
1711900|NCT01372124|Drug|NOX-E36|All subjects included in this study will receive the same dose of NOX E36. In previous clinical trials, single intravenous doses of NOX E36 up to 2 mg/kg body weight and single subcutaneous doses of up to 0.5 mg/kg body weight appeared to be safe and well tolerated in healthy volunteers. Pharmacokinetic analyses have shown dose linearity
1711901|NCT01372111|Drug|Cisplatin|Cisplatin 35 mg/m2 IV weekly during weeks 1 through 6 of IMRT.
1711902|NCT01372111|Radiation|Elective Nodal Irradiation (ENI)|Low risk planning target volume (PTV) of 36 Gy at 2 Gy per fraction daily to bilateral, uninvolved neck nodal regions at risk for harboring microscopic cancer. High risk PTV will receive 70 Gy.
1711903|NCT01372098|Behavioral|NFP + IPV intervention|The intervention focuses on helping women stay safe in a relationship. Strategies for overcoming barriers to using and accessing community resources and services, and community agency interventions for women exposed to IPV is built into the intervention.
1711907|NCT01372072|Device|non-invasive ventilation heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)|Heated humidification (Fisher-Paykel MR810 and MR850 humidifiers)
1711908|NCT01372059|Other|RGRM|RGRM is multi-sensory method. The group including 6-8 participants is headed by a certified therapist of the method using a unique note system. The Note system is the combined body of body symbols in red and blue, with the audio codes and movements and be assembled in countless combinations to stimulate different parts of the brain. The movements are exercised by the hands tapping on the knees and feet stamping on the floor without the need for tools other than the body. The RGRM is developed to stimulate mobility, reading and speech, rhythm-esteem, body image, balance, memory, coordination, motor skills, concentration, perseverance and social skills. The group will have two sessions per week during 12 weeks.
1711909|NCT01372059|Other|Therapeutic riding|The horses walk provides sensory input through movement, which is variable, rhythmic, and repetitive. The many textures, sounds, sights, movement experiences of working around a horse provide an enriched sensory environment. The participants gain from the physical benefits of being on a moving horse and are socially and emotionally stimulated by interacting with a horse and the rest of the group. The intervention is headed by educated therapists (occupational therapist and physical therapist), in conjunction with experienced horse handler and specially trained therapy horses. The treatment is held in group format (4-6 participants) twice per week in 12 weeks which runs in sessions where two participants ride at the same time.
1711910|NCT01372059|Other|Receives no intervention|Receives no intervention and acts as a control group in the analyses but will receive rhythm and music therapy after one year, when the long-term follow-up is completed.
1711911|NCT01372046|Behavioral|Booster Sessions|Provides onsite booster sessions for one year to the group after participating in standard care
1711912|NCT01372046|Behavioral|Training|memorandums, staff meetings
1711913|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions of CBT, twice weekly
1711914|NCT01372033|Behavioral|Cognitive Behavioral Therapy|18 sessions with goals groups drug testing
1711915|NCT01372020|Other|neuromuscular electrical stimulation|The application technique used will be bipolar, with electrodes of the type metal-tipped pen. The electrodes will be placed at the outer edges of the ulcer, on opposite sides of the same and the estimated time of 1 minute at each point. All the edge of the ulcer will be bypassed, thereby separating the injections every 1 cm, returning to the starting point at the end of the application. To ensure that the entire edge of the ulcer to receive the stimulation, the end points of the application, the application will be made for another minute sliding the pen around the whole edge. Thus the application time will be directly proportional to the ulcer area. The subjects will be received 10 applications, three times a week for a period of 4 weeks.
1711916|NCT01372007|Drug|Lanreotide Autogel 120mg|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, study medication (0.246mg lanreotide base/mg solution) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
1711917|NCT01372007|Drug|Placebo|Drain fluid will be checked for hematocrit daily post-surgery. Once hematocrit levels of the drain fluid are <10%, placebo (Sodiumchloride 0,9% 1 ampoule) will be administered. After administration the volume of the drain fluid will be measured every 12 hours for at least 5 days. A sample of the drain fluid will be collected every 24 hours for at least 5 days and frozen at -70°C for total protein content, sodium and chloride analysis afterwards.
1711918|NCT01371994|Drug|solifenacin succinate|oral
1711919|NCT01371994|Drug|Placebo|oral
1711932|NCT01371877|Drug|Vitamin D3|Vitamin D 4000 IU per day for 3 months
1711933|NCT01371877|Drug|Vitamin D3|Vitamin D 600 IU per day
1711934|NCT01371851|Drug|Doxazosin extended release|initially maintained on doxazosin extended release 4 mg once a day for 7 days, then the dose is increased to 8 mg once per day for the duration of the trial.
1711935|NCT01371838|Drug|Ceftaroline|Two consecutive infusions q12h for 5 to 7 days
1711936|NCT01371838|Drug|Ceftriaxone|One dose infusion followed by IV saline placebo infused q24h for 5 to 7 days plus two consecutive saline placebo infusion q24h.
1711937|NCT01371825|Drug|Sebelipase alfa (SBC-102)|Sebelipase alfa is a recombinant human lysosomal acid lipase (rhLAL). The investigational medicinal product is an enzyme replacement therapy intended for treatment of patients with LAL Deficiency. Dosing will occur once weekly for up to three years.
1711938|NCT01371812|Drug|GSK2239633|Drug will be orally administered at the doses and time points detailed in the 'arms' section.
1711939|NCT01371812|Drug|Placebo|Placebo will be orally administered to 4 subjects in each treatment period of each cohort.
1711940|NCT01371799|Drug|Drug|Placebo
1711941|NCT01371799|Drug|Drug|4mg and 8mg Study drug
1711942|NCT01371786|Drug|ciclesonide nasal aerosol|A radiolabeled solution of ciclesonide nasal aerosol supplied in a 37 μg/actuation canister
1711943|NCT01371786|Drug|mometasone Aqueous (AQ) nasal spray|A radiolabeled suspension of mometasone Aqueous (AQ) nasal spray supplied in a 50 μg/actuation bottle
1711944|NCT01371773|Procedure|repositioning method for left-sided double lumen tubes|When a left-sided double lumen tube were placed in right mainstem bronchus, after withdrawing the tube into mid-trachea, it was re-advanced with patient's head turned right and counterclockwise rotation of the tube.
1711945|NCT01371760|Procedure|Venous PTA|PTA of the internal jugular and/or azygous vein
1711946|NCT01371760|Other|Catheter Venography|The patients will undergo catheter venography but not PTA
1711947|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 8.4 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
1711948|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
1711949|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 16.8 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
1711950|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response (Stratum 1)
1711951|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 25.2 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
1711952|NCT01371747|Drug|patiromer|Cohorts 1, 2 and 3 - Patiromer starting dose: 33.6 g/day, orally, as a divided dose, twice daily. The dose of patiromer could be titrated based on participant's serum potassium response. (Stratum 2)
1711953|NCT01371747|Drug|losartan|losartan dose: 100 mg/d, oral, once daily (initiated during Run-In Period; Cohort 1)
1711954|NCT01371747|Drug|spironolactone|Spironolactone dose: 25 mg/d or up to 50 mg/d, oral, once daily (initiated during Run-In Period; Cohort 2)
1711955|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 25, 35, or 50 mg/day based on subject weight at the Baseline visit.
1711956|NCT01371734|Drug|Desvenlafaxine Succinate Sustained-Release|Subjects randomized to DVS SR treatment arm will receive 20, 25, or 35 mg/day based on subject weight at the Baseline visit.
1711957|NCT01371734|Drug|Placebo|Subjects randomized to the Placebo treatment arm will receive placebo tablets
1711958|NCT01371721|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35 or 50 mg/day as prescribed by the investigator.
1711959|NCT01371708|Drug|DVS SR|Subjects will receive a flexible-dose of 20, 25, 35, or 50 mg/day as prescribed by the investigator
1711960|NCT01371682|Drug|Ropinirole XL|Ropinirole XL manufactured at Crawley will be compared to that manufactued at Aranda.
1711961|NCT01371656|Drug|levofloxacin|Given PO or IV
1711962|NCT01371643|Drug|Octreotide LAR|
1711963|NCT01371643|Procedure|transsphenoidal surgery|
1711964|NCT01371630|Drug|Inotuzumab Ozogamycin|"Phase I: 1.3 mg/m2 by vein over 1 hour (+/- 15 min) on Day 3 of the first cycle, then 0.8 mg/m2 by vein for Cycles 3, 5, 7 for a total of 4 doses.
Phase II: 0.6mg/m2 per cycle and given as divided doses in cycles 2 and 4 with 0.3mg/m2 given on days 2 and 8 as determined in Phase I.
Cycle is 28 days."
1711965|NCT01371630|Drug|Rituximab|375 mg/m2 by vein on Day 2 and Day 8 of Cycles 1 - 4 per discretion of physician. The first dose of rituximab will be given as a slow infusion over 6-8 hours.
1711966|NCT01371630|Drug|Cyclophosphamide|150 mg/m2 by vein over 3 hours twice a day Days 1 - 3 for Cycles 1, 3, 5, 7.
1711967|NCT01371630|Drug|Mesna|300 mg/m2 by vein continuous infusion daily for approximately 24 hrs, starting approximately 1 hour prior to cyclophosphamide and completing by approximately 12 hrs after the last dose of cyclophosphamide for Cycles 1, 3, 5, 7.
1711968|NCT01371630|Drug|Vincristine|"2 mg by vein on Day 1 and Day 8 of Cycles 1, 3, 5, 7.
Maintenance: Vincristine 2 mg by vein monthly for 1 year"
1711969|NCT01371630|Drug|Dexamethasone|20 mg by vein or by mouth on Days 1-4 and 11-14 of Cycles 1, 3, 5, 7.
1711970|NCT01371630|Drug|Pegfilgrastim|6 mg subcutaneously on Day 4 of Cycles 1 - 8.
1711971|NCT01371630|Drug|Methotrexate|"Intrathecal methotrexate 12 mg (6 mg via ommaya) on Day 2 (+ 2 days) - cycles 1, 2, 3, and 4.
Methotrexate 50 mg/m2 by vein followed by 200 mg/m2 continuous infusion over approximately 22 hours on Day 1 for cycles 2, 4, 6, and 8.
Maintenance: Methotrexate 10 mg/m2 by mouth weekly for 3 years."
1711972|NCT01371630|Drug|Ara-C|"Intrathecal ara-C 100 mg on Day 8 of cycles 1, 3, 5, 7.
Ara-C 0.5 g/m2 by vein twice a day for 4 doses - Days 2 and 3 of cycles 2, 4, 6, and 8."
1711973|NCT01371630|Drug|6-Mercaptopurine|6-Mercaptopurine 50 mg by mouth twice a day twice a day.
1711974|NCT01371630|Drug|Prednisone|Maintenance: Prednisone 50 mg by mouth daily for 5 days every month for 1 year.
1711975|NCT01371630|Drug|Citrovorum|Citrovorum rescue 50 mg by vein or mouth followed by 15 mg by vein or mouth every 6 hours for 8 doses beginning 12 hrs post MTX completion on Days 2-5 of Cycles 2, 4, 6, and 8.
1711976|NCT01371630|Drug|Blinatumomab|In the first induction cycle, initial dose of Blinatumomab is 9 μg/day for the first 4 days of treatment which then will be escalated (dose step) to 28 μg/day starting on day 5 through day 29 (week 4). For all subsequent cycles, 28 μg/day is the dose for all 4 weeks of continuous treatment.
1711977|NCT01371617|Drug|IPI-926|Single Arm study of oral IPI-926 at 160 mg, 130 mg or 110 mg daily, until progressive disease or intolerability to study treatments or withdrawal of ICF
1711978|NCT01371604|Drug|IDX184|IDX184 50 mg tablet administered orally
1711979|NCT01371604|Biological|Peginterferon alfa-2a (Peg-IFN)|Peginterferon alfa-2 180 microgram prefilled syringe administered subcutaneously once weekly
1711980|NCT01371604|Drug|Ribavirin (RBV)|Ribavirin 200 mg tablets administered orally as a divided dose twice daily. Total daily dose to administered will be 1000 or 1200 mg based on body weight.
1711981|NCT01371604|Drug|Placebo|Matching placebo to IDX184 50 mg tablet administered orally
1711982|NCT01371591|Device|Pill Cam, clinical evaluation|The Pill Cam, VCE, will be used for clinical decisions. VCE will be read by site PI or co-PI and by site GI doctor.
1711983|NCT01371591|Device|Pill Cam, archived|VCE will not be used for clinical decisions. VCE video will be archived and read at a later date.
1711984|NCT01371578|Drug|GS-5885 tablet|30 mg active tablet
1711985|NCT01371578|Drug|GS-9451 tablet|two active 100 mg tablets
1711986|NCT01371578|Biological|peginterferon alfa-2a|peginterferon alfa-2a (solution for injection) 180 µg/week
1711987|NCT01371578|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
1711988|NCT01371565|Drug|Mifepristone|mifepristone at doses from 300mg/day up to 1200mg/day
1711989|NCT01371552|Device|delefilcon A contact lens|Investigational, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1 and one week in Part 2.
1711990|NCT01371552|Device|filcon II 3 contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
1711991|NCT01371552|Device|narafilcon A contact lenses|Commercially marketed, silicone hydrogel, single vision contact lens worn on a daily disposable basis for 3 days in Part 1.
1711992|NCT01371539|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use.
1711993|NCT01371539|Device|Comfilcon A contact lens|Commercially marketed (France), silicone hydrogel, multifocal contact lens for daily wear use.
1711994|NCT01371526|Drug|depot tetracosactide|1mg, 3x weekly by sc injection
1711995|NCT01371513|Other|continuous screening|practice patterns for screening prostate cancer
1711996|NCT01371487|Drug|GSK1120212|Oral/once-daily single doses on Day 1 of Periods 1 and 2
1711997|NCT01371474|Drug|Paroxetine|
1711998|NCT01371461|Drug|Paroxetine|
1711999|NCT01371448|Drug|Paroxetine|
1712000|NCT01371435|Drug|Paroxetine|
1712001|NCT01371422|Other|Paravertebral Block (PVB)|"The T10, T11 and T12 paravertebral spaces on the operative side will be identified with ultrasound in all patients (Sonosite MicroMax, 2-5 MHz curvilinear probe).
In the PVB group, a 90mm 22g Tuohy needle will be inserted in-plane with the live ultrasound image over the transverse process at each of these levels and 5 mL of 0.5% ropivacaine will be injected at each level."
1712002|NCT01371422|Other|Saline|Ultrasonography and local infiltration of saline will only be performed
1712003|NCT01371409|Other|continuous theta burst stimulation|80% active motor threshold, 600 pulses
1712004|NCT01371396|Other|Low-fat diet|The subject will consume a diet that is calorically restricted to cause at least a 6% body weight loss over 4 months. Fat will make up less than 30% of dietary energy.
1712005|NCT01371396|Other|Low-carbohydrate diet|The diet will be restricted in energy to cause at least a 6% loss of body weight over a 4 month period. Carbohydrate will provide less than 40% of total dietary energy.
1712006|NCT01371383|Dietary Supplement|Omega-3 fatty acids|1.6~2.8 gram/day (5 capsules)
1712007|NCT01371383|Dietary Supplement|placebo|5 gram/day (5 capsules)
1712008|NCT01371370|Other|Resistance exercise training|The low intensity resistance exercise training intervention consists of lower-body resistance exercise (machines) 3 times per wk for 12 wk. Two sets the first 2 wk and 3 sets the rest of the intervention, at 40% of the estimated 1 repetition maximum, for 17 to 23 repetitions, with 1 minute of rest in between sets.
1712009|NCT01371370|Other|Hypocaloric diet|The hypocaloric diet intervention consists of 12 wk of the standard Nutrisystem foods plan complemented by fresh produce and dairy. Subjects consume breakfast, lunch, dinner, and one (women) or two (men) snacks per day.
1712010|NCT01371370|Other|Resistance exercise training & diet|Combination of low intensity resistance exercise training and hypocaloric diet
1712011|NCT01371357|Drug|TEST 1|2.4 g/day of guanidinoacetic acid
1712012|NCT01371357|Drug|TEST 2|2.4 g/day of guanidinoacetic acid + 3.0 g/day of choline dihydrogencitrate + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
1712013|NCT01371357|Drug|TEST 3|2.4 g/day of guanidinoacetic acid + 1.6 g/day of betaine HCl + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
1712014|NCT01371357|Drug|TEST 4|2.4 g/day of guanidinoacetic acid + 5 µg/day of B12 + 10 mg/day of B6 + 600 µg/day of folic acid
1712017|NCT01371331|Drug|Tacrolimus granules|oral
1712057|NCT01370967|Other|Human milk feeding|Infants who are exclusively fed human milk at time of enrollment
1712058|NCT01370967|Other|Mixed feeding|Infants who are exclusively fed human milk and the new study formula at time of enrollment
1712100|NCT01370707|Drug|CJ-30001/CJ-30002|0.6/1500mg~0.9/1500mg/day, 24weeks
1712101|NCT01370694|Drug|MK-8808|
1712102|NCT01370694|Drug|cyclophosphamide|
1712018|NCT01371318|Other|Online Wound Electronic Medical Record|Online Wound Electronic Medical Record is a medical informatics tool that synthesizes data about complex wound problems from multiple sources and is innovative in its capability to performing these critical tasks: i) identification of the information needed to make treatment decisions at the point of care in real time ii) use intelligent search and report features to identify patients who require emergency interventions, and iii) provide evidence-based clinical decision support to clinicians
1712019|NCT01371305|Drug|BG00011|BG00011 will be administered at varying doses via subcutaneous (SC) injection
1712020|NCT01371305|Drug|Placebo|Sterile normal saline (0.9% Sodium Chloride for Injection) via Subcutaneous (SC) injections.
1712021|NCT01371292|Behavioral|Transformational Teaching|Physical education teachers randomly assigned to the experimental condition will (through a 1-day workshop format) be provided with the resources to implement transformational approaches in their day-to-day work. In addition, these teachers will be involved in a follow-up support program following the workshop to help them to implement transformational teaching strategies that were developed in the workshop.
1712022|NCT01371292|Behavioral|Standard Educational Practices|Physical education teachers randomly assigned to the control condition will take part in a professional development day workshop provided by their respective School Board. This will involve the same amount of contact time, and will take place on the same day as the transformational teaching workshop. It should be noted that the focus of those alternative workshops is unrelated to transformational leadership training.
1712024|NCT01371266|Dietary Supplement|Honey|60.7 grams orally daily times 14 days
1712025|NCT01371266|Dietary Supplement|High Fructose Corn Syrup 55 (HFCS 55)|65.7 gram daily orally times 14 days
1712026|NCT01371266|Dietary Supplement|CHO (sugar)|50 grams daily orally times 14 days
1712027|NCT01371253|Other|Nintendo wii balance training|
1712028|NCT01371253|Other|EVA-soles|
1712029|NCT01371240|Drug|Secretin Synthetic Human (RG1068)|A maximum dose of 100 consumer unit (CU) of RG1068, synthetic human secretin (Repligen Corporation) or one CU per kg body wt for patients that weight less than 100 kg will be injected (0.2µg of RG1068 are equal to 1CU) (RepliGen Co., Waltham, MA, USA). This dose will be given as an intravenous bolus at 3 minutes before injecting the contrast.
1712030|NCT01371227|Drug|JNS002|30 mg/m2 by intravenous infusion at a rate of = 1 mg/minute on Day 4 of each 21-day cycle.
1712031|NCT01371214|Behavioral|PLIÉ (Preventing Loss of Independence through Exercise)|Integrative exercise program that incorporates elements of Eastern and Western exercise traditions to target the muscles and movements needed to help individuals with mild to moderate dementia maintain functional status and independence.
1712032|NCT01371201|Drug|Sunitinib|sunitinib 37.5 mg per day
1712033|NCT01371201|Drug|Placebo|Placebo 37.5 mg per day
1712034|NCT01371175|Biological|DNA.HIVA|0.5mg DNA.HIVA or placebo
1712035|NCT01371175|Biological|MVA.HIVA|5x10^6 pfu MVA or placebo
1712036|NCT01371175|Biological|MVA.HIVA|5x10^7 pfu MVA or placebo
1712037|NCT01371175|Biological|MVA.HIVA|2.5x10^8 pfu MVA or placebo
1712038|NCT01371162|Drug|RO5428029|Multiple ascending doses
1712039|NCT01371162|Drug|placebo|multiple doses
1712040|NCT01371149|Other|Surface parasternal electromyography (EMG) set up|Ventilation parameters will be manipulated and titrated according to physiological measurements including signal from parasternal EMG and patient- ventilator asynchrony.
1712041|NCT01371136|Procedure|curricular training|"Residents in the curricular training group will participate in the entire ex-vivo training curriculum. They will train to proficiency on a virtual reality simulator. This training program has 8 tasks at an easy, medium and hard level. They will also participate in a cognitive training component. This consists of self-directed reading, and a video training component. In the video training component, residents will watch videos of laparoscopic right and sigmoid colectomies with a staff facilitator. Finally, all residents in the intervention group will participate in a cadaver lab where they will perform a laparoscopic right or sigmoid colectomy on a cadaver."
1712044|NCT01371097|Other|Progressive Resistance strength training|Resistance strength training is given as circle training. The resistance is increased with regularly intervals.
1712045|NCT01371084|Behavioral|Pedal@Work Worksite Wellness|Participants randomized to the intervention group will be provided access to a portable pedal exercise machine, a pedometer and a worksite wellness motivational website for 12 weeks. As part of this website, participants will be emailed behavioral intervention materials a maximum of three times per week targeted at reducing sedentary time.
1712046|NCT01371084|Behavioral|Pedal@Work|Worksite wellness program.
1712047|NCT01371058|Drug|high maintenance clopidogrel|clopidogrel 150 mg/d for 30 days followed by 75 mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
1712048|NCT01371058|Drug|routine dual antiplatelet|clopidogel 75mg/d for at least 1 year； aspirin 300mg/d for 1 month followed by 100mg/d chronically；
1712049|NCT01371058|Drug|policosanol plus dual antiplatelet|aspirin 300 mg/d for 1 month followed by 100 mg/d chronically； clopidogrel 75 mg/d for at least 1 year policosanol 40mg/d for 6 months
1712050|NCT01371045|Other|Oral Glucose Tolerance Test (OGTT)|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
1712051|NCT01371032|Device|VideoMiller|Video-Miller laryngoscope, using the screen (Video laryngoscopy group)
1712052|NCT01371032|Device|Direct Laryngoscopy|Video-Miller laryngoscope, without screen (Direct laryngoscopy group)
1712053|NCT01371006|Drug|low dose|efavirenz single dosing once daily
1712054|NCT01371006|Drug|normal dose|efavirenz once daily
1712055|NCT01371006|Drug|low dose|Efavirenz single dosing once daily
1712056|NCT01370967|Other|Study formula feeding|Infants who are exclusively fed the new study formula at time of enrollment
1712099|NCT01370707|Drug|Metformin|1000~1500mg/day, 24weeks
1712059|NCT01370954|Other|CerefolinNAC®|CerefolinNAC® is an orally-administered medical food, and each caplet contains 2 mg Methylcobalamin, 600 mg N-acetylcysteine, and 6 mg of L-methylfolate Calcium (as Metafolin®), which is the primary biologically active and immediately bioavailable form of folate. Dosage will be 1 caplet QD.
1712062|NCT01370928|Device|Olympus PCF-Y0014-L|Screening colonoscopy with a prototype colonoscope
1712063|NCT01370928|Device|Standard colonoscope|Screening colonoscopy
1712064|NCT01370915|Drug|Pregabalin (Lyrica)|Patients receive oral Pregabalin 150 mg 1 hour before septal surgery, and 12 hours later
1712065|NCT01370915|Drug|Vitamin complex (placebo)|Patients receive oral Placebo(Vitamin complex) 150 mg 1 hour before septal surgery, and 12 hours later
1712066|NCT01370902|Drug|NNC 0141-0000-0100|Single dose administered subcutaneously (under the skin), up to six dose levels. Progression to next dose will be based on safety evaluation. Initiation of the MD s.c. phase will depend on the results from the SD i.v. cohorts as well as the first two dose cohorts of the SD s.c. part
1712067|NCT01370902|Drug|placebo|Single dose administered subcutaneously (under the skin) as a comparator at all dose levels
1712068|NCT01370902|Drug|NNC 0141-0000-0100|Multiple doses administered subcutaneously (under the skin) at 4 different occasions with a dosing interval of two weeks, at five different dose levels.
1712069|NCT01370902|Drug|placebo|Multiple doses administered subcutaneously (under the skin) as a comparator at all dose levels
1712070|NCT01370902|Drug|NNC 0141-0000-0100|Single dose administered intravenously (into a vein), up to nine dose levels. Progression to next dose will be based on safety evaluation. Initiation of the SD s.c. phase will depend on the results from the first three dose cohorts of the SD i.v. part
1712071|NCT01370902|Drug|placebo|Single dose administered intravenously (into a vein), as a comparator at all dose levels
1712072|NCT01370889|Drug|resveratrol|Given PO
1712073|NCT01370889|Other|laboratory biomarker analysis|Correlative studies
1712074|NCT01370876|Drug|Oxaliplatin|Oxaliplatin will be administered as a 2-hour infusion first on Day 1, followed by 5-FU i.v. infusion for 48 hours (Day 1 and Day 2), repeated every 2 weeks, 4 weeks as a cycle.
1712075|NCT01370863|Drug|SPD557|0.5 mg tablet t.i.d. for 4 weeks on top of stable PPI treatment
1712076|NCT01370863|Drug|placebo|matching placebo tablet t.i.d. for 4 weeks on top of stable PPI treatment
1712077|NCT01370837|Other|Intracutaneous injection of Candida albicans antigen.|Intracutaneous injection of 0.05 ml of four different concentrations of Candida albicans antigen on both the arm and foot.
1712078|NCT01370837|Other|Temperature measurement.|Temperature measurement at the site of injection of the highest concentration of Candida albicans antigen on the foot and the same location on the contralateral foot using an infrared thermometer.
1712079|NCT01370824|Procedure|Punch biopsy|Punch biopsy is a 10 minutes treatment at the outpatient department of dermatology. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia (lidocaine 1% with epinephrine) will be given, which is briefly painful. Then a PB of 3 mm is taken from the most suspected area. In the case of continuing bleeding the wound will be sutured. A properly taken biopsy will leave no or minimal scarring, but this is not relevant since a SE will be performed afterwards. In very rare cases post-biopsy bleeding or infection occurs.
1712080|NCT01370824|Procedure|Surgical excision|"Surgical excision takes place in 30 minutes. Patient will lie down on a bed, the skin will be disinfected and local anaesthesia will be given. sBCC and nBCC will be excised with a 3 mm margin, aBCC with a 5 mm margin. Most BCC can be surgically excised, but some have to be treated with Mohs micrographic surgery (MMS). MMS ensures total BCC removal, preserving as much surrounding skin with 100% margin control. All BCCs will be excised with a 2 mm margin and examined under the microscope. This will totally take 1.5-2.0 hours. If tumour is still present, another tissue layer with 2 mm margin will be excised. It usually takes removal of 1-3 tissue layers to complete MMS.
After both treatments, wounds will be sutured and removed after 1-2 weeks, depending on the localisation. Within the first two weeks posttreatment, patients have to avoid physical heavy movements and keep the suture dry. Possible complications: scarring, continuous or subsequent bleeding, infection and dehiscent wounds."
1991177|NCT01400139|Drug|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
1712090|NCT01370772|Drug|Rituximab|"Cycle 1 Rituximab : 375 mg/m² i.v on day 1
Cycle 2-6 Rituximab:500 mg/m² i.v on day 1, repeated every 28 days"
1712091|NCT01370772|Drug|Rituximab|"Prephase: Rituximab:500 mg on day 0, 2000 mg on days 1, 8, and D15
Cycle 1-6 cycle 1 beginning at D22: Rituximab: 500 mg/m2 i.v on day 1, repeated every 28 days"
1712092|NCT01370772|Drug|Cyclophosphamide|•FCR Cycle 1-6: Cyclophosphamide : 250 mg/m² per os, days 2-4, repeated every 28 days
1712093|NCT01370772|Drug|Fludarabine|FCR Cycle 1-6: Fludarabine :40 mg/m² per os, days 2-4, repeated every 28 days
1712094|NCT01370759|Other|Cleaning capsule|Capsules containing the tested materials aimed to improve colon cleansing
1712095|NCT01370733|Device|NEST-1 (NeoSync EEG Synchronized TMS)|The NeoSync EEG Synchronized TMS (NEST) is an electromechanical medical device that produces and delivers a sinusoidal magnetic field to areas of the brain in the treatment of Major Depressive Disorder.
1712096|NCT01370733|Device|SHAM|The sham device is configured to simulate the actual NEST-1 device without sTMS therapy being actively delivered.
1712097|NCT01370720|Dietary Supplement|Recoclix|tablets; 200 mg PEA+20 mg polydatin; 2 tablets/day; 12 weeks
1712098|NCT01370720|Other|Placebo|tablets, 2tablets/day, 12 weeks
1712105|NCT01370681|Drug|Period I : HKB0701 and SLM0807, Period II : CJ30001|
1712106|NCT01370681|Drug|Period I : CJ30001, Period II : HKB0701 and SLM0807|
1712107|NCT01370668|Behavioral|Functional remediation|"The functional remediation program is composed of 21 weekly sessions of 90 minutes, each aimed at improving the following cognitive domains: attention, memory and executive functions and psychosocial functioning.
The program will be performed in an 12- to 15-patient group conducted by 2 experienced neuropsychologists with previous experience with bipolar patients and specific training on patients' group management."
1712108|NCT01370668|Behavioral|Psychoeducation|Group psychoeducation is a tested and manualized intervention consisting of 21 weekly sessions of 90 minutes aimed at improving 4 main issues: illness awareness, treatment adherence, early detection of prodromal symptoms and recurrences, and lifestyle regularity.
1712109|NCT01370668|Behavioral|Treatment as usual|The patients will not receive any add-on psychosocial intervention. All patients will keep on receiving standard psychiatric treatment.
1712110|NCT01370655|Drug|MK-7145|
1712111|NCT01370655|Drug|Hydrochlorothiazide (HCTZ)|
1712112|NCT01370655|Drug|Placebo to MK-7145|
1712113|NCT01370655|Drug|Placebo to HCTZ|
1712114|NCT01370642|Drug|vaniprevir|Capsules containing 150 mg vaniprevir, orally, two in the morning and two in the evening for 12 or 24 weeks
1712115|NCT01370642|Drug|Placebo to vaniprevir|Placebo to vaniprevir, capsules, orally, twice daily for 12 weeks or 24 weeks
1712116|NCT01370642|Biological|Peg-IFN|Peg-IFN 1.5 μg/kg once per week, subcutaneously (SC) for 24 or 48 weeks
1712117|NCT01370642|Drug|ribavirin|Capsules containing 200 mg RBV orally, 3 to 5 capsules, dosage based on the participant's weight (600 mg/day to 1000 mg/day), for 24 or 48 weeks
1712118|NCT01370629|Drug|Vernakalant|Prescribed at the discretion of the physician in accordance with their usual practice
1712119|NCT01370616|Drug|Ertapenem sodium|Ertapenem sodium, 1.0 g IV daily over 30 minutes at Hour 0 for 5 to 28 days
1712120|NCT01370616|Drug|Piperacillin/tazobactam sodium|Piperacillin/tazobactam sodium, 4.5 g, IV every 8 hours, given over 30 minutes at Hours 0, 8, and 16 for 5 to 28 days
1712121|NCT01370616|Drug|Piperacillin/tazobactam-matching placebo|Placebo, IV over 30 minutes, 2 times per day at Hours 8 and 16 for 5 to 28 days
1712122|NCT01370616|Drug|Amoxicillin/clavulunate potassium|If clinically indicated, participants may be switched to Amoxicillin/clavulunate potassium 625 mg administered orally, twice daily, from Day 6 to Day 28
1712123|NCT01370603|Drug|Atorvastatin|40 mg tablet administered orally once daily
1712124|NCT01370603|Drug|Ezetimibe|10 mg tablet administered orally once daily
1712125|NCT01370603|Drug|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/40 mg combination tablet administered orally once daily
1712126|NCT01370603|Drug|Placebo to atorvastatin|Administered orally once daily
1712127|NCT01370603|Drug|Placebo to ezetimibe|Administered orally once daily
1712128|NCT01370603|Drug|Placebo to ezetimibe/atorvastatin|Administered orally once daily
1712129|NCT01370590|Drug|Atorvastatin|20 mg tablet administered orally once daily
1712130|NCT01370590|Drug|Ezetimibe|10 mg tablet administered orally once daily
1712131|NCT01370590|Drug|Ezetimibe/atorvastatin|Ezetimibe/atorvastatin 10 mg/20 mg combination tablet administered orally once daily
1712132|NCT01370590|Drug|Placebo to atorvastatin|Administered orally once daily
1712133|NCT01370590|Drug|Placebo to ezetimibe|Administered orally once daily
1712134|NCT01370590|Drug|Placebo to ezetimibe/atorvastatin|Administered orally once daily
1712135|NCT01370564|Drug|Diuretics|Daily adjustments of diuretics and associated supplements based on cardiac filling pressures.
1712136|NCT01370551|Drug|Gynoflor|Vaginal tablet with lyophilised lactobacilli and 0.03 mg estriol; Once daily for 28 days then 3 times per week for 8 weeks;
1712137|NCT01370538|Drug|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
1712138|NCT01370525|Drug|Esomeprazole|Nexium 20 mg administered as 22.3 mg of esomeprasole magnesium hydrate, capsule, oral dose
1712139|NCT01370512|Drug|Droxidopa|100 mg t.i.d. for 2 days; then 200 mg t.i.d. for another 2 days
1712140|NCT01370512|Drug|Pyridostigmine Bromide|180 mg daily for 4 days
1712141|NCT01370499|Drug|LY2216684|Administered orally
1712142|NCT01370486|Drug|melatonin|melatonin cp 2 mg 1x/d for 1 month
1712143|NCT01370486|Drug|placebo|placebo cp 1x/d for 1 month
1712144|NCT01370460|Drug|Tranexamic Acid|Topical tranexamic acid (2g/100mL 0.9% saline)
1712145|NCT01370460|Drug|Placebo|100mL 0.9% sterile saline
1712146|NCT01370447|Drug|EPI-743|EPI-743 is administered as a dose escalation from 50 mg bid to 100 mg tid
1712147|NCT01370434|Drug|PAD combination|"Bortezomib 1.3 mg/m2/d iv on D 1, 4, 8, 11
Doxorubicin 9 mg/m2/d iv on D 1-4
Dexamethasone 40mg/d po or iv on D1-4, 8-11"
1712148|NCT01370408|Drug|Palonosetron|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV Day 1-2 after IV chemotherapy - Dexamethasone 8 mg PO
1712149|NCT01370408|Drug|ondansetron|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
1712150|NCT01370408|Drug|Dexamethasone|Prior to IV chemotherapy - ondansetron 8mg IV & Dexamethasone 10 mg IV On the last day of chemotherapy - Palonosetron .25 mg IV, dexamethasone 10mg IV
1712151|NCT01370369|Drug|Testosterone gel (FE 99903)|
1712152|NCT01370356|Drug|Varenicline Tartrate|Varenicline Tartrate oral tablets 2 (0.5mg) tablets twice a day for 24 weeks (first week titration)
1712153|NCT01370356|Drug|Placebo|Matching placebo 2 oral tablets twice a day for 24 weeks (first week titration)
1712154|NCT01370343|Drug|PF-04991532 alone|a single dose of 150 mg PF-04991532, fasted
1712155|NCT01370343|Drug|PF-04991532 + cyclosporine|a single dose of 150 mg PF-04991532 + a single dose of 600 mg cyclosporine, fasted
1712251|NCT01369628|Drug|Atacicept|"Regimen 1: Atacicept 25 mg weekly for 12 weeks
Regimen 2: Atacicept 75 mg weekly for 12 weeks
Regimen 3: Atacicept 150 mg weekly for 12 weeks"
1712252|NCT01369615|Drug|Oxycodone hydrochloride controlled-release tablets|Oxycodone hydrochloride controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg to 240 mg daily) every 12 hours.
1712156|NCT01370330|Drug|Metaiodobenzylguanidine (MIBG)|131I-MIBG Therapeutic Administration. Therapeutic 131I-MIBG will be synthesized at Nuclear Diagnostic Products (NDP; Rockaway, New Jersey) with specific activities of 9-18 Ci/mmole. The therapeutic dose (8-18 mCi/kg at investigator's discretion; any dose greater than 12 requires stored stem cells) will be diluted in 25 ml of normal saline, and will be infused intravenously through a patient's central line, if already present, or a peripheral IV if a central line is not present over 120 minutes.
1712157|NCT01370317|Drug|MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
1712158|NCT01370317|Drug|Placebo for MK-1029|Five (5) X 100 mg capsules, orally, once daily for 28 days
1712159|NCT01370304|Other|active rTMS and active Venlafaxine|"rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s.5 sessions per week for 4-6 weeks
Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
1712160|NCT01370304|Other|active rTMS and sham Venlafaxine|rTMS parameters : Intensity of 120% of individually determined motor threshold; frequency : 1 Hz; 360 impulsions; on period : 1 min; off period : 30 s. 5 sessions per week for 4-6 weeks
1712161|NCT01370304|Other|sham rTMS and active Venlafaxine|"rTMS parameters :same coil, same number of pulses but using an angled coil(90 degree)over the frontotemporal region
Venlafaxine: LP:75mg:1capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks"
1712162|NCT01370291|Other|active Risperidone and active rTMS|active Risperidone:------- active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC) negative symptoms:high-frequency（10Hz）applied over the left temporoparietal cortex(LTPC)
1712163|NCT01370291|Other|active rTMS and sham Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
1712164|NCT01370291|Other|sham rTMS and active Risperidone|active Risperidone:------- ; active rTMS:auditory hallucinations:low-frequency(1Hz)applied over the left temporoparietal cortex(LTPC); negative symptoms:high-frequency（10Hz）applied over the left temporoparietal; cortex(LTPC)
1712165|NCT01370278|Other|Normal Saline|Normal saline administered in stent/airway tubes under direct visualization via the bronchoscope.
1712166|NCT01370278|Other|Sodium Bicarbonate|4.2% bicarbonate solution mixed with equal volume of sterile water administered into stent/airway tubes under direct visualization via the bronchoscope.
1712167|NCT01370265|Drug|Regadenoson|Regadenoson (0.4 mg/5 ml IV) was administered intravenously over 10 seconds, followed immediately by saline flush.
1712168|NCT01370265|Drug|Adenosine|Adenosine (140 μg/kg/min) was administered intravenously over 6 minutes.
1712169|NCT01370265|Drug|N-13 ammonia|Ammonia N-13 Injection is a radioactive diagnostic agent for Positron Emission Tomography (PET) indicated for diagnostic PET imaging of the myocardium under rest or pharmacologic stress conditions to evaluate myocardial perfusion in patients with suspected or existing coronary artery disease. The N-13 ammonia used in the study was synthesized by the Mayo Cyclotron Facility as per routine institutional clinical protocol.
1712170|NCT01370239|Biological|Hu3S193|Patients will receive weekly intravenous doses of 20 mg/m2 of the antibody Hu3S193. The infusion will take 60 ± 10 minutes. The antibody should be diluted in 500 mL of normal saline.
1712171|NCT01370226|Behavioral|CBI|"The multimedia, interactive Computer Brief Intervention (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The 30-minute interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
1712172|NCT01370226|Behavioral|TBI|"Participants receive a 30-minute intervention session with a Master's-level clinician. The interventions are designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
1712173|NCT01370213|Drug|Preparative Regimen|"Preparative Regimen:
1) fludarabine 40 mg/m^2 x 4 doses on Days -22 through -19 pretransplant, 2) cyclophosphamide 50 mg/kg x 2 doses on Days -20 and -19 pretransplant, 3) total body irradiation 200 cGy twice a day (BID) (at least 6 hours apart) on Day -18 pretransplant,"
1712174|NCT01370213|Biological|NK Cells|CD3^- CD19^- selected, interleukin-2 (IL-2) activated, haploidentical donor natural killer (NK) cells infused on Day -17 pretransplant.
1712175|NCT01370213|Drug|Interleukin-2|Interleukin-2 6 million units (MU) subcutaneously (SQ) every other day for 6 doses beginning evening of NK cell infusion
1712176|NCT01370213|Biological|Anti-thymocyte globulin|rabbit anti-thymocyte globulin will be administered on day -5 (0.5 mg/kg) and day -4 (2.5 mg/kg) pretransplant per institutional guidelines
1712177|NCT01370213|Biological|Donor TCR α/β-depleted Cells|Single donor TCR α/β-depleted filgrastim-mobilized peripheral blood stem cells (PBSC) graft (minimum cell dose of 5 x 10^6/kg) on day 0
1712178|NCT01370200|Procedure|plasma exchange treatment|the therapeutic plasma exchange is the procedure of removing the plasma of the patient including pathological macromolecules and replacing it with the replacement fluid
1712179|NCT01370187|Drug|Montelukast|Montelukast 4mg daily for 2 months
1712180|NCT01370174|Other|Physical Training Interventions|Subjects will be assigned to one of four training groups. Training will occur three times weekly for twelve consecutive weeks. The IST group will receive waist-pulls by a motorized machine to produce stepping. Subjects in the HST group will perform muscle resistance exercises. Subjects in the combined IST and HST will receive both IST and HST interventions. Participants in the SFR group will perform flexibility and relaxation exercises.
1712253|NCT01369602|Drug|PF-04991532|single dose 300-mg
1712254|NCT01369602|Drug|PF-04991532|single dose 300-mg
1712255|NCT01369602|Drug|PF-04991532|single dose 300-mg
1712256|NCT01369602|Drug|PF-04991532|single dose 300-mg
1712257|NCT01369589|Drug|P-552|P-552 oral rinse ( 10 mL containing 5 mg P-552)
1712181|NCT01370161|Procedure|Transjugular intrahepatic portosystemic shunt|"A 8 mm Fluency stent will be used, that will be dilated to 8 or 10 mm according to the hemodynamic response. The aim will be to reduce the portal pressure gradient (PPG) below to 25-75% of baseline. Not paralleled TIPS or over-dilatation are allowed.
Embolisation, either with coils or bucrylate, can be performed, if it is felt necessary, especially in patients where portography shows the filling of big portosystemic collaterals feeding the varices, in association with a PPG below 16 mmHg
After TIPS, anticoagulation will not be used as a rule, but is allowed if the attending physician thinks that it is warranted"
1712182|NCT01370161|Drug|Non-selective beta blocker + Endoscopic treatment|"Patients will begin treatment with non-selective beta-blockers (either propranolol or nadolol). After an initial dose of 40 mg, the dose of propranolol/nadolol will be increased/decreased step by step to achieve a baseline heart rate of 55 bpm or up to the maximum tolerated dose, within the limit of 160 mg twice a day (bid) for propranolol or to a maximum of 160 mg for nadolol.
The first elective session of endoscopic band ligation should be performed within the first 7-14 days. The following sessions will be performed at 14 + 3 days intervals until variceal eradication (defined as disappearance of the varix, impossibility of suctioning the varix, or a maximum of six continued sessions). Once eradication is achieved, a control endoscopy will be performed one month later for confirmation. The following endoscopies will be scheduled at 6 and 12 months of inclusion and yearly thereafter. If varices reappear, new band ligation will follow."
1712183|NCT01370148|Drug|conivaptan hydrochloride|Intravenous
1712184|NCT01370135|Drug|0.5mg intraocular Ranibizumab (Lucentis)|short- and long-term effects of 0.5mg intraocular Ranibizumab (Lucentis) injections as adjuvant for patients with rubeosis and neovascular glaucoma
1712185|NCT01370122|Other|Survey|
1712186|NCT01370096|Drug|Vasopressin infusion|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure.
1712187|NCT01370096|Drug|Vasopressin infusion and epoprostenol inhalation|An intravenous infusion of vasopressin will be started at an initial rate of 0.0002U/Kg/min via the side arm of the central venous sheath. The infusion will be titrated up by 0.0001U/kg/min every minute until there has been a 20% increase in invasive mean arterial blood pressure (maximum infusion 0.002U/kg/min) and then the infusion may be titrated to maintain this blood pressure. If the target 20% increase in SBP is not achieved with vasopressin titration, the infusion will remain at 0.002U/kg/min. After a period of ten minutes of drug exposure to allow for patient equilibration, subjects will receive nebulized prostacyclin at a dose of 50ng/kg/min for 15 minutes via Aeroneb into the endotracheal tube.
1712188|NCT01370083|Behavioral|Tongue Pressure Profile Training|60 tongue-pressure tasks per session, emphasizing control of the slope of tongue pressure release, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with signals displayed on a computer.
1712189|NCT01370083|Behavioral|Tongue-Pressure Strength-and-Accuracy Training|60 tongue-pressure tasks per session, emphasizing maximum effort strength tasks and accuracy targets within 20-95% of each patient's maximum, informed by biofeedback. Pressures will be measured using a hand-held oral manometer (Iowa Oral Performance Instrument) with amplitude output in kiloPascals displayed on an LCD screen.
1712190|NCT01370070|Drug|MK-2206|200mg weekly repeated q 28 days
1712191|NCT01370057|Device|Thoraco-lumbo-sacral Orthosis|Treatment with Thoraco-lumbo-sacral Orthosis for Adolescent Idiopathic Scoliosis
1712192|NCT01370044|Drug|Carbogen|3 minutes administration of carbogen
1712193|NCT01370044|Drug|Placebo|3 minutes administration of oxygen
1712194|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™|Clenil® Modulite® 250 µg via AeroChamber Plus™ spacer during 14 days
1712195|NCT01370031|Drug|Clenil® Modulite® via Volumatic™ spacer|Clenil® Modulite® 250 µg via Volumatic™ spacer during 14 days
1712196|NCT01370031|Drug|Clenil® Modulite® via AeroChamber Plus™ plus charcoal block|Clenil® Modulite® via AeroChamber Plus™ spacer during 14 days (plus charcoal block at Day 14)
1712197|NCT01370031|Drug|Clenil® Modulite® administered via Volumatic™ spacer plus charcoal block|Clenil® Modulite® administered via Volumatic™ spacer during 14 days (plus charcoal block at day 14)
1712258|NCT01369589|Drug|Vehicle rinse|Water for Injection
1712259|NCT01369576|Drug|Placebo|3.75-7.5mg 14 doses 4 weeks
1712260|NCT01369576|Drug|Zopiclone|3.75-7.5mg 14 doses 4 weeks
1712261|NCT01369550|Other|SDA soybean oil-containing foods|3 servings per day of foods containing 500 mg each SDA soybean oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day.
1712645|NCT01366560|Drug|Active|GSK962040 125mg
1712202|NCT01370005|Drug|Placebo|Placebo matching BI 10773 low dose
1712203|NCT01370005|Drug|BI 10773|BI 10773 high dose once daily
1712204|NCT01370005|Drug|Placebo|Placebo matching BI 10773 low dose
1712205|NCT01370005|Drug|BI 10773|BI 10773 low dose once daily
1712206|NCT01370005|Drug|Placebo|Placebo matching BI 10773 high dose
1712207|NCT01370005|Drug|Placebo|Placebo matching BI 10773 high dose
1712208|NCT01369979|Procedure|Liver vein catheter|Liver vein catheter is placed in the heptic vein via the femoral vein, using fluoroscpoy as guidance.
1712209|NCT01369927|Biological|Shigella Sonnei O-SPC/rBRU|
1712212|NCT01369888|Drug|Cyclophosphamide|60 mg/m^2, intravenous (IV) (in the vein) x 2 days
1712213|NCT01369888|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
1712214|NCT01369888|Biological|Tumor Infiltrating Lymphocytes|IV over 30 minutes on day 0
1712215|NCT01369888|Drug|IL-15|IV over 30 minutes, daily for 10 days, starting 3-4 hours after the TIL infusion. (day 0 to day 9). Doses will be increased every 3-6 patients.
1712216|NCT01369875|Drug|Cyclophosphamide|60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
1712217|NCT01369875|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days (days -5 to -1)
1712218|NCT01369875|Biological|Aldesleukin|720,000 IU/kg intravenous (IV) over 15 min every 8 hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (max. 15 doses.)
1712219|NCT01369875|Biological|Tumor Infiltrating Lymphocytes|Intravenous (IV) over 30 minutes on day 0
1712220|NCT01369862|Biological|GHB16L2|A/Brisbane/59/07(H1N1)-like delNS1, A/Brisbane/10/07(H3N2)-like delNS1, B/Florida/04/06-like delNS1 virus reassortants
1712221|NCT01369862|Biological|Placebo|SPGNH buffer
1712222|NCT01369849|Drug|Akt Inhibitor MK2206|Given PO
1712223|NCT01369849|Drug|Bendamustine Hydrochloride|Given IV
1712224|NCT01369849|Other|Laboratory Biomarker Analysis|Correlative studies
1712225|NCT01369849|Biological|Rituximab|Given IV
1712226|NCT01369836|Drug|Tafamidis meglumin|A single oral dose of 20 mg capsule
1712227|NCT01369836|Drug|Tafamidis meglumin|A single oral dose of 40 mg capsule.
1712228|NCT01369836|Drug|Placebo|A single oral dose of matched placebo.
1712229|NCT01369797|Other|specific intervention|"Patients included in the specific intervention group will benefit from a personalized action plan presented in a multidisciplinary staff that will be established according to the detected frailties. In follow up visits, a new evaluation will be done and the action plan reviewed."
1712230|NCT01369771|Drug|Tafluprost 0.0015%|Eye Drops, Solution. Topical Use. One single-unit dose pipet of 0.3 ml solution including 0.0015 mg/ ml of Tafluprost once daily in the affected eye(s)for 12 months.
1712231|NCT01369758|Device|MyoSure Tissue Removal System|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade. When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
1712232|NCT01369745|Drug|Prednisolone|Prednisolone 2.7 mg daily
1712233|NCT01369745|Drug|dipyridamole|dipyridamole 360 mg daily
1712234|NCT01369745|Drug|Prednisone|Prednisone 5 mg daily
1712235|NCT01369745|Drug|Z102|Prednisolone 2.7 mg plus dipyridamole 360 mg daily
1712236|NCT01369745|Other|placebo|
1712237|NCT01369732|Drug|recombinant human erythropoietin|We administrate the erythropoietin single bolus (500 IU/kg intravenously) 30 min before the commencement of ischemia.
1712238|NCT01369732|Drug|saline|We administrate the saline single bolus (5ml intravenously) 30 min before the commencement of ischemia.
1712239|NCT01369719|Drug|osveral|receive 20 mg/kg daily orally
1712240|NCT01369719|Drug|Desferal|40-50mg/Kg for 6 nights in each week subcutaneously
1712241|NCT01369706|Device|Hand-held metal detector|2 different hand-held metal detectors: (1) PD 140 (CEIA S.p.A., Arezzo, Italy) and (2) MH 5 (Vallon GmbH, Eningen, Germany)
1712242|NCT01369693|Procedure|Buccal administration of nicotine|Oral pouch, oral sachet, 0.3-1g, single dose. One pouch administered between upper lip and gum over 30 minutes
1712243|NCT01369680|Drug|Ketamine|Drug will be given orally three times a day at doses escalating from 0.25mg/kg/dose to 1.5mg/kg/dose in cohorts of 3. Each subject will be administered study drug for 2 weeks.
1712244|NCT01369667|Dietary Supplement|Vitamin D3|
1712245|NCT01369667|Other|Placebo|
1712246|NCT01369654|Behavioral|Computerized decision aid with 1 type of value clarification|Women will be instructed to view a computerized BSO decision support guide.
1712262|NCT01369550|Other|High-oleic sunflower oil containing foods|3 servings per day of foods containing 500 mg high-oleic sunflower oil plus 3 x 500 mg high-oleic sunflower oil in softgels per day
1712263|NCT01369550|Other|Eicosapentaenoic acid|3 x 500 mg per day of Eicosapentaenoic acid as an ethyl ester in softgels plus 3 servings per day of high-oleic sunflower oil-containing foods
1712264|NCT01369511|Drug|LY2495655|Administered subcutaneously
1712265|NCT01369511|Drug|Placebo|Administered subcutaneously
1712266|NCT01369498|Drug|Simtuzumab|Simtuzumab 200 mg or 700 mg administered intravenously over approximately 30 minutes every 2 weeks
1712267|NCT01369498|Drug|Ruxolitinib|In stage 2, participants will be on a stable dose of ruxolitinib and will continue their treatment in combination with simtuzumab
1712268|NCT01369485|Device|(VERV™ System)|Active electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
1712269|NCT01369485|Device|Sham version of (VERV™ System)|Inactive (sham) electrode patches are worn for 12 weeks, one per week. The patch is placed by the subject. All subjects will have access to active patches for 9 months after the sham-controlled 12-week portion of the study is complete.
1712270|NCT01369472|Drug|Dilatrend SR capsule|single oral administration in period 1 or 2, 3 for each sequential group.
1712271|NCT01369459|Behavioral|MIP Protocol|We intend for MIP to be a 5-session, family-based protocol delivered during the early portion of ASU treatment. MIP will contain three elements deemed essential for integrating pharmacological interventions into outpatient behavioral treatment for youth: (1) standardized psychiatric assessment and family-focused psychoeducation about the target problem; (2) an approved medication regimen with demonstrated efficacy for comorbid populations; (3) family-based interventions for medication acceptance and coordination of psychiatric and behavioral services. MIP will incorporate research-proven interventions from each of these core areas.
1712272|NCT01369446|Device|Eeva System Study|The Eeva System will image embryos through cleavage and/or blastocyst stage.
1712273|NCT01369433|Drug|Tivozanib + paclitaxel|Subjects will continue to receive 0.5 mg, 1.0 mg, or 1.5 mg of tivozanib once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment. On days when paclitaxel and tivozanib (AV-951) are co-administered, tivozanib will be administered immediately following the end of the paclitaxel infusion. All subjects will continue to receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off.
1712274|NCT01369433|Drug|Tivozanib + temsirolimus|Subjects will receive 0.5 mg, 1.0 mg or 1.5 mg of tivozanib (AV-951) once daily for 3 weeks, followed by 1 week off. On days when tivozanib (AV-951) and temsirolimus are co-administered, tivozanib (AV-951) will be administered immediately following temsirolimus infusion. Subjects will receive 15 mg or 25 mg temsirolimus IV once weekly.
1712275|NCT01369433|Drug|Tivozanib|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
1712276|NCT01369433|Drug|Tivozanib (AV-951)|Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) capsules once daily for 3 weeks, followed by 1 week off.
1712277|NCT01369433|Drug|Tivozanib + capecitabine|Subjects will receive 1.5 mg of tivozanib once daily for 2 weeks beginning on Day 1, followed by 1 week off. Subjects will receive Capecitabine (Xeloda®) 825 mg/m2 or 1000 mg/m² or 1250 mg/m² oral twice daily. Subjects will receive capecitabine twice daily for 2 weeks beginning on Day 1, followed by 1 week off.
1712278|NCT01369433|Drug|Tivo|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment.
1712279|NCT01369420|Device|NanoKnife Low Energy Direct Current (LEDC) System Ablation|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
1712280|NCT01369407|Other|No Intervention|Not an interventional study
1712281|NCT01369394|Other|Behavioral: Computer-based tailoring system|"Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will generate educational messages based on participants' responses to survey questions. The intervention group will receive tailored educational messages, whereas the control group will receive generic educational messages. The tailored and generic educational messages will be presented as to look like web pages. However, the messages will only exist on the study computer, and will not be linked to any live server or website."
1712282|NCT01369381|Procedure|Endotracheal intubation|Study patients undergo endotracheal intubation using both a conventional direct laryngoscope (Macintosh) and an alternative indirect laryngoscope (Airtraq). The order of intubation (Macintosh then Airtraq--or--Airtraq then Macintosh) is randomized.
1712283|NCT01369368|Drug|Combined use of azacitidine, valproic acid, hydroxurea and eventually donor leukocyte infusions.|Azacitidine 100 mg day 1-3 in each cycle Valproic acid, continuous therapy from day 1 All-trans retinoic acid 22.5 mg/m2 twice daily day 1-14 in each cycle Hydroxurea 500 mg initially eventually increased to 1 g daily. Eventually donor leukocyte infusions on day 10 from the second cycle.
1712284|NCT01369355|Drug|Placebo SC|Placebo will be administered subcutaneously.
1712285|NCT01369355|Drug|Placebo IV|Placebo will be administered as a single Intravenous infusion at week 0.
1712286|NCT01369355|Drug|Ustekinumab 90 mg SC q8w|Ustekinumab 90 mg will be administered subcutaneously every 8 weeks (q8w) through Week 40.
1712287|NCT01369355|Drug|Ustekinumab 130 mg IV|Ustekinumab 130 mg will be administered as a single intravenous infusion at week 0.
1712288|NCT01369355|Drug|Ustekinumab 90 mg SC q12w|Ustekinumab 90 mg will be administered as subcutaneously every 12 weeks (q12w) through Week 40.
1712357|NCT01368887|Other|Vehicle / Placebo|The patient will apply the vehicle twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
1712295|NCT01369316|Procedure|Circumferential Submucosal Incision Resection|The patient is randomized, if in the active arm the procedure will continue as Circumferential Submucosal Incision Endoscopic Mucosal Resection.
1712296|NCT01369316|Procedure|Endoscopic Mucosal Resection|Patients randomised into this Intervention type will have Endoscopic Mucosal Resection performed
1712297|NCT01369303|Drug|Tenofovir 1% vaginal gel|Tenofovir 1% gel is supplied as a clear, transparent, viscous gel packaged in pre-filled single use applicators. Each applicator contains 4.0 mL of tenofovir gel (equal to 4.4 gm) at a concentration of 1% (weight for weight) formulated in purified water with edetate disodium, citric acid, glycerin, methylparaben, propylparaben and hydroxyethylcellulose, and is pH adjusted to 4-5.
1712298|NCT01369290|Drug|Venlafaxine|75 to 375 mg/day for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
1712299|NCT01369290|Drug|bupropion|150 to 300 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
1712300|NCT01369290|Drug|escitalopram|10 to 30 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
1712301|NCT01369290|Other|Psychotherapy|Once weekly CBT psychotherapy session for 12 weeks. If no response at 12 weeks, reassignment to one of the other treatment groups for a further 6 weeks in phase II.
1712302|NCT01369290|Drug|Duloxetine|30 to 60 mg daily for 6 weeks. If no response at 6 weeks, reassignment to one of the other treatment groups for a further 6 to 12 weeks in phase II.
1712303|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (100 mg, 300 mg and 750 mg) in tablet formulation under fasted condition.
1712304|NCT01369277|Drug|Placebo|Single dose administration of matching placebo in tablet formulation at the fasted state
1712305|NCT01369277|Drug|PF-04991532|Single dose administration of PF-04991532 (300 mg and 750 mg) in tablet formulation under fasted condition.
1712306|NCT01369264|Device|true left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor
1712307|NCT01369264|Device|Passive sham left high frequency|10 Hz stimulation will be given at 110% motor threshold for 8 seconds to Brodmann areas 46, 9 and 10 in the left hemisphere. The passive (inactive) coil will be held flat over the skull surface with the coil handle held at approximately 45 degrees to the floor. An active coil will be held vertically in a mechanical holder 50 cm behind the subject head and run at 10 Hz with an intensity set to 150% of motor threshold.
1712308|NCT01369251|Behavioral|Hygiene|
1712309|NCT01369251|Procedure|Usual alcohol care|
1712310|NCT01369238|Device|Bee Venom Acupuncture Therapy|1:4000, SC 1cc/day, 2~3days/wk, for 1 month
1712311|NCT01369238|Drug|zaltoprofen|80mg/Tab, per os 1Tab tid, for 2 months
1712312|NCT01369225|Drug|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
1712313|NCT01369225|Drug|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
1712314|NCT01369225|Drug|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
1712315|NCT01369225|Drug|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
1712316|NCT01369225|Drug|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
1712317|NCT01369212|Drug|Tenofovir|300 mg daily for 192 weeks (4 years)
1712318|NCT01369212|Drug|Peginterferon-alfa 2a and tenofovir|A combination of peginterferon-alfa 2a 180 µg weekly plus tenofovir 300 mg daily for 24 weeks and then only tenofovir 300 mg daily for 168 weeks (3.5 years).
1712319|NCT01369199|Drug|Entecavir and peginterferon|Entecavir 0.5 mg daily orally for 48 weeks plus peginterferon 180 µg sq weekly during weeks 9-48 of treatment.
1712320|NCT01369186|Drug|Morphine|i.v. bolus injection
1712321|NCT01369186|Drug|Placebo|i.v. bolus injection
1712322|NCT01369173|Other|Mexican or American foods|Participants will be randomized to an isocaloric Indigenous Mexican or a Western diet for 24 days. All foods and beverages will be prepared by the Human Nutrition Laboratory at the Fred Hutchinson Cancer Research Center. After a 4-week wash-out period, participants will cross over to the other arm and be given the alternate diet for 24 days. Blood and urine specimens will be collected before and after each feeding period to test baseline and post-intervention metabolic response as defined by various inflammatory and cancer susceptibility biomarkers including insulin-like growth factor 1 (IGF1), insulin-like growth factor binding protein 3 (IGFBP3), leptin, adiponectin, interleukin-6 (IL-6), C-reactive protein (CRP) and SAA (serum amyloid-A). DNA extracted from whole blood will be used to test whether a panel of 128 Ancestry Informative Markers (AIMs) is associated with metabolic response to the diets and other phenotypic traits of obesity, which relate to breast cancer risk.
1712323|NCT01369160|Behavioral|Quality of Life measures|measuring QOL with different therapies
1712324|NCT01369147|Drug|Parenteral nutrition energy dose at 0.6 x measured REE|Participants will be provided a total daily calorie (kcal) intake from parenteral nutrition (PN), dextrose-containing IV fluids (> 500 mL/day), propofol/clevidipine, and any enteral feedings at 0.6 x baseline metabolic energy expenditure (MEE). Total energy dosing based on real-time REE measurements will be adjusted during the ICU stay. The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL) or clevidipine (2 kcal/mL), and any dextrose-containing IV fluid orders exceeding 500 mL/day. Participants will receive a maximum of 28 days of the double blind study energy dose and will be transitioned from PN to enteral feeds as soon as tolerated and clinically indicated.
1712358|NCT01368887|Drug|Calcipotriol Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
1712359|NCT01368887|Drug|Nicotinamide Monotherapy|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
1712646|NCT01366560|Drug|Placebo|Matching Placebo
1712325|NCT01369147|Drug|Parenteral nutrition energy dose at 1.0 x measured REE|Participants will be provided a total daily calorie (kcal) intake from parenteral nutrition (PN), dextrose-containing IV fluids (> 500 mL/day), propofol/clevidipine, and any enteral feedings at 1.0 x baseline metabolic energy expenditure (MEE). Total energy dosing based on real-time REE measurements will be adjusted during the ICU stay. The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL) or clevidipine (2 kcal/mL), and any dextrose-containing IV fluid orders exceeding 500 mL/day. Participants will receive a maximum of 28 days of the double blind study energy dose and will be transitioned from PN to enteral feeds as soon as tolerated and clinically indicated.
1712326|NCT01369147|Drug|Parenteral nutrition energy dose at 1.3 X measured REE|Participants will be provided a total daily calorie (kcal) intake from parenteral nutrition (PN), dextrose-containing IV fluids (> 500 mL/day), propofol/clevidipine, and any enteral feedings at 1.3 x baseline metabolic energy expenditure (MEE). Total energy dosing based on real-time REE measurements will be adjusted during the ICU stay. The PN dose will be written for each 24-hr period taking into account calories provided as lipid emulsion in the sedative propofol (1.1 kcal/mL) or clevidipine (2 kcal/mL), and any dextrose-containing IV fluid orders exceeding 500 mL/day. Participants will receive a maximum of 28 days of the double blind study energy dose and will be transitioned from PN to enteral feeds as soon as tolerated and clinically indicated.
1712327|NCT01369134|Device|Adper Easy Bond Self-etch dental adhesive|Bonding composite to restore Class I or Class II cavities
1712328|NCT01369121|Drug|XERECEPT|BID dosing, subcutaneous for 1 year
1712331|NCT01369095|Drug|Duloxetine|Capsule, Oral, 30-60mg/day, once daily, 7 weeks (Phase B), 7weeks (Phase C&D)
1712332|NCT01369095|Drug|Escitalopram|Capsule, Oral, 10-20 mg/day, once daily, 7 weeks (Phase B), 7 weeks (Phase C&D)
1712333|NCT01369095|Drug|BMS-820836 Placebo|Tablet, Oral, 0.0mg, once daily, 13 weeks (Phase B&C)
1712334|NCT01369095|Drug|BMS-820836|Tablet, Oral, 0.25mg, once daily, 6 weeks (Phase C)
1712335|NCT01369095|Drug|BMS-820836|Tablet, Oral, 0.5 mg, once daily, 6 weeks (Phase C)
1712336|NCT01369095|Drug|BMS-820836|Tablet, Oral, 1.0 mg, once daily, 6 weeks (Phase C)
1712337|NCT01369095|Drug|BMS-820836|Tablet, Oral, 2.0 mg, once daily, 6 weeks (Phase C)
1712338|NCT01369082|Drug|Maintenance Immunosuppressive Treatment|All immunosuppressive and immunomodulatory therapies are used presently to prevent rejection of transplanted islet cells. The agents listed are those used in the parent trials and continued in this trial, CIT08.
1712339|NCT01369069|Drug|IV insulin to maintain target glucose concentration of 80-130 mg/dL|Intervention is to keep glucose concentration 80-130 mg/dL for up to 72 hours after randomization. IV insulin drip will be used to maintain glucose target.
1712340|NCT01369069|Drug|Standard Care control - sliding scale insulin to keep glucose less than 180 mg/dL|Sliding scale sub q insulin given will be given up to 4 times per day based on glucose concentration. It will be given only if glucose concentration greater than or equal to 180 mg/dL.
1712341|NCT01369056|Behavioral|Advanced Adherence Counseling (AdvAdh)|AdvAdh consists of 3 individual sessions (study months 0, 3, 6) -- patient-centered, non-judgmental, Motivational Interviewing- and theory-based, semi-structured, brief, candid conversations with a trained clinical care nurse using Next Step Counseling (NSC) approach. The intervention targets: 1) accurate information about antiretroviral treatment (ART) (mechanisms of HIV and antiretrovirals) and the development of mental imagery around it; 2) promotion of perceived sense of ease and efficacy in working ART regimen into the context of one's daily life and present life circumstances that may challenge drug use persistence; 3) identification, refinement of skills promoting ease of adhering to one's ART regimen across the diverse and challenges contexts.
1712342|NCT01369043|Dietary Supplement|Vitamin E and Vitamin C|Vitamin E 400 iu/dose daily times 56 days Vitamin C 500 mg/dose twice daily times 56 days
1712343|NCT01369030|Other|Deplin®|Deplin® is an orally administered medical food available in a 7.5mg tablet or a 15mg caplet with each containing either 7.5mg or 15mg of L-methylfolate, respectively - which is the primary biologically active and immediately bioavailable form of folate. Dosage for this study will be 1 15mg caplet QD.
1712344|NCT01369017|Drug|Anakinra|Active treatment will consist of 2 doses of 1 mg/kg up to 100 mg of anakinra SQ injection.
1712345|NCT01369017|Drug|Placebo|Injection of NS
1712346|NCT01369004|Behavioral|Daily Self-weighing + weekly feedback+ weekly lessons|Daily self-weighing as a form of self-monitoring of body weight using a smart scale that sends their weights directly to a website (www.bodytrace.com) via the cellular network. They will be able to review weight trends overtime on this website via a graph showing both changes in weight and BMI. They will also receive weekly emailed feedback on their weight loss progress and compliance to the daily self-weighing prescription from a registered dietitian, as well as weekly emailed lessons with content related to behavioral weight control (e.g, how to control portion sizes, how to develop and exercise routine).
1712347|NCT01368991|Device|Kryptonite|Osteoconductive biologic bone cement to be applied upon sternal closure
1712348|NCT01368991|Procedure|Conventional closure|conventional closure, no kryptonite applied
1712349|NCT01368978|Device|InsuPatch|device which apply local heating at 38.5 degrees Celsius to the vicinity of the subcutaneous insulin infusion insertion site.
1712350|NCT01368965|Device|Ulthera® System treatment|Ulthera® System treatment delivering focused ultrasound energy
1712351|NCT01368952|Device|Pure prone positioning|Pure prone positioning device consisted of a pillow mounted on a table designed to keep the subjects sleeping prone.
1712352|NCT01368926|Drug|RO4917523|single oral doses
1712353|NCT01368926|Drug|RO4917523|multiple oral doses
1712354|NCT01368926|Drug|placebo|oral doses
1712355|NCT01368900|Device|Ulthera® System treatment|Focused ultrasound energy delivered below the surface of the skin.
1712356|NCT01368887|Drug|DPS-102|The patient will apply the treatment twice daily in the morning and at bedtime on the involved area only. The scheduled treatment duration is 12 weeks. Patient to begin treatment on the night of Visit 1.
1712360|NCT01368874|Device|Ulthera® System treatment|Single treatment of focused ultrasound energy delivered below the surface of the skin.
1712361|NCT01368848|Drug|Bevacizumab|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging
-> further 3 cycles BCD Q3W -> Bevacizumab Q3W until progression"
1712362|NCT01368848|Drug|Cisplatin|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging
-> further 3 cycles BCD Q3W"
1712363|NCT01368848|Drug|Docetaxel|"3 cycles BCD (Bevacizumab 7,5 mg/kg i.v., Cisplatin 75 mg/m² i.v., Docetaxel 75 mg/m²) Q3W -> Staging
-> further 3 cycles BCD Q3W"
1712364|NCT01368835|Device|Ulthera treatment|treatment of cheeks and upper neck area of face
1712365|NCT01368809|Drug|Saline|2 ml at induction 1-2 ml boluses as needed
1712366|NCT01368809|Drug|Fentanyl|Fentanyl (50 µg/ml) 2 ml at induction, 1-2 ml boluses as needed
1712367|NCT01368796|Biological|Agriflu|0.5mL dose IM vaccination
1712368|NCT01368796|Biological|Fluad|0.5mL dose of vaccine given IM
1712369|NCT01368796|Biological|Intanza|0.5mL dose vaccine given IM
1712370|NCT01368796|Biological|Vaxigrip|0.5mL dose vaccine given IM
1712371|NCT01368783|Drug|atazanavir|400 mg/day for 2 days
1712372|NCT01368783|Drug|Atazanavir(ATZ) and Tenofovir(TDF)|ATZ 400 mg with TDF/day for 2 days
1712373|NCT01368783|Drug|Atazanavir(ATZ) + Ritonavir|ATZ 300 mg + Ritonavir 100 mg/day for 2 days
1712374|NCT01368783|Drug|atazanavir(ATZ) + tenofovir(TDF) + ritonavir|ATZ 300 mg + Ritonavir 100 mg with TDF/day for 2 days
1712375|NCT01368770|Other|Coronary CTA|Coronary CTA using standard protocols
1712376|NCT01368770|Other|Stress MPI SPECT|Stress MPI using standard protocols
1712377|NCT01368757|Drug|Revlimid|"Dose escalation 5mg - 10mg - 15mg - 20mg in cohorts of three patients
The first step of phase I will be 5 mg lenalidomide in a daily regimen, the next step will be 10 mg in a daily regimen, the dosis of the following steps will be increased by 5 mg each until dose limiting toxicity (DLT) is reached.
Phase II will be started at the MTD (1 dose step below DLT) and will be administered in a daily regimen."
1712378|NCT01368744|Device|OSNA Breast Cancer System|"For in vitro diagnostic use only.
The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).
Groups: OSNA Breast Cancer System"
1712379|NCT01368731|Procedure|Prophylactic use of coagulation therapy|The procedure is completed as per usual, and if the patient has been randomized to the intervention group the appropriate coagulation therapy will be applied immediately after standard EMR to visible vessels within the mucosal resection area.
1712380|NCT01368718|Procedure|Active CPAP is compared with sham CPAP as a control intervention.|Patients are randomized into active or control arm. After the first treatment, a washout period is installed,after which therapy is switched according to the cross-over protocol. A CPAP device consists of a unit that generates airflow, which is directed to the airway via a mask. With active CPAP, the generated airflow creates a positive pressure and prevents upper airway collapse. With sham CPAP, the generated airflow creates a very low pressure.
1712381|NCT01368705|Dietary Supplement|Standard protein delivery|Protein delivery of 1.5 g/kg/day.
1712382|NCT01368705|Dietary Supplement|Intervention 1 (2.2g/kg/day)|protein delivery of 2.2g/kg/day
1712383|NCT01368705|Dietary Supplement|Intervention 2 (3.0 g/kg/day)|protein delivery of 3.0 g/kg/day
1712384|NCT01368692|Procedure|position of shoulder retraction|position of shoulder retraction by placing a saline bag between the scapula
1712385|NCT01368692|Procedure|position of neutral shoulder|neutral shoulder position during subclavian vein catheterization
1712386|NCT01368679|Procedure|Endoprothesis Implantation|stent implantation in the abdominal artery using endovascular
1712387|NCT01368666|Device|Perceval S Valve Prosthesis|Replacement of diseased or malfunctioning native aortic valve with the Perceval S valve prosthesis
1712388|NCT01368653|Behavioral|Standard treatment|Standard treatment includes a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling sessions to help smokers quit smoking
1712389|NCT01368653|Behavioral|Standard treatment+practice quitting|This intervention includes standard treatment (a 6-week supply of 21-mg nicotine patches and 4 15-minute individual smoking cessation counseling session) and an experimental treatment that involves practice quitting 7 times prior to a target quit date (for 4-12 hours per day) and returning to smoking by puffing smoke without inhaling
1712390|NCT01368653|Drug|Very low nicotine cigarettes|This intervention will be offered to a subset of smokers from both of the other study arms. To be eligible for this intervention, participants must be smoking at the follow-up interview conducted four weeks after a target quit day in the two arms listed above. Tobacco cigarettes containing very low levels of nicotine (.016-.019 mg in smoke from the cigarettes). These are to be smoked no more often than a smoker normally smokes regular cigarettes and for no longer than 6 weeks.
1712391|NCT01368627|Device|Supralimus® Sirolimus-Eluting Coronary Stent|Supralimus® Coronary Stent System consisting of the MATRIX® Coronary Stent having Sirolimus eluting from Biodegradable Polymeric Matrix on a Stainless Steel Platform, Drug concentration 1.4 µg/mm2
1712392|NCT01368614|Device|AVAPS-AE Mode of Therapy|AVAPS-AE mode is the experimental mode of therapy in this study that includes a combination of already cleared therapy attributes.
1712393|NCT01368614|Device|Respironics OnmiLab BiPAP S mode|Currently cleared NIV therapy modality
1712394|NCT01368614|Device|Respironics OmniLab Advanced CPAP mode|Currently cleared NIV therapy modality
1712395|NCT01368601|Procedure|CPAP (Continuous airway pressure)|To evaluate if continuous positive airway pressure (CPAP) on the lung undergoing lobectomy can decrease the inflammatory response and PPC.
1712396|NCT01368588|Radiation|radiation therapy|Undergo RT using IMRT or 3D-CRT
1712397|NCT01368588|Radiation|Whole-pelvic radiotherapy (WPRT)|Undergo whole-pelvic radiotherapy (WPRT)
1712398|NCT01368575|Procedure|CABG|CABG
1712399|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
1712400|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring|CABG combined with MV repair with remodeling annuloplasty rigid ring
1712401|NCT01368575|Procedure|CABG combined with MV repair with remodeling annuloplasty rigid ring and endoventricularplasty of subvalvular apparatus|CABG combined with MV repair with remodeling annuloplasty
1712402|NCT01368575|Procedure|CABG and MV replacement|coronary artery bypass grafting and mitral valve replacement
1712403|NCT01368562|Drug|Methylnaltrexone|SC
1712405|NCT01368536|Drug|Valturna|Valturna (aliskiren 150 mg/valsartan 160 mg) tablet
1712406|NCT01368536|Drug|Amlodipine|Amlodipine 5 mg and 10 mg capsule
1712407|NCT01368536|Drug|Chlorthalidone|Chlorthalidone 15 mg and 25 mg capsule
1712408|NCT01368536|Drug|Placebo of Valturna Tablet|Matching placebo of valturna tablet
1712409|NCT01368536|Drug|Placebo Capsule|Matching placebo of Amlodipine capsule OR Matching placebo of chlorthalidone capsule
1712410|NCT01368523|Drug|nilotinib|
1712411|NCT01368510|Behavioral|Intensive Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered daily 5 days/week for 4 weeks
1712412|NCT01368510|Behavioral|Waitlist|Minimal contact waitlist weekly for 4 weeks
1712413|NCT01368497|Drug|Entecavir and peginterferon|Entecavir 0.015 mg/kg/day (up to 0.5 mg maximum daily dose) once daily for 48 weeks and Peginterferon alfa-2a 180 µg/1.73m2 subcutaneously once weekly for 40 weeks beginning 8 weeks after entecavir monotherapy).
1712414|NCT01368484|Dietary Supplement|Sunflower oil|1500 mg sunflower/day for 10 weeks
1712415|NCT01368484|Dietary Supplement|Docosahexanoic acid|1500mg/day for 10 weeks
1712416|NCT01368471|Device|MGuard|MGuard™ stent comprises a balloon-expandable, thin-strut stainless steel (316L) bare metal stent platform (strut width 100 µm) with mesh sleeve fibers of polyethyleneterephtalate (fiber width of 20 µm) attached to its outer surface. These fibers act like a net (aperture size 150 x 180 µm) preventing distal embolization of the plaque debris/thrombus placed between the vessel wall and the stent.
1712417|NCT01368471|Device|Control BMS or DES|Control BMS or DES
1712418|NCT01368458|Other|Conversion to Antipsychotic Monotherapy|Patients assigned to the antipsychotic monotherapy group will have the dosage of their secondary (i.e. one due to be reduced) antipsychotic reduced by decreased by approximately 1/3 every 3 weeks. Dosage of the primary antipsychotic will be left unchanged.
1712419|NCT01368445|Drug|azelastine hydrochloride 0.15% Nasal Spray|1644 mcg, 2 sprays per nostril twice daily AM & PM)
1712420|NCT01368445|Drug|azelastine hydrochloride 0.15% and Placebo|822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM)
1712421|NCT01368445|Drug|Azelastine 0.1%, Nasal Spray|1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM & PM)
1712422|NCT01368432|Drug|Escitalopram|Escitalopram 10 mg or 20 mg daily for 12 weeks by mouth
1712423|NCT01368432|Drug|Placebo|Sugar pill placebo
1712424|NCT01368419|Drug|Endostar|75mg Endostar in 235mL normal saline, 24h continuous infusion, 6 weeks
1712425|NCT01368419|Radiation|Radiotherapy|6～15MV X-ray, 2Gy/time，5times/week，6 weeks
1712426|NCT01368406|Behavioral|wellness program|12-week weight management intervention in patients with severe mental disorders. In the 1-hour weekly group sessions topics like dietary choices, lifestyle, physical activity and self-esteem were discussed with outpatients and their relatives
1712427|NCT01368393|Procedure|Electroacupuncture|Patients randomized to the experimental group will receive electroacupuncture at acupoints relevant to the treatment of abdominal pain and anxiety, including Zusanli (stomach meridian ST-36), Hegu (large intestine meridian LI-4), and Neiguan (pericardium meridian PC-6). Electric stimulation will be employed to the needles
1712428|NCT01368393|Procedure|Sham acupuncture|"Sterile blunt-tip needles will be placed (without skin penetration) 15 mm away from the acupoints. Pseudostimulation will be given by deliberately connecting the needle to the incorrect output socket of the electroacupuncture device, thus there will be no flow of electric current."
1712429|NCT01368380|Behavioral|Psychological intervention|Couples in the intervention group attends six to eight couple-sessions performed by a psychologist.
1712430|NCT01368367|Other|Intensive exercise|Both groups, stretching exercise monitored once per week Intensive exercise group An aerobic and resisted exercise program for a minimum of three times per week for a total of approximately 60 minutes per session for six weeks. Aerobic exercise will be conducted on a treadmill, exercise bike or arm ergometer at an intensity of 80 % of VO2peak during initial assessment. For resistance exercise, the three repetition maximum (3RM) (maximum weight able to be lifted a maximum of 3 times) will be established and then resisted exercise will be commenced at 60% of the 3RM in the first week. Resisted exercise will then be progressed weekly by 5-10% by increasing the number of repetitions or the weights lifted. All resisted exercises will be done using variable resistance machines or free weights.
1712431|NCT01368354|Behavioral|CLTS|CLTS (Community Led Total Sanitation) involves facilitating a process to inspire and empower rural communities to stop open defecation and to build and use latrines, without offering external hardware subsidies. Communities are encouraged to appraise and analyse their own sanitation profile, including the extent of open defecation and the spread of faecal-oral contamination. This approach ignites a sense of disgust and share among the community. The community then collectively realises the impact of its unsanitary practices and this realisation mobilises and initiates collective action to improve the existing sanitation profile.
1712432|NCT01368341|Drug|Doxycycline|1 tablet, 100 mg, b.i.d. 14 days
1712433|NCT01368341|Drug|Phenoxymethylpenicillin|Tablet 650 mg, 2 tablets, t.i.d., 14 days
1712434|NCT01368341|Drug|Amoxicillin|Capsula, 500 mg, t.i.d., 14 days
1712435|NCT01368328|Dietary Supplement|Chromium nicotinate|The intervention is offered during three months. There is a placebo group, chromium nicotinate 50 mcg group and chromium nicotinate 200 mcg group. Each patient is oriented to consume one capsule one hour after lunch and one capsule one hour after dinner.
1712436|NCT01368315|Drug|CT327 application|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
1712437|NCT01368315|Drug|Placebo|Topical administration of 0.5 grams cream administered twice daily for ten days to one out of four test fields marked on the patient's back.
1712438|NCT01368315|Drug|Active comparator|Topical administration of an active comparator administered twice daily for ten days to one out of four test fields marked on the patient's back.
1712439|NCT01368315|Drug|No intervention|No intervention to one out of four test fields marked on the patient's back.
1712440|NCT01368302|Behavioral|Attention Bias Modification Treatment (ABMT)|Attention training using a computerized spatial attention task (dot-probe) modified to alter threat-related attention patterns.
1712441|NCT01368289|Procedure|Endoscopic Mucosal Resection|Endoscopic Mucosal Resection of large sessile colonic polyps.
1712442|NCT01368276|Biological|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
1712443|NCT01368276|Drug|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|125 µg/m² subcutaneous injection
1712444|NCT01368263|Drug|goserelin acetate|Given SC
1712445|NCT01368263|Drug|letrozole|Given PO
1712446|NCT01368263|Drug|anastrozole|Given PO
1712447|NCT01368263|Drug|chemotherapy|Standard chemotherapy
1712448|NCT01368263|Procedure|Surgery|
1712449|NCT01368250|Procedure|Transcatheter Aortic Valve Implantation|Minimal Invasive Implantation of a biological prosthesis in Aortic Position
1712450|NCT01368237|Radiation|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and imaging of myocardial perfusion, function and viability.
1712451|NCT01368224|Dietary Supplement|Lactobacillus paracasei NCC 2461 and Bifidobacterium longum NCC3001|"1 treatment unit, in the form of a sachet of powder, to be reconstituted in a glass of water and taken once daily for 8 weeks (from D1 to D57), except if the last visit is bring forward or put back for no more than 3 days, in which case the subject will continue treatment until the final visit.
Oral route."
1712452|NCT01368211|Biological|2-4-day-old Mirasol-treated Platelets Transfusion|"2-4-day-old Mirasol-treated Platelets Units with:
Platelet yield between 2.4x10e11 and 4.5x10e11
Plasma carryover of >32%
Cell count > 800x103/µL"
1712453|NCT01368211|Biological|2-4-day-old Untreated Platelets Transfusion|"2-4-day-old Untreated Platelets Units with:
Platelet yield between 2.4x10e11 and 4.5x10e11
Plasma carryover of >32%
Cell count > 800x103/µL"
1712454|NCT01368198|Other|Systane Balance Lubricating Eye Drops|One instillation of the eye drop in each eye
1712455|NCT01368198|Other|OPTIVE™|One instillation of the eye drop in each eye
1712456|NCT01368172|Behavioral|Physical Activity Guidelines|Participants in the Physical Activity Guidelines Arm will be asked to participate in at least 20 minutes of moderate to heavy intensity aerobic activity 2 times per week as well as strength training exercises (moderate intensity) 2 times per week. The Control Arm will not be supervised to follow the physical activity guidelines
1712457|NCT01368159|Device|Compression Stockings|"The trial objectives are to compare efficacy relative to pain, along the route of the vein following echoguided endovenous injection of sclerotherapeutic foam into the Great Saphenous vein, of class III microfibre compression (centred at 25 mm Hg) versus class I (10-15 mm Hg) versus class III cotton compression (20 to 36 mm Hg) over 21 days. The main contrast will be the comparison between the first two groups mentioned. All other contrasts will be secondary. The Class I compression versus The two class III compressions contrast will also be studied."
1712458|NCT01368146|Device|IV Clear™|Polyurethane film with a silicone adhesive dressing containing chlorhexidine and silver
1712459|NCT01368146|Device|Tegaderm CHG™|Polyurethane film with a polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
1712460|NCT01368146|Device|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
1712461|NCT01368120|Device|IV Clear™ Dressing|Polyurethane film, silicone adhesive dressing with chlorhexidine and silver
1712462|NCT01368120|Device|Tegaderm CHG™|Polyurethane film, polyacrylate adhesive and a polyol hydrogel containing 2% w/w chlorhexidine gluconate
1712463|NCT01368120|Device|Silicone Vehicle Control Dressing|Polyurethane film with silicone adhesive dressing, without antimicrobials
1712464|NCT01368107|Drug|placebo|Placebo before the 1st (D0, D7, D14)and during the 3rd CT cycle (D57, D64, D71)
1712465|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and the placebo during the 3rd CT cycle (D57, D64, D71)
1712466|NCT01368107|Drug|interleukin 7|patients will receive the placebo before the 1st CT cycle (D0, D7, D14) and a delayed treatment with CYT107 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
1712467|NCT01368107|Drug|interleukin 7|patients will receive an induction cycle of CYT107 (10µg/kg/week subcutaneously for 3 weeks) before the 1st CT cycle (D0, D7, D14) and a maintenance cycle of IL-7 (10µg/kg/week subcutaneously for 3 weeks) during the 3rd CT cycle (D57, D64, D71)
1712468|NCT01368094|Procedure|Drain removal at D4|If no pancreatic fistula (PF) or deep SSI is highlighted neither on the CT-scanner nor with biological analysis, on day 3 postoperatively, the drain will be removed on the 4th postoperative day, at the patient's bedside.
1712469|NCT01368094|Procedure|Standard drain removal|If no pancreatic fistula (PF) or deep SSI is highlighted on the CT-scanner on day 3 postoperatively, the drain will be removed following the clinical routine practice of the surgical team that takes the patient in charge. The patient will leave the department when the surgeon deems necessary.
1712470|NCT01368081|Drug|Metformin|Metformin tablets 500-2250 mg a day (twice or three times per day)
1712471|NCT01368081|Drug|BI 10773|BI 10773 low dose tablet once daily
1712472|NCT01368081|Drug|Placebo (low dose)|Placebo tablets once daily
1712473|NCT01368081|Drug|BI 10773|BI 10773 high dose tablet once daily
1712474|NCT01368081|Drug|Placebo (high dose)|Placebo tablets once daily
1712475|NCT01368068|Drug|Tibolone|2.5mg/oral/daily
1712476|NCT01368068|Drug|Escitalopram|10mg/oral/daily
1712477|NCT01368068|Drug|Natvia|serving size: 0.09g per tablet
1712478|NCT01368055|Radiation|70 Gy/CGE|Low Risk
1712479|NCT01368055|Radiation|72.5 Gy/CGE|Intermediate Risk
1712480|NCT01368029|Biological|Lactobacillus rhamnosus GG ATCC 53103 (LGG)|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day on an outpatient basis for 28 days
1712481|NCT01368029|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day on an outpatient basis for 28 days.
1712482|NCT01368016|Drug|Nicotine|A single 6 mg dose of an experimental Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
1712483|NCT01368016|Drug|Nicotine|A single 4 mg dose of a marketed Nicotine Gum, with a 36-hour washout between visits
1712484|NCT01368003|Drug|STA9090|200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
1712485|NCT01368003|Drug|STA9090 with Dutasteride|Dutasteride 3.5 mg orally per day STA9090 200 mg/m^2 IV every week for 3 weeks on, 1 week off (days 1,8,15 on a 28-day cycle)
1712486|NCT01367990|Drug|Norepinephrine|"The occipital scalp zone at risk for alopecia will be identified. The norepinephrine treatment site will be randomized to receive consistent treatment of one half of the scalp risk zone. Approximately 1.6 mL of a 400 mM norepinephrine solution will be applied topically to the norepinephrine site approximately 20 minutes prior to each radiation treatment, and placebo will be applied to the contralateral side (30-35 treatments)."
1712487|NCT01367964|Drug|adrenocorticotropin hormone|ACTH 16 units intramuscular injection once daily for 2 weeks
1712488|NCT01367951|Procedure|Surgical fixation|"The fractures will be reduced and stabilized by use of plates and screws
Attempt will be made to stabilize ribs 3-7, as these are surgically accessible and most important in maintaining integrity of the chest cavity.
Goal is not to fix all the fractures, but to fix sufficient fractures to create an internal splint and allow chest wall motion to occur as a unit. In case of fibs fractured at numerous locations, as many fragments will be reduced and stabilized as necessary to ensure movement as a unit.
Chest tube(s) will be placed at the discretion of the treating surgeon in patients with pre-operative or intra-operative violation of the pleural cavity (ie pre-op pneumothorax/haemothorax, iatrogenic pleural injury). No post-operative drains will be inserted."
1712489|NCT01367912|Drug|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the first day after hCG injection, in addition to vaginal progesterone gel
1712490|NCT01367912|Drug|estradiol tablet|received 2 mg estradiol tablets orally two times daily beginning from the fifth day after hCG injection, in addition to vaginal progesterone gel.
1712491|NCT01367886|Drug|fesoterodine|Fesoterodine 4 mg. tablet by mouth daily for six weeks
1712492|NCT01367873|Drug|Placebo|Oral, matching number of placebo capsule(s) with active arm
1712493|NCT01367873|Drug|VIA-3196|Oral, capsule(s)
1712494|NCT01367860|Procedure|Open microdiscectomy|The open microdiscectomy, will be performed under general anesthesia in the prone position with horizontal. The level of the spine indicated for surgical treatment will be identified with the aid of fluoroscopy. An incision is made about the dorsal disc level involved with dissection of the paravertebral muscles on the side of disc herniation. After laminectomy and resection of part of the yellow ligament, partial discectomy is done under direct vision.
1712495|NCT01367860|Procedure|Percutaneous Diskectomy SpineJet|Percutaneous Diskectomy SpineJet be performed under local anesthesia, in which a needle is placed via percutaneous posterolateral extra-pedicular, below the neural foramen in the center of the disc, using the traditional approach for discography. The researcher will confirm the proper placement of the needle in front and side incidences on the fluoroscopy.
1712496|NCT01367847|Behavioral|Helping the Noncompliant Child (HNC)|Well-established behavioral parent training program (McMahon & Forehand) for parents of 3 to 8 y.o. children with externalizing problems
1712497|NCT01367847|Behavioral|Technology-Enhanced Helping the Noncompliant Child (TE-HNC)|Standard HNC program plus technology-enhancements (see description under Arm)
1712498|NCT01367834|Drug|somatotropin|Subjects will receive 5 mg somatotropin (growth hormone) pens with cartridges. Subcutaneous injections are to be given every evening around bedtime. Dosing regimen: 50 mcg/kg/day to be adjusted at 4 month intervals to the closest 0.1 mg. Subjects will be given 12 months of treatment (from 12 to 24 months of life). Subjects will visit their pediatrician or pediatric endocrinologist at 4 and 8 months of life.
1712499|NCT01367808|Drug|Placebo|The subjects will be given placebo twice a day for 5 days prior to the study
1712500|NCT01367808|Drug|vorikonazole|The subject will be given vorikonazole twice a day for 5 days prior to the study. The dose will be 400 mg twice a day on day one ans 200 mg twice a day on days 2-5.
1712501|NCT01367808|Drug|posakonazole|The subjects will be given posaconazole 400 mg twice a day for 5 days prior to the study.
1712502|NCT01367782|Device|repetitive transcranial stimulation (r-TMS)|Active treatment with the H-coil will include stimulation over the motor cortex (1 Hz stimulation 110% of the motor threshold for 15 minutes) and over the prefrontal cortex (10Hz stimulation 100% of the motor threshold, 2 seconds each train, 20 seconds between trains, for 15 minutes).
1712503|NCT01367782|Device|repetitive transcranial stimulation (r-TMS)|Sham treatment with the H-coil will include sham stimulation over the motor cortex and over the prefrontal cortex.
1712504|NCT01367769|Other|No intervention|There will be no intervention in this study.
1712505|NCT01367756|Drug|RO4995819|multiple oral doses, Days 10-16
1712506|NCT01367756|Drug|citalopram|multiple oral doses, Days 1-16
1712507|NCT01367756|Drug|placebo|multiple oral doses, Days 10-16
1712508|NCT01367743|Drug|epinephrine perfusion|perfusion of commercial epinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
1712509|NCT01367743|Drug|norepinephrine perfusion|perfusion of commercial norepinephrine prepared in syringes in order to obtain a MAP of 65-70 mmHg
1712510|NCT01367717|Dietary Supplement|Creatine Monohydrate|Each subject ingested 10 grams of commercially available creatine monohydrate orally. This was equivalent to two teaspoons according to the manufacturer's recommendations. The creatine was then solubilized in 8 oz. of water and 2 tablespoons of Tang brand orange flavored drink mix.
1712511|NCT01367717|Dietary Supplement|Creatine Ethyl Ester|Each subject ingested 10 grams of creatine ethyl ester orally. This was equivalent to 14.25 pills according to the manufacturer's ingredient description. The pill capsules were ground into a powder, which was added to 8 oz of water along with 2 tablespoons of Tang brand orange drink.
1712512|NCT01367704|Behavioral|"Coaching Boys Into Men program"|Coaching Boys into Men (CBIM) program consists of a 60 minute training for high school coaches led by a violence prevention advocate to introduce coaches to the rationale for CBIM and the CBIM Coaches Kit. The Coaches use this CBIM toolkit to provide weekly discussions with their athletes (generally 10-15 minute mini-sessions) throughout their athletic season (11 weeks). Discussion topics include how to prevent disrespectful and harmful behaviors towards women and girls and how to promote healthy choices and relationships among youth.
1712513|NCT01367691|Device|CRT reprogramming (Medtronic CRT)|CRT devices will be reprogrammed according to CMR analysis
1712514|NCT01367678|Device|Laryngeal Mask Airway Supreme|Directly measured mucosal pressures
1712515|NCT01367678|Device|i-Gel extraglottic airway device|Directly measured mucosal pressures
1712516|NCT01367665|Drug|vismodegib|150 mg once daily until disease progression or unacceptable toxicity
1712517|NCT01367652|Drug|Letrozole|2.5 mg tablet
1712518|NCT01367652|Drug|Letrozole|2.5 mg Tablet
1712519|NCT01367639|Behavioral|Inquiry Based Stress Reduction (IBSR) program|"The IBSR (Inquiry-based stress reduction) intervention, developed by Byron Katie, trains participants to reduce their perceived level of stress by self-inquiry of their thoughts and beliefs connected to stressful circumstances or symptoms. This meditative process, named The Work, enables the participants to identify and question the stressful thoughts that cause their suffering. The core of IBSR is simply four questions and a turnaround, which is a way of experiencing the opposite of what the participant believes. This process is simple, powerful and provides skills for self-inquiry and management of stressful thoughts that can be easily implemented in daily life"
1712520|NCT01367626|Drug|letrozole|2.5 mg tablet
1712521|NCT01367626|Drug|letrozole|2.5 mg tablet
1712522|NCT01367613|Drug|SC Methylnaltrexone|
1712523|NCT01367600|Drug|SC Methylnaltrexone (MNTX)|
1712524|NCT01367587|Drug|IV Methylnaltrexone|
1712525|NCT01367574|Drug|SC MNTX|Dose 1
1712526|NCT01367574|Drug|SC MNTX|Dose 2
1712527|NCT01367574|Drug|SC MNTX|Dose 3
1712528|NCT01367561|Drug|Naloxone|
1712529|NCT01367561|Drug|IV Methylnaltrexone (MNTX)|
1712530|NCT01367561|Drug|Placebo|
1712531|NCT01367548|Drug|IV Methylnaltrexone (MNTX)|
1712532|NCT01367548|Drug|Placebo|
1712533|NCT01367535|Drug|SC Methylnaltrexone (MNTX)|
1712534|NCT01367535|Drug|IV Methylnaltrexone (MNTX)|
1712535|NCT01367535|Drug|Oral Paroxetine|
1712536|NCT01367535|Drug|SC Placebo|
1712537|NCT01367522|Drug|SC Methylnaltrexone (MNTX)|
1712538|NCT01367509|Drug|Methylnaltrexone (MNTX)|
1712539|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 1
1712540|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 2
1712541|NCT01367496|Drug|SC Methylnaltrexone (MNTX)|Dose 3
1712542|NCT01367496|Drug|IV Methylnaltrexone (MNTX)|
1712543|NCT01367483|Drug|IV methylnaltrexone (MNTX)|
1712544|NCT01367470|Dietary Supplement|VSL#3 probiotic preparation|VSL#3 is a mixture of 8 different strains of lactic acid bacteria and bifidobacteria at a concentration of 900 billion bacteria per sachet. The suggested dosage is 1 to 2 sachets per day.
1712545|NCT01367470|Other|Placebo VSL#3|Placebo VSL#3 is a base of corn starch containing no active ingredient.
1712546|NCT01367457|Other|Temsirolimus (Non-Interventional Study)|There is not any intervention in this study.
1712548|NCT01367431|Dietary Supplement|Xanthohumol|PK study with one capsule of one of the three doses randomly assigned
1712549|NCT01367418|Drug|Patient controlled analgesia (PCA)|Morphine 1 mg/ml
1712550|NCT01367418|Drug|Thoracic Epidural Analgesia (TEA)|Intra-operatively: Bupivacaine 0.5% with adrenaline Post-operatively: Ropivacaine 0.2% + sufentanil 1 ug
1712551|NCT01367405|Procedure|Surgical decompression|Surgical decompression within 24 hour postinjury
1712552|NCT01367405|Procedure|Conservative treatment|Usual conservative treatment without surgery
1712553|NCT01367392|Device|biopsy or ablation|biopsy or ablation performed as in standard of care with assistance of ActiSight Needle Guidance system
1712554|NCT01367379|Procedure|24 hour EKG and blood pressure monitor|All subjects will have non-invasive 24 hour EKG and 24 hour EKG monitoring for 24 hours.
1712555|NCT01367379|Other|Blood and urine sampling|Right before and after the duty loading, all subjects will have blood samplings, including CRP, WBC, IL-6, Fibrinogen, insulin, IL-6, Procalcitonin, TNF-alfa, catecholamine level. Right after the duty loading, all subjects will have urine samplings for cortisol and catecholamine level.(blood : 15CC/time and 2~4 times/month)
1712556|NCT01367366|Procedure|PET and EBUS-TBNA|PET and EBUS-TBNA once, respectively
1712557|NCT01367353|Procedure|surgery or debulking surgery|surgery or debulking surgery
1712558|NCT01367340|Behavioral|Loaded sit-to-stand resistance exercise|Loaded STS exercise at home, 3 times a week for 6 weeks
1712559|NCT01367340|Behavioral|Physical activity intervention|The intervention is based on the social cognitive theory and the transtheoretical model. There are two principle components, the individual consultation and the small group PA activities. In the individual consultation, assessment of current stage of readiness for PA will be performed first. Then, individualized, stage-matched feedback will be sent to the participants. Small group PA activities will be held every 2 weeks in order to increase learning opportunity by peer interaction, make exercise fun, and introduce a role model.
1712560|NCT01367327|Behavioral|Loaded sit-to-stand exercise|Loaded sit-to-stand exercise at home, 3 times a week for 6 weeks
1712561|NCT01367327|Behavioral|Synchronized music|Synchronized music for loaded sit-to-stand exercise to guide movement
1712562|NCT01367314|Drug|NVC-422|Dermal Gel applied 3 times per day for 7 days
1712563|NCT01367301|Drug|paclitaxel|Given IV
1712564|NCT01367301|Drug|carboplatin|Given IV
1712565|NCT01367301|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
1712566|NCT01367301|Radiation|brachytherapy|Undergo HDR brachytherapy
1712567|NCT01367301|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1712568|NCT01367301|Other|laboratory biomarker analysis|Correlative studies
1712569|NCT01367288|Drug|Zometa + Neoadjuvant therapy|4 mg (in a 15 min. infusion) every 3 weeks for a total of 8 injections
1712570|NCT01367288|Drug|Neoadjuvant therapy|4 injections of doxorubicin (60 mg/m²) combined with cyclophosphamide (600 mg/m²) every 3 weeks (+/- 2 days), followed by 4 injections of docetaxel (100 mg/m²) every 3 weeks (+/- 2 days)
1712739|NCT01365962|Genetic|gene expression analysis|
1712573|NCT01367262|Drug|LY2886721|Administered orally
1712574|NCT01367249|Drug|Bromfenac Ophthalmic Solution|Sterile ophthalmic solution
1712575|NCT01367249|Drug|Placebo|Sterile ophthalmic solution
1712576|NCT01367236|Drug|standard care|"atazanavir 300 mg daily
ritonavir 100 mg daily
tenofovir 245 mg daily*
emtricitabine 200 mg daily*"
1712577|NCT01367236|Drug|novel treatment|"darunavir 800 mg daily
ritonavir 100 mg daily
lamivudine 300 mg daily** and abacavir 600mgs daily**
maraviroc 150 mg once daily"
1712578|NCT01367223|Dietary Supplement|solution of amino acids supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
1712579|NCT01367223|Dietary Supplement|amino acids not supplemented with glutamine|parenteral nutrition by range of ages (recommendation from ESPGHAN and ESPEN:1 month to 3 years, 3 to 5 years, 6 to 12 and standard adult).Study Parenteral nutrition will be assessed the first 5 days.
1712580|NCT01367210|Drug|Maraviroc, Darunavir/r|Maraviroc 300 mg Darunavir 800 mg Ritonavir 100 mg
1712581|NCT01367210|Drug|current antiretroviral therapy with 3 drugs|To continue the assumption of previous HAART
1712582|NCT01367197|Behavioral|exercise training|group based exercise training
1712583|NCT01367158|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine|The lyophilized Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine reconstituted with one dose of Meningococcal (group B) multicomponent recombinant adsorbed vaccine
1712584|NCT01367158|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine|Liquid Meningococcal (group B) multicomponent recombinant adsorbed vaccine
1712585|NCT01367158|Biological|Tdap|Sterile liquid suspension of tetanus and diphtheria toxoids and acellular pertussis components intended for intramuscular injection
1712586|NCT01367145|Drug|OMACOR|4 capsules OMACOR 1g per day
1712587|NCT01367145|Drug|Placebo|4 capsules placebo per day
1712588|NCT01367132|Procedure|Doppler ultrasound|Ultrasound using Doppler mode to detect blood flow in umbilical cord vasculature and determine the number of vessels present
1712589|NCT01367119|Drug|Ketamine|Subjects were dosed with approximately 1.0 mg/kg, using ketamine as anesthetic.
1712590|NCT01367119|Drug|methohexital|Subjects were dosed with approximately 1.0 mg/kg, using methohexital as anesthetic.
1712591|NCT01367106|Procedure|Euglycemic hyperinsulinemic clamp|Euglycemic hyperinsulinemic clamp will be performed at day 2
1712592|NCT01367080|Drug|DWETR10|Amitriptyline hydrochloride 10mg(DWETR10) single dose
1712593|NCT01367080|Drug|DWETR25|Amitriptyline hydrochloride 25mg(DWETR25) single dose
1712594|NCT01367054|Drug|Metformin|500 mg tablet
1712595|NCT01367054|Drug|Glifage|500 mg tablet
1712596|NCT01367041|Procedure|vibration|Vibration frequency: 40 Hz, duration: 30+30 s, 2mm amplitude
1712597|NCT01367028|Drug|Trastuzumab, Docetaxel|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.
Docetaxel: 100 mg/m2 by 60 min i.v. infusion"
1712598|NCT01367028|Drug|Trastuzumab, Docetaxel, Bevacizumab|"6 cycles - Day1 (Day22 = Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.
Docetaxel: 100 mg/m2 by 60 min i.v. infusion Bevacizumab 15 mg/kg"
1712599|NCT01367028|Drug|Trastuzumab+Docetaxel+NPLD|"6 cycles - Day1 (Day22=Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.
Docetaxel: 75 mg/m2 by 60 min IV infusion NPLD 50 mg/m2 by 60 min i.v. infusion"
1712600|NCT01367028|Drug|Trastuzumab+Docetaxel+NPLD+Bevacizumab|"6 cycles - Day1 (Day22= Day1): Trastuzumab: 8 mg/kg loading dose (1st cycle) i.v.; 6 mg/kg maintenance dose in subsequent cycles i.v.
Docetaxel: 75 mg/m2 by 60 min i.v. infusion NPLD: 50 mg/m2 by 60 min i.v. infusion; Bevacizumab 15 mg/kg"
1712601|NCT01367015|Other|Early Feeding|Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs after randomization at 60+/-12 hrs of life
1712602|NCT01367015|Other|Late Feeding|Nil per oral for another 48 hrs after randomization at 60+/-12 hrs of life followed by Feeding with expressed breast milk @ 8ml/kg/day for 48 hrs
1712603|NCT01367002|Drug|Carboplatin/Paclitaxel|Paclitaxel 175 mg/m2 will administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. 100% of patients will receive Carboplatin/Paclitaxel.
1712604|NCT01367002|Drug|Trastuzumab|Paclitaxel 175 mg/m2 will be administered intravenously every 21 days for 6 cycles. Carboplatin AUC 5 will be administered intravenously every 21 days for 6 cycles. On day 1, an 8 mg/kg loading dose of trastuzumab will be administered over a 90 minute period. Beginning on day 21, patients will receive 6mg/kg of trastuzumab, administered intravenously every 21 days and continued indefinitely every 21 days after 6 cycles of cytotoxic therapy are completed and until progression of the disease or prohibitive toxicities occur. 50% of patients will receive Carboplatin/Paclitaxel with the addition of Trastuzumab.
1712605|NCT01366989|Device|Radiographic evaluation of previously implanted patients|Radiographs of the ankle
1712606|NCT01366976|Drug|Acetaminophen|Acetaminophen 1g every 6 hours for 4 doses over 24 hours
1712607|NCT01366963|Behavioral|Seated Measurements|"The following measurements will take place in a seated position:
Ruff 1 & 7 (visual search and attention processes) Trails A & B (Tests of scanning, mental flexibility and executive processes) Symbol Digit Modalities Test (SDMT)(attention and psychomotor speed) Stroop Test (naming response to certain stimuli) Verbal Fluency (COWA) Randt Wechsler Test of Adult Reading (WTAR)"
1712608|NCT01366963|Behavioral|Standing Measurements|"The following will be measured in a standing position (at least 5 minutes)
Orthostatic Vital Signs Randt Paired Words Subtest Digits Forward and Backward Alternate COWA test"
1712609|NCT01366963|Behavioral|Self-Administered Surveys|Center for Epidemiologic Studies Depression Scale (CES-D) Cognitive-Somatic Anxiety Questionnaire (CSAQ) Subjective Neurocognitive Inventory (SNI)
1712610|NCT01366950|Behavioral|Intelligent physical activity|30 minutes of moderate activity 6 days a week and 45 minutes of high intensity training 1 day a week. Moderate activity is monitored in diaries and high intensity training is monitored by a trainer.
1712643|NCT01366573|Drug|GSK1521498|GSK1521498 20 mg administered with alcohol to determine PK/PD interactions
1712611|NCT01366924|Dietary Supplement|Essential Amino Acids|10 Gram Essential Amino Acid solutions with different leucine contents consumed during two identical endurance exercise trials
1712612|NCT01366924|Other|Endurance exercise|60 minute endurance exercise session
1712613|NCT01366898|Drug|Dexamethasona, Idarubicine, ARA-C, Methotrexate|
1712614|NCT01366885|Drug|Vitamin D3|5000 IU D3 capsule oral/day for entire pregnancy. 7000 IU D3/day during breastfeeding. If not breast feeding, baby gets 400 IU D3/day. Baby increased to 1000 IU D3/day at one year of age.
1712615|NCT01366859|Dietary Supplement|Whey Protein|The experimental study group will consist of thirty children that will be treated with Immunocal® 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months to determine the supplement's effect in core areas of behavior in children with autism.
1712616|NCT01366859|Dietary Supplement|Rice Protein (Placebo)|The control or placebo study group will consist of thirty children that will be treated with rice protein (placebo) 0.5 g/kg if less than 18 kg of body weight or 10 g/day for those children over 18 kg of body weight for three months.
1712617|NCT01366846|Other|Avoidance of peanut|All participants will be assigned to peanut avoidance as per United Kingdom (UK) public health recommendations and will avoid exposure to peanut protein during the study until the last study visit when they will receive the Oral Food Challenge.
1712618|NCT01366833|Radiation|Brachytherapy|Patients in arm B will receive a single dose of brachytherapy (10Gy) via a 10 or 13 mm catheter within 10days of stent insertion. Patients on the study will not be given preferential treatment, and will not be prioritized over patients treated with brachytherapy not on the study.
1712619|NCT01366833|Procedure|Stent insertion|After placement of clips to mark the proximal and distal extent of the tumor, an endoscopically placed self-expanding metallic stent (WallFlex™ Partially Covered Esophageal Stent by Boston Scientific) will be inserted within 10 days of recruitment. This will be the only intervention in Arm A patients.
1712620|NCT01366820|Drug|NNZ-2566|"Solution for intravenous infusion.
Intravenous bolus infusion over 10 minutes followed by a continuous intravenous maintenance infusion for a total of 72 consecutive hours."
1712621|NCT01366794|Other|Macronutrients|Glucose 330 kcal Protein 110 kcal Fat emulsion 110 kcal Mixed meal 550 kcal
1712622|NCT01366781|Other|Meal ingestion|Meal 511 kcal, meal 743 kcal or meal 1034 kcal
1712623|NCT01366768|Other|Oral amino acid mixture|Amino acid mixture 2,93 ml/kg
1712624|NCT01366768|Other|Intravenous amino acid administration|Amino acid mixture 2,93 ml/kg
1712625|NCT01366729|Device|TheraTogs|Orthosis facilitating hemiplegic hip extensor and abductor activity. Worn daily from dressing in the morning to undressing at night. May be removed during therapy or afternoon sleep.
1712626|NCT01366729|Device|Cane walking|All walking activities must take place with cane from waking until sleeping
1712627|NCT01366716|Behavioral|Cash CM|Participants in the cash CM condition will be assigned to the identical 12-week escalating schedule of reinforcement, except that the contingencies will be provided in cash rather than vouchers, and no negotiation process will be involved (although counselors may recommend how clients might best spend their money).
1712628|NCT01366716|Behavioral|Voucher CM|Participants in the voucher condition will earn voucher incentives according to the schedule developed by Higgins (1993, 1994). It involves a 12-week escalating schedule of reinforcement to initiate cocaine abstinence.
1712629|NCT01366703|Device|implantable loop recorder Medtronic reveal XT Full view|Medtronic Reveal implantable loop recorder with home-monitoring using carelink will be implanted in every patient and used to continuously monitor the patients during follow-up to detect symptomatic and asymptomatic arrythmias during follow-up
1712630|NCT01366690|Behavioral|Peer Support|A trained peer supporter is assigned to support newly HIV-positive diagnosed persons.
1712631|NCT01366677|Behavioral|Yoga Intervention|Three yoga classes per week for 8 weeks.
1712632|NCT01366664|Drug|Treatment sequence 2|Treatment Period 1 (stable dose of terazosin [2, 5, or 10 mg] + placebo administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2, 5, or 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days)
1712633|NCT01366664|Drug|Treatment sequence 1|Treatment Period 1 (stable dose of terazosin [2, 5, or 10 mg] + dapoxetine 60 mg administered orally once daily for 5 days) followed up to 14 days later by Treatment Period 2 (stable dose of terazosin [2, 5, or 10 mg] + placebo administered orally once daily for 5 days)
1712634|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=30, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients 12 weeks to <1 year of age.
1712635|NCT01366651|Drug|Doripenem|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous use, every 8 hours for 2 days (total of 5 doses) for patients <12 weeks of age.
1712636|NCT01366638|Drug|TMC435|100 mg capsule taken by mouth once daily for 12 weeks
1712637|NCT01366638|Drug|Peginterferon alfa-2b (pegIFN alfa-2b)|PegIFN alfa-2b will be supplied as a vial containing dried and frozen powder with 74,148 or 222 mcg pegIFN alpha-2b attached to 0.7 ml injection water (50, 100 or 150 mcg/0.5mL pegIFN alpha-2b) and will be administered according to the manufacturer's prescribing information as 1.5 mcg/kg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
1712638|NCT01366638|Drug|Ribavirin (RBV)|The dose of RBV given will be based on body weight. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 capsules of 200 mg) after breakfast and 600 mg (3 capsules of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 capsules of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 capsule of 200 mg) after breakfast and 400 mg (2 capsules of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
1712639|NCT01366625|Device|Renal denervation with a catheter-based procedure (Symplicity® Catheter System)|Disruption of the renal nerves with a catheter-based procedure.
1712640|NCT01366612|Drug|Fludarabine and Busulfan plus/minus Total Body Irradiation (low dose)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.
rATG on days -3, -2 and -1"
1712641|NCT01366612|Drug|Fludarabine and Busulfan + Low Dose Total Body Irradiation (LD TBI)|"Fludarabine 40mg/m2 and Busulfan 130mg/m2 on days -6, -5, -4 and -3 of transplant.
rATG on days -3, -2 and -1 TBI 200cGY (as randomized) on day -1"
1712642|NCT01366599|Drug|HEC or MEC|Any HEC or MEC, including aprepitant
1712647|NCT01366547|Drug|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg|Dolutegravir 50 mg/abacavir 600 mg/lamivudine 300 mg is an experimental fixed dose combination tablet of an experimental integrase inhibitor (dolutegravir) and two FDA approved nucleoside reverse transcriptase inhibitors (abacavir and lamivudine)
1712648|NCT01366547|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class that is being studied for the treatment of HIV infection.
1712649|NCT01366547|Drug|abacavir 600 mg/lamivudine 300 mg|This is an FDA approved fixed dose combination tablet of two nucleoside reverse transcriptase inhibitors
1712650|NCT01366534|Biological|Crucell's replication deficient adenovirus type 35 circumsporozoite malaria vaccine (Ad35.CS.01)|One dose will be administered intramuscularly at Study Day 0.
1712651|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (2 doses)|Two doses will be administered intramuscularly at monthly intervals
1712652|NCT01366534|Biological|GSK Biologicals' malaria vaccine 257049 (3 doses)|Three doses will be administered intramuscularly at monthly intervals
1712653|NCT01366534|Other|Sporozoite challenge|Subjects were challenged with sporozoite-infected mosquitoes to determine whether immune protective response had been induced by vaccination.
1712654|NCT01366521|Biological|Mepolizumab|Monoclonal antibody
1712655|NCT01366508|Other|High calorie lunch|Subject fed a standard high calorie lunch at 1pm
1712656|NCT01366508|Other|Breakfast|At approximately 09:00 the subject will be given breakfast. After this, no food will be served until study procedures for the day are over. However, a 330 ml bottle of still water at room temperature will be given at ~11:00 and at ~13:00. During this period the subject will be required to remain in the unit.
1712657|NCT01366495|Behavioral|Project Bridge|Project Bridge provides intensive case management for individuals with HIV as they transition back into the community from incarceration. The primary goal of the program is to increase continuity of medical care through social stabilization.
1712658|NCT01366482|Device|Cotavance Drug-Eluting Balloon|Treatment with a Paclitaxel-coated angioplasty balloon (without preceding plaque excision)
1712659|NCT01366482|Device|TurboHawk/SilverHawk Device followed by a Cotavance Drug-Eluting Balloon|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
1712660|NCT01366482|Device|TurboHawk/SilverHawk Device followed by a Cotavance Drug-Eluting Balloon (N=25)|Plaque excision followed by treatment with a paclitaxel-coated angioplasty balloon
1712661|NCT01366456|Device|Moxibustion|Comparison of different kinds of moxibustion
1712662|NCT01366443|Procedure|Sterile speculum exam|Sterile vaginal speculum exam to include Nitrazine, ferning and pooling observations
1712663|NCT01366443|Procedure|ROM Plus Exam|Vaginal swab exam for ROM Plus Test
1712664|NCT01366443|Procedure|Chart Reveiw|Post delivery blinded chart review by expereienced obstetrician
1712665|NCT01366430|Procedure|Gufoni|For Gufoni maneuver, the patient was quickly brought down on the healthy side from the sitting position, and the head was then turned about 45 degree down, so that the nose was on the bed. After 2 minutes in this position, the patient was returned to the upright position.
1712666|NCT01366430|Procedure|Sham|The sham maneuver the opposite of the first step for barbecue rotation; lying down from sitting position for 30 seconds, and head turn 90degree to the affected side for 1 minute, and then sit up.
1712667|NCT01366430|Procedure|Barbecue|For barbecue rotation, the head was rotated rapidly 90degree while supine in the direction of the healthy ear, which was immediately followed by a truncal rotation of 90degree in the same direction to lie on the intact side. After 30-60 seconds when the induced nystagmus was dissipated, the patients were subjected to a further 90degree rotation of the head and trunk en block in the same direction to attain the nose-down position. After a further 30-60 seconds, the head was again turned in the same direction so that the affected ear was downward. Finally, after another 30-60s, the patient was brought to sitting position. Only one maneuver was performed per session.
1712668|NCT01366417|Drug|ChloraPrep One-Step|1.5 ml applicator patient preoperative skin preparation
1712669|NCT01366417|Drug|70% isopropyl alcohol|Curity Alcohol Prep Pads
1712670|NCT01366391|Drug|Metformin|Metformin 500 mg tablet (1000 or 1500 mg/day)
1712671|NCT01366378|Drug|methylnaltrexone|
1712672|NCT01366365|Drug|methylnaltrexone|
1712673|NCT01366365|Drug|placebo|
1712674|NCT01366352|Drug|MNTX tablet (Formulation 1)|
1712675|NCT01366352|Drug|MNTX tablet (Formulation 2)|
1712676|NCT01366339|Drug|Oral methylnaltrexone|
1712677|NCT01366339|Drug|Oral placebo|
1712678|NCT01366326|Drug|Methylnaltrexone bromide|Subcutaneous MNTX
1712679|NCT01366313|Drug|Paracetamol|initial doses was 1.5g, with dose adjustment intervals of 0.5g . with maximum dose 2.5 g as an only starting dose / 24 h
1712680|NCT01366313|Drug|Morphine|Initial of morphine was 5mg, with dose adjustment intervals 1 mg .
1712681|NCT01366313|Drug|Paracetamol- Morphine|The initial doses of paracetamol and morphine were 1.5g and 3mg, respectively in the paracetamol-morphine combination group with dose adjustment intervals of 0.25g for paracetamol and 0.5mg for morphine.
1712682|NCT01366300|Drug|Intravenous lidocaine infusion|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, lidocaine 1% infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
1712683|NCT01366300|Other|Placebo (0.9% saline infusion)|Once the dose of propofol required for general anesthesia is stabilized for 5 minutes with BIS values between 40 and 50, 0.9% saline infusion is begun in a bolus of 1.5mg/kg for 5 minutes and then infused at 2 mg/kg/hr until the end of surgery (last skin suture is made).
1712684|NCT01366300|Drug|Propofol 1% (intravenous infusion)|Propofol is administered according to a widely-accepted pharmacokinetic model, initially dosed to a target controlled infusion (TCI) of 4.5 micrograms/ml, and titrated by step increases of 0.5 every minute until loss of conscience is obtained and BIS values are less than 50. During the maintenance phase of anesthesia propofol TCI is actively titrated to maintain BIS values between 40 and 50. If BIS is out of this range for more than 10 seconds, propofol is adjusted in 0.5 ug/mc to maintain BIS values in the predetermined limits.
1712740|NCT01365962|Other|immunohistochemistry staining method|
1712741|NCT01365962|Other|laboratory biomarker analysis|
1712742|NCT01365962|Other|mass spectrometry|
1712743|NCT01365949|Genetic|microarray analysis|
1712685|NCT01366300|Procedure|Placement of arterial line|An arterial line was placed in the anesthetised patient´s right arm by the investigator and arterial samples were obtained every 10 minutes since initiation of the study infusion to determine plasmatic lidocaine and propofol levels (if the infusion was saline the samples were not analyzed). The arterial line was removed before the end of surgery.
1712686|NCT01366287|Drug|PF-03882845|25 mg of PF-03882845 suspension (75% SDD) will be given as a single oral dose under fasted condition
1712687|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fasted condition
1712688|NCT01366287|Drug|PF-03882845|25 mg PF-03882845 Tablet (75% SDD) will be given as a single oral dose under fed condition
1712689|NCT01366274|Other|Protective manual hyperinflation|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 8mls/kg and positive end expiratory pressure in the circuit appropriate to baseline levels
1712690|NCT01366274|Other|Usual method of MHI|Manual hyperinflation for 10 minutes using a Mapleson C circuit and 100% oxygen with volume set at 12mls/kg and no positive end expiratory pressure in the circuit
1712691|NCT01366261|Device|semirigid thoracoscopy|thoracoscopy with semirigid instrument
1712692|NCT01366261|Device|rigid thoracoscopy|thoracoscopy with rigid instrument
1712693|NCT01366235|Drug|chloroquine phosphate 1000 mg|1000 mg, 1day
1712694|NCT01366222|Dietary Supplement|food concentrates: fruit, vegetable, fish oil and probiotics|comparison the effect of food concentrate
1712695|NCT01366209|Drug|Pirfenidone|Pirfenidone, total daily dose of 2403 mg/ day, given as 3 divided doses 3 times per day.
1712696|NCT01366209|Drug|Placebo|Placebo equivalent given as 3 divided doses 3 times per day.
1712697|NCT01366196|Drug|Pregabalin 150 mg|Patients will receive two 75 mg capsules of pregabalin 1 hour before surgery. They continue to take 2 capsules of 75 mg (total 150 mg) until POD 14.
1712698|NCT01366196|Drug|Placebo|Patients will first receive two capsules of the placebo drug (with no active ingredients per dose) one hour before surgery. Patients will continue taking two capsules per day until POD 14.
1712699|NCT01366183|Procedure|Assessment of Therapy Complications|Undergo nutritional status, such as body mass index and weight loss, and comorbidity and hearing impairment assessments
1712700|NCT01366183|Drug|Carboplatin|Undergo chemotherapy
1712701|NCT01366183|Biological|Filgrastim|Undergo chemotherapy
1712702|NCT01366183|Drug|Paclitaxel|Undergo chemotherapy
1712703|NCT01366183|Other|Pharmacological Study|Correlative studies
1712704|NCT01366183|Other|Quality-of-Life Assessment|Ancillary studies
1712705|NCT01366183|Other|Questionnaire Administration|Ancillary studies
1712706|NCT01366170|Genetic|microarray analysis|
1712707|NCT01366170|Genetic|protein expression analysis|
1712708|NCT01366170|Genetic|western blotting|
1712709|NCT01366170|Other|flow cytometry|
1712710|NCT01366170|Other|immunohistochemistry staining method|
1712711|NCT01366170|Other|laboratory biomarker analysis|
1712712|NCT01366170|Other|mass spectrometry|
1712713|NCT01366157|Genetic|microarray analysis|
1712714|NCT01366157|Genetic|protein expression analysis|
1712715|NCT01366157|Other|immunohistochemistry staining method|
1712716|NCT01366157|Other|laboratory biomarker analysis|
1712717|NCT01366144|Drug|Carboplatin|Given IV
1712718|NCT01366144|Other|Laboratory Biomarker Analysis|Correlative studies
1712719|NCT01366144|Drug|Paclitaxel|Given IV
1712720|NCT01366144|Other|Pharmacological Study|Correlative studies
1712721|NCT01366144|Drug|Veliparib|Given PO
1712722|NCT01366131|Drug|MEGF0444A|Intravenous repeating dose
1712723|NCT01366131|Drug|bevacizumab|Intravenous repeating dose
1712724|NCT01366131|Drug|carboplatin|Intravenous repeating dose
1712725|NCT01366131|Drug|paclitaxel|Intravenous repeating dose
1712726|NCT01366131|Drug|placebo|Intravenous repeating dose
1712727|NCT01366118|Drug|Therapeutic target tailored chemotherapy|"All pts were treated with Capecitabine (Cap) 625-825 mg/m2/12h M-F.
Ch combination schema was customized based on:
Top- 1 +: Irinotecan (I) 50mg/m2 / in weekly. Top-1 - and ERCC-1 - : Oxaliplatin (O) 50gm/m2/ weekly. Top- 1 - and ERCC-1 + : Neither I nor O. K-Ras or b-Raf mutated (m) : Bevacizumab (B) 5mg/kg every two weeks. K-Ras and B-Raf native (n): Cetuximab (C) 400/250mg/m2 weekly or B (investigator option). Figure 1.
When Cap was in combination with O or I the 625mg/m2 dose was chosen. When Cap was the only chemotherapy agent in combination with B or C the 825mg/m2 dose was chosen"
1712728|NCT01366105|Device|V.A.C. by K.C.I.|Negative Pressure Wound Therapy, Delivered by Vacuum Assisted Closure (KCI) across closed surgical incision at completion of surgery
1712729|NCT01366092|Drug|Interleukin-2|Daily subcutaneous IL-2 (1 x 10^6 IU/m^2/day) for self-administration for 12 weeks followed by 4-week hiatus
1712730|NCT01366079|Procedure|Position change|Patients change position (cecum to hepatic flexure, left lateral; transverse colon, supine; splenic flexure and descending colon , right lateral) during colonoscopy withdrawal.
1712731|NCT01366079|Procedure|Left lateral|In left lateral position group patients are positioned left lateral decubitus during colonoscopy withdrawal.
1712732|NCT01366066|Device|Transcutaneous mechanical nerve stimulation|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum. The stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz.
A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks."
1712733|NCT01366014|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
1712734|NCT01366014|Drug|Oxycodone hydrochloride (HCl) extended release (ER), opioid agonist; oral|multiple dose, single schedule
1712735|NCT01366014|Drug|Placebo; oral|matching placebo
1712736|NCT01366001|Drug|ALKS 33-BUP|Sublingual administration, ALKS 33 + buprenorphine, administered once daily for 10 consecutive days.
1712737|NCT01366001|Drug|ALKS 33|Sublingual administration, ALKS 33 administered once daily for 10 consecutive days.
1712738|NCT01366001|Drug|Placebo|Sublingual administration, Placebo administered once daily for 10 consecutive days.
1712744|NCT01365949|Genetic|protein analysis|
1712745|NCT01365949|Other|immunohistochemistry staining method|
1712746|NCT01365949|Other|laboratory biomarker analysis|
1712747|NCT01365936|Drug|HMG|In this prospective trial, women with PCOS (according to Rotterdam criteria) were randomized (80 patients) after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
1712748|NCT01365936|Drug|rFSH|Patients were randomized after GnRH analogue suppression to stimulation with HMG (n=38) or rFSH (n=42) using a low dose step up protocol in ICSI cycles.
1712749|NCT01365923|Drug|remifentanil|remifentanil effect site-TCI 2-4ng/ml
1712750|NCT01365923|Drug|dexmedetomidine with remifentanil|remifentanil effect site-TCI 2-4ng/ml with dexmedetomidine 0.5mcg/kg
1712751|NCT01365910|Drug|linifanib|Given PO
1712752|NCT01365897|Drug|Modafinil|Modafinil 200mg
1712753|NCT01365871|Procedure|anesthetics injection|Basal injection of anesthetics or basal + apical injection of anesthetics.
1712754|NCT01365858|Other|Rehabilitation|"The experimental group patients receive rehabilitation by training Virtual Action Planning - Supermarket on a computer 45 minutes 5 times a week during a 2-week period. The control group will receive similar duration cognitive rehabilitation (no extra computer training) during this period (problem solving and occupational therapy)."
1712755|NCT01365845|Radiation|Photon|50.4 Gy to the breast/chest wall and peripheral lymph nodes at 1.8 Gy per fraction
1712756|NCT01365845|Radiation|3D-Proton/Conventional plan or 3D-proton only|50.4 Cobalt Gray Equivalent/Gray to the breast/chest wall and peripheral lymph nodes at 1.8 Cobalt Gray Equivalent/Gray per fraction
1712757|NCT01365832|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is the gold standard for Obstructive Sleep Apnea (OSA) management. Subjects with OSA will be trained in the use of CPAP and will be instructed to use CPAP every night for 6 months. These subjects will then return for a post-treatment blood draw 3 and 6 months after the start of effective CPAP treatment
1712758|NCT01365819|Drug|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
1712759|NCT01365819|Drug|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 9).
1712764|NCT01365780|Procedure|Hyperbaric Oxygen Therapy|The patients receive 10 sessions of HBOT in two weeks, starting on the day after the surgical treatment of their radius fracture. Each session lasts about one hour.
1712765|NCT01365754|Procedure|standard|fusion
1712766|NCT01365754|Procedure|new|dynamic stabilization
1712767|NCT01365741|Other|Upright position|The test person will ingest Efient in an upright position and remain upright for 2 minutes. After 2 minutes, the test person will lie down, and remain supine for 2 hours, the same way as the person did in the control arm
1712768|NCT01365728|Procedure|LASIK with the iFS femtosecond laser|Patients will undergo bilateral simultaneous LASIK surgery for myopia. One eye will have a LASIK flap created with the Intralase FS60 and the fellow eye will have a LASIK flap created with the Intralase iFS. Both eyes will undergo wavefront-guided LASIK surgery with the Visx CustomVue excimer laser.
1712769|NCT01365715|Procedure|Arteriography and preoperative embolization|Arteriography and transcatheter arterial embolization of spinal metastasis/metastases 0-48 hours prior to surgery.
1712770|NCT01365715|Procedure|Arteriography|Arteriography of spinal metastasis/metastases without transcatheter arterial embolization prior to surgery.
1712771|NCT01365676|Drug|GAMALINE® + HIPERICIN®|GAMALINE® 900mg + HIPERICIN 300mg T0 = 2 soft caps of each / day (1st month) T1-T6 = 1 soft caps of each / day (2nd - 6th month)
1712772|NCT01365676|Drug|GAMALINE®|GAMALINE® 900mg T0= 2 soft caps / day (1st month) T1-T6 = 1 soft caps / day (2nd - 6th month)
1712773|NCT01365663|Drug|SPC4955|3 Weekly SC injections
1712774|NCT01365663|Drug|SPC4955|3 Weekly SC injections
1712775|NCT01365663|Drug|SPC4955|3 Weekly SC injections
1712776|NCT01365663|Drug|SPC4955|3 Weekly SC injections
1712777|NCT01365663|Drug|SPC4955|3 Weekly SC injections
1712778|NCT01365663|Drug|Saline 0.9%|3 Weekly SC injections
1712779|NCT01365650|Drug|Ketorolac Tromethamine|Single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 1
1712780|NCT01365650|Drug|Oxymetazoline Hydrochloride|Single intranasal dose of oxymetazoline hydrochloride followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) 30 minutes later on Day 1 of Period 2
1712781|NCT01365650|Drug|Fluticasone Propionate|Seven days of treatment with intranasal fluticasone propionate (between Periods 2 and 3) followed by a single intranasal dose of 30 mg ketorolac tromethamine (one 15 mg spray into each nostril) on Day 1 of Period 3
1712782|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
1712783|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension twice daily
1712784|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
1712785|NCT01365637|Drug|PF-05089771|PF-05089771 will be dosed as a suspension either twice or thrice daily
1712786|NCT01365624|Drug|Ketorolac tromethamine|Single dose of 30 mg of intranasal Ketorolac tromethamine (100 uL of a 15% solution in each nostril)
1712787|NCT01365611|Drug|Ketorolac tromethamine|A single intranasal dose of 30 mg ketorolac tromethamine was administered to all subjects on Days 1 and 6.
1712788|NCT01365611|Drug|Fluticasone Propionate|Daily intranasal dose of 200 ug fluticasone propionate on Days 2-6
1712822|NCT01365286|Drug|Ivabradine (Procoralan)|Ivabradine 7,5 mg b.i.d. for 5 days and Placebo b.i.d. for 5 days (Ivabradine-Placebo)
1714085|NCT01355393|Drug|rintatolimod|Given ID
1712789|NCT01365598|Drug|Primaquine|Single dose of oral primaquine phosphate. Comparator dose is 0.75mg/kg primaquine base. Each experimental arm is a different (reduced) dose of primaquine phosphate. Placebo contains no primaquine phosphate (non-active ingredients only).
1712790|NCT01365585|Drug|sildenafil citrate|Sildenafil citrate, 20mg oral tablets, taken at least three times daily
1712791|NCT01365572|Device|Xiene V stent, Endeavor Resolute stent|for each lesion, randomized either Xience V stent or Endeavor Resolute stent
1712792|NCT01365559|Drug|Group A: Carfilzomib & Non-IMiD Regimen|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.
Combination non-IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.
Maintenance regimen maybe administered if patient does not progress while on study."
1712793|NCT01365559|Drug|Group B: Carfilzomib & IMiD containing regimen.|"Carfilzomib will be administered intravenously starting at a dose of 20 mg/m^2 over 30 minutes for the first cycle and will then be increased to 27, 36 and 45 mg/m2 during cycles 2-4, respectively. Doses will be administered IV once daily on days 1, 2, 8, 9, 15, and 16 of each cycle. Cycles will be 28 days in length.
Combination IMiD drug is dosed on the identical schedule and dosage as patient was in previous bortezomib containing regimen.
Maintenance regimen maybe administered if patient does not progress while on study."
1712794|NCT01365546|Biological|human VWF/FVIII concentrate|intravenous infusion. Dose based on subject's individual invivo-recovery
1712795|NCT01365533|Drug|Roflumilast|Roflumilast 500 μg, one tablet once daily, orally
1712796|NCT01365533|Drug|Placebo|Placebo, one tablet once daily, orally
1712797|NCT01365520|Drug|turoctocog alfa|A single dose will be administered i.v. (into the vein). Subjects will be randomised to one of two lots of NNC 0155-0000-0004.
1712798|NCT01365507|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart injected subcutaneously (under the skin) once daily. Dose individually adjusted.
1712799|NCT01365494|Biological|Purified Chick Embryo Cell Inactivated Rabies Vaccine|Two group (Zagreb and Essen) will receive Rabipur vaccine IM according to either Zagreb or Essen schedules.
1712800|NCT01365481|Drug|Valsartan|week 1: 40/80/160 week 2-78: 80/160/320mg, oral, by mouth, once daily
1712801|NCT01365481|Drug|amlodipine|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
1712802|NCT01365481|Drug|Hydrochlorothiazide|added to valsartan after week 8 if the MSSBP and/or MSDBP was higher than 95th percentile for age, gender and height under the maintenance valsartan dose
1712803|NCT01365468|Drug|Everolimus (RAD001)|oral daily dosing of tablet starting with 2.5 mg
1712804|NCT01365455|Drug|secukinumab 150 mg|secukinumab (AIN457) 150mg or 300mg subcutaneous
1712805|NCT01365455|Drug|placebo to secukinumab 150 mg|Placebo to Match secukinumab (AIN457) 150mg or 300mg subcutaneous
1712806|NCT01365429|Device|XPS™ with Steen Solution™|The XPS™ System is an integrated cardiac bypass system comprised of various components such as a Maquet CardioHelp centrifugal pump (K102726), the HicoVariotherm Heater/Cooler, the Hamilton C2 ICU (intensive care unit) pressure- controlled ventilator (K092148), the perfusate gas monitors, and the display monitors. The XPS™ System is responsible for housing the organ for preservation, providing the normothermic environment, and perfusing the organ with the STEEN Solution™. Donor lungs that meet inclusion criteria are placed on the XPS™ and rewarmed and perfused with STEEN Solution™ and ventilated for 3-6 hours. If the lungs meet transplant suitability, they are cooled down and transplanted into a consented recipient that meet's trial criteria.
1712807|NCT01365403|Drug|RO4917838|Single oral dose, Day 1 of study period 1 and Day 16 of study period 2
1712808|NCT01365403|Drug|carbamazepine|multiple oral doses, Days 1-24 of study period 2
1712809|NCT01365390|Other|Data collection (Retrospective)|For the retrospective part of the study, the parent(s)/ legally acceptable representative(s) of the subjects will be interviewed to collect information on factors potentially related to risk for middle ear diseases. The medical records of the subjects will also be reviewed and all acute otitis media related problems that occurred during the last year prior to enrolment (for subjects aged 1 to < 6 years) or since birth (for subjects aged < 1 year) will be recorded in the electronic case report form.
1712810|NCT01365390|Other|Data collection (Prospective)|For the prospective part of the study, the enrolled subjects will be followed up for a period of 1 year starting from the consent date, during which the parent(s)/ legally acceptable representative(s) will be asked to bring the subject for a visit each time they notice symptoms of acute otitis media or respiratory tract infection in the subject. In case AOM is diagnosed by the investigator, detailed information on the signs, symptoms, severity, course and treatment will be recorded. The parent(s)/ legally acceptable representative(s) of the subjects will also be required to fill up a parental quality of life questionnaire and an Otitis Media-6 children's quality of life questionnaire.
1712811|NCT01365377|Other|booklet deliverance and use in the process of daily information|The brochure shows with text and pictures the day-living of the ICU ; Medical and para-medical staff and organization, the devices, complications and treatment
1712812|NCT01365364|Behavioral|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
1712813|NCT01365364|Behavioral|Aerobic Physical Exercise|All individuals were submitted to physical exercise reaching maximum effort
1712814|NCT01365351|Other|Growth hormone|Drug given by prescription
1712815|NCT01365338|Drug|Placebo|oral solution, single dose
1712816|NCT01365338|Drug|PF-04958242|oral solution, single dose; 0.075mg
1712817|NCT01365338|Drug|PF-04958242|oral solution, single dose; 0.15mg
1712818|NCT01365325|Other|handled echocardiography in home monitoring program|home monitoring with clinical evaluations and ECG every three months and echocardiography examinations at the 6th, 12th and 18th month
1712819|NCT01365325|Other|ecg and clinical evaluation in home monitoring program|home monitoring with clinical evaluations and ECG every three months
1712820|NCT01365312|Drug|Ethanol lock|Placement of 0.5 cc 70% ethanol, every 72 hours, for 15 minutes, into PICC lines randomized to ethanol intervention
1712821|NCT01365312|Drug|Heparinized saline|0.5 cc heparinized saline to be placed once every 72 hours for 15 minutes, in PICC lines randomized to placebo
1712823|NCT01365286|Drug|Placebo|Placebo b.i.d. for 5 days and Ivabradine 7,5 mg b.i.d. for 5 days (Placebo-Ivabradine)
1712824|NCT01365273|Device|Mepitel One|Dressing
1712825|NCT01365260|Device|MM-II|Single intraarticular (knee) injection of MM-II
1712826|NCT01365260|Device|DurolaneTM|Single intraarticular (knee) injection of DurolaneTM
1712827|NCT01365247|Behavioral|Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure|A manualized, twelve-week intervention applying cognitive-behavioral strategies and prolonged exposure (PE) techniques to address substance use and trauma related issues.
1712828|NCT01365247|Behavioral|Relapse Prevention Treatment|Relapse Prevention Treatment is a cognitive-behavioral skills training approach to initiating and maintaining substance use-related goals.
1712829|NCT01365247|Behavioral|Active Monitoring Control Group|Participants meet with study staff on a weekly basis for the self-monitoring of PTSD and SUD symptoms. Visits consists of self-report assessments, urine toxicology, and a brief check-in with staff to confirm general health and safety.
1712830|NCT01365234|Device|Pacing Lead|Implant and follow up of Model 20066 lead
1712831|NCT01365221|Drug|Prasugrel|Patients who have received 600 mg loading dose of clopidogrel will receive a reloading dose of 60 mg prasugrel
1712832|NCT01365221|Drug|Prasugrel|Patients who have not received a loading dose of clopidogrel will receive a 60 mg loading dose of prasugrel.
1712833|NCT01365208|Drug|Chemotherapy|platinum-based chemotherapy
1712834|NCT01365195|Drug|Placebo|Loading and Infusion: Saline at infusion rate calculated and adjusted for weight to match ketamine bolus-infusion rate
1712835|NCT01365195|Drug|Ketamine high-dose|Loading: 1 mg/Kg Infusion: 10 mcg/kg/min
1712836|NCT01365195|Drug|Ketamine low-dose|Loading: 0.5 mg/Kg Infusion: 5 mcg/kg/min
1712837|NCT01365182|Behavioral|BF+SUPPORT|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 group sessions of the Problem-Solving Therapy (teaching self-management skills).
1712838|NCT01365182|Behavioral|BF+PHONE|A session of biofeedback-assisted pelvic floor muscle exercises (PFME) plus 6 telephone sessions of the Problem-Solving Therapy (teaching self-management skills).
1956338|NCT02887209|Behavioral|CBT-I|"Cognitive behavioural therapy for insomnia (CBT-I; Edinger & Carney, 2008) is a standard 4-session cognitive behavioural therapy for insomnia administered biweekly in individual format. The first session involves presenting treatment rationale and introducing a behavioural treatment regimen consisting of a series of sleep habit parameters to follow, and determining a personalized time in bed prescription. The second session involves reviewing past-week sleep diary, discussing the role of cognitions in insomnia, and discussing constructive worrying techniques and the use of thought records. The third and fourth sessions are used to assist in adjusting time in bed prescriptions, to positively reinforce efforts, and to help problem-solve any problems they might have encountered."
1712855|NCT01365156|Procedure|Extraperitoneal laparoscopic lymphadenectomy (EPLND)|Laparoscopic surgical procedure to remove and examine lymph nodes in abdomen, 7-10 days before chemoradiation treatment
1712856|NCT01365156|Radiation|Chemoradiation|Radiation for 5 days in a row for 5 to 5½ weeks plus Cisplatin Chemotherapy cisplatin chemotherapy by vein over about 2 hours, 1 time every week for about 6 weeks.
1712857|NCT01365143|Procedure|Robotic Radical Prostatectomy|Robotic assisted radical prostatectomy
1712858|NCT01365143|Procedure|Open Radical Prostatectomy|Open radical prostatectomy
1712859|NCT01365130|Drug|jevtana|Cabazitaxel 25mg/m2, IV every 21 days until progression
1712860|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|15 subjects in a three-way crossover (three different doses of TI Inhalation Powder [one 20 U, two 20 U and one 40 U cartridges)
1712861|NCT01365117|Drug|Technosphere® Insulin Inhalation Powder|16 subjects in a four-way crossover (four different doses of TI Inhalation Powder [one 20 U, one 20 U plus one 10U, one 30 U (3 U per mg), one 30 U (4 U per mg cartridges)])
1714186|NCT01354353|Drug|LY2140023|Administered orally
1712862|NCT01365104|Drug|desferrioxamine|intravenous infusion at 10mg/kg/hr for a total of 6 hours at final infused doses of 60mg/kg.
1712863|NCT01365091|Drug|Saxagliptin/metformin fixed-dose combination (FDC)|Tablet, oral, 5 mg/500 mg FDC, once on Day 1 only, 1 day
1712864|NCT01365091|Drug|Saxagliptin|Tablet, oral, 5 mg, once on Day 1 only, 1 day
1712865|NCT01365091|Drug|Metformin extended-release (XR)|Tablet, oral, 500 mg, once on Day 1 only, 1 day
1712866|NCT01365091|Drug|Saxagliptin/Metformin FDC|Tablet, Oral, 5 mg/1000 mg FDC, once on Day 1 only, 1 day
1712867|NCT01365091|Drug|Metformin|Tablet, oral, 1000 mg, once on Day 1 only, 1 day
1712868|NCT01365078|Dietary Supplement|Echium oil (SDA-rich oil)|The echium oil will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the experimental period twice a day, i.e. one sachet at lunch and one sachet at dinner
1712869|NCT01365078|Dietary Supplement|high-oleic acid sunflower oil (HOSO) (low in SDA)|The HOSO will be provided in sachets containing 5 g of oil, and should be taken for six weeks during the control period twice a day, i.e. one sachet at lunch and one sachet at dinner
1712870|NCT01365065|Drug|Vorinostat|Vorinostat 400mg (4 x 100mg) orally daily for 14 days
1712871|NCT01365052|Drug|Naproxen sodium 440 mg/DPH 50 mg (BAY98-7111)|2 capsules each containing naproxen sodium 220 mg /diphenhydramine hydrochloride (DPH) 25 mg are taken orally with a full glass of water approximately 30 minutes prior to bedtime for 10 consecutive days
1712872|NCT01365052|Drug|Placebo|2 placebo capsules are taken orally with a full glass of water 30 minutes prior to bedtime for 10 consecutive days
1712873|NCT01365039|Device|Test, daily disposable contact lens|Test lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
1712874|NCT01365039|Device|SofLens daily disposable contact lens|Control lenses will be worn on a daily disposable wear basis. New study lenses will be dispensed at the Screening/Dispensing, 1-Month, and 2-Month Follow-up Visits in sufficient quantities to maintain a daily disposable wear modality.
1712875|NCT01365026|Behavioral|PVS: Programa de Vida Saludable|Lifestyle counseling and prescription
1712876|NCT01365013|Behavioral|DE-PLAN|structured group or individual educational sessions (4 to 5) on diet and physical activity, plus ongoing reminder contacts (e-mails, sms, etc) during 1 year
1712877|NCT01365013|Behavioral|Control group|Standard advice for lifestyle change
1712878|NCT01365000|Drug|NKTR118 Formulation 1|Oral dose, 25 mg
1712879|NCT01365000|Drug|NKTR118 Formulation 2|Oral dose, 25 mg
1712880|NCT01365000|Drug|NKTR118 Formulation 3|Oral dose, 25 mg
1712881|NCT01365000|Drug|NKTR118 Formulation 1a|Oral dose, 25 mg
1712882|NCT01365000|Drug|NKTR118 Formulation 3a|Oral dose, 25 mg
1712883|NCT01364987|Drug|ASP015K|oral
1712884|NCT01364987|Drug|Mycophenolate Mofetil|oral
1712885|NCT01364974|Drug|ASP015K|oral
1712886|NCT01364974|Drug|Placebo|oral
1712887|NCT01364961|Dietary Supplement|Resveratrol capsules|2 x 75 mg resveratrol each day, for 4 weeks
1712888|NCT01364948|Other|Coconut oil application|Four ml coconut oil application twice daily for first week
1712889|NCT01364948|Other|No oil application|Oil application was not done
1712890|NCT01364922|Drug|hydrocodone/acetaminophen extended release|
1712891|NCT01364922|Drug|Placebo|
1712892|NCT01364909|Other|Exercise|"The subjects will be given 2 x 30 minute sessions of exercise per day consisting of either passive, active, active assisted depending on level of sedation and stability of condition.
According to level of sedation and stability they may also perform sitting exercises"
1712893|NCT01364909|Other|Usual practice|These patients will not receive exercise early in their intensive care admission
1712894|NCT01364896|Procedure|Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples|"Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:
Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)
High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria
Anal cytology testing"
1712895|NCT01364883|Biological|Vaccination Schedule One|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
1712896|NCT01364883|Biological|Vaccination Schedule Two|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
1712897|NCT01364883|Biological|Vaccination Schedule Three|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
1712898|NCT01364883|Biological|Vaccination Schedule Four|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
1712899|NCT01364883|Biological|Vaccination Schedule Five|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
1712900|NCT01364883|Biological|Vaccination Schedule Six|Intramuscular injection of 5x10^10 vp of AdCh63 ME-TRAP, intramuscular injection of 2x10^8 pfu of MVA ME-TRAP
1712901|NCT01364883|Biological|Vaccination Schedule Seven|AdCh63 ME-TRAP prime D0, AdCh63 ME-TRAP boost W8, AdCh63 ME-TRAP boost W16, MVA ME-TRAP boost W24
1712945|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
1956361|NCT02880852|Drug|Belimumab|Belimumab will be provided as white uniform lyophilized cake in vials with unit dose strength of 400 mg/vial plus excipients (citric acid/sodium citrate/sucrose/polysorbate) for reconstitution in 4.8 milliliter sterile water for injection (SWFI). Belimumab will be administered as 10 mg/kg intravenous infusion for over 1 hour on Day 0.
1956363|NCT02879110|Dietary Supplement|Sulforaphane|Sulforaphane (SFN) is a compound within the isothiocyanate group of organosulfur compounds. It is obtained from cruciferous vegetables such as broccoli, Brussels sprouts or cabbages.
1712904|NCT01364857|Genetic|search for polymorphisms of RASA1 gene|Blood sample ( 5 mL) at tne inclusion of the child DNA extraction and genetic analysis of the 24 exons of RASA1 gene after specific consent
1712905|NCT01364844|Drug|DS-7423|oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
1712906|NCT01364831|Behavioral|Sleep extension|Athletic performance evaluated at baseline and following about 1.5 hours of sleep extension
1712907|NCT01364805|Drug|Intravenous Vitamin C|The first 5 study visits will all take place in the General Clinical Research Center (GCRC). During these visits you will receive IV doses of Vitamin C. The dose of Vitamin C will be started at 25 grams and may be increased up to 125 grams over a two week period. There may be changes in the amount of Vitamin C that you receive based on your blood test levels. The study staff will go over this in more detail with you. The amount of fluid you receive depends on the dose and can be from 2 1/3 cups to 5 cups.
1712908|NCT01364805|Drug|Gemcitabine|Participants receive dexamethasone 10 mg as pretreatment antiemetic; may be given ondansetron, granisetron, or dolasetron, per oncologist. Gemcitibane 1,000mg/m2 IV over 30 minutes Q 21 days. Cycle of treatment: infusions once weekly for 2 consecutive weeks followed by 1 week of rest to continue treatment schedule until they experience disease progression or unacceptable toxicity. CR, PR or SD: treatment will be continued for at least 6 cycles. Discontinuation of therapy may be considered if agreed upon by the participant and oncologist. Dose Modifications: If the patient experiences more than one toxicity, each requiring a dose reduction, follow the guidelines that give the largest dose reduction for the drug. Subsequent doses can be adjusted to as low as 500 mg/m2 for gemcitabine.
1712909|NCT01364792|Drug|Valaciclovir|4 times 2 grams valaciclovir per day, administrated orally, for seven days.
1712910|NCT01364740|Device|PMP-300E|Data collected from Level 3 device
1712911|NCT01364740|Device|In-lab PSG|Data collected from Type I In-Lab Polysomnography
1712912|NCT01364727|Drug|Amrubicin|35 mg/m2; IV on days 1-3 each 3 week cycle
1712913|NCT01364701|Drug|Sildenafil 100 mg|4 tablets for on demand use
1712914|NCT01364701|Drug|Tadalafil 20 mg|4 tablets on demand
1712915|NCT01364701|Drug|Combination half of maximal dose for sildenafil & tadalafil|4 tablets on demand
1712916|NCT01364688|Drug|oral alfacalcidol|Oral alfacalcidol 0.5 microgram per day
1712917|NCT01364688|Drug|no drug|no drug
1712918|NCT01364675|Drug|Metformin+Enalapril+Simvastatin|Poly-pill - composed of Metformin (500 mg), Enalapril (10 mg) and Simvastatin (10 mg) in single tablet given once daily after dinner for 4 years
1712919|NCT01364675|Drug|Placebo tablet|Identical Placebo Tablet
1712920|NCT01364662|Drug|SPN-810|administered orally
1712921|NCT01364662|Drug|Placebo|administered orally
1712922|NCT01364649|Drug|Vortioxetine|Vortioxetine tablets
1712923|NCT01364649|Drug|Escitalopram|Escitalopram tablets
1712924|NCT01364649|Drug|Placebo|Vortioxetine Placebo-matching capsules
1712925|NCT01364623|Drug|Low dose testosterone nasal gel|Single dose administration
1712926|NCT01364623|Drug|Medium dose testosterone nasal gel|Single dose Administration
1712927|NCT01364623|Drug|High dose testosterone nasal gel|single dose Administration
1712928|NCT01364623|Drug|Medium dose testosterone nasal gel|multiple dose administration
1712929|NCT01364610|Device|Bravo|Bravo pH Monitoring System sited manometrically.
1712930|NCT01364610|Device|Standard Care|Nasally passed pH catheter sited by manometry, accompanied by battery powered data logger. Participant activated event marker in response to symptoms, meals and body position changes.
1956364|NCT02879110|Other|Placebo|Placebo tablet is composed of starch.
1712934|NCT01364571|Biological|SA4Ag vaccine low dose|Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
1712935|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
1712936|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
1712937|NCT01364571|Biological|SA4Ag vaccine mid dose|Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
1712938|NCT01364571|Procedure|Blood sample|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
1712939|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
1712940|NCT01364571|Biological|SA4Ag vaccine high dose|Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
1712941|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
1712942|NCT01364571|Procedure|Colonization swab sample|Colonization swabs will be collected from all subjects at various time points throughout the study.
1712943|NCT01364571|Biological|Placebo|Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
1712944|NCT01364571|Procedure|Blood draw|Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
1712946|NCT01364558|Drug|Diazepam|Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
1712947|NCT01364558|Drug|Diazepam|IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
1712948|NCT01364545|Dietary Supplement|Ketone ester drink|Ketone drink - milligram per kilogram dose, consumed three times daily (at meal times)
1712949|NCT01364545|Dietary Supplement|Placebo (carbohydrate containing) drink|Placebo drink - containing carbohydrates, matched in calories to ketone, consumed three times daily
1712950|NCT01364532|Procedure|Transulnar arterial access|Transulnar arterial access in coronary angiography, ad-hoc or elective PCI
1712951|NCT01364532|Procedure|Transradial arterial access|Transradial arterial access for coronary angiography,ad-hoc or elective PCI
1712952|NCT01364519|Drug|Fluticasone Propionate|Dry powder for inhalation, Single Dose, 500mcg
1712953|NCT01364519|Drug|Placebo for Fluticasone Propionate|Dry powder for inhalation, Single Dose, placebo
1712954|NCT01364506|Other|Water aerobic exercise|"The hydrotherapy program of Prevedel et al.14 was used. One-hour sessions, led by a physiotherapist under the supervision of an obstetrician, were held three times a week in an indoor swimming-pool heated at 28oC-32oC, and consisted of exercises of moderate intensity (60-70% of maximum heart rate). Subgroups of up to 10 subjects participated in each session. Sessions were offered at different times of the day (morning, afternoon, and evening).
The exercises included 5 phases: stretching, warm up, endurance training, strength training and relaxation with breathing exercises, in accordance with the recommendations of ACOG11."
1712955|NCT01364493|Drug|Trastuzumab+Capecitabine+Oxaliplatin|"Trastuzumab will be administered at a loading dose of 8 mg/kg (on day 1) followed by 6mg/kg i.v. infusion every 3 weeks.
Capecitabine 2000mg/m2d, d1-14; q3w, Trastuzumab and capecitabine are to be continued until disease progression or intolerable toxicity.
Oxaliplatin 130mg/m2 d1; q3w, 6 cycles"
1712956|NCT01364480|Device|Implantation of NeuroPort Arrays in the motor cortex|Two Blackrock Microsystems NeuroPort Arrays will be implanted in the motor cortex of study participants.
1712957|NCT01364467|Drug|Placebo|Children aged 7-11 years old will receive placebo 200 mg TID, while children older than 12 will receive Placebo 400 mg TID.
1712958|NCT01364467|Drug|Guaifenesin|Children aged 7-11 years old will receive guaifenesin 200 mg TID, while children older than 12 will receive guaifenesin 400 mg TID.
1712959|NCT01364454|Other|Eligible patients' paper-based reminder|Providing to the general practitioners every four months a list of their patients who are eligible for colorectal cancer screening but did not proceed yet and were not excluded for medical reason
1712960|NCT01364441|Drug|ONO-2952|3 mg to 800 mg at a single dose; 10 mg and 200 mg for food effect study
1712961|NCT01364441|Drug|Placebo|Placebo dosed in the same manner as ONO-2952
1712962|NCT01364428|Drug|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.
Dose was individually adjusted."
1712963|NCT01364428|Drug|insulin degludec|"Injected subcutaneously (under the skin) once daily, in combination with unchanged pre-trial oral anti-diabetic drug (OAD) treatment.
Dose was individually adjusted."
1712964|NCT01364415|Drug|Pasireotide LAR|
1712965|NCT01364402|Drug|Epoetin beta|50,000U intravenously
1712966|NCT01364402|Drug|Saline 0.9%|normal saline intravenously
1712967|NCT01364389|Drug|AIN457|3 mg/kg
1712968|NCT01364389|Drug|ACZ885|3 mg/kg
1712969|NCT01364389|Drug|Prednisone|20 mg
1712970|NCT01364389|Drug|Placebo|Matching placebo to AIN457, ACZ885 and prednisone
1712971|NCT01364376|Drug|S-1; Oxaliplatin; 5-Fu; Leucovorin Calcium|"FOLFOX:
oxaliplatin 130mg/m2 on day 1, CF 400mg/m2 on day 1, 5-Fu 400mg/m2 on day 1; 5-FU 2400 mg/m2 46hr civ regimen repeated every 3 weeks Pre-operative chemotherapy: 2-4 cycles and peri-operative chemotherapy consist of 6 cycles
SOX:
oxaliplatin 130mg/m2 on day 1, S-1 for 14 days regimen repeated every 3 weeks Pre-chemotherapy: 2-4 cycles, totally 6 cycles of perioperative chemotherapy"
1712972|NCT01364363|Procedure|Allogeneic transplantation|Allogeneic transplantation with matched unrelated donors
1712973|NCT01364350|Other|standard of care in general clinical practice|Participants consenting to receive study-provided care may be treated with metformin, insulin, statin, and ace-inhibitor, as needed for glycemic control and for comorbid conditions.
1712974|NCT01364337|Other|DASH diet|DASH diet: A diet rich in whole grain, fruit and vegetable, low-fat dairy products, white meat and nuts; and lower of total fat and saturated fat.
1712975|NCT01364337|Other|lower carbohydrate DASH diet|lower carbohydrate DASH diet: A DASH diet with lower carbohydrate percentage
1712976|NCT01364324|Drug|standard first line anti-TB drugs|We will perform pharmacokinetic study in gastrectomy and non-gastrectomy group, to evaluate the effect of gastrectomy on pharmacokinetic profile of first-line anti-TB drugs in patients with TB
1712977|NCT01364311|Dietary Supplement|Vitamac® Tag and Nacht capsules|"Vitamac® Tag und Nacht Kapseln: Dosage 1 capsule Vitamac® Tag per day ingested in the morning, 1 capsule Vitamac® Nacht per day ingested in the evening.
Vitamac® Tag: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, ginkgo biloba 10mg, Flavinoids 25mg, Fishoil 300mg, administered for 12 weeks Vitamac® Nacht: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selen 20µg, Ginkgo Biloba 10mg, Flavinoids 25mg, Alpha Lipon acid 150mg), administered for 12 weeks"
1712978|NCT01364298|Drug|Gabapentin/B-complex|Gabapentin/B-complex (Gavindo®) tablet will be administered orally at an initial dose of 300 milligram per day (mg/day) on Day 1, followed by 600 mg/day (one 300 milligram [mg] tablet every 12-hour) on Day 2, then 900 mg/day (one 300 mg tablet every 8-hour) on Day 7, then 1800 mg/day (two 300 mg tablets every 8-hour) on Day 21, then 2700 mg/day (three 300 mg tablets every 8-hour) on Day 35, and finally 3600 mg/day (four 300 mg tablets every 8-hour) on Days 56 and 84. Maximum dose allowed will be 3600 mg/day. The total duration of treatment will be 84 days (12 weeks).
1712979|NCT01364298|Drug|Pregabalin|Pregabalin (Lyrica®) capsule will be administered orally at an initial dose of 150 mg/day (one 75 mg capsule every 12-hour) from Day 1 to 7, followed by 300 mg/day (one 150 mg capsule every 12-hour) on Day 7, then 600 mg/day (two 150 mg capsule every 12-hour) on Days 21, 35, 56 and 84. Maximum dose allowed will be 600 mg/day. The total duration of treatment will be 84 days (12 weeks).
1712980|NCT01364259|Drug|Amifostine|Amifostine and CyberKnife stereotactic radiosurgery
1712981|NCT01364259|Procedure|CyberKnife stereotactic radiosurgery|CyberKnife stereotactic radiosurgery
1713079|NCT01363388|Drug|CCX168|BID for 84 days
1712982|NCT01364246|Biological|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
1712985|NCT01364220|Drug|Rosuvastatin|Rosuvastatin 20mg tablet, once daily, for 14 days
1712986|NCT01364220|Other|Placebo tablet|Placebo tablet, once daily, for 14 days
1712987|NCT01364207|Other|Caffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
1712988|NCT01364207|Other|Decaffeinated Coffee|Participants will drink one 8 oz cup in the morning hours. Participants have 15 minutes to drink the coffee but may do so in less time.
1712989|NCT01364194|Drug|0.25% Bupivacaine|Periarticular injection with 20 ml of 0.25% bupivacaine before wound closure.
1712990|NCT01364194|Drug|0.9% normal saline|Periarticular injection with 20 ml of 0.9% normal saline before wound closure.
1712991|NCT01364181|Drug|Udenafil|Udenafil 50mg qd po
1712992|NCT01364155|Drug|LIM-0705|
1712993|NCT01364155|Drug|Placebo capsules|
1712994|NCT01364142|Procedure|endobronchial blocker|After intubation of endotracheal tube, the Uniblocker® was inserted into the endotracheal tube and advanced step by step with inflation of the blocker balloon until the peak inspiratory pressure dropped abruptly.
1712995|NCT01364129|Procedure|Ophthalmic Telemedicine|Participants receiving the intervention have digital images of their retina captured with a non-mydriatic camera. The images are then sent to Devers Eye Institute for review and report generation.
1712996|NCT01364103|Other|volume expansion|fluid loading of 10 mL/kg colloid (voluven)
1712999|NCT01364077|Drug|Ivabradine|Ivabradine 5 mg BID titrated to 7.5 mg if tolerated
1713000|NCT01364077|Drug|Placebo|Matched placebo
1713001|NCT01364064|Drug|TMZ|Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
1713002|NCT01364051|Drug|Cediranib Maleate|Given PO
1713003|NCT01364051|Other|Laboratory Biomarker Analysis|Correlative studies
1713004|NCT01364051|Other|Pharmacological Study|Correlative studies
1713005|NCT01364051|Drug|Selumetinib|Given PO
1713006|NCT01364025|Procedure|uterosacral ligament suspension colpopexy bilateral|Uterosacral ligament suspension colpopexy bilateral
1713007|NCT01364012|Drug|Bevacizumab|Bevacizumab will be administered at 15 mg/kg IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
1713008|NCT01364012|Drug|Carboplatin|Carboplatin will be administered at area under the plasma concentration-time curve (AUC) 6.0 IV on Day 1 of each 3-week cycle, up to 6 cycles.
1713009|NCT01364012|Drug|Paclitaxel|Paclitaxel will be administered at 175 milligrams per square meter (mg/m^2) IV on Day 1 of each 3-week cycle, up to 6 cycles.
1713010|NCT01364012|Drug|Placebo|Bevacizumab matching placebo will be administered IV on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity.
1713011|NCT01363999|Drug|atorvastatin|single dose of atorvastatin on day 1
1713012|NCT01363999|Drug|dalcetrapib|single dose of dalcetrapib on day 1
1713013|NCT01363986|Drug|trastuzumab [Herceptin]|Initial loading dose of 4 mg/kg i.v. infusion, followed by weekly doses of 2 mg/kg for up to 18 weeks.
1713014|NCT01363973|Device|VITALSTIM transcutaneous electrical stimulation|
1713015|NCT01363947|Drug|DNIB0600A|Several dose levels will be evaluated for DNIB0600A administered via IV infusion on Day 1 of each 21-day cycle until disease progression.
1713016|NCT01363934|Drug|GC1113|"Each Group volunteers (n=10) will be administered GC1113 0.3ug/kg to 5ug/kg or Placebo (GC1113:placebo=8:2) once intravenously.
Each Group volunteers (n=10) will be administered GC1113 1ug/kg to 8ug/kg or Placebo (GC1113:placebo=8:2) once subcutaneously."
1713017|NCT01363934|Drug|Darbepoetin alfa|Each Group volunteers (n=8) will be administered Darbepoetin alfa by IV or SC.
1713018|NCT01363921|Device|HCO 1100|Dialysis treatment with HCO1100
1713019|NCT01363908|Drug|SPD602|
1713020|NCT01363895|Procedure|Percutaneous closure of LAA|Percutaneous closure of LAA
1713021|NCT01363895|Procedure|Catheter ablation of AF|Catheter ablation of AF
1713022|NCT01363882|Other|Sleep study-guided adjustment of NIV|Sleep studies will be performed at baseline, within 2 weeks to initially titrate NIV, and at 1, 3 and 6 months to assess NIV performance and adjust it as necessary based on oxygenation and ventilation parameters.
1713023|NCT01363882|Other|Standard initiation of NIV|NIV will be initiated and managed as per current standard of practice. Sleep studies will be performed at baseline, 2 weeks, 1, 3 and 6 months to gather data but will not influence NIV management. NIV will be adjusted by a respiratory therapist or the subject's primary physician per waking symptoms.
1713024|NCT01363869|Dietary Supplement|green tea extracts 2 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.
Total dosage is 2 grams per day."
1713025|NCT01363869|Dietary Supplement|green tea extracts 4 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.
Total dosage is 4 grams per day."
1713026|NCT01363869|Dietary Supplement|green tea extracts 6 gm/day|"Green tea extracts capsule (1 gm per capsule), taken after meal, twice daily for 14 days.
Total dosage is 6 grams per day."
1713027|NCT01363843|Drug|FOLFOX6|FOLFOX6
1713028|NCT01363843|Radiation|RT with concurrent chemotherapy|IMRT 50.4Gy with chemotherapy
1713029|NCT01363843|Procedure|Surgery|
1713030|NCT01363830|Behavioral|Two-Week Post-Operative Restriction|Surgeon recommends the patient restrict bending, lifting, and twisting for two-weeks following discectomy.
1713031|NCT01363830|Behavioral|Six-Week Post-Operative Restriction|Surgeon recommends patient restrict bending, lifting, and twisting for six-weeks following discectomy.
1713032|NCT01363817|Drug|BMS-906024|
1713033|NCT01363817|Drug|Dexamethasone|
1713080|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole , carbon fiber plate; general shoe and rocker sole shoe
1714187|NCT01354353|Drug|Aripiprazole|Administered orally
1713034|NCT01363804|Drug|Tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
1713035|NCT01363791|Other|Dietary fructose|Oral dietary fructose in free (unbound) form in isocaloric exchange for other non-fructose carbohydrate sources (isocaloric trials) or added to a control diet as a source of excess energy (hypercaloric trials).
1713036|NCT01363778|Drug|tivozanib|Tivozanib is a novel and potent pan-vascular endothelial growth factor (VEGF) receptor (VEGFR) tyrosine kinase inhibitor with potent activity against all 3 VEGFRs (VEGFR-1, -2, and -3). In nonclinical models and studies performed in humans, tivozanib has shown strong antiangiogenesis and antitumor activity.
1713037|NCT01363765|Other|Xpert MTB/Rif|Automatized RT-PCR for the detection of Mycobacterium tuberculosis, the agent of TB, in sputum samples
1713038|NCT01363765|Other|Smear microscopy|Sputum smears arriving in the laboratory during the observation period will be submitted to the classic routine smear staining. This would be the non-intervention (control) arm.
1713039|NCT01363752|Drug|Advagraf|oral
1713040|NCT01363752|Drug|Mycophenolate Mofetil|oral
1713041|NCT01363752|Drug|Sirolimus|oral
1713042|NCT01363752|Drug|Corticosteroids|i.v. and oral
1713043|NCT01363713|Drug|DE-114 ophthalmic solution|
1713044|NCT01363700|Drug|DE-114 ophthalmic solution|
1713045|NCT01363700|Drug|Placebo ophthalmic solution|
1713046|NCT01363700|Drug|Olopatadine Hydrochloride 0.1% Ophthalmic Solution|
1713047|NCT01363687|Device|remote ischemic postconditioning|Remote ischemic postconditioning consists of three 5-min cycles of upper limb ischemia, which was induced by an automated cuff-inflator placed on the upper limb free of arteriovenous fistula and inflated to 250 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
1713048|NCT01363674|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
1713049|NCT01363661|Drug|Coruno|Molsidomine 16 mg tablet, per os, once a day
1713050|NCT01363661|Drug|Placebo|Placebo (16 mg tablet, per os; once-daily)
1713051|NCT01363648|Drug|choline alfoscerate|Participants were randomly assigned to twice-daily doses of 400mg choline alphoscerate (alpha-glyceryl phosphoryl choline, Gliatilin®)
1713052|NCT01363648|Drug|placebo (for choline alphoscerate)|Pill manufactured to mimic choline alfoscerate 400mg tablet
1713053|NCT01363609|Drug|Liraglutide treatment 12 weeks|liraglutide will be started with a titration period of 2 weeks: week 1 0.6mg once daily, week 2 1.2mg once daily. If well tolerated, treatment will be continued for 10 more weeks in dosage of 1.8mg once daily
1713054|NCT01363609|Drug|insulin glargine treatment|Insulin glargine treatment consist a treatment period of 12 weeks. Treatment will start with a dosage of 10 IU once daily. Patient will self-titrate the insulin glargine dosage based on self-monitored fasting blood glucose (FBG) concentrations for the previous 3 days using the following guideline: If FBG levels are above 5.6 mmol/L (100-153 mg/dL) on 3 consecutive mornings, the daily dose is to be increased by 2 IU/day. If hypoglycemia documented by glucose concentration < 3.3 mmol/L (60 mg/dL) or requiring assistance occurs without an easily identifiable reason (skipped meal, excessive physical activity), the daily dose is to be downregulated, with -2 IU/day
1713055|NCT01363609|Drug|GLP-1 receptor antagonist|Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min. This will only be during one of the visit for the healthy lean controls and the T2DM group, and during two visits in the group with obesity planned for gastric bypass surgery
1713056|NCT01363596|Other|Creighton Model System in conjunction with Natural Procreative Technology (NPT)|Patients will learn the Creighton Model System to chart their fertility biomarkers, and this information will then be used by their physician in conjunction with Natural Procreative Technology (NPT) to evaluated and treat infertility or history of spontaneous abortion.
1713057|NCT01363583|Drug|epoprostenol versus normal saline|0.5 ng/kilogram/minute during 4 days
1713058|NCT01363583|Drug|normal saline|0.5-1.5 ml/hour during 4 days
1713059|NCT01363570|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
1713060|NCT01363557|Other|whole brain radiotherapy|External beam RT using a total dose of 30 Gy with ten daily fractions of 3.0 Gy given 5 days per week over 2 weeks + Gefitinib 250 mg/day
1713061|NCT01363557|Drug|Gefitinib (IRESSA)|250 mg/day
1713062|NCT01363544|Other|Neurofeedback|30 sessions of theta/beta neurofeedback within 10 weeks.
1713063|NCT01363544|Behavioral|Exercise|30 sessions of individual sports training during 10 weeks.
1713064|NCT01363544|Drug|methylphenidate|The medication treatment is based on the MTA study and includes methylphenidate dosages of 5, 10, 15 (only for children with a weight below 25 kg) and 20 mg (only for children with a weight above 25 kg. The optimum dose will be determined by a double-blind placebo-controlled trial.
1713065|NCT01363531|Other|Antibiotic prescription strategies|The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.
1713066|NCT01363505|Device|BARD® Intra-abdominal Pressure monitor|monitor linked to foley catheter that is able to measure pressure inside bladder
1713067|NCT01363492|Biological|Replagal (agalsidase alfa)|0.2 mg/kg administered over 40 minutes every other week (EOW)
1713071|NCT01363466|Procedure|hysterectomy|
1713072|NCT01363440|Drug|Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)|
1713073|NCT01363440|Procedure|Macular Laser Photocoagulation|Laser therapy
1713074|NCT01363414|Drug|0.18% sodium hyaluronate|one drop of preservative-free, hypotonic 0.18% sodium hyaluronate in one eye
1713075|NCT01363414|Drug|0.9% sodium chloride solution|one drop of sterile 0.9% sodium chloride solution in the other eye
1713076|NCT01363401|Biological|HYNR-CS inj|Intrathecal injection with 1ml/10kg of body weight at an interval of 26 days.
1713077|NCT01363401|Other|Control group|No treatment of HYNR-CS inj
1713078|NCT01363388|Drug|Placebo|BID for 84 days
1713081|NCT01363375|Procedure|Foot orthosis, Footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
1713082|NCT01363375|Procedure|Foot orthosis, footwear|flat insole, total contact insole, carbon fiber plate; general shoe and rocker sole shoe
1713083|NCT01363362|Procedure|Selective Laser Trabeculoplasty|360° selective laser trabeculoplasty, 100 non-overlapping spots, energy 0,5-1,2 mJ
1713084|NCT01363349|Drug|CYP-1020|CYP-1020 (formerly known as BL-1020) is an orally available new chemical entity.
1713085|NCT01363349|Drug|Risperidone|
1713086|NCT01363336|Drug|Nifedipine (Adalat CR, BAYA1040)|patients who are administrated with Adalat CR for hypertension
1713087|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 1
1713088|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 2
1713089|NCT01363323|Drug|Methylnaltrexone (MNTX)|Dose 3
1713090|NCT01363323|Drug|Placebo|
1713091|NCT01363323|Drug|Moxifloxacin|
1713092|NCT01363310|Drug|Quetiapine XR|Dosage form: tablets Day 1-2: 50 mg Day 3-7: 150 mg Day 8-57: either 150 or 300 mg/day (flexible)
1713093|NCT01363310|Drug|Escitalopram|Dosage form: capsules Day 1-7: 10 mg Day 8-57: 10 or 20 mg/day (flexible)
1713094|NCT01363297|Drug|Inotuzumab Ozogamicin|"Part 1: Administered intravenously as 2 - 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total dose per cycle 0.8 mg/m^2 to 2.0 mg/m^2.
Part 2 Expansion and Part 3 Phase 2: Administered intravenously as 3 weekly doses over a 28-day cycle for a maximum of 6 cycles. Total initial dose per cycle 1.8 mg/m^2."
1713096|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
1713097|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
1713098|NCT01363271|Drug|Linezolid|IV and oral forms of linezolid are identified through a pre-specified list of National Drug Codes (NDCs).
1713099|NCT01363271|Drug|Vancomycin|IV form of vancomycin is identified through a pre-specified list of National Drug Codes (NDCs).
1713102|NCT01363245|Behavioral|Telephone Counseling|Telephone counseling: 7 calls over 6 weeks
1713103|NCT01363245|Behavioral|Fax-to-quit|referral to state smoking cessation 'quitline' for counseling - 1 call over 2 weeks
1713104|NCT01363232|Drug|BKM120 + MEK162|
1713105|NCT01363206|Biological|Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF)|GM-CSF will be administered subcutaneously daily for 14 days in a dose of 125 µg/m2 beginning on D1 of each 21-day cycle for 8 cycles until month 6. Maintenance therapy will begin at month 6 and will consist 14 days of GM-CSF repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
1713106|NCT01363206|Biological|Ipilimumab|Patients will be treated with 4 courses of ipilimumab administered every 3 weeks intravenously in a dose of 10 mg/kg, with appropriate stopping/de-escalation rules. Maintenance therapy will begin at month 6 and will consist of ipilimumab in the same dose administered at the end of cycle 4 repeated every 3 months for up to 2 years or until disease progression, whichever occurs first.
1713107|NCT01363193|Drug|Lean Body Weight-based heparin dose|"For patients who meet the inclusion criteria including body mass index of 30 and greater (and do not have any exclusion criteria), will have intravenous weight-based heparin (unfractionated heparin) dose based on their Lean body weight.
Lean Body Weight is based on the formula by Janmahasatian et al. 2005. Calculated by a computer program; Male = [9270 x weight (kg)] / [6680+216 x BMI] Female = [9270 x weight (kg)] / [8780+244 x BMI]"
1713108|NCT01363180|Behavioral|Trier Social Stress Test (TSST)|The TSST is a standardized psychological stress challenge where a participant performs a speech and mental math task in front of 3 unfamiliar individuals, in order to evoke an HPA axis stress response in a laboratory setting.
1713109|NCT01363180|Other|No stress condition|
1713110|NCT01363167|Dietary Supplement|400 IU Cholecalciferol- Vitamin D Daily|Infants who are defined as vitamin D deficient at birth will be randomized to receive either 400 IU vitamin D/day or placebo daily until term age is reached.
1713111|NCT01363154|Other|Mozart K448|Subjects will receive auditory stimulation by exposure to Mozart's Sonata for Two Pianos in D Major, K448.
1713112|NCT01363154|Other|Beethoven's Für Elise|Subjects will receive auditory stimulation by exposure to Beethoven's Für Elise.
1713113|NCT01363154|Other|No music exposure|Subject's will not receive an intervention and will therefore, not receive auditory stimulation and/or exposure to music.
1713114|NCT01363141|Other|Regular AGE Diet|Regular AGE Diet
1713115|NCT01363141|Other|Low AGE Diet|One year reduction in dietary AGE intake.
1713116|NCT01363128|Drug|Cyclophosphamide|300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses on Days 1,2,3 (total dose 1800 mg/m2) for courses 1,3,5,7.
1713117|NCT01363128|Drug|Mesna|600 mg/m^2 by vein over continuous infusion daily for 24 hours, starting approximately 1 hour prior to Cyclophosphamide and completing by approximately 12 hours after last dose of Cyclophosphamide for courses 1,3,5,7.
1713118|NCT01363128|Drug|Doxorubicin|50 mg/m^2 by vein over 24 hours on Day 4 via central venous catheter after last dose of Cyclophosphamide given for courses 1,3,5,7.
1713119|NCT01363128|Drug|Vincristine|2 mg by vein on Day 4 and Day 11 for courses 1,3,5,7.
1713120|NCT01363128|Drug|Dexamethasone|40 mg by vein or mouth daily on Days 1 - 4 and Days 11 - 14 for courses 1,3,5,7.
1713121|NCT01363128|Drug|Ofatumumab|"2000 mg by vein on day 1 and 11 +/- 2 days for courses 1 and 3. (Ofatumumab given at dose of 300 mg on day 1 of cycle 1. Subsequent infusions given at dose of 2000 mg).
2000 mg by vein on Days 1 and 8 for courses 2 and 4."
1713122|NCT01363128|Drug|Methotrexate|"12 mg intrathecally (6 mg via Ommaya reservoir) on Day 2 of courses 1,3,5,7.
200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours on Day 1 of courses 2,4,6,8."
1713123|NCT01363128|Drug|Cytarabine|"100 mg intrathecally on Day 7 for courses 1,3,5,7.
3 g/m^2 by vein over 2 hours every 12 hours for 4 doses on Days 2 and 3 for courses 2,4,6,8."
1713124|NCT01363128|Drug|Pegfilgrastim|Pegfilgrastim 6 mg as a one time dose or filgrastim (G-CSF) 10 mcg/kg (rounded) subcutaneously daily (or 5 mcg /kg twice daily) until post-nadir granulocytes greater than or equal to 1.0 x 109/L.
1713125|NCT01363128|Drug|Filgrastim|Pegfilgrastim 6 mg as a one time dose or filgrastim (G-CSF) 10 mcg/kg (rounded) subcutaneously daily (or 5 mcg /kg twice daily) until post-nadir granulocytes greater than or equal to 1.0 x 109/L.
1713126|NCT01363115|Dietary Supplement|Orange Juice fortified with Calcium and Vitamin D|Three 240 mL glasses of orange juice fortified with 350 mg Ca and 100 IU of D per serving
1713127|NCT01363115|Dietary Supplement|Orange juice without Ca or VitD|Three 240 mL glasses of orange juice without Ca or VitD
1713128|NCT01363115|Behavioral|Nutritional Counseling|Individual and group nutritional counseling by a registered dietitian
1713130|NCT01363089|Drug|Ketorolac tromethamine|30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
1713131|NCT01363089|Drug|Oxymetazoline hydrochloride|Single intranasal dose of oxymetazoline hydrochloride (Afrazine®) (3 sprays of a 0.05% solution into each nostril) followed 30 minutes later by 30 mg of intranasal ketorolac tromethamine (one 100 µL spray into each nostril of a 15%, pH 7.2 solution)
1713132|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 15 mg ketorolac tromethamine for subjects weighing <50 kg.
1713133|NCT01363076|Drug|Ketorolac Tromethamine|Single IN dose of 30 mg ketorolac tromethamine for subjects weighing ≥50 kg.
1713134|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine with a lidocaine hydrochloride free formulation in one nostril and one dose of 15 mg ketorolac tromethamine containing 6% lidocaine hydrochloride in the other nostril
1713135|NCT01363063|Drug|Ketorolac tromethamine|One dose of 15 mg ketorolac tromethamine containing 0% lidocaine hydrochloride into one nostril and either placebo or a single intranasal dose of 15 mg Ketorolac tromethamine containing 0%, 4% or 6% lidocaine hydrochloride into the other nostril
1713136|NCT01363050|Drug|Ketorolac tromethamine|Subjects received intranasal ketorolac tromethamine (30 mg) three times daily (t.i.d.) for three days (seven doses in total). Doses were administered every eight hours.
1713137|NCT01363037|Drug|Dapivirine Vaginal Ring|dosage form: dapivirine vaginal ring dosage:25 mg frequency:continuous use duration:28 days
1713138|NCT01363037|Drug|Maraviroc Vaginal Ring|dosage form: maraviroc vaginal ring dosage:100 mg frequency:continuous use duration:28 days
1713139|NCT01363037|Other|Placebo Vaginal Ring|dosage form: placebo vaginal ring dosage:N/A frequency:continuous use duration:28 days
1713140|NCT01363037|Drug|Dapivirine-Maraviroc Vaginal Ring|dosage form: combination vaginal ring dosage:25 mg dapivirine + 100 mg maraviroc frequency:continuous use duration:28 days
1713141|NCT01363024|Drug|MFGR1877S|Intravenous escalating dose
1713142|NCT01363011|Drug|E/C/F/TDF|E/C/F/TDF (150/150/200/300 mg) STR administered orally once daily
1713143|NCT01363011|Drug|COBI|COBI 150 mg tablet administered with food orally once daily
1713144|NCT01363011|Drug|ATV|ATV 300 mg tablet administered orally once daily
1713145|NCT01363011|Drug|DRV|DRV 800 mg tablet administered orally once daily
1713146|NCT01363011|Drug|NRTI|Participants will receive 2 investigator-selected NRTIs, which may include abacavir (ABC), lamivudine (3TC)/zidovudine (ZDV), didanosine (DDI), emtricitabine (FTC), ABC/3TC, 3TC, tenofovir disoproxil fumarate (TDF), or FTC/TDF, administered according to prescribing information.
1713147|NCT01362998|Drug|Preservative free morphine|3mg given epidurally during the Cesarean section.
1713148|NCT01362998|Drug|Fentanyl|An infusion of epidural fentanyl started during the Cesarean section. It will be given on a patient controlled analgesia basis, with a basal rate of 60 micrograms, a demand dose of 16 micrograms, and a lockout of 15 mins.
1713149|NCT01362959|Drug|Transdermal nicotine patch|The test product is a transdermal nicotine patch. The dosage of the test product depends on the amount of cigarettes used by a specific patient (21 or more or less than 21) delivering 21 or 14 mg nicotine/24 hrs. During the study period of thirty (30) days a patch will be applicated daily.
1713150|NCT01362959|Other|Cutaneous patch, containing no active substances|During the study period of thirty (30) days, the control product will be applicated daily.
1713151|NCT01362946|Behavioral|Reward-Emphasized Treatment|Intensive behavioral treatment delivered in a summer camp setting, with reward components emphasized and punishment components de-emphasized
1713152|NCT01362946|Behavioral|Standard Treatment|Intensive behavioral treatment delivered in a summer camp setting, with rewards and punishment equally emphasized.
1713153|NCT01362933|Procedure|VTE treatment in cancer patient description|proportion of patients treated for evolutive VTE according to international recommendations
1713154|NCT01362907|Device|Delefilcon A contact lens|Investigational, silicone hydrogel, single vision, soft contact lens for daily disposable wear
1713155|NCT01362907|Device|Etafilcon A contact lens|Commercially marketed, HEMA-based, single vision, soft contact lens for daily disposable wear
1713156|NCT01362894|Device|nelfilcon A contact lens|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear.
1713157|NCT01362894|Device|etafilcon A contact lens|Commercially marketed, etafilcon A, toric, soft contact lens for daily disposable wear.
1713158|NCT01362868|Device|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
1713159|NCT01362829|Other|Determined by intended physician|We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
1714802|NCT01349725|Drug|Placebo|Oral; matching placebo
1956372|NCT02875834|Drug|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times per day, in the first 48-hour of the study for all patients (48-hour open label initial phase)
1956373|NCT02875834|Drug|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally once daily for 28 days after the first 48-hour open label initial phase.
1713165|NCT01362777|Behavioral|In-patient rehabilitation|"Individualized exercise training (IET):
Duration : 24 sessions during 4 weeks
IET session (2h) contains:
15' start warming up muscles
30' muscle strengthening exercise for arms and abdominal muscles
45' individualized cycle ergometer endurance training to the ventilatory threshold heart rate measured on the cardiopulmonary exercise test.
15' stretching
15' postural, movement and balance exercises IET session was controlled by a professional instructor using heart rate monitoring. Duration, intensity and attendance were recorded in a logbook.
Educational activities (20h): the 8 themes are comparable to comparator arm. Dietary management: was performed by dietician to ensure that energy intakes are adjusted to energy expenditure. No restrictive diet was prescribe."
1713166|NCT01362777|Behavioral|Educational activities alone|"Educational activities alone contains 10 sessions lasting 1:00 with 8 themes :
Physiological mechanisms of apneas/hypopneas
Effects of apneas/hypopneas on health (vascular morbidity/mortality and sleepiness)
Beneficials effects of CPAP and/or advanced mandibular orthosis
Description of sleep stages and physiological roles of sleep
Known effects of exercise on sleep and metabolism
Importance of good nutritional status and sleep hygiene on quality of life
How to apply theses lessons of rehabilitation in daily life"
1713167|NCT01362764|Drug|Abiraterone acetate suspension Formulation 1|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
1713168|NCT01362764|Drug|Abiraterone acetate suspension Formulation 2|Type=exact, unit=mg/mL, number=25, form=oral suspension, route=oral use, as a single dose of 10 mL
1713169|NCT01362764|Drug|Abiraterone acetate tablets|Type=exact, unit=mg, number= 250, form=tablet, route=oral use, as a single dose
1713170|NCT01362751|Other|No intervention|This study is an observational cohort study > no interventions
1713171|NCT01362738|Procedure|RFCA of PV and extra-PV triggers|PVAI and isolation of extra PV triggers
1713172|NCT01362738|Procedure|LAA isolation along with the conventional ablation strategy|PVAI + isolation of extra PV triggers + LAA isolation
1713173|NCT01362725|Device|Spinal cord stimulation system|An implantable pulse generator (IPG) will deliver low-intensity electrical pulses which travel from the IPG through the leads to the electrodes positioned at the selected nerve fibers to provide the therapeutic stimulation.
1713174|NCT01362712|Radiation|[F18]CP-18 Injection|Normal volunteers dose will not exceed 20 mCi. For cancer subjects, the dose will be closer to 10 mCi.
1713175|NCT01362699|Drug|JNJ-31001074|Type=exact number, unit=mg, number=3, form=tablet, route=oral use. One tablet once daily for 7 days.
1713176|NCT01362699|Drug|Placebo|Form=tablet, route=oral administration. One tablet once daily for 7 days.
1713177|NCT01362686|Drug|Donepezil|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
1713178|NCT01362686|Drug|Galantamine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
1713179|NCT01362686|Drug|Rivastigmine|The study is open-label and the memory care practice physicians will make determinations about initial drug dosage and any dosage changes and the timing of those changes. These physicians will also make the determination about whether to switch to a different anti-dementia drug, add memantine, or any other agent. We will, of course, monitor the frequency and content of such changes in the natural course of patient care.
1713180|NCT01362673|Drug|PF-04171327|Oral single 5 mg dose as one 5 mg tablet
1713181|NCT01362673|Drug|PF-04171327|Oral single 10 mg dose as one 10 mg tablet
1713182|NCT01362673|Drug|PF-04171327|Oral single 30 mg dose as three 10 mg tablets
1713183|NCT01362673|Drug|Placebo|Oral single dose as matching placebo
1713184|NCT01362673|Drug|PF-04171327|Oral multiple 20 mg doses as two 10 mg tablets for 12 days
1713185|NCT01362673|Drug|Placebo|Oral multiple doses as matching placebo for 12 days
1713186|NCT01362660|Other|Unintentional exposure in utero|This study will examine post-natal neurologic and cognitive development of infants who may have been exposed to tanezumab or comparator in-utero during the tanezumab clinical program (whether the exposure is through maternal or paternal participation in a tanezumab clinical study).
1713187|NCT01362647|Procedure|neuromuscular transmission monitoring|The acceleromyographic responses of the adductor pollicis muscle as percent of the train-of-four (TOF%) on stimulation of the ulnar nerve by means of TOF-Watch®, Organon Ireland Ltd., a division of MSD, Swords, Co., Dublin, Ireland.
1713188|NCT01362647|Procedure|Pulse oximetry measurement|Pulse oximetry will be measured continuously throughout the PACU admission, and SpO2 values will be recorded at 1-min intervals for the first 30 min.
1713189|NCT01362634|Behavioral|Trans-theoretical Process of Change Model-self|self-administered, computer-based intervention
1713190|NCT01362634|Behavioral|Trans-theoretical Process of Change Model - interviewer|interviewer-administered intervention
1713191|NCT01362608|Drug|Canakinumab, ACZ885|Canakinumab and placebo matching to triamcinolone acetonide
1713192|NCT01362608|Drug|Triamcinolone acetonide|Triamcinolone acetonide 40 mg and placebo matching to canakinumab
1713193|NCT01362595|Drug|leucine|"Dosage of leucine will be dependent on body surface area (BSA):
leucine 700 mg/m2/dose by mouth three times a day"
1713194|NCT01362582|Drug|SMOF Kabiven|SMOFKabiven® will be given over night with a content of 1100 kcal in 986 ml.
1713195|NCT01362556|Drug|Sodium bicarbonate|"Administration of a calculated amount of sodium bicarbonate 8% [SB] after arterial blood gas measurement according to Base Excess [BE] and Body weight [kg].
Formula: SB [ml] = -BE * kg * 0.1"
1956374|NCT02875834|Drug|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally once daily for 28 days after the first 48-hour open label initial phase.
1713196|NCT01362556|Drug|Sodium Chloride|"Administration of a calculated amount of sodium chloride 0.9% [SC] after arterial blood gas measurement according to Base Excess [BE] and Body weight [kg].
Formula: SC [ml] = -BE * kg * 0.1"
1713197|NCT01362543|Other|Cognitive behavioural therapy (stress management)|Following a manual
1713198|NCT01362543|Other|Cognitive Behavioural Therapy (cognitive restructuring)|Following a manual
1713199|NCT01362530|Drug|Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
1713200|NCT01362530|Drug|Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
1713201|NCT01362530|Drug|Aprepitant powder for suspension (PFS)|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to <12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to <12 years of age
1713202|NCT01362530|Drug|Ondansetron|Day 1: Administered according to product label for pediatric usage or local standard of care
1713203|NCT01362530|Drug|Placebo for Aprepitant 125 mg|On the morning of Day 1: one 125 mg capsule PO 60 minutes prior to chemotherapy for participants 12 to 17 years of age
1713204|NCT01362530|Drug|Placebo for Aprepitant 80 mg|On the morning of Days 2 and 3: one 80 mg capsule PO for participants 12 to 17 years of age
1713205|NCT01362530|Drug|Placebo for Aprepitant PFS|On the morning of Day 1: 3.0 mg/kg (up to 125 mg) PO 60 minutes prior to chemotherapy for participants 6 months to <12 years of age. On the morning of Days 2 and 3: 2.0 mg/kg (up to 80 mg) PO 60 minutes prior to chemotherapy (if applicable) for participants 6 months to <12 years of age
1713206|NCT01362530|Drug|Emetogenic chemotherapy|"Any moderately or highly emetic chemotherapeutic agent such as cyclophosphamide, doxorubicin, methotrexate, carboplatin, cisplatin, irinotecan, carmustine, ifosfamide, and streptozocin, or chemotherapeutics of a lower emetogenicity that were not previously tolerated. No chemotherapeutic agents were specified by the protocol, and many could potentially have been used."
1713207|NCT01362517|Biological|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at 2, 3 and 4 months of age"
1713208|NCT01362491|Drug|Ibuprofen Sodium|Single-dose of ibuprofen sodium tablets (equal to 400 mg ibuprofen)
1713209|NCT01362491|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen tablets (400mg)
1713210|NCT01362491|Drug|Placebo|Single-dose of placebo
1713211|NCT01362465|Procedure|Cardiac Resynchronization Therapy|Implanting device to measure delays between paced chambers in heart failure patients.
1713212|NCT01362452|Genetic|T-Cell Infusion|Infusion of CD19-specific T cells derived from cord blood (CB) 42 days following stem cell transplantation.
1713213|NCT01362452|Procedure|Cord Blood Infusion|Cord blood infusion on Day 0.
1713214|NCT01362439|Drug|Paliperidone ER|Participants will be administered paliperidone extended release (ER) tablets orally (taken by mouth; to be swallowed) once daily in the dose range of 3 to 12 milligram (mg) for 13 weeks. Dose will be increased or decreased as per Investigator's discretion.
1713215|NCT01362426|Drug|paliperidone palmitate|Dosage and administration will be according to the paliperidone palmitate approved Australian Product Information.
1713216|NCT01362400|Drug|IPI 504 plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 & 15 during each 21 day cycle
75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
1713217|NCT01362400|Drug|Placebo plus Docetaxel|"450 mg/m2 (starting dose) IPI-504 or placebo IV (in the vein) day 1, 8 & 15 during each 21 day cycle
75 mg/m2 in US and EU, 60 mg/m2 in South Korea and Taiwan Docetaxel (Taxotere®) will be administered by IV infusion every 3 weeks (Day 1 of each 21-day cycle)"
1713218|NCT01362387|Other|Alternative follow-up protocol|Women (n=1000) will be allocated by chance to one of two groups: alternative follow-up using a standard text message, online or telephone questionnaire and a low sensitivity urine pregnancy test, or standard follow-up which consists of an in person visit with an ultrasound or a telephone call and high sensitivity pregnancy test.
1713219|NCT01362374|Drug|5-FU|5-FU at a dose level of 400 mg/m^2 as intravenous (IV) injection followed by a dose of 2400 mg/m^2 as IV infusion over 46 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
1713220|NCT01362374|Drug|Docetaxel|Docetaxel will be administered at dose level of 75 mg/m^2 as IV infusion over 1 hr on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.
1713221|NCT01362374|Drug|Enzalutamide|Enzalutamide will be administered orally at a dose level of 160 mg once daily continuously as per schedule defined in respective arm until disease progression or unacceptable toxicity.
1713222|NCT01362374|Drug|GDC-0068|GDC-0068 will be administered orally (in escalating doses during Stage 1 followed by at a dose decided during Stage 1) as per schedule defined in the respective arms.
1713223|NCT01362374|Drug|Leucovorin|Leucovorin at a dose level of 400 mg/m^2 as IV infusion over 2 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
1713224|NCT01362374|Drug|Oxaliplatin|Oxaliplatin at a dose level of 85 mg/m^2 as IV infusion over 2 hours will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
1713225|NCT01362374|Drug|Paclitaxel|Paclitaxel at a dose of 90 mg/m^2 as IV infusion over 1 hr will be administered on Days 1, 8, and 15 of each 28-day cycle until disease progression or unacceptable toxicity.
1713226|NCT01362361|Drug|mFOLFOX6 + BIBF 1120|mFOLFOX6 + BIBF1120 (2x200 mg/d d1-d14) (repeated every 14 days)
1713227|NCT01362361|Drug|mFOLFOX6+placebo|mFOLFOX6 + placebo (2x200 mg/d d1-d14) (repeated every 14 days)
1713228|NCT01362348|Drug|pazopanib eye drops|10 mg/mL (1 drop) four times daily
1956375|NCT02875834|Drug|Placebo|Suspension administered orally placebo once daily for 28 days after the first 48-hour open label initial phase.
1713232|NCT01362296|Drug|GSK1120212|Oral once daily
1713233|NCT01362296|Drug|docetaxel|IV once every 3 weeks
1713234|NCT01362283|Other|Blood Sampling|Blood sampling for Fasting Plasma Glucose, Hemoglobin A1C, Cholesterols, Blood Urea Nitrogen, Creatinine
1713235|NCT01362270|Device|Acupuncture Therapy|DOSAGE: 25 acupoints per session FREQUENCY: 2 sessions per day DURATION: 5 days
1713236|NCT01362257|Drug|Treatment Period 1 - IV dose of GSK573719|single dose of 65µg
1713237|NCT01362257|Drug|Treatment Period 2 - Oral dose of GSK573719|single dose of 1000µg
1713238|NCT01362244|Drug|Mepolizumab|750 mg of mepolizumab by IV infusion
1713239|NCT01362244|Drug|Placebo|Placebo by IV infusion
1713240|NCT01362244|Drug|Run In Medication|subjects will undergo a run-in period of 10 - 14 days on a low dose of Intranasal Steroids (INS).
1713241|NCT01362231|Drug|GS-6624|Patients will be treated with GS-6624 (125 or 200 mg) administered IV over 1 hour on specific days during the treatment period.
1713242|NCT01362218|Drug|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril)|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 8 weeks.
1713243|NCT01362218|Drug|Simvastatin, ramipril, acetylsalicylic acid|A once daily oral dose of simvastatin, ramipril, acetylsalicylic acid for 8 weeks
1713244|NCT01362205|Drug|Dexmedetomidine|
1713245|NCT01362205|Drug|Placebos|Inactive placebo (normal saline)
1713246|NCT01362192|Device|532 nm KTP Excel V Laser, manufactured by Cutera, Inc.|"The 532 nm KTP Excel V laser treatment parameters to be used in this study are as follows:
Spot Size: 5 mm
Fluence: 13-15 J/cm2
Pulse Duration: 40 ms
Epidermal contact-cooling: 5° Celsius"
1713247|NCT01362153|Drug|Golimumab|SC injection of 100 mg every 4 weeks through Week 20
1713248|NCT01362153|Drug|Golimumab|IV infusions of 2 mg/kg golimumab on Days 1 and 85.
1713251|NCT01362127|Drug|Chemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
1713252|NCT01362127|Radiation|Radiochemotherapy|Cisplantin 100 mg/m2 day 1. 5-fluoracil 750 mg/m2/24 hours infusion day 1-5. Three cycles. In the chemoradiation arm the radiotherapy start week 4 and continuing until week 7. Dose adjustet according to current LPK and TPK values.
1713253|NCT01362114|Drug|SIHOGAYONGGOLMORYU TANG EXTRACT GRAN|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks
1713254|NCT01362114|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
1713255|NCT01362101|Behavioral|Mindfulness behavioral intervention (MT),cognitive behavioral intervention (CBT)|"60 smokers will enter a separate 4 wk group sessions trial that evaluates efficacy of MT in comparison to CBT for smoking cessation. During the parent study, participants will receive bi-weekly sessions of either MT or CBT, for 4 weeks and to set a quit date at the end of the 2nd week. In this context, we will examine participants at two points:
Week 0-1 of MT/CBT: development of smoking scripts based participant's descriptions of situations that trigger tobacco craving.
Then participants will undergo pre-treatment (week 0-1) and post treatment (week 4) psychophysiological activation to smoking-related cues using the script driven imagery technique, in vivo cues, salivary cortisol testing and to complete a computerized SST protocol."
1713256|NCT01362075|Procedure|Local infiltration analgesia|150 ml ropivacaine, of which 100 ml is with adrenalin
1713257|NCT01362075|Procedure|Interscalene catheter|7 ml ropivacaine interscalene block via catheter, subsequently given 5 ml/h and possibility of 5 ml bolus for the first 48 hours.
1713258|NCT01362062|Drug|Tocilizumab|
1713259|NCT01362049|Other|Physical Therapy rehabilitation: Stabilization exercises.|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles and then incorporation of these isolated contractions into other exercises. The exercise protocol progresses to include trunk flexion and extension strengthening exercises as well as abdominal bracing exercises in supine and quadruped positions, and finally to exercises in more functional positions.
1713260|NCT01362049|Other|Physical Therapy rehabilitation. Movement System Impairment (MSI) classification based exercise|The MSI-classification based approach focuses on education and instruction for modifying movement strategies during functional activities, and on exercises that are specific to the classification category. First there is an analysis of and instruction in modifying a subject's direction-specific alignment and movement strategies during symptomatic functional activities. Second, there is education about the principles of tissue injury and healing, and how cumulative tissue stress contributes to microtrauma and LBP. Unique to the education process is the emphasis on how using one's particular movement strategies during functional activities may accelerate tissue stress accumulation because the strategies are used repetitively. Thirdly, there is exercise prescription that includes practice in performing modified versions of the direction-specific impairment tests from the physical exam, with an emphasis on impairments that can be modified to eliminate LBP symptoms.
1713261|NCT01362036|Drug|TXA127|Cohorts in this study will receive 300, 600, or 900 ug/kg daily by subcutaneous injection
1713262|NCT01362023|Behavioral|lifestyle counseling|"In 3 academic years, the intervention program consisted of three components:
Classroom practice by HPA to highlight healthy lifestyle habits
Teaching practice by HPA using books designed to include the nutritional objectives
Parental activities included with their children
In each of 12 activities (1 h/activity), the classroom practice consisted of three components:
Experimental development of activities regarding each healthy lifestyle habit
Assessment of activity performed in classroom
An activity developed for use at home"
1713263|NCT01362010|Drug|Topical Minocycline Foam FXFM244|Topically applied once a day.
1713264|NCT01361997|Biological|chlorhexidine in isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
1713265|NCT01361997|Biological|Isopropyl alcohol|When a hemoculture is ordered, the laboratory technician will prepare the necessary materials for venipuncture. Previously the technician must take randomly a sealed envelope, where will be writing the antiseptic to be used for antisepsis. The technician will select a site for venipuncture, preferably in the forearm, and will do the antisepsis in the site selected, letting act the substance for 45 seconds. After this procedure, the venipuncture shall be done. The sample will be cultured for 120 hours at 35 +/- 2°C.
1713266|NCT01361984|Drug|Nebulized arformoterol|Arformoterol tartrate 15 µg/2ml (Brovana) nebulized via PARI-LC Plus® nebulizer with a mouthpiece, connected to a PRONEB® Ultra compressor. The nebulization time is ~9 minutes
1713267|NCT01361984|Drug|Salmeterol|Salmeterol 50 mcg (Serevent) via Diskus dry powder inhaler
1713268|NCT01361971|Procedure|Hyperbaric Oxygen Treatment|Participants will undergo 4 treatments of hyperbaric oxygen. Each treatment consists of 90 minutes compression at 2 atmospheres of pressure, with 30 minutes decompression back to 1 atmosphere, during this time, patients will be treated with 100% Oxygen delivered via a hood system.
1713269|NCT01361958|Drug|NOMAC|
1713270|NCT01361945|Drug|AUY922|AUY 922 is given intravenously weekly; letrozole and lapatinib are given orally
1713271|NCT01361932|Other|Video of ED discharge instructions for patient's ED discharge diagnosis|Link provided for a website of 38 ED discharge instruction videos, based on ED discharge diagnosis; patients in study group encouraged to view it upon returning home. Three key questions asked by RA 1 to 5 days later, via phone call, and answers scored.
1956386|NCT02871492|Drug|Pritelivir 5% w/w ointment|
1713276|NCT01361906|Behavioral|Sensomotoric training|"The intervention will be given once a week (2h per occasion) for twelve weeks.
Each occasion is planned to have the following structure:
10 min initial conversation about how participants are feeling today and how it felt after the last time.
70 min guided sensory motor learning. 10 min final talks, reflections on how it felt today."
1713277|NCT01361893|Other|Lifestyle Counseling|We will utilize a combination of quantitative and qualitative techniques to ascertain factors, attitudes, and beliefs of African American parents of infants less than 6 months old.
1713278|NCT01361880|Behavioral|Reduce Infant Mortality|The study's long term goal is to disseminate a new easily implemented and reproducible intervention that based on our previous research is culturally competent and provides a rationale for changing infant sleep position and sleep environment. This intervention if successful will quickly be disseminated and will be an important change to the system of newborn care; the resultant change in parental behavior would ultimately result in a reduction in sleep-related infant mortality rates thereby promoting healthy development.After written consent has been obtained, a brief survey about knowledge of and attitudes toward safe sleep position recommendations, current intent with regards to safe sleep recommendations, and demographics will be completed. Contact information will be obtained from participants to facilitate study follow-up at two weeks of infants birth 2-3 months and 5-6 months.
1713279|NCT01361867|Device|Robot-induced perturbations|A robotic system is used to generate mechanical perturbations and study how subjects generate motor adaptations in response to the mechanical perturbations.
1713280|NCT01361854|Device|polysomnography|home-based polysomnography with hook-up performed ar at home or in the hospital
1713281|NCT01361841|Drug|Latanoprost, bimatoprost, travoprost|topic drops, once a day at bedtime, for years
1713282|NCT01361841|Drug|travoprost, latanoprost and bimatoprost|one drop once a day for life
1713283|NCT01361828|Procedure|Electrophysiology|Visual Evoked Potential and Elctroretinogram
1713284|NCT01361815|Device|H-Coil Deep TMS in combination with SSRIs|The study group will receive DTMS treatment three times a week for four weeks in combination with SSRI medications.
1713285|NCT01361802|Drug|Ambroxol Spray|low dose Ambroxol Spray
1713286|NCT01361802|Drug|Ambroxol Spray|medium dose Ambroxol Spray
1713287|NCT01361802|Drug|Ambroxol Spray|high dose Ambroxol Spray
1713288|NCT01361802|Drug|Placebo Spray|Placebo Spray
1713289|NCT01361789|Drug|parecoxib, valdecoxib, etoricoxib|"40 mg parecoxib (Dynastat, Pfizer®) one hour before surgery and 40 mg valdecoxib (prodrug of parecoxib, Bextra, Pfizer®)were given 8 hour after surgery.
After retraction of parecoxib from the market:
Etoricoxib (Arcoxia, MSD) 120 mg given one hour before surgery"
1713290|NCT01361789|Drug|Dexamethasone|8 mg IV
1713291|NCT01361789|Drug|parecoxib, valdecoxib, parecoxib and dexamethasone|combination of both drugs
1713292|NCT01361776|Biological|FSME-immune|0.5 ml im as scheduled in the 4 arms
1713293|NCT01361763|Drug|Dabigatran|110 mg twice daily
1713294|NCT01361763|Drug|Antiplatelets|100mg once a day
1713295|NCT01361750|Procedure|gastric tube|the stomach will be cut into a narrowed tube-shape conduit
1956387|NCT02871492|Drug|Pritelivir ointment matching placebo|
1956388|NCT02871492|Drug|Zovirax® cream|
1713299|NCT01361711|Biological|alemtuzumab|Given SC
1713300|NCT01361711|Biological|ofatumumab|Given IV
1713301|NCT01361711|Procedure|biopsy|Correlative studies
1713302|NCT01361698|Behavioral|Illness Management and Recovery (IMR)|In this Danish trial IMR will be implemented in group format with 10 patients assigned to each group and two IMR facilitators, and the IMR program will require nine months of weekly sessions to complete.
1713303|NCT01361659|Procedure|shockwave treatment|9 treatments in 3 months
1713304|NCT01361646|Drug|LC350189|Single Ascending Dose: 10, 25, 50, 100, 200, 400, 600mg Multifle Ascending Dose: 100, 200, 400, 600, 800mg
1713305|NCT01361633|Drug|d-cycloserine|single oral administration of 250 mg d-cycloserine
1713306|NCT01361633|Drug|Sugar Pill|Single oral administration 250 mg Sugar Pill
1713307|NCT01361620|Drug|aspirin|aspirin 81mg, 7-10 days
1713308|NCT01361607|Drug|Sativex®|
1713309|NCT01361607|Drug|Placebo (GA-0034)|
1713310|NCT01361594|Other|Regular insulin (intensive treatment)|Titration of the IV insulin rate for glucose goal 100-140 mg/dL
1713311|NCT01361594|Other|Regular Insulin (conventional treatment)|Titration of the IV insulin rate for glucose goal 141-180 mg/dl
1713312|NCT01361568|Drug|CR845|Single i.v. dose (0.04 mg/kg) administered preoperatively
1713313|NCT01361568|Drug|Placebo|Single i.v. dose administered preoperatively
1713314|NCT01361568|Drug|CR845|Single i.v. dose (0.04 mg/kg) administered postoperatively for pain
1713315|NCT01361568|Drug|Placebo|Single i.v. dose administered postoperatively for pain
1713316|NCT01361555|Drug|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, Once daily, 54 weeks
1713317|NCT01361555|Drug|BMS-820836|Tablet, Oral, 0.5 mg, Once daily, 54 weeks
1713318|NCT01361555|Drug|BMS-820836|Tablet, Oral, 1.0 mg, Once daily, 54 weeks
1713319|NCT01361555|Drug|BMS-820836|Tablet, Oral, 2.0 mg, Once daily, 54 weeks
1713320|NCT01361542|Drug|anti TNF alpha agent|Anti TNF alpha therapy included either INFLIXIMAB or ETANERCEPY Infliximab at 3-5 mg/kg at recommended protocols for the duration of the study Etanercept at 50mg weekly for the duration of the study
1713321|NCT01361542|Drug|Anti TNF alpha therapy|Infliximab 3-5 mg/kg as per recommended protocol or Etanercept 50mg/week for 1 year
1713322|NCT01361529|Drug|FLP,dose escalation,MTD|dosage from 93mg/m2 to 331mg/m2, 7 days' continuous dosing, 21 days for one cycle
1713323|NCT01361516|Other|Anaesthesia and Lithotripsy|The efficacy of stone fragmentation during lithotripsy procedure is compared under two types of anaesthesia
1713324|NCT01361464|Drug|Tipifarnib|Given PO
1713325|NCT01361464|Other|Laboratory Biomarker Analysis|Correlative studies
1713326|NCT01361438|Other|Total therapy approach|Total therapy approach
1713327|NCT01361425|Drug|methildopa|methildopa, 1,5g/day (500mg 8/8 hours, orally)
1713328|NCT01361425|Drug|placebo|placebo 500mg 8/8h, orally
1713329|NCT01361412|Biological|ToleroMune Ragweed|Intradermal administration 1x8 administrations, 2 weeks apart
1713330|NCT01361412|Biological|Placebo|Intradermal injection 1x8 administrations, 2 weeks apart
1713331|NCT01361399|Drug|Acetylsalicylic acid (Aspirin, BAYE4465) & Lidocain|Single oral application of a fixed combination of Aspirin and Lidocain (as one lozenge)
1713332|NCT01361399|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral application of Aspirin (as lozenge)
1713333|NCT01361399|Drug|Lidocain|Single oral application of Lidocain (as lozenge)
1713334|NCT01361399|Drug|Placebo|Single oral application of Placebo (as lozenge)
1713335|NCT01361373|Drug|L- DOPA|Sinemet up to 10 mg/kg/ day increasing gradually for 2 weeks
1713336|NCT01361373|Drug|placebo|placebo for 2 weeks
1713337|NCT01361347|Dietary Supplement|milk|milk for milk allergic children (1:25 dilution, whole milk)
1713338|NCT01361334|Drug|Pazopanib|800 mg QD p.o.
1713339|NCT01361308|Drug|Brisdelle (paroxetine mesylate)|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
1713340|NCT01361308|Drug|Placebo capsules|Subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo in a 1:1 ratio, administered once daily at bedtime beginning on Day 1 and continuing up to Day 84
1713341|NCT01361295|Procedure|PVI with PVAC gold|Pulmonary vein isolation using the Medtronic PVAC gold catheter
1713342|NCT01361295|Procedure|PVI with Cooled-RF|Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
1713343|NCT01361269|Drug|Fosmidomycin and clindamycin|The study drugs will be co-administered under supervision by a study physician or nurse in doses of fosmidomycin 30mg/kg/dose + clindamycin 10mg/kg/dose twice daily for three days (total daily dose fosmidomycin 60mg/kg, clindamycin 20mg/kg).
1713344|NCT01361256|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
1713345|NCT01361256|Device|WA-NG Telescope Prothesis|The WA-NG telescope prosthesis (Figure 1) is the next generation telescopic implantable device which, when combined with the optics of the cornea, constitutes a telephoto system for improvement of visual acuity in patients with severe to profound vision impairment due to bilateral, end-stage age-related macular degeneration. The device is implanted in one of the patient's eyes. In this way, the implanted eye provides central vision and the non-implanted eye can continue to provide peripheral vision.
1713348|NCT01361230|Device|"Sedation Trial Monitor is the name of the device used."|This is a pilot unblinded randomised controlled trial comparing sedation management using responsiveness (new intervention) with usual care (control group).
1713350|NCT01361204|Dietary Supplement|Theanine|Taking 4 tablets of theanine two times daily for 16 days
1713497|NCT01359878|Drug|Isotonic Saline|Isotonic saline in equivalent volume - 100 ml
1713351|NCT01361191|Drug|R-MEGACHOP|"If PET + after third cycle: 2 cycles of R-IFE followed by PBSCT
If PET - after third cycle: 3 additional cycles of R-MegaCHOP - R-MegaCHOP: cycles every 21 days RITUXIMAB Dosage: 375mg/m2, IV, day 1 CICLOPHOSPHAMIDE Dosage: 1500 mg/m2, IV, day 1 DOXORUBICIN Dosage: 65 mg/m2, IV, day 1 VINCRISTIN: Dosage 1.4 mg/m2 (max. 2.0 mg/m2, IV, day 1 PREDNISONE Dosage: 60 mg/m2, IV, day 1-5
R-IFE: 2 cycles every 21 days:
IFOSFAMIDE Dosage: continuous perfusion of 10 gr/m2/iv during 72 hours. Therefore, 3.33 gr/m2/corporal weight 24 hours day +1, +2 and +3.
ETOPOSIDE Dosage: total 900 mg/m2, IV, which is 150 mg/m2 during 12 hours (days +1, +2 and +3)."
1713352|NCT01361178|Drug|SQ IVIG|Group 1 will receive SQ IgG at the lower end of the dosing range at 100 mg/kg/week and group 2 will receive SQ IgG at the higher end of the dosing range at 200 mg/kg/week
1713353|NCT01361152|Device|anatomic modular fixed-bearing|anatomic modular (AMK; DePuy) fixed-bearing prosthesis
1713354|NCT01361152|Device|low contact stress rotating platform mobile-bearing|low contact stress rotating platform (LCS RP; DePuy) mobile-bearing prosthesis
1713355|NCT01361126|Biological|Recombinant Coagulation Factor IX Albumin Fusion Protein|Study subjects will receive a single dose of 25IU/kg of rIX_FP for pharmacokinetic analysis. Subjects will then be treated for approximately 5 months. The treatment dose will be based on the subject's PK profile and the subject's bleeding phenotype.
1713356|NCT01361113|Drug|Pazopanib|800 mg orally once daily for 8 weeks, prior to nephrectomy
1713357|NCT01361100|Device|Oncoral® test|The patient rinses his oral cavity for 2 minutes. Then he screws lid back onto a beaker. The investigator holds the beaker straight so that the end of the aspiration mouth is dipped into the liquid. Then, the investigators takes 2 tubes and pushes them one after the other down on the opening of the beaker. The tubes should fill by themselves. The tubes can't be kept more than eleven days and are send to the Clinident Institute for the analysis.
1713358|NCT01361087|Other|Blood draw|This study includes one blood draw to measure circulating blood levels of TGF-B.
1713359|NCT01361074|Behavioral|In Vivo Exposure for Animal Phobia following Öst´s guidelines|"In vivo exposure is applied using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). Exposure is conducted in a single extended session lasting up to 3 hours and implemented individually. The treatment includes participant modelling, in vivo exposure, reinforced practice and cognitive challenge. Treatment in a single session is just a starting point; it is recommended that the participants continue to be exposed to the phobic situations after therapy in their daily lives in order to fully surmount their problems. Participants are informed that the treatment required close collaboration between themselves and the therapist. The exposure session is completed in a gradual and planned way."
1713360|NCT01361074|Behavioral|Augmented Reality Exposure for Animal Phobia following Öst´s guidelines|"Augmented Reality (AR) is a variation of Virtual Reality in which the user sees the real world augmented by various virtual elements; it complements reality rather than replacing it completely (Azuma et al., 2001). The most significant aspect of AR is that the virtual elements add relevant and helpful information to the physical information available in the real world. The system includes the options of changing the number, movement and size of small animals. Preliminary data show the utility of the system for the treatment of insect phobia (Botella et al., 2005). AR exposure is applied in the same way than in vivo exposure, that is, in a gradual, planned and controlled way using one-session treatment guidelines (Öst, Salkovskis and Hellström, 1991). The therapist can see what the participant sees in AR on a monitor and observe the same stimuli."
1713361|NCT01361048|Drug|oral metronidazole|2 gm oral once
1713362|NCT01361048|Drug|neo penotran forte|neo penotran forte intravaginal twice a day for 7 days
1713363|NCT01361048|Drug|neo penotran forte once a day|neo penotran forte intravaginally once a day for 7 days
1713364|NCT01361035|Other|Cancer risk communication skills training|Intervention physicians receive training in cancer risk communication and shared decision making (SDM). At the end of each visit with intervention physicians, standardized patients (SPs) reveal themselves as actors and give structured verbal feedback. After baseline SP visits, each intervention physician undergoes academic detailing with a communication expert. Intervention physicians are directed to a web-based communication skills tutorial where SP ratings are hyperlinked to key references for supplemental reading. Both study groups will receive annual reports detailing their patients' cancer screening status and aggregate ratings of their communication style.
1713365|NCT01361022|Drug|Lendormin tablet|Lendormin tablet 250mc is administrated and compared
1713366|NCT01361022|Drug|Brotizolam tablet|Brotizolam tablet 250mc is administrated and compared
1713367|NCT01361009|Drug|pramipexole|as prescibed by the investigator
1713368|NCT01360996|Drug|3 mg DRSP/20 μg EE|1 pill daily-24 days of drospirenone 3 mg (3 mg DRSP)/ethinyl estradiol 20 μg (20 μg EE)/levomefolate calcium 0.451 mg (folate) -followed by 4 days of levomefolate calcium 0.451 mg (folate)only
1713369|NCT01360970|Biological|hepatitis A vaccine ( HAVRIX or EPAXAL)|1.0 ml im ( Havrix) and 0.5 ml im (Epaxal. Both vaccines are given two times with 6 months interval
1713370|NCT01360957|Dietary Supplement|Black cumin water extract as a traditional medicine|to be given orally in a dosage of 30 ml trice daily for 60 days
1713371|NCT01360944|Drug|LAS41004|once daily, topical, 100 microgram
1713372|NCT01360944|Drug|reference|once daily, 100 microgram
1713373|NCT01360918|Device|Epicardial pulmonary vein isolation|After the CABG procedure, a bilateral epicardial pulmonary vein isolation is performed under general anaesthesia and double-lumen endotracheal ventilation.
1713374|NCT01360918|Other|Usual care|Management of atrial fibrillation according to current guidelines using rate control pharmacological therapy.
1713375|NCT01360866|Drug|OPC-34712 + ADT|Tablets, Oral, 0.5 - 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
1713376|NCT01360853|Drug|ON 01910.Na|ON 01910.Na, 1800 mg/m2 via 2 hr CIV infusions administered twice weekly for 3 weeks of a 4 week cycle.
1713377|NCT01360853|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
1713378|NCT01360853|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 weekly for 3 weeks of a 4 week cycle.
1713379|NCT01360840|Drug|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 1500 milligram (mg) (diluted with 0.9 percent [%] sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
1713548|NCT01359566|Drug|Arbaclofen placarbil 15 mg BID|arbaclofen placarbil 15 mg BID
1713380|NCT01360840|Drug|EMD 525797|Subjects will be administered with EMD 525797 at a dose of 750 mg (diluted with 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
1713381|NCT01360840|Other|Placebo|Subjects will be administered with placebo (as 0.9% sodium chloride) as a 1-hour intravenous infusion every 3 Weeks until disease progression or unacceptable toxicity, whichever comes first, unless the subject stopped the trial treatment for other reasons.
1713382|NCT01360840|Other|Standard of Care (SoC)|All the subjects followed the SoC consisting of the continued treatment with luteinizing-hormone releasing hormone agonists (or antagonists).
1713383|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|3-6 subjects per cohort will receive EMD 1201081 as a weekly subcutaneous injection on Days 1, 8, and 15 in 3-week cycles at dose levels of 0.16, 0.32, and 0.48mg/kg, respectively until progression of disease, unacceptable toxicity, or subject refusal to continue in the trial. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
1713384|NCT01360827|Drug|EMD 1201081 + 5-FU + Cisplatin + Cetuximab|Part 2 seeks to enroll 12 subjects at the MTD of EMD 1201081 in combination with 5-FU/cisplatin + cetuximab; furthermore, an additional 3 to 6 subjects for a total of 9 subjects will be accrued at the 0.16 mg/kg low dose level in Part 2a once the Part 1 0.16 mg/kg dose cohort has been accrued and it is deemed safe to proceed to the 0.32 mg/kg dose cohort. EMD 1201081 will always be given after (within 1 hour) completion of the cetuximab infusion and before the start of chemotherapy.
1713385|NCT01360814|Procedure|quality-of-life assessment|Ancillary studies
1713386|NCT01360814|Behavioral|telephone-based intervention|Receive multidisciplinary structured intervention
1713387|NCT01360814|Other|questionnaire administration|Ancillary studies
1713388|NCT01360814|Other|counseling intervention|Receive multidisciplinary structured intervention
1713389|NCT01360814|Behavioral|exercise intervention|Receive multidisciplinary structured intervention
1713390|NCT01360814|Other|educational intervention|Receive multidisciplinary structured intervention
1713391|NCT01360814|Behavioral|telephone-based intervention|Receive standard care
1713392|NCT01360814|Procedure|standard follow-up care|Receive standard care
1713393|NCT01360788|Drug|Combination ipratropium/salbutamol or placebo (nebulization)|The COPD patients were randomly assigned a combination of ipratropium/salbutamol or a placebo in a double-blind crossover design. The bronchodilation produced by the medication was given in order to evaluate if bronchodilation was effective in increasing exercise tolerance during an endurance shuttle walking test in patients with GOLD stage I COPD.
1713394|NCT01360775|Behavioral|nutritional counseling|Nutritional counseling to caregivers of dependant patients at nutritional risk, Who were participants in the Home Care program conducted by nurses
1713395|NCT01360762|Drug|Pentamidine|Pentamidine isethionate 300 mg for one vial for intramuscular or intravenous route(1 mg of pentamidine isethionate is equivalent to 0.57 mg of pentamidine base)
1713396|NCT01360749|Drug|Lambdalina® (Lidocaine 4% cream)|Lambdaline dose: 2 g for 10 cm2.
1713397|NCT01360749|Drug|Placebo|Placebo dose: 2 g for 10 cm2.
1713398|NCT01360736|Behavioral|Safety Planning - Military (SAFE MIL)|The Safety Planning Intervention (SPI) which is delivered in the SAFE MIL condition aims to help individuals lower their imminent suicide risk by having them collaborate with the study clinician to generate a detailed, hierarchically-arranged action plan for managing suicidal thoughts and urges.
1713399|NCT01360710|Drug|Moxonidine|0.2mg/day for 2 weeks, 0.4mg/day for 6 months
1713400|NCT01360710|Drug|Irbesartan|75 mg/day for 2 weeks and then 150 mg/day for 24 weeks.
1713401|NCT01360697|Other|JADE|"The nurse will complete the CA using standardized protocol including blood & urine tests, eye & feet examination.
Whenever feasible, the nurse will arrange 2-4 hours of diabetes education in groups or on an individual basis as appropriate.
Between each follow-up (FU) visit, the nurse or HCA will contact the patient by phone or email to remind them to attend visits, adhere to medications & healthy lifestyles, perform self blood glucose monitoring as appropriate.
At each FU visit, the patients will first see the nurse or HCA for record of blood pressure, body weight & blood glucose (or A1c) measurement as appropriate. Compliance will also be checked using the 4-item questionnaire.
After the FU visit, the patients will see the nurse or HCA again to clarify any issues & concerns, reinforce compliance & record any changes in medications.
After each FU visit, the HCA will generate summary reports to be given to patients & doctors to promote sharing of information."
1713402|NCT01360697|Other|Non-JADE|Patients will receive a comprehensive assessments at baseline and again after 12 months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
1713403|NCT01360671|Drug|Sildenafil|Loading dose of 0.1 mg/kg for 30 minutes followed by maintenance treatment of 0.03 mg/kg.h for up to 14 days
1713404|NCT01360658|Drug|Intravenous immunoglobulins|Single administration of 2 g/kg intravenous immunoglobulins over 2 days
1713405|NCT01360645|Drug|OPC-34712 + ADT|Tablet, Oral, 2 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
1713406|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
1713407|NCT01360645|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
1713408|NCT01360632|Drug|OPC-34712 + ADT|Tablets, Oral, 1 or 3 mg OPC-34712 and FDA Approved Antidepressant Therapy (ADT)
1713409|NCT01360632|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
1713410|NCT01360632|Drug|Placebo + ADT|Placebo + FDA Approved Antidepressant (ADT)
1713411|NCT01360606|Radiation|Stereotactic Body Radiation Therapy|"SBRT:
Patients will receive one of the following radiation regimens:
50 Gy in 5 fractions (10 Gy/fx) delivered over a 2-week period.
60 Gy in 5 fractions (12 Gy/fx) delivered over a 2-week period.
75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period."
1713412|NCT01360593|Drug|Gemcitabine|"Gemcitabine will be administered for 2 weekly doses every 3 weeks commencing 12 weeks prior to stereotactic radiosurgery as follows:
Gemcitabine 1,000 mg/m2 IV over 30 minutes on Day 1, and 8 of 21- day cycle. This will be done for up to 4 cycles."
1713413|NCT01360593|Drug|Capecitabine|"Capecitabine will be taken orally twice daily on days 1-14 every 3 weeks for 4 cycles (12 weeks) prior to stereotactic radiosurgery as follows:
Capecitabine 650 mg/m2 twice daily for days 1-14 every 3 weeks for up to 4 cycles."
1713549|NCT01359566|Drug|Placebo|Placebo for arbaclofen placarbil 15, 30 and 45 mg BID
1713414|NCT01360593|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"Fractionated SBRT will be delivered to patients that have stable disease, partial response, or complete response after chemo in the following manner:
12 Gy x 3 fractions (36 Gy total) This will be given every other day."
1713415|NCT01360567|Dietary Supplement|Green tea extract|500 mg . one capsule of green tea extract, 3 times per day
1713416|NCT01360567|Dietary Supplement|Placebo|500 mg . one capsule of placebo, 3 times per day
1713417|NCT01360554|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) is provided as 45 mg tablets, continuous oral daily dosing
1713418|NCT01360554|Drug|Active Comparator (erlotinib)|Active comparator (erlotinib) provided as 150 mg tablet, continuous oral daily dosing
1713419|NCT01360554|Drug|Placebo erlotinib|placebo erlotinib, provided as 150 mg tablet, continuous oral daily dosing.
1713420|NCT01360554|Drug|Placebo PF00299804|placebo PF-00299804, provide as 45 mg tablet, continuous oral daily dosing
1713421|NCT01360541|Procedure|Endoscopic radiofrequency ablation|HALO device Use of HALO 360° device for the fist procedure and possible use of HALo 90° device for further treatment sessions Treatment zone of 12cm high maximum. Energy delivered 10 J/cm², power 300W
1713422|NCT01360541|Other|Endoscopic surveillance|Upper gastro-intestinal endoscopy every 6 to 12 month under propofol sedation with acetic acid magnification of mucosa and multiple biopsy samples.
1713423|NCT01360476|Dietary Supplement|cholecalciferol (Vitamin D)|50,000 UI, chewable wafer every 2 weeks for 52 weeks (27 total doses)
1713424|NCT01360476|Dietary Supplement|Placebo|chewable wafer every 2 weeks for 52 weeks (27 total doses)
1713425|NCT01360463|Behavioral|Behavioral Drug and Risk Counseling (BDRC)|"The BDRC counseling is rooted in cognitive behavioral theory. During one hour sessions, the counselors help participant identify short term behavioral goals and work with the participant to develop strategies to achieve their goals. These plans are referred to as contracts and these contracts are reviewed and revised at each subsequent session."
1713426|NCT01360463|Behavioral|methadone maintenance treatment|daily individualized doses of methadone will be provided by the program staff.
1713427|NCT01360450|Drug|Clonidine HCL|At day 5 on opioid and/or benzodiazepine (BZD), the infant will be randomized to receive either placebo (normal saline) or clonidine 1μg/kg/q 4 hrs to a maximum dose of 2μg/kg/q 4. Weaning from the study drug: When the opioid is no longer required, 24 hrs later the study drug (placebo or study drug) will be reduced by 50% and then discontinued 24 hours later provided that the Modified Finnegan scores remain between < 9.
1713428|NCT01360450|Drug|saline|Infants randomized to placebo will be administered IV saline or oral sterile water in the same volume as study drug. The placebo will be give every 4 hrs as outlined in the algorithm for the study.
1713429|NCT01360437|Drug|Prasugrel|Prasugrel 10mg/day
1713430|NCT01360437|Drug|Ticagrelor|Ticagrelor 90mg twice a day
1713431|NCT01360424|Drug|Teriparatide|Daily administration of teriparatide 20 ug s.c. for 24 months
1956407|NCT02870855|Drug|intrauterine injection of HCG|intrauterine injection of HCG berore blastocyst transfer
1713439|NCT01360372|Drug|Methylnaltrexone|Methylnaltrexone 8 mg IV for subjects 38 to 62 kg body weight, Methylnaltrexone12 mg IV for subjects 62.1 to 114 kg body weight
1713440|NCT01360372|Drug|Saline injection|Saline 0.4 to 0.8 ml injection
1713441|NCT01360359|Other|Core Stabilization|"3 Stages: Stage 1: emphasis on neutral spine position, co-contraction of stabilizing muscles with performance feedback through observation and palpation for correct muscle activation; patient education
Stage 2: promotes maintenance of co-contraction while performing movements of the arms/legs and trunk progressing to preformance of these exercises on unstable surfaces; trunk muscle conditioning also emphasized; feedback gradually reduced.
Stage 3: emphasis on maintenance of co-contraction while performing functional activities; stable and unstable surfaces; use of perturbation and random practice to enhance motor learning."
1713442|NCT01360359|Other|Trunk Motion and Fitness|"3 Stages: Stage 1: reducing pain and restoring spine motion and flexibility; patient education
Stage 2: trunk muscle conditioning exercises
Stage 3: trunk muscle conditioning and cardiovascular conditioning exercises"
1713443|NCT01360346|Procedure|Enteral Sedation (EN)|Intravenous propofol or midazolam administration at the ICU admission and stopped within 48h. Melatonin by enteral route (3mg x 2/die) from admission to discharge. Hydroxyzine by enteral route from ICU admission (600mg/die), decreased and stopped as soon as possible. Lorazepam supplementation (maximum 16mg/die) if hydroxyzine is inadequate.
1713444|NCT01360346|Procedure|Control group: Intravenous Sedation (IV)|Propofol or midazolam from ICU admission to discharge at the compatible lowest level with harsh ICU environment.
1713445|NCT01360333|Other|tap water, sodium chloride, carbohydrate rich fluid|Ingestion of three different fluids at three different occasions separated by at least one week, A, Tap water. B. Sodium Chloride. C. Carbohydrate rich fluid.
1713446|NCT01360320|Dietary Supplement|Green tea extract of Camellia Sinensis|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG
Run-in period with 150mg EGCG two times daily (p.o) for 4 weeks
150mg EGCG two times daily (p.o.) over the course of three years.
Colonoscopy after 3 years"
1713550|NCT01359566|Drug|Arbaclofen placarbil 30 mg BID|arbaclofen placarbil 30 mg BID
1714839|NCT01349439|Drug|Propranolol|1mg per Kg (participant weight)
1713447|NCT01360320|Dietary Supplement|Green tea extract of Camellia Sinensis followed by placebo|"Powdered decaffeinated green tea extract of Camellia Sinensis, packed in hard gelatine capsules containing either 150 mg EGCG
Run-in period with 150mg EGCG two times daily (p.o.) for 4 weeks
Placebo two times daily (p.o.) over the course of three years
Colonoscopy after 3 years"
1713448|NCT01360281|Other|Neuromuscular Electrical Stimulation|
1713449|NCT01360281|Other|ECR|Resisted exercises
1956418|NCT02867033|Procedure|biopsy|pre-therapeutic or post-therapeutic biopsy or resected tissues
1713454|NCT01360216|Behavioral|LARC education and training|A CME/CEU accredited Grand Rounds education and training session will be given to clinicians and contraceptive educators practicing in clinics assigned to the intervention arm. Clinicians will have hands-on training as well. The half-day session emphasizes evidence-based contraceptive counseling and provision.
1713455|NCT01360203|Other|Structured Telephone / Remote Outpatient Monitoring|During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
1713456|NCT01360190|Drug|fluoxetine|fluoxetine 20 mg. daily
1713457|NCT01360177|Procedure|124 PET/CT imaging|Standard of Care
1713458|NCT01360177|Drug|Na134I|25 to 150 mCi
1713459|NCT01360177|Drug|Tri-iodothyronine|75 ug/8hr x 4 weeks; oral
1713460|NCT01360177|Drug|Tri-iodothyronine|20 mg/day x 2
1713461|NCT01360164|Biological|human umbilical cord mesenchymal stem cells|Participants will be given hUC-MSCs transplantation.
1713462|NCT01360151|Drug|ranibizumab(Lucentis), verteporfin(Visudyne)|ranibizumab(Lucentis) : 0.5mg/0.05ml - intravitreal injection verteporfin (Visudyne) : 15mg (6mg/m2)- intravenous injection
1713463|NCT01360138|Procedure|Cervical epidural steroid injection|cervical epidural steroid injection with a solution (5 ml) containing 10 mg triamcinolone acetonide suspension, 1.5 ml of 0.75% levobupivacaine hydrochloride, and 3.5 ml of normal saline (0.9% NaCl)
1713464|NCT01360125|Genetic|proteomic profiling|
1713465|NCT01360125|Other|flow cytometry|
1713466|NCT01360125|Other|laboratory biomarker analysis|
1713467|NCT01360086|Biological|cetuximab|6 cycles of intravenous Cetuximab (500mg/m²),
1713468|NCT01360086|Drug|cisplatin|Cisplatine (50mg/m²)
1713469|NCT01360086|Drug|fluorouracil|LV5FU2s (folinic acid 400mg/m², 5FU bolus 400mg/m², and continuous infusion of 5FU 2400mg/m²) every 2 weeks
1713470|NCT01360086|Drug|leucovorin calcium|
1713471|NCT01360086|Procedure|adjuvant therapy|
1713472|NCT01360086|Procedure|neoadjuvant therapy|
1713473|NCT01360086|Procedure|quality-of-life assessment|
1713474|NCT01360086|Procedure|therapeutic conventional surgery|Surgery was planned 3-4 weeks after the end of neaodjuvant CT
1713475|NCT01360060|Drug|Magnesium Sulphate|Magnesium sulphate was infused for the management of preeclampsia at perioperative period.
1713476|NCT01360034|Drug|Nifedipine|Nifedipine: 20 mg as a single dose upon admission and then 10 mg vo every 8 hours for 48 hours.
1713477|NCT01360034|Drug|Indomethacin|Indomethacin: 50 mg vo as a single dose upon admission and then 25 mg vo every 6 hours for 48 hours.
1713478|NCT01360021|Drug|Symbicort|Breath actuated metered dose inhaler
1713479|NCT01360021|Drug|Symbicort|Actuation counter pressured metered dose inhaler
1713480|NCT01360021|Drug|Budesonide|Actuation counter pressured metered dose inhaler
1713481|NCT01359982|Drug|RRx-001|Dose level 1 (10 mg/m2)
1713482|NCT01359982|Drug|RRx-001|Dose Level 2 (16.7 mg/m2)
1713483|NCT01359982|Drug|RRx-001|Dose Level 3 (24.6 mg/m2)
1713484|NCT01359982|Drug|RRx-001|Dose Level 4 (33 mg/m2)
1713485|NCT01359982|Drug|RRx-001|Dose Level 5 (55.0 mg/m2)
1713486|NCT01359982|Drug|RRx-001|Dose Level 6 (83 mg/m2)
1713487|NCT01359969|Drug|rhC1INH|Patients up to 84 kg will receive one i.v. injection of Ruconest at a dose of 50 U/kg. The reconstituted solution should be administered as a slow i.v. injection over approximately 5 minutes. Patients of 84 kg body weight or greater will receive one i.v. injection of Ruconest at the dose of 4200 U (2 vials).
1713488|NCT01359956|Drug|Dacarbazine|900 mg / m2 every 3 weeks
1713489|NCT01359956|Drug|Fotemustine|100 mg / m2 every 3 weeks
1713490|NCT01359956|Drug|Interferon Alfa-2b|5 M units every 3 weeks
1713491|NCT01359943|Biological|secukinumab (AIN457)|"Secukinumab is a human monoclonal antibody. Monoclonal antibodies are proteins that recognize and bind to unique proteins that your body produces. Secukinumab binds and reduces the activity of a cytokine (a messenger protein in the body) called Interleukin 17 (IL-17)."
1713492|NCT01359943|Drug|placebo|Matching placebo to AIN457 i.v. and to AIN457 s.c..
1713493|NCT01359930|Other|placebo|matching placebo
1713494|NCT01359930|Drug|Naltrexone and Bupropion SR|25mg bid/day (NX) 200mg bid/day (BUP)
1713495|NCT01359904|Other|High Dialysate bath|The dialysate bath assigned is 10mmol/L glucose, while the control group is assigned to 5.5 mmol/l glucose solution.
1713496|NCT01359878|Drug|Fibrinogen Concentrate|2 gram intra venous
1956419|NCT02867033|Other|biobank constitution|Constitution of a biobank with pre-therapeutic or post-therapeutic biopsy or resected tissues
1713498|NCT01359865|Procedure|Lumbar Plexus Block|lumbar plexus block followed by a general anesthetic. The lumbar plexus block will be performed by an attending anesthesiologist using ultrasound guidance (for measuring the depth of the psoas compartment) and nerve stimulation. A standardized block solution of 30 mL 0.5% ropivacaine will be injected in fractionated doses when a quadriceps muscle twitch is present to nerve stimulation at <0.50 mA. Fifteen minutes after block completion, the block's effectiveness will be evaluated with an ice test.
1713499|NCT01359852|Drug|[11C] JNJ-42491293|Part B:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection, have a 90 minute PET scan and have arterial and venous blood sampling.
1713500|NCT01359852|Drug|[11C] JNJ-42491293 + JNJ-40411813|Part C:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v.bolus injection. Volunteers will be pre-treated with JNJ-40411813 between 1.5 to 3 hours prior to the second and prior to the third PET scan
1713501|NCT01359852|Drug|[11C] JNJ-42491293 + JNJ-40411813|"Part D:[11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection.
Volunteers will be treated with a single dose of up to 500 mg JNJ-40411813 prior to the second scan and will have a third scan at least 2 hours later to evaluate the rate of clearance of JNJ-40411813 from the brain"
1713502|NCT01359852|Drug|[11C] JNJ-42491293|Part A: [11C] JNJ-42491293 (300 to 370 MBq) will be dosed as an i.v. bolus injection and have a 120 minute PET scan.
1713503|NCT01359839|Behavioral|Relaxation Response and Cognitive Behavioral Therapy|This is a group format which will meet once per week and teach the techniques of cognitive behavioral therapy as well as relaxation response meditation.
1713504|NCT01359826|Drug|Milnacipran|After dose escalations, patients will receive Milnacipran administered at 50 mg twice a day after for 12 weeks or milnacipran 50 mg twice day for 4 weeks and then 100 mg twice a day for an additional 6 weeks depending on tolerability and fatigue response.
1713505|NCT01359813|Drug|Human Albumin|Administration: 1,5 g/kg at Day 1 and 1g/kg at Day 3 In case of a new infection appears in the 3 months, the same doses will be administrated.
1713506|NCT01359787|Drug|Mapracorat|Daily topical application
1713507|NCT01359787|Drug|Vehicle without active|Daily topical application
1713508|NCT01359774|Other|31P-MR spectroscopy|Brain energy deficit is quantified using 31P-MR spectroscopy
1713509|NCT01359774|Other|31P-RMN spectroscopy|Brain energy deficit is quantified using 31P-RMN spectroscopy
1713510|NCT01359761|Behavioral|Post Admission Cognitive Therapy (PACT)|Six (60-90 minutes) individual psychotherapy sessions administered over preferably 3 days of inpatient stay, up to 2 booster sessions during hospitalization, and 4 telephone booster sessions within 3-months post discharge
1713511|NCT01359748|Device|Reference sphygmomanometer|* USED Audible Korotkoff (K5)for Auscultatory sphygmomanometer.
1713512|NCT01359748|Device|Sphygmomanometer under test|Electronic Oscillometric method.
1713513|NCT01359735|Biological|HP802-247|High dose HP 802-247, applied at each visit (Week 1-13) or until healed
1713514|NCT01359735|Biological|Bacitracin Ointment|One dose of Bacitracin ointment consists of 50 units/1 gram. This will be applied daily for 12 weeks (or until healed).
1956420|NCT02867033|Procedure|Coloscopy|For adult patients, a coloscopy with chromoscopy of ascending and sigmoid colon will be performed
1956421|NCT02867033|Procedure|Blood sampling (facultative)|Blood sample can be collected at diagnostic or after medically significant events (progressive disease, local or systemic treatment, pregnancy...)
1713517|NCT01359709|Drug|Nicotine polacrilex|Participants will apply Nicoderm (14 mg) patches everyday during this study.
1713518|NCT01359696|Drug|GDC-0425|Oral escalating dose
1713519|NCT01359696|Drug|gemcitabine|Intravenous repeating dose
1713520|NCT01359683|Device|Dataq Instruments DI-158|Data Acquisition Device (connects to room instrumentation)
1713521|NCT01359670|Drug|Tadalafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; once daily) over 2 weeks
1713522|NCT01359670|Drug|Sildenafil|Escalating dose (0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg; four times daily) over 2 weeks
1713523|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 42 days (cycle 1) 28 days subsequent cycles
1713524|NCT01359657|Biological|Lenalidomide|Tablets, per os (by mouth route of administration) (P.O), 25 mg, daily for 21 days (Day 15-35 in cycle 1; Day 1-21 in subsequent cycles), no dosing in Cycle 1, Cycle 2 +:daily dosing from Day 1-21
1713525|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered with Lenalidomide once every 7 days, 42 days (cycle 1) 28 days subsequent cycles
1713526|NCT01359657|Biological|Anti-CXCR4 (BMS-936564)|Solution, Intravenously, 1-10 mg/kg, Single 60 minute infusion once a week, 35 days (cycle 1) 21 days subsequent cycles
1713527|NCT01359657|Biological|Bortezomib|Intravenous (IV), 1.3 mg/m2, administered on day 15, 18, 22, 25 in cycle 1, then on Day 1, 4, 8, 11 in subsequent cycles, no dosing in Cycle 1, Cycle 2 +:dosing on Day 1, 4, 8, 11
1713528|NCT01359657|Biological|Dexamethasone|Tablets, per os (by mouth route of administration) (P.O), 40 mg, administered on the day of (and the day after) Bortezomib infusion, 35 days (cycle 1) 21 days subsequent cycles
1713529|NCT01359644|Drug|PSI-7977|Tablets, oral, 400 mg, once daily
1713530|NCT01359644|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily
1713531|NCT01359644|Drug|Ribavirin|Tablets, oral, 200 mg
1713532|NCT01359618|Drug|TC-5214|Single dose, oral tablets
1713533|NCT01359618|Other|Placebo comparator|Single dose, oral tablets
1713534|NCT01359618|Drug|Moxifloxacin|Single dose, oral encapsulated tablet
1713535|NCT01359618|Other|Moxifloxacin placebo comparator|Single dose, oral encapsulated tablet
1713536|NCT01359605|Drug|varespladib methyl|500 mg oral suspension
1713537|NCT01359592|Biological|rituximab|
1713538|NCT01359592|Drug|cyclophosphamide|
1713539|NCT01359592|Drug|doxorubicin hydrochloride|
1713540|NCT01359592|Drug|prednisone|
1713541|NCT01359592|Drug|vincristine sulfate|
1713542|NCT01359592|Other|R-CHOP regimen|
1713543|NCT01359592|Other|laboratory biomarker analysis|
1713544|NCT01359592|Radiation|fludeoxyglucose F 18|
1713545|NCT01359592|Radiation|selective external radiation therapy|
1713546|NCT01359592|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1713547|NCT01359579|Drug|varespladib methyl|Single oral 500 mg dose
1713551|NCT01359566|Drug|Arbaclofen placarbil 45 mg BID|arbaclofen placarbil 45 mg BID
1713552|NCT01359553|Other|Intra-articular ultrasound imaging of knee joint during arthroscopy|
1713553|NCT01359553|Other|Non-invasive ultrasound imaging of knee|
1713554|NCT01359553|Other|Quantitative MRI imaging of knee|
1713555|NCT01359553|Other|Contrast-enhanced CT imaging of knee|
1956422|NCT02867033|Other|Pain evaluation|Pain evaluation (EVA scale), anxiety (HADS questionnaire), quality of life questionnaire (EORTC-QLQ-C30)
1956423|NCT02867033|Procedure|Tumor biobank realization|Realization of a tumor biobank is part of classical procedure of participating centers
1713558|NCT01359501|Drug|Chinese medical treatment-LCH1|Start to take the powder of Chinese herb-LCH1 3g*BID just after the 1st chemotherapy, and Stop 2-3 weeks after the final cycle of chemotherapy.
1713559|NCT01359501|Drug|Placebo|Start to take the powder of Placebo 3g*BID just after the 1st chemotherapy, and stop 2-3 weeks after the final chemotherapy.
1713560|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
1713561|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
1713562|NCT01359488|Drug|VRS-317|VRS-317 Single Dose
1713563|NCT01359488|Drug|VRS-317|VRS-317 Single dose
1713564|NCT01359488|Drug|VRS-317|VRS-317 Single dose
1713565|NCT01359475|Procedure|Acetal crown, LD Caulk ltd, USA|Experimental trial of preformed acetal crowns for primary molars
1713566|NCT01359462|Drug|tolvaptan|"Drug: tolvaptan
tablet, 15mg, Qd, for 7 days."
1713567|NCT01359449|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate: Menactra®|0.5 mL, Intramuscular
1713568|NCT01359449|Biological|Meningococcal Group C Conjugate vaccine: MenC|0.5 mL, Intramuscular
1713569|NCT01359436|Device|Electrosensing antibody probing system (e- Ab sensing)|Electrosensing antibody probing system (e- Ab sensing), which was developed for the rapid and sensitive detection of hapten, proteins or viral antigen in medical samples, will be used for analyzing the interaction kinetics between mutation-specific anti-EGFR and its antigen mutant EGFR present in NSCLC. The system incorporates the use of engineered semiconductive antibodies or virus in vertical and lateral chip (eAbchip) or lateral flow through (eAbsignal) formats. In electrosensing antibody probing, semiconductive antibodies are bound as a suitable electrosensing probe which specifically and selectively binds mutant EGFR polypeptide target molecules in the test specimen.
1713570|NCT01359423|Drug|Percutaneous transluminal angioplasty of femoropopliteal artery lesions with primary long|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
1713571|NCT01359423|Drug|short stenting for the primary outcome and use of cilostazol for 12 months for secondary outcome.|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
1713572|NCT01359410|Device|Mesh reinforced staple line (SEAMGUARD)|Reinforce the pancreatic transaction with SEAMGUARD®
1713573|NCT01359410|Device|Stapled without mesh reinforcement (PER-STRIPS DRY)|Stapled without mesh reinforcement (PERI-STRIPS DRY®)
1713574|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab|Her2 - patients only
1713575|NCT01359397|Drug|Docetaxel, Oxaliplatin, Capecitabin, Bevacizumab, Trastuzumab|for Her2 + patients only
1713576|NCT01359345|Drug|gadollinum|use of on injection gadollinum Iv for imaging
1713577|NCT01359332|Procedure|Moderate hypothermia|procedure of moderate hypothermia therapy, between 32 ° and 34 ° C for 24 hours
1713578|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
1713579|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tables|PPatients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
1713580|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
1713581|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
1713582|NCT01359319|Drug|Sialic Acid Extended Release (SA-ER) Tablets|Patients will receive SA-ER tablets orally at one of five (5) dose levels in the single-dose phase,phase and one of four (4) dose levels in the repeat-dose phase. During repeat dosing, the total daily dose will be divided evenly into three doses given in the morning, in the evening, and at bedtime (qHS). No placebo or active comparator will be administered and the study drug will be administered on an open-label basis.
1713583|NCT01359280|Behavioral|Adherence Counseling|5 Sessions of theory-based medication adherence counseling
1713584|NCT01359280|Behavioral|General Health Counseling|5 sessions of health improvement counseling
1713585|NCT01359280|Behavioral|Text Messages|Daily medication regimen tailored adherence reminders delivered by cell phone
1956424|NCT02864615|Radiation|SBRT|Dose and schedule will be depended on metastases location.
1713587|NCT01359254|Drug|Melphalan|Melphalan is given daily for 2 days, overlapping with the completion of fludarabine.
1713588|NCT01359254|Drug|Fludarabine|Fludarabine is given through the vein daily for 5 days.
1713589|NCT01359254|Drug|Antithymocyte Globulin (ATG)|ATG is given every other day for 4 days.
1713590|NCT01359254|Drug|Busulfan|Busulfan is given daily for 4 days.
1713591|NCT01359254|Drug|Total Body Irradiation (TBI)|TBI is given twice on the last day.
1713592|NCT01359241|Procedure|closed-loop insulin delivery|Insulin delivery via subcutaneous pump, adjusted according to computer-based algorithm advice, based on continuous glucose sensor readings
1713593|NCT01359241|Drug|Usual diabetes treatment regimen|Usual non-insulin glucose lowering medications
1713594|NCT01359228|Drug|Rifaximin (XIFAXAN)|Rifaximin (XIFAXAN®) 1650 mg/day (550 mg tablet three times a day) for 14 days
1713595|NCT01359228|Drug|Placebo|Placebo 1 tablet three times a day for 14 days.
1713596|NCT01359202|Biological|rfVIIa|80ug/kg IV bolus
1713597|NCT01359202|Other|Standard saline solution|Saline
1713598|NCT01359189|Device|ProxiScan (scintigraphic rectal probe)|"ProxiScanTM is a compact, high-resolution gamma camera which has been developed for the detection of cancer and other abnormalities in the body by imaging the distribution of radionuclides in the human body using planar imaging techniques. This camera is capable of high-performance imaging of radiopharmaceuticals distributed within anatomical regions of interest located close to the camera head. The ProxiScan compact scintigraphic detector was approved by the FDA to market the device for the following indication: The ProxiScanTM is indicated for use in imaging the distribution of radionuclides in the human body using planar imaging techniques. ProxiScanTM may also be used intraoperatively, on pathological specimens and for endocavity applications if a protective sheath is used."
1713599|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
1713600|NCT01359163|Drug|etynodiol diacetate|tablet, 0.5 mg, single dose
1713601|NCT01359150|Drug|CP-690,550|Treatment Group 1: 10 mg BID CP-690,550 (100 subjects). Strata 1: 10 mg BID CP-690,550 on background methotrexate (50 subjects); Strata 2: 10 mg BID CP-690,550 monotherapy (50 subjects).
1713602|NCT01359150|Drug|placebo|Placebo CP-690,550 (100 subjects). Strata 1: Placebo CP-690,550 on background methotrexate (50 subjects); Strata 2: Placebo CP-690,550 monotherapy (50 subjects). Influenza and pneumococcal vaccines will be administered to all subjects
1713603|NCT01359137|Behavioral|Probation as usual|Routine probation with do deferred jail condition.
1713604|NCT01359137|Behavioral|Deferred Jail|Discretionary deferred jail in response to violations of probation conditions.
1713605|NCT01359137|Behavioral|Arizona's SAFE|Swift Accountable Fair Enforcement (SAFE) uses non-discretionary brief jail sanctions for probation violations.
1713606|NCT01359124|Behavioral|Exercise Cycle|Exercise regimen: three monitored exercise sessions per week for eight weeks using the upright exercise cycle.
1713607|NCT01359124|Behavioral|Land-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the land-based treadmill.
1713608|NCT01359124|Behavioral|Water-based Treadmill|Exercise regimen: three monitored exercise sessions per week for eight weeks using the water-based treadmill.
1713609|NCT01359111|Device|PATH ID Adapter|Intradermal delivery device which fits on the end of a syringe to limit the depth and angle of needle penetration into the skin.
1713610|NCT01359098|Drug|Ciprodex Otic Suspension|4 gtt b.i.d. for 7 days.
1713611|NCT01359098|Drug|Ciprodexa Otic Foam|0.3% Ciprofloxacin, 0.1% Dexamethasone Otic Foam, 1 actuation, q.d. for 7 days
1713612|NCT01359085|Drug|Pregabalin|Pregabalin 75 mg will be given orally as premedication at the night before surgery (at bedtime). Pregabalin 150 mg will be administered orally at 1h preoperatively and at 12h and 24h postoperatively.
1713613|NCT01359085|Procedure|ISBPB - interscalene brachial plexus block|ISBPB will be performed by an anesthesiology consultant experienced in performing the procedure, after the induction of GA. Block will be performed under sterile conditions by injection of 40ml 0.5% bupivacaine with epinephrine 1:100,000 to the plexus sheath through a 5-cm, 23-gauge short-beveled needle.
1713614|NCT01359072|Other|Self administered coping intervention|The self administered coping intervention (i.e. NUCARE workbook) aims to teach individuals how to cope with their cancer. The intervention embraces two major areas: (i) the enhancement of a sense of personal control; and (ii) the learning of emotional and instrumental coping responses. The approach emphasizes training in problem-solving, relaxation techniques, cognitive coping skills, goal setting, communication, social support and lifestyle factors. The didactic material of the Nucare program is comprised of a workbook containing 12 chapters addressing the above mentioned aspects.
1713615|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
1713616|NCT01359059|Drug|Pregabalin|Patients in one set (40 patients/set) will receive 150 mg of PGL or placebo at 20:00 the evening before surgery and 1.5 h before surgery and will undergo surgery under GA. The 2nd set of patients will be randomized similarly but will undergo surgery under epidural analgesia. One physician whose duty in the study will end at the point of preoperative preparation will provide the patients with the preemptive drug. No other premedication will be administered to any patient. Post-operatively, patients who received preoperative PGL patients will be given placebo while the pre-surgery-placebo-treated ones will receive PGL, all at 2 h after surgery. All patients will then be given 150 mg twice daily thereafter, Q 12 h postoperatively up to 96 h.
1713617|NCT01359046|Device|silver SPC|subject randomized to receive Bardex IC Silver impregnated catheter
1713618|NCT01359046|Device|standard SPC|subject randomized to receive standard catheter
1713619|NCT01359020|Drug|ibuprofen, dipyrone, acetaminophen|The dosage for the three drugs was the same: 10 milligrams per kilo, oral administration
1713621|NCT01358981|Drug|LY2881835|Administered orally
1713622|NCT01358981|Drug|Placebo|Administered orally
1713623|NCT01358968|Drug|LY2603618|Administered intravenously.
1713624|NCT01358968|Drug|Desipramine|Administered orally
1713625|NCT01358968|Drug|Pemetrexed|Administered intravenously
1713626|NCT01358968|Drug|Gemcitabine|Administered intravenously
1713627|NCT01358955|Other|group cognitive intervention|The cognitive training will be administered twice a week for 12 weeks, located in hospital-based outpatient memory clinics. Each session will last approximately 90 minutes. The cognitive training programs will be offered in group sessions consisted of 5 participants.
1713628|NCT01358955|Other|Home-based cognitive intervention|The participants will do their paper and pencil homework for 30 minutes every business days for 12 weeks.
1713629|NCT01358929|Drug|Placebo|Placebo to RO6807952
1713630|NCT01358929|Drug|RO6807952|Escalating subcutaneous dose
1713631|NCT01358916|Other|Mailing of antibiotic therapy guidelines to the sentinel physicians|Mailing of antibiotic therapy guidelines to the sentinel physicians and regular feedback on antibiotic prescription
1713632|NCT01358903|Drug|RO5429083|Cohorts receiving multiple escalating doses iv
1713633|NCT01358903|Drug|RO5429083|Cohorts receiving 89Zr-labelled RO5429083 plus RO5429083, followed by RO5429083 until disease progression
1713634|NCT01358890|Other|low carbohydrate diet|Dietary carbohydrate diet was restricted to 20 gram/day within the first week, then increase gradually to 120 gram/day
1713635|NCT01358890|Other|Calories restricted diet|Total energy intake is restricted to 1200 kcal/day for women. Energy from carbohydrate, protein and fat will be kept to approximate 55%, 20% and 25%, respectively. Moreover, saturated fat and dietary cholesterol are restricted to at most 10% energy and 300 mg/day, respectively
1713636|NCT01358877|Drug|5-Fluorouracil|Participants may receive 5-fluorouracil 500-600 milligrams per square meter (mg/m^2) IV q3w.
1713637|NCT01358877|Drug|Carboplatin|Participants may receive carboplatin dose of 6 times Area Under the Concentration Time Curve (AUC) (maximum dose of 900 mg) IV q3w.
1713638|NCT01358877|Drug|Cyclophosphamide|Participants may receive cyclophosphamide 500-600 mg/m^2 IV q3w.
1713639|NCT01358877|Drug|Docetaxel|Participants may receive docetaxel either 75 mg/m^2 IV q3w, or 100 mg/m^2 IV q3w, or 75 mg/m^2 IV q3w for first cycle followed by 100 mg/m^2 IV q3w.
1713640|NCT01358877|Drug|Doxorubicin|Participants may receive doxorubicin 50 mg/m^2 IV q3w.
1713641|NCT01358877|Drug|Epirubicin|Participants may receive epirubicin 90-120 mg/m^2 IV q3w.
1713642|NCT01358877|Drug|Paclitaxel|Participants may receive paclitaxel 80 mg/m^2 IV once weekly.
1713643|NCT01358877|Drug|Pertuzumab|Participants will receive pertuzumab loading dose of 840 mg IV in Cycle 1, followed by 420 mg IV q3w.
1713644|NCT01358877|Drug|Placebo|Participants will receive pertuzumab matching placebo IV q3w.
1713645|NCT01358877|Drug|Trastuzumab|Participants will receive trastuzumab at a loading dose of 8 milligrams per kilogram (mg/kg) followed by 6 mg/kg IV q3w.
1713646|NCT01358864|Drug|BI 201335|BI 201335 once a day (QD) for 24 weeks
1713647|NCT01358864|Drug|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha for 48 weeks
1713648|NCT01358864|Drug|Ribavirin (RBV)|Ribavirin (RBV) for 24 or 48 weeks
1713649|NCT01358864|Drug|Placebo|Placebo to BI201335 for 24 weeks
1713650|NCT01358851|Procedure|Cryotherapy|1-2 times during the treatment time
1713651|NCT01358851|Drug|LAS41005|once daily
1713652|NCT01358838|Device|ablative 10600 nm fractional laser therapy|"Half of the scar, or one of two comparable scars, will be treated with the ablative 10600 nm fractional laser. There wil be 3 treatments, with 8 weeks apart.
Half of the scar, or one of two comparable scars, will receive no treatment at all."
1713653|NCT01358825|Procedure|Blood Sampling|A blood sample will be taken at 5 years of age, after vaccination in the primary study.
1713654|NCT01358812|Drug|FOLFOXIRI + Panitumumab|PANITUMUMAB 6 mg/Kg i.v. over 1 hour followed by IRINOTECAN 150 mg/sqm i.v. over 1 hour followed by OXALIPLATIN 85 mg/sqm i.v. over 2 hours concomitantly with L-LV 200 mg/sqm over 2 hours followed by 5-FLUOROURACIL* 2400 mg/sqm c.i. over 48 hours starting on day 1 repeated every 2 weeks.
1713655|NCT01358799|Device|APTIMA Assay for Chlamydia trachomatis|APTIMA Assay for Chlamydia trachomatis
1713656|NCT01358786|Procedure|quilting suture|"quilting sutures and drains
quilting sutures but no drains"
1713657|NCT01358773|Other|multidisciplinary intervention|Comparison of the polysomnography results, blood collection parameters, resting metabolic rate values, body composition variables, carotid artery thickness values, abdominal and subcutaneous fat and lung function variables baseline, middle and at the end of the one year of interdisciplinary weight loss program combined exercise training with physiotherapy, clinical, nutritional and psychological therapies.
1713658|NCT01358760|Drug|Placebo|Placebo vaginal suppository
1713659|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA
1713660|NCT01358760|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA
1713661|NCT01358747|Drug|BEACOPPesc|
1713662|NCT01358747|Drug|BEACOPPesc - ABVD - PET2|
1713663|NCT01358734|Drug|Azacitidine|Azacitidine at 75 mg/m^2/day subcutaneous on Days 1-7
1713664|NCT01358734|Drug|Lenalidomide|Lenalidomide 50 mg PO daily x 28 days for the first 2 cycles then 25 mg PO daily x 28 days for the next 2 cycles followed by continuous 28-day cycles of lenalidomide 10 mg PO daily
1713665|NCT01358734|Other|Best Supportive Care (BSC)|"The use of BSC was considered as concomitant treatment and must be documented as concomitant medication.
BSC includes, but is not limited to, treatment with Red Blood Celll (RBC) or whole blood transfusions, fresh frozen plasma transfusions, platelet transfusions, antibiotic or antifungal therapy, and nutritional support"
1713669|NCT01358708|Drug|LACTEOL® 340 mg|LACTEOL® 340 mg will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
1713670|NCT01358708|Drug|PLACEBO|Matched LACTEOL® 340 mg Placebo will be taken for a 4-week duration (28 days) as three capsules a day: two capsules in the morning and one capsule in the evening.
1713671|NCT01358695|Biological|ANT-1207|The interventions differ by dose of investigational product applied.
1713672|NCT01358695|Biological|Botulinum Toxin, Type A|The interventions differ by dose of investigational product applied.
1713673|NCT01358695|Biological|Botulinum Toxin Type A|The interventions differ by dose of investigational product applied.
1713674|NCT01357590|Device|Thoracic Endovascular Stent Graft System (ThoraflexTM)|Thoracic Endovascular Stent Graft System
1713675|NCT01357577|Behavioral|Cognitive behavioral therapy for PTSD|The CBT for PTSD model is based on modern theories of posttraumatic reactions that place a premium on the importance of individuals' appraisals of traumatic events, their own reactions and those of others, and the meaning of the experience in terms of oneself and one's place in the world. In addition, the model employs cognitive restructuring to teach individuals how to examine and challenge their trauma-related appraisals.
1956429|NCT02860715|Drug|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
1713677|NCT01357551|Behavioral|Maintenance intervention|Theoretically-informed maintenance intervention that involves in-person group visits that transition to individualized telephone calls, and the frequency of contact gradually decreases over time.
1713678|NCT01357538|Drug|Posiformin 2 %, bibrocathol|A strip of 5 mm eye ointment applied 3 times per day to the eye lid
1713679|NCT01357538|Drug|Placebo Comparator|corresponding vehicle, eye ointment applied to the eye lid
1713680|NCT01357525|Radiation|Stereotactic Body Radiation Therapy (SBRT)|"An SBRT plan will be created by a medical physicist based on the PTV contoured on the CT scan. The plan will be to deliver fractionated SBRT to the isodose line best encompassing the PTV:
12 Gy x 3 fractions (36 Gy total)"
1713681|NCT01358669|Drug|Denosumab|60mg denosumab by injection as a single dose
1713682|NCT01358669|Other|Placebo|Placebo by injection as a single dose
1713683|NCT01358656|Procedure|Single bundle anterior cruciate ligament reconstruction|The surgical technique includes ACL reconstruction with graft of two autologous tendons - the semitendinous and gracilis - fixed in one tibial tunnel and one femoral tunnel. Once the graft is obtained, the arthroscopy-assisted ACL reconstruction is performed using anterolateral, anteromedial and accessory anteromedial portals. The first tunnel to be built is femoral tunnel, through a Smith & Nephew femoral guide inserted into the anteromedial portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. The next tunnel is tibial tunnel. The tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45 degrees. The new ligament is fixed onto the tibia and femur with a biodegradable interference screw.
1713684|NCT01358656|Procedure|Double bundle anterior cruciate ligament reconstruction|The ACL reconstruction is performed with graft of two autologous tendons -the semitendinous and gracilis- fixed in two tibial tunnels and two femoral tunnels. The first tunnel to be built is the anteromedial (AM) femoral tunnel, through femoral guide inserted into the AM portal in the 10:30 h position for the right knee and 1:30 h position for the left knee, with the knee at 120° of flexion. Then we drill the PL femoral tunnel in its anatomical position from the accessory AM portal, with the knee at 120° of flexion. The next tunnels are the PM and AM tunnels. The PL tunnel has its point of entry anterior to the fibers of the superficial medial collateral ligament, and the tibial guide must be adjusted at 45º. The AM tunnel has its point of entry more lateral, and a bone bridge of at least one cm must be left between the tunnels, and the tibial guide adjusted at 55º. Both bundles must be fixed onto the tibia and femur with a biodegradable interference screw.
1713685|NCT01358643|Other|Three home-based diet and exercise programs|"All research activities are outpatient. This pilot study will be a crossover study of two 6-week programs. The participant will be involved for 15 weeks.
Thirty OEF/OIF veterans with BMI > 30 will be recruited to test the diet and exercise programs. Each veteran will test only two of the three programs described above. The participants will use the the programs for six weeks then crossover and use a second program."
1713686|NCT01358617|Other|diagnostic laboratory biomarker analysis|Correlative studies
1713687|NCT01358604|Genetic|polymerase chain reaction|
1713688|NCT01358604|Genetic|protein expression analysis|
1713689|NCT01358604|Genetic|western blotting|
1713690|NCT01358604|Other|flow cytometry|
1713691|NCT01358604|Other|immunohistochemistry staining method|
1713692|NCT01358604|Other|laboratory biomarker analysis|
1713693|NCT01358591|Dietary Supplement|High calcium milk|High calcium milk (9 mg/kgBM)
1713694|NCT01358591|Dietary Supplement|Control|Regular Milk
1713695|NCT01358578|Drug|Placebo|Placebo to Match secukinumab (AIN457) 150mg or 300mg or Placebo to match etanercept
1713696|NCT01358578|Drug|secukinumab (AIN457)|secukinumab (AIN457) 150mg or 300mg subcutaneous
1713697|NCT01358578|Drug|etanercept|etanercept 50mg subcutaneous
1713698|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
1713699|NCT01358565|Drug|Fx-1006A|A single oral 20 mg dose of Fx-1006A will be administered on Day 1 followed by 16 days of follow-up.
1713751|NCT01358175|Drug|Secukinumab (75 mg)|Secukinumab (75 mg)
1713752|NCT01358175|Drug|Secukinumab (150 mg)|Secukinumab (150 mg)
1713753|NCT01358175|Drug|Placebo|Placebo
1956430|NCT02860715|Drug|Placebo|This is the placebo of GX-I7 described above.
1713700|NCT01358552|Other|Néevo®/ NéevoDHA®|Néevo®/NéevoDHA® is an orally administered medical food indicated for the dietary management of impaired metabolic processes in women under a doctor's care who face high to intermediate risk pregnancies and are unable to fully metabolize or absorb folic acid. Néevo®/ NéevoDHA® contains L-methylfolate, the biologically active and immediately bioavailable form of folate.
1713701|NCT01358539|Behavioral|Pain education|Patients receiving pain education
1713702|NCT01358526|Drug|Oxycodone/Naloxone Controlled-release|Oxycodone/Naloxone Controlled-release tablets (10/5 mg, 20/10 mg, 30/15 mg, 40/20 mg) taken orally every 12 hours
1713703|NCT01358526|Drug|Placebo|Placebo tablets to match OXN taken orally every 12 hours
1713704|NCT01358500|Drug|Fentanyl|Intravenous infusion using STANPUMP
1713705|NCT01358487|Behavioral|Online self-help course plus live follow-up if needed|In addition to the self-help mood management course and the email reminders to return to the site to complete assessments at 1, 3, and 6 months (and the monetary incentives), this condition will also receive phone reminders if they do not complete assessments online.
1713706|NCT01358487|Behavioral|Online + incentives Follow-up Group|This group tests online email reminders and monetary online incentives to estimate percentage of participants who will complete online assessments at 1, 3, and 6 month follow-ups.
1713707|NCT01358461|Biological|Blood sampling|Blood sampling
1713708|NCT01358461|Other|ECG-Holter 24 h tape and sino-carotid stimulation test|ECG-Holter 24 h tape and sino-carotid stimulation test
1713709|NCT01358448|Behavioral|growth monitoring|Caretakers will be encouraged to monitor child growth monthly.
1713710|NCT01358448|Behavioral|Growth Monitoring plus Family-based Behavioral Counseling|Caretakers will monitor growth monthly in addition participating in family-based behavioral counseling
1713711|NCT01358435|Biological|30% Regular Insulin Human Neutral and 70%Isophane Insulin|Total Dose per subject is 0.4 IU/Kg given subcutaneously.
1713712|NCT01358435|Biological|Novolin 70/30|Total Dose per subject is 0.4IU/Kg given Subcutaneously.
1713713|NCT01358409|Drug|Nebivolol|Day 1 - Patients will start Nebivolol 5 mg PO daily; after one month, if the subject has tolerated 5 mg PO Nebivolol, the dose will be increased to 10 mg PO daily. If the patients is unable to tolerate 5 mg PO Nebivolol, he/she will be discontinued from the study. After six months, medication will be tapered to 5 mg PO daily for two weeks. Medication will then be tapered to 2.5 mg PO daily for two additional weeks.
1713714|NCT01358396|Other|Respond to therapy for diabetic macular edema|Correlate HBA1c with visual acuity outcome to therapy.
1713715|NCT01358383|Drug|naproxen|250mg, oral dose
1713716|NCT01358383|Drug|esomeprazole|20mg, oral dose
1713717|NCT01358357|Drug|Lurasidone|Lurasidone 20 mg daily (days 1-3), Lurasidone 40 mg daily (days 4-7), Lurasidone 20-80 mg daily (flexible dose) thereafter
1713718|NCT01358357|Drug|Placebo|20-80 mg flexible dose
1713719|NCT01358344|Drug|Pantoprazole|40 mg delayed‑release tablet administered orally in the morning of Days 1-7
1713720|NCT01358344|Drug|SCH 530348 (high percentage)|2.5 mg tablet containing ~46% active pharmaceutical ingredient (API) as free base (46+5%) administered orally on the morning of Day 5
1713721|NCT01358344|Drug|SCH 530348 (standard percentage)|2.5 mg tablet containing ~23% API as free base (STANDARD) administered orally on the morning of Day 5
1713722|NCT01358331|Drug|MK-8353|
1713723|NCT01358318|Other|Satiety|Single consumption of snack bars to determine satiety and food intake at next meal.
1713724|NCT01358305|Other|Protein Blend|Single intake of approximately 20 grams of total protein
1713725|NCT01358292|Procedure|Semi-extended Surgical Technique|Surgical technique with the knee in 10-20 degrees of flexion, to implant the intramedullary tibia nail.
1713726|NCT01358292|Procedure|Standard Surgical Technique|Th e Standard surgical techique is implanting the tibia nail with the knee in 90 degrees of flexion.
1713727|NCT01358279|Procedure|transcranial direct current stimulation|A constant current of 2 mA intensity applied for 20 min over C3 or C4
1713728|NCT01358266|Drug|DE-109|Low dose
1713729|NCT01358266|Drug|DE-109|Medium dose
1713730|NCT01358266|Drug|DE-109|High dose
1713731|NCT01358253|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)(odd courses).
1713732|NCT01358253|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
1713733|NCT01358253|Drug|Vincristine|Consolidation:1.4 mg/m2 (max 2mg) IV on day 4 and day 11 (odd courses). Maintenance:1.4mg/m2(max 2mg) IV monthly from 1st to 12th month.
1713734|NCT01358253|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 and days 11-14(odd courses)
1713735|NCT01358253|Drug|Cytarabine|2g/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
1713736|NCT01358253|Drug|Methotrexate|Consolidation:1000 mg/m2 IV over 24 hours on day 1 (even courses). Maintenance:25mg/m2 weekly for 24 months.
1713737|NCT01358253|Drug|Rituximab|"Consolidation:375 mg/m2 IV day 1 for the odd courses of therapy (total 4 times).
Maintenance:375 mg/m2 IV in 6th month and 12th month."
1713738|NCT01358253|Drug|6-Mercaptopurine|Maintenance:60mg/m2 daily for 24 months.
1713739|NCT01358253|Drug|Prednisone|Maintenance:40mg/m2 from days 1-7 monthly from 1st to 12th month.
1713740|NCT01358253|Drug|L-asparaginase|Maintenance:6000IU/m2 IV on days 1,3,5 of the 3rd and 9th month.
1713741|NCT01358240|Drug|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
1713742|NCT01358240|Drug|Vehicle Foam|Vehicle Foam applied once a day for 4 week
1713743|NCT01358240|Drug|Econazole Nitrate Cream 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
1713744|NCT01358240|Other|Placebo Cream|Placebo cream applied once a day for 4 weeks
1713745|NCT01358227|Drug|PR104|Dose escalation of PR104 to determine maximum tolerated dose for weekly administration
1713746|NCT01358214|Behavioral|Questionnaire on Quality of Life.|The impact of a disease on patient's Quality of Life has meanwhile gained more influences on the choice of treatment alternatives. The benefit of a method is currently not only defined by the objective outcome but also influenced by the Quality of Life. Two questionnaires with 20 respectively 40 Questions should be filled in by the patients.
1713754|NCT01358162|Other|Placebo|Placebo given orally, daily for 14 consecutive days
1713755|NCT01358162|Drug|SQ109|A single oral dose of 300 mg of SQ109 given daily for 14 consecutive days.
1713756|NCT01358149|Other|cocoa-based food|single intake of cocoa-based food
1713757|NCT01358149|Other|cocoa-based food|Single intake of cocoa-based food
1713758|NCT01358110|Other|Early palliative care consultation|Patients will have symptoms assessed, have goals of care discussion with family and team present, and surrogate designated, as well as coordination of care and home services.
1713759|NCT01358110|Other|Care as usual|Standard care as usual which may or may not include palliative care consultation
1713760|NCT01358084|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
1713761|NCT01358084|Drug|Placebo|Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
1713762|NCT01358084|Other|Best Supportive Care|Where applicable and as appropriate according to Institutional clinical practice and literature guidelines. Best supportive care includes antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
1713763|NCT01358071|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion weekly or every 3 or 4 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
1713764|NCT01358071|Drug|Pegylated liposomal doxorubicin|50 mg/m² iv every 4 weeks until confirmed evidence of disease progression
1713765|NCT01358071|Drug|Doxorubicin|60 mg/m^2 iv every 3 weeks for a maximum of 8 cycles
1713766|NCT01358058|Radiation|Proton radiation|Total dose of 54-59.4 Gy(RBE) at 1.8 Gy(RBE) per daily fraction delivered 5 days per week on weekdays for 6-6.5 weeks.
1713767|NCT01358045|Drug|Diclofenac|Application on the lesion 2 times a day 8 weeks.
1713768|NCT01358045|Drug|Diclofenac + Calcitriol|Application on the lesion 2 times a day, both ointments, 8 weeks.
1713769|NCT01358045|Drug|Calcitriol|Application on the lesion, 2 times a day, 8 weeks.
1713770|NCT01358032|Behavioral|an in-home cognitive behavioral program|The in-home cognitive behavioral program aims to learn older persons, living in the community, how to deal with concerns about falling and to increase physical, social and functional activity. The principles of cognitive restructuring are used for shifting maladaptive in adaptive attitudes with respect to falling as well as increasing self efficacy beliefs and feelings of control. The following themes are discussed during the program: concerns about falling, thoughts about falling, physical exercise, assert oneself, overcome personal barriers, recognizing fall-ty habits and managing concerns about falling. Duration of the program is 10 weeks with 7 individual sessions (3 home visits (60, 60 and 75 minutes, respectively) & 4 telephone contacts (35 minutes each). The program is facilitated by trained nurses qualified in the field of geriatrics and working for home care agencies.
1713771|NCT01358019|Drug|LY2523355|Days 1, 2, and 3 in a cycle that consists of 21-days
1713772|NCT01358006|Drug|JNJ-40411813|Cohort 1: Type=2 to 3, unit=mg, number=200 to 300, form=capsule, route=oral use.Capsule(s) taken in the fed state Capsule(s) taken in the fed state.
1713773|NCT01358006|Drug|JNJ-40411813|Cohort 2: Type=up to 7, unit=mg, number=up to 700 mg, form=capsule, route=oral use. Capsule(s) taken in the fed state.
1713774|NCT01357993|Drug|JNS001|18 mg, 27 mg and 36 mg tablets (18-72 mg/day) once daily for 48 weeks
1713775|NCT01357980|Drug|Botulinum type A toxin (Dysport®)|750 U intra detrusor injection on Day 1 (single dose)
1713776|NCT01357980|Drug|Placebo|Intra detrusor injection on Day 1 (single dose)
1713777|NCT01357967|Drug|SSRI monotherapy|SSRI (paxil CR, es-citalopram, fluoxetine, sertraline) start with (paxil CR 12.5mg, es-citalopram 10mg, fluoxetine 20mg, sertraline 50mg) for 1 week up to maximal dosage, flexible dosage, usually in the morning
1713778|NCT01357967|Drug|Seroquel XR adjunctive|"Quetiapine group:
seroquel XR 50mg Day 1 --> 50mg Day 2 --> 150mg Day 3 --> 150mg Day 4 --> adjustment usually at hs but can be daytime"
1713779|NCT01357954|Other|Regular physiotherapy|The child's regular physiotherapy
1713780|NCT01357954|Other|Targeted Training|Targeted training, 5 days a week for 6 months, up to 30 minutes a day
1713781|NCT01357915|Procedure|Blood sampling|"Blood samples will be collected at 2 time points:
At the long-term follow-up at approximately Month 48 of study (= ± 42 months post dose 3) from all subjects in the vaccine group.
At the long-term follow-up at approximately Month 60 of study (= ± 54 months post dose 3) from all subjects."
1713782|NCT01357915|Biological|GSK149203A|GSK Biologicals' Recombinant CMV glicoprotein B Vaccine, Intramuscular injection, 3 doses
1713783|NCT01357902|Drug|Lamotrigine|Lamotrigine is a selective inhibitor of a voltage-sensitive sodium channel, is an anti-epileptic drug of the phenyltriazine class.
1713784|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
1713785|NCT01357889|Biological|albiglutide (GSK716155)|subcutaneous injection administered once a week
1713786|NCT01357876|Other|Metformin|withdrawral
1713787|NCT01357863|Drug|Treatment|Patients treated with Lapatinib-capecitabine after Trastuzumab progression
1713788|NCT01357850|Drug|GSK716155|GSK716155
1713789|NCT01357850|Drug|Placebo|Placebo
1713790|NCT01357837|Drug|Matching Placebo|2 capsules of matching placebo once a day, in the morning, for a total of 28 days
1713791|NCT01357837|Drug|GRT6005|2 capsules containing a total of 75 µg GRT6005 once a day, in the morning, for a total of 28 days
1713792|NCT01357837|Drug|GRT6005|2 capsules containing a total of 200 µg GRT6005 once a day, in the morning, for a total of 28 days
1713793|NCT01357837|Drug|GRT6005|2 capsules containing a total of 400 µg GRT6005 once a day, in the morning, for a total of 28 days
1713794|NCT01357824|Procedure|Application of Sellick´s maneuver.|The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
1713932|NCT01356654|Device|Transcranial Direct current stimulation|Application of true TDCS for 20min, 4 times a week for 4 weeks.
1713795|NCT01357811|Drug|eliglustat; digoxin|repeat oral doses of 150 mg BID (or 100 mg BID if a CYP2D6 poor metabolizer) eliglustat (Day 11 to Day 17) plus singe dose of digoxin 0.25mg on Day 15
1713796|NCT01357811|Drug|digoxin|oral 0.25mg dose of digoxin (single dose) on Day 1
1713797|NCT01357798|Drug|Botulinum toxin type A|Botulinum Toxin group Will have the syringe with Botulinum toxin type A . During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution.
1713798|NCT01357798|Drug|0,9% saline|0,9% saline group Will have the syringe with 0,9% saline. During the study the patients will be following in the headache's clinic where the evaluator will graduate the pathologies' evolution .
1713800|NCT01357772|Drug|Tamoxifen|at daily dose of 5 mg for a total treatment time of 3 years
1713801|NCT01357772|Drug|placebo|placebo at daily dose of 5 mg for a total treatment time of 3 years
1713802|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
1713803|NCT01357759|Drug|MORAb-022|IV infusion of MORAb-022 at increasing doses starting with the minimal anticipated biological effect level (MABEL) which is 0.0085mg/kg.; IV infusion of Placebo (saline)
1713804|NCT01357746|Procedure|Transthoracic pulmonary doppler recording|A 30 min recording of doppler signals from the right chest wall including measurements while the patient performs Valsalva maneuvers
1713805|NCT01357733|Other|Early interim FDG PET/CT after 1 cycle of R-CHOP|FDG PET/CT imaging study obtained after 1 cycle of R-CHOP and before the second cycle of R-CHOP
1713806|NCT01357720|Biological|Quinvaxem|"A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), whole-cell inactive pertussis bacteria (>= 4 IU), 10 mcg Hib oligosaccharide conjugate (approx. 25 mcg CRM197), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at Weeks 6, 10 and 14"
1713807|NCT01357720|Biological|Quinvaxem/Tritanrix|"A single dose (0.5 mL) of Quinvaxem contains:
diphtheria antitoxin (>= 30 IU), tetanus antitoxin (>= 60 IU), inactive pertussis bacteria (>= 4 IU), 10 mcg Hib polysaccharide conjugate (approx. 25 mcg tetanus toxoid), 10 mcg Hepatitis B surface antigen
One dose of Quinvaxem given at Weeks 6, 10 and 14"
1713808|NCT01357707|Genetic|DNA preparation|Taking blood or saliva from the patient to prepare DNA therefrom
1713809|NCT01357694|Behavioral|psychotherapeutic contacts|psychotherapeutic contacts during inpatient hospital stay and up to 3 months outpatient appointments after discharge
1713810|NCT01357681|Drug|(2)-epigallocatechin-3-gallate (EGCG)|Month 01:400 mg /day (200-0-200) Month 02:800 mg /day (400-0-400) Month 03 -12: 1200 mg /day (600-0-600)
1713811|NCT01357681|Drug|Placebo|Placebo
1713812|NCT01357655|Drug|Dasatinib|Tablets, Oral, 100 mg, Once daily, approximately 5 years depending on response
1713813|NCT01357655|Drug|BMS-833923|Capsules, Oral, dose to be determined, Once daily, approximately 2 years depending on response
1713814|NCT01357642|Drug|Epinephrine inhalation aerosol|Epinephrine inhalation aerosol, 125 mcg/inhalation, 2 inhalations QID at 4 - 6 hour intervals
1713815|NCT01357642|Drug|Placebo|Placebo for epinephrine inhalation aerosol, formulation without epinephrine
1713816|NCT01357642|Drug|epinephrine inhalation aerosol|epinephrine inhalation aerosol, 220 mcg/inhalation, 2 inhalations QID at 4-6 hour intervals
1713817|NCT01357616|Drug|Brinzolamide 1% / Timolol 0.5% fixed combination ophthalmic suspension|
1713818|NCT01357616|Drug|Brinzolamide 1% ophthalmic suspension|
1713819|NCT01357616|Drug|Timolol 0.5% ophthalmic solution|
1713820|NCT01357603|Biological|Glargine|dosage form: Subcutaneous injection
1713821|NCT01357512|Device|magnetic resonance imaging, Siemens|Magnetic resonance imaging (MRI) of prostate with Siemens 3-tesla device
1713822|NCT01357499|Device|blood pressure cuff|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times.
1713823|NCT01357499|Device|blood pressure cuff + electric muscle stimulator|A Blood pressure cuff and and the muscle stimulator pads will be applied to one lower leg. The blood pressure Cuff will be inflated with 200 mmHg for 5 minutes. Next reperfusion will be allowed for 5 minutes. This cycle will be repeated for 3 times. In addition electrical muscle stimulation will be performed throughout the whole preconditioning cycle.
1713824|NCT01357486|Drug|sorafenib|patients receiving sorafenib 400 mg - twice a day
1713825|NCT01357486|Drug|Pravastatin|patients receiving pravastatin 40 mg - once a day
1713826|NCT01357486|Drug|Sorafenib + Pravastatin|patients receiving sorafenib 400 mg (twice a day) and pravastatin 40 mg (once a day)
1713827|NCT01357486|Other|patients receiving best supportive care|palliative management
1713828|NCT01357460|Device|Implantation of intrabronchial valves (IBV) (Spiration IBV)|"In advanced emphysema due to alpha1 antitrypsin deficiency even optimum treatment including drugs, physical training and possibly oxygen therapy is unable to influence exercise dyspnoea and exercise capacity.Implantation of intrabronchial valves in the most destroyed and hyperinflated lung lobe can improve the elastic recoil of the small airways by a reduction in lung volume and thus leading to more ergonomic breathing mechanics and diaphragm function.The one-way mechanism of these valves allows air to escape from the downstream lung segment without any influx of new air during inspiration."
1713829|NCT01357447|Drug|Dornase alfa|Dose: 2.5 mg solution BID via nebuliser for 2 weeks
1713830|NCT01357447|Drug|Saline|2.5 ml via nebuliser BID for 2 weeks (alternating with study drug)
1713831|NCT01357434|Behavioral|Fast Food Restaurant|Participants will purchase a meal at Subway and McDonald's, on different days.
1713832|NCT01357421|Drug|TT301|Single iv dose of TT301
1713833|NCT01357421|Drug|Placebo|Single iv dose of 0.9% sodium chloride for injection USP
1713835|NCT01357382|Other|Low carbohydrate diet|restrict carbohydrate consumption to < 20 grams / day while not restricting their caloric intake. Participants will be encouraged to consume vegetables with low carbohydrate content every day including 2 cups of salad greens and 1 cup of vegetables 'that grow above the ground' increase their salt intake by consuming two cups of broth , ½ teaspoon of salt, or tablespoons of salt daily
1713836|NCT01357369|Procedure|Phlebotomy|Blood samples will be drawn from the mother, umbilical vein and artery post delivery, and neonate with other clinical labs.
1713837|NCT01357356|Drug|SER120 (750 ng/day)|
1713838|NCT01357356|Drug|SER120 (1000 ng/day)|SER120 (1000 ng/day)
1713839|NCT01357356|Drug|SER120 (1500 ng/day)|
1713840|NCT01357356|Drug|Placebo|
1713841|NCT01357343|Other|Chiropractic|Spinal manipulation and active and passive therapy.
1713842|NCT01357343|Other|Acupuncture|Acupuncture needling, moxa, Tui Na and cupping.
1713843|NCT01357330|Drug|SAR245408 (XL147)|Pharmaceutical form:capsule and tablet Route of administration: oral
1713844|NCT01357330|Drug|MSC1936369B|Pharmaceutical form:capsule Route of administration: oral
1713845|NCT01357317|Other|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in the lanthanum carbonate arm in spite of consecutive up-titration of the medical dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
1713846|NCT01357317|Other|Diet counseling|If serum phosphorus level exceeds 4.6 mg/dl in spite of consecutive up-titration of the medication dose or due to patients' intolerance of the medication, patient will be considered a treatment failure and other treatment options will be implemented, including diet counseling or another class of phosphorus binder (in this order of preference).
1713847|NCT01357317|Drug|Phosphorus binder|If serum phosphorus level exceeds 4.6 mg/dl after 3 months of concerted efforts, the patient will be considered a treatment failure and treatment with a phosphorus binder of the treating physician's choice will be allowed.
1713848|NCT01357304|Behavioral|Group treatment and PAR|Group treatment (8-12 patients per group) involving an empowerment-based process and the 5-A model and including PAR. Two group sessions, 6 months apart. The estimated total time for both group sessions together is 100 minutes.
1713849|NCT01357291|Behavioral|Recidivism Reduction Program|Assigned to the 21-module Recidivism Reduction Program
1713850|NCT01357291|Behavioral|Business-as-usual|Inmates who receive standard programming offered by New Mexico Department of Corrections prior to release.
1713851|NCT01357278|Procedure|Rehabilitation and patient education|"Supervised rehabilitation consists of exercises for strength, balance and coordination twice weekly, and a home-training programme once weekly.
Patient education will be offered every eight week."
1713852|NCT01357265|Biological|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
1713853|NCT01357252|Drug|vildagliptin|
1713854|NCT01357252|Drug|Placebo|
1713855|NCT01357239|Drug|AFQ056|
1713856|NCT01357239|Drug|Placebo|
1713857|NCT01357213|Drug|XOMA 3AB|Single intravenous infusion of XOMA 3AB in three cohorts at different concentrations.
1713858|NCT01357213|Other|Placebo|Normal saline 100 ml
1713859|NCT01357200|Other|enteral formula|Complete feeding of study enteral formula, route and regime prescribed by the physician.
1713860|NCT01357187|Other|Scheduled removal of posterior instrumentation with AmnioFix|
1713861|NCT01357187|Other|Scheduled removal of posterior instrumentation without AmnioFix|
1713862|NCT01357161|Drug|MK-1775|MK-1775 capsules, orally, twice a day (BID) for a total of 5 doses starting on Day 1 of each 3-week cycle
1713863|NCT01357161|Drug|Placebo|placebo to MK-1775, capsule, orally, BID for a total of 5 doses, starting on Day 1 of each 3-week cycle
1713864|NCT01357161|Drug|paclitaxel|paclitaxel, intravenous (IV) infusion on Day 1 of each 3-week cycle
1713865|NCT01357161|Drug|carboplatin|carboplatin, IV infusion on Day 1 of each 3-week cycle
1713866|NCT01357148|Drug|Sitagliptin Phosphate/Metformin HCl (JANUMET®)|Participants prescribed Sitagliptin Phosphate/Metformin HCl (JANUMET®) in routine clinical practice.
1713867|NCT01357135|Drug|Metformin|
1713868|NCT01357135|Drug|Sitagliptin|
1713869|NCT01357135|Drug|Sulfonylurea|
1713870|NCT01357135|Drug|Antihyperglycemic Medication|
1713871|NCT01357122|Device|NCI Insertion|DSAEK surgery will be performed using the NCI to insert the donor tissue.
1713872|NCT01357122|Procedure|Standard Forceps Insertion|DSAEK surgery will be performed using forceps to insert the donor tissue. This is our long-established technique for DSAEK, with well-documented excellent results.
1713873|NCT01357109|Drug|Bosentan|62.5 mg bid for two weeks and 125 mg bid for two weeks
1713874|NCT01357109|Drug|Placebo|Matched placebo bid
1713875|NCT01357096|Behavioral|Integrated health care team|CAD education fryers, drugs counseling, diet intervention, individualized exercise program, body weight control, smoking cessation program, and distant CAD care monitoring
1713876|NCT01357096|Other|Traditional group|CAD education fryers
1713877|NCT01357070|Dietary Supplement|Brocco-sprout homogenate|Participants will be asked to orally consume on three consecutive days a brocco-sprout homogenate (70g dry weight).
1713878|NCT01357070|Dietary Supplement|Alfalfa sprout homogenate|Participants will be asked to orally consume on three consecutive days an alfalfa sprout homogenate.
1713879|NCT01357044|Dietary Supplement|Extracts of Punica granatum and Alpinia galanga|Tablets, two in the morning and two in the evening
1713880|NCT01357044|Dietary Supplement|Placebo|Tablets, two in the morning and two in the evening
1713881|NCT01357031|Drug|Amitriptyline|It will be administered Amitriptyline (25mg) once a day at bed time. Patients may keep their abortive treatment that they usually used. The drug will be encapsulated in a bottle of 30 capsules will be given to patients at every visit.
1713882|NCT01357031|Drug|Melatonin|It will be administered Melatonin (3mg) at bed time, half an hour before the usual time of sleep of the patient.
1713883|NCT01357031|Drug|Placebo|It will be administered placebo capsules, identical to Melatonin (3mg) and Amitriptyline (25 mg) patients will take the study medication at bed time
1713884|NCT01357005|Other|No intervention would be provided in this research|No intervention would be provided in this research, but need to draw blood
1713931|NCT01356654|Device|Application of Transcranial direct current stimulation (TDCS)|Application of TDCS for 20 minutes, 4 times a week for 4 weeks.
1715111|NCT00000149|Procedure|Argon Laser Trabeculoplasty|
1713885|NCT01356992|Drug|Enoxaparin|Drugs will be provided by the sponsor to the study's patients on the reference presentation: 40 mg/0.4mL, 60 mg/0.6 mL and 80 mg/0.8 mL (solution for injection of enoxaparin sodium, 1 mg/ kg Sanofi-Aventis) or Eurofarma enoxaparin sodium (1 mg/ kg). The patients will use the drug corresponding to the arm of the study to which they were allocated. The drug administration must be performed through subcutaneous via on the dose of 1 mg/kg every 12 hours for at least 2 days and kept until the patient is discharged.
1713886|NCT01356979|Procedure|Medical thoracoscopy|Performing medical thoracoscopy to diagnose pleural diseases after cytological and other investigational tests.
1713887|NCT01356966|Drug|Tetrahydrobiopterin|Tetrahydrobiopterin (BH4) 200 mg PO BID for 12 weeks
1713888|NCT01356966|Drug|Placebo|2 placebo pills PO BID for12 weeks
1713889|NCT01356966|Dietary Supplement|Folate|Folate 1 mg daily for 12 weeks
1713890|NCT01356953|Other|Aerobic exercise|Intensity of aerobic exercise
1713891|NCT01356940|Drug|dalfampridine ER|dalfampridine ER 10mg bid for 4 weeks
1713892|NCT01356940|Drug|placebo|identical placebo tablet administered bid for four weeks
1713893|NCT01356927|Drug|DMPA|DMPA 150 mg IM given on the day of mifepristone 200 mg po for medical abortion
1713894|NCT01356927|Drug|Etonogestrel implant|Etonogestrel implant placed at the time of mifepristone 200 mg po for medical abortion
1713895|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Every Day (QD), 20 days
1713896|NCT01356914|Drug|BMS-914392|Tablets, Oral, 10 mg, Three Times Daily (TID), 20 days
1713897|NCT01356914|Drug|BMS-914392|Tablets, Oral, 20 mg, Three Times Daily (TID), 20 days
1713898|NCT01356914|Drug|Placebo|Tablets, Oral, 0 mg, Three Times Daily (TID), 20 days
1713899|NCT01356888|Device|Percutaneous Coronary Intervention (Abbott Laboratories - Xience Prime DES)|Stenting
1713900|NCT01356888|Device|Percutaneous Coronary Intervention (Orsiro DES)|stenting
1713901|NCT01356875|Drug|BSC|The support group will be receive transfusional BSC, erythropoietin and / or G-CSF as determined by the physician.
1713902|NCT01356875|Drug|HIDRA/VPA|In each cycle (30 days), Hydralazine 50mg tablets every 12 hours and Valproic 500mg tablets every 8 hours will be administrated orally to HYDRA / VPA group.Each patient will receive 6 cycle.
1713903|NCT01356862|Drug|PASIREOTIDE|One INTRAMUSCULAR INECTION OF PASIREOTIDE 60 MG 10 TO 7 DAYS BEFORE SURGERY
1713904|NCT01356862|Drug|PLACEBO|ONE INJECTION OF PLACEBO 10 TO 7 DAYS BEFORE SURGERY
1713905|NCT01356849|Drug|Atrasentan|Subjects will take two tablets daily of either low dose Atrasentan QD or high dose Atrasentan QD for 12 weeks during the treatment period.
1713906|NCT01356849|Drug|Placebo|Subjects will take two tablets daily of placebo QD for 12 weeks during the treatment period.
1713907|NCT01356823|Biological|30μg HPV|Participants would intramuscularly receive 30μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
1713908|NCT01356823|Biological|60μg HPV|Participants would intramuscularly receive 60μg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
1713909|NCT01356823|Biological|90μg HPV|Participants would receive 90μg HPV vaccines which contains 60μg HPV 16 antigen and 30μg HPV 18 antigen
1713910|NCT01356823|Biological|Hepatitis B vaccine|Participants would intramuscularly receive 10μg of hepatitis B vaccine at 0, 1, 6 month for 3 doses.
1713911|NCT01356810|Other|Environmental Intervention|The environmental intervention consisted of daily reorientation, avoidance of sensorial deprivation, longer visiting hours, the availability of a clock, a calendar and the presence of familiar objects in the room.
1713912|NCT01356810|Other|Standard Care|Delirium management by the attending physician's preferences.
1713913|NCT01356797|Drug|hypobaric levobupivacaine with fentanyl|SSSA with 4 mg hypobaric levobupivacaine 0,13% with 10 mcg fentanyl
1713914|NCT01356797|Drug|hyperbaric bupivacaine 0,5%|SUSA with 4 mg hyperbaric bupivacaine 0.5%
1713915|NCT01356784|Other|Tailored Physical Activity|Health counselling (1,5h) and graded physical activity (3×50 min/week in 10 weeks)
1713916|NCT01356784|Behavioral|"Chronic Pain Self-management Programme"|Health counselling (1,5h) and 'Chronic Pain Self-management Program' (2,5h in 6 weeks)
1713917|NCT01356784|Behavioral|Health counselling|Health guidance (1,5h)
1713918|NCT01356771|Other|Surveys & Mailed Materials|"Phase I: Patients are screened for their level of risk for skin cancer. They will complete a survey and undergo a skin exam administered by the research staff. Moderate- and high-risk persons will be invited to enroll in Phase II.
Phase II: Three sets of materials will be sent in the mail over the course of 6 weeks. Pamphlets will contain information about ways to reduce participant's risk of skin cancer, including sun protection practices, benefits of skin screening practices, and how to do skin self-examinations.
The participant will also complete two surveys for this study, one at baseline and then one at follow up approximately three months later.
Each survey will ask the participant about:
Current and past skin cancer screening practices
Current and past sun protection practices
Attitudes about skin cancer and sun protection
Knowledge of melanoma"
1713919|NCT01356758|Drug|biological treatment|patients treated with anti-psoriatic biological agents
1713920|NCT01356745|Drug|Premixed 50% nitrous oxide and oxygen (Kalinox)|15 min inhalation dose (maximum duration of treatment of a subject)
1713921|NCT01356745|Drug|medical air|inhalation gas for inhalation use
1713922|NCT01356732|Drug|Sufentanil|From 0 to 0,05 µg/kg to a maximum of 4 µg/kg of sufentanil. 7 minutes before nursing 3 nursing per day during 3 days
1713925|NCT01356680|Drug|BEACOPPescalated (Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone)|
1713926|NCT01356680|Drug|ABVD (Adriamycin, Bleomycin, Vinblastine, Dacarbazine)|
1713927|NCT01356680|Radiation|30Gy IF-RT (Involved-Field Radiotherapy)|
1713928|NCT01356680|Radiation|30Gy IN-RT (Involved-Node Radiotherapy)|
1713929|NCT01356667|Behavioral|DARTNA|3-hour protocol provided 2x/week over 12 weeks
1713930|NCT01356667|Behavioral|Treatment-As-Usual|Participants will receive typical substance abuse behavior treatment interventions typically provided to patients including individual counseling, group therapy, and standard culturally-based interventions.
1713933|NCT01356641|Drug|Antibiotic treatment alone|Amoxicillin/clavulanic acid 100/10 mg/kg 6-hourly Gentamicin 7 mg/kg once daily At least 48 hours intravenous administration, in total seven days of antibiotics Oral amoxicillin/clavulanic acid 50/12.5mg/kg
1713934|NCT01356641|Procedure|Appendectomy|Appendectomy either open or laparoscopic depending on the surgeon's preference
1713936|NCT01356615|Drug|low molecular weight heparin (enoxaparin sodium)|Enoxaparin sodium (Clexane; 40 mg) was administered 3-4 min before dialysis as a bolus dose, into the arterial line pre-dialyzer.
1713937|NCT01356615|Drug|standard unfractionated heparin|Heparin (sodium heparin 5000 IU/ml) was administered as a bolus dose (50 IU/kg body weight) intravenously into the pre-dialyzer arterial line of the extracorporeal blood circuit, followed by a maintenance dose of 1000 IU sodium heparin per hour.
1713938|NCT01356602|Drug|Canakinumab pre-filled syringe|Canakinumab pre-filled syringe
1713939|NCT01356602|Drug|Canakinumab lyophilized powder|Canakinumab lyophilized powder
1713940|NCT01356602|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide
1713941|NCT01356602|Drug|Placebo|Matching placebo to Canakinumab (PFS), Canakinumab (LYO) and Triamcinolone Acetonide
1713942|NCT01356563|Behavioral|pharmaceutical care|Hemodialysis patients in the intervention group will receive pharmaceutical care delivered by clinical pharmacist, which including personal interview, medication review, medication reconciliation, patient education and recommended actions
1713943|NCT01356550|Drug|RO4917838|single oral dose
1713944|NCT01356524|Drug|Additional vaginal progesterone|The progesterone dose will be raised from 200 mg daily to 300 mg daily
1713945|NCT01356511|Drug|Prednisone|Prednisone, po, 1 mg/kg/d, for 4 weeks.
1713946|NCT01356511|Drug|Dexamethasone|Dexamethasone, po, 40 mg/d, for 4 days.
1713947|NCT01356498|Biological|pegloticase|8 mg intravenous infusion
1713948|NCT01356485|Drug|MP4CO|43 mg/mL pegylated carboxyhemoglobin [≥ 90% CO hemoglobin saturation] in physiological acetate electrolyte solution
1713949|NCT01356485|Drug|Sodium chloride solution|Normal saline (0.9% sodium chloride solution)
1713950|NCT01356472|Drug|Imipenem/cilastatin|the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
1713951|NCT01356459|Device|Mepilex Border Dressing|Soft silicone self adherent dressing
1713952|NCT01356446|Procedure|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implemented
1713953|NCT01356433|Drug|oral vitamin C|"cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.
Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months."
1713954|NCT01356433|Drug|oral vitamin C|Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
1713955|NCT01356420|Dietary Supplement|Cholesterol supplementation|Cholesterol supplementation may be achieved with SLOesterol instead of or in combination with egg yolk. SLOesterol is a powder formulation that contains cholesterol and natural emulsifier. It is considered a medical food developed by Solace Nutrition and available by prescription only.
1713956|NCT01356407|Drug|PICOPREP|
1713957|NCT01356407|Drug|PEG-ELS|
1713958|NCT01356394|Other|dietary intervention|12-week calorie-restricted diet consisting of 50% carbohydrate, 20-25% protein, and 25-30% fat
1713959|NCT01356381|Drug|Vildagliptin|Dosage 50mg b.i.d.
1713960|NCT01356381|Drug|Placebo|50mg bid
1713961|NCT01356368|Drug|Cisplatin, Gemzar, Docetaxel, Alimta|Patients will be assigned to treatment according to the molecular biological results which will analyze excision repair cross-complementing (ERCC1), ribonucleotide reductase subunit M1 (RRM1) and beta-tubulin genes in primary tumor cells which are present in tissues and peripheral blood.
1713962|NCT01356355|Drug|Herbmed plus|one capsule of herbmed plus orally twice a day with meals till the ureteral stent is in situ.
1713963|NCT01356355|Drug|Placebo|One capsule twice a day daily till ureteral stent in situ
1713964|NCT01356355|Drug|Tolterodine|One capsule twice a day daily till ureteral stent in situ
1713965|NCT01356342|Biological|AdimFlu-S 2010-2011, inactivated|"The vaccine contains not less than 90 μg haemagglutinin (HA) per mL. Per mL contains the following three strains: A/California/7/2009 (H1N1)30 μg/mL;A/Perth/16/2009 (H3N2)30 μg/mL;B/Brisbane/60/2008 30 μg/mL
6 months~<3 years;0.25 mL per injection2 injections at 4 weeks apart
3~<9 years;0.5 mL per injection2 injections at 4 weeks apart
9~<18 years;0.5 mL per injection1 injections"
1713966|NCT01356329|Drug|Enoxaparin, Heparin|"Patients who meet the Inclusion Criteria and signed an informed consent will be randomly assigned to 1 of the 2 treatment groups (the Enoxaparin (Group A) and Unfractionated Heparin (Group B)
). Subjects will be assigned consecutive study numbers according to a predetermined random code generated by the Biostatistician."
1713967|NCT01356316|Biological|AdimFlu-S Vaccine 2010-2011|Per ml contains following strains 30μg, A/California/7/2009 (H1N1), A/Perth/16/2009 (H3N2) and B/Brisbane/60/2008
1713968|NCT01356303|Drug|cisplatin, docetaxel|"All patients met the eligibility criteria will undergo treatment with chemotherapy.
Each cycle of chemotherapy administration will be started with docetaxel at dose of 75 mg/m2 in 250 ml of Dextrose 5% in Water or Normal Saline administered as a 1-hour intravenous infusion followed by cisplatin at dose of 75 mg/m2 administered as a 2-hour intravenous infusion every 3 weeks per cycle for totally 4-6 cycles."
1713969|NCT01356290|Drug|Bevacizumab|10mg/kg, intravenous (iv), biweekly, 1 year
1713970|NCT01356290|Drug|Thalidomide|3mg/kg, oral, daily, 1 year
1713971|NCT01356290|Drug|Celecoxib|50-400mg, oral bid, daily, 1 year
1713972|NCT01356290|Drug|Fenofibric acid|90mg/m2, oral, daily, 1 year
1713973|NCT01356290|Drug|Etoposide|35-50 mg/m2, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
1713974|NCT01356290|Drug|Cyclophosphamide|2.5mg/kg, oral, alternating 21-day cycles of daily oral etoposide and cyclophosphamide, 1 year
1713975|NCT01356290|Drug|Etoposide phosphate|0.5mg, intrathecal, day 1-5, every four weeks, alternating with intrathecal liposomal cytarabine, 1 year
1713976|NCT01356290|Drug|Liposomal cytarabine|25-35mg, intrathecal, every four weeks, alternating with intrathecal etoposide phosphate, 1 year
1714193|NCT01354314|Drug|Fluconazole|One 100 MG capsule taken twice daily, 12 hour dosing
1713977|NCT01356277|Behavioral|Action-focused problem-solving|"An Adherence Support Team (AST), consisting of the patient, one or both parents (or primary caregiver), and the study facilitator, will be formed for each participant in the intervention arm. Action-focused problem-solving is informed by two complementary behavioral approaches: problem-solving and implementation intentions.
Implementation intentions are concrete action plans in which an individual specifies, in an if-then or when-then contingency format, when, where, and how he or she will perform a behavior (e.g. When I come home from school, then I will place my medication on the kitchen counter next to the microwave.)."
1713978|NCT01356277|Device|Electronic pillbox monitoring, dose reminders, and feedback|"The multi-dose pillbox is coupled, using wireless technology, to a personalized, password-protected, medication management website. When a compartment of the dose box is opened, a signal is sent, and a date and time stamp is recorded in the electronic record of the patient to whom the device is registered. Adherence data collected with the device is fed back to participants in the intervention group. The pillboxes provide one, or any combination, of the following dose reminder methods: device light flashing, email, or text messages. The reminder method may be changed any time. The devices require only a power supply. Neither a phone line nor an Internet connection is required."
1713979|NCT01356264|Behavioral|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support starting 3-5 weeks before surgery and continuing postoperative for up to 8 weeks
1713980|NCT01356264|Behavioral|multimodal prehabilitation|multimodal prehabilitation program based on exercise, supplemental nutrition and psychological support beginning postoperative and continuing for up to 8 weeks
1713981|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either approximately 3-5 surgical patients or approximately 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
1713982|NCT01356251|Behavioral|Questionnaires & online virtual support group|Part 1 surveys mesothelioma patients' psychological and physical symptom burden and quality of life by administering a set of questionnaires that covers topics including coping, interpersonal support, mood, anxiety, and overall quality of life. All mesothelioma patients who complete the questionnaires in part 1 will be offered an opportunity to participate in a trial of a therapeutic Internet-based discussion group. The groups will consist of either 3-5 surgical patients or 3-5 non-surgical patients. The groups will run for approximately 60 minutes once a week for six consecutive weeks.
1713983|NCT01356238|Other|MRC media|Culture media
1713984|NCT01356238|Other|Sydney IVF media|Culture media
1713985|NCT01356225|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution), single dose
1713986|NCT01356225|Drug|Placebo|IN placebo
1713987|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
1713988|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
1713989|NCT01356212|Drug|Ketorolac tromethamine|30 mg ketorolac (15 mg (100 ul) per nostril) administered intranasally
1713990|NCT01356199|Dietary Supplement|ARTRONAT|Dietary supplement containing Glucosamine, Chondroïtine and manganese. 6 per day for 8 months.
1713991|NCT01356199|Dietary Supplement|PLACEBO|PLACEBO. 6 per day for 8 months.
1713992|NCT01356186|Behavioral|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 6 sessions; 60-90 minutes in duration; administered over preferably 3 days of psychiatric hospitalization
1713993|NCT01356173|Drug|GDC-0349|Oral escalating dose
1713994|NCT01356160|Drug|GS-5885|tablet, 30 mg QD
1713995|NCT01356160|Drug|GS-9451|tablet, 200 mg QD
1713996|NCT01356160|Biological|peginterferon alfa-2a|(solution for injection) 180 µg/week
1713997|NCT01356160|Drug|ribavirin tablet|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
1713998|NCT01356160|Drug|GS-9451 Placebo|Placebo to match GS-9451 QD
1713999|NCT01356147|Drug|Dornase alfa|2.5 mg nebulized endotracheally every 12 hours for 7 days or until extubation
1714000|NCT01356147|Drug|Placebo|No therapy will be given to placebo arm
1714001|NCT01356121|Drug|Propofol|Propofol will be initiated with a .5-1 mg/kg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
1714002|NCT01356121|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
1714003|NCT01356108|Device|Transcatheter Pulmonic Valve Replacement (TPVR) (Edwards SAPIEN™ THV)|The Edwards SAPIEN™ THV is a biological heart valve manufactured with treated bovine pericardial tissue that is mounted into a balloon expandable stainless steel open cell stent. The Edwards SAPIEN™ THV is available in two sizes (23 and 26mm) and is designed for transcatheter implantation in patients with regurgitant pulmonary valved conduit with or without stenosis. This device is commercially available and is used according the current IFU.
1714004|NCT01356095|Other|Knowledge translation intervention|Two part intervention includes an educational outreach intervention for health care workers and a point of care patient education/counselling tool, delivered to providers within health centers randomized to the intervention arm, using a train the trainer on-site training model.
1714005|NCT01356095|Other|Palm-Plus|Clinical guideline and training approach, designed for mid-level healthworkers.
1714006|NCT01356082|Device|CNAP|Non-invasive blood pressure monitor
1714007|NCT01356069|Other|SB-APP|"SB-APP, derived from Brief-Adlerian Psychodynamic Psychotherapy (B-APP) is a time-limited (40 weekly sessions) psychodynamic psychotherapy based on Alfred Adler's theory and delivered in sequential and repeatable modules.
SB-APP is focused specifically on four personality functioning levels (PFL). These are assessed by the therapists on the basis of symptoms, quality of interpersonal relationships, overall social behaviors, cognitive and emotional patterns, and defense mechanisms"
1714008|NCT01356069|Other|treatment as usual|This treatment consisted in a combination of medication, unstructured psychological support focused on socio-relational impairment and rehabilitative interventions provided by nurses and educators.
1714009|NCT01356056|Device|Kinesia HomeView|Quantifies motor symptom severity in the home
1714010|NCT01356043|Drug|S-amlodipine 5mg,Telmisartan 80mg|S-amlodipine 5mg and Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
1714011|NCT01356043|Drug|S-amlodipine 5mg|S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out(19 days)
1714012|NCT01356030|Procedure|ERCP|Endoscopic retrograde cholangiopancreatography (ERCP) is usually clinically indicated to place a stent (a plastic or metal tube) in the bile duct. The ERCP procedure is an endoscopic exam during which a small catheter or wire is placed into the bile duct from the point at which it connects to the small intestine. During such a procedure a stent can then be placed to help drain the bile across the site of blockage, and thereby treat your jaundice.
1714013|NCT01356030|Procedure|EUS FNA|Endoscopic ultrasound (EUS) is a procedure in which a flexible tube with a tiny camera and ultrasound probe at the tip is placed through the mouth, down the esophagus, and into the stomach and duodenum (first part of the small intestine where bile flows from the bile duct into the intestine). This allows the doctor performing the EUS to get a much closer view of your pancreas and bile duct. If a suspicious mass is seen, a small sample of the mass (biopsy) is taken using fine needle aspiration (FNA). FNA involves the use of a thin hollow needle to extract cells for diagnostic purposes and is considered safer and less invasive than surgical biopsies.
1714014|NCT01356017|Drug|Telmisartan 80mg, S-amlodipine 5mg|Telmisartan 80mg and S-amlodipine 5mg, Oral, Once a day, for 9 days + Wash out (19 days)
1714015|NCT01356017|Drug|Telmisartan 80mg|Telmisartan 80mg, Oral, Once a day, for 9 days + Wash out (19 days)
1714016|NCT01356004|Drug|live attenuated chicken pox vaccine|Each immunizing dose was given subcutaneously (SC) in the form of 0.5 ml reconstituted vaccine which contains not less than 1033 plaque forming units (PFU) of the attenuated varicella-zoster-virus (VZV), which meets the World Health Organization (WHO) requirements for biological substances and for varicella vaccines. Doses were given 3 weeks apart for a total duration of 12 weeks (3 months).
1714017|NCT01356004|Drug|saline, efficacy|4 doses of SC saline (0.5 ml) -as a placebo- in the same pattern as group A patients
1714018|NCT01355991|Drug|Tiotropium|18mcg/ capsule inhaled once daily for two weeks.
1714019|NCT01355991|Drug|Salmeterol|50mcg inhalation twice daily for two weeks
1714020|NCT01355978|Device|Noninvasive Open Ventilation System|Noninvasive ventilation system
1714021|NCT01355965|Biological|Autologous T cells|
1714022|NCT01355952|Dietary Supplement|Alpha Lipoic Acid|600mg three times per day (1800mg total) daily for 10 weeks
1714023|NCT01355939|Procedure|Clinically-Indicated Abdominal Re-Exploration Surgery|This is a prospective observational study. Abdominal re-exploration surgery is clinically-indicated and planned as the standard of care for the patients regardless of their decision to participate in the study.
1714024|NCT01355926|Other|Flexible Fiber-based CO2 Laser, Quality of Life forms|. Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
1714025|NCT01355926|Other|electrocautery resection and quality of life forms|Post operative pain will be measured pre-operatively, and post-operatively on post-operative day (POD) 1, 3, 7, 14, 21 and 28 using a numerical pain rating scale. The secondary outcomes will be measured pre-operatively and post-operatively using the University of Washington Quality of Life questionnaire specific for head and neck version 4 (UW-QOL version 4) and the Performance Status Scale for head and neck cancer (PPS-HN) on days 7, 14 and 28. Other secondary aims will be measured intra-operatively and time to return to work and time to normal diet will be measured during timeframes of POD 1, 3, 7,14, 21 and 28.
1956437|NCT02857491|Drug|ranibizumab|intravitreal injection of 0.5 mg ranibizumab before vitrectomy
1956438|NCT02857491|Drug|sham|sham intravitreal injection before vitrectomy
1956439|NCT02857491|Procedure|pars plana vitrectomy|surgical procedure to remove the intravitreal hemorrhage and fibrosis membrane, and re-attach the retina, and perform endo laser photocoagulation on retina.
1714030|NCT01355861|Behavioral|Negative work exercise|Submaximal negative work exercise using an isokinetic dynamometer will be performed twice per week for 12 weeks. Exercise volume will be 3 sets of 10 repetitions for the knee and shoulder extensors.
1714031|NCT01355848|Behavioral|Brief Intervention for Suicidality|Focuses on behavioral elements of care, including building rapport, functional analysis, and crisis planning
1714032|NCT01355835|Device|deep brain stimulation (ACTIVA PC, Medtronic)|High frequent deep brain stimulation with variable (best individual) stimulation on subthalamic contacts and standard parameters on nigral contacts (125 Hz, 60µs, best individual amplitude)
1714033|NCT01355822|Drug|PETN|Pentaerythrithyltetranitrate: 80 mg orally twice a day
1714034|NCT01355822|Drug|Placebo control|orally, twice daily
1714035|NCT01355809|Drug|Inhalation gas|Inhalated gas, medicinal oxygen 100% via NIV with Fi O2 0.35, one time by random, 6 minutes
1714036|NCT01355809|Drug|Inhalation Nitrogen/Oxygen|Inhalated gas, Nitrogen/Oxygen (65%/35%), one time by random, 6 minutes
1714037|NCT01355809|Drug|Inhalation Helium/Oxygen|Inhalated gas, Helium/Oxygen (65%/35%) one time by random, 6 minutes
1714040|NCT01355783|Drug|E7777|Treatment in both arms is for 6 cycles at 21 days/cycle.
1714041|NCT01355757|Device|Baxter INFUSOR System|Regional Analgesia INFUSOR system with Patient Control Module for post-operative analgesia
1714042|NCT01355757|Drug|Single Injection of Local Anesthetic|Single injection of 20 ml ropivacaine 0.5%
1714083|NCT01355393|Biological|HER-2/neu peptide vaccine|Given ID
1714043|NCT01355718|Drug|repaglinide|The dosage and frequency, as well as later changes to either dose, frequency or add-on medication (if applicable), will be determined by the physician, according to the patient's requirements.
1714044|NCT01355705|Drug|Amrubicin|40, 60, or 80 mg/m2 intravenous (IV)
1714045|NCT01355705|Drug|Lenalidomide|15 mg daily by mouth
1714046|NCT01355705|Drug|Dexamethasone|40 mg weekly by mouth
1714047|NCT01355705|Drug|Aspirin|81 or 325 mg daily by mouth
1714048|NCT01355705|Drug|Pegfilgrastim|6 mg subcutaneous on Day 2
1714049|NCT01355692|Device|Nd: YLF laser treatment|grid selective retinal treatment
1714050|NCT01355679|Device|Guided Therapy|A total of 14 eligible neuroblastoma patients who are refractory or relapsed on conventional therapy will be treated. Guided therapy will allow the use of any therapeutic combination (up to 4 agents) provided it includes medications contained in the study report. All patients will be followed for disease response, progression and safety. All patients will be treated according to the discretion of the treating oncologist and study committee (minimum 3 oncologists and one pharmacist). Extent of disease will be measured and assessed for changes throughout the course of the study and at 6-8 week intervals (every 2 cycles).
1714051|NCT01355666|Device|DermaTherapy® Linen and underpads.|"DermaTherapy® Linen is a 100% synthetic silk-like fabric technology designed to provide a cleaner, drier and smoother surface between the skin and support systems for a healthy micro-climate.
Subjects in the DermaTherapy® Linen Group are compared to subjects receiving usual care - bed linen made of cotton-blend fabrics."
1714052|NCT01355653|Device|thermal therapy|heat therapy device, topical, two applications, at 0-3 hours and 4-6 hours on treatment day
1714053|NCT01355653|Device|marketed heatwrap|heatwrap, topical, one time application, 8 hour duration
1714054|NCT01355640|Other|breast-feeding|Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Mothers breast-fed their babies. The study was initiated when the infants were observed to have a large amount of areola in their mouth, with flanged lips and active jaw movements. Then two minutes after the breast-feeding, an experienced technician began to do heel lance, heel lance was given by the same experienced technician.Mothers breast-fed their babies two minutes before, during and eight minutes after the heel lance. Throughout the whole procedure, mothers were encouraged to continue breast-feeding when the babies stopped sucking and/or began to cry.
1714055|NCT01355640|Other|non-nutritive sucking|"Mothers lay on the side of the bed comfortably with their infants in their arms after the infants' soiled diapers were changed. Each mother in this group was given a vacuum pacifier( the brand is Goodbaby) to console her baby. Heel lance was given by the same experienced technician. The study was initiated when the infants can suck the pacifier and hold it by himself without others' help. This generally requires half or one minute. Then two minutes after non-nutritive sucking, an experienced technician began to do heel lance. Babies sucked the pacifier two minutes before, during and eight minutes after heel lance. Throughout the whole procedure, mothers were encouraged to continue non-nutritive sucking when the babies stopped sucking and/or began to cry."
1714056|NCT01355627|Procedure|TachoSil®|Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator. TachoSil® must be applied under aseptic conditions during the closure of the dura.
1714057|NCT01355627|Procedure|Current Practice|"Primary suture must be performed. Duraplasty may be performed at the discretion of the investigator.
In addition to primary suture, whatever means of dura closure deemed necessary by the investigator may be used with the exception of TachoSil®."
1714058|NCT01355614|Drug|QAX576|
1714059|NCT01355614|Drug|Infliximab|
1714060|NCT01355601|Other|Nutritional Beverage|Nutritional Beverage with varying types and levels of carbohydrates
1714061|NCT01355601|Other|Nutritional Beverage|Nutritional beverage with varying types and levels of carbohydrates
1714062|NCT01355588|Drug|Ketorolac Tromethamine|30 mg Ketorolac Tromethamine intranasal (IN)
1714063|NCT01355588|Drug|Ketorolac Tromethamine with 4% Lidocaine hydrochloride (HCl)|30 mg Ketorolac Tromethamine with 4% Lidocaine HCl IN
1714064|NCT01355588|Drug|Ketorolac Tromethamine with 5% Lidocaine HCl|30 mg Ketorolac Tromethamine with 5% Lidocaine HCl IN
1714065|NCT01355588|Drug|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl|30 mg Ketorolac Tromethamine with 6% Lidocaine HCl IN
1714067|NCT01355562|Drug|Interleukin-2 (IL-2)|Daily for 4 doses every 3 weeks for a total of 12 doses in an outpatient setting
1714068|NCT01355549|Biological|Platelet-rich plasma (PRP) therapy|Platelet rich plasma (PRP) describes a new technology in which platelets are isolated from a sample of a person's own blood using simple cell-separating systems such as centrifugation in order to obtain highly concentrated samples of platelets that can be re-injected into an injury site to promote healing.
1714069|NCT01355523|Drug|Melatonin (N-acetyl-5-methoxytryptamine)|6 mg oral melatonin daily 1 hour before bedtime
1714070|NCT01355523|Drug|Placebo|6 mg oral placebo daily 1 hour before bedtime
1714073|NCT01355484|Drug|GTx-024|subjects will be randomized to receive GTx-024 for the full duration of the trial.
1714074|NCT01355484|Drug|placebo|subject will receive placebo for the duration of the trial
1714075|NCT01355471|Drug|CD07805/47 Gel|applied topically once daily
1714076|NCT01355471|Drug|Placebo|applied topically once daily
1714077|NCT01355458|Drug|CD07805/47 gel|applied topically once daily
1714078|NCT01355458|Drug|Placebo|applied topically once daily
1714079|NCT01355445|Drug|Vincristine, Irinotecan|"D1 and D8: Vincristine 1.5 mg/m² (max 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)
D1 to D5: Irinotecan 50 mg/m²/d, IV
cycle / 21 days"
1714080|NCT01355445|Drug|Vincristine, Irinotecan, Temozolomide|"D1 to D5: Temozolomide 125 mg/m²/d, PO (the dose will be escalated to 150 mg/m²/day at cycle 2 for patients who do not experience > grade 3 toxicity of any kind)
D1 and D8: Vincristine 1.5 mg/m² (maximum 2mg) direct IV infusion (0.05 mg/kg for patient ≤ 10 kg)
D1 to D5: Irinotecan 50 mg/m²/d, IV
cycle / 21 days"
1714081|NCT01355432|Other|Observation|There is no intervention, this is an observational study.
1714084|NCT01355393|Biological|sargramostim|Given ID
1714087|NCT01355367|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040 CR 40mg BID
1714088|NCT01355354|Drug|Digoxin|oral tablets, 0.25mg bd on Day 1 and 0.25 Once daily from Day 2 to 15
1714089|NCT01355354|Drug|Fostamatinib|oral tablets, 100mg (2 X 50mg) bd from Day 9 - 15
1714091|NCT01355328|Procedure|laser and radiofrequency|different laser and radiofrequency with different fluences
1714092|NCT01355302|Drug|E7050|E7050 given orally at either 200, 300, or 400 mg once daily.
1714093|NCT01355302|Drug|cisplatin|Cisplatin will be administered at 80 mg/m2 by intravenous infusion over 60 minutes on Day 1 of each 21-day treatment cycle.
1714094|NCT01355302|Drug|capecitabine|Capecitabine will be administered at 1000 mg/m2 orally, twice daily (2000 mg/m2 total daily dose) on Days 1 through 14 of each 21-day treatment cycle.
1714095|NCT01355289|Drug|E5501/Avatrombopag maleate|"All subjects will initiate open-label, once-daily treatment with E5501 at a dose of 20 mg.
After Treatment Period B1, E5501 will be administered in a flexible-dose design. During Treatment Periods B2 and B3, the E5501 dose may be titrated up or down in accordance with their individual response, within the range of a minimum of 5 mg and a maximum of 50 mg."
1714096|NCT01355289|Drug|Placebo|Placebo was given orally for up to 21 days once daily.
1714097|NCT01355276|Drug|Cinitapride|cinitapride 1 mg for each dose, 3 mg/daily, for 4 weeks
1714098|NCT01355276|Drug|domperidone|10 mg for each dose ,30 mg/daily, for 4 weeks
1714099|NCT01355263|Drug|iron and vitamin a|
1714100|NCT01355224|Genetic|Genetic|Relative risk estimates will be presented based on individuals' risk for obesity based on FTO genotype results.
1714101|NCT01355224|Behavioral|Lifestyle|Relative risk estimates will be presented based on individuals' risk for obesity due to lifestyle factors.
1714102|NCT01355198|Dietary Supplement|Cysteine (as n-acetylcysteine) and glycine|Cysteine and glycine will be supplemented at doses of 0.81 mmol/kg/d and 1.31 mmol/kg/d for 2 weeks each
1714103|NCT01355198|Dietary Supplement|Cysteine/glycine|Subjects will receive oral dietary amino-acids (cystiene as n-acetylcysteine, and glycine)
1714104|NCT01355172|Biological|AdimFlu-S|0.25mL per injection 2 injections at 4 weeks apart
1714105|NCT01355159|Drug|Folic Acid 4 mg|Folic Acid 1.0 mg or placebo x 4 tablets will be taken daily by oral administration. The majority of women in the study will routinely take 1.0 mg folic acid in a prenatal vitamin supplement, as recommended by their primary obstetrical provider; the study requirements do not require that participants change their practice. Therefore the actual total daily dose may be up to 5.1 mg of folic acid
1714106|NCT01355159|Drug|Placebo|Placebo x 4 tablets will be taken daily by oral administration.
1714107|NCT01355133|Biological|Transurethral intrasphincteric autologous myoblast implantation|Patients undergo upper arm muscle biopsy to isolate and cultivate autologous myoblasts. Using the ultrasound-directed transurethral medical device, 15-18 aliquots (50 - 100 µl per depot) of the 2 ml myoblasts/media suspension are directly injected into the urethral rhabdosphincter at two different levels. The procedure is a single-dose injection of a cell count in range of 1x106 -5x107 cells, depending of the size/quality of the biopsy and quality of outgrowing cells in order to identify possible dose related effects. To possibly enhance cell integration following implantation, a course of transvaginal electrical stimulation is undertaken.
1714108|NCT01355120|Drug|Ipilimumab|Ipilimumab monotherapy 3mg/kg by four infusion every 3 weeks
1714111|NCT01355081|Drug|Vortioxetine|Vortioxetine tablets
1714112|NCT01355081|Drug|Placebo|Vortioxetine placebo
1714113|NCT01355068|Drug|Epanutin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
1714114|NCT01355068|Drug|Dilantin Infatabs (Phenytoin)|Chewable Tablet, 50 mg, Single dose
1714115|NCT01355029|Behavioral|Stroke Caregiver Education and Support Program|4 week program offered weekly over a 4 week period. Each session is a 2 hour small group guided discussion on the topic area facilitated by 2 trained facilitators. The topics are: Program Introduction, sharing Caregiving Stories and an introduction to Self Management; Community Connections; Session 3 and 4 are chosen by the participants during session 1 from 6 possible options: Communication in your relationship; Cognition, Memory and Personhood; Dealing with your Emotions; Managing your Stress; Changing roles in your relationships and How to be Caregiver Smart?
1714116|NCT01355016|Drug|MDT-637|Inhaled doses of MDT-637 over a 24 hour period
1714117|NCT01354990|Drug|Sitagliptin (JANUVIA®)|Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.
1714118|NCT01354977|Drug|Resveratrol|1,000mg twice daily for 28 days
1714119|NCT01354964|Drug|Vitamin D|Weekly oral vitamin D drops, weight-based calculated dosage, taken on the same day each week for 4 months.
1714188|NCT01354340|Dietary Supplement|Limicol|3 tablets (Limicol) + 3 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
1714189|NCT01354340|Dietary Supplement|Limicol|6 tablets (Limicol) / day during 1 month and follow-up 1 month without treatment
1715225|NCT00000289|Drug|Ondansetron|
1714120|NCT01354951|Other|Prostate Biopsy, Focal Brachytherapy , Assessment of QOL|A re-staging transrectal or transperineal ultrasound-guided prostate biopsy as currently performed at participating institutions. Focal brachytherapy will be performed at 8 weeks following the transrectal or transperineal biopsy or sooner if the patient has recovered from the repeat biopsy and the treating physician determines it is safe to proceed with treatment. The regions will be targeted with the prescription dose and receive 144 Gy of Iodine-125 (I-125). The quality-of-life assessment will focus on erectile function, urinary function, bowel function, and general health related quality of life. The patients will complete this assessment at baseline and then approximately 3 ± 1 months, 6 ± 1 months, 12 ± 2 months, 18 ± 2 months, and 24 ± 2 months after treatment.
1714121|NCT01354938|Drug|Clarithromycin modified release 500 mg|Clarithromycin modified release 500 mg was prescribed. The dosage given was either 1 tablet or 2 tablets once a day, depending on the severity of the treatment.
1714122|NCT01354925|Drug|Insulin treatment during Ramadan|Insulin analogs will be used: Levemir and NovoMix70. The daily insulin dose will be calculated as follows: Sixty percent of the total daily dose will be used as the beginning daily dose at the first day of fasting. Sixty percent of the daily dose will be given as NovoMix70 before the Eftar (the main meal in the evening that breaks the fast). Forty percent of the amount will be given as Levemir (Early in the morning before the beginning of fasting.
1714123|NCT01354925|Drug|Standard of care|Standard of care during Ramadan according to physicians decision
1714124|NCT01354886|Drug|FSH-GEX™|
1714125|NCT01354886|Drug|Comparator 1|
1714126|NCT01354886|Drug|Comparator 2|
1714127|NCT01354886|Drug|Placebo|
1714128|NCT01354860|Other|Moxibustion treatment plus usual care|"Treatment group received moxibustion treatment three times a week for 4 consecutive weeks, totally 12 sessions of treatment in addition to usual care to manage their knee OA.
Moxibustion points include six local acupuncture points on affected knee joint. Up to two additional tender points will be allowed, if necessary. If participants feel knee pain on both knee joints, study practitioners will provide treatment on both knee.
We will use smokeless indirect moxibustion made of wormwood with a diameter of 1.9 centirmeter and a length of 2.1 centimeter in a cylindrical form for this study (Haitnim Bosung Inc, Korea). Free participant-practitioner interaction will be allowed during the treatment session. Expected total time of each treatment session will be 40 - 60 minutes."
1714129|NCT01354860|Other|Usual care alone group|"Usual care alone group can receive or use any kind of treatment other than moxibustion treatment provided as study intervention, which includes surgery, conventional medication, physical treatment, acupuncture, herbal medicine, over-the-counter drugs and other active treatment. This also applies to the moxibustion treatment group.
Education material of information on knee osteoarthritis and current management option and self-exercise sheet with a yoga-mat to enhance regular exercise will be provided in both groups at baseline."
1714130|NCT01354847|Device|Multiple electrode aggregometry analyses (Multiple Electrode Aggregometry, Multiplate(R), Verum Diagnostica, Munich, Germany)|ex vivo platelet aggregation at several intraoperative and postoperative measuring points.
1714131|NCT01354834|Drug|hMG|Patients with a condition
1714132|NCT01354821|Procedure|Endovascular aortic repair|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
1714133|NCT01354821|Procedure|Open surgical repair|Conventional therapy in France with the national database of the M.O.H.
1714134|NCT01354808|Drug|Dual Anti-Platelet Therapy (DAPT)|"Loading: aspirin 300mg + clopidogrel 600mg
Maintenance: aspirin 200mg/d + clopidogrel 75mg/d for 1 month"
1714135|NCT01354808|Drug|Triple Anti-Platelet Therapy (TAPT)|"Loading: cilostazol 200mg + aspirin 300mg + clopidogrel 600mg
Maintenance: cilostazol 100mg bid+ aspirin 200mg/d+ clopidogrel 75mg/d for 1 month"
1714136|NCT01354795|Procedure|1.EUS-FNA with or without suction|During EUS-FNA of the peri-pancreatic mass was performed, with or without self-retracting 10-mL syringe applied.
1714137|NCT01354795|Procedure|2.Pushing the stylet or injecting air|EUS-FNA specimen is expelled from a needle with pushing the stylet or injecting air into the needle
1714138|NCT01354782|Drug|Roflumilast|"Period I: single dose of roflumilast 500 μg orally in the morning.
Period II: repeated dose of roflumilast 500 μg orally in the morning for 14 days."
1714139|NCT01354769|Device|CapnoStream20|The monitor used for data gathering is a CapnoStream20-multi parameter monitor
1714140|NCT01354743|Drug|Dysport|"Patients entering will be based on gender and assessment of procerus and corrugator muscle mass. Muscle mass will be graded separately for males and females as +, ++, or+++ (light/small, moderate/medium, or heavy/large) by assessment of the procerus/corrugator muscles. Male patients will receive 0.3 mL to 0.4 mL (60, 70, or 80 units) in five equally divided doses of Dysport™ Female patients will receive 0.25 mL to 0.35 mL (50, 60 or 70 units) in equally divided doses of Dysport™ at 5 designated injection sites in the glabellar region
Subjects will be treated with Dysport™ 20 or 30 units bilaterally to crow's feet.
Subjects will be treated at baseline and if maximum amount of product has not been used at 1 month follow up subject will receive a touch up. No further treatment will be done for the remaining study visits."
1714141|NCT01354743|Device|Perlane L|The subject will be allowed to receive up to 4 mls between the temporal fossa and the glabella area.
1714142|NCT01354717|Drug|Brand Carac|treatment of actinic keratosis
1714143|NCT01354717|Drug|Generic 0.5% 5-fluorouracil cream|treatment of actinic keratosis
1714144|NCT01354717|Other|Placebo cream|treatment of actinic keratosis
1714145|NCT01354704|Drug|Enoxaparin|enoxaparin 4000 IU 1 injection/day in subcutaneous.
1714146|NCT01354691|Drug|ladostigil hemitartrate|Final dosage strength of 80mg b.i.d will begin at Day 22 following a 21 day dose escalation phase involving 40mg and 60mg b.i.d dosage strengths. Oral, solid dosage.
1714147|NCT01354678|Procedure|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection of bone marrow mononuclear cells
1714148|NCT01354678|Procedure|NOGA XP Cardiac Navigation System|Intramyocardial multiple precision injection with placebo
1714149|NCT01354665|Biological|Interferon beta-1b (Betaferon, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under routine practice setting.
1714190|NCT01354340|Other|Placebo|6 tablets (Placebo) / day during 1 month and follow-up 1 month without treatment
1714191|NCT01354327|Dietary Supplement|Limicol|3 tablets / day during 4 months
1714192|NCT01354327|Dietary Supplement|Placebo|3 tablets / day during 4 months
1714150|NCT01354652|Drug|entecavir, lamivudine|"entecavir: 0.5mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and participants will be followed for the duration of hospital stay, an expected average of 8 weeks.
lamivudine: 100mg/day p.o until development of lactic acidosis, OLT, death, or improvement of hepatic or renal function to MELD score less than 18 and and participants will be followed for the duration of hospital stay, an expected average of 8 weeks."
1714151|NCT01354626|Other|dietary protein|in the low-protein group 13EN% of protein will be provided in the diet; in the high-protein 25EN% of protein will be provided
1714152|NCT01354626|Other|low-protein|The control group will get a diet which is according to healthy eating guidelines.
1714153|NCT01354613|Drug|Dobutamine|IV administration at the initial study visit (all groups) and at the final study visit for the drug intervention arm (HFpEF group only). Administration of low-dose dobutamine at 5mcg/kg/min and 10mcg/kg/min for periods of approximately 30minutes/dose for purposes of performing a low-dose stress exam on the heart.
1714154|NCT01354613|Drug|Amlodipine|Participants will be randomized to treatment with either amlodipine 5 mg daily or placebo, in double-blind fashion, 25 patients in each group. 12 week oral administration of 5mg/day, uptitrated to 10mg/day, determined by PI.
1714155|NCT01354600|Other|Exercise or Sedentary|Daily cycling exercise at 50% maximal aerobic fitness for a total of ~120 minutes/day or no daily exercise (sedentary)
1714156|NCT01354587|Drug|Hizentra|Subjects transition from Vivaglobin to Hizentra using weekly subcutaneous infusions for 32 weeks.
1714157|NCT01354574|Other|High Glycemic Index meals|Dietary intervention with meals containing high glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only high glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
1714158|NCT01354574|Other|Low Glycemic Index meals|Dietary intervention with meals containing low glycemic index carbohydrates. All foods provided to meet the individual's energy needs. Standardized test meal (breakfast)also contained only low glycemic index carbohydrates and energy content was adjusted for each individual, providing 40% of daily energy needs.
1714159|NCT01354561|Procedure|Respiratory physical therapy|Respiratory physical therapy using airway clearance techniques was conducted by a physiotherapist according to a detailed clinical evaluation of each patient, consisting of thoracic percussion, manual vibration, postural drainage, and cough stimulation.
1714160|NCT01354548|Device|TheraBite® Jaw Motion Rehabilitation System™|A portable device which utilizes passive motion and stretching to improve mobility and flexibility of the jaw muscles and associated joints. Patients are given written and verbal information about TheraBite before the commencement of Radiotherapy. Investigators instruct on usage and maintenance of TheraBite. Patients are instructed to start a trainings pass by softening the jaw muscles with a simple exercise. The training programme consists of five stretches performed 5 times per day, each stretch held for 15 seconds, training continually during Radiation Therapy and up to one year after completion of Radiation Therapy.
1714161|NCT01354535|Procedure|Isolated Locked Compression Plate|A lateral thigh incision will be used to expose the fracture site. Surgeons will attempt to minimize devascularization of the bone by meticulous dissection and indirect reduction techniques. An appropriate sized plate will be applied to the lateral aspect of the femur. Fracture reduction will be achieved with the use of intra-operative fluoroscopy and the plate will be secured with locking screws.
1714162|NCT01354535|Procedure|Cable Plating and Strut Allograft with Cerclage Wiring|The plate will be placed laterally with the allograft strut placed on the anterior cortex. Screw fixation will be used distal to the stem and cables and screws will be used proximal to the stem tip. Cerclage cables or wires will be used to secure the strut.
1714163|NCT01354522|Drug|Docetaxel, Doxorubicin, Cyclophosphamide|docetaxel 75 mg/m², iv, day 1 doxorubicin 50 mg/m² or epirubicin 75mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 every 3 weeks for 6 cycles
1714164|NCT01354522|Drug|Docetaxel, Cyclophosphamide, Capecitabine|docetaxel 75 mg/m², iv, day 1 Cyclophosphamide 500 mg/m², iv, day 1 capecitabine 950 mg/m2, twice a day, via oral intake, day 1 to day 14 every 3 weeks for 6 cycles
1714165|NCT01354496|Drug|LY2409021 Reference Form|Administered orally
1714166|NCT01354496|Drug|LY2409021 Test-Med Formulation (medium particle size)|Administered orally
1714167|NCT01354496|Drug|LY2409021 Test-High Formulation (high particle size)|Administered orally
1714168|NCT01354496|Drug|LY2409021 Test-Low Formulation (low particle size)|Administered orally
1714169|NCT01354483|Biological|Umbilical Cord Blood Mononuclear Cell|
1714170|NCT01354483|Biological|Methylprednisolone|30mg/kg i.v. methylprednisolone
1714171|NCT01354483|Drug|Lithium Carbonate Tablet|6 weeks
1714172|NCT01354470|Drug|Modafinil|600 mg Modafinil capsule
1714173|NCT01354457|Drug|Epratuzumab and 90Y-Epratuzumab|Sequential injections of each product with an escalating dose for radiolabeled Epratuzumab between patients
1956449|NCT02852239|Drug|dabrafenib|Single dose dabrafenib 100 mg
1956450|NCT02850978|Drug|Spiolto|
1714179|NCT01354418|Drug|Phenylephrine HCl Extended Release|One phenylephrine HCl 30 mg extended release tablet orally
1714180|NCT01354418|Drug|Phenylephrine HCl Immediate Release|One phenylephrine HCl 10 mg immediate release tablet every 4 hours for three doses
1714181|NCT01354405|Drug|Lanreotide|120 mg every 28 days intramuscular
1714182|NCT01354392|Drug|AZD1152|Up to 6 cycles. Each cycle consists of 800 mg. IV infusion over 96 hrs.
1714183|NCT01354379|Biological|NB-1008|NB-1008 is composed of Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA) and 20% W805EC adjuvant.
1714184|NCT01354379|Biological|Fluzone IN|The active control is Fluzone containing 15 micrograms (mcg) of strain-specific hemagglutinin (HA).
1714185|NCT01354366|Other|Infant formula|
1714194|NCT01354314|Drug|Paroxetine|Two 10 MG capsules paroxetine once daily in the evening
1714195|NCT01354314|Drug|Paroxetine and Fluconazole|One capsule 100 MG fluconazole every 12 hours orally per day; Two 10 MG capsules paroxetine orally once daily in the evening
1714196|NCT01354314|Drug|Placebo|One capsule in the morning, three capsules in the evening
1714197|NCT01354301|Drug|Thymoglobulin|intravenously, beginning within the first 24 hours after graft revascularization. Pre-treatment includes hydrocortisone and dipyrone before antithymocyte globulin infusion, which will be reconstituted according to the package insert.
1714198|NCT01354301|Drug|Everolimus|initial 0.75 mg BID dose of everolimus on day 2. Doses will be adjusted from day 5 on to maintain everolimus whole blood trough concentrations between 4-8 ng/ml.
1714199|NCT01354301|Drug|Basiliximabe|days 0 and 4, according to the package insert instructions.
1714200|NCT01354301|Drug|mycophenolate sodium|720 mg BID. This dose will be reduced according to adverse events.
1714201|NCT01354301|Drug|Tacrolimus|0.05 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-5 ng/ml.
1714202|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml and 3-5 ng/ml after 3 months.
1714203|NCT01354301|Drug|Tacrolimus|0.1 mg/kg BID beginning on day 1. Doses will be adjusted to maintain tacrolimus whole blood trough concentrations between 3-8 ng/ml.
1714204|NCT01354288|Other|Educational tool|Specific educational tool in order to assess its impact on glycemic control, quality of life, knowledge about the disease and its daily management
1714205|NCT01354275|Other|To compare the IVF/ICSI outcomes of GnRH Antagonist cycle versus GnRH agonist cycle|150 IU FSH dose and OCP plus GnRH Agonist (long luteal) IVF/ICSI cycle and 150 IU FSH dose and OCP plus GnRH Antagonist (Fixed protocol) IVF/ICSI Cycle
1714206|NCT01354275|Other|GnRH Antagonist|GnRH Antagonist cycle; 150 IU FSH and sixth day Antagonist will be administered
1714207|NCT01354262|Dietary Supplement|Vitamin D|600 IU daily oral supplementation
1714208|NCT01354262|Dietary Supplement|Vitamin D|50,000 IU supplementation bi-monthly
1714209|NCT01354249|Dietary Supplement|whey protein plus carbohydrate drink|The CHO-P group received 474 ml (evening drink) or 237 ml (3h prior to operation drink) of a solution containing 14% whey protein (100% lactoalbumin), 86% carbohydrates (45% hydrolyzed corn starch and 55% sucrose) and 0% lipids (Resource® Breeze - Nestlé, São Paulo, Brasil)
1714210|NCT01354223|Device|stenfilcon A contact lens|Randomized to stenfilcon A contact lens worn in a daily wear, daily disposable mode
1714211|NCT01354223|Device|ocufilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
1714212|NCT01354210|Behavioral|SMS Text Message Reminder|Daily
1714213|NCT01354184|Drug|CRD007|
1714214|NCT01354184|Drug|CRD007 matching placebo|
1714215|NCT01354171|Device|MRI assisted TRUS guided biopsy|All subjects to have a confirmatory biopsy at one year. Those assigned ARM 1 to have a TRUS guided biopsy and those assigned to ARM 2to have a MRI assisted TRUS guided biopsy
1714216|NCT01354158|Drug|Droxidopa|Dose titration of placebo, 100mg, 200mg, 400mg of Droxidopa will be given to assess the effects of Droxidopa on blood pressure and cerebral blood flow.
1714217|NCT01354145|Drug|Chondroitin sulfate|Chondroitin sulphate 1200 mg/day, 24 months treatment period
1714218|NCT01354145|Drug|Celecoxib|Celecoxib 200 mg/day, 24 months treatment period
1714219|NCT01354132|Drug|n-acetylcysteine|900 mg effervescent PharmaNAC tablet in water or juice: two tablets in the AM, one tablet in PM
1714220|NCT01354132|Drug|Placebo|Placebo tablets are placed in water or juice in the AM and PM
1714221|NCT01354119|Procedure|Aortic stent-graft|Early intervention with aortic stent-graft
1714222|NCT01354106|Device|Skin Trauma|Each participant completed received both treatment arms, the 3M Micropore and 3M Kind Removal Silicone Tape.
1714223|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken twice a day
1714224|NCT01354093|Drug|zeaxanthin|10 mg of EyePromise 10 (zeaxanthin) supplement, taken once a day
1714225|NCT01354080|Other|massage based on the tensegrity rule|The massage consist of brushing the skin, stroking of the lower abdominal integuments. Elastic deformation of the thoracolumbar fascia. Then the abdominal integuments were elastically deformed by kneading to normalize the rest tension of the muscles of the abdominal integuments as well as, indirectly, the myofascial apparatus of the pelvic floor and in this way improve venous blood and lymph outflow from the large intestine and the sigmoid colon area. The next treatment stage - performing circular movements within the limits of the skin's mobility at 1/3 of the medial part of the thigh. By stroking movements in the direction of the armpit in accordance with the run of the thoracoepigastric and costalaxillary veins. Then the intercostal muscles were deformed.
1714226|NCT01354080|Other|massage - classical abdominal|The classical abdominal massage consisted of circular movements performed on the abdominal integuments by superficial and deep stroking techniques according to the colonic route (clockwise)
1714227|NCT01354067|Behavioral|Control group|The control group receives standardized patient education four times, once every two weeks, during the eight week intervention period. Each session will last 60 minutes, consisting of information regarding anatomy, physiology, causes and mechanisms of COPD, drugs, nutrition, aids and energy saving procedures. The information is the same as for the intervention group, given at separate occasions.
1714228|NCT01354067|Behavioral|High-repetitive single limb training|The high-repetitive single limb exercise regime consists of three sessions per week during eight weeks of exercise training, giving a total number of 24 sessions at each location (Umeå and Huddinge University hospitals). The exercise sessions are supervised and conducted by a physical therapist using a group format, six to eight participants in each group. Each session will span for 60 minutes, duration of the major components are: 10 min warm-up followed by 40 minutes of single limb training and 10min cool-down. In addition this experimental group also receives four sessions of patient education once every two week.
1714229|NCT01354054|Procedure|High Frequency TENS|100 usec, 100 Hz, pulse amplitude motor - 10%, 30-40 minutes
1714230|NCT01354054|Procedure|Low frequency TENS|100 usec, 4 Hz, pulse amplitude motor - 10%, 30-40 minutes
1714231|NCT01354054|Procedure|Placebo TENS|100 usec, 100 Hz, motor - 10%, pulse amplitude adjusted and maintained for 30 seconds then ramping down to zero in 15 seconds
1715226|NCT00000290|Drug|Cocaine|
1714232|NCT01354041|Behavioral|Acceptance and Commitment Therapy|Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
1714233|NCT01354028|Other|Massage therapy|An overall massage time of approximately 10 minutes, administered by physical therapists. Almond oil or baby lotion that is currently used in standard care in the ACH NICU will be used to assist with ease of skin to skin contact during moderate pressure massage. Infants will receive two repetitions of 5-1minute periods of 12 strokes lasting approximately 5 seconds each described in protocol. Actigraph device is on infant's ankle to measure sleep.
1714234|NCT01354015|Device|DRMS|USE OF TEXT MESSAGING SYSTEM
1714235|NCT01353976|Drug|Econazole Nitrate Foam 1%|Econazole Nitrate Foam 1% applied once a day for 4 weeks
1714236|NCT01353976|Other|Vehicle Foam|Vehicle foam applied once a day for 4 weeks
1714237|NCT01353963|Drug|desvenlafaxine succinate|50 mg tablet once daily
1714238|NCT01353937|Drug|AMD3100 injection + rhPDGF-BB topical|drug therapy to be given for the first 2 week duration given on a daily basis initiated during the first visit (Day 0).
1714239|NCT01353924|Biological|Bet v 1aF1-Alum + Bet v 1aF2-Alum|subcutaneous injection of equimolar mixture (20µg each) of Bet v 1aF1-Alum and Bet v 1aF2-Alum, three times in monthly intervals and a booster injection after one year
1714240|NCT01353924|Biological|Alum-Placebo|subcutaneous injection of Alum-Placebo, three times in monthly intervals and a booster injection after one year
1714241|NCT01353911|Drug|Grazoprevir|Orally once daily in AM. Blinded or open-label depending on treatment arm.
1714242|NCT01353911|Drug|Boceprevir|Four 200 mg capsules orally three times daily.
1714243|NCT01353911|Drug|Placebo for Grazoprevir|Orally once daily in AM.
1714244|NCT01353911|Drug|Placebo for Boceprevir|Four capsules orally three times daily.
1714245|NCT01353911|Drug|Peg-interferon alfa-2b|1.5 μg/kg/week subcutaneous injection.
1714246|NCT01353911|Drug|Ribavirin|300 mg to 700 mg orally twice daily.
1714247|NCT01353898|Drug|MK-1972|MK-1972 will be supplied as 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
1714248|NCT01353898|Drug|Placebo to MK-1972|Placebo will be supplied as matching 25 and 100 mg capsules, and will be given orally, at a dose dependent on the treatment arm; participants will take ten capsules (active drug and/or placebo) once or twice per day for 10 days
1714249|NCT01353872|Dietary Supplement|Nutrattente / Nutraperf / Nutrarecup|500 mL of Nutrattente before each match 500 mL/h of Nutraperf during each match 250 mL of Nutrarecup after each match
1714250|NCT01353872|Dietary Supplement|Nutrattente placebo / Nutraperf placebo / Nutrarecup placebo|500 mL of Nutrattente placebo before each match 500 mL/h of Nutraperf placebo during each match 250 mL of Nutrarecup placebo after each match
1714251|NCT01353859|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for a total of 6 infusions
1714252|NCT01353859|Drug|methotrexate|10-25 mg orally weekly
1714253|NCT01353846|Other|observation natural cycle|The patients natural reproductive cycle will be observed and compared to the second arm.
1714254|NCT01353846|Drug|Agonist GnRH; estradiol Valerate; progesterone|Medications: Agonist GnRH Acetate Triptoreline and Acetate Triptorelina and Estradiol Valerate and Natural micronized progesterone, 400 mg/12 hours vaginal administration
1714255|NCT01353833|Drug|Aldesleukin|0.33 ; 1 ; 3 ; 0 millions IU of IL-2 per day for arm 1 to 4, respectively. 1 s.c. injection per day for 5 days.
1714256|NCT01353820|Dietary Supplement|1- Low fat drinkable fermented by Lactobacillus Delbruckii lactis (DN111244) - >10E8 <5.10E9 cfu/mL|1- Intervention with test product ( >10E8 to <5.10E9 cfu/ml of L. delbruckii lactis )
1714257|NCT01353820|Dietary Supplement|2- Low fat drinkable fermented by S. thermophilus and L. bulgaricus|2- Intervention with control product
1714258|NCT01353807|Dietary Supplement|Fish oil|4 1-g gelatine capsules per day providing 2,7 grams long chain n-3 fatty acids
1714259|NCT01353807|Dietary Supplement|Olive oil|4 1-g gelatine capsules with virgin olive oil
1714260|NCT01353794|Drug|Sorafenib (Nexavar, BAY43-9006)|The treatment with Sorafenib 200mg tablets should comply with the recommendations written in the local product information. The decision about the duration of treatment is solely at the discretion of the attending physician
1714261|NCT01353781|Drug|AZD5363|Patients will be given AZD5363 capsules administered orally as a single dose, and then multiple twice-daily dosing following 3 to 7 days washout.
1714262|NCT01353768|Other|retrospective chart review|retrospective chart review
1714263|NCT01353755|Drug|Grass pollen specific immunotherapy|"Strength 1 (0.78μg/mL)
Strength 2 (6.25μg/mL)
Strength 3 (50μg/mL)
Strength 4 (200μg/mL)
The subcutaneous injections will be administered at intervals of 7 (+ 7 days)during up-titration. For maintenance the injection intervals are prolonged to 4 weeks (+2). The double blind treatment period is 2 years, followed by 1 year open-label treatment for patients previously treated with verum and 3 years open-label treatment for patients previously recieved placebo."
1714264|NCT01353755|Drug|Placabo|Placebo will be administered in the same way as the test product. Placebo will be identical in terms of appearance to the IMP.
1714265|NCT01353742|Drug|Lamivudine|100mg tablet
1714266|NCT01353742|Drug|Adefovir dipivoxil|10mg tablet
1714267|NCT01353742|Drug|Fixed dose combination (Lamivudine and Adefovir dipivoxil)|100mg/10mg capsule
1714268|NCT01353729|Drug|600 mg zanamivir + moxifloxacin placebo|zanamivir 600 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
1714269|NCT01353729|Drug|1200 mg zanamivir + moxifloxacin placebo|zanamivir 1200 mg IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
1714270|NCT01353729|Drug|zanamivir placebo + moxifloxacin placebo|zanamivir placebo IV over 30 min x 1 dose + moxifloxacin placebo administered orally x 1 dose
1714271|NCT01353729|Drug|zanamivir placebo + 400 mg moxifloxacin|moxifloxacin 400 mg administered orally x 1 dose + zanamivir placebo IV over 30 min x 1 dose
1714272|NCT01353716|Drug|Dolutegravir 50 mg|Dolutegravir is an experimental drug in the integrase inhibitor class of HIV medications. There will be a one single dose of 50 mg.
1714274|NCT01353690|Biological|AMDC|Cell Treatment
1714397|NCT01352663|Biological|Lantus®|Basal bolus Insulin analog glargine (Lantus®) to be injected subcutaneously.
1715227|NCT00000291|Drug|Labetalol|
1714275|NCT01353664|Drug|Romidepsin|The participants will generally continue at the same dose, infusion time and frequency used for the last dose of romidepsin given in the preceding romidepsin study. If the participant entered this rollover study in the middle of a cycle, then the cycle number and cycle day will be carried over from the preceding romidepsin study.
1714276|NCT01353651|Device|Endovascular treatment using self expandable nitinol STENTS|A direct stenting will be performed.
1714277|NCT01353651|Device|Open repair treatment|The surgeon will perform its usual technique to revascularize the common femoral artery
1714278|NCT01353638|Drug|Dipeptiven (Alanyl-glutamine-dipeptide)|Two arms (A and B) and two treatment periods (1 and 2) are scheduled for this study. Each arm includes 14 patients. Schedule arm A: Treatment period 1 with one single peritoneal dialysis exchange (standard PD solution) with Alanyl-Glutamine-Dipeptide as add-on. 17,4 ml Dipeptiven (=3,48g N(2)-L Alanyl-L-Glutamin) will be dissolved at a final concentration of 0,174 %(= 8 mmol/l) in 2 liters of Dianeal®PD4 (at PH:5,5; Glucose-Concentration 3,86 %). After a wash out period (28 days + max 7 days), arm A undergoes treatment period 2, that is one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide. Schedule Arm B: Treatment period 1 with one single peritoneal dialysis exchange with standard PD solution without Alanyl-Glutamine-Dipeptide followed by wash-out. Treatment period 2 for arm B includes one single peritoneal dialysis exchange with standard PD solution with Alanyl-Glutamine-Dipeptide as add-on. Dosages remain exactly the same.
1714279|NCT01353625|Drug|CC-115|"Part A (actively recruiting): Dose level starts with 0.5mg daily by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose schedule is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity).
Part B: Optimal dose schedule is administered in 28-day cycles until disease progression."
1714280|NCT01353599|Drug|Mometasone furoate|220mcg once daily, for eight weeks
1714281|NCT01353586|Device|nMARQ™ System|The nMARQ™ System is indicated for catheter-based electrophysiological mapping for the treatment of drug refractory recurrent symptomatic paroxysmal atrial fibrillatioon.
1714282|NCT01353573|Radiation|Fixed Gantry Radiosurgery|Single fraction radiosurgery will be prescribed using a fixed gantry radiosurgery delivery system
1714283|NCT01353573|Radiation|Robotic Radiosurgery|Single fraction radiosurgery will be prescribed using a robotic radiosurgery system
1714284|NCT01353534|Biological|A/H5N1 Antigen|A/H5N1 Antigen
1714285|NCT01353534|Drug|Vaccine Enhancement Patch|Vaccine Enhancement Patch
1714286|NCT01353521|Procedure|Contrast-enhanced ultrasound|A contrast-enhanced ultrasound utilizes intravenous gas-filled microbubbles to enhance visualization in real time.
1714287|NCT01353508|Drug|LCZ696|200 mg and 400 mg tablets
1714288|NCT01353508|Drug|Valsartan|160 mg tablets
1714290|NCT01353482|Drug|Cisplatin|Cisplatin (75mg/m2 iv) wil be administered on day one of a 21 day cycle for up to 6 cycles
1714291|NCT01353482|Drug|Pemetrexed|Patients will be given Pemetrexed (500mg/m2 iv) on day one of a 21 day cycle for up to 6 cycles
1714292|NCT01353482|Drug|Vorinostat|The dose and frequency of vorinostat will be determined in the Phase I study. Vorinostat will be given concurrently with Cisplatin/Pemetrexed.
1714293|NCT01353482|Drug|Placebo|Patients randomised into the placebo arm of the trial will receive Cisplatin and Pemetrexed as standard as well as placebo.
1714294|NCT01353469|Drug|Insulin human/Insuman Comb 25 (HR1799)|"Pharmaceutical form:Suspension
Route of administration: Subcutaneous"
1714295|NCT01353469|Drug|Insulin human/Novolin® 30R|"Pharmaceutical form:Suspension
Route of administration: Subcutaneous"
1714296|NCT01353456|Drug|Dexmedetomidine|Patient will receive a loading dose of 1μg/kg (0.25ml/kg) intravenous dexmedetomidine over 10 minutes before induction, and then followed by continuous infusion at a rate of 0.5μg/kg/h (0.125ml/kg/h) until wound closure.
1714297|NCT01353456|Drug|Normal Saline|Same volume as dexmedetomidine given
1714298|NCT01353443|Procedure|Optilene® Mesh Elastic|A number of patients will receive a Optilene® Mesh Elastic mesh, which may not be clinically indicated.
1714299|NCT01353417|Other|In this observational study no study specific intervention is planned|Patients with stable kidney function who already receive Tacrolimus Sandoz© capsules before being included in this non-interventional study, are being observed for 6 months by their attending physicians. Routine medical treatment is provided.
1714300|NCT01353404|Drug|Sequence 1|fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral
1714301|NCT01353404|Drug|Sequence 2|fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
1714302|NCT01353404|Drug|Seqeunce 3|fenofibrate 65mg, fasting condition, per oral → fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral
1714303|NCT01353404|Drug|Sequence 4|fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 160mg, fed condition, per oral
1714304|NCT01353404|Drug|Sequence 5|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral
1714305|NCT01353404|Drug|Sequence 6|fenofibrate 160mg, fed condition, per oral → fenofibrate 65mg, fasting condition, per oral → fenofibrate 65mg, fed condition, per oral
1714308|NCT01353378|Drug|dexmedetomidine|Intravenously injecting 0.125microgram/kg for 10ml IV(in the vein)in group 1, 0.25microgram/kg for 10ml in group 2 within 10 minutes as soon as the operation begin. The control group receives 10mlsaline in 10 minutes.
1714399|NCT01352650|Drug|decitabine|decitabine will be given to all cohorts/schedules at 20 mg/m2 IV daily for a 1-hour infusion on days 1-10 for all cycles
1714309|NCT01353352|Other|Clinical decision rule - clearing the c-spine|The goal of phase IV of the Canadian C-Spine Rule project is to evaluate the safety and potential impact of an active strategy to empower ED triage nurses to evaluate and clear the c-spine of very low-risk trauma patients.
1714310|NCT01353339|Drug|Levofloxacin|500mg, PO, once daily for 3 months
1714311|NCT01353326|Device|Cormet|Cementless hip resurfacing system
1714312|NCT01353326|Device|Conserve|Cemented hip resurfacing system
1714313|NCT01353313|Drug|Hydrocortisone|"Hydrocortisone sodium succinate for intravenous administration (unpreserved, Solu-Cortef plain, Pfizer®, reconstituted with unpreserved normal saline to avoid exposure to the benzyl alcohol contained in preserved diluents), to be administered either intravenously or orally if no intravenous line is available at the same dose, and tapered as follows:
4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then
1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
1714314|NCT01353313|Drug|Placebo|"Saline placebo to be administered either intravenously or orally if no intravenous line is available, at the same dose, and tapered as follows:
4mg/kg/day ¸ q 6 hours x 2 days, then 2mg/kg/day ¸ q 6 hours x 3 days; then
1mg/kg/day ¸ q 12 hours x 3 days; then 0.5mg/kg/d as a single dose x 2 days"
1714315|NCT01353300|Genetic|DNA analysis|
1714316|NCT01353300|Genetic|cytogenetic analysis|
1714317|NCT01353300|Genetic|gene expression analysis|
1714318|NCT01353300|Genetic|gene rearrangement analysis|
1714319|NCT01353300|Genetic|mutation analysis|
1714320|NCT01353300|Genetic|polymerase chain reaction|
1714321|NCT01353300|Genetic|polymorphism analysis|
1714322|NCT01353300|Other|laboratory biomarker analysis|
1714323|NCT01353300|Other|medical chart review|
1714324|NCT01353274|Drug|Micamlo|Telmisartan plus Amlodipine T40/A5
1714325|NCT01353248|Drug|GS-5885|tablet, 30 mg QD
1714326|NCT01353248|Drug|Tegobuvir|capsule, 30 mg BID
1714327|NCT01353248|Drug|GS-9451|tablet, 200 mg QD
1714328|NCT01353248|Drug|ribavirin tablet|(weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
1714329|NCT01353248|Drug|GS-5885|tablet, 90 mg QD
1714330|NCT01353235|Drug|Prednisolone|Patients assigned to corticotherapy arm, will receive oral prednisolone 1mg/kg/j as an add on therapy for a maximum of 10 days.
1714331|NCT01353235|Drug|usual care|no drug administered
1714332|NCT01353222|Biological|DN24-02|DN24-02 is an autologous cellular immunotherapy product designed to stimulate an immune response against HER2/neu. It consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), which are activated ex vivo with a recombinant fusion protein, BA7072.
1714333|NCT01353222|Other|Standard of Care|Observation only until documentation of disease recurrence.
1714334|NCT01353209|Drug|Letrozole|2.5 mg daily for twelve months
1714335|NCT01353209|Drug|Placebo|sugar pill given daily for twelve months
1714336|NCT01353183|Procedure|colonoscopy or rectosigmoidoscopy|Usual procedure
1714337|NCT01353170|Other|Dialysate calcium concentration|Calcium dialysate concentrations: 1.25, 1.35 and 1.5 mmol/l
1714338|NCT01353144|Drug|aspirin|aspirin, 100 mg, qd x 8 weeks
1714339|NCT01353118|Biological|gastric bypass|Optimise glucose control within 3 months before operation
1714340|NCT01353105|Procedure|Ex vivo lung transplantation|Evaluation and reconditioning of lungs following lung transplantation
1714341|NCT01353092|Device|Re5 Pulsating ElectroMagnetic Fields|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):
30 minutes of active PEMF therapy in the morning and 30 minutes of active PEMF therapy in the afternoon"
1714342|NCT01353092|Device|Re5 Pulsating ElectroMagnetic Fields (PEMF)|"Re5 Treatment Helmet using Pulsating ElectroMagnetic Fields (PEMF):
30 minutes of sham therapy and 30 minutes of active therapy (morning or afternoon)"
1714343|NCT01353079|Biological|Short Ragweed Pollen Allergenic Extract|Daily sublingual administration of Short Ragweed Pollen Allergenic Extract up to 42 U Amb a 1 for a minimum of 8 weeks prior to the ragweed pollen season.
1714344|NCT01353079|Biological|Placebo|Placebo: Glycero-COCAs sublingual
1714345|NCT01353066|Drug|Intensive Medical Treatment|
1714346|NCT01353066|Other|IMM+Roux-en-Y Gastric Bypass (RYGBP)|
1714347|NCT01353040|Drug|AVI-6003|Single intravenous administration
1714348|NCT01353040|Drug|Placebo|Single intravenous administration
1714349|NCT01353027|Drug|Placebo|Normal saline
1714350|NCT01353027|Drug|AVI-6002|Single intravenous administration
1714351|NCT01353014|Other|Dietary advice with genetic information|This group will receive dietary advice for caffeine, vitamin C, sugar and sodium based on genes that affect the metabolism of or sensitivity to caffeine, vitamin C, sugar and sodium.
1714352|NCT01353014|Other|General dietary recommendations|This group will receive general dietary recommendations from recognized health organizations for caffeine, vitamin C, sugar and sodium, with no genetic information.
1714353|NCT01353001|Behavioral|Diet|Participants will be given a calorie and fat gram goal according to their initial bodyweight. The fat gram goals will be set at 20% to 30% of total caloric intake. Subject calorie and fat gram goals are as follows: Subjects weighing less than 175 pounds will receive a diet prescription of 1200 calories and 27 fat grams per day. Subjects weighing between 175 and 219 pounds will receive a diet prescription of 1500 calories and 33 fat grams per day. Subjects weighing between 220 and 249 pounds will receive a diet prescription of 1800 calories and 40 fat grams per day. Subjects weighing greater than 250 pounds will receive a diet prescription of 2100 calories and 47 fat grams per day.
1714354|NCT01353001|Behavioral|Diet Plus Aerobic Training|Participants will receive all of the components as described for the DIET group. Additionally, this group will participate in supervised progressive aerobic training 3 days per week. Participants will be required to attend 3 sessions per week where they will participate in supervised exercise sessions progressing from 60 to 180 minutes per week of moderate-intensity (3.0-6.0 METS) aerobic exercise. 180 minutes per week of exercise will meet the American College of Sports Medicine and the American Heart Association recommendations of 450-750 METS.min.wk-1.
1714398|NCT01352650|Drug|plerixafor|Cohort 1 will receive plerixafor at a dose of 320 mcg/kg and cohort 2 will receive plerixafor at a dose of 580 mcg/kg. Schedule A will receive plerixafor on the 2nd and 4th cycles and Schedule B will receive plerixafor on the 1st and 3rd cycles of treatment.
1714355|NCT01353001|Behavioral|Diet plus Resistance Training|Participants will receive all of the components as the DIET group. Participants will also participate in supervised resistance training protocol 3 days per week in the form of an individual session. The protocol will start the participants at a low volume of exercise at an intensity of 50-55% of 1-repetition maximum, and oscillate in both volume and intensity during the intervention, with a general trend toward increases in intensity as outlined in the ACSM Position Stand.
1714356|NCT01352988|Drug|Fumaric acid esters|Starting from 1 tablet Fumaderm® initial per day, with titration up to 6 tablets Fumaderm® per day; in case of side effects, the dose will be adapted to the highest tolerable levels
1714360|NCT01352923|Other|blood test|preparation of blood platelets
1714361|NCT01352910|Device|rTMS|120 pulses 0.2 Hz
1714362|NCT01352910|Device|Sham rTMS|120 pulses 0.2 Hz
1714363|NCT01352884|Drug|AMP-224|Escalating doses of AMP-224
1714364|NCT01352884|Drug|AMP-224|Stage 2 will further explore the safety, pharmacokinetics, and preliminary clinical activity of AMP-224 in at least one tumor type based on pharmacodynamic assessments and clinical activity emerging from the Dose-Escalation Phase. Tumor tissue and blood
1714365|NCT01352871|Behavioral|Concentration / meditation|from 30 minutes before endotoxin administration to 1,5 hrs after endotoxin administration the subject is concentrating / meditating with the goal to influence the innate immune response
1714366|NCT01352871|Drug|lipopolysaccharide|lipopolysaccharide 2ng/kg intravenously
1714367|NCT01352858|Drug|TolDC|Tolerogenic dendritic cells (TolDC), derived ex vivo from autologous monocytes, administered arthroscopically into an inflamed knee following saline irrigation.
1714368|NCT01352858|Drug|Arthroscopy & saline irrigation alone|
1714369|NCT01352845|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months
1714370|NCT01352845|Other|Placebo|0.5 mL dose, given at 0, 2 and 6 months
1714371|NCT01352832|Other|Interactive DVD|"An interactive DVD (How To Talk To Your Doctor about NSAIDs, HTTTYD-NSAIDs) that presents culturally appropriate stories through which a viewer can learn risk factors for adverse effects related to NSAIDs; and communication behaviors for talking about NSAIDs with their doctor."
1714372|NCT01352832|Other|Usual Care|Usual Care
1714373|NCT01352806|Procedure|identification of the lumbar interspinous space using fluoroscopy versus ultrasound versuspalpation|Copmarison of multiple technique for identification of the lumbar interspinous space,which is fluoroscopy,ultrasound and palpation
1714374|NCT01352793|Biological|rLP2086 vaccine|120 mcg, 3 doses, at month 0, 2, and 6.
1714375|NCT01352793|Biological|control|HAVRIX: 720 EL.U. or 1440 EL.Ul, 2 doses, at month 0 and 6. Placebo: normal saline injection, 1 dose, at month 2.
1714376|NCT01352780|Behavioral|Motivational interviewing|"Motivational interviewing technique will be used to improve patient adherence to multiple health behaviour changes and support patients with psoriasis to self- manage effectively. The intervention will discuss on four main topics: diet, physical activity, stress management and psoriasis treatment.
Motivational interviewing is a patient centered directive counselling technique that focuses on assisting patients to identify their problems and involves exploring ambivalence in an empathic manner. A key goal in motivational interviewing is to increase the importance of change from the client`s perspective. This is accomplished by using specific types of open ended questions, selective reflections and reflective listening."
1714377|NCT01352767|Device|InsuPad|Heating pad
1714378|NCT01352741|Drug|Tapentadol Prolonged Release|100 - 500 mg per day orally twice daily for a maximum of 12 weeks
1714379|NCT01352741|Drug|Tapentadol Prolonged Release with Pregabalin|Tapentadol Prolonged Release 100 - 300 mg per day with Pregabalin 150 - 300 mg per day orally twice daily for a maximum of 12 weeks
1714380|NCT01352741|Drug|Tapentadol Prolonged Release open label maintenance|100 - 400 mg per day Tapentadol Prolonged Release orally administered twice daily
1714381|NCT01352728|Drug|Axitinib|5 mg daily for 6 cycle with TACE+Axitinib, Axitinib continued until PD.
1714382|NCT01352715|Drug|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as two LPV 200mg/RTV 50mg fixed-dose combination tablets) orally twice daily, with or without food, throughout follow-up.
1714383|NCT01352715|Drug|Lopinavir/ritonavir|Lopinavir 400mg/ritonavir 100mg (given as three LPV 133.3 mg/RTV 33.3 mg fixed-dose combination soft gelatin capsules) orally twice daily, with food, throughout follow-up.
1714384|NCT01352715|Drug|Raltegravir|Raltegravir 400 mg tablet orally twice daily, with or without food, throughout follow-up.
1714385|NCT01352715|Drug|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine 200 mg/tenofovir disoproxil fumarate 300mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
1714386|NCT01352715|Drug|Abacavir/lamivudine/zidovudine|Abacavir 300 mg/lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
1714387|NCT01352715|Drug|Abacavir/lamivudine|Abacavir 600 mg/lamivudine 300 mg fixed-dose combination tablet orally once daily, with or without food, throughout follow-up.
1714388|NCT01352715|Drug|Lamivudine/zidovudine|Lamivudine 150 mg/zidovudine 300 mg fixed-dose combination tablet orally twice daily, with or without food, throughout follow-up.
1714389|NCT01352715|Drug|Abacavir|Abacavir 300 mg tablet orally twice daily or 600 mg (given as two 300 mg tablets) once daily, with or without food, throughout follow-up.
1714390|NCT01352715|Drug|Zidovudine|Zidovudine 300 mg tablet orally twice daily, with or without food, throughout follow-up.
1714391|NCT01352715|Drug|Lamivudine|Lamivudine 150 mg tablet orally twice daily, with or without food, throughout follow-up.
1714392|NCT01352702|Drug|Dabigatran|Patients assigned to this group will receive Dabigatran
1714393|NCT01352702|Drug|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
1714394|NCT01352689|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
1714395|NCT01352689|Drug|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily
Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
1714396|NCT01352663|Biological|Wockhardt's Insulin Analogue (Recomb)|Basal bolus Wockhardt's Recombinant Insulin Analogue to be injected subcutaneously.
1714400|NCT01352637|Drug|DCS (D-Cycloserine ) + Prolonged Imaginal Exposure|50mg DCS (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
1714401|NCT01352637|Drug|DCS (D-Cycloserine ) + Virtual Reality Exposure|50mg DCS (taken once a week on the day of the therapy session) + Virtual Reality Exposure
1714402|NCT01352637|Drug|Placebo + Prolonged Imaginal Exposure|Placebo (taken once a week on the day of the therapy session) + Prolonged Imaginal Exposure
1714403|NCT01352637|Drug|Placebo (sugar pill) + Virtual Reality Exposure|Placebo (taken once a week on the day of the therapy session) + Virtual Reality Exposure
1714404|NCT01352624|Behavioral|$AFE|$teps for Achieving Financial Empowerment ($AFE) is an individualized, psycho-educational intervention that aims to teach veterans with psychiatric disabilities how to save money, create a viable budget, avoid money scams and financial exploitation, and access vocational and mental health resources.
1714405|NCT01352611|Drug|baclofen, intrathecal|Patients will undergo a standard intrathecal baclofen trial procedure. This procedure consists of a single injection of 50 micrograms of baclofen between the 4th and 5th lumbar vertebrae into the spinal fluid.
1714406|NCT01352598|Radiation|stereotactic body radiotherapy|Patients will receive 30 - 40 Gy in 4 - 5 fractions. For high risk patients who also receive external beam radiotherapy, the SBRT will be given as 19 - 21 Gy in 2 - 3 fractions.
1714407|NCT01352585|Drug|Anagrelide hydrochloride|0.5 mg hard capsules, dosing decisions will be made by the treating physician
1714408|NCT01352572|Drug|antidepressant response|Antidepressants administration for 6 weeks under therapeutic dose responders
1714409|NCT01352572|Drug|antidepressant non-response|Antidepressants administration for 6 weeks under therapeutic dose nonresponders
1714410|NCT01352559|Drug|responders|Antidepressants administration for 6 weeks under therapeutic dose
1714411|NCT01352559|Drug|non-responders|Antidepressants administration for 6 weeks under therapeutic dose
1714412|NCT01352546|Biological|BOTOX|150 units of Botox injected intravaginally into the bulbocavernosum, pubococcygeus and puborectalis muscles along the lateral side walls, left and right as a one time injection under anesthesia.
1714413|NCT01352533|Procedure|Running polypropylene closure|Half of every wound will be closed with Standard of Care running polypropylene sutures
1714414|NCT01352533|Procedure|Tissue Adhesive (Derma-Bond)|Approximately half of wounds will be randomized to be closed with tissue adhesive.
1714415|NCT01352533|Procedure|Subcuticular polyglactin-910 combined with tissue adhesive|Approximately half of the experimental wounds will be randomized to be closed with a combination of subcuticular polyglactin-910 and tissue adhesive.
1714416|NCT01352520|Drug|SGN-35|1.8 mg/kg administered by outpatient IV infusion given over approximately 30 minutes on Day 1 of each 21-day cycle.
1714417|NCT01352507|Drug|Tadalafil|Administered Orally
1714418|NCT01352507|Drug|Sildenafil|Administered Orally
1714421|NCT01352481|Other|Early parent-based speech intervention program|Seven 1h sessions during a three-month period.
1714422|NCT01352468|Other|Multifaceted cognitive training|Four computerized training tasks
1714423|NCT01352455|Procedure|Hemodialysis|5 days per week hemodialysis
1714424|NCT01352442|Device|AcuFocus Corneal Inlay ACI 7000PDT|corneal inlay
1714425|NCT01352429|Radiation|Proton Therapy|
1714426|NCT01352429|Radiation|IMRT|
1714427|NCT01352416|Drug|Ranolazine|Ranolazine 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
1714428|NCT01352416|Drug|Placebo|Placebo 1000mg (2-500mg tablets) twice daily. Starting 2 days prior to surgery, morning of surgery and up to 14 days post operative depending when the breathing tube is removed from the patient post operative. If intolerant to the study drug due to adverse effects or the patient is started on diltiazem or verapamil post operative then the dose will be reduced to 500mg (1-500mg tablet) twice daily
1714429|NCT01352403|Procedure|gastric bypass|
1714430|NCT01352403|Behavioral|intensive life style intervention|
1714431|NCT01352390|Behavioral|Planning Prompt|A prompt to have their child their health test reminder mailing to color
1714432|NCT01352390|Behavioral|Control Condition|A basic reminder mailing will prompt each subject to get a health test as specified on the mailing
1714433|NCT01352364|Other|physiotherapy intervention|a program of physical therapy intervention can match or improve motor skills in the deaf children
1714434|NCT01352351|Behavioral|Breastfeeding promotion intervention|"Breastfeeding counseling during monthly microcredit meetings
Weekly cell phone messages about breastfeeding"
1714435|NCT01352338|Drug|Lenalidomide, endoxan, prednisone|dose-finding
1714436|NCT01352338|Drug|lenalidomide, endoxan, prednisone|oral therapy with lenalidomide 25mg a day during 3 of 4 week cycles. Number of Cycles: until progression or unacceptable toxicity develops.
1714437|NCT01352325|Behavioral|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
1714438|NCT01352325|Behavioral|system constellations seminar|individual-centered intervention in a group setting, duration 3 days
1714442|NCT01352299|Device|Macintosh Laryngoscope blade|Laryngoscopy performed with Macintosh Laryngoscope
1714443|NCT01352299|Device|MacCoy|Laryngoscopy performed with MacCoy Laryngoscope
1714444|NCT01352299|Device|Miller|Laryngoscopy performed with Miller Laryngoscope
1714445|NCT01352299|Device|TrueView|Laryngoscopy performed with TrueView laryngoscope
1714447|NCT01352273|Drug|MEK162 + RAF265|
1714450|NCT01352234|Drug|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 160mg pill with lactose
1714451|NCT01352234|Drug|Acetylsalicylic Acid|Capsule containing Acetylsalicylic Acid 80mg pill with lactose
1714454|NCT01352208|Drug|ASP9521|oral
1714456|NCT01352182|Drug|Pioglitazone hydrochloride|Participants will receive a daily dose of pioglitazone at 0.5 mg/kg/dose for 5 days.
1714457|NCT01352143|Drug|Recombinant activated factor VII|Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
1714458|NCT01352143|Drug|Prothrombin Complex Concentrate|Plasma will be spiked in vitro with prothrombin complex concentrate to determine increases in thrombin generation with and without the drug
1714459|NCT01352130|Drug|Ondansetron|Intravenous Ondansetron 8 mgs
1714460|NCT01352130|Drug|Granisetron|Intravenous Granisetron 1 mgs
1714461|NCT01352117|Drug|efavirenz/emtricitabine/tenofovir disoproxil fumarate|600 mg efavirenz/200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally at night
1714462|NCT01352117|Drug|etoposide|50 mg taken orally daily from days 1-7 of each 2-week cycle. For participants without PR or CR after two cycles of therapy and no toxicity greater than Grade 2, the dose of ET was escalated to 100 mg/day orally, days 1-7, every 2 weeks. A cycle could be delayed for a maximum of 14 days. ET could not be initiated prior to 7 days after the last dose in previous cycle. ET could be administered up to a maximum of eight cycles (2 cycles during dose titration and 6 cycles at maximum dose). Participants who could not tolerate escalation of the ET dose to 100 mg/day were treated for a maximum of six cycles.
1714463|NCT01352104|Behavioral|PEP-TE|"PEP-TE for kindergarten teachers of children with externalizing behaviour problems aged 3 to 6 years leads to use classical strategies of changing behaviour (defining rules, appropriate commands, positive and negative consequences) based on the coercive interaction process (cf. Patterson, 1982) as explanatory model for target situations. In 10 units (90-120 minutes) four to six teachers in one group develop individually tailored solutions to specified externalizing behavior problems of the target child. General strategies of improving positive interactions as well as resources and strategies for reducing stress and gaining new energy are discussed. Summary and reflection of the teacher' experiences and ideas of changes in routines prevents relapses."
1714464|NCT01352091|Drug|Zoladex+AI|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would switch to receive Zoladex 3.6mg depot subcutaneously every month and Aromidex 1mg/d po for another 3-2 years
1714465|NCT01352091|Drug|TAM|Patients who took tamoxifen or Fareston for 2-3 years were randomized into 2 groups (335 patients for each group). One group would receive TAM 20mg/d treated for 3-2 years.
1714466|NCT01352065|Drug|Bosentan|tablet, 250 mg per day, twice per day, 8 weeks
1714467|NCT01352065|Drug|Ambrisentan|tablet, 10 mg per day, single per day, 8 weeks
1714468|NCT01352065|Drug|Placebo|Tablet, 10 mg per day, single per day, 8 weeks
1714469|NCT01352052|Other|interdisciplinary rehabilitation|A two-weeks non-residential, group-based, psycho-educative, multi-component treatment course conducted by an interdisciplinary team consisting of a rheumatologist, a nurse, occupational therapists, physical therapists, and a psychologist. The rehabilitation Programme comprises of a combination of lectures and group discussions, as well as instructions during physical exercise and task performance. The main focus is on education and adaptations in everyday life. There is a scheduled Programme for every day, with a daily time schedule between four and six hours. There will be a maximum of eight participants in each group.
1714470|NCT01352039|Biological|Heparin Sodium - Eurofarma|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
1714471|NCT01352039|Biological|Heparin Sodium - APP Pharmaceuticals|Heparin Sodium will be given during 5 to 7 days each 8 hours on dosis 5,000 UI
1714472|NCT01352026|Drug|Metformin|
1714473|NCT01352013|Dietary Supplement|Omega-3 (oil)|5ml daily with breakfast for 56 days.
1714474|NCT01352013|Dietary Supplement|Fatty Acids (placebo)|5ml daily with breakfast for 56 days.
1714475|NCT01352000|Behavioral|Smoking Cessation|Approximately 3400 quitline clients will be randomized to one of three conditions at the point of their 2-week follow-up call.
1714476|NCT01351961|Biological|blood sampling|take a sample of blood, 46 ml
1714477|NCT01351961|Procedure|brain MRI and TEP cerebral|magnetic resonance imaging
1714478|NCT01351961|Other|Assessment of cognitive functions|Folstein MMSE, Mac Nair scale, Depression (GDS) scale, The Benton Visual Retention Test, Test of verbal fluency, formal and categorical, Trail Making Test, Grober et Buschke scale (RL/RI-16), Apathy Robert scale, Praxis rating Scale .
1714479|NCT01351961|Other|Electrocardiogram and blood pressure|Electrocardiogramm Blood pressure monitoring
1714480|NCT01351961|Procedure|Vascular explorations|Pulse wave velocity, VWF, IMT
1714481|NCT01351961|Biological|Urine sample|
1714482|NCT01351948|Biological|AdCh63 AMA1 + MVA AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0, 1.25x10^8 pfu MVA AMA1 Day 56, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
1714483|NCT01351948|Biological|AdCh63 AMA1 + AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0,AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 56. IM injections
1714484|NCT01351948|Biological|AdCh63 AMA1 + AMA1-C1/Alhydrogel®|5x10^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel® (80ug, 800ug respectively) Day 56. IM injections
1714485|NCT01351948|Biological|AdCh63 AMA1 AMA1-C1/Alhydrogel®+ CPG 7909|5x10^10 vp AdCh63 AMA1 Day 0, AMA1-C1/Alhydrogel®+ CPG 7909 (80ug, 800ug, 564ug respectively) Day 112. IM injections
1714486|NCT01351948|Biological|AdCh63 AMA1 + MVA AMA1|5x10^10 vp AdCh63 AMA1 Day 0, 1.25x10^8 pfu MVA AMA1 Day 112. IM injections
1714487|NCT01351935|Drug|AVL-292|125 mg to 625 mg orally, once a day, for 28 days (28 days equals 1 cycle). Number of cycles: until progression or unacceptable toxicity develops
1714488|NCT01351922|Other|No treatment given|Patients will fill out a questionaire by interview.
1714492|NCT01351896|Other|Laboratory Biomarker Analysis|Correlative studies
1714493|NCT01351896|Drug|Lenalidomide|Given PO
1714494|NCT01351896|Other|Pharmacological Study|Correlative studies
1714495|NCT01351896|Biological|Pneumococcal Polyvalent Vaccine|Given IM (concurrently or sequentially)
1714496|NCT01351883|Dietary Supplement|ANOM|the ANOM was given 800ml per day before operation, and added from POD2 to POD 14 gradually from 400ml to 1200ml
1714497|NCT01351870|Radiation|Standard Fractionation Regimen|"1.8 Gy daily, 5 fractions per week
Cranio-spinal axis:
23.4 Gy in 13 fractions of 1.8 Gy
Posterior fossa:
30.6 Gy in 17 fractions of 1.8 Gy"
1714498|NCT01351870|Radiation|Hyperfractionated Radiotherapy|"1 Gy b.d. (minimum interval between fractions 8 hours). 10 fractions per week
Craniospinal axis:
36 Gy in 36 fractions of 1 Gy
Posterior fossa:
24 Gy in 24 fractions of 1 Gy
Tumour Bed:
8 Gy in 8 fractions of 1 Gy"
1714499|NCT01351857|Other|Transition Coordinator|The Transition Coordinator is central to the intervention and will provide ongoing contact with the medical system as well as education and clinical support where appropriate.
1714500|NCT01351844|Behavioral|Education and exercise intervention|An occupational therapist who has clinical experience in hand therapy for breast cancer patients with arthralgia syndrome, will review 4-5 exercises which improve hand range of motion and reduce hand stiffness.
1714501|NCT01351844|Behavioral|Education and General Exercise|A physical therapist with experience in treating breast cancer patients with lymphedema will demonstrate a series of 4-5 general stretching and toning exercises.
1714502|NCT01351831|Other|Rehabilitation with strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of balance-, mobility- and functional training exercises etc. In addition, the participants perform unilateral (operated leg) knee-extensions and leg presses in 2 sets for each strength training exercise, using relative loads of 12 RM (week 1), 10 RM (weeks 2-5), and 8 RM (week 6-7). All sets are performed to failure.
1714503|NCT01351831|Other|Rehabilitation without strength training|The rehabilitation programme lasts 1 hour per session, and is performed twice per week for 7 weeks. The rehabilitation program consists of the same balance-, mobility- and functional training exercises etc. as used in the other experimental arm.
1714504|NCT01351818|Drug|Growth Hormone|
1714505|NCT01351805|Drug|Fish Oil|Subjects will receive marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
1714506|NCT01351805|Dietary Supplement|Vitamin D|Subjects will receive vitamin D3 (cholecalciferol) 2000 IU a day.
1714507|NCT01351805|Other|placebo pill|placebo
1714508|NCT01351792|Drug|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
1714509|NCT01351792|Drug|Symbicort® Turbohaler® 200/6 μg/actuation|Symbicort® Turbohaler® (budesonide 200 μg plus formoterol fumarate 6 μg/actuation), 2 inhalations b.i.d. (daily dose of BUD 800 μg plus FF 24 μg).
1714510|NCT01351766|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to participant's initial nicotine level.
1714511|NCT01351753|Drug|Metformin|
1714512|NCT01351753|Drug|Orlistat|
1714513|NCT01351753|Drug|Topiramate|
1714514|NCT01351753|Drug|Placebo|Placebo pills and capsules for metformin, orlistat and topiramate
1714517|NCT01351714|Procedure|D3 resection|Radical D3 resection of the right colon through the use of preoperative MDCT angiography
1714518|NCT01351688|Drug|AZD3514|Patients will be given AZD3514 tablets or capsules administered orally as a single dose, and then multiple once-daily dosing following a 7 day washout.
1714519|NCT01351675|Drug|Placebo|Oral, once daily
1714520|NCT01351675|Drug|Bardoxolone Methyl: 20 mg|20 mg, oral, once daily
1714521|NCT01351662|Behavioral|Arthritis Self Management Program|Intervention activities will consist of six weekly sessions of the Arthritis Self-Management Program (ASMP). Sessions will be administered in a group setting with the 15 African American lupus patients randomly assigned to the intervention arm of the study. Fifteen other patients will serve as controls and receive usual care. Patients participating in the stress intervention will receive six weeks of peer led sessions ranging in disease-specific and more general self-help content. The intervention will include homework assignments to practice and record use of session techniques and to complete worksheets regarding session-specific topics and activities. Usual care will include a brief explanation of the disease and relevant literature.
1714615|NCT01350960|Drug|SPC5001|3 weekly SC injections
1714616|NCT01350960|Drug|SPC5001|3 weekly SC injections
1714522|NCT01351649|Behavioral|middle school physical activity intervention for girls|"Both the Girls on the Move intervention and attention control conditions will involve 2 components: face-to-face (individual) counseling sessions with a school nurse and an after-school (group) program. The intervention for the attention control group will not address physical activity. Both groups will respond to questionnaires at 0 (baseline) and 6 mos. Our Girls on the Move intervention is designed to help girls achieve physical activity recommendations (≥ 60 min. ≥ 5 days/wk.). The motivational, individually tailored counseling sessions with a school nurse and after-school physical activity club (3-5 times a wk. for 6 mos.) are designed to positively influence all cognitive and affective mediating variables of the Health Promotion Model."
1714523|NCT01351636|Drug|Arotinolol Hydrochloride|Antihypertensive medications plus arotinolol hydrochloride, dosage of arotinolol hydrochloride from 2.5mg bid, 2 days later increased to 5mg bid or 10mg bid, for 18 months
1714524|NCT01351636|Drug|Non arotinolol group|Antihypertensive medications without arotinolol for 18 months
1714525|NCT01351623|Drug|Carfilzomib|Following enrollment patients will be treated with single agent infusional carfilzomib at 56mg/m2. Carfilzomib will be administered intravenously over 30 minutes on Days 1, 2, 8, 9, 15 and 16 of a 28-day cycle. Dexamethasone 8 mg PO/IV will be administered prior to all carfilzomib doses during the first cycle.
1714526|NCT01351610|Biological|PTA + Infusion of MSC_Apceth|percutaneous transluminal angioplasty followed by infusion of MSC_Apceth
1714527|NCT01351610|Procedure|PTA|percutaneous transluminal angioplasty only
1714528|NCT01351597|Drug|docetaxel/ oxaliplatin|"docetaxel - 75 mg/m2 with D5W250ml IV (in the vein)over 1 hr, every 3 weeks
oxaliplatine - 70 mg/m2 with D5W250ml IV (in the vein)over 2 hrs, every 3 weeks"
1714529|NCT01351558|Other|Knee muscle strengthening exercises|Muscle strengthening exercises of the quadriceps and hamstring muscles will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
1714530|NCT01351558|Other|Upper extremity strengthening exercises|Muscle strengthening exercises of the upper amrs and shoulder girdle will be performed based on a standard muscle strengthening exercise paradigm: 3 sets with 6-8 repetitions (corresponding to approximately 80% repetition maximum (RM)) will be performed. The training load will be progressed by means of weekly estimates of muscle strength to ensure a constant load of 80% RM. The exercises will be supervised
1714531|NCT01351558|Other|Cardiovascular fitness exercises|Cardiovascular fitness exercises encompass circuit training including exercises on (but not limited to): ergometer cycles, treadmills (running), and cross-trainers. The exercise intensity is aiming at exercises within 60-85% of maximum heart rate (defined as 220 - age). The heart rate is monitored using a standard heart rate monitor. The exercises will be supervised
1714533|NCT01351532|Behavioral|smoking cessation program|cross-theoretical model integrating smoking cessation counseling, smoking cessation drug utilization, physician interview and telephone counseling persuasion,
1714534|NCT01351532|Behavioral|Lifestyle counseling|ross-theoretical model integrating smoking cessation counseling,physician interview and telephone counseling persuasion
1714535|NCT01351519|Drug|Aminolevulinic Acid|Aminolevulinic Acid will be administered as a single oral dose of 20mg/kg given in 50ml of water three hours before surgery.
1714536|NCT01351493|Drug|Nitric Oxide|Nitric Oxide Gel, once or twice per day, 12weeks
1714537|NCT01351493|Drug|placebo|placebo Gel, once or twice per day, 12weeks
1714538|NCT01351480|Biological|abatacept|Abatacept administered SC weekly at 125 mg dose
1714539|NCT01351454|Behavioral|ACT HEALTHY|ACT HEALTHY is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001) and Life Steps, an HIV medication adherence intervention (Safren, Otto, & Worth, 1999). ACT HEALTHY is based on the belief that the best way to improve mood, remain sober, increase medication adherence, and make long-term life changes is by changing and increasing one's activity level. Treatment includes 16 individual sessions over a 12-week period.
1714540|NCT01351454|Behavioral|Nondirective Therapy (NDT)|In NDT, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. In addition, medication adherence is addressed with the Life Steps HIV medication adherence intervention (Safren, Otto, & Worth, 1999). Treatment includes 16 individual sessions over a 12-week period.
1714541|NCT01351441|Behavioral|Medication adherence consultation|Patients will be counseled in person on day 0 then telephonically every month after until day 365.
1714542|NCT01351441|Other|Medication problems assessment|Patients will be asked if they are having any issues that may be attributable to their current drug therapy on a monthly basis. Any issue that is identified will be addressed by the pharmacist.
1714543|NCT01351441|Other|Beer's Criteria Assessment|The patient's drug therapy will be reviewed for Beer's criteria medications and possible alternatives will be addressed by the pharmacist if deemed appropriate.
1714544|NCT01351441|Behavioral|Health Literacy Assessment|Patients will be given a Health Literacy Assessment on day 0 and day 365 using the Realm-SF.
1714545|NCT01351428|Drug|Nifedipine|30-60 mg, twice daily
1714546|NCT01351415|Drug|Bevacizumab|Participants will receive bevacizumab 7.5 or 15 milligrams per kilogram (mg/kg) intravenously.
1714547|NCT01351415|Drug|Docetaxel|Docetaxel 60 or 75 milligram per meter square (mg/m^2) on Day 1 every 21 days.
1714548|NCT01351415|Drug|Erlotinib|Erlotinib 150 mg daily taken on an empty stomach at least one hour before or two hours after the ingestion of food.
1714549|NCT01351415|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 IV over 10 minutes on Day 1 every 21 days.
1714550|NCT01351402|Procedure|Massage or Rest|Participants either received 15 minutes of moderate pressure Swedish massage on the upper back, or rested quietly sitting in a chair for 15 minutes.
1714617|NCT01350960|Drug|SPC5001|3 weekly SC injections
1714959|NCT01348490|Drug|Ruxolitinib (INCB018424)|Ruxolitinib (INCB018424), 5 mg bid
1714551|NCT01351389|Behavioral|Brief Motivational Intervention (BMI)|The BMI incorporates open-ended exploration, personalized feedback, and discussion about patients' alcohol use and sexual behaviors and the consequences of these behaviors. Using the central principles described by Miller and Rollnick (2002), the goal of the session, conducted in the hospital as soon as possible, is to explore the patient's alcohol use and sexual behaviors and to help patients consider what they might want to change. Also included is a presentation of personalized feedback, and for patients who are interested in change, a focus on establishing goals for reduced drinking and sexual risk abstinence. Collaboratively the counselor and patient develop a plan for the future, identify goals for behavior change, explore barriers to changes, and provide strategic advice.
1714552|NCT01351389|Behavioral|Brief Advice|Patients in the Brief Advice (BA) condition will receive intervention consistent with standard medical practice when alcohol problems or sex-risk behaviors are indicated. Project staff will offer BA about level of alcohol/drug and sexual behaviors and drug problems risk, and will provide a list of treatment resources (including options for HIV testing) in the local area. Patients will be told they show signs of risk associated with alcohol use in that they scored above a cut-score for our alcohol screen, and that they reported recently engaging in sexually risky behaviors. The staff person will advise patients that reducing their alcohol use, and illicit drug use when relevant, and using condoms is advised. BA will take approximately 5 minutes.
1714553|NCT01351376|Device|Low Level Laser Therapy|Placebo LLL combined with CDT
1714554|NCT01351376|Device|Low Level Laser|Active LLL combined with CDT
1714555|NCT01351363|Device|Electrical pain threshold measurement|Assessment of preoperative pain threshold using electrical stimulation using a Painmatcher machine.
1714556|NCT01351363|Device|Measurement of electrical pain threshold|Measurement of preoperative electrical pain threshold and self reporting of postoperative pain scores (for 4 days) on VAS.
1714557|NCT01351350|Drug|MLN0128 + paclitaxel|MLN0128 will be orally administered QDX3d QW or QDX5d QW in combination with IV paclitaxel on Days 1, 8 and 15 of each cycle
1714558|NCT01351350|Drug|MLN0128 + paclitaxel + trastuzumab|MLN0128 will be orally administered QDX3d QW or QDX5d QW in combination with IV paclitaxel on Days 1, 8 and 15 of each cycle and IV trastuzumab on Days 1, 8, 15 and 22 of each cycle
1714559|NCT01351337|Procedure|diffusion tensor tractography neuronavigation and intraoperative subcortical stimulation|All of the patients underwent tumor resection assisted with combined use of Diffusion tensor tractography-integrated functional neuronavigation and intraoperative subcortical stimulation
1714560|NCT01351324|Dietary Supplement|Absence or presence of fish oil|Oral dose of saturated fat with or without fish oil and a heparin infusion
1714561|NCT01351311|Other|Exercise|Resistance Training exercise with swiss ball
1714562|NCT01351311|Other|Drug treatment|Drug treatment
1714563|NCT01351298|Drug|0.05% xylometazoline hydrochloride with 1% lidocaine hydrochloride|Decongestant with local anesthetic
1714564|NCT01351298|Drug|0.05% xylometazoline hydrochloride|Decongestant
1714565|NCT01351298|Drug|Isotonic normal saline|Placebo
1714566|NCT01351285|Drug|up-and-down method to find out effective concentration of remifentanil for preventing cough|During the emergence from anesthesia, if the patient did not cough, the extubation was defined as smooth emergence and the predetermined effect site concentration of remifentanil for the subsequent patient was decreased by 0.5 ng/mL. Likewise, if the patient coughed anytime around extubation, it was considered a failed smooth emergence and the predetermined effect site concentration for the next patient was increased by 0.5 ng/mL. This up-and-down method was conducted independently for each of the three groups. EC50 of the remifentanil of each group was obtained using the Dixon's method.
1714567|NCT01351272|Drug|Methylphenidate, non-retard|Medication (methylphenidate, non-retard) will be titrated to optimal response within 6 weeks, with a maximum of 10 mg/day in week 1, 20 mg/day in week 2, 30 mg/day in week 3, 40 mg/day in week 4, 50 mg/day in week 5, and 60 mg/day in week 6, unless adverse effects emerged. After successful adjustment, medication will be maintained until week 6. Dosing will be based on at least two-weekly evaluations by a psychiatrist, including an interview with a review of symptoms and side effects, completion of the Clinical Global Impression (CGI) scale and completion of a standardised Side Effects Rating Scale for psychostimulants (SERS). The maximal daily dosage of MPH is 60 mg. Within this double blind study the same procedure is applied for the placebo condition.
1714568|NCT01351259|Device|Pneumatic device, cylindrical or tapered cuff|Continuous control of cuff pressure using a pneumatic device (Nosten) Cylindrical (Kimberly Clark tube) or tapered (Covidien tube) tracheal cuff
1714569|NCT01351246|Behavioral|CBT Based Self-help Workbook + Counseling Telephone|"Over a period of 12 months parents work through 8 self-help booklets and additionally receive 14 counseling telephone calls. The intervention has a cognitive-behavioral foundation and is based on the therapy manual Therapy program for children with hyperactive and oppositional problem behavior THOP (Döpfner, Schürmann, & Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, & Lehmkuhl, 2006). Primary purpose of counseling telephone calls is to clarify contents of the booklets and support parents in managing their homework assignments accompanied with each booklet."
1714570|NCT01351233|Procedure|Cataract Surgery|Take the operation of phacoemulsification and implant the AcrySof Toric intraocular lens into the capsular bag in high myopic subjects.
1714571|NCT01351220|Behavioral|Educational program and FOBT kits|Subjects will participate in a CRC small group educational program and receive FOBT kits from community health advisors who have received a one-time training session.
1714572|NCT01351220|Behavioral|Educational program and FOBT kits, and technical assistance|In addition to subjects' receipt of a CRC small group educational program and FOBT kits, leadership training and technical support will be provided to the community health advisors and selected leaders and members of the organization.
1714573|NCT01351207|Other|Eggs|Comparison of a high saturated fat/low fiber meal alone, with eggs, and with a protein/cholesterol matched egg-free pudding
1714574|NCT01351194|Procedure|RFA|For PRFA, we used a commercially available system with a 375-KHz computer-assisted radiofrequency generator (Elektrotom HiTT 106, Berchtold, Medizinelektronik, Germany) and an open-perfused electrode (Berchtold, Tuttlingen, Germany) of 15 cm (or 20 cm), 14 Ga, and a 15 mm (or 20 mm) active electrode tip with microbores. The 14 Ga needle was introduced into the center of the tumor; then, 60 W of the radiofrequency energy was delivered by the generator with an 8-minute duration for every single energy application.
1714575|NCT01351194|Procedure|hepatic resection|SR was carried out under general anesthesia using a right subcostal incision with a midline extension.Intra-operative ultrasonography was performed routinely to evaluate the tumor burden, liver remnant, and the possibility of a negative resection margin. Anatomic resection, in the form of segmentectomy and/or subsegmentectomy as described by Makuuchi et al. (16) was the preferred surgical method of liver resection. Pringle's maneuver was routinely used with a clamp and unclamp time of 10 min and 5 min, respectively; this technique was used repeatedly throughout the entire procedure. Hemostasis of the raw liver surface was done with suturing and application of fibrin glue.
1714576|NCT01351181|Behavioral|Leaflet|Advice Leaflet
1714577|NCT01351181|Behavioral|Exercise Advice|Leaflet
1714578|NCT01351181|Behavioral|Normal Care|Normal Care
1714579|NCT01351168|Drug|Levodopa|CD/LD 25/100, 2 tablets test dose based on subject's current CD/LD dosing; single randomized testing day
1714580|NCT01351168|Drug|Zolpidem first dose|Zolpidem will be given at 10 mg on randomized testing day. The randomization is such that the first dose of Zolpidem given to any subject will always be 10 mg
1714581|NCT01351168|Drug|Zolpidem second dose|Zolpidem will be given at 7.5mg or 15 mg depending on the response from the first zolpidem dose.
1714582|NCT01351168|Drug|sugar pill|a sugar pill (placebo) will all be given orally in identical capsules to the other study drugs
1714583|NCT01351155|Device|Skin protective dressing device|Application of one the three indicated devices (3 active arms) to prevent NIV-induced skin injury
1714584|NCT01351142|Other|blood test and cognitive tests|Specific cognitive tests are performed at day 1, month 6, one year and 2 years Specific Blood samples tests are performed at inclusion, 1 years and 2 years
1714585|NCT01351129|Drug|Formulation 1|150-mg immediate release tablet (single dose)
1714586|NCT01351129|Drug|Formulation 2|150-mg modified release capsule, short duration (single dose)
1714587|NCT01351129|Drug|Formulation 3|150-mg modified release capsule, long duration (single dose)
1714588|NCT01351116|Radiation|EBR plus HDRIB|EBR of 20 Gy in 5 daily fractions over one week plus HDRIB of 14 Gy in 2 fractions over two weeks
1714589|NCT01351116|Radiation|EBR|EBR of 20 Gy in 5 daily fractions over one week
1714590|NCT01351103|Drug|LGK974|
1714591|NCT01351103|Biological|PDR001|
1714592|NCT01351090|Drug|Ketorolac tromethamine|10 mg Intranasal (2 x 100 uL of a 5% solution)
1714593|NCT01351090|Drug|Ketorolac tromethamine|30 mg Intranasal (2 x 100 uL of a 15% solution)
1714594|NCT01351090|Drug|Placebo|Intranasal
1714595|NCT01351077|Other|CHICA DevScreen Module|This module assists in the diagnosis and management of developmental screening
1714596|NCT01351064|Other|CHICA ADHD Module|This module was added to CHICA to help diagnose and manage ADHD
1714597|NCT01351038|Drug|Epirubicine, Oxaliplatin, Capecitabine, Panitumumab|3 cycles (repeated q 21d) Epirubicine 50mg/m² i.v. d1 Oxaliplatin 100mg/m² i.v. d1 Panitumumab 9mg/kg i.v. d1 Capecitabine 500mg/m² bid d1-21
1714598|NCT01351025|Drug|atorvastatin|10 mg daily for 4 weeks, if no symptoms or lab findings suggestive of atorvastatin toxicity, dose increase to 20 mg daily from week 4- week 20
1714599|NCT01351025|Drug|atorvastatin|Starting at week 24, 10 mg daily for 4 weeks. If no symptoms or lab findings suggestive of atorvastatin toxicity were found, 20 mg daily from week 28- week 44.
1714600|NCT01351025|Drug|placebo for atorvastin|One tablet once daily for 4 weeks. If no symptoms or lab findings suggestive of toxicity were found, then increase the dose to two tablets once daily.
1714601|NCT01351012|Other|Corn and safflower oil|The oil (60 g/d/3000 kcal) is given in two daily fruit shakes for 4 weeks
1714602|NCT01351012|Other|Canola oil|The oil (60 g/d/3000 kcal providing 3.8 g ALA) is given in two daily fruit shakes for 4 weeks
1714603|NCT01351012|Other|High oleic acid canola oil|The oil (60 g/d/3000 kcal providing 41.2 g oleic acid and 1.2 g ALA) is given in two daily fruit shakes for 4 weeks
1714604|NCT01351012|Other|DHA enriched high oleic acid canola oil|The oil (60 g/d/3000 kcal providing 1.2 g of ALA and 3.6 g of DHA) is given in two daily fruit shakes for 4 weeks
1714605|NCT01351012|Other|Flax and safflower oil|The oil (60 g/d/3000 kcal providing 6.9 g of ALA) is given in two daily fruit shakes for 4 weeks
1714606|NCT01350999|Drug|omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
1714607|NCT01350999|Drug|Eicosapentaenoic acid-ethyl (EPA)|EPA-E capsules
1714608|NCT01350986|Behavioral|Cognitive-Behavioral Self-help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents work through 8 cognitive-behavioral self-help booklets (FLOH) and additionally receive 10 counseling telephone calls. Primary purpose of telephone calls is to clarify content of the booklets and support parents in managing their homework assignments accompanied with each booklet. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on the therapy manual Treatment program for children with hyperactive and oppositional problem behavior (THOP) (Döpfner, Schürmann, & Frölich, 2007) and the parent self-help book Wackelpeter and Trotzkopf: Help for parents of children with hyperkinetic and oppositional behavior (Döpfner, Schürmann, & Lehmkuhl, 2006)."
1714609|NCT01350986|Behavioral|Non-Directive Self-Help Workbook + Counseling Telephone Calls|"In intervention period of 5 months parents are provided 8 non-directive self-help booklets and additionally receive 10 non-directive counseling telephone calls. If the telephone calls are used to clarify content of the booklets or to discuss other child and parenting related topics is at the parents' discretion. Main focus for counselor is to be congruent, empathic and to have unconditional positive regard toward the parents. 3 and 6 months after intervention period has ended, two additional booster telephone calls are provided. The booklets are based on Parent effectiveness training (Gordon, 1970) and Teaching children self-discipline at home and at school (Gordon, 1989)."
1714610|NCT01350973|Drug|Omega-3-acid ethyl esters 90 (TAK-085)|Omega-3-acid ethyl esters 90 (TAK-085) capsules. Each one gram of fatty acid in TAK-085 contains approximately 465 mg of EPA plus 375 mg of docosahexaenoic acid-ethyl as ethyl esters.
1714611|NCT01350973|Drug|Eicosapentaenoic acid-ethyl (EPA-E)|EPA-E, 0.6 g, orally, three-times daily for up to 12 weeks.
1714612|NCT01350960|Drug|SPC5001|3 weekly SC injections
1714613|NCT01350960|Drug|Saline 0.9%|3 weekly SC injections
1714614|NCT01350960|Drug|SPC5001|3 weekly SC injections
1714618|NCT01350947|Drug|5-Azacitidine|"Administered on Days 1-7 of each Cycle.
Subcutaneous administration:
To provide a homogeneous suspension, the contents of the syringe must be re-suspended by inverting the syringe 2-3 times and vigorously rolling the syringe between the palms for 30 seconds immediately prior to administration.
The 5-azacitidine suspension is administered subcutaneously.
Intravenous Administration:
5-Azacitidine solution is administered intravenously. Administer the total dose over a period of 10-40 minutes."
1714622|NCT01350921|Drug|Ticagrelor|90 mg oral immediate release tablets, single dose on days 1 and 9
1714623|NCT01350921|Drug|Venlaflaxin|37.5 mg oral immediate release tablets, administered twice daily on days 4-8
1714624|NCT01350908|Other|Blood sampling|30mL of peripherical blood will be collected specially for the study. It's an additional blood sampling compare to the normal follow up of the patient.
1714627|NCT01350869|Device|Xience|Patients with Xience
1714628|NCT01350856|Drug|Artesunate 2|Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
1714629|NCT01350856|Drug|Artesunate 4|Artesunate 4 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine
1714630|NCT01350843|Dietary Supplement|Orange Juice|250ml of orange juice or a sugars matched orange drink daily
1714631|NCT01350830|Procedure|anterior hernia repair|Inguinal incision is made, external oblique divided and the cord is encircled after identifying ilioinguinal and iliohypogastric nerves. The sac is dissected and reduced, in case of direct hernia the posterior wall of inguinal canal is plicated with polypropylene suture; in presence of indirect hernia the sac is reduced and a stitch is passed in manner that the deep ring is snug about the cord. A pre-shaped mesh is positioned on the floor of the canal around the cord with the two tails overlapping laterally; the mesh is then anchored to the pubic tubercle. External oblique is reapproximated with the cord transposed in the subcutaneous space and skin is sutured.
1714632|NCT01350830|Procedure|transinguinal preperitoneal patch repair|Through a 5-cm inguinal incision external oblique fascia is divided, cremasteric fibers are separated and the elements of the cord are skeletonized. Indirect or direct hernia is approached and through the hernia orifice, the sac is reduced, preperitoneal space is accessed and dissected to allow easily placement of the patch facilitated by the memory recoil ring. In case of indirect hernia the lateral part of patch is split and the two tails sutured around vas and gonadic vessels. Hernia orifice is closed with a polypropylene stitch through transversalis fascia and the mesh; external oblique is closed followed by skin approximation.
1714633|NCT01350817|Drug|Erlotinib + docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks with erlotinib:150 mg/d per os d2-d16
1714634|NCT01350817|Drug|Docetaxel|docetaxel :75 mg/m² IV day 1 every 3 weeks.
1714635|NCT01350804|Biological|AIN457|AIN457 (Secukinumab) is a human monoclonal antibody. Secukinumab binds and reduces the activity of Interleukin 17 (IL-17). AIN457 was given as i.v. (10mg/kg) at baseline, week 2 and week 4, and then s.c. (75 or 150mg) every 4 weeks starting at week 8.
1714636|NCT01350804|Biological|Placebo|Placebo was given as i.v. at baseline, week 2 and week 4, and then s.c. every 4 weeks starting at week 8.
1714637|NCT01350804|Biological|Abatacept|Abatacept (from 500 to 1000 mg i.v. based on weight) was given as i.v. at baseline, weeks 2 and 4, and then every 4 weeks starting at week 8.
1714638|NCT01350765|Behavioral|Intervention|The LHWs of the selected intervention areas would receive additional training on ENC for identification, management and referral for birth asphyxia, lbw and neonatal sepsis.
1714639|NCT01350765|Behavioral|Control|The LHWs in the control areas would perform their routine tasks as assigned to them by their program
1714640|NCT01350752|Behavioral|RDTs & Provider Training on Malaria Diagnosis and Treatment|In Cameroon and Nigeria, malaria RDTs will be made available in health facilities and health care providers will receive training and job aids on malaria diagnosis and treatment. The training course covers the following topics: clinical and parasitological diagnosis of malaria, how to use a rapid diagnostic test, algorithm based on malaria test result, recommended treatment for confirmed malaria cases (including dosage and regimen for artemisinin-based combination therapies), advice for treatment of test-negative patients
1714641|NCT01350752|Behavioral|Extended provider training (Cameroon only)|2-day training course which supplements basic provider training on malaria diagnosis and treatment, which focuses on understanding change in malaria treatment guidelines, professionalism, and communication skills
1714642|NCT01350752|Behavioral|School based malaria education (Nigeria only)|Schools will be invited to undertake activities to raise awareness about malaria RDTs and treatment among children and community members. The intervention includes training teachers on peer health education, malaria awareness activities and providing support to hold a malaria educational event
1714643|NCT01350739|Procedure|intraumbilical incision|vertical, intraumbilical incision
1714644|NCT01350739|Procedure|infraumbilical incision|incision at the inferior boarder of the umbilicus, circular
1714645|NCT01350713|Drug|povidone iodine|one local application of 10% povidone iodine ointment
1714648|NCT01350635|Biological|BM32|BM32 will be applied in sterile phosphate buffer solution. Drug will be applied in concentrations of 11,33 and 100 micrograms/ml
1714649|NCT01350622|Drug|PENNSAID|active treatment with PENNSAID and oral placebo. Subjects will apply 40 drops of Pennsaid to the affected ankle joint once, and will take a single placebo pill.
1714650|NCT01350622|Drug|Diclofenac hydroxyethylpyrrolidine|active treatment oral Diclofenac and PENNSAID placebo. Patients will take a single 50mg dose of oral diclofenac and will apply 40 drops of placebo lotion (2.3% DMSO) to the affected ankle once.
1715228|NCT00000292|Procedure|Cocaine|
1714651|NCT01350609|Drug|Nifedipine/Candesartan (BAY 98-7106)|Fixed dose combination of 60 mg nifedipine + 32 mg candesartan (1 tablet in one period)
1714652|NCT01350609|Drug|Nifedipine (Adalat, BAY A1040) and Candesartan (Atacand, BAY 12-9333)|Loose combination of 1 tablet nifedpipine 60mg (Adalat LA) and 2 tablets candesartan 16mg (Atacand) (3 tablets in one period) .
1714653|NCT01350596|Drug|Alivium®|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Reference Drug
1714654|NCT01350596|Drug|Ibuprofen|400mg of Ibuprofen equivalent to 8mL (50mg/mL) oral suspension of the Test Drug
1714655|NCT01350583|Drug|Sodium Bicarbonate (NaHCO3)|Treatment consisted of 0.15 g/kg/day Sodium Bicarbonate (NaHCO3) increasing to 0.3 g/kg/day after 1 week if well tolerated. Further dose increment to 0.6 g/kg/day was to be done after 2 weeks of starting sodium bicarbonate if prior dose levels were well tolerated.
1714656|NCT01350570|Other|acupuncture|acupuncture group1, acupoints ST25 and BL25 will be used in this trial.
1714657|NCT01350570|Other|acupuncture group2|Acupoints LI11 and ST37 will be used in this group. LI11 is located at upper limb while ST37 is located at the lower limb.
1714658|NCT01350570|Other|acupuncture group3|All acupoints used in acupuncture group1 and group2 will be used in this group.
1714659|NCT01350570|Drug|Loperamide|Loperamide will be used in this group for a dose of 2mg a time, three time a day.
1714660|NCT01350557|Other|Comprehensive care|Comprehensive care consisted of subacute care plus health-maintenance interventions to manage depressive symptoms, manage malnutrition, and prevent falls.
1714661|NCT01350557|Other|Subacute care|Subacute care included geriatric consultation, continuous rehabilitation, and discharge planning.
1714662|NCT01350544|Behavioral|Treatment Advocacy|Treatment advocacy is a 24-week intervention with booster sessions, including a 4-week intensive intervention followed by a 20-week maintenance period. In the first 4 weeks, all participants receive 4 individual weekly 60-minute sessions and 1 group HIV education session. In the next 20 weeks, all participants receive booster sessions in weeks 12 and 20, and a counselor check-in phone call in week 8 regarding need for new referrals and adherence barriers. Participants who have not demonstrated good adherence (≥90%) during the prior 2 weeks receive ≤4 additional booster sessions at weeks 14, 16, 22, and 24. Clients receive additional linkage with APLA's social service programs, as necessary.
1714663|NCT01350531|Behavioral|Skills training|This component includes skills most proximal to adhering to the eating and weight loss plan (e.g., calorie counting, making healthy food choices, measuring food portions, scheduling snacks and meals, meal planning, completing food logs daily, following an exercise plan).
1714664|NCT01350531|Behavioral|Contingency Management|Contingency management uses behavioral principles to counteract the reinforcing mechanisms of food and inactivity.
1714665|NCT01350518|Dietary Supplement|Benefiber|"Benefiber® powder will be used as our dietary supplement intervention. Benefiber® powder contains wheat dextrin, a 100% natural fiber. Participants in the intervention arm will receive 3 supplement packets to be consumed per day.
Each active dietary supplement packet contains 8 grams of Benefiber® powder and 3 grams of TRUE® lemon flavoring, a 100% natural with no artificial ingredients or sweeteners, preservatives, sodium or gluten."
1714666|NCT01350518|Dietary Supplement|TrueLemon|Each placebo dietary supplement packet contains 8 grams of Splenda and 3 grams of TRUE® Lemon sweetener. Each packet is designed to be added to 8 oz of fluid. The three packets should be consumed each day in a total of 24 fluid ounces.
1714667|NCT01350505|Behavioral|Light exposure|30 minutes of experimental light exposure during the night
1714668|NCT01350492|Behavioral|Resistance Exercise Training|16 weeks of resistance exercise training for the treatment of chronic muscle pain compared to wait-list control
1714671|NCT01350440|Biological|IVIG|Intravenous Immune Globulin
1714672|NCT01350427|Dietary Supplement|Leucine supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 5.6 g of alanine
1714673|NCT01350427|Dietary Supplement|BCAA supplementation|1 bout of resistance exercise and supplementation of 4.0 g of leucine + 2.8 g of isoleucine + 2.8 g of valine
1714674|NCT01350427|Dietary Supplement|Alanine supplementation|1 bout of resistance exercise and supplementation of 9.6 g of alanine
1714675|NCT01350414|Device|Bronchial Thermoplasty with the Alair System|Bronchial Thermoplasty with the Alair System
1714677|NCT01350388|Drug|Febuxostat|80 mg/day of febuxostat for 24 weeks
1714678|NCT01350388|Drug|Placebo|1 placebo tablet per day for 24 weeks
1714679|NCT01350375|Drug|Botox|
1714680|NCT01350375|Drug|Saline|
1714681|NCT01350362|Drug|tideglusib|1000 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
1714682|NCT01350362|Drug|tideglusib|1000 mg of tideglusib as a powder for oral suspension once every other day in an overnight fasted state for 26 weeks/extension
1714683|NCT01350362|Drug|tideglusib|500 mg of tideglusib as a powder for oral suspension once daily in an overnight fasted state for 26 weeks/extension.
1714684|NCT01350362|Drug|Placebo|Powder for oral suspension administered once daily in an overnight fasted state for 26 weeks/extension.
1714685|NCT01350349|Behavioral|Problem Adaptation Therapy (PATH)|Problem Adaptation Therapy (PATH) focuses on the subject, the caregiver, and the subject's home-environment, to encourage problem-solving and adaptive functioning. The goal of PATH is to decrease depression and disability.
1714686|NCT01350349|Behavioral|Supportive Therapy|Supportive Therapy assists subjects in expressing their feelings and focusing on their strengths and abilities in working through current difficulties and transitions.
1714687|NCT01350336|Device|Alair System|Treatment of airways with the Alair System
1714688|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml of aqueous)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
1714689|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+intravitreal injection of bevacizumab (1.25mg/0.05ml)
1715000|NCT01348139|Other|AZD3199 Placebo|Inhaled via Turbuhaler inhaler and SID
1714690|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)+ intravitreal injection of bevacizumab (1.25mg/0.05ml)
1714691|NCT01350323|Procedure|Aqueous sample|Aqueous sample (0.1ml)
1714692|NCT01350310|Procedure|Intramyocardial injection|Electromechanical mapping will be used to identify viable myocardium (unipolar voltage >6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
1714693|NCT01350310|Procedure|Intracoronary injection|Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment. Microcatheter will be placed in the mid segment of the coronary artery supplying the segments of reduced tracer accumulation and repeated intracoronary injections of stem cell solution will be performed.
1714694|NCT01350310|Procedure|Intramyocardial injection|Procedure/Surgery: Intramyocardial injection Electromechanical mapping will be used to identify viable myocardium (unipolar voltage >6.9 mV) and intramyocardial injections in the target areas will be performed with NOGA catheter (25 injections of 0.3 cc).
1714695|NCT01350297|Procedure|reinnervation|anastomosis between right inferior laryngeal nerve and right phrenic nerve
1714696|NCT01350284|Dietary Supplement|Cinnamon|acute oral administration of 3 g cinnamon
1714697|NCT01350284|Dietary Supplement|Placebo control|3 g wheat flour (placebo)- separated by 28 days from cinnamon intervention
1714698|NCT01350271|Drug|Mebendazole polymorph A and C 500 mg|Mebendazole tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg of mebendazole as a 50:50 mixture of Polymorphs A and C
1714699|NCT01350271|Drug|Mebendazole polymorph C|Mebendazole tablets manufactured by the State Pharmaceutical Manufacturing Corporation of Sri Lanka, containing 500mg dose of mebendazole as Polymorph C alone
1714700|NCT01350271|Drug|Placebo|Placebo tablets produced by the State Pharmaceutical Manufacturing Corporation of Sri Lanka
1714701|NCT01350258|Drug|Fludarabine|Part of the conditioning regimen
1714702|NCT01350258|Drug|Thiotepa|Part of the conditioning regimen
1714703|NCT01350258|Radiation|Total Body Irradiation (TBI)|There is one fraction of total body irradiation (2Gy) as part of the conditioning regimen.
1714704|NCT01350258|Biological|Donor Lymphocyte Infusion (DLI)|Immediately following the conditioning regimen of fludarabine, thiotepa, and TBI, the patient receives a set dose of their donor's T cells (DLI), After the DLI, the donor's T cells will react with the remaining parts of the recipients immune system.
1714705|NCT01350258|Drug|Melphalan|Two days after the DLI, Melphalan will be given to eliminate the reacting T cells to avoid graft versus host disease. Non-activated T cells should not be affected by the Melphalan and remain to help fight infection.
1714706|NCT01350258|Device|Hematopoietic stem cell transplantation (HSCT)|"One day after the Melphalan ends, the patient will receive their donor's stem cells. This is the actual day of transplant.
The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
1714707|NCT01350245|Radiation|Total Body Irradiation (TBI)|Total body irradiation is given in 8 fractions over 4 days (total dose of 12 Gy).
1714708|NCT01350245|Biological|Donor Lymphocyte Infusion (DLI)|After TBI, the patients will receive a dose of 2 x 10e8 of their donor's T cells. After this infusion, the patients will have 2 rest days.
1714709|NCT01350245|Drug|Cyclophosphamide|Cyclophosphamide is administered 2 days after the DLI to help tolerize the donor T cells. It is given at a dose of 60 mg/kg/d for 2 days
1714710|NCT01350245|Drug|Mycophenolate Mofetil (MMF)|Started the day before the transplant to prevent graft versus host disease (GVHD)
1714711|NCT01350245|Drug|Tacrolimus|Started the day before the transplant to prevent graft-versus-host disease (GVHD)
1714712|NCT01350245|Device|Hematopoietic stem cell transplantation (HSCT)|"One day after the cyclophosphamide is finished, the patients will receive a CD34 selected-donor stem cell product. This is the day of transplant.
The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
1714713|NCT01350232|Drug|Fludarabine|Subjects will receive fludarabine at a dose of 30 mg/m2 daily for 4 days as part of the preparative regimen
1714714|NCT01350232|Drug|Cytarabine|Subjects will receive cytarabine at a dose of 2 g/m2 daily for 4 days, approximately 4 hours after the fludarabine
1714715|NCT01350232|Device|Cellular Infusions|"Subjects will receive the cellular product in 2 steps. The first is a lymphocyte infusion of 2 X 10e8 lymphocytes/kg on the day they receive total body irradiation. The second is a CD34 enriched stem cell product approximately 48 hours after the cyclophosphamide.
The CliniMACS® Plus Instrument will be used for the selection of human CD34+ hematopoietic stem and progenitor cells in human allogeneic hematopoietic stem cell transplantation."
1714716|NCT01350232|Radiation|Total Body Irradiation|All subjects will receive 200cGy TBI in a single fraction on the AM they receive the lymphocyte infusion
1714717|NCT01350232|Drug|Cyclophosphamide|All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
1714718|NCT01350232|Drug|Bortezomib|Subjects will receive bortezomib 1.3 mg/kg on Day 1,4,8, and 11 of a 21 day cycle. This will be repeated for 2 cycles.
1714719|NCT01350232|Drug|Rituximab|Subjects will receive rituximab 375 mg/m2 on day 1 and day 8 of a 21 day cycle, on days they will also be receiving rituximab. This will be repeated for 2 cycles.
1714720|NCT01350232|Procedure|Plasmapheresis|Subjects who continue to have detectable anti-donor antibody will receive plasmapheresis to reduce the antibody further
1714721|NCT01350219|Device|Stem Cell Educator|For the treatment, commonly the left (or right) median cubital vein, a patient's blood is passed through a Blood Cell Separator that isolates the lymphocytes from the blood according to the recommended protocol by manufacture; consequently, the collected lymphocytes were transferred into the Stem Cell Educator and treated by CB-SC; after that, the educated cells return the blood back to the patient via a dorsal vein of hand. During the MCS+ collection, the whole blood flow rate was maintained at 35 mL/min. The whole procedure was scheduled for 8 ~ 9 hrs.
1714793|NCT01349803|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Formoterol Fumarate 12 μg (Foradil® Aerolizer®) administered BID for 14 days
1714794|NCT01349790|Drug|NewGam|NewGam is a solution of human normal immunoglobulin 10% treated with solvent/detergent and nanofiltered for intravenous administration.
1714795|NCT01349777|Drug|Pregrel®|Pregrel® 75mg daily for 12 months
1714722|NCT01350206|Procedure|hepatic resection|HR was carried out under general anesthesia using a right subcostal incision with a midline extension. Intraoperative ultrasound was routinely performed. Pringle's maneuver was routinely used with a clamp/unclamp time of 10 minutes/5 minutes.Thrombectomy was performed according to the location and extent of PVTT. The en bloc technique was used for patients if the portal vein branch could be ligated with a sufficient safety margin between its root and the tip of the thrombus
1714723|NCT01350206|Procedure|TACE|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg )mixed with iodized oil lipidol
1714724|NCT01350193|Device|Manuka Honey|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
1714725|NCT01350193|Other|Saline Irrigation|The use of the nasal irrigation on post-operative day #1. 30mL of the nasal irrigation will be applied to each nostril by a 60mL Toomey syringe (given to patient at pre-operative clinic visit) twice a day (once in am, once in pm). This will continue until the 6 month post-op visit.
1714726|NCT01350167|Procedure|Screening|"Triphasic CT of the abdomen with and without contrast every 12 months and alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years.
Ultrasound of the upper left quadrant every 6 months with alpha-fetoprotein testing every 6 months. Repeated until HCC diagnosed for up to 10 years."
1714727|NCT01350154|Drug|Sildenafil|20 mg in gelatine capsules, oral, three times daily
1714728|NCT01350154|Drug|Placebo|Lactose monohydrate oral in gelatine capsules, 3 times daily
1956456|NCT02849418|Drug|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). The 30 mL of study drug will be administered as 30 injections each of 1.0 mL, evenly distributed at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents.
1956457|NCT02849418|Drug|Placebo|Placebo injection contains sodium chloride (0.9 milligrams [mg]); 30 mL of the injection will be injected at 30 sites in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered using cystoscopy and under local anesthesia. General anesthesia may be used excluding neuromuscular blocking agents
1714732|NCT01350128|Drug|PT001 MDI|PT001 MDI administered as two puffs BID for 7 days
1714733|NCT01350128|Drug|Ipratropium Bromide HFA Inhalation Aerosol|Taken as 2 inhalations of the 17 µg per actuation strength MDI QID
1714734|NCT01350128|Other|Placebo MDI|Matching placebo to PT001 MDI administered as two puffs BID for 7 days
1714735|NCT01350115|Drug|LDE225|supplied as 100 mg capsules
1714736|NCT01350115|Drug|Placebo|supplied in capsules
1714741|NCT01350089|Drug|Placebo (without alcohol, caffeine, energy drink)|(carbonated) water (volume equivalent to 46.5 g ethanol (inform of vodka (37.5%)) (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture is 500 mL.
1714742|NCT01350089|Drug|Comparator 1 (with alcohol; without caffeine and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), (carbonated) water 250 mL, artificial fruit juice (21 g/L prepared with (carbonated) water). The final volume of the mixture 500 mL.
1714743|NCT01350089|Drug|Comparator 2 (with alcohol and caffeine; without energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), caffeine (80 mg), (carbonated) water (250 ml), artificial fruit juice (21 g/L prepared with (carbonated) water) The final volume of the mixture is 500 mL.
1714744|NCT01350089|Drug|Comparator 3 (with alcohol and energy drink)|Mixture of 46.5 g ethanol (inform of vodka (37.5%)), Red Bull® Energy Drink (250 mL, without flavour mixture to optimize blinding), artificial fruit juice (21 g/L prepared with (carbonated) water).The final volume of the mixture is 500 mL.
1714745|NCT01350076|Drug|conventional liberal fluid regimen|Control group will receive conventional liberal fluid regimen with crystalloid Liberal fluid regimen = Maintenance fluid + fasting fluid + dehydration + third space loss Maintenance fluid = (4X BW 1-10 kg) + (2X1BW11-20 kg) + (1X BW 0ver 21 kg) Fasting fluid = maintenance fluid X fasting duration
1714746|NCT01350076|Drug|restricted fluid regimen|"Study group will receive restricted fluid regimen (the same as control group except third space replacement) plus goal directed fluid therapy to maintain adequate CO guided by USCOM as shown in diagram (figure 1).
Figure 1 goal directed fluid therapy SVV = Stroke volume variation SVI = Stroke volume index CI = Cardiac index"
1714747|NCT01350063|Drug|Sodium dichloroisocyanurate (NaDCC) tablet (Aquatab)|One tablet should be added to 10L container, resulting in a free chlorine dose of 2 mg/L.
1714748|NCT01350063|Device|Water storage container (Jerry can)|Shallow tubewell water should be stored in 10L container.
1714749|NCT01350063|Other|No intervention|
1714750|NCT01350050|Drug|articaine|"Articaine is intermediate-acting local anesthetic (amide type). Like other local anesthetic drugs, articaine causes a transient and completely reversible state of anesthesia (loss of sensation) during (dental) procedures.
In dentistry, articaine is used both for infiltration and block injections."
1714751|NCT01350050|Other|9% Sodium Chloride solution for injection|9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. Each mL contains sodium chloride 9 mg. It contains no bacteriostat, antimicrobial agent or added buffer.
1714752|NCT01350037|Drug|alfentanil|Alfentanil is a potent but short-acting synthetic opioid analgesic drug, used for anaesthesia in surgery. It is an analogue of fentanyl with around 1/10 the potency of fentanyl and around 1/3 of the duration of action, but with an onset of effects 4x faster than fentanyl.It is an OP3 mu-agonist.Alfentanil is administered by the parenteral (injected) route for fast onset of effects and precise control of dosage.
1714796|NCT01349777|Drug|Plavix®|Plavix® 75mg daily for 12 months
1714797|NCT01349764|Drug|Vitamin D3|
1714798|NCT01349751|Drug|isobaric levobupivacaine|0.42% either isobaric levobupivacaine 3 ml spinal injection once
1714799|NCT01349751|Drug|hyperbaric levobupivacaine|0.42% hyperbaric levobupivacaine 3 ml spinal injection once
1714800|NCT01349738|Drug|Antibiotic|Antibiotic (drug) sensitive to most recent culture for these subjects testing ASB positive and also experience Signs and symptoms of a UTI
1714753|NCT01350037|Drug|remifentanil|Remifentanil is a potent ultra short-acting synthetic opioid analgesic drug. It is given to patients during surgery to relieve pain and as an adjunct to an anaesthetic. Remifentanil is used for sedation as well as combined with other medications for use in general anesthesia. The use of remifentanil has made possible the use of high dose opioid and low dose hypnotic anesthesia, due to synergism between remifentanil and various hypnotic drugs and volatile anesthetics.It is administered in the form remifentanil hydrochloride and in adults is given as an intravenous infusion in doses ranging from 0.1 microgram per kilogram per minute to 0.5 (µg/kg)/min.
1714754|NCT01350024|Procedure|Frontal nerve block with 2% lidocaine with 1:100,000 dilution of epinephrine|Frontal Nerve Block 5 cc will be administered preoperatively once.
1714755|NCT01350024|Procedure|Subconjunctival injection of 2% lidocaine with 1:100,000 dilution with epinephrine|Patients will receive a 1.5 cc dose of subconjunctival lidocaine as above
1714756|NCT01350011|Behavioral|Innovative System|In IS, they will receive motivational counseling at months 3,6,12, and 18. If they decide to quit smoking they will be offered up to 10 sessions of behavioral counseling and access to NRT (nicotine patch and gum) If they relapse on NRT, they will be offered varenicline, if it is not contraindicated.
1714757|NCT01350011|Behavioral|Standard Treatment Control (STC)|Participants will receive self help information and referrals for counseling and for pharmacological treatment.
1714758|NCT01349998|Drug|Product 33525|Daily dosing for 2 weeks each recurrence for patients with tinea pedis and Daily dosing for 1 week each recurrence for patients with tinea cruris and tinea corporis
1714759|NCT01349985|Other|AGATE|AGATE is a web-based adherence-enhancement intervention accessible via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
1714760|NCT01349985|Other|SASED|Participants will receive SASED, a web-based alcohol and side-effects diary via smartphone. All participants will be prescribed naltrexone, 50 mg, once daily for eight weeks.
1714761|NCT01349972|Drug|alvocidib|Given IV
1714762|NCT01349972|Drug|daunorubicin hydrochloride|Given IV
1714763|NCT01349972|Drug|mitoxantrone hydrochloride|Given IV
1714764|NCT01349972|Drug|cytarabine|Given IV
1714765|NCT01349959|Drug|Azacitidine|Given SC
1714766|NCT01349959|Drug|Entinostat|Given PO
1714767|NCT01349959|Other|Laboratory Biomarker Analysis|Correlative studies
1714768|NCT01349959|Other|Pharmacological Study|Correlative studies
1714769|NCT01349933|Drug|Akt inhibitor MK2206|Given PO
1714770|NCT01349920|Drug|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg at study Weeks 0, 2, 6, 14, and 22.
1714771|NCT01349907|Drug|Asenapine|One flavored asenapine sublingual tablet (containing either 2.5, 5 or 10 mg asenapine) twice daily (BID), starting at 2.5 mg on Day 1 for three consecutive days. Normally on Day 4, the dose will increase to 5 mg BID beginning with the evening dose. Normally on Day 7, the dose will increase to 10 mg BID beginning with the evening dose. The dose may be up-titrated earlier than Days 4 and 7 at the investigator's discretion. Beginning on Day 8 (or after at least 1 day on 10 mg BID), asenapine dosing will be flexible (2.5, 5, or 10 mg BID) until up to Week 50.
1714772|NCT01349907|Drug|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines (i.e., lorazepam [up to 4 mg/day] or an equivalent dose of short-acting benzodiazepines) and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
1714773|NCT01349894|Device|SNaP® Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
1714774|NCT01349881|Drug|Eflornithine placebo & sulindac placebo|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years
1714775|NCT01349881|Drug|eflornithine & sulindac placebo|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac placebo 1 tablet PO daily for 3 years.
1714776|NCT01349881|Drug|Eflornithine placebo & sulindac|Eflornithine placebo 2 tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
1714777|NCT01349881|Drug|Eflornithine plus sulindac|Eflornithine two 250 mg tablets PO daily for 3 years. Sulindac one 150 mg tablet PO daily for 3 years.
1714778|NCT01349868|Drug|PT005 MDI|PT005 MDI taken as two inhalations
1714779|NCT01349868|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Taken as 1 capsule. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
1714780|NCT01349868|Drug|Formoterol Fumarate 24 μg (Foradil® Aerolizer®)|Taken as 2 capsules. Each capsule contains 12 μg corresponding to 10 µg formoterol fumarate dihydrate delivered from the mouthpiece
1714781|NCT01349868|Other|Placebo MDI|Matching placebo to PT005 MDI taken as two inhalations
1714782|NCT01349855|Drug|Insulin glargine HOE901|Pharmaceutical form:solution for injection: new formulation and marketed formulation Route of administration: subcutaneous
1714783|NCT01349842|Biological|Blood sampling|20ml of patient peripherical blood will be collected
1714784|NCT01349842|Other|Usual clinical and radiological criteria|Clinical examination, tumoral evaluation
1714785|NCT01349829|Biological|HAVpur Junior|"≥12 International Units (IU) hepatitis A antigen coupled to virosomes, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)
Vaccination schedule: single doses at 0 and 6 months"
1714786|NCT01349829|Biological|Havrix 720 Junior|"≥720 ELISA Units (EU) hepatitis A antigen adsorbed to aluminium hydroxide, intramuscularly (i.m.), anterolateral thigh (M. vastus lateralis) or deltoid (M. deltoideus)
Vaccination schedule: single doses at 0 and 6 months"
1714787|NCT01349816|Drug|PT003|PT003 MDI administered as two puffs BID for 7 days
1714788|NCT01349816|Drug|PT001|PT001 MDI administered as two puffs BID for 7 days
1714789|NCT01349816|Drug|PT005|PT005 MDI administered as two puffs BID for 7 days
1714790|NCT01349803|Drug|PT005 MDI|PT005 MDI administered as two puffs BID for 14 days
1714791|NCT01349803|Drug|PT001 MDI|PT001 MDI administered as two puffs BID for 14 days
1714792|NCT01349803|Drug|PT003 MDI|PT003 MDI administered as two puffs BID for 14 days
1714801|NCT01349725|Drug|ARRY-502|Oral; multiple dose, escalating
1714803|NCT01349699|Drug|iron sucrose|1.25 mg/kg iron sucrose is administered intravenously 1 hr before endotoxin administration
1714804|NCT01349699|Drug|Deferasirox|30 mg/kg deferasirox is administered orally 2 hrs before endotoxin administration.
1714805|NCT01349699|Drug|endotoxin|at t=0 2ng/kg purified E.Coli endotoxin is administered intravenously
1714806|NCT01349699|Drug|Placebo|"At t=-2 hrs starch is dissolved in water to serve as a placebo for exjade. It is prepared and administered orally by a research nurse that is unblinded to the protocol.
At t=-1 hrs 0.9% NaCl is administered intravenously serving as a placebo for iron sucrose. The infused volume is identical, and the syringes en tubes are blinded by aluminum foil. The administration is carried out by a research nurse that is unblinded to the protocol."
1714807|NCT01349686|Procedure|Diet|Oral intake of fluids during labour, from admission (dose: two cups of 8 ounces each of clear tea with little sugar).
1714808|NCT01349686|Procedure|Fasting|No intake of fluids during labour.
1714809|NCT01349673|Drug|Budesonide Foam|2mg/25ml BID for 2 weeks followed by 2mg/25ml QD for 4weeks
1714810|NCT01349660|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks
1714811|NCT01349660|Drug|BKM120|BKM120 orally (PO) once daily
1714812|NCT01349647|Biological|vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant. Patients will receive vaccine at weeks 1, 2, 3, 9, 20, and 32. Patients will also receive one cycle of chemotherapy with etoposide and cisplatin or carboplatin at week 6.
1714813|NCT01349647|Biological|Biological/Vaccine: vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant|"Patients will be vaccinated with the pentavalent vaccine comprised of KLH conjugates of GD2L, GD3L, Globo H, fucosyl GM1, and N-propionylated polysialic acid plus OPT-821 adjuvant.
Patients will receive vaccine at weeks 1, 2, 3, 4, 8, and 16."
1714814|NCT01349634|Other|Iodized salt|salt for human consumption is fortified at the national level with iodine. The experimental group will receive iodized salt early. the comparison group will receive it by market forces. presently there is only enough iodized salt to meet 10% of the countries needs, and is targeted mainly to urban areas.
1714815|NCT01349608|Behavioral|Telephonic health coaching|Participants will be given a pedometer and activity log to use daily to track their physical activity accomplishments. Weekly, they will participate in a health coaching telephone session to discuss physical activity and set goals. The health coach is knowledgable in COPD care and will utilize a motivational interviewing approach to support the self-efficacy of the participants to be more active.
1714816|NCT01349595|Drug|Bortezomib|"Patients randomized to bortezomib treatment will receive 2, 4-dose cycles of drug followed by a 2 month hiatus. At the end of this time, subjects will be re-evaluated for the appropriateness of receiving a 3rd and 4th cycle of bortezomib. Bortezomib will be given subcutaneously (under the skin). If unable to give subcutaneously, bortezomib will be given as a single IV (injection into vein) over a time of 3 to 5 seconds. Patients will receive up to 4, four-dose cycles of 1.3 mg/m(2) (based on body surface area)."
1714817|NCT01349582|Procedure|flow diversion|endovascular treatment with flow diversion including standard management of thrombo-embolic risk
1714818|NCT01349582|Other|conservative management|conservative management is watchful observation of the aneurysm until indication for intervention arises
1714819|NCT01349582|Procedure|endovascular coiling|standard endovascular coiling of aneurysm with any type of already approved coil. High porosity stents may be used as an adjunct technique to coiling
1714820|NCT01349582|Procedure|balloon parent vessel occlusion|sacrifice of parent artery of aneurysm by endovascular balloon occlusion with or without bypass
1714821|NCT01349582|Procedure|surgical clipping|clipping of the aneurysm following invasive brain surgery
1714822|NCT01349569|Drug|Lenalidomide|Dosage forms: 5, 10, 15 and 25 mg capsules. Patients will be continued on the same dose of lenalidomide as they were prior to being enrolled in the study. Doses of lenalidomide for investigation can vary from 5- 25 mg/day, orally on days 1 - 21 followed by 7 days rest (28 day cycle).
1714823|NCT01349569|Biological|Allogeneic Myeloma Vaccine|A total of 4 vaccines will be administered. The first three at monthly intervals and a booster at 6 months from the initial vaccine. Each vaccination will consist of five total intra-dermal injections, two each in the right and left anterior upper thighs, and one in the non-dominant upper arm (unless contraindicated). Each dose will be administered on an outpatient basis. The subject must be observed in the clinic for at least 30 minutes after vaccination is completed.
1714824|NCT01349569|Biological|Prevnar-13|Prevnar-13 will be administered at 0.5ml dose by intramuscular injection.
1714825|NCT01349556|Drug|Tretinoin|tretinoin 0.025% cream
1714826|NCT01349543|Biological|RSV A Memphis 37|Intranasal administration
1714827|NCT01349530|Other|Evaluating of usual care|RESEARCH IN CURRENT CARE
1714828|NCT01349530|Other|Evaluation of CREATIF|RESEARCH IN CURRENT CARE
1714829|NCT01349517|Procedure|MIE|The patients in this group would perform minimal invasive three-incision subtotal esophagectomy (thoracoscopic and/or laparoscopic)
1714830|NCT01349517|Procedure|Three-incision thoracotomy|The patients in this group would perform three-incision subtotal esophagectomy (thoracotomy and laparotomy)
1714831|NCT01349517|Procedure|Ivor-Lewis esophagectomy|The patients in this group would underwent Ivor-Lewis esophagectomy
1714832|NCT01349517|Procedure|Sweet esophagectomy|The patients in this group would underwent Sweet esophagectomy.
1714833|NCT01349491|Drug|Ranolazine|Patients will be started on ranolazine 500mg twice daily. The first dose will be administered the day of cardioversion. The dose will be doubled after 2 weeks to 1000mg twice daily as tolerated for a total of six months.
1714834|NCT01349491|Drug|Matching placebo|Patients will be started on a matching placebo twice daily. The first dose will be administered the day of cardioversion and continued for a total of six months.
1714835|NCT01349478|Device|LOKOMAT|Robot-assisted gait training,8 weeks,3 sessions a week,20-45 min each session.
1714836|NCT01349465|Drug|No treatment|No treatment was given to patients during this study as this is a follow-up study of previous Phase IIb or Phase III in which they received a TMC435-containing regimen.
1714837|NCT01349452|Drug|Ganciclovir|Ganciclovir 0.15% Ophthalmic gel
1714838|NCT01349452|Drug|Artificial tear|Artificial tear 5 times per day
1714840|NCT01349439|Drug|Short acting + long acting propranolol + memory reactivation|After completing the double-blind phase of the study, participants will receive short acting propranolol 1mg/kg (patient weight) + long acting propranolol (1 or 1.5 mg/kg) followed by memory reactivation. Dose level for the long-acting propranolol will be randomly assigned across participants.
1714841|NCT01349426|Device|LigaSure Force Triad Vessel Sealing System|Quality of parenchymal pneumostasis comparison after fissure closure: LigaSure vs automatic staplers
1714842|NCT01349413|Drug|Esomeprazole 20mg|Oral Esomeprazole 20mg daily for 8 weeks
1714843|NCT01349413|Other|Placebo|Identical looking placebo
1714844|NCT01349400|Other|Watchful waiting|Watchful waiting means the observation of the hernia. The patient is informed about signs of deterioration or incarceration. The hernia is controlled clinically on defined follow-up visits.
1714845|NCT01349400|Procedure|Hernia repair|"Open or laparoscopic hernia repair with mesh (non-absorbable or partly-absorbable alloplastic material) or with direct suture repair. For hernias measuring ≥ 3 cm mesh repair is recommended. A wide overlap of the mesh over the fascia margin on each side has to be provided.
These are all standard techniques in incisional hernia repair."
1714846|NCT01349387|Drug|Metformin|After inclusion in the study to J0, metformin treatment will be interrupted between J1 and J30, replaced by Januvia 100 mg/day dose, then resumed at J31.
1714847|NCT01349374|Other|skin biopsy|Obtention of skin micro-samples collected from healthy volunteers and diabetic patients (type 2 and MODY), intended to be used afterwards to obtain stem cell lines, in the framework of new therapeutic strategies of type 2 diabetes.
1714848|NCT01349361|Procedure|Daylight mediated photodynamic therapy|
1714849|NCT01349348|Drug|Tolvaptan|tablet, 15 mg, Qd, for 7 days
1714850|NCT01349348|Drug|Tolvaptan|tablet, 7.5 mg, Qd, for 7 days
1714851|NCT01349348|Drug|placebo|tablet, 7.5/15mg , Qd, 7days.
1714852|NCT01349335|Drug|Tolvaptan|tablet, 15 mg, Qd, for 7 days
1714853|NCT01349335|Drug|Tolvaptan|tablet, 30 mg, Qd, 7 days
1714854|NCT01349335|Drug|placebo|tablet, 30 mg, Qd, 7days.
1714855|NCT01349322|Radiation|Whole breast irradiation delivered by 3-dimensional conformal radiation therapy or intensity modulated radiation therapy|Patients undergo whole breast radiotherapy by 3D-CRT or IMRT
1714856|NCT01349322|Radiation|Higher per daily radiation therapy|Patients undergo higher per daily radiation therapy
1714857|NCT01349322|Radiation|Concurrent boost radiotherapy|Patients undergo concurrent boost radiotherapy
1714858|NCT01349322|Radiation|Standard per daily radiation therapy|Patients undergo standard per daily radiation therapy
1714859|NCT01349322|Radiation|Sequential boost radiotherapy|Patients undergo sequential boost radiotherapy
1714860|NCT01349309|Behavioral|Swallowing Exercise Group|"Swallowing Exercises
Perform each exercise 10 times. Do these 3 times a day. Vary the order of the exercises.
Effortful Swallow: As you swallow squeeze hard with all your muscles. (Can do with water or without)
Super Supraglottic Swallow:
Inhale and hold your breath very tightly, bearing down. Keep holding your breath and bearing down as you swallow. Cough when you are finished. (Can do with water or without)
Tongue Hold Maneuver:
Gently hold your tongue in between your front teeth and swallow your saliva.
Tongue Retraction:
Pull the back of your tongue to the back of your mouth and hold.
Mendelsohn Maneuver:
Swallow your saliva and pay attention to your neck as you swallow. Try to feel that something (your Adam's apple of voice box) lifts and lowers as you swallow. Now, when you swallow and you feel something lift as you swallow don't let it drop. Hold it with your muscles for several seconds."
1714861|NCT01349296|Drug|Everolimus + BIBF 1120|Dose level 1: 1x 5mg Everolimus/d + 2x 150mg BIBF 1120/d. Dose level 2: 1x 5mg Everolimus/d + 2x 200mg BIBF 1120/d. Dose level 3: 1x 10mg Everolimus/d + 2x 200mg BIBF 1120/d
1714862|NCT01349283|Biological|HepavaxGene (thiomersal free)|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
1714863|NCT01349283|Biological|Engerix B|10 µg/0.5 mL, intramuscular injection on Day 1, Month 1, Month 6
1714864|NCT01349270|Drug|Immunoglobulin perfusion|patient who received monthly 2g/kg intravenous cure of immunoglobulin
1714865|NCT01349270|Drug|Prednisone|patient who received 0,8mg/kg/day of prednisone progressively tapered over 6 months
1714866|NCT01349257|Drug|BDP/Formoterol|One single day treatment of CHF 1535 100/6 NEXT DPI®: CHF 1535 dry powder for inhalation (fixed combination of beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg per actuation) administered via the NEXT DPI® dry powder inhaler with charcoal block.
1714867|NCT01349231|Drug|ketamine|Ketamine (a single 0.5mg intravenously over 40 minutes).
1714868|NCT01349218|Other|Blood sample drawn from a vein|0.5 ml will be drawn from a vein when an IV is started for the surgery or from an IV already in place. The blood will be placed into a heparinized, 1 ml syringe for venous blood gas analysis.
1714869|NCT01349218|Other|Blood sample drawn from a heel stick|A second blood sample, 0.3 ml will be drawn into a capillary pipette from a heel stick for capillary blood gas analysis.
1714870|NCT01349205|Drug|Caffeine and sodium Benzoate 10 mg/kg IV|IV, 10mg/kg, IVP, 1 time
1714871|NCT01349205|Drug|Caffeine and Sodium Benzoate 20 mg/kg IV|IV, 20 mg/kg, IVP, 1 time
1714872|NCT01349205|Drug|0.9 NS Saline|IV, 0-10 ml, IVP, 1 time
1714873|NCT01349192|Drug|Rifampin|Adult Dose: 300mg twice daily for 14 days. Pediatric Dose: <40kg : 15mg/kg daily for 14 days divided every 12 hours.
1714874|NCT01349192|Drug|Trimethoprim/Sulfamethoxazole|Adult Dose: 320/1600 orally twice daily for 14 days. Pediatric Dose: <40 kg : 8mg/kg trimethoprim / 40 mg/kg sulfamethoxazole twice a day for 14 days.
1714875|NCT01349192|Drug|Minocycline|"only subjects greater or equal to 8 years of age, who are not able to tolerate TMP/SMX or whose screening MRSA is resistant to TMP/SMX should be prescribed minocycline.
Adult dose: 100 mg orally twice daily for 14 days Pediatric dose: < 50 kg : 2mg/kg orally twice daily for 14 days not to exceed 200mg per day."
1714876|NCT01349192|Drug|Mupirocin|1 gram 2% nasal ointment generously applied to each nostril using a cotton swab twice daily for 14 days.
1714877|NCT01349192|Drug|chlorhexidine gluconate oral rinse|for subjects able to swish without swallowing. 0.12% chlorhexidine gluconate oral rinse twice daily for 14 days.
1714878|NCT01349192|Drug|2% Chlorhexidine solution wipes|whole body wash solution wipes once daily for first 5 days.
1714879|NCT01349192|Behavioral|Environmental Decontamination|"wipe down high touch surfaces and medical equipment with surface disinfecting wipes daily for the first 21 days.
wash all linens and towels in hot water once weekly for three weeks."
1714880|NCT01349179|Device|Metal on metal hip arthroplasty operated on 2002|The purpose of the study is to evaluate the presence of geodes acetabular and femoral with scan examination.
1714881|NCT01349166|Behavioral|Behavior: Supervised physical training|protocol designed to evaluate effects of physical activity on cardiometabolic and inflammatory biomarkers according to glucose tolerance
1714882|NCT01349153|Behavioral|Facebook-based Messages/Website|Twelve weekly messages, a pedometer, sixteen group discussions, and access to an exercise website to promote increased physical activity.
1714883|NCT01349153|Behavioral|Facebook-based Self-help Comparison|Twelve weekly messages and a pedometer.
1714884|NCT01349140|Drug|SKY0402|Single-injection femoral nerve block. Initial doses of SKY0402 will begin at 0 mg, and 2 mg (high) for the first subject; and 1 mg (low) and 3 mg (high) for the second subject. The next doses will be between 0-80 mg per side, determined prior to randomization of each subsequent subject. The specific subsequent doses will increase, remain the same, or decrease, determined by the P.I. in consultation with the manufacturer of SKY0402. Doses will always remain within the range of 0-80 mg per side, for a total possible dose of 0-160 mg.
1714885|NCT01349127|Dietary Supplement|20µg Vitamin D3|20µg (800IU) of vitamin D3/day for 12-weeks while lactating, commencing 10-14 days post-partum.
1714886|NCT01349127|Dietary Supplement|20µg Vitamin D3 + 500 mg Calcium|20µg (800IU) of vitamin D3 + 500mg calcium carbonate/day for 12-weeks while lactating, commencing 10-14 days post-partum.
1714887|NCT01349127|Dietary Supplement|Placebo|One gelatin placebo capsule containing zero vitamin D3 taken for 12-weeks while lactating, commencing 10-14 days post-partum.
1714888|NCT01349114|Drug|aliskiren 300 mg once daily|aliskiren 300 mg daily
1714889|NCT01349114|Drug|Placebo/sugar pill|Sugar pill/placebo
1714890|NCT01349101|Radiation|Total Body Irradiation|"Myeloablative HSCT Arm: Total body irradiation (TBI) is given in 8 fractions over 4 days (total dose of 12 Gy)
Reduced Intensity HSCT Arm: TBI is given in one fraction (total dose of 2 Gy)"
1714891|NCT01349101|Drug|Cyclophosphamide|Cyclophosphamide is administered on the third day after the hematopoietic stem cell transplantation (HSCT) to help reduce graft-versus-host disease (GVHD). It is given at a dose of 60 mg/kg/d for 2 days.
1714892|NCT01349101|Drug|Tacrolimus|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
1714893|NCT01349101|Drug|Mycophenolate mofetil|Started the fifth day after the transplant to help prevent graft-versus-host disease (GVHD).
1714894|NCT01349101|Drug|Fludarabine|Started the fifth day before the transplant. Given for four days at 30 mg/m2/d.
1714895|NCT01349101|Drug|Busulfan|Started the fourth day before the transplant. Given for two days at 3.2 mg/kg.
1714896|NCT01349101|Genetic|Hematopoietic stem cell transplantation|Allogeneic marrow transplantation given after the last dose of total body irradiation (TBI)
1714897|NCT01349088|Drug|Ixabepilone|Patients will receive ixabepilone at 40 mg/m2.
1714898|NCT01349088|Drug|Capecitabine|Patients will receive capecitabine at 2000 mg/m2.
1714899|NCT01349088|Drug|Motesanib|Patient will receive motesanib at 100mg or 125mg once daily dependent on outcome of Phase I, which will involve the first 3-6 patients.
1714900|NCT01349075|Radiation|TheraSphere|The target dose of TheraSphere most commonly used is 120 - 140 Gy. Standard radiation safety techniques will be used.
1714901|NCT01349062|Drug|"Kallunk oxide (Immunotherapy) "|"The study is assigned Arm 1 above 450 cu/mm^3 baseline CD + T cells. HIV type-1 subjects will receive one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine (Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 5 mg Kallunk oxide molecules with1995 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 2000 mg for children and adults. This powder form sample size product will be administered once daily dose on 7 days treatment. The Botanical name of the antidote is Piper Longum."
1714904|NCT01349036|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing
1714905|NCT01349023|Other|Energy density (ED), Energy content|Standard or reduced energy content and energy density of pre-portioned entrees
1714906|NCT01349010|Drug|Probucol|250mg (1 tablet) bid. p.o for 8 weeks
1714907|NCT01349010|Drug|Placebo|1 tablet bid. p.o for 8 weeks
1714908|NCT01348997|Behavioral|Project Onward website + 16 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 16 other cancer survivors.
1714909|NCT01348997|Behavioral|Project Onward website + 8 person social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
1714910|NCT01348984|Drug|transdermal fentanyl patch|TFP = transdermal fentanyl patch (50 microgram/hour)
1714911|NCT01348984|Drug|placebo patch|group 2 = placebo patch
1714912|NCT01348971|Dietary Supplement|Sodium nitrate|Preoperative oral administration of sodium nitrate. 700 mg the night before surgery and 700 mg three hours before surgery
1714913|NCT01348971|Other|Sodium chloride|Preoperative oral administration of sodium chloride the night before surgery and three hours before surgery
1714914|NCT01348958|Device|iDXA knee software|"Following surgery, subjects who have undergone knee arthroplasty will have the knee that has undergone arthroplasty (post-operative) scanned at least 8 weeks after surgery.
During one visit, each subject will have the post-operative knee scanned 1 time using Lunar orthopedic application, and 3 times with the subject repositioned between scans using the Lunar orthopedic knee application (total of 4 scans). Lunar iDXA measurement procedures will be done"
1714915|NCT01348945|Other|conventional ACL rehabilitation program|Conventional post-operative physical therapy exercises and rehabilitation, designed for ACL reconstruction for 6 months to 9 months.
1714916|NCT01348919|Drug|CEP-18770|administered on days 1, 8, and 15 of each 28-day cycle
1714917|NCT01348919|Drug|Lenalidomide|administered 25 mg on days 1 through 21 of each 28-day cycle
1714918|NCT01348919|Drug|Dexamethasone|administered 40 mg on days 1, 8, 15, and 22 of each 28-day cycle
1715039|NCT01347853|Drug|Placebo|Intranasal post-surgery for up to 5 days total
1714920|NCT01348893|Behavioral|Yoga|12 to 16 weeks of group yoga classes (approximately 32 classes per student), 30-45 minutes per class, 2-3 times per week, during physical education class. Yoga program includes physical postures and movement, breathing exercises, partner/group games, deep relaxation and meditative techniques.
1714921|NCT01348880|Drug|Vardenafil ODT, (Staxyn, BAY38-9456)|Single dose of 10 mg of vardenafil ODT, taken without water
1714922|NCT01348880|Drug|Placebo|Single dose of placebo to match 10 mg vardenafil ODT. taken without water
1714923|NCT01348867|Other|Structured care led by a nurse consultant|"For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:
i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.
ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit."
1714924|NCT01348854|Device|iFS Femtosecond Laser System|arcuate incisions placed with the iFS femtosecond laser
1714925|NCT01348841|Other|Systematic referral to MDWCT and comprehensive primary care|Systematic referral to, and follow up, by Multi-Disciplinary Wound Care Teams (MDWCTs), co-ordinated by the Case Manager (CM), will occur.There will be immediate referral to the MDWCT of clients with :1/ diabetic lower extremity ulcers,2/peripheral neuropathy, charcot changes,3/wound present longer than 4 mths. ,4/ Ankle Brachial Index less than 0.6, non-diabetics, and not being seen by a vascular surgeon. Subsequent referral to MDWCT will occur if less than 30% healing by week 4.
1714926|NCT01348828|Device|Endovascular Aortic Aneurysm Repair (Endologix Fenestrated Stent Graft System)|Endovascular repair of juxtarenal or pararenal aortic aneurysm using the Endologix Fenestrated Stent Graft System
1714927|NCT01348802|Behavioral|Push + Pull|Push + Pull is evidence on pain that is extracted from medical, nursing, psychology and rehabilitation journals, appraised for quality and relevance, and delivered to clinicians by e-mail alerts or available for searches of the accumulated database.
1714928|NCT01348802|Behavioral|Pull|Pull will be an intervention with a similar front-face but requires clinicians to go to the site and extract evidence from an electronic database.
1714929|NCT01348789|Device|Hair2Go (Mē)|Treatment with Hair2Go (Mē) three times every 2-4 days
1714930|NCT01348776|Device|Hair2Go (Mē)|Treatment with Hair2Go Device 7 times every week with maintenance treatments once a month for 3 months
1714931|NCT01348763|Drug|Maraviroc|Maraviroc 150 mg daily
1714932|NCT01348750|Other|Healing Touch & Guided Imagery|"Healing Touch (HT) is an energy based approach to health and healing. It uses light touch to influence the energy field that surrounds the body, and the energy centers which control the flow of energy to the physical body.
HT complements traditional health care and is used together with other approaches to health and healing.
Guided Imagery (GI) is a form of focused relaxation used to create harmony between the mind and body. Positive mental imagery can promote relaxation, reduce stress and improve mood as well as alter heart rate, blood pressure and breathing."
1714933|NCT01348737|Drug|AZD3839|Single Oral Dose
1714934|NCT01348737|Drug|AZD3839 Placebo|Single Oral Dose
1714935|NCT01348724|Drug|[14C] NKTR-118|Single 25 mg oral dose administered on Day 1
1714936|NCT01348685|Other|Compare the effect of solid vs. liquid forms of sugars on satiety and food intake|
1714937|NCT01348685|Other|the effect of solid vs. liquid forms of gelatin on appetite and food intake|
1714938|NCT01348685|Other|The effect of solid vs. liquid forms of whey protein on food intake|
1714939|NCT01348659|Drug|7.2% NaCl/hydroxyethylstarch|250 ml of 7.2% NaCl in hydroxyethylstarch (HES 200/0,5) will be given into the venous reservoir of the cardiopulmonary bypass circuit after aortic declamping.
1714940|NCT01348659|Drug|NaCl 0.9%|250 ml of NaCl 0.9% will be given into the venous reservoir of the CPB circuit after aortic declamping.
1714941|NCT01348646|Behavioral|Brief intervention|The adolescents were shown a series of photographs of discoloured teeth caused by smoking. Then a mirror was given to the adolescent to let him/her see if similar stains could be seen on his/her teeth. Non-smoking adolescents also received positive feedback for being non-smokers. Duration of a single brief intervention was 2-3 minutes.
1714942|NCT01348620|Device|Single port laparoscopic cholecystectomy SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)|Single port laparoscopic cholecystectomy. SINGLE SITE LAPAROSCOPY ACCESS SYSTEM (Johnson & Johnson Medical Spa)
1714943|NCT01348620|Procedure|Four port laparoscopic cholecystectomy surgery|Four port laparoscopic cholecystectomy surgery
1714944|NCT01348607|Drug|methylphenidate hydrochloride|Given orally
1714945|NCT01348607|Drug|modafinil|Given orally
1714946|NCT01348607|Drug|placebo|Given orally
1714947|NCT01348581|Device|Marigen Wound Dressing|The dressing is changed at least twice a week, with no more than five days between dressing changes. It is extremely important that the dressings are changed sufficiently often. On highly exuding ulcers the three or four dressing changes per week may be necessary. Duration is four weeks.
1714948|NCT01348568|Dietary Supplement|low glycemic index diet with canola oil bread|
1714949|NCT01348568|Dietary Supplement|High fiber diet|
1714950|NCT01348555|Drug|Bronchodilatator|
1714951|NCT01348555|Drug|Bronchodilatator|
1714952|NCT01348542|Drug|Trazodone|50 mg once a day, for 3 months
1714953|NCT01348542|Behavioral|Cognitive Behavioral Therapy|The CBT Protocol is implemented over a period of 12 weeks, with consultations held on a weekly basis.
1714954|NCT01348529|Behavioral|Internet CBT|Internet-delivered cognitive behavioral therapy with therapist support.
1714955|NCT01348516|Drug|KM-023|-KM-023 is dosed orally via 75 mg tablets. Study doses are 75 mg, 150 mg, 300 mg, and 600 mg QD for 1 (SAD) or 7 (MAD) days.
1714956|NCT01348516|Drug|Placebo for KM-023|-Placebo for KM-023 is dosed orally via Placebo for KM-023 tablets. Study doses are 1, 2, 3, and 4 placebo tablets QD for 1 (SAD) or 7 (MAD) days.
1714957|NCT01348503|Drug|Lenalidomide|Escalating doses starting at 15 mg by mouth per day.
1714958|NCT01348503|Drug|Sorafenib|Fixed dose of 400 mg by mouth twice a day.
1714960|NCT01348477|Procedure|Elliptical domed mesh technique|A segment of polypropylene mesh of 10 by 15cm enters the inguinal preperitoneal space, where takes the form of a dome and is fixed by four stitches
1714961|NCT01348464|Procedure|single port appendectomy, three port appendectomy|visual analog scale. questionnaire on wound satisfaction
1714962|NCT01348451|Device|surgical implantation|human spinal cord stem cell implantation in ALS patients
1714964|NCT01348425|Device|Longer Zilver PTX Stents|Treatment with at least one 100 mm or longer Zilver PTX stent
1714965|NCT01348425|Device|Shorter Zilver PTX Stents|Treatment with Zilver PTX stents 80 mm or shorter only
1714966|NCT01348412|Drug|oxaliplatin|130 mg/m²Every 21 days
1714967|NCT01348412|Drug|raltitrexed|3 mg/m² with a maximum of 6 mg every 21 days
1714968|NCT01348412|Drug|other intravenous chemotherapy drugs|
1714969|NCT01348386|Drug|Hydroxide Potassium|Treatment will consist of the application of topical 10% or 15% KOH in an aqueous solution for the two treatment groups, compared to a placebo-treated control group. Topical Application.
1714970|NCT01348386|Drug|Placebo|
1714974|NCT01348334|Procedure|Synthetic sling surgery|An incision of inverted A shape was inflicted on the anterior vaginal wall(AVW)of the vagina.The upper part of A shaped incision was formed into an island belonging to the vaginal wall.This patch was 3×4cm in most of the patients.Proximal AVWwas dissected as a flap.Synthetics mesh materials were first sutured onto the upper part of the A on the vaginal island with absorbable vicrly sutures.Then,with 2polypropilen sutures,these meshes were fixed on both the right and left sides of this island in a helical manner to form a suspension and using curved Kishner needles,the prolene sutures were transferred to suprapubic area.These sutures were ligated on the rectus fascia in a crosswise manner.The mobile lower wing was advanced onto the island and was sutured onto the vaginal skin with intermittent sutures using 3-0 monocryl sutures.After cystoscopy,the prolene sutures were ligated crosswise in the suprapubic region.Special attention was paid notto create much tension on the mesh material.
1714975|NCT01348321|Drug|Levamisole|Group 1: Azithromycin 500 mg per day, three days a week plus oral levamisole 150 mg per day, two days a week. Group 2: Azithromycin 500 mg per day, three days a week. The used medications were not revealed to their physician. A questionnaire was filled for every patient and photos were taken from lesions using a digital camera at first, second and final visit.
1714976|NCT01348308|Drug|Maraviroc (Celsentri)|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Maraviroc at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.
Duration: 72 weeks."
1714977|NCT01348308|Drug|Placebo|"Patients will take cART optimized regimen according to the recommended regimen as first line of treatment in most commonly used guidelines with Placebo at the following dose: 150 mg orally twice a day for patients receiving a Protease Inhibitor Ritonavir-boosted regimen (except Fosamprenavir), 300 mg orally twice a day for patients receiving a Fosamprenavir Ritonavir-boosted regimen or 600 mg orally twice a day for patients receiving Efavirenz-based regimen.
Duration: 72 weeks."
1714978|NCT01348295|Other|Observation|No interventions are made. The purpose of the study is to find out current practices used in pediatric mechanical ventilation.
1714979|NCT01348282|Drug|Lithium|lithium, in tablets, beginning a 2-daily 400 mg dose, and changing further adjusting the dose according to drug levels in serum.
1714980|NCT01348282|Drug|Rivastigmine|rivastigmine, in transdermal patch administration, beginning a once-daily 4.6 mg dose, and changing further increasing the dose up to once-daily 9.5 mg.
1714981|NCT01348269|Drug|Aclasta|1 x intravenous non-current drip (infusion)
1714982|NCT01348269|Drug|Placebo|NaCl Solution
1714984|NCT01348243|Drug|disodium clodronate 200 mg/4 ml with 1% lidocaine|CLODRONATE 200 MG/4 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE EVERY OTHER WEEK
1714985|NCT01348243|Drug|Disodium clodronate 100 mg/3,3 ml with 1% lidocaine|CLODRONATE 100 MG/3,3 ML SOLUTION FOR INTRAMUSCULAR USE WITH 1% LIDOCAINE ONCE-WEEK
1714986|NCT01348230|Other|Urine samples|collect their first morning urine samples before each of their remaining prenatal care appointments for our studies
1714987|NCT01348217|Radiation|"Conformal 3D Radiotherapy with  ENI -type prophylactic irradiation of the lymph node"|40 Gy in 20 fractions / 5 weeks, PTV (1cm in every direction)
1714988|NCT01348217|Radiation|Boost|Boost 10 Gy in 5 fr, PTV = +1cm.
1714989|NCT01348217|Radiation|Boost|Boost 26 Gy in 13 fr, PTV = +1cm.
1714990|NCT01348217|Drug|chemotherapy: FOLFOX 4|6 treatments with 4 courses concomitant to radiotherapy (D1, D15, D29, D43) arm B or 3 courses concomitant to radiotherapy (D1, D15, D29) arm A.
1714991|NCT01348204|Other|quercetin|health food supplement
1714992|NCT01348191|Procedure|Myometrial biopsy|At caesarean section, after birth of the baby but before closure of the uterus, a biopsy from the upper lip of the incision in the lower uterine segment will be taken. This biopsy will measure approximately 2x50mm.
1714993|NCT01348178|Procedure|Follow-up|Follow-up
1714994|NCT01348165|Drug|BI 137882|Powder for oral solution
1714995|NCT01348165|Drug|Placebo|Powder for oral solution
1714996|NCT01348152|Drug|DAIKENCHUTO (TU-100)|Subjects will be randomized to 15 g/day of TU-100. Dosage is granule. Subjects will ingest two 2.5 g doses of TU-100 three times daily for 34 consecutive days.
1714997|NCT01348152|Drug|Placebo|Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
1714998|NCT01348139|Drug|AZD3199|Inhaled via single inhaler device (SID)
1714999|NCT01348139|Drug|AZD3199|Inhaled via Turbuhaler inhaler
1715110|NCT00000149|Procedure|Trabeculectomy|
1715001|NCT01348126|Drug|Docetaxel|75 mg/m2 administered on Day 1 of a 3-week treatment cycle by 1-hour intravenous infusion
1715002|NCT01348126|Drug|Combination of ganetespib and docetaxel|Ganetespib 150 mg/m2 in combination with docetaxel 75 mg/m2. On Day 1 of each 3-week treatment cycle, ganetespib and docetaxel will be administered as separate 1-hour intravenous infusions. Ganetespib 150 mg/m2 will be administered again on Day 15 of each cycle.
1715003|NCT01348113|Other|Brief Alcohol intervention|Brief intervention consists typically in a brief assessment, giving patients personal feedback, dealing with resistance and ambivalence, establishing a goal of reduced alcohol use, and giving a workbook; reinforcement visits or calls are included.
1715004|NCT01348100|Drug|Iloperidone crystalline formulation|Iloperidone was formulated as 100 µm crystals for IM depot injection.
1715005|NCT01348100|Drug|Iloperidone microparticle formulation|Iloperidone was formulated as microparticles for IM depot injection.
1715006|NCT01348100|Drug|Oral iloperidone|Prior to receiving an intramuscular (IM) injection of iloperidone, patients were gradually titrated up with oral iloperidone to stable doses of 12 to 24 mg daily. In Phase A, oral iloperidone dosing lasted for at least 7 days and, in Phases B and C, for at least 10 to 14 days.
1715007|NCT01348087|Drug|AFQ056|The investigational drug, AFQ056, will be provided as hard gelatin capsules. Two different oral dosage strengths, identical in appearance, will be used.
1715008|NCT01348074|Drug|Double dose|For each individual the dose on Day 1 and Day 2 will be twice the one normally taken
1715009|NCT01348048|Other|Specialised palliative care (SPC)|The interventions given by the SPC centres follow the the WHO and the EAPC guidelines for palliative care. It is not possible in advance to describe the interventions more specifically as these will be adjusted to each particular patient. As part of the study the medical records of all patients in the intervention group will be reviewed with the purpose of describing the interventions given for the different symptoms and problems.
1715010|NCT01348009|Drug|Tesetaxel-capecitabine-cisplatin|"Phase 1: Tesetaxel orally on Day 1 of each cycle at dose of 18, 21, 24, or 27 mg/m2. If no dose-limiting toxicity, at least 3 subjects will be treated at each dose level until the maximum tolerated dose or the maximum dose of 27 mg/m2 is reached. At each tesetaxel dose level, capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1.
Phase 2: Tesetaxel orally on Day 1 of each cycle at dose determined in Phase 1. Capecitabine orally at a dose of 2000 mg/m2/day (administered in 2 equally divided doses) on Day 1-Day 14 and cisplatin intravenously at a dose of 60 mg/m2 on Day 1."
1715011|NCT01347996|Drug|histamine dihydrochloride and IL-2|Ceplene 0.5 mg subcutaneously twice daily and IL-2 1 µg/kg [16,400 IU/kg] body weight twice daily for 10, 21 day cycles
1715012|NCT01347983|Drug|Tocilizumab+Methotrexate(MTX)|Tocilizumab: 8 mg/kg every 4 weeks, IV infusion Methotrexate: 10-20 mg/week
1715013|NCT01347970|Drug|carvedilol|Given PO
1715014|NCT01347970|Other|placebo|Given PO
1715015|NCT01347970|Other|pharmacogenomic studies|Correlative studies
1715016|NCT01347970|Other|laboratory biomarker analysis|Correlative studies
1715017|NCT01347970|Procedure|quality-of-life assessment|Ancillary studies
1715018|NCT01347970|Genetic|polymorphism analysis|Correlative studies
1715019|NCT01347970|Genetic|microarray analysis|Correlative studies
1715020|NCT01347970|Genetic|polymerase chain reaction|Correlative studies
1715021|NCT01347970|Other|enzyme-linked immunosorbent assay|Correlative studies
1715022|NCT01347970|Other|questionnaire administration|Ancillary studies
1715023|NCT01347957|Other|Nitric Oxide (NO) Gel|Nitric Oxide (NO) Gel is created by premixing of contents from 2 separate gel bottles. The first bottle, NO gel, is a solution of sodium nitrite (14.6mM) in distilled water with hydroxyethylcellulose (molecular weight 50,000-1,250,000) added for gel formation. The second bottle, Releasing-stimulator gel, is a solution of maleic acid (14.6mM) and ascorbic acid (14.6mM) in distilled water with hydroxyethylcellulose added for gel formation.
1715024|NCT01347957|Other|Placebo gel|The placebo gel is created by premixing of contents from 2 separate gel bottles. The first bottle is phosphate-buffered saline. The second bottle is the second gel bottle (Releasing-stimulator gel) as described in experimental arm.
1715025|NCT01347944|Drug|lenalidomide|Patients who were prescribed Revlimid from 31October 2008 to present.
1715026|NCT01347931|Device|NIOV System|Each subject's standard oxygen therapy will be used as the control treatment and compared to the test ventilator (NIOV) system during selected activities of daily living.
1715027|NCT01347931|Device|Standard Oxygen Cannula|Supplemental oxygen via a standard oxygen cannula connected to a portable oxygen cylinder
1715028|NCT01347918|Device|19F capsule|Two 19F capsules, one filled with hexafluorobenzene (HFB) and the other filled with perfluoro-15-crown-5-ether (PCE) will be administered orally together with 100 ml of water.
1715029|NCT01347918|Dietary Supplement|sterculia|7g of sterculia will be ingested over one week together with the normal breakfast.
1715030|NCT01347905|Other|Stable-isotope techniques|Iron absorption will be estimated using stable-isotope techniques where incorporation of 57Fe and 58Fe into erythrocytes is measured 14 days after administration. The subjects will provide an initial blood sample (20ml) and then receive a test drink, containing 6 mg of 57Fe labeled ferrous sulphate. One hour later, 2 ml of an aqueous solution containing 100 μg 58Fe, as iron citrate in 250cc of normal saline will be infused over 50 min. Post infusion a 4ml blood sample will be taken. This procedure will be performed at baseline (6 weeks post-surgery) and at the end of the study (6-7 months post baseline).
1715031|NCT01347892|Other|DeNovo NT Natural Tissue Graft|DeNovo NT is a juvenile cartilagenous tissue graft, inclusive of a viable human cartilage cells. It is provided as particulated tissue pieces of approximately 1mm3 each
1715032|NCT01347879|Drug|Visonac PDT|cream application prior to illumination with red light
1715033|NCT01347879|Drug|Vehicle cream with PDT|placebo/vehicle cream application prior to illumination with red light
1715038|NCT01347853|Drug|Ketorolac tromethamine|30 mg intranasal post-surgery for up to 5 days total
1715040|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter)of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
1715041|NCT01347827|Device|measurements of brain tissue oxygenation|different monitors((the Hutchinson InSpectra™ StO2 Tissue Oxygenation Monitor) and in cerebral (ForeSight® Cerebral Oximeter and the Somanetics INVOS® Cerebral Oximeter ) and renal tissue (the Somanetics INVOS® Cerebral Oximeter) of brain tissue oxygenation with each other, and assess the correlation between brain tissue oxygenation and oxygenation measurements in renal and muscular tissue, as well as with conventional hemodynamic and metabolic variables, such as central venous oxygen saturation
1715042|NCT00000102|Drug|Nifedipine|
1715043|NCT00000104|Procedure|ERP measures of attention and memory|
1715044|NCT00000105|Biological|Intracel KLH Vaccine|Intracel KLH 1000 mcg (1 mg) without adjuvant, subcutaneous Tetanus Toxoid 0.5 ml intramuscularly.
1715045|NCT00000105|Biological|Biosyn KLH|Biosyn KLH 1000 mcg (1 mg) without adjuvant, subcutaneous tetanus toxoid 0.5 ml intramuscularly.
1715046|NCT00000105|Drug|Montanide ISA51|Emulsify the KLH with Montanide ISA-51. The KLH 1 mg vial will be reconstituted in 0.5 mL sterile water. Once solubilized, add 0.6 mL of Montanide ISA to the vial and administered contents subcutaneously.
1715047|NCT00000105|Biological|Tetanus toxoid|Tetanus Toxoid Adsorbed, Aluminum Phosphate Adsorbed, PUROGENATED® (TT), is a sterile preparation of refined tetanus toxoid for intramuscular use only.
1715048|NCT00000106|Device|Whole body hyperthermia unit|
1715049|NCT00000108|Behavioral|Exercise|
1715050|NCT00000110|Procedure|magnetic resonance spectroscopy|
1715051|NCT00000110|Drug|dietary fat|
1715052|NCT00000111|Procedure|Oral mucosal graft|
1715053|NCT00000113|Other|Progressive Addition Lenses|Varilux comfort with +2.00 addition
1715054|NCT00000113|Other|single vision lenses|
1715055|NCT00000114|Drug|Vitamin E|
1715056|NCT00000114|Drug|Vitamin A|
1715057|NCT00000115|Drug|Acetazolamide|
1715058|NCT00000116|Drug|Vitamin A|
1715059|NCT00000116|Drug|Nutritional Supplement|
1715060|NCT00000117|Drug|Immunoglobulin|
1715061|NCT00000118|Device|Sustained-Release Intraocular Drug Delivery System|
1715062|NCT00000119|Device|Heparin Surface-Modified Intraocular Lens|
1715063|NCT00000120|Drug|Erythromycin Ointment|
1715064|NCT00000120|Drug|Silver Nitrate Drops|
1715065|NCT00000121|Device|Prisms in Eyeglasses|
1715066|NCT00000122|Drug|5-Fluorouracil|
1715067|NCT00000123|Device|Polymethyl Methacrylate-Silicone Contact Lenses|
1715068|NCT00000123|Device|Polymethyl Methacrylate Contact Lenses|
1715069|NCT00000124|Procedure|Brachytherapy|
1715070|NCT00000124|Procedure|Eye Removal|
1715071|NCT00000125|Drug|Topical ocular hypotensive eye drops.|Topical ocular hypotensive eye drops.
1715072|NCT00000126|Procedure|Surgery|
1715073|NCT00000127|Procedure|Optic Nerve Sheath Decompression Surgery|
1715074|NCT00000128|Device|Bifocal Spectacle Lenses|
1715075|NCT00000129|Procedure|Radial Keratotomy|
1715076|NCT00000130|Drug|Intravitreal Antibiotics|
1715077|NCT00000130|Procedure|Initial Pars Plana Vitrectomy|
1715078|NCT00000131|Procedure|Photocoagulation Therapy|
1715079|NCT00000132|Drug|Betaxolol|
1715080|NCT00000132|Procedure|Argon Laser Trabeculoplasty|
1715081|NCT00000133|Procedure|Trans-scleral Cryotherapy|
1715082|NCT00000134|Drug|Ganciclovir|intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day
1715083|NCT00000134|Drug|Foscarnet|intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day
1715084|NCT00000135|Drug|MSL-109|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
1715085|NCT00000135|Other|Placebo|60 mg, IV (in vein) every two weeks, treatment continued until death or common closeout.
1715086|NCT00000136|Drug|Foscarnet|60 mg/kg every 8 hours, 90 mg/kg/day
1715087|NCT00000136|Drug|Ganciclovir|5 mg/kg every 12 hours, 5 mg/kg every 24 hours
1715088|NCT00000137|Procedure|Histocompatibility Matching|
1715089|NCT00000138|Drug|Prednisolone Phosphate|
1715090|NCT00000138|Drug|Acyclovir|
1715091|NCT00000139|Behavioral|Stress|
1715092|NCT00000139|Drug|Acyclovir|
1715093|NCT00000140|Drug|Perfluoropropane|
1715094|NCT00000140|Drug|Sulfur Hexafluoride|
1715095|NCT00000140|Drug|Silicone Oil|
1715096|NCT00000142|Drug|Cidofovir|"Three groups:
the deferral group, treatment deferred until retinitis progressed
Low-dose cidofovir group, 5 mg/kg of body weight once weekly for two weeks, then maintenance therapy with cidofovir, 3mg/kg once every 2 weeks.
High-dose cidofovir group, 5mg/kg once weekly for 2 weeks, then maintenance therapy with cidofovir, 5mg/kg once every two weeks."
1715097|NCT00000143|Device|Ganciclovir implant and oral ganciclovir|oral ganciclovir, 1 gm three times daily
1715098|NCT00000143|Drug|Cidofovir intravenous|intravenous, 5 mg/kg once weekly for two doses, followed by 5 mg/kg every other week
1715099|NCT00000144|Procedure|Argon Laser Treatment|
1715100|NCT00000145|Dietary Supplement|Antioxidants|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene
1715101|NCT00000145|Dietary Supplement|Zinc|80 milligrams zinc oxide; 2 milligrams of cupric oxide
1715102|NCT00000145|Dietary Supplement|Antioxidants and zinc|500 milligrams vitamin C; 400 IUs vitamin E; 15 milligrams beta-carotene; 80 milligrams zinc oxide; 2 milligrams of cupric oxide
1715103|NCT00000146|Drug|Methylprednisolone|
1715104|NCT00000146|Drug|Prednisone|
1715105|NCT00000147|Drug|Methylprednisolone|
1715106|NCT00000147|Drug|Prednisone|
1715107|NCT00000148|Procedure|Argon Laser Trabeculoplasty|
1715108|NCT00000148|Procedure|Trabeculectomy|
1715109|NCT00000149|Drug|Beta Blocker|
1715112|NCT00000150|Procedure|Subfoveal Choroidal Neovascularization Removal|
1715113|NCT00000151|Drug|Aspirin|
1715114|NCT00000151|Procedure|Argon Laser Photocoagulation|
1715115|NCT00000152|Drug|Aspirin|
1715116|NCT00000152|Drug|Beta-Carotene|
1715117|NCT00000153|Procedure|Blue-Green Argon Laser Treatment|
1715118|NCT00000153|Procedure|Red Krypton Laser Treatment|
1715119|NCT00000154|Procedure|Vitrectomy|
1715120|NCT00000156|Device|Goggles|
1715121|NCT00000156|Procedure|Ambient Light Reduction|
1715122|NCT00000157|Drug|Aspirin|
1715123|NCT00000158|Procedure|Argon Blue-Green Laser Photocoagulation|
1715124|NCT00000159|Drug|Sorbinil|
1715125|NCT00000160|Procedure|Xenon Photocoagulation|
1715126|NCT00000160|Procedure|Argon Photocoagulation|
1715127|NCT00000160|Procedure|Photocoagulation|
1715128|NCT00000161|Drug|Aspirin|
1715129|NCT00000161|Drug|Beta-Carotene|
1715130|NCT00000161|Drug|Vitamin C|
1715131|NCT00000161|Drug|Vitamin E|
1715132|NCT00000162|Procedure|Macular Argon Laser Photocoagulation|
1715133|NCT00000162|Procedure|Peripheral Scatter Argon Laser Photocoagulation|
1715134|NCT00000162|Procedure|Scatter Argon Laser Photocoagulation|
1715135|NCT00000167|Procedure|Low-Intensity Laser Treatment|Initial: 60 barely visible burns, grid pattern. Re-treatment at 12 months: 30 barely visible burns, focal treatment.
1715136|NCT00000170|Drug|Atropine|Atropine
1715137|NCT00000170|Device|Eye Patch|Patching
1715138|NCT00000171|Drug|Melatonin|
1715139|NCT00000172|Drug|Galantamine|
1715140|NCT00000173|Drug|Donepezil|
1715141|NCT00000173|Drug|Vitamin E|
1715142|NCT00000174|Drug|Rivastigmine|
1715143|NCT00000175|Drug|Estrogen|
1715144|NCT00000175|Drug|Testosterone|
1715145|NCT00000176|Drug|Estrogen|
1715146|NCT00000176|Drug|Estrogen and Progesterone|
1715147|NCT00000177|Drug|Estrogen|
1715148|NCT00000178|Drug|Prednisone|
1715149|NCT00000179|Drug|Trazodone|
1715150|NCT00000179|Drug|Haloperidol|
1715151|NCT00000180|Drug|AIT-082|
1715152|NCT00000187|Drug|Ritanserin|
1715153|NCT00000188|Drug|Selegiline|
1715154|NCT00000189|Drug|Gepirone|
1715155|NCT00000190|Procedure|Parotid Gland|
1715156|NCT00000191|Drug|Carbamazepine|
1715157|NCT00000192|Drug|Lamotrigine|
1715158|NCT00000193|Drug|Gamma hydroxybutyric|
1715159|NCT00000194|Drug|Cycloserine|
1715160|NCT00000195|Drug|Naltrexone|
1715161|NCT00000196|Drug|Naltrexone|
1715162|NCT00000197|Drug|Propranolol|
1715163|NCT00000198|Drug|Piracetam|
1715164|NCT00000199|Drug|Piracetam|
1715165|NCT00000200|Drug|Methadone|normal maintenance dose
1715166|NCT00000201|Drug|Selegiline|
1715167|NCT00000202|Drug|Buprenorphine|
1715168|NCT00000203|Drug|Buprenorphine|
1715169|NCT00000204|Drug|Buprenorphine|
1715170|NCT00000205|Drug|Buprenorphine|
1715171|NCT00000206|Drug|Buprenorphine|
1715172|NCT00000207|Drug|Buprenorphine|
1715173|NCT00000208|Drug|Buprenorphine|
1715174|NCT00000209|Drug|Buprenorphine|
1715175|NCT00000210|Drug|Buprenorphine|
1715176|NCT00000211|Drug|Buprenorphine|
1715177|NCT00000212|Drug|Desipramine|
1715178|NCT00000213|Drug|Fluoxetine|
1715179|NCT00000214|Drug|Buprenorphine|
1715180|NCT00000215|Drug|Pergolide|
1715181|NCT00000216|Drug|Buprenorphine|
1715182|NCT00000217|Drug|Carbamazepine|
1715183|NCT00000218|Drug|Carbamazepine|
1715184|NCT00000219|Drug|Buprenorphine|
1715185|NCT00000220|Drug|Buprenorphine|
1715186|NCT00000221|Drug|Buprenorphine|
1715187|NCT00000222|Drug|Buprenorphine|
1715188|NCT00000223|Drug|Buprenorphine|
1715189|NCT00000224|Drug|Buprenorphine|
1715190|NCT00000225|Drug|Buprenorphine|
1715191|NCT00000226|Drug|Buprenorphine|
1715192|NCT00000227|Drug|Buprenorphine|
1715193|NCT00000228|Drug|Buprenorphine|
1715194|NCT00000229|Drug|Buprenorphine|
1715195|NCT00000230|Drug|Buprenorphine|
1715196|NCT00000231|Drug|Buprenorphine|
1715197|NCT00000232|Drug|Buprenorphine|
1715198|NCT00000233|Drug|Buprenorphine|
1715199|NCT00000234|Drug|Buprenorphine|
1715200|NCT00000235|Drug|Buprenorphine|
1715201|NCT00000236|Drug|Buprenorphine/naloxone|
1715202|NCT00000237|Drug|Buprenorphine|
1715203|NCT00000238|Drug|Buprenorphine|
1715204|NCT00000239|Drug|Buprenorphine|
1715205|NCT00000240|Drug|Buprenorphine|
1715206|NCT00000268|Drug|Bupropion|
1715207|NCT00000269|Drug|Pergolide|
1715208|NCT00000270|Drug|Cocaine|
1715209|NCT00000271|Drug|Desipramine|Participants were treated with desipramine, up to 300 mg per day, or matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
1715210|NCT00000271|Drug|Placebo|Participants were treated with matching placebo. All participants received weekly individual manual-guided relapse prevention therapy.
1715211|NCT00000273|Drug|opiates|prescription opioids
1715212|NCT00000274|Drug|Flupenthixol|
1715213|NCT00000275|Drug|Flupenthixol|
1715214|NCT00000276|Drug|Bupropion|
1715215|NCT00000277|Drug|Mazindol|
1715216|NCT00000278|Drug|Disulfiram|
1715217|NCT00000279|Drug|Clonidine|
1715218|NCT00000280|Drug|Nimodipine|
1715219|NCT00000281|Behavioral|Amantadine|
1715220|NCT00000282|Drug|Pemoline|
1715221|NCT00000284|Drug|Cotinine fumarate|
1715222|NCT00000285|Drug|Phenytoin|
1715223|NCT00000286|Drug|Nefazodone|
1715224|NCT00000288|Drug|Cotinine fumarate|
1715231|NCT00000295|Drug|Micronized Progesterone|
1715232|NCT00000296|Drug|Cotinine fumarate|
1715233|NCT00000297|Drug|Labetalol|
1715234|NCT00000298|Drug|Buprenorphine/naloxone|
1715235|NCT00000299|Drug|Buprenorphine|
1715237|NCT00000301|Drug|Amantadine|
1715238|NCT00000302|Drug|Buprenorphine|
1715239|NCT00000303|Drug|Baclofen|
1715240|NCT00000304|Drug|Dextroamphetamine|15 mg for first 8 weeks and 30 mg for 2nd 8 weeks
1715241|NCT00000304|Drug|D-Amphetamine|30 mg for the first 8 weeks and 60 for the second 8 weeks (16 weeks total)
1715242|NCT00000304|Drug|Placebo|Placebo
1715243|NCT00000305|Drug|Dextroamphetamine|
1715244|NCT00000306|Drug|Dextroamphetamine|
1715245|NCT00000307|Drug|Naltrexone|
1715246|NCT00000308|Drug|Dextroamphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
1715247|NCT00000308|Drug|D-amphetamine|15 mg of d-amphetamine for first 8 weeks of study and 30 mg for the second 8 weeks
1715248|NCT00000308|Drug|placebo|placebo
1715249|NCT00000309|Drug|Risperidone|
1715250|NCT00000310|Drug|Risperidone|
1715251|NCT00000311|Drug|Buprenorphine|"Experimental Therapeutic Contracting (TC)
Experimental Cognitive Behavioral Coping Skills Therapy (CBT)"
1715252|NCT00000312|Drug|M-CPP|
1715253|NCT00000313|Drug|Fenfluramine|
1715254|NCT00000314|Drug|M-CPP|
1715255|NCT00000315|Drug|Cocaine|
1715256|NCT00000316|Drug|Cocaine|
1715257|NCT00000317|Drug|Risperidone|Risperidone (4mg/day)
1715258|NCT00000317|Drug|Placebo|Placebo
1715259|NCT00000317|Behavioral|Relapse prevention counseling|Modified manual guided relapse prevention counseling. Weekly 20 minute sessions consisting of cognitive behavioral skills. Both arms will receive this intervention.
1715260|NCT00000318|Drug|Buprenorphine|"Experimental Maintenance treatment with daily medication
Experimental Maintenance treatment with thrice-weekly medication"
1715261|NCT00000319|Drug|Buprenorphine|
1715262|NCT00000320|Drug|Buprenorphine formulation: liquid vs. tablet|random assignment to liquid buprenorphine or tablet buprenorphine
1715263|NCT00000321|Drug|Desipramine|
1715264|NCT00000322|Behavioral|Tyrosine|
1715265|NCT00000324|Drug|Tryptophan|
1715266|NCT00000325|Behavioral|Gonadorelin|
1715267|NCT00000326|Drug|Heroin Dependence|
1715268|NCT00000327|Drug|Heroin Dependence|
1715269|NCT00000328|Drug|Opioid-Related Disorders|
1715270|NCT00000329|Drug|Opioid-Related Disorders|
1715271|NCT00000330|Drug|Opioid-Related Disorders|
1715272|NCT00000331|Drug|Test Drug|
1715273|NCT00000331|Drug|Placebo Drug|
1715274|NCT00000332|Drug|Nimodipine|
1715275|NCT00000333|Drug|Benztropine|
1715276|NCT00000334|Drug|Buprenorphine|
1715277|NCT00000335|Drug|Morphine|
1715278|NCT00000336|Drug|Selegiline|
1715279|NCT00000337|Drug|Selegiline|
1715280|NCT00000338|Drug|Lisuride|
1715281|NCT00000339|Drug|Risperidone|
1715282|NCT00000340|Drug|Pemoline|
1715283|NCT00000341|Drug|Buprenorphine|
1715284|NCT00000342|Drug|Risperidone|
1715285|NCT00000343|Behavioral|counseling|
1715286|NCT00000344|Drug|Buprenorphine/naloxone|
1715287|NCT00000345|Drug|Lofexidine|
1715288|NCT00000346|Behavioral|counseling|
1715289|NCT00000347|Drug|Risperidone|
1715290|NCT00000348|Drug|Dihydrexidine|
1715291|NCT00000349|Drug|Flupenthixol|
1715292|NCT00000350|Procedure|radioactive substance|
1715293|NCT00000352|Drug|Dextromethorphan|
1715294|NCT00000353|Drug|Buprenorphine/naloxone|
1715295|NCT00000354|Drug|Lofexidine|
1715296|NCT00000355|Drug|Buprenorphine|
1715297|NCT00000356|Drug|LAAM|
1715298|NCT00000357|Drug|Buprenorphine|
1715299|NCT00000358|Drug|Lofexidine|
1715300|NCT00000359|Behavioral|Canalith repositioning maneuver (Epley maneuver)|Standard passive motion of the head: Dix-Hallpike maneuver, turn head to opposite side, roll over, sit up.
1715301|NCT00000359|Behavioral|Semont maneuver|Sidelying maneuver, flip over 180 deg, sit up.
1715302|NCT00000359|Behavioral|Brandt-Daroff exercises|Active exercise. Sidelying to involved side, sidelying to uninvolved side, sit up.
1715303|NCT00000359|Behavioral|Vestibular habituation exercises|Head shaking exercises in pitch, roll, yaw and circumduction. Titrating from 2 repetitions per exercise to 20 repetitions per exercise, as tolerated.
1715304|NCT00000359|Behavioral|ShamManeuver|Passive movement of the head
1715305|NCT00000361|Drug|Corticosteroids|
1715306|NCT00000361|Drug|Methotrexate|
1715307|NCT00000362|Behavioral|Chin-down position|
1715308|NCT00000362|Behavioral|Thickened liquid administration|
1715309|NCT00000363|Drug|Antihistamine|
1715310|NCT00000363|Drug|Corticosteroid|
1715311|NCT00000367|Drug|Treatment of depression|
1715312|NCT00000367|Behavioral|Suicide prevention intervention|
1715313|NCT00000367|Drug|Suicide prevention treatment|
1715314|NCT00000368|Behavioral|Cognitive behavior therapy|
1715315|NCT00000368|Drug|Paroxetine or other medication - algorithm used|
1715316|NCT00000369|Behavioral|Individual psychotherapy|
1715317|NCT00000369|Drug|Lithium carbonate|
1715318|NCT00000370|Behavioral|Cognitive behavior therapy|
1715319|NCT00000370|Behavioral|Performance-based exposure therapy|
1715320|NCT00000370|Behavioral|Psychosocial intervention|
1715321|NCT00000371|Drug|D-cycloserine|50 mg/daily by mouth
1715322|NCT00000371|Drug|Placebo|50 mg/day of placebo by mouth
1715323|NCT00000372|Drug|D-cycloserine|
1715324|NCT00000372|Drug|Glycine|
1715325|NCT00000372|Drug|Clozapine|
1715326|NCT00000372|Drug|Placebo|
1715327|NCT00000373|Drug|olanzapine + fluoxetine|
1715328|NCT00000373|Drug|placebo + fluoxetine|
1715329|NCT00000374|Drug|Olanzapine|The dosage for Olanzapine will be 2.5 mg to 20mg per day. The dose of the Olanzapine will be based on the participant's clinical improvement and side effects.
1715330|NCT00000374|Drug|Risperidone|The dosage for Risperidone will be 1 mg to 6mg per day. The dose of the Risperidone will be based on the participant's clinical improvement and side effects.
1715335|NCT00000376|Behavioral|Cognitive therapy|
1715336|NCT00000376|Drug|Desipramine|
1715337|NCT00000377|Drug|Nortriptyline|
1715338|NCT00000378|Drug|Sertraline|12 week trial dose up to 200mgs
1715339|NCT00000378|Drug|Nortriptyline|12 week trial dose adjusted to therapeutic level
1715340|NCT00000379|Drug|Fluoxetine|
1715341|NCT00000379|Behavioral|EMDR|
1715342|NCT00000380|Drug|GHRH|
1715343|NCT00000381|Drug|Fluoxetine|
1715344|NCT00000382|Behavioral|Infant-Parent Psychotherapy|
1715345|NCT00000382|Behavioral|Child Protective Services|
1715346|NCT00000382|Behavioral|Psychoeducational Home Visitation|
1715347|NCT00000382|Behavioral|Parent Education|
1715348|NCT00000383|Behavioral|Trauma-Focused CBT|Structured skills, exposure, trauma-specific interventions
1715349|NCT00000383|Behavioral|Child-Centered Therapy|Client-directed supportive interventions
1715350|NCT00000384|Behavioral|Cognitive Behavior Therapy|
1715351|NCT00000384|Behavioral|Educational Support|
1715352|NCT00000384|Drug|Sertraline|
1715353|NCT00000385|Drug|Lithium|Lithium 600 mg to 2700 mg per day
1715354|NCT00000385|Drug|Placebo|Matching placebo
1715355|NCT00000386|Behavioral|Exposure and Response Prevention|
1715356|NCT00000386|Behavioral|Family Treatment Program|
1715357|NCT00000386|Behavioral|Relaxation Training|
1715358|NCT00000386|Behavioral|Behavior therapy|
1715359|NCT00000386|Behavioral|Family Counseling|
1715362|NCT00000388|Behavioral|Psychosocial treatment|
1715363|NCT00000388|Drug|Anti-ADHD medication|
1715364|NCT00000388|Behavioral|Assessment-and-Referral|
1715365|NCT00000389|Drug|Fluvoxamine|
1715366|NCT00000390|Drug|Imipramine hydrochloride|
1715367|NCT00000391|Drug|Peptide T|
1715368|NCT00000392|Drug|Peptide T|
1715369|NCT00000392|Drug|Placebo|
1715370|NCT00000393|Drug|Peptide T|
1715371|NCT00000394|Procedure|Acupuncture therapy|
1715372|NCT00000395|Drug|Methotrexate|
1715373|NCT00000395|Dietary Supplement|Folinic acid|
1715374|NCT00000395|Dietary Supplement|Folic acid|
1715375|NCT00000396|Behavioral|Patient self-care education|
1715376|NCT00000397|Behavioral|Behavioral insomnia therapy|
1715377|NCT00000398|Behavioral|Coping skills training|
1715378|NCT00000398|Behavioral|Physical exercise training|
1715379|NCT00000398|Behavioral|Coping skills training plus physical exercise training|
1715380|NCT00000399|Drug|Hormone replacement therapy|
1715381|NCT00000399|Procedure|Strength training|
1715382|NCT00000400|Drug|Human parathyroid hormone [hPTH-(1-34)]|37 mcg once daily by self-administered sc injection
1715383|NCT00000400|Drug|alendronate|70 mg/week by oral route
1715384|NCT00000401|Drug|Oral bovine type II collagen|Drug can be interrupted or stopped for suspected adverse events.
1715385|NCT00000402|Drug|Calcium|
1715386|NCT00000403|Drug|Doxycycline|
1715387|NCT00000404|Behavioral|Patient education in self-care of knee OA|
1715388|NCT00000405|Procedure|Exercise intervention|
1715389|NCT00000406|Procedure|Progressive resistance exercise|
1715390|NCT00000407|Behavioral|Vocational counseling intervention|
1715391|NCT00000407|Behavioral|Reading materials for control participants|
1715392|NCT00000407|Behavioral|Standard of care|No education or behavioral intervention
1715393|NCT00000408|Procedure|Patient education evaluation|
1715394|NCT00000409|Procedure|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis
1715395|NCT00000409|Other|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated. Any non-operative therapies other than these are accepted and collected as data.
1715396|NCT00000409|Procedure|Fusion--Instrumented|In addition to decompressive laminectomy, additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
1715397|NCT00000409|Procedure|Fusion-Non-instrumented|additional bilateral non-instrumented or instrumented, i.e., posterior pedicle fixation, posterolateral fusion with autogenous bone grafting (utilizing iliac crest harvested from between the tables and/or local bone) will be performed between the transverse processes and the lateral portion of the superior facets of the involved levels.
1715473|NCT00000456|Behavioral|cognitive behavior therapy|
1715474|NCT00000456|Behavioral|motivational enhancement therapy|
1715475|NCT00000457|Drug|bupropion (Wellbutrin)|"1 pill in the am of 150 mg of Bupropion
1 pill (150 mg) in the AM and one in the PM for a total of 300 mg per day for subsequent 44 weeks."
1715476|NCT00000457|Drug|Placebo|placebo pill to match (look alike) the 150 mg pill of the bupropion given in the am for 3 days and then two pills (one in the morning and one at night) for the subsequent 44 mg.
1715477|NCT00000458|Drug|sertraline (Zoloft)|
1715478|NCT00000458|Behavioral|cognitive behavior therapy|
1715479|NCT00000459|Behavioral|diet, fat-restricted|
1715480|NCT00000460|Behavioral|Low intensity exercise|
1715398|NCT00000410|Procedure|Diskectomy|The surgeon will leave the nerve root freely mobile and undamaged following the procedure. During the procedure, the surgeon may consider using loop magnification or a microscope. The surgical incision will be midline and, after reflecting the paraspinous muscles, the interlaminar level will be identified and entered. The nerve root will be clearly identified and mobilized and then gently retracted to prepare for the discectomy. Removal of the medial border of the superior facet may, in some cases, be necessary in order to have a clear view of the lateral border of the involved nerve root. Following the clear view of the nerve root and mobilization, the IDH will be approached by making a small annular incision if necessary, the fragment of disc will then be removed (i.e., limited disc excision). A search of the canal will follow removal of the fragment, along with probing of the intervertebral-foramen for residual disc or bony pathology.
1715399|NCT00000410|Procedure|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
1715400|NCT00000411|Procedure|Decompressive laminectomy|Removal of the hypertrophic inferior and superior articular facets will be performed when they are intruding upon the midline and causing both central and lateral recess stenosis.
1715401|NCT00000411|Other|Non-surgical treatments|Active physical therapy modality, Education/Counseling with home exercise instruction, and an NSAID if tolerated
1715402|NCT00000412|Drug|Alendronate|
1715403|NCT00000412|Drug|Calcitriol|
1715404|NCT00000412|Drug|Placebo Alendronate|
1715405|NCT00000412|Drug|Placebo Calcitriol|
1715406|NCT00000413|Behavioral|Psychoeducational program|
1715407|NCT00000414|Behavioral|Arthritis Self-Management Program|
1715408|NCT00000414|Behavioral|SMART Program|
1715409|NCT00000415|Procedure|Physical activity|
1715410|NCT00000415|Drug|Calcium supplement|
1715411|NCT00000416|Other|Rehabilitation counseling|Provided in 2 in-person meetings and in follow-up phone calls
1715412|NCT00000417|Procedure|Counseling intervention|
1715413|NCT00000417|Device|Informational film|
1715414|NCT00000418|Procedure|Psychosocial intervention|
1715415|NCT00000419|Drug|Premarin and Provera|
1715416|NCT00000420|Drug|Ortho-Novum 777|
1715417|NCT00000421|Drug|Prednisone|
1715418|NCT00000421|Drug|Placebo|
1715419|NCT00000422|Behavioral|Cognitive-behavioral psychotherapy and physical exercise|
1715420|NCT00000423|Behavioral|Social support group|
1715421|NCT00000423|Behavioral|Social support and education group|
1715422|NCT00000424|Procedure|Tidal lavage vs. sham lavage of the knee|
1715423|NCT00000425|Drug|Nonsteroidal anti-inflammatory drugs (NSAIDs)|
1715424|NCT00000425|Drug|Acetaminophen|
1715425|NCT00000426|Drug|Calcium supplement|
1715426|NCT00000427|Drug|Parathyroid hormone|
1715427|NCT00000427|Drug|Alendronate|
1715428|NCT00000428|Drug|Amitriptyline|Amitriptyline 25 mg po
1715429|NCT00000428|Drug|Amitriptyline plus Fluoxitine|Amitriptyline 25 mg po plus Fluoxitine 20 mg po
1715430|NCT00000429|Drug|Calcium carbonate|
1715431|NCT00000430|Drug|Alendronate|
1715432|NCT00000430|Drug|Estrogen/progestin therapy|
1715433|NCT00000431|Drug|PDGF-B/Ad5|This is a dose finding study to evaluate the safety of a single injection of PDGF dna in an adenoviral vector.
1715434|NCT00000432|Behavioral|Education about disease prevention|
1715435|NCT00000433|Drug|Anti-Tumor Necrosis Factor|
1715436|NCT00000434|Behavioral|Fit and Strong!|Fit and Strong! is a multi-component exercise and health education program that includes flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change.
1715437|NCT00000435|Drug|dnaJ peptide|dnaJP1 was taken in pill form at 25mg/day for 6 months
1715438|NCT00000435|Drug|None-placebo|placebo was taken in pill form at 25mg/day for 6 months
1715439|NCT00000436|Behavioral|Self-efficacy and muscle strength training|
1715440|NCT00000436|Procedure|High-intensity strength training|
1715441|NCT00000437|Drug|Naltrexone Tablet and Nicotine Patch|
1715442|NCT00000437|Drug|Naltrexone Tablet and Placebo Patch|
1715443|NCT00000437|Drug|Placebo Tablet and Nicotine Patch|
1715444|NCT00000437|Drug|Placebo Tablet and Placebo Patch|
1715445|NCT00000438|Drug|naltrexone (Revia)|
1715446|NCT00000439|Drug|sodium valproate|subjects were randomized to sodium valproate vs placebo. Serum sodium valproate was monitored. This intervention was added on treatment as usual which was defined as being on lithium carbonate and also attending individual dual recovery counseling.
1715447|NCT00000440|Drug|naltrexone (Revia)|
1715448|NCT00000440|Drug|sertraline (Zoloft)|
1715449|NCT00000441|Drug|lorazepam (Ativan)|
1715450|NCT00000441|Drug|carbamazepine (Tegretol)|
1715451|NCT00000442|Drug|naltrexone (Revia)|
1715452|NCT00000443|Drug|ondansetron (Zofran)|
1715453|NCT00000444|Drug|nicotine replacement patch|
1715454|NCT00000445|Drug|naltrexone (Revia)|
1715455|NCT00000446|Drug|sertraline (Zoloft)|
1715456|NCT00000447|Drug|naltrexone (Revia)|
1715457|NCT00000447|Drug|nicotine replacement patch|
1715458|NCT00000448|Drug|naltrexone|Naltrexone is an opioid receptor antagonist used primarily in the management of alcohol dependence and opioid dependence.
1715459|NCT00000448|Drug|Placebo|A placebo is a simulated or otherwise medically ineffectual treatment for a disease or other medical condition intended to deceive the recipient.
1715460|NCT00000449|Drug|naltrexone (Revia)|
1715461|NCT00000449|Behavioral|cognitive behavioral therapy|
1715462|NCT00000449|Behavioral|cue exposure treatment|
1715463|NCT00000450|Drug|Naltrexone Tablet|
1715464|NCT00000450|Drug|Matched Placebo Tablet|
1715465|NCT00000451|Drug|sertraline|16 week outpatient study
1715466|NCT00000451|Drug|naltrexone|16 week outpatient study
1715467|NCT00000452|Drug|naltrexone (Revia)|
1715468|NCT00000452|Behavioral|Compliance Enhancement Tech.|
1715469|NCT00000452|Behavioral|Cognitive Behavior Therapy|
1715470|NCT00000454|Drug|nicotine replacement patch|
1715471|NCT00000455|Drug|naltrexone|
1715481|NCT00000460|Behavioral|High intensity exercise|
1715482|NCT00000461|Drug|pravastatin|
1715483|NCT00000461|Drug|niacin|
1715484|NCT00000461|Drug|cholestyramine|
1715485|NCT00000461|Drug|gemfibrozil|
1715486|NCT00000461|Drug|fatty acids, omega-3|
1715487|NCT00000462|Procedure|angioplasty, transluminal, percutaneous coronary|
1715488|NCT00000462|Procedure|coronary artery bypass|
1715489|NCT00000463|Drug|lovastatin|
1715490|NCT00000463|Drug|cholestyramine|
1715491|NCT00000463|Drug|warfarin|
1715492|NCT00000464|Drug|amiodarone|
1715493|NCT00000464|Drug|imipramine|
1715494|NCT00000464|Drug|mexiletine|
1715495|NCT00000464|Drug|procainamide|
1715496|NCT00000464|Drug|propafenone|
1715497|NCT00000464|Drug|quinidine|
1715498|NCT00000464|Drug|sotalol|
1715499|NCT00000465|Procedure|angioplasty, transluminal, percutaneous coronary|
1715500|NCT00000465|Procedure|coronary artery bypass|
1715501|NCT00000466|Drug|estrogens, conjugated|
1715502|NCT00000466|Drug|medroxyprogesterone|
1715503|NCT00000466|Drug|progesterone|
1715504|NCT00000466|Drug|estrogen replacement therapy|
1715505|NCT00000467|Behavioral|diet|
1715506|NCT00000467|Behavioral|exercise|
1715507|NCT00000467|Behavioral|smoking cessation|
1715508|NCT00000468|Drug|tissue plasminogen activator|
1715509|NCT00000469|Drug|aspirin|
1715510|NCT00000469|Drug|lovastatin|
1715511|NCT00000470|Procedure|cardiac surgical procedures|
1715512|NCT00000470|Procedure|cardiopulmonary bypass|
1715513|NCT00000471|Behavioral|diet, vegetarianism|
1715514|NCT00000471|Behavioral|diet, fat-restricted|
1715515|NCT00000471|Behavioral|exercise|
1715516|NCT00000471|Behavioral|smoking cessation|
1715517|NCT00000472|Drug|tissue plasminogen activator|
1715518|NCT00000472|Drug|heparin|
1715519|NCT00000473|Behavioral|dietary supplements|
1715520|NCT00000473|Drug|fatty acids, omega-3|
1715521|NCT00000473|Behavioral|diet, fat-restricted|
1715522|NCT00000474|Behavioral|behavior therapy|
1715523|NCT00000475|Behavioral|health education|
1715524|NCT00000476|Drug|digitalis|
1715525|NCT00000477|Drug|lovastatin|
1715526|NCT00000478|Drug|atenolol|
1715527|NCT00000478|Drug|nifedipine|
1715528|NCT00000478|Drug|diltiazem|
1715529|NCT00000478|Drug|isosorbide dinitrate|
1715530|NCT00000478|Procedure|coronary artery bypass coronary artery bypass|
1715531|NCT00000478|Procedure|angioplasty, transluminal, percutaneous coronary|
1715532|NCT00000479|Drug|Aspirin|Participants will receive 100 mg of aspirin every other day.
1715533|NCT00000479|Drug|Vitamin E|Participants will receive 600 IU of vitamin E every other day.
1715534|NCT00000479|Behavioral|Placebo|Participants will receive placebo.
1715535|NCT00000480|Procedure|electrophysiology|
1715536|NCT00000480|Drug|anti-arrhythmia agents|
1715537|NCT00000480|Device|defibrillators, implantable|
1715538|NCT00000481|Behavioral|diet, fat-restricted|
1715539|NCT00000482|Drug|estrogen|
1715540|NCT00000482|Drug|clofibrate clofibrate|
1715541|NCT00000482|Drug|dextrothyroxine sodium|
1715542|NCT00000482|Drug|niacin|
1715543|NCT00000483|Drug|estrogen|
1715544|NCT00000483|Drug|clofibrate|
1715545|NCT00000483|Drug|dextrothyroxine sodium|
1715546|NCT00000483|Drug|niacin|
1715547|NCT00000484|Drug|chlorothiazide|
1715548|NCT00000484|Drug|Rauwolfia alkaloids|
1715549|NCT00000485|Drug|diuretics|
1715550|NCT00000485|Drug|antihypertensive agents|
1715551|NCT00000486|Procedure|coronary artery bypass|
1715552|NCT00000487|Drug|antihypertensive agents|
1715553|NCT00000487|Behavioral|smoking cessation|
1715554|NCT00000487|Behavioral|diet, fat-restricted|
1715555|NCT00000487|Drug|diuretics|
1715556|NCT00000488|Drug|cholestyramine|
1715557|NCT00000488|Behavioral|diet, fat-restricted|
1715558|NCT00000489|Procedure|coronary artery bypass|
1715559|NCT00000490|Procedure|jejunoileal bypass|
1715560|NCT00000490|Behavioral|diet, fat-restricted|
1715561|NCT00000648|Drug|Penicillin G potassium|
1715562|NCT00000648|Drug|Ceftriaxone sodium|
1715563|NCT00000649|Drug|Nevirapine|
1715564|NCT00000649|Drug|Zidovudine|
1715565|NCT00000650|Drug|Ditiocarb sodium|
1715566|NCT00000651|Drug|Zidovudine|
1715567|NCT00000651|Drug|Zalcitabine|
1715568|NCT00000652|Drug|Zidovudine|
1715569|NCT00000652|Drug|Didanosine|
1715570|NCT00000653|Drug|Zalcitabine|
1715571|NCT00000654|Drug|Fialuridine|
1715572|NCT00000655|Drug|Atovaquone|
1715573|NCT00000655|Drug|Sulfamethoxazole-Trimethoprim|
1715574|NCT00000656|Drug|Zidovudine|
1715575|NCT00000656|Drug|Didanosine|
1715576|NCT00000657|Drug|Zidovudine|
1715577|NCT00000657|Drug|Didanosine|
1715578|NCT00000658|Drug|Bleomycin sulfate|
1715579|NCT00000658|Drug|Vincristine sulfate|
1715580|NCT00000658|Drug|Doxorubicin hydrochloride|
1715581|NCT00000658|Drug|Cyclophosphamide|
1715582|NCT00000658|Drug|Allopurinol|
1715583|NCT00000658|Drug|Methotrexate|
1715584|NCT00000658|Drug|Cytarabine|
1715585|NCT00000658|Drug|Leucovorin calcium|
1715586|NCT00000658|Drug|Sargramostim|
1715587|NCT00000658|Drug|Dexamethasone|
1715588|NCT00000659|Drug|CD4 Antigens|
1715589|NCT00000659|Drug|Zidovudine|
1715590|NCT00000660|Drug|Etoposide|
1715591|NCT00000661|Drug|Oxazepam|
1715592|NCT00000661|Drug|Zidovudine|
1715593|NCT00000662|Drug|Zidovudine|
1715594|NCT00000663|Drug|CD4-IgG|
1715595|NCT00000664|Drug|Interleukin-2, Polyethylene Glycolated|
1715596|NCT00000664|Drug|Zidovudine|
1715597|NCT00000665|Drug|Foscarnet sodium|
1715598|NCT00000665|Drug|Ganciclovir|
1715599|NCT00000666|Drug|Pyrimethamine|
1715600|NCT00000667|Biological|gp160 Vaccine (MicroGeneSys)|
1715601|NCT00000668|Drug|Ganciclovir|
1715602|NCT00000669|Drug|Didanosine|
1715603|NCT00000670|Drug|Probenecid|
1715604|NCT00000670|Drug|Zidovudine|
1715605|NCT00000671|Drug|Zidovudine|
1715606|NCT00000671|Drug|Didanosine|
1715607|NCT00000672|Drug|Didanosine|
1715608|NCT00000673|Drug|Ganciclovir|
1715609|NCT00000674|Drug|Pyrimethamine|
1715610|NCT00000674|Drug|Leucovorin calcium|
1715611|NCT00000674|Drug|Clindamycin|
1715612|NCT00000675|Drug|CD4-IgG|
1715613|NCT00000676|Drug|Clotrimazole|
1715614|NCT00000676|Drug|Fluconazole|
1715615|NCT00000677|Drug|SCH 39304|
1715616|NCT00000678|Drug|Zidovudine|
1715617|NCT00000678|Drug|Zalcitabine|
1715618|NCT00000679|Drug|Zidovudine|
1715619|NCT00000679|Drug|Zalcitabine|
1715620|NCT00000680|Drug|Zidovudine|
1715621|NCT00000680|Drug|Aldesleukin|
1715622|NCT00000681|Drug|Bleomycin sulfate|
1715623|NCT00000681|Drug|Vincristine sulfate|
1715624|NCT00000681|Drug|Doxorubicin hydrochloride|
1715625|NCT00000681|Drug|Zidovudine|
1715626|NCT00000681|Drug|Sargramostim|
1715627|NCT00000682|Drug|Zidovudine|
1715628|NCT00000682|Drug|Zalcitabine|
1715629|NCT00000683|Biological|HIVAC-1e|
1715630|NCT00000683|Biological|gp160 Vaccine (MicroGeneSys)|
1715631|NCT00000684|Drug|Dextran sulfate|
1715632|NCT00000685|Drug|Zidovudine|
1715633|NCT00000686|Drug|Stavudine|
1715634|NCT00000687|Drug|Interferon alfa-2a|
1715635|NCT00000687|Drug|Zidovudine|
1715636|NCT00000688|Drug|Ganciclovir|
1715637|NCT00000689|Drug|Bleomycin sulfate|
1715638|NCT00000689|Drug|Vincristine sulfate|
1715639|NCT00000689|Drug|Doxorubicin hydrochloride|
1715640|NCT00000689|Drug|Cyclophosphamide|
1715641|NCT00000689|Drug|Methotrexate|
1715642|NCT00000689|Drug|Cytarabine|
1715643|NCT00000689|Drug|Leucovorin calcium|
1715644|NCT00000689|Drug|Sargramostim|
1715645|NCT00000689|Drug|Dexamethasone|
1715646|NCT00000690|Drug|Dextran sulfate|
1715647|NCT00000691|Drug|Foscarnet sodium|
1715648|NCT00000692|Drug|Butyldeoxynojirimycin|
1715649|NCT00000693|Drug|Zidovudine|
1715650|NCT00000693|Drug|Acyclovir|
1715651|NCT00000694|Drug|Interferon alfa-2b|
1715652|NCT00000694|Drug|Zidovudine|
1715653|NCT00000694|Drug|Sargramostim|
1715654|NCT00000695|Drug|Interferon beta-1b|
1715655|NCT00000695|Drug|Zidovudine|
1715656|NCT00000696|Drug|Interferon alfa-2a|
1715657|NCT00000696|Drug|Zidovudine|
1715658|NCT00000697|Drug|Foscarnet sodium|
1715659|NCT00000698|Drug|Ganciclovir|
1715660|NCT00000699|Drug|Inosine pranobex|
1715661|NCT00000699|Drug|Ribavirin|
1715662|NCT00000700|Drug|Zidovudine|
1715663|NCT00000701|Drug|Zidovudine|
1715664|NCT00000702|Drug|Zidovudine|
1715665|NCT00000703|Drug|Bleomycin sulfate|
1715666|NCT00000703|Drug|Vincristine sulfate|
1715667|NCT00000703|Drug|Doxorubicin hydrochloride|
1715668|NCT00000703|Drug|Cyclophosphamide|
1715669|NCT00000703|Drug|Allopurinol|
1715670|NCT00000703|Drug|Methotrexate|
1715671|NCT00000703|Drug|Cytarabine|
1715672|NCT00000703|Drug|Leucovorin calcium|
1715673|NCT00000703|Drug|Zidovudine|
1715674|NCT00000703|Drug|Dexamethasone|
1715675|NCT00000704|Drug|Zalcitabine|
1715676|NCT00000705|Drug|Zidovudine|
1715677|NCT00000706|Drug|Quinine sulfate|
1715678|NCT00000706|Drug|Probenecid|
1715679|NCT00000706|Drug|Zidovudine|
1715680|NCT00000707|Drug|Pentamidine isethionate|
1715681|NCT00000708|Drug|Flucytosine|
1715682|NCT00000708|Drug|Fluconazole|
1715683|NCT00000708|Drug|Amphotericin B|
1715684|NCT00000709|Drug|Zidovudine|
1715685|NCT00000710|Drug|Didanosine|
1715686|NCT00000711|Drug|Zidovudine|
1715687|NCT00000711|Drug|Sargramostim|
1715688|NCT00000712|Drug|Zidovudine|
1715689|NCT00000712|Drug|Acyclovir|
1715690|NCT00000713|Drug|Ampligen|
1715691|NCT00000714|Drug|Trimetrexate glucuronate|
1715692|NCT00000714|Drug|Leucovorin calcium|
1715693|NCT00000715|Drug|Pentamidine isethionate|
1715694|NCT00000715|Drug|Sulfamethoxazole-Trimethoprim|
1715695|NCT00000716|Drug|Zidovudine|
1715696|NCT00000717|Drug|Primaquine|
1715697|NCT00000717|Drug|Clindamycin|
1715698|NCT00000718|Drug|Zidovudine|
1715699|NCT00000718|Drug|Zalcitabine|
1715700|NCT00000719|Drug|Zidovudine|
1715701|NCT00000719|Drug|Zalcitabine|
1715702|NCT00000720|Drug|Globulin, Immune|
1715703|NCT00000720|Drug|Zidovudine|
1715704|NCT00000721|Drug|CD4 Antigens|
1715705|NCT00000722|Drug|Pentamidine isethionate|
1715706|NCT00000723|Drug|Methotrexate|
1715707|NCT00000723|Drug|Leucovorin calcium|
1715708|NCT00000723|Drug|Zidovudine|
1715709|NCT00000723|Drug|Dexamethasone|
1715710|NCT00000724|Drug|Trimetrexate glucuronate|
1715711|NCT00000724|Drug|Leucovorin calcium|
1715712|NCT00000725|Drug|Interferon alfa-2a|
1715713|NCT00000725|Drug|Zidovudine|
1715714|NCT00000725|Drug|Interferon alfa-n1|
1715715|NCT00000726|Drug|Foscarnet sodium|
1715716|NCT00000727|Drug|Pentamidine isethionate|
1715718|NCT00000727|Drug|Sulfamethoxazole/Trimethoprim|
1715719|NCT00000727|Drug|Sulfadoxine/Pyrimethamine|
1715720|NCT00000727|Drug|Zidovudine|
1715721|NCT00000728|Drug|Zidovudine|
1715722|NCT00000728|Drug|Aldesleukin|
1715723|NCT00000729|Drug|Foscarnet sodium|
1715724|NCT00000730|Drug|Trimetrexate glucuronate|
1715725|NCT00000730|Drug|Methylprednisolone|
1715726|NCT00000730|Drug|Pentamidine isethionate|
1715727|NCT00000730|Drug|Sulfamethoxazole-Trimethoprim|
1715728|NCT00000730|Drug|Leucovorin calcium|
1715729|NCT00000731|Drug|Zidovudine|
1715730|NCT00000731|Drug|Acetaminophen|
1715731|NCT00000732|Drug|Sulfamethoxazole-Trimethoprim|
1715732|NCT00000732|Drug|Zidovudine|
1715733|NCT00000733|Drug|Ribavirin|
1715734|NCT00000734|Drug|Sulfamethoxazole-Trimethoprim|
1715735|NCT00000734|Drug|Zidovudine|
1715736|NCT00000735|Drug|Ampligen|
1715737|NCT00000736|Drug|Zidovudine|
1715738|NCT00000737|Drug|Dronabinol|
1715739|NCT00000737|Drug|Megestrol acetate|
1715740|NCT00000738|Drug|Nimodipine|
1715741|NCT00000738|Drug|Zidovudine|
1715742|NCT00000739|Drug|Dapsone|
1715743|NCT00000740|Drug|Sitamaquine|
1715744|NCT00000741|Drug|Methylprednisolone|
1715745|NCT00000742|Drug|Atevirdine mesylate|
1715746|NCT00000742|Drug|Zidovudine|
1715747|NCT00000742|Drug|Didanosine|
1715748|NCT00000743|Drug|Alvircept sudotox|
1715749|NCT00000743|Drug|Zidovudine|
1715750|NCT00000744|Drug|Fluconazole|
1715751|NCT00000745|Biological|Hepatitis B Vaccine (Recombinant)|
1715752|NCT00000745|Biological|gp160 Vaccine (MicroGeneSys)|
1715753|NCT00000746|Biological|rgp120/HIV-1 SF-2|
1715754|NCT00000746|Biological|Env 2-3|
1715755|NCT00000746|Biological|HIVAC-1e|
1715756|NCT00000746|Biological|gp160 Vaccine (MicroGeneSys)|
1715757|NCT00000747|Drug|Nevirapine|
1715758|NCT00000748|Drug|Sulfamethoxazole-Trimethoprim|
1715759|NCT00000749|Biological|rgp120/HIV-1 SF-2|
1715760|NCT00000750|Drug|Zidovudine|
1715761|NCT00000751|Drug|Anti-HIV Immune Serum Globulin (Human)|
1715762|NCT00000751|Drug|Globulin, Immune|
1715763|NCT00000751|Drug|Zidovudine|
1715764|NCT00000752|Drug|Pseudoephedrine hydrochloride|
1715765|NCT00000752|Drug|Guaifenesin|
1715766|NCT00000752|Drug|Cefuroxime axetil|
1715767|NCT00000752|Drug|Beclomethasone dipropionate|
1715768|NCT00000753|Drug|Atevirdine mesylate|
1715769|NCT00000753|Drug|Zidovudine|
1715770|NCT00000753|Drug|Zalcitabine|
1715771|NCT00000753|Drug|Didanosine|
1715772|NCT00000754|Drug|Interferon alfa-2a|
1715773|NCT00000754|Drug|Zidovudine|
1715774|NCT00000754|Drug|Zalcitabine|
1715775|NCT00000755|Biological|rgp120/HIV-1MN|
1715776|NCT00000755|Drug|Zidovudine|
1715777|NCT00000756|Drug|Lymphocytes, Activated|
1715778|NCT00000757|Biological|gp160 Vaccine (MicroGeneSys)|
1715779|NCT00000758|Drug|Fluorouracil|
1715780|NCT00000760|Drug|Ro 24-7429|
1715781|NCT00000760|Drug|Zidovudine|
1715782|NCT00000760|Drug|Didanosine|
1715783|NCT00000761|Drug|Interferon gamma-1b|
1715784|NCT00000762|Biological|rgp120/HIV-1MN|
1715785|NCT00000762|Biological|rgp120/HIV-1 SF-2|
1715786|NCT00000762|Biological|gp160 Vaccine (MicroGeneSys)|
1715787|NCT00000763|Drug|TNP-470|
1715788|NCT00000764|Drug|Isotretinoin|
1715789|NCT00000764|Drug|Interferon alfa-2a|
1715790|NCT00000765|Drug|Zidovudine|
1715791|NCT00000766|Drug|Foscarnet sodium|
1715792|NCT00000766|Drug|Ganciclovir|
1715793|NCT00000767|Biological|TBC-3B Vaccine|
1715794|NCT00000767|Biological|Smallpox Vaccine|
1715795|NCT00000768|Drug|Glutamic acid hydrochloride|
1715796|NCT00000768|Drug|Ganciclovir|
1715797|NCT00000769|Drug|Interleukin-4|
1715798|NCT00000770|Drug|Nevirapine|
1715799|NCT00000770|Drug|Zidovudine|
1715800|NCT00000770|Drug|Didanosine|
1715801|NCT00000771|Drug|Paromomycin sulfate|
1715802|NCT00000772|Drug|Ribavirin|
1715803|NCT00000772|Drug|Didanosine|
1715804|NCT00000773|Drug|Atovaquone|
1715805|NCT00000774|Biological|rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
1715806|NCT00000774|Biological|rgp120/HIV-1 SF-2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
1715807|NCT00000774|Biological|Placebo version of rgp120/HIV-1MN|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
1715808|NCT00000774|Biological|Placebo version of rgp120/HIV-1SF2|Administered at weeks 0, 4, 8, 12, and 20. Individual group assignment will determine specific dosage and schedule.
1715809|NCT00000775|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
1715810|NCT00000776|Drug|Flucytosine|
1715811|NCT00000776|Drug|Fluconazole|
1715812|NCT00000776|Drug|Amphotericin B|
1715813|NCT00000776|Drug|Dexamethasone|
1715814|NCT00000777|Biological|gp160 Vaccine (MicroGeneSys)|
1715815|NCT00000778|Drug|Isoniazid|
1715816|NCT00000778|Drug|Pyridoxine hydrochloride|
1715817|NCT00000778|Drug|Levofloxacin|
1715818|NCT00000779|Biological|Aluminum hydroxide|
1715819|NCT00000779|Biological|MF59|
1715820|NCT00000779|Biological|rgp120/HIV-1IIIB|
1715821|NCT00000779|Biological|rgp120/HIV-1MN|
1715822|NCT00000779|Biological|rgp120/HIV-1 SF-2|
1715823|NCT00000779|Biological|Env 2-3|
1715824|NCT00000781|Drug|Nevirapine|
1715825|NCT00000781|Drug|Zidovudine|
1715826|NCT00000781|Drug|Zalcitabine|
1715828|NCT00000782|Biological|gp160 Vaccine (Immuno-AG)|
1715829|NCT00000782|Biological|gp160 Vaccine (MicroGeneSys)|
1715830|NCT00000787|Behavioral|Pre- and post-test counseling|
1715831|NCT00000788|Drug|Methadone hydrochloride|
1715832|NCT00000788|Drug|Fluconazole|
1715833|NCT00000789|Drug|Stavudine|
1715834|NCT00000789|Drug|Zidovudine|
1715835|NCT00000790|Drug|Thalidomide|
1715836|NCT00000791|Drug|Glycovir|
1715837|NCT00000791|Drug|Zidovudine|
1715838|NCT00000792|Drug|Hypericin|
1715839|NCT00000793|Drug|Mexiletine hydrochloride|
1715840|NCT00000793|Drug|Benztropine mesylate|
1715841|NCT00000793|Drug|Amitriptyline hydrochloride|
1715842|NCT00000794|Drug|Sulfadiazine|
1715843|NCT00000794|Drug|Clarithromycin|
1715844|NCT00000794|Drug|Atovaquone|
1715845|NCT00000794|Drug|Pyrimethamine|
1715846|NCT00000794|Drug|Leucovorin calcium|
1715847|NCT00000795|Biological|HIV-1 Peptide Immunogen, Multivalent|
1715848|NCT00000796|Drug|Cycloserine|
1715849|NCT00000796|Drug|Ethionamide|
1715850|NCT00000796|Drug|Capreomycin sulfate|
1715851|NCT00000796|Drug|Aminosalicylic acid|
1715852|NCT00000796|Drug|Streptomycin sulfate|
1715853|NCT00000796|Drug|Ethambutol hydrochloride|
1715854|NCT00000796|Drug|Amikacin sulfate|
1715855|NCT00000796|Drug|Isoniazid|
1715856|NCT00000796|Drug|Pyrazinamide|
1715857|NCT00000796|Drug|Pyridoxine hydrochloride|
1715858|NCT00000796|Drug|Levofloxacin|
1715859|NCT00000796|Drug|Rifampin|
1715860|NCT00000796|Drug|Clofazimine|
1715861|NCT00000798|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
1715862|NCT00000799|Drug|Cidofovir|
1715863|NCT00000799|Drug|Probenecid|
1715864|NCT00000800|Drug|Methadone hydrochloride|
1715865|NCT00000800|Drug|Zidovudine|
1715866|NCT00000801|Drug|Filgrastim|
1715867|NCT00000801|Drug|Vincristine sulfate|
1715868|NCT00000801|Drug|Doxorubicin hydrochloride|
1715869|NCT00000801|Drug|Cyclophosphamide|
1715870|NCT00000801|Drug|Cytarabine|
1715871|NCT00000801|Drug|Dexamethasone|
1715872|NCT00000802|Drug|Atovaquone|
1715873|NCT00000802|Drug|Dapsone|
1715874|NCT00000803|Drug|Delavirdine mesylate|
1715875|NCT00000803|Drug|Zidovudine|
1715876|NCT00000803|Drug|Didanosine|
1715877|NCT00000804|Drug|Indinavir sulfate|
1715878|NCT00000805|Drug|Ganciclovir|
1715879|NCT00000806|Drug|Telinavir|
1715880|NCT00000807|Drug|Etoposide|
1715881|NCT00000808|Drug|Nevirapine|
1715882|NCT00000809|Biological|Aluminum hydroxide|
1715883|NCT00000809|Biological|QS-21|
1715884|NCT00000809|Biological|MN rsgp120/HIV-1|
1715885|NCT00000810|Drug|Delavirdine mesylate|
1715886|NCT00000810|Drug|Zidovudine|
1715887|NCT00000810|Drug|Didanosine|
1715888|NCT00000811|Drug|Azithromycin|
1715889|NCT00000811|Drug|Atovaquone|
1715890|NCT00000811|Drug|Sulfamethoxazole-Trimethoprim|
1715891|NCT00000812|Drug|Thalidomide|
1715892|NCT00000813|Biological|ALVAC-HIV gp160MN (vCP125)|
1715893|NCT00000813|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
1715894|NCT00000813|Biological|rgp120/HIV-1 SF-2|
1715895|NCT00000814|Drug|Nevirapine|
1715896|NCT00000814|Drug|Zidovudine|
1715897|NCT00000814|Drug|Didanosine|
1715898|NCT00000815|Biological|Attenuvax|Measles virus vaccine (attenuate)administered subcutaneously at a single dose of 0.5 mL at 6 months of age
1715899|NCT00000815|Biological|M-M-R-II|Measles-Mumps-Rubella vaccine (attenuated)administered subcutaneously as a single dose of 0.5 mL at 12 months of age
1715900|NCT00000816|Drug|Sulfamethoxazole-Trimethoprim|
1715901|NCT00000817|Drug|Amitriptyline hydrochloride|75 mg oral tablet taken daily
1715902|NCT00000817|Drug|Amitriptyline hydrochloride placebo|Oral placebo tablet taken daily
1715903|NCT00000817|Procedure|Point acupuncture|Standardized or alternate acupuncture procedure
1715904|NCT00000818|Drug|Zidovudine|
1715905|NCT00000819|Drug|Prednisone|
1715906|NCT00000820|Drug|Aldesleukin|
1715907|NCT00000821|Drug|Aldesleukin|
1715908|NCT00000822|Drug|Ritonavir|
1715909|NCT00000822|Biological|gp160 Vaccine (Immuno-AG)|
1715910|NCT00000822|Drug|Stavudine|
1715911|NCT00000822|Drug|Didanosine|
1715912|NCT00000823|Drug|Zidovudine|
1715913|NCT00000823|Drug|Didanosine|
1715914|NCT00000824|Drug|Lymphocytes, Activated|
1715915|NCT00000825|Drug|Aldesleukin|
1715916|NCT00000826|Drug|Clarithromycin|
1715917|NCT00000826|Drug|Rifabutin|
1715918|NCT00000826|Drug|Sulfamethoxazole-Trimethoprim|
1715919|NCT00000826|Drug|Dapsone|
1715920|NCT00000826|Drug|Fluconazole|
1715921|NCT00000827|Drug|Anti-HIV Immune Serum Globulin (Human)|
1715922|NCT00000829|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|Administered as an injection at 24 months of age
1715923|NCT00000829|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|Administered as an injection at 0, 2, 4, and 15 months of age
1715924|NCT00000829|Biological|Placebo|Administered at 0, 2, 4, and 15 months of age
1715925|NCT00000831|Drug|Lamivudine|
1715926|NCT00000831|Drug|Stavudine|
1715927|NCT00000831|Drug|Zidovudine|
1715928|NCT00000831|Drug|Didanosine|
1715929|NCT00000832|Biological|MF59|
1715930|NCT00000832|Biological|rgp120/HIV-1 SF-2|
1715931|NCT00000833|Drug|Ribavirin|
1715932|NCT00000833|Drug|Didanosine|
1715933|NCT00000834|Drug|Lamivudine|
1715934|NCT00000834|Drug|Methotrexate|
1715935|NCT00000834|Drug|Zidovudine|
1715936|NCT00000836|Drug|Sevirumab|
1715937|NCT00000837|Biological|Varicella Virus Vaccine (Live)|
1715949|NCT00000249|Drug|20% N2O|20% inhaled N2O
1715950|NCT00000249|Drug|30% N2O|30% inhaled N2O
1715951|NCT00000249|Drug|40% N2O|40% inhaled N2O
1715952|NCT00000250|Drug|0% N2O|Subjects will inhale 100% oxygen with no N2O for 25 min then immerse forearm in warm water and cold water
1715953|NCT00000250|Drug|40% N2O|Subjects will inhale 40% N2O then immerse forearm in warm water and cold water
1715954|NCT00000251|Drug|30% N2O|
1715955|NCT00000251|Drug|0.2% isoflurane|
1715956|NCT00000251|Drug|0.4% isoflurane|
1715957|NCT00000251|Other|100% oxygen|Placebo
1715958|NCT00000252|Drug|0% N2O|
1715959|NCT00000252|Drug|10% N2O|
1715960|NCT00000252|Drug|20% N2O|
1715961|NCT00000252|Drug|30% N2O|
1715962|NCT00000252|Drug|40% N2O|
1715963|NCT00000253|Drug|10% N2O|
1715964|NCT00000253|Drug|20% N2O|
1715965|NCT00000253|Drug|30% N2O|
1715966|NCT00000253|Drug|40% N2O|
1715967|NCT00000254|Drug|40% Nitrous oxide|Used as pain assay positive control
1715968|NCT00000254|Other|Sham comparator|0% isoflurane in oxygen
1715969|NCT00000254|Drug|0.2% isoflurane|
1715970|NCT00000254|Drug|0.4% isoflurane|
1715971|NCT00000254|Drug|0.6% isoflurane|
1715972|NCT00000255|Drug|Nitrous oxide|
1715973|NCT00000256|Drug|20% N2O|
1715974|NCT00000256|Drug|40% N2O|
1715975|NCT00000256|Drug|60% N2O|
1715976|NCT00000256|Drug|80% N2O|
1715977|NCT00000257|Drug|0% N2O and 10% N2O|
1715978|NCT00000257|Drug|0% N2O and 20% N2O|
1715979|NCT00000257|Drug|0% N2O and 30% N2O|
1715980|NCT00000257|Drug|0% N2O and 40% N2O|
1715981|NCT00000258|Drug|Nitrous oxide 10% & placebo|
1715982|NCT00000258|Drug|Nitrous oxide 20% & placebo|
1715983|NCT00000258|Drug|Nitrous oxide 30% & placebo|
1715984|NCT00000258|Drug|Nitrous oxide 40% and placebo|
1715985|NCT00000259|Drug|15 % Nitrous oxide|
1715986|NCT00000259|Drug|0.3 % Sevoflurane|
1715987|NCT00000259|Drug|30% Nitrous oxide|
1715988|NCT00000259|Drug|0.6% Sevoflurane|
1715989|NCT00000259|Other|Placebo|
1715990|NCT00000260|Drug|Nitrous oxide|
1715991|NCT00000261|Drug|30% Nitrous oxide|
1715992|NCT00000261|Other|Placebo|No drug (100% oxygen)
1715993|NCT00000261|Drug|0.2% sevoflurane|
1715994|NCT00000261|Drug|0.4% sevoflurane|
1715995|NCT00000261|Drug|0.6% sevoflurane|
1715996|NCT00000262|Drug|30% Nitrous oxide|
1715997|NCT00000262|Drug|0.4% Sevoflurane|
1715998|NCT00000262|Drug|0.2% sevoflurane|
1715999|NCT00000262|Other|Placebo|
1716000|NCT00000263|Drug|30% Nitrous oxide|
1716001|NCT00000263|Other|0.25 g/Kg ethanol|
1716002|NCT00000263|Other|0.5 g/KG ethanol|
1716003|NCT00000263|Other|0 g/Kg ethanol|
1716004|NCT00000264|Drug|30% Nitrous oxide|
1716005|NCT00000264|Other|0.35 g/Kg ethanol|
1716006|NCT00000264|Other|0.7 g/Kg ethanol|
1716007|NCT00000264|Other|0 g/Kg ethanol|
1716008|NCT00000266|Drug|Flupenthixol|
1716009|NCT00000267|Drug|Risperidone|
1716010|NCT00000839|Drug|Didanosine|
1716011|NCT00000841|Drug|Indinavir sulfate|
1716012|NCT00000841|Drug|Lamivudine|
1716013|NCT00000841|Drug|Stavudine|
1716014|NCT00000841|Drug|Zidovudine|
1716015|NCT00000842|Drug|Nerve Growth Factor, Recombinant Human|
1716016|NCT00000843|Drug|Adefovir dipivoxil|
1716017|NCT00000844|Drug|Interferon alfa-n3|
1716018|NCT00000844|Drug|Interferon alfa-n1|
1716019|NCT00000845|Biological|P3C541b Lipopeptide|
1716020|NCT00000846|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
1716021|NCT00000846|Biological|HIV-1 Peptide Immunogen, Multivalent|
1716022|NCT00000847|Biological|ALVAC-HIV MN120TMG (vCP205)|
1716023|NCT00000847|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
1716024|NCT00000847|Biological|rgp120/HIV-1 SF-2|
1716025|NCT00000848|Drug|Indinavir sulfate|
1716026|NCT00000848|Drug|Saquinavir|
1716027|NCT00000849|Drug|Aldesleukin|
1716028|NCT00000850|Drug|Indinavir sulfate|
1716029|NCT00000850|Drug|Sargramostim|
1716030|NCT00000851|Drug|Stavudine|
1716031|NCT00000851|Drug|Didanosine|
1716032|NCT00000852|Procedure|Allogeneic lymphocyte transfer|
1716033|NCT00000853|Biological|rgp120/HIV-1MN|
1716034|NCT00000854|Drug|Nandrolone decanoate|
1716035|NCT00000855|Drug|Zidovudine|
1716036|NCT00000856|Drug|Foscarnet sodium|
1716037|NCT00000856|Drug|Ganciclovir|
1716038|NCT00000857|Drug|Interleukin-12|
1716039|NCT00000859|Drug|Indinavir sulfate|
1716040|NCT00000859|Drug|Ritonavir|
1716041|NCT00000859|Drug|Nelfinavir mesylate|
1716042|NCT00000861|Drug|Indinavir sulfate|
1716043|NCT00000862|Drug|Zidovudine|
1716044|NCT00000863|Drug|Sitamaquine|
1716045|NCT00000864|Drug|Abacavir sulfate|
1716046|NCT00000864|Drug|Zidovudine|
1716047|NCT00000940|Drug|Ritonavir|
1716048|NCT00000940|Drug|Abacavir sulfate|
1716049|NCT00000940|Drug|Amprenavir|
1716050|NCT00000940|Drug|Lamivudine|
1716051|NCT00000940|Drug|Stavudine|
1716052|NCT00000941|Drug|Pravastatin sodium|
1716053|NCT00000941|Drug|Simvastatin|
1716054|NCT00000941|Drug|Atorvastatin calcium|
1716055|NCT00000941|Drug|Ritonavir|
1716056|NCT00000941|Drug|Nelfinavir mesylate|
1716057|NCT00000941|Drug|Saquinavir|
1716058|NCT00000942|Drug|Nevirapine|
1716059|NCT00000943|Biological|Tetanus Toxoid Vaccine|
1716060|NCT00000943|Biological|Hepatitis A Vaccine (Inactivated)|
1716061|NCT00000943|Biological|HIV-1 Immunogen|
1716062|NCT00000943|Biological|Hepatitis B Vaccine (Recombinant)|
1716068|NCT00000946|Biological|HIV p24/MF59 Vaccine|
1716069|NCT00000946|Biological|ALVAC-HIV MN120TMG (vCP205)|
1716070|NCT00000946|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
1716071|NCT00000946|Biological|rgp120/HIV-1 SF-2|
1716072|NCT00000947|Drug|Azithromycin|
1716073|NCT00000948|Drug|Aldesleukin|Il-2
1716074|NCT00000948|Drug|ART|antiretroviral therapy for the treatment of HIV
1716075|NCT00000949|Drug|Aldesleukin|
1716076|NCT00000950|Drug|Ethambutol hydrochloride|
1716077|NCT00000950|Drug|Isoniazid|
1716078|NCT00000950|Drug|Pyrazinamide|
1716079|NCT00000950|Drug|Pyridoxine hydrochloride|
1716080|NCT00000950|Drug|Rifampin|
1716081|NCT00000951|Drug|Fluconazole|
1716082|NCT00000952|Drug|Ritonavir|
1716083|NCT00000952|Drug|Lamivudine|
1716084|NCT00000952|Drug|Zidovudine|
1716085|NCT00000953|Drug|Sorivudine|
1716086|NCT00000953|Drug|Acyclovir|
1716087|NCT00000954|Drug|Bleomycin sulfate|
1716088|NCT00000954|Drug|Vincristine sulfate|
1716089|NCT00000954|Drug|Doxorubicin hydrochloride|
1716090|NCT00000954|Drug|Zalcitabine|
1716091|NCT00000954|Drug|Didanosine|
1716092|NCT00000955|Drug|Tuberculin Purified Protein Derivative|Administered intradermally at 5 TU per 0.1 mL
1716093|NCT00000956|Biological|gp160 Vaccine (MicroGeneSys)|
1716094|NCT00000957|Biological|gp160 Vaccine (Immuno-AG)|
1716095|NCT00000958|Biological|MTP-PE/MF59|
1716096|NCT00000958|Biological|Env 2-3|
1716097|NCT00000959|Drug|Isoniazid|
1716098|NCT00000959|Drug|Pyridoxine hydrochloride|
1716099|NCT00000960|Drug|Zidovudine|
1716100|NCT00000961|Drug|Anti-HIV Immune Serum Globulin (Human)|
1716101|NCT00000961|Drug|Zidovudine|
1716102|NCT00000962|Drug|Nevirapine|
1716103|NCT00000963|Drug|Didanosine|
1716104|NCT00000964|Drug|Ranitidine hydrochloride|
1716105|NCT00000964|Drug|Foscarnet sodium|
1716106|NCT00000965|Drug|Zidovudine|
1716107|NCT00000966|Drug|Azithromycin|
1716108|NCT00000966|Drug|Pyrimethamine|
1716109|NCT00000966|Drug|Leucovorin calcium|
1716110|NCT00000967|Drug|Interferon alfa-2a|
1716111|NCT00000967|Drug|Zidovudine|
1716112|NCT00000968|Biological|gp160 Vaccine (Immuno-AG)|
1716113|NCT00000969|Drug|Zalcitabine|
1716114|NCT00000969|Drug|Didanosine|
1716115|NCT00000970|Drug|Foscarnet sodium|
1716116|NCT00000970|Drug|Ganciclovir|
1716117|NCT00000971|Drug|Clarithromycin|
1716118|NCT00000971|Drug|Zidovudine|
1716119|NCT00000971|Drug|Didanosine|
1716120|NCT00000972|Biological|MTP-PE/MF59|
1716121|NCT00000972|Biological|Env 2-3|
1716122|NCT00000973|Drug|Pyrimethamine|
1716123|NCT00000973|Drug|Leucovorin calcium|
1716124|NCT00000973|Drug|Zidovudine|
1716125|NCT00000974|Drug|Pentamidine isethionate|
1716126|NCT00000975|Drug|Itraconazole|
1716127|NCT00000976|Drug|CD4-IgG|
1716128|NCT00000976|Drug|Zidovudine|
1716129|NCT00000977|Biological|gp160 Vaccine (MicroGeneSys)|
1716130|NCT00000978|Drug|Zidovudine|
1716131|NCT00000978|Drug|Zalcitabine|
1716132|NCT00000979|Drug|Zidovudine|
1716133|NCT00000979|Drug|Didanosine|
1716134|NCT00000980|Drug|Spiramycin|
1716135|NCT00000981|Drug|Fiacitabine|
1716136|NCT00000982|Drug|Zidovudine|
1716137|NCT00000982|Drug|Didanosine|
1716138|NCT00000983|Drug|Zidovudine|
1716139|NCT00000984|Drug|CD4 Antigens|
1716140|NCT00000985|Drug|Vidarabine|
1716141|NCT00000985|Drug|Acyclovir|
1716142|NCT00000985|Drug|Foscarnet sodium|
1716143|NCT00000986|Drug|Zidovudine|
1716144|NCT00000986|Drug|Aldesleukin|
1716145|NCT00000987|Drug|Bleomycin sulfate|
1716146|NCT00000987|Drug|Vincristine sulfate|
1716147|NCT00000987|Drug|Doxorubicin hydrochloride|
1716148|NCT00000987|Drug|Zidovudine|
1716149|NCT00000988|Drug|Stavudine|
1716150|NCT00000989|Drug|Zidovudine|
1716151|NCT00000989|Drug|Sargramostim|
1716152|NCT00000989|Drug|Ganciclovir|
1716153|NCT00000990|Drug|Zidovudine|
1716154|NCT00000991|Drug|Pentamidine isethionate|
1716155|NCT00000991|Drug|Sulfamethoxazole-Trimethoprim|
1716156|NCT00000991|Drug|Dapsone|
1716157|NCT00000991|Drug|Zidovudine|
1716158|NCT00000992|Drug|Itraconazole|
1716159|NCT00000993|Drug|Zidovudine|
1716160|NCT00000994|Drug|Zidovudine|
1716161|NCT00000995|Drug|Zidovudine|
1716162|NCT00000995|Drug|Ganciclovir|
1716163|NCT00000996|Drug|Doxorubicin hydrochloride|
1716164|NCT00000997|Drug|Zalcitabine|
1716165|NCT00000998|Drug|Trimetrexate glucuronate|
1716166|NCT00000998|Drug|Leucovorin calcium|
1716167|NCT00000999|Drug|Zidovudine|
1716168|NCT00001000|Drug|Ampligen|
1716169|NCT00001001|Drug|Zidovudine|
1716170|NCT00001002|Drug|Zidovudine|
1716171|NCT00001002|Drug|Foscarnet sodium|
1716172|NCT00001003|Drug|Pentamidine isethionate|
1716173|NCT00001003|Drug|Zidovudine|
1716174|NCT00001004|Drug|Tumor Necrosis Factor|
1716175|NCT00001004|Drug|Interferon gamma-1b|
1716176|NCT00001005|Drug|Zidovudine|
1716177|NCT00001005|Drug|Aldesleukin|
1716178|NCT00001006|Drug|AS-101|
1716179|NCT00001007|Drug|Zidovudine|
1716180|NCT00001008|Drug|Methadone hydrochloride|
1716181|NCT00001008|Drug|Zidovudine|
1716182|NCT00001009|Drug|Dextran sulfate|
1716183|NCT00001010|Drug|Zidovudine|
1716184|NCT00001010|Drug|Acyclovir|
1716185|NCT00001011|Drug|Zidovudine|
1716186|NCT00001012|Drug|AL 721|
1716187|NCT00001013|Drug|Trimetrexate glucuronate|
1716188|NCT00001013|Drug|Pentamidine isethionate|
1716189|NCT00001013|Drug|Sulfamethoxazole-Trimethoprim|
1716190|NCT00001013|Drug|Leucovorin calcium|
1716191|NCT00001014|Drug|Trimetrexate glucuronate|
1716192|NCT00001014|Drug|Sulfamethoxazole-Trimethoprim|
1716193|NCT00001014|Drug|Leucovorin calcium|
1716194|NCT00001015|Drug|Ribavirin|
1716195|NCT00001016|Drug|Trimetrexate glucuronate|
1716196|NCT00001016|Drug|Leucovorin calcium|
1716197|NCT00001017|Drug|Fluconazole|
1716198|NCT00001017|Drug|Amphotericin B|
1716199|NCT00001018|Drug|Letrazuril|
1716200|NCT00001019|Biological|rgp120/HIV-1 SF-2|
1716201|NCT00001019|Biological|MTP-PE/MF59|
1716202|NCT00001020|Biological|rgp120/HIV-1IIIB|
1716203|NCT00001020|Biological|rgp120/HIV-1MN|
1716204|NCT00001021|Biological|rgp120/HIV-1IIIB|
1716205|NCT00001021|Biological|rgp120/HIV-1MN|
1716206|NCT00001022|Drug|Zidovudine|
1716207|NCT00001022|Drug|Zalcitabine|
1716208|NCT00001022|Drug|Didanosine|
1716209|NCT00001023|Drug|Clarithromycin|
1716210|NCT00001023|Drug|Azithromycin|
1716211|NCT00001023|Drug|Rifabutin|
1716212|NCT00001024|Drug|Zidovudine|
1716213|NCT00001024|Drug|Didanosine|
1716214|NCT00001025|Drug|Zidovudine|
1716215|NCT00001025|Drug|Didanosine|
1716216|NCT00001026|Biological|gp160 Vaccine (Immuno-AG)|
1716217|NCT00001026|Biological|rgp120/HIV-1IIIB|
1716218|NCT00001026|Biological|rgp120/HIV-1MN|
1716219|NCT00001026|Biological|rgp120/HIV-1 SF-2|
1716220|NCT00001026|Biological|HIVAC-1e|
1716221|NCT00001027|Drug|Pentamidine isethionate|
1716222|NCT00001028|Drug|Pentamidine isethionate|
1716223|NCT00001028|Drug|Dapsone|
1716224|NCT00001029|Drug|Zidovudine|
1716225|NCT00001029|Drug|Zalcitabine|
1716226|NCT00001029|Drug|Didanosine|
1716227|NCT00001030|Drug|Clarithromycin|
1716228|NCT00001030|Drug|Rifabutin|
1716229|NCT00001031|Biological|rgp120/HIV-1MN|
1716230|NCT00001031|Biological|rgp120/HIV-1 SF-2|
1716231|NCT00001032|Drug|Zidovudine|
1716232|NCT00001032|Drug|Zalcitabine|
1716233|NCT00001033|Drug|Ethambutol hydrochloride|
1716234|NCT00001033|Drug|Isoniazid|
1716235|NCT00001033|Drug|Pyrazinamide|
1716236|NCT00001033|Drug|Pyridoxine hydrochloride|
1716237|NCT00001033|Drug|Levofloxacin|
1716238|NCT00001033|Drug|Rifampin|
1716239|NCT00001034|Drug|Ganciclovir|
1716240|NCT00001035|Drug|Interferon alfa-2b|
1716241|NCT00001035|Drug|Zidovudine|
1716242|NCT00001035|Drug|Zalcitabine|
1716243|NCT00001035|Drug|Didanosine|
1716244|NCT00001036|Drug|Thymalfasin|
1716245|NCT00001036|Drug|Interleukin-2, Polyethylene Glycolated|
1716246|NCT00001036|Drug|Zidovudine|
1716247|NCT00001037|Biological|gp160 Vaccine (Immuno-AG)|
1716248|NCT00001038|Drug|Valacyclovir hydrochloride|
1716249|NCT00001038|Drug|Acyclovir|
1716250|NCT00001039|Drug|Ethambutol hydrochloride|
1716251|NCT00001039|Drug|Clarithromycin|
1716252|NCT00001040|Drug|Saquinavir|
1716253|NCT00001040|Drug|Zidovudine|
1716254|NCT00001040|Drug|Zalcitabine|
1716255|NCT00001041|Biological|rgp120/HIV-1MN|
1716256|NCT00001042|Biological|Aluminum hydroxide|
1716257|NCT00001042|Biological|Lipid A, Monophosphoryl|
1716258|NCT00001042|Biological|Lipid A, Liposome-encapsulated monophosphoryl|
1716259|NCT00001042|Biological|Syntex adjuvant formulation|
1716260|NCT00001042|Biological|MF59|
1716261|NCT00001042|Biological|Threonyl Muramyl Dipeptide|
1716262|NCT00001042|Biological|rgp120/HIV-1 SF-2|
1716263|NCT00001042|Biological|MTP-PE/MF59|
1716264|NCT00001043|Biological|gp160 Vaccine (Immuno-AG)|
1716265|NCT00001044|Biological|Aluminum hydroxide|
1716266|NCT00001044|Biological|QS-21|
1716267|NCT00001044|Biological|rgp120/HIV-1MN|
1716268|NCT00001045|Drug|Nevirapine|
1716269|NCT00001045|Drug|Zidovudine|
1716270|NCT00001045|Drug|Didanosine|
1716271|NCT00001046|Biological|MF59|
1716272|NCT00001046|Biological|rgp120/HIV-1 SF-2|
1716273|NCT00001047|Drug|Ethambutol hydrochloride|
1716274|NCT00001047|Drug|Clarithromycin|
1716275|NCT00001047|Drug|Clofazimine|
1716276|NCT00001047|Drug|Rifabutin|
1716277|NCT00001048|Drug|Filgrastim|
1716278|NCT00001048|Drug|Cytarabine|
1716279|NCT00001048|Drug|Zidovudine|
1716280|NCT00001048|Drug|Zalcitabine|
1716281|NCT00001048|Drug|Didanosine|
1716282|NCT00001049|Drug|Zidovudine|
1716283|NCT00001049|Drug|Didanosine|
1716284|NCT00001052|Biological|Aluminum hydroxide|
1716285|NCT00001052|Biological|QS-21|
1716286|NCT00001052|Biological|rgp120/HIV-1MN|
1716287|NCT00001053|Biological|HIV p17/p24:Ty-VLP|
1716288|NCT00001053|Biological|Aluminum hydroxide|
1716289|NCT00001054|Drug|Valacyclovir hydrochloride|
1716290|NCT00001055|Biological|ALVAC-HIV MN120TMG (vCP205)|
1716291|NCT00001055|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
1716292|NCT00001055|Biological|rgp120/HIV-1 SF-2|
1716293|NCT00001056|Biological|gp160 Vaccine (Immuno-AG)|
1716294|NCT00001057|Drug|Zidovudine|
1716295|NCT00001057|Drug|Didanosine|
1716296|NCT00001058|Drug|Indinavir sulfate|
1716297|NCT00001058|Drug|Ritonavir|
1716298|NCT00001058|Drug|Ethambutol hydrochloride|
1716299|NCT00001058|Drug|Clarithromycin|
1716300|NCT00001058|Drug|Rifabutin|
1716301|NCT00001059|Drug|Doxorubicin hydrochloride (liposomal)|
1716302|NCT00001059|Drug|Filgrastim|
1716303|NCT00001059|Drug|Bleomycin sulfate|
1716304|NCT00001059|Drug|Vincristine sulfate|
1716305|NCT00001060|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
1716306|NCT00001061|Drug|Sevirumab|
1716307|NCT00001061|Drug|Foscarnet sodium|
1716308|NCT00001061|Drug|Ganciclovir|
1716309|NCT00001062|Drug|Ganciclovir|
1716310|NCT00001063|Drug|Stavudine|
1716311|NCT00001063|Drug|Zidovudine|
1716312|NCT00001063|Drug|Didanosine|
1716313|NCT00001064|Drug|Allogenic Dendritic Cells|
1716314|NCT00001065|Drug|Amphotericin B|
1716315|NCT00001066|Drug|Lamivudine|
1716316|NCT00001066|Drug|Zidovudine|
1716317|NCT00001066|Drug|Didanosine|
1716318|NCT00001067|Drug|Lamivudine|
1716319|NCT00001067|Drug|Stavudine|
1716320|NCT00001067|Drug|Zidovudine|
1716321|NCT00001068|Drug|Lamivudine|
1716322|NCT00001070|Drug|Oral Vitamin C|
1716323|NCT00001071|Drug|Filgrastim|
1716324|NCT00001072|Biological|ALVAC-HIV MN120TMGNP (vCP300)|
1716325|NCT00001072|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
1716326|NCT00001072|Biological|rgp120/HIV-1 SF-2|
1716327|NCT00001073|Drug|Isotretinoin|
1716328|NCT00001074|Drug|Hydroxyurea|
1716329|NCT00001074|Drug|Didanosine|
1716330|NCT00001075|Drug|Ritonavir|
1716331|NCT00001075|Drug|Lamivudine|
1716332|NCT00001075|Drug|Zidovudine|
1716333|NCT00001076|Biological|ALVAC-HIV MN120TMG (vCP205)|
1716334|NCT00001076|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
1716335|NCT00001076|Biological|rgp120/HIV-1 SF-2|
1716336|NCT00001077|Dietary Supplement|Multivitamin and mineral supplements|Oral tablets taken daily
1716337|NCT00001077|Dietary Supplement|Peptamen|Solution received daily
1716338|NCT00001077|Dietary Supplement|NuBasics|Solution or dietary bar received daily
1716339|NCT00001078|Biological|Hepatitis A Vaccine (Inactivated)|
1716340|NCT00001079|Drug|Testosterone enanthate|
1716341|NCT00001079|Drug|Megestrol acetate|
1716342|NCT00001080|Biological|Influenza Virus Vaccine|
1716343|NCT00001080|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
1716344|NCT00001080|Drug|Lamivudine|
1716345|NCT00001081|Drug|Nitazoxanide|
1716346|NCT00001082|Drug|Levocarnitine|500 mg tablet taken orally daily
1716347|NCT00001082|Drug|Adefovir dipivoxil|120 mg tablet taken orally daily
1716348|NCT00001082|Drug|Adefovir dipivoxil placebo|Oral placebo tablet taken daily
1716349|NCT00001083|Drug|Indinavir sulfate|
1716350|NCT00001083|Drug|Ritonavir|
1716351|NCT00001083|Drug|Nevirapine|
1716352|NCT00001083|Drug|Lamivudine|
1716353|NCT00001083|Drug|Stavudine|
1716354|NCT00001083|Drug|Zidovudine|
1716355|NCT00001084|Drug|Indinavir sulfate|
1716356|NCT00001084|Drug|Lamivudine|
1716357|NCT00001084|Drug|Stavudine|
1716358|NCT00001084|Drug|Zidovudine|
1716359|NCT00001085|Drug|Amprenavir|
1716360|NCT00001085|Drug|Lamivudine|
1716361|NCT00001085|Drug|Zidovudine|
1716362|NCT00001086|Drug|Indinavir sulfate|
1716363|NCT00001086|Drug|Abacavir sulfate|
1716364|NCT00001086|Drug|Efavirenz|
1716365|NCT00001087|Drug|Ritonavir|
1716366|NCT00001087|Drug|Nelfinavir mesylate|
1716367|NCT00001087|Drug|Efavirenz|
1716368|NCT00001087|Drug|Levocarnitine|
1716369|NCT00001087|Drug|Adefovir dipivoxil|
1716370|NCT00001087|Drug|Saquinavir|
1716371|NCT00001087|Drug|Lamivudine|
1716372|NCT00001087|Drug|Stavudine|
1716373|NCT00001087|Drug|Zidovudine|
1716374|NCT00001087|Drug|Zalcitabine|
1716375|NCT00001087|Drug|Didanosine|
1716376|NCT00001088|Biological|APL 400-047|
1716377|NCT00001088|Drug|Bupivacaine hydrochloride|
1716378|NCT00001090|Biological|APL 400-047|
1716379|NCT00001090|Biological|ALVAC-HIV MN120TMG (vCP205)|
1716380|NCT00001090|Drug|Sargramostim|
1716381|NCT00001091|Drug|Ritonavir|
1716382|NCT00001091|Drug|Nelfinavir mesylate|
1716383|NCT00001091|Drug|Nevirapine|
1716384|NCT00001091|Drug|Lamivudine|
1716385|NCT00001091|Drug|Stavudine|
1716386|NCT00001094|Drug|Lamivudine/Zidovudine|
1716387|NCT00001094|Drug|Nelfinavir mesylate|
1716388|NCT00001094|Drug|Saquinavir|
1716389|NCT00001094|Drug|Delavirdine mesylate|
1716390|NCT00001095|Drug|Indinavir sulfate|
1716391|NCT00001095|Drug|Amprenavir|
1716392|NCT00001095|Drug|Nevirapine|
1716393|NCT00001095|Drug|Lamivudine|
1716394|NCT00001095|Drug|Stavudine|
1716395|NCT00001095|Drug|Zidovudine|
1716396|NCT00001096|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
1716397|NCT00001096|Biological|QS-21|
1716398|NCT00001096|Biological|rgp120/HIV-1MN|
1716399|NCT00001100|Drug|ganciclovir|
1716400|NCT00001101|Drug|ceftriaxone|
1716401|NCT00001101|Drug|doxycycline|
1716402|NCT00001104|Drug|Zidovudine|
1716403|NCT00001105|Drug|F105 Monoclonal Antibody (Human)|
1716404|NCT00001106|Drug|Zidovudine|
1716405|NCT00001107|Drug|Fluconazole|
1716406|NCT00001107|Drug|AmBisome|
1716407|NCT00001108|Drug|Ritonavir|
1716408|NCT00001108|Drug|Nelfinavir mesylate|
1716409|NCT00001108|Drug|Saquinavir|
1716410|NCT00001108|Drug|Nevirapine|
1716411|NCT00001108|Drug|Lamivudine|
1716412|NCT00001108|Drug|Stavudine|
1716413|NCT00001108|Drug|Didanosine|
1716414|NCT00001110|Procedure|Bronchoalveolar lavage|
1716415|NCT00001111|Drug|Nevirapine|
1716416|NCT00001111|Drug|Zidovudine|
1716417|NCT00001112|Drug|Zidovudine|
1716418|NCT00001112|Drug|Interferon gamma-1b|
1716419|NCT00001113|Drug|Interferon alfa-2a|
1716420|NCT00001113|Drug|Zidovudine|
1716425|NCT00001116|Drug|Tumor Necrosis Factor soluble receptor-immunoadhesin complex|
1716426|NCT00001118|Drug|Enfuvirtide|
1716427|NCT00001119|Biological|Tetanus Toxoid Vaccine|
1716428|NCT00001119|Drug|Indinavir sulfate|
1716429|NCT00001119|Drug|Lamivudine/Zidovudine|
1716430|NCT00001119|Drug|Ritonavir|
1716431|NCT00001119|Drug|Abacavir sulfate|
1716432|NCT00001119|Drug|Amprenavir|
1716433|NCT00001119|Drug|Efavirenz|
1716434|NCT00001119|Biological|Hepatitis B Vaccine (Recombinant)|
1716435|NCT00001119|Drug|Lamivudine|
1716436|NCT00001119|Drug|Zidovudine|
1716437|NCT00001122|Drug|Nelfinavir mesylate|
1716438|NCT00001122|Drug|Efavirenz|
1716439|NCT00001122|Drug|Stavudine|
1716440|NCT00001122|Drug|Didanosine|
1716441|NCT00001123|Drug|Ribavirin|
1716442|NCT00001125|Biological|Varicella Virus Vaccine (Live)|
1716443|NCT00001126|Drug|Cidofovir|
1716444|NCT00001127|Biological|Influenza virus vaccine (CAIV-T)|
1716445|NCT00001128|Drug|Interleukin-12|
1716446|NCT00001128|Drug|Paromomycin sulfate|
1716447|NCT00001128|Drug|Azithromycin|
1716448|NCT00001129|Device|Electronic Medication Reminder System|
1716449|NCT00001129|Behavioral|Medication Manager|
1716450|NCT00001131|Drug|Aldesleukin|Subcutaneous injection of IL-2 in the amount of 2.0 X 10^6 mIU per day for the entire duration of therapy
1716451|NCT00001131|Drug|HAART|Current HAART regimen to be continued for duration of therapy or until certain criteria specified by the study is met
1716452|NCT00001132|Drug|Abacavir sulfate|
1716453|NCT00001133|Drug|Indinavir sulfate|
1716454|NCT00001133|Drug|Ritonavir|
1716455|NCT00000491|Drug|aspirin|
1716456|NCT00000492|Drug|propranolol|
1716457|NCT00000493|Drug|propranolol|
1716458|NCT00000493|Drug|hyaluronidase|
1716459|NCT00000494|Drug|indomethacin|
1716460|NCT00000494|Procedure|surgery, cardiovascular|
1716461|NCT00000495|Behavioral|diet, reducing|
1716462|NCT00000495|Behavioral|diet, sodium-restricted|
1716463|NCT00000495|Behavioral|alcohol restriction|
1716464|NCT00000495|Behavioral|exercise|
1716465|NCT00000496|Drug|aspirin|
1716466|NCT00000496|Drug|dipyridamole|
1716467|NCT00000497|Behavioral|diet, sodium-restricted|
1716468|NCT00000497|Behavioral|diet, reducing|
1716469|NCT00000498|Behavioral|diet, sodium-restricted|
1716470|NCT00000498|Behavioral|diet, reducing|
1716471|NCT00000498|Behavioral|alcohol restriction|
1716472|NCT00000498|Drug|antihypertensive agents|
1716473|NCT00000499|Drug|chlorthalidone|
1716474|NCT00000499|Drug|reserpine|
1716475|NCT00000499|Drug|hydralazine|
1716476|NCT00000499|Drug|metoprolol|
1716477|NCT00000500|Drug|aspirin|
1716478|NCT00000500|Drug|carotene|
1716479|NCT00000501|Behavioral|diet, sodium-restricted|
1716480|NCT00000501|Behavioral|diet, reducing|
1716481|NCT00000501|Drug|potassium|
1716482|NCT00000502|Procedure|cardiopulmonary resuscitation|
1716483|NCT00000503|Drug|nitroglycerin|
1716484|NCT00000503|Drug|streptokinase|
1716485|NCT00000503|Procedure|heart catheterization|
1716486|NCT00000504|Drug|encainide|
1716487|NCT00000504|Drug|moricizine|
1716488|NCT00000504|Drug|flecainide|
1716489|NCT00000504|Drug|imipramine|
1716490|NCT00000505|Drug|tissue plasminogen activator|
1716491|NCT00000505|Procedure|angioplasty, transluminal, percutaneous coronary|
1716492|NCT00000506|Drug|fenfluramine|
1716493|NCT00000506|Drug|phentermine|
1716494|NCT00000507|Drug|streptokinase|
1716495|NCT00000508|Behavioral|smoking cessation|
1716496|NCT00000508|Behavioral|diet, reducing|
1716497|NCT00000508|Behavioral|exercise|
1716498|NCT00000508|Behavioral|diet, fat-restricted|
1716499|NCT00000509|Behavioral|diet, sodium-restricted|
1716500|NCT00000509|Behavioral|diet, potassium-supplementation|
1716501|NCT00000510|Drug|aspirin|
1716502|NCT00000510|Drug|dipyridamole|
1716503|NCT00000510|Procedure|angioplasty, transluminal, percutaneous coronary|
1716504|NCT00000511|Dietary Supplement|mineral supplements|
1716505|NCT00000511|Dietary Supplement|Trial 1: fatty acids, omega-3; Trial 2: Mineral supplements|
1716506|NCT00000511|Behavioral|dietary supplements|
1716507|NCT00000512|Drug|lovastatin|Lovastatin was begun at a dose of 20 mg twice a day (in the morning and at bedtime). If the LDL cholesterol level did not fall below 3.1 mmol per liter after three months, the dose of lovastatin was increased to 40 mg twice a day.
1716508|NCT00000512|Drug|colestipol|Colestipol was begun at a dose of 5 g three times a day with meals and increased to 10 g three times a day after 10 days, unless side effects delayed the increase. Psyllium hydrophic mucilloid (Metamucil) was provided if dietary bran was insufficient to control constipation.
1716509|NCT00000512|Drug|niacin|Niacin was started at 125 mg twice a day and gradually increased to 500 mg four times a day (with meals and at bedtime) at one month and 1 g four times a day at two months. If the LDL cholesterol level did not fall below 3.1 mmol per liter (120 mg per deciliter) after three months, the dose of niacin was increased to 1.5 g (three tablets) four times a day, but no further.
1716510|NCT00000512|Other|Placebo for colestipol|Placebo for colestipol.
1716511|NCT00000512|Other|Placebo for lovastatin|Placebo for lovastatin
1716512|NCT00000513|Behavioral|diet, reducing|
1716513|NCT00000513|Behavioral|diet, sodium-restricted|
1716514|NCT00000513|Drug|chlorthalidone|
1716515|NCT00000513|Drug|atenolol|
1716516|NCT00000514|Drug|chlorthalidone|
1716517|NCT00000514|Drug|atenolol|
1716518|NCT00000514|Drug|reserpine|
1716519|NCT00000515|Behavioral|diet, reducing|
1716520|NCT00000516|Drug|enalapril|
1716521|NCT00000517|Drug|warfarin|
1716522|NCT00000518|Procedure|electrophysiology|
1716523|NCT00000518|Procedure|electrocardiography, ambulatory|
1716524|NCT00000518|Drug|imipramine|
1716525|NCT00000518|Drug|mexiletine|
1716526|NCT00000518|Drug|procainamide|
1716527|NCT00000518|Drug|quinidine|
1716528|NCT00000518|Drug|sotalol|
1716529|NCT00000519|Behavioral|diet, reducing|
1716530|NCT00000519|Behavioral|exercise|
1716531|NCT00000519|Behavioral|diet, fat-restricted|
1716532|NCT00000520|Drug|immunoglobulins, intravenous|
1716533|NCT00000520|Drug|aspirin|
1716534|NCT00000521|Behavioral|diet, sodium-restricted|
1716535|NCT00000521|Behavioral|diet, potassium-supplemented|
1716536|NCT00000522|Behavioral|diet, sodium-restricted|
1716537|NCT00000522|Behavioral|diet, reducing|
1716538|NCT00000522|Behavioral|exercise|
1716539|NCT00000522|Behavioral|alcohol restriction|
1716540|NCT00000522|Drug|chlorthalidone|
1716541|NCT00000522|Drug|acebutolol|
1716542|NCT00000522|Drug|doxazosin|
1716543|NCT00000522|Drug|amlodipine|
1716544|NCT00000522|Drug|enalapril|
1716545|NCT00000523|Behavioral|exercise|
1716546|NCT00000524|Drug|cyclosporine|
1716547|NCT00000524|Drug|prednisone|
1716548|NCT00000525|Drug|hydrochlorothiazide|
1716549|NCT00000525|Behavioral|diet, potassium supplementation|
1716550|NCT00000525|Behavioral|diet, magnesium supplementation|
1716551|NCT00000525|Drug|triamterene|
1716552|NCT00000525|Drug|chlorthalidone|
1716553|NCT00000526|Drug|encainide|
1716554|NCT00000526|Drug|flecainide|
1716555|NCT00000526|Drug|moricizine|
1716556|NCT00000527|Drug|aspirin|
1716557|NCT00000527|Drug|dipyridamole|
1716558|NCT00000528|Behavioral|diet, sodium-restricted (Phase III) diet, sodium-restricted|
1716559|NCT00000528|Behavioral|diet, reducing (Phase III)|
1716560|NCT00000529|Drug|tamoxifen|
1716561|NCT00000530|Drug|nifedipine|
1716562|NCT00000530|Behavioral|biofeedback (psychology)|
1716563|NCT00000530|Procedure|electromyography|
1716564|NCT00000531|Device|defibrillators, implantable|
1716565|NCT00000531|Drug|amiodarone amiodarone|
1716566|NCT00000531|Drug|sotalol|
1716567|NCT00000532|Behavioral|diet, fat-restricted|
1716568|NCT00000533|Behavioral|social support|
1716569|NCT00000534|Drug|calcium|
1716570|NCT00000534|Behavioral|dietary supplements|
1716571|NCT00000535|Behavioral|diet, reducing|
1716572|NCT00000535|Behavioral|diet, sodium-restricted|
1716573|NCT00000536|Behavioral|sodium, dietary|
1716574|NCT00000537|Behavioral|meditation|
1716575|NCT00000537|Behavioral|relaxation|
1716576|NCT00000538|Behavioral|diet, fat-restricted|
1716577|NCT00000539|Drug|niacin|
1716578|NCT00000539|Drug|pravastatin|
1716579|NCT00000539|Drug|beta-carotene|
1716580|NCT00000539|Drug|vitamin E|
1716581|NCT00000539|Behavioral|dietary supplements|
1716582|NCT00000539|Drug|vitamin C|
1716583|NCT00000539|Drug|warfarin|
1716584|NCT00000540|Device|defibrillators, implantable|
1716585|NCT00000541|Behavioral|dietary supplements|
1716586|NCT00000541|Drug|vitamin C|
1716587|NCT00000541|Drug|vitamin E|
1716588|NCT00000541|Drug|beta-carotene|
1716589|NCT00000541|Drug|folic acid/Vitamin B6/Vitamin B12|
1716590|NCT00000542|Drug|Inhibitors, ACE|
1716591|NCT00000542|Drug|amlodipine|
1716592|NCT00000542|Drug|lisinopril|
1716593|NCT00000542|Drug|doxazosin|
1716594|NCT00000542|Drug|chlorthalidone|
1716595|NCT00000542|Drug|pravastatin|
1716596|NCT00000542|Behavioral|diet, fat-restricted|
1716597|NCT00000543|Behavioral|dietary supplements|
1716598|NCT00000543|Drug|calcium|
1716599|NCT00000544|Behavioral|diet therapy|
1716600|NCT00000545|Behavioral|exercise|
1716601|NCT00000545|Behavioral|diet|
1716602|NCT00000546|Behavioral|meditation|
1716603|NCT00000547|Drug|enalapril|
1716604|NCT00000548|Procedure|mechanical ventilation|
1716605|NCT00000549|Drug|estrogen replacement therapy|
1716606|NCT00000549|Drug|hormone replacement therapy|
1716607|NCT00000549|Drug|estrogens|
1716608|NCT00000549|Drug|progestins|
1716609|NCT00000550|Behavioral|health education|
1716610|NCT00000551|Behavioral|health education|
1716611|NCT00000552|Procedure|angioplasty, transluminal, percutaneous coronary|
1716612|NCT00000552|Procedure|coronary artery bypass|
1716613|NCT00000552|Drug|thrombolytic therapy|
1716614|NCT00000553|Drug|simvastatin|
1716615|NCT00000553|Drug|niacin|
1716616|NCT00000553|Drug|antioxidants|
1716617|NCT00000554|Procedure|Angiography, MRI, Dobutamine-Stress Echocardiography, PET,|
1716618|NCT00000554|Procedure|Myocardial Contrast Echo, Coronary Flow and Vasomotor Testing|
1716619|NCT00000555|Drug|estrogen replacement therapy|
1716620|NCT00000555|Drug|estrogens, conjugated|
1716621|NCT00000555|Drug|progesterone|
1716622|NCT00000555|Drug|hormone replacement therapy|
1716623|NCT00000555|Drug|supplementation, food|
1716624|NCT00000555|Drug|ascorbic acid|
1716625|NCT00000555|Drug|vitamin e|
1716626|NCT00000556|Drug|amiodarone|
1716627|NCT00000556|Drug|sotalol|
1716628|NCT00000556|Drug|propafenone|
1716629|NCT00000556|Drug|flecainide|
1716630|NCT00000556|Drug|quinidine|
1716631|NCT00000556|Drug|moricizine|
1716632|NCT00000556|Drug|disopyramide|
1716633|NCT00000556|Drug|procainamide|
1716634|NCT00000556|Drug|adrenergic beta antagonists|
1716635|NCT00000556|Drug|verapamil|
1716638|NCT00000556|Procedure|catheter ablation|
1716639|NCT00000556|Device|pacemaker, artificial|
1716640|NCT00000557|Behavioral|social support|
1716641|NCT00000558|Drug|angiotensin-converting enzyme inhibitors|
1716642|NCT00000559|Drug|estrogen replacement therapy|
1716643|NCT00000559|Drug|hormone replacement therapy|
1716644|NCT00000559|Drug|estradiol|
1716645|NCT00000559|Drug|medroxyprogesterone|
1716646|NCT00000560|Drug|adrenergic beta antagonists|
1716647|NCT00000561|Device|pacemaker, artificial|
1716648|NCT00000562|Procedure|extracorporeal membrane oxygenation|
1716649|NCT00000563|Drug|dexamethasone|
1716650|NCT00000564|Procedure|oxygen inhalation therapy|
1716651|NCT00000565|Procedure|intermittent positive-pressure breathing|
1716652|NCT00000566|Procedure|ventilation-perfusion ratio|
1716653|NCT00000566|Procedure|angiography|
1716654|NCT00000567|Procedure|high-frequency ventilation|
1716655|NCT00000568|Behavioral|smoking cessation|
1716656|NCT00000568|Drug|ipratropium|
1716657|NCT00000569|Drug|triamcinolone|1200 micrograms of triamcinolone in daily divided doses
1716658|NCT00000569|Other|Placebo|Placebo
1716659|NCT00000570|Drug|pulmonary surfactant|
1716660|NCT00000571|Device|ventilators, negative pressure|
1716661|NCT00000572|Procedure|positive-pressure ventilation|Detailed computer protocol controlled positive pressure ventilation
1716662|NCT00000572|Procedure|extracorporeal membrane oxygenation (CO2 removal)|Detailed computer protocol controlled Extracorporeal CO2 Removal with reduced positive pressure ventilation
1716663|NCT00000573|Procedure|enteral nutrition|
1716664|NCT00000574|Drug|ibuprofen|
1716665|NCT00000575|Drug|Placebo|Two 100 Og puffs budesonide placebo bid + two 90 Og puffs albuterol prn OR four 2 mg puffs nedocromil placebo bid + two 90 Og puffs albuterol prn.
1716666|NCT00000575|Drug|Nedocromil|Four 2 mg puffs bid + two 90 Og puffs albuterol prn
1716667|NCT00000575|Drug|Budesonide|Two 100 Og puffs bid + two 90 Og puffs albuterol prn.
1716668|NCT00000576|Drug|beclomethasone|
1716669|NCT00000577|Drug|Albuterol|
1716670|NCT00000577|Drug|Colchicine|
1716671|NCT00000577|Drug|Adrenal Cortex Hormones|
1716672|NCT00000577|Drug|Adrenergic-Beta Agonists|
1716673|NCT00000578|Drug|theophylline|
1716674|NCT00000578|Drug|beclomethasone|
1716675|NCT00000579|Procedure|Low Tidal Volume Ventilation|
1716676|NCT00000579|Procedure|Positive End-Expiratory Pressure|
1716677|NCT00000579|Drug|Lysofylline|
1716678|NCT00000579|Drug|Methylprednisolone|
1716679|NCT00000579|Drug|Ketoconazole|
1716680|NCT00000579|Procedure|Fluid Management|
1716681|NCT00000579|Procedure|Pulmonary Artery Catheter|
1716682|NCT00000580|Drug|immunoglobulins, intravenous|
1716683|NCT00000581|Procedure|leukocyte transfusions|
1716684|NCT00000582|Drug|factor ix|
1716685|NCT00000583|Biological|hepatitis B vaccines|
1716686|NCT00000584|Drug|immunoglobulins|
1716687|NCT00000585|Drug|penicillin|
1716688|NCT00000586|Drug|hydroxyurea|
1716689|NCT00000587|Procedure|erythropoietin, recombinant|
1716690|NCT00000588|Drug|chelation therapy|
1716691|NCT00000589|Procedure|platelet transfusion|
1716692|NCT00000590|Drug|immunoglobulins|
1716693|NCT00000591|Procedure|lymphocyte depletion|
1716694|NCT00000592|Procedure|blood transfusion|
1716695|NCT00000593|Procedure|blood transfusion|
1716696|NCT00000594|Drug|cholestyramine|
1716697|NCT00000595|Drug|deferoxamine|
1716698|NCT00000596|Drug|prednisone|
1716699|NCT00000596|Drug|cyclophosphamide|
1716700|NCT00000596|Drug|dapsone|
1716701|NCT00000597|Drug|antilymphocyte serum|
1716702|NCT00000597|Drug|nandrolone|
1716703|NCT00000598|Behavioral|diet, fat-restricted|
1716704|NCT00000598|Behavioral|exercise|
1716705|NCT00000599|Drug|colestipol|
1716706|NCT00000599|Drug|niacin|
1716707|NCT00000599|Behavioral|diet, fat-restricted|
1716708|NCT00000600|Drug|Vitamin E|
1716709|NCT00000600|Drug|Vitamin C|
1716710|NCT00000601|Drug|estrogen replacement therapy|
1716711|NCT00000601|Drug|estrogens|
1716712|NCT00000601|Drug|progesterone|
1716713|NCT00000601|Drug|hormone replacement therapy|
1716714|NCT00000602|Drug|hydroxyurea|
1716715|NCT00000603|Procedure|stem cell transplantation|
1716716|NCT00000604|Procedure|cardiopulmonary bypass|
1716717|NCT00000604|Procedure|heart arrest, induced|
1716718|NCT00000605|Drug|hormone replacement therapy|
1716719|NCT00000605|Drug|estrogens|
1716720|NCT00000605|Drug|medroxyprogesterone|
1716721|NCT00000606|Procedure|Lung volume reduction surgery|
1716722|NCT00000607|Device|Left ventricular assist device|A type of implantable heart pump
1716723|NCT00000607|Device|Optimal medical therapy|(non-experimental) One possibility in handling Heart failure effectively is optimal medicine therapy. The most popular treatment medications at present are ACE Inhibitors and Beta Blockers. The result is the heart being able to pump more effectively and allowing blood to circulate freely.
1716724|NCT00000608|Behavioral|diet, fat-restricted|
1716725|NCT00000608|Behavioral|diet, sodium-restricted|
1716726|NCT00000609|Drug|amiodarone|
1716727|NCT00000609|Device|defibrillators, implantable|
1716728|NCT00000610|Drug|magnesium|
1716729|NCT00000611|Drug|hormone replacement therapy|
1716730|NCT00000611|Drug|estrogens|
1716731|NCT00000611|Drug|progestins|
1716732|NCT00000611|Drug|estrogen replacement therapy|
1716733|NCT00000611|Behavioral|diet, fat-restricted|
1716734|NCT00000611|Drug|calcium|
1716735|NCT00000611|Drug|vitamin D|
1716736|NCT00000611|Behavioral|dietary supplements|
1716737|NCT00000612|Drug|estrogens, conjugated|
1716738|NCT00000612|Behavioral|diet, soy proteins|
1716739|NCT00000612|Behavioral|dietary supplements|
1716740|NCT00000613|Behavioral|dietary supplements|
1716741|NCT00000613|Drug|genistein|
1716742|NCT00000613|Behavioral|diet, soy proteins|
1716743|NCT00000614|Drug|warfarin|
1716744|NCT00000615|Behavioral|diet, reducing|
1716745|NCT00000616|Behavioral|diet, sodium-restricted|
1716746|NCT00000616|Behavioral|diet, fat-restricted|
1716747|NCT00000616|Behavioral|exercise|
1716748|NCT00000616|Behavioral|diet, reducing|
1716749|NCT00000616|Behavioral|alcohol drinking|
1716750|NCT00000617|Drug|azithromycin|
1716751|NCT00000619|Procedure|catheterization, Swan-Ganz|
1716752|NCT00000620|Drug|Anti-hyperglycemic Agents|Multiple drugs including insulins and oral anti-hyperglycemic agents as needed to reach Glycemia Trial arm-specific goals (intensive control <6%; standard control 7.0-7.9%).
1716753|NCT00000620|Drug|Anti-hypertensive Agents|Multiple anti-hypertensive agents as needed to reach Blood Pressure Trial arm-specific goals (intensive control <120 mm Hg; standard control <140 mm Hg).
1716754|NCT00000620|Drug|Blinded fenofibrate or placebo plus simvastatin|Double blind administration of 160 mg/day of fenofibrate in participants with estimated glomerular filtration rate (eGFR) ≥50 mL/min/1.73m2 or 54 mg/day in patients with eGFR <50 mL/min/1.73m2 or matching placebo in combination with open label simvastatin 20 - 40 mg/day.
1716755|NCT00000621|Drug|all trans retinoic acid|
1716756|NCT00000621|Drug|13 cis retinoic acid|
1716757|NCT00000621|Drug|placebo|
1716758|NCT00000622|Drug|Anti-Asthmatic Agents|
1716759|NCT00000623|Drug|Deferoxamine|
1716760|NCT00000623|Drug|Deferiprone|
1716761|NCT00000623|Drug|Arginine|
1716762|NCT00000623|Drug|Sildenafil|
1716763|NCT00000623|Drug|Decitabine|
1716764|NCT00000625|Drug|Zidovudine|
1716765|NCT00000625|Drug|Zalcitabine|
1716766|NCT00000625|Drug|Didanosine|
1716767|NCT00000626|Drug|Vinblastine sulfate|
1716768|NCT00000626|Drug|Dacarbazine|
1716769|NCT00000626|Drug|Filgrastim|
1716770|NCT00000626|Drug|Bleomycin sulfate|
1716771|NCT00000626|Drug|Doxorubicin hydrochloride|
1716772|NCT00000627|Drug|Fluconazole|
1716773|NCT00000628|Drug|L-697,661|
1716774|NCT00000628|Drug|Zidovudine|
1716775|NCT00000629|Drug|Valproic acid|
1716776|NCT00000629|Drug|Zidovudine|
1716777|NCT00000630|Biological|HIVAC-1e|
1716778|NCT00000630|Biological|gp160 Vaccine (MicroGeneSys)|
1716779|NCT00000631|Biological|HIVAC-1e|
1716780|NCT00000631|Biological|gp160 Vaccine (MicroGeneSys)|
1716781|NCT00000632|Biological|Env 2-3|
1716782|NCT00000633|Biological|gp160 Vaccine (Immuno-AG)|
1716783|NCT00000633|Biological|Hepatitis B Vaccine (Recombinant)|
1716784|NCT00000634|Drug|Nevirapine|
1716785|NCT00000635|Drug|Trifluridine|
1716786|NCT00000635|Drug|Bacitracin zinc/Polymyxin B sulfate|
1716787|NCT00000636|Drug|Isoniazid|
1716788|NCT00000636|Drug|Pyrazinamide|
1716789|NCT00000636|Drug|Pyridoxine hydrochloride|
1716790|NCT00000636|Drug|Rifampin|
1716791|NCT00000637|Drug|Zidovudine|
1716792|NCT00000637|Drug|Didanosine|
1716793|NCT00000638|Drug|Isoniazid|
1716794|NCT00000638|Drug|Pyrazinamide|
1716795|NCT00000638|Drug|Pyridoxine hydrochloride|
1716796|NCT00000638|Drug|Rifampin|
1716797|NCT00000639|Drug|Itraconazole|
1716798|NCT00000639|Drug|Flucytosine|
1716799|NCT00000639|Drug|Fluconazole|
1716800|NCT00000639|Drug|Amphotericin B|
1716801|NCT00000640|Drug|Primaquine|
1716802|NCT00000640|Drug|Sulfamethoxazole-Trimethoprim|
1716803|NCT00000640|Drug|Dapsone|
1716804|NCT00000640|Drug|Clindamycin|
1716805|NCT00000641|Drug|Ciprofloxacin hydrochloride|
1716806|NCT00000641|Drug|Ethambutol hydrochloride|
1716807|NCT00000641|Drug|Amikacin sulfate|
1716808|NCT00000641|Drug|Azithromycin|
1716809|NCT00000641|Drug|Rifampin|
1716810|NCT00000641|Drug|Clofazimine|
1716811|NCT00000642|Drug|CD4-IgG|
1716812|NCT00000643|Drug|Pyrimethamine|
1716813|NCT00000643|Drug|Leucovorin calcium|
1716814|NCT00000644|Drug|Clarithromycin|
1716815|NCT00000645|Drug|Hypericin|
1716816|NCT00000646|Drug|Pentoxifylline|
1716817|NCT00000647|Drug|CD4-IgG|
1716818|NCT00000647|Drug|Zidovudine|
1716819|NCT00000647|Drug|Interferon alfa-n1|
1716820|NCT00000647|Procedure|Peripheral lymphocyte infusion|
1716821|NCT00000647|Procedure|Bone marrow transplant|
1716822|NCT00001135|Drug|Nevirapine|
1716823|NCT00001136|Biological|ALVAC-HIV MN120TMG (vCP205)|
1716824|NCT00001144|Drug|Modified bone marrow stem cell transplantation|
1716825|NCT00001145|Drug|Bacteriophage|
1716826|NCT00001145|Drug|rhuCD40L|
1716827|NCT00001145|Drug|KLH|
1716828|NCT00001146|Drug|Ethyl Eicosapentaenoic Acid|
1716829|NCT00001146|Drug|OmegaBrite|
1716830|NCT00001151|Drug|1,25-Dihydroxycholecalciferol|Usual doses of 1,25-dihydroycholecalciferol are 0.25-1 ug per day. All patients in this study received very high doses or 5-20 ug per day.
1716831|NCT00001155|Drug|cyclophosphamide|
1716832|NCT00001165|Drug|combined chemotherapy with streptozotocin, 5-fluorouracil, and doxorubicin|
1716833|NCT00001487|Drug|Dehydroepiandrosterone|
1716834|NCT00001493|Genetic|peripheral blood progenitor cells carrying MDR1|
1716835|NCT00001495|Drug|irinotecan (CPT-11)|
1716836|NCT00001498|Drug|methotrexate|
1716837|NCT00001498|Drug|leucovorin|
1716838|NCT00001498|Drug|5-fluorouracil|
1716839|NCT00001498|Drug|cyclophosphamide|
1716840|NCT00001498|Procedure|peripheral blood progenitor cell|
1716841|NCT00001498|Drug|paclitaxel|
1716845|NCT00001499|Procedure|chest radiotherapy|
1716846|NCT00001502|Drug|RMP-7 and carboplatin|
1716847|NCT00001504|Drug|9-cis-Retinoic Acid|
1716848|NCT00001507|Drug|Monoclonal Antibody 3A1|
1716849|NCT00001507|Drug|Monoclonal Antibody 95-5-49|
1716850|NCT00001507|Drug|Monoclonal Antibody 95-6-22|
1716851|NCT00001507|Device|Baxter Isolex 3001 Stem Cell Selection System|
1716852|NCT00001507|Device|Ceprate SC|
1716853|NCT00001509|Drug|IFN-alpha with retinoic acid|
1716854|NCT00001512|Drug|Id-KLH Vaccine|
1716855|NCT00001512|Drug|GM-CSF|
1716856|NCT00001515|Device|virtual bronchoscopy|
1716857|NCT00001520|Drug|neostigmine|
1716858|NCT00001521|Drug|Flutamide and Testolactone|
1716859|NCT00001521|Drug|Deslorelin|
1716860|NCT00001524|Drug|Thalidomide|
1716861|NCT00001526|Drug|Daclizumab (Zenapax)|
1716863|NCT00001533|Drug|cyclosporine|
1716864|NCT00001534|Drug|Losartan|
1716865|NCT00001535|Drug|Syngeneic Lymphocytes (CD4+) Cultured with OKT3 (Ortho) and Interleukin-2 (Chiro|
1716866|NCT00001538|Biological|APL 400-003|
1716867|NCT00001542|Drug|fluconazole|
1716868|NCT00001545|Device|Magstim Super Rapid Magnetic Stimulator|
1716869|NCT00001545|Device|Cadwell MES-10|
1716870|NCT00001550|Drug|IVIg|
1716871|NCT00001554|Device|intraoperative infrared (IR) neuroimaging|
1716872|NCT00001561|Drug|Myeloma Immunoglobulin Idiotype Vaccine-KLH|
1716873|NCT00001561|Drug|GM-CSF|
1716877|NCT00001564|Drug|EF-1 Peptide|
1716878|NCT00001564|Drug|EF-2 Peptide|
1716879|NCT00001564|Drug|PXFK Peptide|
1716880|NCT00001564|Drug|E7 Peptide|
1716881|NCT00001564|Drug|IL-2|
1716882|NCT00001564|Drug|IL-4|
1716883|NCT00001564|Drug|GM-CSF|
1716884|NCT00001564|Drug|CD40 Ligand|
1716885|NCT00001565|Drug|phenylbutyrate|
1716886|NCT00001566|Biological|therapeutic autologous dendritic cells|3 syringes containing 1 x 10^6peptide pulsed dendritic cells
1716887|NCT00001566|Drug|indinavir sulfate|Oral dose, 350 mg/m^2 administered every 8 hours. Maximum dose is 800 mg every 8 hours.
1716888|NCT00001566|Procedure|peripheral blood stem cell transplantation|Harvested autologous T cells, minimum dose 1 x 10^6/kg will be thawed rapidly in 37 degree water bath and infused sequentially over 5-15 minutes.
1716889|NCT00001567|Drug|Roferon-A|
1716890|NCT00001568|Drug|2-Fluoro-2-deoxyglucose|
1716891|NCT00001569|Drug|Cisplatin|
1716892|NCT00001569|Drug|Paclitaxel|
1716893|NCT00001569|Drug|5-FU|
1716894|NCT00001570|Drug|PSC 833|
1716895|NCT00001570|Drug|vinblastine|
1716896|NCT00001572|Drug|Id-KLH Vaccine|
1716897|NCT00001572|Drug|QS-21 (Stimulation-QS-21) Drug|
1716898|NCT00001573|Drug|SU101|
1716899|NCT00001575|Biological|Y-90 Humanized Anti-Tac|10 mCi (if a bone marrow transplant was part of the patient's previous therapy) or 15 mCi of yttrium labeled anti-TAC; followed by calcium trisodium Inj (Ca DTPA).
1716900|NCT00001575|Drug|Calcium-DTPA|Ca-DTPA will be administered intravenously on Days 1-3 to clear the radioactive agent from the body
1716901|NCT00001576|Drug|Melphalan|
1716902|NCT00001576|Drug|Floxuridine|
1716903|NCT00001576|Drug|Leucovorin|
1716904|NCT00001577|Procedure|double isolated limb perfusion with melphalan alone|
1716905|NCT00001579|Drug|5-Fluorouracil|
1716906|NCT00001579|Drug|Ethynyluracil|
1716907|NCT00001579|Drug|Leucovorin|
1716908|NCT00001586|Biological|Rituximab|Rituxan
1716909|NCT00001586|Drug|Fludarabine phosphate|Fludara
1716910|NCT00001586|Other|Leukemic or stroma cells|Patients are eligible to donate cells for the purpose of analyzing leukemic cells. Cells can be donated by apheresis (e.g. 60-90 minute intravenous technique), lymph node biopsy (e.g. 3 biopsy/excision of lymph nodes)bone marrow biopsy (e.g. 2-4 separate bone marrow biopsies), and bone marrow aspiration (e.g. 3 to 5cc of marrow per aspirate).
1716911|NCT00001587|Procedure|Isolated hepatic portal and arterial perfusion|
1716912|NCT00001587|Drug|Melphalan|
1716915|NCT00001598|Drug|Dehydroepiandrosterone|
1716916|NCT00001599|Drug|Thalidomide|
1716917|NCT00001601|Procedure|Electrocardiogram|
1716918|NCT00001601|Procedure|Biopsies|
1716919|NCT00001601|Procedure|Diagnostic imaging|
1716920|NCT00001605|Biological|Nontypeable Haemophilus influenzae|
1716921|NCT00001614|Drug|Chicken type II collagen|
1716922|NCT00001615|Drug|Corticosteroid|
1716923|NCT00001622|Procedure|investigate the relationship between in vivo and in vitro vascular responses|
1716924|NCT00001623|Procedure|Allogeneic Bone Marrow Transplant|
1716925|NCT00001624|Drug|Insulin|
1716928|NCT00001628|Drug|Angiotensin II type 1 receptor antagonists|
1716929|NCT00001629|Drug|Angiotensin II type 1 receptor antagonists|
1716930|NCT00001630|Device|Isolex 300i|
1716931|NCT00001631|Procedure|Magnetic resonance imaging|
1716932|NCT00001633|Procedure|Coronary magnetic resonance angiography imaging|
1716933|NCT00001637|Procedure|Blood cell transplantation|
1716934|NCT00001644|Drug|Indinavir|
1716935|NCT00001644|Drug|Zidovudine|
1716936|NCT00001644|Drug|Lamivudine|
1716939|NCT00001644|Procedure|Lymph node biospy|
1716940|NCT00001644|Procedure|Leukapheresis|
1716941|NCT00001646|Drug|Voriconazole|
1716942|NCT00001646|Drug|Amphotericin B|
1716943|NCT00001647|Procedure|White blood cell infusion|
1716944|NCT00001649|Drug|Valaciclovir|
1716945|NCT00001656|Drug|Olanzapine|tablet; 5-20mg/day; 8 weeks
1716946|NCT00001656|Drug|Clozapine|tablet; 12.5-900mg/day; 8 weeks
1716947|NCT00001658|Drug|Amoxicillin|
1716948|NCT00001662|Drug|CX516 (Ampalex)|
1716949|NCT00001663|Device|Magstim Super Rapid Stimulator|
1716950|NCT00001666|Device|Cadwell High-Speed Magnetoelectric Stimulator|
1716951|NCT00001666|Device|Magpro High-Speed Magnetoelectric Stimulator|
1716952|NCT00001669|Drug|rhIGF-1 (CEP-151)|
1716953|NCT00001676|Drug|SQ Fludarabine|
1716954|NCT00001677|Drug|Methotrexate|
1716955|NCT00001677|Drug|Fludarabine|
1716956|NCT00001680|Drug|Thalidomide|
1716957|NCT00001683|Drug|COL-3|
1716958|NCT00001685|Biological|Immunodominant peptides from three melanoma antigens, MART-1, GP100 and tyrosinase|
1716959|NCT00001688|Drug|Ritonavir|
1716960|NCT00001688|Drug|Nevirapine|
1716961|NCT00001688|Drug|Stavudine|
1716962|NCT00001689|Drug|Vincristine|
1716963|NCT00001693|Drug|Celecoxib (SC-58635)|
1716964|NCT00001696|Drug|Genistein|
1716965|NCT00001698|Drug|Ketorolac Rinse|
1716966|NCT00001703|Biological|incomplete Freund's adjuvant|0.7 ml of ISA-51 (Montanide ISA-51 adjuvant, incomplete Freund's adjuvant) will be mixed with peptide alone and injected subcutaneously every four weeks for a total of four vaccinations.
1716967|NCT00001703|Biological|von Hippel-Lindau peptide vaccine|1000 micrograms administered subcutaneously every four weeks for a total of four vaccinations.
1716968|NCT00001705|Drug|GP100 peptide|
1716969|NCT00001705|Drug|IL-2|
1716970|NCT00001713|Drug|Recombinant Tissue Plasminogen Activator|
1716971|NCT00001713|Drug|Heparin|
1716972|NCT00001713|Drug|Warfarin|
1716973|NCT00001716|Drug|Nitric Oxide|
1716974|NCT00001716|Drug|Nitroglycerin|
1716975|NCT00001718|Device|Electropalatography|
1716976|NCT00001720|Drug|Alendronate|
1716977|NCT00001723|Drug|Orlistat|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
1716978|NCT00001723|Drug|Placebo|Subjects receive drug for 6 months plus a 12 week intensive behavioral weight los program. Subjects return for monthly visits for 3 more months.
1716979|NCT00001724|Drug|Flurbiprofen|
1716980|NCT00001725|Drug|Dextromethorphan|
1716981|NCT00001728|Drug|Fosamax (Alendronate)|
1716982|NCT00000865|Drug|Abacavir sulfate|
1716983|NCT00000865|Drug|Lamivudine|
1716984|NCT00000865|Drug|Stavudine|
1716985|NCT00000865|Drug|Zidovudine|
1716986|NCT00000865|Drug|Didanosine|
1716987|NCT00000866|Biological|MN rgp120/HIV-1|
1716988|NCT00000866|Biological|TBC-3B Vaccine|
1716989|NCT00000867|Drug|Memantine|
1716990|NCT00000868|Biological|Salmonella typhi CVD 908-HIV-1 LAI gp 120 (VVG 203)|
1716991|NCT00000868|Biological|Aluminum hydroxide|
1716992|NCT00000868|Biological|MF59|
1716993|NCT00000868|Biological|rgp120/HIV-1MN|
1716994|NCT00000869|Drug|Nevirapine|
1716995|NCT00000870|Drug|Indinavir sulfate|
1716996|NCT00000870|Drug|Lamivudine|
1716997|NCT00000870|Drug|Stavudine|
1716998|NCT00000870|Drug|Zidovudine|
1716999|NCT00000870|Drug|Didanosine|
1717000|NCT00000870|Drug|Aldesleukin|
1717001|NCT00000871|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
1717002|NCT00000871|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
1717003|NCT00000871|Biological|ALVAC-HIV MN120TMG (vCP205)|
1717004|NCT00000871|Biological|rgp120/HIV-1 SF-2|
1717005|NCT00000872|Drug|Abacavir sulfate|
1717006|NCT00000872|Drug|Nelfinavir mesylate|
1717007|NCT00000872|Drug|Nevirapine|
1717008|NCT00000872|Drug|Lamivudine|
1717009|NCT00000872|Drug|Stavudine|
1717010|NCT00000872|Drug|Zidovudine|
1717011|NCT00000873|Drug|Infant Formula|
1717012|NCT00000875|Drug|Indinavir sulfate|
1717013|NCT00000875|Drug|Diphenhydramine hydrochloride|
1717014|NCT00000875|Drug|Lymphocytes, Activated|
1717015|NCT00000875|Drug|Lamivudine|
1717016|NCT00000875|Drug|Zidovudine|
1717017|NCT00000875|Drug|Acetaminophen|
1717018|NCT00000875|Drug|Aldesleukin|
1717019|NCT00000876|Drug|CD4-IgG2|
1717020|NCT00000877|Drug|Indinavir sulfate|
1717021|NCT00000877|Drug|Rifabutin|
1717022|NCT00000878|Drug|Lamivudine|
1717023|NCT00000878|Drug|Stavudine|
1717024|NCT00000878|Drug|Zidovudine|
1717025|NCT00000879|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1717026|NCT00000879|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
1717027|NCT00000879|Biological|ALVAC-HIV MN120TMG (vCP205)|
1717028|NCT00000880|Drug|Cyclosporine|
1717029|NCT00000881|Drug|Cidofovir|
1717030|NCT00000881|Drug|Probenecid|
1717031|NCT00000882|Drug|Indinavir sulfate|
1717032|NCT00000882|Drug|Delavirdine mesylate|
1717033|NCT00000882|Drug|Lamivudine|
1717034|NCT00000882|Drug|Stavudine|
1717035|NCT00000882|Drug|Zidovudine|
1717036|NCT00000883|Drug|Azithromycin|
1717037|NCT00000884|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|Dosage will vary based on route of administration
1717038|NCT00000884|Biological|ALVAC-HIV MN120TMG (vCP205)|Dosage will vary based on route of administration
1717039|NCT00000884|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|Dosage will vary based on route of administration
1717040|NCT00000885|Drug|Indinavir sulfate|
1717041|NCT00000885|Drug|Abacavir sulfate|
1717042|NCT00000885|Drug|Nelfinavir mesylate|
1717043|NCT00000885|Drug|Efavirenz|
1717044|NCT00000885|Drug|Levocarnitine|
1717045|NCT00000885|Drug|Adefovir dipivoxil|
1717046|NCT00000885|Drug|Lamivudine|
1717047|NCT00000885|Drug|Stavudine|
1717048|NCT00000885|Drug|Zidovudine|
1717049|NCT00000885|Drug|Didanosine|
1717050|NCT00000886|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
1717051|NCT00000887|Drug|Nelfinavir mesylate|
1717052|NCT00000887|Drug|Lamivudine|
1717053|NCT00000887|Drug|Zidovudine|
1717054|NCT00000888|Drug|Ritonavir|
1717055|NCT00000888|Drug|Lamivudine|
1717056|NCT00000888|Drug|Zidovudine|
1717057|NCT00000889|Drug|Aldesleukin|
1717058|NCT00000891|Drug|Ritonavir|
1717059|NCT00000891|Drug|Saquinavir|
1717060|NCT00000891|Drug|Delavirdine mesylate|
1717061|NCT00000891|Drug|Lamivudine|
1717062|NCT00000891|Drug|Stavudine|
1717063|NCT00000891|Drug|Zidovudine|
1717064|NCT00000891|Drug|Didanosine|
1717065|NCT00000892|Drug|Ritonavir|
1717066|NCT00000892|Drug|Nelfinavir mesylate|
1717067|NCT00000892|Drug|Levocarnitine|
1717068|NCT00000892|Drug|Adefovir dipivoxil|
1717069|NCT00000892|Drug|Saquinavir|
1717070|NCT00000892|Drug|Delavirdine mesylate|
1717071|NCT00000893|Drug|Nelfinavir mesylate|
1717072|NCT00000893|Drug|Efavirenz|
1717073|NCT00000894|Drug|Cidofovir|
1717074|NCT00000894|Drug|Probenecid|
1717075|NCT00000894|Drug|Ganciclovir|
1717076|NCT00000895|Drug|Nelfinavir mesylate|
1717077|NCT00000895|Drug|Nevirapine|
1717078|NCT00000895|Drug|Azithromycin|
1717079|NCT00000896|Drug|Indinavir sulfate|
1717080|NCT00000896|Drug|Lamivudine/Zidovudine|
1717081|NCT00000896|Biological|Hepatitis A Vaccine (Inactivated)|
1717082|NCT00000896|Drug|Interleukin-12|
1717083|NCT00000896|Drug|Nevirapine|
1717084|NCT00000896|Drug|Stavudine|
1717085|NCT00000896|Drug|Sargramostim|
1717086|NCT00000897|Drug|Zidovudine|
1717087|NCT00000898|Drug|Ritonavir|
1717088|NCT00000898|Drug|Nelfinavir mesylate|
1717089|NCT00000898|Drug|Saquinavir|
1717090|NCT00000899|Drug|Nelfinavir mesylate|
1717091|NCT00000899|Drug|Lamivudine|
1717092|NCT00000899|Drug|Filgrastim|
1717093|NCT00000899|Drug|Stavudine|
1717094|NCT00000899|Drug|Cyclophosphamide|
1717095|NCT00000901|Drug|Indinavir sulfate|
1717096|NCT00000901|Drug|Lamivudine|
1717097|NCT00000901|Drug|Stavudine|
1717098|NCT00000902|Drug|Ritonavir|
1717099|NCT00000902|Drug|Nelfinavir mesylate|
1717100|NCT00000902|Drug|Nevirapine|
1717101|NCT00000902|Drug|Lamivudine|
1717102|NCT00000902|Drug|Stavudine|
1717103|NCT00000902|Drug|Zidovudine|
1717104|NCT00000902|Drug|Zalcitabine|
1717105|NCT00000902|Drug|Didanosine|
1717106|NCT00000903|Drug|Indinavir sulfate|
1717107|NCT00000903|Drug|Lamivudine/Zidovudine|
1717108|NCT00000903|Drug|Nelfinavir mesylate|
1717109|NCT00000903|Drug|Efavirenz|
1717110|NCT00000904|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1717111|NCT00000904|Biological|gp160 MN/LAI-2|
1717112|NCT00000904|Biological|ALVAC(1)120(B,MN)GNP (vCP1433)|
1717113|NCT00000904|Biological|ALVAC-HIV MN120TMG (vCP205)|
1717114|NCT00000904|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
1717115|NCT00000906|Drug|Ritonavir|
1717116|NCT00000906|Drug|Saquinavir|
1717117|NCT00000906|Drug|Methadone hydrochloride|
1717118|NCT00000909|Drug|Aldesleukin|
1717119|NCT00000912|Drug|Indinavir sulfate|
1717120|NCT00000912|Drug|Abacavir sulfate|
1717121|NCT00000912|Drug|Amprenavir|
1717122|NCT00000912|Drug|Nelfinavir mesylate|
1717123|NCT00000912|Drug|Efavirenz|
1717124|NCT00000912|Drug|Levocarnitine|
1717125|NCT00000912|Drug|Adefovir dipivoxil|
1717126|NCT00000912|Drug|Saquinavir|
1717127|NCT00000913|Drug|Ritonavir|
1717128|NCT00000913|Drug|Nelfinavir mesylate|
1717129|NCT00000913|Drug|Saquinavir|
1717130|NCT00000914|Drug|Indinavir sulfate|
1717131|NCT00000914|Drug|Ritonavir|
1717132|NCT00000914|Drug|Nelfinavir mesylate|
1717133|NCT00000914|Drug|Efavirenz|
1717134|NCT00000915|Behavioral|Vaccine preparedness|
1717135|NCT00000916|Drug|Indinavir sulfate|
1717136|NCT00000916|Drug|Lamivudine/Zidovudine|
1717137|NCT00000916|Drug|Hydroxyurea|
1717138|NCT00000916|Drug|Lamivudine|
1717139|NCT00000916|Drug|Stavudine|
1717140|NCT00000916|Drug|Zidovudine|
1717141|NCT00000916|Drug|Didanosine|
1717142|NCT00000918|Drug|Indinavir sulfate|
1717143|NCT00000918|Drug|Lamivudine/Zidovudine|
1717144|NCT00000918|Drug|Ritonavir|
1717145|NCT00000918|Drug|Amprenavir|
1717146|NCT00000918|Drug|Efavirenz|
1717147|NCT00000918|Drug|Saquinavir|
1717148|NCT00000918|Drug|Lamivudine|
1717149|NCT00000918|Drug|Stavudine|
1717150|NCT00000918|Drug|Zidovudine|
1717151|NCT00000918|Drug|Didanosine|
1717152|NCT00000919|Drug|Indinavir sulfate|
1717153|NCT00000919|Drug|Lamivudine/Zidovudine|
1717154|NCT00000919|Drug|Ritonavir|
1717155|NCT00000919|Drug|Hydroxyurea|
1717156|NCT00000919|Drug|Abacavir sulfate|
1717157|NCT00000919|Drug|Amprenavir|
1717158|NCT00000919|Drug|Nelfinavir mesylate|
1717159|NCT00000919|Drug|Efavirenz|
1717160|NCT00000919|Drug|Lamivudine|
1717161|NCT00000919|Drug|Stavudine|
1717162|NCT00000919|Drug|Zidovudine|
1717163|NCT00000919|Drug|Didanosine|
1717164|NCT00000920|Drug|Ritonavir|
1717171|NCT00000922|Drug|Nelfinavir mesylate|
1717172|NCT00000922|Drug|Efavirenz|
1717173|NCT00000922|Drug|Nevirapine|
1717174|NCT00000922|Drug|Lamivudine|
1717175|NCT00000922|Drug|Stavudine|
1717176|NCT00000922|Drug|Didanosine|
1717177|NCT00000923|Drug|Indinavir sulfate|
1717178|NCT00000923|Drug|Lamivudine|
1717179|NCT00000923|Drug|Stavudine|
1717180|NCT00000923|Drug|Zidovudine|
1717181|NCT00000923|Drug|Didanosine|
1717182|NCT00000923|Drug|Aldesleukin|
1717183|NCT00000924|Drug|Ritonavir|
1717184|NCT00000924|Drug|Nelfinavir mesylate|
1717185|NCT00000924|Drug|Nevirapine|
1717186|NCT00000924|Drug|Stavudine|
1717187|NCT00000924|Drug|Didanosine|
1717188|NCT00000925|Drug|Optimune oral nutritional supplement|
1717189|NCT00000926|Drug|Nonoxynol-9|
1717190|NCT00000927|Drug|BufferGel|
1717191|NCT00000928|Behavioral|Group counseling intervention|Participants will engage in a multi-session group-based condom promotion program for approximately 12 months
1717192|NCT00000929|Drug|Nonoxynol-9|
1717193|NCT00000931|Behavioral|Behavioral intervention|
1717194|NCT00000931|Behavioral|Risk-reduction counseling|
1717195|NCT00000935|Biological|Intravenous immune globulin (IVIG)|given at a dose of 20mL/kg Intravenous Immune Globulin (Human) (IVIG 10% solvent/detergent)
1717196|NCT00000936|Drug|hOKT3|Administered both during and after transplantation in IV form. Dosage determined by individual weight and given for a maximum of 14 days.
1717197|NCT00000936|Drug|Oral Cyclosporine|Administered orally as either sandimmune or neoral at a dose determined by weight. Patients 6 years of age and older begin at a dose of 15 mg/kg/day and patients under 6 years of age receive 500 mg/m2/day, for the duration of the study.
1717198|NCT00000936|Drug|IV Cyclosporine|Administered intravenously (IV) both during and after transplantation at a dosage determined by individual age.
1717199|NCT00000937|Drug|Antibiotics|
1717200|NCT00000938|Drug|ceftriaxone|
1717201|NCT00000938|Drug|doxycycline|
1717202|NCT00000939|Drug|Hydroxyurea|
1717203|NCT00000939|Drug|Efavirenz|
1717204|NCT00000939|Drug|Stavudine|
1717205|NCT00000939|Drug|Didanosine|
1717206|NCT00001729|Drug|Ribavirin|
1717207|NCT00001730|Drug|Thyrogen|
1717208|NCT00001731|Drug|Cyclosporin A|
1717209|NCT00001735|Procedure|Gene therapy|
1717210|NCT00001736|Drug|Cysteamine|
1717211|NCT00001737|Drug|Cyclosporin A Implant|
1717212|NCT00001741|Drug|Losartan|
1717213|NCT00001748|Procedure|Peripheral blood progenitor cell transplant|
1717214|NCT00001749|Drug|Antithymocyte globulin|
1717215|NCT00001749|Drug|Cyclosporine|
1717216|NCT00001750|Drug|Stemgen|
1717217|NCT00001752|Drug|L-arginine|
1717218|NCT00001752|Drug|Estrogen|
1717219|NCT00001753|Procedure|Magnetic resonance imaging|
1717220|NCT00001757|Drug|Voriconazole|
1717221|NCT00001758|Drug|Abacavir|
1717222|NCT00001758|Drug|Amprenavir|
1717223|NCT00001758|Drug|Efavirenz|
1717224|NCT00001901|Drug|Etanercept|
1717225|NCT00001903|Drug|RSV Polyclonal Immunoglobulin|
1717226|NCT00001905|Drug|Interferon gamma|
1717227|NCT00001906|Biological|Combination of autoclaved leishmania antigen with recombinant human interleukin-12 (rhIL-12) and aluminum hydroxide gel as adjuvants|
1717228|NCT00001909|Drug|Soluble recombinantly produced IL-4R|
1717229|NCT00001911|Drug|Interleukin-12|
1717230|NCT00001917|Drug|O15|
1717231|NCT00001917|Drug|[F-18] FP-TZTP|
1717232|NCT00001919|Drug|Hypericum (LI-160)|
1717233|NCT00001923|Procedure|Transcranial magnetic stimulation|
1717234|NCT00001925|Drug|Alcohol|
1717235|NCT00001926|Drug|O15|
1717236|NCT00001926|Device|Cadwell rTMS|
1717237|NCT00001929|Drug|Eliprodil|
1717238|NCT00001930|Drug|Amantadine|
1717239|NCT00001931|Drug|N-0923|
1717240|NCT00001933|Drug|Nefiracetam|
1717241|NCT00001934|Drug|Zenapax|
1717242|NCT00001937|Drug|FK463|
1717243|NCT00001937|Drug|Fluconazole|
1717244|NCT00001940|Drug|Voriconazole|
1717245|NCT00001941|Biological|daclizumab|
1717246|NCT00001944|Drug|Vinorelbine|
1717247|NCT00001944|Drug|XR9576|
1717248|NCT00001946|Procedure|Magnetic resonance angiography|
1717249|NCT00001951|Drug|TMTDS|
1717250|NCT00001954|Drug|Etanercept|
1717251|NCT00001955|Drug|Etanercept|
1717252|NCT00001955|Drug|Celecoxib|
1717253|NCT00001956|Procedure|Blood draw|
1717254|NCT00001956|Procedure|Oral surgery|
1717255|NCT00001956|Procedure|Tissue biopsy|
1717256|NCT00001958|Drug|Hydroxyurea|
1717257|NCT00001959|Drug|Pirfenidone|During the study drug period of 12 months, patients will receive oral pirfenidone daily. For patients whose initial renal function is 50-80 ml/min as assessed by the MDRD equation, the initial pirfenidone dosage will be calculated at 40 mg/kg/d, with a maximum dose of 800 mg TID. For patients whose initial renal function is 30-50 ml/min, the initial dose will be 30 mg/kg/d. For patients whose initial renal function is between 15 and 30 ml/min, the initial dose will be 20 mg/kg/d.
1717258|NCT00001960|Device|Pacemaker therapy|
1717259|NCT00001961|Procedure|MRI|
1717260|NCT00001962|Drug|Daclizumab|Daclizumab, 1mg/kg of body weight, every 2 weeks for a total of 5 infusions.
1717261|NCT00001963|Procedure|hemoglobin-transported nitric oxide|
1717263|NCT00001965|Drug|Cyclosporine A|
1717264|NCT00001966|Drug|Mind-body therapy|
1717265|NCT00001967|Drug|HAART|
1717266|NCT00001968|Drug|Amprenavir|
1717267|NCT00001968|Drug|Ritonavir|
1717268|NCT00001968|Drug|Abacavir|
1717269|NCT00001968|Drug|Lamivudine|
1717270|NCT00001972|Drug|15 O Water|
1717271|NCT00001984|Drug|Alemtuzumab and DSG|Alemtuzumab was administered intravenously at 0.3 mg/kg/dose over 3 hr. Patients received one dose on each of days -1,+1,+3 and +5 relative to transplantation (total dose 1.2 mg/kg). Methylprednisolone was given prior to each dose to limit the cytokine release: 500 mg prior to dose 1, 125 mg prior to dose 2, and 60 mg prior to doses 3 and 4. Deoxyspergualin was dosed as follows. The first two patients received 4 mg/kg as a loading dose on the day of transplant and 2.5 mg/kg daily for 13 additional days (14 days of treatment; 36.5 mg/kg total dose). The next three patients received the same dosing regimen but it was initiated on postoperative day 12 to coincide with the resurgence of monocytes on days 12- 25.
1717272|NCT00001986|Drug|1-Octanol|
1717273|NCT00001989|Drug|Trichosanthin|
1717274|NCT00001989|Drug|Zidovudine|
1717275|NCT00001990|Drug|Atovaquone|
1717276|NCT00001991|Drug|Atovaquone|
1717277|NCT00001992|Biological|rgp120/HIV-1IIIB|
1717278|NCT00001993|Drug|Butyldeoxynojirimycin|
1717279|NCT00001993|Drug|Zidovudine|
1717280|NCT00001994|Drug|Atovaquone|
1717281|NCT00001995|Drug|Rifabutin|
1717282|NCT00001996|Drug|Atovaquone|
1717283|NCT00001996|Drug|Pentamidine isethionate|
1717284|NCT00001997|Drug|Interleukin-2, Polyethylene Glycolated|
1717285|NCT00001997|Drug|Zidovudine|
1717286|NCT00001997|Drug|Didanosine|
1717287|NCT00001998|Drug|Nystatin|
1717288|NCT00001999|Drug|Globulin, Immune|
1717289|NCT00001999|Drug|Ganciclovir|
1717290|NCT00002000|Drug|Valacyclovir hydrochloride|
1717291|NCT00002000|Drug|Acyclovir|
1717292|NCT00002001|Drug|Zidovudine|
1717293|NCT00002001|Drug|Zalcitabine|
1717294|NCT00002001|Drug|Didanosine|
1717295|NCT00002002|Drug|Trimethoprim|
1717296|NCT00002002|Drug|Sulfamethoxazole|
1717297|NCT00002002|Drug|Leucovorin calcium|
1717298|NCT00002003|Drug|Mitoxantrone hydrochloride|
1717299|NCT00002003|Drug|Etoposide|
1717300|NCT00002004|Drug|CD4 Antigens|
1717301|NCT00002005|Drug|CD4 Antigens|
1717302|NCT00002006|Drug|Zidovudine|
1717303|NCT00002006|Drug|Sargramostim|
1717304|NCT00002007|Drug|Zidovudine|
1717305|NCT00002007|Drug|Sargramostim|
1717306|NCT00002008|Drug|Sargramostim|
1717307|NCT00002009|Drug|Sargramostim|
1717308|NCT00002010|Drug|Fluconazole|
1717309|NCT00002011|Drug|Methoxsalen|
1717310|NCT00002012|Drug|Interferon alfa-n3|
1717311|NCT00002013|Drug|Zidovudine|
1717312|NCT00002013|Drug|AS-101|
1717313|NCT00002014|Drug|Zidovudine|
1717314|NCT00002014|Drug|Didanosine|
1717315|NCT00002015|Drug|Ganciclovir|
1717316|NCT00002016|Drug|Sevirumab|
1717317|NCT00002017|Drug|Interleukin-2, Polyethylene Glycolated|
1717318|NCT00002018|Drug|Interferon alfa-n3|
1717319|NCT00002019|Drug|Amphotericin B, Lipid-based|
1717320|NCT00002019|Drug|Amphotericin B|
1717321|NCT00002020|Drug|Zidovudine|
1717322|NCT00002021|Drug|Foscarnet sodium|
1717323|NCT00002022|Drug|Epoetin alfa|
1717324|NCT00002023|Drug|Zidovudine|
1717325|NCT00002024|Drug|Ganciclovir|
1717326|NCT00002025|Drug|Ganciclovir|
1717327|NCT00002026|Drug|Acyclovir|
1717328|NCT00002027|Drug|Diclazuril|
1717329|NCT00002028|Drug|Didanosine|
1717330|NCT00002029|Drug|Fat Emulsion 2%|
1717331|NCT00002029|Drug|Fat Emulsion 20%|
1717332|NCT00002030|Drug|Pentamidine isethionate|
1717333|NCT00002031|Drug|Dinitrochlorobenzene|
1717334|NCT00002032|Drug|Rifabutin|
1717335|NCT00002033|Drug|Zidovudine|
1717336|NCT00002033|Drug|AS-101|
1717337|NCT00002034|Drug|Zidovudine|
1717338|NCT00002034|Drug|Ganciclovir|
1717339|NCT00002035|Drug|Zidovudine|
1717340|NCT00002035|Drug|Didanosine|
1717341|NCT00002036|Drug|Anti-HIV Immune Serum Globulin (Human)|
1717342|NCT00002037|Drug|Trifluridine|
1717343|NCT00002038|Drug|Fluconazole|
1717344|NCT00002039|Drug|Foscarnet sodium|
1717345|NCT00002040|Drug|Fluconazole|
1717346|NCT00002041|Drug|Amphotericin B|
1717347|NCT00002042|Drug|Epoetin alfa|
1717348|NCT00002043|Drug|Dapsone|
1717349|NCT00002044|Drug|Zidovudine|
1717350|NCT00002045|Drug|Zidovudine|
1717351|NCT00002046|Drug|Zidovudine|
1717352|NCT00002047|Drug|Zidovudine|
1717353|NCT00002048|Drug|Zidovudine|
1717354|NCT00002049|Drug|Thymopentin|
1717355|NCT00002050|Drug|Thymopentin|
1717356|NCT00002051|Drug|Thymopentin|
1717357|NCT00002052|Drug|Ceftriaxone sodium|
1717358|NCT00002052|Drug|Ampicillin sodium|
1717359|NCT00002052|Drug|Amoxicillin trihydrate|
1717360|NCT00002053|Drug|Pentamidine isethionate|
1717361|NCT00002054|Drug|Pentamidine isethionate|
1717362|NCT00002055|Drug|Pentamidine isethionate|
1717363|NCT00002056|Drug|Pentamidine isethionate|
1717364|NCT00002057|Drug|Nystatin|
1717365|NCT00002058|Drug|Clofazimine|
1717366|NCT00002059|Drug|Inosine pranobex|
1717367|NCT00002060|Drug|Inosine pranobex|
1717368|NCT00002061|Drug|Inosine pranobex|
1717369|NCT00002062|Drug|Spiramycin|
1717370|NCT00002063|Drug|Zidovudine|
1717371|NCT00002064|Drug|Pyrimethamine|
1717372|NCT00002064|Drug|Clindamycin|
1717373|NCT00002065|Drug|Disulfiram|
1717374|NCT00002066|Drug|Thymopentin|
1717375|NCT00002067|Drug|Megestrol acetate|
1717376|NCT00002068|Drug|Fluconazole|
1717377|NCT00002068|Drug|Amphotericin B|
1717378|NCT00002069|Drug|Ditiocarb sodium|
1717379|NCT00002070|Drug|Sargramostim|
1717380|NCT00002070|Drug|Ganciclovir|
1717381|NCT00002071|Drug|Epoetin alfa|
1717392|NCT00002079|Drug|Butyldeoxynojirimycin|
1717393|NCT00002079|Drug|Zidovudine|
1717394|NCT00002080|Drug|Rifabutin|
1717395|NCT00002081|Drug|Zidovudine|
1717396|NCT00002081|Drug|Zalcitabine|
1717397|NCT00002082|Drug|Azithromycin|
1717398|NCT00002083|Drug|Peptide T|
1717399|NCT00002084|Drug|Valacyclovir hydrochloride|
1717400|NCT00002084|Drug|Acyclovir|
1717401|NCT00002085|Drug|Azithromycin|
1717402|NCT00002086|Drug|Zidovudine|
1717403|NCT00002086|Drug|Zalcitabine|
1717404|NCT00002086|Drug|Interferon alfa-n1|
1717405|NCT00002087|Drug|Alvircept sudotox|
1717406|NCT00002088|Drug|Saccharomyces boulardii|
1717407|NCT00002089|Drug|Azithromycin|
1717408|NCT00002090|Drug|Azithromycin|
1717409|NCT00002091|Drug|Pentoxifylline|
1717410|NCT00002092|Drug|Cimetidine|
1717411|NCT00002093|Drug|Daunorubicin (liposomal)|
1717412|NCT00002093|Drug|Bleomycin sulfate|
1717413|NCT00002093|Drug|Vincristine sulfate|
1717414|NCT00002093|Drug|Doxorubicin hydrochloride|
1717415|NCT00002094|Drug|Atevirdine mesylate|
1717416|NCT00002095|Drug|Ganciclovir|
1717417|NCT00002096|Drug|Zidovudine|
1717418|NCT00002096|Drug|Didanosine|
1717419|NCT00002096|Drug|Ganciclovir|
1717420|NCT00002097|Drug|Nystatin|
1717421|NCT00002098|Drug|Lentinan|
1717422|NCT00002098|Drug|Didanosine|
1717423|NCT00002099|Drug|Lentinan|
1717424|NCT00002099|Drug|Didanosine|
1717425|NCT00002100|Drug|Curdlan sulfate|
1717426|NCT00002101|Drug|Ethambutol hydrochloride|
1717427|NCT00002101|Drug|Clarithromycin|
1717428|NCT00002101|Drug|Rifabutin|
1717429|NCT00002102|Drug|Trimetrexate glucuronate|
1717430|NCT00002102|Drug|Leucovorin calcium|
1717431|NCT00002103|Drug|Trimetrexate glucuronate|
1717432|NCT00002103|Drug|Leucovorin calcium|
1717433|NCT00001180|Drug|Ovine Corticotropin-Releasing Hormone (oCRH)|
1717434|NCT00001181|Drug|Testolactone|
1717435|NCT00001182|Procedure|current standard of care treatments|
1717436|NCT00001188|Procedure|radiation therapy following surgery|
1717437|NCT00001189|Procedure|radiotherapy|
1717438|NCT00001190|Drug|Deslorelin|
1717439|NCT00001191|Drug|Pantoprazole|
1717440|NCT00001191|Drug|Omeprazole|
1717441|NCT00001193|Procedure|high dose melphalan and autologous bone marrow transplantation|
1717442|NCT00001256|Drug|prednisone and methotrexate|
1717443|NCT00001261|Drug|Gamma Globulin|
1717444|NCT00001262|Drug|Copper Histidine|
1717445|NCT00001266|Drug|Suramin|
1717446|NCT00001267|Drug|zidovudine|
1717447|NCT00001267|Drug|2',3'-dideoxyinosine|
1717448|NCT00001269|Drug|IL-3|
1717449|NCT00001270|Drug|interleukin-1|
1717450|NCT00001271|Drug|IgG-RFB4-SMPT-dgA|
1717451|NCT00001272|Drug|taxol|
1717452|NCT00001280|Drug|itraconazole|
1717453|NCT00001282|Drug|Zidovudine (AZT) & Interleukin-2 (IL2)|
1717454|NCT00001287|Drug|intravenous immunoglobulin (IVIg)|
1717455|NCT00001288|Drug|15 O Water|
1717456|NCT00001288|Drug|FDG|
1717457|NCT00001296|Drug|melphalan|
1717458|NCT00001296|Drug|tumor necrosis factor|
1717459|NCT00001296|Drug|interferon-gamma|
1717460|NCT00001296|Procedure|hyperthermic isolated limb perfusion|
1717461|NCT00001298|Drug|carboxypeptidase-G2|
1717462|NCT00001300|Drug|doxorubicin|
1717463|NCT00001300|Drug|ifosfamide|
1717464|NCT00001300|Drug|mesna|
1717465|NCT00001302|Drug|PSC 833|
1717468|NCT00001304|Drug|Synthetic Human Parathyroid Hormone 1-34|twice daily subcutaneous injections
1717469|NCT00001304|Drug|Calcitriol & Calcium|Twice daily oral calcitriol with 1000 mg Calcium carbonate supplementation
1717470|NCT00001305|Drug|Humatrope|Patients receive a subcutaneous injection.
1717471|NCT00001305|Other|Growth hormone|
1717472|NCT00001305|Drug|Nutropin|
1717473|NCT00001305|Drug|GRH|
1717474|NCT00001307|Drug|Oxygen-15 Water|
1717475|NCT00001307|Drug|Capsaicin|
1717476|NCT00001311|Device|heparin-surface modified intraocular lens|
1717477|NCT00001317|Drug|interferon-gamma|
1717478|NCT00001318|Drug|interferon gamma|
1717479|NCT00001325|Drug|18 FDG|
1717480|NCT00001328|Drug|Cytovene (Ganciclovir Sodium)|
1717481|NCT00001328|Device|G1TKSVNa.53 Producer Cell Line|
1717482|NCT00001332|Procedure|CHPP with cisplatin|
1717483|NCT00001333|Drug|topotecan|
1717484|NCT00001335|Drug|ADR-529|
1717485|NCT00001335|Drug|Topotecan|
1717486|NCT00001335|Drug|G-CSF|
1717489|NCT00001338|Drug|FLAC chemotherapy with GM-CSF|
1717490|NCT00001339|Drug|doxorubicin, vincristine, and etoposide with mitotane|
1717491|NCT00001341|Drug|ZD1694 (TOMUDEX)|
1717492|NCT00001343|Drug|Humatrope|
1717493|NCT00001343|Drug|Oxandrolone|
1717494|NCT00001344|Drug|dextromethorphan|
1717495|NCT00001353|Drug|Genetically Marked Syngeneic T Lymphocytes|
1717496|NCT00001354|Drug|Interleukin-2/Zidovudine (AZT)|
1717497|NCT00001357|Drug|Interleukin-2|
1717498|NCT00001359|Drug|Penicillin or Placebo|
1717499|NCT00001365|Drug|dextromethorphan|
1717500|NCT00001368|Procedure|cytokine and leukocyte activation profile|
1717501|NCT00001378|Drug|fenretinide|
1717504|NCT00001381|Drug|suramin|
1717505|NCT00001382|Biological|PROSTVAC|
1717506|NCT00001383|Drug|PSC 833|
1717507|NCT00001383|Drug|paclitaxel|
1717508|NCT00001384|Drug|Adriamycin|
1717509|NCT00001384|Drug|cyclophosphamide|
1717510|NCT00001384|Drug|G-CSF|
1717511|NCT00001384|Drug|paclitaxel|
1717512|NCT00001386|Drug|PCLUS 3-18 MN|
1717513|NCT00001386|Drug|PCLUS 6.1 MN|
1717514|NCT00001387|Drug|paclitaxel|
1717515|NCT00001396|Device|Paragon Pacemaker|
1717516|NCT00001398|Drug|Recombinant Methionyl Human Stem Cell Factor (r-metHuSCF)|
1717517|NCT00001399|Drug|Transduced CD34+ Cells|
1717518|NCT00001402|Device|PET scan|
1717519|NCT00001407|Drug|Interferon Gamma|
1717520|NCT00001409|Drug|Interleukin-2|
1717521|NCT00001410|Drug|Lysodase|
1717522|NCT00001416|Drug|CEREDASE™|
1717523|NCT00001421|Drug|methimazole|
1717524|NCT00001422|Drug|fludarabine|
1717525|NCT00001426|Drug|Cyclophosphamide|
1717526|NCT00001426|Drug|Paclitaxel|
1717527|NCT00001426|Drug|Cisplatin|
1717528|NCT00001426|Drug|G-CSF|
1717529|NCT00001427|Drug|9-aminocamptothecin|
1717530|NCT00001428|Drug|5-fluorouracil|
1717531|NCT00001430|Procedure|PBSC|
1717532|NCT00001430|Drug|IL-2|
1717533|NCT00001430|Drug|EPOCH II|
1717534|NCT00001431|Drug|gemcitabine|
1717535|NCT00001436|Drug|OncoLAR® (Registered Trademark)|
1717536|NCT00001436|Drug|tamoxifen|
1717537|NCT00001437|Drug|pentoxifylline|
1717538|NCT00001438|Drug|all-trans-retinoic acid with IFN-alpha2a|
1717539|NCT00001439|Biological|gp100 human melanoma peptide|
1717540|NCT00001440|Procedure|Autologous T cells|
1717541|NCT00001440|Drug|Interleukin-2|
1717542|NCT00001442|Drug|paclitaxel concurrent with radiation therapy|
1717543|NCT00001443|Drug|indinavir (MK-0639)|
1717544|NCT00001444|Drug|7-hydroxystaurosporine (UCN-01)|
1717545|NCT00001445|Biological|HIV-1 Immunogen|
1717546|NCT00001446|Drug|thalidomide|
1717547|NCT00001449|Drug|gemcitabine|
1717548|NCT00001449|Drug|fluorodeoxyuridine|
1717549|NCT00001449|Drug|leucovorin|
1717550|NCT00001450|Drug|paclitaxel|
1717551|NCT00001450|Drug|cisplatin|
1717552|NCT00001457|Drug|Lamivudine|
1717553|NCT00001460|Behavioral|inpatient evaluation and management|
1717555|NCT00001474|Drug|Interleukin-2|
1717556|NCT00001475|Drug|IL-2 plus Anti-TNF or Thalidomide|
1717557|NCT00001476|Drug|Gene Therapy Method for CGD|
1717558|NCT00001476|Device|Isolex 300i Magnetic Cell Selector|
1717559|NCT00001482|Drug|Lamotrigine (Lamictal® (Registered Trademark)|
1717560|NCT00001482|Drug|Gabapentin (Neurontin® (Registered Trademark))|
1717561|NCT00001483|Drug|buproprion (Wellbutrin)|
1717562|NCT00001483|Drug|sertraline (Zoloft)|
1717563|NCT00001483|Drug|venlafaxine (Effexor)|
1717564|NCT00002104|Drug|Thalidomide|
1717565|NCT00002105|Drug|Doxorubicin hydrochloride (liposomal)|
1717566|NCT00002105|Drug|Bleomycin sulfate|
1717567|NCT00002105|Drug|Vincristine sulfate|
1717568|NCT00002106|Drug|Ranitidine hydrochloride|
1717569|NCT00002107|Drug|Aldesleukin|
1717570|NCT00002108|Drug|Lamivudine|
1717571|NCT00002108|Drug|Zidovudine|
1717572|NCT00002109|Drug|Thymopentin|
1717573|NCT00002109|Drug|Stavudine|
1717574|NCT00002109|Drug|Zidovudine|
1717575|NCT00002109|Drug|Zalcitabine|
1717576|NCT00002109|Drug|Didanosine|
1717577|NCT00002110|Drug|Cysteamine|
1717578|NCT00002110|Drug|Zidovudine|
1717579|NCT00002111|Drug|Saquinavir|
1717580|NCT00002112|Drug|Nystatin|
1717581|NCT00002112|Drug|Fluconazole|
1717582|NCT00002113|Drug|Flucytosine|
1717583|NCT00002113|Drug|Fluconazole|
1717584|NCT00002114|Drug|Procysteine|
1717585|NCT00002115|Drug|Adefovir|
1717586|NCT00002116|Drug|Cidofovir|
1717587|NCT00002117|Drug|Zidovudine|
1717588|NCT00002117|Drug|Zalcitabine|
1717589|NCT00002118|Drug|Zalcitabine|
1717590|NCT00002119|Drug|WF10|
1717591|NCT00002120|Drug|Trimetrexate glucuronate|
1717592|NCT00002120|Drug|Trimethoprim|
1717593|NCT00002120|Drug|Sulfamethoxazole|
1717594|NCT00002120|Drug|Dapsone|
1717595|NCT00002120|Drug|Leucovorin calcium|
1717596|NCT00002121|Drug|Diethylhomospermine|
1717597|NCT00002122|Drug|Azithromycin|
1717598|NCT00002122|Drug|Rifabutin|
1717599|NCT00002122|Drug|Fluconazole|
1717600|NCT00002123|Drug|Delavirdine mesylate|
1717601|NCT00002123|Drug|Didanosine|
1717602|NCT00002124|Drug|Delavirdine mesylate|
1717603|NCT00002124|Drug|Lamivudine|
1717604|NCT00002124|Drug|Zidovudine|
1717605|NCT00002125|Drug|Foscarnet sodium|
1717606|NCT00002126|Drug|Filgrastim|
1717607|NCT00002127|Drug|Thalidomide|
1717608|NCT00002128|Drug|Adefovir dipivoxil|
1717609|NCT00002129|Drug|Vesnarinone|
1717610|NCT00002188|Drug|Alitretinoin|
1717611|NCT00002189|Drug|Paclitaxel|
1717612|NCT00002190|Drug|Saquinavir|
1717613|NCT00002190|Drug|Lamivudine|
1717617|NCT00002192|Drug|Ethambutol hydrochloride|
1717618|NCT00002192|Drug|Clarithromycin|
1717619|NCT00002192|Drug|Azithromycin|
1717620|NCT00002193|Drug|Amprenavir|
1717621|NCT00002194|Drug|Erythromycin|
1717622|NCT00002194|Drug|Nevirapine|
1717623|NCT00002194|Drug|Clarithromycin|
1717624|NCT00002195|Drug|Amprenavir|
1717625|NCT00002195|Drug|Lamivudine|
1717626|NCT00002195|Drug|Zidovudine|
1717627|NCT00002196|Drug|CI-1012|
1717628|NCT00002197|Drug|Abacavir sulfate|
1717629|NCT00002198|Drug|Abacavir sulfate|
1717630|NCT00002199|Drug|Indinavir sulfate|
1717631|NCT00002199|Drug|Lamivudine/Zidovudine|
1717632|NCT00002199|Drug|Abacavir sulfate|
1717633|NCT00002200|Drug|Abacavir sulfate|
1717634|NCT00002201|Drug|Ritonavir|
1717635|NCT00002201|Drug|Nelfinavir mesylate|
1717636|NCT00002202|Drug|Indinavir sulfate|
1717637|NCT00002202|Drug|Amprenavir|
1717638|NCT00002203|Drug|Lamivudine/Zidovudine|
1717639|NCT00002203|Drug|Lamivudine|
1717640|NCT00002203|Drug|Zidovudine|
1717641|NCT00002204|Biological|HIV p24/MF59 Vaccine|
1717642|NCT00002205|Drug|Abacavir sulfate|
1717643|NCT00002205|Drug|Amprenavir|
1717644|NCT00002206|Drug|Adefovir dipivoxil|
1717645|NCT00002207|Drug|Stavudine|
1717646|NCT00002207|Drug|Didanosine|
1717647|NCT00002208|Drug|Indinavir sulfate|
1717648|NCT00002208|Drug|Lamivudine|
1717649|NCT00002208|Drug|Stavudine|
1717650|NCT00002208|Drug|Zidovudine|
1717651|NCT00002209|Drug|CPI-1189|
1717652|NCT00002210|Drug|Delavirdine mesylate|
1717653|NCT00002211|Drug|Nelfinavir mesylate|
1717654|NCT00002211|Drug|Delavirdine mesylate|
1717655|NCT00002211|Drug|Stavudine|
1717656|NCT00002211|Drug|Didanosine|
1717657|NCT00002212|Drug|Bexarotene|
1717658|NCT00002213|Drug|Abacavir sulfate|
1717659|NCT00002213|Drug|Amprenavir|
1717660|NCT00002213|Drug|Efavirenz|
1717661|NCT00002214|Drug|Capravirine|
1717662|NCT00002215|Drug|Emivirine|
1717663|NCT00002215|Drug|Nelfinavir mesylate|
1717664|NCT00002216|Drug|Lamivudine/Zidovudine|
1717665|NCT00002216|Drug|Abacavir sulfate|
1717666|NCT00002216|Drug|Amprenavir|
1717667|NCT00002216|Drug|Nelfinavir mesylate|
1717668|NCT00002217|Drug|Lamivudine/Zidovudine|
1717669|NCT00002217|Drug|Abacavir sulfate|
1717670|NCT00002217|Drug|Amprenavir|
1717671|NCT00002218|Drug|CI-1012|
1717672|NCT00002219|Drug|Nelfinavir mesylate|
1717673|NCT00002219|Drug|Levocarnitine|
1717674|NCT00002219|Drug|Adefovir dipivoxil|
1717675|NCT00002220|Drug|Indinavir sulfate|
1717676|NCT00002220|Drug|Efavirenz|
1717677|NCT00002220|Drug|Levocarnitine|
1717678|NCT00002220|Drug|Adefovir dipivoxil|
1717679|NCT00002221|Drug|Peripheral blood stem cells|
1717680|NCT00002222|Drug|Valganciclovir|
1717681|NCT00002223|Drug|Indinavir sulfate|
1717682|NCT00002223|Drug|Ritonavir|
1717683|NCT00002224|Drug|Nelfinavir mesylate|
1717684|NCT00002224|Drug|Stavudine|
1717685|NCT00002224|Drug|Didanosine|
1717686|NCT00002225|Drug|Efavirenz|
1717687|NCT00002225|Drug|Stavudine|
1717688|NCT00002225|Drug|Didanosine|
1717689|NCT00002226|Drug|SU5416|
1717690|NCT00002227|Drug|Efavirenz|
1717691|NCT00002227|Drug|Lamivudine|
1717692|NCT00002227|Drug|Stavudine|
1717693|NCT00002228|Drug|Enfuvirtide|
1717694|NCT00002229|Drug|Saquinavir|
1717695|NCT00002230|Drug|Hydroxyurea|
1717696|NCT00002230|Drug|Efavirenz|
1717697|NCT00002230|Drug|Stavudine|
1717698|NCT00002230|Drug|Didanosine|
1717699|NCT00002231|Biological|APL 400-003|
1717700|NCT00002232|Biological|APL 400-003|
1717701|NCT00002233|Drug|Indinavir sulfate|
1717702|NCT00002233|Drug|Abacavir sulfate|
1717703|NCT00002233|Drug|Amprenavir|
1717704|NCT00002233|Drug|Lamivudine|
1717705|NCT00002234|Drug|Efavirenz|
1717706|NCT00002234|Drug|Adefovir dipivoxil|
1717707|NCT00002234|Drug|Lamivudine|
1717708|NCT00002234|Drug|Didanosine|
1717709|NCT00002235|Drug|Indinavir sulfate|
1717710|NCT00002235|Drug|Nelfinavir mesylate|
1717711|NCT00002235|Drug|Efavirenz|
1717712|NCT00002236|Drug|Indinavir sulfate|
1717713|NCT00002236|Drug|Delavirdine mesylate|
1717714|NCT00002236|Drug|Zidovudine|
1717715|NCT00002237|Drug|Peldesine|
1717716|NCT00002238|Drug|Interferon beta-1b|
1717717|NCT00002238|Drug|Zidovudine|
1717718|NCT00002239|Drug|Enfuvirtide|
1717719|NCT00002239|Drug|Ritonavir|
1717720|NCT00002239|Drug|Abacavir sulfate|
1717721|NCT00002239|Drug|Amprenavir|
1717722|NCT00002239|Drug|Efavirenz|
1717723|NCT00002240|Drug|Atazanavir|
1717724|NCT00002240|Drug|Nelfinavir mesylate|
1717725|NCT00002240|Drug|Stavudine|
1717726|NCT00002240|Drug|Didanosine|
1717727|NCT00002241|Drug|Indinavir sulfate|
1717728|NCT00002241|Drug|Ritonavir|
1717729|NCT00002241|Drug|Lamivudine|
1717730|NCT00002241|Drug|Stavudine|
1717731|NCT00002243|Drug|Calanolide A|
1717732|NCT00002244|Drug|WF10|
1717733|NCT00002245|Drug|Abacavir sulfate|
1717734|NCT00002245|Drug|Amprenavir|
1717735|NCT00002245|Drug|Lamivudine|
1717736|NCT00002246|Drug|Stavudine|
1717737|NCT00002247|Drug|Ganciclovir|
1717738|NCT00002248|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
1717739|NCT00002249|Drug|Levofloxacin|
1717740|NCT00002250|Drug|CD4-IgG|
1717751|NCT00002259|Drug|Mitoxantrone hydrochloride|
1717752|NCT00002260|Drug|Alovudine|
1717753|NCT00002261|Biological|Smallpox Vaccine|
1717754|NCT00002261|Biological|HIVAC-1e|
1717755|NCT00002261|Biological|gp160 Vaccine (MicroGeneSys)|
1717756|NCT00002262|Drug|Tumor Necrosis Factor|
1717757|NCT00002263|Drug|Zidovudine|
1717758|NCT00002263|Drug|Sargramostim|
1717759|NCT00002264|Drug|Cryptosporidium Immune Whey Protein Concentrate (Bovine)|
1717760|NCT00002265|Drug|Zalcitabine|
1717761|NCT00002266|Drug|AS-101|
1717762|NCT00002267|Drug|Rifabutin|
1717763|NCT00002268|Drug|Sevirumab|
1717764|NCT00002269|Drug|Ampligen|
1717765|NCT00002269|Drug|Zidovudine|
1717766|NCT00002270|Drug|Interferon alfa-2b|
1717767|NCT00002270|Drug|Zidovudine|
1717768|NCT00002271|Drug|Alovudine|
1717769|NCT00002272|Drug|Foscarnet sodium|
1717770|NCT00002273|Drug|Ganciclovir|
1717771|NCT00002274|Drug|Didanosine|
1717772|NCT00002275|Drug|Fat Emulsion 2%|
1717773|NCT00002275|Drug|Fat Emulsion 20%|
1717774|NCT00002276|Drug|Ibuprofen|
1717775|NCT00002276|Drug|Zidovudine|
1717776|NCT00002277|Drug|Fluconazole|
1717777|NCT00002277|Drug|Amphotericin B|
1717778|NCT00002278|Drug|Diclazuril|
1717779|NCT00002279|Drug|Zalcitabine|
1717780|NCT00002280|Drug|Didanosine|
1717781|NCT00002281|Drug|Filgrastim|
1717782|NCT00002281|Drug|Epoetin alfa|
1717783|NCT00002281|Drug|Zidovudine|
1717784|NCT00002282|Drug|Clotrimazole|
1717785|NCT00002282|Drug|Fluconazole|
1717786|NCT00002283|Drug|Trimethoprim|
1717787|NCT00002283|Drug|Sulfamethoxazole|
1717788|NCT00002283|Drug|Dapsone|
1717789|NCT00002284|Drug|Zidovudine|
1717790|NCT00002285|Drug|Zidovudine|
1717791|NCT00002286|Drug|Zidovudine|
1717792|NCT00002287|Drug|Zidovudine|
1717793|NCT00002288|Drug|Zidovudine|
1717794|NCT00002289|Drug|Thymopentin|
1717795|NCT00002290|Drug|Zidovudine|
1717796|NCT00002290|Drug|Acyclovir|
1717797|NCT00002291|Drug|Pentamidine isethionate|
1717798|NCT00002292|Drug|Pentamidine isethionate|
1717799|NCT00002293|Drug|Nystatin|
1717800|NCT00002294|Drug|Fluconazole|
1717801|NCT00002295|Drug|Inosine pranobex|
1717802|NCT00002296|Drug|Inosine pranobex|
1717803|NCT00002297|Drug|Inosine pranobex|
1717804|NCT00002298|Drug|Ribavirin|
1717805|NCT00002299|Drug|Interferon beta-1b|
1717806|NCT00002299|Drug|Ganciclovir|
1717807|NCT00002300|Drug|Megestrol acetate|
1717808|NCT00002301|Drug|Foscarnet sodium|
1717809|NCT00002302|Drug|Epoetin alfa|
1717810|NCT00002303|Drug|Epoetin alfa|
1717811|NCT00002304|Drug|Ketoconazole|
1717812|NCT00002304|Drug|Fluconazole|
1717813|NCT00002305|Drug|Flucytosine|
1717814|NCT00002305|Drug|Fluconazole|
1717815|NCT00002305|Drug|Amphotericin B|
1717816|NCT00002306|Drug|Fluconazole|
1717817|NCT00002307|Drug|Stavudine|
1717818|NCT00002307|Drug|Zidovudine|
1717819|NCT00002308|Drug|Stavudine|
1717820|NCT00002309|Drug|Azithromycin|
1717821|NCT00002310|Drug|Crofelemer|
1717822|NCT00002311|Drug|Wobenzym|
1717823|NCT00002312|Drug|Delavirdine mesylate|
1717824|NCT00002312|Drug|Zidovudine|
1717825|NCT00002313|Drug|Nystatin|
1717826|NCT00002313|Drug|Didanosine|
1717827|NCT00002314|Drug|Ro 24-7429|
1717828|NCT00002315|Drug|Netivudine|
1717829|NCT00002315|Drug|Acyclovir|
1717830|NCT00002316|Drug|Lobradimil|
1717831|NCT00002316|Drug|Amphotericin B|
1717832|NCT00002317|Drug|Trimetrexate glucuronate|
1717833|NCT00002317|Drug|Leucovorin calcium|
1717834|NCT00002318|Drug|Doxorubicin hydrochloride (liposomal)|
1717835|NCT00002318|Drug|Bleomycin sulfate|
1717836|NCT00002318|Drug|Vincristine sulfate|
1717837|NCT00002318|Drug|Doxorubicin hydrochloride|
1717838|NCT00002319|Drug|Doxorubicin hydrochloride (liposomal)|
1717839|NCT00002320|Drug|Lamivudine|
1717840|NCT00002320|Drug|Zidovudine|
1717841|NCT00002321|Drug|Aldesleukin|
1717842|NCT00002322|Drug|Atevirdine mesylate|
1717843|NCT00002322|Drug|Zidovudine|
1717844|NCT00002323|Drug|Nevirapine|
1717845|NCT00002323|Drug|Zidovudine|
1717846|NCT00002324|Drug|Nevirapine|
1717847|NCT00002324|Drug|Zidovudine|
1717848|NCT00002325|Drug|Fluconazole|
1717849|NCT00002326|Drug|Adefovir|
1717850|NCT00002326|Drug|Zidovudine|
1717851|NCT00002327|Drug|Cidofovir|
1717852|NCT00002328|Drug|Azithromycin|
1717853|NCT00002329|Drug|Celgosivir hydrochloride|
1717854|NCT00002330|Drug|Ganciclovir|
1717855|NCT00002331|Drug|Ethambutol hydrochloride|
1717856|NCT00002331|Drug|Clarithromycin|
1717857|NCT00002331|Drug|Clofazimine|
1717858|NCT00002332|Drug|Thymopentin|
1717859|NCT00002333|Drug|Saquinavir|
1717860|NCT00002333|Drug|Zalcitabine|
1717861|NCT00002334|Drug|Saquinavir|
1717862|NCT00002334|Drug|Zidovudine|
1717863|NCT00002334|Drug|Zalcitabine|
1717864|NCT00002335|Drug|Emtricitabine|
1717865|NCT00002336|Drug|Clarithromycin|
1717866|NCT00002337|Drug|Vesnarinone|
1717867|NCT00002338|Drug|Raluridine|
1717868|NCT00002339|Drug|Fluconazole|
1717869|NCT00002340|Drug|Atovaquone|
1717870|NCT00002340|Drug|Pentamidine isethionate|
1717871|NCT00002341|Drug|Itraconazole|
1717872|NCT00002342|Drug|Tecogalan sodium|
1717873|NCT00002343|Drug|Ethambutol hydrochloride|
1717887|NCT00002353|Biological|P3C541b Lipopeptide|
1717888|NCT00002354|Drug|Indinavir sulfate|
1717889|NCT00002354|Drug|Stavudine|
1717890|NCT00002355|Drug|Fomivirsen sodium|
1717891|NCT00002356|Drug|Fomivirsen sodium|
1717892|NCT00002357|Drug|HBY 097|
1717893|NCT00002357|Drug|Zidovudine|
1717894|NCT00002358|Drug|Sorivudine|
1717895|NCT00002359|Biological|HIV-1 Immunogen|
1717896|NCT00002360|Drug|Didanosine|
1717897|NCT00002361|Drug|Indinavir sulfate|
1717898|NCT00002361|Drug|Ritonavir|
1717899|NCT00002362|Drug|Abacavir sulfate|
1717900|NCT00002362|Drug|Efavirenz|
1717901|NCT00002362|Drug|Emtricitabine|
1717902|NCT00002362|Drug|Stavudine|
1717903|NCT00002363|Drug|Peptide Construction 3, Synthetic|
1717904|NCT00002364|Drug|Abacavir sulfate|
1717905|NCT00002365|Drug|LXR015-1|
1717906|NCT00002366|Drug|Ritonavir|
1717907|NCT00002367|Drug|Saquinavir|
1717908|NCT00002367|Drug|Lamivudine|
1717909|NCT00002367|Drug|Zidovudine|
1717910|NCT00002368|Drug|Nevirapine|
1717911|NCT00002368|Drug|Lamivudine|
1717912|NCT00002369|Drug|Indinavir sulfate|
1717913|NCT00002369|Drug|Lamivudine|
1717914|NCT00002369|Drug|Stavudine|
1717915|NCT00002369|Drug|Zidovudine|
1717916|NCT00002370|Drug|Itraconazole|
1717917|NCT00002371|Drug|Indinavir sulfate|
1717918|NCT00002371|Drug|Lamivudine|
1717919|NCT00002371|Drug|Stavudine|
1717920|NCT00002371|Drug|Zidovudine|
1717921|NCT00002372|Drug|Indinavir sulfate|
1717922|NCT00002372|Drug|Amprenavir|
1717923|NCT00002372|Drug|Nelfinavir mesylate|
1717924|NCT00002372|Drug|Saquinavir|
1717925|NCT00002373|Drug|Maribavir|
1717926|NCT00002374|Drug|Ritonavir|
1717927|NCT00002374|Drug|Nelfinavir mesylate|
1717928|NCT00002374|Drug|Saquinavir|
1717929|NCT00002374|Drug|Stavudine|
1717930|NCT00002375|Drug|Indinavir sulfate|
1717931|NCT00002375|Drug|Nelfinavir mesylate|
1717932|NCT00002376|Drug|Indinavir sulfate|
1717933|NCT00002376|Drug|Lamivudine|
1717934|NCT00002376|Drug|Stavudine|
1717935|NCT00002376|Drug|Zidovudine|
1717936|NCT00002376|Drug|Didanosine|
1717937|NCT00002377|Drug|Valganciclovir|
1717938|NCT00002377|Drug|Ganciclovir|
1717939|NCT00002378|Drug|Ritonavir|
1717940|NCT00002378|Drug|Nelfinavir mesylate|
1717941|NCT00002378|Drug|Saquinavir|
1717942|NCT00002378|Drug|Delavirdine mesylate|
1717943|NCT00002378|Drug|Lamivudine|
1717944|NCT00002378|Drug|Stavudine|
1717945|NCT00002378|Drug|Zidovudine|
1717946|NCT00001197|Drug|Hydroxyurea|
1717947|NCT00001202|Drug|Spironolactone|
1717948|NCT00001202|Drug|Testolactone|
1717949|NCT00001202|Drug|Deslorelin|
1717951|NCT00001209|Drug|vincristine, adriamycin and cytoxan, alternating with ifosfamide VP-16|
1717952|NCT00001212|Drug|prednisone|
1717953|NCT00001212|Drug|cyclophosphamide|
1717954|NCT00001212|Drug|cyclosporin A|
1717955|NCT00001213|Drug|Cysteamine|
1717956|NCT00001217|Drug|pre-surgical chemotherapy|
1717957|NCT00001221|Drug|Growth Hormone (Humatrope)|
1717958|NCT00001228|Drug|Interferon|
1717959|NCT00001234|Genetic|human glucocerebrosidase cDNA|
1717960|NCT00001237|Drug|granulocyte-macrophage colony stimulating factor (GM-CSF)|
1717961|NCT00001239|Drug|FLAC with GM-CSF|
1717962|NCT00001249|Drug|Yttrium-90 radiolabeled anti-Tac antibody|
1717963|NCT00001250|Drug|preoperative dose intense chemotherapy (FLAC/G-CSF)|
1717964|NCT00001251|Drug|Mafosfamide|
1717965|NCT00001253|Behavioral|cognitive tests and scales|
1717966|NCT00001255|Drug|ADA PBSC|
1717967|NCT00001255|Drug|ADA Umbilical Cord Blood Cells|
1717968|NCT00001255|Drug|Transduced Lymphocytes|
1717969|NCT00001761|Drug|Interleukin-10|
1717970|NCT00001763|Drug|Interleukin-12|
1717971|NCT00001764|Drug|Mycophenolate Mofetil|
1717972|NCT00001765|Device|Nexell Isolex with T-cell Depletion|
1717973|NCT00001765|Device|Baxter isolex 300i|
1717974|NCT00001766|Drug|Amprenavir, Efavirenz, Abacavir, Nelfinavir, Ritonavir|
1717975|NCT00001768|Drug|Intravenous immunoglobulin|
1717976|NCT00001776|Device|Cadwell Rapid Rate Magnetic Stimulator|
1717977|NCT00001777|Drug|Sertraline|
1717978|NCT00001781|Drug|CGP 77116|
1717979|NCT00001783|Drug|0-15 Water|
1717980|NCT00001784|Drug|Mexiletine|
1717981|NCT00001785|Drug|Recombinant human interferon beta-1a|
1717982|NCT00001789|Drug|BG9588|
1717983|NCT00001790|Drug|FK463|
1717984|NCT00001797|Drug|Recombinant human interleukin-10|
1717985|NCT00001805|Drug|Rituximab|
1717988|NCT00001810|Drug|Voriconazole|
1717989|NCT00001812|Drug|Nystatin|
1717990|NCT00001818|Drug|Hydroxyurea|
1717991|NCT00001827|Biological|aldesleukin|
1717992|NCT00001827|Biological|incomplete Freund's adjuvant|
1717993|NCT00001827|Biological|p53 peptide vaccine|
1717994|NCT00001827|Biological|sargramostim|
1717995|NCT00001827|Biological|therapeutic autologous dendritic cells|
1717996|NCT00001827|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1717997|NCT00001830|Drug|Th2 cells in allo HSCTT|
1717998|NCT00001830|Drug|Th2 Cells|
1718086|NCT00002400|Drug|Delavirdine mesylate|
1718087|NCT00002400|Drug|Lamivudine|
1718088|NCT00002400|Drug|Zidovudine|
1718089|NCT00002401|Drug|Indinavir sulfate|
1717999|NCT00001832|Drug|gp100:209-217 (210M)|"gp100 = gp100:209‑217(210M) peptide - 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus gp100:209‑217(210M) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
MART-1 = MART‑1:26‑35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART‑1:26‑35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections."
1718000|NCT00001832|Drug|Montanide ISA-51|MART-1 = MART‑1:26‑35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART‑1:26‑35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
1718001|NCT00001832|Drug|IL-2|"125,000 IU/kg dose intravenous for 5 days for 6 weeks with 2 days rest per week.
720,000 IU/kg intravenous every 8 hours for a maximum of 12 doses."
1718002|NCT00001832|Drug|MART-1:26-35(27L)|MART-1 = MART‑1:26‑35(27L) peptide- 1 mg in IFA SQ (in the subcutaneous tissue of each thigh) on the morning of the cell infusion, plus MART‑1:26‑35(27L) peptide, 1 mg, in IFA injected into the subcutaneous tissue in two equal volumes, 1.0 mL for each injection, within 2cm of each other, in the thigh daily for five days starting on the morning of the cell infusion and then weekly for 3 more injections.
1718003|NCT00001832|Biological|Abl cells|Abl cells IV = Lymphocytes 10^9‑10^11 IV over 30 minutes on day 0, repeated in 14 to 21 days Abl cells IA = Lymphocytes 10^9‑10^11 IA over 30 minutes on day 0, repeated in 14 to 21 days
1718004|NCT00001832|Drug|Fludarabine|5x25 mg/m^2 intravenous
1718005|NCT00001832|Drug|Cyclophosphamide|2x30 mg/kg, 2x60 mg/kg intravenous
1718006|NCT00001832|Biological|GCSF (Growth colony stimulating factor)|Beginning on day 1 or 2, GCSF will be administered subcutaneously at a dose of 5mcg/kg/day (not to exceed 300 mcg/day. Filgrastim administration will continue daily until neutrophil count > 1.0 x10^9/L x 3 days or > 5.0 x10^9/L.
1718007|NCT00001832|Procedure|Apheresis|
1718008|NCT00001835|Drug|Oxaliplatin|
1718009|NCT00001839|Drug|Antithymocyte globulin|
1718010|NCT00001839|Drug|Cyclosporine|
1718011|NCT00001842|Drug|Granulocyte colony-stimulating factor|
1718012|NCT00001842|Drug|Dexamethasone|
1718013|NCT00001848|Drug|Raloxifene|
1718017|NCT00001854|Drug|Ribavirin|
1718018|NCT00001857|Drug|BG9588|
1718019|NCT00001860|Drug|Sandostatin LAR Depot versus transsphenoidal surgery|
1718020|NCT00001862|Drug|Enbrel|
1718021|NCT00001863|Drug|Leflunomide|
1718022|NCT00001864|Drug|Atropine|
1718023|NCT00001864|Device|Patch|
1718024|NCT00001865|Drug|Daclizumab|
1718025|NCT00001866|Procedure|horizontal muscles of the eye will be cut and then reattached in the same position|
1718026|NCT00001870|Drug|Acetylcholine|
1718027|NCT00001873|Device|Isolex 300i plus MoAbs|
1718028|NCT00001877|Drug|Pentoxifylline|
1718029|NCT00001886|Procedure|Real time 3-dimensional stress echocardiography|
1718030|NCT00001889|Procedure|Myocardial contrast echocardiography|
1718031|NCT00001889|Procedure|Stress echocardiography with dobutamine|
1718032|NCT00001890|Drug|Estrogen therapy|
1718033|NCT00001891|Procedure|Myocardial contrast echocardiography|
1718034|NCT00001891|Procedure|Dobutamine echocardiography|
1718035|NCT00001893|Drug|TNFR:Fc|
1718036|NCT00001894|Procedure|pacemaker implantation|
1718037|NCT00001894|Procedure|percutaneous transluminal septal ablation (PTSA)|
1718038|NCT00001895|Drug|FDG|
1718039|NCT00001895|Drug|NH(3)|
1718040|NCT00002379|Drug|Indinavir sulfate|
1718041|NCT00002379|Drug|Levocarnitine|
1718042|NCT00002379|Drug|Adefovir dipivoxil|
1718043|NCT00002379|Drug|Lamivudine|
1718044|NCT00002379|Drug|Stavudine|
1718045|NCT00002379|Drug|Zidovudine|
1718046|NCT00002380|Drug|Nelfinavir mesylate|
1718047|NCT00002380|Drug|Saquinavir|
1718048|NCT00002381|Drug|Nelfinavir mesylate|
1718049|NCT00002381|Drug|Nevirapine|
1718050|NCT00002381|Drug|Stavudine|
1718051|NCT00002382|Drug|Saquinavir|
1718052|NCT00002383|Drug|Saquinavir|
1718053|NCT00002384|Drug|Cidofovir|
1718054|NCT00002385|Drug|Fozivudine tidoxil|
1718055|NCT00002386|Drug|Indinavir sulfate|
1718056|NCT00002386|Drug|Lamivudine|
1718057|NCT00002386|Drug|Stavudine|
1718058|NCT00002386|Drug|Zidovudine|
1718059|NCT00002386|Drug|Zalcitabine|
1718060|NCT00002386|Drug|Didanosine|
1718061|NCT00002387|Drug|Indinavir sulfate|
1718062|NCT00002387|Drug|Efavirenz|
1718063|NCT00002388|Drug|Abacavir sulfate|
1718064|NCT00002389|Drug|Abacavir sulfate|
1718065|NCT00002389|Drug|Lamivudine|
1718066|NCT00002389|Drug|Zidovudine|
1718067|NCT00002390|Drug|Abacavir sulfate|
1718068|NCT00002391|Drug|Abacavir sulfate|
1718069|NCT00002391|Drug|Lamivudine|
1718070|NCT00002391|Drug|Zidovudine|
1718071|NCT00002392|Drug|Thalidomide|
1718072|NCT00002393|Drug|Indinavir sulfate|
1718073|NCT00002393|Drug|Efavirenz|
1718074|NCT00002394|Drug|Terbinafine hydrochloride|
1718075|NCT00002395|Drug|Topotecan|
1718076|NCT00002396|Drug|Tenofovir disoproxil fumarate|
1718077|NCT00002397|Drug|Nelfinavir mesylate|
1718078|NCT00002397|Drug|Saquinavir|
1718079|NCT00002397|Drug|Lamivudine|
1718080|NCT00002397|Drug|Stavudine|
1718090|NCT00002401|Drug|Delavirdine mesylate|
1718091|NCT00002401|Drug|Lamivudine|
1718092|NCT00002401|Drug|Zidovudine|
1718093|NCT00002402|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
1718094|NCT00002402|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
1718095|NCT00002402|Biological|Aluminum hydroxide|
1718096|NCT00002403|Drug|Zintevir|
1718097|NCT00002404|Drug|Valacyclovir hydrochloride|
1718098|NCT00002412|Drug|Emivirine|
1718099|NCT00002412|Drug|Hydroxyurea|
1718100|NCT00002412|Drug|Stavudine|
1718101|NCT00002412|Drug|Didanosine|
1718102|NCT00002413|Drug|Emivirine|
1718103|NCT00002414|Drug|CPI-1189|
1718104|NCT00002415|Drug|Tenofovir disoproxil fumarate|
1718105|NCT00002416|Drug|Emtricitabine|
1718106|NCT00002416|Drug|Lamivudine|
1718107|NCT00002417|Drug|Amprenavir|
1718108|NCT00002418|Drug|Emivirine|
1718109|NCT00002418|Drug|Hydroxyurea|
1718110|NCT00002418|Drug|Nevirapine|
1718111|NCT00002418|Drug|Stavudine|
1718112|NCT00002418|Drug|Didanosine|
1718113|NCT00002419|Drug|Abacavir sulfate|
1718114|NCT00002419|Drug|Amprenavir|
1718115|NCT00002419|Drug|Efavirenz|
1718116|NCT00002419|Drug|Adefovir dipivoxil|
1718117|NCT00002420|Drug|Emivirine|
1718118|NCT00002420|Drug|Hydroxyurea|
1718119|NCT00002420|Drug|Delavirdine mesylate|
1718120|NCT00002420|Drug|Stavudine|
1718121|NCT00002420|Drug|Didanosine|
1718122|NCT00002422|Drug|HE2000|
1718123|NCT00002423|Drug|Indinavir sulfate|
1718124|NCT00002423|Drug|Abacavir sulfate|
1718125|NCT00002423|Drug|Amprenavir|
1718126|NCT00002423|Drug|Nelfinavir mesylate|
1718127|NCT00002423|Drug|Lamivudine|
1718128|NCT00002424|Drug|L-756423|
1718129|NCT00002424|Drug|Indinavir sulfate|
1718130|NCT00002424|Drug|Lamivudine|
1718131|NCT00002424|Drug|Stavudine|
1718132|NCT00002425|Drug|Saquinavir|
1718133|NCT00002426|Drug|Adefovir dipivoxil|
1718134|NCT00002427|Drug|Hydroxyurea|
1718135|NCT00002427|Drug|Stavudine|
1718136|NCT00002427|Drug|Didanosine|
1718137|NCT00002428|Biological|HIV-1 Peptide Vaccine, Microparticulate Monovalent|
1718138|NCT00002428|Biological|rgp120/HIV-1MN Monovalent Octameric V3 Peptide Vaccine|
1718139|NCT00002429|Drug|Lamivudine/Zidovudine|
1718140|NCT00002429|Drug|Nelfinavir mesylate|
1718141|NCT00002429|Drug|Stavudine|
1718142|NCT00002429|Drug|Didanosine|
1718143|NCT00002430|Drug|Indinavir sulfate|
1718144|NCT00002430|Drug|Nelfinavir mesylate|
1718145|NCT00002430|Drug|Lamivudine|
1718146|NCT00002430|Drug|Stavudine|
1718147|NCT00002431|Drug|Chlorhexidine gluconate|
1718148|NCT00002432|Drug|Foscarnet sodium|
1718149|NCT00002433|Drug|Interferon gamma-1b|
1718150|NCT00002434|Drug|Trimetrexate glucuronate|
1718151|NCT00002434|Drug|Leucovorin calcium|
1718152|NCT00002435|Drug|Thymic Humoral Factor|
1718153|NCT00002435|Drug|Zidovudine|
1718154|NCT00002436|Drug|Lamivudine|
1718155|NCT00002436|Drug|Zidovudine|
1718156|NCT00002436|Drug|Zalcitabine|
1718157|NCT00002437|Drug|Cidofovir|
1718158|NCT00002437|Drug|Probenecid|
1718159|NCT00002438|Drug|Itraconazole|
1718160|NCT00002439|Drug|Alitretinoin|
1718161|NCT00002440|Drug|Indinavir sulfate|
1718162|NCT00002440|Drug|Ritonavir|
1718163|NCT00002440|Drug|Abacavir sulfate|
1718164|NCT00002440|Drug|Amprenavir|
1718165|NCT00002440|Drug|Nelfinavir mesylate|
1718166|NCT00002440|Drug|Saquinavir|
1718167|NCT00002441|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
1718168|NCT00002442|Drug|Indinavir sulfate|
1718169|NCT00002442|Drug|Nelfinavir mesylate|
1718170|NCT00002442|Drug|Lamivudine|
1718171|NCT00002442|Drug|Stavudine|
1718172|NCT00002443|Drug|Indinavir sulfate|
1718173|NCT00002443|Drug|Zidovudine|
1718174|NCT00002444|Drug|Nitazoxanide|
1718175|NCT00002445|Drug|IM862|
1718176|NCT00002446|Drug|Posaconazole|
1718177|NCT00002446|Drug|Fluconazole|
1718178|NCT00002447|Drug|Ritonavir|
1718179|NCT00002447|Drug|Efavirenz|
1718180|NCT00002447|Drug|Saquinavir|
1718181|NCT00002448|Drug|Ritonavir|
1718182|NCT00002448|Drug|Efavirenz|
1718183|NCT00002448|Drug|Saquinavir|
1718184|NCT00002449|Drug|Aldesleukin|
1718185|NCT00002450|Drug|Tenofovir disoproxil fumarate|
1718186|NCT00002451|Drug|Indinavir sulfate|
1718187|NCT00002451|Drug|Ritonavir|
1718188|NCT00002451|Drug|Lamivudine|
1718189|NCT00002451|Drug|Stavudine|
1718190|NCT00002452|Drug|L-756423|
1718191|NCT00002452|Drug|Indinavir sulfate|
1718192|NCT00002453|Drug|Tenofovir disoproxil fumarate|
1718194|NCT00002455|Biological|Corynebacterium granulosum P40|
1718195|NCT00002455|Procedure|adjuvant therapy|
1718196|NCT00002456|Drug|cyclosporine|
1718197|NCT00002456|Drug|methotrexate|
1718198|NCT00002456|Procedure|allogeneic bone marrow transplantation|
1718199|NCT00002458|Biological|monoclonal antibody 3F8|
1718200|NCT00002459|Radiation|radiation therapy|
1718201|NCT00002460|Drug|goserelin acetate|
1718202|NCT00002460|Drug|tamoxifen citrate|
1718203|NCT00002460|Procedure|ablative endocrine surgery|
1718204|NCT00002460|Procedure|oophorectomy|
1718205|NCT00002461|Biological|filgrastim|
1718206|NCT00002461|Biological|sargramostim|
1718207|NCT00002461|Drug|carmustine|
1718208|NCT00002461|Drug|cisplatin|
1718211|NCT00002461|Procedure|autologous bone marrow transplantation|
1718212|NCT00002461|Procedure|in vitro-treated bone marrow transplantation|
1718213|NCT00002461|Procedure|peripheral blood stem cell transplantation|
1718214|NCT00002461|Radiation|radiation therapy|
1718215|NCT00002462|Biological|bleomycin sulfate|
1718216|NCT00002462|Drug|doxorubicin hydrochloride|
1718217|NCT00002462|Drug|mechlorethamine hydrochloride|
1718218|NCT00002462|Drug|prednisone|
1718219|NCT00002462|Drug|procarbazine hydrochloride|
1718220|NCT00002462|Drug|vinblastine sulfate|
1718221|NCT00002462|Drug|vincristine sulfate|
1718222|NCT00002462|Radiation|low-LET cobalt-60 gamma ray therapy|
1718223|NCT00002462|Radiation|low-LET photon therapy|
1718224|NCT00002462|Radiation|radiation therapy|
1718225|NCT00002463|Drug|MOPP Regimen|Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)
1718226|NCT00002463|Drug|Leucovorin Calcium|
1718227|NCT00002463|Drug|Mechlorethamine Hydrochloride|
1718228|NCT00002463|Drug|Methotrexate|
1718229|NCT00002463|Drug|Prednisone|
1718230|NCT00002463|Drug|Procarbazine Hydrochloride|
1718231|NCT00002463|Drug|Vincristine Sulfate|
1718232|NCT00002463|Procedure|Conventional Surgery|
1718233|NCT00002465|Drug|megestrol acetate|
1718234|NCT00002466|Drug|cyclophosphamide|
1718235|NCT00002466|Drug|doxorubicin hydrochloride|
1718236|NCT00002466|Drug|etoposide|
1718237|NCT00002466|Drug|ifosfamide|
1718238|NCT00002466|Drug|vincristine sulfate|
1718239|NCT00002466|Procedure|conventional surgery|
1718240|NCT00002466|Radiation|radiation therapy|
1718241|NCT00002470|Biological|recombinant interferon alfa|
1718242|NCT00002470|Drug|fluorouracil|
1718243|NCT00002471|Drug|asparaginase|
1718244|NCT00002471|Drug|cyclophosphamide|
1718245|NCT00002471|Drug|cytarabine|
1718246|NCT00002471|Drug|daunorubicin hydrochloride|
1718247|NCT00002471|Drug|dexamethasone|
1718248|NCT00002471|Drug|etoposide|
1718249|NCT00002471|Drug|leucovorin calcium|
1718250|NCT00002471|Drug|methotrexate|
1718251|NCT00002471|Drug|methylprednisolone|
1718252|NCT00002471|Drug|therapeutic hydrocortisone|
1718253|NCT00002471|Drug|thiotepa|
1718254|NCT00002471|Drug|vincristine sulfate|
1718255|NCT00002472|Drug|cisplatin|
1718256|NCT00002472|Drug|etoposide|
1718257|NCT00002472|Procedure|conventional surgery|
1718258|NCT00002472|Procedure|neoadjuvant therapy|
1718259|NCT00002472|Radiation|radiation therapy|
1718260|NCT00002473|Procedure|conventional surgery|
1718261|NCT00002474|Drug|carboplatin|
1718262|NCT00002474|Drug|cyclophosphamide|
1718263|NCT00002474|Drug|mitoxantrone hydrochloride|
1718264|NCT00002474|Procedure|autologous bone marrow transplantation|
1718265|NCT00002474|Procedure|bone marrow ablation with stem cell support|
1718266|NCT00002475|Biological|allogeneic tumor cell vaccine|
1718267|NCT00002475|Biological|autologous tumor cell vaccine|
1718268|NCT00002475|Biological|recombinant interferon alfa|
1718269|NCT00002475|Biological|recombinant interferon gamma|
1718270|NCT00002475|Biological|sargramostim|
1718271|NCT00002475|Drug|cyclophosphamide|
1718272|NCT00002476|Biological|bleomycin sulfate|
1718273|NCT00002476|Drug|fluorouracil|
1718274|NCT00002476|Drug|leucovorin calcium|
1718275|NCT00002476|Drug|methotrexate|
1718276|NCT00002476|Drug|vincristine sulfate|
1718277|NCT00002476|Radiation|low-LET cobalt-60 gamma ray therapy|
1718278|NCT00002476|Radiation|low-LET photon therapy|
1718279|NCT00002476|Radiation|radiation therapy|
1718280|NCT00002477|Drug|carboplatin|
1718281|NCT00002477|Drug|cisplatin|
1718282|NCT00002477|Drug|cyclophosphamide|
1718283|NCT00002477|Drug|doxorubicin hydrochloride|
1718284|NCT00002478|Drug|etoposide|
1718285|NCT00002479|Drug|tretinoin|
1718286|NCT00002480|Radiation|radiation therapy|
1718287|NCT00002481|Drug|cisplatin|
1718288|NCT00002481|Drug|cyclophosphamide|
1718289|NCT00002481|Drug|cytarabine|
1718290|NCT00002481|Drug|dexamethasone|
1718291|NCT00002481|Drug|etoposide|
1718292|NCT00002481|Procedure|autologous bone marrow transplantation|
1718293|NCT00002481|Radiation|radiation therapy|
1718294|NCT00002482|Biological|antibody therapy|
1718295|NCT00002482|Biological|biological therapy|
1718296|NCT00002482|Biological|muromonab-CD3|
1718297|NCT00002482|Drug|cyclophosphamide|
1718298|NCT00002484|Radiation|radiation therapy|
1718299|NCT00002485|Procedure|psychosocial assessment and care|
1718300|NCT00002487|Drug|dipyridamole|
1718301|NCT00002487|Drug|methotrexate|
1718302|NCT00002488|Drug|cisplatin|
1718303|NCT00002488|Drug|cyclophosphamide|
1718304|NCT00002488|Drug|etoposide|
1718305|NCT00002489|Biological|dactinomycin|
1718306|NCT00002489|Biological|filgrastim|
1718307|NCT00002489|Drug|carboplatin|
1718308|NCT00002489|Drug|cyclophosphamide|
1718309|NCT00002489|Drug|doxorubicin hydrochloride|
1718310|NCT00002489|Drug|etoposide|
1718311|NCT00002489|Drug|leucovorin calcium|
1718312|NCT00002489|Drug|methotrexate|
1718313|NCT00002489|Drug|vincristine sulfate|
1718314|NCT00002489|Procedure|conventional surgery|
1718315|NCT00002490|Biological|BCG vaccine|
1718316|NCT00002490|Drug|mitomycin C|
1718317|NCT00002490|Radiation|radiation therapy|
1718318|NCT00002492|Drug|cisplatin|
1718319|NCT00002492|Drug|doxorubicin hydrochloride|
1718320|NCT00002492|Drug|isolated limb perfusion|
1718321|NCT00002492|Procedure|conventional surgery|
1718322|NCT00002492|Radiation|brachytherapy|
1718323|NCT00002492|Radiation|radiation therapy|
1718324|NCT00002493|Drug|cisplatin|
1718325|NCT00002493|Drug|doxorubicin hydrochloride|
1718326|NCT00002493|Radiation|low-LET photon therapy|
1718327|NCT00002494|Drug|cyclophosphamide|
1718328|NCT00002494|Drug|cytarabine|
1718329|NCT00002494|Drug|dexamethasone|
1718330|NCT00002494|Drug|doxorubicin hydrochloride|
1718331|NCT00002494|Drug|etoposide|
1718332|NCT00002494|Drug|ifosfamide|
1718333|NCT00002494|Drug|leucovorin calcium|
1718334|NCT00002494|Drug|mesna|
1718335|NCT00002494|Drug|methotrexate|
1718336|NCT00002494|Drug|prednisone|
1718337|NCT00002494|Drug|therapeutic hydrocortisone|
1718338|NCT00002494|Drug|vincristine sulfate|
1718339|NCT00002494|Radiation|low-LET cobalt-60 gamma ray therapy|
1718340|NCT00002494|Radiation|low-LET photon therapy|
1718341|NCT00002495|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15
1718342|NCT00002495|Drug|vinblastine|6 mg/m^2 on days 1 and 15
1718343|NCT00002495|Radiation|standard subtotal nodal irradiation|3600-4000 cGy delivered over 20 fractions
1718344|NCT00002496|Drug|chemotherapy|
1718345|NCT00002496|Drug|cisplatin|
1718346|NCT00002496|Drug|fluorouracil|
1718347|NCT00002496|Procedure|conventional surgery|
1718348|NCT00002496|Radiation|low-LET cobalt-60 gamma ray therapy|
1718349|NCT00002496|Radiation|low-LET electron therapy|
1718350|NCT00002496|Radiation|low-LET photon therapy|
1718351|NCT00002498|Drug|CMF regimen|
1718352|NCT00002498|Drug|cyclophosphamide|
1718353|NCT00002498|Drug|fluorouracil|
1718354|NCT00002498|Drug|methotrexate|
1718355|NCT00002498|Drug|mitoxantrone hydrochloride|
1718356|NCT00002499|Drug|asparaginase|
1718357|NCT00002499|Drug|cytarabine|
1718358|NCT00002499|Drug|daunorubicin hydrochloride|
1718359|NCT00002499|Drug|dexamethasone|
1718360|NCT00002499|Drug|methotrexate|
1718361|NCT00002499|Drug|prednisone|
1718362|NCT00002499|Drug|vincristine sulfate|
1718363|NCT00002499|Radiation|radiation therapy|
1718364|NCT00002501|Biological|filgrastim|
1718365|NCT00002501|Drug|cyclophosphamide|
1718366|NCT00002502|Drug|busulfan|
1718367|NCT00002502|Drug|cyclophosphamide|
1718368|NCT00002502|Drug|cytarabine|
1718369|NCT00002502|Procedure|allogeneic bone marrow transplantation|
1718370|NCT00002503|Radiation|strontium chloride Sr 89|
1718371|NCT00002504|Biological|aldesleukin|
1718372|NCT00002504|Biological|recombinant interferon alfa|
1718373|NCT00002505|Biological|filgrastim|
1718374|NCT00002505|Biological|recombinant interferon gamma|
1718375|NCT00002505|Biological|tumor cell lysate vaccine therapy|
1718376|NCT00002506|Biological|recombinant interferon alfa|
1718377|NCT00002506|Drug|isotretinoin|
1718378|NCT00002507|Drug|mitomycin C|
1718379|NCT00002507|Drug|porfiromycin|
1718380|NCT00002507|Radiation|brachytherapy|
1718381|NCT00002507|Radiation|radiation therapy|
1718382|NCT00002508|Drug|carboplatin|
1718383|NCT00002508|Drug|etoposide|
1718384|NCT00002508|Procedure|autologous bone marrow transplantation|
1718385|NCT00002508|Procedure|peripheral blood stem cell transplantation|
1718386|NCT00002509|Biological|filgrastim|
1718387|NCT00002509|Drug|carboplatin|
1718388|NCT00002509|Drug|cyclophosphamide|
1718389|NCT00002509|Drug|etoposide|
1718390|NCT00002509|Drug|mesna|
1718391|NCT00002509|Procedure|autologous bone marrow transplantation|
1718392|NCT00002509|Procedure|peripheral blood stem cell transplantation|
1718393|NCT00002510|Biological|filgrastim|
1718394|NCT00002510|Drug|cyclophosphamide|
1718395|NCT00002510|Drug|etoposide|
1718396|NCT00002510|Drug|mesna|
1718397|NCT00002510|Procedure|peripheral blood stem cell transplantation|
1718398|NCT00002510|Radiation|radiation therapy|
1718399|NCT00002511|Radiation|low-LET photon therapy|
1718400|NCT00002514|Biological|sargramostim|
1718401|NCT00002514|Drug|asparaginase|
1718402|NCT00002514|Drug|cyclophosphamide|
1718403|NCT00002514|Drug|cytarabine|
1718404|NCT00002514|Drug|daunorubicin hydrochloride|
1718405|NCT00002514|Drug|dexamethasone|
1718406|NCT00002514|Drug|etoposide|
1718407|NCT00002514|Drug|imatinib mesylate|
1718408|NCT00002514|Drug|leucovorin calcium|
1718409|NCT00002514|Drug|mercaptopurine|
1718410|NCT00002514|Drug|methotrexate|
1718411|NCT00002514|Drug|prednisone|
1718412|NCT00002514|Drug|thioguanine|
1718413|NCT00002514|Drug|vincristine sulfate|
1718414|NCT00002514|Procedure|allogeneic bone marrow transplantation|
1718415|NCT00002514|Procedure|autologous bone marrow transplantation|
1718416|NCT00002514|Procedure|peripheral blood stem cell transplantation|
1718417|NCT00002514|Radiation|radiation therapy|
1718418|NCT00002515|Biological|filgrastim|
1718419|NCT00002515|Drug|carboplatin|
1718420|NCT00002515|Drug|thiotepa|
1718421|NCT00002515|Drug|topotecan hydrochloride|
1718422|NCT00002515|Procedure|autologous bone marrow transplantation|
1718423|NCT00002515|Procedure|bone marrow ablation with stem cell support|
1718424|NCT00002515|Procedure|in vitro-treated bone marrow transplantation|
1718425|NCT00002516|Biological|dactinomycin|
1718426|NCT00002516|Drug|cyclophosphamide|
1718427|NCT00002516|Drug|doxorubicin hydrochloride|
1718428|NCT00002516|Drug|etoposide|
1718429|NCT00002516|Drug|ifosfamide|
1718430|NCT00002516|Drug|mesna|
1718431|NCT00002516|Drug|vincristine sulfate|
1718432|NCT00002516|Procedure|conventional surgery|
1718433|NCT00002516|Radiation|low-LET cobalt-60 gamma ray therapy|
1718434|NCT00002516|Radiation|low-LET photon therapy|
1718435|NCT00002517|Drug|cytarabine|
1718436|NCT00002517|Drug|daunorubicin hydrochloride|
1718437|NCT00002517|Drug|dexamethasone|
1718438|NCT00002517|Drug|etoposide|
1718439|NCT00002517|Drug|idarubicin|
1718440|NCT00002517|Drug|mitoxantrone hydrochloride|
1718441|NCT00002517|Drug|thioguanine|
1718442|NCT00002517|Procedure|allogeneic bone marrow transplantation|
1718443|NCT00002517|Radiation|radiation therapy|
1718444|NCT00002519|Drug|chemotherapy|
1718445|NCT00002519|Drug|paclitaxel|
1718446|NCT00002519|Radiation|radiation therapy|
1718447|NCT00002520|Drug|nicotine|
1718448|NCT00002520|Behavioral|Usual Care|
1718449|NCT00002521|Drug|cisplatin|
1718450|NCT00002521|Drug|cyclophosphamide|
1718451|NCT00002521|Drug|etoposide|
1718452|NCT00002521|Procedure|autologous bone marrow transplantation|
1718453|NCT00002521|Procedure|bone marrow ablation with stem cell support|
1718454|NCT00002521|Procedure|peripheral blood stem cell transplantation|
1718455|NCT00002521|Procedure|syngeneic bone marrow transplantation|
1718456|NCT00002521|Radiation|radiation therapy|
1718457|NCT00002522|Drug|cisplatin|
1718458|NCT00002522|Drug|cyclophosphamide|
1718459|NCT00002522|Drug|etoposide|
1718460|NCT00002522|Procedure|autologous bone marrow transplantation|
1718461|NCT00002522|Procedure|bone marrow ablation with stem cell support|
1718462|NCT00002522|Procedure|peripheral blood stem cell transplantation|
1718463|NCT00002522|Procedure|syngeneic bone marrow transplantation|
1718464|NCT00002522|Radiation|radiation therapy|
1718465|NCT00002523|Drug|fluorouracil|
1718466|NCT00002523|Drug|leucovorin calcium|
1718467|NCT00002523|Procedure|conventional surgery|
1718468|NCT00002523|Radiation|radiation therapy|
1718469|NCT00002524|Biological|Bleomycin Sulfate|
1718470|NCT00002524|Biological|Filgrastim|
1718471|NCT00002524|Drug|Cisplatin|
1718472|NCT00002524|Drug|Cyclophosphamide|
1718473|NCT00002524|Drug|Cytarabine|
1718474|NCT00002524|Drug|Doxorubicin Hydrochloride (DOX)|
1718475|NCT00002524|Drug|Etoposide|
1718476|NCT00002524|Drug|Fluorouracil|
1718477|NCT00002524|Drug|Ifosfamide|
1718478|NCT00002524|Drug|Leucovorin calcium|
1718479|NCT00002524|Drug|Methotrexate|
1718480|NCT00002524|Drug|Methylprednisolone|
1718481|NCT00002524|Drug|Pentamidine|
1718482|NCT00002524|Drug|Prednisone|
1718483|NCT00002524|Drug|Trimethoprim-Sulfamethoxazole|
1718484|NCT00002524|Drug|Vincristine Sulfate|
1718485|NCT00002524|Drug|Zidovudine (AZT)|
1718486|NCT00002524|Radiation|Radiation Therapy|
1718487|NCT00002525|Drug|fluorouracil|"Perioperative 5-FU: 600 mg/m^2/d x 7 days continuous IV, beginning within 24 hours of surgery
After surgery, 5-FU was given 425 mg/m^2 IV push on days 1-5"
1718488|NCT00002525|Drug|leucovorin calcium|given after surgery at dose of 20mg/m^2 IV push on days 1-5
1718489|NCT00002526|Biological|filgrastim|
1718490|NCT00002526|Drug|doxorubicin hydrochloride|
1718491|NCT00002526|Drug|ifosfamide|
1718492|NCT00002527|Drug|aspirin|
1718493|NCT00002527|Other|placebo|
1718494|NCT00002528|Drug|tamoxifen citrate|20 mg daily beginning within 6 weeks of surgery for 5 years or until relapse, whichever occurs first.
1718495|NCT00002528|Procedure|conventional surgery|Either total mastectomy or, optionally if the tumor was smaller than 5 cm, a breast conserving procedure (lumpectomy or quadrantectomy).
1718496|NCT00002528|Radiation|radiation therapy|No radiotherapy is to be given after mastectomy. Radiotherapy is optional after breast conserving surgery according to prospectively determined guidelines within each institution. It should be given to the breast only and not to the draining node areas.
1718497|NCT00002528|Procedure|Axillary clearance|Axillary node dissection.
1718498|NCT00002529|Drug|cyclophosphamide|cyclophosphamide 600 mg/m2 i.v. day 1) every 21 days
1718499|NCT00002529|Drug|doxorubicin hydrochloride|doxorubicin 60 mg/m2 i.v. day 1) every 21 days, intravenous.
1718500|NCT00002529|Drug|epirubicin hydrochloride|epirubicin 90 mg/m2 i.v. day 1) every 21 days, intravenous.
1718501|NCT00002529|Drug|tamoxifen citrate|Tamoxifen 20 mg daily.
1718502|NCT00002529|Drug|toremifene|Toremifene 60 mg daily.
1718503|NCT00002531|Drug|asparaginase|
1718504|NCT00002531|Drug|cyclophosphamide|
1718505|NCT00002531|Drug|cytarabine|
1718506|NCT00002531|Drug|daunorubicin hydrochloride|
1718507|NCT00002531|Drug|dexamethasone|
1718508|NCT00002531|Drug|doxorubicin hydrochloride|
1718509|NCT00002531|Drug|etoposide|
1718510|NCT00002531|Drug|ifosfamide|
1718511|NCT00002531|Drug|leucovorin calcium|
1718512|NCT00002531|Drug|mercaptopurine|
1718513|NCT00002531|Drug|methotrexate|
1718514|NCT00002531|Drug|mitoxantrone hydrochloride|
1718515|NCT00002531|Drug|prednisolone|
1718516|NCT00002531|Drug|teniposide|
1718517|NCT00002531|Drug|thioguanine|
1718518|NCT00002531|Drug|vincristine sulfate|
1718519|NCT00002531|Drug|vindesine|
1718520|NCT00002531|Procedure|allogeneic bone marrow transplantation|
1718521|NCT00002531|Procedure|peripheral blood stem cell transplantation|
1718522|NCT00002531|Radiation|radiation therapy|
1718523|NCT00002532|Biological|filgrastim|
1718524|NCT00002532|Drug|asparaginase|
1718525|NCT00002532|Drug|cytarabine|
1718526|NCT00002532|Drug|daunorubicin hydrochloride|
1718527|NCT00002532|Drug|dexamethasone|
1718528|NCT00002532|Drug|etoposide|
1718529|NCT00002532|Drug|idarubicin|
1718536|NCT00002533|Radiation|radiation therapy|
1718537|NCT00002534|Biological|anti-thymocyte globulin|
1718538|NCT00002534|Drug|cyclophosphamide|
1718539|NCT00002534|Drug|cytarabine|
1718540|NCT00002534|Drug|methylprednisolone|
1718541|NCT00002534|Drug|thiotepa|
1718542|NCT00002534|Procedure|allogeneic bone marrow transplantation|
1718543|NCT00002534|Procedure|in vitro-treated bone marrow transplantation|
1718544|NCT00002534|Radiation|low-LET electron therapy|
1718545|NCT00002534|Radiation|low-LET photon therapy|
1718546|NCT00002535|Biological|aldesleukin|
1718547|NCT00002535|Biological|lymphokine-activated killer cells|
1718548|NCT00002535|Biological|therapeutic tumor infiltrating lymphocytes|
1718549|NCT00002535|Drug|cyclophosphamide|
1718550|NCT00002535|Drug|indomethacin|
1718551|NCT00002536|Drug|cisplatin|
1718552|NCT00002536|Drug|vincristine sulfate|
1718553|NCT00002536|Procedure|surgical procedure|
1718554|NCT00002536|Radiation|radiation therapy|
1718555|NCT00002537|Drug|topotecan hydrochloride|
1718556|NCT00002537|Radiation|radiation therapy|
1718557|NCT00002538|Procedure|laparoscopic surgery|
1718558|NCT00002539|Biological|filgrastim|
1718559|NCT00002539|Drug|cisplatin|
1718560|NCT00002539|Drug|doxorubicin hydrochloride|
1718561|NCT00002539|Procedure|conventional surgery|
1718562|NCT00002540|Other|Laboratory Biomarker Analysis|Correlative studies
1718563|NCT00002540|Procedure|Medical Examination|Undergo DRE
1718564|NCT00002540|Other|Screening Questionnaire Administration|Undergo questionnaire assessments
1718565|NCT00002542|Drug|CMF regimen|
1718566|NCT00002542|Drug|cyclophosphamide|
1718567|NCT00002542|Drug|doxorubicin hydrochloride|
1718568|NCT00002542|Drug|epirubicin hydrochloride|
1718569|NCT00002542|Drug|fluorouracil|
1718570|NCT00002542|Drug|methotrexate|
1718571|NCT00002542|Drug|tamoxifen citrate|
1718572|NCT00002542|Radiation|radiation therapy|
1718573|NCT00002543|Drug|gallium nitrate|
1718574|NCT00002544|Drug|docetaxel|
1718575|NCT00002544|Drug|mitoxantrone hydrochloride|
1718576|NCT00002545|Drug|carmustine|
1718577|NCT00002545|Radiation|low-LET photon therapy|
1718578|NCT00002546|Drug|cisplatin|
1718579|NCT00002546|Drug|ifosfamide|
1718580|NCT00002546|Procedure|adjuvant therapy|
1718581|NCT00002546|Radiation|radiation therapy|
1718582|NCT00002547|Drug|busulfan|
1718583|NCT00002547|Drug|cyclophosphamide|
1718584|NCT00002547|Drug|cyclosporine|
1718585|NCT00002547|Drug|cytarabine|
1718586|NCT00002547|Drug|methotrexate|
1718587|NCT00002547|Procedure|allogeneic bone marrow transplantation|
1718588|NCT00002547|Procedure|syngeneic bone marrow transplantation|
1718589|NCT00002548|Biological|recombinant interferon alfa|"3 million units/m2 SQ Monday-Wednesday
-Friday (3 times a week)"
1718590|NCT00002548|Drug|carmustine|20 mg/m2 I.V. day 1 q 35 days
1718591|NCT00002548|Drug|cyclophosphamide|1.5 g/m2 in 100 ml of D5W, IV intravenously over 1 hour every 3 hour x 3 (total dose 4.5 g/m2)
1718592|NCT00002548|Drug|dexamethasone|40 mg/day PO or IVPB days 1-4, 9-12, 17-20 q 5 weeks
1718593|NCT00002548|Drug|doxorubicin hydrochloride|10 mg/m2/day continuous 1 - 4 q 5 weeks
1718594|NCT00002548|Drug|melphalan|140 mg/m2 is given IV within 30 minutes of constitution on Day -5
1718595|NCT00002548|Drug|prednisone|40 mg/m2 PO days 1-7 q 35 days
1718596|NCT00002548|Drug|vincristine sulfate|0.5 mg/day continuous 1 - 4 q 5 weeks
1718597|NCT00002548|Procedure|allogeneic bone marrow transplantation|day 0
1718598|NCT00002548|Procedure|autologous bone marrow transplantation|day 0
1718599|NCT00002548|Procedure|peripheral blood stem cell transplantation|day 0
1718600|NCT00002548|Radiation|radiation therapy|administered in fractionated doses of 150 cGy, 6 - 10 hours apart bid, on Days -4, -3, -2, and -1 (Total 1,200 cGy)
1718601|NCT00002549|Biological|filgrastim|
1718602|NCT00002549|Drug|busulfan|
1718603|NCT00002549|Drug|cyclophosphamide|
1718604|NCT00002549|Drug|cytarabine|
1718605|NCT00002549|Drug|daunorubicin hydrochloride|
1718606|NCT00002549|Drug|etoposide|
1718607|NCT00002549|Drug|idarubicin|
1718608|NCT00002549|Drug|mesna|
1718609|NCT00002549|Drug|mitoxantrone hydrochloride|
1718610|NCT00002549|Procedure|allogeneic bone marrow transplantation|
1718611|NCT00002549|Procedure|autologous bone marrow transplantation|
1718612|NCT00002549|Procedure|peripheral blood stem cell transplantation|
1718613|NCT00002549|Radiation|radiation therapy|
1718614|NCT00002550|Drug|cisplatin|
1718615|NCT00002550|Drug|etoposide|
1718616|NCT00002550|Procedure|conventional surgery|
1718617|NCT00002550|Radiation|radiation therapy|
1718618|NCT00002551|Drug|fluorouracil|See arm assignments.
1718619|NCT00002551|Drug|leucovorin calcium|See arm assignments.
1718620|NCT00002551|Drug|levamisole hydrochloride|See arm assignments.
1718621|NCT00002551|Radiation|radiation therapy|See arm assignments.
1718622|NCT00002552|Biological|filgrastim|
1718623|NCT00002552|Biological|sargramostim|
1718624|NCT00002552|Drug|carmustine|
1718625|NCT00002552|Drug|cyclophosphamide|
1718626|NCT00002552|Drug|cytarabine|
1718627|NCT00002552|Drug|etoposide|
1718628|NCT00002552|Drug|leucovorin calcium|
1718629|NCT00002552|Drug|methotrexate|
1718630|NCT00002552|Drug|perfosfamide|
1718631|NCT00002552|Drug|therapeutic hydrocortisone|
1718632|NCT00002552|Procedure|allogeneic bone marrow transplantation|
1718633|NCT00002552|Procedure|autologous bone marrow transplantation|
1718634|NCT00002552|Procedure|in vitro-treated bone marrow transplantation|
1718635|NCT00002552|Procedure|peripheral blood stem cell transplantation|
1718636|NCT00002552|Procedure|syngeneic bone marrow transplantation|
1718637|NCT00002552|Radiation|radiation therapy|
1718638|NCT00002553|Drug|cyclophosphamide|
1718639|NCT00002553|Procedure|allogeneic bone marrow transplantation|
1718640|NCT00002553|Radiation|low-LET cobalt-60 gamma ray therapy|
1718641|NCT00002554|Drug|busulfan|
1718642|NCT00002554|Drug|cyclophosphamide|
1718643|NCT00002554|Drug|methotrexate|
1718644|NCT00002554|Procedure|allogeneic bone marrow transplantation|
1718645|NCT00002554|Radiation|radioimmunotherapy|
1718646|NCT00002555|Drug|cisplatin|
1718647|NCT00002555|Radiation|low-LET cobalt-60 gamma ray therapy|
1718648|NCT00002555|Radiation|low-LET electron therapy|
1718649|NCT00002555|Radiation|low-LET photon therapy|
1718650|NCT00002556|Drug|vincristine sulfate|Given IV
1718651|NCT00002556|Drug|carmustine|Given IV
1718652|NCT00002556|Drug|melphalan|Given PO
1718653|NCT00002556|Drug|cyclophosphamide|Given IV
1718654|NCT00002556|Drug|prednisone|Given PO
1718655|NCT00002556|Biological|recombinant interferon alfa-2b|Given SC
1718656|NCT00002556|Other|laboratory biomarker analysis|Correlative studies
1718657|NCT00002557|Drug|CHOP regimen|
1718658|NCT00002557|Drug|doxorubicin hydrochloride|
1718659|NCT00002557|Drug|etoposide|
1718660|NCT00002557|Drug|leucovorin calcium|
1718661|NCT00002557|Drug|methotrexate|
1718662|NCT00002558|Biological|filgrastim|
1718663|NCT00002558|Drug|carboplatin|
1718664|NCT00002558|Drug|etoposide|
1718665|NCT00002558|Drug|ifosfamide|
1718666|NCT00002558|Drug|paclitaxel|
1718667|NCT00002558|Procedure|peripheral blood stem cell transplantation|
1718668|NCT00002559|Biological|filgrastim|
1718669|NCT00002559|Drug|cisplatin|
1718670|NCT00002559|Drug|ifosfamide|
1718671|NCT00002559|Drug|paclitaxel|
1718672|NCT00002560|Biological|monoclonal antibody 3F8|
1718673|NCT00002560|Biological|sargramostim|
1718674|NCT00002561|Biological|bleomycin sulfate|10 units/m2
1718675|NCT00002561|Drug|dacarbazine|375mg/m2
1718676|NCT00002561|Drug|doxorubicin hydrochloride|25mg/m2
1718677|NCT00002561|Drug|vinblastine|6mg/m2
1718678|NCT00002561|Radiation|radiation therapy|35Gy in 20 fractions (daily)
1718679|NCT00002562|Drug|paclitaxel|
1718680|NCT00002563|Procedure|psychosocial assessment and care|Evaluate psychosocial function at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
1718681|NCT00002563|Procedure|quality-of-life assessment|Evaluate quality of life at prestudy, 6 months after starting treatment on S9133, and annually at 1-7 years after starting treatment on S9133.
1718682|NCT00002564|Other|educational intervention|
1718683|NCT00002564|Procedure|therapeutic dietary intervention|
1718684|NCT00002565|Biological|bleomycin sulfate|
1718685|NCT00002565|Drug|CHOP regimen|
1718686|NCT00002565|Drug|cisplatin|
1718687|NCT00002565|Drug|cyclophosphamide|
1718688|NCT00002565|Drug|cytarabine|
1718689|NCT00002565|Drug|doxorubicin hydrochloride|
1718690|NCT00002565|Drug|etoposide|
1718691|NCT00002565|Drug|idarubicin|
1718692|NCT00002565|Drug|ifosfamide|
1718693|NCT00002565|Drug|mesna|
1718694|NCT00002565|Drug|methylprednisolone|
1718695|NCT00002565|Drug|mitoxantrone hydrochloride|
1718696|NCT00002565|Drug|prednisone|
1718697|NCT00002565|Drug|vincristine sulfate|
1718698|NCT00002566|Drug|carboplatin|
1718699|NCT00002566|Drug|cisplatin|
1718700|NCT00002566|Drug|cyclophosphamide|
1718701|NCT00002566|Drug|etoposide|
1718702|NCT00002566|Drug|ifosfamide|
1718703|NCT00002566|Drug|vinblastine sulfate|
1718704|NCT00002566|Procedure|autologous bone marrow transplantation|
1718705|NCT00002566|Procedure|conventional surgery|
1718706|NCT00002566|Procedure|peripheral blood stem cell transplantation|
1718707|NCT00002567|Biological|filgrastim|
1718708|NCT00002567|Drug|etoposide|
1718709|NCT00002567|Procedure|peripheral blood stem cell transplantation|
1718710|NCT00002567|Radiation|low-LET electron therapy|
1718711|NCT00002567|Radiation|low-LET photon therapy|
1718712|NCT00002568|Drug|cisplatin|
1718713|NCT00002568|Drug|paclitaxel|
1718714|NCT00002568|Procedure|conventional surgery|
1718715|NCT00002569|Drug|lomustine|
1718716|NCT00002569|Drug|procarbazine hydrochloride|
1718717|NCT00002569|Drug|vincristine sulfate|
1718718|NCT00002569|Radiation|radiation therapy|
1718719|NCT00002570|Drug|fluorouracil|425 mg/m2 IV by bolus injection daily for 5 consecutive days q 28 days
1718720|NCT00002570|Drug|leucovorin calcium|20 mg/m2 IV - number of cycles is determined by patient and physician
1718721|NCT00002571|Biological|bleomycin sulfate|5u/m2 IV Q21days x 6 cycles
1718722|NCT00002571|Biological|filgrastim|5ug/kg SC, Days 9-20, Q 21 days x 6 cycles
1718723|NCT00002571|Drug|cyclophosphamide|490 mg/m2 IV Q 21 days x 6 cycles
1718724|NCT00002571|Drug|cytarabine|225 mg/m2 IV Q 21 days x 6 cycles
1718725|NCT00002571|Drug|doxorubicin hydrochloride|19 mg/m2 IV Q 21 days x 6 cycles
1718726|NCT00002571|Drug|etoposide|90 mg/m2 IV Q 21 days x 6 cycles
1718727|NCT00002571|Drug|leucovorin calcium|25 mg/m2 po 24 hours after methotrexate Q 6 hours x 4 doses for 6 cycles.
1718728|NCT00002571|Drug|methotrexate|90 mg/m2 IV, Q 21 days x 6 cycles.
1718729|NCT00002571|Drug|prednisone|60 mg/m2 po QD x 14days for 6 cycles
1718730|NCT00002571|Drug|trimethoprim-sulfamethoxazole|1 double throughout strength treatment tablet po on Monday, Wednesday, and Friday x 6, 21 day cycles
1718731|NCT00002571|Drug|vincristine sulfate|1.4 mg/m2 IV Q 21 Days x 6 cycles
1718834|NCT00002596|Procedure|autologous bone marrow transplantation|
1718732|NCT00002571|Radiation|radiation therapy|All patients achieving a CR or PR following systemic therapy and IT Ara-C, will receive 2,400 cGy in two hundred cGy fractions to the whole brain. Fields should adequately encompass all meningeal surfaces.
1718733|NCT00002571|Drug|Intrathecal cytarabine|"If initial bone marrow positive:
Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first two cycles of therapy. Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle.
If initial CSF cytology positive:
Ara-C 30 mg/m2 IT per dose x 5 doses spaced evenly during the first cycle of therapy. If CSF negative after above, Ara-C 30 mg/m2 IT Day 1 of each subsequent cycle. If CSF positive after initial five doses of Ara-C, IT MTX 12 mg per dose x 5 doses should be given spaced evenly during the second cycle of therapy.
If initial bone marrow and CSF negative:
Ara-C 30 mg/m2 IT per dose x 5 doses to be given spaced evenly within 1 month of completion of systemic therapy."
1718734|NCT00002572|Biological|aldesleukin|
1718735|NCT00002572|Biological|muromonab-CD3|
1718736|NCT00002572|Biological|therapeutic tumor infiltrating lymphocytes|
1718737|NCT00002572|Procedure|conventional surgery|
1718738|NCT00002574|Biological|recombinant interferon alfa|
1718739|NCT00002574|Drug|omacetaxine mepesuccinate|
1718740|NCT00002575|Procedure|conventional surgery|
1718741|NCT00002575|Procedure|laparoscopic surgery|
1718742|NCT00002576|Drug|cyclophosphamide|
1718743|NCT00002576|Drug|doxorubicin hydrochloride|
1718744|NCT00002576|Drug|mitoxantrone hydrochloride|
1718745|NCT00002576|Drug|prednisolone|
1718746|NCT00002576|Drug|vincristine sulfate|
1718747|NCT00002577|Radiation|radiation therapy|
1718748|NCT00002578|Drug|cytarabine|
1718749|NCT00002578|Drug|gallium nitrate|
1718750|NCT00002578|Drug|leucovorin calcium|
1718751|NCT00002578|Drug|methotrexate|
1718752|NCT00002579|Drug|CMF regimen|
1718753|NCT00002579|Drug|cyclophosphamide|
1718754|NCT00002579|Drug|fluorouracil|
1718755|NCT00002579|Drug|methotrexate|
1718756|NCT00002579|Drug|tamoxifen citrate|
1718757|NCT00002579|Procedure|conventional surgery|
1718758|NCT00002579|Radiation|radiation therapy|
1718759|NCT00002580|Drug|cyclophosphamide|
1718760|NCT00002580|Drug|fluorouracil|
1718761|NCT00002580|Drug|goserelin acetate|
1718762|NCT00002580|Drug|leuprolide acetate|
1718763|NCT00002580|Drug|methotrexate|
1718764|NCT00002580|Drug|tamoxifen citrate|
1718765|NCT00002580|Procedure|conventional surgery|
1718766|NCT00002580|Procedure|laparoscopic surgery|
1718767|NCT00002580|Procedure|oophorectomy|
1718768|NCT00002580|Radiation|radiation therapy|
1718769|NCT00002581|Drug|cyclophosphamide|
1718770|NCT00002581|Drug|fluorouracil|
1718771|NCT00002581|Drug|methotrexate|
1718772|NCT00002581|Drug|tamoxifen citrate|
1718773|NCT00002581|Procedure|conventional surgery|
1718774|NCT00002581|Radiation|radiation therapy|
1718775|NCT00002582|Drug|CMF regimen|
1718776|NCT00002582|Drug|cyclophosphamide|
1718777|NCT00002582|Drug|doxorubicin hydrochloride|
1718778|NCT00002582|Drug|fluorouracil|
1718779|NCT00002582|Drug|goserelin acetate|
1718780|NCT00002582|Drug|leuprolide acetate|
1718781|NCT00002582|Drug|methotrexate|
1718782|NCT00002582|Drug|tamoxifen citrate|
1718783|NCT00002582|Procedure|oophorectomy|
1718784|NCT00002582|Radiation|radiation therapy|
1718785|NCT00002583|Drug|cisplatin|50 mg/m2 IV
1718786|NCT00002583|Drug|vinorelbine ditartrate|25 mg/m2 IV
1718787|NCT00002585|Drug|pyrazoloacridine|
1718788|NCT00002586|Drug|13-cis retinoic acid|
1718789|NCT00002586|Dietary Supplement|Tocopherol|
1718790|NCT00002587|Drug|paclitaxel|
1718791|NCT00002587|Drug|topotecan hydrochloride|
1718792|NCT00002588|Drug|etoposide|
1718793|NCT00002588|Drug|topotecan hydrochloride|
1718794|NCT00002589|Biological|aldesleukin|
1718795|NCT00002589|Biological|muromonab-CD3|
1718796|NCT00002589|Biological|therapeutic autologous lymphocytes|
1718797|NCT00002589|Procedure|adjuvant therapy|
1718798|NCT00002590|Biological|filgrastim|
1718799|NCT00002590|Drug|cyclophosphamide|
1718800|NCT00002590|Drug|cytarabine|
1718801|NCT00002590|Drug|daunorubicin hydrochloride|
1718802|NCT00002590|Drug|doxorubicin hydrochloride|
1718803|NCT00002590|Drug|etoposide|
1718804|NCT00002590|Drug|leucovorin calcium|
1718805|NCT00002590|Drug|methotrexate|
1718806|NCT00002590|Drug|pegaspargase|
1718807|NCT00002590|Drug|prednisone|
1718808|NCT00002590|Drug|thioguanine|
1718809|NCT00002590|Drug|vincristine sulfate|
1718810|NCT00002590|Radiation|radiation therapy|
1718811|NCT00002592|Biological|c-myb antisense oligonucleotide G4460|
1718812|NCT00002592|Biological|filgrastim|
1718813|NCT00002592|Drug|busulfan|
1718814|NCT00002592|Drug|cyclophosphamide|
1718815|NCT00002592|Procedure|autologous bone marrow transplantation|
1718816|NCT00002592|Procedure|in vitro-treated bone marrow transplantation|
1718817|NCT00002593|Drug|fluorouracil|Given IV as described in Arm Description
1718818|NCT00002593|Drug|leucovorin calcium|Given IV as described in Arm description.
1718819|NCT00002593|Drug|levamisole hydrochloride|Given as described in arm description
1718820|NCT00002594|Biological|Sargramostim|Given IV
1718821|NCT00002594|Drug|cyclophosphamide|Given IV
1718822|NCT00002594|Drug|melphalan|Given IV
1718823|NCT00002594|Procedure|autologous bone marrow transplantation|
1718824|NCT00002594|Procedure|bone marrow ablation with stem cell support|
1718825|NCT00002594|Procedure|peripheral blood stem cell transplantation|
1718826|NCT00002595|Drug|toremifene|
1718827|NCT00002595|Procedure|conventional surgery|
1718828|NCT00002596|Biological|bleomycin sulfate|
1718835|NCT00002596|Procedure|bone marrow ablation with stem cell support|
1718836|NCT00002596|Procedure|conventional surgery|
1718837|NCT00002596|Procedure|peripheral blood stem cell transplantation|
1718838|NCT00002596|Radiation|radiation therapy|
1718839|NCT00002597|Drug|flutamide|Two 125 mg capsules (t.i.d., p.o.) beginning two months before RT and continuing until RT is completed.
1718840|NCT00002597|Drug|Zoladex|3.6 mg s.c. monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
1718841|NCT00002597|Drug|Lupron|7.5 mg IM (intramuscular) monthly x 4 beginning two months before RT and continuing until RT is completed. The 3-month preparation may be used instead of three separate monthly injections.
1718842|NCT00002597|Radiation|radiation therapy|46.8 Gy (1.8 Gy/day four to five times a week [26 fx]) to regional lymphatics followed by 19.8 Gy (1.8 Gy/day x 11 fx) for a total of 66.6 Gy to the prostate. Prostate only may be treated in defined circumstances.
1718843|NCT00002598|Biological|recombinant interferon alfa|
1718844|NCT00002598|Biological|sargramostim|
1718845|NCT00002598|Drug|cyclophosphamide|
1718846|NCT00002598|Drug|cytarabine|
1718847|NCT00002598|Drug|etoposide|
1718848|NCT00002598|Drug|methotrexate|
1718849|NCT00002598|Drug|mitoxantrone hydrochloride|
1718850|NCT00002598|Procedure|bone marrow ablation with stem cell support|
1718851|NCT00002598|Radiation|radiation therapy|
1718852|NCT00002599|Biological|filgrastim|
1718853|NCT00002599|Biological|recombinant interferon alfa|
1718854|NCT00002599|Biological|sargramostim|
1718855|NCT00002599|Drug|carmustine|
1718856|NCT00002599|Drug|cyclophosphamide|
1718857|NCT00002599|Drug|doxorubicin hydrochloride|
1718858|NCT00002599|Drug|melphalan|
1718859|NCT00002599|Drug|methylprednisolone|
1718860|NCT00002599|Drug|prednisone|
1718861|NCT00002599|Drug|vincristine sulfate|
1718862|NCT00002599|Radiation|low-LET cobalt-60 gamma ray therapy|
1718863|NCT00002599|Radiation|low-LET photon therapy|
1718864|NCT00002600|Biological|filgrastim|
1718865|NCT00002600|Drug|carboplatin|
1718866|NCT00002600|Drug|cyclophosphamide|
1718867|NCT00002600|Procedure|autologous bone marrow transplantation|
1718868|NCT00002600|Procedure|peripheral blood stem cell transplantation|
1718869|NCT00002601|Biological|filgrastim|5 ug/kg daily following stem cell reinfusion
1718870|NCT00002601|Drug|cisplatin|Course 2 - 100 mg/m2 at an infusion rate of 25 mg/hr
1718871|NCT00002601|Drug|doxorubicin hydrochloride|Course 1 - 150 mg/m2 by continuous intravenous infusion for 96 hours.
1718872|NCT00002601|Drug|ifosfamide|Course 1 - 14 gm/M2 by continuous intravenous infusion for 96 hours.
1718873|NCT00002601|Drug|melphalan|Course 2 - 75 mg/m2 infused at a rate of 5 mg/minute
1718874|NCT00002601|Procedure|peripheral blood stem cell transplantation|Administered on Day 0 following high-dose chemotherapy in both courses 1 and 2
1718875|NCT00002602|Radiation|3D-CRT|3 dimensional conformal radiation therapy
1718876|NCT00002604|Drug|O6-benzylguanine|Patients receive BG IV over 1 hour during week 1, and then BG IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
1718877|NCT00002604|Drug|carmustine|After one hour of receiving BG patients receive BCNU IV over 1 hour during week 3. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity.
1718878|NCT00002604|Drug|chemosensitization/potentiation therapy|
1718879|NCT00002608|Drug|cisplatin|
1718880|NCT00002608|Drug|doxorubicin hydrochloride|
1718881|NCT00002608|Drug|tamoxifen citrate|
1718882|NCT00002608|Procedure|conventional surgery|
1718883|NCT00002608|Radiation|radiation therapy|
1718884|NCT00002609|Biological|lintuzumab|
1718885|NCT00002609|Drug|cytarabine|
1718886|NCT00002609|Drug|idarubicin|
1718887|NCT00002610|Biological|dactinomycin|
1718888|NCT00002610|Biological|filgrastim|
1718889|NCT00002610|Drug|carboplatin|
1718890|NCT00002610|Drug|cyclophosphamide|
1718891|NCT00002610|Drug|doxorubicin hydrochloride|
1718892|NCT00002610|Drug|etoposide|
1718893|NCT00002610|Drug|vincristine sulfate|IV
1718894|NCT00002610|Procedure|conventional surgery|
1718895|NCT00002610|Radiation|radiation therapy|
1718896|NCT00002611|Biological|dactinomycin|
1718897|NCT00002611|Biological|filgrastim|
1718898|NCT00002611|Drug|cyclophosphamide|
1718899|NCT00002611|Drug|doxorubicin hydrochloride|Source and Pharmacology: An anthracycline antibiotic isolated from cultures of Streptomyces peucetius. Binds to DNA and inhibits nucleic acid synthesis, with its major lethal effect occurring during the S phase of the cell cycle. Has some topoisomerase II inhibitory activity. Since it is primarily excreted by the liver, any liver impairment may enhance toxicity. 40% to 50% is excreted in the bile; <5% in the urine. The drug has a very short initial t½ of <20 minutes and a terminal t½ of 17 hours. Animal studies indicate cytotoxic levels persist in tissue for as long as 24 hours.
1718900|NCT00002611|Drug|etoposide|
1718901|NCT00002611|Drug|vincristine sulfate|
1718902|NCT00002611|Procedure|conventional surgery|
1718903|NCT00002611|Radiation|radiation therapy|
1718904|NCT00002615|Drug|cisplatin|
1718905|NCT00002615|Drug|epirubicin hydrochloride|
1718906|NCT00002615|Drug|fluorouracil|
1718907|NCT00002615|Procedure|conventional surgery|
1718908|NCT00002616|Biological|aldesleukin|
1718909|NCT00002616|Biological|filgrastim|
1718910|NCT00002616|Drug|carboplatin|
1718911|NCT00002616|Drug|cyclophosphamide|
1718912|NCT00002616|Drug|thiotepa|
1718913|NCT00002616|Procedure|peripheral blood stem cell transplantation|
1718914|NCT00002618|Biological|filgrastim|
1718915|NCT00002618|Drug|cytarabine|
1718916|NCT00002618|Drug|doxorubicin hydrochloride|
1718917|NCT00002618|Drug|leucovorin calcium|
1718918|NCT00002618|Drug|mercaptopurine|
1718921|NCT00002618|Drug|vincristine sulfate|
1718922|NCT00002618|Radiation|low-LET cobalt-60 gamma ray therapy|
1718923|NCT00002618|Radiation|low-LET electron therapy|
1718924|NCT00002618|Radiation|low-LET photon therapy|
1718925|NCT00002619|Biological|filgrastim|
1718926|NCT00002619|Drug|carboplatin|
1718927|NCT00002619|Drug|thiotepa|
1718928|NCT00002619|Procedure|autologous bone marrow transplantation|
1718929|NCT00002619|Procedure|peripheral blood stem cell transplantation|
1718930|NCT00002620|Drug|carmustine|
1718931|NCT00002620|Drug|chemotherapy|
1718932|NCT00002620|Drug|mitolactol|
1718933|NCT00002620|Radiation|low-LET cobalt-60 gamma ray therapy|
1718934|NCT00002620|Radiation|low-LET photon therapy|
1718935|NCT00002621|Biological|recombinant interferon alfa|
1718936|NCT00002622|Drug|talc|4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time
1718937|NCT00002622|Drug|Talc|4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time
1718938|NCT00002623|Drug|carboplatin|
1718939|NCT00002623|Drug|cisplatin|
1718940|NCT00002623|Procedure|conventional surgery|
1718941|NCT00002623|Radiation|radiation therapy|
1718942|NCT00002624|Procedure|adjuvant therapy|
1718943|NCT00002624|Procedure|diagnostic thoracoscopy|
1718944|NCT00002624|Procedure|therapeutic thoracoscopy|
1718945|NCT00002624|Procedure|video-assisted surgery|
1718946|NCT00002624|Radiation|radiation therapy|
1718947|NCT00002625|Drug|topotecan hydrochloride|
1718948|NCT00002625|Radiation|low-LET electron therapy|
1718949|NCT00002625|Radiation|low-LET photon therapy|
1718950|NCT00002627|Biological|filgrastim|
1718951|NCT00002627|Drug|carboplatin|
1718952|NCT00002627|Drug|cyclophosphamide|
1718953|NCT00002627|Drug|mesna|
1718954|NCT00002627|Drug|paclitaxel|
1718955|NCT00002627|Procedure|peripheral blood stem cell transplantation|
1718956|NCT00002628|Biological|filgrastim|
1718957|NCT00002628|Drug|carboplatin|
1718958|NCT00002628|Drug|cyclophosphamide|
1718959|NCT00002628|Drug|mesna|
1718960|NCT00002628|Drug|paclitaxel|
1718961|NCT00002628|Procedure|peripheral blood stem cell transplantation|
1718962|NCT00002630|Biological|filgrastim|
1718963|NCT00002630|Drug|cyclophosphamide|
1718964|NCT00002630|Drug|melphalan|
1718965|NCT00002630|Procedure|peripheral blood stem cell transplantation|
1718966|NCT00002630|Radiation|low-LET cobalt-60 gamma ray therapy|
1718967|NCT00002630|Radiation|low-LET photon therapy|
1718968|NCT00002130|Drug|Vesnarinone|
1718969|NCT00002131|Drug|Vesnarinone|
1718970|NCT00002132|Drug|Itraconazole|
1718971|NCT00002132|Drug|Fluconazole|
1718972|NCT00002133|Drug|Itraconazole|
1718973|NCT00002134|Drug|Ganciclovir|
1718974|NCT00002135|Drug|Ganciclovir|
1718975|NCT00002136|Drug|Tecogalan sodium|
1718976|NCT00002137|Drug|Tecogalan sodium|
1718977|NCT00002138|Drug|Tecogalan sodium|
1718978|NCT00002139|Drug|Azithromycin|
1718979|NCT00002140|Drug|Ethambutol hydrochloride|
1718980|NCT00002140|Drug|Clarithromycin|
1718981|NCT00002140|Drug|Azithromycin|
1718982|NCT00002141|Drug|Abacavir sulfate|
1718983|NCT00002142|Drug|Cidofovir|
1718984|NCT00002142|Drug|Probenecid|
1718985|NCT00002143|Drug|Acitretin|
1718986|NCT00002144|Drug|Foscarnet sodium|
1718987|NCT00002145|Drug|Foscarnet sodium|
1718988|NCT00002146|Drug|Magnesium sulfate|
1718989|NCT00002146|Drug|Foscarnet sodium|
1718990|NCT00002147|Drug|Doxorubicin hydrochloride (liposomal)|
1718991|NCT00002148|Drug|OPC 14117|
1718992|NCT00002149|Drug|Clavulanate potassium|
1718993|NCT00002149|Drug|Pseudoephedrine hydrochloride|
1718994|NCT00002149|Drug|Amoxicillin trihydrate|
1718995|NCT00002150|Drug|Celgosivir hydrochloride|
1718996|NCT00002151|Drug|Celgosivir hydrochloride|
1718997|NCT00002152|Drug|WF10|
1718998|NCT00002153|Drug|A-007|
1718999|NCT00002154|Drug|Thioctic acid|
1719000|NCT00002154|Drug|Selegiline hydrochloride|
1719001|NCT00002155|Drug|Indinavir sulfate|
1719002|NCT00002155|Drug|Lamivudine|
1719003|NCT00002155|Drug|Zidovudine|
1719004|NCT00002156|Drug|Fomivirsen sodium|
1719005|NCT00002156|Drug|Ganciclovir|
1719006|NCT00002157|Drug|Thalidomide|
1719007|NCT00002158|Drug|Nitazoxanide|
1719008|NCT00002159|Drug|Itraconazole|
1719009|NCT00002159|Drug|Amphotericin B|
1719010|NCT00002160|Drug|Ziconotide|
1719011|NCT00002161|Drug|Adefovir dipivoxil|
1719012|NCT00002162|Drug|Saquinavir|
1719013|NCT00002162|Drug|Lamivudine|
1719014|NCT00002162|Drug|Stavudine|
1719015|NCT00002162|Drug|Zidovudine|
1719016|NCT00002162|Drug|Zalcitabine|
1719017|NCT00002162|Drug|Didanosine|
1719018|NCT00002163|Drug|Abacavir sulfate|
1719019|NCT00002164|Drug|Nelfinavir mesylate|
1719020|NCT00002165|Drug|Nelfinavir mesylate|
1719021|NCT00002166|Drug|Nevirapine|
1719022|NCT00002167|Drug|Tin ethyl etiopurpurin|
1719023|NCT00002168|Drug|Indinavir sulfate|
1719024|NCT00002168|Drug|Lamivudine|
1719025|NCT00002168|Drug|Stavudine|
1719026|NCT00002168|Drug|Zidovudine|
1719027|NCT00002168|Drug|Didanosine|
1719028|NCT00002169|Drug|Nelfinavir mesylate|
1719029|NCT00002170|Drug|Nelfinavir mesylate|
1719030|NCT00002171|Drug|Nelfinavir mesylate|
1719031|NCT00002172|Biological|HIV-1 Immunogen|
1719032|NCT00002173|Biological|HIV-1 Immunogen|
1719034|NCT00002175|Drug|Dinitrochlorobenzene|
1719035|NCT00002176|Drug|Hydroxyurea|
1719036|NCT00002176|Drug|Nelfinavir mesylate|
1719037|NCT00002176|Drug|Stavudine|
1719038|NCT00002176|Drug|Didanosine|
1719039|NCT00002177|Drug|Hydroxyurea|
1719040|NCT00002177|Drug|Nelfinavir mesylate|
1719041|NCT00002177|Drug|Stavudine|
1719042|NCT00002177|Drug|Didanosine|
1719043|NCT00002178|Drug|Ritonavir|
1719044|NCT00002178|Drug|Nelfinavir mesylate|
1719045|NCT00002178|Drug|Saquinavir|
1719046|NCT00002178|Drug|Delavirdine mesylate|
1719047|NCT00002179|Drug|Indinavir sulfate|
1719048|NCT00002179|Drug|Lamivudine|
1719049|NCT00002179|Drug|Zidovudine|
1719050|NCT00002180|Drug|Tenofovir|
1719051|NCT00002181|Drug|Cidofovir|
1719052|NCT00002182|Drug|Megestrol acetate|
1719053|NCT00002183|Drug|Abacavir sulfate|
1719054|NCT00002183|Drug|Amprenavir|
1719055|NCT00002183|Drug|Lamivudine|
1719056|NCT00002183|Drug|Zidovudine|
1719057|NCT00002184|Drug|Nelfinavir mesylate|
1719058|NCT00002184|Drug|Levocarnitine|
1719059|NCT00002184|Drug|Adefovir dipivoxil|
1719060|NCT00002184|Drug|Saquinavir|
1719061|NCT00002184|Drug|Lamivudine|
1719062|NCT00002184|Drug|Stavudine|
1719063|NCT00002184|Drug|Zidovudine|
1719064|NCT00002185|Drug|Nelfinavir mesylate|
1719065|NCT00002186|Drug|Crofelemer|
1719066|NCT00002186|Drug|Acyclovir|
1719067|NCT00002187|Drug|Fomivirsen sodium|
1719068|NCT00002631|Drug|chemotherapy|
1719069|NCT00002631|Drug|cisplatin|
1719070|NCT00002631|Drug|fluorouracil|
1719071|NCT00002631|Radiation|low-LET electron therapy|
1719072|NCT00002631|Radiation|low-LET photon therapy|
1719073|NCT00002632|Drug|paclitaxel|
1719074|NCT00002633|Drug|bicalutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
1719075|NCT00002633|Drug|buserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
1719076|NCT00002633|Drug|flutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
1719077|NCT00002633|Drug|goserelin|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
1719078|NCT00002633|Drug|leuprolide acetate|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
1719079|NCT00002633|Drug|nilutamide|Antiandrogen (optional with orchiectomy) Flutamide 250 mg po TID or Nilutamide 100 mg po TID x 1 mo; then 150 mg po QD or Bicalutamide 50 mg po QD PLUS (patient's choice) Bilateral orchiectomy or LHRH agonist Goserelin 3.6 mg SC (abd) q28d or 10.8 mg SC (abd) Q3mos or Leuprolide 7.5 mg IM q28d (Leuprorelin 3.75 mg) or 22.5 mg IM Q3mos (Leuprorelin 11.25 mg) or 30 mg IM Q4mos or Buserelin 6.3mg SC (abd) Q8wk or 9.45mg SC (abd) Q12wk
1719080|NCT00002633|Procedure|orchiectomy|Optional orchiectomy
1719081|NCT00002633|Radiation|radiation therapy|Radical Radiation Therapy - (65-69 Gy; 35-37 treatments)
1719082|NCT00002634|Biological|filgrastim|
1719083|NCT00002634|Biological|monoclonal antibody 3F8|
1719084|NCT00002634|Drug|cisplatin|
1719085|NCT00002634|Drug|cyclophosphamide|
1719086|NCT00002634|Drug|doxorubicin hydrochloride|
1719087|NCT00002634|Drug|etoposide|
1719088|NCT00002634|Drug|mesna|
1719089|NCT00002634|Drug|perfosfamide|
1719090|NCT00002634|Drug|vincristine sulfate|
1719091|NCT00002634|Procedure|autologous bone marrow transplantation|
1719092|NCT00002634|Procedure|in vitro-treated bone marrow transplantation|
1719093|NCT00002634|Radiation|low-LET cobalt-60 gamma ray therapy|
1719094|NCT00002634|Radiation|low-LET photon therapy|
1719095|NCT00002634|Radiation|radioisotope therapy|
1719096|NCT00002635|Biological|filgrastim|
1719097|NCT00002635|Drug|aminocamptothecin|
1719098|NCT00002637|Biological|aldesleukin|
1719099|NCT00002637|Biological|gene-modified tumor cell vaccine therapy|
1719100|NCT00002637|Biological|recombinant interferon gamma|
1719101|NCT00002638|Biological|filgrastim|
1719102|NCT00002638|Biological|sargramostim|
1719103|NCT00002638|Drug|carmustine|
1719104|NCT00002638|Drug|cyclophosphamide|
1719105|NCT00002638|Drug|cytarabine|
1719106|NCT00002638|Drug|etoposide|
1719107|NCT00002638|Procedure|peripheral blood stem cell transplantation|
1719108|NCT00002638|Radiation|radiation therapy|
1719109|NCT00002639|Drug|chemotherapy|
1719110|NCT00002639|Drug|suramin|
1719111|NCT00002641|Biological|filgrastim|
1719112|NCT00002641|Drug|doxorubicin hydrochloride|
1719113|NCT00002641|Drug|ifosfamide|
1719114|NCT00002641|Drug|isolated perfusion|
1719115|NCT00002641|Procedure|adjuvant therapy|
1719116|NCT00002641|Procedure|conventional surgery|
1719117|NCT00002641|Radiation|radiation therapy|
1719118|NCT00002642|Drug|cisplatin|50 mg/m2, IV Days 1 and 8, two 28 day cycles prior to surgery and two 28 day cycles after surgery
1719119|NCT00002642|Drug|etoposide|50 mg/m2, IV Days 1-5, two 28 day cycles prior to surgery and two 28 day cycles after surgery
1719120|NCT00002642|Procedure|conventional surgery|surgery some time between weeks 9 and 12
1719121|NCT00002642|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, weekly for 5 weeks
1719122|NCT00002643|Biological|filgrastim|
1719123|NCT00002643|Drug|amifostine trihydrate|
1719124|NCT00002643|Drug|cyclophosphamide|
1719125|NCT00002643|Drug|doxorubicin hydrochloride|
1719126|NCT00002643|Drug|etoposide|
1719127|NCT00002643|Drug|ifosfamide|
1719128|NCT00002643|Drug|topotecan hydrochloride|
1719129|NCT00002643|Drug|vincristine sulfate|
1719130|NCT00002643|Procedure|conventional surgery|
1719131|NCT00002643|Radiation|low-LET cobalt-60 gamma ray therapy|
1719132|NCT00002643|Radiation|low-LET electron therapy|
1719133|NCT00002643|Radiation|low-LET photon therapy|
1719134|NCT00002644|Drug|tamoxifen citrate|
1719135|NCT00002646|Drug|fenretinide|
1719136|NCT00002646|Drug|tamoxifen citrate|
1719137|NCT00002647|Drug|verteporfin|
1719138|NCT00002647|Procedure|conventional surgery|
1719139|NCT00002649|Biological|aldesleukin|Given IV
1719140|NCT00002649|Biological|filgrastim|Given SC or IV
1719141|NCT00002649|Drug|cyclophosphamide|Given IV
1719142|NCT00002649|Drug|etoposide|Given IV
1719143|NCT00002649|Radiation|radiation therapy|Undergo radiation therapy
1719144|NCT00002649|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
1719145|NCT00002649|Procedure|bone marrow ablation with stem cell support|Undergo bone marrow ablation with stem cell support
1719146|NCT00002650|Dietary Supplement|folic acid|
1719147|NCT00002651|Drug|bicalutamide|Given orally
1719148|NCT00002651|Drug|goserelin acetate|Given subcutaneously
1719149|NCT00002651|Other|clinical observation|Patients undergo observation in the absence of rising prostate-specific antigen (PSA) or clinical symptoms of progressive disease.
1719150|NCT00002652|Drug|suramin|
1719151|NCT00002653|Drug|carmustine|
1719152|NCT00002653|Drug|cyclophosphamide|
1719153|NCT00002653|Drug|doxorubicin hydrochloride|
1719154|NCT00002653|Drug|melphalan|
1719155|NCT00002653|Drug|prednisone|
1719156|NCT00002653|Radiation|radiation therapy|
1719157|NCT00002654|Drug|chemotherapy|
1719158|NCT00002654|Drug|cisplatin|
1719159|NCT00002654|Radiation|low-LET cobalt-60 gamma ray therapy|
1719160|NCT00002654|Radiation|low-LET electron therapy|
1719161|NCT00002654|Radiation|low-LET photon therapy|
1719162|NCT00002655|Procedure|cryosurgery|
1719163|NCT00002656|Drug|pyrazoloacridine|"Pyrazoloacridine 750 mg/m2 by 3 hour infusion, every 21 day s in the absence of progressive disease or prohibitive toxicity.
Depending on the prior cycle toxicity the dose should be escalated, maintained or reduced, utilizing levels: -1, 0 (initial dose level), 1 - Level +1 (820mg/m2); Level 0 (750mg/m2); Level -1 (600mg/m2)"
1719164|NCT00002657|Biological|bleomycin sulfate|5 mg/m^2
1719165|NCT00002657|Biological|recombinant interferon alfa|3.0 x 10^6 IU/m^2
1719166|NCT00002657|Drug|cyclophosphamide|650 mg/m^2
1719167|NCT00002657|Drug|cytarabine|300 mg/m^2
1719168|NCT00002657|Drug|doxorubicin hydrochloride|25 mg/m^2
1719169|NCT00002657|Drug|etoposide|120 mg/m^2
1719170|NCT00002657|Drug|methotrexate|120 mg/m^2
1719171|NCT00002657|Drug|prednisone|dose varies during initial immunosuppression. During chemotherapy, 60 mg/m^2.
1719172|NCT00002657|Drug|vincristine sulfate|1.4 mg/m^2
1719173|NCT00002657|Procedure|conventional surgery|Simple excision, for those patients who have resectable disease after initial immunosuppression.
1719174|NCT00002657|Radiation|radiation therapy|For treatment of localized disease that remains after initial immunosuppression.
1719175|NCT00002658|Biological|filgrastim|
1719176|NCT00002658|Drug|amsacrine|
1719177|NCT00002658|Drug|cyclophosphamide|
1719178|NCT00002658|Drug|cytarabine|
1719179|NCT00002658|Drug|daunorubicin hydrochloride|
1719180|NCT00002658|Drug|etoposide|
1719181|NCT00002658|Drug|idarubicin|
1719182|NCT00002658|Drug|mitoxantrone hydrochloride|
1719183|NCT00002658|Drug|thioguanine|
1719184|NCT00002658|Drug|tretinoin|
1719185|NCT00002658|Procedure|allogeneic bone marrow transplantation|
1719186|NCT00002658|Procedure|autologous bone marrow transplantation|
1719187|NCT00002658|Procedure|peripheral blood stem cell transplantation|
1719188|NCT00002658|Radiation|radiation therapy|
1719189|NCT00002659|Drug|cisplatin-e therapeutic implant|
1719190|NCT00002662|Drug|docetaxel|
1719191|NCT00002662|Drug|paclitaxel|
1719192|NCT00002745|Drug|aminocamptothecin|850 micrograms/square meter/day (total dose 2550 micrograms/square meter) via central venous catheter using infusion pump over 72 hours + one cycle Cycle repeated every 14 days for minimum of 6 cycles if partial or complete response
1719193|NCT00002746|Biological|aldesleukin|
1719194|NCT00002747|Drug|cisplatin|
1719195|NCT00002747|Drug|fluorouracil|
1719196|NCT00002747|Procedure|conventional surgery|
1719197|NCT00002747|Radiation|low-LET cobalt-60 gamma ray therapy|
1719198|NCT00002747|Radiation|low-LET photon therapy|
1719199|NCT00002748|Biological|gene-modified tumor cell vaccine therapy|
1719200|NCT00002748|Biological|interleukin-2 gene|
1719201|NCT00002749|Drug|carboplatin|
1719203|NCT00002751|Biological|monoclonal antibody Me1-14 F(ab')2|
1719204|NCT00002752|Radiation|iodine I 131 monoclonal antibody 81C6|
1719205|NCT00002753|Radiation|iodine I 131 monoclonal antibody 81C6|
1719206|NCT00002754|Biological|monoclonal antibody Me1-14 F(ab')2|
1719207|NCT00002755|Biological|filgrastim|
1719208|NCT00002755|Drug|CMF regimen|
1719209|NCT00002755|Drug|cyclophosphamide|
1719210|NCT00002755|Drug|doxorubicin hydrochloride|
1719211|NCT00002755|Drug|fluorouracil|
1719212|NCT00002755|Drug|methotrexate|
1719213|NCT00002755|Drug|tamoxifen citrate|
1719214|NCT00002755|Drug|thiotepa|
1719215|NCT00002755|Procedure|autologous bone marrow transplantation|
1719216|NCT00002755|Procedure|peripheral blood stem cell transplantation|
1719217|NCT00002755|Radiation|low-LET cobalt-60 gamma ray therapy|
1719218|NCT00002755|Radiation|low-LET electron therapy|
1719219|NCT00002755|Radiation|low-LET photon therapy|
1719220|NCT00002756|Biological|filgrastim|
1719221|NCT00002756|Drug|asparaginase|
1719222|NCT00002756|Drug|cyclophosphamide|
1719223|NCT00002756|Drug|cytarabine|
1719224|NCT00002756|Drug|daunorubicin hydrochloride|
1719225|NCT00002756|Drug|etoposide|
1719226|NCT00002756|Drug|leucovorin calcium|
1719227|NCT00002756|Drug|mercaptopurine|
1719228|NCT00002756|Drug|methotrexate|
1719229|NCT00002756|Drug|prednisone|
1719230|NCT00002756|Drug|therapeutic hydrocortisone|
1719231|NCT00002756|Drug|vincristine sulfate|
1719232|NCT00002757|Biological|filgrastim|
1719233|NCT00002757|Drug|cyclophosphamide|
1719234|NCT00002757|Drug|cytarabine|
1719235|NCT00002757|Drug|doxorubicin hydrochloride|
1719236|NCT00002757|Drug|etoposide|
1719237|NCT00002757|Drug|methotrexate|
1719238|NCT00002757|Drug|prednisolone|
1719239|NCT00002757|Drug|prednisone|
1719240|NCT00002757|Drug|therapeutic hydrocortisone|
1719241|NCT00002757|Drug|vincristine sulfate|
1719242|NCT00002759|Drug|cyclosporine|
1719243|NCT00002759|Drug|irinotecan hydrochloride|
1719244|NCT00002759|Drug|phenobarbital|
1719245|NCT00002760|Drug|ketoconazole|400 mg PO tid for as long as treatment is effective
1719246|NCT00002760|Drug|therapeutic hydrocortisone|hydrocortisone 30 mg PO q am and 10 mg PO qhs for as long as treatment is effective
1719247|NCT00002760|Other|Withdrawal of antiandrogen therapy|no drugs given
1719248|NCT00002761|Biological|filgrastim|
1719249|NCT00002761|Biological|recombinant interferon gamma|
1719250|NCT00002761|Drug|busulfan|
1719251|NCT00002761|Drug|cyclophosphamide|
1719252|NCT00002761|Drug|cyclosporine|
1719253|NCT00002761|Drug|cytarabine|
1719254|NCT00002761|Drug|idarubicin|
1719255|NCT00002761|Procedure|peripheral blood stem cell transplantation|
1719256|NCT00002762|Behavioral|patient interviewing to obtain menstrual history|
1719257|NCT00002762|Procedure|blood sampling|
1719258|NCT00002763|Biological|recombinant interferon alfa|
1719259|NCT00002764|Biological|filgrastim|
1719260|NCT00002764|Drug|doxorubicin hydrochloride|
1719261|NCT00002764|Drug|ifosfamide|
1719262|NCT00002764|Procedure|conventional surgery|
1719263|NCT00002765|Biological|LMB-2 immunotoxin|
1719264|NCT00002766|Biological|dactinomycin|
1719265|NCT00002766|Biological|sargramostim|
1719266|NCT00002766|Drug|carmustine|
1719267|NCT00002766|Drug|cyclophosphamide|
1719268|NCT00002766|Drug|cytarabine|
1719269|NCT00002766|Drug|daunorubicin hydrochloride|
1719270|NCT00002766|Drug|doxorubicin hydrochloride|
1719271|NCT00002766|Drug|etoposide|
1719272|NCT00002766|Drug|mercaptopurine|
1719273|NCT00002766|Drug|methotrexate|
1719274|NCT00002766|Drug|mitoxantrone hydrochloride|
1719275|NCT00002766|Drug|pegaspargase|
1719276|NCT00002766|Drug|prednisone|
1719277|NCT00002766|Drug|vincristine sulfate|
1719278|NCT00002766|Radiation|radiation therapy|
1719279|NCT00002767|Biological|Detox-B adjuvant|
1719280|NCT00002767|Biological|recombinant interferon alfa|
1719281|NCT00002768|Biological|filgrastim|10 microgram/kg body wt subcutaneously daily beginning on d 14 and con't until peripheral blood collection is completed
1719282|NCT00002768|Drug|busulfan|1 mg/kg PO q 6 hrs for 16 doses on days -7 thru -4.
1719283|NCT00002768|Drug|cytarabine|2000 mg/ sq meter IV over 2 hours q 12 hrs x 8 doses on days 1-4
1719284|NCT00002768|Drug|etoposide|40 mg/kg (total dose) IV cont infusion over 96 hrs on days 1-4 of consolidation therapy and 60 mg/kg IV over 4 hrs on day -3 of transplant
1719285|NCT00002768|Drug|methotrexate|For patients with documented CNS disease at first relapse, 12 mg intrathecal for a total of 6 doses given before and/or after transplantation
1719286|NCT00002768|Procedure|peripheral blood stem cell transplantation|Infusion on Day 0
1719287|NCT00002771|Biological|recombinant interferon alfa|
1719288|NCT00002771|Drug|busulfan|
1719289|NCT00002771|Drug|cytarabine|
1719290|NCT00002771|Drug|hydroxyurea|
1719291|NCT00002771|Drug|idarubicin|
1719292|NCT00002771|Procedure|allogeneic bone marrow transplantation|
1719293|NCT00002771|Procedure|autologous bone marrow transplantation|
1719294|NCT00002771|Procedure|peripheral blood stem cell transplantation|
1719295|NCT00002771|Radiation|radiation therapy|
1719296|NCT00002772|Biological|filgrastim|
1719297|NCT00002772|Drug|carboplatin|
1719298|NCT00002772|Drug|carmustine|
1719299|NCT00002772|Drug|cisplatin|
1719300|NCT00002772|Drug|cyclophosphamide|
1719301|NCT00002772|Drug|doxorubicin hydrochloride|
1719302|NCT00002772|Drug|paclitaxel|
1719303|NCT00002772|Drug|tamoxifen citrate|
1719304|NCT00002772|Drug|thiotepa|
1719305|NCT00002772|Procedure|autologous bone marrow transplantation|
1719306|NCT00002772|Procedure|peripheral blood stem cell transplantation|
1719307|NCT00002772|Radiation|radiation therapy|
1719308|NCT00002773|Biological|allogeneic tumor cell vaccine|
1719309|NCT00002773|Biological|recombinant interferon alfa|
1719310|NCT00002773|Biological|sargramostim|
1719311|NCT00002773|Drug|cyclophosphamide|
1719312|NCT00002774|Drug|Tirapazamine|"Tirapazamine is a benzotriazine with selective cytotoxicity for hypoxic cells. Under hypoxic conditions, it undergoes a 1-electron reduction to form a cytotoxic free radical that poisons topoisomerase II and causes DNA breaks, chromosomal aberrations, and cell death.
Tirapazamine was administered on Days 1 and 22 prior to the administration of neoadjuvant cisplatin and on Days 43, 45, 47, 71, 73, and 75 within 1 or 2 hours prior to each simultaneous cisplatin dose.
Tirapazamine dose was as follows:
Level 1 - 300 mg/m2 during the induction phase and 160 mg/m2 during the simultaneous phase (n = 4)
Level 2 - 330 mg/m2 during the induction phase and 260 mg/m2 during the simultaneous phase (n = 4)
Level 3 - 300 mg/m2 during the induction phase and 220 mg/m2 during the simultaneous phase (n = 25)"
1719313|NCT00002774|Drug|Cisplatin|The simultaneous chemoradiotherapy (CRT) regimen included cisplatin 20 mg/m2 administered 3 times per week.
1719314|NCT00002774|Drug|5-fluorouracil|"100 mg/m2 per day on Days 1 and 22, and continuous infusion (CI) 5-FU at a dose of 1000 mg/m2 per day for 120 hours per cycle starting on Days 1 and 22.
The simultaneous chemoradiotherapy (CRT) regimen included continuous infusion (CI) 5-FU 600 mg/m2 per day for 96 hours per cycle in Weeks 1 and 5 of RT."
1719315|NCT00002774|Radiation|Radiotherapy (RT)|"During the CRT regimen, RT was given within 3 hrs of the tirapazamine infusion. The dose for the parallel opposed fields was 2 Gy/fraction/day given 5 dys/week up to a total dose of 66-70 Gy at the target lesion. The dose to the supraclavicular region was 50 Gy at a depth of 3 cm, delivered in 25 fractions. Supervoltage photons (≥4 megavolts) were used to treat both locations.
After 50 Gy were delivered to the primary site and regional lymph nodes, all sites were reassessed for clinical response by physical exam, direct fiber optic evaluation, and radiographic imaging (CT or MRI).
Subjects with a CR at both the primary site and the neck completed RT treatment to a total dose ≥66 Gy to the primary site and the involved lymph node(s). Subjects with a CR at the primary site but a partial response (PR) at the neck completed RT treatment to the primary site followed by neck dissection. Subjects with a PR at the primary site stopped radiation at 50 Gy and underwent salvage surgery."
1719316|NCT00002775|Drug|docetaxel|
1719317|NCT00002775|Drug|estramustine phosphate sodium|
1719318|NCT00002777|Drug|exemestane|
1719319|NCT00002777|Drug|tamoxifen citrate|
1719320|NCT00002778|Biological|sargramostim|
1719321|NCT00002778|Biological|therapeutic allogeneic lymphocytes|
1719322|NCT00002778|Procedure|allogeneic bone marrow transplantation|
1719323|NCT00002778|Procedure|in vitro-treated bone marrow transplantation|
1719324|NCT00002779|Drug|fludarabine phosphate|
1719325|NCT00002779|Drug|octreotide acetate|
1719326|NCT00002780|Biological|aldesleukin|
1719327|NCT00002780|Biological|cytokine therapy|
1719328|NCT00002780|Biological|sargramostim|
1719329|NCT00002780|Drug|carboplatin|
1719330|NCT00002780|Drug|cyclophosphamide|
1719331|NCT00002780|Drug|thiotepa|
1719332|NCT00002780|Procedure|peripheral blood stem cell transplantation|
1719333|NCT00002781|Drug|boronophenylalanine-fructose complex|
1719334|NCT00002783|Drug|cisplatin|
1719335|NCT00002783|Drug|floxuridine|
1719336|NCT00002783|Drug|fluorouracil|
1719337|NCT00002783|Drug|leucovorin calcium|
1719338|NCT00002783|Procedure|conventional surgery|
1719339|NCT00002784|Biological|filgrastim|Filgrastim 10 mg/kg/d sc for 6 days after randomization.
1719340|NCT00002784|Drug|CMF regimen|Cyclophosphamide 100 mg/m2 orally days 1 - 14, methotrexate 40 mg/m2 iv days 1 and 8, 5-fluorouracil 600 mg/m2 iv days 1 and 8. Repeat every 28 days.
1719341|NCT00002784|Drug|cyclophosphamide|For high-dose EC arm: cyclophosphamide 4 gm/m2 iv as 4 divided doses. For standard chemotherapy arm: cyclophosphamide 600 mg/m2 iv day 1 of 21-day EC cycles, and cyclophosphamide 100 mg/m2 orally on days 1-14 of 28-day CMF cycles.
1719342|NCT00002784|Drug|doxorubicin hydrochloride|Doxorubicin 60 mg/m2 iv on day 1 of 21-day cycles of AC.
1719343|NCT00002784|Drug|epirubicin hydrochloride|Epirubicin 90 mg/m2 iv on day 1 of 21-day cycles of EC.
1719344|NCT00002784|Drug|fluorouracil|5-fluorouracil 600 mg/m2 iv days 1 and 8 of 28-day cycles of CMF.
1719345|NCT00002784|Drug|mesna|MESNA (7.2 gm/m2) on days 2 and 3 of 21-day cycles of dose-intensive EC.
1719346|NCT00002784|Drug|methotrexate|Methotrexate 40 mg/m2 iv on days 1 and 8 of 28-day cycles of CMF.
1719347|NCT00002784|Drug|tamoxifen citrate|Tamoxifen 20mg daily for 5 years or until relapse.
1719348|NCT00002784|Procedure|peripheral blood stem cell transplantation|Peripheral blood progenitor cells (PBPC) infusion on day 5 of each 21-day cycle of dose-intensive EC.
1719349|NCT00002784|Radiation|low-LET electron therapy|Radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
1719350|NCT00002784|Radiation|low-LET photon therapy|radiation therapy to the conserved breast is mandatory, to be carried out according to the prospectively defined guidelines of each participating institution; either after all chemotherapy or integrated into CMF as agreed per institution. Radiotherapy to the chest wall following mastectomy is optional according to the prospectively defined guidelines of each participating institution.
1719351|NCT00002785|Biological|filgrastim|
1719352|NCT00002785|Drug|asparaginase|
1719353|NCT00002785|Drug|cyclophosphamide|
1719354|NCT00002785|Drug|cyclosporine|
1719355|NCT00002785|Drug|cytarabine|
1719356|NCT00002785|Drug|daunorubicin hydrochloride|
1719357|NCT00002785|Drug|dexamethasone|
1719358|NCT00002785|Drug|etoposide|
1719359|NCT00002785|Drug|leucovorin calcium|
1719360|NCT00002785|Drug|mercaptopurine|
1719361|NCT00002785|Drug|mesna|
1719366|NCT00002785|Drug|therapeutic hydrocortisone|
1719367|NCT00002785|Drug|vincristine sulfate|
1719368|NCT00002785|Procedure|allogeneic bone marrow transplantation|
1719369|NCT00002785|Radiation|low-LET cobalt-60 gamma ray therapy|
1719370|NCT00002785|Radiation|low-LET photon therapy|
1719371|NCT00002786|Biological|aldesleukin|
1719372|NCT00002786|Biological|therapeutic tumor infiltrating lymphocytes|
1719373|NCT00002787|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|Given SC
1719374|NCT00002787|Biological|sargramostim|Given SC
1719375|NCT00002787|Biological|aldesleukin|Given SC
1719376|NCT00002787|Other|laboratory biomarker analysis|Correlative studies
1719377|NCT00002788|Biological|filgrastim|
1719378|NCT00002788|Drug|cyclophosphamide|
1719379|NCT00002788|Drug|dexamethasone|
1719380|NCT00002788|Drug|etoposide|
1719381|NCT00002788|Procedure|peripheral blood stem cell transplantation|
1719382|NCT00002788|Radiation|radiation therapy|
1719383|NCT00002789|Drug|busulfan|
1719384|NCT00002789|Drug|cyclophosphamide|
1719385|NCT00002789|Drug|cyclosporine|
1719386|NCT00002789|Drug|methotrexate|
1719387|NCT00002789|Procedure|allogeneic bone marrow transplantation|
1719388|NCT00002789|Procedure|peripheral blood stem cell transplantation|
1719389|NCT00002790|Drug|cyclosporine|
1719390|NCT00002790|Drug|methotrexate|
1719391|NCT00002790|Drug|sirolimus|
1719392|NCT00002791|Biological|filgrastim|
1719393|NCT00002791|Drug|dacarbazine|
1719394|NCT00002791|Drug|doxorubicin hydrochloride|
1719395|NCT00002791|Drug|ifosfamide|
1719396|NCT00002791|Drug|mesna|
1719397|NCT00002791|Procedure|conventional surgery|
1719398|NCT00002791|Radiation|brachytherapy|
1719399|NCT00002791|Radiation|intraoperative radiation therapy|
1719400|NCT00002791|Radiation|radioisotope therapy|
1719401|NCT00002792|Drug|busulfan|
1719402|NCT00002792|Drug|cyclophosphamide|
1719403|NCT00002792|Drug|cyclosporine|
1719404|NCT00002792|Drug|methotrexate|
1719405|NCT00002792|Drug|tacrolimus|
1719406|NCT00002792|Procedure|allogeneic bone marrow transplantation|
1719407|NCT00002792|Procedure|peripheral blood stem cell transplantation|
1719408|NCT00002793|Drug|fluorouracil|
1719409|NCT00002793|Drug|leucovorin calcium|
1719410|NCT00002794|Drug|carboplatin|
1719411|NCT00002794|Drug|vincristine sulfate|
1719412|NCT00002796|Drug|fluorouracil|Given IV
1719413|NCT00002796|Drug|sodium phenylbutyrate|Given IV
1719414|NCT00002796|Drug|indomethacin|Given orally
1719415|NCT00002796|Biological|recombinant interferon gamma|Given subcutaneously
1719416|NCT00002798|Drug|asparaginase|
1719417|NCT00002798|Drug|daunorubicin hydrochloride|
1719418|NCT00002798|Drug|fludarabine phosphate|
1719419|NCT00002798|Drug|therapeutic hydrocortisone|
1719420|NCT00002798|Procedure|allogeneic bone marrow transplantation|
1719421|NCT00002798|Radiation|3-dimensional conformal radiation therapy|
1719422|NCT00002798|Biological|filgrastim|Given SC
1719423|NCT00002798|Drug|cytarabine|Given IV or IT
1719424|NCT00002798|Drug|idarubicin|Given IV
1719425|NCT00002798|Drug|dexamethasone|Given PO
1719426|NCT00002798|Drug|thioguanine|Given PO
1719427|NCT00002798|Drug|etoposide|Given IV
1719428|NCT00002798|Drug|methotrexate|Given IT
1719429|NCT00002798|Drug|cyclophosphamide|Given IV
1719430|NCT00002798|Biological|aldesleukin|
1719431|NCT00002798|Drug|busulfan|
1719432|NCT00002800|Biological|filgrastim|
1719433|NCT00002800|Biological|lintuzumab|
1719434|NCT00002800|Drug|cytarabine|
1719435|NCT00002800|Drug|etoposide|
1719436|NCT00002800|Drug|idarubicin|
1719437|NCT00002801|Drug|leucovorin calcium|
1719438|NCT00002801|Drug|tegafur-uracil|
1719439|NCT00002801|Radiation|radiation therapy|
1719440|NCT00002802|Drug|carboplatin|
1719441|NCT00002802|Drug|cisplatin|
1719442|NCT00002802|Drug|cyclophosphamide|
1719443|NCT00002802|Drug|dacarbazine|
1719444|NCT00002802|Drug|doxorubicin hydrochloride|
1719445|NCT00002802|Drug|etoposide|
1719446|NCT00002802|Drug|ifosfamide|
1719447|NCT00002802|Drug|melphalan|
1719448|NCT00002802|Drug|mesna|
1719449|NCT00002802|Drug|vincristine sulfate|
1719450|NCT00002802|Drug|vindesine|
1719451|NCT00002802|Procedure|autologous bone marrow transplantation|
1719452|NCT00002802|Procedure|conventional surgery|
1719453|NCT00002802|Radiation|low-LET cobalt-60 gamma ray therapy|
1719454|NCT00002802|Radiation|low-LET electron therapy|
1719455|NCT00002802|Radiation|low-LET photon therapy|
1719456|NCT00002802|Radiation|radioisotope therapy|
1719457|NCT00002803|Drug|cyclophosphamide|
1719458|NCT00002803|Drug|doxorubicin hydrochloride|
1719459|NCT00002803|Drug|vincristine sulfate|
1719460|NCT00002803|Procedure|conventional surgery|
1719461|NCT00002804|Biological|filgrastim|
1719462|NCT00002804|Drug|doxorubicin hydrochloride|
1719463|NCT00002804|Drug|ifosfamide|
1719464|NCT00002804|Drug|mesna|
1719465|NCT00002804|Drug|vincristine sulfate|
1719466|NCT00002804|Procedure|conventional surgery|
1719467|NCT00002804|Radiation|brachytherapy|
1719468|NCT00002804|Radiation|low-LET cobalt-60 gamma ray therapy|
1719469|NCT00002804|Radiation|low-LET electron therapy|
1719470|NCT00002804|Radiation|low-LET photon therapy|
1719471|NCT00002805|Biological|filgrastim|
1719472|NCT00002805|Drug|cladribine|
1719473|NCT00002805|Drug|cytarabine|
1719474|NCT00002805|Drug|etoposide|
1719476|NCT00002805|Drug|mitoxantrone hydrochloride|
1719477|NCT00002805|Drug|therapeutic hydrocortisone|
1719478|NCT00002805|Procedure|allogeneic bone marrow transplantation|
1719479|NCT00002805|Procedure|autologous bone marrow transplantation|
1719480|NCT00002805|Procedure|peripheral blood stem cell transplantation|
1719481|NCT00002805|Radiation|low-LET cobalt-60 gamma ray therapy|
1719482|NCT00002805|Radiation|low-LET electron therapy|
1719483|NCT00002805|Radiation|low-LET photon therapy|
1719484|NCT00002806|Drug|lomustine|
1719485|NCT00002806|Drug|procarbazine hydrochloride|
1719486|NCT00002806|Drug|vincristine sulfate|
1719487|NCT00002806|Radiation|low-LET photon therapy|
1719488|NCT00002807|Radiation|radiation therapy|45 Gy in 25 fractions over 5 weeks
1719489|NCT00002809|Biological|anti-thymocyte globulin|
1719490|NCT00002809|Biological|filgrastim|
1719491|NCT00002809|Biological|sargramostim|
1719492|NCT00002809|Biological|therapeutic immune globulin|
1719493|NCT00002809|Drug|cyclophosphamide|
1719494|NCT00002809|Drug|methotrexate|
1719495|NCT00002809|Drug|tacrolimus|
1719496|NCT00002809|Procedure|allogeneic bone marrow transplantation|
1719497|NCT00002809|Radiation|radiation therapy|
1719498|NCT00002810|Biological|filgrastim|
1719499|NCT00002810|Drug|melphalan|
1719500|NCT00002810|Procedure|bone marrow ablation with stem cell support|
1719501|NCT00002810|Procedure|peripheral blood stem cell transplantation|
1719502|NCT00002811|Drug|liposomal T4N5 lotion|
1719503|NCT00002812|Drug|asparaginase|Given IV
1719504|NCT00002812|Drug|cyclophosphamide|Given IV
1719505|NCT00002812|Drug|cytarabine|Given IV
1719506|NCT00002812|Drug|daunorubicin hydrochloride|Given IV
1719507|NCT00002812|Drug|dexamethasone|Given IV
1719508|NCT00002812|Drug|doxorubicin hydrochloride|Given IV
1719509|NCT00002812|Drug|idarubicin|Given IV
1719510|NCT00002812|Drug|mercaptopurine|Given IV
1719511|NCT00002812|Drug|methotrexate|Given PO
1719512|NCT00002812|Drug|pegaspargase|Given IV
1719513|NCT00002812|Drug|prednisone|Given PO
1719514|NCT00002812|Drug|thioguanine|Given IV
1719515|NCT00002812|Drug|vincristine sulfate|Given IV
1719516|NCT00002812|Radiation|radiation therapy|
1719517|NCT00002813|Drug|cisplatin|
1719518|NCT00002813|Drug|vinorelbine tartrate|
1719519|NCT00002814|Biological|filgrastim|
1719520|NCT00002814|Drug|paclitaxel|
1719521|NCT00002814|Drug|topotecan hydrochloride|
1719522|NCT00002816|Drug|cytarabine|Given IV
1719523|NCT00002816|Drug|dexamethasone|Given IV
1719524|NCT00002816|Drug|etoposide|Given IV
1719525|NCT00002816|Drug|idarubicin|Given IV
1719526|NCT00002816|Drug|ifosfamide|Given IV
1719527|NCT00002816|Drug|leucovorin calcium|
1719528|NCT00002816|Drug|mesna|Given IV
1719529|NCT00002816|Drug|pegaspargase|Given IV
1719530|NCT00002816|Drug|therapeutic hydrocortisone|
1719531|NCT00002816|Drug|thioguanine|
1719532|NCT00002816|Drug|vincristine sulfate|Given IV
1719533|NCT00002816|Radiation|low-LET cobalt-60 gamma ray therapy|
1719534|NCT00002816|Radiation|low-LET electron therapy|
1719535|NCT00002816|Radiation|low-LET photon therapy|
1719536|NCT00002816|Drug|Methotrexate|Given IV
1719537|NCT00002817|Biological|sargramostim|
1719538|NCT00002817|Biological|vaccinia-GM-CSF vaccine|
1719539|NCT00002818|Drug|cytarabine|
1719540|NCT00002818|Drug|deoxycytidine|
1719541|NCT00002819|Drug|carboplatin|
1719542|NCT00002819|Drug|cyclophosphamide|
1719543|NCT00002819|Drug|mitoxantrone hydrochloride|
1719544|NCT00002819|Drug|paclitaxel|
1719545|NCT00002819|Procedure|autologous bone marrow transplantation|
1719546|NCT00002819|Procedure|peripheral blood stem cell transplantation|
1719547|NCT00002822|Drug|carboplatin|
1719548|NCT00002822|Drug|cisplatin|
1719549|NCT00002822|Drug|cyclophosphamide|
1719550|NCT00002822|Drug|doxorubicin hydrochloride|
1719551|NCT00002822|Drug|etoposide|
1719552|NCT00002822|Drug|ifosfamide|
1719553|NCT00002822|Drug|mesna|
1719554|NCT00002822|Drug|vincristine sulfate|
1719555|NCT00002822|Radiation|radiation therapy|
1719556|NCT00002823|Drug|cisplatin|
1719557|NCT00002823|Drug|etoposide|
1719558|NCT00002823|Drug|vinblastine sulfate|
1719559|NCT00002823|Drug|vindesine|
1719560|NCT00002823|Drug|vinorelbine tartrate|
1719561|NCT00002823|Radiation|radiation therapy|
1719562|NCT00002824|Biological|gene therapy|
1719563|NCT00002824|Drug|chemotherapy|
1719564|NCT00002824|Drug|ganciclovir|
1719565|NCT00002824|Procedure|conventional surgery|
1719566|NCT00002825|Biological|filgrastim|
1719567|NCT00002825|Drug|docetaxel|
1719568|NCT00002826|Drug|paclitaxel|
1719569|NCT00002826|Drug|valspodar|
1719570|NCT00002827|Biological|bleomycin sulfate|Given IV
1719571|NCT00002827|Biological|filgrastim|Given IV
1719572|NCT00002827|Drug|dexrazoxane hydrochloride|Given IV
1719573|NCT00002827|Drug|doxorubicin hydrochloride|Given IV
1719574|NCT00002827|Drug|etoposide|Given IV
1719575|NCT00002827|Drug|vincristine sulfate|Given IV
1719576|NCT00002827|Radiation|low-LET cobalt-60 gamma ray therapy|
1719577|NCT00002827|Radiation|low-LET electron therapy|
1719578|NCT00002827|Radiation|low-LET photon therapy|
1719579|NCT00002828|Drug|fluorouracil|
1719580|NCT00002828|Drug|raltitrexed|
1719581|NCT00002829|Biological|Recombinant Interferon Alfa|Daily
1719643|NCT00002838|Procedure|Peripheral Blood Stem Cell Transplantation|
1719582|NCT00002829|Drug|Cyclophosphamide|Infused intravenously over 2 hours daily on Day -7 and -6.
1719583|NCT00002829|Drug|Etoposide|Administered intravenously on Day -8
1719584|NCT00002829|Drug|Mesna|Beginning 1 hour after initiation of the cyclophosphamide treatment.
1719585|NCT00002829|Procedure|Bone Marrow Transplantation|Infusion on Day 0.
1719586|NCT00002829|Radiation|Radiation Therapy|Total body irradiation is received on days -4, -3, -2 , and -1.
1719587|NCT00002831|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to the first stem cell collection and before DAC infusion.
1719588|NCT00002831|Drug|Busulfan|Administered orally every 6 hours on consecutive days -6 through -4.
1719589|NCT00002831|Drug|Cyclophosphamide|Given intravenously (IV) over 1 hour on consecutive days -3 and -2.
1719590|NCT00002831|Drug|Cyclosporine|Patients intolerant to tacrolimus receive cyclosporine IV beginning on day -2, then orally following tolerance and engraftment.
1719591|NCT00002831|Drug|Decitabine (DAC)|IV over 4 hours on days -8 and -7.
1719592|NCT00002831|Drug|Methotrexate|Given intrathecally or intraventricularly monthly, beginning on the second month through the eighth month of treatment.
1719593|NCT00002831|Drug|Methylprednisolone|Given according to clinical grade of GVHD procedures.
1719594|NCT00002831|Drug|Tacrolimus|IV beginning one day before stem cell infusion, then orally following tolerance to tacrolimus.
1719595|NCT00002831|Procedure|Allogeneic Bone Marrow Transplantation|Infusion of stem cells on Day 0.
1719596|NCT00002831|Procedure|Peripheral Blood Stem Cell Transplantation|Stem cell infusion on Day 0.
1719597|NCT00002832|Biological|Filgrastim|Subcutaneously (SQ) daily every 12 hours starting 2-4 days prior to first PBSC collection then daily starting 1 day after PBSC infusion until blood counts recover.
1719598|NCT00002832|Drug|Cyclosporine|IV daily on day -2, then orally once dose is tolerable, dose may be escalated.
1719599|NCT00002832|Drug|Decitabine|IV for 6 hours every 12 hr for 5 days.
1719600|NCT00002832|Procedure|Allogeneic Bone Marrow Transplantation|Stem cell infusion on Day 0.
1719601|NCT00002832|Procedure|Peripheral Blood Stem Cell Transplantation|Peripheral blood stem cells (PBSC) are administered 5 days after last dose of decitabine.
1719602|NCT00002833|Biological|Filgrastim|Donors receive Filgrastim SC (Subcutaneously) every 12 hours for 2 days prior to stem cell collection.
1719603|NCT00002833|Drug|Cladribine|Continuous infusion for 5 days, beginning 4 hours before Ara-C first dose.
1719604|NCT00002833|Drug|Cyclosporine|For GVHD prophylaxis, cyclosporine via continuous IV infusion. Oral cyclosporine administered once tolerating oral feeding and continued for 6 months postinfusion. Then dose tapered 10% weekly until discontinued.
1719605|NCT00002833|Drug|Cytarabine (Ara-C)|Group 1A: Ara-C IV over 2 hours on days -7, -6, -5, -4 and -3; Group 1B: Ara-C IV begins 4 hours after fludarabine infusion, continues for 4 hours.
1719606|NCT00002833|Drug|Fludarabine Phosphate|IV over 30 minutes daily on days -6, -5, -4 and -3.
1719607|NCT00002833|Drug|Idarubicin|IV Days -6, -5 and -4.
1719608|NCT00002833|Drug|Methylprednisolone|Begins 5 days after infusion and is gradually tapered.
1719609|NCT00002833|Procedure|Peripheral Blood Stem Cell Transplantation|Cell infusion Day 0.
1719610|NCT00002835|Biological|Bleomycin Sulfate (BLM)|
1719611|NCT00002835|Biological|Filgrastim (G-CSF)|Arm 1: Administered subcutaneously (SC) beginning on day 5 and continuing until blood counts recover through Course 1 then 2 courses administered before PBSC harvest and same regimen with Course 2, then daily with Day 0 of infusion.
1719612|NCT00002835|Biological|Recombinant Interferon Alfa|
1719613|NCT00002835|Drug|Carmustine|Arm 1, Course 3, IV over 1 hour on day -6.
1719614|NCT00002835|Drug|Cisplatin (CDDP)|
1719615|NCT00002835|Drug|Cyclophosphamide|
1719616|NCT00002835|Drug|Cytarabine (ARA-C)|Arm 1, Course 3, every 12 hours on days -5 to -2.
1719617|NCT00002835|Drug|Etoposide (VP-16)|Course 1, IV over 2 hours every 12 hours on days 1-3; Course 3, every 12 hours on days -5 to -2.
1719618|NCT00002835|Drug|Idarubicin|
1719619|NCT00002835|Drug|Ifosfamide|During Course 1, IV continuously; Course 2, IV continuously on days 1-3.
1719620|NCT00002835|Drug|Leucovorin Calcium|
1719621|NCT00002835|Drug|Melphalan|
1719622|NCT00002835|Drug|Methotrexate|
1719623|NCT00002835|Drug|Methylprednisolone|
1719624|NCT00002835|Drug|mitoxantrone hydrochloride (DHAD)|Arm 1, Course 2, IV on day 1.
1719625|NCT00002835|Drug|Vincristine Sulfate|
1719626|NCT00002835|Procedure|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
1719627|NCT00002835|Radiation|Radiation Therapy|
1719628|NCT00002836|Biological|Filgrastim (G-CSF)|For group one (Filgrastim + Chemotherapy), given under the skin (SC) on day 4 every 12 hours until completion of apheresis; for group two (Filgrastim alone), beginning on day of reinfusion twice a day (bid) until white blood count (WBC) reaches a safe level.
1719629|NCT00002836|Drug|Carmustine|Upon recovery of hematopoiesis patients then receive high by vein (IV) doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days
1719630|NCT00002836|Drug|Cisplatin|As part of CVP chemotherapy treatment by vein (IV) on days 1-3.
1719631|NCT00002836|Drug|Cyclophosphamide (CTX)|In group one (Filgrastim + Chemotherapy) as part of CVP chemotherapy treatment by vein (IV) on days 1-3; and group two (Filgrastim alone), upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
1719632|NCT00002836|Drug|Etoposide|CVP chemotherapy treatment IV on days 1-3, with cyclophosphamide (CTX), etoposide, and cisplatin.
1719633|NCT00002836|Drug|Thiotepa|Upon recovery of hematopoiesis receive high IV doses of CBT chemotherapy with CTX, carmustine, and thiotepa for 3 days.
1719634|NCT00002836|Procedure|Peripheral Blood Stem Cell Transplantation|Infusion of stem cells on Day 0.
1719635|NCT00002837|Biological|Filgrastim (G-CSF)|
1719636|NCT00002837|Drug|Cyclophosphamide|
1719637|NCT00002837|Drug|Doxorubicin Hydrochloride|
1719638|NCT00002837|Drug|Paclitaxel|
1719639|NCT00002837|Procedure|Peripheral Blood Stem Cell Transplantation|
1719640|NCT00002838|Biological|Filgrastim (G-CSF)|
1719641|NCT00002838|Drug|Cyclophosphamide|
1719642|NCT00002838|Drug|Fludarabine Phosphate|
1719646|NCT00002839|Procedure|conventional surgery|
1719647|NCT00002839|Procedure|neoadjuvant therapy|
1719648|NCT00002839|Radiation|radiation therapy|
1719649|NCT00002840|Drug|lomustine|
1719650|NCT00002840|Drug|procarbazine hydrochloride|
1719651|NCT00002840|Drug|vincristine sulfate|
1719652|NCT00002840|Radiation|radiation therapy|
1719653|NCT00002842|Drug|floxuridine|Starting dose of 0.2 mg/kg/day for 14 consecutive days.
1719654|NCT00002842|Drug|fluorouracil|300 mg/m2/day by intravenous bolus 24 hours apart for 5 consecutive days.
1719655|NCT00002842|Drug|leucovorin calcium|500 mg/m2/day by continuous intravenous infusion beginning 24 hours prior to the first dose of 5-FU and continuing until 12 hours following the last dose of 5-FU.
1719656|NCT00002842|Procedure|adjuvant therapy|Chemotherapy given after hepatic resection
1719657|NCT00002842|Procedure|conventional surgery|Hepatic resection
1719658|NCT00002844|Drug|Cyclophosphamide|Daily intravenous infusions of cyclophosphamide for two days,
1719659|NCT00002844|Procedure|Allogeneic Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
1719660|NCT00002844|Procedure|Autologous Bone Marrow Transplantation|After completion of the TBI, allogeneic or autologous bone marrow infused intravenously.
1719661|NCT00002844|Radiation|Total Body Irradiation (TBI)|Following 2 days of cyclophosphamide, TBI in four daily exposures then bone marrow transplant.
1719662|NCT00002845|Biological|aldesleukin|
1719663|NCT00002846|Biological|aldesleukin|
1719664|NCT00002846|Procedure|conventional surgery|
1719665|NCT00002847|Biological|aldesleukin|
1719666|NCT00002847|Biological|recombinant interferon alfa|
1719667|NCT00002847|Procedure|conventional surgery|
1719668|NCT00002848|Procedure|psychosocial assessment and care|
1719669|NCT00002848|Procedure|quality-of-life assessment|
1719670|NCT00002849|Biological|recombinant interferon alfa|first 2 years
1719671|NCT00002849|Drug|dexamethasone|40 mg*/d PO 1 - 4, 9 - 12, 17-20 q 35 days for 3 cycles*
1719672|NCT00002850|Drug|ciprofloxacin|Begin oral ciprofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ciprofloxacin (Cipro 500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
1719673|NCT00002850|Drug|ofloxacin|Begin oral ofloxacin when they start chemotherapy for multiple myeloma. Assigned treatment consists of ofloxacin (500 mg po tablet every 12 hours for two months. The patient will continue to be observed one additional month on study continuing regular myeloma chemotherapy.
1719674|NCT00002850|Drug|160 mg trimethoprim and 800 mg sulfamethoxazole|Begin oral TMP-SMX when they start chemotherapy for multiple myeloma. Assigned treatment consists of TMP-SMX (Septra® or Bactrim®) 1 DS tablet [TMP-SMX DS = 160 mg trimethoprim and 800 mg sulfamethoxazole] every 12 hours for two months..
1719675|NCT00002851|Procedure|adjuvant therapy|
1719676|NCT00002851|Radiation|low-LET electron therapy|
1719677|NCT00002851|Radiation|low-LET photon therapy|
1719678|NCT00002852|Drug|paclitaxel|Given IV
1719679|NCT00002852|Drug|carboplatin|Given IV
1719680|NCT00002852|Procedure|therapeutic conventional surgery|Undergo surgery
1719681|NCT00002854|Biological|filgrastim|
1719682|NCT00002854|Drug|carboplatin|
1719683|NCT00002854|Drug|cisplatin|
1719684|NCT00002854|Drug|cyclophosphamide|
1719685|NCT00002854|Drug|etoposide|
1719686|NCT00002854|Drug|ifosfamide|
1719687|NCT00002854|Drug|mesna|
1719688|NCT00002854|Drug|paclitaxel|
1719689|NCT00002854|Procedure|peripheral blood stem cell transplantation|
1719690|NCT00002855|Drug|Bicalutamide|
1719691|NCT00002855|Drug|Doxorubicin hydrochloride|
1719692|NCT00002855|Drug|Estramustine Phosphate Sodium|
1719693|NCT00002855|Drug|Flutamide|
1719694|NCT00002855|Drug|Ketoconazole|
1719695|NCT00002855|Drug|Nilutamide|
1719696|NCT00002855|Drug|Therapeutic Hydrocortisone|
1719697|NCT00002855|Drug|Vinblastine|
1719698|NCT00002855|Procedure|Conventional Surgery|Surgical castration
1719699|NCT00002858|Drug|cisplatin|
1719700|NCT00002858|Drug|cyclophosphamide|
1719701|NCT00002858|Drug|doxorubicin hydrochloride|
1719702|NCT00002858|Drug|etoposide|
1719703|NCT00002858|Radiation|radiation therapy|
1719704|NCT00002860|Procedure|Surgery|Complete surgical resection of metastatic melanoma
1719705|NCT00002862|Drug|perillyl alcohol|
1719706|NCT00002863|Drug|chemotherapy|
1719707|NCT00002863|Procedure|conventional surgery|
1719708|NCT00002863|Procedure|cryosurgery|
1719709|NCT00002864|Drug|octreotide acetate|Octreotide LAR (SMS 201-995 pa LAR) 90 mg depot injection monthly for 2 years (plus Tamoxifen 20 mg PO daily for 5 years)
1719710|NCT00002864|Drug|tamoxifen citrate|20 mg PO for 5 years
1719711|NCT00002865|Biological|filgrastim|
1719712|NCT00002865|Drug|cyclophosphamide|
1719713|NCT00002865|Drug|cytarabine|
1719714|NCT00002865|Drug|dexamethasone|
1719715|NCT00002865|Drug|doxorubicin hydrochloride|
1719716|NCT00002865|Drug|etoposide|
1719717|NCT00002865|Drug|ifosfamide|
1719718|NCT00002865|Drug|leucovorin calcium|
1719719|NCT00002865|Drug|mesna|
1719720|NCT00002865|Drug|methotrexate|
1719721|NCT00002865|Drug|therapeutic hydrocortisone|
1719722|NCT00002865|Drug|vincristine sulfate|
1719723|NCT00002865|Radiation|low-LET cobalt-60 gamma ray therapy|
1719724|NCT00002865|Radiation|low-LET photon therapy|
1719725|NCT00002866|Biological|filgrastim|
1719726|NCT00002866|Drug|docetaxel|
1719727|NCT00002866|Drug|epirubicin hydrochloride|
1719728|NCT00002868|Biological|filgrastim|
1719729|NCT00002868|Biological|recombinant interferon alfa|
1719730|NCT00002868|Drug|busulfan|
1719731|NCT00002868|Drug|cytarabine|
1719732|NCT00002868|Drug|etoposide|
1719735|NCT00002868|Procedure|peripheral blood stem cell transplantation|
1719736|NCT00002869|Biological|recombinant interferon alfa|
1719737|NCT00002869|Drug|cytarabine|
1719738|NCT00002869|Drug|hydroxyurea|
1719739|NCT00002870|Biological|filgrastim|
1719740|NCT00002870|Drug|cyclophosphamide|
1719741|NCT00002870|Drug|epirubicin hydrochloride|
1719742|NCT00002870|Drug|fluorouracil|
1719743|NCT00002870|Drug|thiotepa|
1719744|NCT00002870|Procedure|peripheral blood stem cell transplantation|
1719745|NCT00002872|Biological|bleomycin sulfate|
1719746|NCT00002872|Drug|doxycycline|
1719747|NCT00002872|Other|talc|
1719748|NCT00002873|Radiation|brachytherapy|
1719749|NCT00002874|Drug|bicalutamide|One (150 mg) tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
1719750|NCT00002874|Radiation|radiation therapy|64.8 Gy in 36 fractions (1.8 Gy in 5 daily sessions per week) to the original prostate volume, the tumor resection bed, and the proximal membranous urethra.
1719751|NCT00002874|Drug|placebo|One tablet by mouth daily for two years beginning immediately upon, or just prior to, the initiation of irradiation.
1719752|NCT00002875|Biological|filgrastim|
1719753|NCT00002875|Drug|cisplatin|
1719754|NCT00002875|Drug|cyclophosphamide|
1719755|NCT00002875|Drug|lomustine|
1719756|NCT00002875|Drug|mesna|
1719757|NCT00002875|Drug|vincristine sulfate|
1719758|NCT00002875|Radiation|low-LET electron therapy|
1719759|NCT00002875|Radiation|low-LET photon therapy|
1719760|NCT00002876|Drug|cisplatin|
1719761|NCT00002876|Drug|etoposide|
1719762|NCT00002878|Drug|dexamethasone|
1719763|NCT00002878|Drug|doxorubicin hydrochloride|
1719764|NCT00002878|Drug|valspodar|
1719765|NCT00002878|Drug|vincristine sulfate|
1719766|NCT00002879|Drug|cladribine|
1719767|NCT00002880|Drug|Etoposide phosphate|50 mg PO q day for 21 days; repeat every 28 days escalate dose to 100 mg PO q day if ANC remains greater than 1500/microliter during cycle 1: no specified maximum of cycles if PR or CR
1719768|NCT00002881|Drug|flutamide|
1719769|NCT00002881|Drug|goserelin acetate|
1719770|NCT00002881|Drug|leuprolide acetate|
1719771|NCT00002881|Drug|suramin|
1719772|NCT00002881|Drug|therapeutic hydrocortisone|
1719773|NCT00002881|Procedure|orchiectomy|
1719774|NCT00002882|Biological|Aldesleukin (IL-2)|Infusion for a total of 96 hours on days 1-4
1719775|NCT00002882|Biological|Recombinant Interferon Alfa (IFN-A)|"IFN-A Therapy Groups:
Schedule A: IV IFN-A induction 5 times a week for 4 weeks followed by subcutaneous IFN-A maintenance 3 times a week for 48 weeks.
Schedule B: Subcutaneous IFN-A 3 times a week for 52 weeks
Adjuvant Biochemotherapy Group: IFN-A is given subcutaneously on days 1-5"
1719776|NCT00002882|Drug|Cisplatin|IV Days 1-4
1719777|NCT00002882|Drug|Dacarbazine|IVPB on day 1
1719778|NCT00002882|Drug|Vinblastine|IVPB on days 1-4
1719779|NCT00002882|Procedure|Adjuvant Therapy|Patients receiving adjuvant radiotherapy will start adjuvant systemic therapy within 8 weeks from lymphadenectomy and a week after completion of and recovery from radiotherapy.
1719780|NCT00002883|Drug|cisplatin|
1719781|NCT00002883|Drug|fluorouracil|
1719782|NCT00002883|Procedure|adjuvant therapy|
1719783|NCT00002883|Procedure|conventional surgery|
1719784|NCT00002883|Procedure|neoadjuvant therapy|
1719785|NCT00002884|Drug|chemotherapy|
1719786|NCT00002884|Drug|cisplatin|
1719787|NCT00002884|Drug|fluorouracil|
1719788|NCT00002884|Radiation|brachytherapy|
1719789|NCT00002884|Radiation|radiation therapy|
1719790|NCT00002887|Drug|cisplatin|
1719791|NCT00002887|Drug|etoposide|
1719792|NCT00002887|Drug|hydroxyurea|
1719793|NCT00002887|Drug|vinblastine sulfate|
1719794|NCT00002887|Drug|vindesine|
1719795|NCT00002887|Drug|vinorelbine tartrate|
1719796|NCT00002887|Procedure|drug resistance inhibition treatment|
1719797|NCT00002888|Drug|cisplatin|
1719798|NCT00002888|Drug|fluorouracil|
1719799|NCT00002888|Drug|paclitaxel|
1719800|NCT00002889|Drug|flutamide|
1719801|NCT00002889|Drug|goserelin|
1719802|NCT00002889|Drug|leuprolide acetate|
1719803|NCT00002889|Radiation|low-LET photon therapy|
1719804|NCT00002890|Biological|lintuzumab|
1719805|NCT00002892|Biological|recombinant interferon alfa|
1719806|NCT00002893|Drug|fluorouracil|
1719807|NCT00002893|Drug|leucovorin calcium|
1719808|NCT00002893|Drug|raltitrexed|
1719809|NCT00002894|Drug|carboplatin|
1719810|NCT00002894|Drug|cisplatin|
1719811|NCT00002894|Drug|paclitaxel|
1719812|NCT00002895|Drug|chemotherapy|
1719813|NCT00002896|Drug|chemotherapy|
1719814|NCT00002896|Drug|fluorouracil|
1719815|NCT00002896|Drug|leucovorin calcium|
1719816|NCT00002896|Procedure|conventional surgery|
1719817|NCT00002896|Radiation|low-LET cobalt-60 gamma ray therapy|
1719818|NCT00002896|Radiation|low-LET photon therapy|
1719819|NCT00002897|Drug|cisplatin|
1719820|NCT00002897|Drug|fluorouracil|
1719821|NCT00002897|Procedure|conventional surgery|
1719822|NCT00002898|Biological|dactinomycin|
1719823|NCT00002898|Drug|carboplatin|
1719824|NCT00002898|Drug|cyclophosphamide|
1719825|NCT00002898|Drug|epirubicin hydrochloride|
1719826|NCT00002898|Drug|etoposide|
1719827|NCT00002898|Drug|ifosfamide|
1719828|NCT00002898|Drug|vincristine sulfate|
1719829|NCT00002898|Procedure|adjuvant therapy|
1719830|NCT00002898|Procedure|conventional surgery|
1719831|NCT00002898|Procedure|neoadjuvant therapy|
1719832|NCT00002898|Radiation|brachytherapy|
1719833|NCT00002898|Radiation|radiation therapy|
1719834|NCT00002899|Procedure|adjuvant therapy|
1719835|NCT00002899|Radiation|radiation therapy|
1719836|NCT00002899|Radiation|stereotactic radiosurgery|
1719837|NCT00002900|Procedure|management of therapy complications|
1719838|NCT00002901|Drug|docetaxel|
1719839|NCT00002902|Drug|irinotecan hydrochloride|
1719840|NCT00002902|Drug|raltitrexed|
1719841|NCT00002903|Drug|docetaxel|
1719842|NCT00002904|Drug|trabectedin|
1719843|NCT00002905|Drug|cyclophosphamide|
1719844|NCT00002905|Drug|didanosine|
1719845|NCT00002905|Drug|doxorubicin hydrochloride|
1719846|NCT00002905|Drug|etoposide|
1719847|NCT00002905|Drug|mitoxantrone hydrochloride|
1719848|NCT00002905|Drug|prednimustine|
1719849|NCT00002905|Drug|zidovudine|
1719850|NCT00002907|Drug|bryostatin 1|
1719851|NCT00002908|Drug|bryostatin 1|
1719852|NCT00002908|Drug|vincristine sulfate|
1719853|NCT00002909|Drug|chemotherapy|
1719854|NCT00002909|Drug|oral sodium phenylbutyrate|
1719855|NCT00002911|Drug|marimastat|
1719856|NCT00002912|Drug|etoposide|
1719857|NCT00002912|Drug|mitoxantrone hydrochloride|
1719858|NCT00002912|Drug|valspodar|
1719859|NCT00002913|Drug|paclitaxel|Given IV
1719860|NCT00002913|Drug|cisplatin|Given IV
1719861|NCT00002913|Drug|topotecan hydrochloride|Given IV
1719862|NCT00002913|Biological|filgrastim|Given SC
1719863|NCT00002914|Drug|piritrexim|
1719864|NCT00002915|Drug|penclomedine|
1719865|NCT00002916|Biological|human papillomavirus 16 E7 peptide|
1719866|NCT00002916|Biological|synthetic human papillomavirus 16 E6 peptide|
1719867|NCT00002916|Procedure|adjuvant therapy|
1719868|NCT00002916|Procedure|surgical procedure|
1719869|NCT00002916|Radiation|radiation therapy|
1719870|NCT00002917|Drug|paclitaxel|
1719871|NCT00002919|Biological|filgrastim|
1719872|NCT00002919|Drug|cisplatin|
1719873|NCT00002919|Drug|doxorubicin hydrochloride|
1719874|NCT00002919|Drug|methotrexate|
1719875|NCT00002919|Drug|vinblastine sulfate|
1719876|NCT00002919|Procedure|conventional surgery|
1719877|NCT00002920|Drug|medroxyprogesterone|
1719878|NCT00002920|Drug|tamoxifen citrate|
1719879|NCT00002920|Procedure|adjuvant therapy|
1719880|NCT00002921|Drug|suramin|
1719881|NCT00002921|Drug|therapeutic hydrocortisone|
1719882|NCT00002922|Drug|paclitaxel|
1719883|NCT00002923|Drug|KRN5500|
1719884|NCT00002924|Other|mutation analysis|
1719885|NCT00002925|Drug|ara-C|
1719886|NCT00002925|Drug|Daunorubicin|
1719887|NCT00002925|Drug|Etoposide|
1719888|NCT00002925|Drug|PSC-833|
1719889|NCT00002925|Biological|Aldesleukin|
1719890|NCT00002926|Drug|cytarabine|
1719891|NCT00002926|Drug|etoposide|
1719892|NCT00002926|Drug|idarubicin|
1719893|NCT00002926|Procedure|allogeneic bone marrow transplantation|
1719894|NCT00002926|Procedure|peripheral blood stem cell transplantation|
1719895|NCT00002928|Drug|paclitaxel|
1719896|NCT00002930|Procedure|positron emission tomography|
1719897|NCT00002930|Radiation|fludeoxyglucose F 18|
1719898|NCT00002931|Biological|filgrastim|5 ug/kg bid beginning 4 days prior to and continuing through stem cell collection.
1719899|NCT00002931|Drug|carboplatin|AUC=7, daily X 3
1719900|NCT00002931|Drug|etoposide|20 mg/kg by 2 hours infusion daily X 3
1719901|NCT00002931|Drug|ifosfamide|3 gm/m2 IV over 30 minutes X 3 days
1719902|NCT00002931|Drug|paclitaxel|425 mg/m2 as 24 hour continuous infusion
1719903|NCT00002931|Procedure|autologous bone marrow transplantation|Given in two divided infusions on day -2 and day 0
1719904|NCT00002931|Procedure|bone marrow ablation with stem cell support|Two cycles of high dose chemotherapy followed by stem cell reinfusion
1719905|NCT00002932|Drug|cisplatin|
1719906|NCT00002932|Radiation|radiation therapy|
1719907|NCT00002933|Drug|irinotecan hydrochloride|Irinotecan IV at a starting dose weekly for 4 weeks followed by 2 weeks of rest. Treatment continues in the absence of disease progression or unacceptable toxicity. Tumor status is reassessed every 12 weeks during study. Patients attaining a complete response may receive additional courses of treatment. Patients are followed until death.
1719908|NCT00002934|Procedure|long-term screening|
1719909|NCT00002935|Drug|porfimer sodium|
1719910|NCT00002936|Drug|altretamine|
1719911|NCT00002936|Drug|etoposide|
1719912|NCT00002937|Drug|paclitaxel|
1719913|NCT00002937|Drug|valspodar|
1719914|NCT00002938|Procedure|conventional surgery|Salvage prostatectomy
1719915|NCT00002939|Drug|irinotecan hydrochloride|
1719916|NCT00002939|Drug|paclitaxel|
1719917|NCT00002940|Drug|hydroxyurea|
1719918|NCT00002941|Drug|carmustine|
1719919|NCT00002941|Drug|cyclophosphamide|
1719920|NCT00002941|Drug|etoposide|
1719921|NCT00002941|Drug|mesna|
1719922|NCT00002941|Procedure|peripheral blood stem cell transplantation|
1719923|NCT00002942|Procedure|autologous bone marrow transplantation|
1719924|NCT00002942|Procedure|peripheral blood stem cell transplantation|
1719925|NCT00002943|Drug|carboplatin|
1719926|NCT00002943|Drug|cyclophosphamide|
1719927|NCT00002943|Drug|etoposide|
1719928|NCT00002943|Procedure|autologous bone marrow transplantation|
1719929|NCT00002944|Drug|carboplatin|Given IV
1719930|NCT00002944|Drug|lomustine|Given IV
1719931|NCT00002944|Drug|procarbazine hydrochloride|Given PO
1719932|NCT00002944|Drug|thioguanine|Given PO
1719933|NCT00002944|Drug|vincristine sulfate|Given PO and IV
1719934|NCT00002945|Biological|aldesleukin|IV
1719935|NCT00002945|Biological|filgrastim|IV
1719936|NCT00002945|Drug|cyclophosphamide|IV
1719937|NCT00002945|Drug|cytarabine|IV
1719941|NCT00002945|Procedure|peripheral blood stem cell transplantation|IV
1719942|NCT00002945|Radiation|radiation therapy|delivered to the cancer cells
1719943|NCT00002946|Drug|penclomedine|
1719944|NCT00002947|Radiation|indium In 111 pentetreotide|
1719945|NCT00002948|Biological|filgrastim|
1719946|NCT00002948|Drug|topotecan hydrochloride|
1719947|NCT00002948|Procedure|bone marrow ablation with stem cell support|
1719948|NCT00002948|Procedure|peripheral blood stem cell transplantation|
1719949|NCT00002949|Drug|paclitaxel|Paclitaxel (qwk, starting dose of 20mg/m2 with planned dose escalation increments of 5mg/m2)
1719950|NCT00002949|Drug|vinorelbine tartrate|Vinorelbine (qwk, 10, 15, 20 or 25 mg/m2),
1719951|NCT00002949|Radiation|radiation therapy|Radiation therapy (Total pelvic RT of 45 Gy in 1.8-Gy daily fractions, 85 Gy in cervical cancer patients using intracavitary brachytherapy, 70 Gy in patients treated with interstitial brachytherapy)
1719952|NCT00002950|Biological|sargramostim|
1719953|NCT00002950|Drug|topotecan hydrochloride|
1719954|NCT00002951|Drug|fluorouracil|
1719955|NCT00002951|Drug|hydroxyurea|
1719956|NCT00002951|Procedure|surgical procedure|
1719957|NCT00002951|Radiation|radiation therapy|
1719958|NCT00002952|Biological|MART-1 antigen|Melan-A peptide loaded PBMCs (sc, q3wk x 3)
1719959|NCT00002952|Biological|recombinant MAGE-3.1 antigen|
1719960|NCT00002952|Biological|recombinant interleukin-12|rhIL-12 (4 mcg, sc, days 1, 3 and 5 of every 3 wk cycle)
1719961|NCT00002953|Drug|cyclophosphamide|
1719962|NCT00002953|Drug|epirubicin hydrochloride|
1719963|NCT00002953|Drug|paclitaxel|
1719964|NCT00002955|Drug|fluorouracil|
1719965|NCT00002955|Drug|leucovorin calcium|
1719966|NCT00002955|Drug|trimetrexate glucuronate|
1719967|NCT00002956|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
1719968|NCT00002960|Biological|recombinant adenovirus-p53 SCH-58500|
1719969|NCT00002961|Drug|cyclophosphamide|Arms A and B Day 2 and 3: Cyclophosphamide 60 mg/kg intravenously; Administer 20 mg/ml concentration over 2 hours.
1719970|NCT00002961|Drug|cyclosporine|"graft vs. host disease (GVHD)prophylaxis: starting on day-1, cyclosporin 1.5 mg/kg IV every 12 hours or by continuous infusion.
When the patient tolerates adequate oral intake, cyclosporin therapy may be changed from IV to oral administration. Cyclosporin therapy should be continued at full dose until day +50. if the patient has less than Grade 2 GVHD, cyclosporin may be tapered by 5-10% weekly until completely off cyclosporin therapy."
1719971|NCT00002961|Drug|etoposide|Day 4 (arms A/B): 40 mg/kg over four hours intravenously
1719972|NCT00002961|Drug|methotrexate|"methotrexate 15 mg/m2 IV on day +1 (do not give until 24 hours after marrow infusion), and 10mg/mg2 IV on days +3 and +6.
Methotrexate may be held after two doses for bilirubin .2 mg/dL. If serum creatinine is >2x baseline, methotrexate will be omitted. If the presence of ascites or pleural effusion, methotrexate will be omitted."
1719973|NCT00002961|Procedure|allogeneic bone marrow transplantation|Bone marrow infusion given on day 0
1719974|NCT00002961|Radiation|Total Body Irradiation|Day 0: Marrow Transfusion; Day 1: rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6 and 7: Total Body Irradiation (TBI) [200 cGy twice a day (BID)].
1719975|NCT00002961|Drug|Busulfan|"Conditioning Regimen Arm B:
Day 0: Marrow infusion; Day 1: Rest; Day 2 and 3: Cyclophosphamide 60 mg/kg; Day 4: Etopophos 40 mg/kg over four hours; Day 5,6,7 and 8: Busulfan 0.8 mg/kg intravenous (IV) every 6 hours x 4 doses.
Patients </= 20kg to receive busulfan 1.0 mg/kg/dose IV**Busulfan oral preparation may be substituted: 1mg/kg/dose by mouth (po) for patients >20kg and 1.25 mg/kg/dose by mouth (po) for patients </= 20 kg."
1719976|NCT00002961|Drug|Mesna|Dosing per institutional preference for hemorrhagic cystitis. Mesna 300 mg/m2 as a 15 minute infusion prior to each dose of cyclophosphamide, then at 3,6,9,12, 18 and 21 hours after initiation of each cyclophosphamide infusion. Alternative method of Mesna administration is 10 mg/kg prior to cyclophosphamide and 100 mg/kg/24 hours by continuous infusion.
1719977|NCT00002961|Radiation|Radiation|"Central Nervous System (CNS) therapy:
a) CNS Leukemia prior to study entry: No TBI i) No prior CNS irradiation: 2340 centigray (cGy) in 13 fractions of 180 cGy to the cranial field and 600 cGy in 200 cGy fractions to the spinal field prior to conditioning. II) >/= 1800 cGy prior CNS irradiation: 1800 cGy to cranial field and 600 cGy spinal prior to conditioning. If prior radiation therapy (RT) doses >3000 cGy have been administered or CNS Leukemia prior to study entry: TBI, consult with Principal Investigator (PI). Recommend: 1) no prior CNS irradiation: 600 cGy in 3 fractions to the cranial field prior to conditioning or overlapping with TBI.
Testicular Boost Irradiation: a) overt testicular leukemia at relapse: No TBI 2400 cGy in 12 fractions prior to conditioning; b) overt testicular leukemia at relapse: TBI 1200 cGy in 6 fractions over 8-10 days prior to conditioning. c) No overt testicular leukemia: 200 cGy first and last fractions of TBI-"
1719978|NCT00002963|Drug|aminolevulinic acid hydrochloride|
1719979|NCT00002963|Procedure|conventional surgery|
1719980|NCT00002964|Drug|porfimer sodium|
1719981|NCT00002964|Other|fluorophotometry|
1719982|NCT00002965|Biological|Recombinant Interferon Alfa (INF alpha)|Subcutaneous injection Monday through Friday for 8 weeks.
1719983|NCT00002967|Drug|cyclophosphamide|
1719984|NCT00002967|Drug|doxorubicin hydrochloride|
1719985|NCT00002967|Drug|octreotide pamoate|
1719986|NCT00002967|Drug|tamoxifen citrate|
1719987|NCT00002968|Biological|edrecolomab|Given IV
1719988|NCT00002968|Other|laboratory biomarker analysis|Correlative studies
1719989|NCT00002969|Drug|paclitaxel|
1719990|NCT00002970|Drug|nelarabine|Given IV
1719991|NCT00002970|Drug|methotrexate|Given IT
1719992|NCT00002970|Drug|cytarabine|Given IT
1719993|NCT00002970|Drug|therapeutic hydrocortisone|Given IT
1719994|NCT00002971|Drug|O6-benzylguanine|
1719995|NCT00002972|Drug|paclitaxel|
1719996|NCT00002405|Drug|Amprenavir|
1719997|NCT00002406|Drug|Indinavir sulfate|
1719998|NCT00002407|Drug|Indinavir sulfate|
1719999|NCT00002407|Drug|Nevirapine|
1720000|NCT00002407|Drug|Lamivudine|
1720001|NCT00002407|Drug|Stavudine|
1720002|NCT00002407|Drug|Didanosine|
1720003|NCT00002408|Drug|Crofelemer|
1720004|NCT00002409|Drug|Lamivudine/Zidovudine|
1720005|NCT00002409|Drug|Abacavir sulfate|
1720006|NCT00002410|Drug|Indinavir sulfate|
1720007|NCT00002410|Drug|Lamivudine|
1720008|NCT00002410|Drug|Zidovudine|
1720009|NCT00002411|Drug|Nelfinavir mesylate|
1720010|NCT00002411|Drug|Lamivudine|
1720011|NCT00002411|Drug|Stavudine|
1720012|NCT00002411|Drug|Zidovudine|
1720013|NCT00002411|Drug|Didanosine|
1720014|NCT00002973|Drug|melphalan|
1720015|NCT00002973|Procedure|hyperthermia treatment|
1720016|NCT00002974|Drug|carboplatin|
1720017|NCT00002974|Drug|etoposide|
1720018|NCT00002974|Drug|ifosfamide|
1720019|NCT00002974|Procedure|hyperthermia treatment|
1720020|NCT00002975|Drug|aminolevulinic acid|
1720021|NCT00002976|Drug|conjugated estrogens|
1720022|NCT00002977|Biological|filgrastim|
1720023|NCT00002977|Drug|melphalan|
1720024|NCT00002977|Drug|thiotepa|
1720025|NCT00002977|Procedure|peripheral blood stem cell transplantation|
1720026|NCT00002980|Drug|decitabine|
1720027|NCT00002981|Procedure|positron emission tomography|
1720028|NCT00002981|Radiation|fludeoxyglucose F 18|
1720029|NCT00002981|Radiation|methionine C 11|
1720030|NCT00002982|Biological|filgrastim|
1720031|NCT00002982|Drug|carboplatin|
1720032|NCT00002982|Drug|carmustine|
1720033|NCT00002982|Drug|cytarabine|
1720034|NCT00002982|Drug|etoposide|
1720035|NCT00002982|Drug|ifosfamide|
1720036|NCT00002982|Drug|melphalan|
1720037|NCT00002982|Procedure|autologous bone marrow transplantation|
1720038|NCT00002982|Procedure|peripheral blood stem cell transplantation|
1720039|NCT00002982|Radiation|radiation therapy|
1720040|NCT00002984|Drug|cisplatin|Cisplatin will be given at a dose of 100 mg/m2 at a concentration of 1 mg/ml over one hour on Day 1 and 29 for a total of 2 courses
1720041|NCT00002984|Drug|fluorouracil|5-FU will be given at 500 mg/m2 in 1 liter D5 1/2 by continuous infusion every 12 hours for a total of 8 doses (Total 1.0 g/m2/day X 4 days) on Days 1-4 and 29-32 for a total of 2 courses
1720042|NCT00002984|Drug|paclitaxel|30 mg/m2 - 45 mg/m2 given weekly. The dose each subject receives will depend on when they enter the study
1720043|NCT00002984|Procedure|surgical procedure|Surgical resection should take place approximately 4 weeks following completion of the chemotherapy.
1720044|NCT00002984|Radiation|radiation therapy|The dose of radiation to the tumor and nodal area will be 4500 cGy given as 180 cGy fractions daily, Monday through Friday, for 5 weeks
1720045|NCT00002985|Drug|daunorubicin hydrochloride|
1720046|NCT00002985|Drug|pegylated liposomal doxorubicin hydrochloride|
1720047|NCT00002986|Drug|carmustine|
1720048|NCT00002986|Drug|topotecan hydrochloride|
1720049|NCT00002987|Biological|bleomycin sulfate|
1720050|NCT00002987|Drug|cyclophosphamide|
1720051|NCT00002987|Drug|doxorubicin hydrochloride|
1720052|NCT00002987|Drug|etoposide|
1720053|NCT00002987|Drug|prednisolone|
1720054|NCT00002987|Drug|vincristine sulfate|
1720055|NCT00002987|Radiation|radiation therapy|
1720056|NCT00002988|Drug|carmustine|
1720057|NCT00002988|Drug|irinotecan hydrochloride|
1720058|NCT00002989|Drug|busulfan|
1720059|NCT00002989|Drug|cyclophosphamide|
1720060|NCT00002989|Drug|idarubicin|
1720061|NCT00002989|Drug|melphalan|
1720062|NCT00002989|Radiation|radiation therapy|
1720063|NCT00002990|Biological|BCG vaccine|
1720064|NCT00002993|Drug|cisplatin|
1720065|NCT00002993|Drug|doxorubicin hydrochloride|
1720066|NCT00002993|Drug|mitomycin C|
1720067|NCT00002994|Biological|interleukin 2|low dose: 1 million IU/square meter subq injection q day days 1-7 and 11-20 cycle 1; days 4-14 subsequent cycles Intermediate dose: 12 million IU/square meter subq injection on days 8-10 of cycle 1; days 1-3 of subsequent cycles
1720068|NCT00002994|Biological|rhuMAb|90 min IV infusion day 7 of each cycle
1720069|NCT00002995|Biological|dactinomycin|
1720070|NCT00002995|Biological|filgrastim|
1720071|NCT00002995|Biological|sargramostim|
1720072|NCT00002995|Drug|cyclophosphamide|
1720073|NCT00002995|Drug|vincristine sulfate|
1720074|NCT00002995|Radiation|radiation therapy|
1720075|NCT00002996|Drug|flecainide acetate|
1720076|NCT00002997|Procedure|cryosurgery|
1720077|NCT00002998|Drug|cisplatin|
1720078|NCT00002998|Drug|gemcitabine hydrochloride|
1720079|NCT00002999|Drug|cisplatin|
1720080|NCT00002999|Drug|fluorouracil|
1720081|NCT00002999|Radiation|radiation therapy|
1720082|NCT00003000|Drug|fentanyl citrate|
1720083|NCT00003000|Drug|morphine sulfate|
1720084|NCT00003001|Drug|fluorouracil|
1720085|NCT00003001|Drug|gemcitabine hydrochloride|
1720086|NCT00003001|Drug|leucovorin calcium|
1720087|NCT00003002|Biological|HER-2/neu peptide vaccine|
1720088|NCT00003002|Biological|sargramostim|
1720089|NCT00003003|Biological|sargramostim|
1720090|NCT00003003|Drug|mitomycin C|
1720091|NCT00003003|Drug|mitoxantrone hydrochloride|
1720092|NCT00003022|Radiation|iodine I 131 monoclonal antibody 3F8|
1720093|NCT00003023|Biological|BCG vaccine|
1720094|NCT00003023|Biological|monoclonal antibody A1G4 anti-idiotype vaccine|
1720095|NCT00003025|Biological|vitespen|
1720096|NCT00003026|Drug|bicalutamide|
1720097|NCT00003026|Drug|flutamide|
1720098|NCT00003026|Drug|triptorelin|
1720099|NCT00003026|Radiation|radiation therapy|
1720100|NCT00003027|Biological|aldesleukin|
1720101|NCT00003027|Biological|filgrastim|
1720102|NCT00003027|Biological|recombinant interferon alfa|
1720103|NCT00003027|Drug|cisplatin|
1720104|NCT00003027|Drug|dacarbazine|
1720105|NCT00003027|Drug|vinblastine|
1720109|NCT00003031|Drug|amphotericin B deoxycholate|
1720110|NCT00003031|Drug|voriconazole|
1720111|NCT00003032|Biological|filgrastim|
1720112|NCT00003032|Drug|cisplatin|
1720113|NCT00003032|Drug|cyclophosphamide|
1720114|NCT00003032|Drug|mitoxantrone hydrochloride|
1720115|NCT00003032|Drug|tamoxifen citrate|
1720116|NCT00003034|Drug|doxorubicin hydrochloride|Given IV
1720117|NCT00003034|Drug|ranpirnase|Given IV
1720118|NCT00003035|Biological|filgrastim|
1720119|NCT00003035|Drug|doxorubicin hydrochloride|
1720120|NCT00003035|Drug|paclitaxel|
1720121|NCT00003035|Drug|tamoxifen citrate|
1720122|NCT00003035|Procedure|surgical procedure|
1720123|NCT00003035|Radiation|radiation therapy|
1720124|NCT00003037|Drug|cisplatin|
1720125|NCT00003037|Drug|docetaxel|
1720126|NCT00003037|Drug|gemcitabine hydrochloride|
1720127|NCT00003038|Drug|doxorubicin hydrochloride|
1720128|NCT00003038|Drug|suramin|
1720129|NCT00003039|Drug|alvocidib|
1720130|NCT00003040|Procedure|laser surgery|CO2 supraglottic laryngectomy within 28 days following registration with neck dissection as needed
1720131|NCT00003040|Radiation|radiation therapy|200 cGy per day, five days per week for approximately 6 weeks, to begin 14 days after laser surgery
1720132|NCT00003041|Drug|pyrazoloacridine|
1720133|NCT00003042|Biological|filgrastim|
1720134|NCT00003042|Drug|cisplatin|
1720135|NCT00003042|Drug|cyclophosphamide|
1720136|NCT00003042|Drug|doxorubicin hydrochloride|
1720137|NCT00003042|Drug|melphalan|
1720138|NCT00003042|Drug|mesna|
1720139|NCT00003042|Drug|paclitaxel|
1720140|NCT00003042|Drug|tamoxifen citrate|
1720141|NCT00003042|Procedure|bone marrow ablation with stem cell support|
1720142|NCT00003042|Procedure|conventional surgery|
1720143|NCT00003042|Procedure|peripheral blood stem cell transplantation|
1720144|NCT00003044|Drug|cisplatin-e therapeutic implant|
1720145|NCT00003045|Device|Hyperthermia|Hyperthermia is delivered by the transrectal ultrasound applicator just prior to XRT, at least one week apart, during the first 4 weeks of XRT. The goal of hyperthermia is CEM T 90 43 greater than or equal to 10 minutes. The maximum applied power duration will be 120 minutes per treatment session
1720146|NCT00003045|Radiation|XRT|external beam radiation to a dose of 4500 cGy to a small pelvic field, followed by a boost to a reduced volume for an additional 2160 cGy. XRT is given daily, 5 days a week for 180 cGy per day. Total radiation dose=6660cGy
1720147|NCT00003046|Biological|Recombinant Interleukin-12|Intraperitoneal over 30 minutes once weekly for 4 weeks, repeats every 4 weeks for up to 6 courses
1720148|NCT00003048|Drug|Amifostine Trihydrate|Escalating dose IV for two weeks, followed by 2 weeks of rest. Each treatment cycle is 4 weeks.
1720149|NCT00003049|Drug|fluorouracil|
1720150|NCT00003049|Drug|leucovorin calcium|
1720151|NCT00003049|Procedure|conventional surgery|
1720152|NCT00003049|Radiation|radiation therapy|
1720153|NCT00003050|Drug|cyclophosphamide|
1720154|NCT00003050|Drug|doxorubicin hydrochloride|
1720155|NCT00003050|Drug|paclitaxel|
1720156|NCT00003050|Drug|tamoxifen citrate|
1720157|NCT00003050|Procedure|surgical procedure|
1720158|NCT00003050|Radiation|radiation therapy|
1720159|NCT00003052|Drug|doxorubicin hydrochloride|
1720160|NCT00003052|Drug|etoposide|
1720161|NCT00003052|Drug|ifosfamide|
1720162|NCT00003052|Procedure|conventional surgery|
1720163|NCT00003052|Procedure|hyperthermia treatment|
1720164|NCT00003052|Radiation|radiation therapy|
1720165|NCT00003053|Drug|cisplatin|
1720166|NCT00003053|Drug|etoposide|
1720167|NCT00003053|Procedure|adjuvant therapy|
1720168|NCT00003054|Drug|paclitaxel|
1720169|NCT00003055|Drug|cisplatin|
1720170|NCT00003055|Drug|irinotecan hydrochloride|
1720173|NCT00003057|Drug|loperamide hydrochloride|
1720174|NCT00003057|Drug|octreotide acetate|
1720175|NCT00003058|Drug|troglitazone|
1720176|NCT00003060|Biological|filgrastim|
1720177|NCT00003060|Drug|busulfan|
1720178|NCT00003060|Drug|cyclophosphamide|
1720179|NCT00003060|Drug|cyclosporine|
1720180|NCT00003060|Drug|methotrexate|
1720181|NCT00003060|Procedure|allogeneic bone marrow transplantation|
1720182|NCT00003061|Drug|cytarabine|
1720183|NCT00003061|Drug|methotrexate|
1720184|NCT00003061|Radiation|radiation therapy|
1720185|NCT00003062|Drug|temozolomide|
1720186|NCT00003063|Biological|recombinant interferon alfa|
1720187|NCT00003063|Drug|fluorouracil|
1720188|NCT00003063|Drug|leucovorin calcium|
1720189|NCT00003063|Drug|levamisole hydrochloride|
1720190|NCT00003064|Biological|filgrastim|
1720191|NCT00003064|Drug|carboplatin|
1720192|NCT00003064|Drug|etoposide phosphate|
1720193|NCT00003064|Drug|paclitaxel|
1720194|NCT00003064|Drug|thiotepa|
1720195|NCT00003064|Drug|topotecan hydrochloride|
1720196|NCT00003064|Procedure|peripheral blood stem cell transplantation|
1720197|NCT00003065|Biological|filgrastim|
1720198|NCT00003065|Drug|paclitaxel|
1720199|NCT00003065|Drug|topotecan hydrochloride|
1720200|NCT00003066|Drug|docetaxel|
1720201|NCT00003066|Drug|estramustine phosphate sodium|
1720202|NCT00003067|Biological|aldesleukin|
1720203|NCT00003067|Biological|lymphokine-activated killer cells|
1720204|NCT00003068|Drug|amifostine trihydrate|
1720205|NCT00003068|Drug|cyclophosphamide|
1720206|NCT00003068|Drug|mitoxantrone hydrochloride|
1720207|NCT00003068|Drug|thiotepa|
1720208|NCT00003068|Procedure|peripheral blood stem cell transplantation|
1720209|NCT00003070|Drug|enalapril maleate|
1720210|NCT00003070|Procedure|quality-of-life assessment|
1720211|NCT00003072|Drug|amifostine trihydrate|
1720212|NCT00003072|Drug|carboplatin|
1720213|NCT00003072|Drug|paclitaxel|
1720214|NCT00003073|Drug|liposomal cytarabine|
1720215|NCT00003075|Drug|Fenretinide|Oral Fenretinide daily for 6 months with 3 days of rest every month.
1720216|NCT00003075|Other|Placebo|Oral placebo daily for 6 months with 3 days of rest every month.
1720217|NCT00003076|Drug|eflornithine|
1720218|NCT00003077|Dietary Supplement|omega-3 fatty acid|
1720219|NCT00003078|Drug|cisplatin|
1720220|NCT00003078|Drug|fluorouracil|
1720221|NCT00003078|Radiation|brachytherapy|
1720222|NCT00003078|Radiation|radiation therapy|
1720223|NCT00003079|Drug|bryostatin 1|
1720224|NCT00003079|Drug|cytarabine|
1720225|NCT00003080|Drug|endocrine-modulating drug therapy|
1720226|NCT00003080|Drug|melphalan|
1720227|NCT00003080|Drug|mitoxantrone hydrochloride|
1720228|NCT00003080|Drug|tamoxifen citrate|
1720229|NCT00003080|Drug|thiotepa|
1720230|NCT00003080|Procedure|peripheral blood stem cell transplantation|
1720231|NCT00003081|Biological|filgrastim|
1720232|NCT00003081|Drug|busulfan|
1720233|NCT00003081|Drug|melphalan|
1720234|NCT00003081|Drug|thiotepa|
1720235|NCT00003081|Procedure|peripheral blood stem cell transplantation|
1720236|NCT00003081|Radiation|radiation therapy|
1720237|NCT00003082|Biological|monoclonal antibody A27.15|
1720238|NCT00003082|Biological|monoclonal antibody E2.3|
1720239|NCT00003084|Drug|Doxorubicin Hydrochloride|Doxorubicin IV on days 1, 15, and 29.
1720240|NCT00003084|Drug|Estramustine phosphate sodium|"Arm I: Oral estramustine three times a day for 21 day cycle.
Arm II: Oral estramustine three times a day on days 8-14, 22-28, and 36-42 in 8 week cycle."
1720241|NCT00003084|Drug|Etoposide|Oral etoposide twice daily on days 1-14.
1720242|NCT00003084|Drug|Ketoconazole|Oral ketoconazole three times a day on days 1-7, 15-21, and 29-35.
1720243|NCT00003084|Drug|Paclitaxel|IV over 1 hour on day 2.
1720244|NCT00003084|Drug|Vinblastine|IV on days 8, 22, and 36.
1720245|NCT00003085|Procedure|laparoscopy|
1720246|NCT00003085|Procedure|ultrasound imaging|
1720247|NCT00003086|Biological|filgrastim|
1720248|NCT00003086|Drug|CAF regimen|
1720249|NCT00003086|Drug|carboplatin|
1720250|NCT00003086|Drug|cisplatin|
1720251|NCT00003086|Drug|cyclophosphamide|
1720252|NCT00003086|Drug|doxorubicin hydrochloride|
1720253|NCT00003086|Drug|fluorouracil|
1720254|NCT00003086|Drug|ifosfamide|
1720255|NCT00003086|Drug|melphalan|
1720256|NCT00003086|Drug|paclitaxel|
1720257|NCT00003086|Drug|thiotepa|
1720258|NCT00003086|Procedure|peripheral blood stem cell transplantation|
1720259|NCT00003086|Radiation|samarium Sm 153 lexidronam pentasodium|
1720260|NCT00003087|Drug|cisplatin|
1720261|NCT00003087|Drug|paclitaxel|
1720262|NCT00003087|Procedure|surgical procedure|
1720263|NCT00003087|Radiation|radiation therapy|
1720264|NCT00003088|Drug|cyclophosphamide|given IV
1720265|NCT00003088|Drug|doxorubicin hydrochloride|given IV
1720266|NCT00003088|Drug|paclitaxel|given IV
1720267|NCT00003089|Drug|amifostine trihydrate|
1720268|NCT00003089|Drug|carboplatin|
1720269|NCT00003089|Drug|paclitaxel|
1720270|NCT00003089|Radiation|radiation therapy|
1720271|NCT00003090|Biological|aldesleukin|
1720272|NCT00003091|Biological|aldesleukin|
1720273|NCT00003091|Biological|recombinant interferon alfa|
1720274|NCT00003092|Drug|paclitaxel|
1720275|NCT00003093|Biological|filgrastim|
1720276|NCT00003093|Biological|sargramostim|
1720277|NCT00003093|Drug|carboplatin|
1720278|NCT00003093|Drug|cyclophosphamide|
1720279|NCT00003093|Drug|doxorubicin hydrochloride|
1720280|NCT00003093|Drug|etoposide|
1720281|NCT00003093|Procedure|conventional surgery|
1720282|NCT00003093|Procedure|neoadjuvant therapy|
1720283|NCT00003094|Other|preventative dietary intervention|
1720284|NCT00003096|Genetic|DNA ploidy analysis|
1720285|NCT00003096|Genetic|comparative genomic hybridization|
1720286|NCT00003096|Genetic|cytogenetic analysis|
1720287|NCT00003096|Genetic|fluorescence in situ hybridization|
1720288|NCT00003097|Other|preventative dietary intervention|
1720289|NCT00003098|Other|fat reduction with increased fiber|Patients are randomized to dietary fat reduction with increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
1720290|NCT00003098|Other|fat reduction without increased fiber|Patients are randomized to dietary fat reduction without increased fiber. All patient must successfully complete a dietary run-in phase for 4 weeks before randomization. During the run-in phase, patients are asked to maintain a food record for days 7-14. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 14, 21, and 28. Patients are given 3 prepackaged meals a day for 12 weeks. Patients must maintain a record of all food eaten and return all food containers to the center for documentation. Patients undergo radioisotopic infusion study of sex steroid metabolism on days 70, 77, and 84. At the end of the 12 weeks, patients meet with the dietitian for 30 minutes to receive instructions on maintaining a low fat, high fiber diet for the second phase of the study.
1720291|NCT00003099|Drug|Fenretinide|Daily for 14-28 days.
1720292|NCT00003099|Drug|Tamoxifen Citrate|Daily for 14-28 days.
1720293|NCT00003099|Other|Placebo|Daily for 14-28 days
1720294|NCT00003100|Dietary Supplement|soy isoflavones|
1720295|NCT00003101|Biological|filgrastim|
1720296|NCT00003101|Drug|busulfan|
1720297|NCT00003101|Drug|lomustine|
1720298|NCT00003101|Drug|procarbazine hydrochloride|
1720299|NCT00003101|Drug|thiotepa|
1720300|NCT00003101|Drug|vincristine sulfate|
1720301|NCT00003101|Procedure|autologous bone marrow transplantation|
1720302|NCT00003101|Procedure|peripheral blood stem cell transplantation|
1720303|NCT00003102|Radiation|iodine I 131 chimeric monoclonal antibody G-250|
1720304|NCT00003103|Biological|oblimersen sodium|
1720305|NCT00003103|Drug|docetaxel|
1720306|NCT00003104|Radiation|radiation therapy|
1720307|NCT00003105|Biological|filgrastim|
1720308|NCT00003105|Drug|cisplatin|
1720309|NCT00003105|Drug|doxorubicin hydrochloride|
1720310|NCT00003105|Drug|gemcitabine hydrochloride|
1720311|NCT00003105|Drug|ifosfamide|
1720312|NCT00003105|Drug|paclitaxel|
1720313|NCT00003107|Biological|recombinant interleukin-12|
1720314|NCT00003108|Drug|bryostatin 1|
1720315|NCT00003108|Drug|cisplatin|
1720316|NCT00003109|Drug|irinotecan hydrochloride|
1720317|NCT00003109|Drug|raltitrexed|
1720318|NCT00003110|Biological|bleomycin sulfate|Patients receive bleomycin by continuous infusion for 72 hours every 3 weeks. Induction therapy consists of 3 cycles. Patients who achieve complete remission receive 2 more cycles. Patients with partial remission or stable disease may continue therapy until disease progression or unacceptable toxicity occurs.
1720319|NCT00003111|Drug|carboplatin|
1720320|NCT00003111|Drug|cisplatin|
1720321|NCT00003111|Drug|irinotecan hydrochloride|
1720322|NCT00003111|Drug|paclitaxel|
1720323|NCT00003111|Procedure|neoadjuvant therapy|
1720324|NCT00003111|Procedure|surgical procedure|
1720325|NCT00003111|Radiation|radiation therapy|
1720326|NCT00003113|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor; G-CSF) is given subcutaneously on days 5-21 and 33-42 of each cycle.
1720327|NCT00003113|Drug|cyclophosphamide|Cyclophosphamide are given on days 22-31 of each cycle.
1720328|NCT00003113|Drug|etoposide|Etoposide is given on days 1-3.
1720329|NCT00003113|Drug|lomustine|Lomustine is given on day 1 of cycles 1 and 3 only.
1720330|NCT00003113|Drug|procarbazine hydrochloride|Procarbazine are given on days 22-31 of each cycle.
1720331|NCT00003113|Radiation|radiation therapy|Following the third cycle of chemotherapy, if residual disease is confined to 1 or 2 nodal sites, patients receive radiation therapy.
1720332|NCT00003114|Biological|filgrastim|Filgrastim (granulocyte colony-stimulating factor) is given subcutaneously on days 5-21 and 33-42.The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
1720333|NCT00003114|Drug|cyclophosphamide|Oral cyclophosphamide on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
1720334|NCT00003114|Drug|etoposide|Oral etoposide on days 1-3. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
1720335|NCT00003114|Drug|lomustine|Patients receive oral lomustine on day 1.
1720336|NCT00003114|Drug|procarbazine hydrochloride|Oral and procarbazine on days 22-31. The course is repeated every 6 weeks. A complete or partial response after 1 course of treatment receive two additional courses, but lomustine is omitted in the second course.
1720337|NCT00003114|Radiation|radiation therapy|Patients with partial response or stable disease receive radiation therapy and/or continued chemotherapy.
1720338|NCT00003115|Drug|hydromorphone hydrochloride|
1720339|NCT00003116|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously twice a day beginning 3 hours after completion of cell infusion and continuing until blood counts recover.
1720340|NCT00003116|Drug|busulfan|high-dose oral busulfan every 6 hours on days -8 to -5
1720341|NCT00003116|Drug|cyclophosphamide|cyclophosphamide IV twice a day on days -4 and -3
1720342|NCT00003116|Drug|cyclosporine|cyclosporine IV over 6 hours on day -1 and then 10 hours on day 0 for 2 doses (allogeneic only)
1720343|NCT00003116|Procedure|bone marrow ablation with stem cell support|
1720344|NCT00003116|Procedure|peripheral blood stem cell transplantation|Allogeneic peripheral blood progenitor cells IV are administered on day 0.
1720345|NCT00003117|Drug|carboplatin|
1720346|NCT00003117|Drug|paclitaxel|
1720347|NCT00003118|Drug|cisplatin|
1720348|NCT00003118|Drug|fluorouracil|
1720349|NCT00003118|Procedure|surgical procedure|
1720350|NCT00003118|Radiation|radiation therapy|
1720351|NCT00003119|Biological|filgrastim|
1720352|NCT00003119|Biological|sargramostim|
1720353|NCT00003119|Drug|carboplatin|
1720354|NCT00003119|Drug|cyclophosphamide|
1720355|NCT00003119|Drug|doxorubicin hydrochloride|
1720356|NCT00003119|Drug|etoposide|
1720357|NCT00003119|Procedure|adjuvant therapy|
1720358|NCT00003119|Procedure|conventional surgery|
1720359|NCT00003119|Radiation|radiation therapy|
1720360|NCT00003120|Drug|paclitaxel|135 mg/m2 IV every 28 days
1720361|NCT00003122|Procedure|surgical procedure|
1720362|NCT00003123|Drug|amifostine trihydrate|
1720363|NCT00003124|Drug|flutamide|
1720364|NCT00003124|Drug|leuprolide acetate|
1720365|NCT00003124|Radiation|radiation therapy|
1720366|NCT00003125|Biological|ALVAC-CEA vaccine|
1720367|NCT00003125|Biological|aldesleukin|
1720368|NCT00003125|Biological|sargramostim|
1720369|NCT00003125|Biological|vaccinia-CEA vaccine|
1720370|NCT00003126|Drug|Interleukin-2|High-dose bolus interleukin-2 is a systemic therapy used to treat metastatic RCC
1720371|NCT00003127|Drug|amifostine trihydrate|740 mg/m2 IV, Day 1, q 28 days X 6 cycles
1720372|NCT00003127|Drug|carboplatin|target AUC=6, IV Day 1, q 28 days X 6 cycles
1720373|NCT00003127|Drug|paclitaxel|175 mg/m2, IV, Day 1 q 28 days X 6 cycles
1720374|NCT00003128|Biological|filgrastim|
1720375|NCT00003128|Drug|ifosfamide|
1720376|NCT00003128|Drug|paclitaxel|
1720377|NCT00003129|Drug|valrubicin|
1720378|NCT00003130|Drug|paclitaxel|
1720379|NCT00003131|Drug|chemotherapy|
1720380|NCT00003131|Drug|gemtuzumab ozogamicin|
1720381|NCT00003132|Drug|bryostatin 1|
1720382|NCT00003132|Drug|cisplatin|
1720383|NCT00003133|Biological|filgrastim|
1720384|NCT00003133|Drug|cisplatin|
1720385|NCT00003133|Drug|doxorubicin hydrochloride|
1720386|NCT00003133|Drug|gemcitabine hydrochloride|
1720387|NCT00003133|Drug|paclitaxel|
1720388|NCT00003134|Drug|irinotecan hydrochloride|
1720389|NCT00003135|Drug|fluorouracil|
1720390|NCT00003135|Drug|pegylated liposomal doxorubicin hydrochloride|
1720391|NCT00003135|Procedure|hyperthermia treatment|
1720392|NCT00003136|Biological|filgrastim|
1720393|NCT00003136|Drug|amifostine trihydrate|
1720394|NCT00003136|Drug|carboplatin|
1720395|NCT00003136|Drug|cyclophosphamide|
1720396|NCT00003136|Procedure|peripheral blood stem cell transplantation|
1720397|NCT00003137|Drug|irinotecan hydrochloride|
1720398|NCT00003138|Biological|Erythropoietin|Administered at 150 units/kg subcutaneously every day. Rotating sites should be used. The dose should be rounded off to the nearest 1000 U. The dose should be adjusted based on hematocrit.
1720399|NCT00003138|Biological|Filgrastim|G-CSF should start at a dose of 1 mcg/kg per day or 2.5 mcg/kg three times a week subcutaneously. Rotating sites should be used The dose should be rounded off to the nearest 10 mcg.
1720400|NCT00003138|Procedure|Transfusion|Red cell and platelet transfusions
1720401|NCT00003139|Drug|pilocarpine hydrochloride|5mg pilocarpine hydrochloride tablets
1720402|NCT00003139|Other|Placebo|
1720403|NCT00003140|Drug|letrozole|Given orally
1720404|NCT00003140|Other|placebo|Given orally
1720405|NCT00003141|Biological|filgrastim|Given IV
1720406|NCT00003141|Drug|carboplatin|Given IV
1720407|NCT00003141|Drug|cisplatin|Given IV
1720408|NCT00003141|Drug|cyclophosphamide|Given IV
1720409|NCT00003141|Drug|etoposide|Given IV
1720410|NCT00003141|Drug|thiotepa|Given IV
1720411|NCT00003141|Drug|vincristine sulfate|Given IV
1720412|NCT00003141|Procedure|conventional surgery|
1720413|NCT00003141|Procedure|peripheral blood stem cell transplantation|
1720414|NCT00003143|Drug|Amifostine|
1720415|NCT00003143|Drug|DHAP|
1720416|NCT00003144|Drug|amifostine trihydrate|
1720417|NCT00003144|Drug|cisplatin|
1720418|NCT00003144|Drug|gemcitabine hydrochloride|
1720419|NCT00003145|Drug|Fludarabine Phosphate|Given IV
1720420|NCT00003145|Radiation|Total-Body Irradiation|Undergo TBI
1720421|NCT00003145|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
1720422|NCT00003145|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
1720423|NCT00003145|Drug|Cyclosporine|Given PO or IV
1720424|NCT00003145|Drug|Mycophenolate Mofetil|Given PO or IV
1720425|NCT00003145|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
1720426|NCT00003145|Other|Laboratory Biomarker Analysis|Correlative studies
1720427|NCT00003146|Drug|busulfan|
1720428|NCT00003146|Drug|melphalan|
1720429|NCT00003146|Drug|thiotepa|
1720430|NCT00003146|Procedure|bone marrow transplantation|
1720431|NCT00003146|Procedure|peripheral blood stem cell transplantation|
1720432|NCT00003147|Biological|Ad5CMV-p53 gene|
1720433|NCT00003148|Biological|aldesleukin|
1720434|NCT00003149|Biological|recombinant interleukin-12|
1720435|NCT00003150|Biological|rituximab|
1720436|NCT00003150|Drug|CHOP regimen|
1720437|NCT00003150|Drug|cyclophosphamide|
1720438|NCT00003150|Drug|doxorubicin hydrochloride|
1720439|NCT00003150|Drug|prednisone|
1720440|NCT00003150|Drug|vincristine sulfate|
1720441|NCT00003151|Dietary Supplement|bismuth subcitrate|
1720442|NCT00003151|Drug|amoxicillin|
1720443|NCT00003151|Drug|clarithromycin|
1720444|NCT00003151|Drug|metronidazole hydrochloride|
1720445|NCT00003151|Drug|omeprazole|
1720446|NCT00003151|Drug|tetracycline hydrochloride|
1720447|NCT00003152|Biological|filgrastim|
1720448|NCT00003152|Biological|recombinant interferon alfa|
1720449|NCT00003152|Drug|cyclophosphamide|
1720450|NCT00003152|Drug|prednisone|
1720451|NCT00003152|Drug|vincristine sulfate|
1720452|NCT00003152|Procedure|autologous bone marrow transplantation|
1720453|NCT00003152|Procedure|bone marrow ablation with stem cell support|
1720454|NCT00003152|Procedure|peripheral blood stem cell transplantation|
1720455|NCT00003152|Radiation|radiation therapy|
1720456|NCT00003153|Biological|therapeutic allogeneic lymphocytes|
1720457|NCT00003154|Drug|aminocamptothecin colloidal dispersion|120 hour continuous infusion of aminocamptothecin colloidal dispersion (AC/CD) once a week for 2 weeks, followed by 1 week of rest. Patients are assessed after every 2 courses of therapy. Treatment with aminocamptothecin continues indefinitely if there is tumor shrinkage or stable disease and no significant toxicity is experienced. Patients are followed every 3 months.
1720458|NCT00003156|Drug|topotecan hydrochloride|
1720459|NCT00003157|Drug|cisplatin|
1720460|NCT00003157|Drug|gemcitabine hydrochloride|
1720461|NCT00003157|Radiation|radiation therapy|
1720462|NCT00003158|Drug|carboplatin|
1720463|NCT00003158|Drug|etoposide|
1720464|NCT00003158|Drug|paclitaxel|
1720465|NCT00003158|Radiation|radiation therapy|
1720466|NCT00003159|Drug|carboplatin|
1720467|NCT00003159|Drug|cisplatin|
1720469|NCT00003159|Drug|gemcitabine hydrochloride|
1720470|NCT00003159|Drug|ifosfamide|
1720471|NCT00003159|Drug|mitomycin C|
1720472|NCT00003159|Drug|paclitaxel|
1720473|NCT00003159|Drug|vinblastine sulfate|
1720474|NCT00003159|Drug|vinorelbine tartrate|
1720475|NCT00003159|Procedure|conventional surgery|
1720476|NCT00003159|Procedure|neoadjuvant therapy|
1720477|NCT00003160|Drug|paclitaxel|
1720478|NCT00003162|Procedure|pain therapy|
1720479|NCT00003162|Radiation|radiation therapy|
1720480|NCT00003163|Biological|filgrastim|
1720481|NCT00003163|Biological|sargramostim|
1720482|NCT00003163|Drug|cyclophosphamide|
1720483|NCT00003163|Drug|melphalan|
1720484|NCT00003163|Procedure|autologous bone marrow transplantation|
1720485|NCT00003163|Procedure|peripheral blood stem cell transplantation|
1720486|NCT00003163|Radiation|radiation therapy|
1720487|NCT00003165|Drug|doxorubicin-HPMA conjugate|
1720488|NCT00003166|Drug|bryostatin 1|Given IV
1720489|NCT00003166|Drug|vincristine sulfate|Given IV
1720490|NCT00003166|Other|laboratory biomarker analysis|Correlative studies
1720491|NCT00003167|Biological|Ad5CMV-p53 gene|Given intravesically
1720492|NCT00003170|Dietary Supplement|glutamine|
1720493|NCT00003170|Other|placebo|
1720494|NCT00003171|Drug|bryostatin 1|
1720495|NCT00003172|Biological|filgrastim|
1720496|NCT00003172|Biological|recombinant interferon alfa|
1720497|NCT00003172|Drug|docetaxel|
1720498|NCT00003172|Drug|doxorubicin hydrochloride|
1720499|NCT00003172|Drug|fluorouracil|
1720500|NCT00003172|Drug|hydroxyurea|
1720501|NCT00003173|Biological|filgrastim|
1720502|NCT00003173|Drug|thiotepa|
1720503|NCT00003173|Procedure|autologous bone marrow transplantation|
1720504|NCT00003173|Procedure|peripheral blood stem cell transplantation|
1720505|NCT00003174|Drug|bryostatin 1|
1720506|NCT00003174|Drug|cladribine|
1720507|NCT00003175|Drug|fluorouracil|
1720508|NCT00003176|Drug|carmustine|
1720509|NCT00003176|Drug|temozolomide|
1720510|NCT00003178|Biological|filgrastim|
1720511|NCT00003178|Drug|cladribine|
1720512|NCT00003178|Drug|idarubicin|
1720513|NCT00003179|Drug|medroxyprogesterone|
1720514|NCT00003181|Biological|aldesleukin|
1720515|NCT00003181|Biological|sargramostim|
1720516|NCT00003181|Drug|vinblastine sulfate|
1720517|NCT00003182|Drug|cisplatin|
1720518|NCT00003182|Drug|gemcitabine hydrochloride|
1720519|NCT00003183|Biological|filgrastim|
1720520|NCT00003183|Drug|mitoxantrone hydrochloride|
1720521|NCT00003184|Biological|BCG vaccine|
1720522|NCT00003184|Biological|CD80 breast cancer vaccine|
1720523|NCT00003184|Biological|sargramostim|
1720524|NCT00003185|Biological|autologous tumor cell vaccine|
1720525|NCT00003185|Biological|sargramostim|
1720526|NCT00003185|Biological|tumor-draining lymph node lymphocyte therapy|
1720527|NCT00003185|Drug|cyclophosphamide|
1720528|NCT00003185|Procedure|conventional surgery|
1720529|NCT00003186|Drug|isosulfan blue|
1720530|NCT00003186|Procedure|lymphangiography|
1720531|NCT00003186|Procedure|sentinel lymph node biopsy|
1720532|NCT00003187|Biological|filgrastim|
1720533|NCT00003187|Drug|cyclophosphamide|
1720534|NCT00003187|Drug|cyclosporine|
1720535|NCT00003187|Drug|cytarabine|
1720536|NCT00003187|Drug|methotrexate|
1720537|NCT00003187|Drug|methylprednisolone|
1720538|NCT00003187|Procedure|allogeneic bone marrow transplantation|
1720539|NCT00003187|Procedure|in vitro-treated bone marrow transplantation|
1720540|NCT00003187|Radiation|radiation therapy|
1720541|NCT00003190|Drug|cytarabine|Given IV
1720542|NCT00003190|Drug|daunorubicin hydrochloride|Given IV
1720543|NCT00003190|Drug|etoposide|Given IV
1720544|NCT00003190|Drug|valspodar|Given IV
1720545|NCT00003191|Drug|fenretinide|
1720546|NCT00003192|Drug|aminocamptothecin|
1720547|NCT00003193|Drug|amifostine trihydrate|
1720548|NCT00003193|Drug|paclitaxel|
1720549|NCT00003193|Procedure|conventional surgery|
1720550|NCT00003193|Radiation|radiation therapy|
1720551|NCT00003194|Biological|filgrastim|
1720552|NCT00003194|Drug|carboplatin|
1720553|NCT00003194|Drug|cyclophosphamide|
1720554|NCT00003194|Drug|etoposide|
1720555|NCT00003194|Drug|thiotepa|
1720556|NCT00003194|Drug|topotecan hydrochloride|
1720557|NCT00003194|Procedure|peripheral blood stem cell transplantation|
1720558|NCT00003195|Biological|recombinant interferon alfa|
1720559|NCT00003195|Drug|busulfan|
1720560|NCT00003195|Procedure|allogeneic bone marrow transplantation|
1720561|NCT00003195|Procedure|peripheral blood stem cell transplantation|
1720562|NCT00003195|Radiation|radiation therapy|
1720570|NCT00003197|Dietary Supplement|green tea extract|
1720571|NCT00003198|Drug|ifosfamide|
1720572|NCT00003198|Drug|topotecan hydrochloride|
1720573|NCT00003199|Drug|tamoxifen citrate|Given orally
1720574|NCT00003199|Drug|busulfan|Given orally
1720575|NCT00003199|Drug|thiotepa|Given IV
1720577|NCT00003199|Biological|aldesleukin|Given SC
1720578|NCT00003199|Biological|sargramostim|Given SC
1720579|NCT00003199|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell infusion
1720580|NCT00003199|Radiation|radiation therapy|May undergo radiotherapy after completion of IL-2/GM-CSF
1720581|NCT00003200|Drug|Taxotere|
1720582|NCT00003200|Radiation|Radiation therapy|
1720583|NCT00003202|Drug|cisplatin|
1720584|NCT00003202|Drug|gemcitabine hydrochloride|
1720585|NCT00003202|Radiation|radiation therapy|
1720586|NCT00003203|Biological|filgrastim|Given IV
1720587|NCT00003203|Drug|carboplatin|Given IV
1720588|NCT00003203|Drug|cisplatin|Given IV
1720589|NCT00003203|Drug|cyclophosphamide|Given IV
1720590|NCT00003203|Drug|vincristine sulfate|Given IV
1720591|NCT00003203|Procedure|adjuvant therapy|
1720592|NCT00003203|Radiation|radiation therapy|1.8 Gy/fx x 20fx=36Gy Craniospinal XRT*
1720593|NCT00003204|Drug|cyclophosphamide|Given IV
1720594|NCT00003204|Drug|fludarabine phosphate|Given IV
1720595|NCT00003204|Drug|vincristine sulfate|Given IV
1720596|NCT00003204|Drug|prednisone|Given PO
1720597|NCT00003204|Biological|rituximab|Given IV
1720598|NCT00003204|Other|laboratory biomarker analysis|Correlative studies
1720599|NCT00003205|Drug|bryostatin 1|
1720600|NCT00003206|Drug|carboplatin|
1720601|NCT00003206|Drug|paclitaxel|
1720602|NCT00003207|Drug|pegylated liposomal doxorubicin hydrochloride|
1720603|NCT00003207|Drug|PSC 833|
1720604|NCT00003209|Biological|bleomycin sulfate|
1720605|NCT00003209|Drug|cisplatin|
1720606|NCT00003209|Drug|fluorouracil|
1720607|NCT00003209|Drug|ifosfamide|
1720608|NCT00003209|Drug|methotrexate|
1720609|NCT00003209|Drug|mitomycin C|
1720610|NCT00003209|Drug|vinblastine sulfate|
1720611|NCT00003209|Drug|vindesine|
1720612|NCT00003209|Radiation|radiation therapy|
1720613|NCT00003210|Biological|recombinant interleukin-12|Given subcutaneously
1720614|NCT00003210|Other|laboratory biomarker analysis|Correlative studies
1720615|NCT00003211|Biological|filgrastim|
1720616|NCT00003211|Drug|amifostine trihydrate|
1720617|NCT00003211|Drug|cisplatin|
1720618|NCT00003211|Drug|cyclophosphamide|
1720619|NCT00003211|Drug|vincristine sulfate|
1720620|NCT00003211|Procedure|peripheral blood stem cell transplantation|
1720621|NCT00003211|Radiation|radiation therapy|
1720622|NCT00003212|Drug|doxorubicin hydrochloride|
1720623|NCT00003212|Drug|ifosfamide|
1720624|NCT00003213|Drug|dexamethasone|4 mg Dexamethasone in the morning
1720625|NCT00003213|Drug|granisetron hydrochloride|1 mg Granisetron in the morning
1720626|NCT00003213|Drug|metoclopramide hydrochloride|20 mg Metoclopramide (1 x morning, 1 x afternoon, 1 x evening)
1720627|NCT00003214|Drug|carboplatin|
1720628|NCT00003214|Drug|cisplatin|
1720629|NCT00003214|Drug|cyclophosphamide|
1720630|NCT00003214|Drug|doxorubicin hydrochloride|
1720631|NCT00003214|Drug|in vitro sensitivity-directed chemotherapy|
1720632|NCT00003214|Drug|paclitaxel|
1720633|NCT00003215|Biological|filgrastim|
1720634|NCT00003215|Drug|CHOP regimen|
1720635|NCT00003215|Drug|cyclophosphamide|
1720636|NCT00003215|Drug|cytarabine|
1720637|NCT00003215|Drug|doxorubicin hydrochloride|
1720638|NCT00003215|Drug|etoposide|
1720639|NCT00003215|Drug|leucovorin calcium|
1720640|NCT00003215|Drug|melphalan|
1720641|NCT00003215|Drug|methotrexate|
1720642|NCT00003215|Drug|methylprednisolone|
1720643|NCT00003215|Drug|mitoxantrone hydrochloride|
1720644|NCT00003215|Drug|prednisone|
1720645|NCT00003215|Drug|therapeutic hydrocortisone|
1720646|NCT00003215|Drug|vincristine sulfate|
1720647|NCT00003215|Procedure|bone marrow ablation with stem cell support|
1720648|NCT00003215|Procedure|peripheral blood stem cell transplantation|
1720649|NCT00003215|Radiation|radiation therapy|
1720650|NCT00003216|Drug|fluorouracil|
1720651|NCT00003216|Drug|gemcitabine hydrochloride|
1720652|NCT00003216|Radiation|radiation therapy|
1720653|NCT00003217|Biological|filgrastim|
1720654|NCT00003217|Drug|cyclophosphamide|
1720655|NCT00003217|Drug|cytarabine|
1720656|NCT00003217|Drug|dexamethasone|
1720657|NCT00003217|Drug|doxorubicin hydrochloride|
1720658|NCT00003217|Drug|methotrexate|
1720659|NCT00003217|Drug|vincristine sulfate|
1720660|NCT00003219|Drug|perillyl alcohol|
1720661|NCT00003220|Drug|bryostatin 1|
1720662|NCT00003222|Biological|aldesleukin|Systemic subcutaneous delivery of low-dose IL-2.
1720663|NCT00003222|Biological|gp100 antigen|
1720664|NCT00003222|Biological|incomplete Freund's adjuvant|
1720665|NCT00003222|Biological|sargramostim|
1720666|NCT00003222|Biological|tetanus peptide melanoma vaccine|
1720667|NCT00003222|Biological|tyrosinase peptide|
1720668|NCT00003223|Drug|fenretinide|200 mg/day PO, days 1-25 q 28 days x 6 cycles.
1720669|NCT00003224|Biological|QS21|vaccine adjuvant
1720670|NCT00003224|Biological|IFA (incomplete Freund's adjuvant)|Peptides emulsified in IFA.
1720671|NCT00003224|Biological|p946|This a nonamer peptide YLEPGPVTA from Gp100, used as a melanoma vaccine antigen.
1720672|NCT00003224|Biological|p946/tet-p|This peptide is a longer version of p946 (gp100 [280-288]) sythesized colinearly with the tetanus helper peptide (Tet-p)
1720673|NCT00003224|Biological|Tet-p|modified form of the p2 peptide from tetanus toxoid, used as nonspecific epitope for helper T cells.
1720674|NCT00003225|Drug|amifostine trihydrate|Ethyol 740 mg/m2 will be administered intravenously over 10 minutes. Administered every two weeks for 3 cycles.
1720771|NCT00002676|Drug|doxorubicin hydrochloride|
1720675|NCT00003225|Drug|irinotecan hydrochloride|"10 minutes after completion of the Ethyol infusion, Irinotecan 250 mg/m2 will be given over 90 minutes IV.
Administered every 14 days for 3 cycles"
1720676|NCT00003229|Biological|aldesleukin|
1720677|NCT00003229|Biological|gp100 antigen|
1720678|NCT00003229|Biological|tyrosinase peptide|
1720679|NCT00003230|Drug|paclitaxel|
1720680|NCT00003231|Drug|cisplatin|
1720681|NCT00003231|Drug|docetaxel|
1720682|NCT00003231|Procedure|surgical procedure|
1720683|NCT00003231|Radiation|radiation therapy|
1720684|NCT00003232|Drug|clodronate disodium|
1720685|NCT00003232|Drug|mitoxantrone hydrochloride|
1720686|NCT00003232|Drug|prednisone|
1720687|NCT00003232|Procedure|quality-of-life assessment|
1720688|NCT00003234|Drug|vinorelbine tartrate|
1720689|NCT00003235|Drug|carboplatin|
1720690|NCT00003235|Drug|paclitaxel|
1720691|NCT00003235|Radiation|radiation therapy|
1720692|NCT00003236|Biological|ISIS 3521|
1720693|NCT00003236|Drug|ISIS 5132|
1720694|NCT00003237|Drug|cisplatin|
1720695|NCT00003237|Drug|paclitaxel|
1720696|NCT00003237|Procedure|surgical procedure|
1720697|NCT00003238|Drug|perillyl alcohol|
1720698|NCT00003239|Biological|Recombinant Interferon Alfa|Daily by subcutaneous injection.
1720699|NCT00003239|Drug|Cytarabine|Daily by subcutaneous injection.
1720700|NCT00003239|Drug|Omacetaxine Mepesuccinate|Homoharringtonine is administered by continuous infusion on days 1-5.
1720701|NCT00003240|Drug|cisplatin|
1720702|NCT00003240|Drug|ifosfamide|
1720703|NCT00003240|Drug|mitomycin C|
1720704|NCT00003240|Drug|vinblastine sulfate|
1720705|NCT00003240|Drug|vindesine|
1720706|NCT00003240|Drug|vinorelbine tartrate|
1720707|NCT00003240|Procedure|conventional surgery|
1720708|NCT00003240|Radiation|radiation therapy|
1720709|NCT00003241|Drug|phenylacetate|
1720710|NCT00003242|Drug|bryostatin 1|
1720711|NCT00003242|Drug|cisplatin|
1720712|NCT00003242|Drug|paclitaxel|
1720713|NCT00003243|Biological|aldesleukin|
1720714|NCT00003243|Biological|filgrastim|
1720715|NCT00003243|Biological|therapeutic allogeneic lymphocytes|
1720716|NCT00003243|Drug|cyclophosphamide|
1720717|NCT00003243|Drug|etoposide|
1720718|NCT00003243|Drug|pegylated liposomal doxorubicin hydrochloride|
1720719|NCT00003245|Drug|irinotecan hydrochloride|
1720720|NCT00002663|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|EBV-CTLs are cytotoxic T lymphocytes that specifically kill cells presenting EBV protein antigens including EBV-transformed B lymphocytes responsible for EBV-associated lymphomas and lymphoproliferative disorders.
1720721|NCT00002664|Biological|edrecolomab|
1720722|NCT00002664|Biological|sargramostim|
1720723|NCT00002665|Drug|asparaginase|10,000 units/d IV or IM 15 - 24
1720724|NCT00002665|Drug|cyclophosphamide|con: 650 mg/m2 IV 1, 15, 29 maint: 650 mg/m2 IV 1
1720725|NCT00002665|Drug|cytarabine|cons: 75 mg/m2/d IV Push 2 - 5, 9 - 12, 6 - 19, 23 - 26
1720726|NCT00002665|Drug|daunorubicin hydrochloride|ind: 60 mg/m2 IV 22 and 23
1720727|NCT00002665|Drug|dexamethasone|main: 10 mg/m2/day PO 1 - 28
1720728|NCT00002665|Drug|doxorubicin hydrochloride|main: 25 mg/m2 IV 1, 8, 15, and 22
1720729|NCT00002665|Drug|etoposide|60 mg/kg based on ideal body weight day -3
1720730|NCT00002665|Drug|leucovorin calcium|5 mg q 6 hours for 4 doses, PO 1, 3, 8, 11 after each methotrexate if WBC < 3,000 /μl
1720731|NCT00002665|Drug|mercaptopurine|con: 60 mg/m2 PO 1 - 28
1720732|NCT00002665|Drug|methotrexate|10 mg/m2 IT or IV, d 2, 9, 16, and 23; Maximum 15 mg/admin
1720733|NCT00002665|Drug|prednisone|"ind: 60 mg/m2/d PO 1 - 21*, 22 - 28 Patients will receive full dose through day 8 and then tapered to zero between Day 29 and 42.
ind2: 60 mg/m2/d PO through day 42"
1720734|NCT00002665|Drug|thioguanine|main: 60 mg/m2/day PO 1 - 14
1720735|NCT00002665|Drug|vincristine sulfate|ind: 1.4 mg/m2 2 mg max, IV 1, 8, 15, and 22 ind2: 1.4 mg/m2 2 mg max IV 29 and 36 main: 1.5 mg/m2 2 mg max, IV 1, 8, 15, and 22
1720736|NCT00002665|Procedure|allogeneic bone marrow transplantation|day 0
1720737|NCT00002665|Radiation|radiation therapy|day -7 through day -4 total dose of radiation is 1,320 cGy.
1720738|NCT00002667|Other|cytology specimen collection procedure|
1720739|NCT00002667|Other|immunoenzyme technique|
1720740|NCT00002667|Procedure|study of high risk factors|
1720741|NCT00002668|Behavioral|Observation|
1720742|NCT00002668|Behavioral|Educational Intervention and Behavioral Skills Training|
1720743|NCT00002669|Biological|aldesleukin|
1720744|NCT00002669|Biological|recombinant interferon alfa|
1720745|NCT00002669|Drug|cisplatin|
1720746|NCT00002669|Drug|dacarbazine|
1720747|NCT00002670|Drug|chemotherapy|
1720748|NCT00002670|Drug|cisplatin|
1720749|NCT00002670|Radiation|low-LET cobalt-60 gamma ray therapy|
1720750|NCT00002670|Radiation|low-LET electron therapy|
1720751|NCT00002670|Radiation|low-LET photon therapy|
1720752|NCT00002671|Drug|aminocamptothecin|
1720753|NCT00002673|Procedure|infection prophylaxis and management|
1720754|NCT00002674|Biological|filgrastim|
1720755|NCT00002674|Drug|cytarabine|
1720756|NCT00002674|Drug|etoposide|
1720757|NCT00002674|Drug|hydroxyurea|
1720758|NCT00002674|Drug|mitoxantrone hydrochloride|
1720759|NCT00002674|Procedure|peripheral blood stem cell transplantation|
1720760|NCT00002675|Biological|filgrastim|
1720761|NCT00002675|Drug|carboplatin|
1720762|NCT00002675|Drug|cisplatin|
1720763|NCT00002675|Drug|cyclophosphamide|
1720764|NCT00002675|Drug|etoposide|
1720765|NCT00002675|Drug|mesna|
1720766|NCT00002675|Drug|vincristine sulfate|
1720767|NCT00002676|Drug|carmustine|
1720768|NCT00002676|Drug|cyclophosphamide|
1720769|NCT00002676|Drug|cytarabine|
1720773|NCT00002676|Drug|vincristine sulfate|
1720774|NCT00002676|Radiation|low-LET cobalt-60 gamma ray therapy|
1720775|NCT00002676|Radiation|low-LET photon therapy|
1720776|NCT00002677|Drug|chemotherapy|
1720777|NCT00002677|Drug|tributyrin|
1720778|NCT00002678|Drug|dexamethasone|40 mg daily for four days given orally and repeated every 28 days should commence on day 29 of the twelfth cycle of induction therapy.
1720779|NCT00002678|Drug|melphalan|9 mg/m2 daily for 4 days given orally on an empty stomach every 4 weeks
1720780|NCT00002678|Drug|prednisone|100 mg daily for 4 days given orally on a full stomach with each cycle of melphalan
1720781|NCT00002679|Biological|filgrastim|
1720782|NCT00002679|Drug|cyclophosphamide|
1720783|NCT00002679|Drug|doxorubicin hydrochloride|
1720784|NCT00002679|Drug|paclitaxel|
1720785|NCT00002679|Drug|tamoxifen citrate|
1720786|NCT00002679|Radiation|radiation therapy|
1720787|NCT00002680|Biological|filgrastim|
1720788|NCT00002680|Drug|cyclophosphamide|
1720789|NCT00002680|Drug|megestrol acetate|
1720790|NCT00002680|Drug|melphalan|
1720791|NCT00002680|Drug|tamoxifen citrate|
1720792|NCT00002680|Drug|thiotepa|
1720793|NCT00002680|Procedure|conventional surgery|
1720794|NCT00002680|Procedure|peripheral blood stem cell transplantation|
1720795|NCT00002680|Radiation|radiation therapy|
1720796|NCT00002681|Biological|aldesleukin|
1720797|NCT00002681|Biological|daclizumab|
1720798|NCT00002682|Drug|Amoxicillin|
1720799|NCT00002682|Drug|Bismuth Subsalicylate|
1720800|NCT00002682|Drug|Clarithromycin|
1720801|NCT00002682|Drug|Metronidazole Hydrochloride|
1720802|NCT00002682|Drug|Omeprazole|
1720803|NCT00002682|Drug|Tetracycline Hydrochloride|
1720804|NCT00002684|Drug|cisplatin|
1720805|NCT00002684|Drug|ifosfamide|
1720806|NCT00002684|Drug|paclitaxel|
1720807|NCT00002687|Biological|aldesleukin|
1720808|NCT00002688|Drug|cyclosporine|
1720809|NCT00002688|Drug|etoposide|
1720810|NCT00002688|Drug|mitoxantrone hydrochloride|
1720811|NCT00002689|Drug|dexamethasone|
1720812|NCT00002689|Drug|fluorouracil|
1720813|NCT00002689|Radiation|brachytherapy|
1720814|NCT00002689|Radiation|phosphorus P32|
1720815|NCT00002689|Radiation|radiation therapy|
1720816|NCT00002691|Biological|filgrastim|
1720817|NCT00002691|Drug|asparaginase|
1720818|NCT00002691|Drug|cyclophosphamide|
1720819|NCT00002691|Drug|cytarabine|
1720820|NCT00002691|Drug|daunorubicin hydrochloride|
1720821|NCT00002691|Drug|dexamethasone|
1720822|NCT00002691|Drug|etoposide|
1720823|NCT00002691|Drug|leucovorin calcium|
1720824|NCT00002691|Drug|mesna|
1720825|NCT00002691|Drug|methotrexate|
1720826|NCT00002691|Drug|vincristine sulfate|
1720827|NCT00002692|Drug|fluorouracil|
1720828|NCT00002692|Drug|isolated perfusion|
1720829|NCT00002692|Drug|leucovorin calcium|
1720830|NCT00002693|Biological|filgrastim|
1720831|NCT00002693|Drug|carboplatin|
1720832|NCT00002693|Drug|topotecan hydrochloride|
1720833|NCT00002695|Genetic|DNA stability analysis|
1720834|NCT00002695|Genetic|microsatellite instability analysis|
1720835|NCT00002695|Genetic|mutation analysis|
1720836|NCT00002695|Other|laboratory biomarker analysis|
1720837|NCT00002696|Drug|CAF regimen|
1720838|NCT00002696|Drug|CMF regimen|
1720839|NCT00002696|Drug|cyclophosphamide|
1720840|NCT00002696|Drug|doxorubicin hydrochloride|
1720841|NCT00002696|Drug|fluorouracil|
1720842|NCT00002696|Drug|methotrexate|
1720843|NCT00002696|Procedure|adjuvant therapy|
1720844|NCT00002696|Procedure|conventional surgery|
1720845|NCT00002696|Procedure|neoadjuvant therapy|
1720846|NCT00002696|Radiation|radiation therapy|
1720847|NCT00002697|Biological|filgrastim|
1720848|NCT00002697|Biological|sargramostim|
1720849|NCT00002697|Drug|carboplatin|
1720850|NCT00002697|Drug|etoposide|
1720851|NCT00002697|Drug|ifosfamide|
1720852|NCT00002697|Procedure|autologous bone marrow transplantation|
1720853|NCT00002697|Procedure|bone marrow ablation with stem cell support|
1720854|NCT00002697|Procedure|peripheral blood stem cell transplantation|
1720855|NCT00002697|Radiation|radiation therapy|
1720856|NCT00002700|Drug|asparaginase|
1720857|NCT00002700|Drug|cyclophosphamide|
1720858|NCT00002700|Drug|cytarabine|
1720859|NCT00002700|Drug|daunorubicin hydrochloride|
1720860|NCT00002700|Drug|dexamethasone|
1720861|NCT00002700|Drug|doxorubicin hydrochloride|
1720862|NCT00002700|Drug|leucovorin calcium|
1720863|NCT00002700|Drug|mercaptopurine|
1720864|NCT00002700|Drug|methotrexate|
1720865|NCT00002700|Drug|mitoxantrone hydrochloride|
1720866|NCT00002700|Drug|prednisolone|
1720867|NCT00002700|Drug|prednisone|
1720868|NCT00002700|Drug|therapeutic hydrocortisone|
1720869|NCT00002700|Drug|vincristine sulfate|
1720870|NCT00002700|Procedure|allogeneic bone marrow transplantation|
1720871|NCT00002700|Procedure|autologous bone marrow transplantation|
1720872|NCT00002700|Radiation|radiation therapy|
1720873|NCT00002701|Drug|busulfan|
1720874|NCT00002701|Drug|cyclophosphamide|
1720875|NCT00002701|Drug|cytarabine|
1720876|NCT00002701|Drug|etoposide|
1720877|NCT00002701|Drug|idarubicin|
1720878|NCT00002701|Drug|mercaptopurine|
1720879|NCT00002701|Drug|methotrexate|
1720880|NCT00002701|Drug|mitoxantrone hydrochloride|
1720881|NCT00002701|Drug|thioguanine|
1720882|NCT00002701|Drug|tretinoin|
1720883|NCT00002701|Procedure|allogeneic bone marrow transplantation|
1720884|NCT00002701|Procedure|autologous bone marrow transplantation|
1720885|NCT00002701|Radiation|radiation therapy|
1720886|NCT00002702|Biological|aldesleukin|
1720887|NCT00002702|Procedure|adjuvant therapy|
1720888|NCT00002702|Procedure|conventional surgery|
1720889|NCT00002702|Procedure|neoadjuvant therapy|
1720890|NCT00002702|Radiation|radiation therapy|
1720891|NCT00002703|Radiation|high-LET heavy ion therapy|
1720892|NCT00002703|Radiation|low-LET photon therapy|
1720893|NCT00002704|Biological|filgrastim|
1720894|NCT00002704|Drug|asparaginase|
1720895|NCT00002704|Drug|cyclophosphamide|
1720896|NCT00002704|Drug|daunorubicin hydrochloride|
1720897|NCT00002704|Drug|dexamethasone|
1720898|NCT00002704|Drug|etoposide|
1720899|NCT00002704|Drug|leucovorin calcium|
1720900|NCT00002704|Drug|liposomal cytarabine|
1720901|NCT00002704|Drug|mercaptopurine|
1720902|NCT00002704|Drug|mesna|
1720903|NCT00002704|Drug|methotrexate|
1720904|NCT00002704|Drug|therapeutic hydrocortisone|
1720905|NCT00002704|Drug|thiotepa|
1720906|NCT00002704|Drug|vincristine sulfate|
1720907|NCT00002704|Radiation|low-LET electron therapy|
1720908|NCT00002704|Radiation|low-LET photon therapy|
1720909|NCT00002705|Drug|topotecan hydrochloride|
1720910|NCT00002706|Procedure|Laparoscopic Surgery|Undergo vaginal hysterectomy and BSO via laparoscopy
1720911|NCT00002706|Other|Quality-of-Life Assessment|Ancillary studies
1720912|NCT00002706|Procedure|Therapeutic Conventional Surgery|Undergo total abdominal hysterectomy and BSO via conventional laparotomy
1720913|NCT00002707|Drug|Cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
1720914|NCT00002707|Drug|Docetaxel|100 mg/m2 IV every 21 days for 4 cycles
1720915|NCT00002707|Drug|Doxorubicin|60 mg/m2 IV every 21 days fo 4 cycles
1720916|NCT00002707|Drug|Tamoxifen|20 mg p.o. once daily for 5 years starting on day 1 of ther first AC cycle
1720917|NCT00002708|Procedure|surgical procedure|
1720918|NCT00002708|Radiation|radiation therapy|
1720919|NCT00002708|Radiation|stereotactic radiosurgery|
1720920|NCT00002711|Drug|chemotherapy|
1720921|NCT00002711|Drug|cisplatin|
1720922|NCT00002711|Drug|paclitaxel|
1720923|NCT00002711|Radiation|low-LET electron therapy|
1720924|NCT00002711|Radiation|low-LET photon therapy|
1720925|NCT00002714|Biological|bleomycin sulfate|
1720926|NCT00002714|Drug|Stanford V regimen|
1720927|NCT00002714|Drug|doxorubicin hydrochloride|
1720928|NCT00002714|Drug|etoposide|
1720929|NCT00002714|Drug|mechlorethamine hydrochloride|
1720930|NCT00002714|Drug|prednisone|
1720931|NCT00002714|Drug|vinblastine sulfate|
1720932|NCT00002714|Drug|vincristine sulfate|
1720933|NCT00002714|Radiation|radiation therapy|
1720934|NCT00002715|Biological|bleomycin sulfate|
1720935|NCT00002715|Drug|Stanford V regimen|
1720936|NCT00002715|Drug|doxorubicin hydrochloride|
1720937|NCT00002715|Drug|etoposide|
1720938|NCT00002715|Drug|mechlorethamine hydrochloride|
1720939|NCT00002715|Drug|prednisone|
1720940|NCT00002715|Drug|vinblastine|
1720941|NCT00002715|Drug|vincristine sulfate|
1720942|NCT00002716|Drug|dexamethasone|
1720943|NCT00002716|Drug|floxuridine|
1720944|NCT00002716|Drug|fluorouracil|
1720945|NCT00002716|Drug|leucovorin calcium|
1720946|NCT00002716|Procedure|laparotomy|
1720947|NCT00002716|Procedure|conventional surgery|
1720948|NCT00002717|Drug|cisplatin|
1720949|NCT00002717|Drug|paclitaxel|
1720950|NCT00002718|Biological|anti-thymocyte globulin|
1720951|NCT00002718|Biological|filgrastim|
1720952|NCT00002718|Drug|cyclophosphamide|
1720953|NCT00002718|Drug|cytarabine|
1720954|NCT00002718|Drug|methylprednisolone|
1720955|NCT00002718|Drug|thiotepa|
1720956|NCT00002718|Procedure|in vitro-treated bone marrow transplantation|
1720957|NCT00002718|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1720958|NCT00002718|Radiation|radiation therapy|
1720959|NCT00002719|Biological|filgrastim|
1720960|NCT00002719|Drug|amsacrine|
1720961|NCT00002719|Drug|carmustine|
1720962|NCT00002719|Drug|cytarabine|
1720963|NCT00002719|Drug|etoposide|
1720964|NCT00002719|Drug|idarubicin|
1720965|NCT00002719|Drug|mitoxantrone hydrochloride|
1720966|NCT00002719|Procedure|peripheral blood stem cell transplantation|
1720967|NCT00002720|Drug|tamoxifen citrate|
1720968|NCT00002720|Procedure|conventional surgery|
1720969|NCT00002721|Drug|doxorubicin hydrochloride|
1720970|NCT00002721|Drug|estramustine phosphate sodium|
1720971|NCT00002721|Procedure|drug resistance inhibition treatment|
1720972|NCT00002722|Drug|cisplatin|
1720973|NCT00002722|Drug|fluorouracil|
1720974|NCT00002722|Drug|leucovorin calcium|
1720975|NCT00002723|Drug|suramin|3.192g/square meter total dose given decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65.
1720976|NCT00002723|Drug|suramin|5.320 g/square meter total dose given in decreasing concentrations in 250 cc normal saline via IV over 1 hour on days 1,2,8,9,29,30,36,37,57,58,64,and 65
1720977|NCT00002723|Drug|Suramin|7.661 g/square meter toal dose given in decreasing concentrations in 250 cc normal saline IV over 1 hour on days 1,2,8,9,29,30,36,37,5,58,64,and 65.
1720978|NCT00002725|Drug|bryostatin 1|
1720979|NCT00002725|Drug|chemotherapy|
1720980|NCT00002727|Radiation|radiation therapy|
1720981|NCT00002730|Drug|buthionine sulfoximine|
1720982|NCT00002730|Drug|melphalan|
1720983|NCT00002733|Biological|aldesleukin|
1720984|NCT00002733|Biological|recombinant interferon alfa|
1720985|NCT00002733|Biological|therapeutic tumor infiltrating lymphocytes|
1720986|NCT00002733|Drug|cimetidine|
1720987|NCT00002734|Biological|recombinant interferon alfa|
1720988|NCT00002734|Drug|chemotherapy|
1720989|NCT00002734|Drug|paclitaxel|
1720990|NCT00002734|Drug|topotecan hydrochloride|
1720991|NCT00002734|Radiation|lutetium Lu 177 monoclonal antibody CC49|
1720992|NCT00002734|Radiation|yttrium Y 90 monoclonal antibody CC49|
1720993|NCT00002735|Drug|Induction chemotherapy|Cisplatin and 5-Fluorouracil
1720994|NCT00002735|Drug|cisplatin|Cisplatin 100 mg/m2 IV infusion over 90 minutes Day 1 every 21 days for 2 cycles.
1720995|NCT00002735|Drug|fluorouracil|5-Fluorouracil 1,000 mg/m2/day continuous IV infusion over 24 hours Days 1 through 5 every 21 days for 2 cycles.
1720996|NCT00002735|Radiation|low-LET cobalt-60 gamma ray therapy|180 cGy per day, Days 1-5, every week for eight weeks
1720997|NCT00002737|Biological|recombinant interferon alfa|
1720998|NCT00002737|Drug|chemotherapy|
1720999|NCT00002737|Drug|isotretinoin|
1721000|NCT00002738|Drug|leucovorin calcium|
1721001|NCT00002738|Drug|trimetrexate glucuronate|
1721002|NCT00002740|Biological|filgrastim|
1721003|NCT00002740|Drug|carboplatin|
1721004|NCT00002740|Drug|cyclophosphamide|
1721005|NCT00002740|Drug|doxorubicin hydrochloride|
1721006|NCT00002740|Drug|etoposide|
1721007|NCT00002740|Drug|mesna|
1721008|NCT00002740|Drug|vincristine sulfate|
1721009|NCT00002740|Procedure|conventional surgery|
1721010|NCT00002740|Procedure|peripheral blood stem cell transplantation|
1721011|NCT00002740|Radiation|low-LET cobalt-60 gamma ray therapy|
1721012|NCT00002740|Radiation|low-LET photon therapy|
1721013|NCT00002742|Drug|amphotericin B deoxycholate|
1721014|NCT00002742|Drug|nystatin|
1721015|NCT00002744|Drug|asparaginase|
1721016|NCT00002744|Drug|cyclophosphamide|
1721017|NCT00002744|Drug|cytarabine|
1721018|NCT00002744|Drug|daunorubicin hydrochloride|
1721019|NCT00002744|Drug|dexamethasone|
1721020|NCT00002744|Drug|doxorubicin hydrochloride|
1721021|NCT00002744|Drug|mercaptopurine|
1721022|NCT00002744|Drug|methotrexate|
1721023|NCT00002744|Drug|pegaspargase|
1721024|NCT00002744|Drug|prednisone|
1721025|NCT00002744|Drug|therapeutic hydrocortisone|
1721026|NCT00002744|Drug|thioguanine|
1721027|NCT00002744|Drug|vincristine sulfate|
1721028|NCT00002744|Radiation|low-LET cobalt-60 gamma ray therapy|
1721029|NCT00002744|Radiation|low-LET photon therapy|
1721030|NCT00003248|Biological|rituximab|
1721031|NCT00003248|Drug|fludarabine phosphate|
1721032|NCT00003249|Drug|carboxyamidotriazole|
1721033|NCT00003249|Drug|chemotherapy|
1721034|NCT00003249|Drug|ketoconazole|
1721035|NCT00003250|Drug|fenretinide|
1721036|NCT00003251|Drug|amifostine trihydrate|
1721037|NCT00003251|Drug|cisplatin|
1721038|NCT00003251|Drug|paclitaxel|
1721039|NCT00003251|Radiation|radiation therapy|
1721040|NCT00003252|Drug|amifostine trihydrate|
1721041|NCT00003253|Drug|paclitaxel|
1721042|NCT00003253|Other|antitumor drug screening assay|
1721043|NCT00003254|Drug|ethynyluracil|10mg/m2/dose, PO, Days 1-28, q 5wk
1721044|NCT00003254|Drug|fluorouracil|1.0mg/m2/dose, PO, Days 1-28 BID, q 5wk
1721045|NCT00003255|Drug|carboplatin|
1721046|NCT00003255|Drug|topotecan hydrochloride|
1721047|NCT00003256|Drug|alvocidib|
1721048|NCT00003257|Biological|Ad5CMV-p53 gene|
1721049|NCT00003259|Drug|vinorelbine tartrate|
1721050|NCT00003260|Drug|FOLFIRI regimen|
1721051|NCT00003260|Drug|FOLFOX regimen|
1721052|NCT00003260|Drug|fluorouracil|
1721053|NCT00003260|Drug|irinotecan hydrochloride|
1721054|NCT00003260|Drug|leucovorin calcium|
1721055|NCT00003260|Drug|oxaliplatin|
1721056|NCT00003261|Drug|methotrexate|
1721057|NCT00003261|Drug|zidovudine|
1721058|NCT00003261|Procedure|neoadjuvant therapy|
1721059|NCT00003261|Radiation|radiation therapy|
1721060|NCT00003262|Biological|bleomycin sulfate|
1721061|NCT00003262|Biological|filgrastim|
1721062|NCT00003262|Drug|Stanford V regimen|
1721063|NCT00003262|Drug|doxorubicin hydrochloride|
1721064|NCT00003262|Drug|epirubicin hydrochloride|
1721065|NCT00003262|Drug|etoposide|
1721066|NCT00003262|Drug|mechlorethamine hydrochloride|
1721067|NCT00003262|Drug|prednisone|
1721068|NCT00003262|Drug|vinblastine sulfate|
1721069|NCT00003262|Drug|vincristine sulfate|
1721070|NCT00003263|Biological|recombinant interferon alfa|vaccine
1721071|NCT00003263|Drug|cisplatin|
1721072|NCT00003263|Procedure|surgical procedure|
1721073|NCT00003263|Radiation|radiation therapy|
1721074|NCT00003264|Drug|cisplatin|
1721075|NCT00003264|Drug|gemcitabine hydrochloride|
1721076|NCT00003266|Drug|methylphenidate hydrochloride|
1721077|NCT00003266|Procedure|quality-of-life assessment|
1721078|NCT00003267|Procedure|infection prophylaxis and management|
1721079|NCT00003267|Procedure|management of therapy complications|
1721080|NCT00003267|Procedure|surgical procedure|
1721081|NCT00003268|Drug|amifostine trihydrate|
1721082|NCT00003268|Drug|cytarabine|
1721083|NCT00003268|Drug|idarubicin|
1721084|NCT00003269|Biological|sargramostim|
1721085|NCT00003269|Drug|amifostine trihydrate|
1721086|NCT00003269|Drug|cisplatin|
1721087|NCT00003269|Drug|cyclophosphamide|
1721088|NCT00003269|Drug|etoposide|
1721098|NCT00003273|Biological|filgrastim|
1721099|NCT00003273|Drug|carboplatin|
1721100|NCT00003273|Drug|cisplatin|
1721101|NCT00003273|Drug|cyclophosphamide|
1721102|NCT00003273|Drug|etoposide|
1721103|NCT00003273|Drug|leucovorin calcium|
1721104|NCT00003273|Drug|methotrexate|
1721105|NCT00003273|Drug|temozolomide|
1721106|NCT00003273|Drug|thiotepa|
1721107|NCT00003273|Drug|vincristine sulfate|
1721108|NCT00003273|Procedure|autologous bone marrow transplantation|
1721109|NCT00003273|Procedure|peripheral blood stem cell transplantation|
1721110|NCT00003273|Radiation|radiation therapy|
1721111|NCT00003274|Biological|gp100 antigen|
1721112|NCT00003274|Biological|incomplete Freund's adjuvant|
1721113|NCT00003274|Biological|sargramostim|
1721114|NCT00003274|Biological|tyrosinase peptide|
1721115|NCT00003276|Drug|irinotecan hydrochloride|
1721116|NCT00003278|Drug|dexamethasone|
1721117|NCT00003278|Radiation|radiation therapy|
1721118|NCT00003279|Biological|BCG vaccine|
1721119|NCT00003279|Biological|monoclonal antibody BEC2|
1721120|NCT00003353|Biological|filgrastim|
1721121|NCT00003353|Drug|melphalan|
1721122|NCT00003353|Procedure|bone marrow ablation with stem cell support|
1721123|NCT00003353|Procedure|peripheral blood stem cell transplantation|
1721124|NCT00003354|Procedure|conventional surgery|
1721125|NCT00003354|Procedure|laparoscopic surgery|
1721126|NCT00003356|Biological|aldesleukin|
1721127|NCT00003356|Biological|rituximab|
1721128|NCT00003357|Biological|GM2-KLH vaccine|
1721129|NCT00003357|Biological|QS21|
1721130|NCT00003358|Drug|chemotherapy|
1721131|NCT00003358|Drug|cisplatin|
1721132|NCT00003358|Drug|gemcitabine hydrochloride|
1721133|NCT00003359|Drug|batabulin sodium|
1721134|NCT00003360|Radiation|iodine I 131 monoclonal antibody A33|
1721135|NCT00003361|Drug|decitabine|
1721136|NCT00003362|Biological|QS21|
1721137|NCT00003362|Biological|gp100 antigen|
1721138|NCT00003362|Biological|incomplete Freund's adjuvant|
1721139|NCT00003362|Biological|sargramostim|
1721140|NCT00003362|Biological|tyrosinase peptide|
1721141|NCT00003364|Drug|cisplatin|
1721142|NCT00003364|Drug|cyclophosphamide|
1721143|NCT00003364|Drug|doxorubicin hydrochloride|
1721144|NCT00003364|Drug|etoposide|
1721145|NCT00003364|Drug|vincristine sulfate|
1721146|NCT00003364|Radiation|radiation therapy|
1721147|NCT00003365|Dietary Supplement|curcumin|
1721148|NCT00003365|Dietary Supplement|rutin|
1721149|NCT00003365|Drug|quercetin|
1721150|NCT00003365|Drug|sulindac|
1721151|NCT00003367|Dietary Supplement|green tea|
1721152|NCT00003367|Dietary Supplement|soy protein isolate|
1721153|NCT00003367|Dietary Supplement|vitamin E|
1721154|NCT00003368|Drug|irinotecan hydrochloride|
1721155|NCT00003369|Drug|cisplatin|75 mg/m2 IV as a one-hour infusion after tirapazamine on Day 1 of each 21-day cycle
1721156|NCT00003369|Drug|tirapazamine|260 mg/m2 over two hours prior to cisplatin on Day 1 of each 21-day cycle
1721157|NCT00003370|Drug|irofulven|
1721158|NCT00003372|Drug|topotecan hydrochloride|
1721159|NCT00003375|Drug|lomustine|
1721160|NCT00003375|Drug|procarbazine hydrochloride|
1721161|NCT00003375|Drug|vincristine sulfate|
1721162|NCT00003375|Radiation|radiation therapy|
1721163|NCT00003376|Drug|carboplatin|
1721164|NCT00003376|Drug|cisplatin|
1721165|NCT00003376|Drug|doxorubicin hydrochloride|
1721166|NCT00003376|Drug|methotrexate|
1721167|NCT00003376|Drug|paclitaxel|
1721168|NCT00003376|Drug|vinblastine|
1721169|NCT00003377|Drug|cisplatin|
1721170|NCT00003377|Drug|paclitaxel|
1721171|NCT00003377|Radiation|brachytherapy|
1721172|NCT00003377|Radiation|radiation therapy|
1721173|NCT00003378|Drug|carboplatin|
1721174|NCT00003378|Drug|gemcitabine hydrochloride|
1721175|NCT00003378|Drug|paclitaxel|
1721176|NCT00003379|Drug|cisplatin|
1721177|NCT00003379|Drug|paclitaxel|
1721178|NCT00003379|Radiation|brachytherapy|
1721179|NCT00003379|Radiation|radiation therapy|
1721180|NCT00003380|Drug|etoposide|
1721181|NCT00003380|Drug|pegylated liposomal doxorubicin hydrochloride|
1721182|NCT00003382|Biological|filgrastim|
1721183|NCT00003382|Drug|gemcitabine hydrochloride|
1721184|NCT00003382|Drug|topotecan hydrochloride|
1721185|NCT00003384|Other|Cervical Papanicolaou Test|Undergo Pap smear
1721186|NCT00003384|Procedure|Conization|Undergo cone biopsy
1721187|NCT00003384|Other|Laboratory Biomarker Analysis|Correlative studies
1721188|NCT00003385|Drug|carboplatin|
1721189|NCT00003385|Drug|paclitaxel|
1721190|NCT00003385|Drug|pegylated liposomal doxorubicin hydrochloride|
1721191|NCT00003386|Biological|BCG vaccine|
1721192|NCT00003386|Biological|autologous tumor cell vaccine|
1721193|NCT00003386|Drug|carboplatin|
1721194|NCT00003386|Drug|cisplatin|
1721195|NCT00003386|Drug|cyclophosphamide|
1721196|NCT00003386|Drug|paclitaxel|
1721197|NCT00003386|Other|dinitrophenyl|
1721198|NCT00003386|Procedure|surgical procedure|
1721202|NCT00003387|Radiation|radiation therapy|
1721203|NCT00003388|Biological|filgrastim|
1721204|NCT00003388|Drug|cyclophosphamide|
1721205|NCT00003388|Drug|cytarabine|
1721206|NCT00003388|Drug|methotrexate|
1721207|NCT00003388|Drug|pegylated liposomal doxorubicin hydrochloride|
1721208|NCT00003388|Drug|prednisone|
1721209|NCT00003388|Drug|vincristine sulfate|
1721210|NCT00003388|Radiation|radiation therapy|
1721211|NCT00003389|Drug|Doxorubicin|given IV
1721212|NCT00003389|Drug|Bleomycin|given IV
1721213|NCT00003389|Drug|Vinblastine|given IV
1721214|NCT00003389|Drug|Dacarbazine|given IV
1721215|NCT00003389|Drug|Vincristine|given IV
1721216|NCT00003389|Drug|Mechlorethamine|given IV
1721217|NCT00003389|Drug|Etoposide|given IV
1721218|NCT00003389|Drug|Prednisone|taken orally
1721219|NCT00003389|Drug|Cyclophosphamide|given IV
1721220|NCT00003389|Radiation|Radiotherapy|
1721221|NCT00003390|Drug|irofulven|
1721222|NCT00003391|Biological|monoclonal antibody muJ591|
1721223|NCT00003392|Biological|filgrastim|10 mcg/kg/d, day 2 through last day of leukapheresis
1721224|NCT00003392|Drug|carboplatin|18 AUC IV, approximately days 21, 42
1721225|NCT00003392|Drug|cyclophosphamide|4 gm/m2 IV, day 1
1721226|NCT00003392|Drug|melphalan|140 mg/m2 IV , approximately day 63
1721227|NCT00003392|Drug|paclitaxel|170 mg/m2 IV day 1
1721228|NCT00003392|Procedure|bone marrow ablation with stem cell support|
1721229|NCT00003392|Procedure|peripheral blood stem cell transplantation|
1721230|NCT00003394|Drug|carboplatin|
1721231|NCT00003394|Drug|endocrine-modulating drug therapy|
1721232|NCT00003394|Drug|estramustine phosphate sodium|
1721233|NCT00003394|Drug|goserelin acetate|
1721234|NCT00003394|Drug|leuprolide acetate|
1721235|NCT00003394|Drug|paclitaxel|
1721236|NCT00003395|Drug|arsenic trioxide|
1721237|NCT00003396|Biological|anti-thymocyte globulin|
1721238|NCT00003396|Biological|graft-versus-tumor induction therapy|
1721239|NCT00003396|Drug|cyclophosphamide|
1721240|NCT00003396|Drug|melphalan|
1721241|NCT00003396|Procedure|peripheral blood stem cell transplantation|
1721242|NCT00003396|Radiation|radiation therapy|
1721243|NCT00003397|Biological|filgrastim|
1721244|NCT00003397|Biological|rituximab|
1721245|NCT00003397|Biological|sargramostim|
1721246|NCT00003397|Drug|carmustine|
1721247|NCT00003397|Drug|cisplatin|
1721248|NCT00003397|Drug|cyclophosphamide|
1721249|NCT00003397|Drug|dexamethasone|
1721250|NCT00003397|Drug|etoposide|
1721251|NCT00003397|Drug|gemcitabine hydrochloride|
1721252|NCT00003397|Drug|melphalan|
1721253|NCT00003397|Drug|paclitaxel|
1721254|NCT00003397|Procedure|bone marrow ablation with stem cell support|
1721255|NCT00003397|Procedure|peripheral blood stem cell transplantation|
1721256|NCT00003398|Biological|anti-thymocyte globulin|
1721257|NCT00003398|Biological|filgrastim|
1721258|NCT00003398|Drug|cyclophosphamide|
1721259|NCT00003398|Drug|thiotepa|
1721260|NCT00003398|Procedure|allogeneic bone marrow transplantation|
1721261|NCT00003398|Procedure|bone marrow ablation with stem cell support|
1721262|NCT00003398|Radiation|radiation therapy|
1721263|NCT00003399|Drug|carmustine|
1721264|NCT00003399|Drug|cisplatin|
1721265|NCT00003399|Drug|cyclophosphamide|
1721266|NCT00003399|Drug|dexamethasone|
1721267|NCT00003399|Drug|etoposide|
1721268|NCT00003399|Drug|melphalan|
1721269|NCT00003399|Drug|paclitaxel|
1721270|NCT00003399|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1721271|NCT00003400|Biological|filgrastim|
1721272|NCT00003400|Drug|carmustine|
1721273|NCT00003400|Drug|cisplatin|
1721274|NCT00003400|Drug|melphalan|
1721275|NCT00003400|Drug|vinorelbine tartrate|
1721276|NCT00003400|Procedure|peripheral blood stem cell transplantation|
1721277|NCT00003401|Drug|carmustine|
1721278|NCT00003401|Drug|cisplatin|
1721279|NCT00003401|Drug|cyclophosphamide|
1721280|NCT00003401|Drug|dexamethasone|
1721281|NCT00003401|Drug|etoposide|
1721282|NCT00003401|Drug|gemcitabine hydrochloride|
1721283|NCT00003401|Drug|melphalan|
1721284|NCT00003401|Drug|paclitaxel|
1721285|NCT00003401|Procedure|bone marrow ablation with stem cell support|
1721286|NCT00003401|Procedure|peripheral blood stem cell transplantation|
1721287|NCT00003402|Drug|carmustine|
1721288|NCT00003402|Drug|cisplatin|
1721289|NCT00003402|Drug|cyclophosphamide|
1721290|NCT00003402|Drug|dexamethasone|
1721291|NCT00003402|Drug|etoposide|
1721292|NCT00003402|Drug|melphalan|
1721293|NCT00003402|Drug|paclitaxel|
1721294|NCT00003402|Procedure|bone marrow ablation with stem cell support|
1721295|NCT00003402|Procedure|peripheral blood stem cell transplantation|
1721296|NCT00003403|Drug|GPX-100|
1721297|NCT00003404|Procedure|adjuvant therapy|
1721298|NCT00003404|Radiation|radiation therapy|
1721299|NCT00003405|Biological|recombinant interferon alfa|
1721300|NCT00003405|Drug|amifostine trihydrate|
1721301|NCT00003405|Drug|bromodeoxyuridine|
1721302|NCT00003405|Drug|cytarabine|
1721303|NCT00003405|Drug|idarubicin|
1721304|NCT00003405|Drug|idoxuridine|
1721305|NCT00003405|Drug|isotretinoin|
1721306|NCT00003405|Drug|mitoxantrone hydrochloride|
1721307|NCT00003406|Drug|carboplatin|
1721308|NCT00003406|Drug|docetaxel|
1721309|NCT00003406|Drug|ifosfamide|
1721310|NCT00003406|Procedure|autologous bone marrow transplantation|
1721311|NCT00003406|Procedure|bone marrow ablation with stem cell support|
1721312|NCT00003406|Procedure|peripheral blood stem cell transplantation|
1721313|NCT00003407|Drug|amifostine trihydrate|
1721314|NCT00003407|Drug|cytarabine|
1721315|NCT00003407|Drug|mitoxantrone hydrochloride|
1721316|NCT00003408|Biological|aldesleukin|
1721317|NCT00003408|Biological|recombinant interferon alfa|
1721318|NCT00003408|Biological|sargramostim|
1721319|NCT00003409|Drug|motexafin gadolinium|
1721320|NCT00003409|Radiation|radiation therapy|
1721321|NCT00003410|Drug|motexafin gadolinium|
1721322|NCT00003410|Procedure|magnetic resonance imaging|
1721323|NCT00003410|Procedure|surgical procedure|
1721324|NCT00003411|Drug|motexafin gadolinium|
1721325|NCT00003411|Radiation|radiation therapy|
1721326|NCT00003412|Biological|recombinant interleukin-12|
1721327|NCT00003413|Biological|filgrastim|
1721328|NCT00003413|Drug|carmustine|
1721329|NCT00003413|Drug|cisplatin|
1721330|NCT00003413|Drug|melphalan|
1721331|NCT00003413|Drug|paclitaxel|
1721332|NCT00003413|Procedure|peripheral blood stem cell transplantation|
1721333|NCT00003413|Procedure|surgical procedure|
1721334|NCT00003414|Biological|aldesleukin|
1721335|NCT00003414|Biological|recombinant interferon gamma|
1721336|NCT00003414|Drug|busulfan|
1721337|NCT00003414|Drug|cyclophosphamide|
1721338|NCT00003414|Drug|cyclosporine|
1721339|NCT00003414|Procedure|peripheral blood stem cell transplantation|
1721340|NCT00003414|Radiation|radiation therapy|
1721341|NCT00003415|Drug|amifostine trihydrate|
1721342|NCT00003415|Drug|topotecan hydrochloride|
1721343|NCT00003416|Biological|filgrastim|
1721344|NCT00003416|Biological|recombinant interferon alfa|
1721345|NCT00003416|Drug|dexamethasone|
1721346|NCT00003416|Drug|melphalan|
1721347|NCT00003416|Procedure|peripheral blood stem cell transplantation|
1721348|NCT00003417|Drug|carmustine|
1721349|NCT00003417|Radiation|radiation therapy|
1721350|NCT00003418|Drug|exemestane|
1721351|NCT00003418|Drug|tamoxifen citrate|
1721352|NCT00003419|Procedure|antiviral therapy|
1721353|NCT00003420|Procedure|computed tomography|
1721354|NCT00003421|Biological|bleomycin sulfate|
1721355|NCT00003421|Drug|ABVD regimen|
1721356|NCT00003421|Drug|chlorambucil|
1721357|NCT00003421|Drug|dacarbazine|
1721358|NCT00003421|Drug|doxorubicin hydrochloride|
1721359|NCT00003421|Drug|etoposide|
1721360|NCT00003421|Drug|prednisolone|
1721361|NCT00003421|Drug|procarbazine hydrochloride|
1721362|NCT00003421|Drug|vinblastine sulfate|
1721363|NCT00003421|Drug|vincristine sulfate|
1721364|NCT00003421|Radiation|radiation therapy|
1721365|NCT00003422|Drug|fluorouracil|
1721366|NCT00003422|Drug|leucovorin calcium|
1721367|NCT00003422|Procedure|adjuvant therapy|
1721368|NCT00003422|Procedure|conventional surgery|
1721369|NCT00003422|Procedure|neoadjuvant therapy|
1721370|NCT00003422|Radiation|radiation therapy|
1721371|NCT00003423|Drug|asparaginase|
1721372|NCT00003423|Drug|cyclophosphamide|
1721373|NCT00003423|Drug|cytarabine|
1721374|NCT00003423|Drug|daunorubicin hydrochloride|
1721375|NCT00003423|Drug|dexamethasone|
1721376|NCT00003423|Drug|etoposide|
1721377|NCT00003423|Drug|mercaptopurine|
1721378|NCT00003423|Drug|methotrexate|
1721379|NCT00003423|Drug|prednisolone|
1721380|NCT00003423|Drug|thioguanine|
1721381|NCT00003423|Drug|vincristine sulfate|
1721382|NCT00003424|Drug|tamoxifen citrate|
1721383|NCT00003425|Biological|filgrastim|
1721384|NCT00003425|Drug|amifostine trihydrate|
1721385|NCT00003425|Drug|cyclophosphamide|
1721386|NCT00003425|Drug|melphalan|
1721387|NCT00003425|Procedure|peripheral blood stem cell transplantation|
1721388|NCT00003426|Drug|gemcitabine hydrochloride|
1721389|NCT00003426|Radiation|radiation therapy|
1721390|NCT00003427|Drug|irinotecan hydrochloride|
1721391|NCT00003427|Drug|oxaliplatin|
1721392|NCT00003428|Drug|arzoxifene hydrochloride|
1721393|NCT00003429|Procedure|biopsy|
1721394|NCT00003429|Procedure|computed tomography|
1721395|NCT00003429|Procedure|positron emission tomography|
1721396|NCT00003429|Radiation|fludeoxyglucose F 18|
1721397|NCT00003430|Drug|L-778,123|
1721398|NCT00003431|Biological|recombinant flt3 ligand|
1721399|NCT00003432|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|Approximately 60-90 days after the peripheral blood stem cell transplant, patients receive CEA RNA pulsed dendritic cells IV every 3 weeks for a total of 4 doses.
1721400|NCT00003433|Biological|carcinoembryonic antigen RNA-pulsed DC cancer vaccine|
1721401|NCT00003434|Biological|carcinoembryonic antigen peptide 1|
1721402|NCT00003434|Biological|hepatitis B antigen peptide|
1721403|NCT00003435|Biological|anti-thymocyte globulin|
1721404|NCT00003435|Drug|melphalan|
1721405|NCT00003435|Procedure|antiviral therapy|
1721406|NCT00003435|Procedure|bone marrow ablation with stem cell support|
1721407|NCT00003435|Procedure|peripheral blood stem cell transplantation|
1721408|NCT00003435|Procedure|umbilical cord blood transplantation|
1721409|NCT00003435|Radiation|radiation therapy|
1721410|NCT00003436|Drug|amsacrine|
1721411|NCT00003436|Drug|asparaginase|
1721412|NCT00003436|Drug|cytarabine|
1721413|NCT00003436|Drug|daunorubicin hydrochloride|
1721414|NCT00003436|Drug|etoposide|
1721415|NCT00003436|Drug|methotrexate|
1721416|NCT00003436|Drug|mitoxantrone hydrochloride|
1721417|NCT00003436|Drug|therapeutic hydrocortisone|
1721418|NCT00003436|Procedure|allogeneic bone marrow transplantation|
1721422|NCT00003437|Drug|daunorubicin hydrochloride|
1721423|NCT00003437|Drug|dexamethasone|
1721424|NCT00003437|Drug|doxorubicin hydrochloride|
1721425|NCT00003437|Drug|mercaptopurine|
1721426|NCT00003437|Drug|methotrexate|
1721427|NCT00003437|Drug|pegaspargase|
1721428|NCT00003437|Drug|prednisolone|
1721429|NCT00003437|Drug|thioguanine|
1721430|NCT00003437|Drug|vincristine sulfate|
1721431|NCT00003437|Radiation|radiation therapy|
1721432|NCT00003439|Biological|recombinant interleukin-12|
1721433|NCT00003440|Drug|paclitaxel|Given IV over 1 hour or 3 hours
1721434|NCT00003440|Biological|trastuzumab|Given IV
1721435|NCT00003440|Procedure|quality-of-life assessment|Ancillary studies
1721436|NCT00003440|Other|laboratory biomarker analysis|Correlative studies
1721437|NCT00003441|Drug|Irofulven (MGI-114)|IV over 5 minutes daily for 5 consecutive days. Courses repeated every 28 days. Minimum treatment period is 2 courses.
1721438|NCT00003443|Drug|bryostatin 1|
1721439|NCT00003444|Biological|recombinant interferon alfa|
1721440|NCT00003444|Radiation|radiation therapy|
1721441|NCT00003445|Drug|docetaxel|
1721442|NCT00003446|Drug|fluorouracil|
1721443|NCT00003446|Drug|leucovorin calcium|
1721444|NCT00003446|Drug|trimetrexate glucuronate|
1721445|NCT00003447|Drug|gemcitabine hydrochloride|
1721446|NCT00003447|Drug|vinorelbine tartrate|
1721447|NCT00003449|Drug|dexamethasone|
1721448|NCT00003449|Drug|gemcitabine hydrochloride|
1721449|NCT00003449|Drug|paclitaxel|
1721450|NCT00003450|Biological|Ad5CMV-p53 gene|
1721451|NCT00003451|Biological|recombinant interferon alfa|
1721452|NCT00003451|Biological|recombinant interleukin-12|
1721453|NCT00003452|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Bladder Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721454|NCT00003453|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Adrenal Gland Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721455|NCT00003454|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Breast Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721456|NCT00003455|Drug|antineoplaston A10|
1721457|NCT00003455|Drug|antineoplaston AS2-1|
1721458|NCT00003455|Procedure|alternative product therapy|
1721459|NCT00003455|Procedure|biological therapy|
1721460|NCT00003455|Procedure|biologically based therapies|
1721461|NCT00003455|Procedure|cancer prevention intervention|
1721462|NCT00003455|Procedure|complementary and alternative therapy|
1721463|NCT00003455|Procedure|differentiation therapy|
1721466|NCT00003457|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a persistent or recurrent brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
1721467|NCT00003458|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
1721468|NCT00003459|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with a brain stem glioma will receive Antineoplaston therapy (Atengenal + Astugenal)
1721469|NCT00003460|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primitive neuroectodermal tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
1721470|NCT00003461|Procedure|surgical procedure|
1721471|NCT00003461|Radiation|astatine At 211 monoclonal antibody 81C6|
1721472|NCT00003462|Drug|busulfan|
1721473|NCT00003463|Drug|carmustine|
1721474|NCT00003463|Drug|irinotecan hydrochloride|
1721475|NCT00003463|Drug|polifeprosan 20 with carmustine implant|
1721476|NCT00003463|Procedure|surgical procedure|
1721477|NCT00003464|Drug|temozolomide|
1721478|NCT00003464|Radiation|radiation therapy|
1721479|NCT00003465|Drug|temozolomide|
1721480|NCT00003466|Drug|temozolomide|
1721481|NCT00003467|Drug|carmustine|
1721482|NCT00003467|Drug|polifeprosan 20 with carmustine implant|
1721483|NCT00003467|Procedure|surgical procedure|
1721484|NCT00003468|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a low grade astrocytoma that have not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
1721485|NCT00003469|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a Rhabdoid tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
1721486|NCT00003470|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with an anaplastic astrocytoma that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721491|NCT00003473|Drug|Atengenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
1721492|NCT00003473|Drug|Astugenal|Adults with a recurrent or refractory mixed glioma will receive Antineoplaston therapy (Atengenal + Astugenal).
1721554|NCT00003505|Procedure|complementary and alternative therapy|
1721495|NCT00003475|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Adults with a primary malignant brain tumor that has not responded to standard therapy will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721496|NCT00003476|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a primary malignant brain tumor will receive Antineoplaston therapy (Atengenal + Astugenal).
1721497|NCT00003477|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Children with a visual pathway glioma, which is not amenable to standard therapy or has not responded to standard therapy, will receive Antineoplaston therapy (Atengenal + Astugenal).
1721498|NCT00003478|Procedure|conventional surgery|
1721499|NCT00003478|Radiation|iodine I 131 monoclonal antibody 81C6|
1721500|NCT00003478|Radiation|radiation therapy|
1721501|NCT00003479|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Patients with an ependymoma will receive Antineoplaston therapy (Atengenal + Astugenal).
1721502|NCT00003483|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with a meningioma will receive Antineoplaston therapy (Atengenal + Astugenal).
1721503|NCT00003484|Drug|carmustine|
1721504|NCT00003484|Drug|irinotecan hydrochloride|
1721505|NCT00003484|Procedure|surgical procedure|
1721506|NCT00003484|Radiation|iodine I 131 monoclonal antibody 81C6|
1721507|NCT00003485|Drug|antineoplaston A10, antineoplaston AS2-1 (ANP)|"Patients with metastatic or unresectable Colon Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721508|NCT00003486|Drug|antineoplaston A10|
1721509|NCT00003486|Drug|antineoplaston AS2-1|
1721510|NCT00003486|Procedure|alternative product therapy|
1721511|NCT00003486|Procedure|biological therapy|
1721512|NCT00003486|Procedure|biologically based therapies|
1721513|NCT00003486|Procedure|cancer prevention intervention|
1721514|NCT00003486|Procedure|complementary and alternative therapy|
1721515|NCT00003486|Procedure|differentiation therapy|
1721516|NCT00003487|Drug|antineoplaston A10|
1721517|NCT00003487|Drug|antineoplaston AS2-1|
1721518|NCT00003489|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Advanced Head and Neck Cancer Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721519|NCT00003490|Biological|sargramostim|
1721520|NCT00003490|Drug|cyclophosphamide|
1721521|NCT00003490|Drug|prednisone|
1721522|NCT00003490|Drug|vincristine sulfate|
1721523|NCT00003491|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721524|NCT00003492|Drug|antineoplaston A10|
1721525|NCT00003492|Drug|antineoplaston AS2-1|
1721526|NCT00003493|Drug|dexamethasone|
1721527|NCT00003493|Drug|pegylated liposomal doxorubicin hydrochloride|
1721528|NCT00003493|Drug|vincristine sulfate|
1721529|NCT00003494|Drug|antineoplaston A10|
1721530|NCT00003494|Drug|antineoplaston AS2-1|
1721531|NCT00003495|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV or Recurrent Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721532|NCT00003496|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Recurrent or Extensive-Stage Small Cell Lung Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721533|NCT00003497|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Antineoplaston therapy (Atengenal + Astugenal) capsules orally six to seven times a day. Treatment continues in the absence of disease progression or unacceptable toxicity. absence of disease progression or unacceptable toxicity.
1721534|NCT00003498|Drug|antineoplaston A10|
1721535|NCT00003498|Drug|antineoplaston AS2-1|
1721536|NCT00003499|Drug|antineoplaston A10|
1721537|NCT00003499|Drug|antineoplaston AS2-1|
1721538|NCT00003500|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721539|NCT00003501|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Refractory or Recurrent High-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721540|NCT00003502|Drug|antineoplaston A10|
1721541|NCT00003502|Drug|antineoplaston AS2-1|
1721542|NCT00003502|Procedure|alternative product therapy|
1721543|NCT00003502|Procedure|biological therapy|
1721544|NCT00003502|Procedure|biologically based therapies|
1721545|NCT00003502|Procedure|cancer prevention intervention|
1721546|NCT00003502|Procedure|complementary and alternative therapy|
1721547|NCT00003502|Procedure|differentiation therapy|
1721548|NCT00003505|Drug|antineoplaston A10|
1721549|NCT00003505|Drug|antineoplaston AS2-1|
1721550|NCT00003505|Procedure|alternative product therapy|
1721551|NCT00003505|Procedure|biological therapy|
1721552|NCT00003505|Procedure|biologically based therapies|
1721553|NCT00003505|Procedure|cancer prevention intervention|
1721555|NCT00003505|Procedure|differentiation therapy|
1721556|NCT00003508|Drug|antineoplaston A10|
1721557|NCT00003508|Drug|antineoplaston AS2-1|
1721558|NCT00003509|Drug|antineoplaston A10|
1721559|NCT00003509|Drug|antineoplaston AS2-1|
1721560|NCT00003511|Drug|antineoplaston A10|
1721561|NCT00003511|Drug|antineoplaston AS2-1|
1721562|NCT00003512|Drug|antineoplaston A10|
1721563|NCT00003512|Drug|antineoplaston AS2-1|
1721564|NCT00003513|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Neuroblastoma will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721565|NCT00003514|Drug|antineoplaston A10|
1721566|NCT00003514|Drug|antineoplaston AS2-1|
1721567|NCT00003514|Procedure|alternative product therapy|
1721568|NCT00003514|Procedure|biological therapy|
1721569|NCT00003514|Procedure|biologically based therapies|
1721570|NCT00003514|Procedure|cancer prevention intervention|
1721571|NCT00003514|Procedure|complementary and alternative therapy|
1721572|NCT00003514|Procedure|differentiation therapy|
1721573|NCT00003515|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients With Metastatic, Recurrent, or Refractory Primitive Neuroectodermal Tumors will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721574|NCT00003516|Drug|antineoplaston A10|
1721575|NCT00003516|Drug|antineoplaston AS2-1|
1721576|NCT00003517|Drug|antineoplaston A10|
1721577|NCT00003517|Drug|antineoplaston AS2-1|
1721578|NCT00003517|Drug|bicalutamide|
1721579|NCT00003517|Drug|flutamide|
1721580|NCT00003517|Drug|leuprolide acetate|
1721581|NCT00003517|Procedure|alternative product therapy|
1721582|NCT00003517|Procedure|antiandrogen therapy|
1721583|NCT00003517|Procedure|biological therapy|
1721584|NCT00003517|Procedure|biologically based therapies|
1721585|NCT00003517|Procedure|cancer prevention intervention|
1721586|NCT00003517|Procedure|complementary and alternative therapy|
1721587|NCT00003517|Procedure|differentiation therapy|
1721588|NCT00003517|Procedure|endocrine therapy|
1721589|NCT00003517|Procedure|hormone therapy|
1721590|NCT00003518|Drug|gemcitabine hydrochloride|
1721591|NCT00003518|Drug|paclitaxel|
1721592|NCT00003519|Drug|cyclophosphamide|
1721593|NCT00003519|Drug|docetaxel|
1721594|NCT00003519|Drug|doxorubicin hydrochloride|
1721595|NCT00003520|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Kidney Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721596|NCT00003521|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Soft Tissue Sarcoma will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721597|NCT00003522|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Cancer of the Small Intestine will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721598|NCT00003523|Drug|aminocamptothecin colloidal dispersion|
1721599|NCT00003524|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stomach Cancer will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721600|NCT00003525|Drug|Antineoplaston therapy (Atengenal + Astugenal)|"Patients with Stage IV Cancer of the Cervix and/or Vulva will receive Antineoplaston therapy (Atengenal + Astugenal).
The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1."
1721601|NCT00003526|Drug|antineoplaston A10|
1721602|NCT00003526|Drug|antineoplaston AS2-1|
1721603|NCT00003528|Drug|raltitrexed|Given IV
1721604|NCT00003530|Drug|antineoplaston A10|
1721605|NCT00003531|Drug|antineoplaston A10|
1721606|NCT00003531|Drug|antineoplaston AS2-1|
1721607|NCT00003532|Drug|antineoplaston A10|
1721608|NCT00003532|Drug|antineoplaston AS2-1|
1721609|NCT00003533|Drug|antineoplaston A10|
1721610|NCT00003533|Drug|antineoplaston AS2-1|
1721611|NCT00003534|Drug|antineoplaston A10|
1721612|NCT00003534|Drug|antineoplaston AS2-1|
1721615|NCT00003536|Drug|antineoplaston A10|
1721616|NCT00003536|Drug|methotrexate|
1721617|NCT00003536|Procedure|alternative product therapy|
1721618|NCT00003536|Procedure|biological therapy|
1721619|NCT00003536|Procedure|biologically based therapies|
1721620|NCT00003536|Procedure|cancer prevention intervention|
1721621|NCT00003536|Procedure|chemotherapy|
1721622|NCT00003536|Procedure|complementary and alternative therapy|
1721623|NCT00003536|Procedure|differentiation therapy|
1721624|NCT00003537|Drug|Antineoplaston therapy (Atengenal + Astugenal)|Adults with an anaplastic astrocytoma will receive Antineoplaston therapy (Atengenal + Astugenal).
1721625|NCT00003538|Biological|graft versus host disease prophylaxis/therapy|
1721626|NCT00003538|Procedure|allogeneic bone marrow transplantation|
1721627|NCT00003539|Biological|trastuzumab|
1721628|NCT00003539|Drug|paclitaxel|
1721629|NCT00003540|Drug|gemcitabine hydrochloride|
1721630|NCT00003541|Biological|filgrastim|
1721631|NCT00003541|Drug|CHOP regimen|
1721632|NCT00003541|Drug|carboplatin|
1721633|NCT00003541|Drug|cyclophosphamide|
1721634|NCT00003541|Drug|doxorubicin hydrochloride|
1721635|NCT00003541|Drug|etoposide|
1721636|NCT00003541|Drug|ifosfamide|
1721637|NCT00003541|Drug|prednisone|
1721638|NCT00003541|Drug|vincristine sulfate|
1721639|NCT00003541|Procedure|peripheral blood stem cell transplantation|
1721640|NCT00003541|Radiation|radiation therapy|
1721641|NCT00003542|Biological|pegylated interferon alfa|
1721642|NCT00003543|Biological|monoclonal antibody A33|
1721643|NCT00003543|Drug|carmustine|
1721644|NCT00003543|Drug|fluorouracil|
1721645|NCT00003543|Drug|streptozocin|
1721646|NCT00003543|Drug|vincristine sulfate|
1721647|NCT00003544|Drug|irinotecan hydrochloride|
1721648|NCT00003544|Procedure|surgical procedure|
1721649|NCT00003545|Drug|nelarabine|
1721650|NCT00003546|Drug|gemcitabine hydrochloride|given IV
1721651|NCT00003546|Radiation|radiation therapy|1.8 Gy to tumor bed
1721652|NCT00003548|Drug|aminocamptothecin colloidal dispersion|
1721653|NCT00003549|Drug|CMF regimen|
1721654|NCT00003549|Drug|cyclophosphamide|
1721655|NCT00003549|Drug|fluorouracil|
1721656|NCT00003549|Drug|methotrexate|
1721657|NCT00003551|Drug|aminocamptothecin colloidal dispersion|
1721658|NCT00003552|Drug|allogeneic lymphocytes|
1721659|NCT00003552|Drug|anti-thymocyte globulin|
1721660|NCT00003552|Drug|cyclophosphamide|
1721661|NCT00003552|Drug|fludarabine|
1721662|NCT00003553|Biological|anti-thymocyte globulin|Given IV
1721663|NCT00003553|Drug|cyclophosphamide|Given IV
1721664|NCT00003553|Drug|cyclosporine|Given IV
1721665|NCT00003553|Drug|fludarabine phosphate|Given IV
1721666|NCT00003553|Drug|methotrexate|Given as GVHD prophylaxis
1721667|NCT00003553|Drug|mycophenolate mofetil|Given as GVHD prophylaxis
1721668|NCT00003554|Biological|rituximab|
1721669|NCT00003554|Drug|melphalan|
1721670|NCT00003554|Drug|prednisone|
1721671|NCT00003555|Drug|amifostine trihydrate|
1721672|NCT00003555|Drug|paclitaxel|
1721673|NCT00003556|Biological|ALVAC-hB7.1|
1721674|NCT00003556|Biological|canarypox-hIL-12 melanoma vaccine|
1721675|NCT00003557|Drug|dolastatin 10|
1721676|NCT00003558|Drug|carboplatin|
1721677|NCT00003558|Drug|etoposide|
1721678|NCT00003558|Drug|fluorouracil|
1721679|NCT00003558|Drug|leucovorin calcium|
1721680|NCT00003558|Drug|paclitaxel|
1721681|NCT00003560|Drug|carboplatin|
1721682|NCT00003560|Drug|docetaxel|
1721683|NCT00003561|Biological|recombinant interferon alfa|
1721684|NCT00003561|Biological|sargramostim|
1721685|NCT00003562|Drug|carboplatin|
1721686|NCT00003562|Drug|docetaxel|
1721687|NCT00003563|Radiation|WBRT|3 GY of WBRT daily for a total of 10 days
1721688|NCT00003563|Drug|MGd|5.0 mg /kg MGd plus WBRT
1721689|NCT00003564|Drug|Isotretinoin|Oral isotretinoin is administered every 12 hours on days 15-28 every 28 days.
1721690|NCT00003564|Drug|Procarbazine Hydrochloride|"Arm I: Oral procarbazine once daily on days 1-14 every 28 days for 6 courses of combined therapy.
Arm II: Oral procarbazine once daily on days 1-14 followed by 2 weeks of rest for a total of 6 courses."
1721691|NCT00003565|Drug|docetaxel|
1721692|NCT00003566|Procedure|videothoracoscopy|
1721693|NCT00003567|Biological|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
1721694|NCT00003567|Biological|sargramostim|Patients receive sargramostim (GM-CSF) subcutaneously (SC) once daily on days 1-5 (or G-CSF twice daily alone for 4-5 days).
1721695|NCT00003567|Biological|therapeutic autologous lymphocytes|
1721696|NCT00003567|Drug|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour every 6 weeks for 5 courses. Four weeks after the completion of BG and carmustine, patients receive BG IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
1721697|NCT00003567|Drug|carmustine|Patients receive carmustine IV over 1 hour every 6 weeks for 5 courses.Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
1721698|NCT00003567|Drug|temozolomide|Four weeks after the completion of BG and carmustine, patients receive temozolomide IV over 1 hour every 4 weeks for up to 5 courses, in the absence of hematologic toxicity. Patients with responding disease may continue to receive BG and temzolomide in the absence of disease progression or unacceptable toxicity.
1721699|NCT00003567|Procedure|in vitro-treated peripheral blood stem cell transplantation|Approximately 72 hours after the end of the first course of chemotherapy, patients receive reinfusion of retrovirally-transduced hematopoietic stem cells over 5-10 minutes. Cohorts of 3-6 patients receive escalating numbers of CD34 stem cells targeted for retroviral infection and escalating doses of carmustine.
1721700|NCT00003004|Drug|alvocidib|
1721701|NCT00003004|Drug|cisplatin|
1721702|NCT00003004|Drug|paclitaxel|
1721703|NCT00003005|Drug|Cordycepin|"Dose escalation study using the following doses:
6mg/m2, 12 mg/m2, 24mg/m2, 48mg/m2"
1721704|NCT00003005|Drug|Deoxycoformycin|Dose escalation using the Fibonacci dose escalation sequence starting dose 2mg/m2, escalating to 3mg/m3 intravenous
1721705|NCT00003006|Genetic|reverse transcriptase-polymerase chain reaction|
1721706|NCT00003006|Other|immunohistochemistry staining method|
1721707|NCT00003007|Biological|recombinant interferon alfa|
1721708|NCT00003007|Biological|sargramostim|
1721709|NCT00003007|Drug|cyclophosphamide|
1721710|NCT00003007|Drug|dexamethasone|
1721711|NCT00003007|Drug|melphalan|
1721953|NCT00003671|Drug|thioguanine|
1721712|NCT00003007|Procedure|peripheral blood stem cell transplantation|
1721713|NCT00003008|Drug|indinavir sulfate|
1721714|NCT00003008|Drug|nelfinavir mesylate|
1721715|NCT00003008|Drug|paclitaxel|
1721716|NCT00003008|Drug|ritonavir|
1721717|NCT00003008|Drug|saquinavir mesylate|
1721718|NCT00003009|Biological|aldesleukin|
1721719|NCT00003010|Drug|marimastat|
1721720|NCT00003011|Drug|marimastat|10 mg PO BID
1721721|NCT00003011|Drug|Placebo|10 mg PO BID
1721722|NCT00003012|Drug|CMF regimen|
1721723|NCT00003012|Drug|cyclophosphamide|
1721724|NCT00003012|Drug|epirubicin hydrochloride|
1721725|NCT00003012|Drug|fluorouracil|
1721726|NCT00003012|Drug|methotrexate|
1721727|NCT00003013|Drug|CMF regimen|
1721728|NCT00003013|Drug|cyclophosphamide|
1721729|NCT00003013|Drug|doxorubicin hydrochloride|
1721730|NCT00003013|Drug|fluorouracil|
1721731|NCT00003013|Drug|methotrexate|
1721732|NCT00003013|Drug|paclitaxel|
1721733|NCT00003013|Drug|tamoxifen citrate|
1721734|NCT00003013|Procedure|conventional surgery|
1721735|NCT00003013|Radiation|radiation therapy|
1721736|NCT00003014|Drug|carboplatin|
1721737|NCT00003014|Radiation|radiation therapy|
1721738|NCT00003015|Drug|carboplatin|
1721739|NCT00003015|Drug|vincristine sulfate|
1721740|NCT00003015|Procedure|conventional surgery|
1721741|NCT00003015|Radiation|radiation therapy|
1721742|NCT00003016|Drug|tamoxifen citrate|
1721743|NCT00003016|Procedure|adjuvant therapy|
1721744|NCT00003017|Biological|recombinant interleukin-12|
1721745|NCT00003018|Drug|dipyridamole|75mg/dose, PO, Days 1-28 of 5 week cycle
1721746|NCT00003018|Drug|fluorouracil|200 mg/m^2/day, continuous IV, Days 1-28 of 5 week cycle
1721747|NCT00003018|Drug|leucovorin calcium|30 mg/m^2/day, IV, Days 1,8,15,22 of 5 week cycle
1721748|NCT00003018|Drug|mitomycin C|10 mg/m^2, IV, Day 1 of 6 week cycle (for only 4 cycles)
1721749|NCT00003019|Drug|methotrexate|
1721750|NCT00003019|Drug|vinblastine sulfate|
1721751|NCT00003020|Biological|LMB-7 immunotoxin|
1721752|NCT00003021|Drug|bizelesin|
1721753|NCT00003568|Biological|aldesleukin|
1721754|NCT00003568|Biological|gp100 antigen|
1721755|NCT00003568|Biological|incomplete Freund's adjuvant|
1721756|NCT00003569|Drug|cisplatin|
1721757|NCT00003569|Drug|dimesna|
1721758|NCT00003569|Drug|paclitaxel|
1721759|NCT00003571|Genetic|mutation analysis|
1721760|NCT00003571|Genetic|tumor replication error analysis|
1721761|NCT00003572|Biological|peripheral blood lymphocyte therapy|
1721762|NCT00003572|Drug|mycophenolate mofetil|
1721763|NCT00003572|Drug|tacrolimus|
1721764|NCT00003572|Procedure|allogeneic bone marrow transplantation|
1721765|NCT00003572|Radiation|radiation therapy|
1721766|NCT00003573|Biological|filgrastim|
1721767|NCT00003573|Drug|cisplatin|
1721768|NCT00003573|Drug|cyclophosphamide|
1721769|NCT00003573|Drug|etoposide|
1721770|NCT00003573|Drug|vincristine sulfate|
1721771|NCT00003573|Radiation|radiation therapy|
1721772|NCT00003574|Procedure|surgical procedure|
1721773|NCT00003574|Radiation|brachytherapy|
1721774|NCT00003574|Radiation|intraoperative radiation therapy|
1721775|NCT00003574|Radiation|iodine I 125|
1721776|NCT00003575|Biological|filgrastim|
1721777|NCT00003575|Biological|recombinant interleukin-12|
1721778|NCT00003575|Drug|etoposide|
1721779|NCT00003575|Drug|ifosfamide|
1721780|NCT00003576|Drug|cisplatin|
1721781|NCT00003576|Drug|fluorouracil|
1721782|NCT00003576|Procedure|surgical procedure|
1721783|NCT00003576|Radiation|radiation therapy|
1721784|NCT00003577|Drug|CMF regimen|
1721785|NCT00003577|Drug|cyclophosphamide|
1721786|NCT00003577|Drug|epirubicin hydrochloride|
1721787|NCT00003577|Drug|fluorouracil|
1721788|NCT00003577|Drug|methotrexate|
1721789|NCT00003577|Procedure|adjuvant therapy|
1721790|NCT00003577|Radiation|radiation therapy|
1721791|NCT00003578|Drug|CHOP regimen|
1721792|NCT00003578|Drug|carmustine|
1721793|NCT00003578|Drug|cyclophosphamide|
1721794|NCT00003578|Drug|cytarabine|
1721795|NCT00003578|Drug|doxorubicin hydrochloride|
1721796|NCT00003578|Drug|etoposide|
1721797|NCT00003578|Drug|melphalan|
1721798|NCT00003578|Drug|prednisone|
1721799|NCT00003578|Drug|vincristine sulfate|
1721800|NCT00003578|Procedure|autologous bone marrow transplantation|
1721801|NCT00003578|Procedure|peripheral blood stem cell transplantation|
1721802|NCT00003580|Drug|amifostine trihydrate|
1721803|NCT00003580|Drug|cisplatin|
1721804|NCT00003580|Radiation|radiation therapy|
1721805|NCT00003582|Drug|amifostine trihydrate|
1721806|NCT00003582|Drug|cisplatin|
1721807|NCT00003582|Drug|fluorouracil|
1721808|NCT00003582|Drug|paclitaxel|
1721809|NCT00003582|Procedure|quality-of-life assessment|
1721810|NCT00003582|Radiation|radiation therapy|
1721811|NCT00003583|Drug|amifostine trihydrate|
1721812|NCT00003583|Drug|cisplatin|
1721813|NCT00003583|Drug|etoposide|
1721814|NCT00003583|Radiation|radiation therapy|
1721815|NCT00003584|Drug|estramustine phosphate sodium|
1721816|NCT00003584|Drug|prednisone|
1721817|NCT00003584|Drug|vinorelbine tartrate|
1721818|NCT00003585|Biological|aldesleukin|
1721819|NCT00003585|Biological|recombinant interferon alfa|
1721820|NCT00003585|Drug|fluorouracil|
1721821|NCT00003585|Drug|isotretinoin|
1721822|NCT00003585|Procedure|surgical procedure|
1721823|NCT00003587|Drug|carboplatin|AUC=5.5 day 1 every 21 days X 3
1721824|NCT00003587|Drug|cisplatin|IV cisplatin 100 mg/m^2 day 1 every 21 days X 3
1721825|NCT00003587|Drug|docetaxel|IV docetaxel 75 mg/m^2 day 1 every 21 days X 3
1721826|NCT00003587|Drug|gemcitabine|IV gemcitabine 1,000 mg/m^2/day, days 1 and 8 every 21 days X3
1721827|NCT00003587|Drug|paclitaxel|IV paclitaxel 225 mg/m^2/day, day 1 every 21 days X 3
1721828|NCT00003587|Drug|vinorelbine|IV vinorelbine 25 mg/m^2/day, days 1 and 8 every 21 days X 3
1721829|NCT00003588|Biological|Ad5CMV-p53 gene|
1721830|NCT00003588|Procedure|laparoscopic surgery|
1721831|NCT00003589|Drug|cisplatin|
1721832|NCT00003589|Drug|gemcitabine hydrochloride|
1721833|NCT00003589|Drug|paclitaxel|
1721834|NCT00003590|Drug|hydroxyurea|20 mg/kg/day PO
1721835|NCT00003591|Drug|paclitaxel|
1721836|NCT00003591|Radiation|radiation therapy|
1721837|NCT00003592|Drug|methotrexate|
1721838|NCT00003592|Drug|paclitaxel|
1721839|NCT00003593|Drug|asparaginase|Given IV
1721840|NCT00003593|Drug|cytarabine|Given IT
1721841|NCT00003593|Drug|daunorubicin hydrochloride|Given IV
1721842|NCT00003593|Drug|methotrexate|Given IV
1721843|NCT00003593|Drug|therapeutic hydrocortisone|Given IT
1721844|NCT00003593|Drug|thioguanine|Given IV
1721845|NCT00003594|Drug|irinotecan|
1721846|NCT00003594|Drug|fluorouracil|
1721847|NCT00003594|Drug|leucovorin calcium|
1721848|NCT00003594|Drug|oxaliplatin|
1721849|NCT00003595|Biological|filgrastim|
1721850|NCT00003595|Biological|rituximab|
1721851|NCT00003595|Drug|CHOP regimen|
1721852|NCT00003595|Drug|cyclophosphamide|
1721853|NCT00003595|Drug|doxorubicin hydrochloride|
1721854|NCT00003595|Drug|prednisone|
1721855|NCT00003595|Drug|vincristine sulfate|
1721856|NCT00003596|Drug|cisplatin|
1721857|NCT00003596|Drug|fluorouracil|
1721858|NCT00003596|Drug|mitomycin C|
1721859|NCT00003596|Radiation|radiation therapy|
1721860|NCT00003597|Biological|recombinant human thrombopoietin|
1721861|NCT00003597|Drug|carboplatin|
1721862|NCT00003597|Drug|etoposide|
1721863|NCT00003597|Drug|ifosfamide|
1721864|NCT00003597|Biological|G-CSF|
1721865|NCT00003650|Drug|asparaginase|
1721866|NCT00003650|Drug|cyclophosphamide|
1721867|NCT00003650|Drug|cytarabine|
1721868|NCT00003650|Drug|daunorubicin hydrochloride|
1721869|NCT00003650|Drug|dexamethasone|
1721870|NCT00003650|Drug|etoposide|
1721871|NCT00003650|Drug|mercaptopurine|
1721872|NCT00003650|Drug|methotrexate|
1721873|NCT00003650|Drug|methylprednisolone|
1721874|NCT00003650|Drug|mitoxantrone hydrochloride|
1721875|NCT00003650|Drug|prednisone|
1721876|NCT00003650|Drug|vincristine sulfate|
1721877|NCT00003650|Radiation|radiation therapy|
1721878|NCT00003652|Drug|cisplatin|
1721879|NCT00003652|Drug|fluorouracil|
1721880|NCT00003652|Procedure|neoadjuvant therapy|
1721881|NCT00003652|Radiation|radiation therapy|
1721882|NCT00003653|Drug|bicalutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
1721883|NCT00003653|Drug|buserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
1721884|NCT00003653|Drug|cyproterone acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
1721885|NCT00003653|Drug|flutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
1721886|NCT00003653|Drug|goserelin|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
1721887|NCT00003653|Drug|leuprolide acetate|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
1721888|NCT00003653|Drug|nilutamide|"Patients on the IAS arm should receive a minimum of 4 weeks of antiandrogen and a total of 8 months of LHRH analog during each on-treatment interval. The dose and frequency of LHRH treatment will be determined by the drug being administered (Appendix IX). Patients on the IAS arm should not be given an LHRH analog injection at the end of month 8 unless the patient is transferred to continuous treatment as per protocol upon completion of the 8 month intermittent treatment.
Patients may be treated with any commercially available LHRH analog and antiandrogen during or after protocol treatment (Appendix IX). Patients may switch drugs at any time during or after protocol treatment. The dose and schedule of treatment will depend on the agent used. Patients should continue to receive hormone therapy without interruption until hormone resistance has been documented"
1721889|NCT00003654|Drug|patent blue V dye|
1721890|NCT00003654|Procedure|lymphangiography|
1721891|NCT00003654|Procedure|radionuclide imaging|
1721892|NCT00003654|Procedure|sentinel lymph node biopsy|
1721893|NCT00003654|Radiation|technetium Tc 99m sulfur colloid|
1721894|NCT00003656|Biological|recombinant interferon alfa|
1721895|NCT00003656|Drug|tretinoin liposome|
1721896|NCT00003657|Biological|filgrastim|
1721897|NCT00003657|Drug|Amifostine|
1721898|NCT00003657|Drug|Carboplatin|
1721899|NCT00003657|Drug|Etoposide|
1721900|NCT00003657|Drug|Ifosfamide|
1721901|NCT00003657|Procedure|peripheral blood stem cell transplantation|
1721902|NCT00003658|Biological|filgrastim|
1721903|NCT00003658|Biological|rituximab|
1721904|NCT00003658|Drug|cyclophosphamide|
1721905|NCT00003658|Drug|pentostatin|
1721910|NCT00003661|Biological|anti-thymocyte globulin|
1721911|NCT00003661|Drug|busulfan|
1721912|NCT00003661|Drug|cyclosporine|
1721913|NCT00003661|Drug|melphalan|
1721914|NCT00003661|Drug|methylprednisolone|
1721915|NCT00003661|Procedure|umbilical cord blood transplantation|
1721916|NCT00003661|Radiation|radiation therapy|
1721917|NCT00003662|Biological|anti-thymocyte globulin|
1721918|NCT00003662|Drug|busulfan|
1721919|NCT00003662|Drug|cyclophosphamide|
1721920|NCT00003662|Drug|cyclosporine|
1721921|NCT00003662|Drug|melphalan|
1721922|NCT00003662|Drug|methylprednisolone|
1721923|NCT00003662|Procedure|umbilical cord blood transplantation|
1721924|NCT00003662|Radiation|radiation therapy|
1721925|NCT00003663|Biological|rituximab|
1721926|NCT00003663|Drug|dexamethasone|
1721927|NCT00003664|Biological|aldesleukin|
1721928|NCT00003664|Biological|recombinant interferon alfa|
1721929|NCT00003664|Drug|fluorouracil|
1721930|NCT00003664|Drug|gemcitabine hydrochloride|
1721931|NCT00003665|Biological|dendritic cell-MART-1 peptide vaccine|
1721932|NCT00003665|Biological|gp100 antigen|
1721933|NCT00003665|Biological|therapeutic tumor infiltrating lymphocytes|
1721934|NCT00003665|Biological|tyrosinase peptide|
1721935|NCT00003666|Drug|6-hydroxymethylacylfulvene|11mg/sq m IV infusion over 5 min q day for 5 days each 28 day cycle
1721936|NCT00003667|Drug|cyclophosphamide|
1721937|NCT00003667|Drug|dexrazoxane hydrochloride|
1721938|NCT00003667|Drug|disaccharide tripeptide glycerol dipalmitoyl|
1721939|NCT00003667|Drug|doxorubicin hydrochloride|
1721940|NCT00003667|Drug|vincristine sulfate|
1721941|NCT00003667|Procedure|surgical procedure|
1721942|NCT00003667|Radiation|radiation therapy|
1721943|NCT00003669|Drug|arzoxifene hydrochloride|
1721944|NCT00003670|Drug|arzoxifene hydrochloride|
1721945|NCT00003671|Drug|asparaginase|
1721946|NCT00003671|Drug|cyclophosphamide|
1721947|NCT00003671|Drug|cytarabine|
1721948|NCT00003671|Drug|daunorubicin hydrochloride|
1721949|NCT00003671|Drug|dexamethasone|
1721950|NCT00003671|Drug|leucovorin calcium|
1721951|NCT00003671|Drug|mercaptopurine|
1721952|NCT00003671|Drug|methotrexate|
1721954|NCT00003671|Drug|vincristine sulfate|
1721955|NCT00003673|Drug|chemotherapy|
1721956|NCT00003673|Drug|gemtuzumab ozogamicin|
1721957|NCT00003674|Drug|dalteparin|
1721958|NCT00003674|Drug|standard therapy|
1721959|NCT00003675|Drug|topotecan hydrochloride|1.2 mg/sq m twice a day for 5 days (Arm I) and once a day for 10 days (Arm II)
1721960|NCT00003677|Drug|Dolastatin 10|IV bolus once every 21 days.
1721961|NCT00003678|Drug|tamoxifen citrate|
1721962|NCT00003678|Procedure|adjuvant therapy|
1721963|NCT00003679|Drug|cyclophosphamide|
1721964|NCT00003679|Drug|docetaxel|
1721965|NCT00003679|Drug|doxorubicin hydrochloride|
1721966|NCT00003679|Drug|tamoxifen citrate|
1721967|NCT00003679|Procedure|conventional surgery|
1721968|NCT00003679|Radiation|radiation therapy|
1721969|NCT00003680|Drug|CMF regimen|
1721970|NCT00003680|Drug|cyclophosphamide|
1721971|NCT00003680|Drug|fluorouracil|
1721972|NCT00003680|Drug|methotrexate|
1721973|NCT00003680|Drug|tamoxifen citrate|
1721974|NCT00003680|Drug|thiotepa|
1721975|NCT00003680|Procedure|peripheral blood stem cell transplantation|
1721976|NCT00003680|Radiation|radiation therapy|
1721977|NCT00003681|Biological|epoetin alfa|
1721978|NCT00003681|Drug|amifostine trihydrate|
1721979|NCT00003682|Drug|doxorubicin hydrochloride|
1721980|NCT00003682|Drug|methylprednisolone|
1721981|NCT00003683|Drug|doxorubicin hydrochloride|
1721982|NCT00003683|Drug|ifosfamide|
1721983|NCT00003684|Drug|theophylline|
1721984|NCT00003684|Procedure|quality-of-life assessment|
1721985|NCT00003685|Procedure|fatigue assessment and management|
1721986|NCT00003685|Procedure|nausea and vomiting therapy|
1721987|NCT00003685|Procedure|pain therapy|
1721988|NCT00003685|Procedure|quality-of-life assessment|
1721989|NCT00003685|Radiation|radiation therapy|
1721990|NCT00003686|Drug|pilocarpine hydrochloride|Pilocarpine 5 mg po qid x 4 weeks
1721991|NCT00003686|Drug|Placebo|Placebo 5 mg po qid x 4 weeks
1721992|NCT00003687|Drug|dextromethorphan hydrobromide|
1721993|NCT00003687|Drug|morphine sulfate|
1721994|NCT00003688|Biological|dactinomycin|
1721995|NCT00003690|Drug|alvocidib|
1721996|NCT00003690|Drug|carboplatin|
1721997|NCT00003690|Drug|cisplatin|
1721998|NCT00003691|Biological|filgrastim|
1721999|NCT00003691|Drug|cisplatin|
1722000|NCT00003691|Drug|doxorubicin hydrochloride|
1722001|NCT00003691|Drug|paclitaxel|
1722002|NCT00003692|Procedure|therapeutic thoracoscopy|
1722003|NCT00003692|Procedure|video-assisted surgery|
1722004|NCT00003693|Drug|Dolastatin 10|IV bolus once every 3 weeks.
1722005|NCT00003694|Drug|omacetaxine mepesuccinate|Given IV
1722006|NCT00003694|Drug|cytarabine|Given IV
1722007|NCT00003694|Other|laboratory biomarker analysis|Correlative studies
1722008|NCT00003695|Drug|chemotherapy|
1722009|NCT00003695|Procedure|surgical procedure|
1722010|NCT00003696|Drug|carboplatin|
1722011|NCT00003696|Drug|cyclophosphamide|
1722012|NCT00003696|Drug|doxorubicin hydrochloride|
1722013|NCT00003696|Drug|etoposide|
1722014|NCT00003696|Drug|paclitaxel|
1722015|NCT00003697|Drug|vadimezan|
1722016|NCT00003698|Drug|fosbretabulin disodium|
1722017|NCT00003700|Biological|G-CSF|Courses I, II, IV, V: 5 ug/kg/d subQ injection Day 4 until ANC > 5,000 uL after nadir: 7 day minimum for Courses I & IV
1722018|NCT00003700|Drug|asparaginase|6000 U/sq m subQ or IM injection 2X/wk for 6 doses starting on Day 5: Courses I & IV
1722019|NCT00003700|Drug|cyclophosphamide|1200 mg/sq m IV infusion over 15-30 min Day 1 Courses I & IV (pts < 60y/o) 1000 mg/sq m IV infusion over 15-30 min Day 1 Courses II & V
1722020|NCT00003700|Drug|cytarabine|2000 mg/sq m IV infusion over 3 hrs Days 1,2, & 3: Courses II & V
1722021|NCT00003700|Drug|daunorubicin hydrochloride|80mg/sq m (pts<60y/o)OR 60mg/sq m (pts =/>60y/o) IV infusion over 5-10 min Days 1,2,& 3: Courses I & IV
1722022|NCT00003700|Drug|leucovorin calcium|"Courses III & VI:
25mg/sq m IV infusion Days 2, 9, and 16 5mg/sq m PO q 6 hr for 8 doses or until serum MTX <0.05 uM after ea IV dose"
1722023|NCT00003700|Drug|mercaptopurine|60mg/sq m/d PO every day Course VII
1722024|NCT00003700|Drug|methotrexate|15mg intrathecal Day 1 Courses II & V 1000mg/sq m IV infusion over 3 hrs Days 1, 8, & 15 and 25mg/sq m PO q 6hr x 4 doses after ea IV dose: Courses III & VI.
1722025|NCT00003700|Drug|prednisone|60mg/sq m/day PO Days 1-21 (pts<60y/o) OR Days 1-7 (pts >/= 60y/o) Courses I & IV and Days 1-5 of ea 4 cycle in Course VII
1722026|NCT00003700|Drug|vincristine sulfate|2 mg total IV infusion Days 1,8,15,& 22 Courses I & IV and Days 1, 8, & 15 Courses III & VI, and Day 1 of ea 4 wk cycle in Course VII
1722027|NCT00003700|Drug|Allopurinol|300mg PO q day Days 1-14 Course I
1722028|NCT00003701|Drug|carboplatin|
1722029|NCT00003701|Drug|cisplatin|
1722030|NCT00003701|Drug|doxorubicin hydrochloride|
1722031|NCT00003701|Drug|methotrexate|
1722032|NCT00003701|Drug|paclitaxel|
1722033|NCT00003701|Drug|vinblastine sulfate|
1722034|NCT00003702|Biological|Dactinomycin|Given IV
1722035|NCT00003702|Drug|Methotrexate|Given intramuscularly
1722036|NCT00003703|Drug|SarCNU|
1722037|NCT00003704|Drug|capecitabine|
1722038|NCT00003704|Radiation|radiation therapy|
1722039|NCT00003705|Drug|BMS-184476|
1722040|NCT00003706|Drug|pemetrexed disodium|
1722041|NCT00003707|Drug|gemcitabine hydrochloride|
1722042|NCT00003707|Drug|tipifarnib|
1722109|NCT00003733|Drug|paclitaxel|
1722110|NCT00003733|Drug|topotecan hydrochloride|
1722111|NCT00003734|Drug|flutamide|
1722112|NCT00003734|Drug|triptorelin|
1722113|NCT00003734|Radiation|radiation therapy|
1722114|NCT00003735|Drug|topotecan hydrochloride|given by mouth
1722043|NCT00003708|Drug|temozolomide|Patients receive oral temozolomide on days 1-21. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients are treated at escalating doses of temozolomide. The maximum tolerated dose is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity (DLT) during courses 1 or 2, with at least 2 patients experiencing DLT at the next higher dose level.
1722044|NCT00003709|Drug|carbendazim|Patients receive oral carbendazim weekly for 3 weeks followed by 1 week of rest. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxic effects. Cohorts of 3-6 patients receive escalating doses of carbendazim. If dose limiting toxicity (DLT) is seen in 1 of 3 patients treated at a given dose level, 3 additional patients will be entered at the same dose level. Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience DLT. Patients are followed for up to 30 days posttreatment.
1722045|NCT00003710|Drug|irinotecan hydrochloride|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
1722046|NCT00003710|Drug|mitomycin C|Patients receive mitomycin IV over 20 to 30 minutes on day 1 and irinotecan IV over 90 minutes on days 2, 8, 15, and 22, followed by 2 weeks of rest beginning on day 29. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3 to 6 patients each receive escalating doses of mitomycin and irinotecan until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose at which no more than 1 of 6 patients experiences dose limiting toxicity. Patients are followed for 1 month.
1722047|NCT00003711|Drug|irinotecan hydrochloride|
1722048|NCT00003711|Drug|pemetrexed disodium|
1722049|NCT00003712|Drug|temsirolimus|"•Part I: Patients receive CCI-779 IV over 30 minutes on days 1-5, followed by a 9 day rest period. Treatment courses repeat every 2 weeks in the absence of disease progression or unacceptable toxicity.
The maximum tolerated dose for part I is defined as the dose level at which 33% of patients experience dose limiting toxicity.
•Part II: Patients receive the same treatment schedule as part I. Three patients with CNS tumors are entered at the dose of CCI-779 determined to be the MTD in Part I. At least 3 patients are entered at each dose level in part II."
1722050|NCT00003713|Drug|intoplicine|
1722051|NCT00003714|Drug|Pyrazoloacridine|IV (by vein) over 3 hours every 3 weeks
1722052|NCT00003715|Biological|BCG vaccine|
1722053|NCT00003715|Biological|autologous tumor cell vaccine|
1722054|NCT00003715|Biological|recombinant interferon alfa|
1722055|NCT00003715|Drug|chemotherapy|
1722056|NCT00003715|Drug|cyclophosphamide|
1722057|NCT00003716|Biological|rituximab|
1722058|NCT00003717|Drug|estramustine phosphate sodium|
1722059|NCT00003717|Drug|paclitaxel|
1722060|NCT00003718|Drug|temozolomide|
1722061|NCT00003719|Drug|irinotecan hydrochloride|
1722062|NCT00003720|Drug|semaxanib|
1722063|NCT00003721|Drug|incyclinide|This is a dose escalation study. Patients receive oral COL-3 once daily. Treatment continues in the absence of disease progression and unacceptable toxic effects. Cohorts of 3-6 patients each receive escalating doses of COL-3. Dose escalation to the next level occurs after 3 patients have completed 28 days of treatment without dose limiting toxicity (DLT). Dose escalation continues until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 or more of 6 patients experience DLT.
1722064|NCT00003723|Drug|gemcitabine hydrochloride|Gemcitabine 1000 mg/m^2 days 1, 8 15 (q 28 days)
1722065|NCT00003724|Procedure|surgical procedure|
1722066|NCT00003725|Drug|valrubicin|
1722067|NCT00003725|Procedure|conventional surgery|
1722068|NCT00003726|Biological|lepirudin|lepirudin
1722069|NCT00003727|Biological|filgrastim|
1722070|NCT00003727|Biological|recombinant interferon alfa|
1722071|NCT00003727|Biological|sargramostim|
1722072|NCT00003727|Biological|therapeutic autologous lymphocytes|
1722073|NCT00003727|Drug|carmustine|
1722074|NCT00003727|Drug|cyclophosphamide|
1722075|NCT00003727|Drug|etoposide|
1722076|NCT00003727|Drug|gemcitabine hydrochloride|
1722077|NCT00003727|Drug|melphalan|
1722078|NCT00003727|Procedure|bone marrow ablation with stem cell support|
1722079|NCT00003727|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1722080|NCT00003728|Drug|asparaginase|
1722081|NCT00003728|Drug|cyclophosphamide|
1722082|NCT00003728|Drug|cytarabine|
1722083|NCT00003728|Drug|daunorubicin hydrochloride|
1722084|NCT00003728|Drug|dexamethasone|
1722085|NCT00003728|Drug|doxorubicin hydrochloride|
1722086|NCT00003728|Drug|etoposide|
1722087|NCT00003728|Drug|leucovorin calcium|
1722088|NCT00003728|Drug|mercaptopurine|
1722089|NCT00003728|Drug|methotrexate|
1722090|NCT00003728|Drug|methylprednisolone|
1722091|NCT00003728|Drug|mitoxantrone hydrochloride|
1722092|NCT00003728|Drug|prednisolone|
1722093|NCT00003728|Drug|therapeutic hydrocortisone|
1722094|NCT00003728|Drug|thioguanine|
1722095|NCT00003728|Drug|vincristine sulfate|
1722096|NCT00003728|Drug|vindesine|
1722097|NCT00003728|Procedure|allogeneic bone marrow transplantation|
1722098|NCT00003728|Procedure|peripheral blood stem cell transplantation|
1722099|NCT00003729|Drug|cytarabine|
1722100|NCT00003729|Drug|fludarabine phosphate|
1722101|NCT00003729|Drug|idarubicin|
1722102|NCT00003730|Drug|fluorouracil|
1722103|NCT00003730|Drug|vinorelbine tartrate|
1722104|NCT00003731|Drug|temozolomide|
1722105|NCT00003732|Drug|carboplatin|
1722106|NCT00003732|Drug|paclitaxel|
1722107|NCT00003732|Drug|topotecan hydrochloride|
1722108|NCT00003733|Drug|carboplatin|
1722115|NCT00003736|Drug|motexafin gadolinium|
1722116|NCT00003736|Procedure|biopsy|
1722117|NCT00003736|Procedure|breast imaging study|
1722118|NCT00003736|Procedure|comparison of screening methods|
1722119|NCT00003736|Procedure|magnetic resonance imaging|
1722120|NCT00003736|Procedure|study of high risk factors|
1722121|NCT00003737|Drug|becatecarin|
1722122|NCT00003739|Biological|filgrastim|
1722123|NCT00003740|Biological|trastuzumab|
1722124|NCT00003741|Biological|monoclonal antibody HeFi-1|
1722125|NCT00003742|Drug|cisplatin|
1722126|NCT00003742|Drug|irinotecan hydrochloride|
1722127|NCT00003742|Drug|paclitaxel|
1722128|NCT00003743|Biological|aldesleukin|
1722129|NCT00003744|Drug|gemcitabine|
1722130|NCT00003745|Drug|topotecan hydrochloride|
1722131|NCT00003746|Drug|2-chlorodeoxyadenosine (CDA) daily|Daily administration
1722132|NCT00003746|Drug|2-chlorodeoxyadenosine weekly|Weekly administration
1722133|NCT00003747|Drug|carboplatin|
1722134|NCT00003747|Drug|temozolomide|
1722135|NCT00003748|Drug|irinotecan hydrochloride|One course of therapy is comprised of a 4-week treatment period and a two-week rest period. Drug administration will be based on actual calculated body surface area. Starting dose will be 125 mg/m2/day given once per week on four consecutive weeks.
1722136|NCT00003749|Procedure|adjuvant therapy|
1722137|NCT00003749|Procedure|conventional surgery|
1722138|NCT00003749|Radiation|brachytherapy|
1722139|NCT00003749|Radiation|radiation therapy|
1722140|NCT00003750|Biological|hu14.18-IL2 fusion protein|
1722141|NCT00003751|Drug|penicillamine|
1722142|NCT00003751|Radiation|radiation therapy|
1722143|NCT00003752|Drug|bexarotene|
1722144|NCT00003753|Drug|dexamethasone|
1722145|NCT00003753|Drug|floxuridine|
1722146|NCT00003753|Drug|irinotecan hydrochloride|
1722147|NCT00003753|Procedure|adjuvant therapy|
1722148|NCT00003753|Procedure|conventional surgery|
1722149|NCT00003754|Drug|cyclophosphamide|
1722150|NCT00003754|Drug|thalidomide|
1722151|NCT00003755|Drug|MKC-1|
1722152|NCT00003757|Biological|rituximab|
1722153|NCT00003758|Drug|cytarabine|
1722154|NCT00003758|Drug|idarubicin|
1722155|NCT00003758|Procedure|allogeneic bone marrow transplantation|
1722156|NCT00003758|Procedure|autologous bone marrow transplantation|
1722157|NCT00003758|Procedure|peripheral blood stem cell transplantation|
1722158|NCT00003759|Biological|BCG vaccine|
1722159|NCT00003759|Drug|valrubicin|
1722160|NCT00003759|Procedure|conventional surgery|
1722161|NCT00003760|Drug|irofulven|Patients receive 6-hydroxymethylacylfulvene (MGI 114) IV over 5 minutes on days 1-5. Treatment is repeated every 28 days in the absence of disease progression or unacceptable toxicity. Patients are followed monthly for up to 1 year after therapy initiation.
1722162|NCT00003761|Biological|rV-DF3/MUC1|"- The starting dose for this Phase I study of rV-DF3/MUC1 will be 4.76 x 106 PFU.
-- Dose escalation will proceed with cohorts of at least 6 patients as follows: Per vaccination
Level 1 4.76 x 106 PFU
Level 2 4.76 x 107 PFU
Level 3 4.76 x 108 PFU"
1722163|NCT00003762|Drug|docetaxel|
1722164|NCT00003762|Drug|gemcitabine hydrochloride|
1722165|NCT00003763|Procedure|radionuclide imaging|
1722166|NCT00003763|Radiation|indium In 111 folic acid|
1722167|NCT00003764|Drug|cyclophosphamide|
1722168|NCT00003764|Drug|fludarabine phosphate|
1722169|NCT00003765|Drug|O6-benzylguanine|
1722170|NCT00003765|Drug|carmustine|
1722171|NCT00003766|Drug|O6-benzylguanine|
1722172|NCT00003768|Drug|fosbretabulin disodium|
1722173|NCT00003769|Drug|perillyl alcohol|
1722174|NCT00003769|Procedure|surgical procedure|
1722175|NCT00003771|Biological|therapeutic estradiol|
1722176|NCT00003771|Drug|norethindrone acetate|
1722177|NCT00003772|Procedure|quality-of-life assessment|
1722178|NCT00003773|Drug|oglufanide disodium|
1722179|NCT00003775|Drug|leflunomide|
1722180|NCT00003776|Biological|filgrastim|
1722181|NCT00003776|Drug|cisplatin|
1722182|NCT00003776|Drug|doxorubicin hydrochloride|
1722183|NCT00003776|Drug|ifosfamide|
1722184|NCT00003776|Drug|leucovorin calcium|
1722185|NCT00003776|Drug|methotrexate|
1722186|NCT00003776|Drug|trimetrexate glucuronate|
1722187|NCT00003776|Procedure|surgical procedure|
1722188|NCT00003777|Drug|amifostine trihydrate|
1722189|NCT00003777|Drug|cisplatin|
1722190|NCT00003777|Drug|fluorouracil|
1722191|NCT00003777|Procedure|surgical procedure|
1722192|NCT00003777|Radiation|radiation therapy|
1722193|NCT00003778|Drug|dolastatin 10|
1722194|NCT00003779|Biological|Connaught|Compare two strains of BCG
1722195|NCT00003779|Biological|Tice|Compare two strains of BCG
1722196|NCT00003780|Biological|tumor infiltrating lymphocyte therapy|
1722197|NCT00003780|Drug|gemcitabine hydrochloride|
1722198|NCT00003781|Drug|docetaxel|
1722199|NCT00003781|Procedure|pain therapy|
1722200|NCT00003781|Procedure|quality-of-life assessment|
1722201|NCT00003782|Drug|cyclophosphamide|Arm 1: 600 mg/m2 IV every 21 days for 4 cycles; Arm 3: 500 mg/m2 IV every 21 days for 4 cycles
1722202|NCT00003782|Drug|docetaxel|Arm 1: 100 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 75 mg/m2 IV every 21 days for 4 cycles
1722203|NCT00003782|Drug|doxorubicin|Arm 1: 60 mg/m2 IV every 21 days for 4 cycles; Arms 2 and 3: 50 mg/m2 IV every 21 days for 4 cycles
1722204|NCT00003783|Biological|filgrastim|
1722205|NCT00003783|Drug|asparaginase|
1722206|NCT00003783|Drug|cyclophosphamide|
1722207|NCT00003783|Drug|cytarabine|
1722208|NCT00003783|Drug|daunorubicin hydrochloride|
1722209|NCT00003783|Drug|dexamethasone|
1722210|NCT00003783|Drug|etoposide|
1722211|NCT00003783|Drug|idarubicin|
1722216|NCT00003783|Drug|vincristine sulfate|
1722217|NCT00003783|Radiation|radiation therapy|
1722218|NCT00003784|Drug|CHOP regimen|
1722219|NCT00003784|Drug|cyclophosphamide|
1722220|NCT00003784|Drug|doxorubicin hydrochloride|
1722221|NCT00003784|Drug|prednisone|
1722222|NCT00003784|Drug|vincristine sulfate|
1722223|NCT00003784|Radiation|tositumomab and iodine I 131 tositumomab|
1722224|NCT00003786|Drug|irofulven|
1722225|NCT00003787|Behavioral|educational/counseling intervention|
1722226|NCT00003787|Behavioral|therapeutic dietary intervention|
1722227|NCT00003788|Drug|carmustine|
1722228|NCT00003788|Drug|lomustine|
1722229|NCT00003788|Drug|porfimer sodium|
1722230|NCT00003788|Drug|procarbazine hydrochloride|
1722231|NCT00003788|Procedure|neoadjuvant therapy|
1722232|NCT00003788|Procedure|surgical procedure|
1722233|NCT00003788|Radiation|radiation therapy|
1722234|NCT00003789|Drug|isolated limb perfusion|Undergo isolated limb perfusion
1722235|NCT00003789|Drug|melphalan|Given via limb perfusion
1722236|NCT00003789|Biological|recombinant tumor necrosis factor family protein|Given via slow injection into the arterial line
1722237|NCT00003789|Other|pharmacological study|Correlative studies
1722238|NCT00003789|Other|laboratory biomarker analysis|Correlative studies
1722239|NCT00003790|Genetic|polymerase chain reaction|
1722240|NCT00003790|Other|flow cytometry|
1722241|NCT00003792|Biological|MART-1 antigen|
1722242|NCT00003792|Biological|filgrastim|
1722243|NCT00003792|Biological|flu matrix peptide p58-66|
1722244|NCT00003792|Biological|gp100 antigen|
1722245|NCT00003792|Biological|recombinant MAGE-3.1 antigen|
1722246|NCT00003792|Biological|tyrosinase peptide|
1722247|NCT00003792|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1722248|NCT00003793|Genetic|clonality analysis|
1722249|NCT00003793|Genetic|microsatellite instability analysis|
1722250|NCT00003793|Genetic|mutation analysis|
1722251|NCT00003794|Procedure|psychosocial assessment and care|
1722252|NCT00003794|Procedure|quality-of-life assessment|
1722253|NCT00003795|Procedure|quality-of-life assessment|
1722254|NCT00003796|Drug|irofulven|
1722255|NCT00003797|Biological|trastuzumab|
1722256|NCT00003797|Drug|gemcitabine hydrochloride|
1722257|NCT00003798|Drug|motexafin gadolinium|
1722258|NCT00003798|Radiation|radiation therapy|
1722259|NCT00003799|Drug|fluorouracil|Given IV
1722260|NCT00003799|Drug|oxaliplatin|Given IV
1722261|NCT00003799|Radiation|radiation therapy|Undergo radiotherapy
1722262|NCT00003799|Drug|leucovorin calcium|Given IV
1722263|NCT00003799|Procedure|therapeutic conventional surgery|Undergo surgery
1722267|NCT00003801|Procedure|management of therapy complications|
1722268|NCT00003801|Procedure|quality-of-life assessment|
1722269|NCT00003802|Drug|pyrazoloacridine|
1722270|NCT00003803|Drug|cisplatin|
1722271|NCT00003803|Drug|gemcitabine hydrochloride|
1722272|NCT00003803|Radiation|radiation therapy|
1722273|NCT00003804|Biological|dactinomycin|
1722274|NCT00003804|Drug|vincristine sulfate|
1722275|NCT00003804|Procedure|conventional surgery|
1722276|NCT00003805|Drug|piperacillin sodium|
1722277|NCT00003805|Drug|piperacillin-tazobactam|
1722278|NCT00003805|Drug|tazobactam sodium|
1722279|NCT00003805|Drug|vancomycin|
1722280|NCT00003808|Drug|theophylline|
1722281|NCT00003809|Biological|cetuximab|
1722282|NCT00003809|Drug|cisplatin|
1722283|NCT00003810|Drug|docetaxel|
1722284|NCT00003810|Drug|gemcitabine hydrochloride|
1722285|NCT00003811|Biological|bleomycin sulfate|
1722286|NCT00003811|Drug|amifostine trihydrate|
1722287|NCT00003811|Drug|cisplatin|
1722288|NCT00003811|Drug|etoposide|
1722289|NCT00003811|Procedure|conventional surgery|
1722290|NCT00003812|Biological|filgrastim|
1722291|NCT00003812|Drug|carboplatin|
1722292|NCT00003812|Drug|etoposide|
1722293|NCT00003812|Drug|paclitaxel|
1722294|NCT00003812|Drug|topotecan hydrochloride|
1722295|NCT00003812|Radiation|radiation therapy|
1722296|NCT00003814|Drug|eflornithine|
1722297|NCT00003815|Biological|bleomycin sulfate|
1722298|NCT00003815|Drug|carmustine|
1722299|NCT00003815|Drug|cyclophosphamide|
1722300|NCT00003815|Drug|cytarabine|
1722301|NCT00003815|Drug|doxorubicin hydrochloride|
1722302|NCT00003815|Drug|etoposide|
1722303|NCT00003815|Drug|melphalan|
1722304|NCT00003815|Drug|prednisolone|
1722305|NCT00003815|Drug|vincristine sulfate|
1722306|NCT00003815|Procedure|autologous bone marrow transplantation|
1722307|NCT00003815|Radiation|radiation therapy|
1722308|NCT00003816|Biological|anti-thymocyte globulin|Given IV
1722309|NCT00003816|Drug|busulfan|Given IV
1722310|NCT00003816|Drug|carboplatin|Given IV
1722311|NCT00003816|Drug|cyclophosphamide|Given IV
1722312|NCT00003816|Drug|etoposide|Given IV
1722313|NCT00003816|Drug|fludarabine phosphate|Given IV
1722314|NCT00003816|Drug|melphalan|Given IV
1722315|NCT00003816|Drug|thiotepa|Given IV
1722316|NCT00003816|Radiation|total-body irradiation|Given twice daily for 3 days
1722317|NCT00003817|Drug|dolasetron mesylate|
1722318|NCT00003817|Drug|granisetron hydrochloride|
1722319|NCT00003817|Drug|ondansetron|
1722320|NCT00003817|Drug|tropisetron|
1722321|NCT00003817|Procedure|quality-of-life assessment|
1722323|NCT00003819|Biological|TF(c)-KLH conjugate vaccine|
1722324|NCT00003819|Biological|Thomsen-Friedenreich antigen|
1722325|NCT00003819|Biological|keyhole limpet hemocyanin|
1722326|NCT00003820|Drug|Rituximab|Rituximab (biosimilar is Zytux) is a chimeric monoclonal antibody against the protein CD20, which is primarily found on the surface of immune system B-cells. Rituximab destroys B-cells and is therefore used to treat diseases which are characterized by excessive numbers of B-cells, overactive B-cells, or dysfunctional B-cells. This includes many lymphomas, leukemias, transplant rejection, and autoimmune disorders.
1722327|NCT00003821|Drug|aminopterin|
1722328|NCT00003822|Drug|apomine|
1722329|NCT00003824|Drug|cephalexin|500 mg oral bid for 3 days starting the night before resection
1722330|NCT00003824|Procedure|surgical procedure|
1722331|NCT00003824|Drug|Ciprofloxacin|500 mg oral bid for 3 days starting the night before resection
1722332|NCT00003825|Drug|pentosan polysulfate sodium|
1722333|NCT00003825|Procedure|quality-of-life assessment|
1722334|NCT00003827|Drug|amifostine trihydrate|
1722335|NCT00003827|Drug|cytarabine|
1722336|NCT00003827|Drug|topotecan hydrochloride|
1722337|NCT00003828|Drug|vinorelbine|
1722338|NCT00003829|Drug|cyclophosphamide|
1722339|NCT00003829|Drug|fludarabine phosphate|
1722342|NCT00003831|Procedure|conventional surgery|
1722343|NCT00003832|Drug|bromodeoxyuridine|Given IV
1722344|NCT00003832|Procedure|conventional surgery|Undergo surgery
1722345|NCT00003832|Other|laboratory biomarker analysis|Correlative studies
1722346|NCT00003833|Genetic|DNA stability analysis|
1722347|NCT00003833|Genetic|gene mapping|
1722348|NCT00003834|Drug|fluorouracil|
1722349|NCT00003834|Drug|leucovorin calcium|
1722350|NCT00003834|Drug|oxaliplatin|
1722351|NCT00003835|Drug|leucovorin calcium|Given IV
1722352|NCT00003835|Drug|fluorouracil|Given IV
1722353|NCT00003835|Drug|irinotecan hydrochloride|Given IV
1722354|NCT00003835|Other|laboratory biomarker analysis|Correlative studies
1722355|NCT00003837|Drug|nelarabine|
1722357|NCT00003840|Biological|DTGM fusion protein|
1722358|NCT00003842|Biological|interleukin-4 PE38KDEL cytotoxin|
1722359|NCT00003842|Drug|isolated perfusion|
1722360|NCT00003842|Procedure|surgical procedure|
1722361|NCT00003843|Drug|irinotecan hydrochloride|
1722362|NCT00003843|Genetic|mutation analysis|
1722363|NCT00003843|Genetic|polymorphism analysis|
1722364|NCT00003846|Biological|filgrastim|
1722365|NCT00003846|Drug|carboplatin|
1722366|NCT00003846|Drug|cyclophosphamide|
1722367|NCT00003846|Drug|thiotepa|
1722368|NCT00003846|Drug|vincristine sulfate|
1722369|NCT00003846|Procedure|bone marrow ablation with stem cell support|
1722370|NCT00003846|Procedure|peripheral blood stem cell transplantation|
1722371|NCT00003846|Radiation|radiation therapy|
1722372|NCT00003847|Drug|biricodar dicitrate|
1722373|NCT00003847|Drug|doxorubicin hydrochloride|
1722374|NCT00003847|Drug|vincristine sulfate|
1722375|NCT00003849|Biological|rituximab|
1722376|NCT00003850|Drug|thalidomide|
1722377|NCT00003851|Biological|proteolytic enzymes|
1722378|NCT00003851|Drug|gemcitabine hydrochloride|
1722379|NCT00003851|Procedure|Gonzalez regimen|
1722380|NCT00003852|Biological|filgrastim|
1722381|NCT00003852|Drug|carboplatin|
1722382|NCT00003852|Drug|cyclophosphamide|
1722383|NCT00003852|Drug|epirubicin hydrochloride|
1722384|NCT00003852|Drug|etoposide|
1722385|NCT00003852|Drug|ifosfamide|
1722386|NCT00003852|Drug|paclitaxel|
1722387|NCT00003852|Drug|thiotepa|
1722388|NCT00003852|Procedure|bone marrow ablation with stem cell support|
1722389|NCT00003852|Procedure|peripheral blood stem cell transplantation|
1722390|NCT00003853|Drug|4'-iodo-4'-deoxydoxorubicin|
1722391|NCT00003854|Other|immunohistochemistry staining method|
1722392|NCT00003854|Procedure|lymphangiography|
1722393|NCT00003854|Procedure|sentinel lymph node biopsy|
1722394|NCT00003854|Procedure|therapeutic conventional surgery|
1722395|NCT00003854|Radiation|whole breast irradiation|
1722396|NCT00003855|Procedure|axillary lymph node dissection|
1722397|NCT00003855|Radiation|whole breast irradiation|
1722398|NCT00003856|Drug|temoporfin|
1722399|NCT00003857|Drug|tamoxifen citrate|
1722400|NCT00003857|Procedure|adjuvant therapy|
1722401|NCT00003857|Radiation|radiation therapy|
1722402|NCT00003858|Drug|mitoxantrone hydrochloride|
1722403|NCT00003859|Drug|carboplatin|
1722404|NCT00003859|Drug|cyclophosphamide|
1722405|NCT00003859|Drug|etoposide|
1722406|NCT00003859|Drug|vincristine sulfate|
1722407|NCT00003859|Procedure|surgical procedure|
1722408|NCT00003859|Radiation|radiation therapy|
1722409|NCT00003860|Biological|filgrastim|
1722410|NCT00003860|Drug|carboplatin|
1722411|NCT00003860|Drug|etoposide|
1722412|NCT00003860|Drug|ifosfamide|
1722413|NCT00003860|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1722414|NCT00003861|Other|laboratory biomarker analysis|
1722415|NCT00003862|Drug|cisplatin|
1722416|NCT00003862|Drug|fluorouracil|
1722417|NCT00003862|Drug|leucovorin calcium|
1722418|NCT00003862|Drug|paclitaxel|
1722419|NCT00003862|Procedure|conventional surgery|
1722420|NCT00003862|Procedure|neoadjuvant therapy|
1722421|NCT00003862|Radiation|radiation therapy|
1722422|NCT00003863|Genetic|comparative genomic hybridization|
1722423|NCT00003863|Genetic|cytogenetic analysis|
1722424|NCT00003863|Genetic|fluorescence in situ hybridization|
1722425|NCT00003863|Genetic|gene rearrangement analysis|
1722426|NCT00003864|Drug|carboplatin|
1722427|NCT00003864|Drug|docetaxel|
1722428|NCT00003865|Drug|toremifene|
1722429|NCT00003867|Drug|capecitabine|
1722430|NCT00003867|Drug|irinotecan hydrochloride|
1722431|NCT00003868|Drug|cyclophosphamide|
1722432|NCT00003868|Drug|methotrexate|
1722433|NCT00003868|Procedure|allogeneic bone marrow transplantation|
1722434|NCT00003868|Procedure|peripheral blood stem cell transplantation|
1722435|NCT00003868|Radiation|iodine I 131 monoclonal antibody BC8|
1722436|NCT00003868|Radiation|radiation therapy|
1722437|NCT00003280|Biological|rituximab|
1722438|NCT00003281|Drug|paclitaxel|
1722439|NCT00003281|Drug|topotecan hydrochloride|
1722440|NCT00003281|Radiation|radiation therapy|
1722441|NCT00003282|Drug|EF5|Given IV
1722442|NCT00003282|Procedure|therapeutic conventional surgery|Undergo resection
1722443|NCT00003282|Procedure|biopsy|Undergo biopsy
1722444|NCT00003282|Other|pharmacological study|Correlative studies
1722445|NCT00003283|Drug|octreotide acetate|
1722446|NCT00003283|Drug|prednisone|
1722447|NCT00003284|Biological|filgrastim|
1722448|NCT00003284|Drug|carboplatin|
1722449|NCT00003284|Drug|etoposide|
1722450|NCT00003284|Drug|ifosfamide|
1722451|NCT00003284|Drug|paclitaxel|
1722452|NCT00003284|Procedure|peripheral blood stem cell transplantation|
1722453|NCT00003284|Radiation|radiation therapy|
1722454|NCT00003287|Drug|FOLFOX regimen|
1722455|NCT00003287|Drug|fluorouracil|
1722456|NCT00003287|Drug|leucovorin calcium|
1722457|NCT00003287|Drug|oxaliplatin|
1722458|NCT00003288|Biological|filgrastim|
1722459|NCT00003288|Drug|cyclophosphamide|
1722460|NCT00003288|Drug|tirapazamine|
1722461|NCT00003289|Drug|7-hydroxystaurosporine|
1722462|NCT00003290|Biological|gonadotrophin releasing hormone|
1722463|NCT00003290|Radiation|radiation therapy|
1722464|NCT00003291|Genetic|cytogenetic analysis|
1722465|NCT00003291|Genetic|mutation analysis|
1722466|NCT00003291|Other|laboratory biomarker analysis|
1722467|NCT00003292|Drug|ifosfamide|
1722468|NCT00003293|Drug|leflunomide|
1722469|NCT00003293|Drug|procarbazine hydrochloride|
1722470|NCT00003294|Biological|filgrastim|
1722471|NCT00003294|Drug|amifostine trihydrate|
1722472|NCT00003294|Drug|carboplatin|
1722473|NCT00003294|Drug|paclitaxel|
1722474|NCT00003296|Biological|filgrastim|
1722475|NCT00003296|Drug|pegylated liposomal doxorubicin hydrochloride|
1722476|NCT00003297|Drug|mitoxantrone hydrochloride|
1722477|NCT00003297|Drug|thiotepa|
1722478|NCT00003297|Drug|topotecan hydrochloride|
1722479|NCT00003297|Procedure|peripheral blood stem cell transplantation|
1722480|NCT00003298|Drug|cisplatin|Cisplatin was administered as part of the neoadjuvant regimen. It was given at a dose of 75 mg/m² via IV over approximately one hour, on day 1 of each cycle. Three cycles were given.
1722481|NCT00003298|Drug|fluorouracil|Postoperative regimen 5-FU, along with Leucovorin, was given by IV bolus, with 5-FU given immediately after the Leucovorin
1722482|NCT00003298|Drug|leucovorin calcium|Both 5-FU and Leucovorin will be given via IV bolus, with Leucovorin given immediately before 5-FU.
1722483|NCT00003298|Drug|paclitaxel|Paclitaxel was administered as part of the neoadjuvant regimen. It was given at a dose of 175 mg/m² as a 3 hour continuous intravenous infusion on day 1. Three cycles were given.
1722484|NCT00003298|Procedure|surgery|"The surgical procedure performed involved a radical subtotal or total gastrectomy.
A complete surgical resection was required"
1722485|NCT00003298|Radiation|radiation therapy|Concomitant chemotherapy and radiation therapy course: 5-FU 400 mg/m²/day + Leucovorin 20 mg/m²/day on days 1-4 of week one and days 1-3 of week 5 of XRT. Combined chemotherapy and radiation therapy were to begin 4 weeks after day 1 of the initial course of chemotherapy
1722486|NCT00003299|Drug|cisplatin|
1722487|NCT00003299|Drug|etoposide|
1722488|NCT00003299|Drug|paclitaxel|
1722489|NCT00003301|Drug|irinotecan hydrochloride|
1722490|NCT00003302|Procedure|biopsy|
1722491|NCT00003302|Procedure|magnetic resonance imaging|
1722492|NCT00003302|Procedure|radiomammography|
1722493|NCT00003304|Drug|temozolomide|
1722494|NCT00003305|Drug|aminopterin|
1722495|NCT00003305|Drug|leucovorin calcium|
1722496|NCT00003307|Drug|amifostine trihydrate|
1722497|NCT00003307|Radiation|radiation therapy|
1722498|NCT00003308|Radiation|stereotactic radiosurgery|
1722499|NCT00003309|Biological|filgrastim|
1722500|NCT00003309|Drug|cisplatin|
1722501|NCT00003309|Drug|cyclophosphamide|
1722502|NCT00003309|Drug|etoposide|
1722503|NCT00003309|Drug|vincristine sulfate|
1722504|NCT00003309|Procedure|adjuvant therapy|
1722505|NCT00003309|Radiation|radiation therapy|
1722506|NCT00003311|Biological|filgrastim|
1722507|NCT00003311|Drug|cyclophosphamide|
1722508|NCT00003311|Drug|cytarabine|
1722509|NCT00003311|Drug|dexamethasone|
1722510|NCT00003311|Drug|doxorubicin hydrochloride|
1722511|NCT00003311|Drug|methotrexate|
1722512|NCT00003311|Drug|vincristine sulfate|
1722513|NCT00003312|Radiation|iodine I 125|
1722514|NCT00003313|Biological|filgrastim|
1722515|NCT00003313|Drug|amifostine trihydrate|
1722516|NCT00003313|Drug|carboplatin|
1722517|NCT00003313|Drug|paclitaxel|
1722518|NCT00003313|Radiation|radiation therapy|
1722519|NCT00003315|Biological|sargramostim|
1722520|NCT00003315|Drug|liposomal amphotericin B|
1722521|NCT00003316|Drug|gemcitabine hydrochloride|
1722522|NCT00003317|Drug|carboplatin|
1722523|NCT00003317|Drug|paclitaxel|
1722524|NCT00003317|Radiation|radiation therapy|
1722525|NCT00003317|Procedure|surgery|
1722526|NCT00003320|Procedure|surgical procedure|
1722527|NCT00003320|Radiation|radiation therapy|
1722528|NCT00003320|Radiation|stereotactic radiosurgery|
1722529|NCT00003321|Procedure|psychosocial assessment and care|
1722530|NCT00003321|Procedure|quality-of-life assessment|
1722531|NCT00003322|Drug|cisplatin|
1722532|NCT00003322|Drug|paclitaxel|
1722533|NCT00003322|Procedure|quality-of-life assessment|
1722534|NCT00003323|Drug|finasteride|5 mg/d PO
1722535|NCT00003323|Drug|flutamide|250 mg PO tid
1722536|NCT00003323|Other|quality-of-life assessment|Assessment survey administered at baseline, and 3 & 6 months post initiation of treatment
1722537|NCT00003324|Procedure|conventional surgery|
1722538|NCT00003324|Radiation|radiation therapy|
1722539|NCT00003325|Procedure|Sentinel lymph node mapping|Sentinel lymph node mapping
1722540|NCT00003326|Drug|paclitaxel|
1722541|NCT00003327|Drug|paclitaxel|
1722542|NCT00003328|Drug|porfiromycin|
1722543|NCT00003328|Radiation|radiation therapy|
1722544|NCT00003329|Genetic|gene mapping|
1722545|NCT00003330|Biological|recombinant interleukin-12|
1722546|NCT00003331|Drug|fluorouracil|
1722547|NCT00003331|Drug|leucovorin calcium|
1722548|NCT00003331|Drug|topotecan hydrochloride|
1722549|NCT00003332|Drug|cisplatin|
1722550|NCT00003332|Drug|gemcitabine hydrochloride|
1722551|NCT00003332|Procedure|surgical procedure|
1722552|NCT00003332|Radiation|radiation therapy|
1722553|NCT00003334|Drug|paclitaxel|
1722554|NCT00003334|Drug|pegylated liposomal doxorubicin hydrochloride|
1722555|NCT00003335|Biological|anti-thymocyte globulin|antithymocyte globulin IV for three days on days -3 to -1
1722556|NCT00003335|Drug|busulfan|If TBI is not tolerated, busulfan is substituted and administered orally every 6 hours for 4 days on days -8 to -5.
1722557|NCT00003335|Drug|cyclosporine|Cyclosporine begin on day -2 and continue for 6 months.
1722558|NCT00003335|Drug|melphalan|melphalan IV for three days on days -4 to -2
1722559|NCT00003335|Drug|methylprednisolone|Methylprednisolone IV for three days on days -3 to -1. Methylprednisolone begin on day -2 and continue for 6 months.
1722560|NCT00003335|Procedure|umbilical cord blood transplantation|On day 0, patients receive umbilical cord blood infusion.
1722561|NCT00003335|Radiation|radiation therapy|9 fractions of total body irradiation (TBI) on days -9 to -5
1722562|NCT00003336|Biological|anti-thymocyte globulin|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
1722563|NCT00003336|Drug|busulfan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
1722564|NCT00003336|Drug|cyclophosphamide|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
1722565|NCT00003336|Drug|melphalan|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
1722566|NCT00003336|Drug|methylprednisolone|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
1722567|NCT00003336|Procedure|bone marrow ablation with stem cell support|
1722568|NCT00003336|Procedure|umbilical cord blood transplantation|One day after the conditioning regimen is completed, patients receive the UCBT.
1722569|NCT00003336|Radiation|radiation therapy|The regimen varies according to the underlying cause of the anemia.Patients receive high-dose chemotherapy and/or radiotherapy as a conditioning regimen beginning 6-9 days before the umbilical cord blood transplant (UCBT).
1722570|NCT00003337|Procedure|immunoscintigraphy|
1722571|NCT00003337|Radiation|technetium Tc 99m epratuzumab|
1722572|NCT00003338|Procedure|immunoscintigraphy|
1722573|NCT00003338|Radiation|technetium Tc 99m epratuzumab|
1722574|NCT00003339|Biological|gp100 antigen|
1722575|NCT00003339|Biological|incomplete Freund's adjuvant|
1722576|NCT00003339|Biological|recombinant interleukin-12|
1722577|NCT00003339|Biological|tyrosinase peptide|
1722578|NCT00003340|Drug|cyclophosphamide|
1722579|NCT00003340|Drug|topotecan hydrochloride|
1722580|NCT00003341|Biological|epoetin alfa|
1722581|NCT00003341|Procedure|quality-of-life assessment|
1722582|NCT00003342|Biological|filgrastim|
1722583|NCT00003342|Drug|carboplatin|
1722584|NCT00003342|Drug|doxorubicin hydrochloride|
1722585|NCT00003342|Drug|gemcitabine hydrochloride|
1722586|NCT00003342|Drug|paclitaxel|
1722587|NCT00003343|Drug|endocrine-modulating drug therapy|
1722588|NCT00003343|Drug|mitoxantrone hydrochloride|
1722589|NCT00003343|Drug|prednisone|
1722590|NCT00003343|Drug|prinomastat|
1722591|NCT00003344|Drug|irinotecan hydrochloride|
1722592|NCT00003344|Radiation|radiation therapy|
1722593|NCT00003345|Drug|cisplatin|
1722594|NCT00003345|Drug|irinotecan hydrochloride|
1722595|NCT00003346|Drug|acetaminophen|
1722596|NCT00003346|Drug|acetylcysteine|
1722597|NCT00003346|Drug|carmustine|
1722598|NCT00003348|Drug|O6-benzylguanine|
1722599|NCT00003348|Drug|carmustine|
1722600|NCT00003350|Drug|paclitaxel|Given IV
1722601|NCT00003350|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
1722602|NCT00003350|Other|laboratory biomarker analysis|Correlative studies
1722603|NCT00003350|Procedure|quality-of-life assessment|Ancillary studies
1722604|NCT00003351|Drug|irinotecan hydrochloride|
1722605|NCT00003352|Drug|cyclophosphamide|600 mg/m2, IV, every 3 weeks
1722606|NCT00003352|Drug|Taxotere|60 mg/m2, IV, every 3 weeks
1722607|NCT00003352|Drug|Adriamycin|60 mg/m2, IV, every 3 weeks
1722608|NCT00003869|Drug|carboxyamidotriazole|Given PO
1722609|NCT00003869|Other|placebo|Given PO
1722610|NCT00003869|Procedure|quality-of-life assessment|Ancillary studies
1722611|NCT00003869|Other|laboratory biomarker analysis|Correlative studies
1722612|NCT00003870|Drug|cyclophosphamide|
1722613|NCT00003870|Drug|methotrexate|
1722614|NCT00003870|Procedure|allogeneic bone marrow transplantation|
1722615|NCT00003870|Radiation|iodine I 131 monoclonal antibody BC8|
1722616|NCT00003870|Radiation|radiation therapy|
1722617|NCT00003871|Biological|fowlpox virus vaccine vector|
1722618|NCT00003871|Biological|recombinant vaccinia prostate-specific antigen vaccine|
1722619|NCT00003873|Drug|fluorouracil|Given IV or orally
1722620|NCT00003873|Drug|eniluracil|Given orally
1722621|NCT00003874|Biological|monoclonal antibody CD19|
1722622|NCT00003874|Biological|monoclonal antibody CD20|
1722623|NCT00003874|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1722624|NCT00003875|Drug|busulfan|Given PO or IV
1722625|NCT00003875|Drug|etoposide|Given IV
1722626|NCT00003875|Biological|aldesleukin|Given SC
1722627|NCT00003875|Procedure|peripheral blood stem cell transplantation|Undergo autologous or syngeneic stem cell rescue
1722628|NCT00003876|Drug|polifeprosan 20 with carmustine implant|
1722629|NCT00003876|Procedure|surgical procedure|
1722630|NCT00003876|Radiation|iodine I 125|
1722631|NCT00003877|Biological|filgrastim|
1722632|NCT00003877|Drug|carboplatin|
1722633|NCT00003877|Drug|cyclophosphamide|
1722634|NCT00003877|Drug|paclitaxel|
1722635|NCT00003877|Drug|thiotepa|
1722636|NCT00003877|Procedure|in vitro-treated bone marrow transplantation|
1722637|NCT00003877|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1722638|NCT00003878|Drug|polifeprosan 20 with carmustine implant|
1722639|NCT00003878|Procedure|conventional surgery|
1722640|NCT00003880|Biological|recombinant adenovirus-p53 SCH-58500|
1722641|NCT00003880|Drug|carboplatin|
1722642|NCT00003880|Drug|paclitaxel|
1722643|NCT00003881|Biological|trastuzumab|
1722644|NCT00003881|Drug|carboplatin|
1722645|NCT00003881|Drug|paclitaxel|
1722646|NCT00003882|Drug|anhydrovinblastine|
1722647|NCT00003883|Drug|fluconazole|
1722648|NCT00003883|Drug|itraconazole|
1722649|NCT00003884|Drug|zoledronic acid|
1722650|NCT00003884|Procedure|quality-of-life assessment|
1722651|NCT00003885|Drug|arsenic trioxide|
1722652|NCT00003887|Biological|peripheral blood lymphocyte therapy|
1722653|NCT00003888|Drug|cisplatin|
1722654|NCT00003888|Drug|docetaxel|
1722655|NCT00003888|Drug|fluorouracil|
1722656|NCT00003888|Radiation|radiation therapy|
1722657|NCT00003890|Drug|MG 98|
1722658|NCT00003891|Drug|lurtotecan liposome|
1722659|NCT00003892|Drug|ISIS 5132|4mg/kg/day IV for 21 days every 4 weeks.
1722660|NCT00003893|Drug|CMF regimen|
1722661|NCT00003893|Drug|cyclophosphamide|
1722662|NCT00003893|Drug|doxorubicin hydrochloride|
1722663|NCT00003893|Drug|epirubicin hydrochloride|
1722664|NCT00003893|Drug|fluorouracil|
1722665|NCT00003893|Drug|methotrexate|
1722666|NCT00003893|Drug|mitomycin C|
1722667|NCT00003893|Drug|mitoxantrone hydrochloride|
1722668|NCT00003893|Procedure|adjuvant therapy|
1722669|NCT00003893|Radiation|radiation therapy|
1722670|NCT00003894|Drug|thalidomide|
1722671|NCT00003895|Biological|HPV 16 E7:12-20|Given SC
1722672|NCT00003895|Biological|gp100:209-217(210M)|Given SC
1722673|NCT00003895|Other|laboratory biomarker analysis|Correlative studies
1722674|NCT00003896|Drug|cisplatin|
1722675|NCT00003896|Drug|liposomal doxorubicin|
1722676|NCT00003896|Drug|paclitaxel|
1722677|NCT00003897|Biological|gp100 antigen|
1722678|NCT00003897|Biological|sargramostim|
1722679|NCT00003898|Dietary Supplement|glutamine|Oral
1722680|NCT00004138|Procedure|positron emission tomography|
1722681|NCT00004138|Procedure|radionuclide imaging|
1722682|NCT00004138|Radiation|fludeoxyglucose F 18|
1722683|NCT00004139|Drug|docetaxel|
1722684|NCT00004139|Drug|gemcitabine hydrochloride|
1722685|NCT00004139|Drug|irinotecan hydrochloride|
1722686|NCT00004141|Drug|Cisplatin|
1722687|NCT00004141|Drug|dacarbazine|
1722688|NCT00004141|Drug|Granulocyte-macrophage colony-stimulating factor|
1722689|NCT00004142|Drug|Floxuridine|Part of hepatic arterial chemotherapy on days 1-7. Treatment repeats every 5 weeks for 6 courses.
1722690|NCT00004142|Drug|Fluorouracil (5-FU)|Part of hepatic arterial chemotherapy over 1 hour on days 15, 22, and 29. Treatment repeats every 5 weeks for 6 courses.
1722691|NCT00004142|Procedure|Conventional surgery|Open laparotomy to identify target tumor in liver using intraoperative ultrasound.
1722692|NCT00004142|Procedure|Radiofrequency ablation|Radiofrequency tissue ablation over 20 minutes to each tumor.
1722693|NCT00004143|Drug|Campath, Chemo and/or TBI Allo SCT|Allogeneic PBSC/marrow will be collected/harvested from the donor after granulocyte colony-stimulating factor (G-CSF) priming. The allogeneic PBSCs will be infused as per current institutional practice.
1722694|NCT00004144|Drug|bryostatin 1|
1722695|NCT00004144|Drug|gemcitabine hydrochloride|
1722696|NCT00004145|Biological|anti-thymocyte globulin|
1722697|NCT00004145|Drug|cyclophosphamide|
1722698|NCT00004145|Drug|fludarabine phosphate|
1722699|NCT00004145|Procedure|peripheral blood stem cell transplantation|
1722700|NCT00004146|Radiation|radiation therapy|Undergo radiotherapy
1722701|NCT00004146|Drug|carboxyamidotriazole|Given orally
1722702|NCT00004146|Other|pharmacological study|Correlative studies
1722703|NCT00004147|Drug|incyclinide|
1722704|NCT00004148|Biological|recombinant vaccinia-B7.1 vaccine|
1722705|NCT00004149|Drug|arsenic trioxide|
1722706|NCT00004150|Drug|fluorouracil|
1722707|NCT00004150|Drug|leucovorin calcium|
1722708|NCT00004150|Procedure|adjuvant therapy|
1722709|NCT00004151|Drug|acridine carboxamide|
1722710|NCT00004152|Drug|iodinated contrast dye|
1722711|NCT00004152|Procedure|computed tomography|
1722712|NCT00004152|Procedure|positron emission tomography|
1722713|NCT00004152|Radiation|fludeoxyglucose F 18|
1722714|NCT00004153|Genetic|reverse transcriptase-polymerase chain reaction|
1722715|NCT00004153|Procedure|sentinel lymph node biopsy|
1722716|NCT00004154|Drug|Fenretinide|200 mg/day (two 100 mg capsules) for 25 days of 28 day cycle.
1722717|NCT00004154|Other|Placebo|Two placebo capsules for 25 days of 28 day cycle.
1722718|NCT00004156|Biological|MUC1-KLH vaccine/QS21|
1722719|NCT00004157|Biological|filgrastim|
1722720|NCT00004157|Biological|recombinant interleukin-11|
1722721|NCT00004158|Drug|melphalan|
1722722|NCT00004158|Procedure|peripheral blood stem cell transplantation|
1722723|NCT00004158|Radiation|holmium Ho 166 DOTMP|
1722724|NCT00004159|Drug|gemcitabine hydrochloride|
1722725|NCT00004159|Drug|paclitaxel|
1722726|NCT00004160|Drug|cisplatin|
1722727|NCT00004160|Drug|gemcitabine hydrochloride|
1722728|NCT00004160|Drug|paclitaxel|
1722729|NCT00004160|Radiation|radiation therapy|
1722730|NCT00004161|Drug|fenretinide|
1722731|NCT00004161|Drug|Placebo|
1722732|NCT00004162|Biological|sargramostim|
1722733|NCT00004162|Drug|methotrexate|
1722734|NCT00004162|Drug|pegylated liposomal doxorubicin hydrochloride|
1722735|NCT00004162|Drug|vincristine sulfate|
1722736|NCT00004163|Drug|Trastuzumab|
1722737|NCT00004164|Biological|filgrastim|
1722738|NCT00004164|Drug|cisplatin|
1722739|NCT00004164|Drug|docetaxel|
1722740|NCT00004164|Drug|fluorouracil|
1722741|NCT00004164|Drug|leucovorin calcium|
1722742|NCT00004164|Radiation|radiation therapy|
1722743|NCT00004165|Biological|filgrastim|
1722744|NCT00004165|Drug|melphalan|
1722745|NCT00004165|Procedure|peripheral blood stem cell transplantation|
1722746|NCT00004166|Drug|amifostine trihydrate|
1722747|NCT00004166|Procedure|quality-of-life assessment|
1722748|NCT00004169|Drug|carboplatin|
1722749|NCT00004169|Drug|cyclophosphamide|
1722750|NCT00004169|Drug|etoposide|
1722751|NCT00004169|Procedure|peripheral blood stem cell transplantation|
1722752|NCT00004169|Radiation|radiation therapy|
1722753|NCT00004171|Drug|busulfan|
1722754|NCT00004171|Drug|cyclophosphamide|
1722755|NCT00004171|Procedure|peripheral blood stem cell transplantation|
1722756|NCT00004172|Biological|filgrastim|
1722757|NCT00004172|Drug|carboplatin|
1722758|NCT00004172|Drug|cyclophosphamide|
1722759|NCT00004172|Drug|ifosfamide|
1722760|NCT00004172|Drug|thiotepa|
1722761|NCT00004172|Procedure|peripheral blood stem cell transplantation|
1722762|NCT00004172|Radiation|radiation therapy|
1722763|NCT00004173|Drug|oxaliplatin|
1722764|NCT00004173|Drug|paclitaxel|
1722765|NCT00004174|Biological|filgrastim|
1722766|NCT00004174|Drug|cyclophosphamide|
1722767|NCT00004174|Drug|paclitaxel|
1722768|NCT00004174|Drug|thiotepa|
1722769|NCT00004174|Procedure|peripheral blood stem cell transplantation|
1722770|NCT00004174|Radiation|radiation therapy|
1722771|NCT00004175|Drug|cyclophosphamide|
1722772|NCT00004175|Drug|docetaxel|
1722773|NCT00004175|Drug|doxorubicin hydrochloride|
1722774|NCT00004175|Procedure|conventional surgery|
1722775|NCT00004176|Drug|amifostine trihydrate|
1722776|NCT00004176|Drug|cisplatin|
1722777|NCT00004176|Drug|etoposide|
1722778|NCT00004176|Radiation|radiation therapy|
1722779|NCT00004177|Biological|filgrastim|as prescribed by physician
1722780|NCT00004177|Procedure|peripheral blood stem cell transplantation|1-2 weeks from treatment
1722781|NCT00004177|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
1722782|NCT00004177|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
1722783|NCT00004178|Biological|therapeutic autologous lymphocytes|
1722784|NCT00004179|Biological|rituximab|
1722785|NCT00004179|Drug|CHOP regimen|
1722786|NCT00004179|Drug|cyclophosphamide|
1722787|NCT00004179|Drug|doxorubicin hydrochloride|
1722788|NCT00004179|Drug|prednisone|
1722789|NCT00004179|Drug|vincristine sulfate|
1722790|NCT00004180|Drug|rosiglitazone maleate|
1722791|NCT00004181|Drug|busulfan|
1722792|NCT00004181|Drug|cyclophosphamide|
1722793|NCT00004181|Procedure|allogeneic bone marrow transplantation|
1722794|NCT00004181|Radiation|radiation therapy|
1722795|NCT00004182|Drug|irinotecan hydrochloride|
1722796|NCT00004183|Drug|capecitabine|
1722797|NCT00004184|Biological|monoclonal antibody 4B5 anti-idiotype vaccine|
1722798|NCT00004184|Biological|sargramostim|
1722799|NCT00004184|Drug|alum adjuvant|
1722800|NCT00004186|Drug|carboplatin|
1722801|NCT00004186|Drug|etoposide|
1722803|NCT00004186|Drug|topotecan hydrochloride|
1722804|NCT00004186|Radiation|radiation therapy|
1722805|NCT00004187|Drug|capecitabine|
1722806|NCT00004187|Drug|oxaliplatin|
1722807|NCT00004188|Biological|filgrastim|Given IV
1722808|NCT00004188|Drug|carboplatin|Given IV
1722809|NCT00004188|Drug|cisplatin|Given IV
1722810|NCT00004188|Drug|cyclophosphamide|Given IV
1722811|NCT00004188|Drug|doxorubicin hydrochloride|Given IV
1722812|NCT00004188|Drug|etoposide|Given IV
1722813|NCT00004188|Drug|isotretinoin|Given IV
1722814|NCT00004188|Drug|melphalan|Given IV
1722815|NCT00004188|Drug|topotecan hydrochloride|Given IV
1722816|NCT00004188|Drug|vincristine sulfate|Given IV
1722817|NCT00004188|Procedure|autologous bone marrow transplantation|
1722818|NCT00004188|Procedure|bone marrow ablation with stem cell support|
1722819|NCT00004188|Procedure|conventional surgery|All patients undergo delayed surgical resection of the residual tumor after course 5 of induction chemotherapy
1722820|NCT00004188|Procedure|peripheral blood stem cell transplantation|
1722821|NCT00004188|Radiation|radiation therapy|After completion of consolidation (at least 28 days from stem cell infusion), all patients receive local radiotherapy daily over 7 days
1722822|NCT00004189|Biological|filgrastim|
1722823|NCT00004189|Drug|becatecarin|
1722824|NCT00004189|Drug|cisplatin|
1722825|NCT00004190|Drug|gemcitabine hydrochloride|
1722826|NCT00004190|Drug|oxaliplatin|
1722827|NCT00004192|Biological|filgrastim|
1722828|NCT00004192|Biological|pegfilgrastim|
1722829|NCT00004192|Drug|cisplatin|
1722830|NCT00004192|Drug|cytarabine|
1722831|NCT00004192|Drug|etoposide|
1722832|NCT00004192|Drug|methylprednisolone|
1722833|NCT00004193|Drug|ISIS 2503|
1722834|NCT00004194|Drug|fludarabine phosphate|
1722835|NCT00004195|Drug|eniluracil|Will be given to either subject pre-operative and metastatic disease
1722836|NCT00004195|Procedure|conventional colon surgery|Only if the subject is amenable to surgical resections
1722837|NCT00004196|Biological|recombinant interferon alfa|
1722838|NCT00004196|Procedure|lymphangiography|
1722839|NCT00004196|Drug|Observation|
1722840|NCT00004197|Biological|keyhole limpet hemocyanin|
1722841|NCT00004197|Biological|sargramostim|
1722842|NCT00004197|Biological|tumor cell-based vaccine therapy|
1722843|NCT00004197|Drug|cyclophosphamide|
1722844|NCT00004197|Drug|doxorubicin hydrochloride|
1722845|NCT00004197|Drug|mitoxantrone hydrochloride|
1722846|NCT00004197|Drug|prednisone|
1722847|NCT00004197|Drug|vincristine sulfate|
1722848|NCT00004198|Biological|keyhole limpet hemocyanin|
1722849|NCT00004198|Biological|sargramostim|
1722850|NCT00004198|Biological|tumor cell-based vaccine therapy|
1722851|NCT00004199|Drug|cisplatin|
1722852|NCT00004199|Drug|gemcitabine hydrochloride|
1722853|NCT00004199|Drug|prinomastat|
1722854|NCT00004200|Drug|prinomastat|
1722855|NCT00004200|Drug|temozolomide|
1722856|NCT00004201|Drug|carboplatin|
1722857|NCT00004201|Drug|cisplatin|
1722858|NCT00004201|Drug|gemcitabine hydrochloride|
1722859|NCT00004202|Drug|carboplatin|
1722860|NCT00004202|Drug|chemotherapy|
1722861|NCT00004202|Drug|efaproxiral|
1722862|NCT00004202|Drug|paclitaxel|
1722863|NCT00004202|Radiation|radiation therapy|
1722864|NCT00004203|Drug|oxaliplatin|
1722865|NCT00004204|Drug|temozolomide|
1722866|NCT00004205|Drug|letrozole|Letrozole 2.5 mg daily oral administration.
1722867|NCT00004205|Drug|tamoxifen citrate|Tamoxifen 20 mg daily oral administration.
1722868|NCT00004206|Drug|FOLFOX regimen|
1722869|NCT00004206|Drug|fluorouracil|
1722870|NCT00004206|Drug|leucovorin calcium|
1722871|NCT00004206|Drug|oxaliplatin|
1722872|NCT00004207|Drug|liposomal daunorubicin citrate|
1722873|NCT00004208|Drug|ATG + CSA|Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
1722874|NCT00004208|Behavioral|Supportive care|Patients randomized to this arm will be treated as outpatients.
1722875|NCT00004209|Drug|cisplatin|
1722876|NCT00004209|Drug|mitomycin C|
1722877|NCT00004209|Drug|vinblastine sulfate|
1722878|NCT00004210|Other|loss of heterozygosity analysis|
1722879|NCT00004210|Other|microsatellite instability analysis|
1722880|NCT00004210|Other|mutation analysis|
1722881|NCT00004210|Other|counseling intervention|
1722882|NCT00004211|Biological|PSA RNA-pulsed dendritic cell vaccine|
1722883|NCT00004212|Biological|filgrastim|
1722884|NCT00004212|Drug|exatecan mesylate|
1722885|NCT00004213|Drug|triapine|
1722886|NCT00004215|Biological|filgrastim|
1722887|NCT00004215|Biological|leridistim|
1722888|NCT00004215|Drug|cytarabine|
1722889|NCT00004215|Drug|daunorubicin hydrochloride|
1722890|NCT00004216|Biological|salmonella VNP20009|
1722891|NCT00004216|Drug|cefixime|
1722892|NCT00004216|Drug|ceftriaxone sodium|
1722893|NCT00004216|Drug|ciprofloxacin|
1722894|NCT00004216|Drug|trimethoprim-sulfamethoxazole|
1722895|NCT00004217|Biological|filgrastim|5 μg/kg/day IV or SC
1722896|NCT00004217|Biological|sargramostim|5 μg/kg/day IV or SC starting d 15
1722897|NCT00004217|Drug|cytarabine|Ara-C continuous IV: Hours 2.5 - 170.5 before PSC-833
1722898|NCT00004217|Drug|daunorubicin hydrochloride|continuous IV: Hours 2 - 74 before PSC-833
1722899|NCT00004217|Drug|valspodar|2 mg/kg load IV over 2 hrs (loading); 10 mg/kg/day Continuous hours 0 - 96
1722900|NCT00004218|Drug|chlorambucil|
1722901|NCT00004218|Drug|cyclophosphamide|
1722902|NCT00004218|Drug|doxorubicin hydrochloride|
1722903|NCT00004218|Drug|fludarabine phosphate|
1722905|NCT00004218|Drug|vincristine sulfate|
1722906|NCT00004219|Drug|granisetron hydrochloride|
1722907|NCT00004219|Drug|lerisetron|
1722908|NCT00004219|Radiation|radiation therapy|
1722909|NCT00004220|Drug|gemcitabine hydrochloride|
1722910|NCT00004220|Drug|oxaliplatin|
1722911|NCT00004221|Drug|Carboplatin|Given IV
1722912|NCT00004221|Drug|Cyclophosphamide|Given IV
1722913|NCT00004221|Biological|Filgrastim|Given SQ
1722914|NCT00004221|Drug|Paclitaxel|Given IV
1722915|NCT00004221|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplantation
1722916|NCT00004221|Drug|Topotecan Hydrochloride|Given IV
1722917|NCT00004223|Drug|docetaxel|
1722918|NCT00004223|Drug|gemcitabine hydrochloride|
1722919|NCT00004224|Drug|cyclophosphamide|
1722920|NCT00004224|Drug|etoposide|
1722921|NCT00004224|Drug|vincristine sulfate|
1722922|NCT00004224|Procedure|adjuvant therapy|
1722923|NCT00004224|Procedure|conventional surgery|
1722924|NCT00004224|Radiation|radiation therapy|
1722925|NCT00004225|Biological|Ad5CMV-p53 gene|
1722926|NCT00004225|Radiation|radiation therapy|
1722927|NCT00004226|Radiation|radiation therapy|
1722928|NCT00004227|Biological|cetuximab|
1722929|NCT00004227|Procedure|conventional surgery|
1722930|NCT00004227|Radiation|radiation therapy|
1722931|NCT00004228|Drug|asparaginase|Given IV
1722932|NCT00004228|Drug|cyclophosphamide|Given IV
1722933|NCT00004228|Drug|cytarabine|Given IV
1722934|NCT00004228|Drug|daunorubicin hydrochloride|Given IV
1722935|NCT00004228|Drug|dexamethasone|Given IV
1722936|NCT00004228|Drug|doxorubicin hydrochloride|Given IV
1722937|NCT00004228|Drug|leucovorin calcium|Given IV
1722938|NCT00004228|Drug|mercaptopurine|Given IV
1722939|NCT00004228|Drug|methotrexate|Given IV
1722940|NCT00004228|Drug|prednisone|Given IV
1722941|NCT00004228|Drug|thioguanine|Given PO
1722942|NCT00004228|Drug|vincristine sulfate|Given IV
1722943|NCT00004228|Radiation|radiation therapy|
1722944|NCT00004229|Biological|recombinant human endostatin|
1722945|NCT00004230|Drug|captopril|
1722946|NCT00004230|Drug|cyclophosphamide|
1722947|NCT00004230|Procedure|autologous bone marrow transplantation|
1722948|NCT00004230|Procedure|peripheral blood stem cell transplantation|
1722949|NCT00004230|Radiation|radiation therapy|
1722950|NCT00004231|Biological|aldesleukin|
1722951|NCT00004231|Biological|filgrastim|
1722952|NCT00004231|Biological|recombinant interferon alfa|
1722953|NCT00004231|Drug|busulfan|
1722954|NCT00004231|Drug|cyclophosphamide|
1722955|NCT00004231|Drug|cytarabine|
1722956|NCT00004231|Drug|doxorubicin hydrochloride|
1722957|NCT00004231|Drug|leucovorin calcium|
1722958|NCT00004231|Drug|methotrexate|
1722959|NCT00004231|Drug|prednisone|
1722960|NCT00004231|Drug|teniposide|
1722961|NCT00004231|Drug|vincristine sulfate|
1722962|NCT00004231|Procedure|allogeneic bone marrow transplantation|
1722963|NCT00004231|Procedure|autologous bone marrow transplantation|
1722964|NCT00004231|Procedure|peripheral blood stem cell transplantation|
1722965|NCT00004232|Biological|filgrastim|
1722966|NCT00004232|Drug|cyclosporine|
1722967|NCT00004232|Drug|methylprednisolone|
1722968|NCT00004232|Drug|prednisone|
1722969|NCT00004232|Procedure|allogeneic bone marrow transplantation|
1722970|NCT00004232|Procedure|peripheral blood stem cell transplantation|
1722971|NCT00004233|Drug|fluorouracil|
1722972|NCT00004233|Drug|leucovorin calcium|
1722973|NCT00004233|Drug|triacetyluridine|
1722974|NCT00004234|Procedure|management of therapy complications|
1722975|NCT00004234|Radiation|radiation therapy|
1722976|NCT00004235|Drug|docetaxel|
1722977|NCT00004235|Drug|irinotecan hydrochloride|
1722978|NCT00004236|Drug|pegylated liposomal doxorubicin hydrochloride|
1722979|NCT00004237|Drug|cyclophosphamide|
1722980|NCT00004237|Drug|doxorubicin hydrochloride|
1722981|NCT00004237|Drug|epirubicin hydrochloride|
1722982|NCT00004237|Drug|mitoxantrone hydrochloride|
1722983|NCT00004237|Drug|vinorelbine tartrate|
1722984|NCT00004237|Procedure|conventional surgery|
1722985|NCT00004237|Radiation|radiation therapy|
1722986|NCT00004238|Drug|pralatrexate|
1722987|NCT00004239|Drug|Compound 506U78|
1722988|NCT00004241|Drug|tanespimycin|Given IV
1722989|NCT00004241|Other|pharmacological study|Correlative studies
1722990|NCT00004242|Drug|fluorouracil|
1722991|NCT00004242|Drug|gemcitabine hydrochloride|
1722992|NCT00004242|Drug|oxaliplatin|
1722993|NCT00004243|Drug|docetaxel|
1722994|NCT00004243|Drug|oxaliplatin|
1722995|NCT00004244|Biological|recombinant interferon alfa|
1722996|NCT00004244|Biological|recombinant interleukin-12|
1722997|NCT00004245|Drug|sodium salicylate|
1722998|NCT00004246|Drug|Fludarabine Phosphate|IV on days 1-5 of weeks 6 and 7 of radiotherapy, administered 3-4 hours prior to daily radiotherapy.
1722999|NCT00004246|Radiation|Radiation Therapy (RT)|Days 1-5 for 7 weeks
1723000|NCT00004248|Biological|aldesleukin|
1723001|NCT00004248|Drug|doxorubicin hydrochloride|
1723002|NCT00004249|Biological|QS21|
1723003|NCT00004249|Biological|keyhole limpet hemocyanin|
1723004|NCT00004249|Drug|polysialic acid|
1723005|NCT00004250|Biological|dactinomycin|
1723006|NCT00004250|Drug|isolated limb perfusion|
1723007|NCT00004250|Drug|melphalan|
1723008|NCT00004251|Drug|letrozole|2.5 mg of letrozole per day
1723009|NCT00004252|Drug|fluorouracil|
1723010|NCT00004252|Drug|leucovorin calcium|
1723014|NCT00004253|Radiation|radiation therapy|
1723015|NCT00004254|Drug|raltitrexed|
1723016|NCT00004255|Biological|anti-thymocyte globulin|
1723017|NCT00004255|Biological|filgrastim|
1723018|NCT00004255|Drug|cyclophosphamide|
1723019|NCT00004255|Drug|fludarabine phosphate|
1723020|NCT00004255|Drug|methylprednisolone|
1723021|NCT00004255|Drug|tacrolimus|
1723022|NCT00004255|Procedure|allogeneic bone marrow transplantation|
1723023|NCT00004255|Procedure|in vitro-treated bone marrow transplantation|
1723024|NCT00004255|Radiation|radiation therapy|
1723025|NCT00004256|Biological|sargramostim|
1723026|NCT00004256|Procedure|quality-of-life assessment|
1723027|NCT00004256|Radiation|radiation therapy|
1723028|NCT00004257|Drug|fluorouracil|
1723029|NCT00004257|Drug|oxaliplatin|
1723030|NCT00004257|Procedure|conventional surgery|
1723031|NCT00004257|Radiation|radiation therapy|
1723032|NCT00004258|Drug|cilengitide|dose escalation of cilengitide
1723036|NCT00004260|Biological|recombinant interleukin-12|
1723037|NCT00004260|Biological|rituximab|
1723038|NCT00004261|Drug|EF5|
1723039|NCT00004261|Other|flow cytometry|
1723040|NCT00004261|Other|fluorescent antibody technique|
1723041|NCT00004261|Other|immunohistochemistry staining method|
1723042|NCT00004261|Procedure|biopsy|
1723043|NCT00004262|Procedure|conventional surgery|
1723044|NCT00004262|Radiation|3-dimensional conformal radiation therapy|
1723045|NCT00004262|Radiation|stereotactic radiosurgery|
1723046|NCT00004262|Drug|motexafin gadolinium|Given IV
1723047|NCT00004262|Procedure|magnetic resonance imaging|Undergo MRI with both the clinical 1.5 Tesla and research 8 Tesla magnets
1723048|NCT00004262|Procedure|spectroscopy|Undergo plasma-atomic emission spectroscopy (DCP-AES)
1723049|NCT00004263|Drug|7-hydroxystaurosporine (UCN-01)|20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.
1723050|NCT00004263|Drug|Cytarabine (Ara-C)|Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
1723051|NCT00004264|Drug|amifostine trihydrate|
1723052|NCT00004264|Drug|cisplatin|
1723053|NCT00004264|Drug|docetaxel|
1723054|NCT00004265|Drug|paclitaxel|
1723055|NCT00004266|Drug|Lisinopril|
1723056|NCT00004266|Drug|nifedipine|
1723057|NCT00004266|Drug|simvastatin|
1723058|NCT00004268|Drug|midodrine|
1723059|NCT00004274|Drug|Estrogen|
1723060|NCT00004275|Drug|growth hormone|
1723061|NCT00004275|Drug|oxandrolone|
1723062|NCT00004276|Drug|thalidomide|
1723063|NCT00004278|Drug|ganciclovir|
1723064|NCT00004284|Drug|potassium citrate|
1723065|NCT00004284|Drug|potassium phosphate|
1723066|NCT00004285|Device|Standard dose, low flux hemodialysis|
1723067|NCT00004285|Device|Standard dose, high flux hemodialysis|
1723068|NCT00004285|Device|High dose, low flux hemodialysis|
1723069|NCT00004285|Device|High dose, high flux hemodialysis|
1723070|NCT00004286|Drug|immune globulin|
1723071|NCT00004287|Genetic|H5.001CBCFTR|
1723072|NCT00004288|Drug|olsalazine|
1723073|NCT00004293|Drug|glucocerebrosidase|
1723074|NCT00004294|Genetic|human glucocerebrosidase gene into autologous peripheral blood stem cells|
1723075|NCT00004297|Drug|diazepam|
1723076|NCT00004297|Drug|lorazepam|
1723077|NCT00004300|Drug|bromocriptine|
1723078|NCT00004300|Drug|sertraline hydrochloride|
1723079|NCT00004307|Behavioral|Protein and calorie controlled diet|
1723080|NCT00004307|Genetic|Ornithine transcarbamylase vector|
1723081|NCT00004310|Drug|Clomipramine|
1723082|NCT00004311|Drug|leuprolide acetate|
1723083|NCT00004311|Drug|spironolactone|
1723084|NCT00004313|Drug|dehydroepiandrosterone|
1723085|NCT00004314|Drug|aminomidazole carboxamide riboside|
1723086|NCT00004315|Drug|ursodiol|
1723087|NCT00004316|Drug|capsaicin|
1723088|NCT00004317|Drug|Leucovorin calcium|See arm descriptions
1723089|NCT00004317|Drug|Pyrimethamine|See arm descriptions
1723090|NCT00004317|Drug|Spiramycin|Spiramycin is administered before the fetal diagnosis is made.
1723091|NCT00004317|Drug|Sulfadiazine|See arm descriptions
1723092|NCT00004323|Drug|anti-thymocyte globulin|
1723093|NCT00004323|Drug|cyclophosphamide|
1723094|NCT00004323|Drug|cyclosporine|
1723095|NCT00004323|Drug|mesna|
1723096|NCT00004323|Drug|methotrexate|
1723097|NCT00004323|Drug|methylprednisolone|
1723098|NCT00004327|Drug|octreotide|
1723099|NCT00004328|Drug|enalapril|
1723100|NCT00004328|Drug|polystyrene sulfonate|
1723101|NCT00004330|Drug|luteinizing hormone-releasing factor|
1723102|NCT00004333|Drug|NTBC|
1723103|NCT00004338|Drug|zinc acetate|
1723104|NCT00004339|Drug|tetrathiomolybdate|
1723105|NCT00004339|Drug|trientine|
1723106|NCT00004340|Drug|calcitriol|
1723107|NCT00004340|Drug|growth hormone|
1723108|NCT00004344|Drug|leuprolide|
1723109|NCT00004344|Drug|testosterone|
1723110|NCT00004346|Drug|chenodeoxycholic acid|
1723111|NCT00004346|Drug|lovastatin|
1723112|NCT00004347|Behavioral|diet|
1723113|NCT00004357|Drug|Methylprednisolone|IV
1723114|NCT00004357|Drug|Prednisolone|Oral
1723115|NCT00004358|Drug|calcitonin|
1723116|NCT00004359|Drug|methoxsalen|
1723117|NCT00004360|Drug|chlorothiazide|
1723118|NCT00004361|Drug|calcium gluconate|
1723123|NCT00004366|Procedure|Physical therapy|
1723124|NCT00004367|Procedure|Clinical vestibular tests|
1723125|NCT00004368|Drug|colchicine|
1723126|NCT00004373|Drug|alprazolam|
1723127|NCT00004375|Procedure|ultraviolet A-1 light treatment|
1723128|NCT00004376|Drug|guanfacine|
1723129|NCT00004378|Procedure|Stem Cell Transplantation|
1723130|NCT00003598|Drug|tretinoin|
1723131|NCT00003599|Dietary Supplement|Vitamin E (AT)|Orally daily
1723132|NCT00003599|Drug|Isotretinoin|Orally daily
1723133|NCT00003600|Biological|epoetin alfa|
1723134|NCT00003600|Other|placebo|
1723135|NCT00003601|Drug|fenretinide|
1723136|NCT00003601|Drug|tretinoin|
1723137|NCT00003602|Drug|cytarabine|
1723138|NCT00003602|Drug|etoposide|
1723139|NCT00003602|Drug|idarubicin|
1723140|NCT00003602|Drug|mitoxantrone hydrochloride|
1723141|NCT00003603|Drug|cyclophosphamide|
1723142|NCT00003603|Drug|dexamethasone|
1723143|NCT00003603|Drug|idarubicin|
1723144|NCT00003603|Drug|lomustine|
1723145|NCT00003603|Drug|melphalan|
1723146|NCT00003603|Drug|prednisolone|
1723147|NCT00003604|Biological|aldesleukin|
1723148|NCT00003605|Biological|rituximab|
1723149|NCT00003605|Drug|cyclophosphamide|
1723150|NCT00003606|Drug|cisplatin|
1723151|NCT00003606|Drug|cyclophosphamide|
1723152|NCT00003606|Drug|epirubicin hydrochloride|
1723153|NCT00003606|Drug|etoposide|
1723154|NCT00003606|Radiation|radiation therapy|
1723155|NCT00003607|Radiation|radiation therapy|
1723156|NCT00003610|Dietary Supplement|capsaicin|
1723157|NCT00003610|Other|placebo|
1723158|NCT00003610|Radiation|radiation therapy|
1723159|NCT00003611|Drug|acitretin|
1723160|NCT00003611|Other|placebo|
1723161|NCT00003612|Biological|trastuzumab|
1723162|NCT00003612|Drug|carboplatin|
1723163|NCT00003612|Drug|paclitaxel|
1723164|NCT00003613|Drug|O6-benzylguanine|Given IV
1723165|NCT00003613|Drug|carmustine|Given topically
1723166|NCT00003613|Other|laboratory biomarker analysis|Correlative studies
1723167|NCT00003614|Drug|estramustine phosphate sodium|
1723168|NCT00003614|Drug|paclitaxel|
1723169|NCT00003615|Biological|denileukin diftitox|
1723170|NCT00003616|Drug|irinotecan hydrochloride|
1723171|NCT00003617|Drug|chlorambucil|
1723172|NCT00003617|Drug|clarithromycin|
1723173|NCT00003617|Drug|omeprazole|
1723174|NCT00003617|Drug|tinidazole|
1723175|NCT00003619|Biological|filgrastim|
1723176|NCT00003619|Dietary Supplement|vitamin E|
1723177|NCT00003619|Drug|busulfan|
1723178|NCT00003619|Drug|cytarabine|
1723179|NCT00003619|Drug|etoposide|
1723180|NCT00003619|Drug|fludarabine phosphate|
1723181|NCT00003619|Drug|isotretinoin|
1723182|NCT00003619|Drug|topotecan hydrochloride|
1723183|NCT00003619|Procedure|bone marrow ablation with stem cell support|
1723184|NCT00003619|Procedure|peripheral blood stem cell transplantation|
1723185|NCT00003620|Drug|alvocidib|Given IV
1723186|NCT00003620|Other|laboratory biomarker analysis|Correlative studies
1723187|NCT00003621|Drug|carmustine|
1723188|NCT00003621|Drug|cisplatin|
1723189|NCT00003621|Drug|etoposide|
1723190|NCT00003621|Radiation|radiation therapy|
1723191|NCT00003622|Drug|paclitaxel|
1723192|NCT00003622|Drug|vinorelbine tartrate|
1723193|NCT00003623|Dietary Supplement|multivitamin|
1723194|NCT00003623|Other|Placebo|
1723195|NCT00003624|Drug|amifostine trihydrate|
1723196|NCT00003624|Drug|cisplatin|
1723197|NCT00003624|Drug|paclitaxel|
1723198|NCT00003625|Drug|cyclosporine|
1723199|NCT00003625|Drug|etoposide|
1723200|NCT00003625|Drug|vincristine sulfate|
1723201|NCT00003625|Radiation|radiation therapy|
1723202|NCT00003626|Drug|dolastatin 10|
1723203|NCT00003627|Drug|cisplatin|
1723204|NCT00003627|Drug|fluorouracil|
1723205|NCT00003627|Radiation|radiation therapy|
1723206|NCT00003630|Drug|arsenic trioxide|
1723207|NCT00003631|Biological|filgrastim|
1723208|NCT00003631|Drug|carboplatin|
1723209|NCT00003631|Drug|carmustine|
1723210|NCT00003631|Drug|cyclophosphamide|
1723211|NCT00003631|Drug|cytarabine|
1723212|NCT00003631|Drug|etoposide|
1723213|NCT00003631|Drug|ifosfamide|
1723214|NCT00003631|Drug|melphalan|
1723215|NCT00003631|Procedure|bone marrow ablation with stem cell support|
1723216|NCT00003631|Procedure|peripheral blood stem cell transplantation|
1723217|NCT00003631|Radiation|radiation therapy|
1723218|NCT00003632|Biological|filgrastim|
1723219|NCT00003632|Drug|carmustine|
1723220|NCT00003632|Drug|cytarabine|
1723221|NCT00003632|Drug|etoposide|
1723222|NCT00003632|Drug|melphalan|
1723223|NCT00003632|Drug|methotrexate|
1723224|NCT00003632|Procedure|peripheral blood stem cell transplantation|
1723225|NCT00003633|Drug|docetaxel|
1723226|NCT00003633|Drug|estramustine phosphate sodium|
1723227|NCT00003633|Drug|mitoxantrone hydrochloride|
1723228|NCT00003633|Drug|prednisone|
1723229|NCT00003634|Biological|oregovomab|
1723230|NCT00003635|Drug|nelarabine|
1723231|NCT00003636|Drug|carboplatin|
1723232|NCT00003636|Drug|cisplatin|
1723233|NCT00003636|Procedure|conventional surgery|
1723234|NCT00003636|Procedure|neoadjuvant therapy|
1723235|NCT00003637|Drug|cisplatin|
1723236|NCT00003637|Drug|fluorouracil|
1723237|NCT00003637|Radiation|radiation therapy|
1723238|NCT00003638|Biological|Detox-B adjuvant|
1723239|NCT00003638|Biological|THERATOPE STn-KLH vaccine|
1723240|NCT00003638|Biological|keyhole limpet hemocyanin|
1723241|NCT00003638|Drug|cyclophosphamide|
1723242|NCT00003639|Biological|recombinant interferon alfa|
1723243|NCT00003639|Drug|chlorambucil|
1723244|NCT00003639|Drug|dexamethasone|
1723245|NCT00003639|Drug|idarubicin|
1723246|NCT00003640|Biological|filgrastim|
1723247|NCT00003640|Drug|cisplatin|
1723248|NCT00003640|Drug|doxorubicin hydrochloride|
1723249|NCT00003640|Drug|methotrexate|
1723250|NCT00003640|Drug|vinblastine sulfate|
1723251|NCT00003640|Procedure|surgical procedure|
1723252|NCT00003640|Radiation|radiation therapy|
1723253|NCT00003641|Biological|interferon alfa-2b|Given IV
1723254|NCT00003641|Other|observation|Patients undergo observation for 4 weeks.
1723255|NCT00003642|Drug|cisplatin|
1723256|NCT00003642|Drug|fluorouracil|
1723257|NCT00003642|Radiation|radiation therapy|
1723258|NCT00003643|Biological|bleomycin sulfate|
1723259|NCT00003643|Biological|filgrastim|
1723260|NCT00003643|Drug|cisplatin|
1723261|NCT00003643|Drug|etoposide|
1723262|NCT00003643|Drug|paclitaxel|
1723263|NCT00003644|Drug|carboplatin|
1723264|NCT00003644|Drug|paclitaxel|
1723265|NCT00003645|Drug|Flutamide|10.8 mg intramuscularly once every 3 months for 12 months
1723266|NCT00003645|Drug|Leuprolide Acetate|50 mg tablet orally daily for 12 months
1723267|NCT00003646|Drug|allovectin-7|
1723268|NCT00003647|Drug|allovectin-7|
1723269|NCT00003647|Drug|allovectin-7/dacarbazine|
1723270|NCT00003647|Drug|dacarbazine|
1723271|NCT00003648|Genetic|DNA stability analysis|
1723272|NCT00003648|Genetic|gene rearrangement analysis|
1723273|NCT00003649|Biological|Ad5CMV-p53 gene|
1723274|NCT00004380|Drug|relaxin|
1723275|NCT00004381|Drug|tin mesoporphyrin|
1723276|NCT00004382|Drug|tin mesoporphyrin|
1723277|NCT00004382|Procedure|Phototherapy|
1723278|NCT00004386|Genetic|recombinant adenovirus containing the ornithine transcarbamylase gene|
1723279|NCT00004387|Procedure|fetal nigral transplantation|
1723280|NCT00004390|Drug|desipramine|
1723281|NCT00004390|Drug|methadone|
1723282|NCT00004390|Drug|morphine|
1723283|NCT00004390|Drug|nortriptyline|
1723284|NCT00004393|Drug|risperidone|
1723285|NCT00004396|Drug|heme arginate|
1723286|NCT00004396|Drug|tin mesoporphyrin|
1723287|NCT00004397|Drug|heme arginate|
1723288|NCT00004397|Drug|tin mesoporphyrin|
1723289|NCT00004398|Drug|heme arginate|
1723290|NCT00004398|Drug|tin mesoporphyrin|
1723291|NCT00004399|Drug|magnesium sulfate|
1723292|NCT00004399|Drug|nimodipine|
1723293|NCT00004400|Drug|testosterone|
1723294|NCT00004401|Drug|botulism immune globulin|
1723295|NCT00004402|Drug|calcitriol|
1723296|NCT00004402|Drug|interferon gamma|
1723297|NCT00004403|Drug|albendazole|
1723298|NCT00004403|Drug|dexamethasone|
1723299|NCT00004403|Drug|phenytoin|
1723300|NCT00004404|Drug|clotrimazole|
1723301|NCT00004404|Drug|hydroxyurea|
1723302|NCT00004406|Drug|human parathyroid hormone|
1723303|NCT00004407|Drug|immune globulin|
1723304|NCT00004408|Drug|poloxamer 188|
1723305|NCT00004409|Drug|collagenase|
1723306|NCT00004410|Drug|tauroursodeoxycholic acid|
1723307|NCT00004412|Drug|Arginine Butyrate|To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
1723308|NCT00004412|Other|Standard local care dressing|To heal leg ulcers.
1723309|NCT00004414|Drug|sincalide|
1723310|NCT00004415|Device|Medlink spinal cord electrode|
1723311|NCT00004416|Drug|botulinum toxin type A|
1723312|NCT00004736|Drug|Nelfinavir mesylate|
1723313|NCT00004736|Drug|Ethambutol hydrochloride|
1723314|NCT00004736|Drug|Isoniazid|
1723315|NCT00004736|Drug|Pyrazinamide|
1723316|NCT00004736|Drug|Lamivudine|
1723317|NCT00004736|Drug|Rifabutin|
1723318|NCT00004736|Drug|Stavudine|
1723319|NCT00004736|Drug|Zidovudine|
1723320|NCT00004739|Drug|Antiretroviral therapy|
1723321|NCT00004740|Drug|isoniazid|
1723322|NCT00004744|Drug|immune globulin|
1723323|NCT00004747|Drug|mucoid exopolysaccharide P. aeruginosa immune globulin IV|
1723324|NCT00004748|Drug|colchicine|
1723325|NCT00004748|Drug|methotrexate|
1723326|NCT00004748|Drug|ursodiol|
1723327|NCT00004751|Procedure|Surgery|
1723328|NCT00004751|Procedure|Physical therapy|
1723329|NCT00004754|Drug|epoprostenol|
1723330|NCT00004755|Drug|allopurinol|
1723331|NCT00004755|Drug|glucantime|
1723332|NCT00004756|Procedure|Tailored educational program|
1723333|NCT00004756|Procedure|Educational materials|
1723334|NCT00004757|Drug|acyclovir|
1723335|NCT00004758|Drug|carbamazepine|
1723336|NCT00004758|Drug|corticotropin|
1723337|NCT00004758|Drug|nitrazepam|
1723338|NCT00004758|Drug|pyridoxine|
1723339|NCT00004758|Drug|valproic acid|
1723340|NCT00004758|Procedure|Surgery|
1723341|NCT00004759|Drug|methylprednisolone|
1723342|NCT00004759|Drug|tirilazad|
1723343|NCT00004760|Behavioral|Exercise|
1723344|NCT00004762|Drug|cladribine|
1723345|NCT00004763|Drug|leuprolide|
1723346|NCT00004763|Drug|Ethinyl estradiol/norethindrone|
1723347|NCT00004767|Drug|Sodium Benzoate|
1723348|NCT00004767|Drug|Sodium Phenylacetate|
1723349|NCT00004767|Drug|Sodium Phenylbutyrate|
1723350|NCT00004767|Behavioral|Dietary Intervention|
1723351|NCT00004770|Drug|thioctic acid|
1723352|NCT00004771|Drug|leuprolide|
1723358|NCT00004778|Drug|thyrotropin-releasing hormone|
1723359|NCT00004779|Genetic|Ad5-CB-CFTR|
1723360|NCT00004784|Drug|methotrexate|
1723361|NCT00004784|Drug|ursodiol|
1723362|NCT00004785|Drug|dexamethasone|
1723363|NCT00004785|Drug|methylprednisolone|
1723364|NCT00004786|Drug|iloprost|
1723365|NCT00004787|Drug|filgrastim|
1723366|NCT00004789|Drug|heme arginate|
1723367|NCT00004789|Drug|tin mesoporphyrin|
1723368|NCT00004794|Drug|cidofovir|
1723369|NCT00004795|Drug|dehydroepiandrosterone|
1723370|NCT00004796|Drug|lactulose|
1723371|NCT00004797|Drug|fructose|
1723372|NCT00004797|Drug|placebo|
1723373|NCT00004799|Biological|whole-cell pertussis vaccine|
1723374|NCT00004799|Biological|diphtheria-tetanus vaccine|
1723375|NCT00004800|Biological|diphtheria-tetanus-pertussis vaccine containing whole-cell pertussis|
1723376|NCT00004800|Biological|diphtheria-tetanus vaccine|
1723377|NCT00004801|Drug|monoclonal factor IX replacement therapy|
1723378|NCT00004802|Drug|dichlorphenamide|
1723379|NCT00004804|Drug|interferon alfa|
1723380|NCT00004805|Behavioral|CPR instruction|
1723381|NCT00004806|Genetic|Cystic fibrosis transmembrane conductance regulator|
1723382|NCT00004807|Drug|dextromethorphan|
1723383|NCT00004807|Drug|topiramate|
1723384|NCT00004807|Drug|Donepezil|
1723385|NCT00004808|Drug|fluconazole|
1723386|NCT00004809|Procedure|gene therapy|
1723387|NCT00004810|Drug|-aminosalicylic acid|
1723388|NCT00004811|Drug|itraconazole|
1723389|NCT00004812|Behavioral|Exercise|
1723390|NCT00004814|Drug|copolymer 1|
1723391|NCT00004815|Drug|growth hormone|
1723392|NCT00004816|Drug|monoclonal antibody M-T412|
1723393|NCT00004817|Drug|phenytoin|
1723394|NCT00004817|Drug|valproate sodium|
1723395|NCT00004825|Drug|recombinant human insulin-like growth factor I|
1723396|NCT00004826|Drug|clozapine|
1723397|NCT00004827|Drug|docosahexaenoic acid|
1723398|NCT00004828|Drug|liothyronine I 131|
1723399|NCT00004829|Drug|tobramycin|
1723400|NCT00004831|Drug|cysteine hydrochloride|
1723401|NCT00004832|Drug|3,4-diaminopyridine|
1723402|NCT00004833|Drug|Immune globulin|
1723403|NCT00004834|Drug|imipramine|
1723404|NCT00004834|Behavioral|cognitive-behavioral therapy|
1723405|NCT00004838|Drug|succimer|
1723406|NCT00004840|Drug|thyrotropin-releasing hormone|
1723407|NCT00004842|Drug|budesonide|Oral budesonide, 9 mg daily was administered for 1 year
1723408|NCT00004843|Procedure|parathyroidectomy|Standard parathyroidectomy with a bilateral approach
1723409|NCT00004843|Other|Observation|Usual care
1723410|NCT00004844|Procedure|tissue implantation|
1723411|NCT00004845|Drug|Rofecoxib|
1723412|NCT00004845|Drug|Naproxen|
1723413|NCT00004846|Drug|ABC/Gen-Probe/Chiron HIV-1/HCV 001|
1723414|NCT00004852|Drug|Efavirenz|
1723415|NCT00004852|Drug|Lamivudine|
1723416|NCT00004852|Drug|Zidovudine|
1723417|NCT00004853|Biological|Filgrastim|5 microgram/kg/dose SC daily starting 24-36 hours after last dose of chemotherapy until post-nadir ANC >=10,000/microliter
1723418|NCT00004853|Biological|Filgrastim-SD/01|100 microgram/kg SC 24-36 hours after last dose of chemotherapy (single dose)
1723419|NCT00004854|Drug|Carvedilol|
1723420|NCT00004855|Drug|Lopinavir/Ritonavir|
1723421|NCT00004855|Drug|Abacavir sulfate|
1723422|NCT00004855|Drug|Nevirapine|
1723423|NCT00004855|Drug|Lamivudine|
1723424|NCT00004855|Drug|Stavudine|
1723425|NCT00004856|Biological|trastuzumab|Given IV
1723426|NCT00004857|Biological|alemtuzumab|30 mg subQ injection tiw for 6 weeks
1723427|NCT00004857|Drug|fludarabine phosphate|25mg/sq m/day IV infusion x 5 days Wks 1, 5, 9, and 13
1723428|NCT00004858|Biological|B43-genistein immunoconjugate|
1723429|NCT00004859|Drug|carboplatin|Induction Chemotherapy dosing: AUC=6.0, 15-30 min IV infusion immediately following paclitaxel, Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing, AUC=2; 15- 30 minutes IV infusion immediately following paclitaxel; administered weekly during radiotherapy
1723430|NCT00004859|Drug|paclitaxel|Induction chemotherapy dosing: 225 mg/m² (3 hour infusion) Day 1 and Day 22. Concurrent Chemotherapy / Radiotherapy dosing: 45 mg/m2; administered weekly during radiotherapy over one hour
1723431|NCT00004859|Drug|thalidomide|Induction Chemotherapy dosing: oral daily, starting Day 1 for 24 months or until disease progression. Concurrent Chemotherapy / Radiotherapy dosing: oral daily, begin with 200 mg thalidomide as a single dose at bedtime. The dose is then increased by 100 mg every week as tolerated up to a total dose of 1000 mg.
1723432|NCT00004859|Radiation|radiation therapy|Radiation therapy started between days 43-50 from day 1 of cycle 1. The primary tumor and areas of known nodal disease received 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks to the post chemotherapy tumor volume as seen on computed tomography (CT). The initial 50 Gy was delivered to target volume (TV). The final 10 Gy was delivered to a reduced volume targeting defined by TV
1723433|NCT00004860|Drug|leucovorin calcium|
1723434|NCT00004860|Drug|tegafur-uracil|
1723435|NCT00004861|Drug|gemcitabine hydrochloride|
1723436|NCT00004861|Drug|tacedinaline|
1723437|NCT00004862|Biological|filgrastim|
1723438|NCT00004862|Biological|oblimersen sodium|
1723439|NCT00004862|Drug|cytarabine|
1723440|NCT00004862|Drug|fludarabine phosphate|
1723441|NCT00004863|Drug|GEM 231|
1723442|NCT00004863|Drug|paclitaxel|
1723443|NCT00004864|Drug|GEM 231|
1723444|NCT00004864|Drug|docetaxel|
1723445|NCT00004865|Biological|cetuximab|
1723446|NCT00004865|Drug|cisplatin|
1723447|NCT00004865|Drug|fluorouracil|
1723448|NCT00004865|Drug|paclitaxel|
1723449|NCT00004866|Drug|exatecan mesylate|
1723450|NCT00004867|Procedure|conventional surgery|
1723451|NCT00004867|Procedure|positron emission tomography|
1723452|NCT00004867|Procedure|radionuclide imaging|
1723453|NCT00004867|Radiation|fludeoxyglucose F 18|
1723454|NCT00004867|Drug|chemotherapy|
1723455|NCT00004867|Radiation|Radiotherapy|
1723456|NCT00004868|Drug|semaxanib|
1723457|NCT00004870|Biological|oblimersen sodium|
1723458|NCT00004870|Drug|irinotecan hydrochloride|
1723459|NCT00004871|Drug|azacitidine|
1723460|NCT00004871|Drug|sodium phenylbutyrate|
1723461|NCT00004872|Biological|recombinant human endostatin|
1723462|NCT00004873|Drug|cisplatin|
1723463|NCT00004873|Drug|docetaxel|
1723464|NCT00004873|Drug|epirubicin hydrochloride|
1723465|NCT00004873|Drug|fluorouracil|
1723466|NCT00004874|Radiation|tositumomab and iodine I 131 tositumomab|Dosimetric Dose:Unlabeled anti-B1 (450mg) will be given as peripheral or central IV infusion over one hour or longer depending upon rate-dependent side effects. A trace-labeled dose of 131I-anti-B will be infused over 20 minutes, if rate-dependent side effects permit. An amount of unlabeled Anti-B1 Antibody is added to the 5 mCi of Iodine-131 Anti-B1 Antibody sufficient to result in a final amount of 35 mg of Anti-B1 antibody. On study Day 7 (may be delayed up to study Day 14), patients will receive the therapeutic dose, which consists of an infusion of 450mg of Anti-B1 Antibody followed by an infusion of Iodine-131 Anti-B1 Antibody.
1723467|NCT00004875|Drug|enoxaparin|
1723468|NCT00004875|Drug|heparin|
1723469|NCT00004876|Drug|carboplatin|
1723470|NCT00004876|Drug|thalidomide|
1723471|NCT00004877|Drug|BMS-214662|
1723472|NCT00004878|Biological|therapeutic allogeneic lymphocytes|
1723473|NCT00004878|Drug|cytarabine|
1723474|NCT00004878|Drug|fludarabine phosphate|
1723475|NCT00004878|Drug|idarubicin|
1723476|NCT00004878|Drug|methotrexate|
1723477|NCT00004878|Drug|tacrolimus|
1723478|NCT00004878|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1723479|NCT00004878|Procedure|peripheral blood stem cell transplantation|
1723480|NCT00004879|Biological|panitumumab|
1723481|NCT00004880|Biological|dendritic cell vaccine therapy|
1723482|NCT00004880|Procedure|conventional surgery|
1723483|NCT00004881|Biological|MVA-MUC1-IL2 vaccine|
1723484|NCT00004883|Biological|trastuzumab|Given IV
1723485|NCT00004883|Other|laboratory biomarker analysis|Correlative studies
1723486|NCT00004884|Drug|cisplatin|
1723487|NCT00004884|Drug|docetaxel|
1723488|NCT00004884|Drug|gemcitabine hydrochloride|
1723489|NCT00004885|Drug|FOLFIRI regimen|
1723490|NCT00004885|Drug|fluorouracil|
1723491|NCT00004885|Drug|irinotecan hydrochloride|
1723492|NCT00004885|Drug|leucovorin calcium|
1723493|NCT00004886|Drug|docetaxel|
1723494|NCT00004886|Drug|dofequidar fumarate|
1723495|NCT00004887|Drug|carboplatin|
1723496|NCT00004887|Drug|cisplatin|
1723497|NCT00004887|Drug|ifosfamide|
1723498|NCT00004887|Drug|mitomycin C|
1723499|NCT00004887|Drug|paclitaxel|
1723500|NCT00004887|Drug|vinblastine sulfate|
1723501|NCT00004888|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
1723502|NCT00004888|Drug|docetaxel|Given IV
1723503|NCT00004888|Biological|trastuzumab|Given IV
1723504|NCT00004888|Other|laboratory biomarker analysis|Correlative studies
1723505|NCT00004889|Biological|rituximab|375 mg/m2 given as an intravenous (IV) infusion once weekly for four doses (days 1, 8, 15, and 22). For purposes of this study 4 weekly courses will constitute one cycle of therapy.
1723506|NCT00004890|Biological|aldesleukin|
1723507|NCT00004890|Drug|Biomed 101|
1723508|NCT00004891|Drug|chemotherapy|
1723509|NCT00004891|Procedure|computed tomography|
1723510|NCT00004891|Procedure|conventional surgery|
1723511|NCT00004891|Procedure|neoadjuvant therapy|
1723512|NCT00004891|Procedure|positron emission tomography|
1723513|NCT00004891|Procedure|radionuclide imaging|
1723514|NCT00004891|Radiation|fludeoxyglucose F 18|
1723515|NCT00004891|Radiation|radiation therapy|
1723516|NCT00004892|Drug|O6-benzylguanine|
1723517|NCT00004892|Drug|polifeprosan 20 with carmustine implant|
1723518|NCT00004892|Procedure|conventional surgery|
1723519|NCT00004893|Biological|recombinant interleukin-12|
1723520|NCT00004895|Drug|octreotide acetate|
1723521|NCT00004896|Drug|busulfan|
1723522|NCT00004896|Drug|cyclophosphamide|
1723523|NCT00004896|Procedure|allogeneic bone marrow transplantation|
1723524|NCT00004896|Procedure|bone marrow ablation with stem cell support|
1723525|NCT00004896|Radiation|radiation therapy|
1723526|NCT00004897|Biological|recombinant interferon alfa|
1723527|NCT00004897|Drug|cisplatin|
1723528|NCT00004897|Drug|fluorouracil|
1723529|NCT00004897|Drug|hydroxyurea|
1723530|NCT00004897|Drug|leucovorin calcium|
1723531|NCT00004897|Procedure|conventional surgery|
1723532|NCT00004897|Radiation|radiation therapy|
1723533|NCT00004898|Biological|filgrastim|
1723534|NCT00004898|Drug|cyclophosphamide|
1723535|NCT00004898|Drug|etoposide|
1723536|NCT00004898|Procedure|peripheral blood stem cell transplantation|
1723537|NCT00004898|Radiation|radiation therapy|
1723538|NCT00004899|Biological|filgrastim|
1723539|NCT00004899|Drug|busulfan|
1723540|NCT00004899|Drug|etoposide|
1723541|NCT00004899|Procedure|autologous bone marrow transplantation|
1723542|NCT00004900|Biological|filgrastim|
1723543|NCT00004900|Drug|anastrozole|
1723544|NCT00004900|Drug|carboplatin|
1723545|NCT00004900|Drug|cisplatin|
1723546|NCT00004900|Drug|cyclophosphamide|
1723547|NCT00004900|Drug|etoposide|
1723548|NCT00004900|Drug|thiotepa|
1723549|NCT00004900|Procedure|peripheral blood stem cell transplantation|
1723550|NCT00004900|Radiation|radiation therapy|
1723551|NCT00004901|Drug|ethynyluracil|
1723552|NCT00004901|Drug|fluorouracil|
1723553|NCT00004901|Drug|hydroxyurea|
1723554|NCT00004901|Radiation|radiation therapy|
1723555|NCT00004902|Drug|tocladesine|
1723556|NCT00004903|Biological|filgrastim|
1723557|NCT00004903|Biological|recombinant interferon alfa|
1723558|NCT00004903|Drug|cisplatin|
1723559|NCT00004903|Drug|cyclophosphamide|
1723560|NCT00004903|Drug|cytarabine|
1723561|NCT00004903|Drug|etoposide|
1723562|NCT00004903|Drug|melphalan|
1723563|NCT00004903|Procedure|peripheral blood stem cell transplantation|
1723564|NCT00004904|Biological|anti-thymocyte globulin|
1723565|NCT00004904|Biological|filgrastim|
1723566|NCT00004904|Drug|cladribine|
1723567|NCT00004904|Drug|cyclophosphamide|
1723568|NCT00004904|Drug|etoposide|
1723569|NCT00004904|Drug|methylprednisolone|
1723570|NCT00004904|Drug|tacrolimus|
1723571|NCT00004904|Procedure|allogeneic bone marrow transplantation|
1723572|NCT00004904|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1723573|NCT00004905|Biological|filgrastim|
1723574|NCT00004905|Biological|recombinant interferon alfa|
1723575|NCT00004905|Drug|cyclophosphamide|
1723576|NCT00004905|Drug|cytarabine|
1723577|NCT00004905|Drug|etoposide|
1723578|NCT00004905|Drug|idarubicin|
1723579|NCT00004905|Procedure|peripheral blood stem cell transplantation|
1723580|NCT00004905|Radiation|radiation therapy|
1723581|NCT00004906|Biological|filgrastim|
1723582|NCT00004906|Drug|anastrozole|
1723583|NCT00004906|Drug|carboplatin|
1723584|NCT00004906|Drug|cisplatin|
1723585|NCT00004906|Drug|cyclophosphamide|
1723586|NCT00004906|Drug|docetaxel|
1723587|NCT00004906|Drug|doxorubicin hydrochloride|
1723588|NCT00004906|Drug|etoposide|
1723589|NCT00004906|Drug|pamidronate disodium|
1723590|NCT00004906|Drug|thiotepa|
1723591|NCT00004906|Procedure|peripheral blood stem cell transplantation|
1723592|NCT00004907|Drug|busulfan|
1723593|NCT00004907|Drug|cyclophosphamide|
1723594|NCT00004907|Drug|etoposide|
1723595|NCT00004907|Procedure|allogeneic bone marrow transplantation|
1723596|NCT00004907|Procedure|bone marrow ablation with stem cell support|
1723597|NCT00004907|Procedure|peripheral blood stem cell transplantation|
1723598|NCT00004907|Radiation|radiation therapy|
1723599|NCT00004908|Drug|cyclophosphamide|
1723600|NCT00004908|Procedure|peripheral blood stem cell transplantation|
1723601|NCT00004908|Radiation|radiation therapy|
1723602|NCT00004910|Procedure|bowel obstruction management|
1723603|NCT00004910|Procedure|quality-of-life assessment|
1723604|NCT00004911|Procedure|bowel obstruction management|
1723605|NCT00004911|Procedure|quality-of-life assessment|
1723606|NCT00004912|Drug|megestrol acetate|
1723607|NCT00004912|Procedure|physical therapy|
1723608|NCT00004913|Drug|cisplatin|
1723609|NCT00004913|Drug|docetaxel|
1723610|NCT00004913|Drug|fluorouracil|
1723611|NCT00004913|Drug|leucovorin calcium|
1723612|NCT00004914|Biological|epoetin alfa|
1723613|NCT00004914|Procedure|physical therapy|
1723614|NCT00004915|Drug|raloxifene|
1723615|NCT00004916|Drug|ifosfamide|
1723616|NCT00004916|Drug|paclitaxel|
1723617|NCT00004916|Drug|teniposide|
1723618|NCT00004916|Procedure|peripheral blood stem cell transplantation|
1723619|NCT00004917|Biological|epoetin alfa|
1723620|NCT00004917|Drug|cisplatin|
1723621|NCT00004917|Radiation|radiation therapy|
1723622|NCT00004918|Biological|PR1 leukemia peptide vaccine|Given SC
1723623|NCT00004918|Drug|Montanide ISA 51 VG|Given SC
1723624|NCT00004918|Biological|sargramostim|Given SC
1723625|NCT00004918|Other|laboratory biomarker analysis|Correlative studies
1723626|NCT00004919|Drug|cisplatin|Given IV
1723627|NCT00004919|Drug|irinotecan hydrochloride|Given IV
1723628|NCT00004919|Drug|amifostine trihydrate|Given IV
1723629|NCT00004919|Other|pharmacological study|Correlative studies
1723630|NCT00004920|Drug|cisplatin|
1723631|NCT00004920|Drug|raltitrexed|
1723632|NCT00004921|Biological|filgrastim|
1723633|NCT00004921|Drug|carboplatin|
1723634|NCT00004921|Drug|cyclophosphamide|
1723635|NCT00004921|Drug|melphalan|
1723636|NCT00004921|Drug|paclitaxel|
1723637|NCT00004921|Procedure|adjuvant therapy|
1723638|NCT00004921|Procedure|bone marrow ablation with stem cell support|
1723639|NCT00004921|Procedure|peripheral blood stem cell transplantation|
1723640|NCT00004922|Drug|irinotecan hydrochloride|
1723641|NCT00004923|Drug|docetaxel|
1723642|NCT00004923|Drug|irinotecan hydrochloride|
1723643|NCT00004924|Drug|irinotecan hydrochloride|
1723644|NCT00004924|Drug|paclitaxel|
1723645|NCT00004925|Biological|trastuzumab|
1723646|NCT00004925|Drug|pegylated liposomal doxorubicin hydrochloride|
1723647|NCT00004926|Dietary Supplement|vitamin D3 analogue ILX23-7553|
1723648|NCT00004927|Drug|ixabepilone|
1723649|NCT00004928|Dietary Supplement|calcitriol|
1723650|NCT00004928|Drug|zoledronic acid|
1723651|NCT00004929|Biological|MUC-2-KLH vaccine|
1723652|NCT00004929|Biological|QS21|
1723653|NCT00004930|Drug|doxorubicin hydrochloride|
1723654|NCT00004931|Drug|leucovorin calcium|Given IV
1723655|NCT00004931|Drug|fluorouracil|Given IV
1723656|NCT00004931|Drug|oxaliplatin|Given IV
1723657|NCT00004931|Other|laboratory biomarker analysis|Correlative studies
1723658|NCT00004932|Drug|imatinib mesylate|
1723659|NCT00004933|Drug|hydroxyurea|0.5 to 5 grams PO per day
1723660|NCT00004933|Drug|Homoharringtonine|2.5 mg/ sq m/ day CIVI for 14 days
1723661|NCT00004934|Drug|carboplatin|
1723662|NCT00004934|Drug|epirubicin hydrochloride|
1723663|NCT00004934|Drug|paclitaxel|
1723664|NCT00004934|Procedure|conventional surgery|
1723665|NCT00004935|Drug|Herceptin™ (Her)|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks; at time of progression add chemotherapy
1723666|NCT00004935|Drug|Herceptin™ (Her) + chemo|Herceptin™ (Her) loading dose 4 mg/kg iv, followed by 2 mg/kg iv weekly or loading dose 8 mg/kg iv, followed by 6 mg/kg iv every 3 weeks, and chemotherapy
1723667|NCT00004936|Drug|iodinated contrast dye|
1723668|NCT00004936|Procedure|computed tomography|
1723669|NCT00004936|Procedure|magnetic resonance imaging|
1723670|NCT00004936|Radiation|gadopentetate dimeglumine|
1723671|NCT00004937|Drug|acridine carboxamide|
1723672|NCT00004938|Drug|fluconazole|
1723673|NCT00004939|Drug|,4-diaminopyridine|
1723674|NCT00004940|Drug|cysteine hydrochloride|
1723675|NCT00004941|Drug|monoclonal antibody cA2|
1723676|NCT00004978|Drug|Recombinant interleukin-2 (rIL-2)|Recombinant interleukin-2 at a dose of 7.5 MIU given twice daily subcutaneously for 5 consecutive days every 8 weeks for at least 3 cycles.
1723677|NCT00004979|Drug|paclitaxel|
1723678|NCT00004979|Drug|topotecan hydrochloride|
1723679|NCT00004980|Device|repetitive transcranial magnetic stimulation (rTMS)|a total of 132 minutes of stimulation at one hertz, motor threshold set at 80%, delivered to TP3 scalp site
1723680|NCT00004980|Device|sham stimulation|"132 minutes of stimulation given at 80% motor threshold with coil tilted single wing 45 degrees away from scalp deliverd to TP3 site"
1723681|NCT00004981|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
1723682|NCT00004981|Drug|Lamivudine/Zidovudine|
1723683|NCT00004981|Drug|Abacavir sulfate|
1723684|NCT00004982|Drug|Combination Iron Chelation Therapy|
1723685|NCT00004983|Behavioral|diabetes self-management education|
1723686|NCT00004984|Drug|Crystallized human recombinant insulin|
1723687|NCT00004985|Drug|Capravirine|
1723688|NCT00004985|Drug|Nelfinavir mesylate|
1723689|NCT00004986|Drug|Nitazoxanide|
1723690|NCT00004987|Drug|Dextrin 2-sulfate|
1723691|NCT00004988|Drug|VNP20009|
1723692|NCT00004990|Drug|Dexamethasone|
1723693|NCT00004992|Behavioral|Intensive lifestyle|
1723694|NCT00004993|Drug|Parathyroid hormone (hPTH 1-34)|
1723695|NCT00004997|Drug|Leucovorin|
1723696|NCT00004998|Drug|Lamivudine/Zidovudine|
1723697|NCT00004998|Drug|Capravirine|
1723698|NCT00004998|Drug|Nelfinavir mesylate|
1723699|NCT00004999|Drug|Lamivudine/Zidovudine|
1723700|NCT00004999|Drug|Capravirine|
1723701|NCT00004999|Drug|Nelfinavir mesylate|
1723702|NCT00005000|Drug|Nelfinavir mesylate|
1723703|NCT00005000|Drug|Efavirenz|
1723704|NCT00005000|Drug|Lamivudine|
1723705|NCT00005000|Drug|Keyhole-Limpet Hemocyanin|
1723706|NCT00005000|Drug|Stavudine|
1723707|NCT00005000|Drug|Zidovudine|
1723708|NCT00005000|Drug|Didanosine|
1723709|NCT00005001|Biological|HIV-1 Immunogen|
1723710|NCT00005002|Drug|Lamivudine/Zidovudine|
1723711|NCT00005002|Biological|HIV-1 Immunogen|
1723712|NCT00005002|Drug|Nelfinavir mesylate|
1723713|NCT00003899|Biological|filgrastim|
1723714|NCT00003899|Drug|cyclophosphamide|
1723715|NCT00003899|Drug|melphalan|
1723716|NCT00003899|Drug|paclitaxel|
1723717|NCT00003899|Drug|thiotepa|
1723718|NCT00003899|Procedure|autologous bone marrow transplantation|
1723719|NCT00003899|Procedure|peripheral blood stem cell transplantation|
1723720|NCT00003900|Drug|docetaxel|
1723721|NCT00003900|Drug|irinotecan hydrochloride|
1723722|NCT00003901|Other|immunohistochemistry staining method|
1723723|NCT00003901|Procedure|biopsy|
1723724|NCT00003901|Procedure|surgery|
1723725|NCT00003902|Drug|capecitabine|
1723726|NCT00003902|Drug|vinorelbine tartrate|
1723727|NCT00003903|Procedure|management of therapy complications|
1723728|NCT00003906|Drug|Raloxifene|60 mg/day plus placebo for 5 years
1723729|NCT00003906|Drug|Tamoxifen|20 mg/day plus placebo for 5 years
1723730|NCT00003907|Drug|cisplatin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
1723731|NCT00003907|Drug|doxorubicin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
1723732|NCT00003907|Drug|mitomycin|Doxorubicin 30 mg, mitomycin 30 mg, and cisplatin 100 mg (all in powdered form) should be dissolved in 10-15 cc of contrast agent (such as isovue or optiray).
1723733|NCT00003907|Procedure|embolization|Immediately following delivery of the chemoemulsion, particulate embolization is performed. The particulate embolic material is prepared on a separate table or tray, using absorbable gelatin sponge (Gelfoam, Upjohn, Kalamazoo, MI), in either powder or pledget form. Approximately 1 g of this temporary occlusive agent is dissolved in 20-30 cc of full-strength contrast with 2.4 cc of absolute alcohol.
1723734|NCT00003908|Drug|carboplatin|
1723735|NCT00003908|Drug|docetaxel|
1723736|NCT00003909|Drug|motexafin gadolinium|Given IV
1723737|NCT00003909|Radiation|radiation therapy|Undergo radiation therapy
1723738|NCT00003909|Other|pharmacological study|Correlatives studies
1723739|NCT00003910|Drug|Cyclophosphamide|Patients not responding to MTX after 4 months received Cy orally at 100 mg daily in step two with the same prednisone schedule. In patients showing a partial response, but not a CR, the maximum period of therapy was 1 year.
1723740|NCT00003910|Drug|Methotrexate|Initial treatment consisted of MTX given orally at 10 mg/m2 in divided doses once weekly.
1723741|NCT00003910|Drug|Prednisone|Prednisone was given orally at 1 mg/kg per day for 30 days and then tapered off in the subsequent 24 days.
1723742|NCT00003911|Radiation|stereotactic radiosurgery|
1723743|NCT00003912|Drug|carboplatin|
1723744|NCT00003912|Drug|cisplatin|
1723745|NCT00003912|Drug|doxorubicin hydrochloride|
1723746|NCT00003912|Procedure|conventional surgery|
1723747|NCT00003913|Biological|anti-thymocyte globulin|
1723748|NCT00003913|Biological|filgrastim|
1723749|NCT00003913|Drug|busulfan|
1723750|NCT00003913|Drug|cyclophosphamide|
1723751|NCT00003913|Drug|methylprednisolone|
1723752|NCT00003913|Procedure|umbilical cord blood transplantation|
1723753|NCT00003913|Radiation|radiation therapy|
1723754|NCT00003914|Drug|dolastatin 10|
1723755|NCT00003915|Drug|bicalutamide|
1723756|NCT00003915|Drug|docetaxel|
1723757|NCT00003915|Drug|estramustine phosphate sodium|
1723758|NCT00003915|Drug|leuprolide acetate|
1723759|NCT00003916|Radiation|radiation therapy|
1723760|NCT00003916|Radiation|stereotactic radiosurgery|
1723761|NCT00003917|Drug|topotecan hydrochloride|
1723762|NCT00003920|Biological|filgrastim|
1723763|NCT00003920|Drug|cyclosporine|
1723764|NCT00003920|Procedure|peripheral blood stem cell transplantation|
1723765|NCT00003920|Radiation|indium In 111 monoclonal antibody m170|
1723766|NCT00003920|Radiation|yttrium Y 90 monoclonal antibody m170|
1723767|NCT00003923|Drug|porfimer sodium|
1723768|NCT00003924|Biological|recombinant interferon alfa|
1723769|NCT00003925|Drug|gemcitabine hydrochloride|
1723770|NCT00003925|Drug|leucovorin calcium|
1723771|NCT00003925|Drug|tegafur-uracil|
1723772|NCT00003926|Drug|amifostine trihydrate|"Patients receive amifostine intravenous (IV) over 5 minutes beginning 30 minutes prior to melphalan and thiotepa administration on days -5 to -1.
Cohorts of 3-6 patients receive escalating doses of amifostine until the maximum tolerated dose is determined."
1723773|NCT00003926|Drug|busulfan|Patients receive oral busulfan every 6 hours on days -8 to -6.
1723774|NCT00003926|Drug|filgrastim|All patients receive filgrastim (G-CSF) IV for 1 week.
1723775|NCT00003926|Drug|melphalan|melphalan intravenous (IV) over 30 minutes on days -5 and -4
1723776|NCT00003926|Drug|thiotepa|thiotepa intravenous (IV) over 2 hours on days -3 and -2.
1723777|NCT00003926|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are reinfused on day 0
1723778|NCT00003927|Biological|filgrastim|
1723779|NCT00003927|Drug|amifostine trihydrate|
1723780|NCT00003927|Drug|cyclophosphamide|
1723781|NCT00003927|Drug|doxorubicin hydrochloride|
1723782|NCT00003927|Drug|paclitaxel|
1723783|NCT00003927|Procedure|peripheral blood stem cell transplantation|
1723784|NCT00003928|Drug|cisplatin|Cisplatin IV over 60 minutes on day 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
1723785|NCT00003928|Drug|gemcitabine hydrochloride|Gemcitabine IV over 30 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
1723786|NCT00003929|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously daily on days 12-21 and days 33-42, until absolute neutrophil counts recover. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
1723787|NCT00003929|Drug|lomustine|Oral lomustine on day 1. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
1723788|NCT00003929|Drug|procarbazine hydrochloride|Oral procarbazine on days 1-10 and days 22-31. Patients with a complete response after 6 weeks receive one additional course of chemotherapy prior to radiotherapy.
1723789|NCT00003929|Radiation|radiation therapy|Whole brain radiotherapy is administered daily for 28 days beginning 1-3 weeks following chemotherapy.
1723790|NCT00003930|Drug|cisplatin|
1723791|NCT00003930|Drug|gemcitabine hydrochloride|
1723792|NCT00003930|Drug|paclitaxel|
1723793|NCT00003930|Procedure|conventional surgery|
1723794|NCT00003930|Radiation|radiation therapy|
1723795|NCT00003931|Genetic|reverse transcriptase-polymerase chain reaction|
1723796|NCT00003933|Other|laboratory biomarker analysis|
1723797|NCT00003934|Drug|tretinoin|Given orally
1723798|NCT00003934|Drug|daunorubicin hydrochloride|Given IV
1723799|NCT00003934|Drug|cytarabine|Given IV
1723800|NCT00003934|Drug|mercaptopurine|Given IV
1723801|NCT00003934|Drug|methotrexate|Given IV
1723802|NCT00003934|Drug|arsenic trioxide|Given IV
1723803|NCT00003935|Drug|etoposide|
1723804|NCT00003935|Drug|vincristine sulfate|
1723805|NCT00003935|Radiation|radiation therapy|
1723806|NCT00003936|Drug|bryostatin 1|
1723807|NCT00003937|Drug|cisplatin|
1723808|NCT00003937|Drug|dexrazoxane hydrochloride|
1723809|NCT00003937|Drug|doxorubicin hydrochloride|
1723810|NCT00003937|Drug|etoposide|
1723811|NCT00003937|Drug|ifosfamide|
1723812|NCT00003937|Drug|methotrexate|
1723813|NCT00003937|Procedure|conventional surgery|
1723814|NCT00003938|Drug|liposomal amphotericin B|
1723815|NCT00003939|Drug|trabectedin|
1723816|NCT00003941|Biological|bleomycin sulfate|
1723817|NCT00003941|Biological|filgrastim|
1723818|NCT00003941|Drug|cisplatin|
1723819|NCT00003941|Drug|etoposide|
1723820|NCT00003941|Drug|ifosfamide|
1723821|NCT00003941|Procedure|bone marrow ablation with stem cell support|
1723822|NCT00003941|Procedure|peripheral blood stem cell transplantation|
1723823|NCT00003942|Biological|RevM10 gene|
1723824|NCT00003942|Biological|RevM10/polAS gene|
1723825|NCT00003942|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1723826|NCT00003942|Procedure|peripheral blood stem cell transplantation|
1723827|NCT00003943|Biological|filgrastim|5 ug/kg
1723828|NCT00003943|Drug|carboplatin|AUC 5
1723829|NCT00003943|Drug|cyclophosphamide|3 gm/m2
1723830|NCT00003943|Drug|paclitaxel|250 mg/m2
1723831|NCT00003943|Drug|topotecan hydrochloride|10 mg/m2
1723832|NCT00003943|Procedure|peripheral blood stem cell transplantation|harvest via apheresis
1723833|NCT00003944|Biological|filgrastim|
1723834|NCT00003944|Drug|carboplatin|
1723835|NCT00003944|Drug|cyclophosphamide|
1723836|NCT00003944|Drug|paclitaxel|
1723837|NCT00003944|Drug|topotecan hydrochloride|
1723838|NCT00003944|Procedure|peripheral blood stem cell transplantation|
1723839|NCT00003945|Drug|cisplatin|
1723840|NCT00003945|Drug|topotecan hydrochloride|
1723841|NCT00003946|Drug|danazol|
1723842|NCT00003950|Drug|cyclosporine|
1723843|NCT00003950|Drug|CPT-11|
1723844|NCT00003951|Drug|exatecan mesylate|
1723845|NCT00003953|Biological|filgrastim|Filgrastim (G-CSF) is administered subcutaneously on days 3-10 of each 2 week course.
1723846|NCT00003953|Drug|CMF regimen|Stratum I and II: receive cyclophosphamide, methotrexate, and fluorouracil (CMF) for 4 courses
1723847|NCT00003953|Drug|docetaxel|Docetaxel IV over 1 hour on days 43, 57, and 71.
1723848|NCT00003953|Drug|doxorubicin hydrochloride|Doxorubicin IV on days 1, 15, and 29.
1723849|NCT00003953|Drug|tamoxifen citrate|Patients with positive estrogen or progesterone receptors receive oral tamoxifen daily for 5 years.
1723850|NCT00003953|Procedure|autologous bone marrow transplantation|Stratum III:may receive high dose chemotherapy with stem cell support
1723851|NCT00003953|Procedure|surgical procedure|Fourteen to 21 days following preoperative chemotherapy, patients undergo a radical, modified radical, or breast sparing surgery plus axillary lymph node dissection.
1723852|NCT00003953|Radiation|radiation therapy|Radiotherapy is administered 5 days a week for 5.5 weeks.
1723853|NCT00003954|Drug|melphalan|Given IV
1723854|NCT00003954|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous bone marrow or PBSCT
1723855|NCT00003954|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow or PBSCT
1723856|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo autologous bone marrow or PBSCT
1723857|NCT00003954|Radiation|total-body irradiation|Undergo TBI
1723858|NCT00003954|Procedure|peripheral blood stem cell transplantation|Undergo donor PBSCT
1723859|NCT00003954|Drug|cyclosporine|Given IV and PO
1723860|NCT00003954|Drug|mycophenolate mofetil|Given PO
1723861|NCT00003954|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
1723862|NCT00003955|Biological|dactinomycin|
1723863|NCT00003955|Biological|filgrastim|
1723864|NCT00003955|Biological|pegfilgrastim|
1723865|NCT00003955|Biological|sargramostim|
1723866|NCT00003955|Drug|cyclophosphamide|
1723867|NCT00003955|Drug|irinotecan hydrochloride|
1723868|NCT00003955|Drug|vincristine sulfate|
1723869|NCT00003955|Radiation|radiation therapy|
1723870|NCT00003956|Drug|fluorouracil|
1723871|NCT00003956|Drug|leucovorin calcium|
1723872|NCT00003956|Drug|lonafarnib|
1723873|NCT00003957|Biological|filgrastim|
1723874|NCT00003957|Biological|recombinant human stem cell factor|
1723875|NCT00003957|Drug|cyclophosphamide|
1723876|NCT00003957|Drug|cytarabine|
1723877|NCT00003957|Drug|etoposide|
1723878|NCT00003957|Drug|melphalan|
1723879|NCT00003957|Drug|mitoxantrone hydrochloride|
1723880|NCT00003957|Drug|paclitaxel|
1723881|NCT00003957|Procedure|peripheral blood stem cell transplantation|
1723882|NCT00003958|Biological|dactinomycin|Given IV
1723883|NCT00003958|Drug|vincristine sulfate|Given IV
1723884|NCT00003958|Drug|cyclophosphamide|Given IV
1723885|NCT00003958|Procedure|therapeutic conventional surgery|Undergo surgery
1723886|NCT00003958|Radiation|radiation therapy|Undergo radiotherapy
1723887|NCT00003958|Drug|topotecan hydrochloride|Given IV
1723888|NCT00003958|Biological|filgrastim|Given SC
1723889|NCT00003958|Biological|sargramostim|Given SC
1723890|NCT00003958|Other|laboratory biomarker analysis|Correlative studies
1723891|NCT00003959|Biological|ras peptide cancer vaccine|
1723892|NCT00003959|Biological|sargramostim|
1723893|NCT00003960|Drug|busulfan|
1723894|NCT00003960|Drug|cyclophosphamide|
1723895|NCT00003960|Drug|methylprednisolone|
1723896|NCT00003960|Procedure|allogeneic bone marrow transplantation|
1723897|NCT00003960|Procedure|in vitro-treated bone marrow transplantation|
1723898|NCT00003961|Biological|sargramostim|
1723899|NCT00003962|Biological|aldesleukin|
1723900|NCT00003963|Biological|rituximab|Week 1-4: Rituxan is given at 375 mg/m2 weekly x4. Week 5-8: Rituxan given every 2 weeks. Week 9-12: Schedule same as week 5-8.
1723901|NCT00003963|Drug|vinorelbine ditartrate|"Week 1-4: Vinorelbine (25mg/m2) given 1 week after the first rituxan dose and immediately after the second rituxan dose.
Week 5-8: Vinorelbine given weekly x3, with one week off. Week 9-12: Schedule same as week 5-8. Week 13 and following: If subject doesn't have disease progression, they may continue on Vinorelbine until progression or until clinically indicated."
1723902|NCT00003966|Drug|defibrotide|
1723903|NCT00003967|Drug|etoposide|
1723904|NCT00003967|Drug|topotecan hydrochloride|
1723905|NCT00003968|Drug|bryostatin 1|
1723906|NCT00003969|Drug|tanespimycin|
1723907|NCT00003970|Drug|irinotecan hydrochloride|Given IV
1723908|NCT00003972|Biological|filgrastim|
1723909|NCT00003972|Biological|sargramostim|
1723910|NCT00003972|Drug|busulfan|
1723911|NCT00003972|Drug|carboplatin|
1723912|NCT00003972|Drug|cyclophosphamide|
1723913|NCT00003972|Drug|melphalan|
1723914|NCT00003972|Drug|paclitaxel|
1723915|NCT00003972|Drug|tamoxifen citrate|
1723916|NCT00003972|Drug|thiotepa|
1723917|NCT00003972|Procedure|peripheral blood stem cell transplantation|
1723918|NCT00003972|Radiation|radiation therapy|
1723919|NCT00003974|Biological|lung tumor associated antigen|
1723920|NCT00003974|Drug|DetoxPC|
1723921|NCT00003974|Drug|chemotherapy|
1723922|NCT00003974|Drug|cyclophosphamide|
1723923|NCT00003976|Drug|indisulam|
1723924|NCT00003977|Biological|human papillomavirus 16 E7 peptide|
1723925|NCT00003977|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1723926|NCT00003979|Drug|CHS 828|
1723927|NCT00003980|Drug|BIBX 1382|
1723928|NCT00003981|Drug|indisulam|
1723929|NCT00003982|Drug|sabarubicin|
1723930|NCT00003984|Biological|lintuzumab|
1723931|NCT00003985|Drug|KRN7000|
1723932|NCT00003989|Biological|ISIS 3521|
1723933|NCT00003991|Biological|aldesleukin|
1723934|NCT00003991|Drug|histamine dihydrochloride|
1723935|NCT00003992|Biological|trastuzumab|
1723936|NCT00003992|Drug|cyclophosphamide|
1723937|NCT00003992|Drug|doxorubicin hydrochloride|
1723938|NCT00003992|Drug|paclitaxel|
1723939|NCT00003992|Drug|tamoxifen citrate|
1723940|NCT00003993|Biological|aldesleukin|
1723941|NCT00003993|Drug|bryostatin 1|
1723942|NCT00003994|Procedure|therapeutic conventional surgery|Undergo surgical resection
1723943|NCT00003994|Drug|cisplatin|Given IV
1723944|NCT00003994|Drug|vincristine sulfate|Given IV
1723945|NCT00003994|Drug|fluorouracil|Given IV
1723946|NCT00003994|Drug|amifostine trihydrate|Given IV
1723947|NCT00003994|Drug|carboplatin|Given IV
1723948|NCT00003995|Biological|trastuzumab|
1723949|NCT00003995|Drug|irinotecan hydrochloride|
1723950|NCT00003996|Drug|carmustine|
1723951|NCT00003996|Drug|chemotherapy|
1723952|NCT00003996|Drug|cisplatin|
1723953|NCT00003996|Drug|etoposide|
1723954|NCT00003996|Radiation|radiation therapy|
1723955|NCT00003997|Drug|irofulven|
1723956|NCT00003998|Drug|carboplatin|
1723957|NCT00003998|Drug|docetaxel|
1723958|NCT00003998|Drug|paclitaxel|
1723959|NCT00003998|Procedure|surgical procedure|
1723960|NCT00004001|Drug|docetaxel|
1723961|NCT00004001|Drug|estramustine|
1723962|NCT00004001|Drug|mitoxantrone|
1723963|NCT00004001|Drug|prednisone|
1723964|NCT00004002|Drug|bortezomib|
1723965|NCT00004003|Drug|cisplatin|
1723966|NCT00004003|Drug|fluorouracil|
1723967|NCT00004003|Drug|gemcitabine hydrochloride|
1723968|NCT00004004|Drug|procarbazine hydrochloride|
1723969|NCT00004005|Drug|fluorouracil|
1723970|NCT00004005|Drug|irinotecan hydrochloride|
1723971|NCT00004005|Drug|leucovorin calcium|
1723972|NCT00004005|Procedure|conventional surgery|
1723973|NCT00004005|Radiation|radiation therapy|
1723974|NCT00004006|Biological|filgrastim|
1723975|NCT00004006|Drug|carboplatin|
1723976|NCT00004006|Drug|cyclophosphamide|
1723977|NCT00004006|Drug|doxorubicin hydrochloride|
1723978|NCT00004006|Drug|etoposide|
1723979|NCT00004006|Drug|topotecan hydrochloride|
1723980|NCT00004006|Procedure|autologous bone marrow transplantation|
1723981|NCT00004006|Radiation|radiation therapy|
1723982|NCT00004008|Drug|bryostatin 1|
1723983|NCT00004009|Drug|tipifarnib|
1723984|NCT00004010|Biological|bleomycin sulfate|
1723985|NCT00004010|Biological|filgrastim|
1723986|NCT00004010|Drug|ABVD regimen|
1723987|NCT00004010|Drug|cyclophosphamide|
1723988|NCT00004010|Drug|dacarbazine|
1723989|NCT00004010|Drug|doxorubicin hydrochloride|
1723990|NCT00004010|Drug|etoposide|
1723991|NCT00004010|Drug|prednisone|
1723992|NCT00004010|Drug|procarbazine hydrochloride|
1723993|NCT00004010|Drug|vinblastine sulfate|
1723994|NCT00004010|Drug|vincristine sulfate|
1723995|NCT00004010|Radiation|radiation therapy|
1723996|NCT00004011|Drug|carboplatin|
1723997|NCT00004011|Drug|paclitaxel|
1723998|NCT00004011|Procedure|conventional surgery|
1723999|NCT00004012|Drug|capecitabine|
1724000|NCT00004013|Biological|trastuzumab|
1724001|NCT00004013|Drug|paclitaxel|
1724002|NCT00004014|Drug|pegylated liposomal doxorubicin hydrochloride|Doxorubicin HCl liposome IV over 45 minutes every 3 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Quality of life is assessed at baseline and then every 9 weeks thereafter.
1724003|NCT00004015|Drug|sodium borocaptate|
1724004|NCT00004015|Procedure|adjuvant therapy|
1724005|NCT00004016|Biological|recombinant interferon gamma|
1724006|NCT00004017|Procedure|conventional surgery|
1724007|NCT00004017|Radiation|iodine I 131 monoclonal antibody TNT-1/B|
1724008|NCT00004022|Biological|aldesleukin|
1724009|NCT00004022|Biological|autologous tumor cell vaccine|
1724010|NCT00004022|Biological|muromonab-CD3|
1724011|NCT00004022|Biological|therapeutic autologous lymphocytes|
1724012|NCT00004022|Procedure|surgical procedure|
1724013|NCT00004024|Biological|aldesleukin|
1724014|NCT00004024|Biological|autologous tumor cell vaccine|
1724015|NCT00004024|Biological|muromonab-CD3|
1724016|NCT00004024|Biological|sargramostim|
1724017|NCT00004024|Biological|therapeutic autologous lymphocytes|
1724018|NCT00004024|Procedure|surgical procedure|
1724019|NCT00004024|Radiation|radiation therapy|
1724020|NCT00004025|Biological|aldesleukin|
1724021|NCT00004025|Biological|dendritic cell-gp100-MART-1 antigen vaccine|
1724022|NCT00004026|Drug|CT-2584|
1724023|NCT00004026|Drug|chemotherapy|
1724024|NCT00004028|Drug|carmustine|
1724025|NCT00004028|Procedure|conventional surgery|
1724026|NCT00004029|Biological|recombinant viral vaccine therapy|
1724027|NCT00004029|Biological|sargramostim|
1724029|NCT00004030|Drug|pegylated liposomal doxorubicin hydrochloride|
1724030|NCT00004031|Biological|rituximab|375 mg/m2 IV every 21 days
1724031|NCT00004031|Drug|CHOP regimen|
1724032|NCT00004031|Drug|carmustine|
1724033|NCT00004031|Drug|cyclophosphamide|
1724034|NCT00004031|Drug|doxorubicin hydrochloride|
1724035|NCT00004031|Drug|etoposide|
1724036|NCT00004031|Drug|prednisone|
1724037|NCT00004031|Drug|vincristine sulfate|
1724038|NCT00004031|Procedure|bone marrow ablation with stem cell support|
1724039|NCT00004031|Procedure|peripheral blood stem cell transplantation|
1724040|NCT00004031|Radiation|radiation therapy|
1724041|NCT00004032|Biological|ALVAC-hB7.1|Given IP
1724042|NCT00004032|Biological|recombinant interferon gamma|Given IP
1724043|NCT00004032|Other|laboratory biomarker analysis|Correlative studies
1724044|NCT00004033|Drug|liposomal NDDP|
1724045|NCT00004033|Procedure|therapeutic thoracoscopy|
1724046|NCT00004036|Biological|sargramostim|
1724047|NCT00004036|Drug|amifostine trihydrate|
1724048|NCT00004036|Drug|carboplatin|
1724049|NCT00004036|Drug|cyclophosphamide|
1724050|NCT00004037|Drug|docetaxel|
1724051|NCT00004038|Biological|Ad5CMV-p53 gene|
1724052|NCT00004038|Drug|chemotherapy|
1724053|NCT00004039|Biological|recombinant interferon alfa|
1724054|NCT00004039|Biological|rituximab|
1724055|NCT00004039|Drug|cyclophosphamide|
1724056|NCT00004039|Drug|doxorubicin hydrochloride|
1724057|NCT00004039|Drug|prednisone|
1724058|NCT00004039|Drug|vincristine sulfate|
1724059|NCT00004040|Biological|recombinant interferon alfa|
1724060|NCT00004040|Biological|rituximab|
1724061|NCT00004041|Biological|Ad5CMV-p53 gene|
1724062|NCT00004041|Procedure|conventional surgery|
1724063|NCT00004042|Biological|monoclonal antibody F19|
1724064|NCT00004042|Radiation|iodine I 131 monoclonal antibody F19|
1724065|NCT00004043|Dietary Supplement|calcitriol|
1724066|NCT00004045|Drug|exatecan mesylate|
1724067|NCT00004046|Drug|exatecan mesylate|
1724068|NCT00004047|Drug|exatecan mesylate|
1724069|NCT00004048|Biological|filgrastim|
1724070|NCT00004048|Drug|doxorubicin hydrochloride|
1724071|NCT00004048|Procedure|autologous bone marrow transplantation|
1724072|NCT00004048|Procedure|peripheral blood stem cell transplantation|
1724073|NCT00004048|Radiation|indium In 111 monoclonal antibody MN-14|
1724074|NCT00004048|Radiation|yttrium Y 90 monoclonal antibody MN-14|
1724075|NCT00004049|Drug|apomine|
1724076|NCT00004050|Biological|Leuvectin|Leuvectin injected intratumorally followed by prostatectomy
1724077|NCT00004051|Drug|irinotecan hydrochloride|
1724078|NCT00004052|Biological|QS21|
1724079|NCT00004052|Biological|bcr-abl peptide vaccine|
1724080|NCT00004054|Drug|bicalutamide|Administered orally at a dose of one 50mg tablet per day. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
1724081|NCT00004054|Drug|estramustine phosphate sodium|280 mg three times a day for 14 days and repeated every 3 weeks for 4 cycles
1724082|NCT00004054|Drug|etoposide|50 mg/m^2 in divided doses b.i.d. for 14 days and repeated every 3 weeks for 4 cycles
1724083|NCT00004054|Drug|flutamide|Administered orally at a dose of two 125 mg capsules three times a day for a total daily dose of 750 mg. Begins 8 weeks prior to radiotherapy and continues throughout radiotherapy.
1724084|NCT00004054|Drug|paclitaxel|135 mg/m^2 given as a 1-hour infusion (on day 2 of each cycle) and repeated every 3 weeks for 4 cycles
1724085|NCT00004054|Drug|Luteinizing hormone releasing hormone [LHRH] agonist|Releasing hormone agonists (such as leuprolide, goserelin, buserelin, triptorelin) will be given for 4 months
1724086|NCT00004054|Radiation|Radiation therapy|Radiation will begin 8 weeks following the initiation of hormone administration: 46.8 Gy to the regional lymphatics followed by a 23.4 Gy boost to the prostate to bring the total dose to the prostate to 70.2 Gy. Daily tumor doses will be 1.8 Gy per day, 5 days per week x 7-8 weeks.
1724087|NCT00004054|Drug|warfarin|To keep international normalized ratio (INR) > 1.5 and < 2.5; begins with the start of chemotherapy and will be given continuously until 4 weeks after the end of the fourth cycle of chemotherapy
1724088|NCT00004055|Biological|filgrastim|
1724089|NCT00004055|Drug|paclitaxel|
1724090|NCT00004055|Drug|topotecan hydrochloride|
1724091|NCT00004056|Biological|filgrastim|
1724092|NCT00004056|Drug|asparaginase|
1724093|NCT00004056|Drug|cytarabine|
1724094|NCT00004056|Drug|daunorubicin hydrochloride|
1724095|NCT00004056|Drug|melphalan|
1724096|NCT00004056|Drug|thioguanine|
1724097|NCT00004056|Procedure|peripheral blood stem cell transplantation|
1724098|NCT00004057|Drug|L-778,123|
1724099|NCT00004057|Drug|paclitaxel|
1724100|NCT00004058|Drug|tetradecanoylphorbol acetate|
1724101|NCT00004059|Drug|7-hydroxystaurosporine|
1724102|NCT00004059|Drug|fluorouracil|
1724103|NCT00004060|Drug|exatecan mesylate|
1724104|NCT00004061|Biological|filgrastim|
1724105|NCT00004061|Biological|palifermin|
1724106|NCT00004061|Drug|cyclophosphamide|
1724107|NCT00004061|Drug|etoposide|
1724108|NCT00004061|Drug|ifosfamide|
1724109|NCT00004061|Procedure|peripheral blood stem cell transplantation|
1724110|NCT00004061|Procedure|quality-of-life assessment|
1724111|NCT00004061|Radiation|radiation therapy|
1724112|NCT00004062|Drug|azacitidine|
1724113|NCT00004062|Drug|liothyronine sodium|
1724114|NCT00004062|Radiation|iodine I 131|
1724115|NCT00004063|Biological|recombinant interferon alfa|
1724116|NCT00004063|Drug|cisplatin|
1724117|NCT00004063|Drug|gemcitabine hydrochloride|
1724118|NCT00004063|Procedure|hyperthermia treatment|
1724119|NCT00004064|Biological|oregovomab|
1724120|NCT00004065|Drug|tanespimycin|
1724123|NCT00004066|Drug|gemcitabine hydrochloride|
1724124|NCT00004067|Biological|herceptin|4 mg/kg loading dose then 2 mg/kg weekly for 1 year.
1724125|NCT00004067|Drug|adriamycin|60 mg/m2 IV push every 21 days for 4 cycles.
1724126|NCT00004067|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for 4 cycles
1724127|NCT00004067|Drug|taxol|175 mg/m2 IV every 21 days for 4 cycles
1724128|NCT00004068|Drug|irinotecan hydrochloride|
1724129|NCT00004068|Drug|temozolomide|
1724130|NCT00004068|Procedure|conventional surgery|
1724131|NCT00004068|Radiation|radiation therapy|
1724132|NCT00004070|Biological|IL-12|
1724133|NCT00004071|Drug|leflunomide|
1724134|NCT00004071|Drug|mitoxantrone hydrochloride|
1724135|NCT00004071|Drug|prednisone|
1724136|NCT00004072|Drug|O6-benzylguanine|Patients receive O6-benzylguanine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
1724137|NCT00004072|Drug|carmustine|Followed 1 hour later by carmustine IV over 60 minutes. Courses repeat every 6 weeks in the absence of disease progression or unacceptable toxicity. Patients receive 2 additional courses beyond attainment of best response.
1724138|NCT00004073|Drug|suramin|
1724139|NCT00004073|Radiation|radiation therapy|
1724140|NCT00004074|Biological|recombinant interleukin-12|Given IV
1724141|NCT00004074|Biological|ABI-007/carboplatin/trastuzumab|Given IV
1724142|NCT00004075|Drug|tanespimycin|
1724143|NCT00004076|Drug|mureletecan|
1724144|NCT00004077|Drug|cisplatin|
1724145|NCT00004077|Drug|ifosfamide|
1724146|NCT00004077|Drug|paclitaxel|
1724147|NCT00004078|Drug|irinotecan hydrochloride|Given IV
1724148|NCT00004079|Drug|SarCNU|Given PO
1724149|NCT00004079|Other|pharmacological study|Correlative studies
1724150|NCT00004079|Other|laboratory biomarker analysis|Correlative studies
1724151|NCT00004080|Biological|recombinant adenovirus-p53 SCH-58500|
1724152|NCT00004080|Procedure|conventional surgery|
1724153|NCT00004081|Drug|docetaxel|
1724154|NCT00004082|Drug|carboplatin|
1724155|NCT00004082|Drug|docetaxel|
1724156|NCT00004082|Drug|gemcitabine hydrochloride|
1724157|NCT00004083|Drug|cisplatin liposomal|
1724158|NCT00004084|Radiation|indium In 111 LL2 IgG|single dose, intravenous infusion over 30 minutes
1724159|NCT00004084|Radiation|yttrium Y 90 epratuzumab|single dose, intravenous infusion over 30 minutes
1724160|NCT00004085|Biological|filgrastim|as prescribed by physician
1724161|NCT00004085|Procedure|autologous bone marrow transplantation|1-2 weeks prior to treatment
1724162|NCT00004085|Procedure|peripheral blood stem cell transplantation|1-2 weeks prior to treatment
1724163|NCT00004085|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min, single dose
1724164|NCT00004086|Biological|filgrastim|
1724165|NCT00004086|Drug|cisplatin|
1724166|NCT00004086|Drug|cytarabine|
1724167|NCT00004086|Drug|etoposide|
1724168|NCT00004086|Drug|ifosfamide|
1724169|NCT00004086|Procedure|autologous bone marrow transplantation|
1724170|NCT00004086|Procedure|peripheral blood stem cell transplantation|
1724171|NCT00004086|Radiation|indium In 111 LL2 IgG|
1724172|NCT00004086|Radiation|yttrium Y 90 epratuzumab|
1724173|NCT00004087|Biological|filgrastim|as prescribed by physician
1724174|NCT00004087|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
1724175|NCT00004087|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
1724176|NCT00004087|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
1724177|NCT00004087|Radiation|yttrium Y 90 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
1724178|NCT00004088|Biological|filgrastim|
1724179|NCT00004088|Biological|recombinant interferon alfa|
1724180|NCT00004088|Drug|busulfan|
1724181|NCT00004088|Drug|cyclophosphamide|
1724182|NCT00004088|Drug|melphalan|
1724183|NCT00004088|Drug|pamidronate disodium|
1724184|NCT00004088|Drug|thalidomide|
1724185|NCT00004088|Procedure|peripheral blood stem cell transplantation|
1724186|NCT00004089|Biological|filgrastim|
1724187|NCT00004089|Drug|fluorouracil|
1724188|NCT00004089|Drug|hydroxyurea|
1724189|NCT00004089|Drug|paclitaxel|
1724190|NCT00004089|Procedure|conventional surgery|
1724191|NCT00004089|Radiation|radiation therapy|
1724192|NCT00004090|Drug|cisplatin|
1724193|NCT00004090|Drug|gemcitabine hydrochloride|
1724194|NCT00004091|Other|Papanicolaou test|
1724195|NCT00004091|Other|cytology specimen collection procedure|
1724196|NCT00004091|Other|fluorescent antibody technique|
1724197|NCT00004091|Procedure|colposcopic biopsy|
1724198|NCT00004091|Procedure|study of high risk factors|
1724199|NCT00004092|Biological|filgrastim|Given IV or subcutaneously
1724200|NCT00004092|Drug|carboplatin|Given IV
1724201|NCT00004092|Drug|cyclophosphamide|Given IV
1724202|NCT00004092|Drug|doxorubicin hydrochloride|Given IV
1724203|NCT00004092|Drug|paclitaxel|Given IV
1724204|NCT00004092|Drug|thiotepa|Given IV
1724205|NCT00004092|Procedure|peripheral blood stem cell transplantation|Patients receive autologous peripheral blood stem cells
1724206|NCT00004093|Drug|carboplatin|Carboplatin will be dosed at a target AUC of 5, and will be given on day 1 of each cycle
1724207|NCT00004093|Drug|Gemcitabine|Gemcitabine will be given at 1000 mg/m2 IV over 30 minutes on days 1 and 8 of each 21-day cycle of induction chemo (following carboplatin on day 1).
1724208|NCT00004093|Drug|paclitaxel|Paclitaxel will be given on day 1 of each week for 6 weeks at a dose of 50 mg/m2.
1724209|NCT00004093|Drug|vinorelbine|Vinorelbine will be given on day 1 of each week for 6 weeks at a starting dose of 10 mg/m2, escalating up to 15 mg/m2 if no dose limiting toxicities are observed.
1724210|NCT00004093|Radiation|radiation therapy|Radiation will be given at a dose ranging between 45 to 66 Gy, depending on patient-specific characteristics.
1724211|NCT00004093|Drug|Navelbine|Navelbine will be administered at a dose of 10-15 mg/m2 in 100 cc NS to be administered over 10 minutes I.V. (one dose weekly during radiation therapy)
1724212|NCT00004093|Drug|Taxol|Taxol will be administered at a dose of 50 mg/m2 in 250 cc of NS or D5W over 60 minutes, following Navelbine (one dose weekly during radiation therapy)
1724213|NCT00004094|Drug|carboplatin|
1724214|NCT00004094|Drug|fluorouracil|
1724215|NCT00004094|Drug|hydroxyurea|
1724216|NCT00004094|Drug|paclitaxel|
1724217|NCT00004094|Procedure|conventional surgery|
1724218|NCT00004094|Radiation|radiation therapy|
1724219|NCT00004095|Drug|gemcitabine hydrochloride|
1724220|NCT00004095|Drug|irinotecan hydrochloride|
1724221|NCT00004096|Drug|carboplatin|
1724222|NCT00004096|Drug|vinorelbine ditartrate|
1724223|NCT00004097|Drug|fluorouracil|
1724224|NCT00004097|Drug|gemcitabine hydrochloride|
1724225|NCT00004097|Drug|paclitaxel|
1724226|NCT00004097|Radiation|radiation therapy|
1724227|NCT00004099|Drug|cisplatin|
1724228|NCT00004099|Drug|fluorouracil|
1724229|NCT00004099|Drug|leucovorin calcium|
1724230|NCT00004099|Procedure|neoadjuvant therapy|
1724231|NCT00004100|Drug|cisplatin|
1724232|NCT00004100|Drug|gemcitabine hydrochloride|
1724233|NCT00004100|Drug|vinorelbine tartrate|
1724234|NCT00004101|Biological|apolizumab|
1724235|NCT00004102|Drug|FOLFOX regimen|
1724236|NCT00004102|Drug|fluorouracil|
1724237|NCT00004102|Drug|leucovorin calcium|
1724238|NCT00004102|Drug|oxaliplatin|
1724239|NCT00004103|Drug|cisplatin|
1724240|NCT00004103|Drug|floxuridine|
1724241|NCT00004103|Drug|irinotecan hydrochloride|
1724242|NCT00004103|Procedure|adjuvant therapy|
1724243|NCT00004103|Procedure|conventional surgery|
1724244|NCT00004103|Procedure|neoadjuvant therapy|
1724245|NCT00004104|Biological|liposomal interleukin-2|
1724246|NCT00004104|Biological|polyvalent melanoma vaccine|
1724247|NCT00004104|Biological|recombinant interferon alfa|
1724248|NCT00004105|Drug|estramustine phosphate sodium|
1724249|NCT00004105|Drug|paclitaxel|
1724250|NCT00004105|Drug|vinorelbine ditartrate|
1724251|NCT00004106|Drug|temozolomide|Temozolomid will be administered orally at a dose of 150mg/m2/day for 5 days for a total of 4 weeks
1724252|NCT00004107|Biological|filgrastim|as prescribed by physician
1724253|NCT00004107|Procedure|autologous bone marrow transplantation|1-2 weeks before treatment
1724254|NCT00004107|Procedure|peripheral blood stem cell transplantation|1-2 weeks before treatment
1724255|NCT00004107|Radiation|indium In 111 monoclonal antibody MN-14|intravenous infusion over 30 min; single dose
1724256|NCT00004107|Radiation|yttrium Y 90 epratuzumab|intravenous infusion over 30 min; single dose
1724257|NCT00004108|Drug|exatecan mesylate|
1724258|NCT00004109|Drug|Doxorubicin Hydrochloride|Doxorubicin dose will not exceed 20 mg/m2 per week IV over 4 days every week for 5 weeks
1724259|NCT00004109|Radiation|Radiation Therapy (RT)|External-beam radiotherapy at a dose of 50 Gy (2.0 x 25 fractions, weeks 1-5).
1724260|NCT00004110|Biological|monoclonal antibody 3F8|
1724261|NCT00004110|Drug|etoposide|
1724262|NCT00004110|Drug|isotretinoin|
1724263|NCT00004112|Biological|rituximab|
1724264|NCT00004112|Drug|CHOP regimen|
1724265|NCT00004112|Drug|cyclophosphamide|
1724266|NCT00004112|Drug|doxorubicin hydrochloride|
1724267|NCT00004112|Drug|prednisone|
1724268|NCT00004112|Drug|vincristine sulfate|
1724269|NCT00004113|Drug|temozolomide|
1724270|NCT00004114|Biological|filgrastim|
1724271|NCT00004114|Drug|cyclophosphamide|
1724272|NCT00004114|Drug|cytarabine|
1724273|NCT00004114|Drug|fludarabine phosphate|
1724274|NCT00004114|Procedure|peripheral blood stem cell transplantation|
1724275|NCT00004115|Radiation|yttrium Y 90 monoclonal antibody HMFG1|
1724276|NCT00004122|Biological|BCG vaccine|
1724277|NCT00004122|Biological|recombinant interferon alfa|
1724278|NCT00004123|Drug|Doxorubicin hydrochloride (DOX)|Doxorubicin IV bolus followed immediately by IV over 4 days every week for 5 weeks concurrently with external beam radiotherapy 5 days a week for 4 weeks.
1724279|NCT00004123|Procedure|Conventional surgery|Surgical resection of primary tumor and all adjacent gross disease approximately 6 weeks after chemoradiotherapy
1724280|NCT00004123|Radiation|Intraoperative radiation therapy (IORT)|Intraoperative radiotherapy (IORT) to tumor bed if all gross disease has been resected and if area of maximal tumor adherence to retroperitoneum can be encompassed within a single IORT field (maximum 15 cm).
1724281|NCT00004123|Radiation|Radiation Therapy (RT)|5 days a week for 4 weeks
1724282|NCT00004124|Drug|bicalutamide|
1724283|NCT00004124|Drug|goserelin|
1724284|NCT00004124|Drug|mitoxantrone hydrochloride|
1724285|NCT00004124|Drug|prednisone|
1724286|NCT00004125|Drug|cyclophosphamide|
1724287|NCT00004125|Drug|docetaxel|
1724288|NCT00004125|Drug|doxorubicin hydrochloride|
1724289|NCT00004125|Drug|paclitaxel|
1724290|NCT00004125|Drug|tamoxifen citrate|
1724291|NCT00004125|Radiation|radiation therapy|
1724292|NCT00004126|Drug|oxaliplatin|
1724293|NCT00004126|Drug|paclitaxel|
1724294|NCT00004127|Drug|FOLFOX regimen|
1724295|NCT00004127|Drug|fluorouracil|
1724296|NCT00004127|Drug|leucovorin calcium|
1724297|NCT00004127|Drug|oxaliplatin|
1724298|NCT00004128|Biological|aldesleukin|
1724299|NCT00004128|Biological|filgrastim|
1724300|NCT00004128|Drug|busulfan|
1724301|NCT00004128|Drug|cyclophosphamide|
1724302|NCT00004128|Drug|cytarabine|
1724303|NCT00004128|Drug|daunorubicin hydrochloride|
1724305|NCT00004128|Procedure|autologous bone marrow transplantation|
1724306|NCT00004128|Procedure|peripheral blood stem cell transplantation|
1724307|NCT00004128|Radiation|radiation therapy|
1724308|NCT00004129|Radiation|brachytherapy|
1724309|NCT00004129|Radiation|phosphorus P32|
1724310|NCT00004132|Biological|filgrastim|
1724311|NCT00004132|Biological|palifermin|
1724312|NCT00004132|Drug|cyclophosphamide|
1724313|NCT00004132|Drug|etoposide|
1724314|NCT00004132|Drug|ifosfamide|
1724315|NCT00004132|Procedure|quality-of-life assessment|
1724316|NCT00004132|Radiation|radiation therapy|
1724317|NCT00004135|Biological|filgrastim|
1724318|NCT00004135|Biological|therapeutic allogeneic lymphocytes|
1724319|NCT00004135|Drug|cyclophosphamide|
1724320|NCT00004135|Drug|fludarabine phosphate|
1724321|NCT00004135|Procedure|peripheral blood stem cell transplantation|
1724322|NCT00004136|Procedure|Radiofrequency Ablation|Tumors heated to target temperature by electrodes for maximum of 20 minutes
1724323|NCT00004137|Biological|filgrastim|
1724324|NCT00004137|Drug|carboplatin|
1724325|NCT00004137|Drug|paclitaxel|
1724326|NCT00004137|Drug|topotecan hydrochloride|
1724327|NCT00005005|Drug|PTH|
1724328|NCT00005005|Drug|Alendronate|
1724329|NCT00005006|Drug|Parathyroid Hormone|Alendronate 70mg/week; Teriparatide 20mcg/ day
1724330|NCT00005006|Drug|Alendronate|Alendronate 70mg/week
1724331|NCT00005006|Drug|Teriparatide|Teriparatide 20mcg/day
1724332|NCT00005007|Drug|Etanercept|
1724333|NCT00005009|Biological|Varivax®|Each participant will receive 2 doses of Varivax 6 to 8 weeks apart.
1724334|NCT00005010|Drug|Irbesartan|
1724335|NCT00005010|Drug|Pravastatin|
1724336|NCT00005012|Drug|Peginterferon alfa-2b|
1724337|NCT00005013|Drug|Sertraline|
1724338|NCT00005013|Drug|Hypericum perforatum (St. John's wort)|
1724339|NCT00005014|Drug|Risperidone|
1724340|NCT00005015|Drug|Fluoxetine|
1724341|NCT00005017|Drug|Ritonavir|
1724342|NCT00005017|Drug|Abacavir sulfate|
1724343|NCT00005017|Drug|Amprenavir|
1724344|NCT00005017|Drug|Efavirenz|
1724345|NCT00005017|Drug|Lamivudine|
1724346|NCT00005017|Drug|Stavudine|
1724347|NCT00005018|Drug|Hydroxyurea|
1724348|NCT00005018|Drug|Abacavir sulfate|
1724349|NCT00005018|Drug|Efavirenz|
1724350|NCT00005018|Drug|Didanosine|
1724351|NCT00005021|Biological|filgrastim|
1724352|NCT00005021|Drug|carboplatin|
1724353|NCT00005021|Drug|paclitaxel|
1724354|NCT00005021|Drug|topotecan hydrochloride|
1724355|NCT00005022|Drug|cisplatin|
1724356|NCT00005022|Drug|etoposide|
1724357|NCT00005022|Radiation|radiation therapy|
1724358|NCT00005023|Biological|HER-2/neu peptide vaccine|
1724359|NCT00005023|Biological|sargramostim|
1724360|NCT00005024|Drug|carboplatin|
1724361|NCT00005024|Drug|cyclophosphamide|
1724362|NCT00005024|Drug|doxorubicin hydrochloride|
1724363|NCT00005024|Drug|granisetron hydrochloride|
1724364|NCT00005025|Biological|herpes simplex thymidine kinase|
1724365|NCT00005025|Drug|ganciclovir|
1724366|NCT00005026|Drug|carboplatin|
1724367|NCT00005026|Drug|paclitaxel|
1724368|NCT00005026|Drug|topotecan hydrochloride|
1724369|NCT00005027|Drug|becatecarin|
1724370|NCT00005028|Drug|bryostatin 1|
1724371|NCT00005028|Drug|paclitaxel|
1724372|NCT00005029|Drug|topotecan hydrochloride|
1724373|NCT00005030|Drug|SCH 66336|
1724374|NCT00005030|Procedure|conventional surgery|Exploratory laparotomy and/or resection of hepatic metastases. Patients randomized to no treatment may undergo surgery at any time within 15 days of randomization. Other patients undergo surgery on days 8-15.
1724375|NCT00005031|Drug|irofulven|
1724376|NCT00005032|Biological|oblimersen sodium|
1724377|NCT00005032|Drug|paclitaxel|
1724378|NCT00005059|Drug|carboplatin|
1724379|NCT00005059|Drug|paclitaxel|
1724380|NCT00005060|Drug|Taxotere-Cisplatin-5FU|Preoperatively
1724381|NCT00005060|Drug|Immediate surgery|Immediate surgery followed by Taxotere-Cisplatin-5FU
1724382|NCT00005061|Biological|bevacizumab|
1724383|NCT00005062|Radiation|radiation therapy|
1724384|NCT00005064|Drug|bortezomib|Given IV
1724385|NCT00005065|Drug|paclitaxel|Given IV
1724386|NCT00005065|Drug|carboplatin|Given IV
1724387|NCT00005065|Drug|motexafin gadolinium|Given IV
1724388|NCT00005065|Procedure|conventional surgery|Undergo complete surgical resection
1724389|NCT00005065|Radiation|radiation therapy|Undergo radiation therapy
1724390|NCT00005066|Drug|O6-benzylguanine|
1724391|NCT00005066|Drug|carmustine|
1724392|NCT00005067|Drug|motexafin lutetium|Given IV
1724393|NCT00005067|Drug|photodynamic therapy|Undergo photodynamic therapy
1724394|NCT00005068|Drug|fluorouracil|
1724395|NCT00005068|Drug|irinotecan hydrochloride|
1724396|NCT00005068|Drug|leucovorin calcium|
1724397|NCT00005068|Drug|oxaliplatin|
1724398|NCT00005069|Drug|arsenic trioxide|
1724399|NCT00005070|Drug|irofulven|
1724400|NCT00005071|Procedure|biopsy|
1724401|NCT00005071|Procedure|bronchoscopy|
1724402|NCT00005071|Procedure|computed tomography|
1724403|NCT00005071|Procedure|quality-of-life assessment|
1724404|NCT00005072|Biological|Leuvectin|1000 ug of Leuvectin injected intratumorally
1724405|NCT00005073|Drug|zoledronic acid|
1724406|NCT00005074|Drug|alvocidib|
1724407|NCT00005075|Procedure|high-intensity focused ultrasound ablation|
1724408|NCT00005076|Biological|cetuximab|
1724409|NCT00005076|Drug|irinotecan hydrochloride|
1724410|NCT00005077|Drug|oxaliplatin|
1724414|NCT00005079|Procedure|conventional surgery|
1724415|NCT00005080|Drug|nelarabine|Given IV
1724416|NCT00005081|Drug|O6-benzylguanine|
1724417|NCT00005081|Drug|carmustine|
1724418|NCT00005082|Procedure|biopsy|
1724419|NCT00005082|Procedure|magnetic resonance imaging|
1724420|NCT00005083|Procedure|conventional surgery|
1724421|NCT00005083|Procedure|magnetic resonance imaging|
1724422|NCT00005083|Procedure|magnetic resonance spectroscopic imaging|
1724423|NCT00005084|Procedure|conventional surgery|
1724424|NCT00005084|Procedure|magnetic resonance spectroscopic imaging|
1724425|NCT00005084|Radiation|radiation therapy|
1724426|NCT00005085|Drug|becatecarin|
1724427|NCT00005086|Drug|cisplatin|
1724428|NCT00005086|Drug|docetaxel|
1724429|NCT00005086|Drug|gemcitabine hydrochloride|
1724430|NCT00005086|Drug|methotrexate|
1724431|NCT00005087|Biological|filgrastim|
1724432|NCT00005087|Drug|cisplatin|
1724433|NCT00005087|Drug|paclitaxel|
1724434|NCT00005087|Procedure|conventional surgery|
1724435|NCT00005087|Radiation|radiation therapy|
1724436|NCT00005088|Drug|cisplatin|
1724437|NCT00005088|Radiation|radiation therapy|
1724438|NCT00005089|Biological|rituximab|375 mg/m^2 on days 1,8 of cycle 1, then on days 1-3 of cycles 2-3.
1724439|NCT00005089|Drug|cyclophosphamide|750 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
1724440|NCT00005089|Drug|doxorubicin hydrochloride|50 mg/m^2 on day 10 of cycle 1, then on day 21 of cycles 2-3.
1724441|NCT00005089|Drug|prednisone|100 mg on days 10-14 of cycle 1, then on days 3-7 of cycles 2-3.
1724442|NCT00005089|Drug|vincristine sulfate|1.4 mg/m^2 on day 10 of cycle 1, then on day 3 of cycles 2-3.
1724443|NCT00005089|Radiation|radiation therapy|4000-5500 cGy given in 25 fractions starting 3 weeks after completion of CHOP + Rituximab.
1724444|NCT00005090|Biological|bleomycin sulfate|10 U/m^2 given on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
1724445|NCT00005090|Drug|carmustine|150/m^2 on days -6 to -4 (4-6 days before transplant).
1724446|NCT00005090|Drug|cyclophosphamide|100 mg/kg on day -2 (2 days before transplant).
1724447|NCT00005090|Drug|dacarbazine|375 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
1724448|NCT00005090|Drug|doxorubicin hydrochloride|25 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
1724449|NCT00005090|Drug|etoposide|60 mg/kg on day -4 (4 days before transplant).
1724450|NCT00005090|Drug|vinblastine|6 mg/m^2 on days 1 and 15 for 5 28-day cycles of ABVD. Patients with no disease progression are then randomized to either 3 more cycles of ABVD or 1 more cycle of ABVD + high-dose therapy + stem cell transplant.
1724451|NCT00005090|Procedure|peripheral blood stem cell transplantation|2 x 10^6 CD34+ blood mononuclear cells/kg of actual body weight
1724452|NCT00005091|Drug|exatecan mesylate|
1724453|NCT00005092|Drug|Cyclophosphamide|IV over 2 hours on days 2 and 3
1724454|NCT00005092|Drug|Psoralen|Psoralen treated T-cell allogeneic transplant on day 9
1724455|NCT00005092|Drug|Thiotepa|IV over 2 hours on day 1
1724456|NCT00005092|Procedure|Allogeneic bone marrow transplantation|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
1724457|NCT00005092|Procedure|In vitro-treated peripheral blood stem cell transplantation (PBSCT)|Preserved stem cell or bone marrow allogeneic transplant plus psoralen treated T-cell allogeneic transplant on day 9
1724458|NCT00005092|Radiation|Radiation Therapy (RT)|Whole body radiotherapy on days 5-8.
1724459|NCT00005093|Drug|gemcitabine hydrochloride|
1724460|NCT00005093|Drug|tacedinaline|
1724461|NCT00005094|Drug|celecoxib|Given orally
1724462|NCT00005094|Other|placebo|Given orally
1724463|NCT00005095|Other|laboratory biomarker analysis|Subject's blood collected at their follow-up blood draw will be assessed for biomarkers that could lead to a panel for detecting early stage ovarian cancer.
1724464|NCT00005095|Other|screening questionnaire administration|Questionnaires designed to assess quality of life for women at increased risk of ovarian cancer will be administered to the subjects. Clinical data will also be collected.
1724465|NCT00005095|Procedure|study of high risk factors|Subjects will be assessed for high risk factors.
1724466|NCT00005096|Drug|docetaxel|
1724467|NCT00005097|Drug|Polyphenon E and Placebo|Areas of sun damaged skin with actinic keratoses to be treated will be mapped and photographed on patient's bilateral arms. One of the patient's arms will be assigned to be treated with topical Polyphenon E, the patient's other arm with placebo vehicle in a random, double blind manner. The patient's arm treatment areas will receive daily applications of a premeasured amount of drug or placebo. Patients will be seen every other week for 12 weeks to check for effects of the applications and monitor for compliance or possible side effects.
1724468|NCT00005104|Drug|clomiphene citrate|
1724469|NCT00005104|Drug|metformin|
1724470|NCT00005106|Drug|Lamivudine/Zidovudine|
1724471|NCT00005106|Drug|Abacavir sulfate|
1724472|NCT00005106|Drug|Nelfinavir mesylate|
1724473|NCT00005106|Drug|Lamivudine|
1724474|NCT00005106|Drug|Stavudine|
1724475|NCT00005107|Drug|N-monomethyl-L-arginine|
1724476|NCT00005108|Drug|Estradiol|
1724477|NCT00005108|Drug|Progesterone|
1724478|NCT00005110|Drug|Salmeterol|
1724479|NCT00005110|Drug|Albuterol|
1724480|NCT00005112|Drug|Human recombinant growth hormone|
1724481|NCT00005113|Drug|Cyclosporine|Oral tablet taken daily. Dosage is dependent on weight and is titrated to target trough level.
1724482|NCT00005113|Drug|Sirolimus|Dosage in liquid or tablet form is dependent on body surface area and is titrated to target trough level.
1724483|NCT00005113|Drug|Tacrolimus|dosage is in oral form titrated to target trough level
1724484|NCT00005116|Behavioral|psychotherapy|
1724485|NCT00005117|Drug|pravastatin|
1724486|NCT00005118|Drug|Indinavir sulfate|
1724487|NCT00005118|Drug|Ritonavir|
1724488|NCT00005119|Procedure|Measures of calcium and bone turnover|
1724489|NCT00005120|Drug|Calanolide A|
1724490|NCT00005137|Other|exercise program|subjects were measured before and after a 20-week long on-site exercise training program
1724491|NCT00005195|Procedure|Catheter ablation|
1724494|NCT00004419|Drug|insulin-like growth factor I|
1724495|NCT00004420|Drug|gamma-Linolenic acid|
1724496|NCT00004421|Device|implanted pulse generator|
1724497|NCT00004422|Drug|immune globulin|
1724498|NCT00004423|Drug|-aminosalicylic acid|
1724499|NCT00004424|Drug|fentanyl|
1724500|NCT00004424|Drug|Midazolam|
1724501|NCT00004424|Drug|propofol|
1724502|NCT00004426|Drug|gonadotropin releasing hormone|
1724503|NCT00004426|Drug|leuprolide|
1724504|NCT00004428|Drug|CPX|
1724505|NCT00004429|Drug|growth hormone|
1724506|NCT00004430|Drug|Dihematoporphyrin derivative|
1724507|NCT00004430|Drug|prednisolone|
1724508|NCT00004430|Procedure|Laser surgery|
1724509|NCT00004431|Drug|L-baclofen|
1724510|NCT00004433|Drug|pergolide|
1724511|NCT00004436|Drug|leuprolide|
1724512|NCT00004436|Drug|prednisone|
1724513|NCT00004437|Device|Multichannel Auditory Brain Stem Implant|
1724514|NCT00004438|Drug|leuprolide|
1724515|NCT00004440|Drug|ibuprofen|
1724516|NCT00004441|Drug|tauroursodeoxycholic acid|
1724517|NCT00004441|Drug|ursodiol|
1724518|NCT00004442|Drug|chenodeoxycholic acid|
1724519|NCT00004442|Drug|cholic acid|
1724520|NCT00004442|Drug|ursodiol|
1724521|NCT00004443|Drug|NTBC|
1724522|NCT00004444|Drug|paromomycin|
1724523|NCT00004444|Drug|streptomycin|
1724524|NCT00004445|Procedure|Surgery|
1724525|NCT00004445|Device|IRS-8|
1724526|NCT00004446|Drug|fluoxetine|
1724527|NCT00004448|Drug|omega-3 fatty acids|
1724528|NCT00004448|Drug|prednisone|
1724529|NCT00004449|Behavioral|intensive one-on-one behavioral treatment|Up to 40 hours per week of one-to-one intervention based on applied behavior analysis
1724530|NCT00004449|Behavioral|Individualized in home parent training|Offered to subjects at some sites, involved 3+ months of individualized training for parents on applied behavior analysis intervention
1724531|NCT00004450|Drug|glyceryl trierucate|
1724532|NCT00004450|Drug|glyceryl trioleate|
1724533|NCT00004450|Drug|interferon beta|
1724534|NCT00004450|Drug|thalidomide|
1724535|NCT00004451|Drug|Glucose|
1724536|NCT00004454|Genetic|lymphocyte gene therapy|
1724537|NCT00004464|Drug|cyclophosphamide|
1724538|NCT00004464|Drug|filgrastim|
1724539|NCT00004465|Drug|SYNSORB Pk|
1724540|NCT00004465|Drug|Placebo|
1724541|NCT00004466|Drug|Atorvastatin|
1724542|NCT00004466|Drug|Placebo|
1724544|NCT00004468|Drug|calcitriol|
1724545|NCT00004471|Genetic|pGT-1 gene lipid complex|
1724546|NCT00004474|Drug|Anti-thymocyte globulin|Given via IV over 4 hours
1724547|NCT00004474|Drug|Cyclophosphamide|Given via IV over 60 minutes on Days -5 to -2
1724548|NCT00004474|Procedure|Bone marrow transplantation|Given on Day 0
1724549|NCT00004475|Procedure|genetic testing|
1724550|NCT00004478|Drug|droxidopa|
1724551|NCT00004479|Drug|midodrine|
1724552|NCT00004480|Drug|botulinum toxin type A|
1724553|NCT00004481|Procedure|genetic testing|
1724554|NCT00004482|Drug|Cyclosporine|
1724555|NCT00004482|Drug|methylprednisolone|
1724556|NCT00004482|Drug|Muromonab-CD3|
1724557|NCT00004482|Drug|prednisone|
1724558|NCT00004485|Drug|cyclosporine|
1724559|NCT00004485|Drug|fludarabine|
1724560|NCT00004485|Drug|mycophenolate mofetil|
1724561|NCT00004485|Procedure|Bone Marrow Transplantation|
1724562|NCT00004486|Drug|fluoxetine|
1724563|NCT00004487|Drug|chondrocyte-alginate gel suspension|
1724564|NCT00004488|Drug|alendronate sodium|
1724565|NCT00004488|Drug|calcium carbonate|
1724566|NCT00004488|Drug|cholecalciferol|
1724567|NCT00004489|Drug|alendronate sodium|
1724568|NCT00004489|Drug|calcium carbonate|
1724569|NCT00004489|Drug|cholecalciferol|
1724570|NCT00004490|Drug|sodium dichloroacetate|
1724571|NCT00004492|Drug|clotrimazole|
1724572|NCT00004492|Drug|hydroxyurea|
1724573|NCT00004493|Drug|sodium dichloroacetate|
1724574|NCT00004494|Drug|vasoactive intestinal peptide|
1724575|NCT00004495|Drug|cyanocobalamin|
1724576|NCT00004495|Drug|folic acid|
1724577|NCT00004495|Drug|pyridoxine|
1724578|NCT00004496|Drug|alpha-melanocyte stimulating hormone|
1724579|NCT00004497|Drug|UT-15|
1724580|NCT00004498|Genetic|Adenoviral Vector-Mediated Gene Transfer|
1724581|NCT00004500|Drug|Lucinactant|Lucinactant suspension was administered as 10 mg total phospholipid (TPL)/mL, by bronchoalveolar lavage within 90 minutes of randomization. The dose was determined based on the infant's body weight such that the total dose was 16 mL/kg for each of the 2 lavage procedures and 32 mL/kg overall. Infants received 2 doses of lucinactant. Each dose consisted of separate lavage procedures for each lung within 15 minutes (up to 60 minutes) of each other.
1724662|NCT00004660|Radiation|Sham treatment|
1724663|NCT00004662|Drug|dehydroepiandrosterone|
1724664|NCT00004664|Drug|megestrol|
1724582|NCT00004500|Other|Standard Care|The Standard Care (SC) group received therapies including, but not limited to, the use of oxygen, controlled mechanical ventilation (CMV), sedation, paralysis, vasopressors, and/or alkalinization. The use of adjunctive therapies (namely: high frequency oscillatory ventilation, high frequency jet ventilation, bolus surfactant, inhaled nitric oxide, extra-corporeal membrane oxygenation, or systemic corticosteroids) were not included in SC
1724583|NCT00004533|Drug|Adeno-associated virus-CFTR vector|
1724584|NCT00004547|Procedure|Surgery|Patients will undergo cytoreductive surgery to remove as much tumor as possible. Part of the intestines, pancreas, stomach or the entire spleen may also be removed if they are affected.
1724585|NCT00004547|Procedure|Continuous hyperthermic peritoneal perfusion (CHPP) with Cisplatin|
1724586|NCT00004547|Drug|Postoperative dwell with paclitaxel and 5-FU|Intraperitoneal dwell chemotherapy with a combination of 5-FU and Paclitaxel will be delivered in the early postoperative period (day 7 today 12 after surgery). Patients will be premedicated with hydrocortisone (100 mg/intravenous push (i.v.p.)), diphenhydramine (50 mg i.v.p.) and ranitidine (50 mg i.v.p.) 30 minutes prior to delivering intraperitoneal chemotherapy. One liter of normal saline will be infused containing 5-FU (800 mg/M^2) and 1 L of normal saline containing paclitaxel (125 mg/M^2) will be infused over 60 minutes. The chemotherapy solution will be left in the abdominal cavity permanently for slow absorption.
1724587|NCT00004549|Procedure|Magnetic resonance imaging|
1724588|NCT00004551|Drug|nicotine replacement patch|
1724589|NCT00004551|Behavioral|mood management|
1724590|NCT00004552|Drug|acamprosate (Campral)|
1724591|NCT00004553|Procedure|Electromyography|
1724592|NCT00004554|Drug|naltrexone (Revia)|100mg/day
1724593|NCT00004554|Drug|sertraline (Zoloft)|200mg/day
1724594|NCT00004554|Drug|Placebo|Placebo
1724595|NCT00004558|Behavioral|dietary n-3 polyunsaturated fatty acids|
1724596|NCT00004559|Behavioral|dietary polyunsaturated fatty acid|
1724597|NCT00004560|Device|defibrillator|
1724598|NCT00004561|Behavioral|exercise|
1724599|NCT00004562|Drug|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
1724600|NCT00004562|Drug|Platelet inhibitors|Participants will receive platelet inhibitors.
1724601|NCT00004562|Procedure|PTCA and stents|Participants will undergo percutaneous coronary intervention (PTCA) and coronary stenting.
1724602|NCT00004562|Drug|ACE Inhibitors|Participants will receive ACE inhibitors.
1724603|NCT00004563|Drug|Cyclophosphamide|Cyclophosphamide (Cytoxan, Bristol-Myers Squibb) was initiated with a dose of 1 mg per kilogram of body weight per day (to the nearest 25 mg). The doses were increased monthly by one capsule up to 2 mg per kilogram.
1724604|NCT00004563|Drug|Placebo|Matching gelcaps 25 mgs
1724605|NCT00004564|Drug|Clopidogrel|
1724606|NCT00004564|Drug|Atorvastatin|
1724607|NCT00004567|Drug|Mycophenolate Mofetil|
1724608|NCT00004569|Procedure|Non-invasive technique to diagnose and quantitate sleep-disordered breathing|
1724609|NCT00004572|Procedure|Sustacal challenge|
1724610|NCT00004573|Drug|ganciclovir|
1724611|NCT00004575|Drug|Miconazole, L-NMMA, Bradykinin|
1724612|NCT00004576|Drug|LY300164|
1724613|NCT00004578|Drug|Lopinavir/Ritonavir|Lopinavir, range from 200 mg to 400 mg, every 12 hrs and Ritonavir, range from 100 mg to 200 mg, every 12 hrs
1724614|NCT00004578|Drug|Lamivudine|150 mg, every 12 hours
1724615|NCT00004578|Drug|Stavudine|40 mg every 12 hours
1724616|NCT00004579|Biological|gp160 MN/LAI-2|
1724617|NCT00004579|Biological|ALVAC-HIV MN120TMG (vCP205)|
1724618|NCT00004580|Drug|Lopinavir/Ritonavir|
1724619|NCT00004580|Drug|Nevirapine|
1724620|NCT00004581|Drug|Lopinavir/Ritonavir|
1724621|NCT00004581|Drug|Nevirapine|
1724622|NCT00004582|Drug|Lopinavir/Ritonavir|
1724623|NCT00004582|Drug|Efavirenz|
1724624|NCT00004583|Drug|Lopinavir/Ritonavir|
1724625|NCT00004583|Drug|Nelfinavir mesylate|
1724626|NCT00004583|Drug|Lamivudine|
1724627|NCT00004583|Drug|Stavudine|
1724628|NCT00004584|Drug|Atazanavir|
1724629|NCT00004584|Drug|Ritonavir|
1724630|NCT00004584|Drug|Saquinavir|
1724631|NCT00004585|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
1724632|NCT00004585|Drug|Lamivudine/Zidovudine|
1724633|NCT00004585|Drug|Abacavir sulfate|
1724634|NCT00004585|Drug|Efavirenz|
1724635|NCT00004604|Biological|CEA RNA-pulsed DC cancer vaccine|carcinoembryonic antigen RNA-pulsed dendritic cells
1724636|NCT00004635|Drug|Thalidomide|Thalidomide 200 mg given orally every evening at 9pm. Treatment may continue indefinitely provided that there are no dose-limiting toxicity.
1724637|NCT00004635|Drug|leuprolide acetate|Injections of leuprolide once a month for six months.
1724638|NCT00004635|Drug|goserelin|Injections of Goserelin once a month for six months.
1724639|NCT00004635|Other|Placebo|Patients will receive the placebo if they initially received thalidomide. The starting dose of placebo 200 mg (four capsules of 100-50 mg capsules) orally once daily at bedtime.
1724640|NCT00004637|Drug|Vitamin E|
1724641|NCT00004638|Procedure|pathogenesis study|
1724642|NCT00004639|Procedure|Furlow double z-plasty palatoplasty palate repair|
1724643|NCT00004639|Procedure|Von Langenbeck palatoplasty palate repair|
1724644|NCT00004640|Drug|Chlorhexidine rinse|chlorhexidine solution on tooth loss in low income
1724645|NCT00004642|Drug|SDZ MSL-109|
1724646|NCT00004643|Drug|cytarabine|
1724647|NCT00004644|Drug|acyclovir|
1724648|NCT00004645|Procedure|Plasma exchange|
1724649|NCT00004646|Drug|prednisone|
1724650|NCT00004647|Drug|mexiletine|
1724651|NCT00004650|Drug|conjugated estrogens|
1724652|NCT00004650|Drug|Medroxyprogesterone|
1724653|NCT00004652|Drug|pimozide|
1724654|NCT00004654|Drug|soy protein isolate|
1724655|NCT00004656|Procedure|Metabolic assessment with body composition evaluation|
1724656|NCT00004658|Drug|ribose|
1724657|NCT00004658|Drug|thymidine|
1724658|NCT00004658|Drug|uridine|
1724666|NCT00004665|Drug|dehydroepiandrosterone|
1724667|NCT00004667|Drug|von Willebrand factor|
1724668|NCT00004669|Drug|hydrocortisone|
1724669|NCT00004670|Procedure|pallidotomy|
1724670|NCT00004682|Drug|immune globulin|
1724671|NCT00004685|Drug|albuterol|
1724672|NCT00004686|Drug|methotrexate|
1724673|NCT00004686|Drug|prednisone|
1724674|NCT00004688|Drug|carmustine|
1724675|NCT00004688|Drug|mercaptopurine|
1724676|NCT00004688|Drug|streptozocin|
1724677|NCT00004689|Drug|amithiozone|
1724678|NCT00004689|Drug|clarithromycin|
1724679|NCT00004689|Drug|ethambutol|
1724680|NCT00004689|Drug|rifampin|
1724681|NCT00004689|Drug|streptomycin|
1724682|NCT00004690|Drug|monolaurin cream|
1724683|NCT00004694|Drug|heparin|
1724684|NCT00004695|Drug|PEG-interleukin-2|
1724685|NCT00004696|Drug|morphine|
1724686|NCT00004697|Drug|choline chloride|
1724687|NCT00004699|Drug|insulin-like growth factor I|
1724688|NCT00004700|Drug|insulin-like growth factor I|
1724689|NCT00004705|Drug|amiloride|
1724690|NCT00004705|Drug|uridine|
1724691|NCT00004727|Drug|aspirin|
1724692|NCT00004727|Drug|ticlopidine|
1724693|NCT00004728|Drug|Warfarin|
1724694|NCT00004728|Drug|Aspirin|
1724695|NCT00004729|Behavioral|Ketogenic diet|
1724696|NCT00004730|Drug|magnesium sulfate|
1724697|NCT00004731|Drug|Coenzyme Q10|
1724698|NCT00004732|Procedure|Carotid Endarterectomy (CEA)|CEA involves a neck incision and physical removal of the plaque from the inside of the carotid artery.
1724699|NCT00004732|Device|Carotid Artery Stenting (CAS)|CAS involves insertion of a catheter or tube into an artery in the groin and then threading the catheter through the arteries of the body to the location of the plaque within the carotid artery in the neck. A stent is then placed to cover the plaque and hold the artery open. Participants randomized to this arm of the trial were treated using the RX Acculink Carotid Stent with or without the RX Accunet Embolic Protection Device.
1724700|NCT00004733|Drug|levodopa|
1724701|NCT00004734|Drug|pyridoxine|
1724702|NCT00004734|Drug|cyanocobalamin|
1724703|NCT00004734|Drug|folic acid multivitamin|
1724704|NCT00004735|Biological|Tetanus toxoid|
1724705|NCT00004735|Biological|Hepatitis A Vaccine (Inactivated)|
1724706|NCT00005520|Drug|Hydrochlorothiazide|
1724707|NCT00005520|Drug|Candesartan|
1724708|NCT00005553|Procedure|Catheter Ablation|
1724709|NCT00005555|Behavioral|Exercise|
1724710|NCT00005566|Behavioral|Desperation Scale|
1724711|NCT00005567|Behavioral|Parental knowledge and beliefs about infant sleep position|
1724712|NCT00005569|Drug|SLPI (Secretory Leukocyte Protease Inhibitor)|
1724713|NCT00005571|Drug|h5G1.1-mAb|
1724714|NCT00005574|Drug|Gentamicin|
1724715|NCT00005575|Drug|Imipramine|
1724716|NCT00005575|Behavioral|Cognitive-behavior therapy|
1724717|NCT00005576|Biological|monoclonal antibody Ch14.18|Given IV
1724718|NCT00005576|Drug|isotretinoin|Given orally
1724719|NCT00005576|Biological|aldesleukin|Given IV
1724720|NCT00005576|Biological|sargramostim|Given IV
1724721|NCT00005577|Drug|gemcitabine hydrochloride|
1724722|NCT00005578|Biological|bleomycin sulfate|
1724723|NCT00005578|Biological|filgrastim|
1724724|NCT00005578|Drug|cyclophosphamide|
1724725|NCT00005578|Drug|dexrazoxane hydrochloride|
1724726|NCT00005578|Drug|doxorubicin hydrochloride|
1724727|NCT00005578|Drug|etoposide|
1724728|NCT00005578|Drug|prednisone|
1724729|NCT00005578|Drug|vincristine sulfate|
1724730|NCT00005578|Radiation|radiation therapy|
1724731|NCT00005579|Drug|dolastatin 10|
1724732|NCT00005580|Drug|bryostatin 1|
1724733|NCT00005580|Drug|fludarabine phosphate|
1724734|NCT00005581|Drug|cyclophosphamide|
1724735|NCT00005581|Drug|epirubicin hydrochloride|
1724736|NCT00005581|Drug|fluorouracil|
1724737|NCT00005581|Drug|paclitaxel|
1724738|NCT00005583|Drug|cisplatin|
1724739|NCT00005583|Drug|doxorubicin hydrochloride|
1724740|NCT00005583|Drug|epirubicin hydrochloride|
1724741|NCT00005583|Procedure|adjuvant therapy|
1724742|NCT00005583|Procedure|conventional surgery|
1724743|NCT00005583|Radiation|radiation therapy|
1724744|NCT00005584|Biological|bleomycin sulfate|
1724745|NCT00005584|Drug|ABVD regimen|
1724746|NCT00005584|Drug|BEACOPP regimen|
1724747|NCT00005584|Drug|epirubicin hydrochloride|
1724748|NCT00005584|Drug|prednisone|
1724749|NCT00005584|Drug|vinblastine sulfate|
1724750|NCT00005584|Radiation|radiation therapy|
1724751|NCT00005585|Drug|cyclophosphamide|Given IV
1724752|NCT00005585|Drug|cytarabine|Deoxycytidine analogue which is metabolized to ARA-CTP, a substance which inhibits DNA polymerase.
1724753|NCT00005585|Drug|daunorubicin hydrochloride|Given IV
1724754|NCT00005585|Drug|dexamethasone|Dexamethasone is a synthetic fluorinated glucocorticoid devoid of mineralocorticoid effects.
1724755|NCT00005585|Drug|leucovorin calcium|Synthetic d,l-5 CHO tetrahydrofolate, which is used to bypass the inhibition of dihydrofolate reductase by Methotrexate (MTX)
1724756|NCT00005585|Drug|mercaptopurine|An analogue of the nucleic acid constituent adenine and the physiological purine base hypoxanthine
1724757|NCT00005585|Drug|methotrexate|A folate analogue which inhibits the enzyme dihydrofolate reductase, haltin g DNA, RNA, and protein synthesis
1724758|NCT00005585|Drug|pegaspargase|E-Coli asparaginase deaminates asparagine, thus, is lethal for cells which cannot synthesize asparagine.
1724759|NCT00005585|Drug|thioguanine|Given orally
1724760|NCT00005585|Drug|vincristine sulfate|Given IV
1724761|NCT00005586|Drug|L-leucovorin|
1724762|NCT00005586|Drug|fluorouracil|
1724763|NCT00005586|Procedure|adjuvant therapy|
1724764|NCT00005587|Radiation|radiation therapy|
1724765|NCT00005588|Radiation|radiation therapy|
1724766|NCT00005589|Biological|filgrastim|
1724767|NCT00005589|Biological|rituximab|
1724768|NCT00005589|Drug|carmustine|
1724769|NCT00005589|Drug|cyclophosphamide|
1724770|NCT00005589|Drug|cytarabine|
1724771|NCT00005589|Drug|etoposide|
1724772|NCT00005589|Drug|melphalan|
1724773|NCT00005589|Procedure|bone marrow ablation with stem cell support|
1724774|NCT00005589|Procedure|peripheral blood stem cell transplantation|
1724775|NCT00005590|Drug|levofloxacin|
1724776|NCT00005591|Biological|cetuximab|
1724777|NCT00005591|Drug|gemcitabine hydrochloride|
1724778|NCT00005592|Biological|90-Y-ibritumomab tiuxetan|IDEC-Y2B8 is a mouse monoclonal antibody with small particles of radioactivity that join to the CD20 antigens on lymphoma cells. It is used to deliver radiation therapy to kill lymphoma cells. This is a one time intravenous infusion for eligible patients and is given over a ten-minute time period.
1724779|NCT00005592|Biological|rituximab|Rituxan is a mouse/human monoclonal antibody and reacts with the CD20 antigens found on lymphoma cells and causes the body's immune system to destroy the lymphoma cells. It is infused at a dose of 250 mg/m2 followed by a second infusion approximately one week later of the same dose.
1724780|NCT00005592|Radiation|indium In 111 ibritumomab tiuxetan|IDEC-In2B8 is a mouse monoclonal antibody that contains Indium, routinely used in nuclear medicine. It is given as a one-time intravenous injection over a ten-minute time period immediately following a Rituxan infusion. The physician will then be able to see and evaluate the location and concentration of the antibody in the body.
1724781|NCT00005593|Drug|carboplatin|Patients receive carboplatin IV continuously over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
1724782|NCT00005593|Drug|fludarabine phosphate|Patients receive fludarabine IV over 30 minutes on days 1-5. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
1724783|NCT00005593|Drug|topotecan hydrochloride|This is a dose escalation study of topotecan. Patients receive topotecan IV continuously on days 6-8. Patients with residual leukemia in the bone marrow at day 15 may receive a second induction course. Patients who achieve partial or complete remission after 1-2 induction courses receive 1 consolidation course of fludarabine, carboplatin, and topotecan beginning 4-8 weeks after recovery from induction therapy.
1724784|NCT00005594|Drug|ISIS 2503|Beginning dosage of ISIS 2503 is 6 mg/kg/day given as a continuous i.v. infusion over the first 14 days of a 21-day treatment cycle. This will be repeated for the first two weeks of every three-week treatment cycle.
1724785|NCT00005595|Drug|arsenic trioxide|
1724786|NCT00005596|Drug|cyclophosphamide|
1724787|NCT00005596|Drug|cytarabine|
1724788|NCT00005596|Drug|daunorubicin hydrochloride|30 mg/m2 IV Day 1 of weeks 16, 17, and 18. Give Week 16 dose if ANC ≥ 500/μL and platelets ≥ 75,000/μL. Continue to give during Weeks 17 and 18, even in the face of uncomplicated myelosuppression
1724789|NCT00005596|Drug|dexamethasone|6 mg/m2/day divided BID for 7 days during weeks 8 and 17.
1724790|NCT00005596|Drug|leucovorin calcium|5 mg/m2/dose of leucovorin will be given PO q12h x 2 doses beginning 48 hours after the start of the MTX.
1724791|NCT00005596|Drug|mercaptopurine|50 mg/m2 dose po qhs Weeks 5 through 13 (total 9 wks) and from Week 24 until the end of consolidation. Only hold for uncomplicated myelosuppression, only if IV MTX course is delayed, until ANC > 500/μL and platelets > 75,000/uL
1724792|NCT00005596|Drug|methotrexate|"IV: 1 gm/m2 given as a 200 mg/m2 bolus over 20 min followed by 800 mg/m2 over 23.6 hours given during Weeks 7, 10, 13, 16, 19, and 22.
IT: Doses by age, Weeks 7, 10, 13, 16, 19 and 22."
1724793|NCT00005596|Drug|pegaspargase|2,500 IU/m2 will be given IM x 1 on Days 2,3,or 4 of Week 16; > or = 1 day after the IT MTX
1724794|NCT00005596|Drug|thioguanine|60 mg/m2 po qhs during Weeks 20 and 21 (total 14 days). Start week 20 when ANC > or = 500/ul and platelets > or = 75,000/uL. Continue to give all 14 doses despite uncomplicated myelosuppression.
1724795|NCT00005596|Drug|vincristine sulfate|1.5 mg/m2 IV on Day 1 of Weeks 8, 9, 17 and 18 (max 2 mg)
1724796|NCT00005597|Drug|temozolomide|200 mg/m^2/day, PO, on Days 1-5 of each 28 day cycle.
1724797|NCT00005598|Drug|amifostine trihydrate|
1724798|NCT00005598|Drug|azacitidine|
1724799|NCT00005599|Drug|bryostatin 1|
1724800|NCT00005599|Drug|paclitaxel|
1724801|NCT00005600|Procedure|management of therapy complications|
1724802|NCT00005601|Biological|rituximab|
1724803|NCT00005601|Drug|cisplatin|
1724804|NCT00005601|Drug|cytarabine|
1724805|NCT00005601|Drug|dexamethasone|
1724806|NCT00005601|Drug|sargramostim|
1724807|NCT00005033|Biological|trastuzumab|
1724808|NCT00005033|Procedure|conventional surgery|
1724809|NCT00005035|Drug|oxaliplatin|
1724810|NCT00005036|Drug|irinotecan hydrochloride|Given IV
1724811|NCT00005036|Drug|oxaliplatin|Given IV
1724812|NCT00005036|Drug|leucovorin calcium|Given IV
1724813|NCT00005036|Drug|fluorouracil|Given IV
1724814|NCT00005036|Procedure|quality-of-life assessment|Ancillary studies
1724815|NCT00005037|Drug|temozolomide|
1724816|NCT00005037|Drug|Temozolomide|Temozolomide capsule once a day for 42 days every 10 weeks.
1724817|NCT00005038|Biological|aldesleukin|
1724818|NCT00005038|Drug|histamine dihydrochloride|
1724819|NCT00005039|Biological|recombinant fowlpox-prostate specific antigen vaccine|Given IM
1724820|NCT00005039|Biological|recombinant vaccinia prostate-specific antigen vaccine|Given intradermally
1724821|NCT00005039|Other|laboratory biomarker analysis|Correlative studies
1724822|NCT00005040|Drug|arsenic trioxide|
1724823|NCT00005041|Drug|tipifarnib|
1724824|NCT00005042|Drug|semaxanib|
1724830|NCT00005045|Drug|carboxyamidotriazole|
1724831|NCT00005046|Drug|chemotherapy|
1724832|NCT00005046|Drug|paclitaxel|
1724833|NCT00005047|Drug|cisplatin|
1724834|NCT00005047|Drug|doxorubicin hydrochloride|
1724835|NCT00005047|Drug|methotrexate|
1724836|NCT00005047|Drug|vinblastine|
1724837|NCT00005048|Drug|estramustine phosphate sodium|
1724838|NCT00005048|Drug|paclitaxel|
1724839|NCT00005049|Drug|carboplatin|
1724840|NCT00005049|Drug|cisplatin|
1724841|NCT00005049|Drug|floxuridine|
1724842|NCT00005050|Drug|ethynyluracil|
1724843|NCT00005050|Drug|fluorouracil|
1724844|NCT00005050|Drug|oxaliplatin|
1724845|NCT00005051|Drug|carboplatin|
1724846|NCT00005051|Drug|cisplatin|
1724847|NCT00005051|Drug|paclitaxel|
1724848|NCT00005051|Drug|topotecan hydrochloride|
1724849|NCT00005052|Biological|GM2-KLH vaccine|
1724850|NCT00005052|Biological|QS21|
1724851|NCT00005052|Procedure|adjuvant therapy|
1724852|NCT00005053|Drug|glufosfamide|
1724853|NCT00005054|Drug|temozolomide|
1724854|NCT00005055|Drug|glufosfamide|
1724855|NCT00005056|Drug|bryostatin 1|
1724856|NCT00005057|Biological|adenovirus RSV-TK|
1724857|NCT00005057|Drug|ganciclovir|
1724858|NCT00005058|Procedure|ultrasound imaging|
1724859|NCT00005602|Drug|carboplatin|
1724860|NCT00005602|Drug|cereport|
1724861|NCT00005602|Radiation|radiation therapy|
1724862|NCT00005603|Drug|asparaginase|
1724863|NCT00005603|Drug|cyclophosphamide|
1724864|NCT00005603|Drug|cytarabine|
1724865|NCT00005603|Drug|daunorubicin hydrochloride|
1724866|NCT00005603|Drug|dexamethasone|
1724867|NCT00005603|Drug|doxorubicin hydrochloride|
1724868|NCT00005603|Drug|mercaptopurine|
1724869|NCT00005603|Drug|methotrexate|
1724870|NCT00005603|Drug|prednisone|
1724871|NCT00005603|Drug|thioguanine|
1724872|NCT00005603|Drug|vincristine sulfate|
1724873|NCT00005604|Biological|recombinant interleukin-12|Given IV
1724874|NCT00005604|Biological|aldesleukin|Given SC
1724875|NCT00005604|Other|laboratory biomarker analysis|Correlative studies
1724876|NCT00005606|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
1724877|NCT00005606|Biological|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
1724878|NCT00005607|Drug|FOLFIRI regimen|
1724879|NCT00005607|Drug|fluorouracil|
1724880|NCT00005607|Drug|irinotecan hydrochloride|
1724881|NCT00005607|Drug|leucovorin calcium|
1724882|NCT00005608|Drug|leucovorin calcium|
1724883|NCT00005608|Drug|tegafur-uracil|
1724884|NCT00005609|Biological|rituximab|
1724885|NCT00005610|Biological|sargramostim|
1724886|NCT00005611|Drug|BMS-188797|
1724887|NCT00005612|Biological|filgrastim|
1724888|NCT00005612|Drug|carboplatin|
1724889|NCT00005612|Drug|cyclophosphamide|
1724890|NCT00005612|Drug|etoposide|
1724891|NCT00005612|Drug|paclitaxel|
1724892|NCT00005612|Drug|topotecan hydrochloride|
1724893|NCT00005612|Procedure|peripheral blood stem cell transplantation|
1724894|NCT00005613|Drug|cyclophosphamide|Cyclophosphamide will be given at a dose of 1500 mg/m2/day IV over 1.0 hour on days -6, -5, -4, and -3.
1724895|NCT00005613|Drug|etoposide|Etoposide will be given at a dose of 600 mg/m2/day over 3.0 hours on days -6, -5, and -4.
1724896|NCT00005613|Drug|BCNU|BCNU will be given at a dose of 150 mg/m2/day in 500 cc D5W over 3.0 hours on days -6, -5, and -4
1724897|NCT00005614|Drug|Gemcitabine hydrochloride|Gemcitabine via IV
1724898|NCT00005615|Biological|Interferon alfa|Interferon alfa as outlined in treatment arm.
1724899|NCT00005615|Radiation|Radiation therapy|Radiation therapy as outlined in treatment arm.
1724900|NCT00005616|Procedure|conventional surgery|
1724901|NCT00005616|Procedure|neoadjuvant therapy|
1724902|NCT00005616|Procedure|radionuclide imaging|
1724903|NCT00005616|Radiation|iodine I 131 monoclonal antibody F19|
1724904|NCT00005617|Biological|dendritic cell-MART-1 peptide vaccine|Number DC: dependent on the group route of immunization: dependent on the group subjects will receive 3 biweekly vaccinations. In case of grade III-IV toxicity in 1/3 subjects at any dose group or route, up to 6 subjects will be included in that group.
1724905|NCT00005617|Procedure|leukapheresis|Patients require a single leukapheresis to obtain 2x10^9 PBL, which are cryopreserved in RPMI 1640, 20% autologous serum, 10% DMSO. Aliquots are thawed at days -7, 7 and 21 for the first, second, and third immunizations respectively. Blood is drawn at the time of leukapheresis and on the day of the first vaccination for autologous serum, which is sufficient for the cell cultures of all patient groups.
1724906|NCT00005618|Drug|arsenic trioxide|
1724907|NCT00005619|Genetic|polymerase chain reaction|
1724908|NCT00005619|Other|flow cytometry|
1724909|NCT00005619|Other|immunohistochemistry staining method|
1724910|NCT00005622|Drug|cyclophosphamide|Cyclophosphamide is administered at a dose of 60 mg/kg on each of two successive days (Days -6 and -5)
1724911|NCT00005622|Radiation|TBI|FTBI is performed on day -3 through day 0 The total dose of radiation is 1,320 cGy.
1724912|NCT00005623|Drug|cyproterone acetate|
1724913|NCT00005623|Procedure|quality-of-life assessment|
1724914|NCT00005624|Drug|CI-994|CI-994 as outlined in treatment arm.
1724915|NCT00005625|Drug|trabectedin|
1724916|NCT00005626|Drug|Irinotecan|Irinotecan as outlined in treatment arm
1724917|NCT00005627|Drug|carboplatin|
1724918|NCT00005627|Drug|docetaxel|
1724919|NCT00005627|Drug|estramustine phosphate sodium|
1724920|NCT00005628|Biological|vitespen|
1724921|NCT00005629|Biological|AFP gene hepatocellular carcinoma vaccine|"Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.
Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug"
1724922|NCT00005795|Drug|arsenic trioxide|
1724923|NCT00005796|Procedure|filgrastim|GCSF is given after chemo administration
1724924|NCT00005796|Biological|gene therapy|stem cells are collected and given back to the patients after chemotherapy adminstration
1724925|NCT00005796|Drug|lomustine|chemotherapy is administered every 21 days
1724926|NCT00005796|Drug|procarbazine hydrochloride|chemotherapy is administered every 21 days.
1724927|NCT00005796|Drug|vincristine sulfate|chemotherapy is administered every 21 days
1724928|NCT00005796|Procedure|in vitro-treated peripheral blood stem cell transplantation|stem cells are reinfused after chemotherapy administration
1724929|NCT00005797|Drug|busulfan|administered on Day -7 through Day -4. The total dose is 12.8 mg/kg
1724930|NCT00005797|Drug|Cyclophosphamide|administered at a dose of 60 mg/kg on each of two successive days (Days -3 and -2)
1724931|NCT00005797|Drug|VP-16|administered as a single infusion on Day -3. The dose is 60 mg/kg and is calculated on actual body weight unless the patient's weight is >/= 150% of IBW, in which case adjusted body weight will be used.
1724932|NCT00005797|Radiation|Fractionated Total Body Irradiation (FTBI)|FTBI is performed on day -7 through day -4. The total dose of radiation is 1,320 cGy.
1724933|NCT00005798|Drug|Carboplatin|Carboplatin will be given at a dose of 267 mg/m2 in D5 W IV over one hour daily on days -6, -5, and -4. (Total dose 800 mg/m2)
1724934|NCT00005798|Drug|Cyclophosphamide|Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 6000 mg/m2)
1724935|NCT00005798|Drug|Thiotepa|Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -6, -5, and -4. (Total dose 500 mg/m2 )
1724946|NCT00005800|Biological|Filgrastim|
1724947|NCT00005800|Drug|Docetaxel|
1724948|NCT00005800|Drug|Doxorubicin|
1724949|NCT00005800|Procedure|Surgery|Within 6 weeks of completion of neoadjuvant chemotherapy, patients undergo surgery with mastectomy or lumpectomy and axillary lymph node dissection.
1724950|NCT00005801|Biological|therapeutic allogeneic lymphocytes|
1724951|NCT00005801|Procedure|peripheral blood stem cell transplantation|
1724952|NCT00005801|Radiation|radiation therapy|
1724953|NCT00005802|Biological|aldesleukin|
1724954|NCT00005802|Biological|filgrastim|
1724955|NCT00005802|Biological|therapeutic allogeneic lymphocytes|
1724956|NCT00005802|Drug|cytarabine|
1724957|NCT00005802|Drug|etoposide|
1724958|NCT00005802|Drug|fludarabine phosphate|
1724959|NCT00005802|Drug|methotrexate|
1724960|NCT00005802|Drug|mitoxantrone hydrochloride|
1724961|NCT00005802|Drug|therapeutic hydrocortisone|
1724962|NCT00005802|Radiation|radiation therapy|
1956471|NCT02840500|Other|No intervention|No intervention
1724978|NCT00005804|Drug|cyclophosphamide|
1724979|NCT00005804|Procedure|allogeneic bone marrow transplantation|
1724980|NCT00005804|Radiation|radiation therapy|
1724981|NCT00005805|Dietary Supplement|St. John's wort|
1724982|NCT00005806|Drug|carboplatin|
1724983|NCT00005806|Drug|gefitinib|
1724984|NCT00005806|Drug|paclitaxel|
1724985|NCT00005807|Drug|ixabepilone|
1724986|NCT00005808|Drug|motexafin lutetium|Given IV
1724987|NCT00005808|Drug|photodynamic therapy|Undergo laser therapy
1724988|NCT00005808|Procedure|loop electrosurgical excision procedure|Undergo LEEP
1724989|NCT00005808|Other|laboratory biomarker analysis|Correlative studies
1724990|NCT00005809|Procedure|computed tomography|
1724991|NCT00005809|Procedure|diagnostic colonoscopy|
1724992|NCT00005810|Biological|filgrastim|
1724993|NCT00005810|Drug|carboplatin|
1724994|NCT00005810|Drug|docetaxel|
1724995|NCT00005810|Drug|estramustine phosphate sodium|
1724996|NCT00005811|Drug|topotecan hydrochloride|Given IT
1724997|NCT00005811|Other|laboratory biomarker analysis|Correlative studies
1724998|NCT00005812|Drug|temozolomide|
1724999|NCT00005813|Biological|bispecific antibody MDX447|
1725000|NCT00005813|Biological|lymphokine-activated killer cells|
1725001|NCT00005813|Procedure|conventional surgery|
1725002|NCT00005814|Biological|cetuximab|
1725003|NCT00005814|Drug|cisplatin|
1725004|NCT00005814|Radiation|radiation therapy|
1725005|NCT00005815|Drug|temozolomide|
1725006|NCT00005815|Drug|thalidomide|
1725007|NCT00005816|Biological|therapeutic autologous dendritic cells|
1725008|NCT00005816|Procedure|conventional surgery|
1725009|NCT00005817|Drug|becatecarin|Given IV
1725010|NCT00005817|Other|laboratory biomarker analysis|Correlative studies
1725011|NCT00005818|Drug|irinotecan hydrochloride|Given IV
1725012|NCT00005818|Drug|semaxanib|Given IV
1725013|NCT00005818|Other|laboratory biomarker analysis|Correlative studies
1725014|NCT00005819|Drug|cisplatin|Patients receive cisplatin IV over 30 minutes on day 7. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
1725015|NCT00005819|Drug|fenretinide|Patients receive oral fenretinide twice daily for 7 days. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
1725016|NCT00005819|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.Cohorts of 3-6 patients receive escalating doses of paclitaxel and cisplatin until the maximum tolerated dose (MTD) is determined.
1725017|NCT00005820|Drug|nitrocamptothecin|
1725018|NCT00005821|Drug|patent blue V dye|
1725019|NCT00005821|Procedure|conventional surgery|
1725020|NCT00005821|Procedure|lymphangiography|
1725021|NCT00005821|Procedure|radionuclide imaging|
1725022|NCT00005821|Procedure|sentinel lymph node biopsy|
1725023|NCT00005821|Radiation|Technetium Tc 99m human serum albumin colloid|
1725024|NCT00005822|Drug|doxorubicin hydrochloride|Patients receive doxorubicin IV continuously over 72 hours on days 1-3 of course 1. For all subsequent courses, patients receive doxorubicin as in course 1. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
1725025|NCT00005822|Drug|semaxanib|For all subsequent courses, after course 1 patients SU5416 IV over 1 hour twice weekly (on days 1 and 4) beginning on week 2 of course 2. Treatment repeats every 21 days for 5 courses in the absence of disease progression or unacceptable toxicity.
1725026|NCT00005822|Procedure|conventional surgery|Patients undergo a modified radical mastectomy.
1725027|NCT00005822|Radiation|radiation therapy|Patients undergo radiotherapy to the chest wall and regional lymph nodes.
1725028|NCT00005822|Drug|tamoxifen|Patients with estrogen or progesterone receptor positive disease receive oral tamoxifen for 5 years after radiotherapy.
1725029|NCT00005823|Drug|cytarabine|
1725030|NCT00005823|Drug|daunorubicin hydrochloride|
1725031|NCT00005823|Drug|etoposide|
1725032|NCT00005823|Drug|hydroxyurea|
1725033|NCT00005823|Drug|idarubicin|
1725034|NCT00005823|Drug|mitoxantrone hydrochloride|
1725035|NCT00005823|Drug|thioguanine|
1725036|NCT00005823|Drug|tretinoin|
1725037|NCT00005823|Drug|valspodar|
1725038|NCT00005824|Biological|filgrastim|
1725039|NCT00005824|Drug|busulfan|
1725040|NCT00005824|Drug|cyclophosphamide|
1725041|NCT00005824|Procedure|peripheral blood stem cell transplantation|
1725042|NCT00005825|Drug|cisplatin|
1725043|NCT00005825|Drug|mitomycin C|
1725044|NCT00005825|Drug|tretinoin|
1725045|NCT00005825|Drug|vinorelbine tartrate|
1725046|NCT00005826|Drug|rubitecan|
1725047|NCT00005827|Dietary Supplement|genistein|
1725048|NCT00005828|Dietary Supplement|green tea extract|
1725049|NCT00005829|Drug|gemcitabine hydrochloride|
1725050|NCT00005830|Drug|Doxorubicin Hydrochloride|Given IV
1725051|NCT00005830|Drug|Cisplatin|Given IV
1725052|NCT00005830|Radiation|Radiation Therapy|Undergo radiation therapy
1725053|NCT00005831|Biological|trastuzumab|Given IV
1725054|NCT00005831|Drug|paclitaxel|Given IV
1725055|NCT00005831|Drug|carboplatin|Given IV
1725056|NCT00005831|Drug|gemcitabine hydrochloride|Given IV
1725057|NCT00005831|Other|laboratory biomarker analysis|Correlative studies
1725058|NCT00005832|Drug|R115777|300mg/dose BID, PO, Days 1-21, q 28days
1725059|NCT00005833|Drug|R115777|300mg P.O. BID.
1725060|NCT00005834|Biological|filgrastim|Arms 1 and 2: 300 mcg (pts </= 60 kg) or 480 mcg (pts > 60 kg), SC beginning day 5
1725061|NCT00005834|Drug|cisplatin|Arms 1 and 2: 15 mg/m2/d continuous IV days 1-4
1725062|NCT00005834|Drug|cyclophosphamide|Arms 1 and 2: 400 mg/m2/d continuous IV days 1-4
1725063|NCT00005834|Drug|dexamethasone|Arms 1 and 2: 40 mg/d PO days 1-4
1725064|NCT00005834|Drug|etoposide|Arms 1 and 2: 40 mg/m2/d continuous IV days 1-4
1725065|NCT00005834|Drug|thalidomide|Arm 2: 800 mg/d (max dose) PO daily
1725066|NCT00005835|Drug|buthionine sulfoximine|Dose fixed at a bolus of 3 gm/M2 given over 30 minutes followed by a continuous infusion of 1 gm/M2/hour for 72 hours (total 72.5 hours).Total daily infusion dose (minus the initial bolus)will be 24 gm/m2/day.
1725067|NCT00005835|Drug|melphalan|The dose level of melphalan will be assigned at study entry onto protocol. There will be 6 dose levels ranging from 20mg/m2/day x 2 days (dose level 1a) to 62.5 mg/m2/day x 2 days (dose level 6a). The starting dose level will be 1a, with a decrease to level 0a (15mg/m2/day x2 days) if there is unacceptable toxicity.
1725068|NCT00005835|Procedure|Peripheral blood stem cell infusion|Stem cells will be infused intravenously on day 0 , 24 hours after BSO continuous infusion is completed.Infused within 1.5 hours of thawing via a central venous catheter over 15-30 minutes.
1725069|NCT00005835|Other|Filgrastim|5 microgram/kg/day , subcutaneous or intravenous, given daily beginning day 0. First dose to begin 4 hours after completion of stem cell infusion and then to continue till ANC >/= 1500 mm3 for three consecutive days.
1725072|NCT00005838|Drug|shark cartilage extract AE-941|Given orally
1725073|NCT00005838|Other|placebo|Given orally
1725074|NCT00005838|Drug|cisplatin|Given IV
1725075|NCT00005838|Drug|vinorelbine tartrate|Given IV
1725076|NCT00005838|Drug|carboplatin|Given IV
1725077|NCT00005838|Drug|paclitaxel|Given IV
1725078|NCT00005838|Radiation|radiation therapy|Undergo radiotherapy
1725079|NCT00005839|Drug|capecitabine|
1725080|NCT00005839|Drug|oxaliplatin|
1725081|NCT00005840|Drug|Paclitaxel|Given IV
1725082|NCT00005840|Drug|Cisplatin|Given IV
1725083|NCT00005840|Radiation|Radiation Therapy|Undergo whole abdominal radiation therapy
1725084|NCT00005841|Biological|MART-1 antigen|
1725085|NCT00005841|Biological|gp100 antigen|
1725086|NCT00005841|Biological|incomplete Freund's adjuvant|
1725087|NCT00005841|Biological|progenipoietin|
1725088|NCT00005841|Biological|tyrosinase peptide|
1725089|NCT00005842|Biological|trastuzumab|
1725090|NCT00005842|Drug|tipifarnib|
1725091|NCT00005843|Drug|tipifarnib|
1725092|NCT00005844|Drug|oxaliplatin|
1725093|NCT00005845|Drug|tipifarnib|Given PO
1725094|NCT00005845|Other|laboratory biomarker analysis|Correlative studies
1725095|NCT00005845|Other|pharmacological study|Correlative studies
1725096|NCT00005846|Drug|tipifarnib|
1725097|NCT00005847|Biological|recombinant interferon alfa|
1725098|NCT00005847|Drug|estramustine phosphate sodium|
1725099|NCT00005847|Drug|isotretinoin|
1725100|NCT00005847|Drug|mitoxantrone hydrochloride|
1725101|NCT00005847|Drug|paclitaxel|
1725102|NCT00005847|Drug|vinorelbine ditartrate|
1725103|NCT00005848|Drug|chemotherapy|
1725104|NCT00005848|Drug|tipifarnib|
1725105|NCT00005849|Drug|bryostatin 1|
1725106|NCT00005849|Drug|paclitaxel|
1725107|NCT00005850|Drug|cisplatin|80 mg/m2 administered by intravenous (IV) over 30 minutes on Day 1 following the gemcitabine infusion. Treatment repeated every 21 days for a total of 6 cycles.
1725108|NCT00005850|Drug|fluoxetine|10 mg PO QD (by mouth once daily) starting on week 2 (day 8) and continuing for 7 weeks (days 8-57). After 7 weeks of fluoxetine treatment (day 57), further use of fluoxetine is at the discretion of the patient and physician.
1725109|NCT00005850|Drug|gemcitabine hydrochloride|1000 mg/m2 intravenous (IV) administered by IV over 30 minutes on days 1 and 8. Repeat treatment every 21 days for a total of 6 cycles.
1725110|NCT00005851|Drug|fludarabine phosphate|Given IV
1725111|NCT00005851|Radiation|total-body irradiation|Undergo TBI
1725112|NCT00005851|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
1725113|NCT00005851|Drug|cyclosporine|Given PO or IV
1725114|NCT00005851|Drug|mycophenolate mofetil|Given PO or IV
1725115|NCT00005851|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
1725116|NCT00005851|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
1725117|NCT00005851|Other|laboratory biomarker analysis|Correlative studies
1725118|NCT00005852|Biological|anti-thymocyte globulin|
1725119|NCT00005852|Biological|filgrastim|
1725120|NCT00005852|Biological|muromonab-CD3|
1725121|NCT00005852|Drug|cyclophosphamide|
1725122|NCT00005852|Drug|cyclosporine|
1725123|NCT00005852|Drug|methylprednisolone|
1725124|NCT00005852|Procedure|allogeneic bone marrow transplantation|
1725125|NCT00005853|Biological|anti-thymocyte globulin|
1725126|NCT00005853|Biological|etanercept|
1725127|NCT00005854|Drug|cyclophosphamide|
1725128|NCT00005854|Drug|cyclosporine|
1725129|NCT00005854|Drug|methotrexate|
1725130|NCT00005854|Procedure|allogeneic bone marrow transplantation|
1725131|NCT00005854|Procedure|in vitro-treated bone marrow transplantation|
1725132|NCT00005854|Radiation|radiation therapy|
1725133|NCT00005855|Drug|carmustine|
1725134|NCT00005855|Drug|efaproxiral|
1725135|NCT00005856|Drug|oxaliplatin|Given IV
1725136|NCT00005856|Other|pharmacological study|Correlative studies
1725137|NCT00005857|Biological|trastuzumab|
1725138|NCT00005857|Drug|docetaxel|
1725139|NCT00005858|Biological|LMB-9 immunotoxin|
1725140|NCT00005859|Drug|tipifarnib|
1725141|NCT00005860|Drug|floxuridine|
1725142|NCT00005860|Drug|leucovorin calcium|
1725143|NCT00005860|Drug|oxaliplatin|
1725144|NCT00005861|Drug|pegylated liposomal doxorubicin hydrochloride|
1725145|NCT00005862|Drug|semaxanib|
1725146|NCT00005863|Biological|filgrastim|
1725147|NCT00005863|Drug|cytarabine|
1725148|NCT00005863|Drug|daunorubicin hydrochloride|
1725149|NCT00005863|Drug|etoposide|
1725150|NCT00005863|Drug|fludarabine phosphate|
1725151|NCT00005863|Drug|tretinoin|
1725152|NCT00005864|Drug|chloroquinoxaline sulfonamide|
1725153|NCT00005865|Drug|vinorelbine tartrate|
1725154|NCT00005866|Drug|busulfan|arm 1: 0.44 mg/kg every 6 hours, IV over 2 hours, day -7 to -4
1725155|NCT00005866|Drug|cyclophosphamide|arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
1725156|NCT00005866|Drug|cyclosporine|both arms per published schedule
1725157|NCT00005866|Drug|methotrexate|GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
1725158|NCT00005866|Procedure|allogeneic bone marrow transplantation|day 0
1725159|NCT00005866|Radiation|radiation therapy|both arms: 1200 cGy total dose (6 x 200 fractions)
1725160|NCT00005867|Biological|bleomycin sulfate|
1725161|NCT00005867|Drug|CHOP regimen|
1725162|NCT00005867|Drug|cyclophosphamide|
1725163|NCT00005867|Drug|doxorubicin hydrochloride|
1725164|NCT00005867|Drug|etoposide|
1725165|NCT00005867|Drug|mitoxantrone hydrochloride|
1725166|NCT00005867|Drug|prednisolone|
1725167|NCT00005867|Drug|vincristine sulfate|
1725168|NCT00005868|Drug|cisplatin|
1725169|NCT00005868|Drug|docetaxel|
1725170|NCT00005869|Drug|gemcitabine hydrochloride|
1725171|NCT00005869|Drug|rubitecan|
1725172|NCT00005870|Drug|fluorouracil|
1725173|NCT00005870|Drug|gemcitabine hydrochloride|
1725174|NCT00005870|Drug|mitomycin C|
1725175|NCT00005870|Drug|rubitecan|
1725176|NCT00005871|Drug|fluorouracil|
1725177|NCT00005871|Drug|rubitecan|
1725178|NCT00005872|Drug|rubitecan|
1725179|NCT00005873|Drug|rubitecan|
1725180|NCT00005874|Drug|rubitecan|
1725181|NCT00005875|Drug|rubitecan|
1725182|NCT00005876|Drug|rubitecan|
1725183|NCT00005877|Drug|rubitecan|
1725184|NCT00005878|Drug|celecoxib|
1725185|NCT00005879|Drug|arzoxifene|one tablet daily
1725186|NCT00005879|Drug|Placebo|matched tablet dialy
1725187|NCT00005880|Drug|budesonide|
1725188|NCT00005881|Other|Quality of Life Forms|Completion of the instrument [Minneapolis-Manchester Quality of Life (MM-QOL)] that measures HRQOL in the survivors of childhood cancer in a standardized, valid way and to assess the feasibility of incorporating this endpoint in a variety of clinical trials.
1725189|NCT00005883|Drug|phenethyl isothiocyanate|
1725190|NCT00005884|Drug|eflornithine|
1725191|NCT00005886|Drug|arzoxifene hydrochloride|
1725192|NCT00005886|Drug|tamoxifen citrate|
1725193|NCT00005887|Drug|efaproxiral|
1725194|NCT00005887|Radiation|radiation therapy|
1725195|NCT00005888|Behavioral|Fortified Pasteurized Donor Human Milk supplement|
1725196|NCT00005888|Behavioral|Preterm Formula supplement|
1725197|NCT00005889|Drug|alanine|
1725198|NCT00005889|Drug|amino acids|
1725199|NCT00005889|Drug|glucagon|
1725200|NCT00005889|Drug|glucose|
1725201|NCT00005889|Drug|glutamine|
1725202|NCT00005889|Drug|glycerol|
1725203|NCT00005889|Drug|insulin|
1725204|NCT00005889|Drug|leucine|
1725205|NCT00005889|Drug|lipids|
1725206|NCT00005889|Drug|urea|
1725207|NCT00005890|Drug|corticotropin|
1725208|NCT00005891|Drug|cyclophosphamide|
1725209|NCT00005891|Procedure|Allogeneic Bone Marrow Transplantation|
1725210|NCT00005892|Drug|cyclophosphamide|
1725211|NCT00005892|Procedure|Allogeneic Bone Marrow Transplantation|
1725212|NCT00005893|Drug|anti-thymocyte globulin|
1725213|NCT00005893|Drug|busulfan|
1725214|NCT00005893|Drug|cyclophosphamide|
1725215|NCT00005893|Procedure|Bone marrow transplantation|
1725216|NCT00005896|Drug|filgrastim|
1725217|NCT00005896|Genetic|Autologous stem cells transduced with FACC retroviral vector|
1725218|NCT00005896|Procedure|Autologous Stem Cell Transplantation|
1725219|NCT00005898|Drug|anti-thymocyte globulin|
1725220|NCT00005898|Drug|cyclophosphamide|
1725221|NCT00005898|Drug|cyclosporine|
1725222|NCT00005898|Drug|filgrastim|
1725223|NCT00005898|Drug|fludarabine|
1725224|NCT00005898|Drug|methylprednisolone|
1725225|NCT00005901|Drug|Pamidronate (Aredia)|Patients receive a dose of 1mg/kg/cycle (3-day infusion = 1 cycle)
1725226|NCT00005903|Drug|GDNF & Synchro Med Infusion System|
1725227|NCT00005905|Drug|hu Leptin (A-100)|
1725228|NCT00005906|Drug|Octreotide|Treatment with octreotide starts at a dose of 50 micrograms(ug) twice a day which is increased to 100 ug twice a day after two weeks and to 200 ug twice a day two weeks later. After two months, if there is no response the dose shall be increased to 400 ug twice a day.
1725229|NCT00005908|Drug|Docetaxel - Dose A|Dose A-Cohort 1 Docetaxel 75 mg/m^2 intravenous day 1
1725230|NCT00005908|Drug|Anastrozole|1 mg orally daily for five years
1725231|NCT00005908|Drug|cyclophosphamide|600 mg/m^2 will be diluted in 100 mL 0.9% normal saline (NS) and administered intravenously over 30 minutes on day 1
1725232|NCT00005908|Drug|Docetaxel - Dose B|Dose B - Cohort 2 Docetaxel 60 mg/m^2 intravenous day 1
1725233|NCT00005908|Drug|Doxorubicin hydrochloride|60 mg/m^2 will be administered as a slow intravenous push on day 1
1725234|NCT00005908|Drug|Tamoxifen Citrate|20 mg/day orally for five years
1725235|NCT00005908|Drug|Capecitabine - Dose B|Dose B - Cohort 2 capecitabine 937.5 mg/m^2 orally twice daily day 2-15
1725236|NCT00005908|Drug|Capecitabine - Dose A|capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles
1725237|NCT00005910|Procedure|Intraoperative ultrasound|
1725238|NCT00005912|Drug|Voriconazole|
1725239|NCT00005916|Drug|rV-PSA|
1725240|NCT00005916|Drug|rF-PSA|
1725241|NCT00005916|Drug|rV-B7.1|
1725242|NCT00005918|Drug|Efavirenz|
1725243|NCT00005918|Drug|Lamivudine|
1725244|NCT00005918|Drug|Stavudine|
1725245|NCT00005920|Drug|L-743,872|
1725246|NCT00005921|Drug|L-743,872|
1725247|NCT00005922|Behavioral|Partial schedule of pharmacotherapeutic reinforcement|Dose of 0.1% of Aristocort A on 1-2 of every 4 days for a period of up to 14 weeks.
1725248|NCT00005922|Drug|Dose control for Arm B|Dose of 0.025-0.05% of Aristocort A 2 times per day for a period of up to 14 weeks.
1725249|NCT00005922|Other|Standard pharmacotherapeutic protocol|Full dose of Aristicort A (0.1%) 2 times per day for a period of up to 14 weeks.
1725250|NCT00005925|Drug|Muscimol|
1725251|NCT00005926|Drug|Gemcitabine|
1725252|NCT00005926|Drug|Herceptin|
1725253|NCT00005926|Procedure|Radiation therapy|
1725254|NCT00005928|Drug|Ramipril|
1725255|NCT00005931|Drug|SU5416|
1725256|NCT00005934|Drug|5-Azacytidine|
1725257|NCT00005935|Drug|Mycophenolate mofetil|
1725258|NCT00005935|Drug|Cyclosporine|
1725259|NCT00005937|Drug|Antithymocyte globulin|Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.
1725260|NCT00005937|Drug|Cyclosporine|Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.
1725261|NCT00005938|Drug|exatecan mesylate|
1725263|NCT00005939|Radiation|phosphorus P32|
1725264|NCT00005940|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
1725265|NCT00005940|Drug|busulfan|Given PO
1725266|NCT00005940|Drug|cyclophosphamide|Given IV
1725267|NCT00005940|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic PBSC or bone marrow transplant
1725268|NCT00005940|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
1725269|NCT00005940|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC or bone marrow transplant
1725270|NCT00005940|Drug|cyclosporine|Given IV or PO
1725271|NCT00005940|Drug|methotrexate|Given IV
1725272|NCT00005940|Other|laboratory biomarker analysis|Correlative studies
1725273|NCT00005941|Biological|therapeutic allogeneic lymphocytes|
1725274|NCT00005941|Drug|cyclosporine|
1725275|NCT00005941|Drug|fludarabine phosphate|
1725276|NCT00005941|Drug|mycophenolate mofetil|
1725277|NCT00005941|Procedure|peripheral blood stem cell transplantation|
1725278|NCT00005941|Radiation|radiation therapy|
1725279|NCT00005942|Drug|liposomal daunorubicin citrate|Given IV
1725280|NCT00005942|Drug|semaxanib|Given IV
1725281|NCT00005942|Other|laboratory biomarker analysis|Correlative studies
1725282|NCT00005943|Biological|aldesleukin|
1725283|NCT00005943|Biological|staphylococcal enterotoxin B|
1725284|NCT00005944|Drug|chemotherapy|
1725285|NCT00005944|Drug|fluorouracil|
1725286|NCT00005944|Drug|leucovorin calcium|
1725287|NCT00005944|Drug|mitomycin C|
1725288|NCT00005944|Procedure|conventional surgery|
1725289|NCT00005944|Procedure|laparoscopic surgery|
1725290|NCT00005945|Drug|cyclophosphamide|Given IV
1725291|NCT00005945|Drug|cytarabine|Given IT
1725292|NCT00005945|Drug|daunorubicin hydrochloride|Given IV
1725293|NCT00005945|Drug|dexamethasone|Given PO
1725294|NCT00005945|Drug|doxorubicin hydrochloride|Dose 25 g/m² IV Days 0, 7, 14, given over a period of 15 minutes to 2 hours
1725295|NCT00005945|Drug|mercaptopurine|Given PO
1725296|NCT00005945|Drug|methotrexate|Given PO and IT
1725297|NCT00005945|Drug|pegaspargase|Given IM
1725298|NCT00005945|Drug|thioguanine|Given PO
1725299|NCT00005945|Drug|vincristine sulfate|Given IV
1725300|NCT00005945|Radiation|radiation therapy|Undergo radiation therapy
1725301|NCT00005946|Biological|filgrastim|
1725302|NCT00005946|Biological|therapeutic allogeneic lymphocytes|
1725303|NCT00005946|Drug|cyclophosphamide|
1725304|NCT00005946|Drug|etoposide|
1725305|NCT00005947|Biological|sipuleucel-T|Autologous peripheral blood mononuclear cells, including antigen presenting cells, that have been activated in vitro with a recombinant fusion protein, PAP-GM-CSF. Treatment consist of 3 doses administered approximately 2 weeks apart.
1725306|NCT00005947|Biological|Placebo|Approximately one-third of the autologous quiescent antigen presenting cells (APCs) prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
1725307|NCT00005948|Biological|aldesleukin|
1725308|NCT00005948|Biological|recombinant interferon alfa|
1725309|NCT00005948|Biological|sargramostim|
1725310|NCT00005948|Drug|busulfan|
1725311|NCT00005948|Procedure|peripheral blood stem cell transplantation|
1725312|NCT00005949|Biological|aldesleukin|Given SC
1725313|NCT00005949|Biological|gp100:209-217(210M) peptide vaccine|Given SC
1725314|NCT00005949|Other|laboratory biomarker analysis|Correlative studies
1725315|NCT00005950|Drug|nelarabine|Given IV
1725316|NCT00005951|Drug|irinotecan hydrochloride|
1725317|NCT00005951|Drug|temozolomide|
1725318|NCT00005952|Biological|filgrastim|
1725319|NCT00005952|Drug|temozolomide|
1725320|NCT00005952|Procedure|peripheral blood stem cell transplantation|
1725321|NCT00005954|Drug|temozolomide|
1725322|NCT00005955|Drug|temozolomide|
1725323|NCT00005956|Biological|HER-2/neu intracellular domain protein|
1725324|NCT00005956|Biological|therapeutic autologous dendritic cells|
1725325|NCT00005957|Radiation|Standard Breast Irradiation|Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.
1725326|NCT00005957|Radiation|Breast Radiation plus Regional Radiation|Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.
1725327|NCT00005958|Biological|filgrastim|
1725328|NCT00005958|Drug|docetaxel|
1725329|NCT00005958|Drug|gemcitabine hydrochloride|
1725330|NCT00005959|Biological|filgrastim|
1725331|NCT00005959|Biological|rituximab|
1725332|NCT00005959|Drug|cyclophosphamide|
1725333|NCT00005959|Drug|doxorubicin hydrochloride|
1725334|NCT00005959|Drug|prednisone|
1725335|NCT00005959|Drug|vincristine sulfate|
1725336|NCT00005960|Biological|filgrastim|
1725337|NCT00005960|Drug|cyclophosphamide|
1725338|NCT00005960|Drug|docetaxel|
1725339|NCT00005960|Drug|doxorubicin hydrochloride|
1725340|NCT00005960|Procedure|pain therapy|
1725341|NCT00005961|Drug|O6-benzylguanine|
1725342|NCT00005961|Drug|carmustine|
1725343|NCT00005962|Biological|sargramostim|
1725344|NCT00005962|Drug|cyclophosphamide|
1725345|NCT00005962|Drug|cytarabine|
1725346|NCT00005962|Drug|gemtuzumab ozogamicin|
1725347|NCT00005962|Drug|liposomal daunorubicin citrate|
1725348|NCT00005962|Drug|topotecan hydrochloride|
1725349|NCT00005963|Drug|carboplatin|
1725350|NCT00005963|Drug|docetaxel|
1725351|NCT00005964|Biological|filgrastim|
1725352|NCT00005964|Drug|cyclophosphamide|
1725353|NCT00005964|Drug|doxorubicin hydrochloride|
1725354|NCT00005964|Drug|etoposide|
1725356|NCT00005964|Drug|vincristine sulfate|
1725357|NCT00005965|Drug|bryostatin 1|
1725358|NCT00005965|Drug|cisplatin|
1725359|NCT00005966|Biological|recombinant interferon alfa|
1725360|NCT00005966|Drug|thalidomide|
1725361|NCT00005967|Drug|tipifarnib|
1725362|NCT00005968|Drug|irofulven|
1725363|NCT00005969|Drug|Chemotherapy|
1725364|NCT00005969|Drug|Tretinoin Liposome|Liposome by vein (IV) over 30 minutes every other day for 28 days
1725365|NCT00005970|Drug|Aromatase Inhibition Therapy|Given orally
1725366|NCT00005970|Drug|Cyclophosphamide|Given IV
1725367|NCT00005970|Drug|Doxorubicin Hydrochloride|Given IV
1725368|NCT00005970|Other|Laboratory Biomarker Analysis|Correlative studies
1725369|NCT00005970|Drug|Paclitaxel|Given IV
1725370|NCT00005970|Drug|Tamoxifen Citrate|Given orally
1725371|NCT00005970|Biological|Trastuzumab|Given IV
1725372|NCT00005971|Drug|alvocidib|
1725373|NCT00005972|Drug|gemcitabine hydrochloride|
1725374|NCT00005972|Drug|irinotecan hydrochloride|
1725375|NCT00005973|Drug|BMS-214662|Given IV
1725376|NCT00005973|Other|laboratory biomarker analysis|Correlative studies
1725377|NCT00005974|Drug|alvocidib|Flavopiridol 50 mg/m2 IV over 1 hour daily x 3 days every 3 weeks
1725378|NCT00005975|Drug|Megestrol Acetate 20mg/day|Double blinded Megestrol Acetate 20 mg/day
1725379|NCT00005975|Drug|Megestrol Acetate 40 mg/day|Double blinded Megestrol Acetate 40 mg/day
1725380|NCT00005975|Drug|Megestrol Acetate Placebo 20 mg/day|Megestrol Acetate Placebo 20 mg/day
1725381|NCT00005975|Drug|Megestrol Acetate Placebo 40 mg/day|Megestrol Acetate Placebo 40 mg/day
1725382|NCT00005976|Drug|carboplatin|
1725383|NCT00005976|Drug|pyrazoloacridine|
1725384|NCT00005977|Biological|filgrastim|Given IV
1725385|NCT00005977|Drug|cyclophosphamide|Given IV
1725386|NCT00005977|Drug|cytarabine|Given IV
1725387|NCT00005977|Drug|dexamethasone|Given IV
1725388|NCT00005977|Drug|doxorubicin hydrochloride|Given IV
1725389|NCT00005977|Drug|etoposide|Given IV
1725390|NCT00005977|Drug|ifosfamide|Given IV
1725391|NCT00005977|Drug|leucovorin calcium|Given IV
1725392|NCT00005977|Drug|methotrexate|Given IV
1725393|NCT00005977|Drug|vincristine sulfate|Given IV
1725394|NCT00005978|Biological|filgrastim|
1725395|NCT00005978|Drug|carboplatin|
1725396|NCT00005978|Drug|etoposide|
1725397|NCT00005978|Drug|melphalan|
1725398|NCT00005978|Procedure|autologous bone marrow transplantation|
1725399|NCT00005978|Procedure|peripheral blood stem cell transplantation|
1725400|NCT00005978|Radiation|iobenguane I 131|
1725401|NCT00005978|Radiation|radiation therapy|
1725402|NCT00005979|Drug|FOLFIRI regimen|
1725403|NCT00005979|Drug|fluorouracil|
1725404|NCT00005979|Drug|irinotecan hydrochloride|
1725405|NCT00005979|Drug|leucovorin calcium|
1725406|NCT00005980|Drug|pegylated liposomal doxorubicin hydrochloride|
1725407|NCT00005981|Drug|O6-benzylguanine|Patients receive O6-benzylguanine (BG) IV over 1 hour. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
1725408|NCT00005981|Drug|carmustine|Carmustine IV over 1 hour (beginning 1 hour after completion of BG infusion) on day 1. Treatment continues every 6 weeks in the absence of disease progression or unacceptable toxicity.
1725409|NCT00005982|Drug|nelarabine|Given IV
1725410|NCT00005982|Other|pharmacological study|Correlative studies
1725411|NCT00005983|Radiation|radiation therapy|
1725412|NCT00005983|Procedure|surgery|surgery
1725413|NCT00005984|Drug|cyclophosphamide|intravenously over 2 hours on day 1 and on days -7 and -6
1725414|NCT00005984|Drug|filgrastim|filgrastim (G-CSF) daily subcutaneously (SQ) starting on day 5 and continuing until completion of leukapheresis. Patients also receive G-CSF IV starting on day 0 and continuing until blood counts recover
1725415|NCT00005984|Drug|recombinant interferon alfa|Beginning on Day 1, subcutaneous (SQ) daily administration in the absence of unacceptable toxicity or disease progression
1725416|NCT00005984|Procedure|peripheral blood stem cell transplantation|Patients receive the PBSC transplantation on day 0.
1725417|NCT00005984|Procedure|radiation therapy|total body irradiation twice a day on days -4 through -1
1725418|NCT00005985|Biological|filgrastim|
1725419|NCT00005985|Drug|carmustine|
1725420|NCT00005985|Drug|cyclophosphamide|
1725421|NCT00005985|Drug|cytarabine|
1725422|NCT00005985|Drug|dexamethasone|
1725423|NCT00005985|Drug|etoposide|
1725424|NCT00005985|Drug|mitoxantrone hydrochloride|
1725425|NCT00005985|Procedure|peripheral blood stem cell transplantation|
1725426|NCT00005985|Radiation|radiation therapy|
1725427|NCT00005986|Drug|busulfan|
1725428|NCT00005986|Drug|cyclophosphamide|
1725429|NCT00005986|Drug|filgrastim|
1725430|NCT00005986|Drug|recombinant interferon alfa|
1725431|NCT00005986|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1725432|NCT00005986|Procedure|peripheral blood stem cell transplantation|
1725433|NCT00005986|Procedure|radiation therapy|
1725434|NCT00005987|Drug|carmustine|
1725435|NCT00005987|Drug|cyclophosphamide|
1725436|NCT00005987|Drug|dexamethasone|
1725437|NCT00005987|Drug|etoposide|
1725438|NCT00005987|Drug|filgrastim|
1725439|NCT00005987|Drug|mitoxantrone hydrochloride|
1725440|NCT00005987|Drug|recombinant interferon alfa|
1725441|NCT00005987|Drug|sargramostim|
1725442|NCT00005987|Procedure|bone marrow ablation with stem cell support|
1725443|NCT00005987|Procedure|peripheral blood stem cell transplantation|
1725444|NCT00005987|Procedure|radiation therapy|
1725445|NCT00005988|Drug|cyclophosphamide|
1725446|NCT00005988|Drug|cyclosporine|
1725447|NCT00005988|Drug|leucovorin calcium|
1725448|NCT00005988|Drug|methotrexate|
1725450|NCT00005988|Procedure|in vitro-treated bone marrow transplantation|
1725451|NCT00005988|Radiation|radiation therapy|
1725452|NCT00005989|Drug|tipifarnib|
1725453|NCT00005990|Drug|tipifarnib|
1725454|NCT00005990|Drug|topotecan hydrochloride|
1725455|NCT00005991|Drug|gemcitabine hydrochloride|
1725456|NCT00005991|Drug|pegylated liposomal doxorubicin hydrochloride|
1725457|NCT00005992|Biological|PSA prostate cancer vaccine|
1725458|NCT00005992|Biological|therapeutic autologous dendritic cells|
1725459|NCT00005993|Drug|aldesleukin|
1725460|NCT00005993|Drug|filgrastim|
1725461|NCT00005993|Drug|recombinant human stem cell factor|
1725462|NCT00005993|Procedure|peripheral blood stem cell transplantation|
1725463|NCT00005994|Drug|ondansetron|
1725464|NCT00005995|Drug|shark cartilage extract AE-941|
1725465|NCT00005996|Drug|cisplatin|
1725466|NCT00005996|Drug|gemcitabine hydrochloride|
1725467|NCT00005996|Drug|semaxanib|
1725468|NCT00005305|Other|No interventions - observational study|
1725469|NCT00005398|Other|There is no intervention|No applicable
1725470|NCT00005399|Other|No interventions|No interventions
1725471|NCT00005997|Drug|becatecarin|Cohorts of 3-6 patients receive escalating doses of rebeccamycin analogue until the maximum tolerated dose (MTD) is determined.
1725472|NCT00005998|Drug|carmustine|
1725473|NCT00005998|Drug|cyclophosphamide|
1725474|NCT00005998|Drug|cytarabine|
1725475|NCT00005998|Drug|dexamethasone|
1725476|NCT00005998|Drug|etoposide|
1725477|NCT00005998|Drug|filgrastim|
1725478|NCT00005998|Drug|mitoxantrone hydrochloride|
1725479|NCT00005998|Drug|retrovirus vector LN|
1725480|NCT00005998|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1725481|NCT00005998|Procedure|peripheral blood stem cell transplantation|
1725482|NCT00005998|Procedure|radiation therapy|
1725483|NCT00005999|Drug|arsenic trioxide|
1725484|NCT00006000|Drug|cisplatin|
1725485|NCT00006000|Drug|irinotecan hydrochloride|
1725486|NCT00006000|Drug|semaxanib|
1725487|NCT00006001|Drug|semaxanib|
1725488|NCT00006002|Drug|dexamethasone|
1725489|NCT00006002|Drug|semaxanib|
1725490|NCT00006003|Drug|semaxanib|Given IV
1725491|NCT00006003|Other|laboratory biomarker analysis|Correlative studies
1725492|NCT00006004|Drug|carboplatin|
1725493|NCT00006004|Drug|cisplatin|
1725494|NCT00006004|Drug|gemcitabine hydrochloride|
1725495|NCT00006004|Drug|paclitaxel|
1725496|NCT00006005|Drug|thalidomide|
1725497|NCT00006006|Biological|recombinant interferon alfa|
1725498|NCT00006006|Drug|thalidomide|
1725499|NCT00006007|Drug|gemcitabine hydrochloride|
1725500|NCT00006007|Drug|pemetrexed disodium|
1725501|NCT00006008|Drug|arsenic trioxide|
1725502|NCT00006009|Biological|visilizumab|
1725503|NCT00006010|Drug|docetaxel|
1725504|NCT00006010|Drug|gemcitabine hydrochloride|
1725505|NCT00006011|Drug|Doxorubicin Hydrochloride|Given IV
1725506|NCT00006011|Drug|Cisplatin|Given IV
1725507|NCT00006011|Biological|Filgrastim|Given SC
1725508|NCT00006011|Biological|Pegfilgrastim|Given SC
1725509|NCT00006011|Drug|Paclitaxel|Given IV
1725510|NCT00006012|Biological|filgrastim|
1725511|NCT00006012|Drug|amifostine trihydrate|
1725512|NCT00006012|Drug|cisplatin|
1725513|NCT00006012|Drug|etoposide|
1725514|NCT00006012|Drug|paclitaxel|
1725515|NCT00006012|Drug|topotecan hydrochloride|
1725516|NCT00006012|Radiation|radiation therapy|
1725517|NCT00006013|Drug|semaxanib|
1725518|NCT00006014|Drug|semaxanib|
1725519|NCT00006015|Biological|trastuzumab|4 mg/kg IV infusion Day 1, then weekly 2 mg/kg IV infusion (on Days 8, 15, & 22)
1725520|NCT00006015|Drug|fluorouracil|500 mg/sq m IV push weekly for 3 weeks, followed by a 1 wk break
1725521|NCT00006015|Drug|leucovorin calcium|500 mg/sq m IV infusion over 2 hours weekly for 3 weeks, then a 1 wk break
1725522|NCT00006015|Drug|oxaliplatin|85 mg/sq m IV infusion over 2 hours Days 1 & 15 of each cycle
1725523|NCT00006016|Drug|thalidomide|Given orally
1725524|NCT00006016|Drug|doxorubicin hydrochloride|Given transarterially (chemoembolization)
1725525|NCT00006016|Other|laboratory biomarker analysis|Correlative studies
1725526|NCT00006017|Drug|becatecarin|Arm I: Patients receive rebeccamycin analogue IV over 1 hour on day 1. Arm II: Patients receive rebeccamycin analogue IV over 1 hour on days 1-5. Treatment for both arms repeats every 3 weeks for 6-8 courses in the absence of disease progression or unacceptable toxicity.
1725527|NCT00006018|Drug|BMS-214662|This is a dose-escalation study of BMS-214662. BMS-214662 IV over 1 hour on day 3 of course 1. For all subsequent courses, patients receive BMS-214662 IV over 1 hour on day 1 (30 minutes after paclitaxel). Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
1725528|NCT00006018|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours on day 1 of course 1. For all subsequent courses, patients receive paclitaxel IV over 3 hours on day 1. Treatment repeats every 3 weeks for at least 2 courses in the absence of disease progression or unacceptable toxicity.
1725529|NCT00006019|Drug|azacitidine|
1725530|NCT00006019|Drug|sodium phenylbutyrate|
1725531|NCT00006020|Drug|nelarabine|1.5 gm/m2 IV over 2 hours days 1, 3, 5 q21 days
1725532|NCT00006021|Dietary Supplement|ascorbic acid|
1725533|NCT00006021|Drug|arsenic trioxide|
1725534|NCT00006022|Biological|aldesleukin|
1725535|NCT00006022|Drug|bryostatin 1|
1725536|NCT00006405|Behavioral|Exercise|
1725619|NCT00006464|Drug|7-hydroxystaurosporine|
1725620|NCT00006464|Drug|cisplatin|
1725700|NCT00006517|Device|bright light box|10,000 lux bright light therapy
1725701|NCT00006517|Device|dawn simulator|gradual rise in bedroom illumination prior to wake-up
1725879|NCT00005640|Procedure|Biopsy of Sentinel Lymph Nodes|
1725537|NCT00006409|Behavioral|Trial of Activity for Adolescent Girls (TAAG)|Intervention activities were designed to create (1) environmental and organizational changes supportive of physical activity and (2) cues, messages, and incentives to be more active. The intervention was designed to establish more opportunities, improve social support and norms, and increase self-efficacy, outcome expectations, and behavioral skills to foster greater moderate-vigorous physical activity (MVPA). An innovative feature of TAAG was linking school and community agencies to promote activity programs for girls. Finally, a TAAG Program Champion component was developed to foster sustainability after the 2-year staff-directed intervention. TAAG investigators recruited and trained Program Champions during the staff-directed intervention phase to promote maintenance of the program.
1996985|NCT02295995|Behavioral|Exercise as an Adjuvant Therapy for Veterans with PTSD|Methods: Forty Veterans 60 years and older with PTSD will be recruited to participate in a 12-week physical activity program consisting of aerobic and strength-training activities. Participants will be randomized to an intervention arm or usual care wait-list control. Outcomes: Changes in physical function, PTSD symptom severity, and aerobic endurance will be assessed between the two study arms. Secondary outcomes include compliance with the intervention, pain, sleep, and psychological well-being.
1725539|NCT00006412|Drug|Pravastatin sodium|
1725540|NCT00006412|Drug|Fenofibrate|
1725541|NCT00006413|Procedure|Stem cell transplantation|
1725542|NCT00006417|Procedure|Stem cell transplantation|
1725543|NCT00006418|Procedure|DNA collection|
1725544|NCT00006422|Procedure|current standard of care treatments|
1725545|NCT00006426|Procedure|Achilles tendon-lengthening surgery|
1725546|NCT00006427|Drug|Amitriptyline|
1725547|NCT00006428|Drug|Amitriptyline|
1725548|NCT00006429|Procedure|body weight-supported treadmill training|
1725549|NCT00006430|Biological|Autologous dendritic cells transfected with amplified tumor RNA|
1725550|NCT00006431|Biological|DC RCC-RNA|
1725551|NCT00006432|Procedure|very low fat diet|
1725552|NCT00006433|Drug|Doxil|
1725553|NCT00006433|Procedure|heat treatment|
1725554|NCT00006434|Biological|tumor-pulsed dendritic cells|
1725558|NCT00006438|Device|Shoes with Rocker Soles|
1725559|NCT00006439|Behavioral|Counseling in the home|
1725560|NCT00006441|Drug|Lamivudine/Zidovudine|300/150 mg respectively twice daily for 104 weeks. Patients who develop intolerence to AZT may use Stavudine (d4T) at a dose of 40 mg daily.
1725561|NCT00006441|Drug|Nelfinavir mesylate|1250 mg twice daily for 104 weeks.
1725562|NCT00006441|Drug|Aldesleukin|7.5 million units twice daily. Treatment will last until conclusion of study.
1725563|NCT00006443|Drug|Indinavir sulfate|
1725564|NCT00006443|Drug|Nelfinavir mesylate|
1725565|NCT00006443|Drug|Lamivudine|
1725566|NCT00006443|Drug|Stavudine|
1725567|NCT00006445|Procedure|Ultrasound|
1725568|NCT00006445|Procedure|Serum screen|
1725569|NCT00006446|Procedure|Training in parenting skills and communication|
1725570|NCT00006447|Procedure|Social Support|
1725571|NCT00006448|Behavioral|cognitive therapy|
1725572|NCT00006448|Procedure|Physical Therapy|
1725573|NCT00006448|Drug|Methadone|
1725574|NCT00006449|Drug|naltrexone (Revia)|
1725575|NCT00006449|Behavioral|broad spectrum treatment|
1725576|NCT00006449|Behavioral|motivational enhancement therapy|
1725577|NCT00006450|Drug|Phenylbutyrate|
1725578|NCT00006451|Drug|anti-thymocyte globulin|
1725579|NCT00006451|Drug|cyclophosphamide|
1725580|NCT00006451|Drug|cyclosporine|
1725581|NCT00006451|Drug|methotrexate|
1725582|NCT00006451|Drug|methylprednisolone|
1725583|NCT00006451|Procedure|allogeneic bone marrow transplantation|
1725584|NCT00006451|Procedure|in vitro-treated bone marrow transplantation|
1725585|NCT00006451|Procedure|radiation therapy|
1725586|NCT00006452|Drug|motexafin gadolinium|
1725587|NCT00006452|Radiation|radiation therapy|
1725588|NCT00006453|Drug|carboplatin|
1725589|NCT00006453|Drug|gemcitabine hydrochloride|
1725590|NCT00006454|Drug|carboplatin|
1725591|NCT00006454|Drug|paclitaxel|
1725592|NCT00006454|Drug|topotecan hydrochloride|
1725593|NCT00006455|Drug|cyclophosphamide|
1725594|NCT00006455|Drug|cytarabine|
1725595|NCT00006455|Drug|dexamethasone|
1725596|NCT00006455|Drug|doxorubicin hydrochloride|
1725597|NCT00006455|Drug|etoposide|
1725598|NCT00006455|Drug|ifosfamide|
1725599|NCT00006455|Drug|leucovorin calcium|
1725600|NCT00006455|Drug|methotrexate|
1725601|NCT00006455|Drug|therapeutic hydrocortisone|
1725602|NCT00006455|Drug|vinblastine sulfate|
1725603|NCT00006456|Radiation|stereotactic radiosurgery|
1725604|NCT00006457|Drug|oltipraz|
1725605|NCT00006458|Radiation|indium In 111 monoclonal antibody MN-14|
1725606|NCT00006458|Radiation|yttrium Y 90 monoclonal antibody MN-14|
1725607|NCT00006459|Drug|gemcitabine hydrochloride|
1725608|NCT00006459|Drug|paclitaxel|
1725609|NCT00006460|Drug|hyperbaric oxygen|
1725610|NCT00006460|Radiation|radiation therapy|
1725611|NCT00006461|Drug|cisplatin|Given IV
1725612|NCT00006461|Drug|cyclophosphamide|Given IV
1725613|NCT00006461|Drug|vincristine sulfate|Given IV
1725614|NCT00006461|Drug|etoposide|Given PO
1725615|NCT00006461|Procedure|therapeutic conventional surgery|Undergo surgery
1725616|NCT00006461|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
1725617|NCT00006462|Drug|gemcitabine hydrochloride|
1725618|NCT00006463|Drug|ECTEINASCIDIN 743|
1996986|NCT02295072|Behavioral|A 5-months physical exercise-based program|"The physical exercise program consists of 3-5 after-school sessions/week of 90 min plus exercise homework in the weekends, and will focus on high-intensity aerobic exercise mainly."
1996987|NCT02292446|Drug|Ruxolitinib|
1725621|NCT00006465|Drug|capecitabine|Patients receive oral capecitabine twice daily on days 1-5 weekly for 4 weeks. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
1725622|NCT00006465|Drug|irinotecan hydrochloride|Patients receive irinotecan IV over 30 minutes once weekly for 4 weeks (one hour after oxaliplatin). Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of irinotecan and capecitabine until the maximum tolerated dose(MTD).
1725623|NCT00006465|Drug|oxaliplatin|Patients receive oxaliplatin IV over 2 hours. Treatment repeats every 6 weeks in the absence of disease progression or unacceptable toxicity.
1725624|NCT00006466|Drug|beta alethine|
1725625|NCT00006467|Drug|ISIS 2503|
1725626|NCT00006467|Drug|gemcitabine hydrochloride|
1725627|NCT00006468|Drug|FOLFOX regimen|
1725628|NCT00006468|Drug|fluorouracil|
1725629|NCT00006468|Drug|leucovorin calcium|
1725630|NCT00006468|Drug|oxaliplatin|
1725631|NCT00006469|Drug|carboplatin|
1725632|NCT00006469|Drug|paclitaxel|
1725633|NCT00006469|Procedure|conventional surgery|
1725634|NCT00006469|Procedure|neoadjuvant therapy|
1725635|NCT00006469|Radiation|radiation therapy|
1725636|NCT00006470|Biological|monoclonal antibody 11D10 anti-idiotype vaccine|
1725637|NCT00006470|Biological|monoclonal antibody 3H1 anti-idiotype vaccine|
1725638|NCT00006470|Radiation|radiation therapy|
1725639|NCT00006471|Drug|Fenretinide|1800 mg/m2 per day for seven consecutive days, in two divided doses of 900 mg/m2 12 hours apart, repeated every 3 weeks.
1725640|NCT00006472|Drug|carboplatin|
1725641|NCT00006472|Drug|fluorouracil|
1725642|NCT00006472|Drug|paclitaxel|
1725643|NCT00006472|Procedure|conventional surgery|
1725644|NCT00006472|Radiation|radiation therapy|
1725645|NCT00006473|Drug|oxaliplatin|Given IV
1725646|NCT00006474|Drug|O6-benzylguanine|
1725647|NCT00006474|Drug|temozolomide|
1725648|NCT00006474|Procedure|conventional surgery|
1725649|NCT00006475|Drug|imatinib mesylate|
1725650|NCT00006476|Drug|suramin|
1725651|NCT00006476|Procedure|conventional surgery|
1725652|NCT00006477|Dietary Supplement|mistletoe extract|
1725653|NCT00006478|Biological|autologous tumor cell vaccine|
1725654|NCT00006478|Biological|keyhole limpet hemocyanin|
1725655|NCT00006478|Biological|sargramostim|
1725656|NCT00006478|Procedure|adjuvant therapy|
1725657|NCT00006479|Drug|FOLFOX regimen|
1725658|NCT00006479|Drug|fluorouracil|
1725659|NCT00006479|Drug|leucovorin calcium|
1725660|NCT00006479|Drug|oxaliplatin|
1725661|NCT00006479|Procedure|adjuvant therapy|
1725662|NCT00006479|Procedure|conventional surgery|
1725663|NCT00006479|Procedure|neoadjuvant therapy|
1725664|NCT00006480|Biological|aldesleukin|
1725665|NCT00006480|Biological|therapeutic autologous lymphocytes|
1725666|NCT00006480|Drug|chemotherapy|
1725667|NCT00006480|Drug|ganciclovir|
1725668|NCT00006481|Drug|Biafine cream|
1725669|NCT00006481|Procedure|quality-of-life assessment|
1725670|NCT00006481|Radiation|radiation therapy|
1725671|NCT00006482|Drug|cisplatin|
1725672|NCT00006482|Drug|gemcitabine hydrochloride|
1725673|NCT00006483|Biological|sargramostim|
1725674|NCT00006484|Drug|carboplatin|
1725675|NCT00006484|Drug|paclitaxel|
1725676|NCT00006484|Drug|tirapazamine|
1725677|NCT00006485|Drug|alvocidib|
1725678|NCT00006485|Drug|irinotecan hydrochloride|
1725679|NCT00006486|Drug|carboxyamidotriazole|Given orally
1725680|NCT00006486|Other|placebo|Given orally
1725681|NCT00006487|Drug|cisplatin|"During induction: 50 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion
During consolidation: 60 mg/m2, IV on Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
1725682|NCT00006487|Drug|etoposide|"During induction: 50 mg/m2/day, IV on Days 1 - 5, 29 - 33. 1 hour infusion
During consolidation: 120 mg/m2, IV on Days 1, 2 and 3 at approximately Week 11, Week 14. 1 hour infusion."
1725683|NCT00006487|Drug|tirapazamine|"During induction:
Phase I low dose: 260 mg/m2/day, IV on Days 1, 8, 29, 36. 1 hour infusion
Phase II high dose: 330 mg/m2/day, IV on Days 1, 8, 29, 36 1 hour infusion
During consolidation:
330 mg/ m2, IV Day 1 only at approximately Week 11, Week 14. 1 hour infusion."
1725684|NCT00006487|Radiation|radiation therapy|Radiotherapy should begin within 1 - 3 hours after completion of TPZ infusion on Day 1 of Cycle 1 of induction chemotherapy as outlined above. Computed tomography based treatment planning is strongly recommended.The primary tumor, adjacent mediastinum and other targeted lymph nodes shall receive 4,500 cGy in 25 fractions, five days/week at 180 cGy daily. A 1,600 cGy boost to areas of gross disease will be delivered through reduced off-spinal cord fields in eight fractions, five days/week at 200 cGy daily.
1725685|NCT00006488|Drug|recombinant-methionyl human glial cell line-derived neurotrophic factor|
1725686|NCT00006489|Behavioral|Cognitive-Behavioral Therapy|Twelve weekly 90-minute individual therapy sessions followed by (6) 90-minute sessions every other week
1725687|NCT00006489|Drug|Naltrexone|Daily dosing 100 mg for 24 weeks
1725688|NCT00006489|Drug|Placebo|Pill Placebo daily dosing 24 weeks
1725689|NCT00006493|Drug|Rosiglitazone|
1725690|NCT00006495|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1725691|NCT00006495|Biological|HIV-1 Immunogen|
1725692|NCT00006501|Procedure|ECG|A diagnostic tool that is routinely used to assess the electrical and muscular functions of the heart (non-experimental).
1725694|NCT00006507|Behavioral|Occupational Therapy|
1725695|NCT00006508|Procedure|Controlled hypoglycemia using insulin|
1725696|NCT00006508|Procedure|formula meal|
1725697|NCT00006509|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1725698|NCT00006509|Biological|gp160 MN/LAI-2|
1725699|NCT00006516|Behavioral|Infant stimulation|
1725702|NCT00006517|Device|high-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
1725703|NCT00006517|Device|low-output negative ion generator|automated air ion delivery in bedroom prior to wake-up
1725704|NCT00006517|Device|dawn light pulse|rectangular light pulse matched for lux.time of dawn simulation delivered prior towake-up
1725705|NCT00006519|Drug|Capravirine|
1725706|NCT00006565|Device|HEPA Air Cleaner|Placement of two active HEPA air cleaners in the homes of children
1725707|NCT00006565|Device|Placebo Filtration Unit|Placement of inactive filtration unit in the homes
1725708|NCT00006578|Drug|Ritonavir|
1725709|NCT00006578|Drug|Abacavir sulfate|
1725710|NCT00006578|Drug|Amprenavir|
1725711|NCT00006578|Drug|Lamivudine|
1725712|NCT00006578|Drug|Filgrastim|
1725713|NCT00006591|Drug|Ritonavir|
1725714|NCT00006591|Drug|Amprenavir|
1725715|NCT00006604|Drug|ATV|Participants received varying doses of ATV, depending on their age and weight. The medication was administered as 50 mg, 100 mg, or 200 mg capsules or a powder formulation, depending on which study arm participants were in.
1725716|NCT00006604|Drug|Ritonavir|Administered as 100 mg capsules or oral solution.
1725717|NCT00006617|Drug|Abacavir sulfate|
1725718|NCT00006617|Drug|Amprenavir|
1725719|NCT00006617|Drug|Lamivudine|
1725720|NCT00006617|Drug|Zidovudine|
1725721|NCT00006630|Drug|Vaccinia Immune Globulin (Human)|
1725722|NCT00006656|Drug|carmustine in ethanol|
1725723|NCT00006656|Procedure|conventional surgery|
1725724|NCT00006669|Biological|rituximab|
1725725|NCT00006669|Biological|sargramostim|
1725726|NCT00006669|Drug|EPOCH regimen|
1725727|NCT00006669|Drug|cyclophosphamide|
1725728|NCT00006669|Drug|doxorubicin hydrochloride|
1725729|NCT00006669|Drug|etoposide|
1725730|NCT00006669|Drug|prednisone|
1725731|NCT00006669|Drug|vincristine sulfate|
1725732|NCT00006682|Drug|docetaxel|
1725733|NCT00006682|Drug|vinorelbine ditartrate|
1725734|NCT00006695|Drug|carmustine|300 mg/m2 IV on Day -6
1725735|NCT00006695|Drug|cytarabine|100 mg/m2 BID on Days -5 through -2
1725736|NCT00006695|Drug|etoposide|100 mg/m2 BID on Days -5 through -2
1725737|NCT00006695|Drug|melphalan|140 mg/m2 IV on Day -1
1725738|NCT00006695|Procedure|peripheral blood stem cell transplantation|Following the chemotherapy, on Day 0 of treatment, the previously stored hematopoietic stem cells will be administered to the patient intravenously through a central line to the patient.
1725739|NCT00006695|Radiation|tositumomab and iodine I 131 tositumomab|"Patients will receive two administrations of Iodine-131 Anti-B1 Antibody; the dosimetric dose and the therapeutic dose. The dosimetric dose will consist of an infusion of unlabeled Anti-B1 Antibody (450 mg) immediately followed by an infusion of Anti-B1 Antibody (35 mg) which has been trace labeled with 5 mCi of Iodine-131 Anti-B1 Antibody. Using whole body anterior and posterior gamma camera scans and serial imaging studies over approximately one week, the clearance of the whole body dosimetric dose will be used to calculate the subsequent therapeutic dose of Iodine-131 Anti-B1 Antibody which delivers a total body dose of 75 cGy to the subject"
1725740|NCT00006708|Biological|filgrastim|5 μg/kg/day subcutaneous injection on Days 5-12 every 21 days for 3 cycles.
1725741|NCT00006708|Biological|rituximab|
1725742|NCT00006708|Drug|carboplatin|
1725743|NCT00006708|Drug|etoposide|
1725744|NCT00006708|Drug|ifosfamide|
1725745|NCT00006721|Biological|rituximab|Given IV
1725746|NCT00006721|Drug|cyclophosphamide|Given IV
1725747|NCT00006721|Drug|doxorubicin|Given IV
1725748|NCT00006721|Drug|prednisone|Given orally
1725749|NCT00006721|Drug|vincristine|Given IV
1725750|NCT00006721|Radiation|tositumomab|Given IV
1725751|NCT00006734|Biological|filgrastim|Given IV
1725752|NCT00006734|Drug|cyclophosphamide|Given IV
1725753|NCT00006734|Drug|doxorubicin hydrochloride|Given IV
1725754|NCT00006734|Drug|etoposide|Given IV
1725755|NCT00006734|Drug|ifosfamide|Given IV
1725756|NCT00006734|Drug|vincristine sulfate|Given IV
1725757|NCT00006734|Procedure|adjuvant therapy|
1725758|NCT00006734|Procedure|conventional surgery|
1725759|NCT00006734|Procedure|neoadjuvant therapy|
1725760|NCT00006734|Radiation|brachytherapy|
1725761|NCT00006734|Radiation|radiation therapy|
1725762|NCT00006747|Drug|carmustine|IV
1725763|NCT00006747|Drug|melphalan|IV
1725764|NCT00006747|Drug|etoposide|IV
1725765|NCT00006747|Drug|cytarabine|IV
1725766|NCT00006747|Drug|tacrolimus|IV
1725767|NCT00006747|Drug|methotrexate|IV
1725768|NCT00006747|Drug|sargramostim|IV
1725769|NCT00006747|Procedure|transplant|
1725770|NCT00006760|Biological|filgrastim|subcutaneously or IV over 15-30 minutes beginning 24-36 hours after completion of vinorelbine and continuing daily until blood counts recover.
1725771|NCT00006760|Drug|ifosfamide|V over 24 hours on days 1-4
1725772|NCT00006760|Drug|vinorelbine tartrate|IV over 6-10 minutes on days 1 and 5.
1725773|NCT00006773|Drug|bortezomib|Given IV
1725774|NCT00006786|Biological|bevacizumab|
1725775|NCT00006786|Drug|fluorouracil|
1725776|NCT00006786|Drug|irinotecan hydrochloride|
1725777|NCT00006786|Drug|leucovorin calcium|
1725778|NCT00006799|Drug|megestrol acetate|
1725779|NCT00006799|Procedure|quality-of-life assessment|
1725780|NCT00006812|Drug|capecitabine|
1725781|NCT00006825|Biological|trastuzumab|
1725782|NCT00006825|Drug|pegylated liposomal doxorubicin hydrochloride|
1725783|NCT00006864|Biological|aldesleukin|
1725784|NCT00006877|Drug|temozolomide|
1725785|NCT00006890|Drug|prednisone|Prednisone 50mg on alternate days
1725786|NCT00006890|Drug|thalidomide|THALIDOMIDE 200 mg qhs
1725787|NCT00006903|Drug|Fulvestrant|Given intramuscularly
1725788|NCT00006916|Biological|bleomycin|
1725789|NCT00006916|Device|Ommaya reservoir|
1725790|NCT00006916|Radiation|radiation therapy|60.0 Gy/30 fractions x 2.0 Gy. For the first 46 Gy/23 fractions the treatment volume should include the volume of contrast-enhancing lesion and surrounding edema on pre-operative CT/MRI scan plus a 2 centimeter margin. If no edema is present, the margin should be 2.5 cm. After 46.0 Gy, the tumor volume should include the contrast-enhancing lesion (without edema) on the pre-surgery MRI/CT scan plus a 2.5 centimeter margin.
1725791|NCT00006929|Drug|suramin|Given IV
1725792|NCT00006929|Drug|carboplatin|Given IV
1725793|NCT00006929|Drug|paclitaxel|Given IV
1725794|NCT00006929|Other|pharmacological study|Correlative studies
1725795|NCT00006929|Other|laboratory biomarker analysis|Correlative studies
1725796|NCT00006942|Drug|bryostatin 1|Given IV
1725797|NCT00006942|Drug|cisplatin|Given IV
1725798|NCT00006942|Other|laboratory biomarker analysis|Correlative studies
1725799|NCT00006968|Biological|filgrastim|
1725800|NCT00006968|Drug|cyclosporine|
1725801|NCT00006968|Drug|pentostatin|
1725802|NCT00006968|Procedure|allogeneic bone marrow transplantation|
1725803|NCT00006968|Procedure|peripheral blood stem cell transplantation|
1725804|NCT00006981|Biological|SS1(dsFv)-PE38 immunotoxin|
1725805|NCT00006994|Dietary Supplement|glutamine|20 cc three times daily for 60 days
1725806|NCT00006994|Radiation|radiation therapy|Per institutional standard; minimum of 6,000 cGy with a daily dose of 180-200 cGy.
1725807|NCT00006994|Drug|l-glutamine placebo|20 cc three times daily for 60 days
1725808|NCT00007007|Procedure|management of therapy complications|
1725809|NCT00007007|Procedure|quality-of-life assessment|
1725810|NCT00007020|Drug|Cholic Acids|10-15 mg/kg body weight/day taken orally.
1725811|NCT00007033|Drug|magnesium gluconate|
1725812|NCT00007033|Drug|magnesium sulfate|
1725813|NCT00007059|Drug|mycophenolate mofetil|
1725814|NCT00007085|Device|Tomography, X-ray Computed|
1725815|NCT00007163|Drug|J695|
1725816|NCT00007189|Drug|Naproxen Sodium (Aleve)|
1725817|NCT00007189|Drug|Celecoxib (Celebrex)|
1725818|NCT00007202|Drug|Atazanavir|
1725819|NCT00007202|Drug|Stavudine|
1725820|NCT00007202|Drug|Didanosine|
1725821|NCT00007241|Device|Isometric exercise|
1725822|NCT00007254|Drug|Pain relief for pressure ulcers|
1725823|NCT00007267|Behavioral|Cognitive behavioral therapy|
1725824|NCT00007267|Behavioral|Disease/health education|
1725825|NCT00007267|Behavioral|Self-help cognitive behavioral intervention facilitated by a psychologist|
1725826|NCT00007280|Device|Bioengineered skin|
1725827|NCT00007293|Device|UV-B Lightsource and Fiber Optic Comb|
1725828|NCT00007306|Drug|Parathyroid hormone ointment|
1725829|NCT00007332|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1725830|NCT00007332|Biological|MN rgp120/HIV-1 and GNE8 rgp120/HIV-1|
1725831|NCT00007345|Drug|Romidepsin|
1725832|NCT00007358|Drug|Dexamethasone or other corticosteroid|Administered during the third trimester of pregnancy
1725833|NCT00007423|Biological|ALVAC-HIV MN120TMG (vCP205)|
1725834|NCT00007423|Biological|ALVAC-RG Rabies Glycoprotein (vCP65)|
1725835|NCT00007436|Drug|Tenofovir disoproxil fumarate|
1725836|NCT00007449|Drug|DPC 083|
1725837|NCT00007475|Procedure|Plasma exchange|A course of plasma exchange of 5 treatments over 10 days, then administration of cyclophosphamide.
1725838|NCT00007475|Drug|Cyclophosphamide|For GFR > 50 ml/min/1.73 m2 received oral cyclophosphamide at a dose of 2 mg/kg/ day for 3 months. For GFR < 50 ml/min/1.73 m2 but > 10 ml/min/1.73 m2 will receive oral cyclophosphamide at a 25% reduced dose or 1.5 mg/kg/d for 3 months.
1725839|NCT00007501|Biological|Varicella-zoster vaccine|Immunization with 0.5 ml, live, attenuated (Oka/Merck) varicella-zoster vaccine.
1725840|NCT00007501|Biological|Placebo|Placebo vaccine
1725841|NCT00007527|Drug|naloxone|
1725842|NCT00007527|Drug|buprenorphine|
1725843|NCT00007592|Drug|Chlorthalidone|
1725844|NCT00007592|Drug|Furosemide|
1725845|NCT00007605|Drug|Amiodarone|Patients assigned will receive 400 mg bid for 14 days, 400 mg QAM and 200 mg QHS for 14 days, 300 mg qd for 48 weeks, then 200 mg qd.
1725846|NCT00007605|Drug|Sotalol|Patients assigned will receive 80 mg bid for 7 days and 160 mg bid thereafter.
1725847|NCT00007631|Drug|Tretinoin 0.1% cream or placebo|
1725848|NCT00007631|Other|Placebo|Patients receive placebo for same amount of time
1725849|NCT00007644|Procedure|Radical prostatectomy|Surgical removal of the prostate
1725850|NCT00007657|Procedure|Intensive medical therapy|
1725851|NCT00007657|Procedure|Percutaneous Coronary Intervention (PCI) plus intensive medical therapy|
1725852|NCT00005630|Biological|ras peptide cancer vaccine|
1725853|NCT00005630|Biological|sargramostim|
1725854|NCT00005631|Biological|filgrastim|
1725855|NCT00005631|Biological|rituximab|
1725856|NCT00005631|Drug|carboplatin|
1725857|NCT00005631|Drug|etoposide|
1725858|NCT00005631|Drug|ifosfamide|
1725859|NCT00005632|Biological|MUC1-KLH vaccine/QS21|
1725860|NCT00005633|Biological|OVA BiP peptide|
1725861|NCT00005633|Biological|gp209-2M antigen|
1725862|NCT00005633|Biological|recombinant 70-kD heat-shock protein|
1725863|NCT00005633|Biological|tyrosinase peptide|
1725864|NCT00005634|Drug|vorinostat|
1725865|NCT00005635|Biological|trastuzumab|
1725866|NCT00005635|Drug|paclitaxel|
1725867|NCT00005636|Drug|cisplatin|
1725868|NCT00005636|Drug|pemetrexed disodium|
1725869|NCT00005637|Drug|carmustine|
1725870|NCT00005637|Drug|temozolomide|
1725871|NCT00005638|Drug|cisplatin|
1725872|NCT00005638|Drug|irinotecan hydrochloride|
1725873|NCT00005638|Radiation|radiation therapy|
1725874|NCT00005639|Drug|azacitidine|
1725875|NCT00005639|Drug|sodium phenylbutyrate|
1725876|NCT00005640|Procedure|Preoperative Endoscopy|
1725877|NCT00005640|Radiation|Technetium Tc 99m Sulfur Colloid|
1725880|NCT00005641|Biological|anti-thymocyte globulin|
1725881|NCT00005641|Drug|busulfan|
1725882|NCT00005641|Drug|cyclophosphamide|
1725883|NCT00005641|Drug|cyclosporine|
1725884|NCT00005641|Drug|leucovorin calcium|
1725885|NCT00005641|Drug|methotrexate|
1725886|NCT00005641|Drug|methylprednisolone|
1725887|NCT00005641|Procedure|allogeneic bone marrow transplantation|
1725888|NCT00005641|Procedure|in vitro-treated bone marrow transplantation|
1725889|NCT00005641|Radiation|radiation therapy|
1725890|NCT00005642|Drug|semaxanib|This is a dose-deescalation study. Patients receive SU5416 IV over 1 hour twice weekly for 4 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity. Cohorts of 6-12 patients receive deescalating doses of SU5416 until the maximum target-inhibiting dose (MTID) is determined.
1725891|NCT00005643|Drug|pegylated liposomal doxorubicin hydrochloride|
1725892|NCT00005644|Drug|gemcitabine hydrochloride|
1725893|NCT00005644|Drug|paclitaxel|
1725894|NCT00005645|Drug|ILX-295501|
1725895|NCT00005646|Drug|paclitaxel|150 mg/sq m IV over 3 hours weekly for 6 weeks per cycle
1725896|NCT00005647|Drug|paclitaxel|Patients receive paclitaxel IV over one hour on day 1. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
1725897|NCT00005647|Drug|semaxanib|Patients receive SU5416 IV over one hour on days 1 and 4. Treatment continues weekly in the absence of disease progression or unacceptable toxicity.
1725898|NCT00005648|Drug|Gemcitabine with R115777|R115777 200 mg, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
1725899|NCT00005648|Drug|Gemcitabine with Placebo|Placebo, oral, twice daily at 12-hour intervals throughout the study coadministered with gemcitabine, 1000 mg/m2, iv, every week for the first 7 weeks, followed by 1 week rest, and then every 3 out of 4 weeks thereafter for up to 5 years
1725900|NCT00005649|Drug|capecitabine|
1725901|NCT00005649|Drug|paclitaxel|
1725902|NCT00005652|Drug|rituximab|
1725903|NCT00005654|Drug|clomiphene citrate|
1725904|NCT00005654|Drug|metformin|
1725905|NCT00005655|Biological|rh IL-12|rhIL-12 will be administered intravenously on days 2, 4, 6, 10, 12 and 14 of each cycle.
1725906|NCT00005655|Biological|rh IL-2|rhIL-2 will be administered intravenously every 8 hours x 3 doses on days 1 and 9 of each cycle.
1725907|NCT00005658|Drug|Glycine|
1725908|NCT00005663|Drug|Valacyclovir hydrochloride|
1725909|NCT00005665|Drug|interferon alpha|
1725910|NCT00005666|Procedure|PET scan use in radiotherapy planning|
1725911|NCT00005668|Drug|Itraconazole oral solution|
1725912|NCT00005669|Drug|Metformin HCL|Medication studied for ability to alter body weight and body composition.
1725913|NCT00005669|Drug|Placebo|Control capsules for metformin
1725914|NCT00005673|Drug|Capravirine|
1725915|NCT00005674|Drug|Creatine|
1725916|NCT00005675|Drug|Oral bovine type I collagen|500 mcg of CI daily for 15 months
1725917|NCT00005675|Drug|Placebo|CI placebo daily for 15 months
1725918|NCT00005684|Drug|warfarin|
1725919|NCT00005684|Drug|heparin|
1725920|NCT00005711|Behavioral|Asthma self-management education|"Treatment group children and their families participated in the patient education program which consisted of four separate one-hour sessions. The topics were: symptoms of asthma, causes of asthma (triggers), medications, and peak flow. A bilingual nurse educator working one-on-one with the child and family members delivered these four sessions. The four sessions were delivered over a six week period. Culturally sensitive educational materials include both print (flip charts, take-home brochures) and videotape materials. The videotapes feature children from the clinic and highlight how they successfully manage their asthma. All materials are available in both English and Spanish."
1725921|NCT00005713|Behavioral|Continuing, preventative care|Training for intervention clinic staff was based on National Asthma Education and Prevention Program guidelines for the diagnosis and management of asthma, and included screening to identify new cases and health education to improve family management.
1725922|NCT00005724|Behavioral|Computer Program Intervention Group|A user-friendly, interactive computer program providing dietary counseling tailored to the needs of the participant.
1725923|NCT00005724|Other|Minimal Intervention Group|Dietary Information pamphlets.
1725924|NCT00005724|Behavioral|Health Counselor Intervention Group|Food for Heart Program - a structured diet treatment program for low income patients with high cholesterol, given by a health counselor at 4 treatment visits.
1725925|NCT00005727|Behavioral|Intervention|Classroom-based nutrition education curriculum designed for individuals with low literacy skills.
1725926|NCT00005739|Behavioral|Community-based directly observed therapy (DOT)|A community-based intervention conducted by trained graduates of a TB directly observed therapy (DOT) program (peer workers)
1725927|NCT00005739|Behavioral|Clinic directly observed therapy (DOT)|A traditional self-administered preventive treatment
1725928|NCT00005743|Behavioral|exercise|
1725929|NCT00005743|Behavioral|weight loss|
1725930|NCT00005758|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1725931|NCT00005758|Biological|HIV-1 Immunogen|
1725932|NCT00005762|Drug|Indinavir sulfate|
1725933|NCT00005762|Drug|Ritonavir|
1725934|NCT00005762|Drug|Amprenavir|
1725935|NCT00005762|Drug|Nelfinavir mesylate|
1725936|NCT00005762|Drug|Efavirenz|
1725937|NCT00005762|Drug|Saquinavir|
1725938|NCT00005764|Drug|Lamivudine/Zidovudine|
1725939|NCT00005764|Drug|Abacavir sulfate|
1725940|NCT00005764|Drug|Lamivudine|
1725941|NCT00005765|Drug|nicotine|
1725942|NCT00005765|Drug|alcohol|
1725943|NCT00005766|Drug|Creatinine|
1725944|NCT00005768|Drug|Estrogen|
1725945|NCT00005769|Drug|Hormone Replacement Therapy|
1725946|NCT00005770|Device|Acupuncture|
1725947|NCT00005771|Device|Visual utrasound feedback|
1725948|NCT00005771|Procedure|Abdominal Hollowing Exercise|
1726086|NCT00010361|Drug|mycophenolate mofetil|
1725949|NCT00005772|Device|Induced hypothermia|Whole-body cooling using the Blanketrol II or III Units in the Automatic Control Mode with a YSI 400 series temperature probe placed in the distal esophagus over a 96-hour period
1725950|NCT00005772|Device|Control|Control group: standard care
1725951|NCT00005773|Drug|Inhaled Nitric Oxide|Study gas was initiated at a concentration of 5 ppm, and the dose was increased to 20 ppm when the infant had <=20 mm Hg increase in PaO2 (less than full response).
1725952|NCT00005773|Drug|Standard iNO therapy|Begin a sham initiation of iNO in term and near-term infants in respiratory failure with an oxygenation index (OI) between 15-25; initiated actual iNO therapy based on standard threshold (OI >=25).
1725953|NCT00005774|Drug|Early surfactant|Early surfactant followed by extubation within 30 minutes and application of continuous positive airway pressure (CPAP)
1725954|NCT00005774|Drug|Standard practice|Surfactant according to current center practice, only after initiation of mechanical ventilation.
1725955|NCT00005775|Drug|Glutamine|Infants randomized to glutamine supplementation will receive glutamine any time that parenteral nutrition is required during the first 120 days of hospitalization.
1725956|NCT00005775|Drug|Placebo|TrophAmine given any time that parenteral nutrition is required during the first 120 days of hospitalization.
1725957|NCT00005776|Drug|Inhaled nitric oxide|Inhaled Nitric oxide at a concentration of 20 ppm
1725958|NCT00005776|Drug|Placebo|100% Oxygen
1725959|NCT00005777|Procedure|Minimal mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target (>52 mm Hg)
1725960|NCT00005777|Procedure|Routine mechanical ventilation management|Partial pressure of carbon dioxide (PCO2) target <48 mm Hg)
1725961|NCT00005777|Drug|Dexamethasone|Treatment with the study medication was initiated within 24 hours after birth. The dexamethasone-treated infants received a 10-day tapered course (0.15 mg of dexamethasone per kilogram per day for three days, followed by 0.10 mg per kilogram for three days, 0.05 mg per kilogram for two days, and 0.02 mg per kilogram for two days), with the daily dose divided in half and given at 12-hour intervals intravenously or orally, if an intravenous catheter was no longer in place.
1725962|NCT00005777|Drug|Placebo|The infants in the placebo groups received equal volumes of saline.
1725963|NCT00005778|Drug|High-dose immunoablative therapy|"High dose cyclophosphamide for 4 days.
NIH monthly IV cytoxan for 6 months followed by quarterly for 2 years."
1725964|NCT00005779|Drug|Interleukin-12|
1725965|NCT00005779|Biological|HIV-1 C4-V3 Polyvalent Peptide Vaccine|
1725969|NCT00005782|Drug|Granulocyte colony-stimulating factor|
1725970|NCT00005782|Procedure|Leukapheresis|
1725971|NCT00005783|Drug|Recombinant-methionyl human stem cell factor|
1725972|NCT00005785|Drug|GCSF Mobilized Allogeneic PBSC Cultured w/Cytokines; Transduced w/RV|
1725973|NCT00005786|Drug|arsenic trioxide|Given IV
1725974|NCT00005786|Other|laboratory biomarker analysis|Correlative studies
1725975|NCT00005787|Biological|epoetin alfa|
1725976|NCT00005787|Biological|filgrastim|
1725977|NCT00005787|Biological|recombinant flt3 ligand|
1725978|NCT00005787|Biological|recombinant interleukin-3|
1725979|NCT00005787|Biological|sargramostim|
1725980|NCT00005787|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1725981|NCT00005788|Biological|aldesleukin|
1725982|NCT00005790|Other|laboratory biomarker analysis|
1725983|NCT00005790|Procedure|biopsy|
1725984|NCT00005790|Procedure|magnetic resonance imaging|
1725985|NCT00005790|Radiation|gadopentetate dimeglumine|
1725986|NCT00005791|Drug|cisplatin|
1725987|NCT00005791|Drug|fluorouracil|
1725988|NCT00005791|Drug|irinotecan hydrochloride|
1725993|NCT00005793|Drug|Cytarabine|
1725994|NCT00005793|Drug|Daunorubicin|
1725995|NCT00005793|Drug|Etoposide|
1725996|NCT00005793|Drug|Topotecan|
1725997|NCT00005794|Drug|perifosine|
1725998|NCT00007670|Drug|Carbamazepine|
1725999|NCT00007670|Drug|Gabapentin|
1726000|NCT00007670|Drug|Lamotrigine|
1726001|NCT00007683|Drug|Warfarin titrated to an INR of 2.5-3.0|anticoagulation (administered without blinding) titrated to a target INR of 2.5 to 3.0, monitored by measurements at 6 week intervals after initial titration and stabilization.
1726002|NCT00007683|Drug|Aspirin|an antiplatelet agent whose mechanism is inhibition of thromboxane, a platelet activator) administered in a double blind manner.
1726003|NCT00007683|Drug|Clopidogrel 75|(an antiplatelet agent whose mechanism is ADP inhibition) administered in a double blind manner)
1726004|NCT00007735|Drug|Doxycycline (200mg/day) or Placebo|
1726005|NCT00007748|Behavioral|Aerobic exercise|
1726006|NCT00007748|Behavioral|Cognitive behavioral therapy|
1726007|NCT00007761|Behavioral|Bipolar Disorder Program|
1726008|NCT00007761|Behavioral|Usual (psychiatric) Care|
1726009|NCT00007774|Drug|Haloperidol|
1726010|NCT00007774|Drug|Olanzapine|
1726011|NCT00007787|Biological|Cyclosporine|
1726087|NCT00010374|Device|intramuscular diaphragm electrodes|Conditioning of the diaphragm
1726176|NCT00011531|Procedure|Prevention of Pressure Ulcers|
1726177|NCT00011544|Procedure|Performance Measure|
1726178|NCT00011557|Device|Assistance in Voiding|
1726179|NCT00011570|Device|Bladder & Bowel Control|
1726012|NCT00007787|Biological|Anti-human thymocyte globulin (rabbit)|Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5 mg/kg while undergoing transplantation. Second and subsequent doses of Thymoglobulin® will be administered if, at 24 hours post-anastomosis, the serum creatinine has not decreased by at least 20% from the pre-transplant level. Additional Anti-human thymocyte globulin (rabbit) will be given at a dose of 1.5mg/kg daily for a minimum of 5 days to a maximum of 7 days.
1726013|NCT00007787|Drug|Tacrolimus|
1726014|NCT00007800|Behavioral|Behavioral Group Weight Loss Intervention|
1726015|NCT00007800|Behavioral|Motivational Interviewing|
1726016|NCT00007813|Biological|filgrastim|
1726017|NCT00007813|Drug|carboplatin|
1726018|NCT00007813|Drug|cyclophosphamide|
1726019|NCT00007813|Drug|etoposide|
1726020|NCT00007813|Procedure|autologous bone marrow transplantation|
1726021|NCT00007813|Procedure|peripheral blood stem cell transplantation|
1726022|NCT00007826|Biological|BCG vaccine|
1726023|NCT00007826|Biological|monoclonal antibody 105AD7 anti-idiotype vaccine|
1726024|NCT00007826|Drug|alum adjuvant|
1726025|NCT00007839|Drug|beta alethine|
1726026|NCT00007852|Biological|rituximab|Rituximab at 375 mg/m2 administered approximately one week apart prior to collection of the hematopoietic stem cells. Rituxan at a dose of 375 mg/m2 IV will be given either on the days prior to initiation of the BCNU (days -10 to -7) or on the same day that the BCNU is administered for the BEAM chemotherapy regimen (Day -6). A fourth infusion of Rituxan 375 mg/m2 will be given at 30 day (+/- 20 days) post-transplant. At approximately 6 months post-transplant, if the patients have not had progressive lymphoma, they will receive four weekly doses of Rituxan 375 mg/m2 IV.
1726027|NCT00007852|Drug|carmustine|BCNU 300 mg/M2 IV day -6
1726028|NCT00007852|Drug|cytarabine|100 mg/m2 on days -5 through -2
1726029|NCT00007852|Drug|etoposide|100mg/M2 BID on days -5 through -2
1726030|NCT00007852|Drug|melphalan|140 mg/m2 IV on day -1
1726031|NCT00007852|Procedure|autologous hematopoietic stem cell transplantation|Following the chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
1726032|NCT00007865|Biological|rituximab|
1726033|NCT00007865|Drug|carboplatin|
1726034|NCT00007865|Drug|etoposide|
1726035|NCT00007865|Drug|ifosfamide|
1726036|NCT00007878|Drug|bortezomib|Given IV
1726037|NCT00007878|Drug|fluorouracil|Given IV
1726038|NCT00007878|Drug|leucovorin calcium|Given IV
1726039|NCT00007878|Other|pharmacological study|Correlative studies
1726040|NCT00007878|Other|laboratory biomarker analysis|Correlative studies
1726041|NCT00007891|Biological|filgrastim|
1726042|NCT00007891|Procedure|autologous bone marrow transplantation|
1726043|NCT00007891|Procedure|peripheral blood stem cell transplantation|
1726044|NCT00007891|Radiation|indium In 111 monoclonal antibody BrE-3|
1726045|NCT00007891|Radiation|yttrium Y 90 monoclonal antibody BrE-3|
1726046|NCT00007904|Biological|filgrastim|Neupogen (G-CSF) given at a dose of 10 ugm/kg subcutaneously starting on day 5 and continuing until ANC > 10,000/uL x1 day after the nadir cycles 1-3.
1726047|NCT00007904|Drug|cyclophosphamide|cyclophosphamide 700 mg/m2 daily for 3 day every 3 weeks cycles 1-3
1726048|NCT00007904|Drug|doxorubicin hydrochloride|Patients then receive doxorubicin IV on day 1.
1726049|NCT00007904|Drug|paclitaxel|Paclitaxel 160 mg/m2 given over 72 hours by continuous infusion days 1-3
1726050|NCT00007904|Drug|tamoxifen citrate|tamoxifen at a dose of 20 mg daily for 5 years after chemotherapy is completed
1726051|NCT00007904|Procedure|adjuvant therapy|Patients receive paclitaxel IV continuously and cyclophosphamide IV over 2 hours on days 1-3. Patients also receive filgrastim (G-CSF) subcutaneously (SC) beginning on day 5 and continuing until day 14 or until blood counts recover. Treatment repeats every 21 days for 3 courses. Patients then receive doxorubicin IV on day 1 and G-CSF SC on days 2-11 every 21 days for 4 courses.
1726052|NCT00007904|Radiation|radiation therapy|Beginning 3-6 weeks after the completion of chemotherapy, patients receive radiotherapy 5 days a week for 6-7 weeks.
1726053|NCT00007917|Drug|alvocidib|
1726054|NCT00007917|Drug|gemcitabine hydrochloride|
1726055|NCT00007930|Procedure|conventional surgery|
1726056|NCT00007930|Procedure|laparoscopic surgery|
1726057|NCT00007943|Drug|gemcitabine hydrochloride|
1726058|NCT00007956|Biological|monoclonal antibody mono-dgA-RFB4|
1726059|NCT00007969|Biological|Detox-B adjuvant|
1726060|NCT00007969|Drug|verteporfin|
1726061|NCT00007982|Biological|filgrastim|
1726062|NCT00007982|Drug|carmustine|
1726063|NCT00007982|Drug|cisplatin|
1726064|NCT00007982|Drug|cyclophosphamide|
1726065|NCT00007982|Drug|etoposide|
1726066|NCT00007982|Drug|thiotepa|
1726067|NCT00007982|Procedure|adjuvant therapy|
1726068|NCT00007982|Procedure|autologous bone marrow transplantation|
1726069|NCT00007982|Procedure|bone marrow ablation with stem cell support|
1726070|NCT00007982|Procedure|peripheral blood stem cell transplantation|
1726071|NCT00007995|Biological|filgrastim|
1726072|NCT00007995|Biological|recombinant interferon alfa|
1726073|NCT00007995|Biological|sargramostim|
1726074|NCT00007995|Drug|busulfan|
1726075|NCT00007995|Drug|cyclophosphamide|
1726076|NCT00007995|Drug|melphalan|
1726077|NCT00007995|Procedure|autologous bone marrow transplantation|
1726078|NCT00007995|Procedure|bone marrow ablation with stem cell support|
1726079|NCT00007995|Procedure|peripheral blood stem cell transplantation|
1726080|NCT00010322|Drug|atamestane|
1726081|NCT00010322|Drug|toremifene|
1726082|NCT00010335|Procedure|Stem Cell Transplantation|Participants will receive a stem cell transplantation along with irradiation and the drugs anti-thymocyte globulin, cyclophosphamide, and filgrastim as noted in the text of this record.
1726083|NCT00010335|Device|CD34 selection|CD34+ cells are separated from the rest of the peripheral blood stem cells.
1726084|NCT00010361|Drug|cyclosporine|
1726085|NCT00010361|Drug|fludarabine|
1726088|NCT00010374|Device|Intramuscular diaphragm electrodes|to test the safety, efficacy and clinical utility of diaphragm pacing using IM electrodes placed through a laparoscopic approach to achieve artificial ventilation in spinal cord injured patients who have an internal cardiac pacemaker and require full-time ventilator support.
1726089|NCT00010387|Drug|cyclophosphamide|
1726090|NCT00010387|Drug|filgrastim|
1726091|NCT00010400|Drug|Cyclophosphamide|
1726092|NCT00010400|Drug|filgrastim|
1726093|NCT00010413|Drug|cyclophosphamide|
1726094|NCT00010413|Drug|filgrastim|
1726095|NCT00010426|Drug|cysteamine hydrochloride|
1726096|NCT00010439|Drug|Alendronate|Pill, 35mg or 70mg weekly, depending upon the body weight for 12 months.
1726097|NCT00010452|Drug|picibanil|Up to .2 mg per injection, given intralesionally every 6-8 weeks
1726098|NCT00010465|Procedure|Craniosacral Osteopathic Manipulative Treatment|
1726099|NCT00010465|Drug|Botanicals|
1726100|NCT00010478|Procedure|Acupuncture|
1726101|NCT00010491|Procedure|Acupuncture|
1726102|NCT00010491|Procedure|Moxibustion|
1726103|NCT00010504|Procedure|Acupuncture|
1726104|NCT00010517|Procedure|Acupuncture|
1726105|NCT00010530|Procedure|Meditation|
1726106|NCT00010608|Behavioral|Transcendental Meditation|a mantra meditation technique which originated from the Vedic tradition of India. It is practiced from 20 minutes twice a day sitting comfortably in a chair with eyes closed.
1726107|NCT00010608|Behavioral|Health Education|didactic education classes for lifestyle modification through diet, exercise, substance use control, and salt intake
1726108|NCT00010621|Procedure|Acupuncture|
1726109|NCT00010621|Procedure|chiropractic therapy|
1726110|NCT00010621|Procedure|bodywork therapy|
1726111|NCT00010634|Drug|Connective Tissue Nutrient Formula|
1726112|NCT00010634|Drug|Adaptogenic herbs|
1726113|NCT00010634|Drug|glutamine|
1726114|NCT00010647|Procedure|Acupuncture|
1726115|NCT00010686|Drug|Dietary Phytoestrogens|
1726116|NCT00010699|Drug|Vitamin E|
1726117|NCT00010712|Drug|Black Cohosh|
1726118|NCT00010725|Drug|MAK|
1726119|NCT00010725|Drug|Vitamin Supplements|
1726120|NCT00010738|Procedure|Meditation|
1726121|NCT00010751|Procedure|Reiki|
1726122|NCT00010764|Procedure|Acupuncture|
1726123|NCT00010777|Procedure|Multiple Component Mind/Body therapy|
1726124|NCT00010803|Drug|Ginkgo biloba|120mg twice a day
1726125|NCT00010803|Drug|Placebo|One pill twice daily
1726126|NCT00010816|Drug|Herbal remedies|
1726127|NCT00010829|Behavioral|American Heart Association Step 1 diet|
1726128|NCT00010829|Behavioral|American Heart Association Step 2 diet + 10 g/day flax seed|
1726129|NCT00010829|Behavioral|Macrobiotic dietary intervention|
1726130|NCT00010842|Drug|Ginkgo biloba|
1726131|NCT00010842|Drug|Alpha-lipoic acid|
1726132|NCT00010842|Drug|Vitamin E/Selenium|
1726133|NCT00010842|Drug|Essential fatty acids|
1726134|NCT00010855|Behavioral|Self-hypnotic relaxation|
1726135|NCT00010868|Drug|Omega-3 Fatty Acids|
1726136|NCT00010881|Drug|antioxidants|
1726137|NCT00010881|Behavioral|stress reduction|
1726138|NCT00010907|Drug|NPI-028|
1726139|NCT00010920|Drug|Ginkgo Biloba Extract|
1726140|NCT00010933|Drug|chamomile tea|
1726141|NCT00010933|Procedure|Relaxation/Guided Imagery|
1726142|NCT00010946|Procedure|Acupuncture|
1726143|NCT00010959|Drug|Cimicifuga racemosa|
1726144|NCT00010959|Drug|Trifolium pratense|
1726145|NCT00010972|Procedure|Acupuncture|
1726146|NCT00010985|Procedure|Acupuncture|
1726147|NCT00010985|Procedure|Chiropractic|
1726148|NCT00010985|Procedure|massage|
1726149|NCT00010998|Procedure|Yoga|
1726150|NCT00011011|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1726151|NCT00011024|Procedure|Self Hypnosis|
1726152|NCT00011024|Procedure|Acupuncture|
1726153|NCT00011024|Procedure|Osteopathic Manipulation|
1726154|NCT00011037|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|1 x 10^ 7 TCID50 administered intramuscularly
1726155|NCT00011037|Biological|MN rgp120/HIV-1|0.6 mg administered intramuscularly
1726156|NCT00011037|Biological|ALVAC(2)120(B,MN)GNP (vCP1452) placebo|ALVAC placebo administered intramuscularly
1726157|NCT00011037|Biological|MN rgp120/HIV-1 placebo|Alum placebo administered intramuscularly
1726158|NCT00011063|Drug|Ginkgo Biloba|
1726159|NCT00011076|Drug|Pirfenidone|
1726160|NCT00011089|Drug|Tenofovir disoproxil fumarate|
1726161|NCT00011102|Behavioral|Weight Gain Prevention for Women Project|
1726162|NCT00011115|Behavioral|Weight loss motivations|
1726163|NCT00011128|Behavioral|Antiretroviral Treatment Interruption|
1726164|NCT00011141|Drug|Oral lactobacillus administration|
1726165|NCT00011193|Behavioral|Exercise|Compared the effect of 50%, 100%, and 150% of the NIH Consensus Development Panel recommended physical activity dose on fitness in women.
1726166|NCT00011258|Drug|Paraoxonase|
1726167|NCT00011297|Drug|gabapentin (Neurontin)|
1726168|NCT00011297|Drug|lorazepam (Ativan)|
1726169|NCT00011362|Drug|Dexamethasone Early|Tapering course of dexamethasone in doses given twice a day (0.25 mg per kilogram of body weight per dose for five days, then 0.15 mg, 0.07 mg, and 0.03 mg per kilogram per dose for three days each), followed by two weeks of saline.
1726170|NCT00011362|Drug|Dexamethasone Late|Saline for two weeks, followed by either the same tapering two-week course of dexamethasone given to the first group, if the respiratory-index score was >=2.4 on treatment day 14, or an additional two weeks of saline
1726171|NCT00011375|Drug|Rolipram|
1726172|NCT00011414|Drug|Tariquidar|IV alone for 1 dose (Day -1), then in combo for rest of cycle (Day 1, etc). Given in combo with one of the following: Doxorubicin (50 mg/m2 IV over 15 min on day 1), Vinorelbine (20 mg/m2 IV over 10 min on days 1 and 8), or Docetaxel (75 mg/m2 IV over 60 min on day 1).
1726173|NCT00011479|Drug|Abacavir sulfate|
1726180|NCT00011583|Device|Robot-assisted therapy|1 hour/day of mechanically-assisted upper limb therapy
1726181|NCT00011583|Device|Traditional therapy|1 hour/day of upper limb therapy that includes exposure to, but no manipulation by the robot
1726182|NCT00011596|Procedure|Gait Training|
1726183|NCT00011609|Device|Robotic Arm|
1726184|NCT00011622|Device|Continuous ambulatory subcutaneous glucose monitor|
1726185|NCT00011635|Drug|Silymarin (milk thistle)|
1726186|NCT00011661|Behavioral|Education on behaviors to reduce lead exposure|
1726187|NCT00011713|Other|Completion questionnaires/providing biological samples|Participant completes baseline interview at enrollment, then completes online questionnaire on lifestyle and medical history. Diet questionnaire is completed at home and mailed back. Online questionnaire about personal care product use and medications is completed at each scheduled study visit.
1726188|NCT00011752|Drug|FCWAY|
1726189|NCT00011765|Drug|Fluoxetine|
1726190|NCT00011778|Drug|bortezomib|
1726191|NCT00011778|Radiation|radiation therapy|
1726192|NCT00011804|Drug|Topiramate|
1726193|NCT00011830|Drug|G-CSF|
1726194|NCT00011830|Procedure|Apheresis|
1726195|NCT00011895|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
1726196|NCT00011895|Drug|Efavirenz|
1726197|NCT00011908|Drug|hLL2 (Epratuzumab)|
1726198|NCT00011921|Biological|filgrastim|
1726199|NCT00011921|Drug|carboplatin|
1726200|NCT00011921|Drug|epirubicin hydrochloride|
1726201|NCT00011921|Drug|etoposide|
1726202|NCT00011921|Drug|etoposide phosphate|
1726203|NCT00011921|Drug|ifosfamide|
1726204|NCT00011921|Drug|paclitaxel|
1726205|NCT00011921|Procedure|autologous bone marrow transplantation|
1726206|NCT00011921|Procedure|bone marrow ablation with stem cell support|
1726207|NCT00011921|Procedure|peripheral blood stem cell transplantation|
1726208|NCT00011921|Radiation|radiation therapy|
1726209|NCT00011934|Biological|recombinant interferon alfa|
1726210|NCT00011934|Biological|sargramostim|
1726211|NCT00011934|Procedure|autologous bone marrow transplantation|
1726212|NCT00011960|Drug|cisplatin|
1726213|NCT00011960|Drug|paclitaxel|
1726214|NCT00011960|Procedure|adjuvant therapy|
1726215|NCT00011960|Radiation|radiation therapy|
1726216|NCT00011973|Drug|fenretinide|
1726217|NCT00011986|Drug|Paclitaxel|Given IV
1726218|NCT00011986|Drug|Carboplatin|Given IV
1726219|NCT00011986|Drug|Gemcitabine Hydrochloride|Given IV
1726220|NCT00011986|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|
1726221|NCT00011986|Drug|Topotecan Hydrochloride|Given IV
1726222|NCT00011986|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1726223|NCT00011999|Drug|cisplatin|
1726224|NCT00011999|Drug|paclitaxel|
1726225|NCT00011999|Procedure|conventional surgery|
1726226|NCT00011999|Radiation|radiation therapy|
1726227|NCT00012012|Drug|Amifostine trihydrate|Amifostine will be delivered before each radiation treatment. Amifostine (500 mg) will be given as two equally-divided subcutaneous injections.
1726228|NCT00012012|Drug|Cisplatin|Cisplatin will be given weekly with external beam radiation therapy and once with brachytherapy for a total of six doses. Patients receive 40 mg/m^2 by IV over 30-60 minutes on days 1, 8, 15, 22, 29, and 36.
1726229|NCT00012012|Radiation|Intracavitary brachytherapy|For low dose rate (LDR) brachytherapy, cesium will be given in one to two intracavitary applications, within two weeks of completion of external radiation. The interval between the two applications will be one to three weeks. It is recommended that the total course of treatment be completed in less than eight weeks. High dose rate (HDR) brachytherapy may start as early as week two of external radiation. The minimum cumulative external and intracavitary dose should be 85 Gy.
1726230|NCT00012012|Radiation|External beam radiation therapy|Patients will receive 1.8 Gy daily for five weeks for a total dose of 45 Gy; involved lateral parametrium and/or pelvic nodes should be boosted for a total dose (including intracavitary treatment) of 60 Gy ± 5%.
1726231|NCT00012025|Drug|fulvestrant|
1726232|NCT00012038|Drug|irofulven|
1726233|NCT00012051|Biological|filgrastim|
1726234|NCT00012051|Biological|rituximab|
1726235|NCT00012051|Drug|carmustine|
1726236|NCT00012051|Drug|cisplatin|
1726237|NCT00012051|Drug|cytarabine|
1726238|NCT00012051|Drug|dexamethasone|
1726239|NCT00012051|Drug|etoposide|
1726240|NCT00012051|Drug|ifosfamide|
1726241|NCT00012051|Drug|melphalan|
1726242|NCT00012051|Drug|methotrexate|
1726243|NCT00012051|Procedure|bone marrow ablation with stem cell support|
1726244|NCT00012051|Procedure|peripheral blood stem cell transplantation|
1726245|NCT00012051|Radiation|radiation therapy|
1726247|NCT00012090|Drug|bicalutamide|
1726248|NCT00012090|Drug|goserelin acetate|
1726249|NCT00012103|Other|bronchoalveolar lavage|
1726250|NCT00012103|Other|screening questionnaire administration|
1726251|NCT00012103|Other|sputum cytology|
1726252|NCT00012103|Procedure|bronchoscopic and lung imaging studies|
1726253|NCT00012103|Procedure|bronchoscopy|
1726254|NCT00012103|Procedure|computed tomography|
1726255|NCT00012103|Procedure|study of high risk factors|
1726256|NCT00012116|Drug|temozolomide|Administered in a fasting state, once a day for 6 weeks followed by 4 weeks of rest. Cycles may be repeated every 10 weeks until patients have evidence of progressive disease, intolerable toxicity or unwillingness to continue therapy. Daily dose: 75mg/m2.
1726257|NCT00012129|Drug|liposomal annamycin|
1726258|NCT00012142|Drug|temsirolimus|
1726259|NCT00012155|Biological|NV1020|
1726260|NCT00012168|Drug|isosulfan blue|
1726261|NCT00012168|Genetic|polymerase chain reaction|
1726262|NCT00012168|Other|immunohistochemistry staining method|
1726263|NCT00012168|Procedure|lymphangiography|
1726264|NCT00012168|Procedure|radionuclide imaging|
1726265|NCT00012168|Procedure|sentinel lymph node biopsy|
1726266|NCT00012168|Radiation|technetium Tc 99m sulfur colloid|
1726267|NCT00012181|Drug|alvocidib|Given IV
1726268|NCT00012181|Other|pharmacological study|Correlative studies
1726269|NCT00012194|Drug|7-hydroxystaurosporine|Given IV
1726270|NCT00012194|Drug|cisplatin|Given IV
1726271|NCT00012194|Other|laboratory biomarker analysis|Correlative studies
1726272|NCT00012207|Biological|aldesleukin|
1726273|NCT00012207|Biological|therapeutic autologous lymphocytes|
1726274|NCT00012207|Drug|cyclophosphamide|
1726275|NCT00012207|Drug|prednisone|
1726276|NCT00012207|Drug|vincristine sulfate|
1726277|NCT00012207|Procedure|adjuvant therapy|
1726278|NCT00012220|Drug|cisplatin|50 mg/sq m IV infusion over 30 min on Days 1 & 15 of ea cycle
1726279|NCT00012220|Drug|docetaxel|40 mg/sq m IV infusion over 60 min on Days 1 & 8 of ea treatment cycle
1726280|NCT00012220|Drug|gemcitabine hydrochloride|"Gemcitabine only arm: 1500 mg/sq m in 250 mL NS IV infusion over 150 min Days 1, 8, & 15 of ea cycle
cisplastin arm: 1000 mg/sq m 250 mL NS IV infusion over 30 min Days 1, 8, 15 of ea cycle
docetaxel and + irinotecan arms: 1000 mg/sq m in 250 mL NS IV infusion over 30 min Days 1 & 8 of ea cycle"
1726281|NCT00012220|Drug|irinotecan hydrochloride|100 mg/q m in 500 mL D5W or D5NS IV infusion over 90 min Days 1 & 8 of ea cycle
1726282|NCT00012246|Biological|carcinoembryonic antigen peptide 1-6D|
1726283|NCT00012246|Biological|incomplete Freund's adjuvant|
1726284|NCT00012246|Biological|sargramostim|
1726285|NCT00012259|Drug|troxacitabine|
1726286|NCT00012298|Biological|rituximab|Given IV
1726287|NCT00012298|Biological|yttrium Y 90 ibritumomab tiuxetan|Given IV
1726288|NCT00012298|Biological|indium In 111 ibritumomab tiuxetan|Given IV
1726289|NCT00012298|Biological|oprelvekin|Given subcutaneously
1726290|NCT00012298|Biological|filgrastim|Given subcutaneously
1726291|NCT00012311|Biological|filgrastim|
1726292|NCT00012311|Drug|CMF regimen|
1726293|NCT00012311|Drug|carboplatin|
1726294|NCT00012311|Drug|cyclophosphamide|
1726295|NCT00012311|Drug|docetaxel|
1726296|NCT00012311|Drug|doxorubicin hydrochloride|
1726297|NCT00012311|Drug|etoposide|
1726298|NCT00012311|Drug|fluorouracil|
1726299|NCT00012311|Drug|ifosfamide|
1726300|NCT00012311|Drug|methotrexate|
1726301|NCT00012311|Drug|thiotepa|
1726302|NCT00012311|Procedure|peripheral blood stem cell transplantation|
1726303|NCT00012324|Drug|doxorubicin hydrochloride|
1726304|NCT00012324|Drug|nolatrexed dihydrochloride|
1726305|NCT00012337|Drug|gefitinib|
1726306|NCT00012350|Drug|FTI|
1726307|NCT00012363|Drug|gemcitabine hydrochloride|1,000mg/m2, IV over 30 min, days 1 & 8, q 21 days
1726308|NCT00012363|Drug|irinotecan hydrochloride|100 mg/m2, IV over 90 min, days 1 & 8, q 21days
1726309|NCT00012376|Drug|bryostatin 1|Given IV
1726310|NCT00012376|Biological|sargramostim|Given subcutaneously
1726311|NCT00012376|Other|laboratory biomarker analysis|Correlative studies
1726312|NCT00012376|Other|pharmacological study|Correlative studies
1726313|NCT00012389|Drug|irinotecan hydrochloride|
1726314|NCT00012389|Drug|oxaliplatin|
1726315|NCT00012441|Procedure|hemodialysis|
1726316|NCT00012454|Drug|E-Selectin nasal spray|
1726317|NCT00012467|Drug|Itraconazole|
1726318|NCT00012467|Drug|Flucytosine|
1726319|NCT00012467|Drug|Fluconazole|
1726320|NCT00012467|Drug|Amphotericin B|
1726321|NCT00012467|Drug|Interferon gamma-1b|
1726322|NCT00012506|Drug|TNFR:Fc|
1726323|NCT00012519|Drug|indinavir sulfate|
1726324|NCT00012519|Drug|ritonavir|
1726325|NCT00012558|Drug|lithium|
1726326|NCT00012558|Drug|valproate|
1726327|NCT00012558|Drug|bupropion|
1726328|NCT00012558|Drug|paroxetine|
1726329|NCT00012558|Drug|lamotrigine|
1726330|NCT00012558|Drug|risperidone|
1726331|NCT00012558|Drug|inositol|
1726332|NCT00012558|Drug|tranylcypromine|
1726333|NCT00012558|Behavioral|Cognitive Behavioral Therapy|
1726334|NCT00012558|Behavioral|Family-focused Therapy|
1726335|NCT00012558|Behavioral|Interpersonal and Social Rhythms Therapy|
1726336|NCT00012584|Drug|methylphenidate|
1726337|NCT00012584|Drug|fluvoxamine|
1726338|NCT00012597|Procedure|Web-based telemedicine system for assessment of status of pressure ulcers|
1726339|NCT00012610|Procedure|Telepsychiatry|
1726340|NCT00012636|Procedure|Computer generated statements about guideline concordance of drug therapy deliver to clinicians|
1726341|NCT00012662|Behavioral|Diabetes Self Management Education|
1726342|NCT00012688|Drug|Doxycycline HCI 10mg po for 2 weeks|
1726343|NCT00012688|Procedure|Ultrasonic scaling with 0.12% chlorhexidine gluconate|
1726344|NCT00012714|Behavioral|Case management services|
1726345|NCT00012727|Procedure|Matching Symptom Severity to Service Intensity|
1726346|NCT00012740|Behavioral|Casefinding and Referral System|
1726347|NCT00012753|Procedure|Automated telephone health status assessments with nurse follow-up.|
1726348|NCT00012766|Behavioral|Integrated team care|
1726349|NCT00012779|Behavioral|Health Education Program|
1726350|NCT00012792|Behavioral|Exercise Training|
1726351|NCT00012805|Procedure|Telephone Monitoring|
1726352|NCT00012818|Behavioral|relaxation technique|
1726353|NCT00012818|Behavioral|educational program|
1726354|NCT00012844|Device|Redesigning patient handling tasks using equip: Arjo Bianca Overhead Lift, Hill-Rom Resident Transfer Device, TranSit Chair, Total Care Bed|
1726456|NCT00006052|Drug|imatinib mesylate|
1726457|NCT00006053|Drug|imatinib mesylate|
1726355|NCT00012844|Procedure|Redesigned patient handling tasks using work practice controls: setting bed height at correct level; applying anti-embolism stockings from foot of bed|
1726356|NCT00012857|Drug|acetaminophen 650 mg qid and placebo qid PRN. The other arm was placebo qid and acetaminophen 650 mg qid PRN|
1726357|NCT00012870|Behavioral|Behavioral Management|
1726358|NCT00012883|Behavioral|Homewalking exercise program|
1726359|NCT00012896|Behavioral|Telephone Care + Educational (AV Materials)|
1726360|NCT00012909|Behavioral|Hormone Replacement Therapy Decision-Aid|
1726361|NCT00012922|Behavioral|Low Literacy Intervention for Colorectal Cancer Screening|
1726362|NCT00012935|Behavioral|Help with decision making on prostate cancer treatment|
1726363|NCT00012948|Procedure|Telephone Care|
1726364|NCT00012974|Behavioral|GTelephone-administered Cognitive-Behavioral Therapy (T-CBT)|
1726365|NCT00012974|Procedure|Provider education, computer reminders, nurse case management|
1726366|NCT00012987|Behavioral|Quality Improvement|
1726367|NCT00013000|Behavioral|Test strategy for implementation guideline|
1726368|NCT00013013|Procedure|Systems Support|
1726369|NCT00013026|Behavioral|CHF Self-management Education (Web-based Education)|
1726370|NCT00013039|Behavioral|Computer reminders|
1726371|NCT00013052|Behavioral|Peer led classes. Led by trained veterans with a chronic disease.|
1726372|NCT00013078|Procedure|Physical restoration intervention|
1726373|NCT00013091|Behavioral|Self-management therapy; Psychoeducational group therapy|
1726374|NCT00013117|Behavioral|Telephone specialist consultation|
1726375|NCT00006023|Drug|capecitabine|
1726376|NCT00006024|Drug|lomustine|
1726377|NCT00006024|Drug|temozolomide|
1726378|NCT00006025|Drug|irinotecan hydrochloride|
1726379|NCT00006025|Drug|temozolomide|
1726380|NCT00006026|Drug|rubitecan|
1726381|NCT00006027|Drug|cisplatin|
1726382|NCT00006027|Drug|paclitaxel|
1726383|NCT00006027|Procedure|adjuvant therapy|
1726384|NCT00006027|Radiation|radiation therapy|
1726385|NCT00006028|Drug|cisplatin|
1726386|NCT00006028|Drug|gemcitabine hydrochloride|
1726387|NCT00006029|Drug|gemcitabine hydrochloride|
1726388|NCT00006029|Drug|pegylated liposomal doxorubicin hydrochloride|
1726389|NCT00006029|Drug|vinorelbine tartrate|
1726390|NCT00006030|Drug|tamoxifen citrate|
1726391|NCT00006030|Procedure|conventional surgery|
1726392|NCT00006030|Radiation|radiation therapy|
1726393|NCT00006031|Procedure|Needle localized breast biopsy with specimen x-ray|
1726394|NCT00006031|Procedure|Low dose radioactive seed followed by surgery and mammogram|either iodine I 125 or palladium Pd 103
1726395|NCT00006032|Drug|etoposide|
1726396|NCT00006032|Drug|ifosfamide|
1726397|NCT00006032|Drug|topotecan hydrochloride|
1726398|NCT00006032|Procedure|peripheral blood stem cell transplantation|
1726399|NCT00006033|Biological|gene therapy|
1726400|NCT00006033|Biological|interleukin-2 gene|
1726401|NCT00006033|Drug|methotrexate|
1726402|NCT00006034|Biological|keyhole limpet hemocyanin|Given intradermally and IV
1726403|NCT00006034|Drug|doxorubicin hydrochloride|Given IV
1726404|NCT00006035|Biological|bleomycin sulfate|
1726405|NCT00006035|Drug|electroporation therapy|
1726406|NCT00006036|Drug|cisplatin|
1726407|NCT00006036|Drug|lurtotecan liposome|
1726408|NCT00006037|Drug|fluorouracil|
1726409|NCT00006037|Drug|irinotecan hydrochloride|
1726410|NCT00006037|Drug|oglufanide disodium|
1726411|NCT00006038|Drug|cisplatin|
1726412|NCT00006038|Drug|docetaxel|
1726413|NCT00006038|Drug|floxuridine|
1726414|NCT00006038|Drug|fluorouracil|
1726415|NCT00006038|Drug|leucovorin calcium|
1726416|NCT00006038|Procedure|conventional surgery|
1726417|NCT00006039|Biological|pegylated interferon alfa|
1726418|NCT00006040|Biological|filgrastim|
1726419|NCT00006040|Drug|etoposide|
1726420|NCT00006040|Procedure|autologous bone marrow transplantation|
1726421|NCT00006040|Procedure|peripheral blood stem cell transplantation|
1726422|NCT00006040|Radiation|yttrium Y 90 monoclonal antibody M195|
1726423|NCT00006041|Biological|MUC1-KLH conjugate vaccine|
1726424|NCT00006041|Biological|MUC1-KLH vaccine/QS21|
1726425|NCT00006041|Biological|QS21|
1726426|NCT00006042|Biological|filgrastim|
1726427|NCT00006042|Drug|cyclophosphamide|
1726428|NCT00006042|Drug|fludarabine phosphate|
1726429|NCT00006042|Drug|mycophenolate mofetil|
1726430|NCT00006042|Drug|tacrolimus|
1726431|NCT00006042|Procedure|allogeneic bone marrow transplantation|
1726432|NCT00006042|Radiation|radiation therapy|
1726433|NCT00006043|Drug|temozolomide|
1726434|NCT00006044|Drug|therapeutic testosterone|
1726435|NCT00006045|Biological|lintuzumab|
1726436|NCT00006045|Drug|cytarabine|
1726437|NCT00006045|Drug|etoposide|
1726438|NCT00006045|Drug|mitoxantrone hydrochloride|
1726439|NCT00006046|Biological|monoclonal antibody Hu3S193|
1726440|NCT00006047|Drug|Oral Etoposide|
1726441|NCT00006047|Drug|Oral 9-Nitrocamptothecin|
1726442|NCT00006048|Drug|cisplatin|
1726443|NCT00006048|Drug|gefitinib|
1726444|NCT00006048|Drug|gemcitabine hydrochloride|
1726445|NCT00006049|Drug|carboplatin|
1726446|NCT00006049|Drug|gefitinib|
1726447|NCT00006049|Drug|paclitaxel|
1726448|NCT00006050|Drug|FOLFOX regimen|
1726449|NCT00006050|Drug|fluorouracil|
1726450|NCT00006050|Drug|isolated perfusion|
1726451|NCT00006050|Drug|leucovorin calcium|
1726452|NCT00006050|Drug|oxaliplatin|
1726453|NCT00006051|Drug|cisplatin|
1726454|NCT00006051|Drug|fluorouracil|
1726455|NCT00006051|Radiation|radiation therapy|
1726458|NCT00006054|Drug|anti-thymocyte globulin|
1726459|NCT00006054|Drug|busulfan|
1726460|NCT00006054|Drug|cyclophosphamide|
1726461|NCT00006054|Drug|cyclosporine|
1726462|NCT00006054|Drug|etoposide|
1726463|NCT00006054|Drug|methotrexate|
1726464|NCT00006054|Drug|methylprednisolone|
1726465|NCT00006054|Drug|prednisone|
1726466|NCT00006054|Procedure|Allogeneic Bone Marrow Transplantation|
1726467|NCT00006055|Drug|anti-thymocyte globulin|
1726468|NCT00006055|Drug|cyclophosphamide|
1726469|NCT00006055|Drug|cyclosporine|
1726470|NCT00006055|Drug|filgrastim|
1726471|NCT00006055|Drug|methylprednisolone|
1726472|NCT00006055|Drug|prednisone|
1726473|NCT00006055|Procedure|Autologous Peripheral Blood Stem Cell Transplantation|
1726474|NCT00006056|Drug|anti-thymocyte globulin|
1726475|NCT00006056|Drug|busulfan|
1726476|NCT00006056|Drug|cyclophosphamide|
1726477|NCT00006056|Drug|cyclosporine|
1726478|NCT00006056|Drug|etoposide|
1726479|NCT00006056|Drug|filgrastim|
1726480|NCT00006056|Drug|methotrexate|
1726481|NCT00006056|Procedure|allogeneic hematopoietic stem cell transplantation|
1726482|NCT00006060|Drug|standard gadolinium contrast|
1726483|NCT00006061|Drug|phosphatidylcholine|
1726484|NCT00006062|Drug|oxaliplatin|
1726485|NCT00006063|Drug|pancrelipase with bicarbonate|
1726486|NCT00006066|Biological|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
1726487|NCT00006066|Biological|Diphtheria and Tetanus Toxoids Adsorbed|
1726488|NCT00006066|Biological|Tetanus and Diphtheria Toxoids Adsorbed|
1726489|NCT00006066|Drug|Bacteriophage phi X 174|
1726490|NCT00006066|Drug|Aldesleukin|
1726491|NCT00006068|Procedure|Pancreatic Islet Transplantation|
1726492|NCT00006070|Drug|etanercept (Enbrel)|
1726493|NCT00006072|Drug|Rituxan|
1726494|NCT00006075|Drug|Chlorhexidine gluconate|
1726495|NCT00006077|Drug|NS2330|
1726496|NCT00006077|Drug|Levodopa and Domperidone|
1726497|NCT00006078|Dietary Supplement|lycopene|
1726498|NCT00006079|Drug|Eflornithine|Arm I-II: Patients receive one of two different doses of oral eflornithine daily for 28 days.
1726499|NCT00006079|Other|Placebo|Patients receive oral placebo daily for 28 days.
1726500|NCT00006080|Drug|fenretinide|
1726501|NCT00006081|Drug|Bryostatin-1|40 mcg/m2 one-hour infusion 24 hours after each dose of paclitaxel (i.e., day 2, 9, 16).
1726502|NCT00006081|Drug|Paclitaxel (Taxol)|80 mg/m^2 one-hour infusion weekly x 3 every 4 weeks
1726503|NCT00006082|Drug|rubitecan|
1726504|NCT00006083|Drug|Fragmin|Fragmin at 5000 IU injected subcutaneously daily
1726505|NCT00006083|Other|placebo|placebo injected subcutaneously daily
1726506|NCT00006084|Biological|lintuzumab|
1726507|NCT00006085|Drug|CP-609,754|
1726508|NCT00006086|Drug|BMS-188797|
1726509|NCT00006086|Drug|carboplatin|
1726510|NCT00006087|Procedure|annual screening|
1726511|NCT00006087|Procedure|bronchoscopic and lung imaging studies|
1726512|NCT00006087|Procedure|comparison of screening methods|
1726513|NCT00006087|Procedure|computed tomography|
1726514|NCT00006087|Procedure|radiography|
1726515|NCT00006087|Procedure|study of high risk factors|
1726516|NCT00006088|Drug|vinorelbine tartrate|
1726517|NCT00006089|Biological|trastuzumab|Given IV
1726518|NCT00006089|Other|laboratory biomarker analysis|Correlative studies
1726519|NCT00006090|Drug|arsenic trioxide|
1726520|NCT00006091|Drug|arsenic trioxide|
1726521|NCT00006092|Drug|Arsenic Trioxide|
1726522|NCT00006093|Drug|cilengitide|
1726523|NCT00006094|Drug|oxaliplatin|Given IV
1726524|NCT00006094|Drug|fluorouracil|Given IV
1726525|NCT00006094|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
1726526|NCT00006095|Drug|irinotecan hydrochloride|
1726527|NCT00006095|Drug|vincristine sulfate|
1726528|NCT00006096|Drug|cisplatin|
1726529|NCT00006096|Radiation|radiation therapy|
1726530|NCT00006097|Drug|CC-1088|
1726531|NCT00006098|Drug|bortezomib|
1726532|NCT00006099|Other|immunohistochemistry staining method|
1726533|NCT00006099|Procedure|biopsy|
1726534|NCT00006099|Procedure|immunoscintigraphy|
1726535|NCT00006099|Radiation|indium In 111 monoclonal antibody Hu3S193|
1726536|NCT00006100|Biological|aldesleukin|
1726537|NCT00006100|Biological|allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes|
1726538|NCT00006100|Drug|fludarabine phosphate|
1726539|NCT00006100|Procedure|peripheral blood stem cell transplantation|
1726540|NCT00006101|Drug|eflornithine|
1726541|NCT00006101|Drug|Placebo|
1726542|NCT00006102|Drug|becatecarin|
1726543|NCT00006103|Drug|fluorouracil|
1726544|NCT00006103|Drug|irinotecan hydrochloride|
1726545|NCT00006103|Drug|leucovorin calcium|
1726546|NCT00006104|Biological|trastuzumab|
1726547|NCT00006104|Drug|docetaxel|
1726548|NCT00006105|Drug|amifostine trihydrate|
1726549|NCT00006105|Drug|cisplatin|
1726550|NCT00006105|Drug|gemcitabine hydrochloride|
1726551|NCT00006105|Procedure|adjuvant therapy|
1726552|NCT00006106|Drug|cisplatin|
1726553|NCT00006106|Drug|fluorouracil|
1726554|NCT00006106|Drug|ONYX-015|
1726555|NCT00006107|Drug|Taxotere|
1726556|NCT00006107|Procedure|Surgery|
1726557|NCT00006107|Radiation|radiation therapy|
1726558|NCT00006108|Biological|trastuzumab|
1726559|NCT00006108|Drug|capecitabine|
1726560|NCT00006108|Drug|paclitaxel|
1726561|NCT00006110|Biological|trastuzumab|infusion 4 mg/kg load week 1; 2 mg/kg weekly thereafter for 12 weeks
1726562|NCT00006110|Drug|cyclophosphamide|600 mg/m2, intravenous infusion every 3 weeks for four cycles
1726563|NCT00006110|Drug|doxorubicin hydrochloride|60 mg/m2 intravenously, 5-10 minutes, every 3 weeks, up to 12 weeks
1726564|NCT00006110|Drug|paclitaxel|90 mg/m2 weekly, intravenously 1 hour after herceptin, given weekly up to 12 weeks or 175 mg/m2, intravenously every 3 weeks, up to 12 weeks (only if not receiving Herceptin®)
1726565|NCT00006110|Procedure|conventional surgery|Surgical excision will take place 12-13 weeks for the neo-adjuvant herceptin setting and 12-13 weeks in the non-herceptin setting. Surgery will take place prior to chemotherapy in the adjuvant herceptin setting
1726566|NCT00006111|Drug|cisplatin|
1726567|NCT00006111|Drug|fluorouracil|
1726568|NCT00006111|Procedure|conventional surgery|
1726569|NCT00006111|Radiation|radiation therapy|
1726570|NCT00006112|Drug|chemotherapy|
1726571|NCT00006112|Drug|fluorouracil|
1726572|NCT00006112|Drug|leucovorin calcium|
1726573|NCT00006112|Drug|mitomycin C|
1726574|NCT00006113|Biological|MART-1 antigen|
1726575|NCT00006113|Biological|aldesleukin|
1726576|NCT00006113|Biological|gp100 antigen|
1726577|NCT00006113|Biological|recombinant CD40-ligand|
1726578|NCT00006113|Biological|recombinant interferon gamma|
1726579|NCT00006113|Biological|recombinant interleukin-4|
1726580|NCT00006113|Biological|sargramostim|
1726581|NCT00006113|Biological|therapeutic autologous dendritic cells|
1726582|NCT00006113|Biological|therapeutic tumor infiltrating lymphocytes|
1726583|NCT00006113|Biological|tyrosinase peptide|
1726584|NCT00006113|Radiation|Candida albicans skin test reagent|
1726585|NCT00006114|Drug|mitoxantrone hydrochloride|
1726586|NCT00006114|Drug|vinorelbine tartrate|
1726587|NCT00006115|Drug|FOLFIRI regimen|
1726588|NCT00006115|Drug|FOLFOX regimen|
1726589|NCT00006115|Drug|fluorouracil|
1726590|NCT00006115|Drug|irinotecan hydrochloride|
1726591|NCT00006115|Drug|leucovorin calcium|
1726592|NCT00006115|Drug|oxaliplatin|
1726593|NCT00006116|Drug|cisplatin|
1726594|NCT00006116|Drug|gemcitabine hydrochloride|
1726595|NCT00006117|Drug|gemcitabine hydrochloride|
1726596|NCT00006117|Drug|oxaliplatin|
1726597|NCT00006118|Drug|cisplatin|
1726598|NCT00006118|Drug|gemcitabine hydrochloride|
1726599|NCT00006118|Drug|paclitaxel|
1726600|NCT00006119|Drug|hydroxyurea|
1726601|NCT00006120|Drug|docetaxel|
1726602|NCT00006120|Drug|paclitaxel|
1726603|NCT00006121|Drug|oxaliplatin|
1726604|NCT00006122|Drug|cytarabine|
1726605|NCT00006122|Drug|etoposide|
1726606|NCT00006122|Drug|gemtuzumab ozogamicin|
1726607|NCT00006122|Drug|idarubicin|
1726608|NCT00006122|Drug|mitoxantrone hydrochloride|
1726609|NCT00006123|Biological|trastuzumab|
1726610|NCT00006123|Drug|carboplatin|
1726611|NCT00006123|Drug|carmustine|
1726612|NCT00006123|Drug|cisplatin|
1726613|NCT00006123|Drug|cyclophosphamide|
1726614|NCT00006123|Drug|thiotepa|
1726615|NCT00006123|Procedure|peripheral blood stem cell transplantation|
1726616|NCT00006196|Drug|Vitamin D|
1726617|NCT00006198|Drug|thalidomide|
1726618|NCT00006198|Procedure|chemoembolization with doxorubicin/collagen|
1726619|NCT00006199|Drug|R115777 (farnesyl transferase inhibitor)|
1726620|NCT00006199|Drug|Topotecan|
1726621|NCT00006200|Drug|thalidomide|
1726622|NCT00006200|Drug|dacarbazine|
1726623|NCT00006202|Drug|Lutein|
1726624|NCT00006203|Drug|naltrexone (Revia)|
1726625|NCT00006204|Drug|naltrexone (Revia)|
1726626|NCT00006204|Drug|fluoxetine (Prozac)|
1726627|NCT00006205|Drug|ondansetron + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d)
1726628|NCT00006205|Drug|topiramate + cognitive behavioral therapy|topiramate (up to 300 mg/day)
1726629|NCT00006205|Drug|Placebo + cognitive behavioral therapy|placebo
1726630|NCT00006205|Drug|ondansetron + topiramate + cognitive behavioral therapy|ondansetron (4 mcg/kg b.i.d) + topiramate (up to 300 mg/day)
1726631|NCT00006206|Drug|naltrexone (Revia)|
1726632|NCT00006206|Drug|acamprosate (Campral)|
1726633|NCT00006207|Drug|PRO 2000|
1726634|NCT00006208|Drug|Efavirenz|
1726635|NCT00006208|Drug|Emtricitabine|
1726636|NCT00006208|Drug|Stavudine|
1726637|NCT00006208|Drug|Didanosine|
1726638|NCT00006209|Drug|Tucaresol|
1726639|NCT00006211|Drug|Capravirine|
1726640|NCT00006211|Drug|Nelfinavir mesylate|
1726641|NCT00006212|Drug|cisplatin|
1726642|NCT00006212|Drug|vinblastine sulfate|
1726643|NCT00006212|Radiation|phosphorus P32|
1726644|NCT00006212|Radiation|radiation therapy|
1726645|NCT00006213|Drug|BMS-214662|Given IV
1726646|NCT00006213|Other|pharmacological study|Correlative studies
1726647|NCT00006213|Other|laboratory biomarker analysis|Correlative studies
1726648|NCT00006214|Drug|flutamide|
1726649|NCT00006214|Other|placebo|
1726650|NCT00006215|Biological|filgrastim|
1726651|NCT00006215|Drug|docetaxel|
1726652|NCT00006215|Drug|vinorelbine tartrate|
1726653|NCT00006216|Biological|PA-1-STK ovarian carcinoma vaccine|
1726654|NCT00006216|Drug|ganciclovir|
1726655|NCT00006218|Drug|triapine|
1726656|NCT00006219|Drug|clarithromycin|
1726657|NCT00006219|Drug|prasterone|
1726658|NCT00006220|Drug|arsenic trioxide|
1726659|NCT00006220|Drug|tretinoin|
1726660|NCT00006221|Drug|ixabepilone|
1726661|NCT00006222|Drug|cilengitide|
1726662|NCT00006223|Biological|recombinant flt3 ligand|
1726663|NCT00006224|Drug|gemcitabine hydrochloride|
1726664|NCT00006225|Biological|filgrastim|
1726665|NCT00006225|Biological|recombinant flt3 ligand|
1726666|NCT00006225|Biological|recombinant human thrombopoietin|
1726667|NCT00006225|Biological|recombinant interleukin-3|
1726668|NCT00006225|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1726669|NCT00006226|Drug|thalidomide|Given PO
1726670|NCT00006226|Other|laboratory biomarker analysis|Correlative studies
1726671|NCT00006227|Drug|Paclitaxel|Given IV
1726672|NCT00006228|Biological|trastuzumab|Given IV
1726673|NCT00006228|Biological|aldesleukin|Given SC
1726674|NCT00006228|Other|laboratory biomarker analysis|Correlative studies
1726675|NCT00006228|Other|pharmacological study|Correlative studies
1726676|NCT00006229|Drug|carboplatin|
1726677|NCT00006229|Drug|paclitaxel|
1726678|NCT00006229|Drug|rebimastat|
1726679|NCT00006230|Drug|rubitecan|
1726680|NCT00006231|Procedure|quality-of-life assessment|
1726681|NCT00006231|Procedure|standard follow-up care|
1726682|NCT00006231|Radiation|radiation therapy|
1726683|NCT00006232|Drug|dexamethasone|
1726684|NCT00006232|Drug|doxorubicin hydrochloride|
1726685|NCT00006232|Drug|idarubicin|
1726686|NCT00006232|Drug|vincristine sulfate|
1726687|NCT00006233|Biological|therapeutic allogeneic lymphocytes|
1726688|NCT00006233|Drug|cyclosporine|
1726689|NCT00006233|Drug|fludarabine phosphate|
1726690|NCT00006233|Drug|mycophenolate mofetil|
1726691|NCT00006233|Procedure|peripheral blood stem cell transplantation|
1726692|NCT00006233|Radiation|radiation therapy|
1726693|NCT00006234|Procedure|peripheral blood stem cell transplantation|
1726694|NCT00006234|Radiation|holmium Ho 166 DOTMP|
1726695|NCT00006235|Drug|carboplatin|
1726696|NCT00006235|Drug|pegylated liposomal doxorubicin hydrochloride|
1726697|NCT00006237|Biological|interleukin-2|Given IV
1726698|NCT00006237|Biological|filgrastim|Given subcutaneously
1726699|NCT00006237|Biological|interferon alfa|Given IV and subcutaneously
1726700|NCT00006237|Drug|cisplatin|Given IV
1726701|NCT00006237|Drug|dacarbazine|Given IV
1726702|NCT00006237|Drug|vinblastine|Given IV
1726703|NCT00006239|Drug|sodium phenylbutyrate|
1726704|NCT00006239|Drug|tretinoin|
1726705|NCT00006240|Biological|sargramostim|
1726706|NCT00006240|Drug|dexamethasone|
1726707|NCT00006240|Drug|oral sodium phenylbutyrate|
1726708|NCT00006241|Biological|filgrastim|
1726709|NCT00006241|Drug|chemotherapy|
1726710|NCT00006241|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1726711|NCT00006241|Procedure|peripheral blood stem cell transplantation|
1726712|NCT00006241|Radiation|radiation therapy|
1726713|NCT00006242|Drug|BMS-214662|Given IV
1726714|NCT00006242|Other|laboratory biomarker analysis|Correlative studies
1726715|NCT00006242|Other|pharmacological study|Correlative studies
1726716|NCT00006243|Biological|tyrosinase peptide|Given SC
1726717|NCT00006243|Biological|MART-1:27-35 peptide vaccine|Given SC
1726718|NCT00006243|Biological|gp100 antigen|Given SC
1726719|NCT00006243|Biological|incomplete Freund's adjuvant|Given SC
1726720|NCT00006243|Biological|sargramostim|Given SC
1726721|NCT00006243|Other|laboratory biomarker analysis|Correlative studies
1726722|NCT00006244|Drug|melphalan|Given IV
1726723|NCT00006244|Biological|recombinant interferon alfa|Given SC
1726724|NCT00006244|Biological|aldesleukin|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
1726725|NCT00006244|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo IL2-treated autologous or syngeneic peripheral blood stem infusion
1726726|NCT00006245|Drug|alvocidib|
1726727|NCT00006245|Drug|paclitaxel|
1726728|NCT00006246|Drug|busulfan|
1726729|NCT00006247|Drug|semaxanib|
1726730|NCT00006248|Drug|cisplatin|
1726731|NCT00006248|Drug|fluorouracil|
1726732|NCT00006248|Drug|paclitaxel|
1726733|NCT00006249|Biological|pegylated interferon alfa|
1726734|NCT00006249|Procedure|adjuvant therapy|
1726735|NCT00006250|Drug|chlorambucil|
1726736|NCT00006250|Drug|dexamethasone|
1726737|NCT00006250|Drug|fludarabine phosphate|
1726738|NCT00006250|Drug|mitoxantrone hydrochloride|
1726739|NCT00006251|Radiation|total-body irradiation|Undergo TBI
1726740|NCT00006251|Drug|fludarabine phosphate|Given IV
1726741|NCT00006251|Drug|cyclosporine|Given PO
1726742|NCT00006251|Drug|mycophenolate mofetil|Given PO
1726743|NCT00006251|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
1726744|NCT00006251|Biological|donor lymphocytes|Undergo DLI
1726745|NCT00006251|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
1726746|NCT00006251|Other|laboratory biomarker analysis|Correlative studies
1726747|NCT00006252|Drug|fludarabine phosphate|30 mg/sq m/day IV infusion for 5 days (Days -7 thru -3)
1726748|NCT00006252|Drug|Cyclophosphamide|1 g/sq m/day IV infusion x 3 days (Days -5 thru -3)
1726749|NCT00006252|Biological|PBSC|2-8,000,000/kg CD34+ cells via infusion on Day 0
1726750|NCT00006252|Drug|G-CSF|5 ug/kg/day subQ injection until ANC > 1000/uL for 3 days beginning Day 5
1726751|NCT00006252|Biological|Donor lymphocytes|10,000,000 CD3+ cells/kg via infusion
1726752|NCT00006253|Behavioral|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
1726753|NCT00006253|Behavioral|Non-nurse coach|Receives 6 telephone calls over 8 weeks from a non-nurse coach to assist with symptom management
1726754|NCT00006254|Biological|salmonella VNP20009|
1726755|NCT00006255|Procedure|radiofrequency ablation|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
1726834|NCT00006339|Drug|Didanosine|
1726756|NCT00006255|Procedure|thermal ablation therapy|Undergo thermal ablation by radiofrequency energy under magnetic resonance guidance.Thermal ablation continues until the entire tumor is treated.
1726757|NCT00006256|Drug|paclitaxel|Patients receive paclitaxel IV over 3 hours every 21 days for 4 courses beginning 3 weeks after completion of the last doxorubicin and cyclophosphamide adjuvant regimen.
1726758|NCT00006256|Procedure|adjuvant therapy|doxorubicin and cyclophosphamide adjuvant regimen
1726759|NCT00006256|Radiation|radiation therapy|Patients also undergo concurrent radiotherapy 5 days a week for approximately 6-7 weeks.
1726760|NCT00006257|Drug|paclitaxel|
1726761|NCT00006257|Drug|semaxanib|
1726762|NCT00006258|Biological|filgrastim|
1726763|NCT00006258|Drug|cisplatin|
1726764|NCT00006258|Drug|cyclophosphamide|
1726765|NCT00006258|Drug|etoposide|
1726766|NCT00006258|Drug|methotrexate|
1726767|NCT00006258|Drug|vincristine sulfate|
1726768|NCT00006258|Procedure|adjuvant therapy|
1726769|NCT00006258|Radiation|radiation therapy|
1726770|NCT00006259|Radiation|stereotactic radiosurgery|Patients undergo stereotactic head frame placement, followed by stereotactic radiosurgery using Gamma Knife, on day 1.
1726771|NCT00006260|Drug|cisplatin|cisplatin IV over 30 minutes on days 1-3.
1726772|NCT00006260|Drug|etoposide|etoposide IV over 60-90 minutes on days 1-3.
1726773|NCT00006260|Drug|ifosfamide|ifosfamide IV over 30 minutes on days 1-3.
1726774|NCT00006260|Drug|Mesna|Mesna is administered IV over 15 minutes 30 minutes prior to and 4 hours after ifosfamide, then orally at 8 hours post infusion.
1726775|NCT00006261|Biological|therapeutic allogeneic lymphocytes|Beginning on day 120 after PBSC transplantation, eligible patients receive unmobilized donor lymphocyte infusion (DLI) over 15-30 minutes. Treatment continues monthly for a total of 3 DLIs in the absence of grade III or IV graft versus host disease or marrow aplasia.
1726776|NCT00006261|Drug|cyclophosphamide|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of cyclophosphamide IV over 2 hours on days -3 and -2.
1726777|NCT00006261|Drug|docetaxel|Docetaxel IV over 1 hour. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
1726778|NCT00006261|Drug|doxorubicin hydrochloride|Doxorubicin IV over several minutes on day 1. Treatment continues every 3 weeks for 4 courses in the absence of disease progression or unacceptable toxicity.
1726779|NCT00006261|Drug|fludarabine phosphate|4-10 weeks after completion of salvage chemotherapy, patients achieving complete or partial remission or stable disease receive mini-conditioning comprised of fludarabine IV over 30 minutes on days -8 to -4.
1726780|NCT00006261|Procedure|peripheral blood stem cell transplantation|Filgrastim (G-CSF) and sargramostim (GM-CSF) mobilized allogeneic peripheral blood stem cells (PBSC) IV on day 0.
1726781|NCT00006262|Drug|becatecarin|
1726782|NCT00006263|Biological|filgrastim|
1726783|NCT00006263|Drug|carboplatin|
1726784|NCT00006263|Drug|temozolomide|
1726785|NCT00006264|Biological|aldesleukin|
1726786|NCT00006264|Drug|ganciclovir|
1726787|NCT00006264|Drug|zidovudine|
1726788|NCT00006265|Drug|ara-C|3 g/sq m IV infusion over 3 hours Days 1-5
1726789|NCT00006265|Biological|gemtuzumab ozogamicin|9 mg/sq m IV infusion over 2 hrs D 1 (Cohort I); D 7 (Cohorts II, IA, & IV); & D 14 (Cohort IV) 4.5 mg/sq m IV infusion over 2 hrs D 8 (Cohort I) & D 14 (Cohort II)
1726790|NCT00006267|Drug|rubitecan|
1726791|NCT00006268|Biological|cintredekin besudotox|
1726792|NCT00006268|Drug|isolated perfusion|
1726793|NCT00006268|Procedure|conventional surgery|
1726794|NCT00006269|Drug|irinotecan hydrochloride|
1726795|NCT00006269|Drug|octreotide acetate|
1726796|NCT00006270|Drug|cosyntropin|
1726797|NCT00006270|Drug|metyrapone|
1726798|NCT00006275|Drug|calcitriol|
1726799|NCT00006276|Drug|Micellar Paclitaxel|
1726800|NCT00006279|Drug|Nevirapine|
1726801|NCT00006280|Drug|Tobramycin for Inhalation|
1726802|NCT00006286|Drug|Fluoxetine|
1726803|NCT00006286|Behavioral|Psychotherapy|
1726804|NCT00006289|Drug|Placebo|4 tabs b.i.d.
1726805|NCT00006289|Drug|Neurotropin|4 tabs b.i.d.
1726806|NCT00006291|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1726807|NCT00006291|Drug|Aldesleukin|
1726808|NCT00006292|Drug|Infliximab|
1726809|NCT00006299|Drug|Celebrex|
1726810|NCT00006305|Procedure|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions|Angioplasty, Transluminal, Percutaneous Coronary, other catheter-based interventions
1726811|NCT00006305|Procedure|Coronary Artery Bypass|Coronary Artery Bypass
1726812|NCT00006305|Drug|Biguanides, thiazolidinediones|Biguanides, thiazolidinediones
1726813|NCT00006305|Drug|Insulin, sulfonylurea|Insulin, sulfonylurea
1726814|NCT00006305|Drug|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers|ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Calcium Channel Blockers
1726815|NCT00006320|Procedure|determine blood levels of anti-HIV drugs|
1726816|NCT00006324|Drug|Ethinyl estradiol/levonorgestrel|
1726817|NCT00006324|Drug|Medroxyprogesterone acetate|
1726818|NCT00006325|Drug|Peginterferon alfa-2b|
1726819|NCT00006326|Drug|Indinavir sulfate|
1726820|NCT00006326|Drug|Ritonavir|
1726821|NCT00006326|Drug|Delavirdine mesylate|
1726822|NCT00006327|Biological|MN rgp120/HIV-1 and A244 rgp120/HIV-1|
1726823|NCT00006329|Procedure|Minimally invasive radioguided parathyroidectomy|
1726824|NCT00006330|Drug|Digoxin|
1726825|NCT00006330|Drug|Hawthorn|
1726826|NCT00006331|Procedure|renal transplant|
1726827|NCT00006332|Drug|Tetrathiomolybdate|
1726828|NCT00006337|Drug|KW-6002|
1726829|NCT00006337|Drug|IV Levodopa|
1726830|NCT00006339|Drug|Indinavir sulfate|
1726831|NCT00006339|Drug|Ritonavir|
1726832|NCT00006339|Drug|Hydroxyurea|
1726833|NCT00006339|Drug|Stavudine|
1726837|NCT00006341|Other|Implant|A total of 62 patients with early oral cancer will be recruited; in addition, 22 patients requiring a partial maxillectomy and 40 requiring a partial lateral mandibulectomy will be enrolled. The mandibular defects will be reconstructed with fibula free flap surgery. Following a healing period, implants will be placed and permitted to heal unloaded for six months. Conventional dental prostheses will be fabricated and used by patients for at least 16 weeks during Phase I healing before the implants are exposed and loaded. A few weeks after Phase II surgery, the patients will receive implant-supported dental prostheses.
1726838|NCT00006342|Genetic|chromosomal translocation analysis|
1726839|NCT00006342|Genetic|gene rearrangement analysis|
1726840|NCT00006342|Genetic|mutation analysis|
1726841|NCT00006343|Biological|recombinant interferon alfa|
1726842|NCT00006343|Drug|cytarabine|
1726843|NCT00006343|Drug|imatinib mesylate|
1726844|NCT00006344|Radiation|radiation therapy|
1726845|NCT00006345|Biological|denileukin diftitox|
1726846|NCT00006345|Drug|dexamethasone|
1726847|NCT00006346|Procedure|psychosocial assessment and care|
1726848|NCT00006346|Procedure|quality-of-life assessment|
1726849|NCT00006347|Radiation|indium In 111 monoclonal antibody MN-14|
1726850|NCT00006347|Radiation|yttrium Y 90 monoclonal antibody MN-14|
1726851|NCT00006348|Drug|ondansetron|
1726852|NCT00006348|Other|placebo|
1726853|NCT00006349|Dietary Supplement|vitamin E|
1726854|NCT00006349|Drug|donepezil hydrochloride|
1726855|NCT00006349|Other|placebo|
1726856|NCT00006350|Biological|daclizumab|
1726857|NCT00006350|Biological|therapeutic allogeneic lymphocytes|
1726858|NCT00006350|Drug|mycophenolate mofetil|
1726859|NCT00006350|Drug|tacrolimus|
1726860|NCT00006350|Procedure|peripheral blood stem cell transplantation|
1726861|NCT00006351|Drug|gemcitabine hydrochloride|
1726862|NCT00006351|Drug|lonafarnib|
1726863|NCT00006352|Biological|BCG vaccine|
1726864|NCT00006352|Biological|monoclonal antibody BEC2|
1726865|NCT00006353|Drug|temozolomide|
1726866|NCT00006353|Radiation|radiation therapy|
1726867|NCT00006354|Dietary Supplement|mistletoe extract|
1726868|NCT00006355|Drug|pyrazoloacridine|
1726869|NCT00006355|Procedure|adjuvant therapy|
1726870|NCT00006355|Radiation|radiation therapy|
1726871|NCT00006356|Drug|carboplatin|
1726872|NCT00006356|Drug|cisplatin|
1726873|NCT00006356|Procedure|conventional surgery|
1726874|NCT00006357|Drug|imatinib mesylate|
1726875|NCT00006358|Drug|temozolomide|
1726876|NCT00006358|Drug|thalidomide|
1726877|NCT00006359|Drug|LHRH agonist|Lupron: 22.5mg IM injection q 12 wks x 2 OR Zoladex: 10.8 mg subQ injection q 12 wks x 2
1726878|NCT00006359|Drug|antiandrogen|flutamide 250 mg PO tid for 4 wks OR casodex 50 mg PO daily for 4 wks
1726879|NCT00006359|Radiation|radiation therapy|4500 cGy total dose given days 1-5 for 5 weeks following initiation of androgen suppression (25 fractions)
1726880|NCT00006359|Radiation|Brachytherapy boost|Iodine 125 0.3 to 0.5 U per seed OR palladium 103 1.04 to 1.4 U per seed as implant; prescribed dose of I-125 100 Gy (TG-43) and Pd-103 90 Gy
1726881|NCT00006360|Drug|radioprotection|
1726882|NCT00006360|Radiation|radiation therapy|
1726883|NCT00006361|Drug|semaxanib|
1726884|NCT00006362|Drug|bortezomib|
1726885|NCT00006363|Drug|cytarabine|Given IV
1726886|NCT00006363|Drug|daunorubicin hydrochloride|Given IV
1726887|NCT00006363|Drug|etoposide|Given IV
1726888|NCT00006363|Drug|valspodar|Given IV
1726889|NCT00006363|Biological|filgrastim|Given SC
1726890|NCT00006363|Drug|busulfan|Given orally
1726891|NCT00006363|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
1726892|NCT00006363|Procedure|peripheral blood stem cell transplantation|Undergo autologous PBSCT
1726893|NCT00006363|Biological|aldesleukin|Given SC
1726894|NCT00006363|Other|clinical observation|Undergo clinical observation
1726895|NCT00006363|Other|pharmacological study|Correlative studies
1726896|NCT00006364|Drug|omacetaxine mepesuccinate|Given IV or SC
1726897|NCT00006364|Other|pharmacological study|Correlative studies
1726898|NCT00006364|Other|laboratory biomarker analysis|Correlative studies
1726899|NCT00006365|Radiation|brachytherapy|
1726900|NCT00006365|Radiation|iodine I 125|
1726901|NCT00006365|Radiation|radiation therapy|
1726902|NCT00006366|Drug|fluorouracil|
1726903|NCT00006366|Drug|irinotecan hydrochloride|
1726904|NCT00006366|Procedure|conventional surgery|
1726905|NCT00006366|Radiation|radiation therapy|
1726906|NCT00006367|Biological|filgrastim|
1726907|NCT00006367|Drug|busulfan|
1726908|NCT00006367|Drug|cytarabine|
1726909|NCT00006367|Drug|idarubicin|
1726910|NCT00006367|Procedure|peripheral blood stem cell transplantation|
1726911|NCT00006368|Radiation|yttrium Y 90-edotreotide|
1726912|NCT00006369|Drug|ERA-923|
1726913|NCT00006370|Radiation|yttrium Y 90-edotreotide|
1726914|NCT00006371|Drug|aminoglutethimide|
1726915|NCT00006371|Drug|ketoconazole|
1726916|NCT00006371|Drug|therapeutic hydrocortisone|
1726917|NCT00006372|Drug|gemcitabine hydrochloride|Patients receive gemcitabine IV over 30 minutes on days 1 and 8. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
1726918|NCT00006372|Drug|pegylated liposomal doxorubicin hydrochloride|Patients receive doxorubicin HCl liposome IV over 1-2.5 hours on day 1. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
1726919|NCT00006372|Drug|vinorelbine ditartrate|Patients receive vinorelbine IV over 6-10 minutes on days 1 and 15. Treatment continues every 28 days in the absence of disease progression or unacceptable toxicity.
1726920|NCT00006373|Drug|etoposide|Etoposide IV 500 mg/m2/day over 24 hours Days -5, -4, -3
1727018|NCT00013364|Behavioral|Talker variability|
1726921|NCT00006373|Drug|ifosfamide|Ifosfamide 3,333 mg/m2/day IV over 2 hours (total dose 10,000 mg/m2)Days -8, -7, -6
1726922|NCT00006373|Drug|topotecan hydrochloride|Topotecan 21.3 mg/m2/day (total dose 64 mg/m2 ) IV over 30 minutes Days -8, -7, -6
1726923|NCT00006373|Procedure|autologous bone marrow transplantation|
1726924|NCT00006373|Drug|Mesna|Mesna 1,111 mg/m2/dose IV over 30 minutes; 30 minutes before and 4 and 8 hours after ifosfamide (total dose 10,000 mg/m2) Days -8, -7, -6
1726925|NCT00006374|Biological|filgrastim|
1726926|NCT00006374|Drug|cisplatin|
1726927|NCT00006374|Drug|etoposide|
1726928|NCT00006374|Drug|paclitaxel|
1726929|NCT00006374|Drug|topotecan hydrochloride|
1726930|NCT00006375|Drug|LY293111|
1726931|NCT00006376|Drug|chemotherapy|
1726932|NCT00006376|Drug|tipifarnib|
1726933|NCT00006377|Drug|carboplatin|
1726934|NCT00006377|Drug|doxorubicin hydrochloride|
1726935|NCT00006377|Drug|paclitaxel|
1726936|NCT00006378|Drug|carboplatin|
1726937|NCT00006378|Drug|paclitaxel|
1726938|NCT00006378|Radiation|radiation therapy|
1726939|NCT00006379|Biological|anti-thymocyte globulin|anti-thymocyte globulin IV over at least 4 hours on days -2 and -1
1726940|NCT00006379|Biological|graft-versus-tumor induction therapy|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
1726941|NCT00006379|Drug|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
1726942|NCT00006379|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
1726943|NCT00006379|Procedure|peripheral blood stem cell transplantation|Patients undergo filgrastim (G-CSF)-mobilized allogeneic peripheral blood stem cell transplantation on day 0.
1726944|NCT00006380|Biological|monoclonal antibody muJ591|
1726945|NCT00006380|Radiation|iodine I 131 monoclonal antibody muJ591|
1726946|NCT00006381|Biological|trastuzumab|
1726947|NCT00006381|Drug|celecoxib|
1726948|NCT00006382|Procedure|bronchoscopic and lung imaging studies|
1726949|NCT00006382|Procedure|comparison of screening methods|
1726950|NCT00006382|Procedure|computed tomography|
1726951|NCT00006382|Procedure|radiography|
1726952|NCT00006382|Procedure|study of high risk factors|
1726953|NCT00006383|Drug|liposomal vincristine sulfate|
1726954|NCT00006384|Biological|recombinant interferon alfa|
1726955|NCT00006384|Drug|semaxanib|
1726956|NCT00006385|Biological|MART-1 antigen|
1726957|NCT00006385|Biological|gp100 antigen|
1726958|NCT00006385|Biological|incomplete Freund's adjuvant|
1726959|NCT00006385|Biological|recombinant interferon alfa|
1726960|NCT00006385|Biological|sargramostim|
1726961|NCT00006385|Biological|tyrosinase peptide|
1726962|NCT00006386|Drug|carmustine|
1726963|NCT00006386|Radiation|radiation therapy|
1726964|NCT00006386|Radiation|stereotactic radiosurgery|
1726965|NCT00006387|Biological|QS21|
1726966|NCT00006387|Biological|ras peptide cancer vaccine|
1726967|NCT00006388|Drug|tamoxifen citrate|
1726968|NCT00006388|Radiation|radiation therapy|
1726969|NCT00006389|Drug|bryostatin 1|Given IV
1726970|NCT00006389|Drug|cisplatin|Given IV
1726971|NCT00006389|Other|laboratory biomarker analysis|Correlative studies
1726972|NCT00006390|Biological|alemtuzumab|
1726973|NCT00006390|Biological|filgrastim|
1726974|NCT00006390|Drug|cyclophosphamide|
1726975|NCT00006390|Procedure|peripheral blood stem cell transplantation|
1726976|NCT00006390|Radiation|radiation therapy|
1726977|NCT00006391|Drug|oxaliplatin|
1726978|NCT00006391|Drug|topotecan hydrochloride|
1726979|NCT00006392|Drug|Vitamin E|400 IU daily by mouth for 7-12 years
1726980|NCT00006392|Drug|Selenium|200 mcg daily for 7-12 years
1726981|NCT00006392|Other|Vitamin E placebo|daily for 7-12 years
1726982|NCT00006392|Other|selenium placebo|daily for 7-12 years
1726983|NCT00006394|Drug|growth hormone|
1726984|NCT00006395|Drug|St. John's Wort|
1726985|NCT00006396|Drug|Nevirapine|
1726986|NCT00006396|Drug|Zidovudine|
1726987|NCT00006397|Drug|Indinavir sulfate|
1726988|NCT00006397|Drug|Ritonavir|
1726989|NCT00006397|Drug|Stavudine|
1726990|NCT00006397|Drug|Didanosine|
1726991|NCT00006398|Drug|Timolol Maleate|
1726992|NCT00006398|Drug|Placebo|
1726993|NCT00006399|Drug|Donepezil|
1726994|NCT00006399|Drug|Estrogen|
1726995|NCT00006399|Drug|Progesterone|
1726996|NCT00006400|Drug|Hydroxyurea|Participants will receive hydroxyurea.
1726997|NCT00006400|Drug|Placebo|Participants will receive placebo.
1726998|NCT00006401|Drug|iNO|Inhaled Nitric Oxide for Preventing Chronic Lung Disease in Premature Infants
1726999|NCT00006401|Other|Placebo|Inhaled Nitrogen
1727000|NCT00013130|Behavioral|Provision of health status information to patients provider|
1727001|NCT00013143|Behavioral|Patient risk profiling (potential ADEs) w/provider feedback|
1727002|NCT00013156|Procedure|Effectiveness of Lung Reduction Therapy|
1727003|NCT00013169|Behavioral|Strong Patient Focus|
1727004|NCT00013182|Behavioral|social activity|
1727005|NCT00013195|Behavioral|Telephone Care|
1727006|NCT00013208|Behavioral|Case Management|
1727007|NCT00013221|Behavioral|Exercise|
1727008|NCT00013234|Procedure|Teledermatology|
1727009|NCT00013247|Behavioral|Prostate Cancer Screening Education|
1727010|NCT00013260|Procedure|Integrated model of primary care|
1727011|NCT00013273|Procedure|Physical Conditioning|
1727012|NCT00013286|Device|Prevention Diabetic Foot Ulcer|
1727013|NCT00013299|Device|Prevention of Diabetic Ulcers|
1727014|NCT00013312|Procedure|Determine colonic tone|
1727015|NCT00013325|Procedure|Cardiac Disease|
1727016|NCT00013338|Procedure|Ambulation Training|
1727017|NCT00013351|Procedure|Prevention of Falls|
1727020|NCT00013390|Procedure|Tinnitus Masking|"Tinnitus Masking is a widely-used method for providing relief of tinnitus. The central premise of Tinnitus Masking involves the use of wearable ear-level devices (hearing aids, maskers, or combination instruments) that deliver sound to a patient's ear(s). The primary purpose of the sound presentation is to produce a sense of relief from the annoyance caused by the tinnitus sound. The relief is accomplished by either obscuring, or covering up (masking) the tinnitus sound, or by changing the sound of the tinnitus in some way, usually by reducing its loudness (Vernon, Meikle)."
1727021|NCT00013390|Procedure|Tinnitus Retraining Therapy|"Tinnitus Retraining Therapy (TRT) was derived from a purely psychological approach for facilitating tinnitus habituation (Hallam et al). The current method is based on neurophysiological principles, and aims at retraining brain regions that are involved in processing the tinnitus signal, without attempting to suppress generation of the signal (Jastreboff). The retraining involves a systematic effort aimed at decreasing both the detectability of tinnitus and the transmission of the tinnitus signal to emotional centers of the brain. Habituation of tinnitus thus purportedly occurs at two levels: habituation of emotional reactions to the tinnitus and habituation of tinnitus perception. Habituation is achieved by utilizing directive counseling, along with the use of low-level broadband noise to reduce the detectability of tinnitus for patients with normal or near-normal hearing. When hearing loss is a significant problem to the patient, appropriate hearing aids are fitted."
1727022|NCT00013403|Procedure|Blindness|
1727023|NCT00013416|Procedure|Hearing|
1727024|NCT00013429|Procedure|Visual|
1727025|NCT00013442|Procedure|Auditory Evoked Response|
1727026|NCT00013455|Device|Hearing|
1727027|NCT00013741|Behavioral|Tailored Education Messages|
1727028|NCT00013767|Behavioral|Individual and Community education|
1727029|NCT00013793|Behavioral|Motivational enhancement and ultrasound|
1727030|NCT00013806|Drug|131I-MIBG|
1727031|NCT00013871|Biological|Diphtheria & Tetanus Toxoids & Acellular Pertussis Vaccine Adsorbed|
1727032|NCT00013871|Biological|Measles-Mumps-Rubella Vaccine (Live)|
1727033|NCT00013871|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
1727034|NCT00013871|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|
1727035|NCT00013871|Biological|Hepatitis B Vaccine (Recombinant)|
1727036|NCT00013884|Drug|T-20|
1727037|NCT00013897|Drug|Atazanavir|
1727038|NCT00013897|Drug|Lamivudine/Zidovudine|
1727039|NCT00013897|Drug|Efavirenz|
1727040|NCT00013910|Drug|NNC 90-1170|
1727041|NCT00013923|Drug|Nutritional Supplement|
1727042|NCT00013962|Drug|Vitamin D|
1727043|NCT00014001|Drug|perphenazine|
1727044|NCT00014001|Drug|olanzapine|
1727045|NCT00014001|Drug|quetiapine|
1727046|NCT00014001|Drug|risperidone|
1727047|NCT00014001|Drug|ziprasidone|
1727048|NCT00014001|Drug|clozapine|
1727049|NCT00014001|Drug|fluphenazine decanoate|
1727050|NCT00014014|Drug|Lamivudine/Zidovudine|
1727051|NCT00014027|Drug|Docosahexaenoic acid (DHA)|
1727052|NCT00014027|Drug|Eicosapentaenoic acid|
1727053|NCT00014040|Drug|Nitric Oxide and INOpulse Delivery System|
1727054|NCT00014066|Drug|hematoporphyrin derivative|
1727055|NCT00014066|Radiation|brachytherapy|
1727056|NCT00014079|Genetic|DNA stability analysis|
1727057|NCT00014079|Genetic|loss of heterozygosity analysis|
1727058|NCT00014079|Genetic|microsatellite instability analysis|
1727059|NCT00014092|Biological|aldesleukin|
1727060|NCT00014092|Biological|recombinant interferon alfa|
1727061|NCT00014092|Biological|sargramostim|
1727062|NCT00014092|Drug|temozolomide|
1727063|NCT00014105|Drug|carboplatin|
1727064|NCT00014105|Drug|temozolomide|
1727065|NCT00014118|Drug|carboplatin|
1727066|NCT00014118|Drug|paclitaxel|
1727067|NCT00014118|Procedure|conventional surgery|
1727068|NCT00014118|Radiation|radiation therapy|
1727069|NCT00014131|Biological|Biological/Vaccine: therapeutic autologous dendritic cells.|Biological/Vaccine: therapeutic autologous dendritic cells. Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
1727070|NCT00014144|Drug|gefitinib|
1727071|NCT00014170|Drug|gefitinib|Given orally
1727072|NCT00014170|Other|pharmacological study|Correlative studies
1727073|NCT00014170|Other|laboratory biomarker analysis|Correlative studies
1727074|NCT00014170|Other|questionnaire administration|Ancillary studies
1727075|NCT00014170|Procedure|quality-of-life assessment|Ancillary studies
1727076|NCT00014183|Drug|gefitinib|
1727077|NCT00014196|Drug|cisplatin|
1727078|NCT00014196|Drug|docetaxel|
1727079|NCT00014196|Radiation|radiation therapy|
1727080|NCT00014209|Drug|cisplatin|
1727081|NCT00014209|Drug|dexamethasone|
1727082|NCT00014209|Drug|gemcitabine hydrochloride|
1727083|NCT00014222|Biological|epoetin alfa|40,000 IU
1727084|NCT00014222|Biological|filgrastim|5 mg/kg/d - days 2-13
1727085|NCT00014222|Drug|cyclophosphamide|75, 600 and 830 mg/m2
1727086|NCT00014222|Drug|doxorubicin hydrochloride|60 mg/m2
1727087|NCT00014222|Drug|epirubicin hydrochloride|60 mg/m2
1727088|NCT00014222|Drug|fluorouracil|500mg/m2
1727089|NCT00014222|Drug|paclitaxel|175 mg/m2
1727090|NCT00014235|Drug|fludarabine phosphate|Given IV
1727091|NCT00014235|Radiation|total-body irradiation|Undergo TBI
1727092|NCT00014235|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
1727093|NCT00014235|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo PBSCT
1727094|NCT00014235|Drug|cyclosporine|Given PO or IV
1727095|NCT00014235|Drug|mycophenolate mofetil|Given IV or PO
1727096|NCT00014235|Other|laboratory biomarker analysis|Correlative studies
1727097|NCT00014248|Drug|adenosine triphosphate|
1727098|NCT00014248|Procedure|quality-of-life assessment|
1727099|NCT00014261|Biological|PEG-interferon alfa-2b|
1727102|NCT00014274|Drug|gemcitabine hydrochloride|
1727103|NCT00014274|Drug|methotrexate|
1727104|NCT00014274|Drug|vinblastine sulfate|
1727105|NCT00014287|Drug|gemcitabine hydrochloride|
1727106|NCT00014300|Drug|glufosfamide|
1727107|NCT00014313|Drug|cisplatin|
1727108|NCT00014313|Drug|etoposide|
1727109|NCT00014326|Radiation|radiation therapy|
1727110|NCT00014339|Drug|Wobe-Mugos E|
1727111|NCT00014339|Drug|melphalan|
1727112|NCT00014339|Drug|prednisone|
1727113|NCT00014339|Procedure|quality-of-life assessment|
1727114|NCT00014352|Drug|docetaxel|
1727115|NCT00014352|Drug|doxorubicin hydrochloride|
1727116|NCT00014352|Drug|estramustine phosphate sodium|
1727117|NCT00014352|Drug|ketoconazole|
1727118|NCT00014352|Drug|warfarin|
1727119|NCT00014365|Drug|MKC-1|
1727120|NCT00014378|Drug|Chinese Herb Huanglian (Coptis chinesis)|Patients will receive capsules of the powdered extract of the huanglian root, which will take by mouth 4 times a day (qid).
1727121|NCT00014391|Biological|palivizumab|
1727122|NCT00014391|Drug|ribavirin|
1727123|NCT00014404|Drug|celecoxib|
1727124|NCT00014430|Biological|trastuzumab|"Trastuzumab (INN; trade name Herceptin) is a monoclonal antibody that interferes with the HER2/neu receptor. Its main use is to treat certain breast cancers.
The HER receptors are proteins that are embedded in the cell membrane and communicate molecular signals from outside the cell to inside the cell, and turn genes on and off. The HER proteins regulate cell growth, survival, adhesion, migration, and differentiation—functions that are amplified or weakened in cancer cells. In some cancers, notably some breast cancers, HER2 is over-expressed, and causes breast cells to reproduce uncontrollably."
1727125|NCT00014430|Drug|vinorelbine ditartrate|Vinorelbine (trade name Navelbine) is an anti-mitotic chemotherapy drug that is given as a treatment for some types of cancer, including breast cancer and non-small cell lung cancer.
1727126|NCT00014443|Drug|thalidomide|
1727127|NCT00014443|Drug|topotecan hydrochloride|
1727128|NCT00014456|Biological|filgrastim|
1727129|NCT00014456|Drug|docetaxel|
1727130|NCT00014456|Drug|gemcitabine hydrochloride|
1727131|NCT00014469|Drug|busulfan|
1727132|NCT00014469|Drug|melphalan|
1727133|NCT00014469|Drug|methotrexate|
1727134|NCT00014469|Drug|tacrolimus|
1727135|NCT00014469|Procedure|allogeneic bone marrow transplantation|
1727136|NCT00014482|Procedure|pain therapy|
1727137|NCT00014482|Procedure|psychosocial assessment and care|
1727138|NCT00014495|Biological|filgrastim|
1727139|NCT00014495|Drug|cytarabine|
1727140|NCT00014495|Radiation|bismuth Bi213 monoclonal antibody M195|
1727141|NCT00014508|Biological|sargramostim|
1727142|NCT00014508|Drug|cyclophosphamide|
1727143|NCT00014508|Drug|cyclosporine|
1727144|NCT00014508|Drug|fludarabine phosphate|
1727145|NCT00014508|Drug|melphalan|
1727146|NCT00014508|Procedure|peripheral blood stem cell transplantation|
1727147|NCT00014521|Drug|karenitecin|
1727148|NCT00014534|Biological|filgrastim|6 mg sub Q
1727149|NCT00014534|Drug|cisplatin|60 mg/sq m IV
1727150|NCT00014534|Drug|doxorubicin hydrochloride|50 mg/ sq m IV
1727151|NCT00014534|Drug|gemcitabine hydrochloride|1000 mg/ sq m IV for Gem + cis arm and 2000 mg/sq m IV for gem + dox + peg arm
1727152|NCT00014547|Drug|BBR 3464|
1727153|NCT00014560|Biological|bispecific antibody 4G7xH22|
1727154|NCT00014560|Biological|sargramostim|
1727155|NCT00014573|Biological|aldesleukin|
1727156|NCT00014573|Biological|autologous tumor cell vaccine|
1727157|NCT00014573|Biological|filgrastim|
1727158|NCT00014573|Biological|sargramostim|
1727159|NCT00014573|Biological|therapeutic autologous lymphocytes|
1727160|NCT00014573|Drug|carmustine|
1727161|NCT00014573|Drug|cisplatin|
1727162|NCT00014573|Drug|cyclophosphamide|
1727163|NCT00014573|Drug|paclitaxel|
1727164|NCT00014573|Procedure|autologous bone marrow transplantation|
1727165|NCT00014573|Procedure|conventional surgery|
1727166|NCT00014573|Procedure|peripheral blood stem cell transplantation|
1727167|NCT00014586|Drug|bicalutamide|
1727168|NCT00014586|Drug|goserelin acetate|
1727169|NCT00014586|Procedure|orchiectomy|
1727170|NCT00014599|Drug|paclitaxel|
1727171|NCT00014612|Procedure|axillary lymph node dissection|
1727172|NCT00014612|Procedure|lymphoscintigraphy|
1727173|NCT00014612|Procedure|therapeutic conventional surgery|
1727174|NCT00014612|Radiation|radiation therapy|
1727175|NCT00014625|Drug|indisulam|
1727176|NCT00014638|Drug|letrozole|
1727177|NCT00014651|Drug|vapreotide|
1727178|NCT00014651|Procedure|conventional surgery|
1727179|NCT00014664|Biological|apolizumab|
1727180|NCT00014677|Biological|interleukin-4 PE38KDEL cytotoxin|
1727181|NCT00014677|Procedure|conventional surgery|
1727182|NCT00014690|Drug|plevitrexed|
1727183|NCT00014690|Drug|topotecan hydrochloride|
1727184|NCT00014729|Drug|isotretinoin|
1727185|NCT00014742|Drug|collagenase|
1727186|NCT00014755|Drug|anti-thymocyte globulin|
1727187|NCT00014755|Drug|cyclophosphamide|
1727188|NCT00014755|Drug|filgrastim|
1727189|NCT00014755|Drug|prednisone|
1727190|NCT00014755|Procedure|peripheral blood stem cell transplantation|
1727191|NCT00014755|Procedure|irradiation|
1727192|NCT00014768|Drug|glucose|
1727193|NCT00014768|Drug|insulin|
1727194|NCT00014768|Drug|leucine|
1727195|NCT00014794|Drug|15-O labeled water|
1727196|NCT00014807|Behavioral|Reducing Pesticide Exposure in Minority Families|
1727197|NCT00014833|Other|No intervention|No intervention
1727287|NCT00015990|Drug|thalidomide|Given orally
1727288|NCT00015990|Other|laboratory biomarker analysis|Correlative studies
1727198|NCT00014911|Procedure|Islet Transplantation|Participants will receive portal vein islet infusions (up to 3), e.g., islet transplantations, with a targeted total of exceeding 10,000 islet equivalents per kilogram of body weight (IE/kg) per infusion. Up to three transplants are possible depending on individual results.
1727199|NCT00014911|Drug|Sirolimus|Administered at a dose of 0.2 mg/kg by mouth once pre-transplantation then 0.1 mg/kg daily post-transplantation. Dosing will be adjusted to achieve a trough peripheral blood level of 12-15 ng/mL x3 months after transplantation and 7-12 ng/mL for the remainder of the study.
1727200|NCT00014911|Drug|Tacrolimus|Administered at a dose of 1 mg by mouth once pre-transplantation followed by 1 mg twice daily post transplantation. Levels will be adjusted to achieve a peripheral blood trough level of 3-6 ng/mL for maintenance immunosuppression.
1727201|NCT00014911|Drug|Daclizumab|Administered at a dose of 1 mg/kg intravenously immediately pre-transplantation and 2, 4, 6, and 8 weeks post-transplantation, totaling 5 doses(over 8 weeks). Further daclizumab dosing may be necessary based on individual results and islet transplantation needs.
1727202|NCT00014911|Drug|Sulfamethoxazole|An antibacterial used to prevent opportunistic infections
1727203|NCT00014911|Drug|Ganciclovir|An antiviral used to kill viruses and stop viral replication
1727204|NCT00014911|Drug|Trimethoprim|An antibacterial used to prevent opportunistic infections
1727205|NCT00014911|Drug|Pentamidine|An antiprotozoal used to prevent disease
1727206|NCT00014937|Drug|lopinavir/ritonavir|
1727207|NCT00014937|Drug|lamivudine/zidovudine|
1727208|NCT00014937|Drug|efavirenz|
1727209|NCT00014937|Drug|lamivudine|
1727210|NCT00014937|Drug|stavudine|
1727211|NCT00014937|Drug|zidovudine|
1727212|NCT00014937|Drug|didanosine|
1727213|NCT00014950|Procedure|CF newborn screening|
1727214|NCT00014989|Drug|magnesium sulfate|
1727215|NCT00015002|Drug|Betamethasone|"coded study medication is 12 mg of betamethasone (or placebo) given as 2 ml intramuscular injection in 2 doses, 24 hours apart (the Course). Patients administered weekly courses for 4 weeks, until 33 weeks 6 days gestation or delivery, whichever occurs first."
1727216|NCT00015015|Drug|Dichloroacetate|
1727217|NCT00015028|Drug|Buprenorphine/naloxone|
1727218|NCT00015041|Drug|Buprenorphine|
1727219|NCT00015054|Drug|Methylphenidate|
1727220|NCT00015067|Drug|Methylphenidate|
1727221|NCT00015080|Drug|Naltrexone|
1727222|NCT00015106|Drug|Lamotrigine|
1727223|NCT00015132|Drug|Sertraline|
1727224|NCT00015171|Drug|Buprenorphine/naloxone|
1727225|NCT00015210|Drug|Nefazodone|
1727226|NCT00015210|Behavioral|Psychosocial Treatment|All subjects attended a weekly 1-hour therapy session during the 8 week treatment period.
1727227|NCT00015223|Drug|Methylphenidate|
1727228|NCT00015236|Behavioral|Amantadine|
1727229|NCT00015249|Drug|Amantadine|
1727230|NCT00015275|Behavioral|Cocaine-Related Disorders|
1727231|NCT00015288|Drug|Buprenorphine/naloxone|
1727232|NCT00015301|Drug|Methylphenidate|
1727233|NCT00015340|Drug|Buprenorphine/naloxone|
1727234|NCT00015457|Drug|Amlodipine plus Botulinum toxin|
1727235|NCT00015548|Drug|Olanzapine|
1727236|NCT00015548|Drug|Quetiapine|
1727237|NCT00015548|Drug|Risperidone|
1727238|NCT00015548|Drug|Citalopram|
1727239|NCT00015600|Behavioral|Behavior modification through social marketing|
1727240|NCT00015626|Drug|Metformin|
1727241|NCT00015626|Procedure|skin biopsy|
1727242|NCT00015626|Behavioral|diet and exercise|
1727243|NCT00015626|Drug|pioglitazone|
1727244|NCT00015626|Drug|rosiglitazone|
1727245|NCT00015652|Drug|Ribavirin|
1727246|NCT00015652|Drug|Aldesleukin|
1727247|NCT00015652|Drug|Peginterferon alfa-2b|
1727248|NCT00015665|Drug|Voriconazole|
1727249|NCT00015691|Drug|Metformin hydrochloride|
1727250|NCT00015691|Drug|Rosiglitazone maleate|
1727251|NCT00015704|Drug|Aldesleukin|
1727252|NCT00015769|Drug|levetiracetam|
1727253|NCT00015795|Device|airway interruption test|
1727254|NCT00015808|Drug|Idebenone|
1727255|NCT00015821|Drug|thalidomide|Given PO
1727256|NCT00015821|Other|laboratory biomarker analysis|Correlative studies
1727257|NCT00015834|Drug|imatinib mesylate|Given PO
1727258|NCT00015834|Drug|cytarabine|Given IV
1727259|NCT00015847|Biological|recombinant interferon alfa|IFN-α will be given at a dose ranging up to 5 MIU daily via subcutaneous injection.
1727260|NCT00015847|Drug|imatinib mesylate|Once daily oral administration of STI571 (imatinib mesylate) at a dose of 400 mg or 600mg for 12 months.
1727261|NCT00015860|Drug|daunorubicin hydrochloride|
1727262|NCT00015860|Drug|imatinib mesylate|
1727263|NCT00015860|Drug|prednisone|
1727264|NCT00015860|Drug|vincristine sulfate|
1727265|NCT00015873|Drug|asparaginase|
1727266|NCT00015873|Drug|cytarabine|
1727267|NCT00015873|Drug|mercaptopurine|
1727268|NCT00015873|Drug|methotrexate|
1727269|NCT00015873|Drug|prednisolone|
1727270|NCT00015873|Drug|vincristine sulfate|
1727271|NCT00015886|Drug|docetaxel|75 milligrams per meter squared intraveneously
1727272|NCT00015886|Drug|fluorouracil|350 milligrams intraveneously
1727273|NCT00015899|Drug|lonafarnib|
1727274|NCT00015912|Biological|recombinant interferon alfa|Given IV
1727275|NCT00015912|Drug|thalidomide|Given orally
1727276|NCT00015912|Other|laboratory biomarker analysis|Correlative studies
1727277|NCT00015925|Drug|entinostat|
1727278|NCT00015938|Biological|filgrastim|
1727279|NCT00015938|Drug|docetaxel|
1727280|NCT00015938|Drug|vinorelbine|
1727281|NCT00015951|Biological|bevacizumab|
1727282|NCT00015951|Drug|cytarabine|
1727283|NCT00015951|Drug|mitoxantrone hydrochloride|
1727284|NCT00015964|Drug|ZD1839|
1727285|NCT00015977|Biological|PSA prostate cancer vaccine|
1727286|NCT00015977|Biological|recombinant interleukin-12|
1727289|NCT00016016|Drug|cytarabine|Given IV
1727290|NCT00016016|Drug|mitoxantrone hydrochloride|Given IV
1727291|NCT00016016|Drug|alvocidib|Given IV
1727292|NCT00016016|Other|pharmacological study|Correlative studies
1727293|NCT00016016|Other|laboratory procedure|Correlative studies
1727294|NCT00016029|Other|screening questionnaire administration|
1727295|NCT00016029|Procedure|barium enema injection|
1727296|NCT00016029|Procedure|computed tomography|
1727297|NCT00016029|Procedure|computed tomography colonography|
1727298|NCT00016029|Procedure|diagnostic colonoscopy|
1727299|NCT00016029|Procedure|screening colonoscopy|
1727300|NCT00016042|Biological|lymphokine-activated killer cells|
1727301|NCT00016042|Biological|recombinant interferon alfa|
1727302|NCT00016042|Biological|sargramostim|
1727303|NCT00016042|Drug|fluorouracil|
1727304|NCT00016055|Biological|lymphokine-activated killer cells|
1727305|NCT00016055|Drug|temozolomide|
1727306|NCT00016068|Drug|ganciclovir|
1727307|NCT00016068|Drug|valganciclovir|
1727308|NCT00016081|Drug|ribavirin|
1727309|NCT00016094|Biological|bevacizumab|Given IV
1727310|NCT00016094|Other|laboratory biomarker analysis|Correlative studies
1727311|NCT00016107|Drug|estramustine phosphate sodium|Given orally
1727312|NCT00016107|Drug|docetaxel|Given IV
1727313|NCT00016107|Biological|bevacizumab|Given IV
1727314|NCT00016107|Other|laboratory biomarker analysis|Correlative studies
1727315|NCT00016133|Biological|BCG vaccine|
1727316|NCT00016133|Biological|autologous tumor cell vaccine|
1727317|NCT00016133|Drug|fluorouracil|
1727318|NCT00016133|Drug|leucovorin calcium|
1727319|NCT00016133|Procedure|adjuvant therapy|
1727320|NCT00016146|Biological|GPI-0100|
1727321|NCT00016146|Biological|MUC-2-Globo H-KLH conjugate vaccine|
1727322|NCT00016159|Biological|filgrastim|
1727323|NCT00016159|Biological|lintuzumab|
1727324|NCT00016159|Drug|arsenic trioxide|
1727325|NCT00016159|Drug|idarubicin|
1727326|NCT00016159|Drug|tretinoin|
1727327|NCT00016172|Drug|pegylated liposomal doxorubicin hydrochloride|
1727328|NCT00016172|Drug|picoplatin|
1727329|NCT00016185|Drug|alvocidib|
1727330|NCT00016185|Drug|docetaxel|
1727331|NCT00016198|Drug|FOLFOX regimen|
1727332|NCT00016198|Drug|fluorouracil|
1727333|NCT00016198|Drug|leucovorin calcium|
1727334|NCT00016198|Drug|oxaliplatin|
1727335|NCT00016211|Radiation|radiation therapy|
1727336|NCT00016224|Drug|thalidomide|
1727337|NCT00016237|Biological|tucotuzumab celmoleukin|
1727338|NCT00016250|Drug|MKC-1|
1727339|NCT00016263|Biological|oblimersen sodium|
1727340|NCT00016263|Drug|dacarbazine|
1727341|NCT00016276|Drug|dexrazoxane hydrochloride|Given IV
1727342|NCT00016276|Drug|doxorubicin hydrochloride|Given IV
1727343|NCT00016276|Drug|cyclophosphamide|Given IV
1727344|NCT00016276|Drug|paclitaxel|Given IV
1727345|NCT00016276|Biological|trastuzumab|Given IV
1727346|NCT00016276|Procedure|therapeutic conventional surgery|Undergo breast conservation surgery, modified radical mastectomy, or mastectomy
1727347|NCT00016276|Radiation|radiation therapy|Undergo radiation therapy
1727348|NCT00016276|Drug|tamoxifen citrate|Given orally
1727349|NCT00016276|Other|laboratory biomarker analysis|Correlative studies
1727350|NCT00016289|Biological|recombinant interleukin-12|Given intraperitoneally
1727351|NCT00016302|Drug|prednisone|Given orally
1727352|NCT00016302|Drug|vincristine sulfate|Given IV
1727353|NCT00016302|Drug|daunorubicin hydrochloride|Given IV
1727354|NCT00016302|Drug|asparaginase|Given IM
1727355|NCT00016302|Drug|methotrexate|Given IT and orally
1727356|NCT00016302|Drug|cyclophosphamide|Given IV
1727357|NCT00016302|Drug|cytarabine|Given IV or SC
1727358|NCT00016302|Drug|mercaptopurine|Given orally
1727359|NCT00016302|Drug|leucovorin calcium|Given IV or orally
1727360|NCT00016302|Drug|dexamethasone|Given orally
1727361|NCT00016302|Drug|doxorubicin hydrochloride|Given IV
1727362|NCT00016302|Drug|thioguanine|Given orally
1727363|NCT00016302|Radiation|radiation therapy|Undergo cranial irradiation
1727364|NCT00016302|Drug|nelarabine|Given IV
1727365|NCT00016302|Drug|pegaspargase|Given IM
1727366|NCT00016302|Radiation|radiation therapy|Undergo craniocervical radiotherapy
1727367|NCT00016302|Other|pharmacological study|Correlative studies
1727368|NCT00016302|Other|laboratory biomarker analysis|Correlative studies
1727369|NCT00016315|Drug|carboplatin|
1727370|NCT00016315|Drug|gemcitabine hydrochloride|
1727371|NCT00016315|Drug|paclitaxel|
1727372|NCT00016315|Radiation|radiation therapy|
1727373|NCT00016328|Drug|temsirolimus|Given IV
1727374|NCT00016328|Other|laboratory biomarker analysis|Correlative studies
1727375|NCT00016328|Other|pharmacological study|Correlative studies
1727376|NCT00016341|Biological|filgrastim|
1727377|NCT00016341|Drug|cisplatin|
1727378|NCT00016341|Drug|doxorubicin hydrochloride|
1727379|NCT00016341|Drug|megestrol acetate|
1727380|NCT00016341|Drug|paclitaxel|
1727381|NCT00016341|Drug|tamoxifen citrate|
1727382|NCT00016354|Drug|benzoylphenylurea|
1727383|NCT00016367|Biological|Trastuzumab|"Regimen A: Trastuzumab IV over 90 minutes on days 2 and 8.
Regimen B: Trastuzumab IV over 30-90 minutes on days 1, 8 and 15."
1727384|NCT00016367|Drug|Cisplatin|"Regimen A: Cisplatin IV over 2 hours on day 1 following gemcitabine.
Regimen B: Cisplatin IV over 2 hours on day 1."
1727385|NCT00016367|Drug|Gemcitabine Hydrochloride|"Regimen A: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab.
Regimen B: Gemcitabine IV over 30 minutes on day 1. Gemcitabine IV over 30 minutes on day 8 following Trastuzumab."
1727388|NCT00016380|Procedure|quality-of-life assessment|
1727389|NCT00016393|Drug|ixabepilone|
1727390|NCT00016406|Biological|filgrastim|
1727391|NCT00016406|Drug|cyclophosphamide|
1727392|NCT00016406|Drug|doxorubicin|
1727393|NCT00016406|Drug|paclitaxel|
1727394|NCT00016406|Procedure|surgery|
1727395|NCT00016419|Biological|anti-thymocyte globulin|3.5 mg/kg/d IV over 12 hrs day 1
1727396|NCT00016419|Drug|cyclosporine|3 mg/kg bid days 5-94 then taper to 0 at day 124 PO
1727397|NCT00016432|Drug|exemestane|25 mg for 5 years
1727398|NCT00016432|Drug|Placebo|Placebo
1727399|NCT00016445|Drug|growth hormone|
1727400|NCT00016458|Drug|anti-thymocyte globulin|
1727401|NCT00016458|Drug|cyclophosphamide|
1727402|NCT00016471|Procedure|Audiogram|
1727403|NCT00016471|Procedure|Electroretinogram|
1727404|NCT00016497|Procedure|bilateral myringotomy|
1727405|NCT00016497|Procedure|bilateral myringotomy and tubes|
1727406|NCT00016497|Procedure|adenoidectomy|
1727407|NCT00016523|Drug|Inhaled nitric oxide|Started at 5 ppm and could be increased to 10 ppm
1727408|NCT00016523|Drug|Placebo|Started at 5 ppm and could be increased to 10 ppm
1727409|NCT00016536|Drug|Naphthalene 2-sulfonate polymer|
1727410|NCT00016536|Drug|Carbopol polymer|
1727411|NCT00016549|Biological|Bevacizumab|
1727412|NCT00016588|Drug|Tenofovir disoproxil fumarate|
1727413|NCT00016601|Drug|Indinavir sulfate|
1727414|NCT00016601|Drug|Ritonavir|
1727415|NCT00016601|Drug|Nelfinavir mesylate|
1727416|NCT00016601|Drug|Efavirenz|
1727417|NCT00016601|Drug|Nevirapine|
1727418|NCT00016601|Drug|Medroxyprogesterone acetate|
1727419|NCT00006124|Drug|celecoxib|Given orally
1727420|NCT00006124|Drug|placebo|Given orally
1727421|NCT00006125|Drug|doxorubicin hydrochloride|
1727422|NCT00006125|Drug|topotecan hydrochloride|
1727423|NCT00006126|Drug|busulfan|
1727424|NCT00006126|Drug|cyclophosphamide|
1727425|NCT00006126|Drug|etoposide|
1727426|NCT00006126|Drug|fludarabine phosphate|
1727427|NCT00006126|Procedure|peripheral blood stem cell transplantation|
1727428|NCT00006126|Radiation|radiation therapy|
1727429|NCT00006127|Drug|amifostine|
1727430|NCT00006129|Drug|testosterone|
1727431|NCT00006130|Procedure|Core decompression|
1727432|NCT00006131|Drug|Valacyclovir|
1727433|NCT00006132|Drug|acyclovir|
1727434|NCT00006133|Drug|estradiol|
1727435|NCT00006133|Drug|ethinyl estradiol|
1727436|NCT00006133|Drug|medroxyprogesterone|
1727437|NCT00006133|Drug|norethindrone|
1727438|NCT00006135|Drug|acyclovir|
1727439|NCT00006136|Drug|arginine butyrate|
1727440|NCT00006136|Drug|epoetin alfa|
1727441|NCT00006137|Drug|enalapril|
1727442|NCT00006142|Behavioral|phenylalanine restricted diet|
1727443|NCT00006143|Drug|Somatropin|
1727444|NCT00006144|Drug|Lopinavir/Ritonavir|
1727445|NCT00006144|Drug|Emtricitabine|
1727446|NCT00006144|Drug|Stavudine|
1727447|NCT00006145|Drug|Valganciclovir|
1727448|NCT00006146|Biological|Approved influenza virus vaccine.|
1727449|NCT00006151|Behavioral|Behavioral Therapy|Weekly behavioral therapy based on Project Match Motivational Therapy clinical manual plus systematic cigarette tapering.
1727450|NCT00006152|Drug|Ritonavir|
1727451|NCT00006152|Drug|Abacavir sulfate|
1727452|NCT00006152|Drug|Amprenavir|
1727453|NCT00006153|Biological|HIV-1 Immunogen|
1727454|NCT00006154|Drug|Indinavir sulfate|400 mg tablets equaling 1600 mg daily
1727455|NCT00006154|Drug|Ritonavir|100 mg liquid capsules equaling 400 mg daily
1727456|NCT00006154|Drug|Abacavir sulfate|300 mg capsules equaling 600 mg daily. Administration based on individual results after 16 weeks.
1727457|NCT00006154|Drug|Efavirenz|200 mg capsules equaling 600 mg daily
1727458|NCT00006154|Drug|Stavudine|30-40 mg capsules equaling 60 or 80 mg daily
1727459|NCT00006154|Drug|Didanosine|250-400 mg E.coated tablets equaling 250 or 400 mg daily
1727460|NCT00006154|Drug|Aldesleukin|Subcutaneous injection equaling 15 x 10^6 IU daily dose. Administration based on individual results after 16 weeks and randomization.
1727461|NCT00006155|Drug|SU5416 and carboplatin|
1727462|NCT00006156|Other|Control|No injection of FSH
1727463|NCT00006156|Drug|Drug: FSH|FSH Stimulation Test
1727464|NCT00006157|Drug|Desipramine|
1727465|NCT00006157|Behavioral|Cognitive Behavioral Treatment|
1727466|NCT00006158|Drug|Testosterone|
1727467|NCT00006159|Behavioral|lifestyle (exercise, diet, and family and community support)|
1727468|NCT00006160|Behavioral|home based worker|
1727469|NCT00006161|Procedure|Transjugular Intrahepatic Portosystemic Shunt (TIPS)|
1727470|NCT00006161|Procedure|Distal Splenorenal Shunt|
1727471|NCT00006162|Behavioral|exercise and diet|
1727472|NCT00006163|Behavioral|Personalized Self-management|
1727473|NCT00006163|Behavioral|Community Resources|
1727474|NCT00006164|Drug|Peginterferon alfa-2a + Ribavirin|Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight <75 kg, >75 kg) daily in two divided doses for 24 weeks
1727475|NCT00006164|Drug|Peginterferon alfa-2a|90 mcg/week injection, for 3.5 years
1727476|NCT00006165|Behavioral|'Ohana (Family) Support Lifestyle Intervention|
1727477|NCT00006166|Procedure|Transjugular intrahepatic portasystemic shunts (TIPS)|
1727478|NCT00006166|Procedure|Total paracentecis (TP)|
1727479|NCT00006167|Drug|oxandrolone|
1727480|NCT00006167|Behavioral|Progressive Resistance Training|
1727481|NCT00006168|Drug|Methotrexate|
1727482|NCT00006169|Behavioral|Behavioral Treatment|
1727483|NCT00006170|Drug|Bupropion|smoking cessation medication aid
1727484|NCT00006170|Drug|Placebo|A matched placebo pill
1727485|NCT00006170|Behavioral|weight concerns intervention|cognitive behavioral treatment to address weight concners
1727486|NCT00006170|Behavioral|smoking cessation intervention|Cognitive behavioral intervention for smoking cessation
1727487|NCT00006172|Device|Bright light box|60-min light therapy shortly after awakening
1727488|NCT00006172|Device|High-output negative ion generator|60-min high-density ion exposure shortly after awakening
1727489|NCT00006172|Device|Low-output negative ion generator|60-min low-density ion exposure shortly after awakening
1727490|NCT00006174|Drug|Letrozole|
1727491|NCT00006178|Drug|Sirolimus|
1727492|NCT00006178|Drug|Thymoglobulin|
1727493|NCT00006180|Drug|Alendronate|
1727494|NCT00006181|Behavioral|Team-based intervention|
1727495|NCT00006181|Behavioral|One-on-one intervention|
1727496|NCT00006182|Procedure|Blood Transfusion|
1727497|NCT00006183|Procedure|Cardiopulmonary Bypass with Two Different Intra-Operative Hematocrits|
1727498|NCT00006183|Procedure|Thoracic Surgery|
1727511|NCT00006185|Drug|Avandia administration for 6-12 weeks|
1727512|NCT00006186|Procedure|Autologous fresh whole blood|
1727513|NCT00006187|Drug|Investigational drug|
1727514|NCT00006190|Drug|Nelfinavir mesylate|
1727515|NCT00006190|Drug|Stavudine|
1727516|NCT00006190|Drug|Lamivudine|
1727517|NCT00006190|Drug|Efavirenz|
1727518|NCT00006193|Behavioral|diet|
1727519|NCT00006194|Behavioral|Exercise|
1727520|NCT00006195|Drug|risperidone|
1727521|NCT00006195|Drug|olanzapine|
1727522|NCT00008008|Biological|filgrastim|
1727523|NCT00008008|Biological|sargramostim|
1727524|NCT00008008|Drug|cyclophosphamide|
1727525|NCT00008008|Drug|thiotepa|
1727526|NCT00008008|Procedure|autologous bone marrow transplantation|
1727527|NCT00008008|Procedure|bone marrow ablation with stem cell support|
1727528|NCT00008008|Procedure|peripheral blood stem cell transplantation|
1727529|NCT00008021|Biological|filgrastim|
1727530|NCT00008021|Biological|monoclonal antibody Lym-1|
1727531|NCT00008021|Drug|cyclosporine|
1727532|NCT00008021|Drug|paclitaxel|
1727533|NCT00008021|Procedure|peripheral blood stem cell transplantation|
1727534|NCT00008021|Radiation|indium In 111 monoclonal antibody Lym-1|
1727535|NCT00008021|Radiation|yttrium Y 90 monoclonal antibody Lym-1|
1727536|NCT00008034|Drug|capecitabine|
1727537|NCT00008034|Drug|cyclophosphamide|
1727538|NCT00008034|Drug|epirubicin hydrochloride|
1727539|NCT00008047|Drug|fluorouracil|
1727540|NCT00008047|Drug|hydroxyurea|
1727541|NCT00008047|Drug|paclitaxel|
1727542|NCT00008047|Procedure|conventional surgery|
1727543|NCT00008047|Radiation|radiation therapy|
1727544|NCT00008060|Drug|FOLFIRI regimen|
1727545|NCT00008060|Drug|FOLFOX regimen|
1727546|NCT00008060|Drug|fluorouracil|
1727547|NCT00008060|Drug|irinotecan hydrochloride|
1727548|NCT00008060|Drug|leucovorin calcium|
1727549|NCT00008060|Drug|oxaliplatin|
1727550|NCT00008073|Drug|doxorubicin hydrochloride|
1727551|NCT00008073|Drug|octreotide acetate|
1727552|NCT00008086|Dietary Supplement|calcitriol|
1727553|NCT00008086|Drug|carboplatin|
1727554|NCT00008099|Biological|MUC1 antigen/SB AS-2|
1727555|NCT00008112|Drug|cisplatin|
1727556|NCT00008112|Procedure|hyperthermia treatment|
1727557|NCT00008112|Radiation|brachytherapy|
1727558|NCT00008112|Radiation|radiation therapy|
1727559|NCT00008125|Biological|filgrastim|
1727560|NCT00008125|Drug|carboplatin|
1727561|NCT00008125|Drug|docetaxel|
1727562|NCT00008125|Drug|gemcitabine hydrochloride|
1727563|NCT00008138|Drug|carboplatin|pre-surgery - target AUC=6, Day 1 IV, q 21 days X 3 cycles post-surgery - target AUC=5, Day 1 IP, q 28 days X 6 cycles
1727564|NCT00008138|Drug|paclitaxel|pre-surgery - 175 mg/m2 IV Day 1, q 21 days X 3 cycles post-surgery - 175 mg/m2 IV Day 1, q 28 days X 6 cycles AND 60 mg/m2 IP Day 8, q 28 days X 6 cycles
1727565|NCT00008138|Procedure|debulking surgery|exploratory laparotomy, interval cytoreduction (to < 1 cm residual)
1727566|NCT00008151|Drug|cyclosporine|
1727567|NCT00008151|Drug|fludarabine phosphate|
1727568|NCT00008151|Drug|gemtuzumab ozogamicin|
1727569|NCT00008151|Drug|methotrexate|
1727570|NCT00008151|Drug|mycophenolate mofetil|
1727571|NCT00008151|Procedure|allogeneic bone marrow transplantation|
1727572|NCT00008151|Procedure|peripheral blood stem cell transplantation|
1727573|NCT00008151|Radiation|radiation therapy|
1727574|NCT00008164|Procedure|umbilical cord blood transplantation|
1727575|NCT00008177|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
1727576|NCT00008177|Radiation|total-body irradiation|Undergo total-body irradiation
1727577|NCT00008177|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
1727578|NCT00008177|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
1727579|NCT00008177|Drug|fludarabine phosphate|Given IV
1727580|NCT00008177|Drug|cyclosporine|Given orally or IV
1727581|NCT00008177|Drug|mycophenolate mofetil|Given orally or IV
1727582|NCT00008177|Other|laboratory biomarker analysis|Correlative studies
1727583|NCT00008190|Biological|aldesleukin|
1727584|NCT00008190|Biological|filgrastim|
1727585|NCT00008190|Drug|busulfan|
1727586|NCT00008190|Drug|cyclophosphamide|
1727587|NCT00008190|Drug|etoposide|
1727588|NCT00008190|Drug|melphalan|
1727589|NCT00008190|Procedure|peripheral blood stem cell transplantation|
1727590|NCT00008203|Biological|aldesleukin|
1727591|NCT00008203|Biological|recombinant interferon gamma|
1727592|NCT00008203|Drug|carboplatin|
1727593|NCT00008203|Drug|cyclophosphamide|
1727594|NCT00008203|Drug|cyclosporine|
1727595|NCT00008203|Drug|thiotepa|
1727596|NCT00008203|Procedure|autologous bone marrow transplantation|
1727597|NCT00008203|Procedure|peripheral blood stem cell transplantation|
1727598|NCT00008216|Procedure|Peripheral Blood Stem Cell Transplantation|
1727599|NCT00008229|Biological|filgrastim|
1727600|NCT00008229|Drug|melphalan|
1727601|NCT00008229|Procedure|peripheral blood stem cell transplantation|
1727602|NCT00008229|Radiation|holmium Ho 166 DOTMP|
1727603|NCT00008242|Drug|dexamethasone|
1727604|NCT00008242|Drug|doxorubicin hydrochloride|
1727605|NCT00008242|Drug|thalidomide|
1727606|NCT00008255|Drug|INS316|
1727607|NCT00008255|Other|sputum cytology|
1727608|NCT00008268|Biological|filgrastim|
1727609|NCT00008268|Drug|melphalan|
1727610|NCT00008281|Drug|FOLFOX regimen|
1727611|NCT00008281|Drug|fluorouracil|
1727612|NCT00008281|Drug|leucovorin calcium|
1727613|NCT00008281|Drug|oxaliplatin|
1727614|NCT00008294|Drug|FOLFOX regimen|
1727615|NCT00008294|Drug|dexamethasone|
1727616|NCT00008294|Drug|floxuridine|
1727617|NCT00008294|Drug|fluorouracil|
1727618|NCT00008294|Drug|leucovorin calcium|
1727619|NCT00008294|Drug|oxaliplatin|
1727620|NCT00008307|Biological|anti-thymocyte globulin|
1727621|NCT00008307|Drug|cyclosporine|
1727622|NCT00008307|Drug|fludarabine phosphate|
1727623|NCT00008307|Drug|melphalan|
1727624|NCT00008307|Drug|methylprednisolone|
1727625|NCT00008307|Drug|mycophenolate mofetil|
1727626|NCT00008307|Procedure|allogeneic bone marrow transplantation|
1727627|NCT00008307|Procedure|peripheral blood stem cell transplantation|
1727628|NCT00008307|Procedure|syngeneic bone marrow transplantation|
1727629|NCT00008320|Drug|ceramide|
1727630|NCT00008333|Drug|vinorelbine tartrate|
1727631|NCT00008346|Diagnostic Test|Full Field Digital Mammography|Radiologic test to screen women for Breast cancer using digital detectors
1727632|NCT00008346|Diagnostic Test|Screen Film Mammography|Radiologic test to screen women for Breast cancer using plain film detectors a resolution screen
1727633|NCT00008359|Drug|caspofungin acetate|
1727634|NCT00008359|Drug|liposomal amphotericin B|
1727635|NCT00008372|Drug|chloroquinoxaline sulfonamide|
1727636|NCT00008385|Other|placebo|Given orally
1727637|NCT00008385|Drug|selenium|Given orally
1727638|NCT00008398|Biological|sargramostim|
1727639|NCT00008398|Procedure|quality-of-life assessment|
1727640|NCT00008398|Radiation|radiation therapy|
1727641|NCT00008411|Drug|Docetaxel|Every 3 weeks at a starting dose of 75 mg/m2 IV over 1 hour on day 1, repeated every 21 days.
1727642|NCT00008411|Drug|Docetaxel|35 mg/m2 IV over 30 minutes on days 1, 8, and 15, for 3 weeks followed by one week of rest repeated every 28 days.
1727643|NCT00008424|Drug|irinotecan hydrochloride|
1727644|NCT00008437|Device|high-intensity focused ultrasound ablation|
1727645|NCT00008450|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
1727646|NCT00008450|Drug|Cyclosporine|Given PO or IV
1727647|NCT00008450|Other|Laboratory Biomarker Analysis|Correlative studies
1727648|NCT00008450|Drug|Mycophenolate Mofetil|Given PO or IV
1727649|NCT00008450|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic hematopoietic stem cell transplant
1727650|NCT00008450|Radiation|Total-Body Irradiation|Undergo TBI
1727651|NCT00008463|Drug|Ribavirin|
1727652|NCT00008463|Drug|Interferon alfa-2a|
1727653|NCT00008463|Drug|Peginterferon alfa-2a|
1727654|NCT00008476|Drug|Capsaicin|
1727655|NCT00008489|Drug|Didanosine|
1727656|NCT00008515|Drug|Fluocinolone|
1727657|NCT00008528|Drug|Enfuvirtide|
1727658|NCT00008554|Drug|Abacavir sulfate|
1727659|NCT00008554|Drug|Nelfinavir mesylate|
1727660|NCT00008554|Drug|Lamivudine|
1727661|NCT00008554|Drug|GW433908|
1727662|NCT00008697|Drug|arsenic trioxide|
1727663|NCT00008736|Drug|metoclopramide|
1727664|NCT00008775|Device|Pressure support ventilation|
1727665|NCT00008801|Drug|hOKT3gamma1 (Ala-ala)|
1727666|NCT00008827|Behavioral|Behavioral weight loss|
1727667|NCT00008853|Biological|GBS III-TT-SSI|
1727668|NCT00008853|Biological|GBS III-TT-MPHL|
1727669|NCT00008866|Biological|Tetanus Toxoid Vaccine|
1727670|NCT00008866|Drug|Hydroxyurea|
1727671|NCT00008866|Drug|Didanosine|
1727672|NCT00009009|Drug|immunosuppressive regimen designed to complement HAART|
1727673|NCT00009048|Drug|EMD 128130|
1727674|NCT00009048|Drug|IV Levodopa|
1727675|NCT00009061|Drug|Ritonavir|
1727676|NCT00009061|Drug|Abacavir sulfate|
1727677|NCT00009061|Drug|Nelfinavir mesylate|
1727678|NCT00009061|Drug|Lamivudine|
1727679|NCT00009061|Drug|GW433908|
1727680|NCT00009178|Drug|Fluoxetine|
1727681|NCT00009178|Behavioral|Guided Self-Help|
1727682|NCT00009191|Drug|Sertraline [Zoloft]|
1727683|NCT00009204|Drug|Citalopram [Celexa]|
1727684|NCT00009204|Drug|Perphenazine [Trilafon]|
1727685|NCT00009217|Drug|Haloperidol-Haloperidol|Haloperidol open label flexible dose 1-5 mg daily for 20 weeks followed by haloperidol double-blind 1-5 mg for 24 weeks
1727686|NCT00009217|Drug|Haloperidol-Placebo|Haloperidol open-label flexible dose of 1-5 mg for 20 weeks followed by placebo double-blind for 24 weeks
1727687|NCT00009230|Drug|Celecoxib|
1727688|NCT00009542|Drug|kava (Piper methysticum)|
1727689|NCT00009555|Drug|Testosterone|
1727690|NCT00009581|Drug|L-NMMA|
1727691|NCT00009581|Drug|Acetylcholine|
1727692|NCT00009594|Procedure|Naturopathic Medicine|
1727693|NCT00009594|Procedure|Traditional Chinese Medicine|
1727694|NCT00009620|Drug|Phenobarbital|10 mg of phenobarbital per kilogram of body weight intravenously over a period of 20 to 40 minutes (maximal dose, 1000 mg)
1727695|NCT00009620|Drug|Saline|Infusion of normal sal
1727696|NCT00009646|Drug|indomethacin|Indocid P.D.A., Merck Frosst, Kirkland, Que., Canada, and Merck, West Point, Pa
1727697|NCT00009646|Drug|Indomethacin|0.1 mg per kilogram of body weight
1727698|NCT00009646|Drug|Placebo|0.1 mg per kilogram of body weight
1727699|NCT00009659|Drug|CDB 2914|
1727700|NCT00009672|Drug|Nortriptyline|
1727701|NCT00009672|Drug|Morphine|
1727702|NCT00009685|Drug|VRC4302|
1727703|NCT00009698|Biological|aldesleukin|Given SQ and IV
1727704|NCT00009711|Procedure|management of therapy complications|
1727705|NCT00009737|Drug|5-Fluorouracil|425mg/m2 iv daily from day 1 to day 5 every 28 days.
1727706|NCT00009737|Drug|Leucovorin|20mg/m2 iv daily from day 1 to day 5 every 28 days.
1727707|NCT00009737|Drug|Capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 every 21 days.
1727708|NCT00009750|Biological|filgrastim|
1727709|NCT00009750|Biological|monoclonal antibody m170|
1727710|NCT00009750|Drug|cyclosporine|
1727711|NCT00009750|Drug|paclitaxel|
1727712|NCT00009750|Procedure|peripheral blood stem cell transplantation|
1727713|NCT00009750|Radiation|indium In 111 monoclonal antibody m170|
1727714|NCT00009750|Radiation|yttrium Y 90 monoclonal antibody m170|
1727715|NCT00009763|Biological|filgrastim|
1727716|NCT00009763|Biological|monoclonal antibody m170|
1727717|NCT00009763|Drug|cyclosporine|
1727718|NCT00009763|Drug|paclitaxel|
1727719|NCT00009763|Procedure|peripheral blood stem cell transplantation|
1727720|NCT00009763|Radiation|yttrium Y 90 monoclonal antibody m170|
1727721|NCT00009776|Biological|monoclonal antibody Lym-1|
1727722|NCT00009776|Drug|cyclosporine|
1727723|NCT00009776|Drug|paclitaxel|
1727724|NCT00009776|Radiation|indium In 111 monoclonal antibody Lym-1|
1727725|NCT00009776|Radiation|yttrium Y 90 monoclonal antibody Lym-1|
1727726|NCT00009789|Radiation|accelerated conformational radiotherapy|
1727727|NCT00009802|Dietary Supplement|calcitriol|
1727728|NCT00009802|Drug|paclitaxel|
1727729|NCT00009815|Drug|etoposide|
1727730|NCT00009815|Drug|leucovorin calcium|
1727731|NCT00009815|Drug|tegafur-uracil|
1727732|NCT00009828|Drug|leucovorin calcium|
1727733|NCT00009828|Drug|paclitaxel|
1727734|NCT00009828|Drug|tegafur-uracil|
1727735|NCT00009841|Biological|EGFR antisense DNA|
1727736|NCT00009841|Biological|growth factor antagonist therapy|
1727737|NCT00009841|Drug|DC-cholesterol liposome|
1727738|NCT00009854|Drug|carmustine in ethanol|
1727739|NCT00009854|Procedure|conventional surgery|
1727740|NCT00009867|Drug|arsenic trioxide|Given IV
1727741|NCT00009880|Biological|filgrastim|
1727742|NCT00009880|Drug|cisplatin|
1727743|NCT00009880|Drug|fluorouracil|
1727744|NCT00009880|Drug|paclitaxel|
1727745|NCT00009880|Radiation|radiation therapy|
1727746|NCT00009893|Drug|fluorouracil|
1727747|NCT00009893|Drug|gemcitabine hydrochloride|
1727748|NCT00009893|Drug|leucovorin calcium|
1727749|NCT00009906|Drug|Imatinib Mesylate|Given orally
1727750|NCT00009919|Drug|semaxanib|Given IV
1727751|NCT00009932|Drug|cisplatin|
1727752|NCT00009932|Drug|fenretinide|
1727753|NCT00009932|Drug|paclitaxel|
1727756|NCT00009958|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given SC
1727757|NCT00009958|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
1727758|NCT00009958|Biological|sargramostim|Given SC
1727759|NCT00009958|Other|laboratory biomarker analysis|Correlative studies
1727760|NCT00009971|Drug|fenretinide|
1727761|NCT00009984|Drug|fludarabine phosphate|Given IV
1727762|NCT00009984|Drug|thalidomide|Given orally
1727763|NCT00009997|Biological|trastuzumab|
1727764|NCT00009997|Drug|cyclophosphamide|
1727765|NCT00009997|Drug|doxorubicin hydrochloride|
1727766|NCT00009997|Drug|paclitaxel|
1727767|NCT00009997|Drug|tamoxifen citrate|
1727768|NCT00009997|Procedure|conventional surgery|
1727769|NCT00010010|Drug|exemestane|
1727770|NCT00010010|Drug|goserelin acetate|
1727771|NCT00010023|Drug|capecitabine|
1727772|NCT00010023|Drug|cisplatin|
1727773|NCT00010036|Drug|carboplatin|
1727774|NCT00010036|Drug|irinotecan hydrochloride|
1727775|NCT00010036|Radiation|radiation therapy|
1727776|NCT00010049|Drug|imatinib mesylate|
1727777|NCT00010062|Drug|fluorouracil|
1727778|NCT00010062|Radiation|radiation therapy|
1727779|NCT00010075|Drug|fluorouracil|
1727780|NCT00010075|Drug|leucovorin calcium|
1727781|NCT00010075|Drug|mitoxantrone hydrochloride|
1727782|NCT00010088|Drug|fluorouracil|
1727783|NCT00010088|Drug|gemcitabine hydrochloride|
1727784|NCT00010088|Drug|leucovorin calcium|
1727785|NCT00010088|Procedure|conventional surgery|
1727786|NCT00010088|Radiation|radiation therapy|
1727787|NCT00010127|Biological|therapeutic autologous dendritic cells|
1727788|NCT00010140|Drug|docetaxel|
1727789|NCT00010140|Drug|epirubicin hydrochloride|
1727790|NCT00010140|Drug|tamoxifen citrate|
1727791|NCT00010140|Procedure|adjuvant therapy|
1727792|NCT00010153|Drug|fulvestrant|
1727793|NCT00010153|Procedure|conventional surgery|
1727794|NCT00010166|Drug|gemcitabine hydrochloride|
1727795|NCT00010166|Procedure|adjuvant therapy|
1727796|NCT00010166|Radiation|radiation therapy|
1727797|NCT00010179|Drug|lurtotecan liposome|
1727798|NCT00010192|Biological|rituximab|Given IV
1727799|NCT00010192|Biological|aldesleukin|Given SC
1727800|NCT00010192|Other|laboratory biomarker analysis|Correlative studies
1727801|NCT00010192|Other|pharmacological study|Correlative studies
1727802|NCT00010205|Drug|benzoylphenylurea|Given orally
1727803|NCT00010205|Other|pharmacological study|Correlative studies
1727804|NCT00010218|Drug|karenitecin|
1727805|NCT00010231|Dietary Supplement|calcitriol|
1727806|NCT00010231|Drug|dexamethasone|
1727807|NCT00010244|Radiation|radiation therapy|
1727808|NCT00010257|Drug|carboplatin|Dosed to AUC of 6.0, given IV over 30 minutes day 1 of a 21-day cycle, for up to 6 cycles
1727809|NCT00010257|Drug|paclitaxel|225 mg/m2 given by intravenous (IV) infusion over 3 hours on day 1 of a 21-day cycle, for up to 6 cycles
1727810|NCT00010270|Biological|LMB-9 immunotoxin|
1727811|NCT00010283|Drug|beclomethasone dipropionate|
1727812|NCT00010309|Biological|MART-1 antigen|
1727813|NCT00010309|Biological|gp100 antigen|
1727814|NCT00016653|Drug|Creatine Monohydrate|
1727815|NCT00016653|Drug|Glutamine|
1727816|NCT00016666|Drug|Propranolol|
1727817|NCT00016679|Drug|1-Octanol|
1727818|NCT00016692|Drug|Z-100|
1727822|NCT00016744|Drug|Sodium 4-Phenylbutyrate (4PBA)|The standard oral adult dose is 20g/day (tablets) for 4 days.
1727823|NCT00016744|Drug|Unconjugated Isoflavones 100 (PTI G-4660, 87% Genistein)|Every participant will be administered a perfusion of 50 MicroM of Genistein during the modified NPD procedure.
1727824|NCT00016744|Drug|Placebo|The placebo dose will match the oral tablets in arm 1, maintaining the study blind.
1727825|NCT00016835|Procedure|Supra-gingival scaling and placebo|Included in arm/group description.
1727826|NCT00016835|Procedure|Subgingival scaling and metronidazole|Included in arm/group description.
1727827|NCT00016835|Procedure|Subgingival scaling and doxycycline|Included in arm/group description.
1727828|NCT00016861|Drug|irinotecan hydrochloride|
1727829|NCT00016874|Drug|cisplatin|
1727830|NCT00016874|Drug|paclitaxel|
1727831|NCT00016874|Drug|triapine|
1727832|NCT00016887|Biological|filgrastim|
1727833|NCT00016887|Biological|recombinant interferon alfa|
1727834|NCT00016887|Drug|carmustine|
1727835|NCT00016887|Drug|cyclophosphamide|
1727836|NCT00016887|Drug|cytarabine|
1727837|NCT00016887|Drug|dexamethasone|
1727838|NCT00016887|Drug|etoposide|
1727839|NCT00016887|Drug|melphalan|
1727840|NCT00016887|Procedure|bone marrow ablation with stem cell support|
1727841|NCT00016887|Procedure|peripheral blood stem cell transplantation|
1727842|NCT00016887|Radiation|radiation therapy|
1727843|NCT00016900|Drug|liposomal paclitaxel|
1727844|NCT00016913|Drug|carboplatin|AUC=6 week one of each 4 week cycle
1727845|NCT00016913|Drug|estramustine|2 tablets tid PO 5 of 7 days per week each 4 week cycle
1727846|NCT00016913|Drug|paclitaxel|80 mg/sq m IV infusion over 1 hour weekly for ea 4 week cycle
1727847|NCT00016913|Radiation|radiation therapy|77.4 Gy in 1.8 Gy fractions
1727848|NCT00016913|Drug|leuprolide or goserelin acetate|7.5 mg IM injection once every 4 weeks for 6 months
1727849|NCT00016926|Drug|capecitabine|
1727850|NCT00016939|Drug|alvocidib|
1727851|NCT00016952|Drug|fluorouracil|
1727852|NCT00016952|Drug|irinotecan hydrochloride|
1727853|NCT00016952|Drug|leucovorin calcium|
1727854|NCT00016965|Drug|ixabepilone|
1727855|NCT00016978|Drug|FOLFOX regimen|
1727856|NCT00016978|Drug|fluorouracil|
1727857|NCT00016978|Drug|leucovorin calcium|
1727858|NCT00016978|Drug|oxaliplatin|
1727859|NCT00016991|Drug|gefitinib|
1727860|NCT00017004|Radiation|External Beam Radiation Therapy|Undergo radiation
1727861|NCT00017004|Drug|Cisplatin|Given IV
1727862|NCT00017004|Radiation|Internal Radiation Therapy|Undergo radiation
1727863|NCT00017004|Biological|Epoetin Alfa|Given SC
1727864|NCT00017017|Drug|paclitaxel poliglumex|
1727865|NCT00017030|Drug|trabectedin|
1727866|NCT00019097|Drug|autologous tumor cell vaccine|
1727867|NCT00019097|Drug|keyhole limpet hemocyanin|
1727868|NCT00019097|Drug|melphalan|
1727869|NCT00019097|Drug|sargramostim|
1727870|NCT00019110|Biological|human papillomavirus 16 E7 peptide|
1727871|NCT00019110|Biological|synthetic human papillomavirus 16 E6 peptide|
1727872|NCT00019123|Drug|thalidomide|
1727873|NCT00019136|Biological|MOv-gamma chimeric receptor gene|
1727874|NCT00019136|Biological|aldesleukin|
1727875|NCT00019136|Biological|therapeutic allogeneic lymphocytes|
1727876|NCT00019175|Biological|aldesleukin|
1727877|NCT00019175|Biological|fowlpox virus vaccine vector|
1727878|NCT00019175|Biological|gp100 antigen|
1727879|NCT00019188|Drug|interleukin-12|
1727880|NCT00019201|Other|cytology specimen collection procedure|
1727881|NCT00019201|Other|immunohistochemistry staining method|
1727882|NCT00019201|Other|sputum cytology|
1727883|NCT00019201|Procedure|bronchoscopic and lung imaging studies|
1727884|NCT00019201|Procedure|bronchoscopy|
1727885|NCT00019201|Procedure|comparison of screening methods|
1727886|NCT00019201|Procedure|endoscopic biopsy|
1727887|NCT00019214|Biological|MART-1 antigen|
1727888|NCT00019214|Biological|aldesleukin|
1727889|NCT00019214|Biological|gp100 antigen|
1727890|NCT00019227|Drug|pentetic acid calcium|
1727891|NCT00019227|Radiation|yttrium Y 90 daclizumab|
1727892|NCT00019240|Drug|cidofovir|
1727893|NCT00019318|Drug|romidepsin|
1727894|NCT00019331|Biological|aldesleukin|
1727895|NCT00019331|Biological|ras peptide cancer vaccine|
1727896|NCT00019331|Biological|sargramostim|
1727897|NCT00019331|Drug|DetoxPC|
1727898|NCT00019344|Drug|alvocidib|
1727899|NCT00019357|Biological|aldesleukin|
1727900|NCT00019357|Biological|therapeutic autologous lymphocytes|
1727901|NCT00019357|Biological|therapeutic tumor infiltrating lymphocytes|
1727902|NCT00019383|Biological|aldesleukin|
1727903|NCT00019383|Biological|incomplete Freund's adjuvant|
1727904|NCT00019383|Biological|sargramostim|
1727905|NCT00019383|Biological|tyrosinase peptide|
1727906|NCT00019383|Biological|tyrosinase-related protein-1|
1727907|NCT00019396|Drug|flt3 ligand|
1727908|NCT00019396|Drug|gp100 antigen|
1727909|NCT00019396|Drug|MART-1 antigen|
1727910|NCT00019396|Drug|Montanide ISA-51|
1727911|NCT00019396|Drug|tyrosinase peptide|
1727912|NCT00019409|Drug|asparaginase|
1727913|NCT00019409|Drug|cyclophosphamide|
1727914|NCT00019409|Drug|cytarabine|
1727915|NCT00019409|Drug|daunorubicin hydrochloride|
1727916|NCT00019409|Drug|mercaptopurine|
1727917|NCT00019409|Drug|methotrexate|
1727918|NCT00019409|Drug|prednisone|
1727919|NCT00019409|Drug|therapeutic hydrocortisone|
1727920|NCT00019409|Drug|vincristine sulfate|
1727921|NCT00019409|Radiation|radiation therapy|
1727922|NCT00019422|Drug|carboplatin|
1727923|NCT00019422|Drug|lobradimil|
1727924|NCT00019435|Biological|LMB-9 immunotoxin|
1727925|NCT00019448|Drug|gp100 antigen|
1727926|NCT00019448|Drug|interleukin-2|
1727927|NCT00019461|Drug|carboxyamidotriazole|
1727928|NCT00019461|Drug|chemotherapy|
1727929|NCT00019474|Biological|filgrastim|
1727930|NCT00019474|Biological|recombinant interferon alfa|
1727931|NCT00019474|Drug|fluorouracil|
1727932|NCT00019474|Drug|hydroxyurea|
1727933|NCT00019487|Biological|aldesleukin|
1727934|NCT00019487|Biological|gp209-2M antigen|
1727935|NCT00019487|Biological|incomplete Freund's adjuvant|
1727936|NCT00019500|Drug|raloxifene|
1727937|NCT00019500|Procedure|evaluation of cancer risk factors|
1727938|NCT00019513|Drug|fluorouracil|
1727939|NCT00019513|Drug|gemcitabine hydrochloride|
1727940|NCT00019513|Drug|leucovorin calcium|
1727941|NCT00019539|Drug|bevacizumab|
1727942|NCT00019539|Drug|thalidomide|
1727943|NCT00019552|Drug|irofulven|
1727944|NCT00019565|Procedure|magnetic resonance imaging|
1727945|NCT00019565|Procedure|positron emission tomography|
1727946|NCT00019565|Radiation|fludeoxyglucose F 18|
1727947|NCT00019578|Procedure|Sterotactic radiosurgery|
1727948|NCT00019591|Biological|aldesleukin|
1727949|NCT00019591|Biological|ras peptide cancer vaccine|
1727950|NCT00019591|Procedure|adjuvant therapy|
1727951|NCT00019604|Procedure|computed tomography|Scan to assess the effects of ablation.
1727952|NCT00019604|Procedure|magnetic resonance imaging|Imaging used to assess the effects of this ablative therapy on tumor vascular density.
1727953|NCT00019604|Procedure|positron emission tomography|Physiology based method of imaging disease based on uptake and metabolism of radiopharmaceutical by the tissues.
1727954|NCT00019604|Procedure|radiofrequency ablation|Radiofrequency ablation uses saline infusion into and out of needle/electrode through a closed system. More energy may be deposited without tissue-charring or gas vaporization.
1727955|NCT00019604|Procedure|radionuclide imaging|Imaging following injection of a radioactive material.
1727956|NCT00019604|Procedure|ultrasound imaging|An ultrasound (e.g. sound waves) is used to identify the lesion and needle placement.
1727957|NCT00019604|Radiation|fludeoxyglucose F 18 (FDG-PET)|FDG PET scans rely on metabolic changes to evaluate response to therapy.
1727958|NCT00019604|Radiation|gadopentetate dimeglumine|Food and Drug Administration approved contrast agent.
1727959|NCT00019630|Drug|doxorubicin HCl liposome|
1727960|NCT00019656|Drug|perifosine|
1727961|NCT00019669|Biological|aldesleukin|
1727962|NCT00019669|Biological|fowlpox virus vaccine vector|
1727963|NCT00019669|Biological|gp100 antigen|
1727970|NCT00019695|Drug|alendronate sodium|
1727971|NCT00019695|Drug|ketoconazole|
1727972|NCT00019708|Drug|tanespimycin|Given IV
1727973|NCT00019721|Biological|MART-1 antigen|
1727974|NCT00019721|Biological|aldesleukin|
1727975|NCT00019721|Biological|gp100 antigen|
1727976|NCT00019721|Biological|incomplete Freund's adjuvant|
1727977|NCT00019734|Biological|aldesleukin|
1727978|NCT00019734|Biological|fowlpox virus vaccine vector|
1727979|NCT00019734|Biological|vaccinia-tyrosinase vaccine|
1727980|NCT00019747|Drug|thalidomide|oral thalidomide 100 mg at bedtime once daily for 4 weeks, then progresses to 200 mg at bedtime for 4 weeks, then progresses to 300 mg at bedtime (maintenance dose).
1727981|NCT00019747|Procedure|adjuvant therapy|Initial dose: 100 mg by mouth (po) every bedtime ( Q hs) for four weeks, then progress to 200 mg po Q hs for four weeks, then progress to maintenance dose: 300 mg po Q hs.
1727982|NCT00019747|Other|Placebo|oral placebo once daily
1727983|NCT00019760|Drug|floxuridine|
1727984|NCT00019760|Drug|leucovorin calcium|
1727985|NCT00019760|Drug|melphalan|
1727986|NCT00019773|Drug|capecitabine|
1727987|NCT00019773|Drug|oxaliplatin|
1727988|NCT00019786|Drug|isolated perfusion|
1727989|NCT00019786|Drug|melphalan|
1727990|NCT00019786|Procedure|conventional surgery|
1727991|NCT00019812|Biological|trastuzumab|
1727992|NCT00019812|Drug|paclitaxel|
1727993|NCT00019825|Drug|decitabine|
1727994|NCT00019838|Drug|7-hydroxystaurosporine|
1727995|NCT00019838|Drug|fludarabine phosphate|
1727996|NCT00019864|Biological|filgrastim|
1727997|NCT00019864|Drug|cisplatin|
1727998|NCT00019864|Drug|dexrazoxane hydrochloride|
1727999|NCT00019864|Drug|doxorubicin hydrochloride|
1728000|NCT00019864|Drug|leucovorin calcium|
1728001|NCT00019864|Drug|methotrexate|
1728002|NCT00019864|Procedure|adjuvant therapy|
1728003|NCT00019864|Procedure|conventional surgery|
1728004|NCT00019864|Procedure|neoadjuvant therapy|
1728005|NCT00019890|Drug|dendritic cell-gp100-MART-1 antigen vaccine|
1728006|NCT00019890|Drug|sargramostim|
1728007|NCT00019916|Biological|aldesleukin|
1728008|NCT00019916|Biological|p53 peptide vaccine|
1728009|NCT00019916|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1728010|NCT00019929|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
1728011|NCT00019929|Procedure|adjuvant therapy|
1728012|NCT00019955|Procedure|laparoscopic surgery|
1728013|NCT00019955|Procedure|radiofrequency ablation|
1728014|NCT00019955|Procedure|thermal ablation therapy|
1728015|NCT00019968|Drug|melphalan|
1728016|NCT00019968|Drug|tumor necrosis factor|
1728017|NCT00019994|Biological|MART-1 antigen|
1728018|NCT00019994|Biological|aldesleukin|
1728019|NCT00019994|Biological|gp100 antigen|
1728020|NCT00019994|Biological|incomplete Freund's adjuvant|
1728021|NCT00020007|Drug|isolated perfusion|
1728022|NCT00020007|Drug|paclitaxel|
1728023|NCT00020007|Procedure|hyperthermia treatment|
1728024|NCT00020046|Drug|docetaxel|
1728025|NCT00020046|Drug|thalidomide|
1728026|NCT00020072|Other|laboratory biomarker analysis|
1728027|NCT00020098|Procedure|evaluation of cancer risk factors|
1728028|NCT00020111|Drug|arsenic trioxide|
1728029|NCT00020124|Drug|doxorubicin hydrochloride|
1728030|NCT00020150|Drug|O6-benzylguanine|
1728031|NCT00020150|Drug|temozolomide|
1728032|NCT00020176|Biological|filgrastim|
1728033|NCT00020176|Biological|therapeutic allogeneic lymphocytes|
1728034|NCT00020176|Drug|cyclophosphamide|
1728035|NCT00020176|Drug|cyclosporine|
1728036|NCT00020176|Drug|fludarabine phosphate|
1728037|NCT00020176|Procedure|peripheral blood stem cell transplantation|
1728038|NCT00020189|Drug|acetylsalicylic acid|
1728039|NCT00020189|Drug|alvocidib|
1728040|NCT00020189|Drug|clopidogrel bisulfate|
1728041|NCT00020202|Drug|FR901228|
1728042|NCT00020254|Biological|aldesleukin|
1728043|NCT00020254|Biological|recombinant fowlpox-prostate specific antigen vaccine|
1728044|NCT00020254|Biological|recombinant vaccinia prostate-specific antigen vaccine|
1728045|NCT00020254|Biological|recombinant vaccinia-B7.1 vaccine|
1728046|NCT00020254|Biological|sargramostim|
1728047|NCT00020254|Drug|nilutamide|
1728048|NCT00020267|Drug|interleukin-2|
1728049|NCT00020267|Drug|MAGE-12 peptide vaccine|
1728050|NCT00020267|Drug|Montanide ISA-51|
1728051|NCT00020332|Drug|alvocidib|
1728052|NCT00020332|Drug|docetaxel|
1728053|NCT00020345|Drug|fluorouracil|
1728054|NCT00020345|Drug|gemcitabine|
1728055|NCT00020358|Biological|aldesleukin|
1728056|NCT00020358|Biological|gp100 antigen|
1728057|NCT00020358|Biological|incomplete Freund's adjuvant|
1728058|NCT00020358|Biological|tyrosinase peptide|
1728059|NCT00020371|Drug|BMS-247550|
1728060|NCT00020371|Drug|filgrastim|
1728061|NCT00020397|Biological|NY-ESO-1 peptide vaccine|
1728062|NCT00020397|Biological|aldesleukin|
1728063|NCT00020410|Biological|filgrastim|
1728064|NCT00020410|Procedure|peripheral blood stem cell transplantation|
1728065|NCT00020410|Radiation|yttrium Y 90 monoclonal antibody B3|
1728066|NCT00020449|Biological|recombinant interleukin-12|
1728067|NCT00020449|Drug|paclitaxel|
1728068|NCT00020449|Drug|pegylated liposomal doxorubicin hydrochloride|
1728070|NCT00020462|Biological|autologous tumor cell vaccine|
1728071|NCT00020475|Drug|gp100 antigen|
1728072|NCT00020475|Drug|interleukin-2|
1728073|NCT00020475|Drug|MART-1 antigen|
1728074|NCT00020475|Drug|Montanide ISA-51|
1728075|NCT00020488|Drug|FOLFIRI regimen|
1728076|NCT00020488|Drug|fluorouracil|
1728077|NCT00020488|Drug|irinotecan hydrochloride|
1728078|NCT00020488|Drug|leucovorin calcium|
1728079|NCT00020501|Drug|FOLFIRI regimen|
1728080|NCT00020501|Drug|floxuridine|
1728081|NCT00020501|Drug|fluorouracil|
1728082|NCT00020501|Drug|irinotecan hydrochloride|
1728083|NCT00020501|Drug|leucovorin calcium|
1728084|NCT00020501|Drug|melphalan|
1728085|NCT00020501|Procedure|hyperthermia treatment|
1728086|NCT00020527|Drug|caspofungin acetate|
1728087|NCT00020540|Biological|recombinant CD40-ligand|
1728088|NCT00020540|Biological|recombinant flt3 ligand|
1728089|NCT00020553|Procedure|psychosocial assessment and care|
1728090|NCT00020566|Biological|dactinomycin|Given IV
1728091|NCT00020566|Drug|busulfan|Given orally and IV
1728092|NCT00020566|Drug|doxorubicin hydrochloride|Given IV
1728093|NCT00020566|Drug|etoposide|Given IV
1728094|NCT00020566|Drug|ifosfamide|Given IV
1728095|NCT00020566|Drug|melphalan|Given orally and IV
1728096|NCT00020566|Drug|vincristine sulfate|Given IV
1728097|NCT00020566|Procedure|autologous hematopoietic stem cell transplantation|Given IV
1728098|NCT00020566|Procedure|conventional surgery|Given to patients deemed to require it
1728099|NCT00020566|Radiation|radiation therapy|Given to patients deemed to require it
1728100|NCT00020579|Drug|entinostat|
1728101|NCT00020605|Drug|naloxone hydrochloride|
1728102|NCT00020618|Drug|morphine sulfate|
1728103|NCT00020618|Procedure|quality-of-life assessment|
1728104|NCT00020631|Drug|pirfenidone|
1728105|NCT00020644|Drug|gemcitabine hydrochloride|
1728106|NCT00020657|Drug|dolasetron mesylate|
1728107|NCT00020657|Drug|granisetron hydrochloride|
1728108|NCT00020657|Drug|ondansetron|
1728109|NCT00020657|Drug|prochlorperazine|
1728110|NCT00020657|Procedure|quality-of-life assessment|
1728111|NCT00020670|Biological|CD 40|
1728112|NCT00020683|Drug|incyclinide|High dose given orally
1728113|NCT00020683|Drug|incyclinide|Low dose given orally
1728114|NCT00020683|Other|laboratory biomarker analysis|Correlative studies
1728115|NCT00020696|Drug|cisplatin|
1728116|NCT00020696|Drug|tirapazamine|
1728117|NCT00020709|Drug|cisplatin|Given IV
1728118|NCT00020709|Drug|docetaxel|Given IV
1728119|NCT00020709|Drug|etoposide|Given IV
1728120|NCT00020709|Drug|gefitinib|Given orally
1728121|NCT00020709|Radiation|radiation therapy|Undergo radiation therapy
1728122|NCT00020709|Other|placebo|Given orally
1728123|NCT00020722|Biological|therapeutic autologous lymphocytes|"Immediately after pheresis, the lymphocytes will be activated with soluble monoclonal anti-CD3 antibody (OKT3) which cross-links the CD3 receptors on T cells and activates T cells.
The time for ATC infusions will vary from patient to patient, but the infusion rate will be based on the rate calculated from the endotoxin level in the cell product. All patients will be observed for at least 1 hr after an infusion."
1728124|NCT00020722|Drug|Ifosfamide, carboplatin, and etoposide (ICE) regimen|"Ifosfamide 2,500 mg/m2 given IV daily on day -8, -7, -6, -5, -4, and -3 prior to PBSCT. Ifosfamide 2,500 mg/m2 infused IV over 1 hour (hour 0-1) on days -8 to -3 for a total dose of 15,000 mg/m2.
Mesna will be administered per BMT Standard of Care Guideline at a dose of 25% of the total Ifosfamide dose 30 minutes prior to and then 3, 6, and 9 hours after ifosfamide daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 2500 mg/m2.
Carboplatin at a dose of 250 mg/m2 will be given daily on days -8, -7, -6, -5, -4, and -3 prior to PBSCT for a total dose of 1500 mg/m2.
VP-16 (etoposide) at a dose of 200 mg/m2 will be given IV on days -8, -7, -6, -5, -4 and -3. The total dose of VP-16 given prior to PBSCT will be 2,400 mg/m2. VP-16 will be given 200 mg/m2"
1728125|NCT00020722|Drug|Cyclophosphamide, Thiotepa, Carboplatin (CTC) or STAMP V (CTC)|"Cyclophosphamide will be given at a dose of 2000 mg/m2 in NS IV over one hour daily on days -4, -3, and -2 (total = 6000 mg/m2).
Thiotepa will be given at a dose of 167 mg/m2 in NS IV over one hour daily on days -4, -3, -2 (total = 500 mg/m2) as the preparative regimen followed by PBSCT on day 0.
Carboplatin will be given at a dose of 267 mg/m2 in D5W IV over one hour daily on days -4, -3, and -2.
Mesna will be administered per BMT Standard of Care Guidelines at a dose of 25% of the total cyclophosphamide dose 30 minutes prior to and then 3, 6, and 9 hours after cyclophosphamide daily on days -4, -3, and -2 prior to PBSCT for a total of 2000mg/m2."
1728126|NCT00020722|Procedure|Leukapheresis|Peripheral blood mononuclear cells (PBMC) will be collected by leukapheresis (for generation of ATC) prior to or post G-CSF (16 ug/kg/day) priming for collecting stem cells.
1728127|NCT00020722|Procedure|peripheral blood stem cell transplantation (PBSCT)|Will be collected either before or after peripheral blood stem cell collection for stem cell transplant.
1728128|NCT00020735|Drug|toremifene|
1728129|NCT00020735|Procedure|conventional surgery|
1728130|NCT00020735|Procedure|neoadjuvant therapy|
1728131|NCT00020748|Drug|epirubicin hydrochloride|
1728132|NCT00020748|Drug|irinotecan hydrochloride|
1728133|NCT00020761|Drug|irinotecan hydrochloride|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.
Irinotecan 225 mg/m2 will be infused over 90 minutes every three weeks."
1728134|NCT00020761|Drug|paclitaxel|"The course length is 3 weeks. Treatment will continue until one or more of criteria listed in the protocol are met.
Paclitaxel 100 mg/m2 will be infused over three hours following irinotecan infusion every three weeks."
1728135|NCT00020774|Drug|gemcitabine hydrochloride|
1728136|NCT00020774|Drug|lonafarnib|
1728137|NCT00020774|Procedure|conventional surgery|
1728138|NCT00020787|Biological|G17DT Immunogen|Dose: 500 micrograms in 0.2mL Route: Deep intramuscular Schedule: Days 8, 36, and 64; an additional dose at week 2, cycle 7 will be administered
1728139|NCT00020787|Drug|cisplatin|dose: 100 mg/m2 Route: i.v. infusion in 500 mL in 0.9% NaCl administered up to 3 hours Schedule: day 1, and then every 4 weeks.
1728140|NCT00020787|Drug|fluorouracil|Dose: 1000mg/m2/day Route: 24-hour continuous infusion in 0.9% NaCl over 5 days Schedule: Day 1 to Day 5 (5-day infusion) and then every 4 weeks
1728141|NCT00020800|Biological|rituximab|
1728142|NCT00020800|Drug|fludarabine phosphate|
1728143|NCT00020826|Other|quality-of-life assessment|QLQ-C30 questionnaire administered. STO22 questionnaire administered.
1728144|NCT00020839|Drug|temozolomide|
1728145|NCT00020839|Radiation|radiation therapy|
1728146|NCT00020852|Procedure|conventional surgery|
1728147|NCT00020852|Procedure|cryosurgery|
1728148|NCT00020865|Drug|cefepime hydrochloride|
1728149|NCT00020865|Drug|levofloxacin|
1728150|NCT00020878|Drug|celecoxib|Dosing will occur for a total of 6 months. 400 mg by mouth twice daily.
1728151|NCT00020891|Procedure|computed tomography|
1728152|NCT00020891|Radiation|radiation therapy|
1728153|NCT00020904|Drug|ixabepilone|
1728154|NCT00020917|Biological|cetuximab|
1728155|NCT00020917|Drug|fluorouracil|
1728156|NCT00020917|Drug|irinotecan hydrochloride|
1728157|NCT00020917|Drug|leucovorin calcium|
1728158|NCT00020930|Biological|cetuximab|
1728159|NCT00020943|Biological|filgrastim|5 ug/kg subQ daily day 4 until ANC >10,000 (or ANC> 5000 2X)Tx 1, 2, 4 10 ug/kg subQ daily day 14 until completion of PBSC collection Tx 3
1728160|NCT00020943|Biological|rituximab|375 mg/sq m IV infusion at , or = 400 mg/hr day 1 Tx 1, 2, days 5 & 12 Tx 3, and weekly for 2 doses Tx 5
1728161|NCT00020943|Drug|carmustine|15 mg/kg IV infusion over 2 hours Day 6, Tx 4
1728162|NCT00020943|Drug|cyclophosphamide|2000 mg/sq m IV infusion over 2 hours Day 3, Tx 1 & 2 100 mg/kg IV infusion over 2 hours Day 2, Tx 4
1728163|NCT00020943|Drug|cytarabine|2000 mg/sq m IV infusion BID over 2 hours x 8 doses Days 1-4, Tx 3
1728164|NCT00020943|Drug|doxorubicin hydrochloride|50 mg/sq m IVP Day 3, Tx 1& 2
1728165|NCT00020943|Drug|etoposide|40 mg/kg total dose continuous IV infusion over 96 hours Days 1-4, Tx 3
1728166|NCT00020943|Drug|leucovorin calcium|50 mg/sq m IV infusion q 6 hours x 3 doses after MTX, then 10 mg/sq m IV/PO q 6 hrs until MTX levels <0.05 uM, Tx 1 & 2
1728167|NCT00020943|Drug|methotrexate|300 mg/sq m IV infusion over 4 hrs Day 2 Tx 1 & 2
1728168|NCT00020943|Drug|prednisone|100 mg/sq m PO Days 3-7, Tx 1 & 2
1728169|NCT00020943|Drug|vincristine sulfate|1.4 mg/sq m IVP Day 3, Tx 1 & 2
1728170|NCT00020943|Procedure|peripheral blood stem cell transplantation|Stem cells collected during Tx 3 will be transfused follwing chemotx in Tx 4
1728171|NCT00020969|Drug|arsenic trioxide|
1728172|NCT00020995|Procedure|therapeutic dietary intervention|
1728173|NCT00021008|Drug|picoplatin|
1728174|NCT00021021|Biological|anti-FLT-1 ribozyme|
1728175|NCT00021034|Drug|chemotherapy|
1728176|NCT00021034|Drug|taurolidine|
1728177|NCT00021047|Drug|capecitabine|
1728178|NCT00021047|Drug|carboplatin|
1728179|NCT00021047|Drug|epirubicin hydrochloride|
1728180|NCT00021060|Drug|paclitaxel|Given IV
1728181|NCT00021060|Drug|carboplatin|Given IV
1728182|NCT00021060|Biological|bevacizumab|Given IV
1728183|NCT00021060|Other|laboratory biomarker analysis|Correlative studies
1728184|NCT00021073|Drug|alvocidib|Given IV
1728185|NCT00021073|Drug|leucovorin calcium|Given IV
1728186|NCT00021073|Drug|fluorouracil|Given IV
1728187|NCT00021073|Drug|irinotecan hydrochloride|Given IV
1728188|NCT00021099|Drug|ixabepilone|Given IV
1728189|NCT00021112|Drug|cisplatin|
1728190|NCT00021112|Drug|etoposide|
1728191|NCT00021112|Procedure|conventional surgery|
1728192|NCT00021112|Radiation|radiation therapy|
1728193|NCT00021125|Procedure|adjuvant therapy|
1728194|NCT00021125|Radiation|radiation therapy|
1728195|NCT00021138|Behavioral|smoking cessation intervention|
1728196|NCT00021138|Drug|nicotine|
1728197|NCT00021151|Biological|alemtuzumab|
1728198|NCT00021164|Biological|aldesleukin|
1728199|NCT00021164|Biological|incomplete Freund's adjuvant|
1728200|NCT00021164|Biological|telomerase: 540-548 peptide vaccine|
1728201|NCT00021216|Drug|bortezomib|Given IV
1728202|NCT00021216|Other|laboratory biomarker analysis|Correlative studies
1728203|NCT00021216|Other|pharmacological study|Correlative studies
1728204|NCT00021229|Drug|imatinib mesylate|"Phase 1 Stratum I: Starting dose level of 350 mg/m2/day every 28 days X 13 courses (dose escalation)
Phase I Stratum IIA: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)
Phase I Stratum IIB: Starting dose level of 465 mg/m2/day every 28 days X 13 courses (dose escalation)
Phase II: Phase I Stratum I determined dose (Maximum tolerated dose) every 28 days X 13 courses."
1728205|NCT00021229|Radiation|local irradiation therapy|"Phase I Stratum I: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib.
Phase II: Total dose of 5580 cGy using conventional or conformal volume-based delivery techniques once daily, 5 days/week for six weeks prior to receiving imatinib."
1728206|NCT00021242|Drug|docetaxel|Continuous IV infusion
1728207|NCT00021255|Drug|Doxorubicin|
1728208|NCT00021255|Drug|Cyclophosphamide|
1728209|NCT00021255|Drug|Docetaxel|
1728210|NCT00021255|Drug|Herceptin|
1728211|NCT00021255|Drug|Carboplatin|
1728212|NCT00021268|Drug|tocladesine|
1728213|NCT00021281|Drug|FOLFIRI regimen|
1728214|NCT00021281|Drug|fluorouracil|
1728215|NCT00021281|Drug|irinotecan hydrochloride|
1728216|NCT00021281|Drug|leucovorin calcium|
1728217|NCT00021281|Drug|semaxanib|
1728218|NCT00021294|Drug|eflornithine|
1728219|NCT00021294|Drug|triamcinolone|
1728220|NCT00021307|Drug|carboplatin|
1728221|NCT00021307|Drug|temozolomide|
1728222|NCT00021320|Drug|cisplatin|
1728225|NCT00021320|Procedure|conventional surgery|
1728226|NCT00021320|Procedure|neoadjuvant therapy|
1728227|NCT00021320|Radiation|radiation therapy|
1728228|NCT00021333|Biological|filgrastim|
1728229|NCT00021333|Drug|cisplatin|
1728230|NCT00021333|Drug|paclitaxel|
1728231|NCT00021333|Radiation|radiation therapy|
1728232|NCT00021346|Drug|carboplatin|
1728233|NCT00021346|Drug|gemcitabine hydrochloride|
1728234|NCT00021359|Drug|dexamethasone|
1728235|NCT00021359|Drug|isotretinoin|
1728236|NCT00021372|Drug|estramustine phosphate sodium|
1728237|NCT00021372|Drug|paclitaxel|
1728238|NCT00021385|Drug|carboplatin|
1728239|NCT00021385|Drug|squalamine lactate|
1728240|NCT00021398|Drug|fluorouracil|
1728241|NCT00021398|Drug|leucovorin calcium|
1728242|NCT00021398|Procedure|conventional surgery|
1728243|NCT00021398|Radiation|radiation therapy|
1728244|NCT00021424|Biological|recombinant fowlpox-TRICOM vaccine|
1728245|NCT00021450|Drug|bicalutamide|
1728246|NCT00021450|Drug|goserelin acetate|
1728247|NCT00021450|Procedure|adjuvant therapy|
1728248|NCT00021450|Radiation|radiation therapy|
1728249|NCT00021463|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
1728250|NCT00021463|Drug|Abacavir sulfate|
1728251|NCT00021463|Drug|Efavirenz|
1728252|NCT00021463|Drug|Nevirapine|
1728253|NCT00021476|Behavioral|Behavioral treatments|
1728254|NCT00021476|Behavioral|Physical therapy|
1728255|NCT00021489|Drug|Abacavir sulfate|
1728256|NCT00021489|Drug|Mycophenolate mofetil|
1728257|NCT00021502|Drug|pyridoxalated hemoglobin polyoxyethylene conjugate (PHP)|
1728258|NCT00021528|Drug|citalopram|
1728259|NCT00021528|Drug|BuproprionSR|
1728260|NCT00021528|Drug|buspirone|
1728261|NCT00021528|Drug|Lithium|
1728262|NCT00021528|Drug|mirtazapine|
1728263|NCT00021528|Drug|nortriptyline|
1728264|NCT00021528|Drug|sertraline|
1728265|NCT00021528|Drug|tranylcypromine|
1728266|NCT00021528|Drug|VenlafaxineXR|
1728267|NCT00021528|Behavioral|Cognitive Therapy|
1728268|NCT00021528|Drug|T3 (Triiodothyronine)|
1728269|NCT00021541|Drug|tipifarnib|Given orally, 200 mg/m^2/dose BSA every 12 hours by mouth (po) daily x 21 days, Course is every 28 days
1728270|NCT00021541|Other|placebo|Patients receive oral placebo every 12 hours on days 1-21. Courses repeat as in arm I.
1728271|NCT00021554|Drug|Enfuvirtide|
1728272|NCT00021567|Drug|Interferon Gamma for Aerosol|
1728273|NCT00021580|Procedure|human cadaveric islet cell transplantation|
1728274|NCT00021645|Drug|Vitamin E|
1728275|NCT00021658|Procedure|Pesticide application procedures|
1728276|NCT00021671|Drug|Erythromycin|
1728277|NCT00021671|Drug|Nevirapine|
1728278|NCT00021671|Drug|Ampicillin sodium|
1728279|NCT00021671|Drug|Metronidazole|
1728280|NCT00021697|Drug|AVP-923|
1728281|NCT00021723|Biological|AN-1792 also known as AIP-001|
1728282|NCT00021736|Drug|EYE001 anti-VEGF aptamer|
1728283|NCT00021749|Drug|Oblimerson sodium, G3139|
1728284|NCT00021762|Biological|HIV-1 Immunogen|
1728285|NCT00021762|Procedure|Structured Treatment Interruption|
1728286|NCT00021788|Procedure|islet cell transplantation|
1728287|NCT00021801|Procedure|Islet Cell Transplantation|
1728288|NCT00021814|Drug|Doxazosin|
1728289|NCT00021814|Drug|Finasteride|
1728290|NCT00021827|Drug|Parathyroid hormone-related protein or ''PTHrP''|
1728291|NCT00021853|Behavioral|constraint-induced movement therapy|
1728292|NCT00021866|Behavioral|Differential Abilities Scale|IQ measurement at 3, 4.5 and 6 years of age
1728293|NCT00021866|Behavioral|Neuropsychological Testing|Tests of memory, attention, and behavior administered at 2,3, 4.5 and 6 Years of age
1728294|NCT00021983|Biological|BL22 immunotoxin|
1728295|NCT00021996|Drug|valdecoxib|
1728296|NCT00022009|Drug|gemcitabine hydrochloride|
1728297|NCT00022022|Drug|docetaxel|
1728298|NCT00022022|Procedure|quality-of-life assessment|
1728299|NCT00022035|Biological|trivalent influenza vaccine|
1728300|NCT00022048|Biological|bevacizumab|
1728301|NCT00022074|Drug|gabapentin|
1728302|NCT00022074|Procedure|quality-of-life assessment|
1728303|NCT00022087|Dietary Supplement|calcium salts|1000 mg PO per day
1728304|NCT00022087|Dietary Supplement|cholecalciferol|400 IU PO per day
1728305|NCT00022087|Drug|zoledronic acid|4 mg IV infusion q 3 months, months 1-24 in Zoledronic acid initial tx arm and months 13-36 in calcium + vit D initial tx arm
1728306|NCT00022113|Drug|cilengitide|Given IV
1728307|NCT00022113|Other|pharmacological study|Correlative studies
1728308|NCT00022113|Other|laboratory biomarker analysis|Correlative studies
1728309|NCT00022126|Drug|asparaginase|
1728310|NCT00022126|Drug|cyclophosphamide|
1728311|NCT00022126|Drug|cyclosporine|
1728312|NCT00022126|Drug|cytarabine|
1728313|NCT00022126|Drug|daunorubicin hydrochloride|
1728314|NCT00022126|Drug|dexamethasone|
1728315|NCT00022126|Drug|doxorubicin hydrochloride|
1728316|NCT00022126|Drug|mercaptopurine|
1728317|NCT00022126|Drug|methotrexate|
1728318|NCT00022126|Drug|methylprednisolone|
1728319|NCT00022126|Drug|pegaspargase|
1728320|NCT00022126|Drug|thioguanine|
1728321|NCT00022126|Drug|vincristine sulfate|
1728322|NCT00022126|Procedure|allogeneic bone marrow transplantation|
1728323|NCT00022126|Radiation|radiation therapy|
1728324|NCT00022139|Drug|carboplatin|
1728325|NCT00022139|Drug|fluorouracil|
1728326|NCT00022139|Drug|paclitaxel|
1728327|NCT00022139|Procedure|conventional surgery|
1728328|NCT00022139|Radiation|radiation therapy|
1728329|NCT00022152|Drug|vinorelbine tartrate|
1728330|NCT00022165|Dietary Supplement|selenium|
1728331|NCT00022178|Drug|cisplatin|
1728332|NCT00022178|Drug|cyclophosphamide|
1728333|NCT00022178|Drug|doxorubicin hydrochloride|
1728334|NCT00022178|Drug|epirubicin hydrochloride|
1728335|NCT00022178|Drug|fluorouracil|
1728336|NCT00022178|Drug|vincristine sulfate|
1728337|NCT00022191|Drug|cisplatin|
1728338|NCT00022191|Drug|gemcitabine hydrochloride|
1728339|NCT00022191|Drug|paclitaxel|
1728340|NCT00013468|Procedure|Tinnitus|
1728341|NCT00013481|Procedure|Stroke Rehabilitation|
1728342|NCT00013494|Procedure|Stroke Rehabilitation|
1728343|NCT00013507|Procedure|Falls|
1728344|NCT00013520|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
1728345|NCT00013520|Drug|Atazanavir|
1728346|NCT00013520|Drug|Lamivudine/Zidovudine|
1728347|NCT00013520|Drug|Abacavir sulfate|
1728348|NCT00013520|Drug|Efavirenz|
1728349|NCT00013520|Drug|Nevirapine|
1728350|NCT00013520|Drug|Lamivudine|
1728351|NCT00013520|Drug|Stavudine|
1728352|NCT00013520|Drug|Zidovudine|
1728353|NCT00013520|Drug|Didanosine|
1728354|NCT00013533|Procedure|Stem cell transplantation|>3 x 106/kg CD34+ stem cells by IV infusion
1728355|NCT00013546|Drug|TMTDS|
1728356|NCT00013572|Biological|ALVAC-HIV MN120TMG (vCP205)|
1728357|NCT00013585|Drug|Selegiline hydrochloride|
1728358|NCT00013598|Drug|Pioglitazone|
1728359|NCT00013611|Drug|Proleukin|Recombinant IL-2 was given at a dose of 4.5 MIU twice daily subcutaneously for 5 consecutive days every 8 weeks, in addition to antiretroviral therapy, for 6 cycles. After the first 6 cycles, additional cycles were given to either achieve or maintain the patient's CD4+ cell count goal.
1728360|NCT00013624|Drug|IV Levodopa|
1728361|NCT00013650|Drug|Cyclophosphamate|
1728362|NCT00013663|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1728363|NCT00013663|Drug|Aldesleukin|
1728364|NCT00013689|Drug|Fansidar (pyrimethamine and sulfadoxine)|
1728365|NCT00013702|Drug|Adefovir|
1728366|NCT00022204|Dietary Supplement|vitamin E|
1728367|NCT00022204|Drug|pentoxifylline|
1728368|NCT00022204|Procedure|quality-of-life assessment|
1728369|NCT00022217|Drug|carboplatin|
1728370|NCT00022217|Drug|cisplatin-e therapeutic implant|
1728371|NCT00022217|Drug|paclitaxel|
1728372|NCT00022230|Biological|aldesleukin|
1728373|NCT00022230|Biological|filgrastim|
1728374|NCT00022230|Biological|sargramostim|
1728375|NCT00022230|Biological|therapeutic autologous lymphocytes|
1728376|NCT00022230|Drug|cyclophosphamide|
1728377|NCT00022230|Drug|doxorubicin hydrochloride|
1728378|NCT00022230|Drug|paclitaxel|
1728379|NCT00022243|Drug|batabulin sodium|
1728380|NCT00022256|Drug|motexafin gadolinium|
1728381|NCT00022256|Radiation|radiation therapy|
1728382|NCT00022282|Drug|shark cartilage extract AE-941|
1728383|NCT00022295|Drug|idronoxil|
1728384|NCT00022308|Drug|cisplatin|
1728385|NCT00022308|Drug|irinotecan hydrochloride|
1728386|NCT00022308|Radiation|radiation therapy|
1728387|NCT00022321|Drug|gemtuzumab ozogamicin|
1728388|NCT00022334|Biological|AFP|Increasing doses of AFP will be given to groups of 3 intradermally. Subjects will receive 3 biweekly vaccinations. At least 2 patients at a given dose must have received their complete 3 vaccination schedule with a 30 day observation period after the last vaccination before a higher dose is initiated.
1728389|NCT00022347|Drug|canfosfamide hydrochloride|
1728390|NCT00022360|Drug|taurolidine|
1728391|NCT00022373|Drug|iseganan HCl oral solution|
1728392|NCT00022373|Procedure|management of therapy complications|
1728393|NCT00022386|Biological|epoetin alfa|
1728394|NCT00022386|Procedure|quality-of-life assessment|
1728395|NCT00022399|Drug|celecoxib|
1728396|NCT00022399|Procedure|conventional surgery|
1728397|NCT00022399|Procedure|neoadjuvant therapy|
1728398|NCT00022412|Dietary Supplement|doxercalciferol|Arm 1: Patients receive doxercalciferol once daily for 28 days. Patients then undergo prostatectomy.
1728399|NCT00022412|Procedure|conventional surgery|Procedure: Prostatectomy for prostate cancer
1728400|NCT00022425|Drug|perillyl alcohol|
1728401|NCT00022438|Biological|aldesleukin|
1728402|NCT00022438|Biological|incomplete Freund's adjuvant|
1728403|NCT00022438|Biological|recombinant tyrosinase-related protein-2|
1728404|NCT00022451|Drug|tipifarnib|
1728405|NCT00022464|Drug|temsirolimus|
1728406|NCT00022477|Drug|BMS-247550|
1728407|NCT00022490|Drug|cytarabine|Once daily subcutaneous injection of Ara-C (Cytarabine) at a dose of 20 mg (10 mg or 5 mg if they have been dose reduced) per square meter of calculated body surface area, on days 15-28 of each sequential 28 day cycle
1728408|NCT00022490|Drug|imatinib mesylate|Once daily oral administration of STI571 (Imatinib Mesylate) at a dose of 400 mg for 12 months.
1728409|NCT00022516|Drug|Cyclophosphamide|50 mg/day orally continuously for 1 year
1728410|NCT00022516|Drug|Methotrexate|2.5 mg twice/day orally days 1 and 2 of every week for 1 year
1728411|NCT00022529|Drug|BMS-214662|Given IV
1728412|NCT00022529|Biological|trastuzumab|Given IV
1728413|NCT00022529|Other|pharmacological study|Correlative studies
1728414|NCT00022542|Drug|ixabepilone|Given IV
1728415|NCT00022555|Drug|bryostatin 1|Given IV
1728416|NCT00022555|Drug|vincristine sulfate|Given IV
1728417|NCT00022646|Drug|gemcitabine hydrochloride|
1728418|NCT00022646|Drug|pemetrexed disodium|
1728419|NCT00022659|Biological|bevacizumab|Given IV
1728420|NCT00022659|Other|laboratory biomarker analysis|Correlative studies
1728421|NCT00022672|Drug|trastuzumab (Herceptin®)|4mg/kg iv loading dose, followed by 2mg/kg iv weekly
1728422|NCT00022672|Drug|anastrazole (Arimidex®)|1 mg tablet taken orally daily
1728426|NCT00022711|Drug|temozolomide|150 mg/m2/day Repeat cycles every 28 days following first daily dose of each cycle until toxicity or disease progression for a maximum of six months
1728427|NCT00022724|Drug|temsirolimus|
1728428|NCT00022737|Biological|filgrastim|Given SC
1728429|NCT00022737|Drug|asparaginase|Given IM
1728430|NCT00022737|Drug|cyclophosphamide|Given IV
1728431|NCT00022737|Drug|cyclosporine|Given IV
1728432|NCT00022737|Drug|cytarabine|Given IT and IV
1728433|NCT00022737|Drug|daunorubicin hydrochloride|Given IV
1728434|NCT00022737|Drug|dexamethasone|Given orally
1728435|NCT00022737|Drug|etoposide|Given IV
1728436|NCT00022737|Drug|ifosfamide|Given IV
1728437|NCT00022737|Drug|imatinib mesylate|Given orally
1728438|NCT00022737|Drug|leucovorin calcium|Given IV or orally
1728439|NCT00022737|Drug|mercaptopurine tablet|Given orally
1728440|NCT00022737|Drug|methotrexate|Given IT, IV, and orally
1728441|NCT00022737|Drug|pegaspargase|Given IM
1728442|NCT00022737|Drug|vincristine sulfate|Given IV
1728443|NCT00022737|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
1728444|NCT00022737|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
1728445|NCT00022737|Procedure|umbilical cord blood transplantation|Undergo allogeneic bone marrow, peripheral blood stem cell, or umbilical cord blood transplantation
1728446|NCT00022737|Radiation|radiation therapy|Undergo radiation therapy
1728447|NCT00022750|Behavioral|Nurse Case Manager and Community Health Worker Team|
1728448|NCT00022763|Drug|Enfuvirtide|
1728449|NCT00022776|Procedure|Surgical decompression|Simple decompression not requiring fusion.
1728450|NCT00022776|Procedure|Physical therapy|2 physical therapy sessions per week for 6 weeks Followed by home program.
1728451|NCT00022802|Device|Image-guided surgical system|
1728452|NCT00022815|Device|Tissue ultrafiltration|
1728453|NCT00022828|Device|3-D Laser Imaging Device|
1728454|NCT00022841|Drug|Pamidronate|
1728455|NCT00022854|Procedure|Single-injection femoral nerve block|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous saline infusion
1728456|NCT00022854|Procedure|Femoral nerve block 60-hour continuous injection|Nerve block bolus with 30 mL levobupivacaine 0.25%, followed by continuous infusion (5 mL/hr for 50 hours) of 0.25% levobupivacaine
1728457|NCT00022854|Procedure|Saline (control) injection into femoral nerve envelope|Nerve block bolus with 30 mL saline, followed by continuous saline infusion
1728458|NCT00022867|Drug|Nondigestible oligosaccharide (NDO)|
1728459|NCT00022880|Drug|Iodine-131 Anti-B1 Antibody|
1728460|NCT00022893|Drug|Iodine-131 Anti-B1 Antibody|
1728461|NCT00022906|Drug|Iodine-131 Anti-B1 Antibody|
1728462|NCT00022932|Drug|Iodine-131 Anti-B1 Antibody|
1728463|NCT00022945|Drug|Iodine-131 Anti-B1 Antibody|
1728464|NCT00022945|Drug|Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP)|
1728465|NCT00022958|Drug|Iodine-131 Anti-B1 Antibody|
1728466|NCT00022971|Biological|Apolizumab|Apolizumab IV on Day 1. Administer weekly for 4 weeks
1728467|NCT00022971|Biological|Rituximab|Rituximab IV 24-36 hours after Apolizumab ends. Administer weekly for 4 weeks
1728468|NCT00023127|Procedure|Integrated Pest Management|
1728469|NCT00023153|Drug|Adefovir Dipivoxil|
1728470|NCT00023166|Drug|PEG-paclitaxel|
1728471|NCT00023192|Drug|T-Cell Depleted & CD34+Select/w/StemCell Enriched Product|
1728472|NCT00023205|Behavioral|11th grade reading level arthritis materials|
1728473|NCT00023205|Behavioral|Interactive in-person arthritis education|
1728474|NCT00023218|Drug|Lopinavir/Ritonavir|
1728475|NCT00023218|Drug|Efavirenz|
1728476|NCT00023231|Drug|Daclizumab|1 mg/kg/dose at study entry and Weeks 2, 4, 6, and 8
1728477|NCT00023231|Drug|Methylprednisolone/prednisone|Dosage is dependent on weight and varies throughout study. Refer to protocol for more information.
1728478|NCT00023231|Drug|Mycophenolate mofetil|Solution or oral tablet taken daily. Dosage depends on body surface area.
1728479|NCT00023231|Drug|Sirolimus|Oral tablet taken once prior to transplant. Dosage dependent on body surface area.
1728480|NCT00023231|Drug|Bactrim|Oral tablet taken three times per week. Dosage is dependent on weight.
1728481|NCT00023231|Drug|Ganciclovir|Oral tablet taken daily. Dosage is dependent on weight.
1728482|NCT00023231|Drug|Lipitor|Oral tablet taken daily
1728483|NCT00023244|Drug|Basiliximab|Administered as a bolus intravenous injection. The first dose is given pre-operatively, the second dose is given on post-transplant day four. Dosage is determined by individual weight.
1728484|NCT00023244|Drug|Cyclosporine|Participants receiving cyclosporine microemulsion formula (in lieu of tacrolimus) will have the dose adjusted to maintain a whole blood trough Abbott TDx assay monoclonal level of 175-400 ng/mL (or an equivalent high pressure liquid chromatography (HPLC) level) for the first 2 weeks after transplant. The dose will subsequently be tapered to maintain a trough level of 175-300 ng/mL from week 3 to month 3, and 50-250 ng/mL from month 3 through the end of the study at month 36 (year 3).
1728485|NCT00023244|Drug|Tacrolimus|Participants receiving tacrolimus (in lieu of Cyclosporine) will have the dose adjusted to maintain a whole blood trough level between 10 and 15 ng/mL for the first 4weeks after transplant. Trough levels will be maintained between 5 and 10 ng/mL thereafter throughout the duration of the study.
1728486|NCT00023244|Drug|Sirolimus|Participants take daily (orally, either as tablets or as liquid) starting on postoperative day 1 at a dose of 6 mg/m2 and will be adjusted to maintain a trough level of 10-20 ng/mL throughout the study.
1728487|NCT00023244|Drug|Methylprednisolone|Administered at 10 mg/kg intravenously perioperatively and on postoperative day 1.
1728488|NCT00023244|Drug|Prednisone|Administered orally beginning on Post-Op Day 2 and maintained for all participants until day 180. Randomization will determine whether patients will maintain this treatment following day 180.
1728662|NCT00024193|Drug|doxorubicin hydrochloride|
1728663|NCT00024193|Drug|etoposide|
1728489|NCT00023244|Drug|Bactrim|All subjects will receive TMP SMX (Bactrim), pneumocystis jiroveci (carinii) prophylaxis, beginning on postoperative day 1 and continuing for 6 months following transplant. Dosage: 10 mg/kg taken orally three times weekly (maximum dose 160 mg).
1728490|NCT00023283|Drug|Buprenorphine|"Experimental Standard Medical Management with once-weekly medication dispensing
Experimental Standard Medical Management with thrice-weekly medication dispensing
Experimental Enhanced Medical Management with thrice-weekly medication dispensing"
1728491|NCT00023296|Drug|Nitric Oxide|
1728492|NCT00023296|Device|INO Pulse - NO Delivery System|
1728493|NCT00023309|Drug|Lamivudine and adefovir|Lamivudine (100 mg/day) and adefovir (10 mg/day)
1728494|NCT00023309|Drug|Adefovir alone|Adefovir (10 mg/day)
1728495|NCT00023322|Drug|Peginterferon Alpha-2a|Treatment
1728496|NCT00023335|Drug|Rifapentine|
1728497|NCT00023335|Drug|Isoniazid|
1728498|NCT00023348|Drug|Isoniazid|
1728499|NCT00023348|Drug|Rifabutin|
1728500|NCT00023361|Drug|Rifabutin|
1728501|NCT00023374|Drug|Rifampin|6mos REZ intermittent
1728502|NCT00023374|Drug|Pyrazinamide|6mos REZ intermittent
1728503|NCT00023374|Drug|Ethambutol|6mos REZ intermittent
1728504|NCT00023374|Drug|REZ|Rif+PZA+EMB given 2 or 3 times weekly for 6 months
1728505|NCT00023387|Drug|Rifapentine|
1728506|NCT00023387|Drug|25-desacetyl Rifapentine|
1728507|NCT00023387|Drug|Isoniazid|
1728508|NCT00023400|Drug|Nelfinavir|
1728509|NCT00023400|Drug|Rifabutin|
1728510|NCT00023413|Drug|Rifabutin|
1728511|NCT00023413|Drug|Efavirenz|
1728512|NCT00023426|Drug|rifapentine|
1728513|NCT00023439|Other|Nucleic Acid Amplification Methods for diagnosis|no intervention
1728514|NCT00023452|Drug|RPT + INH once weekly for 3 months given by DOT|"Rifapentine (RPT) 900 mg once-weekly x 12 doses (3 months) for persons > 50.0 kg. For persons < 50.0 kg, the following doses will be given (Weight/Dose): 10.0-14.0 kg / 300 mg; 14.1-25.0 kg / 450 mg; 25.1-32.0 kg / 600 mg; 32.1-50.0 kg / 750 mg.
PLUS
Isoniazid (INH) 15 mg/kg (rounded up to nearest 50 or 100 mg; 900 mg max) once weekly x 12 doses if > 12 years old. INH 25 mg/kg (round up to nearest 50 or 100 mg; 900 mg max) if 2—11 years old.
Therapy will be given by Directly Observed Therapy (DOT)."
1728515|NCT00023452|Drug|Isoniazid (INH) daily for 9 months|Isoniazid (INH) 5 mg/kg (rounded up to nearest 50 or 100 mg; 300 mg max) daily x 270 doses (9 months) For children age 2 - 11, INH 10-15 mg/kg (round up to nearest 50 or 100 mg; 300 mg max) will be given.
1728516|NCT00023465|Procedure|FDG-PET|
1728517|NCT00023465|Procedure|spirometry|
1728518|NCT00023465|Procedure|bronchoscopy with BAL|
1728519|NCT00023530|Drug|fluconazole|
1728520|NCT00023530|Drug|voriconazole|
1728521|NCT00023530|Procedure|bone marrow transplant|
1728522|NCT00023530|Drug|thalidomide|
1728523|NCT00023530|Drug|dexamethasone|
1728524|NCT00023543|Behavioral|Diet, fat-restricted|Reduction in total, saturated, trans fat, cholesterol, calories. Increase in fiber. Promotion of nutrient-dense, high-volume, low calorie foods.
1728525|NCT00023543|Behavioral|Exercise|Rigorous, stepped care approach to reach 150 min/week of physical activity.
1728526|NCT00023595|Procedure|CABG surgery plus MED|CABG plus standard medication management for Coronary Artery Disease
1728527|NCT00023595|Drug|Active Medication Alone|Standard medication for coronary artery disease and heart failure management.
1728528|NCT00023595|Procedure|CABG plus MED and SVR|H02: the experimental arm receives active medical therapy and CABG and surgical ventricular restoration whereas the control group receives active medical therapy and CABG; for H01: the experimental arm receives active medical therapy and CABG whereas the control group receives active medical therapy alone
1728529|NCT00023621|Drug|celecoxib|
1728530|NCT00023634|Biological|KLH|100 mcg w/EGFRvIII
1728531|NCT00023634|Biological|GMCSF|arm 1: 100 mcg w/EGFRvIII
1728532|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
1728533|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
1728534|NCT00023647|Biological|Synchrotope TA2M|Cancer Vaccine, Immunotherapy
1728535|NCT00023660|Drug|celecoxib|
1728536|NCT00023660|Drug|cisplatin|
1728537|NCT00023660|Drug|fluorouracil|
1728538|NCT00023660|Radiation|brachytherapy|
1728539|NCT00023660|Radiation|radiation therapy|
1728540|NCT00023673|Drug|carboplatin|
1728541|NCT00023673|Drug|paclitaxel|
1728542|NCT00023673|Radiation|three-dimensional conformal radiation therapy|
1728543|NCT00023686|Procedure|surgery|
1728544|NCT00023686|Radiation|radiation|
1728545|NCT00023699|Drug|gefitinib|
1728546|NCT00023712|Drug|bortezomib|Given IV
1728547|NCT00023712|Other|laboratory biomarker analysis|Correlative studies
1728548|NCT00023712|Other|pharmacological study|Correlative studies
1728549|NCT00023725|Drug|semaxanib|
1728550|NCT00023725|Procedure|conventional surgery|
1728551|NCT00023725|Radiation|radiation therapy|
1728552|NCT00023738|Biological|filgrastim|
1728553|NCT00023738|Drug|dacarbazine|
1728554|NCT00023738|Drug|doxorubicin hydrochloride|
1728555|NCT00023738|Drug|ifosfamide|
1728556|NCT00023738|Drug|semaxanib|
1728557|NCT00023738|Procedure|conventional surgery|
1728558|NCT00023738|Radiation|radiation therapy|
1728559|NCT00023751|Drug|fluorouracil|
1728560|NCT00023751|Drug|leucovorin calcium|
1728561|NCT00023751|Procedure|conventional surgery|
1728562|NCT00023751|Radiation|radiation therapy|
1728563|NCT00023764|Drug|bortezomib|Given IV
1728564|NCT00023777|Biological|filgrastim|induction: 5 mcg/kg/d IV or SC starting apx day 15
1728565|NCT00023777|Biological|sargramostim|induction: 250 mcg/m2/d IV or SC starting apx day 1
1728566|NCT00023777|Drug|cytarabine|ind: 200 mg/m2/d continuous IV days 1-7 consol: 200 mg/m2/d continuous IV days 1-5
1728567|NCT00023777|Drug|daunorubicin hydrochloride|ind and consol: 45 mg/m2/d continuous IV days 1-3
1728664|NCT00024193|Drug|melphalan|
1728568|NCT00023790|Drug|silicon phthalocyanine 4|Patients receive silicon phthalocyanine 4 (Pc 4) IV over 2 hours on day 1 followed by light therapy over 30-60 minutes on day 2. Treatment repeats in 6 weeks for a total of 2 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of Pc 4.
1728569|NCT00023816|Drug|carbendazim|
1728570|NCT00023829|Drug|bicalutamide|
1728571|NCT00023829|Drug|flutamide|
1728572|NCT00023829|Drug|releasing hormone agonist therapy|
1728573|NCT00023829|Procedure|adjuvant therapy|
1728574|NCT00023829|Radiation|radiation therapy|
1728575|NCT00023842|Biological|BCG vaccine|
1728576|NCT00023842|Drug|mitomycin C|
1728577|NCT00023842|Procedure|adjuvant therapy|
1728578|NCT00023842|Procedure|conventional surgery|
1728579|NCT00023855|Drug|bortezomib|
1728580|NCT00023855|Drug|doxorubicin hydrochloride|
1728581|NCT00023868|Drug|FOLFIRI regimen|
1728582|NCT00023868|Drug|cisplatin|
1728583|NCT00023868|Drug|doxorubicin hydrochloride|
1728584|NCT00023868|Drug|fluorouracil|
1728585|NCT00023868|Drug|irinotecan hydrochloride|
1728586|NCT00023868|Drug|leucovorin calcium|
1728587|NCT00023868|Drug|mitomycin C|
1728588|NCT00023881|Drug|bortezomib|
1728589|NCT00023894|Drug|alvocidib|
1728590|NCT00023907|Drug|paclitaxel|
1728591|NCT00023920|Biological|bevacizumab|Given IV
1728592|NCT00023920|Drug|idarubicin|Given IV
1728593|NCT00023920|Drug|cytarabine|Given SC
1728594|NCT00023933|Drug|iodine I 131 monoclonal antibody CC49-deltaCH2|Given IV
1728595|NCT00023946|Drug|ixabepilone|Given IV
1728596|NCT00023946|Other|laboratory biomarker analysis|Correlative studies
1728597|NCT00023959|Drug|hydroxyurea|Given orally
1728598|NCT00023959|Drug|fluorouracil|Given IV
1728599|NCT00023959|Biological|bevacizumab|Given IV
1728600|NCT00023959|Radiation|radiation therapy|Undergo radiotherapy
1728601|NCT00023959|Biological|filgrastim|Given subcutaneously
1728602|NCT00023959|Other|laboratory biomarker analysis|Correlative studies
1728603|NCT00023972|Drug|exatecan mesylate|
1728604|NCT00023972|Drug|gemcitabine hydrochloride|
1728605|NCT00023985|Biological|autologous tumor cell vaccine|
1728606|NCT00023985|Biological|therapeutic autologous dendritic cells|
1728607|NCT00023985|Procedure|conventional surgery|
1728608|NCT00023998|Drug|doxorubicin hydrochloride|Given IV
1728609|NCT00023998|Drug|cisplatin|Given IV
1728610|NCT00023998|Drug|methotrexate|Given IV
1728611|NCT00023998|Drug|leucovorin calcium|Given IV or orally
1728612|NCT00023998|Biological|filgrastim|Given IV
1728613|NCT00023998|Procedure|therapeutic conventional surgery|Undergo resection
1728614|NCT00023998|Radiation|radiation therapy|Undergo radiotherapy
1728615|NCT00023998|Drug|etoposide|Given IV
1728616|NCT00023998|Drug|ifosfamide|Given IV
1728617|NCT00023998|Biological|trastuzumab|Given IV
1728618|NCT00023998|Other|laboratory biomarker analysis|Correlative studies
1728619|NCT00024011|Drug|bortezomib|Given IV
1728620|NCT00024011|Other|laboratory biomarker analysis|Correlative studies
1728621|NCT00024024|Drug|rebimastat|
1728622|NCT00024037|Procedure|management of therapy complications|
1728623|NCT00024050|Drug|busulfan|
1728624|NCT00024050|Drug|cyclophosphamide|
1728625|NCT00024050|Drug|cyclosporine|
1728626|NCT00024050|Drug|methotrexate|
1728627|NCT00024050|Procedure|allogeneic bone marrow transplantation|
1728628|NCT00024050|Procedure|peripheral blood stem cell transplantation|
1728629|NCT00024063|Drug|orantinib|
1728630|NCT00024076|Procedure|radiofrequency ablation|
1728631|NCT00024089|Drug|gefitinib|
1728632|NCT00024102|Drug|Standard Treatment|Cyclophosphamide 100 mg/sq m PO d 1-14 + MTX 40 mg/sq m IV push d 1 & 8 and 5-FU 600 mg/sq m IV push d 1 & 8 q 28 days for 6 cycles OR doxorubicin 60 mg/sq m IV d 1 + cyclophosphamide 600 mg/sq m IV d 1 q 21 d for 4 cycles
1728633|NCT00024102|Drug|capecitabine|2000 mg/sq m PO d 1-14, 7 day rest then repeat for a total of 6 cycles
1728634|NCT00024115|Drug|BL22 immunotoxin|
1728635|NCT00024115|Procedure|antibody therapy|
1728636|NCT00024115|Procedure|biological response modifier therapy|
1728637|NCT00024115|Procedure|immunotoxin therapy|
1728638|NCT00024128|Biological|anti-thymocyte globulin|
1728639|NCT00024128|Biological|therapeutic allogeneic lymphocytes|
1728640|NCT00024128|Drug|cyclophosphamide|
1728641|NCT00024128|Drug|cyclosporine|
1728642|NCT00024128|Procedure|peripheral blood stem cell transplantation|
1728643|NCT00024128|Radiation|radiation therapy|
1728644|NCT00024141|Drug|fluorouracil|
1728645|NCT00024141|Drug|irinotecan hydrochloride|
1728646|NCT00024154|Biological|trastuzumab|Given IV
1728647|NCT00024154|Drug|gefitinib|Given orally
1728648|NCT00024154|Other|laboratory biomarker analysis|Correlative studies
1728649|NCT00024167|Drug|Docetaxel|75 mg/m2 intravenous piggyback (IVPB) over 1 hour, Day 1, every 3 weeks.
1728650|NCT00024167|Drug|Doxorubicin hydrochloride|20 mg/m2 IV, day 1 on Weeks 1, 3, 5
1728651|NCT00024167|Drug|Estramustine phosphate sodium|140 mg orally 3 x day, Days 1 through 7 on Weeks 2, 4, 6
1728652|NCT00024167|Drug|Ketoconazole|400 mg orally (po) 3 x day, Days 1 through 7
1728653|NCT00024167|Drug|Prednisone|5 mg orally 2 x daily, weeks 1-14
1728654|NCT00024167|Drug|Vinblastine|4 mg/m2 IVPB, Day 1 on Weeks 2, 4, 6
1728655|NCT00024167|Radiation|Strontium chloride Sr 89|One dose (4 mCi total dose) IV
1728656|NCT00024167|Drug|Dexamethasone|4 mg is given orally at 12 and 1 hours before and 12 hours after docetaxel.
1728657|NCT00024180|Drug|romidepsin|
1728658|NCT00024193|Biological|filgrastim|
1728659|NCT00024193|Drug|busulfan|
1728660|NCT00024193|Drug|cisplatin|
1728665|NCT00024193|Drug|vincristine sulfate|
1728666|NCT00024193|Procedure|conventional surgery|
1728667|NCT00024193|Procedure|peripheral blood stem cell transplantation|
1728668|NCT00024206|Drug|orantinib|Given orally
1728669|NCT00024206|Other|laboratory biomarker analysis|Correlative studies
1728670|NCT00024206|Other|pharmacological study|Correlative studies
1728671|NCT00024232|Biological|monoclonal antibody huJ591|
1728672|NCT00024245|Drug|pralatrexate|
1728673|NCT00024245|Drug|probenecid|
1728674|NCT00024258|Drug|arsenic trioxide|
1728675|NCT00024271|Biological|recombinant interferon gamma|
1728676|NCT00024271|Drug|cisplatin|
1728677|NCT00024271|Drug|doxorubicin hydrochloride|
1728678|NCT00024271|Drug|gemcitabine hydrochloride|
1728679|NCT00024271|Drug|mitomycin C|
1728680|NCT00024271|Procedure|conventional surgery|
1728681|NCT00024271|Procedure|hyperthermia treatment|
1728682|NCT00024271|Radiation|radiation therapy|
1728683|NCT00024284|Drug|carboplatin|
1728684|NCT00024284|Drug|irinotecan hydrochloride|
1728685|NCT00024297|Drug|warfarin|
1728686|NCT00024310|Dietary Supplement|folic acid|
1728687|NCT00024310|Drug|lometrexol|
1728688|NCT00024310|Drug|paclitaxel|
1728689|NCT00024323|Drug|cisplatin|
1728690|NCT00024323|Drug|triapine|
1728691|NCT00024336|Drug|tamoxifen citrate|
1728692|NCT00024336|Radiation|radiation therapy|
1728693|NCT00024349|Drug|fluorouracil|
1728694|NCT00024349|Drug|mitomycin C|
1728695|NCT00024349|Radiation|radiation therapy|
1728696|NCT00024362|Drug|BBR 3464|
1728697|NCT00024375|Drug|DHA-paclitaxel|
1728698|NCT00024388|Drug|DHA-paclitaxel|
1728699|NCT00024401|Drug|DHA-paclitaxel|
1728700|NCT00024414|Drug|DHA-paclitaxel|
1728701|NCT00024427|Drug|fluorouracil|High dose 5-FU
1728702|NCT00024427|Drug|gemcitabine hydrochloride|Normal dose to treat pancreatic cancer
1728703|NCT00024427|Drug|triacetyluridine|6 grams (12 tablets)
1728704|NCT00024440|Biological|filgrastim|
1728705|NCT00024440|Biological|oblimersen sodium|
1728706|NCT00024440|Drug|cyclophosphamide|
1728707|NCT00024440|Drug|fludarabine phosphate|
1728708|NCT00024453|Biological|teicoplanin|
1728709|NCT00024466|Biological|autologous tumor cell vaccine|
1728710|NCT00024466|Drug|chemotherapy|
1728711|NCT00024466|Procedure|autologous hematopoietic stem cell transplantation|
1728712|NCT00024466|Procedure|peripheral blood stem cell transplantation|
1728713|NCT00024492|Drug|Liposome Encapsulated Mitoxantrone (LEM)|
1728714|NCT00024518|Drug|30,000 units hrINF-alpha|
1728715|NCT00024518|Drug|5,000 hrINF-alpha|
1728716|NCT00024518|Other|Placebo|placebo was prepared as saline alone with 6mg human serum albumin (HSA).
1728717|NCT00024531|Drug|Atorvastatin calcium|
1728718|NCT00024544|Drug|anti-IL-4 monoclonal antibody (pascolizumab)|
1728719|NCT00024557|Drug|IL13-PE38QQR|
1728720|NCT00024557|Procedure|targeted fusion protein therapy|
1728721|NCT00024557|Procedure|surgery|
1728722|NCT00024570|Drug|IL13-PE38QQR|
1728723|NCT00024570|Procedure|targeted fusion protein therapy|
1728724|NCT00024570|Procedure|surgery|
1728725|NCT00024648|Drug|LErafAON|
1728726|NCT00024661|Drug|LErafAON|
1728727|NCT00024674|Drug|SS1(dsFv)-PE38|
1728728|NCT00024687|Drug|SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin|
1728729|NCT00024934|Drug|B-Lymphocyte Stimulator (BLyS)|
1728730|NCT00024986|Drug|Tenofovir DF|
1728731|NCT00025012|Drug|isotretinoin|
1728732|NCT00025025|Other|sample testing|
1728733|NCT00025038|Drug|tipifarnib|Given orally
1728734|NCT00025038|Drug|isotretinoin|Given orally
1728735|NCT00025038|Drug|fludarabine phosphate|Given IV
1728736|NCT00025038|Drug|cytarabine|Given IV
1728737|NCT00025038|Radiation|radiation therapy|Undergo total body irradiation
1728738|NCT00025038|Drug|cyclophosphamide|Given IV
1728739|NCT00025038|Biological|anti-thymocyte globulin|Given IV
1728740|NCT00025038|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplant
1728741|NCT00025038|Procedure|double-unit umbilical cord blood transplantation|
1728742|NCT00025038|Procedure|umbilical cord blood transplantation|Undergo allogeneic cord blood transplant
1728743|NCT00025038|Other|laboratory biomarker analysis|Correlative studies
1728744|NCT00025051|Drug|celecoxib|
1728745|NCT00025051|Procedure|anti-cytokine therapy|
1728746|NCT00025051|Procedure|antiangiogenesis therapy|
1728747|NCT00025051|Procedure|biological therapy|
1728748|NCT00025051|Procedure|cancer prevention intervention|
1728749|NCT00025051|Procedure|chemoprevention of cancer|
1728750|NCT00025051|Procedure|growth factor antagonist therapy|
1728751|NCT00025064|Biological|bleomycin sulfate|
1728752|NCT00025064|Drug|chlorambucil|
1728753|NCT00025064|Drug|cisplatin|
1728754|NCT00025064|Drug|dacarbazine|
1728755|NCT00025064|Drug|doxorubicin hydrochloride|
1728756|NCT00025064|Drug|etoposide|
1728757|NCT00025064|Drug|ifosfamide|
1728758|NCT00025064|Drug|melphalan|
1728759|NCT00025064|Drug|prednisolone|
1728760|NCT00025064|Drug|procarbazine hydrochloride|
1728761|NCT00025064|Drug|vinblastine sulfate|
1728762|NCT00025064|Drug|vincristine sulfate|
1728763|NCT00025064|Procedure|peripheral blood stem cell transplantation|
1728764|NCT00025064|Radiation|radiation therapy|
1728765|NCT00025077|Biological|filgrastim|
1728766|NCT00025077|Drug|carboplatin|
1728767|NCT00025077|Drug|cyclophosphamide|
1728768|NCT00025077|Drug|thiotepa|
1728876|NCT00017082|Drug|oxaliplatin|
1728769|NCT00025077|Procedure|conventional surgery|
1728770|NCT00025077|Procedure|peripheral blood stem cell transplantation|
1728771|NCT00025077|Radiation|radiation therapy|
1728772|NCT00025090|Drug|cisplatin|
1728773|NCT00025090|Drug|fluorouracil|
1728774|NCT00025090|Drug|mitomycin C|
1728775|NCT00025090|Radiation|radiation therapy|
1728776|NCT00025103|Biological|dactinomycin|
1728777|NCT00025103|Drug|carboplatin|
1728778|NCT00025103|Drug|cyclophosphamide|
1728779|NCT00025103|Drug|doxorubicin hydrochloride|
1728780|NCT00025103|Drug|etoposide|
1728781|NCT00025103|Drug|melphalan|
1728782|NCT00025103|Drug|vincristine sulfate|
1728783|NCT00025103|Procedure|autologous bone marrow transplantation|
1728784|NCT00025103|Procedure|conventional surgery|
1728785|NCT00025103|Procedure|peripheral blood stem cell transplantation|
1728786|NCT00025103|Radiation|radiation therapy|
1728787|NCT00025116|Drug|gefitinib|
1728788|NCT00025129|Drug|laromustine|
1728789|NCT00025142|Drug|FOLFOX regimen|
1728790|NCT00025142|Drug|fluorouracil|
1728791|NCT00025142|Drug|gefitinib|
1728792|NCT00025142|Drug|leucovorin calcium|
1728793|NCT00025142|Drug|oxaliplatin|
1728794|NCT00025155|Drug|ixabepilone|Given IV
1728795|NCT00025168|Drug|gemcitabine hydrochloride|
1728796|NCT00025168|Drug|irinotecan hydrochloride|
1728797|NCT00025168|Radiation|radiation therapy|
1728798|NCT00025181|Biological|MART-1 antigen|
1728799|NCT00025181|Biological|gp100 antigen|
1728800|NCT00025181|Biological|incomplete Freund's adjuvant|
1728801|NCT00025181|Biological|ipilimumab|
1728802|NCT00025181|Biological|tyrosinase peptide|
1728803|NCT00025181|Procedure|adjuvant therapy|
1728804|NCT00025194|Drug|estramustine phosphate sodium|
1728805|NCT00025194|Drug|ixabepilone|
1728806|NCT00025207|Drug|gefitinib|Given orally
1728807|NCT00025207|Other|laboratory biomarker analysis|Correlative studies
1728808|NCT00025220|Drug|Thalidomide|Given PO
1728809|NCT00025220|Other|Laboratory Biomarker Analysis|Correlative studies
1728810|NCT00025233|Biological|bevacizumab|Given IV
1728811|NCT00025233|Other|laboratory biomarker analysis|Correlative studies
1728812|NCT00025246|Drug|imatinib mesylate|Given orally
1728813|NCT00025246|Other|laboratory biomarker analysis|Correlative studies
1728814|NCT00025259|Biological|Bleomycin Sulfate|Given IV or SC
1728815|NCT00025259|Drug|Cisplatin|Given IV
1728816|NCT00025259|Drug|Cyclophosphamide|Given IV
1728817|NCT00025259|Drug|Cytarabine|Given IV
1728818|NCT00025259|Drug|Dexamethasone|Given IV
1728819|NCT00025259|Drug|Doxorubicin Hydrochloride|Given IV
1728820|NCT00025259|Drug|Etoposide|Given IV
1728821|NCT00025259|Biological|Filgrastim|Given SC
1728822|NCT00025259|Radiation|Involved-Field Radiation Therapy|Undergo IFRT
1728823|NCT00025259|Drug|Prednisone|Given orally
1728824|NCT00025259|Drug|Vincristine Sulfate Liposome|Given IV
1728825|NCT00025272|Drug|carboplatin|
1728826|NCT00025272|Drug|etoposide|
1728827|NCT00025272|Drug|topotecan hydrochloride|
1728828|NCT00025272|Radiation|radiation therapy|
1728829|NCT00025285|Drug|carboplatin|
1728830|NCT00025285|Drug|irinotecan hydrochloride|
1728831|NCT00025285|Drug|thalidomide|
1728832|NCT00025298|Drug|amifostine trihydrate|
1728833|NCT00025298|Drug|carboplatin|
1728834|NCT00025298|Drug|cisplatin|
1728835|NCT00025298|Drug|paclitaxel|
1728836|NCT00025298|Radiation|radiation therapy|
1728837|NCT00025311|Drug|topotecan hydrochloride|
1728838|NCT00025324|Biological|filgrastim|
1728839|NCT00025324|Drug|carboplatin|
1728840|NCT00025324|Drug|cyclophosphamide|
1728841|NCT00025324|Drug|etoposide|
1728842|NCT00025324|Drug|thiotepa|
1728843|NCT00025324|Procedure|autologous bone marrow transplantation|
1728844|NCT00025324|Procedure|bone marrow ablation with stem cell support|
1728845|NCT00025324|Procedure|conventional surgery|
1728846|NCT00025324|Procedure|peripheral blood stem cell transplantation|
1728847|NCT00025324|Radiation|radiation therapy|
1728848|NCT00025337|Biological|bevacizumab|Given IV
1728849|NCT00025337|Drug|oxaliplatin|Given IV
1728850|NCT00025337|Drug|leucovorin calcium|Given IV
1728851|NCT00025337|Drug|fluorouracil|Given IV
1728852|NCT00025350|Drug|gefitinib|
1728853|NCT00025363|Drug|vincristine sulfate|Given IV
1728854|NCT00025363|Drug|irinotecan hydrochloride|Given IV
1728855|NCT00025363|Drug|cyclophosphamide|Given IV
1728856|NCT00025363|Drug|doxorubicin hydrochloride|Given IV
1728857|NCT00025363|Drug|ifosfamide|Given IV
1728858|NCT00025363|Drug|etoposide|Given IV
1728859|NCT00025363|Drug|tirapazamine|Given IV
1728860|NCT00025363|Biological|filgrastim|Given SC
1728861|NCT00025363|Biological|sargramostim|Given SC
1728862|NCT00025363|Other|pharmacological study|Correlative studies
1728863|NCT00025363|Other|pharmacogenomic studies|Correlative studies
1728864|NCT00025363|Other|laboratory biomarker analysis|Correlative studies
1728865|NCT00025376|Drug|PS-341|
1728866|NCT00025376|Procedure|Tumor Biopsy|
1728867|NCT00025389|Biological|bevacizumab|
1728868|NCT00025389|Drug|carboplatin|
1728869|NCT00025389|Drug|paclitaxel|
1728870|NCT00025389|Procedure|conventional surgery|
1728871|NCT00025389|Procedure|neoadjuvant therapy|
1728872|NCT00017043|Drug|ixabepilone|
1728873|NCT00017056|Drug|ixabepilone|
1728874|NCT00017069|Drug|arsenic trioxide|
1728875|NCT00017069|Drug|dexamethasone|
1728880|NCT00017095|Drug|epirubicin hydrochloride|
1728881|NCT00017095|Drug|fluorouracil|
1728882|NCT00017095|Genetic|microarray analysis|
1728883|NCT00017095|Other|immunohistochemistry staining method|
1728884|NCT00017095|Other|laboratory biomarker analysis|
1728885|NCT00017095|Procedure|biopsy|
1728886|NCT00017095|Procedure|conventional surgery|
1728887|NCT00017095|Procedure|neoadjuvant therapy|
1728888|NCT00017095|Radiation|radiation therapy|
1728889|NCT00017108|Drug|chlorambucil|
1728890|NCT00017108|Drug|cyclophosphamide|
1728891|NCT00017108|Drug|fludarabine phosphate|
1728892|NCT00017121|Biological|sargramostim|
1728893|NCT00017134|Drug|fenretinide|
1728894|NCT00017134|Procedure|conventional surgery|
1728895|NCT00017147|Drug|carmustine|"40 mg/m^2 IV over 1 hour on day 1 of each cycle 6 hours after O6-BG dose for experimental arm with O6=BG.
200 mg/m^2 IV over 1 hour on day 2 of each cycle for the active comparator arm."
1728896|NCT00017147|Radiation|radiation therapy|5 days/week using one fraction per day and a dose of 180 cGy per fraction. Initial target volume is dose of 5040 cGy in 28 fractions with boost target volume of 1080 cGy in 6 fractions.
1728897|NCT00017147|Drug|O6-Benzylguanine|120 mg/m^2 IV over 1 hour on day 1 of each cycle
1728898|NCT00017160|Drug|doxorubicin|
1728899|NCT00017160|Drug|filgrastim|
1728900|NCT00017160|Drug|ifosfamide|
1728901|NCT00017160|Procedure|biological response modifier therapy|
1728902|NCT00017160|Procedure|brachytherapy|
1728903|NCT00017160|Procedure|chemotherapy|
1728904|NCT00017160|Procedure|colony-stimulating factor therapy|
1728905|NCT00017160|Procedure|conventional surgery|
1728906|NCT00017160|Procedure|cytokine therapy|
1728907|NCT00017160|Procedure|intraoperative radiotherapy|
1728908|NCT00017160|Procedure|radiation therapy|
1728909|NCT00017160|Procedure|surgery|
1728910|NCT00017173|Biological|Ad5CMV-p53 gene|2 intraoperative and one post-operative injection of Ad5CMV-p53.
1728911|NCT00017173|Drug|cisplatin|100 mg/m2 IV Day 1 every 21 days for 3 cycles
1728912|NCT00017173|Procedure|conventional surgery|conventional surgery
1728913|NCT00017173|Radiation|radiation therapy|200 cGy per day Days 105 every week for 6 weeks
1728914|NCT00017186|Drug|epirubicin hydrochloride|
1728915|NCT00017186|Drug|gemcitabine hydrochloride|
1728916|NCT00017199|Drug|bortezomib|
1728917|NCT00017212|Drug|exatecan mesylate|
1728918|NCT00017225|Biological|filgrastim|
1728919|NCT00017225|Drug|carboplatin|
1728920|NCT00017225|Drug|cisplatin|
1728921|NCT00017225|Drug|cyclophosphamide|
1728922|NCT00017225|Drug|dacarbazine|
1728923|NCT00017225|Drug|doxorubicin hydrochloride|
1728924|NCT00017225|Drug|etoposide|
1728925|NCT00017225|Drug|ifosfamide|
1728926|NCT00017225|Drug|melphalan|
1728927|NCT00017225|Drug|tretinoin|
1728928|NCT00017225|Drug|vincristine sulfate|
1728929|NCT00017225|Drug|vindesine|
1728930|NCT00017225|Procedure|autologous bone marrow transplantation|
1728931|NCT00017225|Procedure|conventional surgery|
1728932|NCT00017225|Procedure|peripheral blood stem cell transplantation|
1728933|NCT00017225|Radiation|radiation therapy|
1728934|NCT00017238|Drug|KRN5500|Given IV
1728935|NCT00017238|Other|pharmacological study|Correlative studies
1728936|NCT00017251|Biological|oblimersen sodium|Given IV
1728937|NCT00017251|Drug|carboplatin|Given IV
1728938|NCT00017251|Drug|etoposide|Given IV
1728939|NCT00017251|Other|pharmacological study|Correlative studies
1728940|NCT00017251|Other|laboratory biomarker analysis|Correlative studies
1728941|NCT00017264|Drug|atrasentan hydrochloride|
1728942|NCT00017277|Biological|epoetin alfa|
1728943|NCT00017277|Radiation|radiation therapy|
1728944|NCT00017290|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
1728945|NCT00017290|Biological|keyhole limpet hemocyanin|
1728946|NCT00017290|Biological|sargramostim|
1728947|NCT00017290|Drug|cyclophosphamide|
1728948|NCT00017290|Drug|prednisone|
1728949|NCT00017290|Drug|vincristine sulfate|
1728950|NCT00017303|Drug|carboplatin|
1728951|NCT00017303|Drug|oglufanide disodium|
1728952|NCT00017303|Drug|paclitaxel|
1728953|NCT00017303|Procedure|conventional surgery|
1728954|NCT00017316|Drug|semaxanib|
1728955|NCT00017316|Drug|thalidomide|
1728956|NCT00017329|Drug|bortezomib|
1728957|NCT00017342|Drug|bryostatin 1|
1728958|NCT00017342|Drug|cytarabine|
1728959|NCT00017355|Biological|filgrastim|
1728960|NCT00017355|Biological|therapeutic autologous dendritic cells|
1728961|NCT00017368|Biological|filgrastim|
1728962|NCT00017368|Biological|sargramostim|
1728963|NCT00017368|Drug|carboplatin|
1728964|NCT00017368|Drug|cisplatin|
1728965|NCT00017368|Drug|cyclophosphamide|
1728966|NCT00017368|Drug|doxorubicin hydrochloride|
1728967|NCT00017368|Drug|etoposide|
1728968|NCT00017368|Drug|etoposide phosphate|
1728969|NCT00017368|Drug|ifosfamide|
1728970|NCT00017368|Drug|isotretinoin|
1728971|NCT00017368|Drug|melphalan|
1728972|NCT00017368|Drug|thiotepa|
1728973|NCT00017368|Drug|vincristine sulfate|
1728974|NCT00017368|Procedure|conventional surgery|
1728975|NCT00017368|Procedure|peripheral blood stem cell transplantation|
1728976|NCT00017368|Radiation|radiation therapy|
1728977|NCT00017381|Biological|rituximab|Given IV
1728978|NCT00017381|Drug|cyclophosphamide|Given IV
1728979|NCT00017381|Biological|filgrastim|Given SC
1728980|NCT00017381|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
1728981|NCT00017381|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
1728982|NCT00017394|Biological|bevacizumab|Given IV
1728983|NCT00017394|Drug|vinorelbine tartrate|Given IV
1728984|NCT00017394|Other|laboratory biomarker analysis|Correlative studies
1728985|NCT00017407|Biological|ISIS 3521|
1728986|NCT00017407|Drug|carboplatin|
1728987|NCT00017407|Drug|paclitaxel|
1728988|NCT00017433|Drug|arsenic trioxide|
1728989|NCT00017446|Drug|CP4071|
1728990|NCT00017459|Drug|cisplatin|
1728991|NCT00017459|Drug|tirapazamine|
1728992|NCT00017459|Drug|vinorelbine tartrate|
1728993|NCT00017472|Biological|apolizumab|Given IV
1728994|NCT00017472|Other|laboratory biomarker analysis|Correlative studies
1728995|NCT00017472|Other|pharmacological study|Correlative studies
1728996|NCT00017485|Drug|HPPH|
1728997|NCT00017498|Drug|gemcitabine hydrochloride|
1728998|NCT00017511|Drug|cevimeline hydrochloride|
1728999|NCT00017524|Drug|pelitrexol|
1729000|NCT00017537|Biological|MVF-HER-2(628-647)-CRL 1005 vaccine|
1729001|NCT00017550|Biological|anti-thymocyte globulin|
1729002|NCT00017563|Drug|docetaxel|35 mg/m2 i.v. over 15 - 30 minutes will be administered immediately after the mitoxantrone on the same schedule.
1729003|NCT00017563|Drug|mitoxantrone hydrochloride|Initial dose will be 2 mg/m2 weekly for 3 of every 4 weeks. The dose will then be escalated as described in the dose escalation section up to a maximum dose of 6 mg/m2 weekly for 3 of every 4 weeks.
1729004|NCT00017563|Procedure|conventional surgery|Prostatectomy will be scheduled 2 - 4 weeks after the last dose of chemotherapy.
1729005|NCT00017576|Dietary Supplement|calcitriol|
1729006|NCT00017576|Drug|carboplatin|
1729007|NCT00017589|Biological|oblimersen sodium|
1729008|NCT00017589|Drug|gemtuzumab ozogamicin|
1729009|NCT00017602|Biological|oblimersen sodium|
1729010|NCT00017602|Drug|dexamethasone|
1729011|NCT00017628|Drug|cyclophosphamide|
1729012|NCT00017628|Drug|filgrastim|
1729013|NCT00017628|Drug|methylprednisolone|
1729014|NCT00017628|Procedure|Autologous Stem Cell Transplantation|
1729015|NCT00017641|Drug|anti-thymocyte globulin|
1729016|NCT00017641|Drug|cyclophosphamide|
1729017|NCT00017641|Drug|filgrastim|
1729018|NCT00017641|Procedure|CD34+ Peripheral Blood Stem Cell Reinfusion|
1729019|NCT00017654|Drug|anti-thymocyte globulin|
1729020|NCT00017654|Drug|cyclophosphamide|
1729021|NCT00017654|Drug|cyclosporine|
1729022|NCT00017654|Drug|methylprednisolone|
1729023|NCT00017654|Procedure|Allogeneic Bone Marrow Transplantation|
1729024|NCT00017680|Drug|Melphalan|100 mg/m2 twice a day from Days -2 and -1 as induction therapy
1729025|NCT00017680|Procedure|Autologous Stem Cell Transplantation|Bone marrow and peripheral blood stem cells harvested
1729026|NCT00017693|Biological|Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of 0.75, 1.5, or 3.0 mg dose of recombinant human soluble IL-4 receptor (rsIL-4R)
1729027|NCT00017693|Biological|Placebo for Recombinant human soluble IL-4 receptor|Subjects were randomized to twelve once weekly nebulizations of placebo for recombinant human soluble IL-4 receptor (rsIL-4R). Identically prepared (to the recombinant human soluble IL-4 receptor) in the same volume
1729028|NCT00017706|Behavioral|physician-delivered weight control|
1729029|NCT00017719|Drug|Lamivudine|
1729030|NCT00017719|Drug|Lamivudine/Zidovudine|
1729031|NCT00017719|Drug|Nelfinavir mesylate|
1729032|NCT00017719|Drug|Nevirapine|
1729033|NCT00017719|Drug|Zidovudine|
1729034|NCT00017758|Drug|Pravastatin sodium|
1729035|NCT00017758|Drug|Simvastatin|
1729036|NCT00017758|Drug|Atorvastatin calcium|
1729037|NCT00017758|Drug|Nelfinavir mesylate|
1729038|NCT00017758|Drug|Efavirenz|
1729039|NCT00017784|Drug|Valganciclovir|
1729040|NCT00017810|Behavioral|Dietary intervention|
1729041|NCT00017823|Procedure|Acupressure|
1729042|NCT00017862|Drug|SCH55700|
1729043|NCT00017927|Drug|Pegvisomant|
1729044|NCT00017940|Genetic|Human Nerve Growth Factor|
1729045|NCT00017953|Behavioral|Lifestyle Intervention|The lifestyle intervention is implemented with individual supervision and group sessions and is aimed at achieving and maintaining at least a 7% decrease in weight from baseline and 175 minutes per week in physical activity. It is implemented during a four-year period with the most intensive application during the first year, less frequent attention during the next three years, and a minimum of twice yearly contacts during an extended follow-up period. To help participants achieve and maintain weight loss, a variety of diet strategies (e.g. prepared meals and liquid formula), exercise strategies, and optional weight loss medications are utilized based on a preset algorithm and participant progress.
1729046|NCT00017953|Behavioral|Diabetes Support and Education|Participants assigned to diabetes support and education are offered three sessions each year in diabetes management and social support.
1729047|NCT00017992|Drug|Lopinavir/Ritonavir|
1729048|NCT00017992|Drug|Emtricitabine|
1729049|NCT00017992|Drug|Stavudine|
1729050|NCT00018005|Behavioral|Self-Management|18 in-person group sessions providing self-management training.
1729051|NCT00018005|Other|attention control|18 educational mailings follow by a a telephone call.
1729052|NCT00018018|Drug|CD34+ cells transduced with ADA retrovir|
1729053|NCT00018031|Drug|Peginterferon alfa-2b|Weekly injections for 48 weeks of a dose of 1.5mcg/Kg per week subcutaneously
1729054|NCT00018031|Drug|Ribavirin|Weight based Ribavirin dosing 1-1.2grams/day in divided (twice daily) doses for a total duration of 48 weeks.
1729055|NCT00018070|Procedure|Angiography|
1729056|NCT00018070|Procedure|Laser Treatment|
1729057|NCT00018083|Drug|rifabutin|
1729058|NCT00018083|Drug|isoniazid|
1729059|NCT00018083|Drug|efavirenz|
1729060|NCT00018096|Biological|LPS endotoxin, saline, HDM|instillation of interventional products during bronchoscopy each down a different airway, each subject acts as their own control.
1729061|NCT00018109|Drug|glutamine|
1729062|NCT00018109|Drug|creatine monohydrate|
1729066|NCT00018148|Drug|nortriptyline|Dose titrated to 75 mg daily as tolerated combined with transdermal nicotine 21 mg
1729067|NCT00018148|Drug|transdermal nicotine|Transdermal nicotine 21 mg, titrated down plus placebo
1729068|NCT00018161|Drug|Mecamylamine|
1729069|NCT00018161|Drug|Nicotine Patch|
1729070|NCT00018161|Behavioral|Cigarette brand switching|
1729071|NCT00018174|Drug|Fluoxetine|
1729072|NCT00018174|Behavioral|Behavioral group smoking cessation treatment|
1729073|NCT00018174|Drug|Placebo|
1729074|NCT00018187|Drug|Bupropion|
1729075|NCT00018187|Drug|Mecamylamine|
1729076|NCT00018187|Drug|Nicotine Patch|
1729077|NCT00018200|Drug|Desipramine|Low exposure (40-70 ng/mL), Middle exposure (70-130 ng/mL), High exposure (130-200 ng/mL)
1729078|NCT00018200|Drug|Fluoxetine|Low exposure (200-399 ng/mL), Middle exposure (400-499 ng/mL), High exposure (500-700ng/mL)
1729079|NCT00018200|Drug|Benztropine|Daily dose 0.125 to 0.5mg
1729080|NCT00018213|Drug|Naltrexone Hydrochloride|
1729081|NCT00018213|Drug|Transdermal Nicotine|
1729082|NCT00018226|Behavioral|Case Management|
1729083|NCT00018239|Procedure|Exercise|
1729084|NCT00018252|Behavioral|exercise|
1729085|NCT00018265|Behavioral|Task specific endurance training|
1729086|NCT00018265|Behavioral|Tai Chi|
1729087|NCT00018278|Drug|Aricept|
1729088|NCT00018278|Drug|Exelon|
1729089|NCT00018278|Drug|Nicoderm Patch|
1729090|NCT00018291|Drug|Risperidone|
1729091|NCT00018291|Drug|Gabapentin|
1729092|NCT00018317|Behavioral|low protein diet|
1729093|NCT00018317|Behavioral|resistance training|
1729094|NCT00018317|Behavioral|combination of diet control and exercise|
1729095|NCT00018330|Behavioral|Weight Loss|
1729096|NCT00018343|Drug|estrogen|
1729097|NCT00018356|Procedure|exercise|
1729098|NCT00018356|Drug|testosterone|
1729099|NCT00018382|Drug|rosiglitazone|
1729100|NCT00018421|Procedure|Treadmill Exercise|
1729101|NCT00018447|Drug|PTH 1-34|
1729102|NCT00018447|Drug|MFPSR-fluoride|
1729103|NCT00018460|Drug|Vitamin B|
1729104|NCT00018512|Procedure|Implant-supported denture|
1729105|NCT00018525|Procedure|Lung Volume Reduction Surgery|
1729106|NCT00018538|Drug|calcifidiol|
1729107|NCT00018551|Drug|Folic Acid|
1729108|NCT00018564|Drug|treatments for essential tremor|
1729109|NCT00018603|Drug|guanfacine|
1729110|NCT00018616|Behavioral|MEMS caps|
1729111|NCT00018642|Drug|quetiapine|
1729112|NCT00018642|Drug|haloperidol decanoate|
1729113|NCT00018655|Behavioral|Twelve Step Facilitation|Twelve Step Facilitation Therapy involves focusing on topics from 12-Step programs which support sobriety goals and personal growth.
1729114|NCT00018655|Behavioral|Integrated Cognitive Behavioral Treatment|Integrated Cognitive Behavioral Treatment involves focusing on thoughts, activities, and interactions with people related to depressive symptoms and/or substance use.
1729115|NCT00018668|Drug|Risperidone|
1729116|NCT00018668|Drug|Olanzapine|
1729117|NCT00018668|Drug|Quetiapine|
1729118|NCT00018694|Drug|Chenodeoxycholic Acid|
1729119|NCT00018733|Drug|paroxetine|
1729120|NCT00018733|Drug|Desipramine|
1729121|NCT00018746|Device|repetitive transcranial magnetic stimulation|
1729122|NCT00018759|Drug|paroxetine|
1729123|NCT00018759|Behavioral|ongoing psychological screening|
1729124|NCT00018785|Procedure|donor bone marrow infusion|
1729125|NCT00018811|Behavioral|Relaxation training & thermal biofeedback|
1729126|NCT00018811|Behavioral|Surface EMG biofeedback|
1729127|NCT00018824|Drug|NALTREXONE|
1729128|NCT00018824|Drug|Placebo|
1729129|NCT00018837|Behavioral|Community Re-Entry Program: What is Schizophrenia|
1729130|NCT00018850|Drug|ondansetron|
1729131|NCT00018850|Behavioral|neuropsychological testing|
1729132|NCT00018850|Drug|nicotine|
1729133|NCT00018850|Drug|haloperidol|
1729134|NCT00018863|Drug|Methylphenidate|
1729135|NCT00018876|Procedure|Lumbar nerve root decompression|
1729136|NCT00018876|Procedure|Preoperative low-dose external beam radiation|
1729137|NCT00018902|Drug|Fluoxetine|Standard anti-depressant treatment with the SSRI fluoxetine
1729138|NCT00018902|Drug|Venlafaxine|Standard antidepressant treatment with the non-SSRI medication venlafaxine
1729139|NCT00018902|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT addresses maladaptive beliefs in order to encourage behavioral change
1729140|NCT00018902|Drug|Citalopram|Standard anti-depressant treatment with the SSRI fluoxetine
1729141|NCT00018941|Biological|aldesleukin|
1729142|NCT00018954|Drug|asparaginase|
1729143|NCT00018954|Drug|cyclophosphamide|
1729144|NCT00018954|Drug|cytarabine|
1729145|NCT00018954|Drug|daunorubicin hydrochloride|
1729146|NCT00018954|Drug|doxorubicin hydrochloride|
1729147|NCT00018954|Drug|etoposide|
1729148|NCT00018954|Drug|ifosfamide|
1729149|NCT00018954|Drug|mercaptopurine|
1729150|NCT00018954|Drug|methotrexate|
1729151|NCT00018954|Drug|prednisone|
1729152|NCT00018954|Drug|vincristine sulfate|
1729153|NCT00018954|Procedure|conventional surgery|
1729154|NCT00018954|Radiation|radiation therapy|
1729155|NCT00018967|Drug|glucarpidase|
1729156|NCT00019006|Drug|Detox-B adjuvant|
1729157|NCT00019006|Drug|ras peptide cancer vaccine|
1729158|NCT00019019|Drug|carboxyamidotriazole|
1729159|NCT00019019|Drug|paclitaxel|
1729160|NCT00019032|Biological|monoclonal antibody Mik-beta-1|
1729161|NCT00019058|Drug|chemotherapy|
1729162|NCT00019058|Drug|hydroxyurea|
1729163|NCT00019058|Drug|pentoxifylline|
1729164|NCT00019058|Radiation|radiation therapy|
1729165|NCT00019071|Drug|chemotherapy|
1729167|NCT00019071|Radiation|radiation therapy|
1729168|NCT00019084|Biological|aldesleukin|
1729169|NCT00019084|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
1729170|NCT00019084|Biological|ras peptide cancer vaccine|
1729171|NCT00019084|Biological|sargramostim|
1729172|NCT00019084|Biological|therapeutic autologous lymphocytes|
1729173|NCT00019084|Biological|therapeutic tumor infiltrating lymphocytes|
1729174|NCT00025402|Biological|filgrastim|
1729175|NCT00025402|Biological|recombinant interferon alfa|
1729176|NCT00025402|Drug|busulfan|
1729177|NCT00025402|Drug|cyclophosphamide|
1729178|NCT00025402|Drug|cytarabine|
1729179|NCT00025402|Drug|etoposide|
1729180|NCT00025402|Drug|hydroxyurea|
1729181|NCT00025402|Drug|idarubicin|
1729182|NCT00025402|Procedure|allogeneic bone marrow transplantation|
1729183|NCT00025402|Procedure|peripheral blood stem cell transplantation|
1729184|NCT00025402|Radiation|radiation therapy|
1729185|NCT00025415|Drug|imatinib mesylate|Given orally
1729186|NCT00025415|Other|pharmacological study|Correlative studies
1729187|NCT00025428|Drug|carboplatin|
1729188|NCT00025428|Drug|cyclophosphamide|
1729189|NCT00025428|Drug|doxorubicin hydrochloride|
1729190|NCT00025428|Drug|etoposide|
1729191|NCT00025428|Drug|vincristine sulfate|
1729192|NCT00025428|Procedure|adjuvant therapy|
1729193|NCT00025428|Procedure|conventional surgery|
1729194|NCT00025428|Procedure|neoadjuvant therapy|
1729195|NCT00025441|Biological|dactinomycin|
1729196|NCT00025441|Biological|filgrastim|
1729197|NCT00025441|Drug|carboplatin|
1729198|NCT00025441|Drug|cyclophosphamide|
1729199|NCT00025441|Drug|doxorubicin hydrochloride|
1729200|NCT00025441|Drug|epirubicin hydrochloride|
1729201|NCT00025441|Drug|etoposide|
1729202|NCT00025441|Drug|ifosfamide|
1729203|NCT00025441|Drug|vincristine sulfate|
1729204|NCT00025441|Procedure|peripheral blood stem cell transplantation|
1729205|NCT00025441|Radiation|radiation therapy|
1729206|NCT00025454|Drug|tipifarnib|
1729207|NCT00025467|Drug|thalidomide|Given orally
1729208|NCT00025467|Other|laboratory biomarker analysis|Correlative studies
1729209|NCT00025480|Drug|carboplatin|
1729210|NCT00025480|Drug|paclitaxel|
1729211|NCT00025480|Drug|tipifarnib|
1729212|NCT00025480|Radiation|radiation therapy|
1729213|NCT00025493|Drug|docetaxel|
1729214|NCT00025506|Other|Laboratory Biomarker Analysis|Correlative studies
1729215|NCT00025506|Drug|Thalidomide|Given orally
1729216|NCT00025519|Biological|therapeutic allogeneic lymphocytes|
1729217|NCT00025519|Drug|fludarabine phosphate|
1729218|NCT00025519|Drug|mycophenolate mofetil|
1729219|NCT00025519|Drug|tacrolimus|
1729220|NCT00025519|Drug|thalidomide|
1729221|NCT00025519|Procedure|peripheral blood stem cell transplantation|
1729222|NCT00025519|Radiation|radiation therapy|
1729223|NCT00025532|Other|iodine I 131 monoclonal antibody CC49-deltaCH2|
1729224|NCT00025545|Drug|cyclophosphamide|
1729225|NCT00025545|Drug|methotrexate|
1729226|NCT00025545|Procedure|peripheral blood stem cell transplantation|
1729227|NCT00025545|Radiation|radiation therapy|
1729228|NCT00025558|Biological|filgrastim|
1729229|NCT00025558|Drug|carboplatin|
1729230|NCT00025558|Drug|temozolomide|
1729231|NCT00025558|Drug|thiotepa|
1729232|NCT00025558|Procedure|autologous bone marrow transplantation|
1729233|NCT00025558|Procedure|peripheral blood stem cell transplantation|
1729234|NCT00025571|Drug|HPPH|
1729235|NCT00025584|Drug|bortezomib|Given IV
1729236|NCT00025584|Other|laboratory biomarker analysis|Correlative studies
1729237|NCT00025597|Drug|carboplatin|
1729238|NCT00025597|Drug|cyclophosphamide|
1729239|NCT00025597|Drug|doxorubicin hydrochloride|
1729240|NCT00025597|Drug|etoposide|
1729241|NCT00025597|Drug|vincristine sulfate|
1729242|NCT00025597|Procedure|conventional surgery|
1729243|NCT00025610|Drug|carboplatin|
1729244|NCT00025610|Drug|cyclophosphamide|
1729245|NCT00025610|Drug|doxorubicin hydrochloride|
1729246|NCT00025610|Drug|etoposide|
1729247|NCT00025610|Drug|vincristine sulfate|
1729248|NCT00025623|Drug|carboplatin|
1729249|NCT00025623|Drug|cyclophosphamide|
1729250|NCT00025623|Drug|doxorubicin hydrochloride|
1729251|NCT00025623|Drug|etoposide|
1729252|NCT00025623|Drug|vincristine sulfate|
1729253|NCT00025623|Procedure|conventional surgery|
1729254|NCT00025636|Biological|filgrastim|
1729255|NCT00025636|Drug|carmustine|
1729256|NCT00025636|Drug|cisplatin|
1729257|NCT00025636|Drug|cyclophosphamide|
1729258|NCT00025636|Drug|cytarabine|
1729259|NCT00025636|Drug|dexamethasone|
1729260|NCT00025636|Drug|etoposide|
1729261|NCT00025636|Drug|melphalan|
1729262|NCT00025636|Drug|methotrexate|
1729263|NCT00025636|Drug|vincristine sulfate|
1729264|NCT00025636|Procedure|bone marrow ablation with stem cell support|
1729265|NCT00025636|Procedure|peripheral blood stem cell transplantation|
1729266|NCT00025649|Biological|filgrastim|
1729267|NCT00025649|Drug|busulfan|
1729268|NCT00025649|Drug|carboplatin|
1729269|NCT00025649|Drug|cyclophosphamide|
1729270|NCT00025649|Drug|doxorubicin hydrochloride|
1729271|NCT00025649|Drug|etoposide|
1729272|NCT00025649|Drug|melphalan|
1729273|NCT00025649|Drug|vincristine sulfate|
1729274|NCT00025649|Procedure|autologous bone marrow transplantation|
1729275|NCT00025649|Procedure|conventional surgery|
1729276|NCT00025649|Procedure|peripheral blood stem cell transplantation|
1729277|NCT00025662|Drug|RFT5-SMPT-dgA|A specific anti-interleukin-2 receptor immunotoxin
1729278|NCT00025662|Drug|Isolex system|CD34 selection/ T cell depletion used this system
1729279|NCT00025675|Drug|gefitinib|
1729280|NCT00025688|Drug|carboplatin|
1729281|NCT00025688|Drug|paclitaxel|
1729282|NCT00025727|Drug|Lopinavir/Ritonavir|
1729283|NCT00025727|Drug|Ritonavir|
1729284|NCT00025727|Drug|GW433908|
1729285|NCT00027248|Drug|MBI 226|
1729286|NCT00027261|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1729287|NCT00027287|Drug|Vitamin E|
1729288|NCT00027300|Drug|Natalizumab|Natalizumab 300 mg IV infusion, every 4 weeks, for up to 116 weeks.
1729289|NCT00027300|Drug|Placebo|Placebo, IV infusion, every 4 weeks, for up to 116 weeks.
1729290|NCT00027339|Drug|lopinavir/ritonavir|
1729291|NCT00027339|Drug|indinavir sulfate|
1729292|NCT00027339|Drug|tenofovir disoproxil fumarate|
1729293|NCT00027339|Drug|ritonavir|
1729294|NCT00027339|Drug|fosamprenavir|
1729295|NCT00027365|Biological|Combination Vaccine (NefTat and gp120W61D) Formulated with AS02A|
1729296|NCT00027365|Biological|NefTat|
1729297|NCT00027365|Drug|AS02A Adjuvant|
1729298|NCT00027365|Biological|gp120W61D|
1729299|NCT00027378|Drug|fluoxetine (Prozac)|fluoxetine plus Treatment As Usual (TAU); 12 weeks acute phase; plus 9 month naturalistic follow up
1729300|NCT00027378|Drug|Placebo plus Treatment As Usual|placebo plus Treatment as Usual; 12 weeks acute phase; plus 9 month naturalistic follow up
1729301|NCT00027391|Drug|Albuterol|
1729302|NCT00027391|Drug|Oxandrolone|
1729303|NCT00027404|Drug|Fluoxetine|
1729304|NCT00027417|Drug|Liothyronine sodium/triiodothyronine|
1729305|NCT00027417|Procedure|Cardiopulmonary bypass and cardiac surgery|
1729306|NCT00027430|Drug|TheraDerm|
1729307|NCT00027443|Drug|Muromonab-CD3|
1729308|NCT00027443|Drug|Cyclosporine|
1729309|NCT00027456|Drug|Leptin A-100|
1729310|NCT00027469|Procedure|MRI|
1729311|NCT00027495|Dietary Supplement|curcumin|
1729312|NCT00027508|Drug|trabectedin|
1729313|NCT00027521|Biological|bleomycin sulfate|
1729314|NCT00027521|Drug|electroporation therapy|
1729315|NCT00027534|Biological|TRICOM-CEA(6D)|dendritic cells loaded with TRICOM-CEA(6D)
1729316|NCT00027547|Biological|therapeutic allogeneic lymphocytes|
1729317|NCT00027547|Drug|cyclosporine|
1729318|NCT00027547|Drug|cytarabine|
1729319|NCT00027547|Drug|fludarabine phosphate|
1729320|NCT00027547|Drug|methotrexate|
1729321|NCT00027547|Drug|mycophenolate mofetil|
1729322|NCT00027547|Procedure|allogeneic bone marrow transplantation|
1729323|NCT00027547|Procedure|peripheral blood stem cell transplantation|
1729324|NCT00027547|Radiation|radiation therapy|
1729325|NCT00027560|Biological|alemtuzumab|"Consenting individuals will receive pretransplant immunosuppressive cytoreduction, which will consist of 4 days of Campath-1H, 5 days of fludarabine, and two days of melphalan. All therapy should be completed approximately 24-36 hours before administration of the primary allograft.
Campath-1H (20mg/dose/day) will be administered for each of four days from day -8 to day -5, inclusive. Each dose will be infused intravenously over 8 hours."
1729326|NCT00027560|Drug|cyclosporine|Patients will be treated with Cyclosporine as prophylaxis against GvHD. Cyclosporine will be initiated at least 1 day prior to transplant at a dose of 1.5 mg / kg IV q12h (3 mg / kg / day = total daily dose). Dose will thereafter be adjusted to maintain a trough serum level of 200-300 ng /ml. Cyclosporine will be administered intravenously until the patient tolerates full alimentation, at which time conversion to oral dosing to sustain therapeutic levels will be initiated according to standard BMT service guidelines.
1729327|NCT00027560|Drug|fludarabine phosphate|Fludarabine, 25mg/m2/d will be administered for each of five days from day -8 to day -4, inclusive. Each dose will be infused intravenously over 30 minutes.
1729328|NCT00027560|Drug|melphalan|Melphalan will be administered intravenously over 30 minutes on each of two days from day -3 to day -2, inclusive. The dose for recipients of HLA-matched related grafts will be 50 mg/m2/day x 2. The dose for recipients of HLA-matched unrelated and HLA-single allele disparate related or unrelated marrow or PBSC transplants will be 70 mg/m2/day x 2.
1729329|NCT00027560|Procedure|allogeneic bone marrow transplantation|
1729330|NCT00027560|Procedure|peripheral blood stem cell transplantation|
1729331|NCT00027573|Biological|filgrastim|
1729332|NCT00027573|Biological|therapeutic allogeneic lymphocytes|
1729333|NCT00027573|Drug|cyclophosphamide|
1729334|NCT00027573|Drug|fludarabine phosphate|
1729335|NCT00027573|Drug|methotrexate|
1729336|NCT00027573|Drug|tacrolimus|
1729337|NCT00027573|Procedure|peripheral blood stem cell transplantation|
1729338|NCT00027586|Drug|Imatinib mesylate (STI571)|400 mg twice a day orally
1729339|NCT00027599|Biological|bevacizumab|
1729340|NCT00027599|Biological|prostatic acid phosphatase-sargramostim fusion protein|
1729341|NCT00027599|Biological|sipuleucel-T|
1729342|NCT00027599|Biological|therapeutic autologous dendritic cells|
1729343|NCT00027599|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1729344|NCT00027612|Drug|carmustine|IV
1729345|NCT00027612|Drug|irinotecan hydrochloride|IV
1729346|NCT00027612|Radiation|radiation therapy|
1729347|NCT00027625|Drug|gefitinib|
1729348|NCT00027625|Drug|temozolomide|
1729349|NCT00027638|Drug|thalidomide|
1729350|NCT00027664|Biological|recombinant interferon alfa|
1729351|NCT00027664|Drug|thalidomide|
1729352|NCT00027677|Drug|halofuginone hydrobromide|
1729353|NCT00027690|Drug|Gefitinib|Given orally
1729354|NCT00027690|Other|Laboratory Biomarker Analysis|Correlative studies
1729355|NCT00027703|Drug|gemcitabine hydrochloride|Given IV
1729356|NCT00027703|Drug|cisplatin|Given IV
1729357|NCT00027703|Biological|bevacizumab|Given IV
1729359|NCT00027703|Other|laboratory biomarker analysis|Correlative studies
1729360|NCT00027716|Drug|bortezomib|
1729361|NCT00027729|Biological|etaracizumab|
1729362|NCT00027742|Biological|pegylated interferon alfa|
1729363|NCT00027742|Drug|temozolomide|
1729364|NCT00027768|Procedure|adjuvant therapy|
1729365|NCT00027768|Radiation|iodine I 131 ethiodized oil|
1729366|NCT00027781|Drug|sabarubicin|
1729367|NCT00027794|Procedure|conventional surgery|
1729368|NCT00027807|Biological|Aldesleukin|Subcutaneous injections of IL-2 (3.0 × 105 IU/m2/day) starting 3 days before the 1st armed ATC infusion and ending 7 days after the last armed ATC infusion.
1729369|NCT00027807|Biological|Sargramostim|GM-CSF Injections will be given SQ GM-CSF (250 μg/m2/twice weekly), to start 3 days before the first ATC infusion and ending 1 week after the last ATC infusion.
1729370|NCT00027807|Biological|therapeutic autologous lymphocytes|The time for armed-ATC infusions will vary from patient to patient, but the dose of armed-ATC (up to 40 billion) will be given over 30 min.
1729371|NCT00027820|Drug|Fludarabine Phosphate|Given IV
1729372|NCT00027820|Radiation|Total-Body Irradiation|Undergo TBI
1729373|NCT00027820|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
1729374|NCT00027820|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative PBSCT
1729375|NCT00027820|Drug|Cyclosporine|Given PO
1729376|NCT00027820|Drug|Mycophenolate Mofetil|Given PO
1729377|NCT00027833|Biological|ALVAC-CEA-B7.1 vaccine|
1729378|NCT00027833|Biological|tetanus toxoid|
1729379|NCT00027833|Drug|FOLFIRI regimen|
1729380|NCT00027833|Drug|fluorouracil|
1729381|NCT00027833|Drug|irinotecan hydrochloride|
1729382|NCT00027833|Drug|leucovorin calcium|
1729383|NCT00027846|Biological|filgrastim|Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC >1500/μl given subcutaneously or intravenously.
1729384|NCT00027846|Drug|carboplatin|Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA <0.45m2 the dose is 12.5 mg/kg/day.
1729385|NCT00027846|Drug|cyclophosphamide|Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.
1729386|NCT00027846|Drug|etoposide|Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA < 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.
1729387|NCT00027846|Drug|vincristine sulfate|Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA<0.45m2 the dose is 0.05mg/kg.
1729388|NCT00027846|Radiation|radiation therapy|Given once daily 5 days a week for 6-6½ weeks
1729389|NCT00027846|Drug|Mesna|Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.
1729390|NCT00027846|Procedure|therapeutic conventional surgery|
1729391|NCT00027859|Drug|docetaxel|
1729392|NCT00027859|Drug|estramustine phosphate sodium|
1729393|NCT00027859|Drug|ketoconazole|
1729394|NCT00027859|Drug|therapeutic hydrocortisone|
1729395|NCT00027872|Drug|tipifarnib|Given orally
1729396|NCT00027872|Other|laboratory biomarker analysis|Correlative studies
1729397|NCT00027885|Biological|bevacizumab|Patients receive bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
1729398|NCT00027885|Drug|cyclophosphamide|Approximately 4 weeks after the completion of radiotherapy, patients receive cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
1729399|NCT00027885|Drug|docetaxel|Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6.
1729400|NCT00027885|Drug|doxorubicin hydrochloride|Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
1729401|NCT00027885|Procedure|adjuvant therapy|"After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery. Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
Approximately 4 weeks after the completion of radiotherapy, patients receive doxorubicin IV over 5 minutes and cyclophosphamide IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
1729402|NCT00027885|Procedure|conventional surgery|After the second course, patients with stable or responsive disease undergo modified radical mastectomy or breast-conserving surgery.
1729403|NCT00027885|Procedure|neoadjuvant therapy|"Arm I: Patients receive docetaxel IV over 1 hour once weekly on weeks 1-6 and bevacizumab IV over 60 minutes once every 2 weeks on weeks 1-8.
Arm II: Patients receive docetaxel as in arm I. Treatment in both arms repeats every 8 weeks for 2 courses in the absence of disease progression or unacceptable toxicity."
1729404|NCT00027885|Radiation|radiation therapy|Three to six weeks after surgery, patients undergo radiotherapy 5 days a week for 7 weeks.
1729405|NCT00027898|Drug|bortezomib|Given IV
1729406|NCT00027898|Drug|carboplatin|Given IV
1729407|NCT00027898|Drug|etoposide|Given IV
1729408|NCT00027898|Other|laboratory biomarker analysis|Correlative studies
1729409|NCT00027898|Other|pharmacological study|Correlative studies
1729410|NCT00027911|Biological|NY-ESO-1 peptide vaccine|
1729411|NCT00027911|Biological|sargramostim|
1729412|NCT00027924|Drug|busulfan|
1729413|NCT00027924|Drug|cyclosporine|
1729414|NCT00027924|Drug|fludarabine phosphate|
1729415|NCT00027924|Drug|methotrexate|
1729416|NCT00027924|Procedure|peripheral blood stem cell transplantation|
1729417|NCT00027937|Biological|aldesleukin|
1729418|NCT00027937|Biological|filgrastim|
1729419|NCT00027937|Biological|sargramostim|
1729420|NCT00027937|Drug|busulfan|
1729421|NCT00027937|Drug|cyclophosphamide|
1729425|NCT00027937|Procedure|bone marrow ablation with stem cell support|
1729426|NCT00027937|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1729427|NCT00027963|Drug|gabapentin|
1729428|NCT00027963|Other|placebo|
1729429|NCT00027976|Drug|celecoxib|
1729430|NCT00027976|Drug|Placebo|
1729431|NCT00027989|Drug|gemcitabine hydrochloride|
1729432|NCT00027989|Drug|pegylated liposomal doxorubicin hydrochloride|
1729433|NCT00028002|Drug|imatinib mesylate|Given orally
1729434|NCT00028002|Procedure|conventional surgery|Undergo surgical resection
1729435|NCT00028015|Drug|SarCNU|
1729436|NCT00028028|Drug|temsirolimus|Given IV
1729437|NCT00028028|Other|pharmacological study|Correlative studies
1729438|NCT00028028|Other|laboratory biomarker analysis|Correlative studies
1729439|NCT00028067|Drug|Atazanavir|
1729440|NCT00028067|Drug|Nelfinavir mesylate|
1729441|NCT00028093|Drug|Peginterferon alfa-2a with Ribavirin|Eligible patients were given peginterferon alpha-2a, 180 ug subcutaneous once weekly and weight-based oral ribavirin (1000 mg daily for patients <75 kg and 1200 mg daily for patients >=75 kg) for 48 weeks
1729442|NCT00028093|Drug|Peginterferon alfa-2a|Eligible patients were given peginterferon-alpha-2a, 180 ug subcutaneous once weekly for the first 4 weeks of therapy, after which peginterferon was continued at the same dose and weight-based oral ribavirin was added and continued for an additional 44 weeks.
1729443|NCT00028106|Drug|[131]I-MIBG|
1729444|NCT00028106|Drug|6-[18F]Fluorodopamine|
1729445|NCT00028106|Drug|[123]I-MIBG|
1729446|NCT00028132|Drug|Tenofovir|
1729447|NCT00028145|Behavioral|Adherence assessment|Adherence will be assessed using questionnaires at all study visits.
1729448|NCT00028158|Drug|G207, an oncolytic virus|
1729449|NCT00028171|Drug|Tacrolimus|
1729450|NCT00028236|Drug|Gene-Transduced Autologous CD34+ Stem Cells|
1729451|NCT00028262|Drug|Cystagon|
1729452|NCT00028275|Drug|Gamma Interferon 1b|
1729453|NCT00028288|Drug|Daclizumab|
1729454|NCT00028301|Drug|Atazanavir|
1729455|NCT00028301|Drug|Lopinavir/Ritonavir|
1729456|NCT00028314|Drug|Abacavir sulfate|
1729457|NCT00028314|Drug|Atazanavir/Ritonavir|
1729458|NCT00028314|Drug|Lopinavir/Ritonavir|
1729459|NCT00028314|Drug|Nevirapine|
1729460|NCT00028327|Drug|Lamivudine/Zidovudine|
1729461|NCT00028327|Drug|Nelfinavir mesylate|
1729462|NCT00028327|Drug|Efavirenz|
1729463|NCT00028327|Drug|Lamivudine|
1729464|NCT00028327|Drug|Zidovudine|
1729465|NCT00028353|Drug|GTX-006 (Acapodene)|
1729466|NCT00028366|Drug|Fosamprenavir|
1729467|NCT00028366|Drug|Lopinavir/Ritonavir|
1729468|NCT00028366|Drug|Ritonavir|
1729469|NCT00028366|Drug|Tenofovir disoproxil fumarate|
1729470|NCT00028379|Procedure|Transcranial magnetic stimulation (TMS)|
1729471|NCT00028405|Drug|LS 11(Taporfin Sodium)|
1729472|NCT00028405|Device|Lumaflex Light Delivery Catheter|
1729473|NCT00028418|Drug|Clofarabine|
1729474|NCT00028431|Biological|MDX-CTLA4 Antibody; Tyrosinase/gp100/MART-1 Peptides Melanoma Vaccine|
1729475|NCT00028483|Drug|cBR96-doxorubicin immunoconjugate|
1729476|NCT00028483|Drug|docetaxel|
1729477|NCT00028496|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
1729478|NCT00028496|Biological|sargramostim|Given subcutaneously
1729479|NCT00028496|Biological|recombinant fowlpox GM-CSF vaccine adjuvant|Given intradermally
1729480|NCT00028509|Procedure|management of therapy complications|
1729481|NCT00028522|Drug|R(+)XK469|Given IV
1729482|NCT00028535|Biological|trastuzumab|Given IV
1729483|NCT00028535|Drug|paclitaxel|Given IV
1729484|NCT00028535|Biological|recombinant interleukin-12|Given SC
1729485|NCT00028548|Drug|R(+)XK469|
1729486|NCT00028561|Drug|ixabepilone|Given IV
1729487|NCT00028561|Drug|carboplatin|Given IV
1729488|NCT00028561|Other|laboratory biomarker analysis|Correlative studies
1729489|NCT00028561|Other|pharmacological study|Correlative studies
1729490|NCT00028574|Drug|gabapentin|
1729491|NCT00028574|Other|placebo|
1729492|NCT00028587|Drug|bortezomib|Given IV
1729493|NCT00028587|Drug|paclitaxel|Given IV
1729494|NCT00028587|Drug|carboplatin|Given IV
1729495|NCT00028587|Other|laboratory biomarker analysis|Optional correlative studies
1729496|NCT00028600|Biological|filgrastim|PBSC collection: 10 ug/kg/d subQ inj D 5 until completion of collection Auto transpl: 5 ug/kg/d subQ inj D 5 until ANC >= 1500/uL for 2d or 5000/uL for 1 d Allo transpl: 5ug/kg/d subQ inj D 7 until ANC > 1000/uL for 3 days Donor pheresis: 10ug/kg/d subQ inj d -5 thru -2
1729497|NCT00028600|Biological|CD34+ cells|2-8,000,000/kg IV infusion allogeneic transplant 2,000,000/kg IV infusion autologous transplant
1729498|NCT00028600|Drug|cyclophosphamide|4g/sq m IV infusion over 1-2 hrs D 1 for auto, and 1g/sq m/d IV infusion over 1 hr on D -4 thru -3 for allo, transplant prep
1729499|NCT00028600|Drug|fludarabine phosphate|30mg/sq m/d IVPB over 30 min d -7 thru -3 allo transpl
1729500|NCT00028600|Drug|melphalan|200mg/sq m IV infusion over 15-30 min D 2 auto transpl
1729501|NCT00028600|Drug|methotrexate|5mg/sq m/d IV infusion D 1,3,& 6: allo transpl
1729502|NCT00028600|Drug|tacrolimus|0.03mg/kg PO bid starting dose, D -1 thru +90, then taper thru D +150
1729503|NCT00028613|Radiation|iodine I 131 monoclonal antibody Lym-1|
1729504|NCT00028626|Drug|embolization therapy|
1729505|NCT00028639|Drug|bortezomib|
1729506|NCT00028652|Biological|interleukin-12 gene|
1729507|NCT00028665|Biological|filgrastim|Beginning 36-48 hours after the completion of cyclophosphamide, patients receive filgrastim (G-CSF) subcutaneously (SC) daily until blood counts recover. Patients receive G-CSF SC daily beginning 4 hours after completion of PBSC infusion and continuing until neutrophil engraftment.
1729508|NCT00028665|Biological|rituximab|rituximab IV over 2-5 hours on days 1, 8, and 15
1729509|NCT00028665|Drug|carmustine|After completion of PBSC collection, patients receive high-dose chemotherapy comprising carmustine IV on days -7 to -3
1729510|NCT00028665|Drug|cisplatin|After completion of PBSC collection, cisplatin IV for 3 days during days -7 to -3.
1729511|NCT00028665|Drug|cyclophosphamide|cyclophosphamide IV over 3-6 hours on day 16.
1729512|NCT00028665|Drug|etoposide|After completion of PBSC collection, etoposide IV for 3 days during days -7 to -3.
1729513|NCT00028665|Procedure|bone marrow ablation with stem cell support|Patients then undergo peripheral blood stem cell (PBSC) collection.
1729514|NCT00028665|Procedure|peripheral blood stem cell transplantation|Arm I: Patients receive unmanipulated PBSCs on day 0. Arm II: Patients receive CD34 cell-enriched PBSC on day 0.
1729515|NCT00028665|Radiation|radiation therapy|Patients may undergo involved-field radiotherapy to active or previously bulky (more than 5 cm) tumors daily for 7-10 days.
1729516|NCT00028678|Drug|dalteparin|
1729517|NCT00028678|Radiation|radiation therapy|
1729518|NCT00028691|Drug|chlorambucil|
1729519|NCT00028691|Radiation|radiation therapy|
1729520|NCT00028704|Procedure|conventional surgery|
1729521|NCT00028704|Radiation|radiation therapy|
1729522|NCT00028717|Biological|filgrastim|
1729523|NCT00028717|Biological|rituximab|
1729524|NCT00028717|Drug|cyclophosphamide|
1729525|NCT00028717|Drug|doxorubicin hydrochloride|
1729526|NCT00028717|Drug|prednisone|
1729527|NCT00028717|Drug|vincristine sulfate|
1729528|NCT00028730|Biological|anti-thymocyte globulin|
1729529|NCT00028730|Biological|filgrastim|
1729530|NCT00028730|Drug|cyclophosphamide|
1729531|NCT00028730|Drug|fludarabine phosphate|
1729532|NCT00028730|Drug|thiotepa|
1729533|NCT00028730|Procedure|allogeneic bone marrow transplantation|
1729534|NCT00028730|Radiation|radiation therapy|
1729535|NCT00028743|Drug|carboplatin|Arm 1 = 4 cycles vs Arm 2 = 8 cycles AUC5 (30 mins) day 1 of 21 day cycle
1729536|NCT00028743|Drug|cisplatin|4 cycles 50mg/m2 (60 mins) day 1 of 21 day cycle
1729537|NCT00028743|Drug|paclitaxel|Arm 1 = 4 cycles vs Arm 2 = 8 cycles 175mg/m2 (3 hours) day 1 of 21 day cycle
1729538|NCT00028743|Drug|topotecan hydrochloride|"4 cycles
.75mg/m2 (30 mins) days 1-5 of 21 day cycle"
1729539|NCT00028756|Drug|doxorubicin hydrochloride|Given IV
1729540|NCT00028756|Drug|gemcitabine hydrochloride|Given IV
1729541|NCT00028756|Drug|vinblastine sulfate|Given IV
1729542|NCT00028756|Drug|methotrexate|Given IV
1729543|NCT00028756|Drug|cisplatin|Given IV
1729544|NCT00028756|Biological|filgrastim|Given SC
1729545|NCT00028769|Drug|bicalutamide|
1729546|NCT00028769|Drug|estramustine|
1729547|NCT00028769|Drug|etoposide|
1729548|NCT00028769|Drug|flutamide|
1729549|NCT00028769|Drug|goserelin|
1729550|NCT00028769|Drug|leuprolide|
1729551|NCT00028769|Drug|nilutamide|
1729552|NCT00028769|Drug|paclitaxel|
1729553|NCT00028782|Drug|etanidazole|Given IV
1729554|NCT00028782|Procedure|therapeutic conventional surgery|Undergo surgery
1729555|NCT00028782|Other|laboratory biomarker analysis|Correlative studies
1729556|NCT00028795|Drug|temozolomide|
1729557|NCT00028795|Procedure|adjuvant therapy|
1729558|NCT00028795|Radiation|radiation therapy|
1729559|NCT00028821|Drug|2-methoxyestradiol|Given orally
1729560|NCT00028821|Other|pharmacological study|Correlative studies
1729561|NCT00028821|Other|laboratory biomarker analysis|Correlative studies
1729562|NCT00028834|Drug|gemcitabine hydrochloride|Given IV
1729563|NCT00028834|Biological|bevacizumab|Given IV
1729564|NCT00028834|Other|laboratory biomarker analysis|Correlative studies
1729565|NCT00028847|Drug|cytarabine|
1729566|NCT00028847|Drug|imatinib mesylate|
1729567|NCT00028860|Biological|filgrastim|
1729568|NCT00028860|Drug|carboplatin|
1729569|NCT00028860|Drug|gemcitabine hydrochloride|
1729570|NCT00028860|Drug|ifosfamide|
1729571|NCT00028860|Drug|paclitaxel|
1729572|NCT00028860|Procedure|adjuvant therapy|
1729573|NCT00028873|Drug|docetaxel|
1729574|NCT00028873|Drug|laniquidar|
1729575|NCT00028873|Drug|paclitaxel|
1729576|NCT00028886|Biological|filgrastim|
1729577|NCT00028886|Biological|recombinant interferon alfa|
1729578|NCT00028886|Drug|cyclophosphamide|
1729579|NCT00028886|Drug|dexamethasone|
1729580|NCT00028886|Drug|doxorubicin hydrochloride|
1729581|NCT00028886|Drug|melphalan|
1729582|NCT00028886|Drug|thalidomide|
1729583|NCT00028886|Drug|vincristine sulfate|
1729584|NCT00028886|Procedure|bone marrow ablation with stem cell support|
1729585|NCT00028886|Procedure|peripheral blood stem cell transplantation|
1729586|NCT00028899|Drug|asparaginase|
1729587|NCT00028899|Drug|cytarabine|
1729588|NCT00028899|Drug|gemtuzumab ozogamicin|
1729589|NCT00028899|Drug|mitoxantrone hydrochloride|
1729590|NCT00028912|Drug|bortezomib|
1729591|NCT00028912|Drug|carboplatin|
1729592|NCT00028925|Biological|filgrastim|
1729593|NCT00028925|Drug|carboplatin|
1729594|NCT00028925|Drug|topotecan hydrochloride|
1729595|NCT00028925|Radiation|WBRT|
1729596|NCT00028938|Biological|epoetin alfa|
1729597|NCT00028938|Drug|carboplatin|
1729598|NCT00028938|Drug|paclitaxel|
1729599|NCT00028938|Radiation|radiation therapy|
1729600|NCT00028951|Drug|fibrin sealant|
1729601|NCT00028951|Procedure|surgical wound closure|
1729602|NCT00028964|Dietary Supplement|Chinese herbs|
1729603|NCT00028964|Drug|cyclophosphamide|
1729604|NCT00028964|Drug|doxorubicin hydrochloride|
1729605|NCT00028964|Procedure|adjuvant therapy|
1729606|NCT00028977|Drug|herba scutellaria barbata|
1729607|NCT00028977|Other|herba scutellaria Barbatae (HSB)|
1729608|NCT00028990|Drug|bevacizumab|10 mg/kg following paclitaxel treatment on weeks 1 and 3 of every 4-week cycle
1729609|NCT00028990|Drug|Paclitaxel|90 mg/m2 IV infusion over 1 hour every week for 3 weeks followed by 1 week rest
1729610|NCT00029003|Drug|gefitinib|Given orally
1729611|NCT00029003|Other|laboratory biomarker analysis|Correlative studies
1729612|NCT00029029|Procedure|pain therapy|
1729613|NCT00029029|Procedure|radiofrequency ablation|
1729614|NCT00029042|Drug|Infliximab|
1729615|NCT00029107|Drug|Rituximab|anti-CD20 monoclonal antibody
1729616|NCT00029133|Procedure|mild intraoperative hypothermia (33 degrees Celsius)|
1729617|NCT00029146|Procedure|extracranial-intracranial bypass surgery|Surgical anastomosis of a superficial temporal artery branch to a middle cerebral artery branch through a small craniectomy plus best current practice medical therapy
1729618|NCT00029146|Drug|best medical therapy|best current practice medical therapy
1729619|NCT00029159|Drug|estrogen|Participants were started on ethinyl estradiol at a daily dose of 50ng/kg at the beginning of the 3rd year of the study. The estrogen was continued until study end.
1729620|NCT00029159|Drug|androgen|Oxandrolone or placebo capsule, .06mg/kg/day, orally, for 2 years
1729621|NCT00029159|Other|placebo|an inactive substance
1729622|NCT00029172|Other|case management|
1729623|NCT00029185|Drug|Dehydrex|
1729624|NCT00029198|Procedure|massage|15 massage given tid
1729625|NCT00029198|Procedure|Sham massage|non-massage touch
1729626|NCT00029211|Drug|Echinacea|
1729627|NCT00029224|Drug|zoledronic acid|
1729628|NCT00029237|Behavioral|Cognitive-behavioral relaxation (Positively Living)|
1729629|NCT00029237|Behavioral|Spiritual growth group|
1729630|NCT00029237|Behavioral|Focused Tai Chi|
1729631|NCT00029250|Drug|Garlic powder standardized to allicin|
1729632|NCT00029263|Drug|herbals|
1729633|NCT00029276|Procedure|Prefrontal transcranial magnetic brain stimulation|
1729634|NCT00029289|Drug|Lutein (10 or 30 mg/day) capsules|
1729635|NCT00029315|Drug|Recombinant Tissue Plasminogen Activator (rt-PA)|
1729636|NCT00029328|Drug|etanercept|
1729637|NCT00029341|Behavioral|Treatment Interruption|
1729638|NCT00029380|Drug|Sangstat|
1729639|NCT00029380|Drug|Cyclophosphamide|
1729640|NCT00029380|Drug|Busulfan|
1729641|NCT00029380|Drug|Mycophenolate Mofetil|
1729642|NCT00029380|Drug|Cyclosporine|
1729643|NCT00029380|Procedure|Cord Blood Transplantation|
1729644|NCT00029393|Procedure|Hematopoietic Stem Cell Transplantation|
1729645|NCT00029393|Drug|Immunosuppression|
1729646|NCT00029458|Drug|Clozapine|
1729647|NCT00029484|Behavioral|Tai chi chih|
1729648|NCT00029497|Procedure|Acupuncture|
1729649|NCT00029497|Drug|Amitriptyline|
1729650|NCT00029510|Drug|Magnesium|
1729651|NCT00029523|Drug|Intrathecal (injected into the spinal fluid) DepoCyt|
1729652|NCT00029523|Drug|Intrathecal methotrexate|
1729653|NCT00029523|Drug|Intrathecal cytarabine (also known as ara-C)|
1729654|NCT00029536|Biological|Progesterone Lozenges|200mg Progesterone Lozenges
1729655|NCT00029536|Other|Matched Placebo Lozenges|Matched Placebo Lozenges
1729656|NCT00029575|Device|Surgi-Vision Guidewire Coil|
1729657|NCT00029614|Drug|Atomoxetine|
1729658|NCT00029627|Drug|Yohimbine|
1729659|NCT00029666|Device|Neopulse Magnetic Stimulator|
1729660|NCT00029679|Drug|Gingko biloba|
1729661|NCT00029679|Drug|Borage oil|
1729662|NCT00029692|Drug|Ginseng|
1729663|NCT00029692|Drug|Ginkgo|
1729664|NCT00029731|Drug|Arginine hydrochloride|
1729665|NCT00029757|Drug|Estrogen|
1729666|NCT00029770|Procedure|Chiropractic spinal manipulation|
1729667|NCT00029770|Drug|Acetaminophen|
1729668|NCT00029770|Behavioral|Self-care|
1729669|NCT00029770|Drug|Non-Steroidal anti-inflammatory drugs (NSAIDS)|
1729670|NCT00029770|Drug|Tylenol with codeine|
1729671|NCT00029783|Procedure|Distant Healing|
1729672|NCT00029796|Drug|soy isoflavones|
1729673|NCT00029809|Behavioral|Chinese exercise modalities|
1729674|NCT00029822|Drug|Alfuzosin (SL770499)|
1729675|NCT00029835|Drug|Rimonabant (SR141716)|
1729676|NCT00029848|Drug|Rimonabant (SR141716)|
1729677|NCT00029861|Drug|Rimonabant (SR141716)|
1729678|NCT00029874|Drug|Minocycline|
1729679|NCT00029900|Drug|ADI PEG|
1729680|NCT00029913|Other|Observation|Observation of participants who received HIV preventive vaccine and became infected.
1729681|NCT00029926|Drug|2-deoxy-2 [F-18] fluoro-2-d-glucose|
1729682|NCT00029991|Drug|Gingko Biloba (Herb)|
1729683|NCT00030004|Procedure|spinal manipulation|
1729684|NCT00030004|Drug|midazolam|
1729685|NCT00030030|Drug|Silymarin (milk thistle)|
1729686|NCT00030043|Device|Penetrating auditory brainstem implant|
1729687|NCT00022568|Biological|recombinant vaccinia-TRICOM vaccine|
1729688|NCT00022581|Drug|thalidomide|Given orally
1729689|NCT00022581|Other|laboratory biomarker analysis|Correlative studies
1729690|NCT00022594|Drug|liposomal lurtotecan|
1729691|NCT00022607|Biological|bevacizumab|
1729692|NCT00022607|Drug|thalidomide|
1729693|NCT00022620|Drug|paclitaxel|
1729694|NCT00022633|Drug|gemcitabine hydrochloride|
1729695|NCT00022633|Drug|paclitaxel|
1729696|NCT00030056|Drug|GM-CSF (granulocyte-macrophage colony-stimulating factor, sargramostim)|
1729697|NCT00030069|Drug|Calcitriol|
1729698|NCT00030069|Drug|Dexamethasone|
1729699|NCT00030082|Drug|isolated perfusion|
1729700|NCT00030082|Drug|melphalan|
1729701|NCT00030095|Drug|2-methoxyestradiol|
1729702|NCT00030108|Drug|ixabepilone|
1729703|NCT00030121|Drug|recombinant human atrial natriuretic polypeptide|
1729704|NCT00030147|Drug|Raloxifene|60 mg a day orally administered
1729705|NCT00030147|Drug|Rimostil|1000 mg twice a day administered orally
1729706|NCT00030147|Drug|Transdermal Estradiol|100 microgram per day transdermal estradiol
1729707|NCT00030147|Drug|Placebo skin patch and placebo tablets|matched placebo skin patch to transdermal estradiol and matched tablets to either Raloxifene or Rimostil
1729708|NCT00030160|Behavioral|Strength Training|
1729709|NCT00030173|Drug|Epothilone D (KOS-862)|
1729710|NCT00030186|Drug|CEP-701 60mg|60mg orally 2 times a day for 28 days
1729711|NCT00030186|Drug|Cep-701 80mg|80mg 2 times a day, dependent upon response to cycle 1
1729712|NCT00030186|Drug|Cep-701 40mg|40mg 2 times a day, dependent upon response to cycle 1
1729713|NCT00030225|Biological|ELAD|
1729714|NCT00030225|Other|Standard of care (Control)|
1729715|NCT00030238|Drug|Calcium supplement|Calcium Carbonate capsules prepared by NIH PDS
1729716|NCT00030238|Drug|Placebo|Placebo capsules prepared by the NIH PDS to be identical to Calcium Carbonate capsules
1729717|NCT00030264|Drug|Methotrexate|Methotrexate will be given at a dose of 30mg/m2/week intramuscular (IM) or intravenous (IV) for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first)
1729718|NCT00030264|Drug|Vinblastine|Vinblastine will be given at a dose of 6mg/m2/week intravenous (IV) for for the first 26 weeks, then every 2 weeks for the next 26 weeks or until disease progression (whichever occurs first). Maximum actual dose may not exceed 10mg.
1729719|NCT00030277|Procedure|high-intensity focused ultrasound ablation|
1729720|NCT00030290|Procedure|high-intensity focused ultrasound ablation|
1729721|NCT00030303|Biological|recombinant 70-kD heat-shock protein|
1729722|NCT00030342|Biological|recombinant interferon alfa|
1729723|NCT00030342|Biological|sargramostim|
1729724|NCT00030342|Biological|therapeutic autologous lymphocytes|
1729725|NCT00030342|Drug|fluorouracil|
1729726|NCT00030355|Drug|homoharringtonine|
1729727|NCT00030355|Procedure|chemotherapy|
1729728|NCT00030368|Drug|bortezomib|Given IV
1729729|NCT00030368|Drug|paclitaxel|Given IV
1729730|NCT00030368|Other|laboratory biomarker analysis|Correlative studies
1729731|NCT00030381|Drug|4'-iodo-4'-deoxydoxorubicin|Given IV
1729732|NCT00030381|Other|pharmacological study|Correlative studies
1729733|NCT00030394|Drug|imatinib mesylate|Given orally
1729734|NCT00030394|Other|laboratory biomarker analysis|Correlative studies
1729735|NCT00030394|Other|pharmacological study|Correlative studies
1729736|NCT00030407|Drug|Celecoxib|On day -7 of the first cycle, patients will start, Celecoxib 400 mg po bid daily, each dose to give with meals
1729737|NCT00030407|Drug|Docetaxel|On day 1, 8, and 15 of each cycle patients will receive: Docetaxel 36mg/m2 over 60 minutes, duration of each cycle will be 28 days.
1729738|NCT00030420|Drug|Celecoxib|400mg by mouth, twice a day, each dose given with meals, to start -7 days prior to first cycle of treatment.
1729739|NCT00030420|Drug|Docetaxel|On day 1, 75mg/m2 IV over 60 minutes, repeated every 21 days
1729740|NCT00031811|Drug|raloxifene|
1729741|NCT00031811|Procedure|quality-of-life assessment|
1729742|NCT00031824|Drug|cyclosporine|
1729743|NCT00031824|Drug|hydroxychloroquine|
1729744|NCT00031824|Drug|prednisone|
1729745|NCT00031824|Drug|tacrolimus|
1729746|NCT00031837|Drug|dalteparin|
1729747|NCT00031837|Drug|gemcitabine hydrochloride|
1729748|NCT00031837|Procedure|quality-of-life assessment|
1729749|NCT00031850|Drug|goserelin acetate|
1729750|NCT00031850|Drug|raloxifene|
1729751|NCT00031863|Drug|rofecoxib|
1729752|NCT00031863|Procedure|adjuvant therapy|
1729753|NCT00031876|Drug|capecitabine|
1729754|NCT00031876|Drug|paclitaxel|
1729755|NCT00031889|Drug|Exemestane|Exemestane
1729756|NCT00031889|Drug|Exemestane+bicalutamide|Exemestane as in arm I and oral bicalutamide once daily
1729757|NCT00031902|Biological|bleomycin sulfate|
1729758|NCT00031902|Biological|rituximab|
1729759|NCT00031902|Drug|prednisolone|
1729760|NCT00031902|Drug|vincristine sulfate|
1729761|NCT00031915|Drug|imatinib mesylate|
1729762|NCT00031928|Drug|mafosfamide|
1729763|NCT00031941|Drug|lenalidomide|
1729764|NCT00031954|Drug|carboplatin|
1729765|NCT00031954|Drug|gemcitabine hydrochloride|
1729766|NCT00031954|Drug|paclitaxel|
1729767|NCT00031967|Drug|therapeutic melatonin|
1729768|NCT00031967|Radiation|radiation therapy|
1729769|NCT00031980|Drug|cyclosporine|
1729770|NCT00031993|Drug|erlotinib hydrochloride|Given PO
1729771|NCT00031993|Other|laboratory biomarker analysis|Correlative studies
1729772|NCT00032006|Radiation|brachytherapy|
1729773|NCT00032006|Radiation|radiation therapy|
1729774|NCT00032019|Biological|filgrastim|Cycle 1: 300 ug (BW < = 70 kg) or 480ug (BW >70 kg) sub Q injection Day 6 until ANC > 5000/uL after nadir counts Subsequent cycle dosages based on previous cycle toxicity or Day 1 Tx toxicity
1729775|NCT00032019|Biological|rituximab|375 mg/sq m IV infusion Day 1 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 of tx toxicities
1729776|NCT00032019|Drug|cyclophosphamide|750 mg/sq m IV infusion on Day 5 Cycle 1 Subsequent cycle dosage based on previous cycle or day 1 treatment toxicities
1729777|NCT00032019|Drug|doxorubicin hydrochloride|10 mg/sq m/day continuous IV infusion on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and Day 1 treatment toxicities
1729778|NCT00032019|Drug|etoposide|50 mg/sq m/day continuous IV infusion Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
1729779|NCT00032019|Drug|prednisone|60 mg/sq m PO bid days 1-5 of ea cycle
1729780|NCT00032019|Drug|vincristine sulfate|0.4 mg/sq m/day continuous IV infusion uncapped on Days 1-4 Cycle 1 Subsequent cycle dosages based on previous cycle and day 1 of treatment toxicities
1729781|NCT00032032|Drug|carboplatin|
1729782|NCT00032032|Drug|paclitaxel|
1729783|NCT00032032|Radiation|radiation therapy|
1729784|NCT00032045|Biological|gp100 antigen|
1729785|NCT00032045|Biological|incomplete Freund's adjuvant|
1729786|NCT00032045|Biological|ipilimumab|
1729787|NCT00032058|Procedure|magnetic resonance imaging|
1729788|NCT00032058|Procedure|magnetic resonance spectroscopic imaging|
1729789|NCT00032084|Behavioral|smoking cessation intervention|Physician will deliver the smoking cessation advice, reinforce the established quit date (no sooner than seven days after starting bupropion/placebo), and will distribute patient educational materials and all pharmacotherapy
1729790|NCT00032084|Drug|bupropion hydrochloride|150 mg/day on Days 1-3, 300 mg/day on Day 4-77
1729791|NCT00032084|Drug|nicotine|21 mg patch/day for Weeks 2-7; 14 mg patch/day for Weeks 8-9; 7 mg patch/day for Weeks 10-11.
1729792|NCT00032084|Procedure|psychosocial assessment and care|The nurse/CRA will debrief the patients after the brief physician intervention and will follow-up with a series of 5 phone calls to provide booster advice. All advice will be based on the stage of change model (i.e., tailored to the patient's readiness to quit and/or stay off cigarettes).
1729793|NCT00032097|Drug|motexafin gadolinium|
1729794|NCT00032097|Radiation|radiation therapy|
1729795|NCT00032110|Drug|erlotinib hydrochloride|Given orally
1729796|NCT00032110|Other|pharmacological study|Correlative studies
1729797|NCT00032110|Other|laboratory biomarker analysis|Correlative studies
1729798|NCT00032123|Drug|erlotinib hydrochloride|
1729799|NCT00032136|Drug|exemestane|
1729800|NCT00032136|Drug|tamoxifen citrate|
1729801|NCT00032136|Procedure|adjuvant therapy|
1729802|NCT00032149|Biological|bleomycin sulfate|
1729803|NCT00032149|Biological|filgrastim|
1729804|NCT00032149|Drug|cyclophosphamide|
1729805|NCT00032149|Drug|etoposide|
1729806|NCT00032149|Drug|mitoxantrone hydrochloride|
1729807|NCT00032149|Drug|prednisolone|
1729808|NCT00032149|Drug|vincristine sulfate|
1729809|NCT00032162|Drug|carboplatin|AUC 6 q4w
1729810|NCT00032162|Drug|pegylated liposomal doxorubicin hydrochloride|20/30/40 mg/qm q4w Dose finding study
1729811|NCT00032175|Drug|capecitabine|
1729812|NCT00032175|Drug|gemcitabine hydrochloride|
1729813|NCT00032188|Biological|aldesleukin|Given subcutaneously
1729814|NCT00032188|Drug|bryostatin 1|Given IV
1729815|NCT00032188|Other|laboratory biomarker analysis|Correlative studies
1729816|NCT00032227|Procedure|Early Carpal Tunnel Release for Mild or Moderate CTS|Either open or endoscopic surgery
1729817|NCT00032227|Other|MR Nerve Imaging for CTS|New diagnostic test for CTS to directly image the median nerve
1729818|NCT00032240|Device|Shoe Insert|
1729819|NCT00032279|Drug|Visilizumab|
1729820|NCT00032292|Drug|Visilizumab|
1729821|NCT00032305|Drug|Visilizumab|
1729822|NCT00032331|Procedure|PET Imaging|
1729823|NCT00032331|Procedure|CT scan|
1729824|NCT00032344|Procedure|Colonoscopy|Phase I - Cross-sectional; Phase II - 5 year follow-up; Phase III - 10 year follow-up
1729825|NCT00032357|Procedure|Ferritin reduction to 25 ng/ml by phlebotomy|
1729826|NCT00032370|Procedure|Vascular surgery with best medical treatment|Patients undergo scheduled vascular surgery
1729827|NCT00032370|Procedure|Coronary artery bypass grafting (CABG)|Coronary artery bypass grafting prior to vascular surgery
1729828|NCT00032370|Procedure|Percutaneous transluminal coronary angioplasty (PTCA)|Cardiac revascularization via PTCA prior to vascular surgery
1729829|NCT00032383|Behavioral|Tai Chi|
1729830|NCT00032396|Drug|Retisert Implant|
1729831|NCT00032409|Behavioral|Music therapy-based relaxation/stress reduction|
1729832|NCT00032422|Procedure|Acupuncture|
1729833|NCT00032435|Drug|PAL-40 Active|
1729834|NCT00032435|Drug|PAL-40 Placebo|
1729835|NCT00032448|Procedure|Standardized tension-free herniorrhaphy with prosthesis|Compare the effect of two typs of operative treatment of inguinal hernia.
1729836|NCT00032474|Drug|Ginkgo biloba extract|
1729837|NCT00032487|Drug|Insulin|Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs Arm 1 Insulin (intermediate or long-lasting) in a.m. 1 unit 9 lbs, add one injection of insulin Arm 2
1729838|NCT00032487|Drug|Glimepiride|Glimepiride 2 mg Arm 1 Glimepiride 8 mg Arm 2
1729839|NCT00032487|Drug|Rosiglitazone|Rosiglitazone 4 mg Arm 1 Rosiglitazone 4 mg bid Arm 2
1729840|NCT00032487|Drug|Metformin|Metformin 500 mg (go up to 1000 mg) Arm 1 Metformin 500 mg (go up to 2000 mg) Arm
1729841|NCT00032500|Drug|Echinacea|
1729842|NCT00032526|Drug|Corticosteroids|
1729843|NCT00032526|Behavioral|Classical conditioning to corticosteroid|
1729844|NCT00032591|Procedure|Weekly patient self-testing of prothrombin time|
1729845|NCT00032591|Other|High quality anticoagulation management (HQACM) with conventional monthly testing|HQACM with testing every 4 weeks and as indicated for out of range values, medication/clinical changes.
1729846|NCT00032617|Procedure|Prolonged Exposure|trauma-focused exposure therapy
1729847|NCT00032617|Procedure|Present Centered Therapy|therapy that focuses on current problems
1729848|NCT00032630|Procedure|Coronary artery bypass - on-pump|CABG procedure performed on heart lung machine
1729849|NCT00032630|Procedure|Coronary artery bypass - off-pump|CABG procedure performed without the use of the heart lung machine
1729850|NCT00032643|Drug|DITPA|
1729851|NCT00032669|Drug|HAART|
1729852|NCT00032695|Drug|methionine|
1729853|NCT00032708|Biological|Dryvax|
1729854|NCT00032721|Procedure|Reiki; Subtle energy therapy|
1729855|NCT00032734|Drug|satavaptan (SR121463B)|
1729856|NCT00032747|Drug|Vasopressin V2 Receptor Antagonist|
1729857|NCT00032760|Behavioral|Meditation|
1729858|NCT00032773|Drug|pentostatin for injection|
1729859|NCT00032786|Drug|natalizumab|
1729860|NCT00032799|Drug|natalizumab|
1729861|NCT00032812|Drug|Raclopride|
1729862|NCT00032825|Drug|Ketaconazole|
1729863|NCT00032825|Drug|Docetaxel|
1729864|NCT00032838|Drug|Yohimbine|
1729865|NCT00032890|Drug|glucosamine|
1729866|NCT00032890|Drug|chondroitin sulfate|
1729867|NCT00032890|Drug|glucosamine and chondroitin sulfate combined|
1729868|NCT00032890|Drug|celecoxib|
1729869|NCT00032903|Drug|Gimatecan® (ST 1481)|
1729870|NCT00032916|Drug|NS2359|
1729871|NCT00032929|Drug|Selegiline|
1729872|NCT00032942|Drug|Lofexidine|
1729873|NCT00032955|Drug|Buprenorphine/naloxone|
1729874|NCT00032968|Drug|Buprenorphine/naloxone|
1729875|NCT00032981|Behavioral|Behavior Therapy|
1729876|NCT00032994|Behavioral|Behavior Therapy|
1729877|NCT00033007|Behavioral|Behavior Therapy|
1729878|NCT00033020|Behavioral|Behavior Therapy|
1729879|NCT00033033|Drug|Reserpine|
1729880|NCT00033046|Drug|Modafinil|
1729881|NCT00033059|Drug|Tolcapone|
1729882|NCT00033072|Drug|Selegiline|
1729883|NCT00033085|Drug|Ondansetron|
1729884|NCT00033098|Drug|Metyrapone|
1729885|NCT00033111|Drug|Cabergoline|
1729886|NCT00033111|Drug|Placebo|sugar pill manufactured to mimic cabergoline 05mg tablet
1729887|NCT00033124|Behavioral|Behavior Therapy|
1729888|NCT00033150|Behavioral|Fast ForWord|
1729889|NCT00033150|Behavioral|Computer Assisted Language Intervention|
1729890|NCT00033150|Behavioral|Individual Language Intervention|
1729891|NCT00033150|Behavioral|Academic enrichment|
1729892|NCT00033163|Drug|Adefovir dipivoxil|
1729893|NCT00033163|Drug|Tenofovir disoproxil fumarate|
1729894|NCT00033176|Drug|Alpha Lipoic Acid|
1729895|NCT00033189|Drug|Coenzyme Q10|
1729896|NCT00033202|Drug|Gimatecan® (ST-1481)|
1729897|NCT00033215|Drug|S-3304|
1729898|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 500 ug
1729899|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1000 ug
1729900|NCT00033228|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, 1500 ug
1729901|NCT00033241|Drug|erlotinib hydrochloride|
1729902|NCT00033241|Drug|gemcitabine hydrochloride|
1729903|NCT00033254|Radiation|radiation therapy|Undergo conventional radiation therapy
1729904|NCT00033254|Drug|thalidomide|Given orally
1729905|NCT00033254|Procedure|quality-of-life assessment|Ancillary studies
1729906|NCT00033267|Drug|temsirolimus|Given IV
1729907|NCT00033280|Drug|temozolomide|
1729908|NCT00033280|Procedure|neoadjuvant therapy|
1729909|NCT00033280|Radiation|radiation therapy|
1729910|NCT00033293|Biological|therapeutic immune globulin|Given IV
1729911|NCT00033293|Other|clinical observation|Undergo observation
1729912|NCT00033293|Drug|cyclophosphamide|Given IV
1729913|NCT00033293|Drug|prednisone|Given orally
1729914|NCT00033293|Procedure|magnetic resonance imaging|Correlative studies
1729915|NCT00033293|Other|laboratory biomarker analysis|Correlative studies
1729916|NCT00033293|Drug|Corticotropin-Releasing Hormone|administered subcutaneously
1729917|NCT00033306|Drug|ixabepilone|
1729918|NCT00033306|Drug|Fluoropyrimidine|
1729919|NCT00033306|Drug|Irinotecan|
1729920|NCT00033319|Dietary Supplement|folic acid|
1729921|NCT00033319|Drug|acetylsalicylic acid|
1729922|NCT00033332|Drug|dexamethasone|
1729923|NCT00033332|Drug|pamidronate disodium|
1729924|NCT00033332|Drug|thalidomide|
1729925|NCT00033332|Drug|zoledronic acid|
1729926|NCT00033345|Drug|Indole-3-carbinol|400 mg pill taken daily
1729927|NCT00033345|Drug|Indole-3-carbinol|800 mg pill taken daily
1729928|NCT00033345|Other|Placebo|Placebo pill taken daily during run-in period
1729929|NCT00033358|Drug|medroxyprogesterone|Given intramuscularly
1729930|NCT00033358|Drug|ethinyl estradiol|Given orally
1729931|NCT00033358|Drug|norgestrel|Given orally
1729932|NCT00033358|Other|laboratory biomarker analysis|Correlative studies
1729933|NCT00033371|Drug|Celecoxib|Given 400 mg PO twice a day
1729934|NCT00033371|Other|Placebo|Given PO to match DFMO
1729935|NCT00033371|Drug|eflornithine|Given PO at 0.5 gm/m^2/day rounded down to the nearest 250 mg dose (BSA of < 1.4 = 500 mg/day; BSA of 1.5 - 2.0 = 750 mg/day; BSA of 2.1 - 2.5 = 1000 mg/day; BSA of > 2.6 = 1,250 mg/day).
1729936|NCT00033371|Other|Laboratory biomarker analysis|Correlative studies
1729937|NCT00033371|Other|Questionnaire administration|Ancillary studies
1729938|NCT00033384|Drug|CI-1040|
1729939|NCT00033397|Procedure|biopsy|
1729940|NCT00033397|Procedure|magnetic resonance imaging|
1729941|NCT00033397|Procedure|radiomammography|
1729942|NCT00033397|Procedure|ultrasound imaging|
1729943|NCT00033397|Radiation|gadopentetate dimeglumine|
1729944|NCT00033397|Drug|chemotherapy|
1729945|NCT00033410|Drug|carboplatin|
1729946|NCT00033410|Drug|paclitaxel|
1729947|NCT00033410|Drug|tirapazamine|
1729948|NCT00033410|Radiation|radiation therapy|
1729949|NCT00033423|Biological|rituximab|
1729950|NCT00033423|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1729951|NCT00033436|Dietary Supplement|niacinamide|
1729952|NCT00033436|Drug|carbogen|
1729953|NCT00033436|Radiation|radiation therapy|
1729954|NCT00033449|Drug|gefitinib|Given orally
1729955|NCT00033449|Radiation|radiation therapy|Undergo radiation therapy
1729956|NCT00033449|Drug|cisplatin|Given IV
1729957|NCT00033449|Other|laboratory biomarker analysis|Correlative studies
1729958|NCT00033462|Drug|erlotinib hydrochloride|Given orally
1729959|NCT00033462|Other|laboratory biomarker analysis|Correlative studies
1729960|NCT00033475|Biological|therapeutic allogeneic lymphocytes|
1729961|NCT00033488|Other|cytology specimen collection procedure|
1729962|NCT00033488|Procedure|annual screening|
1729963|NCT00033488|Procedure|comparison of screening methods|
1729964|NCT00033514|Biological|trastuzumab|Day 1 4mg/kg IV 2 mg/kg IV weekly.
1730038|NCT00034086|Drug|Lopinavir/Ritonavir|
1729965|NCT00033514|Drug|erlotinib hydrochloride|100 mg daily on Course 1 Day 2. After three weeks patients who have not experienced specific adverse events, dose will be escalated to 150 mg daily. Patients who have experienced specific adverse events dose will remain 100 mg daily or dose reduced as necessary per protocol.
1729966|NCT00033527|Drug|INS316|
1729967|NCT00033527|Other|sputum cytology|
1729968|NCT00033540|Drug|capecitabine|650 mg/m^2 twice daily (BID), by mouth (PO) at 12 hour intervals, Days 1-14, every 21 days
1729969|NCT00033540|Drug|gemcitabine hydrochloride|1000 mg/m^2, intravenous (IV) over 100 minutes, Days 1,8, every 21 days
1729970|NCT00033553|Drug|carboplatin|Arm A: AUC=6 IV over 30 min for 2 cycles then AUC=2 IV over 30 min q wk for 7 wks Arm B: AUC=5 IV over 30 min for 2 cycles
1729971|NCT00033553|Drug|gemcitabine hydrochloride|1000 mg/sq m IV over 30 min days 1 & 8 repeat q 21 days for 2 cycles; then 35 mg/sq m IV over 30 min 2X wk for 7 wks
1729972|NCT00033553|Drug|paclitaxel|225 mg/sq m IV over 3 hrs q 21 days for 2 cycles, then 45 mg/sq m IV over 1 hr q wk for 7 wks
1729973|NCT00033553|Radiation|radiation therapy|3-D XRT 7400 cGy total after induction (during cycles 3-9)
1729974|NCT00033566|Drug|S-3304|
1729975|NCT00033592|Other|placebo|
1729976|NCT00033592|Drug|bupropion hydrochloride|
1729977|NCT00033592|Drug|nicotine|
1729978|NCT00033605|Drug|octreotide acetate|
1729979|NCT00033605|Other|placebo|
1729980|NCT00033605|Radiation|radiation|
1729981|NCT00033618|Drug|ixabepilone|Given IV
1729982|NCT00033618|Other|laboratory biomarker analysis|Correlative studies
1729983|NCT00033631|Radiation|70.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 70.2 Gy in 39 Fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 70.2 Gy.
1729984|NCT00033631|Radiation|79.2 Gy 3D-CRT/IMRT|Radiation will be delivered via 3D conformal radiation therapy (3D-CRT) or intensity modulated radiation therapy (IMRT) in 1.8 Gy minimum dose fractions to a total of 79.2 Gy in 44 fractions. All fields treated once daily, five fractions per week. No more than 2% of the planning target volume and none of the clinical target volume may receive less than 79.2 Gy.
1729985|NCT00033644|Biological|sargramostim|
1729986|NCT00033644|Drug|cisplatin|
1729987|NCT00033644|Drug|dacarbazine|
1729988|NCT00033644|Drug|doxorubicin hydrochloride|
1729989|NCT00033644|Drug|mitomycin C|
1729990|NCT00033657|Drug|cisplatin|"Days 1 - 35 : Cisplatin 30 mg/m² days 1, 8, 15, 22, 29
Days 63 - 77 : cisplatin 30 mg/m² and irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
1729991|NCT00033657|Drug|irinotecan hydrochloride|"Days 1 - 35 : Irinotecan 65 mg/m² days 1, 8, 22, 29
Days 63 - 77 : irinotecan 65 mg/m² days 1 and 8 of three 3-week cycles"
1729992|NCT00033657|Drug|paclitaxel|"Days 1 - 35 : Paclitaxel 50 mg/m² (1 hr) days 1, 8, 15, 22, 29
Days 63 - 77 : paclitaxel 175 mg/m² and cisplatin 75 mg/m² day 1 of three 3-week cycles"
1729993|NCT00033657|Procedure|conventional surgery|The type of resection (lvor-Lewis, Transhiatal, etc.) was left to the discretion of the operating surgeon. One lymph node dissection was required.
1729994|NCT00033657|Radiation|radiation therapy|The total dose to the prescription point was 4500 cGy given in 25 fractions. The patient was treated with one fraction per day with all fields treated per day. 180 cGy was delivered to the isocenter. If the dose to the supraclavicular fossa (SCF) was less than 4500 cGy, a localized photon or electron boost was allowed in order to increase the SCF dose to 4500 cGy, specified at 3 cm depth from the anterior skin surface.
1729995|NCT00033683|Drug|CMF regimen|
1729996|NCT00033683|Drug|cyclophosphamide|
1729997|NCT00033683|Drug|docetaxel|
1729998|NCT00033683|Drug|epirubicin hydrochloride|
1729999|NCT00033683|Drug|fluorouracil|
1730000|NCT00033683|Drug|methotrexate|
1730001|NCT00033683|Drug|tamoxifen citrate|
1730002|NCT00033683|Procedure|adjuvant therapy|
1730003|NCT00033683|Radiation|radiation therapy|
1730004|NCT00033696|Biological|filgrastim|
1730005|NCT00033696|Drug|carboplatin|
1730006|NCT00033696|Drug|etoposide|
1730007|NCT00033696|Drug|paclitaxel|
1730008|NCT00033696|Drug|topotecan hydrochloride|
1730009|NCT00033696|Radiation|radiation therapy|
1730010|NCT00033709|Drug|temozolomide|
1730011|NCT00033709|Drug|thalidomide|
1730012|NCT00033722|Dietary Supplement|folic acid|
1730013|NCT00033722|Drug|lometrexol|
1730014|NCT00033735|Drug|fluorouracil|5-fluorouracil will be administered via central venous catheter or PICC beginning at 250mg/m2/ day as continous infusion for a 28 day period.
1730015|NCT00033735|Drug|Irofulven|Irofulven will be given at 0.55 mg/kg per infusion on Day 1 and and Day 15 every 28 days as a 30 minute iv infusion.
1730016|NCT00033748|Biological|monoclonal antibody 11D10 anti-idiotype|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
1730017|NCT00033748|Biological|monoclonal antibody 3H1 Alu Gel|2 mg intradermal injection q 14 days for 4 doses, then sub Q monthly for 4 months, following a 6-12 wk rest period after curative hepatic resection
1730018|NCT00033813|Drug|Oxatomide (tinset)|
1730019|NCT00033839|Drug|Civamide (Zucapsaicin)|
1730020|NCT00033852|Procedure|Massage Therapy|
1730021|NCT00033865|Behavioral|Yoga, Relaxation Exercises, Sleep Hygiene|Sleep hygiene and relaxation exercises, with additional yoga
1730022|NCT00033878|Drug|Noni Extract|
1730024|NCT00033904|Drug|autologous human tumor-derived HSPPC-96|
1730025|NCT00033917|Drug|indomethacin|an anti-inflammatory drug
1730026|NCT00033917|Drug|placebo|saline
1730027|NCT00033943|Drug|deligoparin|
1730028|NCT00033956|Drug|M40403|
1730029|NCT00033982|Drug|Posaconazole|
1730030|NCT00034008|Behavioral|Healing Touch|
1730031|NCT00034021|Drug|Ginkgo Biloba|
1730032|NCT00034021|Behavioral|Sex Therapy (genital focus)|
1730033|NCT00034034|Procedure|Acupuncture|
1730039|NCT00034086|Drug|Lamivudine/Zidovudine|
1730040|NCT00034086|Drug|Tenofovir disoproxil fumarate|
1730041|NCT00034086|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
1730042|NCT00034086|Drug|Lamivudine|
1730043|NCT00034086|Drug|Stavudine|
1730044|NCT00034086|Drug|Zidovudine|
1730045|NCT00034086|Drug|Didanosine|
1730046|NCT00034086|Biological|Lyme Disease Vaccine Recombinant OspA|
1730047|NCT00034086|Biological|Haemophilus B Conjugate Vaccine|
1730048|NCT00034112|Procedure|osteopathic manipulative treatment|
1730049|NCT00034125|Drug|LY353381|
1730050|NCT00034125|Drug|tamoxifen|
1730051|NCT00034138|Drug|oregovomab|
1730052|NCT00034151|Drug|S-8184 Paclitaxel Injectable Emulsion|
1730053|NCT00034164|Drug|S-8184 Paclitaxel Injectable Emulsion|
1730054|NCT00034177|Drug|S-8184 Paclitaxel Injectable Emulsion|
1730055|NCT00034177|Drug|Experimental Arm: TOCOSOL Paclitaxel|Doses of 80, 100 and 120mg/m2
1730056|NCT00034190|Drug|S-8184 Paclitaxel Injectable Emulsion|
1730057|NCT00034203|Drug|efalizumab|
1730058|NCT00034229|Drug|Felbamate|
1730059|NCT00034242|Drug|high-dose intravenous immunoglobulin (IVIG)|
1730060|NCT00034255|Drug|INGAP Peptide|
1730061|NCT00034268|Drug|LY900003|
1730062|NCT00034281|Drug|TAK-165|Starting dose of TAK-165 10 mg, tablets, orally, once daily with dose escalation to tolerability for 56 days.
1730063|NCT00034294|Drug|GT160-246|
1730064|NCT00034307|Drug|sitaxsentan sodium|
1730065|NCT00034333|Drug|MTC-DOX for Injection|
1730066|NCT00034346|Drug|ABX-EGF|
1730067|NCT00034346|Drug|paclitaxel|
1730068|NCT00034346|Drug|carboplatin|
1730069|NCT00034359|Drug|ACH-126, 443 (beta-L-Fd4C)|
1730070|NCT00034359|Drug|Lamivudine|
1730071|NCT00034359|Drug|Placebo|
1730072|NCT00034372|Drug|oregovomab|
1730073|NCT00034385|Drug|Valganciclovir|
1730074|NCT00034450|Drug|L-carnitine|
1730075|NCT00034463|Drug|ALIMTA|
1730076|NCT00034463|Drug|folic acid|
1730077|NCT00034463|Drug|multi-vitamins|
1730078|NCT00034476|Drug|sPLA2 Inhibitor|
1730079|NCT00025740|Drug|clonazepam and paroxetine|
1730080|NCT00025753|Drug|rosiglitazone (Avandia)|
1730081|NCT00025753|Behavioral|Aerobic and weight lifting exercise training|
1730082|NCT00025766|Device|PCI with stenting|PCI with stenting of the occluded culprit infarct-related artery
1730083|NCT00025766|Behavioral|Optimal Medical Therapy|Participants will receive optimal medical therapy.
1730084|NCT00025779|Drug|methylphenidate|
1730085|NCT00025779|Drug|guanfacine|
1730086|NCT00025792|Drug|Pramipexole|
1730087|NCT00025805|Drug|G-CSF|
1730088|NCT00025818|Drug|Ophthalmic Emulsion|
1730089|NCT00025883|Drug|Metreleptin|Drug treatment
1730090|NCT00025896|Drug|recombinant human acid alpha-glucosidase (rhGAA)|
1730091|NCT00025909|Procedure|Leukapheresis|
1730092|NCT00025987|Device|Head and Neck Cooling System|
1730093|NCT00025987|Device|Thermometer Pill|
1730094|NCT00026013|Drug|hypericum perforatum|
1730095|NCT00026039|Drug|estrogen|
1730096|NCT00026052|Drug|riluzole|
1730097|NCT00026065|Behavioral|Biofeedback|
1730098|NCT00026078|Drug|docetaxel|
1730099|NCT00026078|Drug|ifosfamide|
1730100|NCT00026091|Drug|fenretinide|Given orally
1730101|NCT00026091|Other|laboratory biomarker analysis|Correlative studies
1730102|NCT00026091|Other|pharmacological study|Correlative studies
1730103|NCT00026104|Drug|gemcitabine hydrochloride|Given IV
1730104|NCT00026104|Drug|paclitaxel|Given IV
1730105|NCT00026104|Drug|tipifarnib|Given orally
1730106|NCT00026104|Radiation|radiation therapy|Undergo radiation therapy
1730107|NCT00026117|Drug|BenFin|
1730108|NCT00026117|Other|placebo|
1730109|NCT00026130|Drug|fluorouracil|200mg/sq m/d CIVI 5/7 days during radiation therapy (wks 1-6)
1730110|NCT00026130|Drug|gemcitabine hydrochloride|200mg/sq m IV infusion over 30 min wkly (on d 1, 2, OR 3) during radiation tx (wks 1-6) 1000mg/sq m IV infusion over 30 min wkly for 3 weeks during ea chemotherapy cycle
1730111|NCT00026130|Radiation|radiation therapy|4500cGy total in 25 fractions M-F followed by 540cGy in 3 fractions (Total dose 5040cGy)during radiation tx (wks 1-6)
1730112|NCT00026143|Biological|recombinant interleukin-12|Given IV
1730113|NCT00026143|Biological|recombinant interferon alfa|Given SC
1730114|NCT00026143|Other|laboratory biomarker analysis|Correlative studies
1730115|NCT00026156|Drug|docetaxel|
1730116|NCT00026156|Drug|vinorelbine tartrate|
1730117|NCT00026169|Drug|imatinib mesylate|Given orally
1730118|NCT00026169|Other|laboratory biomarker analysis|Correlative studies
1730119|NCT00026169|Other|pharmacological study|Correlative studies
1730120|NCT00026182|Biological|rituximab|Given IV
1730121|NCT00026182|Biological|recombinant interleukin-12|Given SC
1730122|NCT00026182|Other|laboratory biomarker analysis|Correlative studies
1730123|NCT00026182|Other|questionnaire administration|Ancillary studies
1730124|NCT00026182|Procedure|quality-of-life assessment|Ancillary studies
1730125|NCT00026195|Drug|irinotecan hydrochloride|
1730126|NCT00026208|Drug|bleomycin|5 u/m2 IV week 2, 4, 6, 8
1730127|NCT00026208|Drug|cyclophosphamide|650 mg/m2
1730128|NCT00026208|Drug|prednisone|40 mg/m2, Oral. Every other day. Taper 10 mg qod during last 2 weeks of chemotherapy
1730129|NCT00026208|Drug|vincristine|1.4 mg/m2; IV wk 2, 4, 6, 8
1730130|NCT00026208|Drug|Adriamycin|25 mg/m2
1730131|NCT00026208|Drug|Velban|6 mg/m2, IV wk 1, 3, 5, 7
1730132|NCT00026208|Drug|VP-16|60 mg/m2 x 2; IV wk 3, 7 (d 15, 16, 43, 44)
1730133|NCT00026221|Biological|Recombinant Interferon Alfa|Given SC
1730134|NCT00026221|Biological|Bevacizumab|Given IV
1730135|NCT00026234|Drug|floxuridine|Given intra-arterially
1730576|NCT00030719|Biological|filgrastim|
1730136|NCT00026234|Drug|dexamethasone|Given intra-arterially
1730137|NCT00026234|Drug|oxaliplatin|Given IV
1730138|NCT00026234|Drug|capecitabine|Given orally
1730139|NCT00026247|Procedure|pain therapy|
1730140|NCT00026247|Procedure|radiofrequency ablation|
1730141|NCT00026260|Drug|semaxanib|
1730142|NCT00026273|Drug|FOLFIRI regimen|
1730143|NCT00026273|Drug|fluorouracil|
1730144|NCT00026273|Drug|irinotecan hydrochloride|
1730145|NCT00026273|Drug|leucovorin calcium|
1730146|NCT00026286|Drug|conjugated estrogens|
1730147|NCT00026286|Drug|medroxyprogesterone|
1730148|NCT00026299|Drug|ZD1839|
1730149|NCT00026299|Drug|oxaliplatin|
1730150|NCT00026312|Biological|Aldesleukin|Given IV
1730151|NCT00026312|Biological|Dinutuximab|Given IV
1730152|NCT00026312|Drug|Isotretinoin|Given PO
1730153|NCT00026312|Other|Laboratory Biomarker Analysis|Correlative studies
1730154|NCT00026312|Other|Pharmacological Study|Correlative studies
1730155|NCT00026312|Other|Quality-of-Life Assessment|Ancillary studies
1730156|NCT00026312|Biological|Sargramostim|Given IV or SC
1730157|NCT00026338|Drug|erlotinib hydrochloride|150 mg po daily
1730158|NCT00026338|Drug|gemcitabine hydrochloride|1000 mg/m2 IV weekly (Cycle 1 -Day 1, 8, 15, 22, 29, 36, 43 of an 8 week cycle, Cycle 2 and subsequent cycles -Day 1,8 and 15 of a 4 week cycle)
1730159|NCT00026351|Biological|rituximab|
1730160|NCT00026351|Drug|pentostatin|
1730161|NCT00026364|Drug|fluorouracil|
1730162|NCT00026364|Drug|gefitinib|
1730163|NCT00026364|Drug|irinotecan hydrochloride|
1730164|NCT00026364|Drug|leucovorin calcium|
1730165|NCT00026377|Drug|bicalutamide|50 mg daily for 1 month
1730166|NCT00026377|Drug|flutamide|250 mg 3 times daily for 1 month
1730167|NCT00026377|Drug|goserelin acetate|3.6 mg once a month for 4 months
1730168|NCT00026377|Drug|leuprolide acetate|7.5 mg once a month for 4 months
1730169|NCT00026377|Drug|SU5416|IV infusion at assigned dose
1730170|NCT00026377|Radiation|radiation therapy|daily for 5 days each week
1730171|NCT00026403|Drug|cisplatin|
1730172|NCT00026403|Drug|gemcitabine hydrochloride|
1730173|NCT00026403|Radiation|radiation therapy|
1730174|NCT00026416|Biological|recombinant interferon alfa|
1730175|NCT00026416|Drug|thalidomide|
1730176|NCT00026416|Procedure|adjuvant therapy|
1730177|NCT00026429|Biological|denileukin diftitox|
1730178|NCT00026442|Drug|capecitabine|
1730179|NCT00026468|Drug|exisulind|
1730180|NCT00026494|Drug|temozolomide|
1730181|NCT00026494|Drug|vinorelbine tartrate|
1730182|NCT00026520|Biological|recombinant interferon alfa|
1730183|NCT00026520|Drug|thalidomide|
1730184|NCT00026533|Drug|thalidomide|
1730185|NCT00026585|Drug|Tamoxifen|
1730186|NCT00026611|Biological|Dryvax vaccine|
1730187|NCT00026624|Biological|ALVAC(2)120(B,MN)GNP (vCP1452)|
1730188|NCT00026624|Drug|Keyhole-Limpet Hemocyanin|
1730189|NCT00026637|Drug|sertraline|Sertraline: 25-200mg PO (orally); Subjects begin at 25mg for week 1 and increase to 50mg at the beginning of week 2. Sertraline is increased in 50mg increments when subjects score in the depressed range on the CES-D, a questionnaire that is administered every 2 weeks over the 16 week intervention period. Subjects may reduce dosage if toxicity occurs.
1730190|NCT00026637|Behavioral|cognitive behavior therapy|CBT (Cognitive Behavior Therapy) - CBT is a psychotherapy based on modifying cognitions, assumptions, beliefs and behaviors, with the aim of influencing disturbed emotions. Subjects will meet with a trained CBT therapist for 1 hour each week over the 16 week intervention period and will be given assignments to work on each week.
1730191|NCT00026819|Drug|Rofecoxib|
1730192|NCT00026858|Behavioral|collaboration|
1730193|NCT00026871|Procedure|Radiotherapy|
1730194|NCT00026897|Procedure|Gamma-camera imaging|
1730195|NCT00026897|Procedure|Low-risk biopsy|
1730196|NCT00026923|Procedure|Laparoscopic surgery|
1730197|NCT00026936|Procedure|Radiotherapy|
1730198|NCT00026962|Procedure|measuring estradiol and progesterone levels in saliva|
1730199|NCT00026975|Procedure|Hyperbaric Oxygen|
1730200|NCT00026988|Drug|Creatine|
1730201|NCT00027001|Behavioral|Aerobic and Resistance Exercises|
1730202|NCT00027001|Behavioral|Qigong|
1730203|NCT00027014|Drug|St. John's Wort|
1730204|NCT00027014|Drug|oxycodone|
1730205|NCT00027014|Drug|fentanyl|
1730206|NCT00027027|Drug|rhuMAb 2C4|
1730207|NCT00027040|Drug|Selegiline hydrochloride|
1730208|NCT00027053|Drug|Trazodone|50 to 150 mg qhs
1730209|NCT00027053|Drug|Placebo|
1730210|NCT00027066|Drug|Active Aspirin|325mg tablet daily
1730211|NCT00027066|Drug|Active Warfarin|2mg scored tablet daily
1730212|NCT00027066|Drug|Aspirin placebo|325mg aspirin placebo pill
1730213|NCT00027066|Drug|Warfarin placebo|2mg scored placebo tablet
1730214|NCT00027079|Drug|ondansetron (Zofran)|
1730215|NCT00027079|Drug|naltrexone (ReVia)|
1730216|NCT00027079|Behavioral|Cognitive Behavioral Therapy|
1730217|NCT00027131|Biological|Heat Shock Protein 70-peptide complexes (HSP70)|
1730218|NCT00027144|Biological|Heat Shock Protein 70 HSP70|
1730219|NCT00027209|Drug|prempro|
1730220|NCT00027222|Procedure|retinal ablation|
1730221|NCT00034489|Drug|pemetrexed|
1730222|NCT00034489|Drug|gemcitabine|
1730223|NCT00034502|Drug|ALIMTA|
1730224|NCT00034502|Drug|irinotecan|
1730225|NCT00034515|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|
1730226|NCT00034528|Drug|Busulfan|0.8 mg/kg/d administered as a single intravenous infusion over 3 hours for 4 days. All infusions are anticipated to be given in the outpatient clinic.
1730227|NCT00034528|Drug|Fludarabine|30 mg/m^2/d administered as a bolus infusion over 30 minutes for 4 days. All infusions are anticipated to be given in the outpatient clinic.
1730228|NCT00034528|Drug|FK506|0.15 mg/kg taken orally daily for 12 to 14 weeks
1730229|NCT00034528|Drug|Prednisone|0.5 mg/kg taken orally four times daily on Day 7 and increase to 1 mg/kg taken orally four times daily on Day 14. Participants will continue regimen until Day 30 before a 20-25% taper per week.
1730230|NCT00034541|Biological|cetuximab|400 mg/m2 i.v. over 120 minutes
1730231|NCT00034541|Drug|paclitaxel|225 mg/m2, infusion
1730232|NCT00034541|Drug|carboplatin|30-minute AUC = 6, infusion.
1730233|NCT00034554|Biological|gp75 DNA vaccine|6 patients will be enrolled in each of the 5 vaccination groups. Patients in vaccination groups 1-3 will receive a total of 5(1 mL) vaccinations. Patients assigned to vaccination group 4 will receive a total of 5 (2.0 mL) vaccinations administered as 2 1 mL injections. Patients assigned to vaccination group 5 will receive a total of 5 (4.0 mL or 8.0 mg)vaccinations administered as 4 1 mL injections per vaccination treatment Patients will receive gp75 DNA vaccinations every 3 weeks for 5 vaccinations. Injection sites will be given intramuscularly and rotated for each dose using all 4 limbs with the exception of a site that had the removal of lymph nodes. Progression to next higher dose level will be based on the 5* patient safely completing the 2nd vaccination at the lower dose level.
1730234|NCT00034580|Drug|olanzapine|
1730235|NCT00034580|Drug|risperidone|
1730236|NCT00034593|Drug|ALIMTA|
1730237|NCT00034593|Drug|gemcitabine|
1730238|NCT00034606|Drug|Pemetrexed (Alimta) in combination with gemcitabine (Gemzar)|
1730239|NCT00034619|Drug|ALIMTA|
1730240|NCT00034619|Drug|Oxaliplatin|
1730241|NCT00034632|Drug|Posaconazole oral suspension|
1730242|NCT00034645|Drug|Posaconazole oral suspension|
1730243|NCT00034658|Drug|Posaconazole|
1730244|NCT00034671|Drug|Posaconazole oral suspension|
1730245|NCT00034684|Drug|Farnesyl Protein Transferase Inhibitor|
1730246|NCT00034697|Drug|temozolomide|
1730247|NCT00034710|Drug|Capsaicin Patch|
1730248|NCT00034736|Drug|Levofloxacin|
1730249|NCT00034749|Drug|Risperidone|
1730250|NCT00034762|Drug|risperidone|
1730251|NCT00034775|Drug|risperidone|
1730252|NCT00034788|Drug|Becaplermin|
1730253|NCT00034801|Drug|olanzapine|
1730254|NCT00034801|Drug|ziprasidone|
1730255|NCT00034814|Drug|Talampanel|Non-enzyme-inducing TLP 35mg TID
1730256|NCT00034814|Drug|Placebo|Enzyme-inducing placebo TID
1730257|NCT00034814|Drug|Talampanel|Enzyme-inducing Talampanel 35 mg TID
1730258|NCT00034814|Drug|Talampanel|Enzyme-inducing TLP 50mg TID
1730259|NCT00034814|Drug|Placebo|Non-enzyme-inducing placebo TID
1730260|NCT00034814|Drug|Talampanel|Non-enzyme-inducing TLP 25mg TID
1730261|NCT00035386|Procedure|trans-right ventricular alcohol septal ablation (TRVASA)|
1730262|NCT00035399|Procedure|Acupuncture|
1730263|NCT00035412|Drug|St. John’s Wort|
1730264|NCT00035425|Drug|linezolid|600mg every 12 hours
1730265|NCT00035425|Drug|vancomycin|1gm every 12 hours. The dose of vancomycin intravenously may be adjusted for renal function, but the patient must be able to receive a 300 mL volume of intravenous fluid at the assigned dosing times of every 12 hours.
1730266|NCT00035438|Drug|St. John’s Wort|
1730267|NCT00035451|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
1730268|NCT00035451|Drug|Placebo|tablets, twice daily for 6 months
1730269|NCT00035451|Drug|Sotalol|160 mg sot twice daily for 6 months
1730270|NCT00035464|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets, twice a day for 6 months
1730271|NCT00035464|Drug|Placebo|placebo tablets, twice a day for 6 months
1730272|NCT00035477|Drug|Azimilide Dihydrochloride|125 mg azimilide tablets once a day for 3 days in hospital and 125 mg azimilide tablets once a day for 6 months as outpatient
1730273|NCT00035477|Drug|Placebo|placebo tablets once a day for 3 days in hospital and placebo tablets once a day for 6 months as outpatient
1730274|NCT00035490|Drug|Azimilide Dihydrochloride|125 mg azimilide, once a day for one year
1730275|NCT00035490|Drug|placebo|placebo tablet, once daily for one year
1730276|NCT00035490|Drug|Azimilide Dihydrochloride|75 mg azimilide, once a day for one year
1730277|NCT00035503|Drug|etiprednol dicloacetate|
1730278|NCT00035516|Drug|Epothilone|
1730279|NCT00035529|Drug|Placebo|Solution, i.v infusion, 0 mg, Days 1 & 15 then monthly, 10 months.
1730280|NCT00035529|Drug|BMS 188667 (Abatacept)|Vial, i.v infusion, 2mg/kg, Days 1 & 15 then monthly, 10 months.
1730281|NCT00035529|Drug|BMS 188667 (Abatacept)|Vial, i.v infusion, 10 mg/kg, Days 1 & 15 then monthly, 10 months.
1730282|NCT00035542|Drug|Glucovance (metformin HCl/glyburide)|
1730283|NCT00035542|Drug|metformin HCl|
1730284|NCT00035542|Drug|glyburide|
1730285|NCT00035555|Drug|Belatacept|Solution, intravenous
1730286|NCT00035555|Drug|Cyclosporine|Oral, capsule
1730287|NCT00035555|Drug|Mycophenolate mofetil (MMF)|Oral, capsule
1730288|NCT00035555|Drug|Corticosteroids|Corticosteroids given daily, orally or intravenously (IV). Day of transplant (Day 1): methylprednisolone, 500 mg, given IV on arrival in operating room; Day 2: methylprednisolone, 250 mg, given IV once daily; Day 3: prednisone, 100 mg, given orally once daily; Day 4: prednisone, 50 mg, given orally once daily; Days 5 through 30: prednisone, 25 mg, given orally once daily; Days 31-44: prednisone, 22.5 mg, given orally once daily; Days 45-58: prednisone, 20 mg, given orally once daily
1730289|NCT00035568|Drug|Glucovance (metformin HCl/glyburide)|
1730290|NCT00035568|Drug|or Metformin HCl alone|
1730291|NCT00035568|Drug|or Glyburide alone.|
1730292|NCT00035581|Drug|poly I-poly C12U|200-400 mg IV infusions 2x/week for 24 weeks
1730293|NCT00035594|Drug|pegfilgrastim|Growth factor (GCSF) administered to promote neutrophil development post-chemotherapy.
1730294|NCT00035607|Drug|Darbepoetin alfa SC|Subcutaneous (SC) injection of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
1730295|NCT00035607|Drug|Darbepoetin alfa IV|Intravenous administration of darbepoetin alfa at 4.5 mcg/kg weekly for weeks 1-6, then 4.5 mcg/kg Q3W
1730296|NCT00035620|Drug|pegfilgrastim|pegfilgrastim
1730882|NCT00040872|Drug|etoposide|
1730297|NCT00035620|Drug|filgrastim|filgrastim
1730298|NCT00035633|Drug|Entecavir|
1730299|NCT00035789|Drug|Entecavir|
1730300|NCT00035802|Drug|Topiramate|"Double-blind period: Up to 400 mg/day (two 100-mg tablets twice a day) for 28 days.
OL period: Up to 600 mg/day (three 100-mg tablets twice a day) for at least 6 months."
1730301|NCT00035802|Drug|Placebo|Double-blind period: Equal number of matching placebo tablets for each of the topiramate tablet strengths twice a day for 28 days.
1730302|NCT00035815|Drug|Insulin like growth factor, type 1|0.05 mg per kg body weight given subcutaneously twice daily
1730303|NCT00035815|Drug|Placebo|The placebo represented the inert suspension vehicle for the IGF-1. It was given as equal volume as the active drug based upon body weight, subcutaneously twice daily.
1730304|NCT00035828|Drug|ABX-IL8|
1730305|NCT00035841|Drug|TLK286|
1730306|NCT00035854|Drug|Zyvox® / Linezolid|
1730307|NCT00035867|Drug|TLK199 HCl Liposomes for Injection|
1730308|NCT00035880|Drug|ABX-CBL|
1730309|NCT00035893|Drug|poly I-poly C12U|200-400 mg IV infusions 2x/week for 64 weeks
1730310|NCT00035906|Drug|DEX PS DDS®|
1730311|NCT00035919|Genetic|Mx-dnG1 Retroviral Vector|
1730312|NCT00035932|Drug|Atazanavir + ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
1730313|NCT00035932|Drug|Atazanavir + saquinavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
1730314|NCT00035932|Drug|Lopinavir/ritonavir + tenofovir + nucleoside|Active Comparator, Capsules, tablets, Oral
1730315|NCT00035945|Drug|ISIS 14803|
1730316|NCT00035958|Drug|Prednisone|
1730317|NCT00035958|Drug|Methotrexate|
1730318|NCT00035958|Drug|Etanercept|
1730319|NCT00035971|Drug|raloxifene HCI and alendronate Na|
1730320|NCT00035984|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
1730321|NCT00035984|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
1730322|NCT00035984|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
1730323|NCT00035984|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
1730324|NCT00035997|Drug|Zometa|
1730325|NCT00036023|Drug|darbepoetin alfa|
1730326|NCT00036036|Drug|CP-461|
1730327|NCT00036062|Drug|Sivelestat|
1730328|NCT00036075|Drug|CP-461|
1730329|NCT00036088|Drug|Olanzapine|
1730330|NCT00036101|Drug|aripiprazole|
1730331|NCT00036114|Drug|aripiprazole|
1730332|NCT00036127|Drug|aripiprazole|
1730333|NCT00036140|Drug|Investigational drug|
1730334|NCT00036153|Drug|Tacrolimus (Prograf®)|
1730335|NCT00036153|Drug|Methotrexate|
1730336|NCT00036166|Drug|FK463|
1730337|NCT00036179|Drug|FK463|
1730338|NCT00036192|Drug|FK614|
1730339|NCT00036205|Drug|sumanirole|
1730340|NCT00036218|Drug|sumanirole|
1730341|NCT00036218|Drug|ropinirole|
1730342|NCT00036231|Drug|RG1068 (Synthetic Human Secretin)|
1730343|NCT00036244|Drug|RG1068 (Synthetic Human Secretin)|
1730344|NCT00036257|Drug|CP-461|
1730345|NCT00036270|Drug|exemestane (Aromasin)|exemestane, orally, 25 mg, for 5 years
1730346|NCT00036270|Drug|tamoxifen + exemestane|tamoxifen, 20 mg, orally, daily, 2-3 years; followed by exemestane, orally, 25 mg, for a total of 5 years of therapy
1730347|NCT00036283|Drug|Celecoxib|
1730348|NCT00036296|Drug|talampanel|75mg per day divided into 3 doses for 22 days
1730349|NCT00036309|Drug|Duloxetine Hydrochloride|
1730350|NCT00036335|Drug|Duloxetine Hydrochloride|
1730351|NCT00036348|Drug|Aripiprazole|
1730352|NCT00036361|Drug|Aripiprazole|
1730353|NCT00036374|Drug|Infliximab|
1730354|NCT00036387|Drug|Infliximab|
1730355|NCT00036400|Drug|epoetin alfa|
1730356|NCT00036413|Drug|TCH346|
1730357|NCT00036426|Biological|FavId (Id-KLH) active immunotherapy|
1730358|NCT00036439|Drug|Infliximab|
1730359|NCT00036452|Drug|lopinavir/ritonavir|
1730360|NCT00036452|Drug|emtricitabine|
1730361|NCT00036452|Drug|stavudine|
1730362|NCT00036452|Drug|tenofovir DF|
1730363|NCT00036465|Behavioral|Treatment regimen change|
1730364|NCT00036491|Drug|Rituximab|Subjects received four weekly infusions of rituximab at a dose of 375 mg/m^2
1730365|NCT00036504|Drug|Insulin Lispro low mixture|
1730366|NCT00036517|Drug|PHY906|
1730367|NCT00036543|Drug|Atrasentan|
1730368|NCT00036556|Drug|Atrasentan|
1730369|NCT00036569|Procedure|adjuvant therapy|
1730370|NCT00036569|Biological|pegylated interferon alfa|0.3 mg/kg subcutaneously once a week for 4 weeks beginning 2-10 weeks after completion of radiation therapy and continued until disease progression or one of the other off study criteria.
1730371|NCT00036582|Drug|Clozapine|
1730372|NCT00036608|Drug|Entecavir|
1730373|NCT00036621|Drug|BMS-275291|
1730374|NCT00036634|Drug|Tenofovir DF|Tenofovir DF tablet administered orally once daily
1730375|NCT00036634|Drug|Tenofovir alafenamide|Tenofovir alafenamide tablet(s) administered orally once daily
1730376|NCT00036647|Drug|Tarceva (erlotinib HCl, OSI-774 )|
1730377|NCT00036660|Drug|SarCNU|
1730378|NCT00036686|Dietary Supplement|Soy protein isolate|Arm I: Patients receive oral soy protein isolate twice daily and oral multivitamins once daily.
1730379|NCT00036686|Other|Placebo|Arm II: Patients receive oral placebo twice daily and oral multivitamins once daily.
1730380|NCT00036712|Procedure|management of therapy complications|
1730381|NCT00036712|Procedure|pain therapy|
1730382|NCT00036738|Drug|Cyclosporine|Given IV or PO
1730383|NCT00036738|Drug|Dasatinib|Given PO
1730384|NCT00036738|Drug|Fludarabine Phosphate|Given IV
1730385|NCT00036738|Drug|Imatinib Mesylate|Given PO
1730386|NCT00036738|Drug|Mycophenolate Mofetil|Given PO
1730387|NCT00036738|Drug|Nilotinib|Given PO
1730388|NCT00036738|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
1730389|NCT00036738|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
1730390|NCT00036738|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
1730391|NCT00036738|Radiation|Total-Body Irradiation|Undergo TBI
1730392|NCT00036751|Drug|imatinib mesylate|Given orally
1730393|NCT00036751|Other|laboratory biomarker analysis|Correlative studies
1730394|NCT00036764|Drug|ixabepilone|Given IV
1730395|NCT00036764|Other|pharmacogenomic studies|Correlative studies
1730396|NCT00036764|Other|laboratory biomarker analysis|Correlative studies
1730397|NCT00036777|Drug|carboplatin|Given IV
1730398|NCT00036777|Drug|7-hydroxystaurosporine|Given IV
1730399|NCT00036777|Other|pharmacological study|Correlative studies
1730400|NCT00036790|Drug|doxorubicin hydrochloride|
1730401|NCT00036790|Drug|motexafin gadolinium|
1730402|NCT00036816|Biological|MART-1 antigen|
1730403|NCT00036816|Biological|NA17-A antigen|
1730404|NCT00036816|Biological|gp100 antigen|
1730405|NCT00036816|Biological|tyrosinase peptide|
1730406|NCT00036829|Procedure|pain therapy|
1730407|NCT00036842|Drug|arsenic trioxide|
1730408|NCT00036855|Biological|rituximab|Given IV
1730409|NCT00036855|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
1730410|NCT00036855|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
1730411|NCT00036855|Procedure|peripheral blood stem cell transplantation|Undergo PBSC transplantation
1730412|NCT00036855|Biological|filgrastim|Given subcutaneously
1730413|NCT00036855|Other|laboratory biomarker analysis|Correlative studies
1730414|NCT00036868|Biological|trastuzumab|
1730415|NCT00036868|Drug|CMF regimen|
1730416|NCT00036868|Drug|cyclophosphamide|
1730417|NCT00036868|Drug|fluorouracil|
1730418|NCT00036868|Drug|methotrexate|
1730419|NCT00036881|Dietary Supplement|zinc sulfate|
1730420|NCT00036881|Other|placebo|
1730421|NCT00036894|Drug|lenalidomide|
1730422|NCT00036920|Drug|canfosfamide hydrochloride|
1730423|NCT00036933|Biological|MUC-2-Globo H-KLH conjugate vaccine|
1730424|NCT00036933|Biological|QS21|
1730425|NCT00036946|Biological|ziv-aflibercept|
1730426|NCT00036959|Drug|ABT-751|
1730427|NCT00036972|Biological|cintredekin besudotox|
1730428|NCT00036972|Procedure|adjuvant therapy|
1730429|NCT00036972|Procedure|conventional surgery|
1730430|NCT00036972|Procedure|neoadjuvant therapy|
1730431|NCT00036985|Drug|cyclophosphamide|
1730432|NCT00036985|Drug|doxorubicin hydrochloride|
1730433|NCT00036985|Procedure|conventional surgery|
1730434|NCT00036985|Procedure|neoadjuvant therapy|
1730435|NCT00036985|Procedure|thermal ablation therapy|
1730436|NCT00036998|Procedure|conventional surgery|
1730437|NCT00036998|Procedure|neoadjuvant therapy|
1730438|NCT00036998|Procedure|thermal ablation therapy|
1730439|NCT00037011|Biological|beta-glucan|
1730440|NCT00037011|Biological|monoclonal antibody 3F8|
1730441|NCT00037024|Procedure|fatigue assessment and management|
1730442|NCT00037024|Procedure|nutritional support|
1730443|NCT00037024|Procedure|physical therapy|
1730444|NCT00037024|Procedure|psychosocial assessment and care|
1730445|NCT00037024|Procedure|quality-of-life assessment|
1730446|NCT00037037|Biological|MAGE-10.A2|
1730447|NCT00037037|Biological|MART-1 antigen|
1730448|NCT00037037|Biological|NY-ESO-1 peptide vaccine|
1730449|NCT00037037|Biological|sargramostim|
1730450|NCT00037037|Biological|tyrosinase peptide|
1730451|NCT00037050|Drug|Linezolid|
1730452|NCT00037050|Drug|Vancomycin|
1730453|NCT00037050|Drug|Oxacillin|
1730454|NCT00037050|Drug|Dicloxacillin|
1730455|NCT00037063|Drug|Thiamine hydrochloride|
1730456|NCT00037063|Drug|Riboflavin|
1730457|NCT00037063|Drug|Ascorbic acid|
1730458|NCT00037063|Drug|Vitamin E|
1730459|NCT00037089|Drug|UFT (Tegafur/Uracil)|
1730460|NCT00037102|Drug|interferon beta 1a|
1730461|NCT00037102|Drug|methotrexate|
1730462|NCT00037115|Drug|interferon beta 1a|
1730463|NCT00037115|Drug|methotrexate|
1730464|NCT00037115|Drug|methylprednisolone|
1730465|NCT00037128|Drug|GL701|
1730466|NCT00037141|Drug|dehydrated alcohol|
1730467|NCT00037154|Drug|Saw Palmetto|
1730468|NCT00037167|Device|Exercise poles|
1730469|NCT00037180|Drug|Celecoxib|
1730470|NCT00037180|Drug|Irinotecan|
1730471|NCT00037180|Drug|5-fluorouracil|
1730472|NCT00037180|Drug|Leucovorin|
1730473|NCT00037206|Drug|Anidulafungin, VER002|
1730474|NCT00037219|Drug|Anidulafungin, VER002|
1730475|NCT00037440|Genetic|Polymorphisms measured|
1730476|NCT00037479|Drug|ceftriaxone|
1730477|NCT00037492|Procedure|home-based sessions/family meetings with trained clinician|
1730478|NCT00037518|Drug|AMG 073|
1730479|NCT00037531|Drug|Sirolimus (RAPAMUNE)|
1730480|NCT00037544|Drug|ReFacto AF|
1730481|NCT00037557|Drug|BeneFIX|
1730482|NCT00037570|Drug|Pantoprazole|
1730483|NCT00037583|Drug|Gemtuzumab Ozogamicin|
1730484|NCT00037596|Drug|Gemtuzumab Ozogamicin|
1730485|NCT00037596|Drug|cytarabine.|
1730486|NCT00037609|Drug|Capecitabine|1000 mg/m^2 taken by mouth twice daily.
1730487|NCT00037609|Drug|Exisulind|125 mg taken by mouth twice daily.
1730488|NCT00037622|Drug|ACH-126, 443 (beta-L-Fd4C)|
1730489|NCT00037635|Drug|AMG 073|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
1730490|NCT00037635|Drug|Placebo|30 mg QD orally 60 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
1730491|NCT00037648|Drug|Anakinra|anakinra
1730492|NCT00037648|Drug|Placebo|placebo
1730493|NCT00037661|Drug|INS365 Ophthalmic Solution|
1730494|NCT00037674|Drug|Topiramate|
1730495|NCT00037687|Drug|rPAF-AH|
1730496|NCT00037700|Drug|anakinra|
1730497|NCT00037700|Drug|pegsunercept|
1730498|NCT00037713|Biological|BEC2 Vaccine|5 vaccinations of BEC2 (2.5 mg) + BCG given day 1 of weeks 0,2,4,6 & 10.
1730499|NCT00037752|Drug|Sibutramine|At the baseline study visit, participants in Group 1 will be given a one month supply of 5 mg/d of sibutramine and a 1-month follow-up visit will be scheduled. After a safety evaluation at the 1-month follow-up visit, participants will have their dose of sibutramine titrated to 10 mg/d, a 1 month supply of the medication will be given to participants, and a 2-month follow-up visit will be scheduled. After a safety evaluation at the 2-month follow-up visit, participants will receive a 1 month supply of sibutramine 10 mg/d and a 3-month follow-up visit will be scheduled. At the 3-month follow-up visit, the sibutramine will be discontinued and participants will be scheduled for 4- and 5-month follow-up visits.
1730500|NCT00037752|Behavioral|Behavioral Smoking Cessation Program|Both groups of participants will take part in a behavioral smoking cessation program.
1730501|NCT00037791|Drug|(PN-152,243)/PN-196,444|
1730502|NCT00037804|Drug|Irinotecan|
1730503|NCT00037817|Drug|Decitabine|assigned dose level on day 4 and day 10 of each 34 day cycle
1730504|NCT00037817|Biological|Depsipeptide|assigned dose level on day 4 and day 10 of each 34 day cycle
1730505|NCT00037817|Drug|Celecoxib|400mg PO BID on days 4 through 34 of each cycle
1730506|NCT00037830|Drug|GM1 ganglioside|100 mg twice per day by subcutaneous injection
1730507|NCT00037830|Drug|Placebo|Twice per day subcutaneous injection, equal volume as active drug
1730508|NCT00037843|Drug|I-131 Iodocholesterol|
1730509|NCT00037869|Drug|I-131 Metaiodobenzylguanidine|
1730510|NCT00037882|Drug|PEG-Intron|Once weekly injection.
1730511|NCT00037895|Procedure|Ambulation training|
1730512|NCT00037908|Procedure|Strength training|
1730513|NCT00037921|Procedure|Bacterial colonization|
1730514|NCT00037934|Device|Upper extremity robot|Robotic upper extremity neuro-rehabilitation
1730515|NCT00037934|Other|Traditional Supervised Upper Extremity Exercises|Arm ergometer, reaching, and stretching exercises
1730516|NCT00037947|Procedure|Hearing in Multiple Sclerosis|
1730517|NCT00037960|Procedure|Constrained Induced Therapy|
1730518|NCT00037973|Behavioral|ventilation feedback|
1730519|NCT00037973|Behavioral|exercise|
1730520|NCT00037986|Device|Hearing Aids|Hearing aid use
1730521|NCT00030433|Drug|gemcitabine hydrochloride|
1730522|NCT00030433|Drug|irinotecan hydrochloride|
1730523|NCT00030446|Drug|carboplatin|
1730524|NCT00030446|Drug|erlotinib hydrochloride|
1730525|NCT00030459|Drug|cisplatin|
1730526|NCT00030459|Drug|mitomycin C|
1730527|NCT00030459|Drug|vinblastine sulfate|
1730528|NCT00030459|Drug|vinorelbine tartrate|
1730529|NCT00030472|Drug|pegylated liposomal doxorubicin hydrochloride|
1730530|NCT00030485|Drug|erlotinib hydrochloride|
1730531|NCT00030498|Drug|erlotinib hydrochloride|Given orally
1730532|NCT00030498|Other|laboratory biomarker analysis|Correlative studies
1730533|NCT00030511|Drug|fluorouracil|
1730534|NCT00030511|Procedure|conventional surgery|
1730535|NCT00030511|Radiation|radiation therapy|
1730536|NCT00030524|Drug|gefitinib|
1730537|NCT00030537|Drug|erlotinib hydrochloride|
1730538|NCT00030550|Drug|thalidomide|
1730539|NCT00030563|Drug|irinotecan hydrochloride|
1730540|NCT00030563|Procedure|adjuvant therapy|
1730541|NCT00030563|Procedure|conventional surgery|
1730542|NCT00030563|Procedure|radiofrequency ablation|
1730545|NCT00030589|Drug|bexarotene|
1730546|NCT00030589|Drug|methoxsalen|
1730547|NCT00030589|Procedure|UV light therapy|
1730548|NCT00030602|Biological|PSA prostate cancer vaccine|
1730549|NCT00030602|Biological|incomplete Freund's adjuvant|
1730550|NCT00030615|Drug|decitabine|Given IV
1730551|NCT00030615|Other|pharmacological study|Correlative studies
1730552|NCT00030615|Other|laboratory biomarker analysis|Correlative studies
1730553|NCT00030628|Radiation|radiation therapy|
1730554|NCT00030628|Procedure|surgery|
1730555|NCT00030628|Radiation|WBRT|
1730556|NCT00030641|Biological|oblimersen sodium|
1730557|NCT00030641|Drug|docetaxel|
1730558|NCT00030654|Drug|bicalutamide|
1730559|NCT00030654|Drug|docetaxel|
1730560|NCT00030654|Drug|doxorubicin hydrochloride|
1730561|NCT00030654|Drug|estramustine phosphate sodium|
1730562|NCT00030654|Drug|flutamide|
1730563|NCT00030654|Drug|ketoconazole|
1730564|NCT00030654|Drug|paclitaxel|
1730565|NCT00030654|Drug|releasing hormone agonist therapy|
1730566|NCT00030654|Drug|vinblastine sulfate|
1730567|NCT00030667|Drug|imatinib mesylate|Given orally
1730568|NCT00030667|Other|laboratory biomarker analysis|Correlative studies
1730569|NCT00030667|Other|pharmacological study|Correlative studies
1730570|NCT00030680|Radiation|radiation therapy|
1730571|NCT00030693|Biological|recombinant fowlpox-B7.1 vaccine|Given intratumorally
1730572|NCT00030693|Biological|recombinant fowlpox-TRICOM vaccine|Given intratumorally
1730573|NCT00030693|Other|laboratory biomarker analysis|Correlative studies
1730574|NCT00030693|Procedure|quality-of-life assessment|Ancillary studies
1730575|NCT00030706|Drug|ixabepilone|
1730577|NCT00030719|Biological|monoclonal antibody Ch14.18|
1730578|NCT00030719|Drug|busulfan|
1730579|NCT00030719|Drug|carboplatin|
1730580|NCT00030719|Drug|cyclophosphamide|
1730581|NCT00030719|Drug|etoposide|
1730582|NCT00030719|Drug|isotretinoin|
1730583|NCT00030719|Drug|melphalan|
1730584|NCT00030719|Drug|vincristine sulfate|
1730585|NCT00030719|Procedure|bone marrow ablation with stem cell support|
1730586|NCT00030719|Procedure|conventional surgery|
1730587|NCT00030719|Procedure|peripheral blood stem cell transplantation|
1730588|NCT00030719|Radiation|radiation therapy|
1730589|NCT00030732|Drug|Gemcitabine + Capecitabine|Gemcitabine + Capecitabine
1730590|NCT00030732|Drug|Gemcitabine alone|Gemcitabine alone
1730591|NCT00030745|Drug|cisplatin|
1730592|NCT00030745|Drug|gemcitabine hydrochloride|
1730593|NCT00030745|Procedure|conventional surgery|
1730594|NCT00030758|Biological|filgrastim|
1730595|NCT00030758|Biological|pegfilgrastim|
1730596|NCT00030771|Drug|Chemotherapy|Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
1730597|NCT00030771|Radiation|Radiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
1730598|NCT00030771|Procedure|Surgery|3-4 weeks after termination of radiotherapy
1730599|NCT00030784|Drug|ifosfamide|
1730600|NCT00030784|Drug|pegylated liposomal doxorubicin hydrochloride|
1730601|NCT00030797|Drug|Irinotecan 70 mg/m2|Irinotecan i.v. 70 mg/m2, day 1, 8, 15, 22, 29
1730602|NCT00030797|Drug|Irinotecan 240 mg/m2|Irinotecan i.v. 240 mg/m2 day 1 and day 22
1730603|NCT00030810|Radiation|Hyperfractionated|Hyperfractionated radiotherapy
1730604|NCT00030810|Drug|Taxotere/Cisplatin|Taxotere/Cisplatin
1730605|NCT00030810|Procedure|conventional surgery|conventional surgery
1730606|NCT00030823|Biological|Globo-H-GM2-Lewis-y-MUC1-32(aa)-sTn(c)-TF(c)-Tn(c)-KLH conjugate vaccine|
1730607|NCT00030823|Biological|QS21|
1730608|NCT00030849|Biological|recombinant interferon alfa|
1730609|NCT00030849|Drug|bexarotene|
1730610|NCT00030862|Drug|cisplatin|
1730611|NCT00030862|Drug|irinotecan hydrochloride|
1730612|NCT00030875|Drug|bortezomib|
1730613|NCT00030888|Drug|7-hydroxystaurosporine|
1730614|NCT00030901|Drug|L-selenomethionine|Randomization between active L-selenomethionine and placebo
1730615|NCT00030901|Drug|L-selenomethionine placebo|Randomization between active L-selenomethionine and placebo
1730616|NCT00030914|Drug|medroxyprogesterone|
1730617|NCT00030914|Drug|venlafaxine|
1730618|NCT00030966|Drug|Natalizumab|Natalizumab, 300 mg, monthly IV infusion for up to 116 weeks.
1730619|NCT00030966|Drug|Placebo|Placebo monthly infusion for up to 116 weeks.
1730620|NCT00030979|Drug|Donepezil|
1730621|NCT00030992|Drug|BMS-247550|One hour infusion on five successive days (daily x 5) every three weeks. Starting dose of 6 mg/m^2/day for a total per cycle dose of 30 mg/m^2
1730622|NCT00030992|Drug|Ranitidine|50 mg 30-60 minutes prior to Ixabepilone (BMS-247550)
1730623|NCT00030992|Drug|Diphenhydramine|50 mg intravenously 30-60 minutes prior to Ixabepilone (BMS-247550)
1730624|NCT00031005|Procedure|modified stem cell transplant|
1730625|NCT00031018|Drug|Aricept|
1730626|NCT00031018|Drug|IFN-alpha2A|
1730627|NCT00031031|Drug|Kanglaite Injection (KLT)|
1730628|NCT00031044|Drug|Enfuvirtide|
1730629|NCT00031044|Drug|Amdoxovir|
1730630|NCT00031057|Drug|Thiamine hydrochloride|
1730631|NCT00031057|Drug|Riboflavin|
1730632|NCT00031070|Drug|Abacavir sulfate, Lamivudine and Zidovudine|
1730633|NCT00031070|Drug|Cyclosporine|
1730634|NCT00031070|Biological|Hepatitis A Vaccine (Inactivated)|
1730635|NCT00031070|Drug|Efavirenz|
1730636|NCT00031070|Biological|Pneumococcal Conjugate Vaccine, Heptavalent|
1730637|NCT00031070|Biological|Rabies Vaccine|
1730638|NCT00031083|Genetic|Interferon-beta|
1730639|NCT00031096|Drug|Azelaic Acid Gel 15% (Finacea, BAY39-6251)|Azelaic Acid 15% gel (SH H 655 BA) applied topically two times per day.
1730640|NCT00031096|Drug|Vehicle gel (SH H 655 PBA)|Vehicle gel (SH H 655 PBA) applied topically two times per day.
1730641|NCT00031109|Biological|gp160 MN/LAI-2|
1730642|NCT00031109|Biological|Aluminum hydroxide|
1730643|NCT00031122|Other|No Intervention|There is no intervention in this study
1730644|NCT00031135|Drug|Choline Chloride|
1730645|NCT00031148|Drug|Recombinant Human Keratinocyte Growth Factor (rHuKGF)|
1730646|NCT00031161|Drug|Nitisinone (NTBC)|
1730647|NCT00031161|Drug|Dichloroacetate|
1730648|NCT00031161|Behavioral|Low-tyrosin diet|
1730649|NCT00031187|Drug|SGN-15 (cBR96-doxorubicin immunoconjugate)|
1730650|NCT00031187|Drug|Taxotere (docetaxel)|
1730651|NCT00031265|Procedure|Family Intervention Telephone Tracking|
1730652|NCT00031278|Drug|CPG 7909|Each 0.01 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
1730653|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
1730654|NCT00031278|Drug|CPG 7909|Each 0.04 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
1730655|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
1730656|NCT00031278|Drug|CPG 7909|Each 0.16 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
1730657|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
1730658|NCT00031278|Drug|CPG 7909|Each 0.32 mg/kg CPG 7909 treatment will consist of a monitored 2-hour infusion given once weekly until disease progression or a maximum of 24 weeks.
1730659|NCT00031278|Drug|Herceptin®|Herceptin® will be administered at a dose of 2 mg/kg IV according to the Herceptin® package insert
1730660|NCT00031291|Drug|Anthrax Immune Globulin|
1730661|NCT00031317|Drug|Paroxetine|
1730662|NCT00031317|Drug|Clozapine|
1730663|NCT00031343|Drug|highly active antiretroviral therapy (HAART)|
1730664|NCT00031395|Drug|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults.
1730665|NCT00031395|Drug|methylphenidate|MPH is FDA-approved for the treatment of ADHD symptoms in children.
1730666|NCT00031395|Other|placebo|an inactive substance
1730667|NCT00031434|Drug|Valganciclovir|Valganciclovir is a mono-valyl ester pro-drug of ganciclovir, which is rapidly converted to ganciclovir on absorption. Valganciclovir oral syrup formulation for administration will be provided as a 15g powder blend containing 3g valganciclovir base, for constitution in 120 mL amber glass bottles. The beginning oral valganciclovir dose under investigation is 14 mg/kg. The dose of oral valganciclovir syrup will be adjusted for the baby's weight and renal function. Weights upon which dosage will be adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35.
1730668|NCT00031434|Drug|Ganciclovir|Ganciclovir for intravenous infusion will be provided as sterile, lyophilized powder in sealed vials containing 500 mg ganciclovir for re-constitution. The dose of intravenous ganciclovir is 6 mg/kg. Intravenous ganciclovir will be adjusted for the baby's weight and renal function. Weights upon which dosage adjustments will be made will be obtained on study days 1, 7, 14, 21, 28, and 35. Each dose of intravenous ganciclovir should be given over 1 hour using an intravenous pump.
1730669|NCT00031447|Drug|Acyclovir|Oral suspension 300 mg/m^2/dose, 3 times per day (TID), for 6 months.
1730670|NCT00031447|Drug|Placebo|Placebo identical to oral acyclovir suspension in appearance and taste.
1730671|NCT00031460|Drug|Acyclovir|Oral banana flavored acyclovir suspension: 300 mg/m^2/dose three times a day (TID), to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
1730672|NCT00031460|Drug|Placebo|Oral banana flavored placebo suspension: to be given at least 6 to 8 hours apart for 6 months. Dosage adjustments will be made monthly to compensate for increases in body surface area.
1730673|NCT00031473|Drug|Virazole (Ribavirin) Inhalation Solution|
1730676|NCT00031499|Drug|Azithromycin|Single 2 gram oral dose (4 tablets) at Day 1.
1730677|NCT00031499|Drug|Benzathine Penicillin|Supplied in pre-filled syringes containing 1.2 million units of benzathine penicillin; 2.4 million units administered intramuscularly at Day 1, in one or both buttocks.
1730678|NCT00031499|Drug|Doxycycline|Baseline visit, 28 capsules dispensed, for a dose of 100 mg twice a day (BID).
1730679|NCT00031512|Drug|Placebo|Placebo.
1730680|NCT00031512|Drug|Pleconaril (VP63843)|5 mg/kg /dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral liquid formulation and 8.5 mg/kg/dose oral every 8 hours for 7 days (21 doses) of a 40 mg/mL oral suspension formulation.
1730681|NCT00031551|Drug|Etanercept|
1730682|NCT00031551|Drug|Placebo|
1730683|NCT00031564|Biological|Interleukin-2|
1730684|NCT00031564|Biological|B7-1|
1730685|NCT00031577|Drug|paclitaxel|
1730686|NCT00031577|Radiation|radiation therapy|
1730687|NCT00031590|Drug|Cisplatin|Given at a dose of 70mg/m2 by intravenous (IV) infusion over 8 hours on day 0 of each cycle (Regimen A only).
1730688|NCT00031590|Drug|Cyclophosphamide|Given at a dose of 1g/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Administration of cyclophosphamide will always be preceded by prehydration and Mesna (Regimen B only).
1730689|NCT00031590|Drug|Etoposide|Given at a dose of 150mg/m2/day by IV infusion on days 0 and 1 of a 6-week cycle. Given orally at a dose of 50mg/m2 as a single daily dose for 21 days beginning on day 14 of a cycle (Regimen B only).
1730690|NCT00031590|Drug|Lomustine|Given at a dose of 75mg/m2 taken orally on days 0 of each 6-week cycle with vincristine and cisplatin (Regimen A only).
1730691|NCT00031590|Drug|Vincristine|Given at a dose of 1.5mg/m2 given by IV infusion once a week for the first six weeks of treatment during radiation therapy. During maintenance therapy, it will be given as an IV push on days 0, 7 and 14 of each 6-week cycle (Regimen A only).
1730692|NCT00031590|Drug|Mesna|Given at a dose of 360mg/m2 by IV 15 minutes prior to every dose of cyclophosphamide and again after each dose of cyclophosphamide (Regimen B only).
1730693|NCT00031590|Radiation|Craniospinal Radiation|Craniospinal radiation will begin within 28 days of surgery. Craniospinal Radiation therapy will last for 6 weeks, five days per week. Once a week during radiation, subjects will also be treated with chemotherapy (vincristine).
1730694|NCT00031616|Drug|brivudine phosphoramidate|
1730695|NCT00031629|Drug|Docetaxel|Given IV
1730696|NCT00031629|Biological|Filgrastim|Given SC
1730697|NCT00031629|Drug|Gemcitabine Hydrochloride|Given IV
1730698|NCT00031629|Biological|Pegfilgrastim|Given IV
1730699|NCT00031642|Biological|rituximab|
1730700|NCT00031642|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1730701|NCT00031655|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
1730702|NCT00031655|Biological|donor lymphocytes|Given IV
1730703|NCT00031655|Drug|cyclosporine|Given PO
1730704|NCT00031655|Radiation|total-body irradiation|Undergo TBI
1730705|NCT00031655|Drug|fludarabine phosphate|Given IV
1730706|NCT00031655|Drug|mycophenolate mofetil|Given PO
1730707|NCT00031655|Other|laboratory biomarker analysis|Correlative studies
1730708|NCT00031655|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSCT
1730709|NCT00031668|Radiation|radiation therapy|
1730710|NCT00031681|Drug|7-hydroxystaurosporine|Given IV
1730711|NCT00031681|Drug|irinotecan hydrochloride|Given IV
1730712|NCT00031681|Other|diagnostic laboratory biomarker analysis|Correlative studies
1730713|NCT00031694|Drug|paclitaxel|Given IV
1730714|NCT00031694|Drug|bryostatin 1|Given IV
1730715|NCT00031707|Dietary Supplement|eicosapentaenoic acid|
1730716|NCT00031707|Drug|megestrol acetate|
1730717|NCT00031707|Other|placebo|
1730718|NCT00031720|Dietary Supplement|soy protein|Given orally
1730719|NCT00031720|Dietary Supplement|isoflavones|Given orally
1730720|NCT00031720|Drug|Tamoxifen|
1730721|NCT00031720|Other|Placebo|Oral
1730722|NCT00031733|Biological|MART-1 antigen|
1730723|NCT00031733|Biological|gp100 antigen|
1730724|NCT00031733|Biological|incomplete Freund's adjuvant|
1730725|NCT00031733|Biological|recombinant interleukin-12|
1730726|NCT00031733|Biological|sargramostim|
1730727|NCT00031733|Biological|tyrosinase peptide|
1730728|NCT00031733|Drug|alum adjuvant|
1730729|NCT00031733|Procedure|adjuvant therapy|
1730730|NCT00031746|Dietary Supplement|soy protein isolate|25 mg daily
1730731|NCT00031746|Dietary Supplement|casein proteins|25 mg daily
1730732|NCT00031759|Drug|imiquimod|
1730733|NCT00031759|Procedure|Ablative or excisional therapy|
1730734|NCT00031772|Procedure|psychosocial assessment and care|Questionnaire and telephone intervention
1730735|NCT00031785|Drug|megestrol acetate|
1730736|NCT00031785|Radiation|radiation therapy|
1730737|NCT00031798|Drug|methylphenidate hydrochloride|
1730738|NCT00031798|Procedure|quality-of-life assessment|
1730739|NCT00031798|Radiation|radiation therapy|
1730740|NCT00037999|Procedure|Testosterone supplement|
1730741|NCT00038012|Drug|Thrombopoietin|
1730742|NCT00038012|Procedure|Platelet-pheresis|
1730743|NCT00038012|Drug|Carboplatin|
1730744|NCT00038025|Drug|Deoxycoformycin (DCF)|Patients received Deoxycoformycin (DCF)/Pentostatin administered by intravenous bolus daily over a consecutive 3-day period. This course was repeated at 3-week intervals.
1730745|NCT00038038|Drug|18F-fluoromisonidazole|Small amount of radioactive traces drug given by intravenous injection prior to PET Scan
1730746|NCT00038038|Procedure|PET scan|Series of pictures using 20 minute scan performed 2 hours after an 18F-fluoromisonidazole injection
1730747|NCT00038051|Drug|Hum-195/rGel|Starting Dose = 3 mg/m^2 twice weekly for 2 weeks.
1730748|NCT00038064|Drug|Darbepoetin alfa|Darbepoetin alfa will be administered 4.5 mcg/kg QW until hemoglobin correction is achieved. Subjects meeting hemoglobin criteria for correction will receive a maintenance dose of darbepoetin alfa of 4.5 mcg/kg Q3W.
1730749|NCT00038064|Drug|rHuEPO|150 IU/kg TIW
1730750|NCT00038077|Drug|Seloken ZOK/Toprol-XL|50 mg
1730751|NCT00038077|Drug|Seloken ZOK/Toprol-XL|200 mg
1730752|NCT00038077|Drug|Placebo|
1730753|NCT00038090|Drug|Thalidomide|100 mg capsules by mouth daily each evening
1730754|NCT00038090|Drug|Dexamethasone|20 mg/m^2 taken by mouth each morning on days 1-4, 9-12 and 17-20.
1730755|NCT00038103|Drug|Exemestane|Patient will be instructed to take a 25 mg exemestane tablet, once a day, every day, with food.
1730756|NCT00038103|Drug|Celecoxib + Exemestane|Exemestane + celecoxib treatment arm, she will be instructed to take also two x 200 mg celecoxib capsules twice a day, every day, with food.
1730757|NCT00038116|Procedure|embryonic dopamine cell implant surgery|Half of the participants received the cell implant surgery, while the other half received the placebo. After the double-blind phase of the study, patients in the placebo group had the option of receiving tissue implants. Fourteen of these patients eventually had transplants.
1730758|NCT00038116|Procedure|placebo|sham surgery
1730759|NCT00038129|Procedure|Intramedullary nail implant|Insertion of an intramedullary nail during tibial fracture fixation with or without prior reaming of the intramedullary canal.
1730760|NCT00038142|Drug|Vincristine|2.0 mg/m^2 (max 2.0 mg) IV x 1 repeated every 3 weeks X 6.
1730761|NCT00038142|Drug|Doxorubicin|90 mg/m^2 IV over 30 min x 1 repeated every 3 weeks X 6.
1730762|NCT00038142|Drug|Cyclophosphamide|2.0 g/m^2 IV daily x 2 days repeated every 3 weeks X 6.
1730763|NCT00038142|Drug|Dexrazoxane|900 mg/m^2 IV (30 min prior to doxorubicin) repeated every 3 weeks X 6.
1730764|NCT00038142|Biological|ImmTher|900 mcg/m^2 IV over 1 hour every week x 50-52 weeks.
1730765|NCT00038155|Procedure|Ambulation training|Recruitment of eligible subjects, ambulatory and resistance training in hospital and post-discharge
1730766|NCT00038168|Drug|Estramustine|Intravenous dose
1730767|NCT00038168|Drug|Taxol|Intravenous dose
1730768|NCT00038181|Drug|Thalidomide|
1730769|NCT00038194|Drug|imatinib mesylate|
1730770|NCT00038194|Drug|docetaxel|
1730771|NCT00038207|Drug|Liposomal Vincristine|Vincristine Sulfate Liposome Injection (VSLI) administered via a central venous catheter at 2.0 mg/m2 over 60 minutes every 14 days + 2 days
1730772|NCT00038220|Drug|Lopinavir/ritonavir|
1730773|NCT00038220|Drug|Efavirenz|
1730774|NCT00038220|Drug|Lamivudine|
1730775|NCT00038220|Drug|Tenofovir DF|
1730776|NCT00038233|Drug|Thalidomide|200 mg at bedtime daily for 14 days (days 1-14), followed by an increase to 400 mg daily for 14 days (days 15-28), 600 mg daily for 14 days (days 29-42), up to a maximum 800 mg (days 43-completion)
1730777|NCT00038246|Drug|Estramustine|140 mg by mouth (po) three times a day on Days 1-5, 8-12
1730778|NCT00038246|Drug|Thalidomide|200 mg by mouth every day once a week with dose escalation every week if no dose limiting toxicity.
1730779|NCT00038246|Drug|Paclitaxel (Taxol)|100 mg/m^2 by vein (IV) over 3 hours Day 3 and Day 10
1730780|NCT00038259|Drug|Aldesleukin|
1730781|NCT00038272|Drug|Mycophenolate mofetil|
1730782|NCT00038272|Drug|Amdoxovir|
1730783|NCT00038285|Procedure|Amputation Prevention|
1730784|NCT00038298|Drug|Placebo|Placebo given 3 times weekly
1730785|NCT00038298|Drug|AMG 719|50 mg 3 times weekly
1730786|NCT00038298|Drug|AGM 719|200 mg 3 times weekly
1730787|NCT00038298|Drug|AMG 719|400 mg 3 times weekly
1730788|NCT00038298|Drug|placebo to AMG 719|Placebo dose given 3 times weekly
1730789|NCT00038311|Drug|PN-152,243)/PN-196,444|
1730790|NCT00038337|Procedure|Health Literacy|
1730883|NCT00040872|Drug|isotretinoin|
1730791|NCT00040404|Drug|CEP-1347 10mg|CEP-1347 10mg, a K252a derivative, retains neuroprotective properties
1730792|NCT00040404|Drug|CEP1347 25mg|CEP1347 25mg, a K252a derivative, retains neuroprotective properties
1730793|NCT00040404|Drug|CEP-1347 50mg|CEP-1347 50mg, a K252a derivative, retains neuroprotective properties
1730794|NCT00040404|Other|Placebo Comparator|Placebo capsules matching the CEP-1347 capsules
1730795|NCT00040417|Drug|FLUDARABINE|
1730796|NCT00040417|Drug|CAMPATH-IH|
1730797|NCT00040417|Procedure|Total Body Irradiation|
1730798|NCT00040417|Drug|FK506|
1730799|NCT00040417|Drug|G-SCF (Granulocyte-colony stimulating factor)|
1730800|NCT00040430|Drug|111In-DAC|
1730801|NCT00040430|Procedure|Diagnostic|
1730803|NCT00040456|Drug|Mg Pidolate|Mag 2 will be used (magnesium pidolate, a granular powder, containing 0.184 g of Mg/packet, equal to 7.6 mmol or 15.2 meq Mg), since this preparation has less side effects such as diarrhea than other Mg preparations. The study medication will be a liquid containing 0.6 meq Mg pidolate/kg body weight per day, divided into 2 daily doses. The Mg pidolate (45 g) will be distributed as a pre-mixed powder containing Koolaid Tropical Punch powder (9 gm), and sucrose (67 gm).
1730804|NCT00040456|Drug|Placebo|The study medication will be a liquid containing an equivalent amount of placebo to the study medication, divided into 2 daily doses.The placebo will have the same amount of sucrose and Tropical Punch powder as the study drug, MG Pidolate, as well as 45 g of lactose. Subjects will continue with the same assignment for 6 months and then switch to the other arm (after a 2-month wash-out period).
1730805|NCT00040469|Drug|Campath -1H|
1730806|NCT00040469|Drug|Dilantin|
1730807|NCT00040469|Drug|Busulfan|
1730808|NCT00040469|Drug|Cyclophosphamide|
1730809|NCT00040482|Drug|Cyclophosphamide|
1730810|NCT00040482|Drug|ATG|
1730811|NCT00040482|Drug|MESNA|
1730812|NCT00040482|Procedure|Radiation therapy|
1730813|NCT00040495|Drug|Pantoprazole|
1730814|NCT00040508|Drug|Sirolimus|
1730815|NCT00040521|Drug|Recombinant Human Interleukin-11 (rhIL-11)|
1730816|NCT00040534|Drug|Farnesyl Protein Transferase Inhibitor|
1730817|NCT00040547|Drug|Farnesyl Protein Transferase Inhibitor|
1730818|NCT00040560|Drug|111In-DAC|
1730819|NCT00040560|Procedure|Diagnostic|
1730820|NCT00040573|Drug|131I-TM-601|
1730821|NCT00040586|Drug|Monoclonal Antibody J591|
1730822|NCT00040586|Drug|Recombinant Interleukin-2|
1730823|NCT00040599|Drug|hMN14 (labetuzumab)|
1730824|NCT00040625|Drug|Pemetrexed|
1730825|NCT00040625|Drug|Cisplatin|
1730826|NCT00040638|Drug|TLK286|
1730827|NCT00040651|Drug|Fludarabine|
1730828|NCT00040651|Drug|Cyclophosphamide|
1730829|NCT00040651|Drug|Thymoglobulin|
1730830|NCT00040651|Procedure|Leukapheresis|
1730831|NCT00040651|Procedure|Self bone marrow transplant|
1730832|NCT00040664|Drug|ritonavir|ritonavir oral capsules or oral solution
1730833|NCT00040664|Drug|fosamprenavir|fosamprenavir oral suspension or tablet
1730834|NCT00040677|Drug|Low Dose ICA-17043|Low dose arm
1730835|NCT00040677|Drug|High dose ICA-17043|150 mg Loading Dose; 10 mg daily dose
1730836|NCT00040677|Drug|Placebo|Placebo Loading dose capsules and maintenance dose tablets matched 10 mg active treatment group
1730837|NCT00040690|Biological|filgrastim|
1730838|NCT00040690|Drug|cyclophosphamide|
1730839|NCT00040690|Drug|cytarabine|
1730840|NCT00040690|Drug|doxorubicin hydrochloride|
1730841|NCT00040690|Drug|etoposide|
1730842|NCT00040690|Drug|ifosfamide|
1730843|NCT00040690|Drug|leucovorin calcium|
1730844|NCT00040690|Drug|methotrexate|
1730845|NCT00040690|Drug|vincristine sulfate|
1730846|NCT00040690|Radiation|radiation therapy|
1730847|NCT00040729|Genetic|mutation analysis|
1730848|NCT00040742|Dietary Supplement|ginger|Given orally
1730849|NCT00040742|Other|placebo|Given orally
1730850|NCT00040755|Drug|rebimastat|Given orally
1730851|NCT00040755|Other|laboratory biomarker analysis|Correlative studies
1730852|NCT00040768|Drug|bortezomib|Given IV
1730853|NCT00040781|Drug|gefitinib|Given orally
1730854|NCT00040781|Other|pharmacological study|Correlative studies
1730855|NCT00040781|Other|laboratory biomarker analysis|Correlative studies
1730856|NCT00040794|Drug|paclitaxel|Given IV
1730857|NCT00040794|Drug|carboplatin|Given IV
1730858|NCT00040794|Drug|gefitinib|Given PO
1730859|NCT00040794|Radiation|radiation therapy|Undergo radiotherapy
1730860|NCT00040794|Other|laboratory biomarker analysis|Optional correlative studies
1730861|NCT00040807|Drug|docetaxel|
1730862|NCT00040807|Drug|irinotecan hydrochloride|
1730863|NCT00040820|Drug|oxaliplatin|
1730864|NCT00040833|Procedure|complementary or alternative medicine procedure|
1730865|NCT00040833|Procedure|pain therapy|
1730866|NCT00040846|Biological|alemtuzumab|Given IV
1730867|NCT00040846|Drug|fludarabine phosphate|Given IV
1730868|NCT00040846|Radiation|total-body irradiation|Undergo TBI
1730869|NCT00040846|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
1730870|NCT00040846|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplantation
1730871|NCT00040846|Drug|mycophenolate mofetil|Given PO
1730872|NCT00040846|Drug|cyclosporine|Given IV or PO
1730873|NCT00040859|Drug|capecitabine|
1730874|NCT00040859|Drug|oxaliplatin|
1730875|NCT00040872|Biological|filgrastim|
1730876|NCT00040872|Biological|monoclonal antibody 3F8|
1730877|NCT00040872|Biological|sargramostim|
1730878|NCT00040872|Drug|carboplatin|
1730879|NCT00040872|Drug|cisplatin|
1730880|NCT00040872|Drug|cyclophosphamide|
1730881|NCT00040872|Drug|doxorubicin hydrochloride|
1730885|NCT00040872|Drug|topotecan hydrochloride|
1730886|NCT00040872|Drug|vincristine sulfate|
1730887|NCT00040872|Procedure|autologous bone marrow transplantation|
1730888|NCT00040872|Procedure|bone marrow ablation with stem cell support|
1730889|NCT00040872|Procedure|conventional surgery|
1730890|NCT00040872|Procedure|drug resistance inhibition treatment|
1730891|NCT00040872|Procedure|peripheral blood stem cell transplantation|
1730892|NCT00040872|Procedure|syngeneic bone marrow transplantation|
1730893|NCT00040872|Radiation|radiation therapy|
1730894|NCT00040885|Biological|infliximab|
1730895|NCT00040885|Drug|docetaxel|
1730896|NCT00040885|Other|placebo|
1730897|NCT00040898|Dietary Supplement|Sho-saiko-to|
1730898|NCT00040911|Procedure|electroacupuncture therapy|
1730899|NCT00040911|Procedure|sham intervention|Undergo electroacupuncture therapy to sham points
1730900|NCT00040911|Procedure|quality-of-life assessment|Ancillary studies
1730901|NCT00040937|Biological|filgrastim|PBSC collection: 10 mcg/kg SQ days 1-10
1730902|NCT00040937|Biological|sargramostim|"PBSC collection: 500 mcg/m2 SQ day 1 through last apheresis
1st and 2nd trans: 500 mcg SC or IV days 6-WBC recovery"
1730903|NCT00040937|Drug|cyclophosphamide|PBSC collection: 1 mg/m2 IV over 45-60 mins day 0
1730904|NCT00040937|Drug|dexamethasone|40 mg/d PO days 1-4, 9-12, 17-20
1730905|NCT00040937|Drug|melphalan|"st trans: 140 mg/m2 IV over 20 mins day -1
nd trans: 200mg/m2 IV over 20 mins day -1"
1730906|NCT00040937|Drug|prednisone|maint: 50 mg/d PO every other day until progression
1730907|NCT00040937|Drug|thalidomide|ind: 50 mg increased by 50 mg every week to max 400 mg PO qhs for 35 days maint: 50 mg/d increased by 50 mg every week to 200 mg PO daily until progression
1730908|NCT00040937|Procedure|peripheral blood stem cell transplantation|2-4 x 10^6/kg IV day 0
1730909|NCT00040950|Biological|rituximab|
1730910|NCT00040950|Drug|agatolimod sodium|
1730911|NCT00040989|Drug|BAY 56-3722|
1730912|NCT00040989|Procedure|enzyme inhibitor therapy|
1730913|NCT00041015|Drug|cisplatin|
1730914|NCT00041015|Drug|etoposide|
1730915|NCT00041015|Drug|topotecan hydrochloride|
1730916|NCT00041028|Drug|EF5|
1730917|NCT00041028|Other|flow cytometry|
1730918|NCT00041028|Other|immunohistochemistry staining method|
1730919|NCT00041041|Drug|imatinib mesylate|Given PO
1730920|NCT00041041|Other|laboratory biomarker analysis|Correlative studies
1730921|NCT00041054|Drug|carboplatin|
1730922|NCT00041054|Drug|etoposide|
1730923|NCT00041054|Drug|exisulind|
1730924|NCT00041067|Biological|filgrastim|
1730925|NCT00041067|Biological|trastuzumab|
1730926|NCT00041067|Drug|docetaxel|
1730927|NCT00041067|Drug|vinorelbine|
1730928|NCT00041080|Drug|tamoxifen citrate|Given orally
1730929|NCT00041080|Drug|thalidomide|Given orally
1730930|NCT00041080|Other|laboratory biomarker analysis|Correlative studies
1730931|NCT00041093|Drug|Docetaxel|Given IV
1730932|NCT00041106|Drug|gemcitabine hydrochloride|Given IV
1730933|NCT00041106|Drug|cisplatin|Given IV
1730934|NCT00041106|Drug|gefitinib|Given PO
1730935|NCT00041106|Other|laboratory biomarker analysis|Correlative studies
1730936|NCT00041119|Drug|AC regimen|Given IV
1730937|NCT00041119|Drug|cyclophosphamide|Given IV
1730938|NCT00041119|Drug|doxorubicin hydrochloride|Given IV
1730939|NCT00041119|Drug|paclitaxel|Given IV
1730940|NCT00041132|Biological|filgrastim|5 ug/kg
1730941|NCT00041132|Biological|rituximab|375 mg/m^2 on day 1 of cycles 1-6
1730942|NCT00041132|Drug|cyclophosphamide|300 mg/m^2 on days 2-4 of cycles 1,3,5,7
1730943|NCT00041132|Drug|cytarabine|12 g/m^2 over days 3-4 of cycles 2,4,6,8
1730944|NCT00041132|Drug|dexamethasone|40 mg on days 2-5 and 12-15 of cycles 1,3,5,7
1730945|NCT00041132|Drug|doxorubicin|16.6 mg/m^2/day for days 5-7 of cycles 1,3,5,7
1730946|NCT00041132|Drug|leucovorin|170 mg over days 3-5 of cycles 2,4,6,8
1730947|NCT00041132|Drug|methotrexate|1000 mg/m^2 over days 2-3 of cycles 2,4,6,8
1730948|NCT00041132|Drug|vincristine|1.4 mg/m^2 on days 5 and 12 of cycles 1,3,5,7
1730949|NCT00041171|Drug|Hypericum perforatum|
1730950|NCT00041171|Drug|docetaxel|
1730951|NCT00041171|Other|placebo|
1730952|NCT00041197|Drug|imatinib mesylate|Given orally (PO)
1730953|NCT00041197|Other|placebo|Given PO
1730954|NCT00041197|Other|laboratory biomarker analysis|Correlative studies
1730955|NCT00041210|Biological|bleomycin sulfate|
1730956|NCT00041210|Drug|ABVD regimen|
1730957|NCT00041210|Drug|Stanford V regimen|
1730958|NCT00041210|Drug|dacarbazine|
1730959|NCT00041210|Drug|doxorubicin hydrochloride|
1730960|NCT00041210|Drug|etoposide|
1730961|NCT00041210|Drug|mechlorethamine hydrochloride|
1730962|NCT00041210|Drug|prednisone|
1730963|NCT00041210|Drug|vinblastine sulfate|
1730964|NCT00041210|Drug|vincristine sulfate|
1730965|NCT00041210|Radiation|radiation therapy|
1730966|NCT00041223|Dietary Supplement|IH636 grape seed proanthocyanidin extract|
1730967|NCT00041236|Drug|exatecan mesylate|
1730968|NCT00041249|Drug|brostallicin|
1730969|NCT00041262|Drug|cisplatin|
1730970|NCT00041262|Drug|epirubicin hydrochloride|
1730971|NCT00041262|Drug|fluorouracil|
1730972|NCT00041262|Procedure|conventional surgery|
1730973|NCT00041262|Procedure|neoadjuvant therapy|
1730974|NCT00041275|Drug|megestrol acetate|
1730975|NCT00041288|Biological|therapeutic allogeneic lymphocytes|
1730976|NCT00041288|Drug|cyclophosphamide|
1730977|NCT00041288|Drug|cyclosporine|
1730978|NCT00041288|Drug|fludarabine phosphate|
1730979|NCT00041288|Drug|methotrexate|
1730980|NCT00041288|Drug|mycophenolate mofetil|
1730981|NCT00041288|Drug|tacrolimus|
1730982|NCT00041288|Procedure|peripheral blood stem cell transplantation|
1730983|NCT00041288|Radiation|radiation therapy|
1730984|NCT00041301|Other|QoL assessment|qol questionnaires
1730985|NCT00041314|Drug|carboplatin|
1730986|NCT00041314|Drug|exisulind|
1730987|NCT00041314|Drug|gemcitabine hydrochloride|
1730988|NCT00041327|Biological|filgrastim|5 ug/kg/d
1730989|NCT00041327|Biological|recombinant interferon alfa|9 mU subcutaneously per day for one year
1730990|NCT00041327|Drug|Etoposide|50 mg/m2/day continuous 96 hr infusion, days 1-4
1730991|NCT00041327|Drug|cyclophosphamide|750 mg/m2 IV on day 5
1730992|NCT00041327|Drug|doxorubicin hydrochloride|10 mg/m2/day as a continuous 96-hour infusion days 1-4
1730993|NCT00041327|Drug|lamivudine|150 mg bid
1730994|NCT00041327|Drug|prednisone|60 mg/m2 given orally days 1-5
1730995|NCT00041327|Drug|vincristine sulfate|0.4 mg/m2/day as a 96-hour continuous infusion days 1-4
1730996|NCT00041327|Drug|zidovudine|300 mg bid
1730997|NCT00041340|Drug|imatinib mesylate|Given orally
1730998|NCT00041340|Other|laboratory biomarker analysis|Correlative studies
1730999|NCT00041353|Other|cytology specimen collection procedure|
1731000|NCT00041353|Procedure|comparison of screening methods|
1731001|NCT00041353|Procedure|study of high risk factors|
1731002|NCT00041379|Drug|beta alethine|
1731003|NCT00041392|Drug|Magnesium|100 mg/kg
1731004|NCT00041392|Drug|0.9% saline|Placebo
1731005|NCT00041431|Drug|Hormone Replacement Therapy|
1731006|NCT00041470|Drug|Paclitaxel|50 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
1731007|NCT00041470|Drug|Vinorelbine|20 mg/m2 IV weekly. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
1731008|NCT00041470|Drug|Herceptin|4 mg/kg IV loading dose day 1 of first week followed by 2 mg/kg IV maintenance dose on each subsequent week. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
1731009|NCT00041470|Drug|Filgrastim|5 mcg/kg daily including the day of IV chemotherapy. Treatment continues until disease progression, excessive toxicity or other reason to remove the patient from protocol treatment.
1731010|NCT00041483|Drug|Anecortave Acetate 15 mg sterile suspension|
1731011|NCT00041483|Other|Photodynamic Therapy (PDT)|
1731012|NCT00041496|Drug|SB-207266|White, oval, biconvex tablets containing either 10mg, 25mg or 40mg
1731013|NCT00041496|Other|Placebo|Placebo to match SB-207266
1731014|NCT00041509|Drug|SB-424323|500 mg, oral, BID for 28 days or 125 mg, oral, BID for 28 days
1731015|NCT00041509|Drug|Placebo|matching placebo, oral, BID for 28 days
1731016|NCT00041535|Drug|OGT 918|
1731017|NCT00041548|Drug|nitric oxide for inhalation|given at 20 ppm for 1 hour then weaned off over 4 hours
1731018|NCT00041548|Drug|Oxygen|given at 20 ppm for one hour, then weaned off over four hours
1731019|NCT00041561|Drug|Nitrogen gas|Nitrogen gas will be given at 5ppm until Day 28 or extubation
1731020|NCT00041561|Drug|inhaled nitric oxide|inhaled nitric oxide will be given at 5 ppm until day 28 or extubation
1731021|NCT00041574|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be delivered through the INOpulse® at a Low Dose Range (3mL to 10mL; in 1mL increments) and Ultra Low Dose Ranges (0.5mL to 4mL; 0.5mL, then 1 to 4mL in 1mL increments).
1731022|NCT00041587|Drug|IL13-PE38QQR|
1731023|NCT00041587|Procedure|targeted fusion protein therapy|
1731024|NCT00041587|Procedure|surgery|
1731025|NCT00041613|Genetic|INGN 201|
1731026|NCT00041626|Genetic|INGN 201|
1731027|NCT00041639|Drug|hMN14 (labetuzumab)|
1731028|NCT00041652|Drug|hMN14 (labetuzumab)|
1731029|NCT00041665|Drug|Recombinant Human Keratinocyte Growth Factor|
1731030|NCT00041678|Drug|aripiprazole|
1731031|NCT00041691|Drug|hMN14 (labetuzumab)|
1731032|NCT00041704|Drug|Anidulafungin, VER002|
1731033|NCT00041717|Drug|Fampridine-SR|25mg bid (twice daily)
1731034|NCT00041717|Other|Placebo|Placebo
1731035|NCT00041730|Biological|Id-KLH|
1731036|NCT00041743|Behavioral|Group Cognitive Behavioral Therapy|
1731037|NCT00041756|Drug|PG-530742|One 25 mg PG-530742 tablet, twice daily for for one year
1731038|NCT00041756|Drug|Placebo|One placebo tablet, twice daily for for one year
1731039|NCT00041756|Drug|50 mg PG-530742|One 50 mg PG-530742 tablet, twice daily for for one year
1731040|NCT00041756|Drug|100 mg PG-530742|100 mg PG-530742 tablet, twice a day for one year
1731041|NCT00041756|Drug|200 mg PG-530742|200 mg PG-530742 tablet, twice a day for one year
1731042|NCT00041769|Procedure|Therapeutic Drug Monitoring (TDM)|
1731043|NCT00041782|Drug|Dalteparin (Fragmin)|200 IU/kg subcutaneously daily (based on actual body weight with a maximum dose of 18,000 IU).
1731044|NCT00041795|Drug|leteprinim potassium (Neotrofin)|
1731045|NCT00041808|Drug|MTC-DOX for Injection|
1731046|NCT00041808|Procedure|Chemotherapy|
1731047|NCT00041821|Procedure|Nasal irritation thresholds and irritant provocation|
1731048|NCT00041860|Procedure|Controlled Exposure to Environmental Contaminant|
1731049|NCT00041899|Drug|CDB-2914|
1731050|NCT00041899|Drug|COB-2914|
1731051|NCT00041925|Drug|CGT003 (E2F Duplex Decoy)|
1731052|NCT00041938|Drug|aspirin|325 mg per day
1731053|NCT00041938|Drug|Warfarin|INR 2.5-3.0; target INR 2.75
1731054|NCT00041977|Drug|doxycycline hyclate 20 mg twice daily|
1731055|NCT00041990|Drug|decitabine (5-aza-2'deoxycytidine)|
1731056|NCT00042003|Drug|decitabine (5-aza-2'deoxycytidine)|
1731057|NCT00042016|Drug|decitabine (5-aza-2'deoxycytidine)|
1731058|NCT00042029|Drug|MK0869, aprepitant|
1731059|NCT00042029|Drug|Comparator: placebo|
1731060|NCT00042042|Behavioral|Family based educational program|
1731061|NCT00042055|Drug|CP-461|
1731062|NCT00042068|Drug|Meloxicam|
1731063|NCT00042081|Drug|CGT003 (E2F Duplex Decoy)|
1731064|NCT00042094|Biological|Cell-Cultured Smallpox Vaccine compared to Dryvax®|
1731065|NCT00042146|Behavioral|Cognitive-behavior therapy|
1731066|NCT00042146|Drug|zolpidem|
1731067|NCT00042159|Device|repetitive transcranial magnetic stimulation|1 Hertz stimulation for 16 minutes per day at 90% motor threshold, 5 sessions each to the two primary cortical targets
1731068|NCT00042172|Drug|Donepezil|
1731069|NCT00042172|Drug|Ginkgo Biloba Extract|
1731070|NCT00042185|Behavioral|Dissonance Eating Disorder Prevention Program|In this intervention, participants voluntarily engaged in verbal, written, and behavioral exercises in which they critiqued the thin-ideal ideal. These exercises were conducted in sessions and in homework activities. For example, they wrote a counter-attitudinal essay about the costs associated with pursuit of the thin-ideal and engaged in a counter-attitudinal role-play in which they attempted to dissuade facilitators from pursuing the thin-ideal.
1731071|NCT00042185|Behavioral|Healthy Weight Intervention|In this intervention, participants were encouraged to make gradual healthy and lasting changes to their diet and physical activity to balance their energy needs with their energy intake, and thereby achieve a healthier weight and body satisfaction. With support from the facilitator and group members, they initiated an individual lifestyle change plan to reduce intake of fat and sugar and to increase exercise using behavioral modification principles. Food and exercise diaries were used to identify behaviors to target in this lifestyle modification and to monitor change. Motivational enhancement activities were used to promote motivation for behavior change.
1731072|NCT00042185|Behavioral|Expressive Writing Control Condition|In this condition, which is based on the work of Pennebaker (1997), participants wrote about emotionally significant topics in three individual weekly 45-minute sessions. They were told that research indicates that body dissatisfaction is linked to emotional issues and that expressive writing helps resolve these issues. Sample topics included relationships or goals. They were told that their work would not be read and were asked to write continuously for the duration of the session about an emotionally important topic.
1731073|NCT00042198|Behavioral|Cognitive behavior therapy|Up to 12 weekly, individual, hour-long sessions
1731074|NCT00042198|Behavioral|Supportive Stress Management|Up to 12 weekly, individual, hour-long sessions, focusing on application of relaxation and other stress management techniques to depressogenic stressors
1731075|NCT00042211|Behavioral|Problem Solving Treatment|Brief Cognitive Behavioral Therapy
1731076|NCT00042211|Behavioral|Control|No treatment control
1731077|NCT00042224|Procedure|Electroconvulsive Therapy (ECT)|ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.
1731078|NCT00042224|Drug|Clozapine|Patients with psychotic symptoms will receive clozapine
1731079|NCT00042237|Behavioral|Schema Therapy|
1731080|NCT00042250|Drug|Chemotherapy for hematologic malignancy|
1731116|NCT00042302|Procedure|Chemotherapy|
1731117|NCT00042302|Drug|tariquidar + paclitaxel/carboplatin|
1731118|NCT00042302|Drug|placebo + paclitaxel/carboplatin|
1731119|NCT00042315|Procedure|Chemotherapy|
1731120|NCT00042315|Drug|tariquidar + vinorelbine|
1731121|NCT00042315|Drug|placebo + vinorelbine|
1731122|NCT00042328|Drug|Valacyclovir|
1731123|NCT00042341|Drug|clofarabine (IV formulation)|
1731124|NCT00042354|Drug|clofarabine (IV formulation)|
1731125|NCT00042367|Drug|Induction therapy (Regimen 1, Course 1, Cycle A1|"2-8 hrs: Cisplatin 3.5 mg/kg + mannitol 0.4 g/kg in D5 NS (1000 ml/m2) over 6 hrs at approximately 167ml/m2/hr. 8-12 hrs: D5 NS (665 ml/m2) + KCl (2 mEq/100 ml) +MgSO4 (0.5 mEq/100 ml) at approximately 167ml/m2/hr.
12-24 hrs: D5 NS + KCl (2 mEq/100 ml) + MgSO4 (0.5mEq/100 ml) at approximately 65 ml/m2/hr.
Days 2,3: 0 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg of IVF over 15 min 15 min: Cyclophosphamide 30 mg/kg IV over 30 min 45 min: Post-chemotherapy hydration - D5 1/2 NS + KCl(1 mEq/100 ml) at approximately 130 ml/m2/hr for at least 24 hours.
3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 4 G-CSF 5 µg/kg subcutaneously, daily until ANC ≥ 2000 on two consecutive days, post ANC nadir.
Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg)"
1731126|NCT00042367|Drug|Regimen 1, Course 1, Cycle A2 (Days 22 - 42)|Drugs and doses are same as in Cycle A1. Cycle A2 begins following recovery from Cycle A1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modifications
1731127|NCT00042367|Drug|Cycle B|"Days 43 - 63) Etoposide, 1.7 mg/kg p.o. qd x 21 days. The dose will be diluted immediately prior to administration in juice flavored syrup to a final concentration of 0.4 Each dose should be aken 1 hour before or 2 hours after a meal.
Cycle B begins following recovery from Cycle A2; however, it begin no sooner than 21 days after the start of Cycle A2.
Monitor weekly CBC/diff/plt. If ANC < 500/mm3 or platelets (unsupported) < 50,000/mm3 then discontinue etoposide. A 25% reduction should be made for the next cycle of oral etoposide.
Interim Response Evaluation (Days 64 - 70) Interim Response Evaluation should be performed the week following the completion of Course 1."
1731128|NCT00042367|Drug|Regimen 1, Course 2|6.3.3 Regimen 1, Course 2 Repeat systemic therapy as per Course 1 (Cycle A1, Cycle A2, and Cycle B) in patients with SD or better at the interim response evaluation (see Figure 2 for IT mafosfamide guidelines). Course 2 should not begin any sooner than 7 days after the completion of Course 1.
1731129|NCT00042367|Drug|Intrathecal Mafosfamide|Regimen 1, Course 1 Mafosfamide, 14 mg, is given two times/week during Cycle A1 and Cycle A2 of Course 1, for 12 total doses during days 1-41. The first dose of Cycles A1 and A2 should be given, if possible, on the same day as the first I.V. cyclophosphamide dose and the second dose 3 to 4 days later. The assigned dose is given one time/week during Cycle B, Course 1 for 3 total doses during days 43 - 63.
1731130|NCT00042367|Drug|Regimen 1 Course 2, IT mafosfamide|"Regimen 1, Course 2 The assigned dose is administered once with IV cyclophosphamide during each of Cycle A1 and Cycle A2, and day 1 of Cycle B for a total of 3 doses during Course 2.
Patients with an initially abnormal flow study, who show no evidence of obstructive hydrocephalus or compartmentalization on the repeat study, may begin intrathecal mafosfamide administration with the initiation of Regimen 1, Course 2. The frequency of intrathecal mafosfamide administration, for such patients, will be as outlined in Regimen 1, Course
1."
1731131|NCT00042367|Drug|Regimen 2, Course 1|"Cycle C1 (Days 1 - 21) Day 1: Prehydrate with D5W 1/2 NS + KCl 2 mEq/100 ml) at 2 times the hourly maintenance rate until the urine specific gravity is < 1.012.
0 hrs: Mesna 6 mg/kg IV over 15 min. Dilute in 0.65 ml/kg IVF. 15 min: Vincristine 0.05 mg/kg IV push (Day 1 only)(max dose = 2 mg) 20 min: Cyclophosphamide 30 mg/kg IV over 30 min. 50 min: Post-chemotherapy hydration - D5 1/2 NS + KCl
(1 mEq/100 ml) at twice the hourly maintenance rate for at least 24 hours. 3 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 6 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 9 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min 12 hrs: Mesna 6 mg/kg IV in 0.65 ml/kg IVF over 15 min Day 2: Repeat day 1, but omit vincristine. Day 3: G-CSF 5 µg/kg/day subcutaneously, daily, until ANC is > 2000 on two consecutive days, post ANC nadir."
1731132|NCT00042367|Drug|Regimen 2, Course, 1, Cycle C1|"Cycle C1, Weeks 2 and 3 Day 8: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Day 15: Vincristine 0.05 mg/kg IV push (max dose = 2 mg) Cycle C2 (Days 22-42) Drugs and doses are same as in Cycle C1. Cycle C2 begins following recovery from Cycle C1, but no sooner than day 21. Patients with delays in recovery beyond day 28 should have dose modificationsCycle D (Days 43 - 63) Etoposide 1.7 mg/kg, po qd x 21 days The dose will be diluted immediately prior to administration in juice or flavored syrup as per section 3.4.3. Each dose should be taken 1 hour before or 2 hours after a meal.
Cycle D should begin following recovery from Cycle C2; however, it should begin no sooner than 21 days after the start of Cycle C2."
1731203|NCT00042939|Biological|cetuximab|Patients received cetuximab intravenous infusions, via infusion pump or syringe pump, once a week for 6 weeks.
1731302|NCT00043147|Drug|beclomethasone dipropionate|
1731133|NCT00042367|Drug|Regimen 2, Course 2|Repeat Course 1 (Cycle C1, Cycle C2, and Cycle D) in patients with SD or better at the interim response evaluation. Chemotherapy should begin as soon as the patient has recovered from the toxicities of oral etoposide in cycle D, course 1. However, it should not begin any sooner than 7 days after the completion of Course 1.
1731134|NCT00042367|Radiation|radiation therapy|"Conformal Irradiation Patients who are initially M0 with a CR, PR, or SD to Regimen 1 induction chemotherapy (with or without second surgery) will receive local irradiation using conformal techniques. Treatment will commence within 2 weeks of completing Regimen 1 or second surgery. Treatment planning and technique may involve 3D conformal,IMRT, or proton planning and delivery, provided the guidelines regarding volume, dose,and normal tissue restrictions are honored.
8.3.1 Fraction Size 180 cGy fractions will be used for all target volumes. 8.3.2 Fractionation Conventional fractionation will be used. Treatments will be given once daily, 5 days/week except for necessary interruptions secondary to medical or administrative reasons."
1731135|NCT00042380|Drug|Novasoy|
1731136|NCT00042393|Drug|Adefovir Dipivoxil|
1731137|NCT00042406|Drug|HuMax-CD4|
1731138|NCT00042432|Drug|cinacalcet (AMG 073)|Initially receive 1 tablet of study medication (cinacalcet or placebo) once daily. Possible sequential dose titrations are 30, 60, 90, 120, 180mg cinacalcet or placebo) daily. The titration phase was 12 weeks and the efficacy assessment phase was 6 weeks.
1731139|NCT00042458|Drug|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
1731140|NCT00042458|Drug|Placebo|The placebo injection will be supplied in the same 5-mL multidose glass vials with a rubber stopper.
1731141|NCT00042471|Drug|Pramlintide acetate|Pramlintide acetate (AC137) injection is a clear, colorless, sterile solution for injection. It consists of pramlintide in sodium acetate buffer, pH 4.0, containing 43mg/mL mannitol as an iso-osmolality modifier and 2.25 mg/mL metacresol as a preservative. The strength of pramlintide is 1.0 mg/mL for SC injection and 0.6 mg/mL for IV bolus injection.
1731142|NCT00042484|Procedure|Community-level intervention & policy change|
1731143|NCT00042497|Biological|autologous dexosomes loaded with tumor-specific peptides|
1731144|NCT00042510|Biological|Treatment group|
1731145|NCT00042536|Drug|Naltrexone HCL/ Yohimbine HCL|
1731146|NCT00042549|Device|Extracorporeal Shock Wave Lithotripsy|
1731147|NCT00042549|Drug|ursodiol|
1731148|NCT00042562|Drug|duloxetine|
1731149|NCT00042575|Drug|Duloxetine|
1731150|NCT00042588|Drug|Recombinant Chimeric Monoclonal Antibody|
1731151|NCT00042601|Drug|Pramlintide acetate|Pramlintide injection will be supplied in 5-mL multidose glass vials with rubber stoppers.
1731152|NCT00042601|Drug|Placebo|placebo injection will be supplied in 5-mL multidose glass vials with a rubber stopper
1731153|NCT00042653|Drug|Placebo|30 mg of placebo taken once daily orally 60 mg of placebo taken once daily orally 90 mg of placebo taken once daily orally 120 mg of placebo taken once daily orally 180 mg of placebo taken once daily orally
1731154|NCT00042653|Drug|AMG 073|30 mg of AMG 073 taken once daily orally 60 mg of AMG 073 taken once daily orally 90 mg of AMG 073 taken once daily orally 120 mg of AMG 073 taken once daily orally 180 mg of AMG 073 taken once daily orally
1731155|NCT00042666|Drug|LY317615|500 mg, oral, daily, up to six 28 day cycles
1731156|NCT00042679|Drug|Gemcitabine|
1731157|NCT00042679|Drug|Carboplatin|
1731158|NCT00042679|Drug|LY900003|
1731159|NCT00042718|Drug|levofloxacin, azithromycin, amoxicillin/clavulanate|
1731160|NCT00042731|Dietary Supplement|Lycopene|Daily administration as outlined in treatment arm(s)
1731161|NCT00042731|Dietary Supplement|Multivitamin|Daily administration as outlined in treatment arm(s)
1731162|NCT00042731|Dietary Supplement|Soy isoflavones|Daily administration as outlined in treatment arm(s)
1731163|NCT00042770|Other|talc|Given intrapleurally
1731164|NCT00042770|Procedure|dyspnea management|No talc
1731165|NCT00042783|Biological|D1/3-MAGE-3-His fusion protein|
1731166|NCT00042783|Biological|SB-AS02B adjuvant|
1731167|NCT00042796|Drug|decitabine|Given IV
1731168|NCT00042796|Other|pharmacological study|Correlative studies
1731169|NCT00042796|Other|laboratory biomarker analysis|Correlative studies
1731170|NCT00042809|Drug|paclitaxel|Given IV
1731171|NCT00042809|Biological|trastuzumab|Given IV
1731172|NCT00042809|Drug|erlotinib hydrochloride|Given orally
1731173|NCT00042809|Other|laboratory biomarker analysis|Correlative studies
1731174|NCT00042809|Other|pharmacological study|Correlative studies
1731175|NCT00042822|Drug|romidepsin|
1731176|NCT00042835|Drug|cisplatin|Given IV
1731177|NCT00042835|Drug|etoposide|Given IV
1731178|NCT00042835|Drug|erlotinib hydrochloride|Given orally
1731179|NCT00042835|Radiation|radiation therapy|Undergo radiotherapy
1731180|NCT00042835|Drug|docetaxel|Given IV
1731181|NCT00042835|Drug|paclitaxel|Given IV
1731182|NCT00042835|Drug|carboplatin|Given IV
1731183|NCT00042835|Other|laboratory biomarker analysis|Correlative studies
1731184|NCT00042848|Drug|modafinil|
1731185|NCT00042861|Drug|7-hydroxystaurosporine|
1731186|NCT00042861|Drug|fluorouracil|
1731187|NCT00042861|Drug|leucovorin calcium|
1731188|NCT00042874|Drug|alvocidib|Given IV
1731189|NCT00042874|Drug|irinotecan hydrochloride|Given IV
1731190|NCT00042874|Drug|fluorouracil|Given IV
1731191|NCT00042874|Drug|leucovorin calcium|Given IV
1731192|NCT00042874|Other|laboratory biomarker analysis|Correlative studies
1731193|NCT00042887|Drug|mitomycin C|
1731194|NCT00042887|Procedure|conventional surgery|
1731195|NCT00042900|Drug|pyroxamide|
1731196|NCT00042913|Biological|epratuzumab|
1731197|NCT00042926|Other|immunohistochemistry staining method|
1731198|NCT00042926|Procedure|conventional surgery|
1731199|NCT00042926|Procedure|lymphangiography|
1731200|NCT00042926|Procedure|radionuclide imaging|
1731201|NCT00042926|Procedure|sentinel lymph node biopsy|
1731202|NCT00042926|Radiation|technetium Tc 99m sulfur colloid|
1731204|NCT00042939|Drug|docetaxel|Docetaxel was administered intravenously over 60 minutes at a dose of 35 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest. Docetaxel was diluted in 100-150 ml of infusion solution.
1731205|NCT00042939|Drug|irinotecan hydrochloride|After the completion of the docetaxel infusion, irinotecan was administered intravenously over 30 minutes at a dose of 50 mg/m² once a week (days 1, 8, 15, 22) for 4 consecutive weeks followed by 2 weeks rest.
1731206|NCT00042952|Drug|imatinib mesylate|Given orally
1731207|NCT00042952|Procedure|therapeutic conventional surgery|Undergo surgical resection
1731208|NCT00042952|Other|laboratory biomarker analysis|Correlative studies
1731209|NCT00042965|Drug|capecitabine|
1731210|NCT00042965|Drug|gemcitabine hydrochloride|
1731211|NCT00042978|Biological|oblimersen sodium|Given IV
1731212|NCT00042978|Drug|carboplatin|Given IV
1731213|NCT00042978|Drug|etoposide|Given IV
1731214|NCT00042991|Drug|gefitinib|Given orally
1731215|NCT00042991|Radiation|radiation therapy|Undergo standard brain irradiation
1731216|NCT00042991|Other|pharmacological study|Correlative studies
1731217|NCT00042991|Other|laboratory biomarker analysis|Correlative studies
1731218|NCT00043004|Biological|bevacizumab|
1731219|NCT00043004|Drug|FOLFOX regimen|
1731220|NCT00043004|Drug|fluorouracil|
1731221|NCT00043004|Drug|leucovorin calcium|
1731222|NCT00043004|Drug|oxaliplatin|
1731223|NCT00043004|Procedure|conventional surgery|
1731224|NCT00043004|Procedure|radiofrequency ablation|
1731225|NCT00043017|Procedure|MRI/MRS|Serial MRI studies evaluated for prognostic properties related to therapeutic response.
1731226|NCT00043017|Radiation|gadopentetate dimeglumine|Imaging agent used for contrast enhancement in each of the MRIs.
1731227|NCT00043030|Procedure|psychosocial assessment and care|
1731228|NCT00043043|Drug|celecoxib|
1731229|NCT00043069|Dietary Supplement|calcium carbonate|
1731230|NCT00043069|Dietary Supplement|cholecalciferol|
1731231|NCT00043069|Drug|Estrogen Antagonists|
1731232|NCT00043069|Drug|risedronate sodium|
1731233|NCT00043069|Other|placebo|
1731234|NCT00043082|Drug|carboplatin|intravenous q 4 weeks
1731235|NCT00043082|Drug|pegylated liposomal doxorubicin hydrochloride|intravenous q 4 weeks
1731236|NCT00043095|Drug|gemcitabine hydrochloride|
1731237|NCT00043095|Drug|ixabepilone|
1731238|NCT00034827|Drug|CI-1040|
1731239|NCT00034840|Drug|telmisartan, valsartan|
1731240|NCT00034853|Drug|meloxicam oral suspension|
1731241|NCT00034853|Drug|naproxen oral suspension|
1731242|NCT00034866|Drug|Protease inhibitor tipranavir|
1731243|NCT00034879|Drug|ZD1839 (Gefitinib)|
1731244|NCT00034892|Drug|Olanzapine, risperidone|
1731245|NCT00034905|Drug|quetiapine fumarate vs risperidone|
1731246|NCT00034918|Drug|ZD6474|
1731247|NCT00034944|Drug|MK0869, aprepitant|
1731248|NCT00034944|Drug|Comparator: placebo|
1731249|NCT00034957|Drug|Investigational drug|
1731250|NCT00034970|Behavioral|Mindfulness-based at therapy|
1731251|NCT00034983|Drug|aprepitant|
1731252|NCT00034983|Drug|Comparator: paroxetine HCL|
1731253|NCT00035009|Drug|MK0869, aprepitant|
1731254|NCT00035009|Drug|Comparator: paroxetine HCL|
1731255|NCT00035022|Drug|BCX-1777|
1731256|NCT00035035|Drug|GEMZAR|
1731257|NCT00035035|Drug|ALIMTA|
1731258|NCT00035048|Drug|aprepitant|
1731259|NCT00035048|Drug|Comparator: placebo (unspecified)|
1731260|NCT00035061|Drug|pemetrexed|
1731261|NCT00035074|Drug|Methotrexate|
1731262|NCT00035087|Drug|epothilone b|
1731263|NCT00035100|Drug|epothilone b|
1731264|NCT00035113|Drug|epothilone b|
1731265|NCT00035126|Drug|epothilone b|
1731266|NCT00035139|Drug|methylphenidate|
1731267|NCT00035152|Drug|Paclitaxel and carboplatin|
1731268|NCT00035165|Drug|epothilone b|intravenous 2.5 mg/m2 as a 5 minutes bolus infusion once every week for three weeks followed by one week off
1731269|NCT00035178|Drug|Argatroban|
1731270|NCT00035191|Drug|galantamine|
1731271|NCT00035204|Drug|galantamine|
1731272|NCT00035230|Drug|Topiramate|
1731273|NCT00035243|Drug|epothilone b|EPO906 administered intravenously at 2.5 mg/m2 as a 5 minute bolus infusion repeated every week for three weeks followed by one week off The final tables and data is not in yet, so I cannot give you info on safety issues.
1731274|NCT00035256|Drug|teriparatide|
1731275|NCT00035256|Drug|raloxifene HCl|
1731276|NCT00035256|Drug|placebo|
1731277|NCT00035269|Drug|Antibiotic|
1731278|NCT00035282|Drug|aprepitant|
1731279|NCT00035282|Drug|Comparator: placebo (unspecified)|
1731280|NCT00035295|Drug|MK0869, aprepitant|
1731281|NCT00035295|Drug|Comparator: placebo|
1731282|NCT00035308|Drug|Abetimus sodium (LJP 394)|
1731283|NCT00035321|Drug|Olanzapine|
1731284|NCT00035321|Drug|Fluoxetine|
1731285|NCT00035334|Drug|NC-503 (Anti-amyloidotic (AA) Agent)|
1731286|NCT00035347|Drug|IV azithromycin|500 mg once daily
1731287|NCT00035347|Drug|ceftriaxone|1 gram once daily for 2 to 5 days
1731288|NCT00035347|Drug|oral azithromycin|2 x 250 mg once daily
1731289|NCT00035347|Drug|IV levofloxacin|500 mg once daily
1731290|NCT00035347|Drug|oral levofloxacin|500 mg once daily
1731291|NCT00035360|Drug|PEG-Intron|
1731292|NCT00043108|Drug|carboplatin|
1731293|NCT00043108|Drug|paclitaxel|
1731294|NCT00043108|Procedure|conventional surgery|
1731295|NCT00043108|Radiation|radiation therapy|
1731296|NCT00043121|Drug|oxaliplatin|Given IV
1731297|NCT00043121|Drug|leucovorin calcium|Given IV
1731298|NCT00043121|Drug|fluorouracil|Given IV
1731299|NCT00043121|Drug|capecitabine|Given orally
1731300|NCT00043121|Other|pharmacological study|Correlative studies
1731305|NCT00043186|Drug|Placebo|Placebo subcutaneous injection
1731306|NCT00043186|Drug|Denosumab|Denosumab for subcutaneous injection
1731307|NCT00043186|Drug|Alendronate|Alendronate 70 mg tablets
1731308|NCT00043199|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
1731309|NCT00043212|Drug|Dendritic cell immunotherapy|
1731310|NCT00043264|Drug|Rifampin|
1731311|NCT00043264|Drug|Azithromycin|
1731312|NCT00043277|Drug|Angiomax (bivalirudin)|
1731313|NCT00043303|Drug|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
1731314|NCT00043316|Drug|interferon gamma-1b|500 or 1000 mcg, inhalation, 3x per week
1731315|NCT00043329|Drug|Actimmune Registry|as administered by physician
1731316|NCT00043342|Drug|interferon gamma-1b|100 or 200 mcg, SQ, 3x per week
1731317|NCT00043355|Drug|interferon gamma-1b|500 mcg, oral, three times weekly
1731318|NCT00043368|Drug|PF-3512676|PF-3512676 IV at doses: 0.01mg/kg, 0.16mg/kg and 0.32mg/kg PF-3512676 Injection given by subcutaneous injection at doses: 0.04mg/kg, 0.16mg/kg, 0.20mg/kg, 0.28mg/kg, 0.32mg/kg, 6mg, 10mg, 40mg.
1731319|NCT00043381|Drug|decitabine (5-aza-2'deoxycytidine)|
1731320|NCT00043394|Drug|0.04 mg/kg CpG 7909|0.04 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
1731321|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
1731322|NCT00043394|Drug|0.08 mg/kg CpG 7909|0.08 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
1731323|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
1731324|NCT00043394|Drug|0.12 mg/kg CpG 7909|0.12 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
1731325|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
1731326|NCT00043394|Drug|0.16 mg/kg CpG 7909|0.16 mg/kg CpG 7909 by subcutaneous Injection once weekly until progression or 24 weeks
1731327|NCT00043394|Drug|Herceptin®|Herceptin® (maintenance dose per the manufacturer's directions) followed by a subcutaneous injection of CpG 7909.
1731328|NCT00043407|Drug|CPG 7909|In the phase I portion of the protocol, patients will be included in escalating dose groups: 0.08, 0.12, 0.16, 0.36, 0.54 or 0.81 mg/kg of CPG 7909 Injection. Patients will be treated once weekly subcutaneously for 24 weeks. In the Phase II portion of the trial patients will be treated at the MTD or the highest dose of 0.81 mg/kg identified in the Phase I dose escalation portion of the trial. All patients in Phase I and Phase II will be treated until disease progression or a maximum of 24 weeks.
1731329|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.08mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
1731330|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.16mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
1731331|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.24mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
1731332|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.28mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
1731333|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.32mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
1731334|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 0.36mg/kg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
1731335|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 10 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
1731336|NCT00043420|Drug|PF-3512676|Weekly subcutaneous injections of 25 mg PF-3512676. Treatment continues for a minimum of 8 weeks unless disease progression or unacceptable toxicity occurs, or a maximum of 24 weeks.
1731337|NCT00043433|Drug|intravenous T900607-sodium|
1731338|NCT00043446|Drug|intravenous T900607-sodium|
1731339|NCT00043459|Drug|intravenous T900607-sodium|
1731340|NCT00046930|Biological|filgrastim|250 μg/m2/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
1731341|NCT00046930|Biological|sargramostim|5 μg/kg/day by either intravenous or subcutaneous injection starting day 12, provided marrow aplasia is achieved, through recovery of absolute neutrophil count (ANC) to > 500 cells/μl, sustained for 3 consecutive days. The dose may be rounded to the nearest vial size.
1731342|NCT00046930|Drug|cytarabine|100 mg/m²/day by continuous intravenous infusion for 7 days (days 1-7).
1731343|NCT00046930|Drug|daunorubicin hydrochloride|45 mg/m²/day by 10 - 15 minute intravenous infusion for 3 days (days 1, 2, and 3).
1731344|NCT00046930|Drug|zosuquidar trihydrochloride|"Zosuquidar 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.
The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3."
1731345|NCT00046930|Drug|Placebo|"Placebo 550 mg/day by continuous intravenous infusion through a central venous catheter over approximately 6 hours on days 1, 2, and 3.
The infusion will begin approximately one hour prior to daunorubicin on days 1, 2 and 3. Placebo consisted of a 1:1000 dilution of Infuvite, appropriately colored."
1731346|NCT00046943|Drug|atrasentan hydrochloride|
1731347|NCT00046969|Biological|epoetin beta|
1731348|NCT00046969|Drug|cisplatin|
1731349|NCT00046969|Radiation|brachytherapy|
1731350|NCT00046969|Radiation|radiation therapy|
1731351|NCT00046995|Drug|carboplatin|
1731352|NCT00046995|Drug|fluorouracil|
1731353|NCT00046995|Drug|leucovorin calcium|
1731354|NCT00046995|Procedure|adjuvant therapy|
1731355|NCT00047008|Drug|cisplatin|100 mg/m^2 intravenously on days 1, 22
1731356|NCT00047008|Radiation|Standard fractionation RT|Radiation will be delivered in 2 Gy per fraction, five fractions a week. The primary tumor and clinically/radiologically involved nodes will receive 70 Gy in 7 weeks and uninvolved nodes will receive 50 Gy in 5 weeks. The anterior lower neck field will be treated with 2 Gy per fraction at 3-cm depth to a total dose of 50 Gy.
1731357|NCT00047008|Radiation|Accelerated fractionation radiation therapy|Radiation to the initial target volume encompassing the gross and subclinical disease sites will be delivered in 1.8 Gy per fraction, five fractions a week to 54 Gy in 30 fractions over 6 weeks. At 32.4 Gy/18 Fx (i.e., latter part of week 4), the boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation of 1.5 Gy/Fx as second daily fraction (at least 6 h interval) for a total of 12 treatment days (18 Gy total). The primary tumor and clinically/radiologically involved nodes will receive 72 Gy in 42 fractions over 6 weeks and uninvolved nodes will receive 54 Gy in 6 weeks. Clinically/radiologically negative posterior neck should receive a minimum dose of 50.4 Gy at 3 cm. The anterior lower neck field will be treated with 1.8 Gy per fraction at 3-cm depth to a total dose of 50.4 Gy in 28 fractions in 5.6 weeks.
1731358|NCT00047008|Procedure|Conventional surgery for select patients|"Surgical removal (salvage resection) of the primary tumor should be performed if biopsy-proven cancer remains more than three months after completion of therapy. The nature of the surgical resection should be dictated by the extent of tumor at the initial evaluation. The operation should be conducted using accepted criteria for primary surgical treatment of the cancer.
A planned neck dissection for patients with multiple neck nodes or with lymph nodes exceeding 3 cm in diameter (N2a, N2b, N3) is mandatory, regardless of the clinical and/or radiographic response. A neck dissection is required for patients with N1 disease if a palpable or worrisome radiographic abnormality persists in the neck six weeks after completion of therapy. Surgery should be performed within 2 weeks once the decision for neck dissection is made."
1731359|NCT00047021|Biological|sargramostim|Sargramostim (GM-CSF) subcutaneously beginning on day 14 and continuing until blood counts recover.
1731360|NCT00047021|Drug|cytarabine|high-dose cytarabine IV over 1 hour on days 1-5
1731361|NCT00047021|Drug|mitoxantrone hydrochloride|high-dose mitoxantrone IV over 15-30 minutes on day 5.
1731362|NCT00047034|Drug|eribulin mesylate|Given IV
1731363|NCT00047034|Other|pharmacological study|Correlative studies
1731364|NCT00047034|Other|laboratory biomarker analysis|Correlative studies
1731365|NCT00047047|Drug|gemcitabine hydrochloride|Given IV
1731366|NCT00047047|Drug|tanespimycin|Given IV
1731367|NCT00047047|Drug|cisplatin|Given IV
1731368|NCT00047047|Other|laboratory biomarker analysis|Correlative studies
1731369|NCT00047060|Drug|Campath-1H|
1731370|NCT00047073|Drug|Rapamycin|"Phase 1: Initial dose 6mg on day 1 and then 2mg each day for 5-7 days before surgery. No dosing during surgery recovery. After recorvery 6mg loading dose on day 1 then 2mg each day. Cycle is every 4 weeks.
Dose escalation: Level 2: 15mg load/5mg/day, Level 3: 30mg load/10mg/day, Level 4: 45mg load/15mg/day.
Phase 2: Will utilize dose established in phase I. Dosing schedule will remain the same."
1731371|NCT00047073|Procedure|Surgery|Surgical resection.
1731372|NCT00047073|Procedure|Supportive Care|"Corticosteroids should be used in smallest dose to control symptoms of cerebral edema and mass effect.
Anti-seizure medications should be used as indicated. Febrile neutropenia may be managed according to local institution's infectious disease guidelines.
If neurosurgical management is required for reasons not due to tumor progression, these procedures must be documented."
1731373|NCT00047099|Drug|cyclophosphamide|
1731374|NCT00047099|Drug|docetaxel|
1731375|NCT00047099|Drug|epirubicin hydrochloride|
1731376|NCT00047099|Drug|fluorouracil|
1731377|NCT00047099|Drug|goserelin acetate|
1731378|NCT00047099|Drug|tamoxifen citrate|
1731379|NCT00047099|Procedure|adjuvant therapy|
1731380|NCT00047099|Radiation|radiation therapy|
1731381|NCT00047112|Drug|cisplatin|
1731382|NCT00047112|Drug|fluorouracil|
1731383|NCT00047112|Procedure|conventional surgery|
1731384|NCT00047112|Procedure|neoadjuvant therapy|
1731385|NCT00047112|Radiation|radiation therapy|
1731386|NCT00047125|Radiation|radiation therapy|
1731387|NCT00047138|Biological|dactinomycin|
1731388|NCT00047138|Drug|carboplatin|
1731389|NCT00047138|Drug|cyclophosphamide|
1731390|NCT00047138|Drug|doxorubicin hydrochloride|
1731391|NCT00047138|Drug|etoposide|
1731392|NCT00047138|Drug|vincristine sulfate|
1731393|NCT00047138|Procedure|adjuvant therapy|
1731394|NCT00047138|Procedure|conventional surgery|
1731395|NCT00047138|Procedure|neoadjuvant therapy|
1731396|NCT00047138|Radiation|radiation therapy|
1731397|NCT00047164|Biological|ipilimumab|
1731398|NCT00047177|Drug|Oxaliplatin|
1731399|NCT00047190|Drug|tipifarnib|Given PO
1731400|NCT00047190|Other|laboratory biomarker analysis|Correlative studies
1731401|NCT00047203|Drug|alvocidib|Given IV
1731402|NCT00047216|Drug|tipifarnib|
1731403|NCT00047229|Biological|oblimersen sodium|
1731404|NCT00047229|Drug|doxorubicin hydrochloride|
1731405|NCT00047242|Drug|7-hydroxystaurosporine|
1731406|NCT00047242|Drug|irinotecan hydrochloride|
1731407|NCT00047255|Biological|trastuzumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.
Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.
Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
1731532|NCT00048165|Drug|Placebo|Matching placebo will be administered on Days 1, 8, 22, 36, and 50.
1731533|NCT00048165|Drug|cyclosporine|Cyclosporine will be administered as 1-4 mg/kg IV or 2-6 mg/kg orally up to 365 days.
1731408|NCT00047255|Drug|carboplatin|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.
Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.
Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
1731409|NCT00047255|Drug|docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.
Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.
Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
1731410|NCT00047255|Biological|trastuxumab|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose administered by IV infusion over 90 minutes, Day 2: Docetaxel (T) 100 mg/m2 by IV infusion over 30 minutes, Day 8: (H) 2mg/kg administered by IV infusion over 30 minutes, Day 15: 2mg/kg administered by IV infusion over 30 minutes.
Subsequent cycles: Day 1: (T) 100mg/m2 as 1 hour IV infusion given every 3 weeks, followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes.
Last cycle: Day 1: (T) 100mg/m2 as 1 hour IV infusion followed by (H) 2 mg/kg IV infusion over 30 minutes, Day 8: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 15: (H) 2 mg/kg administered by IV infusion over 30 minutes, Day 22: (H) 6 mg/kg administered by IV infusion over 30 minutes."
1731411|NCT00047255|Drug|Docetaxel|"Cycle 1: Day 1: Herceptin (H) 4 mg/kg loading dose admin by IV over 90 mins, Day 2: Docetaxel (T) 75 mg/m2 by IV over 1 hour followed by carboplatin (C) at target AUC=6 mg/mL/min admin by IV over 30-60 mins, Day 8: (H) 2mg/kg admin by IV over 30 mins, Day 15: 2mg/kg admin by IV over 30 mins.
Subsequent cycles: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins.
Last cycle: Day 1: (T) 75mg/m2 as 1 hour IV followed by (C) at target AUC=6 mg/mL/min admin by IV 30-60 mins every 3 weeks followed by (H) 2 mg/kg IV over 30 mins, Day 8: (H) 2 mg/kg admin by IV over 30 mins, Day 15: (H) 2 mg/kg admin by IV over 30 mins, Day 22: (H) 6 mg/kg admin by IV over 30 mins."
1731412|NCT00047268|Drug|cytarabine|
1731413|NCT00047268|Drug|mercaptopurine|
1731414|NCT00047268|Other|laboratory biomarker analysis|
1731415|NCT00047268|Procedure|allogeneic bone marrow transplantation|
1731416|NCT00047268|Procedure|biopsy|
1731417|NCT00047268|Procedure|peripheral blood stem cell transplantation|
1731418|NCT00047281|Drug|celecoxib|
1731419|NCT00047281|Drug|cyclophosphamide|
1731420|NCT00047281|Drug|etoposide|
1731421|NCT00047281|Drug|thalidomide|
1731422|NCT00047294|Drug|celecoxib|
1731423|NCT00047294|Drug|temozolomide|
1731424|NCT00047294|Drug|thalidomide|
1731425|NCT00047294|Procedure|adjuvant therapy|
1731426|NCT00047307|Drug|alvocidib|Given IV
1731427|NCT00047307|Drug|gemcitabine hydrochloride|Given IV
1731428|NCT00047307|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
1731429|NCT00047307|Other|laboratory biomarker analysis|Correlative studies
1731430|NCT00047320|Drug|carboplatin|Given IV
1731431|NCT00047320|Drug|etoposide|Given IV
1731432|NCT00047320|Drug|ifosfamide|Given IV
1731433|NCT00047320|Drug|thiotepa|Given IV
1731434|NCT00047320|Procedure|adjuvant therapy|
1731435|NCT00047320|Procedure|conventional surgery|
1731436|NCT00047320|Procedure|neoadjuvant therapy|
1731437|NCT00047320|Procedure|peripheral blood stem cell transplantation|
1731438|NCT00047320|Radiation|radiation therapy|craniospinal irradiation
1731439|NCT00047333|Drug|erlotinib hydrochloride|Given PO
1731440|NCT00047333|Other|laboratory biomarker analysis|Correlative studies
1731441|NCT00047333|Other|pharmacological study|Correlative studies
1731442|NCT00047346|Drug|erlotinib hydrochloride|Given PO
1731443|NCT00047346|Other|pharmacological study|Correlative studies
1731444|NCT00047346|Other|laboratory biomarker analysis|Correlative studies
1731445|NCT00047385|Device|low-dose helical computed tomography|A LDCT is a computerized tomography image with low-dose technique without contrast. The scan is done from the neck to the diaphragm in one breath-hold.
1731446|NCT00047385|Device|chest radiography|The chest x-ray in this study was a single posterior-anterior film done with the participant upright.
1731449|NCT00047424|Drug|simvastatin|
1731450|NCT00047424|Drug|ACE inhibitors|
1731451|NCT00047437|Behavioral|Supervised Exercise Training Program|Exercise 30 minutes minimum three times per week.
1731452|NCT00047450|Drug|Citalopram (Celexa)|Citalopram for 3 months
1731453|NCT00047450|Drug|Placebo|Placebo for 3 months
1731454|NCT00047463|Device|continuous positive airway pressure (CPAP)|a mask treatment for sleep apnea
1731455|NCT00047463|Device|Placebo-CPAP|Placebo-CPAP
1731456|NCT00047476|Drug|dexmethylphenidate(d-mph)|
1731457|NCT00047489|Drug|ABT-751|
1731458|NCT00047502|Drug|Lonafarnib (SCH66336)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day, and SCH66336 100 mg by mouth twice a day.
Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day.
Participants in ACCELERATED OR BLASTIC PHASE receive SCH66336 100 mg by mouth twice a day."
1731459|NCT00047502|Drug|Imatinib Mesylate (Gleevec)|"Participants in CHRONIC PHASE receive Gleevec 400 mg by mouth every day.
Participants in ACCELERATED OR BLASTIC PHASE receive Gleevec 600 mg by mouth every day."
1731460|NCT00047515|Drug|Alcon Investigational Agent|
1731461|NCT00047528|Drug|Alcon Investigational Agent|
1731462|NCT00047541|Drug|Alcon Investigational Agent|
1731463|NCT00047554|Drug|Travoprost, 0.004% ophthalmic solution|
1731464|NCT00047567|Drug|zonisamide|
1731465|NCT00047580|Drug|tizanidine hydrochloride capsule|
1731466|NCT00047593|Drug|IOP Lowering Medications|
1731467|NCT00047606|Drug|IOP Lowering Medications|
1731468|NCT00047619|Procedure|Pulsatile Lavage|pulsatile lavage to wound bed
1731469|NCT00047619|Other|sham pulsatile lavage|pulsatile lavage to not directed at wound or patient
1731470|NCT00047632|Drug|Interferon gamma-1b|100 mcg, SQ, 3x per week
1731471|NCT00047645|Drug|Interferon-gamma 1b|200 mcg, SQ, 3x per week
1731472|NCT00047658|Drug|Interferon-gamma 1b|200 mcg, SQ, 3x per week
1731474|NCT00047684|Behavioral|Brief Integrative Therapy|
1731475|NCT00047697|Drug|Donepezil HCl|Participants will start with 5 mg per day dose of donepezil HCl, then have their dose increased to 10mg per day after 4 weeks.
1731476|NCT00047697|Drug|Placebo|Placebo used in placed of Donepezil HCL
1731477|NCT00047710|Drug|Bevacizumab|Beginning 2 weeks prior to radiotherapy, dose of 5 mg/kg by vein then of 2.5 mg/kg during radiotherapy for four weeks every 2 weeks (three doses).
1731478|NCT00047710|Drug|Capecitabine|650mg/m^2 taken by mouth twice a day 15-52 during the radiotherapy.
1731479|NCT00047710|Radiation|Radiotherapy|Radiography given once a day for 5 days at 50.4 Gy in 28 fractions over 5.5 weeks.
1731480|NCT00047723|Drug|minocycline|
1731481|NCT00047736|Drug|Tarceva (erlotinib HCl)|
1731482|NCT00047749|Drug|Prialt (ziconotide)|
1731483|NCT00047762|Drug|Erlotinib (aka Tarceva or OSI-774)|
1731484|NCT00047762|Drug|Bevacizumab (aka Avastin or Rhu MAb VEGF)|
1731485|NCT00047775|Drug|BiDil|
1731486|NCT00047788|Drug|ZD6474|
1731487|NCT00047788|Drug|VEGF-receptor tyrosine kinase (KDR)|
1731488|NCT00047801|Drug|TLK286 in combination with docetaxel|
1731489|NCT00047814|Drug|FK788|
1731490|NCT00047827|Drug|Micafungin|IV
1731491|NCT00047827|Drug|Liposomal Amphotericin B|IV
1731492|NCT00047840|Drug|ZD6474|
1731493|NCT00047840|Drug|Placebo|
1731494|NCT00047840|Drug|Docetaxel|
1731495|NCT00047879|Biological|PEG-interferon alfa-2b|0.3 µg/kg of IFN alfa-2b (PEG-Intron once weekly) plus daily oral thalidomide, subcutaneous injection
1731496|NCT00047879|Drug|Thalidomide|Two 50mg tablets (100 mg total dose) every night before bedtime starting on day one.
1731497|NCT00047905|Behavioral|examine the process of prenatal genetic counseling|
1731498|NCT00047931|Drug|VRC-HIVDNA009-00-VP|
1731499|NCT00047983|Dietary Supplement|Canola oil|
1731500|NCT00047983|Dietary Supplement|Arginine|
1731501|NCT00047983|Dietary Supplement|Fish oil emulsion|
1731502|NCT00048009|Drug|Dual Integrin Antagonist|
1731503|NCT00048022|Drug|Dual Integrin Antagonist|
1731504|NCT00048035|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of iv administration
1731506|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|2.5mg po daily
1731507|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|100mg po monthly on a single day
1731508|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|100mg po monthly over 2 consecutive days
1731509|NCT00048061|Drug|Ibandronate [Bonviva/Boniva]|150mg po monthly
1731510|NCT00048061|Dietary Supplement|Calcium|500 mg/day
1731511|NCT00048061|Dietary Supplement|Vitamin D|400 IU/day
1731512|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|2mg iv every 2 months
1731513|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|2.5mg po daily
1731514|NCT00048074|Drug|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
1731515|NCT00048087|Drug|ZD1839|250 mg by mouth daily each day for 4 weeks.
1731516|NCT00048087|Drug|Docetaxel|30 mg/m2 by IV on day 1 weekly for the first 3 weeks of each 4 week course.
1731517|NCT00048100|Procedure|Apheresis|Apheresis for T-Cell collection
1731518|NCT00048100|Biological|Stem Cell Transplant|Stem cell or marrow infusions of allogeneic donor lymphocytes activated by acute leukemia derived dendritic cells (DC/ADL).
1731519|NCT00048113|Drug|Alicaforsen|
1731520|NCT00048126|Drug|Irinotecan|100mg/m2 iv on days 1, 8, 15 and 22 of each 6 week cycle.
1731521|NCT00048126|Drug|capecitabine [Xeloda]|1000mg po bid
1731522|NCT00048139|Drug|Irinotecan|250mg/m2 iv on day 1 of each 3 week cycle
1731523|NCT00048139|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
1731524|NCT00048152|Drug|Corticosteroids|As prescribed
1731525|NCT00048152|Drug|Neoral|Low dose (target trough level 50-100ng/mL)
1731526|NCT00048152|Drug|Neoral|Standard dose (target trough level 150-300ng/mL)
1731527|NCT00048152|Drug|Zenapax|2mg/kg iv first dose, then 1mg/kg every 2 weeks
1731528|NCT00048152|Drug|mycophenolate mofetil [CellCept]|1g po bid
1731529|NCT00048165|Drug|Daclizumab|Daclizumab will be administered as 1 mg/kg IV within 12 hours post-op (Day 1), and Days 8, 22, 36 and 50.
1731530|NCT00048165|Drug|Methylprednisolone|Methylprednisolone will be administered as 500-1000 mg IV and peri-operative switch to oral at 0.5-1 mg/kg/day followed by tapering till 0.0-0.15 mg/kg/day (up to 365 days).
1731531|NCT00048165|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be administered as 1.5 grams bid begun post-op, either IV or orally as required up to 365 days.
1731541|NCT00048334|Drug|Depsipeptide, FR901228, FK228|
1731542|NCT00048347|Drug|AVONEX|30µg IM every week for 12 weeks
1731543|NCT00048360|Drug|Extended-release bupropion hydrochloride|
1731544|NCT00048373|Drug|Etanercept|
1731545|NCT00048386|Biological|autologous neuroblastoma vaccine|A vaccine dose of 0.3 x 108 IL-2 secreting cells/patient/injection will be used. Injections will be given twice monthly for two months, then monthly for four months, for a total of eight vaccine injections over six months.
1731546|NCT00048399|Drug|Fludarabine|
1731547|NCT00048399|Drug|CAMPATH 1H|
1731548|NCT00048399|Drug|FK506|
1731549|NCT00048399|Procedure|Stem Cell Transplantation|
1731550|NCT00048412|Drug|FLUDARABINE|
1731551|NCT00048412|Drug|CAMPATH 1H|
1731552|NCT00048412|Drug|FK50|
1731553|NCT00048412|Procedure|Stem Cell Collection and Infusion|
1731554|NCT00048425|Drug|Levosimendan|
1731555|NCT00048438|Drug|paricalcitol|
1731556|NCT00048451|Drug|paricalcitol|
1731557|NCT00048464|Procedure|Infusion of Activated & Expanded Autologous T Cells|
1731558|NCT00048477|Drug|L-NMMA and Sodium Nitrite|
1731559|NCT00048490|Device|transcranial magnetic stimulation (TMS)|
1731560|NCT00048503|Drug|ZARNESTRA, tipifarnib, R115777|
1731561|NCT00048516|Drug|paricalcitol capsule|
1731562|NCT00048529|Drug|T900607-sodium intravenous|
1731563|NCT00048542|Biological|Double-Blind Adalimumab/Placebo + MTX|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) concomitantly with MTX treatment for 32 weeks during the Double-Blind phase. Total body dose of adalimumab was not to exceed 40 mg.
1731564|NCT00048542|Biological|Double-Blind Adalimumab/Placebo|Subcutaneous injection of 24 mg adalimumab or placebo per square meter of body surface area (BSA) every other week (eow) without MTX treatment for 32 weeks during the Double-Blind Phase. Total body dose of adalimumab was not to exceed 40 mg.
1731565|NCT00048542|Drug|OLE BSA Adalimumab +/- MTX|Comparison of subcutaneous injection of 24 mg adalimumab per square meter of body surface area (BSA) every other week (eow) either with or without concomitant MTX treatment for a minimum of 44 weeks (up to a maximum of 136 weeks) during the Open-Label Extension BSA Phase.
1731566|NCT00048542|Drug|OLE FD Adalimumab +/- MTX|Comparison of adalimumab administered subcutaneously every other week (eow) either with or without concomitant MTX treatment for up to 224 weeks during the Open-Label Extension Fixed Dose (FD) Phase.
1731567|NCT00048555|Drug|IDEC-114|Dose Group 1 - 125 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 2 - 250 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 3 - 375 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions Dose Group 4 - 500 mg/m2 x 4 infusions & 375 mg/m2 Rituxan x 4 infusions
1731568|NCT00048568|Drug|Abatacept|Intravenous (IV) Solution, - Weight Titered (500 mg < 60 kg); (750 mg 60-100 kg), )1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
1731569|NCT00048568|Drug|Methotrexate|Tablets, Oral, >= 15 mg, weekly, 1 year
1731570|NCT00048568|Drug|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 1 year
1731571|NCT00048581|Drug|Abatacept|Vials, intravenous (IV), ~10mg/kg abatacept, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
1731572|NCT00048581|Drug|Placebo|Vials, IV, 0mg, One every 2 weeks for first month then every 4 weeks thereafter, 6 months.
1731573|NCT00048581|Drug|Abatacept|Vials, IV, ~10mg/kg abatacept, every 4 weeks, 5.5 years
1731574|NCT00048594|Drug|aprepitant|
1731575|NCT00048594|Drug|Comparator: placebo (unspecified)|
1731576|NCT00048607|Drug|aprepitant|
1731577|NCT00048607|Drug|Comparator: paroxetine HCL|
1731578|NCT00048607|Drug|Comparator: Placebo (Unspecified)|
1731579|NCT00048620|Drug|N-acetylgalactosamine 4-sulfatase|
1731580|NCT00048633|Drug|Chemotherapy|
1731581|NCT00048646|Drug|IV Progesterone|
1731582|NCT00048659|Drug|YM598|
1731583|NCT00048672|Drug|Gleevec|Starting dose of 400 mg orally daily.
1731584|NCT00048698|Procedure|TMS|
1731585|NCT00048698|Procedure|EEG|
1731586|NCT00048711|Drug|N-acetylgalactosamine 4-sulfatase|
1731587|NCT00048724|Biological|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg subcutaneously once weekly for 60 months
1731588|NCT00048737|Drug|Zevalin Radioimmunotherapy|Escalating single dose of 90Y Zevalin 0.2-0.3-0.4 mCi/kg
1731589|NCT00048737|Drug|Rituximab|250 mg/m^2 on day 1 and day 8
1731590|NCT00048737|Drug|Fludarabine|30 mg/m^2/day for 3 days
1731591|NCT00048737|Drug|Cyclophosphamide|750 mg/m^2/day for 3 days, given on the same days as fludarabine, at 4-hour intervals
1731592|NCT00048737|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation 2 days after chemotherapy
1731593|NCT00048750|Drug|Micafungin|IV
1731594|NCT00048750|Drug|Placebo|IV
1731595|NCT00048763|Drug|Pletal|
1731596|NCT00048776|Drug|Pletal|
1731597|NCT00048789|Procedure|Extracorporeal Photopheresis|
1731598|NCT00048802|Drug|Lithium|
1731599|NCT00048802|Drug|Olanzapine|
1731600|NCT00048802|Drug|Divalproex|
1731601|NCT00048802|Drug|Risperidone|
1731602|NCT00048802|Drug|Quetiapine|
1731603|NCT00048802|Drug|Ziprasidone|
1731604|NCT00048802|Drug|Aripriprazole|
1731607|NCT00048828|Drug|Olanzapine|Participants will receive olanzapine for 12 weeks.
1731608|NCT00048828|Drug|Clozapine|Participants will receive 12 weeks of clozapine.
1731609|NCT00048841|Drug|alendronate|
1731610|NCT00048854|Drug|Sertraline|Patients who meet study criteria will be given 50 mg per day of sertraline to be taken an estimated 2 weeks before menstruation.
1731611|NCT00048854|Other|Treatment as usual (TAU)|At the TAU baseline visit, patients will be told of their diagnosis of PMS/PMDD. Those patients who decide to seek treatment outside of the study protocol or do not wish to seek treatment will be asked to participate in the TAU part of this protocol. Patients in TAU will be contacted monthly to obtain monthly information about how they have been feeling (blinded ratings) using the study measures.
1731612|NCT00048880|Drug|HeFi-1 Monoclonal Antibody|
1731613|NCT00048893|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|4 x 10^8 pfu given monthly subcutaneously for three doses in the first series and three doses on each of the intermediate and late re-immunizations (total 9 doses).
1731614|NCT00048893|Biological|recombinant vaccinia-CEA(6D)/TRICOM vaccine|rV-CEA (6D)/Tricom concomitantly with sargramostim (rGM-CSF). 1.2 x 10^8 pfu x 1 dose subcutaneously.
1731615|NCT00048893|Biological|filgrastim|5 mcg/kg/day subcutaneously
1731616|NCT00048893|Biological|sargramostim|100 mcg daily for 4 consecutive days at the same site as the rF-CEA (6D)/Tricom vaccine. The first dose will be given with the vaccine.
1731617|NCT00048893|Drug|cyclophosphamide|"First induction chemotherapy: 2700 mg/m^2 per cycle (900 mg/m^2 per day intravenous over 1 hour for 3 consecutive days, days 1-3).
Second induction: 600 mg/m^2 per cycle (600 mg/m^2 intravenous over 1 hour day 1.
Immune depleting chemotherapy: 2400 mg/m^2 per cycle (600 mg/m^2 per day intravenous over 1 hour for 4 consecutive days, days 1-4)."
1731618|NCT00048893|Drug|doxorubicin hydrochloride|60 mg/m^2 per cycle (60 mg/m^2 slow intravenous push day 1).
1731619|NCT00048893|Drug|fludarabine phosphate|120 mg/m^2 (30 mg/m^2 per day intravenous over 30 minutes for 4 consecutive days (days 1-4)).
1731620|NCT00048893|Drug|paclitaxel|160 mg/m^2 per cycle (53.3 mg/m^2 per day by continuous intravenous infusion over 24 hours for 3 consecutive days 1-3).
1731621|NCT00048893|Drug|Mesna|"Percent equals fraction of total daily cyclophosphamide dose. Initial: 20% of cyclophosphamide dose given intravenously (IV) mixed with cyclophosphamide.
3 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 6 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO) 9 hours post completion of cyclophosphamide: 20% intravenously (IV) or 40% by mouth (PO)"
1731622|NCT00048906|Drug|DRX005B|
1731623|NCT00048932|Drug|Double-blind Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight < 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight > 100 Kg), Once daily, Day 1, 15, and 29.
1731624|NCT00048932|Drug|Double-blind Placebo|Concentrate and diluted in a solution, IV, 0 mg, Once daily, Day 1, 15, and 29.
1731625|NCT00048932|Drug|Open-label Abatacept|Concentrate and diluted in a solution, IV, 500 mg (body weight < 60 Kg); 750 mg (body weight 60-100 Kg); 1000 mg (body weight > 100 Kg), Once daily, Every 28 days.
1731626|NCT00048945|Drug|PEGASYS|
1731627|NCT00048958|Genetic|cytogenetic analysis|
1731628|NCT00048971|Genetic|mutation analysis|
1731629|NCT00048971|Genetic|polymorphic microsatellite marker analysis|
1731630|NCT00048984|Other|laboratory biomarker analysis|Correlative studies
1731631|NCT00048997|Radiation|Radiation therapy|PCI is given to the whole brain in a dose of 2 Gy per fraction, 5 days per week, for 3 weeks for a total dose of 30 Gy.
1731632|NCT00048997|Other|Observation|
1731633|NCT00049010|Genetic|comparative genomic hybridization|
1731634|NCT00049010|Genetic|cytogenetic analysis|
1731635|NCT00049010|Genetic|fluorescence in situ hybridization|
1731636|NCT00049010|Other|immunohistochemistry staining method|
1731637|NCT00049023|Radiation|90Y-DOTA-tyr3-OCTREOTIDE|
1731638|NCT00049036|Biological|rituximab|Given IV
1731639|NCT00049036|Drug|etoposide|Given IV
1731640|NCT00049036|Drug|doxorubicin hydrochloride|Given IV
1731641|NCT00049036|Drug|vincristine sulfate|Given IV
1731642|NCT00049036|Drug|prednisone|Given orally
1731643|NCT00049036|Drug|cyclophosphamide|Given IV
1731644|NCT00049036|Other|laboratory biomarker analysis|Correlative studies
1731645|NCT00049062|Drug|anastrozole|
1731646|NCT00049062|Drug|gefitinib|
1731647|NCT00049075|Drug|fludarabine phosphate|
1731648|NCT00049088|Drug|docetaxel|Given IV
1731649|NCT00049088|Biological|bevacizumab|Given IV
1731650|NCT00049088|Other|laboratory biomarker analysis|Correlative studies
1731651|NCT00049088|Other|pharmacological study|Correlative studies
1731652|NCT00049101|Drug|erlotinib hydrochloride|
1731653|NCT00049101|Drug|fluorouracil|
1731654|NCT00049101|Drug|leucovorin calcium|
1731655|NCT00049101|Drug|oxaliplatin|
1731656|NCT00049114|Drug|doxorubicin hydrochloride|
1731657|NCT00049114|Drug|cyclophosphamide|Given IV
1731658|NCT00049114|Drug|tipifarnib|Given orally
1731659|NCT00049114|Biological|filgrastim|Given subcutaneously
1731660|NCT00049114|Procedure|therapeutic conventional surgery|Undergo complete resection
1731661|NCT00049114|Other|laboratory biomarker analysis|Correlative studies
1731662|NCT00049127|Drug|Imatinib Mesylate|Given PO
1731663|NCT00049127|Other|Laboratory Biomarker Analysis|Optional correlative studies
1731664|NCT00049127|Other|Pharmacological Study|Optional correlative studies
1731665|NCT00049140|Drug|EF5|
1731666|NCT00049140|Other|bioluminescence|
1731667|NCT00049140|Other|flow cytometry|
1731668|NCT00049140|Other|immunohistochemistry staining method|
1731669|NCT00049140|Procedure|biopsy|
1731670|NCT00049166|Drug|erlotinib hydrochloride|Given orally
1731671|NCT00049166|Drug|cisplatin|Given IV
1731672|NCT00049166|Radiation|intensity-modulated radiation therapy|Undergo intensity modulated radiation therapy
1731673|NCT00049166|Other|laboratory biomarker analysis|Correlative studies
1731674|NCT00049179|Drug|cytarabine|ind and consol: 200 mg/m2/d continuous IV days 1-7
1731675|NCT00049179|Drug|gemtuzumab ozogamicin|ind and consol: 6 mg/m2 IV over 2 hrs day 1, 4mg/m2 IV over 2 hrs day 8
1731676|NCT00049192|Biological|oblimersen sodium|Given IV
1731677|NCT00049192|Drug|imatinib mesylate|Given PO
1731678|NCT00049192|Other|laboratory biomarker analysis|Correlative studies
1731679|NCT00049218|Biological|Autologous dendritic cell-adenovirus p53 vaccine|
1731680|NCT00049218|Drug|Carboplatin|
1731681|NCT00049218|Drug|Etoposide|
1731682|NCT00049231|Drug|EF5|
1731683|NCT00049231|Other|immunohistochemistry staining method|
1731684|NCT00049231|Procedure|biopsy|
1731685|NCT00049244|Drug|capecitabine|
1731686|NCT00049244|Drug|ixabepilone|
1731687|NCT00049257|Drug|carboplatin|Administered Day 1 of each cycle. AUC=6.
1731688|NCT00049257|Drug|paclitaxel|administered Days 1, 8, and 15 of each cycle. 100mg/m2
1731689|NCT00049283|Drug|erlotinib hydrochloride|Given orally
1731690|NCT00049283|Drug|docetaxel|Given IV
1731691|NCT00049283|Radiation|radiation therapy|Undergo radiotherapy
1731692|NCT00049283|Procedure|therapeutic conventional surgery|Undergo neck dissection
1731693|NCT00049283|Other|laboratory biomarker analysis|Correlative studies
1731694|NCT00049283|Other|pharmacological study|Correlative studies
1731695|NCT00049296|Drug|docetaxel|"Patients receive docetaxel IV over 30 minutes once weekly. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
1731696|NCT00049296|Drug|thalidomide|"Patients receive oral thalidomide twice daily. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of docetaxel and thalidomide until the maximum tolerated dose (MTD) is determined."
1731697|NCT00049309|Dietary Supplement|dietary intervention|
1731698|NCT00049309|Dietary Supplement|flaxseed|
1731699|NCT00049322|Biological|bevacizumab|"Given IV, 10mg/kg evey two weeks starting 1 week prior to the first chemoembolization.
Patients crossed over to the Bevacizumab arm will receive Bevacizumab after week 14 at the same dose."
1731700|NCT00049335|Drug|capecitabine|1,000 mg/m^2/dose (2,000 mg/m^2/day) BID, PO, on Days 1-14 of 21 day cycle
1731701|NCT00049348|Biological|epoetin alfa|
1731702|NCT00049348|Biological|filgrastim|
1731703|NCT00049348|Drug|cisplatin|
1731704|NCT00049348|Drug|fluorouracil|
1731705|NCT00049348|Drug|gemcitabine hydrochloride|
1731706|NCT00049348|Procedure|adjuvant therapy|
1731707|NCT00049348|Procedure|conventional surgery|
1731708|NCT00049348|Procedure|neoadjuvant therapy|
1731709|NCT00049348|Radiation|radiation therapy|
1731710|NCT00049361|Drug|temozolomide|
1731711|NCT00049361|Drug|thalidomide|
1731712|NCT00049361|Radiation|radiation therapy|
1731713|NCT00049374|Biological|oblimersen sodium|
1731714|NCT00049374|Drug|dexamethasone|
1731715|NCT00049374|Drug|thalidomide|
1731716|NCT00049387|Drug|tipifarnib|Given PO
1731717|NCT00049387|Drug|temozolomide|Given PO
1731718|NCT00049387|Radiation|radiation therapy|Undergo partial brain radiation therapy
1731719|NCT00049400|Drug|BMS-247550|BMS-247550 as a 3-hour infusion on Day 1 of a three-week cycle
1731720|NCT00049413|Biological|rituximab|
1731721|NCT00049413|Drug|cyclophosphamide|
1731722|NCT00049413|Drug|pentostatin|
1731723|NCT00049439|Biological|filgrastim|filgrastim (G-CSF) subcutaneously on days 5-21 and 28-42. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
1731724|NCT00049439|Drug|cyclophosphamide|Oral cyclophosphamide on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
1731725|NCT00049439|Drug|etoposide|Oral etoposide on days 1-3. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
1731726|NCT00049439|Drug|lomustine|Oral lomustine on day 1 (course 1 only). Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
1731727|NCT00049439|Drug|procarbazine hydrochloride|Oral procarbazine on days 22-26. Treatment repeats every 6 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
1731728|NCT00049452|Drug|zoledronic acid|
1731729|NCT00049465|Procedure|fatigue assessment and management|
1731730|NCT00049465|Procedure|management of therapy complications|
1731731|NCT00049465|Procedure|psychosocial assessment and care|
1731732|NCT00049504|Drug|cyclophosphamide|Given IV
1731733|NCT00049504|Drug|fludarabine phosphate|Given IV
1731734|NCT00049504|Drug|tacrolimus|Given IV or orally
1731735|NCT00049504|Drug|mycophenolate mofetil|Given orally
1731736|NCT00049504|Genetic|polymerase chain reaction|Correlative studies
1731737|NCT00049504|Genetic|fluorescence in situ hybridization|Correlative studies
1731738|NCT00049504|Genetic|polymorphism analysis|Correlative studies
1731739|NCT00049504|Genetic|gene expression analysis|Correlative studies
1731740|NCT00049504|Radiation|total-body irradiation|Undergo total-body irradiation
1731741|NCT00049504|Procedure|allogeneic bone marrow transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
1731742|NCT00049504|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo haploidentical hematopoietic bone marrow transplantation
1731743|NCT00049517|Biological|sargramostim|Given IV or as an injection
1731744|NCT00049517|Drug|busulfan|Given IV
1731745|NCT00049517|Drug|cyclophosphamide|Given IV
1731746|NCT00049517|Drug|cytarabine|Given as a continuous infusion
1731747|NCT00049517|Drug|gemtuzumab ozogamicin (GO)|Given IV
1731748|NCT00049517|Drug|Daunorubicin|Given intravenously daily for 3 days at a dose of either 45 or 90 mg/m2.
1731749|NCT00049517|Procedure|Autologous HCT|Autologous hematopoietic cell transplantation
1731750|NCT00049517|Procedure|Allogeneic HCT|Allogeneic hematopoietic cell transplantation
1731751|NCT00049530|Biological|PEG-interferon alfa-2b|Patients receive PEG-interferon alfa-2b subcutaneously (SC) once weekly. Treatment continues until basic fibroblast growth factor level is suppressed to normal or until a maximum weekly dose is reached. If there is disease progression, patients then discontinue treatment. If there is no disease progression, patients receive PEG-interferon alfa-2b SC weekly for up to 1 year in the absence of disease progression or unacceptable toxicity.
1731752|NCT00049543|Drug|gefitinib|Given PO
1731753|NCT00049543|Other|placebo|Given PO
1731754|NCT00049543|Other|laboratory biomarker analysis|Correlative studies
1731755|NCT00049556|Drug|gefitinib|
1731756|NCT00049556|Other|immunohistochemistry staining method|
1731910|NCT00039039|Radiation|radiation therapy|
1731757|NCT00049556|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
1731758|NCT00049556|Procedure|biopsy|
1731759|NCT00049556|Procedure|sentinel lymph node biopsy|
1731760|NCT00049569|Drug|cytarabine|Given IT
1731761|NCT00049569|Drug|methotrexate|Given IT
1731762|NCT00049569|Drug|vincristine sulfate|Given IV
1731763|NCT00049569|Drug|prednisone|Given PO
1731764|NCT00049569|Drug|pegaspargase|Given IM
1731765|NCT00049569|Drug|doxorubicin hydrochloride|Given IV
1731766|NCT00049569|Drug|imatinib mesylate|Given PO
1731767|NCT00049569|Drug|cyclophosphamide|Given IV
1731768|NCT00049569|Drug|etoposide|Given IV
1731769|NCT00049569|Biological|filgrastim|Given SC
1731770|NCT00049569|Drug|leucovorin calcium|Given IV
1731771|NCT00049569|Drug|asparaginase|Given IM
1731772|NCT00049569|Drug|therapeutic hydrocortisone|Given IT
1731773|NCT00049582|Drug|decitabine|Given IV
1731774|NCT00049582|Other|laboratory biomarker analysis|Correlative studies
1731775|NCT00049582|Other|pharmacological study|Correlative studies
1731776|NCT00049595|Biological|bleomycin sulfate|
1731777|NCT00049595|Biological|filgrastim|
1731778|NCT00049595|Biological|pegfilgrastim|
1731779|NCT00049595|Drug|ABVD regimen|
1731780|NCT00049595|Drug|BEACOPP regimen|
1731781|NCT00049595|Drug|cyclophosphamide|
1731782|NCT00049595|Drug|dacarbazine|
1731783|NCT00049595|Drug|doxorubicin hydrochloride|
1731784|NCT00049595|Drug|etoposide|
1731785|NCT00049595|Drug|prednisone|
1731786|NCT00049595|Drug|procarbazine hydrochloride|
1731787|NCT00049595|Drug|vinblastine sulfate|
1731788|NCT00049595|Drug|vincristine sulfate|
1731789|NCT00049608|Dietary Supplement|mistletoe extract|
1731790|NCT00049608|Drug|gemcitabine hydrochloride|
1731791|NCT00049634|Drug|busulfan|
1731792|NCT00049634|Drug|cyclophosphamide|
1731793|NCT00049634|Drug|cyclosporine|
1731794|NCT00049634|Drug|methotrexate|
1731795|NCT00049634|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1731796|NCT00049660|Drug|capecitabine|
1731797|NCT00049660|Drug|vinorelbine tartrate|
1731798|NCT00049673|Drug|prednisone|Given orally
1731799|NCT00049673|Drug|thalidomide|Given orally
1731800|NCT00049686|Drug|laromustine|
1731801|NCT00049699|Drug|laromustine|
1731802|NCT00038350|Behavioral|Lingual Strengthening|8 week lingual strengthening exercise protocol
1731803|NCT00038363|Procedure|Rehabilitation|
1731804|NCT00038363|Procedure|Subacute care|
1731805|NCT00038376|Drug|Isotretinoin (Accutane)|0.5 mg/k (1.0 mg/k total) by mouth twice a day
1731806|NCT00038376|Drug|Interferon Alpha|Starting dose of 3 MU injected under skin once a day for 12 weeks.
1731807|NCT00038389|Drug|Vioxx|Starting dose for patients age 3-14 years 10.0 mg/1.73 m2 and for patients above 14 years of age 12.5 mg for 5 days per week for 6 weeks during radiation treatment, and 7 days per week for 6 months after radiation treatment.
1731808|NCT00038402|Drug|Herceptin|Starting dose of 4 mg/kg by vein, then 2 mg/kg weekly after that until the end of all cycles of neo-adjuvant chemotherapy and during FEC therapy for a total of 24 doses.
1731809|NCT00038402|Drug|Taxol|225 mg/m^2 by vein as a continuous infusion over 24 hours each cycle for a total of 4 cycles.
1731810|NCT00038402|Drug|Fluorouracil|500 mg/m^2 by vein on Days 1 and 4 for 4 cycles at 3-4 week intervals.
1731811|NCT00038402|Drug|Cytoxan|500 mg/m^2 on Day 1 of each cycle for 4 cycles.
1731812|NCT00038402|Drug|Epirubicin|75 mg/m^2 IV on Day 1 of each cycle for 4 cycles.
1731813|NCT00038415|Biological|CLL vaccine using DNA plasmid vector|
1731814|NCT00038428|Drug|TLK286|
1731815|NCT00038441|Drug|DTI-015|DTI-015 injected through a catheter into center of brain tumor.
1731816|NCT00038454|Drug|Hemolink (hemoglobin raffimer IV solution)|
1731817|NCT00038467|Drug|Tamoxifen|Tamoxifen 20 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
1731818|NCT00038467|Drug|Exemestane|Exemestane 25 mg/day tablets administered p.o. for a period ranging from 2.5 to 3 years.
1731819|NCT00038480|Drug|Lopinavir/Ritonavir|
1731820|NCT00038493|Drug|Temozolomide and SCH66336|
1731821|NCT00038506|Drug|abacavir/lamivudine/zidovudine|
1731822|NCT00038506|Drug|tenofovir|
1731823|NCT00038519|Drug|Amprenavir/ritonavir|
1731824|NCT00038519|Drug|Saquinavir/ritonavir|
1731825|NCT00038532|Drug|Amprenavir/ritonavir|
1731826|NCT00038532|Drug|Saquinavir/ritonavir|
1731827|NCT00038532|Drug|Efavirenz|
1731828|NCT00038545|Drug|Filgrastim SD/01|
1731829|NCT00038545|Drug|Paclitaxel|
1731830|NCT00038545|Drug|Topotecan|
1731831|NCT00038558|Drug|Filgrastim SD/01|
1731832|NCT00038558|Drug|Adriamycin|
1731833|NCT00038558|Drug|Bleomycin|
1731834|NCT00038558|Drug|Vinblastine|
1731835|NCT00038558|Drug|DTIC|
1731836|NCT00038571|Drug|PS341 (Bortezomib)|1.5 mg/m2 intravenous (IV) bolus push over 3 to 5 seconds on days 1, 4, 8, and 11, followed by a 10-day rest for a 21-day cycle.
1731837|NCT00038584|Drug|SCH66336|
1731838|NCT00038597|Drug|SCH66336|
1731839|NCT00038610|Drug|Imatinib Mesylate|600 mg by mouth on days 1 - 14 for course 1, and 600 mg by mouth daily days 1-14 (or daily if tolerated with course 1) for courses 2, 4, 6, 8.
1731840|NCT00038610|Drug|Cyclophosphamide|300 mg/m^2 by vein every 12 hours for 6 doses days 1, 2, 3 (total dose 1800 mg/m^2) for courses 1, 3, 5, 7.
1731841|NCT00038610|Drug|Doxorubicin|50 mg/m^2 by vein on day 4 after last dose of CTX for courses 1, 3, 5, 7.
1731842|NCT00038610|Drug|Vincristine|2 mg by vein on day 4 and day 11 for courses 1, 3, 5, 7.
1731843|NCT00038610|Drug|Dexamethasone|40 mg by vein or by mouth daily on days 1 - 4 and days 11 - 14 for courses 1, 3, 5, 7.
1731911|NCT00039052|Biological|interleukin-4 PE38KDEL cytotoxin|
1731844|NCT00038610|Drug|Methotrexate|"12 mg intrathecally (6 mg if via Ommaya reservoir) day 2 for courses 1, 3, 5, 7.
200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours on day 1 of courses 2, 4, 6, 8."
1731845|NCT00038610|Drug|Cytarabine|"100 mg intrathecally day 7 for courses 1, 3, 5, 7.
3 gm/m2 by vein over 2 hrs every 12 hrs for 4 doses on days 2 and 3 for courses 2, 4, 6, 8."
1731846|NCT00038610|Drug|Mesna|600 mg/m^2 by vein daily for 24 hours for courses 1, 3, 5, 7.
1731847|NCT00038610|Drug|G-CSF|10 mcg/kg/day after completion of chemotherapy until neutrophil recovery to 1 x 109/L or higher for all courses.
1731848|NCT00038623|Drug|Yttrium-ibritumomab (Zevalin)|After Rituximab infusion, 111^In Zevalin on Day 1 followed by two whole body imaging performed on Day 1 then Day 2.
1731849|NCT00038623|Drug|Rituximab|250 mg/m^2 in the vein over 6 to 8 hours on Day 1.
1731850|NCT00038636|Drug|Lopinavir/ritonavir|
1731851|NCT00038636|Drug|Ritonavir|
1731853|NCT00038662|Drug|Atrasentan|
1731854|NCT00038675|Drug|Imatinib Mesylate (Gleevec)|Imatinib mesylate 400 mg orally daily, and in HES patients start with imatinib mesylate 100 mg orally daily
1731855|NCT00038688|Behavioral|Peer HIV Education Program|
1731856|NCT00038701|Drug|TNP-470|
1731857|NCT00038714|Drug|SGN-00101|
1731861|NCT00038753|Procedure|Vision Screening|
1731862|NCT00038766|Drug|semapimod|semapipmod 60 mg IV x 5 days
1731863|NCT00038766|Drug|semapimod|IV 30 mg x 5 days
1731864|NCT00038766|Drug|placebo|placebo IV
1731865|NCT00038779|Procedure|Megadose T-cell Depleted HLA-nonidentical Blood Progenitor Cell Transplantation|
1731866|NCT00038792|Drug|Recombinant Human Keratinocyte Growth Factor|
1731867|NCT00038805|Drug|Mylotarg|
1731868|NCT00038818|Biological|CD8 Depleted Donor Lymphocyte|
1731869|NCT00038831|Drug|Mylotarg|Starting dose 2 mg/m^2 over 2-hour intravenous infusion on day -12.
1731870|NCT00038831|Drug|Fludarabine|30 mg/m^2 will be given intravenously daily at the same time over 30 minutes on days -5, -4, -3, -2.
1731871|NCT00038831|Drug|Melphalan|140 mg/m^2 will be given intravenously over 20 minutes starting 2 hours after the beginning of the fludarabine infusion on day -2.
1731872|NCT00038831|Drug|Anti-thymocyte globulin|Patients with an unrelated or mismatched related donor will receive 0.5 mg/kg on day -3 and 1.25 mg/Kg on days -2 and -1, following the chemotherapy.
1731873|NCT00038831|Procedure|Stem cell transplant|Allogeneic Bone Marrow and Peripheral Blood Stem Cell Transplantation: Infusion of blood stem cells or bone marrow cells on day 0.
1731874|NCT00038844|Drug|Campath-1 H (Alemtuzumab)|Starting Dose of 15 mg by vein daily, 3 days in a row.
1731875|NCT00038844|Drug|Fludarabine|30 mg/m2 by vein daily, 3 days in a row.
1731876|NCT00038844|Drug|Cyclophosphamide|1 gm/m2 by vein daily, 3 days in a row.
1731877|NCT00038844|Drug|Rituximab|375 mg/m2 by vein, given (to some patients only, based on the subtypes of lymphomas) eight days before the transplant and then weekly for a total of 4 doses.
1731878|NCT00038857|Procedure|Megadose of CD34 Selected Progenitor Cells|Haploidentical peripheral blood progenitor cell (PBPC) transplants on Day 0.
1731879|NCT00038857|Drug|Melphalan|140 mg/m^2 on day -8
1731880|NCT00038857|Drug|Thiotepa|10 mg/kg on day -7
1731881|NCT00038857|Drug|Fludarabine|160 mg/m^2 over 4 days on days -6, -5, -4, -3
1731882|NCT00038857|Drug|Rabbit ATG|1.5 mg/kg of Rabbit ATG a day times 4 over 4 days on days -6, -5, -4, -3.
1731883|NCT00038870|Biological|Dendritic Cell Activated Lymphocyte|
1731884|NCT00038883|Drug|Campath-1H|10 mg/day x 5, starting with the first day of chemotherapy
1731885|NCT00038896|Drug|Venlafaxine ER|
1731886|NCT00038909|Drug|BDDrFVII|
1731887|NCT00038922|Drug|rhIL-11|
1731888|NCT00038935|Drug|ReFacto AF|
1731889|NCT00038948|Drug|Sirolimus|Sirolimus, Cyclosporine A & Tacrolimus are concentration controlled
1731890|NCT00038948|Drug|tacrolimus|
1731891|NCT00038948|Drug|Cyclosporine A|
1731892|NCT00038961|Drug|fondaparinux sodium|2.5 mg fondparinux sodium, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
1731893|NCT00038961|Other|placebo|placebo, daily, s.c. starting 6 to 8 hours after surgical closure for up to 7 +/- 2 days, administered on top of IPC +/- elastic stockings (ES)
1731894|NCT00038974|Drug|peginterferon alfa-2a|
1731895|NCT00038974|Drug|Ribavirin|
1731896|NCT00038987|Biological|Wetvax (APSV)|
1731897|NCT00039000|Drug|HSPPC-96 or Oncophage|
1731898|NCT00039013|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
1731899|NCT00039013|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5 mcg (0.02 mL) for 4 weeks / AC2993 10 mcg (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
1731900|NCT00039013|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
1731901|NCT00039013|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
1731902|NCT00039026|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
1731903|NCT00039026|Drug|AC2993|Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
1731904|NCT00039026|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
1731905|NCT00039026|Drug|Placebo|Placebo Lead In (0.02 mL) for 4 weeks / Placebo mcg (0.02 mL) for 4 weeks / Placebo (0.04 mL) for 26 weeks - All are subcutaneously injected twice daily
1731912|NCT00039078|Radiation|yttrium Y 90 glass microspheres|
1731913|NCT00039091|Biological|ipilimumab|Given IV
1731914|NCT00039104|Drug|rebimastat|Given PO
1731915|NCT00039104|Drug|zoledronic acid|Given IV
1731916|NCT00039104|Other|laboratory biomarker analysis|Correlative studies
1731917|NCT00039117|Biological|oblimersen sodium|Given IV
1731918|NCT00039117|Drug|cytarabine|Given IV
1731919|NCT00039117|Drug|daunorubicin hydrochloride|Given IV
1731920|NCT00039117|Other|laboratory biomarker analysis|Correlative studies
1731921|NCT00039117|Other|pharmacological study|Correlative studies
1731922|NCT00039130|Biological|filgrastim|5 ug/kg/day sub Q injection day 7 until ANC>5000/ul courses II-VII
1731923|NCT00039130|Biological|rituximab|Day 8 course II 50 mg/sq m IV infusion: d 8 course IV & VI 375mg/sq m IV Day 10 course II: 325 mg/sq m IV infusion Day 12 course II: 375 mg/sq m IV infusion
1731924|NCT00039130|Drug|cyclophosphamide|200 mg/sq m/day IV infusion over 5-15 min days 1-5, courses I, III, V, VII
1731925|NCT00039130|Drug|cytarabine|1 g/sq m/day IV infusion Days 4 & 5, courses II, IV, VI
1731926|NCT00039130|Drug|dexamethasone|10mg/sq m PO or IV Days 1-5 courses II-VII
1731927|NCT00039130|Drug|doxorubicin hydrochloride|25 mg/sq m/day IV infusion Days 4 & 5 courses III,V, VII
1731928|NCT00039130|Drug|etoposide|80 mg/sq m/day IV infusion Days 4 & 5 courses II, IV, VI
1731929|NCT00039130|Drug|ifosfamide|800 mg/sq m/day IV infusion Days 1-5 courses II, IV, VI
1731930|NCT00039130|Drug|leucovorin calcium|25mg/sq m IV infusion over 15 min then 10 mg IV q 6 hrs until serum MTX <10nM, courses II-VII
1731931|NCT00039130|Drug|methotrexate|1.5 g/sq m IV infusion Day 1 courses II-VII
1731932|NCT00039130|Drug|prednisone|60 mg/sq m PO/day Days 1-7 course I
1731933|NCT00039130|Drug|vincristine sulfate|2 mg IV push Day 1 courses II-VII
1731934|NCT00039130|Drug|Allopurinol|300 mg/day PO Days 1-14, course I
1731935|NCT00039156|Drug|ortataxel|
1731936|NCT00039169|Drug|ortataxel|
1731937|NCT00039182|Drug|erlotinib hydrochloride|Given orally
1731938|NCT00039182|Other|laboratory biomarker analysis|Correlative studies
1731939|NCT00039195|Biological|filgrastim|
1731940|NCT00039195|Biological|rituximab|
1731941|NCT00039195|Drug|carboplatin|
1731942|NCT00039195|Drug|cyclophosphamide|
1731943|NCT00039195|Drug|doxorubicin hydrochloride|
1731944|NCT00039195|Drug|etoposide|
1731945|NCT00039195|Drug|ifosfamide|
1731946|NCT00039195|Drug|prednisone|
1731947|NCT00039195|Drug|vincristine sulfate|
1731948|NCT00039195|Procedure|peripheral blood stem cell transplantation|
1731949|NCT00039195|Radiation|radiation therapy|
1731950|NCT00039208|Drug|fluorouracil|
1731951|NCT00039208|Drug|irinotecan hydrochloride|
1731952|NCT00039208|Drug|leucovorin calcium|
1731953|NCT00039208|Drug|oxaliplatin|
1731954|NCT00039234|Biological|aldesleukin|
1731955|NCT00039234|Drug|histamine dihydrochloride|
1731956|NCT00039273|Biological|panitumumab|
1731957|NCT00039286|Procedure|positron emission tomography|
1731958|NCT00039286|Procedure|radionuclide imaging|
1731959|NCT00039286|Radiation|fludeoxyglucose F 18|
1731960|NCT00039299|Biological|therapeutic autologous lymphocytes|
1731961|NCT00039312|Other|Papanicolaou test|
1731962|NCT00039312|Other|cytology specimen collection procedure|
1731963|NCT00039312|Procedure|annual screening|
1731964|NCT00039312|Procedure|colposcopic biopsy|
1731965|NCT00039312|Procedure|comparison of screening methods|
1731966|NCT00039325|Biological|dendritic cell-MART-1 peptide vaccine|Subjects will receive MART-1 adenovirus-transduced dendritic cells (DC)at dose of 10^6 (for arm A) or 10^7 (for arms B-E). Subjects will receive a total of three biweekly vaccinations given intradermally. If significant clinical or immunological response (to be defined later) is noted, subjects will be eligible for up to 6 additional monthly vaccine administrations.
1731967|NCT00039338|Procedure|conventional surgery|Radial hysterectomy
1731968|NCT00039338|Procedure|neoadjuvant chemotherapy|Experimental arm: minimal cumulative cisplatin dose of 225 mg/m2. Comparator arm: cumulative cisplatin dose of 200-240 mg/m2.
1731969|NCT00039338|Radiation|brachytherapy|Brachytherapy at the end of external radiation. Minimal total dose (external with or without external boost + brachytherapy) of 75 Gy EQD2 to point A. Overall treatment less than 50 days.
1731970|NCT00039338|Radiation|radiation therapy|Between 45-50 Gy, in fractions of 1.8 to 2 Gy.
1731971|NCT00039338|Drug|cisplatin|Minimal cumulative 225 mg/m2 (experimental arm). Cumulative 200-240 mg/m2 (comparator arm).
1731972|NCT00039351|Drug|cyclophosphamide|
1731973|NCT00039351|Drug|prednisone|
1731974|NCT00039351|Drug|vincristine sulfate|
1731975|NCT00039351|Radiation|radiation therapy|
1731976|NCT00039364|Drug|imatinib mesylate|
1731977|NCT00039377|Drug|imatinib mesylate|Given PO
1731978|NCT00039377|Drug|methotrexate|Given IT and IV
1731979|NCT00039377|Drug|vincristine sulfate|Given IV
1731980|NCT00039377|Drug|leucovorin calcium|Given IV and PO
1731981|NCT00039377|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
1731982|NCT00039377|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
1731983|NCT00039377|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSCT
1731984|NCT00039377|Radiation|total-body irradiation|Undergo TBI
1731985|NCT00039377|Drug|tacrolimus|Given IV or PO
1731986|NCT00039377|Biological|filgrastim|Given SC
1731987|NCT00039377|Drug|etoposide|Given IV
1731988|NCT00039377|Drug|cyclophosphamide|Given IV
1731989|NCT00039377|Drug|cytarabine|Given IV
1731990|NCT00039377|Other|laboratory biomarker analysis|Correlative studies
1731991|NCT00039390|Drug|capecitabine|Given orally (PO)
1731992|NCT00039390|Drug|gefitinib|Given PO
1731993|NCT00039390|Other|pharmacological study|Correlative studies
1731994|NCT00039390|Other|laboratory biomarker analysis|Correlative studies
1731995|NCT00039403|Drug|7-hydroxystaurosporine|Given IV
1731996|NCT00039403|Drug|gemcitabine hydrochloride|Given IV
1731997|NCT00039403|Other|pharmacological study|Correlative studies
1731998|NCT00039403|Other|laboratory biomarker analysis|Correlative studies
1731999|NCT00039416|Drug|imatinib mesylate|Given orally
1732000|NCT00039416|Other|laboratory biomarker analysis|Correlative studies
1732001|NCT00039429|Drug|atrasentan hydrochloride|
1732002|NCT00039442|Drug|Capecitabine|Given orally
1732003|NCT00039442|Other|Laboratory Biomarker Analysis|Correlative studies
1732004|NCT00039455|Biological|trastuzumab|Given IV
1732005|NCT00039455|Drug|alvocidib|Given IV
1732006|NCT00039455|Other|laboratory biomarker analysis|Correlative studies
1732007|NCT00039455|Other|pharmacological study|Correlative studies
1732008|NCT00039468|Drug|irinotecan hydrochloride|350 or 700 mg/m2 IV every 3 weeks
1732009|NCT00039468|Drug|thalidomide|400mg/day oral
1732010|NCT00039481|Biological|oblimersen sodium|Given IV
1732011|NCT00039481|Drug|dexrazoxane hydrochloride|Given IV
1732012|NCT00039481|Drug|doxorubicin hydrochloride|Given IV
1732013|NCT00039481|Drug|cyclophosphamide|Given IV
1732014|NCT00039481|Biological|filgrastim|Given SC
1732015|NCT00039481|Other|laboratory biomarker analysis|Correlative studies
1732016|NCT00039481|Other|pharmacological study|Correlative studies
1732017|NCT00039494|Drug|erlotinib hydrochloride|Given orally
1732018|NCT00039494|Radiation|3-dimensional conformal radiation therapy|
1732019|NCT00039494|Drug|temozolomide|Given orally
1732020|NCT00039507|Procedure|conventional surgery|
1732021|NCT00039507|Procedure|radiofrequency ablation|
1732022|NCT00039520|Drug|docetaxel|
1732023|NCT00039520|Drug|sulindac|
1732024|NCT00039546|Drug|cyclophosphamide|
1732025|NCT00039546|Drug|epirubicin hydrochloride|
1732026|NCT00039546|Drug|gemcitabine hydrochloride|
1732027|NCT00039546|Drug|paclitaxel|
1732028|NCT00039546|Procedure|adjuvant therapy|
1732029|NCT00039559|Other|Early detection|CA125 is measured in blood and the longitudinal results interpreted with a statistical algorithm to determine if there has been a significant increase from baseline.
1732030|NCT00039572|Drug|boronophenylalanine-fructose complex|
1732031|NCT00039585|Drug|imatinib mesylate|
1732032|NCT00039611|Drug|FOLFOX regimen|
1732033|NCT00039611|Drug|fluorouracil|
1732034|NCT00039611|Drug|leucovorin calcium|
1732035|NCT00039611|Drug|oxaliplatin|
1732037|NCT00039663|Drug|Pravastatin|
1732038|NCT00039663|Drug|Gemfibrozil|
1732039|NCT00039663|Drug|Rosiglitazone|
1732040|NCT00039702|Drug|[123] 5-I-A-85380|
1732041|NCT00039741|Drug|NRTIs (ABC, FTC, FTC/TDF, 3TC, 3TC/AZT, d4T, TDF, ddC, AZT)|Accepted NRTIs: abacavir sulfate (ABC), emtricitabine (FTC), emtricitabine/Tenofovir disoproxil fumarate (FTC/TDF), lamivudine (3TC), lamivudine/zidovudine (3TC/AZT), stavudine (d4T), tenofovir disoproxil fumarate (TDF), zalcitabine (ddC), zidovudine (AZT) Prescribed per participant's doctor
1732042|NCT00039741|Drug|NNRTIs (EFV, NVP)|"Accepted NNRTIs: efavirenz (EFV), nevirapine (NVP)
Prescribed per participant's doctor"
1732043|NCT00039741|Drug|PIs (AMP, IDV, LPV/r, NFV, SQV, RTV)|"Accepted PIs: amprenavir (APV). indinavir sulfate (IDV), lopinavir/ritonavir (LPV/r), nelfinavir mesylate (NFV), saquinavir (SQV), ritonavir (RTV)
Prescribed per participant's doctor"
1732044|NCT00039754|Drug|Holmium-166-DOTMP|
1732045|NCT00039767|Drug|Lepirudin|
1732046|NCT00039780|Drug|BNP7787|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
1732047|NCT00039780|Drug|Placebo|The treatment regimen administered in this study is a single IV doxe of paclitaxel (80 mg/m2) +/- Herceptin given over 1 hour and either BNP7787 (18.4 g/m2) or placebo given over 45 minutes each week. One treatment cycle = 8 weeks.
1732048|NCT00039793|Procedure|Moderate-intensity and low-intensity bodywork therapy|
1732049|NCT00039832|Drug|Abciximab (ReoPro) and Reteplase (Retavase)|
1732050|NCT00039858|Drug|Argatroban|
1732051|NCT00039871|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron (peginterferon alfa-2b) administered at a dose of 1.5 mcg/kg subcutaneously (SC) once a week (QW) for up to 48 weeks
1732052|NCT00039871|Drug|REBETOL (ribavirin; SCH 18908)|REBETOL (ribavirin) administered on a weight basis: 800-1400 mg/day orally (PO) for up to 48 weeks
1732053|NCT00039884|Drug|NESP - Novel Erythropoiesis Stimulating Protein|
1732054|NCT00039910|Drug|(PN-152,243)/ PN-196,444|
1732055|NCT00039936|Behavioral|Cognitive Behavior Treatment|
1732056|NCT00039936|Behavioral|Self Help|
1732057|NCT00039936|Behavioral|Partial Self Help|
1732058|NCT00039962|Drug|thymalfasin (thymosin alpha 1)|
1732059|NCT00039962|Drug|PEGinterferon alfa-2a|
1732060|NCT00039975|Drug|Indinavir sulfate|
1732061|NCT00039975|Drug|Ritonavir|
1732062|NCT00039975|Drug|Amlodipine|
1732063|NCT00039975|Drug|Diltiazem HCl|
1732064|NCT00039988|Drug|Glatiramer acetate|20 mg administered subcutaneously daily
1732065|NCT00039988|Drug|Albuterol|2 mg or 4 mg oral capsules taken daily
1732066|NCT00039988|Drug|Albuterol placebo|Oral placebo capsules will be taken daily
1732067|NCT00040001|Drug|DTI-0009|
1732068|NCT00040014|Drug|exemestane|
1732069|NCT00040027|Drug|thymalfasin (thymosin alpha 1) + PEGinterferon alfa-2a|
1732070|NCT00040027|Drug|placebo + PEGinterferon alfa-2a|
1732071|NCT00040040|Drug|Bupropion|
1732072|NCT00040053|Drug|Ondansetron|
1732073|NCT00040066|Procedure|Cocaine (IV)|
1732074|NCT00040092|Drug|Virulizin®|
1732075|NCT00040105|Drug|Zarnestra (R115777)|"Starting Dose:
300 mg by mouth (PO) Twice daily"
1732231|NCT00051402|Drug|Isoflavones|
1732076|NCT00040105|Drug|Gleevec (Imatinib mesylate)|"Starting Dose:
300 mg By Mouth (PO) daily"
1732077|NCT00040131|Drug|IL-10|
1732078|NCT00040144|Drug|ACH126, 433 (b-L-Fd4C)|
1732079|NCT00040157|Drug|ACH126-443 (Beta-L-Fd4C)|
1732080|NCT00040170|Biological|MVA-MUC1-IL2|
1732081|NCT00040183|Drug|Tarceva (erlotinib HCl, OSI-774)|
1732082|NCT00040209|Drug|JP 1730|
1732083|NCT00040209|Drug|IV Levodopa|
1732084|NCT00040209|Drug|IV Apomorphine|
1732085|NCT00040235|Procedure|magnesium|
1732086|NCT00040248|Drug|Daclizumab|
1732087|NCT00040261|Drug|Memantine HCL|
1732088|NCT00040274|Drug|DPC 817|
1732089|NCT00040287|Behavioral|smoking cessation program|
1732090|NCT00040287|Behavioral|weight control program|
1732091|NCT00040300|Drug|Racivir|
1732092|NCT00040313|Drug|pegaptanib sodium (Macugen)|
1732093|NCT00040326|Procedure|anteromesial temporal resection|surgical treatment for epilepsy
1732094|NCT00040326|Drug|antiepileptic drugs|pharmacotherapy
1732095|NCT00040339|Procedure|hypothermia (body temperature lowered to 33°C or 91.4°F)|
1732096|NCT00040365|Drug|Amifostine trihydrate|1000 mg for the first 18 patients. 2000 mg for the last 12 patients. The syringe of amifostine will be connected to a rectal enema bottle for administration. Administered slowly over 30-60 seconds with the patient in recumbent position 30-45 minutes prior to each radiation treatment (33-39 doses).
1732097|NCT00040365|Radiation|Radiation therapy|The treatment will be delivered in at least two phases. The first field reduction will occur after 46Gy and the second field reduction will occur after 70Gy.
1732098|NCT00040378|Drug|alphatocopherol|400 IU daily
1732099|NCT00040378|Drug|Selenium|200mcg daily
1732100|NCT00040378|Drug|Placebo replacement for vitamin E|1 placebo pill daily
1732101|NCT00040378|Drug|Placebo replacement for Selenium|1 placebo pill daily
1732102|NCT00040391|Drug|Investigational drug|
1732103|NCT00040391|Drug|Irinotecan|
1732104|NCT00040391|Drug|5-fluorouracil|
1732105|NCT00040391|Drug|Leucovorin|
1732106|NCT00049712|Biological|etaracizumab|
1732107|NCT00049725|Drug|Daclizumab|
1732108|NCT00049751|Drug|Adalimumab|
1732109|NCT00049764|Drug|Drotrecogin alfa (activated)|
1732110|NCT00049764|Drug|Placebo|
1732111|NCT00049777|Drug|Drotrecogin Alfa (Activated)|
1732112|NCT00049777|Drug|Unfractionated heparin|
1732113|NCT00049777|Drug|Low molecular weight heparin|
1732114|NCT00049790|Drug|recombinant human Angiostatin protein|
1732115|NCT00049790|Drug|paclitaxel|
1732116|NCT00049790|Drug|carboplatin|
1732117|NCT00049803|Drug|sodium oxybate|
1732118|NCT00049816|Behavioral|Walking exercise|30 minutes/day, 3 times/week for 52 weeks
1732119|NCT00049816|Behavioral|Cycling Exercise|30 minutes/day, 3 times/week for 52 weeks
1732120|NCT00049829|Drug|Zoledronic Acid|
1732121|NCT00049842|Biological|peginterferon alfa-2b (SCH 54031)|0.5 µg/kg Weekly QW SC for 36 months
1732122|NCT00049946|Drug|talnetant|
1732123|NCT00049946|Drug|risperidone|
1732124|NCT00049959|Drug|verteporfin PDT|
1732125|NCT00049972|Drug|paroxetine CR|
1732126|NCT00049985|Drug|Darbepoetin Alfa|
1732127|NCT00049998|Drug|topotecan|
1732128|NCT00050011|Drug|Zoledronic Acid|Participants received Zoledronate 4 mg IV 15-minute infusion every 6 months.
1732129|NCT00050011|Drug|Letrozole|Participants received Letrozole 2.5 mg daily.
1732130|NCT00050037|Procedure|CBT|
1732131|NCT00050531|Drug|Gleevec|400 mg orally twice daily.
1732132|NCT00050531|Drug|Peg-alpha interferon (Peg-Intron)|PEG-IFN 0.5 mcg/kg each week subcutaneously.
1732133|NCT00050531|Drug|Sargramostim (GM-CSF)|125 mcg/m^2 three times per week subcutaneously.
1732134|NCT00050557|Behavioral|Multifamily Psychoeducation Group (MFPG)|MFPG will include 8 weekly 90-minute group therapy sessions.
1732135|NCT00050557|Behavioral|Treatment as usual (TAU)|Participants will receive standard care for mood disorders.
1732136|NCT00050570|Behavioral|Web-based intervention to reduce eating disorder risk factors|
1732137|NCT00050583|Behavioral|Cognitive Behavioral Therapy|Ten Weekly Sessions of Manualized CBT
1732138|NCT00050583|Behavioral|CBT|Cognitive Behavioral Therapy
1732139|NCT00050596|Drug|MDX-010 / MDX-010 + Docetaxel|
1732140|NCT00050609|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 8 weeks
1732141|NCT00050609|Drug|tadalafil|20 mg tadalafil tablet taken by mouth once a day for 8 weeks
1732142|NCT00050609|Drug|placebo|Placebo tablet taken by mouth once a day for 8 weeks
1732143|NCT00050622|Drug|Methylphenidate 0.15 mg/kg|0.15 m/kg/dose immediate-release methylphenidate
1732144|NCT00050622|Behavioral|Low-Intensity BMOD|Lower-intensity behavioral treatment package.
1732145|NCT00050622|Drug|Methylphenidate 0.3 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
1732146|NCT00050622|Drug|Placebo|
1732147|NCT00050622|Drug|Methylphenidate 0.6 mg/kg|0.3 mg/kg/dose immediate-release methylphenidate
1732148|NCT00050622|Behavioral|High Intensity BMOD|Comprehensive high-intensity Summer Treatment Program (STP)
1732149|NCT00050635|Drug|Sandostatin LAR Depot|
1732150|NCT00050648|Drug|Daclizumab|1mg/kg medication every other week on the odd week (week 1-13).
1732151|NCT00050648|Drug|Cyclosporine|2mg/kg/day orally from Day 0 until Day 90 or a total of 13 weeks.
1732152|NCT00050648|Drug|cyclosporine and Daclizumab|1mg/kg plus low dose cyclosporine (2 mg/kg/day)
1732153|NCT00050661|Drug|Daclizumab|Humanized anti-CD25 antibodies (anti-TAC), or placebo (saline solution), will be given as intravenous infusions on the following schedule: 2 mg/kg initially (maximum dose 200 mg) infusion given over 60 minutes, followed by a 1 mg/kg (maximum of 100 mg) infusion given over 30 minutes every two weeks thereafter for a total of 8 doses.
1732154|NCT00050661|Device|NB-UVB|total body NB-UVB at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until for a total of 20 ± 2 treatments total.
1732155|NCT00050674|Drug|Filgrastim-SD/01|6 mg SC on Day 9 (24 hours after the end of the chemotherapy infusion)
1732156|NCT00050687|Drug|Gallium maltolate|
1732157|NCT00050713|Drug|Sirolimus|
1732158|NCT00050726|Drug|Interleukin-2|
1732159|NCT00050765|Drug|MyoCell™ Autologous Myoblasts|
1732160|NCT00050778|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 36 months.
1732161|NCT00050778|Biological|Alemtuzumab 12 mg|Alemtuzumab 12 milligram per day (mg/day) was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the cluster of differentiation 4+ [CD4+] T-cell count was >=100*10^6 cells per liter).
1732162|NCT00050778|Biological|Alemtuzumab 24 mg|Alemtuzumab 24 mg/day was given by intravenous infusion on 5 consecutive days during the first month and on 3 consecutive days at months 12 and 24 (the latter at the treating physicians' discretion if the CD4+ T-cell count was >=100*10^6 cells per liter).
1732163|NCT00050791|Drug|Leptin|Leptin is an adipocyte hormone that functions as an afferent signal in a feedback loop regulating body weight
1732164|NCT00050791|Behavioral|Very Low Calorie Diet|placebo injections
1732165|NCT00050804|Drug|sertraline|
1732166|NCT00050817|Drug|clopidogrel (SR25990)|
1732167|NCT00050830|Drug|CI 1033|
1732168|NCT00050843|Drug|thalidomide|
1732169|NCT00050856|Drug|Enfuvirtide T/20/Ro 29,9800, HIV-1 Infusion Inhibitor|
1732170|NCT00050882|Drug|GM-611|
1732171|NCT00050895|Drug|Lopinavir/ritonavir|
1732172|NCT00050895|Drug|Efavirenz|
1732173|NCT00050895|Drug|Stavudine|
1732174|NCT00050895|Drug|Zidovudine|
1732175|NCT00050895|Drug|Lamivudine|
1732176|NCT00050895|Drug|Tenofovir disoproxil fumarate|
1732177|NCT00050921|Drug|somatropin|
1732178|NCT00050921|Biological|Hepatitis A virus, inactivated|
1732179|NCT00050921|Drug|Keyhole-Limpet Hemocyanin|
1732180|NCT00050934|Drug|oxcarbazepine|
1732181|NCT00050947|Drug|oxcarbazepine|
1732182|NCT00050960|Drug|bexarotene with carboplatin and paclitaxel|bexarotene capsules (400 mg/m^2/day) in combination with carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m^2) every 3 weeks. Subjects in this group also received an antilipid agent which was selected at the discretion of the investigator.
1732183|NCT00050960|Drug|carboplatin and paclitaxel|carboplatin IV (AUC 6) every 3 weeks and paclitaxel IV (200 mg/m^2) every 3 weeks.
1732184|NCT00050973|Drug|bexarotene|
1732185|NCT00050986|Drug|Temozolomide|Starting Dose Level: 100 mg/m^2 taken by mouth once daily for 7 days, followed by 7 days rest and another 7-day dosing period and 7-day rest period.
1732186|NCT00050986|Drug|R115777|Starting Dose Level: 400 mg taken by mouth for 7 consecutive days every other week on alternating weeks (days 8-14 and 22-28) every 4 weeks.
1732187|NCT00050999|Drug|ONTAK|
1732188|NCT00051012|Drug|ONTAK|
1732189|NCT00051025|Drug|ONTAK|
1732190|NCT00051038|Drug|Entecavir|
1732191|NCT00051051|Drug|CI-1033|
1732192|NCT00051077|Drug|Adefovir dipivoxil|
1732193|NCT00051077|Drug|Peginterferon-alfa-2A|
1732194|NCT00051077|Drug|Ribavirin|
1732195|NCT00051077|Procedure|Liver Biopsy|
1732196|NCT00051090|Drug|Telbivudine|Administered orally at a daily dosage of 600 mg for a period of 48 weeks
1732197|NCT00051090|Drug|Lamivudine|Administered orally at a total daily dosage of 300 mg for Weeks 24-48
1732198|NCT00051090|Drug|Efavirenz|Administered orally at a daily dose of 600 mg
1732199|NCT00051090|Drug|Didanosine|Administered orally at a total dosage of either 400 mg or 250 mg determined by individual weight
1732200|NCT00051090|Drug|Abacavir|Administered orally twice daily in doses of 300 mg
1732201|NCT00051103|Drug|Investigational Cancer Drug|
1732202|NCT00051116|Drug|CC-5013|
1732203|NCT00051129|Drug|Anecortave Acetate 15 mg sterile suspension|0.5 ml of 30 mg/ml administered as a posterior juxtascleral injection
1732204|NCT00051129|Other|Anecortave Acetate Vehicle|Administered as a posterior juxtascleral injection
1732205|NCT00051142|Drug|Travoprost|
1732206|NCT00051142|Drug|Latanoprost|
1732207|NCT00051155|Drug|Travoprost (0.004%)|
1732208|NCT00051155|Drug|Latanoprost (0.005%)/Timolol (0.5%)|
1732209|NCT00051168|Drug|Travatan|Travoprost (0.004%) 1 drop each eye once daily
1732210|NCT00051181|Drug|Travoprost (0.004%)|
1732211|NCT00051181|Drug|Latanoprost (0.005%)|
1732212|NCT00051194|Drug|Combination IOP Lowering Therapy|
1732213|NCT00051207|Behavioral|Interpersonal Psychotherapy (IPT)|
1732214|NCT00051207|Behavioral|IPT for Depression with Co-occurring Panic and Anxiety Symptoms (IPT-PS)|
1732215|NCT00051220|Behavioral|One-Session Treatment for Specific Phobias|
1732216|NCT00051233|Procedure|World Wide Web-Based Psychoeducation|
1732217|NCT00051246|Behavioral|Mother-Infant Group Psychotherapy|Mother-infant group psychotherapy consists of weekly 2.5-hour psychotherapy sessions comprised of mother's group therapy, infant developmental therapy, and mother-infant dyadic psychotherapy. Group treatment will last 15 weeks.
1732218|NCT00051246|Behavioral|Interpersonal Psychotherapy|Individual psychotherapy treatment focuses on role transition, interpersonal relationships, and loss. Individual treatment period will last 15 weeks.
1732219|NCT00051259|Drug|Extended-Release Bupropion Hydrochloride|
1732220|NCT00051272|Drug|Extended-release Bupropion Hydrochloride|
1732221|NCT00051285|Drug|Enoximone|Participants receive oral enoximone
1732222|NCT00051285|Drug|Enoximone placebo|Participants receive placebo to match enoximone
1732223|NCT00051298|Drug|Olanzapine|
1732224|NCT00051298|Drug|Placebo|
1732225|NCT00051311|Procedure|Stem cell transplantation|
1732226|NCT00051350|Behavioral|Diet therapy|
1732229|NCT00051376|Drug|L-Arginine|
1732230|NCT00051389|Drug|Fosinopril|
1732232|NCT00051415|Behavioral|Flaxseed-supplemented diet|
1732233|NCT00051428|Procedure|Reiki (distant and direct-contact)|
1732234|NCT00051441|Drug|Benzydamine Hydrochloride 0.15% Oral Rinse|
1732235|NCT00051454|Biological|HIV DNA plasmid vaccine plus recombinant fowlpox vector|
1732236|NCT00051467|Genetic|TNFerade|
1732237|NCT00051480|Genetic|TNFerade|
1732238|NCT00051493|Drug|ALIMTA|
1732239|NCT00051493|Drug|Carboplatin|
1732240|NCT00051506|Drug|ALIMTA|
1732241|NCT00051506|Drug|carboplatin|
1732242|NCT00051506|Drug|cisplatin|
1732243|NCT00051532|Drug|Seocalcitol|
1732244|NCT00051545|Drug|Seocalcitol|
1732245|NCT00051558|Drug|Teriparatide|20 micrograms/day, injection, 36 months
1732246|NCT00051558|Drug|Alendronate Sodium|10 mg/day, oral, 36 months
1732247|NCT00051558|Drug|Placebo|Oral placebo, daily, 36 months
1732248|NCT00051558|Drug|Placebo|Injection placebo, daily, 36 months
1732249|NCT00051571|Drug|SGN-15|
1732250|NCT00051571|Drug|Docetaxel|
1732251|NCT00051584|Drug|SGN-15 (cBR96-Doxorubicin Immunoconjugate)|
1732252|NCT00051584|Drug|Gemzar (Gemcitabine)|
1732253|NCT00051597|Drug|SGN-30 (monoclonal antibody)|
1732254|NCT00051623|Drug|Infliximab|
1732255|NCT00051636|Drug|Zoledronic Acid|Zoledronic acid 5 mg in 5 mL of sterile water intravenous infusion.
1732256|NCT00051636|Drug|Risedronate|Oral risedronate 30 mg capsules.
1732257|NCT00051636|Drug|Placebo to Risedronate|Oral placebo of risedronate capsules.
1732258|NCT00051636|Drug|Placebo to Zoledronic Acid|5 mL of sterile water one dose intravenous infusion.
1732259|NCT00051636|Dietary Supplement|Calcium and Vitamin D|Calcium and vitamin D supplements were supplied.
1732260|NCT00051662|Drug|efalizumab|
1732261|NCT00051675|Drug|ING-1(heMAb)|
1732262|NCT00051688|Drug|tezacitabine|
1732263|NCT00051688|Drug|oxaliplatin|
1732264|NCT00051701|Drug|alemtuzumab|
1732265|NCT00051714|Behavioral|Family-Based Preventive Intervention|
1732266|NCT00051727|Behavioral|Bridges to High School Project|
1732267|NCT00051740|Behavioral|Cognitive Adaptation Therapy (CAT)|
1732268|NCT00051740|Behavioral|Minimal Environmental Supports (MES)|
1732269|NCT00051753|Drug|levofloxacin; amoxicillin/clavulanate|
1732270|NCT00051766|Behavioral|Computer-based Intervention|
1732271|NCT00051779|Drug|CAL|
1732272|NCT00051792|Behavioral|yoga|
1732273|NCT00051805|Behavioral|Promotion of adherence to ARV medications|
1732274|NCT00051818|Behavioral|Treatment interruption/reinitiation schedule|
1732275|NCT00051831|Drug|Emtricitabine|Will be administered as one 200-mg capsule orally daily
1732276|NCT00051831|Drug|Enfuvirtide|Will be administered as a 90-mg (1.0 mL) subcutaneous injection twice daily
1732277|NCT00051831|Drug|Ritonavir|Will be administered as one 100-mg capsule orally twice daily
1732278|NCT00051831|Drug|Saquinavir|Will be administered as five hard gel capsules orally twice daily
1732279|NCT00051831|Drug|Tenofovir disoproxil fumarate|Will be administered as one 300-mg tablet orally daily
1732280|NCT00051844|Drug|Capravirine|
1732281|NCT00051870|Device|Magstim Rapid Magnetic Stimulator|
1732282|NCT00051896|Drug|GBR 12909|
1732283|NCT00051909|Drug|LY451395|
1732284|NCT00051922|Biological|PolyEnv1|Recombinant vaccinia virus vaccine
1732285|NCT00051935|Drug|Alglucosidase alfa|20 mg/kg (qow); intravenous
1732286|NCT00051948|Drug|TLK286|
1732287|NCT00051974|Drug|VELCADE™ (bortezomib) for Injection (formerly PS-341)|
1732288|NCT00051987|Drug|VELCADE TM (bortezomib) for Injection, or PS-341|
1732289|NCT00052000|Drug|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
1732290|NCT00052013|Drug|PTK787/ZK 222584|
1732291|NCT00052026|Drug|carvedilol|low-dose carvedilol administered twice daily for 8 months
1732292|NCT00052026|Drug|placebo|administered twice daily for 8 months
1732293|NCT00052026|Drug|carvedilol|high-dose carvedilol administered twice daily for 8 months
1732294|NCT00052039|Drug|interferon-gamma 1b|This study was terminated prior to enrollment.
1732295|NCT00052039|Drug|azathioprine|This study was terminated prior to enrollment.
1732296|NCT00052052|Drug|interferon-gamma 1b|200 mcg, SQ, 3x per week
1732297|NCT00052065|Drug|TLK286|
1732298|NCT00052078|Drug|Sertraline (SRT)|Participants were treated with sertraline.
1732299|NCT00052078|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants received CBT.
1732300|NCT00052078|Drug|Placebo|Participants were treated with a placebo pill.
1732301|NCT00052091|Behavioral|Problem Solving Therapy|A 12 week cognitive behavioral intervention for depression that teaches patients a structured approach to solving social problems.
1732302|NCT00052091|Behavioral|Brief Supportive Therapy|A 12 week intervention for depression that focuses on supporting patients attempts to cope with depression.
1732303|NCT00052104|Behavioral|Cognitive-Behavioral Family Systems Intervention|
1732304|NCT00052117|Drug|capravirine|
1732305|NCT00052117|Drug|Kaletra|
1732306|NCT00052117|Drug|2 NRTIs|
1732307|NCT00052130|Biological|CancerVax vaccine (CANVAXIN)|
1732308|NCT00052156|Biological|CancerVax vaccine (CANVAXIN)|
1732309|NCT00052169|Drug|ZD1839 in combination with docetaxel|Docetaxel given as 75 mg/m2 IV every 3 weeks combined with ZD1839 (IRESSA) 250 mg orally daily until disease progression or withdrawal criteria are met.
1732310|NCT00052182|Biological|EP HIV-1090|
1732311|NCT00052195|Biological|SRL-172|5 doses of 0.1mL vaccine or placebo given intradermally over 12-months
1732312|NCT00052208|Drug|gefitinib|Given PO
1732313|NCT00052208|Radiation|radiation therapy|Undergo radiation therapy
1732314|NCT00052208|Other|laboratory biomarker analysis|Correlative studies
1732315|NCT00052221|Biological|Epoetin alfa|
1732316|NCT00052221|Other|Placebo|
1732317|NCT00052273|Drug|capecitabine|
1732318|NCT00052273|Drug|enzastaurin hydrochloride|
1732322|NCT00052299|Drug|gemtuzumab ozogamicin|
1732323|NCT00052299|Drug|idarubicin|
1732324|NCT00052299|Drug|mitoxantrone hydrochloride|
1732325|NCT00052312|Drug|cisplatin|
1732326|NCT00052312|Drug|doxorubicin hydrochloride|
1732327|NCT00052312|Drug|paclitaxel|
1732328|NCT00052325|Dietary Supplement|mistletoe extract|
1732329|NCT00052338|Drug|gemcitabine hydrochloride|Given IV
1732330|NCT00052338|Drug|carboplatin|Given IV
1732331|NCT00052338|Drug|bortezomib|Given IV
1732332|NCT00052338|Other|laboratory biomarker analysis|Correlative studies
1732333|NCT00052351|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
1732334|NCT00052351|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
1732335|NCT00052351|Biological|sargramostim|
1732336|NCT00052351|Drug|cyclophosphamide|
1732337|NCT00052351|Drug|doxorubicin hydrochloride|
1732338|NCT00052351|Drug|paclitaxel|
1732339|NCT00052351|Radiation|radiation therapy|
1732340|NCT00052364|Drug|oxaliplatin|Given IV
1732341|NCT00052364|Other|laboratory biomarker analysis|Correlative studies
1732342|NCT00052377|Biological|aldesleukin|Given SC
1732343|NCT00052377|Biological|recombinant interleukin-12|Given SC
1732344|NCT00052377|Other|laboratory biomarker analysis|Correlative studies
1732345|NCT00052390|Biological|bevacizumab|
1732346|NCT00052390|Drug|doxorubicin hydrochloride|
1732347|NCT00052403|Drug|monoclonal antibody anti-anb3 integrin|
1732348|NCT00052403|Procedure|anti-cytokine therapy|
1732349|NCT00052403|Procedure|antiangiogenesis therapy|
1732350|NCT00052403|Procedure|antibody therapy|
1732351|NCT00052403|Procedure|biological response modifier therapy|
1732352|NCT00052403|Procedure|growth factor antagonist therapy|
1732353|NCT00052403|Procedure|monoclonal antibody therapy|
1732354|NCT00052416|Drug|thalidomide|
1732355|NCT00052429|Drug|cisplatin|
1732356|NCT00052429|Drug|fluorouracil|
1732357|NCT00052429|Procedure|adjuvant therapy|
1732358|NCT00052429|Radiation|radiation therapy|
1732360|NCT00052455|Drug|lomustine|
1732361|NCT00052455|Drug|procarbazine hydrochloride|
1732362|NCT00052455|Drug|temozolomide|
1732363|NCT00052455|Drug|vincristine sulfate|
1732364|NCT00052468|Drug|TCG|
1732365|NCT00052468|Drug|TC|
1732366|NCT00052481|Procedure|quality-of-life assessment|
1732367|NCT00052494|Drug|cisplatin|
1732368|NCT00052494|Drug|imatinib mesylate|
1732369|NCT00052494|Drug|irinotecan hydrochloride|
1732370|NCT00052507|Drug|bortezomib|
1732371|NCT00052520|Biological|therapeutic allogeneic lymphocytes|Given IV
1732372|NCT00052520|Biological|aldesleukin|Given SC
1732373|NCT00052520|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
1732374|NCT00052520|Procedure|allogeneic bone marrow transplantation|Undergo transplantation
1732375|NCT00052520|Other|laboratory biomarker analysis|Correlative studies
1732376|NCT00052520|Genetic|gene expression analysis|Correlative studies
1732377|NCT00052520|Other|immunologic technique|Correlative studies
1732378|NCT00052520|Other|flow cytometry|Correlative studies
1732379|NCT00052520|Genetic|polymerase chain reaction|Correlative studies
1732380|NCT00052520|Genetic|cytogenetic analysis|Correlative studies
1732381|NCT00052520|Other|staining method|Correlative studies
1732382|NCT00052559|Biological|bevacizumab|Given IV
1732383|NCT00052559|Drug|fluorouracil|Given IV
1732384|NCT00052559|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
1732385|NCT00052559|Procedure|therapeutic conventional surgery|Undergo surgery
1732386|NCT00052559|Other|laboratory biomarker analysis|Correlative studies
1732387|NCT00052572|Drug|ixabepilone|
1732388|NCT00052585|Drug|irinotecan hydrochloride|Given IV
1732389|NCT00052585|Drug|gefitinib|Given orally
1732390|NCT00052585|Drug|leucovorin calcium|Given IV
1732391|NCT00052585|Drug|fluorouracil|Given IV
1732392|NCT00052598|Biological|therapeutic allogeneic lymphocytes|Given IV
1732393|NCT00052598|Biological|aldesleukin|Given SC
1732394|NCT00052598|Other|laboratory biomarker analysis|Correlative studies
1732395|NCT00052598|Other|flow cytometry|Correlative studies
1732396|NCT00052611|Drug|celecoxib|
1732397|NCT00052624|Biological|transferrin-CRM107|
1732398|NCT00052637|Drug|hexaminolevulinate|
1732399|NCT00052637|Procedure|biopsy|
1732400|NCT00052637|Procedure|cystoscopy|
1732401|NCT00052676|Drug|patent blue V dye|
1732402|NCT00052676|Procedure|radionuclide imaging|
1732403|NCT00052676|Procedure|sentinel lymph node biopsy|
1732404|NCT00052676|Radiation|technetium Tc 99m sulfur colloid|
1732405|NCT00052689|Drug|bortezomib|Given IV
1732406|NCT00052689|Drug|gemcitabine hydrochloride|Given IV
1732407|NCT00052715|Drug|poly ICLC|
1732408|NCT00052728|Drug|tamoxifen citrate|
1732409|NCT00052728|Drug|tipifarnib|
1732410|NCT00052754|Drug|gefitinib|
1732411|NCT00052780|Drug|O6-benzylguanine|Given IV
1732412|NCT00052780|Drug|temozolomide|Given PO
1732413|NCT00052780|Biological|filgrastim|Given SC or IV
1732414|NCT00052780|Other|pharmacological study|Correlative studies
1732415|NCT00052780|Other|laboratory biomarker analysis|Correlative studies
1732416|NCT00052832|Dietary Supplement|doxercalciferol|
1732417|NCT00052845|Drug|docetaxel|70 mg/sq m IV infusion over 1 hour Day 2 of ea cycle
1732418|NCT00052845|Drug|estramustine phosphate sodium|280 mg PO tid Days 1-5 of ea cycle
1732419|NCT00052845|Drug|exisulind|Two 125 mg capsules PO bid Days 1-21 of ea cycle
1732420|NCT00052884|Biological|filgrastim|
1732421|NCT00052884|Drug|amifostine trihydrate|
1732423|NCT00052884|Procedure|bone marrow ablation with stem cell support|
1732424|NCT00052884|Procedure|peripheral blood stem cell transplantation|
1732425|NCT00052897|Biological|HspE7|
1732431|NCT00052923|Biological|filgrastim|
1732432|NCT00052923|Biological|rituximab|
1732433|NCT00052923|Drug|carmustine|
1732434|NCT00052923|Drug|cyclophosphamide|
1732435|NCT00052923|Drug|etoposide|
1732436|NCT00052923|Procedure|peripheral blood stem cell transplantation|
1732437|NCT00052923|Radiation|radiation therapy|
1732438|NCT00052936|Biological|filgrastim|
1732439|NCT00052936|Biological|rituximab|
1732440|NCT00052936|Drug|CHOP regimen|
1732441|NCT00052936|Drug|cyclophosphamide|
1732442|NCT00052936|Drug|doxorubicin hydrochloride|
1732443|NCT00052936|Drug|prednisone|
1732444|NCT00052936|Drug|vincristine sulfate|
1732445|NCT00052936|Radiation|radiation therapy|
1732446|NCT00052949|Drug|imatinib mesylate|Given orally
1732447|NCT00052949|Other|laboratory biomarker analysis|Correlative studies
1732448|NCT00052962|Procedure|Cytoreductive surgery|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.
Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m^2 on day 1 only, leucovorin 200 mg/M^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
1732449|NCT00052962|Procedure|Continuous hyperthermic peritoneal perfusion (HIPEC/CHPP)|"Patients will undergo a laparotomy, surgical incision in the abdomen to assess the peritoneal cavity with cytoreductive surgery or tumor debulking, to reduce tumor size.
Followed by continuous hyperthermic peritoneal perfusion (HIPEC) with 250 mg/m^2 cisplatin. Post operative dwell chemotherapy given once between post op day 7 and 12: 5-fluororacil (5-FU) 800 mg/m^2 and paclitaxel 125 mg/m^2.
Drug: Post operative chemotherapy: systemic oxaliplatin 85 mg/m^2 on day 1 only, leucovorin 200 mg/M^2/day on day 1, 2, 15, and 16, and infusional 5-flurouracil (5-FU) 800 mg/m^2 on day 8, every other week of every four weeks (two weeks per month) starting 4 to 6 weeks after operation and continuing for four cycles { 16 weeks total}."
1732450|NCT00053001|Biological|epoetin alfa|
1732451|NCT00053001|Drug|thalidomide|
1732452|NCT00053014|Biological|therapeutic allogeneic lymphocytes|
1732453|NCT00053014|Drug|cyclosporine|
1732454|NCT00053014|Drug|fludarabine|
1732455|NCT00053014|Drug|mycophenolate mofetil|
1732456|NCT00053014|Procedure|peripheral blood stem cell transplantation|
1732457|NCT00053014|Radiation|radiation therapy|
1732458|NCT00053027|Biological|rituximab|
1732459|NCT00053027|Drug|cladribine|
1732460|NCT00053040|Biological|cintredekin besudotox|IL13-PE38QQR is administered intracerebrally by continuous convection enhanced infusion at a starting concentration of 0.25 μg/mL. Infusion duration will be held constant at 96 hours (4 days). The phase I component of this study is to estimate the maximum safe total flow rate and the maximum safe infusion concentration.
1732461|NCT00053040|Procedure|conventional surgery|Conventional surgery is used for tumor resection prior to catheter placement for IL13-PE38QQR infusion.
1732462|NCT00053053|Dietary Supplement|Juven|
1732463|NCT00053053|Dietary Supplement|Non-Juven Supplement|
1732464|NCT00053092|Biological|rituximab|
1732465|NCT00053092|Drug|cyclophosphamide|
1732466|NCT00053092|Drug|fludarabine phosphate|
1732467|NCT00053105|Drug|cisplatin|
1732468|NCT00053105|Drug|cytarabine|
1732469|NCT00053105|Drug|methylprednisolone|
1732470|NCT00053105|Drug|pixantrone dimaleate|
1732471|NCT00053118|Biological|filgrastim|IV
1732472|NCT00053118|Drug|carboplatin|IV
1732473|NCT00053118|Drug|etoposide|IV
1732474|NCT00053118|Procedure|bone marrow ablation with stem cell support|IV
1732475|NCT00053118|Procedure|peripheral blood stem cell transplantation|IV
1732476|NCT00053131|Biological|filgrastim|
1732477|NCT00053131|Biological|sargramostim|
1732478|NCT00053131|Drug|cytarabine|
1732479|NCT00053131|Drug|mitoxantrone hydrochloride|
1732480|NCT00053144|Drug|cytarabine|
1732481|NCT00053144|Drug|irinotecan hydrochloride|
1732482|NCT00053157|Biological|sargramostim|
1732483|NCT00053183|Procedure|conventional surgery|
1732484|NCT00053183|Radiation|brachytherapy|
1732485|NCT00053183|Radiation|radiation therapy|
1732486|NCT00053196|Biological|anti-thymocyte globulin|2.5mg/kg/day IV infusion over 6 hrs x 4 doses Days -4 to -1 (for MUD and 9/10 related donor transplants only)
1732487|NCT00053196|Biological|G-CSF|5 ug/kg/day subQ injection Day 7 until ANC> 1000/uL for 3 consec days
1732488|NCT00053196|Drug|busulfan|0.8mg/kg IV infusion over 2 hrs q 6 hrs x 8 doses Days -4 thru -3
1732489|NCT00053196|Drug|fludarabine phosphate|30 mg/sq m/day IVBP over 30 min Days -7 thru -3
1732490|NCT00053196|Drug|methotrexate|5 mg/sq m/day IV infusion Days 1, 3, & 6 for HLA-identical donor transplants and Days 1, 3, 6, & 11 for MUD & 9/10 related donor transplants
1732491|NCT00053196|Drug|mycophenolate mofetil|15mg/kg PO bid Day -2 to Day 60, then taper as tolerated (for MUD and 9/10 related donor transplants only)
1732492|NCT00053196|Drug|tacrolimus|target serum level is 5-10 ng/mL. Start with 0.03mg/kg PO bid Day -1 to Day 90, then taper thru Day 150 for HLA identical donor transplants and Day -1 to Day 180 then taper for MUD and 9/10 related donor transplants
1732493|NCT00053196|Procedure|allogeneic cell transplantation|2,000,000-8,000,000 CD34+ cells total via infusion Days 0 and 1
1732494|NCT00053196|Drug|allopurinol|300 mg/day PO Days -8 thru -1
1732495|NCT00053209|Drug|gemcitabine hydrochloride|
1732496|NCT00053209|Drug|pemetrexed disodium|
1732498|NCT00053235|Genetic|Comparative Genomic Hybridization|Correlative studies
1732499|NCT00053235|Other|Laboratory Biomarker Analysis|Correlative studies
1732500|NCT00053235|Genetic|Polymerase Chain Reaction|Correlative studies
1732501|NCT00053248|Drug|arsenic trioxide|
1732502|NCT00053248|Drug|imatinib mesylate|
1732503|NCT00053261|Procedure|management of therapy complications|
1732504|NCT00053287|Drug|carboplatin|Carboplatin IV over 24 hours on days 1-5
1732505|NCT00053287|Drug|fludarabine phosphate|Fludarabine IV over 5-10 minutes on days 1-5.
1732506|NCT00053287|Drug|thalidomide|Oral thalidomide daily beginning within days 1-3 and continuing in the absence of disease progression or unacceptable toxicity.
1732507|NCT00053287|Drug|topotecan hydrochloride|Topotecan IV continuously over 72 hours.
1732508|NCT00053300|Drug|thalidomide|oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity
1732509|NCT00053300|Procedure|adjuvant therapy|Patients receive oral thalidomide daily beginning 3-4 weeks after completion of induction chemotherapy. Treatment continues for 1 year in the absence of disease progression or unacceptable toxicity.
1732510|NCT00053326|Drug|fenretinide|Given orally
1732511|NCT00053326|Other|pharmacological study|Optional correlative studies
1732512|NCT00053339|Drug|tamoxifen|
1732513|NCT00053339|Drug|trastuzumab|
1732514|NCT00044135|Drug|clevudine (drug)|
1732515|NCT00044148|Drug|LY333531|
1732516|NCT00044187|Drug|Sibutramine|
1732521|NCT00044226|Drug|ML-04A|
1732522|NCT00044265|Drug|ramipril|
1732524|NCT00044291|Drug|atamestane|
1732525|NCT00044291|Drug|toremifene|
1732526|NCT00044291|Drug|letrozole|
1732527|NCT00044291|Drug|aromatase inhibition|
1732528|NCT00044291|Procedure|hormone therapy|
1732529|NCT00044291|Procedure|endocrine therapy|
1732530|NCT00044291|Procedure|antiestrogen therapy|
1732532|NCT00044343|Drug|lapatinib|
1732533|NCT00044356|Genetic|Allovectin-7®|
1732534|NCT00044369|Procedure|Varicocele repair|
1732535|NCT00044382|Drug|CC-5013|
1732536|NCT00044395|Drug|Ruboxistaurin mesylate|
1732537|NCT00044408|Drug|Ruboxistaurin mesylate|
1732538|NCT00044421|Drug|Ruboxistaurin mesylate|
1732539|NCT00044434|Drug|bupropion (Wellbutrin)|
1732540|NCT00044447|Drug|Glimepiride|
1732542|NCT00044473|Drug|levofloxacin|
1732543|NCT00044486|Drug|Posaconazole oral suspension|
1732544|NCT00044512|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (Nexavar, BAY43-9006) 400 mg administered bis in die (bid, twice a day)
1732545|NCT00044525|Drug|BAY59-8862 (Cytotoxic Taxane)|1 h intravenous infusion every 3 weeks
1732546|NCT00044538|Drug|BAY59-8862 (Cytotoxic Taxane)|Intravenous dose over 60 minutes every 3 weeks
1732547|NCT00044551|Drug|Taxane (Cytotoxic, BAY59-8862)|Daily 1 h infusion every 3 weeks
1732548|NCT00044564|Drug|Bay 59-8862|75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
1732549|NCT00044577|Drug|abacavir/lamivudine|
1732550|NCT00044577|Drug|abacavir|
1732551|NCT00044577|Drug|lamivudine|
1732552|NCT00044577|Drug|tenofovir|
1732553|NCT00044616|Drug|Fluoxetine|
1732554|NCT00044616|Drug|Lithium|
1732555|NCT00044629|Behavioral|Cognitive-Behavioral Therapy for Insomnia|
1732556|NCT00044629|Drug|zolpidem tartrate (Ambien)|
1732557|NCT00044629|Drug|Placebo|
1732558|NCT00044642|Drug|Lorazepam|
1732559|NCT00044655|Drug|Risperidone|As prescribed by routine prescriber (not dictated by study protocol)
1732560|NCT00044655|Drug|Olanzapine|As prescribed by routine prescriber (not dictated by study protocol)
1732561|NCT00044655|Drug|Ziprasidone|As prescribed by routine prescriber (not dictated by study protocol)
1732562|NCT00044655|Drug|Quetiapine|As prescribed by routine prescriber (not dictated by study protocol)
1732563|NCT00044655|Drug|Aripiprazole|As prescribed by routine prescriber (not dictated by study protocol)
1732564|NCT00044668|Drug|AC2993|Subjects will receive 5 μg AC2993, subcutaneously injected twice daily, for 4 weeks followed by 10 μg AC2993, subcutaneously injected twice daily, during a maintenance period that is expected to continue for at least 11 months.
1732565|NCT00044681|Drug|risperidone|
1732566|NCT00044694|Drug|Placebo 0.01 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.01 mL subcutaneously injected twice daily
1732567|NCT00044694|Drug|Placebo 0.02 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.02 mL subcutaneously injected twice daily
1732568|NCT00044694|Drug|Placebo 0.03 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.03 mL subcutaneously injected twice daily
1732569|NCT00044694|Drug|Placebo 0.04 mL|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of Placebo 0.04 mL subcutaneously injected twice daily
1732570|NCT00044694|Drug|AC2993 2.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 2.5 mcg (0.01 mL) subcutaneously injected twice daily
1732746|NCT00046033|Drug|Tenofovir disoproxil fumarate|
1732571|NCT00044694|Drug|AC2993 5.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 5.0 mcg (0.02 mL) subcutaneously injected twice daily
1732572|NCT00044694|Drug|AC2993 7.5 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 7.5 mcg (0.03 mL) subcutaneously injected twice daily
1732573|NCT00044694|Drug|AC2993 10.0 mcg|2-week placebo lead-in period (0.01 mL) followed by 4 weeks of AC2993 10.0 mcg (0.04 mL) subcutaneously injected twice daily
1732574|NCT00044707|Drug|Pramlintide acetate|Clear, colorless, sterile solution for SC injection.
1732575|NCT00044720|Drug|Rapamune|
1732576|NCT00044733|Drug|Mylotarg (gemtuzumab ozogamicin) Injection|
1732577|NCT00044746|Drug|Piperacillin/Tazobactam|
1732578|NCT00044759|Drug|Piperacillin/Tazobactam (Tazocin)|
1732579|NCT00044772|Drug|Venlafaxine ER|
1732580|NCT00044785|Drug|triacetyluridine|
1732581|NCT00044785|Drug|fluorouracil|
1732582|NCT00044785|Drug|leucovorin|
1732583|NCT00044785|Drug|camptosar|
1732584|NCT00044798|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|Participants will receive 15 treatments of rTMS over 3 weeks.
1732585|NCT00044798|Drug|Citalopram|After completing treatment with rTMS or sham rTMS, participants will take citalopram for 9 weeks.
1732586|NCT00044798|Procedure|Sham rTMS|Participants will receive 15 treatments of sham rTMS over 3 weeks.
1732587|NCT00044811|Drug|Fexofenadine|
1732588|NCT00044824|Drug|Fexofenadine|
1732589|NCT00044837|Drug|Medroxyprogesterone acetate|
1732590|NCT00044837|Drug|Estradiol|
1732591|NCT00044863|Biological|Erbitux (Cetuximab)|400 mg/m2 initial dose, 250 mg/m2 weekly
1732592|NCT00044876|Drug|CDB-2914|
1732593|NCT00044889|Drug|clofarabine (IV formulation)|
1732594|NCT00044902|Drug|epratuzumab|
1732595|NCT00044915|Drug|Repinotan HCl (BAYX3702)|All patients receive 1.25 mg of repinotan
1732596|NCT00044915|Drug|Placebo|All patients receive 1.25 mg of placebo
1732597|NCT00044928|Drug|Piperacillin/Tazobactam|
1732598|NCT00044954|Biological|therapeutic allogeneic lymphocytes|
1732599|NCT00044954|Drug|cyclosporine|
1732600|NCT00044954|Drug|fludarabine phosphate|
1732601|NCT00044954|Drug|mycophenolate mofetil|
1732602|NCT00044954|Procedure|allogeneic bone marrow transplantation|
1732603|NCT00044954|Procedure|peripheral blood stem cell transplantation|
1732604|NCT00044954|Radiation|radiation therapy|
1732605|NCT00044967|Genetic|microsatellite instability analysis|
1732606|NCT00044980|Procedure|nutritional support|
1732607|NCT00044980|Procedure|quality-of-life assessment|
1732608|NCT00044993|Biological|Ad5CMV-p53 gene|
1732609|NCT00044993|Drug|docetaxel|
1732610|NCT00044993|Drug|doxorubicin hydrochloride|
1732611|NCT00044993|Procedure|conventional surgery|
1732612|NCT00044993|Procedure|neoadjuvant therapy|
1732613|NCT00045006|Drug|vorinostat|
1732614|NCT00045019|Other|quality-of-life assessment|QLQ-C30 SAT32
1732615|NCT00045032|Drug|Herceptin|Herceptin will be given as a loading dose of 8 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
1732616|NCT00045032|Drug|Herceptin|Herceptin will be given as a loading dose of 8 mg/kg via IV infusion on Day 1, followed by a maintenance dose of 6 mg/kg via IV infusion 3 weeks later and thereafter every 3 weeks.
1732617|NCT00045045|Procedure|positron emission tomography|
1732618|NCT00045045|Radiation|fludeoxyglucose F 18|
1732619|NCT00045097|Drug|ixabepilone|
1732620|NCT00045110|Drug|erlotinib hydrochloride|given orally
1732621|NCT00045110|Other|laboratory biomarker analysis|correlative studies
1732622|NCT00045110|Other|pharmacological study|correlative studies
1732623|NCT00045123|Drug|tarenflurbil|
1732624|NCT00045123|Procedure|adjuvant therapy|
1732625|NCT00045136|Drug|melphalan|
1732626|NCT00045136|Procedure|peripheral blood stem cell transplantation|
1732627|NCT00045136|Radiation|holmium Ho 166 DOTMP|
1732628|NCT00045149|Biological|aldesleukin|
1732629|NCT00045149|Biological|therapeutic tumor infiltrating lymphocytes|
1732630|NCT00045162|Drug|cisplatin|"Arm 1: 60 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles
Arm 2: 80 mg/m2 IV (over 30-60 min) on Day 1, Q 4 weeks x 4 Cycles"
1732631|NCT00045162|Drug|etoposide|100 mg/m2 IV (over 30-60 min) on Days 1 , 2 & 3. Q 3 weeks x 4 Cycles
1732632|NCT00045162|Drug|irinotecan hydrochloride|60 mg/m2 IV (over 90 min)on Days 1, 8 & 15. Q 4 weeks x 4 Cycles
1732633|NCT00045175|Drug|7-hydroxystaurosporine|
1732634|NCT00045175|Drug|topotecan hydrochloride|
1732635|NCT00045188|Drug|imatinib mesylate|Given PO
1732636|NCT00045188|Other|laboratory biomarker analysis|Optional correlative studies
1732639|NCT00045227|Biological|recombinant fowlpox-prostate specific antigen vaccine|
1732640|NCT00045227|Biological|recombinant vaccinia prostate-specific antigen vaccine|
1732641|NCT00045227|Biological|recombinant vaccinia-B7.1 vaccine|
1732642|NCT00045227|Biological|sargramostim|
1732643|NCT00045227|Drug|docetaxel|
1732644|NCT00045266|Biological|ziv-aflibercept|
1732645|NCT00045279|Biological|PEG-interferon alfa-2b|
1732646|NCT00045292|Drug|acyclovir|
1732647|NCT00045292|Drug|acyclovir sodium|
1732648|NCT00045292|Drug|valacyclovir|
1732649|NCT00045305|Drug|Cyclosporine|Immunosuppressant
1732650|NCT00045305|Drug|Methotrexate|Antimetabolite
1732651|NCT00045305|Drug|Photopheresis|Psoralens
1732652|NCT00045305|Drug|Mycofenolate mofetil|an antibiotic with immunosuppressamt properties isolated from Penicillium spp
1732653|NCT00045305|Drug|Pentostatin|Purine analogue
1732654|NCT00045305|Procedure|allogeneic bone marrow|Unmanipulated allogeneic bone marrow
1732655|NCT00045305|Procedure|peripheral blood stem cell|G-CSF mobilized peripheral blood stem cell
1732656|NCT00045305|Radiation|Total body irradiation|a total of 600 cGy given in 3 200 cGy fractionated doses
1732657|NCT00045318|Drug|exatecan mesylate|
1732658|NCT00045331|Genetic|proteomic profiling|
1732659|NCT00045357|Biological|therapeutic autologous lymphocytes|
1732660|NCT00045370|Biological|recombinant interferon alfa|
1732661|NCT00045370|Drug|temsirolimus|
1732662|NCT00045396|Drug|tipifarnib|Given orally
1732663|NCT00045422|Biological|recombinant interferon alfa|
1732664|NCT00045422|Drug|imatinib mesylate|
1732665|NCT00045435|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
1732666|NCT00045435|Drug|fludarabine phosphate|Given IV
1732667|NCT00045435|Radiation|total-body irradiation|Undergo TBI
1732668|NCT00045435|Drug|cyclosporine|Given PO
1732669|NCT00045435|Drug|mycophenolate mofetil|Given PO
1732670|NCT00045435|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplant
1732671|NCT00045448|Drug|alvocidib|
1732672|NCT00045448|Drug|docetaxel|
1732673|NCT00045461|Drug|carboplatin|
1732674|NCT00045461|Drug|ifosfamide|
1732675|NCT00045461|Procedure|hyperthermia treatment|
1732676|NCT00045474|Procedure|adjuvant therapy|
1732677|NCT00045474|Radiation|iodine I 125|
1732678|NCT00045487|Drug|OSI-774|OSI-774 is an orally active, potent, selective inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase.
1732679|NCT00045500|Drug|7-hydroxystaurosporine|
1732680|NCT00045500|Drug|prednisone|
1732681|NCT00045513|Drug|7-hydroxystaurosporine|
1732682|NCT00045513|Drug|fludarabine phosphate|
1732683|NCT00045526|Drug|erlotinib hydrochloride|Given PO
1732684|NCT00045526|Other|laboratory biomarker analysis|Correlative studies
1732685|NCT00045539|Drug|leucovorin calcium|
1732686|NCT00045539|Drug|methotrexate|
1732687|NCT00045539|Drug|thiotepa|
1732688|NCT00045565|Drug|arsenic trioxide|Given IV
1732689|NCT00045565|Radiation|radiation therapy|Undergo radiation therapy
1732690|NCT00045591|Drug|celecoxib|100 mg PO bid
1732691|NCT00045591|Drug|Celecoxib|400 mg PO bid
1732692|NCT00045604|Drug|cisplatin|
1732693|NCT00045604|Drug|imatinib mesylate|
1732694|NCT00045604|Drug|irinotecan hydrochloride|
1732695|NCT00045617|Biological|monoclonal antibody 11D10 anti-idiotype vaccine|
1732696|NCT00045617|Biological|monoclonal antibody GD2 anti-idiotype vaccine|
1732697|NCT00045617|Drug|cisplatin|
1732698|NCT00045617|Drug|etoposide|
1732699|NCT00045617|Radiation|radiation therapy|
1732700|NCT00045630|Drug|carboplatin|
1732701|NCT00045630|Drug|gemcitabine|
1732702|NCT00045630|Drug|paclitaxel|
1732703|NCT00045630|Procedure|surgery|
1732704|NCT00045669|Drug|imatinib mesylate|
1732705|NCT00045682|Drug|Paclitaxel Poliglumex|Given IV
1732706|NCT00045695|Drug|bortezomib|PS-341 bolus intravenous injection twice weekly* for 2 out of every 3 weeks
1732710|NCT00045721|Drug|O6-benzylguanine|
1732711|NCT00045721|Drug|polifeprosan 20 with carmustine implant|
1732712|NCT00045721|Procedure|adjuvant therapy|
1732713|NCT00045721|Procedure|conventional surgery|
1732714|NCT00045721|Procedure|neoadjuvant therapy|
1732715|NCT00045734|Drug|imatinib mesylate|Given orally
1732716|NCT00045734|Other|laboratory biomarker analysis|Correlative studies
1732717|NCT00045734|Other|pharmacological study|Correlative studies
1732718|NCT00045747|Drug|7-hydroxystaurosporine|
1732719|NCT00045747|Drug|fluorouracil|
1732720|NCT00045760|Drug|Drotrecogin alfa (activated)|
1732722|NCT00045786|Drug|CC-1088|400 mg/day (200 mg orally twice a day) 800 mg/day (400 mg orally twice a day) 1200 mg/day (600 mg orally twice a day) 1500 mg/day (500 mg orally three times daily)
1732723|NCT00045799|Drug|Omeprazole sodium bicarbonate immediate release PWD/FS|
1732724|NCT00045799|Drug|Cimetidine IV|
1732725|NCT00045812|Drug|SCH-58235|
1732726|NCT00045838|Drug|VCR-HIVDNA006-00-VP|
1732727|NCT00045864|Drug|Recombinant Human Interleukin-2 and Rituximab|
1732728|NCT00045877|Drug|Recombinant Human Interleukin-2 and Rituximab|
1732729|NCT00045903|Behavioral|Exposure and Ritual Prevention (Cognitive Behavioral Therapy)|
1732730|NCT00045903|Behavioral|Stress Management Therapy (Cognitive Behavior Therapy)|
1732731|NCT00045916|Procedure|High dosage electroconvulsive therapy|Participants will receive high dosage right unilateral ECT at six times the seizure threshold.
1732732|NCT00045916|Drug|Nortriptyline|Participants will receive nortriptyline.
1732733|NCT00045916|Drug|Venlafaxine|Participants will receive venlafaxine.
1732734|NCT00045916|Drug|Lithium|Participants will receive lithium.
1732735|NCT00045916|Procedure|Low dosage electroconvulsive therapy|Participants will receive low dosage bilateral ECT at one and a half times the seizure threshold.
1732736|NCT00045942|Drug|Itraconazole|Itraconazole was commercially available.
1732737|NCT00045942|Drug|PKC412|PKC412 was supplied as soft gelatin capsules containing 25 mg PKC412.
1732738|NCT00045955|Drug|Fexofenadine, Comparator = Montelukast|
1732739|NCT00045968|Drug|Dendritic cell immunotherapy|Two intradermal (i.d.) injections of DCVax-L(treatment cohort) or autologous PBMC (placebo cohort) per treatment. Treatments will be given at days 0, 10, 20, and at weeks 8, 16, 32, 48, 72, 96 and 120.
1732740|NCT00045981|Drug|ALT-711|
1732741|NCT00045994|Drug|ALT-711|
1732742|NCT00046020|Drug|Venlafaxine ER|
1732743|NCT00046033|Drug|Lopinavir/ritonavir|
1732744|NCT00046033|Drug|Ritonavir|
1732749|NCT00046085|Behavioral|Online Family Education|Families were provided with private, secure access to the website, which features family-to-family chat capabilities, video lectures on the management of schizophrenia, written materials on important issues in schizophrenia management, professionally facilitated online discussions of the material, and additional resource links.
1732750|NCT00046085|Behavioral|Customary care|Participants received care as usual.
1732751|NCT00046111|Drug|topotecan|A topoisomerase I inhibitor used for ovarian and lung cancer treatment
1732752|NCT00046137|Drug|teriparatide|
1732753|NCT00046137|Drug|raloxifene|
1732754|NCT00046137|Drug|placebo|
1732755|NCT00046150|Drug|Insulin glulisine (HMR1964)|
1732756|NCT00046163|Drug|midodrine hydrochloride (ProAmatine®)|
1732757|NCT00046176|Drug|abacavir/lamivudine|
1732758|NCT00046176|Drug|abacavir|
1732759|NCT00046176|Drug|lamivudine|
1732760|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
1732761|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
1732762|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¼g/kg/min, max 10 ¼g/min infusion x 12h
1732763|NCT00046228|Drug|abciximab placebo; reteplase placebo, abciximab, abciximab|placebo bolus; 1-2 placebo bolus; 0.25 mg/kg bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
1732764|NCT00046228|Drug|abciximab; reteplase placebo; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2 placebo boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
1732765|NCT00046228|Drug|Abciximab; reteplase; abciximab placebo; abciximab|0.25 mg/kg bolus; 1-2, 5 unit boluses; placebo bolus; 0.125 ¿g/kg/min, max 10 ¿g/min infusion x 12h
1732766|NCT00046241|Drug|Extended-release bupropion hydrochloride|
1732767|NCT00046254|Drug|Zoledronic Acid|
1732768|NCT00046267|Drug|Niacin|
1732769|NCT00046293|Drug|Reopro|
1732770|NCT00046293|Drug|Retrovase|
1732771|NCT00046306|Drug|Antioxidants|
1732772|NCT00046319|Drug|BSF 208075|
1732773|NCT00046332|Drug|GW810781|
1732774|NCT00046345|Drug|Atazanavir (BMS-232632)|
1732775|NCT00046358|Drug|Lovostatin|
1732776|NCT00046358|Drug|Ibuprofen|
1732777|NCT00046371|Drug|THERATOPE® vaccine|
1732778|NCT00046384|Drug|aripiprazole|
1732779|NCT00046397|Drug|Modified Vaccinia Virus Ankara TBC-M|
1732780|NCT00046423|Drug|ABI-007|
1732781|NCT00046449|Drug|Investigational Seasonal Affective Disorder (SAD) Drug|
1732782|NCT00046462|Drug|Lantus (insulin glargine [rDNA origin] injection)|
1732783|NCT00046462|Drug|Metformin|
1732784|NCT00046462|Drug|Glyburide|
1732785|NCT00046462|Drug|Thiazolidinedione|
1732786|NCT00046475|Drug|Midodrine Hydrochloride|
1732787|NCT00046488|Drug|IDEC-152|6 Dosing groups: 125mg/m2 weekly x 4, 250mg/m2 weekly x 4, 375mg/m2 weekly x 4, 500mg/m2 weekly x 4, 500mg/m2 3 times first week then weekly x 3, 500mg/m2 3 times per week x 4
1732788|NCT00046501|Drug|Lantus (insulin glargine [rDNA origin] injection)|
1732789|NCT00046501|Drug|Humulin N|
1732790|NCT00046501|Drug|Humulin L|
1732791|NCT00046501|Drug|Lispro|
1732792|NCT00046514|Drug|ABI-007|
1732793|NCT00046527|Drug|ABI-007|
1732794|NCT00046540|Drug|Liposome-encapsulated SN38|
1732795|NCT00046553|Drug|RU-486 (Mifepristone)|
1732796|NCT00046566|Dietary Supplement|Soy protein-milk protein-carbohydrate|40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks, and 40 grams of carbohydrate per day for 8 weeks
1732797|NCT00046566|Dietary Supplement|Milk protein-carbohydrate-soy protein|40 grams of milk protein per day for 8 weeks, 40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks.
1732798|NCT00046566|Behavioral|Carbohydrate-soy protein-milk protein|40 grams of carbohydrate per day for 8 weeks, 40 grams of soy protein per day for 8 weeks, 40 grams of milk protein per day for 8 weeks,
1732799|NCT00046683|Drug|alemtuzumab|
1732800|NCT00046696|Drug|NM-3|
1732801|NCT00046709|Drug|Smoked Marijuana|
1732802|NCT00046722|Drug|Smoked Marijuana|
1732803|NCT00046735|Drug|Lenalidomide|The planned doses for investigation are as follows: 5, 10, and 25 mg/day. Lenalidomide will be administered as a single daily dose for 4 weeks followed by a 2-week rest period. Dosing will be in the morning at approximately the same time each day, at least 1 hour before the morning meal. Patients will be assigned to dose level in the order of study entry. No dose adjustments or suspensions are allowed during the first cycle, except discontinuation for DLT
1732804|NCT00046748|Drug|Omalizumab|
1732805|NCT00046761|Drug|ONO-2506|
1732806|NCT00046774|Drug|MRA 003 US|
1732807|NCT00046787|Drug|OSI-211 (Liposomal Lurtotecan)|
1732808|NCT00046800|Drug|OSI-211 (Liposomal Lurtotecan)|
1732809|NCT00046813|Drug|Nicotine patch|
1732810|NCT00046826|Drug|docetaxel|
1732811|NCT00046826|Drug|estramustine phosphate sodium|
1732812|NCT00046826|Drug|thalidomide|
1732813|NCT00046839|Drug|celecoxib|
1732814|NCT00046839|Radiation|radiation therapy|
1732815|NCT00046852|Biological|filgrastim|
1732816|NCT00046852|Biological|pneumococcal polyvalent vaccine|
1732817|NCT00046852|Biological|therapeutic autologous lymphocytes|
1732818|NCT00046852|Biological|therapeutic tumor infiltrating lymphocytes|
1732819|NCT00046852|Drug|carmustine|
1732820|NCT00046852|Drug|cyclophosphamide|
1732821|NCT00046852|Drug|melphalan|
1732822|NCT00046852|Procedure|bone marrow ablation with stem cell support|
1732823|NCT00046852|Procedure|peripheral blood stem cell transplantation|
1732824|NCT00046865|Procedure|acupressure therapy|
1732825|NCT00046865|Procedure|management of therapy complications|
1732826|NCT00046865|Procedure|nausea and vomiting therapy|
1732827|NCT00046878|Drug|O6-benzylguanine|
1732829|NCT00046891|Drug|Ginkgo Biloba|Patients will take 120 mg per day (60 mg BID)
1732830|NCT00046891|Other|Placebo|Patients will take 1 tablet BID
1732831|NCT00046904|Biological|etanercept|
1732832|NCT00046917|Drug|alvocidib|Given IV
1732833|NCT00046917|Drug|irinotecan hydrochloride|Given IV
1732834|NCT00046917|Drug|cisplatin|Given IV
1732840|NCT00053365|Drug|irofulven|Given IV
1732841|NCT00053378|Drug|paricalcitol injection (Zemplar)|
1732842|NCT00053378|Behavioral|Effects on calcium regulation|
1732843|NCT00053378|Behavioral|Administration of elemental Ca during hypocalcemic ICU pts.|
1732844|NCT00053391|Biological|recombinant CD40-ligand|
1732845|NCT00053391|Biological|therapeutic autologous dendritic cells|
1732846|NCT00053417|Drug|Placebo|Placebo for 15 weeks
1732847|NCT00053417|Drug|10 milligram (mg) fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg)
12 weeks stable dose (10 mg)
1 week down titration (10 mg)"
1732848|NCT00053417|Drug|15 mg fampridine-SR (4-aminopyridine, 4-AP)|"10 mg twice daily for 1 week
15 mg twice daily for 14 weeks
2 week up titration (10 mg x 1 week, 15 mg x 1 week)
12 weeks stable dose (15 mg)
1 week down titration (10 mg)"
1732849|NCT00053417|Drug|20 mg fampridine-SR (4-aminopyridine, 4-AP)|"2 week up titration (10 mg x 1 week, 15 mg x 1 week)
12 weeks stable dose (20 mg)
1 week down titration (15 mg x 3 days, 10 mg x 4 days)"
1732850|NCT00053430|Drug|Thalidomide|Tablet taken orally daily
1732851|NCT00053430|Drug|Thalidomide placebo|Placebo tablet taken orally daily
1732852|NCT00053443|Device|Medication Reminder System/Adherence Tracker|
1732853|NCT00053482|Biological|ACAM2000 Smallpox Vaccine|Group 1 dose: 1.0x10-8th PFU/ml, Group 2 dose: 2.0x10-7th PFU/ml, Group 3 dose: 1.0x10-7th PFU/ml, Group 4 dose: 5.0x10-6th PFUL/ml
1732854|NCT00053482|Biological|Vaccinia virus (calf lymph) smallpox vaccine: Dryvax®|Group 5 dose: 1.0x10-8th PFU/ml
1732855|NCT00053495|Biological|Vaccinia virus: ACAM2000 smallpox vaccine|Group 1 dose: 1.0x10-8th PFU/ml Group 2 dose: 2.0x10-8th PFU/ml Group 3 dose: 1.0x10-7th PFU/ml Group 4 dose: 5.0x10-6th PFU/ml
1732856|NCT00053495|Biological|vaccinia virus (calf lymph): Dryvax|Group 5 dose: 1.0x10-8th PFU/ml
1732857|NCT00053508|Biological|ACAM1000|Group 1 dose: 1.4 x 10-8th PFU/ml (350,000 PFU) Group 2 dose: 2.8 x 10-7th PFU/ml (70,000 PFU) Group 3 dose: 5.6 x 10-6th PFU/ml (14,000 PFU)
1732858|NCT00053508|Biological|vaccinia virus (calf lymph) smallpox vaccine: Dryvax|group 4 dose: 1.6 x 10-8th PFU/ml (250,000 PFU)
1732859|NCT00053547|Drug|paricalcitol injection|
1732860|NCT00053560|Drug|Prasterone (GL701)|
1732861|NCT00053573|Biological|Myozyme|20 mg/kg to 40 mg/kg qow
1732862|NCT00053599|Drug|Simvastatin|
1732863|NCT00053612|Drug|Vitamin A|
1732864|NCT00053625|Procedure|deep brain stimulation|Deep brain stimulation (DBS) is a surgical intervention used to treat movement disorders such as Parkinson's disease (PD). Target sites of stimulation may differ among patients. The Gpi and STN are two commonly targeted sites within the brain for treatment of PD, yet differences in outcomes between stimulation at the Gpi vs the STN (unilateral and bilateral) are not currently well understood.
1732865|NCT00053638|Drug|efavirenz|
1732866|NCT00053638|Drug|tenofovir|
1732867|NCT00053638|Drug|abacavir/lamivudine|
1732868|NCT00053651|Behavioral|Survival Skills for Moms with New Babies|
1732869|NCT00053677|Drug|Naltrexone|For subjects who were randomly assigned to naltrexone 50mg/day, 100mg/day, or 150mg/day.
1732870|NCT00053677|Drug|Placebo|For subjects who were randomly assigned to placebo.
1732871|NCT00053690|Behavioral|Cognitive Behavior Treatment|
1732872|NCT00053703|Drug|Risperidone|oral risperidone 0.5mg to 6mg daily for up to 52 weeks
1732873|NCT00053703|Drug|Olanzapine (enrollment closed in this treatment)|oral olanzapine 5-20mg per day for up to 52 weeks
1732874|NCT00053703|Drug|Molindone|oral molindone from 10-140mg/daily for up to 52 weeks
1732875|NCT00057928|Drug|cisplatin|
1732876|NCT00057928|Drug|gemcitabine hydrochloride|
1732877|NCT00057928|Drug|paclitaxel|
1732878|NCT00057941|Drug|anastrozole|Given orally
1732879|NCT00057941|Drug|gefitinib|Given orally
1732880|NCT00057941|Drug|fulvestrant|Given intramuscularly
1732881|NCT00057941|Other|laboratory biomarker analysis|Correlative studies
1732882|NCT00057954|Procedure|Extracorporeal Photopheresis|Day -7 to -4: Extracorporeal Photopheresis may be given as an outpatient therapy on two consecutive days any time between days -7 to -4. This must be performed on UVAR or XTS photopheresis machines (Therakos, Inc.) according to standard procedure as per manufacturer's guidelines.
1732883|NCT00057954|Drug|Pentostatin|Day -3, -2: Pentostatin 4 mg/m²/d by continuous IV infusion (Total dose = 8 mg/m²)
1732884|NCT00057954|Radiation|Total body irradiation (TBI)|Day -1: TBI 400 cGy total dose given in two 200cGy doses. Patients who have received TBI for a previous transplant or radiation as part of previous treatment for a lymphoid malignancy will receive only 200 cGy in 1 dose.
1732885|NCT00057954|Procedure|Allogeneic bone marrow transplantation|Day 0: Infusion of unmanipulated allogeneic bone marrow or stem cells. Minimum cell dose of 2 x 106 CD34 cells/kg recipient and no more than 10 x 10^6 CD34/kg
1732886|NCT00057954|Drug|Cyclosporin (CSA)|Cyclosporin A or tacrolimus will be administered according to institutional GVHD prophylaxis protocols. Therapeutic levels will be maintained and patients will be switched to oral agents when they can tolerate
1732887|NCT00057954|Drug|Mycophenolate mofetil (MMF)|At day 100 MMF will be introduced at a dose of 250 mg po BID and cyclosporine or tacrolimus will be tapered according to the discretion of the investigator. The dosage will be escalated to a maximum of 2 g/d at the discretion of the attending physician and will be tapered and discontinued at 12 months if there is no active cGVHD. Doses should be given on an empty stomach
1732888|NCT00057954|Drug|Methotrexate (MTX)|"The dose of Methotrexate is based on the corrected ideal body weight for patients with > 33% above ideal weight.
Day +1 MTX 15 mg/m² IV push; Day +3 MTX 10 mg/m² IV push (May be omitted if patient develops mouth sores.)"
1732889|NCT00057967|Biological|alemtuzumab|Will be administered as a two-hour IV infusion with a target dose of 30 milligrams three times a week for a maximum of 12 weeks.
1732890|NCT00057980|Drug|celecoxib|
1732891|NCT00057980|Drug|epirubicin hydrochloride|
1732892|NCT00057993|Biological|trastuzumab|
1732893|NCT00057993|Drug|exemestane|
1732894|NCT00058006|Drug|celecoxib|
1732895|NCT00058006|Procedure|adjuvant therapy|
1732896|NCT00058019|Drug|ixabepilone|Given IV
1732897|NCT00058032|Other|screening questionnaire administration|
1732898|NCT00058032|Procedure|annual screening|
1732899|NCT00058045|Biological|aldesleukin|
1732900|NCT00058045|Biological|recombinant human stem cell factor|
1732901|NCT00058058|Procedure|magnetic resonance imaging|
1732902|NCT00058058|Radiation|gadopentetate dimeglumine|
1732903|NCT00058071|Drug|amifostine trihydrate|
1732904|NCT00058084|Drug|ixabepilone|Given IV
1732905|NCT00058084|Drug|mitoxantrone hydrochloride|Given IV
1732906|NCT00058084|Drug|prednisone|Given orally
1732907|NCT00058097|Drug|tipifarnib|Given orally
1732908|NCT00058097|Radiation|radiation therapy|Undergo radiation therapy
1732910|NCT00058149|Drug|gemcitabine hydrochloride|
1732911|NCT00058149|Drug|oxaliplatin|
1732912|NCT00058188|Dietary Supplement|cholecalciferol|Given orally
1732913|NCT00058188|Drug|calcium gluconate|Given orally
1732914|NCT00058188|Drug|zoledronic acid|Given IV
1732915|NCT00058201|Drug|fluorouracil|Given IV
1732916|NCT00058201|Drug|gemcitabine hydrochloride|Given IV
1732917|NCT00058201|Drug|leucovorin calcium|Given IV
1732918|NCT00058201|Other|clinical observation|No intervention
1732919|NCT00058214|Drug|perifosine|Given orally
1732920|NCT00058214|Other|laboratory biomarker analysis|Correlative studies
1732921|NCT00058227|Drug|alvocidib|Given IV
1732922|NCT00058227|Drug|fludarabine phosphate|Given IV
1732923|NCT00058227|Biological|rituximab|Given IV
1732924|NCT00058227|Other|pharmacological study|Correlative studies
1732925|NCT00058240|Drug|alvocidib|Given IV
1732926|NCT00058253|Drug|tanespimycin|Given IV
1732927|NCT00058253|Drug|docetaxel|Given IV
1732928|NCT00058266|Dietary Supplement|genistein|Given orally
1732929|NCT00058266|Procedure|conventional surgery|Patients undergo surgery
1732930|NCT00058279|Biological|aldesleukin|
1732931|NCT00058279|Biological|ipilimumab|
1732932|NCT00058292|Biological|filgrastim|Given at a dose of 5 μg/kg, subcutaneously daily, beginning on Day 0 (stem cell transplant day) until white blood cells measure greater than 1500/ul.
1732933|NCT00058292|Biological|rituximab|Intravenous infusion of 250 mg/m2 on treatment days -22 and -14 (day 0 = stem cell transplant).
1732934|NCT00058292|Drug|Carmustine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Carmustine is given at a dose of 300 mg/m2 intravenous infusion over a 2 hour period on treatment day -6 (Day 0 = stem cell transplant).
1732935|NCT00058292|Drug|cytarabine|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Cytarabine is given at a dose of 100 mg/m2 intravenous infusion over a 1 hour period, every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
1732936|NCT00058292|Drug|etoposide|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Etoposide is given at a dose of 100 mg/m2 intravenous infusion over a 2 hour period every 12 hours on treatment days -5, -4, -3, and -2, for a total of 8 doses (Day 0 = stem cell transplant).
1732937|NCT00058292|Drug|melphalan|Part of high dose BEAM chemotherapy given on study (a combination of carmustine, etoposide, cytarabine, and melphalan). Melphalan is given at a dose of 140 mg/m2 as an intravenous infusion over a 1 hour period on treatment day -1 (Day 0 = stem cell transplant).
1732938|NCT00058292|Procedure|peripheral blood stem cell transplantation|On day 0, a minimum of 2.0 X 106 CD34+ cells/kg unselected peripheral blood progenitor cells (PBPC) will be reinfused following institutional guidelines for the reinfusion procedure.
1732939|NCT00058292|Radiation|yttrium Y 90 ibritumomab tiuxetan|Patients will receive 90Y2B8 at a variable dose on treatment day -14 (Day 0 = stell cell transplant). The initial dose calculated to deliver no more than 100 cGy to critical organs (liver, lung). Doses will be escalated based on cohort of enrollment.
1732940|NCT00058305|Drug|bryostatin 1|Given IV
1732941|NCT00058305|Drug|vincristine sulfate|Given IV
1732942|NCT00058305|Other|laboratory biomarker analysis|Correlative studies
1732943|NCT00058318|Drug|capecitabine|Capecitabine will be given 625 mg/m^2 (1250 mg/m^2/day) by mouth twice a day on day 1-21 for every cycle (1 cycle =28 days) until disease progression
1732944|NCT00058318|Drug|gemcitabine hydrochloride|Gemcitabine will be given 900 mg/m^2 by intravenous infusion over 30 minutes on day 1, 8, and 15 for every cycle (1 cycle = 28 days) until disease progression.
1732945|NCT00058331|Biological|epoetin alfa|
1732946|NCT00058357|Drug|lidocaine|
1732947|NCT00058357|Other|placebo|
1732948|NCT00058370|Drug|cisplatin|
1732949|NCT00058370|Drug|lomustine|
1732950|NCT00058370|Drug|vincristine sulfate|
1732951|NCT00058370|Procedure|adjuvant therapy|
1732952|NCT00058370|Radiation|iodine I 131 monoclonal antibody 3F8|
1732953|NCT00058370|Radiation|radiation therapy|
1732954|NCT00058396|Biological|lumiliximab|
1732955|NCT00058422|Biological|darbepoetin alfa|
1732956|NCT00058422|Biological|filgrastim|
1732957|NCT00058422|Biological|rituximab|
1732958|NCT00058422|Drug|cyclophosphamide|
1732959|NCT00058422|Drug|doxorubicin hydrochloride|
1732960|NCT00058422|Drug|prednisone|
1732961|NCT00058422|Drug|vincristine sulfate|
1732962|NCT00058422|Radiation|indium In 111 ibritumomab tiuxetan|
1732963|NCT00058422|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1732964|NCT00058435|Biological|abagovomab|
1732966|NCT00058461|Drug|ifosfamide|Given IV
1732967|NCT00058461|Drug|etoposide|Given IV
1732968|NCT00058461|Biological|rituximab|Given IV
1732969|NCT00058461|Drug|carboplatin|Given IV
1732970|NCT00058461|Biological|filgrastim|Given SC
1732971|NCT00058461|Drug|methotrexate|Given IT
1732972|NCT00058461|Drug|cytarabine|Given IT
1732973|NCT00058461|Other|laboratory biomarker analysis|Correlative studies
1732974|NCT00058474|Drug|capecitabine|825 mg/m2 oral daily 5 days a week on days of planned RT
1732975|NCT00058474|Drug|fluorouracil|225 mg/m2 IV daily continuous infusion
1732976|NCT00058474|Drug|oxaliplatin|50 mg/m2 IV 5 days a week on days of planned RT
1732977|NCT00058474|Radiation|radiation therapy|Given 5 days a week for 5-6 weeks
1732978|NCT00058487|Drug|epirubicin hydrochloride|
1732979|NCT00058487|Drug|thalidomide|
1732980|NCT00058526|Biological|Immunotherapeutic SB719125 (Primary)|Intramuscular injection
1732981|NCT00058539|Drug|rhuMAb 2C4 (pertuzumab)|
1732982|NCT00058552|Drug|Pertuzumab (rhuMAb 2C4)|
1732983|NCT00058578|Drug|Cyclophosphamide|
1732984|NCT00058578|Drug|Mesna|
1732985|NCT00058578|Drug|G-CSF|
1732986|NCT00058578|Procedure|Leukopheresis|
1732987|NCT00058578|Procedure|Total Body Irradiation|
1732988|NCT00058591|Biological|Intravenous injection of EBV specific CTLS|"The dose levels for this study are as follows:
Level Dose
2 x 107 CTLs/m2
5 x 107 CTLs/m2
1 x 108 CTLs/m2
If patients have a clinical response to the first infusion defined by an improvement in the fatigue score or resolution of clinical abnormalities such as lymphadenopathy or an improvement in laboratory parameters such as a decrease in VCA titer or reduction in free EBV DNA they will be eligible to receive up to 3 additional injections of CTLs at the original dose at 3 monthly intervals."
1732989|NCT00058604|Biological|Intravenous injection of EBV specific CTLs|Each patient will receive injections of 2x10e7 , 5x10e7 , or 10e8 CTLs/m2 via IV injection. 6 weeks = 1 course
1732990|NCT00058617|Biological|Injection of EBV Specific CTLs|"Each patient will receive two injections, 14 days apart, according to the following dosing schedules:
Group One Day 0 2x10^7 cells/m2 Day 14 2x10^7 cells/m2
Group Two Day 0 2x10^7 cells/m2 Day 14 1x10^8 cells/m2
Group Three Day 0 1x10^8 cells/m2 Day 14 2x 10^8 cells/m2
If patients with active disease have stable disease or a partial response by the RECIST criteria at their 8 week or subsequent evaluations they are eligible to receive up to 6 additional doses of CTLs at monthly intervals-each of which will consist of the same cell number as their second injection. Patients will not be able to receive additional doses until the initial safety profile is completed at 6 weeks following the second infusion."
1732991|NCT00058656|Procedure|Infusion of Activated & Expanded Autologous T Cells|
1732992|NCT00058682|Drug|Anidulafungin|
1732993|NCT00058721|Drug|I-123-5-IA85380|
1732994|NCT00058734|Biological|Dendritic Cells Pulsed with HIV antigens|
1732995|NCT00058747|Drug|Autologous HSP-70 Protein-Peptide Complex (AG-858) Plus Gleevec™.|
1732996|NCT00058760|Behavioral|NIA intervention (after school health promotion didactic program)|
1732997|NCT00058773|Drug|Infusion of EBV Specific Cytotoxic T-Lymphocytes|"EBV specific cytotoxic T-lymphocytes will be given by intravenous injection over 1-10 minutes.
Each patient will receive two injections, 14 days apart."
1732998|NCT00058786|Biological|Injection of IL-2-secreting CD40L-expressing autologous B-CLL cells|Patients may be treated with a minimum of three up to six injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window, i.e. in the absence of concurrent cytotoxic therapy. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol (see Section 5.8), determined by previous studies in acute leukemia and in neuroblastoma, in which this level of IL-2 production has been safe. The dose escalation of CD40L-expressing cells is designed to reach the IL2/CD40L ratio shown to be effective in our preclinical models of neuroblastoma and lymphoma.
1732999|NCT00058799|Biological|Tumor Vaccine: CD40 LIGAND AND IL-2 GENE MODIFIED AUTOLOGOUS SKIN FIBROBLASTS AND TUMOR CELLS|"CD40L AND IL-2 GENE MODIFIED AUTOLOGOUS SKIN FIBROBLASTS AND TUMOR CELLS dosed at 3 different levels starting at:
Leukemic Blasts 2x10^7 IL-2 Fibroblasts 2x10^7 CD40L Fibroblasts 2x10^5 TOTAL CELLS 4.02x10^7 Each patient will receive 3 injections of their gene modified leukemia cells, each injection separated by 1-2 wks. If there is evidence of response without excessive toxicity and if more transduced cells are available, the pt may receive up to 3 additional SC injections (injections 4-6) separated by 2 weeks."
1733000|NCT00058812|Biological|EBV specific T cells|One injection of 2x10^7 cells/m2 from Day 45 post transplant. If EBV DNA levels remain elevated above 1000 copies/ug or the patient has persistent disease they will be eligible to receive up to 5 additional injections of CTLs at the original dose at monthly intervals.
1733001|NCT00058825|Biological|Campath 1H|Day -5 to Day -2: Campath 1H dose schedule as per institutional SOP.
1733002|NCT00058825|Drug|Fludarabine|Day -5 to Day -2: Fludarabine 30 mg/m2.
1733003|NCT00058825|Procedure|Stem Cell Transplant|Day 0: Donor stem cells infused.
1733004|NCT00058825|Radiation|Total Body Irradiation (TBI)|Day -6: Total body irradiation of 600 cGy as two doses without blocks at a rate of less than or equal to 10 cGy/minute.
1733005|NCT00058825|Drug|FK506 (Tacrolimus) or Cyclosporine|Day -2: FK506 or Cyclosporine as medically indicated to prevent GvHD.
1733006|NCT00058838|Drug|sumanirole|
1733007|NCT00058851|Procedure|Manual lymph drainage|
1733008|NCT00058851|Procedure|Combined physiotherapy|
1733009|NCT00058851|Procedure|Compression bandaging|
1733010|NCT00058864|Device|Energy absorbing and distributing trochanteric pad|
1733012|NCT00058903|Drug|sertraline|
1733013|NCT00058929|Drug|treprostinil sodium|
1733014|NCT00058942|Device|home drinking water treatment device|
1733015|NCT00058955|Drug|sodium oxybate, triazolam and pentobarbital|sodium oxybate, triazolam and pentobarbital
1733016|NCT00058968|Drug|Duloxetine hydrochloride|
1733017|NCT00058968|Drug|placebo|
1733018|NCT00058981|Drug|DiaPep277|
1733020|NCT00059189|Device|Magstim Rapid Magnetic Stimulator|
1733021|NCT00059202|Drug|Ursodeoxycholic Acid|
1733022|NCT00059215|Drug|Prasugrel (CS-747)|Administered orally
1733023|NCT00059215|Drug|Clopidogrel|Administered orally
1733024|NCT00059228|Drug|17 beta-estradiol|Alora 100 microgram per day by skin patch for 6 weeks.
1733025|NCT00059241|Behavioral|Parent-child communication education|
1733026|NCT00059241|Behavioral|Service learning|
1733027|NCT00059241|Behavioral|Classroom health curriculum|
1733030|NCT00059280|Biological|Myozyme|20 mg/kg qow or 40mg/kg qow
1733031|NCT00059306|Drug|aspirin|Participants receive aspirin + placebo, specifically: aspirin (325 mg) with placebo (an inactive substance). Participants will take 1 of each pill a day until the end of the study.
1733032|NCT00059306|Drug|clopidogrel|Participants will receive aspirin + clopidogrel, specifically: aspirin (325 mg) with clopidogrel (75 mg)-- Participants will take 1 of each pill a day until the end of the study.
1733033|NCT00059306|Other|Target of Blood Pressure|Participants will be assigned to one of 2 groups of blood pressure control. The difference between the two groups is the target level of systolic blood pressure—either 130-149 mmHg or below 130 mmHg; to do so, the scientists will use medications that are already in the market for blood pressure management.
1733034|NCT00059306|Other|placebo|an inactive substance
1733035|NCT00059319|Procedure|single aorta clamp with retrograde cardioplegia|
1733036|NCT00059319|Procedure|multiple aorta clamps with antegrade cardioplegia|
1733037|NCT00059332|Drug|Magnesium Sulfate|Paramedics initiate a loading dose of 4 grams magnesium sulfate IV over 15 minutes, followed after hospital arrival by a maintenance infusion of 16 grams magnesium sulfate IV over 24 hours.
1733038|NCT00059332|Drug|Normal Saline|Paramedics initiate a loading dose of placebo normal saline IV over 15 minutes, followed after hospital arrival by a maintenance infusion of placebo normal saline IV over 24 hours.
1733039|NCT00059345|Procedure|Acupuncture|Electroacupuncture treatments provided two times per week for 6 weeks
1733040|NCT00059345|Procedure|Placebo acupuncture|Placebo acupuncture treatments provided 2 times per week for 6 weeks
1733041|NCT00059345|Other|Usual Care|Usual care for knee osteoarthritis
1733042|NCT00059358|Drug|Ribavirin plus interferon alfa-2b|Oral tablets taken daily
1733043|NCT00059358|Drug|Ribavirin|Oral tablet taken daily
1733044|NCT00059358|Drug|Peginterferon alfa-2b|Subcutaneous injection
1733045|NCT00059371|Procedure|male circumcision|
1733046|NCT00059384|Behavioral|Concentration-controlled therapy|
1733047|NCT00059436|Behavioral|Mental effort in muscle strengthening|
1733048|NCT00059462|Drug|Interleukin-2 SA|HAART and Bay 50-4798
1733049|NCT00059462|Drug|HAART|HAART alone
1733050|NCT00059475|Drug|Glycoprotein 100 (GP100): 209-217 (210M)|
1733051|NCT00059475|Drug|Interleukin-2 (IL-2)|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours and continuing for up to 4 days (a maximum of 12 doses).
1733052|NCT00059475|Drug|Montanide ISA 51|
1733053|NCT00059475|Drug|Melanoma antigen recognized by T-cells (MART)-1: 27-35|
1733054|NCT00059475|Drug|27-35 (27L): melanoma antigen recognized by T-cells (MART)-1|
1733055|NCT00059475|Drug|melanoma antigen recognized by T-cells (MART)-1: 26-35(27L)|
1733056|NCT00059514|Behavioral|Modified Project Toward No Tobacco Use|
1733057|NCT00059527|Behavioral|Healthy Youth Places: a behavior change model|
1733058|NCT00059553|Behavioral|Locomotor treadmill training with body weight support|
1733059|NCT00059592|Drug|Valacyclovir|
1733060|NCT00059605|Genetic|DOTAP:Chol-fus1|Infusion of DOTAP:Chol-fus1 by vein once every 3 weeks.
1733061|NCT00059618|Drug|PS-341 (Bortezomib)|Starting dose 0.8 mg/m^2 given by vein over 5-10 seconds Day 1, 4, 8 and 11 of 28 day cycle for 8 cycles.
1733062|NCT00059618|Drug|Carboplatin|AUC 5 by vein administered over one hour Day 1 of 28 day cycle for 8 cycles.
1733063|NCT00059631|Drug|Mitoxantrone (Novantrone)|Starting dose of 3 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15 and 22) over eight 5 week cycles.
1733064|NCT00059631|Drug|Bortezomib (PS-341)|Starting Dose of 1.4 mg/m^2, four weekly intravenous injections (on Days 1, 8, 15, and 22) over eight 5 week cycles.
1733065|NCT00059644|Drug|Ecraprost in lipid emulsion|
1733066|NCT00059657|Drug|Ecraprost in lipid emulsion|
1733067|NCT00059670|Procedure|Shaker Exercise vs. Traditional Dysphagia Therapy Regime|
1733068|NCT00059683|Procedure|cervical cerclage|Cerclage is a circumferential stitch of non-absorbable suture placed around the cervix
1733069|NCT00059696|Procedure|Constraint-Induced Movement Therapy|
1733070|NCT00059709|Procedure|Mediated Negotiation Training|
1733071|NCT00059722|Drug|ZD6474|
1733072|NCT00059722|Drug|Placebo|
1733073|NCT00059722|Drug|ZD1839|
1733074|NCT00059735|Drug|E7070|
1733075|NCT00059761|Drug|cisplatin|
1733076|NCT00059761|Drug|irinotecan hydrochloride|
1733077|NCT00059761|Radiation|radiation therapy|
1733078|NCT00059787|Drug|paclitaxel|Given IV
1733079|NCT00059787|Drug|carboplatin|Given IV
1733080|NCT00059787|Drug|erlotinib|Given PO
1733081|NCT00059800|Radiation|boron neutron capture therapy|
1733082|NCT00059813|Biological|recombinant interferon alfa|Given SC
1733083|NCT00059813|Biological|oblimersen sodium|Given IV
1733084|NCT00059813|Other|pharmacological study|Correlative studies
1733085|NCT00059826|Biological|interferon-alfa-2b|IV
1733086|NCT00059826|Drug|cisplatin|IV
1733087|NCT00059826|Drug|5-fluorouracil|IV
1733088|NCT00059826|Radiation|radiation therapy|
1733089|NCT00059839|Drug|doxorubicin hydrochloride|Given IV
1733090|NCT00059839|Drug|mercaptopurine|Given by mouth
1733091|NCT00059839|Drug|methotrexate|Given IV and intrathecally
1733092|NCT00059839|Drug|prednisone|Given by mouth
1733093|NCT00059839|Drug|vinblastine sulfate|Given IV
1733094|NCT00059839|Drug|vincristine sulfate|Given IV
1733095|NCT00059852|Drug|erlotinib hydrochloride|
1733096|NCT00059852|Drug|gemcitabine hydrochloride|
1733097|NCT00059865|Drug|gemcitabine hydrochloride|
1733098|NCT00059865|Drug|pemetrexed disodium|
1733099|NCT00059878|Biological|recombinant interferon gamma|
1733100|NCT00059878|Drug|voriconazole|
1733101|NCT00059891|Procedure|conventional surgery|
1733102|NCT00059891|Procedure|management of therapy complications|
1733103|NCT00059904|Biological|aldesleukin|
1733104|NCT00059904|Biological|rituximab|
1733105|NCT00059917|Drug|polyglutamate camptothecin|
1733106|NCT00059930|Drug|FOLFOX regimen|
1733107|NCT00059930|Drug|dexamethasone|
1733108|NCT00059930|Drug|floxuridine|
1733109|NCT00059930|Drug|fluorouracil|
1733110|NCT00059930|Drug|leucovorin calcium|
1733111|NCT00059930|Drug|oxaliplatin|
1733112|NCT00059930|Procedure|adjuvant therapy|
1733113|NCT00059930|Procedure|conventional surgery|
1733114|NCT00059943|Drug|docetaxel|
1733115|NCT00059982|Drug|perifosine|
1733116|NCT00059995|Biological|iratumumab|
1733117|NCT00060008|Radiation|fludeoxyglucose F 18|
1733118|NCT00060008|Radiation|gadopentetate dimeglumine|
1733119|NCT00060021|Procedure|acupuncture therapy|
1733120|NCT00060021|Procedure|management of therapy complications|
1733121|NCT00060021|Procedure|pain therapy|
1733123|NCT00060099|Biological|HspE7|
1733124|NCT00060112|Biological|oblimersen sodium|Given IV
1733125|NCT00060112|Drug|gemcitabine hydrochloride|Given IV
1733126|NCT00060112|Other|pharmacological study|Correlative studies
1733127|NCT00060112|Other|laboratory biomarker analysis|Correlative studies
1733128|NCT00060125|Drug|tipifarnib|Given orally
1733129|NCT00060125|Other|laboratory biomarker analysis|Correlative studies
1733130|NCT00060138|Biological|monoclonal antibody CAL|
1733131|NCT00060138|Drug|zoledronic acid|
1733132|NCT00060151|Drug|pazopanib hydrochloride|
1733133|NCT00060203|Drug|brostallicin|"Patients receive brostallicin IV over 10-30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of 3-6 patients receive escalating doses of brostallicin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which at least 2 of 6 patients experience dose-limiting toxicity."
1733134|NCT00060242|Drug|fosbretabulin disodium|Combretastatin A4 phosphate IV over 10 minutes on days 1, 8, and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 courses beyond documentation of the CR.
1733135|NCT00060255|Drug|busulfan|iv
1733136|NCT00060255|Drug|carboplatin|iv
1733137|NCT00060255|Drug|carmustine|iv
1733138|NCT00060255|Drug|cyclophosphamide|iv
1733139|NCT00060255|Drug|etoposide|iv
1733140|NCT00060255|Drug|melphalan|oral
1733141|NCT00060255|Drug|thiotepa|iv
1733142|NCT00060255|Procedure|autologous bone marrow transplantation|iv
1733143|NCT00060255|Procedure|bone marrow ablation with stem cell support|iv
1733144|NCT00060255|Procedure|peripheral blood stem cell transplantation|iv
1733145|NCT00060255|Radiation|radiation therapy|body x-ray
1733146|NCT00060268|Drug|HPPH|iv
1733147|NCT00060294|Biological|rituximab|
1733148|NCT00060294|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1733149|NCT00060307|Drug|erlotinib hydrochloride|Given orally
1733150|NCT00060307|Other|laboratory biomarker analysis|Correlative studies
1733151|NCT00060320|Dietary Supplement|black cohosh|
1733152|NCT00060320|Other|placebo|
1733153|NCT00060333|Radiation|radiation therapy|
1733154|NCT00060346|Biological|rituximab|Rituximab is given intravenously. The initial rate is 50 mg/hr for the 1st hour. If no toxicity, the rate may be escalated in 50 mg/hr increments at 30-minute intervals to a maximum of 400 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr. If the patient experiences fever and rigors, the antibody infusion is discontinued. The severity of the side effects should be evaluated. If the symptoms improve, the infusion is continued initially at half the previous rate. Following the antibody infusion, the intravenous line should be maintained for medications as needed. If there are no complications after one hour of observation, the intravenous line may be discontinued.
1733155|NCT00060346|Drug|cyclophosphamide|"Cyclophosphamide will be given at a dosage of 750 mg/m² intravenously on day 1 of each cycle (1 cycle =21 days) for 6 cycles. Dose is based on surface area calculated based on actual body weight.
The drug should be administered as a rapid IV infusion over 5 to 30 minutes."
1733156|NCT00060346|Drug|Doxorubicin|"Doxorubicin will be given intravenously at a dosage of 50 mg/m² on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
Doxorubicin should be administered as a continuous infusion into tubing of a freely flowing intravenous line for 5 -15 minutes. Avoid extravasation."
1733157|NCT00060346|Drug|Prednisone|Prednisone will be administered at 100 mg/m² orally, days 1-5 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
1733158|NCT00060346|Drug|Vincristine|"Vincristine will be administered 1.4 mg/m² intravenously (Maximum dose = 2.0 mg) on day 1 of each cycle for 6 cycles (1 cycle =21 days). Dose is based on surface area calculated based on actual body weight.
Given as IV push over 1 minute, using extravasation precautions."
1733159|NCT00060359|Drug|Carboplatin|Given IV
1733160|NCT00060359|Drug|Paclitaxel Poliglumex|Given IV
1733161|NCT00060359|Other|Pharmacological Study|Correlative studies
1733162|NCT00060372|Drug|ipilimumab|Given IV
1733163|NCT00060372|Drug|therapeutic allogeneic lymphocytes|Given IV
1733164|NCT00060385|Drug|CHOP regimen|
1733165|NCT00060385|Drug|EPOCH regimen|
1733167|NCT00060385|Drug|doxorubicin hydrochloride|
1733168|NCT00060385|Drug|etoposide|
1733169|NCT00060385|Drug|prednisone|
1733170|NCT00060385|Drug|vincristine sulfate|
1733171|NCT00060385|Radiation|radiation therapy|
1733172|NCT00060398|Biological|epoetin alfa|
1733173|NCT00060398|Drug|dexamethasone|
1733174|NCT00060411|Drug|erlotinib hydrochloride|Given IV
1733175|NCT00060411|Drug|fluorouracil|Given IV
1733176|NCT00060411|Drug|leucovorin calcium|Given IV
1733177|NCT00060411|Drug|oxaliplatin|Given IV
1733178|NCT00060411|Biological|bevacizumab|Given IV
1956476|NCT02836379|Other|No intervention|No intervention
1733186|NCT00060437|Drug|perifosine|
1733187|NCT00060450|Drug|nitric oxide for inhalation|Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
1733188|NCT00060450|Drug|Placebo|Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
1733189|NCT00060463|Behavioral|Increased access to emergency contraceptive pills|
1733190|NCT00060476|Drug|rofecoxib|
1733191|NCT00060476|Drug|Comparator: placebo (unspecified)|
1733192|NCT00060489|Drug|SEROQUEL (quetiapine fumarate) Tablets|
1733193|NCT00060502|Drug|Infliximab; Gemcitabine|
1733194|NCT00060515|Drug|RG2133 (2',3',5'-tri-O-acetyluridine)|
1733199|NCT00060554|Drug|fondaparinux sodium|
1733200|NCT00060554|Drug|heparin|
1733201|NCT00060554|Procedure|percutaneous coronary intervention (PCI)|
1733202|NCT00060567|Drug|E7070 + irinotecan combination|Escalating doses starting from 125 mg/m2 irinotecan plus 250 mg/m2 E7070 combination.
1733203|NCT00060567|Drug|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
1733204|NCT00060567|Drug|Irinotecan + E7070 combination|Escalating doses starting from 100 mg/m2 irinotecan plus 400 mg/m2 E7070 combination.
1733205|NCT00060580|Procedure|Raman scattering spectroscopy|
1733206|NCT00060606|Procedure|Prenatal Myelomeningocele Repair Surgery|Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.
1733207|NCT00060606|Procedure|Postnatal Myelomeningocele Repair Surgery|Standard postnatal surgical closure of the spina bifida defect
1733208|NCT00060619|Behavioral|thermal biofeedback|
1733209|NCT00060619|Behavioral|relaxation training|
1733210|NCT00060619|Behavioral|cognitive coping skills|
1733211|NCT00060619|Behavioral|parent education|
1733212|NCT00060632|Drug|ridaforolimus|"Administered intravenously once weekly for 4 weeks (1 cycle).
In the absence of disease progression or unacceptable toxicity, patients could continue to receive additional cycles."
1733213|NCT00060645|Drug|ridaforolimus|There are sequential dosage cohorts ranging from 3 mg - 225 mg per dose. AP23573 is given intravenously over 30 minutes, administered once daily for 5 days every 2 weeks.
1733214|NCT00060671|Drug|rituximab|
1733215|NCT00060671|Drug|Pixantrone (BBR 2778)|
1733216|NCT00060684|Drug|Pixantrone (BBR 2778)|
1733217|NCT00060684|Drug|fludarabine|
1733218|NCT00060684|Drug|dexamethasone|
1733219|NCT00060684|Drug|rituximab|
1733220|NCT00060697|Behavioral|Adolescent sexual activity education for mothers|
1733221|NCT00060710|Drug|CP-461|
1733222|NCT00060749|Drug|Docosahexaenoic Acid (DHA) Dietary Supplement|
1733223|NCT00060762|Behavioral|Interpersonal Therapy|20 sessions of interpersonal therapy were provided over a 6-month period
1733224|NCT00060762|Behavioral|Behavioral Weight Loss Treatment|20 sessions of behavioral weight loss treatment were provided over a 6-month period
1733225|NCT00060762|Behavioral|Guided Self Help|10 sessions of guided self help were provided over a 6-month period
1733226|NCT00060801|Drug|BIIL 283 BS (Amelubent)|
1733227|NCT00060814|Other|Combined intervention|300 mg bupropion plus 4mg nicotine gum ad lib plus motivational interviewing counseling
1733228|NCT00060827|Device|Head Impact Recording Technology (HIRT)|
1733229|NCT00060840|Drug|Nitric Oxide|40 ppm of Nitric Oxide continuously administered for 48 hours
1733230|NCT00060840|Drug|Nitrogen|Nitrogen (N2) administered at 40 ppm for 48 hours
1733231|NCT00060866|Drug|Propranolol|
1733232|NCT00043511|Biological|pGA2/JS2 Plasmid DNA Vaccine|
1733233|NCT00043537|Behavioral|Social Effectiveness Therapy for Children (SET-C)|
1733234|NCT00043537|Drug|Fluoxetine|
1733235|NCT00043537|Drug|Pill Placebo|
1733236|NCT00043550|Behavioral|Supportive Expressive Therapy|The aim of supportive-expressive psychotherapy is to help patients understand the causes of relationship conflicts in the context of a supportive relationship.
1733237|NCT00043550|Drug|Sertraline|Participants will receive sertraline.
1733238|NCT00043550|Drug|Pill Placebo|Participants will receive a pill placebo.
1733239|NCT00043550|Drug|Venlafaxine|Participants will receive venlafaxine.
1733240|NCT00043563|Behavioral|Cognitive-Behavior Therapy|
1733241|NCT00043576|Drug|calcitriol|
1733242|NCT00043576|Drug|docetaxel|
1733243|NCT00043589|Drug|donepezil|
1733244|NCT00043589|Procedure|Memory-training class|
1733245|NCT00043602|Behavioral|Standard interpersonal psychotherapy (IPT)|Participants will receive 12 sessions of IPT over 12 weeks.
1733246|NCT00043602|Behavioral|Clinician managed interpersonal psychotherapy (CM-IPT)|Participants will receive 12 sessions of CM-IPT over 1 year.
1733247|NCT00043628|Procedure|Stem Cell Mobilization|
1733248|NCT00043654|Drug|Mifepristone|
1733249|NCT00043667|Drug|Daclizumab|
1733250|NCT00043680|Drug|Celecoxib|
1733251|NCT00043693|Behavioral|Family Intervention for Dual Diagnosis|The family intervention for dual diagnosis program lasts for up to 3 years and includes both single and multiple-family group formats.
1733252|NCT00043693|Behavioral|Family psychoeducation program|The family psychoeducation program consists of 6 weekly sessions.
1733253|NCT00043706|Drug|Human Anti-Transforming Growth Factor Beta-1 Monoclonal Antibody|
1733256|NCT00043732|Drug|SCIO-469|
1733257|NCT00043745|Dietary Supplement|Soy isoflavones|Soy isoflavones extracted from soy protein, compressed into tablets; three tablets taken daily
1733258|NCT00043745|Dietary Supplement|Extract tablets|Extract from soy protein, but devoid of isoflavones; three tablets taken once daily
1733259|NCT00043758|Drug|Tolvaptan|
1733260|NCT00043771|Drug|Tolvaptan|
1733261|NCT00043784|Drug|enoxaparin|
1733262|NCT00043797|Drug|Lidorestat (IDD 676)|
1733263|NCT00043810|Procedure|Gelonin|Gelonin-AntiCD33 purging, 3 purging concentrations (fixed dose of 5 x 10^6 CD34+ cells/kg to be infused) with 3 dose levels of 1 nanomolar, 5.0 nanomolar and 10.0 nanomolar.
1733264|NCT00043810|Drug|Busulfan|130 mg/m2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -6 to -3).
1733265|NCT00043810|Drug|Fludarabine|40 mg/m2 in 100 ml of saline over one (1) hour on each of four (4) consecutive days (days - 6 to -3).
1733266|NCT00043823|Drug|Avastin|7.5 mg/kg By Vein on Day 1 of Every 21 Day Cycle
1733267|NCT00043823|Drug|Tarceva|100 mg By Mouth Daily for 3 Weeks
1733268|NCT00043836|Drug|ALT-711|
1733269|NCT00043849|Drug|Quetiapine|
1733270|NCT00043862|Drug|topotecan|
1733271|NCT00043875|Drug|lamotrigine|
1733272|NCT00043888|Drug|fosamprenavir|
1733273|NCT00043888|Drug|COMBIVIR|
1733274|NCT00043888|Drug|ritonavir|
1733275|NCT00043888|Drug|TRIZIVIR|
1733276|NCT00043901|Drug|lamotrigine|
1733278|NCT00043927|Drug|topotecan/cisplatin|
1733279|NCT00043927|Drug|etoposide/cisplatin|
1733280|NCT00043940|Drug|bivalirudin|Bivalirudin therapy will be given as a 0.75-mg/kg intravenous bolus and 1.75-mg/kg/h intravenous infusion during procedure and up to 4 hours.
1733281|NCT00043953|Drug|Lopinavir/ritonavir|
1733282|NCT00043953|Drug|Saquinavir mesylate|
1733283|NCT00043953|Drug|Lamivudine/zidovudine|
1733284|NCT00043966|Drug|Lopinavir/ritonavir|
1733285|NCT00043966|Drug|Tenofovir DF|
1733286|NCT00043966|Drug|Emtricitabine|
1733287|NCT00043979|Drug|F-18 Fluorodeoxyglucose|
1733288|NCT00043979|Biological|therapeutic allogeneic lymphocytes|Lymphocyte cells are collected from a healthy donor by apheresis and infused into the patient with a central venous catheter.
1733289|NCT00043979|Drug|cyclophosphamide|"Induction - 750 mg/m^2 intravenous (IV) infusion over 30 minutes x 1 dose. Day 5.
Transplant - 1200 mg/m^2 per day IV infusion over 2 hours daily for 4 days; days -6, -5, -4, -3."
1733290|NCT00043979|Drug|cyclosporine|6 mg/kg per dose orally every other day (no day 9 dose).
1733291|NCT00043979|Drug|doxorubicin hydrochloride|Induction - 10 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
1733292|NCT00043979|Drug|etoposide|50 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days. Days 1, 2, 3, 4.
1733293|NCT00043979|Drug|fludarabine phosphate|"Induction - 25 mg/m^2 per day intravenous (IV) infusion over 30 minutes daily for 3 days. Days 1, 2, 3.
Transplant - 30 mg/m^2 per day IV infusion over 30 minutes daily for 4 days; days -6, -5, -4, -3."
1733294|NCT00043979|Drug|melphalan|Transplant - 100 mg/m^2 per day intravenous (IV) infusion over 15 minutes for 1 day; day -2.
1733295|NCT00043979|Drug|prednisone|Induction - 60 mg/m^2 per day in 2-4 divided doses by mouth daily for 5 days; days 1, 2, 3, 4, 5.
1733296|NCT00043979|Drug|sirolimus|Initiated on day +3. Patients >40kg, the initial dose will be 2 mg every 24 hours orally. Patients <40 kg, the initial dose will be 1 mg/m^2.
1733297|NCT00043979|Drug|tacrolimus|Day -1 at least 24 hours before the stem cell infusion at a dose of 0.03 mg/kg/day as a continuous infusion. Twelve hours later oral dose initiated at a dose of 0.1-0.15 mg/kg/day in two divided doses every 12 hours.
1733298|NCT00043979|Drug|vincristine sulfate|Induction - 0.4 mg/m^2 per day continuous intravenous (IV) infusion over 24 hours daily for 4 days; 1, 2, 3, 4.
1733299|NCT00043979|Procedure|peripheral blood stem cell transplantation|Stem cells from a healthy donor are collected and transplanted into the patient using a central venous catheter.
1733300|NCT00043979|Drug|Filgrastim|
1733301|NCT00043979|Procedure|Peripheral Blood Stem Cell donation|
1733302|NCT00044005|Drug|Lurasidone 20 mg|Lurasidone 20mg oral tablet taken once daily for 6-months
1733303|NCT00044005|Drug|Lurasidone 40 mg|Lurasidone 40mg oral tablets taken once daily
1733304|NCT00044005|Drug|Lurasidone 80mg|Lurasidone 80mg oral tablet taken once daily
1733305|NCT00044018|Drug|CDC-501|
1733306|NCT00044031|Biological|G17DT Immunogen|
1733307|NCT00044044|Drug|Lurasidone 20 mg|Lurasidone 20mg/day tablets
1733308|NCT00044044|Drug|Lurasidone 40mg|Lurasidone 40mg/day tablets
1733309|NCT00044044|Drug|Lurasidone 80 mg|Lurasidone 80mg/day - 2 40mg tablets
1733310|NCT00044044|Drug|Haloperidol 10mg|Haloperidol 10mg/day tablets
1733311|NCT00044044|Drug|Placebo|Matching Placebo to Lurasdione and Haloperidol
1733312|NCT00044057|Drug|YM872 (zonampanel), t-PA (alteplase)|
1733313|NCT00044070|Drug|YM872 (zonampanel)|
1733314|NCT00044083|Drug|Tolcapone|Tolcapone 200 mg tid: Placebo 1 week-Wash Out 1 week-Drug 1 week (or vice versa)
1733315|NCT00044109|Device|Magnets|
1733316|NCT00050050|Behavioral|Cognitive behavioral therapy|
1733318|NCT00050063|Biological|Therapeutic vaccinations from A5058s|Participants will receive assigned interventions assigned in study A5058s.
1733319|NCT00050076|Drug|MCC-135|MCC-135 50 mg, tablets, orally, twice daily for up to 12 weeks
1733320|NCT00050076|Drug|MCC-135|MCC-135 100 mg, tablets, orally, once daily for up to 12 weeks
1733321|NCT00050076|Drug|MCC-135|MCC-135 200 mg, tablets, orally, once daily for up to 12 weeks
1733322|NCT00050076|Drug|Placebo|MCC-135 placebo-matching tablets, orally, once daily for up to 12 weeks
1733323|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
1733324|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
1733325|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
1733326|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
1733327|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
1733328|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
1733329|NCT00050089|Other|No Antiretroviral Drug-Free Period (No ARDFP) vs ARDFP|Continuation or interruption of ART treatment
1733330|NCT00050089|Drug|Standard ART vs Mega ART|Standard therapy vs Intensified therapy
1733331|NCT00050102|Drug|MDX-010 (CTLA-4)|
1733332|NCT00050128|Device|rTMS, Magstim|
1733333|NCT00050141|Drug|ZARNESTRA, tipifarnib, R115777|
1733334|NCT00050154|Drug|ZARNESTRA, tipifarnib, R115777|
1733335|NCT00050167|Drug|Paclitaxel|80 mg/m^2 by vein (IV) Weekly Over 1 Hour x 12 Weeks
1733336|NCT00050167|Drug|Docetaxel|75 mg/m^2 by vein (IV) Over 1 Hour Once Every 3 Weeks
1733337|NCT00050167|Drug|Capecitabine|1500 mg/m^2 by mouth Twice Daily x 2 Weeks
1733338|NCT00050180|Drug|Midazolam|
1733339|NCT00050180|Drug|Indinavir|
1733340|NCT00050180|Drug|Saquinavir|
1733341|NCT00050206|Drug|Olanzapine|
1733342|NCT00050206|Drug|Placebo|
1733343|NCT00050232|Drug|AVP-923|
1733344|NCT00050245|Drug|Rituximab|
1733345|NCT00050271|Drug|Acetyl-L-carnitine|
1733346|NCT00050297|Drug|YM598|
1733347|NCT00050323|Drug|Allogeneic DCs and Autologous RCC Tumor Derived Cells|
1733348|NCT00050336|Drug|Lonafarnib (SARASAR)|
1733349|NCT00050349|Drug|EPO906 epothilone B|
1733350|NCT00050362|Drug|Rofecoxib and Bupivacaine|
1733351|NCT00050375|Drug|oregovomab|
1733352|NCT00050388|Genetic|Allovectin-7®|
1733353|NCT00050401|Drug|MERREM I.V. 2g as a 3 hour infusion every 8 hours|
1733354|NCT00050401|Drug|vancomycin I.V. 1 g every 12 hours|
1733355|NCT00050401|Drug|tobramycin I.V. 5 mg/kg every 24 hours|
1733356|NCT00050401|Drug|MERREM I.V. 1g as a 30 minute infusion every 8 hours|
1733357|NCT00050401|Drug|MERREM I.V. 500 mg as a 3 hour infusion every 8 hours|
1733358|NCT00050414|Drug|Trabectedin|Trabectedin 0.58 mg/m2, administered as a 3-hour intravenous infusion, Days 1, 8, and 15 every 28 days for up to approximately 3 years in the absence of disease progression.
1733359|NCT00050414|Drug|Dexamethasone|Dexamethasone 10 mg administered intravenously 30 minutes prior to each trabectedin infusion.
1733360|NCT00050427|Drug|ET743|580 mcg/m2, 3-hour i.v. infusion, on Days 1, 8, and 15 every 28 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
1733361|NCT00050427|Drug|ET743|1,300 mcg/m2, 3 hour i.v. infusion once every 21 days for up to approximately 52 weeks in the absence of disease progression. Dexamethasone, 10 mg i.v, will be administered 30 minutes prior to each trabectedin infusion.
1733362|NCT00050440|Drug|Trabectedin|Trabectedin 1.3 mg/m2 administered intravenously every 21 days.
1733363|NCT00050440|Drug|Dexamethasone|Dexamethasone 4 mg administered orally (by mouth) the day before the trabectedin dose, 30 minutes before the trabectedin dose, and for 2 days following the trabectedin dose
1733364|NCT00050479|Drug|Celecoxib (Celebrex)|
1733365|NCT00050505|Biological|Live vaccinia virus vaccine|Dryvax undiluted. Cohort A receives undiluted dose of Dryvax vaccine
1733366|NCT00050505|Biological|Live vaccinia virus vaccine|Dryvax with diluent (50% glycerin and 0.25% phenol in sterile water). Cohort A-C receives diluted dose of Dryvax vaccine.
1733367|NCT00050518|Biological|Aventis Pasteur Smallpox Vaccine|
1733368|NCT00060892|Genetic|HGF plasmid|Intramuscular injections into index leg on Days 0, 14, and 28
1733369|NCT00060905|Drug|Divalproex Sodium (Depakote ER)|
1733370|NCT00060918|Drug|carvedilol|
1733371|NCT00060918|Drug|metoprolol|
1733372|NCT00060931|Drug|carvedilol|
1733373|NCT00060931|Drug|metoprolol|
1733374|NCT00060944|Drug|Yondelis|1.5 mg/m2 administered as a 24-hour i.v. infusion on Day 1 of every 21-day treatment cycle.
1733375|NCT00060944|Drug|Yondelis|0.58 mg/m2 administered as a 3-hour i.v. infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
1733376|NCT00060944|Drug|Dexamethasone|Pretreatment with 10 mg of dexamethasone i.v. 30 minutes prior to each Yondelis infusion on Days 1, 8, and 15 of each 28-day treatment cycle.
1733377|NCT00060944|Drug|Dexamethasone|Pretreatment with 20 mg of dexamethasone i.v. on Day 1 of each 21- day treatment cycle, 30 minutes prior to each Yondelis infusion.
1733378|NCT00060957|Drug|Botulinum toxin type A|
1733379|NCT00060970|Procedure|Physical Therapy|
1733380|NCT00060983|Procedure|Body weight supported locomotor training|
1733381|NCT00060983|Procedure|Functional electrical stimulation|
1733382|NCT00060996|Drug|Remodulin® (treprostinil sodium) Injection|
1733383|NCT00061022|Drug|NXY-059|
1733384|NCT00061035|Biological|Transgenic Lymphocyte Immunization Vaccine (TLI)|
1733385|NCT00061048|Biological|Alemtuzumab|Infusion of Campath-1H 3 mg on day # 1, 10 mg on day #2, and 30 mg day # 3 followed by maintenance Campath-1H 30 mg intravenously three times per week. Patients are eligible to receive a maximum of 12 weeks of maintenance Campath-1H treatment.
1733386|NCT00061061|Behavioral|Behavior Therapy|
1733387|NCT00061074|Drug|Nicotrol|
1733388|NCT00061087|Drug|Methylphenidate|Methylphenidate 80mg/day
1733389|NCT00061087|Drug|Bupropion|Bupropion 400mg/day
1733390|NCT00061087|Other|Placebo|Placebo
1733391|NCT00061100|Behavioral|Behavior Therapy-RISE|manually-guided HIV intervention RISE: Reduce high risk Intravenous drug use and unsafe Sexual Encounter
1733392|NCT00061100|Behavioral|Standard prevention Education|standard psychosocial Education for HIV/hepatitis prevention
1733393|NCT00061113|Drug|Fluoxetine + outpatient cognitive behavioral therapy|single fixed morning dose 20 mg X 15 weeks
1733394|NCT00061113|Drug|fluoxetine|20mg, QD x 16 weeks
1733395|NCT00061113|Drug|placebo + CBT|single fixed morning dose X 16 weeks
1733396|NCT00061126|Drug|ABX-EGF|
1733397|NCT00061139|Behavioral|Pediatric Constraint-Induced Movement therapy|
1733398|NCT00061139|Behavioral|Conventional pediatric motor rehabilitation therapy|
1733399|NCT00061152|Drug|Capsaicin Dermal Patch|
1733400|NCT00061165|Behavioral|School + family changes promoting healthy eating + activity|
1733401|NCT00061178|Drug|rhuMAb VEGF (Bevacizumab)|
1733402|NCT00061217|Device|Unrectified prosthetic socket|
1733403|NCT00061217|Device|Rectified prosthetic socket|
1733404|NCT00061230|Behavioral|biofeedback-monitored relaxation training|
1733405|NCT00061477|Drug|Pemetrexed|
1733406|NCT00061477|Drug|Gemcitabine|
1733407|NCT00061490|Behavioral|Behavioral weight control and lifestyle exercise|16 weekly educational meetings vs. waitlist control
1733408|NCT00061503|Drug|Travoprost|
1733409|NCT00061516|Drug|BETAXON (levobetaxolol HCl)|levobetaxolol suspension, 0.5%
1733410|NCT00061516|Drug|AZOPT (brinzolamide)|brinzolamide suspension, 1%
1733411|NCT00061529|Drug|Brimonidine Tartrate Ophthalmic Solution|
1733412|NCT00061542|Drug|BETOPTIC S (betaxolol HCl)|betaxolol HC)
1733413|NCT00061542|Drug|Timolol Gel-forming Solution (TGFS)|timolol maleate 0.25% and 0.5%
1733417|NCT00061581|Device|Isolex 300i Stem Cell Selection|
1733418|NCT00061594|Drug|rhuFab V2 (ranibizumab)|
1733419|NCT00061620|Drug|Tezacitabine (FMdC)|7.5 mg/m2 bolus infusion daily x 5
1733420|NCT00061633|Drug|Telavancin|Telavancin 7.5 mg/kg/day IV (intravenously) for up to 14 days
1733421|NCT00061633|Drug|Vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
1733422|NCT00061646|Drug|ABT-510/Thrombospondin-1 mimetic|
1733423|NCT00061646|Drug|Carboplatin/Taxol|
1733424|NCT00061659|Drug|ABT-510 - Thrombospondin-1 mimetic|
1733425|NCT00061672|Drug|ABT-510 - Thrombospondin-1 Mimetic|
1733426|NCT00061698|Behavioral|Cognitive Behavior Therapy Child Only|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief.
1733427|NCT00061698|Behavioral|CBT plus Parent Training|Participants learned and applied coping skills, problem solving, cognitive restructuring strategies and built a positive core belief. Parents learned skills that helped their child to apply the strategies they learned. Parents learned how to better communicate positive information that helped their child build a positive core belief. Parents learned how to use reinforcement to support healthy behavior.
1733428|NCT00061711|Drug|Hormone Replacement Therapy|
1733429|NCT00061711|Drug|Cimicifuga racemosa (Black Cohosh)|
1733430|NCT00061711|Drug|Multibotanical phytoestrogen formula|
1733431|NCT00061750|Drug|ICL670|
1733432|NCT00061750|Drug|deferoxamine|
1733433|NCT00061763|Drug|Deferasirox|
1733434|NCT00061776|Drug|Capsaicin Dermal Patch|
1733435|NCT00061789|Drug|SPECT Imaging of Nicotinic Acetylcholine Receptors in Brain|
1733436|NCT00061802|Drug|risperidone, quetiapine|
1733437|NCT00061815|Biological|cetuximab|400 mg/m2 IV
1733438|NCT00061815|Drug|oxaliplatin|85 mg/m2 IV
1733439|NCT00061815|Drug|leucovorin|200 mg/m2 IV
1733440|NCT00061815|Drug|5-fluorouracil|400 mg/m2 IV
1733441|NCT00061815|Drug|5-fluorouracil|600 mg/m2 IV
1733442|NCT00061815|Biological|cetuximab|250 mg/m2 IV
1733443|NCT00061841|Behavioral|exercise|
1733444|NCT00061854|Drug|soblidotin|
1733445|NCT00061867|Drug|pegylated liposomal doxorubicin hydrochloride|
1733446|NCT00061867|Procedure|hyperthermia treatment|
1733447|NCT00061880|Drug|forodesine hydrochloride|
1733448|NCT00061893|Drug|celecoxib|Given orally, Celecoxib 250 mg/m2 PO BID (500mg/m2/day) from Day 1 of Cycle 1 through Day 21 of Cycle 14. The dose should be rounded off to the nearest 100 mg. If PK studies are being done, Celecoxib should be given 24 hours prior to the other drugs for Cycle 1 only. [Celecoxib may be interrupted for up to 7 days around the time of surgical procedures.] .
1733449|NCT00061893|Drug|cyclophosphamide|Given IV, 1200 mg/m2 IV infusion over 1 hour with MESNA uroprotection, on Day 1. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
1733450|NCT00061893|Drug|doxorubicin hydrochloride|Given IV, Doxorubicin 75 mg/ m2 /course continuous IV infusion over 48 hours, beginning Day 1. Note: The total doxorubicin dose per cycle is 75 mg/ m2, which will be given as 37.5 mg/m2/day x 2 days. Doxorubicin may be given as a continuous infusion or brief infusion.
1733451|NCT00061893|Drug|etoposide|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
1733506|NCT00062101|Drug|erlotinib hydrochloride|Given orally (PO)
1733507|NCT00062101|Drug|celecoxib|Given PO
1733508|NCT00062101|Other|laboratory biomarker analysis|Correlative studies
1733509|NCT00062114|Biological|rituximab|
1733510|NCT00062114|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1733452|NCT00061893|Drug|ifosfamide|Given IV,Ifosfamide 1800 mg/m2 /day IV infusion over 1 hour, Days 1-5 of each cycle. (9,000 mg/m2 max total dose per cycle). Prehydrate for 6 hours, 1,000 ml/m2 total volume (165 ml/m2/hour for 6 hours). For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
1733453|NCT00061893|Drug|vinblastine sulfate|Given IV, Vinblastine 1 mg/m2/d IV push three times per week beginning Day 1 of Cycle 1 and continuing through Day 21 of Cycle 14. In weeks during which vincristine is given, hold one dose of vinblastine and administer only 2 doses of vinblastine during that week. If vinblastine is due the same day as vincristine, hold that dose of vinblastine. [Vinblastine may be interrupted for up to 7 days around the time of surgical procedures.]
1733454|NCT00061893|Drug|vincristine sulfate|Given IV, Vincristine 2 mg/m2 IV push, on Day 1. Maximum dose 2 mg. For children < 1 year treat with 50% doses calculated on a m2 basis. If tolerated (no delay in administration of the next cycle due to delayed count recovery or delayed resolution of other toxicities and no serious toxicities), consider increasing to 75% and then to 100% of the calculated full dose.
1733455|NCT00061893|Procedure|conventional surgery|Patients who respond to induction chemotherapy undergo surgery on week 13. Patients who have inadequate margins after surgery undergo radiotherapy beginning on week 15. (see Detailed Description for frequency of administration and groups evaluated)
1733456|NCT00061893|Radiation|radiation therapy|Patients with unresectable lesions undergo radiotherapy 5 days a week for approximately 6 weeks beginning on week 13. (see Detailed Description for frequency of administration and groups evaluated)
1733457|NCT00061893|Drug|MESNA|The total daily MESNA dose is equal to at least 60% of the daily cyclophosphamide or ifosfamide dose, or by continuous infusion of the 60% dose. MESNA continuous infusion should be started at the same time as the cyclophosphamide/ifosfamide and be completed no sooner than 8 hours after the end of the cyclophosphamide or ifosfamide infusion. The oral dose of MESNA is 2x the IV dose. Patients able to tolerate oral MESNA may receive the final dose by mouth at 40% of the oxazaphosphorine (cyclophosphamide or ifosfamide) dose. The dose should be given two hours earlier than the IV dose would be given. Additionally, if the patient vomits within two hours after the oral dose, the dose should be repeated or IV MESNA given.
1733458|NCT00061893|Drug|Filgrastim|G-CSF (Filgrastim) 5 micrograms/kg/day subcutaneously beginning 24 to 48 hours after the last dose of chemotherapy, and continuing until the absolute neutrophil count is 2,000/µL or greater after nadir.
1733459|NCT00061906|Drug|celecoxib|Treatment will be administered on an outpatient basis. Oral celecoxib will be given at the dose of 400 mg BID for total of 12 months. Patients will be advised to take this medication with food to improve absorption.
1733460|NCT00061919|Drug|Carboplatin, etoposide & thalidomide|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral thalidomide daily beginning on day 1 for up to 24 months.
1733461|NCT00061919|Drug|Carboplatin, etoposide & placebo|Carboplatin IV on day 1 and etoposide IV on day 1 and 2 and, orally Day 3. Oral placebo daily beginning on day 1 for up to 24 months.
1733462|NCT00061932|Drug|bortezomib|Given IV
1733463|NCT00061932|Drug|irinotecan|Given IV
1733464|NCT00061945|Drug|allopurinol|Given PO
1733465|NCT00061945|Drug|cyclophosphamide|Given IV
1733466|NCT00061945|Drug|daunorubicin hydrochloride|Given IV
1733467|NCT00061945|Drug|vincristine sulfate|Given IV
1733468|NCT00061945|Drug|dexamethasone|Given PO and as eye drops
1733469|NCT00061945|Drug|asparaginase|Given SC
1733470|NCT00061945|Biological|filgrastim|Given SC
1733471|NCT00061945|Drug|imatinib mesylate|Given PO
1733472|NCT00061945|Drug|methotrexate|Given IT, IV, and PO
1733473|NCT00061945|Drug|cytarabine|Given IV
1733474|NCT00061945|Drug|trimethoprim-sulfamethoxazole|Given PO
1733475|NCT00061945|Drug|mercaptopurine|Given PO
1733476|NCT00061945|Drug|leucovorin calcium|Given IV and PO
1733477|NCT00061945|Biological|alemtuzumab|Given SC
1733478|NCT00061945|Drug|acyclovir|Given PO
1733479|NCT00061945|Other|laboratory biomarker analysis|Correlative studies
1733480|NCT00061945|Other|pharmacological study|Correlative studies
1733481|NCT00061958|Drug|arsenic trioxide|Given IV
1733482|NCT00061984|Biological|pegfilgrastim|
1733483|NCT00061984|Drug|doxorubicin hydrochloride|
1733484|NCT00061984|Drug|ifosfamide|
1733485|NCT00061984|Procedure|multimodality therapy|
1733486|NCT00061997|Dietary Supplement|inositol|
1733487|NCT00062010|Biological|interferon alpha|Interferon alpha given subcutaneously, 6 million units per square meter of body surface area on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
1733488|NCT00062010|Drug|13-cis-retinoic acid|13-cis-retinoic acid given at 1 mg/kg of body weight by mouth on days 1 and 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
1733489|NCT00062010|Drug|paclitaxel|paclitaxel administered intravenously with premedication at 75 mg/m2 of body surface area on day 2 of each week for 6 weeks, followed by 2 weeks of rest. Given until disease progression or unacceptable toxicity.
1733490|NCT00062023|Drug|Acetylsalicylic acid (Aspirin)|Patients receive oral aspirin once daily for 12 months.
1733491|NCT00062023|Drug|Sulindac|Patients receive oral sulindac twice daily for 12 months.
1733492|NCT00062023|Drug|Ursodiol|Patients receive oral ursodiol three times daily for 12 months.
1733493|NCT00062023|Other|Sulindac Placebo|Oral sulindac placebo twice daily.
1733494|NCT00062036|Biological|aldesleukin|
1733495|NCT00062036|Biological|filgrastim|
1733496|NCT00062036|Biological|incomplete Freund's adjuvant|
1733497|NCT00062036|Biological|interleukin-2 gene|
1733498|NCT00062036|Biological|therapeutic tumor infiltrating lymphocytes|
1733499|NCT00062036|Drug|cyclophosphamide|
1733500|NCT00062036|Drug|fludarabine phosphate|
1733501|NCT00062049|Biological|recombinant interleukin-7|
1733502|NCT00062062|Drug|carboplatin|
1733503|NCT00062062|Drug|gefitinib|
1733504|NCT00062062|Drug|paclitaxel|
1733505|NCT00062075|Drug|romidepsin|Given IV
1733511|NCT00062127|Drug|irinotecan hydrochloride|Given IV
1733512|NCT00062127|Drug|thalidomide|Given orally
1733513|NCT00062127|Other|pharmacological study|Correlative studies
1733514|NCT00062140|Drug|cyclophosphamide|
1733515|NCT00062140|Procedure|allogeneic bone marrow transplantation|
1733516|NCT00062140|Procedure|peripheral blood stem cell transplantation|
1733517|NCT00062140|Radiation|radiation therapy|
1733518|NCT00062179|Drug|carboplatin|Carboplatin: dosed at an AUC of 6 by the Calvert Formula 3 cycles of carboplatin 21 days apart
1733519|NCT00062179|Drug|celecoxib|Celecoxib: 400 mg po BID celecoxib 3-7 days before first dose of chemotherapy
1733520|NCT00062179|Drug|paclitaxel|Paclitaxel: 225 mg/m2 by 3-hour intravenous infusion 3 cycles of paclitaxel 21 days apart
1733521|NCT00062179|Other|Placebo|placebo 3-7 days before first dose of chemotherapy
1733522|NCT00062205|Drug|imatinib mesylate|
1733523|NCT00062231|Drug|amoxicillin-clavulanate potassium|
1733524|NCT00062231|Drug|ciprofloxacin|
1733525|NCT00062231|Drug|moxifloxacin hydrochloride|
1733526|NCT00062231|Procedure|management of therapy complications|
1733527|NCT00062244|Biological|oblimersen sodium|Given IV
1733528|NCT00062257|Drug|irofulven|
1733529|NCT00062270|Drug|cisplatin|
1733530|NCT00062270|Drug|docetaxel|
1733531|NCT00062270|Drug|gefitinib|
1733532|NCT00062270|Drug|gemcitabine hydrochloride|
1733533|NCT00062270|Procedure|conventional surgery|
1733534|NCT00062270|Procedure|neoadjuvant therapy|
1733535|NCT00062270|Radiation|radiation therapy|
1733536|NCT00062283|Drug|L-alanosine|
1733537|NCT00062296|Biological|rituximab|
1733538|NCT00062296|Drug|epirubicin hydrochloride|
1733539|NCT00062309|Radiation|radiation therapy|
1733540|NCT00062322|Drug|cisplatin|
1733541|NCT00062322|Drug|irinotecan hydrochloride|
1733542|NCT00062322|Procedure|conventional surgery|
1733543|NCT00062322|Procedure|neoadjuvant therapy|
1733544|NCT00062322|Radiation|radiation therapy|
1733545|NCT00062335|Radiation|radiation therapy|
1733546|NCT00062348|Drug|boronophenylalanine-fructose complex|
1733547|NCT00062348|Drug|sodium borocaptate|
1733548|NCT00062348|Procedure|conventional surgery|
1733549|NCT00062374|Drug|Cisplatin|Given IV
1733550|NCT00062374|Procedure|Computed Tomography|Undergo FDG and FLT PET/CT
1733551|NCT00062374|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
1733552|NCT00062374|Other|Fluorothymidine F-18|Undergo FLT-PET/CT
1733553|NCT00062374|Drug|Irinotecan Hydrochloride|Given IV
1733554|NCT00062374|Procedure|Positron Emission Tomography|Undergo FDG and FLT PET/CT
1733555|NCT00062374|Procedure|Therapeutic Conventional Surgery|Undergo radical subtotal or total gastrectomy with lymph node dissection
1733556|NCT00062387|Drug|perifosine|
1733557|NCT00062400|Procedure|psychosocial assessment and care|
1733558|NCT00062426|Biological|bevacizumab|
1733559|NCT00062426|Drug|capecitabine|
1733560|NCT00062426|Drug|fluorouracil|
1733561|NCT00062426|Drug|leucovorin calcium|
1733562|NCT00062426|Drug|oxaliplatin|
1733563|NCT00062439|Drug|cisplatin|During induction:50 mg/m2,IV on Days 1, 8, 29 & 36. In any appropriate vehicle over 60 minutes
1733564|NCT00062439|Drug|docetaxel|During consolidation: 75 mg/m2 IV on Day 1, every 21 days for 3 cycles over 60 minutes
1733565|NCT00062439|Drug|etoposide|During induction: 50 mg/m2, IV on Days 1 - 5 Days 29 - 33. In 250 ml of NS over 60 minutes.
1733566|NCT00062439|Procedure|conventional surgery|If, based upon the evaluation in Section 7.4a, there is no evidence of progression (see Section 10.2d for definition), patients will proceed to the next appropriate step: Registration #2 and surgery followed by Registration #3 and additional chemotherapy (Sections 7.5 and 7.6). Response determinations (CR,PR, SD) will be required. If criteria for progressive measurable or nonmeasurable disease (see Section 10.0) are met, the patient will then be removed from protocol treatment and receive follow-up according to the schedule. Surgery will be performed 3 - 7 weeks after completion of chemoradiotherapy.
1733567|NCT00062439|Radiation|radiation therapy|Radiotherapy is to begin within 24 hours following the start of chemotherapy. Day 1 of radiotherapy must be a Monday, Tuesday or Wednesday, but no later in the week to insure simultaneous therapy for the majority of each chemotherapy cycle. The total dose to the prescription point will be 4,500 cGy given in 25 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter.
1733568|NCT00062465|Drug|TwHF|
1733569|NCT00062478|Drug|Karenitecin (BNP1350)|Karenitecin 1.0 mg/m2 administered as a single 60-minute IV infusion daily for five consecutive days. The cycle is repeated every 21 days until occurrence of progressive disease or unacceptable toxicity.
1733570|NCT00062491|Drug|Karenitecin (BNP1350)|Karenitecn (1.0 mg/m2) administered as a single daily 60-minute intravenous infusion for 5 consecutive days repeated every 21 days (1 treatment cycle). Patients who respond (CR< PR, SD) can continue treatment for 6 cycles, unless unacceptable toxicity develops. Treatment will be discontinued if progressive disease or unacceptable toxicity develops.
1733571|NCT00062504|Drug|Talampanel|10mg, 25 mg, 35 mg, 50 mg, 75mg TID for 3 weeks
1733572|NCT00062530|Biological|SCBaL/M9|Oral recombinant Salmonella typhi HIV-1 gp120 vaccine
1733573|NCT00062543|Procedure|Hepatic artery infusion of CD34+ cells|Donor's cells infused directly into liver through a groin catheter (hepatic artery).
1733574|NCT00062543|Device|Cobe Spectra|Mononuclear cells (MNC) collected by continuous-flow centrifugation using a blood cell separator (Cobe Spectra).
1733575|NCT00062556|Drug|Niacin Extended Release and Lovastatin Tablets|
1733576|NCT00062569|Behavioral|Bathing Support Intervention (BSI)|Bathing Support Intervention - Review of caregiver current practices and perceptions and care recipient behavioral symptoms associated with bathing with pattern analysis based on observation; skill building for bathing and communication techniques; coaching for implementation
1733636|NCT00063141|Drug|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
1733637|NCT00063141|Drug|Irinotecan|Vial, IV, 350 mg/m², Q 3 Weeks, Until PD/Toxicity/Pt-PI Decision
1733577|NCT00062569|Behavioral|Caregiver reminiscence with coaching|"BSI plus Reminiscence - BSI as above plus caregiver interview to ascertain pleasant long-term memories (e.g. stories, pictures, music) developed into a crib sheet for caregiver use conversationally prior to and during the bath"
1733578|NCT00062582|Drug|Roflumilast|
1733579|NCT00062595|Drug|phylloquinone (K1)|
1733580|NCT00062595|Drug|menatetranone (MK4)|
1733581|NCT00062608|Behavioral|Written self-disclosure|
1733582|NCT00062621|Procedure|Combined bone marrow and kidney transplant|
1733583|NCT00062634|Behavioral|Female condom skills training|
1733584|NCT00062647|Drug|Telavancin|Telavancin 10mg/kg/day IV every 24 hrs for up to 14 days
1733585|NCT00062647|Drug|Vancomycin, nafcillin, oxacillin, or cloxacillin|Vancomycin 1 Gram every 12 hr IV (intravenously) OR nafcillin, oxacillin, or cloxacillin 2 Grams every 6 hr IV (intravenously) for up to 14 days.
1733586|NCT00062660|Drug|Tipranavir|Tipranavir 250 mg soft elastic capsules
1733587|NCT00062673|Drug|Duloxetine|
1733588|NCT00062673|Drug|Placebo|
1733589|NCT00062686|Drug|GW572016|
1733590|NCT00062699|Drug|Zemplar (paricalcitol injection)|
1733591|NCT00062699|Drug|Calcijex|
1733592|NCT00062712|Drug|Allogeneic Bone Marrow, Anti-Thymocyte Globulin (Sangstat) & Sirolimus (Wyeth-Ay|
1733593|NCT00062738|Drug|paroxetine|Paroxetine CR 12.5 - 25 mg q hs
1733594|NCT00062738|Drug|Nortriptyline|nortriptyline 25 - 75 mg q hs
1733595|NCT00062738|Other|placebo|matching placebo
1733596|NCT00062751|Drug|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) 10 mg daily
1733597|NCT00062751|Drug|Letrozole / Temsirolimus (CCI-779)|Letrozole 2.5 mg daily + Temsirolimus (CCI-779) intermittent 30 mg daily for five days every 2 weeks
1733598|NCT00062751|Drug|Letrozole|Letrozole 2.5 mg daily
1733599|NCT00062764|Drug|Actos (Pioglitazone)|Pts receive drug in a dose of 15 mg daily for at least 1 year; the dose is escalated to 30 mg daily if serum ALT levels do not fall to normal by the 1 year pt; if pts have a biochemical response, drug is continued for 3 years,
1733600|NCT00062790|Drug|Dutasteride|
1733601|NCT00062803|Drug|SR34006|
1733602|NCT00062803|Drug|(LMW)heparin|
1733603|NCT00062803|Drug|Warfarin VKA|
1733604|NCT00062803|Drug|Acenocoumarol VKA|
1733605|NCT00062816|Drug|ISIS 14803, peginterferon alfa, ribavirin|
1733606|NCT00062829|Behavioral|Teen Driving: Program for parents|A behavioral intervention targeting driving risks unique to young drivers, including completing a behavioral contract, was administered to the intervention group. The control group received safety information appropriate for new drivers.
1733607|NCT00062842|Drug|Irinotecan|
1733608|NCT00062855|Procedure|Skin Biopsy|
1733609|NCT00062855|Genetic|Gene Modified Neuroblastoma Cells|"The first two injections will be given at week 1 and week 2 (i.e., separated by one week). Patients will then have a two-week rest and the remaining two injections will be given (again separated by one week) at week 4 and week 5.
A complete evaluation for evidence of toxicity and response will be performed at week 8 (after a 3 week rest).
At the 8 week (month 2) evaluation, in the absence of progressive disease requiring therapy without excessive toxicity and if more transduced cells are available, the patient will have the option to receive four additional SC injections each separated by 1 month at the higher of the two dosage levels they originally received."
1733610|NCT00062868|Biological|LMP1/2 CTLs (Group A)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level One
Day 0: 2 x 10^7 cells/m2; Day 14: 2 x 10^7 cells/m2
Dose Level Two
Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2
Dose Level Three
Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
1733611|NCT00062868|Biological|LMP1/2 CTLs (Group B)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level One
Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2
Dose Level Two
Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2
Dose Level Three
Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
1733612|NCT00062868|Biological|LMP1/2 CTLs (Group C)|"Each patient will receive 2 injections, 14 days apart, according to the following dosing schedules:
Dose Level One
Day 0: 2x10^7 cells/m2; Day 14: 2x10^7 cells/m2
Dose Level Two
Day 0: 2x10^7 cells/m2; Day 14: 1x10^8 cells/m2
Dose Level Three
Day 0: 1x10^8 cells/m2; Day 14: 2x10^8 cells/m2"
1733613|NCT00062881|Drug|Intrathecal Mafosfamide|
1733614|NCT00062894|Drug|Iodine I 131 Tositumomab|
1733615|NCT00062907|Biological|Recombinant DNA- pVAX/L523S|
1733616|NCT00062907|Biological|Recombinant adenovirus- Ad/L523S|
1733617|NCT00062933|Procedure|Laparotomy|
1733618|NCT00062946|Drug|(18F)fallypride|
1733619|NCT00062959|Behavioral|Going Places: School program to prevent problem behavior|
1733620|NCT00062972|Drug|donepezil|
1733621|NCT00062972|Drug|glucose|
1733624|NCT00063011|Behavioral|Calcium rich diet|
1733625|NCT00063011|Behavioral|Weight bearing exercise|
1733626|NCT00063024|Behavioral|Increased calcium intake|
1733627|NCT00063024|Behavioral|Weight-bearing physical activity|
1733628|NCT00063037|Behavioral|Behavioral modification - nutrition education|
1733629|NCT00063050|Behavioral|Physical activity and nutrition intervention|
1733630|NCT00063076|Drug|Targretin Gel 1%|Alopecia lesions on one-half of the head including facial hair treated, and other half on head serves as control (untreated). Starting dose once every day till Week 3 then escalate to twice a day.
1733631|NCT00063089|Drug|S. aureus Immune Globulin Intravenous (Human) 5%|
1733632|NCT00063102|Drug|ABT-751|
1733633|NCT00063128|Drug|insulin|"Administer subcutaneous regular human insulin 30 to 60 minutes before meals, or administer insulin lispro within 15 minutes before meals.
Inject into abdomen only."
1733634|NCT00063128|Drug|human insulin inhalation powder (HIIP)|"Administer HIIP within 15 minutes before meals.
Administer doses in one-capsule increments equivalent to approximately 2 IU or 6 IU of subcutaneous insulin.
Target treatment goals during the treatment sequence are the same as for patients using preprandial injectable insulin"
1733635|NCT00063141|Drug|cetuximab|Vial, IV, 400 mg/m² week 1 then 250 mg/m², weekly, until PD/Toxicity/Pt-PI Decision
1733638|NCT00063154|Drug|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
1733639|NCT00063193|Drug|minocycline|
1733640|NCT00063193|Drug|creatine|
1733641|NCT00063206|Drug|DVS-233 SR|
1733642|NCT00063219|Drug|MAC-321|
1733643|NCT00063232|Drug|Metformin|After complete medical evaluation and liver biopsy, patients who qualified for therapy were started on metformin in an initial dose of 500 mg once daily. After 2 weeks, the dose was increased to 500 mg twice daily and after 4 weeks to the full dose of 1000 mg twice daily. Subsequent dose reductions were carried out based on tolerance, with particular attention to gastrointestinal upset and abdominal bloating. Patients were seen in the out-patient clinic, had a brief medical history and examination and routine blood tests at 2 and 4 weeks after enrolment and every 4 weeks thereafter. The oral and intravenous glucose tolerance tests were repeated after 40 and 44 weeks respectively and liver biopsy and imaging tests at 48 weeks. Metformin was discontinued after 48 weeks in patients without diabetes on the pre-treatment evaluation.
1733644|NCT00063258|Drug|Tarceva (OSI-774)|150 mg/day, starting day 1 and stopping night prior to surgery.
1733645|NCT00063258|Drug|Paclitaxel|Planned dose of 200 mg/m^2 continuous IV infusion over 3 hours on Day 1 of each 21-day cycle.
1733646|NCT00063258|Drug|Carboplatin|Dose of AUC = 6 mg/ml × min began within 60 minutes following completion of paclitaxel infusion, infused over 15-30 minutes on Day 1 of Cycle 1 of each 21-day cycle, and then on Day 1 of each subsequent cycle according to institutional standards.
1733647|NCT00063284|Device|Magstim Rapid Magnetic Stimulator|
1733648|NCT00063297|Drug|R209130|
1733649|NCT00063310|Drug|Leuprolide acetate|
1733650|NCT00063323|Drug|Bupropion|
1733651|NCT00063336|Behavioral|Cognitive Remediation|A computerized cognitive rehabilitation treatment with day-program activities
1733652|NCT00063336|Behavioral|Computer-skills training|A computerized cognitive rehabilitation treatment with day-program activities
1733653|NCT00063362|Drug|Lithium|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over three weeks to a minimum blood level of 0.5 milliequivalent /L (mEq/L).
1733654|NCT00063362|Drug|Lamotrigine|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
1733655|NCT00063362|Drug|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased slowly over five weeks to a minimum blood level of 50 μg/mL.
1733656|NCT00063362|Drug|Placebo|Patients were assigned in a one to one ratio to adjunctive lamotrigine versus placebo after stratification for illness type (bipolar I versus bipolar II), historical response to lithium (response versus non-response), and length of current exposure to combination treatment with lithium and divalproex (< 2 months versus ≥ 2 months). During Phase 2, patients were continued on the same doses of lithium and divalproex as during the open-label treatment phase and equal capsules of double-blind lamotrigine or matching placebo were gradually added per a structured dosing schedule up to a minimum dose of 150 mg and a maximum dose of 200 mg per day.
1733657|NCT00063375|Behavioral|Computer Based Cognitive Behavioral Therapy|
1733658|NCT00063388|Biological|Cetuximab|Cetuximab 400 mg/m2 intravenously (IV) (over 120 minutes) on Day 1 of Cycle 1. followed by weekly doses of 250 mg/m2 (over 60 minutes).
1733659|NCT00063401|Biological|Cetuximab:|400 mg/m2 loading dose, 250 mg/m2 weekly, six 21-day cycles
1733660|NCT00063401|Drug|Paclitaxel|175 mg/m2 Day 1, six 21-day cycles
1733661|NCT00063401|Drug|Carboplatin|AUC = 6 Day1, six 21-day cycles
1733662|NCT00063414|Drug|Alicaforsen|
1733663|NCT00063427|Drug|MAC-321|
1733664|NCT00063453|Dietary Supplement|Vitamin E|vitamin E (400 IU/day all rac-α-tocopheryl acetate)
1733665|NCT00063453|Dietary Supplement|Selenium|selenium (200 μg/d L-selenomethionine)
1733666|NCT00063479|Drug|Zoledronic Acid|
1733667|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 14 days, until disease progression
1733668|NCT00063570|Drug|Gemcitabine|1500 mg/m2, intravenous (IV), every 14 days, until disease progression
1733669|NCT00063570|Drug|Gemcitabine|1000 mg/m2, intravenous (IV), on Days 1 and 8 of 21-day cycle, until disease progression
1733670|NCT00063570|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days, until disease progression
1733671|NCT00063583|Drug|Pirfenidone|Pirfenidone will be administered orally at 1200 or 2400 mg day in divided doses
1733672|NCT00063596|Drug|Vitamin A supplementation|
1733673|NCT00063609|Drug|zoledronic acid|
1733674|NCT00063622|Drug|Pioglitazone|30 mg daily
1733675|NCT00063622|Dietary Supplement|Vitamin E|800 IU daily
1733676|NCT00063622|Drug|Matching placebo|Daily
1733677|NCT00063635|Drug|Metformin|500 mg, twice daily
1733678|NCT00063635|Dietary Supplement|Vitamin E|400 IU, twice daily
1733679|NCT00063635|Drug|Matching placebo|Twice daily
1733680|NCT00063648|Biological|EBV-specific autologous CTL|
1733681|NCT00063674|Behavioral|Nutrition Education|
1733682|NCT00063674|Behavioral|After-school dance class|
1733683|NCT00063687|Drug|Oxypurinol|
1733684|NCT00063700|Procedure|reducing exposure to marketing pressures|
1733685|NCT00063713|Drug|VELCADE TM (bortezomib) for Injection|
1733686|NCT00063726|Drug|bortezomib|
1733687|NCT00063752|Drug|PI-0824|
1733688|NCT00063765|Drug|Ciliary Neurotrophic Factor Implant NT-501|
1733689|NCT00063778|Biological|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
1733690|NCT00063778|Other|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
1733691|NCT00063791|Drug|Bortezomib|
1733692|NCT00063804|Drug|Ritonavir|
1733693|NCT00063804|Drug|AMD070|
1733694|NCT00063817|Drug|MEDI-507|T-cell depleting antibody
1733695|NCT00063817|Procedure|Combined kidney and bone marrow transplant|kidney and bone marrow transplant from same donor
1733696|NCT00063817|Drug|Cyclosporine A|Immunosuppressant
1733697|NCT00063817|Drug|Rituximab|B-cell suppressor
1733698|NCT00063817|Drug|Corticosteroids|Immunosuppressant
1733699|NCT00063830|Drug|Alicaforsen|
1733700|NCT00063843|Biological|Recombinant Protective Antigen, Anthrax Vaccine Adsorbed|
1733701|NCT00063856|Biological|Wetvax (APSV)|
1733702|NCT00063869|Drug|Etanercept|
1733703|NCT00063882|Radiation|iodine I 125|Given as interstitial seeds
1733704|NCT00063882|Radiation|palladium Pd 103|Given as interstitial seeds
1733705|NCT00063882|Radiation|radiation therapy|Given as external beam radiation therapy over 5 weeks
1733706|NCT00063895|Drug|erlotinib hydrochloride|Given PO
1733707|NCT00063895|Other|pharmacological study|Correlative studies
1733708|NCT00063895|Other|pharmacogenomic studies|Correlative studies
1733709|NCT00063895|Other|laboratory biomarker analysis|Correlative studies
1733710|NCT00063934|Biological|oblimersen sodium|Given IV
1733711|NCT00063934|Drug|doxorubicin hydrochloride|Given IV
1733712|NCT00063934|Drug|docetaxel|Given IV
1733713|NCT00063934|Biological|filgrastim|Given SC
1733714|NCT00063934|Biological|pegfilgrastim|Given SC
1733715|NCT00063934|Procedure|therapeutic conventional surgery|Undergo surgical resection
1733716|NCT00063934|Other|pharmacological study|Optional correlative studies
1733717|NCT00063934|Other|laboratory biomarker analysis|Optional correlative studies
1733718|NCT00063947|Drug|erlotinib hydrochloride|Given orally
1733719|NCT00063947|Drug|gemcitabine hydrochloride|Given IV
1733720|NCT00063947|Radiation|radiation therapy|Undergo radiotherapy
1733721|NCT00063947|Other|laboratory biomarker analysis|Correlative studies
1733722|NCT00063960|Drug|floxuridine|
1733723|NCT00063960|Drug|irinotecan hydrochloride|
1733724|NCT00063973|Drug|cilengitide|Given IV
1733725|NCT00063973|Other|laboratory biomarker analysis|Correlative studies
1733726|NCT00063986|Procedure|Minimally invasive esophagectomy (MIE)|Within 4 weeks of registration patients will undergo minimally invasive esophagectomy (MIE). However, there will be up to 5 months allowed between registration and MIE for those patients needing neoadjuvant therapy prior to undergoing MIE.
1733727|NCT00063999|Drug|Carboplatin|Given IV
1733728|NCT00063999|Drug|Cisplatin|Given IV
1733729|NCT00063999|Drug|Doxorubicin Hydrochloride|Given IV
1733730|NCT00063999|Biological|Filgrastim|Given SC
1733731|NCT00063999|Other|Laboratory Biomarker Analysis|Correlative studies
1733732|NCT00063999|Drug|Paclitaxel|Given IV
1733733|NCT00063999|Biological|Pegfilgrastim|Given SC
1733734|NCT00063999|Other|Quality-of-Life Assessment|Ancillary studies
1733735|NCT00064012|Drug|bortezomib|
1733736|NCT00064012|Drug|docetaxel|
1733737|NCT00064025|Other|Laboratory Biomarker Analysis|Correlative studies
1733738|NCT00064025|Drug|Medroxyprogesterone|Given IM
1733739|NCT00064025|Procedure|Therapeutic Conventional Surgery|Undergo surgical hysterectomy
1733740|NCT00064038|Drug|dexamethasone|Given orally
1733741|NCT00064038|Drug|lenalidomide|Given orally
1733742|NCT00064038|Other|placebo|Given orally
1733743|NCT00064051|Drug|gemcitabine hydrochloride|
1733744|NCT00064051|Drug|triapine|
1733745|NCT00064064|Drug|gemcitabine hydrochloride|
1733746|NCT00064064|Drug|triapine|
1733747|NCT00064077|Drug|Cisplatin|Given IV
1733748|NCT00064077|Drug|Gemcitabine Hydrochloride|
1733749|NCT00064077|Drug|Paclitaxel|Given IV
1733750|NCT00064077|Other|Quality-of-Life Assessment|Ancillary studies
1733751|NCT00064077|Drug|Topotecan Hydrochloride|Given IV
1733752|NCT00064077|Drug|Vinorelbine Tartrate|Given IV
1733753|NCT00064090|Drug|cytarabine|
1733754|NCT00064090|Drug|triapine|
1733755|NCT00064103|Biological|Ad5CMV-p53 gene|Given intramucosally or as oral rinse
1733756|NCT00064103|Other|laboratory biomarker analysis|Correlative studies
1733757|NCT00064116|Biological|rituximab|Rituximab 375 mg/m² i.v. day 1
1733758|NCT00064116|Drug|CHOP regimen|Cyclophosphamide 750 mg/m² i.v. day 1 Doxorubicin 50 mg/m² i.v. day 1 Vincristine 2 mg (abs.) i.v. day 1 Prednisone 100 mg/d p.o. days 1 to 5 Recycle day 22 Total number of cycles: 6
1733763|NCT00064142|Drug|halofuginone hydrobromide|Applied topically
1733764|NCT00064142|Other|placebo|Applied topically
1733765|NCT00064142|Other|laboratory biomarker analysis|Correlative studies
1733766|NCT00064142|Other|pharmacological study|Correlative studies
1733767|NCT00064181|Drug|FOLFIRI regimen|
1733768|NCT00064181|Drug|capecitabine|
1733769|NCT00064181|Drug|celecoxib|
1733770|NCT00064181|Drug|fluorouracil|
1733771|NCT00064181|Drug|irinotecan hydrochloride|
1733772|NCT00064181|Drug|leucovorin calcium|
1733773|NCT00064194|Dietary Supplement|selenium|
1733774|NCT00064194|Dietary Supplement|soy protein isolate|
1733775|NCT00064194|Dietary Supplement|vitamin E|
1733776|NCT00055237|Biological|Bevacizumab|15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.
1733777|NCT00055250|Drug|Gemcitabine|
1733778|NCT00055250|Drug|LY293111|
1733779|NCT00055250|Drug|placebo|
1733780|NCT00055263|Drug|DN-101|
1733781|NCT00055302|Drug|Arimidex 1 mg|Arimidex (anastrozole) 1mg once daily by mouth
1733782|NCT00055315|Behavioral|Systems Training for Emotional Predictability and Problem Solving (STEPPS)|STEPPS is a 20-week, manual-based, psychoeducational group treatment that combines skills training with cognitive-behavioral techniques. It includes a systems component to train family members, friends, and significant others.
1733783|NCT00055315|Behavioral|Treatment As Usual (TAU)|
1733784|NCT00055328|Behavioral|Problem-Solving Treatment for Primary Care|
1733785|NCT00055341|Drug|Peginterferon alfa-2a|
1733786|NCT00055341|Drug|Ribavirin|
1733787|NCT00055354|Procedure|Acupuncture|
1733788|NCT00055354|Behavioral|Cognitive Behavioral Therapy|
1733789|NCT00055367|Drug|natalizumab|
1733790|NCT00055380|Procedure|Oral cytobrushing|
1733791|NCT00055393|Drug|Bupropion|18 subjects in this randomly controlled double blind study received bupropion.
1733792|NCT00055393|Drug|Placebo|21 subjects received Placebo.
1733793|NCT00055419|Biological|Cetuximab|400 mg/m2 loading dose Week 1, followed by 250 mg/m2 weekly until disease progression
1733794|NCT00055432|Drug|Gemzar and Alimta|
1733795|NCT00055445|Drug|IdB 1016|
1733796|NCT00055471|Drug|ZD4054 10 mg|1 x 10 mg oral tablets once daily
1733797|NCT00055471|Drug|ZD4054 15 mg|1 x 10 mg + 2 x 2.5 mg oral tablets once daily
1733798|NCT00055471|Drug|ZD4054 22.5 mg|2 x 10 mg + 2 x 2.5 mg oral tablets once daily
1733799|NCT00055484|Drug|zonisamide|
1733800|NCT00055497|Biological|Double-blind (DB) adalimumab placebo|Double-blind nonactive matching subcutaneous injection
1733801|NCT00055497|Biological|DB adalimumab 40 mg eow|Double-blind adalimumab 40 mg every other week by subcutaneous injection
1733802|NCT00055497|Biological|DB adalimumab 40 mg ew|Double-blind adalimumab 40 mg every week by subcutaneous injection
1733803|NCT00055497|Biological|OL adalimumab 40 mg|Open-label adalimumab every other week or every week by subcutaneous injection
1733804|NCT00055510|Drug|BO-653|
1733805|NCT00055523|Drug|Adalimumab (D2E7)|
1733806|NCT00055536|Drug|natalizumab|
1733807|NCT00055549|Drug|Dextromethorphan|
1733808|NCT00055549|Drug|Lorazepam|
1733809|NCT00055562|Drug|CC 5013|
1733810|NCT00055575|Drug|Transderm Scopolamine|
1733811|NCT00055588|Procedure|Locomotor training|
1733812|NCT00055601|Drug|cisplatin|Induction: 15 mg/m2 as a 60-minute infusion on days 1, 2, 3, 8, 9, 10, 15, 16, and 17; Consolidation: 15 mg/m2 as a 60-minute infusion on days 1, 2, 8, and 9; Adjuvant: 35 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
1733813|NCT00055601|Drug|fluorouracil|Induction: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 15, 16, and 17; Consolidation: 400 mg/m2 as a 24-hour infusion on days 1, 2, 3, 8, 9, and 10.
1733814|NCT00055601|Drug|paclitaxel|Induction: 50 mg/m2 as a 60-minute infusion on days 1, 8, and 15; Consolidation: 50 mg/m2 as a 60-minute infusion on days 1 and 8; Adjuvant: 50 mg/m2 as a 60-minute infusion on days 1 and 8 of each 21-day cycle for 4 cycles.
1733815|NCT00055601|Radiation|radiation therapy|Induction: External beam irradiation, 1.6 Gy, will be given to the pelvis in the first treatment followed by an interfraction period of at least 4-6 hours. During the second treatment, 1.5 Gy will be delivered to the whole bladder for the first five sessions (7.5 Gy) then to the tumor plus a margin for eight sessions (12. Gy). Consolidation: Consolidation therapy will start 7-14 days following a cystoscopic re-evaluation demonstrating a complete response to the induction therapy. 1.5 Gy (per fraction) will be given to the pelvis in two treatment fractions per day, with an interfraction period of at least 4-6 hours.
1733816|NCT00055601|Drug|Gemcitabine|Adjuvant: 1000 mg/m2 over 30-60 minutes on days 1 and 8 of each 21-day cycle for 4 cycles.
1733817|NCT00055601|Procedure|Radical cystectomy|Operable patients with pT1 or worse tumor response on re-evaluation following induction therapy will have radical cystectomy.
1733818|NCT00055614|Drug|topotecan hydrochloride|
1733819|NCT00055614|Procedure|adjuvant therapy|
1733820|NCT00055640|Biological|rituximab|Rituximab IV over 3-6 hours.Treatment repeats every 21 days for 3-8 courses.
1733821|NCT00055640|Drug|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 21 days for 3-8 courses.
1733822|NCT00055640|Drug|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 21 days for 3-8 courses.
1733823|NCT00055640|Drug|prednisone|Oral prednisone on days 1-5. Treatment repeats every 21 days for 3-8 courses.
1733824|NCT00055640|Drug|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 21 days for 3-8 courses.
1733825|NCT00055640|Genetic|microarray analysis|genetic testing
1733826|NCT00055653|Biological|anti-thymocyte globulin|
1733827|NCT00055653|Biological|filgrastim|
1733828|NCT00055653|Drug|busulfan|
1733829|NCT00055653|Drug|cyclophosphamide|
1733830|NCT00055653|Drug|cyclosporine|
1733831|NCT00055653|Drug|fludarabine phosphate|
1733832|NCT00055653|Drug|melphalan|
1733833|NCT00055653|Drug|methylprednisolone|
1733834|NCT00055653|Procedure|umbilical cord blood transplantation|
1733835|NCT00055653|Radiation|radiation therapy|
1733836|NCT00055666|Drug|beclomethasone dipropionate|
1733837|NCT00055679|Drug|cyclophosphamide|
1733838|NCT00055679|Drug|epirubicin hydrochloride|
1733839|NCT00055679|Drug|fluorouracil|
1733840|NCT00055692|Biological|bevacizumab|Given orally
1733841|NCT00055705|Biological|PV701|
1733842|NCT00055718|Dietary Supplement|silymarin|
1733843|NCT00055731|Drug|bicalutamide|
1733844|NCT00055731|Drug|buserelin|
1733845|NCT00055731|Drug|cyproterone acetate|
1733846|NCT00055731|Drug|docetaxel|
1733847|NCT00055731|Drug|estramustine phosphate sodium|
1733848|NCT00055731|Drug|flutamide|
1733849|NCT00055731|Drug|goserelin acetate|
1733850|NCT00055731|Drug|leuprolide acetate|
1733851|NCT00055731|Drug|nilutamide|
1733852|NCT00055731|Drug|triptorelin|
1733853|NCT00055731|Procedure|conventional surgery|
1733854|NCT00055731|Procedure|neoadjuvant therapy|
1733855|NCT00055731|Radiation|radiation therapy|
1733856|NCT00055757|Drug|tipifarnib|Given orally
1733857|NCT00055757|Drug|cisplatin|Given IV
1733858|NCT00055757|Drug|gemcitabine hydrochloride|Given IV
1733859|NCT00055757|Other|laboratory biomarker analysis|Correlative studies
1733860|NCT00055770|Drug|erlotinib hydrochloride|Given orally
1733861|NCT00055770|Drug|docetaxel|Given IV
1733862|NCT00055770|Other|laboratory biomarker analysis|Correlative studies
1733863|NCT00055770|Other|pharmacological study|Correlative studies
1733864|NCT00055783|Biological|apolizumab|
1733865|NCT00055809|Biological|PEG-interferon alfa-2b|Given SC
1733866|NCT00055809|Biological|bevacizumab|Given IV
1733867|NCT00055809|Other|laboratory biomarker analysis|Optional correlative studies
1733868|NCT00055822|Biological|oblimersen sodium|
1733869|NCT00055822|Drug|fluorouracil|
1733870|NCT00055822|Drug|leucovorin calcium|
1733871|NCT00055822|Drug|oxaliplatin|
1733872|NCT00055835|Drug|carboplatin|*AUC=5 (by modified Calvert formula), IV, over 15 minutes; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
1733873|NCT00055835|Drug|cisplatin|75 mg/m2 (maximum dose 150 mg), IV, rapid infusion; given q 21 days for 2 cycles (1 cycle = 21 days)
1733874|NCT00055835|Drug|gemcitabine hydrochloride|800 mg/m2, IV, over 30 minutes; given on Days 1 & 8, q 21 days, for a maximum of 3 cycles (1 cycle = 21 days)
1733875|NCT00055835|Drug|paclitaxel|200 mg/m2, IV, over 3 hours; given q 21 days for a maximum of 3 cycles (1 cycle = 21 days)
1733876|NCT00055835|Procedure|neoadjuvant therapy|Neoadjuvant chemotherapy (paclitaxel, carboplatin, and gemcitabine)
1733877|NCT00055835|Radiation|radiation therapy|Radiation treatments will be delivered once daily. Treatment will be given 5 days per week at a dose of 180 to 200 cGy per day. All fields will be treated everyday.
1733878|NCT00055848|Genetic|cytogenetic analysis|
1733879|NCT00055848|Genetic|gene mapping|
1733880|NCT00055848|Genetic|microarray analysis|
1733881|NCT00055861|Biological|bevacizumab|Given IV
1733882|NCT00055861|Drug|docetaxel|Given IV
1733883|NCT00055861|Other|laboratory biomarker analysis|Correlative studies
1733884|NCT00055874|Biological|recombinant interferon alfa|
1733885|NCT00055874|Drug|cytarabine|
1733886|NCT00055874|Drug|hydroxyurea|
1733887|NCT00055874|Drug|imatinib mesylate|
1733888|NCT00055874|Procedure|allogeneic bone marrow transplantation|
1733889|NCT00055874|Procedure|autologous bone marrow transplantation|
1733890|NCT00055874|Procedure|peripheral blood stem cell transplantation|
1733891|NCT00055887|Drug|carboplatin|
1733892|NCT00055887|Drug|cisplatin|
1733893|NCT00055887|Drug|efaproxiral|
1733894|NCT00055887|Drug|gemcitabine hydrochloride|
1733895|NCT00055887|Drug|paclitaxel|
1733896|NCT00055887|Drug|vinorelbine ditartrate|
1733897|NCT00055887|Procedure|radiation therapy|
1733898|NCT00055913|Biological|bevacizumab|Given IV
1733899|NCT00055913|Drug|erlotinib hydrochloride|Given orally
1733900|NCT00055913|Other|laboratory biomarker analysis|Correlative studies
1733901|NCT00055926|Drug|CP-724,714|
1733902|NCT00055939|Drug|exatecan mesylate|
1733903|NCT00055952|Drug|exatecan mesylate|
1733904|NCT00055965|Drug|carboplatin|
1733905|NCT00055965|Drug|cisplatin|
1733906|NCT00055965|Drug|gemcitabine hydrochloride|
1733909|NCT00055991|Drug|bexarotene|This drug is a retinoid. The anti-tumor action of retinoids, as well as their potential in chemoprevention, supports the need to further identify the spectrum of responsive tumors, to identify the molecular mechanisms associated with retinoid action, and to identify and develop new retinoids that have unique properties and an improved therapeutic index.
1733910|NCT00056004|Drug|zileuton|
1733911|NCT00056030|Biological|cetuximab|
1733912|NCT00056030|Drug|fluorouracil|
1733913|NCT00056030|Drug|leucovorin calcium|
1733914|NCT00056030|Drug|oxaliplatin|
1733915|NCT00056056|Drug|bexarotene|The recommended initial dosage of Bexarotene (75 mg Bexarotene capsules to be administered according to body surface area) for patients entered in this trial is 300 mg/m2 /once a day, taken orally, till CCR, PD, unacceptable toxicity, 16 weeks of treatment, whichever comes first
1733916|NCT00056056|Drug|methoxypsoralen|The dose of methoxypsoralen, as conventional capsules or liquid-filled capsules, is based on the patient's weight. The standard dose of 0.6 mg/kg will be given to all patients three times weekly - Increasing dose of PUVA according to a set protocol after a Minimal Phototoxic Dose (MPD) testing.
1733917|NCT00056056|Procedure|UV light therapy|Initial UVA light exposure times should be based on the minimal phototoxic dose (MPD) for the specific light source being used. MPD can be determined by irradiating several skin areas 2 cm in diameter with varying light exposure times and determining the exposure time that produces erythema at 72 hours. The initial dose of UVA administered will be 70% of the MPD. The dose of UVA for the subsequent UVA sessions will be increased according to a standard protocol consisting of 20% increments with each successive treatment session depending on the presence of erythema.
1733918|NCT00056069|Other|questionnaire administration|Participants complete questionnaires regarding caregiver demands and family information over 25-30 minutes within 3-4 months of the initiation of the child's treatment and at the completion of the first year of the child's treatment.
1733919|NCT00056082|Drug|celecoxib|Celecoxib daily for 12 months
1733920|NCT00056095|Biological|therapeutic allogeneic lymphocytes|
1733921|NCT00056095|Drug|cyclophosphamide|
1733922|NCT00056095|Drug|cyclosporine|
1733923|NCT00056095|Drug|fludarabine phosphate|
1733924|NCT00056095|Procedure|allogeneic bone marrow transplantation|
1733925|NCT00056095|Procedure|peripheral blood stem cell transplantation|
1733926|NCT00056134|Biological|denileukin diftitox|
1733927|NCT00056134|Biological|recombinant CD40-ligand|
1733928|NCT00056134|Biological|therapeutic autologous dendritic cells|
1733929|NCT00056147|Drug|denufosol tetrasodium (INS37217)|
1734050|NCT00057278|Drug|gabapentin|
1734051|NCT00057291|Behavioral|Responsive caregiving|Responsive caregiving consisted of operational circumstances and training of caregivers.
1733932|NCT00056173|Drug|GTI-2040|
1733933|NCT00056199|Drug|EYE001|
1733934|NCT00056212|Behavioral|Yoga|
1733935|NCT00056212|Behavioral|Exercise|
1733936|NCT00056225|Drug|Folate|
1733937|NCT00056225|Drug|Vitamin B6|
1733938|NCT00056225|Drug|Vitamin B12|
1733939|NCT00056238|Drug|NC-758 (Anti amyloidotic [Aß] agent)|
1733940|NCT00056251|Procedure|H&P; ECG; Blood tests; voiding diary; Cystoscopy|
1733941|NCT00056264|Drug|Infliximab|
1733942|NCT00056277|Drug|lamotrigine|
1733943|NCT00056290|Biological|VEGF|3 sets of injections, at 2 week intervals
1733944|NCT00056290|Biological|VEGF|3 sets of injections, at 2 week intervals
1733945|NCT00056303|Behavioral|Attachment and Biobehavioral Catch-up|Attachment and Biobehavioral Catch-up is a 10 session in-home intervention that targets synchrony, nurturance, and calming parental behavior.
1733946|NCT00056303|Behavioral|Developmental Education for Families|Developmental Education for Families is a 10-session in home intervention that targets children's cognitive development.
1733947|NCT00056316|Behavioral|Basic Education|Participants receive 37-page Basic Care Guide (Education Institute, 2001) and bi-weekly telephone calls by a trained staff member.
1733948|NCT00056316|Behavioral|Behavioral Skills Training: Experimental|Multicomponent behavioral intervention using 10-session video series (Steffen, et al., 2001) workbook (Steffen, et al., 2001), and weekly telephone coaching sessions.
1733949|NCT00056329|Drug|Vitamin E|1,000 international units twice daily for three years
1733950|NCT00056329|Drug|multivitamin|once daily for three years
1733951|NCT00056329|Drug|Placebo|Placebo twice daily for three years
1733952|NCT00056355|Drug|UVADEX and UVAR XTS Photopheresis System|
1733953|NCT00056368|Drug|Anidulafungin|
1733954|NCT00056368|Drug|Fluconazole|
1733955|NCT00056381|Drug|Anidulafungin|
1733956|NCT00056394|Behavioral|Comprehensive Coping Skills Training|10 weekly, 80-minute coping skills treatment sessions, followed by a series of six biweekly follow-up telephone calls.
1733957|NCT00056394|Behavioral|Arthritis Education Sessions|10 weekly, 80-minute treatment sessions, followed by a series of six biweekly follow-up telephone calls. Participants will learn about the nature and treatment of rheumatoid arthritis as well as the benefits of exercise and joint protection.
1733958|NCT00056394|Behavioral|Standard Care|Usual care from participants' rheumatologists but no treatment sessions.
1733959|NCT00056407|Drug|Dutasteride|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily dosing of 0.5mg of dutasteride orally for up to 4 years.
1733960|NCT00056407|Drug|Placebo|After successful completion of the placebo run-in phase, subjects who continue to meet eligibility requirements will be randomized into the double-blind phase of the study and issued a 6-month supply of study drug. Subjects will self-administer study drug once daily orally for up to 4 years.
1733961|NCT00056433|Drug|Hydroxyurea|
1733962|NCT00056433|Drug|L-Arginine|
1733963|NCT00056433|Drug|Sildenafil|
1733964|NCT00056446|Drug|Vatalanib|
1733965|NCT00056459|Drug|Vatalanib|
1733966|NCT00056472|Drug|Olanzapine|10-20mg/day
1733967|NCT00056472|Drug|Sertraline|150-200mg/day
1733968|NCT00056472|Other|placebo|tablet that ressembles sertraline but contains no medication
1733969|NCT00056485|Behavioral|Pleasant Events-Based Behavioral Intervention|
1733970|NCT00056498|Drug|Placebo|Placebo capsule daily for 16 weeks
1733971|NCT00056498|Drug|Risperdal|Risperdal 4 mg per day for 16 weeks
1733972|NCT00056511|Drug|Fresh garlic or garlic supplements|
1733973|NCT00056524|Drug|AVP-923|
1733974|NCT00056537|Drug|ABR-217620|Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
1733975|NCT00056550|Biological|Recombinant Human Antithrombin (rhAT)|Biological/Vaccine: Recombinant human antithrombin(rhAT) Phase III clinical trial.
1733976|NCT00056563|Device|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) will be assigned on a random basis at the time the patient enters the surgical phase of the trial.
1733977|NCT00056563|Other|best medical therapy|"Participants will initially be randomized to DBS or to 6 months of best medical therapy. BMT participants will then proceed into the surgical phase of the trial. Effective 08/05/05, randomization to the BMT arm has been discontinued since the study has sufficient information to compare the outcomes of DBS and BMT patients at 6 months."
1733978|NCT00056576|Drug|Zonisamide|
1733979|NCT00056589|Drug|catridecacog|Single doses of rFXIII administered intravenously (IV) to two subjects in each of the five dose levels (2, 6, 20, 50 and 75 U/kg).
1733980|NCT00056628|Device|The COGNIShunt® System|
1733981|NCT00056641|Drug|tipranavir|
1733982|NCT00056641|Drug|ritonavir|
1733983|NCT00056641|Drug|saquinavir|
1733984|NCT00056641|Drug|amprenavir|
1733985|NCT00056641|Drug|lopinavir|
1733986|NCT00056654|Drug|Leuprolide acetate|45 mg Intramuscular injection 6 month depot formulation
1734052|NCT00057304|Drug|Insulin sensitizer|
1734053|NCT00057317|Drug|Ro 205-2349|
1734054|NCT00057330|Biological|HSV vaccine or SB208141, GSK Biologicals' glycoprotein D (gD)-Alum/3-deacylated form of Monophosphoryl Lipid A (MPL) candidate genital herpes vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
1734055|NCT00057330|Biological|Havrix™, GlaxoSmithKline (GSK) Biologicals' licensed Hepatitis A vaccine|the vaccine was administered intramuscularly in the non-dominant deltoid
1734056|NCT00057343|Drug|Zevalin (ibritumomab tiuxetan)|
1734057|NCT00057343|Drug|Rituxan (rituximab)|
1734058|NCT00057356|Drug|conivaptan|IV
1733987|NCT00056667|Behavioral|Relaxation response and cognitive behavioral therapy|The cognitive behavioral therapy program wwill incorporate relaxation training, a modified version of the RA treatment program developed by Bradley et al (1987) and shown to be effective. The cognitive behavioral techniques include problem solving, relabeling, enhanced awareness of pain behaviors, and attention refocusing. The RR component includes instruction in diaphragmatic breathing along with progressive skeletal muscle relaxation. The intervention will be modified from the original program in that neither biofeedback training nor participation of family members will be included. Consequently, the number of weekly group sessions will be reduced from 14 to 12. Homework will be given at the end of each session, to be completed and brought in for review to the next session.
1733988|NCT00056667|Behavioral|Relaxation response|The relaxation response (RR) consists of a set of integrated physiological changes elicited when a participant engages in the repetitive mental action of focusing on a word, phrase, or image, while passively ignoring distracting thoughts. These changes include decreased oxygen consumption, heart rate, arterial blood pressure, respiratory rate, and arterial blood lactate, along with slight increases in skeletal muscle blood flow. The long-term physiologic changes of participants eliciting the relaxation response are consistent with reduced norepinephrine end organ responsivity. These latter changes provide a plausible psychophysiological mechanism for longer-term actions of the RR.
1733989|NCT00056667|Other|RA education|RA education programs have been widely used to supplement routine medical care. They have been found to be of modest benefit, particularly in terms of knowledge about the condition and its treatment. The long-term effects on pain and level of function are less. When used as an attention control, such educational programs have been found to be as credible and as well attended as the active experimental treatment (Professor Francis Keefe, Personal Communication). In this study, patients randomized to the control condition will receive 8 weekly sessions of RA education, in groups of 6-10 patients each, using portions of the Arthritis Self-Management Program and incorporating printed and videotaped materials available from the Arthritis Foundation.
1733990|NCT00056680|Behavioral|Psychoeducational video|
1733991|NCT00056680|Behavioral|Infant massage|
1733992|NCT00056680|Behavioral|Brazelton Neonatal Behavioral Assessment Scale|
1733993|NCT00056693|Drug|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity
1733994|NCT00056706|Procedure|Transient deafferentation|
1733995|NCT00056745|Biological|TBC-3B|
1733996|NCT00056758|Biological|Autologous Dendritic Cell HIV Vaccination|
1733997|NCT00056797|Biological|ALVAC HIV vaccine (vCP1452)|
1733998|NCT00056797|Drug|Interleukin-2|
1733999|NCT00056810|Drug|4-aminopyridine (4-AP)|
1734000|NCT00056823|Drug|rhuFab V2 (ranibizumab)|
1734001|NCT00056836|Drug|rhuFab V2 (ranibizumab)|
1734002|NCT00056862|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 90 mcg/week
1734003|NCT00056862|Drug|Peginterferon alfa-2a|180 mcg/week
1734004|NCT00056862|Drug|Ribavirin|800 mg/day
1734005|NCT00056875|Drug|recombinant human keratinocyte growth factor|
1734006|NCT00056927|Behavioral|Anti-smoking Socialization Program|
1734007|NCT00056940|Behavioral|Stages of Change|
1734008|NCT00056940|Behavioral|Safety Check approach|
1734009|NCT00056953|Behavioral|Peer mentoring program|
1734010|NCT00056966|Drug|ANTI-CD45|400ug/kg Day-5 through Day-2
1734011|NCT00056966|Drug|CAMPATH-1H|Day -8 through Day -6 Dosed per Institutional SOP
1734012|NCT00056966|Drug|FK506|Day -2 through Day 30 dose adjusted to maintain level between 5-15 ng/ml.
1734013|NCT00056966|Drug|Fludarabine|Day-8 through Day-5 30 mg/m2
1734014|NCT00056966|Radiation|Total Body Irradiation|Day-1 single dose 450 cGy
1734015|NCT00056966|Procedure|Stem cell infusion|Patients will receive peripheral blood stem cells from a HLA matched or one antigen mismatched related or unrelated donor (target CD34+ cell count >2 x 106/kg). When peripheral stem cells are unavailable or insufficient, bone marrow (target mononuclear cell count >2 x 108/kg) will be substituted.
1734016|NCT00056979|Drug|CAMPATH-1H|
1734017|NCT00056979|Drug|Anti-CD45|
1734018|NCT00056979|Drug|FK506|
1734019|NCT00056979|Drug|Fludarabine|
1734020|NCT00056992|Drug|ADI-PEG 20|
1734021|NCT00057005|Drug|CAMPATH-1H|Day-8 through Day-6 according to institutional SOPs
1734022|NCT00057005|Drug|Anti-CD45|Day-5 400 μg/kg
1734023|NCT00057005|Drug|Ara-C|day-7 through day-5 3000 mg/m2 q 12h
1734024|NCT00057005|Drug|Cyclophosphamide|Day-7 through Day-6 45 mg/kg
1734025|NCT00057005|Drug|Mesna|Days -7 and -6 45 mg/kg divided into 5 doses
1734026|NCT00057005|Radiation|Total Body Irradiation|150 cGy x 2 (5/6 matched related) 180 cGy x 2 (5/6 matched unrelated)
1734027|NCT00057018|Procedure|Constraint-induced movement therapy|
1734028|NCT00057031|Drug|DN-101 (calcitriol)|
1734029|NCT00057044|Behavioral|education and reminder|
1734030|NCT00057057|Behavioral|Telephone Care|
1734031|NCT00057070|Procedure|Smoking cessation information, collection, and dissemination|
1734032|NCT00057083|Other|Telemedicine Care|
1734033|NCT00057096|Procedure|On-site vs. referral methods of care|
1734034|NCT00057122|Drug|Isoniazid|300mg
1734035|NCT00057122|Drug|Rifapentine|Rifapentine 900 mg
1734036|NCT00057122|Drug|Rifampin|Rifampin 600 mg
1734037|NCT00057135|Behavioral|Unit of use medication packaging|
1734038|NCT00057135|Behavioral|Mailed reminders to patient when medication refills are due|
1734039|NCT00057135|Behavioral|Note to Mental Health Provider when refill is overdue|
1734040|NCT00057135|Procedure|Aligning all prescriptions to fall due on same date|
1734041|NCT00057148|Procedure|massage treatment|
1734042|NCT00057161|Behavioral|Coordinated Representative Payeeship with Case Management|
1734043|NCT00057174|Drug|Disease management of gastroesophageal reflux disease|
1734044|NCT00057187|Behavioral|Contracting, Prompting and Reinforcing|
1734045|NCT00057200|Procedure|Telephone, videophone care|
1734047|NCT00057226|Drug|Radafaxine|
1734048|NCT00057239|Drug|Radafaxine|
1734049|NCT00057265|Drug|telbivudine or lamivudine|
1734061|NCT00057382|Drug|T138067 intravenous|
1734062|NCT00057382|Drug|doxorubicin intravenous|
1734063|NCT00057395|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
1734064|NCT00057408|Drug|olanzapine (Zyprexa)|Olanzapine tablets given po at a dosage of 2.5 - 20 mg per day for up to 12 weeks.
1734065|NCT00057408|Drug|Placebo|Matching Placebo
1734066|NCT00057421|Drug|prednisolone|
1734067|NCT00057434|Drug|multivitamin|
1734068|NCT00057447|Drug|Interferon Gamma-1b|100 or 200 mcg, SQ, 3x per week
1734069|NCT00057447|Drug|Rituximab|375 mg per square meters, IV, 1x per week
1734070|NCT00057460|Drug|Talampanel|
1734071|NCT00057473|Drug|carboplatin + irinotecan|Solution, IV, Carbopaltin AUC 4 mg/ml.min every 21 days; irinotecan 12 mg/m2/day x 10 days , Minimum of two cycles of chemotherapy projected to be up to 6.
1734072|NCT00057473|Drug|irinotecan|Solution, IV, irinotecan 12 mg/m2/day x 10 days, minimum of two cycles of chemotherapy projected to be up to 6.
1734073|NCT00057486|Drug|IL-12|
1734074|NCT00057499|Biological|IBC-VS01|IBC-VS01
1734075|NCT00057499|Biological|IBC-VS01 placebo|IBC-VS01 placebo
1734076|NCT00057512|Drug|M4N|Dose escalation study of M4N administered intratumorally on days 1, 8 and 15. Dose escalated in cohorts on three weeks schedule to a target of 20 mg/cm3 tumor volume.
1734077|NCT00057525|Biological|Anthrax|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
1734078|NCT00057525|Biological|Alhdryogel or PBS|Doses will range from 5 _g to 100 _g rPA, and at each dose-level, rPA will either be combined with phosphate-buffered saline (PBS) or adsorbed to Alhydrogel
1734079|NCT00057538|Behavioral|Mantram Repetition|
1734080|NCT00057551|Behavioral|Brief Supportive Psychotherapy|brief supportive psychotherapy
1734081|NCT00057551|Behavioral|CBASP|psychotherapy developed for chronic depression
1734082|NCT00057551|Drug|Medication Only|antidepressant medication
1734083|NCT00057564|Drug|A (Thalidomide + Dexamethasone)|Thalidomide 50mg/day + Dexamethasone 40mg
1734084|NCT00057564|Drug|B (Placebo + Dexamethasone)|Placebo + Dexamethasone 40mg
1734085|NCT00057577|Behavioral|Cognitive Therapy|CT sessions occur weekly during acute treatment and monthly during continuation. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from initial randomization until they meet criteria for recovery. At recovery, patients receiving combined treatment discontinue CT.
1734086|NCT00057577|Drug|Medications|Antidepressant medication is distributed as clinically indicated with augmentation and ancillary medications as needed. Acute treatment may last up to 18 months. Remitted patients are continued on medication for up to 36 months from the point of initial randomization until they meet criteria for recovery. All recovered patients are randomized a second time to either maintenance medication or medication withdrawal. Patients are then monitored over 36 months to ascertain risk for recurrence of depressive symptoms.
1734087|NCT00057590|Behavioral|Care manager outreach and monitoring|
1734088|NCT00057603|Procedure|Deep Brain Stimulation|Deep brain stimulation sends electrical signals to specific parts of the brain, which block the impulses that cause neurological dysfunction.
1734089|NCT00057616|Drug|CC-5013|
1734090|NCT00057629|Behavioral|Prolonged Exposure (PE)|Prolonged Exposure (PE) consists of 10 weekly 90-minute treatment sessions, which may be extended up to 20 sessions, depending on client response. Treatment procedures include education about common reactions to trauma, breathing retraining, prolonged (repeated) exposure to trauma memories, repeated in vivo exposure to situations the client is avoiding due to trauma-related fear, and discussion of thoughts and feelings related to exposure exercises as well as beliefs about self and the world.
1734091|NCT00057629|Behavioral|Treatment as usual group therapy (TUGT)|TUGT is delivered in ten weekly sessions, with 5 to 7 members and two counselors per group. There is not a formal, structured format for these groups; the counselors are sensitive to the participants' needs and follow their lead in terms of content covered in discussions and exercises. TUGT is conceptualized as supportive counseling and is based on the idea that members gain social support and information from one another.
1734092|NCT00057629|Behavioral|Supportive counseling (SC)|Supportive counseling is an individual therapy delivered in 10 weekly, 90 minute sessions. During this treatment, the therapist helps the patient identify daily stresses that may or may not be related to traumatic events and discusses them in a supportive non-directive mode with a problem-solving orientation. The therapist uses active listening, encouragement of expression of feelings, praise, and encouragement. The goal of this present-focused treatment is to provide support and to help the client to identify problems and stresses of daily living and to help her cope with these. No instructions for exposure are given.
1734093|NCT00057642|Drug|Sertraline|
1734094|NCT00057642|Drug|Venlafaxine Extended Release|
1734095|NCT00057668|Behavioral|Multi-Setting Early Intervention|
1734096|NCT00057668|Behavioral|Community Intervention|
1734097|NCT00057681|Drug|Lithium carbonate|Titrated until blood level is 1.1 to 1.3 mEq/L
1734098|NCT00057681|Drug|Valproate|Titrated until blood level is 111 to 125 ug/mL
1734099|NCT00057681|Drug|Risperidone|Titrated by weight until dose is 2.0 mg BID to 3.0 mg BID
1734100|NCT00057707|Drug|Modafinil|Placebo 1 week-Wash out 1 week - Drug 1 week (or vice versa)
1734101|NCT00057707|Procedure|Functional MRI|
1734102|NCT00057707|Procedure|Neuropsychological Testing|
1734103|NCT00057720|Drug|TLK286 HCl for injection|
1734104|NCT00057720|Drug|topotecan hydrochloride for injection|
1734105|NCT00057720|Drug|doxorubicin HCl liposome injection|
1734106|NCT00057733|Procedure|psychosocial assessment and care|
1734107|NCT00057733|Procedure|quality-of-life assessment|
1734108|NCT00057746|Radiation|Prophylactic cranial irradiation, 2.5 Gy fx|Prophylactic cranial irradiation, 2.5 Gy once daily, M-F, in 10 fractions (fx) for a total of 25 Gy
1734109|NCT00057746|Radiation|Prophylactic cranial irradiation, 2.0 Gy fx|Prophylactic cranial irradiation, 2.0 Gy once daily, M-F, in 18 fractions (fx) for a total of 36 Gy
1734110|NCT00057746|Radiation|Prophylactic cranial irradiation, 1.5 Gy fx|Prophylactic cranial irradiation, 1.5 Gy twice daily, M-F, in 24 fractions (fx) for a total dose of 36 Gy
1734111|NCT00057759|Drug|sildenafil citrate|
1734113|NCT00057785|Drug|cisplatin|100 mg/m^2 intravenously on days 1, 22, and 43 and 80 mg/m^2 intravenously on days 71, 99, and 127
1734114|NCT00057785|Drug|fluorouracil|1000 mg/m^2/day as 96-hour continuous infusion on days 71-74, 99-102, and 127-130
1734115|NCT00057785|Radiation|Intensity modulated radiation therapy|The gross tumor and lymph node metastasis, Planning Target Volume (PTV) 70 (Clinical Target Volume [CTV] 70 with a 5 mm margin) will receive 70 Gy in 33 fractions at 2.12 Gy per fraction. Treatment will be delivered once daily, 5 fractions per week, over 6 weeks and 3 days.
1734116|NCT00057798|Drug|gemcitabine hydrochloride|
1734117|NCT00057798|Drug|vinorelbine ditartrate|
1734118|NCT00057798|Genetic|cytogenetic analysis|
1734119|NCT00057798|Genetic|loss of heterozygosity analysis|
1734120|NCT00057798|Genetic|microarray analysis|
1734121|NCT00057798|Procedure|conventional surgery|
1734122|NCT00057798|Procedure|neoadjuvant therapy|
1734123|NCT00057811|Drug|doxorubicin hydrochloride|Given IV, IT, or orally
1734124|NCT00057811|Drug|cyclophosphamide|Given IV
1734125|NCT00057811|Drug|methotrexate|Given IV or IT
1734126|NCT00057811|Drug|rasburicase|Given IV
1734127|NCT00057811|Drug|leucovorin calcium|Given IV or orally
1734128|NCT00057811|Drug|prednisone|Given IV or orally
1734129|NCT00057811|Drug|methylprednisolone|Given IV or orally
1734130|NCT00057811|Biological|filgrastim|Given subcutaneously
1734131|NCT00057811|Biological|rituximab|Given IV
1734132|NCT00057811|Drug|cytarabine|Given IT
1734133|NCT00057811|Drug|etoposide|Given IV
1734134|NCT00057811|Drug|vincristine sulfate|Given IV
1734135|NCT00057811|Drug|hydrocortisone sodium succinate|Given IT
1734136|NCT00057811|Other|laboratory biomarker analysis|Correlative studies
1734137|NCT00057837|Biological|G-CSF|G-CSF will be administered subcutaneously at a dose of 5 mcg/kg once a day starting on day 11 until WBC recovery > 10,000 dL.
1734138|NCT00057837|Drug|Cisplatin|Arm PET: 20 mg/m2 IV on days 8, 9 and 10 of each cycle following Etoposide. Arm PIE: 20 mg/m2 IV on days 1 and 8 of each cycle following Irinotecan.
1734139|NCT00057837|Drug|Etoposide|Arm PET: 70 mg/m2 IV over 60 minutes on days 8, 9 and 10 of each cycle. Arm PIE: 85 mg/m2 orally (divided into 2 doses, 12 hours apart) on day 3 and 10 of each cycle.
1734140|NCT00057837|Drug|Irinotecan|50 mg/m2 IV over 90 minutes on days 1 and 8 of each cycle (Arm PIE only).
1734141|NCT00057837|Drug|Topotecan|Topotecan 0.75 mg/m2 IV over 30 minutes on days 1,2 and 3 of each cycle (Arm PET only).
1734142|NCT00057850|Drug|cisplatin|
1734143|NCT00057850|Drug|ixabepilone|
1734144|NCT00057863|Drug|Paclitaxel|Given IV
1734145|NCT00057863|Drug|Oxaliplatin|Given IV
1734146|NCT00057876|Drug|Gemcitabine|"Induction: Patients receive the first cycle of gemcitabine 1000 mg/m^2 intravenously once per week for 6 weeks followed by 1 week rest.
Consolidation: Following the week of rest, treatment resume with gemcitabine 1000 mg/m^2 administered intravenously once per week for 3 weeks, followed by 1 week rest, for 5 (4-week) cycles."
1734147|NCT00057876|Radiation|radiation therapy|"Induction: Patients receive gemcitabine 600 mg/m^2 intravenous infusion over 30-60 minutes once a week for 6 weeks while receiving radiation therapy. The first gemcitabine dose is given on the first day of radiation therapy (prior to radiation), then weekly thereafter. All patients on Arm B receive radiation therapy Monday through Friday (no radiation on Saturday or Sunday), weeks 1-6, with once/week gemcitabine. The radiation dose per fraction is 180 cGy prescribed to the isocenter. The total dose of radiation is 5040 cGy given in 28 fractions over 5 1/2 weeks.
Consolidation: Additional cycles of gemcitabine begin approximately 4 weeks after completion of radiation therapy."
1734148|NCT00057889|Biological|ipilimumab|
1734149|NCT00057915|Biological|CEA peptide 1-6D|CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System
1734150|NCT00064207|Drug|gemcitabine hydrochloride|
1734151|NCT00064207|Procedure|adjuvant therapy|
1734152|NCT00064207|Radiation|radiation therapy|
1734153|NCT00064220|Drug|soblidotin|
1734154|NCT00064233|Drug|dasatinib|
1734155|NCT00064246|Biological|rituximab|Given IV
1734156|NCT00064246|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
1734157|NCT00064246|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
1734158|NCT00064259|Biological|oblimersen sodium|Given IV
1734159|NCT00064259|Drug|cisplatin|Given IV
1734160|NCT00064259|Drug|fluorouracil|Given IV
1734161|NCT00064272|Drug|ginger extract|Given orally
1734162|NCT00064272|Other|placebo|Given orally
1734163|NCT00064285|Drug|alvocidib|
1734164|NCT00064285|Drug|imatinib mesylate|
1734165|NCT00064298|Dietary Supplement|fruit and vegetable extracts|Given orally
1734166|NCT00064298|Dietary Supplement|placebo|Given orally
1734167|NCT00064311|Drug|ravuconazole|
1734168|NCT00064324|Drug|perifosine|Given orally
1734169|NCT00064324|Other|laboratory biomarker analysis|Correlative studies
1734170|NCT00064324|Other|pharmacological study|Correlative studies
1734244|NCT00065299|Behavioral|Restricted phenylalanine diet|
1734245|NCT00065312|Drug|naveglitazar|
1734246|NCT00065325|Drug|Fulvestrant|intramuscular injection
1734247|NCT00065325|Drug|Exemestane|oral capsule
1734248|NCT00065338|Behavioral|Exercise and behavior modification|Participants will undergo 1000 kcal/day caloric restriction (relative to experimentally determined weight-maintenance caloric needs) for 8 weeks during one phase of study. Additional 11 week period consists of 8 weeks of caloric restriction with an additional daily walking program.
1734249|NCT00065351|Drug|CC-5013|CC-5013 - oral - 30mg daily on days 1-21 every 28 days
1734250|NCT00065364|Behavioral|Newborn Individualized Developmental Care Assessment Program|
1734251|NCT00065377|Drug|Glucosamine Hydrochloride|
1734177|NCT00064350|Drug|Sorafenib|"Step 1 (induction): Sorafenib was giventwice daily for two cycles to all patients. Patients with progression (PD) discontinued treatment. Those who responded after two cycles continued treatment up to 1 year or until PD. With response after 1 year, patients were given the option to continue treatment until PD. Patients who were stable after the end of induction were then randomized onto Step 2 to either continue sorafenib or receive placebo.
Step 2 (randomization): Patients with stable disease after induction will be randomized in a double-blinded manner to placebo or sorafenib. If a patient has progressed, the arm will be unblinded. Patients on placebo with PD can then crossover to receive sorafenib; patients with PD on the sorafenib arm will be removed from the study.
Step 3 (crossover): If patients on placebo progressed within 1 year from randomization, they crossed over to the treatment arm and receive sorafenib for up to 1 year or until PD, unacceptable toxicity, or death."
1734178|NCT00064350|Drug|Placebo|Patients randomized to the placebo arm in step 2 continued receiving placebo until disease progression or one year from randomization. Placebo was given orally twice a day (BID).
1734179|NCT00064363|Drug|talampanel|
1734180|NCT00064376|Drug|paricalcitol|
1734181|NCT00064389|Drug|levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
1734182|NCT00064389|Drug|racemic albuterol|racemic albuterol HFA MDI 180 mcg QID
1734183|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 50 mcg QD
1734184|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 25 mcg BID
1734185|NCT00064402|Drug|arformoterol tartrate inhalation solution|arformoterol 15 mcg BID
1734186|NCT00064402|Drug|Salmeterol|Salmeterol MDI 42 mcg BID
1734187|NCT00064402|Drug|Placebo|Placebo BID
1734188|NCT00064415|Drug|arformoterol|Arformoterol inhalation solution, 50 mcg QD
1734189|NCT00064415|Drug|Salmeterol|Salmeterol MDI, 42 mcg BID
1734190|NCT00064428|Drug|fondaparinux - UFH not indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge
1734191|NCT00064428|Other|Control - UFH not indicated|Fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
1734192|NCT00064428|Drug|Fondaparinux - UFH indicated|2.5mg od, sc (1st dose IV) x 8 days or discharge + UFH-placebo IV bolus x 24-48 hr infusion
1734193|NCT00064428|Drug|Control - UFH|UFH IV bolus +12 IU/kg/hr infusion x 24-48 hr + fondaparinux-placebo od, sc (1st dose IV) x 8 days or discharge
1734194|NCT00064441|Drug|OPC-6535 Tablets (drug)|
1734195|NCT00064454|Drug|OPC-6535 Tablets (drug)|
1734196|NCT00064467|Drug|Extended-release bupropion (HCl)|
1734197|NCT00064922|Behavioral|Behavior Therapy|
1734198|NCT00064935|Procedure|Endometrial biopsy|
1734199|NCT00064961|Behavioral|Individualized dietary-control and exercise program|
1734200|NCT00064961|Behavioral|Weight-management and smoking cessation maintenance|
1734201|NCT00064961|Behavioral|Smoking Cessation program|
1734202|NCT00064974|Drug|CC-5013|CC-5013 10 mg (two 5 mg capsules) daily on days 1-28 every 28 days (28 day cycles)
1734203|NCT00064987|Procedure|Testicular biopsy|Outpatient surgical procedure.
1734204|NCT00064987|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
1734205|NCT00064987|Drug|follicle stimulating hormone (FSH)|75 IU subcutaneous injection daily for four months.
1734206|NCT00065000|Behavioral|Water, Cafeteria and Staff Health Promotion|
1734207|NCT00065013|Behavioral|strength training|
1734208|NCT00065026|Behavioral|Physical activity opportunities for low-income women|
1734209|NCT00065039|Behavioral|Promotion of a healthy diet and physical activity|
1734210|NCT00065039|Behavioral|Avoidance of Alcohol, Drugs, and Tobacco|
1734211|NCT00065052|Behavioral|Behavior modification|
1734212|NCT00065065|Drug|Rosiglitazone|4mg orally twice daily for 12 weeks
1734213|NCT00065065|Drug|Placebo|pill that looks identical to rosiglitazone
1734214|NCT00065078|Procedure|Home dispensing of contraception|
1734215|NCT00065104|Drug|DHEA|
1734216|NCT00065117|Drug|ZD6126|
1734217|NCT00065117|Drug|Placebo|
1734218|NCT00065117|Drug|5-fluorouracil|
1734219|NCT00065117|Drug|leucovorin|
1734220|NCT00065117|Drug|oxaliplatin|
1734221|NCT00065130|Drug|human insulin|
1734222|NCT00065130|Drug|insulin NPH|
1734223|NCT00065130|Drug|insulin aspart|
1734224|NCT00065143|Drug|clofarabine|
1734225|NCT00065143|Drug|Ara-C|
1734226|NCT00065156|Drug|lenalidomide|10 mg orally once daily for 21 days out of a 28-day cycle (syncopated); subsequently amended (Amendment 1, dated 27 August 2003) to employ a continuous dosage regimen in which 10 mg was taken once daily for 28 day cycles (continuous). Subjects who initially began a syncopated regimen and who did not experience a dose-limiting adverse event were allowed to switch to the continuous regimen.
1734227|NCT00065169|Drug|Celecoxib|
1734230|NCT00065195|Procedure|Moving touch therapy|
1734231|NCT00065195|Procedure|Nonmoving touch therapy|
1734232|NCT00065208|Behavioral|Reiki|Energy therapy - 8 biweekly sessions of 30 minutes
1734233|NCT00065208|Behavioral|Pretend Reiki|Touch from untrained pretend practitioners. 8 biweekly sessions of 30 minutes
1734234|NCT00065208|Behavioral|Rest / Guided Imagery|4 weekly sessions of 30 supine rest listening to soft music. One session of Guided Imagery followed at visit 9. Listen to CDs twice a day 3 days prior to and 2 days following surgery (affect only post surgery outcomes)
1734235|NCT00065221|Drug|Ginger|
1734236|NCT00065234|Procedure|Acupuncture|
1734237|NCT00065247|Behavioral|Beat Osteoporosis: Nourish and Exercise Skeletons (BONES) Project|
1734238|NCT00065260|Drug|Campath-1H|Campath-1H IV 10 days. Adults:10mg/day (children:0.2mg/kg/day).
1734239|NCT00065260|Drug|r-ATG|Rabbit ATG 3.5mg/kg/day for consecutive 5 days
1734240|NCT00065260|Drug|CsA|CsA 10mg/kg/day orally twice daily for 6 months (15mg/kg/day for children under 12 yrs.
1734241|NCT00065273|Drug|risperidone|
1734242|NCT00065273|Drug|clozapine|
1734243|NCT00065273|Drug|olanzapine|
1734252|NCT00065390|Drug|Pyrimethamine|
1734255|NCT00065429|Drug|BB-10901|"I.V. Infusion - See Arms for dosage - Once/Week for three weeks - Until Progression of disease."
1734256|NCT00065442|Biological|Sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with a PAP-GM-CSF. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
1734257|NCT00065442|Biological|APC-Placebo|Each dose of APC-Placebo contains approximately one-third of the quiescent APCs prepared from a single leukapheresis procedure. A course of therapy consists of 3 complete doses given at approximately 2-week intervals.
1734258|NCT00065455|Drug|Vitamin A|
1734259|NCT00065468|Drug|Interferon Alfa|Interferon alfa (Roferon) 3 MU given Sub Cutaneously three time /week for the first week, 9 MU given Sub Cutaneously three time /week for the second week, 18 MU given Sub Cutaneously three time /week thereafter.
1734260|NCT00065468|Drug|CCI-779|25 mg of CCI-779 given Intra Venously once per week
1734261|NCT00065468|Drug|Interferon Alfa and CCI-779|15 mg of CCI-779 given Intra Venously once per week; 6 MU of IFN alfa (Roferon) given Sub Cutaneously three time /week
1734262|NCT00065507|Drug|Entecavir (ETV)|Tablets, Oral, 1 mg once daily, 96 weeks from the time the last patient is randomized
1734263|NCT00065507|Drug|Adefovir (ADV)|Tablets, Oral, 10 mg, once daily, 96 weeks from the time the last patient is randomized
1734264|NCT00065533|Drug|pemetrexed|
1734265|NCT00065546|Other|Estrogen plus choline depletion diet|Post-menopausal subjects receive estrogen and are then challenged with a low choline diet to determine if estrogen protects them from induction of choline deficiency.
1734266|NCT00065546|Other|Placebo plus choline depletion diet|Post-menopausal women are randomized to receive a placebo and are then subjected to a low choline diet to determine if clinical signs of choline deficiency can be induced.
1734267|NCT00065546|Other|Pre-menopausal women with SNPs given a low choline diet|Pre-menopausal women with specific genetic polymorphisms in genes related to choline metabolism are placed on a choline depletion diet to determine if the SNPs increase or decrease the risk of diet-induced choline deficiency.
1734268|NCT00065559|Drug|celecoxib|
1734269|NCT00065572|Drug|ZD6126|
1734270|NCT00065572|Drug|Placebo|
1734271|NCT00065585|Procedure|Accupuncture|
1734272|NCT00065611|Drug|Oral dexamethasone|"Stage I: Dexamethasone 25 mg/m2, 2 doses every 2 weeks over 48 weeks or dexamethasone 25 mg/m2, 4 doses every 4 weeks over 48 weeks.
Stage II: 1.) Dexamethasone 50 mg/m2, 2 daily doses every 12 weeks, followed by 25 mg/m2, 2 daily doses every 2 weeks over 36 weeks, or 2.) Dexamethasone 50 mg/m2, 4 daily doses every 4 weeks over 12 weeks, followed by 25 mg/m2, 4 daily doses every 4 weeks over 36 weeks.
over 36 weeks."
1734273|NCT00065624|Drug|lipoic acid|
1734274|NCT00065637|Drug|Teriparatide|Synthetic human parathyroid hormone
1734275|NCT00065637|Drug|Placebo teriparatide|Placebo injections
1734276|NCT00065650|Drug|Vedic Medicine|
1734277|NCT00065650|Behavioral|Vedic Medicine|
1734278|NCT00065663|Genetic|GAM501|
1734280|NCT00065689|Device|high-intensity light therapy|
1734281|NCT00065702|Drug|Active liquid remedy|
1734282|NCT00065715|Dietary Supplement|Echinacea|Echinacea phytochemical profile Each tablet is comprised of the equivalent of 1275 mg of echinacea root, as follows: A) Echinacea purpurea - 675 mg root yields 112.5 mg dried extract, standardized to contain 2.1mg alkamides. B) Echinacea angustifolia - 600 mg root yields 150 mg dried extract, standardized to contain 2.0 mg alkamides. Each batch of tablets is analyzed by Reversed Phase - High Peformance Liquid Chromatography to determine the levels of alkamides and caffeic derivatives present. Caffeic acid derivative levels are typically as follows: caftaric acid = 0.5 to 2.0 mg/tablet; cichoric acid = 3.4 to 8.5 mg/tablet; chlorogenic acid = < 0.5 mg/tablet; dicaffeoyl quinic acids (including cynarin) = 0.7 to 2.0 mg/tablet; echinacoside = 1.0 to 1.7 mg/tablet
1734283|NCT00065715|Other|Blinded placebo|Blinded placebo - Coated tablet
1734284|NCT00065728|Drug|Anecortave Acetate (AL-3789) Sterile Suspension, 30 mg/mL|One 0.5 mL injection of 30 mg/mL Anecortave Acetate sterile suspension into the posterior juxtascleral depot at 6 month intervals for 18 months
1734285|NCT00065741|Drug|silymarin|
1734286|NCT00065754|Drug|placebo|
1734287|NCT00065767|Drug|Raloxifene|
1734288|NCT00065806|Drug|Atorvastatin|Participants weighing more 50 kg will receive 10 mg of atorvastatin po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
1734289|NCT00065806|Drug|Placebo atorvastatin|Participants weighing more 50 kg will receive 10 mg of placebo po qd as a starting dose, which will be increased to 20 mg po qd at the Day 30 visit and continue through month 36. Participants weighing less than 50 kg will receive a maximum of 10 mg po qd for 36 months.
1734290|NCT00065819|Behavioral|HIV Symptom Education Program|
1734291|NCT00065832|Behavioral|Reading Instruction|
1734292|NCT00065845|Procedure|Burch urethropexy at time of sacrocolpopexy|The Burch colposuspension procedure entails the retropubic placement of at least two stitches in the vaginal tissue lateral to each side of the urethra, and suspension of these stitches from Cooper's ligament (the iliopectineal line at the superior aspect of the posterior pubic bone).
1734293|NCT00065858|Drug|BufferGel|
1734294|NCT00065871|Behavioral|Contraceptive Screening by Pharmacist|
1734295|NCT00065871|Behavioral|Contraceptive Prescribing by Pharmacist|
1734296|NCT00065884|Drug|Valproate|
1734297|NCT00065897|Procedure|Amniocentesis|
1734298|NCT00065897|Procedure|Transabdominal chorionic villus sampling (TA CVS)|
1734299|NCT00065910|Behavioral|Caregiver joint attention intervention|
1734300|NCT00065923|Drug|Topiramate|
1734301|NCT00065936|Drug|Naltrexone hydrochloride|
1734302|NCT00065936|Procedure|Transcutaneous sensory nerve stimulation|
1734303|NCT00065949|Drug|magnesium sulfate|
1734304|NCT00065962|Drug|secretin, synthetic porcine|
1734305|NCT00065962|Drug|secretin, biologically derived porcine|
1734306|NCT00065975|Procedure|massage therapy|
1734307|NCT00065975|Procedure|chiropractic|
1734308|NCT00065975|Procedure|acupuncture|
1734309|NCT00065988|Device|Dispersed phase amalgam restoration /composite restoration|
1734310|NCT00066001|Drug|metronidazole|antibiotic that is particularly effective against Gram negative bacterial species
1734311|NCT00066014|Procedure|Implant Overdenture Treatment|All overdenture treatment modalities were provided to each subject using a crossover design.
1734312|NCT00066027|Drug|20 mg doxycycline hyclate|Subjects in the LDD group took 20 mg doxycycline hyclate tablets twice daily for two years
1734313|NCT00066027|Drug|Placebo|Subjects in the placebo group took a placebo look-alike twice daily for two years.
1734314|NCT00066040|Drug|Cervitec chlorhexidine varnish|
1734315|NCT00066040|Drug|Duraphat fluoride varnish|
1734316|NCT00066040|Drug|xylitol gum from Fennobon, Finland|
1734317|NCT00066053|Procedure|Periodontal Treatment: SRP|Scaling and root planing. Subgingival tissue removal. Fluorides as needed. Oral hygiene instructions. Oral hygiene instructions.
1734318|NCT00066053|Procedure|Referral|
1734319|NCT00066066|Procedure|Scaling and root planing|Scaling and root planning (SRP) is the mechanical debridement of the tooth and root surfaces and is standard of care in periodontal therapy.
1734320|NCT00066066|Drug|Metronidazole|Metronidazole (MET) is an antibiotic that is particularly effective against Gram negative bacterial species. The dose for this study is: 250 mg tid x 14d.
1734321|NCT00066066|Drug|Amoxicillin|Amoxicillin (AMOX) is a broad spectrum antibiotic and was prescribed at 500 mg tid for 14d.
1734322|NCT00066066|Drug|Doxycycline|The ATRIDOX (doxycycline hyclate) ® product is a subgingival controlled-release product composed of a two syringe mixing system. Syringe A contains 450 mg of the ATRIGEL® Delivery System, which is a bioabsorbable, flowable polymeric formulation composed of 36.7% poly(DLlactide) (PLA) dissolved in 63.3% N-methyl-2-pyrrolidone (NMP). Syringe B contains 50 mg of doxycycline hyclate which is equivalent to 42.5 mg doxycycline. The constituted product is a pale yellow to yellow viscous liquid with a concentration of 10% of doxycycline hyclate. Upon contact with the crevicular fluid, the liquid product solidifies and then allows for controlled release of drug for a period of 7 days. Doxycycline is a broad-spectrum antibiotic synthetically derived from oxytetracycline.
1734323|NCT00066079|Procedure|massage|
1734324|NCT00066079|Behavioral|relaxation|
1734325|NCT00066092|Drug|pegfilgrastim 12 mg|Pegfilgrastim 12 mg given once for PBPC mobilization
1734326|NCT00066092|Drug|filgrastim|Filgrastim given daily for PBPC mobilization
1734327|NCT00066092|Drug|pegfilgrastim 6 mg|Pegfilgrastim 6 mg given once for PBPC mobilization
1734328|NCT00066118|Device|Dental amalgam restorations|
1734329|NCT00066131|Procedure|Periodontal scaling and root planing|Hard and soft tisse deposits (plaque and calculus) are removed from the tooth and tooth root using hand and ultrasonic instruments.
1734330|NCT00066131|Procedure|Scaling and root planing|Delivered using hand and powered scalers and with topical or local (injected) anesthetics as needed. Procedures performed over 1 to 4 90-minute visits.
1734331|NCT00066144|Drug|Cimicifuga racemosa|
1734332|NCT00066144|Drug|Trifolium pratense|
1734333|NCT00066144|Drug|Black cohosh|
1734334|NCT00066144|Drug|Red clover|
1734335|NCT00066157|Drug|Transdermal estradiol|50 micrograms (low-dose) or 100 micrograms (high-dose) transdermal 17-ß-estradiol patch, changed every 3 days, for 12 months
1734336|NCT00066157|Drug|Medroxyprogesterone|2.5mg tablet daily for 12 months
1734337|NCT00066157|Drug|Placebo Patch|Transdermal placebo patch, changed every 3 days, for 12 months
1734338|NCT00066157|Drug|Placebo|Placebo tablet daily for 12 months
1734339|NCT00066170|Drug|Xyrem|Xyrem oral solution at 6 g/day for 4 weeks and 9 g/day for another 4 weeks.
1734340|NCT00066170|Drug|Xyrem Placebo|Xyrem Placebo oral solution 12 ml per day for 4 weeks and 18 ml per day for another 4 weeks.
1734341|NCT00066170|Drug|Modafinil at established dose|Modafinil oral capsules at 200 to 600 mg per day for 8 weeks.
1734342|NCT00066170|Drug|Modafinil (Placebo)|Modafinil Placebo oral capsules 1 to 3 capsules per day for 8 weeks.
1734343|NCT00066196|Biological|MEDI--522|IV administration supplied in 10 mL vials containing 100 mg of MEDI-522 at a concentration of 10 mg/mL.
1734344|NCT00066196|Biological|Integrin + Dacarbazine|supplied in other formulations
1734345|NCT00066222|Drug|Cisplatin|60 mg/m2 given intravenously. During RT, give on day 1 and day 22. After completion of RT, on days 43 and 64.
1734346|NCT00066222|Drug|Etoposide|120 mg/m2 given intravenously. During RT, give on days 1-3, then days 22-24. After completion of RT, on days 43-45 and days 64-66.
1734347|NCT00066222|Radiation|Radiation therapy|Large field 28.8 Gy: 1.8 Gy per fraction, 5 days per week for 16 fractions. On days 23-26, BID: use anteroposterior and posteroanterior (AP/PA) fields in a.m. at 1.8 Gy per fraction; boost with 2nd treatment in p.m. at 1.8 Gy per fraction. Then off-cord boost, 1.8 Gy, BID, x last 5 days for a total dose of 61.2 Gy in 5 wks.
1734348|NCT00066248|Drug|cyproheptadine hydrochloride|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
1734349|NCT00066248|Drug|megestrol acetate|Receive 0.25mg/kg cyproheptadine hydrochloride once daily for 4 weeks. If subject responds to treatment (stable or increased weigh), go off study. If subject does not respond (loses weigh), subject will switch to10 mg/lg/day of megestrol acetate for 4 weeks.
1734350|NCT00066274|Drug|FOLFIRI regimen|
1734351|NCT00066274|Drug|FOLFOX regimen|
1734352|NCT00066274|Drug|fluorouracil|
1734353|NCT00066274|Drug|irinotecan hydrochloride|
1734354|NCT00066274|Drug|leucovorin calcium|
1734355|NCT00066274|Drug|oxaliplatin|
1734356|NCT00066313|Drug|vandetanib|
1734357|NCT00066313|Procedure|adjuvant therapy|
1734358|NCT00066326|Drug|imatinib mesylate|
1734359|NCT00066326|Drug|tanespimycin|
1734360|NCT00066339|Drug|gefitinib|
1734361|NCT00066352|Drug|bortezomib|
1734362|NCT00066365|Biological|sargramostim|given by inhalation, dosage escalation Level 1 Dose: 240 micrograms, Level 2 Dose: 1,000 micrograms, and Level 3 Dose: 1,750 micrograms.
1734363|NCT00066365|Procedure|conventional surgery|thoracotomy
1734364|NCT00066378|Drug|anastrozole|
1734365|NCT00066378|Drug|gefitinib|
1734366|NCT00066391|Drug|cisplatin|
1734367|NCT00066391|Drug|irinotecan hydrochloride|
1734368|NCT00066391|Procedure|neoadjuvant therapy|
1734369|NCT00066404|Biological|recombinant adenovirus-hIFN-beta|
1734370|NCT00066417|Drug|cyclophosphamide|
1734371|NCT00066417|Drug|cyclosporine|
1734372|NCT00066417|Drug|fludarabine phosphate|
1734373|NCT00066417|Drug|methylprednisolone|
1734374|NCT00066417|Drug|therapeutic allogeneic lymphocytes|
1734375|NCT00066417|Drug|thiotepa|
1734376|NCT00066417|Procedure|allogeneic bone marrow transplantation|
1734377|NCT00066417|Procedure|biological therapy|
1734378|NCT00066417|Procedure|bone marrow ablation with stem cell support|
1734379|NCT00066417|Procedure|bone marrow transplantation|
1734380|NCT00066417|Procedure|chemotherapy|
1734381|NCT00066417|Procedure|leukocyte therapy|
1734382|NCT00066417|Procedure|non-specific immune-modulator therapy|
1734383|NCT00066417|Procedure|peripheral blood lymphocyte therapy|
1734384|NCT00066417|Procedure|peripheral blood stem cell transplantation|
1734385|NCT00066417|Procedure|radiation therapy|
1734386|NCT00066430|Procedure|infrared photocoagulation therapy|
1734387|NCT00066430|Device|Infrared Coagulator|IRC treatment of up to 3 HGAIN lesions at baseline (study initiation). A second IRC treatment may be administered for recurrent lesions at the 3 month visit.
1734388|NCT00066443|Biological|pegfilgrastim|Dose escalation schedule A&B = 6mg fixed dose once per cycle on day 2
1734389|NCT00066443|Drug|docetaxel|Dose Escalation schedule A = 75-85 mg/m2 Dose Escalation schedule B = 50-75 mg/m2
1734390|NCT00066443|Drug|epirubicin hydrochloride|Dose escalation schedule A = 75-120 mg/m2 IV Dose escalation schedule B = 50-90 mg/m2 IV
1734391|NCT00066456|Radiation|3-Dimensional Conformal Radiation Therapy|
1734392|NCT00066456|Drug|Chemosensitization/Potentiation Therapy|
1734393|NCT00066456|Drug|Docetaxel|Given IV
1734394|NCT00066469|Biological|rituximab|Cycles 1 and 2 only: Given IV Incremental: First dosage: < 21 years of age: 0.5mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 50 mg/hr for the 1st hour. Subsequent dosages: < 21 years of age: 1.0mg/kg/hr (maximum of 50 mg/hr) for the 1st hour ≥ 21 years of age: 100 mg/hr for the 1st hour. Days 1, 8 and 15.
1734395|NCT00066469|Drug|cyclophosphamide|Given IV over 30-60 minutes Dose 600 mg/m2 in 50-250 mL of normal saline (NS) or Dextrose-Water 5%(D5W) (at a maximum concentration of 20 mg/ml) over 30-60 minutes on day 1 of each cycle
1734396|NCT00066469|Drug|methylprednisolone|Methylprednisolone 0.8 mg/kg IV over 12 hours on days 1,2,3,4 and 5 of each cycle.
1734397|NCT00066469|Drug|prednisone|Dosage 1 mg/kg orally every 12 hours on days 1,2,3,4 and 5 of each cycle. Oral prednisone may be rounded up to the nearest 2.5 mg as necessary for tablet size
1734398|NCT00066482|Biological|bleomycin sulfate|Given IV over 10 minutes. Children ≥ 12 months: 15 units/m2/dose Children < 12 months: 0.5 units/kg/dose Day 1 (Week 1, 4, 7, 10)
1734399|NCT00066482|Biological|filgrastim|Given SQ once daily 5 micrograms/kg/dose Starting on Day 6 (Week 1, 4, 7, 10) Daily until ANC > 5,000/uL
1734400|NCT00066482|Drug|cisplatin|Children ≥ 12 months: Given IV over one hour Dose: 20 mg/m2/dose Days 1-5 (Week 1,4,7,10) Children < 12 months: Given IV over 4 hours, 0.67 mg/kg/dose Days 1-5 (Week 1,4,7,10)
1734401|NCT00066482|Drug|cyclophosphamide|Given IV over 1 hour. Children ≥ 12 months: Level 1: 1.2 g/m2/dose Level 2: 1.8 g/m2/dose Level 3: 2.4 g/m2/dose Children < 12 months: Level 1: 40 mg/kg/dose Level 2: 60 mg/kg/dose Level 3: 80 mg/kg/dose Day 1 (Week 1, 4, 7, 10)
1734402|NCT00066482|Drug|etoposide|Given IV over 1 hour. Children ≥ 12 months: 100 mg/m2/dose Children < 12 months: 3.3 mg/kg/dose Day 1-5 (Week 1, 4, 7, 10)
1734403|NCT00066482|Procedure|conventional surgery|Stage III/IV extragonadal tumors: biopsy followed by a definitive surgical excision after maximal chemotherapy effect, likely after 4 cycles of therapy
1734404|NCT00066482|Biological|MESNA|Given IV or oral. The total daily MESNA dose is equal to at least 80% of the daily CPM dose. The oral dose of MESNA is 2x the IV dose. Day 1 (Week 1,4,7,10) To be given with CPM.
1734405|NCT00066508|Drug|bortezomib|
1734406|NCT00066547|Biological|monoclonal antibody HuHMFG1|
1734409|NCT00066586|Drug|exemestane|exemestane 25 mg once daily x 1 year
1734410|NCT00066586|Drug|Placebo|placebo once daily x 1 year
1734411|NCT00066599|Drug|voriconazole|
1734412|NCT00066612|Drug|irinotecan hydrochloride|Irinotecan will be given 250 mg/m^2 through intravenous (IV) for 90 minutes on day 1 for every 21 days until tumor progression or unacceptable toxicity or other reason for discontinuation occurs
1734413|NCT00066625|Drug|oxaliplatin|Given IV
1734414|NCT00066625|Drug|bortezomib|Given IV
1734415|NCT00066625|Other|laboratory biomarker analysis|Correlative studies
1734416|NCT00066625|Other|pharmacological study|Correlative studies
1734417|NCT00066638|Drug|Romidepsin|Given IV
1734418|NCT00066638|Other|Laboratory Biomarker Analysis|Correlative studies
1734419|NCT00066651|Biological|SS1(dsFv)-PE38 immunotoxin|
1734420|NCT00066664|Genetic|proteomic profiling|
1734423|NCT00066690|Drug|Exemestane|Exemestane 25mg orally daily for 5 years plus ovarian function suppression
1734424|NCT00066690|Other|Laboratory Biomarker Analysis|Correlative studies
1734425|NCT00066690|Procedure|Oophorectomy|Undergo bilateral surgical oophorectomy
1734426|NCT00066690|Other|Quality-of-Life Assessment|Ancillary studies
1734427|NCT00066690|Radiation|Radiation Therapy|Undergo ovarian irradiation
1734428|NCT00066690|Drug|Tamoxifen|Tamoxifen 20mg orally daily for 5 years
1734429|NCT00066690|Drug|Triptorelin|3.75 mg by im injection q28 days for 5 years
1734430|NCT00066703|Drug|exemestane|
1734431|NCT00066703|Drug|tamoxifen|
1734432|NCT00066703|Drug|triptorelin|
1734433|NCT00066716|Drug|carboplatin|Dosed to an AUC of 6 by the Calvert formula, intravenously over 1 hour after paclitaxel on days 1, 22, and 43.
1734974|NCT00070174|Drug|daunorubicin hydrochloride|
1734975|NCT00070174|Drug|etoposide|
1734434|NCT00066716|Drug|celecoxib|400 mg orally BID begins 3-7 days before the first dose of chemotherapy to the morning of surgery. Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year total, that is, 1 year from the date of surgery + 2 weeks unless tumor recurrence is documented.
1734435|NCT00066716|Drug|paclitaxel|200 mg/m2 as a 3-hour intravenous infusion on days 1, 22, and 43.
1734436|NCT00066716|Procedure|adjuvant therapy|"Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.
Operation will be performed within 6-12 hours from the last dose of celecoxib.
Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection.
Celecoxib 400 mg orally BID will resume post-operatively 4-8 weeks if there is adequate wound healing and will be continued for 1 year."
1734437|NCT00066716|Procedure|conventional surgery|"Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.
Operation will be performed within 6-12 hours from the last dose of celecoxib.
Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
1734438|NCT00066716|Procedure|neoadjuvant therapy|"Surgery will be performed 3-4 weeks after the third dose of paclitaxel and carboplatin.
Operation will be performed within 6-12 hours from the last dose of celecoxib.
Surgery will include an esophagectomy as well as a complete mediastinal and abdominal lymph node dissection."
1734439|NCT00066729|Biological|NY-ESO-1 peptide vaccine|
1734440|NCT00066729|Biological|incomplete Freund's adjuvant|
1734441|NCT00066742|Drug|tirapazamine|Given IV
1734442|NCT00066742|Drug|cisplatin|Given IV
1734443|NCT00066742|Drug|etoposide|Given IV
1734444|NCT00066742|Radiation|radiation therapy|Undergo radiation therapy
1734445|NCT00066742|Other|laboratory biomarker analysis|Correlative studies
1734446|NCT00066768|Drug|suramin|Given IV
1734447|NCT00066768|Drug|docetaxel|Given IV
1734448|NCT00066768|Drug|gemcitabine hydrochloride|Given IV
1734449|NCT00066768|Other|laboratory biomarker analysis|Correlative studies
1734450|NCT00066768|Other|pharmacological study|Correlative studies
1734451|NCT00066781|Drug|gemcitabine hydrochloride|Given IV
1734452|NCT00066781|Drug|irinotecan hydrochloride|Given IV
1734453|NCT00066794|Biological|filgrastim|5 mcg/kg/d IV or SC starting apx day 15
1734454|NCT00066794|Biological|sargramostim|250 mcg/kg/d IV or SC starting apx day 15
1734455|NCT00066794|Drug|cyclosporine|ind: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-74 consol: 6 mg/kg load IV over 2 hrs days 0-2 followed by 16 mg/dg/d continuous IV days 2-50
1734456|NCT00066794|Drug|cytarabine|ind: 200 mg/m2/d cont IV days 2-74
1734457|NCT00066794|Drug|daunorubicin hydrochloride|ind: 45 mg/m2/d cont IV days 2-74
1734458|NCT00066807|Drug|chemotherapy|Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
1734459|NCT00066807|Drug|exemestane|Exemestane 25 mg orally daily for until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
1734460|NCT00066807|Drug|tamoxifen|Tamoxifen 20 mg orally daily until 5 years from date of randomization, unless relapse or intolerance should occur earlier.
1734461|NCT00066807|Drug|triptorelin|Triptorelin (GnRH analogue) 3.75 mg by intramuscular injection every 28 days for 5 years from randomization, unless relapse or intolerance should occur earlier or surgical oophorectomy or ovarian irradiation is subsequently performed.
1734462|NCT00066807|Procedure|oophorectomy|Bilateral surgical oophorectomy via laparotomy or laparoscopy.
1734463|NCT00066807|Procedure|ovarian irradiation|Bilateral ovarian irradiation.
1734464|NCT00066846|Biological|bevacizumab|
1734465|NCT00066846|Drug|fluorouracil|
1734466|NCT00066846|Drug|leucovorin calcium|
1734467|NCT00066859|Drug|Zoloft 50 mg|Zoloft 50 mg by mouth daily for 1 week if tolerated dose may be increased to 100 mg daily for 4 months
1734468|NCT00066859|Dietary Supplement|St. John's Wort 600 mg|St. John's wort 600 mg daily for 1 week, if tolerated. Dose may be increased to 900 mg daily for 4 months.
1734469|NCT00066872|Drug|imiquimod|
1734470|NCT00066872|Procedure|conventional surgery|
1734471|NCT00066885|Drug|calcitriol + docetaxel|
1734472|NCT00066898|Drug|AGI-1067|
1734473|NCT00066937|Drug|Nortriptyline Oral Capsule|Nortriptyline will be titrated up from 25 mg qhs to a maximum dose of 150 mg qhs based on treatment response and side effect profile.
1734474|NCT00066937|Drug|Benztropine Oral Product|Benztropine will be titrated up from .125 mg qhs to a maximum dose of .750 mg qhs based on treatment response and side effect profile.
1734475|NCT00066937|Behavioral|CBT|Six in-person, individual sessions of cognitive-behavioral therapy for pain management include relaxation training, pain coping skills training, cognitive therapy for negative and dysfunctional thoughts, and diaries for monitoring relaxation, goals, and negative thinking.
1734476|NCT00066937|Behavioral|Disease MGT|Six in-person, individual sessions of temporomandibular joint disorder (TMD) disease management (MGT) that include information about the jaw and good oral habits, diet, sleep, and general stress management.
1734477|NCT00066950|Drug|Chlorhexidine gluconate|0.5oz chlorhexidine gluconate 0.12% solution mouth rinse twice daily for 14 days then no rinse for 14 days, repeated for 3 months
1734478|NCT00066950|Device|Fluoride Varnish|0.25ml FV every 6 months from age 12 to 30 months
1734479|NCT00066963|Device|Fluoride Varnish|0.1 mL (1 drop) applied on each of 2 arches
1734480|NCT00066989|Drug|Staphylococcus aureus Immune Globulin (Human) 5%|
1956479|NCT02834832|Device|PECVD coating|SiO2/SiC coatings will be applied to the surface of removable partial dentures and denture teeth.
1734881|NCT00069732|Behavioral|qigong|
1734490|NCT00067015|Drug|bicalutamide|
1734491|NCT00067015|Drug|goserelin acetate|
1734492|NCT00067015|Procedure|assessment of therapy complications|
1734493|NCT00067015|Procedure|quality-of-life assessment|
1734494|NCT00067015|Radiation|radiation therapy|
1734495|NCT00067028|Drug|Clofarabine|30 - 40 mg/m^2 by vein over 1 hour daily for 5 days.
1734496|NCT00067028|Drug|Idarubicin|"Clofarabine + Idarubicin:
10 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle.
Clofarabine + Idarubicin plus Ara-C:
6 mg/m^2 by vein over 30 minutes, around one hour after clofarabine, for the first 3 days of 5 day cycle."
1734497|NCT00067028|Drug|Ara-C|Starting dose: 0.75 g/m^2 by vein over 2 hours for 5 days in a row, on Days 1 to 5 of each cycle.
1734498|NCT00067041|Drug|Remodulin (treprostinil sodium) Injection|
1734499|NCT00067080|Drug|ICL670, deferoxamine|
1734500|NCT00067093|Drug|SanOrg34006|
1734501|NCT00067093|Drug|LMW heparin|
1734502|NCT00067093|Drug|Unfractionated heparin|
1734503|NCT00067093|Drug|Vitamin K antagonist (VKA)|
1734504|NCT00067119|Drug|Aggrenox|
1734505|NCT00067119|Drug|Placebo|
1734506|NCT00067132|Procedure|Juven (nutritional), HMB (nutritional)|
1734507|NCT00067145|Behavioral|Face-to-face maintenance program|
1734508|NCT00067145|Behavioral|Internet maintenance program|
1734509|NCT00067158|Drug|nicotine transdermal system|
1734510|NCT00067171|Behavioral|Behavior Therapy|
1734511|NCT00067184|Device|Toitu 320/325|Fetal monitor
1734512|NCT00067210|Device|Head and Neck Cooling System|
1734513|NCT00067236|Drug|PG-116800 (given as PG-530742)|200 mg tablet of PG-116800 (given as PG-530742)twice a day for 90 days
1734514|NCT00067236|Drug|Placebo tablet|placebo tablet, twice a day for 90 days
1734515|NCT00067262|Drug|Divalproex Sodium Extended-Release Tablets|
1734516|NCT00067288|Behavioral|Meaning-Centered Group Psychotherapy|
1734517|NCT00067288|Behavioral|Standard Supportive Group Psychotherapy|
1734518|NCT00067301|Drug|Polyunsaturated Fatty Acids (PUFA)|
1734519|NCT00067301|Drug|Citalopram|
1734520|NCT00067314|Drug|Edotecarin|
1734521|NCT00067327|Drug|Inosine|
1734522|NCT00067340|Drug|Chlorhexidine mouth rinse|women received daily chlorhexidine oral rinses for two weeks prior to delivery of the infant.
1734523|NCT00067340|Other|Xylitol chewing gum|Women were asked to chew xylitol chewing gum three times per day following the birth of their infant for up to two years postpartum
1734524|NCT00067353|Drug|Fluoride varnish|
1734525|NCT00067366|Behavioral|Cognitive-Behavioral treatment|Cognitive-Behavioral skills training for chronic pain
1734526|NCT00067366|Behavioral|Attention and lifestyle counseling|Attention and lifestyle counseling added to Standard Care
1734527|NCT00067379|Procedure|interceptive orthodontic treatments|orthodontic procedures
1734528|NCT00067392|Procedure|Dental Implant|Dental Implant 4 month time frame
1734529|NCT00067405|Drug|Intravenous micronutrient therapy|
1734530|NCT00067431|Drug|Divalproex Sodium (Depakote® Sprinkle Capsules)|
1734531|NCT00067444|Drug|Paroxetine CR|
1734532|NCT00067457|Drug|alosetron|
1734533|NCT00067470|Drug|Placebo|
1734534|NCT00067470|Drug|N-acetylgalactosamine 4-sulfatase|
1734535|NCT00067496|Drug|Modafinil|
1734536|NCT00067509|Drug|emergency contraception (estrogen/progesterone)|
1734539|NCT00067535|Drug|Cocaine-Related Disorders|
1734540|NCT00067548|Drug|EKB-569|
1734541|NCT00067561|Drug|Alosetron|
1734542|NCT00067574|Behavioral|Structured treatment interruption|
1734543|NCT00067600|Behavioral|Diet with increased fruits, vegetables, and calcium|
1734544|NCT00067600|Behavioral|Increased high impact activity and resistance training|
1734545|NCT00067613|Other|Benchmarking Management Practices|"The Benchmarking intervention included:
Data feedback: Using existing data from the NRN Generic Database and Key Care Practices Survey at their NICU to collect data on the perceptions of care.
Training in Continuous Quality Improvement (CQI) Techniques
Review of best existing evidence
Site visits to the Centers with the Lowest Rates of BPD
Selection of Practices to change: Each site team selected practices for modification at their own center"
1734546|NCT00067613|Other|Standard Management Practices|Centers assigned to the control group continued to receive routine information on their own center's outcomes, and all information routinely supplied within the NRN. Control centers did not participate in organized discussions of the interventions applied within the Benchmarking centers. At the completion of the study, Control Centers were offered a workshop on the Benchmarking techniques.
1734547|NCT00053716|Drug|Liprostin [liposomal Prostaglandin E1]|
1734548|NCT00053742|Drug|Modified Vaccinia Virus Ankara TBC-MVA|
1734549|NCT00053768|Biological|filgrastim|
1734550|NCT00053768|Drug|EPOCH regimen|
1734551|NCT00053768|Drug|cyclophosphamide|
1734552|NCT00053768|Drug|doxorubicin hydrochloride|
1734553|NCT00053768|Drug|etoposide|
1734554|NCT00053768|Drug|prednisone|
1734555|NCT00053768|Drug|vincristine sulfate|
1734556|NCT00053768|Radiation|radiation therapy|
1734557|NCT00053781|Drug|perifosine|
1734558|NCT00053794|Drug|perifosine|
1734559|NCT00053807|Biological|aldesleukin|
1734560|NCT00053807|Biological|recombinant interferon alfa|
1734561|NCT00053807|Drug|fluorouracil|
1734562|NCT00053807|Procedure|adjuvant therapy|
1734563|NCT00053820|Biological|aldesleukin|
1734564|NCT00053820|Biological|recombinant interferon alfa|
1734565|NCT00053820|Drug|fluorouracil|
1734566|NCT00053833|Drug|irinotecan|
1734882|NCT00069732|Behavioral|acupressure-TAT|
1734567|NCT00053846|Drug|buspirone hydrochloride|The dose of buspirone will be 10 mg taken by mouth at bedtime for 3 days, then twice each day, in the morning and at bedtime for the remainder of the 28 day study period
1734568|NCT00053846|Drug|Placebo|Placebo
1734569|NCT00053872|Drug|cisplatin|
1734570|NCT00053872|Drug|lomustine|
1734571|NCT00053872|Drug|vincristine sulfate|
1734572|NCT00053872|Procedure|adjuvant therapy|
1734573|NCT00053872|Radiation|radiation therapy|
1734574|NCT00053885|Drug|PTK787/ZK 222584|oral
1734575|NCT00053898|Drug|anastrozole|1 mg/day and placebo for 5 years
1734576|NCT00053898|Drug|tamoxifen citrate|20 mg/day and placebo for 5 years
1734577|NCT00053898|Radiation|Radiation Therapy|Adjuvant radiation therapy
1734578|NCT00053911|Drug|anastrozole|
1734579|NCT00053911|Drug|cyclophosphamide|
1734580|NCT00053911|Drug|docetaxel|
1734581|NCT00053911|Drug|epirubicin hydrochloride|
1734582|NCT00053911|Drug|fluorouracil|
1734583|NCT00053911|Drug|goserelin acetate|
1734584|NCT00053911|Drug|tamoxifen citrate|
1734585|NCT00053911|Procedure|adjuvant therapy|
1734586|NCT00053924|Drug|perifosine|
1734587|NCT00053937|Drug|pirfenidone|
1734588|NCT00053950|Drug|pyrazoloacridine|Given IV
1734589|NCT00053950|Biological|filgrastim|Given IV or SC
1734590|NCT00053950|Procedure|autologous bone marrow transplantation|Undergo autologous bone marrow transplantation
1734591|NCT00053950|Procedure|peripheral blood stem cell transplantation|Undergo peripheral blood stem cell transplantation
1734592|NCT00053950|Other|laboratory biomarker analysis|Correlative studies
1734593|NCT00053950|Other|pharmacological study|Correlative studies
1734594|NCT00053963|Drug|romidepsin|Given IV
1734595|NCT00053976|Biological|Daclizumab|
1734596|NCT00053976|Drug|methylprednisolone|
1734597|NCT00053976|Drug|Placebo|
1734598|NCT00053989|Biological|anti-thymocyte globulin|iv
1734599|NCT00053989|Biological|graft-versus-tumor induction therapy|iv
1734600|NCT00053989|Biological|sargramostim|iv
1734601|NCT00053989|Biological|therapeutic allogeneic lymphocytes|iv
1734602|NCT00053989|Drug|cyclophosphamide|injection
1734603|NCT00053989|Drug|fludarabine phosphate|iv
1734604|NCT00053989|Drug|methylprednisolone|oral
1734605|NCT00053989|Drug|mycophenolate mofetil|oral
1734606|NCT00053989|Drug|tacrolimus|oral
1734607|NCT00053989|Procedure|allogeneic bone marrow transplantation|iv
1734608|NCT00053989|Procedure|peripheral blood stem cell transplantation|iv
1734609|NCT00053989|Procedure|umbilical cord blood transplantation|iv
1734610|NCT00054002|Procedure|adjuvant therapy|Lung surgery
1734611|NCT00054002|Procedure|conventional surgery|Lung surgery
1734612|NCT00054002|Drug|porfimer sodium|iv
1734613|NCT00054015|Drug|triapine|
1734614|NCT00054028|Drug|suramin|Given IV
1734615|NCT00054028|Drug|paclitaxel|Given IV
1734616|NCT00054028|Other|pharmacological study|Correlative studies
1734617|NCT00054041|Biological|HspE7|Given subcutaneously
1734618|NCT00054041|Procedure|therapeutic conventional surgery|Undergo large loop excision
1734619|NCT00054041|Other|laboratory biomarker analysis|Correlative studies
1734620|NCT00054054|Drug|cisplatin|
1734621|NCT00054054|Drug|docetaxel|
1734622|NCT00054054|Drug|fluorouracil|
1734623|NCT00054054|Radiation|radiation therapy|
1734624|NCT00054067|Drug|cisplatin|
1734625|NCT00054067|Procedure|adjuvant therapy|
1734626|NCT00054067|Procedure|conventional surgery|
1734627|NCT00054067|Radiation|brachytherapy|
1734628|NCT00054067|Radiation|radiation therapy|
1734629|NCT00054106|Drug|buserelin|
1734630|NCT00054106|Drug|custirsen sodium|
1734631|NCT00054106|Drug|flutamide|
1734632|NCT00054106|Procedure|conventional surgery|
1734633|NCT00054106|Procedure|neoadjuvant therapy|
1734634|NCT00054119|Drug|Cositecan|Given IV
1734635|NCT00054119|Other|Pharmacological Study|Correlative studies
1734636|NCT00054132|Biological|Bevacizumab|Given IV
1734637|NCT00054132|Drug|Erlotinib Hydrochloride|Given PO
1734638|NCT00054132|Other|Laboratory Biomarker Analysis|Correlative studies
1734639|NCT00054145|Drug|perifosine|
1734640|NCT00054158|Drug|dexamethasone|
1734641|NCT00054158|Drug|doxorubicin hydrochloride|
1734642|NCT00054158|Drug|thalidomide|
1734643|NCT00054158|Drug|vincristine sulfate|
1734644|NCT00054171|Drug|aminolevulinic acid hydrochloride|
1734645|NCT00054184|Drug|docetaxel|
1734646|NCT00054184|Drug|paclitaxel poliglumex|
1734647|NCT00054197|Drug|gemcitabine hydrochloride|
1734648|NCT00054197|Drug|paclitaxel poliglumex|
1734649|NCT00054197|Drug|vinorelbine tartrate|
1734650|NCT00054210|Drug|carboplatin|
1734651|NCT00054210|Drug|paclitaxel|
1734652|NCT00054210|Drug|paclitaxel poliglumex|
1734653|NCT00054223|Procedure|psychosocial assessment and care|
1734654|NCT00054236|Biological|anti-thymocyte globulin|anti-thymocyte globulin (ATG) IV over at least 4 hours on days -2 to -1
1734655|NCT00054236|Biological|filgrastim|Patients receive filgrastim (G-CSF) subcutaneously beginning on day 7 and continuing until blood counts recover.
1734656|NCT00054236|Drug|cyclophosphamide|cyclophosphamide IV over 2 hours on days -3 to -2
1734657|NCT00054236|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
1734658|NCT00054236|Procedure|umbilical cord blood transplantation|Patients undergo multiple unit umbilical cord blood transplantation on days 0-1.
1734659|NCT00054236|Drug|methylprednisolone|Patients unable to tolerate ATG may receive methylprednisolone IV over 1 hour on days -3 to -1.
1734660|NCT00054249|Drug|T900607|
1734661|NCT00054262|Drug|T900607|
1734883|NCT00069745|Drug|Satraplatin|
1734884|NCT00069745|Drug|Prednisone|
1734662|NCT00054275|Drug|docetaxel|Docetaxel IV infusion weekly for 3 weeks with a one-week break. One cycle is 4 weeks (28 days). Patients' actual weight will be used to calculate dose.
1734663|NCT00054275|Drug|erlotinib hydrochloride|OSI-774 will be taken 1 hour before or 2 hours after meals. Cycle 1 will be administered at dose level -1.If no grade 3 or 4 toxicity occurs during cycle 1, then the patient may proceed to be treated at dose level 0 for the remaining chemotherapy cycles.
1734664|NCT00054288|Drug|gemcitabine hydrochloride|
1734665|NCT00054288|Drug|irinotecan hydrochloride|
1734666|NCT00054301|Procedure|adjuvant therapy|
1734667|NCT00054301|Procedure|conventional surgery|Patients undergo excisional biopsy or surgery.
1734668|NCT00054301|Radiation|intraoperative radiation therapy|Patients undergo excisional biopsy or surgery followed by an intraoperative dose of radiation to the tumor cavity.
1734669|NCT00054314|Drug|ortataxel|
1734670|NCT00054327|Drug|busulfan|Given orally 1mg/kg/dose (or 40mg/m2/dose for young children)
1734671|NCT00054327|Drug|cyclophosphamide|Given IV
1734672|NCT00054327|Drug|cytarabine|Given IV
1734673|NCT00054327|Radiation|radiation therapy|Patients undergo total body irradiation
1734674|NCT00054327|Drug|Etoposide|infusion
1734675|NCT00054327|Procedure|Stem Cell Transfusion|
1734676|NCT00054340|Biological|anti-thymocyte globulin|
1734677|NCT00054340|Drug|busulfan|
1734678|NCT00054340|Drug|cyclophosphamide|
1734679|NCT00054340|Drug|cyclosporine|
1734680|NCT00054340|Drug|methotrexate|
1734681|NCT00054340|Procedure|allogeneic bone marrow transplantation|
1734682|NCT00054340|Procedure|peripheral blood stem cell transplantation|
1734691|NCT00054392|Drug|carboplatin|
1734692|NCT00054392|Drug|gemcitabine hydrochloride|
1734693|NCT00054392|Drug|paclitaxel|
1734694|NCT00054405|Biological|recombinant interleukin-12|Given IV
1734695|NCT00054405|Biological|aldesleukin|Given IV
1734696|NCT00054418|Dietary Supplement|calcium carbonate|calcium 600 mg daily administered orally for one year
1734697|NCT00054418|Dietary Supplement|vitamin D|vitamin D 400 U daily administered orally for one year
1734698|NCT00054418|Drug|risedronate sodium|risedronate 35 mg weekly administered orally
1734699|NCT00054418|Other|placebo|placebo tablet weekly administered orally for one year
1734700|NCT00054431|Drug|imatinib mesylate|Given orally
1734701|NCT00054431|Drug|decitabine|Given IV
1734702|NCT00054431|Other|laboratory biomarker analysis|Correlative studies
1734703|NCT00054444|Drug|Topotecan Hydrochloride Liposomes|Given IV
1734704|NCT00054444|Radiation|3-Dimensional Conformal Radiation Therapy|
1734705|NCT00054444|Drug|Cisplatin|Given IV
1734706|NCT00054457|Drug|capecitabine|
1734707|NCT00054457|Drug|docetaxel|
1734708|NCT00054470|Biological|trastuzumab|
1734709|NCT00054470|Drug|tipifarnib|
1734710|NCT00054483|Drug|bortezomib|Given IV
1734711|NCT00054483|Other|laboratory biomarker analysis|Correlative studies
1734712|NCT00054483|Other|pharmacological study|Correlative studies
1734713|NCT00054496|Drug|erlotinib hydrochloride|
1734714|NCT00054522|Dietary Supplement|calcitriol|
1734715|NCT00054522|Drug|dexamethasone|
1734716|NCT00054535|Biological|aldesleukin|
1734717|NCT00054535|Biological|recombinant fowlpox-tyrosinase vaccine|
1734718|NCT00054535|Biological|vaccinia-tyrosinase vaccine|
1734719|NCT00054548|Biological|oblimersen sodium|Given IV
1734720|NCT00054548|Drug|paclitaxel|Given IV
1734721|NCT00054548|Other|laboratory biomarker analysis|Correlative studies
1734722|NCT00054548|Other|pharmacological study|Correlative studies
1734723|NCT00054561|Biological|recombinant interferon alfa|
1734724|NCT00054561|Dietary Supplement|vitamin E|
1734725|NCT00054561|Drug|isotretinoin|
1734726|NCT00054561|Procedure|adjuvant therapy|
1734727|NCT00054574|Biological|panitumumab|
1734728|NCT00054587|Biological|Trastuzumab|8 mg/kg at month M6, followed by a maintenance dose of 6 mg/kg every 3 weeks for a 1 year (i.e. 18 injections in total)
1734729|NCT00054587|Drug|Cyclophosphamide|500 mg/m², D1 and every 3 weeks
1734730|NCT00054587|Drug|docetaxel|on day D1 of each cycle : dose: 75 mg/m², route: i.v. injection over 1 hour, every 3 weeks
1734731|NCT00054587|Drug|Epirubicin|100 mg/m², D1 and every 3 weeks
1734732|NCT00054587|Drug|Fluorouracil|500 mg/m², D1 and every 3 weeks
1734733|NCT00054600|Drug|Methoxsalen|
1734734|NCT00054600|Procedure|Extracorporeal Photopheresis|
1734735|NCT00054613|Drug|Methoxsalen|
1734736|NCT00054613|Procedure|Extracorporeal Photopheresis|
1734737|NCT00054626|Drug|cisplatin|
1734738|NCT00054626|Drug|gemcitabine hydrochloride|
1734739|NCT00054626|Procedure|adjuvant therapy|
1734740|NCT00054639|Biological|oblimersen sodium|Given IV
1734741|NCT00054639|Biological|rituximab|Given IV
1734742|NCT00054639|Other|laboratory biomarker analysis|Correlative studies
1734743|NCT00054665|Drug|PS-341|1.3 mg/m^2 intravenous injection days 1, 4, 8, 11 every 3 weeks
1734744|NCT00054665|Drug|Etoposide|50 mg/m^2 day continuous intravenous infusion (CIV) days 1-4, 96 hour infusion. Repeat cycle every 21 days.
1734745|NCT00054665|Drug|Doxorubicin|10 mg/m^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
1734885|NCT00069758|Drug|SDX-105|
1734746|NCT00054665|Drug|Vincristine|0.4 mg/m^2 day CIV days 1-4, 96 hour infusion. Repeat cycle every 21 days.
1734747|NCT00054665|Drug|Cyclophosphamide|750 mg/m^2 day IV day 5 bolus. Repeat cycle every 21 days.
1734748|NCT00054665|Drug|Prednisone|60 mg/m^2 by mouth twice a day days 1-5. Repeat cycle every 21 days.
1734749|NCT00054665|Drug|Filgrastim|300 micrograms subcutaneously days 6 to absolute neutrophil count recovery greater than or equal to 5000/mm^3. Repeat cycle every 21 days.
1734750|NCT00054678|Drug|MyoCell™|
1734751|NCT00054678|Device|MyoCath™|
1734752|NCT00054691|Drug|Iressa|250 mg by mouth daily
1734753|NCT00054704|Drug|Riluzole|Riluzole
1734754|NCT00054704|Drug|Placebo|Placebo
1734755|NCT00054717|Drug|Tipranavir|
1734756|NCT00054717|Drug|Ritonavir(r)|
1734757|NCT00054717|Drug|Comparator Protease Inhibitor (CPI)|
1734759|NCT00054743|Procedure|Blood draw|
1734761|NCT00054795|Drug|Motexafin Gadolinium|
1734762|NCT00054808|Drug|gallium nitrate|
1734763|NCT00054821|Procedure|Ankle distraction permitting motion|External fixator is applied to ankle joint for 85 - 95 days; ankle motion is permitted
1734764|NCT00054821|Procedure|Ankle distraction without motion|External fixator is applied to ankel joint for 85 - 95 days; ankle motion is not permitted
1734765|NCT00054834|Drug|hLL2 (epratuzumab)|
1734766|NCT00054847|Procedure|saphenous vein graft|Saphenous vein harvested from the arm is used as a conduit for CABG.
1734767|NCT00054847|Procedure|radial artery graft|Radial artery harvested from the arm is used as a conduit for CABG.
1734768|NCT00054860|Biological|EP HIV-1090|
1734769|NCT00054873|Drug|tezacitabine|
1734770|NCT00054873|Drug|5-fluorouracil|
1734771|NCT00054886|Drug|SU-011,248|
1734772|NCT00054899|Biological|EP2101|
1734773|NCT00054912|Biological|EP2101|
1734774|NCT00054925|Behavioral|Personal contact (PC)|This arm uses brief, individual contacts on a monthly basis which emphasize core elements of weight maintenance. Monthly contacts with an interventionist occur for 30 months after the end of Phase I. Face-to-face contacts occur approximately every four months (e.g., three annually), with telephone contacts occurring every month between FTF contacts.
1734775|NCT00054925|Behavioral|Interactive technology (IT)|The website utilizes collaborative goal setting and problem-solving strategies to identify contingent action plans for perceived obstacles to success. In order to tailor the intervention to the needs of the participant, the action plan can be updated anytime and as frequently as desired by the individual. Participants are encouraged to input data on weight, food records, physical activity, and goals on a weekly basis. Participants are not restricted to logging on to the website only once a week. Rather, participants have the option of logging on to the website to enter data, communicate with other participants, or to seek other information, as frequently as they wish.
1734776|NCT00054938|Drug|pravastatin|
1734777|NCT00054938|Drug|aspirin|
1734778|NCT00054938|Drug|ramipril|
1734779|NCT00054938|Drug|Vitamins: B6, B12, and folate|
1734780|NCT00054938|Behavioral|heart health educational program|
1734781|NCT00054951|Drug|MTC-DOX for Injection|
1734782|NCT00054964|Drug|Albuterol HFA-BOI|Albuterol HFA breath operated inhaler, 90 mcg/sprau
1734783|NCT00054964|Drug|Albuterol HFA-MDI|Albuterol HFA multi-dose inhaler
1734784|NCT00054977|Drug|GM-CT-01|IV infusion over 30 minutes of 6 Dosages escalated from 30 to 280 mg/m2, given for 4 consecutive days in a 28 days cycle.
1734785|NCT00054977|Drug|5-fluorouracil|IV infusion over 30 minutes at Dosage of 500 mg/m2, given in-combination with GM-CT-01, for 4 consecutive days in a 28 days cycle.
1734786|NCT00055042|Drug|Vitamin E|
1734787|NCT00055068|Behavioral|Cognitive Behavioral Therapy (CBT)|
1734788|NCT00055068|Behavioral|Relaxation Training|
1734789|NCT00055081|Behavioral|Critical Time Intervention|
1734790|NCT00055107|Drug|Nitazoxanide|
1734791|NCT00055120|Drug|Emtricitabine/tenofovir disoproxil fumarate|
1734792|NCT00055120|Drug|Lopinavir/ritonavir|
1734793|NCT00055120|Drug|Stavudine|
1734794|NCT00055133|Drug|Micellar Paclitaxel for Injection|
1734795|NCT00055146|Drug|ONTAK|
1734796|NCT00055159|Procedure|Pulse-sprayed injection of recombinant tissue plasminogen activator (rtPA)|
1734797|NCT00055185|Drug|CD4-IgG2 (PRO 542)|
1734798|NCT00055198|Drug|daptomycin|
1734799|NCT00061243|Biological|HIV-1 DNA vaccine with protein vaccine boost|Three doses of DNA vaccination will be administered at weeks 0, 4, and 12, and 2 doses of protein vaccination at weeks 20 and 28
1734800|NCT00061256|Drug|Alendronate|
1734801|NCT00061256|Drug|Calcium carbonate|
1734802|NCT00061256|Drug|Vitamin D|
1734803|NCT00061269|Procedure|Videoscopic-Assisted Retroperitoneal Debridement (VARD)|
1734804|NCT00061282|Drug|Clotrimazole|One retention enema, administered nightly
1734805|NCT00061295|Procedure|Body weight support treadmill training|
1734806|NCT00061308|Drug|Topotecan|
1734807|NCT00061308|Drug|Gemcitabine|
1734808|NCT00061321|Drug|Nevirapine and mulitvitamins|Mothers: One dose of intrapartum nevirapine by mouth (200mg) at onset of labor Infants: One dose of liquid nevirapine by mouth within 72 hours of birth (2mg/kg) Infants: Liquid multivitamins (1ml/day) week 1 through week 6 post-partum Infants (Arm 2 Only): Liquid nevirapine (5 mg/day) by mouth, from week 1 through week 6 post-partum
1734811|NCT00061373|Drug|Aspirin|A single 81 mg aspirin tablet orally (or rectal suppository equivalent dose) given as soon as possible after start of standard iv tPA and consent.
1734812|NCT00061373|Drug|tinzaparin sodium|A single weight-based dose of 80 anti-Xa International Units/kilogram (IU/kg)administered by subcutaneous (SQ) injection.
1734886|NCT00069784|Drug|insulin glargine (HOE901)|Cartridges for use in a pen device, each containing 3 mL of insulin glargine 100 U/mL solution for injection
1734813|NCT00061373|Drug|eptifibatide|Eptifibatide administered iv according to dose escalation group. The five dosing groups for eptifibatide are 0, 45 µg/kg bolus, 90 µg/kg bolus, 90 µg/kg bolus plus 0.25 µg/kg/min infusion for 24 hours, and 90 µg/kg bolus plus 0.5 µg/kg/min infusion for 24 hours.
1734814|NCT00061386|Behavioral|Nutrition and physical activity program|
1734815|NCT00061412|Behavioral|Comprehensive program to improve reading and writing skills|
1734816|NCT00061425|Drug|radiolabeled epratuzumab|
1734817|NCT00061438|Drug|meropenem|
1734818|NCT00061451|Drug|Pemetrexed|
1734819|NCT00061451|Drug|Gemcitabine|
1734820|NCT00061464|Drug|pemetrexed|
1734821|NCT00061464|Drug|gemcitabine|
1734822|NCT00067626|Dietary Supplement|Chromium|500/1000 mcg oral chromium picolinate taken daily or placebo (crossover)
1734823|NCT00067639|Drug|Pegfilgrastim (Neulasta)|12 mg single injection of pegfilgrastim under the skin prior to apheresis.
1734824|NCT00067639|Procedure|Apheresis|Collection of stem cells, repeated daily until target stem cell dose reached, maximum of 5 procedures.
1734825|NCT00067652|Behavioral|Education and awareness about body image issues.|
1734826|NCT00067665|Other|Ultrafiltration|All patients participating in the trial require evaluation of dry-weight at each dialysis visit for evaluation. An initial weight loss of 0.1kg/10 kg body-weight will be prescribed per dialysis. If ultrafiltration is not tolerated based on muscle cramps, need for excessive saline or symptomatic hypotension, the intensity of ultrafiltration will be reduced by 50%. If ultrafiltration is still not tolerated, the weight loss will be further reduced by 50%. If the patient cannot tolerate at least 0.2 kg incremental weight loss per dialysis, the patient will be said to be at goal dry-weight. Thus, by this protocol, all patients must experience symptoms of volume depletion to be at dry weight.
1734827|NCT00067678|Drug|soy protein|
1734828|NCT00067691|Procedure|Acupuncture|
1734829|NCT00067704|Behavioral|Trauma writing|
1734830|NCT00067704|Behavioral|Writing about daily events|
1734831|NCT00067717|Behavioral|Distance healing|
1734832|NCT00067730|Drug|Drotrecogin Alfa (activated)|
1734833|NCT00067743|Drug|Lenalidomide|supplied as 5 mg capsules. Dosing as directed by physician but to start at 10 mg per day
1734834|NCT00067756|Drug|4-PBA|During the first 3 days of this phase baseline serum AAT levels will be determined. The participants will be then given increased amounts of 4-PBA orally in 6 divided doses (day 4-6, 30 g/day and day 7-9, 40/day
1734835|NCT00067769|Behavioral|Internet-based intervention UCanPoopToo|Internet-based intervention to administer Enhanced Toilet Training (ETT).
1734836|NCT00067769|Behavioral|treatment as usual|Routine clinical care.
1734837|NCT00067782|Drug|Atazanavir (immediate switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
1734838|NCT00067782|Drug|Atazanavir (Week 24 switch)|Capsules, Oral, 400mg, Once daily, 48 weeks.
1734839|NCT00067808|Drug|Decitabine|10 mg/m^2 by vein over 1 hour daily for 10 days
1734840|NCT00067808|Drug|Decitabine|20 mg/m2 by vein (IV) over 1 hour daily x 5 days
1734841|NCT00067808|Drug|Decitabine|20 mg/m2 subcutaneous (SQ) daily x 5 days
1734842|NCT00067834|Device|Pulsing electromagnetic field (PEMF)|
1734843|NCT00067847|Behavioral|State-directed nutrition policy change|
1734844|NCT00067860|Drug|recombinant human growth hormone|
1734845|NCT00067860|Behavioral|diet modification|
1734849|NCT00067899|Drug|Vitamin E with and without Vitamin C|
1734850|NCT00067912|Drug|Duloxetine Hydrochloride|
1734851|NCT00067912|Drug|Venlafaxine Extended Release|
1734852|NCT00067925|Behavioral|Incorporating More Physical Activity and Calcium in Teens (IMPACT) Program|
1734853|NCT00067938|Drug|lamotrigine|Lamotrigine
1734854|NCT00067951|Drug|rosiglitazone/metformin|
1734855|NCT00069524|Drug|oyster mushroom|
1734856|NCT00069537|Device|The GlucoWatch® G2™ Biographer (GW2B)|
1734857|NCT00069537|Device|The Continuous Glucose Monitoring System (CGMS™)|
1734858|NCT00069550|Drug|dextromethorphan|
1734859|NCT00069550|Drug|donepezil hydrochloride|
1734860|NCT00069563|Behavioral|Reaching Educators, Children, and Parents (RECAP)|
1734861|NCT00069576|Behavioral|nutritional counseling|
1734862|NCT00069576|Behavioral|self blood glucose monitoring|
1734863|NCT00069602|Device|Continuous Glucose Monitoring System (CGMS)|
1734864|NCT00069602|Device|GlucoWatch G2TM Biographer (GW2B)|
1734865|NCT00069615|Device|GlucoWatch® G2™ Biographer (GW2B)|
1734866|NCT00069615|Device|Continuous Glucose Monitoring System™ (CGMS)|
1734867|NCT00069628|Device|GlucoWatch® G2™ Biographer (GW2B)|
1734868|NCT00069628|Device|Continuous Glucose Monitoring System (CGMS)|
1734869|NCT00069641|Biological|Iduronate-2-sulfatase enzyme replacement therapy|Patients will receive weekly infusions of idursulfase at a dose of 0.5 mg/kg.
1734870|NCT00069641|Biological|iduronate-2-sulfatase enzyme replacement therapy|Patients will receive every other week infusions of idursulfase at a dose of 0.5 mg/kg.
1734871|NCT00069641|Biological|Placebo|Patients will receive weekly infusions of placebo.
1734872|NCT00069654|Procedure|Forearm blood flow study|
1734873|NCT00069654|Procedure|Brachial artery reactivity study|
1734874|NCT00069654|Procedure|Treadmill exercise test|
1734875|NCT00069706|Drug|AL-12182 0.003% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
1734876|NCT00069706|Other|AL-12182 Ophthalmic Solution Vehicle|Placebo
1734877|NCT00069706|Drug|Latanoprost 0.005% Ophthalmic Solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
1734878|NCT00069706|Drug|AL-12182 0.01% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
1734879|NCT00069706|Drug|AL-12182 0.03% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
1734880|NCT00069719|Drug|Glaucoma therapy|
1734887|NCT00069784|Drug|omega-3 polyunsaturated fatty acids (PUFA)|Gelatin capsules (containing icosapent ethyl esters 465 mg and doconexent ethyl esters 375 mg) for oral administration
1734888|NCT00069784|Drug|placebo|Matching placebo gelatin capsules (containing olive oil) for oral administration
1734889|NCT00069784|Device|reusable pen device for insulin injection|
1734890|NCT00069823|Drug|Esomeprazole|Proton pump inhibitor 40 mg orally twice daily
1734891|NCT00069823|Drug|Placebo proton pump inhibitor|Placebo proton pump inhibitor
1734892|NCT00069836|Drug|Rosiglitazone/metformin|
1734893|NCT00069849|Drug|ABT-089|
1734894|NCT00069862|Drug|Deferitrin (GT56-252)|
1734895|NCT00069862|Drug|desferoxamine (DFO)|
1734896|NCT00069875|Drug|Gemcitabine|
1734897|NCT00069875|Drug|LY293111|
1734898|NCT00069875|Drug|cisplatin|
1734899|NCT00069888|Drug|Docetaxel|
1734900|NCT00069901|Drug|CT-2103 (poly(L)glutamate-paclitaxel)|
1734901|NCT00069901|Drug|carboplatin|
1734902|NCT00069927|Drug|Adderall-XR®|Adderall-XR® 10 mg/day for 3-12 weeks depending on subject's response
1734903|NCT00069927|Drug|Concerta®|Concerta® 18 mg/day for 3-12 weeks depending on subject's response
1734904|NCT00069940|Biological|sargramostim|
1734905|NCT00069940|Biological|telomerase: 540-548 peptide vaccine|
1734906|NCT00069953|Biological|filgrastim|During induction therapy, patients ≤ 70 kg will receive 300 μg OR patients >70 kg will receive 480 μg subcutaneously on days 6-15 and 34-42.
1734907|NCT00069953|Biological|pegfilgrastim|During induction therapy, patients receive 6 mg subcutaneously on days 6 and 34.
1734908|NCT00069953|Drug|cisplatin|During induction therapy, patients receive 15 mg/m^2/day by IV over 1 hour on days 1-5 and 29-33. During radiotherapy, patients receive 15 mg/m^2/day by IV over 1 hour beginning on days 57-61.
1734909|NCT00069953|Drug|fluorouracil|During induction therapy, patients receive 650 mg/m^2/day by IV continuously over 96 hours beginning on days 1 and 29. During radiotherapy, patients receive 300 mg/m^2/day by IV continuously over 96 hours beginning on day 57 for 5 cycles.
1734910|NCT00069953|Drug|paclitaxel|During induction therapy, patients receive 200 mg/m^2/day by IV over 2 hours on days 1 and 29.
1734911|NCT00069953|Procedure|conventional surgery|Patients with residual or recurrent esophageal disease 4-6 weeks after completion of chemoradiotherapy may undergo salvage esophagectomy.
1734912|NCT00069953|Radiation|radiation therapy|External beam radiotherapy with megavoltage linear accelerators (> 6 MV) will be used to deliver multiple (> 2) field techniques. Patients will be treated 5 days/week at 1.8 Gy/day for 28 days for a total dose of 50.4 Gy.
1734913|NCT00069966|Biological|filgrastim|
1734914|NCT00069966|Biological|rituximab|
1734915|NCT00069966|Drug|cisplatin|
1734916|NCT00069966|Drug|cytarabine|
1734917|NCT00069966|Drug|methylprednisolone|
1734918|NCT00069966|Drug|pixantrone dimaleate|
1734919|NCT00069966|Procedure|autologous bone marrow transplantation|
1734920|NCT00069966|Procedure|peripheral blood stem cell transplantation|
1734921|NCT00069992|Radiation|Total Body Irradiation|Total body irradiation of 450cGy as a single dose, day -6
1734922|NCT00069992|Drug|Fludarabine|Fludarabine 30mg/m2 Day -5 to -2
1734923|NCT00069992|Drug|Campath 1H|Campath 1H dosing as per institutional SOPs Day -5 to -2
1734924|NCT00070005|Procedure|conventional surgery|
1734925|NCT00070005|Procedure|management of therapy complications|
1734926|NCT00070018|Biological|rituximab|250 mg/m^2, as part of Zevalin regimen
1734927|NCT00070018|Drug|Cyclophosphamide|750 mg/m^2
1734928|NCT00070018|Drug|doxorubicin hydrochloride|50 mg/m^2
1734929|NCT00070018|Drug|prednisone|100 mg
1734930|NCT00070018|Drug|vincristine sulfate|1.4 mg/m^2
1734931|NCT00070018|Radiation|radiation therapy|4000-5000 cGy total
1734932|NCT00070018|Biological|Yttrium-90 ibritumomab tiuxetan|0.4 mCi/kg
1734933|NCT00070018|Biological|Indium-111 ibritumomab tiuxetan|5 mCi
1734934|NCT00070031|Drug|edotecarin|
1734935|NCT00070057|Drug|celecoxib|Given orally
1734936|NCT00070057|Procedure|therapeutic conventional surgery|Undergo surgery
1734937|NCT00070057|Other|pharmacological study|Correlative studies
1734938|NCT00070057|Other|laboratory biomarker analysis|Correlative studies
1734939|NCT00070070|Biological|BCG vaccine|
1734940|NCT00070070|Biological|NY-ESO-1 peptide vaccine|
1734941|NCT00070070|Biological|sargramostim|
1734942|NCT00070083|Biological|oblimersen sodium|
1734943|NCT00070083|Biological|rituximab|
1734944|NCT00070083|Drug|cyclophosphamide|
1734945|NCT00070083|Drug|doxorubicin hydrochloride|
1734946|NCT00070083|Drug|prednisone|
1734947|NCT00070083|Drug|vincristine sulfate|
1734948|NCT00070096|Drug|ixabepilone|
1734949|NCT00070109|Drug|trabectedin|Given IV
1734950|NCT00070109|Other|pharmacological study|Correlative studies
1734951|NCT00070122|Drug|oxaliplatin|Given IV
1734952|NCT00070122|Drug|leucovorin calcium|Given IV
1734953|NCT00070122|Drug|capecitabine|Given orally
1734954|NCT00070122|Biological|bevacizumab|Given IV
1734955|NCT00070122|Drug|fluorouracil|Given IV
1734956|NCT00070122|Other|laboratory biomarker analysis|Correlative studies
1734957|NCT00070135|Biological|filgrastim|Given SC
1734958|NCT00070135|Biological|Anti-Thymocyte Globulin|Given IV
1734959|NCT00070135|Drug|busulfan|Given IV
1734960|NCT00070135|Drug|fludarabine phosphate|Given IV
1734961|NCT00070135|Drug|methotrexate|Given IV
1734962|NCT00070135|Drug|tacrolimus|Given PO or IV
1734963|NCT00070135|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC transplantation
1734964|NCT00070148|Drug|Megestrol Acetate|Megace by mouth for 12 weeks
1734965|NCT00070148|Drug|Oxandrolone 20 mg|20 mg/day for 3 months (12 weeks)
1734966|NCT00070161|Dietary Supplement|EGb761|
1734967|NCT00070161|Drug|donepezil hydrochloride|
1734968|NCT00070161|Procedure|cognitive assessment|
1734976|NCT00070174|Drug|gemtuzumab ozogamicin|
1734977|NCT00070174|Drug|methotrexate|
1734978|NCT00070174|Drug|mitoxantrone hydrochloride|
1734979|NCT00070174|Procedure|allogeneic bone marrow transplantation|
1734980|NCT00070187|Biological|aldesleukin|Given IV
1734981|NCT00070187|Biological|filgrastim|Given IV
1734982|NCT00070187|Biological|recombinant interferon gamma|Given IV
1734983|NCT00070187|Drug|carmustine|Given IV
1734984|NCT00070187|Drug|cyclosporine|Given IV
1734985|NCT00070187|Drug|cytarabine|Given IV
1734986|NCT00070187|Drug|etoposide|Given IV
1734987|NCT00070187|Drug|melphalan|Given IV
1734988|NCT00070187|Procedure|autologous bone marrow transplantation|
1734989|NCT00070187|Procedure|bone marrow ablation with stem cell support|
1734990|NCT00070187|Procedure|peripheral blood stem cell transplantation|
1734991|NCT00070200|Biological|filgrastim|
1734992|NCT00070200|Drug|cisplatin|
1734993|NCT00070200|Drug|cyclophosphamide|
1734994|NCT00070200|Drug|doxorubicin hydrochloride|
1734995|NCT00070200|Drug|etoposide|
1734996|NCT00070200|Drug|isotretinoin|
1734997|NCT00070200|Drug|melphalan|
1734998|NCT00070200|Drug|topotecan hydrochloride|
1734999|NCT00070200|Drug|vincristine sulfate|
1735000|NCT00070200|Procedure|conventional surgery|
1735001|NCT00070200|Procedure|peripheral blood stem cell transplantation|
1735002|NCT00070200|Radiation|radiation therapy|
1735003|NCT00070213|Drug|FOLFOX regimen|
1735004|NCT00070213|Drug|capecitabine|
1735005|NCT00070213|Drug|fluorouracil|
1735006|NCT00070213|Drug|leucovorin calcium|
1735007|NCT00070213|Drug|oxaliplatin|
1735008|NCT00070213|Procedure|quality-of-life assessment|
1735009|NCT00070239|Drug|alvocidib|Given IV
1735010|NCT00070239|Other|pharmacological study|Correlative studies
1735011|NCT00070239|Radiation|fludeoxyglucose F 18|Correlative studies
1735012|NCT00070239|Other|fluorine F 18 fluorothymidine|Correlative studies
1735013|NCT00070239|Procedure|positron emission tomography|Correlative studies
1735014|NCT00070252|Drug|Capecitabine|Given PO
1735015|NCT00070252|Drug|Docetaxel|Given IV
1735016|NCT00070252|Other|Laboratory Biomarker Analysis|Correlative studies
1735017|NCT00070252|Other|Pharmacological Study|Correlative studies
1735018|NCT00070252|Drug|Tipifarnib|Given orally (PO)
1735019|NCT00070265|Drug|oxaliplatin|Given IV
1735020|NCT00070265|Drug|capecitabine|Given orally
1735021|NCT00070265|Procedure|therapeutic conventional surgery|Undergo surgical resection
1735022|NCT00070265|Other|laboratory biomarker analysis|Correlative studies
1735023|NCT00070278|Drug|cyclophosphamide|
1735024|NCT00070278|Drug|epirubicin hydrochloride|
1735025|NCT00070278|Drug|gemcitabine hydrochloride|
1735026|NCT00070278|Drug|paclitaxel|
1735027|NCT00070278|Genetic|comparative genomic hybridization|
1735028|NCT00070278|Genetic|microarray analysis|
1735029|NCT00070278|Genetic|mutation analysis|
1735030|NCT00070278|Procedure|conventional surgery|
1735031|NCT00070278|Procedure|neoadjuvant therapy|
1735032|NCT00070291|Drug|cyclosporine|Cyclosporine doses will be based on actual body weight unless actual body weight is > 15 kg higher than the ideal body weight. Cyclosporine dose will be adjusted to maintain a trough whole blood level of 250-450 ng/mL during the high dose period (weeks 1 -6, starting dose will begin at cyclosporine 3 mg/kg by mouth two times a day (PO BID)) and 150-250 ng/mL during the maintenance period (weeks 7-36, maintenance dose will begin at cyclosporine 2 mg/kg PO BID) in the absence of renal toxicity
1735033|NCT00070304|Biological|filgrastim|Given by mouth or IV, 5 micrograms/kg/dose (up to 10 micrograms/kg/dose) daily starting on day 9 for a minimum of 7 days and until the ANC is greater to or equal to 1,500/uL.
1735034|NCT00070304|Drug|gemcitabine hydrochloride|Given IV over 100 minutes dose 1000 mg/m2/dose in 500 ml NS on days 1 and 8
1735035|NCT00070304|Drug|vinorelbine tartrate|Given IV over 6-10 minutes (central venous catheter). Dose 25 mg/m2/dose on days 1 and 8
1735036|NCT00070317|Drug|Isosulfan Blue|Undergo lymphangiography using isosulfan blue or methylene blue
1735037|NCT00070317|Procedure|Lymph Node Mapping|Undergo lymphatic mapping
1735038|NCT00070317|Procedure|Lymphangiography|Undergo lymphangiography using isosulfan blue or methylene blue
1735039|NCT00070317|Drug|Methylene Blue|Undergo lymphangiography using isosulfan blue or methylene blue
1735040|NCT00070317|Procedure|Radionuclide Imaging|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
1735041|NCT00070317|Procedure|Sentinel Lymph Node Biopsy|Undergo complete pelvic and low para-aortic lymphadenectomy
1735042|NCT00070317|Radiation|Technetium Tc-99m Sulfur Colloid|Undergo radionuclide imaging with technetium Tc 99m sulfur colloid
1735043|NCT00070317|Procedure|Therapeutic Conventional Surgery|Undergo radical hysterectomy
1735044|NCT00070343|Biological|oblimersen sodium|
1735045|NCT00070343|Drug|dacarbazine|
1735046|NCT00070382|Drug|darbepoetin alfa|darbepoetin alfa administered at a dose of 200ug once every 2 weeks over a 16-week treatment period
1735047|NCT00070382|Drug|epoetin alfa|epoetin alfa administered at a dose of 40,000U once every week over a 16-week treatment period
1735048|NCT00070421|Procedure|complementary or alternative medicine procedure|
1735049|NCT00070421|Procedure|management of therapy complications|
1735050|NCT00070421|Procedure|psychosocial assessment and care|
1735051|NCT00070434|Drug|capecitabine|825mg/m2 BID, PO, daily
1735052|NCT00070434|Drug|fluorouracil|Bolus + IV for 46 hrs on Day 1
1735053|NCT00070434|Drug|irinotecan hydrochloride|IV infusion over 90 min on Day 1
1735054|NCT00070434|Drug|leucovorin calcium|200mg/m2 IV 2 hour infusion on Day 1
1735055|NCT00070434|Drug|oxaliplatin|85mg/m2 IV infusion for 90minutes on Day 1
1735176|NCT00071552|Drug|Qvar|Qvar (HFA-propelled beclomethasone dipropionate metered dose inhaler) 160 mcg twice daily for 12 weeks
1735056|NCT00070434|Radiation|radiation therapy|Original Planning Target Volume (PTV1): The total dose to the prescription point shall be 4500 cGy in 25 fractions (Monday - Friday inclusive). Boost Planning Target Volume (PTV2): The cumulative dose within the boost volume to the prescription point shall be 5,040 - 5,400 cGy (per Section 7.5b). Daily Dose: The daily dose to the prescription point of the original and boost volumes shall be 180 cGy. Fractionation: Treatment shall be given 5 days/week. All radiation fields shall be treated once daily.
1735057|NCT00070434|Drug|Pyridoxine|50mg TID, PO daily
1735058|NCT00070447|Biological|rituximab|
1735059|NCT00070447|Drug|cyclophosphamide|
1735060|NCT00070447|Drug|doxorubicin hydrochloride|
1735061|NCT00070447|Drug|prednisone|
1735062|NCT00070447|Drug|vincristine sulfate|
1735063|NCT00070447|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1735064|NCT00070473|Drug|pemetrexed disodium|
1735065|NCT00070486|Drug|carboplatin|given IV
1735066|NCT00070486|Drug|celecoxib|given PO
1735067|NCT00070486|Drug|gemcitabine hydrochloride|given IV
1735068|NCT00070486|Drug|zileuton|given PO
1735072|NCT00070525|Drug|tipifarnib|Given orally
1735073|NCT00070538|Drug|cytarabine|
1735074|NCT00070538|Drug|laromustine|
1735075|NCT00070551|Biological|GTI-2040|Given IV
1735076|NCT00070551|Drug|cytarabine|Given IV
1735077|NCT00070551|Other|pharmacological study|Optional correlative studies
1735078|NCT00070551|Other|laboratory biomarker analysis|Optional correlative studies
1735079|NCT00070564|Biological|pegfilgrastim|Given IV
1735080|NCT00070564|Drug|AC regimen|Given IV
1735081|NCT00070564|Drug|cyclophosphamide|Given IV
1735082|NCT00070564|Drug|doxorubicin hydrochloride|Given IV
1735083|NCT00070564|Drug|paclitaxel|Given IV
1735084|NCT00070590|Drug|Bosentan|
1735085|NCT00070616|Drug|Palifermin 6 x 60 μg/kg/day|
1735086|NCT00070616|Drug|Palifermin 2 x 180 μg/kg/day|
1735087|NCT00070616|Radiation|radiotherapy|
1735088|NCT00070616|Drug|Chemotherapy|
1735089|NCT00070629|Drug|CPG 7909|CPG 7909 Injection will be administered subcutaneously at a starting dose of 0.20 mg/kg at the beginning of Weeks 2 and 3 of the three-week cycle.
1735090|NCT00070629|Drug|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:
Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
1735091|NCT00070629|Drug|Chemotherapy|"A taxane and a platinum compound given on week one of three-week cycles:
Regimen A: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Cisplatin 75 mg/m2 Regimen B: Paclitaxel 175 mg/m2 over 1 - 3 hrs, Carboplatin AUC of 6 Regimen C: Docetaxel 75 mg/m2, Cisplatin 75 mg/m2 Regimen D: Docetaxel 75 mg/m2, Carboplatin AUC of 6"
1735092|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
1735093|NCT00070642|Drug|dacarbazine|dacarbazine 850mg/m2 in three-week cycles until disease progression
1735094|NCT00070642|Drug|Chemotherapy|"Chemotherapy in three-week cycles until disease progression:
dacarbazine 850mg/m2"
1735095|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 10 mg weekly.
1735096|NCT00070642|Drug|CPG 7909 Injection|CPG 7909 Injection administered subcutaneously at a dose of 40 mg weekly.
1735097|NCT00070655|Drug|SR34006 (idraparinux sodium) Injection|
1735098|NCT00070655|Drug|vitamin K antagonist (warfarin or acenocoumarol) tablets|
1735099|NCT00070681|Procedure|Polysomnography|
1735100|NCT00070694|Drug|MDL100.907|
1735101|NCT00070707|Drug|Nasonex|
1735102|NCT00070720|Behavioral|Opinion Leaders, Academic Detailing, Reminders, and Feedback|
1735103|NCT00070733|Drug|testosterone enanthate|
1735104|NCT00070733|Drug|duastride|
1735105|NCT00070759|Drug|Daclizumab|
1735106|NCT00070811|Procedure|Lip revision surgery|Full or partial muscle thickness lip revision surgery.
1735107|NCT00070824|Procedure|acupuncture|
1735108|NCT00070837|Drug|MLN2704 (DM1 conjugated monoclonal antibody MLN591)|
1735110|NCT00070876|Behavioral|Mental health communication skills training|
1735111|NCT00070902|Procedure|Lumbar side-posture spinal adjusting|
1735115|NCT00070928|Drug|valerian|
1735116|NCT00070941|Drug|SAM-e|oral SAM-e in two divided doses, 1200mg or 1800mg daily, with placebo escitalopram.
1735117|NCT00070941|Drug|oral escitalopram|20mg or 30mg daily in two divided doses, along with placebo SAM-e.
1735118|NCT00070941|Drug|placebo|oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.
1735119|NCT00070954|Dietary Supplement|ginkgo biloba|EgB 761
1735120|NCT00070954|Other|matched placebo|Inactive look-alike placebo
1735121|NCT00070967|Procedure|Acupuncture|
1735122|NCT00070980|Procedure|Massage therapy|
1735123|NCT00070993|Drug|creatine monohydrate|
1735124|NCT00071006|Drug|AG-013736 (Axitinib)|patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
1735125|NCT00071032|Biological|Liberal (10 g/dL) Transfusion Strategy|This transfusion strategy will maintains postoperative Hgb levels above 10 g/dL. This threshold strategy will use enough red blood cell units to maintain Hgb levels at or above 10 g/dL through hospital discharge or up to 30 days after randomization.
1735177|NCT00071552|Drug|Flovent Diskus|Flovent Diskus (fluticasone propionate multi-dose dry powder inhaler) 200 mcg twice daily for 12 weeks
1735178|NCT00071578|Behavioral|Group Psychotherapy-Negative Emotion Focus|20 weekly sessions, 2 hours, group format
1735230|NCT00072007|Biological|rituximab|rituximab
1735126|NCT00071032|Biological|Restrictive (Symptomatic) Transfusion Strategy|Transfusion is withheld until the patient develops symptoms from anemia (i.e., chest pain or ECG changes thought to be ischemic, congestive heart failure, unexplained tachycardia or hypotension unresponsive to fluids) or until the hemoglobin level falls below 8 g/dL. Transfusion is permitted, but is not mandatory, if the hemoglobin level falls below 8 g/dL.
1735127|NCT00071058|Drug|XR9576 (Tariquidar)|
1735128|NCT00071071|Drug|HuMax-CD4|
1735129|NCT00071084|Drug|HuMax-CD4|
1735130|NCT00071097|Drug|TMC114/rtv|800mg TMC114/100mg rtv once daily
1735131|NCT00071097|Drug|TMC114/rtv|400mg TMC114/100mg rtv both twice daily
1735132|NCT00071097|Drug|TMC114/rtv|400mg TMC114/100mg rtv once daily
1735133|NCT00071097|Drug|TMC114/rtv|600mg TMC114/100mg rtv twice daily
1735134|NCT00071110|Procedure|Electroacupuncture|For subjects randomized to EA, needles were placed at points GV-20—on the crown of the head and yin tang—on the midline of the forehead roughly at the glabella and treated with electrical stimulation. 30 mm x 0.22 mm sterile stainless steel needles were placed obliquely to a depth of approximately 10 mm and were connected to face-microelectrodes which were connected to the Pantheon Research PENS-Electrostimulator. Electricity was provided at a frequency of 2 Hz and set to a voltage which resulted in the perception of a mild intensity stimulation.
1735135|NCT00071110|Procedure|Sham|For subjects randomized to SA, two needles were placed laterally on the scalp, 3 cuns superior to the temporal attachment of the helix of the ear. This point was selected as it does not correspond to any specific meridian acupuncture point. A disabled electrical cable was connected to the needles and the electrostimulator, with light blinking at 2 Hz but no electrical stimulation provided.
1735136|NCT00071136|Drug|pemetrexed|
1735137|NCT00071136|Drug|gemcitabine|
1735138|NCT00071188|Drug|ZD6474|
1735139|NCT00071188|Drug|Paclitaxel|
1735140|NCT00071188|Drug|Carboplatin|
1735141|NCT00071201|Drug|Adefovir Dipivoxil for oral suspension, 2 mg/mL|
1735142|NCT00071214|Biological|S. aureus Type 5 and 8 Capsular Polysaccharide Conjugate Vaccine|
1735143|NCT00071227|Drug|Triamcinolone Acetonide (TAC-PF)|
1735144|NCT00071240|Drug|Somatropin (recombinant human growth hormone)|3.0mg sc daily for 6 months, followed by 1.5mg sc daily for 6 months. Dose stopped, held or reduced by study investigators as indicated by adverse events
1735145|NCT00071253|Drug|Divalproex Sodium (Delayed-Release Tablets)|
1735146|NCT00071253|Drug|Divalproex Sodium (Extended-Release Tablets)|
1735147|NCT00071253|Drug|Olanzapine|
1735148|NCT00071266|Drug|Niacin Extended Release and Lovastatin Tablets|
1735149|NCT00071279|Drug|SR34006 (idraparinux sodium) Injection|
1735150|NCT00071292|Behavioral|stress reduction program|
1735151|NCT00071292|Behavioral|meditation|
1735152|NCT00071331|Drug|Tolvaptan|
1735153|NCT00071396|Drug|Campath-1H|15 mg/day Continuous infusion by vein (IV) for 6 days then given twice a week for remaining three weeks as 30 mg injection under skin to complete one treatment course of 4 weeks.
1735154|NCT00071396|Drug|Rituximab|375 mg/m^2 IV infusion on day 1, then 500 mg/m^2 on days 8, 15, and 22.
1735155|NCT00071409|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
1735156|NCT00071409|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
1735157|NCT00071409|Drug|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
1735158|NCT00071422|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
1735159|NCT00071422|Drug|INGAP-Peptide|1.5 mL, once daily, self-administered SC injection for 90 days
1735160|NCT00071422|Drug|placebo|1.5 mL, once daily, self-administered SC injection for 90 days
1735161|NCT00071448|Drug|insulin human|
1735162|NCT00071448|Drug|insulin lispro|
1735163|NCT00071448|Drug|insulin aspart|
1735164|NCT00071461|Drug|bosentan|"Initial dose: 62.5 mg b.i.d. for 4 weeks.
Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).
body weight < 40 kg (90 lb): 62.5 mg b.i.d."
1735165|NCT00071461|Drug|Placebo|"Initial dose: 62.5 mg b.i.d. for 4 weeks.
Target dose: - body weight > 40 kg (90 lb): 125 mg b.i.d., (if the initial dose is well tolerated).
body weight < 40 kg (90 lb): 62.5 mg b.i.d."
1735166|NCT00071474|Procedure|shamanic healing|
1735167|NCT00071487|Drug|Placebo|Placebo IV plus standard therapy (SOC) for SLE; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
1735168|NCT00071487|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
1735169|NCT00071487|Drug|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
1735170|NCT00071487|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for SLE; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 52 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on belimumab 10 mg/kg for an additional 24 weeks.
1735171|NCT00071500|Device|MedSignals™|An electronic device that is used to improve medication compliance among HIV patients. It allows convenient storage and transport of antiretroviral medications and functions as an aid to compliance by incorporating reminding alarms at dosing times and usage reporting functions.
1735172|NCT00071513|Behavioral|CAST-T/HSTS|Skills training small group.
1735173|NCT00071513|Behavioral|Brief Intervention|Assessment of needs and referral to services as needed.
1735174|NCT00071539|Drug|TP-38|Recombinant chimeric protein
1735175|NCT00071539|Drug|TP38|recombinant chimeric protein
1735179|NCT00071578|Behavioral|Group Psychotherapy- Self-Esteem Focus|20 weekly sessions, 2 hours, group format
1735180|NCT00071591|Behavioral|Functional Adaptation Skills Training (FAST)|
1735181|NCT00071604|Behavioral|Medication Adherence Therapy|
1735182|NCT00071604|Behavioral|Friendly Support Group|
1735183|NCT00071617|Behavioral|Youth-Nominated Support Team|
1735184|NCT00071630|Behavioral|Cognitive Behavioral Therapy|
1735185|NCT00071643|Behavioral|Problem Solving Therapy|Problem solving therapy aims to make patients aware of symptoms of problems and link those with behaviors associated with solving them.
1735186|NCT00071643|Drug|Escitalopram|Participants will receive escitalopram, a selective serotonin reuptake inhibitor.
1735187|NCT00071643|Other|Placebo|Participants will receive a placebo pill.
1735188|NCT00071656|Behavioral|Psychosocial (behavioral) Intervention|
1735189|NCT00071669|Procedure|Acupuncture|
1735190|NCT00071695|Drug|Duloxetine Hydrochloride|
1735191|NCT00071695|Drug|Venlafaxine Extended Release|
1735192|NCT00071708|Drug|Duloxetine Hydrochloride|
1735193|NCT00071721|Drug|Valproate|250mg tablets beginning with one daily for one week, then two daily for one week, then titrated according to body weight and tolerability to achieve 10-12 mg/kg daily for 2 years, followed by a 2-month washout
1735194|NCT00071721|Drug|Placebo|Placebo tablets beginning with one daily and increasing according to weight and perceived tolerability concerns for two years, followed by a 2-month washout
1735195|NCT00071747|Drug|lamotrigine|
1735196|NCT00071760|Drug|GW433908|Fosamprenavir suspension bid
1735197|NCT00071760|Drug|ritonavir|Ritonavir solution bid
1735198|NCT00071773|Procedure|modified-ETDRS photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
1735199|NCT00071773|Procedure|Mild Macular Grid photocoagulation|A treatment session can be given in single or multiple sittings at the investigator's discretion, as long as the entire treatment session is completed within 6 weeks. Retreatment in Phase 1 of the study should only occur at the 3.5 and 8 month visits.
1735200|NCT00071799|Drug|Azacitidine|Azacitidine was injected subcutaneously (SC) at an initial dose of 75mg/m^2/day for 7 days. The 7-day dosing was repeated every 28 days with dose adjustment based on predefined hematology and renal laboratory results. Number of cycles: Azacitidine treatment was to be continued until the end of the study unless treatment was discontinued due to unacceptable toxicity, relapse after complete or partial response, transformation to AML or disease progression.
1735201|NCT00071799|Other|Physician Choice|"Physician Choice was one of three options:
Best supportive care (BSC) alone,
Low-dose cytarabine subcutaneously for 14 days every 28 to 42 days, or
Standard chemotherapy administered for induction as a continuous intravenous infusion of cytarabine over 7 days plus an anthracycline (daunorubicin, idarubicin, or mitoxantrone) on Days 1, 2, and 3; and, for those eligible, 1 or 2 consolidation cycles administered as continuous intravenous infusions of cytarabine for 3 to 7 days with the same anthracycline that was used at induction on Days 1 and 2 (each cycle between 28 to 70 days from the start of the previous cycle).
All three options included best supportive care"
1735202|NCT00071812|Drug|Placebo|Placebo IV plus standard therapy (SOC) for RA; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, placebo patients who opted to participate received belimumab 10 mg/kg IV plus SOC every 28 days for an additional 24 weeks.
1735203|NCT00071812|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy (SOC) for RA; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
1735204|NCT00071812|Drug|Belimumab 4 mg/kg|Belimumab 4 mg/kg IV plus standard therapy (SOC) for RA; belimumab 4 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate either continued on the same dose of belimumab or may have been switched to belimumab 10 mg/kg at the investigator's discretion for an additional 24 weeks.
1735205|NCT00071812|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy (SOC) for RA; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 24 weeks in the double-blind period. In the open-label extension period, patients who opted to participate continued on the same dose of belimumab (10 mg/kg) for an additional 24 weeks.
1735206|NCT00071838|Drug|Daclizumab|
1735207|NCT00071851|Biological|VRC-HIVDNA009-00-VP|
1735208|NCT00071877|Drug|Replagal|
1735209|NCT00071890|Drug|Interleukin 2|Three cycles of IL-2 (6 MUI bid during 5 days = one cycle)
1735210|NCT00071890|Drug|HAART|HAART from week 0 to week 24
1735211|NCT00071890|Drug|Treatment interruption|HAART is interrupted from week 24 in both arms
1735212|NCT00071929|Drug|oxaliplatin|
1735213|NCT00071942|Biological|recombinant vaccinia-MUC1 vaccine|Given intradermally
1735214|NCT00071942|Biological|recombinant vaccinia-TRICOM vaccine|Given intradermally
1735215|NCT00071942|Other|laboratory biomarker analysis|Correlative studies
1735216|NCT00071942|Procedure|quality-of-life assessment|Ancillary studies
1735217|NCT00071955|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
1735218|NCT00071955|Biological|sargramostim|
1735219|NCT00071968|Drug|temsirolimus|
1735220|NCT00071968|Procedure|conventional surgery|
1735221|NCT00071968|Procedure|neoadjuvant therapy|
1735222|NCT00071981|Biological|incomplete Freund's adjuvant|Given by injection
1735223|NCT00071981|Biological|melanoma helper peptide vaccine|Given by injection
1735224|NCT00071981|Biological|multi-epitope melanoma peptide vaccine|Given by injection
1735225|NCT00071981|Biological|sargramostim|Given by injection
1735226|NCT00071981|Biological|tetanus peptide melanoma vaccine|Given by injection
1735227|NCT00071994|Drug|gefitinib|Given orally
1735228|NCT00071994|Other|laboratory biomarker analysis|Correlative studies
1735229|NCT00072007|Biological|filgrastim|filgrastim
1735231|NCT00072007|Drug|CHOP regimen|CHOP regimen
1735232|NCT00072007|Drug|cladribine|cladribine
1735233|NCT00072007|Drug|cyclophosphamide|cyclophosphamide
1735234|NCT00072007|Drug|doxorubicin hydrochloride|doxorubicin hydrochloride
1735235|NCT00072007|Drug|prednisone|prednisone
1735236|NCT00072007|Drug|vincristine sulfate|vincristine sulfate
1735237|NCT00072020|Drug|zoledronic acid|
1735238|NCT00072020|Procedure|adjuvant therapy|
1735239|NCT00072020|Procedure|neoadjuvant therapy|
1735240|NCT00072033|Drug|Cisplatin and Docetaxel|cisplatin and docetaxel chemo- and radiochemotherapy
1735241|NCT00072046|Biological|bevacizumab|10mg/kg IV infusion on Days 1 & 15 of each cycle
1735242|NCT00072046|Biological|recombinant interferon alfa|9 million units subQ injection 3 x/week for 4 weeks
1735243|NCT00072059|Biological|methoxy polyethylene glycol epoetin beta|
1735244|NCT00072072|Drug|celecoxib|
1735245|NCT00072072|Drug|erlotinib hydrochloride|
1735246|NCT00072085|Biological|aldesleukin|
1735247|NCT00072085|Biological|gp100 antigen|
1735248|NCT00072085|Biological|incomplete Freund's adjuvant|
1735249|NCT00072098|Biological|adenovirus vector|
1735250|NCT00072098|Biological|interleukin-12 gene|
1735251|NCT00072111|Biological|anakinra|
1735252|NCT00072124|Drug|cisplatin|
1735253|NCT00072124|Drug|dacarbazine|
1735254|NCT00072124|Procedure|conventional surgery|
1735255|NCT00072137|Biological|Recombinant Fowlpox-TRICOM Vaccine|Given intravesically
1735256|NCT00072137|Biological|Recombinant Fowlpox GM-CSF Vaccine Adjuvant|Given intravesically
1735257|NCT00072137|Procedure|Therapeutic Conventional Surgery|Undergo cystectomy
1735258|NCT00072137|Other|Pharmacological Study|Correlative studies
1735259|NCT00072137|Other|Laboratory Biomarker Analysis|Correlative studies
1735260|NCT00072150|Drug|bortezomib|Given IV
1735261|NCT00072163|Drug|temozolomide|Given orally
1735262|NCT00072163|Drug|thalidomide|Given orally
1735263|NCT00072176|Drug|temsirolimus|Given IV
1735264|NCT00072176|Other|laboratory biomarker analysis|Correlative studies
1735265|NCT00072189|Drug|7-hydroxystaurosporine|Given IV
1735266|NCT00072189|Other|laboratory biomarker analysis|Correlative studies
1735267|NCT00072189|Other|pharmacological study|Correlative studies
1735268|NCT00072215|Drug|cisplatin|given IV
1735269|NCT00072215|Drug|ifosfamide|given IV
1735270|NCT00072215|Drug|paclitaxel|given IV
1735271|NCT00072215|Drug|vinblastine|given IV
1735272|NCT00072228|Drug|gemcitabine|
1735273|NCT00072228|Drug|soblidotin|
1735274|NCT00072228|Procedure|chemotherapy|
1735275|NCT00064571|Procedure|vocal fold medialization|
1735276|NCT00064571|Procedure|vocal fold reinnervation|
1735277|NCT00064584|Drug|CT53518|
1735278|NCT00064610|Drug|VELCADE TM (bortezomib) for Injection|
1735279|NCT00064623|Drug|Capsaicin Dermal Patch|
1735280|NCT00064636|Drug|VELCADE TM (bortezomib) for Injection, or PS-341|
1735281|NCT00064649|Device|Transurethral Microwave Thermotherapy (TUMT)|type of minimally invasive surgical therapy for BPH
1735282|NCT00064649|Device|Transurethral Needle Ablation (TUNA) Therapy|type of minimally invasive surgical therapy for BPH
1735283|NCT00064649|Drug|Finasteride and Alfuzosin|finasteride in a daily dose of 5 mg and alfuzosin in a daily dose of 10 mg
1735284|NCT00064662|Procedure|Burch Modified Tanagho|The Burch colposuspension is a well-established procedure for surgically treating women with stress urinary incontinence. The Burch modified colposuspension suspends the anterior vaginal wall (at the level of the bladder neck) with permanent sutures tied to the iliopectineal ligament.
1735285|NCT00064662|Procedure|Autologous Fascia Sling|The fascial sling is also a well-established procedure for surgically treating women with stress urinary incontinence. The autologous sling procedure places a harvested strip of rectus fascia transvaginally at the level of the proximal urethra. The fascial strip is secured superiorly to the rectus fascia with permanent sutures
1735286|NCT00064701|Drug|Tacrolimus Modified Release (MR)|The target range for whole blood tacrolimus trough concentrations was 7 to 16 ng/mL for days 0 through 90, and 5 to 15 ng/mL thereafter.
1735287|NCT00064701|Drug|Tacrolimus|The target range for whole blood tacrolimus trough concentrations was the recommended trough concentration range for Prograf: 7 to 16 ng/mL for days 0 through 90 and 5 to 15 ng/mL thereafter.
1735288|NCT00064701|Drug|cyclosporine microemulsion|The target range for whole blood cyclosporine trough concentrations was 125 to 400 ng/mL for days 0 through 90, and 100 to 300 ng/mL thereafter.
1735289|NCT00064701|Drug|mycophenolate mofetil|Oral
1735290|NCT00064714|Drug|AC2993 (exenatide)|Dose-escalation beginning with 2.5 μg administered subcutaneously twice per day (BID); then to 2.5 μg four times a day (QID); then to 5 μg four times a day; then to 10 μg four times a day.
1735291|NCT00064714|Drug|daclizumab (immunosuppressive)|2 mg/kg intravenously infused over 30 minutes every month for 12 months
1735292|NCT00064727|Drug|Avandia (Rosiglitazone)|
1735293|NCT00064727|Drug|Avanclia (Rosiqlitazone)|
1735294|NCT00064740|Behavioral|relaxation response|
1735297|NCT00064766|Drug|doxycycline|
1735298|NCT00064779|Drug|IL13-PE38QQR|
1735299|NCT00064779|Procedure|targeted fusion protein therapy|
1735300|NCT00064779|Procedure|surgery|
1735301|NCT00064792|Drug|Simvastatin Susp.|During the simvastatin phase of the trial, therapy will be initiated at 0.5 mg/kg/day for six weeks and then increased to 1.0 mg/kg/day if adverse side effects are minimal or absent.
1735302|NCT00064792|Drug|OraPlus|During this trial and for two months prior, patients will be maintained on 150 mg/kg/day of dietary cholesterol (150 mg/ml in OraPlus) for the duration of the trial
1735303|NCT00064805|Behavioral|Cognitive Therapy to Improve Reading|
1735304|NCT00064831|Drug|Black Cohosh Extract (BCE)|
1735305|NCT00064844|Behavioral|Cognitive Behavior Therapy for alcohol and smoking cessation|Individual 60-minute treatment sessions were scheduled weekly for the first 3 months, then monthly for the next 3 months for a total of 16 sessions. Alcohol treatment was based on the cognitive behavioral therapy manual developed for Project MATCH, with approximately 40-45 minutes of each session devoted to alcohol treatment. Components of this intervention included identifying alcohol antecedents, coping with alcohol urges, managing thoughts about alcohol, problem solving, drink refusal skills, planning for emergencies, communication and assertiveness training and enhancing social support networks for alcohol abstinence. The smoking cessation intervention was delivered in the same sessions as the alcohol treatment, with approximately 15-20 minutes of each session devoted to smoking cessation. Treatment employed behavioral elements that have been supported empirically according to the USDHHS smoking cessation practice guideline.
1735306|NCT00064857|Drug|Pycnogenol|
1735308|NCT00072267|Drug|7-hydroxystaurosporine|
1735309|NCT00072267|Drug|topotecan hydrochloride|
1735310|NCT00072280|Biological|dactinomycin|Given Slow intravenous (IV) push over 1-5 minutes, dose < 1yr 0.025 mg/kg > or = 1 yr 0.045 mg/kg (max dose 2.5 mg) on days 1,22,43 and 64
1735311|NCT00072280|Drug|cyclophosphamide|Given IV over 60 minutes, dose 25 mg/kg on days 1,22,43 and 64.
1735312|NCT00072280|Drug|etoposide|Given IV over 1 hour, dose 3.3 mg/kg in normal saline (NS) 10 cc/kg (or to equal 0.4 mg/mL concentration) on days 1-5 of IE cycle.
1735313|NCT00072280|Drug|ifosfamide|Given IV over 1 hour, dose 60mg/kg in D5 1/4 NS 10 cc/kg IV on days 1-5 of IE Cycle
1735314|NCT00072280|Drug|vincristine sulfate|Given IV Push over 1 minute, dose 0.05 mg/kg (max dose 2 mg) on days 1,8,15,22,29,36,43,50,57 and 64
1735315|NCT00072280|Procedure|Conventional Surgery|"Applied only when lesion is resectable. Surgery is the primary means of local control in this study and reasonable attempts at achieving clear margins with an envelope of normal tissue should be undertaken at the initial and/or subsequent resections."
1735316|NCT00072280|Biological|MESNA (mercaptoethane sulfonate)|Given orally. Oral daily MESNA dose is equal to at least 60% of the daily cyclophosphamide dose.
1735317|NCT00072280|Biological|Filgrastim|Given IV - Only use filgrastim if chemotherapy has been delayed or modified for hematologic toxicity, or if patient experiences a significant life-threatening toxicity due to bone marrow suppression
1735318|NCT00072293|Procedure|Axillary lymph node dissection|Axillary lymph node dissection
1735319|NCT00072293|Procedure|No axillary lymph node dissection|Therapeutic conventional surgery
1735320|NCT00072319|Biological|filgrastim|
1735321|NCT00072319|Drug|cyclophosphamide|
1735322|NCT00072319|Drug|epirubicin hydrochloride|
1735323|NCT00072319|Drug|paclitaxel|
1735324|NCT00072319|Procedure|adjuvant therapy|
1735325|NCT00072319|Procedure|neoadjuvant therapy|
1735326|NCT00072332|Drug|cisplatin|
1735327|NCT00072332|Drug|edotecarin|
1735328|NCT00072345|Drug|lomustine|
1735329|NCT00072345|Drug|temozolomide|
1735330|NCT00072345|Drug|thalidomide|
1735331|NCT00072358|Biological|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.
1735332|NCT00072358|Biological|anti-GD2 murine IgG3 monoclonal antibody 3F8|The total dosage of 3F8 per cycle is the same as in prior trials (100 mg/m2), administered at 20 mg/m2/day and infused over ~1.5 hr or less (0.5 hr is customary), with analgesics and antihistamines used as needed for expected side-effects. 3F8 is started ~1 hr after completion of GM-CSF administration. GM-CSF is dosed at 250 mcg/m2/day from day -5 to day +1 (Wednesday to Tuesday is customary) , and is 500 mcg/m2/day thereafter (i.e., on days +2 to +4; Wednesday to Friday), as in the predecessor protocol.18,74 Patients come off study if progressive disease occurs or if there is life-threatening grade 4 toxicity from 3F8; otherwise, patients will receive a minimum of 4 cycles of treatment and will continue treatment through 24 months. It is expected that patients will receive ~10 cycles.
1735339|NCT00072410|Radiation|yttrium Y 90 monoclonal antibody Hu3S193|
1735340|NCT00072436|Drug|gemcitabine hydrochloride|Given IV
1735341|NCT00072436|Drug|alvocidib|Given IV
1735342|NCT00072436|Other|pharmacological study|Correlative studies
1735343|NCT00072449|Biological|rituximab|
1735344|NCT00072462|Drug|tamoxifen citrate|Tamoxifen 20mg + Anastrozole placebo
1735345|NCT00072462|Drug|Anastrozole|Anastrozole 1mg + Tamoxifen placebo
1735346|NCT00072475|Drug|vatalanib|Pts registered before 1/15/05 1250 mg/day PO After 1/15/05: Start w/ 750 mg/day PO; escalate q 4 wks in absence of Grade 2 or > tox (1st increase=1000mg/day; 2nd increase 1250 mg/day)
1735347|NCT00072488|Procedure|computed tomography|
1735348|NCT00072488|Procedure|magnetic resonance imaging|
1735349|NCT00072488|Procedure|positron emission tomography|
1735350|NCT00072501|Procedure|breast imaging study|
1735351|NCT00072501|Procedure|comparison of screening methods|
1735352|NCT00072501|Procedure|magnetic resonance imaging|
1735353|NCT00072501|Procedure|radiomammography|
1735354|NCT00072501|Procedure|ultrasound imaging|
1735355|NCT00072514|Drug|gemcitabine hydrochloride|Given IV
1735356|NCT00072514|Drug|carboplatin|Given IV
1735357|NCT00072514|Drug|dexamethasone|Given PO
1735358|NCT00072514|Biological|rituximab|Given IV in CD20-POSITIVE LYMPHOMAS cases
1735359|NCT00072527|Drug|carboplatin|IV
1735360|NCT00072527|Drug|cisplatin|IV
1735361|NCT00072527|Drug|etoposide|IV
1735362|NCT00072527|Drug|irinotecan hydrochloride|IV
1735363|NCT00072527|Radiation|radiation therapy|
1735364|NCT00072540|Drug|celecoxib|
1735365|NCT00072540|Procedure|anti-cytokine therapy|
1735366|NCT00072540|Procedure|antiangiogenesis therapy|
1735367|NCT00072540|Procedure|biological therapy|
1735368|NCT00072540|Procedure|cancer prevention intervention|
1735369|NCT00072540|Procedure|chemoprevention of cancer|
1735370|NCT00072540|Procedure|enzyme inhibitor therapy|
1735371|NCT00072540|Procedure|growth factor antagonist therapy|
1735372|NCT00072553|Drug|celecoxib|
1735373|NCT00072553|Drug|fluorouracil|
1735374|NCT00072553|Drug|leucovorin calcium|
1735375|NCT00072553|Drug|oxaliplatin|
1735376|NCT00072553|Procedure|adjuvant therapy|
1735377|NCT00072553|Procedure|conventional surgery|
1735378|NCT00072553|Procedure|neoadjuvant therapy|
1735379|NCT00072566|Biological|Bevacizumab|Given IV
1735380|NCT00072566|Drug|Cyclophosphamide|Given PO
1735381|NCT00072566|Other|Laboratory Biomarker Analysis|Correlative studies
1735382|NCT00072579|Biological|sargramostim|
1735383|NCT00072592|Drug|Rituximab|
1735384|NCT00072605|Drug|VRC-EBODNA012-00-VP|
1735385|NCT00072618|Drug|Exisulind|
1735386|NCT00072631|Drug|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Intrapatient dose escalation of oral single agent daily erlotinib until intolerable rash
1735387|NCT00073203|Drug|R228060|
1735388|NCT00073203|Drug|Placebo and Paroxetine|
1735389|NCT00073216|Biological|Clade B gag DNA/PLG and env DNA/PLG Microparticles|
1735390|NCT00073216|Biological|Clade B Recombinant, Oligomeric gp140/MF59 Adjuvant|
1735391|NCT00073242|Drug|Leptin|leptin administration
1735392|NCT00073242|Behavioral|Dietary modification|Subjects lose 10% of body weight via dietary restriction
1735393|NCT00073242|Drug|T3 repletion|administer T3
1735394|NCT00073255|Drug|hokt3g1 (ALA-ALA)|
1735395|NCT00073268|Behavioral|Exercise|
1735396|NCT00073281|Procedure|Islet transplantation|
1735397|NCT00073294|Behavioral|diet|
1735398|NCT00073307|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi Kinase Inhibitor
1735399|NCT00073307|Drug|Placebo|Placebo
1735400|NCT00073320|Drug|Paliperidone Palmitate|
1735401|NCT00073333|Behavioral|Social Skills Training|Social skills training once per week
1735402|NCT00073333|Behavioral|Exposure Treatment|Exposure once per week
1735403|NCT00073333|Behavioral|Placebo|Placebo
1735404|NCT00073346|Behavioral|Cognitive Behavioral Treatment|
1735405|NCT00073359|Behavioral|Cognitive Behavioral Therapy|
1735406|NCT00073372|Drug|Abciximab|
1735407|NCT00073385|Drug|Pivanex|
1735408|NCT00073385|Drug|Docetaxel|
1735409|NCT00073398|Biological|Drug: Hyperacute Lung Cancer Cell Vaccine|At dose levels I IV the vaccine cells will be injected intradermally every four weeks for four cycles. Dosage will vary from a total of 3 x 106 to 100 x 106 HyperAcute -Lung Cancer Vaccine cells administered per vaccination cycle. At dose level V patients will receive injections of the HyperAcute -Lung Cancer Vaccine cells to include one (1) initial priming vaccine dose of 500 x 106 cells followed by seven (7) booster vaccine cell doses of 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks. In Phase II, patients will receive 300 x 106 HyperAcute -Lung Cancer cell vaccine cells every two weeks for a total of 8 doses (4 months).
1735410|NCT00073411|Drug|duloxetine|
1735411|NCT00073411|Drug|escitalopram|
1735412|NCT00073411|Drug|placebo|
1735413|NCT00073437|Drug|Infliximab|
1735414|NCT00073450|Drug|Farnesyl Protein Transferase Inhibitor|
1735415|NCT00073463|Genetic|tgAAVCF|
1735416|NCT00073476|Drug|traxiprodil (CP-101,606)|
1735417|NCT00073489|Drug|OSI-461|
1735418|NCT00073502|Drug|OSI-7904L|
1735419|NCT00073515|Drug|Alfimeprase|
1735420|NCT00073528|Drug|Lapatinib (GW572016)|1500 mg orally once a day
1735421|NCT00073528|Drug|Letrozole|2.5 mg orally once a day
1735422|NCT00073541|Drug|EMD 72000|
1735423|NCT00073554|Drug|Alfimeprase|
1735424|NCT00073580|Drug|Angiomax (bivalirudin) anticoagulant|): 250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of the procedure with the option to increase or decrease the infusion rate in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT+) >300 seconds. A low-dose infusion could be administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. An initial dose of 0.1 mg/kg IV bolus followed by an IV infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
1735425|NCT00073593|Drug|Bivalirudin|250 mg vial administered as 0.75 mg/kg intravenous (IV) bolus and 1.75 mg/kg/h IV infusion for the duration of surgery with the option to increase or decrease the infusion in 0.25 mg/kg/h increments or to administer additional 0.1-0.5 mg/kg boluses to maintain an activated clotting time (ACT) >300 seconds (s).
1735426|NCT00073593|Drug|Heparin|: Per institutional practice, at 1.5-3.5 mg/kg (200-400 U/kg) IV bolus to achieve a target ACT of >300 s followed by weight-adjusted boluses as needed during surgery to achieve/maintain the target ACT. Batches from hospital stock.
1735427|NCT00073593|Drug|Protamine|Per institutional practice. Batches from hospital stock.
1735428|NCT00073619|Behavioral|Cognitive-behavioral group therapy|School-based anxiety preventive intervention (cognitive-behavioral group therapy) originally designed for Australian children that was culturally and contextually modified for inner-city children exposed to community violence. Participants received the weekly intervention and rewards for participating in the assessments.
1735429|NCT00073632|Behavioral|Acceptance Based Behavioral Therapy|
1735430|NCT00073645|Behavioral|Peer/Group CBT|Children will be trained to be more helpful and positive toward other children through role-playing activities.
1735431|NCT00073645|Behavioral|Family/Parents CBT|Parents will be trained to manage their children's anxiety and avoidant behaviors by increasing acceptance and warmth toward their children.
1735432|NCT00073658|Drug|Citalopram|
1735433|NCT00073658|Drug|Risperidone|
1735434|NCT00073671|Behavioral|Cognitive-behavioral prevention program|Cognitive-behavioral prevention program includes 8 weekly and 6 monthly group sessions.
1735435|NCT00073671|Other|Usual care|Participants receive usual care
1735436|NCT00073684|Behavioral|Trauma focused cognitive behavioral therapy (TF-CBT)|This study aims to: (1) examine the differential effects of CBT with and without trauma narrative interventions; (2) examine the comparative efficacy of brief and extended (8 vs. 16 sessions) individual CBT; (3) make developmental comparisons between 4-7 year olds and 8-11 year olds as to the appropriateness and therapeutic necessity of exposure interventions and longer treatment; and (4) identify child and parent factors that may significantly mediate the relationships between treatment conditions and outcomes. The findings of this study will help establish clinical as well as developmental markers for the early identification of sexually abused children who may require more focused (i.e., including trauma narrative) and/or longer treatment to achieve optimal outcomes.
1735437|NCT00073684|Behavioral|Brief abuse-focused treatment|Participants will receive 8 sessions of TF-CBT with abuse-focused treatment.
1735438|NCT00073684|Behavioral|Brief coping skills treatment|Participants will receive 8 sessions of TF-CBT with brief coping skills treatment.
1735439|NCT00073684|Behavioral|Extended abuse-focused treatment|Participants will receive 16 sessions of TF-CBT with extended abuse-focused treatment.
1735440|NCT00073684|Behavioral|Extended coping skills treatment|Participants will receive 16 sessions of TF-CBT with extended coping skills treatment.
1735441|NCT00073697|Drug|Escitalopram|Participants will receive escitalopram for a minimum of 32 weeks or approximately 8 months. Participants whose symptoms become stabilized will continue the initial treatment for another 6 months.
1735442|NCT00073697|Behavioral|Interpersonal Psychotherapy|Participants will receive interpersonal psychotherapy (IPT) for 8 months and possibly an additional 6 months.
1735443|NCT00073697|Other|Escitalopram plus IPT|Participants whose symptoms become stabilized will continue the initial treatment for another 6 months. Those who do not will have the second treatment added to their regimen until remission occurs.
1735444|NCT00073710|Drug|Zemplar|
1735445|NCT00073710|Procedure|42 Ca carbonate absorption via single tracer method|
1735446|NCT00073710|Drug|Calcijex|
1735447|NCT00073723|Drug|ABI-007|
1735448|NCT00073736|Drug|MB07133 300mg/m2/day|7-day continuous infusion in 28-day cycles
1735449|NCT00073736|Drug|MB07133 600 mg/m2/day|7-day continuous infusion in 28-day cycles
1735450|NCT00073736|Drug|MB07133 1200 mg/m2/day|7-day continuous infusion in 28-day cycles
1735451|NCT00073736|Drug|MB07133 1800 mg/m2/day|7-day continuous infusion in 28-day cycles
1735452|NCT00073736|Drug|MB07133 2400 mg/m2/day|7-day continuous infusion in 28-day cycles
1735454|NCT00073762|Drug|DVS-233 SR|
1735455|NCT00073788|Procedure|PET Scans|PET Scan to look for coronary flow reserve, heart rate variability, and carotid ultrasound measures (mean intermediate thickness of the far fall of the carotid artery).
1735456|NCT00073814|Drug|Levalbuterol tartrate MDI|levalbuterol MDI 90 mcg QID
1735457|NCT00073814|Drug|racemic albuterol MDI|racemic albuterol MDI 180 mcg QID
1735458|NCT00073814|Drug|Placebo|Placebo MDI QID
1735459|NCT00073827|Drug|levalbuterol tartrate MDI|levalbuterol 90 mcg QID
1735460|NCT00073827|Drug|racemic albuterol MDI|racemic albuterol 180 mcg QID
1735461|NCT00073827|Drug|Placebo|Placebo MDI QID
1735462|NCT00073840|Drug|levalbuterol|"Levalbuterol 90 ųg QID (manufacturing sites A or B);
Racemic Albuterol 180 ųg QID;
Placebo QID"
1735463|NCT00073853|Procedure|Autologous Incubated Macrophages (cell therapy)|
1735464|NCT00073866|Drug|celecoxib|
1735465|NCT00073866|Drug|docetaxel|
1735466|NCT00073866|Drug|irinotecan hydrochloride|
1735467|NCT00073879|Biological|alemtuzumab|
1735468|NCT00073879|Biological|graft-versus-tumor induction therapy|
1735469|NCT00073879|Drug|cyclophosphamide|
1735470|NCT00073879|Drug|fludarabine phosphate|
1735471|NCT00073879|Procedure|allogeneic bone marrow transplantation|
1735472|NCT00073879|Procedure|peripheral blood stem cell transplantation|
1735473|NCT00073892|Drug|PI-88|250 mg/day injected subcutaneously on four consecutive days each week in a 4- week cycle
1735474|NCT00073905|Drug|capecitabine plus gemcitabine|capecitabine plus gemcitabine
1735475|NCT00073918|Drug|cyclophosphamide|Given IV
1735476|NCT00073918|Drug|etoposide|Given IV
1735477|NCT00073918|Radiation|iodine I 131 tositumomab|Given IV
1735478|NCT00073918|Procedure|quality-of-life assessment|Ancillary study
1735479|NCT00073918|Procedure|peripheral blood stem cell transplantation|Undergo ASCT given via central catheter
1735480|NCT00073931|Biological|filgrastim|5 µg/kg/day subcutaneously
1735481|NCT00073931|Biological|sargramostim|250µg/m2/d subcutaneously
1735482|NCT00073931|Procedure|autologous bone marrow transplantation|autologous stem cells given via central catheter
1735483|NCT00073931|Procedure|peripheral blood stem cell transplantation|autologous stem cells given via central catheter
1735484|NCT00073931|Radiation|tositumomab and iodine I 131 tositumomab|given intravenously (test dose of 1.7-10 mg/kg tositumomab antibody radiolabeled with ~10 mCi I-131) or via central catheter (therapy dose of 1.7-10 mg/kg tositumomab radiolabeled with individually calculated therapy dose of I-131)
1735485|NCT00073944|Drug|forodesine hydrochloride|
1735491|NCT00073970|Drug|celecoxib|400mg, given twice daily
1735492|NCT00073983|Biological|filgrastim|filgrastim
1735493|NCT00073983|Biological|pegfilgrastim|pegfilgrastim
1735494|NCT00073983|Drug|docetaxel|docetaxel
1735495|NCT00073983|Drug|gemcitabine hydrochloride|gemcitabine hydrochloride
1735496|NCT00073983|Genetic|microarray analysis|microarray analysis
1735497|NCT00073983|Other|laboratory biomarker analysis|laboratory biomarker analysis
1735498|NCT00073983|Other|pharmacokinetic study|pharmacokinetic study
1735499|NCT00074009|Drug|bortezomib|
1735500|NCT00074022|Biological|GTI-2040|Given IV
1735501|NCT00074022|Drug|docetaxel|Given IV
1735502|NCT00074022|Other|laboratory biomarker analysis|Correlative studies
1735503|NCT00074022|Other|pharmacological study|Correlative studies
1735504|NCT00074035|Drug|pentostatin|4 mg/sq m IV infusion over 20-30 min q 2 weeks
1735505|NCT00074048|Drug|BL22|Dosing via IV on Days 1,3, and 5.
1735506|NCT00074074|Biological|infliximab|
1735507|NCT00074087|Drug|pegylated liposomal doxorubicin hydrochloride|
1735508|NCT00074100|Drug|amonafide dihydrochloride|
1735509|NCT00074139|Drug|cyclophosphamide|
1735510|NCT00074139|Drug|docetaxel|
1735511|NCT00074139|Drug|doxorubicin hydrochloride|
1735512|NCT00074152|Drug|chemotherapy|Given within 10 weeks after surgery.
1735513|NCT00074152|Radiation|radiation therapy|Given within 6 months after surgery
1735514|NCT00074165|Drug|Rituxan|Total dose: 375mg/m2 infused IV; Every 4 weeks for up to one year.
1735515|NCT00074165|Drug|Cyclophosphamide|Dose 330mg/m2 x 2 days infused IV; Every 4 weeks for up to 1 year
1735516|NCT00074165|Drug|Etoposide|Dose 200mg/m2 x 2 days infused IV; Every 4 weeks for up to one year. Etoposide phosphate may be given instead.
1735517|NCT00074165|Drug|Etoposide phosphate|Dose 200mg/m2 infused IV x 2 days; Every 4 weeks for up to one year. Etoposide may be given instead.
1735518|NCT00074165|Drug|Carboplatin|Dose: 200mg/m2 x 2 days infused IA with BBBD; Every 4 weeks for up to one year.
1735519|NCT00074165|Drug|Sodium thiosulfate|"Dose: 4 hrs post carboplatin = 20gm/m2;
Dose: 8 hrs post carboplatin = 16gm/m2
Infused IV x 2 days"
1735520|NCT00074165|Drug|Neupogen|48 hours after chemotherapy, QD x 7-10 days until WBC greater than 5000. Neulasta (Pegfilgrastim) may be given instead.
1735521|NCT00074165|Drug|Neulasta|Dose: 6mg, 24-72 hours after chemotherapy. Neupogen may be given instead.
1735522|NCT00074165|Drug|Cytarabine|Dose: 40mg on Day 14 following chemotherapy
1735523|NCT00074178|Biological|filgrastim|
1735524|NCT00074178|Biological|pegfilgrastim|
1735525|NCT00074178|Drug|cyclophosphamide|
1735526|NCT00074178|Drug|cytarabine|
1735527|NCT00074178|Drug|dexamethasone|
1735528|NCT00074178|Drug|etoposide phosphate|
1735529|NCT00074178|Drug|methotrexate|
1735530|NCT00074191|Drug|cytarabine|
1735531|NCT00074191|Drug|dexamethasone|
1735532|NCT00074191|Drug|lomustine|
1735533|NCT00074191|Drug|methotrexate|
1735534|NCT00074191|Drug|procarbazine hydrochloride|
1735535|NCT00074204|Drug|carboplatin|Carboplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
1735536|NCT00074204|Drug|docetaxel|"Arm I (immediate docetaxel): Patients receive immediate docetaxel IV over 1 hour on day 1.
Arm II (delayed docetaxel): Patients are observed until first evidence of disease progression and then receive docetaxel IV over 1 hour on day 1.
In both arms, treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity."
1735537|NCT00074204|Drug|gemcitabine hydrochloride|Gemcitabine IV over 30-60 minutes on days 1 and 8. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
1735538|NCT00074230|Biological|Autologous Dendritic Cells loaded with MAGE-A3, MelanA and Survivin|Within cohort 1 patients received the vaccine intradermally; in cohort 2 the route of Administration was intravenous Infusion, half of the patients had additional loading with RNA coding for EL-Selektin; in cohort 3 the vaccines was again infused intravenously, the cells were matured not with MCM.mimic as in cohort 1 and 2 but either with TriMix or MCM-mimic plus CD40L-RNA.
1735539|NCT00074243|Drug|CC-8490|
1735540|NCT00074269|Biological|anti-thymocyte globulin|
1735541|NCT00074269|Biological|filgrastim|
1735542|NCT00074269|Biological|graft-versus-tumor induction therapy|
1735543|NCT00074269|Biological|therapeutic allogeneic lymphocytes|
1735544|NCT00074269|Drug|cyclosporine|
1735545|NCT00074269|Drug|fludarabine phosphate|
1735546|NCT00074269|Drug|melphalan|
1735547|NCT00074269|Drug|methotrexate|
1735548|NCT00074269|Procedure|peripheral blood stem cell transplantation|
1735549|NCT00074282|Biological|filgrastim|
1735550|NCT00074282|Biological|pegfilgrastim|
1735551|NCT00074282|Biological|rituximab|
1735552|NCT00074282|Drug|cyclophosphamide|
1735553|NCT00074282|Drug|lenalidomide|
1735554|NCT00074282|Drug|pentostatin|
1735555|NCT00074295|Biological|GVAX lung cancer vaccine|6-7 injections per week in rotating locations for five weeks
1735560|NCT00074321|Drug|irinotecan hydrochloride|Given IV
1735561|NCT00074321|Drug|oxaliplatin|Given IV
1735562|NCT00074321|Drug|capecitabine|Given PO
1735563|NCT00074321|Other|laboratory biomarker analysis|Correlative studies
1735564|NCT00074321|Other|pharmacological study|Correlative studies
1735565|NCT00074334|Biological|TGFa-PE38 immunotoxin|
1735566|NCT00074334|Procedure|conventional surgery|
1735568|NCT00074399|Drug|Nevirapine|Tablet taken orally daily. Dosage depends on age and body surface area
1735569|NCT00074399|Drug|Nevirapine placebo|Placebo tablet taken orally daily
1735570|NCT00074412|Drug|Nevirapine|10 mg/ml oral suspension taken once daily up to 6 months of age. Dosage will increase throughout study.
1735571|NCT00074412|Drug|Nevirapine placebo|Oral suspension taken once daily up to 6 months of age
1735572|NCT00074425|Drug|BufferGel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of BufferGel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
1735573|NCT00074425|Drug|PRO 2000/5 Gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
1735574|NCT00074425|Drug|Placebo gel|Participants will be given single-use, prefilled applicators of gel and will be instructed to apply one dose of PRO 2000/5 Gel intravaginally up to 60 minutes before each vaginal intercourse while in the study.
1735579|NCT00074477|Drug|R092670|
1735592|NCT00074529|Drug|MK0677|
1735593|NCT00074542|Drug|Epanova™ (Omega-3 Free Fatty Acids)|
1735594|NCT00074581|Drug|Atazanavir|300 mg taken orally once daily
1735595|NCT00074581|Drug|Didanosine|400 mg taken orally once daily
1735596|NCT00074581|Drug|Efavirenz|600 mg taken orally once daily
1735597|NCT00074581|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally once daily
1735598|NCT00074581|Drug|Lamivudine|300 mg taken orally once daily
1735599|NCT00074581|Drug|Lopinavir/Ritonavir|200 mg lopinavir/ 50 mg ritonavir tablet taken orally once daily
1735600|NCT00074581|Drug|Nevirapine|200 mg taken orally once daily for 14 days followed by 200 mg taken orally twice daily
1735601|NCT00074581|Drug|Stavudine|Dosage depends on weight
1735602|NCT00074581|Drug|Tenofovir disoproxil fumarate|300 mg taken orally once daily
1735603|NCT00074581|Drug|Zidovudine/Lamivudine|150 mg lamivudine/ 300 mg zidovudine tablet taken orally twice daily
1735604|NCT00074607|Drug|Gemcitabine|"Schedule
Induction: At Dose Level 1athe first cohort of patients will receive intrathecal gemcitabine on a weekly basis for a total of 6 weeks. If that is tolerated, the subsequent cohort will receive intrathecal gemcitabine on a twice-weekly basis (Dose Level 1b) for a total of 6 weeks. Subsequent cohorts (Dose Levels 2 - 6) will receive intrathecal gemcitabine on a twice weekly basis for a total of 6 weeks (12 doses).
In the absence of disease progression or DLT, patients may proceed to consolidation.
Consolidation: Intrathecal gemcitabine will be administered weekly for a total of 6 doses. The first dose of consolidation will be given 1 week after the last induction dose. In the absence of disease progression or DLT, patients may proceed to maintenance.
Maintenance: Intrathecal gemcitabine will be given twice monthly for 4 months and monthly thereafter. In the absence of progressive disease or dose-limiting toxicity, the total duration of therapy will be 1 year."
1735605|NCT00074620|Drug|PEG-hirudin|
1735606|NCT00074633|Behavioral|Health at Every Size (HAES)|
1735607|NCT00074633|Behavioral|Diet (Traditional, moderate energy restriction)|
1735608|NCT00074646|Drug|CC-8490|
1735609|NCT00074698|Drug|FG-3019|
1735610|NCT00074711|Drug|Calcium carbonate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium carbonate.
1735611|NCT00074711|Drug|Calcium Phosphate|Participants will receive teriparatide and vitamin D during the course of the 12-month study. They will also receive calcium phosphate.
1735612|NCT00074724|Procedure|Coronary Artery Bypass|coronary revascularization using arterial or vein conduits
1735613|NCT00074724|Drug|Modern medical management|Therapies with evidence-based recommendations.
1735614|NCT00074724|Device|Dobutamine echocardiography|Incremental dose administration of dobutamine to elicit a contractile response of the myocardium.
1735615|NCT00074724|Drug|Optimal medical therapy|All medical interventions known to improve outcomes in patients with ischemic left ventricular dysfunction.
1735616|NCT00074737|Drug|cenersen|cenersen with standard of care
1735617|NCT00074737|Drug|Idarubicin|standard of care for AML
1735618|NCT00074737|Drug|Cytarabine|standard of care Ara-C and High dose Ara-C
1735619|NCT00074750|Drug|DTGM|Starting dose: 2 mcg/kg by vein three times a week (M,W,F) for two consecutive weeks.
1735620|NCT00074763|Biological|Platelet Transfusion|All receive both platelets frozen with Thrombosol and fresh random platelets (FRP), order received is randomized, i.e. receive either FRP then Thrombosol or Thrombosol then FRP.
1735621|NCT00074776|Drug|Lithium|Participants will receive lithium.
1735622|NCT00074776|Drug|Lamotrigine|Participants will receive lamotrigine.
1735623|NCT00074789|Behavioral|Modified Interpersonal Therapy|Psychiatric mental health nurses will meet with participants 10 times, an hour each time, over a period of 14 weeks. The nurses will continue to work with the mothers over the next 8 weeks by phone, conducting 5 fifteen minute phone sessions.
1735624|NCT00074789|Behavioral|Attention control/usual care|Participants will receive the usual care for depression.
1735625|NCT00074802|Drug|Paroxetine|Treatment with paroxetine will consist of an immediate release, flexible dosage of 20 to 50 mg per day.
1735626|NCT00074802|Behavioral|Cognitive behavioral therapy (CBT)|CBT will consist of 16 weekly treatment sessions.
1735627|NCT00074815|Drug|Serotonin reuptake inhibitors management|"Participants are maintained on their optimized dose of SRI for OCD symptoms (see Other Names section for specific drugs and dosage ranges). If the participant has been treated with an SRI for at least 9 weeks AND has been at a stable dose for the past 3 weeks (e.g., the dose response curve is flat indicating no further improvement in OCD symptoms) OR the participant did not tolerate a dose increase to the next higher dose OR the participant has been at the maximum allowable dose for 3 weeks, then the participant is considered optimized and will be maintained on that dose. During trial, all participants will be maintained on their SRI dose during acute treatment at a constant dose unless side effects warrant downward adjustment of the SRI."
1735628|NCT00074815|Behavioral|Cognitive behavioral therapy by a psychologist|CBT consists of 14 visits over 12 weeks involving: (1) psychoeducation, (2), cognitive training, (3) mapping OCD, and (4) exposure and ritual prevention (EX/RP). The intervention was adapted from March and Mulle (1998) treatment protocol for pediatric OCD.
1735629|NCT00074815|Behavioral|Instructional cognitive behavioral therapy by a psychiatrist|"The psychiatrist who manages medication will also provide instructions in the CBT procedures that have been found to help reduce OCD symptoms, namely EX/RP. MM+I-CBT was constructed as a single-doctor best practice treatment with three primary goals: (1) inclusion of the main psychoeducational and EX/RP components of the full CBT protocol; (2) feasibility of training psychiatrists to perform the CBT component of MM+I-CBT; (3) integration with protocol medication management visits; and (4) feasibility of implementation with the constraints of a busy practice oriented primarily toward pharmacotherapy."
1735630|NCT00074828|Drug|LY517717|
1735631|NCT00074828|Drug|enoxaparin|
1735632|NCT00074841|Drug|Azithromycin/Chloroquine|
1735633|NCT00074841|Drug|Sulfadoxine-Pyrimethamine/Chloroquine|
1735634|NCT00074854|Drug|CP-547,632|
1735635|NCT00074867|Drug|CP-547,632|
1735636|NCT00074893|Device|piezoelectric wrist brace|
1735637|NCT00074906|Drug|Venticute|Patients With Pneumonia or Aspiration of Gastric Contents and Intubation/Ventilation/Oxygenation Impairment
1735638|NCT00074919|Biological|alglucosidase alfa|20 mg/kg qow
1735639|NCT00074932|Biological|Myozyme|20 mg/kg
1735640|NCT00074958|Biological|Fabrazyme (agalsidase beta)|1 mg/kg every 2 weeks
1735641|NCT00074971|Drug|Fabrazyme (agalsidase beta)|
1735642|NCT00074984|Biological|Fabrazyme (agalsidase beta)|1mg/kg Fabrazyme (agalsidase beta) every 2 weeks
1735643|NCT00074984|Biological|Placebo|1 mg/kg placebo intravenously every 2 weeks
1735644|NCT00074997|Other|Placebo|Single intravenous infusion of placebo.
1735645|NCT00074997|Genetic|OZ1|Single intravenous infusion of OZ1.
1735646|NCT00074997|Genetic|CD34+ cells|Autologous CD34+ cells.
1735647|NCT00075010|Drug|Decitabine|15 mg/m^2 by vein over 1 hour times 10 days
1735648|NCT00075010|Drug|Valproic acid|20 mg/kg given orally daily for 10 days
1735649|NCT00075023|Drug|Thalidomide Gel|
1735650|NCT00075023|Drug|Placebo Gel|
1735651|NCT00075049|Biological|RTS,S with AS02A/AS01B adjuvant|
1735652|NCT00075062|Procedure|Flexible Sigmoidoscopy|
1735653|NCT00075062|Procedure|Rectal Biopsy|
1735654|NCT00075075|Drug|Infliximab|
1735655|NCT00075088|Device|Electrocardiogram (ECG) Intervention|"Pre-hospital electrocardiographic (ECG) monitoring with special software to detect myocardial ischemia and to automatically transmit an ECG to the destination hospital emergency department with a voice alarm announcing Incoming ECG from the field and print out in the ED."
1735656|NCT00075088|Other|Routine Clinical Practice|ECG in the ED as part of routine clinical practice.
1735657|NCT00075101|Drug|Dexamethosone|10 day study cycle: 5 day observation pre-steroid,5 day observation post-steroid
1735658|NCT00075114|Behavioral|Bladder Health Class|A two-hour bladder health class presented by two experts in urinary incontinence and followed by an individual follow-up teaching session with an incontinence nurse specialist.
1735659|NCT00075140|Genetic|Mutation in the gene|
1735660|NCT00075166|Procedure|Stereotactic surgery (SRS)|
1735661|NCT00075166|Procedure|Craniotomy|
1735662|NCT00075179|Drug|Nesiritide (Natrecor)|Given initially as a bolus (2 mcg/kg) and than infused for 30 minutes (0.01 mcg/kg/min) during right heart catheterization.
1735663|NCT00075179|Procedure|Right Heart Catheterization|Small tubes placed in neck vein to heart as means of measuring pressure in heart and lungs; treatment with nesiritide delivered during procedure.
1735664|NCT00075192|Drug|CP-675,206 and leuprolide acetate and bicalutamide|
1735665|NCT00075192|Drug|leuprolide acetate and bicalutamide|
1735666|NCT00075205|Drug|SR141716 (Rimonabant)|
1735667|NCT00075218|Drug|Placebo|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
1735668|NCT00075218|Drug|SU011248|50 mg taken orally once a day. 6 week treatment cycle (Schedule 4/2) 4 weeks on study drug/2 weeks off study drug.
1735669|NCT00075231|Drug|Kaletra® (lopinavir/ritonavir)|
1735670|NCT00075231|Drug|Combivir® (lamivudine, zidovudine)|
1735671|NCT00075231|Drug|Sustiva® (efavirenz)|
1735672|NCT00075244|Drug|Replagal|
1735673|NCT00075257|Drug|DVS-233 SR|
1735674|NCT00075270|Drug|Paclitaxel|Active Comparator
1735675|NCT00075270|Drug|GW572016 (Lapatinib)|Oral GW572016 Lapatinib
1735676|NCT00075283|Device|Lokomat (Robotic Orthosis) combined with slat belt treadmill|
1735678|NCT00075348|Genetic|mutation analysis|
1735761|NCT00075725|Drug|doxorubicin hydrochloride|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735679|NCT00075374|Drug|docetaxel|"Patients receive docetaxel IV over 1 hour on day 1. Treatment repeats every 21 days in the absence of disease progression or unacceptable toxicity.
OR Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline, every 2 courses during study treatment, and then at study completion.
Patients are followed at 1 month and then every 2-3 months thereafter."
1735680|NCT00075387|Drug|Carboplatin|Given IA
1735681|NCT00075387|Drug|Cyclophosphamide|Given IV
1735682|NCT00075387|Drug|Etoposide Phosphate|Given IV
1735683|NCT00075387|Other|Quality-of-Life Assessment|Ancillary studies
1735684|NCT00075387|Drug|Sodium Thiosulfate|Given IV
1735685|NCT00075400|Drug|imatinib mesylate|Given PO
1735686|NCT00075400|Other|laboratory biomarker analysis|Correlative studies
1735687|NCT00075413|Drug|arsenic trioxide|
1735688|NCT00075426|Drug|arsenic trioxide|
1735689|NCT00075439|Drug|gefitinib|Given orally
1735690|NCT00075439|Other|laboratory biomarker analysis|Correlative studies
1735691|NCT00075452|Drug|gemcitabine hydrochloride|
1735692|NCT00075452|Drug|oxaliplatin|
1735693|NCT00075465|Drug|docetaxel|
1735694|NCT00075465|Drug|epirubicin hydrochloride|
1735695|NCT00075478|Procedure|Total-Body Irradiation|Undergo TBI
1735696|NCT00075478|Drug|Fludarabine Phosphate|Given IV
1735697|NCT00075478|Drug|Mycophenolate Mofetil|Given PO
1735698|NCT00075478|Drug|Cyclosporine|Given PO
1735699|NCT00075478|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
1735700|NCT00075491|Drug|fenretinide|Given orally
1735701|NCT00075491|Procedure|therapeutic conventional surgery|Undergo surgery
1735702|NCT00075491|Other|pharmacological study|Correlative studies
1735703|NCT00075491|Other|laboratory biomarker analysis|Correlative studies
1735704|NCT00075504|Drug|triapine|Given IV
1735705|NCT00075504|Drug|gemcitabine|Given IV
1735706|NCT00075517|Drug|docetaxel|
1735707|NCT00075517|Drug|gemcitabine hydrochloride|
1735708|NCT00075543|Drug|docetaxel|
1735709|NCT00075543|Drug|oxaliplatin|
1735710|NCT00075556|Drug|capecitabine|
1735711|NCT00075556|Procedure|conventional surgery|
1735712|NCT00075556|Procedure|neoadjuvant therapy|
1735713|NCT00075556|Radiation|radiation therapy|
1735714|NCT00075569|Biological|HspE7|
1735715|NCT00075582|Procedure|conventional surgery|Some patients may undergo second-look surgery
1735716|NCT00075582|Drug|dactinomycin|Given IV
1735717|NCT00075582|Drug|cyclophosphamide|Given IV
1735718|NCT00075582|Drug|vincristine sulfate|Given IV
1735719|NCT00075582|Radiation|radiation therapy|Undergo radiotherapy
1735720|NCT00075595|Drug|FOLFIRI regimen|
1735721|NCT00075595|Drug|fluorouracil|
1735722|NCT00075595|Drug|irinotecan hydrochloride|
1735723|NCT00075595|Drug|leucovorin calcium|
1735724|NCT00075608|Biological|filgrastim|16mcg/kg IV daily beginning three days prior to stem cell collection through last day of stem cell collection
1735725|NCT00075608|Drug|melphalan|140-200 mcg/kg IV over two days
1735726|NCT00075608|Procedure|autologous stem cell transplantation|infusion of previously collected stem cells on Day 0
1735727|NCT00075608|Procedure|stem cell infusion|infusion of previously collected stem cells on Day 0
1735728|NCT00075621|Drug|filgrastim|16 mg/kg/day for 3 days prior to stem cell collection, through day before last collection
1735729|NCT00075621|Drug|melphalan|200 mg/kg over 2 days
1735730|NCT00075621|Procedure|autologous peripheral blood stem cell transplantation|autologous peripheral blood stem cell transplantation
1735731|NCT00075634|Drug|decitabine|Given IV
1735732|NCT00075634|Drug|doxorubicin hydrochloride|Given IV
1735733|NCT00075634|Drug|cyclophosphamide|Given IV
1735734|NCT00075634|Biological|filgrastim|Given SC
1735735|NCT00075634|Biological|pegfilgrastim|Given SC
1735736|NCT00075634|Other|laboratory biomarker analysis|Correlative studies
1735737|NCT00075634|Other|pharmacological study|Correlative studies
1735738|NCT00075647|Drug|temsirolimus|Given IV
1735739|NCT00075647|Other|laboratory biomarker analysis|Correlative studies
1735740|NCT00075660|Drug|triapine|
1735741|NCT00075673|Drug|celecoxib|Patients receive oral celecoxib twice daily on days 1-21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
1735742|NCT00075673|Drug|vinorelbine ditartrate|Patients receive oral vinorelbine on days 7, 14, and 21. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
1735743|NCT00075686|Biological|cetuximab|Loading dose: Cetuxiumab 400mg/m2, IV on Day 1 (cycle 1 only). Weekly maintenance: Cetuximab 250mg/m2, IV on Days 8,15,22 of cycle 1 & days 1,8,15,22 of all subsequent cycles
1735744|NCT00075686|Drug|gemcitabine hydrochloride|1000mg/m2 IV over 30 minutes
1735745|NCT00075699|Drug|cisplatin|
1735746|NCT00075699|Drug|mitomycin C|
1735747|NCT00075699|Drug|vincristine sulfate|
1735748|NCT00075699|Drug|vinorelbine tartrate|
1735749|NCT00075699|Procedure|pain therapy|
1735750|NCT00075699|Procedure|psychosocial assessment and care|
1735751|NCT00075699|Procedure|quality-of-life assessment|
1735752|NCT00075712|Drug|carboplatin|
1735753|NCT00075712|Drug|paclitaxel|
1735754|NCT00075712|Procedure|adjuvant therapy|
1735755|NCT00075712|Procedure|conventional surgery|
1735756|NCT00075712|Procedure|neoadjuvant therapy|
1735757|NCT00075725|Drug|cyclophosphamide|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735758|NCT00075725|Drug|cytarabine|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735759|NCT00075725|Drug|daunorubicin hydrochloride|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735760|NCT00075725|Drug|dexamethasone|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735762|NCT00075725|Drug|leucovorin calcium|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735763|NCT00075725|Drug|mercaptopurine|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735764|NCT00075725|Drug|methotrexate|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735765|NCT00075725|Drug|pegaspargase|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735766|NCT00075725|Drug|prednisone|Given IV or orally
1735767|NCT00075725|Drug|thioguanine|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735768|NCT00075725|Drug|vincristine sulfate|Given IV, orally, intrathecally, intramuscularly, or subcutaneously
1735769|NCT00075725|Radiation|radiation therapy|Patients undergo radiation therapy periodically during study treatment
1735770|NCT00075738|Drug|cisplatin|
1735771|NCT00075738|Drug|fluorouracil|
1735772|NCT00075738|Drug|irinotecan hydrochloride|
1735773|NCT00075738|Drug|leucovorin calcium|
1735774|NCT00075751|Drug|gemcitabine hydrochloride|Given IV
1735775|NCT00075751|Drug|carboplatin|Given IV
1735776|NCT00075751|Drug|bortezomib|Given IV
1735777|NCT00075764|Drug|anastrozole|Given orally
1735778|NCT00075764|Drug|fulvestrant|Given intramuscularly
1735779|NCT00075777|Drug|valproic acid|250 mg by mouth twice a day
1735780|NCT00075803|Drug|Fluconazole|Fluconazole will be administered orally once daily. Fluconazole capsules should be taken at least one hour before or one hour after a meal. If oral drug is not possible, it will be given intravenously once daily in a total volume of 200 mL in patients > 12 years. For adults, each 200 mL infusion will be administered over 2 hours. In patients < 12 years, intravenous doses will be prepared.
1735781|NCT00075803|Drug|Voriconazole|Voriconazole will be administered orally twice daily. Voriconazole capsules should be taken at least one hour before or one hour after a meal. Taken concomitantly with food, bioavailability of voriconazole is reduced. If oral drug is not possible, it will be given intravenously at a dosage of 200 mg every 12 hours over two hours in patients > 12 years. Each voriconazole dose will be diluted to a total volume of 200 mL in patients > 12 years. Volumes of the formulation required to provide 4 mg/kg doses for children age < 12 years.
1735782|NCT00075816|Biological|Allogeneic bone marrow transplantation|Bone marrow transplant from HLA compatible unrelated donors.
1735783|NCT00075816|Biological|Peripheral blood stem cell transplantation|Peripheral blood transplant from HLA compatible unrelated donors.
1735784|NCT00075829|Procedure|One Autologous Transplant|Melphalan will be administered at a dose of 200 mg/m2. Melphalan will be given in one dose infused on Day -2. Melphalan dose is based on ideal body weight (IBW) for patients who weigh 100-120% of their IBW. All patients will receive an autologous graft with a minimum cell dose of 2.0 x 106 CD34+ cells/kg patient weight. Patients will receive ~5 ug/kg/day of Granulocyte-Colony Stimulating Factor (G-CSF) subcutaneously from Day 5 post-transplant until absolute neutrophil count (ANC) > 500/mm3 for two days.
1735785|NCT00075829|Procedure|Non-Myeloablative Allogeneic Transplant|Upon recovery and at least Day 60 post-autograft, patients with an available 6/6 HLA matched sibling will receive an allograft after non-myeloablative conditioning. Day 0 patients will receive Total Body Irradiation (TBI) 2.0 Gy from a linear accelerator ≤ 20 cGy/min, followed by allogeneic peripheral blood stem cell (PBSC) infusion. Commence cyclosporine (CSA) on Day -3 at 5 mg/kg bid PO for a daily dose of 10 mg/kg/day through Day +84 based on actual body weight. Starting on Day 84, patients in partial or complete response with the absence of graph versus host disease (GVHD) will have CSA tapered so the patient will be off CSA by Day 180. Oral administration of Mycophenolate Mofetil will be at a daily dose of 30 mg/kg/day from the evening of Day 0 until Day 27 post-transplant.
1735786|NCT00075829|Procedure|Second Autologous Transplant|Upon recovery from the first autograft, but at least 60 days (preferably between 60-120 days) after the first autograft, patients without an HLA-matched sibling donor will receive a second autograft, also conditioned with melphalan 200 mg/m2.
1735787|NCT00075829|Drug|Thalidomide|Patients will be initiated on a starting dose of 50 mg/day. The dose will be increased weekly by 50 mg as tolerated to achieve a target dose of 200 mg/day. Patients will be treated for 12 months with thalidomide.
1735788|NCT00075829|Drug|Dexamethasone|Patients will receive dexamethasone at a dose of 40 mg per day during Days 1-4 of each month for 12 months. The first dose of dexamethasone to be given the same day the patient starts thalidomide.
1735789|NCT00075829|Behavioral|Observation|One year of observation post-transplants.
1735790|NCT00075842|Dietary Supplement|Valeriana officinalis extract|Given orally
1735791|NCT00075842|Other|placebo|Given orally
1735792|NCT00075855|Drug|therapeutic testosterone|
1735793|NCT00075855|Other|placebo|
1735794|NCT00075868|Drug|octreotide acetate|
1735795|NCT00075868|Other|Placebo|
1735796|NCT00067964|Behavioral|small changes in physical activity and diet|
1735797|NCT00067990|Drug|Losartan 100mg|To be started within three months of transplant and continued for five years.
1735798|NCT00067990|Drug|Placebo|No treatment with continued follow-up for five years.
1735799|NCT00068029|Drug|Pegvisomant/ Sandostatin LAR|
1735800|NCT00068029|Drug|Sandostatin LAR|
1735801|NCT00068029|Drug|Pegvisomant|
1735802|NCT00068042|Drug|Pegvisomant|
1735803|NCT00068042|Drug|Sandostatin LAR|
1735804|NCT00068055|Drug|Omr-lgG-am|Omr-IgG-am™ 5% is provided in 100 ml bottles (5.0 grams) as a sterile solution containing 5% protein, 10% maltose and water for injection. This product is licensed in Israel, but not in the US.
1735805|NCT00068055|Drug|Polygam® S/D|Polygam® S/D is a solvent/detergent treated, sterile, freeze-dried preparation of highly purified immunoglobulin G (IgG) derived from large pools of human plasma. When reconstituted (5%) with the supplied diluent (sterile water for injection, USP) Polygam® S/D contains approximately 50mg of protein per ml (approximately 90% is gamma globulin); 3mg/ml human albumin, 22.5 mg/ml glycine, 20 mg/ml glucose, 2mlg/ml polyethylene glycol (PEG), 1 mcg/ml tri-nbutyl phosphate, 1 mcg/ml octoxynol 9, and 100 mcg/ml polysorbate 80.
1735806|NCT00068055|Drug|Placebo|Normal Saline.
1735807|NCT00068068|Drug|Talaporfin sodium (LS11)|
1735808|NCT00068068|Device|LED-based light infusion device|
1735809|NCT00068068|Device|Light emitting diodes (LED)|
1735810|NCT00068068|Procedure|Photodynamic therapy|
1735811|NCT00068068|Procedure|Phototherapy|
1735813|NCT00068081|Drug|Capsaicin Dermal Patch|
1735814|NCT00068094|Drug|Probiotic-containing powder|
1735815|NCT00068107|Drug|Replagal|enzyme replacement therapy
1735816|NCT00068133|Genetic|Plasmid based Gene Transfer product-VLTS-589|
1735817|NCT00068172|Drug|PI-88|
1735818|NCT00068185|Drug|Black cohosh|
1735819|NCT00068198|Biological|Dryvax|
1735820|NCT00068211|Drug|ILX651|
1735821|NCT00068237|Procedure|Surgery for the primary and neck nodes|
1735822|NCT00068237|Procedure|Submandibular salivary gland transfer|
1735823|NCT00068237|Radiation|Post-operative radiation therapy|
1735824|NCT00068250|Biological|rituximab|
1735825|NCT00068250|Drug|methotrexate|
1735826|NCT00068250|Drug|temozolomide|
1735827|NCT00068250|Radiation|radiation therapy|
1735828|NCT00068263|Radiation|radiation therapy|
1735829|NCT00068276|Dietary Supplement|cholecalciferol|
1735830|NCT00068289|Drug|bortezomib|
1735831|NCT00068302|Drug|sirolimus|3-6 subjects will be enrolled into each dose level
1735832|NCT00068315|Drug|bortezomib|Given IV
1735833|NCT00068315|Drug|fludarabine phosphate|Given IV
1735834|NCT00068315|Biological|rituximab|Given IV
1735835|NCT00068328|Procedure|psychosocial assessment and care|
1735836|NCT00068328|Procedure|quality-of-life assessment|
1735837|NCT00068341|Biological|trastuzumab|Cycle 5-7 post-op only Day 1 4mg/kg IV Day 8, 15 2mg/kg IV Cycle 8 Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV
1735838|NCT00068341|Drug|carboplatin|Cycle 1-8 Day 1 or 2 AUC = 6 IV
1735839|NCT00068341|Drug|docetaxel|Cycle 1-8 Day 1 or 2: 75 mg/m2 IV
1735840|NCT00068341|Biological|trastuzumab|"Cycle 1-4 pre-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV
Cycle 5-7 post-op Day 1 4mg/kg IV Day 8, 15 2mg/kg IV
Cycle 8 Day 1, 8, 15 2mg/kg IV Day 22 6mg/kg IV"
1735842|NCT00068380|Drug|imatinib mesylate|Given orally
1735843|NCT00068380|Other|laboratory biomarker analysis|Correlative studies
1735844|NCT00068393|Drug|Doxorubicin|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
1735845|NCT00068393|Drug|Gemcitabine|Doxorubicin: 50 mg/m² IV slow push followed by gemcitabine 1500 mg/m² IV infusion over 30 minutes on day 1. Cycles repeat every 2 weeks.
1735846|NCT00068393|Drug|G-CSF (granulocyte-colony stimulating factor)|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
1735847|NCT00068393|Drug|Neulasta|Patients will receive G-CSF at a subcutaneous dose of 5mcg/kg/day on days 2 or 3 to 10 or neulasta at a dose of 6mg on day 2. Growth factor must be administered as close as possible to 24 hours after the completion of chemotherapy. It is recommended that neulasta be administered only on day 2 due to its prolonged half-life.
1735852|NCT00068419|Drug|tamoxifen citrate|Given orally
1735853|NCT00068419|Drug|sulindac|Given orally
1735854|NCT00068419|Other|laboratory biomarker analysis|Correlative studies
1735855|NCT00068432|Drug|Celecoxib|Oral celecoxib twice daily on days 1-28. Courses repeat every 4 weeks.
1735856|NCT00068432|Drug|Gemcitabine Hydrochloride|Receive gemcitabine by vein (IV) over 65 minutes on days 1, 8 and 15. Courses repeat every 4 weeks.
1735857|NCT00068445|Drug|lamotrigine|
1735858|NCT00068445|Other|Placebo|
1735859|NCT00068458|Dietary Supplement|Calcium-Rich Diet|1,200 - 2,500 mg/day. 6 month intervention
1735860|NCT00068458|Other|Arm 2: Exercise + Calcium-Rich Diet|Dietary counseling + material promoting strength training an aerobic activity + a calcium intake of 1,200 - 2,500 mg/day. 6 month intervention.
1735861|NCT00068458|Other|Exercise + Fruit & Vegetable, Low Fat + Calcium Diet|1,200 - 2,500 Calcium intake per day. 6 month intervention period.
1735862|NCT00068471|Drug|anidulafungin|
1735863|NCT00068484|Drug|topotecan hydrochloride|Given IV
1735864|NCT00068484|Drug|bortezomib|Given IV
1735865|NCT00068484|Other|pharmacological study|Correlative studies
1735866|NCT00068484|Other|laboratory biomarker analysis|Correlative studies
1735867|NCT00068497|Drug|gefitinib|Given orally
1735868|NCT00068510|Biological|therapeutic autologous dendritic cells|
1735869|NCT00068523|Biological|anti-thymocyte globulin|anti-thymocyte globulin IV over 4 hours on days -2 to -1
1735870|NCT00068523|Drug|cyclophosphamide|cyclophosphamide IV over 1 hour on days -3 to -2
1735871|NCT00068523|Drug|cyclosporine|oral cyclosporine on days -1 to 100
1735872|NCT00068523|Drug|fludarabine phosphate|fludarabine IV over 30 minutes on days -8 to -4
1735873|NCT00068523|Drug|methylprednisolone|methylprednisolone (oral or IV) on days 5-15
1735874|NCT00068523|Procedure|UV light therapy|Patients undergo ultraviolet-B (UVB) light therapy every other day between days -10 and -2 for a total of 3 days. Posttransplantation UVB light therapy: Following PBSC transplantation, patients undergo UVB light therapy twice weekly on week 1 (at least 1 day apart) and three times weekly on weeks 2-4.
1735875|NCT00068523|Procedure|allogeneic bone marrow transplantation|
1735876|NCT00068523|Procedure|peripheral blood stem cell transplantation|Allogeneic peripheral blood stem cell (PBSC) transplantation: Patients undergo PBSC transplantation on day 0.
1735877|NCT00068549|Drug|Gemcitabine Hydrochloride|Given IV
1735878|NCT00068549|Drug|Cisplatin|Given IV
1735879|NCT00068549|Radiation|Radiation Therapy|Undergo whole pelvis radiotherapy
1735880|NCT00068549|Radiation|Internal Radiation Therapy|Undergo brachytherapy
1735881|NCT00068575|Biological|Recombinant Interferon Alfa|3 million units subcutaneously every other day (Monday, Wednesday and Friday) during Days 1-19 and 29-45, for 6 1/2 weeks totaling 17 doses.
1735882|NCT00068575|Drug|Cisplatin|30 mg/m^2 IV over 60 minutes on days 1, 8, 15, 29, 36, 43 - weekly for total 6 doses, during 5 1/2 weeks radiation therapy.
1735883|NCT00068575|Drug|Fluorouracil|175 mg/m^2/day continuous infusion over 6 1/2 weeks for total 3 courses: Days 1-19 and 29-45, Days 71-108 and Days 127-168.
1735884|NCT00068575|Radiation|Radiation Therapy|External beam radiation on days 1-19 and days 29-45, 9 day treatment break on day 20.
1735885|NCT00068588|Biological|GTI-2040|Given IV
1735886|NCT00068588|Drug|capecitabine|Given orally
1735887|NCT00068601|Drug|cyclophosphamide|Part of planned chemotherapy regimen
1735888|NCT00068601|Drug|goserelin acetate|Given subcutaneously
1735889|NCT00068614|Biological|HER-2/neu peptide vaccine|
1735890|NCT00068653|Drug|Celecoxib|Celecoxib 400mg orally two times a day, taken with meals.
1735891|NCT00068653|Drug|ZD1839|ZD1839 250 mg po every day, taken with or without food.
1735892|NCT00068666|Drug|temozolomide|
1735893|NCT00068666|Radiation|radiation therapy|
1735894|NCT00068692|Drug|capecitabine|Given orally
1735895|NCT00068692|Drug|fluorouracil|Given IV
1735896|NCT00068692|Drug|leucovorin calcium|Given IV
1735897|NCT00068692|Drug|irinotecan hydrochloride|Given IV
1735898|NCT00068692|Drug|oxaliplatin|Given IV
1735899|NCT00068692|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
1735900|NCT00068692|Other|laboratory biomarker analysis|Correlative studies
1735901|NCT00068718|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
1735902|NCT00068731|Dietary Supplement|lycopene|
1735903|NCT00068744|Drug|cisplatin|
1735904|NCT00068744|Drug|fluorouracil|
1735905|NCT00068744|Drug|mitomycin C|
1735906|NCT00068744|Radiation|radiation therapy|
1735907|NCT00068757|Biological|trastuzumab|
1735908|NCT00068757|Drug|lonafarnib|
1735909|NCT00068757|Drug|paclitaxel|
1735910|NCT00068757|Other|pharmacological study|
1735911|NCT00068770|Radiation|radiation therapy|Radiation is standard treatment 6000cGy in 30 fractions. Patients will receive celecoxib 400 mg bid during RT treatment
1735912|NCT00068770|Drug|Celecoxib|Celecoxib will begin 1 week prior to RT at 400mg bid orally. One day 1 only 1 dose will be administered. Starting on day 2 and throughout treatment until progression, 2 doses will be administered at least 12 hours apart. Celecoxib will continue throughout the 6 week course of RT.
1735913|NCT00068783|Drug|imatinib mesylate|Given orally
1735914|NCT00068783|Other|laboratory biomarker analysis|Correlative studies
1735915|NCT00068809|Procedure|Short Cycle Antiretroviral Therapy|
1735916|NCT00068822|Device|Percutaneous vertebroplasty|Placement of polymethylmethacrylate (PMMA) into vertebral compression fracture
1735917|NCT00068822|Procedure|Sham vertebroplasty|Participants, following local anesthesia with lidocaine and bupivacaine, were given verbal and physical cues such as pressure on the back, but the needle was not placed.
1735918|NCT00068835|Behavioral|Lindamood-Bell training for dyslexia|
1735919|NCT00068848|Behavioral|Quick start oral contraceptive initiation|
1735920|NCT00068861|Drug|metformin XR|
1735921|NCT00068861|Drug|clomiphene citrate|
1735922|NCT00068874|Behavioral|Coping skills and cognitive restructuring techniques|This is a cognitive psychoeducational program designed to enhance coping and adaptation to SLE. Participants will attend five study visits over 5 months. The first three visits are biweekly, 45-minute sessions during which the adolescent will be taught coping skills and cognitive restructuring techniques. The coping skills training will include training in relaxation, distraction, and problem-solving skills. The cognitive restructuring techniques will assist adolescents in using more accurate and adaptive cognitive responses.
1735923|NCT00068874|Behavioral|Educational training|Participants will attend five study visits that will include disease-appropriate education materials.
1735924|NCT00068913|Drug|Dichloroacetate|
1735925|NCT00068952|Drug|Edotecarin|
1735926|NCT00068952|Drug|Temozolomide|
1735927|NCT00068952|Drug|Carmustine (BCNU)|
1735928|NCT00068952|Drug|Lomustine (CCNU)|
1735929|NCT00068991|Behavioral|HIV skills training program and questionnaire|Two-hour weekly skills training sessions followed by evaluation questionnaire
1735930|NCT00068991|Behavioral|Community-level stigma reduction program|Two-hour training sessions focusing on anti-stigma and anti-discrimination
1735931|NCT00068991|Behavioral|Cross-sectional survey|Survey evaluation of community attitudes towards HIV
1735932|NCT00069017|Biological|MEDI-522|MEDI-522 is formulated in a sterile isotonic solution of 10 mM histidine-HCl at pH 6 containing 100 mg of MEDI-522 protein at a concentration of 100 mg/mL.
1735933|NCT00069017|Other|Placebo|Placebo for MEDI-522 contains 10 mM histidine-HCl at pH 6, 0.1% Tween-80, 1.5% Mannitol, 4.3 µg/mL Vitamin B12, and 2 µg/mL D&C Yellow #10.
1735934|NCT00069030|Biological|VRC-HIVDNA009-00-VP (Gag-Pol-Nef-multiclade-Env) with adjuvant VRC-ADJDNA004-IL2-VP|
1735935|NCT00069056|Procedure|Laser Treatment|
1735937|NCT00069082|Drug|Civamide (Zucapsaicin)|Nasal Solution 0.01%
1735938|NCT00069082|Drug|Sodium Chloride|Nasal Solution 10%
1735939|NCT00069095|Drug|Oxaliplatin 130 mg/m^2|Oxaliplatin was administered in a 2 h infusion before the first dose of capecitabine.
1735940|NCT00069095|Drug|Capecitabine 1000 mg/m^2|Capecitabine was taken within 30 min after the end of breakfast and dinner.
1735941|NCT00069095|Drug|Bevacizumab 7.5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
1735942|NCT00069095|Drug|Placebo for bevacizumab 7.5 mg/kg|Placebo control for bevacizumab (volume equivalent to 7.5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
1735943|NCT00069095|Drug|Oxaliplatin 85 mg/m^2|Oxaliplatin 85 mg/m^2 was administered simultaneously with leucovorin in a 2 h infusion.
1735944|NCT00069095|Drug|Leucovorin 200 mg/m^2|Leucovorin was administered simultaneously with oxaliplatin 85 mg/m^2 in a 2 h infusion.
1735945|NCT00069095|Drug|Fluorouracil 400 mg/m^2|
1735946|NCT00069095|Drug|Bevacizumab 5 mg/kg|Bevacizumab was administered in a 30 to 90 min infusion.
1735947|NCT00069095|Drug|Placebo for bevacizumab 5 mg/kg|Placebo control for bevacizumab (volume equivalent to 5 mg/kg bevacizumab) was administered in a 30 to 90 min infusion.
1735948|NCT00069108|Drug|5 FU|As prescribed, in 2 week cycles
1735949|NCT00069108|Drug|Leucovorin|As prescribed, in 2 week cycles
1735950|NCT00069108|Drug|Oxaliplatin|As prescribed, in 3 week cycles
1735951|NCT00069108|Drug|Oxaliplatin|As prescribed, in 2 week cycles
1735952|NCT00069108|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-15 of each 3 week cycle
1735953|NCT00069121|Drug|capecitabine [Xeloda]|1000mg/m2 iv bid on days 1-15 of each 3 week cycle
1735954|NCT00069121|Drug|Oxaliplatin|As prescribed, in 3 week cycles
1735955|NCT00069121|Drug|Oxaliplatin|As prescribed, in 2 week cycles
1735956|NCT00069121|Drug|Leucovorin|As prescribed, in 2 week cycles.
1735957|NCT00069121|Drug|5 FU|As prescribed, in 2 week cycles
1735958|NCT00069134|Dietary Supplement|sulfur amino acids|Sixteen (16) children with edematous SCU will be randomly assigned to either a supplement of SAA or an isonitrogenous amount of alanine
1735959|NCT00069160|Drug|docetaxel|Patients receive docetaxel intravenous (IV) over 1 hour on days 1 and 8.
1735960|NCT00069160|Drug|tariquidar|Patients receive tariquidar intravenous (IV) over 30 minutes on days 8 and 22.
1735961|NCT00069160|Other|99mTc-sestamibi imaging|Bolus injection of 29 mCi of 99mTc-sestamibi intravenously for each imaging study.
1735962|NCT00069173|Behavioral|Project FAB (Fitness and Bone)|
1735963|NCT00069186|Drug|Creatine Monohydrate|
1735966|NCT00069251|Drug|Bupropion|
1735967|NCT00069264|Drug|E7389|E7389 Dose-escalation starting at 0.25 mg/m^2 intravenous on Days 1, 8, and 15 of a 28 day cycle.
1735968|NCT00069277|Drug|E7389|
1735969|NCT00069316|Drug|Omr-IgG-am|
1735970|NCT00069329|Drug|anakinra|daily injection of subcutaneous injection
1735971|NCT00069355|Drug|Propranolol|
1735972|NCT00069381|Behavioral|Psychotherapy treatment|
1735973|NCT00069407|Procedure|Electroconvulsive Therapy|Electroconvulsive therapy
1735974|NCT00069420|Behavioral|Cognitive Motivational Behavior Therapy|
1735975|NCT00069433|Procedure|Social skills and symptom management training|
1735976|NCT00069446|Drug|rhuMAb VEGF (telbermin)|
1735977|NCT00069459|Drug|Extended-release Bupropion Hydrochloride|Bupropion hydrochloride will be available in dose strength of 150 and 300 milligram (mg). Subjects will receive one tablet of 150 mg bupropion hydrochloride from Day 1 to 7, from Day 8 to Week 27 will receive one tablet of 300 mg bupropion hydrochloride and from Week 28-29 one tablet of bupropion hydrochloride
1735978|NCT00069498|Drug|5-aminosalicylic acid|
1735979|NCT00069511|Drug|UT-231B|
1735980|NCT00075881|Drug|bortezomib|Given IV
1735981|NCT00075881|Other|laboratory biomarker analysis|Optional correlative studies
1735982|NCT00075894|Drug|L-alanosine|
1735983|NCT00075907|Drug|Efavirenz + 2 NRTIs|
1735984|NCT00075907|Drug|Lopinavir/Ritonavir + 2 NRTIs|
1735985|NCT00075907|Procedure|Therapeutic Drug Monitoring|
1735986|NCT00075933|Drug|ARQ 501|
1735987|NCT00075946|Biological|rituximab|Given IV
1735988|NCT00075959|Drug|NXY-059|
1735989|NCT00075972|Behavioral|Mood Tolearance|
1735990|NCT00075972|Behavioral|Mood Management|
1735991|NCT00075972|Drug|Nicotine Replacement therapy|
1735992|NCT00075998|Drug|"Interferon gamma-1b (Actimmune)"|200 mcg, SQ, 3x per week
1735993|NCT00076011|Drug|Vascular Endothelial Growth Factor Receptor [VEGFR] and Platelet-Derived Growth Factor Receptor [PDGFR] inhibitor|
1735994|NCT00076024|Drug|Placebo|5 mg twice daily [bid] continuous dosing
1735995|NCT00076024|Drug|Docetaxel|Standard of care drug administration
1735996|NCT00076024|Drug|AG-013736 (axitinib)|5mg twice daily [bid] continuous dosing
1735997|NCT00076024|Drug|Docetaxel|Standard of care drug administration
1735998|NCT00076037|Biological|HIV CTL MEP administered with RC529-SE adjuvant|
1735999|NCT00076037|Drug|GM-CSF|
1736000|NCT00076050|Dietary Supplement|Soy isoflavones|Purified soy isoflavones (phytoestrogens) in tablet form tablets; 200 mg.
1736001|NCT00076050|Dietary Supplement|Placebo|Placebo soy isoflavones
1736002|NCT00076063|Biological|ALVAC-HIV (vCP1452)|experimental vaccine
1736003|NCT00076063|Biological|LIPO-5|experimental vaccine
1736004|NCT00076076|Drug|Roflumilast|
1736005|NCT00076089|Drug|Roflumilast|
1736006|NCT00076102|Drug|Pirfenidone|Pirfenidone orally as capsules three times a day approximately every 8 hours for cycles of 28 days with no rest period between cycles (28 day treatment cycles); 500 mg/m^2 every 8 hours (1500 mg/m2/day).
1736007|NCT00076115|Drug|Risperidone|
1736009|NCT00076206|Drug|CCI-779|
1736010|NCT00076206|Drug|Placebo|
1736011|NCT00076219|Procedure|renal replacement therapy|renal replacement therapy
1736012|NCT00076232|Drug|Acyclovir|400 mg tablet taken orally twice daily
1736013|NCT00076232|Drug|Acyclovir placebo|Oral tablet taken twice daily
1736014|NCT00076245|Behavioral|Light Therapy|Light therapy will involve exposure to bright light twice a day.
1736015|NCT00076245|Behavioral|Cognitive behavioral therapy (CBT)|CBT attempts to change maladaptive thoughts and beliefs, and will be conducted twice a week.
1736016|NCT00077987|Drug|SU011248|
1736017|NCT00078000|Drug|SU011248|
1736018|NCT00078013|Drug|MCC-135|
1736019|NCT00078026|Drug|Apomine|
1736020|NCT00078039|Drug|Paliperidone ER|
1736021|NCT00078065|Drug|Xcellerated T Cells|
1736022|NCT00078104|Procedure|Extraction of wisdom teeth|
1736023|NCT00078117|Drug|Buprenorphine|
1736024|NCT00078130|Drug|Buprenorphine/naloxone|
1736025|NCT00078143|Behavioral|Behavior Therapy|
1736026|NCT00078156|Behavioral|Behavior Therapy|
1736027|NCT00078169|Behavioral|Behavior Therapy|
1736028|NCT00078182|Drug|Tenofovir DF|
1736029|NCT00078195|Biological|omalizumab|A minimum equivalent dose of 0.016 mg/kg/IgE (IU/mL) every 4 weeks will be administered. Omalizumab is administered in two separate phases. In the pre-treatment period omalizumab will be administered to condition the participants to an immune tolerance state. Omalizumab will be also administered after RIT and during the maintenance immunotherapy phase.
1736030|NCT00078195|Biological|Placebo omalizumab|The placebo for omalizumab will contain the excipients and diluents of the omalizumab.
1736031|NCT00078195|Biological|Ragweed rush immunotherapy (RIT)|RIT will consist of a series of injections containing ragweed extract. The series of injections will have progressively greater amounts of ragweed extract: starting from the 1:1000 dilution of the maintenance vial and progressing to the 0.3 mL of 1:10 dilution of the maintenance vial or the maximally tolerated amount.
1736032|NCT00078195|Biological|Placebo rush immunotherapy (RIT)|The placebo for rush immunotherapy will contain the diluents and histamine.
1736033|NCT00078195|Biological|Ragweed immunotherapy (IT)|Participants will receive weekly maintenance IT dosing for a total of 12 weeks.
1736034|NCT00078195|Biological|Placebo immunotherapy (IT)|The placebo for immunotherapy will contain the diluents and histamine.
1736035|NCT00078221|Device|Rheopheresis blood filtration|
1736036|NCT00078234|Drug|Oblimersen-rituximab-fludarabine|28-day cycles; Cycle 1: oblimersen by continuous IV infusion 1.5 mg/kg/d for 7 consecutive days, completing on Day 8; rituximab by IV infusion on Day 4 (125 mg/m2) and Day 6 (250 mg/m2); fludarabine 25 mg/m2 by IV infusion for 3 days, starting on Day 6. Subsequent cycles: oblimersen 3 mg/kg/d, completing on Day 8; rituximab 375 mg/m2 on Day 5; fludarabine 25 mg/m2 for 3 days starting the same day as rituximab
1736037|NCT00078247|Drug|Abacavir|300 mg tablet taken orally twice daily
1736038|NCT00078247|Drug|Lamivudine|300 mg tablet taken orally daily
1736039|NCT00078247|Drug|Zidovudine|300 mg tablet taken orally twice daily
1736040|NCT00078247|Drug|Tuberculosis treatment|Tuberculosis treatment
1736041|NCT00078260|Drug|pemetrexed|"A: 500 mg/m2, IV, q 21 days until disease progression
B: 900 mg/m2, IV, q 21 days until disease progression"
1736042|NCT00078273|Behavioral|Personalized Feedback Intervention|Sessions lasted for 60-90 minutes and used Motivational Interviewing (MI) to facilitate discussion of feedback from participants' survey responses. Sessions began with open-ended questions about contextual factors associated with participants' gambling, then review of each feedback section: gambling pattern; perceived gambling norms; positive expectancies and negative consequences of gambling; beliefs about control over gambling; and situational self-efficacy to avoid gambling. Participants were encouraged to consider the feedback in light of their personal goals. All participants received a copy of their feedback, a list of skills for limiting gambling and a resource/referral list.
1736043|NCT00078273|Behavioral|Cognitive Behavioral Intervention|Participants completed either six weekly 1-hour sessions or attend four sessions containing the same content. Sessions covered functional analysis and gambling triggers; challenging cognitive distortions, with emphasis on illusions of control; coping with triggers; assertiveness; and relapse prevention. Participants received a pamphlet covering each week's topic (which was reviewed with the participant if a session was missed), as well as homework sheets and gambling diaries. CBI participants were asked to refrain from gambling for the duration of the group to provide an opportunity to practice and develop skills applicable to gambling and other behavior change situations.
1736044|NCT00078286|Drug|Sertraline|Dosage ranging from 50 mg to 200 mg once a day
1736045|NCT00078286|Drug|Placebo|Dosage ranging from 50 mg to 200 mg once a day
1736046|NCT00078312|Drug|CEP-10953 (Armodafinil)|Armodafinil (po) 100 to 250 mg/day up to 12 months
1736047|NCT00078325|Drug|Armodafinil 250 mg/day|Armodafinil 250 mg once daily in the morning
1736048|NCT00078325|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
1736049|NCT00078325|Drug|Placebo|Matching placebo tablets once daily in the morning
1736051|NCT00078351|Procedure|High molecular weight hylan (Synvisc) injection|
1736052|NCT00078364|Procedure|MRI|
1736053|NCT00078377|Drug|Armodafinil|Armodafinil 250 mg once daily in the morning
1736054|NCT00078377|Drug|Armodafinil|Armodafinil 150 mg once daily in the morning
1736055|NCT00078377|Drug|Placebo|Matching placebo tablets once daily
1736056|NCT00078390|Drug|S-3304|
1736057|NCT00078403|Drug|Peginterferon alfa-2a|180 mcg PEG-IFN subcutaneously
1736058|NCT00078403|Drug|Ribavirin|One tablet or capsule containing ribavirin 200 mg
1736059|NCT00078442|Drug|Pegylated interferon alfa-2a|Recombinant PEG-IFN alfa-2a is a synthetic version of IFN and is used in hepatitis C virus treatment
1736060|NCT00078455|Drug|ILX651|
1736061|NCT00078468|Drug|PELITREXOL/AG-2037|
1736062|NCT00078481|Drug|Idebenone|
1736063|NCT00078494|Drug|EBV-LMP-2|
1736064|NCT00078507|Behavioral|Sensory Re-training|
1736065|NCT00078507|Behavioral|Sensory Retraining|Facial Exercises
1736066|NCT00078507|Behavioral|Opening Exercises|
1736067|NCT00078520|Biological|IL-2 AND HUMAN CD40 LIGAND PLASMID GENE MODIFIED AUTOLOGOUS TUMOR CELLS|Patients may be treated with a minimum of 3-6 injections of their IL-2-secreting and CD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window. Any patient whose disease regresses after the administration of 6 injections may be offered further injections (i.e. more than 6 injections) of tumor vaccine at the dose level previously administered, if enough vaccines are available. Patients will receive a fixed dose of IL-2 secreting B-CLL cells throughout the entire treatment protocol while an escalating number of CD40L-expressing B-CLL cells will be given at each dose-level.
1736068|NCT00078533|Biological|CMV CTL infusion|Three dose levels will be explored. The lowest dose level will be 1x10^7cells/m2 and the highest will be 1x10^8/m2. 3-6 pts will be entered at each dose level (depending on toxicity). If there are no toxicities and immunological efficacy is not seen at any dose, then the doses will be further escalated after additional local and federal approval. Additional patients will be treated at dose level 1 in order to assess the secondary objective of virus-specific immunity from the CTL infusions
1736069|NCT00078546|Biological|EBV specific CTL Infusion|"One injection at one of the following dose levels
Dose level I: 2x107/m2 Dose level II: 5x107/m2 Dose level III: 1x108/m2"
1736070|NCT00078546|Biological|Anti CD45 monoclonal antibody|400ug/kg over 6 to 8 hr for 4 days
1736071|NCT00078559|Drug|Alemtuzumab|30mg intravenous infusion on days 0 (transplant), 1, and 2
1736072|NCT00078559|Drug|Sirolimus|2mg/day orally within 24-48 hrs post-transplant, and adjusted to achieve blood levels of 8-12 ng/mL for 1 year
1736073|NCT00078559|Drug|Tacrolimus|2mg orally twice daily, on days 1-60
1736074|NCT00078559|Procedure|Kidney transplant|Kidney transplant with primary cadaveric or non-HLA-identical living donor kidney (0-3 HLA-antigen mismatch)
1736075|NCT00078559|Drug|Methylprednisolone (or equivalent)|250 mg intravenous infusion 60 minutes prior to first dose of alemtuzumab
1736076|NCT00078559|Drug|Acetaminophen|650 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
1736077|NCT00078559|Drug|Diphenhydramine|25 mg may be given 30-60 minutes prior to start of each infusion of alemtuzumab to prevent infusion related side effects such as fever, skin rash and pruritis
1736078|NCT00078559|Drug|Trimethoprim (TMP)/Sulfa (Bactrim, Septra)|1 double strength tablet 3 times a week from day 1 through 1 year post-transplant.
1736079|NCT00078559|Drug|Valgancyclovir|Given orally beginning on day 1 for up to 10 days post-transplant (until participant discharged from hospital if prior to 10 days). Dose adjusted based on participants calculated creatinine clearance
1736080|NCT00078559|Drug|Acyclovir|400 mg orally twice daily or 800 mg orally four times daily (dose adjusted based on calculated creatinine clearance and cytomegalovirus antibody serologic status of donor and recipient) for a minimum of 3 months starting when valganciclovir discontinued.
1736081|NCT00078559|Drug|Pentamidine|300 mg/6 mL inhalation therapy once monthly for a total of 6 treatments. First treatment given within one week post-transplant for participants with a known allergy or intolerance to sulfa
1736082|NCT00078559|Drug|Clotrimazole|10 mg orally four times daily for a minimum of 3 months post-transplant (subjects take either clotrimazole or nystatin, not both)
1736083|NCT00078559|Drug|Nystatin|500,000 units/5 mL orally four times daily for a minimum of 3 months post-transplant (subjects take either nystatin or clotrimazole, not both)
1736086|NCT00078585|Biological|PROSTVAC®-VF/TRICOM™|
1736087|NCT00078598|Drug|Rituximab or Iodine I 131 Tositumomab Therapy|
1736088|NCT00078611|Drug|natalizumab|
1736089|NCT00078624|Other|Traditional exercise therapy for knee osteoarthritis|Exercises include stretching, strengthening, and aerobic exercise
1736090|NCT00078624|Other|Knee stability training|The addition of agility and perturbation training techniques to the traditional exercise program
1736091|NCT00078637|Drug|E7820|
1736092|NCT00078663|Behavioral|Oral Care|
1736093|NCT00078689|Drug|Daclizumab|
1736094|NCT00078715|Drug|Yohimbine hydrochloride|Participants receive yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
1736095|NCT00078715|Drug|Placebo|Participants receive an inactive equivalent of yohimbine 0.125 mg/kg administered over 3 minutes during REM sleep.
1736096|NCT00078728|Behavioral|Family-Based Anxiety Prevention Program|Participants in the prevention program will have weekly sessions with a therapist and will learn skills to help reduce anxiety for 8 weeks. The intervention will begin immediately after randomization to the study.
1736097|NCT00078728|Behavioral|Evaluation only|Participants will undergo evaluations without active treatment for 8 weeks.
1736098|NCT00078741|Behavioral|Cognitive Behavioral Therapy (CBT)|
1736099|NCT00078754|Drug|Fluoxetine|Fluoxetine capsules by mouth, up to 60 mg daily
1736100|NCT00078754|Drug|Divalproex|Divalproex ER capsules by mouth, up to 3000 mg daily
1736101|NCT00078754|Drug|Placebo|Placebo capsules by mouth, up to 8 capsules daily
1736102|NCT00078767|Behavioral|Trauma-Focused Cognitive Behavioral Therapy|12 weeks of Trauma-Focused CBT (TF-CBT)for youth and parent
1736103|NCT00078767|Drug|Sertraline Pill|12 weeks of Sertraline pill, flexible dosage of 50-150 mg/day, to be administered while receiving TF-CBT
1736104|NCT00078767|Drug|Placebo Oral Tablet|12 weeks of Placebo pill, flexible dosage, of 50-150 mg/day, to be administered while receiving TF-CBT
1736105|NCT00078793|Drug|Enbrel®|Etanercept alone, etanercept plus methotrexate or other DMARDs
1736106|NCT00078806|Drug|Enbrel|Enbrel
1736107|NCT00078806|Drug|Placebo|placebo
1736108|NCT00078819|Drug|Enbrel®|0.8 mg/kg (up to an intended dose of 50 mg) once weekly
1736109|NCT00078819|Drug|Placebo|0.8 mg/kg (up to an intended dose of 50 mg) once weekly
1736110|NCT00078832|Drug|anastrozole|aromatase inhibitor
1736111|NCT00078832|Drug|placebo|Arimidex placebo
1736112|NCT00078845|Drug|Amifostine|500 mg three times a week.
1736113|NCT00078858|Drug|fludarabine phosphate|Given IV
1736114|NCT00078858|Radiation|total-body irradiation|Undergo TBI
1736115|NCT00078858|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBMC transplantation
1736116|NCT00078858|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBMC transplantation
1736117|NCT00078858|Drug|cyclosporine|Given PO
1736118|NCT00078858|Drug|mycophenolate mofetil|Given PO or IV
1736119|NCT00078858|Other|laboratory biomarker analysis|Correlative studies
1736120|NCT00078897|Drug|Selenium|Participants will be randomized either to selenium or placebo, taking the randomized intervention for 3 to 5 years, depending on when their recommended follow up colonoscopy is scheduled.
1736121|NCT00078910|Drug|exisulind|
1736122|NCT00078910|Procedure|conventional surgery|
1736123|NCT00078910|Procedure|neoadjuvant therapy|
1736124|NCT00078923|Dietary Supplement|soy isoflavones|
1736125|NCT00078923|Procedure|neoadjuvant therapy|Prostatectomy or Brachytherapy
1736288|NCT00079677|Drug|Placebo|Matching placebo tablets once daily
1736126|NCT00078923|Other|Placebo|Arm I: 4 placebo capsules Arm II: 3 placebo capsules Arm III: 2 placebo capsules
1736127|NCT00078949|Biological|rituximab|Given IV
1736128|NCT00078949|Drug|cisplatin|Given IV
1736129|NCT00078949|Drug|cytarabine|Given IV
1736130|NCT00078949|Drug|dexamethasone|Given IV
1736131|NCT00078949|Drug|gemcitabine hydrochloride|Given IV
1736132|NCT00078962|Biological|GTI-2040|Given IV
1736133|NCT00078962|Drug|gemcitabine hydrochloride|Given IV
1736134|NCT00078962|Other|laboratory biomarker analysis|Correlative studies
1736135|NCT00078962|Other|pharmacological study|Correlative studies
1736136|NCT00078975|Drug|gemcitabine hydrochloride|
1736137|NCT00078975|Drug|triapine|
1736138|NCT00078988|Biological|filgrastim|Given IV
1736139|NCT00078988|Drug|carboplatin|Given IV
1736140|NCT00078988|Drug|etoposide|Given IV
1736141|NCT00078988|Drug|isotretinoin|Given IV
1736142|NCT00078988|Drug|thiotepa|Given IV
1736143|NCT00078988|Procedure|autologous bone marrow transplantation|Peripheral blood stem cells or bone marrow will be reinfused about 72 hours following completion of the last dose of chemotherapy (Day 0)
1736144|NCT00078988|Procedure|peripheral blood stem cell transplantation|Filgrastim is to be given daily in the afternoon for 4 days prior to the first harvest and continued until the completion of the daily harvests. The daily PBSC harvesting should be started prior to the fifth dose of filgrastim.
1736145|NCT00079001|Drug|zoledronic acid|Given IV
1736146|NCT00079001|Other|placebo|Given IV
1736147|NCT00079001|Drug|androgen deprivation therapy|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive androgen deprivation therapy per SWOG-9346. All other patients will receive androgen deprivation therapy at a standard dose and schedule throughout the study.
1736148|NCT00079001|Drug|GnRH agonist|Patients concurrently enrolled on the Phase III study of intermittent androgen deprivation in patients with stage D2 prostate cancer will receive the GnRH agonist per SWOG-9346. All other patients will receive GnRH agonist at a standard dose and schedule throughout the study.
1736149|NCT00079001|Dietary Supplement|Calcium supplement|Patients will receive 500 mg by mouth daily of a calcium supplement or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
1736150|NCT00079001|Dietary Supplement|Vitamin D|Patients will receive a multivitamin tablet containing 400-500 IU vitamin D by mouth daily or a combination tablet containing approximately 500 mg elemental calcium and 400-500 IU vitamin D by mouth daily.
1736151|NCT00079014|Drug|triapine|Given IV
1736152|NCT00079014|Drug|doxorubicin hydrochloride|Given IV
1736153|NCT00079014|Other|laboratory biomarker analysis|Correlative studies
1736154|NCT00079014|Other|pharmacological study|Correlative studies
1736155|NCT00079027|Drug|doxorubicin hydrochloride|
1736156|NCT00079027|Procedure|hepatic artery embolization|
1736157|NCT00079040|Drug|cisplatin|Given IV
1736158|NCT00079040|Drug|etoposide|Given IV
1736159|NCT00079040|Biological|bevacizumab|Given IV
1736160|NCT00079040|Other|laboratory biomarker analysis|Correlative studies
1736161|NCT00079053|Drug|erlotinib hydrochloride|
1736162|NCT00079053|Procedure|adjuvant therapy|
1736163|NCT00079066|Biological|cetuximab|
1736164|NCT00079066|Procedure|quality-of-life assessment|
1736165|NCT00079079|Drug|carboplatin|
1736166|NCT00079079|Drug|cisplatin|
1736167|NCT00079079|Drug|gemcitabine hydrochloride|
1736168|NCT00079092|Drug|procarbazine hydrochloride|
1736169|NCT00079092|Drug|thalidomide|
1736170|NCT00079105|Biological|bleomycin sulfate|Treatment
1736171|NCT00079105|Drug|cyclophosphamide|Treatment
1736172|NCT00079105|Drug|etoposide|Treatment
1736173|NCT00079105|Drug|mitoxantrone hydrochloride|Treatment
1736174|NCT00079105|Drug|prednisolone|Treatment
1736175|NCT00079105|Drug|procarbazine hydrochloride|Treatment
1736176|NCT00079105|Drug|vinblastine sulfate|Treatment
1736177|NCT00079118|Drug|docetaxel|
1736178|NCT00079118|Drug|irinotecan hydrochloride|
1736179|NCT00079131|Biological|oblimersen sodium|Given IV
1736180|NCT00079131|Other|pharmacological study|Correlative studies
1736181|NCT00079131|Other|laboratory biomarker analysis|Correlative studies
1736182|NCT00079144|Biological|NY-ESO-1 peptide vaccine|
1736183|NCT00079144|Biological|aldesleukin|
1736184|NCT00079144|Biological|filgrastim|
1736185|NCT00079144|Biological|incomplete Freund's adjuvant|
1736186|NCT00079144|Biological|therapeutic autologous lymphocytes|
1736187|NCT00079144|Drug|cyclophosphamide|
1736188|NCT00079144|Drug|fludarabine phosphate|
1736189|NCT00079157|Biological|incomplete Freund's adjuvant|
1736190|NCT00079157|Biological|sargramostim|
1736191|NCT00079157|Biological|telomerase: 540-548 peptide vaccine|
1736192|NCT00079170|Dietary Supplement|garlic|
1736193|NCT00079170|Drug|docetaxel|
1736194|NCT00079183|Drug|sirolimus|Given PO
1736195|NCT00079222|Drug|itraconazole|
1736196|NCT00079222|Drug|voriconazole|
1736197|NCT00079235|Drug|temsirolimus|Given IV
1736198|NCT00079235|Other|laboratory biomarker analysis|Correlative studies
1736199|NCT00079248|Biological|therapeutic progesterone|
1736200|NCT00079248|Drug|conjugated estrogens|
1736201|NCT00079261|Drug|CHOP regimen|
1736202|NCT00079261|Drug|cyclophosphamide|
1736203|NCT00079261|Drug|doxorubicin hydrochloride|
1736204|NCT00079261|Drug|gemcitabine hydrochloride|
1736205|NCT00079261|Drug|prednisone|
1736206|NCT00079261|Drug|vincristine sulfate|
1736207|NCT00079274|Drug|irinotecan hydrochloride|Given IV
1736208|NCT00079274|Drug|oxaliplatin|Given IV
1736209|NCT00079274|Drug|leucovorin calcium|Given IV
1736210|NCT00079274|Drug|fluorouracil|Given IV
1736211|NCT00079274|Biological|cetuximab|Given IV
1736212|NCT00079274|Drug|Locally Directed Therapy|Patients determined to have mutated KRAS (or KRAS not evaluable) will be assigned to an event monitoring arm in which adjuvant therapy will be determined and assigned by the treating oncologist. The determination of the type of therapy, duration of treatment, and dose modification will be the responsibility of the treating oncologists.
1736213|NCT00079287|Drug|carboplatin|
1736214|NCT00079287|Drug|docetaxel|
1736215|NCT00079287|Drug|gemcitabine hydrochloride|
1736216|NCT00079287|Drug|paclitaxel|
1736217|NCT00079287|Drug|vinorelbine tartrate|
1736218|NCT00079300|Drug|imiquimod|
1736219|NCT00079300|Procedure|conventional surgery|
1736220|NCT00079313|Drug|Imatinib|
1736221|NCT00079326|Biological|trastuzumab|Given IV
1736222|NCT00079326|Drug|ixabepilone|Given IV
1736223|NCT00079326|Other|laboratory biomarker analysis|Correlative studies
1736224|NCT00079339|Radiation|radiation therapy|Undergo radiotherapy
1736225|NCT00079339|Drug|tipifarnib|Given orally
1736226|NCT00079352|Drug|alvocidib|Given IV
1736227|NCT00079352|Drug|gemcitabine hydrochloride|Given IV
1736228|NCT00079352|Drug|irinotecan hydrochloride|Given IV
1736229|NCT00079365|Drug|fluorouracil|
1736230|NCT00079365|Drug|gemcitabine hydrochloride|
1736231|NCT00079365|Radiation|brachytherapy|
1736232|NCT00079365|Radiation|phosphorus P32|
1736233|NCT00079365|Radiation|radiation therapy|
1736234|NCT00079378|Drug|decitabine|Given IV
1736235|NCT00079378|Drug|valproic acid|Given orally
1736236|NCT00079378|Other|pharmacological study|Correlative studies
1736237|NCT00079378|Other|laboratory biomarker analysis|Correlative studies
1736238|NCT00079391|Device|allogeneic hematopoietic stem cell transplantation|Manipulated Peripheral Blood Stem Cell graft on Day 0. Target CD34+ dose 6 x10e6/kg, (range 3 to 8x10e6/kg) CD3+ dose fixed to 2 x 10e4/kg.
1736239|NCT00079404|Drug|tanespimycin|Given IV
1736240|NCT00079417|Procedure|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
1736241|NCT00079417|Procedure|infrared laser therapy|"Laser therapy or photobiomodulation is the use of specific wavelength of light (red and near-infrared) to create therapeutic effects"
1736242|NCT00079417|Radiation|iodine I 125|Undergo radioactive therapy
1736243|NCT00079417|Radiation|ruthenium Ru 106|Undergo radioactive therapy
1736244|NCT00079417|Drug|carboplatin|Given IV
1736245|NCT00079417|Drug|vincristine sulfate|Given IV
1736246|NCT00079417|Radiation|radiation therapy|Undergo radioactive therapy
1736247|NCT00079430|Procedure|adjuvant therapy|
1736248|NCT00079430|Drug|paclitaxel|Given IV
1736249|NCT00079430|Drug|carboplatin|Given intraperitoneally
1736250|NCT00079430|Biological|bevacizumab|Given IV
1736251|NCT00079443|Drug|romidepsin|Given IV
1736252|NCT00079443|Biological|rituximab|Given IV
1736253|NCT00079443|Drug|fludarabine phosphate|Given IV
1736254|NCT00079443|Other|laboratory biomarker analysis|Correlative studies
1736255|NCT00079456|Drug|temsirolimus|Given IV
1736256|NCT00079456|Other|pharmacological study|Correlative studies
1736257|NCT00079456|Other|laboratory biomarker analysis|Correlative studies
1736258|NCT00079469|Behavioral|smoking cessation intervention|
1736259|NCT00079469|Drug|bupropion hydrochloride|
1736260|NCT00079482|Drug|CEP-701|
1736261|NCT00079482|Drug|high-dose cytarabine|Chemotherapy
1736262|NCT00079482|Drug|Mitozantrone, Etoposide, Cytarabine (combination Chemotherapy)|Chemotherapy
1736263|NCT00079495|Drug|NBI-5788|
1736264|NCT00079508|Drug|Angiomax (bivalirudin)|250 mg vial administered as 1.0 mg/kg intravenous (IV) bolus and 2.5 mg/kg/h IV infusion during the procedure with the option to administer additional 0.1 to 0.5 mg/kg boluses to increase the level of anticoagulation as clinically indicated. A low-dose infusion could have been administered in the preoperative phase (up to 48 hours before the procedure) and in the postoperative phase (up to 14 days after the procedure) as clinically indicated for management of HIT/TS. A starting bolus of 0.1 mg/kg and/or an infusion of 0.2 mg/kg/h titrated to a desired activated partial thromboplastin time (aPTT), eg, 1.5-2.5 times baseline aPTT, was recommended.
1736265|NCT00079521|Procedure|Therapeutic Touch|
1736266|NCT00079534|Behavioral|Non-local/distant healing or prayer|
1736267|NCT00079547|Behavioral|Low-calorie diet|low-calorie diet
1736268|NCT00079547|Behavioral|low-carbohydrate diet|low-carbohydrate diet
1736269|NCT00079560|Drug|dronabinol|dronabinol to prevent development of marijuana withdrawal
1736270|NCT00079573|Behavioral|Atkins diet (extremely low carbohydrate)|
1736271|NCT00079573|Behavioral|Zone diet (low carbohydrate, high protein)|
1736272|NCT00079573|Behavioral|Ornish diet (very low fat)|
1736273|NCT00079586|Drug|Heparin|Unfractionated Heparin per institutional practice
1736274|NCT00079586|Drug|Bivalirudin|1.0 mg/kg IV bolus followed by a 2.5 mg/kg/hr IV infusion
1736275|NCT00079599|Drug|L-carnitine|A study drug, L-carnitine, titrating the doses from 0.5 g to 3 g to reduce the possibility of side effects, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
1736276|NCT00079599|Other|Placebo|A placebo, where patients underwent the dose titration identical to the study patients, lasting for two weeeks followed by an extension phase where all patients recieved L-carnitine for an additional two weeks.
1736277|NCT00079612|Drug|Sorafenib (Nexavar, BAY43-9006)|800mg daily (2x 400mg tabs)
1736278|NCT00079612|Drug|Placebo|2x 400mg tabs daily
1736279|NCT00079625|Drug|Th2/Tc2 Cells|
1736280|NCT00079638|Drug|Niacin|
1736281|NCT00079638|Drug|Atorvastatin|
1736282|NCT00079638|Drug|Simvastatin|
1736283|NCT00079638|Drug|Ezetimibe|
1736284|NCT00079638|Drug|Rosuvastatin|
1736285|NCT00079651|Behavioral|Montessori-based dementia programming|
1736286|NCT00079664|Behavioral|Tai Chi|
1736287|NCT00079677|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg once daily in the morning
1736603|NCT00081848|Drug|Celecoxib|
1736289|NCT00079716|Drug|SGN-40 (anti-huCD40 mAb)|0.5-8 mg/kg IV (in the vein) on Day 1; 0-8 mg/kg on Day 4; 0.5-16 mg/kg on Days 8 and 15; 0-16 mg/kg on Day 29.
1736290|NCT00079742|Drug|Nutropin AQ [somatropin (DNA origin) injection]|
1736291|NCT00079755|Drug|SGN-30 (anti-CD30 mAb)|
1736292|NCT00079768|Drug|Alemtuzumab (Campath)|
1736293|NCT00079781|Procedure|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
1736294|NCT00079781|Device|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
1736295|NCT00079794|Drug|Iscar|
1736296|NCT00079794|Drug|mistletoe|
1736297|NCT00079807|Drug|Alpha-Lipoic Acid|
1736298|NCT00079820|Biological|ACAM3000 MVA Vaccine|Two subcutaneous injections of MVA3000 smallpox vaccine, separated by 28 days
1736299|NCT00079833|Drug|Esomeprazole magnesium (Nexium)|
1736300|NCT00079846|Drug|Implitapide|
1736301|NCT00079859|Drug|Implitapide|
1736302|NCT00079872|Drug|Pemetrexed|
1736303|NCT00079885|Drug|tigecycline|
1736304|NCT00079898|Procedure|Acupuncture|
1736305|NCT00079911|Drug|valacyclovir hydrochloride|valacyclovir hydrochloride
1736306|NCT00079924|Drug|teriparatide|
1736307|NCT00079924|Drug|aldrenodate|
1736308|NCT00079924|Drug|raloxifene|
1736309|NCT00079937|Drug|Omalizumab|The omalizumab dose administered, based on the patient's body weight and total serum IgE level at Screening, and the number of injections and injection volume was determined from the dosing tables in the protocol. Omalizumab 75 to 375 mg was administered subcutaneous (SC) every 2 or 4 weeks depending on the dose.
1736310|NCT00079937|Drug|Placebo|Placebo was administered subcutaneous (SC) every 2 or 4 weeks depending on the dosing schedule in the protocol.
1736311|NCT00079937|Drug|Fluticasone|Patients entered the study using their current formulation of any inhaled steroid (proprietary drug and device) ≥ 200 μg/day equivalent of fluticasone administered with a dry-powder inhaler.
1736312|NCT00079950|Drug|Pegamotecan|
1736313|NCT00079963|Dietary Supplement|Vitamin C|1000 mg/day
1736314|NCT00079963|Dietary Supplement|Vitamin E|800 IU/day
1736315|NCT00079963|Dietary Supplement|Placebo|
1736316|NCT00079976|Drug|Tigecycline|
1736317|NCT00079989|Drug|tigecycline|
1736318|NCT00080002|Drug|Pegamotecan|
1736319|NCT00080015|Drug|Diflomotecan (BN80915)|
1736320|NCT00080028|Drug|Motexafin Gadolinium Injection|
1736321|NCT00080041|Drug|Motexafin Gadolinium Injection|
1736322|NCT00080054|Drug|Motexafin Gadolinium Injection|
1736323|NCT00080080|Drug|talabostat (PT-100) tablets|
1736324|NCT00080080|Drug|Docetaxel|
1736325|NCT00080093|Behavioral|Individual feedback and specially-tailored manuals|Individual feedback and specially-tailored manuals
1736326|NCT00080093|Behavioral|General HIV information feedback and the best-available information|General HIV information feedback and the best-available information
1736327|NCT00080106|Biological|MRK Ad5 HIV-1 gag vaccine|MRK Ad5 HIV-1 gag vaccine injected into the upper arm muscle.
1736328|NCT00080106|Other|Vaccine placebo|MRK Ad5 HIV-1 gag placebo vaccine injected into the upper arm muscle.
1736329|NCT00080119|Drug|Isoniazid (INH)|Antibiotic for the prevention and treatment of TB
1736330|NCT00080119|Drug|Trimethoprim/Sulfamethoxazole (TMP/SMX)|Antibiotic for the prevention and treatment of pneumocystis pneumonia (PCP)
1736331|NCT00080119|Drug|Isoniazid Placebo (PL)|Isoniazid placebo and TMP/SMX
1736332|NCT00080132|Drug|implitapide|
1736333|NCT00080145|Drug|Risperidone|
1736334|NCT00080145|Behavioral|Behavior Therapy|
1736335|NCT00080158|Drug|fluoxetine|
1736336|NCT00080158|Drug|sertraline|
1736337|NCT00080158|Drug|citalopram|
1736338|NCT00080158|Drug|escitalopram|
1736339|NCT00080158|Drug|bupropion|
1736340|NCT00080158|Drug|mirtazapine|
1736341|NCT00080158|Drug|venlafaxine|
1736342|NCT00080158|Drug|lithium|
1736343|NCT00080158|Behavioral|Cognitive Behavioral Therapy|
1736344|NCT00080184|Procedure|Low Energy Neurofeedback System|
1736345|NCT00080197|Drug|E7070|
1736346|NCT00080210|Drug|Puricase|
1736347|NCT00080223|Drug|Pirfenidone|up to 3600 mg/day of pirfenidone given orally administered in divided doses three times daily with food, for the duration of the study
1736348|NCT00080236|Drug|IDN-6556|
1736349|NCT00080236|Drug|Placebo|
1736350|NCT00080262|Drug|Ixabepilone|Solution, IV, 40 mg/m2, every 21 days, extended, until PD or discontinued for other reasons.
1736351|NCT00080275|Drug|Niacin Extended-Release and simvastatin Tablets|
1736352|NCT00080288|Drug|Armodafinil 150 mg/day|Armodafinil 150 mg taken 30 minutes to 1 hour before the start of the night shift, but no later than 2300, only on nights worked.
1736353|NCT00080288|Drug|Placebo|Matching placebo tablets once daily
1736354|NCT00080301|Drug|Ixabepilone + Capecitabine|"Ixabepilone - Intravenous Solution, IV 40mg/m², Day 1 every 21 days, Until progression/unacceptable toxicity
Capecitabine (Active Comparator) - Tablet, Oral, 2000 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity"
1736355|NCT00080301|Drug|Capecitabine|Tablet, Oral, 2500 mg/m², Bid Days 1-14 every 21 days, Until progression/unacceptable toxicity
1736356|NCT00080314|Drug|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
1736357|NCT00080314|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
1736358|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 2mg, Once daily, 6 weeks.
1736359|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 5mg, Once daily, 6 weeks.
1736360|NCT00080327|Drug|Aripiprazole|Tablets, Oral, 10mg, Once daily, 6 weeks.
1736361|NCT00080327|Drug|Placebo|Tablets, Oral, 0mg, Once daily, 6 weeks.
1736362|NCT00080340|Drug|TLK286 (Telcyta) HCl for Injection|
1736363|NCT00080340|Drug|gefitinib (Iressa)|
1736364|NCT00080353|Drug|IL-2|
1736365|NCT00080353|Drug|gp100:209-217|
1736366|NCT00080353|Drug|OKT3|
1736367|NCT00080353|Drug|rF-go 100P209|
1736368|NCT00080353|Drug|Montanide ISA 51|
1736369|NCT00080366|Drug|1-Octanol|
1736370|NCT00080392|Drug|DNA Plasmid Vector|
1736371|NCT00080392|Drug|EW-A-401 DNA Plasmid Vector|
1736372|NCT00080405|Drug|Bortezomib|
1736373|NCT00080418|Drug|Liposome Entrapped Paclitaxel Easy to Use|
1736374|NCT00080431|Drug|Daclizumab|
1736375|NCT00080444|Drug|aprepitant|aprepitant capsules
1736376|NCT00080444|Drug|ondansetron|ondansetron IV preparation
1736377|NCT00080444|Drug|dexamethasone|dexamethasone tablets
1736378|NCT00080444|Drug|placebo to aprepitant|Matching placebo to aprepitant capsules
1736379|NCT00080444|Drug|placebo to dexamethasone|Matching placebo to dexamethasone tablets
1736380|NCT00080444|Drug|rescue medication|Participants are allowed to take rescue medication throughout for nausea or vomiting. At the discretion of the investigator, participants are provided with a prescription for rescue medications. Recommended rescue medications are: 5-HT3 antagonists, phenothiazines, butyrophenones, benzamides, corticosteroids, benzodiazepines, domperidone, H1-receptor antagonist, and piperazine derivatives.
1736381|NCT00080457|Drug|sitaxsentan sodium|
1736382|NCT00080470|Device|bion|battery powered microstimulator
1736383|NCT00080483|Drug|Testosterone plus somatropin|AndoGel 5 grams transdermally a day for two years Somatropin 2 µg/kg body weight/day for two years
1736384|NCT00080483|Drug|testosterone|AndroGel transdermally 5 g a day for two years
1736385|NCT00080496|Drug|Tigecycline|
1736386|NCT00080496|Drug|Imipenem|
1736387|NCT00080496|Drug|Cilastatin|
1736388|NCT00080509|Drug|KOS-862|
1736389|NCT00080522|Behavioral|Monitoring by HIV-trained primary care nurses|
1736390|NCT00080522|Behavioral|Community-based directly observed therapy (DOT)|
1736391|NCT00080522|Drug|stavudine|
1736392|NCT00080522|Drug|lamivudine|
1736393|NCT00080522|Drug|efavirenz|
1736394|NCT00080522|Drug|zidovudine|
1736395|NCT00080522|Drug|didanosine|
1736396|NCT00080522|Drug|lopinavir/ritonavir|
1736397|NCT00080535|Biological|LMB-2|30 micrograms/kg every other day (QOD) x 3 every 4 weeks
1736398|NCT00080574|Procedure|Skin Biopsy|
1736399|NCT00080613|Drug|exemestane|
1736400|NCT00080613|Procedure|adjuvant therapy|
1736401|NCT00080613|Procedure|aromatase inhibition|
1736402|NCT00080613|Procedure|conventional surgery|
1736403|NCT00080613|Procedure|endocrine therapy|
1736404|NCT00080613|Procedure|hormone therapy|
1736405|NCT00080613|Procedure|neoadjuvant therapy|
1736406|NCT00080613|Procedure|surgery|
1736407|NCT00072657|Behavioral|Cognitive Behavioral Therapy|The CBT intervention will have three phases: 1) education on the nature of the adjustment process in chronic illness, 2) coping skill development, and 3) generalization and application of skills to everyday situations. Participants in the CBT group will attend 12 weekly group sessions of about 2 hours each.
1736408|NCT00072657|Behavioral|Tai Chi Chih|Participants in the TCC group will learn to perform 18 movements under the guidance of an expert TCC teacher. TCC participants will have 50- to 60-minute biweekly sessions during the 12-week study.
1736409|NCT00072657|Behavioral|Health Education Seminar|Control group participants will attend weekly group educational sessions; these sessions will provide general knowledge about arthritis health and illness, and they will include lectures, demonstrations, and question-and-answer sessions with experts in rheumatology, sleep science, and behavioral medicine.
1736410|NCT00072670|Drug|Trabectedin|Trabectedin will be administered intravenously as either 0.58 milligram per square meter (mg/m^2) weekly as 3-hour infusion or 1.5 mg/m^2 or 1.2 mg/m^2 every three weeks as 24-hour infusion until disease progression or unacceptable toxicity.
1736411|NCT00072683|Drug|tolvaptan|
1736412|NCT00072709|Drug|TCH346|
1736413|NCT00072722|Drug|CC-4047|
1736414|NCT00072735|Procedure|Electrocardiogram|
1736415|NCT00072748|Drug|EKB-569|
1736416|NCT00072761|Procedure|transfusion therapy|Those in the blood transfusion group will receive at least monthly blood transfusion therapy.
1736417|NCT00072774|Drug|DVS-233 SR|
1736418|NCT00072787|Drug|S-1|
1736419|NCT00072787|Drug|cisplatin|
1736420|NCT00072826|Drug|Oxypurinol|
1736421|NCT00072826|Drug|L-NMMA|
1736422|NCT00072826|Drug|Acetylcholine|
1736423|NCT00072839|Drug|ALX-0600|teduglutide
1736424|NCT00072839|Drug|placebo|placebo solution injected subcutaneously
1736425|NCT00072839|Drug|teduglutide 0.05|0.05 mg/jg/d subcutaneous daily injection into thigh or abdomen
1736426|NCT00072839|Drug|teduglutide 0.2 mg|0.2 mg/kg/d subcutaneously injected into thigh or abdomen
1736427|NCT00072839|Drug|Teduglutide 0.05 dose|0.05 mg/kg/d subcutaneous daily injection into thigh or abdomen
1736428|NCT00072839|Drug|teduglutide 0.1 mg dose|0.1 mg/kg/d daily subcutaneous injection into thigh or abdomen
1736429|NCT00072852|Drug|Irinotecan|
1736430|NCT00072865|Drug|Pemetrexed|
1736431|NCT00072865|Drug|Carboplatin|
1736432|NCT00072891|Behavioral|telephone counseling|
1736433|NCT00072904|Drug|Insulin Asparte|Insulin asparte given 0.5 units per carb per meal
1736434|NCT00072904|Drug|Repaglinide|0.5mg tab with meals tid
1736435|NCT00072930|Biological|MEDI-522|IV at a concentration of 50 mg/mL and 10mL vials
1736436|NCT00072930|Biological|Docetaxel + Prednisone* + Zoledronic Acid|IV 75 mg/m2 IV 3-4 mg 5 mg
1736437|NCT00072943|Drug|anti-Interferon-gamma monoclonal antibody|
1736438|NCT00072969|Drug|Daclizumab|
1736442|NCT00072995|Behavioral|Four Diets Differing in Macronutrient Composition|
1736443|NCT00072995|Behavioral|Diets Low in Saturated Fat|
1736444|NCT00073008|Drug|GW572016 (lapatinib)|tyrosine kinase inhibitor
1736445|NCT00073021|Drug|Asacol 800 mg (mesalamine)|tablets, 4.8 g/day for 6 weeks, 2 - 800 mg Asacol tablets and 2 placebo tablets 3 times daily
1736446|NCT00073021|Drug|Asacol 400 mg (mesalamine)|tablets, 2.4 g/day for 6 weeks, 2 - 400 mg Asacol tablets and 2 placebo tablets 3 times daily
1736447|NCT00073034|Drug|EAA-090|
1736448|NCT00073047|Drug|Daclizumab|
1736452|NCT00073112|Drug|ABT-751|
1736453|NCT00073125|Drug|ABT-510/Thrombospondin-1 mimetic|
1736454|NCT00073138|Drug|ABT-751|
1736455|NCT00073151|Drug|ABT-751|
1736456|NCT00073164|Drug|Divalproex Sodium Extended-Release Tablets|
1736457|NCT00073164|Drug|Olanzapine|
1736458|NCT00073164|Drug|Risperidone|
1736459|NCT00073177|Drug|Roflumilast|
1736460|NCT00073190|Behavioral|Osteoporosis Education|
1736461|NCT00080626|Biological|pegfilgrastim|6 mg injection on day 1 of each cycle
1736462|NCT00080626|Drug|docetaxel|100 mg per meter-squared, every 14 days for 4 cycles
1736463|NCT00080626|Procedure|conventional surgery|lumpectomy or mastectomy at end of treatment
1736464|NCT00080626|Procedure|neoadjuvant therapy|treatment prior to definitive breast surgery
1736465|NCT00080639|Other|physiologic testing|
1736466|NCT00080639|Procedure|study of high risk factors|
1736467|NCT00080665|Drug|docetaxel|Docetaxel (15-30 mg/m2, IV, weekly on days 1, 8, and 15) each 28 day cycle
1736468|NCT00080665|Drug|imatinib mesylate|Imatinib mesylate (400-600 mg, oral, once daily) each 28 day cycle
1736469|NCT00080678|Drug|Docetaxel|
1736470|NCT00080678|Drug|Imatinib Mesylate|
1736471|NCT00080743|Drug|gefitinib|250 mg po once daily
1736472|NCT00080743|Drug|tamoxifen citrate|20 mg po once daily
1736473|NCT00080743|Drug|Placebo|One pill po once daily
1736474|NCT00080756|Biological|therapeutic estradiol|0.35mg/100ul per day as a nasal spray
1736475|NCT00080756|Drug|deslorelin|1mg/100ul per day as a nasal spray
1736476|NCT00080756|Drug|therapeutic testosterone|0.275mg/100ul per day as a nasal spray
1736477|NCT00080756|Procedure|therapeutic conventional surgery|Undergo risk reduction mastectomy
1736478|NCT00080756|Other|active surveillance|Undergo continued surveillance
1736479|NCT00080756|Procedure|quality-of-life assessment|Ancillary studies
1736480|NCT00080756|Other|laboratory biomarker analysis|Correlative studies
1736481|NCT00080782|Drug|Celecoxib|Oral celecoxib twice daily in the absence of disease progression.
1736482|NCT00080782|Drug|Doxorubicin Hydrochloride|By vein (IV) over 30 minutes on days 1, 8, 15, and 22
1736483|NCT00080782|Radiation|Strontium chloride Sr 89|IV on day 1
1736484|NCT00080795|Biological|filgrastim|
1736485|NCT00080795|Drug|cisplatin|
1736486|NCT00080795|Drug|doxorubicin hydrochloride|
1736487|NCT00080795|Drug|gemcitabine hydrochloride|
1736488|NCT00080795|Drug|ifosfamide|
1736489|NCT00080795|Procedure|conventional surgery|
1736490|NCT00080795|Procedure|neoadjuvant therapy|
1736491|NCT00080808|Drug|Alprostadil (E1)|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
1736492|NCT00080808|Drug|Papaverine|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
1736493|NCT00080808|Drug|Phentolamine mesylate|Beginning 6 weeks after surgery, intracavernous Triplemix (prostaglandin E1, papaverine, and phentolamine) injected twice weekly
1736494|NCT00080808|Drug|Sildenafil citrate|Oral sildenafil as needed
1736495|NCT00080808|Procedure|conventional surgery|Unilateral cavernous nerve sparing radical retropubic prostatectomy
1736496|NCT00080834|Drug|DJ-927|
1736497|NCT00080847|Biological|oblimersen sodium|Given IV
1736498|NCT00080847|Biological|rituximab|Given IV
1736499|NCT00080847|Drug|cyclophosphamide|Given IV
1736500|NCT00080847|Drug|doxorubicin hydrochloride|Given IV
1736501|NCT00080847|Drug|vincristine sulfate|Given IV
1736502|NCT00080847|Drug|prednisone|Given orally
1736503|NCT00080847|Other|laboratory biomarker analysis|Correlative studies
1736504|NCT00080860|Genetic|microarray analysis|
1736505|NCT00080860|Other|immunohistochemistry staining method|
1736506|NCT00080860|Procedure|conventional surgery|
1736507|NCT00080860|Procedure|lymphangiography|
1736508|NCT00080860|Procedure|radionuclide imaging|
1736509|NCT00080860|Procedure|sentinel lymph node biopsy|
1736510|NCT00080860|Radiation|technetium Tc 99m sulfur colloid|
1736511|NCT00080873|Drug|Traumeel S|
1736512|NCT00080873|Other|Placebo|
1736513|NCT00080886|Biological|rituximab|
1736514|NCT00080886|Drug|carmustine|
1736515|NCT00080886|Drug|cytarabine|
1736516|NCT00080886|Drug|etoposide|
1736517|NCT00080886|Drug|melphalan|
1736518|NCT00080886|Procedure|autologous bone marrow transplantation|
1736519|NCT00080886|Procedure|peripheral blood stem cell transplantation|
1736520|NCT00080899|Drug|fenretinide|Given orally
1736521|NCT00080899|Other|laboratory biomarker analysis|Correlative studies
1736522|NCT00080912|Radiation|radiation therapy|Given in a single fraction or multiple fractions
1736523|NCT00080925|Biological|filgrastim|
1736524|NCT00080925|Biological|graft-versus-tumor induction therapy|
1736525|NCT00080925|Biological|rituximab|
1736526|NCT00080925|Biological|therapeutic allogeneic lymphocytes|
1736527|NCT00080925|Drug|cyclophosphamide|
1736528|NCT00080925|Drug|cyclosporine|
1736529|NCT00080925|Drug|cytarabine|
1736530|NCT00080925|Drug|doxorubicin hydrochloride|
1736531|NCT00080925|Drug|etoposide|
1736532|NCT00080925|Drug|fludarabine phosphate|
1736533|NCT00080925|Drug|prednisone|
1736534|NCT00080925|Drug|vincristine sulfate|
1736535|NCT00080925|Procedure|peripheral blood stem cell transplantation|
1736536|NCT00080938|Drug|Temozolomide|Temozolomide (TMZ) to be given at a dose of 75 mg/m2/day for 14 days, starting on D1 of whole brain radiotherapy (WBRT). Three weeks after completion of WBRT, TMZ will be given at a dose of 200 mg/m2/day x 5 days (or 150 mg/m2/day if prior chemotherapy) every 28-days,for an additional two cycles.
1736537|NCT00080938|Radiation|Radiation therapy|Standard whole brain radiation therapy 30 Gy in ten fractions.
1736538|NCT00080951|Drug|fluorouracil|
1736539|NCT00080951|Drug|irinotecan hydrochloride|
1736540|NCT00080951|Drug|leucovorin calcium|
1736541|NCT00080951|Drug|oxaliplatin|
1736542|NCT00080977|Biological|aldesleukin|
1736543|NCT00080990|Drug|alvocidib|Given IV
1736544|NCT00080990|Drug|fluorouracil|Given IV
1736545|NCT00080990|Drug|oxaliplatin|Given IV
1736546|NCT00080990|Drug|leucovorin calcium|Given IV
1736547|NCT00081003|Genetic|gene expression analysis|
1736548|NCT00081003|Genetic|protein expression analysis|
1736549|NCT00081003|Other|cytology specimen collection procedure|
1736550|NCT00081003|Other|laboratory biomarker analysis|
1736551|NCT00081003|Other|physiologic testing|
1736552|NCT00081003|Procedure|breast duct lavage|
1736553|NCT00081003|Procedure|endoscopic biopsy|
1736554|NCT00081003|Procedure|study of high risk factors|
1736555|NCT00081029|Procedure|management of therapy complications|
1736556|NCT00081029|Radiation|radiation therapy|
1736557|NCT00081042|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1736558|NCT00081055|Biological|autologous expanded mesenchymal stem cells OTI-010|
1736559|NCT00081055|Drug|busulfan|
1736560|NCT00081055|Drug|cyclophosphamide|
1736561|NCT00081055|Drug|cyclosporine|
1736562|NCT00081055|Drug|methotrexate|
1736563|NCT00081055|Procedure|peripheral blood stem cell transplantation|
1736564|NCT00081055|Radiation|radiation therapy|
1736565|NCT00081068|Biological|alemtuzumab|
1736566|NCT00081484|Drug|epoetin alfa or beta|iv or sc, as prescribed
1736567|NCT00081484|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|30, 50 or 90 micrograms iv or sc (starting dose) every 2 weeks
1736568|NCT00081497|Biological|agalsidase beta|1.0 mg/kg every 2 weeks
1736569|NCT00081510|Drug|Lonafarnib|
1736570|NCT00081510|Drug|Placebo|
1736571|NCT00081510|Drug|anastrozole|
1736572|NCT00081536|Drug|Aroplatin (Liposomal NDDP) in combination with capecitabine|
1736573|NCT00081549|Drug|Aroplatin (Liposomal NDDP, L-NDDP)|
1736574|NCT00081575|Drug|Tigecycline|
1736575|NCT00081575|Drug|Levofloxacin|
1736576|NCT00081588|Drug|TMC114|600/100 mg tablets of TMC114/rtv BID for 144 weeks or until commercial available
1736577|NCT00081601|Drug|CEP-701|
1736578|NCT00081614|Drug|Avastin (bevacizumab)|
1736579|NCT00081614|Drug|Tarceva (erlotinib HCl)|
1736580|NCT00081627|Drug|CoFactor and 5FU|
1736581|NCT00081640|Drug|PRO 2000/5 Gel (P)|
1736582|NCT00081653|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 years
1736583|NCT00081653|Drug|ibandronate [Bonviva/Boniva]|100mg po monthly for 3 years
1736584|NCT00081731|Drug|Atacand/HCT, Caduet|Atacand/HCT and caduet or optimal medical therapy for hypertension
1736585|NCT00081731|Procedure|GENESISTM Embolic Protection Stent and Angioguard Device (Angioplasty plus stenting)|Angioplasty plus stenting of the renal artery GENESISTM Embolic Protection Stent and Angioguard Device
1736586|NCT00081744|Drug|Tigecycline|
1736587|NCT00081757|Drug|Thalidomide|
1736588|NCT00081770|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|1.5 ug/kg/week subcutaneously (SC) for 48 weeks
1736589|NCT00081770|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|1.0 ug/kg/week SC for 48 weeks
1736590|NCT00081770|Drug|REBETOL (ribavirin; SCH 18908)|weight based dose 800-1400 mg/day orally (PO) for 48 weeks
1736591|NCT00081770|Biological|PEGASYS (peginterferon alfa-2a)|180 ug/week SC administered for 48 weeks
1736592|NCT00081770|Drug|COPEGUS (ribavirin)|1000-1200 mg/day PO for 48 weeks
1736593|NCT00081783|Drug|Xcellerated T Cells|
1736594|NCT00081796|Drug|larotaxel (RPR109881, XRP9881)|
1736595|NCT00081796|Drug|capecitabine|
1736596|NCT00081809|Drug|autologous human tumor-derived HSPPC-96|
1736597|NCT00081822|Drug|clofarabine|Clofarabine should be administered by daily intravenous infusion over 2 hours.Following demonstration of DLT at Dose Level -I (22.5 mg/m2/day days 2-6) and demonstration that Dose Level -II (15mg/m2day days 2-6) is the 'optimal phase II dose', an additional Dose Level -1½ (20mg/m2/day, days 2-6) will be added to explore an increased dose of clofarabine intermediate between Dose Levels -I and -II.
1736598|NCT00081822|Drug|Ara-C|Ara-C: Administer Ara-C by continuous infusion of 100mg/m2/day on days 1 to 7 for cycle 1, and on days 1 to 5 for cycles 2 & 3.
1736599|NCT00081835|Drug|NP-016 Vaccine Immune Globulin (IV-VIG)|
1736600|NCT00081848|Drug|rV-CEA(6D)/TRICOM-rF-CEA(6D)/TRICOM|
1736601|NCT00081848|Drug|rF-CEA(6D)/TRICOM|
1736602|NCT00081848|Drug|Recombinant Fowlpox-GM-CSF|
1736604|NCT00081861|Drug|Avastin|10 mg/kg given intravenously every 2 weeks for 4 doses.
1736605|NCT00081861|Drug|Rituximab|375 mg/m^2 given intravenously weekly for 8 doses, 30 minutes to 1 hour following Bevacizumab.
1736606|NCT00081874|Drug|RAD001|"Phase I: Starting dose 5 mg by mouth daily for 28 days.
Phase II: Maximum Tolerated Dose (MTD) from Phase I."
1736607|NCT00081887|Drug|Clofarabine|Starting dose is 10 mg/m^2 as a 1-hour infusion into a vein once every 2 weeks for 4 weeks (1 cycle).
1736608|NCT00081900|Drug|DENSPM )|Each patient will receive DENSPM at an initial dose of 30mg/m^2, then escalating to 120mg/m^2, single IV infusion on D1,3,5,8,10,12 of every 28 days as one cycle, planned for 8 cycles if no withdrawn occur
1736609|NCT00081913|Genetic|Cell Therapy - Autologous CD34 Positive Cells|
1736610|NCT00081926|Drug|Gleevec|
1736613|NCT00081952|Drug|L-norleucine|
1736614|NCT00081965|Procedure|acupuncture therapy|
1736615|NCT00081965|Procedure|hot flashes attenuation|
1736616|NCT00081965|Procedure|management of therapy complications|
1736617|NCT00081978|Drug|TMC125|
1736618|NCT00082017|Drug|UCN-01 (7-hydroxystaurosporine)|"UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 1, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 28 days.
UCN-01 for relapsed or refractory T-cell lymphomas - Cohort 2, Cycle 1: 45 mg/m^2/day continuous intravenous infusion 1 to 3 days (72 hours) for total dose of 135 mg/m^2 Cycle 2: 45 mg/m^2/day continuous intravenous infusion 1 to 2 days (36 hours) for total dose of 68 mg/m^2; Repeat cycles every 21 days."
1736619|NCT00082043|Drug|Dutasteride|
1736620|NCT00082043|Drug|Placebo oral capsule|
1736621|NCT00082069|Biological|Shigella flexneri 2a Invaplex 50|
1736622|NCT00082082|Drug|Thymalfasin (thymosin alpha-1)|
1736623|NCT00082082|Procedure|Trans arterial chemoembolization (TACE)|
1736624|NCT00082095|Drug|Pegylated liposomal doxorubicin|Type=exact number, unit=mg/m2, number=40, form=infusion, route=intravenous. Pegylated liposomal doxorubicin will be administered on Day 1 of each cycle. Cycle will be repeated every 28 days, up to 1 year.
1736625|NCT00082095|Drug|Capecitabine|Type=exact number, unit=mg, number=500, form=tablet, route=oral. Capecitabine will be administered at a dosage of 1000 mg/m2 twice daily for 14 consecutive days followed by a 7-day rest period. Cycle is repeated every 21 days, up to one year.
1736626|NCT00082121|Drug|TP10|
1736627|NCT00082134|Drug|ILX651|
1736629|NCT00082160|Behavioral|Meditation|
1736630|NCT00082160|Procedure|Functional Magnetic Resonance Imaging|
1736631|NCT00082173|Drug|Moxifloxacin|400mg daily for 8 weeks
1736632|NCT00082186|Drug|bosentan|Oral bosentan tablets 62.5 mg twice daly for 4 weeks, then 125 mg twice daily for 20 weeks.
1736633|NCT00082199|Drug|Aripiprazole|Tablets, Oral, 2-30mg, Once daily, 12 weeks.
1736634|NCT00082199|Drug|Placebo|Tablets, Oral, Once daily, 12 weeks.
1736635|NCT00082212|Biological|Cetuximab|400 mg/m2 loading dose, 250 mg/m2 weekly X 2 Cycles
1736636|NCT00082225|Biological|CD45 antibodies|The antibody solution is administered by a syringe pump in incremental doses, 0.2-0.8 mg in the first hour and up to 10 mg/hr thereafter, for a maximum infusion time of 8 hrs.
1736637|NCT00082225|Biological|EBV specific T cells|"The following dose levels will be evaluated: Each patient will receive 1 injection, according to the following dosing schedules:
2 x 10e7 cells/m2 5 x 10e7 cells/m2
1 x 10e8 cells/m2"
1736638|NCT00082238|Drug|Ibuprofen|
1736639|NCT00082251|Drug|Niacin extended release and simvastatin tablets|
1736640|NCT00082277|Drug|Anastrozole|1mg/Day Oral
1736641|NCT00082277|Drug|Risedronate Sodium|35mg/week, oral
1736642|NCT00082290|Other|massage therapy|
1736643|NCT00082290|Other|visit with a volunteer|
1736644|NCT00082290|Other|period of quiet time|
1736645|NCT00082290|Behavioral|questionaire about pain|
1736646|NCT00082303|Behavioral|Music Imagery|
1736647|NCT00082316|Drug|Capsaicin Dermal Patch|
1736648|NCT00082329|Drug|AMD 3100 (Mozobil plerixafor)|Healthy volunteers will be administered AMD 3100 (Mozobil plerixafor) and granulocyte colony stimulating factor (G-CSF) to determine cytokine polarization status of cluster of differentiation (CD 4) T-cells collected by apheresis
1736649|NCT00082342|Device|Phoressor II (IOMED)|sham stimulation
1736650|NCT00082342|Device|Phoressor II (IOMED)|real tDCS stimulation
1736651|NCT00082355|Drug|Alteplase (Activase, Genentech)|Dose of Alteplase will not exceed 10 mg/d/leg and is delivered in a concentration of 100ug/mL. The actual dose delivered is based upon the length of the thrombosed vein and 1 mL is injected directly into each centimeter of a thrombosed vein in a lower extremity. The treatment will be repeated up to 4 times over a 4 day period.
1736652|NCT00082368|Drug|Tariquidar|3 days after initial PET patients will receive tariquidar and repeat imaging.
1736653|NCT00082368|Drug|Tc-94m Sestamibi|Patients over 18 years of age, who are eligible for, or have completed enrollment in an active NCI (National Cancer Institute) protocol for treatment of cancer will undergo a PET sestamibi scan
1736654|NCT00082381|Drug|Exenatide (AC2993)|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 22 weeks
1736655|NCT00082381|Drug|Insulin glargine|subcutaneous injection, once daily; forced titration to target blood glucose level
1736656|NCT00082394|Drug|Trizivir|
1736657|NCT00082394|Drug|atazanavir|
1736659|NCT00082407|Drug|exenatide|subcutaneous injection, twice daily; 5 mcg for 4 weeks followed by 10 mcg for 48 weeks
1736660|NCT00082407|Drug|biphasic insulin aspart|subcutaneous injection, twice daily; titration to target blood glucose level
1736661|NCT00082433|Drug|Ixabepilone + Capecitabine|Ixabepilone lypholized powder/Diluent for solution for injection/Tablets, IV/Oral, 40 mg/m2 + Capecitabine 2000 mg/m2, Ixabepilone on Day 1 and Capecitabine twice daily Days 1-14 of 21 day cycle
1736662|NCT00082433|Drug|Capecitabine|Tablet, Oral, 2500 mg/m2, Capecitabine twice daily Days 1-14 of 21 day cycle
1736663|NCT00082446|Biological|Live vaccinia virus vaccine|Dryvax®: 0.25 mL of vaccine will be administered by the standard route of scarification using a bifurcated needle on day 112 for Groups A, B, C, D and F.
1736664|NCT00082446|Biological|MVA Smallpox Vaccine|Imvamune/MVA-BN 1x10^8 will be administered intramuscularly to Group F on day 0 and day 28.
1736665|NCT00082446|Biological|MVA Smallpox Vaccine|Imvamune/MVA-BN Groups A, B C and E will be administered subcutaneously: 2x10^7, 5x10^7, 1x10^8, 1x10^8, respectively, on days 0 and day 28.
1736666|NCT00082446|Other|Placebo|Group E will receive sterile saline placebo for injection via scarification on day 112.
1736667|NCT00082446|Other|Placebo|Group D will receive sterile saline placebo for injection subcutaneously on day 0 and day 28.
1736668|NCT00082459|Biological|autologous human tumor-derived HSPPC-96|
1736669|NCT00082472|Drug|Doxorubicin HCl Inhalation Solution|
1736670|NCT00082472|Drug|Docetaxel|
1736671|NCT00082472|Drug|Cisplatin|
1736672|NCT00082485|Drug|Baclofen|Dose escalation 10-60mg (week 1) 60 mg (weeks 2-7) Dose taper (week 8)
1736673|NCT00082485|Other|Placebo|Placebo
1736674|NCT00082498|Drug|SCH-D (vicriviroc)|Group 2 will receive 5 mg vicriviroc daily; Group 3 will receive 10 mg vicriviroc daily; and Group 4 will receive 15 mg vicriviroc daily. If at or after Week 16 a participant's viral load has not met certain criteria, a dose increase of vicriviroc may occur and the participant will enter Step 2. As of 10/12/05, patients in Group 2 and any patients who entered Step 2 following virologic failure in Step 1 will be unblinded and offered either 15 mg vicriviroc daily through this study or the option of seeking alternative treatment.
1736675|NCT00082498|Drug|Placebo|Patients in Group 1 will receive placebo.
1736676|NCT00082511|Drug|Prasterone (GL701)|"There were 4 arms to the study:
During a previous 6 month db RCT, patients received either prasterone 200 mg/day or placebo. Upon entry into this open-label study, they were re-assigned by randomized allocation to receive either prasterone 200 mg/day or 100 mg/day. Hence, there were 4 possible treatment arms extending over the 18 months of observation between the double-blind study and the subsequent 12 month open-label extension study."
1736677|NCT00082524|Drug|caspofungin acetate|Duration of Treatment - 7-90 days
1736678|NCT00082537|Drug|caspofungin acetate|Duration of Treatment: 28-90 days
1736679|NCT00082537|Drug|Comparator: AmBisome|Duration of Treatment: 28-90 days
1736680|NCT00082563|Drug|Azithromycin/Chloroquine|
1736681|NCT00082563|Drug|Chloroquine|
1736682|NCT00082576|Drug|Azithromycin/Chloroquine|
1736683|NCT00082576|Drug|Mefloquine|
1736684|NCT00082589|Drug|Eplerenone|
1736685|NCT00082602|Drug|galantamine ER|
1736688|NCT00082654|Procedure|psychosocial assessment and care|
1736689|NCT00082667|Drug|gefitinib|
1736690|NCT00082667|Procedure|Surgery|
1736691|NCT00082706|Drug|5-Fluorouracil (5-FU)|Day: 1 - 5 Dose: 200 mg/m2 IVCI daily x 5 days
1736692|NCT00082706|Drug|Leucovorin|Day: 1 - 5 Dose:10 mg/m2 daily x 5 days
1736693|NCT00082706|Drug|Cisplatin|Day: 1 - 5 Dose: 20 mg/m2 daily x 5 days
1736694|NCT00082706|Drug|Gemcitabine|Day: 1 & 5 Dose: 200 mg/m2 (Two doses only)
1736695|NCT00082719|Biological|Recombinant Interferon Alfa|"In all arms, treatment begins at pre-operative visit and continues until cystoscopy.
Arm I: Low-dose interferon alfa subcutaneously (SC) twice daily. Arm II: Interferon alfa as in arm I at a higher dose. Arm III: Interferon alfa SC once daily. Arm IV: Interferon alfa as in arm III at a higher dose."
1736696|NCT00082732|Behavioral|behavioral dietary intervention|
1736697|NCT00082732|Dietary Supplement|dietary intervention|
1736698|NCT00082732|Procedure|therapeutic dietary intervention|
1736699|NCT00082745|Other|Laboratory Biomarker Analysis|Correlative studies
1736700|NCT00082745|Other|Questionnaire Administration|Ancillary studies
1736701|NCT00082758|Biological|hu14.18-Interleukin-2 fusion protein|Given IV
1736702|NCT00082784|Drug|Bortezomib|Given IV
1736703|NCT00082784|Drug|Alvocidib Hydrochloride|Given IV
1736704|NCT00082784|Other|Pharmacological Study|Correlative studies
1736705|NCT00082797|Drug|leucovorin calcium|
1736706|NCT00082797|Drug|methotrexate|
1736707|NCT00082810|Drug|fulvestrant|Given intramuscularly
1736708|NCT00082810|Drug|tipifarnib|Given IV
1736709|NCT00082823|Biological|ziv-aflibercept|
1736710|NCT00082836|Biological|rituximab|
1736711|NCT00082836|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1736712|NCT00082862|Biological|recombinant interferon alfa|
1736713|NCT00082862|Drug|cisplatin|
1736714|NCT00082862|Drug|gemcitabine hydrochloride|
1736715|NCT00082862|Procedure|hyperthermia treatment|
1736716|NCT00082875|Drug|cilengitide|Given IV
1736717|NCT00082875|Other|pharmacological study|Correlative studies
1736718|NCT00082875|Other|laboratory biomarker analysis|Correlative studies
1736719|NCT00082888|Other|Laboratory Biomarker Analysis|Correlative studies
1736720|NCT00082888|Drug|Tipifarnib|Given PO
1736721|NCT00082914|Biological|denileukin diftitox|
1736722|NCT00082927|Drug|ibandronate sodium|
1736723|NCT00082940|Biological|denileukin diftitox|
1736724|NCT00082966|Drug|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|Given IV
1736725|NCT00082979|Genetic|cytogenetic analysis|
1736726|NCT00082979|Genetic|proteomic profiling|
1736727|NCT00082979|Other|cytology specimen collection procedure|
1736728|NCT00082979|Other|immunohistochemistry staining method|
1736729|NCT00082979|Other|laboratory biomarker analysis|
1736730|NCT00082979|Procedure|breast duct lavage|
1736731|NCT00083005|Drug|docetaxel|
1736732|NCT00083005|Drug|estramustine phosphate sodium|
1736733|NCT00083005|Drug|thalidomide|
1736734|NCT00083018|Genetic|cytogenetic analysis|
1736735|NCT00083018|Genetic|proteomic profiling|
1736736|NCT00083018|Other|cytology specimen collection procedure|
1736737|NCT00083018|Other|immunohistochemistry staining method|
1736738|NCT00083018|Other|laboratory biomarker analysis|
1736739|NCT00083018|Procedure|breast duct lavage|
1736740|NCT00083031|Biological|bevacizumab|
1736741|NCT00083031|Drug|cyclophosphamide|
1736742|NCT00083031|Drug|methotrexate|
1736743|NCT00083057|Drug|gefitinib|
1736744|NCT00083057|Drug|paclitaxel|
1736745|NCT00083057|Radiation|radiation therapy|
1736746|NCT00083070|Drug|temozolomide|
1736747|NCT00083083|Drug|carboplatin|
1736748|NCT00083083|Drug|cisplatin|
1736749|NCT00083083|Drug|docetaxel|
1736750|NCT00083083|Drug|etoposide|
1736751|NCT00083083|Drug|paclitaxel|
1736752|NCT00083083|Drug|vinblastine sulfate|
1736753|NCT00083083|Drug|vinorelbine tartrate|
1736754|NCT00083083|Genetic|gene expression analysis|
1736755|NCT00083083|Procedure|positron emission tomography|
1736756|NCT00083083|Radiation|fludeoxyglucose F 18|
1736757|NCT00083083|Radiation|radiation therapy|
1736758|NCT00083096|Drug|lonafarnib|
1736759|NCT00083096|Drug|temozolomide|
1736760|NCT00083109|Drug|Fluorouracil|Given IV
1736761|NCT00083109|Other|Pharmacological Study|Correlative studies
1736762|NCT00083109|Drug|Suramin|Given IV
1736763|NCT00083122|Drug|cisplatin|Given IV
1736764|NCT00083122|Drug|alvocidib|Given IV
1736765|NCT00083122|Drug|cisplatin/flavopiridol|Given IV
1736766|NCT00083135|Biological|filgrastim|
1736767|NCT00083135|Procedure|autologous bone marrow transplantation|
1736768|NCT00083135|Procedure|peripheral blood stem cell transplantation|
1736769|NCT00083135|Radiation|iobenguane I 131|
1736770|NCT00083148|Drug|capecitabine|
1736771|NCT00083148|Drug|irinotecan hydrochloride|
1736772|NCT00083161|Drug|cisplatin|60 mg/m2 IV day 1, every 21 days for 4 cycles.
1736773|NCT00083161|Drug|cyclophosphamide|25 mg by mouth BID days 8-19 or each cycle x 4 cycles. After restaging (if no progression) maintenance cyclophosphamide alone 25 mg by mouth BID daily until disease progression
1736774|NCT00083161|Drug|etoposide|120 mg/m2 IV days 1-3 OR 120 mg/m2 IV day 1 and 120 mg/m2 by mouth BID days 2-3
1736776|NCT00083187|Drug|hydroxyurea|
1736777|NCT00083187|Drug|laromustine|
1736778|NCT00083213|Biological|ziv-aflibercept|
1736779|NCT00083226|Drug|doxorubicin|Given IV
1736780|NCT00083226|Drug|bortezomib|Given IV
1736781|NCT00083239|Drug|talabostat (PT-100) tablets|
1736782|NCT00083252|Drug|talabostat (PT-100) tablets|
1736783|NCT00083252|Drug|cisplatin|
1736784|NCT00083278|Drug|MDX-010|
1736785|NCT00083304|Drug|Efaproxiral|"75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).
Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days."
1736786|NCT00083304|Radiation|Whole Brain Radiation Therapy (WBRT)|3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
1736787|NCT00083304|Other|Supplemental Oxygen|"4 L/minute by nasal cannula.
Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days."
1736788|NCT00083330|Drug|VRC-HIVADV014-00-VP|
1736789|NCT00083343|Drug|MK0991, caspofungin acetate/Duration of Treatment: variable|
1736790|NCT00083356|Procedure|Wisdom tooth extraction|
1736791|NCT00083382|Drug|Pamidronate|Patients will receive either pamidronate or zometa. Pamidronate is administered at a dose of 90 mg by continuous infusion over 90 minutes, every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 90 mg every 4 weeks as maintenance therapy.
1736792|NCT00083382|Drug|Thalidomide|"All Patients will receive thalidomide 200 mg as an oral, once daily dose. Dose may be reduced to as low as 50 mg qod in the event of severe toxicity. Thalidomide will continue daily as tolerated until criteria to remove from study are met.
Patients will receive appropriate regimen to prevent constipation (i.e., colace, dulcolax, milk of magnesia, or lactulose)"
1736793|NCT00083382|Drug|Zometa|Patients will receive either pamidronate or zometa. Zometa is administered at a dose of 4 mg by continuous infusion every two weeks for 2 months. Disease will be reassessed after two cycles. Those with stable disease or better will receive 4 mg every 4 weeks as maintenance therapy.
1736794|NCT00083408|Drug|Pamidronate|
1736795|NCT00083408|Drug|Thalidomide|
1736796|NCT00083421|Drug|ONO-2506PO|
1736797|NCT00083434|Drug|Epoetin alfa|
1736798|NCT00083447|Drug|TransMID™|
1736799|NCT00083460|Drug|PS-341|Arm 1 a dose of 1.0mg/m2. Arm 2 a dose of 1.3mg/m2
1736800|NCT00083460|Drug|Thalidomide|In cohort 1, a dose of 50mg for cycles 2-8. Cohort 2, 100mg for cycles 2-8. Cohort 3, 150mg for cycles 2-8. Cohort 4, 200mg for cycles 2-8.
1736801|NCT00083460|Drug|Dexamethasone|A dose of 20mg for cylces 3-8.
1736802|NCT00083473|Drug|Pivanex|
1736803|NCT00083486|Drug|epoetin alfa|
1736804|NCT00083525|Drug|WX-UK1 in combination with Capecitabine|
1736805|NCT00083538|Drug|Dexamethasone|
1736806|NCT00083538|Drug|Thalidomide|
1736807|NCT00083538|Drug|Cisplatinum|
1736808|NCT00083538|Drug|Adriamycin|
1736809|NCT00083538|Drug|Cyclophosphamide|
1736810|NCT00083538|Drug|Etoposide|
1736857|NCT00083824|Drug|Medroxyprogesterone 17-Acetate|2.5 mg/day QID for 3 years
1736811|NCT00083551|Drug|Thalidomide|All patients will be randomly assigned to receive thalidomide 400 mg as an oral, once daily dose throughout induction and 100mg between transplants after platelets are greater than 50,000μl and 200 mg post transplant consolidation, and a reduced dose of 100 mg on alternating days during the first year of maintenance and 50 mg qod thereafter versus no thalidomide. Thalidomide will be held during conditioning, transplant procedure, and recovery following transplant. It may be resumed once plateletrecovery is complete after each transplant
1736812|NCT00083551|Drug|Ara-C|"Cytarabine (Ara-C) 400 mg/m2 in 250 ml D5W over one hour daily for four days (on days -5, -4, -3, -2).
Start infusion 30 minutes after completion of BCNU on day -5."
1736813|NCT00083551|Drug|BCNU|Carmustine (BCNU) 300 mg/m2 in 1 liter of D5W in glass bottle (protect from light) to infuse over 2 hours on day -5. Check blood pressure every 15 minutes during infusion and 30 minutes after completion
1736814|NCT00083551|Drug|Cisplatin|"Cisplatin* 15 mg/m2/day Continuous infusion 1-4 (DCEP CYCLE 2) Cisplatin* 7.5 mg/m2 Continuous infusion 1-4 (DPACE cycle)
*Cisplatin doses will be modified for renal insufficiency as follows: Cisplatin dose Creatinine 15 mg/m2 (full dose) < 1.5 mg/dl 10 mg/m2 1.6 - 2.0 mg/dl 7.5 mg/m2 2.1 - 3.0 mg/dl 0 mg (hold Cisplatin) > 3.0 mg/dl"
1736815|NCT00083551|Drug|Cytoxan|Cycle 2 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cycle 3 - CAD and PBSC Collection #1 Cyclophosphamide 750 mg/m2/day Continuous infusion 1-4 Cycle 4 - DCEP Cyclophosphamide 400 mg/m2/day Continuous infusion 1-4 Cytoxan/VP-16 and PBSC Collection-Cyclophosphamide 2 grams/m2 (Total dose 4 gm/m2) IV by CI 1 and 2 Post-Transplant Consolidation-Cyclophosphamide 300 mg/m2 Continuous infusion 1-4
1736816|NCT00083551|Drug|Dexamethasone|Induction cycle 1 VAD Dexamethasone 40 mg/day PO 1-4, 9-12, 17-20 Cycle 2 - DCEP Dexamethasone 40 mg/day PO 1-4 Cycle 3 - CAD and PBSC Collection #1 Dexamethasone 40 mg/day PO 1-4 Cycle 4 - DCEP and PBSC Collection #2 Dexamethasone 40 mg/day PO 1-4 Post-Transplant Consolidation Dexamethasone 40 mg PO 1-4 Dexamethasone Consolidation Patients that do not achieve adequate platelet recovery (defined as < 80,000/μl) will receive consolidation with Dexamethasone 40 mg x 4 days every 28 days for 1 year Maintenance year one Dexamethasone 40 mg PO q 3 months, day 1-4, 9-12, 17-20
1736817|NCT00083551|Drug|Doxorubicin|Doxorubicin may be further diluted in 5% dextrose or sodium chloride injection and should be administered slowly into tubing of a freely flowing intravenous infusion with great care taken to avoid extravasation.
1736818|NCT00083551|Drug|Etoposide|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
1736819|NCT00083551|Drug|Filgrastim|G-CSF will be administered at a dose of 10mcg/kg or GM-CSF at a dose of 10 mcg/kg. G-CSF or GM-CSF will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
1736820|NCT00083551|Drug|Recombinant GM-CSF|GM-CSF at a dose of 10 μg/kg SC, divided in 2 doses each day, will begin one day after completion of chemotherapy and continued during repeated apheresis and discontinued upon completion of apheresis.
1736821|NCT00083551|Drug|Interferon-alpha-2b|AGENT DOSE ROUTE DAYS Intron-A 3 million units/m2 SQ TIW Thalidomide (for those randomized at initial registration) 50 mg QOD PO Every other day (qod
1736822|NCT00083551|Drug|Melphalan|Etoposide (VP16) 200 mg/m2 in 500 ml D5W over one hour daily for four days (on days -5, -4, -3, -2). Start infusion 30 minutes after completion of BCNU on day -5. Start infusion at completion of cytarabine on following three days
1736823|NCT00083551|Drug|Vincristine|Formulation: 1 mg/1 ml, 2 mg/2 ml, and 5 mg/ 5 ml vials. Vincristine should be administered intravenously through a freely-running IV. If it extravasates, it produces a severe local reaction with skin slough. FATAL IF GIVEN INTRATHECALLY, FOR INTRAVENOUS USE ONLY.
1736824|NCT00083564|Drug|STR(TM) (Skeletal Targeted Radiotherapy, Holmium-166-DOTMP)|
1736825|NCT00083577|Drug|Thalidomide|
1736826|NCT00083590|Drug|Huperzine A|
1736827|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^7 pfu /2mL administered in each deltoid
1736828|NCT00083603|Biological|rFPV-HIV (rFPV-HIV env/gag + rFPV-HIV tat/rev/nef-RT)|Vaccines administered as two separate 1-mL intramuscular injections, with rFPV-HIV env/gag into the left deltoid, rFPV-HIV tat/rev/nef-RT into the right deltoid
1736829|NCT00083603|Biological|Empty TBC-FPV|Empty FPV 10^9 pfu/2mL administered as two separate 1 mL intramuscular injections, one into each deltoid.
1736830|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^8 pfu /2mL administered in each deltoid
1736831|NCT00083603|Biological|rMVA-HIV (rMVA-HIV env/gag + rMVA-HIV tat/rev/nef-RT)|rMVA 10^9 pfu /2mL administered in each deltoid
1736832|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^7 pfu/2mL administered into each deltoid
1736833|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^8 pfu/2mL administered into each deltoid
1736834|NCT00083603|Biological|TBC-MVA and TBC-FPV|Empty MVA 10^9 pfu/2mL administered into each deltoid
1736835|NCT00083616|Biological|Panitumumab|Panitumumab 6 mg/kg every once 2 weeks weeks administered by intravenous (IV) infusion.
1736836|NCT00083629|Procedure|PET|
1736837|NCT00083668|Drug|Paliperidone ER|
1736838|NCT00083681|Drug|Thalidomide|
1736839|NCT00083681|Drug|Dexamethasone|
1736840|NCT00083681|Drug|Cytoxan|
1736841|NCT00083681|Drug|Etoposide|
1736842|NCT00083681|Drug|Cisplatin|
1736843|NCT00083681|Drug|G-CSF|
1736844|NCT00083694|Drug|Thalidomide|
1736845|NCT00083707|Drug|Thalidomide|
1736846|NCT00083720|Biological|cetuximab|Initial dose of 400 mg/m2 intravenously (i.v.) over 120 minutes, followed by 250 mg/m2 weekly i.v. over 60 minutes
1736847|NCT00083759|Drug|natalizumab|
1736848|NCT00083759|Drug|placebo|
1736849|NCT00083772|Drug|Nesiritide|Initial dose by vein of 2 mcg/kg then infusion by vein of 0.01 mcg/kg/min continuously for 48 hours.
1736850|NCT00083785|Drug|Talaporfin sodium (LS11)|
1736851|NCT00083785|Device|LED-based light infusion device|
1736852|NCT00083785|Device|Light emitting diodes (LED)|
1736853|NCT00083785|Procedure|Photodynamic therapy|
1736854|NCT00083785|Procedure|Phototherapy|
1736855|NCT00083785|Procedure|Chemotherapy|
1736856|NCT00083824|Drug|Estrogens, Conjugated (USP)|0.625 mg/day QID for 3 years
1737215|NCT00088400|Drug|TransMID|
1736858|NCT00083824|Drug|Placebo|2 pills/day QID for 3 years
1736859|NCT00083876|Drug|Thalidomide|
1736860|NCT00083889|Drug|Interferon-alfa|3 MIU first week, 6 MIU second week, and 9 MIU thereafter three times a week (non-consecutive days) until progression or unacceptable toxicity
1736861|NCT00083889|Drug|SU011248|50 mg orally daily for 4 weeks and 2 weeks off treatment until progression or unacceptable toxicity
1736862|NCT00083902|Drug|Thalidomide|
1736863|NCT00083902|Drug|Dexamethasone|
1736871|NCT00083928|Drug|Å6 subcutaneous injection|
1736872|NCT00083941|Biological|TroVax in combination with IL-2|1ml intramuscular injection
1736873|NCT00083954|Drug|Quetiapine Fumarate|
1736874|NCT00083967|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
1736875|NCT00083980|Drug|Venlafaxine ER|75 to 225 mg daily
1736876|NCT00083980|Drug|Sugar pill|Upto 3 per day for venlafainxe and 4 per day for kava placebos.
1736877|NCT00083980|Drug|Kava|140 to 280 mg per day
1736878|NCT00083993|Drug|Temsirolimus (CCI-779) for 34 months|
1736879|NCT00083993|Drug|Letrozole for 34 months|
1736880|NCT00084019|Drug|Atazanavir|
1736881|NCT00084019|Drug|Ritonavir|
1736882|NCT00084032|Behavioral|Structured treatment interruption|Treatment interruption schedule is dependent on the Arm in which participants are enrolled in Step 2
1736883|NCT00084032|Drug|Antiretroviral regimen|Participants will take any combination of FDA-approved ARV medications prescribed by their physician
1736884|NCT00084045|Procedure|Intrapartum HIV counseling/testing|
1736885|NCT00084045|Procedure|Postpartum HIV counseling/testing|
1736886|NCT00084058|Drug|Lopinavir/ritonavir|
1736887|NCT00084058|Drug|Saquinavir|
1736888|NCT00084071|Drug|Tifacogin|
1736889|NCT00084084|Drug|Agalsidase alfa|0.2 mg/kg agalsidase alfa administered by IV infusion over 40 (+/- 10) minutes every other week for 52 weeks, with periodic reassessments for study continuation beyond 52 weeks
1736890|NCT00084097|Drug|Omalizumab|
1736891|NCT00084123|Behavioral|Healing Touch Therapy|
1736892|NCT00084123|Behavioral|Relaxation Therapy|
1736893|NCT00084123|Behavioral|Standard Care|Standard Care
1736894|NCT00084136|Drug|Atazanavir|400 mg taken orally daily
1736895|NCT00084136|Drug|Didanosine (enteric-coated)|400 mg taken orally daily
1736896|NCT00084136|Drug|Efavirenz|600 mg taken orally daily
1736897|NCT00084136|Drug|Emtricitabine|200 mg taken orally daily
1736898|NCT00084136|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg/300 mg taken orally once daily
1736899|NCT00084136|Drug|Lamivudine/Zidovudine|150 mg/300 mg taken orally twice daily
1736900|NCT00076258|Behavioral|SSRI + LD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
1736901|NCT00076258|Behavioral|SSRI + PHD|Eligible participants who have completed an adequate trial of SSRI monotherapy and all screening visits are randomly assigned to 24 weeks of SSRI augmentation with : a low dose of aerobic exercise (LD) or a public health dose of aerobic exercise (PHD). The acute phase of TREAD consists of the first 12 weeks of exercise augmentation intervention and includes: a) an individualized PHD- or LD aerobic exercise prescription; b) an empiricallybased behavioral intervention, including selfmonitoring tools and an interactive website, designed to maximize exercise adherence and minimize drop-out; and c) exercise instruction and supervised training sessions at The Cooper Institute (CI) as well as self-administered, home-based training sessions.
1736902|NCT00076284|Drug|GW873140|
1736903|NCT00076310|Drug|Docetaxel|60 mg/m^2 IV repeated every 21 days.
1736904|NCT00076310|Drug|OSI-774|100 mg oral administered daily. May have a dose escalation of 150 mg pending on prior dose toleration. Patients will continue on daily OSI-774 until a study endpoint or removal from study is reached.
1736905|NCT00076310|Drug|Cisplatin|75 mg/m^2 IV every 21 days.
1736906|NCT00076323|Drug|Primaquine|
1736907|NCT00076336|Drug|Telbivudine|600mg/day oral tablet for 104 weeks
1736908|NCT00076336|Drug|Lamivudine|100mg/day oral tablet for 104 weeks
1736909|NCT00076336|Drug|Placebo|Telbivudine matching placebo or lamivudine matching placebo tablet.
1736910|NCT00076349|Drug|bendamustine and rituximab|Patients will receive rituximab on the first day of a cycle at a dose of 375 mg/m2, followed on the second and third day of a cycle by SDX-105 (bendamustine) at a dose of 90 mg/m2/day of treatment. Four cycles are planned. Patients will receive a dose of rituximab alone 7 days prior to the first cycle of the combination and a dose of rituximab 28 days after the last cycle of the combination. If there is documented disease regression, a fifth and sixth cycle of SDX-105 plus rituximab may be administered.
1736911|NCT00076362|Drug|Sandostatin LAR|
1736912|NCT00076375|Drug|Nanocrystalline silver cream (NPI)|
1736913|NCT00076388|Drug|Gefitinib|
1736914|NCT00076388|Drug|Docetaxel|
1736915|NCT00076401|Drug|Motexafin gadolinium|
1736916|NCT00076414|Drug|Acetylcholine|
1736917|NCT00076414|Drug|L-NMMA|
1736918|NCT00076440|Drug|Leuprolide acetate|
1737288|NCT00088894|Other|pharmacogenomic studies|Correlative studies
1736919|NCT00076453|Device|Lateral wedge orthotic shoe inserts|Customized lateral wedge orthotic shoe inserts
1736920|NCT00076453|Device|Standard orthotic shoe inserts|Neutral orthotic inserts
1736921|NCT00076492|Drug|CoQ10|
1736922|NCT00076492|Drug|GPI 1485|
1736923|NCT00076518|Drug|Fenofibrate|
1736924|NCT00076518|Drug|Fish Oil|
1736925|NCT00076531|Drug|Leuprolide Acetate for Injectable Suspension 22.5 mg|
1736926|NCT00076544|Drug|Ziconotide|
1736927|NCT00076557|Genetic|Adeno-Associated Viral with Human Factor IX|
1736928|NCT00076570|Drug|Sirolimus|
1736929|NCT00076570|Drug|Tacrolimus|
1736930|NCT00076609|Drug|PHY906|
1736931|NCT00076609|Drug|capecitabine|
1736934|NCT00076635|Drug|Interferon gamma-1b|200 mcg, SQ, 3x per week
1736935|NCT00076648|Drug|Poly SFH-P Injection|
1736936|NCT00076674|Drug|Intravenous Levodopa|
1736937|NCT00076687|Biological|botulinum toxin Type A|botulinum toxin Type A 240 U injection on Day 1, Week 12, Week 18
1736938|NCT00076687|Biological|botulinum toxin Type A|botulinum toxin Type A 360 U injection at Day 1, Week 12, Week 18
1736939|NCT00076687|Drug|saline|Saline injection at Day 1, Week 12, Week 18
1736940|NCT00076726|Drug|Infliximab|
1736941|NCT00076752|Drug|fludarabine phosphate|Conditioning and transplant regimen: 30 mg/m^2 day intravenous infusion over 30 minutes daily, 4 days (transplant days -6, -5, -4, -3)
1736942|NCT00076752|Drug|cyclophosphamide|Priming regimen: 2000 mg/m^2 intravenous infusion over 2 hours, day 2. Conditioning and transplant regimen: 1200 mg/m^2 day intravenous infusion daily, 4 days (-6, -5, -4, -3).
1736943|NCT00076752|Biological|Rituxan (rituximab)|Priming regimen: 375 mg/m^2 intravenous day 1, 4. Conditioning and transplant regimen: 750 mg/m^2 intravenous infusion, day -7.
1736944|NCT00076752|Biological|filgrastim|Priming regimen: 10 micrograms/kg/day subcutaneous, starting day 6. Conditioning and transplant regimen: 5 micrograms/kg/day subcutaneous, day +1 until ANC >500 microliters.
1736945|NCT00076752|Drug|methylprednisolone|Priming regimen:1000 mg intravenous over 30 minutes, day 1.
1736946|NCT00076752|Other|immunologic technique|Lymphoablative regimen using cyclophosphamide, rituximab, and fludarabine followed by a CD34 cell selected autologous stem cell transplant.
1736947|NCT00076752|Other|laboratory biomarker analysis|Standard human immunology research laboratory ex vivo studies.
1736948|NCT00076752|Procedure|autologous hematopoietic stem cell transplantation|Day 0, product will be infused rapidly intravenously after premedication with diphenhydramine 25-60 mg orally or intravenous.
1736949|NCT00076752|Drug|Diphenhydramine|Conditioning and transplant regimen 25-50 mg orally or intravenously.
1736950|NCT00076752|Drug|Mesna|Priming regimen: 600 mg/m^2 intravenous immediately prior to cyclophosphamide and repeat at 4 and 7 hours after the first dose, day 2. Conditioning and transplant regimen:1200 mg/m^2 per day continuous 24 hour intravenous infusion, daily for 4 days, start concurrently with the start of cyclophosphamide.
1736951|NCT00076791|Drug|Emtricitabine/Tenofovir disoproxil fumarate|900 mg of TDF combined with 600 mg emtricitabine
1736952|NCT00076791|Drug|Tenofovir disoproxil fumarate|600 mg oral dose of TDF
1736953|NCT00076804|Behavioral|Directly Observed Therapy|Use of a patient nominated peer supporter who will observe the morning dose of ARVs
1736954|NCT00076817|Biological|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine
1736955|NCT00076817|Biological|ALVAC-HIV (vCP205)|Canarypox virus vector vaccine placbo
1736957|NCT00076856|Drug|Temozolomide|
1736958|NCT00076869|Drug|MK0991, caspofungin acetate|
1736959|NCT00076869|Drug|Comparator: amphotericin B|
1736960|NCT00076869|Drug|Comparator: lipid formulation of amphotericin B and/or azole|
1736961|NCT00076934|Drug|RG2077 (CTLA4-IgG4m)|RG2077
1736962|NCT00076947|Biological|EnvPro|
1736963|NCT00076960|Drug|Stanate (TM) [stannsoporfin, tin-mesoporphyrin]|Treatment with 4.5 mg/kg
1736964|NCT00076973|Drug|montelukast sodium|Duration of Treatment: 6 months
1736965|NCT00076973|Drug|Comparator: placebo|Duration of Treatment: 6 months
1736966|NCT00076986|Drug|IL13-PE38QQR|
1736967|NCT00076986|Procedure|surgery and catheter placement (2 procedures)|
1736968|NCT00076986|Drug|prolifespan 20 with carmustine implant (GLIADEL® Wafer)|
1736969|NCT00076986|Procedure|surgery and wafer placement (1 procedure)|
1736970|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
1736971|NCT00076999|Drug|TPV oral solution|Tipranavir oral solution
1736972|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
1736973|NCT00076999|Drug|RTV oral solution|Ritonavir oral solution
1736974|NCT00077012|Drug|QLT0074|
1736975|NCT00077012|Drug|Photodynamic therapy|
1736976|NCT00077025|Drug|Gefitinib|ZD1839 (gefitinib, IRESSA) 250 mg/DAY PO + 1 mg Anastrozole (ZD1033, Arimidex)
1736977|NCT00077025|Drug|Anastrozole|1 mg Anastrozole (ZD1033, Arimidex) + PLACEBO 1 TABLET/DAY PO
1736978|NCT00077051|Drug|cisplatin|
1736979|NCT00077051|Drug|cytochlor|
1736980|NCT00077051|Drug|tetrahydrouridine|
1736981|NCT00077051|Radiation|radiation therapy|
1736983|NCT00077077|Drug|DJ-927|
1736984|NCT00077077|Drug|capecitabine|
1736985|NCT00077090|Drug|hyperbaric oxygen|
1736986|NCT00077103|Biological|filgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
1736987|NCT00077103|Biological|pegfilgrastim|filgrastim (G-CSF) subcutaneously (SC) on days 3-21 or pegfilgrastim SC on day 2.
1736988|NCT00077103|Drug|cisplatin|cisplatin IV over 30-60 minutes on day 1
1736989|NCT00077103|Drug|doxorubicin hydrochloride|doxorubicin IV over 5-10 minutes
1736990|NCT00077103|Drug|fosbretabulin disodium|Combined Modality Phase:Patients also receive CA4P IV over 10 minutes weekly on the fifth day of radiotherapy. Beginning 4-6 weeks after the completion of the combined modality phase, patients receive CA4P IV over 10 minutes on days 1, 8, and 15. Treatment repeats every 28 days for 2 courses.
1736991|NCT00077103|Radiation|radiation therapy|Beginning on day 22, patients undergo radiotherapy twice daily, 5 days a week, for 3-4 weeks.
1736992|NCT00077116|Drug|busulfan|
1736993|NCT00077116|Drug|cyclophosphamide|
1736994|NCT00077116|Drug|cytarabine|
1736995|NCT00077116|Drug|gemtuzumab ozogamicin|
1736996|NCT00077116|Drug|idarubicin|
1736997|NCT00077116|Procedure|allogeneic bone marrow transplantation|
1736998|NCT00077116|Procedure|peripheral blood stem cell transplantation|
1736999|NCT00077116|Radiation|radiation therapy|
1737000|NCT00077129|Drug|carboplatin|
1737001|NCT00077129|Drug|paclitaxel|
1737002|NCT00077142|Drug|TAC-101|Once daily by mouth on days 1-14, repeat every 21 days for 2 courses.
1737003|NCT00077155|Drug|cilengitide|
1737004|NCT00077168|Drug|anastrozole|
1737005|NCT00077168|Drug|tamoxifen citrate|
1737006|NCT00077168|Procedure|adjuvant therapy|
1737007|NCT00077168|Radiation|radiation therapy|
1737008|NCT00077181|Drug|cytarabine|Given IV
1737009|NCT00077181|Drug|triapine|Given IV
1737010|NCT00077181|Other|laboratory biomarker analysis|Correlative studies
1737011|NCT00077194|Drug|romidepsin|
1737012|NCT00077207|Drug|carboplatin|Given IV
1737013|NCT00077207|Drug|temozolomide|Given orally
1737014|NCT00077207|Drug|vincristine sulfate|Given IV
1737015|NCT00077220|Drug|carboplatin|
1737016|NCT00077220|Drug|paclitaxel|
1737017|NCT00077220|Procedure|adjuvant therapy|
1737018|NCT00077220|Radiation|radiation therapy|
1737019|NCT00077233|Drug|cetuximab|IV
1737020|NCT00077233|Drug|5-FU|IV
1737021|NCT00077233|Drug|irinotecan|IV
1737022|NCT00077233|Drug|leucovorin|IV
1737023|NCT00077233|Drug|oxaliplatin|IV
1737024|NCT00077246|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1737025|NCT00077259|Drug|epothilone D|
1737026|NCT00077285|Biological|filgrastim|
1737027|NCT00077285|Drug|carboplatin|
1737028|NCT00077285|Drug|cyclophosphamide|
1737029|NCT00077285|Drug|dexrazoxane hydrochloride|
1737030|NCT00077285|Drug|doxorubicin hydrochloride|
1737031|NCT00077285|Drug|etoposide|
1737032|NCT00077285|Drug|ifosfamide|
1737033|NCT00077285|Drug|irinotecan hydrochloride|
1737034|NCT00077285|Drug|vincristine sulfate|
1737035|NCT00077285|Procedure|conventional surgery|
1737036|NCT00077285|Radiation|radiation therapy|
1737037|NCT00077298|Biological|cetuximab|Given IV
1737038|NCT00077298|Biological|bevacizumab|Given IV
1737039|NCT00077298|Drug|irinotecan hydrochloride|Given IV
1737040|NCT00077298|Other|laboratory biomarker analysis|Correlative studies
1737041|NCT00077311|Biological|darbepoetin alfa|200 mcg sub Q on day 1 of each cycle if HgB < or = 11 g/dL
1737042|NCT00077311|Biological|pegfilgrastim|6 mg sub Q day 2 of each cycle
1737043|NCT00077311|Drug|cisplatin|75 mg/sq m IV over 1 hr Day 1 of each cycle
1737044|NCT00077311|Drug|docetaxel|75 mg/sq m IV over 1 hr Day 1 of each cycle
1737045|NCT00077311|Drug|BNP7787|40 g IV over 30 min Day 1 of each cycle
1737046|NCT00077324|Genetic|proteomic profiling|
1737047|NCT00077324|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
1737048|NCT00077324|Procedure|biopsy|
1737049|NCT00077324|Procedure|surgery|
1737050|NCT00077337|Drug|romidepsin|
1737051|NCT00077350|Drug|triapine|Given IV
1737052|NCT00077350|Drug|gemcitabine hydrochloride|Given IV
1737053|NCT00077350|Other|laboratory biomarker analysis|Correlative studies
1737054|NCT00077363|Drug|tipifarnib|Given PO
1737055|NCT00077363|Drug|capecitabine|Given PO
1737056|NCT00077376|Biological|trastuzumab|Given IV
1737057|NCT00077376|Drug|ixabepilone|Given IV
1737058|NCT00077376|Drug|carboplatin|Given IV
1737059|NCT00077376|Other|laboratory biomarker analysis|Correlative studies
1737060|NCT00077389|Drug|carboplatin|
1737061|NCT00077389|Drug|cisplatin|
1737062|NCT00077389|Drug|doxorubicin hydrochloride|
1737063|NCT00077389|Procedure|adjuvant therapy|
1737064|NCT00077389|Procedure|conventional surgery|
1737065|NCT00077389|Procedure|neoadjuvant therapy|
1737066|NCT00077402|Drug|fenretinide|
1737067|NCT00077415|Drug|gemcitabine hydrochloride|
1737068|NCT00077415|Drug|triapine|
1737069|NCT00077428|Drug|bortezomib|Given IV
1737070|NCT00077428|Drug|doxorubicin hydrochloride|Given IV
1737071|NCT00077428|Other|laboratory biomarker analysis|Correlative studies
1737072|NCT00077441|Drug|bortezomib|Given IV
1737073|NCT00077441|Other|laboratory biomarker analysis|Correlative studies
1737074|NCT00077454|Drug|erlotinib hydrochloride|Given orally (PO)
1737075|NCT00077454|Drug|temozolomide|Given PO
1737076|NCT00077454|Other|pharmacological study|Correlative studies
1737077|NCT00077454|Other|laboratory biomarker analysis|Correlative studies
1737078|NCT00077467|Drug|bortezomib|Given IV
1737079|NCT00077467|Other|pharmacological study|Correlative studies
1737080|NCT00077467|Other|laboratory biomarker analysis|Correlative studies
1737081|NCT00077493|Drug|BL22 immunotoxin|BL22 immunotoxin IV over 30 minutes on days 1, 3, and 5 OR on days 1, 3, 5, 7, 9, and 11. Treatment repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients who achieve a complete response (CR) or unconfirmed CR (CRu) receive 2 additional courses beyond CR or CRu for a maximum of 6 courses.
1737082|NCT00077493|Procedure|antibody-drug conjugate therapy|CD22 antibody, RFB4 on day 7
1737083|NCT00077493|Procedure|immunotoxin therapy|tested for immunogenicity to CAT-8015 before each cycle and at end of study.
1737084|NCT00077493|Procedure|monoclonal antibody therapy|administered intravenously over 30 minutes.
1737085|NCT00077519|Drug|tipifarnib|
1737086|NCT00077519|Radiation|radiation therapy|
1737087|NCT00077532|Biological|gp100 antigen|
1737088|NCT00077532|Biological|incomplete Freund's adjuvant|
1737089|NCT00077532|Biological|ipilimumab|
1737090|NCT00077545|Drug|triapine|Given IV
1737091|NCT00077545|Drug|cisplatin|Given IV
1737092|NCT00077558|Drug|fludarabine phosphate|
1737093|NCT00077558|Drug|triapine|
1737094|NCT00077584|Drug|Bosentan 62.5 mg|Oral tablets containing 62.5 mg of bosentan
1737095|NCT00077584|Drug|Bosentan 125 mg|Oral tablets containing 125 mg of bosentan
1737096|NCT00077584|Drug|Placebo|Oral tablets matching bosentan 62.5-mg tablets and bosentan 125-mg tablets
1737097|NCT00077597|Drug|epoetin|3 times a week iv, as prescribed.
1737098|NCT00077597|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv (starting dose) once every 2 weeks
1737099|NCT00077610|Drug|Epoetin alfa or beta|intravenously 3 times weekly for 52 weeks, as prescribed
1737100|NCT00077610|Drug|RO0503821 (1x/2 Weeks)|60, 100, or 180 microgram (mcg) (starting dose) once every two weeks intravenously for 52 weeks.
1737101|NCT00077610|Drug|RO0503821 (1x/4 Weeks)|120, 200 or 360 mcg (starting dose) once every four weeks intravenously for 52 weeks.
1737102|NCT00077623|Drug|epoetin alfa or beta|iv 3 times weekly, as prescribed
1737103|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 2 weeks
1737104|NCT00077623|Drug|methoxy polyethylene glycol-epoetin beta (Mircera)|60, 100 or 180 micrograms sc (starting dose) every 4 weeks
1737105|NCT00077636|Drug|Copegus|400mg po bid for 16 weeks
1737106|NCT00077636|Drug|Copegus|400mg po bid for 24 weeks
1737107|NCT00077636|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 16 weeks
1737108|NCT00077636|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks
1737109|NCT00077649|Drug|ribavirin [Copegus]|600mg po bid for 48 weeks
1737110|NCT00077649|Drug|ribavirin [Copegus]|800mg po bid for 48 weeks
1737111|NCT00077649|Drug|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|180 micrograms sc weekly for 48 weeks
1737112|NCT00077649|Drug|peginterferon alfa-2a (PEG-IFN alfa-2a) [Pegasys]|270 micrograms sc weekly for 48 weeks
1737113|NCT00077675|Drug|Telavancin|Telavancin 7.5 mg/kg/day, amended to 10 mg/kg/day, IV (intravenously) for up to 14 days
1737114|NCT00077675|Drug|vancomycin or antistaphylococcal penicillin|Vancomycin 1 Gram IV (intravenously) every 12 hrs or nafcillin 2 Grams, oxacillin 2 Grams, or (in South Africa) cloxacillin 0.5 - 1 Gram, IV (intravenously) every 6 hrs for up to 14 days.
1737115|NCT00077688|Drug|TOCOSOL Paclitaxel|
1737116|NCT00077714|Drug|Paliperidone ER|
1737117|NCT00077727|Drug|Extended-release galantamine hydrobromide|
1737118|NCT00077753|Drug|enoxaparin sodium|
1737119|NCT00077766|Drug|Darbepoetin alfa|Darbepoetin alfa was administered IV, every week or every 2 weeks during Weeks 1 through 52.
1737120|NCT00077766|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|RO0503821 was administered IV, every 2 weeks during Weeks 1 through 52. The starting dose of RO0503821 (60, 100, or 180 micro gram [µg]) was based on the dose of darbepoetin alfa at the time of randomization (< 40, 40 to 80, or > 80 µg per week, respectively).
1737121|NCT00077779|Drug|Adalimumab|
1737122|NCT00077792|Drug|Enoxaparin sodium (XRP4563)|
1737123|NCT00077805|Drug|Enoxaparin sodium|
1737124|NCT00077818|Drug|Enoxaparin sodium|
1737125|NCT00077831|Behavioral|neurobehavioral development|observational study of infant and child development
1737126|NCT00077844|Drug|Enoxaparin sodium|
1737127|NCT00077857|Drug|capecitabine (Xeloda®)|825 mg/m^2 or 1250 mg/m2 orally twice a day on days 1 to 14 of each 3 week cycle.
1737128|NCT00077857|Drug|docetaxel (Taxotere®)|75 mg/m^2 intravenous on day 1 of each 3 week cycle
1737129|NCT00077870|Drug|ocrelizumab|
1737130|NCT00077883|Drug|TLK286, cisplatin|TLK286 administered once every 3 weeks (± 2 days) at two dose-ranging levels (750 mg/m²) and 1,000 mg/²) in combination with two dose levels of cisplatin (75 mg/m² and 100 mg/m²) of cisplatin once every 3 weeks (± 2 days).
1737131|NCT00077896|Procedure|Direct Current Polarization|
1737132|NCT00077922|Drug|LMB-2|40 micrograms/kg every other day (QOD) x 3 every 4 weeks
1737133|NCT00077935|Drug|Civamide|Cream 0.075%, TID for 52 weeks
1737134|NCT00077948|Drug|Enoximone|Enoximone administered orally
1737135|NCT00077948|Drug|Metoprolol succinate|Metoprolol succinate administered orally
1737136|NCT00077948|Drug|Placebo to match enoximone|Placebo to match match enoximone administered orally
1737137|NCT00077948|Drug|Placebo to match metoprolol succinate|Placebo to match metoprolol succinate administered orally
1737138|NCT00077961|Drug|CAMPATH (alemtuzumab)|
1737139|NCT00077974|Drug|SU011248|50-mg orally taken daily for 4 weeks and off treatment for 2 weeks until progression or unacceptable toxicity
1737142|NCT00084175|Behavioral|Behavior Therapy|
1737143|NCT00084188|Behavioral|Behavior Therapy|
1737144|NCT00084201|Drug|Cranberry juice|
1737145|NCT00084201|Drug|Amoxicillin|
1737146|NCT00084214|Drug|STA-4783|
1737147|NCT00084214|Drug|Paclitaxel|
1737148|NCT00084227|Drug|Azithromycin/Chloroquine|
1737149|NCT00084227|Drug|Atovaquone/Proguanil|
1737150|NCT00084240|Drug|Azithromycin/Chloroquine|
1737151|NCT00084240|Drug|Sulfadoxine-Pyrimethamine/Chloroquine|
1737152|NCT00084253|Drug|Atazanavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 200 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD, Once daily, 96 weeks.
1737153|NCT00084253|Drug|Atazanavir-Ritonavir/ Stavidine / Lamivudine|Capsules, Oral, ATV (2 x 150 mg) QD + RTV (1 x 100 mg) QD + 3TC (2 x 150 mg) QD + Zerit XR (1 x 100 mg) QD*, Once daily, 96 weeks.
1737154|NCT00084266|Drug|linezolid (Zyvox)|Subjects to receive either linezolid 600 mg IV (Intravenous) or PO (orally) q 12 h (every 12 hours) for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
1737155|NCT00084266|Drug|vancomycin|Subjects to receive vancomycin 15mg/kg IV (Intravenous) q12h (every 12 hours), adjusted for renal function, for 7-14 days, except in cases of documented bacteremia where it could be extended to 21 days based upon investigator's discretion.
1737156|NCT00084279|Drug|Consensus Interferon-Alpha, Interferon Gamma-1b, Ribavirin|interferon gamma-1b: 0.25 and 0.5 mL, SQ, 3x per week interferon alfacon: 0.3 mL and 0.5 mL, SQ, once a day Ribavirin: 2 capsules in a.m., 3 capsules in p.m.; daily
1737157|NCT00084318|Biological|cetuximab|400 mg/m^2 intravenously over 120 minutes on day 1 (week 1) followed by 250 mg/m^2 intravenously over 60 minutes in weeks 2 through 7.
1737158|NCT00084318|Drug|cisplatin|30 mg/m^2 intravenously infused over over 60 minutes in weeks 2 through 7.
1737159|NCT00084318|Drug|docetaxel|15 mg/m^2 intravenously infused over 30 minutes in weeks 2 through 7.
1737160|NCT00084318|Radiation|radiation therapy|60 Gy (2 Gy once a day, 5 times a week)
1737161|NCT00084344|Drug|4-hydroxytamoxifen|
1737162|NCT00084344|Procedure|breast imaging study|
1737163|NCT00084344|Procedure|radiomammography|
1737164|NCT00084370|Drug|celecoxib|Patients receive ora celecoxib twice daily for 3 months prior to prophylactic oophorectomy.
1737165|NCT00084370|Procedure|oophorectomy|
1737166|NCT00084383|Biological|GVAX pancreatic cancer vaccine|"Patients will receive vaccinations consisting of 5E8 vaccine cells. The first vaccination is administered 6-8 weeks after surgery. Four to eight weeks following the completion of the last cycle of adjuvant radiation and chemotherapy (chemo-radiation therapy is standard of care and not part of the protocol) eligible patients will receive three additional vaccinations at one month intervals. Patients who continue to remain disease-free will receive a fifth booster vaccination, six months following the fourth vaccination."
1737167|NCT00084396|Drug|letrozole|
1737168|NCT00084396|Procedure|conventional surgery|
1737169|NCT00084409|Drug|iloprost|Given orally
1737170|NCT00084409|Other|placebo|Given orally
1737171|NCT00084422|Drug|lestaurtinib|Given orally twice daily x 5 consecutive days followed by a two day rest. 28 days = 1 treatment course. Courses repeated indefinitely without gap provided patient has recovered course from toxicities and no DLTs. Dose level assigned according to the planned dose escalation schedule.
1737172|NCT00084435|Drug|cisplatin|75 mg/m2 IV, Day 1, q 21 days for 3 cycles
1737173|NCT00084435|Drug|docetaxel|15 mg/m2 IV, Day 1, 1 7 days for 6 doses
1737174|NCT00084435|Radiation|radiation therapy|200 cGy/day, Days 1-5, q week for 6 weeks
1737175|NCT00084448|Drug|celecoxib|
1737176|NCT00084448|Drug|paclitaxel|
1737177|NCT00084461|Drug|romidepsin|Given IV
1737178|NCT00084461|Other|laboratory biomarker analysis|Correlative studies
1737179|NCT00084487|Drug|becatecarin|Given IV
1737180|NCT00084513|Biological|trastuzumab|
1737181|NCT00084513|Drug|imatinib mesylate|
1737182|NCT00084526|Procedure|computed tomography|
1737183|NCT00084526|Procedure|ultrasound imaging|
1737184|NCT00088101|Drug|STA-5312|
1737185|NCT00088114|Drug|STA-4783/paclitaxel|
1737186|NCT00088140|Drug|IDN-6556|
1737187|NCT00088140|Drug|Placebo|
1737188|NCT00088153|Drug|Physiologic Estrogen/progesterone|Vivelle Dot patch 100 mcg twice weekly; Provera 2.5 mg daily for the first 10 days of the month
1737189|NCT00088153|Other|Placebo|Placebo patches twice weekly; Placebo pills daily for the first 10 days of every month
1737190|NCT00088166|Drug|hCRF|hCRF ; open-label dexamethasone that the patient is currently taking
1737191|NCT00088166|Drug|placebo hCRF|placebo hCRF 2mg/day and open-label dexamethasone that they are taking
1737192|NCT00088179|Drug|pexelizumab in conjunction with CABG|
1737193|NCT00088192|Drug|pegaptanib sodium|
1737194|NCT00088205|Drug|enzastaurin|500 mg, oral, daily, up to six 28 day cycles
1737195|NCT00088218|Drug|Clofarabine|1-hour IV infusion 30 mg/m^2 daily times 5 days (Days 1-5)
1737196|NCT00088218|Drug|Ara-C|20 mg/m^2 subcutaneously daily times 14 days (Days 1-14). On Days 1 to 5 of each course, clofarabine will precede injection of ara-C by approximately 4 hours (+/- 1 hour).
1737197|NCT00088231|Drug|Imatinib Mesylate (Gleevec)|"600 mg by mouth every day (for AML, CML-BP) for a 28 day cycle.
400 mg by mouth every day (for AMM) for a 28 day cycle."
1737198|NCT00088231|Drug|PTK 787 (vatalanib)|"For 1 week prior to receipt of the study combination regimen, all patients will receive single agent PTK 787 at the dose specified for that dose level of the study combination regimen to allow stabilization of PTK 787 levels.
Starting dose: 250 mg by mouth every day for a 28 day cycle."
1737199|NCT00088270|Drug|OSI-7904L|
1737200|NCT00088270|Drug|5-Fluorouracil/Leucovorin|
1737201|NCT00088283|Drug|pegaptanib sodium|
1737202|NCT00088296|Procedure|Blood Draw|
1737203|NCT00088309|Procedure|Eye exam|
1737204|NCT00088309|Procedure|Oral exam|
1737205|NCT00088309|Procedure|CT scan|
1737206|NCT00088309|Procedure|Neuropsychological testing|
1737207|NCT00088309|Procedure|Electrocardiogram|
1737208|NCT00088309|Procedure|Echocardiogram|
1737209|NCT00088374|Drug|17 allylamino-17-demethoxygeldanamycin|17 allylamino-17-demethoxygeldanamycin (17 AAG) given intravenously at a dose of 300 mg/m2 on days 1,8 and 15 of 28 day cycles.
1737210|NCT00088374|Drug|18 FDG (Fludeoxyglucose 18F)|18FDG PET performed at baseline and 12 weeks after treatment. At each timepoint participants can receive 250mCi 0-15 water and 15 mCi F18-FDG.
1737211|NCT00088374|Drug|[15-O] H2O|[15-0] H20 performed at baseline and 12 weeks after treatment. At each time point participants can receive 250mCi 0-15 water and 15 mCi F18-FDG. The water scans were done as several intravenous injections for several scans but not over a total of 250 mCi.
1737212|NCT00088374|Drug|EPL diluent|17AAG is formulated with this diluent. Supplied in a 50 mL flint vial containing 48 mL of 2% egg phospholipids, and 5% dextrose in Water for Injection, USP. Patients with a history of serious allergic reactions to eggs should not receive this agent.
1737213|NCT00088387|Drug|Divalproex|
1737214|NCT00088387|Drug|Lithium|
1737219|NCT00088452|Drug|ethosuximide|Ethosuximide is a common treatment for childhood absence epilepsy.
1737220|NCT00088452|Drug|lamotrigine|Lamotrigine is a common treatment for childhood absence epilepsy.
1737221|NCT00088452|Drug|valproic acid|Valproic acid is a common treatment for childhood absence epilepsy.
1737222|NCT00088465|Drug|Intramuscular olanzapine depot|45-405 milligram (mg), intramuscular injection, on a 2-, 3-, or 4-week interval.
1737223|NCT00088478|Drug|Intramuscular Olanzapine Depot|
1737224|NCT00088478|Drug|Placebo|
1737225|NCT00088491|Drug|Intramuscular Olanzapine Depot|
1737226|NCT00088491|Drug|Oral Olanzapine|
1737227|NCT00088504|Drug|Merimepodib|
1737228|NCT00088504|Drug|PEG-Interferon-alpha 2a (Pegasys®)|
1737229|NCT00088504|Drug|Ribavirin (Copegus®)|
1737230|NCT00088517|Drug|[11C]NNC-112|
1737231|NCT00088530|Drug|pixantrone, cyclophosphamide, vincristine, rituximab, prednisone|Day 1: pixantrone (150 mg/m2), cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
1737232|NCT00088530|Drug|Vinorelbine, Oxalplatin, Ifosfasmide, Etoposide, Mitoxatrone, Gemcitabine or Rituximab|Day 1: cyclophosphamide (750 mg/m2), vincristine (1.4 mg/m2), rituximab (375 mg/m2) Days 1-5: prednisone (100 mg/day)
1737233|NCT00088543|Biological|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 4.5 mg/kg
1737234|NCT00088543|Biological|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|total dose 8.5 mg/kg
1737235|NCT00088556|Drug|TLK286|Every 3 Weeks with a starting dose of TLK286 @ 400 mg/m²
1737236|NCT00088556|Drug|carboplatin|AUC 6 mg/mL/min Once every 3 weeks
1737237|NCT00088556|Drug|paclitaxel|200 mg/m² Once every 3 weeks
1737238|NCT00088569|Drug|0-15 Water|
1737239|NCT00088582|Drug|Pasireotide (SOM230), Octreotide (Sandostatin)|
1737240|NCT00088595|Drug|Pasireotide (SOM230)|Open label. Patients received starting dose of 300 µg of study drug subcutaneously (s.c.) twice (total of 600 µg ) daily for three days, which could be increased in 150 µg increments up to 900 µg twice daily (total 1800 µg daily) if control of symptoms was not achieved. Prior sponsor agreement was required for a higher dose. A dose of 2400 µg/day was the maximum allowed. Dose reductions of 300 µg/day were allowed at any time if unacceptable toxicity occurred.
1737241|NCT00088608|Drug|SOM230 s.c.|
1737242|NCT00088621|Drug|Lurasidone 80mg tablet|
1737243|NCT00088634|Drug|Lurasidone|80 mg AM dosing once daily
1737244|NCT00088634|Drug|Placebo|Matching Placebo to 40mg lurasidone tablets
1737245|NCT00088647|Drug|MST-997|
1737246|NCT00088660|Biological|PANVAC™-VF|
1737247|NCT00088673|Drug|3APS|
1737248|NCT00088686|Drug|Capsaicin (Intramucosal Injection)|
1737249|NCT00088699|Drug|Ketamine|
1737250|NCT00088699|Drug|Riluzole|
1737251|NCT00088738|Drug|[18F] SPA-RQ|
1737252|NCT00088764|Behavioral|Coping skills training|8 sessions of pain and stress coping skills training
1737253|NCT00088764|Behavioral|Written emotional disclosure|4 sessions of writing about stress
1737254|NCT00088764|Behavioral|Arthritis education|8 sessions of learning about rheumatoid arthritis
1737255|NCT00088764|Behavioral|Health behavior writing|4 sessions of writing about various health behaviors
1737256|NCT00088777|Behavioral|Behavioral coping skills training plus physical therapy|10 hours coping sessions, 6 hours activating physical therapy, 4 hours physical therapy education
1737257|NCT00088777|Behavioral|Stress management education plus physical therapy|10 hours stress management education, 6 hours activating physical therapy, 4 hours physical therapy education
1737258|NCT00088790|Drug|AZD5438|
1737259|NCT00088803|Genetic|molecular genetic technique|
1737260|NCT00088803|Genetic|polymerase chain reaction|
1737261|NCT00088803|Genetic|polymorphism analysis|
1737262|NCT00088816|Drug|cisplatin|
1737263|NCT00088816|Drug|tegafur-gimeracil-oteracil potassium|
1737264|NCT00088816|Procedure|adjuvant therapy|
1737265|NCT00088816|Procedure|conventional surgery|
1737266|NCT00088816|Procedure|neoadjuvant therapy|
1737267|NCT00088829|Drug|paclitaxel|subjects will receive paclitaxel neoadjuvantly
1737268|NCT00088829|Genetic|microarray analysis|subjects will have a biopsy to collect tissue for gene microarray analysis
1737269|NCT00088829|Procedure|biopsy|All subjects will have a biopsy to collect tissue
1737270|NCT00088829|Procedure|neoadjuvant therapy|paclitaxel is given neoadjuvantly
1737271|NCT00088829|Drug|Paclitaxel|All patients will receive paclitaxel neoadjuvantly
1737272|NCT00088855|Drug|Bortezomib|Given IV
1737273|NCT00088855|Other|Laboratory Biomarker Analysis|Correlative studies
1737274|NCT00088855|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
1737275|NCT00088868|Drug|alvespimycin hydrochloride|
1737276|NCT00088881|Biological|rituximab|Given IV
1737277|NCT00088881|Drug|prednisone|Given orally
1737278|NCT00088881|Drug|cyclophosphamide|Given IV
1737279|NCT00088881|Drug|doxorubicin|Given IV
1737280|NCT00088881|Drug|vincristine|Given IV
1737281|NCT00088881|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
1737282|NCT00088881|Radiation|radiation therapy|Undergo radiotherapy
1737283|NCT00088881|Procedure|positron emission tomography|Undergo PET scans
1737284|NCT00088894|Drug|gemcitabine hydrochloride|Given IV
1737285|NCT00088894|Biological|bevacizumab|Given IV
1737286|NCT00088894|Other|placebo|Given IV
1737287|NCT00088894|Other|laboratory biomarker analysis|Correlative studies
1737289|NCT00088894|Other|pharmacological study|Correlative studies
1737290|NCT00088907|Drug|docetaxel|Given IV
1737291|NCT00088907|Other|placebo|Given orally
1737292|NCT00088907|Drug|gefitinib|Given orally
1737293|NCT00088933|Drug|recombinant fowlpox-CEA(6D)/TRICOM vaccine|Given intradermally
1737294|NCT00088933|Drug|recombinant vaccinia-CEA(6D)-TRICOM vaccine|Given intradermally
1737295|NCT00088933|Drug|docetaxel|Given IV
1737296|NCT00088933|Drug|sargramostim|Given subcutaneously
1737297|NCT00088946|Dietary Supplement|Polyphenon E|4-200mg capsules PO daily for 12 months
1737298|NCT00088946|Drug|erlotinib hydrochloride|100 mg PO daily for 12 months
1737299|NCT00088946|Other|Erlotinib placebo|identical to Erlotinib in look and appearance of dosing.
1737300|NCT00088946|Other|Polyphenon E|identical to Polyphenon E in look and appearance of dosing.
1737301|NCT00088959|Drug|erlotinib hydrochloride|Given orally
1737302|NCT00088959|Drug|celecoxib|Given orally
1737303|NCT00088959|Other|laboratory biomarker analysis|Correlative studies
1737304|NCT00088972|Drug|celecoxib|Given orally
1737305|NCT00088972|Other|placebo|Given orally
1737306|NCT00088985|Biological|therapeutic autologous dendritic cells|10 μg/kg subcutaneously (sc) each day for four days or g-CSF at 5 μg/kg sc each day for four days with GM-CSF 250 μg/m2 sc each day for four days. G-CSF and/or GM- CSF will be self-administered. On the fifth day patients will have two intravenous lines placed in the apheresis area of the Blood Bank and then undergo a 15 litre apheresis collection
1737307|NCT00088985|Biological|trastuzumab|4 mg/kg intravenously, every 14 days
1737308|NCT00088985|Drug|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered intravenously, every 14 days
1737309|NCT00088998|Biological|bevacizumab|
1737310|NCT00088998|Drug|capecitabine|
1737311|NCT00088998|Drug|docetaxel|
1737312|NCT00089011|Drug|fludarabine phosphate|Given IV
1737313|NCT00089011|Radiation|total-body irradiation|Undergo radiotherapy
1737314|NCT00089011|Drug|mycophenolate mofetil|Given IV or PO
1737315|NCT00089011|Drug|tacrolimus|Given IV or PO
1737316|NCT00089011|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
1737317|NCT00089011|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood stem cell transplant
1737318|NCT00089011|Other|laboratory biomarker analysis|Correlative studies
1737319|NCT00089024|Drug|fluorouracil|2700 mg/m5 IV over 24 hr after gemcitabine weeks 1 & 2; Repeat one 3-week cycle starting day 22
1737320|NCT00089024|Drug|gemcitabine hydrochloride|750 (females) or 900 (males) mg/m5 IV over 30 min (day 2)weeks 1 & 2; Repeat one 3-week cycle starting day 22
1737321|NCT00089024|Drug|leucovorin calcium|20 mg/m5 PO (day 1) and 20 mg/m5 IV (day 2) weeks 1 and 2; Repeat one 3-week cycle starting day 22
1737322|NCT00089024|Drug|oxaliplatin|48 mg/m5 IV over 2 hr weeks 1, 2, 4, and 5
1737323|NCT00089024|Procedure|adjuvant therapy|"Patients who have undergone surgical resection, after post-operative recovery, will receive two additional cycles of gemcitabine/5-FU/leucovorin. Patients will then be followed at 3 month intervals with a history and physical exam, CT scan of the chest/abdomen/pelvis, and tumor markers.
If surgical resection is not possible, patients with stable or responsive disease will resume gemcitabine/5-FU/leucovorin and continue on it indefinitely until disease progression provided the patient tolerates it and wishes to remain on therapy."
1737324|NCT00089024|Procedure|conventional surgery|Restaging with repeat imaging studies will be performed four weeks after completion of the chemo-radiation. If no contraindication for surgical resection is identified, resection will be performed six to eight weeks after completing chemoradiation. At the time of surgical resection, an extensive examination of the abdomen will be performed to exclude the presence of metastatic disease. All operations will be performed with curative intent with resection of all gross tumor (ie R0 [negative margins] or R1 [positive microscopic margins]). Resection of adjacent involved organs or vascular structures will be performed as clinically indicated.
1737325|NCT00089024|Procedure|neoadjuvant therapy|Eligible patients will receive an initial two cycles of chemotherapy with gemcitabine 750 (females) or 900 (males) mg/m5 over 30 minutes followed by a 24-hour infusion of fluorouracil 2700 mg/m5 on days 2 and 9 of a 21-day cycle . Calcium leucovorin 20 mg/m5 will be given orally on days 1 and 8 and by IV push on days 2 and 9 prior to the 5-FU. A window of -2 up to +7 days will be allowed to start planned cycles of therapy provided all other criteria to restart the new cycle has been met. Patients will require a central venous catheter (Port, Hickman or Groshong catheter) for the administration of 5-FU.
1737326|NCT00089024|Radiation|radiation therapy|A re-staging CT scan, which will be obtained as part of the radiation simulation, will be used to assess any possible response to the initial two cycles of chemotherapy. Unless the patient has developed evidence of metastatic disease, chemoradiation will proceed. Patients who required no treatment delays will commence chemoradiation on day 42. If a one-week delay is needed before cycle 2 of neo-adjuvant chemotherapy can be delivered, the patient will begin chemoradiation on day 49 provided treatment-related toxicity has resolved. If cycle 2 could not be given (2 or more week delay for resolution of treatment-related toxicity), then chemoradiation will begin once toxicity has resolved (may be earlier than day 42).
1737327|NCT00089037|Drug|methotrexate|
1737328|NCT00089037|Drug|sirolimus|
1737329|NCT00089037|Drug|tacrolimus|
1737330|NCT00089050|Drug|cyclosporine|
1737331|NCT00089050|Drug|gemtuzumab ozogamicin|
1737332|NCT00089063|Biological|tyrosinase peptide|Given SC
1737333|NCT00089063|Biological|gp100 antigen|Given SC
1737334|NCT00089063|Biological|MART-1 antigen|Given SC
1737335|NCT00089063|Biological|incomplete Freund's adjuvant|Given SC
1737336|NCT00089063|Drug|Montanide ISA 51 VG|Given SC
1737337|NCT00089063|Biological|sargramostim|Given SC
1737338|NCT00089063|Other|laboratory biomarker analysis|Correlative studies
1737339|NCT00089076|Biological|ipilimumab|Given IV
1737340|NCT00089076|Other|laboratory biomarker analysis|Correlative studies
1737341|NCT00089089|Drug|decitabine|Given IV
1737342|NCT00089089|Other|pharmacological study|Correlative studies
1737343|NCT00089089|Other|laboratory biomarker analysis|Correlative studies
1737344|NCT00089102|Drug|gemcitabine hydrochloride|
1737345|NCT00089102|Drug|irinotecan hydrochloride|
1737346|NCT00089115|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
1737347|NCT00089115|Biological|rituximab|
1737348|NCT00089115|Biological|sargramostim|
1737349|NCT00089128|Drug|gemcitabine hydrochloride|
1737350|NCT00089128|Drug|irinotecan hydrochloride|
1737351|NCT00089141|Drug|mycophenolate mofetil|Given orally
1737352|NCT00089141|Drug|placebo|Given orally
1737353|NCT00089154|Biological|apolizumab|Given IV
1737354|NCT00089154|Other|laboratory biomarker analysis|Correlative studies
1737355|NCT00089154|Other|pharmacological study|Correlative studies
1737356|NCT00089167|Biological|filgrastim|
1737357|NCT00089167|Drug|dexamethasone|
1737358|NCT00089167|Drug|melphalan|
1737359|NCT00089167|Drug|thalidomide|
1737360|NCT00089180|Drug|liposomal T4N5 lotion|Given topically
1737361|NCT00089180|Other|placebo|Given topically
1737362|NCT00089180|Other|laboratory biomarker analysis|Correlative studies
1737363|NCT00089193|Biological|incomplete Freund's adjuvant|
1737364|NCT00089193|Biological|multi-epitope melanoma peptide vaccine|
1737365|NCT00089193|Biological|sargramostim|
1737366|NCT00089206|Biological|incomplete Freund's adjuvant|
1737367|NCT00089206|Biological|multi-epitope melanoma peptide vaccine|
1737368|NCT00089206|Biological|sargramostim|
1737369|NCT00089219|Biological|IFA|vaccine adjuvant
1737370|NCT00089219|Biological|6MHP|melanoma helper peptides
1737371|NCT00089219|Biological|GM-CSF|vaccine adjuvant
1737372|NCT00089245|Radiation|iodine I 131 monoclonal antibody 8H9|
1737373|NCT00089258|Biological|beta-glucan|
1737374|NCT00089258|Biological|monoclonal antibody 3F8|
1737375|NCT00089258|Biological|sargramostim|
1737376|NCT00089258|Drug|isotretinoin|
1737377|NCT00089271|Drug|alvespimycin hydrochloride|Given IV
1737378|NCT00089271|Other|laboratory biomarker analysis|Correlative studies
1737379|NCT00089284|Drug|Rituxan|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
1737380|NCT00089284|Drug|motexafin gadolinium|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
1737381|NCT00089284|Drug|111Indium-Zevalin and 90Yttrium-Zevalin|Patients receive motexafin gadolinium IV over 30-60 minutes on days 1-4 and 8-11. At least 1 hour after motexafin gadolinium administration, patients receive rituximab IV over 3-4 hours on days 1 and 8. After rituximab administration, patients receive indium In 111 ibritumomab tiuxetan IV over 10 minutes on day 1. Patients undergo gamma camera scanning on days 1, 2*, 4*, and 7 and dosimetry on days 2, 4, and 7. If safe biodistribution is demonstrated, patients receive yttrium Y 90 ibritumomab tiuxetan IV over 10 minutes (after rituximab administration) on day 8.
1737382|NCT00089297|Biological|Cetuximab|"Induction: An initial dose of cetuximab (C225) 400 mg/m2 (over 2 hours) was given week 1 only. Then, C225 was administered at dose of 250 mg/m2 (over 1 hour) weekly for 5 weeks.
Concurrent Chemoradiation (Weeks 9-13): C225 was administered at 250 mg/m2/wk (over 1 hour).
Restaging Biopsy of Primary Site (Week 14): Patients with positive biopsy of the primary site at week 7 or patients without a clinical complete response at the primary site after induction therapy were scheduled for re-biopsy of the primary site at week 14 after concurrent therapy (50 Gy). If the biopsy were negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).
Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
1737383|NCT00089297|Drug|Carboplatin|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.
Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).
Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
1737384|NCT00089297|Drug|Paclitaxel|"Induction Therapy (Week 1-6): The induction chemotherapy starting at week 1 included paclitaxel 90 mg/m2 IV over 1 hour weekly and carboplatin AUC = 2 IV over 30 minutes weekly. The paclitaxel and carboplatin doses were given on the same day, 1 hour after C225 dose was administered. For paclitaxel and carboplatin therapy, rounding of doses (to next decimal if above 0.5 and to lower decimal if below 0.5) was permitted.
Concurrent Chemoradiation (Weeks 9-13): Concurrent chemotherapy was consisted of paclitaxel following cetuximab at 30 mg/m2/wk (over 1 hour) and carboplatin following paclitaxel at AUC = 1/week (over 15 minutes).
Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
1737451|NCT00089609|Other|pharmacological study|Plasma concentrations of docetaxel and thalidomide will be determined to assess interactions between docetaxel (and thalidomide) and the concomitant therapy.The analysis will be performed using a validated method based on liquid chromotography with mass-spectrometric detection.
1737385|NCT00089297|Radiation|Radiation therapy|"Concurrent Chemoradiation (Weeks 9-13): Radiation was given at 200cGy/d/5 weeks for a total dose of 50Gy (5000 cGy). Patients with a negative initial biopsy at week 7 were scheduled to continue concurrent therapy to complete radiation (68-72Gy).
If the biopsy was negative after concurrent therapy, the patients were scheduled to continue concurrent therapy to complete radiation (68-72 Gy).
Additional Concurrent Chemoradiation (weeks 15, 16 and 17): Concurrent therapy was consisted of C225 at 250mg/m2/week IV over 1 hour followed by paclitaxel 30mg/m2/week IV over 1 hour followed by carboplatin AUC = 1/week over 15 minutes and RT for three weeks."
1737386|NCT00089310|Radiation|technetium-99|0.25 mCi in 4 equal doses
1737387|NCT00089323|Procedure|Bone Marrow Aspiration|
1737388|NCT00089349|Biological|alemtuzumab|Given IV
1737389|NCT00089349|Drug|methotrexate|Given IV
1737390|NCT00089349|Drug|mercaptopurine|Given PO
1737391|NCT00089362|Drug|alvespimycin hydrochloride|Given IV
1737392|NCT00089362|Other|laboratory biomarker analysis|Correlative studies
1737393|NCT00089362|Other|pharmacological study|Correlative studies
1737394|NCT00089388|Drug|cilengitide|Given IV
1737395|NCT00089401|Drug|isolated perfusion|
1737396|NCT00089401|Drug|melphalan|
1737397|NCT00089401|Procedure|conventional surgery|
1737398|NCT00089414|Drug|Ethinyl Estradiol/Drospirenone|Drug administered dependent upon arm.
1737399|NCT00089414|Drug|Placebo|
1737400|NCT00089414|Drug|CDB 2914|
1737401|NCT00089427|Drug|IL13-PE38QQR|
1737402|NCT00089427|Procedure|Surgery for placement|
1737403|NCT00089427|Procedure|Radiation therapy|
1737404|NCT00089427|Drug|Temozolomide with radiation therapy|
1737405|NCT00089440|Drug|Aripiprazole|
1737406|NCT00089453|Drug|Dexamethasone|Dexamthasone 40mg every day, days -5 to -1 only will be given.
1737407|NCT00089453|Drug|Cyclophosphamide|A dose of 60mg/kg (using calculated body weight - see appendix A.) will be infused on day-3, and -2. Cyclophosphamide is administered by intravenous infusion over 2-4 hrs in 250 mLs of Normal Saline (0.9%) or D5W Standard MESNA (60% or 36mg/kg) protection to prevent hemorrhagic cystitis will be given on day -3, -2 and -1.
1737408|NCT00089453|Drug|Melphalan|Melphalan will be given as a single dose of 140mg/m2 on day -1. Subject weighing more than 60kg will be dosed according to their calculated body weight.Melphalan will be diluted in normal saline(0.9%NaCl) to a concentration of 1.5mg/ml. A dose of 140mg/m2 will be administered intravenously over a period <or= 20 minutes on day -1.
1737409|NCT00089453|Drug|Fludarabine|dose of 1.0mg/m2 on days -8,-5,-2.
1737410|NCT00089453|Drug|Bortezomide|A dose of 1.0mg/m2 will be given as a bolus dose on day-8, day-5 and day-2 as per standard practice
1737411|NCT00089453|Procedure|Leukapheresis|On day 0 to collect donor cells for NK cell isolation
1737412|NCT00089453|Drug|Interleukin|2 at 3x10x6 IU on days +1 to 13.
1737413|NCT00089453|Procedure|Infusion #1|Infusion of donor NK Cells #1 on day 0
1737414|NCT00089453|Procedure|Leukapheresis #2|on day +2
1737415|NCT00089453|Procedure|Infusion #2|on day +2
1737416|NCT00089453|Procedure|Auto Graft|on day +14
1737417|NCT00089466|Drug|AMD11070|AMD11070 taken daily. Dosage dependent on arm.
1737418|NCT00089479|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
1737419|NCT00089479|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
1737420|NCT00089479|Drug|Taxotere|100mg/m2 iv on day 1 of each 3 week cycle
1737421|NCT00089492|Drug|Optimized Background ARVs|As prescribed
1737422|NCT00089492|Drug|enfuvirtide [Fuzeon]|180mg sc once daily for 48 weeks
1737423|NCT00089492|Drug|enfuvirtide [Fuzeon]|90mg sc bid for 48 weeks
1737424|NCT00089505|Drug|Emtricitabine|200 mg taken orally
1737425|NCT00089505|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200/300 mg taken orally
1737426|NCT00089505|Drug|Lopinavir/Ritonavir|400/100 mg taken orally
1737427|NCT00089505|Drug|Nevirapine|200 mg taken orally
1737428|NCT00089505|Drug|Tenofovir disoproxil fumarate|300 mg taken orally
1737429|NCT00089518|Drug|Valsartan|
1737430|NCT00089531|Drug|VRC-HIVDNA016-00-VP|
1737431|NCT00089544|Drug|doxorubicin hydrochloride|Given IV
1737432|NCT00089544|Drug|ifosfamide|Given IV
1737433|NCT00089544|Drug|dacarbazine|Given IV
1737434|NCT00089544|Biological|filgrastim|Given subcutaneously
1737435|NCT00089544|Radiation|radiation therapy|Undergo radiotherapy
1737436|NCT00089544|Drug|thalidomide|Given orally
1737437|NCT00089544|Procedure|therapeutic conventional surgery|Undergo surgical resection
1737438|NCT00089544|Other|laboratory biomarker analysis|Correlative studies
1737439|NCT00089557|Drug|Capsaicin Dermal Patch|
1737441|NCT00089583|Drug|LEXIVA (GW433908)|Fosamprenavir suspension or tablet bid
1737442|NCT00089583|Drug|Ritonavir|Ritonavir solution bid
1737443|NCT00089596|Procedure|Expansion of umbilical cord stem cells|
1737444|NCT00089609|Drug|Docetaxel|Docetaxel 75 mg/m^2 intravenously over 60 minutes on cycle 1 day 1 repeated every 21 days.
1737445|NCT00089609|Drug|Thalidomide|Thalidomide 200 mg by mouth daily throughout the cycle.
1737446|NCT00089609|Drug|Prednisone|Prednisone 10 mg by mouth daily throughout the cycle.
1737447|NCT00089609|Biological|bevacizumab|Bevacizumab 15 mg/kg intravenously on cycle 1 day 1 every 21 days.
1737448|NCT00089609|Genetic|polymorphism analysis|Two buffy coat tubes (two 7mL blue tiger top tubes) will be obtained and wrapped in foil when the patient enters onto the study. DNA (deoxyribonucleic acid) will be isolated only for the purpose of genotype analysis of enzymes with putative relevance for docetaxel or thalidomide disposition.
1737449|NCT00089609|Other|immunoenzyme technique|The PBMC (peripheral blood mononuclear cells) of patients will be analyzed pre-treatment and post cycle 2 for any changes in the function of regulatory T cells. The following analysis will be performed: flow cytometry analysis, CD4 CD25 T cell enrichment, and immunosuppression assay.
1737450|NCT00089609|Other|laboratory biomarker analysis|Serum and urine samples will be collected at baseline and monthly to measure VEGF (vascular endothelial growth factor) levels.
1737516|NCT00090116|Drug|Neramexane|
1737452|NCT00089622|Drug|Intravenous Levodopa|
1737453|NCT00089622|Drug|Lisuride Transdermal System|
1737454|NCT00089635|Drug|ABX-EGF (panitumumab)|Panitumumab 6 mg/kg every 2 weeks
1737455|NCT00089648|Drug|Sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
1737456|NCT00089661|Drug|Placebo|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
1737457|NCT00089661|Drug|AMG 162 / Denosumab|60 mg (1.0 mL) administered subcutaneously every six months, beginning on Study Day 1, for a total treatment period of 24 months
1737458|NCT00089674|Drug|AMG 162|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
1737459|NCT00089674|Drug|Placebo|60 mg (1.0mL) administered subcutaneously at Day 1, Months 6, 12, 18, 24, 30
1737460|NCT00089687|Drug|GBR 12909|
1737461|NCT00089700|Drug|TNX-355|
1737462|NCT00089713|Drug|alagebrium chloride (ALT-711)|
1737463|NCT00089726|Biological|CG8123|
1737464|NCT00089726|Drug|Cyclophosphamide|
1737465|NCT00089752|Device|Continuous Positive Airway Pressure (CPAP) Treatment|CPAP device used at night
1737466|NCT00089752|Device|Sham CPAP device - CPAP device with pressure delivered <1 cm H20|Sham CPAP device used at night
1737467|NCT00089765|Drug|Ranibizumab|
1737468|NCT00089778|Drug|117-126:Fibroblast growth factor 5 (FGF-5)|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
1737469|NCT00089778|Drug|Fibroblast growth factor 5 (FGF-5):172-176/217-220|Two 1 ml injection in the anterior thigh deep subcutaneous tissue within 2c of each other.
1737470|NCT00089778|Other|IL-2|720,000 IU/kg as an intravenous bolus over a 15 minute period every 8 hours beginning on the day after immunization and continuing for up to 4 days (a maximum of 12 doses).
1737471|NCT00089791|Drug|placebo|Placebo administered by subcutaneous injection
1737472|NCT00089791|Drug|Denosumab|Denosumab 60 mg administered by subcutaneous injection
1737473|NCT00089804|Drug|abetimus sodium (LJP 394) and/or placebo solution|300 mg (50 mg/mL)abetimus sodium (three 2 mL vials of of abetimus sodium plus six 2 mL vials of normal saline) administered i.v. (in the vien) weekly for 52 weeks
1737474|NCT00089804|Drug|abetimus sodium (LJP 394)|900 mg (50 mg/mL) abetimus sodium (nine 2 mL vials) administered i.v. (in the vien) weekly for 52 weeks.
1737475|NCT00089804|Drug|Phosphate-buffered saline|A volume of 18 mL (nine 2 mL vials of normal saline) of identically appearing placebo (phosphate-buffered saline) administered i.v. (in the vien) weekly for 52 weeks
1737476|NCT00089830|Drug|MSI-1256F (Squalamine Lactate)|
1737477|NCT00089843|Drug|Testosterone|Testosterone patch 150mcg daily
1737478|NCT00089843|Drug|Actonel (risedronate)|Actonel (risedronate) 35mg PO one time weekly
1737479|NCT00089843|Drug|Placebo Actonel (risedronate)|Placebo tablet identical in appearance to active Actonel (risedronate) tablet
1737480|NCT00089843|Drug|Placebo testosterone|Placebo patch identical in appearance to testosterone patch
1737481|NCT00089856|Biological|Immunotherapy with allogeneic prostate vaccine|Immunotherapy with allogeneic prostate vaccine
1737482|NCT00089856|Drug|Chemotherapy (Taxotere and prednisone)|Chemotherapy (Taxotere and prednisone)
1737483|NCT00089869|Drug|olanzapine|
1737484|NCT00089869|Drug|atomoxetine|
1737485|NCT00089869|Drug|placebo|
1737486|NCT00089882|Procedure|APOE Genetic susceptibility testing|
1737487|NCT00089895|Drug|Eptifibatide (Integrilin)|intravenous; 180 mcg/kg bolus followed by infusion of 2 mcg/kg/min for 12 to 96 hours (or longer if necessary to complete the 18- to 24-hour post-PCI infusion period, or up to 120 hours in patients who proceed to CABG [coronary artery bypass graft]); second bolus of 180 mcg/kg administered 10 minutes after first bolus.
1737488|NCT00089895|Drug|Placebo|intravenous; delivery to match eptifibatide to maintain blind
1737489|NCT00089908|Biological|rDEN1delta30|Live attenuated rDEN1delta30 vaccine
1737490|NCT00089908|Biological|Placebo|Placebo for rDEN1delta30
1737491|NCT00089921|Drug|SCIO-469|60 mg capsule three times daily for 12 weeks
1737492|NCT00089921|Drug|SCIO-469|30 mg capsule three times daily for 12 weeks
1737493|NCT00089921|Drug|Placebo|2 capsules three times daily and one tablet daily
1737494|NCT00089921|Drug|SCIO-469|100 mg tablet once daily for 12 weeks
1737495|NCT00089947|Drug|Thymoglobulin [Anti-Thymocyte Globulin (Rabbit)]|
1737496|NCT00089960|Drug|AMG 706|AMG 706 125 mg daily for 48 weeks, or until progressive disease or unacceptable toxicity.
1737498|NCT00089986|Drug|Intravenous GR270773- Phospholipid Emulsion|
1737499|NCT00089986|Other|Placebo|
1737500|NCT00089999|Drug|Lapatinib|
1737501|NCT00090012|Drug|Olanzapine|
1737502|NCT00090012|Drug|Quetiapine|
1737503|NCT00090025|Drug|becatecarin|Dose: 140 mg/m2 x day Mode of administration: i.v. via central venous catheter Duration of treatment: Days 1 through 5 of a 28 day cycle
1737504|NCT00090025|Drug|5-Fluorouracil Plus Leucovorin|5-Fluorouracil (5-FU) + Leucovorin (LV) Dose: 375 mg /m2/day + 25 mg/m2/day Mode of administration: i.v. via central venous catheter or alternative i.v. administration.Duration of treatment: Days 1 through 5 of a 28 day cycle
1737505|NCT00090038|Drug|rituximab|Dose, schedule,and duration specified in protocol
1737506|NCT00090051|Drug|Rituximab|Intravenous repeating dose
1737507|NCT00090051|Drug|Fludarabine Phosphate|Intravenous repeating dose
1737508|NCT00090051|Drug|Cyclophosphamide|Intravenous repeating dose
1737509|NCT00090064|Drug|3,4-methylenedioxymethamphetamine (MDMA)|125 mg and 62.5 mg MDMA
1737510|NCT00090064|Drug|lactose (placebo|two capsules placebo matched in weight with MDMA capsules
1737511|NCT00090064|Behavioral|Psychotherapy|Psychotherapy provided by a team of two co-therapists
1737512|NCT00090077|Drug|GW695634|
1737513|NCT00090090|Drug|Elsamitrucin|
1737514|NCT00090103|Drug|dutasteride 0.5mg once daily for 4 years|combination or single agent
1737515|NCT00090103|Drug|tamsulosin 0.4mg once daily for 4 years|combination agent or single agent
1737517|NCT00090129|Drug|Onercept|Onercept will be administered subcutaneously three times a week at a dose of 150 mg, for 12 weeks of first treatment (FT) period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment or until relapse, whichever occurs first. Subjects then will be reassigned to either Onercept (150 mg) or placebo, subcutaneously three times a week, for 16 weeks. Subjects not showing 75 percent improvement in PASI score at Week 12 will receive only Onercept (150 mg) subcutaneously three times a week, for 40 weeks as open-label treatment.
1737518|NCT00090129|Drug|Placebo|Matching Placebo will be administered subcutaneously three times a week, for 12 weeks in the FT period. Subjects showing 75 percent improvement in PASI score at Week 12 will be observed for 24 weeks without treatment and then again assigned to either placebo or Onercept (150 mg), subcutaneously three times a week, for 16 weeks.
1737519|NCT00090142|Drug|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
1737520|NCT00090142|Drug|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
1737521|NCT00090155|Drug|MK0869, aprepitant|
1737522|NCT00090155|Drug|Comparator: ondansetron IV|
1737523|NCT00090168|Drug|MK0653A , ezetimibe (+) simvastatin|
1737524|NCT00090168|Drug|Comparator: atorvastatin|
1737525|NCT00090168|Drug|Duration of Treatment: 6 weeks|
1737526|NCT00090181|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
1737527|NCT00090181|Drug|Comparator: diclofenac / Duration of Treatment: 4 weeks|
1737528|NCT00090194|Biological|Immune Globulin Intravenous (Human), 10%|
1737529|NCT00090207|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
1737530|NCT00090207|Drug|Comparator: ondansetron / Duration of Treatment: 4 days|
1737531|NCT00090220|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|qHPV intramuscular injection in three 0.5 mL doses over 6 months in the Base Study or EXT1
1737532|NCT00090220|Biological|Comparator: Placebo|Placebo intramuscular injection in three 0.5 mL doses over 6 months.
1737533|NCT00090233|Biological|Rotateq™|3 doses of 2.0 mL RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
1737534|NCT00090233|Biological|Comparator: Placebo|3 doses of 2.0 mL Placebo to RotaTeq administered orally. Dose 1 will be given at study entry, Dose 2 will be given 4-10 weeks after Dose 1, Dose 3 will be given 4-10 weeks after Dose 2.
1737535|NCT00090246|Drug|MK0869, aprepitant|
1737536|NCT00090246|Drug|Comparator: ondansetron IV|
1737537|NCT00090259|Drug|Losartan 50 mg|50-mg losartan oral tablet
1737538|NCT00090259|Drug|Losartan 150 mg|100-mg losartan oral tablet + 50-mg losartan oral tablet
1737539|NCT00090272|Drug|MK0826, ertapenem sodium|
1737540|NCT00090272|Drug|Comparator: cefotetan|
1737541|NCT00090285|Biological|(Gardasil™) human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Duration of Treatment: 6 months
1737542|NCT00090285|Biological|Comparator: placebo (unspecified)|Duration of Treatment: 6 months
1737543|NCT00090298|Drug|MK0653A, ezetimibe (+) simvastatin|
1737544|NCT00090298|Drug|Comparator: Rosuvastatin|
1737545|NCT00090311|Drug|quetiapine fumarate|
1737546|NCT00090324|Drug|quetiapine fumarate tablets|
1737547|NCT00090337|Procedure|acupuncture therapy|Patients undergo acupuncture for 20-30 minutes once weekly for 4 weeks
1737548|NCT00090337|Procedure|standard follow-up care|Patients undergo standard care
1737549|NCT00090363|Drug|ZD4054 15 mg|15 mg oral tablet once daily
1737550|NCT00090363|Drug|Placebo|
1737551|NCT00090363|Drug|ZD4054 10 mg|10mg oral tablet once daily
1737552|NCT00090376|Drug|GPI 1485|
1737553|NCT00090389|Procedure|Chinese Acupuncture|
1737554|NCT00090402|Dietary Supplement|Fish Oil|Fish oil capsule
1737555|NCT00090402|Dietary Supplement|Lipoic Acid|Lipoic acid capsule
1737556|NCT00090402|Other|Fish Oil Placebo|Soybean oil placebo capsule
1737557|NCT00090402|Other|Lipoic Acid Placebo|Lipoic acid (LA) placebo capsule containing no LA
1737558|NCT00090415|Behavioral|Intensive behavioral therapy|Participants will undergo a magnetic resonance imaging (MRI) scan and will complete various activities to determine brain functioning. In addition, children with autism will take part in intensive behavioral therapy at least 4 hours every day for the duration of the study.
1737559|NCT00090428|Behavioral|Gluten- and casein-free diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. All children received individual EIBI interventions to decrease the confound of different types of therapies.
1737560|NCT00090428|Behavioral|Placebo controlled diet|Participants will follow a gluten-free and casein-free diet for 18 weeks. They will receive double blind placebo controlled challenge snacks that contain gluten, casein, gluten+casein or placebo with measurement of response. They remain on the gluten free and casein free diet for the entire study period.
1737561|NCT00090480|Biological|HyperAcute - Breast cancer vaccine|Cells will be injected intradermally for four weeks for four cycles. Dosage will vary from 10 million to 100 million HAB cells.
1737562|NCT00090493|Biological|MAGE-A3|vaccinations at 2- week intervals (days 22,36,50) with the MAGE-A3 or NY-ESO-1 peptide and GM-CSF adjuvant. The peptides will be given s.c. in a dose of 300μg; GM-CSF (250μg) will be administered to promote attraction, maturation and longevity of DCs. #2 will be thawed and re-infused after transplant on day 81 and any anti-myeloma T-cells in this leukapheresis product will be boosted immediately by re-vaccinating the patient 3 times at 14 day intervals (vaccination #4-6: days 82, 96, and 110). Vaccines #4-6 will be identical to vaccines 1-3. Thereafter, 6 monthly vaccines will be given to further boost the anti-MM-T-cells.
1737563|NCT00090493|Biological|MAGE-A3 AND NY-ESO-1 IMMUNOTHERAPY|Three injections with 300µg per injection (in 1.5mls) of peptide will be given subcutaneously together with the adjuvant GM-CSF at 500µg (same site in 0.5 mls) at two-week intervals
1737564|NCT00090506|Behavioral|Yoga|
1737565|NCT00090519|Drug|ruboxistaurin|32 mg once daily (QD) oral for up to 36 months
1737566|NCT00090519|Drug|placebo|QD oral for up to 36 months
1737567|NCT00090532|Drug|AG-013,958|
1737568|NCT00090545|Drug|BAY 43-9006|400 mg BAY 43-9006 orally twice daily in 28 day cycles.
1737569|NCT00090558|Drug|nitroglycerin|
1737570|NCT00090584|Drug|Tolterodine|4mg/d for 10 weeks. Could be reduced to 2mg/d for managing side effects.
1737571|NCT00090584|Behavioral|Behavioral training|Training in pelvic floor muscle control and exercises; behavioral strategies to diminish urgency, suppress bladder contractions and prevent incontinence; delayed voiding; and individualized fluid management.
1737572|NCT00090610|Drug|Docetaxel|"For Arm 1: 30mg/m2 mg IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression combined with carboplatin
For Arm 2: 30mg/m2 IV on Days 1 and 8 repeated every 21 days for six cycles until disease progression followed by carboplatin"
1737573|NCT00090610|Drug|Carboplatin|"Arm 1: AUC 6 IV on Days 1 and 8, repeated every 21 days for 6 cycles or until disease progression, combined with docetaxel.
Arm 2: AUC 6 IV every 21 days for 6 cycles or until disease progression, following six cycles of treatment with docetaxel"
1737574|NCT00090623|Drug|rhuFab V2 (ranibizumab)|
1737575|NCT00090649|Drug|DVS-233 SR|
1737576|NCT00090675|Drug|ZD1839|
1737577|NCT00090688|Biological|meCS6 + LT(R192G)|
1737578|NCT00090701|Drug|AG2037|
1737579|NCT00090714|Genetic|pVGI.1(VEGF2)|
1737580|NCT00090727|Drug|AQ4N|
1737581|NCT00090753|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in 2-mL glass vials containing 1 mL solution or in single-use sterile pre-filled syringes (PFSs) containing 0.3 mL or 0.6 mL injectable solution. The injectable solution was available in vials with the following strengths: 50, 100, 200, 400, and 1000 μg/mL. The injectable solution was available in PFSs with the following strengths: 30, 40, 50, 60, 75, 100, 120, 150, 200, and 250 μg/0.3 mL; and 360 and 400 μg/0.6 mL.
1737582|NCT00090753|Drug|Epoetin alfa|Epoetin alfa was provided with commercial packaging in English with country-specific labels (10,000 IU, 20,000 IU).
1737583|NCT00090753|Drug|Epoetin beta|Epoetin beta was provided with commercial packaging in English with country-specific labels (50,000 IU, 100,000 IU).
1737584|NCT00090753|Drug|Darbepoetin alfa|Darbepoetin alfa was provided with commercial packaging in English with country-specific labels (vials and PFSs in various strengths).
1737585|NCT00081094|Procedure|18F-Fluorodeoxyglucose-PET (FDG-PET)|
1737586|NCT00081094|Procedure|11Carbon-Acetate-PET|
1737587|NCT00081107|Drug|epothilone D|
1737588|NCT00081133|Drug|arsenic trioxide|
1737589|NCT00081133|Drug|imatinib mesylate|
1737590|NCT00081159|Drug|Doxorubicin hydrochloride|Doxorubicin 20 mg/m^2 is administered intravenously either over 15 to 30 minutes via a peripheral line or over 24 hours via a central line on days 1, 8, and 15 every 28 days for 2 cycles.
1737591|NCT00081159|Drug|Goserelin acetate|
1737592|NCT00081159|Drug|Leuprolide acetate|
1737593|NCT00081159|Drug|Zoledronic acid|4 mg given intravenously over 15 minutes every 28 days for a total of 6 doses.
1737594|NCT00081159|Procedure|orchiectomy|
1737595|NCT00081159|Radiation|strontium chloride Sr|1 dose of strontium-89 (4 millicurie (mCi) total dose) administered intravenously on the first day of treatment
1737596|NCT00081172|Radiation|lutetium Lu 177 monoclonal antibody J591|
1737597|NCT00081211|Biological|PV701|Given intratumorally
1737598|NCT00081224|Drug|capecitabine|
1737599|NCT00081224|Drug|celecoxib|
1737600|NCT00081224|Radiation|radiation therapy|
1737601|NCT00081224|Procedure|surgery|
1737602|NCT00081237|Drug|OSI-7904L|
1737603|NCT00081237|Drug|oxaliplatin|
1737604|NCT00081250|Dietary Supplement|creatine monohydrate|Given orally
1737605|NCT00081250|Other|placebo|Given orally
1737606|NCT00081263|Drug|Celecoxib|Given orally
1737607|NCT00081263|Other|Laboratory Biomarker Analysis|Correlative studies
1737608|NCT00081263|Other|Placebo|Given orally
1737609|NCT00081276|Drug|triapine|Given IV
1737610|NCT00081276|Drug|cisplatin|Given IV
1737611|NCT00081276|Other|laboratory biomarker analysis|Correlative studies
1737612|NCT00081289|Radiation|Radiation Therapy|Pelvic radiation therapy given once daily 5 days a week for 6 weeks, 45 Gy in 25 fractions + boost of 5.4 Gy in 3 fractions for a total dose of 50.4 Gy.
1737613|NCT00081289|Drug|Capecitabine 1650 mg/m^2/day|825 mg/m^2 q12 hours (1650 mg/m^2/day) orally 5 days per week during radiotherapy.
1737614|NCT00081289|Drug|Capecitabine 1200 mg/m^2/day|600 mg/m^2 q12 hours(1200 mg/m^2/day) orally 5 days per week during radiotherapy.
1737615|NCT00081289|Drug|Irinotecan|50mg/m^2 IV over 1 hour on days 1, 8, 22, and 29
1737616|NCT00081289|Drug|Oxaliplatin|50mg/m^2 IV over 2 hours on days 1, 8, 15, 22, and 29
1737617|NCT00081289|Procedure|Surgery|All patients will undergo surgery four to eight weeks following the completion of radiation therapy. The choice of procedure abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis is at the discretion of the surgeon.
1737618|NCT00081289|Drug|Folinic Acid|400 mg/m^2 IV over 2 hours Day 1 (postoperatively) ,every 14 days, for nine 14-day cycles.
1737619|NCT00081289|Drug|Fluorouracil|"5-fluorouracil bolus 400 mg/m^2 IV push Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
5-fluorouracil infusion 2400 mg/m^2 IV continuous infusion over 46 hours, beginning day 1, every 14 days, for nine 14-day cycles."
1737620|NCT00081289|Drug|Oxaliplatin|85 mg/m^2 IV over 2 hours Day 1 (postoperatively), every 14 days, for nine 14-day cycles.
1737621|NCT00081302|Biological|cetuximab|
1737622|NCT00081302|Drug|carboplatin|
1737623|NCT00081302|Drug|paclitaxel|
1737624|NCT00081302|Radiation|radiation therapy|
1737625|NCT00081315|Drug|Amifostine|
1737626|NCT00081328|Drug|Metformin|capsule, 1000 mg bid
1737627|NCT00081328|Drug|Rosiglitazone|capsule, 4 mg bid
1737628|NCT00081328|Behavioral|Lifestyle Program|a lifestyle change (LC) phase of weekly sessions for months 1-6, followed by a bi-weekly lifestyle maintenance (LM) phase through months 7-12, and a continued contact (CC) phase from months 13 through the end of the study. The CC phase sessions are scheduled monthly for the initial 12 months (study months 13-24) and then quarterly or 4 times a year to the end of the study
1737629|NCT00081367|Behavioral|CBT|Participants will receive ten weekly sessions of treatment. Suicidal thoughts or attempts, hopelessness, depression, health care utilization, and overall psychological and social adaptation will be assessed.
1737630|NCT00081367|Behavioral|Standard care alone|Participants will receive standard care for suicide prevention.
1737631|NCT00081380|Drug|Seroquel®, quetiapine fumarate (atypical antipsychotic)|
1737632|NCT00081380|Drug|lithium (mood stabilizer)|
1737633|NCT00081380|Drug|divalproex (mood stabilizer)|
1737634|NCT00081406|Behavioral|Individual Child CBT|
1737635|NCT00081406|Behavioral|Family CBT|
1737636|NCT00081406|Behavioral|Education/Support/Attention|
1737637|NCT00081458|Drug|Placebo|placebo injectable subcutaneously daily into thigh or abdomen
1737638|NCT00081458|Drug|Teduglutide 0.05 mg/kg/d|Teduglutide 0.05 mg/kg/d daily injectable subcutaneously into the thigh or abdomen
1737639|NCT00081458|Drug|Teduglutide 0.1 mg/kg/d|Teduglutide 0.1 /g/kg/d daily injection subcutaneously into thigh or abdomen
1737640|NCT00081471|Drug|darbepoetin alfa|0.45 micrograms/kg sc (starting dose) weekly
1737641|NCT00081471|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.6 micrograms/kg sc (starting dose) once every 2 weeks
1737642|NCT00090766|Drug|valganciclovir [Valcyte]|po daily (dose based on body surface area and CrCL)
1737643|NCT00090779|Drug|Emtricitabine/ tenofovir disoproxil fumarate|once daily
1737644|NCT00090779|Drug|Lopinavir/Ritonavir|twice daily
1737645|NCT00090844|Drug|triptorelin|3.75 mg TRELSTAR DEPOT (triptorelin) administered monthly as single intramuscular injection
1737646|NCT00090857|Drug|Letrozole|
1737647|NCT00090857|Other|Placebo|
1737648|NCT00090870|Biological|PEG-interferon alfa-2b|
1737649|NCT00090870|Biological|sargramostim|
1737650|NCT00090870|Drug|thalidomide|
1737651|NCT00090896|Biological|maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody|
1737652|NCT00090909|Drug|cisplatin|
1737653|NCT00090909|Drug|dexamethasone|
1737654|NCT00090909|Drug|gemcitabine hydrochloride|
1737655|NCT00090961|Other|educational intervention|
1737656|NCT00090961|Other|supervised exercise program|
1737657|NCT00090974|Procedure|quality-of-life assessment|
1737658|NCT00090987|Drug|imatinib mesylate|400 mg orally once a day for up to 6 months.
1737659|NCT00091026|Biological|cetuximab|Given IV
1737660|NCT00091026|Drug|gemcitabine hydrochloride|Given IV
1737661|NCT00091026|Biological|bevacizumab|Given IV
1737662|NCT00091026|Drug|erlotinib hydrochloride|Given orally
1737663|NCT00091039|Biological|recombinant fowlpox GM-CSF vaccine adjuvant|
1737664|NCT00091039|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
1737665|NCT00091039|Biological|recombinant vaccinia-CEA(6D)-TRICOM vaccine|
1737666|NCT00091039|Drug|carboplatin|
1737667|NCT00091039|Drug|paclitaxel|
1737668|NCT00091039|Radiation|radiation therapy|
1737669|NCT00091052|Biological|sargramostim|
1737670|NCT00091052|Radiation|radiation therapy|
1737671|NCT00091078|Biological|oblimersen sodium|Given IV
1737672|NCT00091078|Drug|imatinib mesylate|Given orally
1737673|NCT00091078|Other|laboratory biomarker analysis|Correlative studies
1737674|NCT00091091|Other|medical chart review|
1737675|NCT00091091|Other|questionnaire administration|
1737676|NCT00091091|Procedure|management of therapy complications|
1737677|NCT00091104|Biological|MART-1:27-35 peptide vaccine|
1737678|NCT00091104|Biological|aldesleukin|
1737679|NCT00091104|Biological|filgrastim|
1737680|NCT00091104|Biological|incomplete Freund's adjuvant|
1737681|NCT00091104|Biological|therapeutic autologous lymphocytes|
1737682|NCT00091104|Biological|therapeutic tumor infiltrating lymphocytes|
1737683|NCT00091104|Drug|cyclophosphamide|
1737684|NCT00091104|Drug|fludarabine phosphate|
1737685|NCT00091104|Procedure|autologous hematopoietic stem cell transplantation|
1737686|NCT00091104|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1737687|NCT00091104|Radiation|total-body irradiation|
1737688|NCT00091117|Drug|bortezomib|Given IV
1737689|NCT00091117|Other|pharmacological study|Correlative studies
1737690|NCT00091130|Biological|HspE7|Given SC
1737691|NCT00091130|Other|placebo|Given SC
1737692|NCT00091130|Other|laboratory biomarker analysis|Correlative studies
1737693|NCT00091143|Biological|gp100 antigen|
1737694|NCT00091143|Biological|incomplete Freund's adjuvant|
1737695|NCT00091143|Biological|keyhole limpet hemocyanin|
1737696|NCT00091143|Drug|fludarabine phosphate|
1737697|NCT00091143|Procedure|peripheral blood stem cell transplantation|
1737698|NCT00091156|Drug|gefitinib|
1737699|NCT00091156|Procedure|adjuvant therapy|
1737700|NCT00091169|Dietary Supplement|levocarnitine|Given orally
1737701|NCT00091169|Other|placebo|Given orally
1737702|NCT00091182|Drug|oxaliplatin|Given IV
1737703|NCT00091195|Drug|romidepsin|
1737704|NCT00091234|Drug|gemtuzumab ozogamicin|
1737705|NCT00094484|Drug|Cinacalcet HCl|
1737706|NCT00094497|Drug|Etoposide|
1737707|NCT00094497|Drug|Doxorubicin|
1737708|NCT00094497|Drug|Cisplatin|
1737709|NCT00094497|Drug|Streptozotocin|
1737710|NCT00094497|Drug|Mitotane|
1737711|NCT00094523|Drug|fosamprenavir|
1737712|NCT00094536|Device|Extended treatment regimen using Her Option Cryotherapy|Extended treatment regimens using the Her Option Endometrial Cryotherapy System to more effectively ablate the endometrial lining, reducing menstrual levels to normal or less.
1737713|NCT00094549|Drug|olanzapine|
1737714|NCT00094549|Drug|divalproex sodium|
1737715|NCT00094549|Drug|placebo|
1737716|NCT00094562|Drug|Fish oil supplement|
1737717|NCT00094575|Procedure|Endovascular Repair|Endovascular Repair
1737718|NCT00094575|Procedure|Standard Open Repair|Standard Open Repair
1737719|NCT00094614|Drug|Atropine|
1737720|NCT00094627|Drug|gaboxadol|Duration of Treatment - 6 weeks
1737721|NCT00094627|Drug|Comparator: placebo (unspecified)|Duration of Treatment - 6 weeks
1737722|NCT00094640|Drug|Intramuscular Olanzapine Depot|
1737723|NCT00094653|Drug|MDX-010 (anti-CTLA4) monoclonal antibody|3mg/kg (intravenous [iv] infusion over 90 minutes), every 3 weeks for 4 doses
1737724|NCT00094653|Biological|MDX-1379 (gp100) Melanoma Peptide Vaccine|2mL (2 subcutaneous injections of 2 mL each, 1 to each thigh), every 3 weeks for 4 doses.
1737725|NCT00094666|Drug|MK0928, gaboxadol / Duration of Treatment - 6 weeks|
1737726|NCT00094666|Drug|Comparator: placebo / Duration of Treatment - 6 weeks|
1737727|NCT00094679|Device|Eye patch|adhesive patch to cover the sound eye
1737728|NCT00094692|Device|Eye patch|
1737729|NCT00094692|Device|spectacles|
1737730|NCT00094692|Drug|atropine|
1737731|NCT00094705|Biological|rDEN2/4delta30(ME) Vaccine|Live attenuated rDEN2/4delta30(ME) vaccine (one of two doses)
1737732|NCT00094705|Biological|Placebo|Placebo for rDEN2/4delta30(ME) vaccine
1737733|NCT00094718|Biological|WN/DEN4-3'delta30|Live attenuated WN/DEN4-3'delta30 vaccine (one of three doses)
1737734|NCT00094718|Biological|Placebo|Placebo for WN/DEN4-3'delta30 vaccine
1737735|NCT00094731|Procedure|Memory Training|
1737736|NCT00094744|Device|Eye patch|adhesive eye patch used to cover the sound eye
1737737|NCT00094757|Drug|Comparator: sitagliptin 100 mg|sitagliptin 100 mg oral tablet once daily for 54 weeks
1737738|NCT00094757|Drug|Comparator: sitagliptin 200 mg|sitagliptin 200 mg (2- 100 mg oral tablets) once daily for 54 weeks
1737739|NCT00094757|Drug|Comparator: placebo|placebo oral tablet once daily during Phase A (Weeks 0-18)
1737740|NCT00094757|Drug|Comparator: pioglitazone|pioglitazone 30 mg oral tablet once daily during Phase B (Weeks 18-54)
1737741|NCT00094770|Drug|sitagliptin (MK0431)|Sitagliptin 100 mg oral tablets of sitagliptin once daily.
1737742|NCT00094770|Drug|Comparator: glipizide|Glipizide 1 tablet (5 mg) per day. Patients could then up-titrated to a total daily dose of 4 tablets twice daily (20mg/day) based on their glycemic control.
1737743|NCT00094783|Procedure|MRI|
1737744|NCT00094796|Procedure|Exercise cardiopulmonary metabolic testing|
1737745|NCT00094796|Procedure|Skeletal muscle biopsy|
1737746|NCT00094796|Procedure|Brachial artery reactivity testing|
1737747|NCT00094809|Drug|Placebo|Subjects randomized to placebo will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
1737748|NCT00094809|Drug|Pegfilgrastim|Subjects randomized to pegfilgrastim will receive a 6 mg subcutaneous injection once per cycle at least 24 hours after completion of 5-FU chemotherapy infusion. Subjects will continue to receive one injection per cycle until completion of 4 cycles, or until early termination from the study treatment period, whichever occurs first.
1737749|NCT00094822|Other|PI Discretion|PI Discretion
1737750|NCT00094835|Biological|Panitumumab|9.0 mg/kg on Day 1 of each 21-day cycle administered by intravenous infusion over approximately 60 minutes.
1737751|NCT00094835|Drug|Motesanib diphosphate|Dose-finding with an initial dose of 50 mg once daily and up to 125 mg once daily. 75 mg twice daily was also to be tested.
1737752|NCT00094835|Drug|Paclitaxel|Paclitaxel 200 mg/m^2 administered by IV infusion over 3 hours.
1737753|NCT00094835|Drug|Carboplatin|Carboplatin was administered IV over approximately 30 minutes. Carboplatin was dosed using the glomerular filtration rate (GFR) and Calvert formula to AUC/time curve of 6 mg/mL×min.
1737754|NCT00094848|Drug|TRAIL-R1 mAb (TRM-1; HGS-ETR1)|
1737755|NCT00094861|Drug|Palifermin|
1737756|NCT00094861|Drug|Placebo|
1737757|NCT00094861|Radiation|Radiotherapy|
1737758|NCT00094861|Drug|Paclitaxel|
1737759|NCT00094861|Drug|Carboplatin|
1737760|NCT00094874|Procedure|Acupuncture|
1737761|NCT00094887|Drug|Nitric Oxide|Nitric oxide will be delivered for 4 hours at 80 ppm through a face mask. The dose will then be reduced to 40 ppm for 4 hours. After a total of 8 hours of treatment through face mask, the patient will get 6 mL/puls/breath of NO at 800 ppm or 3 m//pulse/breath, depending on patient weight.
1737762|NCT00094887|Drug|Placebo|Nitrogen gas will be delivered in the same manor as the experimental drug.
1737763|NCT00094900|Drug|IL-1 Trap|
1737764|NCT00094926|Drug|Risperdal Consta|25, 37.5 or 50mg IM injections every 2wks for 52wks
1737765|NCT00094926|Drug|placebo|matching placebo IM injections every 2wks for 52wks
1737766|NCT00094965|Drug|Oxaliplatin (SR96669)|oxaliplatin in combination with FOLFOX4
1737767|NCT00094978|Drug|Depsipeptide|
1737768|NCT00094978|Drug|Flavopiridol (alvocidib)|
1737769|NCT00094991|Drug|Muraglitazar|
1737770|NCT00095004|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
1737771|NCT00095004|Drug|Comparator: placebo / Duration of Treatment: 1 day|
1737772|NCT00095017|Drug|MK0663, etoricoxib / Duration of Treatment: 4 weeks|
1737773|NCT00095030|Drug|muraglitazar|
1737774|NCT00095043|Drug|MK0928, gaboxadol|
1737775|NCT00095043|Drug|Comparator: placebo|
1737776|NCT00095056|Drug|sitagliptin|One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min; not on dialysis) tablets of 25 mg Sitagliptin daily.
1737777|NCT00095056|Drug|Placebo to Sitagliptin|One (participants with visit 1 estimated creatinine clearance <30 mL/min or undergo regular dialysis) or Two (participants with visit 1 creatinine clearance of =30 to <50 mL/min and not on dialysis) tablets of placebo to sitagliptin 25 mg daily.
1737778|NCT00095056|Drug|glipizide|One 5 mg glipizide tablet per day. The dose of glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
1737779|NCT00095056|Drug|Placebo to glipizide|One placebo to glipizide 5 mg tablet per day. The dose of placebo to glipizide administered per day may be increased after 2 weeks and at 2-week intervals thereafter up to 20 mg based upon fingerstick glucose determinations.
1737780|NCT00095069|Drug|MK0928, gaboxadol / Duration of Treatment - 1 year|
1737781|NCT00095069|Drug|Comparator: placebo / Duration of Treatment -1 year|
1737782|NCT00095082|Drug|insulin detemir|
1737785|NCT00095095|Device|Lumbar Interbody Fusion|
1737786|NCT00095108|Drug|Recombinant Human Interleukin-21|
1737787|NCT00095121|Drug|Placebo (PLB)|Matching placebo
1737788|NCT00095121|Drug|Adefovir Dipivoxil (ADV)|10-mg tablet or 2-mg/mL oral suspension
1737789|NCT00095121|Drug|Lamivudine|100-mg tablet administered according to package labeling. Lamivudine was to be added to the open-label ADV regimen of subjects with a serum HBV DNA concentration >= 1000 copies/mL at 2 consecutive study visits at or after Study Week 96. If the HBV DNA concentration remained >= 1000 copies/mL at 2 consecutive study visits after the addition of lamivudine, the investigator was required to discontinue all study drugs, perform the early termination ssessments, and have the subject return every 4 weeks for 16 weeks of posttreatment evaluations.
1737790|NCT00095134|Drug|risperidone|
1737791|NCT00095147|Drug|Abatacept (ABA) + Methotrexate (MTX), double-blind (DB)|Abatacept, intravenous (IV) Solution, Infusion, Depends on participant weight, Monthly, 12 months.
1737792|NCT00095147|Drug|Infliximab (INF) + MTX, DB|Infliximab, IV Solution, Infusion, Depends on participant weight, Every 2 Months, 12 months.
1737793|NCT00095147|Drug|Placebo (PLA) + MTX, DB|Placebo, IV Solution, Infusion, Depends on participant weight, Monthly, 6 months.
1737794|NCT00095147|Drug|PLA + MTX switched to ABA+ MTX, DB|Placebo=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months. Abatacept=IV Solution, Infusion, Depends on participant weight, Monthly, 6 months
1737795|NCT00095147|Drug|ABA, open-label (OL)|Abatacept, IV solution, Infusion. Depends on participant weight, Monthly, 12+ months
1737796|NCT00095160|Drug|852A|
1737797|NCT00095173|Drug|Abatacept|IV infusions, IV, 10mg/kg body weight, every 4 weeks, 6 months (unless a disease flare discontinued the patient earlier).
1737798|NCT00095173|Drug|Placebo|IV infusions, IV, N/A, every 4 weeks, 6 months.
1737799|NCT00095173|Drug|Abatacept|Solution, intravenous, Approximately 10 mg/kg fixed dose, based on subject's body weight; 500 mg for subjects weighing < 60kg; 750 mg for subjects weighing 60 to 100 kg; and 1 gram for subjects weighing > 100 kg, monthly
1737800|NCT00095186|Drug|Recombinant Human Lactoferrin|
1737801|NCT00095199|Drug|Pemetrexed|Pemetrexed 500 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
1737802|NCT00095199|Biological|Cetuximab|Cetuximab 400/250 mg/m^2 (initial/weekly) administered intravenously on Days 1, 8, and 15 (3-week) cycles until disease progression or unacceptable toxicity.
1737803|NCT00095199|Drug|Docetaxel|Docetaxel 75 mg/m^2 administered intravenously on Day 1 of 3 weeks cycle until disease progression or unacceptable toxicity for up to six (3-week) cycles.
1737804|NCT00095212|Drug|1 Transdermal Testosterone (Patch)|300 micrograms twice a week
1737805|NCT00095212|Drug|2 Placebo Patch|Placebo patch (0 micrograms of testosterone) applied twice a week
1737806|NCT00095225|Drug|Avastin (bevacizumab)|
1737807|NCT00095225|Drug|Tarceva (erlotinib HCl)|
1737808|NCT00095238|Drug|Irbesartan|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
1737809|NCT00095238|Drug|Placebo|Tablets, Oral, titration from 75 to 300 mg, once daily up to 6 years
1737810|NCT00095251|Drug|Dexmedetomidine|a bolus dose of 1 μg/kg infused over 10 minutes followed by an infusion started at 0.15- 0.45 μg/kg/hr. Dexmedetomidine will be titrated every 10 minutes to achieve set target RASS score. The maximum dexmedetomidine infusion will be 1.5 μg/kg/hr.
1737811|NCT00095251|Drug|Lorazepam|Patients in the lorazepam arm will receive a bolus dose of 1-3 mg followed by an infusion started at 1-3 mg/hr. Lorazepam infusion will be titrated every 10 minutes to achieve set target RASS score. The maximum lorazepam infusion will be 10 mg /hr.
1737812|NCT00095264|Drug|Darbepoetin Alfa|
1737813|NCT00095277|Drug|Darbepoetin Alfa|
1737814|NCT00095290|Drug|Ramipril + Irbesartan|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Irbesartan target dose, Once daily, 20 weeks.
1737815|NCT00095290|Drug|Ramipril + Placebo|Tablets + Capsules, Oral, 10mg Ramipril + 300mg Placebo target dose, Once daily, 20 weeks.
1737816|NCT00095303|Behavioral|Brief Strategic Family Therapy (BSFT)|"BSFT is a family therapy approach that consists of 12 to 16 sessions (each 1 to 1.5 hours long) over a 4-month period during the Main Study, and up to 8 booster sessions. Interventions are delivered to adolescents and relevant family members in non-restrictive community settings (e.g., clinics, homes, school)."
1737817|NCT00095303|Behavioral|Treatment as Usual|TAU varies depending on site, however each will offer services that include at least 1 therapy session (individual or group therapy) per week during the Main Study, as well as participation in ancillary services (e.g., case management, self help groups, etc.) over a four month period.
1737818|NCT00095316|Drug|Caspofungin|Caspofungin is an antifungal agent of the echinocandin class of glucan synthase inhibitor. Subjects receive Caspofungin acetate 50mg/day IV for 28 days.
1737819|NCT00095316|Other|Placebo|Normal saline equivalent to that used to deliver the caspofungin given intravenously as a single daily dose infused over approximately 1 hour for 28 days
1737820|NCT00095329|Biological|sirolimus|
1737821|NCT00095342|Drug|TMI-005|
1737822|NCT00095355|Drug|Lithium|
1737823|NCT00095355|Drug|Divalproex|
1737824|NCT00095368|Drug|Amoxicillin Pulsatile Release Multiparticulate Tablet (drug)|
1737825|NCT00095381|Drug|forodesine hydrochloride (BCX-1777)|
1737826|NCT00095394|Drug|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150mg/HCTZ 12.5 mg, Once daily, 7 weeks.
1737827|NCT00095394|Drug|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 7 weeks.
1737828|NCT00095420|Behavioral|Social skills training targeting children with autism|Sessions will focus on improving the social skills of autistic children. Thirty-minute sessions will be held twice a week for 6 weeks.
1737829|NCT00095420|Behavioral|Social skills training of peers without autism|Sessions will involve educating the peers of autistic children to increase their acceptance of their autistic peers. Thirty-minute sessions will be held twice a week for 6 weeks.
1737830|NCT00095420|Behavioral|Combination treatment of social skills/education about autism|The combination treatment includes children with and without autism. Sessions will involve social skills training and education about autism to increase acceptance of autistic peers. Training will be conducted twice a week for 6 weeks
1737831|NCT00095420|Behavioral|Usual training|Participants will receive the usual training offered in their local school districts.
1737832|NCT00095433|Drug|rhuFab V2 (ranibizumab)|
1737833|NCT00095446|Drug|insulin aspart|
1737834|NCT00095459|Drug|Bevacizumab|
1737835|NCT00095459|Drug|BAY 43-9006|
1737836|NCT00095472|Drug|L-NMMA|
1737837|NCT00095472|Drug|Sodium Nitrite|
1737838|NCT00095498|Drug|placebo|placebo subcutaneous injection
1737839|NCT00095498|Drug|denosumab|For subcutaneous injection
1737840|NCT00095511|Drug|aripiprazole|
1737841|NCT00095524|Drug|Aripiprazole|
1737842|NCT00095537|Drug|panHer|Tablets, Oral, A modified Fibonocci dose escalation system initiated at 100mg and escalating up to 880mg maximum dose (rounded down to 20mg increments based on smallest tablet size); -2 40mg -33%; -1 60mg -40%; 1 100mg --; 2 200mg 100%; 3 320mg 67%; 4 480mg 50%; 5 660mg 40%; 6 880mg 33.3%, Daily, Until DLT or study MTD is reached.
1737843|NCT00095550|Drug|Irbesartan/HCTZ|Tablets, Oral, Irbesartan 150 mg/HCTZ 12.5 mg, Once daily, 12 weeks.
1737844|NCT00095550|Drug|Irbesartan monotherapy|Tablets, Oral, 150 mg, Once daily, 12 weeks.
1737845|NCT00095550|Drug|HCTZ monotherapy|Tablets, Oral, 12.5 mg, Once daily, 12 weeks.
1737846|NCT00095563|Drug|lapatinib ditosylate|Given orally
1737847|NCT00095563|Other|laboratory biomarker analysis|Correlative studies
1737848|NCT00095576|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 ad-vg/dose)|"Trivalent MRKAd5 HIV-1 gag/pol/nef (1.5x10^10 adenovirus genomes [ad-vg]/dose).
This dose is equivalent to 3x10^10 vp/dose used in study V520-016."
1737849|NCT00095576|Drug|Comparator: placebo|Placebo to Trivalent MRKAd5 HIV-1 gag/pol/nef in three 1 mL doses at Day 1, Week 4, and Week 26 administered intramuscularly.
1737850|NCT00095589|Genetic|loss of heterozygosity analysis|
1737851|NCT00095589|Genetic|microarray analysis|
1737852|NCT00095589|Genetic|microsatellite instability analysis|
1737853|NCT00095589|Other|cytology specimen collection procedure|
1737854|NCT00095589|Other|laboratory biomarker analysis|
1737855|NCT00095589|Procedure|computed tomography|
1737856|NCT00095589|Procedure|cystoscopy|
1737857|NCT00095628|Drug|ispinesib|Given IV
1737858|NCT00095628|Other|laboratory biomarker analysis|Correlative studies
1737859|NCT00095628|Other|pharmacological study|Correlative studies
1737860|NCT00095641|Drug|capecitabine|
1737861|NCT00095641|Procedure|adjuvant therapy|
1737862|NCT00095641|Procedure|chemotherapy|
1737863|NCT00095654|Drug|Ramipril|
1737864|NCT00095654|Drug|Rosiglitazone|
1737865|NCT00095667|Drug|lapatinib ditosylate|Given orally
1737866|NCT00095667|Other|laboratory biomarker analysis|Correlative studies
1737867|NCT00095680|Drug|SCIO-469|two 30-mg capsules three times daily
1737868|NCT00095680|Drug|SCIO-469 and bortezomib|The addition of bortezomib (treatment regimen or bolus) to monotherapy of SCIO-469 or bortezomib combination with SCIO-469 will be dependent upon clinical response or disease progression during the study
1737869|NCT00095693|Drug|sorafenib tosylate|Given PO
1737870|NCT00095693|Other|laboratory biomarker analysis|Correlative studies
1737871|NCT00095693|Other|pharmacological study|Correlative studies
1737872|NCT00095693|Radiation|fludeoxyglucose F 18|Correlative studies
1737873|NCT00095693|Procedure|positron emission tomography|Correlative studies
1737874|NCT00095693|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
1737875|NCT00095706|Drug|Bevacizumab (drug), Herceptin (drug)|
1737876|NCT00095719|Drug|Aripiprazole|IM Solution, IM, Cohort 1 - 2.5mg (.33cc) maximum dose 5.0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 5.0mg (.67cc) maximum dose 10 mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 10 mg (1.3cc) or 5.0 mg (.67cc) maximum dose 15mg; 1 injection, 24 hour observation for all cohorts.
1737877|NCT00095719|Drug|Placebo|IM Solution, IM, Cohort 1 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 2 - 0mg; 2 injections 2nd injection 2 hours after first; Cohort 3 - 0mg; 1 injection, 24 hour observation for all cohorts.
1737878|NCT00095732|Drug|Liprotamase|Administered orally as either Size 2 capsules (20,000 Units lipase; 20,000 Units protease; and 3,000 Units amylase) or Size 5 capsules (5,000 Units lipase; 5,000 Units protease; and 750 Units amylase)
1737879|NCT00095732|Drug|Placebo|Administered orally in either Size 2 or Size 5 capsules
1737880|NCT00095745|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-30mg Aripiprazole, once daily, 52-weeks.
1737881|NCT00095758|Drug|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
1737882|NCT00095758|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
1737883|NCT00095771|Drug|arsenic trioxide|
1737884|NCT00095771|Radiation|radiation therapy|
1737887|NCT00095797|Drug|R(+)XK469|Given IV
1737888|NCT00095797|Other|pharmacological study|Correlative studies
1737889|NCT00095797|Other|laboratory biomarker analysis|Optional correlative studies
1737890|NCT00095810|Drug|aripiprazole|Tablets, Oral, 1-10mg, Once daily, 6 weeks.
1737891|NCT00095823|Drug|Antidepressant + Placebo|Antidepressant Caps/Tablets Placebo Tablets, Oral, 2-20 mg Placebo, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
1737892|NCT00095823|Drug|Antidepressant + Aripiprazole|Antidepressant Caps/Tablets Aripiprazole Tablets, Oral, 2-20 mg Aripiprazole, once daily, 6 weeks following an 8 week Prospective Treatment (Baseline) Phase.
1737893|NCT00095836|Drug|Gefitinib|Taken orally once a day for duration of benefit. Treatment is continuous until there is evidence of disease progression or unacceptable toxicity.
1737894|NCT00095862|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|
1737895|NCT00095862|Biological|recombinant interferon alfa|
1737896|NCT00095862|Drug|cyclophosphamide|
1737897|NCT00095875|Drug|carboplatin|Given IV
1737898|NCT00095875|Drug|cisplatin|Given IV
1737899|NCT00095875|Drug|docetaxel|Given IV
1737900|NCT00095875|Drug|fluorouracil|Given IV
1737901|NCT00095888|Drug|triapine|Given IV
1737902|NCT00095888|Drug|gemcitabine hydrochloride|Given IV
1737903|NCT00095888|Other|laboratory biomarker analysis|Correlative studies
1737904|NCT00095888|Other|pharmacological study|Correlative studies
1737905|NCT00095901|Drug|capecitabine|
1737906|NCT00095914|Drug|paclitaxel|
1737907|NCT00095914|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1737908|NCT00095927|Drug|Amifostine|Given subcutaneously
1737909|NCT00095927|Drug|Carboplatin|Given IV
1737910|NCT00095927|Drug|Paclitaxel|Given IV
1737911|NCT00095927|Radiation|radiation|Given once daily for 4 weeks and then twice daily for 2 weeks.
1737912|NCT00095940|Drug|lapatinib ditosylate|Given orally
1737913|NCT00095940|Procedure|therapeutic conventional surgery|Undergo surgery
1737914|NCT00095940|Other|laboratory biomarker analysis|Correlative studies
1737915|NCT00095940|Other|pharmacological study|Correlative studies
1737916|NCT00095940|Procedure|positron emission tomography|Correlative studies
1737917|NCT00095940|Procedure|magnetic resonance imaging|Correlative studies
1737918|NCT00095953|Drug|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks.
1737919|NCT00095966|Drug|sorafenib tosylate|Given orally
1737920|NCT00095966|Drug|gemcitabine hydrochloride|Given IV
1737921|NCT00095979|Drug|ixabepilone|Given IV
1737922|NCT00095992|Drug|ispinesib|SB-715992 will be given as a 1 hour intravenous infusion in a dose of 18 mg/m2 once every 3 weeks
1737923|NCT00096005|Drug|tanespimycin|Given IV
1737924|NCT00096005|Drug|bortezomib|Given IV
1737925|NCT00096005|Other|laboratory biomarker analysis|Correlative studies
1737926|NCT00096018|Drug|fludarabine phosphate|Given IV
1737927|NCT00096018|Drug|thalidomide|Orally
1737928|NCT00096031|Biological|cetuximab|1 time Cetuximab 400mg/m2 IV over 120 minutes followed by weekly Cetuximab 250mg/m2 IV over 60 minutes.
1737929|NCT00096044|Biological|rituximab|IV
1737930|NCT00096044|Drug|lenalidomide|Oral
1737931|NCT00096057|Biological|monoclonal antibody HuHMFG1|
1737932|NCT00096070|Radiation|radiation therapy|Undergo radiation therapy
1737933|NCT00096070|Drug|oxaliplatin|Given IV
1737934|NCT00096070|Drug|fluorouracil|Given IV
1737935|NCT00096070|Drug|gemcitabine hydrochloride|Given IV
1737936|NCT00096083|Drug|isolated perfusion|
1737937|NCT00096083|Drug|melphalan|
1737938|NCT00096096|Drug|mycophenolate mofetil|
1737939|NCT00096096|Drug|tacrolimus|
1737940|NCT00096109|Drug|tanespimycin|Given IV
1737941|NCT00096109|Other|laboratory biomarker analysis|Correlative studies
1737942|NCT00096122|Drug|cytarabine|Given IV
1737943|NCT00096122|Drug|idarubicin|Given IV
1737944|NCT00096122|Drug|tipifarnib|Given orally
1737945|NCT00096135|Biological|filgrastim|given subcutaneously (SC)
1737946|NCT00096135|Drug|cyclophosphamide|IV over 15-30 minutes
1737947|NCT00096135|Drug|cytarabine|IV over 3 hours twice daily
1737948|NCT00096135|Drug|daunorubicin hydrochloride|IV over 15 minutes
1737949|NCT00096135|Drug|dexamethasone|oral twice daily
1737950|NCT00096135|Drug|etoposide|IV over 1 hour
1737951|NCT00096135|Drug|leucovorin calcium|rescue IV over 24 hours
1737952|NCT00096135|Drug|mercaptopurine|oral
1737953|NCT00096135|Drug|methotrexate|intramuscularly (IM)
1737954|NCT00096135|Drug|pegaspargase|intramuscularly (IM)
1737955|NCT00096135|Drug|therapeutic hydrocortisone|
1737956|NCT00096135|Drug|vincristine sulfate|given IV
1737957|NCT00096135|Radiation|radiation therapy|Patients with isolated testicular relapse will start Induction with a single dose of high-dose methotrexate (HDMTX) and will not receive either testicular or cranial radiation. Patients with isolated CNS relapse will NOT receive the initial dose of HDMTX prior to Induction, but will receive 1200 cGy of cranial radiation after completing the initial 12 months of intensive systemic chemotherapy.
1737958|NCT00096148|Drug|idarubicin|Given IV
1737959|NCT00096148|Drug|cytarabine|Given IV
1737960|NCT00096148|Biological|bevacizumab|Given IV
1737961|NCT00096148|Other|laboratory biomarker analysis|Correlative studies
1737962|NCT00096161|Drug|Cyclosporine|Given PO
1737963|NCT00096161|Drug|Mycophenolate Mofetil|Given PO
1737964|NCT00096161|Drug|Pentostatin|Given IV
1737965|NCT00096161|Biological|Therapeutic Allogeneic Lymphocytes|Given IV
1737966|NCT00096174|Biological|cetuximab C225|400 mg/m^2 IV over 120 minutes on Day 1, 250 mg/m^2 IV over 60 minutes on Day 8, then weekly
1737967|NCT00096174|Drug|cisplatin|75 mg/m^2 IV over 30-60 minutes starting day 15 every 3 weeks * 3 (Days 1, 22, and 43 of radiation therapy (RT))
1737968|NCT00096174|Radiation|radiation therapy|RT 70 Gy / 35 starting Day 15, 200cGy / d * 7 weeks (35 fractions)
1737969|NCT00096187|Drug|pemetrexed disodium|
1737970|NCT00096200|Drug|Carboplatin|Given IV
1737971|NCT00096200|Drug|Paclitaxel|Given IV
1737972|NCT00096200|Drug|Sorafenib Tosylate|Given orally
1737973|NCT00096213|Procedure|conventional surgery|surgery
1737974|NCT00096226|Drug|Induction Carboplatin|
1737975|NCT00096226|Drug|Induction Paclitaxel|
1737976|NCT00096226|Procedure|Resection|
1737977|NCT00096226|Drug|Consolidation Carboplatin|
1737978|NCT00096226|Radiation|Radiation Therapy|
1737979|NCT00096226|Drug|Consolidation Paclitaxel|
1737980|NCT00096239|Drug|CP-547,632|
1737981|NCT00096265|Drug|erlotinib hydrochloride|Given orally
1737982|NCT00096265|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiation therapy once daily for approximately 3 weeks
1737983|NCT00096265|Radiation|stereotactic radiosurgery|Patients undergo surgery after radiation therapy
1737984|NCT00096265|Drug|temozolomide|Given orally
1737985|NCT00096278|Drug|oxaliplatin|Given IV
1737986|NCT00096278|Drug|leucovorin calcium|Given IV
1737987|NCT00096278|Drug|fluorouracil|Given IV
1737988|NCT00096278|Biological|bevacizumab|Given IV
1737989|NCT00096291|Other|Doxorubicin followed by Paclitaxel|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:
Doxorubicin followed by Paclitaxel Paclitaxel followed by Doxorubicin"
1737990|NCT00096291|Other|Paclitaxel followed by Doxorubicin|"Patients will be randomized into 2 groups based on sequence of neoadjuvant chemotherapy:
Doxorubicin followed by Paclitaxel versus Paclitaxel followed by Doxorubicin"
1737991|NCT00096304|Drug|docetaxel|
1737992|NCT00096304|Drug|epirubicin hydrochloride|
1737993|NCT00096317|Drug|ixabepilone|
1737994|NCT00096317|Drug|ketoconazole|
1737995|NCT00096330|Dietary Supplement|dietary intervention|oral folic acid supplementation once daily on days 57-84
1737996|NCT00096330|Dietary Supplement|folic acid|oral folic acid supplementation once daily on days 1-56.
1737997|NCT00096343|Drug|carboplatin|
1737998|NCT00096343|Drug|paclitaxel|
1737999|NCT00096356|Dietary Supplement|CoQ10 & Vitamin E|
1738000|NCT00096356|Dietary Supplement|Placebo & Vitamin E|
1738001|NCT00096369|Drug|tamoxifen citrate|
1738002|NCT00096382|Biological|aldesleukin|high dose: 720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days (maximum 5 doses) or low dose: 250,000 IU/kg subcutaneously daily for 5 days, after a two day rest, 125,000 IU/kg subcutaneously daily for 5 days for five weeks (2 days rest per week)
1738003|NCT00096382|Biological|filgrastim|10 mcg/kg/day daily subcutaneously until neutrophil count >1x10^9/1.
1738004|NCT00096382|Biological|therapeutic tumor infiltrating lymphocytes|Lymphocytes that are isolated from the tumor, grown in the laboratory to high amounts and then infused into the patient.
1738005|NCT00096382|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenously over 1 hour
1738006|NCT00096382|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggyback daily over 15-20 minutes for 5 days
1738007|NCT00096382|Radiation|radiation therapy|Patients will receive 2Gy of total body irradiation (TBI) at a rate of 0.07 Gy/minute using a linear accelerator.
1738008|NCT00096395|Drug|gemcitabine hydrochloride|Given IV
1738009|NCT00096395|Drug|sorafenib tosylate|Given orally
1738010|NCT00096395|Other|laboratory biomarker analysis|Correlative studies
1738011|NCT00096408|Procedure|Total Abdominal Hysterectomy|For patients with clinical stage I disease, removal of the uterus and both tubes and ovaries are considered current standard treatment in Australia.
1738012|NCT00096408|Procedure|Total Laparoscopic Hysterectomy|The technique of total laparoscopic hysterectomy (TLH), utilising the McCartney tube, has been developed by Anthony J. McCartney over the last 10 years. It allows the completion of the hysterectomy entirely laparoscopically, without the need for additional vaginal surgery.
1738013|NCT00096421|Behavioral|Tight control of blood glucose levels|
1738014|NCT00096421|Behavioral|Conventional control of glucose levels|
1738015|NCT00096434|Drug|sorafenib tosylate|Given orally
1738016|NCT00096434|Other|laboratory biomarker analysis|Correlative studies
1738017|NCT00096447|Drug|lapatinib ditosylate|
1738018|NCT00096460|Drug|Cyclophosphamide and Rituximab|Prior to undergoing HSCT, all patients will receive Cyclophosphamide 4 gm/m2 with Rituximab 375 mg/m2 x 2 doses and G-CSF support.
1738019|NCT00096460|Drug|Filgrastim|Autologous HSCT patients will receive 10 mcg/kg/day and allogeneic HSCT patients will receive 5 mcg/kg/day subcutaneous (SQ) or intravenous (IV) starting 2 days after the initiation of Cyclophosphamide.
1738020|NCT00096460|Radiation|Chemotherapy or Radiation therapy|"Chemotherapy - BCNU 15 mg/kg IV x 1 dose to be administered over 2 hours on Day -6 pre-HSCT. VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4.
Radiation - administered at a rate of < 20 cGy/min in one of the following doses; 120 cGy/fraction are administered at no less than 4-hour intervals three times/day or 2 times/day for a total of 10 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5), or doses of 150 cGy/fraction twice daily for a total of 8 doses (1200 cGy) over 4 days (Day -8, -7, -6 and -5). VP-16 60 mg/kg IV x 1 dose to be administered over 4 hours on Day -4 pre-HSCT.
Cyclophosphamide 100 mg/kg IV x 1 dose to be administered over 2 hours on Day -2 pre-HSCT. G-CSF 5 mcg/kg SQ or IV to start on Day +5 post-HSCT and continue until ANC > 500/mm3 x 3 days."
1738021|NCT00096460|Drug|Non-myeloablative Conditioning regimen|Fludarabine 30 mg/m2 IV x 3 doses total to be administered daily over 30 minutes on Days -6, -5 and -4 pre-HSCT. Cyclophosphamide 750 mg/m IV x 3 doses total to be administered daily over 1 hour on Days -6, -5 and -4 pre-HSCT. Administer cyclophosphamide approximately 4 hours after start of fludarabine infusion. Rituximab 375 mg/m2 IV x 4 doses total to be administered on Days -13 and -6 pre HSCT and Days +1 and +8 post HSCT.
1738022|NCT00096460|Procedure|Allogeneic transplant|Infusion of G-CSF mobilized allogeneic hematopoietic stem cells
1738023|NCT00096460|Procedure|Autologous transplant|Infusion of G-CSF mobilized autologous hematopoietic stem cells
1738024|NCT00096460|Drug|Rituximab maintenance therapy|"Patients must have sufficiently recovered from autologous HSCT in order to receive rituximab maintenance therapy as specified below:
Dose #1: Day +42 post-autologous HSCT Dose #2: Day +49 post-autologous HSCT Dose #3: Day +56 post-autologous HSCT Dose #4: Day +63 post-autologous HSCT"
1738025|NCT00096460|Drug|GVHD Prophylaxis|Tacrolimus 0.09 mg/kg/day PO, based on body weight formulas will start on Day -2 and continue until Day +90 post-HSCT. Tacrolimus (or cyclosporine, if applicable) will be given orally in a twice-daily divided dose. Methotrexate 5 mg/m2 Intravenous Pyelogram (IVP) will be administered on Days +1, +3 and +6 post-HSCT.
1738026|NCT00096473|Drug|Donepezil hydrochloride|
1738027|NCT00096486|Drug|everolimus|
1738028|NCT00096486|Drug|gefitinib|
1738029|NCT00096499|Drug|ispinesib|Given IV
1738030|NCT00096499|Other|pharmacological study|Correlative studies
1738031|NCT00096499|Other|laboratory biomarker analysis|Correlative studies
1738032|NCT00096512|Drug|sorafenib tosylate|Given orally
1738033|NCT00096512|Other|laboratory biomarker analysis|Correlative studies
1738034|NCT00096525|Drug|lenalidomide|
1738035|NCT00096538|Drug|valganciclovir|
1738036|NCT00096551|Drug|Recombinant Vaccinia-PSA(L155)/TRICOM (PROSTVAC-V/TRICOM)|
1738037|NCT00096551|Drug|Recombinant Fowlpox-PSA(L155)/TRICOM (PROSTVAC-F/TRICOM)|
1738038|NCT00096551|Drug|Recombinant Fowlpox-GM-CSF|
1738039|NCT00096590|Other|coagulation study|
1738040|NCT00096590|Other|immunoenzyme technique|
1738041|NCT00096590|Other|laboratory biomarker analysis|
1738042|NCT00096590|Other|physiologic testing|
1738043|NCT00096590|Procedure|study of high risk factors|
1738044|NCT00096603|Drug|Raptiva (efalizumab)|
1738045|NCT00096616|Drug|Combivent® CFC MDI|
1738046|NCT00096616|Drug|Albuterol HFA MDI|
1738047|NCT00096629|Biological|human prostate-specific membrane antigen plasmid DNA vaccine|
1738048|NCT00096629|Biological|mouse prostate-specific membrane antigen plasmid DNA vaccine|
1738049|NCT00096642|Behavioral|Cognitive Behavioral Therapy|Cognitive behaviour versus standard care
1738050|NCT00096655|Drug|Infliximab|
1738051|NCT00096668|Drug|TOCOSOL(R) Paclitaxel|
1738052|NCT00096694|Device|Levonorgestrel-releasing intrauterine device (IUD)|
1738053|NCT00096707|Drug|2-deoxy-D-glucose (2DG)|
1738054|NCT00096720|Drug|levodopa|
1738055|NCT00096720|Drug|Mirapex (pramipexole)|
1738056|NCT00096720|Procedure|[123I]ß-CIT and SPECT imaging|
1738057|NCT00096746|Drug|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
1738058|NCT00096746|Drug|LPV/RTV + 2NRTIs|Tablets, Oral, Variable, Twice daily, 48 weeks.
1738059|NCT00096759|Behavioral|Tai Chi Chih|
1738060|NCT00096759|Behavioral|Relaxation training|
1738061|NCT00096785|Drug|entecavir|Tablets, Oral, ETV 0.5 mg, once daily, up to 96 weeks
1738062|NCT00096785|Drug|adefovir|Tablets, Oral, ADV 10 mg, once daily, up to 96 weeks
1738063|NCT00096798|Drug|Ethyl-eicosapentanoic acid (ethyl-EPA)|
1738064|NCT00096811|Drug|Entecavir|Tablets, Oral, 1 mg once daily. Until subject achieves a complete response or until ETV approved and marketed in a given country.
1738065|NCT00096824|Behavioral|Neurological assessment|All participants will undergo neurological examinations and neuropsychological assessments.
1738066|NCT00096837|Drug|Motexafin Gadolinium Injection|
1738067|NCT00096850|Drug|Atazanavir|From Days 9 to 19, participants will receive a 300 mg tablet orally daily. From Days 20 to 27, participants will receive a 400 mg tablet orally daily.
1738068|NCT00096850|Drug|Rifampin|From Days 1 to 27, participants will receive a 600 mg tablet orally daily.
1738069|NCT00096850|Drug|Ritonavir|From Days 9 to 19, participants will receive a 100 mg tablet orally daily. From Days 20 to 27, participants will receive a 100 mg tablet orally twice daily.
1738070|NCT00096863|Drug|Ziprasidone|
1738071|NCT00096863|Drug|Haloperidol|
1738072|NCT00096863|Other|Placebo|
1738073|NCT00096902|Procedure|Tilt table test|
1738074|NCT00096915|Drug|Darbepoetin Alfa|"QM administration for 32 weeks, allowable doses:
15, 20, 30, 40, 50, 60, 80, 100, 150, 200, 300, 400, 500, 600 and 800 mcg"
1738075|NCT00096941|Drug|Pertuzumab|Pertuzumab was supplied as a single-use liquid formulation.
1738076|NCT00096954|Drug|omalizumab (Xolair)|Omalizumab (Xolair) was administered subcutaneously every 2 or 4 weeks. The dose (mg) and dosing frequency were determined by serum total IgE level (IU/mL), measured before the start of treatment, and body weight (kg). Assignment of the study drug dose was determined by using the study drug-dosing table. Doses of > 150 mg were divided among more than one injection site to limit injections to no more than 150 mg per site.
1738077|NCT00096954|Drug|placebo|The dose of placebo consisting of sucrose, L-histidine, L-histidine hydrochloride monohydrate, and polysorbate 20 was administered by subcutaneous injection every 2 or 4 weeks.
1738078|NCT00096967|Drug|Avastin (bevacizumab)|
1738079|NCT00096980|Drug|Raptiva (efalizumab)|
1738080|NCT00096993|Drug|Placebo|Placebo was provided as a single-use formulation for infusion.
1738081|NCT00096993|Drug|Gemcitabine|Gemcitabine was provided as a solution for infusion.
1738082|NCT00096993|Drug|Pertuzumab|Pertuzumab was provided as a single-use formulation for infusion.
1738083|NCT00097019|Drug|bevacizumab|
1738084|NCT00097032|Drug|risperidone; quetiapine|
1738085|NCT00085423|Biological|aldesleukin|‡Interleukin-2 (aldesleukin) IV (600,000 U/kg; Chiron, Emeryville, CA): two 5-day courses on days 8 and 22. Interleukin-2 was given over 15 minutes every 8 hours. Goal is 14 doses/5-day course
1738086|NCT00085423|Biological|sargramostim|GM-CSF was given subcutaneously daily from day 8 until absolute granulocyte count exceeds 5,000 cells/mL for 2 consecutive days.
1738087|NCT00085423|Drug|cyclophosphamide|Cyclophosphamide (60 mg/kg/d; Baxter, Deerfield, IL) intravenously (IV) for 2 days with sodium 2- mercaptoethanesulfonate (Mesna; Sicor, Irvine, CA) at 20% of cyclophosphamide dose IV 15 minutes before and 40% of the cyclophosphamide dose orally at 2 and 6 hours after the initiation of chemotherapy.
1738088|NCT00085423|Drug|fludarabine phosphate|Fludarabine IV (25 mg/M2/day)-five daily doses from Day 3
1738089|NCT00085436|Biological|Aldesleukin,|Recombinant human interleukin-2 (Proleukin, Chiron Therapeutics) will be administered as a five day (120 hr) continuous intravenous infusion at a dose of 18x106 IU per square meter of body surface area per day as per the Negrier regimen (21). The treatment schedule consists of two induction cycles and three maintenance cycles. Each induction cycle consists of two five-day courses of interleukin-2 infusion separated by a nine-day break. Each maintenance cycle consists of a five-day infusion followed by 23-day rest period of no therapy.
1738090|NCT00085436|Biological|autologous tumor cell vaccine|we will administer 1 X 107 DC cells. The autologous tumor cell vaccine (1 X 107 cells/1cc) in lactated ringers solution and injected into one (or two if clinically necessary) inguinal lymph nodes under ultrasound guidance. Each cycle of DC vaccine will be administered alternately in the right and left inguinal lymph nodes.
1738091|NCT00085436|Biological|recombinant interferon alfa|Recombinant human interferon alfa-2a (Roferon, Roche), at a dose of 6 million IU per day three times a week subcutaneously will be given during the two interleukin-2 induction cycles and during each interleukin-2 maintenance cycle
1738092|NCT00085449|Biological|alemtuzumab|
1738093|NCT00085449|Drug|cyclosporine|
1738094|NCT00085449|Drug|fludarabine phosphate|
1738095|NCT00085449|Drug|melphalan|
1738096|NCT00085449|Drug|mycophenolate mofetil|
1738097|NCT00085449|Procedure|peripheral blood stem cell transplantation|
1738098|NCT00085449|Radiation|radiation therapy|
1738099|NCT00085462|Biological|aldesleukin|
1738100|NCT00085462|Biological|filgrastim|
1738101|NCT00085462|Biological|gp100-fowlpox vaccine|
1738102|NCT00085462|Biological|therapeutic autologous lymphocytes|
1738103|NCT00085462|Biological|therapeutic tumor infiltrating lymphocytes|
1738104|NCT00085462|Drug|cyclophosphamide|
1738105|NCT00085462|Drug|fludarabine phosphate|
1738106|NCT00085475|Drug|imatinib mesylate|
1738107|NCT00085475|Procedure|conventional surgery|
1738108|NCT00085488|Biological|autologous tumor cell vaccine|
1738109|NCT00085488|Biological|therapeutic autologous dendritic cells|
1738110|NCT00085501|Drug|cetuximab|"Arm 1: 400 mg/m2 (Initial dose), 2 hour IV infusion on Day 1, Week 1 only. 250 mg/m2 (Subsequent doses), 1 hour IV infusion, on Day 1 weekly starting at Week 2.
Arm 2: 400 mg/m2 (Initial dose), 2 hour IV infusion on Week 13 ONLY 250 mg/m2 (Subsequent doses), 1 hour IV infusion, weekly starting at Week 14."
1738111|NCT00085501|Drug|carboplatin|"Arm 1: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 2
Arm 2: AUC=6 30 minute IV infusion immediately following paclitaxel on Day 1 q 21 days x 4 starting at Week 1"
1738112|NCT00085501|Drug|paclitaxel|"Arm 1: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 4.
Arm 2: 225 mg/m2 3 hour IV infusion 1 hour following cetuximab on Day 1, q 21 days x 4 Starting at Week 1."
1738113|NCT00085527|Drug|depsipeptide|
1738114|NCT00085540|Drug|depsipeptide|Given IV
1738115|NCT00085553|Drug|Erlotinib Hydrochloride|Given PO
1738116|NCT00085553|Other|Laboratory Biomarker Analysis|Correlative studies
1738117|NCT00085553|Other|Pharmacological Study|Correlative studies
1738118|NCT00085553|Drug|Tipifarnib|Given PO
1738119|NCT00085566|Drug|everolimus|
1738120|NCT00085566|Drug|gefitinib|
1738121|NCT00085579|Biological|aldesleukin|
1738122|NCT00085579|Biological|sargramostim|
1738123|NCT00085579|Procedure|adjuvant therapy|
1738124|NCT00085631|Drug|cisplatin|Given IV
1738125|NCT00085631|Procedure|hyperthermia treatment|Patients undergo hyperthermia treatment over 60-90 minutes
1738126|NCT00085631|Radiation|brachytherapy|Patients undergo brachytherapy for 2-3 days
1738127|NCT00085631|Radiation|external beam radiation therapy|Patients undergo external beam radiation therapy once daily on days 1-5
1738128|NCT00085644|Biological|adalimumab (D2E7)|Adalimumab 40 mg every other week, subcutaneous
1738129|NCT00085644|Biological|placebo|Placebo every other week, subcutaneous
1738130|NCT00085696|Drug|VELCADE and rituximab|
1738131|NCT00085709|Drug|gemtuzumab ozogamicin|Given IV, induction Arm1 6mg/m2 D4; post-consolidation 5mg/m2 3 doses >/= 28 days apart
1738132|NCT00085709|Other|observation|No treatment given
1738133|NCT00085709|Drug|Cytosine arabinoside|IV; induction Arms1/2 and reinduction 100 mg/m2/d days 1-7; consolidation 3gm/m2 q3hrs D1, 3, 5
1738134|NCT00085709|Drug|Daunomycin|IV; induction Arm1 45mg/m2 D1-3; Arm2 and reinduction 60 mg/m2 D1-3;
1738135|NCT00085722|Procedure|Dextrose Prolotherapy|Injection procedure: 50% dextrose is diluted with .9% 'normal' saline and 1% lidocaine to achieve 15% dextrose for ligament injections and 25% dextrose for intra-articular injection.
1738136|NCT00085722|Procedure|Saline Prolotherapy|7 mL 9% 'normal' saline and 3mL 1% lidocaine
1738137|NCT00085722|Other|At-home physical therapy exercise group|Subjects in the at-home physical therapy exercise group will receive a patient information pamphlet about knee osteoarthritis and conservative care instructions for standard at-home physical therapy exercises
1738138|NCT00085735|Drug|Cisplatin|Given IV
1738139|NCT00085735|Radiation|Craniospinal Irradiation|Undergo craniospinal Irradiation
1738140|NCT00085735|Drug|Cyclophosphamide|Given IV
1738141|NCT00085735|Radiation|Involved-Field Radiation Therapy|Undergo smaller volume boost (involved-field radiation therapy)
1738142|NCT00085735|Other|Laboratory Biomarker Analysis|Correlative studies
1738143|NCT00085735|Drug|Lomustine|Given orally
1738144|NCT00085735|Other|Quality-of-Life Assessment|Ancillary studies
1738145|NCT00085735|Radiation|Radiation Therapy|Undergo standard volume boost (whole posterior fossa radiation therapy)
1738146|NCT00085735|Drug|Vincristine Sulfate|Given IV
1738147|NCT00085748|Drug|paliperidone ER|
1738148|NCT00085761|Drug|Capsaicin Dermal Patch|
1738149|NCT00085774|Drug|albuterol aerosol by HFA MDI|albuterol HFA MDI 160 mcg
1738150|NCT00085774|Drug|albuterol aerosol by HFA BOI|albuterol HFA BOI 160 mcg
1738151|NCT00085774|Drug|placebo aerosol by HFA|placebo HFA
1738152|NCT00085787|Drug|ARRY-142886, MEK inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
1738153|NCT00085813|Drug|Ispinesib|
1738154|NCT00085826|Drug|Exisulind|
1738155|NCT00085839|Drug|Tarceva (Trademark) (erlotinib HCl, OSI-774)|Erlotinib tablets administered orally, 150 mg/day (starting dose) or 100 mg/day (reduced dose), continuous therapy
1738156|NCT00085839|Drug|Combination carboplatin and paclitaxel|Paclitaxel 200 mg/m^2 IV infusion over 3 hours and carboplatin AUC 6 mg/mL x min IV over 15 - 30 minutes, both given on Day 1 every 21 days for 4 cycles
1738157|NCT00085852|Biological|BLVR|10 mL Hydrogel
1738158|NCT00085878|Drug|SB-485232|
1738159|NCT00085891|Drug|Quetiapine Fumarate|
1738160|NCT00085904|Drug|SB-485232|
1738161|NCT00085917|Drug|Double dose pegylated interferon with weight based Ribavirin|pegylated interferon alfa -2a 180ug/twice weekly and weight based ribavirin for 4 weeks then pegylated interferon alfa -2a 180ug/ weekly for the remainder of the treatment
1738162|NCT00085917|Drug|standard dose pegylated interferon alfa -2a and ribavirin|pegylated interferon alfa -2a 180ug weekly and weight based ribavirin for duration of the treatment
1738163|NCT00085930|Biological|14g2a.zeta chimeric receptor transduced autologous EBV specific cytotoxic T-lymphocytes (EBV-CTL) w/o lymphodepletion|CTLs: 2x10e7 cells/m2
1738164|NCT00085943|Drug|LEXIVA (GW433908)|
1738165|NCT00085943|Drug|Ritonavir|
1738166|NCT00085943|Drug|KALETRA|
1738167|NCT00085943|Drug|EPIVIR|
1738169|NCT00085943|Drug|Abacavir/Lamivudine|
1738170|NCT00085943|Drug|Fosamprenavir|
1738171|NCT00085956|Drug|Arzoxifene|
1738172|NCT00085956|Drug|Placebo|
1738173|NCT00085969|Drug|Placebo 0.04 mL twice daily|Subcutaneously injected, 0.04 mL, twice daily
1738174|NCT00085969|Drug|Placebo 0.04 mL once daily|Subcutaneously injected, 0.04 mL, once daily
1738175|NCT00085969|Drug|Placebo 0.08 mL once daily|Subcutaneously injected, 0.08 mL, once daily
1738176|NCT00085969|Drug|B - Exenatide 10 mcg twice daily|Subcutaneously injected, 10 mcg (0.04 mL), twice daily
1738177|NCT00085969|Drug|C - Exenatide 10 mcg once daily|Subcutaneously injected, 10 mcg (0.04 mL), once daily
1738178|NCT00085969|Drug|Exenatide 20 mcg once daily|Subcutaneously injected, 20 mcg (0.08 mL), once daily
1738180|NCT00086021|Procedure|Acupuncture|
1738181|NCT00086034|Drug|Motexafin gadolinium|
1738182|NCT00086047|Behavioral|Coping Skills Training|8 weekly sessions of behavioral treatment
1738183|NCT00086047|Behavioral|Education|8 weekly sessions of fibromyalgia education
1738184|NCT00086060|Behavioral|Exercise regimen|Aerobic Exercise is a self-management technique that increases personal control over pain by enhancing physical fitness. Patients will be encouraged to choose activities best suited to their tastes and current lifestyle, incorporating lifestyle physical activities (climbing stairs, household chores, etc) and more traditional exercise activities (walking, cycling, etc.). Subjects will use ratings of perceived exertion (RPE) to guide their effort. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for exercise, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
1738185|NCT00086060|Behavioral|Relaxation training|Relaxation is a self-management technique that increases personal control over pain by relaxing tense muscles, allowing the body to rest, and improving mental clarity through concentration and attention and has a great deal of empirical research supporting its effectiveness as a means of pain management. A variety of relaxation skills will be taught with some being based on muscle relaxation, and others focused more on cognitive relaxation and imagery. The intervention will consist of two-hours of face-to-face contact followed by weekly telephone contact for 8 weeks. Face-to-face contract will include receiving a standardized instruction manual for relaxation, a demonstration on how to perform relaxation, and tailoring homework assignments to be monitored on the weekly phone call.
1738186|NCT00086060|Behavioral|Standard Care|Participants in the standard care control group will not receive any additional intervention beyond that which they are receiving from their routine health care professional.
1738187|NCT00086086|Drug|Darbepoetin Alfa|
1738188|NCT00086099|Drug|Idarubincin and Amufostine (Ethyol)|Starting doses of Idarubincin(12,18 mg/m2 to 21 mg/m2), ara-C, plus amofostine (N-36)
1738189|NCT00086099|Drug|Idarubincin|Idarubincin (12mg/m2) and ara-C(N-18)
1738190|NCT00086112|Drug|risperidone oral tablets|
1738191|NCT00086125|Drug|ridaforolimus|AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
1738192|NCT00086138|Drug|Sertraline (Zoloft)|Sertraline: range of 25 to 125 mg per day for 24 weeks
1738193|NCT00086138|Drug|Placebo|Placebo designed to mimic sertraline taken daily for 24 weeks
1738194|NCT00086164|Drug|edifoligide (E2F Decoy)|
1738195|NCT00086177|Drug|8% progesterone vaginal gel|Progesterone 8% Vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
1738196|NCT00086177|Drug|Placebo Vaginal Gel|Placebo vaginal gel, once daily, maximum duration from 18 07 weeks gestation to 37 0/7 weeks gestation
1738197|NCT00086190|Drug|paroxetine|Paroxetine 10 mg tablets or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the paroxetine or matching placebo will be increased to 20 mg, followed by a 10 mg increase every two weeks (if tolerated). Dosage for this study will not exceed 40 mg.
1738198|NCT00086190|Drug|venlafaxine|Venlafaxine XR 37.5 mg capsules or matching placebo given once a day for the first two weeks. If depression is not being effectively treated then the venlafaxine XR capsules or matching placebo will be increased to 75 mg followed by 75 mg increments every 2 weeks (if tolerated). Dosage for this study will not exceed 225 mg.
1738199|NCT00086190|Other|placebo|an inactive substance
1738200|NCT00086203|Drug|Talabostat mesylate (PT-100) tablets|
1738201|NCT00086203|Drug|Rituximab|
1738202|NCT00086216|Drug|Atiprimod|Oral, once a day, 14 days on 14 days off
1738203|NCT00086229|Drug|Glucosamine|
1738204|NCT00086229|Drug|Chondroitin|
1738205|NCT00086242|Other|counseling intervention|
1738206|NCT00086242|Procedure|psychosocial assessment and care|
1738207|NCT00086242|Procedure|quality-of-life assessment|
1738208|NCT00086255|Drug|Tiagabine|
1738209|NCT00086268|Drug|zoledronic acid|
1738210|NCT00086268|Drug|Taxotere|
1738211|NCT00086268|Drug|Carboplatin|
1738212|NCT00086281|Drug|Xyrem (X)|Xyrem (Sodium Oxybate) Oral Solution
1738213|NCT00086281|Drug|Zolpidem (Z)|Zolpidem 10 mg oral tablets
1738214|NCT00086281|Drug|Modafinil (M)|Modafinil Oral Tablets
1738215|NCT00086281|Drug|Placebo (P)|Placebo Oral Solution
1738216|NCT00086294|Drug|Intravenous Levodopa|
1738217|NCT00086294|Drug|ACP-103|
1738218|NCT00086307|Drug|Pramipexole|Pramipexole will be titrated so patients receive the following medication three times per day during the weeks noted: .125 milligrams (mg) in week 1, .250 mg in week 2, .5 mg in week 3, and .75 mg in weeks 4 to 6.
1738219|NCT00086307|Drug|Escitalopram|Escitalopram will be started at 10 mg/day and patients will continue on this throughout the study.
1738220|NCT00086320|Drug|Paliperidone ER|
1738221|NCT00086333|Drug|SGN-15, Docetaxel|
1738222|NCT00086346|Drug|Sirolimus (Rapamune)|
1738223|NCT00086346|Drug|Cyclosporine or Tacrolimus|
1738224|NCT00086359|Drug|Abacavir sulfate, lamivudine, and zidovudine|one pill twice daily
1738225|NCT00086359|Drug|Lamivudine/zidovudine|one pill twice daily
1738226|NCT00086359|Drug|Lopinavir/ritonavir|four pills twice daily
1738341|NCT00087178|Drug|adriamycin|adriamycin 60 mg/m2 IV every 21 days for 4 cycles
1738227|NCT00086385|Drug|Nicotine polacrilex, Bupropion|Subjects receive 12 weeks of bupropion treatment and 10 weeks of nicotine replacement.
1738228|NCT00086398|Behavioral|Behavior Therapy|
1738229|NCT00086411|Drug|nicotine transdermal system|starting with 21 or 14mg dependent on number of cigarettes per day smoked upon entry in the study; titrated down over 8 weeks.
1738230|NCT00086411|Drug|bupropion|150 mg/day X 3 days 300mg/day for 60 days Total 9 weeks
1738231|NCT00086411|Behavioral|Medication Management|Brief manual based therapy; four 15 minute session over 10 weeks.
1738232|NCT00086411|Behavioral|Mayo Counseling|Manual based therapy; Weekly 30 minute sessions for 10 weeks
1738233|NCT00086411|Drug|placebo patch|placebo patch containing no nicotine
1738234|NCT00086411|Drug|placebo bupropion|placebo pills
1738235|NCT00086450|Procedure|Coronary Artery Bypass Graft|For CABG, participants will receive general anesthesia and will have a breathing tube placed in their throat and they will be unconscious during the operation. An incision is made through the chest bone and muscle, which allows the surgeon access to the heart and diseased vessels. The surgeon will use one or more healthy vessels (either from an artery in the shoulder or a vein in the leg) and will bypass the diseased vessel with the healthy vessel(s). This bypass will provide needed blood supply to the heart.
1738236|NCT00086450|Device|Percutaneous Coronary Intervention|"For PCI, the participant will have two or more drug-eluting stents permanently implanted in their clogged arteries. Drug-eluting stents are coated with a drug that may prevent the disease in the vessel from coming back. The brand names of the stents used in this study are TAXUS and CYPHER.
The participant will receive a local anesthetic. A small puncture will be made and a balloon-tipped catheter is introduced through the small puncture in the leg/arm and advanced through the artery to the diseased heart vessel. The balloon is then inflated to enlarge the opening in the vessel. After enlarging the vessel, the drug-eluting stent will be placed using a similar balloon catheter. This balloon will be inflated, expanding the stent and placing it in the diseased vessel. Once the stent is fully expanded, the balloon is deflated and removed, leaving the stent in place in the artery."
1738237|NCT00086463|Drug|Iloprost or placebo|
1738238|NCT00086489|Drug|CP-675,206|pts treated at 10 mg/kg dose level on a monthly regimen
1738239|NCT00086489|Drug|CP-675,206|pts treated at 15 mg/kg dose level on a quarterly regimen
1738240|NCT00086502|Drug|Comparator: Sitagliptin|Sitagliptin 100 mg once daily, from Visit 4 through Visit 8. Day 1 through week 24
1738241|NCT00086502|Drug|Comparator: Placebo|Placebo (to match Sitagliptin 100 mg) once daily, from Visit 4 through Visit 8. Day 1 through Week 24
1738242|NCT00086502|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg or 45 mg once daily, Visit 2 through Visit 8
1738243|NCT00086502|Drug|Metformin|"Metformin rescue for patients meeting
pre-specified glycemic criteria. Metformin 500 mg,once daily, Visit 4 through Visit 8"
1738244|NCT00086515|Drug|Sitagliptin (MK0431)|Sitagliptin 100 mg once daily, from Visit 4 through Final Visit, week 104
1738245|NCT00086515|Drug|Placebo/Glipizide 5 mg|Placebo (to match Sitagliptin 100 mg) from Visit 4 through Visit 8; Glipizide 5 mg from Visit 8, week 24 to Final Visit (Week 104)
1738246|NCT00086515|Drug|Metformin|Metformin 1500 mg, once daily, from Visit 2 to Final Visit (Week 104)
1738247|NCT00086515|Drug|Pioglitazone|Pioglitazone 15 mg once daily, for patients not meeting specific glycemic goals during the placebo-controlled treatment period [Phase A], from Visit 5 (Week 6) to Visit 8 (Week 24)
1738248|NCT00086528|Drug|XL647|Administered orally as a solution with mass-based dosing in early cohorts or as 50-mg tablets at a fixed dose at the MTD. A minimum of 3 subjects was planned for each dosing cohort with dose escalation dependent on subject tolerance of the prior dose. During the Treatment Period, subjects in each cohort were administered a single dose of XL647 on Day 1 followed by a 72-hour period of observation. If there were no XL647-related dose limiting toxicities, subjects received 5 daily doses of XL647 on Days 4-8. Twenty-one days after the initial dose, in the absence of unacceptable toxicity or disease progression, subjects could enter a Treatment Extension Period that consisted of repeated 2-week cycles of five oral doses of XL647 followed by a 9-day observation period.
1738249|NCT00086541|Drug|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
1738250|NCT00086580|Biological|FluCAM [Fludara + Campath]|"Phase A: Escalating Doses of alemtuzumab (Campath) Alone
Day 1: alemtuzumab 3 mg intravenously (IV) over 2 hours.
Day 2: alemtuzumab 10 mg IV over 2 hours if 3 mg was tolerated, else repeat 3 mg daily until tolerated.
Day 3: alemtuzumab 30 mg IV over 2 hours if 10 mg was tolerated, else repeat 10 mg daily until tolerated.
Participants were allowed 3-14 days to escalate to 30 mg. Once 30 mg was tolerated, the participant had to begin Phase B within 7 days.
Phase B: FluCAM
Cycle 1: Days 1,2,3 fludarabine phosphate administered at 30 mg/m^2 over 30 minutes IV, followed within 1 hour by alemtuzumab 30 mg IV over 2 hours. A similar schedule is set for Cycles 2 through 6; duration of alemtuzumab infusions vary from 2-6 hours. Each 28-day period is 1 cycle. Fludarabine phosphate dosage is based on participants' body surface area at the beginning of each cycle. FluCAM administered up to a maximum of 6 cycles, based upon participants' response to therapy and toxicity."
1738251|NCT00086580|Biological|fludarabine phosphate|Fludarabine phosphate (Fludara) is administered at a dose of 25 mg/m^2 IV over 15 to 30 minutes daily for 5 consecutive days (days 1 through 5) every 28 days (per package instructions). Each 28-day period is 1 cycle. The dose of fludarabine phosphate will be based on the participant's body surface area as calculated at the beginning of each cycle. Participants treated with fludarabine phosphate up to a maximum of 6 cycles, based upon their response to therapy and toxicity.
1738252|NCT00086593|Drug|lamotrigine|
1738253|NCT00086606|Drug|Xolair (omalizumab)|
1738254|NCT00086619|Drug|synthetic hPTH 1-34|Either daily treatment with self-injected hPTH 1-34 or ascending dose treatment at 6-month intervals of hPTH 1-34
1738255|NCT00086632|Drug|oregovomab|
1738256|NCT00086645|Drug|citalopram hydrobromide|10mg/5ml solution
1738257|NCT00086645|Other|placebo|up to equivalent of 20 mg of active comparator daily
1738258|NCT00086658|Drug|mepolizumab|
1738259|NCT00086671|Drug|ABT-874/Human monoclonal antibody against IL-12|
1738260|NCT00086671|Drug|Placebo|
1738261|NCT00086684|Drug|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule 3 times a day (morning, afternoon, and evening) for 24 weeks
1738262|NCT00086684|Drug|Placebo|One placebo capsule 3 times a day (morning, afternoon and evening) for 24 weeks
1738263|NCT00086684|Drug|Pentosan polysulfate sodium 100 mg|One 100 mg pentosan polysulfate sodium capsule in the morning, and 1 matching placebo capsule in the afternoon and evening for 24 weeks
1738264|NCT00086710|Drug|Fuzeon|
1738265|NCT00086723|Biological|recombinant tissue plasminogen activator|
1738266|NCT00086723|Drug|captopril|
1738267|NCT00086736|Drug|bicalutamide|
1738268|NCT00086736|Drug|eflornithine|
1738269|NCT00086736|Drug|oral eflornithine placebo|
1738270|NCT00086736|Drug|oral bicalutamide placebo|
1738271|NCT00086762|Behavioral|MR Therapy|Arm I: Participants receive Mindfulness Relaxation (MR) therapy as in the pilot phase. Instructions given on breathing techniques and other practices to help relax mind and body.
1738272|NCT00086762|Behavioral|Relaxing Music (RM) Therapy|Participants listen to relaxing music (with no instructions on relaxation techniques) for 30 minutes before and during each chemotherapy session AND at least once daily for the entire duration of chemotherapy treatment
1738273|NCT00086762|Behavioral|Standard Symptom Management|Participants receive standard symptom management education. General information received about how to manage symptoms that develop due to the chemotherapy.
1738274|NCT00086762|Behavioral|Questionnaires|Questionnaire completion at baseline, during the middle of chemotherapy treatment, and at chemotherapy completion.
1738275|NCT00086775|Biological|alemtuzumab|
1738276|NCT00086775|Biological|rituximab|
1738277|NCT00086775|Drug|fludarabine phosphate|
1738278|NCT00086801|Drug|doxorubicin hydrochloride|given IV
1738279|NCT00086801|Drug|gemcitabine hydrochloride|given IV
1738280|NCT00086801|Drug|vinblastine|given IV
1738281|NCT00086801|Procedure|fludeoxyglucose F 18 positron-emission tomography (PET) scan|
1738282|NCT00086801|Procedure|CT scan|
1738283|NCT00086827|Drug|romidepsin|Given IV
1738284|NCT00086827|Other|laboratory biomarker analysis|Correlative studies
1738285|NCT00086840|Drug|temsirolimus|Given IV
1738286|NCT00086840|Other|laboratory biomarker analysis|Correlative studies
1738287|NCT00086866|Biological|D1/3-MAGE-3-His fusion protein|
1738288|NCT00086866|Biological|SB-AS02B adjuvant|
1738289|NCT00086866|Biological|SB-AS15 adjuvant|
1738290|NCT00086879|Drug|carmustine|
1738291|NCT00086879|Drug|erlotinib hydrochloride|
1738292|NCT00086879|Drug|temozolomide|
1738293|NCT00086892|Biological|cetuximab|
1738294|NCT00086892|Drug|carboplatin|
1738295|NCT00086931|Drug|capecitabine|oral dose escalating, twice daily.
1738296|NCT00086931|Drug|oxaliplatin|IV over 2 hours on days 1, 8, 15, 22, and 29.
1738297|NCT00086931|Procedure|conventional surgery|curative-intent surgery 6-8 weeks after the completion of chemoradiotherapy
1738298|NCT00086931|Procedure|neoadjuvant therapy|chemotherapy and radiation prior to surgery
1738299|NCT00086931|Radiation|radiation therapy|once daily 5 days a week for 5.5 weeks
1738300|NCT00086944|Biological|oblimersen sodium|Given IV
1738301|NCT00086944|Biological|rituximab|Given IV
1738302|NCT00086944|Drug|ifosfamide|Given IV
1738303|NCT00086944|Drug|carboplatin|Given IV
1738304|NCT00086944|Drug|etoposide|Given IV
1738305|NCT00086944|Biological|filgrastim|Given SC
1738306|NCT00086944|Biological|pegfilgrastim|Given SC
1738307|NCT00086944|Other|laboratory biomarker analysis|Correlative studies
1738308|NCT00086957|Biological|trastuzumab|Cycle 1 loading dose of 8 mg/kg, followed by 6 mg/kg every 3 weeks for subsequent cycles.
1738309|NCT00086957|Drug|docetaxel|75 mg/m2 every three weeks, or 60 mg/m2 every three weeks depending on study findings
1738310|NCT00086957|Drug|gefitinib|250 mg daily or 250 mg daily on days 2 through 14 depending on study findings
1738311|NCT00086970|Drug|ifosfamide|Given IV
1738312|NCT00086970|Drug|O6-benzylguanine|Given IV
1738313|NCT00086983|Drug|becatecarin|Given IV
1738314|NCT00086983|Drug|oxaliplatin|Given IV
1738315|NCT00086983|Other|pharmacological study|Correlative studies
1738316|NCT00086996|Drug|fluorouracil|Before surgery: 180 mg/m2/day by 24-hour infusion days 8 through 43. After surgery:180 mg/m2/day by 24-hour infusion days 1 through 36.
1738317|NCT00086996|Drug|oxaliplatin|Before surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29. After surgery: 85 mg/m2 by 2-hour IV infusion days 1, 15, and 29.
1738318|NCT00086996|Procedure|conventional surgery|The surgical technique will depend upon the location and extent of tumor and individual surgeon preference.
1738319|NCT00086996|Radiation|radiation therapy|Starting Day 8, patients will be treated 5 days/week at 180 centigray (cGy)/day times 25 fractions to a total dose of 4,500 cGy.
1738320|NCT00087009|Biological|beta-glucan|Given orally
1738321|NCT00087009|Biological|rituximab|Given IV
1738322|NCT00087022|Biological|girentuximab|Given IV
1738323|NCT00087022|Other|placebo|Given IV
1738324|NCT00087035|Drug|docetaxel|Administered as an IV infusion of 60m/m2 over a 1-hour period, once every 21 ± 2 days
1738325|NCT00087035|Drug|erlotinib hydrochloride|Will be taken at a starting daily dose of 150mg
1738326|NCT00087048|Drug|topotecan hydrochloride|
1738327|NCT00087061|Drug|gimatecan|
1738328|NCT00087074|Drug|temsirolimus|Given IV
1738329|NCT00087074|Other|laboratory biomarker analysis|Optional correlative studies
1738330|NCT00087087|Drug|pemetrexed disodium|
1738331|NCT00087100|Drug|pemetrexed disodium|
1738332|NCT00087113|Drug|pemetrexed disodium|
1738333|NCT00087126|Drug|topotecan hydrochloride|
1738334|NCT00087139|Drug|ixabepilone|Given IV
1738335|NCT00087152|Drug|Capecitabine|1,000 mg/m^2 by mouth twice daily Days 1-14 of each 21 day cycle
1738336|NCT00087152|Drug|Imatinib mesylate|400 mg by mouth daily
1738340|NCT00087178|Drug|cyclophosphamide|Arm 1: cyclophosphamide 600 mg/m2 IV every 21 days for 4 cycles; Arm 2: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
1738342|NCT00087178|Drug|epirubicin|epirubicin 100 mg/m2 IV every 21 days for 6 cycles
1738343|NCT00087178|Drug|fluorouracil|fluorouracil 500 mg/m2 IV every 21 days for 6 cycles
1738344|NCT00087191|Drug|EF5|Given IV
1738345|NCT00087191|Drug|motexafin lutetium|Given IV
1738346|NCT00087191|Other|pharmacological study|Correlative studies
1738347|NCT00087204|Drug|becatecarin|Given IV
1738348|NCT00087204|Other|laboratory biomarker analysis|Correlative studies
1738349|NCT00087217|Drug|tanespimycin|Given IV
1738350|NCT00087217|Drug|paclitaxel|Given IV
1738351|NCT00087217|Other|laboratory biomarker analysis|Correlative studies
1738352|NCT00087217|Other|pharmacological study|Correlative studies
1738353|NCT00087256|Drug|Celecoxib|
1738354|NCT00087256|Other|placebo|
1738355|NCT00087269|Drug|erlotinib hydrochloride|Given orally
1738356|NCT00087269|Procedure|therapeutic endoscopic surgery|Undergo surgical resection
1738357|NCT00087269|Other|laboratory biomarker analysis|Correlative studies
1738358|NCT00087282|Drug|alvocidib|
1738359|NCT00087282|Drug|irinotecan hydrochloride|
1738360|NCT00087295|Drug|Depsipeptide|Depsipeptide wil be given 13 mg/m^2 through an intravenous (IV) over 4 hours on day 1, 8, and 15 for every 28 days (1 cycle = 28 days) until progression. Patients achieving a complete response (CR) will receive two additional cycles of treatment, and then be removed from protocol treatment.
1738361|NCT00087334|Drug|capecitabine|
1738362|NCT00087334|Drug|gefitinib|
1738363|NCT00087334|Drug|oxaliplatin|
1738364|NCT00087347|Drug|ferumoxytol|
1738365|NCT00087347|Procedure|magnetic resonance imaging|
1738366|NCT00087360|Other|counseling intervention|
1738367|NCT00087360|Other|physiologic testing|
1738368|NCT00087360|Procedure|evaluation of cancer risk factors|
1738369|NCT00087373|Biological|recombinant fowlpox-TRICOM vaccine|Given intratumorally
1738370|NCT00087373|Other|laboratory biomarker analysis|Correlative studies
1738371|NCT00087386|Drug|tanespimycin|Given IV
1738372|NCT00087386|Other|laboratory biomarker analysis|Correlative studies
1738373|NCT00087399|Drug|gabapentin|
1738374|NCT00087399|Drug|antidepressant|
1738375|NCT00087412|Drug|erlotinib hydrochloride|Given orally
1738376|NCT00087412|Other|laboratory biomarker analysis|Correlative studies
1738377|NCT00087425|Biological|rituximab|
1738378|NCT00087425|Drug|bryostatin 1|
1738379|NCT00087438|Radiation|stereotactic body radiation therapy|
1738380|NCT00087451|Drug|AP23573|ridaforolimus
1738381|NCT00087464|Drug|Emtricitabine|
1738382|NCT00087464|Drug|Nevirapine|
1738383|NCT00087464|Drug|Tenofovir disoproxil fumarate|
1738384|NCT00087477|Drug|Pivanex|
1738385|NCT00087490|Drug|linezolid|
1738386|NCT00087490|Drug|vancomycin|
1738387|NCT00087503|Drug|Edotecarin|
1738388|NCT00087516|Drug|Sitagliptin (MK0431)|Phase A: Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
1738389|NCT00087516|Drug|Sitagliptin|Phase A: Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
1738390|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 100 mg once a day for 24 weeks. Phase B: Sitagliptin 100 mg once a day for 80 weeks.
1738391|NCT00087516|Drug|Placebo|Phase A: Placebo matching Sitagliptin 200 mg once a day for 24 weeks. Phase B: Sitagliptin 200 mg once a day for 80 weeks.
1738392|NCT00087516|Drug|Metformin - Rescue|Phase A: Patients not meeting specific glycemic goals will receive open-label metformin as 500 mg, 850 mg, and 1000 mg oral tablets titrated at the discretion of the investigator. Phase B: These patients will not initiate Phase B double-blind medication.
1738393|NCT00087529|Drug|placebo|Intravenous repeating dose
1738394|NCT00087529|Drug|rituximab|Intravenous repeating dose
1738395|NCT00087542|Drug|ACP-103|
1738396|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 4.5 g per day in divided doses, 2.25 g at bedtime and another 2.5 g two and a half to four hours later for 8 weeks.
1738397|NCT00087555|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution 6.0 g per night in divided doses of 3 g at bedtime and 3 g at 2.5 to 4 hours later for 8 weeks.
1738398|NCT00087555|Drug|Placebo|Placebo one of two doses matching active treatment by volume for 8 weeks.
1738399|NCT00087568|Drug|Ribavirin|1000/1200mg po bid for 36 or 60 weeks
1738400|NCT00087568|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 36 weeks (non-responders) or 60 weeks (non-tolerators)
1738401|NCT00087581|Drug|Mycophenolate mofetil|Depending on body surface area and age, MMF may be given in capsule, tablet, oral suspension, or IV form. The initial dose will be at least 1 gram BID in adults and 600 mg/m^2 in pediatrics. In Groups A and B, subsequent doses will be adjusted to maintain blood MPA levels ≥1.3 μg/mL with cyclosporine or ≥1.9 μg/mL with tacrolimus. In Group C, subsequent doses are not to be adjusted, except in the case of unacceptable toxicity.
1738402|NCT00087581|Drug|Cyclosporine|Cyclosporine will be given as 100-mg soft gelatin capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Cyclosporine target concentrations are as follows: Days 1-30, 250-325 ng/mL; Days 30-90, 125-165 ng/mL (reduced) or 250-270 ng/mL (full); Days 90 through end of study, 95-145 ng/mL (reduced) or 190-220 ng/mL (full).
1738403|NCT00087581|Drug|Tacrolimus|Tacrolimus will be given as 1-mg and 5-mg capsules and dosed to maintain either reduced (Group A) or standard/full (Groups B and C) blood concentrations. Tacrolimus target concentrations are as follows: Days 1-30, 8-12 ng/mL; Days 30-90, 4-6 ng/mL (reduced), 8-10 ng/mL (full); Days 90 through end of study, 3-5 ng/mL (reduced), 6-8 ng/mL (full).
1738404|NCT00087594|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 24 weeks (G 2/3) or 48 weeks (G 1)
1738405|NCT00087594|Drug|ribavirin|1000/1200mg (< or >= 75 kg, respectively), po in two doses daily for 48 weeks (G 1) or 800 mg po in two doses daily for 24 weeks (G 2/3)
1738406|NCT00087607|Drug|Ribavirin|1000/1200mg/day po
1738407|NCT00087607|Drug|Peginterferon alfa-2b (PEG-Intron)|1.5 micrograms/kg sc weekly
1738408|NCT00087607|Drug|Ribavirin|1000/1200mg/day po
1738409|NCT00087607|Drug|Peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly
1738410|NCT00087620|Drug|XELODA [capecitabine]|
1738411|NCT00087633|Drug|peginterferon alfa-2a [Pegasys]|135 micrograms subcutaneously (SC) weekly for 4 weeks followed by 180 micrograms SC weekly for 44 weeks
1738412|NCT00087633|Drug|Copegus|400 mg orally (PO) daily escalating to 1200 mg PO daily, for 48 weeks
1738413|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 72 weeks
1738414|NCT00087646|Drug|Ribavirin|1000/1200mg po daily for 48 weeks
1738415|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 60 weeks
1738416|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly for 12 weeks, followed by 180 micrograms sc weekly for 36 weeks.
1738417|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 72 weeks
1738418|NCT00087646|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
1738419|NCT00087659|Drug|zoledronic acid|
1738420|NCT00087672|Drug|CC-5013|10 mg orally (2 capsules) daily
1738421|NCT00087685|Drug|RAD001|10 mg by mouth Daily
1738422|NCT00087698|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 4 cycles
1738423|NCT00087698|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 4 cycles
1738424|NCT00087711|Drug|pemetrexed|500 mg/m2, IV q 21 days x 6 cycles
1738425|NCT00087711|Drug|gemcitabine|1250 mg/m2, IV, day 1 and 8 q 21 days x 6 cycles
1738426|NCT00087711|Drug|cisplatin|75 mg/m2, IV, q 21 days x 6 cycles
1738427|NCT00087724|Drug|FK962|
1738428|NCT00087737|Drug|DVS-233 SR|
1738429|NCT00087737|Drug|Venlafaxine ER|
1738430|NCT00087750|Drug|Quetiapine|
1738431|NCT00087763|Drug|Macugen ™ (pegaptanib sodium injection)|
1738432|NCT00087776|Drug|Chemotherapy|
1738433|NCT00087789|Genetic|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 x 10^10 vg, CERE-110 1.0 x 10^11 vg, CERE-110 2.0 x 10^11 vg
1738434|NCT00087802|Drug|gemcitabine/Eloxatin (GEMOX)|GEMOX [gemcitabine/Eloxatin™ (Oxaliplatin) - 21 day cycle] Gemcitabine 1000 mg/m2 will be administered over 30 minutes on Days 1 and 8 and Eloxatin™ 130 mg/m2 will be administered over 2 hours on Day 1, after gemcitabine administration, every 21 days [3-week cycle]
1738435|NCT00087802|Drug|carboplatin/paclitaxel (CP)|"CP [carboplatin/paclitaxel - 21 day cycle]
o Paclitaxel 225 mg/m2 will be administered over 3 hours on Day 1 followed by carboplatin at a dose calculated to produce an area under the concentration-time curve (AUC) of 6.0 over 30-60 minutes on Day 1 every 21 days [3-week cycle]"
1738436|NCT00087815|Drug|dexamethasone|
1738437|NCT00087815|Drug|hyperbaric oxygen|
1738438|NCT00087815|Procedure|cognitive assessment|
1738439|NCT00087815|Procedure|magnetic resonance imaging|
1738440|NCT00087815|Procedure|positron emission tomography|
1738441|NCT00087815|Procedure|quality-of-life assessment|
1738442|NCT00087828|Drug|Cranberry juice cocktail|
1738443|NCT00087841|Behavioral|Self-hypnotic relaxation|
1738444|NCT00087854|Drug|Amonafide L-malate (drug)|
1738445|NCT00087867|Drug|SCIO-469|two 30-mg capsules three times daily
1738446|NCT00087867|Drug|SCIO-469 and bortezomib|In addition to SCIO-469, patients with disease progression will receive bortesomib 1.0 mg/m2 intravenously as a bolus injection on Days 1, 4, 8, and 11 of a 21-day cycle, followed by a 10-day rest period
1738447|NCT00087880|Drug|Bupropion and NRT|All participants receive standard 12 week treatment of NRT, bupropion and five group counseling sessions. At week 11, subjects are randomly assigned to one of five treatment groups (1) Bupropion/Low Contact; (2) Placebo/Low Contact; (3) Bupropion/Relapse Prevention; (4) Placebo/Relapse Prevention; (5) No Further Treatment. Data is collected at Week 0, and at weeks 12, 24, 52, 64, and 104.
1738448|NCT00087945|Drug|Abacavir sulfate|
1738449|NCT00087945|Drug|Abacavir sulfate, lamivudine, and zidovudine|
1738450|NCT00087958|Drug|XRP9881|
1738451|NCT00087984|Biological|MB-002|Dendritic Cell Immunotherapy
1738452|NCT00087997|Drug|STA-4783|
1738453|NCT00088010|Drug|Arzoxifene|20mg, oral, tablet, once a day for 36 months
1738454|NCT00088010|Drug|Placebo|oral, tablet, once a day for 36 months
1738455|NCT00088023|Drug|PT-523 for Injection|
1738456|NCT00088036|Drug|Olanzapine|
1738457|NCT00088049|Drug|Olanzapine|
1738458|NCT00088049|Drug|Aripiprazole|
1738459|NCT00088062|Drug|STA-5326|
1738460|NCT00088075|Drug|Risperidone|
1738461|NCT00088088|Drug|Paclitaxel|
1738462|NCT00088088|Drug|Carboplatin|
1738463|NCT00088088|Drug|STA 4783|
1738464|NCT00097045|Drug|omega interferon|
1738465|NCT00097045|Drug|Ribavirin|
1738466|NCT00097071|Drug|insulin lispro|
1738467|NCT00097071|Drug|insulin aspart|
1738468|NCT00097084|Drug|insulin detemir|
1738469|NCT00097084|Drug|insulin glargine|
1738470|NCT00097084|Drug|insulin aspart|
1738471|NCT00097097|Procedure|Neonatal Resuscitation|
1738472|NCT00097110|Drug|Vitamin C and E|
1738473|NCT00097123|Drug|Misoprostol|
1738474|NCT00097149|Procedure|Systematic pediatric care|
1738475|NCT00097162|Procedure|Anodal stimulation|
1738476|NCT00097188|Drug|rituximab|
1738477|NCT00097214|Drug|Carboplatin|AUC= 6 IV will be given on the first day of each 3-week cycle, beginning on Day 8.
1738478|NCT00097214|Biological|Cetuximab|400 mg/m2 IV on Day 1, followed by weekly doses of 250 mg/m2 IV beginning on Day 8.
1738479|NCT00097227|Biological|Cetuximab|"(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion.
A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B."
1738480|NCT00097227|Drug|Carboplatin|(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
1738481|NCT00097227|Drug|Paclitaxel|225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
1738668|NCT00098787|Drug|irinotecan hydrochloride|Given IV
1738482|NCT00097253|Behavioral|Exposure to relaxant and stimulant odors|A yellow-tinted cotton ball containing 100 ml of the essential oil or distilled water was taped between the nose and upper lip on top of a piece of surgical tape; use of the barrier tape avoided percutaneous absorption . This method provided continuous and uniform exposure across subjects that would not have been possible with ambient room inhalation, and helped maintain experimenter blindness.
1738483|NCT00097266|Drug|Placebo|Tablets/capsules, oral, 0 mg, once daily, 3 weeks (switched to arm B for an additional 9 weeks).
1738484|NCT00097266|Drug|Aripiprazole|Tablets, oral, 15-30 mg, once daily, 12 weeks.
1738485|NCT00097266|Drug|Haloperidol|Capsule, oral, 5-15 mg, once daily, 12 weeks.
1738486|NCT00097279|Drug|biphasic insulin aspart|
1738487|NCT00097279|Drug|pioglitazone|
1738488|NCT00097279|Drug|metformin|
1738489|NCT00097305|Behavioral|Body-Oriented Therapy|
1738490|NCT00097305|Behavioral|Standardized Massage Therapy|
1738491|NCT00097318|Drug|Interferon beta-1a|
1738493|NCT00097344|Drug|Atamestane|
1738494|NCT00097344|Drug|Toremifene|
1738495|NCT00097344|Drug|Letrozole|
1738496|NCT00097344|Drug|Aromatase inhibition|
1738497|NCT00097344|Drug|Estrogen receptor blocker|
1738498|NCT00097344|Procedure|Hormone therapy|
1738499|NCT00097344|Procedure|Endocrine therapy|
1738500|NCT00097344|Procedure|Antiestrogen therapy|
1738501|NCT00097357|Drug|Apixaban|Tablets, Oral, 12 +/- 2 days
1738502|NCT00097357|Drug|Enoxaparin|Injection, SQ, Q12H, 12 +/- 2 days
1738503|NCT00097357|Drug|Warfarin|Tablets, Oral, QD, 12 +/- 2 days
1738504|NCT00097357|Drug|Enoxaparin Placebo|Injection, SQ, BID, 12 +/- 2 days
1738505|NCT00097357|Drug|Apixaban Placebo|Tablets, Oral, BID, 12 +/- 2 days
1738506|NCT00097370|Drug|mepolizumab|Study Drug
1738507|NCT00097383|Drug|ALIMTA plus Epirubicin|
1738508|NCT00097396|Biological|rF1V vaccine|
1738509|NCT00097448|Drug|prednisone|Oral, 19 days
1738510|NCT00097448|Drug|methylprednisolone sodium succinate|Four intratympanic injections delivered to the middle ear over 2 weeks
1738511|NCT00097474|Drug|Hydrocortisone|Upon morning arrival at the new destination, volunteers take 20 mg hydrocortisone (or placebo) and at the target bedtime of (10 pm to midnight local time) they will take 5 mg of melatonin (or placebo) for four days.
1738512|NCT00097474|Other|Placebo|Upon morning arrival at the new destination, volunteers take 20 mg hydrocortisone (or placebo) and at the target bedtime of (10 pm to midnight local time) they will take 5 mg of melatonin (or placebo) for four days.
1738513|NCT00097474|Drug|Hydrocortisone and Melatonin|Upon morning arrival at the new destination, volunteers take 20 mg hydrocortisone (or placebo) and at the target bedtime of (10 pm to midnight local time) they will take 5 mg of melatonin (or placebo) for four days.
1738514|NCT00097474|Drug|Melatonin|
1738515|NCT00097500|Drug|exenatide|subcutaneous injection, titrated up to a maximum of 20mcg three times a day in order to meet defined blood glucose targets
1738516|NCT00097500|Drug|Insulin glargine|subcutaneous injection, once a day, titrated as necessary in order to meet defined blood glucose targets
1738517|NCT00097500|Drug|Metformin|Patients usual dosage
1738518|NCT00097539|Biological|Somatrem|
1738519|NCT00097539|Biological|Somatropin|
1738520|NCT00097591|Drug|Prasugrel|Administered orally
1738521|NCT00097591|Drug|Clopidogrel|Administered orally
1738522|NCT00097604|Dietary Supplement|Valerian root extract|Valerian root extract, 100 mg softgels, 3 softgels each night for 2 weeks, 30 minutes before bedtime
1738523|NCT00097630|Procedure|SAT: Spontaneous Awakening Trial|
1738524|NCT00097630|Procedure|SBT: Spontaneous Breathing Trial|
1738525|NCT00097643|Behavioral|exercise|
1738526|NCT00097643|Behavioral|health promotion|
1738527|NCT00097656|Other|multi-center, randomized, controled periodontal therapy|periodontal therapy
1738531|NCT00097695|Drug|Icatibant|30 mg (3mL) subcutaneous icatibant injection in the abdominal region
1738532|NCT00097695|Drug|Placebo|Solution for injection, matched to study drug Single dose: 3 mL
1738533|NCT00097708|Drug|experimental anti-anxiety drug|
1738534|NCT00097721|Drug|E7389|The first cohort of subjects were to receive E7389 1.4 mg/m^2 as an intravenous (IV) bolus on Days 1, 8, and 15 of a 28-day cycle. A second cohort of subjects was added and were to receive E7389 1.4 mg/m^2 as an IV bolus on Days 1 and 8 of a 21-day cycle.
1738535|NCT00097734|Drug|ertapenem|
1738536|NCT00097747|Drug|Placebo|
1738537|NCT00097747|Drug|peginesatide|
1738538|NCT00097760|Drug|Natalizumab|Natalizumab 300 mg, IV infusion, every 4 weeks in addition to 20 mg of glatiramer acetate SC, daily, for up to 20 weeks.
1738539|NCT00097760|Drug|Natalizumab|Natalizumab, 300 mg IV infusion, every 4 weeks for up to 20 weeks.
1738540|NCT00097760|Drug|Placebo|Placebo, by IV infusion, every 4 weeks in addition to 20 mg glatiramer acetate, by SC injection, daily, for up to 20 weeks.
1738541|NCT00097773|Drug|Tobramycin solution for inhalation (TOBI)|Tobramycin solution for inhalation, 300 mg, administered twice daily for 28 days administered only when quarterly respiratory cultures are found positive for Pa.
1738542|NCT00097773|Drug|Oral placebo|Oral placebo for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive placebo, twice daily.
1738543|NCT00097773|Drug|Oral ciprofloxacin|Oral ciprofloxacin for six consecutive quarterly cycles. For the initial 14 days of the 28-day treatment period, the participants will receive oral ciprofloxacin, 15-20 mg/kg/dose, twice daily.
1738595|NCT00098293|Drug|Maraviroc + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg once daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
1738596|NCT00098293|Drug|Efavirenz + Zidovudine/Lamivudine|efavirenz (600 mg once daily) added to zidovudine/lamivudine (300 mg/150 mg twice daily)
1738597|NCT00098293|Drug|Maraviroc (UK-427,857) + Zidovudine/Lamivudine|maraviroc (UK-427,857) 300 mg twice daily added to zidovudine/lamivudine (300 mg/150 mg twice daily)
1738544|NCT00097786|Drug|Valsartan 160 mg + nateglinide 60 mg|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
1738545|NCT00097786|Drug|Valsartan 160 mg + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
1738546|NCT00097786|Drug|Nateglinide 60 mg + valsartan placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
1738547|NCT00097786|Drug|Valsartan placebo + nateglinide placebo|The double-blinding of the randomized study medication was maintained by the use of identical placebo and active tablets and capsules for nateglinide and valsartan, respectively. Patients were instructed not to take the morning dose of either medication nor to eat breakfast on the day of a scheduled study visit, but to wait until after the visit was completed. Patients not tolerating the higher dose (Level 2) were down-titrated to receive Level 1. Patients not tolerating the lower dose (Level 1) had a treatment interruption. Starting at Week 2 and throughout the study, attempts were to be made to reach the highest dose level (Level 2), if medically acceptable. Following each change in dose level or re-initiation of treatment, tolerability was assessed after 2 weeks of exposure.
1738548|NCT00097799|Drug|Tipranavir|500 mg twice daily
1738549|NCT00097799|Drug|Ritonavir|200 mg twice daily
1738550|NCT00097812|Drug|zoledronic acid|
1738551|NCT00097825|Drug|Zoledronic Acid|
1738552|NCT00097838|Biological|AVX101|Alphavirus replicon particle vaccine expressing HIV Gag antigen
1738553|NCT00097838|Other|placebo|phosphate buffered saline, pH 7.2, HSA, sodium gluconate, and sucrose
1738554|NCT00097851|Drug|docetaxel|
1738555|NCT00097851|Drug|PI-88|
1738556|NCT00097877|Drug|biphasic insulin aspart|
1738557|NCT00097877|Drug|insulin glargine|
1738558|NCT00097890|Drug|Replagal (Agalsidase Alfa)|
1738559|NCT00097890|Drug|Replagal|
1738560|NCT00097903|Drug|Karenitecin (BNP1350)|Phase 1 study,dose-escalation design
1738561|NCT00097916|Drug|memantine HCl|
1738562|NCT00097929|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
1738563|NCT00097942|Drug|memantine HCl|
1738564|NCT00097955|Drug|aliskiren|
1738565|NCT00097968|Drug|everolimus|
1738566|NCT00097981|Drug|Thalidomide|Participants will receive thalidomide orally every night (at bedtime) without food on days 1-28 and dosing will gradually increase during Cycle 1 starting at 50 mg on 1 to 7 days, 100 mg on 8 to 14 days, 150 mg on 15 to 21 days, and 200 mg 22 to 28 days. Thalidomide 200 mg per day will be administered for subsequent cycles. Participants will receive thalidomide for minimum of 4 cycles and a maximum of 12 cycles.
1738567|NCT00097981|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally on Days 1 to 4, 9 to 12 and 17 to 20.
1738568|NCT00097981|Drug|DOXIL|DOXIL 40 mg/m2 will be administered iintravenously (into a vein) on Day 1.
1738569|NCT00098007|Drug|Everolimus (Certican)|
1738574|NCT00098033|Drug|clofarabine|
1738575|NCT00098046|Drug|famciclovir|
1738576|NCT00098059|Drug|Famciclovir|Famciclovir sprinkle capsules, 25 mg and 100 mg, using OraSweet® syrup vehicle
1738581|NCT00098085|Biological|HSPPC-96|
1738582|NCT00098098|Biological|rBV A/B|
1738583|NCT00098111|Drug|azathioprine|
1738584|NCT00098124|Drug|milnacipran hydrochloride|
1738586|NCT00098163|Biological|ALVAC-HIV vCP1521|One 1-ml dose of HIV-1 vaccine administered after birth on or before Day 3 and at weeks 4, 8, and 12.
1738587|NCT00098163|Biological|ALVAC HIV-1 vCP1521|One 1-ml dose of HIV-1 vaccine placebo administered after birth on or before Day 3 and at Weeks 4, 8, and 12.
1738588|NCT00098202|Drug|Low phytic acid maize|
1738589|NCT00098202|Drug|Zinc|
1738590|NCT00098215|Behavioral|Pediatric residency training on tobacco|
1738591|NCT00098228|Drug|QAB149|
1738592|NCT00098241|Drug|Certican|
1738593|NCT00098254|Drug|BAY 43-9006 (Sorafenib)|Self administered oral doses at 400 mg twice a day with 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly) continuously in a 28 day cycle. Tablets may be taken with or without food.
1738594|NCT00098280|Drug|Eculizumab|
1738598|NCT00098306|Drug|Maraviroc (UK-427,857)|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
1738599|NCT00098306|Drug|Optimized Background Therapy|Maraviroc was given either once or twice per day with the dose adjusted according to the optimized background therapy
1738600|NCT00098306|Drug|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
1738601|NCT00098306|Drug|Placebo|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
1738602|NCT00098306|Drug|Optimized Background Therapy|Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment.
1738603|NCT00098319|Drug|Folic acid (0.4mg vs. 4.0mg)|
1738604|NCT00098332|Drug|forodesine hydrochloride|
1738605|NCT00098345|Drug|ZD6474 (vandetanib)|oral once daily tablet
1738606|NCT00098358|Drug|Zileuton|
1738607|NCT00098371|Drug|alvocidib|
1738608|NCT00098384|Drug|rifaximin|
1738609|NCT00098397|Drug|romidepsin|Given IV
1738610|NCT00098397|Other|laboratory biomarker analysis|Optional correlative studies
1738611|NCT00098423|Drug|tanespimycin|Given IV
1738612|NCT00098423|Drug|cytarabine|Given IV
1738613|NCT00098436|Drug|laromustine|
1738614|NCT00098436|Drug|temozolomide|
1738615|NCT00098462|Drug|gefitinib|
1738616|NCT00098462|Drug|sirolimus|
1738621|NCT00098488|Drug|tanespimycin|Given IV
1738622|NCT00098488|Biological|rituximab|Given IV
1738623|NCT00098501|Drug|pelitinib|
1738624|NCT00098501|Drug|temsirolimus|Given PO
1738625|NCT00098514|Drug|talotrexin ammonium|
1738626|NCT00098527|Drug|romidepsin|Given IV
1738627|NCT00098527|Other|laboratory biomarker analysis|Correlative studies
1738628|NCT00098540|Drug|sorafenib tosylate|Given orally
1738629|NCT00098540|Other|laboratory biomarker analysis|Correlative studies
1738630|NCT00098553|Drug|everolimus|
1738631|NCT00098579|Drug|alvocidib|Given IV
1738632|NCT00098579|Drug|doxorubicin hydrochloride|Given IV
1738633|NCT00098605|Drug|lapatinib ditosylate|Given orally
1738634|NCT00098605|Other|laboratory biomarker analysis|Correlative studies
1738635|NCT00098605|Procedure|quality-of-life assessment|Ancillary studies
1738636|NCT00098605|Other|questionnaire administration|Ancillary studies
1738637|NCT00098618|Drug|sorafenib tosylate|Given orally
1738638|NCT00098618|Biological|recombinant interferon alfa|Given orally
1738639|NCT00098618|Other|laboratory biomarker analysis|Correlative studies
1738640|NCT00098631|Drug|lapatinib ditosylate|Given orally
1738641|NCT00098631|Other|laboratory biomarker analysis|Correlative studies
1738642|NCT00098670|Biological|alemtuzumab|Given SC
1738643|NCT00098670|Biological|rituximab|Given IV
1738644|NCT00098670|Drug|fludarabine phosphate|Given IV
1738645|NCT00098683|Drug|amifostine trihydrate|
1738646|NCT00098709|Device|Fetal pulse oximeter|
1738647|NCT00098722|Drug|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
1738648|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
1738649|NCT00098722|Drug|Maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
1738650|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
1738651|NCT00098722|Drug|optimized background therapy|[OBT (3-6 drugs based on treatment history and resistance testing)]
1738652|NCT00098735|Drug|FTY720|
1738653|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
1738654|NCT00098748|Drug|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken once daily
1738655|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
1738656|NCT00098748|Drug|maraviroc (UK-427,857)|maraviroc (UK-427,857) 150 mg taken twice daily
1738657|NCT00098748|Drug|Optimized Background Therapy (OBT)|OBT (3-6 drugs based on treatment history and resistance testing)
1738658|NCT00098761|Drug|laromustine|This is a dose escalation study. Participants receive 20, 30, 45, 60, 78, 103, 137, 182, or 242 mg/m2/day intravenously over 30 minutes for 5 consecutive days every 6 weeks up to 48 weeks.
1738659|NCT00098774|Biological|filgrastim|5 mcg/kg subQ injection daily Day 14 until ANC > or = 500 uL for 2 days or 1500 uL for 1 day (Cycle 6)
1738660|NCT00098774|Biological|rituximab|375 mg/sq m IV infusion (max rate of 400 mg/hr) on Days 3, 10, 17, & 24 of Cycle 1 nad Days 3 & 10 of Cycle 2
1738661|NCT00098774|Drug|cytarabine|2 g/sq m IV infusion over 2 hours q 12 hrs x 8 doses Days 1-4 of Cycle 6
1738662|NCT00098774|Drug|etoposide|5 mg/kg IV infusion over 12 hrs q 12 hrs x 8 doses Days 1-4 of Cycle 6
1738663|NCT00098774|Drug|leucovorin calcium|100 mg/sq m IV infusion q 6 hrs starting 24 hrs after ea MTX dose until serum MTX < or = 0.05uM Cycles 1-5.
1738664|NCT00098774|Drug|methotrexate|8 g/sq m IV infusion over 4 hrs Days 1 & 15 Cycles 1, 2, & 3; Day 15 Cycle 4 and Day 1 Cycle 5.
1738665|NCT00098774|Drug|temozolomide|150 mg/sq m PO Days 7-11 Cycles 1-5.
1738666|NCT00098787|Biological|bevacizumab|Given IV
1738667|NCT00098787|Drug|fluorouracil|Given IV
1738669|NCT00098787|Drug|leucovorin calcium|Given IV
1738670|NCT00098787|Drug|Oxaliplatin|Given IV
1738671|NCT00098800|Drug|fenretinide|
1738672|NCT00098813|Drug|romidepsin|Given IV
1738673|NCT00098813|Other|laboratory biomarker analysis|Correlative studies
1738674|NCT00098813|Procedure|positron emission tomography|Correlative studies
1738675|NCT00098826|Drug|ispinesib|Given IV
1738676|NCT00098826|Other|laboratory biomarker analysis|Correlative studies
1738677|NCT00098826|Other|pharmacological study|Correlative studies
1738678|NCT00098839|Drug|L-asparaginase|Given IM
1738679|NCT00098839|Drug|doxorubicin hydrochloride|Given IV
1738680|NCT00098839|Drug|therapeutic hydrocortisone|40 mg/m2/day PO divided BID or TID
1738681|NCT00098839|Drug|vincristine sulfate|Given IV
1738682|NCT00098839|Biological|epratuzumab|Given IV
1738683|NCT00098839|Drug|cytarabine|Given IT
1738684|NCT00098839|Drug|prednisone|Given orally
1738685|NCT00098839|Drug|pegaspargase|Given IM
1738686|NCT00098839|Drug|dexrazoxane hydrochloride|Given IV
1738687|NCT00098839|Drug|methotrexate|Given IT
1738688|NCT00098839|Drug|etoposide|Given IV
1738689|NCT00098839|Drug|cyclophosphamide|Given IV
1738690|NCT00098839|Drug|leucovorin calcium|Given IV
1738691|NCT00098839|Biological|filgrastim|Given SC
1738692|NCT00098852|Drug|rosiglitazone maleate|
1738693|NCT00098865|Drug|temozolomide|The lower 150/m2 Temozolomide dose was for patients who had previously received significant therapy to the bone marrow (chemotherapy or radiation) or cranial spinal raditation.
1738694|NCT00098865|Drug|thalidomide|Calculated dose was rounded down to the nearest 50mg, or up to 50mg if calculated dose was less than 50mg. Patients increased the daily dose by 50mg (one capsule) on a weekly basis unitl either unacceptable toxicity or a maximum dose.
1738695|NCT00098878|Drug|carboplatin|
1738696|NCT00098891|Drug|entinostat|Given orally
1738697|NCT00098891|Drug|isotretinoin|Given orally
1738698|NCT00098917|Drug|autologous tumor cell vaccine|
1738699|NCT00098917|Drug|therapeutic autologous dendritic cells|
1738700|NCT00098917|Procedure|adjuvant therapy|
1738701|NCT00098917|Procedure|biological therapy|
1738702|NCT00098917|Procedure|conventional surgery|
1738703|NCT00098917|Procedure|surgery|
1738704|NCT00098917|Procedure|tumor cell derivative vaccine|
1738705|NCT00098917|Procedure|vaccine therapy|
1738706|NCT00098943|Biological|CNGRC peptide-TNF alpha conjugate|
1738707|NCT00098956|Drug|topotecan hydrochloride|Given IV
1738708|NCT00098956|Drug|7-hydroxystaurosporine|Given IV
1738709|NCT00098969|Drug|resveratrol|
1738710|NCT00098982|Drug|bortezomib|
1738711|NCT00098982|Drug|fluorouracil|
1738712|NCT00098982|Drug|leucovorin calcium|
1738713|NCT00098982|Drug|oxaliplatin|
1738714|NCT00098995|Drug|cisplatin|
1738715|NCT00098995|Drug|tirapazamine|
1738716|NCT00098995|Radiation|brachytherapy|
1738717|NCT00098995|Radiation|radiation therapy|
1738718|NCT00099008|Dietary Supplement|Genistein|oral Genistein twice daily on days 1-84
1738719|NCT00099008|Dietary Supplement|Placebo|oral Placebo twice daily on days 1-84
1738720|NCT00099021|Drug|pioglitazone hydrochloride|Given PO
1738721|NCT00099047|Drug|celecoxib|Given PO
1738722|NCT00099047|Drug|placebo|Given PO
1738723|NCT00099047|Other|laboratory biomarker analysis|Correlative studies
1738724|NCT00099060|Drug|lapatinib ditosylate|"For patients receiving enzyme inducing anti-epileptic drugs (EIAEDs):
Phase I: starting dose for first cohort: 1000 mg GW572016 po b.i.d.; actual dose assigned at registration; intra patient dose escalation permitted ONCE in phase I patients ONLY if specified criteria met (see section 8.6).
Phase II: Recommended phase II dose from phase I portion of the study, given po b.i.d.
For patients NOT receiving enzyme inducing anti-epileptic drugs (NON-EIAEDs):
• Phase II: 750 mg GW572016 po b.i.d.
For all patients:
• Dose reductions as required based on adverse events."
1738725|NCT00099086|Drug|Bicalutamide|Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
1738726|NCT00099086|Drug|docetaxel|Docetaxel will be administered weekly during radiotherapy. The docetaxel dose will be escalated as part of the study. Dose levels are: 10mg/m2; 15 mg/m2; 20 mg/m2 and 25 mg/m2
1738727|NCT00099086|Drug|GnRh analog|"A GnRH analog (goserelin acetate, leuprolide acetate) will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)
Bicalutamide will be administered for approximately 28 months: prior to radiotherapy (2 months), during radiotherapy (2 months), and after radiotherapy (24 months)"
1738728|NCT00099086|Radiation|radiotherapy|External beam photon radiotherapy utilizing 3-D-conformal or intensity modulated radiotherapy (IMRT) shall be used to deliver 77.4 4 Gy in 43 fractions of 1.8 Gy fractions.
1738729|NCT00099099|Behavioral|Caloric Restriction (CR)|
1738730|NCT00099112|Genetic|microarray analysis|
1738731|NCT00099112|Procedure|biopsy|
1738732|NCT00099112|Procedure|evaluation of cancer risk factors|
1738733|NCT00099125|Drug|irinotecan hydrochloride|
1738734|NCT00099125|Drug|temozolomide|
1738735|NCT00099125|Procedure|adjuvant therapy|
1738736|NCT00099125|Radiation|radiation therapy|
1738737|NCT00099138|Behavioral|Caloric Restriction (CR)|
1738738|NCT00099138|Behavioral|Exercise|
1738739|NCT00099151|Behavioral|Caloric Restriction (CR)|
1738740|NCT00099151|Behavioral|Exercise|
1738741|NCT00099164|Drug|17 alpha-hydroxyprogesterone caproate (17P)|Study coded medication is 250 mg of 17P as a 1 ml intramuscular injection (or 1 ml of placebo inert oil). Patients are seen weekly to administer the study drug through 34 weeks 6 days gestation or delivery, whichever occurs first.
1738742|NCT00099177|Drug|ibandronate [Bondronat]|6mg iv on days 1-3, and 50mg po from day 22 to week 24
1738743|NCT00099177|Drug|zoledronic acid|4mg iv on day 1, and every 3-4 weeks
1738744|NCT00099190|Drug|ARQ 501|
1738745|NCT00099203|Drug|ibandronate [Bondronat]|6mg iv on days 1-3, and every 3-4 weeks
1738746|NCT00099203|Drug|zoledronic acid|4mg iv on day 1 and every 3-4 weeks
1738747|NCT00099216|Drug|Rivastigmine|
1738748|NCT00099229|Drug|Licarbazepine|
1738750|NCT00099255|Drug|SGN-30|
1738751|NCT00099268|Drug|Carbidopa/levodopa/entacapone|Carbidopa/Levodopa/Entacapone 12.5/50/200 mg and 25/100/200 mg capsules.
1738752|NCT00099268|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 12.5/50 mg and 25/100 mg capsules.
1738753|NCT00099281|Drug|YMB 1002|
1738754|NCT00099294|Drug|Glufosfamide|
1738755|NCT00099320|Drug|exenatide|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer 20 mcg of exenatide (2 units [5 μg] ), twice daily by subcutaneous injection, for the first 4 weeks of therapy, and then 40 μL of study drug (4 units [10 μg] of exenatide) twice daily by subcutaneous injection, for the remaining 12 weeks of therapy.
1738756|NCT00099320|Drug|Placebo|After a 2-week placebo lead-in period (twice daily, given subcutaneously) in addition to their current therapy regimen, subjects will administer placebo (in equivalent amounts to exenatide) for 16 weeks of therapy.
1738757|NCT00099333|Drug|exenatide|Exenatide 5 mcg subcutaneously injected twice daily for 4 weeks; then 10 mcg subcutaneously injected twice daily for 12 weeks.
1738758|NCT00099333|Drug|Insulin|Insulin will be taken according to the subject's current regimen
1738759|NCT00099346|Drug|MK0457, VX-680 (Aurora Kinase Inhibitor)|
1738760|NCT00099359|Drug|Zidovudine|Given for 6 weeks. 12mg PO BID if birthweight (BW) > 2000 grams 8 mg PO BID if BW < 2000 grams
1738761|NCT00099359|Drug|Nevirapine (NVP)|"Standard of Care (Zidovudine) plus
NVP, first dose initiated within 48 hrs of birth, second dose 48 hrs (+ 4 hours) after the first dose, and third dose 96 hours (+ 4 hours) after the second dose :
12 mg PO per dose if BW > 2000 grams, 8 mg PO per dose if BW < 2000 grams"
1738762|NCT00099359|Drug|Epivir (3TC)|"Stand of care (Zidovudine) plus
3TC, given for 2 weeks: 6 mg po bid if BW > 2000 grams 4 mg po bid if BW < 2000 grams AND
NFV, given for 2 weeks:
200 mg po bid if BW > 3000 grams 150 mg po bid if BW > 2,000 - 3000 grams 100 mg PO BID if BW < 2000 grams"
1738763|NCT00099359|Drug|Nelfinavir (NFV)|200 mg BID if birth weight (BW) > 3000 grams for 2 weeks;150 mg BID if BW > 2000-3000 grams for 2 weeks; 100 mg BID BW </= 2000 grams for 2 weeks
1738764|NCT00099385|Behavioral|Social Development Instruction|Weekly instruction during regular classroom time by classroom teacher using PATHS (Greenberg & Kusche) curriculum.
1738765|NCT00099424|Behavioral|High-intensity exercise training|
1738766|NCT00099437|Drug|Fulvestrant|intramuscular injection
1738767|NCT00099450|Drug|INS50589 Intravenous Infusion|
1738768|NCT00099463|Procedure|Blood Test|
1738769|NCT00099463|Procedure|Urine Test|
1738770|NCT00099463|Procedure|Physical Exam|
1738771|NCT00099463|Drug|Vaccine|
1738772|NCT00099463|Drug|VRC-SRSDNA015-00-VP|
1738773|NCT00099476|Behavioral|Effects of dark chocolate|
1738774|NCT00099489|Drug|Interferon Beta-1a|
1738775|NCT00099502|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250mcg administered s.c. every other day
1738776|NCT00099502|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|500mcg administered s.c. every other day
1738777|NCT00099502|Drug|Copaxone|20 mg administered s.c. once daily.
1738778|NCT00099515|Drug|LY041001 (HIIP)|Inhalation, capsule, TID 3 times per day min 6 IU max 60 IU
1738779|NCT00099515|Drug|LY041001 (HIIP)|Inhalation, Capsule, TID 3 times per day min 6 IU max 60 IU
1738780|NCT00099528|Drug|REN-1654|
1738781|NCT00099541|Drug|zoledronic acid|
1738782|NCT00099554|Drug|Etanercept|
1738783|NCT00099580|Drug|AC2592|continuous subcutaneous infusion (via pump), dose based on subject body weight
1738784|NCT00099580|Drug|placebo|continuous subcutaneous infusion (via pump), dose based on subject body weight
1738785|NCT00099593|Biological|Autologous Dendritic Cell Vaccine|
1738786|NCT00099606|Drug|Dasatinib|Tablets, Oral, Dose Finding Study - Range was 35 mg BID, 5 days on/2 days off - 120 mg BID Continuous Daily Dosing, Once daily, Patients remained on study until treatment discontinuation due to unacceptable toxicity, disease progression or death.
1738787|NCT00099619|Drug|exenatide/insulin glargine|Subcutaneously injected exenaide 10 mcg twice daily for 16 weeks; then insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels
1738788|NCT00099619|Drug|insulin glargine/exenatide|Subcutaneously injected insulin glargine subcutaneously injected once daily for 16 weeks given in a dose that varies for individuals to achieve target glucose levels; then exenaide 10 mcg twice daily for 16 weeks
1738789|NCT00099632|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate|200mg/300mg as one tablet taken orally once daily
1738790|NCT00099632|Drug|Lamivudine/Zidovudine|150mg/300mg as one tablet taken orally twice daily
1738791|NCT00099632|Drug|Lopinavir/Ritonavir|133.3mg/33.3mg as three capsules taken orally twice daily
1738792|NCT00099632|Drug|single dose Nevirapine|one 200 mg tablet taken orally
1738793|NCT00099645|Drug|Mifepristone|
1738794|NCT00099658|Biological|Pneumococcal polysaccharide-protein conjugate vaccine|Injection administered three times before the age of 24 weeks
1738795|NCT00099671|Drug|Recombinant human interleukin-7|
1738796|NCT00099684|Drug|Ezetimibe|
1738797|NCT00099697|Drug|DHEA|
1738798|NCT00099710|Dietary Supplement|Curcumin C3 Complex|
1738799|NCT00099723|Drug|VSL#3|
1738800|NCT00099736|Drug|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids|FTY720 5 mg + reduced-dose Neoral (RDN) + corticosteroids
1738801|NCT00099736|Drug|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids|FTY720 2.5 mg + full dose Neoral (FDN) + corticosteroids
1738802|NCT00099736|Drug|MMF 2 g + full-dose Neoral (FDN) + corticosteroids|mycophenolate mofetil (MMF) + full-dose Neoral (FDN) + corticosteroids
1738803|NCT00099749|Drug|FTY 720|
1738804|NCT00099775|Drug|Caspofungin|
1738805|NCT00099788|Drug|Ranolazine|IV to oral transition.
1738806|NCT00099788|Drug|Placebo|IV to oral transition.
1738808|NCT00099814|Procedure|Two different loop designs which deliver distinctive forces|
1738809|NCT00099827|Behavioral|Education|Individuals will receive information about depression
1738810|NCT00099840|Procedure|Procalcitonin guided antibiotic therapy|
1738811|NCT00099853|Drug|Vildagliptin|Vildagliptin 50 mg tablets
1738812|NCT00099853|Drug|pioglitazone|pioglitazone 45 mg qd
1738813|NCT00099853|Drug|Placebo|Vildagliptin matching placebo
1738814|NCT00099866|Drug|vildagliptin|
1738815|NCT00099866|Drug|Metformin Comparator|
1738816|NCT00099879|Drug|BMS-275183|
1738817|NCT00099892|Drug|vildagliptin|
1738818|NCT00099905|Drug|vildagliptin|
1738819|NCT00099918|Drug|vildagliptin|
1738820|NCT00099931|Drug|vildagliptin|
1738821|NCT00099944|Drug|vildagliptin|
1738822|NCT00099944|Drug|Glimepiride|Glimepiride 4 mg qd
1738823|NCT00099944|Drug|LAF237 placebo|
1738824|NCT00099957|Drug|vildagliptin|
1738825|NCT00099970|Drug|M200 (volociximab) in Combination with Dacarbazine (DTIC)|
1738826|NCT00099983|Drug|Risperidone|Initiate treatment with a low dose (1 mg/day HS) for week one, increasing by 1 mg/day weekly to a target dose of 3 mg/day. Escalation to a maximum of 4 mg/day will be allowed after a minimum of 4 weeks at the target dose (3 mg/day). Reduction to a lower dose will be allowed at any time, based on adverse effects. Treatment will continue for 6 months. Patients who discontinue treatment will be allowed to resume treatment at any time.
1738827|NCT00099983|Drug|Placebo|Placebo
1738828|NCT00099996|Drug|SCH-58235|
1738829|NCT00099996|Drug|Ezetimibe|
1738830|NCT00100009|Drug|TAC-PF|
1738831|NCT00100009|Drug|Triamcinolone Acetonide|
1738832|NCT00100035|Procedure|Polarity therapy|
1738833|NCT00100048|Drug|Comparator: MK0518 monotherapy|MK0518 twice daily for 10 days
1738834|NCT00100048|Drug|Comparator: MK0518 combination therapy|MK0518 twice daily for 48 weeks
1738835|NCT00100048|Drug|Comparator: efavirenz|efavirenz 600 mg every night at bedtime for 48 weeks
1738836|NCT00100048|Drug|Comparator: tenofovir|tenofovir 300 mg daily for 48 weeks
1738837|NCT00100048|Drug|Comparator: lamivudine|lamivudine 300 mg daily for 48 weeks
1738838|NCT00100048|Drug|Placebo monotherapy|Placebo to MK0518 twice daily
1738839|NCT00100061|Drug|Cranberry juice|liquid juice taken daily
1738840|NCT00100061|Dietary Supplement|Cranberry Juice|Taken orally
1738841|NCT00100061|Dietary Supplement|Placebo cranberry juice|Placebo comparitor
1738842|NCT00100074|Drug|Lobeline|
1738843|NCT00100087|Device|Ocular Brachytherapy|
1738844|NCT00084539|Radiation|Radiation therapy|
1738845|NCT00084552|Radiation|radiation therapy|Patients undergo conventional intensity-modulated radiotherapy (IMRT) once daily 5 days a week for approximately 7.5 weeks.
1738846|NCT00084565|Drug|estramustine phosphate sodium|
1738847|NCT00084565|Drug|paclitaxel|
1738848|NCT00084565|Drug|topotecan hydrochloride|
1738849|NCT00084578|Drug|celecoxib|
1738850|NCT00084578|Drug|rosiglitazone maleate|
1738851|NCT00084578|Procedure|conventional surgery|
1738852|NCT00084578|Procedure|neoadjuvant therapy|
1738853|NCT00084591|Drug|capecitabine|
1738854|NCT00084591|Procedure|conventional surgery|
1738855|NCT00084591|Procedure|neoadjuvant therapy|
1738856|NCT00084591|Radiation|radiation therapy|
1738857|NCT00084604|Drug|irinotecan hydrochloride|Given IV
1738858|NCT00084604|Biological|bevacizumab|Given IV
1738859|NCT00084604|Drug|cisplatin|Given IV
1738860|NCT00084604|Procedure|computed tomography|Correlative studies
1738861|NCT00084604|Other|laboratory biomarker analysis|Correlative studies
1738862|NCT00084617|Drug|oxaliplatin|Given IV
1738863|NCT00084617|Drug|irinotecan hydrochloride|Given IV
1738864|NCT00084617|Drug|capecitabine|Given orally
1738865|NCT00084630|Drug|imatinib mesylate|Given orally
1738866|NCT00084630|Other|laboratory biomarker analysis|Correlative studies
1738867|NCT00084643|Biological|GTI-2040|Given IV
1738868|NCT00084643|Drug|oxaliplatin|Given IV
1738869|NCT00084643|Drug|capecitabine|Given orally
1738870|NCT00084643|Other|pharmacological study|Correlative studies
1738871|NCT00084643|Other|laboratory biomarker analysis|Correlative studies
1738872|NCT00084656|Biological|ipilimumab|IV over 90 mins on day 1, wks 1,9,17,25,33,41,53 Dose: 3 mg/kg (Part I), 10 mg/kg (Part II)
1738873|NCT00084656|Biological|Tyrosinase/gp100/MART-1 Peptides|(All subjects in Part I and HLA-A*0201 positive subjects only in Part II): SC, day 1 of wks 1,3,5,7,9,11,17, 21,25,33,41,53 Dose: 1 mg peptide emulsified in 1 mL Montanide ISA 51 VG.)
1738874|NCT00084669|Drug|venlafaxine|
1738875|NCT00084669|Drug|zolpidem tartrate|
1738876|NCT00084669|Procedure|management of therapy complications|
1738877|NCT00084682|Drug|romidepsin|Given IV
1738878|NCT00084695|Biological|anti-thymocyte globulin|Given IV
1738879|NCT00084695|Drug|busulfan|Given orally
1738880|NCT00084695|Drug|cyclophosphamide|Given IV
1738881|NCT00084695|Drug|fludarabine phosphate|Given IV
1738882|NCT00084695|Drug|melphalan|Given IV
1738883|NCT00084695|Drug|methylprednisolone|Given IV
1738884|NCT00084695|Radiation|radiation therapy|Patients undergo radiation therapy two times daily on days -7 to -4.
1738885|NCT00084708|Dietary Supplement|calcitriol|
1738886|NCT00084708|Drug|dexamethasone|
1738887|NCT00084708|Drug|gefitinib|
1738888|NCT00084721|Drug|celecoxib|
1738889|NCT00084721|Drug|irinotecan hydrochloride|
1738890|NCT00084734|Drug|capecitabine|Oral
1738891|NCT00084734|Drug|cisplatin|IV
1738892|NCT00084734|Drug|docetaxel|IV
1738893|NCT00084747|Drug|bortezomib|
1738894|NCT00084773|Biological|cetuximab|
1738895|NCT00084773|Drug|fluorouracil|
1738896|NCT00084773|Procedure|neoadjuvant therapy|
1738897|NCT00084773|Radiation|radiation therapy|
1738900|NCT00084799|Biological|monoclonal antibody Hu3S193|
1738901|NCT00084812|Drug|cisplatin|
1738902|NCT00084812|Drug|safingol|
1738903|NCT00084825|Drug|Docetaxel|30 mg/m^2 IV on days 1, 8, 15, and 22 every 42 days
1738904|NCT00084825|Drug|Imatinib mesylate|600 mg orally daily
1738905|NCT00084838|Biological|filgrastim|
1738906|NCT00084838|Drug|cisplatin|
1738907|NCT00084838|Drug|cyclophosphamide|
1738908|NCT00084838|Drug|cytarabine|
1738909|NCT00084838|Drug|dexrazoxane hydrochloride|
1738910|NCT00084838|Drug|doxorubicin hydrochloride|
1738911|NCT00084838|Drug|etoposide|
1738912|NCT00084838|Drug|leucovorin calcium|
1738913|NCT00084838|Drug|methotrexate|
1738914|NCT00084838|Drug|temozolomide|
1738915|NCT00084838|Drug|therapeutic hydrocortisone|
1738916|NCT00084838|Drug|vincristine sulfate|
1738917|NCT00084838|Radiation|radiation therapy|
1738918|NCT00084838|Drug|Dactinomycin|
1738919|NCT00084864|Dietary Supplement|calcitriol|Given orally
1738920|NCT00084864|Drug|dexamethasone|Given orally
1738921|NCT00084864|Other|clinical observation|No intervention before surgery
1738922|NCT00084877|Drug|triapine|Given IV
1738923|NCT00084877|Drug|irinotecan hydrochloride|Given IV
1738924|NCT00084877|Other|laboratory biomarker analysis|Correlative studies
1738925|NCT00084877|Other|pharmacological study|Correlative studies
1738926|NCT00084890|Drug|carboplatin|30 minute infusion dosed based on glomerular filtration rate of patient
1738927|NCT00084890|Drug|docetaxel|escalating doses ofstarting at 25 milligrams per meter squared
1738928|NCT00084903|Procedure|Colposcopic biopsy|Two small samples of cervical tissue (biopsy) removed from 2 sites as spectroscopy readings.
1738929|NCT00084903|Procedure|Light-Scattering Spectroscopy|Spectroscopy readings taken in 2 regions of cervix.
1738930|NCT00084916|Drug|temsirolimus|Given IV
1738931|NCT00084916|Other|laboratory biomarker analysis|Correlative studies
1738932|NCT00084929|Procedure|CT Colonography|CT colonography performed for comparison with colonoscopy results performed during the same screening assessment.
1738933|NCT00084942|Drug|capecitabine|
1738934|NCT00084942|Drug|gemcitabine hydrochloride|
1738935|NCT00084981|Drug|decitabine|Given IV
1738936|NCT00084981|Drug|valproic acid|Given PO
1738937|NCT00084981|Other|pharmacological study|Correlative studies
1738938|NCT00084981|Other|laboratory biomarker analysis|Correlative studies
1738939|NCT00085020|Biological|trastuzumab|
1738940|NCT00085020|Drug|lapatinib ditosylate|
1738941|NCT00085059|Drug|boronophenylalanine-fructose complex|
1738942|NCT00085098|Biological|filgrastim|Given by infusion or injection
1738943|NCT00085098|Drug|carboplatin|Given IV over 1 hour
1738944|NCT00085098|Drug|cisplatin|Given IV over 6 hours
1738945|NCT00085098|Drug|cyclophosphamide|Given IV over 1 hour
1738946|NCT00085098|Drug|etoposide|Given IV over 2 hours
1738947|NCT00085098|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week
1738948|NCT00085111|Biological|bevacizumab|Given IV
1738949|NCT00085124|Biological|oblimersen sodium|Given IV
1738950|NCT00085124|Drug|cytarabine|Given IV
1738951|NCT00085124|Drug|daunorubicin hydrochloride|Given IV
1738952|NCT00085124|Other|laboratory biomarker analysis|Correlative studies
1738953|NCT00085150|Biological|LMB-2 immunotoxin|
1738954|NCT00085163|Drug|celecoxib|
1738955|NCT00085163|Drug|fluorouracil|
1738956|NCT00085163|Drug|leucovorin calcium|
1738957|NCT00085163|Procedure|adjuvant therapy|
1738958|NCT00085176|Procedure|management of therapy complications|
1738959|NCT00085176|Procedure|psychosocial assessment and care|
1738960|NCT00085189|Biological|gp100 antigen|Given SC
1738961|NCT00085189|Biological|tyrosinase peptide|Given SC
1738962|NCT00085189|Biological|recombinant MAGE-3.1 antigen|Given SC
1738963|NCT00085189|Biological|multi-epitope melanoma peptide vaccine|Given SC
1738964|NCT00085189|Biological|incomplete Freund's adjuvant|Given SC
1738965|NCT00085189|Drug|Montanide ISA 51 VG|Given SC
1738966|NCT00085189|Drug|agatolimod sodium|Given SC
1738967|NCT00085189|Other|laboratory biomarker analysis|Correlative studies
1738968|NCT00085202|Biological|filgrastim|Given subcutaneously
1738969|NCT00085202|Drug|cisplatin|Given IV
1738970|NCT00085202|Drug|cyclophosphamide|Given IV
1738971|NCT00085202|Drug|vincristine|Given IV
1738972|NCT00085202|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
1738973|NCT00085202|Radiation|radiation therapy|Patients undergo craniospinal radiotherapy once daily 5 days a week for 6 weeks.
1738974|NCT00085228|Biological|oblimersen sodium|
1738975|NCT00085228|Drug|docetaxel|
1738976|NCT00085254|Drug|cilengitide|Given IV
1738977|NCT00085254|Drug|temozolomide|Given orally
1738978|NCT00085254|Radiation|radiation therapy|Undergo radiotherapy
1738979|NCT00085254|Other|laboratory biomarker analysis|Correlative studies
1738980|NCT00085254|Other|pharmacological study|Correlative studies
1738981|NCT00085280|Drug|erlotinib hydrochloride|Given orally
1738982|NCT00085280|Other|laboratory biomarker analysis|Correlative studies
1738983|NCT00085293|Drug|Decitabine|Starting dose 6 mg/m^2 intravenously over 1 hour every day for 5 successive days for 2 weeks (10 doses), with possible second course.
1738984|NCT00085293|Radiation|Iodine I 131|Undergo thyrotropin-alfa stimulated radioactive iodine scan
1738985|NCT00085293|Biological|Recombinant thyrotropin alfa|Undergo thyrotropin-alfa stimulated radioactive iodine scan
1738986|NCT00085293|Radiation|Fludeoxyglucose F 18|Optional correlative studies
1738987|NCT00085293|Procedure|Positron emission tomography|Optional correlative studies
1738988|NCT00085306|Biological|recombinant interferon beta|recombinant interferon beta
1738993|NCT00085345|Procedure|chemosensitization/potentiation|
1738994|NCT00085345|Procedure|chemotherapy|
1738995|NCT00085358|Drug|carboplatin|Given intraperitoneally
1738996|NCT00085358|Drug|paclitaxel|Given IV or intraperitoneally
1738997|NCT00085358|Drug|docetaxel|Given IV
1738998|NCT00085358|Biological|bevacizumab|Given IV
1738999|NCT00085371|Drug|triapine|Given IV
1739000|NCT00085384|Biological|PEG-interferon alfa-2b|Starting dose 1.0 mg/kg/week given subcutaneously
1739001|NCT00085384|Drug|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b
Dose 1.25 mg/kg/week given subcutaneously"
1739002|NCT00085384|Biological|PEG-interferon alfa-2b|"Biological/Vaccine: PEG-interferon alfa-2b
Dose 1.5 mg/kg/week given subcutaneously
EG-Intron"
1739003|NCT00085397|Biological|autologous dendritic cell-tumor fusion vaccine|Given subcutaneously
1739004|NCT00085397|Biological|gp100 antigen|Given IV
1739005|NCT00085397|Biological|therapeutic autologous dendritic cells|Given IV
1739006|NCT00085410|Drug|bortezomib|Given IV
1739007|NCT00091247|Drug|tetracycline hydrochloride|
1739008|NCT00091247|Other|placebo|
1739009|NCT00091260|Drug|dexamethasone|dexamethasone 20 mg daily (10 mg BID) on Days 1-4, 9-12, and 17-20 of every other 28-day cycle.
1739010|NCT00091260|Drug|lenalidomide|15 mg/day, for 21 days with 7 days rest (28 day cycle) with or without dexamethasone
1739011|NCT00091273|Biological|incomplete Freund's adjuvant|
1739012|NCT00091273|Biological|ovarian cancer peptide vaccine|
1739013|NCT00091273|Biological|sargramostim|
1739014|NCT00091273|Biological|tetanus toxoid helper peptide|
1739015|NCT00091273|Procedure|adjuvant therapy|
1739016|NCT00091286|Biological|HER-2-neu, CEA peptides, GM-CSF, Montanide ISA-51 vaccine|
1739017|NCT00091299|Drug|warfarin|
1739018|NCT00091312|Drug|FOLFIRI regimen|
1739019|NCT00091312|Drug|fluorouracil|
1739020|NCT00091312|Drug|irinotecan hydrochloride|
1739021|NCT00091312|Drug|leucovorin calcium|
1739022|NCT00091312|Procedure|adjuvant therapy|
1739023|NCT00091325|Dietary Supplement|defined green tea catechin extract|
1739024|NCT00091338|Biological|MART-1 antigen|
1739025|NCT00091338|Biological|gp100 antigen|
1739026|NCT00091338|Biological|incomplete Freund's adjuvant|
1739027|NCT00091338|Biological|recombinant interleukin-7|
1739028|NCT00091351|Procedure|conventional surgery|
1739029|NCT00091351|Radiation|radiation therapy|
1739030|NCT00091377|Drug|cisplatin|IV 40 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
1739031|NCT00091377|Drug|paclitaxel|IV 80 mg/m2 on Day 2 Number of Cycles: until progression or unacceptable toxicity or other withdrawal criteria are met.
1739032|NCT00091377|Drug|phenoxodiol|IV 3 mg/kg
1739033|NCT00091390|Radiation|HDR brachytherapy boost|Brachytherapy could be performed before or after the external beam radiotherapy. The overall treatment course (external beam radiotherapy and brachytherapy) was limited to no longer than 8 weeks. 19 Gy in two fractions was to be given only to the clinical target volume (CTV). The first HDR treatment was to be delivered on the day of the catheter placement. The second treatment was to be delivered within 24 hours after the first treatment, but no less than 6 hours between implants.
1739034|NCT00091390|Radiation|radiation therapy|1.8 Gy given five times per week for a total dose of 45 Gy.
1739035|NCT00091416|Biological|VRC-HIVADV014-00-VP|
1739036|NCT00091429|Drug|Ranolazine|
1739037|NCT00091442|Drug|Docetaxel|Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
1739038|NCT00091442|Drug|DOXIL|DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
1739039|NCT00091468|Drug|Transdermal nicotine patch|double-blind phase: 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks open label phase: 5mg for 1 week, 10mg. for 2 weeks, 15mg. for 23 weeks taper down: 10mg. for 2 weeks, 5mg. for 1 week
1739040|NCT00091468|Drug|Placebo transdermal patch|placebo patch, 5mg for 1 week, 10mg for 2 weeks, 15mg for 23 weeks
1739041|NCT00091481|Drug|Zemplar|
1739042|NCT00091507|Drug|GIK|Intravenous solution, 1.5ml/kg/hour, continuous infusion for total of 12 hours.
1739043|NCT00091507|Drug|Placebo|Intravenous solution of Dextrose 5 percent at 1.5 ml/kg/hour for a total of 12 hours.
1739044|NCT00091520|Drug|Nesiritide|
1739045|NCT00091845|Drug|AVI-4020 Injection|
1739046|NCT00091858|Drug|Darbepoetin Alfa|6.75 mcg/kg Q4W
1739047|NCT00091858|Drug|Placebo|Placebo Q4W
1739048|NCT00091897|Drug|Rituximab|
1739049|NCT00091897|Drug|rituximab or placebo|A fixed dose of Rituximab or placebo 1GM on Day 1 and 1GM on day 15 (+/- 2 days)
1739050|NCT00091910|Drug|Epoetin alfa|
1739051|NCT00091923|Device|Eye patch|
1739052|NCT00091923|Device|Spectacles|
1739053|NCT00091936|Drug|Didanosine|
1739054|NCT00091936|Drug|Efavirenz|
1739055|NCT00091936|Drug|Lamivudine|
1739056|NCT00091936|Drug|Standard TB treatment|
1739057|NCT00091949|Drug|pioglitazone|a thiazolidinedione drug
1739058|NCT00091949|Drug|placebo|an inactive substance
1739059|NCT00091962|Behavioral|Psychoeducation; Treatment recommendations|Counseling program
1739060|NCT00091962|Drug|Pharmacotherapy|Recommendations to patients' PCP for medication to treat depression
1739061|NCT00091962|Other|Usual Care|Physicians' Usual care
1739062|NCT00091975|Drug|Zemplar Capsule|
1739063|NCT00091988|Behavioral|Lifestyle & Behavioral Change Program|Participants in the weight loss arm will receive an intensive group-based behavioral weight loss program. In the first six months of the intervention, all participants in the weight loss arm will be given skill-based diet and exercise prescriptions for weight loss and will be taught specific cognitive and behavioral skills to assist in the modification of their eating and exercise habits. Participants will meet weekly for 6 months in group sessions led by a nutritionist, exercise physiologist, or behaviorist and will follow a structured protocol. This intervention strategy is modeled on interventions that have been successful in other overweight populations and is similar to the programs implemented in our ongoing studies, such as Look AHEAD. With this intervention, women are expected to lose on average of 7-9% of their initial body weight.
1739064|NCT00091988|Behavioral|Structured Education Program|Women randomized to the Structured Education Program will be invited to participate in hour long group educational sessions at months 1, 2, 3, and 4. At months 6, 9 and 15, the groups will meet again for group support sessions. The content of these education and support sessions will include information about weight loss, physical activity, healthy eating habits and general health promotion. The educational sessions will be delivered primarily in a group format, with individual make up sessions provided for participants who miss group sessions.
1739065|NCT00092001|Drug|Sunitinib|Sunitinib 50 mg by oral capsule daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
1739066|NCT00092014|Drug|Alendronate|Alendronate sodium, 70 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
1739067|NCT00092014|Drug|Risedronate 35 mg|Risendronate, 35 mg, once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
1739068|NCT00092014|Dietary Supplement|Elemental Calcium|Elemental calcium at least 1,000 mg daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
1739069|NCT00092014|Dietary Supplement|Vitamin D|Vitamin D at least 400 international units daily (diet plus supplements). Medications were taken fasting which was maintained for 30 minutes postdose.
1739070|NCT00092014|Drug|Risendronate placebo|Risendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
1739071|NCT00092014|Drug|Alendronate placebo|Alendronate placebo was taken once weekly for up to 24 months. Medications were taken fasting which was maintained for 30 minutes postdose.
1739072|NCT00092027|Drug|MK0217, alendronate sodium/Duration of Treatment: 6 months|
1739073|NCT00092027|Drug|Comparator: placebo / Duration of Treatment: 6 months|
1739074|NCT00092040|Drug|MK0217, alendronate sodium/Duration of Intervention: 12 mo|
1739075|NCT00092040|Drug|Comparator: risedronate / Duration of Intervention: 12 mo|
1739076|NCT00092053|Drug|Placebo|tablets
1739077|NCT00092053|Drug|ibandronate|50 mg tablets
1739078|NCT00092066|Drug|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 15 weeks|
1739079|NCT00092079|Drug|MK0217A, alendronate sodium (+) cholecalciferol / Duration of Treatment: 24 weeks|
1739080|NCT00092092|Drug|Montelukast chewable tablets|Montelukast sodium 5 mg chewable tablets
1739081|NCT00092092|Drug|Budesonide inhaler|Budesonide 200 mcg inhalation powder
1739082|NCT00092092|Drug|Placebo to montelukast chewable tablets|Placebo chewable tablets
1739083|NCT00092092|Drug|Placebo to budesonide inhaler|Placebo inhalation powder
1739084|NCT00092105|Drug|MK0476, montelukast sodium|
1739085|NCT00092105|Drug|Comparator: placebo|
1739086|NCT00092118|Drug|Montelukast|one 10 mg tablet, taken once daily at bed time for 6 weeks
1739087|NCT00092118|Drug|Comparator: Placebo|one placebo tablet, taken once daily at bed time for 6 weeks
1739088|NCT00092131|Drug|Comparator: Montelukast|Montelukast 10 mg tablet administered orally as a single witnessed dose before exercise challenge
1739089|NCT00092131|Drug|Comparator: Placebo|Placebo tablet administered orally as a single witnessed dose before exercise challenge
1739090|NCT00092144|Drug|MK0476, montelukast sodium / Duration of Treatment: 4 weeks|
1739091|NCT00092144|Drug|Comparator: placebo / Duration of Treatment: 4 weeks|
1739092|NCT00092157|Drug|MK0733, simvastatin|
1739093|NCT00092157|Drug|Comparator: simvastatin|
1739094|NCT00092170|Drug|MK0826, ertapenem sodium|
1739095|NCT00092170|Drug|Comparator: Ticarcillin/Clavulanate|
1739096|NCT00092183|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
1739097|NCT00092183|Drug|Comparator: ondansetron / Duration of Treatment: 3 days|
1739098|NCT00092196|Drug|MK0869, aprepitant / Duration of Treatment: 3 days|
1739099|NCT00092209|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium|
1739100|NCT00092209|Drug|Comparator: placebo, losartan, hydrochlorothiazide|
1956491|NCT02831764|Drug|Dolutegravir (DTG)|DTG is available as 50 mg white, round, biconvex, film coated tablet debossed on one side with 'SV 572' and on the other side with '50'. The tablets are packaged into high density polyethylene (HDPE) bottles with induction seals and child resistant closures. Each 45 ml bottle contains 30 tablets and a desiccant. DTG 50 mg tablet will be orally administered once daily with or without food upto 148 weeks.
1956492|NCT02831764|Drug|Lamivudine (3TC)|Lamivudine is available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg lamivudine to visually match overencapsulated TDF/FTC FDC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated 3TC 300 mg tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, lamivudine will be dispensed as 300 mg white, diamond shaped, scored, film coated tablets debossed with 'GX CJ7' on both sides, packed in over labelled HDPE bottles with child-resistant closures each containing 30 tablets.
1739114|NCT00092274|Drug|HuMax-CD20|
1739115|NCT00092287|Drug|lanreotide Autogel (somatostatin analogue)|
1739116|NCT00092287|Drug|Sandostatin long acting release (LAR) Depot (somatostatin analogue)|
1739117|NCT00092300|Drug|MK0966, rofecoxib|
1739118|NCT00092300|Drug|Comparator: valdecoxib|
1739119|NCT00092313|Drug|MK0966, rofecoxib|
1739120|NCT00092313|Drug|Comparator: oxycodone and acetaminophen|
1739121|NCT00092326|Drug|MK0966, rofecoxib|
1739122|NCT00092326|Drug|Comparator: oxycodone with acetaminophen, placebo|
1739123|NCT00092339|Drug|MK0966, rofecoxib|
1739124|NCT00092339|Drug|Comparator: valdecoxib, placebo|
1739125|NCT00092352|Drug|MK0966, rofecoxib|
1739126|NCT00092352|Drug|Comparator: celecoxib, placebo|
1739127|NCT00092365|Drug|MK0966, rofecoxib|
1739128|NCT00092365|Drug|Comparator: celecoxib, placebo|
1739129|NCT00092378|Drug|MK0966, rofecoxib|
1739130|NCT00092378|Drug|Comparator: diclofenac sodium, placebo|
1739131|NCT00092391|Biological|Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live|0.5 mL subcutaneous injection of one of three sub-lots on Day 0
1739132|NCT00092391|Biological|Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)|0.5 mL subcutaneous injection on Day 0
1739133|NCT00092404|Biological|measles, mumps, and rubella virus vaccine live|
1739134|NCT00092404|Biological|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
1739135|NCT00092417|Biological|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of higher potency zoster vaccine (~207,000 plaque-forming units [PFU]/0.65-mL dose)
1739136|NCT00092417|Biological|Comparator: Varicella Zoster Virus Vaccine|Single 0.65 mL subcutaneous injection of lower potency zoster vaccine (~58,000 plaque-forming units [PFU]/0.65-mL dose)
1739137|NCT00092430|Biological|V221, measles, mumps, rubella and varicella (Oka/Merck) virus vaccine live / Duration of Treatment: 12 weeks|
1739138|NCT00092443|Biological|RotaTeq™, rotavirus vaccine, live, oral, pentavalent|Three doses of RotaTeq™ administered 28 to 70 days apart.
1739139|NCT00092443|Biological|Comparator: Placebo matching RotaTeq™|Placebo matching RotaTeq™ administered 28 to 70 days apart.
1739140|NCT00092456|Biological|rotavirus vaccine, live, oral, pentavalent|Three oral doses (~8.81 X 10^7 IU/Dose for Lot 1; ~8.01 X 10^7 IU/Dose for Lot 2; and ~6.91 X 10^7 IU/Dose for Lot 3) of RotaTeq™ (rotavirus vaccine, live, oral, pentavalent) administered at 3 separate visits scheduled 4 to 10 weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination
1739141|NCT00092456|Biological|Placebo|"Placebo-matching RotaTeq™ administered at 3 separate visits scheduled 4 to 10
weeks (28 to 70 days) apart with up to 42 days of safety follow up after each vaccination"
1739142|NCT00092469|Biological|V441, diptheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), & Haemophilus influenza type b conjugate vaccine|
1739143|NCT00092482|Biological|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine / Duration of Treatment: 4 years|
1739144|NCT00092495|Biological|V501, Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|qHPV Vaccine (20, 40, 60 or 100% dose formulation) 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
1739145|NCT00092508|Drug|OPC-6535|
1739146|NCT00092508|Drug|Asacol®|
1739147|NCT00092521|Biological|V501|Final Manufactured Product (FMP) quadrivalent HPV vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
1739148|NCT00092521|Biological|Comparator: Placebo|a 0.5 mL intramuscular placebo injection given at Day 1, Month 2 and Month 6.
1739149|NCT00092521|Biological|Human Papillomavirus (HPV) 16 Monovalent|HPV 16 Monovalent vaccine, a 0.5 mL intramuscular injection given at Day 1, Month 2 and Month 6.
1739150|NCT00092534|Biological|Gardasil, human papillomavirus (type 6, 11, 16, 18) recombinant vaccine|Duration of Treatment: 6 months
1739151|NCT00092534|Biological|Matching Placebo|Matching Placebo to Quadrivalent Human Papillomavirus Vaccine
1739152|NCT00092547|Biological|V501|0.5 mL intramuscular injection of V501
1739153|NCT00092547|Biological|Comparator: Placebo|0.5 mL intramuscular injection of placebo
1739154|NCT00092560|Drug|MK0653, ezetimibe|
1739155|NCT00092560|Drug|Comparator: fenofibrate monotherapy|
1739156|NCT00092573|Drug|MK0653, ezetimibe|
1739157|NCT00092573|Drug|Comparator: fenofibrate monotherapy|
1739158|NCT00092586|Drug|MK0653, ezetimibe|
1739159|NCT00092586|Drug|Comparator: statins|
1739160|NCT00092599|Drug|MK0653, ezetimibe|
1739161|NCT00092599|Drug|Comparator: ezetimibe, placebo|
1739162|NCT00092612|Drug|MK0653, ezetimibe|
1739163|NCT00092612|Drug|Comparator: ezetimibe, placebo|
1739164|NCT00092625|Drug|MK0653, ezetimibe|
1739165|NCT00092625|Drug|Comparator: ezetimibe, placebo|
1739166|NCT00092638|Drug|MK0653, ezetimibe|
1739167|NCT00092638|Drug|Comparator: ezetimibe, placebo|
1739168|NCT00092651|Drug|MK0653A, ezetimibe (+) simvastatin|
1739169|NCT00092651|Drug|Comparators: simvastatin and ezetimibe|
1739170|NCT00092664|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 14 weeks|
1739171|NCT00092677|Drug|ezetimibe (+) simvastatin|Duration of Treatment: 4 years
1739172|NCT00092677|Drug|Comparator: Placebo|matching Placebo
1739173|NCT00092690|Drug|MK0653A, ezetimibe (+) simvastatin|
1739174|NCT00092690|Drug|Comparator: atorvastatin|
1739175|NCT00092703|Drug|MK0663, etoricoxib|
1739176|NCT00092703|Drug|Comparator: Diclofenac sodium|
1739177|NCT00092716|Drug|MK0653, ezetimibe / Duration of Treatment: 28 weeks|
1739178|NCT00092716|Drug|Comparator: atorvastatin / Duration of Treatment: 28 weeks|
1739462|NCT00100802|Drug|lomustine|Capsule
1739179|NCT00092729|Drug|etoricoxib (MK0663)|Two etoricoxib 60 mg tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
1739180|NCT00092729|Drug|Comparator: placebo (unspecified)|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg placebo tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
1739181|NCT00092729|Drug|Comparator: naproxen sodium|Two etoricoxib 60 mg placebo tablets and one naproxen sodium 550 mg tablet, single-dose, following onset of moderate-to-severe pain due to primary dysmenorrhea
1739182|NCT00092742|Drug|MK0663, etoricoxib|
1739183|NCT00092742|Drug|Comparator: Diclofenac sodium|
1739184|NCT00092755|Drug|MK0663, etoricoxib|
1739185|NCT00092755|Drug|Comparators: ibuprofen and placebo|
1739186|NCT00092768|Drug|MK0663, etoricoxib|
1739187|NCT00092768|Drug|Comparator: celecoxib|
1739188|NCT00092781|Drug|MK0663, etoricoxib|
1739189|NCT00092781|Drug|Comparator: celecoxib|
1739190|NCT00092807|Drug|MK0653, ezetimibe|
1739191|NCT00092807|Drug|Comparator: placebo|
1739192|NCT00092820|Drug|MK0653, ezetimibe|
1739193|NCT00092820|Drug|Comparator: placebo|
1739194|NCT00092833|Drug|Comparator: ezetimibe|Ezetimibe (MK0653) 10 mg once daily for 3 years.
1739195|NCT00092846|Drug|MK0803, lovastatin|
1739196|NCT00092846|Behavioral|Self-Management System|
1739197|NCT00092859|Drug|MK0557|
1739198|NCT00092872|Drug|MK0557|
1739199|NCT00092885|Drug|MK0476, montelukast sodium|
1739200|NCT00092885|Drug|Comparator: placebo|
1739201|NCT00092898|Drug|MK0653, ezetimibe|
1739202|NCT00092898|Drug|Comparator: placebo|
1739203|NCT00092911|Drug|DVS-233 SR|
1739204|NCT00092924|Drug|TRAIL-R1 mAb (TRM-1;HGS-ETR1)|
1739205|NCT00092937|Drug|Busulfan|
1739206|NCT00092950|Behavioral|Physical activity|
1739207|NCT00092963|Drug|MK0462, rizatriptan benzoate / Duration of Treatment: 1day|
1739208|NCT00092963|Drug|Comparator: placebo / Duration of Treatment: 1 day|
1739209|NCT00092976|Drug|ReFacto|
1739210|NCT00092989|Drug|montelukast sodium|Duration of Treatment: 1 dose
1739211|NCT00092989|Drug|placebo|Duration of Treatment: 1 dose
1739212|NCT00093002|Drug|Fulvestrant|250 mg & 500 mg intramuscular injection
1739213|NCT00093015|Drug|Placebo|Volume and dose frequency changes resembling dosing in the active treatment group
1739214|NCT00093015|Drug|darbepoetin alfa|Starting dose : 0.75 mcg/kg subcutaneous (SC) every two weeks (Q2W); subsequent doses titrated to achieve hemoglobin (Hb) target of 13.0 g/dL
1739215|NCT00093028|Drug|CC-5013 (Revlimid™)|N/A Study Complete
1739216|NCT00093028|Drug|bortezomib|N/A Study Complete
1739217|NCT00093041|Drug|Zalutumumab|Weekly infusion
1739218|NCT00093054|Drug|Cranberry juice|TID dosage for UTI treatment
1739219|NCT00093054|Dietary Supplement|Placebo cranberry juice|TID placebo dosage to match active comparator
1739220|NCT00093067|Drug|daptomycin|
1739221|NCT00093080|Drug|ridaforolimus|12.5 mg of ridaforolimus is given intravenously over 30 minutes once daily for 5 days, every 2 weeks
1739222|NCT00093093|Drug|Viramidine|
1739223|NCT00093093|Drug|Ribavirin|
1739224|NCT00093093|Drug|pegylated interferon alfa-2a|
1739225|NCT00093119|Drug|ABI-007|
1739226|NCT00093132|Drug|Satraplatin|Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based drugs have been clinically proven to be one of the most effective classes of anticancer therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given orally.
1739227|NCT00093145|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
1739228|NCT00093145|Drug|Carboplatin|Carboplatin dose was calculated using a modified Calvert formula (creatinine clearance was substituted for GFR): Total dose (mg) = (target AUC) x (creatinine clearance + 25). Note: AUC = 6 was initially targeted, but could be decreased due to toxicity.
1739229|NCT00093145|Drug|Herceptin®|Administered by IV infusion
1739230|NCT00093158|Drug|Angiomax (bivalirudin) anticoagulant|
1739231|NCT00093171|Drug|rFIX|
1739232|NCT00093184|Drug|Angiomax (bivalirudin) anticoagulant|
1739233|NCT00093197|Drug|KAI-9803 for Injection|0.05 mg
1739234|NCT00093197|Drug|KAI-9803 for Injection|0.5 mg
1739235|NCT00093197|Drug|KAI-9803 for Injection|1.25 mg
1739236|NCT00093197|Drug|KAI-9803 for Injection|5 mg
1739237|NCT00093197|Drug|Placebo|
1739238|NCT00093210|Drug|rFIX|
1739239|NCT00093210|Drug|rFIX-R|
1739240|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|Single or duel doses of 35mg/m^2 ABI-007, administered IV, administered after placement of denovo stent(s).
1739241|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|
1739242|NCT00093223|Drug|Paclitaxel Nanoparticle Albumin Bound|35mg/35 infusion time is 3.5 minutes
1739243|NCT00093236|Procedure|Early Periodontal Treatment|Subjects will receive scaling and root planing at baseline. Three weeks after initiation of the study, they will return and be re-evaluated for the need for periodontal surgery. If indicated, they will then receive definitive periodontal surgery over the next 4 weeks. At the 12-week time point, periodontal surgery will be reevaluated and further therapy provided as needed and make repeated visits as needed to achieve periodontal health.comprehensive periodontal treatment
1739244|NCT00093236|Procedure|Usual Dental Hygiene|Subjects will receive routine oral hygiene visits at the 3 and 12-week time points. After a 12-week period (24 week time point) to allow healing and resolution of a systemic inflammatory state, patients will return for follow-up measurements of periodontal parameters, vascular function and inflammation.
1739245|NCT00093249|Drug|clevidipine|Clevidipine (0.5 mg/mL in 20% lipid emulsion)will be administered intravenously at an initial infusion rate of 0.4 µg/kg/min and will be titrated, as tolerated, at the discretion of the investigator, in doubling increments approximately every 90 seconds up to a maximum of 3.2 µg/kg/min, in order to achieve the desired blood pressure lowering effect. Clevidipine may be titrated upwards or downwards and may be temporarily interrupted and restarted to attain the desired blood pressure effect. The maximum study drug infusion rate of 8.0 µg/kg/min may not be exceeded.
1739246|NCT00093249|Drug|placebo|Placebo (20% lipid emulsion - vehicle) will be administered intravenously in a fashion identical to clevidipine as described above.
1739247|NCT00093262|Drug|clevidipine|
1739248|NCT00093262|Drug|placebo|
1739249|NCT00093275|Drug|HP184|
1739250|NCT00093288|Drug|bupropion XL|
1739251|NCT00093301|Drug|Levosimendan|
1739252|NCT00093301|Drug|Dobutamine|
1739253|NCT00093314|Drug|HuMax-CD20|
1739254|NCT00093327|Procedure|Acupuncture|
1739255|NCT00093353|Drug|cefixime|
1739256|NCT00093353|Drug|irinotecan hydrochloride|
1739257|NCT00093353|Drug|temozolomide|
1739258|NCT00093366|Biological|etanercept|
1739259|NCT00093366|Drug|arsenic trioxide|
1739260|NCT00093379|Drug|Capecitabine|825 mg/m^2 orally twice a day (BID), Mon-Fri during weeks 1, 2, 4, and 5.
1739261|NCT00093379|Drug|Oxaliplatin|50 mg/m^2 by vein (IV) over 2 hours on days 1, 8, 22, and 29.
1739262|NCT00093379|Radiation|Radiation Therapy (XRT)|Undergo radiotherapy* once daily on days 1-3, 6-10, 13-17, 20-24, 27-31, 34-38, and 41-42. *Patients with T3-4 lesions undergo radiotherapy once daily on days 43 and 44.
1739263|NCT00093405|Drug|tanespimycin|
1739264|NCT00093418|Drug|tipifarnib|Given orally
1739265|NCT00093444|Drug|lyso-thermosensitive liposomal doxorubicin|
1739266|NCT00093444|Procedure|radiofrequency ablation|
1739267|NCT00093457|Drug|sorafenib tosylate|BAY 43-9006 given orally at 400 mg BID in a 28 day cycle
1739268|NCT00093470|Procedure|Clinical Observation|Undergo observation
1739269|NCT00093470|Drug|Tipifarnib|Given PO
1739270|NCT00093483|Biological|filgrastim|Subcutaneously beginning 12 hours after the last dose of chemotherapy and continuing until blood counts recover.
1739271|NCT00093483|Drug|arsenic trioxide|IV over 1 hour on day 1
1739272|NCT00093483|Drug|cytarabine|IV over 1 hour every 12 hours on days 1-6
1739273|NCT00093483|Drug|idarubicin|IV over 30 minutes on days 2-4 (immediately after doses 3, 5 and 7 of cytarabine).
1739274|NCT00093496|Drug|gemcitabine hydrochloride|Given IV
1739275|NCT00093496|Drug|tanespimycin|Given IV
1739276|NCT00093509|Drug|doxorubicin hydrochloride|To be dosed at 75 mg/m2 i.v. push every 4 weeks for 4 cycles. This treatment is optional and will not be used on all subjects.
1739277|NCT00093509|Drug|ifosfamide and mesna|2 gm / m2 ifosfamide mixed in 1000 cc D5W infused continuously over 24 hours daily for 6 days (144 hours); total ifosfamide dose 12 gm/ m2. For the day infusion only MESNA (sodium 2-mercapto-ethanesulphonate) is mixed with ifosfamide as above and given at 2.5 gm / m2 / 24 hours.
1739278|NCT00093509|Procedure|hyperthermia treatment with an MRI Compatible Radiofrequency Extremity Hyperthermia Applicator|Patients will receive hyperthermia throughout the course of radiotherapy delivered once weekly for a total of 5 treatments. Each treatment will last 1-2 hours with a goal of delivering a cumulative thermal dose of 10-100 CEM 43˚T90.
1739279|NCT00093509|Radiation|radiation therapy|External beam megavoltage (≥ 4 MV) beams will be used at SSD, SAD ≥ 70 cm at a dose rate of > 100 cGy/min. Fraction sizes of 180 cGy will be used 5 times per weeks in a continuous course. Total dose will be 45 Gy + 10%, consistent with sites being treated.
1739280|NCT00093522|Biological|autologous tumor cell vaccine|
1739281|NCT00093522|Biological|keyhole limpet hemocyanin|
1739282|NCT00093522|Biological|therapeutic autologous dendritic cells|
1739283|NCT00093522|Drug|fludarabine phosphate|
1739284|NCT00093522|Procedure|conventional surgery|
1739285|NCT00093548|Biological|alpha fetoprotein adenoviral vector vaccine|
1739286|NCT00093548|Biological|alpha fetoprotein plasmid DNA vaccine|
1739287|NCT00093548|Biological|sargramostim plasmid DNA hepatocellular carcinoma vaccine adjuvant|
1739288|NCT00093561|Dietary Supplement|lycopene|
1739289|NCT00093587|Biological|anti-thymocyte globulin|
1739290|NCT00093587|Drug|busulfan|
1739291|NCT00093587|Drug|cyclophosphamide|
1739292|NCT00093587|Drug|cyclosporine|
1739293|NCT00093587|Procedure|allogeneic bone marrow transplantation|
1739294|NCT00093587|Procedure|peripheral blood stem cell transplantation|
1739295|NCT00093587|Radiation|radiation therapy|
1739296|NCT00093600|Drug|cytarabine|
1739297|NCT00093600|Drug|daunorubicin hydrochloride|
1739298|NCT00093600|Drug|midostaurin|
1739299|NCT00093613|Drug|sorafenib tosylate|Given PO
1739300|NCT00093613|Other|pharmacological study|Correlative studies
1739301|NCT00093626|Other|Laboratory Biomarker Analysis|Correlative studies
1739302|NCT00093626|Drug|Sorafenib Tosylate|Given orally
1739303|NCT00093639|Drug|everolimus|
1739304|NCT00093639|Drug|imatinib mesylate|
1739305|NCT00093652|Drug|gefitinib|
1739306|NCT00093652|Drug|oxaliplatin|
1739307|NCT00093652|Procedure|conventional surgery|
1739308|NCT00093652|Procedure|neoadjuvant therapy|
1739309|NCT00093652|Radiation|radiation therapy|
1739310|NCT00093665|Drug|cisplatin|
1739311|NCT00093665|Drug|fluorouracil|
1739312|NCT00093665|Radiation|radiation therapy|
1739313|NCT00093678|Drug|celecoxib|
1739314|NCT00093678|Procedure|anticachectic therapy|
1739315|NCT00093678|Procedure|nutritional support|
1739316|NCT00093678|Procedure|pain therapy|
1739317|NCT00093678|Procedure|supportive care/therapy|
1739318|NCT00093704|Drug|bortezomib + ganciclovir|Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8 and 11. Patients also receive ganciclovir IV twice daily on days 1-14. Treatment repeats every 21 days for a maximum of 3 courses.
1739319|NCT00093730|Drug|BMS-59926|
1739320|NCT00093743|Drug|fludarabine phosphate|Given IV
1739321|NCT00093743|Drug|cyclosporine|Given IV or PO
1739322|NCT00093743|Radiation|total-body irradiation|Undergo TBI
1739323|NCT00093743|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
1739324|NCT00093743|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplantation
1739463|NCT00100802|Drug|temozolomide|Capsule
1739325|NCT00093743|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplantation
1739326|NCT00093743|Drug|mycophenolate mofetil|Given PO or IV
1739327|NCT00093756|Radiation|3-dimensional conformal radiation therapy|
1739328|NCT00093756|Drug|bortezomib|Given IV
1739329|NCT00093756|Drug|paclitaxel|Given IV
1739330|NCT00093756|Drug|carboplatin|Given IV
1739331|NCT00093769|Drug|bortezomib + rituximab|"Arm I: Patients receive bortezomib IV over 3-5 seconds on days 1, 4, 8, and 11. Patients also receive rituximab IV on days 1, 8, and 15 of course 1 only and on day 1 of course 2 only. Treatment with repeats every 21 days for up to 5 courses in the absence of disease progression or unacceptable toxicity.
Arm II: Patients receive bortezomib IV over 3-5 seconds on days 1, 8, 15 and 22. Patients also receive rituximab IV on days 1, 8, 15, and 22 of course 1 only. Treatment repeats every 35 days for up to 3 courses in the absence of disease progression or unacceptable toxicity.
Patients in either arm may crossover to the other arm if treatment is found to be ineffective."
1739332|NCT00093782|Drug|temsirolimus|Given IV
1739333|NCT00093782|Other|laboratory biomarker analysis|Correlative studies
1739334|NCT00093795|Drug|Cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: cyclophosphamide 600 mg/m2 IV every 14 days for 4 cycles"
1739335|NCT00093795|Drug|Docetaxel|75 mg/m2 IV every 21 days for 6 cycles
1739336|NCT00093795|Drug|Gemcitabine|2000 mg/m2 IV every 14 days for 4 cycles
1739337|NCT00093795|Drug|Paclitaxel|175 mg/m2 IV every 14 days for 4 cycles
1739338|NCT00093795|Drug|Doxorubicin|"Group 1: 50 mg/m2 IV every 21 days for 6 cycles
Group 2 and Group 3: 60 mg/m2 IV every 14 days for 4 cycles"
1739339|NCT00093808|Biological|trastuzumab|
1739340|NCT00093808|Drug|capecitabine|
1739341|NCT00093808|Drug|vinorelbine tartrate|
1739342|NCT00093821|Drug|tanespimycin|Given IV
1739343|NCT00093821|Other|pharmacological study|Correlative studies
1739344|NCT00093821|Other|laboratory biomarker analysis|Correlative studies
1739345|NCT00093834|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|The first three patients will receive a dose of 5 X 107 cells, and the next three will receive a dose of 5 X 108 cells. Then, if these two doses of vaccine alone are found to be safe, a fixed vaccine dose of 5 X 108 cells will be tested in combination with chemotherapy based on the safety of the allogeneic breast vaccine alone and the safety and bioactivity of a dose of 5 X 108 cells in the allogeneic pancreatic vaccine trial
1739346|NCT00093834|Drug|cyclophosphamide|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
1739347|NCT00093834|Drug|doxorubicin hydrochloride|This trial will be a dose ranging study of a fixed sequence of drug doses in a three by three factorial matrix modeled after the theories of Plackett and Burman (Plackett et al., 1946), and is designed to determine the doses of CY and DOX that maximize the immunologic response to vaccination
1739348|NCT00093847|Drug|S-adenosyl methione (SAMe)|Oral SAMe tosylate, up to 1600 mg per day for 6 weeks
1739349|NCT00093847|Drug|Placebo|Placebo to be taken daily for 6 weeks
1739350|NCT00093860|Drug|Propranolol|
1739351|NCT00093873|Drug|Anti-angiogenesis|Anti-angiogenesis
1739352|NCT00093873|Drug|AMG 706|Anti-angiogenesis
1739353|NCT00093886|Drug|clevidipine|
1739354|NCT00093886|Drug|nitroglycerin|
1739355|NCT00093899|Drug|ezetimibe (+) simvastatin|Duration of Treatment: 6 months
1739356|NCT00093912|Drug|clevidipine|
1739357|NCT00093912|Drug|sodium nitroprusside|
1739358|NCT00093925|Drug|clevidipine|
1739359|NCT00093925|Drug|nicardipine|
1739360|NCT00093938|Drug|Cranberry juice|
1739361|NCT00093951|Drug|SGS742|
1739364|NCT00093977|Drug|darbepoetin alfa SF|"Frequency of dosing depends on frequency at randomization:
rHuEPO QW = darbepoetin alfa SF Q2W (dosing conversion table in protocol) rHuEPO biw or tiw = darbepoetin alfa SF QW (dosing conversion table in protocol) darbepoetin alfa RB = darbepoetin alfa SF at same dose and frequency PFS 10, 15, 20, 30, 40, 50, 60, 80, 100, 150, 200 or 300 mcg; Hb maintained between 11.0 - 13.0 g/dL"
1739365|NCT00093990|Drug|Tipifarnib;Zarnestra; R115777|
1739366|NCT00094003|Drug|NS-9 [Poly I: Poly C]|
1739367|NCT00094016|Drug|beclomethasone dipropionate|
1739368|NCT00094029|Drug|Sutent|Sutent, 25, 37.5, or 50 mg daily
1739369|NCT00094042|Drug|Iron Supplement, 120mg|
1739370|NCT00094055|Drug|AG013736|AG013736, tablets 5 mg BID daily until tumor progression or toxicity
1739371|NCT00094081|Drug|tirapazamine (SR259075)|
1739372|NCT00094081|Drug|cisplatin|
1739373|NCT00094081|Procedure|Radiation Therapy|
1739374|NCT00094094|Drug|axitinib|Axitinib (AG-013736) tablet administered orally at a dose of 5 milligrams (mg) twice daily (BID) in cycles of 4 weeks.
1739375|NCT00094107|Drug|Axitinib [AG-013736]|VEGFR [vascular endothelial growth factor Receptor] and PDGFR [Platelet-Derived Growth Factor Receptor] inhibitor: Single agent AG-013736 starting dose 5 mg BID +/- 20% according to toxicity. Treatment until progression or unacceptable toxicity occurs.
1739376|NCT00094120|Drug|MSI-1256F (Squalamine Lactate)|
1739377|NCT00094133|Procedure|hot flashes attenuation|
1739378|NCT00094133|Procedure|hypnotherapy|
1739379|NCT00094146|Drug|Sandostatin LAR Depot|
1739380|NCT00094159|Drug|SNS-595|
1739381|NCT00094172|Drug|Atorvastatin|atorvastatin at the dose of 80 mg/day. Participants will be allowed to decrease the daily dose to 40 mg/day if the higher dose is not well-tolerated
1739382|NCT00094172|Drug|Placebo|tablet form
1739383|NCT00094250|Behavioral|Resistance and Aerobic Training|
1739384|NCT00094276|Behavioral|Facilitated Asthma Communication Intervention (FACI)|A caregiver/PCP communication intervention designed to facilitate communication between parents and PCPs about a child's asthma severity and recommended therapy.
1739385|NCT00094276|Behavioral|Breathmobile intervention|A community-based service that is specifically designed to deliver asthma screening and special consultation directly to families and children in high-risk neighborhoods.
1739386|NCT00094289|Drug|Disulfiram|
1739387|NCT00094302|Drug|Spironolactone|Spironolactone (an aldosterone antagonist) is supplied as 15 mg tablets. Drug is taken orally by subjects. The initial study drug dose is 15 mg/day (one tablet) and may be titrated up to 30 mg/day (two tablets) or 45 mg/day (three tablets). Subjects are on study drug for the duration of the trial.
1739388|NCT00094302|Drug|Placebo|Placebo of spironolactone
1739389|NCT00094315|Drug|Cocaine (IV)|
1739390|NCT00094328|Drug|Bicalutamide|oral
1739391|NCT00094328|Drug|Anastrozole|oral
1739392|NCT00094341|Drug|Etanercept|
1739393|NCT00094367|Drug|Abacavir/Lamivudine|
1739394|NCT00094380|Drug|CTLA4-IgG4m (RG2077)|
1739395|NCT00094380|Drug|Cyclophosphamide|
1739396|NCT00094406|Procedure|Bronchoscopy|
1739397|NCT00094406|Procedure|Bronchoalveolar lavage|
1739398|NCT00094406|Drug|Endotoxin|
1739399|NCT00094406|Drug|Carbon Monoxide|
1739400|NCT00094432|Drug|Aripiprazole|Tablets, Oral, 10mg (2 5mg tablets), Once daily, 8 weeks.
1739401|NCT00094432|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
1739402|NCT00094445|Drug|Curcumin|8 gm per day
1739403|NCT00094458|Biological|infliximab infusion; AZA placebo caps|Infliximab 5 mg/kg at weeks 0, 2, 6, 14, and 22 and placebo AZA capsules
1739404|NCT00094458|Other|infliximab (IFX) infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and IFX infusions 5 mg/kg at weeks 0, 2, 6, 14, and 22
1739405|NCT00094458|Drug|infliximab (IFX) placebo infusion; azathioprine (AZA) caps|AZA daily 2.5 mg/kg/day and placebo IFX infusions at weeks 0, 2, 6, 14, and 22
1739406|NCT00100100|Drug|Modafinil|
1739407|NCT00100113|Drug|GBR 12909|
1739408|NCT00100126|Drug|Amoxicillin Pulsatile Release Multiparticluate Sprinkle|
1739409|NCT00100139|Drug|Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU)|
1739410|NCT00100139|Drug|Paclitaxel for injection (Taxol)|
1739411|NCT00100152|Drug|MK0752, (Notch Inhibitor)|
1739414|NCT00100178|Drug|Mycophenolate mofeteil (MMF)|
1739415|NCT00100178|Drug|Daclizumab (DZB)|
1739416|NCT00100178|Drug|Placebo control for Mycophenolate mofeteil (MMF)|Placebo pills taken orally
1739417|NCT00100178|Drug|Placebo control for Daclizumab (DZB)|saline intravenous infusions
1739418|NCT00100191|Procedure|uterine artery embolization|
1739419|NCT00100191|Procedure|hysterectomy|
1739421|NCT00100243|Drug|Plenaxis|
1739422|NCT00100256|Drug|Rhenium (Re 188 P2045, BAY86-5284)|Infusion once only
1739423|NCT00100269|Drug|Menevit anti-oxidant|
1739424|NCT00100282|Drug|PPI-1019 (APAN)|
1739425|NCT00100295|Drug|Hypericum perforatum|300 mg capsule taken three times a day
1739426|NCT00100295|Other|Placebo|300 mg given three times a day, containing rice protein powder
1739427|NCT00100308|Drug|Unfractioned heparin|Low-dose continuous-infusion, 500 units/hour per seven days
1739428|NCT00100308|Drug|saline|Saline placebo
1739429|NCT00100334|Drug|PPI-1019 (APAN)|
1739430|NCT00100347|Drug|PPI-2458|
1739431|NCT00100373|Drug|RSV challenge material|
1739432|NCT00100386|Procedure|Intensive Control Strategy|
1739433|NCT00100386|Behavioral|Standard Control Strategy|
1739434|NCT00100399|Biological|Fluarix|
1739435|NCT00100412|Drug|Graded dobutamine infusions|
1739436|NCT00100412|Drug|Graded phenylephrine injections|
1739437|NCT00100412|Behavioral|Psychosocial challenge involving socioevaluative public speaking|
1739438|NCT00100425|Procedure|Viceral Perception Testing|
1739439|NCT00100620|Drug|Zoledronic Acid|
1739440|NCT00100633|Drug|CpG7909 oligodeoxynucleotides (ODN)|
1739441|NCT00100633|Biological|Hepatitis B virus vaccine|
1739442|NCT00100646|Behavioral|Structured treatment interruption|Interruptions in treatment will last 2, 4, and 8 weeks in between 16-week periods of ART
1739443|NCT00100646|Drug|Lamivudine|300 mg tablet taken orally daily
1739444|NCT00100646|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
1739445|NCT00100646|Drug|Stavudine|Dosage dependent on weight
1739446|NCT00100646|Biological|Rabies de novo antigen|Vaccine injected intramuscularly
1739447|NCT00100659|Drug|Pegylated Interferon/ribavirin|
1739448|NCT00100672|Drug|LErafAON-ETU|
1739449|NCT00100685|Drug|Volociximab (anti-α5β1 integrin monoclonal antibody)|Volociximab intravenously (Cohort 1: 10 mg/kg every other week or Cohort 2: 15 mg/kg once a week) for up to 104 weeks or until disease progression, whichever occurs first.
1739450|NCT00100698|Drug|recombinant human growth hormone|growth hormone dosed by weight and IGF-1 level,subcutaneously once a day, 18 months
1739451|NCT00100698|Drug|placebo|placebo subcutaneously once a day, 18 months
1739452|NCT00100711|Drug|Motexafin Gadolinium|
1739453|NCT00100724|Biological|rPA102|
1739454|NCT00100737|Drug|interleukin-2|
1739455|NCT00100737|Drug|rituximab|
1739456|NCT00100750|Drug|Gemcitabine Hydrochloride|Given IV
1739457|NCT00100750|Drug|Tipifarnib|Given PO
1739458|NCT00100750|Other|Laboratory Biomarker Analysis|Correlative studies
1739459|NCT00100776|Drug|Olanzapine|
1739460|NCT00100789|Drug|gemcitabine|3,000 mg/m2 IV over 30 minutes on days 1 and 15 (q28 days).
1739461|NCT00100789|Drug|paclitaxel|150 mg/m2 IV over 1 hour on days 1 and 15 (q 28 day cycle), administered after gemcitabine
1739464|NCT00100802|Procedure|adjuvant therapy|
1739465|NCT00100802|Radiation|radiation therapy|
1739466|NCT00100815|Biological|bevacizumab|30-90 minutes on day 1, every 21 days up to 12 months.
1739467|NCT00100815|Drug|capecitabine|twice daily on days 1-14. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
1739468|NCT00100815|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8. Courses repeat every 21 days for up to 12 months in the absence of disease progression or unacceptable toxicity.
1739470|NCT00100841|Biological|cetuximab|Given IV
1739471|NCT00100841|Biological|bevacizumab|Given IV
1739472|NCT00100841|Drug|oxaliplatin|Given IV
1739473|NCT00100841|Drug|leucovorin calcium|Given IV
1739474|NCT00100841|Drug|fluorouracil|Given IV
1739475|NCT00100854|Drug|erlotinib hydrochloride|Given orally
1739476|NCT00100854|Drug|fulvestrant|Given intramuscularly
1739477|NCT00100880|Drug|lenalidomide|Given PO
1739478|NCT00100880|Procedure|perfusion-weighted magnetic resonance imaging|Correlative studies
1739479|NCT00100880|Procedure|diffusion-weighted magnetic resonance imaging|Correlative studies
1739480|NCT00100880|Other|laboratory biomarker analysis|Correlative studies
1739481|NCT00100893|Dietary Supplement|IH636 grape seed proanthocyanidin extract|Dose escalation as follows: 50 mg/day, 300 mg/day, 1000 mg/day, 2000 mg/day, 2800 mg/day, 4000 mg/day, 4800 mg/day and 6000 mg/day in separate patient groups for each dosage
1739482|NCT00100906|Drug|IL-2|Immunotherapy with interleukin-2
1739483|NCT00100906|Drug|ATRA|
1739484|NCT00100932|Drug|E7389 28 Day Cycle|E7389 1.4 mg/m^2 IV bolus on Days 1, 8, and 15 of a 28 day cycle.
1739485|NCT00100932|Drug|E7389 21 Day Cycle|E7389 1.4 mg/m^2 IV bolus on Days 1 and 8 of a 21 day cycle.
1739486|NCT00100945|Drug|gefitinib|
1739487|NCT00100958|Drug|indole-3-carbinol|
1739488|NCT00100971|Drug|autologous tumor cell vaccine|
1739489|NCT00100971|Drug|therapeutic autologous dendritic cells|
1739490|NCT00100971|Procedure|tumor cell-derivative vaccine therapy|
1739491|NCT00100984|Drug|FUZEON [enfuvirtide]|
1739492|NCT00100997|Drug|tanespimycin|
1739493|NCT00101010|Biological|Filgrastim|5 mcg/kg, SC daily, start 24 hours after chemotherapy
1739494|NCT00101010|Biological|Pegfilgrastim|6 mg SC one time (24 hours after chemotherapy)
1739495|NCT00101010|Biological|Rituximab|375 mg/m^2 intravenous piggy back (IVPB) on day 1, administered 1st
1739496|NCT00101010|Drug|Cyclophosphamide|750 mg/m^2 IVPB on day 1
1739497|NCT00101010|Drug|Pegylated liposomal doxorubicin hydrochloride|40 mg/m^2 IV (maximum dose 90 mg) infusion over 1 hour on day 1
1739498|NCT00101010|Drug|Prednisone|40 mg/m^2 oral days 1 - 5.
1739499|NCT00101010|Drug|Vincristine Sulfate|2 mg IV, day 1
1739500|NCT00101036|Drug|lapatinib ditosylate|Given PO
1739501|NCT00101036|Other|laboratory biomarker analysis|Correlative studies
1739502|NCT00101062|Drug|celecoxib|
1739503|NCT00101062|Drug|letrozole|
1739504|NCT00101075|Drug|Capecitabine|
1739505|NCT00101075|Drug|Oxaliplatin|
1739506|NCT00101088|Drug|imatinib mesylate|Given orally
1739507|NCT00101088|Drug|temsirolimus|Given IV
1739508|NCT00101088|Other|laboratory biomarker analysis|Correlative studies
1739509|NCT00101101|Drug|Cyclophosphamide|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
1739510|NCT00101101|Drug|Doxorubicin|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
1739511|NCT00101101|Drug|Vincristine|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
1739512|NCT00101101|Drug|Prednisone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
1739513|NCT00101101|Drug|Dexamethasone|Participants receive conventional chemotherapy comprising 6 courses of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) OR 3 courses of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high-dose methotrexate and cytarabine (hyper-CVAD) for patients who have relapsed after CHOP.
1739514|NCT00101101|Biological|Autologous Tumor Cell-Based Vaccine|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
1739515|NCT00101101|Drug|IL-2|Participants receive vaccine comprising autologous tumor cells and GM.CD40L intradermally on day 1 and low-dose interleukin-2 (IL-2) subcutaneously twice daily on days 1-14. Treatment repeats every 28 days for 4 courses. Patients who have stable or responding disease at 12 months receive 4 additional courses of booster vaccine and low-dose IL-2 as above.
1739516|NCT00101114|Drug|sorafenib tosylate|Given PO
1739517|NCT00101114|Biological|recombinant interferon alfa-2b|Given SC
1739518|NCT00101114|Other|laboratory biomarker analysis|Optional correlative studies
1739519|NCT00101127|Biological|filgrastim|
1739520|NCT00101127|Biological|pegfilgrastim|
1739521|NCT00101127|Drug|docetaxel|
1739522|NCT00101127|Drug|gemcitabine hydrochloride|
1739532|NCT00101153|Drug|cytarabine|
1739533|NCT00101153|Drug|daunorubicin hydrochloride|
1739534|NCT00101153|Drug|tipifarnib|
1739535|NCT00101166|Biological|Bystander-Based Autologous Tumor Cell Vaccine|The vaccine, consisting of one mL of cell suspension (GM.CD40L bystander cells admixed with an equivalent number of thawed autologous tumor cells), was administered into 8 separate injection sites, as described in treatment arm.
1739538|NCT00101192|Biological|cetuximab|
1739539|NCT00101192|Drug|cisplatin|
1739540|NCT00101205|Drug|oxaliplatin|Given IV
1739541|NCT00101205|Drug|etoposide|Given IV
1739542|NCT00101231|Drug|alvocidib|Given IV
1739543|NCT00101244|Drug|ispinesib|Given IV
1739544|NCT00101244|Other|laboratory biomarker analysis|Correlative studies
1739545|NCT00101244|Other|pharmacological study|Correlative studies
1739546|NCT00101257|Biological|therapeutic autologous lymphocytes|
1739547|NCT00101270|Drug|irinotecan hydrochloride|Given IV
1739548|NCT00101270|Drug|oxaliplatin|Given IV
1739549|NCT00101283|Drug|pemetrexed disodium|500 mg/m2 IV over 10 minutes on day 1 of a 21-day cycle
1739550|NCT00101283|Drug|gemcitabine hydrochloride|1000 mg/m2 IV over 30 minutes on days 1 and 8 of a 21-day cycle
1739551|NCT00101283|Drug|carboplatin|Given by IV over 30 minutes at an area under the curve (AUC) of 5 on day 1 of a 21-day cycle
1739552|NCT00101296|Drug|tipifarnib|Given orally
1739553|NCT00101296|Other|pharmacological study|Correlative studies
1739554|NCT00101296|Other|laboratory biomarker analysis|Correlative studies
1739555|NCT00101309|Biological|aldesleukin|
1739556|NCT00101309|Biological|autologous EBV-transformed B lymphoblastoid-tumor fusion cell vaccine|
1739557|NCT00101309|Biological|therapeutic autologous lymphocytes|
1739558|NCT00101335|Drug|celecoxib|
1739559|NCT00101348|Drug|erlotinib hydrochloride|Given orally
1739560|NCT00101348|Biological|cetuximab|Given IV
1739561|NCT00101348|Biological|bevacizumab|Given IV
1739562|NCT00101348|Other|laboratory biomarker analysis|Correlative studies
1739563|NCT00101361|Drug|Oxandrolone|Patients will receive oxandrolone (10mg BID) until full healing occurs or for 24 weeks, which ever comes first.
1739564|NCT00101361|Drug|Placebo|Patients will receive an identically appearing placebo capsule until full healing occurs or for 24 weeks, which ever comes first.
1739565|NCT00101374|Drug|Leflunomide|
1739566|NCT00101387|Other|Lumbar PENS + General Conditioning and Aerobic Exercise|As above
1739567|NCT00101387|Other|Lumbar PENS|As above
1739568|NCT00101387|Other|Control Lumbar PENS|Identical needle placement as with PENS procedure, but only control needles stimulated for 5 minutes.
1739569|NCT00101387|Other|Control PENS + exercise|as above
1739570|NCT00101400|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg administered twice daily (b.i.d.)
1739571|NCT00101413|Drug|Sorafenib (Nexavar, BAY43-9006)|BAY43-9006 400 mg bid X 28 day cycles [Continuous treatment for a maximum of 2 years; potential for compassionate use and long term survival follow-up post drug discontinuation.
1739572|NCT00101426|Drug|ranirestat, (AS-3201)|
1739573|NCT00101439|Drug|ezetimibe|
1739574|NCT00101439|Drug|Comparator: placebo|
1739575|NCT00101452|Drug|S-adenosyl-l-methionine|1600 mg per day with possibility of increasing to 3200 mg per day at 6 weeks
1739576|NCT00101452|Drug|Escitalopram|10 mg per day, with possibility of increasing to 20 mg/day at 6 weeks
1739577|NCT00101452|Drug|Placebo|placebo capsules look like escitalopram capsules and SAMe capsules
1739578|NCT00101491|Behavioral|Health Communication DVD video|Interactive, testimonial-based, stage of change-matched Health Communication DVD video interventions
1739579|NCT00101543|Device|Electrical Stimulation with Intramuscular Electrodes|
1739580|NCT00101543|Procedure|Body Weight Supported Treadmill Training|
1739581|NCT00101569|Drug|Aripiprazole|Tablets, Oral, 15 -30 mg, once daily, 2 weeks (days 1 -14).
1739582|NCT00101569|Drug|Aripiprazole|Oral Solution, Oral, 15-30 ml, once daily, 1 week (days 15 -21).
1739583|NCT00101582|Drug|Placebo|
1739584|NCT00101582|Drug|palifermin|
1739585|NCT00101582|Drug|cisplatin chemotherapy|Commercially available cisplatin was administered as an intravenous infusion at a dose of 100 mg/m^2 on Days 1, 22, and 43.
1739586|NCT00101582|Radiation|Radiotherapy|Radiotherapy was delivered in 200 cGy daily fractions, 5 days a week.
1739587|NCT00101595|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or untolerable toxicity, switch to the roll-over study or study closure
1739588|NCT00101608|Drug|vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
1739589|NCT00101621|Drug|M40403|
1739590|NCT00101634|Drug|Paliperidone palmitate|
1739591|NCT00101647|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, until disease progression or intolerable toxicity, switch to the roll-over study or study closure
1739592|NCT00101660|Drug|Dasatinib|Tablets; oral; 70 mg BID, depending on response
1739593|NCT00101673|Drug|vildagliptin|
1739594|NCT00101686|Drug|Modified Bolus 5-FU/LV with Irinotecan|Day 1 & 8: Irinotecan (125 mg/m2 IV over 90 minutes), LV (20 mg/m2 IV bolus), 5-FU (500 mg/m2 IV bolus). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID [two times a day] (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
1739636|NCT00102011|Procedure|screening colonoscopy|Patients undergo baseline screening colonoscopy
1739595|NCT00101686|Drug|FOLFIRI + bevacizumab|"Day 1 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.
I m m e d i a t e l y f o l l o w e d b y :
5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Every 2 weeks
Amendment 2 Bevacizumab 5mg/kg IV 90 minutes prior to irinotecan/LV Irinotecan 180 mg/m2 IV 90 minutes Leucovorin 400 mg/m2 IV 2 hours - given with irinotecan without mixing.
I m m e d i a t e l y f o l l o w e d b y :
5-FU 400 mg/m2 IV bolus 5-FU 2400 mg/m2 IV Continuous infusion over 46 hours Celecoxib/placebo 400 mg BID [two times a day] oral Every 2 weeks"
1739596|NCT00101686|Drug|miFL + bevacizumab|Day 1 Bevacizumab 7.5mg/kg IV *over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Every 3 weeks Amendment 2 Day 1 Bevacizumab 7.5mg/kg IV over 90 minutes - given prior to irinotecan, 5-FU, and leucovorin Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo 400 mg BID [two times a day] oral Day 8 Irinotecan 125 mg/m2 IV over 90 minutes Leucovorin 20 mg/m2 IV bolus 5-FU 500 mg/m2 IV bolus Celecoxib/placebo -- 400 mg po BID [two times a day] continues daily without interruption Every 3 weeks
1739597|NCT00101686|Drug|Infusional 5-FU/LV with Irinotecan|Day 1: Irinotecan (180 mg/m2) IV over 90 minutes, LV (racemic mixture 400 mg/m2) over 2 hours during irinotecan infusion but without mixing, immediately followed by 5-FU IV bolus (400 mg/m2) and 5-FU continuous infusion (2400 mg/m2) over 46 hours. FOLFIRI regimen is repeated every 2 weeks. Celecoxib/placebo treatment will commence on the same day at a dose of 400 mg po BID [two times a day](800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
1739598|NCT00101686|Drug|Oral Capecitabine with Irinotecan|Day 1: Irinotecan (250 mg/m2 IV) over 90 minutes; Day 1-14: capecitabine 1000 mg/m2 PO BID [two times a day] (28 single doses). All chemotherapy cycles repeated every 3 weeks. Celecoxib/placebo treatment will commence on the same day as chemotherapy treatment (i.e. Day 1 of treatment on study). Celecoxib/placebo will be taken at a dose of 400 mg po BID (800 mg/day) and will continue daily without interruption (no rest period for celecoxib/placebo treatment).
1739599|NCT00101712|Drug|vildagliptin|
1739600|NCT00101712|Drug|Vildagliptin Placebo|
1739601|NCT00101725|Drug|crofelemer|
1739602|NCT00101738|Drug|Myfortic|
1739603|NCT00101751|Drug|biphasic insulin aspart|
1739604|NCT00101751|Behavioral|dietary regimen|
1739605|NCT00101764|Drug|Triamcinolone Acetonide|
1739606|NCT00101790|Drug|pamidronate|There will be four study groups, each with 7 subjects randomly assigned to pamidronate and 4 to placebo. The groups will occur in succession, not parallel. The dosage for group 1 will be 30 mg , 60 mg for group 2, and 90 mg for group 3. Group 4 will receive 2 treatments of 90mg IV pamidronate or placebo.
1739607|NCT00101803|Drug|vildagliptin|
1739608|NCT00101816|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, Until disease progression or intolerable toxicity, switch to the roll-over study or study closure.
1739610|NCT00101842|Drug|Pemetrexed|
1739611|NCT00101842|Drug|Gemcitabine|
1739612|NCT00101842|Drug|Platinol|
1739613|NCT00101855|Procedure|An evidence based tailored web site|
1739614|NCT00101868|Device|Discharge communication software|Computerized physician order entry software used by discharging physician
1739615|NCT00101868|Other|Usual care discharge process|Handwritten
1739616|NCT00101881|Device|Defibrillation (biphasic versus monophasic shock)|Administration of monophasic or biphasic waveform defibrillation
1739617|NCT00101894|Drug|FOLFOX-4|"The FOLFOX-4 regimen will be administered every 2 weeks as follows:
Day 1: oxaliplatin (ELOXATIN™) 85 mg/m2 IV infusion and leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion given over 120 ± 10 minutes at the same time in separate bags using a Y-line, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed by 5-FU 600 mg/m2 IV infusion as a 22-hour ± 2 hours continuous infusion Day 2: leucovorin racemate 200 mg/m2 (or 100 mg/m2 l-LV) IV infusion over 120 ± 10 minutes, followed by 5-FU 400 mg/m2 IV bolus given over 2 to 4 minutes, followed"
1739618|NCT00101894|Drug|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively inhibiting all known VEGF receptors, PDGF receptor, and Kit.
1739619|NCT00101894|Biological|Panitumumab (Part 1a only)|Panitumumab will be administered by IV infusion at a dose of 6 mg/kg on day 1 of each 2-week cycle.
1739620|NCT00101894|Drug|FOLFIRI|Irinotecan will be administered over 90 minutes ± 15 minutes on day 1 of each 2-week cycle. Leucovorin will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing, immediately followed by a 5-FU bolus and a 5-FU 46-hour ± 2-hour continuous intravenous infusion.
1739621|NCT00101907|Drug|AMG 706|AMG 706 will be provided as 25-mg and 100-mg tablets and will be continuously self-administered orally once or twice daily based on cohort assignment starting on day 1 of Cycle 1.
1739622|NCT00101907|Biological|Panitumumab|Panitumumab will be administered by intravenous (IV) infusion at a dose of 9 mg/kg on Day 1 of each 3-week cycle.
1739623|NCT00101907|Drug|Gemcitabine|Gemcitabine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle at a dose of 1250 mg/m^2.
1739624|NCT00101907|Drug|Cisplatin|Cisplatin will be administered intravenously on Day 1 of each 3-week cycle at a dose of 75 mg/m^2.
1739625|NCT00101920|Drug|ABX-EGF|2.5 mg/kg by an infusion pump over one hour
1739626|NCT00101933|Device|Medtronic DBS Therapy for epilepsy|Stimulation On
1739627|NCT00101933|Device|Medtronic DBS Therapy for epilepsy|Stimulation Off
1739629|NCT00101959|Drug|Rebif|
1739630|NCT00101972|Biological|monoclonal antibody RAV12|Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks
1739631|NCT00101985|Drug|talnetant|
1739632|NCT00101998|Drug|alvimopan|
1739633|NCT00101998|Drug|placebo|
1739634|NCT00102011|Procedure|annual screening|Participants with negative baseline FOBT undergo FOBT annually for up to 4 years in the absence of a positive FOBT
1739635|NCT00102011|Procedure|fecal occult blood test|Participants undergo a baseline fecal occult blood test (FOBT)
1739637|NCT00102011|Procedure|standard follow-up care|Standard care
1739638|NCT00102024|Drug|Unconjugated IDEC-159|
1739639|NCT00102024|Drug|111In-IDEC-159|
1739640|NCT00102024|Drug|90Y-IDEC-159|
1739641|NCT00102037|Drug|eptacog alfa (activated)|
1739642|NCT00102050|Drug|NM-702 (phosphodiesterase inhibitor)|
1739643|NCT00102063|Drug|Aripiprazole tablet, 10 mg|Aripiprazole tablet 10 mg po qd x 42 days
1739644|NCT00102063|Drug|Aripiprazole tablet, 30 mg|Aripiprazole tablet 30 mg po qd x 42 days
1739645|NCT00102063|Drug|Placebo tablet|Placebo tablet po qd x 42 days
1739646|NCT00102089|Biological|VRC-HIVADV014-00-VP booster|
1739647|NCT00102089|Drug|VRC-HIVADV014-00-VP|
1739648|NCT00102102|Drug|[18F]SPA-RQ|
1739649|NCT00102115|Drug|Talaporfin Sodium (LS11) Photodynamic Therapy (PDT)|
1739650|NCT00102128|Drug|Cellular Therapy (Cultured Autologous Skeletal Myoblast Transplantation)|
1739651|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 3 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
1739652|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 2 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
1739653|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Drospirenone 1 mg + 1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
1739654|NCT00102141|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|1mg 17ß-estradiol, given as tablets orally once daily in the morning for 8 weeks
1739655|NCT00102141|Drug|Placebo|Placebo, given as tablets orally once daily in the morning for 8 weeks
1739656|NCT00102154|Drug|MK0928, gaboxadol / Duration of Treatment: 10 months|
1739657|NCT00102167|Drug|gaboxadol|Duration of Treatment -1 day
1739658|NCT00102193|Device|Adacolumn Apheresis System|
1739659|NCT00102206|Drug|Abacavir sulfate|
1739660|NCT00102206|Drug|Emtricitabine|
1739661|NCT00102206|Drug|Lamivudine|
1739662|NCT00102206|Drug|Lopinavir/ritonavir|
1739663|NCT00102206|Drug|Saquinavir|
1739664|NCT00102206|Drug|Tenofovir disoproxil fumarate|
1739665|NCT00102206|Drug|Zidovudine|
1739666|NCT00102219|Drug|Pemetrexed|
1739667|NCT00102219|Drug|Doxorubicin|
1739668|NCT00102232|Procedure|supplementation with phosphatidylcholine|
1739669|NCT00102258|Drug|Growth Hormone Therapy|
1739670|NCT00102271|Drug|Oxypurinol|
1739671|NCT00102271|Drug|Sodium Nitrite|
1739672|NCT00102284|Drug|levodopa|
1739673|NCT00102284|Drug|rivastigmine|
1739674|NCT00102284|Drug|pergolid|
1739675|NCT00102284|Drug|modafinil|
1739676|NCT00102297|Drug|FG-3019|
1739677|NCT00102310|Drug|YM443|
1739678|NCT00102323|Drug|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
1739679|NCT00102323|Biological|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
1739680|NCT00102336|Biological|AMG 531|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. AMG 531 is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
1739681|NCT00102336|Drug|Placebo|Weekly subcutaneous dosing based on screening weight and platelet count. Starting dose is at 1mcg/kg up to a maximum dose of 15mcg/kg. Placebo is supplied as a lyophilized power in a 5 mL single use glass vial.
1739682|NCT00102349|Behavioral|Behavior Therapy|
1739683|NCT00102362|Behavioral|Behavior Therapy|
1739684|NCT00102375|Drug|Topotecan|
1739685|NCT00102388|Drug|vildagliptin|
1739686|NCT00102388|Drug|Gliclazide|
1739687|NCT00102401|Behavioral|Internet-based Dyspnea Self-Management Program|
1739688|NCT00102401|Behavioral|Face-to-face Dyspnea Self-Management Program|
1739689|NCT00102414|Drug|Gemcitabine|
1739690|NCT00102427|Behavioral|Telephone-based collaborative care management|
1739691|NCT00102440|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 52 weeks.
1739692|NCT00102440|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 52 weeks.
1739693|NCT00102440|Drug|Allopurinol|Allopurinol 300 mg, capsules, orally, once daily for up to 52 weeks.
1739694|NCT00102453|Drug|Pentoxifylline|Pentoxifylline dosing: 20mg/Kg/day in a 20 mg/mL solution. Maximum dose of 1200mg/day. Dosing split into two equal parts taken morning and night with food.
1739695|NCT00102466|Drug|vildagliptin|
1739696|NCT00102466|Drug|Gliclazide|
1739697|NCT00102466|Drug|Metformin|
1739698|NCT00102479|Drug|Aripiprazole|
1739700|NCT00102505|Drug|Motexafin Gadolinium Injection|
1739701|NCT00102518|Drug|Aripiprazole|2 to 30 mg/day orally (2, 5, 10, 15, 20, 25, or 30 mg/day); tablets in strengths of 2, 5, 10, and 15 mg were used to achieve desired doses
1739702|NCT00102531|Drug|Cisplatin liposomal|
1739703|NCT00102557|Drug|Hydroxychloroquine|
1739704|NCT00102583|Drug|Subconjunctival Cyclosporine Implant|
1739705|NCT00102596|Drug|1-Octanol|1-Octanol is an long-chain alcohol with potential therapeutic benefits in treating alcohol-responsive tremors based on unknown mechanisms. The intervention consisted of either 1) 1-octanol adsorbed to microcrystalline cellulose, NF (Avicel PH 102, FMC Corp., Philadelphia, PA), and fine particle silica (Sipernat 50S, Evonik Degussa Corp., Parsippany, NJ) and encapsulated in 50 mg and 250 mg dosages; or 2) a soft-gel capsule containing 1-octanol embedded in soybean oil at 50 mg and 800 mg dosages (Best Formulations Inc, City of Industry, CA).
1739706|NCT00102609|Drug|Doxorubicin|Doxorubicin 50 to 75 mg/m2 administered intravenously on Day 1
1739707|NCT00102609|Drug|Trabectedin|Trabectedin 0.9 to 1.3 mg/m2 administered intravenously on Day 1 every 3 weeks for up to 6 cycles
1739708|NCT00102609|Drug|Dexamethasone|Dexamethasone 20 mg administered intravenously within 1 hour before the start of doxorubicin
1739709|NCT00102622|Biological|Intraperitoneal tgDCC-E1A|Starting Dose Level: 1.8 mg DNA/m^2 intraperitoneal every 7 days +/- 2 days for a total of 6 treatments each cycle.
1739710|NCT00102622|Drug|Paclitaxel|80 mg/m^2 intravenous (IV) every 7 days +/- 2 days for a total of 6 treatments.
1739711|NCT00102635|Drug|Fenretinide (4-HPR)|Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
1739712|NCT00102635|Drug|SCH66336|Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
1739713|NCT00102648|Drug|Sarasar|Starting dose 100 mg by mouth twice a day, with water, for 7 consecutive days (days 8 through 14 and days 22 through 28). Cycle is 28 days.
1739714|NCT00102648|Drug|Temodar|150 mg/m^2 by mouth once a day, after fasting one hour, for 7 consecutive days (days 1 through 7 and days 15 through 21). Cycle is 28 days.
1739715|NCT00102661|Drug|Campath-1H|15 mg daily infused over 24 hours, continuous infusion x 7 days (Days 1 through 7). Each 15 mg dose prepared daily, immediately prior to starting the infusion. Starting day 10, CAMPATH-1H administered at dose of 30 mg subcutaneously three times weekly for 11 additional weeks.
1739716|NCT00102674|Drug|cangrelor|
1739717|NCT00102687|Drug|azacitidine|"Azacitidine is administered subcutaneously
Total of 18 cycles on treatment or early discontinuation."
1739718|NCT00102700|Drug|ARQ 501 in combination with gemcitabine|
1739719|NCT00102713|Drug|Divalproex Sodium (Depakote Sprinkle Capsules)|
1739720|NCT00102726|Drug|SB497115|SB497115/Placebo will be administered for at least 2 cycles. Additional cycles are permited if: 1) chemotherapy is continued, 2) the subject appears to be benefitting from the study drug, and 3) the subject has not encountered greater than moderate toxicity with the study drug. The maximum number of cycles would be 8.
1739721|NCT00102726|Other|Placebo|Placebo administered orally daily on days 2 through 11 of each 21-day cycle.
1739722|NCT00102739|Drug|SB497115|
1739723|NCT00102752|Drug|Glufosfamide|
1739724|NCT00102752|Drug|Gemcitabine|
1739725|NCT00102765|Drug|fluticasone propionate/salmeterol powder|
1739726|NCT00102765|Drug|fluticasone propionate powder|
1739727|NCT00102778|Drug|GW873140|
1739728|NCT00102778|Drug|Kaletra (lopinavir/ritonavir)|
1739729|NCT00102791|Drug|ICA-17043|
1739730|NCT00102804|Drug|Pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV) administration, every (q) 21 days, until disease progression
1739731|NCT00102804|Drug|Placebo|IV administration, q 21 days
1739732|NCT00102804|Other|Best Supportive Care|Treatment without a specific antineoplastic regimen, given with the intent to maximize quality of life, as judged by the treating physician.
1739733|NCT00102817|Drug|somatropin|
1739734|NCT00102830|Drug|AMG 386|
1739735|NCT00102843|Procedure|supplementation with folic acid and betaine|
1739736|NCT00102856|Drug|Pramipexole|
1739737|NCT00102856|Drug|Rivastigmine|
1956493|NCT02831764|Drug|Tenofovir disoproxil fumarate/Emtricitabine (TDF/FTC FDC)|Tenofovir disoproxil fumarate and Emtricitabine are available as swedish orange, 'AA' sized elongated double blind HPMC capsules containing 300 mg TDF and 200 mg FTC to visually match overencapsulated 3TC tablet. The capsules are packaged into HDPE bottles with induction seals and child resistant closures. Each 150 mL bottle contains 30 capsules and a desiccant. Overencapsulated tenofovir disoproxil fumarate/emtricitabine tablet will be orally administered once daily with or without food upto 96 weeks. From Week 96 to Week 148, tenofovir disoproxil fumarate/emtricitabine will be dispensed as 300/200 mg white, blue, capsule shaped, film coated tablets debossed with 'GILEAD' on one side and '701' on another side, packed in overlabelled HDPE bottles with polypropylene childresistant closures each containing 30 tablets and a desiccant.
1739739|NCT00102882|Drug|fluticasone propionate/salmeterol|
1739740|NCT00102882|Drug|salmeterol xinafoate|
1739741|NCT00102895|Drug|CP-724,714|
1739744|NCT00102921|Drug|CCX282-B|
1739745|NCT00102934|Drug|Enfuvirtide-intensified HAART|90 mg tablet taken orally twice daily
1739746|NCT00102947|Drug|daptomycin (up to 14 days)|
1739754|NCT00102973|Drug|TLK286 in Combination with Carboplatin|Experimental Arm
1739755|NCT00102973|Drug|Doxorubicin HCl Liposome Injection|Active Comparator
1739756|NCT00102986|Drug|Lopinavir/ritonavir|
1739757|NCT00103012|Drug|Gingko Biloba|Ginkgo Biloba 120 mg twice daily for 14 days
1739758|NCT00103012|Drug|Echinacea purpurea|Echinacea purpurea 500 mg three times daily for 14 days
1739759|NCT00103012|Drug|Panax ginseng|Panax ginseng 500 mg twice daily
1739760|NCT00103025|Drug|Sodium Nitrite|
1739761|NCT00103025|Drug|Sodium Nitrite Injection|
1739762|NCT00103038|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
1739763|NCT00103038|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DCE-MRI
1739764|NCT00103038|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo 3T DSC-MRI
1739765|NCT00103038|Drug|Ferumoxytol|Given IV
1739766|NCT00103038|Drug|Gadolinium|Given IV
1739767|NCT00103038|Procedure|MRI-Based Angiogram|Undergo MRA
1739768|NCT00103051|Drug|cisplatin|
1739769|NCT00103051|Drug|gefitinib|
1739770|NCT00103051|Drug|gemcitabine hydrochloride|
1739771|NCT00103051|Procedure|conventional surgery|
1739772|NCT00103051|Procedure|neoadjuvant therapy|
1739773|NCT00103090|Drug|Fenretinide|Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
1739774|NCT00103090|Drug|Lonafarnib|Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
1739775|NCT00103103|Drug|bortezomib|
1739776|NCT00103103|Drug|fluorouracil|
1739777|NCT00103103|Drug|leucovorin calcium|
1739778|NCT00103116|Biological|autologous dendritic cell cancer vaccine|"Dendritic cells made from white blood cells obtained through out-patient leukapheresis procedure.
Vaccine given by injection under the skin in the front, upper thigh. Two vaccine injections total, given one month a part."
1739779|NCT00103142|Biological|falimarev|Given subcutaneously and intradermally
1739780|NCT00103142|Biological|inalimarev|Given subcutaneously and intradermally
1739781|NCT00103142|Biological|sargramostim|Given subcutaneously
1739782|NCT00103142|Biological|therapeutic autologous dendritic cells|Given subcutaneously and intradermally
1739783|NCT00103155|Procedure|conventional surgery|
1739784|NCT00103155|Procedure|radiofrequency ablation|
1739785|NCT00103168|Drug|imatinib mesylate|
1739786|NCT00103168|Procedure|adjuvant therapy|
1739787|NCT00103181|Radiation|3-dimensional conformal accelerated partial breast irradiation|
1739788|NCT00103181|Radiation|brachytherapy|
1739789|NCT00103181|Radiation|whole breast irradiation|Patients undergo radiation therapy once daily (days 1-5) for up to 7 weeks
1739790|NCT00103181|Radiation|MammoSite or other single-entry intracavitary device|
1739791|NCT00103194|Drug|lapatinib ditosylate|Given PO
1739792|NCT00103194|Other|laboratory biomarker analysis|Correlative studies
1739793|NCT00091559|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment 6 Months|
1739794|NCT00091572|Drug|Temozolomide|"oral capsule; 150 mg/m2/day PO (by mouth), on 7 consecutive days every 14 days (7 days on / 7 days off continuously); one cycle of temozolomide is defined as a 6-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop."
1739795|NCT00091572|Drug|Dacarbazine|intravenous solution; dacarbazine 1000 mg/m2 IV (in the vein), on Day 1 +/- 3 days every 3 weeks; one cycle of dacarbazine is defined as a 3-week period; treatment will continue until progression of the disease, unacceptable toxicity, subject refusal, or opinion of the treating physician that it is in the subject's best interest to stop.
1739796|NCT00091585|Drug|SNS-595|
1739797|NCT00091598|Drug|Ambrisentan|
1739798|NCT00091611|Drug|IL-2 (interleukin-2)|
1739799|NCT00091611|Drug|OKT3|
1739800|NCT00091611|Drug|Cyclophosphamide|
1739801|NCT00091611|Drug|Fludarabine|
1739802|NCT00091611|Drug|Mesna|
1739803|NCT00091624|Drug|CC-5013|
1739804|NCT00091637|Drug|Pexelizumab|Pexelizumab (2 mg/kg) intravenous , bolus for 10 minutes once
1739805|NCT00091637|Drug|Placebo infusion|bolus infusion over a 10 minute period once
1739806|NCT00091650|Drug|Olanzapine|
1739807|NCT00091650|Drug|placebo|
1739808|NCT00091663|Drug|Tarceva (erlotinib HCl)|
1739809|NCT00091676|Biological|FNHLId1|5 monthly vaccinations over a 6 month time period consisting of 0.5 mg ID-KLH s.c. on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
1739810|NCT00091676|Biological|KLH + GM-CSF|5 monthly vaccinations at month 1, 2, 3, 4, and 6 consisting of 0.5 mg KLH s.c on day 1 and 100 mcg/m²/day GM-CSF s.c. on days 1-4
1739811|NCT00091689|Drug|852A|
1739812|NCT00091702|Biological|Cold-adapted live attenuated influenza vaccine (FluMist)|
1739813|NCT00091702|Biological|Inactivated influenza vaccine (IAIV)|
1739814|NCT00091715|Drug|bosentan|65 mg tablet twice a day for 4 weeks followed by 125 mg tablet twice a day until end of study
1739815|NCT00091715|Drug|placebo|placebo for 6 months followed by an open-label period
1739816|NCT00091728|Drug|Depo Medroxyprogesterone acetate|
1739817|NCT00091728|Drug|Combined oral contraceptives|
1739818|NCT00091741|Drug|Etanercept (Enbrel)|
1739819|NCT00091793|Drug|AMG 162|60 mg/mL denosumab given day 1, month 6, month 12 and month 18
1739820|NCT00091793|Drug|Placebo|Placebo given at day 1, month 6, month 12 and month 18
1739821|NCT00091806|Drug|panitumumab (ABX-EGF)|6 mg/kg once every 2 weeks
1739822|NCT00091806|Drug|Panitumumab|9 mg/kg once every 3 weeks
1739823|NCT00091819|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
1739824|NCT00091819|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 14 days.
1739825|NCT00091832|Biological|Denosumab|Denosumab administered by subcutaneous injection
1739826|NCT00091832|Drug|IV Bisphosphonates|Commercially available intravenous (IV) bisphosphonates administered per package insert, included pamidronate, ibandronic acid, and zoledronic acid
1739828|NCT00097422|Drug|OPT-80|
1739829|NCT00097435|Drug|Albuferon|
1739830|NCT00097435|Drug|Ribavirin|
1739831|NCT00103207|Biological|cetuximab|
1739832|NCT00103220|Drug|SJG-136|Given IV
1739833|NCT00103233|Biological|trastuzumab|
1739834|NCT00103233|Drug|vinorelbine tartrate|
1739835|NCT00103246|Drug|silicon phthalocyanine 4|Patients receive topical silicon phthalocyanine 4 (Pc 4). One hour later, patients undergo photodynamic therapy. Treatment repeats weekly for up to 3 weeks (up to 3 total treatments for the same lesion OR up to 3 lesions treated if multiple lesions are present).Cohorts of 3 patients receive escalating doses of Pc 4 and visible light until the maximum tolerated dose (MTD) is determined.
1739836|NCT00103259|Drug|bortezomib|Given IV
1739837|NCT00103259|Drug|irinotecan hydrochloride|Given IV
1739838|NCT00103259|Other|laboratory biomarker analysis|Optional correlative studies
1739839|NCT00103272|Drug|tanespimycin|Given IV
1739840|NCT00103272|Drug|bortezomib|Given IV
1739852|NCT00103298|Drug|FOLFOX regimen|
1739853|NCT00103298|Drug|fluorouracil|
1739854|NCT00103298|Drug|isolated perfusion|
1739855|NCT00103298|Drug|leucovorin calcium|
1739856|NCT00103298|Drug|melphalan|
1739857|NCT00103298|Drug|oxaliplatin|
1739858|NCT00103311|Drug|ispinesib|Given IV
1739859|NCT00103311|Other|laboratory biomarker analysis|Correlative studies
1739860|NCT00103324|Drug|lapatinib ditosylate|Given orally
1739861|NCT00103324|Other|laboratory biomarker analysis|Correlative studies
1739862|NCT00103337|Drug|cilengitide|Given IV
1739863|NCT00103337|Other|laboratory biomarker analysis|Correlative studies
1739864|NCT00103350|Drug|TG100-115|
1739865|NCT00103363|Other|cytology specimen collection procedure|
1739866|NCT00103363|Other|physiologic testing|
1739867|NCT00103363|Procedure|annual screening|
1739868|NCT00103363|Procedure|study of high risk factors|
1739869|NCT00103376|Drug|bicalutamide|
1739870|NCT00103376|Drug|bortezomib|
1739871|NCT00103376|Drug|flutamide|
1739872|NCT00103376|Drug|goserelin acetate|
1739873|NCT00103376|Drug|leuprolide acetate|
1739874|NCT00103389|Drug|PI-88|PI-88+docetaxel
1739875|NCT00103389|Drug|docetaxel|docetaxel only
1739876|NCT00103402|Drug|Alfuzosin|
1739877|NCT00103415|Behavioral|Endurance training|
1739878|NCT00103415|Behavioral|Weight-lifting training|
1739879|NCT00103428|Biological|CG7870|
1739880|NCT00103454|Drug|GW685698X|
1739881|NCT00103467|Biological|rPA102 Vaccine|
1739882|NCT00103493|Behavioral|Motivational interviewing|
1739883|NCT00103493|Behavioral|Targeted DVD-based educational program|
1739884|NCT00103506|Drug|Bortezomib (VELCADE)|1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles.
1739885|NCT00103506|Drug|Bortezomib (VELCADE)|1.3 mg/m^2 by rapid (bolus) i.v. administration given on Days 1, 4, 8, and 11 of each 21-day cycle for up to 8 cycles..
1739886|NCT00103506|Drug|Doxorubicin hydrochloride (DOXIL/CAELYX)|mg/m^2 by i.v. infusion will be given on Day 4 of every 21-day cycle after the administration of bortezomib (VELCADE) for up to 8 cycles.
1739887|NCT00103519|Drug|DITPA (3,5-diiodothyropropionic acid)|
1739888|NCT00103519|Drug|Placebo|Placebo
1739889|NCT00103532|Behavioral|Healthy Choices - Motivational Enhancement Intervention|Participants who are randomized to the intervention group will participate in four sessions (over approximately 3 months) of Healthy Choices; a motivational enhancement intervention specifically designed to target multiple risk behaviors in HIV+ youth. Participants will receive individualized referrals at the fourth session.
1739890|NCT00103532|Behavioral|Standard care|Participants will receive standard care plus referrals at three months post-baseline
1739891|NCT00103545|Biological|ACA 125|
1739892|NCT00103558|Drug|Lumiliximab with FCR|Dose, schedule, and duration specified in protocol
1739895|NCT00105534|Drug|AzaSite|"1.0% AzaSite contains 1.0% azithromycin, sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. AzaSite was prescribed as a single topical drop to the infected
eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days."
1739896|NCT00105534|Other|Vehicle|Vehicle contains sodium hydroxide, mannitol, poloxamer 407, citric acid anhydrous, sodium citrate, DuraSite® (polycarbophil, sodium chloride, EDTA disodium and water for injection) and benzalkonium chloride 0.003%. Vehicle was prescribed as a single topical drop to the infected eye(s) for 5 days, twice on the first two days (once in the morning and at bedtime) and once a day in the morning (between 7-10 AM) for the following three days.
1739897|NCT00105547|Drug|MPC-7869|oral 800 mg BID
1739898|NCT00105547|Drug|MPC-7869|Oral BID dosing
1739900|NCT00105573|Behavioral|Maternal interpersonal psychotherapy (IP)|Participants will receive 16 weekly sessions of maternal IP designed to directly treat maternal depression.
1739901|NCT00105573|Behavioral|Infant-parent psychotherapy|Participants will receive 1 year of in-home, infant-parent psychotherapy, an intervention addressing relationship difficulties between depressed mothers and their infants.
1739902|NCT00105573|Behavioral|Informational meetings plus treatment as usual|Participants will be invited to attend informational meetings as well as be referred to local services available to people with depression.
1739903|NCT00105586|Drug|Escitalopram|Participants will either take 10 to 20 mg of escitalopram or placebo. Participants who wish to participate in the open-label extension receive an additional 12 weeks of escitalopram.
1739904|NCT00105599|Behavioral|End of life care coordination|
1739905|NCT00105599|Procedure|FairCare System|
1739906|NCT00105612|Device|Memory and Organizational Aid|
1739907|NCT00105612|Behavioral|Standard Informed Consent Process|The informed consent protocol for a hypothetical early-phase drug trial will be administered by a trained interviewer in the patient's home
1739908|NCT00105638|Behavioral|educational program, by telephone|
1739909|NCT00105651|Behavioral|Combined nursing invention|
1739910|NCT00105664|Procedure|Collaborative care model|
1739911|NCT00105664|Procedure|Group interventions|
1739912|NCT00105664|Procedure|Facilitated consultation|
1739913|NCT00105690|Behavioral|Telemedicine intervention|
1739914|NCT00105703|Behavioral|Case management using advanced nurse practitioners|
1739915|NCT00105716|Behavioral|Telephone behavioral education|
1739916|NCT00105716|Behavioral|Computer behavioral education|
1739917|NCT00105729|Behavioral|Intensive referral to 12-step self-help groups|
1739918|NCT00105742|Procedure|Diagnosis|
1739919|NCT00105755|Device|personal dermal thermometer (DT)|
1739920|NCT00105755|Device|Device|
1739921|NCT00105768|Behavioral|Advisor-Teller Money Management-Substance Abuse Counselling|
1739922|NCT00105781|Behavioral|Exercise counseling|
1739923|NCT00105794|Procedure|Psychiatric Advance Directives intervention|
1739924|NCT00105807|Behavioral|participation in low intensity exercise|
1739925|NCT00105807|Behavioral|participation in art and music activities|
1739926|NCT00105820|Procedure|System level depression care quality improvement|
1739927|NCT00105833|Behavioral|Collaborative Care - Depression Decision Support (DDS)|Multifaceted collaborative intervention for depression based in primary care
1739928|NCT00105846|Procedure|Home care telemedicine|
1739929|NCT00105859|Behavioral|Education and Counseling|
1739930|NCT00105872|Behavioral|Cognitive-Behavioral Therapy|
1739931|NCT00105885|Procedure|telephone care|Patients randomized to receive telephone care will be scheduled to see their provider at twice the recommended clinical visit interval, and two ten-minute telephone contacts will be scheduled at a specific time at standard 0.67 and 1.3 times the multiple of the recommended interval.
1739932|NCT00105898|Procedure|Web-based care management|Participants interact with a care manager, sending and receiving messages using an internet portal that accepts uploads from glucose and BP meters
1739933|NCT00105898|Procedure|Telephone and face-to-face care management|Participants interact with a care manager via face-to-face and telephone contact
1739934|NCT00105898|Procedure|Internet access alone|Participants are given internet access and encouraged to seek diabetes information to help in their self management
1739935|NCT00105911|Behavioral|Cognitive Behavioral Therapy|
1739936|NCT00105937|Drug|OraVescent fentanyl citrate|
1739938|NCT00105963|Behavioral|Education about infant crying|
1739939|NCT00105976|Drug|MM-093|
1739940|NCT00105989|Drug|Duloxetine|
1739941|NCT00105989|Drug|placebo|
1739942|NCT00106002|Drug|pemetrexed|600 mg/m2, intravenous (IV), every 14 days until complete response or disease progression
1739943|NCT00106028|Drug|risedronate sodium (Actonel)|risedronate tablet once a day for one year followed by risedronate once a day for two years
1739944|NCT00106028|Drug|Placebo|placebo tablet once a day for one year followed by risedronate once a day for two years
1739945|NCT00106041|Behavioral|Veterans Integrated Palliative Care Nurse Case Manager|Palliative Care nurse case management
1739946|NCT00106054|Drug|Combination therapy of irinotecan with 5-FU, leucovorin plus bevacizumab in the neoadjuvant setting.|
1739947|NCT00106067|Behavioral|coping and communication support (CCS) intervention|"Trained clinical nurse specialists with masters� degrees in mental health will serve as CCS practitioners and they will be available to patients and family caregivers on a 24/7 basis to assist with coping and communication challenges as they may arise.
The CCS intervention is tailored to individual preferences over time, and designed to accommodate different age groups, especially older adults and their families."
1739948|NCT00106080|Behavioral|Audit and Feedback|Intervention patients and clinicians received a one-page patient-specific individualized summary, based on questionnaire responses, to stimulate conversations.
1739949|NCT00106106|Procedure|NMR-spectroscopy|Scans were performed on a 3T scanner using the echo-time-averaged PRESS sequence previously published to detect glutamate's resonance line at 2.35 ppm and average out the interferences from glutamine, NAA and the macromolecules.
1739950|NCT00106106|Drug|Oral acamprosate|For subjects randomized to active treatment, the first 3 acamprosate doses were 1332 mg every 8 hours in an attempt to more rapidly achieve active plasma concentrations, followed by 666 mg acamprosate every 8 hours for the remainder of the study.
1739951|NCT00106119|Drug|Liothyronine and Levothyroxine|Hypothyroid patients are treated with Liothyronine and Levothyroxine in 2 crossover, randomized phases
1739952|NCT00106132|Drug|Triamcinolone Acetonide|
1739953|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor|Dose escalating beginning with rising dose levels of 300, 450, and 600 mg/day in a continuous dosing schedule.
1739954|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 450 mg|Dose 450 mg capsules daily for 28 day cycles.
1739955|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off|Dose escalating in a repeating intermittent dosing schedule of 3 days on and 4 days off at rising dose levels of 450, 600, 800, 1000, 1200, and 1400 mg/day.
1739956|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 1 day on, 6 off|Dose escalating in a repeating intermittent dosing schedule of 1 day on/6 days off at rising dose levels of 600, 900, 1200, 1500, 1800, 2400, 3200 mg/day once weekly and then increase at 33% increments.
1739957|NCT00106145|Drug|Comparator: MK0752, Notch Inhibitor - 3 days on, 4 off 350 mg|Dose 350 mg capsules daily intermittent 3 days on/4 days off dosing. THIS DOSING SCHEDULE IS NO LONGER UNDER INVESTIGATION
1739958|NCT00106158|Biological|protein vaccination|
1739959|NCT00106171|Drug|Highly active antiretroviral therapy (HAART)|Regimens will be assigned by investigators
1739960|NCT00106184|Drug|Rituximab|Treatment Group A - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum dose of 1 gram at Weeks 0 and 1 Group B - intravenous rituximab 750mg/m2 BSA (Body Surface Area) up to a maximum does of 1 gram at Weeks 8 and 9
1739961|NCT00106184|Drug|Placebo|"Treatment Group A: placebo infusion at Weeks 8 and 9
Treatment Group B: placebo infusion at Weeks 0 and 1"
1739962|NCT00106197|Drug|Bupropion|Participants will start with 150 mg daily. If no adverse symptoms, dosage will be increased to twice daily. Treatment will last for 8 weeks.
1739963|NCT00106210|Behavioral|Early intervention blending several tx approaches, w/ focus|Early intervention blending several different treatment approaches, with a focus on certain skills
1739964|NCT00106210|Behavioral|Early intervention blending several treatment approaches|Early intervention blending several different treatment approaches
1739965|NCT00106223|Behavioral|Cognitive behavioral therapy (CBT)|Participants will receive a total of 22 sessions of individual, manual-based CBT. The CBT sessions will occur weekly during the course of the study. During the sessions, participants will receive education about BDD and CBT, engage in activities that help them confront their BDD, learn new ways of thinking about body image, and learn relapse prevention techniques.
1739966|NCT00106236|Behavioral|exercise|
1739967|NCT00106249|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Stimulus train of 30 min duration, 1Hz frequency, and 110% of the motor threshold intensity given once a day, 5 days a week, for 4 weeks by Magstim SuperRapid Magnetic Stimulator.
1739968|NCT00106249|Device|Sham|Sham rTMS will be administered using the Magstim Sham coil which contains a mu-metal shield that diverts the majority of the magnetic flux such that a minimal (less than 3%) magnetic field is delivered to the cortex in order to provoke a subjective sensation similar to that obtained with the real stimulation but without inducing significant cortical stimulation.
1739969|NCT00106262|Drug|Velcade (bortezomib)|
1739970|NCT00106262|Drug|Irinotecan|
1739971|NCT00106275|Behavioral|Mindfulness Based Stress Reduction|
1739972|NCT00106288|Drug|Micafungin|IV
1739973|NCT00106288|Drug|Liposomal Amphotericin B|IV
1739974|NCT00106301|Drug|FK228 (romidepsin)|Patients were continued at the same dose of romidepsin as in the previous study, which could have been 13 mg/m2 or a reduced dose of 10 mg/m2, administered intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
1739975|NCT00106314|Drug|Dehydroepiandrosterone [DHEA]|
1739976|NCT00106327|Behavioral|Exercise|6 months of supervised treadmill exercise or strength training, three times per week, followed by a 6 month home-based program.
1739977|NCT00106327|Behavioral|Diet|11 nutrition education sessions
1739978|NCT00106340|Drug|vildagliptin|
1739979|NCT00106340|Drug|glimepiride|
1739980|NCT00106340|Drug|Metformin|
1739981|NCT00106340|Drug|Vildagliptin matching placebo|
1739982|NCT00106340|Drug|Glimepiride matching placebo|
1739983|NCT00106353|Drug|Torisel|60-minute intravenous (IV) infusion once weekly to pediatric subjects with advanced solid tumors. Part 1 is an ascending-dose study to evaluate the safety of IV temsirolimus given once weekly to subjects ages 1 to 21 years with advanced solid tumors disease that is recurrent or refractory to standard therapy or for whom standard therapy is not available. (enrollment completed) Part 2 will be conducted in three groups of children with refractory or relapsed pediatric solid tumors. Subjects with the following tumor types will be enrolled: neuroblastoma, rhabdomyosarcoma, and high-grade gliomas. Subjects will receive IV temsirolimus once weekly until disease progression or unacceptable toxicity.
1739984|NCT00106366|Drug|insulin detemir|
1739985|NCT00106366|Drug|insulin glargine|
1739986|NCT00106366|Drug|insulin aspart|
1739987|NCT00106379|Drug|Truvada (tenofovir DF + emtricitabine)|
1739988|NCT00106379|Drug|Emtriva (emtricitabine)|
1739989|NCT00106379|Drug|Viread (tenofovir DF)|
1739990|NCT00106392|Drug|Tacrolimus|oral
1739991|NCT00106392|Drug|Placebo|oral
1739992|NCT00106405|Drug|Memantine HCl|
1739993|NCT00106418|Drug|Romidepsin|13 mg/m2 of romidepsin intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
1739994|NCT00106431|Drug|romidepsin (depsipeptide, FK228)|Study patients received romidepsin at a dose of 14 mg/m^2 intravenously over 4 hours on Days 1, 8 and 15 of each 28-day cycle. The duration of study treatment was 6 cycles although patients who showed an objective response or stable disease could continue to receive therapy, at the discretion of the investigator, until disease progression or another withdrawal criterion was met.
1739995|NCT00106496|Drug|Protopic|topical
1739996|NCT00106496|Drug|Corticosteroid|topical
1739997|NCT00106496|Drug|placebo|topical
1739998|NCT00106509|Drug|tolevamer potassium-sodium (GT267-004)|
1739999|NCT00106522|Drug|Methotrexate|10-25mg weekly
1740000|NCT00106522|Drug|Placebo|iv every 4 weeks
1740001|NCT00106522|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
1740002|NCT00106522|Drug|tocilizumab [RoActemra/Actemra]|4mg/kg iv every 4 weeks
1740003|NCT00106535|Drug|tocilizumab [RoActemra/Actemra]|4 mg/kg or 8 mg/kg IV/month every 4 weeks.
1740004|NCT00106535|Drug|Placebo|IV/month
1740005|NCT00106535|Drug|Methotrexate|10-25 mg/week
1740006|NCT00106548|Drug|tocilizumab [RoActemra/Actemra]|4mg/kg iv / month
1740007|NCT00106548|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv / month
1740008|NCT00106548|Drug|Placebo|iv / month
1740009|NCT00106548|Drug|Methotrexate|10-25mg/week
1740010|NCT00106561|Drug|Spironolactone|
1740011|NCT00106561|Drug|Irbesartan|
1740012|NCT00106574|Drug|Placebo|iv every 4 weeks
1740013|NCT00106574|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
1740014|NCT00106587|Device|paclitaxel coated balloon catheter (device with drug)|
1740015|NCT00106600|Drug|Pixantrone IV infusion|
1740016|NCT00106613|Drug|FK228 (romidepsin)|Patients receive 13 mg/m2 of romidepsin (FK228) intravenously over 4 hours on Days 1, 8, and 15 of each 28-day cycle.
1740017|NCT00106626|Drug|vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) in combination with Pemetrexed and Cisplatin|Dose escalation study starting with vorinostat (Suberoylanilide Hydroxamic Acid [SAHA]) capsules 200 mg b.i.d. in combination with Pemetrexed and Cisplatin (see table for Reporting Groups).
1740018|NCT00106639|Drug|CP-690,550|15 mg twice daily
1740019|NCT00106639|Drug|CP-690,550|30 mg twice daily
1740020|NCT00106639|Drug|tacrolimus|dose adjusted according to level
1740023|NCT00106704|Drug|Comparator: Sitagliptin|sitagliptin 10 mg tablet, once daily for 54 weeks
1740024|NCT00106704|Drug|Comparator: Placebo|Placebo oral tablet once daily for 24 weeks
1740025|NCT00106704|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg tablet once daily for 30 weeks
1740026|NCT00106717|Procedure|Narrative medicine|
1740027|NCT00106769|Drug|VRC-WNVDNA017-00-VP|
1740028|NCT00106782|Procedure|Transcranial Electrical Polarization (TEP)|
1740029|NCT00106808|Drug|Muraglitazar|
1740030|NCT00106808|Drug|Pioglitazone|
1740031|NCT00106821|Drug|Tiotropium Bromide Inhalation Powder|
1740032|NCT00106834|Drug|Infliximab|
1740033|NCT00106847|Drug|Infliximab|
1740034|NCT00106860|Drug|a benzodiazepine drug|
1740035|NCT00106886|Drug|Folic acid, vitamin B6 and B12 or placebo|
1740036|NCT00106899|Procedure|Magnetic Resonance Imaging (MRI)|MRI scans
1740037|NCT00106899|Procedure|Positron Emission Tomography (PET)|PET scans
1740038|NCT00106899|Procedure|Lumbar Puncture (LP)|collection of cerebrospinal fluid
1740039|NCT00106938|Device|Carotid artery stenting with filter (interventional)|Carotid artery stenting with filter (interventional)
1740040|NCT00106938|Procedure|Carotid artery endarterectomy (surgical)|Carotid artery endarterectomy (surgical)
1740041|NCT00106964|Biological|Engerix-B 20 mcg|A single dose of 1 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Weeks 4 and 24.
1740042|NCT00106964|Biological|Engerix-B 40 mcg|A single dose of 2 mL (20 mcg/mL) will be administered in the deltoid muscle at Entry, Week 4 and 24.
1740043|NCT00106964|Biological|Twinrix 720 EIA HAV Ag plus 20 mcg HBsAg|"Arm 3: 720 EIA HAV Ag, 20 mcg HBsAg/ml:
A single dose of 1 mL will be administered in the deltoid muscle."
1740044|NCT00107003|Drug|lapatinib ditosylate|
1740045|NCT00107003|Procedure|Adjuvant therapy|
1740046|NCT00107003|Procedure|Conventional surgery|
1740047|NCT00107003|Procedure|Neoadjuvant therapy|
1740048|NCT00107016|Drug|RAD001, Letrozole 2.5mg|
1740049|NCT00107016|Drug|Letrozole 2.5mg|
1740050|NCT00107042|Biological|Recombivax|Participants receive doses of Recombivax at weeks 0 and 24.
1740051|NCT00107042|Biological|Twinrix|Participants receive doses of Twinrix at weeks 0 and 24.
1740052|NCT00107055|Drug|REN-1654|
1740053|NCT00107068|Procedure|[A] Aerobic isokinetic cycling exercise|
1740054|NCT00107068|Procedure|[B] Progressive Resistance Training|
1740055|NCT00107068|Procedure|[A] + [B]|
1740056|NCT00107081|Drug|ciprofloxacin and amoxicillin|
1740057|NCT00107081|Procedure|Outpatient management|
1740058|NCT00107081|Drug|i.v. antibiotics|
1740059|NCT00107081|Procedure|inpatient management|
1740060|NCT00107094|Drug|Abraxane|
1740061|NCT00107107|Drug|pramlintide acetate|Syringe vial and Pen-cartridge
1740062|NCT00107120|Drug|Escitalopram|Escitalopram 10mg per day for three weeks, 10-20mg per day for up to the remaining 5 weeks
1740063|NCT00107120|Drug|Placebo|Placebo once daily for up to 8 weeks
1740064|NCT00107159|Biological|autologous dendritic cell-allogeneic melanoma tumor cell lysate vaccine|
1740065|NCT00107172|Procedure|surgery|
1740066|NCT00107172|Radiation|brachytherapy|
1740067|NCT00107185|Biological|therapeutic autologous dendritic cells|
1740068|NCT00107198|Drug|doxorubicin hydrochloride|Given IV
1740069|NCT00107198|Procedure|conventional surgery|Undergo surgery
1740070|NCT00107198|Drug|cyclophosphamide|Given IV
1740071|NCT00107198|Drug|prednisone|Given IV or PO
1740072|NCT00107198|Drug|vincristine sulfate|Given IV
1740073|NCT00107198|Radiation|radiation therapy|Undergo IFRT
1740074|NCT00107211|Biological|therapeutic autologous dendritic cells|
1740075|NCT00107211|Procedure|conventional surgery|
1740076|NCT00107211|Procedure|neoadjuvant therapy|
1740077|NCT00107237|Drug|AEE788|AEE788 was available in the form of a hard gelatin capsule of 50 mg or 100 mg strengths and packaged in bottles.
1740078|NCT00107237|Drug|everolimus|Everolimus was formulated as tablets of 2.5 mg and 5 mg strength and supplied in blister packs.
1740079|NCT00107250|Drug|capecitabine|1000 mg/m2 orally twice daily (total of 2000 mg/m2 per day) for the first 14 days of a 21 day cycle for a maximum of 6-8 cycles.
1740080|NCT00107250|Drug|carboplatin|AUC 6; IV; 30 minutes; Every 21 days for a maximum of 6-8 cycles
1740081|NCT00107250|Drug|cediranib maleate|Given daily; orally with approximately 240 ml of water whilst in an upright position
1740082|NCT00107250|Drug|paclitaxel|200mg/m2; IV; 3 hours; Every 21 days for a maximum of 6-8 cycles
1740083|NCT00107263|Drug|letrozole|
1740084|NCT00107263|Drug|zoledronic acid|
1740085|NCT00107276|Drug|capecitabine|
1740086|NCT00107276|Drug|cyclophosphamide|
1740087|NCT00107289|Radiation|iobenguane I 131|"Patients receive a single dose of iodine I 131 metaiodobenzylguanidine (^131I-MIBG) IV over 30 minutes to 4 hours on day 0. Patients undergo radiation dosimetry following the first dose of ^131I-MIBG to determine if a second dose can be safely administered. Some patients may receive a second dose of iodine I 131 metaiodobenzylguanidine (^131I-MIBG) 6-8 weeks after the first dose if response is achieved and patients do not experience major toxicity. After blood radioactivity has fallen below 1 μCi/mL, patients may undergo autologous stem cell transplantation.
After completion of study treatment, patients are followed at 4-6 weeks after ^131I-MIBG administration and then every 3 months for up to 1 year."
1740088|NCT00107315|Biological|bevacizumab|
1740089|NCT00107315|Drug|capecitabine|
1740090|NCT00107341|Drug|bortezomib|
1740091|NCT00107341|Drug|carboplatin|
1740092|NCT00107341|Drug|paclitaxel|
1740093|NCT00107354|Biological|aldesleukin|
1740094|NCT00107354|Biological|therapeutic allogeneic lymphocytes|
1740095|NCT00107354|Biological|therapeutic autologous lymphocytes|
1740096|NCT00107354|Drug|cytarabine|
1740097|NCT00107354|Drug|etoposide|
1740098|NCT00107354|Drug|mitoxantrone hydrochloride|
1740099|NCT00107354|Procedure|allogeneic bone marrow transplantation|
1740100|NCT00107354|Procedure|peripheral blood stem cell transplantation|
1740101|NCT00107367|Procedure|conventional surgery|
1740102|NCT00107367|Radiation|intraoperative radiation therapy|
1740103|NCT00107380|Biological|rituximab|
1740104|NCT00107380|Drug|cyclophosphamide|
1740105|NCT00107380|Drug|doxorubicin hydrochloride|
1740106|NCT00107380|Drug|prednisone|
1740107|NCT00107380|Drug|vincristine sulfate|
1740108|NCT00107380|Radiation|tositumomab and iodine I 131 tositumomab|
1740109|NCT00107393|Biological|trastuzumab|
1740110|NCT00107393|Drug|capecitabine|
1740111|NCT00107419|Drug|pemetrexed disodium|pemetrexed, 500 mg/m2, IV, every 21 days until two cycles after complete response or until progression
1740112|NCT00107432|Drug|sorafenib tosylate|Given orally
1740113|NCT00107432|Other|laboratory biomarker analysis|Correlative studies
1740116|NCT00107471|Biological|filgrastim|Given PO
1740117|NCT00107471|Drug|topotecan hydrochloride|Given IV
1740118|NCT00107471|Radiation|radiation therapy|
1740119|NCT00107484|Drug|ferumoxtran-10|
1740120|NCT00107484|Procedure|magnetic resonance imaging|
1740121|NCT00107484|Procedure|sentinel lymph node biopsy|
1740122|NCT00107497|Procedure|adjuvant therapy|
1740123|NCT00107497|Radiation|radiation therapy|
1740124|NCT00107510|Biological|pegfilgrastim|
1740125|NCT00107510|Drug|carboplatin|
1740126|NCT00107510|Drug|docetaxel|
1740127|NCT00107510|Procedure|conventional surgery|
1740128|NCT00107523|Drug|cytarabine|
1740129|NCT00107523|Drug|idarubicin|
1740130|NCT00107523|Drug|pravastatin|
1740131|NCT00107536|Drug|lapatinib ditosylate|
1740132|NCT00107536|Other|laboratory biomarker analysis|Correlative studies
1740133|NCT00107549|Biological|rMVA-HIV (env/gag [TBC-M358] + tat/rev/nef-RT [TBC-M335)])|Recombinant experimental therapeutic vaccine using the modified vaccinia Ankara vector given at study entry and Week 4
1740134|NCT00107549|Biological|rFPV-HIV (env/gag [TBC-F357] + tat/rev/nef-RT [TBC-F349])|Recombinant experimental therapeutic vaccine using fowlpox vector given at Weeks 8 and 24
1740135|NCT00107562|Behavioral|Adolescent Safer Sex Social Network Intervention|
1740136|NCT00107575|Behavioral|Standard treatment plus brief alcohol intervention|Standard smoking cessation treatment with nicotine patch plus a brief alcohol-focused intervention
1740137|NCT00107575|Other|Standard treatment (ST)|Behavioral smoking cessation counseling and nicotine patch.
1740138|NCT00107588|Behavioral|Reinforcement for homework completion|Provides contingent reinforcement for engaging in homework activities designed to enhance coping skills
1740139|NCT00107588|Behavioral|Reinforcement for Abstinence|Provides contingent reinforcement for submitting marijuana-free urine specimen
1740140|NCT00107588|Behavioral|Case Management|Will control for the effect of therapist-client contact by providing supportive case management as an active control condition.
1740141|NCT00107601|Drug|Insulin|
1740142|NCT00107614|Drug|DT PACE + Rituxan|INDUCTION PHASE DT PACE + Rituxan DT PACE + Rituxan + PBSC Collection Response Assessment TRANSPLANT PHASE Transplant 1 (MEL 200 (patients with < 50% response to induction) OR MEL-DT PACE (Patients with > 50% response to Induction) Transplant 2 (identical to the first, except patients with progressive or proliferative disease, will receive BEAM) MAINTENANCE PHASE Rituxan every 3 months x 1 year
1740143|NCT00107627|Other|Caprosyn subcuticular sutures.|Caprosyn subcuticular sutures.
1740144|NCT00107627|Other|Monocryl subcuticular sutures.|Monocryl subcuticular sutures.
1740145|NCT00107627|Other|Skin staples;|Skin staples;
1740146|NCT00107640|Behavioral|Patient-provider education|Experimental patients received an intervention consisting of the following components: written reports and educational materials, a telephone health educator intervention (at baseline, 3 and 6 months), and a brief provider intervention.
1740147|NCT00107653|Drug|Ribavirin|1000-1200mg po daily for 48 weeks
1740148|NCT00107653|Drug|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
1740149|NCT00107653|Drug|Ribavirin|1000-1200mg po daily for 48 weeks
1740150|NCT00107653|Drug|Peginterferon alfa-2a|180 micrograms sc/week for 48 weeks
1740151|NCT00107666|Drug|CTI-01 (ethyl pyruvate)|
1740152|NCT00107692|Behavioral|Physical activity and diet|
1740153|NCT00107705|Biological|Tree MATA MPL|
1740155|NCT00107731|Drug|quetiapine fumarate|
1740156|NCT00107731|Drug|lithium|
1740157|NCT00107731|Drug|divalproex|
1740159|NCT00107757|Drug|GW685698X|
1740160|NCT00107770|Drug|sodium phenylbutyrate|histone deacteylase inhibitor
1740161|NCT00107783|Drug|Nitisinone (NTBC)|Treatment
1740162|NCT00107796|Drug|Modafinil|
1740163|NCT00107809|Drug|Modafinil|
1740164|NCT00107822|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
1740165|NCT00107835|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine was applied topically. The study drug remained on the treatment area for 20-30 minutes for minor dermal procedures and 60 minutes for major dermal procedures
1740166|NCT00107848|Drug|Modafinil|
1740167|NCT00107861|Drug|Ad.hIFN-β (BG00001, IDEC-201)|
1740168|NCT00107874|Drug|misoprostol|
1740169|NCT00107887|Drug|INH preventive therapy|Clinics will receive training regarding the use of IPT for prevention of Tuberculosis
1740170|NCT00107887|Drug|TST (tuberculin skin test)|Clinics will be trained in the use of TST for assessing exposure to TB
1740171|NCT00107900|Drug|DU-176b|
1740172|NCT00107913|Drug|Doxil|
1740173|NCT00107926|Drug|Licarbazepine|
1740174|NCT00107926|Drug|Placebo|
1740175|NCT00107939|Drug|Licarbazepine|
1740176|NCT00107952|Drug|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days.
1740177|NCT00107952|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs for up to 21 days
1740178|NCT00107965|Drug|PEP005|0.0025% PEP005 Topical Gel (Day 1,2 application)
1740179|NCT00107965|Drug|PEP005|0.01% PEP005 Topical Gel (Day 1,2 application)
1740180|NCT00107965|Drug|PEP005|0.05% PEP005 Topical Gel (Day 1,2 application)
1740181|NCT00107965|Drug|PEP005|Vehicle Gel (Day 1,2 application)
1740182|NCT00107965|Drug|PEP005|0.0025% PEP005 Topical Gel (Day 1,8 application)
1740183|NCT00107965|Drug|PEP005|0.01% PEP005 Topical Gel (Day 1,8 application)
1740184|NCT00107965|Drug|PEP005|0.05% PEP005 Topical Gel (Day 1,8 application)
1740185|NCT00107965|Drug|PEP005|Vehicle Gel (Day 1,8 application)
1740186|NCT00107978|Drug|Telavancin|Telavancin 10 mg/kg/day, IV for up to 14 days.
1740187|NCT00107978|Drug|Vancomycin|Vancomycin 1 Gm IV administered every 12 hrs for up to 14 days.
1740188|NCT00107991|Drug|etanercept|etanercept 50 mg/week subcutaneous injection
1740263|NCT00108381|Behavioral|tailored cognitive behavior therapy|tailored psychological treatment
1740189|NCT00108004|Drug|pramlintide acetate|Pramlintide (0.6 mg/mL) in 5.0-mL multiple-draw glass vials for SC injection for 12weekes and after Pramlintide (1.0 mg/mL) 1.5 mL pen-cartridge. Subjects who do not switch to the pen-cartridge device at Week 12 will continue to administer pramlintide using a syringe and vial.
1740190|NCT00108017|Drug|MK0507A, dorzolamide hydrochloride (+) timolol maleate|
1740191|NCT00108017|Drug|Comparator: timolol maleate|
1740192|NCT00108017|Drug|Duration of Treatment: Part 1) 6 wk timolol maleate run in|
1740193|NCT00108017|Drug|Part 2) 6 wk washout pd Part 3) two 8 wk active tx pds|
1740194|NCT00108030|Procedure|Partial Body-weight supported Treadmill Training|
1740195|NCT00108030|Procedure|PBWST + Power training|
1740196|NCT00108030|Procedure|"Usual physiotherapy care"|
1740197|NCT00108043|Procedure|FES-evoked functional upright gait|
1740198|NCT00108056|Drug|Enzastaurin (LY317615) monohydronchloride|
1740199|NCT00108069|Drug|Tamoxifen citrate|oral dose 120 mg twice a day, every day
1740200|NCT00108069|Drug|Bortezomib|intravenous (IV) injection 1.3 mg/m^2 days 3, 6, 10, 13, 24, 27,31,34 on every 6 week cycle
1740201|NCT00108082|Drug|carvedilol MR|Study drug
1740202|NCT00108082|Drug|atenolol|Comparator
1740203|NCT00108082|Drug|lisinopril|Comparator
1740204|NCT00108095|Drug|intravenous ondansetron|
1740205|NCT00108108|Drug|HCD122|
1740206|NCT00100451|Procedure|exercise|
1740207|NCT00100464|Drug|Paroxetine|
1740208|NCT00100464|Drug|5HTP|
1740209|NCT00100477|Drug|Topotecan|
1740210|NCT00100477|Drug|Mitozantrone|
1740211|NCT00100477|Drug|Etoposide|
1740212|NCT00100542|Behavioral|Psychiatric interviews|Measures and questionnaires regarding mental health, pain, and adherence to treatment. No actual treatment or intervention is given as part of this study.
1740213|NCT00100555|Drug|zoledronic acid|
1740214|NCT00100568|Drug|Efavirenz|600 mg tablet taken orally daily
1740215|NCT00100568|Drug|Lamivudine/zidovudine|150mg lamivudine/300mg zidovudine tablet taken orally twice daily
1740216|NCT00100581|Drug|Efavirenz|
1740217|NCT00100581|Drug|Lamivudine|
1740218|NCT00100581|Drug|Lopinavir/ritonavir|
1740219|NCT00100581|Drug|Pegylated interferon alfa-2a|
1740220|NCT00100581|Drug|Ribavirin|
1740221|NCT00100581|Drug|Tenofovir disoproxil fumarate|
1740222|NCT00100594|Drug|Efavirenz|
1740223|NCT00100594|Drug|Lamivudine/zidovudine|
1740224|NCT00100607|Drug|AAE581|
1740225|NCT00108121|Drug|PEP005|
1740226|NCT00108134|Drug|PEP005|
1740227|NCT00108147|Procedure|Circuit Training|
1740228|NCT00108147|Procedure|Cardiac Rehabilitation|
1740229|NCT00108147|Procedure|Flexibility and toning|
1740230|NCT00108160|Drug|Mupirocin Ointment [Treatment]|The impact of the treatment arm versus placebo arm on development of new (recurrent) S. aureus infection will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
1740231|NCT00108160|Drug|Polyethylene Glycol Ointment [Placebo]|The impact of the treatment arm versus placebo arm on development of S. aureus re-infections will be assessed as the primary end point. Change in S. aureus strains (MSSA versus MRSA) will be assessed as the secondary end point.
1740232|NCT00108173|Drug|Zyban|
1740233|NCT00108186|Drug|Celecoxib|Eight subjects will be assigned to one of three cohorts. Subjects will receive Celecoxib in escalating doses per cohort, starting with 200mg twice a day by mouth; 400mg twice a day by mouth; and increasing to 600mg twice a day by mouth, for a total of 7 days. Subjects will have blood taken before the start of Celecoxib, and after completion of 7-days of Celecoxib.
1740234|NCT00108199|Behavioral|Problem-Solving Training|
1740235|NCT00108199|Behavioral|Work-Related Social Skills Training|
1740236|NCT00108212|Behavioral|Diet|
1740237|NCT00108225|Other|LoBag Diet - test phase|A Low Biologically Available Glucose (LOBAG30), weight maintaining diet consisting of 30% carbohydrate, 30% protein, 40% fat will be provided to subjects for 5 weeks.
1740238|NCT00108225|Other|LoBAG Diet - control phase|A control, weight maintaining diet consisting of 55% carbohydrate, 15% protein, 30% fat will be provided to subjects for 5 weeks
1740239|NCT00108238|Drug|Estradiol followed by progesterone|
1740240|NCT00108238|Drug|Raloxifene|
1740241|NCT00108251|Drug|Eplerenone|aldosterone receptor blocker
1740242|NCT00108251|Drug|Placebo|matching placebo
1740243|NCT00108264|Biological|Tumor RNA transfected dendritic cells|
1740244|NCT00108277|Behavioral|Breathing Training-Raise CO2|while breathing 9 breaths per minute, patients are instructed to raise CO2
1740245|NCT00108277|Behavioral|Breathing Training- Lower CO2|while breathing 9 breaths per minute, patients are instructed to lower CO2
1740246|NCT00108290|Drug|Chemotherapy|
1740247|NCT00108303|Other|Diagnostic|Diagnostic evaluation for schizophrenia. Schizophrenia includes schizophrenia and schizoaffective disorder.
1740248|NCT00108316|Drug|Fluoxetine (Liquid Prozac)|
1740249|NCT00108329|Behavioral|Weight Loss|
1740250|NCT00108342|Drug|Nicotine gum - 2 mg and 4 mg|
1740251|NCT00108342|Drug|Nicotine lozenges - 2 mg and 4 mg|
1740252|NCT00108342|Drug|"Nicotine inhaler (4 mg yield) - low and high dosage by frequency of puffing"|can yield 4 mg from 10 mg device - infrequent and frequent puffing
1740253|NCT00108342|Other|Computer learning|
1740254|NCT00108355|Drug|Albumin|Intravenous Albumin at a dose of 8g/liter of ascitic fluid removed
1740255|NCT00108355|Drug|Intravenous Saline Infusion (Albumin placebo)|Intravenous saline Infusion (Albumin placebo)
1740256|NCT00108355|Drug|Midodrine|Midodrine oral tablet at 10 mg three times a day.
1740257|NCT00108355|Drug|Oral tablet (Midodrine placebo)|Oral tablet (Midodrine placebo) three times a day
1740258|NCT00108355|Drug|Octreotide LAR|Octreotide LAR 20 mg intramuscular injection every 30 days
1740259|NCT00108355|Drug|Saline injection (Octreotide LAR placebo)|Saline intramuscular injection 5 cc every 30 days.
1740260|NCT00108355|Procedure|Large Volume Paracentesis|Procedure to remove large amounts (more than 5 liter) of ascitic fluid via a catheter.
1740264|NCT00108381|Behavioral|standard care|standard psychological treatment
1740265|NCT00108394|Drug|pamidronate|
1740266|NCT00108407|Behavioral|Integrated Cognitive Behavioral Therapy|
1740267|NCT00108407|Behavioral|Twelve Step Facilitation Therapy|
1740268|NCT00108420|Drug|Prazosin|
1740269|NCT00108433|Drug|Cefazolin IV|
1740270|NCT00108433|Drug|Linezolid IV|
1740271|NCT00108433|Drug|Vancomycin (IV)|
1740272|NCT00108446|Drug|dextromethorphan|
1740273|NCT00108446|Drug|naloxone|
1740274|NCT00108446|Drug|fentanyl|
1740275|NCT00108446|Drug|lidocaine|
1740276|NCT00110825|Behavioral|Cognitive Behavior Therapy|extended treatment with cognitive behavior therapy
1740277|NCT00110838|Procedure|Supplementation with fish oil versus placebo|
1740278|NCT00110851|Drug|rosiglitazone|
1740279|NCT00110851|Drug|metformin|
1740280|NCT00110851|Drug|PN2034|
1740281|NCT00110864|Drug|PN2034|
1740282|NCT00110864|Drug|Insulin|
1740283|NCT00110877|Drug|LPV/rtv|One 400mg LPV tablet twice daily with 100mg RTV
1740284|NCT00110877|Drug|TMC114/rtv|Two 300mg TMC114 tablets twice daily with 100mg RTV
1740285|NCT00110890|Drug|cinacalcet|Treatment with cinacalcet will be initiated at a dose of 30 mg/day. Possible daily doses of cinacalcet are 30, 60, 90, 120, and 180 mg.
1740286|NCT00110890|Other|Standard of care|Subjects randomised to the standard care arm are to receive appropriate therapy in accordance with the investigator's practice in an attempt to achieve the K/DOQI PTH, serum calcium, phosphorus, and Ca x P treatment targets.
1740287|NCT00110903|Drug|Etanercept Liquid|
1740288|NCT00110916|Drug|Intra-articular metHuIL-1ra (anakinra)|anakinra
1740289|NCT00110916|Drug|placebo|placebo
1740290|NCT00110929|Drug|AMG 073|
1740291|NCT00110942|Drug|Systemic AMG 108|300 mg SC AMG 108 Q4W for 3 doses
1740292|NCT00110942|Other|Placebo|SC placebo injection Q4W for 3 doses
1740293|NCT00110955|Drug|Darbepoetin alfa|Q3W 300 mcg darbepoetin alfa
1740294|NCT00110955|Drug|Placebo|Q3W dosing of placebo
1740295|NCT00110968|Drug|Itopride hydrochloride|
1740296|NCT00110981|Device|NB-UVB|Three times a week (TIW) for 12 weeks
1740297|NCT00110981|Drug|Etanerept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
1740298|NCT00110981|Drug|Etanercept|50 mg subcutaneously twice weekly (SC BIW) for 12 weeks
1740299|NCT00110994|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg, 2 tablets (200 mg each) po (per os) bid (twice daily) Study days 1-21
1740300|NCT00110994|Drug|Placebo|Placebo, 2 tablets, po (per os) bid (twice daily) Study days 1-21
1740301|NCT00110994|Drug|Dacarbazine|Dacarbazine, 1000 mg/m^2 intravenous on Study Day 1
1740302|NCT00111007|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib, 400 mg po (per os), 2 tablets (200 mg each) bid Study Days 2-19
1740303|NCT00111007|Drug|Carboplatin/Paclitaxel|Paclitaxel (225 mg/m^2 iv) and Carboplatin (AUC 6 iv) on Study Day 1
1740304|NCT00111007|Drug|Placebo|Placebo, 2 tablets bid Study Days 2-19
1740305|NCT00111020|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor: 400 mg of Sorafenib, orally, twice a day, on a continuous basis as a single agent for the treatment of advanced RCC
1740306|NCT00111046|Drug|Ibuprofen|
1740307|NCT00111046|Drug|Tramadol|
1740308|NCT00111072|Drug|dexamethasone 0.01% solution|
1740310|NCT00111098|Drug|Darbepoetin Alfa|QM administration for 28 weeks, adjusted as necessary to maintain Hb between 11.0 - 13.0 g/dL PFS concentrations: 20, 30, 40, 50, 60, 80, 100, 150, 200 and 300 mcg.
1740311|NCT00111111|Drug|Etanercept|
1740312|NCT00111124|Drug|Enbrel®|
1740313|NCT00111137|Drug|rHuEPO|rHuEPO 40,000U QW for 4 weeks. Dose will be increased to 60,000U/week at week 5 if inadequate response through week 12.
1740314|NCT00111137|Drug|Darbepoetin alfa|4.5 mcg/kg QW for 4 weeks then Q3W starting at week 5 through week 11.
1740315|NCT00111150|Drug|Tenofovir Disoproxil Fumarate 300 mg daily|
1740316|NCT00111163|Drug|sulfadoxine-pyrimethamine with artesunate|
1740317|NCT00111163|Drug|amodiaquine with artesunate|
1740318|NCT00111163|Drug|chlorproguanil-dapsone|
1740319|NCT00111176|Device|Endovascular repair|Endovascular repair.
1740320|NCT00111176|Procedure|Surgical|Surgical endovascular repair
1740321|NCT00111189|Drug|Placebo|Placebo every 4 wk up to 24 mo
1740322|NCT00111189|Drug|Paliperidone Palmitate|25, 50, 75 or 100 mg eq every 4 wk for up to 24 mo
1740323|NCT00111215|Drug|Tranexamic Acid|
1740324|NCT00111215|Drug|Desmopressin Acetate|
1740325|NCT00111228|Device|Guardian RT|
1740327|NCT00111254|Procedure|Microdermabrasion|Treatment will consist of 3 passes in different directions (horizontal, vertical and oblique) with the microdermabrasion handpiece (Parisian Peel, Prestige model, medical microdermabrasion device).
1740328|NCT00111267|Behavioral|vitamin B12 supplementation|
1740329|NCT00111267|Behavioral|vitamin B12 + folic acid combined supplementation|
1740330|NCT00111280|Drug|TMC125|
1740331|NCT00111306|Drug|epratuzumab|
1740332|NCT00111319|Drug|bortezomib|
1740333|NCT00111332|Behavioral|Progressive resistance and aerobic training|
1740334|NCT00111345|Drug|Anthracyclines|3x12 mg/qm
1740335|NCT00111345|Drug|liposomal daunorubicin|3x80 mg/qm
1740336|NCT00111345|Drug|2-CDA|2x6 mg/qm
1740337|NCT00111345|Drug|AI|AI
1740338|NCT00111358|Behavioral|Lifestyle Modification|
1740339|NCT00111358|Other|No lifestyle modification|
1740340|NCT00111371|Drug|Levodopa|
1740341|NCT00111397|Procedure|Cytokine therapy|
1740342|NCT00111397|Drug|Interferon Gamma, GM-CSF|
1740343|NCT00111410|Drug|Anakinra (r-metHuIL-1ra)|
1740344|NCT00111423|Drug|Pegsunercept (PEG sTNF-RI)|
1740345|NCT00111436|Drug|Etanercept|Enbrel 50 mg once weekly or 50 mg twice weekly
1740346|NCT00111449|Drug|Etanercept|
1740347|NCT00111462|Drug|Darbepoetin alfa|
1740348|NCT00111475|Drug|AMG 531|
1740349|NCT00111488|Device|Flex 4 and Generator|
1740350|NCT00111501|Behavioral|Tobacco Use Disorder|Web-based psychoeducational intervention culturally-tailored to the LGBT community including a social support component
1740351|NCT00111501|Behavioral|Standard Web-based intervention|General psychoeducational Web-based smoking cessation intervention
1740352|NCT00111514|Biological|Leish-111f + MPL-SE vaccine|
1740353|NCT00111527|Other|Optimized echo-guided CRT pacing|Echo-TDI guided VV-delay optimization
1740354|NCT00111527|Other|normal RV pacing|PM or ICD implant according to patient indication
1740355|NCT00111540|Drug|exenatide|subcutaneous injection, 5 mcg, twice a day for 4 weeks (transition period), then 10 mcg twice a day till study termination
1740356|NCT00111553|Biological|Leish-111f + MPL-SE vaccine|
1740357|NCT00111566|Drug|eptifibatide|
1740358|NCT00111579|Biological|CAIV-T|A total vol. of 0.2 mL will be administered intranasally (approx. 0.1 mL into each nostril)for ea. of two doses.
1740359|NCT00111579|Other|TIV|A total vol. of 0.25 will be administered intramuscularly for each of two doeses.
1740360|NCT00111592|Procedure|current usual care|current usual care
1740361|NCT00111592|Procedure|treatment protocol with clear indications for therapy|treatment protocol with clear indications for therapy
1740362|NCT00111605|Biological|HIV-1 gag DNA|A 0.75 mL intramuscular injection of HIV gag DNA vaccine into the deltoid
1740363|NCT00111605|Biological|HIV-1 gag DNA plus IL-12 DNA adjuvant|Injection IL-12 DNA adjuvant intramuscularly into the deltoid
1740364|NCT00111605|Biological|CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)|A 1 mL intramuscular injection in the deltoid
1740365|NCT00111605|Biological|Sodium chloride injection (0.9%)|"All placebo groups will receive an intramuscular injection of sodium chloride (0.9%) in the deltoid.
Group 1 will receive a 0.75 mL injection on Days 0, 28, and 84. Group 2 will receive a 0.8 mL injection on Days 0, 28, and 84. Group 3 will receive a 1.0 mL injection on Days 0, 28, and 84. Group 4 will receive a 1.5 mL injection on Days 0, 28, and 84. Group 5 will receive a 0.75 mL injection on Days 0, 28, 84, 168, and 273. Group 6 will receive a 1.5 mL injection on Days 0, 28, 84, 168, and 273. Group 7 will receive a 1.5 mL injection on Days 0, 28, and 84 and a 1 mL injection into the deltoid on Days 168 and 273."
1740366|NCT00111618|Drug|AS1404 (DMXAA)|
1740367|NCT00111631|Drug|DPP-IV Inhibitor|Escalating doses po bid
1740368|NCT00111631|Drug|Metformin|As prescribed
1740369|NCT00111631|Drug|Placebo|po bid
1740370|NCT00111644|Drug|Ceftriaxone|1000mg iv daily
1740371|NCT00111644|Drug|beta-lactam|750mg iv q 23h for 3-14 days
1740372|NCT00111644|Drug|beta-lactam|1500mg iv q 12h for 3-14 days
1740373|NCT00111657|Biological|Pegloticase|8 mg of Pegloticase administered IV every 3 weeks; total number of infusions is 5
1740374|NCT00111670|Drug|DPP-IV Inhibitor|Escalating doses po bid or qd
1740375|NCT00111670|Drug|Placebo|po bid or qd
1740376|NCT00111683|Drug|MK0457|
1740377|NCT00111696|Biological|MEDI-522|Supplied at a concentration of 50 mg/mL in both 2 mL and 10mL vials
1740378|NCT00111709|Drug|MK0462, rizatriptan benzoate / Duration of Treatment -1 day|
1740379|NCT00111709|Drug|Comparator: placebo / Duration of Treatment - 1 day|
1740380|NCT00111722|Drug|MK0462, rizatriptan benzoate / Duration of Treatment -1day|
1740381|NCT00111722|Drug|Comparator: placebo / Duration of Treatment - 1 day|
1740382|NCT00111735|Drug|Thyroxine|
1740383|NCT00111748|Drug|Velcade, Thalidomide, Dexamethasone|"Dosage and Administration Schedule Each cycle will consist of 3 weeks (21 days). AGENT DOSE ROUTE DAYS Velcade 1.0 mg/m2 IV 1, 4, 8, and 11 Thalidomide 100 mg PO Daily, hs Dexamethasone 20 mg PO Days 1, 2, 4,5, 8, 9, 11, 12 Lovenox 40 mg SQ Days 1-14
This 21-day period will be considered one treatment cycle; Cycle 2 would commence on Day 22 (Cycle 2, Day 1). The next cycle of treatment may be delayed up to day 29 due to non-toxicity reasons. Patients may continue to receive treatment every 21 days, provided there is no evidence of disease progression or no unacceptable toxicity for a maximum of eight cycles. At the discretion of the treating physician, patients may be eligible to receive treatment at their local physician after completion of the 1st cycle. These patients will need to return to MIRT prior to every cycle for cycles 2-4, cycles 6 and 8, and final visit."
1740384|NCT00111761|Drug|Irinotecan|Part 1: 125 mg/m^2 IV infusion once a week on weeks 1 through 4 of each 6-week treatment cycle. Part 2: 180 mg/m^2 IV infusion every other week until disease progression or unable to tolerate.
1740385|NCT00111761|Biological|Panitumumab|Intravenous (IV) infusions of panitumumab 2.5 mg/kg once a week delivered in 6-week cycles.
1740386|NCT00111761|Drug|5-Fluorouracil|Part 1: IV bolus 500 mg/m^2 on weeks 1 through 4 of each 6-week cycle. Part 2: IV bolus 400 mg/m^2 and infusional 2400-3000 mg/m^2 over 46 hours once every other week until disease progression or unable to tolerate.
1740387|NCT00111761|Drug|Leucovorin|Part 1: IV bolus 20 mg/m^2 on weeks 1 through 4 of each 6-week cycle. Part 2: 400 mg/m^2 every other week until disease progression or unable to tolerate.
1740388|NCT00111774|Drug|ABX-EGF|
1740392|NCT00111813|Drug|vorinostat|Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).
1740393|NCT00111813|Drug|bortezomib|Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
1740394|NCT00111826|Device|Celacade™ system|
1740398|NCT00111852|Drug|Desmoteplase|Desmoteplase 90 mcg/kg, intravenous administration.
1740399|NCT00111852|Drug|Desmoteplase|Desmoteplase 125 mcg/kg, intravenous administration.
1740400|NCT00111852|Drug|Placebo|Dose-Match Placebo, intravenous administration.
1740401|NCT00111865|Behavioral|Aerobic Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 days/week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 80% of their VO2 reserve over the course of the intervention.
1740402|NCT00111878|Drug|MEDI-534|
1740403|NCT00111891|Drug|niacin (+) laropiprant|
1740404|NCT00111891|Drug|Comparator: placebo (unspecified)|
1740405|NCT00111904|Drug|paclitaxel-loaded polymeric micelle|
1740406|NCT00111917|Drug|Infliximab|anti-TNF
1740407|NCT00111917|Other|Placebo|Placebo infusion
1740408|NCT00111930|Drug|DHEA|
1740409|NCT00111943|Drug|1% tenofovir gel|
1740410|NCT00111956|Drug|Etanercept|
1740411|NCT00111956|Drug|Placebo|
1740412|NCT00111969|Device|Celacade™ system|
1740413|NCT00111982|Biological|Liatermin|Liatermin
1740414|NCT00111995|Drug|Aranesp®|
1740415|NCT00112008|Drug|De Novo Administration of Darbepoetin Alfa|Administration Q2W for 18 weeks. starting dose is 0.75 mcg/kg rounded to the nearest dose: 20, 30, 40, 50, 60, 80, 100, 150, 200 0r 300 mcg. Titrate to maintain Hb within 11.0 - 13.0 g/dL
1740416|NCT00112021|Drug|pramlintide acetate|
1740417|NCT00112034|Drug|Methotrexate|
1740418|NCT00112034|Drug|IV methylprednisolone|
1740419|NCT00112047|Drug|Emtricitabine (FTC)|Capsule containing 200 mg FTC, taken once daily, for 96 weeks
1740420|NCT00112047|Drug|Tenofovir Disoproxil Fumarate (TDF)|Tablet containing 300 mg TDF, taken once daily, for 96 weeks
1740421|NCT00112047|Drug|Efavirenz (EFV)|Tablet containing 600 mg EFV, taken once daily, for 96 weeks
1740422|NCT00112047|Drug|FTC/TDF|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg, once daily, from Week 96 to 144
1740423|NCT00112047|Drug|FTC/TDF/EFV|Fixed-dose combination tablet containing FTC 200 mg/TDF 300 mg/EFV 600 mg, taken once daily, from Week 144 to 240
1740424|NCT00112047|Drug|Lamivudine/zidovudine|Fixed-dose combination tablet containing lamivudine 150 mg/zidovudine 300 mg, taken twice daily, for 240 weeks
1740425|NCT00112060|Drug|PT-523 for Injection|
1740426|NCT00112073|Drug|bapineuzumab|IV, Q13w
1740427|NCT00112073|Other|placebo|IV Q13w
1740428|NCT00112086|Drug|Neoadjuvant chemotherapy (Paclitaxel and Carboplatin)|
1740429|NCT00112099|Procedure|Surgery: Splenectomy|Procedure/Surgery: Surgery: Splenectomy
1740430|NCT00112099|Procedure|Surgery: Spleen-preservation|Procedure/Surgery: Surgery: Spleen-preservation
1740431|NCT00112112|Biological|FluMist|"The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril). Each dose contained approximately 10 to 7th TCID 50 (median tissue culture infectious dose) of each of three influenza virus strains. During the 2005 enrollment period, the three 2004/2005 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/Wyoming/03/2003(H3N2), and B/Jilin/20/2003). During the 2006 and 2007 enrollment periods, the three 2005/2006 influenza virus strains were used: A/New Caledonia/20/99(H1N1), A/California/7/2004(H3N2), and B/Jiangsu/10/2003 (B/Shanghai/361/2002-like.
brief description of the arm. This element may not be necessary if the associated intervention descriptions contain sufficient information to describe the arm."
1740432|NCT00112112|Biological|Placebo|Placebo intranasal mist was composed of allantoic fluid stabilized with buffer containing sucrose, potassium phosphate, and monosodium glutamate. The total volume of 0.5 mL was administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
1740433|NCT00112125|Device|OPTIMIZER System|
1740434|NCT00112138|Drug|gabapentin|
1740435|NCT00112151|Drug|LowT|Low Dose Testosterone Group applies one 2.5 gm active packet and one placebo packet, titrated to a target blood range of 400-550 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
1740436|NCT00112151|Behavioral|Resistance Training|Weight training 45-60 minutes 3 times per week
1740437|NCT00112151|Drug|Placebo|2.5 gm gel packets applied once daily. Sham adjustments made during the first 12 weeks. Duration is 52 weeks.
1740438|NCT00112151|Drug|HighT|High Dose Testosterone Group applies two 2.5 gm active packets, titrated to a target blood range of 600-1000 pg/ml)during the first 12 weeks. Total exposure duration is 52 weeks.
1740439|NCT00112164|Drug|Xigris|
1740440|NCT00112177|Drug|Itopride Hydrochloride|
1740441|NCT00112190|Drug|Itopride Hydrochloride|100 mg tid
1740442|NCT00112190|Drug|itopride|100 mg three times daily
1740443|NCT00112203|Drug|Itopride|
1740444|NCT00112216|Biological|Melan-A analog peptide|
1740445|NCT00112216|Biological|FluMa peptide|
1740446|NCT00112216|Biological|Mage-A10 peptide|
1740447|NCT00112216|Biological|SB AS-2 adjuvant|
1740448|NCT00112216|Biological|Montanide adjuvant|
1740449|NCT00112229|Biological|group 1|Melan-A analog peptide + CpG + Montanide
1740450|NCT00112229|Biological|group 2|Melan-A natural peptide + CpG + Montanide
1740451|NCT00112229|Biological|group 3|Melan-A natural peptide + Tyrosinase YMD peptide + CpG + Montanide
1740452|NCT00112229|Biological|group 4|Melan-A analog peptide + Tyrosinase YMD peptide + CpG + Montanide
1740453|NCT00112242|Biological|Montanide + Melan-A analogue peptide|1 ml Montanide+ 500 mcg Melan-A analog peptide
1740454|NCT00112242|Biological|Montanide + Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide|1 ml Montanide + 500 mcg Melan-A analog peptide + 500 mcg NY-ESO-1 analog peptide + 500 mcg Mage10 peptide
1740455|NCT00112242|Biological|Montanide + CpG-7909 / PF-3512676+Melan-A analog peptide + NY-ESO-1 analog peptide + Mage10 peptide|1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 500 mcg Melan-A analog peptide, 500 mcg + NY-ESO-1 analog peptide + 500 mcg Mage10 peptide
1740456|NCT00112242|Biological|Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide|1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 100 mcg Melan-A native and analog peptides + 500 mcg NY-ESO-1 long peptide + 100 mcg Mage10 peptide
1740457|NCT00112242|Biological|Montanide + CpG-7909/PF-3512676 + Melan-A native and analog peptides + NY-ESO-1 long peptide + Mage10 peptide + low dose IL-2|1 ml Montanide + 2.5 mg CpG-7909/PF-3512676 + 100 mcg Melan-A native and analog peptides + 500 mcg NY-ESO-1 long peptide + 100 mcg Mage10 peptide + low dose IL-2
1740458|NCT00112255|Behavioral|Practice nurse-led partner notification|
1740524|NCT00112645|Drug|cyclosporine|
1740459|NCT00112255|Behavioral|Referral to specialist genitourinary clinic|
1740460|NCT00112268|Behavioral|QuitLink (office support system for quit line referral)|
1740461|NCT00112281|Drug|Tilarginine Acetate Injection intravenous infusion|
1740462|NCT00112294|Drug|Paclitaxel (Taxane)|IV, 225 mg/m^2
1740463|NCT00112294|Drug|Docetaxel (Taxane)|IV, 75 mg/m^2
1740464|NCT00112294|Drug|Carboplatin|AUC=6, q 3 weeks (6 cycles maximum)
1740465|NCT00112294|Drug|Cetuximab|Intravenous, 400 mg/m^2, initial dose followed by 250 mg/m^2, weekly starting on Week 2
1740466|NCT00112307|Procedure|Brachytherapy|
1740467|NCT00112320|Procedure|PVR plus RV remodeling|PVR and surgical RV remodeling, which includes bioprosthetic pulmonary valve insertion and resection of akinetic scarred areas on the anterior RV wall to reduce RV volume
1740468|NCT00112320|Procedure|Standard PVR|PVR alone, which includes bioprosthetic pulmonary valve insertion and, when present, resection of right ventricular outflow tract (RVOT) aneurysm
1740469|NCT00112333|Procedure|fMRI|A liquid meal (Ensure 1Kcal/cc) will be infused into the stomach via a nasogastric tube at a rate of 60cc/min till the subject reaches maximal satiety. The amount of liquid meal will differ per subject.
1740470|NCT00112346|Drug|Cetuximab + platinum + gemcitabine|Solution, IV, Cetuximab: 400mg/m2 on Day 1 then given weekly at 250mg/m2 starting on Day 8 + Gemcitabine given at 1250mg/m2 (Day 1 & Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks. Cetuximab is given weekly, Maximum of 6 cycles (18 weeks) Cetuximab will be continued during the period following discontinuation of chemotherapy, until disease progression or cetuximab intolerance.
1740471|NCT00112346|Drug|Platinum + Gemcitabine|Solution, IV, Gemcitabine given at 1250mg/m2 (Day 1 & Day 8 of each cycle) + Cisplatin given at 75mg/m2 or Carboplatin AUC=5, Cycle of therapy is every 3 weeks, Maximum of 6 cycles = 18 weeks.
1740472|NCT00112359|Drug|AZLI 75 mg three times a day (TID)|
1740473|NCT00112359|Drug|Placebo three times a day (TID)|
1740474|NCT00112372|Drug|Ridaforolimus|10 mg tablet of ridaforolimus administered orally according to one of several different dosing regimens for a four-week treatment cycle.
1740475|NCT00112385|Drug|Etanercept|Etanercept 50 mg will be injected subcutaneously once per week for 52 weeks
1740476|NCT00112385|Drug|Placebo|Placebo, contained in 50mg syringes, will be injected subcutaneously once per week for 52 weeks.
1740477|NCT00112398|Procedure|Extended interventions by advanced level prehospital providers|may include rapid sequence intubation (RSI) airway management, blood transfusions, surgical procedures, etc.
1740478|NCT00112411|Drug|Bronchodilator|
1740479|NCT00112424|Procedure|Diagnostic cardiac MRI|Routine cardiac MRI done under general anesthesia as pre-operative evaluation.
1740480|NCT00112424|Procedure|Cardiac catheterization|Routine cardiac catheterization prior to Glenn operation.
1740481|NCT00112437|Drug|MK0822|MK0822 3 mg, once weekly for 24 months
1740482|NCT00112437|Drug|MK0822|MK0822 10 mg, once weekly for 24 months
1740483|NCT00112437|Drug|MK0822|MK0822 25 mg, once weekly for 24 months
1740484|NCT00112437|Drug|MK0822|MK0822 50 mg, once weekly for 24 months
1740485|NCT00112437|Dietary Supplement|Vitamin D3|Vitamin D3, two 2800 IU weekly throughout the study
1740486|NCT00112437|Dietary Supplement|Calcium Carbonate|Patient who have a calcium intake less than 1000 mg/day will receive daily calcium supplements providing 500 mg of elemental calcium.
1740487|NCT00112437|Drug|Placebo|Placebo to MK0822 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
1740488|NCT00112463|Drug|romidepsin|DEP is administered at a dose of 13 mg/m2 as a 4-hour intravenous infusion in the outpatient setting.
1740489|NCT00112476|Drug|bryostatin 1|Given IV
1740490|NCT00112476|Drug|temsirolimus|Given IV
1740491|NCT00112489|Drug|carboplatin|
1740492|NCT00112489|Drug|paclitaxel|
1740493|NCT00112502|Drug|Celecoxib|400 mg orally twice a day continuous dosing
1740494|NCT00112502|Drug|Isotretinoin|40 mg/m^2 orally twice a day (total daily dose = 80 mg/m^2) days 1-21 of a 28 day cycle.
1740495|NCT00112502|Drug|Temozolomide|150 mg/m2 orally daily, 7 days on treatment, 7 days off.
1740496|NCT00112502|Drug|Thalidomide|400 mg orally every day continuous dosing (starting at 200 mg each day and escalating weekly by 100 mg until the maximum dose of 400 mg/day is achieved)
1740497|NCT00112515|Drug|modafinil|
1740498|NCT00112515|Procedure|cognitive assessment|
1740499|NCT00112515|Procedure|psychosocial assessment and care|
1740500|NCT00112515|Procedure|quality-of-life assessment|
1740501|NCT00112528|Biological|bevacizumab|
1740502|NCT00112528|Drug|gemcitabine hydrochloride|
1740503|NCT00112528|Drug|oxaliplatin|
1740504|NCT00112554|Drug|cytarabine|Given IV
1740505|NCT00112554|Drug|laromustine|Given IV
1740506|NCT00112554|Other|placebo|Given IV
1740507|NCT00112567|Drug|fludarabine phosphate|
1740508|NCT00112567|Drug|thiotepa|
1740509|NCT00112567|Procedure|peripheral blood stem cell transplantation|
1740510|NCT00112567|Radiation|radiation therapy|
1740511|NCT00112580|Biological|ipilimumab|
1740512|NCT00112593|Drug|fludarabine phosphate|Given IV
1740513|NCT00112593|Radiation|total-body irradiation|Undergo TBI
1740514|NCT00112593|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic bone marrow or peripheral blood stem cell transplantation
1740515|NCT00112593|Drug|cyclosporine|Given IV or PO
1740516|NCT00112593|Drug|mycophenolate mofetil|Given IV or PO
1740517|NCT00112593|Other|laboratory biomarker analysis|Correlative studies
1740518|NCT00112619|Drug|topotecan hydrochloride|Participants receive intraventricular topotecan, .2 mg, administered via an indwelling ventricular reservoir daily for 5 consecutive days during weeks 1 and 3 of the first four weeks of therapy (induction), during weeks 5 and 8 of the next 6 weeks of therapy (consolidation), and during weeks 11, 15, 19, 23, 27, 31, 35, 39, 43, 47, and 51 (maintenance therapy).
1740519|NCT00112632|Drug|imatinib mesylate|
1740520|NCT00112632|Procedure|conventional surgery|
1740521|NCT00112632|Procedure|neoadjuvant therapy|
1740522|NCT00112645|Biological|anti-thymocyte globulin|
1740523|NCT00112645|Drug|busulfan|
1740528|NCT00112645|Procedure|allogeneic bone marrow transplantation|
1740529|NCT00112645|Procedure|peripheral blood stem cell transplantation|
1740530|NCT00112645|Procedure|umbilical cord blood transplantation|
1740531|NCT00112658|Drug|fluorouracil|
1740532|NCT00112658|Drug|gemcitabine hydrochloride|
1740533|NCT00112658|Drug|irinotecan hydrochloride|
1740534|NCT00112658|Drug|leucovorin calcium|
1740535|NCT00112658|Drug|oxaliplatin|
1740536|NCT00112671|Drug|sorafenib tosylate|Given orally 400mg orally twice daily
1740537|NCT00112671|Other|laboratory biomarker analysis|Correlative studies
1740538|NCT00112684|Drug|alvocidib|Given IV
1740539|NCT00112684|Other|pharmacological study|Correlative studies
1740540|NCT00112684|Other|laboratory biomarker analysis|Correlative studies
1740541|NCT00112697|Drug|cisplatin|
1740542|NCT00112697|Drug|docetaxel|
1740543|NCT00112697|Drug|fluorouracil|
1740544|NCT00112697|Radiation|radiation therapy|
1740545|NCT00112710|Drug|carboplatin|
1740546|NCT00112710|Drug|cisplatin|
1740547|NCT00112710|Drug|gemcitabine hydrochloride|
1740548|NCT00112723|Drug|alvocidib|Given IV
1740549|NCT00112736|Drug|erlotinib|Given orally
1740550|NCT00112736|Drug|temsirolimus|Given IV
1740551|NCT00112736|Procedure|therapeutic conventional surgery|Undergo surgical resection
1740552|NCT00112736|Other|laboratory biomarker analysis|Correlative studies
1740553|NCT00112736|Other|pharmacological study|Correlative studies
1740554|NCT00112749|Biological|infliximab|A single infusion of 1mg/kg will be administered.
1740555|NCT00112749|Other|Clinical Assessment|Medical, psychiatric, and immune evaluation.
1740556|NCT00112749|Other|Self-report questionnaires|Fatigue Symptom Inventory, Multidimensional Fatigue Symptom Inventory, Hamilton Depression Rating Scale, Beck Depression Inventory II, Hamilton anxiety Rating Scale, Pittsburgh Sleep Quality Index, Brief Pain Inventory, MOS SF-36.
1740557|NCT00112749|Other|Immune Assessment|Proinflammatory cytokines and markers of cytokine activity and lymphocyte subsets and CBC.
1740558|NCT00112775|Drug|dasatinib|
1740559|NCT00112775|Drug|imatinib mesylate|
1740560|NCT00112827|Radiation|total marrow irradiation|Undergo irradiation
1740561|NCT00112827|Drug|melphalan|Given IV
1740562|NCT00112827|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
1740563|NCT00112827|Biological|filgrastim|Given IV
1740564|NCT00112827|Genetic|fluorescence in situ hybridization|Correlative studies
1740565|NCT00112827|Genetic|cytogenetic analysis|Correlative studies
1740566|NCT00112827|Drug|cyclophosphamide|Given IV
1740567|NCT00112827|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo transplantation
1740568|NCT00112827|Drug|lenalidomide|Given orally
1740569|NCT00112840|Drug|CCI-779|CCI-779 is taken IV on days 1, 8, 15, 22 of a 28-day cycle. Dose level is dependent on phase.
1740570|NCT00112840|Drug|Bevacizumab|Bevacizumab is taken IV on Days 1 and 15 of a 28-day cycle. Dose Level determined by phase.
1740571|NCT00112853|Drug|tipifarnib|Given orally
1740572|NCT00112853|Drug|etoposide|Given orally
1740573|NCT00112866|Drug|cilengitide|Given IV
1740574|NCT00112866|Procedure|therapeutic conventional surgery|Undergo tumor resection
1740575|NCT00112866|Other|pharmacological study|Correlative studies
1740576|NCT00112866|Other|laboratory biomarker analysis|Correlative studies
1740577|NCT00112879|Drug|arsenic trioxide|
1740578|NCT00112879|Drug|ascorbic acid|
1740579|NCT00112879|Drug|dexamethasone|
1740580|NCT00112879|Drug|thalidomide|
1740581|NCT00112879|Procedure|anti-cytokine therapy|
1740582|NCT00112879|Procedure|antiangiogenesis therapy|
1740583|NCT00112879|Procedure|biological therapy|
1740584|NCT00112879|Procedure|chemotherapy|
1740585|NCT00112879|Procedure|drug resistance inhibition|
1740586|NCT00112879|Procedure|growth factor antagonist therapy|
1740587|NCT00112879|Procedure|non-specific immune-modulator therapy|
1740588|NCT00112892|Dietary Supplement|selenium|
1740589|NCT00112892|Drug|irinotecan hydrochloride|
1740590|NCT00112905|Drug|sorafenib tosylate|Given PO
1740591|NCT00112905|Other|laboratory biomarker analysis|Optional correlative studies
1740592|NCT00112918|Biological|Bevacizumab|Administered as an intravenous infusion over 30 - 90 minutes.
1740593|NCT00112918|Drug|Capecitabine|Film-coated tablets
1740594|NCT00112918|Drug|5-Fluorouracil (5-FU)|Administered as either a bolus injection or continuous intravenous infusion over 22 hours.
1740595|NCT00112918|Drug|Leucovorin calcium|Administered as a 200 mg/m^2 infusion over 2 hours.
1740596|NCT00112918|Drug|Oxaliplatin|Administered as an intravenous infusion over 2 hours.
1740599|NCT00112957|Biological|fowlpox-NY-ESO-1 vaccine|iv
1740600|NCT00112957|Biological|recombinant vaccinia-NY-ESO-1 vaccine|iv
1740601|NCT00112957|Procedure|adjuvant therapy|additional therapy
1740602|NCT00112983|Biological|eculizumab|
1740603|NCT00112996|Drug|alpha-lipoic acid|Oral two 300 mg ALA sustained release tablets initiated 4 days after last dose of platinum and discontinued 2 days before next scheduled platinum dose, continued for 24 weeks.
1740604|NCT00112996|Other|placebo|Given orally two similar color and sized placebo control tablets three times a day continued for 24 weeks.
1740605|NCT00113009|Drug|VLTS-934|
1740606|NCT00113022|Drug|Org 24448|250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
1740607|NCT00113022|Drug|Placebo|Inactive equivalent of 250 mg once per day for first week, 250 mg twice per day for second week, 500 mg twice per day for third and fourth weeks, if response minimal or worse at four weeks then 750 mg twice per day for additional weeks
1740608|NCT00113048|Drug|CAMPATH (alemtuzumab)|
1740610|NCT00113074|Drug|Nicotine Replacement Therapy|Nicotine replacement therapy program
1740611|NCT00113074|Behavioral|Diet|Diet program
1740612|NCT00113087|Drug|Enalapril|Enalapril to target dose of .4mg/kg/day divided to twice per day (BID)
1740613|NCT00113087|Drug|Placebo|Participants will receive placebo
1740614|NCT00113100|Drug|Topical 17-beta estradiol in ethanol/propylene glycol (ETOH/PG)|
1740615|NCT00113113|Drug|Rubitecan|
1740616|NCT00113126|Drug|Treatment interruption|
1740617|NCT00113139|Behavioral|Telephone-based coping skills/stress management|Telephone-based coping skills/stress management: 12 weekly sessions.
1740618|NCT00113139|Other|Usual Care|Usual care participants continued their routine and usual treatments and do not receive the 12 telephone training sessions.
1740620|NCT00113178|Device|Catheter-based cardiac cryoablation|
1740621|NCT00113191|Drug|Veronate|
1740622|NCT00113204|Drug|IPI-504|
1740623|NCT00113217|Drug|Bevacizumab|10 mg/kg IV on day 1 of each 14-day cycle.
1740624|NCT00113230|Drug|Avastin (Bevacizumab, RHUMAB VEGF)|Starting Dose 5 mg/kg intravenously on day one of radiotherapy, given every 2 weeks +/- 2 days for a total of 3 doses.
1740625|NCT00113230|Drug|Capecitabine|900 mg/m^2 by mouth twice a day during days of radiation for all five weeks of therapy.
1740626|NCT00113230|Radiation|Radiation Therapy|45 Gy in 25 fractions to the pelvis followed by 5.4 Gy as a boost dose to the primary tumor with margin, for a total dose of 50.4 Gy over 28 treatment days.
1740627|NCT00113243|Drug|adult stem cells|
1740628|NCT00113256|Drug|Rubitecan|
1740629|NCT00113269|Drug|basiliximab|IV
1740630|NCT00113269|Drug|rabbit anti-thymocyte globulin|IV
1740631|NCT00113269|Drug|tacrolimus|oral
1740632|NCT00113269|Drug|alemtuzumab|Intravenous (IV)
1740633|NCT00113269|Drug|mycophenolate mofetil|oral
1740634|NCT00113269|Drug|steroids|IV and/or oral
1740635|NCT00113282|Drug|Interleukin-2 (IL-2)|
1740636|NCT00113295|Drug|Continued Paroxetine CR|
1740637|NCT00113295|Drug|Quetiapine|
1740638|NCT00113295|Drug|Placebo|
1740640|NCT00113321|Drug|Decitabine|20 mg/m2 IV over 1 hour daily x 5 days.
1740641|NCT00113334|Drug|ABT-510|100 mg subcutaneously twice daily
1740642|NCT00113347|Drug|Erlotinib|Beginning on Day 2 of treatment, 100, 125, or 150 mg by mouth once a day every day while on treatment, except on days docetaxel is received.
1740643|NCT00113347|Drug|Docetaxel|15 mg/m^2 or 20 mg/m^2 by vein over 15 to 30 minutes on Days 1, 8, 15, and 22 of treatment.
1740644|NCT00113347|Radiation|Radiation Therapy|Radiation therapy to head/neck beginning on day 1 of treatment once daily 5 times per week (Monday through Friday), delivered in 40 fractions.
1740645|NCT00113360|Drug|RAD001|Starting dose of 5 or 10 mg by mouth daily.
1740646|NCT00113360|Drug|Octreotide Depot|30 mg injection into the muscle of either buttock once every 28 (±7) days.
1740647|NCT00113373|Drug|lapatinib ditosylate|Given orally
1740648|NCT00113373|Other|laboratory biomarker analysis|Correlative studies
1740649|NCT00113386|Biological|filgrastim|Consolidation chemotherapy
1740650|NCT00113386|Biological|pegfilgrastim|Consolidation chemotherapy
1740651|NCT00113386|Drug|cisplatin|
1740652|NCT00113386|Drug|docetaxel|
1740653|NCT00113386|Procedure|adjuvant therapy|
1740654|NCT00113386|Procedure|conventional surgery|
1740655|NCT00113386|Procedure|neoadjuvant therapy|
1740656|NCT00113386|Radiation|radiation therapy|
1740657|NCT00113399|Biological|filgrastim|
1740658|NCT00113399|Drug|cisplatin|
1740659|NCT00113399|Drug|docetaxel|
1740660|NCT00113399|Drug|fluorouracil|
1740661|NCT00113399|Drug|paclitaxel|
1740662|NCT00113399|Radiation|radiation therapy|
1740663|NCT00113412|Drug|SP01A|
1740664|NCT00103571|Drug|Olanzapine|
1740665|NCT00103571|Drug|Aripiprazole|
1740666|NCT00103584|Biological|LC16m8 Smallpox Vaccine|
1740667|NCT00103597|Drug|Fludrocortisone|
1740668|NCT00103597|Drug|Domperidone|
1740669|NCT00103597|Behavioral|Conservative Measures for Orthostatic Hypotension|
1740670|NCT00103610|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
1740671|NCT00103610|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
1740672|NCT00103623|Drug|Plenaxis|
1740673|NCT00103636|Procedure|Extending peripheral intravenous (IV) cannula dwell times|
1740674|NCT00103649|Drug|xaliproden (SR57746A)|
1740708|NCT00103935|Drug|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 0.8 mcg
1740709|NCT00103935|Drug|placebo|Subcutaneously injected placebo 0.02 mL twice daily as lead-in followed by once weekly injected amount equivalent to exenatide LAR 2.0 mcg
1740675|NCT00103662|Drug|Granulocyte colony-stimulating factor plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of plerixafor (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of plerixafor followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
1740676|NCT00103662|Drug|Granulocyte colony-stimulating factor plus placebo|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) (10 µg/kg/day) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received placebo, administered by SC injection. On Day 5, participants received a morning dose of G-CSF (10 µg/kg) and underwent apheresis approx. 10 to 11 hours after the dose of placebo (within 60 minutes of G-CSF administration). Participants continued to receive an evening dose of placebo followed by a morning dose of G-CSF and apheresis for up to 4 aphereses or until ≥ 6*10^6 CD34+ cells/kg were collected. Participants who participated in the rescue procedure underwent an additional daily treatment with plerixafor (240 µg/kg) and apheresis for up to 4 days.
1740677|NCT00103675|Procedure|Acupuncture|
1740678|NCT00103701|Drug|Dasatinib|Tablets, Oral, 15- 240 mg, Once or twice daily, 0-3 years depending on response.
1740679|NCT00103714|Drug|denufosol tetrasodium (INS37217)|
1740680|NCT00103727|Drug|Talnetant|talnetant
1740681|NCT00103727|Other|placebo|Placebo Comparator
1740682|NCT00103727|Other|risperidone|Active Comparator
1740683|NCT00103740|Drug|zoledronic acid|5 mg zoledronic acid in 5 mL of sterile water for infusion
1740684|NCT00103740|Drug|placebo to zoledronic acid|5 mL of sterile water for infusion
1740685|NCT00103740|Drug|Risedronate|30mg oral tablets overencapsulated to match the placebo capsules
1740686|NCT00103740|Drug|Placebo to risedronate|oral capsules
1740687|NCT00103740|Drug|Calcium and vitamin D supplements|Calcium and vitamin D supplements were supplied
1740688|NCT00103753|Drug|deferiprone|
1740689|NCT00103766|Drug|Alteplase|
1740690|NCT00103779|Drug|SGN-40 (anti-huCD40 mAb)|1 mg/kg IV (in the vein) on Day 1; 1-2 mg/kg IV on Day 4; 2-4 mg/kg IV on Day 8; 3-8 mg/kg on Days 15, 22 and 29.
1740691|NCT00103792|Drug|mycophenolate mofetil|2000 mg mycophenolate per day combined with steroids for induction remission, followed by azathioprine standard maintenance therapy
1740692|NCT00103792|Drug|cyclophosphamide|2 mg/kg/d, combined with steroids, for remission induction, followed by standard azathioprine maintenance therapy
1740693|NCT00103805|Drug|levodopa|
1740694|NCT00103818|Drug|gaboxadol|Duration of Treatment: 3 months
1740695|NCT00103818|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 3 months
1740696|NCT00103831|Drug|Oral Taxane|
1740697|NCT00103844|Drug|Dasatinib|Tablets, oral, 20 mg and 50mg, twice daily, up to 96 weeks
1740698|NCT00103844|Drug|Imatinib|Tablets, Oral, 400mg and 100mg, twice daily, up to 96 weeks
1740699|NCT00103857|Drug|Comparator: MK0431 50 mg b.i.d. (b.i.d. = twice daily)|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take MK0431 50 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
1740700|NCT00103857|Drug|Comparator: MK0431 100 mg q.d. (q.d. = once daily)|MK0431 oral tablets will be started on Day 1 as two 50 mg tablets (100 mg q.d.) (q.d. = once daily) and continued at this dose throughout the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
1740701|NCT00103857|Drug|Comparator: Placebo (Phase A)/Metformin (Phase B)|During the placebo-controlled period (Day 1 through Week 24/Phase A), metformin and MK0431 matching placebos will be dispensed as oral tablets. At the beginning of the 30-week active-controlled period (Phase B), metformin will be started as 500 mg q.d. (q.d. = once daily) and up-titrated in 500 mg weekly increments to a stable dose of 1000 mg b.i.d. Patients who complete the 54-week base study and who enter the 50-week extension study will continue to take metformin 1000 mg b.i.d. (b.i.d. = twice daily) for a total placebo/metformin treatment duration of up to 104 weeks.
1740702|NCT00103857|Drug|Comparator: Metformin 500 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased after 1 week to a stable dose of 500 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 500 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
1740703|NCT00103857|Drug|Comparator: Open-Label MK0431/Metformin 50/1000 mg b.i.d.|MK0431 oral tablets will be started on Day 1 at 50 mg q.d. (q.d. = once daily) and increased after one week to a stable dose of 50 mg b.i.d. (b.i.d. = twice daily) Metformin oral tablets will be started on Day 1 at 500 mg q.d. and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. The open-label treatment period is 24 weeks.
1740704|NCT00103857|Drug|Comparator: Metformin 1000 mg b.i.d.|Metformin oral tablets will be started on Day 1 at 500 mg q.d. (q.d. = once daily) and increased by increments of 500 mg per week to achieve a stable dose of 1000 mg b.i.d. (b.i.d. = twice daily) Patients will continue to take metformin 1000 mg b.i.d. for the remainder of the 54-week base study (including the 24-week placebo-controlled Phase A and 30-week active-controlled Phase B) and during the 50-week extension study (for patients who complete the 54-week base study and enter the 50-week extension study) for a total treatment duration of up to 104 weeks.
1740705|NCT00103870|Procedure|Electrodermal stimulation|
1740706|NCT00103870|Procedure|Music listening task|
1740913|NCT00113503|Drug|Azathioprine weight-based dose|
1740710|NCT00103935|Drug|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 0.8 mcg.
1740711|NCT00103935|Drug|Exenatide LAR|Subcutaneously injected exenatide 5 mcg (0.02 mL) twice daily as lead-in followed by once weekly injected exenatide LAR 2.0 mcg.
1740712|NCT00103948|Drug|Aricept|
1740713|NCT00103961|Behavioral|Questionnaire|A behavioral questionnaire will occur at Week 8
1740714|NCT00103974|Biological|BHT-3009-01|
1740715|NCT00104013|Drug|xaliproden (SR57746A)|
1740716|NCT00104052|Biological|peginterferon alfa-2b (PEG2b) (SCH 54031)|PEG2b 1.5 μg/kg/wk given subcutaneously (once weekly) for 48 weeks.
1740717|NCT00104052|Drug|ribavirin (SCH 18908)|15 mg/kg/day for up to 48 weeks
1740718|NCT00104065|Drug|CG53135-05, velafermin|
1740719|NCT00104078|Drug|MYO-029|
1740720|NCT00104091|Drug|TP-38|TP-38 is a recombinant chimeric protein composed of the epidermal growth factor (EGFR) binding ligand (TGF-α)and a genetically engineered form of the Pseudomonas exotoxin, PE-38.
1740721|NCT00104104|Drug|zoledronic acid|4 mg zoledronic acid in 250 mL of calcium-free solution (i.e., 0.9% sodium chloride or 5% glucose) administered intravenously.
1740722|NCT00104117|Drug|XL999|XL999 was to be given biweekly to an initial cohort of subjects at 0.20 mg/kg and to successive cohorts at doses that escalated by cohort according to a design for safely determining an MTD. After determination of the MTD, one or more additional cohorts were to receive XL999 weekly at the MTD or a lower dose, as determined by the CRC on the basis of interim safety and PK data. By a protocol amendment after initiation of the study, subjects were to be enrolled in an additional cohort to receive a weekly XL999 dose of 200 mg.
1740723|NCT00104130|Drug|KOS-862|
1740724|NCT00104143|Drug|A4I Antagonist|
1740725|NCT00104156|Procedure|External Qigong therapy|
1740726|NCT00104169|Drug|Epoetin Alfa|
1740727|NCT00104182|Drug|insulin detemir|
1740728|NCT00104182|Drug|insulin NPH|
1740729|NCT00104234|Drug|N-acetylgalactosamine 4-sulfatase|
1740730|NCT00104234|Drug|Placebo/rhASB|
1740731|NCT00104247|Drug|sapropterin dihydrochloride, 6R-BH4, tetrahydrobiopterin|
1740732|NCT00104260|Drug|sapropterin dihydrochloride|
1740733|NCT00104273|Drug|Rasagiline|
1740734|NCT00104286|Drug|Troxatyl™ (Cytotoxic Chemotherapeutic)|
1740735|NCT00104299|Drug|Rituximab plus cyclophosphamide placebo (rituximab group)|375 mg/m^2 infusions once weekly for 4 week
1740736|NCT00104299|Drug|Cyclophosphamide plus rituximab placebo (control group)|2 mg/kg/day orally for months 1-3
1740737|NCT00104299|Drug|Azathioprine|2 mg/kg/day orally for months 4-6
1740738|NCT00104299|Drug|Methylprednisolone (or other glucocorticoid)|1 g/day intravenously for up to 3 days within 14 days prior to receiving rituximab
1740739|NCT00104299|Drug|Prednisone|During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
1740740|NCT00104338|Drug|FK778|
1740741|NCT00104364|Drug|MK0731|
1740742|NCT00104377|Biological|Grass MATA MPL|
1740743|NCT00104390|Biological|Grass MATA MPL|
1740747|NCT00104416|Drug|lamotrigine (LAMICTAL) extended-release|Primary experimental dosage form
1740748|NCT00104416|Drug|Placebo|Placebo control
1740749|NCT00104429|Drug|GW873140|
1740750|NCT00104429|Drug|Combivir|
1740751|NCT00104442|Drug|Rivastigmine|
1740752|NCT00104455|Drug|activated recombinant human factor VII|
1740753|NCT00104468|Drug|Troxatyl™ (Cytotoxic Chemotherapeutic)|
1740754|NCT00104481|Behavioral|cognitive behavior therapy|
1740755|NCT00104494|Drug|Zinc acetate (20mg/d)|Randomized to receive either 20mg/d zinc as zinc acetate or an identical placebo
1740756|NCT00104507|Drug|APD356|
1740757|NCT00104520|Drug|AZLI 75 mg two times a day (BID)/three times a day (TID)|
1740758|NCT00104520|Drug|Placebo two times a day (BID)/three times a day (TID)|
1740759|NCT00104533|Device|Magnets|
1740760|NCT00104546|Procedure|Acupuncture point injection of vitamin K|
1740761|NCT00104559|Behavioral|iMIC-generated consent form and tutorial|Computer-based consent form and tutorial
1740762|NCT00104559|Behavioral|Standard paper consent form|Standard paper consent form
1740763|NCT00104572|Drug|Androgel (Testosterone Gel)|1 mg tablet for 12 months
1740764|NCT00104572|Drug|Anastrozole (Aromatase Inhibitor)|
1740765|NCT00104572|Drug|Placebo tablet|Daily for 12 months
1740766|NCT00104572|Drug|Placebo gel|Daily for 12 months
1740767|NCT00104572|Dietary Supplement|Calcium Cardone 500mg with vitamin D 400 IU|1 tablet three times a day
1740768|NCT00104598|Drug|Bupropion|
1740769|NCT00104598|Behavioral|Smoking Abstinence Program|This investigation was a randomized controlled study of two framed message conditions for smoking cessation in combination with open label bupropion SR (300 mg/day). Two hundred fifty-eight cigarette smokers were randomly assigned to receive either gain- or loss-framed video and printed messages encouraging smoking abstinence. Preproduced video and printed information were chosen as the intervention media because of their reliability in delivering specific framed messages. All participants were seen at a community mental health center for 6 months and received a 7-week supply of bupropion SR.
1740770|NCT00104611|Device|Repetitive Transcranial Magnetic Stimulation|
1740771|NCT00104624|Drug|docetaxel|
1740772|NCT00104624|Procedure|quality-of-life assessment|
1740773|NCT00104637|Drug|sildenafil citrate|sildenafil citrate 25 mg by mouth thrice daily (po tid)
1740774|NCT00104637|Drug|Placebo|25 mg po tid
1740775|NCT00104650|Genetic|AMG 162 180 mg (SC) q 12 weeks|A 180 mg AMG 162 (SC) administered every 12 weeks for 2 doses (Day 1 and wk 13) in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 12 weeks for 9 doses.
1740914|NCT00113503|Drug|Azathioprine individualised dose|
1740987|NCT00114231|Drug|oxaliplatin|Given IV
1740776|NCT00104650|Drug|IV Bisphosphonate q 4 weeks|IV Bisphosphonate (eg pamidronate or zoledronic acid) every 4 weeks for 6 doses as described by package insert during the treatment phase. If enrolled to the extension phase, subject will be assigned to the AMG 162 180mg (SC) every 4 weeks for 26 doses.
1740777|NCT00104650|Genetic|AMG 162- 180 mg q 4 weeks|A 180 mg AMG 162 (SC) administered every 4 weeks for 6 doses in the treatment phase. If subjected are enrolled in the extension phase, they will continue to receive a 180 mg AMG 162 (SC) administered every 4 weeks for 26 doses.
1740778|NCT00104663|Drug|Quinacrine|
1740779|NCT00104676|Biological|bleomycin sulfate|At least one course administered
1740780|NCT00104676|Drug|cisplatin|At least one course administered
1740781|NCT00104676|Drug|etoposide|At least one course administered
1740782|NCT00104676|Drug|ifosfamide|Given in a dose-dense sequential fashion
1740783|NCT00104676|Drug|oxaliplatin|Given in a dose-dense sequential fashion
1740784|NCT00104676|Drug|paclitaxel|Given in a dose-dense sequential fashion
1740785|NCT00104689|Drug|capecitabine|
1740786|NCT00104689|Drug|oxaliplatin|
1740787|NCT00104702|Procedure|adjuvant therapy|
1740788|NCT00104702|Procedure|conventional surgery|
1740789|NCT00104702|Radiation|radiation therapy|
1740790|NCT00104715|Drug|antiandrogen therapy|
1740791|NCT00104715|Drug|docetaxel|
1740792|NCT00104715|Drug|goserelin acetate|
1740793|NCT00104715|Procedure|orchiectomy|
1740794|NCT00104728|Drug|ZD1839|
1740795|NCT00104741|Drug|flutamide|
1740796|NCT00104741|Drug|triptorelin|
1740797|NCT00104741|Procedure|neoadjuvant therapy|
1740798|NCT00104741|Radiation|radiation therapy|
1740799|NCT00104754|Drug|liposomal SN-38|
1740800|NCT00104767|Drug|celecoxib|
1740801|NCT00104780|Biological|EP-2101|
1740802|NCT00104780|Biological|incomplete Freund's adjuvant|
1740803|NCT00104793|Drug|carboplatin|
1740804|NCT00104793|Drug|irinotecan hydrochloride|
1740805|NCT00104806|Dietary Supplement|cholecalciferol|100 milligrams orally once a day for 28 days
1740806|NCT00104806|Drug|arsenic trioxide|0.3 milligram/kilogram weight intravenously for 5 days (loading) then 0.25/kg weight intravenously biweekly
1740807|NCT00104819|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
1740808|NCT00104819|Biological|sargramostim|
1740809|NCT00104845|Biological|human gp100 plasmid DNA vaccine|
1740810|NCT00104845|Biological|mouse gp100 plasmid DNA vaccine|
1740811|NCT00104858|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HSCT
1740812|NCT00104858|Drug|Cyclosporine|Given PO
1740813|NCT00104858|Drug|Fludarabine Phosphate|Given IV
1740814|NCT00104858|Other|Laboratory Biomarker Analysis|Correlative studies
1740815|NCT00104858|Drug|Mycophenolate Mofetil|Given PO
1740816|NCT00104858|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo HSCT
1740817|NCT00104858|Other|Pharmacological Study|Correlative studies
1740818|NCT00104858|Biological|Rituximab|Given IV
1740819|NCT00104858|Radiation|Total-Body Irradiation|Undergo TBI
1740820|NCT00104871|Drug|Bortezomib|Administered IV at the dose of 1.3 mg/m^2 on a twice-weekly schedule for 2 consecutive weeks on days 1, 4, 8, and 11, followed by a 10 day rest period on days 12-21 (one cycle). In the absence of clinical progression, treatment continued for a minimum of 4 treatment cycles (or 12 weeks).
1740821|NCT00104884|Drug|Depsipeptide|Given IV
1740822|NCT00104897|Drug|tanespimycin|
1740823|NCT00104910|Radiation|Internal Radiation Therapy|
1740824|NCT00104910|Radiation|3-Dimensional Conformal Radiation Therapy|
1740825|NCT00104910|Biological|Cetuximab|Given IV
1740826|NCT00104910|Drug|Cisplatin|Given IV
1740827|NCT00104923|Drug|fenretinide|Current dose level as an IV continuous infusion via central line over 5 days. Cycle is repeated every 3 weeks for up to 6 cycles
1740828|NCT00104936|Procedure|adjuvant therapy|
1740829|NCT00104936|Radiation|radiation therapy|
1740830|NCT00104936|Radiation|stereotactic radiosurgery|
1740831|NCT00104949|Biological|trastuzumab|
1740832|NCT00104962|Drug|lenalidomide|Given orally
1740833|NCT00104975|Biological|alemtuzumab|
1740834|NCT00104975|Biological|therapeutic allogeneic lymphocytes|
1740835|NCT00104975|Drug|fludarabine phosphate|
1740836|NCT00104975|Drug|melphalan|
1740837|NCT00104975|Drug|tacrolimus|
1740838|NCT00104975|Drug|thiotepa|
1740839|NCT00104975|Procedure|peripheral blood stem cell transplantation|
1740840|NCT00104988|Drug|temozolomide|75 mg/m^2/day PO daily for 6 weeks followed by a 2-week break
1740841|NCT00104988|Drug|thalidomide|200 mg/day PO daily
1740842|NCT00105001|Drug|Fludarabine Phosphate|Given IV
1740843|NCT00105001|Radiation|Total-Body Irradiation|Undergo total-body irradiation
1740844|NCT00105001|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
1740845|NCT00105001|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplantation
1740846|NCT00105001|Drug|Tacrolimus|Given IV or PO
1740847|NCT00105001|Drug|Mycophenolate Mofetil|Given PO
1740848|NCT00105001|Drug|Sirolimus|Given PO
1740849|NCT00105027|Other|Standard Care|CRVO: observation; BRVO: standard care
1740850|NCT00105027|Drug|intravitreal triamcinolone injection|1 mg dose
1740851|NCT00105027|Drug|intravitreal triamcinolone injection|4 mg
1740852|NCT00105040|Drug|Levetiracetam|Oral tablets or oral solution at 20-60 mg/kg/d, divided into twice daily dosing.
1740853|NCT00105040|Other|Placebo (PB)|Oral tablets and oral solution
1740915|NCT00113516|Drug|carboplatin|AUC of 6 mg*min/mL via IV infusion every 21 days for 4 cycles as per institutional practices.
1740916|NCT00113516|Drug|paclitaxel|175-225 mg/m2 via IV infusion every 21 days for 4 cycles as per institutional practices.
1740988|NCT00114231|Procedure|neoadjuvant therapy|Undergo surgery
1740854|NCT00105053|Biological|HyperAcute-Prostate Cancer Vaccine|Before enrollment in the Phase I and Phase II- Arm A studies, the patient must be determined to have measurable disease with biopsies on first recurrence or bone metastases. In the Phase II- Arm B study, patients will be men with non-measurable progressive disease as evidenced by elevated PSA only. Cells will be injected intradermally every two weeks for 12 cycles on a prime-boost regimen. Dosage will vary from 30 million to 500 million HAP cells.
1740855|NCT00105066|Drug|Metformin|850mg tablet once a day for one month, then twice a day for 3 months
1740856|NCT00105066|Drug|Placebo|placebo tablet once a day for one month, then twice a day for 3 months
1740857|NCT00105079|Drug|saquinavir [Invirase]|1000 milligram (mg) Oral (po) twice daily (bid)
1740858|NCT00105079|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg po bid
1740859|NCT00105079|Drug|Emtricitabine/tenofovir disoproxil fumarate|Emtricitabine/tenofovir disoproxil fumarate 200/300 mg po qd
1740860|NCT00105079|Drug|Ritonavir|100 mg po bid
1740861|NCT00105092|Drug|Enzastaurin HCL|
1740862|NCT00105105|Drug|Mifepristone|
1740863|NCT00105118|Device|Magstim Super Rapid Magnetic Stimulator|
1740864|NCT00105144|Drug|Micafungin|IV
1740865|NCT00105144|Drug|Caspofungin|IV
1740866|NCT00105157|Drug|Comparator: MK0518|MK0518 oral tablets 200 mg b.i.d, for 24 weeks
1740867|NCT00105157|Drug|MK0518|MK0518 oral tablets 400 mg b.i.d, for 24 weeks
1740868|NCT00105157|Drug|MK0518|MK0518 oral tablets 600 mg b.i.d, for 24 weeks
1740869|NCT00105157|Drug|Placebo|Placebo to MK0518, oral tablet b.i.d, for 24 weeks
1740870|NCT00105170|Drug|hCBE-11|
1740871|NCT00105183|Biological|Placebo|placebo infusion, single
1740872|NCT00105183|Biological|EZ-2053|single IV infusion, 9 mg/kg
1740873|NCT00105183|Biological|EZ-2053 5mg/kg|single IV infusion, 5mg/kg
1740874|NCT00105196|Drug|Aripiprazole+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
1740875|NCT00105196|Drug|Placebo+ ADT|Tablets, Oral, 2 - 20 mg variable dose once daily, 14 weeks
1740876|NCT00105209|Drug|Aspirin|
1740877|NCT00105209|Drug|clopidogrel|
1740878|NCT00105222|Drug|Sodium Nitrite|
1740879|NCT00105235|Drug|Alemtuzumab|T-cell depleting monoclonal antibody; two doses by intravenous infusion on Days 0 and 4
1740880|NCT00105235|Drug|Cyclosporine|Oral immunosuppressant
1740881|NCT00105235|Drug|Mycophenolate mofetil|Oral immunosuppressant
1740882|NCT00105235|Drug|Tacrolimus|Oral immunosuppressant
1740883|NCT00105235|Procedure|Liver transplant|Occurs at study entry
1740884|NCT00105235|Procedure|Immunosuppression withdrawal|Beginning no earlier than Year 1
1740885|NCT00105248|Behavioral|patient-centered communication training|
1740886|NCT00105287|Drug|OraVescent fentanyl (OVF)|
1740887|NCT00105300|Drug|Adalimumab|
1740888|NCT00105313|Drug|MEDI-507|
1740889|NCT00105326|Drug|paliperidone ER|
1740890|NCT00105352|Procedure|Mixed Meal Tolerance Test|
1740891|NCT00105352|Procedure|Glucagon Stimulation Test|
1740892|NCT00105365|Device|Shoe insert|Subjects with knee OA underwent gait analysis and knee pain and function assessment at baseline while wearing walking shoes and after four weeks of wearing walking shoes with lateral-wedged insoles.
1740893|NCT00105365|Other|walking shoes|walking shoes
1740894|NCT00105378|Behavioral|Dutch EASYcare Study Geriatric Intermediate Care Programme|
1740895|NCT00105404|Drug|Triamcinolone Acetonide|
1740896|NCT00105417|Drug|IL-7|
1740897|NCT00105430|Procedure|Deep Brain Stimulation|
1740898|NCT00105443|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg was administered orally at a dose of 400 mg (2 x 200 mg tablets) twice daily (bid); 2 dose reductions to predefined levels of 400 mg once daily (OD) and 400 mg every other day were permitted for adverse events related to study treatment.
1740899|NCT00105443|Drug|Placebo|Sorafenib-matching placebo tablets were orally administered twice daily (bid).
1740900|NCT00105469|Drug|AzaSite|AzaSite ophthalmic solution; one topical drop to the infected eye or eyes twice daily (in the morning and at bedtime) on Days 1 and 2 followed by once daily (in the morning between 7 and 10am) on Days 3 through 5.
1740901|NCT00105469|Drug|Tobramycin|Tobramycin ophthalmic solution; one topical drop to the infected eye or eyes four times daily at 4 to 6 hour intervals (first dose in the morning between 7 and 10am) for 5 days.
1740902|NCT00105482|Drug|Naltrexone|Drug: Naltrexone 12.5 mg oral capsule once per day for 1 day then 25 mg oral capsule once per day for 27 weeks
1740903|NCT00105482|Drug|Transdermal nicotine replacement|Transdermal nicotine replacement (21 mg for first 6 weeks post-quit then 14 mg for 2 weeks) once per day + naltrexone 25 mg oral capsule once per day
1740904|NCT00105482|Behavioral|Behavioral counseling|Brief behavioral counseling and research assessments are provided for two sessions prior to the quit date and then weekly for two weeks, bi-weekly for a month and every four weeks thereafter.
1740905|NCT00105495|Drug|Ferriprox (deferiprone)|
1740906|NCT00105495|Drug|Desferal (deferoxamine)|
1740907|NCT00113425|Device|V-Beam laser, Candela Corp., 595 nm wavelength|Subjects will receive a series of up to 6 laser therapy sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, laser treatment parameters will be within the guidelines normally used clinically with the V-Beam laser, and thus fluences used will not exceed 15 J/cm2.
1740908|NCT00113438|Drug|Combretastatin A-4 Phosphate + Paclitaxel + Carboplatin|Combretastatin A-4 Phosphate is administered IV at 45 mg/m2 or 60 mg/m2 on Days 1, 8 and 15 followed by paclitaxel (3 hour infusion at 200 mg/m2) and carboplatin (1 hour infusion at AUC = 6) on Day 2 of each cycle. The treatment cycle is 21 days with a maximum of 21 days. Following cycle 6, subjects that have not progressed may continue on CA4P monotherapy, which will be administered at 45 mg/m2 or 60 mg/m2 on Days 1 and 8 with rest on Day 15, repeated every 21 days until disease progression.
1740909|NCT00113477|Drug|Q10|
1740910|NCT00113477|Drug|Selen|
1740911|NCT00113490|Biological|motavizumab (MEDI-524)|Patients will receive 15 mg/kg MEDI-524 administered IM every 30 days for a total of 4-5 injections.
1740912|NCT00113490|Biological|palivizumab 15 mg/kg|Patients will receive 15 mg/kg palivizumab administered IM every 30 days for a total of 4-5 injections.
1740985|NCT00114218|Drug|Docetaxel|Given IV
1740917|NCT00113516|Drug|sunitinib|50 mg orally daily for 4 weeks followed by 2 weeks off treatment up to 1 year (after completing 1 year of treatment, pts deriving clinical benefit may continue to receive sunitinib in a separate continuation protocol).
1740918|NCT00113529|Drug|Gefitinib + Sunitinib|Until disease progression or unacceptable toxicity.
1740919|NCT00113542|Drug|Tetrathiomolybdate (TM)|
1740921|NCT00113568|Drug|Tranexamic acid tablets (XP12B)|Two 650 mg tranexamic acid tablets (XP12B) taken 3 times daily (3900 mg/Day) for a maximum of 5 days during monthly menstruation
1740922|NCT00113581|Drug|EMD 72000 (matuzumab) + ECX|
1740923|NCT00113594|Drug|Olanzapine|
1740924|NCT00113607|Drug|Trabectedin|Type=exact number, unit=mg/m2, number=1.1, form=solution, route=IV. Trabectedin will be administered over 3 hours every 3 weeks.
1740925|NCT00113607|Drug|DOXIL|Type=exact number, unit=mg/m2, number=30, 50, form=solution, route=IV. DOXIL will be administered over 90 minutes every 4 weeks when administered alone (monotherapy) and every 3 weeks when administered with trabectedin.
1740926|NCT00113607|Drug|Dexamethasone|Type=exact number, unit=mg, number=20, form=solution, route=IV. Dexamethasone or its equivalent will be administered over 30 minutes prior to the DOXIL infusion.
1740927|NCT00113620|Drug|Neurodex|
1740928|NCT00113633|Behavioral|Intervention Subjects|The subject's family will view a brief educational video about asthma control and therapy developed using provider and patient focus groups; a mailed reminder will be sent to the family to schedule a follow-up appointment.
1740929|NCT00113646|Drug|MEDI-507|MEDI-507 0.1 mg/kg on transplant day-8, 0.6 mg/kg on days-7 and -6
1740930|NCT00113646|Procedure|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|Cyclophosphamide 60 mg/kg on transplant days -7 and -6; Fludarabine 25 mg/m2 days -5,-4,-3,-2,-1; MEDI-507 0.1 mg/kg on day -8, 0.6 mg/kg on days -7,-6
1740931|NCT00113659|Dietary Supplement|Probiotic|Daily dose of ten to the tenth colony-forming units of Lactobacillus GG and 225 mg of inulin for the first 6 months of life.
1740932|NCT00113659|Dietary Supplement|Placebo|Daily dose of placebo supplement containing 325mg inulin for the first 6 month of life.
1740933|NCT00113672|Behavioral|Increase healthy activity and increase healthy eating|Increase participants to 60 minutes of activity per day and 5 fruits and vegetables per day over a 3 week prescription phase
1740934|NCT00113672|Behavioral|Decrease unhealthy activity and increase healthy eating|Decrease sedentary activity by 90 minutes per day and increase fruits and vegetables to 5 servings per day over the course of a 3 week prescription phase
1740935|NCT00113672|Behavioral|Increase physical activity and decrease unhealthy eating|Increase physical activity up to 60 minutes per day and decrease saturated fat to an average of 8% per day over the course of a 3 week prescription phase
1740936|NCT00113672|Behavioral|Decrease sedentary activity and decrease unhealthy eating|Decrease sedentary activity by 90 minutes per day and decrease saturated fat to and average of 8% per day over the course of a 3 week prescription phase
1740937|NCT00113685|Drug|Hypertonic Saline-Dextran Solution|
1740938|NCT00113685|Drug|Lactated Ringer's Solution|
1740939|NCT00113698|Drug|Enalapril|Up-titration period is to reach the highest tolerated dose up to a maximum of 0.4 mg/kg/day
1740940|NCT00113698|Other|Placebo|Placebo An inert preparation with similar appearance and taste to the drug
1740941|NCT00113711|Behavioral|smoking cessation|
1740942|NCT00113711|Behavioral|reducing diet|
1740943|NCT00113724|Drug|TPI 287 Injection|
1740944|NCT00113737|Drug|fluoxetine|
1740945|NCT00113737|Behavioral|cognitive behavioral therapy|
1740946|NCT00113750|Biological|TreeMATA MPL|
1740947|NCT00114036|Behavioral|Quality improvement strategies|
1740948|NCT00114049|Drug|GW406381|
1740949|NCT00114062|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
1740950|NCT00114075|Procedure|Surgery with gait analysis report|Orthopaedic surgery with access to gait analysis report
1740951|NCT00114075|Procedure|Surgery without gait analysis report|Orthopaedic surgery without access to gait analysis report
1740952|NCT00114088|Procedure|hysterectomy|
1740953|NCT00114088|Procedure|endometrial ablation|
1740960|NCT00114114|Drug|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 10 gms topically each day
1740961|NCT00114114|Drug|Testosterone|Androgel placebo or 1.25, 2.5, 5. or 7.5 gms topically each day
1740962|NCT00114114|Drug|Anastrazole|1 mg by mouth daily
1740963|NCT00114114|Drug|Goserelin acetate|3.6 gms sc every 4 weeks
1740964|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day
1740965|NCT00114127|Drug|Duloxetine|60 mg duloxetine 1x per day + 60mg duloxetine 1x per day
1740966|NCT00114127|Drug|Placebo|60mg placebo 1x per day
1740970|NCT00114153|Drug|capecitabine|
1740971|NCT00114153|Drug|carboplatin|
1740972|NCT00114153|Procedure|conventional surgery|
1740973|NCT00114153|Radiation|radiation therapy|
1740974|NCT00114166|Drug|topotecan hydrochloride|
1740975|NCT00114179|Drug|capecitabine|Given orally
1740976|NCT00114179|Radiation|radiation therapy|Undergo radiotherapy
1740977|NCT00114179|Biological|bevacizumab|Given IV
1740978|NCT00114179|Procedure|therapeutic conventional surgery|Undergo surgery
1740979|NCT00114179|Drug|gemcitabine hydrochloride|Given IV
1740980|NCT00114192|Drug|docetaxel|
1740981|NCT00114192|Drug|thalidomide|
1740982|NCT00114205|Drug|docetaxel|
1740983|NCT00114205|Procedure|therapeutic thoracoscopy|
1740984|NCT00114218|Drug|Gemcitabine Hydrochloride|Given IV
1740989|NCT00114231|Radiation|radiation therapy|Undergo radiotherapy
1740990|NCT00114244|Drug|sorafenib tosylate|Given PO
1740991|NCT00114244|Drug|gemcitabine hydrochloride|Given IV
1740992|NCT00114244|Other|laboratory biomarker analysis|Correlative studies
1740993|NCT00114257|Drug|decitabine|
1740994|NCT00114257|Drug|romidepsin|
1740995|NCT00114270|Drug|letrozole|
1740996|NCT00114270|Drug|zoledronic acid|
1740997|NCT00114283|Drug|lapatinib ditosylate|Given PO
1740998|NCT00114283|Other|laboratory biomarker analysis|Correlative studies
1740999|NCT00114296|Dietary Supplement|omega-3 fatty acid|
1741000|NCT00114309|Drug|131-I-TM-601|131I-TM601, in solution, delivered intracavitarily following surgical resection 3 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
1741001|NCT00114309|Drug|131I-TM601|131I-TM601, in solution, delivered intracavitarily following surgical resection 6 weekly administrations, 0.8 mg TM601 and 40mCi 131Iodine, per dose.
1741002|NCT00114322|Device|light exposure from LED source at narrow 468 nm or broader 400-700 nm wavelength|
1741003|NCT00114348|Procedure|R-Blocks|
1741004|NCT00114348|Procedure|Protocol II-Ida|
1741005|NCT00114361|Drug|Ribavirin|1200 mg a day, 48 weeks
1741006|NCT00114361|Drug|Peginterferon alpha 2a|180 µg per week, 48 weeks
1741007|NCT00114374|Drug|Escitalopram|
1741008|NCT00114387|Drug|DL-alpha-tocopherol|
1741009|NCT00114400|Drug|folic acid|
1741010|NCT00114400|Drug|vitamin B12|
1741011|NCT00114400|Drug|vitamin B6|
1741012|NCT00114413|Drug|Inhaled corticosteroids|Used for both regular asthma control and as a rescue inhaler
1741013|NCT00114413|Procedure|eNO measurement|measured by Aerocrine® NIOX device
1741014|NCT00114426|Device|non-invasive mechanical ventilation|
1741015|NCT00114439|Drug|Lithium carbonate|
1741016|NCT00114452|Drug|Provacel|
1741017|NCT00114465|Drug|VSL#3|VSL#3 1 sachet twice a day
1741018|NCT00114465|Other|Placebo|Placebo 1 sachel twice a day
1741021|NCT00114491|Drug|Rosuvastatin|
1741022|NCT00114504|Drug|simvastatin|simvastatin 5-10 mg/day
1741023|NCT00114517|Drug|Oral 17B-estradiol|Oral 17B-estradiol 1 mg daily
1741024|NCT00114517|Drug|Placebo|Matched placebo oral 17B-estradiol
1741025|NCT00114530|Biological|mHSCT|Hematopoietic progenitors were mobilized with G-CSF. After leukapheresis and CD34+ cell enrichment, the autologous product was cryopreserved. Fractionated TBI (800 cGy), CY (120 mg/kg) and equine antithymocyte globulin (90 mg/kg) were administered as previously reported (References provided in citation section of this ClinicalTrials.gov record: PubMed ID: 17452515 citation and 2.) PubMed ID: 12176878 citation).
1741026|NCT00114530|Drug|cyclophosphamide|An initial intravenous dose of 500 mg/m^2 was followed by 11 infusions of 750 mg/m^2 with mesna given for bladder protection.
1741027|NCT00114543|Procedure|Aggressive Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-14.
1741028|NCT00114543|Procedure|Aggressive Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach 5 mg/dl during days of life 1-7, and started, stopped, and/or restarted when levels reach 7 mg/dl during days of life 8-14.
1741029|NCT00114543|Procedure|Conservative Phototherapy 501-750g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥8.0 mg/dl during days of life 1-14.
1741030|NCT00114543|Procedure|Conservative Phototherapy 751-1000g|Phototherapy started, stopped, and/or restarted when total serum bilirubin levels reach ≥10.0 mg/dl during days of life 1-14.
1741031|NCT00114556|Drug|zoledronic acid|
1741032|NCT00114569|Drug|lorazepam|
1741033|NCT00114582|Procedure|family style dinner|
1741034|NCT00114595|Drug|eicosapentaenoic acid|
1741035|NCT00114608|Device|The Focus™ Neuromuscular Stimulation System|"Electrical foot stimulation was produced by surface electrodes placed on the sole of the foot over the plantar muscle group. Electrical stimulation was delivered by The Focus™ Neuromuscular Stimulation System, Empi, Inc. (St. Paul, MN.) The crucial stimulus parameters were: biphasic symmetrical square wave at 50 pulses per second, phase duration of 300 microseconds, a starting ramp up time of 2 seconds and a finishing ramp down time of 2 seconds per stimulation cycle, and a stimulation cycle of 12 seconds on and 48 seconds off per minute. Stimulation was increased to an intensity just sufficient to create a slight visible muscle twitch. This level of intensity caused no evident discomfort in any of the subjects in our first study. Subjects were continually monitored throughout this study for any indication of discomfort.The Focus™ Neuromuscular Stimulation System created electrical stimulation of the plantar foot muscles."
1741036|NCT00114621|Drug|Anthrax Vaccine|
1741037|NCT00114621|Procedure|Blood Chemistry|
1741038|NCT00114621|Procedure|Hematology|
1741039|NCT00114621|Procedure|Urinalysis|
1741040|NCT00114634|Dietary Supplement|Egg yolk preparation with cholesterol|Egg yolk preparation with cholesterol
1741041|NCT00114634|Dietary Supplement|Egg substitute, without cholesterol|Placebo control. Egg substitute, without cholesterol
1741042|NCT00114660|Drug|Cocoa butter application|
1741043|NCT00114686|Drug|Quetiapine fumarate|
1741044|NCT00114686|Drug|lithium|
1741045|NCT00114686|Drug|divalproex|
1741046|NCT00114699|Drug|CCR5mAb004|
1741047|NCT00114725|Procedure|Laser-assisted intracytoplasmic sperm injection|
1741048|NCT00114738|Drug|Rituximab (R)|Rituximab is given with EPOCH and bortezomib every 3 weeks for 6 cycles.
1741049|NCT00114738|Biological|EPOCH|EPOCH is given with Rituximab and bortezomib every 3 weeks for 6 cycles.
1741050|NCT00114738|Drug|Bortezomib (B)|Bortezomib is given alone for one cycle.
1741051|NCT00114738|Drug|Bortezomib|Bortezomib is given with EPOCH and rituximab every 3 weeks for 6 cycles.
1741052|NCT00114738|Drug|Bortezomib or observation|At the beginning of Part C, patients are randomized to receive bortezomib maintenance or be observed w/o bortezomib.
1741053|NCT00114764|Drug|filgrastim|Filgrastim given daily after induction chemotherapy
1741054|NCT00114764|Drug|pegfilgrastim|Pegfilgrastim given once after induction chemotherapy
1956518|NCT02825992|Device|AcQMap System|3D imaging and mapping system for cardiac chambers
1741058|NCT00114790|Radiation|boronophenylalanine-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
1741059|NCT00114803|Drug|Calcitonin nasal spray (salmon)|
1741060|NCT00114816|Drug|capecitabine|
1741061|NCT00114816|Drug|docetaxel|
1741062|NCT00114829|Procedure|MR colonography with dynamic contrast uptake|
1741063|NCT00114842|Procedure|MR colonography|
1741064|NCT00114855|Drug|HYPOCOL®|
1741065|NCT00114868|Drug|Vitamin A|
1741066|NCT00114894|Other|Safe Sea ™|Safe Sea ™ applied one time at 2 mg/cm2 coverage
1741067|NCT00114894|Other|Placebo|Placebo Coppertone® SPF15 sunscreen(Schering-Plough) applied at 2 mg/cm2 body coverage
1741068|NCT00114907|Behavioral|Consumption of black tea|
1741069|NCT00114920|Drug|Resiquimod|
1741070|NCT00114933|Drug|Stopping nucleosides and continuing lopinavir/ritonavir monotherapy|
1741071|NCT00114946|Drug|Avastin|
1741072|NCT00114959|Drug|Homoharringtonine|"Participants are administered homoharringtonine (omacetaxine) 2.5 mg/m^2 by continuous 24-hour intravenous (IV) infusion daily on Days 1-5 of each 4 week treatment cycle. Participants who do not achieve a meaningful hematologic or cytogenetic response by the end of the fourth cycle are discontinued from the study. Otherwise, participants may continue additional cycles of this combined treatment for a maximum of 12 cycles.
Participants who achieved a molecular or cytogenetic response, or a complete hematologic remission (CHR), could undergo subsequent cycles with a maintenance schedule of homoharringtonine 2.5 mg/m^2 by continuous 24-hour IV infusion daily for 2 days every 4 weeks. Dose escalations in subsequent cycles were allowed by one day at a time if the participant was unable to maintain CHR in the maintenance schedule."
1741073|NCT00114959|Drug|Imatinib Mesylate|Taken by mouth with a daily dose of 400 mg for participants in the chronic phase of chronic myeloid leukemia (CML) or 600 mg for participants in the accelerated or blast phase of CML. For the first cycle of therapy only, imatinib was started on Day 4 of homoharringtonine treatment.
1741074|NCT00114972|Device|Polymer-based Paclitaxel-Eluting TAXUS Express2-SR Stent|Drug Eluting Stent
1741075|NCT00114972|Procedure|Coronary Artery Bypass Surgery|Coronary Artery Bypass Surgery
1741076|NCT00114985|Device|Prostate Immobilization Device|Device placed during radiation treatment
1741077|NCT00115011|Drug|Escitalopram|
1741078|NCT00115024|Drug|Micronized 17B-estradiol|
1741085|NCT00115050|Drug|TMC114|
1741086|NCT00115063|Behavioral|group sessions|group sessions lead by a trained primary care clinic employee
1741087|NCT00115063|Drug|sibutramine, orlistat, diethylpropion|dosage modified according to package insert instructions at discretion of primary care physicians
1741088|NCT00115063|Behavioral|Low Calorie Diet, Health One|liquid diet for 8-12 weeks to induce weight loss
1741089|NCT00115063|Other|Intensive Medical Combination Therapy for Obesity|"Very Low Calorie Liquid diet, Group Behavioral Therapy, Meal Replacement Therapy, Obesity Pharmacotherapy and a Treatment Toolbox."
1741090|NCT00115063|Other|Control Condition|Access to the Mayo Clinic weight management website and usual care from the primary care physician
1741091|NCT00115076|Drug|Efalizumab|24 weekly doses of 1.0 mg/kg Efalizumab. Study drug will be administered by SC injection
1741092|NCT00115089|Drug|R926112|
1741093|NCT00115089|Drug|Beclomethasone dipropionate|
1741094|NCT00115102|Drug|fentanyl|
1741095|NCT00115102|Drug|S-ketamine|
1741096|NCT00115115|Drug|Dopamine infusion to brain dead organ donors|Dopamine infusion administered at a dosage of 4µg/kg/min starting after brain death has been proven until to surgical procurement of the kidneys
1741097|NCT00115128|Drug|filgrastim|Normal donors being treated with filgrastim for PBPC mobilization and collection
1741098|NCT00115141|Drug|Resiquimod|
1741099|NCT00115154|Drug|Aldara (imiquimod) cream, 5%|
1741100|NCT00115167|Drug|Placebo|Q4W
1741101|NCT00115167|Drug|Darbepoetin alfa|Q4W
1741102|NCT00115180|Other|No intervention|No intervention
1741103|NCT00115193|Drug|pegfilgrastim|pegfilgrastim 6 mg on day 1 of each cycle (within 4 hours of chemotherapy completion)
1741104|NCT00115193|Drug|pegfilgrastim|pegfilgrastim 6 mg on day 2 of each cycle (at least 24 hours after chemotherapy completion)
1741105|NCT00115206|Drug|Neulasta® (pegfilgrastim)|
1741106|NCT00115219|Drug|Etanercept|
1741107|NCT00115245|Drug|Telbivudine (LdT)|
1741108|NCT00115245|Drug|Adefovir Dipivoxil|
1741109|NCT00115258|Other|parenteral nutrition titrated to measured REE|
1741110|NCT00115271|Drug|Nutritional supplements|
1741111|NCT00115284|Behavioral|ABIM asthma practice improvement module|
1741234|NCT00116311|Behavioral|withdrawal of medication|
1956527|NCT02820844|Drug|GSK1358820|GSK1358820 injection contains botulinum toxin type A (100 U), sodium chloride (0.9 milligrams [mg]), and human serum albumin (0.5 mg). 10 mL of the drug will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 centimeter (cm) apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
1741112|NCT00115297|Drug|Montelukast|Participants who are 2 to 3 years old received 5-mg montelukast tablets and participants who are 12 months to 2 years old received 4-mg montelukast granules.
1741113|NCT00115297|Drug|Placebo|Participants who were 2 to 3 years old received placebo montelukast tablets and participants who were 12 months to 2 years old received placebo montelukast granules.
1741114|NCT00115310|Drug|NGX-4010|
1741115|NCT00115323|Behavioral|Problem Solving|Problem solving intervention
1741116|NCT00115323|Behavioral|Attention Control|Attention control intervention
1741117|NCT00115336|Drug|Intravenous Ketorolac|Intravenous ketorolac
1741118|NCT00115336|Drug|Ibuprofen|Ibuprofen, taken orally
1741119|NCT00115349|Drug|Deferoxamine|Deferoxamine will be given daily for 12-24h/day 7 days a week either subcutaneous or intravenous at up to 50-60 mg/kg/day.
1741120|NCT00115349|Drug|Deferiprone (L1)|The dose of L1, 75mg/kg in three divided oral doses, is the maximum dose at which toxicity has been tested in prospective trials
1741121|NCT00115362|Drug|venlafaxine|
1741122|NCT00115375|Drug|Clopidogrel (SR25990)|
1741123|NCT00115388|Procedure|Screening for chlamydia using self-taken vaginal swabs|Women in the intervention group will be tested for chlamydia and those found to be infected will be referred for treatment and partner notification
1741124|NCT00115414|Drug|pegfilgrastim|
1741125|NCT00115414|Drug|docetaxel|
1741126|NCT00115414|Drug|doxorubicin|
1741127|NCT00115414|Drug|cyclophosphamide|
1741128|NCT00115427|Drug|Liatermin (r-metHuGDNF)|
1741129|NCT00115440|Radiation|Bononophenylalanine (BPA)-based BNCT|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
1741130|NCT00115453|Radiation|irradiation|Boronophenylalanine is infused into a peripheral vein prior to neutron irradiation.
1741131|NCT00115466|Procedure|Non-surgical autologous implant of ASCs|
1741132|NCT00115479|Drug|intensive insulin therapy to maintain normoglycemia|
1741133|NCT00115492|Drug|Fluticasone Propionate/Salmeterol Combination Product|
1741134|NCT00115492|Drug|Salmeterol|
1741135|NCT00115505|Other|quality-of-life assessment|Complete Subjective Significance Questionnaire, MOS Social Support Survey, Patient Preferences, CALGB Background Information, and EQ-5D and QOL Assessment Form, EORTC QLQ-C30 and EORTC QLQ-BR23
1741136|NCT00115505|Other|Questionnaire Administration|Complete the Employment and Informal Care Cost Assessment and Peripheral Neuropathy Assessments
1741137|NCT00115518|Drug|cetuximab|After Cetuximab loading dose. weekly cetuximab during RT. 13 weeks cetuximab weekly maintenance
1741138|NCT00115531|Biological|Trivalent inactivated influenza vaccine|Standard Dose Influenza Vaccine Fluzone® (15 µg HA / viral strain; 45 µg/0.5 mL dose) will be administered to Arm 1: 200 subjects intramuscularly on day 0.
1741139|NCT00115531|Biological|Trivalent inactivated influenza vaccine|High Dose Influenza Fluzone® Vaccine (60 µg HA / viral strain; 180 µg/0.5 mL dose) will be administered to Arm 2: 200 subjects intramuscularly on Day 0.
1741140|NCT00115544|Drug|Stanate|Intramuscular injection of stannsoporfin at 0.75 or 1.5mg/kg for treatment of severe hyperbilirubinemia to prevent exchange transfusion
1741141|NCT00115557|Other|Practice intervention|Performance feedback, academic detailing, practice facilitation, IT support
1741142|NCT00115557|Other|Practice intervention 2|Performance feedback only.
1741143|NCT00115570|Drug|Insulin glulisine|Subcutaneous injection
1741144|NCT00115570|Drug|insulin lispro|Subcutaneous injection
1741145|NCT00115570|Drug|insulin glargine|Subcutaneous injection once daily
1741146|NCT00115570|Drug|NPH insulin|subcutaneous injection twice daily
1741147|NCT00115583|Drug|Drug Infusion (BQ-123)|
1741148|NCT00115596|Other|Formal Curriculum; Low-Fidelity Simulation|The intervention was a formal procedural skills training curriculum consisting of didactic lectures and simulation training.
1741149|NCT00115609|Drug|efavirenz|800mg for patients treated by rifampicine 600mg for other patients
1741150|NCT00115609|Drug|tenofovir DF|300mg once a day
1741151|NCT00115609|Drug|emtricitabine|one pill of 200mg once a day
1741152|NCT00115622|Drug|fluticasone furoate|
1741153|NCT00115635|Drug|docetaxel|
1741154|NCT00115635|Drug|gemcitabine|
1741155|NCT00115648|Drug|Nevirapine|Oral NVP daily dosage
1741156|NCT00115648|Drug|AZT|Oral AZT daily
1741157|NCT00115648|Drug|NVP and AZT|Oral single dose NVP plus oral daily AZT during the first weeks
1741158|NCT00115648|Drug|NVP|Oral NVP daily to age 14 weeks
1741159|NCT00115648|Drug|NVP+AZT|Oral NVP daily plus oral AZT daly to age 14 weeks
1741160|NCT00115661|Drug|Rosiglitazone|
1741161|NCT00115687|Drug|placebo|
1741162|NCT00115687|Drug|2 mg nicotine polacrilex|
1741163|NCT00115700|Drug|Cyclophosphamide|1000 mg/m2 I.V. on day 1
1741164|NCT00115700|Radiation|Radiotherapy|The prescribed dose to the target volume will be 30 Gy. Daily fractions of 1.5-2.0 Gy will be employed.
1741165|NCT00115700|Drug|Vincristine|1.4 mg/m2 (maximum single dose of 2 mg) I.V. on day 1
1741166|NCT00115700|Drug|Prednisolone|50 mg/m2 orally daily for days 1 - 5
1741167|NCT00115700|Drug|Rituximab|375 mg/m2 IV Infusion day 1
1741168|NCT00115713|Behavioral|Aerobic Exercise Training|
1741169|NCT00115713|Behavioral|Resistance Exercise Training|
1741170|NCT00115726|Drug|furosemide|for patients on chronic furosemide therapy, patients are randomized to furosemide (at their previous dose) or placebo (given in identical form to ensure masking)
1741171|NCT00115726|Drug|placebo|patients will be given placebo capsules (identical to experimental arm in color) at the equivalent dose as to their chronic furosemide therapy.
1741172|NCT00115739|Drug|Imatinib|Imatinib 400 mg capsules were administered twice daily with food for 4 week cycles.
1741173|NCT00115752|Drug|Valdecoxib|
1741174|NCT00115752|Drug|COX Inhibitor|
1741175|NCT00115765|Drug|Oxaliplatin Based Chemotherapy|Oxaliplatin-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) consisting of Oxaliplatin, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
1741176|NCT00115765|Drug|Panitumumab|PanitumumabPanitumumab is a high affinity (Kd = 5 x 10-11 M) fully human IgG2 monoclonal antibody that is directed against the human EGFr. Panitumumab will be administered by a 30-60 minute IV infusion at a dose of 6 mg/kg once every 2 weeks on the same day of the oxaliplatin- or irinotecan-based chemotherapy and bevacizumab.
1741177|NCT00115765|Drug|Irinotecan Based Chemotherapy|Irinotecan-based Chemotherapy Every 2 Week Regimens (Q2W Cycles) - Irinotecan, Leucovorin (LV), 5-Fluorouracil (5-FU) - To be determined by physician. On Day 1 irinotecan and LV are given at the same time using different bags and a Y-line followed by 5-FU administration.
1741178|NCT00115765|Drug|Bevacizumab|Bevacizumab is a vascular endothelial growth factor (VEGF)-targeted antibody therapy that was administered to subjects intravenously Q2 weeks as per usual standard of care on the same day of chemotherapy and panitumumab administration .
1741180|NCT00115791|Drug|RSD1235|IV
1741181|NCT00115791|Drug|placebo|IV
1741182|NCT00115804|Drug|Fluoxetine|Fluoxetine po 10-60 mg/day for 12 weeks. Fluoxetine was started at 10 mg once daily. The dose was flexibly dosed based on pain efficacy and tolerability to a final dose between 10 and 60 mg once daily
1741183|NCT00115817|Drug|Atorvastatin|
1741184|NCT00115830|Drug|Atorvastatin|
1741185|NCT00115830|Drug|Rosuvastatin|
1741186|NCT00115843|Device|Mobile Cardiac Outpatient Telemetry|
1741187|NCT00115856|Procedure|Intravascular MRI|Arterial imaging of atherosclerosis
1741188|NCT00115869|Behavioral|Social-influences|grades 3-10, school-based social influences tobacco use prevention curriculum
1741189|NCT00115882|Behavioral|MI + CBST|The HS Study intervention consisted of proactive identification and recruitment of eligible smokers (and selected nonsmokers) within the target population, and a protocol-guided series of counselor-initiated, personally-tailored telephone calls (from 1 to 10, depending on participant's interest) to eligible high school senior smokers and nonsmokers in experimental high schools. The telephone-delivered behavioral intervention integrated Motivational Interviewing and Cognitive Behavioral Skills building. Content and dose were tailored to the individual.
1741190|NCT00115895|Drug|Radioactive iodine|Radioiodine is radionuclear treatment given in oral capsules in two activies 1,1 and 3,7 GBq
1741191|NCT00115908|Drug|Albuferon|
1741192|NCT00115908|Drug|Ribavirin|
1741193|NCT00115908|Drug|PEG-IFNalfa2a|
1741194|NCT00115921|Behavioral|Provision of antimalarial treatment at home|
1741195|NCT00115934|Procedure|Blalock-Taussig pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
1741196|NCT00115934|Procedure|Right ventricular to pulmonary artery shunt|Performed at stage I palliative surgery for babies born with HLHS
1741197|NCT00115947|Drug|Terlipressin|
1741198|NCT00115960|Biological|HIV-1 gag DNA|DNA vaccine containing the HIV gene gag
1741199|NCT00115960|Biological|IL-15 DNA adjuvant|Cytokine injection
1741200|NCT00115960|Biological|IL-12 DNA adjuvant|Cytokine injection
1741201|NCT00115973|Device|pump|
1741202|NCT00115973|Drug|insulin aspart|
1741203|NCT00115986|Biological|Influenza A/H5N1 Vaccine|
1741204|NCT00115999|Drug|alfimeprase|
1741205|NCT00116012|Drug|rNAPc2|
1741206|NCT00116025|Drug|Human acylated ghrelin|
1741207|NCT00116038|Device|Femoral implant (Versys Fiber Metal Taper®)|
1741208|NCT00116051|Device|Acetabular implant, Monoblock cup|
1741209|NCT00116064|Drug|intranasal lorazepam|
1741210|NCT00116064|Drug|intramuscular paraldehyde|
1741211|NCT00116103|Drug|Tacrolimus Inhalation Aerosol|
1741212|NCT00116116|Drug|efavirenz, stavudine extended release, lamivudine|
1741213|NCT00116129|Drug|Ibutamoren Mesylate (MK-0677)|Ibutamoren Mesylate 25 mg/day
1741214|NCT00116142|Drug|Docetaxel|60 mg/m² q 3 weeks for 3 cycle at the start of treatment followed by weekly Docetaxel at 20 mg/m² per week beginning at week one of radiation therapy and continuing for seven weeks.
1741215|NCT00116142|Drug|Androgen Hormonal Suppression and Radiation|Total Androgen Ablation and external beam radiation therapy
1741216|NCT00116142|Drug|Androgen Suppression Therapy and Radiation Therapy|Total Androgen Ablation and External Beam Radiation Therapy
1741217|NCT00116155|Biological|CV787 (CG7870)|
1741218|NCT00116168|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, subcutaneous (SC) dose
1741219|NCT00116168|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, SC dose
1741220|NCT00116168|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, SC dose
1741221|NCT00116168|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, SC dose
1741222|NCT00116181|Drug|Etanercept|"All subjects will administer etanercept 50 mg twice weekly subcutaneously (2 injections of 25 mg etanercept SC within 1 hour twice weekly) for the first 12 weeks of study.
Subjects randomized to the continuous therapy arm will then receive 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) for weeks 13 through 24. Subjects randomized to the intermittent therapy arm will be assessed for response. Those who achieve a responder status on the PGA (PGA score £ 2 and improved from baseline) at week 12 will discontinue therapy. Upon relapse of PGA responder status, etanercept will be administered 50 mg once weekly SC (2 injections of 25 mg etanercept SC within 1 hour once weekly) through week 24."
1741223|NCT00116194|Behavioral|Physical Activity|
1741224|NCT00116207|Drug|ORAL ANTIOXIDANT|Comparison of triple antioxidant combination therapy vs placebo.
1741225|NCT00116220|Drug|Flutamide (Eulexin) and Lupron or Zoladex|Androgen suppression therapy
1741226|NCT00116220|Radiation|External Beam Radiotherapy|Once a day, 4-5 days per week for approximately 2 months
1741227|NCT00116233|Device|REPEL-CV|
1741228|NCT00116246|Procedure|McRobert's manoeuvre|
1741229|NCT00116259|Drug|Aripiprazole|
1741230|NCT00116272|Drug|Etanercept|Pregnant women previously exposed to etanercept during the first trimester. Etanercept was not administered in this non-interventional study.
1741231|NCT00116285|Biological|Ragweed MATA MPL|
1741232|NCT00116298|Drug|stavudine, efavirenz, lamivudine|
1741233|NCT00116311|Behavioral|allergen inhalation|
1741235|NCT00116311|Procedure|sputum induction|
1741236|NCT00116324|Drug|Montelukast|
1741237|NCT00116337|Procedure|Spinal Cord Stimulation|Participants will have small electrodes (metal discs) placed — by a routine surgical procedure — over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are then activated at subsequent study visits using the external control unit.
1741238|NCT00116337|Device|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
1741239|NCT00116350|Drug|Misoprostol|800 mcg sublingual misoprostol
1741240|NCT00116350|Drug|Oxytocin|40 IU Oxytocin IV
1741241|NCT00116363|Genetic|investigational drug INGN 241|
1741242|NCT00116376|Drug|AEE788|
1741243|NCT00116389|Drug|talabostat mesylate tablets|
1741244|NCT00116389|Drug|gemcitabine|
1741245|NCT00116402|Drug|fluticasone and salmeterol|"will start with fluticasone 220 mcg BID first and then crossover to combination therapy with salmeterol 50 mcg BID
will start with salmeterol 50 mcg BID first and then crossover to combination therapy with fluticasone 220 mcg BID."
1741246|NCT00116415|Drug|efavirenz; didanosine EC; lamivudine|
1741249|NCT00116441|Biological|Therapeutic Cellular Vaccine, GM-CSF Producing|
1741250|NCT00116454|Drug|131 I-lipiodol|intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment
1741251|NCT00116467|Biological|GVAX leukemia vaccine (therapeutic cellular vaccine, GM-CSF producing)|
1741252|NCT00116480|Drug|Misoprostol|600 mcg of sublingual misoprostol
1741253|NCT00116493|Dietary Supplement|Iron-folic acid and mebendazole|"100 mg iron for pregnant women, 25 mg iron for children
1 mg of folic acid for pregnant women, 100 ug folic acid for children 500 mg of mebendazole for both pregnant women and children"
1741254|NCT00116493|Drug|Mebendazole|100 mg twice a day for 3 days; Iron-folic acid also given
1741255|NCT00116493|Dietary Supplement|Multivitamins|Iron-folic acid also given; Includes vitamins A, C, B12, E, and B2
1741256|NCT00116493|Drug|Mebendazole + Multivitamin|Multivitamins + Mebendazole at 100 mg twice a day for 3 days; Iron-folic acid also given
1741257|NCT00116506|Drug|erlotinib|
1741258|NCT00116506|Drug|FOLFOX|
1741259|NCT00116506|Drug|bevacizumab|
1741260|NCT00108459|Behavioral|Low Carbohydrate Diet|
1741261|NCT00108485|Drug|Extended release niacin|Extended release niacin 1500-2000mg once daily
1741262|NCT00108485|Other|Placebo|Placebo tablets
1741263|NCT00108498|Drug|mirtazapine|
1741264|NCT00108511|Drug|Gemfibrozil|
1741265|NCT00108524|Behavioral|Low carbohydrate ketogenic diet|A low-carb diet limits carbohydrates - such as grains, starchy vegetables and fruit - and emphasizes dietary protein and fat.
1741266|NCT00108524|Drug|Orlistat|In addition to the low fat diet, Orlistat is taken 3 times daily.
1741267|NCT00108524|Behavioral|Low-fat diet|Participants receive counseling on a low fat diet over 48 weeks aimed at reducing fat and calorie intake
1741268|NCT00108537|Drug|bupropion and transdermal patch|
1741269|NCT00108537|Drug|transdermal patch and nicotine inhaler|
1741270|NCT00108550|Drug|gabapentin|Gabapentin 300m on Day 1, with daily or weekly increase to 3600 mg (maximum) by mouth by Week 5 of the 12-week trial
1741271|NCT00108550|Drug|Inert placebo|Inactive placebo capsule, one capsule on Day 1 with daily or weekly increase to 9 capsules daily by Week 5 of the 12-week trial
1741272|NCT00108563|Drug|Citalopram or Placebo|
1741273|NCT00108576|Drug|Divalproex|anticonvulsant; mood stabilizer
1741274|NCT00108576|Other|placebo|Look-a-like placebo
1741275|NCT00108589|Drug|S-adenosylmethionine|
1741276|NCT00108602|Drug|acetazolamide|
1741277|NCT00108615|Drug|Metformin|
1741278|NCT00108615|Drug|Pioglitazone|
1741279|NCT00108615|Drug|Metformin|
1741280|NCT00108615|Drug|Pioglitazone|
1741281|NCT00108615|Radiation|CT scans|To measure changes in adipose tissue volumes
1741282|NCT00108615|Procedure|Oral glucose tolerance test|To detect a change in glucose tolerance
1741283|NCT00108628|Behavioral|Imagery Rehearsal|IR is a manual-based CBT predicated on the idea that waking mental activity influences nighttime dreams. Veterans examine the content of a recurrent nightmare, use imagery to alter disturbing aspects of the nightmare to promote mastery and control, and rehearse the new dream nightly, before bedtime.
1741284|NCT00108628|Behavioral|Sleep and Nightmare Management|This comparison condition involved psychoeducation about PTSD, sleep and nightmares, progressive muscle relaxation and standard CBT for insomnia. This latter part included education about sleep hygiene (e.g., avoidance of caffeine and alcohol close to bedtime, benefit of regular bed time routines), stimulus control and sleep restriction (i.e., reestablishing a conditioned association between the bed/bedroom and sleep by reducing time spent tossing and turning in bed). Therapists worked with patients to identify problem areas in their sleep habits and to problem-solve about possible treatment targets
1741285|NCT00108654|Drug|VRC-HIVADV014-00-VP|
1741286|NCT00108667|Drug|IV Levodopa|
1741287|NCT00108667|Drug|Talampanel|
1741288|NCT00108706|Drug|Candesartan|
1741289|NCT00108732|Drug|Bicalutamide|Given orally
1741290|NCT00108732|Drug|Goserelin Acetate|Given SC
1741291|NCT00108732|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
1741292|NCT00108732|Biological|Recombinant Vaccinia-TRICOM Vaccine|Given SC
1741293|NCT00108732|Biological|Sargramostim|Given SC
1741294|NCT00108745|Other|Clinical Observation|Undergo observation
1741295|NCT00108745|Other|Laboratory Biomarker Analysis|Correlative studies
1741296|NCT00108745|Drug|Paclitaxel|Given IV
1741297|NCT00108745|Drug|Paclitaxel Poliglumex|Given IV
1741298|NCT00108745|Procedure|Quality-of-Life Assessment|Ancillary studies
1741299|NCT00108758|Drug|activated recombinant human factor VII|
1741300|NCT00108771|Drug|ZR-02-01 Fentanyl Transdermal Matrix Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period.
1741301|NCT00108771|Drug|Placebo Patch|Study patches were replaced every 72 hours and were to be applied on the upper chest or lateral aspect of the upper arms. The patch application sites were to be rotated so the patch was not applied to the same skin site for successive applications. Patients were supplied with Tegaderm if needed to keep the patches adhered during the 72 hour wear period
1741302|NCT00108784|Behavioral|Reduced-energy-density diet|
1741303|NCT00108797|Drug|eptacog alfa (activated)|
1741304|NCT00108797|Drug|Feiba VH|
1741305|NCT00108810|Drug|Transdermal Ketoprofen Patch with CHADD|12 hours patch application for 28 days
1741306|NCT00108810|Drug|Placebo transdermal patch|12 hours application for 28 days
1741307|NCT00108823|Drug|Roflumilast|
1741308|NCT00108836|Drug|XBD173|
1741309|NCT00108849|Drug|estradiol, 10 mcg|
1741310|NCT00108862|Other|Strategy: Immediate ART|The intervention is the strategy of initiating antiretroviral therapy (ART) after approximately 2 weeks of rifampin (RIF)- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is efavirenz (EFV) 600 mg (1 tablet orally), emtricitabine (FTC) 200 mg (1 capsule orally), and tenofovir disoproxil fumarate (TDF) 300 mg (1 tablet orally) daily. Substitutions with other locally available U.S. Food and Drug Administration (FDA)-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
1741311|NCT00108862|Other|Strategy: Deferred ART|The intervention is the strategy of initiating ART either after 8-12 weeks of RIF- or other rifamycin-based TB treatment according to in-country national TB treatment guidelines. The study-provided ART is EFV 600 mg (1 tablet orally), FTC 200 mg (1 capsule orally), and TDF 300 mg (1 tablet orally) daily. Initiation outside of these windows, on a case by case basis, is permitted at the discretion of the site investigator. Substitutions with other locally available U.S. FDA-approved or tentatively approved antiretrovirals that are compatible with TB treatment may be used at the discretion of the site investigator. The TB treatment will be supplied and monitored by the host country TB control program.
1741312|NCT00108875|Biological|Survivin peptide vaccine|
1741313|NCT00108901|Behavioral|Aerobic exercise program|Vigorous intermittent physical activity in group format conducted in research gymnasium after school by research staff. Heart rate monitors documented each child's average heart rate on a daily basis. Small incentives were offered for achieving goal of >150 bpm average HR each day and attending at least 80% of sessions (4 days/week).
1741314|NCT00108914|Drug|GW685698X|
1741315|NCT00108927|Behavioral|TRANSLATE|
1741316|NCT00108953|Drug|Sorafenib (Nexavar, BAY43-9006) plus Doxorubicin|Multi kinase inhibitor plus Chemotherapy
1741317|NCT00108953|Drug|Doxorubicin/Placebo|Chemotherapy plus Placebo
1741318|NCT00108979|Drug|Escitalopram|
1741319|NCT00108992|Drug|Diclofenac, topical|
1741320|NCT00109005|Drug|Revlimid|oral dose (1 capsule) 25 mg per day 7 days a week for cohort 1 oral dose (1 capsule) 5 mg per day 7 days a week for cohort 2
1741321|NCT00109031|Drug|palifermin|Administered as one daily intravenous bolus.
1741322|NCT00109031|Radiation|Total Body Irradiation|To be delivered before the administration of chemotherapy in 6, 8, or 10 fractions over 3 or 4 days.
1741323|NCT00109031|Drug|Cyclophosphamide|Cyclophosphamide is administered at a total dose of 100 mg/kg given in 1 dose on Day -2
1741324|NCT00109031|Drug|Etoposide|Etoposide may be administered (optional) as a single intravenous infusion over 4 hours on the day after the last fTBI fraction.
1741325|NCT00109031|Drug|Placebo|Administered as one daily intravenous bolus.
1741326|NCT00109044|Drug|Escitalopram|
1741327|NCT00109057|Drug|Avastin (bevacizumab)|
1741328|NCT00109070|Drug|Avastin (bevacizumab)|
1741329|NCT00109083|Drug|RWJ-333369|
1741330|NCT00109096|Drug|Pemetrexed|
1741331|NCT00109109|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA) / Duration of Treatment - Up to 8 Cycles or 6 months|
1741332|NCT00109122|Biological|zoster vaccine live (Oka/Merck)|
1741333|NCT00109122|Biological|Comparator: placebo (unspecified)|
1741334|NCT00109135|Drug|taranabant|
1741335|NCT00109148|Drug|MK0364|
1741336|NCT00109161|Drug|Daclizumab (Anti-CD25 Humanized Monoclonal Antibody)|
1741338|NCT00109187|Drug|Xolair (omalizumab)|
1741339|NCT00109200|Drug|Xolair (omalizumab)|
1741340|NCT00109213|Procedure|Lumbar Laminectomy with Instrumented Pedicle Screw Fusion|Removal of bone to decompress spinal nerves with placement of spinal screws and extra bone to strengthen the spine
1741341|NCT00109213|Procedure|Lumbar Laminectomy|Removal of bone to decompress spinal nerves
1741342|NCT00109226|Drug|Avastin (Bevacizumab)|
1741343|NCT00109239|Drug|rhuMAb VEGF (Bevacizumab)|
1741344|NCT00109252|Drug|Raptiva (efalizumab)|
1741345|NCT00109265|Drug|Erlotinib HCl (OSI-774)|
1741346|NCT00109278|Biological|V205C, measles, mumps, and rubella virus vaccine live|
1741347|NCT00109278|Biological|Comparator: Measles, Mumps, and Rubella Virus Vaccine Live|
1741348|NCT00109291|Drug|Placebo|
1741349|NCT00109291|Drug|peginesatide|
1741350|NCT00109304|Biological|VEE 3526|
1741351|NCT00109317|Drug|Raptiva (efalizumab)|
1741352|NCT00109330|Biological|Combined diphtheria, tetanus, acellular pertussis vaccine|
1741353|NCT00109343|Biological|Comparator: ProQuad™ (V221)|0.5-mL subcutaneous injection of measles, mumps, rubella, varicella virus vaccine live (MMRV)
1741354|NCT00109343|Biological|Comparator: PREVNAR™ (pneumococcal 7-valent conjugate vaccine)|0.5-mL intramuscular injection of pneumococcal 7-valent conjugate vaccine
1741355|NCT00109356|Drug|AQ4N (Chemotherapy)|
1741356|NCT00109369|Other|Information and decision support for providers and patients|Laboratory-based decision support, reminders, and population report cards.
1741357|NCT00109382|Drug|Aspirin|
1741358|NCT00109382|Drug|Clopidogrel|
1741359|NCT00109382|Drug|Simvastatin|
1741360|NCT00109395|Drug|Lorazepam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
1741361|NCT00109395|Drug|Midazolam|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
1741362|NCT00109395|Drug|Lorazepam CI|Intravenous dosage forms, administered at dose and frequency per protocol in order to achieve adequate sedation as measured by the Comfort score
1741363|NCT00109408|Drug|Methotrexate|7.5-20mg po weekly
1741364|NCT00109408|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
1741365|NCT00109421|Behavioral|Project ÒRÉ|Community-based adolescent social network HIV/STI intervention tailored to African American culture
1741366|NCT00109460|Behavioral|Tobacco Use Disorder|
1741367|NCT00109473|Drug|growth hormone|Nutropin AQ 0.075mg/kg/day subcutaneously daily
1741368|NCT00109473|Drug|cortecosteroid|As prescribed by the referring gastroenterologist
1741369|NCT00109486|Drug|GW685698X|
1741370|NCT00109499|Drug|AdGVPEDF.11D|
1741371|NCT00109512|Drug|NBI-56418 (GnRH antagonist)|
1741372|NCT00109512|Drug|placebo|
1741373|NCT00109538|Drug|Lonafarnib|200 mg twice daily (BID, ie, approximately 12 hours apart with food), oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
1741374|NCT00109538|Other|Placebo|BID, oral, continuously, or until unacceptable toxicity or transformation to AML, or disease progression, or other discontinuation criteria
1741375|NCT00109551|Drug|zinc sulphate dietary supplement|
1741376|NCT00109551|Drug|iron sulphate-folic acid dietary supplement|
1741377|NCT00109564|Drug|ispronicline (nicotinic acetylcholine receptor agonist)|
1741378|NCT00109577|Drug|MCN36 (nutritional supplement)|nutritional supplement
1741379|NCT00109577|Drug|Placebo|nutritional supplement
1741380|NCT00109590|Drug|Didanosine, enteric-coated|once daily
1741381|NCT00109590|Drug|Lopinavir/ritonavir|twice daily
1741382|NCT00109590|Drug|Nevirapine|single-dose at the onset of labor
1741383|NCT00109590|Drug|Zidovudine|twice daily
1741384|NCT00109603|Drug|Tenofovir disoproxil fumarate|
1741385|NCT00109616|Behavioral|Newborn skin cleansing with 0.25% chlorhexidine solution|
1741386|NCT00109616|Behavioral|Cleansing of umbilical cord with soap and water solution|
1741387|NCT00109616|Behavioral|Cleansing of umbilical cord with 4% chlorhexidine|
1741388|NCT00109629|Drug|VRC-HIVDNA016-00-VP|
1741389|NCT00109629|Drug|VRC-HIVADV014-00|
1741390|NCT00109655|Biological|Oncolytic adenovirus (serotype 5) - CG0070|Intravesical administration of CG0070 (in suspension) directly into the bladder
1741391|NCT00109668|Drug|beclomethasone dipropionate (QVAR)|
1741392|NCT00109681|Drug|Iloprost Inhalation Solution (Ventavis)|
1741393|NCT00109707|Drug|Nilotinib|
1741394|NCT00109720|Behavioral|Diabetes Self-Management Consultant|services of a Diabetes Self-Management Consultant
1741395|NCT00109720|Behavioral|Enhanced Usual Care Control Group|Usual care plus results of metabolic assessments obtained during the study
1741396|NCT00109733|Biological|recombinant human growth hormone|0.005 mg/kg/day for 30 days then increasing, with the Investigator's approval, to 0.010 mg/kg/day from Day 31 to Week 24.
1741397|NCT00109733|Biological|recombinant human growth hormone|0.010 mg/kg/day for 14 days with the opportunity to dose escalate, with the Investigator's approval, on Day 15 to 0.02 mg/kg/day and Day 29 to 0.03 mg/kg/day.
1741398|NCT00109746|Dietary Supplement|chromium picolinate|HIV+ and control may receive 500µg of chromium picolinate or placebo twice daily for two months.
1741399|NCT00109759|Biological|RagweedMATAMPL|
1741400|NCT00109772|Drug|lenalidomide|Two 5 mg capsules taken one time per day
1741401|NCT00109772|Drug|Placebo|Two placebo capsules taken one time per day
1741402|NCT00109785|Procedure|positron emission tomography|
1741403|NCT00109785|Radiation|fludeoxyglucose F 18|
1741404|NCT00109785|Radiation|iodine I 124 iododeoxyuridine|
1741405|NCT00109798|Drug|temozolomide|Patient will take drug on day 1-5 of 28 day schedule
1741406|NCT00109798|Drug|topotecan hydrochloride|Patient will have IV on days 2-6 on a 28-day schedule
1741407|NCT00109811|Biological|PSA:154-163(155L) peptide vaccine|Given subcutaneously
1741408|NCT00109811|Biological|incomplete Freund's adjuvant|Given subcutaneously
1741409|NCT00109811|Other|laboratory biomarker analysis|Correlative studies
1741410|NCT00109824|Drug|decitabine|Given IV
1741411|NCT00109824|Drug|valproic acid|Given PO
1741412|NCT00109824|Other|pharmacological study|Correlative studies
1741413|NCT00109824|Other|laboratory biomarker analysis|Correlative studies
1741414|NCT00109837|Biological|filgrastim|As needed per physician discretion
1741415|NCT00109837|Drug|cyclophosphamide|Cyclophosphamide Consolidation: 650 mg/m2; IV; days 1, 15, 29 Post-consolidation course 3: 650 mg/m2; IV; day 1
1741416|NCT00109837|Drug|cytarabine|Induction 2: 3 g/m2; IV over 3 hrs; days 1-5 Consolidation: 75 mg/m2/d; IV push; days 2-5 and 16-19 Post-consolidation course 3: 75 mg/m2/d; IV push; days 3-6 and 10-13
1741417|NCT00109837|Drug|daunorubicin|Induction: 60 mg/m2/d; IV; days 1, 2, and 3
1741418|NCT00109837|Drug|dexamethasone|Induction 2: 0.1% QID; eye drops; days 1-6 Post consolidation course 2: 10 mg/m2/d; PO; days 1-28
1741419|NCT00109837|Drug|doxorubicin|Post consolidation: 25 mg/m2; IV; days 1, 8, 15, and 22
1741420|NCT00109837|Drug|leucovorin|For CNS during induction: 5 mg every 6 hrs for 4 doses; PO; days 1, 4, 8, 11, etx.; after methotrexate if WBC < 3,000
1741421|NCT00109837|Drug|mercaptopurine|Consolidation: 60 mg/m2; PO; days 1-28 Post-consolidation course 1: 60 mg/m2/d; PO; days 1-63 Post-consolidation course 4: 60 mg/m2/d; PO; daily for 2 yrs
1741422|NCT00109837|Drug|methotrexate|Consolidation: 12 mg; intrathecal or intraventricularly; days 2, 9, 16, and 23 Post-consolidation course 1: 20 mg/m2/wk; PO; days 1, 8 15, 22, 29, 36, 43, 50, 57 Post-consolidation course 4: 20 mg/m2; PO; weekly for 2 yrs
1741423|NCT00109837|Drug|mitoxantrone|Induction 2: 80 mg/m2; IV; day 3
1741424|NCT00109837|Drug|Asparaginase|Induction: 2,000 IU/m2; IM or IV; day 15
1741425|NCT00109837|Drug|prednisone|Induction: 60 mg/m2/d; PO or IV; days 1-35
1741426|NCT00109837|Drug|thioguanine|Post-consolidation course 3: 60 mg/m2/d; PO; days 1-14
1741427|NCT00109837|Drug|vincristine|Induction: 1.4 mg/m2/d (2 mg max); IV; days 1, 8, 15, 22
1741428|NCT00109837|Radiation|radiation therapy|For CNS during consolidation: cranial radiation after blasts are no longer present in spinal fluid. Total dose of 1800 cGy over 2 wks in 10 fractions of 180 cGy 5 days/wk.
1741429|NCT00109837|Drug|allopurinol|300 mg/d PO Days 1-7
1741430|NCT00109837|Drug|bactrim|1 double strenth tablet 2x/d, 2x/wk, PO, begin with prednisone
1741431|NCT00109850|Biological|cetuximab|400mg/m^2 loading dose, intravenous (IV) over 120 min, day 1 of cycle 1 only. 250mg/m^2 maintenance dose, IV over 60 min, Days 8 & 15 of Cycle 1 and Days 1, 8, and 15 of subsequent cycles.
1741432|NCT00109850|Drug|cisplatin|30mg/m^2, bolus intravenous (IV), on Days 1 & 8 of each cycle.
1741433|NCT00109850|Drug|irinotecan hydrochloride|65mg/m^2, intravenous (IV) over 30 min, on Days 1 & 8 of each cycle.
1741434|NCT00109850|Radiation|radiation therapy|The total dose to the prescription point will be 5,040 cGy given in 28 fractions. The patient will be treated with one fraction per day with all fields treated per day. 180 cGy will be delivered to the isocenter. The dose variation in the planning target volume (PTV) will be +7% and -5% of the prescription point dose.
1741435|NCT00109863|Biological|hu14.18-IL2 fusion protein|
1741436|NCT00109876|Procedure|Computed Tomography-Guided Optical Sensor-Guided Radiofrequency Ablation|Undergo RFA
1741437|NCT00109889|Procedure|magnetic resonance imaging|magnetic resonance imaging (MRI)
1741438|NCT00109889|Procedure|positron emission tomography|positron emission tomography (PET)
1741439|NCT00109928|Drug|cisplatin|
1741440|NCT00109928|Drug|etoposide|
1741441|NCT00109928|Drug|gemcitabine|
1741442|NCT00109928|Drug|methylprednisolone|
1741443|NCT00109941|Biological|opioid growth factor|OGF was administered in saline at 250 ug/kg intravenously over 45 minutes
1741444|NCT00109941|Biological|metenkephalin, OGF-opioid growth factor|OGF given in saline iv 250 ug/kg weekly
1741445|NCT00109954|Drug|cisplatin|
1741446|NCT00109954|Radiation|brachytherapy|
1741447|NCT00109954|Radiation|yttrium Y 90 glass microspheres|
1741448|NCT00109967|Biological|rituximab|375 mg/m^2 Given IV
1741449|NCT00109967|Drug|temsirolimus|25 mg given IV
1741450|NCT00109993|Biological|alemtuzumab|alemtuzumab IV over 2 hours on days 4-6, 18, and 32
1741451|NCT00109993|Drug|methylprednisolone|methylprednisolone IV on days 1-3 and then orally or IV on days 4-14
1741452|NCT00109993|Drug|tacrolimus|tacrolimus IV continuously on days 1-7 and then orally once or twice daily on days 8-180, followed by a taper in the absence of chronic graft-vs-host disease
1741453|NCT00110006|Biological|rituximab|Rituximab IV over 3-6 hours. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
1741454|NCT00110006|Drug|cyclophosphamide|Cyclophosphamide IV over 30 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
1741455|NCT00110006|Drug|doxorubicin hydrochloride|Doxorubicin IV over 5 minutes. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
1741456|NCT00110006|Drug|prednisone|Oral prednisone once daily on days 1-5. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
1741457|NCT00110006|Drug|vincristine sulfate|Vincristine IV over 5 minutes on day 1. Treatment repeats every 14-21 days for up to 4 courses in the absence of unacceptable toxicity.
1741458|NCT00110006|Procedure|positron emission tomography|Beginning 1 hour after receiving fludeoxyglucose F 18, patients undergo whole-body positron emission tomography (PET) scanning. Patients undergo repeat ^18FDG-PET scanning between days 7-10 of course 1, between courses 3 and 4, and then at the completion of R-CHOP.
1741459|NCT00110006|Radiation|fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (^18FDG) IV.
1741460|NCT00110019|Drug|Carboplatin|Given IV
1741461|NCT00110019|Other|Laboratory Biomarker Analysis|Correlative studies
1741462|NCT00110019|Drug|Paclitaxel|Given IV
1741463|NCT00110019|Other|Pharmacological Study|Correlative studies
1741464|NCT00110019|Other|Placebo|Given PO
1741465|NCT00110019|Drug|Sorafenib Tosylate|Given PO
1741466|NCT00110032|Drug|EF5|Given IV
1741467|NCT00110032|Procedure|conventional surgery|Undergo surgery
1741468|NCT00110032|Procedure|positron emission tomography|Undergo PET
1741469|NCT00110032|Radiation|fluorine F 18 EF5|Given IV
1741470|NCT00110032|Other|pharmacological study|Correlative studies
1741471|NCT00110045|Drug|caspofungin acetate|
1741472|NCT00110058|Biological|recombinant interferon alfa|
1741473|NCT00110058|Biological|therapeutic allogeneic lymphocytes|
1741474|NCT00110058|Drug|cyclosporine|
1741475|NCT00110058|Drug|fludarabine phosphate|
1741476|NCT00110058|Drug|imatinib mesylate|
1741477|NCT00110058|Drug|mycophenolate mofetil|
1741478|NCT00110058|Procedure|peripheral blood stem cell transplantation|
1741479|NCT00110058|Radiation|radiation therapy|
1741480|NCT00110071|Drug|fludarabine phosphate|Given IV
1741481|NCT00110071|Procedure|peripheral blood stem cell transplantation|Undergo transplantation (infusion of autologous or syngeneic PBSC via central line)
1741482|NCT00110071|Radiation|iodine I 131 tositumomab|Given IV (dosimetric dose) or via central line (therapeutic dose)
1741483|NCT00110071|Other|laboratory biomarker analysis|Correlative studies
1741484|NCT00110071|Other|flow cytometry|Correlative studies
1741485|NCT00110071|Genetic|polymerase chain reaction|Correlative studies
1741486|NCT00110084|Drug|Gemcitabine|1000 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
1741487|NCT00110084|Drug|Paclitaxel protein-bound particles for injectable suspension (albumin-bound)|125 mg/m2 (IV over 30 min) (days 1 and 8) on 21 day cycle
1741488|NCT00110110|Biological|filgrastim|Given after chemo cycle for 7 days or until neutrophil counts return to normal.
1741489|NCT00110110|Drug|Carboplatin|Given at 28 mg/kg/dose.
1741490|NCT00110110|Drug|Cyclosporine|Given at 33 mg/kg/dose
1741491|NCT00110110|Drug|Etoposide|Given at 12 mg/kg/dose
1741492|NCT00110110|Drug|vincristine sulfate|Given at 0.025 mg/kg/dose for the first cycle and 0.05 mg/kg/dose for subsequent cycles if first cycle well-tolerated
1741493|NCT00110110|Procedure|cryosurgery|Local application of extreme cold to destroy residual tumor.
1741494|NCT00110110|Procedure|laser therapy|Local and precise application of laser beams to destroy residual tumor.
1741495|NCT00110123|Drug|fotemustine|
1741496|NCT00110123|Drug|isolated perfusion|
1741497|NCT00110136|Drug|St. John's Wort|St. John's Wort 300mg tablet three times per day
1741500|NCT00110162|Drug|antiandrogen therapy|
1741501|NCT00110162|Drug|releasing hormone agonist therapy|
1741502|NCT00110162|Procedure|orchiectomy|
1741503|NCT00110188|Drug|ridaforolimus|
1741504|NCT00110201|Drug|Nesiritide|
1741505|NCT00110214|Drug|docetaxel|Given IV
1741506|NCT00110214|Other|placebo|Given IV
1741507|NCT00110214|Drug|prednisone|Given orally
1741508|NCT00110214|Biological|bevacizumab|Given IV
1741509|NCT00110214|Other|laboratory biomarker analysis|Correlative studies
1741510|NCT00110227|Behavioral|12-week Tai Chi Program|24 tai chi sessions. 2 sessions/week for 12 weeks.
1741511|NCT00110227|Behavioral|12-week Education Program|24 Educational sessions. 2 sessions/week for 12 weeks.
1741512|NCT00110240|Drug|vildagliptin|
1741513|NCT00110253|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel is composed of a 1:1 eutectic mixture of 7% lidocaine, and 7% tetracaine, which was applied topically. The S Caine Peel was applied at approximately 1 mm in thickness and remained on the treatment area for 30 or 60 minutes
1741514|NCT00110266|Drug|Deferasirox|20 mg/kg/day over one year in patients with MDS
1741515|NCT00110279|Biological|H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
1741516|NCT00110292|Behavioral|Age-specific parenting newsletters and developmental toys|
1741517|NCT00110292|Behavioral|Parent-completed Ages & Stages Questionnaires|
1741518|NCT00110292|Behavioral|Clinic-based distribution of children's books|
1741519|NCT00110305|Drug|TMC278 25 mg|TMC278 25 mg tablet will be administered once daily.
1741520|NCT00110305|Drug|TMC278 75 mg|TMC278 75 mg (1 X 25 mg + 1 X 50 mg) tablets will be administered once daily.
1741521|NCT00110305|Drug|TMC278 150 mg|TMC278 150 mg (1 X 50 mg + 1 X 100 mg) tablets will be administered once daily.
1741522|NCT00110305|Drug|Efavirenz|Efavirenz 600 mg (1 x 600 mg tablet or 3 x 200 mg capsules, depending on formulation locally available) will be administered once daily.
1741523|NCT00110305|Drug|Non-nucleoside reverse transcriptase inhibitor (NRTIs)|Investigator selected 2 NRTIs: (1) Zidovudine and lamivudine (Combivir) and (2) tenofovir disoproxil fumarate and emtricitabine (Truvada) will be administered as per the package inserts, along with the TMC278 during the study period.
1741524|NCT00110318|Procedure|Manual therapy and therapeutic exercise|
1741525|NCT00110318|Procedure|Corticosteroid injections|
1741526|NCT00110344|Drug|Nexavar (Sorafenib, BAY43-9006)|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (Sorafenib, BAY 43-906; this arm) or matching placebo (see below) for 14 days. Dose range will be depending on hematologic and other toxicity between 400 mg (2 tablets of 200 mg) orally twice bid and 400 mg orally every 2 days. Cycle 2: patients who are eligible undergo nephrectomy. After the post-nephrectomy recovery period, all patients will receive 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.Cycle 3+: 400 mg of BAY 43-906, twice daily (administered as two 200 mg tablets) in an open-label fashion.
1741527|NCT00110344|Drug|Placebo|Cycle 1. Patients are randomized in a double-blind fashion to receive either Nexavar (see above) or matching placebo (this arm) for 14 days. Dose range will be depending on hematologic and other toxicity between 400mg (2 tablets of 200mg) orally twice bid and 400mg orally every 2 days. Cycle 2 and 3: see above (no placebo application)
1741528|NCT00110357|Drug|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
1741529|NCT00110357|Drug|Cetuximab + Irinotecan|Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
1741530|NCT00110370|Drug|Lispro Mixture Therapy|
1741531|NCT00110370|Drug|Glargine Basal-Bolus Therapy|
1741532|NCT00110383|Behavioral|School-Based Supervised Asthma Therapy|Child's inhaled steroid use supervised daily at school
1741533|NCT00110396|Biological|Interferon-beta-1a FBS-free/HSA-free|Pre-filled syringes 44mcg/injected subcutaneous 3x per week. Total study period is 96 weeks.
1741534|NCT00110409|Behavioral|Asthma Education in Adults|The intervention involves enhancing asthma education, asthma self-efficacy and asthma-related social support and is administered during a single in-person session in the ED (or hospital for admitted patients) followed by telephone reinforcement.
1741535|NCT00110409|Behavioral|Standard Emergency Room Asthma Education|Participants will receive standard emergency room education about asthma.
1741536|NCT00110422|Drug|Irbesartan|Tablets, Oral, 150 mg. titrated to 300 mg, once daily, 28 weeks.
1741850|NCT00118313|Biological|tetanus toxoid helper peptide|
1741537|NCT00110422|Drug|Hydrochlorothiazide|Tablets, Oral, 12.5 mg. titrated to 25 mg, once daily, 28 weeks.
1741538|NCT00110435|Drug|MK0653A, ezetimibe (+) simvastatin|
1741539|NCT00110435|Drug|Duration of Treatment: 4 wk placebo run in then 6 wk active|
1741540|NCT00110435|Drug|Comparator: atorvastatin|
1741541|NCT00110448|Drug|Aspirin|Aspirin 81 mg or 100 mg per day
1741542|NCT00110448|Drug|No aspirin|No aspirin use
1741543|NCT00110461|Drug|Aripiprazole|Treatment Arm 1 (10 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, and aripiprazole 10 mg QD as the target dose starting on Day 5. Subjects remained on the 10 mg dose for the remainder of the treatment period Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
1741544|NCT00110461|Drug|Aripiprazole|Treatment Arm 2 (30 mg treatment arm): Aripiprazole 2 mg QD for 2 days, aripiprazole 5 mg QD for 2 days, aripiprazole 10 mg QD for 2 days, aripiprazole 15 mg QD for 2 days, aripiprazole 20 mg QD for 2 days, aripiprazole 25 mg QD for 2 days, and aripiprazole 30 mg QD as the target dose starting on Day 13. Subjects remained on the 30 mg dose for the remainder of the treatment period. Subjects reached their target dose through a forced titration schedule and proceeded with treatment at their target dose until Week 4. If the subject reached Week 4, he or she continued into the Extension Phase, a 6-month double-blind treatment period, beginning at the same dose taken at the end of the Acute Phase.
1741545|NCT00110461|Drug|placebo|Placebo tablet
1741546|NCT00110474|Drug|Glucosamine sulfate|
1741547|NCT00110474|Drug|Acetaminophen|
1741548|NCT00110487|Drug|ERB-041|
1741549|NCT00110500|Genetic|hVEGF-A|
1741550|NCT00110513|Biological|Recombinant human antithrombin (rhAT)|Up to 24 hours prior to the scheduled elective surgical procedure, caesarean section, or delivery induction, each patient will receive an initial intravenous loading dose followed by a continuous intravenous infusion of recombinant human antithrombin (rhAT) that will target and maintain an AT activity that is > 80% and < 120% of normal. The dosing objective for all study patients is maintenance of the AT activity at > 80% and < 120% of normal during the high-risk period for thromboembolic events. Dosing and dose adjustments will be based on the results of AT activity determinations performed prior to and during treatment.
1741551|NCT00110526|Genetic|Ad.hIL-12|Ad.hIL-12 intraprostatic injection IND
1741552|NCT00110539|Behavioral|Complementary and alternative medicine education|
1741553|NCT00110552|Drug|Salvia officinalis (sage)|oral dosage
1741554|NCT00110565|Device|Pulsed magnetic field pad|
1741555|NCT00110578|Procedure|Adoptive transfer of HIV-specific CD8+ T cells|
1741556|NCT00110578|Drug|Aldesleukin|
1741557|NCT00110591|Drug|PRO 140|Monoclonal antibody to CCR5
1741558|NCT00110604|Behavioral|folic acid (0.8 mg)|
1741559|NCT00110617|Drug|Deferasirox (ICL670)|Deferasirox was provided in 125 mg, 250 mg, and 500 mg dispersible tablets and was administered orally at an initial dose of 20 mg/kg/day.
1741560|NCT00110617|Drug|Deferoxamine (DFO)|Deferoxamine was supplied in vials of 500 mg and 2000 mg administered subcutaneously for a weekly dose of 175 mg/kg.
1741561|NCT00110630|Behavioral|10-week smoking cessation group therapy combined with NicoDerm CQ|
1741562|NCT00110643|Device|CoolTouch II laser|
1741563|NCT00110656|Other|Observations|This is a non-interventional study- only observational.
1741564|NCT00110669|Drug|Prednisone|"Prednisone and dummy preparations for this study will be obtained from Frank's Pharmacy in Ocala, FL and will be supplied as a tablet containing 2.5mg, 5mg, 10mg, 20mg or 50mg Prednisone. Inactive dummy pills of similar look/taste will be supplied to maintain blinding."
1741565|NCT00110682|Drug|Imiquimod used as an adjunct to cryotherapy|
1741566|NCT00110695|Drug|Nanoparticle albumin bound paclitaxel followed by FEC|Nanoparticle albumin bound paclitaxel 100 mg/m2 IV for 30 minutes once weekly for 12 weeks followed by FEC (5-FU 500mg/m2 IV push; epirubicin 100 mg/m2 IV over 15 min. [or if given with trastuzumab 75 mg/m2 IV over 15 min.]; cyclophosphamide 500 mg/m2 IV over 30 min.) on Day 1 every 21 days
1741567|NCT00110708|Drug|Oralgam (human immunoglobulin)|
1741568|NCT00110721|Drug|GM-CT-01 plus 5-Fluorouracil|Single use vials, combined regimen of GM-CT-01 / 5-Fluorouracil (280 mg/m2 /500 mg/m2) given for 4 consecutive days in a 28 day cycle until disease progression.
1741569|NCT00110734|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|
1741570|NCT00110747|Drug|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel comprising a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
1741571|NCT00110747|Drug|Placebo Peel|Peel was applied topically. A thin layer of the peel (approximately 1 mm in thickness) was applied and remained on the treatment area for 30 minutes (±2 minutes).
1741572|NCT00110760|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel was composed of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine and was applied topically. S-Caine Peel was applied with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
1741573|NCT00110760|Drug|Placebo Peel|Placebo Peel applied topically with a uniform thickness of approximately 1 mm and remained on the treatment area for 30 minutes (+/- 2 minutes).
1741574|NCT00110773|Drug|S-Caine™ Peel (lidocaine and tetracaine topical cream 7%/7%)|S-Caine Peel, composed of a 1:1 (w:w) eutectic mixture of 7% lidocaine and 7% tetracaine, applied topically. S-Caine Peel applied at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
1741575|NCT00110773|Drug|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 20 minutes (±2 minutes).
1741576|NCT00110786|Biological|Ragweed MATAMPL|
1741577|NCT00110799|Drug|SB497115|Approximately 160 subjects will be randomized equally to one of four treatment groups of approximately 40 subjects (A-D). Subjects will receive oral tablets of SB-497115-GR at 30mg, 50 mg, 75 mg or placebo administered once daily for a total of 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
1741851|NCT00118313|Drug|dimethyl sulfoxide|
1741578|NCT00110799|Other|Placebo|Placebo administered orally daily for 12 weeks beginning 4 weeks prior to initiating 8 weeks of antiviral therapy and for 8 weeks during weekly antiviral therapy.
1741579|NCT00110812|Drug|IL-2|7.5 MIU injected intramuscularly; one arm uses Proleukin together with HAART of choice (protease inhibitor and at least 2 nucleoside/nucleotide reverse transcriptase inhibitors)
1741580|NCT00116519|Drug|PPAR alpha|
1741581|NCT00116519|Drug|placebo|
1741582|NCT00116532|Drug|Escitalopram|
1741583|NCT00116545|Drug|troglitazone|
1741585|NCT00116571|Drug|Lemuteporfin for injection|
1741586|NCT00116571|Device|Transurethral drug delivery system|
1741587|NCT00116571|Device|Transurethral light delivery system|
1741589|NCT00116597|Genetic|Intranodal immunization with a recombinant vaccinia virus expressing 5 transgenes|
1741590|NCT00116597|Biological|Intranodal booster immunizations with synthetic melanoma associated epitopes|
1741591|NCT00116610|Drug|picoplatin|
1741592|NCT00116623|Drug|Indomethacin|
1741593|NCT00116623|Drug|Magnesium sulfate|
1741594|NCT00116636|Drug|Kaletra|
1741595|NCT00116649|Drug|imiquimod cream|imiquimod 5% cream applied in doses ranging from one packet (12.5 mg) to 6 packets (75 mg) to either single or multiple body regions for up to 3 cycles
1741596|NCT00116662|Drug|Resiquimod|
1741597|NCT00116675|Drug|Resiquimod|
1741598|NCT00116688|Biological|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
1741599|NCT00116701|Drug|Aranesp®|
1741600|NCT00116714|Drug|DMARD|All subjects were required to initiate, add or change DMARD therapy at study entry.
1741601|NCT00116727|Drug|ENBREL®|50 mg/wk SC
1741602|NCT00116740|Drug|APD356|
1741603|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (40 mg/mL) at months 1, 3, 6 and 9
1741604|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 3, 6 and 9
1741605|NCT00116753|Drug|Degarelix|Drug: Degarelix subcutaneous 240 mg (40 mg/mL) initiation dose, maintenance dose 240 mg (60 mg/mL) at months 1, 4, 7 and 10
1741606|NCT00116766|Device|anti-mosquito plant use|
1741607|NCT00116779|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Maintenance dose given in twelve 28-day cycles.
1741608|NCT00116792|Procedure|Percutaneous Coronary Intervention (PCI)|
1741609|NCT00116805|Drug|TDF|300 mg tablet administered orally once daily
1741610|NCT00116805|Drug|ADV|10 mg tablet administered orally once daily
1741611|NCT00116805|Drug|TDF placebo|Tablet administered orally once daily
1741612|NCT00116805|Drug|ADV placebo|Tablet administered orally once daily
1741613|NCT00116805|Drug|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
1741614|NCT00116818|Drug|GW685698X aqueous nasal spray|
1741615|NCT00116831|Drug|Glipizide|oral anti-diabetic medication
1741616|NCT00116831|Drug|rosiglitazone maleate|oral antidiabetic medication
1741618|NCT00116896|Drug|OSI-7904L|
1741619|NCT00116896|Drug|Cisplatin|
1741620|NCT00116909|Drug|OSI 7904L|
1741621|NCT00116922|Drug|Avandamet [Rosiglitazone 2mg/Metformin 500mg] BID|[Rosiglitazone 2mg/ Metformin 500mg] twice daily
1741622|NCT00116935|Drug|imatinib mesylate|imatinib 400 mg/day orally qd for 12 months
1741623|NCT00116935|Drug|imatinib|imatinib 400 mg/d orally qd for 36 months
1741624|NCT00116935|Drug|imatinib|imatinib 400 mg/d orally qd for 36 months
1741625|NCT00116948|Device|ReCap, Hip resurfacing system, Biomet|ReCap total hip arthroplasty inserted according to manufactures manual.
1741626|NCT00116961|Drug|Velcade|
1741627|NCT00116961|Drug|Doxil|
1741628|NCT00116961|Drug|Dexamethasone|
1741629|NCT00116974|Procedure|Scaling and root planing|Scaling and root planing
1741630|NCT00116987|Device|Dual chamber cardiac pacemaker|Physiologic pacemakers usually have two leads - one positioned in the right atrium (upper heart chamber) and one positioned in the right ventricle.
1741631|NCT00116987|Device|Single chamber cardiac pacemaker|Ventricular pacemakers have a single lead (wire) positioned in the right ventricle (lower pumping chamber) to sense and pace the ventricle.
1741632|NCT00117000|Drug|testosterone undecanoate|
1741633|NCT00117013|Drug|Fluorine-19-Fluoroded Xyglucose|
1741634|NCT00117013|Drug|Topotecan|
1741635|NCT00117026|Drug|Placebo|Placebo for benfotiamine
1741636|NCT00117026|Drug|Benfotiamine|300mg/day
1741637|NCT00117039|Drug|Aranesp®|
1741638|NCT00117052|Drug|cinacalcet|All eligible subjects were assigned to receive once daily oral doses of cinacalcet, but were randomised in a 1:1 ratio to receive the drug either with the first meal after dialysis or during the dialysis visit on dialysis days.
1741639|NCT00117065|Drug|Aranesp®|
1741640|NCT00117078|Drug|Aranesp®|
1741641|NCT00117091|Drug|Anakinra (Kineret®)|
1741642|NCT00117104|Drug|Aranesp®|
1741643|NCT00117117|Drug|Aranesp|
1741644|NCT00117130|Drug|Aranesp®|
1741645|NCT00117143|Drug|AMG 531|
1741646|NCT00117156|Drug|Fludarabine|
1741647|NCT00117156|Drug|Rituximab|
1741648|NCT00117169|Procedure|multi-detector helical computed tomography|
1741649|NCT00117182|Drug|Dry powder mannitol|
1741650|NCT00117182|Drug|Budesonide 400mcg administered via turbuhaler|
1741651|NCT00117182|Drug|Ipratropium bromide 80mcg|
1741652|NCT00117182|Drug|Salbutamol 400mcg|
1741769|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
1741770|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
1741653|NCT00117195|Device|Automated Neuropsychological Assessment Matrix|"This study will evaluate a profile of neurophysiologic tests for potentially predictive signs of PD or PS in individuals with PD or PS, those who may be at risk for PD or PS and in a population of individuals without parkinsonian symptoms or any other neurologic conditions.
In addition, the study will evaluate serum samples for changes in proteins or metabolites that may be indicators of early changes associated with Parkinson's disease or parkinsonian syndrome."
1741654|NCT00117208|Drug|mannitol|400mg BD for 12 weeks
1741655|NCT00117208|Drug|mannitol + pulmozyme|combination
1741656|NCT00117208|Drug|Dornase alpha|2.5mg daily for 2 weeks
1741657|NCT00117234|Drug|darbepoetin alfa|
1741658|NCT00117247|Drug|darbepoetin alfa|
1741659|NCT00117260|Drug|Seasonale (levonorgestrel and ethinyl estradiol)|
1741660|NCT00117273|Drug|Seasonale [levonorgestrel (LNG)/ethinyl estradiol (EE)]|1 tablet daily
1741661|NCT00117273|Drug|Seasonique (LNG/EE and EE)|1 tablet daily
1741662|NCT00117273|Drug|Portia (LNG/EE)|1 tablet daily x 28 days
1741663|NCT00117286|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
1741664|NCT00117299|Drug|PTK787/ZK222584|PTK787/ZK222584 is administered at the dosage of 1250 mg o.d. orally
1741665|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 40 mg (10 mg/mL), subcutaneous injection.
1741666|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 80 mg (20 mg/mL), subcutaneous injection.
1741667|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
1741668|NCT00117312|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
1741670|NCT00117338|Drug|montelukast sodium|Montelukast IV 5.25 mg lyophilized (reconstituted in 20 mL of 3.3% dextrose/0.3% sodium chloride) for a study approximately 120 minutes in duration
1741671|NCT00117338|Drug|Comparator: placebo (unspecified)|Pbo for a study approximately 120 minutes in duration
1741672|NCT00117351|Drug|VELCADE|
1741673|NCT00117364|Drug|SACCHACHITIN patch|
1741674|NCT00117377|Drug|Pimecrolimus|Pimecrolimus cream 1 % bid
1741675|NCT00117377|Drug|Placebo|Placebo application bid
1741676|NCT00117390|Procedure|Measurement of inulin clearance|
1741677|NCT00117403|Drug|Vitamin E, Vitamin C, and Alpha-lipoic Acid|vitamin E 800 IU, vitamin C 200 mg, and alpha-lipoic acid 600 mg formulated into three capsules, one capsule given three times per day with meals
1741678|NCT00117403|Drug|Coenzyme Q|400 mg, compounded as a wafer, two wafers three times per day with meals
1741679|NCT00117403|Drug|Placebo capsules|one placebo capsule three times per day with meals
1741680|NCT00117403|Drug|Placebo wafers|two placebo wafers three times per day with meals
1741681|NCT00117416|Procedure|controlling the MAP|
1741682|NCT00117429|Biological|HIV gp120/NefTat/AS02A Vaccine|im injection, 0.6-0.7 ml
1741683|NCT00117442|Drug|carboplatin|Chemotherapy
1741684|NCT00117442|Drug|paclitaxel|chemotherapy
1741685|NCT00117442|Drug|pegfilgrastim|Growth factor for mobilization
1741686|NCT00117455|Drug|pegfilgrastim|
1741687|NCT00117455|Drug|filgrastim|
1741688|NCT00117468|Drug|DR-2011|Administered vaginally from Day 14 to Day 31
1741689|NCT00117468|Drug|Progesterone 8% Vaginal Gel|Administered vaginally from Cycle Day 14 to Day 31
1741690|NCT00117481|Drug|DR-2001a|DR-2001a administered vaginally each month
1741691|NCT00117481|Drug|DR-2001b|DR-2001b administered vaginally each month
1741692|NCT00117481|Other|Placebo|Placebo administered vaginally each month
1741693|NCT00117494|Drug|Pravastatin|
1741694|NCT00117494|Drug|Rosuvastatin|
1741695|NCT00117507|Drug|deferasirox|deferasirox 20 mg/kg/day taken over one year.Deferasirox should be taken every morning 30 minutes before breakfast, if possible consistently around the same time between 7:00 and 9:00 AM. The tablets should be dropped into water or orange juice and gently stirred for 1 to 3 minutes until completely dispersed.
1741696|NCT00117520|Drug|Caffeine|
1741697|NCT00117533|Drug|pegylated IFN alfa-2b plus ribavirin|
1741698|NCT00117546|Drug|alpha methyldopa|500 mg twice a day
1741699|NCT00117559|Behavioral|Telehealth Treatment|Participants receive a 15-minute telephone call for 8 weeks
1741700|NCT00117572|Drug|docetaxel|75 mg/m2 on day 1
1741701|NCT00117572|Drug|cisplatin|75 mg/m2 on day 1
1741702|NCT00117572|Drug|hydroxyurea|Each cycle: 500 mg PO q 12 hours x 6 days (11 doses)
1741703|NCT00117572|Drug|fluorouracil|750 mg/m2/day on days 1-5 of induction
1741704|NCT00117572|Procedure|chemotherapy|See protocol for details
1741705|NCT00117572|Procedure|radiotherapy|See protocol for details
1741706|NCT00117585|Other|Treatment Phase 1|"Patient Education
Physical Therapy Exercises
Increased Salt Intake
Elevation of head of bed with 2-4 inch wedge
Medication Review by MD, Pharma"
1741707|NCT00117585|Drug|Treatment Phase 2|"Subjects receive Treatment Phase 2 if they are still orthostatic after receiving Treatment Phase 1.
Fludrocortisone
Salt tablet"
1741708|NCT00117585|Other|Treatment Phase 3|Subjects still experiencing orthostatic hypotension after receiving Treatment Phases 1 and 2 move on to Treatment Phase 3. Individualized treatment is based on subspecialty or orthostatic hypotension consultation at the medical center. Subjects are followed for the duration of their hospital stay, on average 4 weeks.
1741771|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 120 mg (30 mg/mL), subcutaneous injection.
1741772|NCT00117949|Drug|Degarelix|One dose (2 x 2 mL) of degarelix 160 mg (40 mg/mL), subcutaneous injection.
1741773|NCT00117962|Biological|cetuximab|400 mg/sq m IV over 120 min: Day 1; Week 1 250 mg/sq m IV over 60 min weekly for 6 more weeks.
1741774|NCT00117962|Drug|carboplatin|AUC = 5 q 21 days for 4 cycles
1741852|NCT00118313|Drug|imiquimod|
1956528|NCT02820844|Drug|Placebo|Placebo injection is made up of sodium chloride (0.9 mg). 10 mL of the injection will be injected at 20 sites (0.5 mL at each site) in the detrusor muscle, spaced approximately 1 cm apart. The injection will be administered under local anesthesia, via cystoscopy. Permitted anesthesia options for cystoscopy are intraurethral lidocaine (or similar) gel, and for treatment administration, installation of 1-2% lidocaine (or similar anesthetic) into the bladder.
1741712|NCT00117611|Drug|Anti-IgE antibody omalizumab or placebo|given subcutaneously oce or twice monthly depending on dose
1741713|NCT00117624|Drug|darbepoetin alfa|
1741714|NCT00117637|Drug|Sorafenib (Nexavar, BAY43-9006)|Multi kinase inhibitor
1741715|NCT00117637|Drug|Interferon|Interferon
1741716|NCT00117650|Biological|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections
1741717|NCT00117650|Biological|Ad2/HIF-1α/VP16|one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
1741718|NCT00117650|Biological|Ad2/HIF-1α/VP16|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
1741719|NCT00117650|Other|Saline (Placebo Control)|a one time treatment of 20 IM injections of 0.01 ML each into each leg for a total of 40 injections.
1956529|NCT02820844|Drug|Antibiotic therapy|Subjects will use prophylactic antibiotic therapy approved for the indication of UTIs, at the discretion of the investigator, with the exception of those in the class of aminoglycosides. The therapy will begin 1 to 3 days prior to the administration of study treatment, and continue for 1 to 3 days following the treatment.
1741721|NCT00117676|Drug|TDF|300 mg tablet administered orally once daily
1741722|NCT00117676|Drug|ADV|10 mg tablet administered orally once daily
1741723|NCT00117676|Drug|TDF placebo|Tablet administered orally once daily
1741724|NCT00117676|Drug|ADV placebo|Tablet administered orally once daily
1741725|NCT00117676|Drug|FTC/TDF|200/300 mg fixed-dose combination (FDC) tablet administered orally once daily
1741726|NCT00117689|Biological|Thymoglobulin|Antibody inductions with tacrolimus and corticosteroid sparing maintenance therapy
1741727|NCT00117689|Drug|Corticosteroid|For a minimum of 3 months
1741728|NCT00117689|Drug|Tacrolimus|Between Day 3 the last dose of Thymoglobulin
1741729|NCT00117689|Drug|Mycophenolate Mofetil|for at least 1 month posttransplant
1741730|NCT00117702|Drug|Tacrolimus|day 0-100, then taper
1741731|NCT00117702|Drug|Everolimus|day 0-56
1741732|NCT00117715|Procedure|Genotyping and Phenotyping using dextromethorphan and caffeine as probes|Single doses of dextromethorphan (0.3 mg/kg)and caffeine (3.0 mg/kg) are administered and urine is collected overnight for measurement of drug and metabolites to determine drug biotransformation activity.
1741733|NCT00117728|Drug|nevirapine|
1741734|NCT00117741|Behavioral|Dialectical Behavior Therapy|Weekly individual DBT, DBT group skills training, as needed phone calls for coaching, team meeting for psychotherapists, suboxone
1741735|NCT00117741|Behavioral|Drug Counseling|Weekly individual counseling and weekly group therapy following guidelines of drug counseling treatment manual,
1741736|NCT00117754|Drug|Terbinafine hydrochloride|
1741737|NCT00117767|Drug|Terbinafine hydrochloride (HCl)|Terbinafine hydrochloride (HCl) pediatric formulation (minitablets)o.d. administration
1741738|NCT00117767|Drug|Griseofulvin|Griseofulvin pediatric suspension o.d. administration
1741739|NCT00117780|Drug|insulin detemir|
1741740|NCT00117780|Drug|insulin aspart|
1741741|NCT00117793|Device|Total Surface Bearing Suction Socket|Current clinical practice
1741742|NCT00117793|Device|Vacuum assisted socket system|Novel socket system
1741743|NCT00117806|Behavioral|Arm 1|SCI-VIP: Supported employment implemented for veterans with spinal cord injury.
1741744|NCT00117806|Behavioral|Arm 2|Standard Care: varies slightly between participating VA SCI centers, however, usually involves referral outside SCI center
1741745|NCT00117819|Drug|[123I]ß CIT and SPECT imaging|To assess [123I]ß CIT and SPECT imaging
1741746|NCT00117832|Drug|Azelastine nasal spray|
1741747|NCT00117845|Biological|Denileukin diftitox (Ontak)|Patients will be treated with Denileukin Diftitox 9 mcg/kg/d intravenously for 5 days every 2 weeks.
1741748|NCT00117858|Procedure|Anodal DC polarization of left prefrontal cortex|
1741749|NCT00117871|Drug|Resiquimod|
1741750|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741751|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741752|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741753|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741754|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741755|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741756|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741757|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741758|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741759|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741760|NCT00117884|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1741761|NCT00117897|Drug|pegfilgrastim|
1741762|NCT00117897|Drug|Filgrastim|
1741763|NCT00117910|Drug|pegfilgrastim|
1741764|NCT00117923|Drug|Resiquimod|
1741765|NCT00117936|Drug|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141)|One time injection of 2 ug/kg of FGF 1-141, via a catheter
1741766|NCT00117936|Drug|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141)|One time injection of 20 ug/kg FGF 1-141 via a catheter
1741767|NCT00117936|Drug|Human Recombinant Fibroblast Growth Factor-1 (FGF 1-141)|One time injection of 40 ug/kg FGF 1-141, via a catheter
1741768|NCT00117936|Drug|Human Recombinant Fibroblast Growth Factor-1 (FGF1-141)|One time injection of 0 ug/kg (placebo group), via a catheter
1741849|NCT00118313|Biological|sargramostim|
1741775|NCT00117962|Drug|pemetrexed disodium|500 mg/sq m IV q 21 days during chemoradiation and consolidation chemotherapy phases
1741776|NCT00117962|Radiation|radiation therapy|Thoracic radiotherapy: 70 Gy for 7 weeks beginning on Day 1.
1741777|NCT00117975|Biological|galiximab|given IV
1741778|NCT00117975|Biological|rituximab|Given IV
1741779|NCT00117988|Drug|tanespimycin|
1741780|NCT00118001|Behavioral|Worry exposure|
1741781|NCT00118001|Behavioral|Applied relaxation|
1741782|NCT00118014|Drug|Sertraline|
1741783|NCT00118014|Behavioral|Habit Reversal Training|
1741784|NCT00118027|Drug|sulphadoxine-pyrimethamine intermittent preventive treatment|
1741785|NCT00118040|Drug|genistein|Given orally
1741786|NCT00118040|Other|laboratory biomarker analysis|Correlative studies
1741787|NCT00118040|Other|placebo|Given orally
1741788|NCT00118040|Procedure|therapeutic conventional surgery|Undergo cystoscopic excision, transurethral resection of the bladder tumor, or cystectomy.
1741789|NCT00118040|Other|pharmacological study|Correlative studies
1741790|NCT00118053|Biological|herceptin|
1741791|NCT00118053|Drug|carboplatin|
1741792|NCT00118053|Drug|docetaxel|
1741793|NCT00118053|Procedure|conventional surgery|Modified radical mastectomy or lumpectomy and axillary node dissection
1741794|NCT00118053|Procedure|radiation therapy|Whole breast or chest wall irradiation (as determined by radiologist)
1741795|NCT00118066|Dietary Supplement|calcitriol|Given orally
1741796|NCT00118066|Procedure|observation|No initial intervention
1741797|NCT00118092|Drug|tanespimycin|Given IV
1741798|NCT00118092|Other|laboratory biomarker analysis|Correlative studies
1741799|NCT00118105|Biological|bevacizumab|Preoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3 Postoperative: 7.5 mg/kg, IV, Day 1 of cycles 1,2,3,4
1741800|NCT00118105|Drug|capecitabine|Pre & Post Operative: 1,700 mg/m^2/day, PO at 12 hr interval, Days 1-14 of cycles 1,2,3,4
1741801|NCT00118105|Drug|oxaliplatin|130 mg/m^2, IV, Day 1 of cycles 1,2,3,4
1741802|NCT00118105|Procedure|conventional surgery|Resection
1741803|NCT00118131|Drug|cisplatin|
1741804|NCT00118131|Drug|docetaxel|
1741805|NCT00118144|Drug|bortezomib|Given IV
1741806|NCT00118157|Other|Laboratory Biomarker Analysis|Correlative studies
1741807|NCT00118157|Drug|Lapatinib Ditosylate|Given PO
1741808|NCT00118157|Drug|Tamoxifen Citrate|Given PO
1741809|NCT00118170|Drug|sorafenib tosylate|Given orally
1741810|NCT00118170|Other|pharmacological study|Correlative studies
1741811|NCT00118183|Drug|docetaxel|Given IV
1741812|NCT00118183|Biological|cetuximab|Given IV
1741813|NCT00118183|Drug|bortezomib|Given IV
1741814|NCT00118196|Drug|arsenic trioxide|
1741815|NCT00118196|Drug|azacitidine|
1741816|NCT00118209|Biological|rituximab|IV
1741817|NCT00118209|Drug|cyclophosphamide|IV
1741818|NCT00118209|Drug|doxorubicin|IV or CIVI
1741819|NCT00118209|Drug|vincristine|IV or CIVI
1741820|NCT00118209|Drug|prednisone|oral
1741821|NCT00118209|Drug|etoposide|CIVI
1741822|NCT00118209|Drug|filgrastim|IV
1741823|NCT00118209|Drug|pegfilgrastim|IV
1741824|NCT00118222|Drug|porfimer sodium|All patients receive porfimer sodium IV.
1741825|NCT00118222|Procedure|adjuvant therapy|All patients receive porfimer sodium IV.
1741826|NCT00118222|Procedure|conventional surgery|All patients receive porfimer sodium IV. One day later, patients undergo craniotomy and tumor resection.
1741827|NCT00118235|Drug|cisplatin|Given IV
1741828|NCT00118235|Drug|irinotecan hydrochloride|Given IV
1741829|NCT00118235|Biological|bevacizumab|Given IV
1741830|NCT00118235|Other|laboratory biomarker analysis|Correlative studies
1741831|NCT00118248|Drug|tanespimycin|Given IV
1741832|NCT00118261|Biological|bevacizumab|Beginning in course 3, patients also receive bevacizumab IV over 30 minutes. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
1741833|NCT00118261|Drug|erlotinib hydrochloride|Courses 1-3: oral erlotinib once daily on days 1-14. Patients who do not develop grade 2 toxicity after the first 3 courses (6 weeks) will have their erlotinib dose escalated. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
1741834|NCT00118261|Drug|fluorouracil|Starting with course 2: fluorouracil IV continuously over 46 hours on days 1 and 2. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
1741835|NCT00118261|Drug|leucovorin calcium|Starting with course 2: Leucovorin calcium IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
1741836|NCT00118261|Drug|oxaliplatin|Starting with course 2: oxaliplatin IV over 2 hours on day 1. Courses repeat every 14 days in the absence of disease progression or unacceptable toxicity.
1741837|NCT00118274|Biological|incomplete Freund's adjuvant|Given intradermally and subcutaneously
1741838|NCT00118274|Biological|melanoma helper peptide vaccine|Given intradermally and subcutaneously
1741839|NCT00118274|Biological|multi-epitope melanoma peptide vaccine|Given intradermally and subcutaneously
1741840|NCT00118274|Biological|tetanus toxoid helper peptide|Given intradermally and subcutaneously
1741841|NCT00118274|Drug|cyclophosphamide|Given IV
1741842|NCT00118287|Drug|azacitidine|Given SC or IV
1741843|NCT00118287|Biological|etanercept|Given SC
1741844|NCT00118300|Drug|capecitabine|Patients also receive oral capecitabine twice daily 7 days a week in weeks 1-5 and 7-8. Courses repeat every 12 weeks in the absence of disease progression or unacceptable toxicity.
1741845|NCT00118300|Radiation|brachytherapy|1 or 2 applications of low-dose rate intracavitary brachytherapy in weeks 7-8 OR 5 applications of high-dose rate (HDR)* intracavitary brachytherapy once weekly in weeks 4-8.
1741846|NCT00118300|Radiation|radiation therapy|Patients undergo external beam radiotherapy to the whole pelvis once daily 5 days a week in weeks 1-5.
1741847|NCT00118313|Biological|incomplete Freund's adjuvant|
1741848|NCT00118313|Biological|multi-epitope melanoma peptide vaccine|
1741853|NCT00118313|Procedure|adjuvant therapy|
1741854|NCT00118326|Biological|filgrastim|
1741855|NCT00118326|Procedure|allogeneic bone marrow transplantation|
1741856|NCT00118339|Drug|chemoprotection|
1741857|NCT00118339|Procedure|complementary or alternative medicine procedure|
1741858|NCT00118339|Procedure|management of therapy complications|
1741859|NCT00118352|Biological|alemtuzumab|Given IV
1741860|NCT00118352|Radiation|total-body irradiation|Undergo low-dose TBI
1741861|NCT00118352|Drug|fludarabine phosphate|Given IV
1741862|NCT00118352|Drug|cyclosporine|Given PO or IV
1741863|NCT00118352|Drug|mycophenolate mofetil|Given PO
1741864|NCT00118352|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
1741865|NCT00118352|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
1741866|NCT00118352|Biological|graft versus host disease prophylaxis/therapy|Undergo GVHD prophylaxis/therapy
1741867|NCT00118352|Other|laboratory biomarker analysis|Correlative studies
1741868|NCT00118365|Other|placebo|Given orally
1741869|NCT00118365|Drug|eflornithine|Given orally
1741870|NCT00118365|Drug|sulindac|Given orally
1741871|NCT00118365|Other|laboratory biomarker analysis|Correlative studies
1741872|NCT00118378|Drug|Modafinil|50 mg per day, increasing to 200 mg per day as clinically indicated
1741873|NCT00118378|Drug|Placebo|50 mg per day, increasing to 200 mg per day as clinically indicated
1741874|NCT00118391|Behavioral|Cognitive behavior therapy|Receive 8 50-minute sessions of one-on-one cognitive behavioral therapy
1741875|NCT00118391|Behavioral|Contingency management|Receive vouchers that can be spent on rewards for completing activities that support abstinence from gambling
1741876|NCT00118404|Behavioral|Continuation phase cognitive therapy|Continuation phase cognitive therapy included 10 sessions over 8 months.
1741877|NCT00118404|Drug|Continuation phase fluoxetine|The dosage of fluoxetine was increased to 40 mg over 8 months.
1741878|NCT00118404|Other|Continuation phase pill placebo|The dosage of pill placebo was increased to 40 mg over 8 months.
1741879|NCT00118404|Behavioral|Acute phase cognitive therapy|For the first 12 weeks, all participants received between 16 and 20 cognitive therapy sessions.
1741880|NCT00118417|Drug|Clonazepam|Participants will receive clonazepam.
1741881|NCT00118417|Drug|Sertraline|Participants will receive sertraline.
1741882|NCT00118417|Behavioral|Cognitive behavioral therapy|Participants will receive cognitive behavioral therapy
1741883|NCT00118430|Behavioral|Stepped Care|Stepped care will consist of 12 weeks of antidepressant therapy, followed by a pain self-management program (PSMP) in those who fail to achieve both a good pain and global clinical response to antidepressant therapy. Treatment will be delivered by a nurse depression-pain clinical specialist (DPCS) who will be trained in providing both components of the stepped care treatment. The DPCS will meet weekly to review cases with a physician-investigator who will also be available to discuss any management issues that arise between the weekly case meetings. All participants will have six clinical contacts with the DPCS during the acute treatment phase and two clinical contacts during the continuation phase to assess medication adherence, adverse effects, and depression response.
1741884|NCT00118430|Drug|Antidepressants|Participants will be assigned to one of the following antidepressant regimens: venlafaxine (37.5 mg, increased to 75, 150, 225 mg); duloxetine (60 mg, increased to 120 mg); fluoxetine (20 mg, increased to 30 to 40 mg); sertraline (50 mg, increased to 100 to 150 mg); citalopram (20 mg, increased to 30 to 40 mg); paroxetine (20 mg, increased to 30 to 40 mg); or nortriptyline (25 mg, increased to 50 to 75 mg).
1741885|NCT00118430|Drug|Usual Care|This group will receive care as usual from their providers and completes the same outcome assessments as the stepped care group.
1741886|NCT00118443|Behavioral|Question, Persuade, Refer (QPR) training|
1741887|NCT00118456|Drug|AEE788|
1741888|NCT00118469|Behavioral|Psychoeducation|
1741889|NCT00118469|Behavioral|Cognitive behavior therapy|
1741890|NCT00118482|Drug|fludrocortisone acetate|Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily
1741891|NCT00118495|Drug|Non-prescription Zestra(TM): patented formulation|
1741892|NCT00118508|Drug|risedronate (including placebo)|risedronate 35mg weekly
1741893|NCT00118521|Procedure|Foot Orthotics|
1741894|NCT00118521|Procedure|Physiotherapy|
1741895|NCT00118534|Behavioral|Integrated Care for Smoking Cessation in PTSD patients|Smoking cessation therapy is integrated with PTSD therapy.
1741896|NCT00118534|Behavioral|Standard of Care|Patients interested in quitting smoking are referred to a separate smoking cessation clinic, per standard of care.
1741897|NCT00118547|Behavioral|In home monitoring with feedback|Behavioral counseling
1741898|NCT00118560|Behavioral|Physical exercise|treadmill walking
1741899|NCT00118560|Behavioral|Physical walking|calf muscle exercise
1741900|NCT00118573|Procedure|EVAR (Endovascular repair of Abdominal Aortic aneurysm)|AAA repair with endografting
1741901|NCT00118573|Procedure|Surveillance|Surveillance of AAA without any repair until AAA will reach 5.5cm, become tender or rapidly grow
1741902|NCT00118612|Biological|Tree MATA MPL|
1741903|NCT00118625|Biological|Tree MATA MPL|
1741904|NCT00118638|Drug|Darbepoetin alfa - 2.25 mcg/kg|Darbepoetin alfa 2.25 mcg/kg QW dosing/ placebo Q3W
1741905|NCT00118638|Drug|Darbepoetin alfa - 500mcg|Darbepoetin alfa 500mcg Q3W dosing / placebo QW
1741906|NCT00118677|Procedure|Treatment interruption|
1741907|NCT00118690|Drug|Fluticasone propionate/salmeterol|
1741908|NCT00118703|Drug|GW685698X|
1741910|NCT00118729|Drug|GW685698X Aqueous Nasal Spray|
1741911|NCT00118742|Drug|mycophenolate mofetil [CellCept]|1-1.5 g orally or intravenously twice daily
1741912|NCT00118742|Drug|Tacrolimus|As prescribed, for 12 months
1741913|NCT00118742|Drug|Cyclosporine|As prescribed, for 12 months
1741914|NCT00118742|Drug|Sirolimus|2-4 mg orally once daily for 9-11 months
1741915|NCT00118755|Drug|capecitabine|850 mg/m^2 po bid on Days 1-14 of each 3-week cycle
1741978|NCT00119119|Drug|pentoxyphilline|
1741916|NCT00118755|Drug|Oxaliplatin|130 mg/m^2 IV on Day 1 of each 3-week cycle
1741917|NCT00118755|Drug|bevacizumab|7.5 mg/kg IV on Day 1 of each 3-week cycle
1741918|NCT00118755|Drug|capecitabine|1500 mg/m^2 po bid on Days 1-7 of each 2-week cycle
1741919|NCT00118755|Drug|Oxaliplatin|85 mg/m^2 IV on Day 1 of each 2-week cycle
1741920|NCT00118755|Drug|bevacizumab|5 mg/kg IV on Day 1 of each 2-week cycle
1741921|NCT00118768|Drug|valopicitabine|
1741922|NCT00118768|Drug|Pegylated Interferon Alfa|
1741923|NCT00118781|Drug|iseganan hydrochloride|
1741924|NCT00118794|Drug|Chlorproguanil-dapsone (Lapdap)|
1741925|NCT00118794|Drug|Lumefantrine-artemether (Coartemether )|
1741926|NCT00118807|Drug|Amodiaquine plus artesunate (AQ/AS)|
1741927|NCT00118807|Drug|Sulfadoxine-pyrimethamine plus chloroquine (SP/CQ)|
1741928|NCT00118807|Drug|Sulfadoxine-pyrimethamine plus amodiaquine (SP/AQ)|
1741929|NCT00118820|Drug|IV Preoperative antibiotic or placebo|
1741930|NCT00118833|Drug|Hypericum perforatum (St. John's wort)|
1741931|NCT00118846|Dietary Supplement|25 g soy protein supplement|25 g soy protein admisitered in equally divided dosage twice daily
1741932|NCT00118846|Other|Matching placebo|Milk protein administered twice daily
1741933|NCT00118859|Behavioral|Integrative care for low back pain|
1741934|NCT00118859|Behavioral|Conventional treatment for low back pain|
1741935|NCT00118872|Drug|LGG yogurt|Lactobacillus GG containing yogurt
1741936|NCT00118872|Other|Placebo yogurt|Yogurt NOT containing the active LGG bacteria
1741937|NCT00118885|Behavioral|Tai Chi Chih|
1741938|NCT00118898|Drug|Abacavir/Lamivudine|600 mg abacavir/300 mg lamivudine tablet taken orally daily
1741939|NCT00118898|Drug|Atazanavir|300 mg tablet taken orally daily
1741940|NCT00118898|Drug|Efavirenz|600 mg tablet taken orally daily
1741941|NCT00118898|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate tablet taken orally daily
1741942|NCT00118898|Drug|Ritonavir|100 mg tablet taken orally daily
1741943|NCT00118898|Drug|Abacavir/Lamivudine placebo|Placebo tablet taken orally daily
1741944|NCT00118898|Drug|Emtricitabine/Tenofovir disoproxil fumarate placebo|Placebo tablet taken orally daily
1741945|NCT00118911|Behavioral|Cognitive behavioral therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
1741946|NCT00118911|Other|Relaxation techniques and education about ADHD|Participants are provided with education about ADHD, instruction in relaxation techniques, and support in applying relaxation techniques to ADHD symptoms.
1741947|NCT00118924|Biological|LGT(TP21)/DEN4|Live attenuated LGT(TP21)/DEN4 vaccine (one of two doses)
1741948|NCT00118924|Biological|Placebo|Placebo for LGT(TP21)/DEN4 vaccine
1741949|NCT00118937|Drug|Metformin|Tablet Metformin 500 mg, Dosage: 1000 mg two times daily (2000 mg total daily dose).
1741950|NCT00118937|Drug|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 1 tablet per day.
1741951|NCT00118937|Drug|Placebo.|Tablet Placebo (corresponding to 500 mg metformin). Dosage: 2 tablets two times daily.
1741952|NCT00118950|Drug|Metformin|Tablet Metformin 500 mg; Dosage: 1000 mg two times daily. Duration: Four months.
1741953|NCT00118950|Drug|Repaglinide|Tablet Repaglinide 1 mg; Dosage: 2 mg three times daily. Duration: Four months.
1741954|NCT00118950|Drug|Placebo-Metformin.|Tablet Placebo (corresponding to 500 mg Metformin). Dosage: 2 tablets two times daily. Duration: Four months.
1741955|NCT00118950|Drug|Placebo-Repaglinide.|Tablet Placebo (corresponding to 1 mg Repaglinide). Dosage: 2 tablets three times daily. Duration: Four months.
1741956|NCT00118950|Other|Diet-only.|Diet-only treatment. Duration: One month.
1741957|NCT00118963|Drug|Metformin|Tablets of 500 mg; 1000 mg two times daily.
1741958|NCT00118963|Drug|Insulin BIAsp30 (Novolog 70/30)|Subcutaneous injection. Starting dose 6 units. Titration according to glycaemic targets during the entire intervention period.
1741959|NCT00118963|Drug|Repaglinide|Tablets of 1 mg; Dosage: 2 mg three times daily.
1741960|NCT00118963|Drug|Placebo-Metformin|Tablets corresponding to 500 mg; two tablets two times daily.
1741961|NCT00118963|Drug|Placebo-Repaglinide|Tablet corresponding to 1 mg; two tablets three times daily.
1741962|NCT00118976|Drug|Lisinopril|
1741963|NCT00118989|Dietary Supplement|Curcuminoids|Curcuminoids C3 Complex® or placebo to be taken orally via capsule form in the dose of 4 grams daily for a duration of four months
1741964|NCT00119002|Drug|dexamethasone|1mg/kg dexamethasone
1741965|NCT00119002|Drug|Placebo|1mg/kg placebo
1741966|NCT00119015|Drug|Placebo|
1741967|NCT00119015|Drug|Montelukast|
1741968|NCT00119015|Drug|Fluticasone propionate|
1741969|NCT00119028|Procedure|Depression Care Quality Improvement Implementation|We will used a randomized design to evaluate long term (18-month) cost effectiveness of TIDES collaborative care in six intervention clinics with fully-implemented collaborative care compared to three matched and randomly-assigned usual care clinics. We used a non-randomized quasiexperimental design (untreated control group with pretest and posttest) to measure impacts on clinician performance, knowledge, and attitudes in 6 newly-implemented collaborative care intervention clinics compared to 6 matched usual care clinics
1741970|NCT00119041|Behavioral|The Diabetes Treatment Satisfaction Questionnaire|A six question likert scale questionnaire regarding the patients treatment satisfaction. The responses range from very dissatisfied to very satisfied.
1741971|NCT00119041|Behavioral|Diabetes Empowerment Scale|A twenty-eight question likert scale questionnaire regarding the patients attitude towards diabetes. The responses range from strongly agree to strongly disagree.
1741972|NCT00119041|Behavioral|CBOC's undergo half-day joint-clinics via teleconference|A patient has Diabetes/Endo clinic visit via teleconferencing. A patient is at a CBOC and the Diabetes/Endo physician is at Wade Park.
1741973|NCT00119054|Behavioral|In Home Health Messaging Device|
1741975|NCT00119080|Biological|meningococcal conjugate vaccine (Menactra)|
1741976|NCT00119093|Procedure|Laboratory and clinical monitoring regimens|
1741980|NCT00119132|Drug|artesunate-amodiaquine|
1741981|NCT00119132|Drug|sulphadoxine-pyrimethamine|
1741982|NCT00119145|Drug|artesunate-amodiaquine|
1741983|NCT00119145|Drug|coartem|
1741984|NCT00119145|Drug|artesunate-lapdap|
1741985|NCT00119158|Drug|Combination of pimecrolimus and fluticasone|Pimecrolimus cream twice a day and fluticasone cream once a day
1741986|NCT00119158|Drug|pimecrolimus|apply daily with fluticasone cream for flares
1741987|NCT00119171|Drug|Ispinesib|
1741988|NCT00119171|Drug|Capecitabine|
1741989|NCT00119184|Procedure|External cephalic version with and without spinal anesthesia|7.5 mg bupivacaine intrathecally
1741990|NCT00119197|Biological|killed whole cell oral cholera vaccine|"Bivalent oral killed cholera vaccine: each dose of this vaccine contains:
Inactivated V.Cholerae Inaba (569B), Classical biotype - 25.109 cells
Inactivated V.Cholerae Ogawa (Cairo 50) Classical biotype - 25.109 cells
Inactivated V.Cholerae Inaba (Phil 6973) El Tor biotype - 50.109 cells
Inactivated V.Cholerae O139 - 50.109 cells
each 1.5 mL dose given orally, two doses given 14 days apart"
1741991|NCT00119197|Biological|Heat Killed E. coli|"Escherichia coli K12 strain placebo: each dose of placebo contains heat-killed E. coli K12 strain in an amount whose optical turbidity is identical to that for the cholera vaccine.
Each 1.5 mL dose given orally, two doses given 14 days apart"
1741992|NCT00119210|Drug|Bupropion SR|
1741993|NCT00119210|Other|placebo|
1741994|NCT00119236|Drug|tanespimycin|
1741995|NCT00119236|Drug|irinotecan hydrochloride|
1741996|NCT00119249|Drug|sorafenib tosylate|Given orally
1741997|NCT00119249|Other|laboratory biomarker analysis|Correlative studies
1741998|NCT00119262|Drug|doxorubicin hydrochloride|Given IV
1741999|NCT00119262|Drug|cyclophosphamide|Given IV
1742000|NCT00119262|Biological|bevacizumab|Given IV
1742001|NCT00119262|Drug|paclitaxel|Given IV
1742002|NCT00119262|Biological|filgrastim|Given SC
1742003|NCT00119262|Biological|pegfilgrastim|Given SC
1742004|NCT00119262|Radiation|radiation therapy|Undergo radiation therapy
1742005|NCT00119262|Drug|tamoxifen citrate|Given orally
1742006|NCT00119262|Drug|aromatase inhibition therapy|Receive aromatase inhibition therapy
1742007|NCT00119301|Drug|leucovorin calcium|
1742008|NCT00119301|Drug|methotrexate|
1742009|NCT00119301|Drug|trimetrexate glucuronate|
1742010|NCT00119314|Drug|capecitabine|
1742011|NCT00119314|Drug|docetaxel|
1742012|NCT00119314|Drug|gemcitabine hydrochloride|
1742013|NCT00119314|Procedure|positron emission tomography|
1742014|NCT00119340|Drug|cyclosporine|
1742015|NCT00119340|Drug|fludarabine phosphate|
1742016|NCT00119340|Drug|mycophenolate mofetil|
1742017|NCT00119340|Procedure|peripheral blood stem cell transplantation|
1742018|NCT00119340|Radiation|radiation therapy|
1742019|NCT00119366|Radiation|iodine I 131 monoclonal antibody BC8|Given IV
1742020|NCT00119366|Drug|fludarabine phosphate|Given IV
1742021|NCT00119366|Radiation|total-body irradiation|Undergo TBI
1742022|NCT00119366|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo PBSC transplantation
1742023|NCT00119366|Procedure|peripheral blood stem cell transplantation|Undergo PBSC transplantation
1742024|NCT00119366|Drug|cyclosporine|Given IV or PO
1742025|NCT00119366|Drug|mycophenolate mofetil|Given PO
1742026|NCT00119366|Other|laboratory biomarker analysis|Correlative studies
1742027|NCT00119379|Drug|NucleomaxX|NucleomaxX 36 grams TID every other day
1742028|NCT00119379|Drug|Tenofovir Disoproxil Fumarate|Switch of thymidine nucleoside reverse transcriptase inhibitors to Tenofovir Disoproxil Fumarate
1742029|NCT00119392|Biological|rituximab|Given IV
1742030|NCT00119392|Drug|cyclosporine|Given orally
1742031|NCT00119392|Drug|fludarabine phosphate|Given IV
1742032|NCT00119392|Drug|mycophenolate mofetil|Given orally
1742033|NCT00119392|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
1742034|NCT00119392|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
1742035|NCT00119392|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
1742036|NCT00119392|Radiation|total-body irradiation|Undergo TBI
1742037|NCT00119418|Drug|TU 025 Keishi Bukuryo Gan|
1742038|NCT00119431|Drug|C1 inhibitor concentrate|
1742039|NCT00119444|Procedure|Periacetabular osteotomy|osteotomy of the pelvis to increase acetabular coverage
1742040|NCT00119457|Drug|TTP889|
1742041|NCT00113763|Other|Best supportive care|Best supportive care as site routine excluding: antineoplastic chemotherapy, investigational agents, anti-EGFr(Epidermal growth factor receptor) targeting agents other than ABX-EGF(Panitumumab), experimental or approved anti-tumor therapies (e.g. Avastin), chemotherapy, radiotherapy (with the exception of radiotherapy for pain control limited to bone metastases).
1742042|NCT00113763|Drug|Panitumumab|Intravenous infusion at a dose of 6 mg/kg once every 2 weeks.
1742043|NCT00113776|Drug|ABX-EGF|
1742044|NCT00113789|Other|PI Discretion|PI Discretion
1742045|NCT00113802|Drug|Epratuzumab (hLL2- anti-CD22 humanized antibody)|
1742046|NCT00113815|Drug|topiramate|15 mg/kg/day
1742047|NCT00113815|Drug|topiramate|5 mg/kg/day
1742048|NCT00113815|Drug|topiramate|25 mg/kg/day
1742049|NCT00113815|Drug|placebo|placebo
1742050|NCT00113828|Procedure|Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7 and 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days-7,-6; fludarabine 25 mg/m2 on days -5, -4, -3, -2, -1.
Non-myeloablative Ex-Vivo T-cell Depleted PBSC Transplant."
1742051|NCT00113828|Procedure|T-cell depleted peripheral blood stem cell transplant|"Rabbit anti-thymocyte globulin 0.5 mg/kg on transplant day-8, 2.5 mg/kg on day-7, 3.0 mg/kg on day-6; cyclophosphamide 60 mg/kg on days -7, -6; fludarabine 25 mg/m2 on days -5 through -1.
T-cell depleted peripheral blood stem cell transplant ."
1742052|NCT00113841|Drug|Curcumin|2 grams (Capsules) orally in 2 divided doses (a.m., p.m.)
1742053|NCT00113841|Drug|Bioperine|5 mg (Tablets) orally twice daily
1742055|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
1742056|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
1742057|NCT00113880|Biological|FluMist|Nasal Sprayer dose of FluMist with annual follow up
1742058|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 30 mg thrice daily (90 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
1742059|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 60 mg thrice daily (180 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
1742060|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 90 mg thrice daily (270 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
1742061|NCT00113893|Drug|SCIO-469|SCIO-469 tablet will be administered orally at a dose of 120 mg thrice daily (360 mg per day) for 16 weeks. Participants with hematologic improvement at Week 16 and as per Investigator's discretion on clinical benefit from treatment will continue the treatment for additional 36 weeks.
1742062|NCT00113906|Drug|melatonin|
1742064|NCT00113932|Procedure|High-Dose Density Therapy|Dexamethasone 40mg po 1-4, Thalidomide 200 mg po 1-6hrs then daily after transplant; Cisplatin* 10 mg/m2 Continuous infusion 1-4;Adriamycin 10 mg/m2 Continuous infusion 1-4;Cyclophosphamide 400 mg/m2 Continuous infusion 1-4; Etoposide 40 mg/m2 Continuous infusion 1-4; Pegfilgrastim 6 mg subcutaneously 6 and 13; Darbepoetin 200μg subcutaneously Between -6 to-1 +12, & every 2 weeks until HB >12 gm/dl***; Lovenox (or other LMWH) 40 mg subcutaneously Daily until Pltcount <30,000/μl
1742065|NCT00113945|Drug|Cinacalcet|
1742066|NCT00113958|Drug|Cinacalcet|
1742067|NCT00113971|Drug|epratuzumab|
1742068|NCT00113984|Biological|PROSTVAC-V/TRICOM|
1742069|NCT00113984|Biological|PROSTVAC-F/TRICOM|
1742070|NCT00113984|Drug|MDX-010|
1742071|NCT00113984|Drug|Sargramostim|
1742072|NCT00113997|Drug|REG1|
1742073|NCT00114010|Drug|AMA1/Alhydrogel|
1742074|NCT00114023|Drug|Imiquimod 5% cream|
1742075|NCT00119470|Procedure|EUS-FNA|
1742076|NCT00119470|Procedure|Conventional Surgical Technique|
1742077|NCT00119483|Drug|Nebido (Testosterone Undecanoate)|
1742078|NCT00119496|Drug|rosiglitazone|oral tablet, 4mg bd for 4 weeks
1742079|NCT00119496|Drug|theophylline|Oral theophylline, 200mg bd
1742080|NCT00119496|Drug|beclomethasone|inhaled beclomethasone, 200mcg bd
1742081|NCT00119496|Drug|inhaled beclomethasone and oral theophylline|inhaled beclomethasone (400mcg/day), oral theophylline (400mg/day)
1742082|NCT00119509|Procedure|HPV DNA testing|
1742083|NCT00119509|Procedure|Conventional management (repeat Pap smear at 6 months)|
1742084|NCT00119509|Procedure|Decision aid with choice of management|
1742085|NCT00119535|Behavioral|Implementation of Proactive Diabetes Eye Care Program|
1742086|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
1742087|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
1742088|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
1742089|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
1742090|NCT00119548|Other|Rates of HIV testing and receipt of results|Rates of HIV testing and receipt of results
1742091|NCT00119548|Other|Sexual risk reduction; HIV knowledge improvement|Sexual risk reduction; HIV knowledge improvement
1742092|NCT00119561|Behavioral|Telephone Support|Each telephone support group of 5 caregivers and a group leader met 14 times over a year. The hour calls were semi-structured with an educational component and a support component, led by a trained Group Leader. Topics included knowledge of dementia, safety, caregiver health and well being, communication, managing behavioral challenges and caregiver stress and coping.
1742093|NCT00119574|Procedure|Collaborative Chronic Illness Model|
1742094|NCT00119587|Drug|darbepoetin alfa|
1742095|NCT00119600|Drug|AMG 114|
1742096|NCT00119613|Drug|placebo|placebo
1742097|NCT00119613|Drug|darbepoetin alfa|darbepoetin alfa
1742098|NCT00119626|Drug|NXY-059|
1742099|NCT00119639|Drug|Sorafenib (BAY43-9006, Nexavar)|All subjects were given a open-label, single dose of 400mg sorafenib
1742100|NCT00119652|Drug|quetiapine fumarate (Seroquel)|
1742101|NCT00119652|Drug|paroxetine|
1742102|NCT00119652|Behavioral|mood stabilizing activity|
1742103|NCT00119665|Drug|MF101|
1742104|NCT00119678|Drug|Abatacept|Injectable, intravenous, 10 mg/kg, abatacept every 28 days, 12 months
1742105|NCT00119678|Drug|Placebo|Injectable, intravenous, 0 mg, every 28 days, 12 months
1742106|NCT00119678|Drug|Prednisone|Tablets, oral, 30 mg, daily for 28 days then taper off, 12 months
1742107|NCT00119678|Drug|Abatacept|Injectable, intravenous, 10 mg/kg, every 28 days
1742108|NCT00119691|Drug|Nesiritide|Nesiritide: 1 mcg/kg bolus, followed by a continuous infusion at 0.005 mcg/kg/min which can be titrated every 3 hours by 0.005 mcg/kg/min to maximum dose of 0.03 mcg/kg/min until adequate diuresis achieved.
1742109|NCT00119704|Drug|Botulinum toxin A injection or normal saline|
1742110|NCT00119717|Device|NeuroFlo™ catheter|45 minute treatment
1742111|NCT00119717|Other|Control|ASA Guidelines
1742112|NCT00119730|Drug|Fludarabine|Given on days 1-3 of each 28-day cycle
1742113|NCT00119730|Drug|Mitoxantrone|Given on day 1 of each 28-day cycle
1742114|NCT00119730|Drug|Rituximab|Given on day 1 of each 28-day cycle
1742115|NCT00119730|Drug|Zevalin|After two cycles if there is no disease progression, zevalin treatment will be given. Rituximab will be given followed by an imaging dose of zevalin. Two or three scans will be performed over a week to determine if it is safe to give the full treatment dose of zevalin. The treatment dose is given with the second infusion or rituximab, seven days after the first dose.
1742116|NCT00119743|Biological|undecavalent pneumococcal-protein D conjugate vaccine|
1742117|NCT00119756|Drug|paliperidone palmitate|
1742118|NCT00119769|Drug|Placebo|Placebo, 0.7 mg/day injected subcutaneously
1742119|NCT00119769|Drug|Genotropin (human recombinant Growth hormone)|Genotropin, 0.7 mg/day injected subcutaneously
1742120|NCT00119782|Behavioral|Diet|A dietary intervention that will promote lower calorie intake
1742121|NCT00119782|Behavioral|Exercise|A physical activity intervention combining increased daily physical activity and regular, structured exercise
1742122|NCT00119782|Behavioral|Environment|Increase worksite access to both healthy foods and physical activity
1742123|NCT00119795|Behavioral|Exercise|Increase Physical Activity to 150 min/wk
1742124|NCT00119795|Behavioral|Weight Loss|Lose 7-10% of body weight and increase physical activity to 150 min/wk
1742125|NCT00119795|Behavioral|Health Education Control|Lectures on information relevant to successful aging
1742126|NCT00121043|Device|SimpleJectTM|
1742127|NCT00121043|Drug|Kineret® (Anakinra)|
1742128|NCT00121056|Drug|Enbrel®|
1742129|NCT00121056|Drug|Kineret®|
1742130|NCT00121069|Drug|Escitalopram|
1742131|NCT00121095|Drug|Samarium Sm-153 lexidronam + Docetaxel|1 mCi/kg Sm153 + 75 mg/m2 docetaxel
1742132|NCT00121108|Biological|MEDI-524|15 mg/kg motavizumab administered intramuscularly every 30 days for a maximum of 5 injections during the RSV season
1742133|NCT00121108|Other|Placebo|15 mg/kg placebo administered intramuscularly every 30 days for a maximum of 5 injections during the RSV season.
1742134|NCT00121121|Biological|Lipopeptides LIPO-4|
1742135|NCT00121134|Drug|Bevacizumab|Group A: Once every 3 weeks for 12 months Group B: Once every 3 weeks for 12 months
1742136|NCT00121134|Drug|Cyclophosphamide|Once a day for 6 months
1742137|NCT00121134|Drug|Methotrexate|Twice daily for the first two days of every week for 6 months
1742138|NCT00121134|Drug|Capecitabine|"Capecitabine: 2000 mg/m2 a day, on Days 1-14 of a 21 day cycle, for at total of 6 cycles (18 weeks)
Bevacizumab: 15 mg/kg IV day 1 every 3 weeks x 1 year (17 cycles)"
1742139|NCT00121147|Drug|Travatan|
1742140|NCT00121147|Drug|Azopt|
1742141|NCT00121147|Drug|Alphagan P|
1742142|NCT00121160|Behavioral|Cognitive Behavioral Stress Management (CBSM) group intervention|Participants will meet in closed, structured groups of 4 to 6 women for ten weekly, 2-hour group sessions. The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Group members and group leaders are used as role models for effective coping and the use of social support. The groups also encourage emotional expression and provide an opportunity to practice techniques learned in the group and experience social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Each week participants also experience a different relaxation technique. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
1742144|NCT00121186|Drug|fludarabine phosphate|30 mg/m^2 on days -6 to -2 (2-6 days before transplant).
1742145|NCT00121186|Drug|melphalan|70 mg/m^2 on days -3 and -2 (2-3 days before transplant).
1742146|NCT00121186|Drug|methotrexate|5 mg/m^2 on days 1, 3, and 7 post-transplant.
1742147|NCT00121186|Drug|tacrolimus|0.03 mg/kg bid on days -3 to 100 post-transplant.
1742148|NCT00121186|Procedure|allogeneic bone marrow transplantation|if donor bone marrow stem cells are harvested
1742149|NCT00121186|Procedure|peripheral blood stem cell transplantation|if donor peripheral blood stem cells are harvested
1742150|NCT00121199|Biological|rituximab|Given IV
1742151|NCT00121199|Biological|bevacizumab|Given IV
1742152|NCT00121199|Drug|cyclophosphamide|Given IV
1742153|NCT00121199|Drug|doxorubicin hydrochloride|Given IV
1742154|NCT00121199|Drug|vincristine sulfate|Given IV
1742155|NCT00121199|Drug|prednisone|Given PO
1742156|NCT00121199|Other|laboratory biomarker analysis|Correlative studies
1742157|NCT00121212|Procedure|carbon-11 acetate PET scan|
1742158|NCT00121225|Drug|vorinostat|Patients will receive vorinostat by mouth once a day for 4 weeks. Treatment may repeat every 4 weeks for as long as benefit is shown. Patients will be evaluated for 4 weeks and every 3 months thereafter.
1742159|NCT00121238|Drug|cilengitide|Given IV
1742160|NCT00121251|Drug|Capecitabine|Given PO
1742161|NCT00121251|Drug|Gemcitabine Hydrochloride|Given IV
1742162|NCT00121251|Drug|Sorafenib Tosylate|Given PO
1742163|NCT00121264|Drug|sorafenib tosylate|Given orally
1742164|NCT00121264|Drug|tanespimycin|Given IV
1742165|NCT00121264|Other|laboratory biomarker analysis|Correlative studies
1742166|NCT00121264|Other|pharmacological study|Correlative studies
1742167|NCT00121264|Procedure|magnetic resonance imaging|Correlative studies
1742168|NCT00121277|Drug|capecitabine|
1742169|NCT00121277|Drug|vorinostat|
1742170|NCT00121290|Drug|SJG-136|Given IV
1742171|NCT00121290|Other|laboratory biomarker analysis|Correlative studies
1742172|NCT00121290|Other|pharmacological study|Correlative studies
1742173|NCT00121303|Drug|cytarabine|
1742174|NCT00121303|Drug|daunorubicin hydrochloride|
1742175|NCT00121303|Drug|gemtuzumab ozogamicin|
1742176|NCT00121316|Drug|Pimecrolimus|Pimecrolimus Cream 1 %
1742177|NCT00121316|Drug|Placebo|Vehicle cream (placebo cream)
1742178|NCT00121329|Drug|Intrauterine lidocaine infusion 4%|
1742181|NCT00121381|Drug|Pimecrolimus plus topical corticosteroid (TCS)|Pimecrolimus 1 % cream plus topical corticosteroid (TCS) twice daily
1742182|NCT00121381|Drug|Pimecrolimus vehicle (Placebo) plus topical corticosteroid (TCS)|twice daily administration
1742183|NCT00121394|Procedure|Chlorhexidine vaginal and infant wash|
1742184|NCT00121407|Drug|Visudyne for injection|
1742185|NCT00121420|Drug|Motexafin gadolinium|
1742186|NCT00121433|Drug|leptin|
1742187|NCT00121446|Drug|tenecteplase|
1742188|NCT00121446|Drug|enoxaparin|
1742189|NCT00121446|Drug|clopidogrel|
1742190|NCT00121446|Procedure|percutaneous coronary intervention|
1742191|NCT00121459|Device|Ortho All-Flex diaphragm and Replens lubricant gel|
1742192|NCT00121472|Device|Thoratec HeartMate II Left Ventricular Assist System (LVAS)|Implantation of ventricular assist device to provide hemodynamic support
1742193|NCT00121485|Device|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
1742194|NCT00121498|Drug|Lidocaine (local anesthetics) 20 ml of 1 % subcutaneously|
1742195|NCT00121511|Drug|Efudex (5-fluorouracil)|
1742196|NCT00121524|Drug|Epinephrine|Epinephrine 1 mg is given iv. every 3 min during CPR
1742197|NCT00121524|Device|Intravenous needle|An intravenous needle in placed as soon as possible during CPR
1742198|NCT00121524|Drug|Atropine|Atropine 3 mg iv in initial systole
1742199|NCT00121524|Drug|Amiodarone|amiodarone 300 mg iv after repeated failed defibrillation attempts
1742200|NCT00121537|Device|Wound Care -Wound Vacuum Assisted Closure (VAC)|
1742201|NCT00121537|Procedure|Wound Care - Wet to Dry Dressing Changes|
1742202|NCT00121550|Drug|clarithromycin|
1742203|NCT00121563|Drug|Thalidomide, Ibuprofen or Diazepam|
1742204|NCT00121589|Drug|Lutein|
1742205|NCT00121602|Drug|Darbepoetin Alfa|Initial dose, frequency and route of administration of study drug will be the same as that administered for darbepoetin alfa prior to enrollment. Frequency either once a week or once every two weeks, frequency may not change for duration of study. Route of administration either subcutaneous or intravenous, route of administration may not change for duration of study. Study drug provided in pre-filled syringes at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100 or 150 ug.
1742206|NCT00121615|Drug|etanercept|
1742207|NCT00121628|Drug|AMG 706|
1956530|NCT02820844|Other|Bladder diary|The bladder diary is a self-reporting tool to record subject's data on micturition. Subjects will enter data in the diary over 3 consecutive days. During Screening, data will be collected within 28 days prior to first treatment. During treatment periods, data will be collected within a week prior to each scheduled visit. The bladder diary will capture the following information: 1) Date and time of urinary episode, 2) episodes of micturition, 3) episodes of urinary incontinence, 4) episodes of urgency, 5) intensity of urgency, 6) episodes of nocturia, 7) use of CIC, and 8) urine volume. Diary data will not be collected when a subject experiences symptoms of a UTI.
1956531|NCT02820844|Other|King's Health Questionnaire (KHQ)|The KHQ will assess the impact of urinary incontinence on QOL. It is a questionnaire with 21 items and the following 9 domains: 1) General health, 2) Incontinence impact, 3) Role limitations, 4) Physical limitations, 5) Social limitations, 6) Personal relationships, 7) Emotion, 8) Sleep/energy, 9) Severity measure. The items are answered by subjects themselves, and scores are summated using a defined algorithm.
1956532|NCT02820844|Other|Overactive Bladder Symptom Score (OABSS)|The OABSS will comprehensively assess symptoms of OAB, such as frequency of micturition, nocturia, urinary urgency, and urge incontinence. It consists of 4 questions which will be responded by subjects themselves, by selecting the most appropriate answer for each question.
1742216|NCT00121654|Device|Spinal cord stimulation|Under sterile conditions and local anesthesia, the epidural space is punctured at the level of T5-T6 and a quadripolar electrode catheter is introduced and advanced under X-ray control into the epidural space. A suitable position for the electrode catheter is sought for, corresponding to the site where a prickling sensation (paresthesia) is felt and covers the area of radiation of angina pain under neurostimulation. The electrode catheter is connected to an internal pulse generator placed in a subcutaneous abdominal or gluteal pocket through an extension lead connected to the electrode by subcutaneous tunneling.
1742223|NCT00121693|Behavioral|Music therapy (listening to specific music)|Listening to Music
1742224|NCT00121706|Behavioral|Condition A (see detailed summary)|
1742225|NCT00121706|Behavioral|Condition B (see detailed summary)|
1742226|NCT00121706|Behavioral|Condition C (see detailed summary)|
1742227|NCT00121719|Drug|Lenvatinib|Lenvatinib tablets taken orally, once daily.
1742228|NCT00121732|Drug|E7974|Maximum tolerated dose = 0.15 mg/m^2 administered on Days 1, 8, 15 of 28-day cycle.
1742229|NCT00121732|Drug|E7974|Maximum tolerated dose = 0.37 mg/m^2 administered on Days 1 and 8 of 21-day cycle.
1742230|NCT00121745|Genetic|Rexin-G Dose 1|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose I 3- 6 Days 1-7, 15-21 7.5 x 10e9 cfu 500 ml
1742231|NCT00121745|Genetic|Rexin-G Dose 2|Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose II 3- 6 Days 1-7, 15-21 1.1 x 10e10 cfu 500 ml
1742232|NCT00121745|Genetic|Rexin-G Dose 3|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose
III 3- 6 5 days/wk x 4 wks 3.0 x 10e10 cfu 500 ml"
1742233|NCT00121745|Genetic|Rexin-G Dose 4|"Dose Level # Patients Treatment Days Vector Dose/Day Max.Volume/Dose
IV 3- 6 5 days/wk x 4 wks 8.0 x 10e10 cfu 500 ml"
1742234|NCT00121758|Biological|LIPO-5|
1742235|NCT00121771|Biological|FP9 CS|
1742236|NCT00121771|Biological|MVA CS|
1742237|NCT00121784|Drug|mycophenolate mofetil [CellCept]|1
1742238|NCT00121797|Procedure|urine culture|
1742239|NCT00121797|Drug|antibiotics according to culture|
1742240|NCT00121810|Drug|mycophenolate mofetil [CellCept]|1.0-1.5 g oral dose twice daily
1742241|NCT00121810|Drug|Corticosteroids|As prescribed
1742242|NCT00121810|Drug|Calcineurin inhibitors|As prescribed
1742243|NCT00121810|Drug|Sirolimus|As prescribed
1742244|NCT00121823|Biological|FP9 ME-TRAP|
1742246|NCT00121836|Drug|Capecitabine|1000 mg/m² PO BID on Days 1-15 of each 3-week cycle
1742247|NCT00121836|Drug|Bevacizumab|15 mg IV on Day 1 of each 3-week cycle
1742248|NCT00121849|Biological|Leish-111f + MPL-SE vaccine|
1742249|NCT00121862|Biological|Leish-111f + MPL-SE vaccine|
1742250|NCT00121875|Drug|somatropin (rDNA)|"Form/Strength: 10 mg aqueous suspension; 5 mg/ml
Dosage/Frequency: 0.35 mg/kg/week, daily divided doses
Duration: 6 months with 3-month washout period"
1742251|NCT00121888|Behavioral|Prolonged Exposure Therapy|
1742252|NCT00121888|Drug|Paroxetine-CR|
1742253|NCT00121901|Drug|glyceryl nitrate|
1742254|NCT00121914|Procedure|percutaneous ethanol instillation (PEI)|
1742255|NCT00121927|Behavioral|Atkins diet (15 grams/day carbohydrates)|
1742256|NCT00121940|Behavioral|Guided Care|"Specially trained registered nurse (Guided Care Nurse) based in a primary care practice collaborates with two primary care physicians to provide seven services for 40-60 high-risk patients: comprehensive assessment and care planning; best practices for chronic conditions; self-management; healthy lifestyles; coordinating care; educating and supporting unpaid caregivers; and accessing community resources."
1742257|NCT00121953|Drug|Rosiglitazone|
1742258|NCT00121966|Drug|Insulin Aspart|
1742259|NCT00121966|Drug|Insulin NPH|
1742260|NCT00121966|Drug|Metformin|
1742261|NCT00121966|Drug|Rosiglitazone|
1742262|NCT00121979|Drug|Racivir, a non-nucleoside reverse transcriptase inhibitor|
1742263|NCT00121992|Drug|Docetaxel/Doxorubicin/cyclophosphamide (75/50/500) mg/m2 q3w|
1742264|NCT00122005|Biological|GM-CSF gene transduced allogeneic vaccine GVAX|
1742265|NCT00122018|Drug|N-acetylcysteine|
1742266|NCT00122018|Drug|fenoldopam|
1742267|NCT00122031|Device|Deep Brain Stimulation with Medtronic Activa Neurostimulator|Deep brain stimulation (DBS) at 130 Hz
1742268|NCT00122044|Drug|trihexyphenidyl|
1742269|NCT00122057|Drug|antibiotic treatment|
1742270|NCT00122070|Drug|Quetiapine Fumarate|Dosage can vary from 50 to 150 mg at PI's discretion
1742271|NCT00122083|Device|Health education information|
1742272|NCT00122096|Drug|valdecoxib|
1742273|NCT00122109|Behavioral|12 sessions Anger Management Therapy.|Anger Management Treatment (AMT), a 12-session manual-driven cognitive-behavioral intervention developed and found efficacious for anger management treatment with substance abuse veterans and has been applied to the PTSD population. AMT is highly structured with both psychoeducational and psychotherapy components. AMT is aimed at reducing anger affect and aggression through increasing anger management skills.
1742274|NCT00122122|Behavioral|Enhanced Pharmacy Care|
1742275|NCT00122135|Other|Values Inventory (VI)|The Values Inventory was given to patients for self-administration while they were awaiting their clinic appointment. They were instructed to bring it to their physician's attention right at the beginning of their clinic visit.
1742276|NCT00122148|Behavioral|Feedback on provision of care|
1742277|NCT00122161|Behavioral|ATHENA Decision Support System, An Automated Clinical Decision Support System for Health Care Providers|
1742278|NCT00122161|Behavioral|Profiling performance|
1742279|NCT00122174|Behavioral|Stress Busting Program for family caregivers|
1742280|NCT00122187|Device|Electronic Consult System|Consult system is an event notification system programmed to function within the VA electronic medical record system.
1742281|NCT00122213|Behavioral|Behavior change on physical activity and diet|
1742282|NCT00122226|Drug|Lopinavir/ritonavir + zidovudine + lamivudine|
1742283|NCT00122226|Drug|Lopinavir/ritonavir + nevirapine|
1742284|NCT00122278|Drug|dexamethasone 10mg IV|corticosteroid
1742285|NCT00122291|Drug|Capecitabine|
1742286|NCT00122291|Procedure|Pelvic radiation|
1742287|NCT00122304|Drug|eculizumab|
1742288|NCT00122317|Drug|eculizumab|600 mg intravenous infusion every week x 4 then 900 mg iv every two weeks
1742289|NCT00122330|Drug|eculizumab|
1742290|NCT00122343|Drug|ridaforolimus|AP23573 will be administered intravenously (IV) at a fixed dose of 12.5 mg over 30 minutes once daily for 5 days (QDx5) every 2 weeks. A 4-week period comprised of 2 courses of AP23573 is defined as a cycle of treatment.
1742291|NCT00122356|Drug|Alendronate sodium|70mg tablets, once weekly
1742292|NCT00122369|Behavioral|Self-hypnotic Relaxation|A research assistant read to the patient a self-hypnotic relaxation script while displaying empathic attention.
1742293|NCT00122369|Behavioral|Empathic Attention|A research assistant displayed defined behaviors of empathic attention.
1742294|NCT00122382|Drug|Abatacept|abatacept 10 mg/kg IV monthly, methotrexate weekly, for 24 months
1742295|NCT00122382|Drug|placebo|placebo IV, monthly, methotrexate weekly for 12 months followed by abatacept 10 mg/kg IV monthly, methotrexate weekly for 12 months
1742296|NCT00122382|Drug|methotrexate|Oral, titrated to at least 15 mg per week not to exceed 20 mg per week administered every 28 days from Month 12 to Month 24
1742297|NCT00122395|Behavioral|Screening via pen and paper|
1742298|NCT00122395|Behavioral|Screening via audiotape|
1742299|NCT00122408|Dietary Supplement|Ergyphilus|5 pills a day of Ergyphilus or placebo
1742300|NCT00122421|Behavioral|Pharmacist recommendations to primary care providers|recommendations based on chart review by pharmacist, given to pcp at time of visit
1742301|NCT00122421|Other|pharmacist recommendations|recommendations based on chart review by pharmacist, given to pcp at time of visit
1742302|NCT00122434|Drug|BEA 2180 BR|
1742303|NCT00122434|Drug|tiotropium|
1742304|NCT00122447|Drug|Aspirin|325 mg PO QD
1742305|NCT00122447|Drug|Alpha lipoic acid|600 mg PO BID
1742306|NCT00122447|Drug|Olmesartan|40 mg PO QD
1742307|NCT00122447|Drug|Placebo|"Identical placebo for each active comparator:
placebo aspirin 325 mg PO QD; placebo for alpha lipoic acid 600 mg PO BID; placebo for olmesartan 40 mg PO QD"
1742378|NCT00122928|Behavioral|Diet|Healthy Choices in vending machines; Healthy Choices in cafeteria; Catering (Healthy Choices in site meetings, shutdowns, OT meals, etc.); Targeted Messages: Nutrition; Site Based Rewards and Recognition - Individual Employees Weight Management Tracking Program
1742550|NCT00124553|Behavioral|Intensive dietary advice|
1742308|NCT00122460|Drug|Cetuximab + Platinum (Cisplatin or Carboplatin) + 5Fluorouracil (5-FU)|Subjects in will receive initial dose of 400 mg/m^2 cetuximab (over 2 hours) followed by weekly doses of 250 mg/m^2 (over 1 hour). All doses will be given by intravenous (IV) infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (Area under the curve (AUC) 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks
1742309|NCT00122460|Drug|Platinum (Cisplatin or Carboplatin) + 5-FU|All doses will be given by IV infusion. Subjects will receive either Cisplatin (100 mg/m^2 on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks or Carboplatin (AUC 5 IV on day 1) + 5-FU (1000 mg/m^2 continuous IV from day 1 to day 4) every 3 weeks
1742310|NCT00122473|Drug|Imatinib (Glivec)|
1742311|NCT00122486|Drug|Tenofovir Disoproxil Fumarate|
1742312|NCT00122499|Drug|tadalafil|
1742313|NCT00122512|Drug|Tenofovir Disoproxil Fumarate|
1742314|NCT00122525|Procedure|Male Circumcision|
1742315|NCT00122538|Drug|Efavirenz (EFV)|
1742316|NCT00122538|Drug|Lamivudine (3TC)|
1742317|NCT00122538|Drug|Didanosine (ddI)|
1742318|NCT00122551|Procedure|Intermittent antiretroviral therapy|
1742319|NCT00122564|Biological|HIV-1 gp 160|
1742320|NCT00122564|Biological|DC-Chol|
1742321|NCT00122577|Drug|Tenofovir|
1742322|NCT00122577|Drug|Atazanavir|
1742323|NCT00122577|Drug|Ritonavir|
1742324|NCT00122590|Drug|nelfinavir|
1742325|NCT00122590|Drug|lopinavir/r|
1742326|NCT00122590|Drug|indinavir|
1742327|NCT00122590|Drug|ritonavir|
1742328|NCT00122603|Drug|Fosamprenavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill twice a day) + FPV (700mg: 1 pill twice a day)
1742329|NCT00122603|Drug|Saquinavir|ATV (150mg: 2 pills per day) + RTV (100mg: 1 pill per day) + SQV (500mg: 3 pills per day)
1742330|NCT00122616|Biological|Peginterferon alpha-2a (Pegasys®)|Peg-Interferon Alpha2a by subcutaneous injection, 180µg, once weekly
1742331|NCT00122616|Drug|Ribavirin|Ribavirin: tablet oral, weight-based dose, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over 75 kg, once daily
1742332|NCT00122616|Drug|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
1742333|NCT00122616|Drug|HIV antiretroviral therapy|All antiretroviral drugs are allowed, their choice being left to the discretion of the investigator. Particular attention will be carried to the patients with antiretroviral susceptible to cause a cumulative toxicity with anti-VHC drugs
1742334|NCT00122629|Drug|peg-interferon alfa-2b|
1742335|NCT00122629|Drug|ribavirin|
1742336|NCT00122629|Drug|amantadine|
1742337|NCT00122642|Procedure|Alcohol-lock|The intervention is the instillation of ethanol 70% solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
1742338|NCT00122642|Drug|placebo-lock|The intervention is the instillation of placebo solution in the catheter lumen (or lumina) for 15minutes per day during hospital stay and for 15minutes per week for patients not in the hospital.
1742339|NCT00122655|Drug|non-nucleoside reverse transcriptase inhibitors|
1742340|NCT00122655|Drug|nucleoside reverse transcriptase inhibitors|
1742341|NCT00122655|Drug|protease inhibitors|
1742342|NCT00122668|Drug|non-nucleoside reverse transcriptase inhibitors|
1742343|NCT00122668|Drug|nucleoside reverse transcriptase inhibitors|
1742344|NCT00122668|Drug|protease inhibitor|
1742345|NCT00122681|Biological|Cervarix™|Intramuscular injection, 3 doses
1742346|NCT00122681|Biological|Havrix™-based investigational formulation|Intramuscular injection, 3 doses
1742347|NCT00122694|Drug|carbon monoxide|
1742348|NCT00122707|Device|catheters|
1742349|NCT00122720|Drug|Darbepoetin Alfa|
1742350|NCT00122733|Drug|loxapine|
1742351|NCT00122746|Radiation|Radiotherapy alone|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A
1742352|NCT00122746|Radiation|Radiotherapy with cisplatin|EBRT pelvis 46 Gy 4 field box technique + ICBT LDR 1x30 Gy/A or HDR 3x8 Gy/A + weekly cisplatin 30 mg/m2 during EBRT
1742353|NCT00122759|Drug|ketamine|
1742354|NCT00122772|Radiation|Radiotherapy|"External Beam Radiation 46Gy in 23 daily fractions
High Dose Brachytherapy 2 fractions of 9Gy"
1742355|NCT00122772|Radiation|Radiotherapy|"External Beam Radiotherapy 46Gy in 23 daily fractions
High Dose Brachytherapy 4 fractions of 7Gy"
1742356|NCT00122772|Radiation|Radiotherapy/Cisplatin|"External Beam Radiation 46Gy in 23 daily fractions
High Dose Brachytherapy 2 fractions of 9Gy
Cisplatin 40 mg/sqm weekly"
1742357|NCT00122772|Radiation|Radiotherapy/Cisplatin|"External Beam Radiotherapy 46Gy in 23 daily fractions
High Dose Brachytherapy 4 fractions of 7Gy
Cisplatin 40mg/sqm weekly"
1742358|NCT00122785|Drug|dexamethasone|
1742359|NCT00122798|Procedure|Stroke treatment|
1742360|NCT00122811|Drug|Indapamide SR 1.5mg; Perindopril 2-4mg|
1742361|NCT00122824|Drug|duloxetine hydrochloride|
1742362|NCT00122824|Drug|placebo|
1742363|NCT00122837|Drug|Duloxetine|
1742364|NCT00122837|Drug|venlafaxine|
1742365|NCT00122837|Drug|placebo|
1742366|NCT00122850|Drug|Duloxetine|
1742367|NCT00122850|Drug|venlafaxine|
1742368|NCT00122850|Drug|placebo|
1742369|NCT00122863|Drug|Duloxetine Hydrochloride|
1742370|NCT00122863|Drug|placebo|
1742371|NCT00122876|Procedure|Photodynamic therapy|
1742372|NCT00122876|Drug|Talaporfin Sodium|
1742373|NCT00122889|Drug|Garlic powder with high allicin content|
1742374|NCT00122889|Drug|Garlic powder with low allicin content|
1742375|NCT00122889|Drug|Garlic oil|
1742376|NCT00122889|Drug|Aged garlic|
1742377|NCT00122915|Device|Cortical lead, 8 electrodes (Model 2976) with Synergy neurostimulator|
1742379|NCT00122928|Behavioral|Exercise|Walking Paths/Routes; Weight Management Tracking Program; Targeted Messages: Physical Activity; Site Based Rewards and Recognition - Individual Employees
1742380|NCT00122928|Behavioral|Environmental Obesity Program - Healthy Culture|Site Goal Setting; Work Group Alignment to Site Goals; Reporting to Senior Leadership; Leadership Training; Site Leadership, Cross Discipline Teams, Work Groups, Healthy Culture Focal Point Rewards and Recognition
1742381|NCT00122941|Dietary Supplement|multiple micronutrients|
1742382|NCT00122954|Drug|Fish oil concentrate|fish oil concentrate at a daily dose of 6 grams (2.1 gram EPA and 1.5 gram DHA).
1742383|NCT00122954|Drug|Placebo|soybean oil with 1% fish oil at a daily dose of 6 grams
1742384|NCT00122980|Procedure|Red Cell Transfusions|Red Blood Cell Transfusions
1742385|NCT00122980|Procedure|Iron Chelation|Iron Chelation Therapy
1742386|NCT00122980|Drug|Hydroxyurea|Hydroxyurea
1742387|NCT00122980|Procedure|Phlebotomy|Phlebotomy
1742388|NCT00122993|Behavioral|Healthful eating and food choices behavior change programs and changes in worksite food availability and prices|Food choices and eating behavior programs and environmental changes will be implemented for 18 months in intervention garages.
1742389|NCT00122993|Behavioral|Physical Activity|Physical activity programs are offered at the intervention garages for an 18 month period.
1742390|NCT00122993|Behavioral|Environment|Changes in the food and physical activity environment are made for an 18 month period in intervention garages. These include improving the healthfulness of the foods available in vending machines, and improving the fitness rooms at the garages.
1742391|NCT00123006|Behavioral|Dietary Approaches to Stop Hypertension (DASH)|4 week feeding intervention
1742392|NCT00123006|Behavioral|Control Diet|4 week feeding intervention
1742393|NCT00123019|Behavioral|Exercise and diet|Advice and measurement only
1742394|NCT00123019|Behavioral|Diet, Weight Reducing|Measurement, advice, environmental and behavioral group interventions
1742395|NCT00123019|Behavioral|Level 1|Annual assessment of weight and waist circumference, questionnaire on work, health issues, advice on diet, physical activity and other health issues.
1742396|NCT00123019|Behavioral|Level 2|All Level 1 activities plus ongoing environmental interventions in worksite and weight management groups in worksite over a 24 month period.
1742397|NCT00123032|Behavioral|Diet|Increase the availability of fruits and vegetables, serve recommended portion sizes and reduce availability of excessive energy-dense foods at school cafeterias to improve the diet of participants at school breakfast, lunch and snacks.
1742398|NCT00123032|Procedure|Exercise|Increase active recess time, implement classroom action breaks and increase school PE class time to increase physical activity among participants.
1742399|NCT00123045|Behavioral|health education|
1742400|NCT00123058|Behavioral|Nurse administered|Subjects received a nurse administered behavioral intervention via telephone every 8 weeks for 24 months.
1742401|NCT00123058|Device|BP Monitor|Subjects received a study provided home BP monitor and recorded home BP 3 times per week for 24 months.
1742402|NCT00123084|Behavioral|Voice/Respiration Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort exercises focusing on increased loudness and good voice quality.
1742403|NCT00123084|Behavioral|Speech/Articulation Treatment|Therapy is 4 1-hour sessions per week for 4 weeks. Tasks include high-effort articulation exercises to promote more enunciated speech.
1742404|NCT00123084|Behavioral|No intervention (PD)|Subjects with PD in the no intervention group will receive no therapy during the study. Subjects will receive therapy after completion of the study.
1742405|NCT00123084|Behavioral|HC control|Subjects without PD in the HC control group will not receive any therapy, either during or after completion of the study.
1742406|NCT00123097|Combination Product|Chlorinated polyethylene elastomer|Chlorinated polyethylene
1956533|NCT02820844|Other|Treatment Benefit Scale (TBS)|"The TBS consists of one question (My condition has), to which the subject will answer by selecting one of the following responses: greatly improved, improved, not changed, worsened. The TBS will assess treatment benefit of GSK1358820."
1742411|NCT00123123|Drug|chlorhexidine gluconate oral rinse (0.12%)|chlorhexidine gluconate oral rinse
1742412|NCT00123123|Drug|placebo|
1742413|NCT00123136|Device|foot energizer|
1742414|NCT00123149|Drug|Epoetin alfa|
1742415|NCT00123162|Drug|Sildenafil Citrate|A single vaginal dose of sildenafil citrate 100 mg and monitored for 4 hours.
1742416|NCT00123162|Drug|Placebo|A single vaginal dose of placebo and monitored for 4 hours.
1742417|NCT00123175|Device|Intrauterine Device|Mirena and Provera
1742418|NCT00123188|Procedure|Ultrasound and Biopsy|Transvaginal ultrasound and Endometrial Biopsy
1742419|NCT00123201|Drug|Dronabinol MDI|
1742420|NCT00123214|Drug|Controlled Dietary Intervention|
1742421|NCT00123227|Drug|Rosiglitazone|
1742422|NCT00123240|Behavioral|Low calorie high carbohydrate diet|65% carbohydrate, 15% protein, 20% fat (7% SFA, 8% MFA, 4% PUFA), P/S 0.63, 152 mg cholesterol/1500 kcal
1742423|NCT00123240|Behavioral|Low calorie high fat/protein diet|High Fat/Protein Diet: 10% carbohydrate, 25% protein, 65% fat (26% SFA, 25% MFA, 9% PUFA), P/S 0.33, 458 mg cholesterol/1500 kcal
1742424|NCT00123253|Drug|TH9507|
1742425|NCT00123266|Drug|Microplasmin|2 mg/kg, IA over 75 mins
1742426|NCT00123279|Drug|Microplasmin|25ug injected 1 hr prior to PPV, 24 hr and 7 days prior to PPV, 50ug injected 24 hr prior to PPV, 75ug injected 24 hr prior to PPV and 125ug injected 24 hr prior to PPV.
1742427|NCT00123292|Drug|Microplasmin|An infusion of 0.45, 0.60 and 0.90 mg/kg/hr will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
1742428|NCT00123292|Drug|Microplasmin|An infusion of 0.45 mg/kg/hr in conjunction with distal protection device will be administered for up to 4 hours. Study drug will be administered intra-arterially (into the thrombotic occlusion).
1742429|NCT00123292|Drug|Microplasmin|An infusion of 20 or 40 mg (20 mg for the 15 cm treatment length device; 40 mg for the 30 cm treatment length device) over 10 minutes via the Trellis-8 Peripheral Infusion System catheter, in accordance with the Trellis-8 Instructions for Use. For occlusive lesions that are longer than the treatment length of the Trellis-8 device, a repeat infusion of the same dose and duration may be administered.
1742430|NCT00123305|Drug|Microplasmin|1mg/kg bolus of microplasmin solution followed by 1,2 or 3mg/kg infusion of mircroplasmin solution.
1742431|NCT00123305|Drug|Microplasmin|1mg/kg bolus of placebo solution followed by 1,2 or 3mg/kg infusion of placebo solution
1742432|NCT00123318|Drug|epirubicin|50mg/m2 IV day 1
1742433|NCT00123318|Drug|cisplatin|60mg/m2 IV day 1
1742434|NCT00123318|Drug|5-fluorouracil|5-FU 200mg/m2/d IV 21 day continuous infusion Cont. infusional 5-FU 225mg/m2/day, 7 days/wk throughout entire period RT via CADD pump through PICC line
1742435|NCT00123318|Radiation|Radiotherapy|45Gy 25 Fractions, 5 days/week for 5 weeks
1742436|NCT00123331|Drug|Cyclosporine discontinuation|
1742437|NCT00123331|Drug|Rapamycin medication|
1742438|NCT00123344|Device|AT501 pacemaker|
1742439|NCT00123370|Drug|Modafinil|
1742440|NCT00123383|Drug|Modafinil|
1742441|NCT00123396|Behavioral|BioCASES and BioTESTS|
1742442|NCT00123409|Behavioral|Telephone disease management|Telephone based care management
1742443|NCT00123409|Behavioral|Usual Care|Usual care
1742444|NCT00123422|Behavioral|Breathing retraining|exercise training with computerized training program
1742445|NCT00123422|Behavioral|Heliox|exercise training with a helium oxygen combination
1742446|NCT00123422|Behavioral|Exercise|exercise training
1742447|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
1742448|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
1742449|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
1742450|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
1742451|NCT00123435|Device|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
1742452|NCT00123435|Behavioral|Nutritional counseling|The nutritional counseling is based on the six-session Medical Nutrition Therapy Protocol for Weight Management published by the American Dietetics Association. The categories include the following: a) Meal planning (food, hydration, fiber, alcohol), b) Food label reading, c) Recipe modification, d) Food preparation, e) Dining out and f) Physical activity.
1742453|NCT00123435|Behavioral|Walking program|As part of the discussion of physical activity, participants in the control group will be encouraged to walk and dietitians will discuss goal setting using timed walks instead of total daily step-counts at each of the control group sessions. As a general guideline, participants will be encouraged to increase their daily walking target by 5-10 minutes (control group with time goals) or to increase their average daily step counts by 10-25% (pedometer group with step count goals) following each of the nutritional counseling sessions.
1742454|NCT00123435|Device|Simple pedometer|Device to be worn during waking hours to give an objective measure of steps taken each day.
1742455|NCT00123435|Device|Enhanced pedometer|Simple pedometer with the addition of web-based feedback.
1742456|NCT00123461|Drug|Hectorol (doxercalciferol capsules), 0.5mcg|
1742457|NCT00123474|Drug|dasatinib|Tablets, Oral, 50 mg BID, indefinitely, survival study
1742458|NCT00123474|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
1742459|NCT00123474|Drug|dasatinib|Tablets, Oral, 100 mg QD, indefinitely, survival study
1742460|NCT00123474|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
1742461|NCT00123487|Drug|dasatinib|Tablets, Oral, 70 mg BID, indefinitely, survival study
1742462|NCT00123487|Drug|dasatinib|Tablets, Oral, 140 mg QD, indefinitely, survival study
1742463|NCT00123500|Behavioral|Diet|Diet
1742464|NCT00123500|Behavioral|Physical Activity|Physical Activity
1742465|NCT00123500|Behavioral|Environment|Environment
1742466|NCT00123500|Other|Control Group|Control Group
1742467|NCT00123513|Behavioral|Diet|Environmental changes in the food and physical activity environment. Cafeteria and vending machine changes, food brought from home, walking routes, and awareness building.
1742468|NCT00123513|Behavioral|Exercise|Increase routing physical activity, walking routes, stairs intervention, etc.
1742469|NCT00123513|Behavioral|Environment|Cafeteria and vending machine changes and identification of opportunities of physical activity.
1742470|NCT00123526|Behavioral|Diet|Participants will also follow a healthy diet, characterized by higher intakes of fruits, vegetables, fish, poultry, legumes, and whole grains. Participants will consume less high fat foods and refined grains, and reduce their total caloric intake through smaller portion sizes.
1742471|NCT00123526|Behavioral|Physical Activity|The intervention will promote active living, in which physical activity is incorporated into each participants' daily routine.
1742472|NCT00123539|Drug|Estrogen Replacement Therapy|
1742473|NCT00123539|Procedure|Surgery|
1742474|NCT00123552|Drug|Amodiaquine+Artesunate|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; Artesunate 4 mg/kg/d for three days
1742548|NCT00124540|Drug|misoprostol|
1742549|NCT00124540|Drug|placebo|placebo resembling misoprosotl
1742475|NCT00123552|Drug|Amodiaquine+Sulfadoxine/Pyrimethamine|Amodiaquine 10 mg/kg on day 1, then 5 mg/kg on day 2 and 3; S/P at 25 mg/kg sulfadoxine and 1.25 mg/kg pyrimethamine single dose
1742476|NCT00123552|Drug|Artemether+Lumefantrine|Artemether 20 mg + Lumefantrine 120 mg 6 dose regimen at 0 and 8 hours on day 1 and twice daily on days 2 and 3:5 kg to < 15 kg: 1 tab/dose; 15 to 24 kg: 2 tabs/dose; >35 kg:4 tabs per dose
1742477|NCT00123565|Drug|Hexadecasaccharide (SR123781A)|
1742478|NCT00116857|Drug|Sertraline/omega-3|Sertraline (50 mgs) plus omega-3 (2 grams)
1742479|NCT00116857|Drug|Sertraline/Corn Oil|Sertraline (50 mgs) plus corn oil (2 grams) (placebo)
1742480|NCT00116870|Drug|lovastatin|
1742481|NCT00116883|Drug|GW685698X aqueous nasal spray|
1742482|NCT00123578|Drug|Lorazepam|Lorazepam
1742483|NCT00123578|Drug|Pentobarbital|Pentobarbital
1742484|NCT00123591|Drug|activated recombinant human factor VII|
1742485|NCT00123604|Drug|Carvedilol|25 mg twice daily for five months.
1742486|NCT00123604|Drug|Metoprolol|200 mg twice daily for five months.
1742487|NCT00123617|Procedure|Phase III group-based cardiac rehabilitation|Phase III group-based cardiac rehabilitation
1742488|NCT00123630|Drug|omalizumab|omalizumab dosed IV based on IgE level and weight every 2 - 4 weeks
1742489|NCT00123630|Drug|Placebo|Placebo given IV once every 2-4 weeks based on weight
1742490|NCT00123643|Drug|rosiglitazone|
1742491|NCT00123643|Drug|glyburide|
1742492|NCT00123656|Drug|esomeprazole|esomeprazole dosed qam for 8 weeks
1742493|NCT00123656|Drug|fluticasone|fluticasone dosed 220 mcg 2 puffs swallowed BID for 8 weeks
1742494|NCT00123669|Drug|500 mg of depot hydroxy-progesterone|An intramuscular injection of 500 mg of depot hydroxy-progesterone 5 to 15 days prior to surgery.
1742495|NCT00123682|Procedure|Proactive outreach to counseling|Project staff reach out to engage referred smoker into telephone counseling
1742496|NCT00123682|Procedure|Reactive outreach to counseling|Project staff send a letter to referred smoker, asking them to call to engage in telephone counseling
1742497|NCT00123682|Procedure|Intensive counseling|Multi-session telephone counseling, delivered by California Smokers' Helpline
1742498|NCT00123682|Procedure|Self-help|Project staff send out self-help materials for smoking cessation
1742499|NCT00123734|Drug|ThromboView|
1742500|NCT00123747|Procedure|Positron Emission Tomography (PET) scan Imaging|
1742501|NCT00123760|Procedure|Positron Emission Tomography (PET) scan|
1742502|NCT00123773|Procedure|Positron Emission Tomography|
1742503|NCT00123786|Procedure|Positron Emission Tomography|Positron Emission Tomography
1742504|NCT00123799|Procedure|Positron Emission Tomography Imaging|
1742505|NCT00123825|Drug|Gemcitabine|
1742506|NCT00123825|Drug|Cisplatin|
1742507|NCT00123838|Device|Calypso® 4D Localization System|Localization of prostate irradiation.
1742508|NCT00123851|Drug|Tarceva (OSI-774)|
1742509|NCT00123851|Drug|Capecitabine|
1742510|NCT00123851|Drug|Oxaliplatin|
1742511|NCT00123864|Procedure|Intensity-modulated radiation therapy|
1742512|NCT00123877|Drug|GPX-100 (13-deoxydoxorubicin)|
1742513|NCT00123890|Drug|GW873140|
1742517|NCT00123916|Drug|Benznidazole|Daily po Benznidazole or placebo (weight based) during 60 days,
1742518|NCT00123916|Drug|Placebo|a dose calculated as 5mg/kg/day for 60 days, now administered as a fixed daily dose of 300mg during 40 to 80 days of treatment - period adjusted according to the patient's body weight to a total minimum dose of 12g (corresponding to 40kg) and a total maximum dose of 24g (corresponding to 80kg)
1742519|NCT00124241|Drug|telbivudine|
1742520|NCT00124241|Drug|lamivudine|
1742521|NCT00124254|Procedure|Silicone metacarpophalangeal joint arthroplasty|Intervention involves reconstructing the metacarpophalangeal joint using the Swanson silastic implant.
1742522|NCT00124254|Other|Usual care|Non-surgical usual care
1742523|NCT00124267|Drug|Intrarectal quinine|
1742524|NCT00124280|Drug|RAD001|
1742525|NCT00124293|Drug|activated recombinant human factor VII|
1742526|NCT00124306|Drug|Amitriptyline|Amitriptyline will be titrated over a 6-week period as tolerated, to a maximum dose of 75mg. During the 6-week titration period, the patient who cannot tolerate a scheduled increased dose may adjust the medication dose for tolerance by tapering down one 25mg tablet.
1742527|NCT00124306|Other|Placebo|Placebo will be dosed exactly as active arm.
1742528|NCT00124332|Drug|Rimonabant (SR141716)|
1742529|NCT00124332|Drug|Placebo|
1742530|NCT00124345|Device|MR730|humidity measurement inside the helmet by a capacitative hygrometer and evaluation of patients' comfort
1742531|NCT00124358|Drug|Buprenorphine|
1742532|NCT00124358|Behavioral|Integrated HIV care and office-based opioid dependence treatment|
1742533|NCT00124371|Behavioral|a nurse led home-based education and support programme|
1742534|NCT00124384|Behavioral|CBT-I|
1742535|NCT00124384|Drug|modafinil|
1742536|NCT00124397|Drug|Atorvastatin|
1742537|NCT00124423|Procedure|Megavoltage CT scan|
1742538|NCT00124436|Drug|alitretinoin|
1742539|NCT00124449|Drug|Abatacept|"solution, intravenous injection, monthly, 169 days
weight based:
<60 kg = 500 mg
60 to 100 kg = 750 mg
>100 kg = 1 g"
1742540|NCT00124449|Drug|placebo|solution, intravenous injection, 0 mg, monthly, 169 days
1742541|NCT00124462|Device|Realigning knee brace and custom orthodic|A valgus brace, customized functional orthotic for neutral foot position and motion control footwear
1742542|NCT00124462|Device|Non realigning knee brace and flat orthodic|A neutral brace that does not have any varus/valgus angulation, control foot orthodic and shoes with flexible midsole
1742543|NCT00124475|Drug|alitretinoin|
1742544|NCT00124488|Device|Tomotherapy Treatment Planning|
1742545|NCT00124501|Behavioral|Biofeedback-assisted relaxation training|10 sessions BART
1742546|NCT00124514|Drug|Triptorelin pamoate|IM injection given monthly
1742547|NCT00124527|Drug|Irofulven + capecitabine|
1742551|NCT00124566|Drug|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.45 mg/kg on Days 1 and 8 every 3 weeks.
1742552|NCT00124566|Drug|Prednisone|Subjects will also receive oral prednisone at a dose of 10 mg per day in the morning.
1742553|NCT00124566|Drug|Mitoxantrone|Subjects will receive mitoxantrone in an intravenous (IV) infusion (5 to 15 minutes) at a dose of 12 mg/m^2 per day, once every 3 weeks.
1742554|NCT00124566|Drug|Capecitabine|Subjects will receive oral capecitabine at a dose of 1000 mg/m^2 twice daily for 15 days every 28 days.
1742555|NCT00124566|Drug|Irofulven|Subjects will receive irofulven in a 30 minute intravenous (IV) infusion at a dose of 0.4 mg/kg on Days 1 and 15 every 4 weeks.
1742556|NCT00124579|Drug|bortezomib|induction: 1 mg/m2 IV push days 1, 4, 8, 11 every 21 days
1742557|NCT00124579|Drug|dexamethasone|induction: 20 mg/d PO days 1, 2, 4, 5, 8, 9, 11, 12 every 21 days maintenance: 40 mg days 1-4 every 28 days until progression
1742558|NCT00124579|Drug|thalidomide|100 mg/d PO days 1-21 every 21 days
1742559|NCT00124605|Drug|pamidronate disodium|Given IV
1742560|NCT00124605|Drug|arsenic trioxide|Given IV
1742561|NCT00124605|Other|laboratory biomarker analysis|Correlative studies
1742562|NCT00124605|Other|pharmacological study|Correlative studies
1742563|NCT00124618|Biological|cetuximab|
1742564|NCT00124618|Radiation|radiation therapy|
1742565|NCT00124644|Drug|cytarabine|
1742566|NCT00124644|Drug|daunorubicin hydrochloride|
1742567|NCT00124644|Drug|etoposide|
1742568|NCT00124644|Drug|tipifarnib|
1742569|NCT00124644|Procedure|chemotherapy|
1742570|NCT00124644|Procedure|enzyme inhibitor therapy|
1742571|NCT00124644|Procedure|high-dose chemotherapy|
1742572|NCT00124657|Drug|Erlotinib hydrochloride|This study has 2 components: a Phase I component which estimated the MTD and DLT(s) of erlotinib given once a day during and after conventionally fractionated RT for a period of 8 weeks (DLT-evaluation period), followed by continuous administration of this medication for up to 3 years; and a Phase II component where erlotinib will be given at the MTD during and after RT for 2 years. The recommended dose of erlotinib for the Phase II component of the current study is 120mg/m2 per day (maximum dose of 200mg per day).
1742573|NCT00124683|Drug|Bupropion|
1742574|NCT00124683|Drug|nicotine transdermal patch|
1742575|NCT00124696|Drug|Cocaethylene|
1742576|NCT00124709|Drug|Pimecrolimus|Pimecrolimus cream 1 %
1742577|NCT00124709|Drug|Corticosteroid|conventional corticosteroid-based treatment
1742578|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.45 mg/kg prior to intubation.
1742579|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 0.6 mg/kg prior to intubation.
1742580|NCT00124722|Drug|Rocuronium bromide (Zemuron)|A single IV Zemuron bolus dose of 1.0 mg/kg prior to intubation.
1742581|NCT00124735|Drug|Rocuronium bolus maintenance|Subjects received a bolus dose of rocuronium for intubation followed by bolus doses for maintenance of muscle relaxation
1742582|NCT00124735|Drug|rocuronium continuous infusion maintenance|Subjects received a bolus dose of rocuronium for intubation followed by continuous infusion of rocuronium for maintenance of muscle relaxation
1742583|NCT00124748|Drug|Imatinib mesylate|Imatinib is packaged in bottles as 100mg and 400mg tablets
1742584|NCT00124761|Procedure|Surgery + WBRT|Surgery - complete excision of Solitary Brain Metastasis with 30 Gy in 10 fractions over 2 2 1/2 weeks
1742585|NCT00124761|Radiation|Radiosurgery + WBRT|Radiosurgery - Marginal dose based on maximum tumour diameter
1742586|NCT00124774|Procedure|Nucleoplasty|
1742587|NCT00124787|Drug|Dimenhydrinate|Dimenhydrinate PO q 6 hours x 4 doses
1742588|NCT00124787|Drug|Placebo|Placebo PO q 6 hours x 4 doses
1742589|NCT00124800|Behavioral|Tinnitus retraining therapy|Sound therapy and counseling
1742590|NCT00124800|Device|Sound therapy|sound therapy and counselling
1742591|NCT00124813|Drug|thalidomide|
1742592|NCT00124813|Drug|idarubicin|oral idarubicin
1742593|NCT00124826|Drug|Insulin|
1742594|NCT00124839|Drug|Naltrexone|Daily oral administration (capsules): 50mg naltrexone and placebo or 200mg naltrexone and placebo or placebo and naltrexon 50mg or placebo and 200mg naltrexone
1742595|NCT00124852|Behavioral|n-3 Fatty Acid Supplementation|
1742596|NCT00124865|Biological|rFla-MBP|
1742597|NCT00124878|Procedure|Male circumcision|Sleeve circumcision
1742598|NCT00124891|Drug|Double-blind investigational anti-arrhythmic|
1742599|NCT00124891|Drug|GAP-486|
1742600|NCT00124904|Behavioral|Biofeedback|
1742601|NCT00124904|Behavioral|Kegel exercises|
1742602|NCT00124917|Radiation|Radiation|Areas of pathologically confirmed malignancy will undergo dose escalation as described below. Areas of image abnormality that could not be biopsied or were without definite pathologic evidence of malignancy will be given intermediate doses. The remainder of the prostate gland will receive standard dose (as per the Radiation Therapy Oncology Group (RTOG) 9406 study) 7560 cGy in 180 cGy daily fractions.[1]
1742603|NCT00124930|Drug|Olanzapine|
1742604|NCT00124930|Drug|Haldol|
1742605|NCT00124943|Drug|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, administered via intracoronary catheter.
1742606|NCT00124956|Drug|Doxorubicin|
1742607|NCT00124969|Drug|Amlodipine|10mg
1742608|NCT00124969|Drug|Placebo|10mg
1742609|NCT00124982|Drug|Abatacept|IV solution, IV infusion, between 500mg and 1gram based on body weight, monthly, 6 months.
1742610|NCT00124982|Drug|Non-biologic Disease Modifying Anti-Rheumatic Drug (DMARD)|During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at the time of abatacept treatment onset (Day 1).
1742611|NCT00124982|Drug|Anti-Tumor Necrosing Factor (TNF) Therapy|Any of the anti-TNF therapies (Infliximab, Adalimumab, Etanercept, etc.)administered at the approved label dose for at least 3 months
1742612|NCT00124995|Drug|terbutaline|
1742613|NCT00125008|Biological|Typhoid Vi vaccine|single 0.5ml dose (25ug of purified Vi polysaccharide of S. typhi)
1742718|NCT00125918|Drug|placebo|placebo tablet taken by mouth once a day for 16 weeks
1742614|NCT00125008|Biological|Hepatitis A vaccine|720 EL.U. of inactivated hepatitis A viral antigen for children 1440 EL.U. of inactivated hepatitis A viral antigen for adults
1742615|NCT00125021|Drug|Capecitabine|Given twice a day for 14 days followed by 7 days of no capecitabine (1 cycle is 21 days).
1742616|NCT00125021|Drug|OSI-774|Given once daily
1742617|NCT00125034|Biological|Cetuximab|"Cetuximab will always be administered first, followed by oxaliplatin at least 1 hour later. Following completion of the oxaliplatin infusion or simultaneously with oxaliplatin folinic acid (FA) will be administered (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-Fluorouracil (5-FU) (as a bolus of 400 mg/m^2/day intravenously (IV) over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).
Until progression or unacceptable toxicity develops"
1742618|NCT00125034|Drug|Oxaliplatin|"Oxaliplatin will always be administered first or simultaneously with FA (at a dose of 200 mg/m^2, infused over 120 minutes, on day 1 and day 2, every two weeks) and then 5-FU (as a bolus of 400 mg/m^2/day IV over 2-4 minutes followed by 600 mg/m^2/day infused over 22-hour, on day 1 and day 2, every two weeks).
Until progression or unacceptable toxicity develops"
1742619|NCT00125047|Biological|Typhoid Vi vaccine|Single 0.5ml dose containing 25ug purified Vi polysaccharide of S. typhi.
1742620|NCT00125047|Biological|Hepatitis A vaccine|single 0.5ml dose contains 720 EL.U. of inactivated hepatitis A viral antigen
1742621|NCT00125060|Drug|Simvastatin (20mg versus 80mg/day)|
1742622|NCT00125073|Behavioral|Postoperative nutritional counseling|
1742623|NCT00125086|Device|autologous platelet gel|
1742624|NCT00125099|Biological|VRC-HIVDNA009-00-VP|
1742625|NCT00125112|Behavioral|Internet-based intervention designed to reduce binge eating and improve healthy weight regulation|
1742626|NCT00125125|Drug|Fluvastatin|
1742627|NCT00125138|Drug|Melperone HCl|20 mg/day. Strength of melperone syrup is 5 mg/mL
1742628|NCT00125138|Drug|Melperone HCl|40 mg/day. Strength of melperone syrup is 5 mg/mL
1742629|NCT00125138|Drug|Melperone HCl|60 mg/day. Strength of melperone syrup is 5 mg/mL
1742630|NCT00125138|Drug|Placebo|Syrup formulation
1742631|NCT00125151|Drug|C1 inhibitor concentrate (C1-esteraseremmer-N)|
1742632|NCT00125164|Drug|rhIGF-1 (mecasermin, Tercica, Inc.)|Twice Daily Injection
1742633|NCT00125177|Behavioral|Knack therapy|
1742634|NCT00125190|Drug|rhIGF-1 (mecasermin) for a period of 86 weeks|once a day rhIGF-1 injections
1742635|NCT00125203|Drug|Botulinum toxin type B (Myobloc)|
1742636|NCT00125203|Procedure|Injection of salivary glands|
1742637|NCT00125216|Behavioral|Response Elaboration Training|Therapist modeling, reinforcement and forward-chaining are used to stimulate verbal descriptions of pictures
1742638|NCT00125229|Drug|Mannitol|
1742639|NCT00125229|Drug|Hypertonic Saline|
1742640|NCT00125242|Behavioral|Semantic Feature Analysis (SFA)Training|SFA entails having the speech-language pathologist (SLP) guide the participant through generation of pertinent semantic features for pictured treatment items (e.g., category membership, physical description, location of item in context, personal associations, action associated with item). For some participants, treatment items were grouped according to typicality of category membership (e.g,, a robin-typical bird and penguin-atypical bird). Training of atypical items may stimulate a broader semantic activation of the category and thus, may promote greater generalization. Treatment was applied sequentially to sets of items in the context of single-subject, multiple baseline designs. In this way, replication of treatment effects could be evaluated within and across participants. Treatment was administered by certified SLPs three times per week until prescribed accuracy levels were met during nontreatment probes or a maximum number of treatment sessions was completed.
1742641|NCT00125255|Drug|S-Caine™ Peel (lidocaine and tetracaine cream 7%/7%)|S-Caine Peel comprising of a 1:1 eutectic mixture of 7% lidocaine and 7% tetracaine was applied topically. The study drug was applied at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
1742642|NCT00125255|Drug|Placebo Peel|Placebo Peel applied topically at approximately 1 mm in thickness and remained on the treatment area for 30 minutes
1742643|NCT00125268|Device|MIRE|Monochromatic near infrared photo energy (MIRE). A 30-minute application of MIRE results in a radiant exposure of 43.2 joules per square centimeter (J/cm^2). The design of the flexible pads allows the infrared energy to be delivered perpendicular to and in contact with the involved site. MIRE applied to the skin facilitates the release of a small molecule of the free radical nitric oxide from hemoglobin and other proteins in surrounding tissue. Increased levels of nitric oxide improve the circulation of blood enhancing wound healing and reducing pain.
1742644|NCT00125268|Device|Sham Device|The sham device is non-active but otherwise identical to the study device.
1742645|NCT00125281|Drug|S-adenosyl-methionine (SAMe) capsules|
1742646|NCT00125294|Drug|Methadone|
1742647|NCT00125307|Drug|tacrolimus|
1742648|NCT00125320|Drug|RSD1235|
1742649|NCT00125333|Drug|NF-kappaB Decoy|
1742650|NCT00125346|Drug|Tobramycin Inhalation Powder|
1742651|NCT00125359|Drug|erlotinib and bexarotene|Daily Erlotinib 150mg and daily bexarotene oral capsules 400mg.
1742652|NCT00125372|Drug|erlotinib (Tarceva) and bexarotene (Targretin)|Erlotinib 150 mg and bexarotene 400 mg/m2/day will be administered orally for 7 to 9 days prior to thoracotomy
1742653|NCT00125385|Biological|GC1008|0.3 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
1742654|NCT00125385|Biological|GC1008|1.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
1742655|NCT00125385|Biological|GC1008|2.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
1742656|NCT00125385|Biological|GC1008|4.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
1742657|NCT00125385|Biological|GC1008|8.0 mg/kg, IV on Day 0 and return to the clinic on 3,7, 10, 14, 21, 28, 42, 56, 84, 112, 140 post infusion for safety follow-up.
1742658|NCT00125398|Drug|AQUAVAN (fospropofol disodium; GPI 15715 )|
1742716|NCT00125918|Drug|tadalafil|tadalafil 20 mg and placebo tablets taken by mouth once a day for 16 weeks.
1742717|NCT00125918|Drug|tadalafil|tadalafil 40 mg and placebo tablets taken by mouth once a day for 16 weeks.
1742659|NCT00125411|Drug|satraplatin and docetaxel|"Satraplatin - oral administration within 2 hours of docetaxel infusion. Subsequent dosing will be on days 2-5 at approximate 24 hour intervals.
Docetaxel will be administered as intravenous infusion over 1 hour followed by saline flush."
1742660|NCT00125424|Drug|AQUAVAN® (fospropofol disodium) Injection|
1742661|NCT00125424|Drug|Midazolam HCl|
1742662|NCT00125437|Drug|spironolactone|
1742663|NCT00125450|Procedure|Chest Physiotherapy with Forced Expiratory Technique|Chest Physiotherapy with Forced Expiratory Technique
1742664|NCT00125450|Procedure|Nasopharyngeal Aspiration|Nasopharyngeal Aspiration
1742665|NCT00125463|Drug|Candesartan cilexetil|
1742666|NCT00125476|Behavioral|Exercise|
1742667|NCT00125489|Drug|chloroquine sulfate|
1742668|NCT00125489|Drug|sulfadoxine/pyrimethamine|
1742669|NCT00125502|Biological|CMV gB vaccine|CMV gB is combined with a novel adjuvant, MF59, a proprietary oil-in-water emulsion, administered at 0, 1, and 6 months.
1742670|NCT00125502|Drug|MF59 adjuvant|Oil-in-water emulsion
1742671|NCT00125502|Drug|Placebo|Normal saline solution
1742672|NCT00125515|Drug|Memantine|One arm receives 30 mg bid and the other arm receives receives 15mg bid
1742673|NCT00125515|Drug|Naltrexone|Patients received the equivalent of 50 mg/day. Dispensed as 100 mg on Mondays and Wednesdays and 150 mg on Fridays.
1742674|NCT00125528|Drug|D-cycloserine|D-cycloserine 50 mg bid; D-cycloserine 100 mg bid; D-cycloserine 200 mg bid
1742675|NCT00125528|Drug|placebo|placebo bid
1742676|NCT00125541|Drug|C1 inhibitor concentrate (C1-esteraseremmer-N)|every 5-7 days
1742677|NCT00125554|Drug|Metyrapone|
1742678|NCT00125567|Drug|Stalevo (levodopa/carbidopa/entacapone)|Oral, 50-150 mg levodopa four times daily, for up to 2 years
1742679|NCT00125567|Drug|Levodopa/carbidopa|Oral capsules, 50-150 mg levodopa four times daily, for up to 2 years
1742680|NCT00125580|Behavioral|Infant sleep instruction|
1742681|NCT00125593|Drug|Simvastatin 20 mg|Once daily
1742682|NCT00125593|Drug|Ezetimibe 10mg|Once daily
1742683|NCT00125593|Drug|Placebo|Once daily
1742684|NCT00125606|Procedure|conditioning for allogeneic HSCT|
1742685|NCT00125619|Behavioral|Locomotor training|This study compares two forms of Iocomotor training: 1) standard or manual - in which an individual is provided partial body weight support while walking on a treadmill with assistance of 1-3 therapists to move the legs and stabilize the trunk/pelvis and 2) robotic-guided - in which an exoskeleton robot (Lokomat) guides movement of the walking pattern. Partial body-weight support, treadmill walking and treadmill speed are consistent between the study arms.
1742686|NCT00125632|Procedure|Eccentric Viewing Training for Reading|
1742687|NCT00125645|Drug|irbesartan|
1742688|NCT00125658|Other|Control|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Functional Task Practice (FTP) followed by 10 weeks of Power training (dynamic resistance exercise). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
1742689|NCT00125658|Other|Experimental|Following an initial testing session, you will complete a 5 week no training period. At the end of this period you will then participate in a 20 week therapy program - 10 weeks of Power training (dynamic resistance exercise) followed by 10 weeks of Functional Task Practice (FTP). Each 10 week block has 30 therapy sessions for a total of 60 sessions, each lasting approximately 1-1/2 hours. Follow up evaluations will be scheduled at 6 months and 12 months after completion of the entire 20 week therapy program.
1742690|NCT00125671|Drug|Warfarin|
1742691|NCT00125684|Drug|morphine|
1742692|NCT00125697|Procedure|3T MRI Scanning|pre-radiation therapy, week 4 radiation therapy, 2 months post radiation therapy and every 4 months for the first year
1742693|NCT00125723|Other|PI Discretion|PI Discretion
1742694|NCT00125736|Drug|Teprenone|
1742695|NCT00125749|Biological|Dendritic cell vaccination|Autologous Dendritic Cells Derived from PBMC, Cultured with Cytokines, Pulsed Ex Vivo with Irradiated Allogeneic (Colo 829) Melanoma Cells
1742697|NCT00125775|Biological|Engerix-B|Engerix-B at 0, 1, 6 months
1742698|NCT00125788|Drug|L-glutamine|Approximately 0.3 g/kg total daily dose of L-glutamine will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
1742699|NCT00125788|Drug|Placebo|Approximately 0.3 g/kg total daily dose of maltodextrin placebo will be orally administered (over two doses), with a maximum total daily dose of 30 grams.
1742700|NCT00125801|Drug|Subcutaneous hydromorphone delivered by pain pen|Subcutaneous hydromorphone delivered by pain pen during breakthrough pain episodes, at max 4 daily. Dose established by opioid conversion from baseline opioids.
1742701|NCT00125814|Drug|Interferon alfa-2b|
1742702|NCT00125814|Procedure|Structured treatment interruptions|
1742703|NCT00125827|Drug|clofarabine (oral formulation)|Cohorts of 3 patients each were to receive oral clofarabine administered daily for 5 days followed by 23 days of rest (1 cycle) and repeated every 28 days depending on toxicity and response. The starting dose of clofarabine was to be 1 mg/m2/day with subsequent dose escalation to occur in increments of 50% for the first 5 dose levels (1.5, 2.25, 3.5, and 5.0 mg/m2/day) and in increments of 25% thereafter until the MTD/RP2D was determined.
1742704|NCT00125840|Drug|clofarabine (IV formulation)|
1742705|NCT00125853|Drug|Nebivolol|Nebivolol 25mg daily
1742706|NCT00125853|Drug|Atenolol|Atenolol 25mg daily
1742707|NCT00125866|Behavioral|Flavonoid rich or flavonoid depleted chocolate drink|
1742708|NCT00125879|Biological|Myozyme|20 mg/kg qow or 40 mg/kg qow
1742709|NCT00125892|Drug|duloxetine|
1742710|NCT00125905|Behavioral|Advice|
1742711|NCT00125905|Behavioral|Motivational Interviewing|
1742712|NCT00125905|Drug|Nicotine Gum and Patch|
1742713|NCT00125905|Drug|Bupropion|
1742714|NCT00125918|Drug|tadalafil|tadalafil 2.5 mg and placebo tablets taken by mouth once a day for 16 weeks.
1742715|NCT00125918|Drug|tadalafil|tadalafil 10 mg and placebo tablets taken by mouth once a day for 16 weeks.
1743127|NCT00127959|Drug|tenofovir|
1742719|NCT00125931|Drug|Talwin Nx|Talwin NX 50mg po twice
1742720|NCT00125944|Biological|FluMist|
1742721|NCT00125957|Drug|Wellbutrin|
1742722|NCT00125957|Drug|Placebo|
1742723|NCT00125970|Biological|VRC-HIVDNA016-00-VP|4 mg administered in deltoid
1742724|NCT00125970|Biological|VRC-HIVADV014-00-VP|1 x 10^10 PU administered in deltoid
1742725|NCT00125970|Biological|VRC-HIVDNA016-00-VP placebo|1 mL administered at study entry and Months 1 and 2
1742726|NCT00125970|Biological|VRC-HIVADV014-00-VP placebo|1 mL administered at Month 6
1742727|NCT00125983|Drug|Lopinavir/ritonavir|
1742728|NCT00125983|Drug|Ortho Novum 1/35|
1742729|NCT00125983|Drug|Ortho Evra|
1742730|NCT00125996|Drug|Venofer (intravenous iron sucrose)|
1742731|NCT00126009|Drug|Amisulpride|
1742732|NCT00126022|Drug|Tedisamil sesquifumarate|
1742733|NCT00126035|Device|Migraid|
1742734|NCT00126048|Drug|Atorvastatin|40mg tablet
1742735|NCT00126048|Drug|Placebo|Placebo tablet
1742736|NCT00126061|Drug|Tedisamil sesquifumarate|
1742737|NCT00126074|Drug|Tedisamil sesquifumarate|
1742738|NCT00126087|Drug|dopamine|
1742739|NCT00126100|Drug|G-CSF Granulocyte-Colony Stimulating Factor|Patients were randomly assigned to receive subcutaneously a daily dose of 10 microg/kg of G-CSF for 5 days.
1742740|NCT00126100|Other|Placebo|Patients were randomly assigned to receive subcutaneously either a daily dose of 10 microg/kg of G-CSF or placebo for 5 days.
1742741|NCT00126113|Behavioral|PPT-based Counseling|Counseling based on Performance-Perceptual Discrepancy (PPDIS) consisting of explanation of hearing tests plus recommendations based on PPDIS
1742742|NCT00126113|Behavioral|Standard Educational Counseling|Standard educational counseling consisting of explanation of hearing tests
1742743|NCT00126126|Other|EBAR Program|Evidence Based Amputee Rehabilitation Program
1742744|NCT00126139|Drug|Abciximab|
1742745|NCT00126152|Behavioral|Exercise, education and medical management|
1742746|NCT00126165|Procedure|radiotherapy|
1742747|NCT00126178|Biological|HSPPC-96|
1742748|NCT00126191|Drug|Rituximab|Low Risk: Intravenously on Day 3 of the first cycle (One cycle is 14 days) then day 1 for next 2 cycles (Regimen A) High Risk: Regimen A followed by a 5-day cycle where rituximan is given on day 1
1742749|NCT00126191|Drug|Cyclophosphamide|Low Risk/High Risk: Intravenously on day 1 and day 2 of a 14-day cycle for 3 cycles (regimen A)
1742750|NCT00126191|Drug|Doxorubicin|Low Risk/High Risk: Given on day 1 of a 14-day cycle for 3 cycles (regimen A)
1742751|NCT00126191|Drug|Vincristine|Low Risk/High Risk: Given intravenously on day 1 and day 10 of a 14-day cycle for 3 cycles (regimen A)
1742752|NCT00126191|Drug|Methotrexate|Low Risk: Given on day 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: Regimen A followed by methotrexate on day 3 and day 5 of a 5-day cycle
1742753|NCT00126191|Drug|Leucovorin|Low Risk/High Risk: Given on days 11, 12 and 13 of a 14-day cycle for 3 cycles (regimen A)
1742754|NCT00126191|Drug|Ifosfamide|High Risk: After Regimen A, Ifosomide given on days 1-5 of a 5 day cycle
1742755|NCT00126191|Drug|Etoposide|High Risk: After Regimen A, etoposide given days 1-5 of a 5-day cycle
1742756|NCT00126191|Drug|Cytarabine|Low Risk: Given on days 1, 3, 5 and 10 of a 14-day cycle for 3 cycles (regimen A) High Risk: After regimen A, cytarabine given on days 1 and 2 of a 5-day cycle
1742757|NCT00126191|Drug|Mesna|High Risk: After regimen A, mesna is given on days 1-5 of a 5-day cycle
1742758|NCT00126204|Drug|Doxycycline|
1742759|NCT00126217|Biological|Bacille Calmette Guerin (BCG)|0,1 ml, revaccination at 19 months of age
1742760|NCT00126230|Drug|docetaxel and samarium|
1742761|NCT00126243|Drug|rituximab|
1742762|NCT00126243|Drug|CHOP|
1742763|NCT00126256|Drug|5-fluorouracil|
1742764|NCT00126256|Drug|leucovorin|
1742765|NCT00126256|Drug|irinotecan|
1742766|NCT00126256|Drug|oxaliplatin|
1742767|NCT00126269|Drug|cisplatin|
1742768|NCT00126269|Drug|gemcitabine|
1742769|NCT00126282|Behavioral|behavior therapy|
1742770|NCT00126282|Drug|D-Cycloserine|
1742771|NCT00126295|Device|'What you need to know about stroke' education package|
1742772|NCT00126308|Device|poly-L-lactic acid|immediate injections poly-L-lactic acid (4 bilateral treatments - 8 vials)
1742773|NCT00126308|Device|poly-L-lactic acid|delayed (24 weeks) poly-L-lactic acid injections (4 bilateral treatment - 8 vials)
1742774|NCT00126321|Drug|cladribine|2-chlorodeoxyadenosine, 2-CdA
1742775|NCT00126334|Procedure|Packed Red Blood Cell Transfusion|transfusion of 1 unit of PRBCs
1742776|NCT00126347|Procedure|supplementation with betaine, serine, and folic acid|
1742777|NCT00126360|Drug|Timing of Anastrozole in respect to radiotherapy|
1742778|NCT00126373|Drug|Wellbutrin (bupropion)|bupropion 150mg-300mg daily
1742779|NCT00126386|Drug|Zoledronic acid (Zometa)|
1742780|NCT00126399|Drug|doxycycline|
1742781|NCT00126412|Drug|123I-mIBG (meta-iodobenzylguanidine)|
1742782|NCT00126425|Drug|123I-mIBG (meta-iodobenzylguanidine)|Single dose
1742783|NCT00126438|Drug|123I-mIBG (meta-iodobenzylguanidine)|Single Dose
1742784|NCT00126451|Drug|MK0683, vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|
1742785|NCT00126451|Drug|Duration of Treatment - During each treatment cycle, treatment is administered twice daily for 14 days, followed by 7 days of rest for a total of 10 cycles|
1742786|NCT00126464|Drug|fulvestrant|
1742787|NCT00126464|Drug|tamoxifen citrate|
1742788|NCT00126464|Procedure|conventional surgery|
1742789|NCT00126464|Procedure|neoadjuvant therapy|
1742790|NCT00126477|Procedure|cognitive assessment|
1742791|NCT00126477|Procedure|management of therapy complications|
1742792|NCT00126477|Procedure|psychosocial assessment and care|
1742793|NCT00126477|Procedure|quality-of-life assessment|
1742794|NCT00126490|Biological|Aldesleukin|Given subcutaneously
1742795|NCT00126490|Biological|Bevacizumab|Given IV
1742796|NCT00126490|Other|Laboratory Biomarker Analysis|Correlative studies
1742797|NCT00126503|Biological|Bevacizumab|Given IV
1742798|NCT00126503|Drug|Sorafenib Tosylate|Given PO
1742799|NCT00126503|Other|Pharmacological Study|Correlative studies
1742800|NCT00126503|Other|Laboratory Biomarker Analysis|Correlative studies
1742801|NCT00126516|Drug|Angiotensin II Receptor Antagonists|any dosage, frequency, and duration
1742802|NCT00126516|Drug|Angiotensin-converting Enzyme Inhibitors|any dosage, frequency, and duration
1742803|NCT00126542|Biological|bevacizumab|Given IV
1742804|NCT00126542|Drug|erlotinib hydrochloride|Given orally
1742805|NCT00126542|Other|laboratory biomarker analysis|Correlative studies
1742806|NCT00126555|Drug|Gefitinib|Oral Gefitinib induction therapy given daily for 2 months at 250 mg/day, once a day for 30 days (1 cycle = 30 days) with at least 2 cycles of treatment (60 days) given. After 2 months evaluate for clinical response (15 days) and resectability (60 days). If after 15 days with no tumor response, daily dose doubled (500 mg), and discontinuation if tumor progression.
1742807|NCT00126555|Radiation|Radiotherapy|Undergo radiation therapy treatments once a day Monday through Friday for about 7 weeks. Each treatment takes about 15 minutes.
1742808|NCT00126555|Procedure|Conventional surgery|Undergo surgery
1742809|NCT00126555|Other|laboratory biomarker analysis|Correlative studies
1742810|NCT00126568|Drug|sorafenib tosylate|Given orally
1742815|NCT00126594|Drug|Sorafenib Tosylate|Given orally 400 mg orally (PO) every 12 hours
1742816|NCT00126594|Biological|Recombinant Interferon Alfa-2b|Given subcutaneously (SC) 0.5 million with +/- 5 % variance (0.475 MU - 0.525 MU); Dose level 0: 0.5 X 10^6 international units twice daily
1742817|NCT00126594|Other|Laboratory Biomarker Analysis|Correlative studies
1742818|NCT00126607|Biological|trastuzumab|Given IV
1742819|NCT00126607|Other|laboratory biomarker analysis|Correlative studies
1742820|NCT00126620|Drug|erlotinib hydrochloride|
1742821|NCT00126620|Drug|sorafenib tosylate|
1742822|NCT00126633|Biological|bevacizumab|
1742823|NCT00126633|Drug|cisplatin|
1742824|NCT00126633|Drug|gemcitabine hydrochloride|
1742825|NCT00126646|Drug|BL22 immunotoxin|
1742826|NCT00126646|Procedure|antibody-drug conjugate therapy|
1742827|NCT00126646|Procedure|immunotoxin therapy|
1742828|NCT00126659|Procedure|therapeutic conventional surgery|Undergo cytoreductive nephrectomy
1742829|NCT00126659|Drug|sorafenib tosylate|Given orally
1742830|NCT00126659|Other|laboratory biomarker analysis|Correlative studies
1742831|NCT00126672|Drug|sirolimus|
1742832|NCT00126685|Biological|autologous tumor cell vaccine|
1742833|NCT00126685|Biological|therapeutic autologous dendritic cells|
1742834|NCT00126698|Drug|trimethoprim-sulfamethoxazole|
1742835|NCT00126698|Drug|ciprofloxacin|
1742836|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^11 DRP/mL
1742837|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^11 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
1742838|NCT00126724|Genetic|tgAAC94 placebo|placebo
1742839|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^12 DRP/mL tgAAC94
1742840|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^12 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
1742841|NCT00126724|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^13 DRP/mL tgAAC94
1742842|NCT00126724|Genetic|tgAAC94 gene therapy vector|Second dose of 1x10^13 DRP/mL tgAAC94 administered once target joint reaches predetermined criteria for re-injection (on or after Week 12) at the same concentration as initial dose.
1742843|NCT00126737|Other|Weight Control Nutritional Program|a week of food diary and information about dietary fat intake and proper proportions of vegetables.
1742844|NCT00126737|Other|Home-based exercise program|24 week home-based exercise program encompassed aerobic exercises, isometric and isotonic exercises, and stretching exercises.
1742845|NCT00126750|Behavioral|VA MI Plus Interactive|The experimental intervention, customized to the individual clinician in real-time consists of Internet learning modules integrating case-based education with audit, feedback, and benchmarking of practice profiles.
1742846|NCT00126763|Drug|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and was available in 25, 50,75 and 100 mcg/hr patches. For patients who were using transdermal fentanyl (ie,Duragesic®), the initial dose of ZR-02-01 was the same as their current Duragesic dose. For patients who were taking oral opioids, the initial dose of ZR-02-01 was determined by the investigator using sponsor-provided conversion guidelines. The patches were worn on the chest or upper arm and an overlay was placed over the patch. Patches (and overlays) were replaced every 3 days
1742847|NCT00119821|Behavioral|Weight Reducing Diet|Behavioral intervention
1742848|NCT00119821|Behavioral|Exercise|Moderate exercise implemented plus behavioral intervention.
1742849|NCT00119821|Behavioral|Smoking Cessation|"Nicotine Patch in dosages given based on number of cigarettes per day smoked. 21 mg patch, 14 mg patch, 7 mg patch for total of 6 weeks duration of therapy.
NRT gum is being provided to assist with relapse prevention. At the randomization visit the participant is given one (1) box of 2mg NRT gum, which consists of (110) pieces. The participant may request up to two (2) more boxes, for a maximum of three (3) boxes per participant."
1742850|NCT00119834|Device|Mechanical Circulatory Support Device (MCSD)|INTERMACS is an observational registry of adult and pediatric patients with end stage heart failure that receive a legally utilized Mechanical Circulatory Support Device.
1742851|NCT00119847|Drug|Beta Adrenergic Blockers|
1742852|NCT00119847|Drug|Platelet Inhibitors|
1742853|NCT00119847|Drug|ACE Inhibitors|
1742854|NCT00119847|Procedure|PTCA and/or Stents|
1742855|NCT00119873|Biological|VRC-HIVADV014-00-VP|
1742856|NCT00119886|Drug|Botulinum toxin|
1742857|NCT00119899|Procedure|FDG-PET scan|
1743128|NCT00127959|Drug|emtricitabine|
1742858|NCT00119912|Procedure|A 1 Intervention arm Flex Sig|Screening by flexible sigmoidoscopy
1742859|NCT00119912|Procedure|A 2 Intervention arm Flex Sig + iFOBT|In addition to Flexible Sigmoidoscopy, half of arm A (randomised 1:1) is invited to provide stool samples for FOBT
1742860|NCT00119925|Behavioral|patient education|patient leaflets about national guideline contents
1742861|NCT00119925|Behavioral|professional audit and feedback (guideline adherence)|feedback on current practice according to quality indicators
1742862|NCT00119925|Behavioral|professional education (communication/shared decision making)|educational tools for professionals concerning communication and shared decision making
1742863|NCT00119925|Other|information tools|tools and checklists to improve information provision
1742864|NCT00119938|Behavioral|Access to online patient portal|
1742865|NCT00119951|Behavioral|Participation on the ACOR Listserv|
1742866|NCT00119964|Behavioral|internet based weight management tools|
1742867|NCT00119977|Procedure|1 Periacetabular osteotomy|pelvic osteotomy to increase acetabular coverage
1742868|NCT00119990|Drug|Icodextrin (dialysate)|2 liter of extraneal are given with one fill for 4 hours.
1742869|NCT00119990|Drug|Physioneal (dialysate) 1.36% and 2.27%|2 liter of Physioneal of 1.36% or 3.86% are given with one fill for 4 hours one two different days.
1742870|NCT00120003|Drug|Candesartan Cilexetil|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
1742871|NCT00120003|Drug|Placebo|4 mg on day 1; 8 mg on day 2; 16 mg on days 3-7
1742872|NCT00120016|Behavioral|dietary counseling|telephone counseling
1742873|NCT00120029|Behavioral|weight loss counseling|
1742874|NCT00120042|Drug|Misoprostol|600 mcg misoprostol swallowed after delivery of fetus
1742875|NCT00120042|Drug|Oxytocin|10 units oxytocin administered intramuscularly after delivery fetus
1742876|NCT00120055|Drug|Atorvastatin (Lipitor)|
1742877|NCT00120068|Behavioral|Nursing inservices|
1742878|NCT00120068|Procedure|Academic detailing to MDs; concurrent review and feedback|
1742879|NCT00120081|Biological|Na-ASP-2/Alhydrogel Hookworm Vaccine|The recombinant hookworm protein Na-ASP-2 formulated on aluminum hydroxide adjuvant (Alhydrogel), in one of three dose concentrations, compared to a saline placebo control.
1742880|NCT00120081|Biological|Saline placebo|Inactive saline placebo control
1742881|NCT00120107|Drug|Black Tea|
1742882|NCT00120120|Drug|Lenalidomide (CC-5013)|Lenalidomide 2-5 mg capsules taken one time per day
1742883|NCT00120133|Drug|Atorvastatin|
1742884|NCT00120172|Drug|oxaliplatin, capecitabine, bevacizumab|
1742885|NCT00120185|Drug|Interleukin-2|
1742886|NCT00120198|Drug|CDOP plus rituximab|
1742887|NCT00120211|Radiation|Accelerated Radiotherapy Fractionation|Radiation Therapy 6 fractions per week
1742888|NCT00120211|Radiation|Accelerated Radiotherapy Fractionation|Radiotherapy 5 fractions per week
1742889|NCT00120237|Drug|Misoprostol|600 mcg oral misoprostol administered during third stage of labor
1742890|NCT00120250|Drug|Eszopiclone|The total study duration is 8 weeks, with subjects receiving 3mg eszopiclone or placebo nightly for 3 weeks, followed by a 1 week washout period, followed by 3 weeks of the alternate condition, followed by another 1 week washout.
1742891|NCT00120263|Procedure|Plasma Exchange|
1742892|NCT00120276|Device|Less invasive mitral valve repair|
1742893|NCT00120289|Drug|Extended release niacin|2,000 mg/day or 1,500 mg/day if higher dose not tolerated
1742894|NCT00120289|Drug|Simvastatin|Dose adjusted to achieve LDL-C 40 mg/dL - 80 mg/dL, adding ezetimibe (10 mg/day) if needed to achieve LDL-C target
1742895|NCT00120302|Drug|Pimecrolimus|Pimecrolimus cream 1 %
1742896|NCT00120302|Drug|Placebo|Matching vehicle cream
1742897|NCT00120315|Drug|esomeprazole|esomeprazole, original Nexium, 40 mg pills Up to once a day
1742898|NCT00120315|Procedure|Helicobacter pylori c-13 breath test|Breath test done at entry to find Helicobacter pylori
1742899|NCT00120328|Drug|SPP301|
1742900|NCT00120341|Device|Anodyne Therapy System|
1742901|NCT00120354|Procedure|Blood Testing|
1742902|NCT00120354|Procedure|Percutaneous Liver Biopsy|
1742903|NCT00120354|Procedure|Lamivudine Therapy|
1742904|NCT00120367|Drug|Enfuvirtide|
1742905|NCT00120367|Drug|Tenofovir-Emtricitabine|
1742906|NCT00120380|Drug|Aerosolized iloprost|
1742907|NCT00120380|Drug|Placebo|
1742908|NCT00120393|Drug|atazanavir/ritonavir +2 NRTIs (immediate Switch Group)|Capsules, Oral, ATV 300mg/RTV 100mg + 2 NRTIs, QD, 48 weeks.
1742909|NCT00120393|Drug|LPV/r +2 NRTIs (Delayed/optional Switch Group)|Capsules, Oral, LPV 400mg/RTV 100mg +2 NRTIs, BID, 24 weeks then option to switch to ATV arm or stay until 48 weeks.
1742910|NCT00120406|Device|Zilver® PTX™ Drug Eluting Vascular Stent|Stenting of the Superfemoropopliteal Artery
1742911|NCT00120406|Procedure|Angioplasty|Angioplasty of the Superfemoropopliteal Artery
1742912|NCT00120419|Drug|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
1742913|NCT00120432|Drug|1% tropicamide and 10% phenylephrine|single dose vs three doses of 1%tropicamide and 10%phenylephrine
1742914|NCT00120445|Procedure|air|0.3 ml of filtered air
1742915|NCT00120445|Procedure|expansile gas|0.3 ml of perfluoropropane gas
1742916|NCT00120458|Dietary Supplement|Black cohosh|"32 to 128 mg (black cohosh)
1 to 4 capsules daily (placebo)"
1742917|NCT00120471|Drug|Tenofovir disoproxil fumarate|600-mg tablet taken orally once daily
1742918|NCT00120471|Drug|Tenofovir disoproxil fumarate|4-mg/kg oral suspension taken at birth and on Days 3 and 5 after birth
1742919|NCT00120471|Drug|Tenofovir disoproxil fumarate|6-mg/kg oral suspension taken at birth and daily for 7 days after birth
1742920|NCT00120484|Drug|Vitamin B12|
1742921|NCT00120497|Drug|somatropin (rDNA)|"Dosage form/strength: 13.8 mg powder in 2-chamber cartridge; reconstitutes to 10 mg/ml
Dosage regimen: 0.48 mg/kg/week
Route/rate of administration: subcutaneous injection, daily dose"
1742922|NCT00120510|Drug|Efavirenz|Non-nucleoside reverse transcriptase inhibitor dosed at 600mg taken by mouth every 24 hours at bedtime
1742923|NCT00120510|Drug|Lamivudine/Zidovudine|Nucleoside reverse transcriptase inhibitor dosed at 150mg/300mg fixed dose combination taken by mouth every 12 hours
1742924|NCT00120523|Drug|Pimecrolimus|Pimecrolimus cream 1 %
1742925|NCT00120523|Drug|Topical corticosteroids|TCS
1742926|NCT00120536|Drug|vildagliptin|
1742927|NCT00120549|Procedure|Assisted embryo hatching|
1742928|NCT00120562|Procedure|Gastric Bypass Surgery|
1742929|NCT00120575|Procedure|hemofiltration|
1742930|NCT00120588|Drug|magnesium|
1742931|NCT00120601|Drug|Naltrexone|
1742932|NCT00120601|Drug|Acamprosate|
1742933|NCT00120614|Behavioral|Premature infant behavior and development information|
1742934|NCT00120614|Behavioral|Parental activities to support premature infant information|
1742935|NCT00120627|Behavioral|Mantram Repetition Program (MRP) plus Usual Care|"The MRP teaches 3 strategies to train attention and manage symptoms: Mantram Repetition, Slowing Down and One-Pointed Attention. A mantram is a self-selected, sacred word or phrase that is meaningful to the participant. Slowing down refers to setting priorities and doing things carefully so one is not rushed or does not make mistakes. One-pointed attention refers to concentrating on one thing at a time (similar to mindfulness). These three tools are presented to work together synergistically and cumulatively to interrupt negative thoughts and emotional states such as anger, rage, irritability and hyper-arousal. The unique focus on spiritual words is linked to what one might call inner spiritual resources. MRP was delivered in a 6-week (90 minutes/week) group setting."
1742936|NCT00120627|Other|Usual care consisting of medication and case management|Usual care consisted of case management or meeting with Veterans at least once per month and monitoring medications, if prescribed.
1742937|NCT00120640|Drug|17 hydroxyprogesterone caproate intramuscular injections|
1742938|NCT00120653|Drug|Metoclopramide|
1742939|NCT00120679|Drug|darbepoetin alfa|
1742940|NCT00120679|Drug|recombinant human erythropoietin (rHuEPO)|
1742941|NCT00120692|Drug|Darbepoetin Alfa|
1742942|NCT00120692|Drug|Recombinant Human Erythropoietin|
1742943|NCT00120705|Drug|darbepoetin alfa|
1742944|NCT00120718|Drug|fasudil|
1742945|NCT00120731|Drug|Potassium Citrate|
1742946|NCT00120731|Drug|Acetazolamide|
1742947|NCT00120731|Behavioral|Diet low in oxalate and purines|
1742948|NCT00120744|Drug|Ondansetron Oral Disintegrating Tablet|
1742949|NCT00120757|Drug|Alendronate|
1742950|NCT00120770|Drug|Cellulose Sulfate Vaginal Gel (Microbicide)|
1742951|NCT00120783|Drug|Indinavir|
1742952|NCT00120783|Drug|Lamivudine|
1742953|NCT00120783|Drug|Ritonavir|
1742954|NCT00120796|Drug|Lamivudine|
1742955|NCT00120796|Biological|Recombinant hepatitis B surface antigen|
1742956|NCT00120809|Drug|Sulfadoxine-pyrimethamine|
1742957|NCT00120822|Drug|Folic acid|
1742958|NCT00120835|Drug|valopicitabine|
1742959|NCT00120835|Drug|pegylated interferon|
1742960|NCT00120848|Biological|HPV 16/18 VLP AS04|
1742961|NCT00120861|Drug|valopicitabine|
1742962|NCT00120861|Drug|pegylated interferon|
1742963|NCT00120861|Drug|ribavirin|
1742964|NCT00120874|Behavioral|Individualized management of AD including caregiver training|Individualized management program: consists of home visits to get the patient exercising, doing enjoyable activities and cognitive stimulation, educational sessions for caregivers on coping with difficult situations and a caregiver support group to help with questions and emotional concerns.
1742965|NCT00120874|Drug|Memantine|Patients receive 10 milligrams of memantine twice daily.
1742966|NCT00120887|Drug|Atorvastatin|
1742968|NCT00120913|Drug|Birth control pills|
1742969|NCT00120926|Drug|Parenteral Nutrition|
1742970|NCT00120939|Drug|Motexafin Gadolinium|
1742971|NCT00120952|Device|Bi-Metric femoral implant (titanium versus cobalt-chromium)|
1742972|NCT00120965|Device|AutoPulse|Standard device settings
1742973|NCT00120965|Other|Manual CPR|Manual CPR
1742974|NCT00120978|Drug|Advair|
1742975|NCT00120978|Drug|Flovent|
1742976|NCT00120991|Procedure|Coronary artery bypass grafting|
1742977|NCT00121004|Behavioral|Advance Directive Selection|
1742978|NCT00121017|Drug|Kaletra (lopinavir/ritonavir)|
1742979|NCT00121017|Drug|Sustiva (efavirenz)|
1742980|NCT00121017|Drug|Truvada (emtricitabine/tenofovir disoproxil fumarate)|
1742981|NCT00121030|Drug|darbepoetin alfa|
1742982|NCT00121030|Drug|recombinant human erythropoietin (rHuEPO)|
1742983|NCT00126776|Behavioral|case management|case/self management for COPD vs usual care
1742984|NCT00126776|Behavioral|usual care|usual care for COPD
1742985|NCT00126789|Drug|Fentanyl Transdermal Matrix Patch ZR-02-01|ZR-02-01 patch contains fentanyl dispersed in a solid matrix, and will be available in 25, 50, 75 and 100 mcg/hr patches. The patches will be worn on the chest or upper arm and an overlay will be placed over the patch. Patches (and overlays) will be replaced every 3 days by the patient and/or responsible caregiver. If a patient experiences end-of-dose-failure, the dosing interval may be changed by the physician investigator to every 2 days. The maximum dose allowed in this study is 300 mcg/hr.
1742986|NCT00126802|Procedure|Tomotherapy|Standard 45 Gy in 25 fractions in 5 weeks
1742987|NCT00126828|Procedure|External beam radiotherapy|
1742988|NCT00126841|Procedure|CT and MR fusion|
1742989|NCT00126854|Procedure|Magnetic Resonance Spectroscopy Imaging|
1742990|NCT00126880|Drug|AVX754|apricitabine, 600mg BID or 800mg BID
1742991|NCT00126880|Drug|3TC|3TC, 150mg BID
1742992|NCT00126893|Drug|CC-401|
1742993|NCT00126906|Drug|Monthly sulfadoxine/pyrimethamine|
1742994|NCT00126906|Drug|2-dose sulfadoxine/pyrimethamine|
1742995|NCT00126919|Device|SonoPrep|
1742996|NCT00126932|Device|SonoPrep|
1742997|NCT00126945|Biological|Meningococcal Vaccine|
1742998|NCT00126958|Procedure|urinary analysis|
1742999|NCT00126971|Drug|chlorproguanil-dapsone|
1743000|NCT00126984|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
1743129|NCT00127959|Drug|zidovudine|
1743130|NCT00127959|Drug|efavirenz|
1743001|NCT00126984|Biological|DTPa/Hib containing vaccine|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
1743002|NCT00126984|Biological|Meningitec|One intramuscular dose during the primary vaccination study in subjects of 12-14 months of age
1743003|NCT00126984|Biological|Mencevax ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (group E) and subcutaneous administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (group C, group E)
1743004|NCT00126997|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
1743005|NCT00127010|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
1743006|NCT00127023|Biological|Measles, Mumps, Rubella and Chickenpox (live vaccine)|
1743007|NCT00127036|Drug|XELOX|XELOX: Oxaliplatin 130 mg/m^2 intravenously (IV); Capecitabine 825 mg/m^2 by mouth (po)
1743008|NCT00127036|Drug|XELIRI|XELIRI: Irinotecan 240 mg/m^2 IV; Capecitabine 825 mg/m^2 by mouth (po)
1743009|NCT00127036|Drug|Bevacizumab|7.5 mg/kg intravenously (IV)
1743010|NCT00127049|Drug|gemcitabine, ifosfamide, cisplatin, G-CSF|
1743011|NCT00127062|Other|Exposure|
1743012|NCT00127075|Drug|nomegestrol acetate|10 mg/day
1743013|NCT00127075|Drug|estradiol|75 mcg, once a week
1743014|NCT00127075|Drug|placebo|matching placebo treatments
1743015|NCT00127088|Drug|docetaxel|
1743016|NCT00127088|Procedure|laparoscopic radical prostatectomy|
1743017|NCT00127101|Drug|vorinostat|Dose escalation study starting with vorinostat 200 mg q.d. capsules (1 capsule daily) and rising up to vorinostat 400 mg q.d. capsules (1 capsule daily). Up to 6 months of treatment.
1743018|NCT00127101|Drug|Comparator: bexarotene|Dose escalation with bexarotene 150 mg/m2 capsules rising up to 300 mg/m2 capsules (1 capsule daily). Up to 6 months of treatment.
1743019|NCT00127127|Drug|vorinostat, Suberoylanilide Hydroxamic Acid (SAHA)|vorinostat; level 1: 100 mg BID 14-day, level 2: 200 mg BID 14-day, level 3: 400 mg QD 14 day, level 5: 500 mg QD 14-day
1743020|NCT00127140|Drug|vorinostat|
1743021|NCT00127153|Biological|V110, pneumococcal vaccine polyvalent|
1743022|NCT00127166|Drug|Montelukast sodium|Montelukast 5 mg chewable tablet once daily
1743023|NCT00127166|Drug|Salmeterol xinafoate|Salmeterol 50 mcg dry powder per actuation inhaled twice daily
1743024|NCT00127166|Drug|Fluticasone propionate|Fluticasone (50 mcg per actuation) 100 mcg inhaled twice daily
1743025|NCT00127166|Drug|Montelukast matching placebo|Matching placebo to montelukast oral tablet administered once daily.
1743026|NCT00127166|Drug|Salmeterol matching placebo|Matching placebo to salmeterol dry powder for inhalation administered twice daily
1743027|NCT00127179|Drug|MK0906, finasteride / Duration of Treatment: 48 weeks|
1743028|NCT00127179|Drug|Comparator: placebo / Duration of Treatment: 48 weeks|
1743029|NCT00127192|Drug|sitagliptin phosphate|sitagliptin phosphate 25 mg, 50 mg, 100 mg QD, or 200 mg QD 12-weeks.
1743030|NCT00127192|Drug|Comparator: placebo (unspecified)|placebo QD 12-weeks
1743031|NCT00127205|Drug|clodronate disodium|Given orally
1743032|NCT00127205|Drug|ibandronate sodium|Given orally
1743033|NCT00127205|Drug|zoledronic acid|Given IV
1743034|NCT00127218|Drug|any statin|Participants will be provided a prescription for fluvastatin 80 mg to be taken on a daily basis, or they may continue their ongoing or any other cholesterol-lowering drugs such as pravastatin 80 mg daily, simvastatin 20 mg daily, atorvastatin up to 20 mg daily or rosuvastatin up to 20 mg daily for 18 months
1743035|NCT00127218|Drug|niacin|long-acting niacin daily for 18 months
1743036|NCT00127218|Drug|Placebo|matching placebo pill daily for 18 months
1956537|NCT02817984|Biological|Acellular Adipose Tissue (AAT)|The components of the adipose-derived scaffold are all naturally occurring AAT proteins and proteoglycans that provide a natural scaffold. The nature of the AAT also enhances host tissue integration since matrix components can be easily degraded by cell-secreted enzymes as tissue remodeling takes place. Mechanisms for matrix turnover are already established in host cells, avoiding any concerns over proper clearance of scaffold materials from the body.
1743039|NCT00127244|Procedure|Periodontal Treatment|
1743040|NCT00127257|Behavioral|Biofeedback|
1743041|NCT00127257|Drug|Diazepam|
1743042|NCT00127257|Behavioral|Pelvic floor retraining|
1743043|NCT00127270|Drug|Darifenacin|Darifenacin tablets 7,5 mg once daily with the possibility to up-titrate to 15 mg once daily
1743044|NCT00127270|Drug|Darifenacin|Darifenacin tablets 7,5 mg or 15 mg once daily
1743045|NCT00127270|Behavioral|Behavioral therapy|Behavioral Modification Programme for symptoms of overactive bladder
1743046|NCT00127283|Drug|eptacog alfa (activated)|
1743047|NCT00127296|Device|FlexPen®|
1743048|NCT00127296|Device|vial and syringe|
1743049|NCT00127309|Drug|Glutathione|
1743050|NCT00127335|Drug|cellulose placebo vs. atorvastatin|drug
1743051|NCT00127348|Device|CPAP (Continuous Positive Airway Pressure)|
1743052|NCT00127361|Behavioral|doula training|
1743053|NCT00127374|Behavioral|Dietary and physical activity modifications|
1743054|NCT00127387|Drug|Enbrel|
1743055|NCT00127400|Behavioral|anger management therapy|
1743056|NCT00127413|Behavioral|Cognitive Behavioral Therapy - Pain|Pain treatment
1743057|NCT00127413|Behavioral|Cognitive Behavioral Therapy-Integrated|Integrated treatment
1743058|NCT00127413|Behavioral|Cognitive Processing Therapy - PTSD|Cognitive processing therapy
1743059|NCT00127413|Behavioral|Treat as Usual|Treatment as usual
1743061|NCT00127452|Dietary Supplement|margarine spread|Daily use of margarine spread (approximately 20 grams) during 40 months
1743062|NCT00127465|Procedure|Issue of information booklet|
1743063|NCT00127478|Drug|Atrasentan|
1743131|NCT00127972|Drug|stavudine|
1743132|NCT00127972|Drug|lamivudine|
1743064|NCT00127491|Procedure|Placement of an esophageal balloon measurements|In both groups an esophageal balloon will be placed and baseline measurements recorded. In the EP group the mechanical ventilation settings will be determined based on these measurements. In the control group measurements will be recorded but ventilation will be based in the existing standard of care wich is the ARDSnet low tidal volume ventilation study. measurements will be repeated at 24, 48 and 72 hours or as needed.
1743065|NCT00127491|Other|Low tidal volume ventilation|Low tidal volume ventilation strategy (ARDSnet)
1743066|NCT00127491|Other|Transpulmonary pressure-directed ventilation (EPVent)|Transpulmonary pressure-directed ventilation using measurements from the esophageal balloon.
1743067|NCT00127504|Drug|Rifampin|
1743068|NCT00127504|Drug|Azithromycin|
1743069|NCT00127517|Drug|peptide-nucleic acid solution AVR118|
1743070|NCT00127530|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 14 weeks
1743071|NCT00127530|Drug|Placebo|sugar pill, twice a day (b.i.d.)
1743072|NCT00127543|Behavioral|Medication Education for Children|
1743073|NCT00127556|Procedure|Label applied to blood bag|
1743074|NCT00127569|Drug|Rituximab|
1743075|NCT00127582|Procedure|Electrophysiological study|
1743076|NCT00127582|Device|pacemaker (PM) implant, internal cardiac defibrillator (ICD) implant, loop-recorder implant|
1743077|NCT00127595|Drug|gemcitabine, oxaliplatin|
1743079|NCT00127621|Procedure|early tracheotomy|
1743080|NCT00127621|Procedure|prolonged endotracheal intubation|
1743081|NCT00127634|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months, up to 36 months
1743082|NCT00127634|Drug|Injectable Insulin|patient specific dose, injectable, before meals, 24 months, up to 36 months.
1743083|NCT00127634|Drug|Insulin Glargine|patient specific dose, injectable, as needed, 24 months up to 36 months
1743084|NCT00127647|Drug|montelukast sodium|montelukast sodium; 5 mg, 10 mg QD 2-weeks.
1743085|NCT00127647|Drug|Comparator: pranlukast|Pranlukast 225 mg BID 2-weeks.
1743086|NCT00127660|Behavioral|Menu: calories=yes, value pricing=no|
1743087|NCT00127660|Behavioral|Menu: calories=yes, value pricing = yes|
1743088|NCT00127660|Behavioral|Menu: calories=no, value pricing = no|
1956545|NCT02812095|Procedure|Refeeding|when amount of feeding reach to 120mL/kg a day,
1956546|NCT02811003|Device|Rotation Medical Bioinductive Implant|Placement of bioinductive implant over repair of insertional Achilles tendinopathy
1743091|NCT00127686|Drug|Dextromethorphan|
1743092|NCT00127686|Drug|Buckwheat Honey|
1743093|NCT00127699|Procedure|Alcohol swab of umbilical cord|
1743094|NCT00127712|Drug|Amiodarone|
1743095|NCT00127725|Device|Pulsed electromagnetic field stimulation|
1743096|NCT00127738|Procedure|Angiographic renal revascularization|
1743097|NCT00127751|Behavioral|Enhance health lifestyle changes and medication compliance|
1743098|NCT00127764|Drug|dexamethasone (50mg 1dd6, 3 consecutive days/month)|
1743099|NCT00127777|Drug|Amantadine sulphate (in addition to standard treatment)|
1743100|NCT00127790|Behavioral|CBT for Insomnia (CBT-I)|
1743101|NCT00127790|Behavioral|CBT for Pain (CBT-P)|
1743102|NCT00127803|Biological|Placebo (vaccine diluent)|0.5 mL, intramuscular (IM) on Days 0, 28, and 56, respectively.
1743103|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
1743104|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
1743105|NCT00127803|Biological|Clostridium difficile vaccine|0.5 mL, intramuscular on Days 0, 28, and 56, respectively.
1743106|NCT00127816|Procedure|Permanent prostate implant|
1743107|NCT00127829|Drug|Gefitinib|Oral tablet
1743108|NCT00127842|Drug|Etanercept|Administered according to the product monograph by subcutaneous (SC) injection
1743109|NCT00127855|Biological|Hib-MenCY-TT vaccine (MenHibrix)|Three doses were administered intramuscularly (IM) in left thigh at Months 0,2 and 4 respectively
1743110|NCT00127855|Biological|Meningitec®|Three doses were administered IM in right lower thigh at Months 0,2 and 4.
1743111|NCT00127855|Biological|ActHIB®|Three doses were administered IM in left thigh at Months 0,2 and 4.
1743112|NCT00127855|Biological|Infanrix® Penta|Three doses were administered IM in right upper thigh at Months 0,2 and 4 respectively.
1743113|NCT00127855|Biological|Prevenar®|Three doses were administered IM in right lower thigh at Months 0,2 and 4 respectively.
1743114|NCT00127855|Biological|Mencevax® ACWY|One fifth of one dose was administered IM in deltoid region of right arm at Month 10 as booster.
1743115|NCT00127855|Biological|PRP (Polyribosyl Ribitol Phosphate)|One dose was administered IM in deltoid region of left arm at Month 10 as booster.
1743116|NCT00127868|Drug|oral griseofulvin, selenium sulfide shampoo 1%, ciclopirox shampoo , ketoconazole shampoo 2%, baby shampoo|
1743117|NCT00127881|Drug|HuMax-CD4 (zanolimumab)|Monoclonal Antibody, 12 weekly infusions.
1743118|NCT00127907|Drug|epinephrine (1 mg/1 mL)|
1743119|NCT00127907|Drug|arginine-vasopressin (40 UI/2 mL)|
1743120|NCT00127920|Drug|Avastin|Paclitaxel, Carboplatin and Avastin given on day 1 every 21 days
1743121|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
1743122|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
1743123|NCT00127933|Drug|Herceptin (HER2-neu positive patients only)|4mg/kg iv (loading dose) followed by 2mg/kg iv weekly
1743124|NCT00127933|Drug|capecitabine [Xeloda]|825mg/m2 po bid on days 1-14 of each 3 week cycle
1743125|NCT00127933|Drug|Taxotere|75mg/m2 iv on day 1 of each 3 week cycle
1743126|NCT00127946|Procedure|AMNIOECHANGE|The AMNIOECHANGE consists of a transabdominal infusion of saline (heated to 37 ° C) with a needle 18 or 20 gauge under ultrasound monitoring while avoiding the placenta. In the case of a normal amniotic fluid, it must be replaced volume per volume of saline (eg depending on the tank where the puncture is made, it can be 300 per 300 ml). The total amount of amniotic fluid exchange is 600-900 ml. In cases of oligohydramnios, the AMNIOECHANGE results in a normalized volume of amniotic fluid.
1743136|NCT00127985|Drug|6-methyl-prednisolone|iv, 2 mg/kg/day, qid
1743137|NCT00127998|Drug|chloroquine|
1743138|NCT00127998|Drug|sulfadoxine-pyrimethamine|
1743139|NCT00127998|Drug|amodiaquine|
1743140|NCT00127998|Drug|amodiaquine+artesunate|
1743141|NCT00127998|Drug|amodiaquine+sulfadoxine-pyrimethamine|
1743142|NCT00127998|Drug|sulfadoxine-pyrimethamine+artesunate|
1743143|NCT00127998|Drug|artemether-lumefantrine|
1743144|NCT00127998|Drug|mefloquine|
1743145|NCT00128011|Biological|killed oral cholera vaccine|
1743146|NCT00128024|Drug|lipid-lowering treatment|
1743147|NCT00128037|Drug|mitomycin C, vindesine, cisplatin and radiotherapy|
1956547|NCT02810873|Device|Positron Emission Mammography|Undergo PEM Positron Emission Mammography scan
1956548|NCT02810873|Device|Positron Emission Tomography|Undergo PET Positron Emission Tomography scan
1956549|NCT02810873|Radiation|Fludeoxyglucose F-18|Undergo Fludeoxyglucose F-18 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
1743151|NCT00128063|Drug|succinylated human serum albumin|
1743152|NCT00128076|Procedure|All-Arthroscopic repair|joint techniques and repair are both performed entirely through the arthroscope
1743153|NCT00128076|Procedure|Mini-open repair|repair is performed though a small incision and the arthroscope can be used to address problems within the joint (as per traditional diagnostic procedures)
1743154|NCT00128089|Behavioral|Dietary treatment|
1743155|NCT00128102|Drug|vorinostat|Vorinostat three 100 mg capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
1743156|NCT00128102|Drug|Placebo|Placebo capsules twice daily for 3 consecutive days of treatment followed by 4 days of rest repeated weekly, in 21-day cycles. Treatment will continue until disease progression or unacceptable toxicity.
1743157|NCT00128115|Drug|MK0677|
1743158|NCT00128128|Drug|Cranberry juice cocktail|Participants will consume 4 or 8 ounces of Cranberry Juice Cocktail or Placebo daily for 6 months.
1743159|NCT00128141|Behavioral|Tactile stimulus|four times a day
1743160|NCT00128154|Drug|Chromium picolinate|
1743161|NCT00128167|Drug|Liquid CAIV-T|
1743162|NCT00128180|Drug|Methylprednisolone|Intravenous methylprednisolone 16 mg/kg/day for 3 days as follows: 8 mg/kg (up to 500 mg) given over first hour followed by 8 mg/kg over the next 23 hours; then 16 mg/kg (up to 1000 mg) on days 2 and 3 administered over 24 hours.
1743163|NCT00128180|Drug|Placebo|Placebo
1743164|NCT00128193|Biological|Tuberculin, Purified Protein Derivative|A tuberculin skin test used to diagnose latent tuberculosis (TB) infection. 2 TU dose
1743165|NCT00128193|Other|MLSA-LAM|Mycobacterium leprae soluble antigen with minimal amounts of immunosuppressive lipoglycans; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
1743166|NCT00128193|Other|MLCwA|Cell wall-associated proteins of Mycobacterium leprae; dosages 0.1 and 1.0 micrograms; administered in sterile diluent 0.9% saline (NaCl).
1743167|NCT00128193|Biological|Tuberculin, Purified Protein Derivative|Licensed TB reagent, 100 microliters, 5 TU dose.
1743168|NCT00128193|Other|Placebo|Saline (NaCl) serves as a diluent control in Stage A and B only.
1743169|NCT00128206|Drug|Isoniazid|Isoniazid 900 mg twice weekly
1743170|NCT00128206|Drug|Rifampin|Rifampin 600mg once per day
1743171|NCT00128219|Biological|GBS III-TT|50 mcg GBS Type III capsular polysaccharide conjugated to 32 mcg of tetanus toxoid. A single dose of vaccine administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml.
1743172|NCT00128219|Biological|Tetanus and diptheria toxoids vaccine|Td vaccine is a sterile solution of alum-precipitated toxoids in isotonic sodium chloride solution. A single dose of vaccine will be administered by intramuscular (IM) injection in the upper arm. All subjects will receive a volume of 0.5 ml. Each 0.5 ml dose is formulated to contain 5 Lf (flocculation units) of tetanus toxoid and 2 Lf of diphtheria toxoid.
1743173|NCT00128232|Drug|Octreotide LAR|
1743174|NCT00128245|Drug|Pimecrolimus|
1743175|NCT00128258|Procedure|Injection of bone marrow cells in the heart|Biological implant into the heart
1743176|NCT00128258|Biological|Biological bone marrow cell therapy|Biological implant into the heart
1743177|NCT00128271|Drug|Bavituximab|
1743178|NCT00128297|Drug|Pamidronate|
1743179|NCT00128310|Drug|gemcitabine|
1743180|NCT00128323|Drug|Gentian violet 1% solution|
1743181|NCT00128323|Drug|Gentian violet 0.00165% solution|
1743182|NCT00128323|Drug|Nystatin solution|
1743183|NCT00128336|Behavioral|Lifestyle: diet and exercise intervention|
1743184|NCT00128362|Procedure|Radio-guided sentinel node biopsy|
1743185|NCT00128362|Procedure|Axillary sampling|
1743186|NCT00128375|Behavioral|Financial incentives|
1743187|NCT00128388|Other|PFPP|Psychoanalytic Psychotherapy for panic disorder
1743188|NCT00128388|Other|ART|Applied Relaxation Training
1743189|NCT00128401|Drug|D-Cycloserine|
1743190|NCT00128401|Drug|Placebo|
1743191|NCT00128414|Drug|Colchicine (for 6 months)|colchicine 1.0 mg twice daily for the first day followed by a maintenance dose of 0.5 mg twice daily for 1 month in patients ≥70 kg, and halved doses for patients <70 kg or intolerant to the highest dose.
1743192|NCT00128414|Drug|Placebo|Tablets identical in colour, shape, and taste were provided in blister packs.
1743193|NCT00128427|Drug|Colchicine (for 1 month)|
1743194|NCT00128440|Drug|BEA 2180 BR|
1743195|NCT00128440|Drug|tiotropium|
1743196|NCT00128453|Drug|Colchicine (for 3 months)|Colchicine 0.5mg BID (patients>70Kg) or 0.5mg once daily
1743197|NCT00128453|Drug|Placebo|placebo
1743198|NCT00128466|Drug|gentamicin|
1743199|NCT00128466|Drug|streptomycin|
1743200|NCT00128479|Drug|mifepristone|mifepristone 300 mg daily for 7 dats
1743201|NCT00128479|Drug|mifepristone matched placebo|daily for 7 days
1743202|NCT00128479|Drug|mifepristone 600 mg|mifepristone 600 mg daily for 7 days
1743203|NCT00128479|Drug|mifepristone 1200 mg|mifepristone 1200 mg daily for 7 days
1743204|NCT00128492|Drug|AZLI 75 mg two times a day (BID)/ three times a day (TID)|
1743205|NCT00128505|Drug|Mifepristone|
1743206|NCT00128518|Drug|Indapamide (T2)|1.5 mg/day during 4 weeks
1743207|NCT00128518|Drug|Perindopril (T1)|4 mg/day during 1 week then 8 mg/day during 3 weeks
1743208|NCT00128518|Drug|Placebo of Perindopril (P1)|1 pill/day during 1 week then 2 pills/day during 3 weeks
1743209|NCT00128518|Drug|Placebo of Indapamide (P2)|1 pill/day during 4 weeks
1743210|NCT00128531|Drug|leuprolide acetate|
1743211|NCT00128544|Drug|telbivudine|
1743212|NCT00128544|Drug|valtorcitabine|
1743213|NCT00128557|Drug|vitamin A supplementation (50,000 IU)|
1743214|NCT00128570|Behavioral|behavioral dietary intervention|
1743215|NCT00128570|Other|educational intervention|
1743216|NCT00128570|Other|internet-based intervention|
1743217|NCT00128570|Other|preventative dietary intervention|
1743218|NCT00128570|Procedure|evaluation of cancer risk factors|
1743219|NCT00128583|Biological|polyvalent melanoma vaccine|
1743220|NCT00128596|Drug|arsenic trioxide|
1743221|NCT00128622|Biological|denileukin diftitox|
1743222|NCT00128622|Biological|recombinant fowlpox-CEA(6D)/TRICOM vaccine|
1743223|NCT00128622|Biological|therapeutic autologous dendritic cells|
1743224|NCT00128635|Radiation|iodine I 131 monoclonal antibody TNT-1/B|
1743225|NCT00128661|Biological|human papillomavirus 16/18 L1 virus-like particle/AS04 vaccine|Three doses of Cervarix vaccine administered on a 0, 1, 6-month schedule
1743226|NCT00128661|Biological|hepatitis A inactivated virus vaccine|Three doses of Havrix vaccine administered on a 0, 1, 6-month schedule
1743227|NCT00128687|Behavioral|risk reduction|Participants receive intensive case management for CHD risk reduction for 15 months and then a maintenance program for a minimum of 12 months. Lifestyle modification was strongly emphasized as a critical component of achieving CHD prevention goals. Dietary management was emphasized, including recommendation of a low saturated fat (less than 7% of caloric intake), low cholesterol (< 150 mg/day), mainly plant-based diet with calorie restrictions for overweight/obese persons. Stress management and coping skills were emphasized, including a regular exercise regimen (≥ 30 minutes of moderate intensity on most days). Cigarette smokers were encouraged to join a stop smoking program.
1743228|NCT00128700|Drug|temozolomide|
1743229|NCT00128700|Drug|vatalanib|
1743230|NCT00128700|Procedure|adjuvant therapy|
1743231|NCT00128700|Radiation|radiation therapy|
1743232|NCT00128713|Procedure|Medium Dose Prophylactic Platelet Transfusions|2.2 x 10^11 platelets per m^2 BSA
1743233|NCT00128713|Procedure|Lower Dose Prophylactic Platelet Transfusions|1.1 x 10^11 platelets per m^2 BSA
1743234|NCT00128713|Procedure|Higher Dose Prophylactic Platelet Transfusions|4.4 * 10^11 platelets per m^2 BSA
1743235|NCT00128739|Drug|Budesonide|
1743236|NCT00128752|Behavioral|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
1743237|NCT00128765|Behavioral|an integrated self-management education program|disease specific self-management program 'Living Well with COPD', developed in Montreal, Canada
1743238|NCT00128765|Behavioral|regular practice nurse review (monitoring controls)|protocol based on existing Guidelines: Dutch College of General Practitioners (NHG) Global Initiative for Chronic Obstructive Lung Disease (GOLD)
1743239|NCT00128765|Behavioral|care at initiative of the patient (usual GP care)|care at initiative of the patient (usual GP care)
1743240|NCT00128778|Drug|Pegylated liposomal doxorubicin (Caelyx)|
1743241|NCT00128791|Drug|Nitroprusside|
1743242|NCT00128804|Behavioral|absorption and conversion of beta-carotene in human gastrointestinal (GI) tract|
1743243|NCT00128817|Radiation|Concurrent Chemoradiation|60-70 Gy at 2Gy/5days a week for 6 to 7 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
1743244|NCT00128817|Procedure|Laryngectomy + adjuvant radiotherapy/chemoradiotherapy|Surgery: Total Laryngectomy with or without partial pharyngectomy or Near-Total Laryngectomy with or wothout partial pharyngectomy Adjuvant Radiation 2- 3 weeks following surgery: 50-60Gy at 2Gy/5days a week for 5 to 6 weeks Cisplatin (CDDP) 100 mg/m2 over 20-30 minutes on days 1, 22, and 43.
1743245|NCT00128830|Drug|Etravirine (ETR)|Participants will receive 800 mg of ETR (2 x 4 tablets of formulation TF035) twice daily and after the formulation switch they will receive 200 mg of ETR (2 x 2 tablets of formulation F060) twice daily until the participants benefitted from etravirine or it became comercially available.
1743246|NCT00128830|Drug|Nucleotide reverse transcriptase inhibitors (NRTIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
1743247|NCT00128830|Drug|Protease inhibitors (PIs)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
1743248|NCT00128830|Drug|Enfuvirtide (ENF)|Participants will receive 2 additonal approved antiretrovirals (ARVs) along with ETR. ARVs may be NRTIs and/or allowed protease inhibitors (PIs) and/or enfuvirtide (ENF).
1743249|NCT00128843|Drug|Exemestane|
1743250|NCT00128843|Drug|Anastrozole|
1743251|NCT00128856|Drug|gemcitabine|
1743252|NCT00128856|Drug|doxorubicin|
1743253|NCT00128856|Drug|paclitaxel|
1743254|NCT00128869|Procedure|spine mobilizations|
1743255|NCT00128869|Procedure|spine manipulations|
1743256|NCT00128882|Drug|Anti-D|Subcutaneous injection
1743257|NCT00128895|Drug|azathioprine|azathioprine 2 mg/kg oral once daily, duration according to arm
1743258|NCT00128908|Drug|Standard Continuous Highly Active Antiretroviral Therapy (HAART)|
1743259|NCT00128908|Drug|Rapidly Cycled HAART|
1743309|NCT00129298|Drug|Tiagabine|The tiagabine group will start receiving tiagabine 4mg in the evening of the first day on week 2. The dose will be titrated every third day, until the target dose of 32mg/day is achieved by week 5. The study medication must be titrated to 32 mg/day or to the subject's maximum tolerated dose (MTD).
1743395|NCT00124228|Drug|Human Albumin|albumin 1.5g/kg body weight the first day of inclusion plus 1g/kg/body weight the 3th day of inclusion.
1743396|NCT00129688|Drug|cloxacillin and amikacin (once or twice daily dosage)|
1743260|NCT00128921|Drug|VELCADE™|"Patients will receive two cycles of VELCADE™ (1.3 mg/m2, 1.0 mg/m2 or 0.7 mg/m2) on days 1, 4, 8, and 11, on a 21 day cycle. No growth factors or bisphosphonates will be allowed during study treatment. Bone markers will be measured:
Days 1, 4, 8, 11: Pre-dose, post-dose, and every 2-4 hours for 8 hours Days 2-3, 5-7, 9-10, 12-21: every 24 hours, beginning with the immediate post-dose sample (+/- 2 hours) Other laboratory and radiologic studies will be performed as detailed in the Study Calendar.
Patients will complete the study after two cycles of VELCADE™. However, if a patient continues to receive VELCADE™ as part of his/her treatment for relapsing MM, routine bone markers may be monitored for the duration of VELCADE™ treatment as clinically indicated."
1743261|NCT00128934|Drug|levonorgestrel/ethinyl estradiol|
1743262|NCT00128947|Drug|Mycophenolic Acid|
1743263|NCT00128947|Drug|Mycophenolate 7-O-Phenolic Glucuronide|
1743264|NCT00128986|Procedure|Tomotherapy|3T MRS scans (3T magnetic resonance spectroscopy)
1743265|NCT00128999|Procedure|Intensity-Modulated Radiation Therapy|
1743266|NCT00129012|Procedure|Tomotherapy|
1743267|NCT00129025|Procedure|Hypofractionated radiotherapy|
1743268|NCT00129038|Drug|modified-release dipyridamole/aspirin|
1743269|NCT00129038|Drug|aspirin|
1743270|NCT00129051|Procedure|Tomotherapy|
1743271|NCT00129064|Behavioral|Electronic referral system|
1743272|NCT00129077|Procedure|plastic wrap over eye & lubrication applied q6 hrs|
1743273|NCT00129090|Drug|R-CHOEP 14 with 12x Rituximab|after amendment 3 patients receive 4x 375mg/m2 in cycle 1 (day 0,1,4,8), 2x 375/m2 in cycle 2 (day1,8) and 1x 375mg/m2 cycle 3-8 (day 1 of each cycle)
1743274|NCT00129116|Biological|Hib-MenCY-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
1743275|NCT00129116|Biological|Hib-MenC-TT vaccine|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
1743276|NCT00129116|Biological|Menjugate ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in left thigh.
1743277|NCT00129116|Biological|Infanrix penta ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
1743278|NCT00129116|Biological|Infanrix hexa ®|Three doses during the primary vaccination and one booster dose administered intramuscularly (IM) in right thigh.
1743279|NCT00129129|Biological|GSK Biologicals' Haemophilus influenza type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine 792014 vaccine|Primary phase: 3 IM doses Booster phase: 1 IM dose
1743280|NCT00129129|Biological|ActHIB|Primary phase: 3 IM doses Booster phase: 1 IM dose
1743281|NCT00129129|Biological|Pediarix|Primary phase: 3 IM doses
1743282|NCT00129129|Biological|Prevnar|Primary phase: 3 IM doses Booster phase: 1 IM dose
1743283|NCT00129129|Biological|Menomune|Primary phase: 1 SC dose
1743284|NCT00129142|Drug|Toremifene Citrate|
1743285|NCT00129155|Drug|treosulfan|
1743286|NCT00129168|Drug|Zosuquidar|
1743287|NCT00129168|Drug|Daunorubicin|
1743288|NCT00129168|Drug|Cytarabine|
1743289|NCT00129181|Drug|cabergoline|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
1743290|NCT00129181|Drug|carbidopa/levodopa|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
1743291|NCT00129181|Procedure|DATscan and SPECT imaging|Approximately 120 Parkinson's disease subjects will be randomized to receive either carbidopa/levodopa, cabergoline or no treatment during a twelve week period. Subjects will undergo SPECT imaging with DATscan at screening and after 12 weeks. After twelve weeks carbidopa/levodopa and cabergoline treatment will be withdrawn and all subjects will undergo SPECT imaging with DATscan after 8 weeks (20 weeks after baseline).
1743292|NCT00129194|Drug|KP-1461|
1743293|NCT00129207|Drug|bortezomib|
1743294|NCT00129220|Drug|olanzapine|5-20 mg, oral, once daily (evening), for 6 weeks
1743295|NCT00129220|Drug|haloperidol|2.5-10 mg, oral, twice daily (morning and evening), for 6 weeks.
1743296|NCT00129220|Drug|placebo|placebo, oral tablets, twice daily (morning and evening), for 3 weeks
1743297|NCT00129233|Drug|Valsartan|valsartan 80 to 160 mg daily
1743298|NCT00129233|Drug|Amlodipine|Amlodipine 5 to 10 mg daily.
1743299|NCT00129246|Drug|Naltrexone|Participants received naltrexone hydrochloride on the sixth day of bupropion treatment, and the initial dose was 12.5 mg, followed by 25 mg daily for the duration of the 7-week treatment.
1743300|NCT00129246|Drug|Bupropion|Starting with the baseline visit, all participants received 150 mg of bupropion SR once per day for 3 days, then twice per day for the duration of the 7-week treatment period.
1743301|NCT00129259|Biological|Anti-CD3 mAb|Daily 14-day dose escalation course at study entry, with possible second course after 12-month interval
1743302|NCT00129259|Other|Diabetes Standard of Care Treatment|Receipt of intensive diabetes standard of care treatment/management under the care of a physician: dietary counseling, insulin dosing and multiple consultations during the course of the trial with the clinical diabetes management team.
1743303|NCT00129259|Dietary Supplement|Iron supplementation|Immediately following randomization, all participants regardless of arm allocation begin iron supplementation with either ferrous sulfate or multivitamin with iron.
1743304|NCT00129272|Drug|Bupropion-SR|150mg tablets taken orally twice daily for 9 weeks.
1743305|NCT00129272|Other|Placebo|Matching placebo (to Buproion-SR) twice daily for 9 weeks.
1956550|NCT02810873|Drug|Copper Cu 64 TP3805|Undergo copper Cu 64 TP3805 PET (Positron Emission Tomography) /PEM (Positron Emission Mammography) scan
1743394|NCT00124215|Biological|GI-5005|Heat-killed yeast cell transfected with NS3-Core fusion protien.
1743310|NCT00129311|Drug|Selegiline|5 mg capsules taken by mouth. Participants take 5 mg once a day for the first week of the study, then increase the dose to 5 mg twice a day for 6 weeks, then take 5 mg once a day during the last week of the study. Participants receiving the placebo pill take 1 pill per day for the first week of the study and 1 pill twice a day for the other weeks.
1743311|NCT00129311|Drug|Placebo|
1743312|NCT00129324|Procedure|Lead Hazard Control Intervention|Prior to their child's birth, participants randomized to Lead Reduction Group received lead hazard reduction controls to reduce residential exposure to lead.
1743313|NCT00129324|Procedure|Injury Hazard Control Intervention|Between 3 and 6 months of age, participants randomized to Injury Reduction Arm received injury hazard controls to reduce the number of residential injuries.
1743314|NCT00129337|Drug|Bavituximab|Bavituximab is a sterile drug solution supplied in glass bottles. Bavituximab will be intravenously administered over approximately 90 minutes on days 0, 7, 14 and 21 (dosage determined based on dose cohort and body weight).
1743315|NCT00129350|Procedure|Pulmonary rehabilitation programme|
1743316|NCT00129363|Drug|Carvedilol|
1743317|NCT00129376|Drug|docetaxel|
1743318|NCT00129389|Drug|FAC|FAC x 6: 5-fluorouracil 500 mg/m2 i.v. + doxorubicin 50 mg/m2 i.v. + cyclophosphamide 500 mg/m2 i.v. every 3 weeks, for 6 cycles.
1743319|NCT00129389|Drug|paclitaxel|"FAC x 4 -> Taxol x 8:
5-fluorouracil 500 mg/m2 i.v. + doxorubicin 50 mg/m2 i.v. + cyclophosphamide 500 mg/m2 i.v. every 3 weeks, for 4 cycles followed by weekly Taxol 100 mg/ m2 for 8 cycles (days 1, 8, 15, 22, 29, 36, 43 y 50)."
1743320|NCT00129402|Drug|ezetimibe with simvastatin|Ezetimibe 10 mg plus simvastatin 10 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 20 mg once a day for six weeks, or Ezetimibe 10 mg plus simvastatin 40 mg once a day for six weeks
1743321|NCT00129402|Drug|simvastatin|Ezetimibe matching placebo plus simvastatin 10 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 20 mg once a day for six weeks, or Ezetimibe matching placebo plus simvastatin 40 mg once a day for six weeks
1743322|NCT00129415|Procedure|UVA1 Irradiation|The affected areas on the body will be treated with UVA1 (Sellemed UVA1 light source) for up to 5 times per week for 16 weeks. The UVA1 dose will be up to 130 J/cm2.
1743323|NCT00129415|Procedure|UVB Irradiation|The affected areas on the body will be treated with UVB light for up to 5 times per week for 16 weeks. The maximum UVB dose will be 4000 mJ/cm2.
1743324|NCT00129428|Procedure|UVB Irradiation|A dose of up to 320 mJ/cm2 from a UVB irradiation device will be administered at maximum 5 times per week for 16 weeks.
1743325|NCT00129441|Drug|Merck L-830982|The initial dose of L-830982 was 3.0 mg twice daily (b.i.d.) the dosage increased to 5.0 mg b.i.d. at the end of week 1 and 8.0 mg b.i.d. at the end of week 2, which was continued for the remaining 2 weeks of the trial. Medications were dispensed weekly in blister packs by the hospital pharmacy.
1743326|NCT00129441|Drug|Placebo|Medications were dispensed weekly in blister packs by the hospital pharmacy, using the same number of pills as those on active drug.
1743327|NCT00129454|Behavioral|Cognitive Behavioral Therapy|"The investigators adapted two previously validated CBT manuals for use in both Telephone and In-Person groups (the Personal Health Improvement Program and Dr. Charles Engel's group treatment for GWI). Treatment included the following standard components of CBT: Didactic or educational material about the causes of GWI and an explanation of how thinking can cause stress (ABC model); Assessment of psychological distress and behavioral problems that may be targets of therapeutic intervention (e.g. symptom-related anxiety); Assessment of thinking errors that lead to psychological distress and trigger behavioral problems (e.g. catastrophizing); Cognitive restructuring to teach disputing skills or how to correct thinking errors; Cognitive and behavioral homework assignments (e.g. written self-disclosure); Didactic homework assignments (e.g. listen to previous treatment session)."
1743328|NCT00129454|Behavioral|Cognitive Behavioral Therapy|This description is the same as the experimental treatment only disseminated in person rather than over the telephone.
1743329|NCT00129467|Drug|Methylphenidate|"Subjects will take methylphenidate 5 mg twice daily (bid) for 3 days, then 10 mg bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of methylphenidate, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%. During the 18-day blinded treatment period the total daily dose will not exceed 20 mg.
If subjects have side effects when increasing to 10 mg bid, they will drop back to 5 mg bid. If the participant develops psychosis or cardiac events, they will be discontinued from methylphenidate.
Subjects who receive methylphenidate and respond with a 50% reduction in MADRS score will have the option to continue in the open label portion of the study for up to 6 weeks. For patients taking methylphenidate 10 mg bid whose MADRS score is > 10 at day 18, the dose may be increased to 15 mg bid."
1743330|NCT00129467|Drug|Placebo|"Subjects assigned to placebo will receive 1 capsule of placebo twice per day (bid) for 3 days and then 2 capsules bid for the remainder of the study. Should a subject have a 50% decrease in their depressive symptoms as measured by the Montgomery Asberg Depression Rating Scale (MADRS) at the initial dose of placebo, they will be maintained at that lower dose as long as their MADRS score remains reduced by 50%.
If subjects have side effects when increasing the dose to 2 capsules bid, they will drop back to 1 capsule bid. If the participant develops psychosis or cardiac events, they will be discontinued from the intervention."
1743331|NCT00129467|Drug|Selective Serotonin Uptake Inhibitor (SSRI)|"Each subject will be treated with a SSRI. Patients who are taking an SSRI at the time of enrollment will continue on the same medication during the 18-day blind treatment period. The prescribed dose will only be adjusted if it is more than the highest dose in the recommended range (fluoxetine to 40 mg, paroxetine to 40 mg, citalopram to 40 mg, sertraline to 150 mg). Patients who are not on a SSRI at the time of enrollment will be prescribed citalopram 10 mg per day for 2 weeks, then 20 mg per day.
A subject's SSRI may be discontinued if the subject experiences moderate to severe side effects likely attributable to a SSRI. If subjects experience similar symptoms when increasing their citalopram dose to 20 mg per day, they will drop back to 10 mg per day. During the open label extension, the SSRI may be increased, decreased, or changed to a different SSRI or other antidepressant with the exception of venlafaxine and bupropion"
1743332|NCT00129480|Behavioral|Assistance with Pain treatment|Care management intervention including assessment, decision support, patient activation, education and followup, provider education, feedback to providers. Intervention delivered for 12 months.
1743397|NCT00129701|Procedure|Telephone consultation|
1743333|NCT00129493|Behavioral|Group medical visits|Our intervention aims to develop and implement a model of group medical visits in iterative steps, to evaluate whether group medical visits improve patient adherence to prescribed antihypertensive medications and improve BP control, and to assess patient, physician, and health care system factors involved in successfully making organizational changes to encompass group medical visits.
1743334|NCT00129506|Drug|methotrexate + misoprostol|
1743335|NCT00129506|Drug|misoprostol|
1743336|NCT00129519|Drug|Imiquimod 5% cream|Imiquimod 5% cream applied once daily 5x/week for up to 6 weeks
1743337|NCT00129532|Drug|1.0% C31G SAVVY vaginal gel|
1743338|NCT00129545|Device|WATCHMAN Left Atrial Appendage Closure Technology|Implant of WATCHMAN Left Atrial Appendage Closure Technology
1743339|NCT00129545|Drug|Warfarin|Subjects receive warfarin
1743340|NCT00129558|Drug|PT-523 for Injection|
1743341|NCT00129571|Drug|XL820|
1743342|NCT00129584|Procedure|Emphasys Endobronchial Valve and procedure|
1743343|NCT00129597|Drug|ketalar|
1743344|NCT00129610|Behavioral|Virtual Reality Therapy|
1743345|NCT00129610|Behavioral|Cognitive Behavior Therapy|
1743346|NCT00129623|Drug|Placebo|po monthly for 1 year
1743347|NCT00129623|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 1 year
1743348|NCT00129636|Procedure|Additional specific letter written to patient|
1743349|NCT00129649|Behavioral|Telephone reminder call|
1743350|NCT00129662|Behavioral|Pictorial action plan|
1743351|NCT00129675|Drug|[123I]ß CIT|"Single Photon Emission Computed Tomography
SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
1743352|NCT00123929|Drug|docetaxel|100 mg/m2 every 3 weeks times 4
1743353|NCT00123929|Drug|doxorubicin|75 mg/m2 every 3 weeks times 4
1743354|NCT00123942|Drug|MEDI-507|
1743355|NCT00123955|Drug|Spironolactone|25mg tablet daily for 9 months
1743356|NCT00123955|Drug|Placebo|Placebo tablet daily for 9 months
1743357|NCT00123968|Biological|VRC-HIVDNA016-00-VP|1x10^11 per unit vaccine administered intramuscularly via Bioinjector
1743358|NCT00123968|Biological|VRC-HIVADV014-00-VP|4 mg administered intramuscularly via injection
1743359|NCT00123968|Biological|VRC-DILUENT013-DIL-VP|Administered intramuscularly via Bioinjector
1743360|NCT00123968|Biological|VRC-HIVADV014-00-VP placebo|4 mg administered intramuscularly via injection
1743361|NCT00123981|Procedure|Off-Pump Coronary Artery Bypass Grafting|
1743362|NCT00123994|Behavioral|Tai Chi classes|
1743363|NCT00123994|Behavioral|Hydrotherapy classes|
1743364|NCT00124007|Biological|VRC-HIVADV014-00-VP|
1743365|NCT00124007|Biological|VRC-HIVDNA016-00-VP|
1743366|NCT00124020|Drug|Telavancin|Telavancin 10 mg/kg/day IV for up to 21 days
1743367|NCT00124020|Drug|Vancomycin|Vancomycin 1 Gm administered every 12 hrs IV for up to 21 days
1743368|NCT00124033|Procedure|Transcystic Stenting (Facilitated ERCP)|
1743369|NCT00124046|Procedure|Surgery|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
1743370|NCT00124046|Procedure|Medical Treatment|Surgery for this diagnosis is a standard of care, as is the medical treatment. We are comparing the two
1743371|NCT00124059|Drug|Seroquel|400mg/day quetiapine
1743372|NCT00124059|Drug|Placebo|400mg/day placebo
1743373|NCT00124072|Drug|Simvastatin 20 mg daily|Simvastatin 20 mg tablet once daily
1743374|NCT00124072|Dietary Supplement|Folic acid 2 mg + vitamin B12 1 mg daily|Folic acid 2 mg + vitamin B12 1 mg tablet once daily
1743375|NCT00124072|Drug|Simvastatin 80 mg daily|Simvastatin 80 mg tablet once daily
1743376|NCT00124072|Drug|Placebo|Placebo vitamin B12/folic acid tablet once daily
1743377|NCT00124085|Behavioral|Disease Management|
1743378|NCT00124085|Behavioral|Disease Management + Educational Home Visits|
1743379|NCT00124098|Drug|Aranesp® (darbepoetin alfa)|
1743380|NCT00124111|Drug|pegfilgrastim|
1743381|NCT00124111|Drug|cyclophosphamide|
1743382|NCT00124111|Drug|methotrexate|
1743383|NCT00124111|Drug|5-fluorouracil|
1743384|NCT00124124|Drug|KLH; Peptides; Dendritic Cells|Upon entry into the study, patients randomized to the dendritic cell arm will undergo a complete baseline evaluation and leukapheresis 0.5 to 3 x 106 DCs per peptide antigen (total not to exceed 18 x 106 cells) will be administered intradermally as per injection SOP. They will receive up to 3 booster DC injections (total not to exceed 18 x 10 6 cells per injection) at monthly intervals for a total of 4 injections. The booster injections will not contain KLH, as our volunteer studies have shown that priming occurs following a single injection of DCs
1743385|NCT00124124|Drug|KLH, peptides plus Montanide|Patients randomized to the Montanide arm will also undergo complete baseline evaluation but not leukapheresis. The peptides will be mixed with the adjuvant, Montanide, and administered subcutaneously at a dose of 100 microgram of each peptide +100 microgram KLH mixed with an equal volume of Montanide. They will receive up to 3 booster injections at monthly intervals for a total of 4 injections. The booster injections will not contain KLH.
1743386|NCT00124137|Device|Aquadex system|
1743387|NCT00124137|Drug|IV diuretic|
1743388|NCT00124150|Drug|Intravenous magnesium sulfate infusion|80mg per day
1743389|NCT00124163|Procedure|Imaging procedure of CT colonography|
1743390|NCT00124176|Drug|Racemic albuterol (R+S albuterol)|20mg/hr continuous racemic albuterol
1743391|NCT00124176|Drug|Levalbuterol (R albuterol)|10mg/hr continuous nebulized levalbuterol
1743392|NCT00124189|Drug|GRN163L|Weekly intravenous infusion
1743393|NCT00124202|Behavioral|a fatty meal|Approximately one hour before ERCP procedure, patient will have a fatty meal in the study group and normal saline in control group
1743400|NCT00129727|Drug|Paclitaxel|Given intravenously
1743401|NCT00129727|Drug|Carboplatin|Given intravenously
1743402|NCT00129727|Drug|Bevacizumab|Given intravenously
1743403|NCT00129740|Drug|Nilotinib|400 mg orally twice daily
1743404|NCT00129753|Drug|Alemtuzumab (Campath-1H)|Escalating dose 3mg, 10 mg, 30 mg on three consecutive days, then 30 mg three times per week by subcutaneous injections for 12 weeks. Each 30 mg dose will be divided in 2 injections to be administered in each thigh.
1743405|NCT00129766|Biological|motavizumab (MEDI-524)|Motavizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
1743406|NCT00129766|Biological|palivizumab|Palivizumab, 15 mg/kg administered intramuscularly for 5 monthly doses
1743407|NCT00129779|Behavioral|Intermediate care package|
1743408|NCT00129792|Drug|Dietary supplement for weight loss|The dietary supplement being investigated in this study is a natural product designed to reduce metabolic syndrome by decreasing hunger, increasing energy, and improving insulin function.
1743409|NCT00129792|Behavioral|Education and counseling for weight loss|Hour and a half weight loss education session weekly for 12 weeks.
1743410|NCT00129805|Drug|MCI-9042|
1743411|NCT00129805|Drug|Aspirin|
1743412|NCT00129818|Drug|Famciclovir|
1743413|NCT00129831|Drug|QAB149|
1743414|NCT00129844|Drug|Motexafin Gadolinium|
1743415|NCT00129857|Drug|Dexanabinol|
1743416|NCT00129870|Drug|oxaliplatin|
1743417|NCT00129883|Behavioral|Professional education|
1743418|NCT00129883|Behavioral|Implementation of a Critical Care Pathway|
1743419|NCT00129883|Behavioral|Professional audit and feedback|
1743420|NCT00129883|Behavioral|Process analysis and redesign|
1743421|NCT00129896|Drug|Myocet|
1743422|NCT00129896|Drug|Taxotere|
1743423|NCT00129896|Drug|Herceptin|
1743424|NCT00129909|Drug|fixed dose combination therapy|
1743425|NCT00129922|Drug|paclitaxel|
1743426|NCT00129935|Drug|epirubicin|
1743427|NCT00129935|Drug|docetaxel|
1743428|NCT00129935|Drug|capecitabine|
1743429|NCT00129948|Drug|Troxatyl™ (troxacitabine)|
1743430|NCT00129961|Drug|sirolimus|
1743431|NCT00129961|Drug|cyclosporine or tacrolimus|
1743432|NCT00129974|Drug|pemetrexed and gemcitabine|
1743433|NCT00129987|Behavioral|Self management education|
1743434|NCT00130000|Drug|Eculizumab|
1743435|NCT00130013|Drug|Oral Amoxicillin|
1743436|NCT00130078|Drug|1.0% C31G SAVVY vaginal gel|
1743437|NCT00130091|Drug|clonidine|2 mcg clonidine added to local anesthetic
1743438|NCT00130104|Procedure|Transthecal Metacarpal Block|
1743439|NCT00130117|Drug|r-metHuLeptin|Starting dose: 0.08mg/kg once daily Subcutaneous injection.
1743440|NCT00130117|Drug|Oral Contraceptive Pills (OCPs)|Sprintec taken orally once daily.
1743441|NCT00130117|Other|Placebo|placebo (no active medication)
1743442|NCT00130143|Drug|Ethyol (Amifostine)|
1743443|NCT00130156|Drug|Bunazosin|Patients will be randomized to the add-on treatment with Bunazosin (Detantol-R) 3 mg once-daily after breakfast for a total of eight weeks.
1743444|NCT00130156|Drug|Doxazosin|Patients will be randomized to the add-on treatment with Doxazosin (Doxaben XL) 4 mg once-daily after breakfast for a total of eight weeks.
1743445|NCT00130156|Drug|Valsartin|After wash-out period, the eligible subjects will be treated with Valsartin (Diovan) 80 mg as the mono therapy for 5 weeks. If the blood pressures are inadequately responded, then the patients will be randomized to either Bunazosin (Detantol-R) or Doxazosin (Doxaben XL) along with Valsartin as the add-on treatment for 8 weeks.
1743446|NCT00130169|Drug|E7974|Maximum Tolerated Dose defined as 0.35 mg/m^2 administered on Days 1 and 15 only of a 28-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
1743447|NCT00130182|Drug|denufosol tetrasodium (INS37217)|
1743448|NCT00130195|Drug|imatinib|
1743449|NCT00130195|Drug|cyclophosphamide|
1743450|NCT00130195|Drug|daunorubicin|
1743451|NCT00130195|Drug|vincristine|
1743452|NCT00130195|Drug|prednisolone|
1743453|NCT00130195|Drug|methotrexate|
1743454|NCT00130195|Drug|cytarabine|
1743455|NCT00130195|Drug|dexamethasone|
1743456|NCT00130208|Drug|Sulodexide|
1743457|NCT00130221|Drug|2% chlorhexidine gluconate impregnated cloth|
1743458|NCT00130234|Drug|Xolair® (Omalizumab)|
1743459|NCT00130247|Drug|Pyrazinamide|1st line bactericidal agent; dosages are 15-30 mg/kg/d, up to 2 grams (gm)/d.
1743460|NCT00130247|Drug|Rifampin|1st line bactericidal agent which inhibits deoxyribonucleic acid (DNA)-dependent ribonucleic acid (RNA) polymerase; dosages are 10 mg/kg/d (up to 600 mg/d).
1743461|NCT00130247|Drug|Isoniazid|Hydrazide of isonicotininc acid; antimicrobial activity is limited to mycobacteria where it inhibits the synthesis of mycolic acids.
1743462|NCT00130247|Drug|Ethambutol|Mycobacteriostatic agent given to prevent emergence of drug resistance to other 1st line drugs; dosages are 15-25 milligram (mg)/ kilogram (kg)/day (d).
1743463|NCT00130260|Biological|Staph aureus types 5 and 8 conjugate vaccine|each IM dose contains 200 mc total conjugate
1743464|NCT00130260|Biological|placebo|placebo to match StaphVAX
1743465|NCT00130273|Behavioral|Managed problem solving|Participants in the managed problem solving group will have four study visits and will receive three phone calls for the first 3 months of the study, and one phone call every month for the following 9 months. At each study visit, participants will identify barriers to adherence. During the phone calls, participants will be asked about any steps they have taken to improve their adherence. A medication event monitoring system (MEMS) will be used to assess participants' treatment adherence. MEMS uses microelectronic monitors on the caps of medication bottles to record the timing and frequency of bottle openings. Participants whose adherence has decreased or remained the same at the end of 12 months will be evaluated for regimen changes. Blood collection at the beginning and end of the study will be used to measure viral load and CD4 count.
1743466|NCT00130273|Behavioral|Standard care|Participants will receive standard of care for 12 months.
1743467|NCT00130286|Drug|Rosiglitazone|4 mg tablet twice a day x 12 weeks (double-blind phase)
1743468|NCT00130286|Drug|Recombinant human growth hormone + rosiglitazone|Recombinant human growth hormone or placebo 3 mg s.c. x 12 weeks (double-blind phase)
1743469|NCT00130299|Behavioral|low glycemic load diet|
1743470|NCT00130299|Behavioral|low fat diet|
1743471|NCT00130312|Drug|Sulodexide|
1743472|NCT00130325|Drug|Isoniazid|Isoniazid 900mg, tablets, twice a week for 6 months
1743473|NCT00130325|Drug|Isoniazid|INH 900mg twice weekly for 6 months
1743474|NCT00130325|Drug|Placebo of Isoniazid tablets 300mg|Isoniazid BP 0mg twice weekly for 6 months
1743475|NCT00130338|Drug|Rivastigmine|
1743476|NCT00130351|Device|formoterol|
1743477|NCT00130364|Drug|Pimecrolimus|Pimecrolimus 1 % cream
1743478|NCT00130364|Drug|Placebo|Pimecrolimus vehicle cream (placebo)
1743479|NCT00130377|Biological|cell therapy|autologous or allogeneic cells
1743480|NCT00130390|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily for 28 days
1743481|NCT00130390|Other|Placebo|One placebo tablet twice daily for 28 days
1743482|NCT00130403|Drug|risedronate sodium|
1743483|NCT00130416|Behavioral|E-mail coaching to improve patient communication with doctor|
1743484|NCT00130429|Drug|PYM50028|
1743485|NCT00130442|Drug|PI-88 and dacarbazine|190 mg daily by subcutaneous injection for PI-88 and 1000 mg/m2 on day 1 of each 21 day cycle by intravenous infusion
1743486|NCT00130442|Drug|dacarbazine or DTIC|intravenous infusion 1000 mg/m2 on day 1 of every 21 day cycle
1743487|NCT00130455|Drug|escitalopram|
1743488|NCT00130468|Drug|Hyalgan (sodium hyaluronate)|
1743489|NCT00130481|Drug|Atorvastatin 20 mg daily for 3 months|
1743490|NCT00130494|Drug|Zoledronic acid|
1743491|NCT00130507|Drug|Control Group|Vinorelbine 25 mg/m2 iv days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, p.o., b.i.d. days 1-14 each cycle (21 days).
1743492|NCT00130507|Drug|Experimental|Trastuzumab, 4 mg/kg (charge dose in first week); Later 2 mg/kg iv. in following weeks plus Vinorelbine 25 mg/m2 iv days 1 and 8 each cycle (21 days), followed of capecitabine 825 mg/m2, p.o., b.i.d. days 1-14 each cycle (21 days).
1743493|NCT00130520|Drug|bevacizumab|10mg/kg every two weeks IV-bevacizumab
1743494|NCT00130520|Drug|erlotinib|150mg daily by mouth-erlotinib
1743495|NCT00130533|Drug|Capecitabine|1000 mgrs/m2 twice a day, tablets, 8 cycles
1743496|NCT00130546|Device|Paclitaxel-eluting TAXUS(TM)|TAXUS(TM) Paclitaxel-eluting stent
1743497|NCT00130546|Device|Sirolimus eluting Cypher Select(TM)|Sirolimus eluting Cypher Select(TM) stent
1743498|NCT00130559|Procedure|BNP guided diagnostics and initial therapy|BNP guided diagnostics and initial therapy
1743499|NCT00130572|Drug|Pimecrolimus|
1743500|NCT00130585|Behavioral|Controlled diet|
1743501|NCT00130585|Behavioral|folic acid supplement|
1743502|NCT00130585|Behavioral|13C11-labelled folic acid supplement|
1743503|NCT00130598|Drug|NaCl 0.9% i.v. or NaBic 1.4% i.v. or NaBic 1.4% i.v. + NaBic p.o. (Nephrotrans®)|"control group: preventive hydration with 154mEq/l saline at 1ml/kg per hour of 12 hours prior and after the procedure.
7h-sodium bicarbonate: before contrast 3ml/kg NaHCO3 166mEq/l for one hour, followed by NaHCO3 166mEq/l (1ml/kg per hour until 6h after contrast).
short-term sodium bicarbonate: NaHCO3 166mEq/l (3ml/kg) as a bolus 20 minutes before contrast; ingestion of Nephrotrans® (500mg NaHCO3/capsule: 1 capsule/10kg) with 1-2 dl non-sparkling mineral water at the start of the infusion. Ingestion of non-sparkling mineral water in the first 6 hours after contrast."
1743504|NCT00130611|Other|BNP measurement|
1743505|NCT00130611|Other|Clinical examination|
1743506|NCT00130624|Procedure|Multidisciplinary intervention: primary or secondary care|
1743507|NCT00130637|Drug|Daclizumab|
1743508|NCT00130650|Device|Pain Ease|
1743509|NCT00130663|Device|PDA blood pressure screening program and chart reminder|
1743510|NCT00130676|Drug|Mifepristone|daily for 7 days
1743511|NCT00130676|Drug|matching placebo|daily for 7 days
1743512|NCT00130689|Drug|Cetuximab|
1743513|NCT00130702|Drug|gefitinib|gefitinib (Iressa) at a dose of 750 mg, once per day
1743514|NCT00130715|Device|Seprafilm Bioresorbable Membrane|
1743518|NCT00130741|Drug|CHT - herbal therapy|
1743519|NCT00130754|Drug|Thymoglobuline|IV 7.5 mg/kg
1743520|NCT00130767|Drug|finasteride|
1743521|NCT00130780|Drug|Pre-surgical Treatment with Bevacizumab plus Chemotherapy|On Cycle 1 Day 1,patient will receive bevacizumab 15 mg/kg. On Cycle 1 Day 15, patients receive docetaxel (75 mg/m2), cisplatin (75 mg/m2). Cycle 2 begins 21 days after administration of docetaxel and cisplatin in Cycle 1. In Cycles 2 thru 3, patients will receive 2 preoperative 21-day cycles of docetaxel (75 mg/m2), cisplatin (75 mg/m2), and bevacizumab (15 mg/kg), all given on Day 1 of each cycle. The sequence of administration will be docetaxel, followed by cisplatin, followed by bevacizumab according to MSKCC Chemotherapy Guidelines. In Cycle 4 Day 1, patients will receive docetaxel (75 mg/m2) and cisplatin (75 mg/m2). Bevacizumab will not be given with Cycle 4. During Cycle 4, the only scheduled clinic visit will be on Day 1. Surgery will occur at least 42 days after the last treatment with bevacizumab. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
1743588|NCT00131209|Dietary Supplement|fortified spread (RUTF)|
1743589|NCT00131209|Dietary Supplement|maize and soy flour|
1743590|NCT00131222|Procedure|Food supplement: fortified spread|
1743591|NCT00131222|Procedure|Food supplement: maize and soy flour|
1743592|NCT00131235|Drug|Sulfadoxine-pyrimethamine treatment twice during pregnancy|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks.
2 placebo tablets for azithromycin taken at the same time points."
1743655|NCT00131729|Behavioral|Educational programme|
1743656|NCT00131742|Drug|telbivudine|
1743522|NCT00130780|Drug|Pre-Surgical Docetaxel and Cisplatin and Adjuvant Bevacizumab|Patients will receive preoperative 21-day cycles of cisplatin (75 mg/m2) and docetaxel (75 mg/m2) both given on Day 1 of each cycle.Patients will undergo repeat CT imaging after 2 cycles of therapy and patients with at least 10% reduction in bidimensional tumor volume will receive 2 additional neoadjuvant cycles of therapy (total 4 cycles of therapy).Surgery will occur at least 4 weeks after the last treatment with docetaxel and cisplatin.Adjuvant bevacizumab (15 mg/kg q21 days for 1 year, total 18 cycles) will be administered to all patients who undergo resection. Adjuvant bevacizumab will begin between days 42 and 56 after surgery.Patients may be referred for post-operative radiation therapy at the discretion of the treating physician. Every attempt will be made to administer the treatment on schedule. The treatment may be given +/- 3 days, and additionally 2 weeks after it is scheduled, if necessary.
1743523|NCT00130793|Biological|Comparator: zoster vaccine live (Oka/Merck) refrigerated formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Merck) refrigerated formulation at Day 1
1743524|NCT00130793|Biological|Comparator: zoster vaccine live (Oka/Merck) frozen formulation|1 dose of 0.65-mL/dose subcutaneous injection of zoster vaccine live (Oka/Meck) frozen formulation at Day 1
1743525|NCT00130806|Drug|MK0478 (muraglitazar)|
1743526|NCT00130806|Drug|Comparator: placebo|
1743527|NCT00130819|Behavioral|Clinic-based substance abuse treatment with buprenorphine|Subjects receive integrated opioid-dependence treatment with buprenorphine/naloxone at the HIV clinic
1743528|NCT00130819|Behavioral|Case management and referred substance abuse treatment|Subjects receive case management and referral to an off-site opioid treatment program for their opioid dependence
1743529|NCT00130832|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Three doses of rotavirus vaccine, live, oral, pentavalent. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
1743530|NCT00130832|Biological|Comparator: Oral Poliovirus Vaccine (OPV)|Three doses OPV. Dose 1 was given on Day 1, Dose 2 was given 56 to 84 days post Dose 1, and Dose 3 was given 56 to 84 days post Dose 2.
1743531|NCT00130832|Biological|Comparator: Oral Poliovirus Vaccine (OPV) (staggered)|Three doses OPV. Dose 1 was given 14 to 28 days post Dose 1 of RotaTeq, Dose 2 was given 14 to 28 days post Dose 2 of RotaTeq, and Dose 3 was given 14 to 28 days post Dose 3 of RotaTeq.
1743532|NCT00130845|Drug|Octreotide Acetate in Microspheres|
1743533|NCT00130845|Drug|Placebo|
1743534|NCT00130858|Drug|Topotecan|
1743535|NCT00130858|Drug|Carboplatin|
1743536|NCT00130871|Drug|levosimendan|
1743537|NCT00130884|Drug|levosimendan|
1743538|NCT00130897|Drug|Sutent|Sutent, 25, 37.5. or 50 mg daily
1743539|NCT00130910|Drug|Albendazole|Albendazole 400mg x 3 first dose observed
1743540|NCT00130910|Drug|Placebo|Albendazole Placebo 400mg x 3 first dose observed
1743541|NCT00130923|Drug|Risperidone Long Acting|Dose 25.00, 37.50 or 50.00 mg q two weeks
1743542|NCT00130923|Drug|oral risperidone|0.50-6.00 mg oral risperidone daily
1743543|NCT00130936|Drug|Epirubicin|
1743544|NCT00130936|Drug|Carboplatin|
1743545|NCT00130936|Drug|Capecitabine|
1743546|NCT00130949|Drug|ALGRX 4975|
1743547|NCT00130962|Drug|ALGRX 4975|
1743548|NCT00130975|Drug|Candesartan|
1743549|NCT00130988|Behavioral|DEPENAS cognitive and behavioural techniques|
1743550|NCT00131001|Procedure|contrast-enhanced magnetic resonance angiography|
1743551|NCT00131027|Drug|Cyclophosphamide|
1743552|NCT00131027|Drug|Daunorubicin|
1743553|NCT00131027|Drug|Vincristine|
1743554|NCT00131027|Drug|Prednisolone|
1743555|NCT00131027|Drug|L-asparaginase|
1743556|NCT00131027|Drug|Cytarabine|
1743557|NCT00131027|Drug|Etoposide|
1743558|NCT00131027|Drug|Dexamethasone|
1743559|NCT00131027|Drug|Methotrexate|3 g/sqm (high dose)
1743560|NCT00131027|Drug|Mercaptopurine|
1743561|NCT00131027|Drug|Doxorubicin|
1743562|NCT00131027|Drug|Methotrexate|0.5 g/sqm (intermediate dose)
1743563|NCT00131040|Drug|Aprotinin|
1743564|NCT00131053|Drug|Methotrexate|
1743565|NCT00131053|Drug|Prednisolone|
1743566|NCT00131053|Drug|Dexamethasone|
1743567|NCT00131053|Drug|Vincristine|
1743568|NCT00131053|Drug|Pirarubicin|
1743569|NCT00131053|Drug|Cyclophosphamide|
1743570|NCT00131053|Drug|L-asparaginase|
1743571|NCT00131053|Drug|Cytarabine|
1743572|NCT00131053|Drug|Hydrocortisone|
1743573|NCT00131053|Drug|Mercaptopurine|
1743574|NCT00131066|Other|Follow up from previous treatment with MEDI-507|There will be no investigational drugs administered under this protocol.
1743575|NCT00131079|Behavioral|Experimental Programme for Physical Activity Promotion|"General practitioner's (GP) physical activity (PA) assessment and advise using a web-based software that prompted open questions to elicit believes about benefits of PA, graphical information about risks of inactivity and examples of type sentences to provide medical advise.
Educational materials summarizing benefits, risks and motivation.
Prescription: 15 minutes educational session in which GP negotiated a goal, addressed possible barriers and anticipated solutions using web-based tools for lack of time, community resources, and health problems. Finally, they designed a 3-month PA activity plan that derived in a standardized printed prescription of frequency, duration, intensity and progression of a selected PA or exercise that included a self-monitoring log."
1743576|NCT00131079|Behavioral|Control|Control general practitioners assessed physical activity and performed recruitment in a similar way but offered usual care
1743577|NCT00131092|Behavioral|The Stanford Active Choices program|
1743578|NCT00131092|Behavioral|The TLC system|
1743579|NCT00131105|Behavioral|The Stanford Active Choices program|
1743580|NCT00131118|Drug|Zoledronic Acid|
1743581|NCT00131131|Behavioral|Exercise|
1743582|NCT00131144|Drug|Octreotide Acetate in Microspheres 20 mg|
1743583|NCT00131144|Drug|Octreotide Acetate in Microspheres|
1743584|NCT00131144|Drug|Placebo|
1743585|NCT00131157|Procedure|expert support for interpretation of spirometry|
1743586|NCT00131170|Procedure|paravertebral block|
1743593|NCT00131235|Drug|Sulfadoxine-pyrimethamine at 4-week intervals|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.
2 placebo tablets for azithromycin taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
1743594|NCT00131235|Drug|Sulfadoxine-pyrimethamine every 4 weeks + azithromycin twice|"Sulfadoxine-pyrimethamine, 3 tablets (each containing 500mg of sulfadoxine and 25mg of pyrimethamine), taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and then at 4 week intervals until 37.0 gestation weeks.
2 azithromycin tablets (each 500 mg) taken once at antenatal care enrolment (14.0-25.9 gestation weeks) and another time between 28.0 and 33.9 gestation weeks."
1743595|NCT00131248|Drug|Metaclopramide|
1743596|NCT00131248|Drug|Ranitidine|
1743597|NCT00131248|Drug|placebo|
1743598|NCT00131261|Drug|PXD101|
1743599|NCT00131261|Drug|Dexamethasone|
1743600|NCT00131274|Drug|Imatinib Mesylate (Gleevec)|
1743601|NCT00131287|Drug|Extract of Agaricus blazei Murill|
1743602|NCT00131300|Device|Synvisc (hylan G-F 20)|
1743603|NCT00131313|Drug|Nipent, Cytoxan, Rituxan|
1743604|NCT00131326|Device|Synvisc (hylan G-F 20)|
1743605|NCT00131339|Behavioral|Cognitive behavioral therapy|
1743606|NCT00131339|Drug|D-cycloserine|
1743607|NCT00131352|Device|hylan G-F 20|Single injection of 6 mL of hylan G-F 20 (Synvisc).
1743608|NCT00131352|Other|Phosphate Buffered Saline|Single injection of 6 mL phosphate buffered saline.
1743609|NCT00131365|Device|ExAblate 2000|
1743610|NCT00131378|Drug|Nutropin AQ growth hormone|Participants will give themselves injections of growth hormone every night for 6 months.
1743611|NCT00131378|Drug|Placebo Growth Hormone|Participants will give themselves injections of placebo growth hormone every night for 6 months.
1743612|NCT00131391|Drug|Comparator: taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule. 52 week treatment period.
1743613|NCT00131391|Drug|Comparator: placebo|Placebo capsule once daily . 52 week treatment period.
1743614|NCT00131404|Drug|taranabant|taranabant 2 mg capsule, 4 mg capsule, 6 mg capsule once daily. 52 week treatment period.
1743615|NCT00131404|Drug|Comparator: Placebo|Placebo capsule once daily. 52 week treatment period.
1743616|NCT00131417|Drug|ready-to-use therapeutic food|
1743617|NCT00131430|Drug|taranabant|
1743618|NCT00131443|Drug|Topiramate|
1743619|NCT00131456|Drug|Venlafaxine|375mg/day
1743620|NCT00131456|Drug|Placebo|Placebo
1743621|NCT00131469|Drug|Teriparatide (FORTEO)|Teriparatide (FORTEO) 20mcg, subcutaneous injection, once daily
1743622|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous injection of Chrysalin 3 micrograms at the fracture site at the time of surgery.
1743623|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 1 microgram at the fracture site at the time of surgery.
1743624|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 10 micrograms at the fracture site at the time of surgery.
1743625|NCT00131482|Drug|Chrysalin|Patients were treated with a single percutaneous administration of Chrysalin 30 micrograms at the fracture site at the time of surgery.
1743626|NCT00131482|Drug|Placebo|Patients were treated with a single percutaneous administration of placebo at the fracture site at the time of surgery.
1743627|NCT00131495|Drug|Testosterone (transdermal patches)|Testosterone patch (300mcg/day, changed twice a week for one year
1743628|NCT00131495|Drug|Placebo patch|placebo patch changed twice a week for one year
1743629|NCT00131508|Drug|Glutamine|0.6 gm/kg of oral glutamine per day, in two doses for one year.
1743630|NCT00131508|Drug|Placebo|Placebo
1743631|NCT00131521|Drug|mucomyst|
1743632|NCT00131521|Drug|sodium chloride (saline)|
1743633|NCT00131534|Behavioral|Individual therapy|Stage-based individual therapy for trauma survivors
1743634|NCT00131534|Behavioral|Group therapy|Stage-based group therapy for trauma survivors
1743635|NCT00131547|Behavioral|Dietary Counseling|Dietary Counseling, use of a food diary and pedometer
1743636|NCT00131560|Genetic|VRX496-Modified Autologous T cells|Genetic: Anti-HIV antisense
1743637|NCT00131573|Device|bion|battery powered bion microstimulator
1743638|NCT00131599|Drug|5FU/LV|5FU/LV
1743639|NCT00131612|Drug|FEC 100|5-fluoruracil, epirubicin and cyclophosphamide every three weeks for six treatments
1743640|NCT00131625|Behavioral|Health education according to WHO recommendations|
1743641|NCT00131638|Drug|Placebo|Single IV dose of placebo at 120 μg/kg, 3 days before the start of Radiotherapy, plus 6 once weekly placebo doses at the same dose during a 6-week radiotherapy / chemotherapy course.
1743642|NCT00131638|Drug|Palifermin|Single IV dose of palifermin at 120 μg/kg, 3 days before the start of radiotherapy plus 6 once weekly palifermin doses at the same dose level during a 6-week Radiotherapy / chemotherapy course
1743643|NCT00131651|Drug|ATN-161|
1743644|NCT00131664|Drug|Avandamet|Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily compared to Avandia 4 mg and Amaryl 1 mg once daily over 6 months or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
1743645|NCT00131664|Drug|Avandia and Amaryl|Avandia 4 mg and Amaryl 1 mg once daily compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily, or compared to Metformin 500 mg twice daily up to 1000 mg over 6 months.
1743646|NCT00131664|Drug|Metformin|Metformin 500 mg twice daily up to 1000 mg over 6 months compared to Avandia 4 mg and Amaryl 1 mg once daily or compared to Avandamet 2 / 500 mg twice daily titration up to 4 mg / 1000 mg twice daily
1743647|NCT00131677|Drug|tenofovir disoproxil fumarate|study product taken daily
1743648|NCT00131677|Drug|placebo|study product taken daily
1743649|NCT00131690|Drug|Nescafé Gold Blend (exposed)|
1743650|NCT00131690|Drug|Nescafé Decaffeinated (controls)|
1743651|NCT00131703|Drug|Amodiaquine|
1743652|NCT00131703|Drug|Sulphadoxine-pyrimethamine|
1743653|NCT00131703|Drug|Chloroquine|
1743654|NCT00131716|Drug|sulfadoxine-pyrimethamine|
1743659|NCT00131768|Device|Synvisc (hylan G-F 20)|
1743660|NCT00131781|Behavioral|Cognitive Therapy|
1743661|NCT00131781|Behavioral|Supportive Therapy|
1743662|NCT00131794|Biological|BCG|
1743663|NCT00131807|Procedure|Blood Pressure Measurement|
1743664|NCT00131807|Procedure|Questionnaire|
1743665|NCT00131820|Biological|Typhoid Vi vaccine|
1743666|NCT00131820|Biological|Hepatitis A (control)|
1743667|NCT00131833|Biological|Typhoid Vi vaccine|
1743668|NCT00131833|Biological|Meningococcal A (control)|
1743669|NCT00131846|Drug|Thiazide diuretics|Any dosage, frequency, and duration
1743670|NCT00131846|Drug|No diuretics|Any antihypertensive regimen other than diuretics
1743671|NCT00131859|Procedure|Diffusion-tensor imaging|Obtain a Diffusion tensor MRI of brain.
1743672|NCT00131872|Device|Expedial Vascular Access Graft|
1743673|NCT00131885|Dietary Supplement|Placebo Control (Placebo Herb)|Placebo herb three times daily (ground cellulose) for 4-6 weeks
1743674|NCT00131885|Dietary Supplement|St. John's Wort|St. John's Wort (Hypericum perforatum) orally or 4-6 weeks
1743675|NCT00131885|Drug|Levonorgestrel|Levonorgestrel in a single oral dose
1743676|NCT00131898|Procedure|Surgical Resection|
1743677|NCT00131898|Procedure|Intensity Modulated Radiation Therapy (IMRT)|
1743678|NCT00131911|Drug|sorafenib tosylate|400 mg given orally
1743679|NCT00131924|Biological|esterified estrogens|
1743680|NCT00131937|Drug|sorafenib tosylate|Given orally
1743681|NCT00131950|Other|physiologic testing|
1743682|NCT00131950|Other|study of socioeconomic and demographic variables|
1743683|NCT00131950|Procedure|breast imaging study|
1743684|NCT00131950|Procedure|study of high risk factors|
1743685|NCT00131963|Drug|cyclophosphamide|Given IV
1743686|NCT00131963|Drug|doxorubicin|Given IV
1743687|NCT00131963|Drug|paclitaxel|Given IV
1743688|NCT00131989|Drug|sorafenib tosylate|Given orally
1743689|NCT00131989|Other|pharmacological study|Correlative studies
1743690|NCT00131989|Other|laboratory biomarker analysis|Correlative studies
1743691|NCT00132002|Drug|vorinostat|Given PO
1743692|NCT00132002|Other|laboratory biomarker analysis|Correlative studies
1743693|NCT00132015|Drug|tanespimycin|
1743694|NCT00132028|Drug|vorinostat|Given orally
1743695|NCT00132028|Other|laboratory biomarker analysis|Correlative studies
1743696|NCT00132041|Procedure|radiofrequency ablation|
1743697|NCT00132054|Drug|amrubicin hydrochloride|
1743698|NCT00132054|Drug|irinotecan hydrochloride|
1743699|NCT00132067|Drug|vorinostat|Given orally
1743700|NCT00132080|Drug|Steroids|This study evaluates the efficacy and safety of pulse steroid therapy, when added to conventional treatment with IVIG plus aspirin, in treatment of children with acute Kawasaki disease.
1743701|NCT00132093|Drug|Eplerenone|
1743702|NCT00132106|Drug|phentolamine|
1743703|NCT00132119|Drug|nalmefene HCl|Nalmefene HCl film-coated tablets, 20 or 40 mg, administered orally once daily for 10 weeks.
1743704|NCT00132119|Other|Placebo|Placebo tablet
1743705|NCT00132132|Behavioral|Behavioral education program|Monthly 4 hr session which incorporates: exercise, empowerment, education, and incentives
1743706|NCT00132145|Behavioral|Vascular Management Program|
1743707|NCT00132145|Behavioral|Clinical Care Coordinators|
1743708|NCT00132145|Behavioral|Web-based Vascular Tracker for Patient and Physician|
1743709|NCT00132145|Behavioral|Automated Telephone Reminder System|
1743710|NCT00132158|Drug|Irinotecan (Camptosar), Gefitinib (Iressa)|See Detailed Description for treatment plan.
1743711|NCT00132171|Drug|Sequential therapy|
1743712|NCT00132184|Drug|Vitamin D|
1743713|NCT00132197|Behavioral|Cognitive Behavioral Therapy|1. Specialised treatment includes cognitive groups therapy in 9 modules of 3,5 hours within 3½ months, in all 31,5 hours, consultancy over the phone to the patients' GPs and tuition in groups headed by an experienced social worker. Detailed treatment manuals are worked out separately for each module. Experienced psychotherapists (clinical psychologists and psychiatrists), who also function as consultants, will do the treatment. The Ph.D.-student functions as co-therapist.
1743714|NCT00132197|Procedure|Recommendation of care (letter to general practitioner [GP])|After the diagnostic assessment the patient does not receive any treatment offers at the research clinic, but the patient and the GP will be informed about the diagnosis, and the GP will receive advice on further treatment possibilities.
1743715|NCT00132210|Drug|pegylated interferon|Pegylated interferon alfa-2a or -2b in standard dosage Ribavirin in case of genotype 1 or 4 at 1000 or 1200 mg/d according to body weight ist recommended.
1743716|NCT00132223|Drug|Contrast agent|
1743717|NCT00132236|Drug|nicotine sublingual tablets|
1743718|NCT00132236|Behavioral|low and high behavior support|
1743719|NCT00132262|Behavioral|Brief intervention based on motivational interviewing|The intervention was an approximately 30 minute discussion about alcohol-related risk behaviors and motivation to change
1743720|NCT00132262|Behavioral|Standard Care including referral for treatment|Standard hospital care provided the patient with information and referral for treatment as necessary.
1743721|NCT00132275|Drug|Amoxicillin potassium clavulanate|
1743722|NCT00132288|Behavioral|Motivational support|Participants in the PALS program at SE Seattle Senior Center are assigned a volunteer phone buddy who uses motivational interviewing techniques during bi weekly or monthly phone calls to encourage the participant to become more physically active.
1743723|NCT00132288|Behavioral|PALS - Physical activity for lifetime success|Referral by a primary care provider to a community based support program to enhance uptake or maintenance of physical activity by the participants.
1743724|NCT00132301|Drug|Docetaxel|Chemotherapy agent
1743725|NCT00132301|Drug|Prednisone|steroid in combination with chemotherapy agent
1743726|NCT00132314|Drug|IM risperidone|long-acting injectable risperidone
1743727|NCT00132314|Drug|oral antipsychotic medication|doctor's choice (excluding other long-acting injectable medications but not specifying any particular oral agents or dosages)
1743728|NCT00132340|Device|Electrodes|
1743729|NCT00132379|Drug|ABR-217620|10.3, 16.5 or 22 mcg/kg, IV, daily 5 minute bolus injection for 4 consecutive day per cycle; up to 6 cycles
1743730|NCT00132379|Drug|docetaxel|75mg/m^2, IV, single 60 minute infusion, beginning on Day 5 then every third week
1743731|NCT00132392|Drug|ALGRX 4975|
1743732|NCT00132405|Drug|ALGRX 3268|
1743733|NCT00132418|Drug|Enbrel|Enbrel
1743734|NCT00132418|Drug|Placebo|Placebo
1743735|NCT00132431|Drug|Sensipar|
1743736|NCT00132444|Drug|topical vaginal application of UC-781 gel|UC-781 gel (arms 1 and 2) or placebo (arm 3) applied vaginally twice daily for 14 days
1743737|NCT00132457|Procedure|Self-collected vaginal swab for chlamydia testing|
1743738|NCT00132470|Drug|AX200 (G-CSF)|
1743739|NCT00132483|Behavioral|Instruction in physical training program|Instruction in physical training program.
1743740|NCT00132496|Drug|rabeprazole sodium|administered orally and once daily to patients randomized to receive either 10 mg or 20 mg.
1743741|NCT00132509|Drug|DFIL|Alteplase : 0.8mg/kg over 90 minutes
1743742|NCT00132509|Drug|NINDS|Alteplase : 0.9mg/kg over 60 minutes
1743743|NCT00132522|Drug|EMD 273066|"dose-escalating study and subjects enrolled in the study may receive a maximum of 6 cycles of the assigned regimen over 18 weeks. Each cycle will be 3 weeks (21 days) with cyclophosphamide on Day 1 and EMD 273066 on Days 2 to 4, followed by 17 days with no experimental pharmaceutical product.
Each cycle, cyclophosphamide at 300 mg/m2 given per institutional guidelines 1 day (22-28 hours) prior to 3 consecutive days of EMD 273066 as a 4-hour IV infusion at 1 of 6 planned dose levels of 0.5, 1, 2, 3, 4, or 6 mg/m2."
1743744|NCT00132535|Drug|sulfadoxine-pyrimethamine intermittent preventive treatment|
1743745|NCT00132535|Drug|chloroquine|
1743746|NCT00132548|Drug|Pyrimethamine/sulfadoxine|
1743747|NCT00132548|Drug|Amodiaquine|
1743748|NCT00132548|Drug|Artesunate|
1743749|NCT00127114|Drug|Amantadine|
1743750|NCT00127114|Drug|Placebo|
1743751|NCT00132561|Drug|Sulfadoxine/pyrimethamine and artesunate|
1743752|NCT00132574|Behavioral|Minimization of milk and dairy products in the diet|
1743753|NCT00132587|Device|cement Palacos R40 and LV40|
1743754|NCT00132600|Drug|bacitracin (allergen)|
1743755|NCT00132613|Procedure|Observation alone after pericardial drainage|
1743756|NCT00132613|Drug|Pericardial instillation of bleomycin after drainage|
1743757|NCT00132626|Procedure|[123I]ß-CIT and SPECT imaging|
1743758|NCT00132639|Drug|Preoperative docetaxel-cisplatin combination chemotherapy|Preoperative docetaxel-cisplatin combination chemotherapy
1743759|NCT00132639|Drug|Preoperative docetaxel monotherapy|Preoperative docetaxel monotherapy
1743760|NCT00132652|Drug|Lamivudine|
1743761|NCT00132652|Drug|Telbivudine|
1743762|NCT00132665|Procedure|A: Radiotherapy alone|Procedure/Surgery: A: Radiotherapy alone
1743763|NCT00132665|Drug|B: CBDCA and Radiotherapy|Drug: B: CBDCA and Radiotherapy
1743764|NCT00132678|Drug|Risperdal Consta|12.5, 25, 37.5 or 50mg intramuscular (IM) injection every 2 weeks
1743765|NCT00132678|Drug|Placebo|Matching placebo intramuscular (IM) injection every 2 weeks
1743766|NCT00132691|Drug|fluocinolone acetonide intraocular implant|RETISERT™ (fluocinolone acetonide intravitreal implant) 0.59 mg is a sterile implant designed to release fluocinolone acetonide locally to the posterior segment of the eye at a nominal initial rate of 0.6 μg/day, decreasing over the first month to a steady state between 0.3-0.4 μg/day over approximately 30 months.
1743767|NCT00132691|Drug|oral corticosteroid with immunosuppressive agents as needed|Prednisone
1743768|NCT00132704|Radiation|Ionizing radiation (IR) therapy|Tumors will be sliced into 0.5cm fragments, incubated in culture medium and then irradiated to evaluate the kinetics and dose-dependencies of the endothelial apoptotic response. We will irradiate tumor fragments ex vivo at 0, 7, 13, 15, 17, and 25 Gy.
1743769|NCT00132704|Radiation|Ionizing radiation (IR)|Tissue fragments of a total quantity of at least a 4x4x4 cm3 will be required. For each tumor a paraffin block will also be made for routine staining and IHC. Endothelial cell populations (at least 500 cells) will then be exposed to radiation at 0, 7, 11, 13, 15, 17, and 25 Gy and harvested at 4, 5 and 8 hours post IR.
1743770|NCT00132717|Drug|MK0653A (ezetimibe [+] simvastatin)|
1743771|NCT00132717|Drug|Comparator: atorvastatin|
1743772|NCT00132717|Drug|Comparator: fluvastatin|
1743773|NCT00132717|Drug|Comparator: lovastatin|
1743774|NCT00132717|Drug|Comparator: pravastatin|
1743775|NCT00132717|Drug|Comparator: rosuvastatin|
1743776|NCT00132717|Drug|Comparator: simvastatin|
1743777|NCT00132730|Drug|MK-0873 2.5 mg|
1743778|NCT00132730|Drug|MK-0873 1.25 mg|
1743779|NCT00132730|Drug|MK-0873 0.75 mg|
1743780|NCT00132730|Drug|Placebo to MK-0873|
1743781|NCT00132730|Drug|Usual Care|
1743782|NCT00132743|Device|Stent|Stent
1743783|NCT00132743|Behavioral|Supervised Exercise Therapy|Supervised exercise therapy, three times per week
1743784|NCT00132743|Drug|Cilostazol|Cilostazol, 100 mg twice a day
1743785|NCT00132756|Drug|Doxil and Estramustine|
1743786|NCT00132769|Drug|MK-0873|MK-0873 1.25 mg twice daily for 12 weeks
1743787|NCT00132769|Drug|Comparator: Placebo|Matching placebo to MK-0873 1.25 mg twice daily for 12 weeks
1743788|NCT00132795|Behavioral|Daily monitoring of alcohol & drug use, & therapy skills|Comparison(s): patients completing group CBT for substance abuse will be randomly assigned to two conditions. In one condition, patients will have unlimited access to the therapeutic telephone system for 4 months. The other condition is standard care (i.e., no formal relapse prevention).
1743789|NCT00132795|Behavioral|control group|standard care (no added treatment)
1743790|NCT00132808|Drug|Zoledronic Acid|Zoledronic acid 5 mg intravenous
1743791|NCT00132808|Drug|Placebo|Physiologic 0.9% normal saline
1743792|NCT00132821|Drug|Bupropion|Days 1-3, 150 mg Bupropion in am; days 4-63, 300 mg Bupropion (150 mg in am and 150 mg in pm)
1743793|NCT00132821|Drug|Transdermal Nicotine Patch|21-mg nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg patch applied in AM for 2 weeks; 7-mg patch applied in AM for 1 week
1743920|NCT00137683|Behavioral|one-on-one education, group education, small media|
1743794|NCT00132821|Drug|Placebo Bupropion|Days 1-3, 150 mg placebo Bupropion in am; days 4-63, 300 mg placebo Bupropion (150 mg in am and 150 mg in pm)
1743795|NCT00132821|Drug|Placebo transdermal nicotine patch|21-mg placebo nicotine patch applied in AM for 6 weeks, starting on the morning of quit day; 14-mg placebo patch applied in AM for 2 weeks; 7-mg placebo patch applied in AM for 1 week
1743796|NCT00132834|Device|R-Tube or EcoScreen|Device for collection of exhaled breath condensates (EBC) collection (i.e. condensing and collecting breath vapor from a cold, solid surface)
1743797|NCT00132847|Biological|German Cockroach Allergen extract|
1743798|NCT00132860|Drug|azithromycin|
1743799|NCT00132873|Drug|Xyrem (sodium oxybate) oral solution|Xyrem (sodium oxybate) oral solution
1743800|NCT00132886|Drug|tolvaptan|
1743801|NCT00136617|Drug|chlordiazepoxide|
1743802|NCT00136643|Drug|Invisible Condom®|
1743803|NCT00136656|Drug|antibiotic|cephalosporine by oral route : cefixime
1743804|NCT00136656|Drug|antibiotics|cephalosporine : ceftriaxone by intra venous route and cefixime by oral route
1743805|NCT00136669|Procedure|Acupuncture|
1743806|NCT00136682|Drug|patient-controlled epidural analgesia (PCEA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
1743807|NCT00136682|Drug|patient-controlled intravenous analgesia (PCA)|During the consent process you will be given a patient data sheet to assess your baseline pain and itchiness. While in the hospital you will be given a patient data sheet to fill out information regarding pain, nausea, when you passed gas, and when you ate food. This will be done once a day by a research assistant or by the research investigators.
1743808|NCT00136695|Drug|anastrozole|1 mg QD
1743809|NCT00136708|Procedure|Neonatal Resuscitation|
1743810|NCT00136734|Drug|Methylphenidate|
1743811|NCT00136734|Other|placebo|placebo
1743812|NCT00136747|Drug|Memantine|Two capsules of Memantine twice daily for 12 days.
1743813|NCT00136747|Drug|bupropion|
1743814|NCT00136747|Drug|placebo|
1743815|NCT00136760|Drug|Bupropion|Contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
1743816|NCT00136760|Drug|Contingent reinforcement plus placebo|contingent reinforcement plus placebo (3 weeks)
1743817|NCT00136760|Drug|non-contingent reinforcement plus bupropion|non-contingent reinforcement plus bupropion (300 mg/day for 3 weeks)
1743818|NCT00136760|Drug|Non-contingent reinforcement plus placebo|Non-contingent reinforcement plus placebo
1743819|NCT00136773|Drug|amlodipine/benazepril|
1743820|NCT00136786|Drug|Memantine|
1743821|NCT00136799|Drug|Fluvastatin|
1743822|NCT00136812|Behavioral|stage-tailored intervention|This intervention consists of nicotine patch therapy during hospitalization; a stage-based self-help manual; an individualized, expert-system, feedback report at intake, 3 months and 6 months post-hospitalization with carbon copies sent to participants' outpatient clinicians; and an individual 30-min smoking cessation counseling sessions during hospitalization. Additionally, up to 10 weeks of nicotine patch is provided to intervention participants intending to stay quit following hospital discharge.
1743823|NCT00136825|Drug|N-Acetylcysteine|
1743824|NCT00136825|Drug|Placebo|
1743825|NCT00136838|Behavioral|Neutral or active cigarette cues|Packets of cigarettes or cigarette smoke.
1743826|NCT00136851|Drug|amlodipine besylate/benazepril hydrochloride|
1743827|NCT00136864|Procedure|PET Diagnostic Imaging|Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
1743828|NCT00136877|Procedure|(adeno)tonsillectomy|
1743829|NCT00136890|Procedure|PET Imaging|Patients randomized to PET staging will undergo FDG-PET or PET-CT as well as some form of cranial imaging (CT or MRI)
1743832|NCT00136916|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
1743833|NCT00136916|Drug|Subcutaneous insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
1743834|NCT00136929|Drug|Thrombolytic therapy|
1743835|NCT00136929|Procedure|Percutaneous coronary intervention (PCI)|
1743836|NCT00136942|Drug|Atorvastatin|
1743837|NCT00136955|Drug|Irinotecan|An Open Labeled, Single-Arm, Multicentre Phase II Study To Evaluate The Efficacy And Safety Of Weekly Irinotecan (60mg/sqm, D1, 8, 15) Plus Cisplatin (60mg/sqm, D1) As First-Line Chemotherapy For Advanced Or Recurrent Squamous Cell Carcinoma Of The Uterine Cervix
1743838|NCT00136968|Drug|Voriconazole|
1743839|NCT00136981|Drug|torcetrapib/atorvastatin|
1743840|NCT00136981|Drug|atorvastatin|
1743841|NCT00136994|Drug|Ziprasidone|
1743842|NCT00137007|Drug|Azithromycin|
1743843|NCT00137007|Drug|Ampicillin/sulbactam|
1743844|NCT00137020|Drug|ziprasidone|
1743845|NCT00137033|Drug|Celecoxib|
1743846|NCT00137033|Drug|Naproxen|
1743847|NCT00137033|Drug|ASA|
1743848|NCT00137046|Drug|Subcutaneous Insulin|Subcutaneous insulin with dose adjusted according to premeal blood glucose
1743849|NCT00137046|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose
1743850|NCT00137059|Drug|acetaminophen sustained-release|
1743851|NCT00137072|Drug|Viagra (Sildenafil Citrate) 100 mg|
1743852|NCT00137085|Drug|ketamine|
1743853|NCT00137098|Drug|Caffeine|
1743854|NCT00137111|Drug|Prednisone, Dexamethasone, Vincristine, Daunorubicin|See Detailed Description sections for details on treatment interventions.
1743855|NCT00137111|Drug|Doxorubicin, L-asparaginase, PEG-L-asparaginase, Erwinia asparaginase|See Detailed Description sections for details on treatment interventions.
1743856|NCT00137111|Drug|Methotrexate, Cyclophosphamide, Cytarabine, Etoposide|See Detailed Description sections for details on treatment interventions.
1743857|NCT00137111|Drug|Mercaptopurine, Imatinib|See Detailed Description sections for details on treatment interventions.
1743858|NCT00137111|Procedure|chemotherapy, intrathecal chemotherapy|See Detailed Description sections for details on treatment interventions.
1743859|NCT00137111|Procedure|steroid therapy, hematopoietic stem cell transplantation|See Detailed Description sections for details on treatment interventions.
1743860|NCT00137124|Drug|L-Arginine|oral administration of L-arginine for 4 weeks
1743861|NCT00137137|Procedure|Placement of the mini-screw|
1743862|NCT00137150|Procedure|Placement of implants|
1743863|NCT00137163|Device|Dermafill Dressing|
1743864|NCT00137176|Drug|Rebif|Rebif 44mcg TIW
1743865|NCT00137189|Procedure|Resource-oriented music therapy|
1743866|NCT00137189|Procedure|Standard care|
1743867|NCT00137202|Drug|Ondansetron (Zofran)|
1743868|NCT00137202|Drug|Diphenhydramine (Benadryl)|
1743869|NCT00137215|Device|Silverlon|dressing for donor site mamagement
1743870|NCT00137228|Procedure|figure-of-eight hand measurements|
1743871|NCT00137228|Procedure|water volumetry hand measurements|
1743872|NCT00137254|Drug|Insulin|IV insulin
1743873|NCT00137254|Drug|Stable Isotopes|IV administration of stable isotopes
1743874|NCT00137254|Drug|Indocyanine Green|IV administration of ICG
1743875|NCT00137267|Behavioral|Time limited case management|This group will receive treatment as usual on Acute Psychiatry and at the Day Treatment Center along with an enhanced Time Limited Case Management community linkage intervention (TLC). Patients assigned to TLC will be offered enhanced services that begin on Acute Psychiatry and continue for a total of eight weeks through the community and Day Treatment Center transition.
1743876|NCT00137267|Behavioral|Health Education|This group will receive treatment as usual in Acute Psychiatry and at the Day Treatment Center in addition to participating in four group and one individual health education sessions (i.e., the attention control group). The length of the health education sessions (four group sessions and one individual session) will match the amount of attention provided to the treatment group. The health education sessions will cover topics such as nutrition, disease prevention, injury prevention, and healthy aging.
1743877|NCT00137280|Behavioral|Collaborative Chronic Illness Care Model|A care model that integrates greater availability of clinical information, reorganizes the practice system and provider roles, fosters care coordination, and focuses on evidence-based protocols--specifically supported employment and wellness services for individuals with schizophrenia.
1743878|NCT00137293|Drug|GAP-486 (ZP-123)|
1743879|NCT00137293|Drug|0.9% Sodium Chloride, USP|
1743880|NCT00137306|Procedure|Facilitate evidence-based treatment for depression|
1743881|NCT00137319|Device|Impedance threshold device|
1743882|NCT00137332|Drug|GAP-486 (ZP-123)|
1743883|NCT00137332|Drug|0.9% Sodium Chloride, USP|
1743884|NCT00137345|Drug|sirolimus|
1743885|NCT00137358|Procedure|Radiation Therapy|
1743886|NCT00137358|Drug|Cisplatin|
1743887|NCT00137358|Drug|Amifostine|
1743888|NCT00137371|Drug|PVC (daily for 21 days, 7 days off)|
1743889|NCT00137371|Drug|PVC (twice weekly)|
1743890|NCT00137397|Drug|Tolterodine ER|
1743891|NCT00137397|Drug|Placebo|
1743892|NCT00137410|Drug|Celebrex|
1743893|NCT00137423|Drug|SU011248 (sunitinib)|37.5 mg/day, oral, continuous daily dosing
1743894|NCT00137436|Drug|Docetaxel|Docetaxel Phase 1 - escalating doses (60 and 75 mg/m2), intravenous therapy (IV), administered every 3 weeks. Phase 2 - Phase 1 optimal combination dose (75 mg/m2, IV, every 3 weeks).
1743895|NCT00137436|Drug|Prednisone|Prednisone Phase1/2 - 5 mg twice a day (BID), oral.
1743896|NCT00137436|Drug|SU011248|SU011248 Phase 1 - escalating doses (12.5, 37.5, and 50 mg), oral, administered on a 2-weeks on, 1-week off daily regimen (Schedule 2/1). Phase 2 - Phase 1 optimal combination dose (37.5 mg/day, oral, Schedule 2/1).
1743897|NCT00137449|Drug|SU011248|37.5 mg once daily on a continuous daily dosing schedule. Study medication continued as long as patient was obtaining clinical benefit, or until significant toxicity, or withdrawal of consent, for up to 1 year on study.
1743898|NCT00137462|Drug|torcetrapib/atorvastatin|
1743899|NCT00137462|Drug|atorvastatin|
1743900|NCT00137475|Procedure|Intensity-Modulated Radiation Therapy|
1743901|NCT00137488|Device|imaging and angiogenic profiles|Image tumor angiogenesis by DCE-MRI using 1.5- or 3-T MRI instruments (13,14,15) pre-and postoperatively (before biopsy or surgery).
1743902|NCT00137501|Drug|Nifedipine|"Arm A:
Nifedipine 20 mg sublingual, repeated after 30 minutes if contractions do not decrease in intensity. Maintenance of 120-160 mgs of slow-release nifedipine daily for 48 hours.Once contractions cease, nifedipine will be maintained at 80-120 mg daily in divided doses up to 36 weeks.
Arm B:
Nifedipine 10 mg sublingual crushed, then 10 mg in 15 min, followed by 10 mg PO Q 15 mins PRN to a maximum of 40 mg in the first hour. Maintenance of 60-80 mgs of slow-release nifedipine daily for 48 hours. Once contractions cease, nifedipine will be maintained at 60 mg daily in divided doses up to 36 weeks."
1743903|NCT00137514|Drug|chloroquine|
1743904|NCT00137514|Drug|amodiaquine|
1743905|NCT00137527|Device|Optimizing hemodynamic and anesthetic parameters to improve cerebral perfusion|
1743906|NCT00137540|Device|RF ablation|
1743907|NCT00137540|Drug|anti-arrhythmic drug therapy|
1743908|NCT00137553|Drug|Sulfadoxine-pyrimethamine (Fansidar)|
1743911|NCT00137579|Procedure|Influenza vaccine intramuscular administration route|
1743912|NCT00137592|Behavioral|small media, group education (multicomponent)|
1743913|NCT00137605|Biological|Pneumovax|
1743914|NCT00137605|Biological|Prevnar|
1743915|NCT00137618|Behavioral|Educational Intervention to Increase Informed Decision Making for Prostate Cancer Screening|
1743916|NCT00137631|Behavioral|Many Men, Many Voices (3MV)|Small-group, 6-session HIV prevention intervention for Black MSM.
1743917|NCT00137644|Behavioral|Preventing AIDS Through Live Movement and Sound (PALMS)|
1743918|NCT00137657|Drug|Cotrimoxazole (trimethoprim sulfamethoxazole)|
1743919|NCT00137670|Device|Video-based HIV/STD prevention intervention|
1743921|NCT00137696|Biological|Vaccination with inactivated polio vaccine|
1743922|NCT00137696|Procedure|Collection of serum|
1743923|NCT00137709|Drug|Sodium valproate|Week 1 & 2 - 200mg twice daily Week 3 onwards - 400mg twice daily
1743924|NCT00137709|Drug|Lamotrigine|Week 1 - 25mg mane Week 2 - 25mg twice daily Week 3 - 25mg mane, 50mg nocte Week 4 onwards - 50mg twice daily
1743925|NCT00137722|Behavioral|Education of providers and their staff|
1743926|NCT00137722|Behavioral|Case management|
1743927|NCT00137722|Behavioral|Payment for desired behaviors|
1743928|NCT00137735|Drug|Gabapentin|300mg tds
1743929|NCT00137735|Other|placebo|tds
1743930|NCT00137748|Drug|CMV-Ig|Drug: CMV-Ig
1743931|NCT00137761|Drug|ZD 1839|Taken orally once daily
1743932|NCT00137761|Drug|Docetaxel|Given intravenously once weekly for 2 out of 3 weeks
1743933|NCT00137774|Drug|Bevacizumab|Given intravenously every other week. Participants can continue to receive study drug as long as there is no disease progression or serious side effects.
1743934|NCT00137774|Drug|Temozolomide|Given once daily for one week followed by a one week rest period. This one-week on/one-week off scheduled will be continued as long as there is no disease progression or serious side effects.
1743935|NCT00137787|Drug|ciprofloxacin|
1743936|NCT00137787|Drug|cefepime|
1743937|NCT00137800|Drug|OSI-774 (Tarceva)|Once daily without interruption as long as there is no disease progression or serious side effects experienced.
1743938|NCT00137813|Drug|Docetaxel|Given intravenously once a week for 3 out of four weeks for a minimum of 8 weeks and maximum of a year and a half
1743939|NCT00137813|Drug|Bevacizumab|Given intravenously once a week for every other week for a minimum of 8 weeks and a maximum of a year and a half
1743940|NCT00137826|Drug|Erlotinib|Taken orally once daily. Participants may continue on study treatment until disease progresses or they experience serious side effects.
1743941|NCT00137826|Drug|Bevacizumab|Given intravenously over 30-90 minutes, on day 1 of each 21-day cycle. Participants may continue on study treatment until disease progresses or they experience serious side effects.
1743942|NCT00137839|Drug|Erlotinib|Given orally once a day until disease progression or serious side effects occur.
1743943|NCT00137852|Drug|Cisplatin|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy.
1743944|NCT00137852|Drug|Irinotecan|Given weekly on weeks 1, 2, 4 and 5 during radiation therapy
1743945|NCT00137852|Drug|Celecoxib|Given twice daily 3 days prior to radiation and up until one week prior to surgery. It will then be started again once the participant is released from the hospital following surgery for 26 weeks.
1743946|NCT00137852|Procedure|Radiation Therapy|5 days a week for 5-6 weeks
1743947|NCT00137852|Procedure|Esophagectomy|Within 4-8 weeks of chemoradiation therapy
1743948|NCT00137865|Genetic|EGEN-001 (phIL-12-005/PPC)|
1743949|NCT00137878|Drug|TNFerade™|
1743950|NCT00137891|Drug|Modified Release rhTSH|
1743951|NCT00137917|Biological|Meningococcal serogroup B vaccine|
1743952|NCT00137930|Biological|Live attenuated rotavirus vaccine|
1743953|NCT00137943|Behavioral|Full Parent communication intervention|
1743954|NCT00137943|Behavioral|Brief Parent Communication Intervention|
1743955|NCT00137943|Behavioral|Control Parent Intervention|
1743956|NCT00137956|Device|Emphasys Endobronchial Valve (EBV) Device and Procedure|
1743957|NCT00137969|Drug|Rituximab|Rituximab will be supplied as a sterile liquid for IV administration.
1743958|NCT00137969|Drug|Placebo|Placebo will be supplied as a sterile liquid for IV administration.
1743959|NCT00137969|Drug|Prednisone|
1743960|NCT00137969|Drug|Acetaminophen|
1743961|NCT00137969|Drug|Diphenhydramine|
1743962|NCT00137982|Procedure|Treatment of ectopic pregnancy|
1743963|NCT00137995|Drug|Rituximab|375 mg/m² D-2/D1
1743964|NCT00137995|Drug|Etoposide|100 mg/m² D1-D2-D3
1743965|NCT00137995|Drug|Carboplatine|max 800mg D2
1743966|NCT00137995|Drug|Ifosfamide + Mesna|5 g/m² from D2 to D13
1743967|NCT00137995|Drug|Cisplatine|100 mg/m² from D1 to D13
1743968|NCT00137995|Drug|Cytosine Arabinoside|2000 mg/m²/12 h D2 D3
1743969|NCT00137995|Drug|Dexamethasone|40 mg From D1 to D4
1743970|NCT00137995|Procedure|Autologous Stem Cell Transplantation|
1743971|NCT00137995|Drug|BCNU|300mg/m² on D-6
1743972|NCT00137995|Drug|Etoposide|200 mg/m² from D-6 to D-3
1743973|NCT00137995|Drug|Cytarabine|100 mg/m² from D-6 to D-3
1743974|NCT00137995|Drug|Melphalan|140 mg/m² on D-2
1743975|NCT00138008|Drug|endocrine therapy|Drug: endocrine therapy
1743976|NCT00138008|Procedure|radiotherapy|Procedure/Surgery: radiotherapy
1743977|NCT00138021|Device|Computerized cognitive training program|"The cognitive training model used in the McGurk et al. (2005) study is referred to as the Thinking Skills for Work program. The program is a manualized, remediative and compensatory training intervention that is integrated with SE services. The program includes a cognitive trainer, a structured training manual (McGurk & Mueser, unpublished training manual) and a computer-based cognitive training program (described below)."
1743978|NCT00138034|Procedure|Percutaneous coronary intervention (PCI)|PCI with bare metal stent placement of the culprit lesion the in the infarct related artery
1743979|NCT00138047|Drug|zinc supplementation|
1743980|NCT00138060|Drug|irinotecan|180 mg/m² or 260 mg/m² in 90 minutes every 15 days
1743981|NCT00138060|Drug|5 fluorouracil|400 mg/m² in bolus in day 1 and 2400 mg/m² in 46 hours perfusion
1743982|NCT00138073|Device|Web-based waveform interpretation guide|Use of an educational website.
1743983|NCT00138086|Drug|Zevalin plus BEAM|
1743984|NCT00138099|Drug|Fragmin (dalteparin sodium)|
1743985|NCT00138112|Drug|Empirical Vancomycin|
1743986|NCT00138112|Drug|Prophylactic Vancomycin|
1743987|NCT00138125|Drug|Faslodex|Administered IM at 500 mg on day 1 of cycle 1, followed by 500 mg on day 15 of cycle 1, then 500 mg on day 1 of each cycle thereafter.
1743988|NCT00138125|Biological|Herceptin|Given at 4 mg/kg IV on day 1 (cycle 1) then 2mg/kg IV weekly
1743989|NCT00138138|Drug|Ritalin|
1743990|NCT00138151|Biological|recombinant interferon alpha-2b|Interferon alpha-2b at a dose of 6 mU/m2 SQ qd days 1-4 of each cycle
1743991|NCT00138151|Drug|isotretinoin|Cis-retinoic acid at a dose of 1 mg/kg/day PO qd days 1-4 of each cycle
1743992|NCT00138151|Drug|paclitaxel|Paclitaxel 175 mg/m2 will be given on day 4. Cycles will be repeated every 21 days
1743993|NCT00138164|Biological|denileukin diftitox|
1743994|NCT00138177|Drug|oxaliplatin|Given IV
1743995|NCT00138177|Drug|leucovorin calcium|Given IV
1743996|NCT00138177|Drug|vorinostat|Given orally
1743997|NCT00138177|Drug|fluorouracil|Given IV
1743998|NCT00138203|Drug|vorinostat|Given PO
1743999|NCT00138203|Other|laboratory biomarker analysis|Correlative studies
1744000|NCT00138216|Drug|irinotecan hydrochloride|
1744001|NCT00138216|Drug|temozolomide|
1744002|NCT00138216|Drug|vincristine sulfate|
1744003|NCT00138229|Biological|aldesleukin|
1744004|NCT00138229|Biological|filgrastim|
1744005|NCT00138229|Biological|therapeutic autologous lymphocytes|
1744006|NCT00138229|Drug|cyclophosphamide|
1744007|NCT00138229|Drug|fludarabine phosphate|
1744008|NCT00138242|Drug|carboplatin|
1744009|NCT00138242|Drug|docetaxel|
1744010|NCT00138242|Procedure|adjuvant therapy|
1744011|NCT00138281|Biological|FluMist|
1744012|NCT00138281|Biological|Fluzone|
1744013|NCT00138294|Biological|live attenuated and inactivated influenza vaccines|Live Attenuated Influenza Vaccine (LAIV) and Inactivated Influenza Vaccine (IIV) were administered to eligible children through a research program to improve vaccination coverage in school-aged children. Children 4 years of age and older in the intervention cites (Temple, Belton, Academy, Troy, Salado, Rogers, and Holland) will be offered LAIV or IIV through a school-based research vaccination program. Children living in the comparison cities (Waco, Bryan and College Station) which are within 90 miles of the intervention cites received LAIV or IIV from the local healthcare providers
1744014|NCT00138359|Drug|Niclosamide|
1744015|NCT00138385|Biological|FluMist|
1744016|NCT00138385|Biological|Fluzone|
1744017|NCT00138398|Biological|Commercial TriValent Split Influenza Virus|
1744018|NCT00138411|Drug|Ciprofloxacin 500 mg|
1744019|NCT00138411|Drug|ETI-204 (Anthim)|
1956553|NCT02809170|Dietary Supplement|Arginine|Arginine is an amino acids
1956554|NCT02809170|Dietary Supplement|Citrulline|Citrulline is an amino acid
1744022|NCT00138476|Drug|Placebo|120 mL of the sodium bicarbonate solution, followed by 82 mL of sterile water, United States Pharmacopeia (USP) without virus; followed by 500 mg of sodium bicarbonate aqueous solution taken 5 minutes after placebo inoculation.
1744023|NCT00138476|Biological|Norwalk Virus|Prepared and packaged from liquid feces (DC544) by clarification, centrifugation, and serial dilutions; desired doses [reverse transcription polymerase chain reaction (RT-PCR) Units] 4800, 48, 4.8, 0.48.
1744024|NCT00138515|Drug|vildagliptin|
1744025|NCT00138528|Drug|Fluvastatin|
1744026|NCT00138541|Drug|vildagliptin|
1744027|NCT00138554|Drug|vildagliptin|
1744028|NCT00138554|Drug|pioglitazone|pioglitazone 45 mg qd
1744029|NCT00138567|Drug|vildagliptin|
1744030|NCT00138580|Drug|vildagliptin|
1744031|NCT00138593|Drug|vildagliptin|
1744032|NCT00138606|Drug|vildagliptin|
1744033|NCT00138619|Drug|vildagliptin|
1744034|NCT00138632|Drug|PTK787|Visudyne® + PTK787, 500 mg/day
1744035|NCT00138632|Drug|PTK787|Visudyne® + PTK787 1000 mg/day
1744036|NCT00138632|Drug|Placebo|Visudyne® + Placebo
1744037|NCT00138645|Behavioral|MicroDiet|MicroDiet
1744038|NCT00138645|Behavioral|Healthy Diet|Participants randomized to the Healthy Diet group will be prescribed a traditional food-based diet that contains the same number of kilocalories (1200/day) as the MicroDiet but will be instructed not to use meal replacements
1744039|NCT00138658|Drug|custirsen sodium|Custirsen sodium (OGX-011) was to be infused intravenously over 2 hours on Days -7, -5, and 3 of Cycle 1 (pretreatment loading dose). OGX 011 was then to be infused for 2 hours weekly on Days 1, 8, and 15 of a 21-day cycle. Gemcitabine (GEM) was to be infused intravenously for 30 minutes on Days 1 and 8 and either cisplatin (CIS) or carboplatin (CARBO) were to be infused intravenously on Day 1 of this 21-day cycle. Patients were to receive a maximum of 6 cycles (1 cycle = 21 days)
1744040|NCT00138671|Drug|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
1744041|NCT00138671|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
1744042|NCT00138684|Procedure|venesection|Venesection therapy is realised every 7 - 14 days until iron desaturation completion.
1744043|NCT00138697|Drug|IVIG-L|
1744044|NCT00138710|Drug|Letrozole (Femara)|
1744045|NCT00138723|Drug|SPM 907|
1744046|NCT00138736|Drug|Mannan Binding Lectin (MBL)|
1744047|NCT00138736|Drug|Mannan Binding Lectin|"MBL dose at a twice weekly dose interval (3 or 4 days):
0.2 mg/kg, for a 3-day interval; 0.3 mg/kg, for a 4-day interval"
1744048|NCT00138749|Drug|SS-RBX|
1744049|NCT00138762|Drug|torcetrapib/atorvastatin|
1744050|NCT00138762|Drug|atorvastatin|
1744051|NCT00138762|Drug|placebo|
1744052|NCT00138775|Drug|D-serine|
1744053|NCT00138788|Procedure|Radiotherapy, dose fractionation|
1744054|NCT00138801|Drug|Ceftriaxone|
1744055|NCT00138801|Drug|Doxycycline|
1744056|NCT00138814|Procedure|Radiotherapy (boost versus no boost)|
1744057|NCT00138827|Drug|Biotene (mouth care)|
1744058|NCT00138840|Drug|STA-5326 mesylate|
1956555|NCT02809404|Drug|Everolimus|
1956556|NCT02804282|Combination Product|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
1744059|NCT00138853|Device|Tibial component|Tibial component inserted at the time of surgery
1744060|NCT00138866|Drug|Risedronate|
1744061|NCT00138892|Procedure|Waiting time (access time to Total joint replacement)|See Detailed Description.
1744062|NCT00138905|Device|UMTS mobile basestation radiation|
1744063|NCT00138918|Biological|OGX-011|See Detailed Description, Treatment Plan
1744064|NCT00138931|Procedure|Blood draw (genetic testing)|Blood draw (genetic testing)
1744065|NCT00138944|Drug|placebo|od
1744066|NCT00138944|Drug|eplerenone|50mg od
1744067|NCT00138957|Procedure|Laparoscopic parastomal hernia repair with mesh|
1744068|NCT00138970|Drug|Zenapax®, CellCept® and prednisolone|
1744069|NCT00138970|Drug|Sandimmun Neoral®, CellCept® and prednisolone|
1744070|NCT00138983|Drug|Alendronate versus alfacalcidol (1-alpha OH vitamin D)|
1744071|NCT00138996|Device|automated direct feedback on CPR from defibrillator|
1744072|NCT00139009|Drug|Cyclosporine A|
1744073|NCT00139022|Device|Continuous Positive Airway Pressure|
1744074|NCT00139035|Drug|cyclosporine A|
1744075|NCT00139048|Behavioral|Decision Aid|
1744076|NCT00139061|Drug|Torcetrapib/Atorvastatin|
1744077|NCT00139061|Drug|Fenofibrate|
1744078|NCT00139074|Drug|Quetiapine fumarate|oral variable dose
1744079|NCT00139074|Drug|sodium valproate|oral
1744080|NCT00139087|Behavioral|Telephone Outreach for Therapy|
1744081|NCT00130026|Drug|Caffeine|500 mg IV
1744082|NCT00130039|Drug|clopidogrel|Clopidogrel 75mg once a day plus placebo of cilostazol twice a day
1744083|NCT00130039|Drug|Cilostazol|Cilostazol 100mg twice a day plus placebo of clopidogrel once a day
1744084|NCT00130065|Drug|Sulfadoxine-pyrimethamine/folic acid|
1744085|NCT00130065|Drug|Sulfadoxine-pyrimethamine/placebo|
1744086|NCT00139100|Drug|antimicrobial agent in soap|
1744087|NCT00139113|Biological|hepatitis A vaccine|2 doses of inactivated hepatitis A vaccine manufactured by GSK in licensed pediatric formulation of 720 EL. U. per dose given on 3 different schedules: aged 6 and 12 months, 12 and 18 months, and 15 and 21 months. Within each group, subjects were randomized to achieve a relatively equal number of children born to anti-HAV positive and anti-HAV negative mothers.
1744088|NCT00139126|Behavioral|Fire safety education|Education on smoke alarm maintenance based on behavioral theories
1744089|NCT00139139|Biological|Hepatitis A vaccine|
1744090|NCT00139152|Drug|Placebo|Saline, Sub-Cuteanous (SQ)
1744091|NCT00139152|Drug|Xolair|Xolair, 0.016 mg/kg Immunoglobulions E (IgE) , SQ
1744092|NCT00139165|Drug|Budesonide|Capsule. Oral 6 mg o.d. for 24 weeks
1744093|NCT00139165|Procedure|sigmoidoscopy|Sigmoidoscopy performed 2 times during the study period.
1744094|NCT00139178|Drug|Different HAART regimens|
1744095|NCT00139191|Procedure|C-11 acetate PET scan|
1744096|NCT00139204|Procedure|C11 Methionine PET scan|
1744097|NCT00139217|Drug|iNO|
1744098|NCT00139217|Procedure|Non-invasive nitric oxide|
1744099|NCT00139230|Drug|Taxotere|
1744100|NCT00139230|Drug|Cisplatin|
1744101|NCT00139230|Drug|5-Fluorouracil|
1744102|NCT00139230|Drug|Leucovorin|
1744103|NCT00139230|Drug|G-CSF|
1744104|NCT00139230|Drug|Ciprofloxacin|
1744105|NCT00139243|Drug|Taxotere|
1744106|NCT00139243|Drug|Cisplatin|
1744107|NCT00139243|Drug|5-Fluorouracil|
1744108|NCT00139243|Drug|Leucovorin|
1744109|NCT00139256|Drug|Betamethasone|Betamethasone injection
1744110|NCT00139269|Drug|Docetaxel|
1744111|NCT00139269|Drug|Cisplatin|
1744112|NCT00139269|Drug|5-Fluorouracil|
1744113|NCT00139282|Drug|Squalamine Lactate|
1744114|NCT00139295|Device|Hylastan|
1744115|NCT00139308|Device|high frequency stimulation|
1744116|NCT00139321|Device|Force platform and electromyography|
1744117|NCT00139334|Biological|Rotavirus|
1744118|NCT00139347|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
1744119|NCT00139360|Drug|Bevacizumab|Anti angiogenesis treatment
1744120|NCT00139373|Drug|donepezil|
1744121|NCT00139386|Drug|Candesartan|Candesartan Cilexetil (4-12 mg per day)
1744122|NCT00139399|Procedure|Coronary artery bypass surgery|Radial artery versus long saphenous vein grafted to the left circumflex coronary artery territory during CABG surgery
1744123|NCT00139425|Behavioral|Disease Management Assessment|
1744124|NCT00139438|Behavioral|Disease Management Assessment|
1744125|NCT00142974|Drug|Tegaserod|
1744126|NCT00142987|Drug|Tegaserod|
1744127|NCT00143000|Drug|Peginterferon alfa-2a 40KD and Ribavirin|
1744128|NCT00143026|Drug|carbidopa, levodopa, entacapone|
1744129|NCT00143039|Procedure|Tandem MS test for inborn errors of metabolism|Tandem MS spectrometry test will be done on all maternal blood, amniotic fluid and newborn blood samples for both groups.
1744130|NCT00143065|Drug|Fludarabine|25 mg/m2/day for 5 days every 28 days (Week 2,6,10,14, 18,and 22) will be administered by IV over 10-30 minutes. (Fludarabine should be given AFTER rituximab on all days on which both drugs will be administered.)
1744131|NCT00143065|Drug|Rituximab|"Day 1, week 2 of cycle 1 rituximab 100 mg will be administered by IV, without dose escalation, over 4 hours (rate: 25 mg/hr). Day 3, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 50 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 50 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.
On Day 5, week 2 of cycle 1 rituximab 375 mg/m2 will be administered by IV. Rituximab can be administered at 100 mg/hr. If hypersensitivity or infusion related events do not occur, the infusion rate will be escalated in 100 mg/hr increments every 30 minutes to a maximum of 400 mg/hr.
Rituximab 375 mg/m2 will be repeated on Day 1 of Week 6, 10, 14, 18, and 22. During these treatments, acetaminophen and diphenhydramine prophylactic treatment is left to the discretion of the treating physician."
1744193|NCT00143611|Drug|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.1 mg/kg/h (2.4 mg/kg/day), injection, subcutaneously over 96 hours.
1744132|NCT00143065|Drug|Alemtuzumab|The dose of alemtuzumab will be escalated during Week 1 of therapy. On Day 1 of Week 1, a dose of 3 mg should be administered IV over 2-hours. If this dose is well tolerated(grade 2 or less infusion or skin related toxicity), then the dose on Day 2 can be increased to 10 mg IV over 2 hours. If this dose is well tolerated, then the dose on Day 3 will be increased to 30 mg IV over 2-hours, and if tolerated, then day 5 and all subsequent alemtuzumab doses will be 30 mg. Vital signs (blood pressure, pulse, respiration rate,temperature, and O2 saturation) and skin assessment should be assessed at baseline, 1-hour, and 1-hour post administration during week 1 and 2. Following successful escalation to 30 mg of alemtuzumab, all subsequent doses of alemtuzumab will be 30 mg administered on the second day of fludarabine therapy (week 2,6,10,14,18,and 22).
1744133|NCT00143091|Drug|CP-316,311|
1744134|NCT00143091|Drug|Placebo|
1744135|NCT00143091|Drug|Sertraline|
1744136|NCT00143104|Drug|Inhaled insulin|
1744137|NCT00143117|Drug|UK-390,957|
1744138|NCT00143130|Drug|Pregabalin|Pregabalin
1744139|NCT00143143|Drug|Pregabalin|
1744140|NCT00143156|Drug|pregabalin|
1744141|NCT00143169|Drug|Parecoxib and placebo|
1744142|NCT00143182|Drug|Asenapine|Asenapine , 9 weeks
1744143|NCT00143182|Drug|Olanzapine|Olanzapine, 9 weeks
1744144|NCT00143195|Drug|Amlodipine|
1744145|NCT00143195|Drug|iso- 5 - mononitrate|
1744146|NCT00143195|Procedure|Blood tests|
1744147|NCT00143195|Procedure|Exercise Stress Test|
1744148|NCT00143208|Drug|Xalacom|
1744149|NCT00143221|Drug|Viagra|
1744150|NCT00143221|Drug|Placebo|
1744151|NCT00143234|Drug|Amlodipine/atorvastatin single pill|
1744152|NCT00143247|Drug|Exubera® (inhaled insulin)|Treatment of type 1 and type 2 diabetes with short-acting insulin
1744153|NCT00143260|Drug|Viagra (Sildenafil Citrate) 100 mg|
1744154|NCT00143273|Drug|lasofoxifene|0.05 mg tablets
1744155|NCT00143273|Drug|Placebo|0 mg
1744156|NCT00143273|Drug|Lasofoxifene|0.25 mg tablets
1744157|NCT00143273|Drug|Lasofoxifene|0.5 mg tablets
1744158|NCT00143286|Drug|varenicline (CP-526,555)|
1744159|NCT00143299|Drug|varenicline (CP-526,555)|
1744160|NCT00143312|Drug|voriconazole|Voriconazole is given to patients at least 48 hours after chemotherapy
1744161|NCT00143325|Drug|varenicline (CP-526,555)|
1744162|NCT00143338|Drug|Inhaled insulin|
1744163|NCT00143351|Drug|Ziprasidone|
1744164|NCT00143364|Drug|varenicline (CP-526,555)|
1744165|NCT00143377|Drug|tolterodine SR, overactive bladder|
1744166|NCT00143390|Drug|exemestane|take orally one tablet per day of exemestane 25 mg and one tablet per day of anastrozole placebo daily after meal
1744167|NCT00143390|Drug|anastrozole|take orally one tablet of anastrozole 1 mg and one tablet of exemestane placebo daily after meal
1744168|NCT00143403|Drug|Irinotecan + 5 FU + folinic acid|irinotecan 180 mg/m2 folinic acid 400 mg/m2 (DL) followed by 5 FU bolus 400 mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
1744169|NCT00143403|Drug|Folinic Acid + 5 FU|folinic acid 400 mg/m2(DL) followed by bolus 5 FU 400mg/m2 5 FU continuous infusion (2400 mg/m2 over 46 hours) every 2 weeks
1744170|NCT00143416|Drug|Pegvisomant|
1744171|NCT00143429|Drug|Xalatan|
1744172|NCT00143442|Drug|[S,S]-Reboxetine|
1744173|NCT00143455|Drug|Etoposide + cisplatin|etoposide 100 mg/m2 days 1, 2 and 3 cisplatin 80 mg/m2 day 1 3 week cycle
1744174|NCT00143455|Drug|Irinotecan + cisplatin|irinotecan 65 mg/m2 day 1 and 8 cisplatin 80mg/m2 day 1 3 week cycle
1744175|NCT00143468|Behavioral|mechanical ventilation|measurement of specific lung elastance during mechanical ventilation
1744176|NCT00143481|Drug|Tolterodine ER 4mg QD|
1744177|NCT00143494|Procedure|measurement of abdominal pressure|measurement of abdominal pressure with different volume and saline temperature
1744178|NCT00143507|Drug|Ivabradine|
1744179|NCT00143507|Drug|Placebo|
1744180|NCT00143520|Drug|Rivoglitazone|
1744181|NCT00143520|Drug|Pioglitazone|
1744182|NCT00143520|Drug|Placebo|
1744183|NCT00143533|Drug|Irinotecan, Cefpodoxime|See Detailed description section for treatment details.
1744184|NCT00143546|Drug|Defibrotide|Defibrotide to be administered approximately every 6 hours at an initial dose of 6.25 mg/kg/dose. Subsequent doses will be escalated with a plateau of 15 mg/kg/dose (or 60 mg/kg/day total). For patients with persistent VOD, the dose may be escalated by 10 mg/kg/day as needed to a maximum of 110 mg/kg/day total.
1744185|NCT00143559|Drug|Systematic chemotherapy and antibodies|"Systemic chemotherapy and antibodies as follows:
Transplant recipients received a reduced intensity conditioning regimen consisting of OKT-3, fludarabine, thiotepa, and melphalan followed by an infusion of a T-cell depleted haploidentical hematopoietic stem cell graft. The antibody Rituximab was administered within 24 hours of the infusion in an effort to prevent PTLPD. In addition to T -cell depletion of the donor product, Mycophenylate mofetil was provided over several months as prophylaxis for GVHD"
1744186|NCT00143559|Procedure|Allogeneic stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device
1744187|NCT00143559|Device|Miltenyi CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
1744188|NCT00143572|Drug|Magnesium Pidolate, Hydroxyurea|Intervention Description: Mg pidolate in combination with HU in patients with sickle cell disease who have been on a therapeutic dose (15-30 mg/kg/day) of HU for at least 6 months. Mg pidolate will be given at an initial dose of 0.6 mEq/kg/day divided into 2 daily doses for the first cohort of patients. This dose will be escalated for the subsequent patient cohorts as defined by a classic Phase I design (according to toxicity).
1744190|NCT00143598|Device|Knee-length, graduated elastic compression stocking|Worn daily for 2 years, 30-40 mm Hg
1744191|NCT00143598|Device|Knee-length, placebo stocking|Worn daily for two years
1744192|NCT00143611|Drug|Resatorvid|Resatorvid 1.2 mg/kg, injection, subcutaneously for thirty minutes; then resatorvid 0.05 mg/kg/h (1.2 mg/kg/day), injection, subcutaneously over 96 hours.
1744260|NCT00144170|Drug|Comparator protease inhibitor(CPI)/low dose ritonavir(r)|
1744194|NCT00143611|Drug|Placebo|Resatorvid placebo-matching injection, subcutaneously for thirty minutes; then resatorvid placebo-matching injection, subcutaneously over 96 hours.
1744195|NCT00143624|Drug|Rosiglitazone maleate|See Detailed Description.
1744196|NCT00143624|Drug|Placebo|See detailed description.
1744197|NCT00143637|Other|Office dust|airborne office dust spiked with glucan
1744198|NCT00143637|Other|clean air|Clean air
1744199|NCT00143650|Behavioral|House dust|
1744200|NCT00143663|Drug|Lapaquistat Acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 12 weeks
1744201|NCT00143663|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks
1744202|NCT00143676|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
1744203|NCT00143676|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
1744204|NCT00143676|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg to 40 mg stable dose for up to 24 weeks.
1744205|NCT00143689|Drug|lopinavir/ritonavir; nevirapine; Zidovudine; Lamivudine|See Detailed Description.
1744206|NCT00143702|Drug|d4T|See Detailed Description.
1744207|NCT00143702|Drug|Abacavir|See Detailed Description.
1744208|NCT00143702|Drug|Riboflavin and Thiamine (Supplementation)|See Detailed Description.
1744209|NCT00143715|Drug|Phytonadione (Vitamin K1)|1.25 mg given orally
1744210|NCT00143728|Drug|Lamivudine|See Detailed Description.
1744211|NCT00143741|Drug|Atorvastatin (Lipitor)|20mg every day, taken by mouth. Dose could be increased up to 60mg every day during the course of the trial if tests indicate this is needed.
1744212|NCT00143754|Procedure|Hydration|
1744213|NCT00143780|Biological|The polysaccharide vaccine used is Pneumovax (Merck vaccines)|
1744214|NCT00143780|Biological|The conjugate vaccine used is Prevnar (Wyeth-Ayerst vaccines)|
1744215|NCT00143806|Drug|Transitioning patients from cyclosporine to alefacept|
1744216|NCT00143819|Drug|Neuroskin Forte|Subjects will apply study drug sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
1744217|NCT00143819|Drug|Placebo Application|Subjects will apply placebo sprays 3 times a day (with optional 4th application) to the assigned, randomized sides of the body for 8 weeks
1744218|NCT00143845|Procedure|Reduced intensity conditioning|Busulfan and Fludarabine regimen
1744219|NCT00143845|Procedure|Rapid immunosuppressive taper|Taper of Tacrolimus, Methotrexate and Mycophenolate Mofetil
1744220|NCT00143845|Procedure|Prophylactic donor leukocyte infusions|If the patient has GVHD overall grade 0-1 or skin grade 1 on day +100, then 5 x 107 CD3+ cells/kg recipient weight are given.
1744221|NCT00143858|Device|Pulse Volume Measurement|patients will wear a newly designed calf monitor that will be hooked up to a computer that will monitor leg peripheral pulse volumes which will then be correlated to pressures obtained with Swan Ganz monitoring. The calf monitor is gut two bands with sensors that are wrapped around the ankle and below the knww
1744222|NCT00143871|Drug|Rituximab|
1744223|NCT00143884|Procedure|Reduced intensity conditioning|
1744224|NCT00143884|Procedure|Prophylactic donor leukocyte infusions|
1744225|NCT00143910|Other|observation|
1744226|NCT00143923|Behavioral|Nutrition, Exercise, Stress Management Counseling|Individualized advice
1744227|NCT00143923|Other|usual care|usual care
1744228|NCT00143936|Behavioral|Low- Carbohydrate -Atkins Diet|Low Carbohydrate Diet
1744229|NCT00143936|Behavioral|Low Calorie Diet|Maintain a low calorie diet
1744230|NCT00143949|Drug|enalapril|
1744231|NCT00143949|Drug|losartan|
1744232|NCT00143962|Behavioral|Low Carbohydrate Diet|
1744233|NCT00143975|Drug|Cytarabine|3 g/m2 bid. i.v day 1-3
1744234|NCT00143975|Drug|Mitoxantrone|12 mg/m2 i.v. day 2 and 3
1744235|NCT00143975|Drug|Gemtuzumab Ozogamicin|3mg/m² i.v. day 1
1744236|NCT00143975|Drug|All-trans-Retinoid Acid|45 mg/m2 p.o. day 4-6 15 mg/m2 p.o. day 7-28
1744237|NCT00143988|Behavioral|Treadmill testing|Patients will have a exercise stress test using a Bruce protocol during which time heart rates and blood pressures will be monitored and the patient's percieved exertion level monitored and recorded
1744238|NCT00143988|Behavioral|Ambulatory Blood Pressure and Heart Rate Monitoring|Patients will wear an ambulatory blood pressure monitor and an heart rate monitor during one sexual encounter.
1744239|NCT00144014|Drug|V10153|Single acute intravenous bolus dose up to 10 mg/kg
1744240|NCT00144027|Behavioral|Antipsychotic medication adherence intervention|The medication adherence intervention will include using a computer to complete a brief set of questions related to medication adherence before mental health clinic visits.
1744241|NCT00144040|Behavioral|Physician & patient education on appropriate antibiotic use|
1744242|NCT00144040|Procedure|Rapid C-reactive protein testing to guide antibiotic treatment|
1744243|NCT00144053|Drug|Cisplatin+Vindesine+MMC/ concurrent radiation|
1744244|NCT00144053|Drug|Irinotecan+Carboplatin/concurrent radiation|
1744245|NCT00144053|Drug|Paclitaxel+Carboplatin/concurrent radiation|
1744246|NCT00144066|Drug|platinum-based chemotherapy alone (up to six cycles)|
1744247|NCT00144066|Drug|platinum-based chemotherapy followed by maintenance therapy with gefitinib|
1744248|NCT00144079|Procedure|external beam radiotherapy|
1744249|NCT00144092|Procedure|stem cell source|
1744250|NCT00144105|Drug|TPV500mg/RTV200mgBID|
1744251|NCT00144105|Drug|TPV500mg/RTV100mgBID|
1744252|NCT00144105|Drug|LPV400mg/RTV100mgBID|
1744253|NCT00144118|Drug|sevoflurane or isoflurane|
1744254|NCT00144131|Drug|Aranesp®|
1744255|NCT00144144|Drug|Angiotensin II receptor antagonists, Calcium channel blocker|
1744256|NCT00144157|Drug|Nevirapine|
1744257|NCT00144157|Drug|Zidovudine|
1744258|NCT00144157|Drug|3TC|
1744259|NCT00144170|Drug|Tipranavir (with low dose ritonavir)|
1744411|NCT00134199|Drug|CP-945,598|
1744261|NCT00144183|Drug|Nevirapine (NVP)|Nevirapine 200mg once daily for 14 days followed by 200mg twice daily thereafter for the remainder of the treatment period. Combivir®, one tablet twice daily.
1744262|NCT00144183|Drug|Zidovudine (ZCV)|
1744263|NCT00144183|Drug|3TC|
1744264|NCT00144196|Drug|tiotropium (Spiriva)|
1744265|NCT00144209|Drug|pramipexole|
1744266|NCT00144209|Drug|levodopa in combination with benserazide|
1744267|NCT00144222|Drug|Telmisartan 40 mg/HCTZ 12.5 mg|
1744268|NCT00144222|Drug|Telmisartan 40 mg|
1744269|NCT00144235|Drug|Pharmaton PHL 00749|
1744270|NCT00144235|Drug|Placebo|
1744271|NCT00144248|Drug|nevirapine|
1744272|NCT00144261|Drug|nevirapine|
1744273|NCT00144274|Drug|Ambroxol Lozenge|
1744274|NCT00144287|Drug|Tipranavir/Ritonavir|
1744275|NCT00144300|Drug|Mirapex|Standard marketed product dispensed according to manufacturer's guidelines
1744276|NCT00144300|Drug|Requip|Standard marketed product dispensed according to manufacturer's guidelines
1744277|NCT00144313|Biological|hepatitis B vaccine|
1744278|NCT00144326|Drug|Tiotropium Bromide|
1744279|NCT00144326|Drug|Placebo|
1744280|NCT00144339|Drug|tiotropium|
1744281|NCT00144339|Drug|placebo|
1744282|NCT00144352|Drug|sulfadoxine-pyrimethamine|
1744283|NCT00144365|Drug|Antiretroviral therapy|
1744284|NCT00144378|Drug|Irinotecan|
1744285|NCT00144391|Drug|Transdermal Testosterone gel|2.0 mg per pump of transdermal testosterone gel. Study patients receive either 2 pumps of transdermal testosterone gel per thigh per day or they receive 2 pumps per placebo gel per thigh per day for 6 months.
1744286|NCT00144417|Drug|Moxifloxacin (with rifampin, pyrazinamide, and ethambutol)|Moxifloxacin 400mg daily, 8 weeks
1744287|NCT00144417|Drug|isoniazid|isoniazid, oral, 300 mg, daily, 8 weeks
1744288|NCT00144430|Drug|Pentostatin|The drug, Pentostatin, is given every 2 weeks. This drug will be given by intravenous (IV) infusion.
1744289|NCT00144443|Behavioral|Basic home repair|
1744290|NCT00144443|Behavioral|Asthma Trigger Education|
1744291|NCT00144456|Drug|ED-71|0.75μg/day(p.o.)for 144 weeks
1744292|NCT00144456|Drug|Alfacalcidol|1.0μg/day(p.o.)for 144 weeks
1744293|NCT00144456|Drug|ED-71 placebo|0 μg/day(p.o.)for 144 weeks
1744294|NCT00144456|Drug|Alfacalcidol placebo|0 μg/day(p.o.)for 144 weeks
1744295|NCT00144469|Drug|peginterferon alfa-2a|
1744296|NCT00144469|Drug|rivavirin|
1744297|NCT00144482|Drug|recombinant human erythropoietin|36000IU（0.5mL）s.c./week for 8 weeks
1744298|NCT00144482|Drug|recombinant human erythropoietin placebo|0 IU(0.5mL)s.c./week for 8 weeks
1744299|NCT00144495|Drug|recombinant human erythropoietin|3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks
1744300|NCT00144495|Drug|recombinant human erythropoietin|36000IU(s.c.)/week for 12 weeks
1744301|NCT00144508|Drug|MRA (Tocilizumab)|8mg /kg /4week for 52 weeks
1744302|NCT00144508|Other|current treatment|continue current treatment
1744303|NCT00144521|Drug|MRA(Tocilizumab)|8mg/kg/4week(i.v.)for 24 weeks
1744304|NCT00144521|Drug|MRA placebo|0mg/kg/4week(i.v.) for 24 weeks
1744305|NCT00144521|Drug|MTX|8mg/week(p.o.) for 24 weeks
1744306|NCT00144521|Drug|MTX placebo|0mg/week(p.o.) for 24 weeks
1744307|NCT00144534|Drug|MRA (Tocilizumab)|8mg/kg/4 weeks
1744308|NCT00144547|Drug|MRA(Tocilizumab)|8mg/kg(i.v.)/4weeks
1744309|NCT00144560|Drug|MRA(Tocilizumab)|
1744310|NCT00144573|Drug|MRA(Tocilizumab)|
1744311|NCT00144586|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks
1744312|NCT00144599|Drug|MRA(Tocilizumab)|
1744313|NCT00144599|Drug|placebo|
1744314|NCT00144612|Drug|MRA(Tocilizumab)|8mg/kg/2weeks
1744315|NCT00144625|Drug|MRA(Tocilizumab)|8mg/kg/4weeks
1744316|NCT00144651|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks for 1 year
1744317|NCT00144664|Drug|MRA(Tocilizumab)|
1744318|NCT00144677|Drug|sirolimus|
1744319|NCT00144677|Drug|tacrolimus|
1744320|NCT00144690|Drug|E2007 (perampanel)|
1744321|NCT00144690|Drug|Placebo|
1744322|NCT00144703|Drug|Sirolimus|
1744323|NCT00144703|Drug|Tacrolimus|
1744324|NCT00144716|Device|Insect Repellent plus Insecticide Treated Net|
1744325|NCT00144729|Procedure|Bone marrow transplant|
1744326|NCT00144755|Drug|Darbepoetin alfa|prophylactic administration of darbepoetin alfa in experimental arm
1744327|NCT00144768|Drug|laronidase|dose of 0.58mg/kg body weight IV every week
1744328|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
1744329|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every week
1744330|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.2 mg/kg every other week
1744331|NCT00144781|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|1.8 mg/kg every other week
1744332|NCT00144807|Drug|rituximab|
1744333|NCT00144807|Drug|doxorubicin|
1744334|NCT00144807|Drug|cyclophosphamide|
1744335|NCT00144807|Procedure|autologous stem cell transplantation|
1744336|NCT00144820|Drug|Injection of Hyaluronan or Saline|
1744337|NCT00144833|Drug|fosamprenavir/ritonavir (700mg/100mg BID)|
1744338|NCT00144833|Drug|fosamprenavir/ritonavir (1400mg/100mg BID)|
1744339|NCT00144833|Drug|fosamprenavir/lopinavir/ritonavir (1400mg/533mg/100mg BID)|
1744341|NCT00144859|Drug|SB681323|
1744342|NCT00144872|Drug|Lamotrigine|Lamotrigine will be given as chewable dispersible tablets with dosing strengths of 2, 5, 25, and 100 milligrams.
1744343|NCT00144885|Behavioral|Modification of therapy|Modification of the surgery date if adapted, modification of the antibiotics if adapted, based on RMI results
1744344|NCT00144898|Procedure|Sentinel Node Resection|Sentinel Node Resection
1744345|NCT00144898|Procedure|Conventional Axillary Dissection|Conventional Axillary Dissection
1744346|NCT00144911|Drug|Salmeterol|
1744412|NCT00134199|Drug|sibutramine|
1744347|NCT00144911|Drug|Fluticasone Propionate/Salmeterol Combination Product|
1744348|NCT00144924|Procedure|pyloromyotomy|laparoscopic pyloromytomy
1744349|NCT00144937|Drug|Stepwise therapy for dyslipidemia, hypertension and diabetes|
1744350|NCT00144937|Behavioral|Dietary recommendations|
1744351|NCT00144937|Behavioral|Increase in physical activity|
1744352|NCT00144937|Behavioral|Smoking cessation|
1744353|NCT00144950|Drug|insertion of a chest drain with urokinase instillation|
1744354|NCT00144950|Procedure|primary video-assisted thorascopic surgery|
1744355|NCT00144963|Drug|Vincristine Sulfate Liposomes Injection|Study treatment consists of infusion of VSLI intravenously over 60 minutes on Day 1 and Days 8, 15 and 22 (+/- 2 days).
1744356|NCT00144963|Drug|Dexamethasone|Study treatment consists of 40 mg dexamethasone, daily orally or intravenously, on Days 1-4 (+/- 2 days) and Days 11-14 (+/- 2 days).
1744357|NCT00144976|Drug|Tarceva|Tarceva will be administered at dosage 150 mg od one hour before or two hours after meat. Patients will receive Tarceva between 18 and 28 days.
1744358|NCT00144989|Drug|Etoposide and cisplatin after chemoradiotherapy|Etoposide and cisplatin after chemoradiotherapy
1744359|NCT00144989|Drug|Irinotecan and cisplatin after chemoradiotherapy|Irinotecan and cisplatin after chemoradiotherapy
1744360|NCT00145002|Drug|VCAP-AMP-VECP with G-CSF and intrathecal prophylaxis|
1744361|NCT00145002|Drug|biweekly-CHOP with G-CSF and intrathecal prophylaxis|
1744362|NCT00145015|Behavioral|Increased dietary intake of salmon or cod|
1744363|NCT00145028|Drug|Carboplatin|
1744364|NCT00145041|Drug|Vincristine Sulfate Liposomes Injection|Marqibo (VSLI) 1.0 mg/m2 delivered by intravenous infusion over 1 hour every 2 weeks.
1744365|NCT00145054|Behavioral|MoodHelper Internet program for Depression Self-Help|
1744366|NCT00145067|Behavioral|Disease Management Assessment|
1744367|NCT00145080|Behavioral|Disease Management Assessment|
1744368|NCT00145093|Drug|Baker’s yeast (Bio Chromium)|
1744369|NCT00145106|Drug|Tazarotene 0.1% gel + placebo capsule, Oral minocycline (100 mg capsule) + vehicle gel, Tazarotene 0.1% gel + oral minocycline (100 mg capsule)|
1744370|NCT00145132|Procedure|β-CIT-SPECT, Neurophysiology|β-CIT-SPECT scans and EEG recordings, two assessments each
1744371|NCT00145145|Biological|MAGE-3.A1 peptide and CpG 7909|
1744372|NCT00145158|Biological|8 HLA-A2 restricted peptides and Montanide ISA-51|
1744373|NCT00145171|Drug|apomorphine HCl injection|
1744374|NCT00145184|Dietary Supplement|Multivitamin supplement containing vitamins B, C, and E|A daily oral dose of between 1.5 to 3 times the age- appropriate Recommended Dietary Allowance (RDA) of each vitamin taken for two months starting at enrollment.
1744375|NCT00145184|Drug|Placebo|Placebo pill taken orally once per day for two months starting at enrollment.
1744376|NCT00145197|Behavioral|Improving the Delivery of Effective Care to Minorities|The intervention consists of: a) reminders to prompt surgeons to refer patients for adjuvant treatment, and b) an individual to track referrals for and receipt of adjuvant treatments. We will recruit all physicians who treat patients with early stage breast cancer. Physicians who agree to participate will identify a point person in their office who will inform the research team if the patient has a follow up appointment with radiation or medical oncologists. Following the appointment date, we will contact each office to confirm the patient's visit. If the patient has connected with radiation and/or medical oncologist, we will let the surgeon's office know and stop calling his/her office. However, if the patient has not made the appropriate visits, we will continue to call the surgeon's office every week for a total of 3 calls to let them know that the patient has not connected with the oncologist.
1744377|NCT00145210|Drug|Nebivolol and Atenolol|
1744378|NCT00145236|Drug|Nebivolol|
1744379|NCT00145249|Drug|Amphotericin B|Amphotericin B 0.7 mg/kg IV for the first 14 days of treatment. This period may be extended up to an additional 7 days.
1744380|NCT00145249|Drug|Fluconazole|Fluconazole 400 or 800 mg daily. Among subjects whose baseline weight is less than 40 kg, randomized fluconazole doses will be 200 mg/kg daily or 400 mg/kg daily.
1744381|NCT00145262|Procedure|Autologous Bone Marrow Mononuclear Cell Implantation|
1744382|NCT00145275|Drug|zoledronic acid|
1744383|NCT00145301|Drug|Lumiracoxib|
1744384|NCT00145314|Drug|FLOX (5-fluorouracil/folinic acid/oxaliplatin)|FLOX every 2nd week
1744385|NCT00145314|Drug|FLOX (5-fluorouracil/folinic acid/oxaliplatin) and Cetuximab|FLOX every 2nd week Cetuximab weekly
1744386|NCT00145314|Drug|FLOX (5-fluorouracil and folinic acid and oxaliplatin) intermittently and maintenance cetuximab|"FLOX every 2nd week for 8 cycles. Stop of FLOX until progression then FLOX is reintroduced.
Cetuximab weekly."
1744387|NCT00145327|Drug|Zoledronic Acid|Zoledronic Acid 5 mg in 100 mL physiologic 0.9% normal saline for intravenous infusion.
1744388|NCT00145327|Drug|Placebo|100 mL physiologic 0.9% normal saline for intravenous infusion.
1744389|NCT00145340|Drug|pioglitazone|30 Mg/day
1744390|NCT00145353|Drug|Insulin NovoRapid versus Actrapid|
1744391|NCT00145366|Drug|Recombinant human thyrotropin (Thyrogen)|
1744392|NCT00145379|Drug|Tablet Metformin 500 mg|
1744393|NCT00145379|Drug|Placebo|
1744394|NCT00145405|Drug|Lanreotide Autogel and Octreotide LAR|
1744395|NCT00145418|Drug|Oxaliplatin + Docetaxel|Oxaliplatin 85mg/m2 Docetaxel 30mg.m2
1744396|NCT00145431|Drug|torcetrapib/atorvastatin|
1744397|NCT00145431|Drug|atorvastatin|
1744398|NCT00145431|Drug|fenofibrate|
1744399|NCT00145444|Drug|olanzapine|
1744400|NCT00145444|Drug|ziprasidone|
1744401|NCT00145457|Procedure|Blood sample|
1744402|NCT00145457|Procedure|Radiography|
1744403|NCT00134108|Behavioral|Cognitive Behaviour Therapy|
1744404|NCT00134134|Drug|efalizumab|
1744405|NCT00134147|Drug|Inhaled Insulin|
1744406|NCT00134160|Drug|Olmesartan medoxomil|Olmesartan medoxomil 40mg/Day
1744407|NCT00134160|Drug|Calcium channel blockers (amlodipine, azelnidipine)|Olmesartan medoxomil 20mg/Day with Calcium channel blockers (amlodipine or azelnidipine)
1744408|NCT00134173|Drug|torcetrapib/atorvastatin|
1744409|NCT00134173|Drug|atorvastatin|
1744410|NCT00134186|Drug|motexafin gadolinium|
1744413|NCT00134212|Drug|Dopexamine and norepinephrine|
1744414|NCT00134212|Drug|Epinephrine|
1744415|NCT00134225|Device|Muscle Pattern Recognition (MPR)|
1744416|NCT00134238|Drug|torcetrapib/atorvastatin|
1744417|NCT00134238|Drug|atorvastatin|
1744418|NCT00134251|Drug|SLV308|
1744419|NCT00134264|Drug|torcetrapib/atorvastatin|
1744420|NCT00134264|Drug|atorvastatin|
1744421|NCT00134277|Procedure|Infragenual dilatation|Infragenual dilatation
1744422|NCT00134277|Procedure|Infragenual dilatation with stenting|Infragenual dilatation with stenting
1744423|NCT00134277|Procedure|Infragenual dilatation with cutting balloon|Infragenual dilatation with cutting balloon
1744424|NCT00134277|Procedure|Laser therapy|Laser therapy
1744425|NCT00134290|Drug|metformin|
1744426|NCT00134290|Behavioral|"standard diet advice"|
1744427|NCT00134290|Behavioral|"personal diet advice"|
1744428|NCT00134303|Drug|Metformin|Metformin is used.
1744429|NCT00134316|Behavioral|psychoeducational intervention|three 75 minute long individual psychoeducational sessions
1744430|NCT00134329|Procedure|Filling out a questionnaire on the possible occurrence of erectile dysfunction|
1744431|NCT00134342|Other|T-SPOT TB ELISPOT test|ELISPOT test for detecting T cell responses to tuberculosis antigens.
1744432|NCT00134355|Drug|PTK787|
1744433|NCT00134368|Drug|Etanercept|
1744434|NCT00134381|Drug|Green Tea|Green tea product (EGCG or caffeine) in vehicle will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
1744435|NCT00134381|Drug|Placebo|Placebo (vehicle alone) will be applied immediately after and at sequential time points after exposure of a 5x5-cm area of skin to a dose of UVB that is 0.5-2 times the subject's minimal erythema dose (MED)
1744436|NCT00134394|Drug|Etanercept plus tacrolimus|
1744437|NCT00134407|Procedure|Normal diet|
1744438|NCT00134407|Procedure|Nutrition via jejunal needle-catheter|
1744439|NCT00134420|Drug|Nutropin AQ|Growth Hormone (Nutropin AQ) treatment given to Group 1 immediately Growth Hormone (Nutropin AQ) treatment given to Group 2 after one year observation
1744440|NCT00134420|Procedure|Arginine and Clonidine Stimulation Testing|This testing was done to determine growth hormone status prior to starting treatment.
1744441|NCT00134420|Procedure|Growth Factors Laboratory Testing|This involved assessment of growth factors such as IGF#1 before treatment was initiated.
1744442|NCT00134420|Procedure|Neuropsychological Testing|This testing was done prior to treatment and at the end of treatment.
1744443|NCT00134433|Genetic|intramyocardial VEGF angiogenesis (at a dose of 2 mg)|
1744444|NCT00134433|Drug|oral L-arginine supplementation (at a dose of 6 g/day)|
1744445|NCT00134446|Device|transcranial magnetic stimulation|
1744446|NCT00134459|Drug|Bifeprunox|
1744447|NCT00134459|Drug|Placebo|
1744448|NCT00134472|Procedure|Therapeutic mild hypothermia|Keeping 32 - 34 degree celsius of core temperature at least for 72 hours.
1744449|NCT00134485|Drug|torcetrapib/atorvastatin|
1744450|NCT00134485|Drug|atorvastatin|
1744451|NCT00134498|Drug|torcetrapib/atorvastatin|
1744452|NCT00134498|Drug|atorvastatin|
1744453|NCT00134511|Drug|Torcetrapib/atorvastatin|
1744454|NCT00134524|Procedure|MME procedure|
1744455|NCT00134537|Device|Interspinous process and dynamic stabilization|Interspinous process and dynamic stabilization
1744456|NCT00134537|Device|Conservative Care|Medication, exercise and spinal injections
1956557|NCT02804035|Combination Product|sc2Wear Furosemide|Drug-device combination product of buffered furosemide injection, (Furosemide Injection Solution), 8 mg/mL, and patch pump (sc2Wear Furosemide Pump)
1744458|NCT00134563|Drug|Teriflunomide|"Film-coated tablet
Oral administration"
1744459|NCT00134563|Drug|Placebo (for teriflunomide)|"Film-coated tablet
Oral administration"
1744460|NCT00134576|Behavioral|Computer Assisted Education for Behavioral Change|TLC-Detect will provide subjects in the intervention group with information about each diagnosed mental health disorder. TLC-Detect will then give the Treatment Module and will tell the intervention subjects that it will call back in one month for a follow-up or the next week if a subject is comorbid with other disorders.
1744461|NCT00134589|Behavioral|Academic Detailing (Medical Practices)+Decision Aids (Patients)|
1744462|NCT00134602|Behavioral|Needs assessment followed by tailored intervention|
1744463|NCT00134615|Behavioral|RQP patient health education module|
1744464|NCT00134628|Procedure|Hyperbaric Oxygen Therapy|HBO at 2.0 ATA
1744465|NCT00134628|Procedure|Sham treatment|Normal air under pressure (1.1 ATA)
1744466|NCT00134641|Drug|gemcitabine|
1744467|NCT00134641|Drug|vinorelbine|
1744468|NCT00134654|Drug|Premarin|Group A: 1.25mg once a day Group B: 1.25mg three time a day Group A has been closed and participants have been given the option of enrolling in Group B. Treamtment can continue until disease progression or serious side effects.
1744469|NCT00134667|Drug|Photodynamic Therapy (PDT) with Visudyne (verteporfin)|
1744470|NCT00134667|Drug|Macugen (pegaptanib sodium)|
1744471|NCT00134680|Drug|Letrozole|Letrozole tablets 2.5 mg by mouth daily
1744472|NCT00134680|Drug|Trastuzumab|Weekly trastuzumab (4 mg/kg loading dose given by IV over 90 minutes folowed by 2 mg/kg given by IV weekly over 30 minutes, provided the previous dose was well tolerated.
1744475|NCT00134706|Drug|Docetaxel|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
1744476|NCT00134706|Drug|Carboplatin|Given intravenously over 2-3 hours once every three weeks. Participant can continue to receive treatment as long as there is no disease progression or serious side effects.
1744477|NCT00134719|Biological|MenHibrix (Hib-MenCY-TT)|One intramuscular dose at 2, 4 and 6 months of age ( group A) and one intramuscular dose at 12 to 15 months of age (groups A and B)
1744478|NCT00134719|Biological|Infanrix® Penta|One intramuscular dose at 2, 4 and 6 months of age
1744479|NCT00134719|Biological|Prevenar®|One intramuscular dose at 2, 4 and 6 months of age
1744480|NCT00134719|Biological|ActHIB®|One intramuscular dose at 2, 4 and 6 months of age
1744481|NCT00134719|Biological|Meningitec®|One intramuscular dose at 2, 4 and 6 months of age
1744482|NCT00134719|Biological|M-M-R®II|One subcutaneous dose at 12-15 months of age
1744483|NCT00134719|Biological|Varivax®|One subcutaneous dose at 12 to 15 months of age
1744484|NCT00134719|Biological|PedvaxHIB®|One intramuscular dose at 12 to 15 months of age
1744485|NCT00134732|Biological|Live attenuated human rotavirus vaccine|
1744486|NCT00134745|Drug|estradiol|tablets, 2 mg day 1 through day 22 of the menstrual cycle for 5 years
1744487|NCT00134758|Drug|Ursodeoxycholic acid|"During 2 years :
between 40 and 50 kg : 500 mg/day
between 51 and 75 kg : 750 mg/day
between 76 and 100 kg : 1000 mg/day"
1744488|NCT00134758|Drug|Placebo|"During 2 years :
between 40 and 50 kg : 2 tabs/day
between 51 and 75 kg : 3 tabs/day
between 76 and 100 kg : 4 tabs/day"
1744489|NCT00134771|Drug|Nutrient enriched infant formula|
1744490|NCT00134784|Drug|[123I]B-CIT SPECT imaging|To assess [123I]B-CIT SPECT imaging
1744491|NCT00134810|Drug|Botulinum type A toxin (Dysport®)|
1744492|NCT00134823|Other|weight based dosing decision support|weight based dosing decision support
1744493|NCT00134836|Behavioral|Preventive Primary Care Outreach|Nurse home visit at baseline, 6 months, 12 months, including comprehensive assessment using MDS HC, care planning, referral to appropriate services
1744494|NCT00134875|Drug|Buprenorphine/naloxone|Acute doses of buprenorphine/naloxone in each experimental test session. Doses delivered by either sublingual or parenteral routes, and are: 4/1, 8/2, 16/4 mg.
1744495|NCT00134888|Drug|Buprenorphine/naloxone|
1744496|NCT00134901|Drug|Memantine|Memantine
1744497|NCT00134901|Drug|placebo|placebo
1744498|NCT00134914|Drug|Buprenorphine|single doses given by sublingual and parenteral routes
1744499|NCT00134953|Drug|Rivastigmine|
1744500|NCT00134966|Drug|capsules containing: carbidopa (25 mg), levodopa (100 mg), entacapone (200 mg)|
1744501|NCT00134979|Drug|Formoterol|
1744502|NCT00134992|Drug|Prednisolone acetate|
1744503|NCT00135005|Drug|AMN107, STI571|
1744504|NCT00135018|Drug|celecoxib and chemotherapy|
1744505|NCT00135031|Drug|Bifidobacterium infantis 35624|
1744506|NCT00135044|Procedure|intravenous taurine in nutritional supplement|
1744507|NCT00135057|Drug|insulin glulisine|
1744508|NCT00135057|Drug|insulin glargine|
1744509|NCT00135070|Drug|Detemir|
1744510|NCT00135083|Drug|insulin glulisine|"Once Daily Insulin: Subjects will receive insulin glulisine administered once daily 0-15 minutes before the greatest glycemic impact meal of the day starting at one-tenth the total dose of insulin glargine with maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.
Twice Daily: Subjects will receive insulin glulisine administered twice daily 0-15 minutes before the 2 greatest glycemic impact meals of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units, and with additional monitoring as shown in the table below.
Three Times Daily: Subjects will receive insulin glulisine administered 3 times daily 0-15 minutes before each meal of the day starting at one-tenth the total dose of insulin glargine with a maximum starting dose of 10 Units for each meal and additional monitoring as shown in the table below."
1744511|NCT00135096|Drug|insulin glulisine|PREMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day 0-15 min before the three main meals; metformin (if applicable); and Lantus qd for 52 weeks.
1744512|NCT00135096|Drug|insulin glargine|POSTMEAL ARM: Subjects randomized to this arm will receive Apidra administered three times per day immediately after a meal (20 min after the start of a meal); metformin (if applicable); and Lantus qd for 52 weeks.
1744513|NCT00135109|Drug|SPM 927|
1744514|NCT00135122|Drug|prednisolone|Prednisolone 60mg day 1 and 2 , 40mg day 3 and 4 , 20mg day 5 and 6
1744515|NCT00135135|Drug|Gefitinib, Irinotecan, Cycophosphamide, Doxorubicin, Etoposide, Cisplatin, Topotecan, Carboplatin, Melphalan, 13-cis retinoic acid|See Detailed Description.
1744516|NCT00135135|Procedure|Radiation therapy, Surgery, Peripheral Stem cell transplant|See Detailed Description.
1744517|NCT00135148|Procedure|Filling out a questionnaire on libido and possible partner relationship|
1744518|NCT00135148|Procedure|Sex steroid analysis|
1744519|NCT00135161|Procedure|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).|FDG-PET-based dose escalation using intensity modulated radiation therapy (IMRT).
1744520|NCT00135187|Drug|VELCADE|"VELCADE will be used biweekly at 1.3 mg/m2 during week 1 and 2 on (days
1, 4, 8, and 11) followed by a 1-week break."
1744521|NCT00135187|Drug|Doxil|Doxil will be administered at 30 mg/m2 IV on day 4
1744522|NCT00135187|Drug|Dexamethasone|Dexamethasone at 40 mg during the first cycle and 20 mg during cycles 2-6 po or IV daily on days of VELCADE and day after VELCADE (i.e. days 1, 2, 4, 5, 8, 9, 11, 12). The patient will be treated for six 3-week cycles followed by three 5-week maintenance cycles.
1744523|NCT00135200|Drug|Iodine I 131 Tositumomab|"The Bexxar therapeutic regimen is delivered in two sets of intravenous infusions given 7-14 days apart. Nonradioactive Tositumomab is given before both the dosimetric infusion and the therapeutic infusion to improve distribution of these doses throughout the body. A trace amount of radioactive Iodine 131 attached to Tositumomab is initially given to enable physicians to evaluate the clearance of radiation from your body with gamma camera scans. Calculations made on the basis of these individualized radiation clearance rates allow the therapeutic dose (given 7-14 days after the dosimetric infusion) to be tailored for each patient. The therapeutic dose contains Tositumomab labeled with the amount of Iodine 131 tositumomab specifically calculated for you based on the scans performed following the dosimetric dose."
1744524|NCT00135213|Behavioral|training in smoking cessation|
1744525|NCT00135226|Drug|aspirin|
1744526|NCT00135226|Drug|Omega-3-acid Ethyl Esters|
1744527|NCT00135226|Drug|Placebo Aspirin|
1744528|NCT00135226|Drug|Placebo omega-3-Ethyl Esters|
1744590|NCT00135694|Drug|corticosteroids|3-month course of corticosteroids
1744591|NCT00135694|Other|immunosuppression withdrawal|One year after transplantation, participants eligible for withdrawal are randomly assigned in a 4 to 1 ratio to immunosuppression withdrawal or to maintenance.
1745052|NCT00149201|Drug|MTX + 5-FU sequential therapy|
1744529|NCT00135239|Procedure|Study care|All study patients will be assessed initially by a physician in the CNOSP outpatient clinic to confirm that they meet the inclusion/exclusion criteria of the study. Patients receiving the EBC intervention will then receive re-assurance, advice to avoid passive treatments, acetominophen (except where contraindicated) for a period of 2-4 weeks, a four week course of lumbar spine spinal manipulative therapy administered by a CNOSP Chiropractor and advice to return to work in some capacity within eight weeks following the start of treatment. Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
1744530|NCT00135239|Procedure|Usual care|Patients randomized to the UC treatment arm will undergo the treatment(s) recommended by their family physicians.
1744531|NCT00135252|Procedure|nasal cannula oxygen delivery|
1744532|NCT00135252|Procedure|supplemental oxygen delivery by hood|
1744533|NCT00135265|Behavioral|smoking cessation, practice change|Providers will be trained in a brief smoking cessation intervention for teens.
1744535|NCT00135291|Procedure|Leukoreduced blood transfusion|
1744536|NCT00135304|Drug|Sensipar®|Cinacalcet hydrochloride
1744537|NCT00135304|Drug|Vitamin D|Vitamin D administered IV
1744538|NCT00135317|Drug|darbepoetin alfa|
1744539|NCT00135330|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
1744540|NCT00135330|Drug|rosiglitazone|oral tablet, 2mg or 4mg, twice a day
1744541|NCT00135343|Drug|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral, ATV 300 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
1744542|NCT00135343|Drug|Atazanvir/ritonavir + efavirenz|Capsules (ATV and RTV) Tablets (EFV), Oral ATV 400 mg + RTV 100 mg + EFV 600 mg, Once daily, 48 weeks.
1744543|NCT00135356|Drug|Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs)|Capsules, Oral, ATV 300 mg + RTV 100 mg once daily up to 96 weeks
1744544|NCT00135356|Drug|continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)|Protease inhibitor [PI] combination + 2 NRTIs
1744545|NCT00135369|Drug|stavudine extended-release, lamivudine, efavirenz|
1744546|NCT00135382|Drug|Videx EC|
1744547|NCT00135382|Drug|Epivir|
1744548|NCT00135382|Drug|Sustiva|
1744549|NCT00135395|Drug|Atazanavir+ritonavir|Capsules, Oral, 300mg/100mg, once daily, 24 weeks.
1744550|NCT00135395|Drug|Lopinavir+ritonavir|Capsules, Oral, 800mg/200mg, twice daily, 24 weeks.
1744551|NCT00135408|Drug|Ipilimumab+ Placebo|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
1744552|NCT00135408|Drug|Ipilimumab+ Budesonide|Solution/Capsule, Intravenous/Oral, 10 mg/kg + 9 mg, 3 weeks (Ipilimumab) + once daily until week 16 (Budesonide), 12 - 48 weeks depending on the response.
1744553|NCT00135421|Drug|Pexacerfont|Tablets & Capsules, Oral, 100 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation
1744554|NCT00135421|Drug|Escitalopram|Tablets & Capsules, Oral, 20 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
1744555|NCT00135421|Drug|Placebo|Tablets & Capsules, Oral, 0 mg, Once daily, Up to 8 weeks followed by 8 weeks of observation.
1744556|NCT00135434|Drug|Atazanavir/Ritonavir/Lopinavir/ritonavir|
1744557|NCT00135460|Drug|nucleoside analogue sparing HAART regimen|
1744558|NCT00135473|Drug|10% Hemohes® (10% Hydroxyethyl starch)|
1744559|NCT00135473|Drug|Sterofundin® (Ringer lactate solution)|
1744560|NCT00135473|Drug|Actrapid® (Insulin)|
1744561|NCT00135486|Biological|MenC-TT|
1744562|NCT00135486|Biological|Hib-MenC-TT|
1744563|NCT00135499|Drug|CHOP plus rituximab|
1744564|NCT00135499|Drug|ACVBP plus rituximab|
1744566|NCT00135525|Drug|Paroxetine|"Fixed Dose (20 mg/day): The fixed dose of 20 mg/day was selected, because it is the recommended dose for the treatment of GAD in the US and other countries.
Flexible Dose (20 - 40 mg/day): Overseas, the maximum dose in the treatment of GAD is 50 mg/day. However, 40 mg/day was selected as the maximum dose for this flexible dose session, because overseas clinical studies have indicated that paroxetine is sufficiently effective at doses of 20 - 40 mg/day and this is the dose range approved for depression/depressive episodes in Japan."
1744567|NCT00135525|Drug|Placebo|Placebo
1744568|NCT00135538|Device|Noninvasive positive pressure ventilation|
1744569|NCT00135551|Drug|Angiotensin receptor blockers|benidipine+angiotensin receptor blocker, titlation scheme
1744570|NCT00135551|Drug|β-blockers|benidipine+β-blockers, titlation scheme
1744571|NCT00135551|Drug|thiazide diuretics|benidipie+thiazide diuretics, titlation scheme
1744572|NCT00135564|Biological|MenC-TT|
1744573|NCT00135564|Biological|Hib-MenC-TT|
1744574|NCT00135577|Drug|alvimopan|
1744575|NCT00135577|Drug|placebo|
1744576|NCT00135590|Dietary Supplement|Protein pulse-feeding|Dietary protein (80% of daily intake) was consumed in one meal (12.00h)
1744577|NCT00135590|Dietary Supplement|Spread diet|Dietary protein was spread over the four meals.
1744578|NCT00135603|Drug|amoxicillin/clavulanate potassium|1 gramme, 3 times a day, intra venous initially and then orally for one or two weeks
1744579|NCT00135603|Procedure|appendectomy|ablation of the appendix by laparotomy or laparoscopy
1744580|NCT00135616|Device|surgical placement of a suburethral sling tvt or tvt-o|
1744581|NCT00135629|Biological|Sublingual Alutard SQ grass pollen tablets (Phleum pratense)|
1744582|NCT00135629|Procedure|Venepuncture: 100ml blood sample taken on 12 separate visits|
1744583|NCT00135642|Biological|Subcutaneous Alutard SQ grass pollen (Phleum pratense)|
1744584|NCT00135642|Procedure|Venepuncture: 20 ml blood sample taken on 2 separate visits|
1744585|NCT00135655|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
1744587|NCT00135681|Drug|nedocromil budesonide|
1744588|NCT00135694|Drug|calcineurin inhibitor-based immunosuppression|May be cyclosporine, mycophenolate mofetil, or tacrolimus
1744589|NCT00135694|Procedure|liver transplant|Occurs at study entry
1744593|NCT00135720|Drug|Enbrel (Etanercept)|
1744594|NCT00135733|Drug|Amevive (Alefacept)|
1744595|NCT00135733|Drug|Placebo|
1744596|NCT00135746|Drug|nicotine transdermal system|
1744597|NCT00135759|Drug|Naltrexone|low dose naltrexone in addition to daily methadone taper
1744598|NCT00135759|Drug|Placebo comparator|1 capsule/day for 6 days
1744599|NCT00135759|Drug|naltrexone|0.125 mg capsule/day for 6 days
1744600|NCT00135759|Drug|naltrexone|0.250 mg capsule/day for 6 days
1744601|NCT00135785|Drug|Bupropion|
1744602|NCT00135785|Drug|Placebo|
1744603|NCT00135798|Drug|LADR Treatment|"PEG-Intron (peginterferon alfa-2b (PEGIFN)) Redipen; Rebetol (ribavirin (RBV) United States Pharmacopeia (USP)) Capsules:
Treatment was initiated with PEGIFN 0.75 µg/kg/week and RBV 600 mg/day. Dose escalations were performed at weeks 1 (PEGIFN 1.5 µg/kg/week and RBV 800 mg/day), 2 (RBV 1.0 g/day), and 3 (RBV 1.2 g/day for patients who weighed more then 75 kg) based upon patient tolerance and weekly blood counts. Once a patient reached the target RBV dose of 1-1.2 g/day (approximately 10.6 to 13.2 mg/kg/day), no further increases in RBV dose were made. Subsequent doses of PEGIFN and RBV were adjusted based upon adverse events, patient tolerability, and blood counts. If the highest tolerated dose of PEGIFN was <0.5 ug/kg, PEGIFN was permanently discontinued."
1744604|NCT00135811|Drug|Cyclosporin|Participants assigned to this group will initiate treatment with CSA, 5-6 mg/kg per day with a 250 mg/day maximum starting dose, divided into two daily doses. The CSA dose will be adjusted based on drug levels determined at specified study visits in order to achieve a 12-hour trough concentration in the therapeutic range of 100-250 ng/ml.
1744605|NCT00135811|Drug|MMF and Dexamethasone|"MMF, 25-36 mg/kg per day with a maximum dose of 2 g/day divided into two daily doses. The dose range reflects the use of fixed size (250 mg) capsules and application of defined daily doses to specific weight ranges (see Table below). In younger children or those participants who are unable to swallow capsules, a liquid formulation will be used to provide 36 mg/kg per day to a maximum of 2 g per day. The starting MMF dose will be 0.5-0.67 of the full dose for 2 weeks before advancing to the full dose for the duration of the 12-month treatment period.
Dexamethasone, 0.9 mg/kg per dose, with a maximum dose of 40 mg"
1744606|NCT00135824|Drug|Povidone K25 eye drops (povidone)|
1744607|NCT00135837|Drug|Verteporfin for injection|
1744608|NCT00135850|Genetic|VEGF-A165 plasmid|
1744609|NCT00135863|Drug|tinzaparin|
1744610|NCT00135876|Drug|dalteparin|
1744611|NCT00135889|Drug|Femoral perineural infusion|
1744612|NCT00135902|Drug|17 alpha-Hydroxyprogesterone Caproate and Omega-3 fish oils|
1744613|NCT00135928|Drug|Granulocyte Colony Stimulating Factor G-CSF (Neupogen®)|
1744614|NCT00135941|Drug|insulin glargine|Sequence 1 (Lantus + Apidra first, then Premix): Subjects randomized to this sequence will receive ApidraTM administered three times per day 0-15 minutes before main meals using a fixed bolus regimen following titration based on preprandial blood glucose values; as well as Lantus qd for 12 weeks. After the first 12 weeks, subjects will cross over to the premix insulin for a further treatment of 12 weeks.
1744615|NCT00135941|Drug|insulin glulisine|Sequence 2 (Premix first, then Lantus + Apidra): Subjects randomized to this sequence will receive premix insulin (either Humalog Mix 75/25 or Novolog Mix 70/30, depending on which insulin they were taking at entry into the study) once or twice per day for 12 weeks. After the first 12 weeks, subjects will cross over to the Lantus plus Apidra sequence for a further treatment of 12 weeks.
1744616|NCT00135954|Drug|Cyclophosphamide and steroids|comparison of difference in time of start of therapy
1744617|NCT00135967|Drug|mycophenolate mofetil orally 1000 mg twice a day (BID)|
1744618|NCT00135967|Drug|prednisone 0,5 mg/kg orally on alternate days|
1744619|NCT00135967|Drug|intravenous (i.v.) methylprednisolone 1000 mg, total 9|
1744620|NCT00135980|Behavioral|professional audit and feedback|
1744621|NCT00135980|Behavioral|integrated care programmes|
1744622|NCT00135993|Drug|Rotigotine|
1744623|NCT00136006|Behavioral|Study to determine the burden of disease|Unspecified
1744624|NCT00136019|Drug|SPM 927|
1744625|NCT00136032|Drug|Somatropin|Stratified based on age and estrogen status from 3 to 6 mcg/kg/day
1744626|NCT00136032|Drug|Placebo|Dosage based on age and estrogen status ranging from 3 to 6 mcg/kg/day
1744627|NCT00136045|Drug|Rotigotine|
1744628|NCT00136058|Procedure|bone densitometry (DEXA)|
1744629|NCT00136058|Drug|alendronate or risedronate|
1744630|NCT00136071|Device|Transobturator tape-ARIS|
1744631|NCT00136071|Device|TVT-O|
1744632|NCT00136084|Drug|Cladribine, Cyclophosphamide, Cytarabine, Daunorubicin, Dexamethasone|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
1744633|NCT00136084|Drug|Etoposide, Cytarabine, Gemtuzumab, L-asparaginase, Mercaptopurine, methotrexate, Mitoxantrone, Prednisone, Vincristine|Since limited characters are allowed in this passage, please see detailed Description to know the dosage, dosage form, frequency of administration for the above mentioned drugs
1744634|NCT00136097|Device|Placement of a silver impregnated central venous catheter|
1744635|NCT00136110|Drug|Sodium Valproate|
1744636|NCT00136123|Procedure|Placement of functional loaded synthetic teeth after placement implants|Placement of functional loaded synthetic teeth after placement implants
1744637|NCT00136136|Procedure|Registration of the bispectral index and spectral edge frequency|Registration of the bispectral index and spectral edge frequency
1744638|NCT00136149|Procedure|Immediate implants|Immediate implants are used.
1744639|NCT00136175|Drug|Paclitaxel|
1744640|NCT00136175|Drug|Carboplatin|
1744641|NCT00136175|Drug|Gemcitabine|
1744642|NCT00136188|Drug|Folic Acid|oral administration of folic acid 5mg /d for 4 weeks
1744643|NCT00136201|Drug|tigecycline|
1744644|NCT00136227|Behavioral|small media intervention using video, flip chart, and pamphlets and a tailored interactive multimedia intervention|
1744645|NCT00136240|Behavioral|Computer Assisted Education for Behavior Change|
1744646|NCT00136253|Behavioral|Help dietitians and patients address specific nutritional barriers|
1744647|NCT00136266|Drug|Ferrous sulphate drops with vitamins A, D, and C|
1744648|NCT00136266|Drug|Ferrous fumarate sprinkles with vitamins and minerals|
1744649|NCT00136279|Behavioral|Linking Lives parent-based intervention|Parent intervention consists of mothers attending two, 2.5 hour-long, face-to-face sessions at the school during which they are given an intervention manual, two homework assignments, and a manual for their adolescent. Parents also receive two booster telephone calls approximately one-month and six-months after completing the intervention. As part of the comparison condition, school-based interventions for adolescents also consist of two, 2.5 hour-long, face-to-face sessions at schools during which they complete either the Project TNT intervention for preventing tobacco use or the Making a Difference intervention for reducing sexual risk behavior.
1744650|NCT00136292|Drug|daptomycin|
1744651|NCT00136305|Behavioral|Pictorial asthma action plan|
1744652|NCT00136305|Behavioral|Written asthma action plan|
1744653|NCT00136318|Drug|Escitalopram|
1744654|NCT00136318|Drug|Placebo|
1744655|NCT00136318|Drug|Peginterferon alfa-2a|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with PEGinterferon-alfa2a, 180 mcg weekly. Patients with genotype 2 or 3 received PEGinterferon-alfa2a, 180 mcg weekly.
1744656|NCT00136318|Drug|Ribavirin|Patients with HCV genotype 1 or 4 received treatment for 48 weeks with ribavirin, 1000 mg per day (body weight 75 kg) or 1200 mg per day (body weight, 75 kg). Patients with HCV genotype 2 or 3 received ribavirin, 800 mg per day for 24 weeks.
1744657|NCT00136331|Biological|Pandemic influenza vaccine|
1744658|NCT00136344|Drug|Cefuroxime|
1744659|NCT00136344|Drug|Levofloxacin|
1744660|NCT00136357|Behavioral|Mind-Body Skills Groups|12 week mind-body skills group program including guided imagery, relaxation techniques,autogenic training, meditation, biofeedback, drawings, genograms and movement techniques.
1744661|NCT00136370|Drug|Chlorhexidine|
1744662|NCT00136370|Procedure|Birth canal wipe|
1744663|NCT00136370|Procedure|sterile water external genital wipe|
1744664|NCT00136383|Drug|paroxetine versus duloxetine|
1744665|NCT00136396|Drug|Rituximab|Given once weekly for 4 weeks followed by a 4 week observation therapy.
1744666|NCT00136409|Drug|Imatinib mesylate|400mg orally once daily until disease progression or unacceptable side effects
1744667|NCT00136422|Biological|autologous tumor cells|
1744668|NCT00136435|Drug|prednisone|Induction Phase: Given orally on days 1-28
1744669|NCT00136435|Drug|doxorubicin|Induction Phaese: Given intravenously on day 1 and day 2 CNS Therapy: Given intravenously on day 1 Intensification: Given day 1 of each cycle
1744670|NCT00136435|Drug|vincristine|"Induction: Given intravenously on days 1, 8, 15, and 22. If complete remission not acheived, will be given on days 29, 36 and 43.
CNS Therapy: Given intravenously on day 1. Intensification: Given intravenously on day 1 of each cycle. Continuation: Given intravenously on day 1 of each cycle"
1744671|NCT00136435|Drug|methotrexate|Induction: Given intravenously on day 3. CNS Therapy: Given intrathecally 4 times over two weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intravenously weekly and intrathecally every 18 weeks
1744672|NCT00136435|Drug|asparaginase|Induction: Given into the muscle on day 5
1744673|NCT00136435|Drug|dexamethasone|Intensification: Given orally on days 1-5 of each cycle
1744674|NCT00136435|Radiation|cranial radiation|Given in 10 daily treatments during CNS therapy phase
1744675|NCT00136435|Drug|leucovorin|Induction: Given intravenously or orally 36 hours after methotrexate
1744676|NCT00136435|Drug|cytarabine|Induction: Given intrathecally days 1, 15, 29 CNS Therapy: Given intrathecally 4 times over 2 weeks Intensification: Given intrathecally every 18 weeks Continuation: Given intrathecally every 18 weeks
1744677|NCT00136435|Drug|hydrocortisone|Induction: Given intrathecally on days 15 and 29. Intensification: Given intrathecally every 18 weeks. Continuation: Given intrathecally every 18 weeks.
1744678|NCT00136435|Drug|6-mercaptopurine (6-MP)|CNS Therapy: Taken orally on days 1-14. Intensification: Taken orally on days 1-14. Continuation: Taken orally on days 1-14.
1744679|NCT00136435|Drug|e. coli L-asparaginase|Intensification: Given in to the muscle weekly.
1744680|NCT00136448|Drug|cytosine arabinoside (ara-C)|
1744681|NCT00136448|Drug|daunomycin|
1744682|NCT00136448|Drug|interleukin-2|
1744683|NCT00136461|Drug|All-trans retinoic acid|
1744684|NCT00136461|Drug|Bryostatin 1|
1744685|NCT00136474|Drug|Amifostine|Given 30-60 minutes prior to daily radiation therapy
1744686|NCT00136474|Radiation|Radiation Therapy|Daily radiation therapy
1744687|NCT00136487|Drug|Celecoxib|
1744688|NCT00136513|Drug|SB-743921|
1744689|NCT00136526|Drug|Docetaxel and Diethylstilbestrol (DES)|Subjects receive docetaxel 36 Mg/m2weekly for ten cycles (3 weeks out of every 4) and DES 1 mg daily for 40 weeks or until there is evidence of disease progression, whichever occurs first.
1744690|NCT00136539|Drug|Herceptin|Given intravenously once weekly for 12 weeks prior to surgery.
1744691|NCT00136539|Drug|Taxol|Given intravenously every 3 weeks (weeks 1, 4, 7, and 10) before surgery.
1744692|NCT00136539|Drug|Adriamycin|Given every three weeks for 12 weeks after surgery.
1744693|NCT00136539|Drug|Cytoxan|Given every three weeks for 12 weeks after surgery.
1744694|NCT00136552|Drug|rituximab|
1744695|NCT00136565|Drug|Velcade + ACVBP regimen|
1744696|NCT00136578|Drug|SB-715992|SB-715992 will be available either as 5 milliliter (mL) vial containing 4 milligram (mg) of SB-715992 or 4 mL vial containing 5 mg of SB-715992 at a concentration of 1 mg/mL OR a 10 mL vial that contains 10 mg of SB-715992 in a 10 mL solution at a concentration of 1 mg/mL.
1744697|NCT00136578|Drug|carboplatin|Carboplatin will be available as sterile, lyophilized white powder available in single-dose vials containing 50 mg, 150 mg, and 450 mg of carboplatin for administration by IV infusion. Each vial will be reconstituted with either Sterile Water for Injection, USP, 5% Dextrose in Water (D 5 W), or 0.9% Sodium Chloride Injection, USP.
1744698|NCT00136591|Drug|Bortezomib|Arm A: a 21-day cycle of 1.5 mg/m2 Velcade™ twice weekly for 2 weeks. Days 1, 4, 8, and 11 of a 21-day cycle
1744866|NCT00147745|Drug|Insulin glargine (Lantus)|Insulin glargine for 12 weeks
1744867|NCT00147758|Drug|Colesevelam hydrochloride|
1744699|NCT00136591|Drug|Bortezomib|Arm B: a 35-day cycle of 1.6 mg/m2 Velcade™once weekly for 4 weeks. Days 1, 8, 15, and 22 of a 35-day cycle. Subjects in this treatment arm will receive a total of 6 cycles of treatment, approximately 30 weeks.
1744701|NCT00145470|Drug|Asenapine|Asenapine fast dissolving tablets 5 and 10 mg; starting dose 5 mg BID 1 day; 10 mg BID after Day 1
1744702|NCT00145470|Drug|placebo|Placebo fast dissolving tablets BID
1744703|NCT00145483|Drug|Sildenafil|
1744704|NCT00145496|Drug|Asenapine|5-10 mg sublingually twice daily for up to 26 weeks
1744705|NCT00145496|Drug|Olanzapine|5-20 mg by mouth once daily for up to 26 weeks
1744706|NCT00145509|Drug|Asenapine|Asenapine 5 or 10 mg twice daily (BID) sublingually for 40 weeks
1744707|NCT00145509|Drug|Placebo|Fast-dissolving tablet; twice daily (BID) sublingually for 40 weeks
1744708|NCT00145522|Drug|17ß-Estradiol/Dydrogesterone|1/5 mg/day for 12 cycles of 28 days
1744709|NCT00145522|Drug|Tibolone|2,5 mg/day for 12 cycles of 28 days
1744710|NCT00145535|Device|SOLX Titanium Sapphire Laser (TiSaLT)|Spot laser treatment, ~50 spots over 180°
1744711|NCT00145535|Device|Argon Laser Trabeculoplasty (ALT)|Spot laser treatment, ~50 spots over 180°
1744712|NCT00145548|Device|Intra Bronchial Valve|
1744713|NCT00145561|Drug|Saquinavir and Ritonavir|
1744714|NCT00145574|Drug|colesevelam HCl|Tablets
1744715|NCT00145574|Drug|placebo|Matching Tablets
1744716|NCT00145587|Procedure|Stem Cell Transplantation|An infusion of HLA partially matched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
1744717|NCT00145587|Device|Miltenyi Biotec CliniMACS|Stem cell selection device
1744718|NCT00145587|Drug|Systemic chemotherapy and antibodies|"Haploidentical stem cell transplant recipients will receive a reduced intensity conditioning regimen consisting of OKT-3, Fludarabine, Thiotepa , and Melphalan followed by an infusion of a T-cell depleted donor stem cell product. Rituximab will be administered within 24 hours of the infusion in an effort to prevent post transplantation lymphoproliferative disorders (PTLPD). In addition to T-cell depletion of the donor product, cyclosporine will be provided as prophylaxis for (GVHD)Graft versus Host Disease
Recipients of a matched sibling donor product will receive a myeloablative conditioning regimen consisting of busulfan and cyclophosphamide. Cyclosporine will be administered for GVHD prophylaxis."
1744719|NCT00145600|Drug|12 Week Stanford V Chemotherapy|12 weeks of Stanford V chemotherapy plus low-dose, involved-field RT in children
1744720|NCT00145600|Drug|4 cycles of VAMP chemotherapy|4 cycles of VAMP chemotherapy alone in patients who achieve a complete response after 2 cycles of VAMP chemotherapy. For patients that do not achieve a complete response after 2 cycles of VAMP, they will receive low low-dose involved field radiotherapy at the end of all chemotherapy.
1744721|NCT00145600|Drug|2 alternating cycles of VAMP/COP chemotherapy|2 alternating cycles of VAMP/COP chemotherapy (total 4 cycles of chemotherapy) plus low-dose, involved-field RT.
1744722|NCT00145600|Drug|3 alternating cycles of VAMP/COP chemotherapy|3 alternating cycles of VAMP/COP chemotherapy (total 6 cycles of chemotherapy) plus low-dose, involved-field RT
1744723|NCT00145613|Procedure|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
1744724|NCT00145613|Device|Miltenyi Biotec CliniMACS|stem cell selection device
1744725|NCT00145613|Drug|Systemic chemotherapy and antibodies|Transplant recipients received a non-TBI based reduced intensity conditioning regimen consisting of OKT-3, Fludarabine Thiotepa, and Melphalan. Rituximab was administered within 24 hours of the transplant in an effort to prevent PTLPD. In addition to T-cell depletion of the haploidentical stem cell product, Mycophenolate mofetil was provided as prophylaxis for GVHD.
1744726|NCT00145626|Drug|Chemotherapy and antibodies|Study participants will receive a non-TBI based preparative regimen consisting of Cyclophosphamide, fludarabine, thiotepa, melphalan, and muromonab-CD3 (OKT3) followed by an infusion of a T-lymphocyte depleted haploidentical hematopoietic stem cell graft. Seven days posttransplant, participants will receive an infusion of additional donor derived cells called NK cells.
1744727|NCT00145626|Device|Miltenyi Biotec CliniMACS|Stem cell selection device
1744728|NCT00145626|Procedure|Allogeneic stem cell transplantation|Allogeneic natural killer (NK)cell infusion
1744729|NCT00145639|Drug|Ifosfamide, Carboplatin, Doxorubicin|See Detailed Description for treatment plan.
1744730|NCT00145639|Procedure|Limb Sparing|See Detailed Description for treatment plan.
1744731|NCT00145652|Drug|Neo-Recormon and Venofer|
1744732|NCT00145665|Procedure|FLT-PET scan|PET scan using FLT
1744733|NCT00145678|Behavioral|Psychodynamic Therapy|Dynamic deconstructive psychotherapy is a time-limited (12-18 month) manual-based form of psychodynamic therapy that aims to remediate specific neurocognitive capacities responsible for processing of emotional experiences.
1744734|NCT00145678|Behavioral|Optimized Community Care|individual and group psychotherapy in a private practice, clinic, and/or rehab setting, with an eclectic orientation
1744735|NCT00145691|Drug|Oxcarbazepine|
1744736|NCT00145704|Drug|bisphosphonate therapy (risedronate)|Bisphosphonate therapy given to patients with growth hormone deficiency
1744737|NCT00145704|Dietary Supplement|Vitamin D supplement|Vitamin D given to patients with growth hormone deficiency
1744738|NCT00145704|Dietary Supplement|Calcium|calcium supplement given to patients with growth hormone deficiency
1744739|NCT00145717|Drug|Plant sterol enriched milk tea|
1744740|NCT00145730|Drug|Ibuprofen|
1744741|NCT00145743|Behavioral|physio,pain,psychotherapy;social,nutrit.counselling&sports|profile and treatment recommendations based on the profile vs. routine psychooncology
1744742|NCT00145756|Drug|low sodium high potassium salt substitute|
1744743|NCT00145769|Drug|Short Course Adjuvent Chemotherapy|Post operative adjuvant chemotherapy: 5FU (425mg/m2) preceded by Folinic acid (20mg/m2) delivered over 5 days for 6 monthly cycles
1744744|NCT00145769|Drug|Long Course Adjuvant Chemotherapy|Post operative adjuvant 5FU (425mg/m2) preceded by folinic acid (20mg/m2) delivered over 5 days for 4 monthly cycles
1744745|NCT00145769|Radiation|Short Course Radiotherapy|25 Gy in 5 fractions over 5 days.
1744746|NCT00145769|Radiation|Long Course Radiotherapy|50.4 Gy delivered in 1.8 Gy fractions over 5 1/2 weeks.
1744747|NCT00145769|Drug|Concurrent Chemotherapy|5FU 225mg/m2/day delivered IV over continous 7 day period for the duration of radiotherapy (5 1/2 weeks).
1744748|NCT00145769|Procedure|Initial Surgery|Surgery is to be performed according to the NHMRC Guidelines for the prevention, early detection and management of colorectal cancer: Elective surgery for rectal cancer
1744749|NCT00145782|Behavioral|Life style|
1744750|NCT00145795|Drug|Kaletra + Current Dual NRTI Backbone|
1744751|NCT00145795|Drug|Current Regimen|
1744752|NCT00146731|Drug|SP|
1744753|NCT00146731|Drug|SP + amodiaquine|
1744754|NCT00146731|Drug|AQ + artesunate|
1744755|NCT00146731|Drug|chlorproguanil-dapsone|
1744756|NCT00146744|Biological|Mtb72F/AS02A|
1744757|NCT00146757|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|100 U/kg every week
1744758|NCT00146757|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|200 U/kg every week (Week 26 onwards)
1744759|NCT00146770|Biological|Aldurazyme|Placebo for 26 weeks then 0.58 mg/kg Aldurazyme every week for 182 weeks
1744760|NCT00146770|Biological|Aldurazyme|0.58 mg/kg Aldurazyme every week for 208 weeks
1744761|NCT00146770|Biological|placebo|Placebo for 26 weeks
1744762|NCT00146783|Drug|Sulphadoxine-pyrimethamine|
1744763|NCT00146783|Drug|Sulphadoxine-pyrimethamine, amodiaquine|
1744764|NCT00146796|Device|Rapid diagnostic test for malaria|
1744765|NCT00146809|Drug|Minocyline|
1744766|NCT00146822|Device|ENDOTAK RELIANCE G lead|
1744767|NCT00146835|Biological|Pediarix|1 or more injections
1744768|NCT00146835|Biological|Licensed DTPa containing vaccine|1 or more injections
1744769|NCT00146835|Biological|Prevnar®: (Wyeth)|Concomitant vaccination
1744770|NCT00146848|Device|Atrial support pacing through cardiac resynchronization therapy. Device: RENEWAL family of CRT-D devices|"All subjects in this trial receive the same device. For the purpose of this trial, intervention is programming mode and lower rate limit to deliver atrial support pacing in the two treatment arms, while the control arm will receive programming where limited atrial support pacing is delivered. DDD-70 and DDDR-40 are the treatment arms programmed to receive atrial support pacing and will be compared to the DDD-40 arm."
1744771|NCT00146861|Device|sensor programming|
1744772|NCT00146874|Device|cardiac resynchronization therapy|
1744773|NCT00146887|Procedure|coronary catheterization|
1744774|NCT00146900|Procedure|Cognitive Behavioral Therapy|12 weekly 1.5 hours weekly session of cognitive behavioral therapy (Prolonged Exposure)
1744775|NCT00146900|Procedure|Cognitive Therapy|12 weekly 1.5 hours weekly session of cognitive therapy without exposure
1744776|NCT00146900|Drug|Escitalopram|Twelve weeks of treatment with Escitalopram at Max. daily dose of 20mg
1744777|NCT00146900|Other|Placebo|Twelve weeks of treatment with placebo pills resembling the original Escitalopram 10mg tablets but containing no active substance
1744778|NCT00146913|Drug|Imatinib mesylate 600mg/day|
1744779|NCT00146913|Drug|Peg-Interféron at 90 microg/week|
1744780|NCT00146926|Drug|kétamine 20mg|
1744781|NCT00146926|Drug|ephedrine 3mg|
1744782|NCT00146926|Drug|lidocaine 40mg|
1744783|NCT00146952|Device|Vibrotactile feedback|
1744784|NCT00146978|Procedure|intra-arterial treatment|
1744785|NCT00147004|Drug|hydrocortisone sodium succinate|50 mg intravenous bolus every six hours for 5 days, then tapered to 50 mg intravenously every 12 hours for days 6-8, 50 mg every 24 hours for days 9-11 and then stopped
1744786|NCT00147004|Drug|Placebo|
1744787|NCT00147030|Procedure|Whole body mild induced hypothermia|Target rectal temperature 33-34°C for 72 hours, commencing by 6 hours of age; followed by re-warming at 0.5°C to normothermia
1744788|NCT00147043|Procedure|Leukapheresis|
1744789|NCT00147043|Procedure|Infusion of stem cells via image guided scan|
1744790|NCT00147056|Device|ExAblate transcranial system|MRI-Guided Focused Ultrasound Feasibility Study for Brain
1744791|NCT00147108|Device|ExAblate 2000|
1744792|NCT00147121|Drug|Rituximab + Standard CHOP|Rituximab + Standard CHOP
1744793|NCT00147121|Drug|Rituximab + Bi-weekly CHOP|Rituximab + Bi-weekly CHOP
1744794|NCT00147134|Procedure|open colectomy|Procedure/Surgery: open colectomy
1744795|NCT00147134|Procedure|laparoscopic colectomy|Procedure/Surgery: laparoscopic colectomy
1744796|NCT00147147|Procedure|Gastrectomy with D2 or greater lymph node dissection|
1744797|NCT00147147|Drug|Gastrectomy+ chemotherapy|
1744798|NCT00147160|Drug|Temozolomide, Cisplatinum|
1744799|NCT00147186|Device|Hylan G-F 20|
1744800|NCT00147199|Drug|Inhaled treprostinil|Doses are titrated to 9 breaths four times daily. Each breath produces an 18 mcg dose of inhaled treprostinil.
1744801|NCT00147199|Drug|Placebo inhalation solution|Doses are titrated to 9 breaths four times daily.
1744802|NCT00147212|Drug|ET 743|ET-743 administered IV by 24-hr infusion every 3 weeks
1744803|NCT00147225|Drug|AMG 531|"Beginning with Cycle 2, administered in one of two schedules, either on day after chemotherapy and 2 days later (study cycle) or on day -5 (pre dose) and on day after chemotherapy (post dose) or combination of pre/post days of 21-28 day treatment cycle. Combination if Optimal biological dose (OBD) not reached, additional treatment at 10 mcg/kg dose level, with AMG 531 administered on day -5 (pre dose) and on day after chemotherapy (post dose).
1, 3, or 10 mcg/kg given as injection under the skin (subcutaneous)"
1744804|NCT00147225|Drug|Carboplatin|AUC=11; Cycle 1 chemotherapy alone then 3 weeks later, in Cycle 2, same dose of chemotherapy followed by AMG 531.
1744805|NCT00147225|Drug|Adriamycin|75-90 mg/m^2 IV
1744806|NCT00147225|Drug|Ifosfamide|10 gm/m^2 IV; OR, High dose ifosfamide = 14 gm/m^2.
1744807|NCT00147238|Drug|Ferumoxtran-10 (USPIO)|Intravenous infusion of 2.6 mg/kg of ferumoxtran-10
1744808|NCT00147238|Procedure|MR lymphangiography|First MRI examination before ferumoxtran-10 contrast injected and second MRI examination about 24 hours after injection of contrast agent, each MRI taking 20 minutes.
1744809|NCT00147251|Drug|FDA approved drugs to treat blood pressure and cholesterol|
1744810|NCT00147264|Drug|Telmisartan (Micardis®) vs. Placebo|
1744811|NCT00147264|Behavioral|Low-Glycemic Index Diet vs. Control Diet|
1744812|NCT00147277|Device|Implantable Cardiac Defibrillator|Medtronic Marquis Family ICD, capable of Anti Tachy Pacing (ATP) for Fast Ventricular Tachycardia (FVT) via Ventricular Fibrillation (VF) zone
1744813|NCT00147290|Device|Implantable Cardiac Defibrillator|Implantable cardiac defibrillator with programmable Fast Ventricular tachycardia detection (FVT) window
1744814|NCT00147303|Drug|MCI-9042|
1744815|NCT00147316|Drug|Alteplase|0.6mg/kg intravenous alteplase with 10% being administered as a bolus followed by continuous infusion of the remainder over 1 hour
1744816|NCT00147329|Drug|MM-093|
1744817|NCT00147355|Drug|ondansetron, ibuprofen, paracetamol|ondansetron 4mg bid + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
1744818|NCT00147355|Drug|Ondansetron, ibuprofen, paracetamol|Ondansetron 4mg bid + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
1744819|NCT00147355|Drug|metoclopramide, ibuprofen, paracetamol|metoclopramide 10mg qds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
1744820|NCT00147355|Drug|Metoclopramide, codeine phosphate, ibuprofen, paracetamol|metoclopramide 10mg qds + codeine phosphate 15mg tds + Ibuprofen 200mg qds + paracetamol 1g qds days 1-6 inclusive of rIL-2 dosing cycle
1744821|NCT00147368|Drug|intravenous (IV) arginine|
1744822|NCT00147381|Drug|Alemtuzumab|"Day 0: Campath-1H 20 mg IV infusion over 3-6 hours
Day 1: Campath-1H 20 mg IV infusion over 3-6 hours"
1744823|NCT00147381|Drug|Tacrolimus|"Day 0: Tacrolimus will be given pre-operatively or immediately post transplant surgery. The recommended initial daily starting dose is 0,1 mg/kg/d orally (0,05 mg/kg/bid) to aim at a whole blood level of 8-12 ng/ml.
till Month 6: Aim at blood level of 8-12 ng/ml (try to prevent the Tacrolimus trough level falling below 10 ng/ml in the first 3 months).
Month 7-12: Maintain the Tacrolimus blood level at 5-8 ng/ml after 6 months."
1744824|NCT00147381|Drug|Alemtuzumab|"Day 0: Campath-1H 30 mg IV infusion over 3-6 hours
Day 1: Campath-1H 30 mg IV infusion over 3-6 hours"
1744825|NCT00147394|Drug|Risperidone|
1744826|NCT00147420|Drug|Zhi Byed 11|
1744827|NCT00147446|Behavioral|Individual Stress Management|Stress management therapy for multiple sclerosis (SMT-MS) is a manualized, validated, published stress management program designed for patients with MS. Participants met with a therapist for 16 individual 50-minute sessions conducted over 20-24 weeks. The first 6 sessions focused on teaching problem solving skills, relaxation, increasing positive activities, cognitive restructuring, and enhancement of social support. Participants were able to tailor the treatment to meet their needs using optional treatment modules including communication and assertiveness training, fatigue management, anxiety reduction, pain management, management of cognitive problems, insomnia treatment, and management of sexual dysfunction.
1744828|NCT00147446|Other|Wait List Control|Wait List Control provided treatment as usual for the first 10+ months of participation. A 5-hour workshop was provided after the 10th month. This allowed at least 2 post-treatment MRI evaluation that were not contaminated by the workshop.
1744829|NCT00147459|Biological|HBV vaccine booster|
1744830|NCT00147472|Other|PET scan in addition to conventional CT imaging|PET scans, Pre and post radiation treatment
1744831|NCT00147485|Drug|AG-024322|
1744832|NCT00147498|Drug|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 6 weeks
1744833|NCT00147498|Drug|CP-690,550|Oral tablets administered at a dose of 15 mg BID for 6 weeks
1744834|NCT00147498|Drug|CP-690,550|30 mg BID for 6 weeks
1744835|NCT00147498|Other|Placebo|Placebo tablets
1744836|NCT00147511|Drug|linezolid|
1744837|NCT00147524|Drug|quinapril|
1744838|NCT00147524|Procedure|Laser Doppler imaging|
1744839|NCT00147537|Drug|CP-751,871|"Phase 2 Arm A:
CP‑751,871 20 mg/kg IV over 2.5 hours up to 17 cycles"
1744840|NCT00147537|Drug|paclitaxel|"Phase 2 Arm A:
Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles
Phase 2 Arm B:
Paclitaxel 200 mg/m2, IV over 3 hours up to 6 cycles"
1744841|NCT00147537|Drug|carboplatin|"Phase 2 Arm A:
Carboplatin AUC 6, IV over 15‑60 minutes up to 6 cycles
Phase 2 Arm B:
Carboplatin AUC 6, IV over 15‑60 minutes up to 6 cycles"
1744842|NCT00147537|Drug|CP-751,871|Phase 1b Dose Escalation/Expansion: CP‑751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles) Phase 1b Erlotinib Extension: CP‑751,871 20 mg/kg IV over 2.5 hours (up to 17 cycles)
1744843|NCT00147537|Drug|paclitaxel|Phase 1b Dose Escalation/Expansion: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles) Phase 1b Erlotinib Extension: paclitaxel 200 mg/m2, IV over 3 hours (up to 6 cycles)
1744844|NCT00147537|Drug|carboplatin|Phase 1b Dose Escalation/Expansion: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles) Phase 1b Erlotinib Extension: carboplatin AUC 6, IV over 15-60 minutes (up to 6 cycles)
1744845|NCT00147537|Drug|erlotinib|Phase 1b Erlotinib Extension: erlotinib 150 mg/day orally every day (up to 17 cycles)
1744846|NCT00147550|Drug|PD-0325901|Administered orally either once or twice a day; several dosing schedules evaluated; current dosing schedule is 5 days on-drug, 2-days off drug for 3 weeks in a 28-day cycle. Doses evaluated ranged from 1 mg once a day to 30 mg twice daily.
1744847|NCT00147563|Drug|Eplerenone|
1744848|NCT00147576|Drug|CP-866,087|
1744849|NCT00147589|Drug|Eplerenone|
1744850|NCT00147602|Drug|atorvastatin|
1744851|NCT00147615|Drug|Eplerenone|
1744852|NCT00147628|Drug|sildenafil citrate|
1744853|NCT00147628|Drug|placebo for sildenafil citrate|
1744854|NCT00147654|Drug|Tolterodine ER 4 mg QD|
1744855|NCT00147654|Drug|Tamsulosin 0.4 mg QD|
1744856|NCT00147667|Drug|Erythromycin|
1744857|NCT00147680|Drug|Paclitaxel, Carboplatin|
1744858|NCT00147693|Behavioral|Diagnosis of caregivers' problems|
1744859|NCT00147693|Behavioral|Professional service: treatment of problems by counseling or practical support|
1744860|NCT00147706|Procedure|Tailored Healthmedia programs on EHR Patient Portal|
1744861|NCT00147719|Drug|Colesevelam hydrochloride|
1744862|NCT00147732|Radiation|Accelerated radiotherapy|68 Gy over 5.5 weeks
1744863|NCT00147732|Radiation|ARCON|68 Gy over 5.5 weeks Carbogen: 98% oxygen plus 2% carbon dioxide Nicotinamide 60 mg/kg daily
1744864|NCT00147745|Drug|Colesevelam|Colesevelam 3.8g for 12 weeks
1744865|NCT00147745|Drug|Colesevelam matching placebo|Colesevelam matching placebo for 12 weeks
1744868|NCT00147771|Drug|Imiquimod 5% cream|Treatment will last for 36 weeks. Patients will be instructed to apply Imiquimod three times per week for 4 weeks. If no local side effects are noted at the 4 week- follow-up visit, the frequency of the application will be increased to 5 weekly applications.
1744869|NCT00147784|Drug|Ribavirin|800 mg pr. os daily, 400 mg morning and 400 mg evening (200 mg/tbl.) for 14 weeks
1744870|NCT00147784|Drug|Pegylated Interferon|180 mikrogram in 0,5 ml solution s.c. once a week for 14 weeks
1744871|NCT00147810|Procedure|Telephone outreach to enhance asthma care|
1744872|NCT00147823|Device|Vitoss Alone|Synthetic bone graft material
1744873|NCT00147823|Device|Vitoss with Bone Marrow Aspirate|Vitoss mixed with Bone Marrow aspirate
1744874|NCT00147836|Drug|Human Insulin (Novolin-R, Novo Nordisk)|
1744875|NCT00147836|Device|H-Tron Plus V100; Disetronic Medical System, Burgdorf, Switzerland|
1744876|NCT00147836|Other|Pre-meal|
1744877|NCT00147836|Drug|Novolin-R|
1744878|NCT00147836|Drug|Human Insulin NPH (Novolin-N, Novo Nordisk)|
1744879|NCT00147836|Drug|Gliclazide (Diamicron, Servier)|
1744880|NCT00147836|Drug|Diamicron and Glucophage|
1744881|NCT00147849|Behavioral|mailing of printed educational materials|
1744882|NCT00147849|Behavioral|a combination of interactive educational meetings, educational outreach visits, and reminders|
1744883|NCT00147849|Behavioral|identification of local opinion leaders and establishment of local consensus processes|
1744884|NCT00147862|Drug|Tranexamic Acid|
1744885|NCT00147875|Drug|Prednisone|
1744886|NCT00147875|Drug|Vinblastine|
1744887|NCT00147875|Drug|Doxorubicin (Adriamycin)|
1744888|NCT00147875|Drug|Gemcitabine|
1744889|NCT00147888|Procedure|Acoustic rhinometry (procedure)|Acoustic rhinometry is a procedure that uses sound waves to measure the cross-sectional area and volume of the nasal cavity.
1744890|NCT00147901|Drug|FCCam|After an initial subcutaneous dose escalation of alemtuzumab over 2 days, 30 mg alemtuzumab s.c., cyclophosphamide 200 mg/m2 i.v. and 25 mg/m2 fludarabine i.v. were administered on three consecutive days. Treatment was repeated after 28 days for up to six cycles
1744891|NCT00147914|Drug|Cefdinir (drug)|cefdinir 300mg per orally twice daily for 10 days
1744892|NCT00147914|Drug|amoxicillin/clavulanate|1000mg /62.5mg extended release per orally twice daily for 10 days
1744893|NCT00147927|Behavioral|Sequential emails and web support|
1744894|NCT00147940|Procedure|Acoustic rhinometry (procedure)|
1744895|NCT00147953|Drug|Rituximab|
1744896|NCT00147953|Procedure|Total nodal irradiation|
1744897|NCT00147966|Drug|rituximab|treatment with rituximab
1744898|NCT00147979|Device|Bridging by PTFE with bounded heparin|Bridging by PTFE with bounded heparin
1744899|NCT00147979|Device|Bridging by PTFE without bounded heparin|Bridging by PTFE without bounded heparin
1744900|NCT00147992|Procedure|Immediate loading of implants in totally edentate upper and lower jaw|Immediate loading of implants in totally edentate upper and lower jaw.
1744901|NCT00148005|Procedure|Questionnaire and micturition and drinking diaries|
1744902|NCT00148005|Procedure|Clinical and functional examination (uroflowmetry, bladder scan and video-urodynamic examination)|
1744903|NCT00148005|Behavioral|Adaptation of the drinking scheme|
1744904|NCT00148005|Drug|Anticholinergic therapy|
1744905|NCT00148005|Behavioral|Micturition clock|
1744906|NCT00148018|Drug|Bortezomib|
1744907|NCT00148018|Drug|Dexamethasone|
1744908|NCT00148031|Drug|Pegylated Interferon and Ribavirin|Both groups with receive the same medical intervention but offered at different locations
1744909|NCT00148031|Behavioral|Psychosocial|Assessment of the likelihood of HCV treatment initiation and completion
1744910|NCT00148031|Behavioral|On-site (MMT Clinic) HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
1744911|NCT00148031|Behavioral|Off-site HCV evaluation and treatment|Standard HCV treatment with Pegylated Interferon and Ribavirin
1744912|NCT00148044|Procedure|Blood sampling for determination of uremic toxins|
1744913|NCT00148057|Behavioral|Low-fat diet|
1744914|NCT00148070|Drug|Docetaxel|You will then receive your first dose of docetaxel chemotherapy. It is put through your IV over 1-2 hours. you will receive docetaxel every 3 weeks in the Cancer Center Infusion area.
1744915|NCT00148070|Procedure|Erythromycin Breath Test (ERMBT)|you will have an erythromycin breath test, which is an experimental test which is used to estimate the amount of enzyme produced by your liver which can metabolize the chemotherapy, docetaxel. For this test, you go to the GCRC where you will receive an injection of erythromycin (an antibiotic) which is labeled with a very small amount of radioactive substance. 20 minutes later you will blow air from your mouth into a blue solution until it clears. Your doctors will calculate the dose of docetaxel to be given to you based on this blood test, on your body's albumin level (a protein determined on the blood test), and on your height and weight.
1744916|NCT00148083|Drug|Risperdal Consta (drug)|
1744917|NCT00148083|Behavioral|Social Skills Training|
1744918|NCT00148096|Device|Mechanical Heat Recovery Ventilation|De-humidification without loss of heat
1744919|NCT00148109|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes.
1744920|NCT00148109|Drug|Cetuximab|Cetuximab 400 mg/m2 over 120 min IV initial does followed by weekly Cetuximab 250 mg/m2 over 60 min
1744921|NCT00148122|Drug|Docetaxel|Each four-week cycle consists of three infusions through a vein of docetaxel, on days 1, 8, and 15. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
1744972|NCT00148538|Behavioral|Resistance and/or Aerobic Exercise|Resistance and/or Aerobic Exercise
1744973|NCT00148551|Drug|Triamcinolone Acetonide|
1744974|NCT00148564|Drug|olanzapine|treatment with either Olanzapine or Ziprasidone
1744922|NCT00148122|Drug|Capecitabine|Each four-week cycle consists of fourteen days of a medication that the subject will take two times a day orally, on days 5-18. If the subject's disease has decreased significantly, he/she will continue to receive docetaxel on the every four-week schedule. If the subject's disease has not decreased significantly but there is no evidence the disease is getting worse, he/she will continue on the same treatment until: a) there is evidence that the treatment is no longer working to control the growth of his/her disease, b) He/she experiences unacceptable toxicity, c) his/her disease progresses, or d) he/she chooses to stop therapy.
1744923|NCT00148135|Drug|Carboplatin|
1744924|NCT00148135|Drug|Gemcitabine|
1744925|NCT00148135|Drug|Capecitabine|
1744926|NCT00148148|Drug|caspofungin|
1744927|NCT00148148|Drug|liposomal amphotericin B|
1744928|NCT00148174|Behavioral|Intensive telephone followup|Telephone calling
1744929|NCT00148226|Behavioral|Decision Aid|
1744930|NCT00148239|Behavioral|Caregiver Only Intervention|A multi-component psycho-educational intervention designed to reduce the negative emotional and behavioral responses of the caregiver and reduce the risk of mental and physical health problems.
1744931|NCT00148239|Behavioral|Dual Treatment|Complements the caregiver only intervention by targetting both caregiver and SCI person with multi-component psycho-educational intervention
1744932|NCT00148239|Behavioral|Control|Participants given written educational materials at beginning of study; no treatment beyond this
1744933|NCT00148252|Drug|Mycophenolate mofetil withdrawal|
1744934|NCT00148252|Drug|Cyclosporione A withdrawal|
1744935|NCT00148265|Drug|Triamcinolone acetate|Eyes assigned to IVTA received an intravitreal injection of 0.1 ml of Kenacort 40© [40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia] on the day of the baseline visual acuity measurement under sterile conditions in a minor procedures area as an outpatient procedure. Eyes assigned to placebo were prepared in the same way but had the barrel of the syringe without a needle pushed firmly against the eye to simulate an injection.
1744936|NCT00148278|Drug|norepinephrine and dobutamine|continuous infusion of norepinephrine titrated to maintain a mean arterial pressure at 70mmHg or more and dobutamine could be added as a continuous infusion when cardiac index was of less than 2.5 liters per squared meter of body surface
1744937|NCT00148278|Drug|epinephrine plus placebo of dobutamine|epinephrine was titrated to maintain a mean arterial pressure at 70mmHg or more and placebo of dobutamine was titrated in case of a cardiac index lower than 2.5 liters per squared meters of body surface
1744938|NCT00148291|Drug|Patients were randomized to receive either docetaxel 60 mg/m2 on day 1 or vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles.|
1744939|NCT00148317|Drug|Bortezomib|During Induction Phase (6 cycles): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11 During 21-day mobilization cycle (1 cycle): Bortezomib 1.3 mg/m2 on days 1, 4, 8, and 11
1744940|NCT00148317|Drug|dexamethasone|During Induction Phase (6 cycles): dexamethasone 40 mg on days 1-4, 8-11, and 15-18
1744941|NCT00148317|Drug|liposomal doxorubicin|If patients achieve less then a PR during the induction phase after 2 cycles, or less then a CR after 4 cycles: Liposomal doxorubicin was added at 30 mg/m2 on day 4 for the remaining cycles
1744942|NCT00148317|Drug|cyclophoshamide|During the 21 day mobilization phase (1 cycle): cyclophosphamide at 3 g/m2 on day 8
1744943|NCT00148317|Drug|filgrastim|During the 21 day mobilization phase (1 cycle): 10 μg/kg/day for 10 consecutive days starting 24 hours after cyclophosphamide administration on day 9
1744944|NCT00148330|Drug|Triamcinolone acetate|When indicated, intravitreal triamcinolone (0.1 ml of Kenacort 40© [40mg/ml triamcinolone acetonide, Bristol-Myers Squibb pharmaceuticals, Australia]) was injected into the vitreous under sterile conditions in a minor procedures area.
1744945|NCT00148343|Device|Odstock Dropped-Foot Stimulator (ODFS)|Device implementation & use for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The ODFS then will be returned to the investigators.
1744946|NCT00148343|Other|Conventional Standard of Care|Conventional standard of care (which may include implementation & use of a study-specific Custom Molded Hinged Ankle Foot Orthosis (AFO)) for ~13 weeks (until 2nd Outcomes Assessment (1st post-treatment Outcomes Assessment)). The AFO, if implemented, may continue to be used afterwards since it is an element of the standard of care for this patient population.
1744947|NCT00148343|Procedure|Traditional Physical Therapy Treatment|Traditional physical therapy treatment for 12 weeks.
1744948|NCT00148356|Device|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
1744949|NCT00148356|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
1744950|NCT00148369|Drug|Safety observation|Subjects previously enrolled in a GDNF protocol observed for 2 years after discontinuation of drug.
1744951|NCT00148382|Drug|ATL-962|
1744952|NCT00148395|Drug|Gemcitabine|
1744953|NCT00148395|Drug|Navelbine|
1744954|NCT00148395|Drug|Carboplatin|
1744955|NCT00148395|Drug|Cisplatin|
1744956|NCT00148395|Drug|Mitomycin|
1744957|NCT00148395|Drug|Ifosfamide|
1744958|NCT00148408|Drug|Montelukast|
1744959|NCT00148408|Behavioral|Education|
1744960|NCT00148421|Drug|Darbepoetin alfa and Epoetin alfa|
1744961|NCT00148434|Behavioral|Patient-held guideline for hypertension|
1744962|NCT00148447|Drug|escitalopram|
1744963|NCT00148460|Drug|TNK-tPA|
1744964|NCT00148460|Drug|rt-PA|
1744965|NCT00148473|Drug|Misoprostol|
1744966|NCT00148486|Drug|NS 2330|
1744967|NCT00148499|Drug|Ambroxol hydrochloride (Mucoangin?)|
1744968|NCT00148499|Drug|benzocaine|
1744969|NCT00148512|Drug|1. Tesofensine (NS 2330)|
1744970|NCT00148525|Behavioral|Social Cognitive Theory|6 mo dietary intervention. This arm received an diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on social cognitive theory.
1744971|NCT00148525|Behavioral|goal system theory|This arm received a 6 mo diet intervention designed to maintain changes in fruit and vegetable consumption. The intervention components were based on goal systems theory and delivered by an automated telephone system.
1744975|NCT00148564|Drug|Ziprasidone|treatment with either Olanzapine or Ziprasidone
1744976|NCT00148577|Device|Transcutaneous Electrical Nerve Stimulation|
1744977|NCT00148590|Drug|Memantine|Daily dose of 10mg memantine Vs. Placebo
1744978|NCT00148590|Drug|Placebo|Daily dose of 10mg memantine Vs. Placebo
1744979|NCT00148603|Drug|montelukast|
1744980|NCT00148616|Drug|Memantine|Daily dosage of 10mg Memantine vs. Placebo
1744981|NCT00148629|Drug|multivitamin, mebendazole|
1744982|NCT00148642|Device|silver salts coated endotracheal tube|intubation with silver coated tube
1744983|NCT00148642|Device|uncoated endotracheal tube|intubation
1744984|NCT00148655|Device|Decision Board|Decision board that explains the risks and benefits of treatment options
1744985|NCT00148668|Drug|Herceptin|One dose given followed by an MRI, then weekly injections beginning week 3 and ending week 14.
1744986|NCT00148668|Drug|Navelbine|Weekly injections given starting week 3 and ending week 14
1744987|NCT00148668|Drug|Taxotere|Given every three weeks starting week 3 and ending on week 14
1744988|NCT00148668|Drug|Carboplatin|Given every three weeks starting week 3 and ending on week 14
1744989|NCT00148681|Drug|Herceptin|Intravenously every week for 12 weeks (weeks 1-12) Intravenously every three weeks for 40 weeks (weeks 32-72)
1744990|NCT00148681|Drug|Navelbine|Intravenously every week for 12 weeks
1744991|NCT00148681|Drug|Doxorubicin|Every 3 weeks for 12 weeks
1744992|NCT00148681|Drug|Cyclophosphamide|Intravenously every 3 weeks for 12 weeks
1744993|NCT00148681|Drug|Paclitaxel|Weekly for 12 weeks (or a similar schedule)
1744994|NCT00148694|Drug|Cisplatin|Intravenously once every three weeks for a total of 12 weeks
1744995|NCT00148707|Drug|CT-2103 (Xyotax)|
1744996|NCT00148720|Drug|Capecitabine|Taken orally twice a day for 14 days and treatment will repeat every 21 days (1 cycle) for 4 cycles
1744997|NCT00148733|Drug|Zinc|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
1744998|NCT00148746|Drug|Pimecrolimus|
1744999|NCT00148746|Drug|Tacrolimus|
1745000|NCT00148746|Drug|Prednisolone|
1745001|NCT00148746|Drug|Ciclosporin A|
1745002|NCT00148746|Drug|Dermatop|
1745003|NCT00148759|Drug|LPV/r|LPV/r 800/200 mg once daily
1745004|NCT00148772|Drug|Erlotinib (Tarceva)|
1745005|NCT00148785|Drug|Indinavir/Ritonavir/Fosamprenavir|
1745006|NCT00148798|Drug|cetuximab + cisplatin + vinorelbine|cetuximab given as an intravenous (i.v.) infusion every week (400mg/m^2 initial dose and 250mg/m^2 subsequent doses) until progressive disease (PD) + cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
1745007|NCT00148798|Drug|cisplatin + vinorelbine|cisplatin 80mg/m^2 i.v. infusion on day 1 of each 3-week cycle + vinorelbine 25mg/m^2 i.v. infusion on days 1 and 8 of each 3-week cycle.
1745008|NCT00148824|Biological|7-valent pneumococcal conjugate vaccine (vaccine)|
1745009|NCT00148824|Biological|23-valent pneumococcal conjugate vaccine (vaccine)|
1745010|NCT00148837|Drug|Peg-interferon alpha 2b (drug)|
1745011|NCT00148837|Drug|Ribavirin (drug)|
1745012|NCT00148837|Drug|Prazosin (drug)|
1745013|NCT00148850|Drug|Pioglitazone|
1745014|NCT00148863|Drug|Peg-interferon alpha 2a (drug)|
1745015|NCT00148863|Drug|Ribavirin (drug)|
1745016|NCT00148863|Drug|Interferon gamma (drug)|
1745017|NCT00148876|Drug|Capecitabine|Capecitabine 2500 mg/m² orally day 1-14 q day 22
1745018|NCT00148876|Drug|Trastuzumab|Trastuzumab 6 mg/kg body weight every 3 weeks i.v.
1745019|NCT00148889|Device|Deep brain stimulation (DBS)|Bilateral pallidal stimulation with an implanted DBS device
1745020|NCT00148902|Drug|lapatinib and docetaxel|
1745021|NCT00148915|Drug|ibandronate|
1745022|NCT00148915|Drug|Placebo|matching placebo
1745023|NCT00148928|Biological|P501-AS15 vaccine|
1956562|NCT02802631|Drug|Minocin (minocycline) for Injection|Intravenous formulation of minocycline, a derivative of tetracycline
1745025|NCT00148954|Device|VITALITY 2 Implantable Cardioverter Defibrillator|VITALITY 2 ICD
1745026|NCT00148954|Device|Medtronic Implantable Cardioverter Defibrillator|Maximo, Marquis, Intrinsic, Virtuoso, or Entrust ICD
1745027|NCT00148967|Device|Implantable Cardioverter Defibrillator|
1745028|NCT00148980|Device|DBM for creation of bone marrow microenvironment|
1745029|NCT00148993|Biological|Tumor Cell Vaccine|
1745030|NCT00149006|Procedure|Cell therapy|
1745031|NCT00149019|Drug|Cell therapy with bispecific antibodies|
1745032|NCT00149032|Procedure|DLI sensitized against antigens expressed by the host.|
1745033|NCT00149058|Drug|Erythropoietin|
1745034|NCT00149071|Device|rTMS|15 treatments of rTMS active with a duration of 30 minutes each
1745035|NCT00149071|Device|TMS|Transcraniel Magnetic Stimulation active and sham
1745036|NCT00149071|Device|rTMS|active Transcranial Magnetic Stimulation
1745037|NCT00149071|Device|rTMS|daily for three weeks
1745038|NCT00149084|Drug|Lansoprazole, clarithromycin, amoxicillin|
1745039|NCT00149110|Procedure|Sleep deprivation|3 days with a normal night between
1745040|NCT00149110|Procedure|Light therapy|Daily light therapy for 29 weeks
1745041|NCT00149110|Procedure|Diurnal rhythms|Keeping the day-night cycle constant by use of educational measures
1745042|NCT00149110|Behavioral|Exercise|Moderate intensity daily exercise for 30 minutes at least
1745043|NCT00149110|Drug|duloxetine|60 mg daily
1745044|NCT00149110|Drug|duloxetine|60 mg daily
1745045|NCT00149123|Drug|hydrocortisone 200 mg/day|
1745046|NCT00149136|Drug|imatinib|
1745047|NCT00149149|Drug|Zinc carnosine|
1745048|NCT00149162|Drug|proleukin|"One cycle of treatment : D1 : 2.5 MUI/m2 (subcutaneous); D2 to D5 : 5 MUI / m2 (subcutaneous)
1 cycle of treatment each month during 12 months"
1745049|NCT00149175|Other|Blood sampling, skin biopsy|Blood sampling, skin biopsy in the field of the medical follow-up
1745050|NCT00149188|Drug|Lanreotide (Autogel formulation)|
1745051|NCT00149201|Drug|5-FU continuous infusion|
1745053|NCT00149214|Drug|pemetrexed|500 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)
1745054|NCT00149214|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days, 4 cycles (1-4)
1745055|NCT00149214|Drug|doxorubicin|60 mg/m^2, intravenous (IV), every 21 days, 4 cycles (1-4)
1745056|NCT00149214|Drug|docetaxel|100 mg/m^2, intravenous (IV), every 21 days, 4 cycles (5-8)
1745057|NCT00149227|Drug|Valsartan|Valsartan add-on arm: valsartan 40-160 mg per day, and an additional antihypertensive drugs other than ARB and ACEI are administered if necessary.
1745058|NCT00149227|Drug|Non-ARB|'Non-ARB' was defined conventional anti-hypertensive treatment except for ACEIs and ARBs
1745059|NCT00149240|Drug|Botulinum toxin type A (Dysport)|
1745060|NCT00149253|Drug|a single-dose of Etoricoxib before induction of anesthesia|
1745061|NCT00149266|Procedure|Surgery: abdominal and transhiatal approach|
1745062|NCT00149266|Procedure|Surgery: left thoraco-abdominal approach|
1745063|NCT00149279|Procedure|Surgery: D2 dissection|
1745064|NCT00149279|Procedure|Surgery: D2+paraaortic dissection|
1745065|NCT00132899|Drug|Methotrexate|Methotrexate and infliximab combination
1745066|NCT00132899|Drug|Placebo|Placebo and infliximab combination therapy.
1745067|NCT00132912|Drug|SCH 530348|
1745068|NCT00132925|Drug|Triamcinolone|
1745069|NCT00132938|Drug|telithromycin|
1745070|NCT00132951|Drug|Telithromycin|Telithromycin (AECB: 2 tablets per day for Days 1-5; CAP: 2 tablets per day for Days 1-7)
1745071|NCT00132951|Drug|Azithromycin|Azithromycin (AECB: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5; CAP: 2 tablets on Day 1 then 1 tablet + 1 placebo tablet per day for Days 2-5 then 2 placebo tablets per day for Days 6-7)
1956563|NCT02802631|Other|Placebo|Placebo - Normal Saline
1745074|NCT00132977|Device|Cardiac Resynchronization Therapy|
1745075|NCT00132990|Device|Deep brain stimulation|
1745076|NCT00133003|Drug|Abciximab|0.25 mg/kg of body weight bolus, followed by a 0.125-microg/kg per minute [maximum, 10 microg/min] infusion for 12 hours, plus heparin, 70 U/kg of body weight
1745077|NCT00133003|Drug|Placebo|Placebo consist of placebo bolus and infusion of 12 hours (NaCl 0.9%), plus heparin bolus, 140 U/kg of body weight
1745078|NCT00133016|Procedure|Amniotomy|
1745079|NCT00133029|Drug|Timing of prophylactic antibiotic administration|
1745080|NCT00133042|Drug|omalizumab|
1745081|NCT00133055|Behavioral|Self-help treatment booklet and telephone support|The Parenting Matters treatment program consisted of a self-help treatment booklet and two telephone coaching calls from a paraprofessional telephone coach at Weeks 2 and 5 of the program. Two booklets were used in the three trials; one addressed sleep issues and the second discipline problems.
1745082|NCT00133055|Behavioral|Usual care by a family physician|Parents in the usual care condition were told to continue with care from their family physician and/or any other treatment recommended by the physician.
1745083|NCT00133068|Behavioral|Computer|Computer intervention only
1745084|NCT00133068|Behavioral|Reduction in financial barrier|Copay only
1745085|NCT00133068|Behavioral|Computer intervention & reduction of financial barrier|computer intervention & copay
1745086|NCT00133068|Behavioral|Control|No intervention
1745087|NCT00133081|Drug|All registered antiepileptic drugs|
1745088|NCT00133094|Drug|Simvastin|
1745089|NCT00133094|Procedure|Computer-based decision support technology|
1745090|NCT00133107|Drug|efalizumab|
1745091|NCT00133133|Drug|ALGRX 4975|
1745092|NCT00133146|Biological|Grass MATAMPL|
1745093|NCT00133159|Biological|Grass MATAMPL|
1745094|NCT00133172|Drug|Tacrolimus|IV
1745095|NCT00133172|Drug|mycophenolate mofetil|IV
1745096|NCT00133172|Drug|Prednisone|IV
1745097|NCT00133185|Drug|telmisartan 40 mg/hydrochlorothiazide 12.5 mg|
1745098|NCT00133185|Drug|losartan 50 mg/hydrochlorothiazide 12.5 mg|
1745099|NCT00133198|Drug|Pramipexole|
1745100|NCT00133211|Procedure|Radiofrequency ablation|Pulmonary vein isolation
1745101|NCT00133224|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
1745102|NCT00133224|Drug|Chemotherapy (docetaxel and prednisone)|Chemotherapy (docetaxel and prednisone)
1745103|NCT00133237|Device|Sirolimus-eluting stent|cypher stent is implanted due to randomization.
1745104|NCT00133237|Device|Paclitaxel-eluting stent|taxus stent is implanted due to randomization.
1745105|NCT00133250|Drug|Abciximab|Abciximab bolus and infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 10 mg abciximab. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
1745106|NCT00133250|Other|Placebo Heparin Sodium|Placebo bolus plus infusion is given. Study medication includes 3 identical vials, each with 5 ml solution containing 3000 U Heparin. The bolus dose to be given should be rated at 0.125 ml/kg of patient's weight. After the bolus, a total dose of 0.045 ml/kg study substance (up to a maximal quantity of 3.6 ml) should be given over 12 hours.
1745107|NCT00133263|Behavioral|Primary Bereavement Care|a standardized bereavement intervention in Primary Care
1745108|NCT00133263|Behavioral|the current bereavement care in primary care|the non-standardized bereavement care that usually provided family physicians in primary care
1745109|NCT00133276|Drug|Escitalopram|OD 5mg for 2 weeks; OD 10mg for 24 weeks; OD 5mg for 2 weeks
1745110|NCT00133276|Other|Placebo|
1745111|NCT00133289|Device|Pacemaker with Automatic Capture|
1745112|NCT00133302|Drug|Standard CHOP|
1745113|NCT00133302|Drug|Bi-CHOP (dose intensified CHOP)|
1745114|NCT00133315|Drug|Infliximab|
1745115|NCT00133315|Drug|Etanercept|
1745116|NCT00133315|Drug|Adalimumab|
1745117|NCT00133328|Drug|valsartan|
1745118|NCT00133341|Drug|Goldnatriomthiosulphate, MDBGN, parthenolide|
1745169|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml subcutaneously in the deltoid.
1745293|NCT00141284|Drug|nelfinavir 1,250 mg twice daily|
1745119|NCT00133354|Drug|Arimidex (Anastrozole)|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
1745120|NCT00133354|Drug|Placebo|Subjects will be randomized in a 1:1 ratio to be given either Arimidex 1 mg or placebo orally. Subjects will receive trial treatment for 36 months while continued on GH.
1745121|NCT00133354|Drug|Growth Hormone|GH (Nutropin®, Genentech, So. San Francisco, CA) will be administered throughout the trial at a dose of ~0.3mg/kg.w (no more than 0.4mg/kg.w) given subcutaneously (SC) at bedtime daily. Dose adjustments on the GH dose will be made by the investigator at least every 6mo.
1745122|NCT00133367|Drug|Tacrolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
1745123|NCT00133367|Drug|Sirolimus|Given three days before transplant and every day for 3-6 months after transplant. After first 100 days post-transplant, the dose will be reduced.
1745124|NCT00133367|Drug|G-CSF|Given starting on day 5 after transplant until the subjects white blood cell count recovers.
1745125|NCT00133367|Drug|Antithymocyte globulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
1745126|NCT00133367|Drug|Thymoglobulin|Given intravenously for 4 days before transplant (days 7, 5, 3, 1).
1745127|NCT00133367|Drug|Fludarabine|Given intravenously for six days prior to transplant (days 8,7,6,5,4,3).
1745128|NCT00133367|Drug|Melphalan|Given intravenously on day 2 before transplant.
1745129|NCT00133380|Drug|PPAR alpha|
1745130|NCT00133380|Drug|atorvastatin|
1745131|NCT00133380|Drug|placebo|
1745132|NCT00133393|Drug|Pentoxifylline|
1745133|NCT00133406|Drug|Glutamine|0.8gm/kg, ie up to a total daily dose of 16.2gm/day,with juice daily for 10 days
1745134|NCT00133406|Drug|Vitamin A|100,000 IU for children under 12 months of age (or placebo) and PO 200,000 IU for children at least 12 months of age (or placebo), both q months for 1 year at 0, 4 and 8 months.
1745135|NCT00133406|Drug|glycine|0.4gm/kg; ie up to 8.3gm/d, with juice daily for 10 days
1745136|NCT00133406|Drug|zinc|40 mg twice weekly for 12 months
1745137|NCT00133419|Drug|Vitamin + Zinc + micronutrient mixture|
1745138|NCT00133419|Drug|Vitamin A|
1745139|NCT00133419|Drug|Vitamin A + Zinc|
1745140|NCT00133432|Drug|Zinc|
1745141|NCT00133445|Biological|DTaP-Hep B-IPV Vaccine|U.S. licensed 13-Dec-2002. Dosage equal to 0.5 mL administered intramuscularly. Combination vaccine.
1745142|NCT00133445|Biological|Monovalent Hep B Vaccine|U.S. licensed monovalent hepatitis B vaccine; each 0.5 mL dose contains 10 mcg of hepatitis B surface antigen absorbed on 0.25 mg aluminum hydroxide. The vaccine is given to infants as a 0.5 mL dose intramuscularly.
1745143|NCT00133445|Drug|Placebo|Commercially prepared normal saline. The dose will be 0.5 mL administered intramuscularly.
1745144|NCT00133458|Drug|Albendazole|
1745145|NCT00133471|Biological|Influenza A/H9N2 vaccine|A single lot of monovalent inactivated SA influenza A/H9N2 vaccine. All injections will be administered in a 0.5-mL volume into the deltoid muscle. Dosage levels are: 3.75-, 7.5-, 15-, and 30-mcg of HA of the vaccine strain with and without MF59 adjuvant.
1745146|NCT00133471|Drug|MF59 adjuvant|MF59 adjuvant is an oil-in-water emulsion.
1745147|NCT00133484|Biological|Anthrax vaccine absorbed made from Bacillus anthracis (AVA)|
1745148|NCT00133484|Biological|Recombinant protein antigen (rPA) made from Bacillus anthrax|
1745149|NCT00133484|Biological|Recombinant protein antigen (rPA) made from Escherichia coli|
1745150|NCT00133497|Biological|MF-59|Microfluoridized adjuvant 59 (MF59).
1745151|NCT00133497|Drug|Placebo|0.5 mL of saline placebo.
1745152|NCT00133497|Biological|CMV gB vaccine|CMV glycoprotein B (gB) delivered as 20 mcg in 0.5 mL of vaccine.
1745153|NCT00133510|Biological|Trivalent Subviron Influenza vaccine (Fluzone)|
1745154|NCT00133523|Biological|Cold-adapted live attenuated influenza virus vaccine, trivalent|Live-attenuated influenza vaccine; single annual dose administered as an intranasal spray.
1745155|NCT00133523|Other|Placebo|Physiological saline administered as an intramuscular injection.
1745156|NCT00133523|Biological|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection..
1745157|NCT00133523|Biological|Trivalent inactivated influenza vaccine|Inactivated influenza vaccine; single annual dose administered as an intramuscular injection.
1745158|NCT00133523|Other|Placebo|Normal allantoic fluid administered annually as an internasal spray.
1745159|NCT00133536|Biological|Influenza A/H5N1 Vaccine|Monovalent inactivated subvirion influenza H5N1 vaccine (derived from A/Vietnam/1203/04). Packaged in single-dose vials of 90 mcg/mL (0.7 mL/vial). Dosage 45 mcg/0.5 mL administered intramuscularly.
1745160|NCT00133536|Drug|Placebo|Normal saline administered intramuscularly.
1745161|NCT00133549|Drug|Placebo|Saline placebo administered in a volume of 0.5 ml intramuscularly.
1745162|NCT00133549|Biological|PNU-IMUNE®23|The 23-valent pneumococcal vaccine (PS) vaccine will contain a mixture of 25 micrograms purified, pneumococcal polysaccharide of each of 23 serotypes of Streptococcus pneumoniae per 0.5 ml dose in isotonic saline and 0.01% thimerosal. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
1745163|NCT00133549|Biological|Nine-valent pneumococcal conjugate (PNCRM9)|Cross-reactive material 197 (CRM 197) is a product of the Corynebacterium diphtheria C7. Vaccine is prepared from pneumococcal polysaccharides of types 1, 4, 5, 9V, 14, 18C, 19F, 23F (2 mcg each) and 6B (4 mcg) covalently linked to CRM197 by reductive amination. The protein-polysaccharide combination is prepared as a lyophilized powder with aluminum phosphage which is reconsitituted before use. The vaccine will be administered in a volume of 0.5 ml intramuscularly.
1745164|NCT00133562|Drug|Alanyl-glutamine|
1745165|NCT00133562|Drug|Glycine|
1745166|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^7 or 10^8 TCID50 intramuscularly (IM).
1745167|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^7 or 10^8 TCID50 subcutaneously (SC).
1745168|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml intradermally in the deltoid.
1745362|NCT00141843|Genetic|BDDrFVIII|
1745170|NCT00133575|Biological|MVA Smallpox Vaccine|MVA smallpox vaccine (ACAM3000 MVA) administered in two doses approximately 28 days apart in the following dose/route combination: 10^6 or 10^7 TCID50 intradermally (ID).
1745171|NCT00133575|Biological|Live vaccinia virus vaccine|Dryvax® smallpox vaccine administered at approximately day 180, dosage 10^8 pfu/ml.
1745172|NCT00133575|Other|Placebo|Sterile saline (0.9%) volume of 0.5 ml intramuscularly in the deltoid.
1745173|NCT00133588|Biological|Trivalent split Inf|
1745174|NCT00133601|Behavioral|Cognitive Behavioral Therapy|CBT-I including sleep restriction, stimulus control, sleep hygiene instructions and one session of cognitive therapy devoted to catastrophic thoughts about the consequences of insomnia.
1745175|NCT00133614|Procedure|Prone Positioning|
1745176|NCT00133627|Drug|Ketotifen|
1745177|NCT00133640|Drug|cholecalciferol|
1745178|NCT00133640|Behavioral|Physiotherapy|
1745179|NCT00133653|Behavioral|Observational|
1745180|NCT00133666|Behavioral|Asthma Communication Education|
1745181|NCT00133666|Behavioral|Standard Asthma Education|
1745182|NCT00133679|Drug|sildenafil|Sildenafil 0.5 mg/kg every 6 hours orally x 45 d
1745183|NCT00133679|Drug|Placebo|Placebo suspension (equal volume to experimental drug) x 45 days
1745184|NCT00133692|Drug|Verapamil SR/Trandolapril/Hydrochlorothiazide (HCTZ)|
1745185|NCT00133692|Drug|Atenolol/HCTZ/Trandolapril|
1745186|NCT00133705|Drug|Mifepristone|Mifepristone 5mg/day by mouth for 6 months
1745187|NCT00133705|Drug|Inert Capsule|sugar pill
1745188|NCT00133718|Drug|Combined lifestyle intervention and optimisation of pharmacological treatment|"6 months non-pharmacological treatment, 18 months with polypharmacy for glucose control (metformin, repaglinide/glimepiride, pioglitazone or insulin)
standard care"
1745189|NCT00133731|Drug|Otamixaban (XRP0673)|
1745190|NCT00133731|Drug|Unfractionated Heparin|
1745191|NCT00133731|Procedure|Percutaneous Coronary Intervention|
1745192|NCT00133744|Dietary Supplement|folic acid|pills by mouth, one per day, from the first prenatal visit until delivery, 400 micrograms (mcg) folic acid
1745193|NCT00133744|Dietary Supplement|folic acid plus iron|pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe
1745194|NCT00133744|Dietary Supplement|supplements with multiple vitamins and minerals|pills, one per day, from the first prenatal visit until delivery; folic acid 400 mcg, Fe 30 mg, vitamin(vit) A 800 mcg, vit E 10 mg, vit D 5 mcg, vit C 70 mg, vit B1 1.4 mg, vit B2 1.4 mg, vit B6 1.9 mg, vit B12 2.6 mcg, Niacin 18 mg, Zn 15 mg, Cu 2mg, Iodine 150 mcg, Selenium 65 mcg
1745195|NCT00140465|Drug|Clopidogrel|after PCI
1745196|NCT00140465|Drug|Clopidogrel|after PCI
1745197|NCT00140478|Drug|Mifepristone|200mg orally once daily
1745198|NCT00140491|Device|Vision Restoration Therapy (NOVAVISION)|
1745199|NCT00140504|Other|Medcheck message|Participants selected at random will receive one email message asking them questions about their prescription which will be forwarded to their physician
1745200|NCT00140517|Drug|sulphadoxine-pyrimethamine|
1745201|NCT00140517|Drug|chloroquine|
1745202|NCT00140530|Device|Paclitaxel-eluting stent (Taxus)|patients has been implanted the Paclitaxel-eluting stent.
1745203|NCT00140530|Device|Rapamycin-eluting stent|patients has been implanted the Rapamycin-eluting stent.
1745204|NCT00140543|Drug|sirolimus versus mycophenolate mofetil|
1745205|NCT00140556|Radiation|Chemoradiotherapy|External beam radiation daily (M-F)
1745206|NCT00140556|Drug|Cisplatin|Cisplatin week 1 and 5 of radiation
1745207|NCT00140556|Drug|Bevacizumab|Bevacizumab (Avastin) day 1 of weeks 1, 3, and 5 of radiation
1745208|NCT00140556|Drug|Erlotinib|Erlotinib daily during radiation
1745209|NCT00140569|Procedure|CHVP + interferon|
1745210|NCT00140569|Drug|fludarabine|
1745211|NCT00140569|Procedure|CHOP + TBI and autotransplant|
1745212|NCT00140582|Drug|Rituximab|rituximab 375 mg/m2 every 8 weeks for 24 months (12 injections) or control with no treatment
1745213|NCT00140595|Drug|rituximab|
1745214|NCT00140595|Drug|doxorubicin|
1745215|NCT00140595|Drug|cyclophosphamide|
1745216|NCT00140608|Device|Seprapack Sinus Dressing|
1745217|NCT00140621|Drug|Agalsidase beta|
1745218|NCT00140634|Biological|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap.
1745219|NCT00140647|Drug|Ramipril|
1745220|NCT00140647|Drug|Rosiglitazone|
1745221|NCT00140660|Drug|rituximab|375 mg/m2 on D1
1745222|NCT00140673|Biological|Rotavirus|
1745223|NCT00140686|Biological|Rotavirus (vaccine)|
1745224|NCT00140699|Behavioral|Balance|
1745225|NCT00140712|Drug|Ropinirole Immediate Release|Ropinirole Immediate Release
1745226|NCT00140725|Drug|Lamivudine plus Polyethylene glyco-interferon alfa-2b|
1745227|NCT00140725|Drug|Lamivudine|
1745229|NCT00140751|Drug|Lopinavir/ritonavir (drug)|
1745230|NCT00140764|Drug|Metronidazole gel versus placebo gel|
1745231|NCT00140790|Drug|valsartan|valsartan 40 or 160 (80) mg per day
1745232|NCT00140803|Drug|Visudyne|
1745233|NCT00140803|Drug|Kenalog|
1745234|NCT00140816|Behavioral|Increased intake of dairy products|
1745235|NCT00140855|Drug|Anti-CTLA4 (monoclonal antibody MDX-010)|
1745236|NCT00140868|Device|Luminal stents|
1745237|NCT00140868|Procedure|Minimally Invasive Surgical Bowel Diversion|
1745238|NCT00140881|Drug|MK0476; montelukast sodium|
1745239|NCT00140881|Drug|Comparator: placebo|
1745240|NCT00140894|Drug|MK0966; rofecoxib / Duration of Treatment: 24 weeks|
1745241|NCT00140894|Drug|Comparator: placebo / Duration of Treatment: 24 weeks|
1745242|NCT00140907|Drug|losartan potassium|25 mg of oral losartan once daily, with an up-titration to 50 mg of losartan once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
1745461|NCT00142701|Behavioral|diet|
1745243|NCT00140907|Drug|Comparator: Placebo|25 mg of oral placebo once daily, with an up-titration to 50 mg placebo once daily in later visits if serum creatinine did not increase more than 25%. Patients take medication in the morning.
1745244|NCT00140920|Drug|MK0966; rofecoxib|
1745245|NCT00140920|Drug|Comparator: diclofenac 2x 75 mg|
1745246|NCT00140933|Drug|MK0966; rofecoxib|
1745247|NCT00140933|Drug|Comparator: diclofenac, placebo|
1745248|NCT00140946|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
1745249|NCT00140946|Drug|Comparator: placebo / Duration of Treatment: 16 weeks|
1745250|NCT00140959|Drug|MK0954, losartan potassium/Duration of Treatment: 18 weeks|
1745251|NCT00140959|Drug|Comparator: losartan, HCTZ, amlodipine, atenolol/Duration of Treatment: 18 weeks|
1745252|NCT00140972|Drug|MK0663; etoricoxib / Duration of Treatment:4 Weeks|
1745253|NCT00140972|Drug|Comparator: diclofenac sodium tablet 75 mg / Duration of Treatment:4 Weeks|
1745254|NCT00140985|Drug|MK0954, losartan potassium/Duration of Treatment: 20 weeks|
1745255|NCT00140985|Drug|Comparator: amlodipine / Duration of Treatment: 20 weeks|
1745256|NCT00140998|Drug|17 beta estradiol|
1745259|NCT00141024|Biological|EP HIV-1043|"Recombinant protein vaccine containing the 18 HIV proteins from HIV genes Pol, Vpu, and Gag.
The vaccine is provided in single-use 1.1-mL vials."
1745260|NCT00141024|Biological|EP HIV-1090|DNA plasmid vaccine containing the genes Gag, Pol, Vpr, Nef, Rev, and Env. The vaccine is provided in single-use 1.1-mL vials.
1745261|NCT00141037|Drug|Daclizumab|"Steroid-Based Immunosuppression(Prednisone) arm: 1 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, and 8 (e.g., standard dose of daclizumab induction until the second month post-transplant)
Steroid-Free Immunosuppression (Extended daclizumab induction) arm: 2 mg/kg pre-transplant followed by 1 mg/kg at weeks 2, 4, 6, 8, 11, and months 4, 5, and 6 (e.g., extended daclizumab induction until the sixth month post-transplant)"
1745262|NCT00141037|Drug|Mycophenolate mofetil (MMF)|Intravenous MMF was dosed at 1200 mg/m^2/day in two divided doses preoperatively and for the first 48 hours postoperatively. Oral MMF was dosed at 600 to 900 mg/m^2/day in two divided doses; the dose range allowed for dose titration according to tolerability and side effects of MMF. This regimen was used in both arms.
1745263|NCT00141037|Drug|Prednisone|Administered as 10 mg/kg peri-operatively followed by 2 mg/kg/day in subjects weighing <40 kg and 1.5 mg/kg/day in subjects weighing >40 kg. The prednisone dosing was tapered as follows: by the end of wks 1, 2, 4,6,12 and 16, dosages were 0.5, 0.4, 0.3, 0.2, 0.15 and 0.1 mg/kg/day, respectively. The prednisone dose of 0.1 mg/kg was achieved by no later than 6 months post-transplant.
1745264|NCT00141037|Drug|Tacrolimus|Taken orally from immediately preoperatively to those>age 5 yrs. (starting dose= 0.1 mg/kg/dose twice daily (BID) for living donor recipients; 0.1 mg/kg/dose daily for deceased donor recipients).Subjects <age 5 yrs. received drug from immediately preoperatively at 0.15 mg/kg/dose BID (two preoperative doses) for living donor recipients and 0.15 mg/kg/dose daily (one preoperative dose) for deceased donor recipients. Postoperatively: 0.07 mg/kg/dose BID w/adjustment to achieve target levels of 12-14 ng/mL (days 0-7), 10-12 ng/mL (wks. 2-8), 7-10 ng/mL (wks. 9-12) &5-7 ng/mL >= 12 wks. Evidence of drug toxicity on any protocol biopsy resulted in a further lowering of the drug target level to 4-6 ng/mL before yr 1 & 3-5 ng/mL after yr 1 post-transplant. This regimen was used in both arms.
1745265|NCT00141037|Drug|Ganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
1745266|NCT00141037|Drug|Valganciclovir|Cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) Prophylaxis: All participants will receive intravenous ganciclovir 5 mg/kg/day beginning after transplantation until tolerating oral medications, at which time oral valganciclovir will be initiated and continued for a minimum of 100 days.
1745267|NCT00141037|Drug|Trimethoprim and sulfamethoxazole|Pneumocystis pneumonia (PCP)/Urinary Tract Infection (UTI) Prophylaxis: Trimethoprim/sulfamethoxazole (Septra®) 2 mg/kg by mouth will be administered daily at bedtime for a minimum period of the first 6 months post-transplant. If unable to tolerate Septra®, inhaled pentamidine (8 mg/kg to a maximum dose of 300 mg monthly) or Dapsone (2 mg/kg PO to a maximum dose of 100 mg/day) may be substituted for a minimum of the first 6 months post-transplant. For UTI prophylaxis, if Septra® is not tolerated, nitrofurantoin (Macrodantin®), 2.5 mg/kg/day, may be given at bedtime up to a maximum dose of 100 mg/day.
1745268|NCT00141050|Drug|Focalin XR|
1745269|NCT00141063|Drug|Focalin XR|
1745270|NCT00141076|Behavioral|low vs high glycemic index diet|
1745271|NCT00141089|Drug|Tegaserod|
1745272|NCT00141102|Drug|Celecoxib|Participants are assigned to one of two groups in parallel for the duration of the study
1745273|NCT00141102|Drug|Diclofenac + Omeprazole|Participants are assigned to one of two groups in parallel for the duration of the study
1745274|NCT00141115|Drug|levetiracetam|Levetiracetam 1500 mg BID
1745275|NCT00141128|Drug|SS-RBX|
1745276|NCT00141141|Drug|Atorvastatin|
1745277|NCT00141141|Drug|Simvastatin|
1745278|NCT00141154|Drug|Celecoxib|
1745279|NCT00141154|Drug|Placebo|
1745280|NCT00141154|Drug|Loxoprofen|
1745281|NCT00141167|Drug|varenicline|
1745282|NCT00141180|Drug|CP-481,715|
1745283|NCT00141193|Drug|Celecoxib|
1745284|NCT00141206|Drug|varenicline (CP-526,555)|
1745285|NCT00141219|Drug|pregabalin|150-600mg/day, BID
1745286|NCT00141219|Drug|Placebo|Placebo
1745287|NCT00141232|Drug|Atorvastatin and Omega-3 fatty acids|
1745288|NCT00141245|Drug|Pregabalin|
1745289|NCT00141258|Drug|pregabalin|
1745290|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-6, then flexible dosing starting on day 7 between 20-40mg bid (20mg bid or 40mg bid) for the remainder of the 6 week trial
1745291|NCT00141271|Drug|Geodon (Ziprasidone)|Subjects will start at 20mg bid days 1-2, then 40mg bid days 3-4, them 60mg bid for days 5-6 then flexible dosing starting on day 7 between 60-80mg bid (60 mg bid or 80mg bid) for the remainder of the 6 week trial
1745292|NCT00141271|Drug|Placebo|Subjects will start on placebo and remain on placebo for the remainder of the 6 week trial
1745294|NCT00141284|Drug|Zidovudine 300 mg twice daily|
1745295|NCT00141284|Drug|Lamivudine 150 mg twice daily|
1745296|NCT00141297|Drug|PD-0332991|Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
1745297|NCT00141310|Drug|Sildenafil citrate|
1745298|NCT00141323|Drug|lasofoxifene|0.5 mg once per day, orally
1745299|NCT00141323|Other|placebo|placebo
1745300|NCT00141323|Drug|lasofoxifene|0.25 mg once per day, orally
1745301|NCT00141336|Drug|Pregabalin|
1745302|NCT00141349|Drug|UK-369,003|
1745303|NCT00141362|Drug|Pregabalin|
1745304|NCT00141375|Drug|Pregabalin|
1745305|NCT00141388|Drug|Pregabalin|
1745306|NCT00141401|Drug|Pregabalin|
1745307|NCT00141414|Drug|Pregabalin|
1745308|NCT00141427|Drug|Pregabalin|
1745309|NCT00141440|Procedure|mechanical ventilation|evaluated the effect of two different cycling off criteria on breathing pattern, respiratory effort, and gas exchange in patients with chronic obstructive pulmonary disease
1745310|NCT00141453|Drug|olmesartan medoxomil|Tablets 10, 20, or 40 mg
1745311|NCT00141453|Drug|Placebo Tablets|Matching placebo tablets
1745312|NCT00141466|Behavioral|Education for professionals|
1745313|NCT00141466|Behavioral|Distribution of educational materials|
1745314|NCT00141466|Behavioral|Feedback for professionals|
1745315|NCT00141466|Behavioral|Reminders for professionals|
1745316|NCT00141479|Drug|Bifeprunox|
1745317|NCT00141492|Drug|Androgel (testosterone gel)|
1745318|NCT00141505|Drug|Bifeprunox|
1745319|NCT00141518|Drug|Levodopa-carbidopa intestinal gel (LCIG)|
1745320|NCT00141518|Device|CADD-Legacy® 1400 ambulatory infusion pump|
1745321|NCT00141518|Device|percutaneous endoscopic gastrostomy tube (PEG tube)|
1745322|NCT00141518|Device|jejunal extension tube (J-tube)|
1745323|NCT00141531|Drug|Apaziquone|"Apaziquone (EOquinTM) 4 mg/40 mL was administered by intravesical instillation once a week for 6 consecutive weeks.
In addition, patients with CIS were to receive further maintenance therapy of 3 weekly apaziquone (EOquinTM) instillations at 3, 6, and 12 months from the date of histological diagnosis."
1745324|NCT00141544|Drug|esterified estrogens 1.25 mg and methyltestosterone 2.5 mg|ESTRATEST® administered orally QD
1745325|NCT00141544|Drug|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
1745326|NCT00141557|Drug|esterified estrogens 1.25mg and methyltestosterone 2.5mg|ESTRATEST® administered orally QD
1745327|NCT00141557|Drug|Esterified estrogens 1.25 mg|Esterified estrogens 1.25 mg administered orally QD
1745328|NCT00141570|Drug|esterified estrogens 0.625 mg and methyltestosterone 1.25 mg|
1745329|NCT00141583|Drug|Enalapril 20 mg bd|
1745330|NCT00141583|Drug|Candesartan 8 mg bd|
1745331|NCT00141596|Drug|Cardura XL 4 mg bd|
1745332|NCT00141596|Drug|Amiloride 5 mg bd|
1745333|NCT00141596|Drug|Furosemide 40 mg bd|
1745334|NCT00141609|Drug|Slow Sodium|
1745335|NCT00141622|Drug|Slow sodium|
1745336|NCT00141635|Behavioral|physio,pain,psychotherapy;social,nutrit.counselling&sports|
1745337|NCT00141648|Drug|Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone.|Given intravenously on days 1,11,43: Cyclophosphamide 750mg/m2, doxorubicin 50mg/m2, vincristine 1.4mg/m2. Given orally on days 1-5,22-27: Pednisolone 50mg/m2
1745338|NCT00141648|Radiation|Radiotherapy|Total 45 Gy in 25 fractions
1745339|NCT00141661|Drug|PF-04494700 - Low Dose Arm|30 mg loading dose for 6 days, followed by 10 mg daily
1745340|NCT00141661|Drug|PF-04494700 - High Dose Arm|60 mg loading dose for 6 days, followed by 20 mg daily
1745341|NCT00141661|Drug|Placebo Comparator|Matching placebo.
1745342|NCT00141674|Procedure|Blood Transfusion|This is a single centre randomized trial in severely head injured patients requiring a blood transfusion. Randomization will be by computer generated random numbers paced in sealed envelopes. Patients would be randomized to receive either blood less than 5 days old or greater than 20 days old. The decision to transfuse and all other intensive care management will be unaltered by enrolment in the study.
1745343|NCT00141687|Procedure|Early ECV between 34 0/7 and 35 6/7 weeks|Early external cephalic version between 34 0/7 and 35 6/7 weeks of gestation
1745344|NCT00141687|Procedure|Delayed ECV at or after 37 0/7 weeks|Delayed external cephalic version at or after 37 0/7 weeks of gestation
1745345|NCT00141700|Drug|Rituximab|
1745346|NCT00141713|Drug|Etanercept|Patients enrolled on the study will receive etanercept at 0.4 mg/kg per dose up to a maximum of 25 mg per dose subcutaneously twice a week. Etanercept must be initiated within 72 hours of starting solumedrol.
1745347|NCT00141726|Drug|Etanercept|Etanercept will be given on an open label, single arm basis to patients with non-infectious, sub-acute lung injury. 0.4 mg/kg/dose to a maximum of 25 mg, subcutaneously, twice weekly, for a total of 24 dosages.
1745348|NCT00141739|Drug|Etanercept|"Etanercept 0.4 mg/kg per dose [maximum dose 25 mg] SC for prophylaxis. To start in the 24 hour time period along with the initiation of the preparative regimen for the stem cell transplant.
Etanercept will be administered twice weekly until day +56 (8 weeks) post transplant."
1745349|NCT00141752|Device|Toronto Bedside Swallowing Screening Test (TOR-BSST)|Toronto Bedside Swallowing Screening Test
1745350|NCT00141765|Procedure|Myeloablative Chemotherapy|High dose chemotherapy (carboplatin and thiotepa) transplant rescue
1745351|NCT00141765|Procedure|Stem Cell Rescue|autologous stem cell transplantation
1745352|NCT00141778|Drug|Placebo|Matching placebo taken once a day
1745353|NCT00141778|Drug|Ramipril|Taken orally, once a day
1745354|NCT00141778|Drug|Spironolactone|Taken orally, once a day
1745355|NCT00141791|Drug|Etanercept|
1745356|NCT00141804|Drug|Sirolimus|
1745357|NCT00141817|Drug|pantoprazole for approximately 9 weeks.|
1745358|NCT00141830|Drug|Methotrexate plus ERB-041 for 12 weeks|
1745359|NCT00141830|Drug|Placebo for 12 weeks|
1745360|NCT00141843|Genetic|ReFacto AF|
1745361|NCT00141843|Genetic|B-Domain deleted Recombinant Factor VIII|
1745363|NCT00141856|Behavioral|Telephone care|
1745364|NCT00141882|Drug|memantine|
1745365|NCT00141895|Drug|Misoprostol|2 tablets 200 micrograms Vaginal route
1745366|NCT00141895|Drug|Misoprostol|2 tablets of 200 micrograms Sublingual route
1745367|NCT00141908|Drug|17-alpha Hydroxyprogesterone Caproate|250 mg IM weekly
1745368|NCT00141908|Drug|Castor oil|weekly IM injections
1745369|NCT00141921|Drug|Etanercept|Open-label at a dose of 0.8 mg/kg (up to an intended dose of 50 mg) given once weekly by subcutaneous injection
1745370|NCT00141934|Drug|AD 452|
1745371|NCT00141947|Drug|bexarotene (Targretin)|
1745372|NCT00141960|Drug|Famotidine|
1745373|NCT00141986|Dietary Supplement|vitamin D3|2000 IU per day
1745374|NCT00141986|Dietary Supplement|vitamin D3|400 IU per os once daily
1745375|NCT00141999|Biological|hepatitis B vaccine|
1745376|NCT00142012|Behavioral|Nutrition Intervention|
1745377|NCT00142025|Drug|Oxcarbazepine|
1745378|NCT00142038|Drug|Docetaxel|
1745379|NCT00142038|Drug|Capecitabine|
1745380|NCT00142051|Drug|nitric oxide|80 ppm 8 hrs, 40 ppm 8 hrs, 20 ppm 4 hrs, 10 ppm 4 hrs
1745381|NCT00142051|Drug|oxygen|oxygen fi02 21% (room air)
1745382|NCT00142064|Behavioral|observed levels of pain|
1745383|NCT00142077|Device|Electronic health record and messaging system|
1745384|NCT00142090|Drug|3% Hypertonic saline|
1745385|NCT00142090|Drug|Placebo|Normal saline
1745386|NCT00142103|Drug|CPG10101|CPG10101 subcutaneous, 0.20mg/kg, weekly, 12wks
1745387|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks
1745388|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Ribavirin, oral, 800-1400mg, daily, 12wks
1745389|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
1745390|NCT00142103|Drug|Control|Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
1745391|NCT00142103|Drug|CPG10101|CPG10101, subcutaneous, 0.20mg/kg, weekly, 12wks Pegylated Interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg (weight-based), daily, 12wks
1745392|NCT00142116|Drug|Thalidomide|200mg orally once a day for 14 weeks if that dosage is tolerated well, it will be increased to 400mg for up to 50 weeks.
1745393|NCT00142116|Drug|Rituximab|Given intravenously once weekly for 4 weeks beginning the second week of study treatment. If tolerated well, this may be repeated 8 weeks later.
1745394|NCT00142129|Drug|Bortezomib (Velcade)|
1745395|NCT00142155|Drug|Rituximab|
1745396|NCT00142155|Drug|monoclonal antibodies|
1745397|NCT00142168|Drug|CC-5103 (lenalidomide)|Taken orally once a day for 21 days followed by 7 days of no CC-5103 (lenalidomide)
1745398|NCT00142168|Drug|Rituximab|Begins on week 2 of treatment and is given intravenously once a week for 4 weeks
1745399|NCT00142181|Drug|Campath-1H|Participant will receive three test doses of Campath-1H (3, 10, and 30mg). If this is tolerated then they will receive Campath-IH three times a week for 6 weeks.
1745400|NCT00142207|Drug|Intermittent preventive treatment:sulphadoxine-pyrimethamine|Two doses given twice during pregnancy (once in the second trimester, and once in the third trimester). Oral medication in tablet form: single daily dose given on each occasion
1745401|NCT00142207|Device|Insecticide-treated mosquito bed net|Insecticide-treated mosquito bed net
1745402|NCT00142220|Drug|Defined percentage of omega-3-fatty acids|
1745403|NCT00142233|Drug|Magnesium (15 mmol/d)|
1745404|NCT00142233|Drug|ANTOX (vers.) 1.2 (300 µg organic selenium, 54000 IU beta carotene, 750 mg vitamin C, 540 IU vitamin E, 2700 mg methionine)|
1745405|NCT00142246|Drug|Intermittent preventive treatment (SP and amodiaquine)|Oral medication. SP: single dose given over one day; amodiaquine: 3 daily doses over 3 days. Dosage has given according to age.
1745406|NCT00142246|Other|Placebo|Three doses given over three days (Day 1: placebo SP + placebo AQ; Days 2 and 3: placebo AQ). Dosage given according to age
1745407|NCT00142259|Device|Deep brain stimulation of the internal globus pallidus|
1745408|NCT00142272|Drug|Ciprofloxacin|
1745409|NCT00142285|Drug|Zinc sulphate (20 mg)|
1745410|NCT00142298|Drug|Telbivudine (LdT)|Telbivudine was to be supplied as white to off-white, oval, bi-convex tablets for the 200 mg tablets and white to off-white ovaloid, slightly curved, beveled edges, film coated tablets for the 600 mg tablets. Study drug (600 mg) was to be self-administered by patients orally (p.o.) in a once daily regimen for 104 weeks; for study consistency, the daily dose had to be taken at the same time each day, with or without food.
1745411|NCT00142324|Drug|Donepezil|
1745412|NCT00142337|Drug|Zidovudine (ZDV)|Zidovudine 300 mg, twice daily, for one month postpartum. Note: after July 03, 2005, all women received 200 mg, twice daily, for the same duration.
1745413|NCT00142337|Drug|Didanosine (ddI)|250 mg ddI-EC (400 mg if body weight >60 kg) once daily, starting at the onset of labor and for one month postpartum
1745414|NCT00142350|Drug|continuous infusion of 5-fluorouracil|
1745415|NCT00142350|Drug|combination of irinotecan and cisplatin|
1745416|NCT00142350|Drug|oral administration of S-1|
1745417|NCT00142389|Biological|pneumococcal polysaccharide and protein conjugate vaccines|
1745418|NCT00142402|Drug|Modafinil|
1745419|NCT00142415|Drug|111-In-DOTA-cG250|On Day 1, each subject received a single intravenous (IV) infusion of 10 mg of cG250 coupled to DOTA and labeled with 5 mCi of 111-In.
1745420|NCT00142415|Drug|177-Lu-DOTA-cG250|On Day 8, 9, or 10, each subject received a single IV infusion of 10 mg of cG250 coupled to DOTA and labeled with a dose of 177-Lu at a starting dose of 30 mCi/m^2 in the initial cohort.
1745421|NCT00142428|Drug|Cetuximab|The initial dose of cetuximab was 400 mg/m2 (cycle 1 only) given intravenously followed by weekly intravenous infusions at 250 mg/m2. Each cycle was defined as 6 consecutive weekly intravenous treatments. Treatment was continued until 1 of the following criteria was met: disease progression per RECIST criteria, unacceptable toxicity, patient refusal, or the need to delay therapy more than 3 weeks.
1745422|NCT00142441|Device|Pulsed dye laser|
1745423|NCT00142454|Biological|NY-ESO-1 protein|
1745424|NCT00142454|Drug|Imiquimod|
1745425|NCT00142467|Drug|Gemcitabine|
1745426|NCT00142467|Drug|Oxaliplatin|
1745427|NCT00142467|Drug|Bevacizumab|
1745428|NCT00142480|Drug|Capecitabine|Given orally for 14 consecutive days (days 1-14) followed by a week of no capecitabine then another week of 14 consecutive days (days 21-28).
1745429|NCT00142480|Drug|Oxaliplatin|Given intravenously once weekly during weeks 1, 2, 4 and 5 on days 1, 8, 22 and 29
1745430|NCT00142480|Drug|Bevacizumab|Given intravenously every two weeks during weeks 1, 3 and 5 on days 1, 15 and 29.
1745431|NCT00142480|Procedure|Radiation therapy|Once daily for 5 days (Monday through Friday) for a total of 28 treatments.
1745432|NCT00142493|Drug|Propofol|1.2ug/ml
1745433|NCT00142493|Drug|Thiopental Sodium|2.0ug/ml
1745434|NCT00142493|Drug|Dexmedetomidine Hydrochloride|0.5ng/ml
1745435|NCT00142493|Drug|Midazolam Hydrochloride|60ng/ml
1745436|NCT00142493|Drug|placebo|intralipid, saline, saline with multi-Vit solution
1745439|NCT00142519|Drug|Methadone|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 2 mg
1745440|NCT00142519|Drug|methadone and morphine|Upon the 1st request for analgesic medication morphine 2 mg, upon the 2nd request for analgesic medication morphine 1 mg and methadone 1 mg
1745441|NCT00142532|Procedure|Acupuncture and Questionnaires|"Acupuncture 30 day treatment BL12 - 19 and extra point Wei Guan Xia Shu Each side of the spine,1.5 cun (~2.5cm) lateral to the lower border of spinous process of the T2 - 10 spinal vertebrae respectively 4 weeks ST36, Below the knee, 3 cun (~7.5cm) inferior to the lower border of the patella, one finger breadth lateral to the anterior crest of the tibia. One week following removal of epidural.
Shenmen, bilaterally. At the lateral 1/3 of the triangular fossa in the auricle.One week following removal of epidural.
Questionnaires 30 / 60 / 90 Day and 12 Month Follow-up-Numerical rating scale of pain; total opioid use; Medication Quantification Scale; length of stay; Brief Pain Inventory"
1745442|NCT00142532|Procedure|Placebo Acupuncture, Questionnaires|"The back studs will be placed halfway between the upper and lower border of spinous processes T2 to T10, approximately 0.5 cun (~1.25cm) from the spine. The leg studs will be placed at 2 cun (~5cm) posterior to GB34 on the posterior of the lower leg. No studs will be placed in the ear; rather studs will be placed on the anterior arm, 3 cun (~ 5cm) proximal and 3 cun (~ 5cm) medial to the midpoint of the antecubital crease.
Pain will be assessed by a 0 - 10 point numerical rating scale (NRS) marked no pain at one end and worst pain at the other."
1745443|NCT00142545|Drug|apomorphine HCl injection|
1745444|NCT00142558|Drug|MK0663; etoricoxib / Duration of Treatment: 5 Days|
1745445|NCT00142558|Drug|Comparator: indomethacin 75 mg sustained release capsule / Duration of Treatment: 5 Days|
1745446|NCT00142571|Drug|Gemcitabine|
1745447|NCT00142571|Drug|Docetaxel|
1745448|NCT00142584|Drug|Nebivolol|Patients randomized to nebivolol will initiate therapy with nebivolol 5 mg once daily for 4 weeks.
1745449|NCT00142584|Drug|Metoprolol|Patients randomized to metoprolol will initiate therapy with 100 mg once daily for 4 weeks.
1745450|NCT00142597|Device|Acupuncture|"Involves the insertion and manual stimulation of thin acupuncture needles into specific points in the body.
Fibromyalgia participants will be randomized to receive 9 acupuncture treatments over the course of four weeks.
All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
1745451|NCT00142597|Other|Sham treatment|"Fibromyalgia participants will be randomized to receive 9 sham treatments over the course of four weeks.
All participants will be scanned twice using the fMRI scanner. The PET portion of the study is optional."
1745452|NCT00142610|Dietary Supplement|Vitamin|This is designed as a placebo controlled study of 500 mg alpha tocopherol combined with 2,000 mg of ascorbate, each orally administered daily for 12 weeks, on airway antioxidant levels in asthmatics.
1745453|NCT00142623|Behavioral|Tailored DVDs|Five DVDs aimed at reducing exposure to ETS
1745454|NCT00142649|Behavioral|diet|
1745455|NCT00142649|Behavioral|physical activity|
1745456|NCT00142662|Behavioral|diet|
1745457|NCT00142662|Behavioral|financial incentives|
1745458|NCT00142675|Behavioral|Physical Activity|
1745459|NCT00142688|Behavioral|Physical activity|Tailored print-based intervention in which participants complete questionnaires and receive tailored feedback based on responses to the questionnaires. The intervention is delivered monthly during the first month, bi-monthly during months 2 and 3, and monthly during months 4-6. The intervention is completed through the mail.
1745460|NCT00142688|Behavioral|Wellness|Participants receive wellness materials delivered through the mail on the same schedule as the experimental condition. Physical activity materials are given to this group upon completion of the study.
1745462|NCT00142701|Behavioral|physical activity|
1745463|NCT00142701|Behavioral|stress management|
1745464|NCT00142701|Behavioral|smoking cessation|
1745465|NCT00142714|Procedure|Sympathetic manipulation on sexual arousal in women|
1745466|NCT00142727|Drug|Methadone|
1745467|NCT00142727|Drug|Full opioid agonist|
1745468|NCT00142727|Drug|Partial opioid agonist|
1745469|NCT00142727|Drug|Opioid antagonist|
1745470|NCT00142753|Biological|Engerix B|Standard adult dose for A1; increased adult dose for A2. Doses at Entry, Weeks 4 and 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at Week 48.
1745471|NCT00142753|Biological|Twinrix for ATN 024|Standard adult dosage, taken at Entry, Weeks 4 and 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive Engerix-B increased adult dose at week 48.
1745472|NCT00142753|Biological|Recombivax|Dosage at entry and week 24; non-responders ((<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive 3rd dose of Recombivax during weeks 48-72.
1745473|NCT00142753|Biological|Twinrix for ATN 025|Doses at Entry and Week 24. Non-responders (<10 IU/mL of antibody at week 28/4 weeks after dose #3) will receive a dose of Recombivax during week 48-72.
1745474|NCT00142766|Behavioral|Nurse Implemented Goal-Directed Comfort Algorithm|See description
1745475|NCT00142779|Drug|Fluoxetine|
1745477|NCT00142805|Drug|Ketasyn™ (AC-1202)|
1745478|NCT00142818|Drug|Naltrexone|150 mg daily for males; 100 mg daily for females
1745479|NCT00142818|Drug|Modafinil|400 mg daily
1745480|NCT00142818|Drug|Placebo|400 mg and/or 100-150 mg placebo pills
1745481|NCT00142831|Drug|Pharmacotherapies for Smoking Cessation|Bupropion-SR or Identical Placebo
1745482|NCT00142844|Drug|Naltrexone|
1745483|NCT00142844|Drug|Disulfiram|
1745484|NCT00142844|Drug|Placebo|
1745485|NCT00142870|Drug|Bupropion|150 mg, twice a day
1745486|NCT00142883|Drug|Pregabalin|pregabalin compared to placebo
1745487|NCT00142883|Drug|placebo|sugar pill compared to pregabalin
1745488|NCT00142896|Drug|Tramadol|
1745489|NCT00142896|Drug|Naloxone|
1745490|NCT00142896|Drug|Morphine|
1745491|NCT00142909|Drug|Lofexidine|Participants will receive lofexidine. The dosing will be initiation at 0.4 mg bid and increased to 0.8mg in week 1 and 1.0 and 1.2 mg bid in week 2, and maintained at 1.2mg bid for weeks 3 to 12. They are then tapered down to 0 over the course of four days in week 12. While the target dose will be 2.4 mg daily, if any subject shows reduced tolerability at this or a lower dose, the dose will be adjusted to the maximum tolerated dose for that subject.
1745492|NCT00142909|Drug|Placebo|Lofexidine Placebo
1745493|NCT00142922|Behavioral|Breaking Down Barriers|completed
1745494|NCT00142935|Behavioral|Pre-release Initiation of MMT|Participants assigned to arm 1 will undergo extensive assessment (physical, medical history, drug use and treatment history) prior to initiating treatment. MMT will begin 1-30 days prior to release from incarceration. MMT first dose will begin at 5 mg with 2 mg increase per day until release or therapeutic dose of 60-120 mg is achieved. Daily observation by dosing nurses and twice weekly symptom review by Research Assistant will occur. Additionally, participants assigned to Arm 1 will have all logistical arrangements made for entry into a community methadone clinic program within 24 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
1745495|NCT00142935|Behavioral|Post Release Initiation of MMT.|Participants assigned to Arm 2 will have all logistical arrangements made for entry into a community methadone clinic program within 24-48 hours of release from incarceration. The study will fully pay for MMT for 12 weeks and half the costs of treatment for the next 12 weeks.
1745496|NCT00142935|Behavioral|Standard of Care Plus|Participants assigned to Arm 3 will not begin treatment prior to release from incarceration or have treatment paid for by the study. However, study staff will work with participants to identify ways to pay for treatment, including assisting with medicaid applications, etc. Further, the study will make the logistical arrangements for entering treatment if participant has a means to finance MMT.
1745497|NCT00142948|Drug|Naltrexone|naltrexone
1745498|NCT00142948|Drug|Placebo|placebo
1745499|NCT00142961|Drug|Atomoxetine|atomoxetine
1745500|NCT00142961|Other|placebo|
1745501|NCT00149292|Drug|LY2140023|
1745502|NCT00149292|Drug|olanzapine|
1745503|NCT00149292|Drug|placebo|
1745504|NCT00149305|Other|Genetic analyses|
1745505|NCT00149305|Other|Genetic analyses|
1745506|NCT00149318|Other|Biochemical analyses.|Biochemical analyses.
1745507|NCT00149331|Behavioral|Structured education program|
1745508|NCT00149344|Radiation|Vertical scar versus inferior pedicle reduction mammoplasty|Vertical Scar Reduction Mammoplasty Inferior Pedicle Reduction Mammoplasty
1745509|NCT00149357|Other|Thrombophilia Testing|TP testing in Group 1 and 3 only
1745510|NCT00149370|Procedure|Breast reduction surgery|
1745511|NCT00149383|Drug|Rosiglitazone|
1745512|NCT00149383|Drug|Placebo|
1745514|NCT00149409|Dietary Supplement|Omacor|
1745515|NCT00149422|Device|NT-proBNP measurements|
1745516|NCT00149448|Behavioral|TB Contact Priority Model|
1745517|NCT00149461|Behavioral|Written Asthma Action Plan|
1745518|NCT00149474|Behavioral|Peak Flow Monitoring|
1745519|NCT00149487|Behavioral|Tailored Problem Solving Intervention|
1745520|NCT00149487|Behavioral|Family Education Intervention|
1745610|NCT00150644|Drug|Asoprisnil|Asoprisnil 10mg Tablet, oral Daily for 12 weeks
1745611|NCT00150644|Drug|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for 12 weeks
1745522|NCT00149513|Behavioral|Targeted Case Management|A nurse case manager will assess and follow intervention arm subjects for six months. Nurse case manager will help subjects acquire needed community health services.
1745523|NCT00149513|Behavioral|Usual care|Participants will receive usual care.
1745524|NCT00149526|Behavioral|Shared Decision-Making|
1745525|NCT00149539|Drug|Buprenorphine/naloxone|
1745526|NCT00149552|Dietary Supplement|zinc|supplementation with zinc gluconate
1745527|NCT00149565|Drug|IFN-α2b|
1745528|NCT00149578|Drug|Gemcitabine Oxaliplatin 5FU and Leucovorin|
1745529|NCT00149591|Procedure|coronary balloon-angioplasty with stenting|
1745530|NCT00149604|Drug|conjugated estrogens|
1745531|NCT00149604|Drug|Raloxifene|
1745532|NCT00149604|Behavioral|exercise plus mild caloric restriction for weight loss|
1745533|NCT00149617|Drug|Buspirone|
1745534|NCT00149903|Drug|Mycophenolate sodium (enteric coated)|
1745535|NCT00149916|Drug|Mycophenolate sodium (enteric coated)|
1745536|NCT00149929|Drug|Mycophenolate sodium (enteric coated)|
1745537|NCT00149942|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
1745538|NCT00149968|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|Patient on MMF treatment completes questionnaire and switch to equimolar doses of Myfortic. Maximum daily dose 1440 mg
1745539|NCT00149981|Drug|everolimus (RAD)|Everolimus
1745540|NCT00149994|Drug|Cyclosporine A|
1745541|NCT00149994|Drug|Tacrolimus|
1745542|NCT00149994|Drug|Basiliximab|Each patient was given two 20mg doses of Basiliximab as intravenous bolus injection at Day 0 and Day 4 post-transplant surgery.
1745543|NCT00149994|Drug|Methylprednisolone|Methylprednisolone was given as an intravenous bolus of 500mg during transplant surgery
1745544|NCT00149994|Drug|Prednisone|Post-operatively prednisone was tapered from an initial dose of 20mg/day to zero at 3 months or continued at 5-10mg if the indication for Orthotopic Liver Transplantation (OLTx) was of auto-immune nature.
1745545|NCT00150007|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
1745546|NCT00150020|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|
1745547|NCT00150046|Drug|Everolimus|
1745548|NCT00150059|Drug|Pimecrolimus Cream 1%|
1745549|NCT00150072|Drug|imatinib|
1745550|NCT00150085|Drug|cyclosporine micro-emulsion|
1745551|NCT00150098|Behavioral|Enhanced HIV risk reduction and HIV vaccine education|
1745552|NCT00150111|Drug|Methimazole|
1745553|NCT00150111|Drug|Rituximab|
1745554|NCT00150111|Biological|Immunization with various vaccines|
1745555|NCT00150124|Drug|MTZ+LT4|
1745556|NCT00150124|Drug|Methimazole|
1745557|NCT00150137|Drug|Methimazole|
1745558|NCT00150150|Procedure|Interstitial laser photocoagulation|
1745559|NCT00150176|Drug|Asenapine - Open Label|Open Label Phase: All subjects received 26 weeks of open label asenapine treatment (cross titration period up to first 4 weeks, with target dose of 10 mg twice daily by week 1).
1745560|NCT00150176|Drug|Placebo - Double Blind|Double Blind Phase: Following Open Label Phase, matching placebo sublingual twice daily for 26 weeks.
1745561|NCT00150176|Drug|Asenapine - Double Blind|Double Blind Phase: Following the Open Label Phase, asenapine 5 or 10 mg sublingual twice daily for 26 weeks.
1745562|NCT00150189|Behavioral|Sucrose|
1745563|NCT00150202|Drug|pegaptanib sodium|
1745564|NCT00150215|Drug|PF-00184562|
1745565|NCT00150215|Drug|Olanzapine|
1745566|NCT00150228|Drug|CP-526,555 (varenicline)|
1745567|NCT00150241|Drug|CP-526,555 (varenicline)|
1745568|NCT00150254|Drug|CP-526,555 (varenicline)|
1745569|NCT00150267|Drug|Xalacom|
1745570|NCT00150280|Drug|celecoxib and ibuprofen SR|
1745571|NCT00150293|Drug|Pregabalin|
1745572|NCT00150306|Drug|Zoloft (Sertraline)|
1745573|NCT00150319|Drug|Vfend®; I.V.|
1745574|NCT00150332|Drug|linezolid|
1745575|NCT00150345|Drug|voriconazole (Vfend)|voriconazole, early treatment
1745576|NCT00150345|Drug|voriconazole (Vfend)|voriconazole, deferred treatment
1745577|NCT00150358|Drug|Sildenafil Citrate|
1745578|NCT00150371|Drug|atorvastatin|
1745579|NCT00150384|Drug|Amlodipine/Atorvastatin|
1745580|NCT00150397|Drug|Tofimilast|
1745581|NCT00150410|Drug|Inhaled insulin|
1745582|NCT00150423|Drug|Pregabalin|
1745583|NCT00150436|Drug|Pregabalin|
1745584|NCT00150449|Drug|Pregabalin|
1745585|NCT00150462|Drug|Carfilzomib|Administered as an IV bolus dose
1745586|NCT00150462|Drug|Dexamethasone|Administered orally prior to carfilzomib
1745587|NCT00150475|Procedure|Powered Air purifying respirator|
1745588|NCT00150488|Device|Uracyst|2% weekly for 6 weeks, monthly for 4 months
1745589|NCT00150514|Drug|Oralgen|
1745590|NCT00150514|Procedure|Nasal biopsy|
1745591|NCT00150514|Procedure|Nasal washing|
1745592|NCT00150514|Procedure|Peak nasal inspiratory flow|
1956583|NCT02788305|Drug|Misoprostol|Misoprostol 25 micrograms every 6 hours will be given to obese and non obese groups
1745597|NCT00150540|Drug|Lanthanum carbonate|
1745598|NCT00150553|Drug|Extended-release carbamazepine|
1745599|NCT00150566|Drug|Lanthanum carbonate|
1745600|NCT00150579|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate|
1745601|NCT00150592|Drug|SPD503 (Guanfacine HCl)|
1745602|NCT00150592|Drug|Placebo|
1745603|NCT00150605|Drug|Extended-release carbamazepine|
1745604|NCT00150618|Drug|SPD503 (1 mg)|
1745605|NCT00150618|Drug|SPD503 (2 mg)|
1745606|NCT00150618|Drug|SPD503 (3 mg)|
1745607|NCT00150618|Drug|SPD503 (4 mg)|
1745608|NCT00150618|Drug|Placebo|
1745609|NCT00150631|Drug|Candesartan|placebo controlled double blind
1745612|NCT00150644|Drug|Placebo|Placebo Tablet, oral Daily for 12 weeks
1745613|NCT00150657|Drug|bevacizumab|
1745614|NCT00150657|Drug|carboplatin|
1745615|NCT00150657|Drug|gemcitabine|
1745616|NCT00150670|Drug|TS-1 and cisplatin|TS-1(40-60 mg per body surface area) was given orally, twice daily for 3 consecutive weeks, and 60 mg/m2 cisplatin was given intravenously on day 8, followed by a 2-week rest period, within a 5-week cycle.
1745617|NCT00150670|Drug|TS-1|TS-1(40-60 mg per body surface area) was given orally, twice daily for 4 consecutive weeks, followed by a 2-week rest period, within a 6-week cycle.
1745618|NCT00150683|Device|vibration and passive standing versus passive standing alone|
1745619|NCT00150696|Drug|Risedronate|
1745620|NCT00150709|Drug|Levetiracetam (Keppra)|
1745621|NCT00150722|Drug|atorvastatin (or other tolerated statin + Niaspan/placebo)|atorvastatin 80 mg for all, randomized to 1500 mg niacin/placebo and then crossed over
1745622|NCT00150735|Drug|LEVETIRACETAM|
1745623|NCT00150748|Drug|Levetiracetam 166 mg|"Active Substance: Levetiracetam
Pharmaceutical Form: Tablet
Concentration: 166 mg
Route of Administration: Oral use"
1745624|NCT00150748|Drug|Levetiracetam 250 mg|"Active Substance: Levetiracetam
Pharmaceutical Form: Tablet
Concentration: 250 mg
Route of Administration: Oral use"
1745625|NCT00150748|Drug|Levetiracetam 500 mg|"Active Substance: Levetiracetam
Pharmaceutical Form: Tablet
Concentration: 500 mg
Route of Administration: Oral use"
1745626|NCT00150761|Drug|Levocetirizine (drug)|
1745627|NCT00150774|Drug|Levetiracetam|
1745628|NCT00150787|Drug|LEVETIRACETAM|
1745629|NCT00150800|Drug|Brivaracetam|"Active Substance: Brivaracetam
Pharmaceutical Form: Tablet
Concentration: 10 mg and 25 mg
Route of Administration: Oral"
1745630|NCT00150813|Drug|LEVETIRACETAM|
1745631|NCT00150826|Drug|Quinapril|Quinapril will be started at 40mg daily and titrated to 80mg daily for 16 weeks.
1745632|NCT00150826|Drug|Placebo|Placebo will be given in a capsule form once daily for 16 weeks.
1745633|NCT00150839|Drug|Mirtazapine|Patients receive mirtazapine 45mg and placebo.
1745634|NCT00150839|Drug|Venlafaxine|Patients receive mirtazapine 45mg and venlafaxine 300mg.
1745635|NCT00150852|Drug|Vancomycin|
1745637|NCT00150878|Other|Conditioning therapy|Preparation before allogeneic transplantation
1745638|NCT00150891|Procedure|Kidney transplantation|
1745639|NCT00150891|Drug|cyclosporine A|
1745640|NCT00150891|Drug|tacrolimus|
1745641|NCT00150891|Drug|azathioprine|
1745642|NCT00150891|Drug|mycophenolate mofetil|
1745643|NCT00150904|Procedure|venous blood puncture|
1745644|NCT00150917|Behavioral|Supportive-Expressive Group Therapy|
1745645|NCT00150930|Device|narrowband UVB phototherapy at home|
1745646|NCT00150943|Device|Renal artery stent|
1745647|NCT00150956|Procedure|Daily home hemodialysis|
1745648|NCT00150969|Dietary Supplement|vitamin K1 (phylloquinone)|
1745649|NCT00150969|Dietary Supplement|placebo|1 pill daily
1745650|NCT00150982|Drug|Mechanism of action of alefacept|
1745651|NCT00150995|Drug|Tetrathiomolybdate|
1745652|NCT00151008|Drug|Bexarotene/NBUVB vs placebo NBUVB|
1745653|NCT00151021|Behavioral|Tailored web-based walking program|
1745654|NCT00151034|Drug|Trastuzumab|
1745655|NCT00151034|Drug|Paclitaxel|
1745656|NCT00151034|Drug|Carboplatin|
1745657|NCT00151034|Drug|Gemcitabine|
1745658|NCT00151047|Drug|Capecitabine|
1745659|NCT00151047|Drug|Docetaxel|
1745660|NCT00151060|Drug|Estramustine|
1745661|NCT00151060|Drug|Etoposide|
1745662|NCT00151060|Drug|Paclitaxel|
1745663|NCT00151073|Drug|Zoledronic acid|
1745664|NCT00151073|Drug|Estramustine|
1745665|NCT00151073|Drug|Docetaxel|
1745666|NCT00151086|Drug|Estramustine|
1745667|NCT00151086|Drug|Vinorelbine|
1745668|NCT00151099|Drug|high caloric drink with protein|
1745669|NCT00151112|Procedure|Positioning and plexus anesthesia|positioning during plexus anesthesia
1745670|NCT00151125|Drug|recombinant interleukin-11|25 mcg/kg subcutaneously daily for seven days
1745671|NCT00151125|Drug|recombinant interleukin-11|50 mcg/kg subcutaneously daily for 7 days
1745672|NCT00151125|Drug|recombinant interleukin-11|10 mcg/kg subcutaneously daily for 7 days
1745673|NCT00151138|Drug|Atenolol (drug), Lisinopril (drug)|
1745674|NCT00151151|Behavioral|Computer-Assisted Motivational Intervention|
1745675|NCT00151151|Behavioral|Didactic Educational Counseling|
1745676|NCT00151164|Procedure|donor bone marrow cell injection into thymus gland|
1745677|NCT00151177|Device|non-invasive continuous positive airway pressure ventilation|
1745678|NCT00151177|Device|CPAP-treatment|night time CPAP-mask ventilation
1745679|NCT00151190|Behavioral|Education for diabetes self-management|
1745680|NCT00151203|Drug|Clarithromycin, Lenalidomide, Dexamethasone|"Dexamethasone (Decadron®) will be given orally at a dose of 40 mg on days 1, 2, 3, 8, 15 and 22 during the first cycle and once a week on days 1, 8, 15, and 22 for each subsequent cycle.
Clarithromycin (Biaxin®) will be given orally at a dose of 500 mg twice a day beginning on day 2 of cycle 1.
Lenalidomide (Revlimid®) will be given orally at a dose of 25 mg daily beginning on day 3 and ending on day 21 of cycle 1 and on days 1-21 of subsequent cycles."
1745681|NCT00151216|Genetic|AAV2CUhCLN2 (3x10^12 particle units)|gene transfer; one-time administration via neuro surgery procedure
1745682|NCT00151229|Other|target blood pressure|
1745683|NCT00151242|Drug|Cytarabine|100mg/m² kont. i.v. day 1-7 (induction therapy) 3g/m² 2x/die i.v. day 1,3,5 or day 1,2,3
1745684|NCT00151242|Drug|Idarubicin|12mg/m² i.v. day 1,3,5 (first induction cycle) 12mg/m² i.v. Tag 1,3 (second induction cycle)
1745685|NCT00151242|Drug|Etoposide|100mg/m² i.v. day 1-3 (induction therapy)
1745686|NCT00151242|Drug|All-trans retinoic acid|45mg/m² p.o. day 6-8 (induction therapy) 15mg/m² p.o. day 9-21 (induction therapy) 15mg/m² p.o. day 6-21 (consolidation therapy)
1745687|NCT00151242|Drug|Pegfilgrastim|6mg s.c day 10 (cohort 1), 6mg s.c. day 8 (cohort 2)
1745688|NCT00151255|Drug|Cytarabine|100mg/m² kont. i.v. day 1-5 (induction therapy); 1000 mg/m² 2x/die i.v. day 1-3 (first consolidation cycle)
1745689|NCT00151255|Drug|Idarubicin|12mg/m² i.v. day 1+3 (induction therapy); 12mg/m² i.v. Tag 1+3 (second consolidation cycle)
1745690|NCT00151255|Drug|All-trans retinoic acid|45mg/m² p.o. day 4-6, 15mg/m² p.o. day 7-28 (induction therapy); 15mg/m² p.o. day 4-28 (consolidation therapy)
1745691|NCT00151255|Drug|Mitoxantrone|10mg/m² i.v. day 2-3 (first consolidation cycle)
1745692|NCT00151255|Drug|Etoposid|100mg/m² i.v. Tag 1-5 (second consolidation cycle)
1745693|NCT00151281|Drug|PEPC|"Induction phase (month 1-3)
• PEPC daily (prednisone 20 mg/day, cyclophosphamide 50 mg/day, etoposide 50 mg/day, and procarbazine 50 mg/day) until expected drop in neutrophil count (ANC < 3000), unless due to disease. After ANC returns to above 2,000/ul, PEPC resumes at alternate day or fractionated weekly basis.
Maintenance phase (month 4-12) • PEPC QOD or fractionated weekly basis.
Post-Month 12 Maintenance phase (post-month 12 until disease progression)
• PEPC QOD or fractionated weekly basis"
1745694|NCT00151281|Drug|Thalidomide|"Induction phase (month 1-3)
• Daily thalidomide at 50 mg/day for the first 8 weeks, then dose escalated as tolerated to a maximum of 100 mg/day.
Maintenance phase (month 4-12) • Daily low dose thalidomide (50-100 mg/d)
Post-Month 12 Maintenance phase (post-month 12 until disease progression)
• Daily low dose thalidomide (50-100mg/d)"
1745695|NCT00151281|Drug|Rituximab|"Induction phase (month 1-3)
• Rituximab weekly x 4 (375 mg/m2/week) starting at week 1.
Maintenance phase (month 4-12) • Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months.
Post-Month 12 Maintenance phase (post-month 12 until disease progression)
• Rituximab (375 mg/m2/week) weekly x 4 administered every 4 months"
1745696|NCT00151294|Drug|escitalopram oxalate antidepressant|
1745697|NCT00151307|Device|INVOS cerebral oximeter|
1745698|NCT00151320|Drug|Bortezomib, CHOP, Rituximab|"Standard CHOP chemotherapy administered every 21 days (full dose) for six cycles Rituximab administered (375 mg/m2) day 1 of each cycle (with usual premedications)
VELCADE (Bortezomib) is administered prior to rituximab and CHOP on day 1 of each cycle. The dose of VELCADE will be determined by the following dose escalation schedule:
Level Dose/Schedule (-2) 0.7 mg/m2 on day 1 of each cycle (-1) 0.7 mg/m2 on days 1 and 8 (0) 0.7 mg/m2 on days 1 and 4 (+1) 1.0 mg/m2 on days 1 and 4 (+2) 1.3 mg/m2 on days 1 and 4"
1745699|NCT00151333|Drug|SRA-333|
1745700|NCT00151346|Drug|Bupivacaine and Fentanyl (for CSE)|Bupivacaine 0.25% x 1 cc + Fentanyl 20 mcg, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
1745701|NCT00151346|Drug|Bupivacaine and Fentanyl (for traditional epidural)|Bupivacaine 0.0625% with Fentanyl 2 mcg/mL x 15 cc, followed by infusion of Bupivacaine 0.0625% with Fentanyl 2 mcg/mL at 12 cc/hr
1745702|NCT00151359|Device|SoleSensor|
1745703|NCT00151372|Behavioral|Treatment Adherence Intervention|The care management intervention aims at facilitating adherence to a treatment algorithm based on the Agency for Health Care Policy and Research (AHCPR) guidelines. The investigators hypothesize that this intervention, in comparison to usual care, will increase the prescription of adequate antidepressant treatment by physicians, enhance treatment adherence by patients, and reduce depressive symptoms, suicide ideation, and disability.
1745704|NCT00151372|Behavioral|Enhanced Care|For subjects in the Enhanced Care group, physicians providing aftercare will receive no clinical instructions by the research team, but will be informed in writing of the patients' diagnosis and will be provided with a copy of the Agency for Health Care Policy and Research (AHCPR) guidelines for the treatment of depression in primary care with an addendum updating the tables describing Selective Serotonin Reuptake Inhibitors (SSRI) side effect and dosage profiles. The investigators expect that these physicians will continue to base their practice on clinical judgment about how best to treat depression in chronic obstructive pulmonary disease patients.
1745705|NCT00151385|Procedure|single blood draw|
1745706|NCT00151398|Drug|lecozotan SR|"evaluation of long term therapy with 3 doses of lecozotan sr ( 2, 5, and 10 mg)administered to patients with AD who have completed week 12 evaluations in the short-term study. Patient duration is 42 weeks.
Arms include lecozotan sr 2 mg, 5mg, and 10 mg as well as donepezil."
1745707|NCT00151398|Drug|Donepezil|10 mg donepezil QD dosed up to 40 weeks
1745711|NCT00151424|Drug|asenapine|Asenapine 5-10mgBID
1745712|NCT00151424|Drug|Placebo|Matched against asenapine and olanzapine
1745713|NCT00151424|Drug|Olanzapine|10-20 mg QD
1745714|NCT00151437|Drug|Pegvisomant treatment|
1745715|NCT00151437|Procedure|Medical History, demographics|
1745716|NCT00151437|Procedure|Sign and symptoms: questionnaire|
1745717|NCT00151437|Procedure|Blood tests: IGF-1, AST/ALT/ALP/TBIL, GTT|
1745718|NCT00151437|Procedure|MRI|
1745719|NCT00151450|Drug|Pregabalin|
1745720|NCT00151450|Drug|Venlafaxine XR|
1745721|NCT00151463|Drug|sildenafil citrate|
1745722|NCT00151476|Drug|Celecoxib|800 mg total daily dosing
1745723|NCT00151476|Other|Routine Medical Care|
1745724|NCT00151489|Drug|pregabalin|
1745725|NCT00151489|Drug|placebo|
1745726|NCT00151502|Drug|Atorvastatin|
1745727|NCT00151515|Drug|minoxidil|Topical 5% minoxidil foam, BID, for sixteen weeks
1745728|NCT00151528|Drug|Pregabalin|
1745729|NCT00151541|Drug|Dapsone Topical Gel + adapalene gel 0.1%|
1745730|NCT00151541|Drug|Dapsone Topical Gel + benzoyl peroxide gel 4%|
1745731|NCT00151541|Drug|Dapsone Topical Gel + vehicle control|
1745732|NCT00151554|Behavioral|ICU-specific information program|The intervention group receives a standardized information program with specific procedural, sensory and coping information about the ICU in addition to standard information given by surgeons and anesthetists.
1745733|NCT00151567|Drug|Tamsulosin|Oral tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
1745852|NCT00133887|Drug|tacrolimus|Blood residual level < or = to 8 ng/ml
1745734|NCT00151567|Drug|Placebo|Oral placebo of tamsulosin once a day until stone elimination or the end of the follow-up (42 days)
1745735|NCT00151580|Drug|Ribavirin|18 months of oral ribavirin maintenance treatment
1745736|NCT00151580|Drug|Placebo|18 months oral placebo treatment
1745737|NCT00151593|Other|Celsior®|Graft preservation solution
1745738|NCT00151606|Procedure|Reinforced isolation + Muciprocine|
1745739|NCT00151619|Drug|Amlodipine|
1745740|NCT00151632|Drug|Mycophenolate mofetil|Mycophenolate mofetil is administered at a dose of 1,5 g x 2 / day for the 6 first weeks, then 1g x 2 / day until M12.
1745741|NCT00151632|Drug|Tacrolimus|"In arm 1: Tacrolimus is administered at half recommended dose: 0,040 mg/Kg x 2 , in order to maintain plasma levels between 6 and 10 ng/ml for the 6 first weeks, between 5 and 8 ng/ml from week 7 to M6 and between 4 and 6 ng/ml between M6 and M12.
In arm 2: Tacrolimus is administered at the recommended dose: 0,075 mg/Kg x 2 , in order to maintain plasma levels between 12 and 20 ng/ml for the 6 first weeks, between 10 and 15 ng/ml from week 7 to week 12, between 8 and 12 ng/ml between M4 and M6 and between 6 and 10 ng/ml between M6 and M12."
1745742|NCT00151645|Drug|activated lymphocytes|
1745743|NCT00151658|Device|Coronary Drug Eluting Stents for PCI|
1745744|NCT00151671|Drug|Oral Impact®|Oral nutritional supplement containing L-arginin, ω3 polyunsaturated fatty acids, and nucleotides. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
1745745|NCT00151671|Drug|Placebo|Oral solution of placebo. Given three times a day for the 7 last preoperative and the first 3 postoperative days.
1745746|NCT00151684|Drug|Diazoxide|
1745747|NCT00151697|Drug|Novomix 30|
1745748|NCT00151697|Drug|Novorapid and Amaryl|
1745749|NCT00151697|Drug|Lantus|
1745750|NCT00151710|Drug|Pioglitazone|
1745751|NCT00151723|Procedure|treatment with 131I|
1745752|NCT00151736|Drug|Chlorambucil|Chlorambucil 2mg tablets
1745753|NCT00151736|Drug|R-etodolac + chlorambucil|R-etodolac 600mg tablets + chlorambucil 2mg tablets
1745754|NCT00151749|Drug|Colesevelam hydrochloride|
1745755|NCT00151762|Drug|Colesevelam hydrochloride|
1745756|NCT00151775|Drug|olmesartan medoxomil|"Cohorts A and B: 2.5mg to 40mg olmesartan, as a suspension (depending on weight), once daily. Tablets were used to prepare a suspension.
Cohort C: 0.3mg/kg olmesartan ,as a suspension, once daily"
1745757|NCT00151775|Drug|placebo|Cohorts A, B, C: placebo, once daily
1745758|NCT00151775|Drug|olmesartan medoxomil|"Cohorts A and B: Open label olmesartan medoxomil suspension or tablets 10mg - 40 mg. Tablets were used to prepare the suspension or were given directly.
Cohort C: Open label olmesartan medoxomil suspension 0.3 mg/kg - 0.6 mg/kg"
1745759|NCT00151788|Drug|Pactimibe sulfate|
1745760|NCT00151801|Drug|estroprogestins|
1745761|NCT00151801|Drug|interferon-beta 1a|
1745762|NCT00151814|Drug|Olmesartan medoxomil|Children less than 6 years old: oral suspension or tablets equal to 0.3 mg/kg; 20 mg or 40 mg tablets for older children depending on weight.
1745763|NCT00151827|Drug|Olmesartan medoxomil|Olmesartan oral tablets 20 or 40 mg + losartan placebo. Medications are taken once daily before breakfast with water.
1745764|NCT00151827|Drug|Losartan|Medications are taken once daily before breakfast with water.
1745765|NCT00151827|Drug|Furosemide oral tablets|If its use is necessary, the dose of furosemide allowed is 20 to 120 mg per day at the discretion of the investigator
1745766|NCT00151840|Drug|IVIG-L|
1745767|NCT00151853|Drug|PPSB-SD|
1745768|NCT00151866|Procedure|platelet transfusion|
1745769|NCT00151879|Drug|SPM 927|
1745770|NCT00151892|Drug|SPD476|2.4 g/day Once Daily (QD)
1745771|NCT00151892|Drug|Asacol|1.6g/day administered 800 mg Twice Daily (BID)
1745772|NCT00151905|Drug|3 % hypertonic saline|
1745773|NCT00151918|Drug|Lanthanum carbonate|
1745774|NCT00151931|Drug|Lanthanum carbonate|
1745775|NCT00151944|Drug|SPD476 (mesalazine)|
1745776|NCT00151957|Drug|Methylphenidate Transdermal System|MTS Patch 27.5mg, 41.3mg, 55mg, and 82.5mg for 7 Weeks
1745777|NCT00151970|Drug|Methylphenidate Transdermal System|MTS 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes
1745778|NCT00151970|Drug|Placebo|Placebo patch 10mg/12.5cm2, 15mg/18.75cm2, 20mg/25cm2, and 30mg/37.5cm2 patch sizes applied daily
1745779|NCT00151970|Drug|Concerta|CONCERTA® is available in doses of 18mg, 27mg, 36mg, 54mg, and 72mg tablets daily
1745780|NCT00151983|Drug|Methylphenidate Transdermal System|To assess the efficacy of 4- and 6-hour wear times of SPD485 (MTS) compared to placebo
1745781|NCT00151996|Drug|Methylphenidate + SPD503 (Guanfacine hydrochloride)|
1745782|NCT00151996|Drug|Amphetamine + SPD503|
1745783|NCT00152009|Drug|SPD503 (Guanfacine hydrochloride) (2 mg)|
1745784|NCT00152009|Drug|SPD503 (3 mg)|
1745785|NCT00152009|Drug|SPD503 (4 mg)|
1745786|NCT00152009|Drug|Placebo|
1745787|NCT00152022|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulphate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
1745788|NCT00152035|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d, l-amphetamine aspartate monohydrate.|
1745789|NCT00152048|Drug|Eflornithine hydrochloride|
1745790|NCT00152061|Drug|3TC and FTC|
1745791|NCT00152074|Behavioral|Reduce salt intake|
1745792|NCT00152087|Device|Brachytherapy|
1745793|NCT00152100|Procedure|Stem cell transplant|
1745794|NCT00152100|Drug|Filgrastim, Alemtuzumab|
1745795|NCT00152100|Device|Miltenyi CliniMACS|
1745796|NCT00152113|Procedure|Hematopoietic Stem Cell Transplantation|Allogeneic stem cell transplant Haploidentical stem cell transplant Mismatched family member donor stem cell transplant T cell selection CD34 enrichment
1745797|NCT00152113|Device|CliniMACS|
1745853|NCT00133900|Procedure|Phlebotomy|Peripheral blood draws for evaluation of circulating tumor cells
1745854|NCT00133913|Procedure|Phlebotomy|Peripheral blood draws for testing of circulating tumor cells
1745856|NCT00133939|Procedure|Mechanical ventilation|
1745798|NCT00152113|Drug|See intervention description|Hydroxyurea and azathioprine were administered for a 3 month period prior to the initiation of the transplant procedure in an effort to help prevent rejection of the donor product. Approximately 10 days prior to the transplant procedure, all participants received the same preparative regimen consisting of Busulfan, cyclophosphamide, low-dose thiotepa, and OKT3. MMF was administered for GVHD prophylaxis. Two separate infusions of donor stem cells were administered with fixed doses of CD3 and CD34 cells. These haploidentical stem cells were processed using the investigational CliniMACS device.
1745799|NCT00152126|Procedure|Stem Cell Transplantation|Autologous stem cell transplantation
1745800|NCT00152126|Drug|Busulfan, Melphalan|Transplant recipients will receive high dose Busulfan and Melphalan followed by autologous CD133+ antigen specific hematopoietic stem cell infusion. The autologous graft product will be selected using the investigational CliniMACS device.
1745801|NCT00152139|Procedure|Allogeneic Stem Cell Transplantation|An infusion of HLA matched unrelated bone marrow or peripheral blood stem cells.
1745802|NCT00152139|Drug|Chemotherapy and antibodies|Participants received a standard conditioning regimen consisting of total body irradiation, cyclophosphamide, thiotepa and ATG. GVHD prophylaxis consisted of cyclosporine and Methotrexate.
1745803|NCT00152152|Procedure|Radiostereometric Analysis beads inserted during surgery|
1745804|NCT00152165|Procedure|Radiostereometric Analysis beads inserted during surgery|
1745805|NCT00152178|Drug|UFT (uracil, tegafur) and tamoxifen|UFT(uracil, tegafur:270 mg/m2/day (p.o.) for 2 years) and tamoxifen:20 mg/body/day(p.o.) for 2 years.
1745806|NCT00152178|Drug|CMF(cyclophosphamide, methotrexate, fluorouracil) and tamoxifen|CMF 6 cycles(q28 days X 6 cycles of cyclophosphamide:65mg/m2/day(p.o.)day 1-14, methotrexate:40mg/m2(i.v.)day 1,8 and fluorouracil:500mg/m2(i.v.)day 1,8) and tamoxifen:20mg /body/day(p.o.) for 2 years.
1745807|NCT00152191|Drug|UFT (uracil, tegafur)|uracil, tegafur was orally administered by 300 mg per square meter per day for 2 years
1745808|NCT00152191|Drug|cyclophosphamide, methotrexate, and fluorouracil|cyclophosphamide:100 mg, po, day 1-14 methotrexate:40 mg/m2, day 1, 8 q28 days x 6 cycles fluorouracil:500 mg/m2, day 1, 8
1745811|NCT00152217|Drug|TS-1 (S-1)|80 mg of oral S-1 per square meter of body-surface area per day was given for 4 weeks and no chemotherapy was given for the following 2 weeks
1745812|NCT00152217|Procedure|Surgery|Stage II or III gastric cancer who underwent gastrectomy were assigned to surgery only
1745813|NCT00152230|Drug|UFT (uracil, tegafur)|to receive oral uracil-tegafur 400 mg square meter for one year
1745814|NCT00152230|Procedure|Surgery alone|Standardized mesorectal excision with selective lateral pelvic lymphadenectomy of stage III rectal cancer.
1745815|NCT00152243|Drug|UFT (uracil, tegafur)|uracil-tegafur 360 mg per square meter per day orally 16 months
1745816|NCT00152243|Procedure|Surgery alone|Gastrectomy of tumour node metastasis(TNM) stage T2N1-2 gastric cancer.
1745817|NCT00152256|Drug|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for 6 months
1745818|NCT00152256|Drug|Asoprisnil|Asoprisnil 25mg Tablet, oral Daily for 6 months
1745819|NCT00152256|Drug|Placebo|Placebo Tablet, oral Daily for 6 months
1745820|NCT00152269|Drug|Asoprisnil|10mg Tablet, oral Daily for 12 months
1745821|NCT00152269|Drug|Asoprisnil|25mg Tablet, oral Daily for 12 months
1745822|NCT00152269|Drug|Placebo|Placebo, Tablet, oral Daily for 12 months
1745823|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 5mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
1745824|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 10mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
1745825|NCT00152282|Drug|Asoprisnil/Premarin|Asoprisnil 25mg and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
1745826|NCT00152282|Drug|Placebo and Premarin|Placebo and Premarin 0.625 mg Tablets, oral Daily for 12 weeks
1745827|NCT00152295|Drug|Asoprisnil/Premarin|10 mg (2-5mg tablets) asoprisnil and 0.625 mg Premarin tablets, oral daily for 6 months
1745828|NCT00152308|Device|2% rapamycin-eluting YUKONdes PEARL-stent|
1745829|NCT00152308|Device|1% rapamycin-eluting YUKONdes PEARL-stent|
1745830|NCT00152308|Device|YUKONdes PEARL-stent coated with placebo (ethanol)|
1745831|NCT00152321|Behavioral|Patients (education, counseling) and Physicians (reminders,1-page guidelines).|
1745832|NCT00152321|Behavioral|Multifaceted intervention|Educational materials, counseling, opinion leader based guidelines, reminders
1745833|NCT00152321|Other|Usual Care|
1745834|NCT00152334|Drug|Botox|All patients meeting the inclusion criteria will undergo manipulation and casting until hindfoot stall is encountered. Hindfoot stall is defined as forefoot abduction to 60 degrees but persistence of hindfoot equinus. At hindfoot stall, subjects received Botox injections at 10 IU/kg into the gastrosoleus muscle complex. Following injections, subjects were recasted.
1745835|NCT00152347|Drug|Botox|See Detailed Description
1745836|NCT00152360|Drug|Orlistat|See Detailed Description.
1745837|NCT00152373|Drug|Levetiracetam|
1745838|NCT00152386|Drug|Certolizumab pegol (CDP870)|
1745839|NCT00133757|Drug|Bupropion SR|
1745840|NCT00133770|Drug|pantoprazole|The continuous IV pantoprazole compared to the once a day IV pantoprazole for 72 hours in the treatment of severe erosive esophagitis
1745841|NCT00133783|Behavioral|intermedin|
1745842|NCT00133796|Drug|Herceptin|IV
1745843|NCT00133809|Drug|Transplantation of Human Islets|Human islets, at least 9,000 islet equivalents per kilogram of body weight. Transplant involves surgical procedure
1745844|NCT00133822|Drug|Sertraline and Risperidone|
1745845|NCT00133835|Procedure|Extracorporeal shock wave lithotripsy|
1745846|NCT00133835|Procedure|Endoscopic drainage of the main pancreatic duct|
1745847|NCT00133848|Drug|SB-275833 ointment, 1%|
1745848|NCT00133861|Drug|Botulinum toxin|
1745849|NCT00133874|Drug|SB-275833 ointment, 1%|
1745850|NCT00133887|Drug|rapamycin|3 to 5 mg/day
1745851|NCT00133887|Drug|ciclosporine|Blood residual level < or = to 125 ng/ml
1745857|NCT00133952|Drug|Ruboxistaurin|Administered orally
1745858|NCT00133952|Drug|Placebo|Administered orally
1745859|NCT00133965|Behavioral|Dignity Psychotherapy|At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires.will also receive three visits by a mental health professional over a period of five to seven days. You will be asked to fill out some brief questionnaires during this session which ask about feelings about your illness, symptoms, emotional reactions, and support you have available. The second meeting will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the Research Staff.The third meeting you will also be asked to fill out several questionnaires,including a specific questionnaire regarding your thoughts about the Dignity Psychotherapy Intervention. Total time commitment for this study should be approximately 120-150 minutes.
1745860|NCT00133965|Behavioral|Supportive Psychotherapy|you will receive the standard care you normally would receive, but will also receive three visits by a mental health professional over a period of five to seven days. The initial visit will take approximately 45 minutes. You will be asked to fill out brief questionnaires (described above) during this session.A second contact will be scheduled as soon as you are able to do so, within no more than 24 to 48 hours from your initial session with the research staff. During this second session, you will have the opportunity to discuss with a supportive research therapist issues or topics relevant to your experience of coping with cancer.The third and final contact,you will be asked you to fill out questionnaires similar to those you filled out at the beginning of the study. Total time commitment for this study should be approximately 120-150 minutes.
1745861|NCT00133965|Behavioral|Standard Palliative Care|"If you are in the Standard Palliative Care group you will receive the standard care that is usually provided here at Memorial Hospital. This can include services such as consultations by physicians, nurses and other healthcare professionals. In addition, referrals to community resources and services can also be made. The study period will be between five and seven days. At the beginning and at the end of the study, you will be asked to fill out a series of questionnaires as described above. Total time commitment for this study should be approximately 60-90 minutes."
1745862|NCT00133978|Other|Glutamine|0.35 gm/kg/day parenterally and 30 gms/day enterally
1745863|NCT00133978|Other|Antioxidants|500 micrograms of selenium/day parenterally and selenium 300 microgram, zinc 20 mg, beta carotene 10 mg, vitamine E 500 mg and vitamin C 1500 mg per day enterally
1745864|NCT00133978|Other|Glutamine + Antioxidants|0.35 g/kg/day glutamine parenterally and 30 g/day of glutamine enterally. 500 mcg selenium parenterally plus the following administered enterally: selenium 300 mcg, zing 20 mg, beta-carotene 10 mg, vitamin E 500 mg and vitamin C 1500mg
1745865|NCT00133978|Other|Placebo|Normal saline intravenously and EN placebo formula (from Fresenius Kabi, Germany)
1745866|NCT00133991|Biological|filgrastim|
1745867|NCT00133991|Biological|pegfilgrastim|
1745868|NCT00133991|Biological|rituximab|
1745869|NCT00133991|Drug|cyclophosphamide|
1745870|NCT00133991|Drug|cytarabine|
1745871|NCT00133991|Drug|leucovorin calcium|
1745872|NCT00133991|Drug|methotrexate|
1745873|NCT00133991|Drug|prednisone|
1745874|NCT00133991|Drug|therapeutic hydrocortisone|
1745875|NCT00133991|Drug|vincristine sulfate|
1745876|NCT00134004|Drug|cyclophosphamide|
1745877|NCT00134004|Drug|fludarabine phosphate|
1745878|NCT00134004|Drug|mycophenolate mofetil|
1745879|NCT00134004|Drug|tacrolimus|
1745880|NCT00134004|Procedure|allogeneic bone marrow transplantation|
1745881|NCT00134004|Radiation|radiation therapy|
1745882|NCT00134017|Drug|busulfan|
1745883|NCT00134017|Drug|cyclophosphamide|
1745884|NCT00134017|Drug|mycophenolate mofetil|
1745885|NCT00134017|Drug|tacrolimus|
1745886|NCT00134017|Procedure|allogeneic bone marrow transplantation|
1745887|NCT00134017|Procedure|bone marrow ablation with stem cell support|
1745888|NCT00134030|Drug|doxorubicin hydrochloride|Given IV
1745889|NCT00134030|Drug|cisplatin|Given IV
1745890|NCT00134030|Drug|methotrexate|Given IV
1745891|NCT00134030|Procedure|therapeutic conventional surgery|Undergo amputation or limb salvage surgery
1745892|NCT00134030|Biological|peginterferon alfa-2b|Given subcutaneously
1745893|NCT00134030|Drug|ifosfamide|Given IV
1745894|NCT00134030|Drug|etoposide|Given IV
1745895|NCT00134030|Procedure|quality-of-life assessment|Ancillary studies
1745896|NCT00134030|Other|questionnaire administration|Ancillary studies
1745897|NCT00134043|Drug|vorinostat|Given orally
1745898|NCT00134056|Drug|atrasentan hydrochloride|Given orally
1745899|NCT00134056|Drug|docetaxel|Docetaxel given IV and prednisone given orally
1745900|NCT00134056|Drug|prednisone|Docetaxel given IV and prednisone given orally
1745901|NCT00134056|Other|placebo|Given orally
1745902|NCT00134069|Drug|sorafenib tosylate|Given orally
1745903|NCT00134069|Drug|cetuximab|Given IV
1745904|NCT00134069|Drug|irinotecan hydrochloride|Given IV
1745905|NCT00134082|Biological|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
1745906|NCT00134082|Biological|filgrastim|
1745907|NCT00134082|Biological|rituximab|
1745908|NCT00134082|Drug|cyclophosphamide|
1745909|NCT00134095|Drug|irinotecan hydrochloride|
1745910|NCT00134095|Drug|tegafur-gimeracil-oteracil potassium|
1745911|NCT00134095|Procedure|adjuvant therapy|
1745912|NCT00134095|Procedure|conventional surgery|
1745913|NCT00134095|Procedure|neoadjuvant therapy|
1745914|NCT00139451|Drug|Pediasure|With the assistance of a research dietician, we will prescribe and monitor the use of a liquid food supplement (Pediasure). Adjustments to the supplementation will be made based on weight measurements in the clinic with subjects wearing paper gowns at 2 and 4w, and monthly thereafter, and repeat dietary intake and TEE assessment at 6 and 12mo.
1745915|NCT00139451|Drug|GH|Growth Hormone will be 0.3mg/kg/week, given SC once daily.
1745916|NCT00139477|Drug|Metformin|Metformin, 250mg by mouth twice a day with meals will be started and if tolerated increased to 500mg twice a day in 3 days in those less than 12 years old and titrated further to 1000mg twice a day if tolerated.
1746094|NCT00146549|Drug|Docetaxel|
1745917|NCT00139477|Behavioral|Dietary modification with caloric restriction|The life style intervention changes will include a hypocaloric diet representing at least a 500 kcal/day reduction based on their dietary histories and Resting Energy Expenditure (REE) determined by the initial calorimetry.
1745918|NCT00139477|Behavioral|Establishment of exercise protocol|Participants will attend the Fitness Center 3 times per week and supervised by an exercise technician or exercise specialist. Exercise will be individually prescribed for each participant based on their functional abilities. Exercise will consist of 5-10 minutes for warm up and stretching, followed by 15-30 minutes of cardiovascular exercise (i.e. treadmill, bicycle ergometer, rower, nustep, etc), 10-20 minutes of strength training (supervised using weight stack equipment), and 5-10 minutes of cool down and stretching. As children typically do not need an exercise prescription based on heart rate, we will familiarize them with perceived exertion scales and monitor that they are exercising in the moderate to hard range of perception of effort. Participants will be started at 15 minutes of cardiovascular exercise and 10 minutes of strength training exercise, progressing by 2-3 minutes every week until 30 and 20 minutes is achieved for each respectively.
1745919|NCT00139490|Behavioral|Health Education Program|The augmented intervention will consist of just-in-time nurse, patient and physician information and feedback during the post-acute period, plus transition to an ongoing Home-Based HTN Support Program within approximately 30 days after the patient's admission to home health care. The augmented intervention adds an HTN Nurse Specialist (advanced practice nurse) and a lay community health worker, who will be responsible for assuring a patient's smooth transition to the Home-Based HTN Support Program and for delivering the main components of that intervention, backed up by the project physician.
1745920|NCT00139490|Behavioral|Basic Group|"The basic information and referral intervention will deliver key just-in-time information to nurses, patients and patients' physicians while the patient is receiving post-acute home care services. The basic intervention relies on care provided by home health nurses during the routine home health stay."
1745921|NCT00139490|Behavioral|Control Group|Usual Care
1745922|NCT00139516|Behavioral|self-help|
1745923|NCT00139516|Drug|nicotine replacement therapy|
1745924|NCT00139516|Behavioral|smoking cessation|
1745925|NCT00139529|Behavioral|Motivational Interviewing Telephone Counseling|Participants will receive up to 5 phone calls.
1745926|NCT00139529|Behavioral|Educational Intervention|Educational intervention will be completed during pregnancy.
1745927|NCT00139542|Other|One shock per minute AED protocol|Single shocks; No post-shock pulse checks; 60 sec CPR before first shock; 30 sec CPR between rhythm analysis and shock delivery.
1745928|NCT00139542|Other|Guidelines 2000 AED protocol|Up to 3 consecutive shocks in a stack; No initial CPR prior to the first shock; Post-shock pulse checks after each non-shockable rhythm analysis; 60 sec CPR after each non-shockable rhythm analysis.
1745929|NCT00139555|Drug|amlodipine/benazepril|
1745930|NCT00139568|Drug|Tegaserod|
1745931|NCT00139581|Drug|Pimecrolimus|Pimecrolimus cream 1 % applied twice daily (b.i.d.)
1745932|NCT00139581|Drug|Pimecrolimus|Pimecrolimus cream 1 % applied once daily (o.d.) and placebo applied once daily (o.d.)
1745933|NCT00139594|Drug|licarbazepine|
1745934|NCT00139607|Drug|Paracoxib|
1745935|NCT00139620|Drug|Tarceva, erlotinib, OSI-774|
1745936|NCT00139633|Drug|carboplatin, 5FU, Taxol and radiation|
1745937|NCT00139646|Drug|Parecoxib|
1745938|NCT00139646|Drug|Diclofenac|
1745939|NCT00139659|Drug|Inhaled Insulin|Inhaled insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or NPH insulin, or a single bedtime dose of insulin glargine.
1745940|NCT00139659|Drug|Subcutaneous Insulin|Subcutaneous short-acting insulin with dose adjusted according to premeal blood glucose plus oral antidiabetic agent(s) and/or either once or twice daily doses of either Ultralente or neutral protamine hagedorn (NPH) insulin, or a single bedtime dose of insulin glargine.
1745941|NCT00139672|Drug|PD-217,014|
1745942|NCT00139685|Drug|Depo-Provera Contraceptive Injection - DP150CI|
1745943|NCT00139698|Drug|olmesartan alone or in combination with hydrochlorothiazide|
1745944|NCT00139711|Drug|Irinotecan|
1745945|NCT00139711|Drug|Docetaxel|
1745946|NCT00139724|Drug|tolterodine extended release capsule|
1745947|NCT00139737|Drug|Ziprasidone|20mg capsules BID, 40mg capsules BID, 60mg BID or 80mg BID until drug commercialisation in Italy.
1745948|NCT00139750|Drug|CP-526,555 (varenicline)|
1745949|NCT00139763|Procedure|Educational Materials|
1745950|NCT00139776|Drug|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind celecoxib 200 mg daily.
Placebo used as flare medication when directed."
1745951|NCT00139776|Drug|Celecoxib|"24 weeks of study treatment: 2 weeks open-label celecoxib 200 mg daily followed by 22 weeks of randomized double blind placebo daily.
Usual or intermittent use of celecoxib 200 mg daily as flare medication when directed."
1745952|NCT00139789|Drug|Kemstro|
1745953|NCT00139802|Device|Coronary Stent Implantation|
1745954|NCT00139815|Drug|Fondaparinux|fondaparinux 2.5 mg, s.c. injection once daily x 8 days or Hospital Discharge if earlier and placebo-enoxaparin 1mg/kg s.c. injection twice daily x 2-8 days or until clinically stable
1745955|NCT00139815|Drug|enoxaparin|enoxaparin 1mg/kg s.c. injection twice daily x 2 to 8 days
1745956|NCT00139828|Drug|human coagulation Factor IX|
1745957|NCT00139841|Drug|Bendamustine HCl|Dose of 120 mg/m2 on Day 1 and Day 2 of each treatment cycle (every 21 days). Patients who are continuing to experience clinical benefit at Cycle 6, as assessed by the investigator, may receive up to 2 additional cycles, to a maximum of 8 cycles.
1745958|NCT00139854|Drug|Alprazolam orally disintegrating tablets|
1745959|NCT00139867|Drug|PARCOPA|
1745960|NCT00139880|Drug|Parcopa|
1745961|NCT00139893|Drug|Reglan ODT|
1745962|NCT00139906|Drug|Bifeprunox|
1745963|NCT00139919|Drug|Bifeprunox|
1745964|NCT00139932|Drug|formoterol fumarate|
1745965|NCT00139945|Drug|Human acylated ghrelin|5 pmol/kg body weight per min
1745966|NCT00139971|Drug|gemicitabine 1000mg/m2, day1 and day 8, every 3 week, 6|
1745967|NCT00139971|Drug|UFT 250mg/m2, daily for 1 year|
1745968|NCT00139984|Device|24 hour blood pressure measurement|
1745969|NCT00139997|Device|Litebook treatment devices|Litebook LED phototherapy device used for 30 min before 8 am
1745970|NCT00139997|Device|Inactivated negative ion generator|Equivalent exposure to inactivated negative ion generator
1745971|NCT00140010|Drug|erythropoietin beta|30,000 units in 6 mL of 0.9% saline IV for 15 minutes every other day for 3 doses within 72 hours after aneurysmal subarachnoid hemorrhage
1745972|NCT00140023|Drug|Azithromycin microspheres 2.0 single dose|
1745973|NCT00140036|Procedure|Blood draw|
1745974|NCT00140049|Drug|Xalacom|
1745975|NCT00140049|Drug|Cosopt|
1745976|NCT00140062|Drug|latanoprost 0.005% (Xalatan)|
1745977|NCT00140075|Drug|Epirubicin with Cyclophosphamide, followed by a Taxane|"Epirubicin = 90 mg/m2 Cyclophosphamide = 600 mg/m2
Followed by a taxane; paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
1745978|NCT00140075|Drug|Epirubicin with a Taxane|"Epirubicin = 75 mg/m2 per cycle
Taxane = paclitaxel = 175 mg/m2 or docetaxel = 75 mg/m2"
1745979|NCT00140088|Drug|ALGRX 3268|
1745980|NCT00140101|Device|ZoMaxx™ Drug-Eluting Coronary Stent System|Drug eluting stent implantation stent in the treatment of coronary artery disease.
1745981|NCT00140101|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
1745982|NCT00140114|Drug|Misoprostol (Cytotec®)|50 micrograms of sublingual or vaginal misoprostol every 4 hours for a maximum of 5 doses
1745983|NCT00140140|Drug|ABI-007|Weekly intravenous infusions over 30 minutes.
1745984|NCT00140140|Drug|vinorelbine|Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
1745985|NCT00140140|Drug|Trastuzumab|"Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.
Trastuzumab is commercially available and was not supplied by the Sponsor."
1745986|NCT00140140|Biological|G-CSF|"During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.
In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was >20,000/mm^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.
G-CSF is commercially available and was not supplied by the Sponsor."
1745987|NCT00140153|Drug|testosterone gel (Androgel)|
1745988|NCT00140166|Drug|niacinamide|
1745989|NCT00140166|Drug|pyridoxine|
1745990|NCT00140166|Drug|ascorbate|
1745991|NCT00140179|Drug|valnoctamide|
1745992|NCT00140192|Drug|creatine|
1745994|NCT00140218|Drug|R(+) pramipexole dihydrochloride monohydrate|10 mg tid oral
1745995|NCT00140231|Drug|r-metHuLeptin|recombinant human leptin
1745996|NCT00140231|Other|placebo|placebo (no active drug)
1745997|NCT00140244|Drug|r-metHuLeptin|
1745998|NCT00140244|Drug|Placebo|
1745999|NCT00140257|Drug|Escitalopram|
1746000|NCT00140270|Behavioral|PEP program|
1746001|NCT00140283|Procedure|Educational interactive intervention|
1746002|NCT00140296|Behavioral|Contraceptive counseling|
1746003|NCT00140309|Drug|moxifloxacin (with isoniazid, rifampin, pyrazinamide)|
1746004|NCT00140322|Behavioral|Exercise, fall risk reduction|
1746005|NCT00140335|Behavioral|handwashing|
1746006|NCT00140348|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
1746007|NCT00140361|Drug|Sulfadoxine-pyrimethamine|
1746008|NCT00140361|Drug|sulfadoxine-pyrimethamine plus artesunate|
1746009|NCT00140361|Drug|lumefantrine plus artemether|
1746010|NCT00140361|Behavioral|Sleeping under insecticide-treated bednet|
1746011|NCT00140374|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
1746012|NCT00140387|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
1746013|NCT00140400|Biological|Immunotherapy allogeneic GM-CSF secreting cellular vaccine|
1746014|NCT00140413|Drug|Nutropin AQ|Daily injection. Dosage dependent on weight.
1746015|NCT00140426|Drug|Risperidone|risperidone titrated 0.5 to 4 mg over study enrollment. Mean Length of Phase 1 is currently 10 weeks.
1746016|NCT00140426|Drug|Placebo|Comparison of risperidone versus placebo for the treatment of symptoms related to anorexia nervosa.
1746017|NCT00140439|Behavioral|Emergency Department based asthma follow-up clinic|"The clinical activities of the intervention followed a fully specified protocol and provided education and care in three domains:
Asthma self-monitoring and management: Educators first reviewed the basic physiology of asthma with emphasis on its chronicity. After evaluating asthma severity and treatment history, the physician completed an individualized medical action plan (MAP) and provided any necessary device teaching.
Environmental modification and trigger control: After evaluation of potential environmental triggers in the home, each family was educated on their control. Each child was provided hypoallergenic bed encasings.
Linkages and referrals to ongoing primary care: Clinic staff stressed the importance of longitudinal asthma care by a PCP. A full report of the clinic visit was mailed to each child's PCP. In addition, the asthma educator scheduled a follow-up appointment with the PCP within 4 weeks"
1746018|NCT00140452|Drug|Thalidomide|Thalidomide will start at a dose of 100mg/day, dose escalated every 2 weeks by 100mg/day to a target dose of 400mg/day.
1746019|NCT00145808|Device|Given® Diagnostic System|
1746020|NCT00145834|Behavioral|community based trial|
1746021|NCT00145847|Drug|Naltrexone or Placebo|Naltrexone or Placebo 50 mg per day
1746022|NCT00145873|Drug|nesiritide, continuous infusion|
1746023|NCT00145886|Drug|rhPTH|Subjects will be treated with rhPTH for 12 months.
1746024|NCT00145912|Behavioral|MI + CATCH-IT Internet Site|MI + CATCH-IT Internet Site
1746172|NCT00153361|Behavioral|Video Discussion Group|
1746025|NCT00145912|Behavioral|BA (brief advice) + CATCH-IT Internet site|BA (brief advice) + CATCH-IT Internet site
1746026|NCT00145925|Drug|Perindopril-indapamide|
1746027|NCT00145925|Drug|Gliclazide MR-based glucose lowering|
1746028|NCT00145938|Drug|sildenafil|
1746029|NCT00145951|Behavioral|motivational interviewing, brief advice in primary care|motivational interviewing, brief advice in primary care
1746032|NCT00145990|Drug|methacholine|
1746033|NCT00145990|Device|KoKo Digidoser|
1746034|NCT00145990|Device|Rosethal Dosimeter|
1746035|NCT00146003|Drug|Efalizumab treatment|
1746036|NCT00146016|Drug|Amantadine|
1746037|NCT00146042|Drug|Docetaxel|
1746038|NCT00146042|Drug|Trastuzumab|
1746039|NCT00146042|Procedure|Erythromycin Breath Test (ERMBT)|
1746040|NCT00146055|Procedure|Reduced intensity conditioning with allogeneic transplant|
1746041|NCT00146068|Drug|Avonex/Zocor|
1746042|NCT00146081|Behavioral|Weight Management|Participants (Index Participants) who identify 1 or 2 family members or friends (Co-Participants) to enroll with them are randomly assigned into either program A or B, and those who choose to enroll by themselves are randomly assigned to either program C or D. All Index Participants are invited to attend weekly group behavior change educational sessions; weekly in first 6 months, biweekly in next 6 months, and monthly in year 2. Co-Participants in program A are invited to attend all sessions with their Index Participant, but only the field workshops and personal counseling sessions if enrolled in program B.
1746043|NCT00146094|Procedure|BMD Measurement|
1746044|NCT00146107|Behavioral|Diet|10 percent weight loss through diet and behavioral modification
1746045|NCT00146107|Other|Exercise|Multicomponent (resistance, aerobic, balance) exercise three times a week
1746046|NCT00146107|Other|Weight Loss and Exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
1746047|NCT00146120|Drug|Idarubicin|
1746048|NCT00146120|Drug|Cytosin-Arabinosid|
1746049|NCT00146120|Drug|Etoposide|
1746050|NCT00146120|Drug|All-trans Retinoid acid|
1746051|NCT00146133|Behavioral|diet, exercise|
1746052|NCT00146146|Drug|testosterone undecanoate alone|1000 mg/12 weeks
1746053|NCT00146146|Drug|testosterone undecanoate plus letrozole|TU 1000 mg/12 weeks Letrozole 2.5 mg/day
1746054|NCT00146146|Drug|testosterone undecanoate plus dutasteride|TU 1000 mg/12weeks Dutasteride 0.5 mg/day
1746055|NCT00146159|Drug|Mitoxantrone|dosage
1746057|NCT00146185|Drug|ALGRX 3268|
1746058|NCT00146198|Drug|ALGRX 4975|
1746059|NCT00146211|Drug|Ethyl-EPA (Miraxion™)|
1746060|NCT00146224|Drug|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
1746061|NCT00146224|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 10.0 - 13.0 g/dL and within -1.0 to +1.5 g/dL of the subject's baseline Hb.
1746062|NCT00146237|Drug|phenytoin|
1746063|NCT00146250|Drug|Nitrous oxide|
1746064|NCT00146263|Behavioral|computerized cognitive training|
1746065|NCT00146276|Drug|gemcitabine|
1746066|NCT00146289|Drug|MICARDIS® (telmisartan)|
1746067|NCT00146302|Biological|Bacille Calmette Guerin (BCG)|
1746068|NCT00146315|Behavioral|Supervised exercise on a stationary bicycle, 3-5 days a week|Supervised exercise on a stationary bicycle, 3-5 days a week, plus a secondary prevention program for coronary heart disease
1746069|NCT00146315|Behavioral|Secondary prevention program for coronary heart disease|Secondary prevention program for coronary heart disease
1746070|NCT00146328|Drug|Tipranavir|
1746071|NCT00146341|Drug|Telmisartan/HCTZ|
1746072|NCT00146341|Drug|Telmisartan|
1746073|NCT00146354|Behavioral|Hospitalists Results Manager|
1746074|NCT00146367|Behavioral|Active Living Every Day|
1746075|NCT00146380|Drug|Zidovudine/Lamivudine and either Nevirapine or Nelfinavir|"Zidovudine 300mg po bid from 34 weeks gestation to 6 months postpartum Lamivudine 150mg po bid from 34 weeks gestation to 6 months postpartum AND EITHER Nevirapine 200mg po qd for 2 weeks as lead in then bid from 34 weeks gestation to 6 months postpartum OR Nelfinavir 1250mg po bid from 34 weeks gestation to 6 months postpartum
ARVs continued for those that meet WHO treatment criteria"
1746076|NCT00146380|Behavioral|Breastfeeding for 6 months postpartum|Exclusive breastfeeding till five and one half months with rapid weaning over 2 weeks and cessation of breastfeeding at 6 months when ARVs are discontinued
1746077|NCT00146393|Behavioral|People with Arthritis Can Exercise program|
1746078|NCT00146406|Behavioral|Project Connect|
1746079|NCT00146419|Behavioral|Reduction in behaviors capable of sexually transmitting HIV|Clinic-level risk reduction counseling
1746080|NCT00146432|Procedure|Immunoadsorption of LPS, IL-6 and C5a|
1746081|NCT00146445|Behavioral|Peer Mentoring Intervention|
1746082|NCT00146458|Procedure|18F-fluorodeoxyglucose positron emission tomography|
1746083|NCT00146471|Drug|Levetiracetam|1500-2000 mg daily add-on or Placebo Diazepam as needed
1746084|NCT00146471|Drug|Placebo|1500-2000 mg daily add-on or Placebo Diazepam as needed
1746085|NCT00146484|Drug|Twice Daily versus Three Times Daily Insulin Injections|
1746086|NCT00146497|Drug|Budesonide-Surfactant|
1746087|NCT00146510|Behavioral|HealtheLifestyle Program|
1746088|NCT00146510|Behavioral|step counters with monthly feedback on logs|
1746089|NCT00146523|Drug|Mifepristone|
1746090|NCT00146523|Drug|placebo|
1746091|NCT00146549|Drug|Trastuzumab|
1746092|NCT00146549|Drug|Vinorelbine|
1746093|NCT00146549|Drug|Paclitaxel|
1746095|NCT00146562|Drug|Darbepoetin Alfa|Given day before chemotherapy of red blood cell count is below normal
1746096|NCT00146562|Drug|Pegfilgrastim|Given as an injection the day before chemotherapy for a total of 8 injections
1746097|NCT00146562|Drug|Paclitaxel|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
1746098|NCT00146562|Drug|Doxorubicin|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
1746099|NCT00146562|Drug|Cyclophosphamide|As part of standard adjuvant chemotherapy: Given every two weeks for 8 cycles
1746100|NCT00146575|Device|Sirolimus-eluting stent (Cypher)|patients have been implanted a Cypher stent
1746101|NCT00146575|Device|Paclitaxel-eluting stent (Taxus)|patients have been implanted a Taxus stent
1746102|NCT00146588|Drug|Cyclophosphamide|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
1746103|NCT00146588|Drug|Epirubicin|Intravenously on day 1 of each 21-day treatment cycle for 12-18 weeks depending upon response.
1746104|NCT00146588|Drug|Capecitabine|Given orally on days 4-17 of each 21-day treatment cycle for 12-18 weeks depending upon response.
1746105|NCT00146601|Drug|Fulvestrant|
1746106|NCT00146614|Drug|Sirolimus|
1746107|NCT00146614|Drug|Tacrolimus|
1746108|NCT00146614|Drug|Methotrexate|
1746109|NCT00146614|Procedure|Stem Cell Transplantation|
1746110|NCT00146627|Drug|Eflornithine|
1746111|NCT00146627|Drug|Nifurtimox|
1746113|NCT00146666|Device|Intermittent compression|
1746114|NCT00146679|Behavioral|Psychoeducational Telephone counseling (TC)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided through telephone sessions
1746115|NCT00146679|Behavioral|Psychoeducational Intervention by Group (SG)|Educational and Counseling, symptom management training and cognitive behavioral intervention to teach coping skills provided in 4 group sessions
1746116|NCT00146679|Behavioral|Usual Care|Usual Care provided by providers
1746117|NCT00146692|Behavioral|Free medical treatment|
1746118|NCT00146705|Procedure|blood samples are taken once|
1746119|NCT00146718|Drug|Amodiaquine and Sulphadoxine/Pyrimethamine|
1746120|NCT00152399|Drug|Somatostatin UCB (drug)|
1746121|NCT00152412|Drug|Levocetirizine oral solution|
1746122|NCT00152425|Drug|Certolizumab Pegol (CDP870)|
1746123|NCT00152438|Drug|Oral Micronized Progesterone (Prometrium®)|300 mg per day in 3 - 100 mg pills, to be taken in the evening immediately before sleep.
1746124|NCT00152438|Other|Placebo|3 identical placebo pills daily, no active ingredient.
1746125|NCT00152451|Drug|Seletracetam (ucb 44212)|
1746127|NCT00152477|Drug|Carboplatin|"10mg/mL vial AUC6. Dosed intravenously over 15-30 minutes immediately following paclitaxel, Day 0 of each cycle.
Each cycle to be repeated every three weeks for a maximum of six cycles."
1746128|NCT00152477|Drug|Paclitaxel|6mg/mL vial 200 mg/m2 iv over three hours, Day 0. Each cycle to be repeated every 3 weeks for a maximum of 6 cycles.
1746129|NCT00152477|Drug|CDP791 10mg/kg|CDP791 20mg/mL vial CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
1746130|NCT00152477|Drug|CDP791 20mg/kg|CDP791 20mg/kg CDP791 diluted (10mg/kg or 20mg/kg) in 0.9% saline will be given as a 200mL iv infusion over approximately 60 minutes following administration of standard chemotherapy.
1746131|NCT00152490|Drug|Certolizumab Pegol (CDP870)|
1746132|NCT00152503|Drug|Seletracetam (ucb 44212)|
1746133|NCT00152516|Drug|levetiracetam (LEV)|Per protocol oral tablets or oral solution at 10 to 30mg/kg/day bid for 48 weeks, or approximately 52 weeks should a subject choose to discontinue levetiracetam (LEV) at the end of the maintenance period.
1746134|NCT00152529|Behavioral|Screening (Behavior)|
1746135|NCT00152542|Drug|Inhaled nitric oxide|1 day of iNO at 10 ppm, then 5 ppm of iNO for days 2-7
1746136|NCT00152542|Drug|Placebo|No iNO given for days 1-7
1746137|NCT00152555|Behavioral|Physical Therapy or Relaxation Therapy|
1746138|NCT00152568|Behavioral|Car Seat Check (behavior)|At time of well child visit, family receives the services of a certified child passenger safety technician, including assessment, car seat distribution if needed and training.
1746139|NCT00152581|Drug|Pegylated interferon-alfa2a (Pegasys); ribavirin|
1746140|NCT00152594|Drug|voriconazole|
1746141|NCT00152607|Procedure|donor right hepatic lobectomy|
1746142|NCT00152620|Drug|Dexamethasone|
1746143|NCT00152620|Drug|Methylprednisolone|
1746144|NCT00152633|Drug|Losartan|
1746145|NCT00152633|Drug|Metoprolol|
1746146|NCT00152633|Drug|Losartan|Treatment with Losartan
1746147|NCT00152646|Drug|placebo, aspirine, clopidogrel|
1746148|NCT00152659|Procedure|Tissue sample (procedure/screening)|Tissue sampling
1746149|NCT00152672|Device|nCPAP vs oral appliance|
1746150|NCT00152685|Drug|human serum albumin|
1746151|NCT00152698|Drug|Irbesartan|
1746152|NCT00152711|Device|nCPAP|
1746165|NCT00153283|Drug|Gabapentin|
1746166|NCT00153296|Drug|Carbamazepine|
1746167|NCT00153309|Behavioral|People with Arthritis Can Exercise|
1746168|NCT00153322|Behavioral|Nurtition and Physical Activity Education|
1746169|NCT00153335|Behavioral|patient-provider interaction|
1746170|NCT00153348|Behavioral|Women's health|
1746171|NCT00153361|Behavioral|Discussion Group|
1746173|NCT00153374|Behavioral|Women's health|
1746174|NCT00153387|Behavioral|Women's health|
1746177|NCT00153426|Behavioral|West Virginia WISEWOMAN|Print-based tailored health communications and computer-based interactive nutrition program
1746178|NCT00153439|Behavioral|Motivational enhancements, parent training|
1746179|NCT00153452|Behavioral|perpetration of intimate partner violence|
1746180|NCT00153465|Behavioral|Motivational intervention, parent training|
1746181|NCT00153478|Behavioral|Brief Motivational Counseling|
1746182|NCT00153491|Drug|artemether-lumefantrine|
1746183|NCT00153504|Behavioral|Housing and Health Study housing rental assistance|
1746184|NCT00153504|Behavioral|Standard local practice housing assistance|
1746185|NCT00153517|Drug|oral versus vaginal metronidazole|
1746186|NCT00153530|Drug|methotrexate|"chemotherapy with radiotherapy
chemotherapy without radiotherapy"
1746187|NCT00153530|Radiation|radiotherapy|whole-brain irradiation
1746188|NCT00153543|Biological|Pneumococcal polysaccharide vaccine|
1746189|NCT00153543|Biological|Pneumococcal conjugate vaccine|
1746190|NCT00153556|Biological|Hib conjugate vaccine (HbOC, Wyeth Vaccines)|
1746191|NCT00153569|Biological|Tyrosinase, MAGE-3, GnTV|
1746192|NCT00153582|Biological|WT1 126-134 peptide|
1746193|NCT00153595|Drug|EWO1|
1746194|NCT00153608|Biological|WT1 126-134 peptide|
1746195|NCT00153634|Drug|IV amikacin|5-7.5 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
1746196|NCT00153634|Drug|PO azithromycin|250 mg once daily
1746197|NCT00153634|Drug|IV ceftazidime|50 mg/kg every 8 hours, up to 2 grams every 8 hours
1746198|NCT00153634|Drug|PO ciprofloxacin|500 mg every 12 hours if weight <50 kg 750 mg every 12 hours if weight ≥50 kg
1746199|NCT00153634|Drug|IV meropenem|40 mg/kg every 8 hours, up to 2 grams every 8 hours
1746200|NCT00153634|Drug|IV piperacillin-tazobactam|100 mg/kg of piperacillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
1746201|NCT00153634|Drug|IV ticarcillin-clavulanate|100 mg/kg of ticarcillin component every 6 hours, up to 3 grams every 6 hours; antibiotic combination formulated in a fixed ratio, thus dosing is described for first component only
1746202|NCT00153634|Drug|IV tobramycin|2.5-3.3 mg/kg every 8 hrs or previous dose; start at previous recent stable dose then monitor serum levels and adjust dose, if needed, per standard clinical practice at the site
1746203|NCT00153647|Procedure|Cap-assisted colonoscopy|Cap-assisted colonoscopy
1746204|NCT00153647|Procedure|Cap-assisted colonoscopy|Cap-assisted colonoscopy
1746205|NCT00153660|Drug|Celecoxib(drug)|Celecoxib 100 mg bd
1746206|NCT00153660|Drug|Naproxen(drug)|Naproxen 500 mg bd
1746207|NCT00153673|Drug|celecoxib|Celecoxib 200mg bd
1746208|NCT00153673|Drug|Dologesics|Dologesics 2 tablets bd
1746209|NCT00153686|Procedure|capsule endoscopy|capsule endoscopy of small intestine
1746210|NCT00153686|Procedure|Mesenteric Angiogram|Mesenteric Angiogram
1746211|NCT00153699|Drug|Topiramate|
1746212|NCT00153725|Drug|Aspirin and Pantoloc|
1746213|NCT00153738|Drug|phytosterol|
1746214|NCT00153751|Drug|Traditional Chinese Medicine|They are Common peony root, Rhizoma Atractylodis Macrocephalae, Radix Paeoniae Lactiflorae, Cortex Magnoliae Officinalis, Rhizoma Curcumae Longae, Fructus Schisandrae Chinensis, Pericarpium Citri Reticulatae, and Rhizoma Corydalis Yanhusuo.
1746215|NCT00153751|Drug|Holopon|holopon
1746216|NCT00153751|Other|placebo|placebo
1746217|NCT00153764|Drug|Cooper Complete One-A-Day Vitamin Supplement|
1746218|NCT00153777|Drug|Cellulose Sulfate gel (6%)|
1746219|NCT00153790|Drug|PhosphoLean|
1746220|NCT00153803|Drug|Erlotinib (tarceva)|Erlotinib 150mg orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events, death or completion of 5 years of therapy.
1746221|NCT00153803|Drug|Placebo|Matched placebo orally each day. Patients will be treated on a continuous, once daily oral dosing schedule until disease progression, withdrawal of consent, unacceptable adverse events death or completion of 5 years of therapy.
1746225|NCT00153829|Behavioral|Multifaceted outreach facilitation for chronic illness care|
1746227|NCT00153868|Drug|darbepoetin alfa|The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience <1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations >13.0 g/dL.
1746228|NCT00153881|Drug|Capecitabine (Xeloda)|"Neoadjuvant Chemotherapy:
Docetaxel every 3 weeks for 2 cycles Carboplatin every 3 weeks for 2 cycles with prophylactic antibiotics and antiemetics as needed.
Concomitant chemotherapy and radiation:
Docetaxel weekly for 5 doses without premedication Capecitabine orally, one dose prior to each fraction of irradiation (28 cycles)."
1746229|NCT00153894|Behavioral|Strength training|One-on-One training with a personal trainer for 50 minutes twice a week using Nautilus machines for 16 weeks.
1746230|NCT00153894|Behavioral|Endurance training|Cardiovascular training at home for 30 minutes three times per week for 16 weeks.
1746231|NCT00153907|Drug|Navelbine|Given orally on day 1 and 8 of each cycle, dose will vary. If participant is at highest dose they will take navelbine on day 1, 8 and 15 until disease progression or unacceptable side effects occur.
1746292|NCT00154349|Drug|Imatinib Mesylate|
1746232|NCT00153907|Drug|Capecitabine|Taken twice a day on days 1-14 until disease progression or unacceptable side effects occur.
1746233|NCT00153920|Drug|bortezomib|
1746234|NCT00153933|Drug|Bortezomib|Given intravenously on days 1, 2, 8, 11 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
1746235|NCT00153933|Drug|CC-5013|Orally on days 1-14 of each 21-day cycle. Participants can remain on study treatment as long as their disease doesn't worsen and they don't experience any serious side effects.
1746236|NCT00153946|Drug|Edaravone|30mg/20mL vial, twice per day, not longer than two weeks
1746237|NCT00153959|Behavioral|acute psychiatric day care|
1746238|NCT00153972|Drug|Cabergoline|
1746239|NCT00153972|Drug|Levodopa|
1746240|NCT00153985|Drug|Busulfex|Given once daily for 4 days
1746241|NCT00153985|Drug|Fludarabine|Given intravenously once daily for 4 days
1746242|NCT00153985|Drug|Alemtuzumab|One day before fludarabine and busulfex are started, alemtuzumab will be given once daily for 5 days.
1746243|NCT00153985|Procedure|Stem Cell Transfusion|Performed three days after the end of chemotherapy
1746244|NCT00153998|Drug|Cetuximab|
1746245|NCT00153998|Procedure|Liver resection|
1746246|NCT00153998|Drug|Cetuximab and FOLFIRI|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:
Cetuximab 250 mg/m² (1.0 h i.v.) weekly
Irinotecan 180 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
1746247|NCT00153998|Drug|Cetuximab and FOLFOX|"Cetuximab 400 mg/m² (2.0 h i.v.) (first dose only), followed by:
Cetuximab 250 mg/m² (1.0 h i.v.) weekly
Oxaliplatin 100 mg/m² (2.0 h i.v.) all compounds day 1, repeated at day 15 Folinic acid (D,L) 400 mg/m² (2.0 h i.v.) 5-FU 400 mg/m² (bolus i.v.) 5-FU 2400 (-3000) mg/m² (46 h i.v.)"
1746248|NCT00154011|Drug|rosiglitazone (drug)|
1746249|NCT00154024|Drug|atorvastatin|
1746250|NCT00154024|Drug|irbesartan|
1746251|NCT00154037|Drug|Pioglitazone (drug) and/or candesartan (drug)|
1746252|NCT00154050|Drug|candesartan (drug) or quinapril (drug)|
1746253|NCT00154063|Drug|E2007|
1746254|NCT00154063|Other|Placebo|
1746257|NCT00154089|Drug|EM-1421|EM-1421 administered intravaginally every 3 weeks as 45 mg (1% w/w) EM-1421 or 90 mg (2% w/w) EM-1421
1746258|NCT00154102|Drug|Cetuximab|Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Number of Cycles: until progression or unacceptable toxicity develops
1746259|NCT00154102|Drug|FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)|Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops
1746260|NCT00154115|Drug|levosimendan|Intravenous infusion, blus 24 mcg/kg in 30-minutes followed by 0.2 mcg/kg/min up to 24 hours
1746261|NCT00154115|Drug|placebo|Placebo
1746262|NCT00154128|Device|occlusal appliance|
1746263|NCT00154141|Drug|Fibrin sealant (FS2)|
1746264|NCT00154154|Behavioral|General Psychiatric Management|General Psychiatric Management (GPM) condition consisting of a structured algorithmic medication intervention plus psychosocial counseling.
1746265|NCT00154154|Behavioral|Dialectical Behaviour Therapy|Modification of behaviours achieved with reframing thoughts and impulses
1746266|NCT00154167|Drug|NV-101 (phentolamine mesylate solution)|
1746267|NCT00154180|Drug|Conjugated equine estrogens 0.45 mg/day|Pill, 1 pill taken daily each month for the study duration
1746268|NCT00154180|Drug|Transdermal estradiol, 50 mcg/day|Patch; 1 patch is applied to the skin weekly. Patch site is rotated on a weekly basis.
1746269|NCT00154180|Drug|Micronized progesterone, 200 mg/day x 12 d/month|capsule, 1 capsule taken daily for the first 12 days of each month for the study duration
1746270|NCT00154180|Drug|CEE , progesterone, estradiol patch or placebo for each|CEE 0.45mg 1 PO QD Progesterone 200 mg 1 PO HS first 12 days of the month estradiol patch use 1 per week
1746271|NCT00154180|Drug|CEE, progesterone, transdermal patch or the placebo|CEE 0.45 mg 1 PO QD or placebo equivalent Prometrium 200 mg 1 PO qHS for first 12 dasy of each month or placebo equivalent transdermal patch 0.05 mg use 1 patch per week or placebo equivalent
1746272|NCT00154193|Drug|cyclosporine|patients will receive maintenance triple immunosuppression according to local practice consisting of Sandimmun Neoral, MMF/ECMPA or azathioprin and steroids.
1746273|NCT00154206|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1746274|NCT00154219|Drug|Lumiracoxib (drug)|
1746275|NCT00154232|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1746276|NCT00154245|Drug|Enteric-Coated Mycophenolate sodium (EC-MPS)|
1746277|NCT00154258|Drug|Clozapine|
1746278|NCT00154271|Drug|Valsartan, Valsartan HCT|
1746279|NCT00154284|Drug|Everolimus (Certican)|
1746280|NCT00154284|Drug|Cyclosporine (Neoral)|
1746281|NCT00154284|Drug|Steroid|Each patient was administered i.v. prednisone (or equivalent) pre- or intra-operatively according to center practice.
1746282|NCT00154284|Drug|Basiliximab (Simulect)|
1746283|NCT00154297|Drug|Everolimus (RAD001)|
1746284|NCT00154310|Drug|Everolimus|Everolimus tablets orally twice a day to maintain a level of 6- 10 ng/mL.
1746285|NCT00154310|Drug|Cyclosporine|Tablets orally twice a day to maintain protocol specific target blood levels
1746286|NCT00154310|Drug|Enteric-coated mycophenolate sodium|Enteric-coated mycophenolate sodium orally twice a day to achieve a target dose of 1440 mg/day.
1746287|NCT00154310|Drug|Corticosteroids|Corticosteroids were added to the immunosuppressive regimen with a minimum dose of 5mg prednisolone or equivalent and had to be continued throughout the first year.
1746288|NCT00154323|Drug|Oxcarbazepine|
1746289|NCT00154336|Drug|Imatinib|
1746290|NCT00154336|Drug|Methotrexate|
1746291|NCT00154336|Drug|Imatinib Placebo|
1746294|NCT00154375|Drug|Imatinib mesylate|Imatinib was supplied as 100 mg and 400 mg tablets packaged in polyethylene bottles.
1746295|NCT00154375|Drug|Hydroxyurea|
1746296|NCT00154388|Drug|Imatinib mesylate|
1746297|NCT00154401|Drug|liraglutide|
1746298|NCT00154414|Drug|liraglutide|
1746299|NCT00154427|Drug|activated recombinant human factor VII|
1746300|NCT00154440|Drug|proton pump inhibitor|
1746301|NCT00154440|Drug|clarithromycin|
1746302|NCT00154440|Drug|amoxicillin|
1746303|NCT00154440|Drug|metronidazole|
1746304|NCT00154440|Procedure|radiation therapy|
1746305|NCT00154453|Procedure|obtain surgical specimen for analysis|
1746306|NCT00154466|Behavioral|cardiac rehabilitation|Those in the training group participated in a 3-month rehabilitation training program at an exercise intensity of 55% to 70% of peak oxygen uptake (VO2); those in the nontraining group continued their usual lifestyle.
1746307|NCT00154492|Drug|activated recombinant human factor VII|
1746308|NCT00154505|Device|Lateral trunk support of wheelchair seating|
1746309|NCT00154518|Procedure|Orthodontic treatment|
1746310|NCT00154557|Behavioral|elite judo athletes program|
1746311|NCT00154570|Device|EGG, 24 hour esophageal pH monitor|
1746312|NCT00154609|Drug|Gu-Sui-Bu (Davallia Divaricata)|
1746313|NCT00154622|Behavioral|work hardening program|
1746314|NCT00154635|Drug|DCB-AD1|
1746315|NCT00154648|Procedure|CE-MRA|
1746316|NCT00154661|Drug|pentoxifylline|
1746317|NCT00154674|Device|ICY catheter, Thermoguard device|
1746318|NCT00154687|Drug|Paclitaxel, Cisplatin, 5-Fluorouracil|
1746319|NCT00154700|Drug|Paclitaxel,Cisplatin,5-Fu,Folic Acid|
1746320|NCT00154713|Biological|CEA pulsed dendritic cells|
1746321|NCT00154726|Drug|Paclitaxel-HDFL|
1746322|NCT00154739|Drug|Gemcitabine|
1746323|NCT00154739|Drug|Cisplatin|
1746324|NCT00154739|Drug|Epirubicin|
1746325|NCT00154752|Procedure|CCRT, Pelvic lymphadenoectomy.|
1746326|NCT00154765|Device|sling suspension exercises|
1746327|NCT00154778|Drug|Taxol, UFT,Leucovorin|
1746328|NCT00154791|Drug|oxaliplatin|
1746329|NCT00154791|Drug|gemcitabine|
1746330|NCT00154791|Drug|5-FU/LV|
1746331|NCT00154804|Drug|Paclitaxel, Cisplatin,Surgery, CCRT|
1746332|NCT00154817|Procedure|radiotherapy|
1746333|NCT00154830|Behavioral|cerebral palsy|
1746334|NCT00154830|Behavioral|crouch gait|
1746335|NCT00154843|Drug|Lycopene|A: Lycopene15 mg/day ; B: Lycopene30 mg/day
1746336|NCT00154856|Behavioral|Detect the variation of limb lengthening|
1746337|NCT00154869|Drug|Peginterferon Alfa-2a plus Ribavirin|
1746338|NCT00154882|Drug|Paclitaxel (Phyxol) , Cisplatin|
1746339|NCT00154895|Drug|intrapleural minocycline instillation|
1746340|NCT00154986|Procedure|immunohistochemical staining, transfection, invasion assay|
1746341|NCT00155064|Drug|captopril, Losartan (drug)|
1746342|NCT00155220|Device|Low Stretch Bandage and Kinesio Tape|
1746343|NCT00155233|Drug|Nalbuphine and morphine|
1746344|NCT00155246|Drug|pentoxifylline (drug)|
1746345|NCT00155259|Drug|Docetaxel , Cisplatin , Capecitabine|
1746346|NCT00155272|Drug|Thalidomide|
1746347|NCT00155285|Procedure|computed tomography|
1746348|NCT00155311|Procedure|orthodontic treatment|
1746349|NCT00155324|Device|Extracorporeal Shock Wave Therapy (Device)|
1746350|NCT00155337|Procedure|photodynamic therapy|
1746351|NCT00155350|Drug|pioglitazone|
1746352|NCT00155363|Device|conventional artificial kidney (AK) vs. high flux AK|
1746353|NCT00155376|Drug|morphine and glucagon|
1746354|NCT00155389|Drug|Helicobacter pylori eradication|"For subjects who received the first-line treatment, the costs included the initial 13C-UBT, one-week triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and clarithromycin 500mg twice daily), and the confirmatory 13C-UBT. For subjects in whom the initial treatment failed, the costs further included the re-treatment consisting of ten-day triple therapy (esomeprazole 40mg once daily, amoxicillin 1g twice daily, and levofloxacin 500mg once daily), and the confirmatory 13C-UBT.
The first round of study was between 2004 and 2005, the second round was between 2008 and 2009, and the third round was between 2012 and 2013."
1746355|NCT00155402|Drug|tissue fibrin glue application (Tisseel)|Apply several droplets within several seconds to several minutes
1746356|NCT00155415|Behavioral|Different timing of taking polyethylene glycol(PEG)|
1746357|NCT00155428|Procedure|rapid prototyping|
1746358|NCT00155428|Procedure|computed tomography|
1746360|NCT00155454|Procedure|Intravitreal long acting gas (10% C3F8)|At the end of surgery, fluid-gas exchange with 10% C3F8 were done in the eye of study group
1746361|NCT00155467|Procedure|CT|
1746362|NCT00155480|Procedure|computed tomography|
1746363|NCT00155493|Procedure|obtain surgical specimen for analysis|
1746364|NCT00155532|Procedure|3 mm-punch biopsies of the skin|
1746365|NCT00155545|Behavioral|Motion analysis of patients|
1746366|NCT00155558|Drug|5-Fluorouracil, Leucovorin|
1746367|NCT00155597|Behavioral|home physical therapy|
1746368|NCT00155610|Device|intravesical current perception test|
1746369|NCT00155662|Behavioral|work-hardening program|
1746370|NCT00155675|Drug|GUSUIBU|
1746371|NCT00155714|Drug|type-5 phosphodiesterase Inhibitor (Sildenafil)|
1746372|NCT00155766|Biological|HPV16 E7 peptide-pulsed autologous DCs|
1746373|NCT00149630|Drug|Disulfiram|Disulfiram 250 mg/day by mouth daily during study weeks 2-13. Disulfiram discontinued during study weeks 14-15.
1746374|NCT00149630|Drug|Methadone|Initial dose 25 mg; increased by 5 mg at each subsequent daily dosing until 60 mg maintenace dose reached.
1746375|NCT00149630|Behavioral|CBT|1-hour weekly, individual, manual-guided Cognitive Behaviorial Therapy.
1746376|NCT00149630|Other|Lactose|Lactose was added to both the active disulfiram and placebo doses so they tasted identical.
1746377|NCT00149643|Drug|Fluoxetine|Gelatin capsules Fluoxetine 10 mg, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of fluoxetine 20 mg, 2 capsules barring side effects.
1746378|NCT00149643|Other|Placebo|Gelatin capsules Placebo capsules, identical to Fluoxetine capsules, 1 capsule every a.m. Medication will be increased by one capsule, to a daily dose of placebo, 2 capsules barring side effects.
1746379|NCT00149656|Dietary Supplement|Multivitamins|dietary supplement of multivitamins
1746380|NCT00149656|Dietary Supplement|Selenium|dietary supplement of selenium only
1746381|NCT00149656|Other|Placebo|placebo pill
1746382|NCT00149669|Behavioral|employment-based reinforcement|Work Plus Naltrexone Contingency participants were required to ingest naltrexone to work, and received a brief pay decrease for missing a dose.
1746383|NCT00149682|Behavioral|6-month educational program|
1746384|NCT00149682|Behavioral|6-month standard care program|
1746385|NCT00149695|Behavioral|Weekly home delivery of milk products|
1746386|NCT00149708|Drug|growth hormone administration for 6 months|depot GH (Nutropin depot) 13.4 mg every 14 days
1746387|NCT00149721|Procedure|Ventriculo-peritonal shunting|
1746388|NCT00149734|Drug|Ondansetron followed by placebo|Participants will take 16mg of ondansetron daily for the first three months followed by 3 months of placebo. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
1746389|NCT00149734|Drug|Placebo followed by Ondansetron|Participants will take placebo daily for the first three months followed by 3 months of 16mg of ondansetron daily. An atypical antipsychotic drug (olanzapine,quetiapine, or aripiprazole) will also be taken throughout the 6 months treatment period.
1746390|NCT00149747|Behavioral|Moderate-Intensity Aerobic Physical Activity|Moderate-Intensity Aerobic Physical Activity. 4+ days per week, 60+ minutes per day, moderate or greater intensity physical activity
1746391|NCT00149747|Behavioral|Health Education Class|2 classes a week, 90+minutes per class, general health education, excluding information on physical activity
1746392|NCT00149760|Behavioral|Augmented Standard Medical Care|Participants' physicians will receive a letter making specific treatment recommendations for primary care treatment.
1746393|NCT00149760|Behavioral|Cognitive-Affective Behavior Therapy|Individually-administered cognitive-behavioral therapy with an emotional focus in addition to augmented standard medical care
1746394|NCT00149773|Behavioral|Cognitive Therapy|
1746395|NCT00149786|Behavioral|Family Based Therapy|Family therapy will be given for a total of 24 hours over the course of 12 months.
1746396|NCT00149786|Behavioral|Ego-Oriented Individual Psychotherapy|Individual therapy will be given for a total of 24 hours over the course of 12 months.
1746397|NCT00149799|Drug|Escitalopram|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
1746398|NCT00149799|Drug|Placebo|At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
1746399|NCT00149812|Behavioral|Family Functioning Intervention|
1746400|NCT00149825|Drug|Escitalopram|5 to 20 mg for 12 weeks
1746401|NCT00149825|Behavioral|CBTI|Cognitive Behavioral Treatment for Insomnia
1746402|NCT00149825|Behavioral|CTRL|Control Therapy consists of Pseudo-desensitization Therapy for Insomnia
1746407|NCT00149851|Drug|Tegaserod|
1746408|NCT00149864|Drug|Mycophenolate sodium (enteric coated)|
1746409|NCT00149877|Drug|Tegaserod|
1746410|NCT00149890|Drug|Basiliximab|Basiliximab (10 mg) was supplied as a lyophilisate in vials with ampoules of sterile water for injection (5 mL) and had to be given of 10 mg (body weight <35 kg) or 20 mg (body weight ≥35 kg) strength.
1746411|NCT00149890|Drug|Cyclosporine/cyclosporine microemulsion|Cyclosporine/cyclosporine microemulsion had to be started with 100 mg/m²/day intravenous (i.v) (2x4h) for 7 days and was to be continued i.v. or orally from day 8 onwards as per center practice. During the 6 months treatment period Cyclosporine doses had to be adjusted according to Cyclosporine A (CsA)-trough levels.
1746412|NCT00149890|Drug|Steroid|Intravenous prednisolone (loading dose: 300 mg/m2, maximum 500 mg) had to be administered intraoperatively only in treatment arm 1 (day 0). The first dose of steroids in treatment arm 2 (day 0) had to be administered within 8 hours after reperfusion of the graft. Beginning from day 1 to day 6 doses of 15 mg/m2/day had to be given intravenously (i.v.) in both treatment arms. Then, the steroid doses (oral prednisone or its equivalent) were to be decreased from 10 mg/m²/day orally (day 7-13), to 7.5 mg/m²/day orally (day 14-30), to 4 mg/m²/day orally (until end of month 2), to 2.5 mg/m²/day orally (until end of month 3) and to 1 mg/m²/day orally (until end of month 6).
1746413|NCT00155870|Behavioral|questionnaires|
1746414|NCT00155883|Drug|Taxteral|
1746415|NCT00155883|Drug|5-Fluorouracil|
1746416|NCT00155883|Drug|Leucovorin|
1746417|NCT00155935|Procedure|venous puncture|
1746418|NCT00155974|Biological|Community-based vaccine outreach intervention|
1746419|NCT00155987|Procedure|Early decompressive craniectomy|Large bifrontotemporal decompressive craniectomy
1746420|NCT00156000|Device|Fetal Fibronectin|fFN test done during pregnancy
1746421|NCT00156000|Device|Salivary Estriol|Salivary Estriol done during pregnancy
1746423|NCT00156026|Procedure|loop electrosurgical excision procedure (LEEP)|1. loop electrosurgical excision procedure
1746424|NCT00156039|Behavioral|Follow-up Strategy for Breast Cancer|
1746425|NCT00156052|Radiation|Conventional whole breast radiation schedule|
1746426|NCT00156052|Radiation|Hypofractionated whole breast radiation schedule|
1746427|NCT00156065|Drug|Haloperidol|2-8 mg BID
1746428|NCT00156065|Drug|Asenapine|5 or 10 mg BID
1746429|NCT00156065|Drug|Asenapine|5 or 10 mg BID
1746430|NCT00156078|Drug|pregabalin|
1746431|NCT00156091|Drug|Olanzapine|5- 20 mg QD
1746432|NCT00156091|Drug|Asenapine|5 or 10 mg BID
1746433|NCT00156091|Other|Placebo|
1746434|NCT00156104|Drug|Asenapine|5 mg BID
1746435|NCT00156104|Drug|Asenapine|10 mg BID
1746436|NCT00156104|Drug|Haloperidol|4 mg BID
1746437|NCT00156104|Other|Placebo arm|
1746438|NCT00156910|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label extension phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
1746439|NCT00156910|Other|Placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
1746440|NCT00156923|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 3.5 years.
1746441|NCT00156923|Drug|Medisorb naltrexone 190 mg|Administered via IM injection once every 4 weeks for up to 3.5 years.
1746442|NCT00156936|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks. Subjects in this dosing group also received this treatment throughout the base study.
1746443|NCT00156936|Drug|Oral naltrexone to Medisorb naltrexone 380 mg|Subjects in this dosing group received oral naltrexone 50 mg in the base study, but received only Medisorb naltrexone 380 mg in this extension study, administered via IM injection once every 4 weeks.
1746444|NCT00156949|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
1746445|NCT00156962|Drug|Epoetin alfa DT|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
1746446|NCT00156962|Drug|Epoetin alfa RB|Receive drug at same frequency and dose as at the time of randomization Change dose by+/- 25% in order to maintain Hb between 11.0 - 13.0 g/dL
1746447|NCT00156975|Drug|Capecitabine|
1746448|NCT00156975|Drug|Oxaliplatin|
1746449|NCT00156988|Drug|cerium nitrate-silver sulfadiazine (cerium-flamazine)|
1746450|NCT00157001|Procedure|Photopheresis Post Angioplasty|
1746456|NCT00157027|Procedure|Extracorporeal photochemotherapy with UVADEX|"Photopheresis (or extracorporeal photoimmunetherapy [ECP]) is a process developed by THERAKOS, Inc., a Johnson and Johnson Company. During the process of ECP, whole blood is drawn from the patient over several cycles, centrifuged and separated into the components of plasma, white cells (or buffy coat), and red blood cells. A portion of the white cells and the plasma are saved in a separate compartment. The remaining plasma and red blood cells are immediately returned to the patient.
The saved buffy coat (white blood cells) and plasma are inoculated with the photosensitizing agent UVADEX. Photoactivation begins when the suspension is exposed to a prescribed amount of ultraviolet-A light. After photoactivation is complete, the treated suspension is returned to the patient."
1746459|NCT00157066|Drug|Ergocalciferol|
1746464|NCT00157131|Biological|Fibrin Sealant, ARTISS 4IU/ml VH SD|FS 4IU VH S/D, a two-component fibrin sealant with 4 IU/mL human thrombin, vapor heated, solvent detergent treated, provided in a frozen, ready-to-use formulation. Administration by a topical spray application using the TISSOMAT device and Spray Set.
1746465|NCT00157131|Other|Staples|Administration by mechanical/multiple point fixation.
1746466|NCT00157157|Biological|Recombinant Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator).
The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care.
For incremental recovery assessments, a single infusion at 50 +/- 5 IU/kg was to be given.
Immune tolerance induction (ITI) therapy for subjects who developed factor VIII inhibitors was at the discretion of the investigator, based on the institution's guidelines or described in peer-reviewed literature, and was to be approved by the sponsor's medical director.
rAHF-PFM was to be administered intravenously via bolus infusion, except for perioperative management when it may have been given either by continuous or bolus infusion."
1746467|NCT00157170|Behavioral|supervised exercise|
1746468|NCT00157183|Device|Nocturnal oxygen , nocturnal bi-level positive pressure ventilation|
1746469|NCT00157196|Biological|Tecemotide (L-BLP25)|After receiving single low-dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide [L-BLP25]) at 6-week intervals, commencing at Week 13, until disease progression is documented.
1746470|NCT00157196|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
1746471|NCT00157196|Other|Best standard of care (BSC)|The BSC will be provided at the investigator's discretion, and may include but not be limited to psychosocial support, nutritional support and other supportive therapies.
1746472|NCT00157209|Biological|Tecemotide (L-BLP25)|After receiving single low dose cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 1000 microgram (mcg) of tecemotide (L-BLP25) at weeks 0, 1, 2, 3, 4, 5, 6 and 7 followed by maintenance vaccinations (1000 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until discontinuation from the study due to ECOG status of 4, participation in alternate trial, serious adverse event, or reasons that preclude assessment of clinical status in the opinion of the investigator, and in case of unavailability of study vaccine.
1746473|NCT00157209|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
1746474|NCT00157209|Other|Best Supportive Care (BSC)|The BSC will be provided at the investigator's discretion, and may include palliative radiation, psychosocial support, analgesics and nutritional support. Second-line chemotherapy is permitted when indicated for treatment of progressive disease.
1746475|NCT00157235|Drug|Tiotropium bromide|
1746476|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
1746477|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
1746478|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
1746479|NCT00157248|Drug|dabigatran etexilate|dosage used at study start
1746480|NCT00157261|Drug|tenecteplase|
1746481|NCT00157274|Drug|alemtuzumab|
1746482|NCT00157287|Procedure|Evidence based weaning protocol|
1746483|NCT00157300|Drug|Epoetin beta|intravenous, 33000 IU, 3 consecutive days, starting 3-4 hours before transplantation. Total dose 100.000 IU.
1746484|NCT00157313|Behavioral|Integrated treatment, family involvement|
1746485|NCT00157313|Behavioral|Social skills training|
1746486|NCT00157326|Drug|tadalafil|
1746487|NCT00157339|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 12 months
1746488|NCT00157339|Drug|injected insulin|patient specific dose, injected, before meals, 12 months.
1746489|NCT00157378|Drug|Risperidone, Haloperidol|
1746490|NCT00157482|Drug|Ezetimibe|
1746491|NCT00157482|Drug|Simvastatin|
1746492|NCT00157508|Drug|nitroaspirin|
1746493|NCT00157521|Drug|L-arginine|
1746494|NCT00157534|Drug|Celgosivir|
1746495|NCT00157547|Drug|Selective serotonin reuptake inhibitors (SSRI)|Selective serotonin reuptake inhibitors (SSRI)
1746496|NCT00157560|Drug|Chemotherapy, multiple agents|
1746497|NCT00157573|Drug|GM-CSF, sargramostim|GM-CSF subcutaneous injection
1746498|NCT00157586|Drug|Delapril, Delapril-Manidipine Fixed combination|
1746499|NCT00157599|Procedure|various diagnostic measures for DVT (e.g., CUS)|
1746500|NCT00157612|Procedure|a clinical pathway for the management of nursing home acquired pneumonia|
1746501|NCT00157625|Behavioral|Automatic stop order|
1746502|NCT00157638|Behavioral|integration of pharmacist into primary care|
1746503|NCT00157638|Drug|optimizing therapeutic treatments|
1746504|NCT00157638|Behavioral|optimizing processes of care|
1746507|NCT00157677|Procedure|D-dimer testing|Uniform D-dimer use
1746508|NCT00157677|Procedure|D-dimer testing|Selective D-Dimer use
1746509|NCT00157690|Drug|Alendronate|70 mg 1x weekly for 12 months
1746510|NCT00157690|Drug|Placebo|70 mg 1 x weekly for 12 months
1746511|NCT00157703|Drug|G207|1 x 10E9 plaque forming units, administered by stereotactic injections into the tumor (single administration)
1746512|NCT00157716|Drug|(MC-1) Pyridoxal-5’-phosphate|
1746513|NCT00157729|Drug|pyridoxal-5'-phosphate with and without ACE inhibitor|
1746514|NCT00157742|Procedure|Spinal Cord Stimulation (SCS)|
1746515|NCT00157742|Procedure|Percutaneous Myocardial Laser Revascularisation (PMR)|
1746516|NCT00157755|Device|Enterra Therapy|Gastric electrical stimulation using Enterra Therapy.
1746517|NCT00157768|Device|Implantable cardioverter defibrillator|
1746518|NCT00157781|Device|Medtronic AT500|
1746519|NCT00157794|Device|Search AV+ algorithm|
1746520|NCT00157807|Procedure|bipolar radiofrequency ablation of persistent and permanent AF|
1746521|NCT00157820|Device|Single Chamber Implantable Cardioverter Defibrillator|Single chamber ICD implantation: Medtronic GEM, Medtronic Marquis family of SC ICD
1746522|NCT00157820|Device|Dual Chamber implantable cardioverter defibrilator|Dual chamber ICD implantation: Jewel AF & GemIII AT as DC ICDs (DC true and SC sim arms)
1746523|NCT00157833|Drug|Artekin / Coartemther|
1746524|NCT00157846|Device|CRT-P or CRT-D Device|Upgrade from ICD or pacemaker to CRT-D/CRT-P (Insync III, Insync Marquis, Insync Sentry, Insync Maximo, Concerto)
1746525|NCT00157859|Drug|Chloroquine and sulphadoxine-pyrimethamine|
1746526|NCT00157872|Drug|MK0966; rofecoxib|
1746527|NCT00157872|Drug|Comparator: naproxen tablet 500 mg|
1746528|NCT00157885|Drug|Amodiaquine plus artesunate; Artekin|
1746529|NCT00157898|Drug|MK0826; ertapenem sodium|
1746530|NCT00157898|Drug|Comparator: ceftriaxone + metronidazole|
1746531|NCT00157911|Drug|MK0653; ezetimibe / Duration of Treatment: 12 weeks|
1746532|NCT00157911|Drug|Comparator: simvastatin / Duration of Treatment: 12 weeks|
1746533|NCT00157924|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg.
1746534|NCT00157924|Drug|atorvastatin|atorvastatin 10mg
1746535|NCT00157937|Drug|MK0476; montelukast sodium/Duration of Treatment: 16 weeks|
1746536|NCT00157937|Drug|Comparator: theophylline ER/Duration of Treatment: 16 weeks|
1746537|NCT00157950|Biological|Gardasil™|Gardasil™ 3 dose regimen (Day 1, Month 2 and Month 6)
1746538|NCT00157950|Biological|Placebo|Gardasil™ matching placebo 3 dose regimen (Day 1, Month 2 and Month 6)
1746897|NCT00160485|Drug|Insulin|variable dosage to obtain glucose control
1746539|NCT00157963|Drug|MK0954A; hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 weeks|
1746540|NCT00157976|Drug|Photrex (rostaporfin)|
1746541|NCT00157989|Procedure|Controlled tidal volume resuscitation|
1746542|NCT00158002|Drug|Topiramate|
1746543|NCT00158028|Drug|Risperidone|The dosage of risperidone was titrated upward in a stepwise design, beginning with 0.25 mg/d for the first week, 0.5 mg/d for weeks 2 and 3, 1.0 mg/d for weeks 4 and 5, 1.5 mg/d for weeks 6 and 7, and 2.0 mg/d for the remaining weeks.
1746544|NCT00158028|Drug|Placebo|placebo match in identical tablets
1746545|NCT00158041|Drug|Amifostine administered subcutaneously|
1746546|NCT00158054|Behavioral|Enhanced depression care|Initial patient preference for problem-solving therapy and/or pharmacotherapy, then a stepped-care approach.
1746547|NCT00158054|Behavioral|Referred depression care|Physician notified of depression symptoms, usual care followed.
1746548|NCT00158067|Device|external Responsive Neurostimulator (eRNS) System|
1746549|NCT00158080|Procedure|hemofiltration|
1746550|NCT00158093|Drug|Nebivolol|
1746551|NCT00158093|Drug|Atenolol|
1746552|NCT00158093|Drug|Moxifloxacin|
1746553|NCT00158106|Procedure|Speech and Language therapy for dysarthria and/or aphasia|
1746554|NCT00158119|Behavioral|InVEST (Increased Velocity Exercise Specific to Task)|
1746555|NCT00158132|Drug|Propranolol|Propranolol 100mg/day in 3 divided doses
1746556|NCT00158132|Drug|Amantadine|Amantadine 100mg three times daily
1746557|NCT00158132|Drug|Placebo|Placebo pills
1746558|NCT00158158|Drug|Usual Care|If unable to quit at quit date, offered usual care to set another quit date.
1746559|NCT00158158|Other|Smoking Reduction|If unable to quit smoking, reduce smoking rate prior to quit date.
1746560|NCT00158171|Drug|Nicotine Replacement Therapies|Nicotine gum 2 & 4 mg dependent on baseline smoking rate
1746561|NCT00158171|Drug|Nicotine patch|21, 14 or 7 mg patch dependent on baseline smoking rate
1746562|NCT00158171|Dietary Supplement|Folic Acid|400 mg
1746563|NCT00158184|Drug|oxycodone 15 mg|15 mg/70 kg oxycodone administered once per day, orally.
1746564|NCT00158184|Drug|oxycodone 30 mg|30 mg/70 kg oxycodone administered once per day, orally.
1746565|NCT00158184|Drug|Placebo 0 mg|0 mg placebo dose administered once a day, orally.
1746566|NCT00158197|Behavioral|contingency management voucher|participants receive vouchers for the provision of methamphetamine-negative urines. Vouchers can be redeemed for goods and services compatible with non-drug using behaviors.
1746567|NCT00158210|Drug|Rivastigmine|
1746568|NCT00158223|Drug|Pimozide|Each capsule of active treatment will contain 2 mg of pimozide. Dosing will be flexible and will range from a minimum of 2 mg per day to 8 mg per day. Dosing will begin at Week 1 with 1 capsule per day. This will be slowly titrated at a rate of 1 capsule per week to a maximum of 4 capsules depending upon clinical response and side effects.
1746569|NCT00158223|Drug|Placebo|Active drug and placebo will be encapsulated in an identical fashion. The placebo capsule will be made to match in appearance and weight. There will be flexible dosing, allowing a minimum of 1 capsule per day to 4 capsules per day, in order to match the dosing range of the active treatment.
1746570|NCT00158236|Drug|Buprenorphine|
1746571|NCT00158236|Drug|Buprenorphine and Naloxone|
1746572|NCT00158236|Drug|Hydromorphone|
1746573|NCT00158249|Drug|citicoline|2 gm/day, 8 weeks treatment
1746574|NCT00158249|Drug|placebo|matched for physical appearance
1746575|NCT00158262|Drug|Propranolol|Propranolol short-acting or long-acting capsule
1746576|NCT00158262|Drug|Placebo|Placebo-matching propranolol short-acting or long-acting capsule
1746580|NCT00158288|Behavioral|LAAM|
1746581|NCT00158301|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions will focus on teaching participants skills to manage depressed moods and to identify situations which might put them at risk for a relapse in depressive symptoms.
1746582|NCT00158301|Drug|Drug therapy|All participants will receive 12 weeks of treatment with antidepressant therapy. Responders to initial treatment will continue medication during the continuation phase (both treatment arms).
1746583|NCT00158314|Behavioral|Referral to Gamblers Anonymous|
1746584|NCT00158314|Behavioral|Cognitive behavioral therapy|
1746585|NCT00158314|Behavioral|Cognitive behavioral self-help manual|
1746586|NCT00158327|Behavioral|Telephone-based collaborative care|Participants assigned to the telephone-based program will have a choice of what type of treatment they will receive. The choices will include pharmacotherapy, workbook training designed to help participants improve their coping skills, referral to a community mental health specialist, or some combination of these treatments. Participants will receive telephone calls one to two times every month for 12 months. During the calls, participants will be asked about their attitude toward and adherence to their treatment regimen. They will also be asked about recent episodes of anxiety they have experienced and what coping techniques they have used.
1746587|NCT00158327|Behavioral|Usual care|Usual care may include one or more of several different treatments such as pharmacotherapy and cognitive behavioral therapy; the treatments will be chosen by participants' physicians and will be delivered for 12 months.
1746588|NCT00158340|Behavioral|Guided self-help cognitive behavioral therapy (CBT)|Participants receive eight sessions of guided self-help CBT.
1746589|NCT00158340|Behavioral|Usual clinical care|Control group participants receive treatment as usual.
1746590|NCT00158353|Behavioral|GirlPOWER! mentoring program|GirlPOWER! mentoring program includes monthly 3-hour workshops for youth and mentors combined with monthly supplemental activities to be completed independently by youth-mentor pairs.
1746591|NCT00158353|Behavioral|Traditional mentoring|Traditional mentoring includes a community-based mentoring program, in which the youth-mentor spends time together in activities of their choosing 2 to 4 times a month.
1746592|NCT00158366|Behavioral|Behavioral training|The behavioral training will teach participants ways to control their diet and increase their physical activity.
1746593|NCT00158366|Behavioral|Social skills training|The social skills training will teach participants how to indirectly control their weight by making social contacts and seeking social support.
1746594|NCT00158366|Behavioral|Behavioral training booster sessions|During biweekly booster treatment sessions, participants will discuss their response to different diet and exercise regimens, and researchers will discuss strategies for increasing one's success with the regimens.
1746595|NCT00158379|Drug|Paclitaxel|4 cycles of Carboplatin AUC 5 every 3 weeks. 12 weekly infusions of 80 mg/m² Taxol®
1746596|NCT00158405|Procedure|Structured Treatment Interruption|
1746597|NCT00158405|Drug|Zidovudine (ZDV)|
1746598|NCT00158405|Drug|Lamivudine (3TC)|
1746599|NCT00158405|Drug|Efavirenz (EFV)|
1746600|NCT00158405|Drug|Ritonavir (NRV)|
1746601|NCT00158405|Drug|Indinavir (IDV)|
1746602|NCT00158418|Procedure|Cemented Humeral Stem|
1746603|NCT00158418|Procedure|Uncemented Humeral Stem|
1746604|NCT00158431|Procedure|Arthroscopy plus Medical Management|Arthroscopic Surgery
1746605|NCT00158431|Other|Medical Management|education, optimized medication, weight loss where needed, HA or cortisone injections if needed, physiotherapy
1746606|NCT00158444|Device|HemiCAP Resurfacing|intraoperative joint surface mapping and implantation of patient specific, matching inlay resurfacing prosthetic
1746607|NCT00158457|Drug|Tenofovir (TDF)|
1746608|NCT00158457|Drug|Emtricitabine (FTC)|
1746609|NCT00158457|Drug|Efavirenz (EFV)|
1746610|NCT00158470|Drug|efavirenz|
1746611|NCT00158470|Drug|didanosine|
1746612|NCT00158470|Drug|lamivudine|
1746613|NCT00158483|Drug|Acyclovir (ACV)|
1746614|NCT00158496|Drug|pegylated interferon alpha2a|
1746615|NCT00158496|Drug|ribavirin|
1746616|NCT00158509|Drug|Valacyclovir|
1746617|NCT00158522|Drug|pegylated interferon alpha2a|
1746618|NCT00158535|Procedure|liver transplantation|
1746619|NCT00158548|Drug|SP, chloroquine, amodiaquine, primaquine, artesunate|
1746620|NCT00158561|Drug|sulfadoxine-pyrimethamine and chlorproguanil-dapsone|
1746621|NCT00158574|Drug|sulphadoxine-pyrimethamine|
1746622|NCT00158574|Drug|mefloquine|
1746623|NCT00158574|Drug|Chlorproguanil-dapsone|
1746624|NCT00158574|Drug|Placebo|Placebo
1746625|NCT00158574|Drug|Sulphadoxine-pryrimethamine|IPTi doses 1 and 2, at ages 2 and 3 months, sulphadoxine 250mg, pyrimethamine 12.5mg IPTi doses 3, at 9 months of age, sulphadoxine 500mg, pyrimethamine 25mg
1746626|NCT00158574|Drug|IPTi mefloquine|IPTi doses 1 & 2 at ages 2 & 3 months, mefloquine 125mg IPTi dose 3 at 9 months, mefloquine 250mg
1746627|NCT00158574|Drug|Chlorproguanil dapsone|IPTi doses 1 and 2 at ages 2 and 3 months, doses 15mg chlorproguanil and 18.75mg dapsone IPTi dose 3 at 9 months of age, doses 22.5mg chlorproguanil and 28.13mg dapsone
1746628|NCT00158587|Drug|primaquine|
1746629|NCT00158600|Biological|alglucosidase alfa|IV infusion of 20mg/kg; qow for 78 weeks.
1746630|NCT00158600|Drug|Placebo|Placebo Comparator; qow for 78 weeks.
1746631|NCT00158613|Biological|Carticel (autologous cultured chondrocyte) implantation|Each Carticel vial of autologous cultured chondrocytes contains approximately 12 million cells implanted into the defect and secured with a periosteal flap
1746632|NCT00158626|Behavioral|pelvic floor muscle training|
1746634|NCT00158652|Procedure|Conventional radiotherapy 70 Gy in 7 weeks|2 gy per fraction, 1 fraction per day, 5 fractions per week
1746635|NCT00158652|Procedure|middle accelerated radiotherapy 70 Gy in 6 weeks|5 x 2gy/week until 40 Gy in 20 fractions and 4 weeks, then 2 fractions of 1.5Gy per day for 30 additional Gy in 2 weeks
1746636|NCT00158652|Procedure|very accelerated radiotherapy 64.8 Gy in 3.5 weeks|2 fractions of 1.8 Gy per day for 64.8 Gy in 3.5 weeks
1746637|NCT00158652|Drug|5FU, Paraplatin|5FU 600mg/m²/D, Paraplatin 70mg/m²/D In arm 1: D1-4, 3 cycles during Rth (D1, D22, D43) In arm 2: D1-5, 2 cycles during Rth (D1, D29)
1746642|NCT00158691|Drug|Ethyol|
1746643|NCT00158704|Drug|Hepsera|
1746644|NCT00158717|Drug|Hepsera|
1746645|NCT00158730|Drug|AmBisome|
1746646|NCT00158743|Drug|Anti-digoxin antibody (FAB fragment)|intravenous administered, dose based on weight (assuming 4ng/mL EDLF concentration). Dose every 6 hours x 48 hours.
1746647|NCT00158743|Other|sodium chloride|
1746648|NCT00158756|Biological|Tritanrix™-HepB|GSK Biologicals' combined diphtheria-tetanus-whole cell Bordetella pertussis -hepatitis B vaccine.
1746649|NCT00158756|Biological|Rotarix™|GSK Biologicals' live attenuated human rotavirus vaccine
1746650|NCT00158756|Biological|Zilbrix™|GSK Biologicals Kft's combined diphtheria-tetanus whole-cell B. pertussis-hepatitis B vaccine
1746651|NCT00158756|Biological|Triple Antigen™|Commonwealth Serum Laboratory's (CSL's) combined diphtheria-tetanus-whole cell B. pertussis vaccine.
1746652|NCT00158756|Biological|Engerix™-B|GSK Biologicals' hepatitis B vaccine
1746653|NCT00158756|Drug|Placebo|Placebo for the Rotarix™ vaccine
1746654|NCT00158769|Drug|Intravenous GR270773 - Phospholipid emulsion|GR270773 (lipid emulsion) is a sterile, white to off-white, semi-translucent liquid for intravenous injection.
1746655|NCT00158782|Drug|GW786034|
1746656|NCT00158782|Drug|lapatinib|
1746657|NCT00158795|Biological|Haemophilus Influenza type b vaccine|
1746658|NCT00158808|Biological|Diphteria, tetanus, whole-cell pertussis, hepatitis B & Hib|
1746898|NCT00160498|Drug|Lercanidipine|
1746659|NCT00158821|Drug|Viread (tenofovir disoproxil fumarate)|Tenofovir DF 300 mg tablets once daily
1746660|NCT00158821|Drug|Sustiva (Efavirenz)|efavirenz capsules 600 mg once daily
1746661|NCT00158821|Drug|Epivir (Lamivudine)|lamivudine 150 mg tablets twice daily
1746662|NCT00158821|Drug|Zerit (Stavudine) Placebo|stavudine placebo capsules twice daily
1746663|NCT00158834|Drug|Salmeterol/Fluticasone propionate combination product|
1746664|NCT00158834|Drug|Fluticasone propionate|
1746665|NCT00158847|Drug|fluticasone 500 mcg|
1746666|NCT00158847|Drug|fluticasone 500 mcg + salmeterol 50 mcg|
1746668|NCT00158873|Drug|midazolam|
1746669|NCT00158873|Drug|lorazepam|
1746670|NCT00158873|Drug|fentanyl|
1746671|NCT00158873|Drug|morphine|
1746672|NCT00158873|Drug|remifentanil|
1746673|NCT00158873|Drug|propofol|
1746674|NCT00158886|Drug|Hycamtin|
1746675|NCT00158899|Drug|GW501516 oral tablets|
1746676|NCT00158912|Device|Implantable Cardioverter Defibrillator|
1746677|NCT00158925|Device|EASYTRAK EPI lead|EASYTRAK EPI lead
1746678|NCT00158938|Device|EASYTRAK 3 left ventricular pacing lead|
1746679|NCT00158951|Device|CONTAK RENEWAL 2/4/4HE CRT-D|
1746680|NCT00158951|Device|EASYTRAK 2 Lead|
1746681|NCT00158964|Device|EASYTRAK 4 STEERABLE LV lead|
1746682|NCT00158977|Device|CONTAK RENEWAL 3 AVT|CONTAK RENEWAL 3 AVT
1746683|NCT00158990|Drug|triiodothyronine|
1746684|NCT00158990|Drug|sertraline|
1746685|NCT00159016|Drug|Glivec|
1746686|NCT00159055|Biological|CMV vaccine|
1746687|NCT00159081|Drug|Haloperidol, Risperidone (drug)|targeted dose of 2-4 mg/day over 1 year
1746688|NCT00159094|Drug|Doxil and Vinorelbine|
1746689|NCT00159107|Drug|Acamprosate|Acamprosate
1746690|NCT00159107|Behavioral|Integrative behavior therapy|Integrative behavior therapy
1746691|NCT00159107|Drug|Placebo|Placebo
1746692|NCT00159120|Other|maintained antipsychotic treatment vs. stepwise drug discontinuation|maintained antipsychotic treatment (in low dose) vs. stepwise drug discontinuation; both supplemented by prodrome-based early intervention; 1 year
1746693|NCT00159133|Drug|antipsychotics vs. Lorazepam (Drugs)|Early intervention with low-dose antipsychotics vs. lorazepam (up to 3 mg/day) in case of early warning signs of an impending relapse;
1746694|NCT00159146|Drug|Pindolol and venlafaxin|pindolol 20 mg and venlafaxin 150 mg
1746695|NCT00159159|Drug|Ciclosporine 130 µg/l < T0 ciclosporinemia < 200 µg/l|
1746696|NCT00159159|Drug|Ciclosporine 200 µg/l < T0 ciclosporinemia < 300 µg/l|
1746697|NCT00159172|Device|Motor cortex stimulation|
1746698|NCT00159211|Drug|UMULINE NPH|UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
1746699|NCT00159211|Drug|pioglitazone|30mg daily. After 2 months, if HbA1c has not decreased at least of 1%, the dosage should be increased to 45 mg daily
1746700|NCT00159224|Drug|Lopinavir/ritonavir simplification strategy|Simplification
1746701|NCT00159237|Procedure|blood test|
1746702|NCT00159250|Drug|AVI-4658 (PMO)|morpholino antisense oligonucleotide
1746703|NCT00159263|Procedure|Induced Sputum|
1746704|NCT00159263|Drug|Symbicort, Formoterol, Budesonide and Placebo|
1746705|NCT00159276|Procedure|Induced Sputum|
1746706|NCT00159289|Procedure|Inhalation of LPS|
1746707|NCT00159289|Procedure|Placebo|
1746708|NCT00159302|Procedure|Induced Sputum|
1746709|NCT00159302|Procedure|Exhaled Nitric Oxide|
1746710|NCT00159302|Procedure|Nasal Nitric Oxide|
1746711|NCT00159302|Procedure|Blood Tests|
1746712|NCT00159302|Procedure|24hr Urine Samples|
1746713|NCT00159302|Procedure|Exhaled Breath Condensate|
1746714|NCT00159302|Procedure|Spirometry|
1746715|NCT00159315|Procedure|Inhalation Challenge with ATP|
1746716|NCT00159315|Procedure|Inhalation Challenge with AMP|
1746717|NCT00159328|Procedure|Magnetic Resonance Guided Focused Ultrasound|
1746718|NCT00159341|Procedure|Nasal lavage|Nasal lavage was carried out at specified timepoints
1746719|NCT00159341|Procedure|Nasal filter paper|Nasal filter paper was placed at specified timepoints
1746720|NCT00159341|Procedure|Blood sampling|Blood sampling was performed as a routine safety check
1746721|NCT00159354|Drug|predisolone|
1746722|NCT00159367|Device|Repetitive magnetic stimulation to the quadriceps|
1746723|NCT00159380|Procedure|Inhalation of aminoguanidine and oral intake and inhalation of L-arginine|
1746724|NCT00159380|Procedure|Exhaled Breath Condensate|
1746725|NCT00159380|Procedure|Nasal Lavage|
1746726|NCT00159380|Procedure|Saliva|
1746727|NCT00159380|Procedure|Spirometry|
1746728|NCT00159393|Other|registry and database|data collection
1746729|NCT00159406|Other|Registry and Database|Data Collection
1746730|NCT00159419|Drug|Alendronate|
1746731|NCT00159419|Drug|Pamidronate|
1746732|NCT00159432|Drug|Oxaliplatin|
1746733|NCT00159432|Drug|Bevacizumab|
1746734|NCT00159432|Drug|Capecitabine|
1746735|NCT00159445|Drug|gemcitabine, capecitabine|
1746736|NCT00159458|Drug|Gemcitabine and oxaliplatin|
1746737|NCT00159471|Drug|capecitabine, gemcitabine, docetaxel|
1746738|NCT00159484|Drug|EPO906, celecoxib|EPO906 IV, every three weeks, celecoxib by mouth twice a day every day
1746739|NCT00159497|Device|porous coated Trilogy®|THA
1746740|NCT00159497|Device|Trilogy Calcicoat®|THA
1746741|NCT00159510|Drug|Methylene blue|Injection bolus of 2 mg/kg PBW and infusion of 0.2 mg/kg/hr
1746742|NCT00159510|Drug|Nitric oxide|An inhalation of NO via ETT at 10 ppm, partially weaned by 72 hrs of therapy
1746743|NCT00159510|Drug|Methylene blue & nitric oxide|See the dosage in the previous arms
1746744|NCT00152737|Procedure|Exercise test with Transcutaneous oxygene pressure|Ce marked devices
1746745|NCT00152737|Procedure|Ankle and arm pressure values|one test before and one test after surgery
1746747|NCT00152763|Behavioral|Cognitive Behaviour Therapy (CBT)|Cognitive behavior therapy tailored to psychological adaptation to an ICD, included 8 telephone counselling sessions, plus psycho-educational booklet and a therapist manual.
1746748|NCT00152763|Other|Usual Cardiac Care (UCC)|Usual cardiac care (UCC) was defined as whatever the respective ICD treatment sites routinely offer their patients. All patients received standard educational materials explaining their heart disease and the ICD device. Follow-up appointments include device interrogation (i.e., to extract arrhythmia events and ICD therapies) and trouble-shooting at 6-months intervals, cardiac care as necessary, and nonsystematic supportive reassurance delivered informally in the clinic. Each centre also had access to a cardiac rehabilitation program and psychiatric consultation as needed.
1746749|NCT00152776|Drug|ovaria comp 10 globuli 3 times per day|
1746750|NCT00152789|Procedure|Oxygen measurement - Eppendorf machine|
1746751|NCT00152802|Biological|The polysaccharide vaccine Pneumovax (Merck-Frosst)|
1746752|NCT00152802|Biological|The conjugate vaccine used will be Prevnar (Wyeth vaccines)|
1746753|NCT00152815|Drug|antioxidant vitamin E|Vitamin E 800IU per day for 12 months
1746754|NCT00152815|Behavioral|weight reduction and exercise|Patients will be asked to consume a self-selected, low fat, low-calorie diet of approximately 1200 kcal/d, which is consistent with American Heart Association guidelines for healthy weight reduction. Subjects will be provided with a videotape involving a structured 20 min aerobic exercise to be performed 3x/week.
1746755|NCT00152828|Drug|Celecoxib|
1746756|NCT00152841|Drug|Iron supplement 300-600 mg/day|
1746757|NCT00152841|Drug|Vitamin E 800IU|
1746758|NCT00152854|Drug|Acetaminophen|acetaminophen 1g po qid
1746759|NCT00152854|Drug|acetaminophen|acetaminophen 1g po qid for 7 days
1746760|NCT00152854|Drug|placebo, sugar pill|
1746761|NCT00152867|Drug|Dexamethasone|dexamethasone 4mg PO bd for 2 days post chemotherapy
1746762|NCT00152893|Drug|chromium nicotinate|
1746763|NCT00152893|Drug|Placebo|
1746764|NCT00152906|Procedure|Stereotactic radiotherapy (SRT) or highly conformal (CRT)|SRT or CRT is radiation delivered precisely conforming the high dose region to the tumor, usually in a few highdose fractions.
1746765|NCT00152919|Drug|Meloxicam|
1746766|NCT00152932|Drug|Dorzolamide 2% drops|
1746767|NCT00152932|Device|HRF and CLBF|
1746768|NCT00152945|Drug|Intravenous Intralipid|intravenous infusion
1746769|NCT00152945|Drug|Intravenous leucine, glycerol|intravenous infusion
1746770|NCT00152958|Drug|Pramipexole|
1746771|NCT00152971|Drug|Dabigatran Dose 1 - day 2 to completion|low dose regimen taken once daily
1746772|NCT00152971|Drug|Dabigatran Dose 1 - day 1|low dose regimen taken once daily
1746773|NCT00152971|Drug|Dabigatran Dose 2 - day 2 to completion|high dose regimen taken once daily
1746774|NCT00152971|Drug|Dabigatran Dose 2 - day 1|high dose regimen taken once daily
1746775|NCT00152971|Drug|Enoxaparin|30 mg subcutaneously twice daily
1746776|NCT00152984|Drug|Tiotropium inhalation capsules|
1746777|NCT00152984|Drug|Placebo inhalation capsules|
1746778|NCT00152997|Drug|Pramipexole 0.125 mg tablets|
1746779|NCT00152997|Drug|Pramipexole 0.125 mg tablets Placebo|
1746780|NCT00153010|Drug|NS 2330 (Tesofensine)|
1746781|NCT00153023|Drug|Telmisartan|
1746782|NCT00153023|Drug|Valsartan|
1746783|NCT00153036|Drug|rt-PA 0.9 mg/kg verum or placebo Intravenous|
1746784|NCT00153049|Drug|Telmisartan|
1746785|NCT00153049|Drug|Hydrochlorothiazide|
1746786|NCT00153049|Drug|Telmisartan + Hydrochlorothiazide|
1746787|NCT00153062|Drug|Aggrenox|25mg aspirin, 200 mg dipyridamole
1746788|NCT00153062|Drug|Aggrenox|25mg aspirin, 200 mg dipyridamole
1746789|NCT00153062|Drug|Clopidogrel placebo|placebo
1746790|NCT00153062|Drug|Clopidogrel placebo|placebo
1746791|NCT00153062|Drug|Micardis|80 mg micardis
1746792|NCT00153062|Drug|Micardis|80 mg micardis
1746793|NCT00153062|Drug|Aggrenox placebo|placebo
1746794|NCT00153062|Drug|Aggrenox placebo|placebo
1746795|NCT00153062|Drug|Clopidogrel|75 mg clopidogrel
1746796|NCT00153062|Drug|Clopidogrel|75 mg clopidogrel
1746797|NCT00153062|Drug|Micardis placebo|placebo
1746798|NCT00153062|Drug|Micardis placebo|placebo
1746799|NCT00153075|Device|Berodual Respimat|
1746800|NCT00153075|Device|Berodual HFA-MDI|
1746801|NCT00153088|Drug|Telmisartan capsule 40 mg|
1746802|NCT00153088|Drug|Placebo|
1746803|NCT00153088|Drug|Telmisartan capsule 80 mg|
1746804|NCT00153101|Drug|Telmisartan|
1746805|NCT00153101|Drug|Combination of Telmisartan and Ramipril|
1746806|NCT00153101|Drug|Ramipril|
1746807|NCT00153114|Drug|polyethyleneglycol3350|
1746808|NCT00153127|Drug|polyethyleneglycol3350|
1746809|NCT00153140|Drug|polyethyleneglycol3350|
1746810|NCT00153153|Drug|polyethyleneglycol3350|
1746811|NCT00153166|Drug|atorvastatin and pioglitazone|atorvastatin 80 mg orally once daily (to reduce inflammation) and pioglitazone 30 mg orally once daily (to improve insulin sensitivity)
1746812|NCT00153166|Drug|atorvastatin/placebo|atorvastatin 80 mg orally once daily and matching placebo orally twice daily
1746813|NCT00153166|Drug|pioglitazone/placebo|pioglitazone 30 mg orally once daily and matching placebo orally once daily
1746814|NCT00153166|Drug|placebo/placebo|placebo orally three times daily
1746815|NCT00153179|Drug|acipimox|subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit
1746816|NCT00153179|Drug|placebo|matching placebo
1746817|NCT00153192|Drug|Marinol (dronabinol)|
1746818|NCT00153205|Behavioral|computerized physician order entry|
1746819|NCT00153231|Device|IVS|Infracoccygeal sacropexy
1746820|NCT00153231|Procedure|Sacrospinofixation|
1746821|NCT00153244|Drug|Lamotrigine|
1746822|NCT00153257|Device|Ugytex|
1746823|NCT00153270|Drug|Sodium Valproate|
1746824|NCT00159523|Dietary Supplement|Probiotic|
1746826|NCT00159536|Drug|Metformin|Metformin 1000 mg x 2 per day. Orally. From inclusion (before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
1746827|NCT00159536|Drug|Placebo|Placebo, 2 tablets x 2 daily.Orally. From inclusion (that is before gestational week 12) to delivery. Verbal and written diet and lifestyle advices at inclusion to the study
1746828|NCT00159549|Behavioral|education and training program|
1746829|NCT00159562|Behavioral|individual education|individual sessions of psycho-education
1746830|NCT00159562|Behavioral|Group education|group psycho-education in 10 weekly sessions and then a session every third month for two years
1746831|NCT00159575|Drug|Metformin / Placebo treatment for 4 months|M: Metformin 2000mg daily- 12-14 weeks of pretreatment + metformin 2000mg daily through conventional IVF ending on the day of pregnancy test; IE. 14 days after embryo transfer. P: Or identical placebo treatment for the same period
1746832|NCT00159588|Drug|Betablockers or other preventive drugs|Several preventive drugs based on each individual
1746833|NCT00159614|Drug|KW-3902IV|
1746834|NCT00159627|Drug|KW-3902IV|
1746835|NCT00159640|Drug|PD-217,014|
1746836|NCT00159653|Drug|Xalacom|
1746837|NCT00159653|Drug|Xalatan|
1746838|NCT00159653|Drug|Timolol|
1746839|NCT00159666|Drug|pregabalin|
1746840|NCT00159679|Drug|Pregabalin|
1746841|NCT00159692|Drug|Amlodipine|
1746842|NCT00159705|Drug|pregabalin|
1746843|NCT00159718|Drug|amlodipine|
1746844|NCT00159718|Drug|atorvastatin|
1746845|NCT00159731|Drug|Pregabalin|
1746846|NCT00159744|Drug|Asenapine|Asenapine, 3 weeks
1746847|NCT00159744|Drug|Olanzapine|Olanzapine, 3 weeks
1746848|NCT00159744|Drug|Placebo|placebo, 3 weeks
1746849|NCT00159757|Drug|ziprazidone|
1746850|NCT00159770|Drug|ziprasidone versus olanzapine , risperidone or quetiapine|
1746851|NCT00159770|Behavioral|Panss , CGI-C, UKU-SERS-Pa|
1746852|NCT00159770|Procedure|Blood tests|
1746853|NCT00159783|Drug|asenapine|Asenapine, 40 weeks
1746854|NCT00159783|Drug|Olanzapine|Olanzapine, 40 weeks
1746855|NCT00159796|Drug|Asenapine|Asenapine, 3 weeks
1746856|NCT00159796|Drug|Olanzapine|Olanzapine, 3 weeks
1746857|NCT00159796|Drug|Placebo|placebo, 3 weeks
1746858|NCT00159809|Drug|Viagra (Sildenafil citrate)|
1746859|NCT00159822|Drug|Voriconazole|"Voriconazole oral : loading dose on day 1 : 400mg/12 hours; maintenance dose 200 mg /12 hours for 6 to 12 months depending on clinical response.
Alternatively, patients may start on Voriconazole, IV, for 7 days loading dose, 6mg/Kg/12 hours on day one and maintenance dose 4 mg/Kg/12 hours"
1746860|NCT00159835|Drug|atorvastatin|
1746861|NCT00159835|Drug|simvastatin|
1746862|NCT00159848|Behavioral|Treatment Optimization Program (educational material)|
1746863|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
1746864|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.15 MT
1746865|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.15 EE/0.30 MT
1746866|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.30 MT
1746867|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE
1746868|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.30 EE/0.60 MT
1746869|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.45 EE
1746870|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, 0.60 MT
1746871|NCT00160342|Drug|Esterified Estrogens (EE) and Methyltestosterone (MT)|oral tablet, QD, 12 weeks, Placebo
1746872|NCT00160355|Procedure|Hematopoietic stem cell transplantation|To determine the safety in regards to engraftment and toxicity within 100 days of infusing a haploidentical T- and B-cell depleted hematopoietic stem cell graft into patients with Wiskott-Aldrich syndrome who have received a reduced intensity conditioning regimen.
1746873|NCT00160355|Device|Miltenyi CliniMACS selection system|This system depletes the hematopoietic stem cell graft of T and B lymphocytes.
1746874|NCT00160355|Drug|Fludarabine, Melphalan, Thiotepa|Participants will receive a reduced intensity conditioning regimen consisting of Fludarabine, Melphalan, Thiotepa, and OKT3 prior to receipt of the haploidentical stem cell graft. Rituximab will be given in an effort to prevent PTLPD. In addition to T-cell depletion of the donor product, cyclosporine will be given for GVHD prophylaxis.
1746875|NCT00160368|Behavioral|Potassium supplementation|
1746876|NCT00160381|Drug|Asoprisnil|10mg Tablet, oral Daily for 12 months
1746877|NCT00160381|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 months
1746878|NCT00160381|Drug|Placebo|Tablet, oral Daily for 12 months
1746879|NCT00160394|Drug|Duac® Gel / Differin® Gel|
1746880|NCT00160407|Drug|Orlistat (Xenical)|
1746881|NCT00160407|Behavioral|1400 kcal diet (30% fat)|
1746882|NCT00160420|Drug|Asoprisnil|5mg Tablet, oral Daily for 12 months
1746883|NCT00160433|Drug|Asoprisnil|0.5 mg Tablet, oral Daily for 12 weeks
1746884|NCT00160433|Drug|Asoprisnil|1.5 mg Tablet, oral Daily for 12 weeks
1746885|NCT00160433|Drug|Asoprisnil|5.0 mg Tablet, oral Daily for 12 weeks
1746886|NCT00160433|Drug|Placebo|Tablet, oral Daily for 12 weeks
1746887|NCT00160446|Drug|Asoprisnil|5mg Tablet, oral Daily for 12 weeks
1746888|NCT00160446|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
1746889|NCT00160446|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
1746890|NCT00160446|Drug|Placebo|Tablet, oral Daily for 12 weeks
1746891|NCT00160459|Drug|Asoprisnil|5 mg Tablet, oral Daily for 12 weeks
1746892|NCT00160459|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 weeks
1746893|NCT00160459|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 weeks
1746894|NCT00160459|Drug|Placebo|Tablet, oral Daily for 12 weeks
1746895|NCT00160472|Procedure|removal of ovarian vessels|
1746896|NCT00160485|Drug|Glyburide|dosage required to obtain adequate glucose control
1746900|NCT00160524|Biological|Certolizumab Pegol (CDP870)|Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Week 2, and every 4 weeks thereafter until Week 362. Up to 84 months of therapy in this study.
1746901|NCT00160537|Drug|Levocetirizine|
1746902|NCT00160550|Drug|Levetiracetam|
1746903|NCT00160563|Drug|LEVOCETIRIZINE|5mg/mL oral drops, 0.125 mg/kg body weight, bid for 18 months
1746904|NCT00160563|Other|Placebo|Oral drops, bid for 18 months
1746905|NCT00160576|Drug|Levetiracetam|
1746906|NCT00160589|Drug|Levocetirizine|
1746907|NCT00160602|Drug|Certolizumab Pegol|
1746908|NCT00160615|Drug|levetiracetam|
1746909|NCT00160628|Drug|Levetiracetam|
1746910|NCT00160641|Biological|Certolizumab Pegol|"Strength and Form: 1 ml of Liquid product containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.
Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.
Duration: Until end of study."
1746911|NCT00160654|Drug|Levetiracetam|
1746916|NCT00160693|Biological|Certolizumab Pegol|400 mg of Certolizumab Pegol subcutaneously every 4 Weeks
1746917|NCT00160706|Biological|Certolizumab Pegol (CDP870)|"Liquid for subcutaneous injection, 200 mg/ml. 400 mg at Weeks 0, 2, 4 and thereafter every 4 weeks until Week 360.
Up to 84 months of therapy in this study."
1746918|NCT00160719|Procedure|retrieve blood samples|blood samples obtain pre-op, 6 and 12 months post-op
1746919|NCT00160732|Drug|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, celcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
1746920|NCT00160732|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
1746921|NCT00160745|Drug|Rosuvastatin|
1746922|NCT00160758|Procedure|retrieve massive allograft|Allograft constructs removed because of infection or cancer complications will be retained for biomechanical testing
1746923|NCT00160771|Behavioral|Joint Motion Analysis|Joint motion will be recorded for analysis.
1746924|NCT00160784|Procedure|Arthroscopy|Randomized placement into 2 groups; arthroscopic manipulation or home therapy
1746925|NCT00160784|Procedure|Arthroscopic manipulation|Manipulation of shoulder performed during arthroscopy
1746926|NCT00160784|Other|Home therapy|Shoulder exercise program performed at home that may increase shoulder function
1746927|NCT00160797|Device|MIS™ Minimally Invasive Solutions™ TKA System|
1746928|NCT00160823|Procedure|Self-administered leaflet|
1746929|NCT00160836|Device|"Tissue sampling (G.I.U.M. catheter)"|
1746930|NCT00160849|Drug|Lopinavir/r|
1746931|NCT00160862|Drug|SLV317|
1746932|NCT00160875|Drug|Irinotecan hydrochloride trihydrate|Irinotecan (65mg/m2) weeks 1-2, 4-5, 7-8
1746933|NCT00160875|Drug|Cisplatin|Cisplatin (30 mg/m2) weeks 1-2, 4-5, 7-8
1746934|NCT00160888|Drug|sodium nitroprusside, bradykinin, acetylcholine|
1746935|NCT00160901|Drug|two complex naturopathic add-on therapies, leaflet 5-a-day|
1746936|NCT00160914|Behavioral|Identification/management of childhood obesity (behavior)|In this project, we plan to conduct a national survey of pediatricians to assess common strategies for identification and management of childhood obesity, along with pediatricians' attitudes and beliefs about childhood obesity.
1746937|NCT00160927|Device|local heating|
1746938|NCT00160927|Device|iontophoresis|
1746939|NCT00160927|Drug|actylcholine|
1746940|NCT00160927|Drug|sodium nitroprusside|
1746941|NCT00160953|Procedure|Endorectal Coil Magnetic Resonance Images|
1746942|NCT00160966|Drug|Ciclosporin and Mycophenolate-mofetil|according to the Giessen protocol
1746943|NCT00160966|Drug|Tacrolimus and Mycophenolate-mofetil|according to Giessen protocol
1746944|NCT00160966|Drug|Tacrolimus and Mycophenolate-mofetil with change from Mycophenolate-mofetil to Everolimus|according to Giessen protocol
1746945|NCT00160979|Procedure|Pre-treatment tumour oxygen measurements|Pre-treatment tumour oxygen measurements
1746946|NCT00160992|Biological|Melan-A analog peptide|
1746948|NCT00161018|Drug|Quetiapine, Risperidone, Fluphenazine|
1746949|NCT00161031|Drug|Atomoxetine|
1746950|NCT00161044|Drug|Galantamine|
1746951|NCT00161070|Drug|anticoagulation|
1746952|NCT00161070|Drug|aspirin and dipyridamole|
1746953|NCT00161070|Drug|aspirin alone|
1746954|NCT00161083|Drug|ursodeoxycholic acid|
1746955|NCT00161096|Drug|pantoprazole 20 mg (drug)|
1746956|NCT00161122|Biological|trivalent inactivated influenza vaccine|
1746957|NCT00161122|Biological|combined heptavalent pneumococcal conjugate vaccine and trivalent inactivated influenza vaccine|
1746958|NCT00161148|Drug|Probiotics|
1746959|NCT00161187|Biological|therapeutic allogeneic lymphocytes|The total CD3+ cell dose target is 1.8 x 108 CD3+ cells/kg +/- 1.0 x 108 CD3+ cells/kg. Up to 6 cycles.
1746960|NCT00161200|Drug|Ranitidine & Pantoprazole|
1746961|NCT00161213|Drug|gemcitabine hydrochloride|
1746962|NCT00161213|Drug|imatinib mesylate|
1746963|NCT00161226|Device|Levonorgestrel intrauterine system|
1746964|NCT00161239|Drug|Doxil, Methotrexate, L-Asparaginase, Prednisone|
1746965|NCT00161265|Procedure|tissue procurement|tissue procurement
1746966|NCT00161278|Drug|Carboplatin|
1746967|NCT00161278|Drug|Paclitaxel|
1746968|NCT00161278|Procedure|Gene expression profiling (analysis) of tumor samples|
1747095|NCT00162487|Drug|Albuterol (1,200 μg) through metered-dose inhaler|
1746969|NCT00161291|Drug|Letrozole in combination with Bevacizumab|Patients will be administered Letrozole at 2.5 mg PO a day and Avastin at 15 mg/kg IV every 3 weeks for 24 weeks. Patients will then undergo surgical treatment and receive adjuvant therapy according to the treating physician.
1746970|NCT00161304|Drug|Testosterone Enanthate|
1746971|NCT00161317|Behavioral|Living with Hope Program|
1746972|NCT00161330|Drug|oral amoxicilline/clavulanic acid|
1746973|NCT00161330|Drug|iv ceftriaxone|
1746974|NCT00161343|Behavioral|Health Improvement Project for Teens on HIV Prevention|Comparison of 2 facilitator-led intervention groups: (1) HIV prevention, and (2) general health promotion. Outcome measures: sexual risk behaviors in adolescent girls
1746975|NCT00161356|Drug|Ambisome|5mg/kg IV - one time dose during liver transplant
1746976|NCT00161356|Procedure|Liver Biopsy|post drug delivery (60 min. after completion of Ambisome infusion)
1746977|NCT00161382|Behavioral|HIV, STD, and pregnancy prevention curriculum|"This HIV, STD, and pregnancy intervention program entitled, It's Your Game...Keep it Real, consists of 12 lessons delivered in Grades 7 and 8. In each grade, the program integrates group-based classroom activities (e.g., role plays, group discussion, small group activities) with personalized journaling and individual tailored activities delivered on laptop computers. A life skills decision-making paradigm (Select, Detect, Protect) underlies the activities, teaching students to select personal limits regarding risk behaviors, to detect signs or situations that might challenge these limits, and to use refusal skills and other tactics to protect these limits."
1746978|NCT00161382|Behavioral|Standard sexual education curriculum|Control curriculum consists of standard sexual education.
1746979|NCT00161395|Behavioral|Instruction in the Creighton Model Fertility Care System|Instruction in the Creighton Model Fertility Care System.
1746980|NCT00161395|Behavioral|Preconception advice|Preconception advice for diet and frequency of intercourse.
1746981|NCT00161408|Behavioral|cognitive behavioural therapy|
1746982|NCT00161408|Behavioral|psychoeducation|
1746983|NCT00161421|Drug|Oral Testosterone|200 mg (Formulation A) Day 1 400 mg (Formulation A) Day 2, fasting; Day 3, with food 200 mg (Formulation B) Day 8, fasting 400 mg (Formulation B) Day 9, fasting; Day 10, with food
1746984|NCT00161421|Drug|Leuprolide (Lupron)|7.5 mg injection into muscle (once) (Day -14)
1746985|NCT00161421|Drug|Dutasteride|24.5 mg load (3.5 mg x 7 capsulesDay -14 only) 0.5 mg daily (Day -13 to day -1)
1746986|NCT00161434|Drug|valacyclovir|1 gram daily for 8 weeks
1746987|NCT00161434|Drug|placebo|matching placebo for 8 weeks
1746988|NCT00161447|Drug|Acyline|Acyline 300 mcg/kg SQ every 2 weeks for 12 weeks
1746989|NCT00161447|Drug|Testosterone Gel|Testosterone Gel (10 g daily
1746990|NCT00161447|Drug|Depo-Medroxyprogesterone|DMPA (injected into muscle) Day 0 & month 3
1746991|NCT00161460|Behavioral|colorectal cancer screening intervention|Enrolled subjects receive tailored education from a registered nurse who also facilitates ordering and completion of screening tests
1746992|NCT00161473|Drug|prazosin|"Participants taking prazosin. Prazosin was administered as 1 or 2 mg capsules. Doses were initiated at 1 mg at bedtime. Titration based on tolerability was conducted up to a dose of 2 mg in the morning plus 4mg at bedtime.
Duration was 8 weeks."
1746993|NCT00161473|Drug|placebo (inert substance)|Placebo is an inert substance used as a standard comparator in clinical pharmacologic trials. Duration is 8 weeks.
1746994|NCT00161486|Drug|Testosterone gel|Testosterone gel 100 mg daily for 4 weeks
1746995|NCT00161486|Drug|Acyline|Acyline 300 μg/kg every two weeks (2 doses) for 4 weeks
1746996|NCT00161486|Drug|Placebo acyline|Placebo acyline injections every two weeks (2 doses)
1746997|NCT00161486|Drug|Placebo Testosterone gel|placebo testosterone gel daily for 4 weeks
1746998|NCT00161525|Procedure|Pneumatic displacement|Pneumatic displacement of the subretinal hemorrhages is attempted with an intravitreous injection of 0.4 ml of pure C2F6 or 2 injections of 0.2 ml on subsequent days. The gas is withdrawn from a laboratory cylinder through a millipore filter and injected into the eye through a 30 gauge needle inserted 4.0 mm posterior to the limbus in the superior temporal quadrant. The tip of the needle is monitored in the vitreous by indirect ophthalmology prior to injecting the gas.Post injections the central retinal artery is examined whether is patent.The intraocular gas expands 3.3 times over the next 3 days to create a 40% bubble.The patient is asked to assume a gaze position 40° below the horizontal for 20 minutes every hour while awake and to sleep on 2 pillows with his head turned to the right.
1746999|NCT00161538|Device|Pacing leads to be implanted according randomization.|
1747000|NCT00161538|Device|Selection 9000 prevent AF an Diagnose AF|
1747001|NCT00161551|Device|Vitatron T70 DR|
1747002|NCT00161564|Drug|Rituximab|
1747003|NCT00161577|Drug|Ketorolac|Intravenous ketorolac every 6 hours for 24 hours
1747004|NCT00161577|Other|Placebo|Placebo Comparator
1747005|NCT00161590|Drug|CHOP and alemtuzumab|
1747006|NCT00161603|Behavioral|Semi-structured, open-ended interviews|
1747007|NCT00161616|Drug|InductOs|InductOs is rhBMP-2/ACS 1.5 mg/ml implanted once at the time of definitive fracture coverage
1747008|NCT00161629|Drug|rhBMP-2/CPM|
1747009|NCT00161642|Drug|CMD-193|
1747010|NCT00161655|Drug|Etanercept|
1747011|NCT00161655|Drug|Methotrexate|
1747012|NCT00161668|Drug|Mylotarg|
1747013|NCT00161681|Drug|Levonorgestrel/Ethinyl Estradiol|
1747014|NCT00161694|Dietary Supplement|sucrose solution|
1747017|NCT00161733|Drug|Fibrin Sealant Vapor Heated Solvent/Detergent Treated (FS VH S/D)|
1747018|NCT00161733|Drug|TISSEEL VH fibrin sealant|
1747019|NCT00161746|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
1747020|NCT00161759|Drug|Sheet skin grafts affixed with Fibrin Sealant (lyophilized) with 4 IU/mL Thrombin|
1747021|NCT00161772|Biological|Tick-borne Encephalitis Vaccine|
1747022|NCT00161785|Biological|FSME-IMMUN 0.5ml|
1747023|NCT00161798|Biological|Tick-borne encephalitis vaccine|
1747024|NCT00161811|Biological|Vero Cell-derived Influenza Vaccine|
1747025|NCT00161811|Biological|Egg cell-derived Influenza Vaccine|
1747026|NCT00161824|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
1747027|NCT00161837|Biological|Vero Cell-derived Influenza Vaccine|
1747028|NCT00161837|Biological|Egg-derived Influenza Vaccine|
1747029|NCT00161850|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
1747030|NCT00161863|Biological|FSME-IMMUN NEW 0.25 ml|
1747031|NCT00161876|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
1747032|NCT00161889|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
1747033|NCT00161902|Drug|Fibrin Sealant Vapor-Heated Solvent/Detergent-treated|
1747034|NCT00161915|Drug|Fibrin Sealant|
1747035|NCT00161928|Biological|Group C Meningococcal Polysaccharide-Tetanus Toxoid Conjugate Vaccine (GCMP-TT)|
1747036|NCT00161954|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|
1747037|NCT00161967|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive one vaccination with either FSME-IMMUN 0.25 ml or FSME-IMMUN 0.5 ml, depending on their age.
1747038|NCT00161980|Drug|Fibrin Sealant VH S/D|
1747039|NCT00161980|Procedure|Surgical intervention alone without Fibrin Sealant VH S/D application|
1747044|NCT00162032|Drug|Sestamibi|Sestamibi
1747045|NCT00162045|Drug|Technetium Tc99m Sestamibi|Rest and/or stress SPECT imaging study
1747046|NCT00162058|Drug|Peflutren Lipid Microsphere Injectable Suspension|
1747047|NCT00162071|Drug|apadenoson|
1747048|NCT00162084|Drug|apadenoson|
1747049|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
1747050|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
1747051|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
1747052|NCT00162097|Drug|efavirenz containing antiretroviral regimen|Capsule or Tablet, Oral, once daily for 2 days
1747053|NCT00162110|Drug|cetuximab|mg, IV, 225 mg/m2, weekly, 4-52 weeks depending on response.
1747055|NCT00162136|Drug|Ixabepilone|Intravenous (IV) Infusion; 10, 20, 30, 35, 40 & 45 mg/m2, once every 21 days (1 cycle), up to 9 cycles
1747056|NCT00162149|Drug|Nevirapine|Tablets, Oral, 200 mg, Twice daily, 3 days.
1747057|NCT00162149|Drug|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 300/100 mg, twice daily + once daily, 10 days.
1747058|NCT00162149|Drug|Nevirapine + Atazanavir/Ritonavir|Tablets + Capsules/Capsules, Oral, 200 mg + 400/100 mg, twice daily + once daily, 10 days.
1747059|NCT00162149|Drug|Atazanavir + Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
1747060|NCT00162175|Drug|Muraglitazar|
1747061|NCT00162188|Drug|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
1747062|NCT00162201|Drug|Abatacept|Parenteral, IV, 500 mg if < 60 kg; 750 mg if > 60 & < 100 kg; 1000 mg if > 100 kg, Monthly, 4 months.
1747063|NCT00162214|Drug|Dasatinib + Ketoconazole|Tablets, Oral, Segment 1: escalating single dose of dasatinib starting at 140 mg q24 hours on Day 1-8; single dose of ketoconazole 200 mg q12 hours on Days 3-8; Segment 2: single daily oral doses of dasatinib, once daily, until disease progression or unacceptable toxicity.
1747064|NCT00162227|Drug|Efavirenz|Oral Solution, Oral 200 - 600 mg (weight based), once daily. Until further treatment with Sustiva Oral Solution is not warranted.
1747065|NCT00162240|Drug|Muraglitazar|
1747066|NCT00162253|Drug|BMS 587101|
1747067|NCT00162266|Drug|Abatacept (BMS-188667)|IV, 10 mg/Kg, monthly, for the duration of the trial
1747068|NCT00162266|Drug|Abatacept (BMS-188667)|Intravenous (IV) infusion, 2 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
1747069|NCT00162266|Drug|Abatacept (BMS-188667)|Intravenous (IV) infusion, 10 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
1747070|NCT00162266|Drug|Placebo|Intravenous (IV) infusion, 0 mg/kg, infused intravenously for approximately 30 min, infusions on Days 1, 15, 30 and monthly thereafter for 12 months
1747071|NCT00162279|Drug|Abatacept|
1747072|NCT00162292|Drug|BMS-582949 and Methotrexate|
1747073|NCT00162305|Drug|BMS-512148|Capsules, Oral, 100 mg, Once daily, 14 days.
1747074|NCT00162305|Drug|BMS-512148|Capsules, Oral, 25 mg, Once daily, 14 days.
1747075|NCT00162305|Drug|BMS-512148|Capsules, Oral, 5 mg, Once daily, 14 days.
1747076|NCT00162305|Drug|Placebo|Capsules, Oral, 0 mg, Once daily, 14 days.
1747077|NCT00162318|Drug|Cetuximab + Gefitinib|IV solution + tablet, IV + oral, ERB (100 mg/m2, 200 mg/m2 + 250 mg/m2 IV) +GEF 250 mg tablet, ERB weekly/ GEF once daily, Until disease progression.
1747078|NCT00162331|Drug|Technetium Tc99m Sestamibi|
1747079|NCT00162344|Drug|Technetium Tc99m Sestamibi|
1747080|NCT00162357|Drug|Technetium Tc99m Sestamibi|
1747081|NCT00162370|Drug|Perflutren Lipid Microsphere Injectable Suspension|Activated DEFINITY 10ug/kg by bolus injection
1747082|NCT00162383|Drug|Debrisoquine|
1747083|NCT00162383|Drug|Mephenytoin|
1747084|NCT00162383|Drug|Dapsone|
1747085|NCT00162383|Drug|Caffeine|
1747086|NCT00162396|Drug|Albuterol|
1747087|NCT00162409|Drug|Folic acid|
1747088|NCT00162422|Drug|albuterol|
1747089|NCT00162435|Drug|Warfarin|
1747090|NCT00162448|Drug|BMS-394136|Oral Solution, Oral, 100 mg, Single dose, 1 day.
1747091|NCT00162448|Drug|Placebo|Oral Solution, Oral, 0 mg, Single dose, 1 day.
1747092|NCT00162461|Drug|Phenytoin single dose (300 mg)|
1747093|NCT00162474|Drug|Warfarin|
1747094|NCT00162474|Drug|Phenytoin|
1747096|NCT00162500|Biological|Peptide Vaccine (MUC-1)|
1747097|NCT00162513|Biological|Allogeneic tumor cell vaccine|
1747098|NCT00162526|Drug|Tocopherol|
1747099|NCT00162539|Other|echography|Correlation of neonatal thyroid volume with maternal iodine deficiency
1747100|NCT00162552|Drug|pentoxifylline|Patients with severe cirrhosis treated with Pentoxifylline
1747101|NCT00162552|Drug|PLACEBO|Patients with severe cirrhosis treated with a placebo
1747102|NCT00162565|Drug|beta-blocker treatment|beta-blocker treatment
1747103|NCT00162591|Drug|remifentanyl|
1747104|NCT00162604|Drug|Cefuroxime|
1747105|NCT00162617|Drug|Red blood cell transfusion|
1747106|NCT00162630|Procedure|Fascia Iliaca Compartment Blockade|
1747107|NCT00162643|Drug|zidovudine+lamivudine+lopinavir/ritonavir|
1747108|NCT00162643|Drug|zidovudine + lamivudine + efavirenz|
1747109|NCT00162656|Drug|half cyclophosphamide|
1747110|NCT00162656|Drug|without COPADM3|
1747111|NCT00162656|Drug|mini CYVE, without 3 maintenance courses|
1747112|NCT00162656|Drug|LMB B|
1747113|NCT00162656|Drug|LMB C|
1747114|NCT00162669|Drug|bevacizumab|
1747115|NCT00162682|Procedure|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment will use the standard viral load (VL) based monitoring strategy, where switching is performed when VL is confirmed (within one month) above 400 copies per mL.
1747116|NCT00162682|Procedure|Antiretroviral Drug Combination Switching Criteria|Antiretroviral treatment is monitored using a CD4 based monitoring strategy where switching is performed when a confirmed (within one month) relative decline in CD4 count of more than 30% from peak values is observed within 200 cells from baseline.
1747117|NCT00162695|Drug|Ifosfamide, oncovin, actinomycine D, epirubicine, carboplatinum, etoposide|
1747118|NCT00162708|Procedure|Radiotherapy 62-64 Gy in 5 W (31-32 f. of 2 Gy BID)|
1747119|NCT00162708|Procedure|Radiotherapy 62-64 Gy in 22-23 D (31-32 f of 2 Gy BID)|
1747120|NCT00162708|Drug|CDDP, 5 Fu|
1747121|NCT00162721|Drug|doxorubicin, ifosfamide, cisplatin|
1747122|NCT00162734|Drug|Daily Infergen (Interferon Alfacon-1, CIFN) (9 or 15 µg) + Ribavirin (1000-1200 mg, based on body weight) PO Daily for up to 48 wks|
1747123|NCT00162747|Drug|Aquaphor|
1747124|NCT00162747|Drug|Sunflower Seed Oil|
1747125|NCT00162760|Drug|Thalidomide|
1747126|NCT00162773|Drug|omalizumab|150-375 milligrams administered by subcutaneous injection every 2-4 weeks depending on body weight and serum IgE.
1747127|NCT00162773|Other|Placebo|150-375 milligrams depending on body weight and serum IgE.
1747128|NCT00162786|Drug|Rupatadine|
1747129|NCT00162786|Drug|Hydroxyzine|
1747130|NCT00162786|Drug|Placebo|
1747131|NCT00162799|Drug|Triflusal (DCI)|
1747132|NCT00162812|Drug|Epirubicin|100 mg/m² every three weeks (4 cycles) or every two weeks (6 cycles)
1747133|NCT00156117|Drug|asenapine|5 mg BID or 10mg BID
1747134|NCT00156117|Drug|Placebo|Placebo
1747135|NCT00156117|Drug|olanzapine|olanzapine 15 mg QD
1747136|NCT00156130|Radiation|Conventional radiotherapy schedule|50 Gy in 25 fractions over 35 days
1747137|NCT00156130|Radiation|Accelarated radiotherapy schedule|42.5 Gy in 16 fractions over 22 days
1747138|NCT00156143|Procedure|Blood sample|
1747139|NCT00156143|Procedure|Radiography|
1747140|NCT00156156|Drug|Asoprisnil|Asoprisnil 10 mg Tablet, oral Daily for up to 2 years
1747141|NCT00156156|Drug|Asoprisnil|Asoprisnil 25 mg Tablet, oral Daily for up to 2 years
1747142|NCT00156169|Drug|Dunaliella|
1747143|NCT00156182|Drug|Asoprisnil|10mg Tablet, oral Daily for 6 months
1747144|NCT00156195|Drug|Asoprisnil|10 mg Tablet, oral Daily for 12 months
1747145|NCT00156195|Drug|Asoprisnil|25 mg Tablet, oral Daily for 12 months
1747146|NCT00156208|Drug|Asoprisnil|10mg Tablet, oral Daily for 18 months
1747147|NCT00156208|Drug|Asoprisnil|25 mg Tablet, oral Daily for 18 months
1747148|NCT00156234|Behavioral|One-knee extension ergometer|
1747149|NCT00156247|Drug|acitretin|Patients who have been taking etanercept 50 mg/week for at least 3 months (12 weeks) will take acitretin 25 mg pill once daily for 6 months.
1747150|NCT00156260|Procedure|Ductal lavage|
1747151|NCT00156286|Drug|Gleevec|
1747152|NCT00156299|Drug|choline magnesium trisalicylate|1500mg orally every 8 hours beginning at hour 0 and continuing until hour 48.
1747153|NCT00156299|Drug|Dexamethasone|10mg orally every 6 hours beginning at hour 0 and continuing until hour 48.
1747154|NCT00156312|Drug|Docetaxel|
1747155|NCT00156312|Drug|Capecitabine|
1747156|NCT00156325|Drug|Escitalopram (Lexapro)|
1747157|NCT00156338|Procedure|fluid management|volume and sodium restriction
1747158|NCT00156338|Procedure|fluid management|volume restriction
1747159|NCT00156338|Procedure|fluid management|liberal fluid management
1747160|NCT00156351|Behavioral|Physical activity promotion|
1747161|NCT00156377|Drug|Mupirocin|
1747162|NCT00156390|Device|echo-guided left ventricular lead placement|placement of the LV lead of the biventricular pacing device under echocardiographic guidance
1747163|NCT00156390|Other|LV lead placement as per standard of care (without echo guidance)|
1747164|NCT00156403|Drug|amlodipine (drug)|
1747165|NCT00156416|Behavioral|Mindfulness Meditation|8 weeks of meditation training
1747166|NCT00156468|Behavioral|Provider Prompt|
1747167|NCT00156507|Behavioral|Asthma education for parents of very low birth weight infants|Asthma education is provided to parents of children in the experimental group prior to nicu discharge.
1747168|NCT00156520|Drug|aprotonin; epsilon aminocaproic acid|
1747169|NCT00156533|Drug|Zolpidem|10 mg of Zolpidem
1747170|NCT00156533|Drug|Sugar Pill|
1747171|NCT00156546|Drug|antibiotic to reduce the recurrence of infection|
1747172|NCT00156572|Procedure|Sodium supplementation|
1747173|NCT00156572|Procedure|Fluid restriction|
1747174|NCT00156611|Procedure|Balloon Angioplasty|
1747175|NCT00156611|Drug|ReoPro|
1747176|NCT00156624|Drug|Balloon Angioplasty with or without drug administration|
1747177|NCT00156637|Behavioral|Team-Based Quality Improvement Intervention|Intervention to improve recommended dosing and side effect monitoring of antipsychotic medications using a team-based quality improvement effort
1747178|NCT00156637|Behavioral|Opinion Leader Intervention|Intervention to improve recommended dosing and side effect monitoring of antpsychotic medications using an Opion leader quality improvement effort
1747179|NCT00156637|Behavioral|Team Based Quality Improvement|Intervention to increase appropriate use of clozapine through a team based quality intervention.
1747180|NCT00156650|Drug|Acyline|Acyline 300 mcg/kg SQ(Subcutaneously)twice monthly for 12 weeks
1747181|NCT00156650|Drug|Testosterone Gel|Testosterone (T) gel 10 g daily for 6 months
1747182|NCT00156650|Drug|Depo-Medroxyprogesterone|300 mg IM every 3 months
1747183|NCT00156663|Behavioral|Caring for Women Veterans|
1747184|NCT00156676|Device|Body-weight supported treadmill|
1747185|NCT00156676|Device|Lokomat|
1747186|NCT00156676|Device|Body-weight supported treadmill|
1747187|NCT00156676|Device|Lokomat|
1747188|NCT00156689|Drug|levetiracetam|
1747189|NCT00156702|Behavioral|Feedback and Motivational Interviewing|
1747190|NCT00156702|Behavioral|Smoking Prevention Video|
1747191|NCT00156715|Drug|Quetiapine|After patients provided informed consent and completed baseline measures, quetiapine was initiated in all participants and titrated up to a target dose of 600 mg (in divided daily doses) over two weeks as the previous antipsychotic medication was slowly tapered and discontinued. Participants met with study physicians weekly to assess tolerability and response to the medication. Concomitant medications were held constant. After the initial titration period, quetiapine was dosed in a flexible manner up to 800 mg /day, with dose adjustments based on symptomatic response and side effects.
1747192|NCT00156728|Device|Vitatron biventricular pacemaker|
1747193|NCT00156741|Device|Vitatron C50 D Model C50A2 of Vitatron C60 DR model C60A2|
1747194|NCT00156741|Procedure|Required pacemaker setting|
1747195|NCT00156780|Drug|AI-700|
1747196|NCT00156793|Procedure|AI-700 contrast-enhanced echocardiography|
1747197|NCT00156806|Procedure|Aloe barbadensis topical application in a moisturizing cream vehicle.|
1747198|NCT00156819|Drug|fluticasone|fluticasone (100 microgram twice daily) treatment
1747199|NCT00156819|Drug|montelukast|Montelukast (5 or 10 mg each night).
1747200|NCT00156819|Drug|Fluticasone plus salmeterol|fluticasone (100 microgram) plus salmeterol (50 microgram) each night
1747201|NCT00156845|Procedure|AI-700 contrast-enhanced echocardiography|
1747202|NCT00156858|Drug|intravenous busulfan|
1747203|NCT00156871|Behavioral|exercise|
1747204|NCT00156884|Drug|strontium-89|
1747205|NCT00156884|Drug|cisplatin|
1747206|NCT00156897|Drug|ATL-962|
1747207|NCT00156897|Drug|Orlistat|
1747208|NCT00162851|Drug|alemtuzumab|
1747209|NCT00162864|Drug|montelukast sodium|
1747210|NCT00162877|Drug|Rabeprazole vs. Esomeprazole|
1747211|NCT00162890|Behavioral|Therapeutic exercise|
1747212|NCT00162916|Drug|citalopram|20mg or 40mg, once daily, for 40 weeks
1747213|NCT00162916|Drug|Placebo|Cornstarch
1747214|NCT00162929|Biological|AdHer-2/neu transduced dendritic cells|Group 1 1 ×10'7 expanded cells (2.5 ×106 DCs per injection site) Group 2 5 ×10'7 expanded cells (1.25 ×107 DCs per injection site) Group 3 1 ×10'8 expanded cells (2.5 ×107 DCs per injection site)
1747215|NCT00162942|Device|Adacolumn|"Ten apheresis sessions:
One hour of Adacolumn Apheresis System procedure per visit. Patient had two procedures per week for the first two weeks followed by one apheresis session per weeks for two weeks (Weeks 1-4). then a week break occurs for rest followed by one apheresis session per week for 4 weeks (weeks 6-9)."
1747216|NCT00162942|Device|Sham|Sham, ten apheresis sessions within 9 weeks
1747217|NCT00162955|Drug|Valsartan|Patients allocated into ARB administration group take Valsartan (80mg/day) from the day of the start of 1st CHOP until the completion of all the evaluations.
1747218|NCT00162968|Drug|escitalopram|
1747219|NCT00162981|Drug|Clobazam Low Dose|5 to 10 mg/day with doses in the morning and at bedtime; orally
1747220|NCT00162981|Drug|Clobazam High Dose|5 to 40 mg/day with doses in the morning and at bedtime; orally
1747221|NCT00162994|Procedure|adenoidectomy and tymapanostomy|
1747222|NCT00163007|Procedure|Nutritional support|
1747223|NCT00163020|Drug|17-alpha-hydroxyprogesterone caproate injectable|250mg of 17-alpha-hydroxyprogesterone caproate (+ preservatives) injectable weekly starting as early as 19wks gestation until 34.0wks gestation of delivery which ever comes first.
1747224|NCT00163020|Drug|Placebo|Weekly doses of placebo (NS + preservatives) via injection as early as 19weeks until 34.0weeks gestation or delivery which ever comes first.
1747225|NCT00163033|Drug|estetrol|
1747226|NCT00163046|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime for 28 days
1747227|NCT00163046|Drug|Placebo|Matched placebo 30 minutes prior to bedtime for 28 days
1747228|NCT00163059|Drug|NMDA Antagonist, CP-101,606 (traxoprodil)|
1747229|NCT00163072|Drug|transdermal Megace|oral vs transdermal levels
1747230|NCT00163085|Drug|NR2B NMDA Antagonist CP-101,606 (traxoprodil)|
1747231|NCT00163098|Drug|UK-369,003|
1747232|NCT00163111|Drug|VFENDÂ® I.V., Oral|
1747233|NCT00163111|Drug|Conventional amphotericin B|
1747234|NCT00163111|Drug|Diflucan IV, oral|
1747235|NCT00163124|Procedure|spinal manipulation & patient education/nutrition|
1747236|NCT00163137|Drug|lasofoxifene|lasofoxifene 0.25mg
1747237|NCT00163137|Drug|raloxifene|raloxifene 60 mg/day
1747238|NCT00163137|Drug|Placebo|0 mg/day
1747239|NCT00163150|Drug|Atorvastatin|
1747240|NCT00163163|Procedure|Echographic measurements|
1747241|NCT00163163|Procedure|Blood samples|
1747242|NCT00163462|Drug|Ciclesonide|
1747243|NCT00163475|Drug|Roflumilast|
1747244|NCT00163488|Drug|Ciclesonide|
1747245|NCT00163501|Drug|Ciclesonide|
1747246|NCT00163514|Drug|Ciclesonide|
1747247|NCT00163527|Drug|Roflumilast|
1747336|NCT00164463|Drug|Isoniazid|isoniazid 300 mg po qd 5/7 days per week
1747248|NCT00163540|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
1747249|NCT00163553|Drug|Pethidine|
1747250|NCT00163553|Drug|Placebo|
1747251|NCT00163566|Drug|Dihydrotestosterone (0.7%) in hydroalcoholic gel|transdermal gel, 0.7% DHT, 0.35 mg/day or 0.70 mg/day total daily dose (or placebo gel), applied twice per day
1747252|NCT00163579|Drug|Bryophyllum|
1747253|NCT00163592|Drug|Tissucol®|
1747254|NCT00163592|Procedure|Control: Conventional treatment, i.e. compression with swabs|
1747255|NCT00163605|Device|Macroporous Biphasic Calcium Phosphate-Fibrin Sealant Vapor Heated Solvent/Detergent Treated 4 IU/ML Thrombin (MBCP-FS)|
1747256|NCT00163618|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
1747257|NCT00163644|Procedure|aereobic plus resisted exercise|
1747258|NCT00163644|Procedure|aerobic plus active exercise|
1747259|NCT00163644|Other|No formal exercise plus phone calls|
1747260|NCT00163657|Drug|Daclizumub|anti-rejection drug
1747261|NCT00163657|Drug|Tacrolimus|anti rejection drug
1747262|NCT00163657|Drug|Cyclosporine|anti rejection drug
1747263|NCT00163657|Drug|MMF|anti rejection drug
1747264|NCT00163683|Behavioral|Dietary Therapy|
1747265|NCT00163709|Procedure|BNP test|
1747266|NCT00163722|Other|Culture and histology|
1747267|NCT00163722|Other|Aspergillus galactomannan and PCR|
1747268|NCT00163735|Drug|Administration of wine fined with potential food allergens|
1747269|NCT00163748|Drug|gemcitabine, vinorelbine|
1747270|NCT00163761|Drug|gemcitabine, vinorelbine, ifosfamide, filgastrim|Drug
1747271|NCT00163761|Drug|gemcitabine, vinorelbine, filgastrim|Drug
1747272|NCT00163774|Device|Brain oxygenation and microdialysis catheters|
1747273|NCT00163787|Behavioral|outcome measures and self report|
1747274|NCT00163813|Procedure|Early jejunal feeding (using frictional NJ tube)|
1747275|NCT00163813|Procedure|Standard feeding (using nasogastric [NG] tube)|
1747276|NCT00163839|Behavioral|Dietary Therapy|
1747277|NCT00163852|Drug|Normal saline IV, salt tablets|
1747278|NCT00163878|Procedure|Sensory Stimulation|
1747279|NCT00163878|Device|Sesnory Modality Assessment and Rehabilitation Technique|
1747280|NCT00163891|Behavioral|Chest physiotherapy|
1747281|NCT00163904|Behavioral|High mono-unsaturated fat/low carbohydrate diet|
1747282|NCT00163904|Behavioral|High carbohydrate/low fat diet|
1747283|NCT00163917|Device|Virtual reality relaxation|
1747284|NCT00163943|Behavioral|Dietary weight loss +/- aerobic exercise|
1747285|NCT00163969|Drug|ketamine|
1747286|NCT00163982|Drug|Norfloxacin|
1747287|NCT00163995|Drug|urotensin II|
1747288|NCT00164008|Drug|zoledronic acid vs pamidronate|
1747289|NCT00164021|Procedure|Physiotherapy, exercise, percutaneous gastrostomy feeds|
1747290|NCT00164021|Drug|Anti-reflux pharmacotherapy|
1747291|NCT00164034|Device|Real time computer prompted trauma algorithms|
1747292|NCT00164047|Drug|Nitrous Oxide|
1747293|NCT00164073|Procedure|Liver biopsy|
1747294|NCT00164086|Drug|atorvastatin|
1747295|NCT00164099|Drug|Synbiotic 2000|See protocol - 4 bacteria, 4 fiber mixture
1747296|NCT00164112|Drug|Cooperstown 5+1 alone|
1747297|NCT00164112|Drug|Azithromycin plus Cooperstown 5+1|
1747298|NCT00164112|Drug|Telithromycin plus Cooperstown 5+1|
1747299|NCT00164112|Drug|Levofloxacin plus Cooperstown 5+1|
1747300|NCT00164125|Drug|polyethyleneglycol3350|
1747301|NCT00164138|Procedure|Pelvic floor training group|pelvic floor training, electrotherapy, bladder retraining.
1747302|NCT00164151|Drug|HalfLytely|
1747303|NCT00164151|Drug|Visicol|
1747304|NCT00164164|Drug|HalfLytely|
1747305|NCT00164164|Drug|NuLytely|
1747306|NCT00164177|Drug|HalfLytely|
1747307|NCT00164190|Procedure|Routine Early Percutaneous Coronary Intervention after Thrombolysis|early or delayed PCI
1747308|NCT00164203|Behavioral|Cognitive Behavioral Therapy|12-session, weekly, school-based protocol based on cognitive restructuring, tailored to children Grades 3 to 6; comparison with activity control condition of equal duration.
1747309|NCT00164203|Behavioral|School-based CBT|12 sessions, weekly
1747310|NCT00164203|Behavioral|activity control condition|weekly games & activities x 12 weeks
1747311|NCT00164216|Drug|mefloquine plus artesunate|
1747312|NCT00164229|Behavioral|math|
1747313|NCT00164229|Behavioral|behavior regulation|
1747314|NCT00164242|Drug|Galantamine|
1747315|NCT00164255|Drug|sulfadoxine/pyrimethamine|
1747316|NCT00164255|Drug|sulfadoxine/pyrimethamine plus artesunate|
1747317|NCT00164268|Behavioral|Ke Ala Lokahi (Native Hawaiian cultural intervention)|
1747318|NCT00164281|Drug|Isoniazid|Daily 300 mg isoniazid supplemented with 25 mg pyridoxine for 6 months vs 36 months.
1747319|NCT00164294|Behavioral|Brief intervention|
1747320|NCT00164307|Behavioral|Parent assisted social skills training|
1747321|NCT00164320|Behavioral|TEAM|
1747322|NCT00164333|Behavioral|TAP: Treatment Advocacy Program|
1747323|NCT00164346|Behavioral|neurocognitive habilitation|
1747324|NCT00164359|Drug|Amodiaquine plus artesunate|
1747325|NCT00164359|Drug|chlorproguanil-dapsone plus artesunate|
1747326|NCT00164372|Behavioral|Peer Education Intervention|
1747327|NCT00164385|Behavioral|Adolescent Impact|
1747328|NCT00164398|Behavioral|HIP: HIV Intervention for Providers|
1747329|NCT00164411|Biological|Tetanus-diphtheria toxoids (Td)|
1747330|NCT00164411|Biological|7-valent pneumococcal conjugate vaccine|
1747331|NCT00164411|Biological|23-valent polysaccharide vaccine|
1747332|NCT00164424|Drug|Acyclovir|
1747333|NCT00164437|Behavioral|educational CD-ROM|
1747334|NCT00164450|Drug|Rifapentine + isoniazid once weekly for 3 months|
1747335|NCT00164463|Drug|Moxifloxacin|400 mg po qd 5/7 days per week
1747337|NCT00164476|Behavioral|Preventive Services Prevention Kit|
1747338|NCT00164476|Behavioral|peer mentors (control group)|
1747339|NCT00164489|Behavioral|Weight control and physical activity promotion|
1747340|NCT00164502|Behavioral|Community-based eight session group self-management program|
1747341|NCT00164515|Behavioral|Personalized exercise programme (PEP)|Physician referred overweight and obese clients to 24 month personalized exercise programme at the U. of Illinois, Chicago
1747342|NCT00164528|Behavioral|Positive Behavior Support|
1747343|NCT00164541|Behavioral|Arts Based Program|
1747344|NCT00164541|Behavioral|Curriculum|
1747345|NCT00164554|Behavioral|Parent-child Interaction Therapy (PCIT)|
1747346|NCT00164567|Behavioral|Onsite IPV specialist|
1747347|NCT00164567|Behavioral|Empowerment focused intervention|
1747348|NCT00164580|Behavioral|Community-Level Intervention|
1747349|NCT00164593|Behavioral|Youth Empowerment Solutions for Peaceful Communities|YES is a multi-faceted program that (1) engages 7th and 8th graders in a youth development program, (2) enhances neighborhood organizations' ability to include youth in their activities, and (3) connects the youth participants and adults in neighborhood organizations (e.g., crime watches, block groups, neighborhood associations) to carry out neighborhood improvement activities (e.g., community gardens, parks cleanup).
1747350|NCT00164606|Behavioral|Positive Parenting Program (Triple-P)|
1747351|NCT00164619|Behavioral|VOICES/VOCES|45-minute intervention for small groups of African American and Hispanic heterosexual men and women. Group members are same gender and race/ethnicity. View culturally-specific condom promotion video. Facilitated group discussion to build skills in condom use and condom negotiation. Education on condom varieties to overcome participants' personal barriers to condoms use. Distribution of 3 specialty condoms of participant's choice (i.e., different sizes, textures, thicknesses, lubrication, material). [see Brief Summary above]
1747352|NCT00164619|Biological|Standard STD clinic services|Individual physical exam, STD/HIV tests, treatment as indicated
1747353|NCT00164632|Behavioral|counselling, exercise, referrals (behavior)|
1747354|NCT00164645|Behavioral|Problem Solving intervention|
1747355|NCT00164658|Behavioral|Familial risk assessment and personalized prevention messages|
1747356|NCT00164671|Behavioral|POWER|
1747357|NCT00164684|Behavioral|Father Friendly Initiative|
1747358|NCT00164697|Behavioral|Parenting group|Weekly and periodic (10 weeks blocks with 6 week break) parenting group meetings (2.5-3 hr), periodic one-on-one meetings (2 hr), visits to community resources (2-3 hr per event). Legacy intervention activities are designed to enhance sensitive and responsive parenting, parent/child interaction, and promote a sense of community. Other activities include verbal and cognitive stimulation through parent and parent/child group meetings, visits to the home, and participation in community events.
1747359|NCT00164710|Drug|sulfadoxine-pyrimethamine|
1747360|NCT00164710|Drug|amodiaquine plus sulfadoxine-pyrimethamine|
1747361|NCT00164710|Drug|amodiaquine plus artesunate|
1747362|NCT00164710|Drug|chlorproguanil-dapsone plus artesunate|
1747363|NCT00164710|Drug|lumefantrine-artemether|
1747364|NCT00164723|Procedure|Capsule endoscopy|Capsule endoscopy and colonoscopy
1747365|NCT00164736|Drug|Maternal zidovudine/lamivudine/lopinavir-ritonavir|Total daily dose: zidovudine 600mg, lamivudine 300mg, (taken as Combivir 1 tab twice a day with food). Lopinavir/ritonavir 400/100mg (taken as 2 tabs twice a day). Commencing after delivery and through to 28 weeks.
1747366|NCT00164736|Drug|Infant nevirapine|"Nevirapine suspension once daily dose. 0-14days: 10mg; 3-18weeks: 20mg; 19-28weeks: 30mg.
To 28 weeks while breastfeeding."
1747367|NCT00164736|Dietary Supplement|Maternal protein and calorie supplement|High energy, nutrient-dense, micronutrient fortified nutritional supplement. Daily: Energy 700kcal, Protein 20g, 100% of recommended dietary allowance for all micronutrients during the 6 months of lactation. Vitamin A is excluded.
1747368|NCT00164749|Drug|Placebo and ginkgo extract|Placebo once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
1747369|NCT00164749|Drug|Curcumin and ginkgo extract|1 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
1747370|NCT00164749|Drug|Curcumin and ginkgo extract|4 g curcumin once daily, either as capsules or as powder to be mixed with food. All patients also received 120 mg/day standardized ginkgo leaf extract.
1747371|NCT00164775|Drug|Imipramine|25mg nocte for first 2 weeks then 50 mg nocte for 10 weeks
1747372|NCT00164775|Drug|Placebo|One tab nocte for first 2 weeks then 2 tabs for 10 weeks
1747373|NCT00164788|Drug|Intravenous bolus injection of esomeprazole|80mg followed by continuous intravenous infusion of 8mg per hour for 24 hours
1747374|NCT00164788|Drug|Oral esomeprazole|40mg every 12 hours for 24 hours
1747375|NCT00164801|Drug|Baclofen, Diltiazem|
1747376|NCT00164827|Device|Endoscopic placement of Capsule endoscope adjacent to the peptic ulcer|
1747377|NCT00164840|Drug|Esomeprazole|
1747378|NCT00164853|Procedure|endoscopic balloon dilatation|Refer to description under arms
1747379|NCT00164853|Procedure|Standard sphincterotomy|Refer to under arms
1747380|NCT00164866|Drug|Omeprazole|
1747381|NCT00164879|Procedure|Endoscopic stenting followed by elective laparoscopic resection|
1747382|NCT00164892|Drug|Oral Vioxx (Rofecoxib)|
1747383|NCT00164905|Device|Doppler ultrasound probe|Applying to ulcer base to assess the blood flow underneath the ulcer
1747384|NCT00164918|Device|nasogastric tube|
1747385|NCT00164931|Drug|Intravenous omeprazole infusion|
1747386|NCT00164931|Procedure|Scheduled second endoscopy|
1747387|NCT00164944|Procedure|Colonoscopy|To determine the adenomas during colonoscopy
1747388|NCT00164944|Procedure|Colonoscopy|To determine the adenomas during colonoscopy
1747389|NCT00164957|Device|continuous pump feeding|
1747390|NCT00164957|Other|intermittent bolus feeding|
1747391|NCT00164970|Dietary Supplement|Vitamin B12|
1747392|NCT00164970|Dietary Supplement|folate|
1747393|NCT00164996|Procedure|Local pharyngeal anaesthesia|
1747394|NCT00164996|Device|Ultrathin endoscope|
1747623|NCT00167700|Dietary Supplement|Probiotics|
1747395|NCT00165009|Device|Resolution clip (endo-clipping device)|Resolution clip (endo-clipping device)
1747396|NCT00165035|Device|CoStar Paclitaxel Drug Eluting Coronary Stent System|Drug eluting stent
1747397|NCT00165035|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent|Drug eluting stent
1747398|NCT00165048|Drug|Vioxx (Rofecoxib)|
1747399|NCT00165061|Procedure|Esophagectomy|
1747400|NCT00165061|Procedure|Chemoradiation|
1747401|NCT00165074|Drug|Infasurf (drug)|Infasurf 3 cc/kg instilled via endotracheal tube q 12-24 hours x 2 doses
1747402|NCT00165087|Drug|asparaginase (E. Coli)|
1747403|NCT00165087|Drug|asparaginase (Erwina)|
1747404|NCT00165087|Drug|dexrazoxane|
1747405|NCT00165087|Drug|doxorubicin|
1747406|NCT00165087|Procedure|cranial radiation (once daily fractionation)|
1747407|NCT00165087|Procedure|cranial radiation (twice-daily fractionation)|
1747408|NCT00165087|Procedure|Intrathecal chemotherapy without radiation|
1747409|NCT00165100|Procedure|Dynamic Area Telethermometry (DAT)|
1747410|NCT00165126|Procedure|Radiation therapy|Given as standard therapy
1747411|NCT00165139|Drug|Vincristine|Described under detailed description
1747412|NCT00165139|Drug|Cyclophosphamide|Described under detailed description
1747413|NCT00165139|Drug|Adriamycin|Described under detailed description
1747414|NCT00165139|Drug|Etoposide (VP-16)|Described under detailed description
1747415|NCT00165139|Drug|Cisplatin|Described under detailed description
1747416|NCT00165139|Drug|Carboplatin|Described under detailed description
1747417|NCT00165139|Drug|Melphalan|Described under detailed description
1747418|NCT00165139|Drug|Ifosfamide|Described under detailed description
1747419|NCT00165139|Drug|G-CSF (granulocyte-colony stimulating factor)|Described under detailed description
1747420|NCT00165139|Drug|Mesna|Described under detailed description
1747421|NCT00165152|Procedure|Genetic Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
1747422|NCT00165152|Procedure|Informed Consent Counseling|Two visits with a specially trained genetic counselor or nurse in conjunction with a medical oncologist and/or a medical specialist will be done in which information will be given either about genetic counseling or enhanced informed consent. These visits will be audio-taped to monitor how the project staff is covering the important information about testing.
1747423|NCT00165178|Drug|prednisone|Induction Phase: Given orally or intravenously Days 0-28 Intensification Phase: Given orally Days 1-5 of each cycle Continuation Phase: Given orally Days 1-5 of each cycle
1747424|NCT00165178|Drug|dexamethasone|Intensification Phase: Given orally days 1-5 of each cycle Continuation Phase: Given orally days 1-5 pf each cycle
1747425|NCT00165178|Drug|doxorubicin|Induction Phase: Intravenously on Days 0,1 Intensification Phase: Intravenously on Day 1 of each cycle
1747426|NCT00165178|Drug|E. coli asparaginase|Intensification Phase: In the muscle weekly. Dose will vary
1747427|NCT00165178|Drug|vincristine|Induction: Intravenously on days 0, 7, 14, 21 MLL Intensification Phase: Intravenously on Days 1, 8, 15, 22 CNS Therapy: Intravenously on Day 1 Intensification Phase: Intravenously on day 1 of each cycle Continuation Phase: Intravenously on Day 1 of each cycle
1747428|NCT00165178|Drug|methotrexate|Induction: Intravenously on Day 2 MLL Intensification: Intravenously on Days 1, 8 Intensification: (when doxorubicin completed) Intravenously or into the muscle weekly Continuation: Intravenously or into the muscle weekly
1747429|NCT00165178|Drug|Leucovorin|Induction Phase: Intravenously or orally begins 36 hours after methotrexate MLL Intensification: Intravenously or orally begins 36 hours after methotrexate
1747430|NCT00165178|Drug|Asparaginase|Induction: Into the muscle on Day 4 MLL Intensification: Into the muscle on Days 16, 23
1747431|NCT00165178|Drug|cytarabine|Induction: Intrathecal on Days 0, 14, 28 MLL Intensification: Intravenously on Days 15, 16, 22, 23
1747432|NCT00165178|Drug|Methotrexate/Hydrocortisone|Induction: Intrathecal on Days 14, 28 MLL Intensification: Intrathecal on Days 2,9
1747433|NCT00165191|Drug|Doxorubicin|
1747434|NCT00165191|Drug|Cisplatin|
1747435|NCT00165191|Drug|5-fluorouracil|
1747436|NCT00165204|Drug|Tibolone|
1747437|NCT00165217|Drug|Capecitabine|
1747438|NCT00165217|Drug|Thalidomide|
1747439|NCT00165230|Drug|Thalidomide|
1747440|NCT00165230|Drug|Temodar|
1747441|NCT00165243|Procedure|Tangential radiation|Radiation given over 6 1/2 weeks
1747442|NCT00165256|Other|Observation|Wide excision of DCIS and a minimum of 1cm histologically negative margin of breast tissue
1747443|NCT00165269|Procedure|Mantle irradiation|Limited to above the diaphragm
1747444|NCT00165282|Behavioral|Mindfulness training|Taught mindfulness meditation by mindfulness instructor (trained health care professional/RN) and audio c/d
1747445|NCT00165282|Behavioral|Nurse education|Meets with oncology nurse to have questions answered about medical treatments and side effects
1747446|NCT00165295|Drug|Sildenafil citrate (Viagra)|
1747447|NCT00165308|Drug|Tamoxifen|Given orally, daily for one year.
1747448|NCT00165334|Drug|Cetuximab|
1747449|NCT00165334|Drug|Vinorelbine (Navelbine)|
1747450|NCT00165347|Drug|PTK787/ZK222584|
1747451|NCT00165360|Drug|Temozolomide|Given once daily for 49 days followed by 28 days with no drug for a maximum of a year and a half
1747452|NCT00165373|Drug|rhEndostatin|Given by continuous infustion for 28 days (one of two dosing groups) for a total of 2 cycles. Treatment can be extended if tolerated well.
1747453|NCT00165386|Procedure|Magnetic Resonance Imaging|
1747454|NCT00165386|Procedure|Bone Marrow Biopsy|
1747455|NCT00165399|Drug|Docetaxel|Given intravenously on day 2 of four three-week cycles
1747456|NCT00165399|Drug|Estramustine|Taken orally three times a day for 5 days starting on day one of each three-week cycles (4 cycles)
1747457|NCT00165399|Drug|Casodex|Started 3 weeks after last chemotherapy treatment; taken orally once a day for 15 months
1747458|NCT00165399|Drug|Zoladex|Started one week after the start of casodex; zolades is given as an injection (in the stomach once every 3 months for a total of 5 injections.
1747459|NCT00165412|Procedure|breast MRI|Repeated once a year for three years
1747460|NCT00165412|Procedure|Mammogram|Repeated once a year for three years
1747461|NCT00165425|Procedure|Echo/Stress Echo|Participants will under resting echocardiogram and stress echocardiogram (echo and stress echo) and the results will be interpreted by a cardiologist
1747462|NCT00165438|Procedure|Pulmonary Function Tests|Tests include; total lung capacity, vital capacity, functional residual capacity, forced vital capacity, forced expiratory volume in 1 second, carbon monoxide diffusing capacity, pulse oximetry before and after a 6 minute walk and Pulmonary Status and Dyspnea Questionnaire
1747463|NCT00165438|Procedure|CAT Scan|Obtained at different time points during the study depending upon standard of care chemotherapy treatment
1747464|NCT00165451|Drug|Thalidomide|Oral administration once daily at night starting at 3mg/Kg for 6 months.
1747465|NCT00165451|Drug|Celecoxib|Oral administration twice daily starting at 100mg/dose for 6 months.
1747466|NCT00165451|Drug|Etoposide|Oral administration once daily at night starting at 50mg/m2 3 weeks on and 3 weeks off for 6 months.
1747467|NCT00165451|Drug|Cyclophosphamide|Oral administration once daily at night starting at 3.5mg/m2 3 weeks on and 3 weeks off for 6 months.
1747468|NCT00165464|Drug|Taxotere|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
1747469|NCT00165464|Drug|Cisplatin|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
1747470|NCT00165464|Drug|Irinotecan|Given once weekly for 2 weeks followed by a one week rest period (1 cycle is 3 weeks) Participants may continue on treatment unless there is disease progression or intolerable toxicities.
1747471|NCT00165477|Drug|lenalidomide|Given orally once a day for 21 days followed by a 1 week rest period. Subject may continue to receive study drug as long as the disease does not worsen and they experience serious side effects
1747472|NCT00165477|Radiation|Radiation|Starting 4-7 days after the start of lenalidomide and given once a day, 5 days a week for 6-7 weeks
1747473|NCT00165490|Drug|Cetuximab|Given once per week on weeks 1-8 and restarted 4 weeks after surgery, once weekly for 6 months.
1747474|NCT00165490|Drug|Cisplatin|Given once per week on weeks 1, 2, 4,and 5.
1747475|NCT00165490|Drug|Irinotecan|Given once per week on weeks 1, 2, 4,and 5.
1747476|NCT00165490|Device|Radiation therapy|Once daily for 28 treatments (5 1/2 weeks)
1747477|NCT00165490|Procedure|Surgery|Surgery performed 4-8 weeks after chemoradiation therapy.
1747478|NCT00165503|Drug|Cisplatin|
1747479|NCT00165503|Drug|Sodium Thiosulfate|
1747480|NCT00165503|Drug|ALIMTA|
1747481|NCT00165516|Drug|Cisplatin|Heated and given as an one-hour lavage of the chest and abdomen during surgery
1747482|NCT00165516|Drug|Sodium Thiosulfate|After the one-hour lavage, sodium thiosulfate is given intravenously
1747483|NCT00165542|Other|A PROTEIN level|
1747484|NCT00165555|Drug|Cisplatin|Given as a heated one-hour lavage to the hemithorax after surgery.
1747485|NCT00165555|Drug|Sodium Thiosulfate|Given intravenously over 6 hours after the cisplatin lavage.
1747486|NCT00165568|Drug|Bevacizumab|
1747487|NCT00165581|Device|High Dose Intracavitary Brachytherapy|
1747488|NCT00165594|Drug|E7070|
1747489|NCT00165607|Drug|MENATETRANONE|
1747490|NCT00165620|Drug|Iomeprole|
1747491|NCT00165633|Drug|Menatetrenone|45 mg capsule, orally, three times a day, after meals.
1747492|NCT00165633|Drug|Menatetrenone|90 mg capsule, orally, three times a day, after meals.
1747493|NCT00165633|Drug|Placebo|Placebo capsule, orally, three times a day, after meals.
1747494|NCT00165646|Drug|E3810|E3810 5mg: once daily orally for 4 weeks
1747495|NCT00165646|Drug|E3810|E3810 10mg: once daily orally for 4 weeks
1747496|NCT00165646|Drug|Placebo|Placebo: once daily orally for 4 weeks
1747497|NCT00165659|Drug|DONEPEZIL HYDROCHLORIDE|
1747498|NCT00165672|Drug|RABEPRAZOLE SODIUM|rabeprazole sodium 5 mg: once daily orally for 4 weeks
1747499|NCT00165672|Drug|RABEPRAZOLE SODIUM|rabeprazole sodium 10 mg: once daily orally for 4 weeks
1747500|NCT00165685|Drug|Sibutramine Hydrochloride Monohydrate|
1747501|NCT00165698|Drug|menatetranone|15 mg three times a day orally for 12 months
1747502|NCT00165698|Drug|alfacalcidol|0.25 μg twice a day orally for 12 months
1747503|NCT00165711|Drug|Mecobalamin|
1747504|NCT00165724|Drug|Donepezil Hydrochloride|
1747505|NCT00165737|Drug|Donepezil Hydrochloride|
1747506|NCT00165750|Drug|DONEPEZIL HYDROCHLORIDE|One 5mg table, once daily. (After 4 weeks treatment, the dose can be increased 10mg once daily.)
1747507|NCT00165763|Drug|donepezil hydrochloride (Aricept)|5 mg donepezil HCl given once a day and increased to 10 mg per day if side effects, when present, are tolerated.
1747508|NCT00165776|Drug|BOTULINUM TOXIN TYPE B|
1747509|NCT00165789|Drug|E2007|
1747510|NCT00165802|Drug|E7974|Maximum Tolerated Dose defined as 0.45 mg/m^2 administered on Day 1 only of a 21-day cycle; the E7974 compound is administered as a bolus infusion; no placebo is given.
1747511|NCT00165815|Drug|ARICEPT|
1747512|NCT00165828|Drug|Zonegran|Intravenous injection; initial daily dose of 50 mg zonisamide (2x25 mg) in both treatment groups; following a prospective or retrospective baseline phase of 8 weeks the study drug will be administered twice daily during 16 consecutive weeks.
1747513|NCT00165841|Drug|Rabeprazole 20 mg|rabeprazole sodium tablet 20 mg once daily
1747514|NCT00165854|Drug|E7070|
1747515|NCT00165867|Drug|E7070|
1747516|NCT00165880|Drug|E7070|
1747517|NCT00165893|Device|Accu-Spina Device/IDD therapy|
1747518|NCT00165893|Procedure|Physical Therapy|
1747519|NCT00165919|Other|None. Not a clinical trial. Specimens taken for basic research in laboratory.|
1747520|NCT00165958|Procedure|Excisional surgery of epidermal cyst|Traditional extirpation of cyst en toto
1747521|NCT00165958|Procedure|Punch incision of epidermal cyst|removal of cyst first with incisional effort with a punch biopsy tool
1747522|NCT00165971|Procedure|BIS monitoring|
1747523|NCT00159861|Drug|Sildenafil citrate|
1747524|NCT00159874|Drug|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 20 mg 3 times a day (tid) subjects with body weight >20 - 45 kg: 40 mg 3 times a day (tid) subjects with body weight >45 kg: 80 mg 3 times a day (tid)
1747525|NCT00159874|Drug|Sildenafil citrate|Oral,10 mg 3 times a day (tid), only subjects with body weight >20 kg
1747526|NCT00159874|Drug|Sildenafil citrate|Oral, subjects with body weight ≥8 - 20 kg: 10 mg 3 times a day (tid); subjects with body weight >20 - 45 kg: 20 mg 3 times a day (tid); subjects with body weight >45 kg: 40 mg 3 times a day (tid)
1747527|NCT00159887|Drug|Sildenafil citrate|
1747528|NCT00159900|Drug|Sildenafil Citrate|
1747529|NCT00159913|Drug|Sildenafil citrate|oral; 20mg, 40mg and 80 mg; 3 times a day(TID)
1747530|NCT00159913|Drug|Sildenafil citrate|oral; 10mg, 20mg and 40mg; 3 times a day(TID)
1747531|NCT00159913|Drug|Placebo|oral; 3 times a day(TID)
1747532|NCT00159913|Drug|Sildenafil citrate|oral; 10 mg; 3 times a day(TID)
1747533|NCT00159926|Procedure|Cell saver|Cell saver intraoperatively for coronary artery bypass grafting using cardiopulmonary bypass
1747534|NCT00159926|Procedure|No cell saver|Conventional suction for coronary artery bypass grafting using cardiopulmonary bypass
1747535|NCT00159939|Procedure|prone positioning|prone positioning
1747536|NCT00159952|Procedure|intensive insulin therapy|"control: glycemia will be controlled with insulin administration when higher than 215 mg/dL.
treatment: glycemia will be controlled with be controlled with insulin administration when higher than 110 mg/dL"
1747537|NCT00159965|Drug|sertraline|flexible dose sertraline
1747538|NCT00159965|Drug|placebo|flexible dose placebo
1747539|NCT00159978|Procedure|18F-FLT and 18F-MISO-PET|18F-FLT-PET-images will be acquired one hour after injection of 250 MBq FLT. 18F-MISO-PET: 400 MBq FMISO will be injected intravenously. Marker administration: The day before surgery (≤ 24h) pimonidazole (500 mg/m2) will be administered intravenously in 100 ml saline over 20 min. IdUrd (200 mg) will be administered as bolus injection 20 min before surgery.
1747540|NCT00159991|Procedure|Total arterial revascularization|Coronary artery bypass grafting using LIMA and RIMA and/or radial artery grafts
1747541|NCT00159991|Procedure|Conventional revascularization|Coronary artery bypass grafting using LIMA and saphenous vein grafts
1747542|NCT00160004|Behavioral|Intensive Controlled Exercise|
1747543|NCT00160017|Behavioral|Breakthrough collaborative|Participants (professionals) participate in a Breakthrough Collaborative to improve diabetes care
1747544|NCT00160030|Drug|FOLFOX 4|total treatment of six 2-weekly cycles of FOLFOX 4, the first 3 cycles starting on D1, D15 and D29 concomitant with 5 weeks' radiotherapy.
1747545|NCT00160030|Drug|5-FU / Cisplatin|two cycles of 5-FU / Cisplatin on week 1 and 5 of radiotherapy and two cycles of chemotherapy with 5-FU / Cisplatin on week 8 and 11 (one cycle each three weeks after the end of radiotherapy).
1747546|NCT00160043|Drug|SH T00268C|1250 mg experimental drug od
1747547|NCT00160043|Drug|PTK787/ ZK 222584|1250 mg experimental drug bid (500mg + 750mg)
1747548|NCT00160056|Procedure|Hypoglycemia|
1747549|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour infusion, every 3 weeks
1747550|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-min infusion, every 3 weeks
1747551|NCT00160069|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour infusion, every 3 weeks
1747552|NCT00160082|Drug|Xepol|
1747553|NCT00160108|Behavioral|dietary intervention|
1747554|NCT00160121|Drug|Lanthanum carbonate|
1747555|NCT00160134|Drug|SLV320|
1747556|NCT00160147|Drug|bifeprunox|One week titration with dose adjustments
1747557|NCT00160147|Drug|Placebo|Placebo
1747558|NCT00160160|Drug|eprosartan/HCTZ|
1747559|NCT00160173|Drug|Estradiol|
1747560|NCT00160186|Drug|Pancreatin|2 capsules Pancreatin with 25 000 lipase units per main meal (3 meals) and 1 capsule per snack (2-3 snacks)
1747561|NCT00160186|Drug|Placebo|Placebo
1747562|NCT00160199|Drug|PROMETRIUM® 300 mg|300 mg (3x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
1747563|NCT00160199|Drug|PROMETRIUM® 400 mg|400 mg (4x100mg capsules) by mouth once daily at bedtime for 10 days X 3 cycles
1747564|NCT00160212|Drug|Daglutril|
1747565|NCT00160225|Drug|Daglutril|
1747566|NCT00160238|Drug|Betahistine 24 mg bid (Betaserc)|
1747567|NCT00160251|Drug|Boceprevir (BOC)|100 or 200 mg capusles taken orally as 100 mg, 200 mg, 400 mg, or 800 mg TID
1747568|NCT00160251|Biological|PegIntron (PEG)|1.5 mcg/kg weekly subcutaneously
1747569|NCT00160251|Drug|Ribavirin (RBV)|200 mg capsules taken twice daily (BID) (total daily dose of 800-1400 mg/day, depending on weight [weight-based dosing {WBD}])
1747570|NCT00160264|Drug|Lactulose, Vitamin D, Calcium|
1747571|NCT00160277|Drug|Moxonidine|
1747572|NCT00160290|Drug|Lactulose|15 mL / 12 hours
1747573|NCT00160290|Drug|Plantago ovata|3,5 g / 12 hours
1747574|NCT00160303|Drug|Prolotherapy|
1747575|NCT00160303|Drug|Local Corticosteroid Therapy|
1747576|NCT00160316|Drug|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone|p.o. daily
1747577|NCT00160329|Drug|Atazanavir|300 mg with ritonavir boosting or 400 mg without
1747578|NCT00166010|Drug|Nesiritide|Standard dose of nesiritide which is a loading dose of 1 mcg/kg IV over 30 minutes followed by a nesiritide infusion at 0.01mcg/kg/min. All patients will be continually evaluated. At any time the attending physician may add or adjust treatment if deemed clinically indicated.
1747579|NCT00166036|Drug|Atorvastatin|12 Weeks of Oral Atorvastatin 10 mg therapy.
1747580|NCT00166036|Drug|Pravastatin|12 Weeks of Oral Pravastatin 80 mg therapy.
1747620|NCT00167700|Behavioral|Dietary counselling and placebo|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Placebo capsules.
1747621|NCT00167700|Behavioral|Dietary counselling and probiotics|Counseling to conform with the dietary recommendations. Food products commercially available including spreads and salad dressing. Probiotics
1747581|NCT00166049|Behavioral|Family Partnership Intervention (FPI)|HF patient and family receive structured patient and family education sessions plus intervention to improve family communication one month after enrollment.Patient and family member received one individual dyadic education/counseling session after baseline data collection, and two group sessions (2-3 months after baseline) focused on developing family approaches to HF self management.Telephone counseling for the dyad and reinforcing mailed newsletters at 5-6 months after baseline.
1747582|NCT00166049|Behavioral|Patient and Family Education|HF Patient and one family member receive structured education sessions one month after enrollment.Two sessions, one indivdual with patient-family member dyad after baseline, and one in a group setting between 2-3 months after baseline. The group session was 2 hours in duration. Telephone counseling for the dyad ast 5-6 months, mailed newsletters at Mailed newsletters at 5-6 months.
1747583|NCT00166049|Behavioral|Usual care with educational material|Usual care with provision of printed educational material, provided once at baseline
1747584|NCT00166062|Procedure|Screening patients for IPV|
1747585|NCT00166075|Procedure|Computer screen with community resource printout|Patients participated in the screening process via a computer kiosk. Questions regarding IPV and mental health symptoms were asked using validated tools
1747586|NCT00166088|Dietary Supplement|Mediterranean Diet|The Mediterranean diet group will receive all meals as a prototypical Mediterranean diet for 4 consecutive weeks prepared by the GCRC metabolic kitchen with dietary instruction. During the second month of the study they will be asked to follow a Mediterranean diet using their own home-cooked meals
1747587|NCT00166088|Dietary Supplement|Mediterranean Dietary Supplement|The subjects randomized to the typical diet + targeted Mediterranean dietary supplement group will not receive dietary counseling. They will be given a one-month supply of specific supplements by the GCRC nutritionists and advised to consume these daily, in addition to their usual diet.
1747588|NCT00166114|Drug|Escitalopram|10 mg of Escitalopram, and titrated up to 20 mg of Escitalopram after day 22 of intervention
1747589|NCT00166114|Drug|Desipramine|25 mg of Desipramine for day 1-3, 50 mg of Desipramine for day 4-7, 75 mg of Desipramine for day 8-14, 100 mg of Desipramine for day 15-21. Titrated between 125 mg to 200 mg of Desipramine for day 22-56 of intervention
1747590|NCT00166127|Drug|Levosimendan|
1747591|NCT00166153|Drug|Mycophenolate Mofetil|
1747592|NCT00166166|Drug|Tetraethylammonium (TEA)|5 minute intra-arterial infusion of Tetraethylammonium at 1 mg/min
1747593|NCT00166166|Drug|L-NG-monomethyl Arginine (L-NMMA)|5 minute intra-arterial infusion of L-NMMA 8 μmol/min
1747594|NCT00166166|Drug|Bradykinin|Intra-arterial infusion of bradykinin at 100, 200, and 400 ng/min. Each dose will be given for 5 minutes.
1747595|NCT00166166|Drug|Sodium nitroprusside|Intra-arterial infusion of sodium nitroprusside at 1.6 and 3.2 mg/min. Each dose will be given for 5 minutes.
1747596|NCT00166166|Drug|Acetylcholine|Intra-arterial infusion of acetylcholine at 7.5, 15 and 30 μg/min. Each dose will be given for 5 minutes.
1747597|NCT00166166|Drug|Saline|5 minute intra-arterial infusion of 0.9% saline at 2.5ml/min
1747598|NCT00166166|Drug|Fluconazole|5 minute intra-arterial infusion of fluconazole at 0.4 mg/L/min
1747599|NCT00166192|Procedure|Jessner's solution chemical peel|
1747600|NCT00166192|Procedure|Trichloroacetic acid chemical peel|
1747601|NCT00166205|Device|Swedish Adjustable Gastric Band|Long term implantable device.
1747602|NCT00166218|Device|near-infrared spectroscopy|
1747603|NCT00166244|Drug|Mycophenolate Mofetil|"1 g for adult patients and 300 mg/m2 for paediatric patients. Fixed dose arm: 1 g twice a day (bid) for adults and 600mg/m2 bid for paediatric patients.
Concentration controlled arm: initial dose will be 1 g bid for adults and 600mg/m2 bid for paediatric patients. Abbreviated AUCs (taken at timepoints: 0, 30min and 120min in fasted patients) on Days 3 and 10, Week 4, Months 3, 6 and 12 will be performed to determine mycophenolic acid levels in plasma."
1747604|NCT00166257|Device|Percutaneous closure of patent foramen ovale|Percutaneous implantation of an AMPLATZER® PFO Occluder
1747605|NCT00166257|Drug|Medical antitrhombotic treatment|Investigator's choice: Anticoagulation to INR 2.0 - 3.0 OR Aspirin 100-325 mg/d OR Clopidogrel 75-150 mg/d
1747606|NCT00166270|Device|ExAblate 2000|
1747607|NCT00166283|Behavioral|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
1747608|NCT00166283|Behavioral|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 training sessions).
1747609|NCT00166296|Drug|Escitalopram|15 mg/day starting 2 weeks before and 12 weeks during interferon therapy
1747610|NCT00166296|Drug|Placebo|Placebo, 15 mg/day, starting 2 weeks before and for 12 weeks during interferon therapy.
1747611|NCT00166309|Drug|FEIBA and NovoSeven|
1747612|NCT00166322|Procedure|IBZM-SPECT (bolus and constant infusion paradigm)|single IBZM-SPECT assessment at study inclusion
1747614|NCT00167648|Drug|Leuprolide or goserelin|Leuprolide 7.5 mg (4-week depot) or goserelin 3.6 mg (4-week depot)
1747615|NCT00167648|Drug|Transdermal estradiol|Estradiol patches, six at 0.1 mg each, changed every 3-4 days
1747616|NCT00167661|Drug|Campath-1H|two intravenous 20mg/m2/doses, the first on the day of transplant and the second dose on day 1 post transplant
1747617|NCT00167674|Drug|Combined short-course zidovudine/nevirapine|300 mg of ZDV was given twice daily from 34 weeks gestation until labor then every 3 hours until delivery; 200 mg of NVP was given as a single oral dose at the onset of labor; and a single 2 mg/kg (6 mg if birthweight > 2.5 kg) oral dose of NVP suspension was administered to the infant within 72 hours of delivery.
1747618|NCT00167674|Drug|HAART|300 mg of zidovudine (ZDV), 150 mg of lamivudine, and 200 mg nevirapine (NVP) was given twice daily from 34 weeks gestation until six months after delivery.
1747619|NCT00167687|Drug|prazosin|"Pharmacological treatment: In order to prevent the possible side effect of first-dose hypotension, all participants will receive only 1mg of study medication or placebo nightly for the first two days of study participation. Titration will proceed according to the following schedule:
Prazosin Dosing: 9 AM 3 PM 9 PM Days 1-2 1 mg (one capsule) Days 3-4 1 mg 1 mg 1 mg Days 5-7 2 mg 2 mg 2 mg Day 8-10 2 mg 2 mg 6 mg Day 11-14 4 mg 4 mg 6 mg Day 15-42 4 mg 4 mg 8 mg"
1747622|NCT00167700|Dietary Supplement|Placebo capsules|Placebo capsules
1747624|NCT00167700|Dietary Supplement|Prebiotics|
1747625|NCT00167713|Drug|Ibuprofen|
1747626|NCT00167739|Drug|Quinine plus sulfadoxine-pyrimethamine|
1747627|NCT00167765|Drug|Abciximab|
1747628|NCT00167778|Device|Transverse plane rotation adaptor pylon|Potential future practice
1747629|NCT00167778|Device|Rigid pylon|Current clinical practice
1747630|NCT00167791|Drug|rituximab|Rituximab 375mg/m2 IV weekly times 4 weeks
1747631|NCT00167804|Behavioral|Virtual Reality Exposure|VRE uses computer generated environments to conduct exposure therapy.
1747632|NCT00167817|Drug|Aripiprazole|
1747633|NCT00167830|Behavioral|Motivational Interviewing|Biweekly meetings with a behavior specialist to review subject's progress with the protocol and explore challenges subject is facing in adopting healthy lifestyle behaviors.
1747634|NCT00167830|Behavioral|Strength and Cardiovascular Conditioning|Subjects take part in an exercise program to include 30 minutes of cardiorespiratory exercise at 70% maximum heart rate, and 30 minutes of strength training on Nautilus machines.
1747635|NCT00167830|Behavioral|Food selection and portion control|Subjects meet on a biweekly basis with a registered dietitian who presents educational information about healthy food selection and portion control.
1747636|NCT00167843|Drug|sulfadoxine-pyrimethamine|
1747637|NCT00167856|Drug|Venalafaxine hydrochloride|Norepinephrine/Serotonin Reuptake Inhibitor (NSRI)
1747638|NCT00167869|Behavioral|dairy peptides|
1747639|NCT00167882|Drug|5-aminosalicylate (Pentasa, Ferring)|
1747640|NCT00167895|Procedure|Adding platelet concentrate to the wound|
1747641|NCT00167908|Drug|Ethyol (drug)|
1747642|NCT00167921|Drug|Premarin® Vaginal Cream|
1747643|NCT00167921|Drug|Premarin® oral tablets|
1747646|NCT00167947|Drug|Cyclosporine|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
1747647|NCT00167947|Drug|Steroids|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
1747648|NCT00167947|Drug|Rapamune (Sirolimus)|"Arm 1= Rapamune+ low dose Cyclosporine+steroids Arm 2= 1° day rapamune 15 mg/die + steroids 2°-7° day Rapamune 5mg/die + steroids In both arms, Cylcoporine is stopped "
1747649|NCT00167960|Drug|Piperacillin/tazobactam and other β-lactam/β-lactamase|
1747650|NCT00167986|Drug|vancomycin-resistant enterococci and ESBL|
1747651|NCT00167999|Drug|piperacillin-tazobactam|
1747652|NCT00168012|Drug|Immunoglobulins Intravenous (Human)|
1747653|NCT00168025|Drug|Immunoglobulins Intravenous (Human)|
1747654|NCT00168038|Biological|Immunoglobulin Intravenous (Human)|A dose of 1 g IgG per kg body weight (bw) administered on two consecutive days resulting in the total treatment dosage of 2 g IgG per kg bw.
1747655|NCT00168051|Drug|ReFacto|
1747656|NCT00168051|Drug|Advante|
1747657|NCT00168064|Drug|mechlorethamine-MCH (nitrogen mustard)|All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment
1747658|NCT00168077|Drug|Prothrombin Complex Concentrate|
1747659|NCT00168090|Drug|Blood coagulation Factor VIII and vWF, human|
1747660|NCT00168103|Biological|C1 Esterase Inhibitor|Single application of C1-INH administered intravenously by slow injection or infusion at a recommended rate of 4mL/min.
1747661|NCT00168103|Biological|Placebo|Single application of physiological saline solution equivalent to the volume calculated for subjects in the C1-INH 20 U/kg bw arm.
1747662|NCT00168116|Procedure|radiation treatment and surgery|
1747663|NCT00168116|Procedure|radiation alone|
1747664|NCT00168129|Procedure|Helical tomotherapy|
1747665|NCT00168155|Drug|perioperative chemotherapy|
1747666|NCT00168168|Drug|G-CSF/Filgrastim|
1747667|NCT00168181|Procedure|Submandibular gland Transfer|
1747668|NCT00168181|Drug|Salagen|
1747669|NCT00168272|Device|Transcranial Magnetic Stimulation|
1747670|NCT00168285|Behavioral|Pulmonary Rehabilitation|
1747671|NCT00168298|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
1747672|NCT00168298|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
1747673|NCT00168298|Other|Sham Injection|Sham injection on Day 0.
1747674|NCT00168311|Device|Transcranial Magnetic Stimulation|Participants were sequentially randomly assigned to either 15 active bilateral treatments or 15 sham bilateral treatments that were administered on a daily basis, five days per week.
1747675|NCT00168311|Device|sham TMS|
1747676|NCT00168324|Drug|700 µg Dexamethasone|700 µg dexamethasone intravitreal implant administered on Day 0 and/or Day 180.
1747677|NCT00168324|Drug|350 µg Dexamethasone|350 µg Dexamethasone intravitreal implant administered on Day 0.
1747678|NCT00168324|Other|Sham Injection|Sham injection on Day 0.
1747679|NCT00168337|Drug|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
1747680|NCT00168337|Other|Sham|Sham posterior segment drug delivery system-needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
1747681|NCT00168350|Drug|memantine|
1747682|NCT00168363|Drug|brimonidine|
1747683|NCT00168376|Device|Transcranial Magnetic Stimulation|
1747684|NCT00168389|Drug|Dexamethasone|350 µg or 700 µg dexamethasone posterior segment drug delivery system - injection into the vitreous cavity not less than every 6 months for up to 36 months.
1747685|NCT00168389|Other|Sham|Sham posterior segment drug delivery system - needle-less drug delivery system without study medication not less than every 6 months for up to 36 months.
1747686|NCT00168402|Drug|Botulinum Toxin Type A|
1747687|NCT00168415|Biological|Botulinum Toxin Type A|100 U up to 6 times during the study depending on the response to treatment
1747688|NCT00168428|Biological|Botulinum Toxin Type A|Two treatment sessions in the double-blind phase and three treatment sessions in the open-label phase. Total minimum dose is 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas with the total maximum dose of 195 U with 39 head/neck injections.
1747689|NCT00168428|Other|placebo (saline)|Two treatment sessions in the double-blind phase. Total minimum dose in 155 U with 31 fixed-site, fixed dose injections across seven specific head/neck muscle areas and the total maximum dose is 195 U with 39 head/neck injections.
1747690|NCT00168441|Drug|Botulinum Toxin Type A|
1747691|NCT00168454|Biological|botulinum toxin Type A|botulinum toxin Type A injected into detrusor on Day 1
1747692|NCT00168454|Drug|Placebo|Placebo (normal saline) injected into detrusor on Day 1
1747693|NCT00168467|Drug|Ramipril|
1747694|NCT00168480|Biological|Botulinum Toxin Type A|100 U, repeated treatments at > 4 month intervals up to Month 32, over a 36-month study period
1747695|NCT00168493|Drug|antidepressants primarily selective serotonin reuptake inhibitors|normal clinical dosages used according to clinical response as determined by a psychiatrist
1747696|NCT00168506|Drug|SSRI|
1747697|NCT00168506|Drug|CBT|
1747698|NCT00168506|Drug|CBT/SSRI|
1747699|NCT00168519|Drug|nitroprusside, pentalong, imdur, AICAR, isoptin|"Sodium Nitroprusside - one 30 minute intravenous infusion
Pentalong - two tablets orally (total 160mg)
Imdur - two tablets orally (total 120mg)"
1747700|NCT00168532|Drug|Sulfamethoxazole-Trimethoprim|
1747701|NCT00168545|Biological|Measles vaccine|
1747702|NCT00168558|Biological|Measles vaccine|"The children will be randomised to the following three arms:
Arm 1 - Very early two-dose: V (EZ) 4½ mo of age + V (EZ) 9 mo of age.
Arm 2 - 9 months one- or two-dose: V (SW) 9 mo of age + V (SW)/or nothing 18 mo of age.
Arm 3 - 9 months one- or two-dose: V (EZ) 9 mo of age + V (EZ)/or nothing 18 mo of age.
V = measles vaccination, EZ = standard titre Edmonston-Zagreb measles vaccine, SW = standard titre Schwarz measles vaccine"
1747703|NCT00168571|Biological|Measles vaccine|
1747704|NCT00168584|Drug|Vitamin A|
1747705|NCT00168597|Drug|Vitamin A|
1747706|NCT00168610|Drug|Vitamin A|
1747707|NCT00168623|Drug|Vitamin A|
1747708|NCT00168636|Drug|Vitamin A|
1747709|NCT00168649|Drug|Vitamin A|
1747710|NCT00168662|Biological|Measles and inactivated polio vaccine|
1747711|NCT00168688|Dietary Supplement|multi micronutrient supplement|
1747712|NCT00168688|Dietary Supplement|MN1|Vitamin A 800 μg RE, Vitamin D 200 IU, Vitamin E 10 mg, Vitamin B1 1.4 mg, Vitamin B2 1.4 mg, Niacin 18 mg, Folic acid 400 μg, Vitamin B6 1.9 mg, Vitamin B12 2.6 μg, Vitamin C 70 mg, Zinc 15 mg, Iron 30 mg, Copper 2.0 mg, Selenium 65 μg, Iodine 150 μg
1747713|NCT00168688|Dietary Supplement|MN2|Vitamin A 1600 μg RE, Vitamin D 400 IU, Vitamin E 20 mg, Vitamin B1 2.8 mg, Vitamin B2 2.8 mg, Niacin 36 mg, Folic acid 800 μg, Vitamin B6 3.8 mg, Vitamin B12 5.2 μg, Vitamin C 140 mg, Zinc 30 mg, Iron 30 mg, Copper 4.0 mg, Selenium 130 μg, Iodine 300 μg
1747714|NCT00168701|Drug|BG00012|
1747715|NCT00168714|Drug|BG9418 (interferon beta-1a)|Exposure to Avonex during pregnancy
1747716|NCT00168727|Drug|ibritumomab tiuxetan (Zevalin®)|
1747717|NCT00168740|Drug|rituximab|
1747718|NCT00168753|Drug|Alefacept|IM
1747719|NCT00168766|Drug|Interferon-beta-1a (Avonex) plus methylprednisolone|oral administration given on 3 consecutive days, monthly as described in protocol.
1747720|NCT00168779|Drug|telmisartan 80 mg / hydrochlorothiazide 25 mg|
1747721|NCT00168779|Drug|valsartan 160 mg / hydrochlorothiazide 25 mg|
1747722|NCT00168779|Drug|placebo|
1747723|NCT00168792|Drug|Tenecteplase|
1747724|NCT00168792|Procedure|PCI|
1747725|NCT00168805|Drug|enoxaparin|40 mg once daily
1747726|NCT00168805|Drug|dabigatran etexilate|150 mg once daily
1747727|NCT00168805|Drug|dabigatran etexilate|220 mg once daily
1747728|NCT00168818|Drug|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
1747729|NCT00168818|Drug|dabigatran etexilate|daily dose 150 mg once daily, half a dose on the day of surgery
1747730|NCT00168818|Drug|enoxaparin|40 mg once daily
1747731|NCT00168831|Drug|Tiotropium Inhalation Solution|
1747732|NCT00168831|Other|Placebo|
1747733|NCT00168844|Drug|Tiotropium Inhalation Solution|
1747734|NCT00168844|Other|Placebo|
1747735|NCT00168857|Drug|telmisartan|
1747736|NCT00168857|Drug|losartan|
1747737|NCT00168870|Drug|Gemcitabine|
1747738|NCT00168870|Drug|Treosulfan|
1747739|NCT00168883|Drug|Carboplatin|
1747740|NCT00168883|Drug|Paclitaxel|
1747741|NCT00168883|Drug|Vinorelbine|
1747742|NCT00168896|Drug|Carboplatin plus Irinotecan vs Carboplatin plus Etoposide|
1747743|NCT00168909|Drug|alfacalcidol|alfacalcidol 1 µg once daily, oral, for 3 years
1747744|NCT00168909|Drug|placebo|placebo once daily, oral, for 3 years
1747745|NCT00168922|Drug|Bendamustin/Ribomustin|
1747746|NCT00168935|Drug|Fresubin protein energy Drink (CAVE! nutritional intervention)|
1747747|NCT00168948|Drug|Sulfadoxin (12.5) Pyrimethamine (250 mg)|
1747748|NCT00168961|Dietary Supplement|High Protein Energy, Fresenius-Kabi (nutritional intervention)|
1747749|NCT00168987|Drug|oral nutritional supplement rich in eicosapentanoic acid|
1747750|NCT00169000|Drug|Capecitabine|"Capecitabine at the following dose levels for 14 days every 21 days, beginning with dose level 1
Dose level -2 600 mg/m2 po BID
Dose level -1 700 mg/m2 po BID
Dose level 1 825 mg/m2 po BID
Dose level 2 1000 mg/m2 po BID"
1747751|NCT00169000|Drug|Docetaxel|75 mg/m2 over one hour on day 8 of each cycle
1747752|NCT00169013|Drug|Gabapentin|
1747753|NCT00169026|Drug|Clozapine versus typical (conventional) and atypical antipsychotic medications|
1747754|NCT00169039|Drug|Clozapine|
1747755|NCT00169039|Drug|Chlorpromazine|
1747756|NCT00169052|Behavioral|Health Care Management and Supported Rehabilitation|
1747757|NCT00169065|Drug|Clozapine|
1747758|NCT00169065|Drug|Olanzapine|
1747759|NCT00169078|Drug|Chloroquine|
1747833|NCT00169559|Drug|GW590735|1µg to 20µg daily doses of GW590735
1747760|NCT00169091|Drug|Clozapine|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 12.5 mg on Day 1 to up to 300 mg on Day 12.
1747761|NCT00169091|Drug|Haloperidol|Medication will be divided into twice daily dosing and administered in a blinded fashion. The medication will be tapered from 2 mg on Day 1 to up to 12 mg on Day 12.
1747762|NCT00169104|Drug|G-CSF|5 mcgm/kg daily Monday through Friday weeks 3-14
1747763|NCT00169104|Drug|trastuzumab|4 mcgm/kg intravenously (IV) over 90 minutes week 1, then 2 mg/kg IV over 30 minutes weeks 2-14
1747764|NCT00169104|Drug|vinorelbine|25 mg/m2 over 6 minutes IV weekly, weeks 3, 4, 6, 7, 9, 10, 12, 13
1747765|NCT00169104|Drug|G-CSF|5 mcgm/kg SQ daily for ten days, Monday through Friday of the first two weeks of the study
1747766|NCT00169104|Drug|saline|Saline will be given SQ daily for ten days, Monday through Friday of the first two weeks of the study
1747767|NCT00169117|Behavioral|Songs/posters aimed at behaviour change|This was a behavioural intervention, using songs and posters composed/designed by community members which aimed at behaviour change to increase repair and maintenance of mosquito nets
1747768|NCT00169130|Drug|doxorubicin|
1747769|NCT00169130|Drug|cyclophosphamide|
1747770|NCT00169130|Procedure|Autologous stem cell transplantation|
1747771|NCT00169143|Drug|Rituximab + ACVBP regimen plus Pegfilgrastim|
1747772|NCT00169143|Procedure|Autologous stem cell transplant|
1747773|NCT00169156|Drug|Rituximab|375 mg/m2 D1
1747774|NCT00169156|Drug|Prednisone|40 mg/m2 D1 to D5
1747775|NCT00169156|Drug|Doxorubicine|50 mg/m2 D1
1747776|NCT00169156|Drug|Cyclophosphamide|750 mg/m2 D1
1747777|NCT00169156|Drug|Vincristine|1,4 mg/m2 D1
1747778|NCT00169169|Drug|ACVBP|
1747779|NCT00169169|Drug|ACE|
1747780|NCT00169169|Drug|rituximab|
1747781|NCT00169169|Procedure|Autologous stem cell transplant|
1747782|NCT00169182|Drug|DOCETAXEL|
1747783|NCT00169195|Drug|Gemcitabine-Oxaliplatin plus Rituximab (R-GEMOX)|
1747784|NCT00169208|Drug|rituximab|
1747785|NCT00169208|Drug|fludarabine|
1747786|NCT00169208|Drug|mitoxantrone|
1747787|NCT00169221|Drug|Iressa (Gefitinib)|postoperative chemoradiotherapy with cisplatin + gefitinib
1747788|NCT00169221|Radiation|chemoradiotherapy with cisplatin|postoperative chemoradiotherapy with cisplatin
1747791|NCT00169247|Drug|cetuximab|
1747792|NCT00169247|Drug|Cisplatin|
1747793|NCT00169247|Procedure|Radiotherapy 70 Gy, 35 fractions|
1747794|NCT00169260|Behavioral|motivational counseling|behavioral motivational counselling
1747795|NCT00169260|Behavioral|placebo|
1747801|NCT00169299|Drug|Black cohosh|
1747802|NCT00169299|Drug|Multibotanical preparation|
1747803|NCT00169299|Drug|Multibotanical preparation + dietary soy counseling|
1747804|NCT00169299|Drug|Conjugated equine estrogen +/- medroxyprogesterone acetate|
1747805|NCT00169312|Behavioral|behavioral dietary intervention|
1747806|NCT00169312|Dietary Supplement|dietary intervention|
1747807|NCT00169312|Other|educational intervention|
1747808|NCT00169312|Other|internet-based intervention|
1747809|NCT00169312|Other|preventative dietary intervention|
1747810|NCT00169312|Procedure|evaluation of cancer risk factors|
1747811|NCT00169325|Procedure|Magnetic resonance imaging|
1747812|NCT00169338|Procedure|Deep brain stimulation|internal pallidal deep brain stimulation
1747813|NCT00169364|Device|positron emission tomography|
1747814|NCT00169377|Procedure|deep brain stimulation|Stimulator on followed by off
1747815|NCT00169377|Procedure|Off|Stimulator off followed by on
1747816|NCT00169403|Procedure|Deep brain stimulation|
1747817|NCT00169416|Drug|valaciclovir HCl granules|
1747818|NCT00169442|Biological|Tritanrix™-HepB/Hiberix™ Kft.|GlaxoSmithKline (GSK) Biologicals Korlatolt Felelossegu Tarsasag [Kft] (Limited Company) combined diphtheria (D), tetanus (T), whole cell Bordetella pertussis (Pw), hepatitis B vaccine with new sources of D, T and Pw antigens mixed with Haemophilus influenzae type b (Hib2.5) vaccine.
1747819|NCT00169442|Biological|Tritanrix™-HepB/Hiberix™|GSK Biologicals' combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B and Haemophilus Influenzae type b vaccine
1747820|NCT00169442|Biological|Hiberix™|GSK Biologicals' Haemophilus influenzae type b vaccine
1747821|NCT00169442|Biological|Polyribosil-Ribitol-Phosphate (PRP) vaccine|plain PRP polysaccharide vaccine
1747822|NCT00169442|Biological|Tritanrix™-HepB Kft|GSK Biologicals Korlatolt Felelossegu Tarsasag [Kft] (Limited Company) combined diphtheria, tetanus, whole cell Bordetella pertussis, hepatitis B vaccine with new sources of D, T and Pw antigens produced at GSK Biologicals Kft., Gödöllö, Hungary.
1747823|NCT00169455|Biological|Live attenuated human rotavirus vaccine|
1747824|NCT00169468|Drug|Rituximab -CHOP plus Velcade|
1747825|NCT00169481|Biological|Pneumococcal (vaccine)|
1747826|NCT00169494|Biological|HPV-16/18 L1/AS04|
1747827|NCT00169507|Biological|Pneumococcal (vaccine)|
1747828|NCT00169520|Drug|docetaxel|
1747829|NCT00169520|Drug|SB-715992|
1747830|NCT00169533|Drug|GW572016 oral tablets|Lapatinib either at 750, 1000, 1250 or 1500 mgs
1747831|NCT00169546|Drug|Salmeterol/fluticasone propionate|
1747832|NCT00169546|Drug|Fluticasone propionate|
1747834|NCT00169559|Drug|fenofibrate|Marketed Drug
1747835|NCT00169572|Drug|Aprepitant|
1747836|NCT00169572|Drug|Ondansetron|
1747837|NCT00169572|Drug|GW679769|
1747838|NCT00169572|Drug|Dexamethasone|
1747839|NCT00169585|Drug|Levofloxacin oral tablets|
1747840|NCT00169598|Procedure|positron emission tomography|
1747841|NCT00169611|Drug|methylphenidate|
1747842|NCT00169624|Drug|Metformin|
1747843|NCT00169624|Drug|Gliclazide|
1747844|NCT00169637|Drug|rhGH|
1747845|NCT00169650|Other|Registry and database|Subjects undergoing laparoscopic pyeloplasty for ureteropelvic junction obstruction at Methodist Urology in Indiana will be asked to participate in a registry and database to review outcomes of the surgery.
1747846|NCT00169676|Other|observation|registry and database for surgery outcomes
1747847|NCT00169689|Procedure|"rTMS, repetitive transcranial magnetic stimulation"|10 Hz rTMS (10.000 stimuli) over left dorsolateral prefrontal cortex
1747848|NCT00169689|Other|rTMS|repetitive transcranial magnetic stimulation, 10 Hz, 10.000 stimuli, 2 weeks
1747849|NCT00169702|Behavioral|weight management program|12 sessions, psychoeducation
1747850|NCT00169702|Behavioral|weight management program|2 weekly, 12 sessions, psychoeducational weight management
1747851|NCT00169715|Procedure|Percutaneous Caliceal Diverticuli|Standard of care to remove a stone from a caliceal diverticulum is to do a percutaneous procedure for stone removal and then fulgerate the diverticulum to prevent stone recurrence. We plan to aspirate urine from this diverticulum and compare it to urine collected from the renal pelvis of the same kidney.
1747852|NCT00169728|Biological|DTaP-IPV-HBV/Hib combination vaccine, Infanrix hexa|
1747853|NCT00169728|Biological|heptavalent pneumococcal conjugate vaccine, Prevenar|
1747854|NCT00169741|Other|Renogram|Subjects who enroll in this study will undergo a nuclear scan called a renogram to assess renal function prior to surgery (baseline), approximately one hour after surgery (to assess percutaneous effects on renal function) and finally approximately 6 weeks post-operatively (to assess return to baseline).
1747855|NCT00169754|Other|mapping kidney anatomy|videotape of surgical procedure to document location of attached stones and condition of calyces and papilla.
1747856|NCT00169767|Other|Comparison study between KTP and HoLAP for BPH|Comparison study between KTP and HoLAp for BPH
1747857|NCT00169780|Radiation|High definition helical CT (64 head scanner)|"Patients who require a CT scan for diagnostic purposes prior to kidney stone surgery will undergo a high definition helical CT rather than the standard CT scan. This high resolution scan will then be reviewed by the researchers to help determine the type of treatment needed for the kidney stone removal. The aim is to see if the higher resolution will show more of the stone anatomy which will help the surgeon determine if the stone will be amenable to shock wave lithotripsy or if another type of treatment would best serve the patient needs."
1747858|NCT00169793|Other|evaluation of kidney stone risk after bariatric surgery|24 hour urine collections done pre and post surgery
1747859|NCT00169793|Other|Evaluate risk of kidney stones after bariatric surgery|24 hour urine collections are done before and after surgery
1747860|NCT00169806|Other|videotape for mapping of renal anatomy and papillary biopsy|Subjects who enroll in this study will have their renal anatomy videotaped for mapping purposes. Stone location and characteristics will be documented as will papilla and calyces. One or more papillary biopsies will be taken for analysis.
1747861|NCT00169819|Drug|Abciximab|
1747862|NCT00169832|Drug|Rosiglitazone or placebo|Rosiglitazone 4 to 8 mg/day or placebo, for 12 months
1747863|NCT00169845|Dietary Supplement|Alpha-Tocopherol and Beta-Carotene|Provided by Roche Vitamins Inc.
1747864|NCT00169845|Dietary Supplement|Placebo|Provided by Roche Vitamins Inc
1747865|NCT00169858|Biological|Engerix-B|10 mkg per dose; 3 doses according to 0, 1, 6 month schedule; booster doses 5, 10 or 15 years post-primary vaccination.
1747866|NCT00169884|Behavioral|cognitive-behavioural therapy|
1747867|NCT00169897|Behavioral|Pulmonary rehabilitation (teaching and exercise)|After a 4-week education program, patients took part to home-based rehabilitation or outpatient hospital-based rehabilitation for 8 weeks. Patients were subsequently followed for 40 weeks to complete the one-year study.
1747868|NCT00169910|Drug|AUC monitored withdrawal of MMF or CNI|AUC monitored withdrawal of MMF or CNI from a immunosuppressive drug regimen with steroids, CNI and MMF in stable renal transplant recipients
1747869|NCT00169923|Drug|rosiglitazone|
1747870|NCT00169936|Device|Magnetocardiograph|
1747871|NCT00169949|Drug|aripiprazole|
1747872|NCT00169962|Drug|rhDNAse (pulmozyme)|
1747873|NCT00169975|Device|Magnetocardiograph|MCG and ECG recordings sequentially at the four pre-defined bed positions and watches the real-time magnetocardiogram traces on the computer screen. At each position, nine sensors record MCG data, thus forming a 3 x 3 point grid square with point-to-point separation of 40 mm. The number of cardiac cycles recorded at each position should be adequate for signal averaging. Recording time per position is typically 90 seconds. At the end of 4 sequential recordings, raw, unfiltered MCG data are stored.
1747874|NCT00169988|Drug|risperidone|
1747875|NCT00169988|Drug|sertraline-primary|
1747876|NCT00170001|Drug|Nexium|40 mg bid dosing
1747877|NCT00170001|Drug|Sugar Pill|40 mg BID
1747878|NCT00170014|Device|Magnetocardiograph|
1747879|NCT00170027|Device|Magnetocardiograph|
1747880|NCT00170053|Drug|Sirolimus|10 mg oral loading dose followed by 5 mg/day. Measure Sirolimus level weekly and adjust to level of 10-15 ng/ml.
1747881|NCT00170079|Behavioral|Smoking Cessation Intervention|"A common approach to increasing long-term adherence and control of chronic medical problems such as hypertension in both general and preventive medicine is the concept of step care. The purpose of this study is to evaluate the long-term efficacy of a step care model for smoking cessation that is disseminable in primary care settings. With that introduction, we propose the following specific aims:
Aim 1: To enroll approximately 400 adult cigarette smokers recruited mainly from primary care settings;
Aim 2: To randomize these participants to: 1) State of the Art Smoking Cessation + Recycling or 2) State of the Art Smoking Cessation + Step Care; and
Aim 3: To evaluate the long-term (24 months post-randomization) relative success of the interventions. It is predicted that long-term cessation rates will be significantly higher in the step care condition."
1747882|NCT00170118|Behavioral|motivational interviewing|
1747883|NCT00170144|Drug|Branchamin 4%|
1747884|NCT00170157|Drug|Bicalutamide|Given orally
1747885|NCT00170157|Drug|Flutamide|Given orally
1747886|NCT00170157|Drug|Goserelin Acetate|Given SC
1747887|NCT00170157|Drug|Ipilimumab|Given IV
1747888|NCT00170157|Drug|Leuprolide Acetate|Given IM
1747889|NCT00170157|Other|Pharmacological Study|Correlative study
1747890|NCT00163189|Drug|Somatropin|Liquid, daily, during 3 years and extended to 5 years Dosage: 0,46 mg/kg/week - the maximum dose should not exceed 50 µg/kg/day
1747891|NCT00163202|Procedure|Blood samples|
1747892|NCT00163202|Drug|Atorvastatin|
1747893|NCT00163215|Drug|Somatropin|Adapted dosage based on IGF 1 level and weight Form: liquid; Dosage and Frequency: from 0.0033mg/kg/day to 0.0067 mg/kg/day; Duration: 3 years
1747894|NCT00163241|Drug|celecoxib|
1747895|NCT00163254|Drug|abciximab|
1747896|NCT00163254|Device|stent and drug eluting stent|
1747897|NCT00163267|Drug|clopidogrel|Best endovascular treatment either with one or the other drug arm should be investigated
1747898|NCT00163280|Drug|ATL-104|Daily does of ATL-104 (50,100 or 150mg) or placebo for 3 days prior to the start of chemotherapy and peripheral blood stem cell transplantation. Following stem cell transplantation patients received 3 further daily doses of ATL-104 (50, 100 or 150mg) or placebo.
1747901|NCT00163306|Drug|Pantoprazole|
1747902|NCT00163319|Drug|Ciclesonide|
1747903|NCT00163332|Drug|Ciclesonide|
1747904|NCT00163345|Drug|Ciclesonide|
1747905|NCT00163358|Drug|Ciclesonide|
1747906|NCT00163371|Drug|Ciclesonide|
1747907|NCT00163384|Drug|Ciclesonide|
1747908|NCT00163397|Drug|Ciclesonide|
1747909|NCT00163410|Drug|Ciclesonide|
1747910|NCT00163423|Drug|Ciclesonide|
1747911|NCT00163436|Drug|Ciclesonide|
1747912|NCT00163449|Drug|Ciclesonide|Efficacy and Safety of Ciclesonide
1747913|NCT00163449|Drug|Placebo|Placebo
1747914|NCT00170183|Drug|Nesiritide|
1747915|NCT00170196|Drug|prednisone|
1747916|NCT00170209|Drug|Isoniazid|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-15 mg/kg/day (max=300mg/day). Total duration of treatment is 9 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
1747917|NCT00170209|Drug|Rifampin|The dosage of the medication is determined according to the weight of the child. The dose is once per day, 10-20 mg/kg/day (max=600mg/day). Total duration of treatment is 4 months. Both a detailed dose chart calculating doses by weight and age and protocols for preparation of medications (crushing pills, mixing suspensions) are available.
1747918|NCT00170222|Drug|doxycycline|
1747919|NCT00170235|Other|Prehabilitation|Exercise class pre-surgery
1747920|NCT00170235|Other|Usual care|Exercise booklet, physiotherapy if needed
1747921|NCT00170248|Device|computer-based decision support for asthma management|The asthma management decision support system uses data from the patient problem and medication list to provide patient-specific management recommendations based on Canadian Consensus guidelines for asthma management. Web-enabled technology for asthma education nurses is used to collect home-monitoring information from patients between visits and feedback to primary care physicians in accordance with options selected by the physician for each patient.
1747922|NCT00170261|Device|Use of an Implantable Loop Recorder|
1747923|NCT00170274|Device|Activation of preventive and therapeutic algorithms for treatment of AF|Algorithms in At 500 or Enrhyhtm for prevention and termination of Atrial Fibrillation
1747924|NCT00170274|Device|AF Prevention and Therapy Algorithms On|Activation of AF-prevention and termination algorithms in AT 500 or EnRhyhtm
1747925|NCT00170287|Procedure|ICD Ablation plus VT-ablation|ICD-Therapy for the treatment of unstable VT´s plus catheter ablation for substrate modification
1747926|NCT00170287|Device|ICD Therapy|ICD Therapy for the Treatment of unstable VT´s
1747927|NCT00170300|Device|Implantable Cardiac Resynchronisation (pacing) device|
1747928|NCT00170313|Device|Conducted AF-Response Algorithm (CAFR) On|Algorithm will be enabled.
1747929|NCT00170313|Device|Conducted AF-Response Algorithm (CAFR) Off|Algorithm will be disabled.
1747930|NCT00170326|Procedure|dual-chamber pacemaker implantation|Dual Chamber pacing via conventional DDD(R) right ventricular pacemaker or in case of ICD indication a standard dualchamber ICD device.
1747931|NCT00170326|Procedure|biventricular dual-chamber pacemaker implant|Biventricular pacemaker system or in case in ICD indication a BIV ICD
1747932|NCT00170352|Procedure|Hyperbaric Oxygen Treatment (HBOT)|
1747933|NCT00170352|Procedure|Enhanced Oxygen Treatment (Enhanced FiO2)|
1747934|NCT00170365|Behavioral|Restorative Yoga|
1747935|NCT00170378|Drug|Enoxaparin|
1747936|NCT00170391|Behavioral|Quarter of an Hour rule|
1747937|NCT00170404|Drug|Folic Acid|
1747938|NCT00170404|Drug|Micronutrients: Vitamins B1, B2, B6, Niacin, B12, C, E.|
1747939|NCT00170404|Drug|Selenium|
1747940|NCT00170404|Drug|Vitamin A|
1747941|NCT00170417|Behavioral|Cognitive Behaviour Therapy|
1747942|NCT00170430|Drug|Fluconazole|
1747943|NCT00170430|Drug|Metronizadole|
1747944|NCT00170443|Biological|rHAO Trivalent Influenza Vaccine|
1747945|NCT00170456|Biological|rPA vaccine containing alhydrogel|
1747946|NCT00170469|Biological|AVA|
1747947|NCT00170469|Biological|rPA vaccine containing alhydrogel|
1747948|NCT00171561|Drug|valsartan/hydrochlorothiazide|
1747949|NCT00171574|Drug|Valsartan|
1747950|NCT00171574|Drug|Valsartan plus HCTZ|
1747951|NCT00171574|Drug|Lisinopril|
1747952|NCT00171587|Drug|PTK787/ZK 222584 (vatalanib)|
1747953|NCT00171600|Drug|VALSARTAN, VALSARTAN PLUS HCTZ, LISINOPRIL, LISINOPRIL PLUS HCTZ|
1747954|NCT00171613|Drug|Octreotide|
1747955|NCT00171626|Drug|Diclofenac Topical Sodium Gel 1%|
1747956|NCT00171639|Drug|zoledronic acid|
1747957|NCT00171652|Drug|Diclofenac sodium gel 1%|
1747958|NCT00171665|Drug|Diclofenac topical sodium gel 1%|
1747959|NCT00171678|Drug|Diclofenac Topical Sodium Gel 1%|
1747960|NCT00171691|Drug|Diclofenac Topical Sodium Gel 1%|
1747961|NCT00171704|Drug|Letrozole|2.5 mg tablets and supplied in bottles with 6-monthly supplies.
1747962|NCT00171704|Drug|Tamoxifen|20 mg tablets in bottles as 6-monthly supplies (supplied to Novartis as Tamofen from Schering Oy, Subsidiary of Schering AG, Pansiontie 47, FIN-2010 Turku, Finland)
1747963|NCT00171717|Drug|Cyclosporine - cyclosporine microemulsion|
1747964|NCT00171730|Drug|Pasireotide|
1747965|NCT00171743|Drug|Cyclosporine microemulsion|
1747966|NCT00171756|Drug|valsartan/atenolol|
1747967|NCT00171769|Drug|Certoparin|
1747968|NCT00171782|Drug|VALSARTAN+HYDROCHLOROTHIAZIDE|
1747969|NCT00171795|Drug|Rivastigmine|
1747970|NCT00171808|Drug|Letrozole|
1747971|NCT00171821|Drug|Deferasirox|
1747972|NCT00171834|Drug|Patupilone|Patupilone (2.5 mg/mL) was supplied as a clear, colorless concentrate for solution for infusion in glass vials containing 5 mg/2 mL in Phase I and 10 mg/4 mL in Phase II part of the study. Patupilone was administered as a single intravenous (i.v.) infusion over 5 to 10 minutes (Amendment 1) till Amendment 2 and over 10 to 20 minutes (Amendment 2) till the completion of Phase I part of the study. Patupilone was administered as a single i.v. infusion over 20 minutes (Amendment 4), once every 3 weeks in Phase II part of the study.
1747973|NCT00171847|Drug|Letrozole|
1747974|NCT00171847|Drug|Trastuzumab plus Letrozole|
1747975|NCT00171847|Drug|Letrozole|
1747976|NCT00171860|Drug|imatinib mesylate|
1747977|NCT00171873|Drug|Octreotide LAR (Long-acting release)|30 mg intramuscularly every 28 days
1747978|NCT00171873|Drug|Placebo|Sodium chloride intramuscularly every 28 days
1747979|NCT00171886|Drug|Octreotide|
1747980|NCT00171899|Drug|imatinib mesylate|
1747981|NCT00171912|Drug|imatinib mesylate|
1747982|NCT00171925|Drug|Zoledronic acid|Zoledronic acid administered via normal saline intravenous infusion (over 15 minutes) every 4 weeks. Dosage was according to calculated creatinine clearance: patients with baseline creatinine clearance > 60 ml/min received 4 mg; for patients with mild to moderate renal impairment, doses were calculated to achieve the same AUC as that achieved in patients with creatinine clearance of 75 ml/min, assuming target AUC of 0.66 (mg*hr/l).
1747983|NCT00171925|Dietary Supplement|Calcium / Vitamin D|Patients on zoledronic acid received 500 mg calcium and 400-500 IU vitamin D combination tablet daily.
1747984|NCT00171938|Drug|imatinib mesylate|
1747985|NCT00171951|Drug|Pasireotide|
1747986|NCT00171964|Drug|Zoledronic acid in combination with therapy|
1747987|NCT00171977|Drug|Imatinib Mesylate|
1747988|NCT00171990|Drug|Famciclovir|
1747989|NCT00172003|Drug|Zoledronic acid|
1747990|NCT00172016|Drug|Zoledronic acid|
1747991|NCT00172029|Drug|Zoledronic acid|
1747992|NCT00172042|Drug|Zoledronic acid 4 mg|Zoledronic acid 4 mg in 5 mL concentrated solution prepared with 100 mL calcium free infusion solution (0.9 % sodium chloride or 5% glucose solution).
1747993|NCT00172055|Drug|Zoledronic acid|
1747994|NCT00172068|Drug|Zoledronic acid + Calcium/Vitamin D|
1747995|NCT00172081|Drug|placebo|Daily subcutaneous injection with placebo
1747996|NCT00172081|Drug|ALX1-11|PTH (1-84) 100 mcg injected subcutaneously into the thigh or abdomen
1747997|NCT00172094|Drug|NPS 1776 (800 mg)|NPS 1776 (800 mg) powder
1747998|NCT00172094|Drug|PLACEBO|Placebo in non-carbonated fruit flavored drink (150 ml)
1747999|NCT00172094|Drug|NPS 1776 (400 mg)|NPS1776 in powdered form to be mixed with a non-carbonated fruit flavored drink
1748000|NCT00172107|Drug|ALX1-11 50 mcg|PTH(1-84) 50 mcg for subcutaneous injection into thigh or abdomen
1748001|NCT00172107|Drug|placebo|placebo powder for subcutaneous injection
1748002|NCT00172107|Drug|ALX1-11 75mcg|PTH(1-84)75 mcg for subcutaneous injection
1748003|NCT00172107|Drug|ALX1-11|PTH (1-84) 100mcg for subcutaneous injection into thigh or abdomen
1748004|NCT00172120|Drug|ALX1-11|
1748005|NCT00172133|Drug|ALX1-11 (drug)|100 mcg PTH(1-84) injected subcutaneously daily in either the thrigh and abdomen.
1748006|NCT00172159|Procedure|Hepatic resection|
1748007|NCT00172172|Drug|PTH/Calcium|PTH(1-84) subcutaneous injection and calcium 700 mg oral
1748008|NCT00172172|Drug|PTH/placebo|PTH (1-84) injected subcutaneously and placebo provided orally
1748009|NCT00172172|Drug|placebo|Placebo injected subcutaneously and 700 mg calcium orally
1748010|NCT00172185|Drug|teduglutide 0.05 mg/kg/d|0.05 mg/kg/d subcutaneous injection
1748011|NCT00172185|Drug|teduglutide 0.10 mg/kg/d|0.10 mg/kg/d subcutaneous injection
1748012|NCT00172198|Drug|Omegaven 10%|
1748013|NCT00172211|Drug|Physioneal|
1748014|NCT00172263|Procedure|blood sampling|
1748015|NCT00172302|Drug|vitamin C, intravenous injection|
1748016|NCT00172328|Biological|Hepatitis B vaccine|
1748017|NCT00172341|Drug|Staloral TM|
1748018|NCT00172354|Drug|Hydrocortisone|
1748019|NCT00172367|Drug|Lycopene|
1748020|NCT00172380|Drug|Docetaxel Plus CDDP|docetaxel 36mg/m2 and cisplatin 75mg/m2
1748021|NCT00172419|Drug|Atorvastatin|Atorvastatin, 40 mg/day for 12 weeks
1748022|NCT00172445|Procedure|blood sampling, neck lymph node biopsy|
1748023|NCT00172484|Procedure|education program|A well-designed questionnaire concerning about awareness of stroke symptoms, knowledge, and management was done in adults of stroke victims' family members and general population.
1748024|NCT00172484|Procedure|nursing program|To establish a systemic stroke prevention, education protocol
1748080|NCT00166530|Drug|simvastatin|Zocor®; simvastatin 40 mg once daily for 12 weeks. Tablets
1748081|NCT00166530|Drug|atorvastatin|20 mg atorvastatin once daily for 12 weeks. Tablets
1748082|NCT00166543|Drug|TAS-108|
1748083|NCT00166556|Drug|Campath-1H and Tacrolimus|
1748084|NCT00166582|Device|electronic medication monitoring system|
1748025|NCT00172484|Procedure|rehabilitation program|From a sample of 648 stroke patients who were referred to rehabilitation between November 2002 and October 2002, 345 charts were successfully reviewed. Besides, 126 subjects were randomly selected and successfully contacted for telephone follow-up; and data from 87 subjects of telephone survey were included for statistical analysis. Comparison of functional status between early rehabilitation and ordinary scheduled rehabilitation for acute stroke patients was done from admission to 3 months after stroke onset. The efficacy of early application of electric stimulation for the upper paralyzed extremity was performed.
1748026|NCT00172510|Procedure|blood drawing|
1748027|NCT00172536|Behavioral|Exercise training|Subjects attended a supervised treadmill training session three times per week in an outpatient facility for three months. Training duration was 30 minutes per session, including a 5-minute warm-up and cool-down phase. Training intensity was initially set at about 60% of HR reserve and close to the anerobic threshold (AT) and the gradually increased as tolerated.
1748028|NCT00172536|Other|Control|Subjects received general education including proper diet, regular physical activity or medical care if necessary through an interview with a physical therapist.
1748029|NCT00172601|Procedure|mobilization|
1748030|NCT00172653|Procedure|functional tasks|
1748031|NCT00172809|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 135 ug/week for 24 weeks
1748032|NCT00172809|Drug|Interferon alfa-2a|Interferon alfa-2a 3 MU tiw for 24 weeks
1748033|NCT00172939|Procedure|foreskin from healthy adults|
1748034|NCT00173017|Device|wearing N95 masks|
1748035|NCT00173082|Procedure|Glucose tolerance test|
1748036|NCT00173108|Behavioral|clinic-based intervention program and home-based intervention program|The intervention includes education of child development skills, health and feeding consultation, intervention of mother-infant interaction, and parent support. Clinic-based intervention program is delivered in clinic while home-based intervention program is delivered at home.
1748037|NCT00173251|Procedure|obtain surgical specimen for analysis|
1748038|NCT00173407|Procedure|immunohistochemical, methylation, gene transfection|
1748039|NCT00173472|Drug|Chemotherapy|
1748040|NCT00173511|Device|24 hr Holter monitor|
1748041|NCT00173524|Behavioral|PharmacoEconomic Assessment|Collecting PE data.
1748042|NCT00173537|Procedure|for BMPR II study|
1748043|NCT00173537|Genetic|BMPRII|
1748044|NCT00173550|Procedure|Hysterectomy and Bilateral salpingo-oophorectomy|
1748045|NCT00173615|Procedure|Extracorporeal membrane oxygenation|
1748046|NCT00173628|Procedure|blood drawing|
1748047|NCT00173641|Procedure|blood drawing|
1748048|NCT00173654|Procedure|blood drawing|
1748049|NCT00173667|Drug|Nifedipine 30 mg GITS|
1748050|NCT00173693|Behavioral|exercise for strength, balance, health education|
1748051|NCT00173706|Drug|L-Carnitine Injection|
1748052|NCT00173719|Device|Standard cane|
1748053|NCT00173745|Drug|botulinum toxin A injection|
1748054|NCT00173758|Procedure|co-culture of embryos and endometrial cells|
1748055|NCT00173862|Drug|Gemcitabine, Ifosfamide|
1748056|NCT00173875|Drug|Iressa|
1748057|NCT00173888|Drug|Docetaxel, Cisplatin|docetaxel 36mg/m2 IF 30 mins on day 1,8,15 cisplatin 75mg/m2 IF 2 hrs on day 15
1748058|NCT00173888|Drug|Gemcitabine, Cisplatin|gemcitabine 1000mg/m2 IF 30mins on D 1,8,15, cisplatin 75mg/m2 IF 2 hrs on day 15
1748059|NCT00173901|Drug|ceftazidime|
1748060|NCT00173953|Procedure|immune response|
1748061|NCT00173992|Behavioral|Balance and Exercise|
1748062|NCT00166348|Behavioral|Cognitive Group Therapy|
1748063|NCT00166361|Device|Memokath 051 Ureteral Stent|The Memokath 051 ureter stent is used for the treatment of malignant or benign ureteric strictures in both men and women. The stent design consists of a tightly-coiled nickel-titanium alloy, with a diameter of 10.5 French (Fr) and a fluted proximal diameter expanding to 22 Fr. The stent is manufactured in multiple lengths which are chosen to position the device across the narrowed area rather than crossing the ureteropelvic or ureterovesical junction. It has a thermal memory system for its predetermined shape; the stent softens at temperatures below 10 degrees Celsius but regains its shape when heated above 55 degrees Celsius.
1748064|NCT00166361|Device|JJ Stent|A JJ stent is a flexible plastic tube that drains urine from the kidney to the bladder and is supposed to stay in place temporarily. There is a coil on each end to keep the stent in place, preventing the stent from migrating down and out from the kidney or up from the bladder into the ureter. The stent can stay in place for few weeks to 3 months or more depending on the indication. If left for more than 6-9 months some stents may get encrusted leading to stone formation around the stent.
1748065|NCT00166374|Procedure|balloon kyphoplasty|
1748066|NCT00166387|Procedure|Blood draw|A single blood draw.
1748067|NCT00166400|Drug|metoprolol succinate|Treatment with potent beta-blockade titrated to the maximally tolerated dose.
1748068|NCT00166413|Drug|CC-5013|40 mg/day orally on days 1-4 and 15-18 of each 28-day cycle
1748069|NCT00166426|Drug|Exisulind|
1748070|NCT00166439|Drug|Oxaliplatin, Cytosine Arabinoside, Dexamethasone With Rituxan (ROAD)|"rituximab 375 mg/m2 IV Weekly x 4 1 cycle only
dexamethasone 40 mg PO/IV Days 2-5 q 21 days 2 cycles
oxaliplatin 130 mg/m2 IV Day 2 q 21 days 2 cycles
cytosine arabinoside 2000 mg/m2 x 2 doses IV Days 2-3 q 21 days 2 cycles
pegfilgrastim 6 mg SQ Day 4 q21 days 2 cycles"
1748071|NCT00166452|Drug|Lenalidamide|
1748072|NCT00166465|Drug|ALIMTA plus Oxaliplatin versus Oxaliplatin plus 5-Fluorouracil and Leucovorin (FOLFOX 4 Regimen)|
1748073|NCT00166478|Drug|Exisulind Therapy|
1748074|NCT00166491|Drug|Insulin|
1748075|NCT00166504|Drug|ezetimibe (+) simvastatin|simvastatin/ezetimibe 10/20 mg
1748076|NCT00166504|Drug|atorvastatin|atorvastatin 10 mg
1748077|NCT00166517|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
1748078|NCT00166517|Biological|Comparator: Placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 70 days post Dose 1, and 28 to 70 days post Dose 2
1748079|NCT00166530|Drug|ezetimibe (+) simvastatin|Vytorin® combination tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily for 12 weeks. Tablets
1748085|NCT00166582|Behavioral|parent-adolescent communication and problem-solving skills|
1748086|NCT00166595|Drug|Risperidone|
1748087|NCT00166608|Procedure|Blood sampling|
1748088|NCT00166621|Drug|Buspirone|
1748089|NCT00166634|Procedure|Ambulatory Blood Pressure Monitoring (ABPM)|
1748090|NCT00166647|Procedure|Blood Sampling|
1748092|NCT00166673|Device|FreeStyle Navigator Continuous Glucose Monitoring System|
1748093|NCT00166686|Drug|Clonidine|
1748094|NCT00166699|Procedure|ultrasound|The use of ultrasound to guide the insertion of combined spinal epidural needle
1748095|NCT00166712|Drug|Tacrolimus (TAC)|Tacrolimus (TAC) will be given standard of care by prescription twice a day (2.0 mg), orally. Doses will be adjusted by serum levels. The dose will be modified to achieve 12 hour trough concentrations of 5-8 ng/mL.
1748096|NCT00166712|Drug|Sirolimus|Sirolimus will be given standard of care by prescription, dosed at 5mg daily. The dosage will be adjusted by serum level to achieve 24 hour trough concentrations of 8-12 ng/mL by HPLC assay.
1748097|NCT00166712|Drug|Alemtuzumab|Patients receiving alemtuzumab will be premedicated with 50mg of diphenhydramine hydrochloride, and 650mg of acetaminophen 30-60 minutes to the first Alemtuzumab infusion. The of 30mg will be diluted in 100cc sterile 0.9% normal saline and infused over 2 hours. The infusion line must contain an in-line 0.22-micron filter. Alemtuzumab will be administered on the day of transplant (intraoperatively), and on post-operative day 2. Both doses will be administered while the patient is in the hospital. Alemtuzumab is supplied in single-use clear glass ampoules containing 30mg of alemtuzumab in 3mL of solution.
1748098|NCT00166712|Drug|Mycophenolate mofetil (MMF)|MMF will be given at 1.0-1.5gm, twice daily, orally. The first dose will be given pre-transplant, open label fashion.
1748099|NCT00166725|Drug|Octreotide LAR|
1748100|NCT00166777|Procedure|exercise training|
1748101|NCT00166790|Drug|chemotherapy agents|
1748102|NCT00166790|Procedure|suction curettage|
1748103|NCT00166803|Drug|Rosiglitazone|Rosiglitazone , 4 mg daily
1748104|NCT00166816|Drug|sirolimus, cyclosporine, tacrolimus|
1748105|NCT00166829|Drug|sirolimus, tacrolimus, mycophenolate mofetil|
1748106|NCT00166842|Drug|sirolimus, cyclosporine, tacrolimus|
1748107|NCT00166855|Procedure|dynamic MRI and bone marrow sampling|
1748108|NCT00166868|Drug|Lactobacillus casei rhamnosus (Lcr35)|
1748109|NCT00166868|Drug|Neomycin|
1748110|NCT00166881|Drug|Docetaxel-Irinotecan|Docetaxel-Irinotecan, weekly, days 1, 8, 15, repeated every 4 weeks
1748111|NCT00166907|Behavioral|Balance and Exercise|
1748112|NCT00166946|Procedure|foreskin from healthy adults for organotypic culture|
1748113|NCT00167011|Procedure|CT|
1748114|NCT00167089|Behavioral|Treadmill Training|Partian body weight support treadmill training, 30 min/day * 3 days /week
1748115|NCT00167102|Drug|Alefacept|Study participants will receive weekly IM administration of placebo or 15 mg of alefacept for 12 weeks, to be followed by a 12-week post-treatment period during which the safety, efficacy, and durability of effect in treatment responders will be assessed on weeks 2, 4, 8 and 12.
1748116|NCT00167115|Drug|Alcohol|
1748117|NCT00167128|Device|hearing aid, Phonak EduLink-FM System|
1748118|NCT00167141|Drug|injection of hormonal male contraceptive|testosterone injections 4 times
1748119|NCT00167154|Drug|Risperidone and placebo comparator|Up to 2 mg risperidone or matching placebo daily
1748120|NCT00167167|Procedure|Donor Lymphocyte Infusion|"Certain immune cells in your donor's blood called lymphocytes have been shown to fight cancer after bone marrow transplantation. We plan to transfuse large numbers of donor's lymphocytes in the hope of activating the recipient's immune system to attack cancer."
1748121|NCT00167180|Procedure|Donor Lymphocyte Infusion|donor cells infused over 2 hrs at cell dose of 0.5 dx 10^8 CD3+T-cells/kg
1748122|NCT00167180|Drug|Induction Chemotherapy|Fludarabine 25 mg/m2 IV Cyclosphosphamide 60 mg/kg IV
1748123|NCT00167206|Procedure|Hematopoietic Stem Cell Transplant|Bone marrow failure may be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
1748124|NCT00167206|Procedure|Thymic Shielding During Radiation|protecting the thymus during total body radiation (450 cGy administered)
1748125|NCT00167206|Procedure|Total Body Irradiation|Six days before the stem cells are given (day -6), subjects will receive total body irradiation with thymic shielding. Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
1748126|NCT00167206|Drug|Cyclophosphamide, Fludarabine|Day -5 through Day -2, subjects will receive a chemotherapy regimen of Fludarabine, Cyclophosphamide via central line
1748127|NCT00167219|Biological|Stem Cell Transplant|Transplantation on Day 0.
1748128|NCT00167219|Drug|Preparative Regimen|"Busulfan
Cyclophosphamide
Mesna
Melphalan
Anti-thymocyte Globulin (ATG)"
1748129|NCT00167232|Drug|Naltrexone|
1748130|NCT00167245|Drug|Topiramate|300mg/day for 13 weeks
1748131|NCT00167245|Drug|placebo|placebo pills
1748132|NCT00167258|Behavioral|Voucher Reinforcement|
1748133|NCT00167258|Behavioral|Extra Counseling Services|
1748134|NCT00167258|Behavioral|Voucher Reinforcement + Extra Counseling Services|
1748238|NCT00176215|Procedure|survival failure of more than 20 %|
1748135|NCT00167271|Behavioral|Cognitive Behavior Therapy|Experimental: Computerized cognitive, behavioral therapy with Body Media armband to collect data about activity, which subjects could review each evening.
1748136|NCT00167284|Behavioral|physician and patient education; physician practice redesign|
1748137|NCT00167297|Drug|Atomoxetine|
1748138|NCT00167310|Drug|Eicosapentaenoic acid (omega-3 fatty acid)|2 g of Eicosapentaenoic acid in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
1748139|NCT00167310|Drug|Placebo|2 g of Placebo (soy bean oil) in 4 x 500 mg capsules daily for baseline, 1 month, 2 months and 4 months
1748140|NCT00167323|Behavioral|Adherence therapy|
1748141|NCT00167362|Behavioral|Cognitive enhancement therapy (CET)|Using 80 to 100 hours of graduated exercises in computer assisted training, coupled with structured but unrehearsed in vivo social group interactions, CET tries to shift an early developmental reliance on effortful, serial and verbatim cognitive processing to a more gistful, less effortful and spontaneous abstraction of social themes. CET uses attention, memory and problem solving software from three exercises from Ben-Yishay's Orientation Remediation Module (the Attention Reaction Conditioner, Zero Accuracy Conditioner, and Time Estimates) that are graduated in difficulty and designed to enhance vigilance, selective attention, the ability to shift between auditory and visual modalities, and rapid decision-making.
1748142|NCT00167362|Behavioral|Enriched supportive therapy (EST)|EST is the commonly recommended (Spaulding 1992) treatment for control and experimental subjects in psychosocial trials. EST is a two-staged treatment that requires weekly one-hour sessions in Phase 1 and biweekly sessions in Phase 2. Some practice principles (e.g., psychoeducation and relaxation training) are provided during the group exercises for CET patients, but individually for EST patients. No attempt is made to control for hours of contact between EST and CET, since offering three hours of supportive therapy to EST subjects is neither logistically feasible nor faithful to the goals and methods of supportive therapy. Further, neurobiological hypotheses related to treatment specificity would be best tested by clear differences in treatment intensity and content.
1748143|NCT00167375|Drug|eszopiclone 3 mg qHS|
1748144|NCT00167375|Behavioral|General cognitive/behavioral interventions for insomnia|
1748145|NCT00167388|Other|feed during blood transfusion|babies receiving the intervention are fed during the PRBC transfusion
1748146|NCT00167401|Drug|docetaxel|
1748147|NCT00167401|Drug|cisplatin|
1748148|NCT00167401|Procedure|radiation treatment|
1958291|NCT01801449|Drug|Rilonacept|
1748151|NCT00167453|Procedure|Exercise, Education|
1748152|NCT00167466|Device|Soladey-3 toothbrush|subject to brush with experimental Soladey-3 brush for 4 week
1748153|NCT00167466|Device|Placebo Soladey-3 toothbrush|subjects will brush with placebo Soladey-3 toothbrush for 4 weeks
1748154|NCT00167479|Drug|risperidone (Risperdal)|
1748155|NCT00167492|Drug|Myfortic|720 mg by mouth every 12 hours
1748156|NCT00167505|Behavioral|Risk Avoidance Intervention|The risk avoidance intervention is a Title V compliant curriculum emphasizing abstinence until marriage and strong character development. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
1748157|NCT00167505|Behavioral|Risk Reduction Intervention|The risk reduction intervention is a curriculum providing skills for abstinence and condom and other contraceptive use. The curriculum includes 12 classroom and CD-ROM based lessons delivered in the 7th and 8th grade. Lessons include topics such as puberty, reproduction, healthy relationships, consequences of sex, and refusal skills.
1748158|NCT00167518|Drug|Triamcinolone acetate|
1748159|NCT00167531|Behavioral|treadmill walking with partial weight support|
1748160|NCT00167531|Behavioral|assisted overground walking|30 minutes per day of overground walking with the assistance of one therapist
1748161|NCT00167544|Drug|Hydrocortisone|Hydrocortisone 3 mg/kg/d divided q 12h IV/PO tapered over 7 days
1748162|NCT00167544|Drug|Placebo|Saline
1748163|NCT00167557|Drug|Pegylated Interferon|180mcg SC weekly starting 30 days post transplant
1748164|NCT00167557|Drug|Ribavirin|goal dose 13mg/kg starting 120 days post transplant for a minimum of 48 wks
1748165|NCT00167557|Procedure|Liver Biopsy|Liver biopsies performed at 9 points in time from time of liver transplant
1748166|NCT00167570|Device|Prosthetic socket fabricated using selective laser sintering|
1748167|NCT00167583|Drug|Cyclosporin A|3 mg/kg bw, augmented to 5 mg if necessary and combined with prednisolone. Adapted to serum levels
1748168|NCT00167583|Drug|Interferon-alpha2a|3-6 million iU per day sc., augmented to up to 9 if necessary, later reduced (according to clinical response) to 3 x 3 million iU /week.
1748169|NCT00167596|Device|Near Infrared Spectroscopy|resuscitation will be based on Surviving Sepsis Campaign guidelines AND on increasing StO2 to 80% or more in at least 2 out of the 3 following sites: thenar, masseter and deltoid
1748170|NCT00167596|Device|conventional|resuscitation will be based according to Surviving Sepsis Campaign
1748171|NCT00167609|Drug|dehydroepiandrosterone 100 and 400 mg|
1748172|NCT00167622|Procedure|mechanical ventilation|Non invasive mechanical ventilation at least 6 hours per day - if difficult swallowing, tracheal intubation and invasive mechanical ventilation
1748173|NCT00167622|Procedure|physiotherapy and oxygen if needed|oxygen will be delivered via facial mask whenever needed and physiotherapy
1748174|NCT00174161|Behavioral|self-care, health behavior|
1748175|NCT00174174|Drug|Modafinil|
1748176|NCT00174187|Drug|Somatropin|liquid, daily, until final height Dosage: 0,46 mg/kg/week . The maximum dose should not exceed 50 µg/Kg/day
1748177|NCT00174200|Drug|Risperidone 2 mg|
1748178|NCT00174226|Drug|Atomoxetine|
1748179|NCT00174226|Drug|Buspirone|
1748180|NCT00174239|Drug|cabergoline|
1748181|NCT00174239|Drug|controlled-release levodopa / carbidopa|
1748182|NCT00174252|Drug|Genotonorm (Somatropin)|0.40 mg/kg/week dived in 7 daily subcutaneous injections during 2 years
1748183|NCT00174265|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
1748184|NCT00174265|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
1748185|NCT00174278|Drug|Somatropin|
1748186|NCT00174291|Drug|Somatropin|Liquid, daily to final height Maximum Dosage: 50 µg/kg/day
1748187|NCT00174304|Drug|Amlodipine/atorvastatin single pill|
1748188|NCT00174317|Drug|Celecoxib|
1748189|NCT00174317|Drug|Diclofenac|
1748190|NCT00174330|Drug|atorvastatin|
1748191|NCT00174330|Drug|amlodipine|
1748192|NCT00174343|Drug|exemestane (Aromasin®)|
1748193|NCT00175721|Procedure|The Combined Cardiac Kidney Diabetes Care Clinic|See Detailed Description.
1748194|NCT00175734|Procedure|High Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
1748195|NCT00175734|Procedure|Low Hemoglobin Concentration|The purpose of this study is to document relevant and related clinical changes associated with different hemoglobin concentrations in diabetic hemodialysis patients.
1748196|NCT00175747|Drug|Inhaled Budesonide 800 µg twice daily|
1748197|NCT00175760|Procedure|Diagnosis of Celiac Disease|During GI endoscopy a minimum of 4 small intestinal biopsies will be taken from all subjects and controls.
1748198|NCT00175812|Drug|all-trans retinoic acid (ATRA)|All-trans retinoic acid 22.5 mg/square meter twice daily days 1-14
1748199|NCT00175812|Drug|Valproic acid|Valproic acid, highest dose without side effects from day 3 until progression
1748200|NCT00175812|Drug|Theophyllin|Theophyllin, targetted serum level 50-100 from day 3 until progression
1748205|NCT00175838|Drug|Hydroxyurea|Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
1748206|NCT00175838|Drug|Aspirin|Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
1748207|NCT00175851|Drug|Seletracetam (ucb 44212)|
1748208|NCT00175864|Drug|Seletracetam (ucb 44212)|
1748209|NCT00175877|Biological|Certolizumab Pegol|"Strength and Form: Lyophilized product reconstituted to 1 ml containing 200 mg of Certolizumab Pegol (CZP) given as a subcutaneous injection.
Dosage and Frequency: 400 mg every two weeks for at least 6 months, then 200 mg every two weeks.
Duration: Until end of study."
1748210|NCT00175890|Drug|Levetiracetam|Dosing was stratified by age. A dose of 20 mg/kg/day titrating to 40 mg/kg/day for children one month to less than six months old and a dose of 25 mg/kg/day titrating to 50 mg/kg/day for children 6 month to less than 4 years old, was used in this study. The total daily dose was administered b.i.d.
1748211|NCT00175890|Other|Placebo|Placebo solution, which is indistinguishable from the Levetiracetam oral solution.
1748212|NCT00175903|Drug|Levetiracetam|Daily dose of 1000 to 3000 mg film-coated oral tablets, 250-500 mg twice daily.
1748213|NCT00175903|Drug|Carbamazepine Controlled Release (CBZ-CR)|Daily dose of 600-1600 mg CR oral tablets, 200 mg and 400 mg twice daily.
1748214|NCT00175903|Drug|Valproate Extended Release|Daily dose of 1000-2000 mg ER oral tablets, 300 mg and 500 mg twice daily.
1748215|NCT00175916|Drug|Brivaracetam (ucb 34714)|10 mg and 25 mg tablets. Flexible dosing up to 200 mg/day, twice daily. For each subject, the study will last from study entry until either regulatory approval of brivaracetam has been granted by any Health Authority in an indication of adjunctive treatment of partial onset seizures; or until the Sponsor decides to close the study; until a managed access program, named patient program, compassionate use program, or similar type of access program is established as allowed per country-specific requirements in addition to legal and regulatory guidelines, or until the investigational product development is stopped by the Sponsor.
1748216|NCT00175929|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of placebo in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
1748217|NCT00175929|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
1748218|NCT00175929|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 150 mg/day in a double-blinded way for the 10-week Treatment Period (3 weeks up-titration followed by 7-week maintenance period)
1748219|NCT00175955|Drug|Levetiracetam|
1748220|NCT00175968|Procedure|bed rest, hypocaloric nutrition|
1748221|NCT00175981|Drug|sildenafil, fluvoxamine|
1748222|NCT00176007|Procedure|Hypoxia|
1748223|NCT00176020|Drug|nicotinic acid|
1748224|NCT00176046|Drug|viscum album pini|s.c. injection of 0,001-20 mg 3 times per week
1748225|NCT00176046|Drug|viscum album pini|s.c. injection 0,001-20 mg 3 times per week
1748226|NCT00176059|Drug|intravenous immunoglobulins (IVIG)|
1748227|NCT00176059|Procedure|kidney transplantation|
1748228|NCT00176098|Procedure|Hypnoanalgesia; Hypnotic shielding|
1748229|NCT00176111|Procedure|peripheral nerve stimulation (procedure)|
1748230|NCT00176124|Procedure|leukocyte depletion of whole blood|
1748231|NCT00176124|Other|Leukocyte filtration/Depletion|leukocyte depletion filters as used routinely: filters (prestorage) inherent to the blood bag sets by gravity force following storage on cold plate for 2 hours
1748232|NCT00176137|Procedure|preoperative radiochemotherapy|
1748233|NCT00176163|Behavioral|Operant behavioral treatment; Drug: THC|
1748234|NCT00176176|Device|EEG|
1748235|NCT00176189|Device|All ceramic FPDs|
1748236|NCT00176202|Drug|Divalproex Sodium|Divalproex sodium is a mood stabilizer
1748237|NCT00176202|Drug|risperidone|Risperidone is a second generation antipsychotic and antimanic drug
1748239|NCT00176228|Drug|Lamotrigine|"It is a mood stabilizer that is clinically the first choice if patients present with depression and is effective in adults for mania in maintenance phase. So it is administered to see how effective it is in children and adolescents.
The dose of lamotrigine will be 12.5 mg per day beginning the first day. It is increased in 12.5 mg increments every week until it reaches 50 mg and 25 mg per week of increment thereafter until maximum dose of 150 mg in those below 50 kg and 200-400 mg depending on clinical response in those above 50 kg."
1748240|NCT00176241|Drug|gemcitabine|2000-3000mg/m2 IV on days 1 & 15
1748241|NCT00176241|Drug|paclitaxel|150 mg/m2 IV on days 1 & 15
1748242|NCT00176241|Radiation|radiation|50-80 cGy on days 1,2,15,16
1748243|NCT00176254|Radiation|Radiotherapy|80 centigray (cGy) on Day 1 & 2 and 22 & 23 of chemotherapy
1748244|NCT00176254|Drug|Paclitaxel|225 mg/m2 intravenously over three hours on Days 1 and 22
1748245|NCT00176254|Drug|Carboplatin|Area under the curve (AUC) of 6 will be given intravenously over 30 minutes on days 1 and 22
1748246|NCT00176267|Radiation|Radiotherapy|50 cGy on days 1, 2, 8, 15, 22, 23, 29 & 36 of chemotherapy
1748247|NCT00176267|Drug|Paclitaxel|75 mg/m2 intravenously over one hour on Days 1, 8, 15, 22, 29 and 36
1748248|NCT00176267|Drug|Carboplatin|AUC of 6 on Days 1 & 22
1748249|NCT00176280|Drug|Leukine|
1748250|NCT00176280|Drug|Dexamethasone|
1748251|NCT00176293|Drug|dexamethasone|oral dexamethasone, 12mg BID on days 1, 2, 3, 4, & 5 of each 28-day cycle
1748252|NCT00176293|Drug|doxorubicin|Doxorubicin 50mg/m^2 I.V. on day 5
1748253|NCT00176306|Drug|Levofloxacin 750 mg IV|PK in obesity
1748254|NCT00176319|Behavioral|Aerobic endurance exercise training (ergometer)|
1748255|NCT00176332|Drug|rosuvastatin|
1748256|NCT00176345|Behavioral|Exercise Training|
1748257|NCT00176358|Device|PTCA and Stent Implantation|
1748258|NCT00176358|Behavioral|Exercise Training|
1748259|NCT00176371|Behavioral|physical exercise|
1748260|NCT00176384|Behavioral|Aerobic endurance exercise training (ergometer)|
1748261|NCT00176397|Procedure|Percutaneous coronary intervention (left main)|
1748262|NCT00176410|Drug|fluvastatin|40mg fluvastatin daily
1748263|NCT00176423|Drug|galantamine|
1748264|NCT00176436|Behavioral|Diet support group|Diet support group weekly and exercise sessions 3 times/week, placebo medication
1748265|NCT00176436|Behavioral|Group counseling and exercise|Support group weekly and exercise sessions 3 times/week for 24 weeks
1748266|NCT00176449|Drug|Bupropion SR|150mg twice a day (starting with 150mg once a day for three days)
1748267|NCT00176449|Drug|Placebo Oral Tablet|Comparable placebo
1748268|NCT00176462|Drug|aminopterin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
1748269|NCT00176462|Drug|L-asparaginase|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
1748270|NCT00176462|Drug|cyclophosphamide|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
1748271|NCT00176462|Drug|cytarabine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
1748272|NCT00176462|Drug|daunomycin|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
1748273|NCT00176462|Drug|dexamethasone|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
1748274|NCT00176462|Drug|6-mercaptopurine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
1748275|NCT00176462|Drug|methotrexate|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
1748276|NCT00176462|Drug|6-thioguanine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
1748277|NCT00176462|Drug|vincristine|Therapy will be divided into five phases: Induction, Consolidation, Delayed Intensification (only for those patients meeting clinical criteria defining a high risk of relapse), Intensive Continuation, and Continuation
1748278|NCT00176462|Drug|Triple Intrathecal Therapy (MTX, Cytarabine, Hydrocortisone)|
1748279|NCT00176462|Drug|Leucovorin|
1748280|NCT00176475|Biological|rituximab|Patients will receive a single day infusion of standard dose rituximab (375 mg/m2) on days -1, 6, 13, 20 approximately every 4 months (in conjunction with alternating doses of the lymphocyte infusion).
1748281|NCT00176475|Biological|therapeutic allogeneic lymphocytes|The product will then be assigned to the specific patient and the released product will be transported to and administered to the patient at CINJ, after premedication of the patient with acetaminophen 650 mg PO and diphenhydramine- HCl 25 mg PO. Blood product administration will be every 8 weeks and undertaken according to CINJ standard procedures
1748282|NCT00176488|Drug|epirubicin|Epirubicin (100 mg/m2) will be given on Day 1
1748283|NCT00176488|Drug|vinorelbine|Vinorelbine (18.75 mg/m2) will be given on Days 3 and 17.
1748284|NCT00176501|Biological|therapeutic allogeneic lymphocytes|If a partially HLA-matched donor is identified and other eligibility criteria are met, the patient will receive irradiated lymphocyte infusion(s).
1748285|NCT00176514|Drug|Administration of the antineoplastic|
1748286|NCT00176527|Biological|recombinant interferon alfa-2b|
1748287|NCT00176527|Drug|docetaxel|
1748288|NCT00176527|Drug|estramustine phosphate sodium|
1748290|NCT00176527|Genetic|polyacrylamide gel electrophoresis|
1748291|NCT00176527|Genetic|protein expression analysis|
1748292|NCT00176527|Other|immunohistochemistry staining method|
1748293|NCT00176540|Drug|dextromethorphan hydrobromide|
1748294|NCT00176553|Drug|Dextromethorphan|Patients will receive an inert carrier with or without dextromethorphan. The study drug will be administered at 1.5 mg/kg/dose on a BID schedule. The first dose to be given prior to each scheduled intravenous and/or intrathecal administration of methotrexate and continued for a total of seven days.
1748295|NCT00176566|Drug|Lozenge Intake|of green tea lozenges weighing 6 grams each, containing 0.45 grams of green tea solids eight (8) times daily for 12 weeks to patients with oral leukoplakia compared to the administration of a lozenge that does not contain green tea (i.e. a placebo lozenge).
1748296|NCT00176579|Procedure|dual x-ray absorptiometry|Dual x-ray absortiometry by densitometer will be performed to measure bone mineral density
1748297|NCT00176592|Drug|Betaseron|Betaseron 250 micrograms injected SQ every other day
1748298|NCT00176592|Drug|Copaxone|Copaxone 20 mg injected SQ every day (glatiramer acetate)
1748299|NCT00176605|Drug|Etoposide|50 mg per day of Etoposide orally for 21 consecutive days. Etoposide will be alternated with oral cyclophosphamide. The drug is administered at night just prior to bed. Week 1 of each cycle will begin with etoposide.
1748300|NCT00176605|Drug|Cyclophosphamide|50 mg per day of cyclophosphamide orally for 21 consecutive days. Cyclophosphamide will be alternated with oral etoposide. The drug is taken 2 hours after breakfast. The patient will be asked to increase hydration throughout the day. Recommendation is at least 6, 8oz glasses of water or other non-caffeinated beverage. Week 4 of the each cycle will begin with cylcophosphamide. Chronic administration of cyclophosphamide at this dose has been well tolerated
1748301|NCT00176618|Drug|sulindac|Sulindac 150 mg po BID
1748302|NCT00176618|Drug|curcumin|Curcumin 250 mg po BID
1748303|NCT00176631|Dietary Supplement|licorice root extract|Licorice root is started on Day 1 and is given at a dose of 6.75 g each day (five 450 mg capsules tid) for a total of 21 days in each cycle.
1748304|NCT00176631|Drug|docetaxel|All the patients will be treated with docetaxel at a dose of 60 mg/m2 every 21 days on Day 1 of the treatment cycle.
1748305|NCT00176644|Drug|Transdermal Estradiol|"application of 4 transdermal estradiol patches, each patch releases a dose of 0.1 mg/day for a total dose of 0.4 mg/day. All four patches will be changed every 7 days. This continuous weekly schedule will be followed until the patient goes off-study.
The patch will be applied to a clean, dry, intact area of the lower abdomen or the upper quadrant of the buttock. The sites should be rotated weekly. If a patch falls off during the 7 days, a new patch will be applied for the remainder of the 7 day period. At the end of the 7 days all four patches will be changed."
1748306|NCT00176657|Drug|HEMOBAG Assessment|
1748307|NCT00176670|Drug|midazolam or GameBoy or parental presence|
1748308|NCT00176683|Procedure|Capnography|device which measures carbon dioxide at intubation
1748309|NCT00176696|Device|Use of FACE monitor and BIS monitor|Face monitor records facial muscle activity
1748310|NCT00176722|Other|table tilt|One group randomized to table tilt. One group will be flat.
1748311|NCT00176735|Drug|Capecitabine|
1748312|NCT00176748|Drug|AG 6013736|5 mg po bid
1748313|NCT00176761|Drug|Interleukin-2 (IL-2)|
1748314|NCT00176774|Drug|Irinotecan|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
1748315|NCT00176774|Drug|5-Fluorouracil|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
1748316|NCT00176774|Drug|Leucovorin|Irinotecan by intravenous infusion (needle in a vein in your arm) over 90 minutes immediately followed by intravenous LV and 5-FU weekly for 4 weeks (days 1, 8, 15 and 22) followed by two weeks of no treatment.
1748317|NCT00176774|Drug|Tetrathiomolybdate|one 40 mg oral (by mouth) dose of TM three times a day with meals and one 60 mg oral dose (without food) at bedtime beginning at bedtime on day 1 of your first 6-week cycle of treatment. The between meal dose must be taken at least one hour before or one hour after a meal.
1748318|NCT00176787|Drug|Capecitabine|
1748319|NCT00176787|Procedure|Radiation|
1748320|NCT00176787|Procedure|Surgery|
1748321|NCT00176800|Drug|Tetrathiomolybdate (TM)|Tetrathiomolybdate: 20mg p.o. per day with largest meal. This will be started 4-6 weeks post-op, and continued x 2 years or until progression of disease is documented.
1748322|NCT00176800|Procedure|Radiation|Radiation treatments will be administered twice per day with each dose separated by more than 6 hours, on Days 1-5, 8-12 and 15-19.
1748323|NCT00176800|Procedure|Surgery|The persons's esophagus will be surgically removed (esophagectomy) on approximately Day #50.
1748324|NCT00176813|Drug|Gemcitabine|
1748325|NCT00176813|Drug|Cisplatin|
1748326|NCT00176813|Drug|Celecoxib|
1748327|NCT00176826|Procedure|Stem Cell Transplant|Infusion of hematopoietic stem cells (bone marrow, cord blood, peripheral blood stem cells) following myeloablative conditioning regimen.
1748328|NCT00176826|Drug|Myeloablative conditioning regimen|Busulfan intravenously for 4 days followed by cyclophosphamide intravenously for 4 days. Rabbit ATG is given intravenously for 4 doses pre-transplant.
1748329|NCT00176839|Procedure|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
1748330|NCT00176839|Drug|Busulfan|Prior to transplantation, subjects will receive BUSULFAN via the central venous line, four times a day for four days (days -7 through -4).
1748331|NCT00176839|Drug|Cyclophosphamide|Prior to stem cell transplantation, subjects will receive CYCLOPHOSPHAMIDE via the central venous line once a day for two days on days -3 and -2.
1748332|NCT00176839|Drug|Melphalan|MELPHALAN will be given via the central venous line for one day, on day -1, prior to stem cell transplantation.
1748333|NCT00176839|Drug|G-CSF|G-CSF is to be given daily IV beginning on day +1 until ANC 2.5 x 109/L.
1748334|NCT00176839|Drug|ATG|ATG will be administered to umbilical cord blood recipients.
1748335|NCT00176852|Drug|Busulfan, Fludarabine, ATG, TLI|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -8 and -7 Fludarabine 35 mg/m2 IV Days -6 through -2 Antithymocyte globulin (ATG) 30 mg/kg IV Days -2 and -1 Total lymphoid radiation 300 cGy
1748336|NCT00176852|Drug|Busulfan, Cyclophosphamide, ATG, GCSF|Busulfan 0.8 mg/kg/dose intravenous (IV) Days -9 through -6 Cyclophosphamide 50 mg/kg IV Days -5 through -2 ATG 30 mg/kg IV Day -1 GCSF 5 mcg/kg/day IV until ANC >2500 x 2 days.
1748337|NCT00176852|Drug|Campath, Fludarabine, Cyclophosphamide|Receives Campath-1H 0.2 mg/kg Days -10 through -6, Fludarabine 35 mg/m2 intravenous (IV) Days -6 through -2, total body irradiation (TBI) 300 cGy Day -1.
1748338|NCT00176852|Radiation|Total Body Irradiation|300 cGY Day -1
1748339|NCT00176852|Procedure|Stem cell infusion|Given Day 0
1748340|NCT00176865|Procedure|Stem Cell Transplant|IV on Day 0
1748341|NCT00176865|Drug|Fludarabine|30mg/m^2 IV Day -7 through Day -3
1748342|NCT00176865|Drug|Melphalan|140 mg/m^2 IV Day -1
1748343|NCT00176865|Drug|Anti-thymocyte globulin (ATG)|30 mg/kg IV Day -5 through Day -1
1748344|NCT00176865|Drug|Campath 1H|0.2 mg/kg IV X 5 days (used as an alternative to Anti-thymocyte globulin (ATG) if unable to tolerate ATG) Day -10 through Day -6
1748345|NCT00176865|Drug|Cyclosporin A|2.5 mg/kg IV every 12 hours (adults) or every 8 hours (children <40 kg) maintaining a level of >200mg/L Day -3 until Day +180 when, if no GVHD, the dose will be tapered 10% per week beginning on day 181
1748346|NCT00176865|Drug|Mycophenolate mofetil|15 mg/kg IV or orally bid and discontinued on Day +45 unless GVHD is present
1748347|NCT00176865|Drug|Intravenous immunoglobulin (IVIG)|500 mg/kg IV weekly beginning on Day +7 until Day +100
1748348|NCT00176878|Procedure|Stem cell transplant|Stem cell transplant on Day 0 - healthy marrow from an unrelated individual. A minimum of 1.0 x 10^9/kg nucleated cells/kg ideal body weight will be collected with a goal of 2.0 x 10^9/kg.
1748349|NCT00176878|Drug|Fludarabine monophosphate|fludarabine 175 mg/m^2 (total) on Days -6 through -3.
1748350|NCT00176878|Procedure|Total lymphoid irradiation|Dose 500 cGy radiation therapy to specific areas of the body
1748351|NCT00176878|Drug|Busulfan|Busulfan 8 mg/kg (total) on Days - 8 and -7 (orally or through the catheter),
1748352|NCT00176878|Biological|anti-thymocyte globulin|anti-thymocyte globulin (ATG) 15 mg/kg on days -2 and -1 via catheter
1748355|NCT00176904|Procedure|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains an enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
1748356|NCT00176904|Drug|Busulfan, Cyclophosphamide, Antithymocyte Globulin|"Subjects will receive BUSULFAN intravenously (IV)- patients < or= 12 kg 1.1 mg/kd/dose IV every 6 hours for 16 doses; patients > 12kg 0.8 mg/kg/dose IV every 6 hours for 16 doses - via the Hickman line four times daily for 4 days, CYCLOPHOSPHAMIDE intravenously (50 mg/kg/day IV over 2 hours) via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV (15 mg/kg/day over 2 hours) via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
1748357|NCT00176917|Procedure|Stem Cell Transplant|The purpose of hematopoietic cell transplantation is to introduce hematopoietic cells from a normal donor that contains the enzyme able to get rid of the substances that have accumulated in the body of patients with storage diseases. Hematopoietic cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e. blood taken from the umbilical cord after a baby is born and umbilical cord is cut).
1748358|NCT00176917|Drug|Busulfan, Cyclophosphamide, ATG|"Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG."
1748359|NCT00176930|Procedure|Stem Cell Transplant|Certain cancers can be treated by giving patients stem cells that come from someone else. This is called a stem-cell transplant. As part of the transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover. (Allowable sources of stem cells = related or unrelated bone marrow or peripheral blood, for Busulfan/cyclophosphamide/ATG preparative chemo only, umbilical cord blood is also permitted.)
1748360|NCT00176930|Drug|Cyclophosphamide|60 mg/kg intravenously (IV) Days -6 and -5 or 50 mg/kg/day IV Days -5 through -2.
1748361|NCT00176930|Radiation|Total Body Irradiation|On Day -4, -3, -2, -1 total body irradiation is given twice daily.
1748362|NCT00176930|Drug|Busulfan|When not receiving total body irradiation, administered Days -9 through -6, 0.8 mg/kg/dose by intravenous dosing every 6 hours.
1748363|NCT00176943|Drug|Aldara Cream 5%|
1748364|NCT00176956|Procedure|Skin Biopsy|Skin biopsy.
1748365|NCT00176969|Drug|Capsaicin|
1748366|NCT00176982|Drug|Hydroxychloroquine|
1748367|NCT00176995|Drug|15% Eflornithine Hdyrochloride|
1748368|NCT00177008|Drug|Aripiprazole|
1748369|NCT00177021|Drug|Aldara Cream 5%|
1748370|NCT00177034|Drug|Narrow Band UVB Treatment|
1748414|NCT00177489|Behavioral|multicomponent psychosocial intervention|The intervention addressed caregiver depression, burden, self-care, and social support and care recipient problem behaviors through 12 in-home and telephone sessions over 6 months.
1748371|NCT00177047|Procedure|Stem Cell Transplant|As part of the stem cell transplant process, patients receive high doses of chemotherapy and/or radiation to treat their underlying disease, such as cancer. As one of its effects, this treatment also kills the healthy stem cells that are already in the marrow. The transplant provides new stem cells for the patient from a healthy donor; that replace the bone marrow and allow the blood counts to recover.
1748372|NCT00177047|Drug|Cyclophosphamide + Mesna|Cyclophosphamide: 4mg/m^2 + Mesna. Mesna is used to reduce the undesired side effects of certain chemotherapy drugs.
1748373|NCT00177047|Drug|Melphalan|Administered intravenously 200 mg/m^2
1748374|NCT00177047|Biological|Granulocyte-colony stimulating factor|Administered intravenously 10 ug/kg/day pretransplant then 5 ug/kg/day post-transplant.
1748375|NCT00177060|Drug|hydromorphone|
1748376|NCT00177086|Other|Alfuzosin Hydrochloride|One tablet every day for 4 weeks
1748377|NCT00177099|Drug|FK506, GP11046, GP11511|
1748378|NCT00177112|Procedure|clean patient preparation for cystoscopy|
1748379|NCT00177112|Procedure|sterile patient preparation for cystoscopy|
1748380|NCT00177125|Device|ErectAid|
1748381|NCT00177138|Drug|Tacrolimus|Starting POD #1 0.06 mg/kg/day in 2 divided doses;
1748382|NCT00177138|Drug|Alemtuzumab|30 mg IV intra-op and POD #12; then 30 mg IV >monthly for 1 year (only if ALC>200 mm, up to a total of 10 doses in year)
1748383|NCT00177164|Drug|Injectable Risperidone (Consta) or oral antipsychotic|"Injectable Risperidone (Consta) from 12.5 to 50 mg q 2 weeks
Oral antipsychotic agents, olanzapine, quetiapine, ziprasidone, aripiprazole in doses approved in the US for bipolar disorder"
1748384|NCT00177177|Drug|L-carnosine (dietary supplement)|an antioxidant and AGE inhibitor, 500 mg/day, titration each week to reach 2000 mg/day in 4 weeks L-Carnosine is a dietary supplement
1748385|NCT00177203|Behavioral|Brief Behavioral Treatment of Insomnia or Information|"The behavioral treatment involves education about sleep and its disorders; habits that help and hurt sleep; and recommendations about sleep hours and time in bed. It involves two meetings with a nurse who is part of the research team.
In the information condition, participants are given similar information in printed brochures that are published by the American Academy of Sleep Medicine. They are instructed to read the information."
1748386|NCT00177216|Drug|Zolpidem|The benzodiazepine receptor agonist (BzRA), zolpidem was given in an initial dose of 5 mg by mouth every night, 30 minutes prior to bedtime. The dose was increased to a maximum of 10 mg after the first week if there was no improvement in overall symptoms (CGI score of 4 or >). The dose was decreased to 5 mg if side effects occurred.
1748387|NCT00177216|Drug|Escitalopram|The antidepressant, escitalopram was initiated at 5 mg by mouth every night, 30 minutes prior to bedtime. If there were no side effects, the dose was increased every four days until the target dose of 20 mg (maximum dose) was reached by day 13. If significant side effects appeared, the highest tolerated dose was used.
1748388|NCT00177216|Drug|Placebo|A placebo capsule was given with instructions to take it every night by mouth, 30 minutes prior to bedtime.
1748389|NCT00177229|Behavioral|Family-based treatment|20 weekly group contacts with individual coaching over first 6 months, brief monthly contacts over next 6 months, no contacts over last 6 months. Medical monitoring throughout study period.
1748390|NCT00177242|Drug|Gefitinib|
1748391|NCT00177255|Drug|Docetaxel|"Docetaxel 30 mg/m2 will be administered as a 30-minute infusion on days 1 and 8. Each cycle will consist of 21 days.
Cycle 2 will begin on day 22."
1748392|NCT00177255|Drug|Capecitabine|"Capecitabine 825 mg/m2 bid (total daily dose 1650 mg/m2) will be administered orally for 14 days (days 1-14).
Each cycle will consist of 21 days.
Cycle 2 will begin on day 22."
1748393|NCT00177268|Other|Blood draw or skin biopsy|Up to 9 blood draws/year of 60 ml of whole blood. One 6 mm punch biopsy may be obtained up to 4 times per year.
1748394|NCT00177281|Drug|S CKD602|
1748395|NCT00177294|Drug|Escitalopram|Escitalopram 10 mg daily for first 6 weeks, followed by escitalopram 20 mg daily for 16 additional weeks.
1748396|NCT00177294|Behavioral|Interpersonal Psychotherapy|16 sessions of interpersonal psychotherapy (IPT)
1748397|NCT00177294|Behavioral|Clinical Monitoring|16 weeks of depression care management(DCM). No psychotherapy will be provided.
1748398|NCT00177307|Drug|Bevacizumab|Bevacizumab 5 mg/kg by 90-30 minute IV infusion IV q 2 weekly Until disease progression or unacceptable toxicity
1748399|NCT00177307|Drug|Capecitabine|Capecitabine will be administered orally at twice daily 1250 mg/m2 (equivalent to a total daily dose of 2500 mg/m2) as intermittent therapy (1 week of treatment followed by one week without treatment) and this cycle repeated every 14 days. The first dose of capecitabine will be given on day 1 of each cycle as evening dose and the last dose will be given on day 8 as morning dose (for a total of 14 single doses per cycle).
1748400|NCT00177307|Drug|Oxaliplatin|Oxaliplatin will be administered at the dose of 85 mg/m2 given as a 2-hour intravenous infusion on day 1 of a two-week cycle, prior to the first dose of capecitabine
1748401|NCT00177333|Drug|Doxycycline|
1748402|NCT00177346|Device|CAS with cerebral protection|
1748403|NCT00177346|Device|CAS without cerebral protection|
1748404|NCT00177359|Behavioral|gait intervention|
1748405|NCT00177372|Drug|mifepristone/misoprostol|mifepristone 200 mg followed 24 hours later by misoprostol 800 mcg vaginally
1748406|NCT00177385|Behavioral|Modest sleep deprivation with sleep hygiene education|
1748407|NCT00177398|Drug|Glargine insulin vs regular insulin|
1748408|NCT00177411|Drug|Parathyroid Hormone-related Protein|Parathyroid Hormone-related Protein in doses started at a 4 microgram single bolus intravenous dose. Dose will be increase to a maximum of 400 micrograms or until a dose limiting toxicity occurs at a lower dose.
1748409|NCT00177424|Drug|sertraline|Subjects will initially be started on either sertraline 12.5mg/d or placebo and will receive this dose for 3 days. Subjects will then be increased to 25mg/d for 4 days, then 50mg/d for 7 days, then increased to 75mg/d. Seventy-five mg per day is the target dose for the remainder of the subject's participation in the study. The study medication will not be titrated past 75mg/d.
1748410|NCT00177424|Drug|Placebo|matching placebo tablets
1748411|NCT00177437|Behavioral|home testing kit|
1748412|NCT00177463|Drug|L-carnosine|an antioxidant and AGE inhibitor, 500 mg/day, increasing each week in titration reaching 2000 mg/day in 4 weeks and maintained for rest of trial
1748413|NCT00177476|Behavioral|behavioral weight loss|
1748415|NCT00177489|Other|Control arm|"Caregivers in the control group received 2 brief check-in telephone calls during the 6-month intervention."
1748416|NCT00177502|Behavioral|behavioral exercise intervention|
1748417|NCT00177515|Behavioral|"video doctor, computer module"|computerized counseling about emergency contraception and peri-conception folate
1748418|NCT00177528|Drug|venlafaxine-XR|
1748419|NCT00177541|Behavioral|Biofeedback, pelvic floor muscle training, fMRI|Biofeedback, pelvic floor muscle training, fMRI
1748420|NCT00177554|Drug|Chemotherapy and Radioimmunotherapy|CHOP-R x 3 cycles followed by zevalin and extended rituximab
1748421|NCT00177567|Drug|lithium carbonate|
1748422|NCT00177567|Drug|Depakote-ER|
1748423|NCT00177567|Drug|risperidone|
1748424|NCT00177567|Drug|olanzapine|
1748425|NCT00177567|Drug|paroxetine|
1748426|NCT00177567|Drug|bupropion|
1748427|NCT00177567|Drug|lamotrigine|
1748428|NCT00177567|Drug|venlafaxine|
1748429|NCT00177567|Drug|tranylcypromine|
1748430|NCT00177567|Drug|mirtazapine|
1748431|NCT00177580|Drug|Pravastatin|
1748432|NCT00177593|Behavioral|behavioral weight loss|
1748433|NCT00177606|Behavioral|withdrawal of life sustaining treatments|
1748434|NCT00177619|Drug|Alendronate|
1748435|NCT00177632|Behavioral|behavioral weight loss|
1748436|NCT00177645|Procedure|sodium bicarbonate|inhalation of sodium bicarbonate or sodium chloride
1748437|NCT00177671|Drug|Escitalopram|Escitalopram, 10mg to 20mg daily.
1748438|NCT00177671|Drug|Donepezil|Donepezil, 5mg to 10mg daily.
1748439|NCT00177671|Drug|Venlafaxine|Venlafaxine, 150mg to 300mg daily.
1748440|NCT00177671|Drug|Placebo|
1748441|NCT00177671|Drug|Duloxetine|
1748442|NCT00177684|Drug|Amphotericin B|
1748443|NCT00177697|Behavioral|behavioral weight loss program|
1748444|NCT00177710|Drug|Amphotericin B|
1748445|NCT00177749|Drug|Posaconazole|
1748446|NCT00177762|Behavioral|behavior weight loss|
1748447|NCT00177775|Drug|MucoMilk product|
1748448|NCT00177840|Procedure|acupuncture|
1748449|NCT00177853|Drug|celecoxib|Patients will start celecoxib (200mg PO BID) beginning 3-5 days prior to chemoradiation at home and receive the drug until 30 days following the completion of chemoradiation.
1748450|NCT00177853|Drug|irinotecan|Preoperative chemoradiation will consist of escalating doses of irinotecan (30 50 mg/m2 IV) once weekly for a total of 4 doses.
1748451|NCT00177853|Procedure|concurrent radiotherapy|50.4 cGy of standard external beam radiation. The radiation will be given in 28 treatments of 1.8 cGy per treatment over 5.5 weeks. This will be given in an outpatient setting.
1748452|NCT00177866|Drug|Celebrex|"Celebrex 200 mg PO BID for the first 8 weeks, followed by a 1 week washout period then placebo PO BID for the remaining 8 weeks - or - placebo PO BID for the first 8 weeks, followed by a 1 week washout period then Celebrex 200 mg PO BID for the remaining 8 weeks."
1748453|NCT00177866|Drug|placebo|placebo PO BID for either the first eight weeks or the last eight weeks of the study.
1748454|NCT00177879|Behavioral|website comparison|
1748455|NCT00177892|Procedure|sleep disruption|experimentally-induced Sleep Fragmentation
1748456|NCT00177892|Procedure|sleep with and without positive pressure|OSAH patients with and without chronic positive airway pressure therapy
1748457|NCT00177970|Drug|intravenous immunoglobulin G (IVIG)|IVIG to be given IV to patients with C-Diff .
1748458|NCT00177970|Drug|Placebo|Placebo to be given IV to patients with C-Diff
1748459|NCT00177983|Behavioral|(relapse rate)|
1748460|NCT00177996|Drug|sertraline hydrochloride|The study was a double-blind study in which subjects diagnosed with major depression complicated by lifetime panic spectrum symptomatology were randomized to either high (but still within the standards of normal clinical practice) or low dose titration schedules of sertraline. The doses and titration schedules used in this study are consistent with recommended FDA guidelines.
1748461|NCT00178009|Behavioral|self-paced instruction|Patients and caregivers review a DVD as often as they wish on how to care for routine and emergency procedures associated with their artificial heart
1748462|NCT00178022|Behavioral|Case management and problem solving therapy|
1748463|NCT00178035|Drug|paroxetine|
1748464|NCT00178035|Behavioral|One night of Total Sleep Deprivation|
1748465|NCT00178048|Drug|paroxetine|
1748466|NCT00178061|Behavioral|Interpersonal Social Rhythm Therapy (IPSRT)|
1748467|NCT00178074|Behavioral|total sleep deprivation|
1748468|NCT00178074|Procedure|PET imaging|
1748469|NCT00178100|Behavioral|Interpersonal Psychotherapy|
1748470|NCT00178100|Drug|paroxetine|
1748471|NCT00178113|Drug|- Lyc-O-Mato (dietary supplement, 30 mg lycopene/day)|
1748472|NCT00178113|Drug|- Certagen (multivitamins with minerals)|
1748473|NCT00178126|Device|Skin Protection Wheelchair Seat Cushion|Cushion receiving CMS code for Skin Protection Wheelchair Cushion
1748474|NCT00178126|Device|Segmented Foam Wheelchair Seat Cushion|General use class wheelchair seat cushion
1748475|NCT00178139|Behavioral|Music Therapy|Music Therapy
1748476|NCT00178165|Procedure|Skill Training Condition – problem solving training|
1748477|NCT00178165|Procedure|REACH for TLC (Telephone Linked Computer) system|
1748478|NCT00178178|Device|Breg Pain Care 3000 Catheter|Device: Breg Pain Care 3000 Catheter
1748479|NCT00178178|Drug|Bupivicaine 0.5%|Drug: Bupivicaine 0.5 %
1748480|NCT00178178|Drug|Placebo|Drug: Placebo
1748481|NCT00178191|Other|Bladder diary|3-day bladder diary
1748482|NCT00178191|Other|Questionnaires|Incontinence Quality of Life questionnaires
1748483|NCT00178191|Procedure|Urodynamics|Urodynamics
1748484|NCT00178191|Other|Pad weight|Pad weight
1748541|NCT00171054|Drug|Hydrochlorothiazide|At Week 12, patients who did not meet target Blood Pressure for both Systolic Blood Pressure < 140 mmHg and Diastolic Blood Pressure < 90 mmHg were eligible to receive 12.5 mg open-label Hydrochlorothiazide for the following 26 weeks.
1748542|NCT00171067|Drug|valsartan|
1748543|NCT00171067|Drug|lisinopril|
1748544|NCT00171080|Drug|valsartan|
1748485|NCT00178217|Behavioral|Music Therapy|The music therapy intervention will consist of approximately 30 minutes of active music making and/or improvisation. The session will begin at least 15 minutes prior to receiving the Botox injections, followed by the necessary time of the procedure and 10 minutes following. During this time the patient will be encouraged to actively engage in a musical activity of his/her choice. After the last injection has been administered, the monitoring and music therapy will continue for up to 10 minutes, and focus on soothing and relaxation rather than on distraction.
1748486|NCT00170508|Biological|Fluzone®|
1748487|NCT00170534|Behavioral|Behavior|
1748488|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain.. Group 4: 382 subjects receive Fluzone 15 mcg IM on day 0
1748489|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain. Group 1: 382 subjects receive 6 mcg ID with BD system. Group 2: 382 subjects receive 9 mcg ID with BD system, all doses on day 0.
1748490|NCT00170547|Biological|Trivalent inactivated influenza vaccine|A synthetic vaccine consisting of three inactivated influenza viruses: two different influenza type A strains and one influenza type B strain..Group 3: 382 subjects receive 3 mcg Fluzone ID using Mantoux technique on day 0.
1748492|NCT00170586|Device|Underglove coating (skin barrier)|
1748493|NCT00170612|Biological|Pneumovax 23|23-valent PPS, 25 micrograms/serotype
1748494|NCT00170612|Biological|Prevnar|7-valent PCV, 2 micrograms/serotype, except serotype 6B which is 4 micrograms/serotype
1748495|NCT00170625|Drug|Hycamtin|Topotecan: 1,0 mg/m²/d, day 1-3; q21d Carboplatin: AUC 5 on day 3 after Topotecan, q21d
1748496|NCT00170664|Drug|Paclitaxel|
1748497|NCT00170664|Drug|Carboplatin|
1748498|NCT00170677|Drug|Topotecan|Topotecan 4,0 mg/m² administered in day 1, 8 und 15 as i.v. infusion for 30 minutes. A cycle lasts 28 days.
1748499|NCT00170677|Drug|Topotecan|Topotecan 1,25 mg/m²/day, day 1-5 as i.v. infusion of 30 minutes. Repeat after 21 day.
1748500|NCT00170690|Drug|Treosulfan|Treosulfan 600 mg/m² p.o. on daý 1-28, 57-84, etc
1748501|NCT00170690|Drug|Treosulfan|Treosulfan 7000 mg/m² i.v. on day 1, 29, 57 etc
1748502|NCT00170703|Device|Cortical Electrical Stimulation|
1748503|NCT00170716|Device|Cortical Stimulation and rehabilitation|Cortical stimulation is provided concomitantly with rehabilitation therapy. Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
1748504|NCT00170716|Other|Rehabilitation|Rehabilitation is for 2.5 hrs per day for 26 days over a period of 6 weeks.
1748505|NCT00170729|Drug|Prednisolone acetate|
1748506|NCT00170742|Drug|Octreotide, 30 mg i.m. LAR formulation|
1748507|NCT00170755|Drug|Darifenacin|Darifenacin 7,5 mg tablets, Darifenacin 15 mg tablets administered once daily
1748508|NCT00170768|Drug|Darifenacin|Darifenacin modified release 7,5 mg tablets once daily titrated to 15 mg once daily
1748509|NCT00170768|Drug|Oxybutynin|Oxybutynin extended release 10 mg tablet once daily titrated to 15 mg, then to 20 mg once daily
1748510|NCT00170768|Drug|Placebo|Placebo once daily tablet (sham titration)
1748511|NCT00170781|Drug|Lumiracoxib|
1748512|NCT00170794|Drug|Everolimus (RAD001)|
1748513|NCT00170820|Drug|Everolimus|
1748514|NCT00170833|Drug|Everolimus|
1748515|NCT00170846|Drug|Everolimus (RAD001)|
1748516|NCT00170846|Drug|Calcineurin Inhibitors (CNI)|
1748517|NCT00170846|Drug|Mycophenolate acid (MPA)/Azathioprine (AZA)|
1748518|NCT00170846|Drug|Steroids|
1748519|NCT00170859|Drug|Everolimus|
1748520|NCT00170872|Drug|Lumiracoxib|
1748521|NCT00170885|Drug|Everolimus|
1748522|NCT00170898|Drug|Lumiracoxib|
1748523|NCT00170911|Drug|AAE581|
1748524|NCT00170924|Drug|Valsartan|
1748525|NCT00170937|Drug|valsartan plus hydrochlorothiazide|
1748526|NCT00170950|Drug|Benazepril/amlodipine 20/5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/amlodipine besylate 10/5 mg capsules for oral administration once daily.
1748527|NCT00170950|Drug|Benazepril/amlodipine 40/5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/amlodipine besylate 20/5 mg capsules for oral administration once daily.
1748528|NCT00170950|Drug|Benazepril/amlodipine 40/10 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/amlodipine besylate: 40/10 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
1748529|NCT00170950|Drug|Benazepril/hydrochlorothiazide 20/12.5 mg - Dose Level 1 from Day 1 to Month 1|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 20/12.5 mg capsules for oral administration once daily.
1748530|NCT00170950|Drug|Benazepril/hydrochlorothiazide 40/12.5 mg - Dose Level 2 from Month 1 to Month 2|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/12.5 mg capsules for oral administration once daily.
1748531|NCT00170950|Drug|Benazepril/hydrochlorothiazide 40/25 mg - Dose Level 3 from Month 2 to Month 3 and thereafter|Benazepril hydrochloride (HCl)/hydrochlorothiazide (HCTZ) 40/25 mg capsules for oral administration once daily. Patients titrated to this dose level had the possibility of subsequent free add-on antihypertensive agents after month 3 based on target blood pressure.
1748532|NCT00170963|Drug|valsartan/amlodipine|
1748533|NCT00170976|Drug|valsartan + amlodipine|
1748534|NCT00170989|Drug|valsartan plus hydrochlorothiazide|
1748535|NCT00171002|Drug|valsartan/amlodipine|
1748536|NCT00171015|Drug|valsartan plus hydrochlorothiazide|
1748537|NCT00171028|Drug|valsartan|
1748538|NCT00171041|Drug|valsartan|
1748539|NCT00171054|Drug|Valsartan 320 mg|Patients received 160 mg valsartan for 4 weeks. Patients were then up-titrated to receive either 320 mg valsartan for the following 8 weeks.
1748540|NCT00171054|Drug|Amlodipine 10 mg|Patients received 5 mg amlodipine for four weeks. Patients were then up-titrated to receive 10 mg amlodipine for the following 8 weeks.
1748545|NCT00171080|Drug|irbesartan|
1748546|NCT00171093|Drug|valsartan + simvastatin|
1748551|NCT00171132|Drug|hydrochlorothiazide|
1748552|NCT00171145|Drug|Darifenacin|Darifenacin 15 mg tablets once daily
1748553|NCT00171145|Drug|Placebo|Placebo tablets once daily
1748554|NCT00171158|Drug|imatinib mesylate|
1748555|NCT00171171|Drug|deferasirox|
1748556|NCT00171184|Drug|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
1748557|NCT00171184|Drug|Placebo|Placebo tablet once daily with sham titration
1748558|NCT00171210|Drug|Deferasirox|Tablets taken orally once a day.
1748559|NCT00171223|Drug|imatinib mesylate|
1748560|NCT00171236|Drug|Fluvastatin|
1748561|NCT00171249|Drug|imatinib mesylate|
1748562|NCT00171262|Drug|Fluvastatin|
1748563|NCT00171275|Drug|Fluvastatin|
1748564|NCT00171288|Drug|fluvastatin, ezetimibe|
1748565|NCT00171301|Drug|Deferasirox|Deferasirox was administered orally once daily. Deferasirox was available as 125 mg, 250 mg, and 500 mg tablets.
1748566|NCT00171314|Drug|Zoledronic acid|Zoledronic acid 4 mg Intravenous (IV)15 minute infusion every 6 months.
1748567|NCT00171314|Drug|Letrozole|Letrozole tablets 2.5 mg/day/taken orally for 5 years.
1748568|NCT00171327|Drug|valsartan, fluvastatin|
1748569|NCT00171340|Drug|Zoledronic acid|Zolendronic acid 4 mg Intravenous (IV) 15 minute infusion every 6 months.
1748570|NCT00171340|Drug|Letrozole|Letrozole tablets 2.5 mg/day taken orally for 5 years.
1748571|NCT00171353|Drug|valsartan|
1748572|NCT00171366|Drug|amlodipine/benazepril|
1748573|NCT00171379|Drug|Enteric-Coated Mycophenolate Sodium|
1748574|NCT00171392|Drug|Enteric-coated mycophenolate sodium|
1748575|NCT00171405|Drug|aliskiren|
1748576|NCT00171418|Drug|Tegaserod|
1748577|NCT00171431|Drug|Tegaserod|
1748578|NCT00171444|Behavioral|Medical education|
1748579|NCT00171457|Drug|Tegaserod|
1748580|NCT00171470|Drug|Tegaserod|
1748581|NCT00171483|Drug|Tegaserod|
1748582|NCT00171496|Drug|Cyclosporine microemulsion|
1748583|NCT00171496|Drug|Tacrolimus|
1748584|NCT00171509|Drug|Cyclosporine microemulsion|
1748585|NCT00171522|Drug|Tegaserod and Polyethylene Glycol 3350|
1748586|NCT00171535|Drug|valsartan/amlodipine|
1748587|NCT00178243|Procedure|3D Conformal Radiation Therapy and Radiosurgery|
1748588|NCT00178256|Drug|Paclitaxel|On Mondays, Wednesdays, and Fridays, paclitaxel infusion will begin early in the morning and complete before 10:30 am.
1748589|NCT00178256|Procedure|Radiation Therapy|Thoracic XRT will be given in late afternoon, after 4:00 PM, if possible
1748590|NCT00178269|Drug|docetaxel|
1748591|NCT00178269|Procedure|Radiation Therapy|
1748592|NCT00178282|Procedure|Pelvic Floor Muscle exercises|
1748593|NCT00178295|Radiation|Radiation Therapy|standard of care for the cancer being treated
1748594|NCT00178321|Device|earplugs|
1748595|NCT00178347|Radiation|Exposure to irradiation|Treatment for Cancer using Radiation -dose will be the standard of Care for the type of Cancer being treated
1748596|NCT00178360|Behavioral|Music Therapy|"During individual Music Therapy sessions, subjects will participate in a variety of active music-making opportunities, including: playing musical instruments, singing, improvising, learning relaxation techniques, song writing, and/or lyric analysis. The activities for each session will be determined by both subject and therapist, and will be selected based on preference, emotional state, and desired goals for the day.
Group music therapy sessions will focus on improving socialization, depression, and group dynamics. In this setting, the Music Therapist will choose from the following interventions:
Group singing
Group drumming
Music assisted relaxation
Group song writing
Lyric analysis
Improvisation
Music with art"
1748597|NCT00178373|Drug|Modafinil|
1748598|NCT00178373|Drug|sugar pill|
1748599|NCT00178399|Procedure|Stereotactic Body Radiation Therapy|
1748600|NCT00178412|Behavioral|Care Project for Hospitalized Elders & Family Caregivers|"Phase 1 in-hospital contact: Family caregivers complete baseline data, listen to a tape about helping the elderly relative cope with hospitalization, and work on a mutual agreement/identification of goals for participation in family member's hospital care (i.e., selection of two complications to focus on based on patient's illness condition)
Phase 2 pre-hospital discharge: Family caregivers listen to a second tape about coping with the hospital experience, participating in their family member's in-hospital care, and preparing for hospital discharge/transition to home"
1748601|NCT00178412|Behavioral|Comparison Group|"Phase 1 in-hospital contact: Family caregivers complete baseline data and listen to an informational tape about hospital policies.
Phase 2 pre-hospital discharge: Family caregivers listen to a second informational tape about the hospital and medical center."
1748602|NCT00178425|Procedure|Serial blood sampling as described in protocol|
1748603|NCT00178425|Procedure|Estimation of Creatinine Clearance at regular intervals|
1748604|NCT00178438|Device|Capsule Endoscopy|
1748605|NCT00178451|Drug|Abciximab|
1748606|NCT00178464|Drug|aspirin|81 mg flavored chewable tablets. Subjects between the ages of 2.0 and 4.99 years will receive half of an 81 mg aspirin tablet each day. Those older than 5.0 years will receive a daily 81 mg aspirin tablet. The subject will receive the study drug for a period of 12 months.
1748607|NCT00178477|Procedure|MRI with breath-holding|Breath holding for diminished tumor motion.
1748608|NCT00178490|Drug|High blood pressure treatment|Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
1748609|NCT00178503|Drug|Methylphenidate-extended release|Methylphenidate-extended release was taken in the morning of the MPH treatment trial. Each participant underwent 1 week of the each of the doses as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 10 mg Ritalin LA to 20 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took from 10 mg Ritalin LA to 30 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 20 mg Ritalin LA to 40 mg.
1748669|NCT00180622|Procedure|St Georges Questionnaire|
1748610|NCT00178503|Drug|Methylphenidate-immediate release|Methylphenidate-immediate release was taken in the late afternoon. Each participant underwent 1 week at each of the 3 dose levels as determined by body weight. The lower body weight group (20 to 24 kg/44 to 52.8 lbs) took 2.5 mg IR-MPH and 2 weeks of 5 mg. The medium body weight group (25 to 33 kg/55 to 72.6 lbs) took 2 weeks of 5 mg IR-MPH and 1 week of 10 mg. The higher body weight group (34 to 59 kg/74.8 to 129.8 lbs) took 1 week of 5 mg IR-MPH and 2 weeks of 10 mg.
1748611|NCT00178503|Other|Placebo|Participants will take a placebo for 1 full week of the randomized drug trial. They will take one capsule in the morning and one capsule in the afternoon.
1748612|NCT00178516|Other|behavior, procedure|
1748613|NCT00178529|Behavioral|Psychoeducation, Counseling and Skill Training|
1748614|NCT00178555|Device|DCI Video Intubation System-Macintosh Laryngoscope|
1748615|NCT00178555|Device|Macintosh Laryngoscope|
1748616|NCT00178568|Behavioral|Stress Management and Healthy Sleep Practices|Eight weekly sessions of 1 hour each reviewing stress management techniques and tips for improving sleep.
1748617|NCT00180076|Drug|Budesonide|
1748618|NCT00180089|Drug|Budesonide|
1748619|NCT00180102|Drug|Cytarabine vs. Cytarabine+Amsacrine+Mitoxantrone|
1748620|NCT00180102|Procedure|early allogeneic PBSCT within induction therapy|
1748621|NCT00180102|Procedure|autologous PBSCT|
1748622|NCT00180115|Drug|Cytarabine Dosage|
1748623|NCT00180128|Drug|all-trans retinoid acid|
1748624|NCT00180128|Drug|idarubicin|
1748625|NCT00180128|Drug|mitoxantrone|
1748626|NCT00180128|Drug|daunorubicin|
1748627|NCT00180128|Drug|cytarabine|
1748628|NCT00180141|Drug|Elidel-Creme|
1748629|NCT00180167|Drug|randomization between two established Chemotherapies|
1748630|NCT00180206|Device|Birmingham Hip Resurfacing|
1748631|NCT00180258|Device|Cardiac Resynchronization Therapy with & without defibrillator|
1748632|NCT00180271|Device|Cardiac resynchronization therapy with defibrillation|Boston Scientific Corporation Market Released Cardiac Resynchronization therapy with defibrillation
1748633|NCT00180271|Device|Implantable Cardioverter Defibrillator (ICD)|Boston Scientific Corporation Market Released Implantable Cardioverter Defibrillator
1748634|NCT00180284|Device|SITELINE 2 Polyurethane (pacing lead)|SITELINE 2 Polyurethane (pacing lead)
1748635|NCT00180297|Device|Endotak Reliance G|Reliance G is a defibrillation lead to be placed in the right ventricle.
1748636|NCT00180310|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
1748637|NCT00180310|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
1748638|NCT00180323|Device|Renewal|Renewal is a CRT-D device for cardiac resynchronization therapy
1748639|NCT00180336|Device|CRT-D|
1748640|NCT00180349|Device|Endotak Reliance|Endotak Reliance is a defibrillation lead delivering pacing and defibrillation therapy to the ventricle as needed.
1748641|NCT00180362|Device|procedure|
1748642|NCT00180375|Device|Prizm, Vitality, Renewal|Follow-up during 2 years
1748643|NCT00180388|Procedure|endoscopic vein harvesting|
1748644|NCT00180388|Procedure|open vein harvesting|
1748645|NCT00180401|Behavioral|CRT-P and CRT-D devices|
1748646|NCT00180414|Device|CRT devices with ventricular rate regulation [VRR] (CE labeled)|
1748647|NCT00180427|Device|ICD|
1748648|NCT00180440|Device|ICD|all models of Guidant/Bsc ICD's
1748649|NCT00180453|Device|Coronary artery drug eluting stent placement|Coronary artery drug eluting stent placement
1748650|NCT00180453|Device|Coronary artery stent placement|Coronary artery stent placement
1748651|NCT00180479|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
1748652|NCT00180479|Device|TAXUS® EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
1748653|NCT00180492|Device|RX ACCULINK(TM) Carotid Stent System and RX ACCUNET(TM) Embolic Protection System|
1748654|NCT00180505|Device|ABSOLUTE™: Self-Expandable Peripheral Nitinol Stent|A prospective, non-randomized, multi-center study to investigate the performance of the ABSOLUTE™ .035 Peripheral Self-Expanding Stent System (ABSOLUTE™ Stent) in preventing restenosis of occluded or stenotic superficial femoral or proximal popliteal arteries. Follow up at 30, 180, 270, 365 days and 2 years.
1748655|NCT00180518|Device|Over-the-wire & Rapid Exchange ACCULINK (tm) Carotid Stent & ACCUNET (tm) embolic protection system|"Two rapid exchange devices will be evaluated: the RX ACCUNET Embolic Protection System (RX ACCUNET) and the RX ACCULINK Carotid Stent System (RX ACCULINK).
The RX ACCUNET Embolic Protection System is intended to facilitate the placement of diagnostic and therapeutic devices during interventional procedures and to capture embolic material that may be present during carotid artery interventional procedures.
The RX ACCULINK™ Carotid Stent System is intended for the treatment of carotid artery stenosis in the internal carotid artery (ICA), with or without involvement of the contiguous common carotid artery (CCA), in asymptomatic patients and symptomatic patients."
1748656|NCT00180531|Device|Renewal TR2|
1748657|NCT00180544|Device|Stenting: Renal Artery|Male and female patients, who meet study eligibility criteria, agree to participate in the trial, and sign an informed consent, will be enrolled in the study. A HERCULINK™ 14 Peripheral Stent will be used in the treatment of suboptimal post- procedural percutaneous transluminal angioplasty (PTA) atherosclerotic renal artery stenoses.
1748658|NCT00180557|Device|Flextend II, Fineline 2, Fineline Atrial J, Selute Picotip|
1748659|NCT00180570|Device|FineLine II Sterox, FineLine II Sterox, FineLine II Sterox EZ|
1748660|NCT00180583|Device|Guidant GALILEO Intravascular Radiotherapy System|Treatment of single or multivessel long diffuse coronary stenosis with the Guidant GALILEO Intravascular Radiotherapy System
1748661|NCT00180596|Device|Contak heart failure devices|
1748662|NCT00180609|Device|Automatic threshold test in Insignia Pacemakers from Guidant|
1748663|NCT00180622|Procedure|Spirometry|
1748664|NCT00180622|Procedure|Exhaled Nitric Oxide and Carbon Monoxide|
1748665|NCT00180622|Procedure|Exhaled Breath Condensate|
1748666|NCT00180622|Procedure|Induced Sputum|
1748670|NCT00180622|Procedure|Bodypletysmography|
1748671|NCT00180635|Procedure|Inhalation of aminoguanidine and oral intake and inhalation of L-arginine|
1748672|NCT00180635|Procedure|Exhaled Breath Condensate|
1748673|NCT00180635|Procedure|Nasal Nitric Oxide|
1748674|NCT00180635|Procedure|Nasal Lavage|
1748675|NCT00180635|Procedure|Spirometry|
1748676|NCT00180674|Drug|Warfarin|
1748677|NCT00180687|Drug|Nebulised Bupivacaine intraperitoneally|Nebulised Marcaine (Bupivacaine)
1748678|NCT00180687|Drug|Normal Saline|Nebulised Normal Saline
1748679|NCT00180687|Drug|Injected Bupivacaine intraperitoneally|Injected Marcaine directly into the peritoneal cavity
1748680|NCT00180687|Other|No Intraperitoneal Therapeutics|No Intraperitoneal Therapeutics given
1748681|NCT00180700|Behavioral|Self-hypnosis|
1748682|NCT00180700|Behavioral|Johrei - a Japanese stress management system|
1748683|NCT00180713|Drug|Simvastatin|Simvastatin 40mg od for 1 month, then 80mg od for 11 months
1748684|NCT00180713|Drug|Placebo|Placebo tablet once daily.
1748685|NCT00180726|Procedure|Blood sampling, Endoscopic Bronchoscopy, Spirometry|
1748686|NCT00180739|Procedure|Magnetic Resonance Guided Focused Ultrasound|
1748687|NCT00180765|Procedure|Up to 100ml blood will be taken by venupuncture.|
1748688|NCT00180778|Drug|Low dose steroids|
1748689|NCT00180791|Drug|Etoposide, carboplatin, melphalan, cisplatin, thiotepa|
1748690|NCT00180830|Drug|Glivec|
1748691|NCT00180830|Drug|Gleevec|
1748692|NCT00180843|Drug|salbutamol + ipratropium bromide nebules|
1748693|NCT00180843|Drug|nebulized saline|
1748694|NCT00180856|Procedure|Radiofrequency ablation|
1748695|NCT00180869|Procedure|transfusion of allogeneic red blood cell concentrate|
1748696|NCT00180869|Procedure|transfusion of leuko-reduced red blood cell concentrate|
1748697|NCT00180882|Drug|rituximab|
1748698|NCT00180895|Drug|Rituximab|
1748699|NCT00180908|Drug|Etoposide, Ifosfamide, Methotrexate|
1748700|NCT00180908|Drug|Doxorubicin, Methotrexate|
1748701|NCT00180921|Drug|Imatinib|
1748702|NCT00180934|Procedure|Reirradiation with concomitant chemotherapy|
1748703|NCT00180947|Drug|Vinorelbine, cyclofosfamide|
1748704|NCT00180960|Drug|Oxaliplatin and irinotecan|
1748705|NCT00180973|Drug|Hydroxyurea|
1748706|NCT00180986|Procedure|Platelet concentrates|
1748707|NCT00180999|Drug|Erythropoiétine|
1748708|NCT00181012|Drug|Lidocaine|
1748709|NCT00181025|Drug|Tasonermine (TNFa)|
1748710|NCT00181025|Drug|Melphalan|
1748711|NCT00181038|Device|Peri-Neuronal Catheter|
1748712|NCT00181051|Device|Alaris AEP monitor|
1748713|NCT00181064|Behavioral|Modified Atkins diet|15 grams of carbohydrates per day - high fat diet
1748714|NCT00181077|Drug|2% buffered hypertonic saline administration|
1748715|NCT00181090|Behavioral|Modified Atkins diet|
1748716|NCT00181116|Drug|Levetiracetam|
1748717|NCT00181129|Behavioral|home based self paced walking program|
1748718|NCT00181142|Drug|Zenapax|
1748719|NCT00181155|Drug|Allopurinol|intravenous infusion of allopurinol (300mg)
1748720|NCT00181155|Drug|Placebo|intravenous infusion of 50 ml dose of 5% dextrose
1748722|NCT00181181|Drug|atorvastatin|Atorvastatin 80 mg daily for 3 months
1748723|NCT00181181|Other|placebo|placebo daily
1748724|NCT00181194|Device|Asthma Control and Communication Instrument|
1748726|NCT00181220|Drug|valproic acid|
1748727|NCT00181246|Drug|Transdermal Fentanyl|
1748728|NCT00181272|Drug|azithromycin|
1748730|NCT00181298|Drug|Memantine|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4.
1748731|NCT00181298|Drug|Placebo|Dispensing initially 5 mg. Dose Increased by 5 mg weekly to 20 mg/d final dose by week 4
1748732|NCT00181311|Procedure|hysterectomy|
1748733|NCT00181350|Device|Relocatable fixation system|
1748735|NCT00181506|Procedure|dose escalation (radiotherapy treatment schedule)|
1748736|NCT00181532|Drug|Celecoxib|
1748737|NCT00181545|Procedure|escalation of dose (radiotherapy treatment)|
1748738|NCT00181558|Drug|Atrasentan|
1748739|NCT00181558|Drug|Zoledronic Acid (Zometa)|
1748740|NCT00181571|Drug|methylphenidate HCl (Concerta)|up to a maximum dose of 1.3 mg Concerta/kg/day, and not more than 144 mg/day for any subject regardless of weight.
1748741|NCT00181571|Drug|Placebo|up to a maximum dose of 1.3 mg Placebo /kg/day, and not more than 144 mg/day for any subject regardless of weight.
1748742|NCT00181584|Drug|Zoledronic acid|Given intravenously once.
1748743|NCT00181584|Other|Placebo|Given intravenously once.
1748744|NCT00181597|Drug|Trilostane|Taken orally once a day for three days then twice daily thereafter.
1748745|NCT00181597|Drug|Hydrocortisone|Taken orally with trilostane.
1748746|NCT00181610|Drug|Recombinant Human Prolactin|60 mcg/kg every 12 hours
1748747|NCT00181610|Biological|Recombinant human prolactin|60 mcg/kg given every 12 hours or every 24 hours
1748748|NCT00181610|Biological|Normal Saline|twice per day
1748749|NCT00181623|Drug|Recombinant Human Prolactin|
1748750|NCT00181636|Drug|Galantamine-CR|
1748751|NCT00181649|Drug|Recombinant human prolactin|
1748752|NCT00181662|Drug|Curcumin|
1748753|NCT00181675|Drug|galantamine HBr|
1748754|NCT00181688|Drug|Iressa (ZD1839)|
1748755|NCT00181688|Drug|Arimidex (Anastrozole)|
1748756|NCT00181701|Drug|Paclitaxel|
1748757|NCT00181701|Drug|Carboplatin|
1748937|NCT00174915|Drug|Febuxostat|Febuxostat 120 mg, orally, once daily for up to 28 weeks.
1748938|NCT00174915|Drug|Febuxostat|Febuxostat 240 mg, orally, once daily for up to 28 weeks.
1748758|NCT00181714|Drug|methylphenidate HCl (Concerta)|OROS MPH will be openly prescribed to a maximum of 1.5 mg/kg/day (maximum 126 mg/day). Doses will be titrated according to clinical assessment of efficacy and tolerability.
1748759|NCT00181727|Drug|divalproex sodium extended release|
1748760|NCT00181740|Drug|atomoxetine (Strattera)|
1748761|NCT00181753|Drug|standard vs. glutamine enteral or parenteral feeding.|Patient in each group will continue on the same diet for > 3 days before we conduct stable isotope tracer measurements.
1748762|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours of primed constant infusion
1748763|NCT00181753|Dietary Supplement|Stable isotope study|7 hours of primed constant infusion of stable isotope tracers.
1748764|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours of primed constant stable isotope tracer infusion.
1748765|NCT00181753|Dietary Supplement|Stable isotope tracer study|7 hours primed constant infusion of stable isotope tracer study
1748766|NCT00181766|Drug|Strattera (atomoxetine)|Up to maximum of 1.2mg atomoxetine/kg PO QD, or 120 mg atomoxetine PO QD (whichever is less).
1748767|NCT00181779|Drug|aripiprazole (Abilify)|
1748768|NCT00181818|Drug|bupropion SR (sustained-release)|
1748769|NCT00181831|Device|Proton Magnetic Resonance Spectroscopy|
1748770|NCT00181844|Drug|lamotrigine|Open-label, flexible-dose, BID treatment of lamotrigine (Lamictal). For children <12 years, dosing began at 0.35 mg/kg/day, divided in 2 doses, rounded down to nearest 5mg, to be increased weekly depending on response and tolerability to maintenance dose of 5-15 mg/kg/day (maximum 400 mg/day in 2 divided doses). For children ≥12 years, dose began at 25 mg/day in 1 dose, to be increased weekly depending on response and tolerability to maintenance dose of 300-500 mg/day in 2 divided doses.
1748771|NCT00181870|Drug|carbamazepine ER (Equetro)|
1748772|NCT00181883|Drug|quetiapine|2.5 - 5.0mg/kg PO BID quetiapine
1748773|NCT00181896|Drug|bupropion SR|Open-label prescription of Bupropion SR for 8 weeks.
1748774|NCT00181909|Behavioral|Smoking cessation counseling delivered by telephone|
1748775|NCT00181922|Drug|ziprasidone (Geodon)|
1748776|NCT00181935|Drug|risperidone (Risperdal)|
1748777|NCT00181935|Drug|olanzapine (Zyprexa)|
1748778|NCT00181948|Drug|atomoxetine (Strattera)|
1748779|NCT00181961|Drug|Maca Root|
1748780|NCT00181974|Drug|Tisseel Fibrin Sealant|
1748781|NCT00181987|Drug|methylphenidate HCl (Concerta)|
1748782|NCT00182000|Drug|seromycin|100mg tablet administered 1 hour prior to each therapy session
1748783|NCT00182000|Behavioral|Behavior Therapy|10 weekly hour-long behavior therapy sessions
1748784|NCT00182013|Drug|Risperidone|Open treatment with Risperidone
1748785|NCT00182013|Drug|Olanzapine|Open treatment with Olanzapine
1748786|NCT00182013|Drug|Quetiapine|Open treatment with Quetiapine
1748787|NCT00182026|Behavioral|personal feedback report|A computer-generated feedback report that provides personalized diabetes self-management recommendations to participants based on their responses to a self-administered questionnaire.
1748788|NCT00182039|Drug|Metoprolol controlled release (CR)|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
1748789|NCT00182039|Drug|Placebo|Patients received the first dose of the study drug (i.e., oral metoprolol CR or matching placebo 100 mg) 2-4 hours prior to surgery. Administration of the study drug at each dosing time required a patient to have a heart rate ≥ 50 beats per minute (bpm) and a systolic blood pressure (SBP) ≥ 100 mmHg. If the patient's heart rate was ≥ 80 bpm and their SBP ≥ 100 mmHg at any time during the first 6 hours after surgery, the patient received their first postoperative dose (i.e., 100 mg of the study drug) orally. Patients who did not receive the study drug during the first 6 hours after surgery received 100 mg of the study drug orally at 6 hours after surgery. Twelve hours after the first postoperative dose patients started taking oral metoprolol CR or placebo 200 mg daily for 30 days.
1748790|NCT00182052|Drug|Rosiglitazone|Given orally twice daily. Participants may continue study treatment as long as their disease does not progress and they don't experience any serious side effects.
1748791|NCT00182052|Other|Placebo|Given orally twice daily.
1748792|NCT00182078|Drug|Placebo|The placebo was administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the placebo was tapered at a rate of 25mg every 3 days until it was discontinued.
1748793|NCT00182078|Drug|Sertraline|The drugs were administered for 24 weeks on a flexible fixed schedule beginning at 25mg per day, and increasing as high as 150 mg/day. Both groups received the assigned medication and dose over a 24-week period. At Week 12, the medication was tapered at a rate of 25mg every 3 days until it was discontinued.
1748794|NCT00182091|Drug|Recombinant human growth hormone|Starting dose based on age, sex, and estrogen status and ranged from 3-6 mcg/kg/day. GH doses were adjusted based on IGF-1 levels to target the mid-normal range for age.
1748795|NCT00182091|Drug|Saline|To maintain study-subject blinding, doses were sham adjusted.
1748796|NCT00182104|Drug|Warfarin vs ASA|
1748797|NCT00182130|Procedure|Quality Initiative in Rectal Cancer (QIRC) strategy|
1748800|NCT00182169|Drug|Human recombinant growth hormone|
1748801|NCT00182182|Behavioral|Primary care based disease management strategy|
1748802|NCT00182195|Procedure|Control Ventilation Strategy|
1748803|NCT00182208|Device|Veno-device (Venowave)|
1748804|NCT00182221|Procedure|MDA D-Dimer Testing|
1748980|NCT00175240|Behavioral|Evidence summaries endorsed by local opinion leaders|
1748805|NCT00182234|Behavioral|Community Interlink Program|The study intervention is a referral to a specialized oncology nursing program. The standardized care provided by this program includes comprehensive assessment and care planning specific to breast and colorectal cancers during the initial phases of treatment, with a minimum of two home visits. Through consultation with the patient, nurses either provide direct (non-medical) care to address needs identified and/or coordinate linkage to services in the community.
1748806|NCT00182247|Procedure|venogram|
1748807|NCT00182260|Drug|Proton Pump Inhibitors|
1748808|NCT00182260|Procedure|Laparoscopic Nissen Fundoplication|
1748809|NCT00182273|Procedure|Canalith repositioning maneuver (CRM)|
1748810|NCT00182286|Behavioral|Assessment of continuity of care from the patient perspective|
1748811|NCT00182286|Behavioral|Relationship between continuity of care, patient outcomes, and costs|
1748812|NCT00182299|Procedure|porcine small intestine submucosa (SIS)|
1748813|NCT00182312|Drug|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.
Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.
Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
1748814|NCT00182325|Behavioral|personalized web-based prenatal information|
1748815|NCT00182351|Procedure|D-dimer|
1748816|NCT00182351|Procedure|Serial Compression Ultrasound|
1748817|NCT00182364|Drug|Fragmin (Dalteparin) LMWH verus Unfractionated Heparin (UFH)|
1748818|NCT00182377|Drug|Pentastarch (displace either 500 ml or 1000 ml of pump prime with pentastarch)|
1748819|NCT00182390|Procedure|Red blood cell transfusion|
1748820|NCT00182403|Drug|UFH 250 U/kg or LMWH 100 U/kg sc twice daily|
1748821|NCT00182416|Device|pacemaker|
1748822|NCT00182429|Drug|Metronidazole and Rifampin|
1748823|NCT00182442|Drug|Olanzapine & Quetiapine|
1748824|NCT00182455|Drug|Topiramate|25 - 400 mg/day x 12 weeks
1748825|NCT00182455|Drug|Placebo|25 - 400 mg/day x 12 weeks
1748826|NCT00182468|Other|Screening for intimate partner violence|Women are screened for intimate partner violence prior to seeing a health care provider.
1748827|NCT00182481|Procedure|Induced sputum cell counts|
1748828|NCT00182481|Drug|inhaled corticosteroids and other asthma drugs|
1748829|NCT00182494|Behavioral|Modified diabetes prevention protocol & Metformin|
1748830|NCT00182507|Drug|Olanzapine|
1748831|NCT00182520|Drug|Topiramate|25 mg - 400 mg/day x 12 weeks
1748832|NCT00182520|Drug|placebo|25 - 400 mg/day x 12 weeks
1748833|NCT00182533|Drug|Sertraline|25 - 200 mg/day x 16 weeks
1748834|NCT00182533|Drug|Placebo|25 - 200 mg/day x 16 weeks
1748835|NCT00182546|Procedure|Two diagnostic management strategies|
1748836|NCT00182559|Drug|Ciclosporin|Maintain ciclosporin in combination with/without mycophenolate mofetil and with/without steroids at target trough levels of 70-150ng/mL.
1748837|NCT00182559|Drug|Tacrolimus|Conversion from ciclosporin to tacrolimus at target trough levels of 5-8 ng/mL in combination with/without mycophenolate mofetil and with/without steroids.
1748838|NCT00182572|Drug|buprenorphine|
1748839|NCT00182572|Drug|naltrexone|
1748840|NCT00182572|Procedure|behavior therapy|
1748841|NCT00182572|Procedure|voucher-based contingency management|
1748842|NCT00182585|Procedure|computer-based HIV, STD & Hepatitis Education|
1748843|NCT00182585|Procedure|educator-delivered HIV, STD and Hepatitis education|
1748844|NCT00182598|Procedure|computer-based psychoeducational intervention|
1748845|NCT00182598|Procedure|community-based substance abuse counseling|
1748846|NCT00182611|Drug|cisplatin|
1748847|NCT00182611|Drug|tegafur-gimeracil-oteracil potassium|
1748848|NCT00182611|Procedure|adjuvant therapy|
1748849|NCT00182611|Procedure|conventional surgery|
1748850|NCT00182611|Procedure|neoadjuvant therapy|
1748851|NCT00182637|Drug|bortezomib|
1748852|NCT00182650|Biological|aldesleukin|
1748853|NCT00182650|Biological|rituximab|
1748854|NCT00182650|Biological|therapeutic autologous lymphocytes|
1748855|NCT00182650|Drug|fludarabine phosphate|
1748856|NCT00182663|Drug|clarithromycin|Given PO
1748857|NCT00182663|Drug|thalidomide|Given PO
1748858|NCT00182663|Drug|dexamethasone|Given PO
1748859|NCT00182689|Drug|sorafenib tosylate|Given orally
1748860|NCT00182702|Drug|ixabepilone|Given IV
1748861|NCT00182702|Other|laboratory biomarker analysis|Correlative studies
1748862|NCT00182715|Biological|cetuximab|
1748863|NCT00182715|Drug|capecitabine|
1748864|NCT00182715|Drug|fluorouracil|
1748865|NCT00182715|Drug|leucovorin calcium|
1748866|NCT00182715|Drug|oxaliplatin|
1748867|NCT00182728|Procedure|surgery|conventional
1748868|NCT00182728|Procedure|therapy|neoadjuvant
1748869|NCT00182728|Radiation|radiation therapy|intraoperative radiation therapy
1748870|NCT00174356|Drug|CI 1033|
1748871|NCT00174356|Drug|PACLITAXEL|
1748872|NCT00174356|Drug|CARBOPLATIN|
1748873|NCT00174369|Drug|PD-0325901|15 mg BID
1748874|NCT00174382|Drug|Donepezil|donepezil 5mg/day for 6 weeks and then 5 to 10mg/day for 18 weeks
1748875|NCT00174395|Drug|eletriptan|
1748876|NCT00174408|Drug|Genotropin|
1748877|NCT00174421|Drug|Treatment with Genotropin in different dosages|
1748878|NCT00174434|Drug|SU011248|SU011248 provided as capsules. The starting dose is 25 mg orally, daily in a continuous regimen beginning on day 2. Dose rest for 1 week is allowed. Dose escalation to 37.5 mg po OD is allowed within the constraints of acceptable toxicity parameters. Dosing will continue for 1 year or until disease progression or unacceptable toxicity, whichever comes first.
1748879|NCT00174434|Drug|Paclitaxel|Paclitaxel is provided as an intravenous infusion for 1 hour weekly for 3 weeks followed by a 1-week rest. The starting dose is 90 mg/m2. The weekly dose may be decreased to 65 mg/m2 in subsequent cycles based on tolerability. Dosing will continue for 1 year or until maximum benefit, disease progression or unacceptable toxicity, whichever comes first.
1748880|NCT00174447|Drug|Ziprasidone|Dosage may subsequently be adjusted according to clinical status, only at each protocol visit and step by step between 40, 60 and 80 mg bid
1748881|NCT00174460|Drug|Somatropin|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. Children randomized to the control group will get the possibility to continue treatment for a further year. The study will end after 2 and 3 years of observation, respectively.
1748882|NCT00174460|Other|Control Arm|Controlled, prospective, randomized, multicenter study with an untreated (control) group during the first year. The children will be randomized into treatment or untreated (control) group. After one year the control group will undergo GH-therapy, too. The study will end after 2 and 3 years of observation, respectively. Children randomized to the control group will get the possibility to continue treatment for a further year.
1748883|NCT00174473|Drug|Voriconazole|
1748884|NCT00174486|Drug|UK0369,003|
1748885|NCT00174486|Drug|Cialis (Tadalafil)|
1748886|NCT00174499|Drug|2 mg nicotine gum|2 mg nicotine gum
1748887|NCT00174499|Drug|4 mg nicotine gum|4 mg nicotine gum
1748888|NCT00174512|Drug|GTN|
1748889|NCT00174512|Drug|Moxifloxacin|
1748890|NCT00174525|Drug|AAB-001|
1748891|NCT00174538|Drug|Codeine (30 mg)|
1748892|NCT00174551|Drug|prazosin|
1748893|NCT00174564|Drug|oxaliplatin|
1748894|NCT00174577|Drug|Risperidone|
1748895|NCT00174590|Drug|risperidone|
1748896|NCT00174603|Drug|quetiapine|
1748897|NCT00174616|Drug|Oxaliplatin, capecitabine, radiotherapy|"Oxaliplatin 50mg/m² I.V. 2 hours weekly x 5 doses
Capecitabine 825mg/m² P.O. B.I.D. daily x 5 days x 5 weeks
Radiotherapy 45 Gy total (1.8Gy/dose) 25 fractions daily x 5 days x 5 weeks"
1748898|NCT00174629|Drug|Docetaxel/DDP|
1748899|NCT00174629|Drug|docetaxel/gemcitabine|
1748900|NCT00174642|Drug|Insulin Glargine|One daily injection in the evening. 100 U/ml
1748901|NCT00174642|Drug|Insulin Glulisine|Given immediately before each of the three main meals. 100 U/ml
1748902|NCT00174642|Drug|Metformin|At same dosages as the previous treatment
1748903|NCT00174642|Drug|insulin secretagogue|sulfonylurea or glinide
1748904|NCT00174655|Drug|Doxorubicine + docetaxel sequential|doxorubicin 75 mg/m² i.v. day 1, q 21 days for 3 cycles, followed by docetaxel 100 mg/m² i.v., 1 hour infusion, day 1, q 21 days for 3 cycles, followed by CMF for 3 cycles
1748905|NCT00174655|Drug|doxorubicine + cyclophosphamide sequential|doxorubicin 75 mg/m² i.v. day 1 q 21 days for 4 cycles, followed by CMF (C: cyclophosphamide 100 mg/m² orally days 1-14, M: methotrexate: 40 mg/m² i.v. days 1 and 8, FU; 5-fluorouracil: 600 mg/m²) i.v. days 1 and 8, q 28 days for 3 cycles
1748906|NCT00174655|Drug|doxorubicine + cyclophosphamide combined|doxorubicin 60 mg/m² i.v. + cyclophosphamide 600 mg/m² i.v., day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
1748907|NCT00174655|Drug|doxorubicine + docetaxel combined|doxorubicin 50 mg/m² i.v. + docetaxel 75 mg/m² i.v. 1 hour infusion (1 hour after doxorubicin), day 1, q 21 days for 4 cycles, followed by CMF for 3 cycles.
1748908|NCT00174668|Drug|Insulin Glulisine|insulin glulisine 3 x daily (TID) subcutaneously 15 min before the start of a meal
1748909|NCT00174668|Drug|Insulin Therapy|NPH (70%) plus regular insulin or insulin aspart (30%)
1748910|NCT00174668|Drug|Insulin Glargine|1 x daily (OD) subcutaneously at any time (but every day at the same time) according to BG
1748911|NCT00174681|Drug|Insulin Glargine|
1748912|NCT00174694|Drug|Telithromycin|
1748913|NCT00174707|Drug|epidoxorubicine, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by ciclophosphamide/Methotrexate/fluorouracile (±TAM)
1748914|NCT00174707|Drug|epidoxorubicine, docetaxel, ciclophosphamide, methotrexate, fluorouracile|Sequential Epidoxorubicin followed by Docetaxel followed by ciclophosphamide/methotrexate/fluorouracile (± TAM)
1748915|NCT00174707|Drug|epidoxorubicine, docetaxel, cyclophosphamide|Sequential Intensified Epidoxorubicin followed by Docetaxel followed by Cyclophosphamide (± TAM)
1748916|NCT00174720|Drug|Ciclesonide (XRP1526)|
1748917|NCT00174733|Drug|Ciclesonide (XRP1526)|
1748918|NCT00174746|Drug|AVE2635A|
1748919|NCT00174759|Drug|Clopidogrel|
1748920|NCT00174772|Drug|docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy|docetaxel (75mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemoradiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy
1748921|NCT00174772|Drug|docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin|docetaxel (20mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
1748922|NCT00174785|Drug|dronedarone (SR33589)|oral administration (tablets)
1748923|NCT00174785|Drug|placebo|oral administration (tablets)
1748924|NCT00174798|Drug|SSR240600C|once daily
1748925|NCT00174798|Drug|Placebo|oral
1748926|NCT00174798|Drug|Tolterodine|once daily
1748927|NCT00174811|Drug|telithromycin (HMR3647)|
1748928|NCT00174824|Drug|Insulin glargine|
1748929|NCT00174837|Drug|Tirapazamine|in combination with cisplatin and concomitant radiation
1748930|NCT00174837|Drug|Cisplatin|with concomitant radiation
1748931|NCT00174850|Drug|Gaitril|
1748932|NCT00174863|Drug|SR31747A|
1748933|NCT00174876|Drug|Drug Abilify|
1748934|NCT00174889|Drug|Pregnenolone|
1748935|NCT00174902|Drug|inderal (drug), acetylsalicylic acid (drug)|
1748936|NCT00174915|Drug|Febuxostat|Febuxostat 80 mg, orally, once daily for up to 28 weeks.
1748939|NCT00174915|Drug|Allopurinol|Allopurinol, orally, once daily for up to 28 weeks. Dose of allopurinol received was based on renal status. Subjects with serum creatinine ≤1.5 mg/dL received 300 mg once daily; subjects with serum creatinine >1.5 mg/dL and ≤2.0 mg/dL received 100 mg once daily.
1748940|NCT00174915|Drug|Placebo|Placebo, orally, once daily for up to 28 weeks.
1748941|NCT00174928|Drug|Lansoprazole|Lansoprazole 0.5 mg/kg/day suspension, orally, once daily for up to 5 days.
1748942|NCT00174928|Drug|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
1748943|NCT00174941|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily, based on serum urate level.
1748944|NCT00174941|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily, based on serum urate level.
1748945|NCT00174941|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily, based on serum urate level.
1748946|NCT00174954|Procedure|MRI|Subjects underwent MRI to evaluate tophi.
1748947|NCT00174967|Drug|Placebo|Febuxostat placebo-matching tablets, orally, once daily for up to 4 weeks.
1748948|NCT00174967|Drug|Febuxostat|Febuxostat 40 mg, tablets, orally, once daily for up to 4 weeks.
1748949|NCT00174967|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily for up to 4 weeks.
1748950|NCT00174967|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily for up to 4 weeks.
1748952|NCT00174993|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily for up to 48 months.
1748953|NCT00174993|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 48 months
1748954|NCT00175006|Other|Measurement of Tophi to validate procedure|Intra- and Inter-rater Reproducibility measurements of the area (in mm2) of each tophus nodule.
1748955|NCT00175019|Drug|Febuxostat|Febuxostat 80 mg, tablets, orally, once daily.
1748956|NCT00175019|Drug|Febuxostat|Febuxostat 120 mg, tablets, orally, once daily.
1748957|NCT00175019|Drug|Allopurinol|Allopurinol 100 mg or 300 mg, tablets, orally, once daily.
1748958|NCT00175032|Drug|Lansoprazole and naproxen and aspirin|Lansoprazole 30 mg, capsules, orally once daily; Naproxen 500 mg, capsules, orally, twice daily; and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
1748959|NCT00175032|Drug|Celecoxib and aspirin|Celecoxib 200 mg, capsules, orally once daily and aspirin 81 mg or 325 mg, tablets, orally, once daily for up to 12 weeks.
1748960|NCT00175045|Drug|Lansoprazole|Lansoprazole 30 mg, intravenous injection, once daily for up to 7 days.
1748961|NCT00175045|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 7 days.
1748962|NCT00175058|Device|AO Therapy (aqueous oxygen)|90-min adjunctive reperfusion of hyperoxemic blood into target coronary artery, immediately following revascularization by means of PCI with stenting
1748963|NCT00175071|Behavioral|Comparison of cooking oils|30 subjects will consume each of the two diets in randomized order for 5 weeks each. Diets will be designed to maintain body weight; will have 30% of energy as fat which 2/3 or 20% of energy will be either the conventional or reformulated fat. Blood lipids and C reactive protein (CRP) as well as indicators of how lipids are processed in the blood will be measured at the end of each dietary phase.
1748964|NCT00175084|Behavioral|Comparison of dietary protein amino acid profile|Healthy adults over 50 years of age (men and postmenopausal women) will be assigned to one of two diets differing in lysine to arginine ration (0.7 vs. 1.4) for a 5 week period and then switched to the alternate diet, with a 2 to 4-week washout period, in a randomized crossover design. Blood samples will be collected three times in the fasted state and once 4-hours after the evening meal during the last week of each dietary period of measurement of concentration of plasma lipids, lipoproteins, apolipoproteins, arginine, C-reactive protein, nitrites/nitrates, homocysteine, lecithin-cholesterol acetyltransferase (LCAT), cholesteryl ester transfer protein (CETP), and LDL-receptor messenger ribonucleic acid (mRNA) expression.A 24-hour urine sample will be collected at the end of each phase to measure F2-isoprostanes as an indicator of whole body oxidation.
1748965|NCT00175097|Other|Diet: soybeans and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybeans and products made thereof.
1748966|NCT00175097|Other|Diet: soybean flour and products made thereof|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean flour and products made thereof.
1748967|NCT00175097|Other|Diet: soybean milk|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate soybean milk.
1748968|NCT00175097|Other|Diet: Animal protein based diet|The macronutrient composition of each diets will be similar. The difference will be the type of protein (animal or soybean) or form of soybean incorporated into various food mixtures. This diet will incorporate animal protein.
1748969|NCT00175110|Behavioral|herbal therapy/botanical therapy (Hibiscus sabdariffa)|
1748970|NCT00175123|Drug|Botulinum A toxin|Intravesical injection. 12 IE/kg b.w.
1748971|NCT00175136|Device|Maxim TKA|Operation with Total Knee Arthroplasty and either an I-beam stem or a wedge stem of the tibial component.
1748972|NCT00175149|Drug|Alfacalcidiol|Alfacalcidiol are given to patientwith CKD 3-4 and secondary hyperparathyrodism. The PTH level is lowered to normal range. with increasing dose of alfacalcidiol and are followed for 6 month.
1748973|NCT00175162|Device|Osteopal G vs. Refobacin-Palacos R bone cement|Bone cement
1748974|NCT00175175|Behavioral|"Allied health professional-run osteoporosis service (case-management)"|
1748975|NCT00175188|Device|Avanta (PIP joint implant with a titanium porous coating)|Implant is inserted at the time of surgery, after written consent
1748976|NCT00175201|Procedure|Proactive care and rehabilitation|
1748977|NCT00175214|Behavioral|Multifaceted intervention (patient education, physician guidelines, reminders)|
1748978|NCT00175227|Drug|intravenous saline hydration + mannitol + furosemide|500 mls half-normal saline + 25g mannitol + 100 mg furosemide
1748979|NCT00175227|Drug|intravenous saline hydration|500 mls half-normal saline
1748981|NCT00175253|Drug|alemtuzumab|
1748982|NCT00175253|Procedure|islet transplant|
1748983|NCT00175266|Drug|alemtuzumab|
1748984|NCT00175266|Procedure|islet transplant|
1748985|NCT00175266|Drug|infliximab|
1748986|NCT00175279|Behavioral|Opinion leader generated and endorsed evidence summaries|
1748987|NCT00175292|Drug|Probiotic - VSL#3|
1748988|NCT00175305|Drug|Sandostatin LAR|
1748989|NCT00175318|Behavioral|Motivational Interviewing|Beginning at 12 months of age, regular application of fluoride varnish will be an option that a mother in the MI group may choose for her child. Control families will receive dental health information from a pamphlet, and will have access to fluoride varnish at local dental clinics.
1748990|NCT00175344|Procedure|Scar massage.|To objectively evaluate the effects of scar massage, those who agree to participate will be randomly assigned to one of two groups. One group will be taught to perform self-massage of the scars as soon as the scars have adequately healed. The massage should be done about 10 minutes each day for a total of 6 months. The other group will not be taught self-massage and will be asked to not massage their breast scars.
1748991|NCT00175357|Drug|Methadone|The dose of the drug will be determined by a physician. The oral drug will be administered 1 dose per days, 7 days per week.
1748992|NCT00175357|Drug|Diamorphine hydrochloride|The dose of the drug will be determined by a physician. The injected drug will be administered up to 3 doses per day, 7 days per week.
1748993|NCT00175370|Drug|Vancomycin|Randomized double-blind equivalence trial to test the hypothesis that 2 days is equivalent to 7 days of vancomycin treatment for intravascular device associated bacteremia due to coagulase negative staphylococcus. The definitions for the surveillance of intravascular device associated bacteremia from the Laboratory Centre for Disease Control-Health Canada will be used. Surveillance blood cultures on days 4 and 9 following removal of intravascular device. Relatedness of strains will be determined by pulsed-field gel electrophoresis (PFGE).
1748994|NCT00175383|Drug|luteinizing hormone-releasing hormone (LHRH) short acting or long acting|See Detailed Description.
1748995|NCT00175396|Procedure|Androgen suppression, radiotherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by an external beam radiation boost lasting 3.2-4 weeks (32 Gy in 16 equal fractions).
1748996|NCT00175396|Procedure|Androgen suppression, radiotherapy, iodine 125 brachytherapy|Total of 12 months of androgen suppression. 8 months after the start of androgen suppression 4.2-5 weeks external beam radiation (46 Gy in 23 equal fractions) followed by iodine 125 brachytherapy carried out 14-25 days after the last external beam treatment.
1748997|NCT00175409|Procedure|Blood collection|For the standard care condition, infants will remain in their isolettes and will be positioned in prone and given a pacifier to suck on throughout the blood collection.
1748998|NCT00175409|Procedure|Blood collection|For the feeding condition, infants will be held and then breast fed by their mother during the blood collection.
1748999|NCT00175422|Behavioral|The Period of PURPLE Crying Program|There are two treatment arms in the study. The first half of all subjects (n=500) will receive the PURPLE intervention materials (a video and a pamphlet) about infant crying. The second arm will receive comparable materials on infant safety and SIDS.
1749000|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator
1749001|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
1749002|NCT00175435|Biological|Resiquimod gel|3 doses HPV vaccine 0.5 mL given IM with Topical Immune Modulator.
1749003|NCT00175448|Procedure|physiotherapy|See Detailed Description.
1749004|NCT00175461|Procedure|hip surgery|Comparison of the clinical effectiveness and cost-effectiveness of the MIS anterolateral approach (MIS Watson Jones, G3) versus anterolateral mini or posterolateral mini approaches in primary total hip arthroplasty
1749005|NCT00175474|Procedure|knee surgery|Unspecified
1749006|NCT00175487|Procedure|Hip replacement|This study evaluates femoral head resurfacing versus a large femoral head (Durom®) total hip system. This is a prospective randomized trial.
1749007|NCT00175500|Device|Large Diameter Femoral Head|Unspecified
1749008|NCT00175513|Drug|Valacyclovir (Valtrex)|Unspecified
1749009|NCT00175526|Behavioral|preeclampsia|This research project, 'a severity score for pre-eclampsia,' will develop such a clinical tool that is specific to the condition. To develop and validate the tool w
1749010|NCT00175539|Behavioral|psychoeducational intervention|three 1.5 hour long group psychoeducational sessions
1749011|NCT00175552|Behavioral|Psychotherapy Training|
1749012|NCT00175565|Drug|inhaled fluticasone 500 mcg b.i.d.|
1749013|NCT00175591|Procedure|Administration of a femoral nerve block (bupivacaine HCL)|No details specified
1749014|NCT00175604|Drug|Botox|The babies that require a neck collar for CMT will be randomly placed into two groups. One group will receive standard treatment which includes physiotherapy and occupational therapy. The other group will receive standard treatment plus an injection of Botox.
1749015|NCT00175617|Drug|Spironolactone|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
1749016|NCT00175617|Drug|Minoxidil|This study evaluates the efficacy of therapy with the anti-androgen spironolactone compared to topical minoxidil in female pattern hair loss.
1749017|NCT00175630|Procedure|Administration of a femoral nerve block (bupivacaine HCL)|See Detailed Description
1749018|NCT00175643|Drug|imiquimod|
1749019|NCT00175656|Procedure|Elimination of titanium elastic nail prominence at the insertion site and leaving the nails in situ|See Detailed Description.
1749020|NCT00175669|Drug|Botox injections|Data not known.
1749021|NCT00175682|Drug|Prazosin HCL|See Detailed Description
1749022|NCT00175695|Drug|Recombinant human activated protein C or drotrecogin alpha|We are going to investigate a compound (recombinant human activated protein C (rhAPC)) that has the potential to modify disease activity in pre-eclampsia by reducing coagulation and inflammation disorders.
1749023|NCT00182741|Dietary Supplement|calcitriol|
1749024|NCT00182741|Drug|mitoxantrone hydrochloride|
1749025|NCT00182741|Drug|prednisone|
1749026|NCT00182754|Drug|octreotide acetate|Given subcutaneously
1749027|NCT00182754|Other|placebo|Given subcutaneously
1749028|NCT00182767|Drug|ixabepilone|Given IV
1749029|NCT00182767|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
1749032|NCT00182793|Biological|trastuzumab|Cycle 1: 6 mg/kg on day -2 from PBSC reinfusion Cycle 2: 6 mg/kg on day -7 from PBSC reinfusion
1749033|NCT00182793|Drug|carboplatin|Cycle 2: 800 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
1749034|NCT00182793|Drug|cyclophosphamide|Cycle 2: 6000 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
1749035|NCT00182793|Drug|melphalan|Cycle 1: 150 mg/m2 on day -1 from PBSC reinfusion
1749036|NCT00182793|Drug|thiotepa|Cycle 2: 500 mg/m2/96 hours on days -7 to -3 from PBSC reinfusion
1749037|NCT00182793|Procedure|adjuvant therapy|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation and helical tomotherapy or loco-regional radiotherapy.
1749038|NCT00182793|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation.
1749039|NCT00182793|Procedure|bone marrow ablation with stem cell support|Tandem high-dose chemotherapy comprising melphalan, carboplatin, thiotepa, and cyclophosphamide with or without trastuzumab (Herceptin®) followed by autologous peripheral blood stem cell transplantation
1749040|NCT00182793|Radiation|radiation therapy|"After recovery from high-dose chemotherapy and autologous PBSC transplantation; patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Treatment should be delivered daily M-F @ 180-200 cGY/day to a total of 4,500 to 5,040 cGy.
Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites. Treatment should be delivered daily @180-220 cGY/day to a total of 4,000-5,000 cGy."
1749041|NCT00182806|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 2 and 9. Courses repeat every 21 days.
1749042|NCT00182806|Drug|irinotecan hydrochloride|IV over 90 minutes on days 1 and 8. Courses repeat every 21 days.
1749043|NCT00182819|Drug|temozolomide|Temozolomide 75 mg/m2 daily x 21 days, q 28 days until progression or for max. 12 cycles
1749044|NCT00182819|Radiation|radiation therapy|50.4 Gy, standard fractionation (28 x 1.8 Gy), conformal techniques
1749045|NCT00182832|Behavioral|e-CHAMP (Enhancing Care for Hospitalized Older Adults with Cognitive Impairment)|Cognitive screening plus Computerized Decision Support System: proactive screening program for cognitive impairment combined with computerized review of the electronic medical record
1749046|NCT00182832|Behavioral|Standard Care|Standard care for hospitalized older patients with cognitive impairment
1749047|NCT00182845|Drug|Donepezil|
1749048|NCT00182871|Drug|testosterone|
1749049|NCT00182884|Drug|Donepezil|
1749050|NCT00182897|Behavioral|Skills Building for Caregiver Health and Care-recipient|
1749051|NCT00182936|Behavioral|Delirium Abatement Program|
1749052|NCT00182962|Behavioral|Geriatric Resources for Assessment & Care of Elders (GRACE)|
1749053|NCT00182975|Drug|DHEA replacement|
1749054|NCT00183001|Drug|Vitamin K|
1749055|NCT00183014|Behavioral|The Lifetime Fitness Program|A series of 4 weekly 1-hour group discussion sessions that utilize attribution retraining techniques from the field of motivational psychology in combination with behavioral strategies based in social cognitive theory; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
1749056|NCT00183014|Behavioral|Exercise class|1-hour exercise class aimed at increasing strength, flexibility and endurance; weekly for 4 weeks, monthly for 11 months, then every two months for 12 months (total duration = 24 months
1749057|NCT00183027|Behavioral|Dietary composition and energy intake|
1749058|NCT00183040|Drug|Topical testosterone|
1749059|NCT00183040|Drug|Recombinant human growth hormone|
1749060|NCT00183053|Device|BedEx Patient Occupancy Monitoring System|
1749061|NCT00183079|Behavioral|Motivationally-focused brief alcohol intervention|Brief, motivationally-focused alcohol intervention
1749062|NCT00183807|Drug|irinotecan, cisplatin, celecoxib|
1749063|NCT00183820|Drug|paclitaxel, gemcitabine, and oxaliplatin|"Paclitaxel 170 mg/m2 IV d 1 14 days
Gemcitabine 800 mg/m2 IV d 1 14 days
Oxaliplatin 100 mg/m2 IV d 1 14 days"
1749064|NCT00183833|Drug|capecitabine, imatinib mesylate|Capecitabine and imatinib mesylate will both be taken by mouth twice a day
1749065|NCT00183846|Drug|irinotecan|
1749066|NCT00183846|Procedure|radiation therapy|
1749067|NCT00183859|Drug|irinotecan|Intraperitoneal Irinotecan given every three weeks
1749068|NCT00183872|Drug|irinotecan, docetaxel|docetaxel 30 mg/m2 IV infusion days 1 and 8, with irinotecan 65 mg/m2 IV infusion on days 1 and 8.
1749069|NCT00183885|Drug|mitomycin-c, cisplatin|Intra-arterial cisplatin 60 mg/m2 and mitomycin-C 12 mg/m2 every 8 weeks
1749070|NCT00183898|Drug|oxaliplatin, capecitabine|cetuximab 400 mg/m2, followed by weekly cetuximab 250 mg/m2 with oxaliplatin 130 mg/m2 on day 1 (every 3 weeks) with capecitabine 850 mg/m2 bid, daily on days 1-14, every 3 weeks.
1749071|NCT00183911|Drug|floxuridine, 5-Fluorouracil, leucovorin|
1749072|NCT00183911|Procedure|External Beam Radiotherapy|
1749073|NCT00183911|Procedure|Surgery|
1749074|NCT00183924|Drug|Estramustine|
1749075|NCT00183924|Drug|Docetaxel|
1749076|NCT00183924|Drug|Carboplatin|
1749077|NCT00183937|Drug|PS 341|PS 341 1.6 mg/m2 IV (in the vein) on days 1 and 8 of each 21 day cycle up to 12 cycles.
1749078|NCT00183937|Drug|Docetaxel|Docetaxel 75mg/m2 IV (in the vein) on day 1 of each 21 day cycle up to 12 cycles.
1749079|NCT00183950|Drug|Noscapine|
1749080|NCT00183963|Drug|Tamoxifen|20mg
1749081|NCT00183963|Drug|Fulvestrant|250mg
1749082|NCT00183963|Drug|Fulvestrant|500 mg IM
1749083|NCT00183976|Drug|Pegylated Liposomal Doxorubicin (Doxil) and Rituximab|
1749084|NCT00183989|Drug|Fludarabine, Mitoxantrone and Rituximab|
1749134|NCT00184548|Drug|eptacog alfa (activated)|"Sterile, freeze-dried powder in single-use vials to be reconstituted with sterile water for injection.
Three doses of 200, 100 and 100 mcg/kg to be administered bolus i.v. (intravenous) over approx. three hours."
1749085|NCT00184002|Drug|Doxorubicin, Rituxan, Cyclophosphamide, Vincristine and Prednisone|"Cycle 1 Doxil 40 mg/m2 iv day 1 over a minimum of 60 min.
Cyclophosphamide 750 mg/m2 iv day 1 over a minimum of 60 min.
Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum).
Prednisone 100 mg po days 1-5.
Cycle 2 until study completion
Doxil 40 mg/m2 iv day 1
Rituxan 375 mg/m2 iv day 1
Cyclophosphamide 750 mg/m2 iv day 1
Vincristine 1.4 mg/m2 iv bolus day 1 (2.0 mg maximum)
Prednisone 100 mg po days 1-5
1 cycle = 21 days.
Continue treatment until 2 cycles beyond documentation of CR for a maximum of 8 cycles."
1749086|NCT00184015|Drug|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.0 or 1.3 mg/m2 on days 1, 4, 8 and 11 every 21 days
1749087|NCT00184015|Drug|Bevacizumab and Bortezomib|Bevacizumab 15 mg/kg on day 1 with Bortezomib 1.6 or 1.8 mg/m2 on days 1 and 8 every 21 days
1749088|NCT00184028|Drug|Taxotere|Taxotere is given at 60 mg/m2 as a 1-hour intravenous infusion.
1749089|NCT00184028|Drug|Oxaliplatin|Oxaliplatin will be administered intravenously over 2 hours at a rate of 10mg/m2/min. on day 1 every 3 weeks.
1749090|NCT00184041|Drug|Daunorubicin, Vincristine, Prednisone, Methotrexate, PEG-Asparaginase, 6-Mercaptopurine, Cytoxan, Cytosine Arabinoside, VM-26 and 6-Thioguanine|Induction I/II, consolidation I/II/III/IV and Maintenance
1749091|NCT00184054|Drug|Arsenic Trioxide (ATO)|Arsenic Trioxide .25 mg/kg/day
1749092|NCT00184054|Drug|Ascorbic Acid|Ascorbic Acid 1000 mg every other day for 25 days
1749093|NCT00184067|Biological|Montanide ISA 51|
1749094|NCT00184080|Drug|Elsamitrusin|
1749095|NCT00184093|Drug|Gemcitabine|Gemcitabine weekly x 6 wks with concurrent external radiation
1749096|NCT00184106|Drug|Seroxat, Cognitive therapy, Seroxat+ cognitive therapy|Seroxat was administered over 24 weeks 20-50 mg/d, and Cognitive therapy was provided over 12 weeks. The patients were assessed at pre, post and 1 yrs follow up
1749097|NCT00184119|Procedure|Psychiatric Intensive Care Unit|
1749098|NCT00184119|Procedure|Care in whole acute unit|psychiatric acute care as usual
1749099|NCT00184132|Procedure|Psychiatric intensive care unit in Norwegian home style|
1749100|NCT00184132|Procedure|Psychiatric intensive care unit sparsely furnished and not decorated|
1749101|NCT00184145|Other|EMDR (Eye Movement Desensitization and Reprocessing)|Psychotherapy which is approved for PTSD.
1749102|NCT00184145|Other|Exposure therapy|All participants in the study received exposure therapy som second treatment. Exposure therapy is the therapy of choice for animal phobia.
1749103|NCT00184158|Procedure|decompression|Conservative, simple decompression and nerve transfer
1749104|NCT00184171|Drug|Budesonide|Budesonide 9 mg
1749105|NCT00184171|Drug|Bismuth|Bismuth mixture
1749106|NCT00184171|Drug|Fiber|Fiber for control
1749107|NCT00184197|Drug|Botulinum toxin|
1749108|NCT00184197|Drug|Placebos|
1749109|NCT00184223|Behavioral|Motivational Interviewing|2 sessions of 45 minutes each with manual guided motivational interviewing delivered individually by a trained therapist.
1749110|NCT00184223|Other|Treatment as usual|Treatment as usual is individualized according to the clinical condition of the patients during the stay and in accordance with general national and international medical standards. It includes detoxification, pharmacotherapy, and general psychotherapy. Also, treatment is given for any coexisting non-substance-related disorder, including psychiatric disorders.
1749111|NCT00184236|Behavioral|Multitreatment approach|12 months regimen consisting of group meetings every 2 weeks involving a physician, psychologist, physiotherapist and clinical nutritional physiologist. 21 h treatment during the first 3 months: 3 activity sessions (3 h) and 3 group conversations (4 h). Attendance inclusion criterium was set to minimum of 80%
1749112|NCT00184236|Behavioral|Aerobic interval training|Walking/running 'uphill' on a treadmill twice a week for 3 months. 10 min warming-up at 70% of Hfmax before performing 4x4 intervals at 90-95% of Hfmax. 3 min active recovery at 70% of Hfmax between each interval. 5 min cool-down period, giving a total of 40 min.
1749113|NCT00184249|Procedure|Bipolar radiofrequency ablation|Ablation using CE marked bipolar ablation devices
1749114|NCT00184262|Behavioral|ERP cognitive therapy|15 exposure and response prevention (ERP) sessions in 3 months with a cognitive therapy rationale
1749115|NCT00184262|Behavioral|ERP behavioral therapy|15 exposure and response prevention (ERP) sessions in 3 months with a behavioral therapy rationale
1749116|NCT00184301|Behavioral|inpatient treatment|inpatient treatment during 1 year
1749117|NCT00184301|Behavioral|outpatient treatment|intensive outpatient treatment consisting of two-weekly group sessions during 1 year
1749118|NCT00184327|Behavioral|Intensive family therapy - inpatient|2-4 weeks (5days) family inpatient assessment and treatment
1749119|NCT00184327|Behavioral|Diagnostic assessment - child and adolescent psychiatry|
1749120|NCT00184340|Device|eTherapy|secured e-mail system between patient and therapist
1749121|NCT00184366|Drug|efalizumab|efalizumab
1749122|NCT00184379|Behavioral|Psychoeducation|Structured disorder-related educational program for relatives
1749123|NCT00184392|Procedure|debridement or saline irrigation|debridement of crusts, blood and secretions from the nose 1 week and 2 weeks after surgery
1749124|NCT00184431|Behavioral|Physical therapy technique and exercises|The experimental group receives task specific physical therapy three times a week for the first four weeks after discharge from hospital and one session pr week for the next eight weeks in addition to ordinary physical therapy The active comparator group receives only ordinary physical therapy during this period.
1749125|NCT00184444|Behavioral|Hypoxic interval training|4 x 4 minutes interval training in hypoxic air, 3 times per week at 90-95% HR max
1749126|NCT00184444|Behavioral|Normoxic interval training|4 x 4 minutes normoxic interval training, 3 times per week at 90-95% HR max
1749127|NCT00184457|Behavioral|Strength training intervention|
1749128|NCT00184483|Procedure|Lichtenstein's operation|Lichtenstein's operation to repair primary unilateral inguinal hernia
1749129|NCT00184483|Procedure|Prolene Hernia System|Prolene Hernia System to repair primary unilateral inguinal hernia
1749130|NCT00184496|Drug|Methadone|To methods for switching morphine to methadon. Stop-and go versus overlap
1749131|NCT00184509|Behavioral|integrated psychosocial treatment (behavior)|
1749132|NCT00184522|Drug|Aflurax|
1749133|NCT00184522|Drug|esomeprazole|
1749135|NCT00184548|Drug|placebo|placebo
1749136|NCT00184561|Drug|biphasic insulin aspart|
1749137|NCT00184574|Drug|biphasic insulin aspart|
1749138|NCT00184574|Drug|metformin|
1749139|NCT00184587|Drug|candesartan cilexetil|
1749140|NCT00184587|Drug|placebo|
1749141|NCT00184600|Drug|biphasic insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
1749142|NCT00184600|Drug|insulin detemir|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, once or twice daily plus option for insulin aspart
1749143|NCT00184600|Drug|insulin aspart|Treat-to-target (individually adjusted dose), subcutaneously (under the skin) injection, twice daily plus option for insulin detemir
1749144|NCT00184613|Device|pump|
1749145|NCT00184613|Drug|insulin glargine|
1749146|NCT00184613|Drug|insulin aspart|
1749147|NCT00184626|Drug|biphasic insulin aspart|
1749148|NCT00184626|Drug|insulin glargine|
1749149|NCT00184626|Drug|metformin|
1749150|NCT00184639|Drug|insulin detemir|
1749151|NCT00184652|Drug|somatropin|
1749152|NCT00184665|Drug|insulin detemir|
1749153|NCT00184665|Drug|insulin NPH|
1749154|NCT00184665|Drug|insulin aspart|
1749155|NCT00184678|Drug|somatropin|
1749156|NCT00184691|Drug|somatropin|
1749157|NCT00184717|Drug|somatropin|0.033 mg/kg/day of NN-220 for s.c. injection in cartridge
1749158|NCT00184717|Drug|somatropin|0.067 mg/kg/day of NN-220 for s.c. injection in cartridge
1749159|NCT00184730|Drug|somatropin|
1749160|NCT00184743|Drug|somatropin|
1749161|NCT00184756|Drug|somatropin|
1749162|NCT00184769|Drug|somatropin|
1749163|NCT00184782|Procedure|FDG-PET|
1749164|NCT00184795|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
1749165|NCT00184795|Drug|0.5 mg estradiol / 0.25 mg norethisterone acetate (NETA)|One tablet per day for 24 weeks
1749166|NCT00184795|Drug|placebo|Placebo tablets for 24 weeks
1749167|NCT00184821|Procedure|Ischemic preconditioning|
1749168|NCT00184821|Procedure|Forearm ischemic exercise|
1749169|NCT00184821|Procedure|Annexin A5 scintigraphy|
1749170|NCT00184821|Drug|Diazoxide|
1749171|NCT00184821|Drug|glibenclamide|
1749172|NCT00184821|Drug|adenosine|
1749173|NCT00184834|Behavioral|quality of life|
1749174|NCT00184847|Drug|acetylcholine|
1749175|NCT00184847|Procedure|twenty minutes of forearm ischemia|
1749176|NCT00184847|Procedure|three 5-minute periods of forearm ischemia|
1749177|NCT00184847|Drug|adenosine|
1749178|NCT00184847|Drug|caffeine|
1749179|NCT00184860|Procedure|PET-scan, MRI-scan|
1749180|NCT00184873|Behavioral|Health Counseling|
1749181|NCT00184886|Drug|Methotrexate 15 mg/week for 12 weeks|
1749182|NCT00184899|Drug|Intravenous infusion of Intralipid/heparin|
1749183|NCT00184899|Drug|Intravenous infusion of Glycerol/heparin|
1749184|NCT00184912|Drug|caffeine|
1749185|NCT00184912|Drug|Technetium-TC99m-labeled Annexin A5|
1749186|NCT00184912|Procedure|ten minutes forearm ischemia|
1749187|NCT00184912|Procedure|ischemic forearm exercise|
1749188|NCT00184925|Procedure|Tracheostomy|trachesotomy with subglottic drainage
1749189|NCT00184925|Device|cannula with subglottic drainage|
1749190|NCT00184938|Drug|morphine|
1749191|NCT00184938|Drug|naloxone|
1749192|NCT00184938|Drug|Technetium-TC99m-labeled Annexin A5|
1749193|NCT00184938|Procedure|forearm ischemic exercise|
1749194|NCT00184938|Procedure|ten minute forearm ischemia|
1749195|NCT00184951|Drug|Rosuvastatin|
1749196|NCT00184964|Procedure|CT-scan, PET-scan|
1749197|NCT00184977|Drug|N-acetylcysteine|
1749198|NCT00184977|Drug|fluticasone propionate|
1749199|NCT00184990|Drug|Aminoguanidine|
1749200|NCT00184990|Drug|endotoxin|
1749201|NCT00185003|Drug|endotoxin|
1749202|NCT00185003|Drug|Potassium channel blockers: TEA, Quinin, Tolbutamide|
1749203|NCT00185003|Drug|L-NMMA|
1749204|NCT00185016|Behavioral|a training to improve recognition of partner abuse.|
1749205|NCT00185029|Procedure|Ferumoxtran-10 enhanced MRI (MRL)|
1749206|NCT00185042|Drug|Pactimibe, CS-505|
1749207|NCT00185055|Drug|Olmesartan medoxomil|
1749208|NCT00185055|Drug|Irbesartan|
1749209|NCT00185055|Drug|Valsartan|
1749210|NCT00185068|Drug|Olmesartan medoxomil|
1749211|NCT00185068|Drug|Olmesartan medoxomil/hydrochlorothiazide|
1749212|NCT00185068|Drug|Hydrochlorothiazide|
1749213|NCT00185081|Drug|Indium labeled IMP-205xm734|
1749214|NCT00185094|Drug|Olmesartan medoxomil|
1749215|NCT00185094|Drug|Losartan potassium|
1749216|NCT00185094|Drug|Atenolol|
1749217|NCT00185107|Drug|Colesevelam Hydrochloride|
1749218|NCT00185107|Drug|Ezetimibe|
1749219|NCT00185107|Drug|Simvastatin|
1749220|NCT00185120|Drug|Olmesartan medoxomil|
1749221|NCT00185120|Drug|Hydroclorothiazide|
1749222|NCT00185120|Drug|Benazepril|
1749223|NCT00185120|Drug|Amlodipine|
1749224|NCT00185133|Drug|Olmesartan medoxomil|
1749225|NCT00185133|Drug|Amlodipine|
1749226|NCT00185146|Drug|Pactimibe|
1749227|NCT00185159|Drug|Olmesartan medoxomil|tablets
1749228|NCT00185159|Drug|Placebo Tablets|Tablets
1749229|NCT00185172|Other|placebo|Placebo oral tablets for 2 weeks
1749230|NCT00185172|Drug|olmesartan medoxomil|olmesartan medoxomil oral tablets for 8 weeks
1749231|NCT00185172|Drug|olmesartan medoxomil oral tablets, hydrochlorothiazide oral tablets|olmesartan medoxomil oral tablets,or olmesartan medoxomil oral tablets + hydrochlorothiazide oral tablets
1749232|NCT00185185|Drug|Olmesartan medoxomil|
1749233|NCT00185185|Drug|Atenolol|
1749234|NCT00185185|Drug|Hydrochlorothiazide|tablets
1749235|NCT00185185|Drug|olmesartan medoxomil|tablets
1749236|NCT00185185|Drug|atenolol|tablets
1749237|NCT00185198|Drug|Testogel (Testosterone, BAYV001915)|50mg (5g gel sachet), 75mg (5g+2.5g sachet) or 100mg (2x5g sachet) per day applied to the skin of the shoulders, arms or abdomen for 18 months
1749238|NCT00185198|Drug|Placebo|5g gel sachet, 5g+2.5g sachet or 2x5g sachets per day applied to the skin of the shoulders, arms or abdomen for 6 months followed by 12 months treatment with testosterone 1% gel as described for arm 1
1749239|NCT00185211|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Initial Betaferon/Betaseron treatment (Interferon beta-1b, IFNB-1b), 250 ug administered s.c. (subcutaneous) every other day, continued in Follow-up phase
1749240|NCT00185211|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Initial placebo treatment; Betaferon/Betaseron, 250 ug administered s.c. (subcutaneous) every other day offered in Follow-up phase (= this trial)
1749241|NCT00185224|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 treatment cycles of 28 days each (no tablet-free intervals); Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27 - 28: Placebo
1749242|NCT00185224|Drug|SH D00264A (Triquilar)|7 treatment cycles of 28 days each (no tablet-free intervals);Days 1-6: 0.03 mg EE + 0.05 mg LNG; Days 7-11: 0.04 mg EE + 0.075 mg LNG; Days 12-21: 0.03 mg EE + 0.125 mg LNG;Days 22-28: Placebo
1749243|NCT00185237|Drug|Menostar (estradiol transdermal delivery system)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
1749244|NCT00185237|Drug|Placebo|Placebo patch
1749245|NCT00185250|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1 and 4 MIU per application in weeks 2 to 24 given subcutaneously every other day
1749246|NCT00185250|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2 MIU per application in week 1, 4 MIU per application in weeks 2 to 3 and 8 MIU per application in weeks 4 to 24 given subcutaneously every other day
1749247|NCT00185250|Drug|Placebo|0.25 ml in week 1 and 0.50 ml in weeks 2 to 24 given subcutaneously every other day
1749248|NCT00185250|Drug|Placebo|0.25 ml in week 1, 0.50 ml in weeks 2 to 3 and 1.00 ml in weeks 4 to 24 given subcutaneously every other day
1749249|NCT00185263|Genetic|AdF5FGF-4 vs. Placebo|Intracoronary infusion
1749250|NCT00185276|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: lower dose corresponding approx. 0.1 mmol/kg body weight
1749251|NCT00185276|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Single intravenous injection on the study day: higher dose corresponding approx. 0.2 - 0.3 mmol/kg body weight
1749252|NCT00185289|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 8-24: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
1749253|NCT00185302|Drug|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 3 mg on Days 1 and 15 of a 4-week cycle
1749254|NCT00185302|Drug|Histone Deacetylase Inhibitor, MS-275 (BAY 86-5274, ZK 244894)|MS-275, 7 mg on Days 1, 8 and 15 of a 4-week cycle
1749255|NCT00185315|Drug|Ventavis (Iloprost, BAYQ6256)|Inhaled iloprost
1749256|NCT00185328|Drug|Estradiol/DRSP (Angeliq, BAY86-4891)|1 tablet of 2 mg drospirenone and 1 mg estradiol, orally administered once daily, over three 28-day treatment cycles
1749257|NCT00185341|Drug|CCR1-Antagonist (BAY86-5047, ZK811752)|Given orally in a dose of 600 mg three times daily over 12 weeks
1749258|NCT00185341|Drug|Placebo|Placebo
1749259|NCT00185354|Drug|BAY86-5016, SH P00331F|Drug amount per patch: 0.9 mg EE2 + 1.9 mg gestodene (GSD)
1749260|NCT00185354|Drug|SH P00331N|Drug amount per patch: 0.6 mg EE2 + 6 mg NGM
1749261|NCT00185367|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-2: 3.0 mg EV; Day 3-7: 2.0 mg EV + 2.0 mg DNG; Day 8-24: 2.0 mg EV + 3.0 mg DNG; Day 25-26: 1.0 mg EV; Day 27-28: placebo;In addition SH D 593 B (Miranova) matching placebo
1749262|NCT00185367|Drug|SH D 593 B (Miranova)|7 cycles each consisting of 28 days (no tablet-free intervals); Day 1-21: 0.02 mg EE + 0.10 mg LNG; Day 22-28: placebo; In addition EV/DNG (Qlaira, BAY86-5027, SH T00658K) matching placebo
1749263|NCT00185380|Drug|Levonorgestrel IUS (BAY86-5028, G04209B)|Levonorgestrel intrauterine contraception system (IUS) releasing 12 microg/24 h in vitro, to be used for three years
1749264|NCT00185380|Drug|Levonorgestrel IUS (BAY86-5028, G04209C)|Levonorgestrel intrauterine contraception system (IUS) releasing 16 microg/24 h in vitro, to be used for three years
1749265|NCT00185380|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel Intrauterine contraception system (IUS) releasing 20 microg/24 h to be used for three years
1749266|NCT00185393|Biological|Zevalin ([90]Y-ibritumomab tiuxetan, BAY86-5128)|treatment with 90 Yttrium-labeled anti CD 20 antibody
1749267|NCT00185393|Other|no treatment|no treatment
1749268|NCT00185419|Drug|Yasmin|30 µg ethinylestradiol, 3mg drospirenone
1749269|NCT00185419|Drug|Marvelon|30 µg ethinylestradiol, 150 µg desogestrel
1749270|NCT00185445|Drug|Fludarabine Phosphate (Fludara)|All patients will receive fludarabine phosphate orally for 3 consecutive days per cycle and mitoxantrone on day 1. Each patient will receive up to six treatment cycles. Treatment cycles will be given at 4 weeks intervals.
1749271|NCT00185458|Drug|LNG IUS|LNG IUS (initial in vitro release 20 µg/24h) intrauterine for minimum of 9 months and maximum of 60 months - 2 phases: a) Contraception Phase b) HRT Phase. For outcome measures (vaginal bleeding variables), five 90-day Reference Periods were defined, which were used for comparison during statistical analysis: Reference Period -1 in Contraception Phase; Reference Periods 1-4 in HRT Phase. 90-day reference periods for analyzing vaginal bleeding data are defined by WHO guideline. Reference Period -1 is the last 90-day reference period that the subject had before starting the HRT. Reference Period 1 covers the first 90-days of the HRT phase, Reference Period 2 covers days 91 to 180, Reference Period 3 days 181 to 270, and Reference Period 4 days 271 to 360 of the HRT phase.
1749272|NCT00185484|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|Oral administration of YAZ (0.02mg ethinyl estradiol-ß-cyclodextrin clathrate and 3mg drospirenone, 24 day hormone tablets followed by 4 days of placebo tablets for 13 cycles
1749273|NCT00185510|Drug|Methylprednisolone Aceponate (Advantan, BAY86-4862)|In maintenance phase, Methylprednisolone Aceponate cream is applied topically twice a week.
1749274|NCT00185510|Drug|Placebo|2 days a week Vehicle (Advabase)
1749275|NCT00185523|Procedure|Allogeneic hematopoietic cell transplantation|
1749276|NCT00185536|Behavioral|Packaging and identification of source|
1749277|NCT00185549|Behavioral|CF. DOC|
1749278|NCT00185562|Drug|Adalimumab|
1749279|NCT00185575|Drug|duloxetine|
1749280|NCT00185588|Drug|Vatalanib|Vatalanib 250 mg PO Q12 hours x 7 days, 8th day forward 500 mg PO Q12 hours
1749281|NCT00185588|Drug|Gemcitabine|850 mg/m2
1749282|NCT00185601|Behavioral|Internet Diabetes Self-Management Program|
1749288|NCT00185640|Drug|Cyclosporine|starting day -3 at a dose of 5 mg/kg orally twice daily with a target trough level of 350 to 450 ng/mL
1749289|NCT00185640|Drug|Anti-Thymocyte Globulin|1.5 mg/kg for total dose of 7.5mg/kg, IV starting on day -11 to day -7 before HCT
1749290|NCT00185640|Drug|mycophenolate mofetil|Begins on day 0 after HCT at a dose of 15 mg/kg. Patients who received related donor grafts received MMF twice daily and those who received unrelated donor grafts received MMF 3 times daily.
1749291|NCT00185640|Drug|Granulocyte-Colony Stimulating Factor|Received on day 0
1749292|NCT00185640|Radiation|Total Lymphoid Irradiation|0.8 Gy/day from day -11 to day -7 (inclusive) from day -4 to day -2 (inclusive) with 2 additional fractions of 0.8 Gy delivered on day -1 for total dose of 8 Gy.
1749293|NCT00185653|Procedure|Autologous followed by non-myeloablative allogeneic transplantation|
1749294|NCT00185666|Procedure|Stereotactic radiosurgery|
1749295|NCT00185679|Device|CliniMACS System|"The CliniMACS System is a cell selection device consisting of the following components:
Computer-controlled instrument;
Sterile disposable tubing set (PVC tubing, filters and bags connected to two separation columns containing an iron/plastic matrix)
Anti-CD34 antibody reagent (murine monoclonal antibody chemically coupled to a magnetic particle)
Wash buffer"
1749296|NCT00185692|Procedure|non-myeloablative hematopoietic cell transplantation|TLI and ATG infusion of the donor graft Post-transplant immunosuppression with cyclosporine and mycophenolate mofetil.
1749297|NCT00185692|Drug|Anti-Thymocyte Globulin|1.5 mg/kg QD x 5, IV. Dosage will be based on body weight. Purified, sterile IgG fraction of immune serum of rabbits immumixied with human thymus lymphocyte. This drug acts to modify the number and function of lymphocytes.
1749298|NCT00185692|Drug|Cyclosporine|6.25 mg/kg BID, PO.Mechanism of action is inhibition of T-cell activation by binding to a cytoplasmic protein (cyclophillin).
1749299|NCT00185692|Drug|Mycophenolate Mofetil|15 mg/kg Q 8 hours, PO. Inhibtis the enzme inosine monophsophate dehydrogenase (MPDII) noncompetitively which blocks the de nobo synthesis of guanosine required for DNA synthesis and has an effect on T and B cells.
1749300|NCT00185692|Drug|G-CSF|16 mg/kg, SQ Growth factor used to make bone marrow produce more blood cells
1749301|NCT00185692|Drug|Solumedrol|1.0 mg/kg IV 2 hours prior to ATG Used to treat severe inflamation
1749302|NCT00185692|Drug|Acetaminophen|650 mg PO, 30 minutes prior to infusion Pain reliever
1749303|NCT00185692|Drug|Diphenydramine|50 mg IV, 30 minutes prior to infusion Used to relieve allergy symptoms
1749304|NCT00185692|Drug|Hydrocortisone|100 mg IV, 1 hour prior to infusion Used to relieve itching, redness and swelling of the skin
1749305|NCT00185705|Drug|Telmisartan|
1749307|NCT00185744|Radiation|Intra-Operative Radiotherapy (IORT)|single dose in the operating room after lumpectomy
1749308|NCT00185744|Procedure|Lumpectomy|
1749309|NCT00185744|Radiation|Whole Breast Radiotherapy|six and a half week treatment
1749310|NCT00185744|Radiation|Intracavitary Brachytherapy|5 day treatment
1749311|NCT00185744|Radiation|Accelerated External Beam 3-D Conformal Radiotherapy|5 day treatment
1749312|NCT00185744|Radiation|Stereotactic APBI|4 day treatment
1749313|NCT00185757|Drug|Cytokine Induced Killer Cells|CIK cell dose escalation will be performed in cohorts of three patients per group. The initial dose utilized will be 1x107 expanded cells/kg. Previously, unmanipulated donor lymphocytes administered at this dose did not result in significant GVHD 7. The expansion of the CIK cell population is expected to diminish the T cell subsets responsible for GVHD further reducing the risk of GVHD to recipients. The dose will be increased to 5x107 expanded cells/kg and 1x108 expanded cells/kg in successive escalations based on no significant infusional toxicity or GVHD in the recipients
1749314|NCT00185770|Behavioral|Reducing television and other screen time (SMART curriculum)|
1749315|NCT00185783|Drug|Hydrocortisone Administration (Standard of Care Therapy)|
1749316|NCT00185796|Procedure|Total Lymphoid Irradiation (TLI)|TLI is administered ten times in 120cGy fractions on day -11 through day -7 and day -4 through day -1
1749317|NCT00185796|Procedure|Anti-Thymocyte Globulin as Conditioning (ATG)|Thymoglobulin will be administered five times intravenously at 1.5 mg/kg/day from day -11 through day -7 for a total dose of 7.5 mg/kg. Thymoglobulin doses will be based on the adjusted ideal body weight if the patient is greater than or equal to 15 kg over ideal body weight.
1749318|NCT00185835|Drug|ZD-1839|
1749319|NCT00185835|Drug|Cisplatin|
1749320|NCT00185848|Radiation|[18F]FHBG|< 7mCi and 2 ug, iv
1749321|NCT00185861|Drug|Arsenic Trioxide|
1749322|NCT00185861|Procedure|Stereotactic radiosurgery|
1749323|NCT00185874|Biological|Intratumoral Dendritic Cell Immunotherapy|
1749324|NCT00185874|Biological|autologous dendritic cells|
1749325|NCT00185887|Drug|Terbutaline|Terbutaline 250 micrograms intravenously for intrapartum fetal resuscitation. Nitroglycerine 400 micrograms intravenously for intrapartum fetal resuscitation.
1749326|NCT00185900|Drug|Magnesium Sulfate|Preterm labor treatment with Magnesium Sulfate 4 gram bolus followed by 2 gm per hour infusion. 2 Gm bolus as needed and/or rate increase up to 4gm per hour were allowed at the discretion of the treating physician.
1749327|NCT00185900|Drug|Nifedipine|Preterm labor treatment with Nifedipine 10 mg. sublingually every 20 minutes for three doses, followed by 20 mg. orally every 4 or 6 hours.
1749328|NCT00185939|Drug|Augmentin|
1749329|NCT00185952|Drug|Nifedipine|Nifedipine 10 mg tablets, two tablets orally every 6 hours. Placebo tablets, two tablets orally every 6 hours.
1749330|NCT00185965|Drug|CPG 7909|6 mg intratumoral injection, administered immediately before 2 Gy radiotherapy (RT) to a designated tumor lesion, about 24 hours later after a 2nd 2 Gy RT dose, then weekly for 8 additional weeks (total of 10 injections).
1749331|NCT00185978|Behavioral|diet, physical activity, reduced sedentary behavior|
1749332|NCT00185991|Drug|gentamicin|"Daily gentamicin (5 mg/kg intravenously, then placebo doses IV after 8 and 16 hours).
Eight hour gentamicin (2 mg/kg intravenously, then 1.5 mg/kg IV after 8 and 16 hours)."
1749333|NCT00186004|Device|Continuous Glucose Monitor|Subjects are fitted with a CGM system and perform self blood glucose measures three or more times per day for 3 days.
1749334|NCT00186017|Drug|Olanzapine/Zyprexa|Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.
1749335|NCT00186030|Behavioral|HIV Skills-based Prevention|
1749336|NCT00186043|Drug|Quetiapine/Seroquel|Quetiapine/Seroquel
1749337|NCT00186043|Drug|Placebo|Placebo
1749338|NCT00186056|Drug|Mifepristone|Glucocorticoid antagonist
1749339|NCT00186056|Drug|Placebo Oral Tablet|Inactive placebo tab
1749340|NCT00186069|Drug|Magnesium Sulfate|Magnesium Sulfate 4 gram bolus, followed by a maintenance dose at 2 grams per hour. Rate increases up to 4 grams per hour may be administered per physician discretion.
1749341|NCT00186069|Other|Normal Saline|Normal Saline infusion of 4 gram bolus, followed by 2 grams per hour with rate increases up to 4 grams per hour per physician discretion.
1749342|NCT00186082|Drug|Cefotetan or Cefoxitin vs placebo|"Cefotetan or Cefoxitin, 1 g intravenously, or Clindamycin, 900 mg intravenously.
Normal Saline, 100 ml intravenously for placebo arm."
1749343|NCT00186095|Procedure|autologous followed by nonmyeloablative allogeneic transplant|
1749344|NCT00186108|Drug|Oral Triamcinalone|
1749347|NCT00186134|Behavioral|physical activity|
1749348|NCT00186147|Procedure|collection and storage of tissue samples for research|Tissue samples include blood draws for the donor and recipient. A bone marrow sample may be obtained from the recipient. If the recipient undergoes a tissue biopsy for clinical reasons, a small fraction may be removed for research purposes. A small fraction of the donor graft may be removed at the time of collection for research.
1749349|NCT00186173|Behavioral|After school sports program|After school team sports intervention designed specifically for overweight and obese children
1749350|NCT00186173|Behavioral|After school health education|After school health and nutrition education program
1749351|NCT00186186|Drug|Depakote ER|Depakote ER
1749352|NCT00186212|Behavioral|workbook/journal on coping with breast cancer|
1749353|NCT00186212|Behavioral|standard educational materials on breast cancer|
1749354|NCT00186225|Procedure|ablative allogeneic hematopoietic cell transplantation|
1749355|NCT00186238|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
1749356|NCT00186251|Procedure|high dose chemo then auto hematopoietic cell transplant|
1749357|NCT00186264|Drug|venlafaxine XR|
1749358|NCT00186264|Drug|hydrocortisone|
1749359|NCT00186277|Drug|Oxaliplatin|Calculated per patient
1749360|NCT00186277|Drug|Taxotere|Calculated per patient
1749361|NCT00186290|Procedure|ablative allogeneic hematopoietic cell transplantation|
1749362|NCT00186303|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
1749363|NCT00186303|Procedure|ablative allogeneic hematopoietic cell transplant|
1749364|NCT00186316|Biological|Idiotype-pulsed allogeneic dendritic cells|
1749365|NCT00186329|Drug|Natrecor, a recombinant form of B-type Natriuretic Peptide, made by Scios, Inc. vs. placebo|
1749366|NCT00186342|Procedure|ablative allogeneic hematopoietic cell transplantation|
1749367|NCT00186355|Procedure|high dose chemo then auto hematopoietic cell transplant|
1749368|NCT00186381|Procedure|high dose chemotherapy then autologous hematopoietic cell transplant|
1749369|NCT00178581|Drug|Glutamine|
1749373|NCT00178633|Procedure|Bariatric surgery|Bariatric surgery was not part of this trial. This was observational trial of persons post-bariatric surger.
1749375|NCT00178659|Other|Blood/saliva samples for protein/molecular analysis|Bloods samples - healthy volunteers(1 time) head injury subjects (5 times). Blood and/or saliva samples mild TBI patients (2 times) and healthy volunteers (2 times)
1749376|NCT00178672|Device|Angioguard XP distal protection device|Standard of care stenting of carotid arteries protocol is used.
1749377|NCT00178672|Procedure|Heart Catheterization -Angioplasty|Standard of care carotid stenting. A catheter is inserted in the femoral vein into the carotid artery where a balloon is inflated and shortly thereafter a stent is placed in the target lesion area.
1749378|NCT00178672|Device|stenting|stenting of carotid arteries
1749379|NCT00178685|Behavioral|Self-determination Intervention for Tobacco Dependence|autonomy supported behavioral intervention for tobacco dependent individuals
1749380|NCT00178698|Other|thermochemotherapy|cisplatin 60 mg/m2 i.v. over 4 hours on day 1 gemcitabine 600 mg/m2 i.v. over 60 minutes on day 3 interferon-alpha 1 million international units s.c. daily for protocol duration
1749423|NCT00179179|Behavioral|exercise|resistance training on a duel leg press consisting of 3 sets of 8-12 repetitions; the first 5 study visits over a 12-month period
1749381|NCT00178698|Drug|Cisplatin, Gemcitabine, Interferon-a|cisplatin 60 mg/m2 i.v. over 4 hours gemcitabine 600 mg/m2 i.v. over 1 hour interferon-alpha 100,000 i.u. s.c.daily fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration
1749382|NCT00178698|Other|thermochemotherapy|After hydration and anti-emetics, cisplatin 60 mg/m2 i.v. is given over 4 hours on day 1. Also on day 1, begin daily low-dose interferon-alpha 1 million international units s.c. On day 3, 36 hours after cisplatin infusion, induce fever-range whole-body thermal therapy to 40 oC (104 oF) for a duration of 6 hrs. When the target temperature of 40 oC is reached, gemcitabine 600 mg/m2 is administered i.v. over 60 minutes, and the temperature is maintained at plateau for a total of 6 hours. The cycle is repeated at 21 to 28 day intervals.
1749383|NCT00178711|Device|Hypothermia|Induction of moderate hypothermia to 33 degrees celsius, within 2.5 hours from time of injury and maintained for 48 hours
1749384|NCT00178724|Other|No Treatment Given|Intervention is not given.
1749385|NCT00178737|Behavioral|Electronic reminder message|
1749386|NCT00178750|Device|18G Tuohy epidural needle|
1749387|NCT00178750|Device|CompuFlo® computerized syringe pump|
1749388|NCT00178763|Device|Heckel Infrared Radiant Heat Device|thermotherapy, maintain a core temperature of 40 degrees centigrade for 6 hours duration
1749389|NCT00178763|Other|cisplatin, gemcitabine, interferon-alpha|cisplatin 60 mg/m2 administered over 3 hours intravenously 36 hours before heat. gemcitabine 600 mg/m2 administered intravenously over 1 hour during 40 degree heat. interferon-alpha 1 million international units subcutaneously daily during protocol.
1749390|NCT00178763|Other|thermochemotherapy|fever-range whole-body thermal therapy to 40 degrees centigrade combined with cisplatin 60 mg/m2 + gemcitabine 600 mg/m2 + daily interferon alpha 1 million units.
1749391|NCT00178776|Behavioral|Transtheoretical Model Group Therapy|
1749392|NCT00178776|Behavioral|Education & Advice|
1749393|NCT00178802|Other|thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)|"5-fluorouracil 400 mg/m2 i.v. over 24 hours for 5 days
Doxil (liposomal doxorubicin) 40 mg/m2 over 1 hour
Fever-range whole-body thermal therapy to 40 oC (104 oF) for 6 hours duration daily
Low-dose interferon-alpha 100,000 i.u. s.c. daily for the duration of the protocol"
1749394|NCT00178828|Drug|sertraline|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
1749395|NCT00178828|Drug|bupropion|Patients will be assigned by random selection to sertraline (50mg daily for one week, then 100mg daily) or bupropion (SR formulation, 150 mg daily for 1 week, then 150 mg BID). A second CSF collection will be completed after 4 weeks of the sertraline treatment (during week 5).
1749396|NCT00178841|Drug|Rosiglitazone and Bexarotene|rosiglitazone added to bexarotene capsules
1749397|NCT00178854|Drug|Risperidone|
1749398|NCT00178919|Drug|L-NMMA|IV infusion of 125, 250 and 500 mcg/Kg/min for 15 minutes each dose. The main outcome is the maximal increase in blood pressure produced at the end of the infusions or a maximal systolic blood pressure of 160 mm Hg. It could be achieved after the first dose or the third.
1749399|NCT00178919|Drug|Trimethaphan|IV infusion for the duration of the study at 4-6 mg/min depending on autonomic blockade. This is only to produce transient pharmacological blockade of the autonomic nervous system in order to allow the full expression of the inhibition of nitric oxide synthase. There is no direct outcome associated with this intervention.
1749400|NCT00178932|Procedure|genetic analysis|genetic assay of blood sample drawn with patient's consent
1749401|NCT00178932|Procedure|genetic assay|genetic assay of blood sample drawn with patient's consent
1749402|NCT00178945|Drug|Botulinum Toxin Type A|
1749403|NCT00178958|Device|Holter Monitor|
1749404|NCT00178971|Drug|adjunctive treatment with buspirone|buspirone 15-30 mg qd
1749405|NCT00178971|Drug|placebo|placebo
1749408|NCT00179023|Drug|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 2-4 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1 hour
1749409|NCT00179023|Drug|Trimethaphan|Start dose: 0.05 ml/min (0.5 mg/min), IV infusion. The dose will be increased every 30 minutes to 1, 2, 4, and 5 mg/min. Total duration: 1-2 hours
1749410|NCT00179023|Drug|Pseudoephedrine|30mg tablet,VO. Single dose.
1749411|NCT00179062|Drug|olanzapine versus risperidone|Participants are to be randomized to olanzapine or risperidone. Antipsychotic medication will be given as per package insert daily for the twelve month duration of the trial.
1749412|NCT00179088|Behavioral|Patient may be able to put weight on the operated leg|
1749413|NCT00179101|Procedure|Deep Brain Stimulation|
1749414|NCT00179114|Drug|Botulinum Toxin Type A|
1749415|NCT00179114|Drug|Intrathecal baclofen administered by the Medtronic SyncroMed(TM) pump (ITB)|
1749416|NCT00179127|Drug|glargine|0.3u/kg of glargine, subq, once
1749417|NCT00179127|Drug|saline|0.3cc/kg of saline, subq, once
1749418|NCT00179140|Drug|nutritional supplementation|oral administration of protein supplement (Nepro) during hemodialysis; every other day, 3 days per week for 6 months; Nepro is a lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat
1749419|NCT00179140|Behavioral|exercise|either before or during hemodialysis, patients will perform a leg press exercise; every other day, 3 days per week, for 6 months
1749420|NCT00179153|Dietary Supplement|Nepro nutritional supplement|oral nutritional supplement (Nepro); every other day, 3 days per week, for 6 months
1749421|NCT00179166|Drug|TPN nutritional supplement|intravenous administration of nutritional supplement for 4 hours at a dosage of 30 kcal/kg/day, in the form of lipids, carbohydrates and protein; the non-protein calories are comprised of lipids (30%) and carbohydrates (70%)
1749422|NCT00179179|Drug|nutritional supplementation|2 oral ingestions per study visit of protein supplement containing a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat; 6 study visits over a 12-month period
1749424|NCT00179192|Procedure|angioplasty|angioplasty performed at the time of the angiogram; approach and technique to be determined by the interventional radiologist
1749425|NCT00179192|Procedure|surgery|surgical revision of patient's PTFE in a timely fashion not to exceed 72-96 hours after the angiogram; method of revision to be determined by the surgeon performing the procedure
1749426|NCT00179205|Drug|Nepro nutritional supplement|oral nutritional supplement (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 480 calories: 71 calories from protein, 206 calories from carbohydrates and 206 calories from fat.
1749427|NCT00179205|Drug|placebo|oral placebo (1 can) administered during the hemodialysis procedure; every other day, 3 days per week, for 3 months; each can contains a total of 60 calories: 0 calories from protein, 60 calories from carbohydrates, and 0 calories from fat.
1749428|NCT00179218|Drug|nutritional supplementation|oral administration of 2 cans of protein supplement (lactose-free formula that contains a total of 960 kilocalories: 132.8 kilocalories from protein, 412.8 kilocalories from carbohydrates, and 412.8 kilocalories from fat); every other day, 3 days per week, for 6 months
1749429|NCT00179218|Behavioral|exercise|leg press exercise; every other day, 3 days per week, for 6 months
1749430|NCT00179231|Drug|olanzapine vs. clozapine|
1749431|NCT00179244|Drug|Rispridone (drug) and Bupropion ER (drug)|
1749432|NCT00179257|Drug|sertraline (Zoloft)|
1749433|NCT00179283|Drug|sertraline|
1749434|NCT00179283|Drug|venlafaxine XR|
1749435|NCT00179309|Drug|Docetaxel|35 mg/m^2 intravenous 30-60 minutes once a week for 3 consecutive weeks with 1 week off drug.
1749436|NCT00179309|Biological|PANVAC-V|2 x 10^8 PFU
1749437|NCT00179309|Biological|PANVAC-F|1 x 10^9 PFU
1749438|NCT00179309|Biological|Sargramostim|Given subcutaneously under the skin, usually in the thigh on the day of vaccination and daily for the next 3 days.
1749439|NCT00179335|Procedure|Blood drawing to determine drug levels|
1749440|NCT00179348|Procedure|Quality-of-Life Assessment|Ancillary studies
1749441|NCT00179348|Procedure|Yoga|Undergo a yoga-based rehabilitation program
1749442|NCT00179374|Behavioral|Tailored telephone intervention of education|Tailored telephone intervention to promote metabolic control of diabetes
1749443|NCT00179374|Behavioral|Print educational intervention|diabetes educational materials by mail
1749444|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Psycho-educational group
1749445|NCT00179387|Behavioral|Mind-Body Psychotherapy Group|Spiritual-Existential Group
1749446|NCT00179400|Drug|Pioglitazone/EPA|
1749447|NCT00179400|Drug|Placebo|
1749448|NCT00179413|Drug|PEG -Intron|
1749449|NCT00179413|Drug|Colchicine|0.6mg twice a day
1749450|NCT00179439|Procedure|nasal potential difference testing|
1749451|NCT00179452|Behavioral|Yoga|
1749452|NCT00179465|Drug|Tiagabine|Up to 36 mg daily
1749453|NCT00179465|Drug|Placebo|Placebo
1749454|NCT00179478|Drug|interferon beta 1a 30 ug IM once weekly|Immediate treatment group refers to those patients who were randomized to the interferon beta 1a 30 ug IM once weekly treatment arm of the original, controlled phase III CHAMPS study; Delayed treatment group refers to those patients who were randomized to the placebo group during the original controlled, phase III CHAMPS study and did not start treatment, if at all, until they completed the CHAMPS study protocol at a later date.
1749455|NCT00179491|Behavioral|Intercessory Prayer|14 days of intercessory prayer from 3 sites
1749456|NCT00179504|Behavioral|Relaxation Response|Relaxation training
1749457|NCT00179517|Drug|Anastrozole 1mg|
1749458|NCT00179517|Drug|Placebo Oral Tablet|
1749459|NCT00179530|Behavioral|Relaxation Response|Relaxation training
1749460|NCT00179543|Behavioral|Relaxation response|
1749461|NCT00179556|Drug|Isoflavone supplement|
1749462|NCT00179569|Behavioral|Relaxation response|8 weeks of relaxation response training
1749463|NCT00179582|Drug|VSL#3|
1749464|NCT00179595|Behavioral|relaxation response- meditation|
1749465|NCT00179608|Drug|CC-5013|
1749466|NCT00179621|Drug|Lenalidomide 5 mg|Lenalidomide 5 mg daily 28/28 days
1749467|NCT00179621|Drug|Lenalidomide 10 mg|Lenalidomide 10 mg daily 21/28 days
1749468|NCT00179621|Drug|Placebo|Placebo, matching to active study drug arms
1749469|NCT00179634|Behavioral|Visualization relaxation|
1749470|NCT00179634|Behavioral|Visual Milieu Enhancement (Fine art photograph)|
1749471|NCT00179647|Drug|lenalidomide|Lenalidomide, 5 mg to 25 mg, QD, orally, for 21 days every 28 days, with or without dexamethasone
1749472|NCT00179647|Drug|dexamethasone|Dexamethasone, 20 mg to 40 mg, QD, orally, administered under a variety of dosing regimens
1749473|NCT00179660|Drug|Lenalidomide|Capsules for oral administration.
1749474|NCT00179673|Drug|Lenalidomide|Lenalidomide 25 mg orally once daily on Days 1 to 21 of every 28-day cycle for up to 52 weeks or until disease progression developed
1749475|NCT00179686|Drug|CC-5013|
1749476|NCT00179699|Drug|CC-5013|
1749477|NCT00179699|Drug|pemetrexed|
1749478|NCT00179712|Drug|CC-5013|
1749479|NCT00179712|Drug|topotecan|
1749480|NCT00179725|Drug|CC-5013|
1749481|NCT00179725|Drug|liposomal doxorubicin|
1749482|NCT00179738|Drug|CC5013|
1749483|NCT00179751|Drug|CC-5013|
1749484|NCT00179751|Drug|gemcitabine|
1749485|NCT00179764|Procedure|Immunoablative Hematopoietic PBSC Transplant|Immunoablative conditioning chemotherapy regimen, followed by transplantation of peripheral blood stem cells on Day 0 of the conditioning regimen.
1749486|NCT00179764|Procedure|Busulfan pharmacokinetics|Pharmacokinetics of once-a-day dosing of intravenous busulfan as a 3-hour infusion
1749487|NCT00179764|Radiation|Central Nervous System (CNS) prophylaxis radiation|"Patients diagnosed with ALL over 1 year of age and without prior CNS disease will receive CNS prophylaxis radiation to the whole brain prior to transplant.
Patients diagnosed with ALL with prior CNS disease over the age of 1 year will be treated with prophylaxis radiation to the whole brain and spine prior to transplant."
1749488|NCT00179777|Dietary Supplement|hydrolysed infant formula|hydrolysed infant formula
1749489|NCT00179777|Dietary Supplement|nonhydrolysed infant formula|nonhydrolysed infant formula
1749490|NCT00179790|Procedure|Extracorporeal Photopheresis|Patient will undergo ECP treatment pre and post stem cell transplant infusion
1749491|NCT00179803|Procedure|Stem Cell Transplant|"Group A: recurrent medulloblastoma, recurrent germ cell tumor
Cytoxan treatment
Stem cell autologous harvest
Group B: GBM, high grade astrocytoma, rhabdoid tumors, pineoblastoma, or supratentorial PNET
Carboplatin and Etoposide treatment
Autologous stem cell harvest
The preparatory regimen used for Stem Cell Rescue #1 will be Carboplatinum, VP-16 and Thiotepa. If the patient has recuperated his ANC to >1,000 within 50 days after Stem Cell Rescue #1, (sustained without G-CSF support) a neuroradiographic evaluation will be performed. If there is lack of progression, the patient will then proceed to Stem Cell Rescue # 2 with Cyclophosphamide and Melphalan, followed by stem cell rescue."
1749492|NCT00179816|Drug|High-Dose Chemotherapy with Tandem PBSC Rescue.|Patients on this study will undergo a tandem Peripheral Blood Stem Cell Rescue following high-dose chemotherapy. The first Peripheral Blood Stem Cell Rescue will consist of Etoposide, Carboplatin, Cyclophosphamide, and Mesna. Once the patient recovers, the patient will be evaluated again and will then undergo a second stem cell transplant consisting of the chemotherapy drugs; Melphalan, Cyclophosphamide, and Mesna.
1749493|NCT00179829|Procedure|WT 1 Testing|
1749494|NCT00179842|Procedure|Stem Cell Transplant|
1749495|NCT00179855|Procedure|Extracorporeal Photopheresis|"ECP will be performed using the UVAR® XTS™ photopheresis system (Therakos). Whole blood is drawn and separated by centrifuge to collect the buffy coat (lymphocyte solution). Methoxsalen (8-MOP) is added to the blood, and the final solution of cells is passed as a film, 1mm thick, through a disposable plastic device, exposed to a UVA light source (2J/cm2/cell) and then returned to the patient.
ECP will be performed weekly on 2 consecutive days for 4 weeks. After 4 weeks the interval will be prolonged to every 2 weeks and ECP will be stopped after maximal response has been maintained for 2 weeks. The actual study finishes at d56 but ECP may be continued beyond that (off-study) at the discretion of the physician."
1749496|NCT00179868|Behavioral|C-Reactive Protein levels|"Each patient enrolled in the study will have a serum quantitative c-reactive protein (crp) level drawn on the day of transplant, day 7 of transplant, and twice weekly after that until recovery of neutrophil count (approximately 20-25 days). Patients will be followed for 100 days post-transplant for the development of the following complications:
Sepsis- defined as fever, positive blood culture, need for fluid resuscitation and/or pressor support.
Acute GVHD > grade II defined according to the Seattle criteria
VOD- defined according to the modified Seattle criteria"
1749497|NCT00179881|Drug|Carboplatin|
1749498|NCT00179881|Drug|Thalomid|
1749499|NCT00179881|Procedure|External Beam Radiation Therapy|
1749500|NCT00179894|Behavioral|Physician training|Physicians are trained in guidelines for medication management.
1749501|NCT00179907|Procedure|Photon Radiosurgery System (Intrabeam)|In this study we had intended to perform a similar dose escalation study with doses ranging from 10-19 Gy, 10-16 Gy and 10 - 14 Gy for tumors < 20 mm, 21-25 mm and 26-40 mm respectively
1749502|NCT00179920|Drug|Carboplatin|
1749503|NCT00179920|Drug|VP-16|
1749504|NCT00179920|Procedure|Local Surgery|
1749505|NCT00179920|Procedure|Cryotherapy|
1749506|NCT00179920|Procedure|Laser hyperthermia|
1749507|NCT00179933|Behavioral|Newborn Individualized Assessment Program|
1749508|NCT00179946|Procedure|HLA typing|
1749509|NCT00179959|Drug|Sodium hypochlorite (bleach) baths|Sodium hypochlorite (bleach) baths twice weekly for 3 months
1749510|NCT00179959|Drug|Mupirocin ointment|Intranasal mupirocin 2% ointment BID x five days (3 times total for subjects; one time only for family members)
1749511|NCT00179959|Drug|Water|Water baths twice weekly for three months
1749512|NCT00179959|Drug|Petrolatum Ointment|Intranasal petrolatum ointment twice daily for five days
1749513|NCT00179972|Device|Adhesive and non-adhesive oximetry sensors|A sample of 32 premature infants will be recruited to participate in this study in which an adhesive sensor and a nonadhesive sensor are compared. Both sensors will be simultaneously tested in each subject, for a period of 14 days, with one sensor on the right foot and the other sensor on the left foot. Data will be collected on sensor longevity, skin integrity at the sensor site, reason for sensor replacement and ease of use rating by the clinician. Data will be summarized using descriptive statistics.
1749515|NCT00180011|Drug|Omalizumab|injectable medication
1749516|NCT00180024|Drug|irbesartan (drug)|
1749517|NCT00180037|Drug|Coenzyme Q10 Nanodispersion (Nanoquinone)|
1749518|NCT00180037|Drug|Placebo|
1749519|NCT00180050|Drug|Budesonide|
1749520|NCT00180063|Drug|L-NMMA(drug)|
1749521|NCT00186394|Procedure|ablative allogeneic hematopoietic cell transplantation|
1749522|NCT00186407|Procedure|high dose chemo then auto hematopoietic cell transplant|
1749523|NCT00186420|Drug|Taxotere|
1749524|NCT00186446|Drug|bupropion and smoking cessation behavioral intervention|
1749525|NCT00186459|Behavioral|Hypocaloric diet of varying macronutrient composition|
1749526|NCT00186472|Behavioral|Brief Cognitive Behavioral Treatment|
1749527|NCT00186485|Device|MagStim|The MagStim delivers low frequency 1Hz stimulation to the right frontal area of the brain
1749529|NCT00186511|Behavioral|workbook/journal on coping with breast cancer|
1749530|NCT00186511|Behavioral|supportive expressive group therapy using videoconferencing|
1749531|NCT00186524|Behavioral|Breast Cancer Support Group|
1749532|NCT00186537|Drug|Rosiglitazone|
1749533|NCT00186537|Drug|Fenofibrate|
1749534|NCT00186537|Behavioral|Weight Loss|
1749535|NCT00186550|Behavioral|Supportive Expressive Group Psychotherapy|
1749536|NCT00186550|Behavioral|Education|
1749537|NCT00186563|Procedure|Micro-plasmapheresis|
1749538|NCT00186576|Procedure|nonmyeloablative allogeneic hematopoietic cell transplant|
1749539|NCT00186589|Drug|90Y Ibritumomab tiuxetan|
1749540|NCT00186602|Behavioral|Peer counseling|
1749544|NCT00186641|Procedure|high dose chemo and auto hematopoietic cell transplant|
1749545|NCT00186654|Procedure|Acupuncture|
1749546|NCT00186654|Procedure|Perinatal massage|
1749547|NCT00186667|Procedure|high dose chemotherapy and autologous hematopoietic cell transplant|
1749548|NCT00186680|Procedure|high dose chemo then auto hematopoietic cell transplant|
1749550|NCT00186732|Procedure|Subcuticular Suture|
1749551|NCT00186732|Procedure|Surgical Staples|
1749552|NCT00189657|Procedure|5FU/LV Mayo Clinic or LV5FU2|
1749553|NCT00189657|Procedure|LV5FU2 + irinotecan|
1749554|NCT00189670|Procedure|6 TEC q 3 weeks|
1749555|NCT00189670|Procedure|4 EC q 2 weeks followed by 4 TXT q 2 weeks|
1749556|NCT00189670|Procedure|4 TXT q 2 weeks followed by 4 EC q 2 weeks|
1749557|NCT00189683|Procedure|Monitoring|
1749558|NCT00189683|Procedure|Xeloda|
1749559|NCT00189696|Drug|YM060|
1749560|NCT00189709|Drug|Micafungin|IV
1749561|NCT00189709|Drug|fluconazole|IV
1749562|NCT00189722|Drug|Tacrolimus|
1749563|NCT00189735|Drug|FK778|
1749564|NCT00189748|Drug|Tacrolimus|
1749565|NCT00189761|Drug|Tacrolimus|
1749566|NCT00189774|Drug|nateglinide|
1749567|NCT00189787|Drug|tacrolimus|
1749568|NCT00189800|Drug|Solifenacin succinate|
1749569|NCT00189813|Drug|YM060|
1749570|NCT00189826|Drug|tacrolimus|immunosuppression
1749571|NCT00189839|Drug|tacrolimus|Immunosuppression
1749572|NCT00189852|Device|Chronic heart failure monitoring system|
1749573|NCT00189852|Device|Lifestyle monitoring system|
1749574|NCT00189878|Drug|Methotrexate (drug)|Methotrexate 10 to 15 mg weekly for 8 weeks
1749575|NCT00189878|Drug|placebo capsules|4-6 placebo capsules - identical to capsules containing methotrexate
1749577|NCT00189917|Biological|IMVAMUNE (MVA-BN)|
1749578|NCT00189930|Biological|MVA-nef|3 imm.: 5E8_TCID50 MVA-nef, 1E8_TCID50 MVA-nef in non-dominant upper arm
1749579|NCT00189930|Biological|IMVAMUNE|3 immunizations: 1E8_TCID50 IMVAMUNE
1749581|NCT00189956|Biological|IMVAMUNE (MVA-BN)|Two vaccinations of 0.5 ml MVA-BN vaccine, separated by a 4 week interval.
1749582|NCT00189969|Biological|Elstree-BN|
1749584|NCT00189995|Drug|clozapine|
1749585|NCT00189995|Drug|haloperidol|
1749586|NCT00190008|Drug|piracetam|
1749587|NCT00190021|Drug|donepezil|
1749588|NCT00190034|Drug|N-Acetylcysteine 600mg/tab|
1749589|NCT00190047|Drug|DP-b99|
1749590|NCT00190060|Drug|Transdermal testosterone gel (Testogel 1% )|Transdermal testosterone gel (Testogel 1% ), 50 mg/d for 6 months
1749591|NCT00190060|Drug|Matched transdermal placebo gel|Matched transdermal placebo gel, 50mg/d for 6 months
1749592|NCT00190099|Device|Dexamethasone-Eluting Stent|
1749593|NCT00190112|Procedure|ventral cardiac denervation|
1749594|NCT00190138|Device|Bi-ventricular pacing|
1749595|NCT00190151|Drug|ciprofloxacin|
1749596|NCT00190164|Procedure|Macular hole surgery with alleviated positioning|Macular hole surgery with alleviated positioning
1749597|NCT00190164|Procedure|Macular hole surgery with no alleviated positioning|Macular hole surgery with no alleviated positioning
1749598|NCT00190190|Procedure|With Peeling of Limiting the Intern of the Retina|With Peeling of Limiting the Intern of the Retina
1749599|NCT00190190|Procedure|Internal limiting membrane peeling|Traditional Procedure Without Peeling of Limiting
1749600|NCT00190203|Procedure|Decompressive hemicraniectomy and duraplasty|Decompressive hemicraniectomy and duraplasty
1749601|NCT00190203|Procedure|hemicraniectomy|hemicraniectomy
1749602|NCT00190216|Device|Magnetic stimulator|
1749603|NCT00190229|Drug|Cyclophosphamide|Cyclophosphamide
1749604|NCT00190242|Drug|group1|Havrix at 1440IU was administrated à weeks S0, S4 and S24
1749605|NCT00190242|Drug|group2|Havrix (1440IU) was administrated at weeks S0 and S24 according to RECOMMANDATIONS
1749606|NCT00190255|Procedure|CY2PC9 genotyping|CY2PC9 genotyping
1749607|NCT00190268|Drug|3,4-diaminopyridine|3,4-diaminopyridine
1749608|NCT00190294|Drug|MIFEPRISTONE 200 mg and misoprostol 400 µg|MIFEPRISTONE 200 mg and misoprostol 400 µg
1749609|NCT00190307|Drug|aspirin 75 mg/day|aspirin 75 mg/day
1749610|NCT00190320|Procedure|Induction of labor vs waiting|
1749611|NCT00190333|Drug|escitalopram|escitalopram
1749612|NCT00190346|Device|Humidification devices: HH vs HME|
1749613|NCT00190372|Behavioral|Controlled diet|Controlled diet
1749614|NCT00190372|Behavioral|Self-hypnotic relaxation|Self-hypnotic relaxation
1749615|NCT00190385|Procedure|Ultrasonographic screening|Ultrasonographic screening
1749616|NCT00190398|Device|Carotid angioplasty and stenting with cerebral protection|Carotid angioplasty and stenting with cerebral protection
1749617|NCT00190411|Drug|celiprolol|celiprolol
1749618|NCT00190411|Drug|Control|Untreated controls excluding betablockers
1749619|NCT00190424|Drug|CpG-ODN|
1749620|NCT00190437|Drug|Amoxicillin-clavulanic|Amoxicillin-clavulanic
1749622|NCT00190463|Drug|Amphotericin B|
1749623|NCT00190476|Drug|Weekly docetaxel alone|
1749624|NCT00190476|Drug|Weekly docetaxel + cisplatin combination|
1749625|NCT00190489|Drug|AC (ADM 40mg/m2+CPA 500mg/m2) q21 days x 6 cycles|
1749626|NCT00190489|Drug|Docetaxel 60mg/m2 every 21 days for 6 cycles|
1749627|NCT00190489|Drug|AC and Docetaxel 60mg/m2 alternately q21 days for 6 cycles|
1749628|NCT00190502|Drug|Polyclonal anti-T-cell antibodies|
1749629|NCT00190515|Drug|5FU+l-leucovorin|5FU+l-leucovorin
1749630|NCT00190515|Drug|UFT+Leucovorin|UFT+Leucovorin
1749631|NCT00190528|Drug|neoadjuvant chemotherapy + radical hysterectomy|
1749632|NCT00190528|Procedure|radical hysterectomy|
1749633|NCT00190541|Procedure|Mesorectal excision with lateral lymph node dissection|Mesorectal excision with lateral lymph node dissection
1749634|NCT00190541|Procedure|Mesorectal excision without lateral lymph node excision|Mesorectal excision without lateral lymph node excision
1749635|NCT00190554|Drug|Surgery +(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2|
1749636|NCT00190554|Drug|(Cisplatin 80 mg/㎡+5FU 800mg/㎡×5days)×2＋Surgery|
1749637|NCT00190567|Drug|duloxetine|
1749638|NCT00190567|Drug|Placebo|
1749639|NCT00190580|Drug|valsartan|valsartan, dosage from 20mg to 180mg, once or twice a day plus conventional antihypertensive drugs
1749640|NCT00190580|Drug|Conventional antihypertensive drugs|Conventional antihypertensive drugs including calcium channel blockers, diuretics, angiotensin converting enzyme inhibitors and/or beta-blockers
1749641|NCT00190593|Drug|raloxifene|
1749642|NCT00190593|Drug|placebo|
1749643|NCT00190606|Drug|Duloxetine|
1749644|NCT00190606|Procedure|Pelvic Floor Muscle Training (PFMT)|
1749645|NCT00190606|Procedure|Imitation PFMT|
1749646|NCT00190606|Drug|placebo|
1749647|NCT00190619|Drug|Duloxetine|
1749648|NCT00190619|Drug|Placebo|
1749649|NCT00190632|Drug|Duloxetine|
1749650|NCT00190645|Drug|Duloxetine|
1749651|NCT00190658|Drug|Somatropin (rDNA origin) for injection|
1749652|NCT00190671|Drug|pemetrexed|Pemetrexed: 600 mg/m2, intravenous (IV), every 21 days x 8 cycles
1749653|NCT00190671|Drug|cyclophosphamide|600 mg/m2, intravenous (IV), every 21 days x 8 cycles
1749654|NCT00190671|Drug|pemetrexed|1800 mg/m2, intravenous (IV), every 21 days x 8 cycles
1749655|NCT00190684|Drug|atomoxetine|0.5-1.8 mg/kg/day, by mouth (PO), for up to 5 years
1749656|NCT00190697|Drug|arzoxifene|
1749657|NCT00190710|Drug|Gemcitabine|
1749658|NCT00190710|Drug|Carboplatin|
1749659|NCT00190723|Drug|Enzastaurin|
1749660|NCT00190736|Drug|Atomoxetine Hydrochloride|
1749661|NCT00190736|Drug|placebo|
1749662|NCT00190749|Drug|olanzapine|5-20 mg, oral, capsules, daily, 12 weeks.
1749663|NCT00190749|Drug|risperidone|2-6 mg, oral, capsules, twice daily (BID), 12 weeks.
1749664|NCT00190762|Drug|Pemetrexed|
1749665|NCT00190775|Drug|Atomoxetine Hydrochloride|Atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 60/80/100 mg as determined by the investigator up to 24 weeks, orally
1749666|NCT00190775|Drug|Placebo|Placebo is administered QD, orally for 24 weeks. At the end of 24 weeks, the placebo arm is titrated to atomoxetine 40 mg QD for 3 days followed by 80 mg QD for 11 days OR 40 mg QD for 7 days followed by 80 mg QD for 7 days, then 40-100 mg QD, orally.
1749667|NCT00190788|Drug|Drotrecogin Alfa (Activated)|
1749668|NCT00190788|Drug|placebo|
1749669|NCT00190801|Drug|pemetrexed|
1749670|NCT00190801|Drug|cisplatin|
1749671|NCT00190814|Drug|duloxetine|
1749672|NCT00190814|Drug|placebo|
1749673|NCT00190827|Drug|duloxetine|
1749674|NCT00190827|Drug|placebo|
1749675|NCT00190840|Drug|pemetrexed|
1749676|NCT00190853|Drug|Duloxetine|
1749677|NCT00190866|Drug|Duloxetine|
1749678|NCT00190866|Drug|placebo|
1749679|NCT00190879|Drug|Atomoxetine hydrochloride|
1749680|NCT00190879|Drug|placebo|
1749681|NCT00190892|Drug|olanzapine|
1749682|NCT00190892|Drug|carbamazepine|
1749683|NCT00190905|Drug|duloxetine HCl|
1749684|NCT00190918|Drug|Pemetrexed|
1749685|NCT00190931|Drug|Atomoxetine Hydrochloride|
1749686|NCT00190931|Drug|placebo|
1749687|NCT00190944|Drug|Teriparatide|
1749688|NCT00190944|Drug|placebo|
1749689|NCT00190957|Drug|Atomoxetine|
1749690|NCT00190957|Drug|placebo|
1749691|NCT00190970|Drug|Ruboxistaurin|
1749692|NCT00190983|Drug|Pemetrexed|Pemetrexed: 900 mg/m2 (700 mg/m2 for patients with prior radiotherapy) intravenous (IV) over 10 minutes every 21 days until disease progression.
1749693|NCT00190996|Drug|Duloxetine Hydrochloride|
1749694|NCT00190996|Drug|placebo|
1749695|NCT00191009|Drug|atomoxetine hydrochloride|
1749696|NCT00191009|Drug|placebo|
1749697|NCT00191022|Drug|LY686017|
1749698|NCT00191022|Drug|paroxetine|
1749699|NCT00191022|Drug|placebo|
1749700|NCT00191035|Drug|Atomoxetine|
1749701|NCT00191048|Drug|Atomoxetine|
1749702|NCT00191061|Drug|duloxetine hydrochloride|
1749703|NCT00191074|Drug|somatropin, rDNA origin, for injection|
1749704|NCT00191087|Drug|Duloxetine|
1749705|NCT00191100|Drug|Gemcitabine|
1749706|NCT00191100|Drug|Cisplatin|
1749707|NCT00191100|Radiation|Brachytherapy|Brachytherapy, 30-35 Gy over 1 week
1749708|NCT00191100|Radiation|Pelvic radiation|Pelvic radiation, 1.8 Gy/day, 5 days/week, 6 weeks
1749709|NCT00191113|Drug|Somatropin|0.05 mg/kg/dose by subcutaneous injection 6 times per week, until Core study completion criteria are met (protocol final height).
1749848|NCT00192023|Drug|atomoxetine 1.2 mg/kg/day|atomoxetine 1.2 mg/kg/day QD, PO
1749971|NCT00183768|Behavioral|Psychopharmacology|
1749710|NCT00191113|Drug|Ethinyl estradiol|escalating doses 2.5-20.0 mcg tablets daily after age 13 and at least one year on study, continuing until Core study completion criteria are met.
1749711|NCT00191113|Drug|Medroxyprogesterone acetate|10 mg tablets, ten days monthly, after age 15, continuing until Core study completion criteria are met.
1749712|NCT00191126|Drug|gemcitabine|1250 mg/m2, IV, day 1 and 8, q 21 days x 3 cycles
1749713|NCT00191126|Drug|Cisplatin|75 mg/m2, IV, q 21 days x 3 cycles
1749714|NCT00191126|Procedure|surgery|surgery
1749715|NCT00191139|Drug|gemcitabine|After induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In both treatment arms, gemcitabine 1000 milligrams per meter squared (mg/m2), is administered intravenously (IV), on days 1 and 8 of every 21-day cycle for 3 cycles.
1749716|NCT00191139|Drug|docetaxel|Following cisplatin-etoposide induction chemotherapy, radiation therapy and 10 weeks with no disease progression, randomized consolidation treatment begins. In this treatment arm, docetaxel 75 mg/m2, is administered IV on day 1 of each 21-day cycle for 3 cycles. Docetaxel is given after gemcitabine.
1749717|NCT00191139|Drug|cisplatin|As part of induction chemotherapy, cisplatin is given 50 mg/m2, IV, day 1, 8, 29 and 36 (spans 2 cycles)
1749718|NCT00191139|Drug|etoposide|As part of induction chemotherapy, etoposide is given 50 mg/m2, IV, days 1-5 and 29-33 (spans 2 cycles)
1749719|NCT00191139|Radiation|radiation therapy|In conjunction with induction chemotherapy, radiation therapy is administered at a dose of 200 centi Gray (cGy) per day, Monday through Friday for 6 weeks
1749720|NCT00191152|Drug|gemcitabine|1000 mg/m2, intravenous (IV) day 1 and day 8 every 21 days until disease progression
1749721|NCT00191152|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression
1749722|NCT00191152|Drug|capecitabine|1000 mg/m2, by mouth (PO) twice a day (BID), days 1-14, every 21 days until disease progression
1749723|NCT00191165|Drug|Somatropin|Doubled dosage with respect to the pre-enrollment (in-label) dosage
1749724|NCT00191165|Drug|Somatropin|In-label dosage
1749725|NCT00191178|Drug|insulin lispro protamine suspension:insulin lispro rDNA origin low mix|
1749726|NCT00191178|Drug|insulin glargine|
1749727|NCT00191191|Drug|Pemetrexed 500 mg/m2|500 mg/m2, intravenous (IV), every 21 days, one year from registration date
1749728|NCT00191191|Drug|Pemetrexed 1000 mg/m2|1000 mg/m2, intravenous (IV), every 21 days, one year from registration date
1749729|NCT00191204|Drug|Duloxetine|
1749730|NCT00191230|Drug|gemcitabine|
1749731|NCT00191230|Drug|carboplatin|
1749732|NCT00191230|Drug|cisplatin|
1749733|NCT00191243|Drug|Gemcitabine|"A: second line therapy - 1000 mg/m2, IV, day 1 and day 8 q 21 days until disease progression
B: 1000 mg/m2, IV, day 1 and day 8 q 21 days, until treatment failure"
1749734|NCT00191243|Drug|docetaxel|"A: 80 mg/m2, IV, q 21 days until treatment failure followed by second line single agent gemcitabine
B: 80 mg/m2, IV, q 21 days until treatment failure"
1749735|NCT00191256|Drug|Gemcitabine|
1749736|NCT00191256|Drug|Carboplatin|
1749737|NCT00191256|Drug|Paclitaxel|
1749738|NCT00191269|Drug|gemcitabine|1000 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
1749739|NCT00191269|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days
1749740|NCT00191282|Drug|Insulin lispro|Patient adjusted dose, three times a day (TID), injected subcutaneous (SC) before each meal until patient completes study
1749741|NCT00191282|Drug|Human insulin isophane suspension (NPH)|Patient adjusted dose, daily at bedtime, injected subcutaneous (SC) until patient completes study. To be added to the arm only if patient has two consecutive HbA1c values >8.0%
1749742|NCT00191282|Drug|Insulin glargine|Insulin glargine injected subcutaneous (SC) once daily in the evening until patient completes study.
1749743|NCT00191282|Drug|Human insulin isophane suspension|Patient adjusted dose, twice daily, injected subcutaneous (SC) before morning and evening meals until patient completes study.
1749744|NCT00191282|Drug|Human insulin 30/70|Patient adjusted dose, twice daily before the morning and evening meals, injected subcutaneous (SC) until patient completes study. To replace insulin regimen in this arm only if patient has two consecutive HbA1c values >8.0%.
1749745|NCT00191295|Drug|Atomoxetine|
1749746|NCT00191295|Drug|Placebo|
1749747|NCT00191308|Drug|pemetrexed|500 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
1749748|NCT00191308|Drug|cisplatin|75 mg/m^2 IV q 21 days for 3 cycles unless disease progression occurs
1749749|NCT00191308|Procedure|Radical Non-Small Cell Lung Cancer (NSCLC) surgery|All participants proceeded to surgery within 4-8 weeks from the last dose of pemetrexed.
1749750|NCT00191321|Drug|Teriparatide|
1749751|NCT00191334|Drug|gemcitabine|1250 mg/m2, intravenous (IV) day 1 and day 8, every 21 days x 6 cycles or disease progression or unacceptable toxicity
1749752|NCT00191334|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles or disease progression or unacceptable toxicity
1749753|NCT00191347|Drug|pemetrexed|
1749754|NCT00191347|Drug|gemcitabine|
1749755|NCT00191360|Drug|Somatropin|
1749756|NCT00191373|Drug|Gemcitabine|
1749757|NCT00191373|Drug|Trastuzumab|
1749758|NCT00191386|Drug|Atomoxetine hydrochloride|0.5 milligrams per kilogram (mg/kg) twice daily (BID), orally (PO) titrated to 1.2 mg/kg BID, PO over 2 weeks then 1.2 to 1.8 mg/kg BID, PO for 6 months and up to 4 years
1749759|NCT00191399|Drug|Olanzapine|
1749760|NCT00191399|Drug|Fluoxetine|
1749761|NCT00191412|Drug|Pemetrexed|
1749762|NCT00191425|Drug|Teriparatide|
1749763|NCT00191425|Drug|Raloxifene|
1749764|NCT00191438|Drug|gemcitabine|
1749765|NCT00191438|Drug|capecitabine|
1749766|NCT00191438|Drug|docetaxel|
1749767|NCT00191451|Drug|Gemcitabine|Day 1 of 14 day cycle (Cycles 1-9):1500 milligram per square meter (mg/m2) intravenous (IV) (30 minute infusion)
1749768|NCT00191451|Drug|Carboplatin|Day 1 of 14 day cycle (Cycles 1-9): Carboplatin area under the curve (AUC)=2.5 intravenous (IV) (30-60 minute infusion).
1749849|NCT00192023|Drug|atomoxetine 1.2-1.4 mg/kg/day|atomoxetine 1.2 - 1.4 mg/kg/day QD, PO
1749972|NCT00183781|Behavioral|FITT: Family Intervention - Telephone Tracking|
1749769|NCT00191451|Drug|Herceptin|"Day 1 of 14 day cycle (Cycle 1): 8 milligrams per kilogram (mg/kg) intravenous (IV) (90 minute infusion).
Day 1 of 14 day cycle (Cycles 2-9): 4 mg/kg IV (30 minute infusion). Day 1 of 21 day cycle (Cycles 10+): 6 mg/kg IV (30 minute infusion)."
1749770|NCT00191464|Drug|premeal insulin lispro mixtures|
1749771|NCT00191464|Drug|insulin glargine|
1749772|NCT00191464|Drug|metformin|
1749773|NCT00191477|Drug|Gemcitabine|2000 mg, intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
1749774|NCT00191477|Drug|Placebo|intravesicular instillation x 1 immediately post transurethral resection of the bladder tumor (TUR-BT)
1749775|NCT00191490|Drug|Gemcitabine|
1749776|NCT00191490|Drug|docetaxel|
1749777|NCT00191490|Drug|cisplatin|
1749778|NCT00191503|Drug|Pemetrexed|
1749779|NCT00191503|Drug|Gemcitabine|
1749780|NCT00191516|Drug|Atomoxetine|
1749781|NCT00191529|Drug|somatropin|
1749782|NCT00191542|Drug|Atomoxetine|
1749783|NCT00191542|Drug|Placebo|
1749784|NCT00191555|Drug|olanzapine|
1749785|NCT00191555|Drug|haloperidol|
1749786|NCT00191568|Drug|Gemcitabine|
1749787|NCT00191568|Drug|Oxaliplatin|
1749788|NCT00191568|Procedure|Radiotherapy|
1749789|NCT00191581|Drug|Humalog Mix 50|
1749790|NCT00191581|Drug|Human Insulin Mix 50:50|
1749791|NCT00191594|Drug|Duloxetine Hydrochloride|
1749792|NCT00191607|Drug|Gemcitabine|
1749793|NCT00191607|Drug|liposomal doxorubicin|
1749794|NCT00191620|Drug|Gemcitabine|
1749795|NCT00191620|Drug|cisplatin|
1749796|NCT00191633|Drug|Atomoxetine|
1749797|NCT00191646|Drug|Gemcitabine|"1000 mg/m^2, Intravenously (IV), day 1 and day 8 every (q) 21 days x 6 cycles
If anything other than complete response in Paclitaxel arm patients, 1000 mg/m^2, IV, day 1 and day 8 q 21 days until complete response, disease progression or unacceptable toxicity"
1749798|NCT00191646|Drug|Paclitaxel|"175 mg/m^2, IV, Day 1, q 21 days x 6 cycles
If complete response both Paclitaxel and Gemcitabine arms may elect to receive consolidation therapy, 135 mg/m^2, IV, 3 hours q 28 days x 12 cycles (1 year)
If no complete response, then Gemcitabine arm patients may receive 175 mg/m^2, IV, Day 1, q 21 days until complete response, disease progression or unacceptable toxicity"
1749799|NCT00191646|Drug|Carboplatin|"Gemcitabine/Carboplatin AUC 5, IV, Day 1, q 21 days x 6 cycles
Paclitaxel/Carboplatin AUC 6, IV, Day 1, q 21 days x 6 cycles"
1749800|NCT00191659|Drug|Atomoxetine Hydrochloride|
1749801|NCT00191672|Drug|Gemcitabine|
1749802|NCT00191672|Drug|Paclitaxel|
1749803|NCT00191672|Drug|Docetaxel|
1749804|NCT00191685|Drug|duloxetine|
1749805|NCT00191698|Drug|atomoxetine hydrochloride|
1749806|NCT00191698|Drug|placebo|
1749807|NCT00191711|Drug|Gemcitabine|
1749808|NCT00191724|Drug|Drotrecogin Alfa (Activated)|6 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
1749809|NCT00191724|Drug|Enoxaparin|1 milligram/kilogram (mg/kg), subcutaneous, every 12 hours until the target International Normalized Ratio (INR) is reached, minimum of 5 days
1749810|NCT00191724|Drug|Placebo|intravenous (IV), one infusion, over 12 hours
1749811|NCT00191724|Drug|Drotrecogin Alfa (Activated)|12 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
1749812|NCT00191724|Drug|Drotrecogin Alfa (Activated)|18 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
1749813|NCT00191724|Drug|Drotrecogin Alfa (Activated)|24 micrograms/kilograms/hour (ug/kg/hr), intravenous (IV), one infusion, over 12 hours
1749814|NCT00191737|Drug|Atomoxetine|
1749815|NCT00191750|Drug|Pemetrexed|
1749816|NCT00191763|Drug|Gemcitabine|
1749817|NCT00191763|Drug|cisplatin|
1749818|NCT00191789|Drug|gemcitabine|1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8)
1749819|NCT00191789|Drug|doxorubicin|60 mg/m^2, IV, every 21 days x 4 cycles (1-4)
1749820|NCT00191789|Drug|cisplatin|70 mg/m^2, IV, every 21 days x 4 cycles (5-8)
1749821|NCT00191789|Procedure|surgery|Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.
1749822|NCT00191802|Drug|teriparatide|
1749823|NCT00191815|Drug|Gemcitabine|Gemcitabine (30 min intravenous infusion) dose of 1000mg/m2 on Day 1 and Day 8 (21 day cycle).
1749824|NCT00191815|Drug|cisplatin|Cisplatin (30-120 min intravenous infusion) dose of 35 mg/m2 on Day 1 and Day 8 (21 day cycle).
1749825|NCT00191828|Drug|olanzapine|
1749826|NCT00191841|Drug|gemcitabine|
1749827|NCT00191841|Drug|Cisplatin|
1749828|NCT00191854|Drug|gemcitabine|2500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles
1749829|NCT00191854|Drug|paclitaxel|150 mg/m2, IV, every 14 days x 8 cycles
1749830|NCT00191854|Drug|carboplatin|Area Under the Curve (AUC) 2.5, IV, every 14 days x 8 cycles
1749831|NCT00191854|Drug|cisplatin|50 mg/m2, IV, every 14 days x 8 cycles
1749832|NCT00191867|Drug|Teriparatide|
1749833|NCT00191880|Drug|atomoxetine|
1749834|NCT00191893|Drug|teriparatide|
1749835|NCT00191906|Drug|Atomoxetine Hydrochloride|Atomoxetine, 1.2 mg/kg/day, by mouth (PO)
1749836|NCT00191906|Drug|placebo|Placebo, every day (QD), by mouth (PO)
1749837|NCT00191919|Drug|Duloxetine Hydrochloride|
1749838|NCT00191919|Drug|Placebo|
1749839|NCT00191932|Drug|Duloxetine|
1749840|NCT00191945|Drug|Atomoxetine Hydrochloride|
1749841|NCT00191945|Drug|placebo|
1749842|NCT00191971|Drug|Gemcitabine|
1749843|NCT00191984|Drug|pemetrexed|400 mg/m^2, intravenous (IV), every 14 days x 12 cycles
1749844|NCT00191984|Drug|irinotecan|180 mg/m^2, intravenous (IV), every 14 days x 12 cycles
1749845|NCT00191997|Drug|Olanzapine|
1749846|NCT00192023|Drug|atomoxetine 0.5 mg/kg/day|atomoxetine 0.5 milligrams per kilogram per day (mg/kg/day) daily (QD), by mouth (PO)
1749847|NCT00192023|Drug|placebo|
1750128|NCT00193440|Drug|Rituximab|
1749850|NCT00192036|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days x 3 cycles (1-3) then 300 mg/m2 x 2 cycles (4-5)
1749851|NCT00192036|Drug|cisplatin|80 mg/m2, IV, every 21 days x 5 cycles
1749852|NCT00192036|Radiation|radiation|63 Gray (Gy) in 35 treatments over 7 weeks concurrent with chemotherapy cycles 4 and 5
1749853|NCT00192049|Drug|Gemcitabine|
1749854|NCT00192049|Drug|mitomycin C|
1749855|NCT00192062|Drug|gemcitabine|
1749856|NCT00192062|Drug|vinorelbine|
1749857|NCT00192075|Drug|Gemcitabine|900 mg/m2 IV over 90 minutes after Folinic Acid weekly for 6 weeks every 8 weeks until progression.
1749858|NCT00192075|Drug|avastin|5 milligrams per kilogram (mg/kg)
1749859|NCT00192075|Drug|5FU/folinic acid|"Folinic Acid: 100 milligrams per square meter (mg/m2) intravenous (IV) over 60 minutes (A+FFG).
Folinic Acid: 200 mg/m2 as a 2-hr infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4).
5-Fluorouracil: 450 mg/m2 as an IV bolus in middle of Folinic Acid (A+FFG). 5-Fluorouracil: 400 mg/m2 bolus plus a 600 mg/m2 22-hour infusion on Days 1 and 2 of a 14-day cycle (A+FOLFOX 4)."
1749860|NCT00192075|Drug|oxaliplatin|85 mg/m2 as a 2-hour infusion on Day 1 of a 14 day cycle.
1749861|NCT00192088|Drug|pemetrexed|
1749862|NCT00192088|Drug|oxaliplatin|
1749863|NCT00192101|Drug|gemcitabine|
1749864|NCT00192101|Drug|cisplatin|
1749865|NCT00192114|Drug|Enzastaurin HCl|1200 mg loading dose then 500 mg, oral, daily, up to six 28 day cycles
1749866|NCT00192127|Biological|FluMist|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0.
1749867|NCT00192127|Other|Placebo|A single dose of either bivalent vaccine or placebo mist by intranasal spray on Study Day 0
1749868|NCT00192140|Biological|FluMist|A single intranasal dose of FluMist will be administered to approx. 300 subjects.
1749869|NCT00192153|Biological|CAIV-T or TIV|
1749870|NCT00192166|Biological|CAIV-T|
1749871|NCT00192179|Biological|Cold-adapted influenza vaccine trivalent (CAIV-T)|The total volume of 0.2 ml was administered intranasally with a spray applicator (approximately 0.1 ml into each nostril). Each dose of CAIV-T used in this study contained approximately 10^7+/-0.5 fluorescent focus units (FFU) (equivalent to 10^7+/-0.5 TCID50) of each of the following three influenza virus strains: Influenza Cold Adapted Virus Type H1N1, strain A/New Caledonia/20/99; Influenza Cold Adapted Virus Type H3N2, strain A/ Panama/2007/99; Influenza Cold Adapted Virus Type B, strain B/Hong Kong/ 330/01.
1749872|NCT00192179|Biological|Placebo|The placebo consisted of physiologic normal saline.
1749873|NCT00192192|Biological|CAIV-T|
1749874|NCT00183092|Drug|Quinacrine|100mg by mouth three times a day
1749875|NCT00183092|Drug|Placebo|100mg by mouth three times a day
1749876|NCT00183105|Behavioral|Brief Intervention (adaptation of motivational interviewing)|
1749877|NCT00183118|Behavioral|Adapted Enhanced-RESPECT (HIV prevention intervention)|
1749878|NCT00183131|Behavioral|Brief Personalized Feedback|
1749879|NCT00183144|Behavioral|Contingency management|
1749880|NCT00183157|Behavioral|Brief Motivational Intervention|One-third of the enrollees will receive an assessment, a brief motivational interview performed by a trained peer counselor, direct referrals to community-based resources for adolescents, and a 10-day follow-up phone call. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
1749881|NCT00183157|Behavioral|Assessment and list of resources|One-third will receive only the assessment and a list of community resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
1749882|NCT00183157|Behavioral|Referral to Community Resources|All patients aged 14 to 21 get a brief alcohol and drug screen, and those whose scores indicate they drink or use marijuana are invited to participate in the study. One-third of the enrollees will receive only a list of resources. All participants will be followed over time and re-screened to measure the impact of the initial brief intervention on their drinking and drug-taking. The key hypothesis is that individuals who receive the brief motivational interview in the emergency department setting will have lower rates of alcohol and illicit drug use and fewer health consequences over time.
1749883|NCT00183170|Drug|Beer (alcohol)|
1749884|NCT00183183|Behavioral|Screening and Brief Intervention|
1749885|NCT00183196|Drug|Naltrexone|Naltrexone (50 mg/day) plus gabapentin placebo in divided doses for the first 6weeks. Naltrexone (50 mg/day) for rest of 16-weeks
1749886|NCT00183196|Drug|Naltrexone plus Gabapentin|naltrexone (50 mg/day) for 16-weeks plus gabapentin (up to 1200 mg/day in divided doses) for the first 6 weeks
1749887|NCT00183196|Other|Inactive Placebo|Placebo
1749888|NCT00183209|Behavioral|Family First|Family First = 14 sessions lasting 1.5 hours each based on Social Action Theory and Motivational Interviewing (7 sessions on reducing alcohol and drug use and 7 sessions on reducing parenting challenges). Brief Video Intervention was a single session designed to increase motivation to reduce/eliminate problem drinking or drug use.
1749889|NCT00183222|Drug|naltrexone (up to 50 mg/day) for 8 days; ondansetron (0.25 mg twice a day) for 8 days|
1749890|NCT00183235|Drug|aripiprazole (up to 15 mg/day) for 8 days|
1749891|NCT00183248|Drug|Alemtuzumab|Immunosuppressant; 2 doses of drug by intravenous (IV) infusion on Days 0 and 4
1749892|NCT00183248|Drug|Mycophenolate mofetil|Immunosuppressant; oral daily dose starting Day 0 until withdrawal or end of the study
1749893|NCT00183248|Drug|Sirolimus|Immunosuppressant; oral daily dose starting between Months 4 and 6 post-transplant until withdrawal or end of the study
1749894|NCT00183248|Drug|Tacrolimus|Immunosuppressant; daily dose starting Day 1 until withdrawal or end of the study
1749895|NCT00183248|Procedure|Donor bone marrow stem cell infusion|2 doses of kidney donor's bone marrow stem cells by IV infusion on Day 5 and sometime between Months 4 and 6
1749896|NCT00183248|Procedure|Kidney transplant|Occurs at study entry
1749970|NCT00183768|Behavioral|Cognitive Behavioral Therapy|
1749897|NCT00183261|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5 x 1010 Ad vg/mL, 1.0 mL administered intramuscularly
1749898|NCT00183261|Biological|MRKAd5 HIV-1 gag/pol/nef placebo|1.0 mL administered intramuscularly
1749899|NCT00183274|Drug|Venlafaxine XR|Six month intervention of Venlafaxine XR treatment with flexible range of 75 to 225 mg/d
1749900|NCT00183274|Drug|Placebo|six month intervention with placebo drug
1749901|NCT00183300|Behavioral|Prolonged Exposure Therapy|
1749902|NCT00183313|Behavioral|Nurse case management|Nurse case management is a population-based medical case management program to improve the delivery of primary medical care to patients with serious mental illness in a Community Mental Health Center (CMHC) in Atlanta GA. The treatment draws on elements from the primary care, nursing case management, chronic disease, health behavior change literature, and from the study team's experience in integrating primary care services for patients with serious mental illnesses.
1749903|NCT00183313|Behavioral|Usual care|Usual care includes standard mental health services.
1749904|NCT00183326|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT is a psychotherapeutic intervention designed to help children, youth, and their parents overcome the negative effects of traumatic life events. It was developed by integrating cognitive and behavioral interventions with traditional child abuse therapies that focus on enhancement of interpersonal trust and empowerment. It targets PTSD symptoms, which often co-occur with depression and behavioral problems. TF-CBT also targets other issues experienced by those suffering a trauma including poor self-esteem, mood instability, and difficulty trusting others.
1749905|NCT00183326|Behavioral|Child-centered supportive therapy (CCT)|CCT demonstrates an empathic approach to healing. An environment consisting of empathy, unconditional positive regard and acceptance are key elements in this mode of therapy.
1749906|NCT00183339|Drug|Fluoxetine|Between 2 mg per day and 20 mg per day of liquid fluoxetine will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
1749907|NCT00183339|Drug|Placebo|Between 0.5ml per day and 5ml per day of liquid placebo will be given in the morning using a flexible dosing strategy, following a 36-week dose titration schedule.
1749908|NCT00183365|Behavioral|Parent Skills Training|Parent skills training will include 10 weeks of psychoeducational and skills training group sessions for parents.
1749909|NCT00183365|Behavioral|Protecting Families Program (PFP)|Participants will receive 10 weeks of PFP, which will include a community meal at the beginning of each session, a parent skills training group, and a concurrent cognitive behavioral therapy (CBT) group for the focal child.
1749910|NCT00183378|Behavioral|Walking Program|The therapist introduces a walking program and assists the caregiver in establishing a walking routine of 30 minutes/day for the study participant.
1749911|NCT00183378|Behavioral|Light Exposure Program|The therapist provides a light box and teaches the caregiver how to use the box so that the study participant's daily exposure to bright light is one hour.
1749912|NCT00183378|Behavioral|Combined Education, Walking and Light Exposure Program|The therapist provides a combination of education plus assistance setting up an individualized sleep program, a daily walking routine, and a schedule for daily light exposure.
1749913|NCT00183378|Behavioral|Routine Medical Care with Education|The therapist provides information about the nature of sleep changes in people with Alzheimer's disease, general information about treatments for insomnia, and caregiver support. Participants are free to use whatever medical services they wish during study participation.
1749916|NCT00183404|Drug|Olanzapine|Olanzapine tablets, dosed once or twice per day, dosage 2.5 to 20 mg per day
1749917|NCT00183417|Behavioral|Cognitive behavior therapy (CBT)|Participants will complete worksheets and group discussion on how to increase positive mood and activity.
1749918|NCT00183417|Behavioral|Supportive/expressive (S/E) therapy|Participants will be encouraged to express feelings and emotions without advice giving.
1749919|NCT00183417|Behavioral|Bibliotherapy|Participants will be given a book on how to increase their mood.
1749920|NCT00183430|Drug|Prazosin|Prazosin capsules 1 to 25 mg are taken orally twice per day in divided doses at 10 am and bedtime.
1749921|NCT00183430|Drug|Placebo|Placebo capsules are taken orally twice per day at 10 am and bedtime.
1749922|NCT00183430|Behavioral|Psychotherapy|All participants will undergo psychotherapy during medication treatment period.
1749926|NCT00183456|Behavioral|Peer-oriented intervention|The peer-oriented intervention program emphasized social identity and the goals of protecting family and community. The peer program also trained participants to provide HIV/STD education to their peers.
1749927|NCT00183456|Behavioral|Group cognitive behavioral therapy (CBT)|Group CBT will focus on teaching ways to modify thoughts and behaviors associated with risky sexual behaviors.
1749928|NCT00183469|Drug|Lamotrigine|If the participant is naive to LAM, LAM will be started at 25 mg every day for the first 2 weeks, then 50 mg per day for the next 2 weeks. The dose of LAM can be increased to 100 mg at week 5 and increased to maximum of 200 mg at week 6 based on symptoms, tolerability, and ratings of the rating scales. If the participant is already taking LAM, the dose will be increased to up to 200 mg using the same guide lines. Upon randomization the participant in the placebo comparator will have their dosage titrated to doubled since the potentiating effect of the Divalproex will no longer exist. It will remain at this dosage until the end of the study with the possibility of one adjustment for side effects.
1749929|NCT00183469|Drug|Divalproex (DIV) ER|If the participant is naive to DIV and if LAM was initiated before the start of treatment with DIV, DIV can be started at any point of time in the study provided the participant has been on LAM for at least 2 weeks. DIV will be started at 500 mg and titrated by increments of 500 mg every 3 to 4 days until a therapeutic blood level is attained up to 2500 mg.
1749930|NCT00183469|Drug|Placebo|During the randomized phase participants randomized to placebo comparator group will discontinue DIV and will start taking the placebo in the same fashion.
1749931|NCT00183482|Behavioral|Family Cognitive Behavioral Therapy (CBT)|
1749932|NCT00183482|Behavioral|Depression Education|
1749933|NCT00183508|Behavioral|Cognitive behavioral therapy|Participants will learn cognitive behavioral strategies for symptom reduction
1749934|NCT00183508|Behavioral|Psychoeducation|Participants will receive psychoeducation regarding common reactions to traumatic events
1749935|NCT00183521|Behavioral|Raise-CO2 breathing regulation training|Reverse hyperventilation (defined by low arterial CO2) is often characteristic of individuals with panic disorder. Participants will be randomly assigned to one of three groups: raise-CO2 breathing, lower-CO2 breathing, or a control group. Participants in the raise-CO2 group will be taught techniques to recover from hyperventilation faster.
1749936|NCT00183521|Behavioral|Lower-CO2 breathing regulation training|According to the false suffocation alarm theory, anxiety is experienced when an overly sensitive hypothalamic mechanism is triggered by rising pCO2. Participants in the lower-CO2 group will be taught techniques to reach hyperventilation levels, then switch to breathing techniques that reduce hyperventilation symptoms.
1749937|NCT00183521|Behavioral|Control|Participants in the control group will not be taught any breathing techniques but will be included in all assessments.
1749938|NCT00183547|Behavioral|"Living in Harmony depression prevention program"|Weekly therapy sessions consisting of cognitive behavioral therapy (CBT), culturally-relevant education, and support
1749939|NCT00183547|Behavioral|Depression-prevention education and support|Weekly therapy sessions offering general depression-prevention education and support
1749940|NCT00183560|Behavioral|Mindfulness based cognitive therapy (MBCT)|Following antidepressant discontinuation, participants receive MBCT, an 8-week group program that integrates aspects of cognitive therapy and mindfulness meditation.
1749941|NCT00183560|Drug|Antidepressants|Participants continue on dosage of the antidepressant that was used to achieve clinical remission.
1749942|NCT00183560|Drug|Placebo plus clinical management|Following discontinuation of active antidepressant, participants are placed onto the placebo and clinical management regimen.
1749943|NCT00183573|Behavioral|Brief Motivational Intervention|15-20 minute, motivational one-on-one counseling
1749944|NCT00183573|Behavioral|Brief Informational Intervention|15 minute informational DVD on safer sex
1749945|NCT00183573|Behavioral|Intensive Informational Intervention|4-hour, information-only intensive group workshop
1749946|NCT00183573|Behavioral|Intensive Info-Motivation-Behavioral Skills Intervention|4-hour, intensive group workshop with emphasis on motivation and skills
1749947|NCT00183586|Behavioral|Family therapy (FT)|FT is a family-based treatment that will be given for a total of 24 hours over the course of 12 months.
1749948|NCT00183586|Behavioral|Individual therapy (IT)|IT is an ego-oriented psychotherapy treatment that will be given for a total of 24 hours over the course of 12 months.
1749949|NCT00183599|Behavioral|5 Minutes of Simple Advice|
1749950|NCT00183599|Behavioral|Motivational Enhancement Therapy (MET)|
1749951|NCT00183599|Behavioral|Cognitive Behavioral Therapy (CBT)|
1749952|NCT00183612|Drug|Olanzapine|
1749953|NCT00183625|Behavioral|Individual Placement and Support (Supported Employment)|
1749954|NCT00183625|Behavioral|Social Skills Training|
1749955|NCT00183625|Drug|Olanzapine|
1749956|NCT00183625|Drug|Risperidone|
1749957|NCT00183638|Behavioral|Internet-based tailored prevention messages|Participants will receive five 30-second flash clips promoting condom norms, positive attitudes, self-efficacy, and risk awareness. Participants in the Youthnet program will be asked their gender and ethnicity so they may be assigned to a role model of the same gender and ethnicity via a computer program. This role model will appear online 5 times during the survey to deliver interactive messages that will be tailored to HIV/STD risk reduction and will specifically address attitudes about condom usage.
1749958|NCT00183638|Behavioral|Non-tailored messages|The control program will deliver five general, non-tailored messages containing information on reproductive health not specific to condoms or STDs.
1749959|NCT00183651|Behavioral|Standard dialectical behavior therapy (SDBT)|Standard DBT includes: 1) individual DBT therapy (1 hour per week), 2) DBT group skills training (2.5 hours per week), 3) telephone consultation (as needed), and 4) therapist consultation team (1 hour per week).
1749960|NCT00183651|Behavioral|Individual DBT with no DBT group sessions (DBT-I)|Individual DBT (DBT-I) is 1 hour per week of individual therapy and 2.5 hours per week with the psychosocial activities group.
1749961|NCT00183651|Behavioral|Group Skills DBT with no DBT individual sessions (DBT-S)|DBT group skills training is 2.5 hours per week and includes individual case management.
1749962|NCT00183677|Drug|Escitalopram|Escitalopram 10 to 30 mg per day for 12 weeks
1749965|NCT00183716|Behavioral|Trauma Recovery and Empowerment Model (TREM)|TREM is a 29-session group intervention for women who have experienced psychological trauma (e.g., childhood physical or sexual abuse), focusing on skill development, understanding the effects of trauma, and empowerment.
1749966|NCT00183716|Behavioral|Usual care|Participants will receive usual care for women who have experienced psychological trauma.
1749967|NCT00183729|Drug|Memantine|Memantine dosage is started at 10 mg daily and is increased at Week 1 as tolerated to 10 mg two times a day.
1749968|NCT00183729|Other|Placebo|Placebo distribution is planned to mimic the active drug.
1749969|NCT00183742|Drug|liposomal doxorubicin and docetaxel|
1956595|NCT02787785|Device|Subcutaneous Implantable Cardioverter Defibrillator|The S-ICD is an entirely subcutaneous implantable cardioverter defibrillator.
1749973|NCT00183794|Drug|Docetaxel and Gemcitabine|Docetaxel 75 mg/m2 IV over 15-30 minutes on day 1 followed by Gemcitabine 800 mg/m2 IV over 30 minutes on Days 1 and 8 of each 3 weeks (21 days) cycle.
1749974|NCT00192205|Biological|CAIV-T or TIV|
1749975|NCT00192218|Biological|FluMist|0.5 ml of vaccine intranasally (0.25 ml in each nostril) which contains approximately 107 TCID50 of each type
1749976|NCT00192231|Biological|CAIV-T|
1749977|NCT00192244|Biological|CAIV-T, Liquid|
1749978|NCT00192257|Biological|CAIV-T and TIV|
1749979|NCT00192270|Biological|CAIV-T|Each dose of the vaccine was formulated to contain approximately 1 x 10^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of ~3 x 10^7 TCID50 per dose.
1749980|NCT00192283|Biological|CAIV-T|The total single-dose volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
1749981|NCT00192283|Other|Placebo|A single dose of placebo volume of 0.2 mL was administered intranasally with the spray applicator intended for commercial use (approximately 0.1 mL into each nostril).
1749982|NCT00192296|Biological|MEDI-528 0.3 mg/kg|MEDI-528 (0.3 mg/kg) administered as a single, intravenous (IV) dose
1749983|NCT00192296|Biological|MEDI-528 1 mg/kg|MEDI-528 (1 mg/kg) administered as a single, IV dose
1749984|NCT00192296|Biological|MEDI-528 3 mg/kg|MEDI-528 (3 mg/kg) administered as a single, IV dose
1749985|NCT00192296|Biological|MEDI-528 9 mg/kg|MEDI-528 (9 mg/kg) administered as a single, IV dose
1749986|NCT00192309|Biological|CAIV-T|Liquid CAIV-T vaccine for this study consisted of three cold-adapted, attenuated, reassortant strains representing the hemagglutinin (HA) and neuraminidase (NA) antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2) and B/Yamanashi/166/98 influenza virus strains. The reassortant vaccine strains were grown in specific pathogen-free (SPF) eggs and the allantoic fluid, which contained virus, was harvested, concentrated and purified. Each dose of CAIV-T used in this study was formulated to contain approximately 107 FFU of each of the 6:2 influenza reassortant vaccine strains.
1749987|NCT00192309|Biological|TIV|TIV in this study consisted of Flushield™, manufactured by Wyeth Vaccines, Marietta, PA, USA. Each 0.5 mL dose contained no less than 15 ug of the hemagglutinin antigens from each of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Yamanashi/166/98 strains, making TIV in this study antigenically matched to the influenza strains contained in CAIV-T.
1749988|NCT00192309|Biological|Placebo|Placebo in this study consisted of physiological saline. The total volume of 0.2 mL was administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
1749989|NCT00192322|Biological|CAIV-T 10^7|a single intranasal 0.2 mL dose of liquid CAIV-T 107 (approximately 0.1 mL into each nostril)
1749990|NCT00192322|Biological|CAIVT 10^5|a single intranasal 0.2 mL dose of CAIV-T <10^5
1749991|NCT00192322|Biological|Placebo|a single intranasal 0.2 mL dose of placebo
1749992|NCT00192322|Biological|TIV|commercially available TIV injected intramuscularly
1749993|NCT00192335|Biological|CAIV-T|
1749994|NCT00192335|Biological|CAIVT|The total volume of 0.2 mL will be administered intranasally with a spray applicator (approximately 0.1 mL into each nostril).
1749995|NCT00192335|Biological|FluMist|The total volume of 0.5 mL will be administered intranasally with a spray applicator (approximately 0.25 mL into each nostril).
1749996|NCT00192348|Biological|CAIV-T|
1749997|NCT00192361|Biological|CAIV-T|
1749998|NCT00192374|Biological|CAIV-T, Liquid|
1749999|NCT00192387|Biological|CAIV-T, Liquid|
1750000|NCT00192400|Biological|CAIV-T|
1750001|NCT00192413|Biological|Cold-adapted influenza vaccine trivalent (CAIV-T)|Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
1750002|NCT00192413|Biological|Trivalent Inactivated Vaccine (TIV)|Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).
1750003|NCT00192426|Biological|CAIV-T|
1750004|NCT00192439|Behavioral|High Risk Respiratory Disease|
1750005|NCT00192452|Drug|MEDI-507|
1750006|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp.1: 3 mg/kg IV (single dose)
1750007|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 2: 15 mg/kg IV (single dose)
1750008|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 3: 30 mg/kg IV (single dose)
1750009|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp. 4: 3 mg/kg IM (single dose)
1750010|NCT00192465|Biological|MEDI-524 (Numax-TM)|Grp.5: 3 mg/kg IM (two doses)
1750011|NCT00192478|Biological|Medi-524|IM doses of MEDI-524 administered at 3 mg/kg or 15 mg/kg at 30 day intervals
1750012|NCT00192491|Biological|FluMist|Nasal Sprayer of one dosage of FluMist and other experimental
1750013|NCT00192491|Biological|FluMist|Nasal sprayer of FluMist
1750014|NCT00192491|Other|Placebo|Nasal Sprayer of Placebo
1750015|NCT00192504|Biological|MEDI-524|
1750016|NCT00192517|Drug|MEDI-522|4 mg/kg (for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
1750017|NCT00192517|Other|Placebo|4 mg/kg(for 12 weeks based on patient's weight, to the nearest kg, obtained on Study Day 0)
1750018|NCT00192543|Behavioral|diet of fish and fruit|fish and fruit in specified quantities
1750019|NCT00192543|Behavioral|fruit and fish|no drugs
1750020|NCT00192543|Behavioral|diet only|Fish and fruit
1750021|NCT00192543|Behavioral|regular diet|no change in regular diet
1750022|NCT00192712|Drug|irinotecan, gemcitabine|
1750023|NCT00192725|Other|rapid tryptophan depletion|Amino-acid mixture without tryptophan
1750024|NCT00192751|Behavioral|Psychoeducational group sessions|
1750025|NCT00192764|Drug|high-dose cyclophosphamide|
1750026|NCT00192777|Drug|Xeloda|
1750027|NCT00192777|Procedure|External Beam Radiotherapy|
1750028|NCT00192803|Drug|candesartan|
1750029|NCT00192816|Behavioral|reaction to pain|
1750030|NCT00192829|Procedure|Blood sample withdrawal|
1750031|NCT00192842|Drug|curcumin (+ gemcitabine)|
1750032|NCT00192855|Drug|Entacapone|Entacapone 600mg BID
1750033|NCT00192868|Procedure|Distal protection and drug eluting stent|
1750034|NCT00192881|Device|Bx Sonic & Cypher stent from Cordis|
1750035|NCT00192920|Behavioral|Transfusion practice|
1750036|NCT00192933|Procedure|NovoSeven treatment according to guideline|
1750037|NCT00192946|Procedure|Temporary cardiac resynchronization therapy|
1750038|NCT00192959|Drug|Xenon vs propofol|
1750039|NCT00192972|Procedure|Catheter ablation (pulmonary vein isolation)|
1750040|NCT00192985|Device|Nitrofuranzone coated bladder catheter|
1750041|NCT00193011|Drug|Docetaxel|Docetaxel
1750042|NCT00193011|Drug|Cyclophosphamide|Cyclophosphamide
1750043|NCT00193011|Drug|Methotrexate|Methotrexate
1750044|NCT00193011|Drug|5-Fluorouracil|5-Fluorouracil
1750045|NCT00193024|Drug|Docetaxel|
1750046|NCT00193024|Drug|Epirubicin|
1750047|NCT00193037|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin
1750048|NCT00193037|Drug|Docetaxel|Docetaxel
1750049|NCT00193050|Drug|Gemcitabine|Gemcitabine
1750050|NCT00193050|Drug|Epirubicin|Epirubicin
1750051|NCT00193050|Drug|Docetaxel|Docetaxel
1750052|NCT00193063|Drug|Trastuzumab|Trastuzumab
1750053|NCT00193063|Drug|Gemcitabine|Gemcitabine
1750054|NCT00193076|Drug|Gemcitabine|Gemcitabine
1750055|NCT00193076|Drug|Carboplatin|Carboplatin
1750056|NCT00193076|Drug|Trastuzumab|Trastuzumab
1750057|NCT00193089|Drug|Docetaxel|Docetaxel
1750058|NCT00193089|Drug|Vinorelbine|Vinorelbine
1750059|NCT00193089|Drug|Trastuzumab|Trastuzumab
1750060|NCT00193102|Drug|Thalidomide|Thalidomide
1750061|NCT00193102|Drug|Capecitabine|Capecitabine
1750062|NCT00193115|Drug|Docetaxel|
1750063|NCT00193115|Drug|Doxorubicin|
1750064|NCT00193115|Drug|Cyclophosphamide|
1750065|NCT00193128|Drug|Oxaliplatin|40 mg/m2 IV over 2 hours on days 1, 8, 15, 22, and 29 in both treatment cohorts
1750066|NCT00193128|Drug|Docetaxel|20 mg/m2 IV over 30 minutes was administered on days 1, 8, 15, 22, and 29 in both cohorts
1750067|NCT00193128|Drug|Capecitabine|In Cohort 2, capecitabine was administered 1000 mg/m2 orally twice daily on days 1 to 7, 15 to 21, and 29 to 35.
1750068|NCT00193128|Radiation|Radiation therapy|In both cohorts, radiation therapy began concurrently with day 1 of chemotherapy at a dose of 1.8 Gy/d Monday through Friday to a total of 45 Gy (25 fractions).
1750069|NCT00193141|Drug|Paclitaxel|
1750070|NCT00193141|Drug|Carboplatin|
1750071|NCT00193141|Drug|5-Fluorouracil|
1750072|NCT00193154|Drug|OSI-774|150mg PO, days 1-28, cycle repeated every 28 days
1750073|NCT00193154|Drug|Bevacizumab|10mg/kg, IV infusion, Days 1 and 15, 28 day cycles
1750074|NCT00193167|Drug|Topotecan|
1750075|NCT00193180|Drug|Imatinib|Imatinib
1750076|NCT00193180|Drug|Docetaxel|Docetaxel
1750077|NCT00193193|Drug|Paclitaxel|
1750078|NCT00193193|Drug|Estramustine|
1750079|NCT00193193|Drug|Carboplatin|
1750080|NCT00193206|Drug|Gemcitabine|Gemcitabine 2000 mg/m2 IV D1 q 14 days x 6 cycles
1750081|NCT00193206|Drug|Epirubicin|Epirubicin 50 mg/m2 D1 q 14 days x 6 cycles
1750082|NCT00193206|Drug|Albumin-bound Paclitaxel|ABI-007 175 mg/m2 D1 q 14 days x 6 cycles
1750083|NCT00193219|Drug|Bevacizumab|5 mg/kg IV
1750084|NCT00193219|Drug|Cetuximab|400 mg/m2 (first cycle only) IV on day 1 and 250 mg/m2 IV on day 8 with all subsequent cycles 250 mg/m2 IV on days 1 and 8
1750085|NCT00193219|Drug|5-fluorouracil|400 mg/m2 bolus IV bolus followed by 2400 mg/m2 administered as continuous IV infusion over 46 hours via pump (outpatient)
1750086|NCT00193219|Drug|Leucovorin|350 mg IV
1750087|NCT00193219|Drug|Oxaliplatin|85 mg/m2 IV
1750088|NCT00193232|Drug|Docetaxel|
1750089|NCT00193232|Drug|Bortezomib|
1750090|NCT00193245|Drug|Topotecan|
1750091|NCT00193245|Drug|Docetaxel|
1750092|NCT00193258|Drug|Bevacizumab|10mg/kg IV infusion every 2 weeks
1750093|NCT00193258|Drug|Erlotinib|150 mg po daily
1750094|NCT00193258|Drug|Imatinib|400-600mg daily
1750095|NCT00193271|Drug|Docetaxel|
1750096|NCT00193271|Drug|Estramustine|
1750097|NCT00193284|Drug|Gefitinib|
1750098|NCT00193284|Drug|Docetaxel|
1750099|NCT00193284|Drug|Carboplatin|
1750100|NCT00193284|Drug|Fluorouracil|
1750101|NCT00193297|Drug|Topotecan|
1750102|NCT00193297|Drug|Paclitaxel|
1750103|NCT00193297|Drug|Carboplatin|
1750104|NCT00193310|Drug|Paclitaxel|
1750105|NCT00193310|Drug|Carboplatin|
1750106|NCT00193323|Drug|Docetaxel|
1750107|NCT00193323|Drug|Gemcitabine|
1750108|NCT00193336|Drug|ZD1839|
1750109|NCT00193349|Drug|Imatinib|
1750110|NCT00193349|Drug|Irinotecan|
1750111|NCT00193349|Drug|Carboplatin|
1750112|NCT00193362|Drug|Paclitaxel|
1750113|NCT00193362|Drug|Carboplatin|
1750114|NCT00193362|Drug|Gemcitabine|
1750115|NCT00193362|Drug|Vinorelbine|
1750116|NCT00193375|Drug|Irinotecan|50mg/m2 days 1 & 8 each 21-day cycle 1 & 2, 28-day cycle 3 & 4
1750117|NCT00193375|Drug|Carboplatin|AUC 5
1750118|NCT00193375|Drug|Bevacizumab|10mg/kg IV every 2 weeks for 10 doses starting week 16
1750119|NCT00193375|Radiation|Radiation|
1750120|NCT00193388|Drug|Topotecan|
1750121|NCT00193401|Drug|Topotecan|
1750122|NCT00193414|Drug|Pemetrexed|500mg/m2 IV over 10 min, Day 1, prior to gemcitabine
1750123|NCT00193414|Drug|Gemcitabine|1500mg/m2, 30min IV
1750124|NCT00193427|Drug|Docetaxel|30mg/m2 administered on days 1 and 8, 21-cycle days, 3 cycles
1750125|NCT00193427|Drug|Gemcitabine|1000 mg/m2 administered by 30-minute IV infusion on day 1 and 8, 21-cycle days, 3 cycles
1750126|NCT00193427|Drug|Carboplatin|AUC = 1.5 weekly x 7
1750127|NCT00193427|Radiation|Radiation|To 63 Gy
1750131|NCT00193440|Drug|Ibritumomab Tiuxetan|
1750132|NCT00193453|Drug|Gemcitabine|1000mg/m2 30min IV, Day 1 & 8
1750133|NCT00193453|Drug|Docetaxel|30mg/m2, 30min IV, day 1 & 8
1750134|NCT00193453|Drug|Cetuximab|100mg/m2 IV, Cycle 1 Day 1, 250mg/m2 IV day 8 & 15, all subsequent cycles 250mg/m2 IV day 1, 8, & 15
1750135|NCT00193466|Drug|Rituximab|
1750136|NCT00193466|Drug|Fludarabine|
1750137|NCT00193466|Drug|CAMPTH-1H|
1750138|NCT00193479|Drug|Cyclophosphamide|Cyclophosphamide
1750139|NCT00193479|Drug|Mitoxantrone|Mitoxantrone
1750140|NCT00193479|Drug|Vincristine|Vincristine
1750141|NCT00193479|Drug|Prednisone|Prednisone
1750142|NCT00193479|Drug|Rituximab|Rituximab
1750143|NCT00193492|Drug|Bevacizumab|
1750144|NCT00193492|Drug|Rituximab|
1750145|NCT00193505|Drug|Ifosfamide|
1750146|NCT00193505|Drug|Carboplatin|
1750147|NCT00193505|Drug|Etoposide|
1750148|NCT00193505|Drug|Rituximab|
1750149|NCT00193505|Drug|90Y Zevalin|
1750150|NCT00193518|Drug|Arsenic Trioxide|
1750151|NCT00193531|Drug|Paclitaxel|
1750152|NCT00193531|Drug|Carboplatin|
1750153|NCT00193531|Drug|Etoposide|
1750154|NCT00193544|Drug|Arsenic Trioxide|
1750155|NCT00193544|Drug|Thalidomide|
1750156|NCT00193557|Drug|Bortezomib|
1750157|NCT00193570|Drug|Topotecan|
1750158|NCT00193570|Drug|Docetaxel|
1750159|NCT00193583|Drug|Topotecan|
1750160|NCT00193583|Drug|Carboplatin|
1750161|NCT00193596|Drug|Etoposide|50 mg alternating with 100 mg PO, days 1 and 10 in regimen A
1750162|NCT00193596|Drug|Gemcitabine|1000 mg/m2 IV, days 1 and 8, in regimen B
1750163|NCT00193596|Drug|Irinotecan|1000 mg/m2 IV days 1 and 8 in regimen B
1750164|NCT00193596|Drug|Paclitaxel|200 mg/m2 by 1-hour IV infusion, day 1, regimen A
1750165|NCT00193596|Drug|Carboplatin|Area under the curve (AUC) 6.0 IV, day 1, regimen A
1750166|NCT00193609|Drug|Oxaliplatin|130 mg/m2 IV day 1 of 21 day cycle
1750167|NCT00193609|Drug|Capecitabine|1000 mg/m2 by mouth twice daily on days 1-14 of each 21 day cycle
1750168|NCT00193622|Drug|Bevacizumab|
1750169|NCT00193622|Drug|Erlotinib|
1750170|NCT00193635|Drug|mycophenolate mofetil|oral drug administration
1750171|NCT00193648|Drug|Rosiglitazone (Avandia)|oral drug administration
1750172|NCT00193648|Drug|Adalimumab (Humira)|Injection of drug biweekly
1750173|NCT00193661|Drug|Testosterone Gel (1%)|
1750174|NCT00193674|Drug|Dydrogesterone|20 mg/day, oral
1750175|NCT00193674|Drug|Placebo|Placebo
1750176|NCT00193687|Drug|bifeprunox|
1750177|NCT00193700|Drug|Testosterone Gel (1%)|
1750178|NCT00193713|Drug|bifeprunox|
1750179|NCT00193726|Drug|Tab Premarin (Ethinyl estradiol)|Tab Premarin 0.625 mg (Ethinyl estradiol) once a day for 5 days prior to each cycle of chemotherapy
1750180|NCT00193726|Drug|Placebo|Placebo once a day for 5 days prior to each cycle of chemotherapy
1750185|NCT00193752|Other|PET IMAGING|PET imaging in cervical cancers to predict, prognosticate outcome in cervical cancers
1750186|NCT00193765|Procedure|Elective neck dissection in early oral cancer|Elective neck dissection in early node negative oral cancers at the time of primary surgery
1750187|NCT00193765|Procedure|Therapeutic Neck Dissection|There is no active intervention for the neck at the time of primary surgery. Therapeutic Neck Dissection at the time of nodal relapse
1750188|NCT00193778|Procedure|Surgery for breast cancer|This group will receive standard loco-regional treatment i.e. surgery (modified radical mastectomy (MRM)/ Simple SMAC/BCT) +/- radiotherapy
1750189|NCT00193778|Other|No Loco-regional treatment|This group will not receive any loco-regional treatment
1750190|NCT00193791|Other|CT + RT|Injection Cisplatin 40mg/m2 weekly for 5 weeks during the entire course of external radiation therapy
1750191|NCT00193804|Radiation|IMRT|IMRT in cervical cancers
1750192|NCT00193817|Procedure|Two field vs Three field lymphadenectomy|
1750193|NCT00193830|Procedure|HIgh Dose Rate Vs Low DOse Rate Brachytherapy|
1750194|NCT00193843|Procedure|Post-operative chemoradiotherapy / accelerated radiotherapy|
1750198|NCT00193869|Drug|Dexamethasone|
1750199|NCT00193882|Drug|Cisplatin|80mg/m2 IV day 1
1750200|NCT00193882|Radiation|Radiotherapy|35 Gy in 15 fractions
1750201|NCT00193882|Drug|5-Fluorouracil|800mg/m2/day IV days 1 - 4
1750202|NCT00193895|Drug|Carboplatin|Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.
1750203|NCT00193895|Radiation|Radiotherapy|60 Gy OR 66Gy in 2Gy/fraction 5days/week
1750204|NCT00193908|Drug|Cavilon (TM) Durable Barrier Cream|Cavilon (TM) Durable Barrier Cream will be applied to either the medial or the lateral side of the treated breast. Side will depend on randomisation.
1750205|NCT00193908|Drug|Sorbolene|Sorbolene will be applied to either the medial or the lateral side of the treated breast. Side will be determined by randomisation
1750206|NCT00193908|Radiation|Radiotherapy|Minimum prescribed dose to the chest wall is 45Gy in 25 fractions. Planning and Treatment is per the study protocol
1750207|NCT00193921|Drug|Vinorelbine|IV, 25mg/m2, days 1, 8, 22
1750208|NCT00193921|Radiation|High dose Radiotherapy|External beam radiation, 40 Gy/20#/5 per week
1750209|NCT00193921|Drug|Gemcitabine|200mg (flat dose) IV days 1, 8, 15
1750210|NCT00193921|Drug|Cisplatin|20mg/m2, IV, weekly
1750211|NCT00193921|Radiation|High Dose Radiotherapy|External beam radiation, 30 Gy/15#/5 per week
1750212|NCT00193960|Procedure|1) Intraocular pressure 2) visual acuity|
1750213|NCT00193973|Drug|Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C|Idarubicin 15mg/m2 days 1, 22. Filgrastim 5mcg/kg until neutrophil recovery days 2, 23. Methotrexate 1g/m2 days 15, 36 and 50.
1750214|NCT00193973|Radiation|Radiation Therapy|Whole brain Irradiation, 30Gy in 20 fractions over 4 weeks
1750215|NCT00193986|Device|Arbitrary Waveform Defibrillator|
1750216|NCT00193999|Device|Placement of nasogastric tube|
1750217|NCT00194012|Drug|Aripiprazole|Addressed in arm description.
1750218|NCT00194012|Drug|Placebo|Addressed in arm description.
1750219|NCT00194025|Drug|Valproate|Enrolled individuals received adjunctive, open-label valproate semisodium, initially started as valproate semisodium delayed -release 250 mg at bedtime for two weeks, then changed to valproate semisodium extended- release 500 mg at bedtime. Medication was administered on an outpatient/ambulatory basis, and adjusted as tolerated to target serum levels of 50-100 µg/mL. In cases where sedation or other side effects occurred, dosage was reduced. Valproate semisodium was prescribed in a single dose at bedtime.
1750220|NCT00194038|Drug|Aripiprazole|Patients were continued on treatment with their existing mood stabilizing medication, and upon enrollment were initiated on aripiprazole augmentation treatment. The initial starting dose of aripiprazole was 5 mg/day, with gradual upward titration as tolerated. Initiation of new additional antipsychotic medications was not permitted during the course of the study, and antipsychotic medications prescribed at study start were tapered and discontinued by week 4 of the study if possible.
1750221|NCT00194051|Procedure|gastric bypass surgery|
1750222|NCT00194064|Drug|Olanzapine|
1750223|NCT00194077|Drug|Aripiprazole|dosing will occur at 2mg, 5mg, 7mg, 10 mg, 12mg, or 15 mg based on weight, side effects and efficacy
1750224|NCT00194077|Drug|Placebo|subjects in phase 2 will be randomized to active abilify or placebo
1750225|NCT00194090|Drug|celecoxib|
1750226|NCT00194103|Behavioral|Telephone Monitoring and Feedback|In addition to attending IOP, participants receive phone contact from our counselors but only to receive a monitoring assessment. There is no feedback or counseling from study staff in this condition.
1750227|NCT00194103|Behavioral|Telephone Monitoring and Counseling|In addition to attending IOP, participants have phone contact with study counselors, which includes monitoring, feedback, and counseling.
1750228|NCT00194116|Drug|Divalproex Sodium ER|Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
1750229|NCT00194116|Drug|Placebo|. Tablets will be available in 250mg and 500mg strengths. Divalproex will be titrated to a minimum blood level of 50 mg/L. However, the investigators will titrate divalproex to the maximum tolerable dose with an expected average dose of 2000mg per day. By dosing in this manner, all subjects will have a minimum blood level of 50 mg/L, but the mean level is likely to be considerably higher.
1750232|NCT00194181|Drug|TPA Infusion|
1750233|NCT00194194|Behavioral|moderate|moderate behavioral management with RD
1750234|NCT00194194|Device|Resting Metablic Rate measurements|intensive behavior management
1750235|NCT00194272|Drug|Methotrexate|Two dose methotrexate
1750236|NCT00194285|Procedure|FDG-PET Imaging|
1750237|NCT00194298|Procedure|FDG-PET Imaging|
1750238|NCT00194324|Drug|Miconazole nitrate|
1750239|NCT00194324|Procedure|Magnetic resonance imaging|
1750240|NCT00194324|Behavioral|Moderate levels of exercise|
1750241|NCT00194337|Procedure|breast imaging study|
1750242|NCT00194337|Procedure|comparison of screening methods|
1750243|NCT00194337|Procedure|magnetic resonance imaging|
1750244|NCT00194337|Procedure|positron emission tomography|
1750245|NCT00194337|Procedure|radiomammography|
1750246|NCT00194337|Procedure|ultrasound imaging|
1750247|NCT00194337|Radiation|fludeoxyglucose F 18|
1750248|NCT00194350|Procedure|Test for Factor V Leiden gene mutation|
1750249|NCT00194363|Behavioral|Strength training|13 weeks of supervised strength training (twice weekly for 90 minutes per session), 39 weeks of unsupervised strength training (twice weekly for 90 minutes per session)
1750250|NCT00194376|Procedure|Continuous positive airway pressure ventilation|CPAP ventilation is a therapeutic modality which uses positive pressure of air through a sealed nasal mask to treat a condition known as sleep apnea
1750251|NCT00194402|Drug|Slo-Niacin, atorvastatin|Atorvastatin 10 mg qd for 12 or 24 weeks. Time-released niacin 1500 mg qd (titrated from 500mg to 1000mg and then to 1500 mg at 4 week intervals) taken for 12 or 24 weeks.
1750252|NCT00194415|Behavioral|Safer-sex counseling|Subjects will receive safer-sex counseling during pregnancy
1750253|NCT00194415|Procedure|Type specific serologic HSV testing|Subjects will be testing for HSV by Western Blot
1750254|NCT00194428|Behavioral|Almond enriched diet|Subjects will consume 2 oz. of almond per day in addition to a low-fat diet
1750255|NCT00194428|Behavioral|Low fat caloric diet|Low fat caloric diet
1750256|NCT00194441|Other|Bedside display of cerebral perfusion pressure information|Continually updating highly visible color coded bar graph bedside computer display of cerebral perfusion pressure
1750368|NCT00187226|Procedure|Radiation Therapy|External Beam Radiation Therapy: 59.4Gy administered at 1.8Gy per day for high-grade glioma and selected ependymoma.
1750257|NCT00194454|Behavioral|Modified cognitive behavioral therapy plus problem-solving|9 sessions with a psychosocial nurse practitioner in which participants learn to use behavioral strategies and specific problem-solving approaches to reduce or prevent behavioral and mood disturbances characteristic of stroke.
1750258|NCT00194454|Other|usual care|Usual care with primary provider plus a booklet about mood and behavioral changes following stroke
1750259|NCT00194467|Drug|valganciclovir|900 mg once a day for 8 weeks
1750260|NCT00194467|Drug|placebo|matching placebo, once a day for 8 weeks
1750261|NCT00194480|Drug|Pegylated Interferon|Weekly injections of pegIntereferon
1750262|NCT00194493|Behavioral|ESRA-C|Graphical summary of patient symptoms and quality of life
1750263|NCT00194506|Behavioral|Internet co-management module|
1750264|NCT00194519|Drug|Generic acyclovir|400 mg twice-daily oral
1750265|NCT00194519|Drug|Placebo|twice-daily oral
1750266|NCT00194532|Drug|Cefpodoxime|Cefpodoxime 100mg twice a day(BID)for 3 days
1750267|NCT00194532|Drug|Ciprofloxacin|Ciprofloxacin 250mg twice a day (BID)for 3 days
1750268|NCT00194545|Behavioral|Medication diaries|Caregivers expected to complete medication diaries daily
1750269|NCT00194558|Behavioral|Internet co-management module|
1750270|NCT00194571|Behavioral|Educational counseling intervention|This intervention involves 5 face to face educational counseling sessions with a specially trained patient educator; sessions are fully manualized and complemented by handouts given to the diagnosed parent.
1750271|NCT00194584|Behavioral|7 week Building on Family Strengths Program|Parents in intervention group attend a 2 hr class for seven weeks. These classes provide information, time for discussion and creation of an action plan for the parent to complete in the intervening week.
1750272|NCT00194597|Drug|Viagra (sildenafil citrate)|
1750273|NCT00194610|Drug|Botox|Botox 25 international units per injection injected in two places in the bladder neck, with option to inject two other tender points with 25 units each
1750274|NCT00194610|Other|normal saline|Normal saline injected into the bladder neck via the perineum, 1 cc each given at positions 3 o'clock and 9 o'clock
1750275|NCT00194623|Drug|Botulinum Toxin A (Botox)|
1750276|NCT00194636|Procedure|nerve block|
1750277|NCT00194649|Drug|Miglustat (Zavesca)|100 mg Miglustat BID (twice daily) for six weeks
1750278|NCT00194675|Drug|Dutasteride|Dutasteride 0.5 mg orally daily
1750279|NCT00194675|Drug|Testosterone gel|Testosterone gel 7.5 g daily topical
1750280|NCT00194675|Drug|Placebo dutasteride|placebo dutasteride orally daily
1750281|NCT00194688|Drug|H. pylori treatment|
1750282|NCT00194701|Behavioral|Walking exercise|
1750283|NCT00194714|Biological|HER-2/neu Peptide Vaccine|Given ID
1750284|NCT00194714|Other|Laboratory Biomarker Analysis|Correlative studies
1750285|NCT00194727|Drug|Vinorelbine|20 mg/m2 IV weeks 1, 2 and 3 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
1750286|NCT00194727|Drug|Capecitabine|825 mg/m2 twice a day; days 1 - 14 of each 3 week cycle. Treatment continues until disease progression, excessive toxicity or other reason to remove patient from protocol therapy.
1750287|NCT00194740|Drug|Docetaxel|60 mg/m2, IV, day 1 of each 21 day cycle
1750288|NCT00194740|Drug|Vinorelbine|27.5 mg/m2, IV, days 8 & 15 of each 21 day cycle
1750289|NCT00194740|Drug|Filgrastim|5 µg/kg/day s.c., to be administered days 2-21 of each cycle.
1750290|NCT00194753|Drug|Paclitaxel|80 mg/m2 IV for 12 weeks following completion of doxorubicin and cyclophosphamide
1750291|NCT00194753|Drug|Doxorubicin|24 mg/m2 IV weekly x 12
1750292|NCT00194753|Drug|Cyclophosphamide|60 mg/m2 PO daily for 12 weeks
1750293|NCT00194753|Drug|G-CSF|5 mcg per kg subcutaneously days 2 - 7 during doxorubicin and cyclophosphamide for 12 weeks
1750294|NCT00194766|Drug|Temozolomide|Temozolomide 75 mg/m2 daily for 6 weeks followed by a two week rest period for a total cycle length of 8 weeks. Treatment is repeated until disease progression, excessive toxicity or other reason to suspend protocol treatment.
1956604|NCT02780804|Drug|Entinostat|Given PO
1956605|NCT02780804|Other|Laboratory Biomarker Analysis|Correlative studies
1956606|NCT02780804|Other|Pharmacological Study|Correlative studies
1750309|NCT00194792|Drug|exemestane|Given PO
1750310|NCT00194792|Drug|triptorelin pamoate|Given IM
1750311|NCT00194792|Drug|capecitabine|Given PO
1750312|NCT00194792|Drug|methotrexate|Given IV
1750313|NCT00194792|Drug|vinorelbine tartrate|Given IV
1750314|NCT00194792|Drug|paclitaxel|Given IV
1750315|NCT00194792|Procedure|therapeutic conventional surgery|Undergo lumpectomy or mastectomy
1750316|NCT00194792|Radiation|radiation therapy|Undergo radiation therapy
1750317|NCT00194792|Other|laboratory biomarker analysis|Correlative studies
1750318|NCT00194805|Behavioral|Telehealth for Diabetes Self Management|
1750319|NCT00194805|Other|Telehealth for Diabetes Self Management|Web based education format delivered for a six month period
1750320|NCT00194818|Drug|Asacol (mesalamine)|Available in 400mg delayed release tablet. Randomized to either 6 tablets BID (4.8 g/day) or 4 tablets TID (4.8 g/day) for a total of 12 weeks.
1750321|NCT00194844|Behavioral|Nurse Caring|Nurse Caring: Couples receive three one hour counseling session with a nurse interventionist at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
1750322|NCT00194844|Behavioral|Self Caring|Self Caring: Couples receive a mailed videotape and workbook at approximately 1, 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
1750323|NCT00194844|Behavioral|Combined Caring|Combined Caring: Couples receive one counseling session from a nurse interventionist at approximately one week after enrollment. Upon completion of the session the nurse will hand the couple a self-caring videotape and workbook. Couples will be mailed an additional videotape and workbook at approximately 5 and 11 weeks after enrollment. Content for the intervention comes from Swanson's phenomenologically derived Meaning of Miscarriage Model. The process for the intervention is based on Swanson's Theory of Caring.
1750324|NCT00194857|Drug|erythropoietin, GCSF|
1750325|NCT00194870|Procedure|computer-assisted analysis of the digitally-recorded EEG signals|computer-assisted analysis of the digitally-recorded EEG signals
1750326|NCT00194883|Drug|Recombinant Human Growth Hormone|
1750327|NCT00194896|Drug|rosiglitazone|Tablet taken orally at a dosage of 4 mg once per day and increase to twice per day if adequate glycemic control was not achieved. Study drug was taken up to 3 years.
1750328|NCT00194896|Drug|glyburide|Tablet taken orally, initially 2.5 mg in the morning or dose subject received prior to starting the study. Dosage was increased by 2.5 mg in the evening up to a maximum of 10 mg twice a day if necessary to achieve desired glycemic control. Study drug was taken up to 3 years.
1750329|NCT00194909|Drug|sildenafil (Viagra)|
1750330|NCT00194922|Dietary Supplement|E. Coli Strain M17 Probiotic|30 ml PO BID for 12 weeks
1750331|NCT00194935|Drug|Topotecan|
1750332|NCT00194948|Drug|escitalopram|
1750333|NCT00194948|Behavioral|interpersonal psychotherapy|
1750334|NCT00194961|Drug|Recombinant Human Growth Hormone|
1750335|NCT00194974|Drug|methyldopa|
1750336|NCT00194974|Drug|labetalol|
1750337|NCT00194974|Drug|nifedipine|
1750338|NCT00194974|Drug|clonidine|
1750339|NCT00194987|Drug|IVIG (Intravenous Immunoglobulin)|one to two mg per kg once-twice weekly
1750340|NCT00195000|Drug|Mylotarg|6 mg/m2 on day 1
1750341|NCT00195000|Drug|Cytarabine|100 mg/m2 given as continuous infusion daily for 7 days.
1750342|NCT00195013|Drug|glutamine|10 grams three times a day (orally) for four days and then stop
1750343|NCT00195013|Drug|Placebo|10 grams three times a day (orally) for four days and then stop
1750344|NCT00195026|Device|Infrared Breast Scan|Patients already scheduled for breast biopsies will receive an additional infrared scan
1750345|NCT00195039|Drug|177Lu Radiolabeled Monoclonal Antibody HuJ591 (177Lu -J591)|"Eligible patients will receive a single dose of 177Lu-J591 (65 or 70 mCi/m2) consisting of J591 chelated at a specific activity of 12-15 mCi of 177Lu per mg of antibody plus sufficient non-radiolabeled, non-DOTA-conjugated (naked) J591 to achieve a total antibody dose of 20 mg. Each dose will be administered by an IV infusion at a rate not to exceed 5 mg/min."
1750346|NCT00195065|Behavioral|Semi-structured, open-ended interviews|
1750347|NCT00195078|Drug|ZD1839 (IRESSA)|
1750348|NCT00195078|Drug|Cisplatin|
1750349|NCT00195078|Procedure|Radiation Therapy|
1750350|NCT00195091|Drug|Tetrathiomolybdate|"Induction with Tetrathiomolybdate (TM) Tetrathiomolybdate 40 mg. p.o. TID with meals and tetrathiomolybdate 60 mg at bedtime for a total of 4 doses (180 mg) per day.
Induction goal Total tetrathiomolybdate dose per day = 180 mg until serum ceruloplasmin (Cp) level decreases to 5-15mg/dL.
When target Cp window is reached, then the maintenance phase begins.
Maintenance with Tetrathiomolybdate Total tetrathiomolybdate dose per day = 100 mg
Tetrathiomolybdate 40 mg p.o. BID with meals and tetrathiomolybdate 20 mg at bedtime."
1750351|NCT00195104|Drug|Arsenic Trioxide (Tricenox)|
1750352|NCT00195104|Drug|Cytarabine|
1750353|NCT00195117|Behavioral|Intervention Group|Subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
1750354|NCT00195130|Behavioral|There are no interventions in this study|
1750355|NCT00195143|Genetic|Surgical infusion of AAV-GAD into the subthalamic nucleus|
1750356|NCT00195156|Drug|ATRA-IV|
1750357|NCT00195156|Drug|Depakote|
1750358|NCT00195182|Behavioral|Self affirmation and positive affect induction vs. control|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
1750359|NCT00195195|Drug|Sirolimus|Transplantation patients treated with sirolimus who consent to participate in the study (register)
1750360|NCT00187161|Drug|Prednison, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Doxorubicin|The additional information is contained in the Detailed Description section.
1750361|NCT00187174|Drug|Everolimus|The drug is given orally in 28 day courses.
1750362|NCT00187187|Device|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
1750363|NCT00187187|Device|Implantable Defibrillator (ICD)|Implantable Defibrillator (ICD)
1750364|NCT00187200|Device|Simultaneous VV Pacing|Right ventricular and left ventricular pacing delivered simultaneously.
1750365|NCT00187200|Device|Sequential VV Pacing|Right ventricular and left ventricular pacing delivered sequentially.
1750366|NCT00187213|Device|Cardiac Resynchronization Therapy|
1750367|NCT00187226|Procedure|Radiation Therapy|External Beam Radiation Therapy: 54Gy administered at 1.8Gy per day for low-grade glioma, craniopharyngioma and selected ependymoma.
1750369|NCT00187239|Device|Autointrinsic Conduction Search Algorithm|Autointrinsic conduction search is programmed on in those patients randomized to AICS ON.
1750370|NCT00187252|Device|Atrial Overdrive Pacing|Pacemaker/ ICD implant
1750371|NCT00187265|Device|Cardiac Resynchronization Therapy|
1750374|NCT00187291|Device|T-Wave Alternans test|
1750375|NCT00187304|Device|Aortic valve replacement|
1750376|NCT00187317|Behavioral|Balance training (exercise)|Perturbation-based balance training. 30-minute sessions three times per week for six weeks.
1750377|NCT00187317|Other|Flexibility and relaxation exercise|30-minute sessions, three times per week for six weeks.
1750378|NCT00187330|Drug|Intravenous N-acetylcysteine|
1750379|NCT00187343|Device|Breast IMRT|
1750380|NCT00187356|Procedure|Radial Artery and Saphenous Vein Grafts Randomized to either right coronary or left circumflex coronary artery territories|Each patient will receive both study grafts (Radial artery and Study Saphenous vein graft). The within-patient randomization scheme will dictate whether the radial goes to the right or circumflex territory. The saphenous vein graft will go to the opposing territory.
1750381|NCT00187369|Procedure|Method of Delivery|CS or VB
1750382|NCT00187382|Drug|Multiple vs. single courses of antenatalcorticosteroids|
1750383|NCT00187395|Procedure|Randomized to either a 'less tight' group or a 'tight' group|
1750384|NCT00187408|Drug|Low Molecular Weight Heparin (dalteparin)|
1750385|NCT00187421|Procedure|Indocyanine green intraoperative angiogram and transit-time flowmetry|"ICG graft angiography following each distal anastomosis, and imaging of proximal anastomoses after all grafts completed.
transit time flowmetry performed on all grafts after all grafts completed."
1750386|NCT00187434|Device|Infant Flow System|
1750387|NCT00187434|Device|Bubble CPAP|
1750388|NCT00187447|Drug|indomethacin (two different dosing regimens)|
1750389|NCT00187460|Behavioral|Publicly released hospital cardiac report cards|Participating hospital corporations were randomized to either early feedback or delayed feedback (21 months later) in the form of publicly released hospital report cards of performance on a set of cardiac process-of-care quality indicators.
1750390|NCT00187473|Procedure|liver biopsy|Liver biopsy every 5 years
1750391|NCT00187486|Drug|Tarceva|Tarceva (erlotinib hydrochloride; previously referred to as OSI-774), a quinazoline, is an orally active, potent, selective inhibitor of EGFR tyrosine kinase. 100 - 300 milligrams (mg) every day (QD) orally (PO) every (q) 28 days depending on EIAED Status
1750392|NCT00187486|Drug|Temodar|Temodar 200 mg/m^2/day x 5 days every 28 days
1750393|NCT00187486|Procedure|Radiation Therapy|Radiotherapy will be administered in 180 centigray(cGy)/day - 200cGy/day fractions delivered 5 days per week to a total dose of 5940cGy - 6100cGy. A total of 4500cGy will be delivered to the clinical tumor volume consisting of T2-bright edema + a 2centimeter margin, or, if no edema, the contrast enhancing lesion +2.5 centimeter margin. An additional boost of 1440cGy will be delivered to the gross tumor volume consisting of the contrast enhancing lesion + a 1 centimeter margin.
1750394|NCT00187499|Drug|Inhaled fluticasone 500 ug BID for 8 weeks|
1750395|NCT00187525|Drug|Memantine|
1750396|NCT00187538|Behavioral|Dietary|dietary
1750397|NCT00187551|Other|Interruption of enfuvirtide|treatment interruption
1750398|NCT00187551|Other|enfuvirtide interrupton|enfuvitide will be interrupted in patients harboring resistant virus
1750399|NCT00187564|Drug|controlled-release oral alpha-lipoic acid|
1750400|NCT00187577|Drug|Latanoprost (Xalatan)|
1750401|NCT00187577|Drug|Bimatoprost (Lumigan)|Bimatoprost solution will be applied to affected eyelid(s) with cotton-tipped applicator daily.
1750402|NCT00187577|Drug|Topical application of latanoprost solution to eyelid|Subject will apply latanoprost to affected eyelid with cotton-tipped applicator daily.
1750403|NCT00187590|Behavioral|Case manager phone call after an ER visit|
1750404|NCT00187603|Behavioral|tobacco cessation program|
1750405|NCT00187629|Behavioral|dietary phosphorus|varying amts dietary phosphorus
1750406|NCT00187655|Drug|Cefotaxime|Cefotaxime will be administered as a single IV push of 2 grams over 5 minutes.
1750407|NCT00187681|Drug|Metformin|2 doses of Metformin Day 1 1000mg, Day 2 850 mg
1750408|NCT00187707|Drug|Gabapentin|Subjects will take a single dose of 400 mg of gabapentin
1750409|NCT00187720|Drug|Metformin|Subjects will be given a single oral dose of 850 mg of metformin
1750410|NCT00187733|Other|Fasting blood and urine collection|Not applicable no drugs dispensed
1750411|NCT00187746|Drug|Adefovir dipivoxil|Subjects will be given a single oral dose of 10 mg of adefovir dipivoxil
1750412|NCT00187759|Drug|cephalexin|
1750413|NCT00187772|Behavioral|Child-Parent Psychotherapy (CPP)|
1750414|NCT00187785|Behavioral|Spanish speaker level|
1750415|NCT00187798|Drug|Metformin HCl|Subjects will be given a single oral dose in tablet form containing 850 mg of metformin
1750416|NCT00187811|Procedure|Delta amino leavulinic acid photodynamic therapy|
1750417|NCT00187837|Procedure|SW|Stepwise removal of carious tissue in 2 stages
1750418|NCT00187837|Procedure|DCE|one complete excavation
1750419|NCT00187850|Procedure|PP|Partial pulpotomy
1750420|NCT00187850|Procedure|DPC|Direct pulp capping
1750421|NCT00187863|Behavioral|pain perception|pain perception
1750422|NCT00187876|Procedure|ACL reconstruction control|The intervention consists of the reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
1750423|NCT00187876|Procedure|ACL Biocleanse, surgical|The intervention consists of the surgical reconstruction of the ACL ligament using patellar tendon allografts that have undergone the BioCleanse™ process.
1750426|NCT00187915|Drug|Mycophenolate mofetil + Tacrolimus|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
1750834|NCT00199654|Procedure|PET|
1750427|NCT00187915|Drug|Mycophenolate mofetil + Cyclosporin|Target MPA exposure to 30-60 mg/L/h during first month post-transplant
1750428|NCT00187928|Drug|Topiramate|
1750429|NCT00187941|Drug|Mycophenolate Mofetil|Targeted MPA exposure to 30-60 mg/L/h during the first month post-transplant.
1750430|NCT00187967|Device|pumps used for cardiopulmonary bypass|
1750431|NCT00187993|Drug|Growth hormone|
1750432|NCT00188006|Device|heparin-coated cardiopulmonary bypass|
1750433|NCT00188019|Procedure|diagnosis methods|
1750434|NCT00188032|Procedure|Computer-Assisted diagnostic Decision Support|
1750435|NCT00188032|Procedure|written diagnostic guidelines|
1750436|NCT00188032|Procedure|electronic therapeutic reminders|
1750438|NCT00188058|Device|Setting of positive end-expiratory pressure|
1750442|NCT00188084|Procedure|DNA Index|
1750443|NCT00188084|Procedure|S-Phase%|
1750444|NCT00188084|Procedure|CD45 expression|
1750445|NCT00188084|Procedure|P16 metabolic way|
1750446|NCT00188097|Behavioral|Diagnosis of variceal bleeding and dits control in cirrhosis|
1750447|NCT00188110|Procedure|Water-Enema Computed Tomography|
1750448|NCT00188136|Drug|Melphalan, ATG, Fludarabine|allo Tx during aplasia
1750449|NCT00188149|Drug|Combined chemotherapy (ABVD, BACOPP-D)|
1750450|NCT00188149|Procedure|Radiation therapy|
1750451|NCT00188162|Device|CT|
1750452|NCT00188175|Radiation|Intensity Modulated Radiation Therapy|Pre-op Intensity Modulated Radiation Therapy for lower limb soft tissue sarcoma.
1750453|NCT00188188|Drug|quinipril|
1750454|NCT00188214|Procedure|contrast-enhanced dynamic CT perfusion study|contrast-enhanced dynamic CT perfusion study pre treatment and post treatment
1750455|NCT00188227|Drug|Midazolam (sedative)|
1750456|NCT00188227|Drug|Piritramid (analgetic)|
1750457|NCT00188227|Behavioral|Cognitive exercises|
1750458|NCT00188240|Drug|Pegasys; Copegus.|
1750459|NCT00188266|Drug|cisplatinum combined with infusional fluorouracil (5 FU)|Continuous 5FU via intravenous PICC line + 4 doses of Cisplatin every 2 weeks
1750460|NCT00188279|Procedure|Minimum Dose Computed Tomography (MnDCT) scan|Minimum Dose Computed Tomography (MnDCT) scan at regular follow up intervals for up to 5 years post-operatively.
1750461|NCT00188305|Behavioral|General health counselling and risk information|General health counselling and risk information
1750462|NCT00188318|Procedure|hyperfractionated accelerated radiotherapy|
1750463|NCT00188331|Behavioral|Neuropsychological Testing|neuropsychological testing with traditional tests, CANTAB and six elements test as well as questionnaires
1750464|NCT00188344|Procedure|pneumatic dilatation|"The patient is on a liquid diet for 2 days prior to procedure. A sedative and pain killer by IV are given and the throat will be sprayed with local anesthetic.
The gastroenterologist may perform an endoscopy prior to the dilatation to safely guide the dilator into position. A special dilator with a small balloon will be passed down the esophagus until it meets the stomach then the balloon will be inflated with air until the narrow part of the esophagus is opened. The patient will then be assessed for any perforation of the esophagus and monitored in the post-procedure unit for a few hours."
1750465|NCT00188344|Procedure|laparoscopic myotomy with partial fundoplication|The abdomen is inflated with gas and cameras and instruments are inserted. The junction between the esophagus and stomach is identified. The muscle of the lower esophageal sphincter is divided. A portion of the stomach wall is secured to the lower esophagus. After surgery the patient is taken to the recovery room and when well enough moved to a ward. The patient may be discharged the following day.
1750466|NCT00188357|Behavioral|Education|
1750467|NCT00188370|Procedure|high frequency ultrasound imaging|
1750468|NCT00188383|Drug|Amantadine|
1750469|NCT00188396|Drug|Citalopram|
1750470|NCT00188409|Procedure|CT scan|
1750471|NCT00188422|Procedure|low dose CT|
1750472|NCT00188435|Procedure|Minimum Dose CT|
1750473|NCT00188448|Device|MRI|
1750474|NCT00188461|Device|CT Thorax|
1750475|NCT00188474|Behavioral|LCADLS, FACIT-PAL, FACIT-TS questionnaires|LCADLS, FACIT-PAL, FACIT-TS questionnaires
1750476|NCT00188487|Device|magnetic resonance imaging (MRI) of the thorax|
1750477|NCT00188500|Behavioral|atkins diet|
1750478|NCT00188500|Behavioral|ability to follow low carbohydrate diet|
1750479|NCT00188513|Procedure|conformal intensity modulated radiotherapy (IMRT)|
1750480|NCT00188526|Device|lung biopsy|
1750481|NCT00188539|Procedure|Pre-treatment tumour oxygen measurements (under anesthesia)|
1750482|NCT00188552|Drug|pentoxifylline|
1750483|NCT00188552|Drug|α-Tocopherol|
1750484|NCT00188565|Drug|Celecoxib|
1750485|NCT00188578|Procedure|Intensity Modulated Radiation Therapy Boost|All patients shall receive a continuous course of IMRT consisting of 25.2 Gy in 14 fractions over 3 weeks
1750486|NCT00188604|Drug|sodium selenite|
1750487|NCT00188617|Drug|GEFITINIB|250 mg once a day for 28 days before surgery
1750488|NCT00188630|Drug|N-acetylcysteine|
1750489|NCT00188630|Other|5% dextrose solution|
1750490|NCT00188643|Drug|Venlafaxine and Lamotrigine|
1750491|NCT00188656|Procedure|CT thorax|
1750492|NCT00188669|Drug|pentoxifylline|
1750493|NCT00188669|Drug|alpha-Tocopherol|
1750494|NCT00188695|Procedure|MRI contrast agent Combidex (ferumoxtran-10)|Combidex as an MR-lymph node contrast agent for the detection of small lymph nodes and lymph metastases.
1750495|NCT00188708|Procedure|hypoxia measurement|transrectal oxygen measurement
1750496|NCT00188747|Procedure|Thromboelastograph, Point of Care|
1750497|NCT00188773|Drug|N-acetylcysteine, intralipid, heparin|One visit subject will receive N-acetylcysteine plus intralipid and heparin, another visit n-acetylcyksteine plus saline, another visit intralipid and heparin and another visit saline alone
1750498|NCT00188786|Procedure|daily Cone Beam CT for imaging guidance for radiotherapy|
1750499|NCT00188799|Procedure|daily Xray volume imaging for planning radiotherapy|
1750500|NCT00188812|Drug|donepezil hcl|
1750501|NCT00188825|Other|placebo|
1750502|NCT00188825|Drug|basiliximab|
1750503|NCT00188838|Behavioral|Psychoeduction|
1750504|NCT00188838|Behavioral|Cognitive-Behavioral Therapy|
1750505|NCT00188851|Drug|therapeutic management strategy|
1750506|NCT00188864|Drug|dexamethasone|
1750507|NCT00188877|Procedure|intensity modulated radiation therapy|
1750508|NCT00188877|Drug|cisplatinium and fluorouracil - standard treatment|
1750509|NCT00188903|Procedure|Diastolic measurements during TEE|Transesophageal echocardiography with diastolic measurements
1750510|NCT00188929|Procedure|PET Scan with [18F]Fluoro-2-deoxyglucose (FDG)|
1750511|NCT00188942|Drug|Fluoxetine+Olanzapine|
1750512|NCT00188942|Drug|Olanzapine|
1750513|NCT00188942|Procedure|Functional Magnetic Resonance Imaging|
1750514|NCT00188955|Drug|sirolimus|
1750515|NCT00188968|Procedure|Nasal Continuous Positive Airway Pressure|
1750516|NCT00188968|Procedure|Synchronized Nasal Positive Pressure Ventilation|
1750517|NCT00188994|Drug|Insulin Cardioplegia|
1750518|NCT00189007|Drug|Allopurinol sodium|Allopurinol sodium 500 mg / 50 mL, intravenously, single dose
1750519|NCT00189007|Drug|Mannitol|Mannitol 500 mg/50 mL water for injection, intravenously, single dose
1750520|NCT00189020|Biological|PCV7|PCV7 at age 2 and 4 months
1750521|NCT00189020|Biological|PCV7|PCV7 at age 2, 4 and 11 months
1750522|NCT00189033|Drug|psyllium fibre (dietary supplement)|
1750523|NCT00189033|Drug|wheat bran (dietary supplement)|
1750524|NCT00189033|Drug|rice wheat (placebo)|
1750525|NCT00189046|Behavioral|driving and laboratory tests|
1750526|NCT00189059|Drug|amitriptyline|
1750527|NCT00189072|Drug|gabapentin|
1750528|NCT00189085|Drug|simvastatin and ezetimibe|
1750529|NCT00189098|Drug|Sulfamethoxazole-trimethoprim|18 mg/kg, two times a day
1750530|NCT00189098|Drug|Placebo|
1750531|NCT00189111|Procedure|Cardiac Imaging + Treatment|
1750532|NCT00189124|Drug|Dehydroepiandrosterone (DHEA)|
1750533|NCT00189137|Drug|ifosfamide and doxorubicin vs gemcitabine and docetaxel|"Arm 1 will consist of the two drug combination of doxorubicin and ifosfamide (with mesna) Treatment will be delivered over 3 days at 21 day intervals. Patients will receive filgrastim days 4-10 or peg-filgrastim on day 4 as a myeloid growth factor.
Arm 2 will consist of the two drug combination of gemcitabine (day 1, 8) and docetaxel (day 8) repeated at 21 day intervals. Patients will receive filgrastim as a myeloid growth factor days 9-15 or peg-filgrastim on day 4.
All patients will receive 4 cycles of chemotherapy unless there is unacceptable toxicity or disease progression that may adversely impact the surgical plan for complete resection."
1750534|NCT00189150|Drug|Mycophenolate mofetil|
1750535|NCT00189150|Drug|Valganciclovir|
1750536|NCT00189163|Drug|Pioglitazone|30 mg, taken orally, once per day, for 48 weeks
1750537|NCT00189163|Drug|Placebo Oral Tablet|Sugar Pill, taken orally, once per day, for 48 weeks
1750538|NCT00189176|Drug|Tetrathiomolybdate|
1750539|NCT00189189|Behavioral|parent management training|
1750540|NCT00189202|Drug|Sirolimus|Thymoglobulin induction, sirolimus and no maintenance corticosteroid
1750541|NCT00189215|Device|cardiac stabilizer instead of cardiopulmonary bypass|
1750543|NCT00189241|Drug|imiquimod|
1750544|NCT00189254|Drug|Imiquimod|No defined treatments were given during this study.
1750545|NCT00189267|Drug|Imiquimod 5 % Cream|
1750546|NCT00189280|Drug|Imiquimod|cream 5%, 5 days out of seven, for 6 weeks
1750547|NCT00189293|Drug|Imiquimod|"Imiquimod 5% cream three times per week for 4 weeks (1 sachet)
1 or 2 sachet(s)"
1750548|NCT00189293|Other|vehicle cream|"vehicle cream three times per week for 4 weeks (1 sachet)
1 or 2 sachet(s)"
1750549|NCT00189306|Drug|Imiquimod 5% cream|Aldara (imiquimod) 5% cream - 250 mg / packet - once daily 7 days per week for 6 weeks
1750550|NCT00189319|Drug|Flecainide controlled release|
1750551|NCT00189332|Drug|852A|
1750552|NCT00189345|Biological|anti-EpCAM x anti-CD3 (removab)|
1750553|NCT00189358|Drug|ZD1839|
1750554|NCT00189358|Drug|tamoxifen|
1750555|NCT00189371|Drug|paclitaxel, carboplatin, epoetin alpha|
1750556|NCT00189384|Drug|ceftriaxone, procaine penicillin and gentamicin, oral cotrimoxazole and gentamicin|
1750557|NCT00189397|Drug|azathioprine and corticosteroids for Parthenium dermatitis|
1750558|NCT00189410|Drug|Pegylated Liposomal Doxorubicin and Carboplatin|
1750559|NCT00189423|Device|Use of an impedance threshold device (ITD) during the performance of active compression decompression CPR (ACD-CPR)|"The ITD selectively prevents the influx of unnecessary respiratory gases into the patient during the chest wall recoil phase of CPR.
The ResQPump, a hand-held device containing a suction cup, attaches to the chest and actively compresses and actively re-expands the chest during the performance of CPR."
1750560|NCT00189423|Procedure|Standard cardiopulmonary resuscitation (S-CPR)|Conventional standard cardiopulmonary resuscitation (S-CPR)
1750561|NCT00189436|Drug|Nebulized Budesonide|Subject is treated with nebulized budesonide 0.5 BID for 3 weeks
1750562|NCT00189436|Drug|Usual care (albuterol with or without oral steroid)|Subject is treated with usual care as prescribed by the doctor (normally albuterol with or without oral steroid)
1750563|NCT00189462|Drug|Montelukast|
1750564|NCT00189475|Drug|Montelukast|
1750565|NCT00189488|Drug|Palifermin|Administered as an intravenous (IV) bolus.
1750566|NCT00189488|Drug|Placebo|Administered as an intravenous (IV) bolus.
1750567|NCT00189488|Other|Conditioning Regimen|"Each participant received 1 of the following conditioning regimens:
Cyclophosphamide (Cy) / total body irradiation (TBI) with and without etoposide (VP-16)
TBI/VP-16
Melphalan (Mel)/TBI (TBI regimens must include fully ablative doses ie > 1100 cGy; sequence of chemotherapy/radiation (CT/RT) flexible)
Busulfan (Bu)/Cy
Bu/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])
Fludarabine (Flu)/Mel (non-TBI but fully ablative regimens/doses [Mel dose > 140 mg/m^2])"
1750568|NCT00189488|Procedure|Allogeneic stem cell transplant|Allogeneic marrow/peripheral blood progenitor cell transplantation
1750569|NCT00189488|Drug|Methotrexate|
1750570|NCT00189501|Drug|Sensipar®|
1750571|NCT00189514|Drug|pramlintide acetate|Subcutaneous injection, twice a day or three times a day, at doses of 120mcg, 240mcg, or 360mcg
1750572|NCT00189514|Drug|placebo|subcutaneous injection, three times a day, volumes equivalent to 120mcg, 240mcg, or 360mcg of pramlintide acetate
1750573|NCT00189527|Procedure|respiratory settings|
1750576|NCT00189553|Drug|Pegylated liposomal doxorubicin|30 mg/m² every 4 weeks during 6 cycles or until progression
1750577|NCT00189553|Drug|Carboplatin|AUC 5 every 3/4 weeks during 6 cycles or until progression
1750578|NCT00189553|Drug|Paclitaxel|175 mg/m² at day 1 every 3 weeks during 6 cycles or until progression
1750579|NCT00189566|Drug|Paclitaxel|
1750580|NCT00189566|Drug|Topotecan|
1750581|NCT00189566|Drug|Carboplatin|
1750582|NCT00189579|Drug|Herceptin|
1750583|NCT00189592|Device|ArthroCare TOPAZ™ MicroDebrider™ using Coblation|Percutaneous treatment of plantar fascia using the Topaz device. No incision performed.
1750584|NCT00189592|Procedure|Surgical Fasciotomy|Standard surgical fasciotomy using an incision to treat the plantar fascia.
1750585|NCT00189605|Device|Perc-DLR/Perc-DLG|Device technique will be used per IFU
1750586|NCT00189605|Drug|Fluoroscopy guided transforaminal epidural steroid injection (TFESI)|Injection of steroid solution into the lumbar level
1750587|NCT00189618|Drug|Aspirin|100mg p.o. OD
1750588|NCT00189618|Drug|Clopidogrel|75mg p.o. OD
1750589|NCT00189631|Procedure|UFT/LV|
1750590|NCT00189631|Procedure|Observation|
1750591|NCT00189644|Procedure|6 FEC 100|
1750592|NCT00189644|Procedure|4 FEC 100 followed by 4 Taxol|
1750593|NCT00195208|Drug|Pantoprazole for approximately 9 weeks|
1750594|NCT00195234|Biological|HIV CTL MEP 1000 micrograms, 19 months per subject|
1750595|NCT00195247|Drug|TTI-237|
1750596|NCT00195260|Drug|bosutinib|Dose levels evaluated 50mg, 100mg, 200mg, 300mg, 400mg, 500mg and 600mg. 500mg was identified as MTD, however due to GI toxicities at that dose, 400mg was selected as the RP2D. Drug was administered as long as tolerable and disease under study did not worsen.
1750597|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
1750598|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
1750599|NCT00195260|Drug|bosutinib|400mg QD bosutinib, as long as tolerated and disease under study does not worsen.
1750600|NCT00195273|Drug|sirolimus|15 mg loading dose, followed by 5 mg/day to achieve target trough levels of 10-15 ng/mL at months 1-6, then 8-12 ng/mL at months 7-12
1750601|NCT00195273|Drug|cyclosporine|Initial dose of 10 mg/kg/day, then twice daily to achieve target trough levels of 300-400 ng/mL at weeks 0-4; 200-300 ng/mL at months 1-2; 150-250 ng/mL at months 2-3; 100-200 ng/mL at months 3-6; 75-150 ng/mL months 6-12
1750602|NCT00195273|Drug|mycophenolate mofetil|1 g twice daily; may be reduced to 750 mg BID for adverse events, or to 500 mg BID for persisting adverse events
1750603|NCT00195273|Drug|corticosteroids|As per center practice. By day 8 prednisolone tapered to 20 mg/day; by day 30 to 15 mg/day; by day 60 to 10 mg/day; after 4 to 6 months to 5-7.5 mg/day
1750604|NCT00195273|Drug|daclizumab|IV: 1 mg/kg to a maximum of 100 mg/dose. 5 doses at 2, 4, 6, and 8 weeks after transplantation
1750605|NCT00195286|Drug|piperacillin/tazobactam|
1750606|NCT00195299|Drug|Temsirolimus|
1750607|NCT00195312|Biological|HIV-1 gag DNA (formulated with bupivacaine)|
1750608|NCT00195312|Biological|IL-15 DNA (formulated with bupivacaine)|
1750609|NCT00195312|Biological|IL-12 DNA (formulated with bupivacaine)|
1750610|NCT00195312|Biological|Sodium chloride injection USP (0.9%)|
1750611|NCT00195325|Drug|TTI-237|
1750612|NCT00195338|Drug|etanercept|
1750613|NCT00195351|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
1750614|NCT00195351|Drug|ceftriaxone sodium + metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
1750615|NCT00195364|Drug|Etanercept|
1750616|NCT00195377|Drug|Etanercept|
1750617|NCT00195390|Biological|Prevenar|Prevenar 0.5ml/ Vial and PFS
1750618|NCT00195403|Drug|Etanercept|Etanercept 25mg Injection, 2 times/week
1750619|NCT00195416|Drug|Etanercept|Etanercept 25mg Injection, 2 times/week
1750620|NCT00195429|Drug|Tacrolimus|
1750621|NCT00195429|Drug|Sirolimus|
1750622|NCT00195429|Drug|prednisone|
1750623|NCT00195442|Drug|Moroctocog alfa|Patients will be treated in accordance with the requirements of the labeling of ReFacto (Moroctocog alfa) in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
1750624|NCT00195455|Drug|Trimegestone|
1750625|NCT00195455|Drug|17b Estradiol|
1750626|NCT00195468|Drug|CYCLOSPORINE|
1750627|NCT00195481|Drug|Rapamune|
1750628|NCT00195494|Drug|Etanercept|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2
Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2
Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
1750629|NCT00195494|Drug|Methotrexate|"Group 1a: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 & 2
Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2
Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2
Group 2b: Oral Methotrexate weekly for both Periods 1 and 2"
1750630|NCT00195494|Drug|Placebo|"Group 1b: Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 1 then Etanercept 50 mg SC injections weekly + Placebo weekly for Period 2
Group 2a: Oral Methotrexate weekly + Placebo for Period 1, then Etanercept 50 mg SC injections weekly + oral Methotrexate weekly for Period 2"
1750631|NCT00195507|Drug|Etanercept|
1750632|NCT00195520|Drug|Totelle®|
1750633|NCT00195533|Drug|piperacillin-tazobactam|
1750634|NCT00195533|Drug|glycopeptide|
1750635|NCT00198887|Procedure|Operations research|
1750636|NCT00198900|Behavioral|survey of information|
1750637|NCT00198913|Behavioral|lower fat food supplied and education|
1750638|NCT00198913|Behavioral|gift cards for grocery foods and written education|
1750639|NCT00198926|Behavioral|covert v overt nutrition labeling|
1750640|NCT00198926|Behavioral|varying meal nutrition manipulation|
1750641|NCT00198939|Behavioral|Integrated Family and Cognitive-Behavioral Drug Prevention Intervention|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
1750642|NCT00198939|Other|Psychoeducation|Drug education curriculum was delivered to participants assigned to this condition.
1750643|NCT00198952|Drug|DietPro|
1750644|NCT00198952|Drug|Placebo|
1750645|NCT00198965|Behavioral|dietary education|
1750646|NCT00198965|Behavioral|dietary education and provided full fat snack foods|
1750647|NCT00198965|Behavioral|dietary education and provided fat free snack foods|
1750648|NCT00198978|Drug|Cyclophosphamide|
1750649|NCT00198978|Drug|Dexamethasone / Prednisolone|
1750650|NCT00198978|Drug|Cytarabine|
1750651|NCT00198978|Drug|Idarubicin|
1750652|NCT00198978|Drug|Granulocyte-Colony-Stimulating Factor|
1750653|NCT00198978|Drug|Mercaptopurine|
1750654|NCT00198978|Drug|Methotrexate|
1750655|NCT00198978|Drug|Rituximab|
1750656|NCT00198978|Drug|HDARAC|
1750657|NCT00198978|Drug|Vincristine|
1750658|NCT00198978|Drug|Depocyte|
1750659|NCT00198978|Drug|Asparaginase|
1750660|NCT00198991|Drug|Cyclophosphamide|
1750661|NCT00198991|Drug|Dexamethasone|
1750662|NCT00198991|Drug|Vincristine|
1750663|NCT00198991|Drug|daunorubicin|
1750664|NCT00198991|Drug|Asparaginase|
1750665|NCT00198991|Drug|Methotrexate|
1750666|NCT00198991|Drug|Cytarabine|
1750667|NCT00198991|Drug|Mercaptopurine|
1750668|NCT00198991|Drug|G-CSF|
1750669|NCT00198991|Drug|Vindesine|
1750670|NCT00198991|Drug|VP16|
1750671|NCT00198991|Drug|Prednisolone|
1750672|NCT00198991|Drug|Adriamycin|
1750673|NCT00198991|Drug|Thioguanine|
1750674|NCT00198991|Drug|VM26|
1750675|NCT00198991|Procedure|CNS irradiation|
1750676|NCT00198991|Procedure|Mediastinal Irradiation|
1750677|NCT00198991|Procedure|Stem cell transplantation|
1750678|NCT00198991|Drug|Idarubicin|
1750679|NCT00198991|Drug|Fludarabine|
1750680|NCT00198991|Drug|Cladribine|
1750681|NCT00199004|Drug|Cyclophosphamide|
1750682|NCT00199004|Drug|Dexamethasone / Prednisolone|
1750683|NCT00199004|Drug|Vincristine|
1750684|NCT00199004|Drug|Daunorubicin|
1750685|NCT00199004|Drug|Asparaginase|
1750686|NCT00199004|Drug|Methotrexate|
1750687|NCT00199004|Drug|Cytarabine|
1750688|NCT00199004|Drug|Mercaptopurine|
1750689|NCT00199004|Drug|G-CSF|
1750690|NCT00199004|Drug|Vindesine|
1750691|NCT00199004|Drug|VP16|
1750692|NCT00199004|Drug|Adriamycin|
1750693|NCT00199004|Drug|Thioguanine|
1750694|NCT00199004|Drug|VM26|
1750695|NCT00199004|Drug|Rituximab|
1750696|NCT00199004|Procedure|CNS irradiation|
1750697|NCT00199004|Procedure|Mediastinal irradiation (if residual TU)|
1750698|NCT00199004|Procedure|Stem cell transplantation|
1750699|NCT00199017|Drug|Dexamethasone/Prednisolone|
1750700|NCT00199017|Drug|Cyclophosphamide|
1750701|NCT00199017|Drug|Vincristine|
1750702|NCT00199017|Drug|Daunorubicin|
1750703|NCT00199017|Drug|Asparaginase|
1750704|NCT00199017|Drug|G-CSF|
1750705|NCT00199017|Drug|Mercaptopurine|
1750706|NCT00199017|Drug|Cytarabine|
1750707|NCT00199017|Drug|Methotrexate|
1750708|NCT00199017|Drug|VP16|
1750709|NCT00199017|Drug|Vindesine|
1750710|NCT00199017|Drug|Adriamycin|
1750711|NCT00199017|Drug|Thioguanine|
1750712|NCT00199017|Drug|HDARAC|
1750713|NCT00199017|Procedure|CNS irradiation|
1750714|NCT00199017|Procedure|Mediastinal irradiation|
1750715|NCT00199017|Drug|Cladribine|
1750716|NCT00199030|Drug|Alemtuzumab (MabCampath)|
1750717|NCT00199030|Drug|Cladribine|
1750718|NCT00199043|Drug|Allopurinol|
1750719|NCT00199043|Drug|Rasburicase|
1750720|NCT00199056|Drug|Dexamethasone / Prednisolone|
1750721|NCT00199056|Drug|Cyclophosphamide|
1750722|NCT00199056|Drug|Methotrexate|
1750723|NCT00199056|Drug|Vincristine / Vindesine|
1750724|NCT00199056|Drug|Daunorubicin|
1750725|NCT00199056|Drug|Asparaginase|
1750726|NCT00199056|Drug|G-CSF|
1750727|NCT00199056|Drug|Cytarabine|
1750728|NCT00199056|Drug|6-Mercaptopurine|
1750729|NCT00199056|Drug|VP16|
1750730|NCT00199056|Drug|Adriamycin|
1750731|NCT00199056|Drug|Thioguanine|
1750732|NCT00199056|Drug|VM26|
1750733|NCT00199056|Drug|Idarubicin|
1750734|NCT00199056|Drug|Fludarabine|
1750735|NCT00199056|Drug|Ifosfamide|
1750736|NCT00199056|Procedure|CNS irradiation|
1750737|NCT00199056|Procedure|Mediastinal irradiation (if residual tumor)|
1750738|NCT00199056|Procedure|stem cell transplantation|
1750739|NCT00199069|Drug|Asparaginase|
1750740|NCT00199069|Drug|Vincristine|
1750741|NCT00199069|Drug|Daunorubicin, Adriamycin|
1750742|NCT00199069|Drug|Cyclophosphamide|
1750743|NCT00199069|Drug|Ifosfamide|
1750744|NCT00199069|Drug|Cytarabine|
1750745|NCT00199069|Drug|Mitoxantrone|
1750746|NCT00199069|Drug|Methotrexate|
1750747|NCT00199069|Drug|6-Mercaptopurine|
1750748|NCT00199069|Drug|6-Thioguanine|
1750749|NCT00199069|Drug|VM26|
1750750|NCT00199069|Drug|Dexamethasone / Prednisolone|
1750751|NCT00199069|Procedure|CNS Irradiation|
1750752|NCT00199069|Procedure|Mediastinal Irradiation|
1750753|NCT00199069|Procedure|Stem Cell Transplantation|
1750754|NCT00199082|Drug|Adriamycin|
1750755|NCT00199082|Drug|Cyclophosphamide|
1750756|NCT00199082|Drug|Cytarabine|
1750757|NCT00199082|Drug|Dexamethasone/Prednisolone|
1750758|NCT00199082|Drug|VP16|
1750759|NCT00199082|Drug|Ifosfamide|
1750760|NCT00199082|Drug|Methotrexate|
1750761|NCT00199082|Drug|G-CSF|
1750762|NCT00199082|Drug|Rituximab|
1750763|NCT00199082|Drug|Vincristine/Vindesine|
1750764|NCT00199082|Procedure|Irradiation (in specific conditions)|
1750765|NCT00199095|Drug|Adriamycin|
1750766|NCT00199095|Drug|Cyclophosphamide|
1750767|NCT00199095|Drug|Cytarabine|
1750768|NCT00199095|Drug|Dexamethasone|
1750769|NCT00199095|Drug|Idarubicin|
1750770|NCT00199095|Drug|Ifosfamide|
1750771|NCT00199095|Drug|Methotrexate|
1750772|NCT00199095|Drug|Mercaptopurine|
1750773|NCT00199095|Drug|VM26|
1750774|NCT00199095|Drug|Vincristine|
1750775|NCT00199108|Drug|Depocyt|
1750776|NCT00199108|Drug|Dexamethasone|
1750777|NCT00199121|Drug|Zidovudine (drug)|
1750778|NCT00199134|Drug|Letrozole|Size of the tumor is followed
1750779|NCT00199147|Drug|Cytarabine|
1750780|NCT00199147|Drug|Etoposide|
1750781|NCT00199147|Drug|Idarubicin|
1750782|NCT00199147|Drug|G-CSF|
1750783|NCT00199147|Drug|Fludarabine|
1750784|NCT00199147|Procedure|Stem cell apheresis|
1750785|NCT00199147|Procedure|Stem cell transplantation|
1750786|NCT00199160|Drug|BAY 43-9006|
1750787|NCT00199173|Device|SIR Spheres intra-arterial hepatic|
1750788|NCT00199186|Drug|imatinib|
1750789|NCT00199186|Drug|vincristine|
1750790|NCT00199186|Drug|cyclophosphamide|
1750791|NCT00199186|Drug|cytosine arabinoside|
1750792|NCT00199186|Drug|dexamethasone|
1750793|NCT00199186|Drug|idarubicin|
1750794|NCT00199186|Drug|methotrexate (intrathecal)|
1750795|NCT00199186|Drug|AraC (intrathecal)|
1750796|NCT00199186|Drug|dexamethasone (intrathecal)|
1750797|NCT00199212|Drug|Combination of trastuzumab and PS-341|Trastuzumab and velcade are used according standard procedure
1750798|NCT00199225|Drug|Rupatadine|
1750799|NCT00199225|Drug|moxifloxacin|
1750800|NCT00199225|Procedure|Continous electrocardiographic register|
1750801|NCT00199225|Procedure|Pharmacokinetic profile|
1750802|NCT00199238|Drug|RUPATADINE (ANTI-HISTAMINE)|
1750803|NCT00199251|Drug|RUPATADINE|
1750804|NCT00199264|Drug|Albaconazole oral solution|
1750805|NCT00199277|Drug|i.v. iron sucrose|
1750806|NCT00199277|Drug|Oral iron|
1750807|NCT00199290|Drug|Trafermin (genetical recombination)|
1750808|NCT00199303|Drug|pre-operatively followed by 30 mg three times per day after surgery|
1750809|NCT00199316|Drug|spinal morphine|
1750810|NCT00199329|Drug|ondansetron adding in PCA|
1750811|NCT00199342|Drug|KW-2871|potentially therapeutic monoclonal antibody for the treatment of advanced stage four melanoma
1750812|NCT00199355|Drug|Istradefylline (KW-6002)|
1750813|NCT00199368|Drug|Istradefylline ( KW-6002)|
1750814|NCT00199381|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily.
1750815|NCT00199394|Drug|Istradefylline (KW-6002)|
1750816|NCT00199407|Drug|Istradefylline (KW-6002)|
1750817|NCT00199420|Drug|Istradefylline (KW-6002)|
1750818|NCT00199433|Drug|Istradefylline (KW-6002)|
1750819|NCT00199446|Drug|Istradefylline (KW-6002)|
1750820|NCT00199472|Procedure|Dynamic Contrast Enhanced CT & Diuretic Renogram|
1750821|NCT00199485|Drug|Angelica Sinensis|Angelica Sinensis / placebo
1750822|NCT00199498|Device|Apical RV lead placement|RV lead implanted ( according to randomization )at the apex
1750823|NCT00199498|Device|Septal RV lead placement|RV lead is implanted (according to randomization), on septum
1750824|NCT00199511|Drug|Administration of Hypertonic Solution 7.5% vs Mannitol 20%|
1750825|NCT00199524|Device|Navigator Ureteral Access Sheath|ureteral access sheath
1750826|NCT00199550|Procedure|Bipolar Transurethral Resection of the Prostate|Bipolar TURP
1750827|NCT00199550|Procedure|Monopolar Transurethral Resection of the Prostate|Monopolar TURP
1750828|NCT00199563|Drug|Viagra|Sildenafil 100mg daily for 12 weeks
1750829|NCT00199576|Drug|Methylprednisolone|
1750830|NCT00199589|Drug|Botulinic toxin (Botox)|Patients may benefit, depending on the draw, in addition to their orthosis, intramuscular injections of botulinum toxin.These injections are among 6 in the muscles posterior (rear) of the leg paralyzed with tracking electromyographic to ensure the accuracy of the injection.
1750831|NCT00199602|Drug|warfarine - low molecular heparin|
1750832|NCT00199615|Procedure|PET|Intravenous injection of glucose labeled Fluor 18.Le patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during which the patient should not move.
1750833|NCT00199641|Device|enteral nutrition|
1750835|NCT00199667|Drug|Mycophenolate Mofetil|
1750836|NCT00199680|Procedure|PET|
1750837|NCT00199706|Drug|7.2% NaCl in 6% hydroxyethyl starch solution|
1750838|NCT00199719|Drug|Ribavirine|
1750839|NCT00199745|Drug|atorvastatin|
1750840|NCT00199758|Drug|cisplatin|
1750841|NCT00199758|Drug|Gemcitabine|
1750842|NCT00199758|Drug|Taxol|
1750843|NCT00199771|Drug|7.5% NaCl in 6% dextran 70 solution|
1750844|NCT00199784|Drug|Phenylephrine|
1750845|NCT00199797|Drug|huA33 antibody plus chemotherapy|"huA33 will be administered intravenously over a period of 30 minutes once a week at a dose of 10 mg/m2. Every second week, Oxaliplatin, 5-FU and Leucovorin are administered additionally. Oxaliplatin and Leucovorin will be given as an infusion over 2 hours. Afterwards patients will receive an bolus infusion of 5-FU intravenously followed by an infusion of 5-FU over 22 hours.
The doses of Oxaliplatin will be 85mg/m2, Leucovorin 200mg/m2, 400mg/m2 of 5-FU as an bolus infusion and 600mg/m2 as an continuous infusion. A complete treatment cycle consists of 12 weekly treatment days."
1750846|NCT00199823|Genetic|Intracoronary aotologous stem cell transplantation|
1750847|NCT00199836|Biological|NY-ESO-1b peptide plus CpG 7909 and Montanide ISA-51|
1750848|NCT00199849|Biological|NY-ESO-1 plasmid DNA Cancer Vaccine|
1750849|NCT00199862|Drug|Iodine-124 labeled humanized A33 (antibody)|Patients will receive a single intravenous or intraarterial infusion of 10mg huA33, labeled with 4mCi-10mCi of 124I in 5-30ml of 5% HSA in normal saline (NS), over 5-10 minutes. On study days 2, 3, and/or 4 patients will have the option to receive up to 2g/kg of IVIG. Patients will be evaluated with 124I-huA33 positron-emission tomography (PET) with ex vivo quantitation of tumor uptake.
1750850|NCT00199875|Drug|Yttrium-90 conjugated chimeric G250 (90Y-cG250)|
1750851|NCT00199888|Drug|124-Iodine-cG250 (124I-cG250)|
1750852|NCT00199901|Biological|NY-ESO-1 ISCOMATRIX®|"100 μg of NY-ESO-1 protein formulated with 120 μg of ISCOMATRIX® adjuvant.
Each patient will receive four intramuscular injections of either NY-ESO-1 ISCOMATRIX® vaccine or ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
1750853|NCT00199901|Biological|ISCOMATRIX® adjuvant|"120 μg of ISCOMATRIX® alone.
Each patient will receive four intramuscular injections of either NY-ESO-1 ISCOMATRIX® vaccine or ISCOMATRIX® adjuvant alone. The first three doses will be given at four-week intervals, days 1, 29, and 57, (± 3 days of scheduled date). The fourth injection will be given at month 6 (day 183 ± 3 days)."
1750854|NCT00199914|Device|Shortwave diathermy|continuous shortwave diathermy, 20 min/session, 3 sessions/week for 3 weeks
1750855|NCT00199927|Drug|Fluvastatin|Starting dose of Fluvastatin of 40 mg/day uptitrated to 80 mg/day
1750856|NCT00199927|Drug|standard therapy|standard therapy
1750857|NCT00199940|Drug|Ziprasidone|
1750858|NCT00199953|Drug|Rabeprazole 20 mg twice a day for 90-day period treatment|
1750859|NCT00199966|Drug|Divalproex sodium extended release|
1750860|NCT00199979|Drug|Nevirapine|
1750861|NCT00199992|Procedure|application of autologous platelet gel|
1750862|NCT00200005|Device|Type: Implantable neurostimulator; InterStim|Treatment with InterStim Therapy: all patients meeting inclusion/exclusion criteria undergo test screening and those who have successful outcomes receive a permanent implant.
1750863|NCT00200018|Device|Enterra Therapy System (H9900014)|
1750864|NCT00200031|Device|Interstim therapy|
1750865|NCT00200044|Device|Gatekeeper Reflux Repair System|The Gatekeeper System™ consists of a specialized 16-mm overtube assembly, a 2.4-mm diameter prosthesis delivery system (1-mm diameter needle, dilator, and 2.4-mm diameter sheath), a pushrod assembly and Gatekeeper Prosthesis. Up to 4 prostheses will be implanted at the initial procedure and retreatment with up to four more prostheses will be allowed at 3-months if the subject has a GERD HRQL score >15.
1750866|NCT00200057|Device|InterStim Sacral Nerve Stimulation Therapy|Open label study. All subjects that qualify for the study will be implanted.
1750867|NCT00200070|Device|Spinal Cord Stimulation|
1750868|NCT00200083|Device|Transcend II Model 8848|"All subjects will be implanted with the IGS device and then randomized to on or off for 12 months. After 12 months all subjects will be turned on through 24 month follow up."
1750869|NCT00200096|Procedure|Acupuncture and questionnaires|"Acupuncture once weekly for six weeks Brief Fatigue Inventory, Hospital Anxiety and Depression Scale, Functional Assessment of Cancer Treatment scale. Patients will repeat the BFI and FACT-G at seven and eight weeks after randomization, approximately one and two weeks after their final treatment. HADS will be repeated at week seven. At the end of the study, patients will be asked to state whether they were thought they on true or placebo acupuncture and why.
On the day of the final session of acupuncture treatment (approximately day 35), blood samples will be collected and tested for hemoglobin, thyroid function tests, as described in pretreatment evaluation. The results will be designated posttreatment values. Actigraphic monitoring will be conducted in week seven. Patients will be asked to wear the device for seven days just like during baseline evaluation."
1750870|NCT00200096|Procedure|placebo acupuncture|"During the placebo phase, placebo acupuncture needles (68) will be applied a few mm away from the points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. However, the needle does not penetrate the skin and instead moves upward inside the handle. Needles will be applied after sterile swabbing of the skin and kept in place for 20 minutes in both group.Patients in the placebo group will be offered true acupuncture after receipt of the week seven and eight fatigue diaries.
Patients will complete the BFI, HADS and FACT-G at baseline, approximately two weeks before randomization and their first treatment. The BFI and FACT-G will be repeated after seven days, that is, one week before randomization. The use of repeat measurement decreases intrapatient variability and hence increases the precision of the baseline measure."
1750871|NCT00200109|Device|Occipital Nerve Stimulation|Each group had a different plan
1750872|NCT00200122|Device|Spinal Cord Stimulation|
1750920|NCT00200577|Drug|TIL + IL2|Patients are treated with 2 injections Of TIL (1st injection M1 and the second M2)The received concomitant IL2 at M1 and M2 on days Jo (injection TIL) to J5 and J8 to J12
1750921|NCT00200590|Drug|acetaminophen and nalbuphine|
1750922|NCT00200590|Drug|acetaminophen and morphine|
1750923|NCT00200590|Drug|acetaminophen and reduced dosage of prostaglandin|
1750873|NCT00200148|Procedure|Normovolemic Hemodilution (ANH)|For those patients randomized to ANH, the pre-calculated volume of blood will be withdrawn to a target hemoglobin of 8.0 - 8.5 g/dl (maximum of 3 L) using the formula VL=EBV x (HO-HF)/Hav, as above. The removed blood will be stored in a standard citrate-phosphate-dextrose buffer solution in blood storage bags in the operating room. During removal of blood, colloid and crystalloid solutions will be administered via peripheral intravenous lines in order to maintain euvolemia. For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.For patients randomized to ANH, autologous blood will be re-infused in the reverse order from which it was removed, and allogeneic blood will given only after all autologous blood has been given.
1750874|NCT00200148|Procedure|Standard of care|An 8.5 French central venous catheter and an arterial line will be placed in all patients. If the patient has a central line already in place, this may be used in place of the 8.5 French internal jugular catheter. Continuous monitoring of heart rate, blood pressure, ECG (II, V5), CVP, end tidal CO2, oxygen saturation, temperature and urine output will be performed for all patients.For all hepatic resections, standard low CVP anesthetic management will be employed.For all patients, arterial blood will be sampled every 30 minutes during the resection for assessment of arterial blood gases/pH; Hgb levels will be measured every 30 minutes.All patients will receive standard postoperative management. Routine laboratory studies, including comprehensive panel, CBC and coagulation profile, will be obtained daily in the post-operative period.
1750875|NCT00200161|Drug|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 then Temozolomide 50mg/m2 will be given to patients on days 1-28 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
1750876|NCT00200161|Drug|Temozolomide|Focal RT 6000 cGy/ Temozolomide 75 mg/m2 plus Temozolomide 150 mg/m2 will be given to patients on days 1-7 and 15-21 of each 28 day cycle. Maintenance cis-retinoic acid. This therapy will start at the completion of 6 cycles of adjuvant temozolomide in all patients who have had no clinical or radiographic evidence of tumor progression.Treatment will continue in 28 day cycles until tumor progression.
1750877|NCT00200174|Drug|Raloxifene followed by combination therapy|Patients will be randomized to either Raloxifene at 60mg P.O. (each day) for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
1750878|NCT00200174|Drug|Exemestane followed by combination therapy|Patients will be randomized to Exemestane at 25mg P.O. for 2 weeks (time designated: week- 2) After two weeks of single agent therapy, patients will be started on combination therapy with oral raloxifene (60mg/day) and oral exemestane (25mg/day) (time designated week 0), and continued on both drugs for one year (month 12). Patients will be required to start supplemental calcium (900-1500 mg/day) plus vitamin D (400-600 units/day) P.O. each day during week 0.
1750879|NCT00200187|Procedure|low venous pressure general anesthesia|
1750880|NCT00200187|Procedure|combined spinal-epidural anesthesia|
1750881|NCT00200200|Drug|Bevacizumab HAI plus systemic chemotherapy|Oxaliplatin (mg/m2) IV, over 2 hours, 5 FU (mg/m2) continuous infusion, over two days, leucovorin (mg/m2) IV, over 2 hours
1750882|NCT00200200|Drug|HAI plus systemic chemotherapy|Irinotecan (mg/m2) IV, over 30 minutes, 5 FU (mg/m2) continuous infusion over two days, leucovorin (mg/m2) IV, over 30 minutes
1750883|NCT00200213|Behavioral|portion or unportioned food|
1750884|NCT00200226|Drug|misoprostol|misoprostol 400mcg 12 hrs prior to procedure
1750885|NCT00200226|Drug|vitamin B6|Vitamin B6 50 mg orally 12 hrs prior to procedure
1750886|NCT00200239|Behavioral|Eating breakfast with portion and unportioned foods|Behavioral: eating breakfast with portion and unportioned foods
1750887|NCT00200252|Drug|oxytocin|
1750888|NCT00200265|Behavioral|diet|diet
1750889|NCT00200278|Behavioral|PROJECT STRIDE|
1750890|NCT00200291|Behavioral|hypocaloric, low-fat diet|hypocaloric, low-fat diet
1750891|NCT00200304|Behavioral|Internet weight loss with SlimFast and human counseling|
1750892|NCT00200304|Behavioral|Internet weight loss with SlimFast and computer counseling|
1750893|NCT00200304|Behavioral|Internet weight loss program with SlimFast|
1750894|NCT00200317|Behavioral|Internet and print-based interventions|
1750895|NCT00200330|Behavioral|Behavioral weight loss treatment|
1750896|NCT00200330|Behavioral|Behavioral and home environment weight loss treatment|
1750897|NCT00200343|Drug|Ursodeoxycholic acid 150mg / day|Ursodeoxycholic acid, 150mg/ day, three times a day at meals
1750898|NCT00200343|Drug|Ursodeoxycholic acid 600mg / day|Ursodeoxycholic acid, 600mg/ day, three times a day at meals
1750899|NCT00200343|Drug|Ursodeoxycholic acid 900mg / day|Ursodeoxycholic acid, 900mg/ day, three times a day at meals
1750900|NCT00200356|Drug|Edaravone|Edaravone, at 30 mg, is intravenously administered by drip over 30 minutes b.i.d., in the morning and the evening.
1750901|NCT00200356|Drug|Sodium Ozagrel|Sodium Ozagrel, at 80 mg, is intravenously administered by drip over 2 hours b.i.d., in the morning and the evening.
1750902|NCT00200369|Device|MEMS cap|
1750903|NCT00200382|Drug|PS-341 (Velcade-drug)|
1750904|NCT00200395|Drug|Erlotinib (drug)|
1750905|NCT00200421|Drug|Nebivolol and Atenolol|
1750906|NCT00200434|Drug|Nebivolol|
1750907|NCT00200447|Drug|carbidopa/l-dopa|
1750908|NCT00200447|Drug|carbidopa/l-dopa/entacapone|
1750909|NCT00200447|Drug|Stalevo|
1750910|NCT00200447|Procedure|[123I]-IBZM imaging|
1750911|NCT00200460|Drug|Nebivolol|
1750912|NCT00200473|Drug|Nebivolol|
1750913|NCT00200499|Drug|Nebivolol|
1750914|NCT00200512|Drug|apomorphine HCl injection|
1750915|NCT00200525|Drug|apomorphine HCl injection|
1750916|NCT00200538|Drug|memantine|
1750917|NCT00200551|Drug|Cyclosporin, mycophenolate mofetil, antilymphocyte serum and corticoids.|
1750918|NCT00200551|Drug|Cyclosporin, mycophenolate mofetil, antilymphocyte serum without corticoids.|
1750919|NCT00200564|Drug|ketamine|
1750924|NCT00200603|Device|calcium phosphate macroporous bioceramics|
1750925|NCT00200616|Procedure|Antimicrobial prophylaxis|
1750926|NCT00200629|Procedure|Adenosine SPECT myocardial perfusion imaging|
1750927|NCT00200629|Procedure|Combined adenosine / exercise SPECT myocardial perfusion imaging|
1750928|NCT00200642|Device|Stretta® System|
1750929|NCT00200655|Drug|Pravastatin|
1750930|NCT00200655|Drug|Placebo|
1750931|NCT00200668|Drug|FDG = fluorodeoxyglucose|
1750932|NCT00200681|Drug|Velcade|
1750933|NCT00200694|Drug|ramipril 5 mg + valsartan 80 mg/day,|
1750934|NCT00200694|Drug|ramipril 10 mg + valsartan 160 mg/day,|
1750935|NCT00200694|Drug|ramipril 5 mg + valsartan 80 mg/day + increased dosage of furosémide.|
1750936|NCT00200707|Procedure|Intracoronary injection of autologous bone marrow mononuclear cells|
1750937|NCT00200720|Behavioral|Atkins diet (low carbohydrate diet)|
1750938|NCT00200720|Behavioral|DASH diet (high carbohydrate diet)|
1750939|NCT00200746|Drug|Arginine|Amino Acid Arginine
1750940|NCT00200759|Drug|Cranberry juice and capsules|
1750941|NCT00200785|Dietary Supplement|garlic powder added to ambient water|consumed 2.7 grams of garlic powder added to ambient water (equivalent to 8 grams fresh or raw garlic) in a sandwich, once a day for four weeks
1750942|NCT00200785|Dietary Supplement|garlic powder added to boiling water|consumed 2.7 grams of garlic powder added to boiling water (equivalent to 8 grams of cooked garlic) in a sandwich, once a day for four weeks
1750943|NCT00200824|Drug|Soy Isoflavone Nutritional Supplements|
1750944|NCT00200850|Biological|Hose Dust Mite SLIT|low dose SLIT 143 AU/ml daily
1750945|NCT00200850|Biological|High dose SLIT|House Dust Mite SLIT- 10,000 AU/ml daily
1750946|NCT00200850|Biological|Placebo SLIT|Placebo SLIT daily
1750947|NCT00200863|Device|Monochromatic visible light exposure|Monochromatic light in the visible range from 420-620 nm up to 60uW/cm2 for 6.5 hours
1750948|NCT00200876|Procedure|Hypertonic saline|To elicit pain
1750949|NCT00200876|Procedure|Isotonic saline|Non-painful control
1750950|NCT00200889|Device|Manual acupuncture|Acupuncture needle will be inserted and stimulated by manual twisting by an acupuncturist.
1750951|NCT00200889|Procedure|Electro-acupuncture|Acupuncture needle will be inserted and electrodes attached to this needle. Electrical current will be passed to stimulate the body via the needle. Current strength will be below pain thresholds.
1750952|NCT00200889|Procedure|Sensory stimulation|A sham stimulation will be produced over the body location. no insertion will be made.
1750953|NCT00200889|Device|acupuncture|different forms of acupuncture and sensory stimulation will be used
1750954|NCT00200902|Drug|venlafaxine (Effexor)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
1750955|NCT00200902|Drug|duloxetine (Cymbalta)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
1750956|NCT00200902|Drug|escitalopram (Lexapro)|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
1750957|NCT00200902|Other|placebo|Subjects assigned to the placebo (PBO) or medication (MED) condition will enter double-blind treatment with either venlafaxine XR, duloxetine, escitalopram, or placebo after lead-in. They will undergo the same schedule, structure, and intensity of visits as in the ICI condition, but also will be randomized to receive treatment with a pill. Subjects randomized to medication will be started on one tablet each morning of either venlafaxine XR 75 mg., duloxetine 30 mg., or escitalopram 10 mg. Dosages will be increased in a double-blinded manner by increasing the number of pills administered by one pill every three to five days until the final dose is achieved (225 mg., 90 mg., and 30 mg. respectively for venlafaxine XR, duloxetine, and escitalopram). In order to maintain blinding during dosage increase, the number of tablets of placebo will be increased every three to five days as well.
1750958|NCT00200928|Biological|BCG|
1750959|NCT00200941|Drug|Topiramate|
1750960|NCT00200954|Dietary Supplement|Probiotic bacteria|3 x 10e9 CFU of a mixture of probiotic bacteria, once daily to the pregnant mothers last 6 weeks of pregnancy.To their offspring during the first year of life.
1750961|NCT00200954|Dietary Supplement|Placebo|The placebo consists of the carrier of the probiotic bacteria mixture, i.e. rice starch and maltodextran
1750962|NCT00200967|Drug|salmeterol|50 micrograms (mcg) twice per day (BID) (Serevent 50 mcg diskus, GlaxoSmithKline (GSK), North Carolina)
1750963|NCT00200967|Drug|beclomethasone HFA|240 mcg beclomethasone HFA (QVAR, Teva Pharmaceutical Industries)
1750964|NCT00200993|Behavioral|physical activity|
1750965|NCT00201006|Behavioral|Face-to-face counseling|Biweekly group behavioral counseling sessions conducted in a face-to-face format
1750966|NCT00201006|Behavioral|Telephone counseling|Biweekly telephone counseling sessions conducted in a one-on-one format
1750967|NCT00201006|Other|Mail contact|Biweekly written newsletters with weight management advice delivered via U.S. mail
1750968|NCT00201019|Behavioral|Physician-pharmacist collaborative intervention|Participants receive assessment and medication and lifestyle recommendations from a clinical pharmacist.
1750969|NCT00201045|Other|Physician/Pharmacist Collaborative Teams|The patient's physician collaborates with a clinical pharmacist to improve management of hypertension
1750970|NCT00201058|Behavioral|Tailored Web-based Asthma Management|Web-based asthma management
1750971|NCT00201058|Behavioral|Generic web-based asthma education|4 computer sessions over a period of 180 days
1750972|NCT00201084|Behavioral|Uncertainty reduction|At physician discretion, 24 hour ambulatory BP monitoring and/or electronic bottle cap monitoring and/or lifestyle counseling
1750973|NCT00201110|Behavioral|Problem Solving Skills|Intensive Intervention: CVD Risk Self-Management Education (1 session) + Intensive Health Problem-Solving Training (8 sessions)
1750974|NCT00201110|Behavioral|Problem Solving Skills|Brief Intervention: CVD Risk Self-Management Education (1 session) + Brief Problem-Solving Training (1 session)
1750975|NCT00201123|Drug|Aerosol Interferon-Gamma|Participants will receive aerosol interferon-gamma.
1750976|NCT00201123|Drug|Subcutaneous interferon-gamma|Patients will receive subcutaneous interferon-gamma
1750977|NCT00201123|Other|Placebo|
1750978|NCT00201136|Behavioral|Lifestyle interventions to lower blood pressure for patients|Weight loss, DASH dietary pattern, increased physical activity, reduced salt intake, moderation of alchohol intake.
1750979|NCT00201136|Behavioral|MD CQI-type intervention|CQI-type intervention for MD adherence to JNC guidelines for BP management
1750980|NCT00201149|Behavioral|Patient-centered Counseling|To improve patients' adherence with prescribed anti-hypertensive medication, improve blood pressure control and doctor-patient communication, we propose a three-armed randomized controlled trial in the internal medicine clinics of a large metropolitan teaching hospital which serves a large percentage of poor African American and white patients. We will implement an intervention strategy by teaching clinicians to counsel patients about hypertension control through the use of patient-centered counseling and by providing office-based support; critical to facilitating clinicians' use of this strategy. Through this intervention we will provide clinicians with communication skills that are proven to help patients change risk-related behaviors, and which will enhance doctor-patient communication.
1750981|NCT00201162|Behavioral|diet, soy proteins|
1750982|NCT00201162|Behavioral|dietary supplements|
1750983|NCT00201188|Behavioral|Status Reports|Interpreted Analysis of Peak-Flow Monitoring Trends
1750984|NCT00201201|Other|Education Intervention|Adults aged 60 and over with hypertension were randomized to usual care and intervention groups. Both groups entered medication taking behaviors on the PEP-NG and answer questions related to knowledge and self-efficacy regarding adverse self-medication behaviors. The education intervention group received a tailored education program.
1750985|NCT00201201|Other|Control|Control group receiving care as usual after interfacing with the surveys on the PEP-NG
1750986|NCT00201214|Drug|Citrulline|Phase I - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with dosage escalation study 50mg/kg, 100mg/kg, 150mg/kg IV at 6, 12, 24, 48 hours post operative. Phase II - 150mg/kg IV bolus after initiation of cardiopulmonary bypass with 9mg/kg/hr continuous IV starting 4 hours post bolus and infusing for 48 hours or discharge from PCCU.
1750987|NCT00201227|Other|practice guideline adherence|Project facilitator assist primary care practice clinicians and staff work in effective quality improvement teams through the use of facilitated collaborative meetings.
1750988|NCT00201240|Biological|CD34+ selection with CliniMACS device|CD34+ cell selection will be performed according to procedures given in the CliniMACS Users Operating Manual and institutional Standard Operating Procedures (SOPs) in place and validated at the study sites. CliniMACS (Miltenyi device) to target CD34+ >5 x 10*6/kg and CD3+ < 1 x 10*5/kg
1750989|NCT00201253|Other|Bronchoalveolar lavages and venipunctures only|
1750990|NCT00201266|Procedure|Screening|Characterization tests including blood group typing, measures of lung function, measures of allergy, and collection of DNA.
1750991|NCT00201279|Drug|13-cis Retino Acid|
1750992|NCT00201305|Drug|Gemcitabine+5FU+Leucovorin|
1750993|NCT00201318|Drug|Cyclophosphamide Doxorubicin Vincristine Lamivudine|
1750994|NCT00201331|Drug|leucovorin+5-FU|
1750995|NCT00201344|Drug|Cisplatin,5-FU,Leucovorin|
1750996|NCT00201357|Drug|Thalidomide (THADO)|patients who receive thalidomide (100 mg BID).
1750997|NCT00201383|Drug|cisplatin|
1750998|NCT00201396|Radiation|CCRT|Radiation with weekly Cisplatin
1750999|NCT00201396|Drug|Mitomycin C,Epirubicin,Cisplatin,5-Fluorouracil,Leucovorin|Induction C/T + CCRT
1751000|NCT00201409|Drug|Placebo|Placebo will be administered by slow intravenous infusion once daily for 14 days.
1751001|NCT00201409|Drug|GM-CSF|Recombinant human GM-CSF (250 mcg/M2) will be administered by slow intravenous infusion once daily for 14 days.
1751002|NCT00201422|Other|Omeprazole, Amoxicillin, Clarithromycin|Omeprazole20 mg,Clarithromycin500 mg b.i.d.,Day 1-14 plus Amoxicillin 500 mg q.i.d.,Day 1-14 plus
1751003|NCT00201435|Drug|Paclitaxel weekly in combination with capecitabine|
1751004|NCT00201435|Drug|Docetaxel every 3 week in combination with capecitabine|
1751005|NCT00186745|Drug|Tinzaparin|Dose: 175 IU/kg subcutaneously once daily, up to 7 days. Dose reduction as per protocol if anti-Xa levels exceed pre-defined limits.
1751006|NCT00186758|Device|Transcranial Magnetic Stimulation (TMS)|"Phase l clients receive either True or Sham TMS treatments on left or right side of head for 10 days.
Phase ll clients will receive either Sham or True TMS treatments on the other side of the head - the same type as in phase l -"
1751007|NCT00186771|Device|Paired Pulse|True treatment with rTMS over the temporoparietal cortex.
1751008|NCT00186771|Device|Paired Pulse|Sham treatment with rTMS over the temporoparietal cortex.
1751009|NCT00186784|Procedure|Transcranial Magnetic Stimulation (TMS)|treatment for 10 days
1751010|NCT00186797|Procedure|Allogeneic stem cell transplant|
1751011|NCT00186797|Drug|Fludarabine, Cyclophosphamide|
1751012|NCT00186810|Drug|Busulfan, Cyclophosphamide, Horse ATG|Transplant recipients received a myeloablative conditioning regimen of cyclophosphamide, Anti-Thymocyte Globulin (horse), and Busulfan. Cyclosporine and methotrexate were administered for GVHD prophylaxis.
1751013|NCT00186810|Procedure|Allogeneic stem cell transplant|Allogeneic stem cell transplant Matched sibling donor transplant Cord blood transplant
1751014|NCT00186823|Device|Miltenyi Biotec CliniMACS|A stem cell selection device.
1751015|NCT00186823|Procedure|Stem Cell Transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
1751016|NCT00186823|Drug|TBI, systemic chemotherapy and antibodies as follows:|Transplant recipients received a myeloablative conditioning regimen consisting of total body irradiation, thiotepa, cyclophosphamide, ATG, and OKT3. Rituximab was provided prior to transplant for PTLPD prophylaxis. In addition to T cell depletion of the donor product, cyclosporine was administered for GVHD prophylaxis.
1751017|NCT00186836|Biological|Engerix-B and Twinrix|
1751018|NCT00186849|Drug|Topotecan, Cyclophosphamide, Cisplatin, Doxorubicin, Etoposide, Ifosfamide, Carboplatin|See Detailed Description section for details of treatment interventions.
1751019|NCT00186849|Procedure|Peripheral Blood Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
1751020|NCT00186862|Drug|Interleukin-2|"A genetically modified (retroviral) allogeneic tumor vaccine coupled with the human interleukin-2. Patients were treated with 4 injections of these gene-modified tumor cells. The first two were given at weeks 1 and 2. Patients then had a 2 week rest and the remaining 2 injections were given at weeks 4 and 5. A complete evaluation for evidence of toxicity and response were performed at week 8.
At this week 8 evaluation, if there was no excessive toxicity, progressive disease requiring therapy, and if more transduced cells are available, patients had the option to receive 4 additional injections. These additional injections were separated by 1 month at the higher of the two dosage levels originally received."
1751021|NCT00186875|Drug|Etoposide, cytarabine, vincristine, dexamethasone|See Detailed Description section for details of treatment interventions.
1751022|NCT00186875|Drug|methotrexate, teniposide, PEG-asparaginase|See Detailed Description section for details of treatment interventions.
1751023|NCT00186875|Drug|mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine|See Detailed Description section for details of treatment interventions.
1751024|NCT00186875|Drug|L-asparaginase, erwinia asparaginase|See Detailed Description section for details of treatment interventions.
1751025|NCT00186875|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
1751026|NCT00186875|Procedure|Hematopoietic Stem Cell Transplant|See Detailed Description section for details of treatment interventions.
1751027|NCT00186875|Procedure|Natural Killer (NK) Cell Transplant|See Detailed Description section for details of treatment interventions.
1751028|NCT00186888|Procedure|Enucleation|"Enucleation (possibly associated with all treatment strata/arms. For Stratum A, patients with bilateral disease will have surgery to remove the advanced eye before chemotherapy, or patients that have disease progression after chemotherapy may have surgery to remove the affected eye.
For Stratum B, Surgical removal of the affected eye may be required in cases of disease progression For Stratum C, first intervention is removal of the affected eye."
1751029|NCT00186888|Drug|Vincristine, Carboplatin|(Stratum A subjects receive 8 courses every 3-4 weeks, Stratum B subjects receive this combination for Courses 3, 4, 6, 7, 9, and 10 after the window, if they respond to window therapy) Vincristine dosage< 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1.
1751030|NCT00186888|Procedure|Focal Therapies|Method will be at the discretion of the treating team, used after second course of chemotherapy. Cryotherapy- freezing of affected tissue, Laser photocoagulation- using lasers to destroy affected tissue, Thermotherapy and thermochemotherapy- using heat or heat/chemotherapy combination to destroy diseased tissue, and Episcleral plaque brachytherapy- radiation insertions in the diseased area to destroy affected tissue.
1751031|NCT00186888|Radiation|External Beam Radiation|44-46 Gy administered using standard practices , limiting dose to normal tissues to subjects with recurrent or progressive disease not considered controllable with focal treatments, Stratum B subjects with suspected active disease after completing therapy, or patients considered to have high-risk disease.
1751032|NCT00186888|Drug|Vincristine + Topotecan|(Stratum B subjects receive two up-front courses of vincristine and topotecan, given in 21-day intervals, then those who respond receive 3 additional courses (courses 5, 8, and 11) after the window. Dosages are the same for both window and subsequent courses: Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Topotecan: TSE of 140 ± 20 ng/ml*hr, daily for 5 consecutive days, infused over 30 minutes.
1751033|NCT00186888|Drug|Vincristine + Carboplatin + Etoposide|"Stratum B patients that do not respond to window receive 6 courses of this combination.
Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, < 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3"
1751034|NCT00186888|Drug|Vincristine + Cyclophosphamide + Doxorubicin|(High risk Stratum C patients in courses 2, 4, and 6 after enucleation, intermediate risk stratum C patients for four consecutive courses after enucleation) Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Cyclophosphamide: < 12 months of age: 40 mg/kg i.v. day 1, ≥ 12 months of age: 1,200 mg/m2 i.v. day 1, MESNA 200 mg/m2 at 0, 3, 6, and 9 hours Doxorubicin < 12 months of age: 1.5 mg/kg i.v. day 1, ≥ 12 months of age: 45 mg/m2 i.v. day 1
1751035|NCT00186888|Drug|Vincristine+Carboplatin+Etoposide|High risk Stratum C patients in courses 1, 3, and 5 after enucleation: Vincristine: < 12 months of age: 0.05 mg/kg i.v. day 1, ≥ 12 months of age: 1.5 mg/m2 i.v. day 1 (max. dose 2 mg) Carboplatin will be administered i.v. to achieve an AUC of 6.5 mg/ml/min, day 1 Etoposide, < 12 months of age: 3.3 mg/kg/d i.v. days 1 - 3, ≥ 12 months of age: 100 mg/m2/d i.v. days 1 - 3
1751075|NCT00187122|Drug|Daunomycin|See Detailed Description section for description of treatment plan.
1751076|NCT00187122|Drug|L-Asparaginase|See Detailed Description section for description of treatment plan.
1751036|NCT00186888|Procedure|Periocular carboplatin|Periocular (subtenon) carboplatin 20 mg, one injection, in courses 5, 8, and 11 in patients responding to the VT window, and in courses 1, 3, and 6 of VCE in patients not responding to the VT window, when active vitreous disease is present. Carboplatin 20 mg will be diluted in 2 mL of NS or D5W and given by subtenon administration while the patient is under general anesthesia.
1751037|NCT00186888|Other|G-CSF|G-CSF (5 mcg/kg/day), will be administered starting 24-36 hours after the completion of each course of chemotherapy, for 7 to 10 days, until ANC is > 2,000/mL in one occasion after the expected nadir.
1751038|NCT00186901|Drug|Calcium carbonate (Tums), vitamin D|Calcium carbonate 100mg/day (Tums), vitamin D 800 units/day
1751039|NCT00186901|Other|Placebo|Placebo
1751040|NCT00186914|Biological|Marrow stromal cell infusion|"This is a pilot study of infusions of ex vivo expanded, gene marked donor bone marrow stromal cells following allogeneic bone marrow transplantation. The study is a within patient dose escalation safety evaluation. It is believed that this patient population may benefit from these donor stromal cell infusions.
As the stromal cells will be obtained from the original stem cell donor, no conditioning is required.
Patients will receive two infusions of mesenchymal cells (MSC) approximately 14 to 21 days apart unless there is unacceptable toxicity after the first infusion. The first dose of cells to be given will be 1x10^6 MSC/kg and the second dose of cells will be 5x10^6 MSC/kg. The patients will be followed for approximately 28 days following the second infusion for any toxicity. Only after all six patients have safely completed both infusions will we consider 5 x 10^6 MSC/kg a safe dose of allogeneic mesenchymal stem cells for infusion."
1751041|NCT00186927|Biological|Sendai virus vaccine|Enders strain; a live, unmodified intranasally administered Sendai virus vaccine; given once in a dose escalation study, 5 x 10^5 to 5 x 10^7 EID(50) units.
1751042|NCT00186940|Drug|Rasburicase|Rasburicase 0.2 mg/kg/dose by the intravenous route for up to 7 days.
1751043|NCT00186953|Drug|Optison|"Intervention description:
Based on recommendation by the FDA, we began with a dose of 0.125ml/m^2 and escalated at 0.15 ml/m^2 increments, to 0.275 ml/m^2 and 0.425ml/m^2 and 0.500ml/m^2. We will now continue to escalate the dose of Optison at 0.300ml/m^2 increments to a maximum single dose of 4ml or a total cumulative dose of 8.7 ml as recommended by the manufacturer."
1751044|NCT00186966|Drug|Fludarabine, Cytarabine, Liposomal daunorubicin (DaunoXome)|See Detailed Description section for details of treatment interventions.
1751045|NCT00186966|Drug|Etoposide, Thioguanine, Cyclophosphamide, Busulfan, Melphalan|See Detailed Description section for details of treatment interventions.
1751046|NCT00186966|Procedure|Hematopoietic stem cell transplant|See Detailed Description section for details of treatment interventions.
1751047|NCT00186966|Radiation|Total body irradiation|See Detailed Description section for details of treatment interventions.
1751048|NCT00186979|Drug|Irinotecan, ZD1839, Vincristine, Cefixime, Cefpodoxime.|See Detailed Description section for details of treatment interventions.
1751049|NCT00186992|Radiation|image-guided radiotherapy|Conformal limited image radiotherapy is radiation therapy that targets tumors with a prescribed dose of radiation which allows the surrounding normal tissues to remain basically untreated.
1751050|NCT00187005|Drug|Prednisone, Dexamethasone, Vincristine, Daunorubicin, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
1751051|NCT00187005|Drug|L-asparaginase, Methotrexate, Idarubicin, Etoposide, Cyclophosphamide, Cytarabine, Mercaptopurine|See Detailed Description section for details of treatment interventions.
1751052|NCT00187018|Biological|Bone marrow transplant|
1751053|NCT00187031|Drug|Topotecan, Filgrastim (G-CSF), Pegfilgrastim|See detailed description section for additional details.
1751054|NCT00187044|Biological|PolyEnv1 vaccine|administered subcutaneously as 10*7 pfu in 0.8 mL
1751055|NCT00187057|Drug|vinblastine, vincristine, prednisone, daunorubicin|See Detailed Description section for details of treatment interventions.
1751056|NCT00187057|Drug|doxorubicin, methotrexate, cyclophosphamide, L-asparaginase|See Detailed Description section for details of treatment interventions.
1751057|NCT00187057|Drug|etoposide, cytarabine, mercaptopurine|See Detailed Description section for details of treatment interventions.
1751058|NCT00187057|Drug|dexamethasone, procarbazine|See Detailed Description section for details of treatment interventions.
1751059|NCT00187057|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
1751060|NCT00187070|Drug|Doxorubicin, Cotrimoxazole, Carboplatin, Ifosfamide, Dexamethasone, Prednisone, Vincristine, Cytarabine, Methotrexate, Etoposide, Cyclophosphamide, Vinblastine|See Detailed Description section for details of treatment interventions.
1751061|NCT00187070|Procedure|Stem cell transplant,|See Detailed Description section for details of treatment interventions.
1751062|NCT00187070|Radiation|Radiation Therapy|See Detailed Description section for details of treatment interventions.
1751063|NCT00187083|Drug|Topotecan, dexamethasone, vincristine|See Detailed Description section for details of treatment interventions.
1751064|NCT00187083|Drug|E. coli Asparaginase, PEG-L-asparaginase|See Detailed Description section for details of treatment interventions.
1751065|NCT00187083|Drug|erwinia asparaginase|See Detailed Description section for details of treatment interventions.
1751066|NCT00187083|Drug|fludarabine, methotrexate, mercaptopurine|See Detailed Description section for details of treatment interventions.
1751067|NCT00187083|Drug|idarubicin, etoposide, cytarbine, teniposide|See Detailed Description section for details of treatment interventions.
1751068|NCT00187083|Procedure|chemotherapy, intrathecal chemotherapy, steroid therapy|See Detailed Description section for details of treatment interventions.
1751069|NCT00187096|Drug|Cyclophosphamide, Fludarabine, Clofarabine, Etoposide, Interleukin-2|See Detailed Description section for additional details of treatment interventions.
1751070|NCT00187096|Procedure|Natural Killer Cell Infusion|See Detailed Description section for additional details of treatment interventions.
1751071|NCT00187096|Device|CliniMACS System|See Detailed Description section for additional details of treatment interventions.
1751072|NCT00187109|Drug|Recombinant Human Thrombopoietin|
1751073|NCT00187122|Drug|Vincristine|See Detailed Description section for description of treatment plan.
1751074|NCT00187122|Procedure|Radiation Therapy|See Detailed Description section for description of treatment plan.
1751267|NCT00203697|Drug|minocycline|
1751077|NCT00187122|Drug|Cytarabine|See Detailed Description section for description of treatment plan.
1751078|NCT00187122|Drug|Methotrexate|See Detailed Description section for description of treatment plan.
1751079|NCT00187122|Drug|Mercaptopurine|See Detailed Description section for description of treatment plan.
1751080|NCT00187122|Drug|Etoposide|See Detailed Description section for description of treatment plan.
1751081|NCT00187122|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
1751082|NCT00187122|Drug|Prednisone|See Detailed Description section for description of treatment plan.
1751083|NCT00187122|Drug|Dexamethasone|See Detailed Description section for description of treatment plan.
1751084|NCT00187135|Drug|Fentanyl|"Fentanyl - 1 mcg/kg in 3 ml normal saline
Fentanyl - 0.5 mcg/kg in 3 ml normal saline"
1751085|NCT00187135|Drug|EMLA|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). EMLA application has to be over at least 60 minutes and not to exceed 5 hours.
1751086|NCT00187135|Drug|L.M.X4|All patients will have EMLA or LMX4 cream applied at the anticipated site of the bone marrow aspiration to ensure topical anesthesia, and will receive a total intravenous anesthetic technique (TIVA). In order to optimize transdermal anesthesia LMX4 application has to be over at least 30 minutes.
1751087|NCT00187135|Drug|Propofol|Propofol - 1 mg/kg increments every 30 seconds-1minute until loss of consciousness is indicated by lack of response to verbal command and loss of eyelid reflex.
1751088|NCT00187148|Biological|EnvDNA|administered as 100 mcg of DNA in 1.5mL PBS every 28 days for 3 injections
1751089|NCT00192556|Behavioral|food|
1751090|NCT00192569|Drug|Pegylated Interferon alfa 2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
1751091|NCT00192569|Drug|Ribavirin (HIV conifected patients only)|"genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg)
Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients"
1751093|NCT00192595|Drug|Tenofovir|
1751094|NCT00192595|Drug|Zidovudine (AZT), lamivudine (LAM), efavirenz (EFV)|
1751095|NCT00192608|Drug|saquinavir 500 formulation|NRTIs + SQV/RTV 1000/100 mg BID using 200 mg SQV capsules switched at entry to ATV/SQV/RTV 300/1500/100 mg QD using 500 mg SQV tablet for 48 weeks with PK at days 0 and 8.
1751096|NCT00192608|Drug|cross-over arm|either ATV/SQV/RTV 300/1500/100 QD (500 mg SQV tabs) for 7 days then after PK SQV changed to 1600 mg QD (200 mg caps) with PK day 15, or ATV/SQV/RTV 300/1600/100 QD for 7 days with switch to SQV 1500 mg QD. After day 15 PK both groups switch to ATV/SQV/RTV 300/1500/100 QD to week 48
1751097|NCT00192621|Drug|Combivir (zidovudine [AZT] / lamivudine [3TC])|
1751098|NCT00192621|Drug|Kaletra (lopinavir [LPVr])|
1751099|NCT00192634|Drug|Emtricitabine 200mg - Tenofovir 300mg|1 tablet once daily for 96 weeks
1751100|NCT00192634|Drug|Abacavir 600mg - Lamivudine 300mg|1 tablet once daily for 96 weeks
1751101|NCT00192647|Drug|PEG-IFN alfa-2a|PEG-IFN alfa-2a will be administered once weekly for 48 weeks, at doses specified in respective arms.
1751102|NCT00192647|Drug|Ribavirin|Ribavirin 1000 or 1200 mg orally daily in divided doses, with the dose determined based on body weight, for 48 weeks.
1751103|NCT00192660|Drug|Lamivudine|
1751104|NCT00192660|Drug|Stavudine|
1751105|NCT00192660|Drug|Didanosine|
1751106|NCT00192660|Drug|Zidovudine|
1751107|NCT00192660|Drug|Tenofovir|
1751108|NCT00192660|Drug|Abacavir|
1751109|NCT00192660|Drug|Efavirenz (EFV)|
1751110|NCT00192660|Drug|Nevirapine|
1751111|NCT00192660|Drug|Indinavir|
1751112|NCT00192660|Drug|Saquinavir|
1751113|NCT00192660|Drug|Amprenavir|
1751114|NCT00192660|Drug|Ritonavir|
1751115|NCT00192660|Drug|Nelfinavir|
1751116|NCT00192660|Drug|Tipranavir|
1751117|NCT00192660|Drug|enfuvirtide (T20)|
1751118|NCT00192673|Drug|PEG-asparaginase|
1751119|NCT00192686|Procedure|culture a.m. Kamme-Lindberg|
1751120|NCT00192699|Device|Bimetric femoral stem|Cemented Bi-Metric femoral stem
1751121|NCT00201448|Biological|Hepatitis A Vaccine|Single dose give IM
1751122|NCT00201448|Biological|Towne CMV Vaccine|Single dose given subcutaneously
1751123|NCT00201461|Device|STARFlex septal closure system|transcatheter placement of STARFlex device to close a patent foramen ovale
1751124|NCT00201461|Drug|Best medical therapy|aspirin (325 mg daily) and/or warfarin (target INR = 2.5)
1751125|NCT00201513|Behavioral|Isolated Transversus abdominis (TrA) exercise|Eight weeks Isolated Transversus abdominis (TrA) exercise(low load) program; Isolated TrA control through biofeedback
1751126|NCT00201513|Behavioral|sling exercise|Eight weeks sling(high load) exercise program; Isolated TrA control through biofeedback
1751127|NCT00201513|Behavioral|group exercise|Eight weeks non-specific group exercise program; Isolated TrA control through biofeedback
1751128|NCT00201539|Drug|single dose Morphine|
1751129|NCT00201539|Drug|double dose Morphine|
1751130|NCT00201539|Drug|placebo|purchased from the manufacturer of morphine tablets (Nycomed Pharma, Oslo, Norway)
1751131|NCT00201552|Drug|Statin|
1751132|NCT00201591|Behavioral|Exercise training for 10 weeks|
1751133|NCT00201617|Device|Bone-anchored hearing aid|
1751134|NCT00201630|Drug|Uroxatrol (drug)|
1751135|NCT00201643|Drug|Betamethasone or Dexamethasone (2nd course of ACS)|Course of Betamethasone or Dexamethasone
1751136|NCT00201643|Drug|Placebo|Course of Placebo (NS)
1751137|NCT00201656|Procedure|Retention of Cerclage|Retain Cerclage until clinical removal is indicated by protocol
1751138|NCT00201656|Procedure|Removal of Cerclage|Immediate removal of Cerclage following randomization
1751139|NCT00201656|Procedure|Removal vs. Retention of Cervical Cerclage|Immediate removal of cerclage following randomization vs. retention of cerclage until labor, chorioamnionitis, or fetal distress
1751140|NCT00201669|Drug|Clofarabine|Clofarabine 30 mg/m2/day will be administered as a 2-hour intravenous infusion (IVI) on days 1-5.
1751141|NCT00201682|Drug|Etanercept|25 mg SQ twice weekly weeks 1-5
1751142|NCT00201682|Drug|Rituximab|(375 mg/m2) Using Stepped-Up Dosing Thrice Weekly, weeks 2-5
1751143|NCT00201695|Drug|Doxil®|40 mg/m2 IV day 1
1751144|NCT00201695|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) IV day 1
1751145|NCT00201695|Drug|Dexamethasone|40 mg PO days 1-4
1751146|NCT00201695|Drug|Arsenic Trioxide|0.25 mg/kg IV over 1-4 hours twice per week, week 1-4 of each cycle (i.e., days 1 and 4; 8 and 11; 15 and 18; 22 and 25)
1751147|NCT00201708|Drug|Docetaxel|Arm A:75 mg/m2 every 2 weeks)for 4 cycles. Arm B:75 mg/m2 every 2 weeks for 4 cycles.
1751148|NCT00201708|Drug|Doxorubicin|60 mg/m2 intravenously as push over 2-5 minutes, every 14 days for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide) , Arm B (Docetaxel after doxorubicin/cyclophosphamide)
1751149|NCT00201708|Drug|Cyclophosphamide (AC)|600 mg/m2 over 30 to 60 minutes every 14 days (2 weeks) for 4 cycles. Arms: Arm A (Docetaxel before doxorubicin/cyclophosphamide), Arm B (Docetaxel after doxorubicin/cyclophosphamide)
1751150|NCT00201721|Drug|Pentostatin|2 mg/m2 IV over 30 minutes in 250 mL NS on day 1 during cycles 1-6.
1751151|NCT00201721|Drug|Rituximab|For the first week only: Day 1 of therapy 100 mg IV over 4 hours. Day 3 of therapy 375 mg/m2 IV at 50 mg/hr and increase by 100 mg/hr at 30-minute intervals to a maximum of 400 mg/hr. Day 5 of therapy 375 mg/m2 IV at 100 mg/hr for the first 15 minutes the remainder goes in at 45 minutes. The remaining weeks 375 mg/m2 will be repeated as a single IV infusion Day 1 of Week 4, 7, 10, 13 and 16 during cycles 2-6.
1751152|NCT00201721|Drug|Cyclophosphamide|600 mg/m2 IV in 250 mL NS over 30 minutes on day 1 cycles 1-6
1751153|NCT00201734|Drug|Capecitabine|Level 1: 500 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 2: 750 mg/m2 orally twice daily Days 8 - 21 of each cycle. Level 3 - 5: 1000mg/m2 orally twice daily Days 8 - 21 of each cycle.
1751154|NCT00201734|Drug|Carboplatin|Levels 1-5: AUC of 6 every 4 weeks.
1751155|NCT00201734|Drug|Paclitaxel|Level 1-3: 60 mg/m2/week. Level 4: 80 mg/m2/week. Level 5: 100 mg/m2/week.
1751156|NCT00201747|Drug|CPT-11|CPT-11 will be administered intravenously on days 2 and 9 (24 hours after MMC, when the MMC is required) Two weeks of rest (beginning days 15 and 22) (drug free) will complete the cycle, with therapy planned to be resumed on day 29.
1751157|NCT00201747|Drug|Mitomycin C|MMC will be administered intravenously on day 1 (Arm A) and days 1 and 8 (Arm B)
1751161|NCT00201773|Drug|Exemestane|25 mg orally once per day for 16 weeks.
1751162|NCT00201773|Drug|Celecoxib|given orally at two 200 mg capsules (400 mg) twice per day. Patients assigned to receive 400 mg twice per day should be instructed to take the drug with food.
1751163|NCT00201773|Other|Correlative studies|
1751164|NCT00201786|Drug|Pentostatin|Pentostatin is given at a dose of 1.5 mg/m2/day IV x 3 consecutive days. Each IV infusion of pentostatin will be administered over 20-30 minutes in 100-250 ml of D5W or NS. To prevent nephrotoxicity, patients will also receive 500 ml normal saline as pre- and post drug hydration (total 1000 ml).
1751165|NCT00202904|Drug|ezetimibe|ezetimibe 10 mg tablets, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
1751166|NCT00202904|Drug|placebo|placebo tablets matched to ezetimibe, one tablet taken daily with atorvastatin 10 mg daily for 6 weeks
1751167|NCT00202917|Drug|Fludarabine|
1751168|NCT00202917|Drug|Thiotepa|
1751169|NCT00202917|Drug|Melphalan|
1751170|NCT00202917|Drug|OKT-3|
1751171|NCT00202917|Procedure|CD3/CD19 depletion on CliniMACS|
1751172|NCT00202930|Drug|anti-CD20 (Rituximab)|
1751173|NCT00202943|Procedure|TCRFVR and LAUP|
1751174|NCT00202956|Drug|Bugusan|
1751175|NCT00202969|Drug|S-1|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 28 repeated 6 weeks.
1751176|NCT00202969|Drug|S-1 plus CDDP|S-1 40 mg/m2 administered orally BID after breakfast and evening meal from Day 1 through Day 21 with a single dose of CDDP 60 mg/m2 will be administered as an 1- to 3-hour IV infusion following the morning dose of S-1 on Day 8. The combination therapy will be repeated every 5 weeks.
1751177|NCT00202969|Drug|5-FU plus CDDP|5-FU 600 mg/m2/24 hours administered intravenously as a CI over 120 hours (Days 1 through 5) along with a 30-minute infusion CDDP 20 mg/m2 from Day 1 through Day 5. The control treatment arm will be repeated every 4 weeks.
1751178|NCT00202982|Drug|glatiramer acetate 20 mg|glatiramer acetate 20 mg
1751179|NCT00202982|Drug|glatiramer acetate 40 mg|glatiramer acetate 40 mg
1751180|NCT00202995|Drug|Glatiramer Acetate|20 mg s.c. daily
1751181|NCT00202995|Drug|Betaseron|250 mg every other day
1751182|NCT00202995|Drug|Rebif|44 ug 3 times a week
1751183|NCT00203021|Drug|Glatiramer acetate|Glatiramer acetate 20mg and mannitol 40mg contained in same pre-filled syringe; subcutaneous injection once daily.
1751184|NCT00203034|Drug|rasagiline mesylate|0.5 mg rasagiline mesylate oral once daily
1751185|NCT00203034|Drug|1.0 mg rasagiline mesylate|1.0 mg rasagiline mesylate oral once daily
1751186|NCT00203034|Other|Placebo|oral placebo once daily
1751187|NCT00203047|Drug|Glatiramer Acetate|20mg glatiramer acetate (GA) administered by daily subcutaneous injections
1751188|NCT00203047|Drug|Placebo|Placebo for prednisone given daily
1751189|NCT00203047|Drug|Prednisone|Prednisone 1250 mg taken daily
1751190|NCT00203060|Drug|Rasagiline Mesylate|tablet, 1 or 2 mg, daily, 58 weeks
1751191|NCT00203060|Drug|placebo|tablet, once daily, 58 weeks
1751192|NCT00203073|Drug|glatiramer acetate 20 mg|glatiramer acetate 20 mg
1751193|NCT00203073|Drug|glatiramer acetate 20 mg, with mitoxantrone|glatiramer acetate 20 mg, with mitoxantrone
1751194|NCT00203099|Drug|Glatiramer Acetate, N-Acetylcysteine|Subcutaneous glatiramer acetate 20 mg and concomitant oral administration of N-Acetylcysteine divided into two 2.5 g doses.
1751195|NCT00203112|Drug|glatiramer acetate with minocycline|Subcutaneous injection glatiramer acetate 20mg, with oral minocycline 100mg
1751196|NCT00203112|Drug|Glatiramer acetate with placebo|Subcutaneous injection glatiramer acetate 20mg, with oral placebo
1751197|NCT00203125|Drug|rasagiline mesylate|0.5 or 1 mg oral, once-daily
1751198|NCT00203125|Other|tyramine|50 mg once daily
1751199|NCT00203138|Drug|rasagiline mesylate|
1751200|NCT00203151|Drug|edratide|0.5 mg, 1.0 mg, 2.5 mg injection once weekly
1751201|NCT00203164|Drug|rasagiline mesylate|rasagiline mesylate 1 mg oral once daily
1751202|NCT00203177|Drug|rasagiline mesylate|0.5 rasagiline mesylate
1751203|NCT00203177|Drug|rasagiline mesylate 1.0 mg|1.0 mg rasagiline mesylate
1751204|NCT00203190|Drug|Topiramate|
1751205|NCT00203203|Device|Intramyocardial Injection of stem cells via NOGA Mapping|Subject is randomized to receive intramyocardial injection of stem cells (stem cell therapy) via NOGA mapping to deliver cells in the active arm of the protocol.
1751206|NCT00203203|Other|Control, then Stem Cell Therapy|Subject is randomized to receive a NOGA mapping and no injections (sham treatment)at time of active enrollment and treatment then offered stem cell therapy at 6 months.
1751207|NCT00203216|Drug|levetiracetam|Daily dose of open label levatiracetam was 3000 mg. or maximally tolerated dose. (Maximum daily dose: 3000 mg. Minimum daily dose allowed for study participation:1000 mg)
1751208|NCT00203216|Procedure|Transcranial Magnetic Stimulation|
1751209|NCT00203229|Drug|lamotrigine|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal). This drug is an anti-seizure medication.
1751210|NCT00203229|Drug|Placebo|The intervention type is 'drug' and this arm is a placebo pill created and supplied by the manufacturers of lamotrigine (Lamictal) to be exact replicas of the actual drug being studied. The placebo arm is titrated in the exact same manor as the active drug arm.
1751211|NCT00203242|Drug|Depacon IV and Depakote ER|
1751212|NCT00203255|Drug|Soy Isoflavones|
1751213|NCT00203268|Drug|dihydroergotamine mesylate|1.0 mg. intramuscularly
1751214|NCT00203281|Drug|tacrolimus|
1751215|NCT00203281|Drug|mycophenolate mofetil|
1751216|NCT00203281|Drug|daclizumab|
1751217|NCT00203281|Drug|intravenous immune globulin|
1751218|NCT00203281|Procedure|plasmapheresis|
1751219|NCT00203294|Drug|lidocaine, bupivicaine and saline|lidocaine, bupivicaine and saline-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
1751220|NCT00203294|Drug|lidocaine plus bupivicaine plus triamcinolone (steroid)|lidocaine, bupivicaine and triamcinolone (steroid)-2 cc were injected to each GON and 0.5 cc to each trigger point. Total injected volume = 10 cc.
1751221|NCT00203307|Drug|Olanzapine during first intervention period and placebo during second intervention period|Olanzapine (5-10 mg) daily during first intervention period, then placebo(matching)druing second intervention period (after a washout period)
1751222|NCT00203307|Drug|Placebo during first intervention period, then olanzapine during second intervention period|Placebo (matching) during first intervention period, then olanzapine (5-10 mg. daily) during the second intervention period (after a washout phase).
1751223|NCT00203320|Drug|etanercept given by perispinal administration|
1751224|NCT00203333|Device|Medtronic REVEAL|
1751225|NCT00203346|Procedure|Greater Occipital Nerve Block|
1751226|NCT00203359|Drug|etanercept given by perispinal administration|
1956619|NCT02775617|Drug|Ivermectin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Ivermectin will be offered as a a single dose 200μg/kg on Day 1 and Day 8.
1956620|NCT02775617|Drug|Azithromycin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Azithromycin will be offered as single dose of 30mg/kg, max 2G.
1751231|NCT00203385|Drug|Divalproex|Depakote up to 2000mg/d
1751232|NCT00203411|Drug|Capecitabine (Xeloda)|1000mg/m^2 administered orally twice daily for two weeks followed by one week rest period
1751233|NCT00203411|Drug|Bevacizumab|7.5 mg/kg IV will be administered every 3 weeks
1751234|NCT00203424|Drug|Erlotinib + Bevacizumab|Erlotinib every day for 24 weeks and Bevacizumab every 3 weeks for a total of 8 doses
1751235|NCT00203450|Drug|Zonegran|zonisamide
1751236|NCT00203450|Drug|Placebo|Placebo pill
1751237|NCT00203463|Drug|topiramate|
1751238|NCT00203476|Drug|Niacin|
1751239|NCT00203476|Drug|Colestipol|
1751240|NCT00203476|Drug|Ezetimibe|
1751241|NCT00203489|Device|KERLIX A.M.D. Gauze|
1751242|NCT00203502|Drug|Bevacizumab|IV 15mg/kg 21 days
1751243|NCT00203502|Drug|Cyclophosphamide|500mg per meter squared, IV every 21 days
1751244|NCT00203502|Drug|Docetaxel|60 mg per meter squared, IV every 21 days
1751245|NCT00203515|Device|Standard Latex Foley Catheter|
1751246|NCT00203515|Device|Silver Coated Latex Foley Catheter|
1751247|NCT00203528|Drug|divalproex sodium ER|
1751248|NCT00203528|Drug|risperidone|
1751249|NCT00203541|Device|TELFA™ A.M.D. Island dressing|
1751250|NCT00203554|Genetic|Poly methylmetacrylate, PMMA|
1751251|NCT00203567|Drug|carbamazepine ER|Active study drug, no comparator
1751252|NCT00203580|Drug|Tinzaparin sodium|
1751253|NCT00203593|Behavioral|Exercise|
1751254|NCT00203593|Device|Blood volume|
1751255|NCT00203593|Procedure|VO2max test|
1751256|NCT00203593|Procedure|Lower body negative pressure|
1751257|NCT00203593|Behavioral|Heart Rate|
1751258|NCT00203593|Procedure|Blood Pressure|
1751259|NCT00203593|Behavioral|Total Peripheral Resistance|
1751260|NCT00203606|Drug|pegylated interferon alfa-2a ( Roche) and ribavirin|pegylated interferon alfa-2a ( Roche) and ribavirin
1751261|NCT00203619|Device|Wireless capsule endoscopy|wire less capsule endoscopy
1751262|NCT00203619|Other|standard care|standard diagnostic evaluation as decided by treating physician
1751263|NCT00203632|Drug|rosiglitazone/placebo|
1751264|NCT00203645|Behavioral|Self-help treatment|"Workbook Becoming a Winner,"
1751265|NCT00203658|Drug|Tinzaparin sodium|
1751266|NCT00203684|Drug|Flunisolide-HFA|
1751268|NCT00203710|Device|Concentric Retriever Device|
1751269|NCT00203723|Drug|Risperidone|
1751270|NCT00203736|Drug|Sulfadoxine-pyrimethamine|
1751271|NCT00203736|Drug|Artesunate plus sulfadoxine-pyrimethamine|
1751272|NCT00203749|Behavioral|Community-Based HIV VCT|"COMMUNITY MOBILIZATION. This component of the intervention uses community outreach to enhance the uptake of VCT, thus increasing the rate of HIV testing and frequency of discussions about HIV and reducing stigma through community education and mobilization.
EASY ACCESS TO VCT. This component is designed to remove practical barriers and increase safety of VCT. Mobile vans or temporary units set up at local community sites will provide free, anonymous VCT in specific, chosen sites where people gather, such as market areas, shopping centers, and community centers.
POST-TEST SUPPORT SERVICES. This component is designed to build psychosocial support to improve the quality of life for individuals diagnosed with HIV. The expected outcomes include a reduction in social harm, an increase in social support through disclosure to those most likely to provide support, and a reduction in internalized stigma. Social support should also decrease the behavioral risk of further transmission."
1751273|NCT00203749|Behavioral|Standard clinic-based VCT|Control communities will receive Standard Clinic-Based VCT (SVCT) instead of the community-based VCT (CBVCT) intervention. Each of these communities will have access to SVCT that reflects local access to health care. The training for VCT counselors will be the same in the CBVCT and SVCT communities; however, no active recruitment for participation in the SVCT services will be made beyond the standard procedures of each clinic for informing patients of services (e.g., telling individual patients that VCT is available, posting of a flyer in the clinic announcing VCT availability, etc). As such, no active outreach or community mobilization will be conducted by the study staff in the SVCT settings (although it is possible that such activities will occur due to local initiative).
1751274|NCT00203762|Behavioral|Public sector antiretroviral treatment programmes|
1751275|NCT00203775|Drug|risperidone|
1751276|NCT00203788|Behavioral|Individual Placement and Support|Supported education/employment
1751277|NCT00203788|Behavioral|Workplace Fundamentals Module|Group skills training on job/school topics
1751278|NCT00203788|Behavioral|Brokered Vocational Rehabilitation|Vocational rehabilitation through traditional separate state-funded agency
1751279|NCT00203788|Drug|Oral risperidone|Risperidone, starting target dosage was 6 mg, adjusted to level judged optimal by treating psychiatrist
1751280|NCT00203788|Behavioral|Skills training group|Group social skills training that did not focus primarily on work situations
1751281|NCT00203801|Drug|Sulfadoxine-pyrimethamine|
1751282|NCT00203801|Drug|Artesunate plus sulfadoxine-pyrimethamine|
1751283|NCT00203801|Drug|Artemether-lumefantrine|
1751284|NCT00203814|Drug|Sulfadoxine-pyrimethamine|
1751285|NCT00203814|Drug|Artesunate plus sulfadoxine-pyrimethamine|
1751286|NCT00203853|Device|pillbox, wristwatch|
1751287|NCT00203866|Drug|G250 peptide|
1751288|NCT00203866|Drug|IL-2|
1751289|NCT00203879|Drug|MAGE-3/Melan-A/gp100/NA PBMC, rhIL-12 (drug)|draft
1751290|NCT00203879|Drug|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2|MAGE-3/Melan-A/gp100/NA17 Peptide-pulsed autologous PBMC, rhIL-12 with IL-2
1751291|NCT00203892|Biological|modified CEA peptide (10mcg)|Vaccine contained the modified CEA peptide (10mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
1751292|NCT00203892|Biological|modified CEA peptide (100mcg)|Vaccine contained the modified CEA peptide (100mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
1751293|NCT00203892|Biological|modified CEA peptide (1000mcg)|Vaccine contained the modified CEA peptide (1000mcg), Montanide ISA-51, and sargramostim (GM-CSF) 250mcg. Vaccine was administered on Day 1 of each 14 day cycle until progressive disease or dose-limiting toxicity for a maximum of 24 cycles. Vaccine administration site was the proximal thigh.
1751294|NCT00203905|Drug|5-Fluorouracil, Hydroxyurea-[FHX], Bevacizumab|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Bevacizumab at 10 mg/kg as a 90-minute infusion; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
1751295|NCT00203905|Drug|5-Fluorouracil, Hydroxyurea-[FHX]|Hydroxyurea at 500 mg PO q 12 hours x 6 days; Infusion of 5-FU (600 mg/m2/day) X 5 days (120 hours)
1751296|NCT00203918|Behavioral|Survey, interview|A survey is administered to patients visiting the urology clinic to undergo prostate biopsies to validate a method of utility assessment, and understand patients' individual evaluations of treatment-related health states. Medical records will also be reviewed 00 days after the survey was administered to determine whether this data reflects actual treatment decisions.
1751297|NCT00203918|Behavioral|patient utility scores (i.e. patient preference weights)|comparison of patient preferences
1751298|NCT00203931|Drug|Cetuximab|
1751299|NCT00203931|Drug|Pemetrexed|
1751300|NCT00203944|Behavioral|Behavioral, Development|
1751301|NCT00203957|Drug|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
1751302|NCT00203957|Drug|Istradefylline|Patients will receive starting dose of 40mg/d. The allowable doses are 20 and 40mg/d
1751303|NCT00203970|Behavioral|Observation|Using a data abstraction form, we wish to gather the following information: 1) Patient demographics 2) identity of the attending, residents, and interns caring for the patient 3)whether the patient had any absolute or relative contraindications for receiving LMWH 4) how the patient was treated for his/her condition
1751304|NCT00203996|Device|continuous positive airway pressure (CPAP)|CPAP is the most effective treatment available for sleep disordered breathing. CPAP provides a constant, controllable pressure to keep your upper airway open during sleep so that you can breathe normally. The pressure acts much in the same way as a splint and holds the airway open.
1751356|NCT00204516|Biological|mRNA coding for melanoma associated antigens|mRNA vaccine s.c. applied weekly
1751357|NCT00204516|Drug|GM-CSF|Given s.c. as adjuvant drug one day after vaccine
1751358|NCT00204529|Drug|pegylated interferon-alpha-2a|
1751359|NCT00204529|Drug|interferon-alpha-2a|
1751360|NCT00204542|Drug|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 3 months
1751305|NCT00203996|Drug|depot leuprolide plus estrogen/progestin replacement|Depot leuprolide is a long-acting, modified version of the natural brain hormone, gonadotropin releasing hormone (GnRH). This study drug will temporarily reduce the pituitary hormones that stimulate the ovaries to make both female (estrogen) and male (testosterone) hormones. The effect of this study drug will last approximately 12 weeks. During this time, your female hormone levels will be brought to normal by the use of a patch that contains estrogen and progesterone. This patch is placed on the skin and is changed twice a week. The subject will continue to wear this patch for 4 weeks after the end of the study, until the effects of the Lupron injection wear off.
1751306|NCT00203996|Drug|pioglitazone|Pioglitazone (Actos). Pioglitazone is an oral medication approved in the Unites States for the treatment of patients with type 2 diabetes (however it is not approved for studies in this protocol). This is one of a class of drugs known as thiazolidinediones. This class of drugs has been associated with potential beneficial changes in the metabolism (use of glucose by the body) as well as lipids (fats) in the blood.
1751307|NCT00203996|Procedure|REM frag|Rapid eye movement (REM) sleep will be fragmented by experimentally induced microarousals for 3 consecutive nights and non-REM sleep will be left undisturbed.
1751308|NCT00203996|Procedure|SWS supp|SWS: Slow wave activity will be suppressed without awakening the subject and REM sleep will be left undisturbed.
1751309|NCT00204009|Behavioral|Disease Surveillance, Family Studies, Questionnaire Followup|
1751310|NCT00204022|Drug|Mycophenolate mofetil|Mycophenolate mofetil
1751311|NCT00204022|Drug|Azathioprine|Azathioprine
1751312|NCT00204035|Behavioral|Evaluation (behavior)|TEACH is a precollege enrichment program for highschool students to encourage and promote these students towards careers in clinical research. To accomplish this, instruments designed to evaluate the knowledge, attitudes, and behaviors are administered during their participation in the TEACH program.
1751313|NCT00204048|Behavioral|Observation (behavior)|Inpatients admitted in GenMed at the University of Chicago will be consented to participate in an inpatient interview that consists of questions related to quality of care and satisfaction. The patient will also be interviewed over the phone 30 days after discharge and will be asked questions related to current health and their satisfaction during their stay at University of Chicago.
1751314|NCT00204061|Behavioral|Supportive management|The needs-focused intervention could include psychoeducation, crisis intervention, family counselling and assistance with education or work-related difficulties, according to need. Regular psychotherapy was not permitted.
1751315|NCT00204061|Drug|Amisulpride|Daily doses could range from 50 to 800 mg, with increments of 50 mg at first step and 100 mg at further steps. As a guideline, it was suggested that the dosage be increased as long as attenuated or brief limited intermittent positive symptoms were present. The interval between such steps should be at least 14 days if brief limited symptoms were absent and the APS score had improved.
1751316|NCT00204074|Drug|17-beta-estradiol (drug)|
1751317|NCT00204087|Behavioral|Cognitive behavioral therapy (CBT)|
1751318|NCT00204087|Behavioral|Supportive Counselling (SC)|
1751319|NCT00204100|Device|Surface Functional Electrical Stimulation|
1751320|NCT00204113|Device|Multi-purpose rehabilitation frame|
1751321|NCT00204113|Device|Surface Functional Electrical Stimulation|
1751322|NCT00204126|Device|Treadmill with partial body weight support|
1751323|NCT00204126|Device|Surface Functional Electrical Stimulation|
1751324|NCT00204139|Procedure|Routine midtrimester pregnany ultrasound scan|
1751325|NCT00204152|Behavioral|(Condition 1) Behavioral Activation; (Condition 2) Behavioral Activation and Stress Innoculation|
1751326|NCT00204165|Procedure|MRI of the small bowel|
1751327|NCT00204178|Behavioral|Oxidative stress in kidney transplant recipients|
1751328|NCT00204191|Drug|tacrolimus|
1751329|NCT00204217|Device|endotracheal intubation|
1751330|NCT00204230|Drug|mycophenolate mofetil (drug)|
1751331|NCT00204243|Drug|Naltrexone|surgically implanted naltrexone releasing during 5 to 6 months
1751332|NCT00204243|Drug|Methadone|Methadone maintenance treatment, flexible high dose (80 to 120 mg / Day)
1751333|NCT00204256|Drug|Iron sucrose|
1751334|NCT00204269|Drug|Testosterone Gel Wolff|
1751335|NCT00204282|Behavioral|Educational presentation, group discussion, questionnaires|
1751336|NCT00204295|Drug|O-(2-[F-18]Fluorethyl)-L-Tyrosin (FET) - PET|
1751337|NCT00204308|Drug|Combination tenofovir-emtricitabine|Tenofovir disoproxil 300 mg / emtricitabine 200 mg taken as a single dose during labor
1751338|NCT00204321|Drug|sirolimus (drug), mmf (drug)|
1751339|NCT00204334|Drug|darbopoeitin|
1751340|NCT00204347|Drug|risperidone|
1751341|NCT00204373|Drug|Lansoprazole (Prevacid)|Lansoprazole 30mg capsules. dose is individualized to each subject based on gastric acid production. The range is 30 mg to 450 mg daily.
1751342|NCT00204386|Drug|Topiramate|
1751343|NCT00204399|Behavioral|Telephone counseling support|
1751344|NCT00204412|Dietary Supplement|Flax lignan|543 mg SDG per day
1751345|NCT00204412|Behavioral|Exercise (walking)|walking 45 minutes per day 5 days per week
1751346|NCT00204425|Dietary Supplement|exercise/soy isoflavone|Exercise 6 days per week, 90 mg/day aglycone isoflavone Exercise placebo (stretching), isoflavone placebo
1751347|NCT00204438|Drug|0.15mg desogestrel /0.03mg ethinyl estradiol|
1751348|NCT00204451|Drug|0.75 levonorgestrel|
1751349|NCT00204451|Drug|50 mg ethinyl estradiol/0.5 mg levonorgestrel|
1751350|NCT00204464|Procedure|Exercise|
1751351|NCT00204477|Dietary Supplement|soy protein|soy protein
1751352|NCT00204477|Dietary Supplement|cow's milk protein|cow's milk protein
1751353|NCT00204490|Dietary Supplement|isoflavones|soy isoflavones: Each tablet contains 246 mg Novasoy, 676 mg calcium, 15 mg riboflavin, and other innert materials to a total weight of 1000 mg. Subject takes two isoflavone tablets plus 1 multi-vitamin per day for five days per week for upto 2 years.
1751354|NCT00204490|Dietary Supplement|carbohydrate|carbohydrate: 246 mg maltodextrin, 676 mg calcium, 15 mg riboflavin and other innert ingredients to a total weight of 1000 mg per tablet. subject takes two tablets plus one multivitamin per day for five days per week for upto 2 years.
1751355|NCT00204503|Drug|Depakote ER|
1751432|NCT00196339|Drug|Placebo|Matching placebo
1751361|NCT00204542|Drug|Diclofenac|Solaraze® (Diclofenac sodium) 2x/day topical for 6 months
1751362|NCT00204555|Drug|Imiquimod|
1751363|NCT00204568|Drug|Adriamycin|60 mg/m2, d1, W d22
1751364|NCT00204568|Drug|Trofosfamide|300 mg absolute d1-7, followed by 150 mg absolute continuously
1751365|NCT00204581|Drug|Interleukin-2 (Proleukin)|6-12 MIE/d 3times a week
1751366|NCT00204594|Drug|rM28|
1751367|NCT00204594|Drug|autologous PBMCs|
1751368|NCT00204607|Biological|mRNA|
1751369|NCT00204607|Drug|GM-CSF s.c.|
1751370|NCT00204620|Drug|Bendamustin|
1751371|NCT00204633|Drug|Darbepoetin alfa|
1751372|NCT00204646|Drug|Adriamycin|
1751373|NCT00204646|Drug|Ifosfamide|
1751374|NCT00204646|Drug|Etoposide|
1751375|NCT00204646|Drug|Carboplatin|
1751376|NCT00204659|Drug|Rituximab + CHOP chemotherapy|standard Rituximab + CHOP chemo-immunotherapy
1751377|NCT00204672|Drug|Achipex|
1751378|NCT00204685|Drug|dornase alfa|
1751379|NCT00204698|Drug|Aciphex|20 mg of aciphex taken twice daily
1751380|NCT00204737|Drug|prednisone|20mg x 2 weeks
1751381|NCT00204737|Drug|placebo|placebo
1751382|NCT00204750|Procedure|Bougie Dilation|Bougie dilation will be performed as standard
1751383|NCT00204750|Procedure|Needle-knife incision|Needle-knife incision will be performed
1751384|NCT00204763|Device|Air filled balloon catheter|The new air filled balloon catheter will be tested against the solid state catheter
1751385|NCT00204763|Device|Solid state catheter|The standardly used solid state catheter will be tested against the new air filled balloon catheter
1751386|NCT00204776|Drug|Capecitabine and Oxaliplatin|
1751387|NCT00204789|Drug|Difluoromethylornithine|
1751388|NCT00204802|Behavioral|Patient-Centered Advance Care Planning|
1751389|NCT00204854|Behavioral|telephone counseling|
1751390|NCT00204867|Other|CTC surveillance|In vivo CTC surveillance of 6-9 mm polyp
1751392|NCT00204906|Dietary Supplement|vitamin D supplementation|
1751393|NCT00204919|Drug|Vitamin D|once-monthly vitamin D oral capsules (50,000 units)
1751394|NCT00204919|Drug|placebo|once-monthly placebo capsules
1751395|NCT00204932|Drug|conjugated linoleic acid|4 grams per day of 39% cis-9, trans-11 CLA; 39% trans-10, cis-12 CLA, and 22% safflower oil for 6 months
1751396|NCT00204945|Drug|nesiritide|a bolus, then infusion of nesiritide for 10-15 minutes
1751397|NCT00204958|Drug|nutritional supplement|
1751398|NCT00204958|Drug|glutamine popsicle|
1751399|NCT00204971|Dietary Supplement|Enteral glutamine powder|nutritional supplement
1751400|NCT00204971|Other|placebo|placebo control
1751401|NCT00204984|Drug|oral hydralazine and intravenous nesiritide|vasodilators
1751402|NCT00204997|Procedure|Laparoscopic ovarian transposition|Laparoscopic ovarian transposition
1751403|NCT00205010|Procedure|Lymphoscintigraphy|
1751404|NCT00205023|Procedure|Sonohysterography|SHG during surgery for endometrial cancer.
1751405|NCT00205049|Drug|pentoxifylline|daily dosing
1751406|NCT00205062|Procedure|PET-CT|
1751407|NCT00205114|Behavioral|Individualized multifactorial intervention for community-living high-risk older adults|
1751408|NCT00205114|Behavioral|Health professional education program about fall prevention|
1751409|NCT00205127|Procedure|Cardiac PET imaging- rest and pharmacological stress|
1751410|NCT00205153|Behavioral|Pharmacy TEAM monitoring and counseling|Pharmacy team monitors and counsels patient using automatic BP monitors and special TEAM tools for assessing and improving patient adherence, barriers to adherence, lifestyle, drug therapy, BP control, and collaboration with physicians.
1751411|NCT00205166|Procedure|Cardiac SPECT imaging Rest and Stress|adenosine perfusion scintigraphy
1751412|NCT00205166|Drug|Caffeine|Caffeine 400 mg po
1751413|NCT00205166|Drug|Caffeine|Caffeine 200 mg po
1751416|NCT00205192|Procedure|Cardiac resynchronization pacing|various pacemaker modes used over 1 hour
1751417|NCT00205205|Behavioral|peer mentoring|
1751418|NCT00205231|Drug|etanercept|
1751419|NCT00205244|Behavioral|Healing images, relaxation and distraction materials|
1751420|NCT00205270|Drug|Influenza vaccine|influenza vaccine 0.5 ml intramuscularly each season
1751421|NCT00205283|Drug|Nelfinavir|
1751422|NCT00205296|Behavioral|exercise|this will test the effect of exercise on insulin sensitivity, fitness and body composition
1751423|NCT00205322|Drug|chemotherapy (capecitabine, oxaliplatin, 5-FU, leucovorin)|
1751424|NCT00205335|Device|Ascencia Breeze Glucose meter|All study participants received glucose meter and test strips.
1751425|NCT00205335|Device|Breeze Glucose Monitor (Bayer)|Each participant received a Breeze monitor and glucose test strips.
1751426|NCT00205374|Drug|Cidofovir|With regard to cidofovir concentration, the FDA has allowed us to inject a concentration of 5 mg/ml into both children and adults. The injection will add less than 2 additional minutes to the surgery time and discharge time will not be affected. Because the volumes of cidofovir injected into the airway will be reasonably small (typically less than 2 mL), the total systemic dose of cidofovir administered per visit will be far below the FDA-approved systemic limit of 5 mg/kg for HIV-related CMV retinitis.
1751427|NCT00205374|Drug|Placebo|On the baseline study day, patients will be randomized into either a treatment group (cidofovir injection) or a placebo group. A restricted randomization procedure, in groups of 4, will be used to encourage uniformity in sample sizes between groups.
1751428|NCT00205387|Procedure|cardiac elastography and echocardiography|standard echocardiogram
1751429|NCT00205400|Procedure|medical care delivery model|
1751430|NCT00196326|Drug|DR-1011|Eighty-four orange, embossed tablets, each containing 100 μg levonorgestrel (LNG) / 20 μg ethinyl estradiol (EE) and 7 yellow, embossed tablets, each containing 10 μg of EE. One combination tablet was to be taken each day for 84 days followed by 7 days of EE tablets in 91-day cycles repeated consecutively for approximately one year (four 91-day cycles).
1751431|NCT00196339|Drug|Cyproterone acetate 5|Cyproterone acetate 5 mg
1751433|NCT00196339|Drug|Cyproterone acetate 15|Cyproterone acetate 15 mg
1751434|NCT00196339|Drug|Cyproterone acetate 25|Cyproterone acetate 25 mg
1751435|NCT00196352|Drug|Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets|1 tablet daily
1751436|NCT00196365|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily
1751437|NCT00196365|Drug|levonorgestrel/EE 0.15/0.03 mg tablets and placebo|1 tablet daily
1751438|NCT00196378|Drug|Synthetic Conjugated estrogens, B|1 (0.3mg) tablet daily
1751439|NCT00196378|Other|Placebo|1 tablet daily
1751440|NCT00196391|Drug|DR-2021a|1 capsule daily for 10 days
1751441|NCT00196391|Drug|DR-2021b|1 capsule daily for 10 days
1751442|NCT00196391|Drug|DR-2021c|1 capsule daily for 10 days
1751443|NCT00196391|Drug|DR-2021d|1 capsule daily for 10 days
1751444|NCT00196391|Drug|DR-2021e|1 capsule daily for 10 days
1751445|NCT00196391|Other|Placebo|1 matching placebo capsule for 10 days
1751446|NCT00196404|Drug|DR-3001a|4mg daily vaginally
1751447|NCT00196404|Drug|DR-3001b|6 mg vaginally daily
1751448|NCT00196404|Other|Placebo|Administered vaginally to match experimental arms
1751449|NCT00196417|Drug|Standard heparin (UFH) versus certoparin (LMWH)|
1751450|NCT00196430|Device|silver-contained textiles|
1751451|NCT00196430|Drug|corticosteroid|
1751452|NCT00196443|Device|urea contained compressing stockings|
1751453|NCT00196443|Device|compressing stockings|
1751454|NCT00196456|Procedure|photosensitisation|
1751455|NCT00196469|Drug|heparin|
1751456|NCT00196482|Drug|changing of fortifier|
1751457|NCT00196495|Device|Polypropylene Mesh|
1751458|NCT00196508|Device|High Viscosity DERMABOND|
1751459|NCT00196521|Device|Tension-free vaginal tape obturator system|
1751460|NCT00196534|Drug|Human Thrombin|
1751461|NCT00196534|Drug|Bovine Thrombin|
1751462|NCT00196547|Drug|Montelukast (drug)|
1751463|NCT00196560|Device|Immobilization in External Rotation|
1751464|NCT00196573|Procedure|Shoulder bursectomy alone|
1751465|NCT00196586|Drug|Interleukin 2|
1751466|NCT00196586|Drug|pegylated interferon alpha 2a|
1751467|NCT00196586|Drug|ribavirin|
1751468|NCT00196599|Drug|emtricitabine, FTC (drug)|
1751469|NCT00196599|Drug|didanosine, ddI (drug)|
1751470|NCT00196599|Drug|efavirenz (drug)|
1751471|NCT00196612|Drug|emtricitabine, FTC (drug)|
1751472|NCT00196612|Drug|didanosine, ddI (drug)|
1751473|NCT00196612|Drug|efavirenz (drug)|
1751474|NCT00196625|Drug|Amprenavir (drug)|
1751475|NCT00196625|Drug|ABT-378/r (drug)|
1751476|NCT00196625|Drug|Ritonavir (drug)|
1751477|NCT00196638|Drug|Antiretroviral combination (drugs)|
1751478|NCT00196638|Drug|Pegylated Interferon alpha (drug)|
1751479|NCT00196651|Drug|IL-2|
1751480|NCT00196651|Biological|LIPO-6T|
1751481|NCT00196651|Biological|ALVAC VIH 1433|
1751482|NCT00196664|Drug|Paroxetine|
1751483|NCT00196677|Drug|Vitamins, minerals and medical herbs|
1751484|NCT00196690|Drug|Donepezil|
1751485|NCT00196703|Drug|memantine|
1751486|NCT00196703|Procedure|constraint-induced language therapy|
1751487|NCT00196716|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg Fabrazyme every two weeks for approximately six months followed by 0.3 mg/kg Fabrazyme every two weeks for approximately 18 months
1751488|NCT00196729|Drug|Thyrogen + Radioiodine (131I)|
1751489|NCT00196755|Drug|Sevelamer Hydrochloride (Renagel®)|Sevelamer hydrochloride three times per day with each meal
1751490|NCT00196755|Drug|Calcium acetate (PhosLo® )|Calcium acetate three times per day with each meal
1751491|NCT00196768|Drug|Arsenic trioxide|
1751492|NCT00196768|Drug|Trisenox|
1751493|NCT00196781|Behavioral|CD-ROM-based prostate cancer treatment education|The goal was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
1751494|NCT00196781|Behavioral|CD-ROM-based prostate ca treatment education+decision tools|The goal of the present study was to explore men's use of a CD-ROM-based decision aid for early-stage PCa treatment decisions.
1751495|NCT00196794|Drug|Tolevamer potassium-sodium (GT267-004)|
1751496|NCT00196807|Behavioral|patient decision aid (print-based)|To evaluate the impact of the decision aid intervention (information plus decision aid (IDA) vs. usual care (UC)), and timing of intervention delivery (at Home (pre-screening) vs. in the Clinic (screening day)) on key patient outcome variables of PCa knowledge and decisional satisfaction.
1751497|NCT00196820|Drug|Capecitabine|
1751498|NCT00196846|Drug|Goserelin|
1751499|NCT00196859|Drug|Ibandronate, Capecitabine|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs plus Capecitabine 2000 mg/m2 days 1-14 q d22 x6
1751500|NCT00196859|Drug|Ibandronate|Ibandronate 50 mg p.o. daily or 6 mg i.v., q4W, 2yrs
1751501|NCT00196872|Drug|Epirubicine|Epirbubicne is given
1751502|NCT00196872|Drug|Cyclophosphamide|Cyclophosphamide is given
1751503|NCT00196872|Drug|Taxol|Taxol is given
1751504|NCT00196872|Drug|Xeloda|Xeloda is given
1751505|NCT00196872|Drug|Ibandronat|Ibandronat is given
1751506|NCT00196885|Drug|N-acetylcysteine|
1751507|NCT00196911|Procedure|Implantation of stimulation electrodes in the STN|
1751508|NCT00196924|Biological|HPV-16/18 L1/AS04|
1751509|NCT00196937|Biological|Cervarix™|Three doses of vaccine administered intramuscularly according to a 0, 1, 6 months
1751510|NCT00196950|Biological|Meningococcal (vaccine)|
1751511|NCT00196963|Biological|Meningococcal (vaccine)|
1751512|NCT00196976|Biological|Conjugated meningococcal ACWY-TT (vaccine)|One intramuscular dose during the primary vaccination
1751513|NCT00196976|Biological|DTPa-IPV/Hib vaccine (Infanrix™-IPV/Hib)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Greece only
1751514|NCT00196976|Biological|DTPa-HBV-IPV/Hib vaccine (Infanrix hexa™)|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age, in Austria only
1751515|NCT00196976|Biological|Meningitec™|One intramuscular dose during the primary vaccination study in subjects of 12-24 months of age
1751516|NCT00196976|Biological|Mencevax™ACWY|One subcutaneous dose during the primary vaccination study in subjects of 3-5 years of age (Group E) and intramuscular administration of 1/5 dose during the booster vaccination study in subjects of 12-14 months of age (Groups A and E)
1956621|NCT02775617|Drug|Permethrin|Participants will be offered treatment for both yaws and scabies either in parallel or in sequence. Individuals with a contra-indication to ivermectin will be offered Permethrin instead.
1751519|NCT00197002|Biological|Hepatitis A|Two doses
1751520|NCT00197015|Biological|Havrix®|2 doses administered intramuscularly
1751521|NCT00197015|Biological|M-M-R®II|1 dose administered subcutaneously
1751522|NCT00197015|Biological|VARIVAX®|1 dose administered subcutaneously
1751523|NCT00197028|Biological|RTS,S/AS02D|3-dose intramuscular injection in the thigh
1751524|NCT00197028|Biological|TETRActHib™|3-dose intramuscular injection in the thigh.
1751525|NCT00197028|Biological|Engerix-B®|3-dose intramuscular injection in the thigh.
1751526|NCT00197041|Biological|RTS,S/AS02A|
1751528|NCT00197067|Biological|RTS,S/AS02D and RTS,S/AS02A|
1751529|NCT00197080|Drug|Ropinirole Extended Release (XR)|
1751530|NCT00197093|Drug|SB773812|
1751531|NCT00197106|Drug|Salmeterol/ fluticasone propionate Diskus® inhaler 50/100 mcg|comparator
1751532|NCT00197106|Drug|fluticasone propionate 2 x 100 mcg|comparator
1751533|NCT00197119|Biological|Twinrix™ Adult|Intramuscular administration in the deltoid region (2 doses).
1751534|NCT00197119|Biological|Twinrix™ Junior|Intramuscular administration in the deltoid region (3 doses).
1751535|NCT00197132|Drug|Avandia|
1751537|NCT00197158|Biological|Hepatitis B vaccine|
1751538|NCT00197171|Biological|Combined Hepatitis A and B vaccine|
1751539|NCT00197184|Biological|Twinrix™ Adult|Intramuscular injection in the left deltoid, 2 doses, Adult formulation in primary study.
1751540|NCT00197184|Biological|Twinrix™ Junior|Intramuscular injection in the left deltoid, 3 doses, junior formulation in primary study.
1751541|NCT00197197|Drug|GW873140|
1751542|NCT00197210|Biological|Rotavirus|
1751543|NCT00197223|Biological|Influenza vaccine|
1751544|NCT00197236|Biological|Havrix™|2 intramuscular injections, 6 months apart
1751545|NCT00197236|Biological|Infanrix™|1 intramuscular injection
1751546|NCT00197236|Biological|ActHIB™|1 intramuscular injection
1751547|NCT00197249|Biological|Combined Vi polysaccharide typhoid vaccine and hepatitis A vaccine- Hepatyrix|
1751548|NCT00197262|Drug|GW685698X Aqueous Nasal Spray|
1751549|NCT00197275|Biological|Hib-MenAC mixed with Tritanrix™-HepB|
1751550|NCT00197288|Biological|Influenza|
1751551|NCT00197301|Biological|Vaccination|
1751552|NCT00197314|Behavioral|circular muscle exercises versus pelvic floor exercises|
1751553|NCT00197327|Drug|Epidural bupivacaine (0.25% versus 0.0625%)|
1751554|NCT00197340|Drug|Epidural ropivacaine|
1751555|NCT00197353|Drug|Epidural bupivacaine (dose/concentration/volume ranging)|
1751556|NCT00197379|Drug|roxithromycin|
1751557|NCT00197392|Device|Bactiseal TM EVD|Standard of care implantation of external ventricular drainage catheter
1751558|NCT00197392|Device|Standard EVD Catheter|Standard of care EVD system other than Bactiseal.
1751559|NCT00197418|Drug|rabeprazole, amoxicillin, clarithromycin, metronidazole|
1751560|NCT00197431|Drug|S-1|
1751561|NCT00197444|Drug|CDGP/5-FU combined with radiation|Low-dose of Nedaplatin (CDGP) 10 mg/body/day was daily administered on day 1-5, 8-13, 15-19, 22-26 and 5-FU 500 mg/body/day was continuously administered on day 1-5, 8-13, 15-19, 22-26.
1751562|NCT00197444|Radiation|Radiotherapy|Fractionated external radiotherapy was performed from the first day of chemotherapy and a total dose of 50.4-66 Gy was delivered at the rate of 1.8-2.0 Gy per fraction.
1751563|NCT00197457|Procedure|serum pepsinogen|
1751564|NCT00197457|Procedure|urea breath test|
1751565|NCT00197470|Procedure|IL-1, TNF-alpha, Il-10|
1751566|NCT00197483|Drug|Pergolide (drug)|
1751567|NCT00197496|Procedure|Body weight supported treadmill training|hip fracture patients walk on a treadmill with body weight support
1751568|NCT00197509|Behavioral|Sit-To-Stand Protocol and Extra Practice in Sit-To-Stand|
1751569|NCT00197522|Biological|CD34+ derived DCs|
1751570|NCT00197548|Dietary Supplement|Multivitamins-vitamins B-complex, C, and E|One daily oral dose of 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 mg of C, and 30 mg of vitamin E from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
1751571|NCT00197548|Dietary Supplement|Placebo|One daily oral dose of a placebo pill taken from randomization until delivery. Participants may continue taking this intervention until 18 months post-partum if they are re-randomized to it after delivery.
1751572|NCT00197561|Dietary Supplement|Placebo|Taken orally once per day from randomization through delivery and through the first 6 months after delivery.
1751573|NCT00197561|Dietary Supplement|Selenium|200 ug of selenomethionine taken orally once per day from randomization through delivery and for the first 6 months after delivery
1751574|NCT00197587|Drug|Nevirapine|All women received a background of zidovudine from 34 weeks' gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
1751575|NCT00197587|Drug|No intervention|All women received a background of zidovudine from 34 weeks'gestation through delivery, and all infants received single-dose nevirapine at birth and zidovudine from birth through 1 month. Women were randomized to receive either single-dose nevirapine or placebo during labor.
1751576|NCT00197613|Drug|(A) zidovudine, lamivudine and nevirapine|
1751577|NCT00197613|Drug|(B) zidovudine, lamivudine and efavirenz|
1751578|NCT00197613|Drug|(C) zidovudine, didanosine, and nevirapine|
1751579|NCT00197613|Drug|(D) zidovudine, didanosine, and efavirenz|
1751580|NCT00197613|Drug|(E) stavudine, lamivudine, and nevirapine|
1751581|NCT00197613|Drug|(F) stavudine, lamivudine and efavirenz|
1751582|NCT00197613|Procedure|Adherence Strategy Standard of Care (SOC)|
1751583|NCT00197613|Procedure|Adherence Strategy Community-Based DOT|
1751584|NCT00197639|Drug|Ritonavir-boosted indinavir|
1751585|NCT00197678|Dietary Supplement|Multivitamins-Multiples of RDA|20 mg B1, 20 mg B2, 25 mg B6, 50 mcg B12, 100 mg niacin, 500 mg C, 30 mg E, 0.8 mg folic acid taken orally once per day until 6 weeks after delivery
1751586|NCT00197678|Dietary Supplement|Multivitamins-Single RDA|1.4 mg B1, 1.4 mg B2, 1.9 mg B6, 50 mcg B12, 100 mg niacin, 70 mg C, 10 mg E, and 0.4 mg folic acid taken orally once per day until 6 weeks after delivery
1751587|NCT00197691|Procedure|blood draws, etc.|
1751588|NCT00197704|Dietary Supplement|Multivitamins|5000 IU of retinol, 20 mg of B1, 20 mg of B2, 25 mg of B6, 100 mg of niacin, 50 mcg of B12, 500 of C, 200 mg of E, 0.8 mg of folic acid, and 100 mcg of selenium taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
1751589|NCT00197704|Other|Placebo|Placebo pill taken orally on a daily basis from the start of TB therapy through 8 months of anti-TB therapy
1751590|NCT00197730|Drug|Multivitamins - vitamins B complex, C and E|Age-appropriate dosages of vitamin C, vitamin E, thiamine, riboflavin, niacin, vitamin B6, folate, and vitamin B12 administered orally to children aged 6 weeks to 6 months, and two capsules per day for children aged older than 6 months for at least 12 months
1751591|NCT00197730|Drug|Placebo|Placebo capsules administered orally once day orally to children aged 6 weeks to 6 months, and twice per day for children aged older than 6 months
1751592|NCT00197743|Dietary Supplement|Vitamin A + Beta Carotene|one daily oral dose of 30 mg beta-carotene + 5000 IU preformed vitamin A
1751593|NCT00197743|Dietary Supplement|Multivitamins|one daily oral dose of 20 mg thiamine (vitamin B-1), 20 mg riboflavin (vitamin B-2), 25 mg vitamin B-6, 100 mg niacin, 50 ug cobalamin (vitamin B-12), 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid
1751594|NCT00197743|Other|Placebo|Placebo pill
1751595|NCT00197756|Dietary Supplement|Vitamin A alone|30 mg beta-carotene plus 5000 IU preformed vitamin A) taken orally once per during pregnancy and lactation
1751596|NCT00197756|Dietary Supplement|Multivitamins excluding vitamin A|30 mg thiamine, 20 mg riboflavin, 20 mg B-6, 100 mg niacin, 50 ug vitamin B-12, 500 mg vitamin C, 30 mg vitamin E, 0.8 mg folic acid taken orally once per day during pregnancy and lactation
1751597|NCT00197756|Dietary Supplement|multivitamins including vitamin A|20 mg thiamine, 20 mg riboflavin, 25 mg vitamin B6, 100 mg niacin, 50 ug vitamin B12, 500 mg vitamin C, 30 mg vitamin E, and 0.8 mg folic acid taken once per day orally during pregnancy and lactation
1751598|NCT00197756|Other|Placebo|Placebo pill taken orally once per day during pregnancy and lactation
1751599|NCT00197769|Biological|9 valent pneumococcal con jugate vaccine|
1751600|NCT00197782|Biological|Hib conjugate vaccine|
1751601|NCT00197795|Biological|"Meningococcal outer membrane vesicle vaccine MenBVac"|
1751602|NCT00197808|Biological|menjugate|men C conjugate vaccine
1751603|NCT00197808|Biological|Men C conjugate vaccine|men C conjugate vaccine
1751604|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
1751605|NCT00197808|Biological|Men C Conjugate|men C conjugate vaccine
1751606|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
1751607|NCT00197808|Biological|Men C conjugate|men C conjugate vaccine
1956622|NCT02774161|Other|Ultrasound Tomography|Undergo B-mode ultrasound imaging
1751609|NCT00197834|Drug|Depakote|
1751610|NCT00197860|Biological|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate-pulsed dendritic cells i.d. 1,6 mg Thymosin alpha 1 (Zadaxin®, SciClone) is administered s.c. twice a week and from the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
1751611|NCT00197873|Dietary Supplement|Lactobacillus Rhamnosus supplementation|Lactophilus supplementation is administered during chemotherapy.
1751612|NCT00197873|Other|Placebo administration.|Placebo is administered during chemotherapy.
1751613|NCT00197886|Drug|Changing dose of norepinephrine and blood pressure|
1751614|NCT00197899|Drug|E. Coli endotoxin|
1751615|NCT00197912|Biological|tumor antigen loaded autologous dendritic cells|DC vaccination regime consists of primary 10 intradermal injections of 1-2 weeks interval (q1w x 4 → q2w x 6). HLA-A2 positive patients are treated with p53, survivin and telomerase peptide-pulsed dendritic cells, and HLA-A2 negative patients are treated with allogeneic tumor lysate pulsed dendritic cells. 50 mg cyclophosphamide (Sendoxan®, Baxter A/S) is administered p.o. twice a day bi-weekly and 200 mg celecoxib (Celebra®, Pfizer) is given p.o. every day. From the 2nd vaccine, 2 MIU Interleukin-2 is administered s.c. on day 2-6.
1751616|NCT00197925|Biological|Onco-peptide loaded autologous dendritic cells|
1751617|NCT00197938|Procedure|Measurement of rectal lactic acid.|
1751618|NCT00197951|Drug|Treatment of psychiatric symptoms associated to alcoholism|
1751619|NCT00197964|Behavioral|Enhance asthma knowledge, self-efficacy, social support|
1751620|NCT00197977|Behavioral|Educational program to address patients' expectations|
1751621|NCT00198003|Behavioral|Educational program to address patients' expectations|
1751622|NCT00198016|Device|Coil|
1751623|NCT00198029|Device|Synvisc (hylan G-F20)|32 subjects in the pilot study have received 3 1ml injections of Synvisc intraarticular over the course of 3 weeks and then followed for 6 months post injection
1751624|NCT00198042|Procedure|Surgical reconstruction of the ACL|Surgical reconstruction of the ACL
1751625|NCT00198055|Drug|aripiprazole|Aripiprazole 5 mg per day for 2 weeks, then can be increased to 10mg per day if tolerated for 2 weeks, then can be increased to 15 mg per day for 4 weeks.
1751626|NCT00198081|Drug|COX-2 Inhibitor 6-8 weeks prior to surgery|400 mg BID 6-8 weeks prior to surgery
1751627|NCT00198081|Drug|COX-2 Inhibitor for 6 months prior to follow-up EUS or ERCP|400 mg BID for 6 months prior to follow-up EUS or ERCP
1751628|NCT00198094|Drug|Sertraline and Alprazolam XR|
1751756|NCT00205868|Device|Precision Spinal Cord Stimulation System|Stimulation on throughout study
1751632|NCT00198120|Drug|D-cycloserine|D-Cycloserine 0.6mg/kg/day in week 1 D-Cycloserine 1.1mg/kg/day in week 2 D-Cycloserine 1.7mg/kg/day in week 3-8 Flexible dosing based on response. Capsule Strength: 10mg, 20mg
1751633|NCT00198120|Drug|Placebo|Placebo: same dosing schedule and capsule strength
1751634|NCT00198133|Drug|Premetrexed (Alimta)|Pemetrexed will be 500 mg/m2 IV every 3 weeks
1751635|NCT00198146|Drug|Zenapax|
1751636|NCT00198159|Drug|ZD1839 Iressa|
1751637|NCT00198172|Drug|Cisplatin plus Epirubicin|
1751638|NCT00198185|Procedure|Placement of Platelet Rich Fibrin Matrix During Arthroscopic Rotator Cuff Surgery|
1751639|NCT00198198|Drug|Aripiprazole|
1751640|NCT00198224|Procedure|phlebotomy|
1751641|NCT00198237|Drug|docetaxel & capecitabine|
1751642|NCT00198250|Drug|venlafaxine|Venlafaxine taper dose from 37.5mg for one week to 75 mg for 3 weeks
1751643|NCT00198263|Combination Product|Medpulser Electroporation with Bleomycin|The MedPulser device will be used in conjunction with injection of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
1751644|NCT00198276|Combination Product|MedPulser Electroporation with bleomycin|The MedPulser device will be used in combination with Bleomycin Sulfate injection around the tumor area in a concentration of 1 U/ml per cm3 of tumor treatment area.
1751645|NCT00198289|Drug|Aurexis® (tefibazumab)|
1751646|NCT00198302|Drug|Aurexis®|
1751647|NCT00198315|Combination Product|Medpulser electroporation with Bleomycin|Patients receive electroporation with injection of bleomycin sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area.
1751648|NCT00198315|Procedure|Tumor surgical excision|Patients have their tumor surgically removed.
1751649|NCT00198328|Combination Product|Medpulser Electroporation with Bleomycin|Patients receive injections of Bleomycin Sulfate at a concentration of 1 U/ml per cm3 of tumor treatment area followed by electroporation.
1751650|NCT00198328|Procedure|Surgical Excision|Patients have their tumor surgically removed.
1751651|NCT00198341|Procedure|Radiological Arm|Clinical Visit + X-Ray Chest
1751652|NCT00198341|Procedure|Scannographic arm|Clinical visit + X-Ray Chest + CT-Scan + Fibroscopy (for squamous cell)
1751653|NCT00198354|Drug|gemcitabine + cisplatine|gemcitabine 1250 mg/m², D1+D8 cisplatine 80 mg/m², D1 (D1=D22)
1751654|NCT00198354|Drug|Paclitaxel + Carboplatine|paclitaxel 200 mg/m², D1 carboplatin AUC 6, D1 (D1=D22)
1751655|NCT00198367|Drug|Cisplatin-Gemzar|
1751656|NCT00198367|Drug|Cisplatin-Navelbine-Radiotherapy|
1751657|NCT00198367|Drug|Carboplatin-Taxol-Radiotherapy|
1751658|NCT00198380|Drug|Gefitinib|Gefitinib 250 mg/day, until progression or severe toxicity
1751659|NCT00198393|Drug|Gefitinib|250 mg/day, until progression
1751660|NCT00198393|Drug|gemcitabine|1250 mg/m² D1 and D8 (D1=D28, until progression)
1751661|NCT00198393|Drug|Docetaxel|75 mg/m² D1 (D1=D22, until progression)
1751662|NCT00198406|Procedure|diagnostic and therapeutic management|
1751663|NCT00198419|Drug|Vitrase|
1751664|NCT00198432|Drug|Paclitaxel, vinorelbine, cisplatin|
1751665|NCT00198445|Drug|Bromfenac|One drop in study eye every 12 hours for 14 days
1751666|NCT00198445|Drug|Placebo|One drop in study eye every 12 hours for 14 days
1751667|NCT00198458|Drug|Vitrase|
1751668|NCT00198471|Drug|Vitrase|
1751669|NCT00198484|Drug|Vitrase|
1751670|NCT00198497|Drug|Placebo|
1751671|NCT00198497|Drug|Vitrase|Hyaluronidase 55 IU in saline solution
1751672|NCT00198497|Drug|Vitrase|Hyaluronidase 75 IU in saline solution
1751673|NCT00198510|Drug|Vitrase|7.5 IU of Vitrase
1751674|NCT00198510|Drug|Vitrase|55 IU of Vitrase
1751675|NCT00198510|Drug|Vitrase|75 IU of Vitrase
1751676|NCT00198523|Drug|Prednisolone and Tobramycin|
1751677|NCT00198523|Drug|Prednisolone|
1751678|NCT00198536|Drug|Ecabet 2.83%|
1751679|NCT00198536|Drug|Ecabet 3.70%|
1751680|NCT00198536|Drug|Vehicle|
1751681|NCT00198549|Drug|Vitrase (ovine hyaluronidase) Lyophilized|
1751682|NCT00198562|Drug|Amlodipine, Losartan|amlodipine: 2.5-10 mg once daily for 5 years losartan: 25-100 mg once daily for 5 years
1751683|NCT00198588|Drug|argatroban|beginning dose: 0.7microgram/kg/H
1751684|NCT00198601|Drug|Gentamicin in Uniject Pre-filled syringe|
1751685|NCT00198614|Drug|Carvedilol versus Metoprolol|
1751686|NCT00198627|Drug|Co-Trimoxazole; TMP-SMZ|
1751687|NCT00198640|Procedure|Antibiotic use|
1751688|NCT00198653|Behavioral|Newborn Thermal Care Practice|
1751689|NCT00198666|Drug|Zinc|Elemental Zinc
1751690|NCT00198679|Drug|Chlorhexidine|
1751691|NCT00198692|Behavioral|self-management|
1751692|NCT00198705|Behavioral|Improved management of severe neonatal infections|
1751693|NCT00198718|Drug|Vitamin A (retinyl palmitate)|
1751694|NCT00198731|Behavioral|Care Seeking for Obstetric Complication|This is a descriptive study of knowledge, practices and outcomes related to maternal morbidity during pregnancy, childbirth and postpartum.
1751695|NCT00198744|Behavioral|Medifast FIT! for Kids|
1751696|NCT00198744|Behavioral|standard recommendations for dietary intake in children|
1751697|NCT00198744|Behavioral|both diet plans with and without a parent dieting|
1751698|NCT00198757|Behavioral|Medifast Plus for Diabetics Meal Replacement Supplements|
1751699|NCT00198757|Behavioral|Standard ADA recommended diet for type 2 diabetics|
1751757|NCT00205881|Device|HiRes 90K Bionic Ear System|Cochlear implant system
1751700|NCT00198770|Dietary Supplement|dietary substitution to assess level of caloric compensation|Mushrooms substituted for meat in dishes
1751701|NCT00198796|Biological|H10407|The primary objective of the proposed clinical investigation is to validate a dose for ETEC H10407 that will cause diarrhea in 50% or more of subjects without causing high output diarrhea
1751702|NCT00198809|Drug|Biolean + Diet education|
1751703|NCT00198809|Drug|Biolean Free + Diet education|
1751704|NCT00198809|Drug|Placebo + Diet education|
1751705|NCT00198822|Dietary Supplement|Vitamin A or Beta-Carotene Supplements|weekly dosage of either 7000 µg retinol equivalents as preformed vitamin A or 42 mg of beta-carotene from 1st trimester of pregnancy through 12 weeks after termination of pregnancy
1751706|NCT00198835|Behavioral|Maternal nutrition and infant feeding advice|
1751707|NCT00198848|Drug|Iron-folic acid supplement|
1751708|NCT00198861|Other|Injection and Non-Injection Drug Users|(1) the degree to which specific executive dysfunctions predispose heroin and cocaine users to high-risk injection practices or sex behaviors, and (2) whether observed relationship between executive dysfunction and HIV-risk behaviors can be understood independent of levels of drug -taking frequency, or whether the observed data are more consistent with complex patterns of interdependency between executive dysfunction, drug-taking frequency, and HIV-risk-behaviors.
1751709|NCT00198874|Behavioral|Integrated Family and Cognitive-Behavioral Therapy|The family therapy component of IFCBT includes engagement, active treatment, and maintenance phases. The cognitive program focuses on harmful effects of drugs and strategies to better manage drug abuse risks. The cognitive-behavioral program introduces youths to problem-solving behavior change principles and study skills to promote school achievement.
1751710|NCT00198874|Other|Education|Drug education curriculum was delivered to participants assigned to this condition.
1751711|NCT00205426|Drug|Natrecor|Natrecor will be initiated as a bolus dose of 2 mcg/kg followed by a continuous infusion via infusion pump after induction of anesthesia but prior to incision. Natrecor infusion will be started at the recommended rate of 0.01mcg/kg/min. This dose may be adjusted by the investigator(s) only based on hemodynamic monitoring and pulmonary parameters. Study drug will be infused for a minimum of 24 hours and a maximum of 96 hours.
1751712|NCT00205465|Drug|VX-765|
1751713|NCT00205478|Drug|VX-702|
1751714|NCT00205491|Drug|Venlafaxine|
1956627|NCT02764437|Biological|Whole lung antigen challenge, segmental allergen challenge|Whole lung antigen challenge with housedust mite, short ragweed or cat hair allergen extracts. Segmental allergen challenge with housedust mite, short ragweed or cat hair allergen extracts.
1751716|NCT00205517|Procedure|Daily interruption of sedation versus sedation algorithm|
1751717|NCT00205530|Behavioral|Brain Injury Family Intervention (BIFI)|The Brain Injury Family Intervention (BIFI) was developed over the last decade based upon considerable clinical experience and research review. The BIFI is a structured approach to helping families address their most common and salient issues, concerns, and challenges. The BIFI is implemented in five 90-minute sessions.
1751718|NCT00205543|Procedure|uvulopalatopharyngoplasty with or without sutures|standard UPPP
1751721|NCT00205569|Behavioral|First Steps Educational Curriculum|10 sessions with the research participant to review an educational curriculum regarding brain injury rehabilitation and community reintegration
1751722|NCT00205582|Device|Positron Emission Tomography|
1751723|NCT00205595|Device|Positron Emission Tomography|
1751724|NCT00205608|Device|Positron Emission Tomography|camera is new
1751725|NCT00205621|Device|Positron Emission Tomography|
1751726|NCT00205634|Drug|Biaxin ( clarithromycin)|
1751727|NCT00205647|Drug|Oral N-acetycystein (NAC)|
1751728|NCT00205660|Drug|ziprasidone|Subjects are randomized to continue current ziprasidone or to switch to aripiprazole
1751729|NCT00205660|Drug|risperidone|Subjects are randomized to continue current risperidone or to switch to aripiprazole
1751730|NCT00205660|Drug|olanzapine|Subject's are randomized to continue current olanzapine or switch to aripiprazole
1751731|NCT00205660|Drug|quetiapine|Subject's are randomized to continue current use of quetiapine or switch to aripiprazole
1751732|NCT00205660|Drug|aripiprazole|participants randomized to stay on current treatment (ziprasidone) or switch to aripiprazole
1751733|NCT00205660|Drug|aripiprazole|Participants randomized to stay on current treatment (risperidone) or switch to aripiprazole
1751734|NCT00205660|Drug|aripiprazole|Participants randomized to stay on current treatment (olanzapine) or switch to aripiprazole.
1751735|NCT00205660|Drug|aripiprazole|Participants are randomized to either stay on their current treatment (quetiapine) or switch to aripiprazole
1751736|NCT00205686|Drug|DHEA|
1751737|NCT00205686|Behavioral|exercise|
1751741|NCT00205712|Drug|Ketamine|Ketamine without dexmedetomidine
1751742|NCT00205712|Drug|Dexmedetomidine|Ketamine plus dexmedetomidine
1751743|NCT00205725|Drug|Ziprasidone, Olanzapine|
1751744|NCT00205738|Drug|Risperidone, Olanzapine|
1751745|NCT00205751|Drug|Thalidomide/Dexamethasone vs Melphalan/Prednisone|
1751746|NCT00205764|Drug|Melphalan|
1751747|NCT00205777|Drug|Bazedoxifene Acetate|BZA 20mg, daily, oral
1751748|NCT00205777|Other|Placebo|Placebo, daily, oral
1751749|NCT00205790|Device|Vascular graft|
1751750|NCT00205803|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
1751751|NCT00205803|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnC)|
1751752|NCT00205816|Drug|Tigecycline|
1751753|NCT00205829|Device|battery-powered bion(R) microstimulator system|Stimulation on from initial activation and on.
1751754|NCT00205842|Drug|alvimopan|
1751755|NCT00205855|Device|Precision SCS|Advanced Bionics totally implantable Spinal Cord Stimulation (SCS) System, the Stimulus System. This system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable low back pain and leg pain.
1751758|NCT00205894|Device|bion microstimulator|
1751759|NCT00205907|Biological|BLVR Hydrogel|10 mL BLVR Hydrogel
1751760|NCT00205920|Biological|BLVR Hydrogel|10 mL BLVR Hydrogel
1751761|NCT00205946|Drug|Bupropion|150 mg of bupropion administered 5 hours before fMRI scanning
1751762|NCT00205946|Drug|Placebo|Administered 5 hours prior to fMRI scanning (randomly assigned, double blind)
1751763|NCT00205959|Device|Locking proximal humerus plate|
1751764|NCT00205959|Device|Proximal Humerus Internal Locking System|
1751765|NCT00205959|Device|Proximal Humerus Nail|
1751766|NCT00205972|Device|Humerus Nail or LC Plate|
1751767|NCT00205985|Device|Scaphoid screw|Conservative treatment versus application of scaphoid screw
1751768|NCT00205998|Device|Locking Compression Plate 2,4mm|
1751769|NCT00205998|Device|Locking Compression Plate 3,5mm|
1751770|NCT00206011|Procedure|Endoscopic surgery|Open surgical intervention compared to endoscopic intervention
1751771|NCT00206024|Drug|Esomeprazole magnesium (Nexium)|
1751772|NCT00206037|Device|COLLOSS E|
1751773|NCT00206037|Device|TomoFix Plate|
1751774|NCT00206050|Drug|Esomeprazole|
1751775|NCT00206050|Drug|pantoprazole|
1751776|NCT00206063|Drug|EXANTA|
1751777|NCT00206076|Drug|mycophenolate mofetil|mycophenolate mofetil and half their baseline dose of calcineurin inhibitor
1751778|NCT00206076|Drug|mycophenolate mofetil|mycophenolate mofetil monotherapy
1751779|NCT00206089|Drug|EXANTA|
1751780|NCT00206102|Drug|quetiapine fumarate|flexible dose oral
1751781|NCT00206102|Drug|risperidone|flexible dose oral
1751782|NCT00206115|Drug|Seroquel Sustained Release (SR)|
1751783|NCT00206115|Drug|Seroquel Immediate Release (IR)|
1751784|NCT00206115|Drug|Placebo|
1751785|NCT00206128|Drug|Seroquel SR|
1751786|NCT00206141|Drug|Quetiapine Fumarate (Seroquel™) drug, mood stabilizer (mood)|
1751787|NCT00206154|Drug|Budesonide/formoterol pMDI|
1751788|NCT00206154|Drug|Budesonide pMDI|
1751789|NCT00206154|Drug|Formoterol Turbuhaler|
1751790|NCT00206167|Drug|Budesonide/formoterol pMDI|
1751791|NCT00206167|Drug|Formoterol Turbuhaler|
1751792|NCT00206180|Drug|esomeprazole magnesium (oral medication)|
1751793|NCT00206193|Drug|mifepristone|
1751794|NCT00206193|Drug|misoprostol|
1751795|NCT00206193|Drug|sulprostone|
1751796|NCT00206206|Procedure|Hyperglycemia Protocol Procedure|
1751797|NCT00206219|Drug|Gefitinib|
1751798|NCT00206219|Drug|methotrexate|
1751799|NCT00206232|Drug|Spironolactone|Research subjects are randomized to placebo versus spironolactone 25mg daily and followed for 6 months.
1751800|NCT00206245|Drug|AZD0865|
1751801|NCT00206258|Drug|Pramlintide and glucagon|
1751802|NCT00206271|Behavioral|neck collar; advice to act-as-usual; active mobilisation|
1751803|NCT00206284|Drug|AZD0865|
1751804|NCT00206297|Drug|Pramlintide|
1751805|NCT00206310|Drug|CRESTOR|
1956630|NCT02764125|Drug|Stalevo|levodopa/carbidopa/entacapone
1751808|NCT00206375|Drug|Growth hormone|Growth hormone + Synthroid + Lupron
1751809|NCT00206375|Drug|Growth hormone treatment and puberty|Lupron once a month and growth hormone daily
1751810|NCT00206388|Drug|Zolendric acid|IV, 2mg/m2/dose on day 0
1751811|NCT00206388|Drug|Cyclophosphamide|fixed dose of 25mg/m2/dose days 0-27
1751812|NCT00206401|Drug|Lantus and short acting analogs Vs NPH and short acting analogs|
1751813|NCT00206414|Drug|Iressa Day 1 given with Arimidex and Faslodex|timing of administration of iressa is the study factor
1751814|NCT00206414|Drug|Iressa Day 21 given with Arimidex and Faslodex|Timing of Iressa is the study factor
1751815|NCT00206427|Drug|GW572016|Lapatinib, 500 mg
1751816|NCT00206427|Drug|lapatinib|Lapatinib 500 mg PO
1751817|NCT00206440|Drug|esomeprazole|nexium
1751818|NCT00206440|Drug|Esomeprazole (aka Nexium)|Esomeprazole (20 mg daily ranitidine 300 mg daily) during Cycle 1 Days 1-5 and Cycle 2 Days 1-5
1751819|NCT00206440|Other|Placebo|Placebo 1 pill daily Cycle 1 Days 1-5 and Cycle 2 Days 1-5
1751820|NCT00206453|Drug|Taxotere|Chemotherapy IV
1751821|NCT00206466|Drug|Taxotere|Docetaxel (Taxotere) 100 mg/m2 is to be administered on day 1. A core biopsy is to be performed one day after chemotherapy (day 2) and on days 8, 15 and 22. On day 22, after repeat core biopsy, a second cycle of docetaxel (Taxotere) chemotherapy (100 mg/m2) will be given. Docetaxel (Taxotere) will be given three-weekly for a total of four cycles. Primary surgery will then be conducted, if operable, following completion of neoadjuvant treatment. Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
1751822|NCT00206466|Drug|Adriamycin/cytoxan|Adjuvant AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every three weeks) for four cycles will then be administered. Adjuvant radiotherapy will be considered following completion of AC chemotherapy. Patients whose tumors were ER and/or PgR positive would be commenced on tamoxifen for five years after completion of AC chemotherapy.
1751823|NCT00206492|Drug|Iressa|Iressa
1751824|NCT00206492|Drug|Tamoxifen|Tamoxifen
1751825|NCT00206505|Drug|Taxotere|
1751826|NCT00206518|Drug|Taxotere/Docetaxel|Taxotere
1751827|NCT00206518|Drug|Adriamycin/Cytoxan|Adriamycin/Cytoxan
1751828|NCT00206518|Drug|doxorubicin|AC (doxorubicin 60 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks) for 4 cycles before surgery.
1751829|NCT00206544|Drug|Tamoxifen|40 mg daily of adjunctive tamoxifen in oral capsule
1751830|NCT00206544|Drug|Progesterone|20 mg daily of adjunctive progesterone in oral capsule
1751831|NCT00206544|Other|placebo|adjunctive placebo daily in oral capsule
1751832|NCT00206557|Drug|Raloxifene|
1751833|NCT00206557|Drug|Estradiol/dyhydroprogestrone|
1751834|NCT00206570|Drug|Estradiol|
1751988|NCT00208143|Drug|Quetiapine|
1751835|NCT00206583|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|GA: Estradiolvalerate (EV)/Dienogest (DNG) Tablet p.o. (oral) Tablet, p.o. (oral)
1751836|NCT00206596|Drug|Sargramostim (Leukine)|Once daily via subcutaneous injection for up 22 weeks
1751837|NCT00206596|Drug|Placebo|Once daily via subcutaneous injection for up 22 weeks
1751838|NCT00206609|Procedure|Oxygen and air administration|
1751839|NCT00206622|Drug|Climara PRO (Estradiol / Levonorgestrel transdermal)|2.2mg 17 Beta-estradiol/0.69mg levonorgestrel combination transdermal patch
1751840|NCT00206622|Drug|Menostar (Estradiol transdermal)|1mg 17 Beta-estradiol transdermal patch
1751841|NCT00206622|Drug|Placebo transdermal|Placebo
1751842|NCT00206635|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Betaseron was not administered as part of this study, only the treatment and disease status was assessed. As part of the MRI analysis Gadolinium was administered in patients who underwent this procedure
1751843|NCT00206648|Drug|Betaferon/Betaseron|Betaseron 250 µg SC every other day
1751844|NCT00206648|Drug|Betaferon/Betaseron|Avonex 30 µg IM once per week
1751845|NCT00206661|Drug|Sargramostim (Leukine)|4 mcg sargramostim with and without corticosteroids
1751846|NCT00206661|Drug|Sargramostim (Leukine)|6 mcg sargramostim with and without corticosteroids
1751847|NCT00206674|Drug|Sargramostim (Leukine)|6µg/kg SARGRAMOSTIM subcutaneous daily for 8 weeks
1751848|NCT00206674|Drug|Placebo|Sterile liquid solution, inactive excipient only subcutaneous daily for 8 weeks
1751849|NCT00206687|Biological|Spheramine (BAY86-5280)|Bilateral implantation of Spheramine into the postcommissural putamen, each side at a dose of 325,000 cells
1751850|NCT00206687|Procedure|Placebo|Sham surgery procedure without penetration of the dura mater. Nothing wil be implanted into the brain.
1751851|NCT00206700|Drug|Sargramostim (Leukine)|Open Label, 8 week cycle
1751852|NCT00206713|Drug|Sargramostim (Leukine)|6 μg/kg sargramostim administered SC once daily for 8 weeks
1751853|NCT00206713|Drug|Placebo|Placebo administered SC once daily during the randomized retreatment phase.
1751854|NCT00206726|Drug|Alemtuzumab plus Fludarabine|Alemtuzumab (Campath) 30mg subcutaneous (SC) plus Fludarabine (Fludara) 25mg/m² intravenous (IV), Days 1-5 every 28 days
1751855|NCT00206739|Drug|Sulfadoxine (12.5 mg)/Pyrimethamine (250 mg)|
1751856|NCT00206752|Radiation|Radiation therapy|definitive external beam radiation in the ipsilateral neck.
1751857|NCT00206752|Radiation|definitive external beam radiation in the ipsilateral neck|definitive external beam radiation in the ipsilateral neck
1751858|NCT00206765|Drug|Risperidone|
1751859|NCT00206765|Drug|Paroxetine|
1751860|NCT00206778|Drug|Lamotrigine|
1751861|NCT00206778|Drug|Sodium Valproate|
1751862|NCT00206791|Device|MBCP-Gel (tm)|
1751863|NCT00206817|Device|Triage CardioProfilER (Troponin I, Myoglobin, CK-MB, BNP)|
1751864|NCT00206830|Device|Triage Profiler S.O.B. Panel|
1751865|NCT00206843|Device|Triage BNP Test|
1751866|NCT00206856|Device|Triage® B-Type Natriuretic Peptide (BNP) Test|
1751867|NCT00206869|Behavioral|exercise|
1751868|NCT00206869|Behavioral|heat|
1751869|NCT00206869|Procedure|red light illumination|
1751870|NCT00206882|Drug|corticosteroids|
1751871|NCT00206895|Procedure|Photodynamic therapy|
1751872|NCT00206921|Device|Pulsed dye laser|
1751873|NCT00206921|Device|Intense pulsed light|
1751874|NCT00206934|Drug|Escitalopram|Either 10 mg of escitalopram or placebo will be administered to a group of healthy volunteers
1751875|NCT00206934|Drug|escitaolpram|Either 15 mg of escitalopram or placebo will be administered to healthy volunteers
1751876|NCT00206947|Drug|donepezil (5-10 mg/day)|Donepezil will be administered in a dose optimized for treatment, to patients who are stabilized on a ziprasidone treatment
1751877|NCT00206947|Drug|Placebo|Placebo will be added to the medication of schizophrenia patients who are first stabilized on a ziprasidone treatment
1751878|NCT00206960|Drug|zuclopenthixol|Patients will be administered zuclopenthixol orally in doses between 4 -24 mg/day, depending on an effective reduction of symptoms
1751879|NCT00206960|Drug|risperidone|Patients will be administered risperidone orally in doses between 1-6 mg/day, depending on an effective reduction of symptoms
1751880|NCT00206973|Procedure|mannitol test|
1751881|NCT00206986|Drug|clonidine|Either placebo or 25 ug, 50 uG 75 ug or 150 ug of clonidine will be added to the current medication of patients with schizophrenia, who are stable on their current medication
1751882|NCT00206986|Drug|clonidine|0.15 mg of clonidine will be administered to 20 healthy male volunteers
1751883|NCT00206999|Drug|imipramine|Either 50 mg of imipramine or placebo will be administered to healthy male volunteers
1751884|NCT00207012|Drug|BMS-599626|
1751885|NCT00207025|Drug|BMS-275183|
1751886|NCT00207051|Drug|Brivanib + Cetuximab|Tablets/IV, Oral/IV , Brivanib 800 mg + Erbitux 400 mg/m2 X 1, followed by 250mg/m2, Brivanib QD / Erbitux QW, up to 48 weeks
1751887|NCT00207064|Drug|quetiapine|flexible doses according to the clinical condition
1751888|NCT00207077|Drug|Cetuximab + Erlotinib|IV solution + tablet, IV+ oral, ERB 100 mg/m2, 200 mg/m2, 250 mg/m2 IV + Erl 150 mg tablet, ERB weekly/ Erl once daily, Until disease progression.
1751889|NCT00207090|Drug|ixabepilone|ixabepilone solution, intravenous, 40 mg/m2, once every 3 weeks until disease progression
1751890|NCT00207090|Drug|Rifampin|rifampin tablets, oral, 600 mg once daily, only on Days 15 to 21 of Cycle 1 and Days 1 to 7 of Cycle 2
1751891|NCT00207103|Drug|Brivanib|Tablets, Oral, 180 mg, once daily, until disease progression
1751892|NCT00207103|Drug|Brivanib|Tablets, Oral, 320 mg, once daily, until disease progression
1751893|NCT00207103|Drug|Brivanib|Tablets, Oral, 600 mg, once daily, until disease progression
1751894|NCT00207103|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression
1751895|NCT00207103|Drug|Brivanib|Tablets, Oral, 800 mg, once daily (5 days on, 2 days off), until disease progression
1751896|NCT00207103|Drug|Brivanab|Tablets, Oral, 1000 mg, once daily, until disease progression
1751897|NCT00207116|Drug|Cetuximab|IV solution, IV, 400 mg/m2 initial dose followed by weekly doses of 250 mg/m2, Weekly, until disease progression.
1751989|NCT00208143|Drug|Risperidone|
1751898|NCT00207129|Drug|Ixabepilone|Solution, I.V. infusion, 40 mg/m2, Cycles 1-18: once per cycle (Day 1) cycles 2-18 (6-54 weeks) depending on response.
1751899|NCT00207129|Drug|Capecitabine|Tablets, Oral, 1000 mg/m2, Cycle 1: Once (Day 1) Cycle 2: Twice daily (Days 1-5) Cycles 3-18: None, 2 cycles (6 weeks).
1751900|NCT00207142|Drug|Atazanavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
1751901|NCT00207142|Drug|Atazanavir + Ritonavir + 2 NRTIs|Capsules, tablets, Oral, 48 weeks (after a 26-to-30-week induction phase with ATV 300 mg + RTV 100 mg + 2 NRTIs)
1751902|NCT00207155|Drug|Cetuximab|IV solution, IV, 400 mg/m2 initial dose + 250-400 mg/m2 weekly, Weekly, Until disease progression.
1751903|NCT00207168|Behavioral|Compliance|
1751904|NCT00207194|Behavioral|Automated Telephone Program|The intervention incorporated principles of social cognitive theory, the transtheoretical model of behavioral change, and motivational interviewing, and was tailored to the user's values. Content was also adapted to cultural characteristics of culturally African-American adults (i.e., not Caribbean-American, Black-Hispanic, etc.). These participants also received the same health behavior education those in the control condition received.
1751905|NCT00207194|Behavioral|Health Behavior Education|Participants received a 75-page resource manual that described hypertension, listed dietary recommendations, heart healthy food recipes, and local resources for exercise, and provided information to support antihypertensive medication adherence. They received a 20-min education session based on the content of this manual, and were given a pedometer and a digital weight scale (Healthometer, model # HDR900KD01).
1751906|NCT00207207|Procedure|Alternate site blood glucose testing|
1751907|NCT00207220|Procedure|arterial tonometry|used to determine peripheral arterial vascular tone by measuring blood pressure waveforms via a probe attached to the finger.
1751908|NCT00207220|Procedure|echocardiography|ultrasound test using sound waves to create a moving picture of the heart
1751909|NCT00207233|Behavioral|MCT oil hypocaloric liquid diet|"The MCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 34 grams MCT oil (Life Enhancement Products, Inc. Petaluna, CA; 8.3 kcal/gm) added per day to the HMR shakes.
The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
1751910|NCT00207233|Behavioral|LCT hypocaloric liquid diet|"The LCT diet will consist of 5 liquid meals using a commercial product (HMR 800 Health Management Resources, Inc.; 160 kcal/shake) plus 31.5 grams LCT oil (corn oil; 9 kcal/gm) per day. Both diets will be isocaloric (1083 kcal/day) consisting of 38% CHO, 28% pro, 34% fat.
The intervention will last 3 months. After the first 6 weeks you will be assessed for 5% weight loss. If reach this weight change you will continue on the same intervention for another 6 weeks. Those who do not lose 5% of their baseline weight will be withdrawn from the study."
1751911|NCT00207233|Procedure|Subcutaneous abdominal adipose tissue biopsy|"Subcutaneous adipose tissue biopsies from human subjects will provide tissue samples for ex vivo analysis of adipocytokine production and cell size. Subcutaneous adipose tissue will be sampled by needle biopsy at the suprailiac crest skinfold using standard sterile technique. After a 10 cm area is isolated, cleaned and anesthetized with 1% lidocaine, a small cutaneous incision (1 cm) will be performed. A 50 cc syringe with a 19-gauge needle will be used to aspirate approximately 150 mg of adipose tissue which will require 2 to 6 passes of the needle. Sutures will be used to close the skin incision and a dry sterile dressing applied.
This will be performed at baseline, 6 weeks, and 12 weeks."
1751912|NCT00207259|Behavioral|Reiki & Relaxation Response Therapy with Cognitive Restructuring|"Relaxation Therapy: Practice of focus on breathing or repeated word while ignoring random thoughts without bias. Designed to lower heart rate, blood pressure and stress.
Reiki: Practice of laying on hands by a Reiki therapist in order to channel patient's energy, considered calming and pleasant."
1751913|NCT00207272|Behavioral|1170-1870 kcal/day liquid diet|
1751914|NCT00207272|Procedure|Gastric bypass surgery|
1751915|NCT00207272|Procedure|Biopsy.visceral adipose tissue|
1751916|NCT00207272|Procedure|Biopsy.omental adipose tissue|
1751917|NCT00207272|Procedure|Biopsy. subcutaneous abdominal adipose tissue|
1751918|NCT00207272|Procedure|Blood sample|
1751919|NCT00207285|Behavioral|Sleep Hygiene Education|Baseline general meetings with officers in intervention districts, in which we will provide an introductory program on optimal caffeine use (caffeine re-education) and sleep hygiene, as these are cost-effective measures that may effectively address difficulties adjusting to night work, and low-grade sleep disorders such as mild shift work sleep disorder across the cohort as a whole.
1751920|NCT00207285|Procedure|Screening and Treatment of Sleep Disorders|All individuals who screen positive in the questionnaires on the baseline survey will be referred to one of the physicians at Sleep HealthCenters® or other sleep clinics in Massachusetts. Individuals will be paid $40 for attending an initial consultation visit with a sleep clinician and $400 if they are then asked to undergo an overnight sleep study and they complete the sleep study. Individuals will also be asked to wear an ApneaLink device for 2 nights at home and for 1 night during the overnight visit at Sleep HealthCenters®. Subjects may be asked to wear the ApneaLink device for more than 2 nights if there are not 4 hours of usable data each night. If the data is inadequate, subjects will be asked to wear the device until 4 hours of usable data on 2 nights is achieved. The ApneaLink device is an FDA approved sleep-screening tool that is used to identify individuals that are at risk for Obstructive Sleep Apnea Syndrome.
1751921|NCT00207298|Procedure|Positron Emission Tomography|
1751922|NCT00207311|Drug|Xenical, Pegasys, Copegus|Xenical 120mg three times daily for 36 weeks or xenical placebo (Arm 1). Pegasys 180 mcg weekly for 48 weeks. Ribavirin daily for 48 weeks.
1751923|NCT00207311|Behavioral|Xenicare Program|Xenicare program for 36 weeks.
1751924|NCT00207324|Device|Silver Leaf Dressing|
1751925|NCT00207337|Device|Exhale Drug-Eluting Stent|
1751926|NCT00207350|Device|Interstitial Laser Therapy|Device
1751927|NCT00207363|Drug|Ribavirin, Peg interferon alfa 2b|Peg interferon alfa 2b 1.5mcg/kg/wk for 48 weeks ribavirin 13+/-2 mg/kg daily for 48 weeks
1751928|NCT00207363|Drug|induction therapy|Peg Intron 3.0mcg/kg/wk for 12 weeks then Peg interon 1.5mcg/kg/week for 36 weeks
1751929|NCT00207376|Device|Solysafe Septal Occluder|
1751990|NCT00208156|Drug|Mifepristone|
1751930|NCT00207402|Drug|rosiglitazone|Infergen 15mcg/ d Avandia qd Ribavirin bid
1751931|NCT00207415|Behavioral|ASHC and CDSMP|
1751932|NCT00207428|Drug|Carbamazepine|
1751933|NCT00207441|Behavioral|Arthritis Self management program|
1751934|NCT00207441|Behavioral|Chronic Disease Self Management Program|
1751935|NCT00207454|Behavioral|Social Cognitive Counseling|
1751936|NCT00207467|Behavioral|Patient-delivered partner treatment|
1751937|NCT00207467|Behavioral|Booklet-enhanced partner referral|
1751938|NCT00207480|Behavioral|Brief, motivational interviewing intervention|
1751939|NCT00207493|Behavioral|Kit enhancement to referral|
1751940|NCT00207493|Procedure|patient referral versus contract referral|
1751941|NCT00207506|Behavioral|HoMBReS: A lay health advisor approach to STD prevention|
1751942|NCT00207519|Behavioral|weekly behavioral modification group|
1751943|NCT00207519|Behavioral|liquid meal replacements|
1751944|NCT00207532|Drug|folic acid|
1751945|NCT00207558|Drug|folic acid|
1751946|NCT00207571|Behavioral|Computer|
1751947|NCT00207584|Drug|Doxycycline treatment|
1751948|NCT00207610|Behavioral|Daily iron supplements of 65 mg a day for 3 months|
1751949|NCT00207610|Behavioral|Universal anemia screening and treatment|
1751950|NCT00207610|Behavioral|Selective anemia screening and treatment|
1751951|NCT00207623|Behavioral|Arthritis Basics for Change Education program|
1956631|NCT02764125|Drug|levodopa MR|levodopa MR/carbidopa/ODM-104
1751953|NCT00207649|Behavioral|Shared decision-making for PSA screening tool|Interventions to Improve Shared Decision-Making: Prostate Cancer Screening is a prospective study of educational interventions to improve shared decision-making of physicians and their patients about prostate cancer screening. Physicians will be randomized by practice site to receive standard informational brochures (control group) or a novel web-based interactive curriculum that provides education about prostate cancer screening, including potential benefits and harms, fundamentals of effective patient counsel, and shared decision-making. In addition, patients at intervention sites will be randomized to receive either the brochure or a patient-oriented interactive curriculum covering content similar to that contained in the physician tool. Physicians in all groups will also see one unannounced standardized patient (SP) trained to portray a patient interested in discussing PSA.
1751954|NCT00207662|Drug|infliximab or placebo|
1751955|NCT00207675|Drug|infliximab|
1751956|NCT00207688|Drug|Infliximab 5 mg/kg|Patients who received infliximab 5 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
1751957|NCT00207688|Drug|Infliximab 10 mg/kg|Patients who received infliximab10 mg/kg from C0168T37, C0168T46, C0168T72 studies will be observed.
1751958|NCT00207688|Drug|Placebo|Patients who received placebo from C0168T37, C0168T46, C0168T72 studies will be observed.
1751959|NCT00207701|Drug|infliximab|
1751960|NCT00207714|Drug|Golimumab|Type=exact, unit=mg/ml, number= 50 to 100 , form=powder for solution for infusion, route=sub cutaneous.
1751961|NCT00207714|Drug|MTX|Type=exact, unit=mg/ml, number= 10, form=powder for solution for infusion, route=sub cutaneous
1751962|NCT00207714|Drug|Placebo|Type=exact, unit=mg/ml, form=powder for solution for infusion, route=sub cutaneous
1751963|NCT00207714|Drug|Infliximab|Type=exact, unit=mg/ml number= 10, form=powder for solution for infusion, route=sub cutaneous
1751964|NCT00207727|Drug|CNTO 1275|
1751965|NCT00207740|Drug|CNTO148|Type=exact type, unit=mg, number=50, 75, 100, 150, 200 and 300, form=injection, route=subcutaneous. Every 4 weeks partciapnts will receive injections in 4 parallel treatment arms
1751966|NCT00207740|Drug|Placebo|Type=exact type, unit=mg, form=injection, route=subcutaneous. Placebo will be given from from Week 0 through Week 52.
1751967|NCT00207753|Drug|albendazole vs. combined albendazole/ivermectin treatment|
1751968|NCT00207766|Drug|infliximab or placebo|
1751969|NCT00207779|Device|heparin impregnated central venous catheters|
1751970|NCT00207792|Drug|filgrastim|
1751971|NCT00207805|Procedure|autologous PBSC transplant|optimal timining of a second autologous transplant
1751972|NCT00207818|Device|self assembled skin substitute (SASS)|Wound care with self assembled skin substitute (SASS)
1751973|NCT00207831|Drug|Tegafur and Uracil|
1751974|NCT00207844|Drug|Selenium as sodium selenite|
1751975|NCT00207935|Behavioral|Swallow instruction|
1751976|NCT00207948|Drug|Dose adjustment of Kaletra|Adjust the dose by up to +50% of reccomended dosa off the drug to meet target therapeutic concentrations
1751977|NCT00207974|Drug|Marine active|
1751978|NCT00208000|Drug|Marine active|
1751980|NCT00208039|Drug|Infasurf|Infasurf 3 cc/kg instilled via endotracheal tube, repeated 3 and 7 days later if infant stable and continues to meet criteria
1751981|NCT00208065|Drug|almotriptan or pseudoephedrine|
1751982|NCT00208078|Device|pressure support ventilator|Non invasive ventilation 4h/d 5 days a week
1751983|NCT00208091|Drug|Botulinum toxin, type B|Diluted botulinum toxin (500 Units/0.1 ml) is injected to the affected muscle(s) through a hollow core needle using electromyographic guidance. Dosage according to muscle(s) and symptom severity. Injection occurs at first visit only, after neurological evaluation.
1751984|NCT00208104|Behavioral|Motivational Interviewing|Trained nurses will interview the group using motivational interview counseling techniques. All sessions will be conducted with the aid of an adapted version of a standardized structured adherence counseling script. This script was specifically developed for use in medication adherence studies of HIV positive patients and has been provided for this trial.
1751985|NCT00208117|Drug|Sertraline (Zoloft)|Patients randomized to sertraline will receive 50 mg/d for the first 6 weeks. Based on clinical response and tolerability, the dosage will be increased to 2 tablets (100 mg/d) at the end of week 6 until the end of the study (8 weeks). If adverse events occur, the dosage will be reduced by 50 mg (1 tablet) at a time, as long as a minimum daily dose of 50 mg is maintained.
1751986|NCT00208117|Drug|Simvastatin (Zocor)|The placebo drug will be administered for 8 weeks. To ensure blinding of research assessments and the patient, all medications, including the placebo, will be reformulated into a matching number of identical-appearing pills.
1751987|NCT00208130|Drug|Topiramate|
1751996|NCT00208221|Drug|ramipril-telmisartan|
1751997|NCT00208234|Drug|Omalizumab|0.016 mg/kg IgE
1751998|NCT00208234|Drug|Placebo for Omalizumab|Placebo
1751999|NCT00208234|Drug|omalizumab|Monoclonal antibody against IgE. 0.016 mg/kg IgE
1752000|NCT00208247|Behavioral|Cognitive behavioral psychotherapy|
1752001|NCT00208260|Drug|FOLFIRI|FOLFIRI : Irinotecan : 180 mg/m² 90 min continuous perfusion during levorin d1 every 2 weeks
1752002|NCT00208260|Drug|FOLFOX-4|FOLFOX 4 : Oxaliplatine : 85 mg/m² 2h continuous perfusion during levorin d1 every 2weeks
1752003|NCT00208260|Drug|FOLFIRI-HD|High Dose FOLFIRI : Irinotecan : 260 mg/m² in 90min continuous perfusion during levorin d1 every 2 weeks
1752004|NCT00208260|Drug|FOLFOX-7|FOLFOX 7 : Oxaliplatine : 130 mg/m² in 2h continuous perfusion during levorin d1 every 2 weeks
1752005|NCT00208260|Drug|FOLFIRINOX|FOLFIRINOX : Oxaliplatine : 85 mg/m² 2h continuous perfusion followed by 1H rest followed by 90 min continuous perfusion of irinotecan : 180 mg/m² during levorin d1 every 2 weeks
1752006|NCT00208273|Drug|Letrozole - Concomitant|
1752007|NCT00208273|Drug|Letrozole - Sequential|
1752008|NCT00208286|Device|PFC Sigma Fixed Bearing|PFC Sigma Fixed Bearing system for use in total knee arthroplasty
1752009|NCT00208286|Device|PFC Sigma Mobile Bearing|PFC Sigma Mobile Bearing system for use in total knee arthroplasty
1752010|NCT00195546|Drug|DVS-233|
1752011|NCT00195559|Drug|Levonorgestrel/Ethinyl Estradiol|
1752012|NCT00195572|Drug|Isovorin|
1752013|NCT00195572|Drug|TS-1|
1752014|NCT00195585|Drug|Isovorin|
1752015|NCT00195585|Drug|UFT|
1752016|NCT00195598|Drug|VENLAFAXINE|
1752017|NCT00195598|Drug|Paroxetine|
1752018|NCT00195611|Drug|Prevenar|
1752021|NCT00195650|Biological|Adalimumab|Subcutaneous injection of 40 mg adalimumab every other week (eow) or monthly for up to 520 weeks (10 years)
1752022|NCT00195663|Biological|Adalimumab|
1752023|NCT00195663|Drug|Methotrexate|
1752024|NCT00195663|Biological|Adalimumab placebo|
1752025|NCT00195663|Drug|Methotrexate placebo|
1752026|NCT00195676|Drug|adalimumab|40 mg every other week or 40 mg every week by subcutaneous injection
1752027|NCT00195689|Biological|Human anti-TNF monoclonal antibody/adalimumab|
1752028|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 20 mg adalimumab (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
1752029|NCT00195702|Biological|Adalimumab|Self-administered, subcutaneous injection of 40 mg adalimumab (1.6 mL/injection) every other week (eow) for up to 52 weeks.
1752030|NCT00195702|Drug|Placebo|Self-administered, subcutaneous injection of placebo (1.6 mL/injection) once weekly (ew) for up to 52 weeks.
1752031|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 20 mg (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
1752032|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of adalimumab 40 mg (1.6 mL/injection) every other week (eow) (with a placebo 1.6 mL/injection on alternate weeks) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL injection) eow for up to Week 520.
1752033|NCT00195702|Biological|Adalimumab|Self-administration, subcutaneous (SC) injection of placebo solution (1.6 mL/injection) once weekly (ew) for 52 weeks, followed by self-administration, SC injection of adalimumab 40 mg (0.8 mL/injection) every other week (eow) for up to Week 520.
1752034|NCT00195715|Biological|Adalimumab|Adalimumab 40 mg by subcutaneous injection every other week or every week
1752035|NCT00195728|Drug|Hydrocodone/Acetaminophen on Extended Release|2 tablets twice daily
1752036|NCT00195741|Drug|divalproex sodium|
1752037|NCT00195754|Drug|divalproex sodium|
1752038|NCT00195767|Drug|divalproex sodium|
1752039|NCT00195780|Drug|Divalproex Sodium (Depakote ER)|
1752040|NCT00195793|Drug|fenofibrate|
1752041|NCT00195793|Drug|ezetimibe|
1752042|NCT00195793|Drug|atorvastatin|
1752043|NCT00195806|Drug|divalproex sodium|
1752044|NCT00195819|Biological|adalimumab (D2E7)|Adalimumab 40 mg every other week (eow)
1752045|NCT00195819|Biological|placebo|Placebo every other week (eow)
1752046|NCT00195845|Drug|Galantamine|
1752047|NCT00195845|Drug|Placebos|
1752048|NCT00195858|Behavioral|aerobic and resistance exercise|aerobic and resistance exercise
1752051|NCT00195884|Behavioral|Aerobic and Resistance Exercise|"Aerobic activities are performed on a cycle ergometer or treadmill. Exercise intensity is standardized using Polar Heart rate monitors that display the subject's heart rate.
Resistance training:Exercises are performed at weight machines arranged in a circuit. Throughout the resistance training program, subjects will alternate between the exercises of group A and group B below.
Group A: abdominal crunches, seated row, seated biceps curls, supine bench press, leg press, shoulder press; leg extension Group B: abdominal crunches, lat pulldown, sitting chest press, leg press, upright row, triceps pushdown, leg curls.
Combined aerobic and resistance training group will perform both aerobic and resistance training programs, as described above.
Control: members of this group are asked to revert to their pre-study activity levels for 5 months, at which point they begin the combined aerobic and resistance exercise program."
1752052|NCT00195910|Drug|Morphine and Hydromorphone|
1752053|NCT00195923|Drug|Ampicillin, gentamicin, clindamycin, flagyl, ceftazidime|
1752054|NCT00195936|Drug|Cinacalcet|
1752055|NCT00195949|Procedure|Laparoscopic pyloromyotomy|
1752056|NCT00195988|Drug|tacrolimus, steroids, mycophenolate mofetil|
1752057|NCT00196027|Device|PFX Closure System|
1752058|NCT00196040|Device|PFX Closure System|
1752059|NCT00196053|Device|Archimedes Constant Flow Implantable Pump|
1752060|NCT00196066|Device|Peripheral Vessel Stenting|
1752062|NCT00196092|Device|Roll-in|Proctored entry.
1752063|NCT00196092|Device|Surgical|Surgery
1752064|NCT00196092|Device|Standard Risk|Standard Endovascular repair
1752065|NCT00196092|Device|High Risk|High Risk Endovascular repair.
1752066|NCT00196092|Device|Compassionate Use|Endovascular repair for compassionate use patients.
1752067|NCT00196092|Device|Treatment for females|Endovascular repair in female patients
1752068|NCT00196092|Device|Standard Risk Continued Access|Continued Access Endovascular repair for standard risk patients.
1752069|NCT00196092|Device|High Risk Continued Access|Continued Access Endovascular Repair for High Risk Patients.
1752070|NCT00196105|Device|6 mm Nitinol Zilver Stent|
1752071|NCT00196105|Device|10 mm Nitinol Zilver Stent|
1752072|NCT00196105|Device|10 mm Stainless Steel Wallstent|
1752073|NCT00196118|Device|Günther Tulip Vena Cava Filter|
1752074|NCT00196131|Drug|morphine|only patients with a head injury currently receiving Morphine continuously or prm can and have an ICP drain can be enrolled into study
1752075|NCT00196144|Device|Individualized Programming of PVAB|Performance of a test to detect far-field R-wave sensing
1752076|NCT00196144|Device|Nominal PVAB|nominal pacemaker settings
1752077|NCT00196157|Procedure|linear anatomically oriented ablations|linear lesions to ablate persistent atrial fibrillation
1752078|NCT00196157|Procedure|focal electrophysiological oriented ablations|focal electrophysiologically guided ablations to treat persistent atrial fibrillation
1752079|NCT00196170|Procedure|RF ablation of the cavo-tricuspid isthmus|8mm tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
1752080|NCT00196170|Procedure|cryo ablation of the cavo-tricuspid isthmus|Cryo 10mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
1752081|NCT00196170|Procedure|irrigated tip radiofrequency ablation of the cavo-tricuspid isthmus|irrigated tip ablation catheter is used for the radiofrequency ablation of the cavo-tricuspid isthmus in typical atrial flutter
1752082|NCT00196170|Procedure|cryo 6.5mm tip ablation of the cavotricuspid isthmus|cryo 6.5mm tip ablation catheter is used for the cryo ablation of the cavo-tricuspid isthmus in typical atrial flutter
1752083|NCT00196183|Procedure|trigger-guided catheter-ablation|trigger-guided ablation of paroxysmal atrial fibrillation
1752084|NCT00196183|Procedure|trigger+substrate-guided catheter ablation|trigger-+substrate guided ablation of paroxysmal atrial fibrillation
1752085|NCT00196196|Device|Codman VPV System|Valve Positioning Verification (VPV) System
1752086|NCT00196209|Procedure|catheter ablation|catheter ablation to treat persistent atrial fibrillation
1752087|NCT00196209|Procedure|external electric cardioversion|external cardioversion and drug prophylaxis to treat persistent atrial fibrillation
1752088|NCT00196222|Procedure|RF-ablation|RF ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
1752089|NCT00196222|Procedure|cryo ablation|Cryo ablation/modulation of the slow pathway in AV nodal reentrant tachycardia
1752090|NCT00196313|Drug|levonorgestrel/EE 0.15/0.03 and EE 0.01 mg tablets|1 tablet daily by mouth
1752091|NCT00196313|Drug|Placebo tablet|1 tablet daily by mouth
1752092|NCT00201799|Drug|Infliximab|"A total of 6 doses of Infliximab will be administered as follows:
Dose 1: 10 mg/kg IV one day prior to commencing the myeloablative preparative regimen Dose 2: 10 mg/kg IV on day 0 to be given after peripheral blood stem cell infusion Dose 3: 10 mg/kg IV on day +7 Dose 4: 10 mg/kg IV on day +14 Dose 5: 10 mg/kg IV on day +28 Dose 6: 10 mg/kg IV on day +42"
1752093|NCT00201812|Drug|Etanercept|7 days prior to treatment with docetaxel. Administered twice weekly throughout the study.
1752094|NCT00201812|Drug|Docetaxel|Administered intervenously (IV) over 30 minutes through an infusion pump once a week (every 7 days). A cycle will comprise six weekly treatments followed by 2 weeks of rest.
1752095|NCT00201812|Drug|Dexamethasone|Administered orally 8 mg 12 hours prior to docetaxel, immediately prior to docetaxel (two hours after etanercept), and 12 hours after docetaxel to complete a total of 3 doses (total dose 24 mg/week) on treatment weeks.
1752096|NCT00201825|Drug|Capecitabine|1250 mg/m2/day in 2 oral daily divided doses of 625 mg/m2 on day 5 of every cycle and continued for 14 days.
1752097|NCT00201825|Drug|Docetaxel|36 mg/m2 IV weekly for 3 weeks every 4 weeks.
1752098|NCT00201838|Drug|Gemcitabine|The starting dose will be 1000mg/m2 IV, weekly x 7 with a one week rest followed by weekly x 3 with one week rest for the remainder of treatment.
1752099|NCT00201838|Drug|Etanercept|Etanercept will be self administered subcutaneously by patients with injections 11 prepared by the investigational pharmacy, beginning 7 days prior to the first dose of gemcitabine and continued twice weekly for the duration of the study.
1752100|NCT00201851|Drug|Tamoxifen|20 mg po daily x 5 years
1752101|NCT00201851|Procedure|Surgery: Oophorectomy|Group A-Surgical oophorectomy and mastectomy in estimated 5 days in mid-luteal phase of menstrual cycle (b, c) Group B-Surgical oophorectomy and mastectomy (1-6 days from randomization)(b, c) Group C-Surgical oophorectomy and mastectomy(1-6 days from registration)(c)
1752102|NCT00201864|Drug|Exemestane|25 mg orally per day
1752103|NCT00201864|Drug|Fulvestrant|250 mg IM starting on Day 8 and then every 28 days.
1752104|NCT00201877|Drug|Velcade|"Induction: 1.3 mg/m2 IV days 1 and 4 of weeks 1, 2, 4, 5, 7, 8, 10, 11, 13 & 14.
Maintenance: 1.3 mg/m2 IV day 1 weekly x 2 weeks beginning week 20 and continuing every 6 months until month 23."
1752105|NCT00201877|Drug|Rituximab|"Induction: 375 mg/m2 IV day 1 of weeks 4, 5, 7, 8, 10, 11, 13 and 14 prior to Velcade administration.
Maintenance: 375 mg/m2 day 1 weekly x 4 weeks."
1752106|NCT00201890|Procedure|Lymphatic Massage (Decongestive Lymphatic Therapy) (Arm 1)|20 weeks of lymphatic massage therapy by a certified LMT in the Vodder technique Elastic Compression Sleeve and GLove
1752107|NCT00201916|Procedure|5250 cGy/20 fractions over 28 days|see above
1752108|NCT00201916|Procedure|6600 cGy/33 fractions over 45 days|see above
1752109|NCT00201929|Procedure|Standard Decision Board|
1752110|NCT00201929|Procedure|Computer Decision Board|
1752111|NCT00201929|Procedure|Paper Decision Board|
1752112|NCT00201942|Procedure|PET scan|
1752113|NCT00201955|Drug|Rebamipide|
1752223|NCT00208338|Procedure|Rotator cuff repair|Standard surgical repair of torn rotator cuff
1752114|NCT00201968|Device|Compex Motion Stimulator|Functional Electrical Stimulation applied to the lower limbs of SCI individuals in order to stimulate walking while on Body Weight Support Treadmill
1752115|NCT00201968|Device|Compex Motion Stimulator|Specific functional electrical stimulation program developed for each individual applied while walking on the treadmill.
1752116|NCT00201968|Other|Conventional Exercise|An aerobic and resistance training program.
1752117|NCT00201981|Drug|Rebamipide|"OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks
OPC as a single drop per eye (approx 50 µL) 4 times per day for 52 weeks"
1752118|NCT00201994|Drug|Tolvaptan|
1752119|NCT00202007|Drug|Aripiprazole tablet, 5-30mg/day, oral, 6 weeks|
1752120|NCT00202007|Drug|Risperidone tablet, 1-6mg/day, oral, 6 weeks|
1752121|NCT00202020|Drug|Cilostazol 200mg/day Oral|
1752122|NCT00202020|Drug|Aspirin 100mg/day Oral|
1752123|NCT00202033|Behavioral|frequency of self monitoring blood glucose|Evaluate the impact of self monitoring blood glucose frequency on glycemic control in patients with type 2 diabetes.
1752124|NCT00202059|Drug|Zoledronic acid|
1752125|NCT00202059|Behavioral|Physical activity intervention|
1752126|NCT00202098|Procedure|Variable ventilation|"Patients will be mechanically ventilated with Variable Ventilation (3 step with increased level of variability) and traditional CMV, for a total of 4 step. Each step lasts in 60 minutes. During this period the investigators will record the gas exchange parameters and the mechanics of the respiratory system."
1752127|NCT00202111|Procedure|Laparoscopic-assisted colectomy|
1752128|NCT00202111|Procedure|Conventional open colectomy|
1752129|NCT00202124|Drug|Tryptophan|
1752130|NCT00202137|Behavioral|Home blood pressure monitoring|Monitor blood pressure using home blood pressure monitor
1752131|NCT00202137|Behavioral|Physician monitoring of blood pressure|Blood pressure measured as standard care from physician (no home monitor given for blood pressure monitoring)
1752132|NCT00202150|Behavioral|Application of a management action plan|
1752133|NCT00202163|Drug|DHEA|
1752134|NCT00202163|Drug|Testosterone|
1752135|NCT00202176|Drug|Ipratropium Bromide|Nebulized Ipratropium Bromide (4 mL) or saline solution (0.9% NaCl) (4mL) will be administered to subjects once only.
1752136|NCT00202189|Drug|Budesonide|Nebulized Budesonide (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered to subjects once only.
1752137|NCT00202202|Procedure|consultation format|
1752138|NCT00202215|Behavioral|Chrysalis Day Program|
1752139|NCT00202228|Drug|cofactor supplementation (thiamine, riboflavin, L-carnitine)|Thiamine: 50 mg po od; Riboflavin: 100 mg po od; L-carnitine: 990 mg po bid.
1752140|NCT00202241|Procedure|testosterone injection|
1752141|NCT00202254|Behavioral|Physiotherapy|
1752142|NCT00202254|Behavioral|Occupational therapy|
1752143|NCT00202254|Behavioral|Speech pathology|
1752144|NCT00202267|Device|Four-layer Bandage (Elastomeric)|Precise components of the four-layer system depend on the circumference of the ankle. All the bandages are discarded after a single use, usually one week.
1752145|NCT00202267|Device|Short-stretch Bandage (Non-elastomeric)|These bandages are applied in a figure-eight technique; two bandages are applied at full extension in opposite directions up the leg (i.e., clockwise and counter clockwise). The participant will wash the short-stretch wherever possible and reused. The number of bandages supplied to each patient will be recorded on the visit record.
1752146|NCT00202280|Drug|Folic Acid 5mg, Vitamin B12 0.4mg and B6 50mg|
1752147|NCT00202293|Drug|Olanzapine|
1752148|NCT00202293|Drug|Lithium|
1752149|NCT00202293|Drug|Chlorpromazine|
1752150|NCT00202306|Drug|lithium carbonate|
1752151|NCT00202319|Procedure|Sedation management protocol|
1752152|NCT00202332|Procedure|Coronary artery bypass|
1752153|NCT00202345|Drug|Iron sucrose|
1752154|NCT00202358|Drug|atenolol|
1752155|NCT00202358|Drug|placebo|
1752156|NCT00202371|Procedure|Red Blood Cell transfusion|
1752157|NCT00202397|Drug|Riluzole|capsule-shaped 50 mg tablets bid for 8 weeks
1752158|NCT00202397|Other|placebo|capsule-shaped tablet bid for 8 weeks
1752161|NCT00202423|Drug|Sativex|
1752162|NCT00202436|Procedure|Phlebotomy|Removal of 500 ml whole blood
1752163|NCT00202436|Procedure|Erythrocytapheresis|machinal removal of erythrocytes
1752164|NCT00202449|Drug|prazosin|taken by mouth, twice daily, titrated up to efficacy or a maximum of 5 mg at 10a and 25 mg at bedtime for duration of study
1752165|NCT00202449|Drug|paroxetine|20 mg taken at 10a for duration of the study
1752166|NCT00202449|Drug|Placebo|Placebo
1752167|NCT00202462|Drug|Testosterone gel|Testosterone gel 7.5 gm qd
1752168|NCT00202475|Procedure|eythrocytapheresis|machinal collection of erythrocytes
1752169|NCT00202475|Procedure|whole blood collection|collection of whole blood
1752170|NCT00202488|Drug|H. pylori treatment|
1752171|NCT00202501|Device|Nasal CPAP (Continuous Positive Airway Pressure)|
1752172|NCT00202514|Drug|divalproex sodium extended release|
1752173|NCT00202527|Device|Nasal continuos positive airway pressure|
1752179|NCT00202605|Drug|Neutral salts of dextroamphetamine sulfate, USP, amphetamine sulfate, USP, d-amphetamine saccharate, d,I-amphetamine aspartate monohydrate|
1752182|NCT00202631|Device|Surface Functional Electrical Stimulation|
1752185|NCT00202657|Procedure|echocardiography|
1752186|NCT00202696|Drug|nalmefene|Nalmefene HCl film-coated tablets administered orally, twice daily, for total daily dosage of 40 or 80 mg, for 5 weeks (following a 2-week titration period).
1752187|NCT00202696|Other|Placebo|Placebo tablets, administered orally, twice daily for 5 weeks (following a 2-week titration period).
1752188|NCT00202709|Behavioral|Thought Field Therapy (TFT)|Treatment with TFT twice in one week
1752189|NCT00202722|Drug|Remifentanil|Intravenous patient controlled analgesia (ivpca) during labour
1752190|NCT00202735|Procedure|Arm1:Immobilization in external rotation|Immobilization in external rotation (ER) All patients in the ER group use a prefabricated shoulder immobilizer (Don Joy Ultrasling Er,15˚ version).To control the position,a line at the top of the immobilizer is to be parallel with the frontal plane when the arm is correctly placed in 15 degrees of external rotation.
1752191|NCT00202735|Procedure|immobilization in internal rotation|All the patients in the internal rotation(IR) group are immobilized with their arm/shoulder in internal rotation by using a normal collar and cuff device.
1752194|NCT00202761|Behavioral|PIH|Intensified training
1752195|NCT00202774|Drug|(capecitabine, oxaliplatin, 5-fluorouracil)|
1752196|NCT00202787|Drug|FOLFOX-4+cetuximab|"Cetuximab; Weekly administration of Cetuximab IV (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes);
FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2"
1752197|NCT00202787|Drug|FOLFOX-4|FOLFOX-4: Every two week Oxaliplatin; 85 mg/m2 ; day 1 Folinic acid; 200 mg/m2 ; day 1 and 2 5-FU ; Bolus 400 mg/m2 + CI 600 mg/m2 22 h day 1 and 2
1752198|NCT00202800|Drug|Gemcitabine, Etoposide|Pancreatic cancer is a devastating disease. Previous research shows a correlation between a specific oncogene change (ras-mutation) and enhanced sensitivity to two chemotherapy drugs combined: gemcitabine and etoposide. This Phase II trial will evaluate this drug combination for locally advanced and metastatic pancreatic cancer
1752199|NCT00202813|Device|Cook Spectrum Pediatric Central Venous Catheter Anti-microbial Impregnated Polyurethane and Arrow Pediatric Central Venous Catheter|
1752200|NCT00202826|Procedure|Video Assisted Thorascopic Surgery Thoracostomy Tube Placement & Drainage|
1752201|NCT00202839|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program
1752202|NCT00202839|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Powder for injection in vial (120 microgram strength), subcutaneous, dose of 1.5 micrograms/kg weekly for 24 weeks during the pilot treatment program followed by 1.2 to 1.5 microgram/kg weekly for 24 weeks during the extended treatment program
1752203|NCT00202839|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program
1752204|NCT00202839|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 1000 or 1200 mg, daily for for 24 weeks during the pilot treatment program and for 24 weeks during the extended treatment program
1752205|NCT00202852|Other|Placebo|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
1752206|NCT00202852|Drug|MTX|Placebo infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose >=12.5 mg/week given orally or parenterally, maximum 20 mg/week
1752207|NCT00202852|Biological|Infliximab|Infliximab 3 mg/kg given as an infusion at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX
1752208|NCT00202852|Drug|MTX|3 mg/kg infliximab infusions at Weeks 0, 2, and 6 and every 8 weeks through Week 22 + MTX; MTX dose >=12.5 mg/week given orally or parenterally, maximum 20 mg/week
1752209|NCT00202865|Biological|infliximab|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6 and every 8 weeks thereafter. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
1752210|NCT00202865|Biological|Placebo|Placebo infusions at Weeks 0, 2, and 6. Subjects will be evaluated at Week 12 after which they will receive infliximab 3 mg/kg at Weeks 16, 18, and 22 then every 8 weeks. Subjects who lose response according to a pre-specified criteria at weeks 22 or 38 visit will increase the dose of infliximab to 5 mg/kg (rounded up to the nearest vial).
1752211|NCT00202878|Drug|ezetimibe/simvastatin|Ezetimibe/simvastatin 10/40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
1752212|NCT00202878|Drug|simvastatin|Simvastatin 40 mg per day from randomization through the end of participation. As per the original protocol, if LDL-C response was inadequate, the dose of simvastatin in the VYTORIN arm or simvastatin arm, could be increased to 80 mg (Note: per June 2011 protocol amendment, criteria for continued use of 80 mg simvastatin were modified and new increases of simvastatin dose to 80 mg were stopped).
1752213|NCT00202878|Drug|Placebo for simvastatin 40 mg|one or two tablets orally daily
1752214|NCT00202878|Drug|Placebo for ezetimibe 10 mg/simvastatin 40 mg combination|one tablet orally daily.
1752215|NCT00202891|Drug|sisomicin|
1752216|NCT00208299|Drug|Regadenoson|0.4 mg, bolus intravenous injection
1752217|NCT00208299|Drug|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
1752218|NCT00208312|Drug|Regadenoson|0.4 mg, bolus intravenous injection
1752219|NCT00208312|Drug|Adenosine|0.14 mg/kg/min for 6 minutes, intravenous infusion
1752220|NCT00208325|Device|P.F.C Sigma Fixed Bearing total knee system|Orthopaedic implant for total knee replacement
1752221|NCT00208325|Device|P.F.C Sigma RP Mobile Bearing knee system|Orthopaedic implant for total knee replacement
1752222|NCT00208338|Device|RESTORE SIS Patch|Surgical repair of torn rotator cuff with RESTORE Porcine Small Intestine Submucosa patch (RESTORE SIS Patch) reinforcement
1752558|NCT00212901|Drug|High dose ACE-I vs ARB|
1752224|NCT00208351|Device|Ultima LX Collared Stem - Non-Polished/Blasted Finished|A collared non-polished/blasted finished cementless femoral component for use in total hip replacement.
1752225|NCT00208351|Device|Ultima LX Collared Stem - Polished Finished|A collared polished finished cementless femoral component for use in total hip replacement.
1752226|NCT00208351|Device|Ultima LX Collarless Stem - Non-Polished/Blasted Finished|A collarless non-polished/blasted finished cementless femoral component for use in total hip replacement.
1752227|NCT00208351|Device|Ultima LX Collarless Stem - Polished finished|A collarless polished finished cementless femoral component for use in total hip replacement.
1752228|NCT00208364|Device|Pinnacle Acetabular Cup System|A cementless acetabular cup with metal liner for use in total hip replacement
1752229|NCT00208377|Device|DePuy ASR Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty
1752230|NCT00208390|Device|Summit Tapered Hip System|A cementless, tapered femoral component for use in total hip replacement
1752231|NCT00208403|Device|Acryloc™ GHV|A high viscosity bone cement for use in total hip replacement
1752232|NCT00208403|Device|Palacos R|A high viscosity bone cement for use in total hip replacement
1752233|NCT00208416|Procedure|DePuy MI System|A minimally invasive surgical technique used in total hip replacement.
1752234|NCT00208416|Procedure|Conventional surgical technique|A conventional surgical technique used in total hip replacement
1752235|NCT00208429|Device|Pinnacle Acetabular System|
1752236|NCT00208442|Device|Marathon™|Moderately cross-linked polyethylene liner in a modular acetabular component
1752237|NCT00208442|Device|Enduron|Standard polyethylene liner in a modular acetabular component
1752238|NCT00208455|Device|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
1752239|NCT00208468|Device|European Hip|A cementless femoral component for use in total hip replacement
1752240|NCT00208468|Device|Zweymüller|A cementless femoral component for use in total hip replacement
1752241|NCT00208468|Device|CLS Spotorno|A cementless femoral component for use in total hip replacement
1752242|NCT00208494|Device|Total Hip Replacement|Total hip replacement
1752243|NCT00208494|Device|Total hip replacement|Total hip replacement
1752244|NCT00208507|Device|28 mm ceramic head on ceramic acetabular liner.|Total hip replacement with 28 mm ceramic head on ceramic liner articulation
1752245|NCT00208507|Device|28 mm ceramic head on polyethylene liner|Total hip replacement with 28 mm ceramic head on a polyethylene liner articulation.
1752246|NCT00208520|Drug|Carbamazepine|
1752247|NCT00208520|Drug|Lamotrigine|
1752248|NCT00208520|Drug|Levetiracetam|
1752249|NCT00208533|Drug|Aripiprazole|Aripiprazole 5 mg to 30mg, individually titrated
1752250|NCT00208546|Drug|21Capecitabine + bevacizumab + oxaliplatin|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1.
1752251|NCT00208546|Drug|1Capecitabine + oxaliplatin + bevacizumab + cetuximab|3-weekly cycles: Ca 1000 mg/m2 orally day 1-14, O 130 mg/m2 i.v. day 1 (6 cycles), B 7,5 mg/kg i.v. day 1, Ce 250 mg/m2 i.v. day 1, 8, 15 (day 1 cycle 1: 400 mg/m2).
1752252|NCT00208559|Drug|Ziprasidone|Ziprasidone 40mg to 60mg per day, individually titrated
1752253|NCT00208572|Drug|Citalopram|
1752254|NCT00208585|Drug|sertraline|
1752255|NCT00208611|Dietary Supplement|Vitamin B12 Supplementation|1000 micrograms daily
1752256|NCT00209365|Procedure|exposure to grass pollen/starch granules|
1752257|NCT00209378|Other|regional anticoagulation with citrate|Regional anticoagulation with trisodium citrate is compared with standard systemic heparinization.
1752258|NCT00209378|Other|HfCitPre|regional anticoagulation with citrate containing replacement solution
1752259|NCT00209391|Drug|Gadodiamide Injection|
1752260|NCT00209404|Drug|Iodixanol 320 mg I/Ml|
1752261|NCT00209417|Drug|Iodixanol 320-Arm 1|
1752262|NCT00209417|Drug|Iopamidol 300-Arm 2|
1752263|NCT00209430|Drug|Iodixanol 320 mgI/mL|
1752264|NCT00209443|Drug|Gadodiamide Injection|
1752265|NCT00209456|Drug|DatSCAN|
1752266|NCT00209469|Drug|alendronate sodium|
1752267|NCT00209482|Drug|glucophage XR|
1752268|NCT00209495|Drug|Pregabalin; Dexamethasone|Comparing combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
1752269|NCT00209508|Drug|GPI 1485|
1752270|NCT00209521|Drug|fospropofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from AQUAVAN were 0.7 μg/mL (sedation) and 2.5 μg/mL (maintain anesthesia).
1752271|NCT00209521|Drug|propofol|Using a Target Controlled Infusion (TCI) system, the target plasma concentrations of propofol to be administered from Disoprivan were 1.0 μg/mL (sedation) and 3.0 μg/mL (maintain anesthesia).
1752272|NCT00209534|Drug|fospropofol disodium|
1752273|NCT00209547|Drug|fospropofol disodium|
1752274|NCT00209560|Drug|fospropofol disodium|
1752275|NCT00209573|Drug|fospropofol disodium|
1752276|NCT00209586|Drug|fospropofol disodium|
1752277|NCT00209599|Drug|fospropofol disodium|
1752278|NCT00209612|Drug|Taxol|Day1,15 X mg/m2, IV (in the vein)
1752279|NCT00209612|Drug|Campt, Topotesin|Day1,15 Y mg/m2, IV (in the vein)
1752280|NCT00209625|Drug|irinotecan|
1752281|NCT00209625|Drug|leucovorin|
1752282|NCT00209625|Drug|fluorouracil|
1752283|NCT00209638|Drug|irinotecan|
1752284|NCT00209638|Drug|S-1|
1752285|NCT00209651|Drug|Campto, Topotesin|q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
1752286|NCT00209651|Drug|TS-1|80 mg/m2, PO (oral) on day 1~14 of each 28 day cycle.
1752287|NCT00209664|Drug|irinotecan|
1752288|NCT00209664|Drug|S-1|
1752289|NCT00209677|Drug|Gemcitabine|
1752290|NCT00209677|Drug|S-1|
1752291|NCT00209690|Drug|Taxotere|X mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1752292|NCT00209690|Drug|5-FU|800 mg/m2, CIV (conti.in the vein) on day 1~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1752293|NCT00209690|Drug|Briplatin|15 mg/m2, IV (in the vein) on day 1~4 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1752294|NCT00209703|Drug|Oxaliplatin|
1752295|NCT00209703|Drug|l-Leucovorin|
1752296|NCT00209703|Drug|5-Fluorouracil|
1752297|NCT00209716|Drug|Taxotere|30 mg/m2, IV (in the vein) on day 1 of each 28 day cycle.
1752298|NCT00209716|Drug|5-Fluorouracil|800 mg/m2, CIV (CIV.in the vein) on day 1~5 of each 28 day cycle.
1752299|NCT00209716|Drug|Briplatin|15 mg/m2, IV (in the vein) on day 1~4 of each 28 day cycle.
1752300|NCT00209729|Drug|Taxotere|X mg/m2, IV (in the vein) on day 1 and 15 of each 28 day cycle.
1752301|NCT00209729|Drug|TS-1|Day 1-14, P.O. everyday
1752302|NCT00209742|Drug|UFT|P.O. everyday
1752303|NCT00209742|Drug|USEL/Leucovorin|P.O. everyday
1752304|NCT00209742|Drug|Krestin|P.O. everyday
1752305|NCT00209755|Procedure|therapeutic drug monitoring of ribavirin and dose adaptation|
1752306|NCT00209768|Device|Filter: NOE96E, ELD96E, NLF1E, TNA1E|
1752307|NCT00209781|Drug|Sulfadoxine-Pyrimethamine (Fansidar)|
1752308|NCT00209781|Device|ITNs|
1752309|NCT00209794|Drug|Sulfadoxine-Pyrimethamine (Fansidar)|
1752310|NCT00209807|Drug|escitalopram|escitalopram 10 mg/d for 6 weeks
1752311|NCT00209807|Drug|Reboxetine|Reboxetine 8 mg/d for 6 weeks
1752312|NCT00209807|Other|No intervention|This group of healthy volonteers will receive no drug and will be a healthy comparator.
1752313|NCT00209820|Behavioral|Supervised Nordic Walking|
1752314|NCT00209820|Behavioral|Unsupervised Nordic Walking|
1752315|NCT00209820|Behavioral|Advice to stay active|
1752316|NCT00209833|Drug|Cytarabine|
1752317|NCT00209833|Drug|Idarubicin|
1752318|NCT00209833|Drug|Etoposide|
1752319|NCT00209833|Drug|Fludarabine|
1752320|NCT00209833|Drug|G-CSF|
1752321|NCT00209833|Drug|Daunorubicine|
1752322|NCT00209846|Drug|Gaboxadol|
1752323|NCT00209859|Drug|Methotrexate|
1752324|NCT00209859|Drug|Intraarticular betamethasone|
1752325|NCT00209859|Drug|Cyclosporine/placebo-cyclosporine|
1752326|NCT00209872|Drug|Gabapentin|
1752327|NCT00209872|Drug|Lidocaine|
1752328|NCT00209872|Drug|S-ketamine|
1752329|NCT00209872|Procedure|Epidural analgesia|
1752330|NCT00209885|Drug|Gabapentin|
1752331|NCT00209885|Drug|S-ketamine|
1752332|NCT00209885|Drug|Lidocaine|
1752333|NCT00209885|Drug|Droperidol|
1752334|NCT00209898|Procedure|Fast initiation procedure|
1752335|NCT00209911|Procedure|cardioversion|
1752336|NCT00209924|Drug|Gaboxadol|
1752337|NCT00209937|Drug|Gaboxadol|
1752338|NCT00209950|Drug|Gaboxadol|
1752339|NCT00209963|Drug|Gaboxadol|
1752340|NCT00209989|Drug|Zarnestra|ZARNESTRA 100 bid (phase II recommended dose defined in phase I)will be administered continuously from one week prior to start of radiation therapy until the last day of radiation therapy.
1752341|NCT00209989|Procedure|standard Radiation therapy|Radiotherapy will be focused on the initial tumour volume with a reasonable margin of safety (2 cm). A total dose of 60 Gray (Gy) will be given to the Clinical Target Volume
1752342|NCT00210002|Drug|Darbepoetin alfa (Aranesp®)|
1752343|NCT00210002|Drug|Ferric saccharose(Venofer®)|
1752344|NCT00210015|Drug|INS37217 Nasal Spray|
1752345|NCT00210028|Drug|Tamoxifen|
1752346|NCT00210028|Drug|Zarnestra|
1752347|NCT00210041|Drug|Gemcitabine|Gemzar IV infusion 30 minutes Day 1/ Day 15 1250 mg/m²/j
1752348|NCT00210041|Drug|Cisplatin|Cisplatin 50 mg/m²/day 1 h IV infusion at Day 1 / Day 15
1752349|NCT00210054|Drug|denufosol tetrasodium (INS37217)|
1752350|NCT00210067|Drug|denufosol tetrasodium (INS37217) Intravitreal Injection|
1752351|NCT00210080|Drug|Uridine 5'-Triphosphate (UTP) Solution for Inhalation|
1752352|NCT00210093|Drug|denufosol tetrasodium (INS37217)|
1752353|NCT00210106|Device|Ablathermy|
1752354|NCT00210119|Drug|Imatinib mesylate and zoledronic acid|
1752355|NCT00210132|Drug|Ropivacaine|
1752356|NCT00210145|Behavioral|Aesthetic care|
1752357|NCT00210158|Procedure|Nitrous oxyde|
1752358|NCT00210171|Procedure|Toxicity : Time to progression, 1 and 2 years survival|
1752359|NCT00210184|Drug|Irinotecan associated to fluorouracil and leucovorin|
1752360|NCT00210197|Procedure|Blood collection (pre and postoperative): plasma coagulation parameters|
1752361|NCT00210210|Drug|Ketamine|
1752362|NCT00210223|Procedure|Radiofrequency|
1752363|NCT00210236|Procedure|Conventional surgery|
1752364|NCT00210262|Behavioral|Feedback and Education|
1752365|NCT00210275|Behavioral|Printed Educational Message|Three forms of printed educational materials (short or long educational messages and patient reminder notes)
1752366|NCT00210288|Biological|SC599|
1752367|NCT00210301|Drug|Provigil (modafinil)|
1752368|NCT00210314|Drug|high dose methotrexate|
1752369|NCT00210314|Drug|high dose cytarabine|
1752370|NCT00210314|Radiation|radiotherapy|
1752371|NCT00210327|Drug|Bortezomib (drug)|
1752372|NCT00210340|Drug|intrathecal rituximab|
1752373|NCT00210353|Drug|chlorambucil (drug)|chlorambucil 6 mg/m2 daily during the first 6 weeks of treatment, two weeks rest, chlorambucil 6 mg/m2 daily during the first two of a four weeks cycles (total of 4 cycles)
1752374|NCT00210353|Drug|rituximab+chlorambucil|rituximab 375 mg/m2 iv, d1, 8, 15, 22, chlorambucil 6 mg/m2 os, daily during the first 6 weeks of treatment, ; two weeks rest; chlorambucil 6 mg/m2 os, daily during the first two of a four weeks cycles (total of 4 cycles) rituximab 375 mg/m2 iv at day 1 of each cycle
1752375|NCT00210353|Drug|rituximab|rituximab 375 mg/m2 iv on days 1, 8, 15, 22, 56, 84, 112, 140
1752376|NCT00210366|Drug|Idarubicin|
1752377|NCT00210379|Drug|rituximab|
1752378|NCT00210379|Drug|CHOP|
1752379|NCT00210379|Drug|intrathecal methotrexate|
1752380|NCT00210379|Procedure|radiotherapy|
1752381|NCT00210392|Drug|Bortezomib (drug)|Bortezomib 1,3 mg/m2 iv d1,4,8,11 every 21 days. Total 6 cycles
1752382|NCT00210405|Dietary Supplement|"Sprinkles containing mulitple micronutrients"|
1752383|NCT00210405|Behavioral|Education/communication on use of micronutrient sprinkles|
1752384|NCT00210405|Dietary Supplement|Fortified food aid (corn-soy blend)|This intervention was part of the overall food assisted maternal and child health and nutrition program, and included fortified food aid commodities. Corn soy blend was targeted to the child, while the family also received wheat, lentils and oil.
1752385|NCT00210418|Dietary Supplement|Fortified food rations|The Fortified food rations were included in both arms, but targeted to all children 6-24 months of age in the 'preventive' arm and to malnourished children (WAZ <-2 Z-scores) in the 'recuperative arm. Food rations included Corn-Soy Blend, lentils, oil and wheat.
1752386|NCT00210418|Behavioral|Education and communication to improve feeding practices|The education and communication to improve infant and young child feeding was an integral part of the intervention. In the preventive arm, this intervention was targeted to pregnant and lactating mothers and mothers of children 0-24 months of age. The education was done using mother's groups In the recuperative arm, the BCC intervention was only targeted to pregnant and lactating women and mothers of malnourished children under the age of five.
1752387|NCT00210444|Drug|Botulinum toxin type A (Dysport)|
1752388|NCT00210457|Drug|Lanreotide (Autogel formulation)|
1752389|NCT00210470|Biological|IRX-2|IRX-2 for 10 days (2 s.c. injections of 1 mL each day), 1 initial injection of cyclophosphamide, and 3 weeks of indomethacin (tablets or injection) and zinc supplementation (multivitamin tablet)
1752390|NCT00210470|Drug|Cyclophosphamide|Single i.v. injection of low-dose (300 mg/m2) on Day 1
1752391|NCT00210470|Drug|Indomethacin|21 days of oral indomethacin, 25 mg. 3 times daily
1752392|NCT00210470|Drug|Zinc|21 days of zinc gluconate (65 mg) as part of an oral multivitamin
1752393|NCT00210470|Drug|Omeprazole|21 days of 20 mg. orally
1752394|NCT00210483|Drug|almotriptan malate|
1752395|NCT00210496|Drug|topiramate; almotriptan malate|
1752396|NCT00210509|Drug|almotriptan malate|
1752397|NCT00210522|Drug|RWJ 333369|Open-Label Extension: One 200 mg to 600mg tablet taken twice daily (up to a maximum of 1200mg/day) up to 1 year or the time that RWJ-333369 is available by prescription or the study is terminated by Sponsor.
1752398|NCT00210535|Drug|Topiramate; Placebo|
1752399|NCT00210548|Drug|paliperidone palmitate|
1752400|NCT00210561|Drug|tramadol hydrochloride , acetaminophen|
1752401|NCT00210574|Drug|topiramate|
1752402|NCT00210587|Drug|epoetin alfa|
1752403|NCT00210600|Drug|PROCRIT (Epoetin alfa)|
1752404|NCT00210613|Drug|Dapoxetine|
1752405|NCT00210626|Drug|PROCRIT|40,000 IU/mL/week for max of 12 weeks
1752406|NCT00210626|Drug|Placebo|40,000 IU/mL/week for max of 12 weeks
1752407|NCT00210639|Drug|No intervention|This is an observational study. Participants rceiving dosing regimen from the respective Phase 3 levofloxacin clinical studies will be observed in this study.
1752408|NCT00210652|Drug|RWJ 333369:|Open-Label Extension: One 250mg tablet twice daily up to a total of 1200mg/day up until RWJ-33369 is available by prescription or study is terminated by sponsor
1752410|NCT00210678|Behavioral|No intervention|No treatment is given to the patients as this is an observational study.
1752411|NCT00210691|Drug|Risperidone|
1752412|NCT00210704|Drug|Dapoxetine|
1752413|NCT00210717|Drug|paliperidone palmitate|
1752414|NCT00210730|Drug|epoetin alfa|
1752415|NCT00210743|Drug|epoetin alfa|
1752416|NCT00210756|Drug|epoetin alfa|
1752417|NCT00210769|Drug|paliperidone ER Oros|
1752418|NCT00210782|Drug|topiramate, phenytoin|
1752419|NCT00210795|Drug|epoetin alfa|
1752420|NCT00210808|Drug|topiramate|
1752421|NCT00210821|Drug|topiramate|
1752422|NCT00210834|Drug|epoetin alfa|
1752423|NCT00210847|Drug|tramadol, acetaminophen|
1752424|NCT00210860|Drug|topiramate|
1752425|NCT00210873|Drug|topiramate|
1752426|NCT00210886|Drug|levofloxacin|
1752427|NCT00210899|Drug|ceftobiprole medocaril|
1752428|NCT00210899|Drug|Vancomycin plus Ceftazidime|
1752429|NCT00210912|Drug|topiramate|
1752430|NCT00210925|Drug|topiramate|
1752431|NCT00210938|Drug|Doripenem|
1752432|NCT00210951|Other|No Intervention|Participants will not receive any intervention in this study. Participants with chronic renal disease receiving treatment with epoetin alfa or other recombinant erythropoietins will be prospectively observed to monitor incidence of pure red cell aplasia and/or antibodies to erythropoietin. Participants will receive standard-of-care treatment for their chronic renal (or other) disease from their individual Investigators.
1752433|NCT00210964|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
1752434|NCT00210964|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
1752435|NCT00210977|Drug|No intervention|This is an observational study. All participants will be maintained on their regular dose regimen of standard-of-care treatment, under the guidance of the treating physician/investigator.
1752436|NCT00210990|Drug|doripenem|
1752437|NCT00211003|Drug|doripenem|
1752438|NCT00211016|Drug|doripenem|
1752439|NCT00211042|Other|No intervention|This is an observational study. No medication will be given to the participants. Participants will receive standard-of-care treatment from their individual physicians.
1752440|NCT00211068|Drug|No intervention|This study is an observational study. No medication will be provided or administered to the participants. Participants will receive standard-of-care treatment from their individual physicians.
1752559|NCT00212914|Behavioral|Reminder letter|
1752560|NCT00212940|Behavioral|Supportive Therapy for Adherence to ART (behavior)|
1752441|NCT00211081|Drug|Spironolactone (drug)|1 mg/kg/day; afer 2 weeks doubled to 2/mg/kg/day. Patient's with endothelium-dependent brachial artery vasodilation and single-ventricle should show improvement within 4-8 weeks. Patients and their labs who are receiving Spironolactone will be followed.
1752442|NCT00211094|Drug|Dapoxetine|
1752443|NCT00211107|Drug|Dapoxetine|
1752444|NCT00211120|Drug|Epoetin Alfa|
1752445|NCT00211133|Drug|epoetin alfa|
1752446|NCT00211146|Drug|epoetin alfa|
1752447|NCT00211159|Drug|EPAX 1050TG|
1752448|NCT00211172|Behavioral|Beta-blocker adherence after an AMI|The intervention consisted of 2 mailed communications. A personalized letter was mailed first, followed approximately 2 months later by a similar letter and an accompanying brochure. Both mailings also included a wallet card that suggested questions for the patient to ask their clinician, space to list their medications, and space to record additional queries.
1752450|NCT00211198|Drug|ONTAK (denileukin difitox, DAB389IL-2)|
1752451|NCT00211211|Device|Balloon Kyphoplasty|
1752452|NCT00211224|Drug|Riluzole|
1956642|NCT02762487|Device|The LINX® Reflux Management System|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
1752455|NCT00211250|Drug|Valproic Acid and Depakote ER|
1752456|NCT00211263|Behavioral|Enhanced Clinical Intervention|
1752457|NCT00211263|Drug|mood stabilizer|
1752458|NCT00211276|Drug|ONTAK (denileukin diftitox)|
1752459|NCT00211289|Behavioral|Education by community pharmacist|
1752460|NCT00211302|Drug|aripiprazole|10-15 mg/day; if needed, dosage may be increased to 30 mg/day after week 2; maintenance 15 mg/day; periodically reassessed
1752461|NCT00211315|Drug|anecortave acetate|
1752462|NCT00211328|Drug|anecortave acetate|
1752464|NCT00211354|Drug|Anecortave Acetate|ancortave acetate 15 mg. juxtascleral injection every 6 months for 24 months.
1752465|NCT00211367|Drug|Anecortave Acetate|
1752466|NCT00211380|Drug|aripiprazole|10-15 mg daily; if needed dosage may be increased to 30 mg daily after 2 weeks; maintenance 15 mg/day, periodically reassessed.
1752467|NCT00211393|Drug|ketoconazole|600mg. /day for 6 weeks
1752468|NCT00211406|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
1752469|NCT00211419|Drug|Anecortave Acetate 15 mg|
1752470|NCT00211419|Drug|Triamcinolone Acetate 4 mg|
1752471|NCT00211419|Procedure|Photodynamic Therapy with Verteporfin|
1752472|NCT00211419|Procedure|Thermal Laser|
1752473|NCT00211432|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
1752474|NCT00211445|Procedure|Photodynamic Therapy with Verteporfin|
1752475|NCT00211445|Drug|verteporfin|
1752476|NCT00211458|Drug|Anecortave Acetate Sterile Suspension (15 mg)|
1752477|NCT00211471|Drug|anecortave acetate|
1752478|NCT00211484|Drug|Anecortave Acetate|
1752479|NCT00211497|Drug|MBI 226 Acne Solutions|
1752480|NCT00211510|Device|Paradigm 722 sensor augmented pump|Subjects use the Paradigm 722 sensor augmented pump
1752481|NCT00211510|Device|Paradigm 715 insulin pump|Subjects use the Paradigm 715 insulin pump
1752482|NCT00211523|Drug|MBI 226 Acne Solutions|
1752483|NCT00211536|Drug|Medtronic MiniMed Implantable Pump Human Recombinant Insulin|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
1752484|NCT00211536|Device|Medtronic MiniMed Implantable Pump System|The implantable pump system is intended to provide continuous intraperitoneal delivery of insulin in subjects with diabetes.
1752485|NCT00211536|Drug|Aventis HOE21PH U400|400 IU per ml - dosage based on the Investigators clinical judgement and the individual subject requirements.
1752486|NCT00211549|Drug|IDEA-033|
1752487|NCT00211562|Drug|Olanzapine, Omega 3, Vitamin E+C|No adverse event nor SAE noted.
1752488|NCT00211575|Behavioral|Disease Management Assessment|
1752489|NCT00211588|Drug|galantamine|
1752490|NCT00211601|Behavioral|Disease Management Assessment|
1752491|NCT00211614|Drug|Lansoprazole|
1752492|NCT00211627|Device|KEEPASLEEP enhanced breathing device|
1752493|NCT00211653|Drug|N-Acetylcysteine|
1752494|NCT00211666|Behavioral|Nurse management, home blood pressure monitors, and a chronic disease self management course.|
1752495|NCT00211679|Drug|Botulinum Toxin Type A|
1752496|NCT00211692|Drug|consensus interferon (Interferon Alfacon-1) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
1752497|NCT00211692|Drug|Consensus Interferon alfa (CIFN) and ribavirin|CIFN (15 mcg/day SQ) and RBV (1-1.2 g/d PO) given for either 52 weeks (group A, n = 33) or 52-72 weeks (from time of viral response +48 weeks) (group B)
1752498|NCT00211705|Behavioral|Diet|
1752499|NCT00211705|Drug|Diet+pravastatin|
1752500|NCT00211718|Drug|intra-articular botulinum toxin type a|
1752501|NCT00211731|Behavioral|Chronic Disease Self Management Course|
1752502|NCT00211744|Drug|topiramate|
1752503|NCT00211757|Drug|Divalproex sodium|Study drug.
1752504|NCT00211757|Drug|Placebo|Placebo comparator.
1752505|NCT00211770|Behavioral|Behavioral Assessment|functional behavioral assessments are conducted at two separate visits for each subject.
1752506|NCT00211783|Procedure|fMRI|there is no intervention
1752507|NCT00211796|Drug|Divalproex Sodium ER|
1752508|NCT00211809|Behavioral|Cognitive Behavioral Therapy|standard psychiatric evaluation
1752509|NCT00211809|Drug|Venlafaxine|start dose of 37.5 mg/day and increased to a minimum of 150mg/day, generally over the first 4 weeks and then maintained at that dose for 8 weeks.
1752510|NCT00211822|Procedure|fMRI|fMRI
1752561|NCT00212953|Procedure|Advanced Life Support|
1752511|NCT00211835|Behavioral|Cognitive behavioral therapy|Individual psychotherapy focused on identifying and correcting maladaptive cognitions and behaviors with the goal of improving mood. The intervention has adapted CBT specifically to address cognitive deficits associated with TBI, which compound the cognitive distortions typical of depression. CBT therapists embed compensatory strategies within treatment sessions to address cognitive limitations of each participant.
1752512|NCT00211835|Behavioral|Supportive psychotherapy|A client-centered individual psychotherapy treatment approach designed to address depressive disorders commonly experienced by individuals following a TBI. In line with traditional supportive psychotherapy approaches, the objective of SPT is to improve the individual's ability to deal with problems of daily living more effectively through problem identification, praise, reassurance, encouragement, psychoeducation, advice, anticipatory guidance, and expanding awareness.
1752513|NCT00211848|Drug|Polyenylphosphatidylcholine (PPC)|
1752514|NCT00211848|Drug|Pegylated Interferon|
1752515|NCT00211848|Drug|Ribavirin|
1752516|NCT00211874|Behavioral|Nurse-management|bilingual nurses counseled patients on diet, medication adherence, and self-management of symptoms through an initial visit and regularly scheduled follow-up telephone calls and facilitated evidence-based changes to medications in discussions with patients' clinicians.
1752517|NCT00211887|Drug|Interferon beta 1-a|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
1752518|NCT00211887|Drug|glatiramer acetate|The single agent arm is divided into two groups, IFN and GA providing for 3 treatment arms: IFN IM and GA SC (50% of the patients), IFN IM and placebo SC (25% of the patients) and GA SC and placebo IM (25% of the patients).
1752519|NCT00211887|Other|placebo|an inactive substance
1752520|NCT00211900|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Vaccine|single IM dose totalling 200 mcg of conjugate
1752521|NCT00211913|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single IM dose totalling 200 mcg of conjugate
1752522|NCT00211913|Biological|placebo|single IM dose
1752523|NCT00211926|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|single dose of vaccine containing 100 mcg of each serotype conjugate
1752524|NCT00211926|Biological|placebo|single dose of placebo
1752525|NCT00211939|Drug|calcium acetate|667 mg gelcap, 2-4 t.i.d titrated to serum phosphorus level
1752526|NCT00211939|Drug|sevelamer|1-3 tablets t.i.d, titrated to serum phosphorus level
1752527|NCT00211939|Drug|atorvastatin|20 mg PO qD (in PhosLo group), or held until D60 (sevelamer group); titrate by LDL levels and liver function tests
1752528|NCT00211952|Drug|celecoxib|
1752529|NCT00211965|Biological|S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate|single IM dose of 200 mcg total conjugate
1752530|NCT00211965|Biological|placebo|single dose IM
1752531|NCT00211978|Drug|calcium acetate|667 mg gelcaps, 1-3 t.i.d. (titrated to serum phosphorus level)
1752532|NCT00211978|Drug|placebo|gelcap, 1-3 t.i.d. (titrated to serum phosphorus level)
1752533|NCT00211991|Biological|S. aureus Type 5 & 8 Capsular Polysaccharide Conjugate|
1752534|NCT00212004|Drug|pioglitazone|
1752535|NCT00212004|Drug|sulfonylurea agents|
1752536|NCT00212017|Drug|voglibose|
1752537|NCT00212030|Drug|nicorandil|(0∙067 mg/kg as a bolus, followed by 1∙67 μg/kg per min as a 24-h continuous intravenous infusion
1752538|NCT00212030|Drug|placebo|Control
1752539|NCT00212043|Drug|carboplatin and gemcitabine|
1752540|NCT00212056|Drug|ANP(hANP)|0∙025 μg/kg per min for 3 days(intravenous)
1752541|NCT00212056|Drug|Control|placebo
1752542|NCT00212069|Drug|gemcitabine, carboplatin|
1752543|NCT00212082|Drug|doxorubicin, docetaxel|
1752544|NCT00212095|Drug|docetaxel and ketoconazole|"Docetaxel will be obtained locally from the manufacturer. Storage conditions for unopened vials, reconstitution, and storage conditions for the reconstituted solution will follow the manufacturer's recommendations. Docetaxel solutions should be prepared and stored in glass, polypropylene or polyolefin containers. Non-PVC containing and polyethylene-lined administration sets should be used.
Ketoconazole is available commercially in 200 mg tablet. Ketoconazole is to be administered at a dose of 200mg BID orally for six doses, starting two days before docetaxel administration. The fifth dose should be administered on the day of and before administering docetaxel, while the sixth dose should be administered in the evening of the day of docetaxel administration."
1752545|NCT00212108|Drug|celecoxib, gefitinib|The dose of ZD1839 to be administered is 250mg. ZD1839 will be taken once daily in the morning at approximately the same time each day. If the patient inadvertently did not take the dose in the morning, the patient may take that dose anytime up to 10pm that same day. The daily treatment will be resumed the next day at the scheduled morning dose. Celecoxib will be administered at 400 mg bd.
1752546|NCT00212121|Radiation|high dose boost|high dose boost
1752547|NCT00212121|Procedure|boost|low dose versus high dose
1752548|NCT00212134|Device|hyperopic correction of infant surgical aphakia with Contact Lens|optical correction of infant surgical aphakia with Contact lens
1752549|NCT00212134|Device|primary implantation of aphakic intraocular lens|optical correction of surgical aphakia with intraocular lens
1752550|NCT00212147|Drug|general anesthesia|anesthesia regimen with nitrous oxide or without nitrous oxide
1752551|NCT00212160|Procedure|omentectomy|RYGB with omentectomy
1752552|NCT00212173|Drug|Sibutramine|
1752553|NCT00212173|Dietary Supplement|Slim Fast|
1752554|NCT00212186|Drug|Selenium Supplements (essential nutrient)|
1752555|NCT00212862|Other|Patients with chemotherapy induced anemia|Physicians are instructed to continue to treat all patients according to their own best clinical judgment, but to submit information on the parameters and outcomes of this treatment to the database. Patients will have to fill the questionaire at the time of enrollment and baseline.
1752556|NCT00212875|Drug|epoetin alfa|
1752562|NCT00212979|Other|non intervention study|
1752563|NCT00212992|Procedure|fixed versus escalating biphasic defibrillation|
1752564|NCT00213005|Drug|Carraguard (PC-515)|
1752565|NCT00213018|Drug|Carraguard (PC-515)|
1752566|NCT00213031|Drug|Carraguard (PC-515)|
1752567|NCT00213044|Drug|Carraguard (PC-515)|
1752568|NCT00213057|Drug|Carraguard (PC-515)|
1752569|NCT00213070|Drug|Miglitol|
1752570|NCT00213083|Drug|Carraguard (PC-515)|
1752571|NCT00213096|Drug|Nestorone/ethinyl estradiol contraceptive vaginal ring; levonorgestrel/ethinyl estradiol oral contraceptive|
1752572|NCT00213109|Drug|Miglitol|
1752573|NCT00213122|Drug|miglitol|
1752574|NCT00213135|Drug|Cladribine 5.25 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the treatment period of 96 weeks.
1752575|NCT00213135|Drug|Cladribine 3.5 mg/kg|Cladribine tablet will be administered as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 48, and 52 and placebo matched to cladribine tablet will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
1752576|NCT00213135|Other|Placebo|Placebo matched to cladribine tablet will be administered over a course of 4 or 5 consecutive days of 28-day period at Weeks 1, 5, 9, 13, 48 and 52 during the treatment period of 96 weeks.
1752581|NCT00213161|Drug|iron supplement, iron drops|
1752582|NCT00213174|Behavioral|school playgrounds|
1752583|NCT00213187|Behavioral|Aerobic and Qi gong Exercise|
1752584|NCT00213200|Drug|morphine, amethocaine|
1752585|NCT00213213|Drug|Sucrose|
1752586|NCT00213226|Drug|dexamethasone|
1752587|NCT00213239|Drug|Remifentanil|The first patient in this group will receive 4 mg/kg propofol and 0.5 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
1752588|NCT00213239|Drug|Remifentanil|The first patient in this group will receive 2 mg/kg propofol and 1.0 ug/kg respectively. The dose of remifentanil in subsequent patients will be determined by the Dixon up-and-down method.
1752589|NCT00213252|Drug|Montelukast plus prednisolone|Single dose of oral prednisolone with a subsequent daily five-day course of oral Montelukast
1752590|NCT00213252|Drug|Prednisolone|Six daily doses of oral prednisolone
1752591|NCT00213265|Biological|7-valent pneumococcal conjugate vaccine|For transplant patients, vaccination will be started at 4 months or greater after transplantation. The second dose will be given 8 weks following the frist, the third dose 8 weeks after the second, and the fourth will be given 8 weeks after the third.
1752592|NCT00213265|Biological|Pneumococcal 7-valent Conjugate Vaccine|"Healthy infants: The Prevnar schedule for healthy infants consists of 3 doses of 0.5 ml each, at approximately 2 month intervals, followed by a fourth dose of 0.5 ml at 12-15 months of age (i.e., 2, 4, 6, and 12-15 months)
Previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, should receive the follwong schedule:
7-11 months of age: 3 doses (2 doses at least 4 weeks apart with the third dose after the first birthday and separated from the second dose by at least two months)
12-23 months of age: 2 doses (at least 2 months apart)
≥24 months through 9 years of age: 1 dose"
1752593|NCT00213278|Drug|vinblastine sulphate injection|Vinblastine dose: 6 mg/m^2 (10 mg max.) route intravenous administration once a week over a period of 10 weeks. If response at week 10 is greater than or equal to stable, weekly Vinblastine will be continued for 42 weeks.
1752594|NCT00213291|Drug|darbepoetin alfa|Darbepoetin alfa will be administered by SC/IV injection every 14-28 days. Patients starting on the 14 day dose regimen will receive two times their baseline weekly dose; patients on the 28 day schedule will receive four times their average weekly dose. The exception to a Q14 or Q28 dosing schedule will be for patients requiring 10 mcg every 10 days. These patients will go to 20 mcg Q21 days before extending to the Q28 day schedule. Naive patients will start on a dose of 0.9 mcg/kg every 14 days. Study subjects who are successfully treated for 12 weeks on the 14 day schedule may be enrolled in the 28 day schedule study.
1752595|NCT00213304|Biological|varicella vaccine (VARIVAX)|
1752596|NCT00213317|Procedure|lombo-sacral magnetic stimulation|repetitive lombo-sacral nerve magnetic stimulation active and placebo performed during colonic recordings after bisacodyl instillation
1752597|NCT00213330|Procedure|rectal distension|
1752598|NCT00213395|Device|Interface for noninvasive ventilation|
1752599|NCT00213408|Procedure|Radiofrequency catheter ablation of typical atrial flutter|
1752600|NCT00213421|Drug|Dermoval|group 1 elevated corticosteroids : attack treatment 2 tubes of 10g (4t/d) decreasing treatment : one month: 2 tubes/J (2t/d); 2 months : 2 tubes 1d sur 2 (1d/j); 4 months : 2 tubes 2 fois /week (0,6t/d); 4 months : 2 tubes 1 fois /week (0,3t/d)fois /week (0,3t/d) group 2 low corticosteroids : for paucibullous form with weight < 45kg attack treatment 1 tubes of 10g (1t/d)decreasing treatment 1 month : 1 tube every 2d (0,5t/d; 1 month : 1 tubes 2 fois /week (0,3t/d) 1 month : 1 tubes 1 fois/week (0,15t/d); for paucibullous form with weight > 45kg or for multibullous form with weight < 45kg attack treatment 2 tubes of 10g (2t/d)decreasing treatment 1 month : 2 tubes every 2j (1t/d; 1 month : 2 tubes 2 fois /week (0,6t/d) 1 month : 2 tubes 1 fois /week (0,3t/d)and for multibullous form attack with weigth > 45kg treatment 3 tubes of 10g (3t/d)decreasing treatment 1 month : 3 tubes every 2days (1,5t/d) 1 month : 3 tubes 2 fois /week (1t/j)1 mois : 3 tubes 1 fois /week (0,45t/d)
1752601|NCT00213434|Device|Herbst oral appliance|
1752602|NCT00213486|Drug|irinotecan|
1752603|NCT00213499|Procedure|non invasive ventilation|
1752604|NCT00213512|Drug|Mabthera|
1752605|NCT00213525|Other|Questionnary for environmental factors research|Questionnary for environmental factors research
1752606|NCT00213538|Drug|Response to anakinra associated with methotrexate|
1752607|NCT00213551|Drug|Glutamine|
1752608|NCT00213551|Drug|Glucose|
1752609|NCT00213551|Drug|glutamine-antioxidants containing solution|
1752610|NCT00213564|Drug|response to infliximab associated with methotrexate|
1752611|NCT00213577|Drug|type A botulinum toxin|
1752612|NCT00213590|Drug|cyclosporine A|The usual-exposure level was based on the mean area-under-the-concentration-time curve (AUC0-12h). In the usual-exposure group, the cyclosporine AUC0-12h target was 4.3 (3.5 to 4.8, range) mg•h/L and in the low-exposure group the target was 50% or 2.2 (2.0 to 2.6, range) mg•h/L. Ranges were asymmetrical for safety reasons, i.e., to prevent the occurrence of rejection in the low-exposure arm and nephrotoxicity in the usual-exposure arm.The AUC 0-12h was estimated using a Bayesian estimator and a three-point limited sampling strategy (0, 1, and 3 hours). A computer program was used to calculate the dose adjustment required to reach the therapeutic target. Doses were adjusted in increments of 25% to reach the target within 2 months. Cyclosporine AUC0-12h was determined every 2 months.
1752613|NCT00213616|Procedure|surgical reinnervation|laryngeal reinnervation with a phrenic nerve root
1752614|NCT00213629|Other|transcriptome analysis|transcriptome analysis from muscle biopsy
1752615|NCT00213629|Other|T cell repertoire analysis|blood T cell repertoire analysis
1752616|NCT00213655|Biological|bladder tumor recurrence|bladder tumor recurrence assessed by clinical and biological exams
1752617|NCT00213668|Dietary Supplement|glutamine (dipeptiven)|
1752618|NCT00213681|Device|Boussignac CPAP - bilevel ventilation support|
1752619|NCT00213694|Drug|docetaxel and celecoxib|
1752620|NCT00213759|Drug|filgrastim|The G-CSF (filigrastin) will be administered by intravenous way with the amount of 10 µg/kg/day during 3 days . The infusion will last from 20 to 40 minutes according to weight of the child and the product will be diluted in dextrose 5%.
1752621|NCT00213759|Drug|dextrose 5%|The placebo (dextrose 5% ) will be injected by intravenous way with the amount of 0.66 ml/kg during 3 days consecutive. The infusion will last from 20 to 40 minutes.
1752622|NCT00213798|Procedure|Biopsy samples|
1752623|NCT00213811|Behavioral|clinical, biological, and radiological|
1752624|NCT00213837|Device|Mandibular prosthesis made of a new highly biointegratable material|Replacement of mandibular bone after partial or total mandible resection,avoiding then bone grafting. The porous titanium prosthesis is implanted under general anaesthesia in laryngeal surgeries. Bone resection and prosthesis placement is performed during the same surgical intervention. The prosthesis is attached onto the healthy bone with surgical screws. Simultaneous grafting of vascularised tissues may be done if the prosthesis surrounding area has been strongly irradiated.
1752625|NCT00213850|Procedure|EFR|
1752626|NCT00213863|Device|Vocal fold medialization (thyroplasty) prosthesis by insertion of a new implant allowing very easy and quick setting|The porous titanium prosthesis is implanted under local anaesthesia. Neck incision is performed in order to expose the thyroidal cartilage. A window is then opened in this cartilage, and the implant is placed in contact with the vocal muscles. The patient is then asked to speak in order to achieve the implant best setting.
1752627|NCT00213889|Other|None: molecular genetics diagnosis procedure only|None: molecular genetics diagnosis procedure only
1752628|NCT00213915|Drug|12 g of L-arginine glutamate during 6 weeks twice a day|
1752629|NCT00213928|Drug|Horse Chestnut Seed Extract|Control (no intervention) vs Horse Chestnut Seed Extract
1752630|NCT00213941|Device|Echocardiography|
1752631|NCT00213954|Procedure|ultrasound-guidance with echography|Locoregional anesthesia with or without ultrasound guidance practice
1752632|NCT00213967|Device|22 gauge 1 1/2 inch needles on a 3 ml syringe|cold needles or needles kept at room temperature
1752634|NCT00213993|Drug|antiperspirant|antiperspirant topically once daily to one foot
1752635|NCT00214019|Drug|salmeterol|salmeterol diskus 50 mcg twice per day
1752636|NCT00214019|Drug|Fluticasone|placebo diskus, fluticasone MDI 88 mcg twice per day
1752637|NCT00214019|Drug|Placebo|placebo diskus
1752638|NCT00214032|Drug|Pycnogenol|pycnogenol 300 mg daily
1752639|NCT00214032|Drug|Placebo|placebo 3 capsules daily
1752641|NCT00214058|Drug|Carboplatin|
1752642|NCT00214058|Drug|Docetaxel|
1752643|NCT00214071|Biological|Influenza vaccine|
1752644|NCT00214084|Drug|Allopurinol|
1752646|NCT00214110|Drug|Tamoxifen|
1752647|NCT00214123|Radiation|radiation therapy (radiotherapy)|Bin assignment based on tumor volume
1752649|NCT00214149|Radiation|brachytherapy|breast brachytherapy to 34 Gy
1752650|NCT00214162|Behavioral|Comprehensive Health Enhancement Support System|Full CHESS
1752651|NCT00214162|Behavioral|computer with internet|computer with internet use x 1 year
1752652|NCT00214201|Drug|Calcineurin inhibitor withdrawal|stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
1752653|NCT00214214|Drug|Campath 1H® (Alemtuzumab)|
1752654|NCT00214240|Drug|CMV Immune globulin|CMV IvIg 150mg/kg x 6 doses
1752655|NCT00214253|Drug|Thiazolidinedione|Thiazolidinedione vs. no intervention with standard immunosuppression using Edmonton Protocol
1752656|NCT00214266|Drug|Campath 1H®, Rituximab, mycophenolate mofetil|Induction therapy with Campath 30mg IV x 2 doses, Rituximab 375mg/m2 x 1, corticosteroids, and mycophenolate 1000mg bid
1752657|NCT00214279|Drug|Corticosteroid withdrawal|prednisone withdrawal, with maintenance mycophenolate mofetil therapy and either cyclosporine or tacrolimus
1752658|NCT00214292|Procedure|fluorescence spectroscopy and diffuse spectroscopy|
1752659|NCT00214305|Behavioral|Range of Motion Therapy Program|The program involves exercises and maneuvers that include voluntary maximal movements of the tongue, pitch range exercises, head lifting (Shaker exercise), resistance to laryngeal excursion (Mendelsohn Maneuver), breath holding after swallow and cough, thermal-tactile stimulation (ice), suck-swallow, optimal posturing, and dietary changes.
1752755|NCT00215306|Device|Anterior Interbody Fusion with BAK Cage|
1752756|NCT00215319|Device|Lumbar I/F with cage and pedicle screws|Surgical Titanium Mesh™ with MOSS-Miami™ Pedicle Screws
1752660|NCT00214305|Behavioral|Postural Sensory Therapy Program|The program involves all of the above, except that range of motion exercises (voluntary maximal movements of the tongue, pitch range exercises, head lifting, resistance to laryngeal excursion, breath holding after swallow and cough) are not performed.
1752661|NCT00214318|Drug|Terbutaline plus Metoprolol or carvedilol|
1752662|NCT00214331|Drug|ciprofloxacin|ciprofloxacin 500 mg twice a day for five doses.
1752663|NCT00214331|Drug|azithromycin|azithromycin 500 mg on day 1 followed by 250 mg on days 2-5
1752664|NCT00214331|Drug|gentamicin|a single intravenous dose of gentamicin 1.5mg/kg infused over 60 minutes
1752665|NCT00214344|Behavioral|family preparation for withdrawing life support|
1752666|NCT00214357|Behavioral|Mindfulness-based stress reduction|
1752667|NCT00214370|Drug|Propofol-Fentanyl|
1752668|NCT00214370|Drug|Propofol alone|
1752669|NCT00214383|Behavioral|CHESS Internet telehealth|CHESS Internet telehealth
1752671|NCT00214435|Drug|once daily minimum 3-drug regimen of anti-retroviral medications|
1752672|NCT00214461|Biological|Vaccine diluent buffer (Placebo)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
1752673|NCT00214461|Biological|C. difficile toxoid vaccine (2 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
1752674|NCT00214461|Biological|C. difficile toxoid vaccine (10 µg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
1752675|NCT00214461|Biological|C. difficile toxoid vaccine (50 µg)|0.5 mL, Intramuscular on Day 0, Day 28, and Day 56, respectively.
1752676|NCT00214474|Behavioral|ATSM Intervention|Participants randomized to ATSM Intervention received weekly, automated (pre-recorded) telephone calls over 39 weeks (9 months). Patient responses triggered either immediate, automated health education messages and/or subsequent nurse phone follow-up.
1752677|NCT00214474|Behavioral|GMV Intervention|GMV Intervention involved 90-minute monthly sessions over 9 months, involving 6-10 participants, co-facilitated by a primary care physician and health educator.
1752678|NCT00214487|Device|Bifocal Contact Lenses|Use of bifocal contact lenses of varying add powers to control the progression of myopia
1752679|NCT00214487|Device|Placebo Control|Single vision soft contact lenses
1752680|NCT00214500|Drug|AT1001 (migalastat hydrochloride)|AT1001 was administered as follows during the 12-week treatment period; a 6-week dose escalation from 25, to 100, to 250 mg twice daily, then 6 weeks of 25 mg twice daily. Subjects opting to participate in two treatment extension periods from 12 - 48 weeks and then 48 - 96 weeks were administered 50 mg every day.
1752681|NCT00214513|Behavioral|Home-based exercise training|
1752682|NCT00214526|Procedure|Bronchial thermoplasty with the Alair System|Conventional therapy with ICS+LABA plus bronchial thermoplasty with the Alair System.
1752683|NCT00214526|Drug|Conventional therapy with ICS+LABA|Conventional therapy with ICS+LABA.
1752684|NCT00214539|Procedure|Bronchial Thermoplasty with the Alair System|Alair treatment plus standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤ 30 mg/day.
1752685|NCT00214539|Drug|Control|Standard-of-care therapy of high dose inhaled corticosteroids and long acting beta-agonists with or without oral corticosteroids at a dose of ≤30 mg/day.
1752686|NCT00214552|Drug|rabeprazole|
1752687|NCT00214565|Drug|Galida|
1752688|NCT00214578|Drug|Seroquel (quetiapine)|
1752689|NCT00214591|Drug|GALIDA|
1752690|NCT00214604|Drug|Rosuvastatin|10mg
1752691|NCT00214604|Drug|rosuvastatin|20mg
1752692|NCT00214604|Drug|pravastatin|40mg
1752693|NCT00214617|Drug|Rosuvastatin at 5 mg/day and 40 mg/day|
1752694|NCT00214630|Drug|rosuvastatin calcium|
1752695|NCT00214630|Drug|atorvastatin|
1752696|NCT00214643|Drug|Fosmidomycin|30 mg/kg
1752697|NCT00214643|Drug|clindamycin|10 mg/kg
1752698|NCT00214656|Drug|Recombinant Activated Factor VII|
1752699|NCT00214669|Behavioral|PACE (Professional Asthma Care Education)|Education for intervention specialist nurse and GPs and practice nurses from intervention practices, using our adaptation of Clarke's self-regulation education programme, designed to improve shared-decision making, goal-setting and patient-clinician partnership.
1752700|NCT00214669|Behavioral|Lay Led Expert Patient Programme|Lay-led 'expert-patient' education in small groups for patients, using an adaptation of Stanford University's chronic disease self-management programme.
1752701|NCT00214669|Behavioral|Asthma self management education by a specialist nurse|asthma education and self management, asthma action plans
1752702|NCT00214682|Drug|Folate (400mcg) and Vitamin B12 (100 mcg)|The vitamin intervention was a daily oral dose of one tablet consisting of folic acid 400 mcg + vitamin B12 100 mcg. The folic acid dose of 400 mcg / day was selected as it has been shown to be the dose associated with 90% of the maximal decrease in plasma homocysteine concentration for older individuals. Participants received 1 bottle x 200 tablets in six-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months).
1752703|NCT00214682|Behavioral|mediated physical activity promotion|Individuals in the Physical Activity Promotion group received a manual designed to promote older individuals' physical activity participation to the level recommended to gain both physical and mental health benefits. The framework of the physical activity manual was informed by social cognitive theory and the transtheoretical model, and comprised five sections that reflect stages of behaviour change, including; precontemplation, contemplation, preparation, action, and maintenance. The manual contained evidence-based strategies and skills to assist people in increasing their physical activity levels. Participants received a pedometer at the commencement of the intervention as pedometry step / minute values are useful as an indicator of moderate to vigorous physical activity with total number of steps for one week recorded during the brief telephone calls at 1-5 weeks, and 4-, 8-, 13-, 18-, and 22- months.
1752757|NCT00215332|Device|CHARITE|Lumbar Total Disc Replacement
1752758|NCT00215345|Drug|Taxotere|
1752759|NCT00215345|Drug|Celecoxib|
1752760|NCT00215358|Drug|Formoterol Fumarate|
1752704|NCT00214682|Behavioral|Mental health literacy|Comprises 10 modules, with nine of these specifically written for older adults. Modules 1 to 5 comprised information on depression and the evidence-based treatment for older adults. The additional MHL modules were booklets addressing evidence-based strategies and treatments for depression. It was delivered in a way to foster support and ensure that participants worked through the material systematically. Modules 1 to 5 were delivered in consecutive weeks as previous research indicates that the maximum impact of MHL on depressive symptoms may occur within the first six weeks of the intervention. Telephone interviewers contacted participants once a week for 5 consecutive weeks to motivate and support participants. There were an additional 5 check-in telephone calls, and Modules 6 to 10 of the MHL material that were delivered via postal mail at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10).
1752705|NCT00214682|Drug|placebo|A placebo tablet was the attention control intervention for the folic acid + vitamin B12 intervention group. Participants received 1 bottle x 200 tablets in 6-month supplies at baseline, 6 months, 12 months, and 18 months. Adherence was monitored by telephone interviews (6 weeks, 6-, 12-, and 24 months) and 10 brief telephone tracking calls (1 - 5 weeks, and 4-, 8-, 13-, 18-, and 22-months) during which participants counted their left-over tablets.
1752706|NCT00214682|Behavioral|Nutrition information|The attention control intervention for the physical activity intervention was printed nutrition literacy and included information concerning the recommended dietary guidelines for older Australians, as well as strategies and additional information to facilitate beneficial dietary behaviours. The same procedure was adhered to as the physical activity intervention to ensure adequate attention control. Participants in the nutrition promotion intervention received 5 brief telephone calls from an interviewer to facilitate adherence to the intervention, and to offer support and clarification of the materials. Participants received five further brief telephone calls as well as nutrition newsletters that were delivered via postal mail at 4-, 8-, 13-, 18-, and 22- months.
1752707|NCT00214682|Behavioral|pain and arthritis management information|Pain and Arthritis Information was used as the attention control intervention for the MHL intervention and comprised 10 modules. Modules 1 to 5 were contained in an Arthritis Australia consumer guide for arthritis management. Modules 6 to 10 were a series of information pamphlets on pain management, osteoporosis and falls prevention. The delivery of the Pain Information was identical to the MHL intervention with Modules 1 to 5 distributed via postal mail in five consecutive weeks (1-5 weeks), while the remaining intervention modules were delivered at 4- (Module 6), 8- (Module 7), 13- (Module 8), 18- (Module 9), and 22- months (Module 10). Participants also received 10 brief calls from a telephone interviewer that coincided with receiving the print intervention materials.
1752708|NCT00214695|Drug|Experimental Peritoneal Dialysis Solution|
1752709|NCT00214708|Procedure|Screening for Tuberculosis|
1752710|NCT00214721|Drug|Experimental Peritoneal Dialysis Solution|
1752712|NCT00214747|Drug|Vehicle gel formulations|
1752713|NCT00214760|Device|PGET|resolbable liner
1752714|NCT00214760|Device|PMMA|cement liner
1752715|NCT00214786|Biological|Islet cell transplantation|Allogenic islet transplantation
1752716|NCT00214812|Drug|HEC placebo gel|
1752717|NCT00214825|Drug|eplerenone|50 mg daily for 6 weeks with placebo
1752718|NCT00214825|Drug|Hydrochlorothiazide|HCTZ 12.5 mg with potassium (10 mEq) daily for 6 weeks
1752719|NCT00214838|Drug|Atiprimod|
1752720|NCT00214851|Drug|Kineret (anakinra)|Kineret (anakinra 100 mg. s/c daily x 4 weeks
1752721|NCT00214864|Drug|docetaxel, capecitabine|cohort 1 = capecitabine 900mg/m2 BID POx14 days and docetaxel 36mg/m2 day1&8 cohort 2 = capecitabine 650mg/m2 BID POx14 days and docetaxel 30mg/m2 day1&8 cohort 3 = capecitabine 850mg/m2 BID POx14 days and docetaxel 30mg/m2 day1&8
1752722|NCT00214877|Drug|Methylene Blue|
1752723|NCT00214890|Drug|Tenofovir|300 mg once daily
1752724|NCT00214890|Drug|Abacavir|600 mg once daily
1752725|NCT00214916|Drug|intensive insulin therapy (Actrapid IV to normoglycemia)|intensive insulin therapy (Actrapid IV in continuous infusion to age-dependent normoglycemia)
1752726|NCT00214916|Drug|conventional insulin therapy (Actrapid IV only for excessive hyperglycemia)|conventional insulin therapy (Actrapid IV in continuous infusion only to treat blood glucose levels exceeding 220 mg/dl)
1752727|NCT00214929|Behavioral|treatment at home|
1752728|NCT00214942|Drug|ORAVESCENT Fentanyl Citrate|
1752729|NCT00214955|Drug|ORAVESCENT Fentanyl Citrate|
1752730|NCT00214968|Drug|Modafinil|maximum dosage 400 mg/day (4 tablets)
1752731|NCT00214981|Drug|Modafinil|
1752732|NCT00214994|Drug|Gabitril|
1752733|NCT00215007|Drug|Levofloxacin|
1752734|NCT00215046|Drug|Vinblastine|drug - dosage and frequency is based on size of patient and response to treatment.
1752735|NCT00215046|Drug|Methotrexate|drug - dosage is based on size of patient and frequency and duration is based on response to treatment.
1752736|NCT00215111|Behavioral|Low carbohydrate, reduced glycemic load, and a control diet|
1752737|NCT00215124|Drug|Filgrastim|
1752738|NCT00215137|Drug|escitalopram|Open label Treatment: Escitalopram 10 mg/day for 1 week and then 20 mg /day for 7 weeks. Double Blind Treatment: Escitalopram 20 mg/day.
1752739|NCT00215137|Drug|Placebo ( sugar pill)|Placebo Comparator in double.blind phase.
1752740|NCT00215150|Drug|Ziprasidone|Sertraline augmentation with ziprasidone
1752741|NCT00215150|Drug|Sertraline|Treatment by sertraline in open label phase, followed by ziprasidone/placebo randomized augmentation in the randomized phase
1752742|NCT00215163|Drug|Cognitive-behavioral therapy and paroxetine-CR|
1752743|NCT00215176|Drug|modafinil|
1752744|NCT00215189|Behavioral|In SHAPE (Pilot Health Promotion Intervention)|
1752745|NCT00215202|Drug|Iressa (ZD1839)|
1752746|NCT00215215|Device|Vagus Nerve Stimulation Therapy|
1752747|NCT00215228|Drug|duloxetine vs. escitalopram|
1752748|NCT00215241|Drug|sertraline and risperidone|
1752749|NCT00215254|Drug|quetiapine|
1752750|NCT00215267|Drug|praziquantel|
1752751|NCT00215280|Drug|ivermectin and albendazole|
1752752|NCT00215293|Device|Cervical I/F Cage|
1752753|NCT00215293|Device|Autograft or allograft with a plate, or autograft alone.|
1752754|NCT00215306|Device|CHARITÉ Artificial Disc|
1752761|NCT00208637|Behavioral|moderate carbohydrate, high protein diet (MCHP)|
1752762|NCT00208637|Behavioral|high carbohydrate-high fibre (HCHF) diet|
1752763|NCT00208702|Drug|Triiodothyronine|
1752764|NCT00208702|Other|Placebo|
1752765|NCT00208702|Drug|Sertraline|
1752766|NCT00208715|Drug|Provigil|
1752767|NCT00208728|Device|PC/SMART cardiopulmonary bypass circuit|
1752768|NCT00208728|Device|PMEA modified cardiopulmonary bypass circuit|
1752769|NCT00208728|Device|Standard of care uncoated cardiopulmonary bypass circuit|
1752770|NCT00208741|Drug|Gabitril|
1752771|NCT00208767|Drug|Valsartan|Valsartan was titrated to a target dose of 320 mg orally daily
1752772|NCT00208767|Drug|Placebo|A matched placebo pill will be given orally daily.
1752773|NCT00208780|Drug|Tetrahydrobiopterin|
1752774|NCT00208780|Drug|Tetrahydrobiopterin|
1752775|NCT00208793|Dietary Supplement|Calcium and vitamin D3 combined|Calcium 2,000 mg (as calcium carbonate) + vitamin D3 800 IU given in equal divided doses twice daily with food over 6 months
1752776|NCT00208793|Drug|Placebo|Placebo
1752777|NCT00208793|Dietary Supplement|Calcium|Calcium 2,000 mg/day as calcium carbonate in two divided doses with meals over 6 months
1752778|NCT00208793|Dietary Supplement|Vitamin D3|Vitamin D3 800 IU given as 400 IU twice daily with food over 6 months
1752779|NCT00208806|Other|congestive heart failure patients|observational echo data on congestive heart failure patients
1752780|NCT00208819|Drug|risperidone|
1752781|NCT00208819|Drug|quetiapine|
1752782|NCT00208819|Drug|olanzapine|
1752783|NCT00208819|Drug|divalproex|
1752784|NCT00208832|Procedure|Graphic medication schedule (Pill card)|
1752785|NCT00208832|Procedure|Refill reminder postcard|
1752786|NCT00208858|Drug|Topiramate|
1752787|NCT00208871|Procedure|Stereoscopic Digital Mammography|screening digital 3D mammogram
1752788|NCT00208897|Drug|Fluoxetine|
1752789|NCT00208910|Behavioral|Odorant Cue|
1752790|NCT00208923|Drug|Busulfan, Cyclophosphamide and Fludarabine|"Bulsufan 1mg/kg/dose P.O. every 6 hours for 4 days. If intravenous, busulfan dose will be 0.8 mg/kg every 6 hours for 16 doses.
Fludarabine 40 mg/m2 a day for 5 days via IV over 2 hours, dose based on weight.
Cyclophosphamide given via IV over 1 hour at dose of 60 mg/kg/day for 2 consecutive days."
1752791|NCT00208936|Drug|Taxol, Cisplatin, 5-Fluorouracil, G-CSF|
1752792|NCT00208949|Drug|G-CSF|G-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
1752793|NCT00208949|Drug|GM-CSF|GM-CSF, solution given subcutaneously twice per day, total dosage varies by weight.
1752794|NCT00208962|Procedure|chemotherapy and blood stem cell transplantation|A combination of conventional dose chemotherapy, granulocyte-colony stimulating factor (G-CSF) mobilized HLA-identical related allogeneic PBSC transplant, and post transplant infusions of donor leukocytes.
1752795|NCT00208975|Drug|Mitoxantrone/Cyclophosphamide, Fludarabine, Rituximab and GM-CSF|"Initial patients (n=9) received fludarabine (25 mg/m^2 intravenously) and mitoxantrone (10 mg/m^2 intravenously)with sequential administration of GM-CSF(Granulocyte-macrophage colony stimulating factor) (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m^2) on day 8.
After a change in the protocol, all additional patients (n=6) received fludarabine (25 mg/m^2 intravenously) and cyclophosphamide (250 mg/m^2 intravenously)with sequential administration of GM-CSF (500 µcg subcutaneously) on days 6 and 7 and rituximab (375 mg/m^2) on day 8. All patients received additional doses of GM-CSF (days +8 through +14) were given for patients to reduce variability in neutropenic management."
1752796|NCT00208988|Procedure|Educational handout about prostate cancer screening|
1752797|NCT00208988|Procedure|Simple cue for patient to talk to doctor|
1752798|NCT00209001|Procedure|Acupuncture|Acupuncture using enhanced Ming Men technique for 20 minutes, twice during 1st week, then once during week 2, 3,and 4.
1752799|NCT00209001|Procedure|Sham acupuncture therapy|Sham procedure will be insertion of 5 needles for 20 minutes provided twice during first week, then once per week thereafter.
1752800|NCT00209014|Drug|Thalidomide|
1752801|NCT00209027|Other|fMRI|fMRI scanning during behavioral reward task
1752802|NCT00209027|Drug|Aripiprazole|30 mg by mouth once daily
1752803|NCT00209040|Procedure|acoustic startle testing|See protocol description for methodological details
1752804|NCT00209053|Procedure|Coronary Artery Bypass|
1752805|NCT00209079|Drug|Gleevec, Taxotere|Gleevec taken 4 times daily, 100 mg per tablet. Taxotere intravenously once a week for two weeks.
1752806|NCT00209092|Drug|Docetaxel|"Sequential Therapy: Docetaxel will be given at 100 mg/m^2 Intravenously (IV)Day 1 every 3 weeks for 4 cycles.
Concurrent Therapy: Docetaxel will be given at 50 mg/m^2 IV Day 1."
1752807|NCT00209092|Drug|Capecitabine|Sequential Therapy: administration of capecitabine 1000 mg/m^2 twice a day by mouth Day 1-14 every 3 weeks for 4 cycles (total 8 cycles) Concurrent Therapy: capecitabine 1000 mg/m^2 twice a day by mouth Day 1-7 every 2 weeks for 8 cycles (total 16 weeks).
1752808|NCT00209105|Drug|DEX-CRF stimulation test|1 ug/kg body weight of CRF for determining hpa response post dexamethasone ingestion
1752809|NCT00209105|Behavioral|Psychosocial stress induction|Laboratory stress induction, no drug administration
1752810|NCT00209105|Procedure|Brain imaging of sad mood , self-reference, reward|Brain imaging
1752811|NCT00209105|Behavioral|Acoustic startle|No drugs involved
1752812|NCT00209118|Drug|paroxetine|
1752813|NCT00209131|Drug|Flomax|0.4mg Flomax pills will be given to patients to take once daily for one month following shock wave lithotripsy to aid the stone passage.
1752814|NCT00209131|Drug|Sugar pill|Comparable sugar pills will be given to the placebo group to take daily for one month following shock wave lithotripsy to aid stone passage.
1752815|NCT00209144|Drug|Intensive insulin therapy|
1752816|NCT00209170|Behavioral|Beating the Blues|Beating the Blues is a computerized cognitive behavioral therapy.
1752817|NCT00209170|Drug|Escitalopram|Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant. It's a 10 mg pill taken once or twice daily for 6 months.
1752818|NCT00209170|Drug|Placebo|A sugar pill taken as one to two tablets daily for 6 months.
1752819|NCT00209209|Drug|Rituximab|antibody
1752820|NCT00209209|Drug|Cyclophosphamide|chemotherapy
1752821|NCT00209209|Drug|Doxorubicin|chemotherapy
1752822|NCT00209209|Drug|Vincristine|chemotherapy
1752823|NCT00209209|Drug|Prednisone|coricosteroide
1752824|NCT00209209|Drug|Fludarabine|chemotherapy
1752825|NCT00209209|Drug|Interferon-alpha|cytokine
1752826|NCT00209209|Drug|pegylated formula Interferon-alpha 2b|cytokine
1752827|NCT00209209|Procedure|chemotherapy: R-CHOP|immuno-chemotherapy
1752828|NCT00209209|Procedure|chemotherapy: R-FC|immuno-chemotherapy
1752829|NCT00209209|Procedure|Interferon maintenance|cytokine
1752830|NCT00209209|Procedure|Rituximab maintenance|antibody
1752831|NCT00209222|Drug|Rituximab|antibody
1752832|NCT00209222|Drug|Cyclophosphamide|chemotherapy
1752833|NCT00209222|Drug|Doxorubicin|chemotherapy
1752834|NCT00209222|Drug|Vincristine|chemotherapy
1752835|NCT00209222|Drug|Prednisone|corticosteroide
1752836|NCT00209222|Drug|Cisplatinum|chemotherapy
1752837|NCT00209222|Drug|Ara-C|chemotherapy
1752838|NCT00209222|Drug|Dexamethasone|corticosteroide
1752839|NCT00209222|Drug|BCNU|chemotherapy
1752840|NCT00209222|Drug|Melphalan|chemotherapy
1752841|NCT00209222|Drug|Etoposide|chemotherapy
1752842|NCT00209222|Drug|G-CSF|growth factor
1752843|NCT00209222|Procedure|chemotherapy: R-CHOP|immuno-chemotherapy
1752844|NCT00209222|Procedure|chemotherapy: R-DHAP|immuno-chemotherapy
1752845|NCT00209222|Procedure|chemotherapy: Dexa-BEAM|chemotherapy
1752846|NCT00209222|Procedure|stem cell harvest|procedure
1752847|NCT00209222|Procedure|total body irradiation|radiation
1752848|NCT00209222|Procedure|high-dose chemotherapy: Cyclophosphamide|chemotherapy
1752849|NCT00209222|Procedure|high-dose chemotherapy: Ara-C /Melphalan|chemotherapy
1752850|NCT00209235|Behavioral|neurocognitive and psychosocial testing|
1752851|NCT00209261|Drug|MINIRIN Oral Lyophilisate|
1752852|NCT00209261|Drug|Minirin tablet|
1752853|NCT00209274|Device|Percutaneous mitral valve repair using MitraClip implant|MitraClip Implant
1752854|NCT00209274|Procedure|Mitral valve repair or replacement surgery|Repair or replacement of mitral valve
1752855|NCT00209287|Behavioral|Observe patients with inactive ulcerative colitis|Observe patients with inactive ulcerative colitis
1752856|NCT00209300|Drug|Pentasa|
1752857|NCT00209313|Drug|Acyclovir|Acyclovir 800 mg twice daily or placebo
1752858|NCT00209326|Drug|FE200440|
1752859|NCT00209339|Device|Percutaneous mitral valve repair (MitraClip Implant)|Phase I evaluation of the safety and effectiveness of an endovascular approach to the repair of mitral valve regurgitation using the Evalve MitraClip Cardiovascular Valve Repair System.
1752860|NCT00209352|Drug|Acyclovir|
1752861|NCT00215371|Drug|Formoterol Fumarate|
1752862|NCT00215384|Drug|Formoterol Fumarate|
1752863|NCT00215397|Drug|Formoterol Fumarate|
1752864|NCT00215410|Drug|Formoterol Fumarate|
1752865|NCT00215423|Drug|Formoterol Fumarate|
1752866|NCT00215436|Drug|Formoterol Fumarate|
1752867|NCT00215449|Drug|Formoterol Fumarate|
1752868|NCT00215462|Drug|Vinorelbine|
1752869|NCT00215501|Drug|Capecitabine|Orally twice a day for 14 days (dosage will vary)
1752870|NCT00215501|Drug|5-Fluorouracil (5-FU)|Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
1752871|NCT00215501|Drug|Irinotecan|Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
1752872|NCT00215501|Drug|Cisplatin|Intravenously weekly for 2 weeks followed by a one week rest period
1752873|NCT00215514|Drug|Epirubicin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
1752874|NCT00215514|Drug|Cisplatin|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
1752875|NCT00215514|Drug|5-Fluorouracil (5-FU)|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
1752876|NCT00215514|Procedure|Radiation|Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> One-week rest --> External Beam Radiation Therapy plus 5-FU CI --> Four-week rest --> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21)--> Epirubicin (Day 1), Cisplatin (Day 1), 5-FU (Days 1-21).
1752877|NCT00215527|Drug|laronidase|0.58 mg/ml solution for intravenous injection, dose 1.74 mg intrathecally once per month for four injections.
1752878|NCT00215540|Drug|Lucinactant 175 mg/kg|Administered via slow intra-tracheal instillation at a dose of 175 mg/kg (5.8 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to day of life (DOL) 18).
1752879|NCT00215540|Drug|Lucinactant 90 mg/kg|Administered via slow intra-tracheal instillation at a dose of 90 mg/kg (3.0 mL/kg of a 30-mg/mL suspension). Initial treatment given no later than 1 hour after randomization. Additional treatments were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
1752880|NCT00215540|Drug|Placebo|Sham air was administered via slow intratracheal instillation at a dose of 3.0 mL/kg volume of air. The initial treatment was given no later than 1 hour after randomization. Additional treatment were administered every 48 hours up to a maximum of 5 doses (up to DOL 18).
1752881|NCT00215553|Drug|Lucinactant|Suspension for instillation
1752882|NCT00215553|Other|Standard of Care|Standard ARDS management and ICU care
1752883|NCT00215566|Drug|DDP733|
1752884|NCT00215579|Drug|Depot Risperidone Microsphere (Consta)|
1752885|NCT00215592|Drug|Zonegran|
1752886|NCT00215605|Drug|XL184|Flavored liquid suspension or gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing or intermittent schedule (daily dosing followed by dosing holiday in cycles)
1753066|NCT00217477|Drug|paricalcitol|Given IV
1752887|NCT00215618|Device|Uterine Balloon Therapy|UBT with post procedure curettage
1752888|NCT00215618|Device|Uterine Balloon Therapy|UBT without post procedure curettage
1752889|NCT00215631|Drug|tadalafil|
1752892|NCT00215657|Drug|Degarelix|Degarelix 120 mg (20 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
1752893|NCT00215657|Drug|Degarelix|Degarelix 120 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
1752894|NCT00215657|Drug|Degarelix|Degarelix 160 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
1752895|NCT00215657|Drug|Degarelix|Degarelix 200 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
1752896|NCT00215657|Drug|Degarelix|Degarelix 200 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
1752897|NCT00215657|Drug|Degarelix|Degarelix 240 mg (40 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
1752898|NCT00215657|Drug|Degarelix|Degarelix 240 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
1752899|NCT00215657|Drug|Degarelix|Degarelix 320 mg (60 mg/mL). Participants received same dose as in main study (FE200486 CS07; NCT00818623). Administration intervals were individualised for each participant (based on the duration of testosterone suppression in study FE200486 CS07).
1752900|NCT00215670|Drug|pegaptanib sodium (Macugen)|
1752901|NCT00215683|Drug|Degarelix|Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 28 days until the end of the study.
1752902|NCT00215696|Genetic|BioBypass®|
1752903|NCT00215709|Drug|docetaxel|
1752904|NCT00215722|Drug|Cetuximab|
1752905|NCT00216060|Drug|Risedronate|Daily oral risedronate combined with androgen deprivation
1752906|NCT00216060|Drug|Placebo|Daily oral placebo combined with androgen deprivation
1752907|NCT00216073|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
1752908|NCT00216073|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
1752909|NCT00216073|Drug|Trastuzumab|Trastuzumab 6mg/kg IV, day 1. 8 mg/kg loading dose given in cycle 1 for patients without previous trastuzumab therapy only.
1752910|NCT00216086|Drug|Capecitabine|"Capecitabine 1000* mg/m2 po bid day 1-14; repeat every three weeks for two cycles
*For calculated creatinine clearance of 30-50 mL/min or patients > 70 years old, capecitabine starting dose is 825 mg/m2 po bid"
1752911|NCT00216086|Drug|Irinotecan|Irinotecan 200 mg/m2 IV, day 1
1752912|NCT00216086|Procedure|EUS|biopsy per EUS
1752913|NCT00216086|Drug|Neoadjuvant Chemotherapy|"Irinotecan 200 mg/m2 IV, day 1
Capecitabine 1000 mg/m2 po bid day 1-14; repeat every three weeks for two cycles"
1752914|NCT00216086|Procedure|Preoperative Radiation|Pelvic XRT 45 Gy/1.8 GY/fx/qd+5/4 Gy/1.8 Gy/fx/qd for T3+9 Gy/1.8/Gy/fx/qd for T4
1752915|NCT00216086|Procedure|Surgery|Surgery within 8 weeks following chemoradiotherapy
1752916|NCT00216086|Procedure|Adjuvant Chemotherapy|Adjuvant chemotherapy at investigator's discretion
1752917|NCT00216099|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV over 10 minutes, day 1 of 21-day cycle
1752918|NCT00216099|Dietary Supplement|Folic Acid|All participants received oral Folic Acid 350-100ug once per day for 7 days preceding the first pemetrexed dose and continuing throughout the study and and for 21 days after the last dose of pemetrexed.
1752919|NCT00216099|Dietary Supplement|Vitamin B12|All patients received vitamin B12 1000ug intramuscular injection the week preceding the first pemetrexed dose and received additional 1000ug intramuscular injections every three cycles thereafter on the same day of pemetrexed administration.
1752920|NCT00216112|Drug|Imatinib Mesylate|Imatinib mesylate 600 mg po qd
1752921|NCT00216112|Drug|Docetaxel|Docetaxel 30 mg/m2 (4 of 6 weeks); 1 cycle = 6 weeks
1752922|NCT00216125|Drug|Cisplatin|Cisplatin 50 mg/m2 day 1, 8, 29, 36
1752923|NCT00216125|Drug|Etoposide|Etoposide 50 mg/m2, days 1-5, 29-33
1752924|NCT00216125|Radiation|Radiation|Radiation 5940 cGy (180 cGy/day)
1752925|NCT00216125|Drug|Docetaxel|docetaxel 75mg/m2 q3wk x 3 cycles
1752926|NCT00216138|Drug|Docetaxel|Docetaxel 60 mg/m2 for 60 minutes, day 1 of each cycle
1752927|NCT00216138|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
1752928|NCT00216138|Drug|Premedication|Dexamethasone and antiemetic premedication
1752929|NCT00216151|Drug|Zoledronic Acid|Zoledronic Acid 4mg, every three months
1752930|NCT00216164|Drug|Rituximab|Rituximab 375 mg/m2, day 1 of 21 day cycle
1752931|NCT00216164|Drug|Gemcitabine|Gemcitabine 1000 mg/m2, days 1 and 8 of 21 day cycle
1752932|NCT00216177|Drug|Infliximab|Remicade
1752933|NCT00216177|Drug|Adalimumab|Humira
1752934|NCT00216190|Drug|Dexmedetomidine HCL Injection|
1752935|NCT00216190|Drug|Midazolam Injection|
1752936|NCT00216203|Drug|Pemetrexed|Pemetrexed at the assigned dose, day 1 of each 21 day cycle for a maximum of 6 cycles
1753185|NCT00218218|Drug|placebo patch|
1752937|NCT00216203|Drug|Cetuximab|"Cetuximab 400 mg/m2, week 1, day 1
Cetuximab 250 mg/m2, day 1, 8, 15 of each 21 day cycle"
1752938|NCT00216216|Drug|Pemetrexed|Pemetrexed 500 mg/m2 IV q 3 weeks
1752939|NCT00216229|Biological|Combined vaccine against hepatitis A and B (Twinrix)|
1752940|NCT00216242|Biological|Influenza virus vaccine (Fluviral)|
1752941|NCT00216242|Biological|Saline placebo|
1752942|NCT00216255|Drug|Pagoclone|
1752943|NCT00216255|Drug|Placebo|
1752944|NCT00216268|Drug|Ribavirin|
1752945|NCT00216281|Drug|Clozapine augmented with atomoxetine up to 40 mg or placebo|
1752947|NCT00216320|Device|WalkAide|Arm 1 - Subjects wear WalkAide for 6 weeks then cross over to AFO wear for 6 weeks
1752948|NCT00216320|Device|AFO|Arm 2 - Subjects wear AFO for 6 weeks then cross over to WalkAide wear for 6 weeks
1752949|NCT00216320|Device|AFO|Arm 3 - Subjects wear AFO for entire 12 weeks with no crossover
1752950|NCT00216333|Drug|combined fixed dose combination|
1752951|NCT00216346|Drug|Paromomycin sulfate|
1752952|NCT00216346|Drug|Amphotericin B|
1752953|NCT00216359|Drug|Fuzeon (Enfuvirtide)|
1752954|NCT00216359|Procedure|Laboratory diagnostic (CD4-cells)|
1752955|NCT00216359|Procedure|Laboratory diagnostics (HIV-1 viral load)|
1752956|NCT00216359|Drug|antiretroviral co-medication beside Fuzeon|
1752957|NCT00216372|Drug|Lanreotide (microparticle formulation)|A single 30 mg intra-muscular injection on day 0. The duration of the blinded phase is 10 days. Patients may enter the open phase where they receive 30 mg intra-muscular injections, every 10 days until investigator/or patient decide to stop treatment.
1752958|NCT00216372|Other|Placebo|A single intra-muscular injection on day 0.
1752959|NCT00216385|Drug|Gatifloxacin combined regimen|
1752960|NCT00216398|Drug|Lanreotide (Autogel formulation)|
1752961|NCT00216411|Drug|Botulinum type A toxin (Dysport)|
1752962|NCT00216424|Drug|Capecitabine (Xeloda)|
1752963|NCT00216437|Drug|Capecitabine (Xeloda)|
1752964|NCT00216450|Drug|rabeprazole sodium|
1752965|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 200 mg subcutaneous injection - every other week for 11 weeks
1752966|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - 4 loading doses within the first 11 days followed by: 100 mg subcutaneous injection - every other week for 11 weeks
1752967|NCT00216463|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection - every week for 13 weeks
1752968|NCT00216463|Drug|ISIS 301012 or Placebo|400 mg subcutaneous injection - every week for 13 weeks
1752969|NCT00216463|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection - every week for 13 weeks
1752970|NCT00216476|Drug|Aripiprazole|10-30 mg oral once daily for 104 weeks
1752971|NCT00216476|Drug|Risperidone Long Acting Injectable (LAI)|25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.
1752972|NCT00216476|Drug|Quetiapine|Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.
1752973|NCT00216489|Drug|rabeprazole sodium|
1752974|NCT00216502|Drug|galantamine hydrobromide|
1752975|NCT00216515|Drug|galantamine hydrobromide|
1752976|NCT00216528|Drug|risperidone|
1752977|NCT00216541|Drug|epoetin alfa|
1752978|NCT00216554|Drug|risperidone|
1752979|NCT00216567|Drug|topamax|
1752980|NCT00216580|Drug|Risperidone, long-acting injectable|
1752981|NCT00216593|Drug|galantamine hydrobromide|
1752982|NCT00216606|Drug|topiramate|
1752983|NCT00216619|Drug|Topiramate|topiramate treatment started with one tablet per day, taken in the evening, for the first 7 days of the OL phase. Each tablet contained 25 mg topiramate. After one week, the dose was raised to two tablets per day: one tablet was taken in the morning, the other in the evening.
1752984|NCT00216619|Drug|Topiramate - Placebo|the trial medication consisted of topiramate 25 mg tablets or matching placebo tablets which were identical in appearance, taste and smell. DB randomisation phase (after the 26-weeks OL phase) were randomly allocated (1:1) to one of the two treatment groups (topiramate or placebo). The randomisation took place at Visit 6 (Week 26)
1752985|NCT00216632|Drug|risperidone|
1752986|NCT00216645|Drug|doxorubicin hydrochloride|
1752987|NCT00216658|Drug|fentanyl|
1752988|NCT00216671|Drug|early initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at baseline. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
1752989|NCT00216671|Drug|routine initiation of treatment with Risperdal Consta|25 mg to 50 mg Risperdal Consta intrmuscular injection every 14 days starting at week 12. Treatment with oral antipsychotics or risperidone will continue 21 days after the first injection of Risperdal Consta. This treatment will then be tapered off within the next 7 days.
1752990|NCT00216684|Drug|fentanyl|
1752991|NCT00216697|Drug|bortezomib|
1752992|NCT00216710|Behavioral|Home Visiting|
1752993|NCT00216723|Drug|Aripiprazole|"The recommended starting and target dose for Abilify is 10 or 15mg/day administered on a once-a-day schedule without regard to meals.
(Administer 10 to 30 mg/day according to the patient's condition)"
1752994|NCT00216736|Drug|Dexamethasone|Single dose oral dexamethasone 8mg at time of ED discharge
1752995|NCT00216736|Drug|placebo|Single dose oral placebo at ED discharge
1752996|NCT00216762|Drug|Rituximab|Rituxan ® 1000 mg IV x 2 infusions, 2 weeks apart
1752997|NCT00216775|Drug|interferon-alfa-2b and ribavirin|
1752999|NCT00216827|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
1753000|NCT00216840|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
1753001|NCT00216866|Drug|Dalteparin|
1753002|NCT00216866|Drug|Warfarin|
1753003|NCT00216879|Drug|Calcipotriol plus betamethasone dipropionate gel (LEO 80185)|
1753004|NCT00216892|Drug|Calcipotriol, (calcipotriol + betamethasone)|
1753005|NCT00216918|Drug|Atomoxetine Hydrochloride|
1753006|NCT00216931|Drug|iloprost|
1753007|NCT00216944|Procedure|Tracheal intubation for respiratory care in preterm infants|Premedication with atropine 0.02 mg/kg and morphine 0.03 mg/kg
1753008|NCT00216944|Procedure|Tracheal intubation for respiratory care in preterm infants|Premedication with glycopyrronium 0.005 mg/kg, thiopental 2-3 mg/kg (< 2 kg 2 mg/kg), suxamethonium 2 mg/kg and remifentanil 0.001 mg/kg
1753009|NCT00216957|Procedure|Coronary bypass surgery without cardiopulmonary bypass|
1753010|NCT00216970|Dietary Supplement|Alteration in nutritional support|The subject is randomized into one of two groups - One receives TPN that does not have arginine, proline or glutamate. The other will receive TPN with extra glutamine. The subject takes part in 3 tracer studies while in the hospital. For each tracer study, the subject will receive a different randomly assigned diet. Blood and air are sampled and the patient receives a stable isotope after which the tests are repeated.
1753011|NCT00217009|Procedure|Narrowband Ultraviolet B (TL-01UVB) Therapy|
1753012|NCT00217009|Procedure|Topical Psoralen plus ultraviolet A (PUVA)|
1753013|NCT00217022|Other|Placebo|Placebo, 3 tablets daily
1753014|NCT00217022|Drug|Budesonide|9 mg daily (three tablets)
1753015|NCT00217035|Dietary Supplement|TPN or TPN enriched with glutamine|Each patient undergoes two nutritional support periods either with or without Glutamine supplementation.
1753016|NCT00217048|Drug|Yohimbine, oral|
1753017|NCT00217061|Device|Decision Aid Statin Choice|
1753018|NCT00217074|Other|acupuncture|
1753019|NCT00217087|Procedure|Endoscopic Mucosal Resection|Endoscopic mucosal resection at time of endoscopy if indicated.
1753020|NCT00217087|Procedure|Photodynamic Therapy|Porfimer sodium 2mg/kg
1753021|NCT00217100|Dietary Supplement|Multivitamin|1 tablet a day
1753022|NCT00217100|Dietary Supplement|Placebo|1 tablet a day
1753023|NCT00217113|Behavioral|Geriatric home visit and Action Plan|
1753024|NCT00217139|Drug|Celgosivir|
1753025|NCT00217152|Drug|CellCept|
1753026|NCT00217165|Drug|taurine|taurine 2mg BID po
1753027|NCT00217178|Drug|Vitamins: Folic acid, B6, B12|
1753028|NCT00217191|Drug|Ibuprofen|
1753029|NCT00217204|Drug|Pancrelipase microtablets|
1753031|NCT00217230|Biological|CAIV-T|
1753032|NCT00217243|Other|Evoked fields before and after a local block (Xylocaine)|MEG registration after electrical median and ulnar nerve stimulation in subjects and patients. In the patient group another MEG was performed after an anaesthetic block (1-2 ml Lidocaine 1%) at the site of the nerve injury producing a painfree state
1753033|NCT00217256|Device|Percutaneous Coronary Stenting|Endeavor Drug Eluting Stent
1753034|NCT00217256|Device|Percutaneous Coronary Stenting|Cypher Drug Eluting Stent
1753035|NCT00217269|Device|Coronary Artery Stenting|Endeavor Drug eluting stent
1753036|NCT00217269|Device|Coronary Artery Stenting|Taxus Drug Eluting Stent
1753037|NCT00217282|Drug|oxaliplatin, gemcitabine, bevacizumab|"Gemcitabine 1000mg/m2 IV over 30 minutes, on days 1 and 8 followed by Oxaliplatin 130mg/m2 IV over 2 hours on day 1 followed by Bevacizumab 15 mg/kg IV over 90* minutes, on day 1 Cycles q 3 weeks x 4 cycles One cycle equals 3 weeks. Patients will be re-evaluated every 2 cycles. If CR, PR or SD, patients will continue treatment up to four cycles or until progression or unacceptable toxicity.
Patients achieving CR, PR, or SD after 4 cycles will continue Bevacizumab maintenance:
Bevacizumab 15 mg/kg IV q 3 weeks until relapse/progression"
1753038|NCT00217295|Drug|Avonex and Topamax|
1753039|NCT00217308|Drug|Lactobacilli GR-1 and RC-14|Probiotic Lactobacilli will be compared to placebo
1753040|NCT00217334|Behavioral|Volunteer-led pharmacy sessions with feedback to physicians|
1753041|NCT00217347|Device|Esophageal Capsule Endoscopy|
1753042|NCT00217360|Behavioral|a customised multifactorial falls prevention program|
1753043|NCT00217373|Biological|Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine|Given SC
1753044|NCT00217373|Biological|Recombinant Interferon Alfa-2b|Given SC
1753045|NCT00217373|Biological|Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine|Given SC
1753046|NCT00217373|Biological|Sargramostim|Given SC
1753047|NCT00217386|Biological|anti-thymocyte globulin|
1753048|NCT00217386|Biological|etanercept|
1753049|NCT00217399|Drug|sorafenib tosylate|Given orally
1753050|NCT00217399|Drug|anastrozole|Given orally
1753051|NCT00217412|Drug|vorinostat|Given orally
1753052|NCT00217412|Drug|isotretinoin|Given orally
1753053|NCT00217425|Biological|bevacizumab|"A - CHOP: 15 mg/kg IV infusion once every 21 days for 6-8 cycles. Bevacizumab is to be administered prior to CHOP therapy. Continuous bevacizumab: 15 mg/kg IV infusion once every 21 days.
Initial dose should be infused over 90 minutes. If no adverse reactions occur, the second dose should be administered over 60 minutes. Again, if no adverse reactions occur, the third and subsequent doses should be administered over 30 minutes. If infusion-related adverse reactions occur, subsequent infusions should be administered over the shortest period that is well-tolerated. Infusions should be run in via a volumetric infusion device. Do NOT administer as an IV push or bolus."
1753054|NCT00217425|Drug|cyclophosphamide|IV infusion per institutional guidelines.
1753055|NCT00217425|Drug|doxorubicin|Intravenously, either as a bolus injection or as a continuous infusion through a central venous line.
1753056|NCT00217425|Drug|prednisone|Prednisone is taken orally.
1753057|NCT00217425|Drug|vincristine|IV push using extravasation precautions.
1753058|NCT00217438|Drug|melphalan|Given IV
1753059|NCT00217438|Drug|amifostine trihydrate|Given IV
1753060|NCT00217438|Procedure|peripheral blood stem cell transplantation|Undergo PBSCT
1753061|NCT00217438|Genetic|fluorescence in situ hybridization|Correlative study
1753062|NCT00217438|Procedure|bone marrow ablation with stem cell support|Undergo transplant
1753063|NCT00217451|Drug|Fosmidomycin-clindamycin|
1753064|NCT00217464|Drug|fulvestrant|intramuscularly
1753065|NCT00217477|Drug|gemcitabine hydrochloride|Given IV
1753067|NCT00217490|Behavioral|dietary counseling via computer|An interactive computer program that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
1753068|NCT00217490|Behavioral|dietary counseling via nutritionist|A one on one counseling sessions to addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
1753069|NCT00217490|Behavioral|combined computer and nutritionist|An interactive computer program plus one on one nutrition counseling that addresses dietary change, barriers to change and possible solution to barriers to develop an action plan
1753070|NCT00217490|Other|physical activity counseling via computer|An interactive computer program that addresses increase to physical activity, barriers to change and possible solution to barriers to develop an action plan
1753071|NCT00217503|Biological|bevacizumab|
1753072|NCT00217503|Biological|filgrastim|
1753073|NCT00217503|Biological|pegfilgrastim|
1753074|NCT00217503|Drug|bortezomib|
1753075|NCT00217503|Drug|cyclophosphamide|
1753076|NCT00217503|Drug|doxorubicin hydrochloride|
1753077|NCT00217503|Drug|etoposide|
1753078|NCT00217503|Drug|ganciclovir|
1753079|NCT00217503|Drug|valganciclovir|
1753080|NCT00217503|Drug|zidovudine|
1753081|NCT00217516|Drug|selenium|Given orally
1753082|NCT00217516|Other|placebo|Given orally
1753083|NCT00217529|Biological|pegfilgrastim|
1753084|NCT00217529|Drug|carboplatin|
1753085|NCT00217529|Drug|docetaxel|
1753086|NCT00217529|Drug|erlotinib hydrochloride|
1753087|NCT00217542|Biological|recombinant interferon alfa-2b|Given SC
1753088|NCT00217542|Drug|amifostine/azacitidine|Given SC
1753089|NCT00217555|Drug|gemcitabine hydrochloride|
1753090|NCT00217555|Drug|topotecan hydrochloride|
1753091|NCT00217568|Biological|pegfilgrastim|
1753092|NCT00217568|Drug|carboplatin|
1753093|NCT00217568|Drug|docetaxel|
1753094|NCT00217581|Biological|Bevacizumab|Must be administered 1st before Docetaxel & Oxaliplatin.7.5 mg/kg, IV, day 1 of each cycle; During the first cycle, bevacizumab will be delivered over 90 + or - 15 minutes. If the 1st IV infusion is tolerated w/o infusion-associated adverse events, the 2nd infusion may be delivered over 60 + or - 10 minutes. If the 60 min infusion is well tolerated, all subsequent infusions may be delivered over 30 min + or - 10 mins.
1753095|NCT00217581|Drug|Docetaxel|Must be administered 2nd after Bevacizumab and followed by Oxaliplatin.70 mg/m(2), IV over 60 minutes, day 1 of each cycle;
1753096|NCT00217581|Drug|Oxaliplatin|Must be administered 3rd after Bevacizumab and Docetaxel. 75 mg/m(2), IV over 120 minutes, Day 1 of each cycle.
1753098|NCT00217607|Drug|paclitaxel|
1753099|NCT00217620|Drug|sorafenib|800 mg per day, daily until progression
1753100|NCT00217633|Procedure|Conventional Surgery|
1753101|NCT00217646|Drug|Sorafenib Tosylate|Given orally
1753102|NCT00217659|Drug|anastrozole|
1753103|NCT00217659|Drug|goserelin acetate|
1753104|NCT00217672|Biological|bevacizumab|Patients receive bevacizumab 15 mg/kg intravenously (I.V.) every 3 weeks until disease progression, unacceptable toxicity, or consent withdrawal.
1753105|NCT00217672|Drug|Docetaxel|docetaxel: 75 mg/m2 IV q3 weeks. Subjects continue on dosing until they experience unacceptable toxicity, disease progression, or withdrawal of patient consent.
1753106|NCT00217698|Drug|cisplatin|
1753107|NCT00217698|Drug|gefitinib|
1753108|NCT00217698|Drug|gemcitabine hydrochloride|
1753109|NCT00217711|Drug|Capecitabine|capecitabine
1753110|NCT00217711|Drug|irinotecan hydrochloride|irinotecan hydrochloride
1753111|NCT00217711|Drug|oxaliplatin|oxaliplatin
1753112|NCT00217724|Dietary Supplement|glutamine|Given orally
1753113|NCT00217724|Other|placebo|Given orally
1753119|NCT00217763|Drug|3APS|
1753120|NCT00217776|Behavioral|Open Airways Educational Intervention|
1753121|NCT00217776|Behavioral|Peer Asthma Action Educational Intervention|
1753122|NCT00217789|Procedure|Bronchoalveolar Lavage and Venipuncture|
1753123|NCT00217802|Behavioral|six-session telephone counseling program|
1753124|NCT00217815|Drug|Mycograb, Docetaxel|
1753125|NCT00217828|Drug|citalopram|
1753126|NCT00217841|Drug|Aurograb|
1753127|NCT00217854|Procedure|Bronchoscopic|Bronchoscopic procedure
1753128|NCT00217867|Behavioral|Animated character intervention with telephone follow-up|Animated character will teach the discharge plan before discharge, then this teaching will be reinforced by computerized telephone system.
1753129|NCT00217880|Procedure|Bronchoscopy|A bronchoscopy test will occur to view the participant's airways.
1753130|NCT00217893|Behavioral|Counseling|One-on-one behavioral counseling with pre-teen child; 8 to 10 weekly or bi-weekly sessions; focus on identifying sources of exposure to ETS and means to avoid exposure; goal-setting, role-playing, monitoring progress, feedback includes reported info and urine cotinine level.
1753131|NCT00217893|Behavioral|Urine Cotinine Feedback|Urine collected from child at each weekly/bi-weekly counseling session; cotinine level discussed at subsequent session.
1753132|NCT00217893|Behavioral|Contingent Incentives|Child earns small prizes for on-task behavior in sessions, plus earns tokens redeemable for other prizes based on reduction in ETS exposure (reported and cotinine level).
1753133|NCT00217893|Behavioral|Usual education program|Participants will receive the usual education about ETS.
1753134|NCT00217906|Behavioral|A+ Asthma early intervention program|
1753186|NCT00218231|Drug|300 mg/day bupropion-sr|300 mg/day for 1 week
1753187|NCT00218231|Drug|0 mg/day bupropion-sr|0 mg/day bupropion-sr
1753188|NCT00218244|Other|Lower Nicotine Smokeless Tobacco Product|Skoal for 50% reduction;Skoal bandits for 75% reduction.
1753252|NCT00212316|Drug|sodium phenylbutyrate|
1753135|NCT00217919|Behavioral|Health-Counselor Mediated Telephone Counseling Intervention|"A trained health counselor will conduct the TC sessions, which will occur every 6 weeks (total 8 calls). We expect the initial call to last 30 minutes, with subsequent calls lasting 20 minutes. Our intervention for our primary outcome of LDL-C lowering is expected to take most of this time. We will spend approximately 5 minutes addressing physical activity at the end of each session, using methods similar to those in our pilot TC study.
We will use patient-centered counseling to promote adherence to lipid-lowering medication and LDL-C lowering diet. The intervention will also activate patients to discuss initiation or dose increase of lipid-lowering drugs with their physicians. While the focus of our intervention will be on LDL-C lowering, the TC intervention will also devote approximately 5 minutes of the typical 20 minute call to increasing physical activity."
1753136|NCT00217932|Drug|Divalproex Sodium (Depakote)|
1753137|NCT00217945|Behavioral|Shared-Decision Making|
1753138|NCT00217958|Behavioral|SHS reduction intervention based on social cognitive learning theory|
1753139|NCT00217971|Drug|Dronabinol|Dronabinol
1753140|NCT00217971|Drug|Placebo|placebo
1753143|NCT00218023|Drug|Modafinil|The modafinil dose began at 200 mg (day 1) and increased to the fixed dose of 200 mg twice daily (day 2) during the 12 weeks of Phase I.
1753144|NCT00218023|Drug|Levodopa/Carbidopa|Levodopa-carbidopa, in the sustained-release formulation (Sinemet CR), began at a dose of levodopa/carbidopa 400/100 mg (day 1) and increased to the fixed dose of 400/100 mg twice daily (day 2) during the 12 weeks of Phase I.
1753145|NCT00218023|Drug|Naltrexone HCl|Naltrexone hydrochloride (HCl) doses began at 25 mg (day 1) and increased to the fixed dose of 25 mg twice daily (day 2) during the 12 weeks of Phase I.
1753146|NCT00218023|Drug|Placebo|Placebo capsules were identical in appearance to active drug capsules, and each contained 50 mg riboflavin for subsequent evaluation of medication compliance.
1753147|NCT00218023|Behavioral|Motivational Interviewing (MI)|The primary goal of motivational interviewing (MI) was to assist patients in achieving initial abstinence by increasing motivation and commitment to change. The MI intervention consisted of two 1-h individual therapy sessions on the first and eighth day of Phase I. The client-centered, MI-style sessions focused on building motivation for change, exploring ambivalence, obtaining a commitment to change, making a plan for abstinence (Session 1), providing personalized feedback, reassessing commitment for change, and reevaluating the change plan (Session 2). Masters-level therapists were trained and supervised by the therapy supervisor (ALS), an expert in motivation-based therapies.
1753148|NCT00218023|Behavioral|Contingency management (CM)|Contingency management (CM) is a voucher-based intervention. Subjects earned vouchers for cocaine abstinence (during phase I) and medication compliance (during phase II).
1753149|NCT00218023|Behavioral|Cognitive-Behavioral Therapy (CBT)|Subjects received weekly, 1-h, individual Cognitive-Behavioral Therapy (CBT) sessions during Phase II. This therapy component focused on coping-skills training for resisting cocaine use in high-risk situations, based on relapse-prevention theory and manual-guided techniques. Therapy sessions were conducted by master's-level licensed professional counselors supervised by a licensed clinical psychologist, who monitored manual adherence and competency.
1753150|NCT00218036|Drug|Modafinil 200mg|10 day medication run-up to Modafinil 200mg while subject is methadone maintained at 1/2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
1753151|NCT00218036|Drug|Modafinil 400mg|10 day medication run-up to 400mg of Modafinil while subject is methadone maintained at 1.2 mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
1753152|NCT00218036|Drug|Citalopram 20mg|10 day run-up to Citalopram 20mg while subject is methadone maintained at 1.2mg/kg. On full dose for 12 weeks and then titrated down for 10 days.
1753153|NCT00218036|Drug|Citalopram 40mg|10 day medication run-up to Citalopram 40 mg while subjects are methadone maintained (1.2 mg/kg). On full dose for 12 weeks and then titrated down for 10 days.
1753154|NCT00218036|Drug|Placebo|Placebo while patient is methadone maintained on standard dose of 1.2 mg/kg
1753155|NCT00218049|Drug|GBR 12909|50mg GBR 12909 over 12 days
1753156|NCT00218049|Drug|GBR 12909|GBR 12909 75 mg over 12 day period
1753157|NCT00218049|Drug|GBR 12909|GBR 12909 100 mg over 12 day period
1753158|NCT00218062|Drug|D-Amphetamine 30mg|
1753159|NCT00218062|Drug|D-Amphetamine 60mg|
1753160|NCT00218062|Drug|Modafinil 200mg|
1753161|NCT00218062|Drug|Modafinil 400mg|
1753162|NCT00218062|Behavioral|Therapy|Manual-based, cognitive-behavioral therapy was provided for 1 hour each week by master's-level therapists. The cognitive-behavioral therapy emphasized relapse prevention and coping skills.
1753163|NCT00218062|Drug|Placebo|
1753164|NCT00218075|Drug|Levodopa|
1753165|NCT00218075|Drug|Carbidopa|
1753166|NCT00218075|Behavioral|Clinical Management|
1753167|NCT00218075|Behavioral|Relapse Prevention Therapy|
1753168|NCT00218075|Behavioral|Contingency Management|
1753169|NCT00218101|Drug|Buprenorphine|
1753170|NCT00218114|Drug|Divalproex Sodium|Participants are titrated over 2 weeks, as tolerated to 10 mgs / pound, and blood levels are checked to determine that the blood level is between 50-110 micrograms / ml.
1753171|NCT00218114|Drug|Placebo|Participants will be on matching placebo.
1753172|NCT00218127|Drug|Levoacetyl Methadol|WtDosing up to 1.0 mg/kg Stable 1.0 mg/kg/day
1753173|NCT00218127|Drug|Levoacetyl Methadol|MaxEffect+CBT evaluation to 48 mg Adjust to effect (+/-)
1753174|NCT00218127|Drug|Levoacetyl Methadol|LAAM Fixed Dose evaluation up to 48 mg 48 mg
1753175|NCT00218140|Drug|nicotine transdermal system|
1753176|NCT00218153|Drug|Naltrexone|
1753177|NCT00218166|Drug|GABA Agonists|GABA drugs administered acutely by mouth
1753178|NCT00218179|Other|Non-intervention|Measured total NNAL and PheT as biomarkers of exposure
1753179|NCT00218192|Behavioral|Behavior Therapy|
1753180|NCT00218205|Drug|Epirubicin|
1753181|NCT00218205|Drug|Estramustine Phosphate|
1753182|NCT00218205|Drug|Celecoxib|
1753183|NCT00218218|Drug|Transdermal Nicotine Patch|42 mg transdermal nicotine
1753184|NCT00218218|Drug|21 mg transdermal nicotine|
1753189|NCT00218244|Other|Behavioral Counseling|Behavioral counseling alone for reduction in tobacco use.
1753190|NCT00218257|Drug|Progesterone|200mg progesterone BID
1753191|NCT00218257|Other|placebo|
1753192|NCT00218270|Drug|Tobacco free snuff|Tobacco free snuff
1753193|NCT00218283|Drug|Nicotine Lozenge|Oral Nicotine replacement product
1753194|NCT00218283|Behavioral|Behavioral Counseling|Use of behavioral counseling to reduce tobacco use.
1753197|NCT00218309|Drug|Hydromorphone|
1753198|NCT00218322|Drug|Atomoxetine hydrochloride|Atomoxetine up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
1753199|NCT00218322|Drug|Placebo|Placebo up to maximum dose of 40 to 100mg/day in daily dosing based on body weight up to 12 weeks of the study.
1753200|NCT00218335|Behavioral|Intervention Condition|In the intervention Condition participants were trained to be Health Educators. The intervention focused on HIV risk reduction by teaching knowledge and skills to reduce injection, drug splitting, and sex risk, and by teaching communication skills to conduct outreach to personal risk network members. The intervention consisted of five group-based sessions, one individual session, and one dyad session with a risk network member.
1753201|NCT00218335|Behavioral|Control Condition|The control condition focused on injection drug-use related topics (e.g. HIV testing, Hepatitis C and drug overdose). The sessions were educational and did not include skills training. The control condition consisted of five group-based sessions.
1753202|NCT00218348|Drug|Dextro-Amphetamine Sulfate|
1753203|NCT00218361|Drug|Hydromorphone|
1753204|NCT00218374|Drug|Gabapentin|Gabapentin initiated up to a daily dose of 2400mg PO x 5 weeks
1753205|NCT00218387|Drug|Modafinil|200mg Modafinil
1753206|NCT00218387|Drug|Modafinil|400mg Modafinil
1753207|NCT00218387|Drug|Matching Placebo|Matching Placebo
1753208|NCT00218413|Biological|NicVAX|100 μg, Formulation A, on Days 0, 21, 42, 91 & 182
1753209|NCT00218413|Biological|NicVAX|200 μg, Formulation A, on Days 0, 21, 42, 91 & 182
1753210|NCT00218413|Biological|NicVAX|200 μg, Formulation B, on Days 0, 21, 42m 91 & 182
1753211|NCT00218413|Biological|NicVAX|300 μg, Formulation B, on Days 0, 21, 42, 91 & 182
1753212|NCT00218413|Biological|NicVAX|400 μg, Formulation B, on Days 0, 21, 42, 91 & 182
1753213|NCT00218426|Drug|naltrexone implant|The implant is 1000 mg naltrexone
1753214|NCT00218426|Drug|Oral naltrexone|oral naltrexone 50 mg/day
1753215|NCT00218426|Drug|placebo oral and placebo implant|placebos resemble active medications
1753216|NCT00218439|Drug|Paroxetine|10 mg for 1 week followed by 20 mg for 3 weeks
1753217|NCT00218439|Drug|Placebo|
1753218|NCT00218452|Behavioral|Lifestyle counseling|assigned to a 6-week individual behavioral treatment involving: 1) a novel brief office intervention for cigarette smoking that includes a treatment component intended to eliminate binge drinking
1753219|NCT00218465|Drug|GW468816|Pharmacotherapies for Relapse Prevention
1753220|NCT00218465|Drug|Placebo Comparator: Placebo|
1753221|NCT00218478|Behavioral|Cue Desensitization|During the study session, both groups will be shown a nature video and will be asked to handle and smell various items; these will act as the neutral, non marijuana-related cues. Next, the participants will watch a video of individuals smoking marijuana and will be asked to handle and smell marijuana-related items; these will act as the marijuana-related cues.
1753222|NCT00218491|Drug|N-Acetylcysteine|1200mg N-Acetylcysteine
1753223|NCT00218491|Drug|N-Acetylcysteine|2400mg N-Acetylcysteine
1753224|NCT00218491|Drug|Matching Placebo|Matching Placebo
1753225|NCT00218504|Drug|Tetrahydrocannabinol|Participants will be randomly assigned to receive an oral dose of 10 mg of THC, 20 mg of THC, or placebo.
1753226|NCT00218517|Drug|Selegiline hydrochloride|Daily oral selegiline, 5 mg po qd x 7 days, then 5 mg po bid for 7 weeks
1753227|NCT00218517|Drug|Placebo|Matching placebo capsules using blue 00 capsules
1753228|NCT00218530|Drug|Lofexidine|
1753229|NCT00218543|Drug|Atomoxetine|At the start of week 7, patients will be maintained at 80 mg/day or increased to the maximal dose of 100 mg/day if less than a 50% reduction of symptoms on the ADHD Rating Scale occurs, and if the patient is tolerating the medication well.
1753230|NCT00218556|Behavioral|Cognitive behavioral treatment for depression|Cognitive behavioral intervention to prevent depressive symptoms during treatment for hepatitis C
1753231|NCT00218569|Drug|Naltrexone|Naltrexone
1753232|NCT00218569|Drug|Placebo|Placebo
1753233|NCT00218582|Behavioral|Double Trouble in Recovery|Dual focus 12 step mutual aid groups for persons with co-occurring disorders (psychiatric and substance use disorders), provided within the context of standard psychiatric day treatment
1753234|NCT00218582|Behavioral|Standard psychiatric day treatment|Individual counseling, groups, medication
1753235|NCT00212199|Drug|orlistat|
1753236|NCT00212199|Behavioral|Brief cognitive behavioral counseling|
1753237|NCT00212212|Dietary Supplement|selenium|200 µg selenium as selenate
1753238|NCT00212212|Dietary Supplement|selenium|400 µg selenium as selenate
1753239|NCT00212212|Dietary Supplement|selenium|200 µg selenium as selenomethionine
1753240|NCT00212212|Dietary Supplement|placebo|placebo tablet
1753241|NCT00212238|Behavioral|internet behavioral weight loss program|
1753242|NCT00212251|Behavioral|moderate exercise and healthy, low-fat diet|
1753243|NCT00212264|Behavioral|Behavioral Therapy|Pelvic Floor Muscle Exercises and Bladder control strategies
1753244|NCT00212264|Device|Pelvic Floor Electrical Stimulation|Pelvic Floor Electrical Stimulation daily for 8 weeks
1753245|NCT00212264|Behavioral|Biofeedback|Pelvic Floor Muscle training via biofeedback
1753246|NCT00212264|Other|No Treatment|No treatment
1753247|NCT00212277|Drug|Norethindrone,Ethinyl Estradiol|
1753248|NCT00212290|Drug|pioglitazone|
1753249|NCT00212290|Drug|nateglinide|
1753250|NCT00212290|Drug|placebo|
1753251|NCT00212303|Behavioral|Exercise training for 6 months|Exercise 3 times/week for 6 months. Exercise consists of aerobic and resistance exercise
1753253|NCT00212329|Procedure|T Cell Proliferation and Autoreactivity Assays|
1753254|NCT00212329|Procedure|Cellular Immunoblot Assays|
1753255|NCT00212329|Procedure|Tetramer Studies|
1753256|NCT00212329|Procedure|Cytokine ELISPOT|
1753257|NCT00212342|Drug|Norethisterone,Ethinylestradiol|
1753258|NCT00212342|Drug|Sugar pill|
1753259|NCT00212355|Drug|NPC-02|zinc acetate
1753260|NCT00212368|Drug|Zinc acetate|
1753261|NCT00212381|Drug|di indolylmethane (DIM)|This is the agent being studies. Similar agents have been reported to have potential activity.
1753262|NCT00212381|Dietary Supplement|Red rice bran|"this will act as the active comparator. The sponsor provided this as the placebo arm since it is a filler component of their DIM capsules"
1753263|NCT00212407|Biological|Umbilical Cord Blood Transplantation|
1753264|NCT00212420|Procedure|parenteral nutrition; enteral nutrition|
1753265|NCT00212433|Drug|Tagitol V, Lo So, Readi-Cat 2|
1753266|NCT00212446|Device|Electrical Intervention (EI)|Electrical intervention (EI) is bipolar, constant-current (1-20 mA), square-wave pulses in 20% duty cycles. Women in preterm labor have an electrode placed vaginally; tocodynamometric contraction timing and fetal heart rate are monitored continuously. Successive 20-minute periods include pre-control period (C1); the EI period, in which a 10-second current burst is delivered at expected contraction times; and a post-EI control period (C2).
1753267|NCT00212459|Behavioral|Counseling|Patients are contacted every two weeks after initial counseling to discuss the completion of bleeding records.
1753268|NCT00212459|Behavioral|Control|No more contacts are made with control patients after the initial counseling session.
1753269|NCT00212472|Drug|Factor VIII concentrates|To be determined at the discretion of the investigator.
1753270|NCT00212472|Other|Low-dose treatment|50 FVIII u/kg three times a week.
1753271|NCT00212472|Other|High-dose treatment|200 FVIII u/kg per day.
1753272|NCT00212485|Procedure|Power Doppler Sonography|Power Doppler with gray-scale sonography is used to detect and quantify alterations in vascularity inside knee, elbow and ankle joints.
1753273|NCT00212485|Procedure|MRI|Magnetic Resonance Imaging with intravenous gadolinium contrast will be done using a standardized protocol, including a spin echo T2 weighted image and gradient echo images.
1753274|NCT00212498|Procedure|Develop a bank of blood samples from patients infected with TB for future molecular genetics studies and serological studies|Blood sample
1753275|NCT00212550|Procedure|Obtain standard three daily sputum samples vs. three samples on the first day for the diagnosis of pulmonary TB.|Sputum induction
1753276|NCT00212576|Behavioral|Video Interaction Project|While waiting to see the primary care provider for well child care, the family meets with a child development specialist, who videotapes the parent and infant interacting together. The videotape is then rewound and watched together by the parent and child development specialist. This leads to a discussion about child development, infant cues and parenting, with the child development specialist building on observed strengths in the interaction. In addition, families are provided with parenting pamphlets developed for the project, and with inexpensive developmentally stimulating toys.
1753277|NCT00212576|Behavioral|Building Blocks Project|This project employs a public health approach to facilitate parental engagement in child development. Families are sent monthly newsletters that focus on child development, infant cues and parenting; included with each newsletter is an inexpensive, developmentally stimulating toy. In addition, families periodically receive Ages and Stages Questionnaires, which they complete and mail back to the program. Based on the questionnaires, the program determines whether the infant has screened positive for possible developmental delay and provides this information to both the family and the primary care provider.
1753278|NCT00212589|Drug|Capecitabine|
1753279|NCT00212589|Drug|Fluorouracil + folinic acid|
1753280|NCT00212602|Drug|ONO-7436|
1753281|NCT00212615|Drug|Oxaliplatin (Eloxatin)|
1753282|NCT00212615|Drug|Capecitabine (Xeloda)|
1753283|NCT00212628|Drug|Minodronic acid hydrate|
1753284|NCT00212641|Drug|ONO-5129|
1753285|NCT00212654|Drug|ONO-1101|
1753286|NCT00212667|Drug|ONO-5920|
1753287|NCT00212680|Drug|ONO-1101|
1753288|NCT00212693|Drug|ONO-2506PO|
1753289|NCT00212706|Drug|ONO-8025 (KRP-197)|
1753290|NCT00212719|Drug|ONO-5920|
1753291|NCT00212732|Drug|ONO-8025 (KRP-197)|
1753292|NCT00212745|Behavioral|Andrews/Reiter behavioral treatment for epilepsy|The behavioral intervention in this study uses lifestyle counseling to avoid triggers for seizures and strategies to stop beginning seizures. Participants are taught to practice meditative relaxation exercises.
1753293|NCT00212758|Drug|Nutropin AQ|Nutropin AQ
1753294|NCT00212771|Drug|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
1753295|NCT00212771|Drug|olanzapine|Flexible dose, 1-2 capsules oral once per day (in the morning). Each capsule contains 10 mg olanzapine or matching placebo.
1753296|NCT00212784|Drug|asenapine|Flexible dose, 1-2 tablets sublingual two times per day (1 or 2 tablets in the morning and 1 or 2 tablets in the evening). Each tablet contains either 5 mg asenapine or matching placebo.
1753297|NCT00212784|Drug|olanzapine|Oral capsules (5 mg or placebo); 1 to 2 tablets twice daily
1753298|NCT00212797|Drug|Org 34517|low dose Org 34517
1753299|NCT00212797|Drug|Org 34517|high dose Org 34517
1753300|NCT00212797|Drug|Placebo|placebo
1753301|NCT00212810|Drug|Topiramate|
1753302|NCT00212823|Drug|almotriptan malate|
1753303|NCT00212836|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
1753304|NCT00212836|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
1753305|NCT00218595|Behavioral|DBT|Dialectical behavior therapy plus opiate replacement medication.
1753306|NCT00218595|Behavioral|I/GDC|Individual and group drug counseling plus opiate replacement medication.
1753307|NCT00218608|Drug|Disulfiram|Disulfiram at 0, 62.5, 125 and 250 mg/day were administered during weeks 3-14
1753308|NCT00218621|Procedure|Buprenorphine / methadone|Parallel study to double blind, double dummy study evaluating safety and efficacy of buprenorphine vs methadone treatment for pregnant opioid dependent women
1753309|NCT00218634|Behavioral|CBT-AD|Cognitive behavioral therapy for adherence and depression consisting of 1 session focusing on adherence and 8 sessions consisting of cognitive behavioral therapy for medication adherence and depression.
1753310|NCT00218634|Behavioral|ETAU|Enhanced treatment as usual consisting of 1 session focused on adherence (the same session as the CBT-AD intervention) and 8 sessions for participants to complete self-reports and collect adherence data.
1753311|NCT00218660|Drug|Naltrexone|150mg/day Naltrexone
1753312|NCT00218660|Behavioral|BRENDA|Psychosocial Treatment
1753313|NCT00218660|Behavioral|CBT|Cognitive Behavioral Therapy
1753314|NCT00218660|Drug|Placebo|
1753315|NCT00218673|Behavioral|Peer mentor intervention|groups sessions, 8
1753316|NCT00218686|Behavioral|psychoeducational|psychoeducational
1753317|NCT00218686|Behavioral|control|VTC
1753318|NCT00218699|Behavioral|Cognitive-Behavioral Intervention|
1753319|NCT00218712|Behavioral|Cognitive behavioral intervention|Cognitive behavioral intervention will include personalized cognitive counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
1753320|NCT00218712|Behavioral|Standard counseling|Participants will receive standard counseling. All participants will attend two counseling sessions: the first will occur at study entry and the second will occur 6 months later.
1753321|NCT00218725|Behavioral|Cognitive Therapy|The cognitive therapy intervention for suicide attempters has been designed to provide a brief, timely, flexible intervention that can be incorporated into general and psychiatric inpatient and outpatient services and applied to the population of patients who attempt suicide. A central feature of the intervention is the adaptation of cognitive therapy to the population of patients who attempt suicide. The focus of the intervention is the identification of core beliefs and key automatic thoughts that were elicited prior to and during the most recent suicide attempt. Once these beliefs and thoughts have been articulated, the counselor and patient develop more adaptive responses during an acute suicidal crisis.
1753322|NCT00218725|Other|Enriched Care|The Enriched Care condition will be used as the treatment comparison condition for this study. The Enriched Care condition consists of the usual care that patients may obtain in the community as well as the assessment and referral services provided by the case managers. Participation in the study does not restrict patients in any way in their access to other health care, and all patients in both conditions will be allowed to receive any additional mental health and substance abuse treatment in the community.
1753323|NCT00218751|Behavioral|Home Visiting|
1753324|NCT00218777|Behavioral|Comprehensive Behavioral Intervention for Tics|
1753325|NCT00218790|Procedure|Cool Dialysate|Decreased temperature of the dialysis bath
1753326|NCT00218803|Behavioral|Nurse asthma education intervention|Asthma Education
1753327|NCT00218803|Behavioral|Control Group|Asthma Education
1753328|NCT00218816|Behavioral|Nebulizer Education Intervention|Asthma Education
1753329|NCT00218816|Behavioral|Standard Asthma Education Groups|Asthma Education
1753330|NCT00218842|Behavioral|Individualized exercise|individualized exercise, physical activity and training in daily life situations given by trained physical therapists and occupational therapists
1753331|NCT00218855|Drug|thalidomide|tablets thalidomide start 100 mg x 2 escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. The same procedure is repeated by first relapse.
1753332|NCT00218855|Drug|placebo|100 mg x 2 mg tablets escalating to 200 mg x 2 until plateau phase. Maintenance 100 mg x 2 until relapse. This procedure is repeated by first relapse.
1753333|NCT00218868|Procedure|Skin scrape|scrape cytology using two different cytological staining techniques, and additional touch imprint cytology compared with histopathology of superficial basal cell carcinoma and actinic keratosis
1753334|NCT00218881|Procedure|HIV educational video|
1753335|NCT00218894|Procedure|Cataract surgery|surgery one one or two eyes by use of two different types of lenses and correcting for refraction
1753336|NCT00218907|Procedure|Educational video|
1753338|NCT00218933|Behavioral|Moderate intensity exercise training|12-weeks, 2-3 times per week moderate exercise-intensity (70% of peak heart rate)
1753339|NCT00218933|Behavioral|High intensity exercise training|12-weeks, 2-3 times per week high-intensity interval-training (95% of peak heart rate)
1753340|NCT00218946|Drug|Sucrose|30 % sucrose
1753341|NCT00218946|Device|Pacifier|
1753342|NCT00218946|Other|sterile water|
1753343|NCT00218959|Behavioral|Narrative Exposure Therapy|Exposure based treatment for PTSD developed especially for refugees. Built upon Prolonged exposure treatment (Edna Foa) and Testimonial Therapy (Cientifuegos & Monelli).
1753344|NCT00218959|Behavioral|treatment as usual|
1753345|NCT00219141|Drug|Aliskiren 150/300 mg|Aliskiren 150 mg tablets
1753346|NCT00219141|Drug|Losartan 50/100 mg|Losartan 50 or 100 mg capsules
1753347|NCT00219141|Drug|Aliskiren placebo|Aliskiren 150 mg placebo tablet
1753348|NCT00219141|Drug|Losartan 50/100 mg placebo|Losartan 50/100 mg placebo capsules
1753349|NCT00219154|Drug|aliskiren|
1753350|NCT00219167|Drug|aliskiren|
1753351|NCT00219180|Drug|aliskiren|
1753352|NCT00219193|Drug|aliskiren|
1753353|NCT00219219|Drug|Zoledronic acid|
1753354|NCT00219232|Drug|Rivastigmine Transdermal Patch|
1753355|NCT00219245|Drug|Rivastigmine|
1753356|NCT00219258|Drug|Zoledronic acid|
1753357|NCT00219271|Drug|Zoledronic acid|
1753358|NCT00219284|Drug|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone was administered in 1 of 3 dose combinations: 12.5/50/200 mg, 25/100/200 mg, or 37.5/150/200 mg. The selected combination dose contained the same doses of carbidopa and levodopa the patient was receiving prior to switching to carbidopa/levodopa/entacapone.
1753359|NCT00219297|Drug|Patupilone|
1753360|NCT00219310|Drug|Famciclovir|
1753361|NCT00219323|Drug|Omalizumab|
1753426|NCT00219856|Drug|Desflurane|Inhaled desflurane aiming an alveolar concentration of 4 to 6 per cent.
1753427|NCT00219869|Drug|Galantamine|
1753558|NCT00221286|Drug|pegIFN / TDF / FTC combination therapy|
1753805|NCT00223574|Drug|high carbohydrate, low glycemic index foods|
1753362|NCT00219336|Behavioral|Self-guided Motivational Intervention|Using a randomized two-group design, a self-guided motivational intervention based on Project CHOICES will be compared to an informational only intervention, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS.
1753363|NCT00219336|Behavioral|Informational Only|Using a randomized two-group design, an informational intervention using a brochure from the CDC will be compared to a self-guided motivational intervention based on Project CHOICES, both directed at preventing alcohol-exposed pregnancies (AEPs) with students and nonstudents. Participants will be women 18 to 44 years of age who are at risk of an AEP. All materials are sent to participants through the USPS
1753366|NCT00219362|Biological|one injection of vCP1452 at W0, W4, W8 and W20|
1753367|NCT00219362|Biological|one injection of vCP1452 at W4, W8 and W20|
1753368|NCT00219362|Biological|one injection of placebo at W0, W4, W8, W20 or at W4, W8,W20|
1753369|NCT00219375|Drug|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
1753370|NCT00219375|Drug|Sivelestat sodium hydrate|0.2 mg/kg/hr continuous i.v. infusion - up to 14 days
1753371|NCT00219388|Drug|Levosimendan|
1753372|NCT00219401|Biological|Pneumococcal 7 valent conjugate vaccine (Prevenar®)|Accelerated PCV vaccinaton.
1753373|NCT00219414|Device|Adacolumn Apheresis System|
1753374|NCT00219440|Other|Actos plus standard diet|Actos plus standard diet
1753375|NCT00219440|Other|Actos plus structured diet|Actos plus structured diet
1753376|NCT00219440|Other|Metformin plus standard diet|Metformin plus standard diet
1753377|NCT00219453|Device|Jet Injector with Protector Cap (HSI-500)|
1753378|NCT00219466|Other|Zinc Oxide Diaper Rash Ointment|Desitin Original at diaper change
1753379|NCT00219466|Other|Aloe Vera/Tocopherol/Zinc Oxide Cream|Desitin Creamy at diaper change
1753380|NCT00219479|Drug|Phenytoin (Dilantin) levels during change in enteral feeding|
1753381|NCT00219505|Procedure|acupuncture|
1753382|NCT00219518|Procedure|defecography|insertion of catheter to record pressure. Insertion of barium to outline rectum and fluoroscopy to define change in rectal contour and expulsion of barium during the study.
1753383|NCT00219531|Behavioral|perception of rectal balloon distention|fMRI study with measurement of brain MRI response to rectal balloon distention.
1753384|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 150mg/day (75mg BID)
1753385|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 300 mg/day (150mg BID)
1753386|NCT00219544|Drug|Pregabalin (Lyrica)|pregabalin 600/day (300mg BID)
1753387|NCT00219544|Drug|Placebo|Placebo
1753388|NCT00219557|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks
1753389|NCT00219557|Drug|AG-013736|Axitinib (AG-013736) 5 mg tablet orally BID starting from Day 1 of Cycle 1, in cycles of 4 weeks.
1753390|NCT00219557|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 30 minutes IV infusion on Day 1, 8 and 15 of each cycle, in cycles of 4 weeks.
1753391|NCT00219570|Drug|clindamycin|
1753392|NCT00219570|Drug|nadifloxacin|
1753393|NCT00219583|Drug|UK-390,957|
1753394|NCT00219596|Drug|Xalacom|
1753395|NCT00219596|Drug|unfixed Latanoprost and Timolol|
1753396|NCT00219609|Drug|UK-390,957|
1753397|NCT00219622|Drug|tofimilast|
1753398|NCT00219635|Drug|UK-390,957|
1753399|NCT00219648|Drug|PEP03|
1753401|NCT00219674|Behavioral|Group I: Video training|"Participants will receive the AED with a video that provides instructional training."
1753402|NCT00219674|Behavioral|Group II: Video training + enhanced self-efficacy (SE)|Partcipants will receive the AED with instructional video, a manikin, and additional training materials by mail.
1753403|NCT00219674|Behavioral|Group III: In-person training + enhanced SE|Participants will receive a face-to-face training session in their home as well as the AED with instructional video, manikin and training materials.
1753404|NCT00219674|Behavioral|Group IV: In-person training + enhanced SE + support|Participants will receive a face-to-face training session in their home as well as the AED, instructional video, manikin, and a resource manual with information to enhance the family member's confidence in their role as care provider.
1753405|NCT00219687|Other|dispatcher-assisted CPR with compressions & ventilations|Delivery of telephone CPR instructions to lay callers with chest compressions and ventilations when the patient is identified to be in cardiac arrest
1753406|NCT00219687|Other|dispatcher-assisted CPR instructions with compressions only|Delivery of telephone CPR instructions to lay callers with hands-only chest compressions when the patient is identified to be in cardiac arrest
1753407|NCT00219700|Drug|Ibuprofen-PC|
1753408|NCT00219713|Drug|nitrous oxide and oxygen|
1753409|NCT00219726|Drug|Imatinib mesylate|
1753410|NCT00219739|Drug|Imatinib mesylate 400 mg|
1753411|NCT00219739|Drug|Imatinib mesylate 600 mg|
1753412|NCT00219739|Drug|Imatinib 400 mg + Peg-Interferon|
1753413|NCT00219739|Drug|Imatinib mesylate 400 mg + Cytarabine|
1753414|NCT00219752|Drug|Imatinib mesylate 400 mg|
1753415|NCT00219765|Drug|Imatinib mesylate 600 mg|
1753416|NCT00219765|Drug|Cytarabine|
1753417|NCT00219765|Drug|Daunorubicine|
1753418|NCT00219778|Drug|mifepristone|
1753419|NCT00219791|Drug|glucarpidase (50 Units/kg)|
1753420|NCT00219804|Drug|tetrabenazine or placebo|
1753421|NCT00219817|Drug|RC-1291 HCl|
1753422|NCT00219830|Behavioral|cardiac rehabilitation program|Attended a formal cardiac rehabilitation program/did not attend
1753423|NCT00219843|Drug|PV-10 (rose bengal disodium, 10%)|
1753424|NCT00219856|Drug|Propofol|"Induction : intravenous propofol aiming a concentration of 4 to 8 µg/ml
Maintenance : intravenous propofol aiming a concentration of 3 to 6 µg/ml"
1753425|NCT00219856|Drug|Penthotal|Intravenous penthotal at the dose of 3 to 5 mg/kg
1753428|NCT00219882|Drug|standardized turmeric root extract|1.5 gm of standardized tumeric root extract three times per day for seven consecutive days, followed by 3 gm of standardized tumeric root extract three times per day for seven consecutive days
1753429|NCT00219895|Drug|Ibuprofen|
1753430|NCT00219908|Drug|Mitoxantrone|
1753431|NCT00219921|Drug|Intrathecal morphine at surgery, 0.1mg and placebo|
1753432|NCT00219921|Drug|Patient Controlled Analgesia with iv morphine and placebo|
1753433|NCT00219921|Drug|intrathecal morphine AND patient controlled analgesia with iv morphine|
1753434|NCT00219934|Drug|Antiretroviral therapy|HAART therapy
1753435|NCT00219947|Other|blood draw|"T cell subset enumeration
Serologic reactivity with HIV antigens
Viral load assays by bDNA, PCR, or RT-PCR
Routine Laboratory assessments (chemistries, liver function tests, hepatitis serology, RPR)
HIV-1 Resistance Testing"
1753436|NCT00219960|Drug|North American Ginseng (Panax Quinquefolius)|
1753437|NCT00219973|Drug|Bemiparin|Bemiparin 3.500 IU/day for 28 days compared to 8 days
1753438|NCT00219986|Drug|Potent HAART during acute or early HIV-1 infection|
1753439|NCT00220012|Procedure|Folate depletion and supplementation|
1753440|NCT00220025|Device|Phototherapy|The patient begins total body NBUVB that day at a dose that is 50% of the MED. Patients are treated 3-7 times per week, with increasing doses at every treatment if no burning occurs. This is continued until clearance of disease or maximum efficacy.
1753441|NCT00220038|Behavioral|smell tests|subjects are instructed to sniff two vials, one containing the solvent, the other a dilution of the odorant. They are asked to scan the vial with the stronger odor.
1753442|NCT00220051|Drug|Oxaliplatin, Capecitabine|
1753443|NCT00220051|Procedure|Pre operative radiotherapy|
1753444|NCT00220051|Procedure|Surgical Resection|
1753445|NCT00220064|Drug|Irinotecan, 5-Fluorouracil, Leucovorin|
1753446|NCT00220077|Procedure|Endoscopy|
1753447|NCT00220090|Drug|dexloxiglumide|
1753448|NCT00220103|Drug|epirubicin, capecitabine, cisplatin|
1753449|NCT00220103|Procedure|Surgical resection|
1753450|NCT00220116|Drug|Capecitabine, Oxaliplatin|
1753451|NCT00220129|Drug|Epirubicin, Cisplatin, Capecitabine|
1753452|NCT00220129|Procedure|Surgical Resection|
1753453|NCT00220155|Drug|Gemcitabine|
1753454|NCT00220168|Drug|Irinotecan, Capecitabine|
1753455|NCT00220194|Drug|leuprolide acetate|
1753456|NCT00220207|Behavioral|Internet co-management module|
1753457|NCT00220220|Drug|olmesartan medoxomil|
1753458|NCT00220220|Drug|amlodipine|
1753459|NCT00220233|Drug|olmesartan medoxomil|
1753460|NCT00220233|Drug|amlodipine|
1753461|NCT00220233|Drug|hydrochlorothiazide|
1753462|NCT00220259|Drug|Fluticasone or placebo|
1753463|NCT00220272|Drug|SR57667B|
1753464|NCT00220285|Drug|Zevalin (SH L 749 , BAY86-5128)|0,3mCi/kg
1753465|NCT00220285|Drug|Zevalin (SH L 749 , BAY86-5128)|0,4mCi/kg
1753466|NCT00220298|Drug|Testosterone undecanoate (TU) - NebidoTM|Drug treatment with 14 injections of one ampoule of Nebido (1000 mg of testosterone undecanoate) at individually adjusted injection intervals
1753467|NCT00220311|Drug|Fludarabine Phosphate (Fludara)|6 cycles (1 cycle: 5 treatment days every 28 days)
1753468|NCT00220324|Drug|Minisiston (SH D00342A)|Daily oral administration in 21 days per cycle, followed by a 7-day pill-free interval
1753469|NCT00220337|Drug|lacosamide|Lacosamide film-coated tablets; two times per day; up to 400 mg/day for 2.75 years
1753470|NCT00220350|Drug|leuprolide acetate|
1753471|NCT00220363|Drug|SPM 907|
1753472|NCT00220376|Drug|SPM 907|
1753473|NCT00220389|Drug|SPM 907|
1753474|NCT00220402|Drug|SPM 907|
1753475|NCT00220415|Drug|SPM 927|
1753476|NCT00220428|Biological|T-Cell Vaccination|
1753477|NCT00220441|Behavioral|Aerobic exercise|
1753478|NCT00220454|Drug|Climara|
1753479|NCT00220454|Drug|Hydrocortone|
1753480|NCT00220467|Behavioral|Aerobic exercise|
1753481|NCT00220480|Drug|escitalopram|10 to 30 mg / day
1753482|NCT00220493|Drug|Ritalin|
1753483|NCT00220506|Drug|Provigil|
1753484|NCT00220519|Drug|Lactobacillus GG|
1753485|NCT00220532|Drug|Folic acid with riboflavin|
1753486|NCT00220545|Procedure|Laparoscopic ovarian diathermy|
1753487|NCT00220558|Device|Coronary placement of bare metal stent vs. drug eluting stent|
1753488|NCT00220571|Device|Coronary Angioplasty (PTCA)|
1753489|NCT00220584|Drug|donepezil|donepezil 5 mg daily for 3 weeks (days 1-21); 10 mg daily for 3 weeks (days 22-42)
1753490|NCT00220597|Behavioral|Trauma-focused group therapy|
1753491|NCT00220610|Device|Transcranial magnetic stimulation|
1753492|NCT00220623|Drug|antidepressant medications, flexible drug choice|
1753493|NCT00220623|Behavioral|CBT, Psychodynamic or Supportive Psychotherapy|
1753494|NCT00220636|Drug|Aripiprazole|Aripiprazole dose ranging from 5 to 30 mg/day, augmenting antidepressant treatment. Aripiprazole is used as an augmenting medication on an open label basis for patients on antidepressant medication who continue to have depressive symptoms. This is an open label case series in which all subjects receive aripiprazole augmentation. There is no comparator group.
1753495|NCT00220649|Drug|gemcitabine; irinotecan; leucovorin; 5-fluorouracil; oxaliplatin|
1753496|NCT00220662|Behavioral|Readiness and Motivation Therapy|
1753497|NCT00220675|Drug|Erythropoietin infusion|
1753498|NCT00220688|Device|Acupressure Wristbands|
1753499|NCT00220701|Drug|Lexapro (escitalopram)|antidepressant drug selective serotonin reuptake inhibitor (SSRI)
1753500|NCT00220714|Drug|atypical antipsychotics:oral vs. long-acting route|
1753501|NCT00220714|Behavioral|Family Psychoeducation|
1753502|NCT00220727|Drug|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|IGIV-C 10% at a dose of 1.0g/kg was to be given on 2 occasions as a single daily infusion: Group 1 were to receive their first IGIV-C, 10-% infusion at a rate of 0.08 mL/kg/min and a second infusion at 0.14 mL/kg/min. and Group 2 were to receive their first IGIV-C, 10-% infusion at a rate of 0.14 mL/kg/min and a second infusion at a rate of 0.08 mL/kg/min.
1753503|NCT00220740|Drug|Immune Globulin IV (Human), 10% Caprylate/Chromatography Purified|2 g/kg body weight ideally over 2-4 days . Thereafter, study drug infusion (IGIV-C) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
1753504|NCT00220740|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin 25%, USP diluted with dextrose 5% to a final concentration of 0.1% as an intravenous infusion. Alternatively, it may be a bottled placebo of 0.1% Albumin (Human) in 0.2 M Glycine, 1.1 mm sodium caprylate, 0.25% sodium chloride. 2 g/kg body weight ideally over 2-4 days . Thereafter, infusion (placebo) will be administered every 3 weeks at a dose of 1 g/kg bw, given over 1-2 days for a total of 7 additional infusions
1753505|NCT00220753|Device|IQAir Allergen 100 Air cleaners|Two air cleaners are installed in the patient's room, one in his bedroom, and one in the living room. The cleaners can be run at 5 different speeds: Speed 1 filtrates 60m3 of air per hour, speed 2 filtrates 90 m3 per hour, speed 3 filtrates 130 m3 per hour, speed 4 filtrates 240 m3 per hour, and speed 5 filtrates 380 m3 per hour. A timer-on period can be pre-set for every day of the week, but the cleaner can be run even in the timer-off period, at a speed pre-set and different from the timer-on period. Different timer-on off periods cannot be selected for different days, but the different days of the week can be pre-set to apply timer-on periods or not.
1753506|NCT00220766|Drug|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|
1753507|NCT00220766|Drug|Dextrose, 5% in Water|
1753508|NCT00220779|Drug|Immune Globulin IV [Human], 10% Caprylate/Chromatography Purified|
1753509|NCT00220779|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|
1753510|NCT00220792|Behavioral|Brief supportive-expressive group therapy|
1753511|NCT00220805|Drug|Immune Globulin Intravenous [Human], 10% Caprylate/Chromatography Purified|The dose per infusion cycle was 2 g/kg body weight over 5 consecutive days (= 4 mL/kg body weight/infusion). The infusion duration was approximately 1.5 - 2 h.
1753512|NCT00220805|Drug|Albumin (Human) 25%, United States Pharmacopeia (USP)|Albumin (Human) 20% or 25% will be diluted with 5% glucose to a final concentration of 0.1%.
1753513|NCT00220818|Drug|Lansoprazole|Lansoprazole 1.0 mg/kg/day suspension, orally, once daily for up to 5 days.
1753514|NCT00220818|Drug|Lansoprazole|Lansoprazole 2.0 mg/kg/day suspension, orally, once daily for up to 5 days.
1753515|NCT00220831|Drug|Natural source Vitamin E 400IU/day|
1753516|NCT00220844|Drug|Desipramine|
1753517|NCT00220844|Drug|Amitriptyline|
1753518|NCT00220857|Drug|Rabeprazole|
1753519|NCT00220870|Behavioral|Decision aid|
1753520|NCT00220896|Drug|Donepezil|
1753521|NCT00220909|Drug|Lansoprazole|
1753522|NCT00220922|Procedure|Alcohol Wipes vs. No Alcohol Wipes|
1753523|NCT00220935|Device|Orthotrac Pneumatic Vest|
1753524|NCT00220948|Procedure|CERSR Myoelectric monitoring during standardized tasks|
1753525|NCT00220961|Drug|Pioglitazone|Pioglitazone tablets - 45 mg/day
1753526|NCT00220961|Drug|Placebo|Placebo tablets similar to pioglitazone tablets - 1 tablet/day
1753527|NCT00220974|Behavioral|Internet-based tailored advice on cardiovascular risk|
1753528|NCT00220987|Other|Intensive Insulin Therapy|Maintain blood glucose 4.5 - 6.o mmol/L
1753529|NCT00220987|Other|Conventional Insulin therapy|Maintain blood glucose 8-10mmol/L
1753530|NCT00221000|Drug|Methoxsalen|
1753531|NCT00221000|Procedure|Extracorporeal Photopheresis|
1753532|NCT00221013|Procedure|"augmented CRRT regimen"|We randomly assigned critically ill patients with acute kidney injury to receive CRRT in the form of post-dilution continuous veno-venous hemodiafiltration (CVVHDF) at 25 ml/kg/hr (lower intensity) or 40 ml/kg/hr (higher intensity) of effluent flow.
1753533|NCT00221026|Drug|Methoxsalen +ECP|ECP + Uvadex given at weeks 1-12 weeks.
1753534|NCT00221026|Procedure|Extracorporeal Photopheresis|ECP given at weeks 1 through 12.
1753535|NCT00221039|Drug|Methoxsalen+ECP|UVAdex+ECP will be administered: Treatment consists of two photopheresis treatments on successive days every 4 weeks for six months
1753536|NCT00221052|Drug|Diclofenac|
1753537|NCT00221065|Device|Nasal Continuous positive airway pressure - Tyco 420G|CPAP at determined pressure nightly for 1 month
1753538|NCT00221078|Device|Neuroprosthesis|The Compex Motion neuroprosthesis, developed by Drs.R. Popovic and Thierry Keller, and company Compex SA, is a flexible device designed to improve grasping function in both SCI and stroke patients. This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp, and holds a number of advantages over the other existing neuroprostesis.
1753539|NCT00221091|Procedure|ventriculo-peritoneal shunt|
1753542|NCT00221130|Procedure|surgical operation of cell transplantation|
1753543|NCT00221143|Genetic|Autologous peripheral blood CD34 positive cell therapy|
1753544|NCT00221156|Drug|Acarbose|
1753545|NCT00221169|Procedure|Surgical resection|pet ct prior to surgery
1753546|NCT00221182|Genetic|Autologous peripheral blood CD34 positive cell therapy|
1753547|NCT00221195|Drug|activated prothrombin complex concentrate (FEIBA)|"FEIBA for prophylaxis therapy dosed at 85 U/Kg +/- 15% on three non-consecutive days each week for 6 months
FEIBA for on-demand therapy dosed at 85 U/Kg +/- 15% for bleeding episodes for 6 months"
1753548|NCT00221208|Behavioral|Resistance Training|
1753549|NCT00221221|Device|Pedometer|
1753550|NCT00221221|Device|Exercise guidebook|
1753551|NCT00221234|Behavioral|Print materials, pedometers/logbooks|
1753552|NCT00221234|Behavioral|Print materials, pedometers/logbooks, telephone counselling|
1753553|NCT00221247|Procedure|Acupuncture|acupuncture
1753554|NCT00221260|Procedure|anesthesia|Intraoperative general anesthesia AND postoperative IV narcotic analgesia.
1753555|NCT00221273|Procedure|ACL surgery|Unspecified
1753556|NCT00221286|Drug|pegylated interferon alfa-2a|
1753557|NCT00221286|Drug|tenofovir DF / emtricitabine combination therapy|
1753559|NCT00221299|Drug|Risedronate|One 35mg tab of risedronate/placebo taken once a week for one year.
1753560|NCT00221299|Drug|Parathyroid Hormone|This medication comes in a pre packaged 28 day supply pen. Medication is administered once a day by a subcutaneous injection (under the skin) into the thigh or abdomen. For this study, this medication will be taken for one year.
1753561|NCT00221312|Drug|Fosamax|
1753562|NCT00221325|Drug|Intraventricular Rituximab Plus MTX|"Intraventricular injection of rituximab into an Ommaya reservoir on day 1 of each week. Intraventricular rituximab plus methotrexate (MTX) on day 4 of each week.
First three patients at dose A : 25 mg rituximab on day 1, and MTX (12 mg) plus rituximab (10 mg) on day 4 each week.
If there are no dose limiting toxicities at Dose A in all of the first 3 patients or in 5 of the first 6 patients, the next 3 patients will receive dose level B: 25 mg rituximab on day 1, and combination MTX (12 mg) plus rituximab (25 mg) on day 4 of each week.
Oral leucovorin rescue 24 hours after each MTX administration. Maximum injections will be 16 over 9-weeks. Subjects who experience a partial response at week 10 will be given the option for extended dosing."
1753563|NCT00221338|Drug|Gabapentin|This is a Double blind, placebo-controlled experimental study in which gabapentin adjusted for renal clearance (or placebo) is given preoperatively and also the first three postoperative days
1753564|NCT00221351|Procedure|CRP point of care testing|
1753565|NCT00221364|Drug|Mass treatment with oral azithromycin to an entire village|
1753566|NCT00221377|Device|Intubation using tracheal tubes with or without cuff|
1753567|NCT00221390|Drug|Ropinirole (+ physical therapy)|
1753568|NCT00221390|Drug|(vs.) Placebo + physical therapy|
1753569|NCT00221403|Drug|Risperidone Valproate|liquid, BID dosing.
1753570|NCT00221416|Drug|Aripiprazole|5-20 mg/day
1753571|NCT00221429|Drug|lithium sodium divalproex|
1753572|NCT00221442|Drug|Zonegran|zonegran (zonisamide)
1753573|NCT00221442|Drug|sugar pill|fake pill
1753574|NCT00221455|Behavioral|Patient diabetic self-management using the diabetic patient portal tools|
1753575|NCT00221455|Behavioral|A variety of educational interventions for non-adopters of the technology, and for non-compliant patients.|
1753576|NCT00221468|Drug|quetiapine|100mg of quetiapine on day 1 and titrated to a maximum dose of 400mg by day 4, with flexible dosing to 600mg by day 28. The total duration of treatment will be 84 days (12 weeks).
1753577|NCT00221481|Drug|divalproex or olanzapine|
1753578|NCT00221494|Drug|citalopram + tiodothyronine, or + pindolol, or + placebo|
1753579|NCT00221507|Behavioral|Reminder-Recall-Outreach|
1753580|NCT00221507|Behavioral|Case Management|
1753581|NCT00221507|Behavioral|Patient Navigator|
1753582|NCT00221520|Drug|midazolam with 2 different levels of sedation scores|
1753583|NCT00221546|Drug|Giving DHA-rich supplement|Giving DHA-rich supplement to patients.
1753584|NCT00221559|Procedure|Blood sampling for determination of serum Zn|
1753585|NCT00221572|Procedure|Determination of bot density of Cystic Fibrosis patients|Determination of bot density of Cystic Fibrosis patients.
1753586|NCT00221585|Behavioral|Psychosocial treatment/Psychodynamic treatment|
1753587|NCT00221598|Procedure|Haemodialysis with different dialysate temperatures|Haemodialysis with different dialysate temperatures is used.
1753588|NCT00221611|Drug|Administration of intrathecal baclofen|
1753589|NCT00215735|Device|debridement, dressing, and APC|ebridement, dressing, and APC
1753590|NCT00215748|Drug|Dexamethasone|
1753591|NCT00215774|Drug|Flecainide|Flecainide 2 - 3 x 100 mg/d The main difference between the two active therapy groups is the duration of treatment.
1753592|NCT00215787|Drug|lansoprazole|Lansoprazole 30 mg BID for 1 year
1753593|NCT00215800|Drug|Ampligen|
1753594|NCT00215813|Drug|Poly I: Poly C12U (Rintatolimod)|200-400 mg IV infusions given twice weekly over a period of 30-60 minutes
1753595|NCT00215826|Drug|Alferon LDO|
1753596|NCT00215839|Drug|Peginterferon a-2a plus Ribavirin|
1753597|NCT00215852|Drug|Alferon LDO|500 IU, taken orally each evening, for 10 consecutive days while holding in the mouth for at least 2 minutes prior to swallowing, for 10 daysday 5 of each 28 day cycle.
1753598|NCT00215865|Drug|PEGIntron plus ribavirin|
1753599|NCT00215878|Drug|D-serine (~2g /day)|Two 6 weeks treatment arms under a cross over design. In one arm adjuvant treatment with experimental medication (D-serine ~2g /day), in the second arm adjuvant treatment with placebo (~2g /day)
1753600|NCT00215891|Drug|PEG-Interferon a-2b + Ribavirin|
1753601|NCT00215904|Drug|D-serine (~2g/day)|Two 6 weeks treatment arms. One arm: adjuvant treatment with D-serine (~2g/day). Second arm : adjuvant treatment with placebo (~2g/day).
1753602|NCT00215917|Drug|D-serine 2100 mg daily|
1753603|NCT00215930|Drug|Vinorelbine|Ribonucleotide reductase subunit 1(RRM1)above 16.5 and Excision repair cross-complementing group 1 gene(ERCC1)above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days.
1753604|NCT00215930|Drug|Docetaxel|"RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days.
RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days.
RRM1 above 16.5 and ERCC1 above 8.7: Treat patients with Docetaxel and Vinorelbine (DV). DV group was treated with vinorelbine (45mg/m2ondays 1 and 15) and docetaxel (60mg/m2ondays 1 and 15) every 28 days."
1753605|NCT00215930|Drug|Gemcitabine|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.
RRM1 below 16.5 and ERCC1 above 8.7: Treat patients with Gemcitabine and Docetaxel (GD). GD group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and docetaxel (40 mg/m2 on days 1 and 8) every 21 days."
1753667|NCT00222014|Procedure|TIPS|Transjugular intrahepatic portosystemic shunt with covered PTFE
1753668|NCT00222014|Procedure|Paracenthese|Paracenthese
1753669|NCT00222027|Procedure|Collection of treatment-stratefying prognostic factors|
1753606|NCT00215930|Drug|Carboplatin|"Ribonucleotide reductase subunit 1(RRM1) below 16.5, and Excision repair cross-complementing group 1 gene(ERCC1) below 8.7: Patients treated with Gemcitabine and Carboplatin (GC). GC group was treated with gemcitabine (1,250 mg/m2 on days 1 and 8) and carboplatin (area under the concentration-time curve [AUC] of 5 on day 1) every 21 days.
RRM1 above 16.5 and ERCC1 below 8.7: Treat patients with Docetaxel and Carboplatin (DC). DC group was treated with docetaxel (75 mg/m2 on day 1) and carboplatin (AUC 5 on day 1) every 21 days."
1753607|NCT00215943|Drug|zoledronic acid|Patients were randomized to receive zoledronic acid I.V. on either Day 1 or 15 of each cycle. This schedule continued monthly as long as the patient remained on study. The dose was calculated based on the patients' monthly creatinine clearance.
1753608|NCT00215943|Drug|dexamethasone|As outlined in VAD Treatment arm and Thalidomide and Dexamethasone Treatment arm
1753609|NCT00215943|Drug|thalidomide|As outlined in Thalidomide and Dexamethasone Treatment arm
1753610|NCT00215943|Drug|vincristine|As outlined in VAD Treatment Arm
1753611|NCT00215943|Drug|adriamycin|As outlined in VAD Treatment arm
1753612|NCT00215956|Drug|topotecan|Preoperative treatment: oral topotecan 5 days per week for up to 5 weeks
1753613|NCT00215956|Procedure|radiation|Preoperative radiation
1753614|NCT00215956|Procedure|surgery|surgery to remove tumor 4 to 8 weeks following completion of preoperative treatment
1753615|NCT00215982|Drug|capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 PO BID, for a total daily dose of 1650 mg/m2. Capecitabine will be administered on days 1-14 followed by 7 day treatment free rest period and days 21-35 followed by a 7 day treatment-free rest period, every six weeks (42 days) of treatment is considered one cycle.
1753616|NCT00215982|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 130 mg/m2 IV over 120 minutes in 250-500 ML D5W on day 1, every 42 days.
1753617|NCT00215982|Drug|Irinotecan|Irinotecan will be administered at a dose of 180mg/m2 IV over 90 minutes on day 21 every 42 days.
1753618|NCT00215995|Drug|Cisplatin|As outlined in Detailed Description
1753619|NCT00215995|Drug|Irinotecan|As outlined in Detailed Description
1753620|NCT00215995|Drug|ZD 1839|As outlined in Detailed Description
1753621|NCT00216008|Drug|docetaxel|
1753622|NCT00216008|Drug|cisplatin|
1753623|NCT00216008|Procedure|radiation|
1753624|NCT00216008|Procedure|surgery|
1753625|NCT00216021|Drug|Capecitabine|Capecitabine 825 mg/m2 po bid, days 1-14
1753626|NCT00216021|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV, day 1
1753627|NCT00216034|Drug|Tegafur-gimeracil-oteracil potassium (TS-1)|From 4-8 weeks after surgery to 27-31 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 21 day cycle. Number of Cycles: 8 From 28-32 weeks after surgery to 53-57 weeks after surgery, 80 mg/m2, PO from day 1 to day 14 of each 28 day cycle. Number of Cycles: 7
1753628|NCT00216034|Drug|Krestin (PSK)|From 4-8 weeks after surgery to 53-57 weeks after surgery, 3 g/day, PO every day
1753629|NCT00216047|Drug|PTK787|PTK787 daily
1753630|NCT00216047|Drug|Trastuzumab|Trastuzumab 4 mg/kg IV week 1, followed by 2 mg/kg weekly with disease evaluation every other cycle*
1753631|NCT00221624|Drug|Peginterferon alfa-2a|
1753632|NCT00221624|Drug|ribavirin|
1753633|NCT00221624|Drug|amantadine|
1753634|NCT00221637|Drug|Sodium Valproate|
1753635|NCT00221650|Drug|Peginterferon alfa2a|
1753636|NCT00221650|Drug|Ribavirin|
1753637|NCT00221663|Device|surgery techniques (sternotomy for aortic valve replacement)|
1753638|NCT00221676|Biological|Alfarix|
1753639|NCT00221689|Drug|baclofen (drug)|
1753640|NCT00221702|Drug|PegIntron|100 mcg SC/week for 36 months
1753641|NCT00221702|Drug|intron A|3mui TIWW SC for 18 months
1753642|NCT00221715|Device|femoropopliteal artery bypass|Bypass by autologous saphenous vein
1753643|NCT00221715|Device|femoropopliteal artery bypass|bypass by dacron or PTFE Prosthesis
1753644|NCT00221728|Device|Radiofrequency|
1753645|NCT00221728|Procedure|conservative surgery|
1753646|NCT00221741|Drug|Fresh Frozen Plasma (blood product)|
1753647|NCT00221754|Drug|Pravastatin (drug)|
1753648|NCT00221767|Device|Brindley technique (bladder system)|Sacral posterior rhizotomies and implantation of Brindley device on sacral anterior roots
1753649|NCT00221780|Device|left ventricular pacing|
1753650|NCT00221793|Procedure|Deep brain stimulation|Brain Stimulation of the Subthalamic Nucleus
1753651|NCT00221806|Device|endothelialised prosthesis|
1753652|NCT00221819|Device|heated humidifier (device)|
1753653|NCT00221819|Device|Heat and moisture exchanger (device)|
1753654|NCT00221845|Drug|ACE Inhibition|ACE inhibitor ramipril (6 mg/m²/day) will be given to all subjects.
1753655|NCT00221845|Drug|Intensified Blood Pressure Control|Any antihypertensive drugs except ACE inhibitors and angiotensin receptor blockers will be allowed.
1753656|NCT00221845|Drug|Add-on Angiotensin Receptor Blockade|In patients who show persistent or breakthrough proteinuria at the end of the initial study period, telmisartan (50 mg/m²/day) will be added to the existing medication.
1753657|NCT00221858|Procedure|Ultrasound guided blocks|
1753658|NCT00221871|Drug|Different dosages of Ketamine|
1753659|NCT00221884|Procedure|Ultrasound|
1753660|NCT00221910|Procedure|Ultrasound|
1753661|NCT00221936|Behavioral|Self-administration or nurse administered medication|
1753662|NCT00221949|Device|Ultrasound|
1753663|NCT00221975|Drug|Divalproex|Once a therapeutic blood level of lithium was achieved, Divalproex was initiated at 250 mg twice daily and increased slowly over 5 weeks to a minimum blood level of 50 μg/mL.
1753664|NCT00221975|Drug|Lamotrigine|Lithium monotherapy was initiated at 450 mg once daily and titrated slowly over 3 weeks to a minimum blood level of 0.5 mEqlL.
1753665|NCT00221975|Drug|Lithium|Subjects who did not respond to the combination of Lithium and Divalproex were then randomly assigned in a 1:1 ratio to adjunctive lamotrigine versus placebo after stratification by illness type (bipolar I versus bipolar II), historical response to lithium (response versus oon-response), and the length of current exposure to the combination treatment with lithium and divalproex (<2 months versus ≥2 months).
1753666|NCT00221988|Drug|Levetiracetam (Keppra)|
1753670|NCT00222040|Radiation|Ultrasound|2-MHz, low intensity transcranial ultrasound
1753671|NCT00222040|Drug|Levovist|D-Galactose and palmitic palmitique intravenous 4 g
1753672|NCT00222053|Drug|Thalidomide|Per os thalidomide
1753673|NCT00222053|Drug|Biphosphonates|Biphosphonates
1753674|NCT00222066|Procedure|Fetal ovarian cyst aspiration|Fetal ovarian cyst aspiration performed under ultrasound guidance and maternal local anesthesia
1753675|NCT00222079|Drug|Esomeprazole (Nexium)|
1753676|NCT00222105|Drug|Doxil|Doxil 40 mg/m2 IV day 1
1753677|NCT00222105|Drug|Thalidomide|50-100 mg day 1-28
1753678|NCT00222105|Drug|Dexamethasone|Dexamethasone 40 mg day 1-4 and 15-18
1753679|NCT00222118|Behavioral|labor/birth preparation classes|prenatally, peer counselor/advanced practice nurse team, hospital visit, peer counselor telephone support for 4 weeks
1753680|NCT00222118|Other|intervention|prenatal classes and phone calls from peer counselor, peer counselor/lactatin consultant, hospital visit, telephone support to 4 weeks postpartum
1753681|NCT00222118|Other|usual care|no intervention
1753684|NCT00222144|Drug|Gleevec and Taxotere|Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
1753685|NCT00222170|Drug|Rabeprazole|
1753686|NCT00222183|Drug|Elidel (pimecrolimus)|
1753687|NCT00222196|Procedure|lifestyle, PTA|
1753688|NCT00222209|Behavioral|Experimental heat pain model|
1753689|NCT00222222|Procedure|vein puncture|comparison of different inflammatory markers in the blood of septic patients
1753690|NCT00222235|Drug|d-cycloserine|
1753691|NCT00222235|Drug|glycine|
1753692|NCT00222235|Drug|placebo|
1753693|NCT00222248|Behavioral|Pelvic floor muscle training and bladder training|
1753694|NCT00222261|Drug|aspirin|Aspirin 160 mg once daily for two years
1753695|NCT00222261|Drug|clopidogrel|clopidogrel 75 mg once daily for two years
1753696|NCT00222274|Behavioral|RSA Biofeedback|RSA Biofeedback Condition. The biofeedback will consist of 10 weekly sessions of training, at the same time of day for each subject. The details of the procedure for RSA biofeedback are described in Appendix A. One single practitioner, a certified biofeedback technician, will provide the biofeedback following the aforementioned protocol. In each session, 20 minutes of biofeedback will be delivered using a J&J C-2+ Physiograph. The participant will be taught to breathe at her resonant frequency, as a first step to training the individual how to produce maximal increases in amplitude of RSA.
1753697|NCT00222274|Behavioral|EEG Biofeedback Condition|EEG Biofeedback Condition. Participants assigned to this condition will receive 10 sessions of EEG alpha biofeedback. In each session, 20 minutes of biofeedback will be delivered using a J&J I-330-C2+ physiograph. The participant will learn how to modify specific brainwave activity known as alpha. In particular, participants will be taught to increase amplitude of alpha in the range of 8-12 Hz. Increased amplitude is this range is associated with relaxation and reduction of anxiety, but not baroreflex gain. Participants will also practice for two 20-minute periods daily using the same methods used to increase alpha found in lab sessions.
1753698|NCT00222287|Behavioral|Feldenkrais Movement class|
1753699|NCT00222300|Behavioral|Strength training program|
1753700|NCT00222326|Behavioral|Pelvic floor muscle training and lifestyle modification|
1753701|NCT00222339|Behavioral|task-specific training|
1753702|NCT00222365|Drug|Arnica montana, 5 CH|
1753703|NCT00222365|Drug|Bryonia alba, 5 CH|
1753704|NCT00222365|Drug|Hypericum perforatum, 5 CH|
1753705|NCT00222365|Drug|Ruta graveolens, 3 DH|
1753706|NCT00222417|Procedure|myringoplasty|Myringoplasty is an operative procedure to close tympanic membrane perforations.
1753707|NCT00222417|Procedure|Stapes surgery|Operative procedure aimed to replace non-functioning stapes with a synthetic prosthesis
1753708|NCT00222430|Procedure|Fluoroscopy|Use of fluoroscopy during arterial insertion of coronary catheter
1753709|NCT00222430|Procedure|Active Comparator|Standard coronary angiography technique; no fluoroscopic assistance
1753710|NCT00222443|Drug|Irinotecan|
1753711|NCT00222456|Behavioral|Sensitizing parents|
1753712|NCT00222469|Drug|bevacizumab|10mg/kg IV on Day 1 Q 2 weeks
1753713|NCT00222469|Drug|gemcitabine|1000mg/m2 as fixed-rate infusion at 10mg/m2/min on Day 1 and Q 2 weeks.
1753714|NCT00222469|Drug|oxaliplatin|100mg/m2 on Day 2 and Q 2 weeks.
1753715|NCT00222482|Drug|Depakote ER|
1753716|NCT00222495|Drug|quetiapine|
1753717|NCT00222495|Drug|olanzapine|
1753718|NCT00222495|Drug|risperidone|
1753719|NCT00222521|Drug|Glargine insulin|
1753720|NCT00222534|Drug|Acetazolamide|
1753721|NCT00222534|Drug|Placebo|
1753722|NCT00222547|Drug|Vitamin A|
1753723|NCT00222547|Drug|Albendazole|
1753724|NCT00222560|Behavioral|Intensive physical activity counselling by an integrated physical activity counsellor|
1753725|NCT00222573|Drug|clopidogrel and metoprolol|
1753726|NCT00222612|Other|Reduced intensification|Deletion of one 7 week treatment block containing dexamethasone, vincristine, doxorubicin, Peg-asparaginase, intrathecal methotrexate, cyclophosphamide, cytarabine.
1753727|NCT00222612|Drug|Standard childhood UK ALL protocol|No additional treatment to standard protocol.
1753728|NCT00222612|Drug|Intensified treatment including Capizzi maintenance|Augmented consolidation: vincristine, Peg-asparaginase. Capizzi maintenance: iv methotrexate and peg-asparaginase
1753729|NCT00222625|Drug|rFVIIa + (vit K in AO patients)|
1753730|NCT00222625|Drug|FFP or aPCC+ vit K in AO treated patients|
1753731|NCT00222638|Drug|Influenza vaccination|
1753732|NCT00222651|Drug|tenecteplase|
1753733|NCT00222664|Biological|Hep-V Vax|
1753734|NCT00222677|Drug|aspirin|100 mg daily
1753735|NCT00222703|Behavioral|Smoking relapse prevention|
1753736|NCT00222716|Behavioral|Problem solving counseling|Telephone nurse counseling behavioral intervention focused on problem solving.
1753737|NCT00222729|Drug|Pemetrexed|500 mg/m2 day 1 q 21 days
1753738|NCT00222729|Drug|Bevacizumab|15 mg/kg IV q 21 days following pemetrexed
1753739|NCT00222742|Procedure|induced moderate hypothermia|Subjects assigned to the treatment arm will be cooled to 32-33 °C for 48 hours and then slowly warmed.
1753740|NCT00222755|Behavioral|Disease Management|Self-management, care management, guidelines
1753741|NCT00222794|Drug|Atomoxetine (Strattera)|
1753742|NCT00222820|Drug|escitalopram|
1753743|NCT00222820|Behavioral|Interpersonal Psychotherapy|
1753744|NCT00222833|Drug|Aripiprazole|
1753745|NCT00222846|Behavioral|Attention control|Participants attend 3 educational seminars, receive a lay diabetes journal, pedometer, and glucose monitoring supplies.
1753746|NCT00222846|Behavioral|Intervention|Behavioral intervention of diabetes self-management paired with PDA-based monitoring of dietary intake and physical activity. Participants also receive a pedometer and glucose self-monitoring supplies.
1753747|NCT00222872|Drug|Parathyroid Hormone-related Protein|PTHrP(1-36) starting at 500 micrograms, then increasing by 125 micrograms up to a maximum of 1,500 micrograms.
1753748|NCT00222872|Drug|Placebo|Placebo drug via subcutaneous injection in single blinded fashion daily for 3 weeks
1753749|NCT00222898|Procedure|DNA analysis of pancreatic cyst fluid / buccal swab|
1753750|NCT00222911|Device|dorsiflexion night splint|
1753751|NCT00222911|Device|medial arch support|
1753752|NCT00222924|Behavioral|weight loss/ exercise|
1753753|NCT00222937|Behavioral|Lessac-Madsen Resonant Voice Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
1753754|NCT00222937|Behavioral|Casper-Based Confidential Flow Therapy|Patients receive 8 sessions of therapy over a course of 4 weeks, with one double session per week.
1753755|NCT00222976|Drug|Naproxen|Treatment allocation either A Naproxen PO + placebo PR or B Placebo PO + Naproxen PR
1753756|NCT00222989|Drug|PPI|
1753757|NCT00223002|Drug|Chlorhexidine|sample collected at time of procedure and then analysed for bacterial contamination
1753758|NCT00223015|Drug|Fluvastatin, Tacrolimus, Mycophenolat Mofetil|
1753759|NCT00223028|Drug|sirolimus, mycophenolat mofetil, fluvastatin|
1753760|NCT00223041|Drug|Fluvastatin|Arm A receives fluvastatin Arm b receives no fluvastatin
1753761|NCT00223054|Drug|tacrolimus|retrospective analyze of drug levels in comparison to polymorphism
1753762|NCT00223054|Drug|sirolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
1753763|NCT00223054|Drug|everolimus|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
1753764|NCT00223054|Drug|cyclosporin A|retrospective of drug blood trough levels in comparison to polymorphism of enzymes of drug metabolism
1753765|NCT00223067|Drug|TAIZ|
1991219|NCT01357395|Drug|Amuvatinib|Amuvatinib 300 mg PO TID
1753768|NCT00223093|Drug|TAIZ|
1753769|NCT00223106|Device|Vaginal Sling|
1753770|NCT00223119|Device|Absorbable Sutures|
1753771|NCT00223132|Device|Absorbable sutures|
1753772|NCT00223145|Radiation|Radiotherapy 70 Gy|Radiotherapy to the prostate
1753773|NCT00223145|Radiation|Radiotherapy 76 Gy|Radiotherapy to the prostate
1753774|NCT00223145|Drug|Androgen blockade|Duration : 6 months
1753775|NCT00223158|Drug|Liothyronine|
1753776|NCT00223171|Drug|Androgen blockade + radiation therapy|Androgen blockade + radiation therapy
1753777|NCT00223197|Drug|Pregnenolone|
1753778|NCT00223210|Drug|Quetiapine|Active Quetiapine
1753779|NCT00223210|Drug|PLacebo|Placebo
1753780|NCT00223223|Drug|Levetiracetam, Keppra|
1753781|NCT00223236|Drug|Citicoline|Citicoline or placebo will be given beginning at one table (500mg)/day with an increase to two tablets (1000mg)/day at week 2, three tablets (1500mg)/day at week 4 and four tablets (2000mg)/day at week 6. Patients will remain on 2000mg/day through week 12. Doses will be decreased if needed due to side effects.
1753782|NCT00223236|Drug|Placebo|Placebo matching active medication in all other aspects.
1753783|NCT00223249|Drug|Quetiapine|
1753784|NCT00223262|Drug|Lamotrigine (Drug)|
1753785|NCT00223275|Drug|Naltrexone|
1753786|NCT00223288|Drug|Lexapro|
1753787|NCT00223301|Drug|Mycophenolate Mofetil (cellcept)|
1753788|NCT00223314|Behavioral|HIV, STD, Pregnancy Prevention Curriculum|The curriculum is designed to change students' knowledge, perceptions of norms, beliefs, self-efficacy, interpersonal skills (i.e., refusal skills), and high-risk behaviors related to HIV. The curriculum included use of facilitators for selected lessons such as role playing. Intervention strategies included demonstrations of skills by role playing, use of role model stories, and other experiential learning techniques. The curriculum was delivered during the school days by facilitators (project staff) who received intensive training prior to implementation and coaching and support during implementation.
1753789|NCT00223340|Behavioral|Patient Activation and Diabetes Registry|
1753790|NCT00223353|Other|Prosthetics, Orthotics and Physical Therapy|Gait Analysis.
1753791|NCT00223379|Procedure|Endodontic procedure with varied apical preparation size|Comparison of two commonly used techniques for performing root canal treatment: 1) Lightspeed method 2)Buchannan method
1753792|NCT00223405|Device|crown placement|
1753793|NCT00223418|Drug|aripiprazole|
1753794|NCT00223431|Device|all-ceramic fixed partial denture|
1753795|NCT00223457|Behavioral|Factors that influence compliance|
1753796|NCT00223483|Genetic|Isolation of genomic DNA|One time blood draw
1753797|NCT00223496|Drug|Aripiprazole|Aripiprazole5mg - 30mg, every day (QD), for 12 weeks.
1753798|NCT00223509|Drug|Lamotrigine|
1753799|NCT00223522|Device|MEMS caps|
1753800|NCT00223535|Behavioral|Cognitive Remediation|
1753801|NCT00223535|Behavioral|Social Skills Training|
1753802|NCT00223548|Drug|sodium 2-mercaptoethane sulfonate|
1753803|NCT00223561|Drug|methylphenidate|
1753804|NCT00223574|Drug|Control - high carbohydrate, high glycemic index foods|
1753806|NCT00223574|Drug|low carbohydrate, high monounsaturate fat foods|
1753807|NCT00223587|Other|1 week of treatment discontinuation|1 week of treatment discontinuation during allergic rhinitis season
1753808|NCT00223600|Behavioral|Nutritional and life style counseling|
1753809|NCT00223613|Drug|daily intranasal administration of insulin|
1753810|NCT00223626|Drug|Topiramate|the maximum topiramate test dose is 200 mg/d.
1753811|NCT00223639|Drug|Topiramate|200mg twice a day
1753812|NCT00223652|Behavioral|Telephone cognitive behavioral therapy|An initial treatment phase consisting of 12 weekly sessions aimed at reducing symptoms of depression, and a booster phase in which 4 sessions are provided at increasingly greater intervals to target maintenance of treatment gains.
1753813|NCT00223665|Drug|Flutamide|250 mg tid
1753814|NCT00223665|Drug|Leuprolide Acetate|7.5 mg q month
1753815|NCT00223678|Drug|Rapamycin|Rapamycin will start within 24 hours of last calcineurin inhibitors (Cya, Prograf). Initial dose of Rapamune 10mg will be given for 3 days and then dose will be adjusted to attain a target whole blood trough of 5-15
1753816|NCT00223691|Drug|Atomoxetine|10-50 mg, PO. Single dose. Alone or in combination with Yohimbine or Mestinon.
1753817|NCT00223691|Drug|Acarbose|25-100 mg, PO. Single dose.
1753818|NCT00223691|Drug|Pyridostigmine Bromide|30 mg-180 mg PO. Single dose. Alone or in combination with Yohimbine or atomoxetine.
1753819|NCT00223691|Drug|Yohimbine|2.7, 5.4 or 10.8 mg PO. Single dose. Alone or in combination with Atomoxetine or Pyridostigmine.
1753820|NCT00223691|Drug|Midodrine HCl|2.5, 5.0, 7.5, 10 mg PO. Single dose
1753821|NCT00223691|Drug|placebo|PO.Single dose.
1753822|NCT00223691|Drug|Modafinil|50-400 mg PO. Single dose
1753823|NCT00223691|Drug|Octreotide|5-50 µg, S.C. Single dose.
1753824|NCT00223691|Other|water intake|Tap water 2 onz., 8 oz., 16 oz. PO, alone or in combination with any of the above medications. Single dose.
1753825|NCT00223691|Drug|Diphenhydramine Hydrochloride|12.5 mg-100 mg PO. Single dose. Alone or in combination with Ranitidine
1753826|NCT00223691|Drug|Ranitidine HCL|150-300 mg PO. Single dose. Alone or in combination with Diphenhydramine.
1753827|NCT00223691|Drug|Tranylcypromine|5 - 40 mg PO. Single dose
1753828|NCT00223691|Drug|Ergotamine/ Caffeine|Ergotamine: 1.0 mg PO. Single dose. Caffeine 100 mg PO.Single dose
1753829|NCT00223691|Drug|Celecoxib|50-200 mg PO. Single dose
1753830|NCT00223691|Drug|Pseudoephedrine|15, 30 or 60 mg, PO. Single dose.
1753831|NCT00223691|Drug|Methylphenidate|5 or 10 mg PO. Single dose.
1753832|NCT00223691|Drug|Indomethacin|25, 50 or 75 mg, PO. Singe dose.
1753833|NCT00223691|Drug|Ibuprofen|300, 600 or 900 mg, PO. Single dose.
1753834|NCT00223691|Drug|Oxymetazoline 0.05% nasal solution|1-2 sprays/ nostril. Single dose.
1753835|NCT00223691|Dietary Supplement|Bovril|6-10 g, PO. Single dose.
1753836|NCT00223691|Drug|Acetazolamide|125-1000 mg PO. Single dose. Alone or in combination with yohimbine or midodrine
1753837|NCT00223691|Drug|Rivastigmine tartrate|1.5-6 mg PO. Single dose.
1753838|NCT00223691|Drug|Carbidopa/levodopa|10mg/100mg or 25mg/100mg. 1-2 tab PO. Single dose. Alone or in combination with carbidopa (Lodosyn) 25-175 mg
1753839|NCT00223691|Device|Inflatable abdominal binder|External abdominal compression (20-40 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
1753840|NCT00223691|Device|inflatable abdominal binder (sham)|External abdominal compression (5 mm Hg) with an inflatable abdominal binder applied after a pressor agent (e.g. midodrine, yohimbine).
1753841|NCT00223704|Drug|HOE 140|HOE 140 (a bradykinin B2 receptor antagonist) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. HOE 140 was given as an intravenous bolus of 22 µg/kg over one-half hour followed by an infusion of 18 µg/kg/hr.
1753842|NCT00223704|Drug|Aminocaproic Acid|Aminocaproic acid (an antifibrinolytic drug) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery. Aminocaproic acid was given as an intravenous bolus of 100 mg/kg over one-half hour followed by an infusion of 30 mg/kg/hr.
1753843|NCT00223704|Drug|Placebo|Normal saline (placebo) was started in the operating room after induction of anesthesia and before heparinization, continued throughout the bypass period, and discontinued at the end of surgery.
1956663|NCT02756819|Drug|Azilsartan Medoxomil|Azilsartan medoxomil tablets
1754100|NCT00226096|Drug|Hydralazine Hydrochloride|
1753868|NCT00223730|Drug|Citrulline|Oral provision of amino acid citrulline to support impaired urea cycle function during escalated dose chemotherapy for stem cell transplant
1753869|NCT00223730|Drug|Placebo|
1753871|NCT00223756|Other|Low Vision Intervention - Outpatient Training Program|Patients receive LV therapy as outpatients
1753872|NCT00223769|Drug|Oxandrolone|
1753873|NCT00223782|Behavioral|Gait Training with Feedback|
1753874|NCT00223782|Behavioral|Gait Training with no feedback|
1753876|NCT00223808|Other|Robot-Low|1 hour/day of robot-assisted upper limb exercise therapy in addition to usual physical and occupational therapy
1753877|NCT00223808|Other|Robot-High|2 hours/day of robot-assisted therapy in addition to usual physical and occupational therapy
1753878|NCT00223808|Other|Control|1 hour/day of additional upper limb therapy that includes exposure to, but no manipulation by the robot
1753879|NCT00223821|Drug|Oxybutynin chloride, extended-release, individually-titrated|Individually-titrated, extended-release oxybutynin chloride with management of side-effects.
1753880|NCT00223821|Behavioral|Behavior Training|Behavioral training consists of teaching urge suppression strategies and pelvic floor muscle training.
1753881|NCT00223834|Behavioral|single session of Motivational Interviewing|
1753882|NCT00223847|Behavioral|Constraint Induced Language Therapy|
1753883|NCT00223860|Drug|Human chorionic gonadotropin (hCG)|
1753884|NCT00223860|Drug|Luteinizing hormone releasing hormone (LHRH)|
1753885|NCT00223873|Procedure|Penile Vibratory Stimulation|
1753886|NCT00223899|Genetic|VCL-IM01 (encoding IL-2) with Electroporation|IL-2-encoding plasmid formulated in phosphate-buffered saline at 0.5 mg/mL, 1.5 mg/mL, and 5.0 mg/mL (VCL-IM01) intratumorally injected and followed by electroporation with Inovio MedPulser® 1.0 cm array with needles up to 3 cm long (one 6-pulse cycle per tumor).
1753887|NCT00223912|Device|ERGYS BikeFunctional Electrical Stimulation Ergometry|A
1753888|NCT00223925|Drug|Maribavir|
1753889|NCT00223925|Drug|Placebo|
1753890|NCT00223938|Drug|Oral Iron|Oral Iron
1753891|NCT00223938|Drug|sodium ferric gluconate|weekly intravenous injection Dose 1
1753892|NCT00223938|Drug|sodium ferric gluconate|weekly intravenous injection Dose 2
1753893|NCT00223951|Drug|R89674 (generic name not yet established)|
1753894|NCT00223964|Drug|Ferrlecit (sodium ferric gluconate complex in sucrose injection)|
1753895|NCT00223977|Drug|Sodium Ferric Gluconate Complex|125 mg weekly x 8 weeks
1753896|NCT00223977|Drug|Sodium Ferric Gluconate Complex|250 mg weekly x 4
1753897|NCT00223977|Drug|Oral Iron|325 mg ferrous sulfate orally three times daily x 8 weeks
1753898|NCT00223990|Biological|FMP1/AS02A|
1753899|NCT00224003|Drug|Sodium Ferric Gluconate Complex in Sucrose.|
1753900|NCT00224016|Drug|Oxybutynin|1.3, 2.6, 3.9 mg/day transdermal
1753901|NCT00224016|Drug|Oxybutynin|5 to 15 mg/day immediate release or extended release tablets, or syrup
1753902|NCT00224029|Drug|Oxybutynin transdermal system|3.9 mg/day, 7.8 mg/day, 9.1 mg/day or 11.7 mg/day transdermal per titration
1753903|NCT00224042|Drug|Sodium Ferric Gluconate complex in sucrose|Sodium ferric gluconate complex in sucrose, 250 mg IV weekly for 4 doses
1753904|NCT00224042|Drug|Ferrous sulfate tablets|ferrous sulfate 325 mg three times daily for 6 weeks
1753905|NCT00224055|Drug|Sodium Ferric Gluconate Complex in Sucrose Injection|Sodium Ferric Gluconate Complex in Sucrose Injection (Ferrlecit®), 250 mg IV weekly for 4 weeks
1753906|NCT00224055|Drug|Ferrous sulfate tablets|ferrous sulfate, 325 mg oral, three times daily for 6 weeks
1753907|NCT00224068|Drug|Sodium ferric gluconate, ferrous sulfate, standard of care|
1753908|NCT00224081|Drug|Sodium ferric gluconate,|Sodium ferric gluconate, 125 mg IV given at 8 consecutive hemodialysis sessions
1753909|NCT00224094|Drug|Premarin® (oral) vs. Alora® (transdermal)|
1753910|NCT00224107|Drug|Silodosin|8 mg daily for 12 weeks
1753911|NCT00224107|Other|Placebo|1 capsule daily for 12 weeks
1753912|NCT00224120|Drug|Silodosin|8 mg daily for 12 weeks
1753913|NCT00224120|Other|Placebo|One capsule daily for 12 weeks
1753914|NCT00224133|Drug|Silodosin|8 mg daily
1753915|NCT00224146|Drug|oxybutynin transdermal delivery system (Oxytrol(r))|
1753916|NCT00224159|Behavioral|Drug and Dietary behavior|
1753917|NCT00224185|Procedure|Bronchopulmonary Lung Lavage|Lung Lavage is a Washing. Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways. Once the fluid has been collected, the fluid is centrifuged and the cells are collected and counted.
1753918|NCT00224185|Procedure|Bronchial Brushing|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. During the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently (in up to 20 different sites in the large and small airways) to obtain epithelial cells lining the airway. Cells collected by airway brushing will be washed, counted, and evaluated for viability. They will also be studied for differential cell count by standard procedures. Collected airway cells will be used to carry out studies assess expression of various genes and to study viral gene transfer.
1753919|NCT00224185|Procedure|Bronchial Wall Biopsy|This is a safe and widely used investigative method in pulmonary medicine. In this procedure, a small biopsy forceps is passed through the bronchoscope and, under direct vision, a small biopsy (in up to 5 sites) is obtained from the bronchial wall. A biopsy obtains tissue to a depth of 2-3 mm, and includes epithelial and subepithelial tissue.
1754101|NCT00226096|Drug|Glycerol Trinitrate|
1956668|NCT02749630|Drug|Placebo (IV escalating doses)|Matching placebo to UTTR1147A administered intravenously
1753920|NCT00224198|Procedure|Lung Disease|Bronchoscopy consists of the passage via the mouth or nose of a flexible fiberoptic bronchoscopy into the airways. In the lavage (washing) procedure, sterile 0.9% saline (5 x 20 ml aliquots in 1 to 3 sites) is instilled into the lung and immediately suctioned back, washing off cells lining the airways.In the brushing procedure, a small cytology brush is passed through the bronchoscope, and a small area of the airway wall is brushed gently to obtain epithelial cells lining the airway. Certain individuals may have bronchial wall biopsy carried out. In this procedure, a small biopsy forceps is passed through the bronchoscope and a small biopsy is obtained from the bronchial wall.
1753921|NCT00224211|Behavioral|Music|
1753922|NCT00224250|Procedure|One- versus two-layer hysterotomy closure|
1753923|NCT00224263|Drug|Lingzhi (Ganoderma)|
1753924|NCT00224289|Drug|Latanoprost 0.005%|Latanoprost 0.005% ophthalmic solution QHS 8 weeks
1753925|NCT00224302|Drug|Duloxetine|
1753926|NCT00224315|Drug|ziprasidone|
1753927|NCT00224315|Drug|risperidone|
1753928|NCT00224328|Device|ODISsey Tissue Oximeter|
1753929|NCT00224341|Device|Pacemaker Vitatron Selection 9000|
1753930|NCT00224341|Device|Pacemaker Vitatron T70|
1753931|NCT00224354|Biological|IL-2 secreting and hCL4OL-expressing autologous B-CLL cells|Patients will be treated with six subcutaneous injections of their IL-2-secreting and hCD40L-expressing autologous B-CLL cells, separated by one to two weeks in an immunological treatment window
1753932|NCT00224354|Biological|IL-2|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
1753933|NCT00224354|Biological|CD40L|subcutaneous (SC) injections of autologous leukemic cells modified ex vivo to secrete human interleukin-2 (hIL-2) and to express human CD40 ligand (hCD40L).
1753934|NCT00224354|Drug|ONTAK|an interleukin-2 immunotoxin directed to the CD25 antigen (denileukin diftitox, ONTAK
1753935|NCT00224354|Biological|immunotoxin dose|Days 0, 2, and 4 (18 ug/kg) i.v
1753936|NCT00224367|Behavioral|time to first ambulation|
1753937|NCT00224380|Behavioral|Using Medications Effectively|
1753938|NCT00224393|Drug|Enbrel|
1753939|NCT00224406|Drug|repertaxin|
1753940|NCT00224419|Behavioral|Motivational interviewing for smoking cessation|All participants received a tailored CBT (TCBT) intervention that included: a written self-help guide, info about the importance of reducing nicotine exposure to the fetus, 5 face to face and 1 telephone counseling session. Women in the TCBT + NRT arm were guided through a process of deciding on nicotine gum, lozenge or patch. To minimize fetal exposure, the dose of NRT was customized to the woman's current level of smoking. Women who smoked 5-10 cigarettes a day were given the 14 mg patch or instructed to use one 2 mg lozenge or 2 mg piece of gum to replace each cigarette she usually smoked per day. Those who smoked 11 cigarettes or more per day were given the 21 mg patch or instructed to use no more than one lozenge (2 mg) or piece of gum (2 mg) to replace each cigarette she usually smoked per day, not to exceed 15 lozenges or pieces of gum per day.
1753941|NCT00224419|Behavioral|Cognitive behaviors therapy|6 counseling sessions delivered over the phone or in person
1753942|NCT00224419|Drug|CBT + NRT|Includes CBT from arm 1 plus choice of NRT (lozenge, gum, or patch) tailored to smoking amount
1753943|NCT00224432|Drug|probiotics: Lactobacillus GG, lactobacillus Rhamnosus|
1753944|NCT00224445|Drug|Truvada|Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg tablet) administered orally once daily (QD)
1753945|NCT00224445|Drug|Atazanavir|Atazanavir 300 mg (given as two 150-mg capsules) administered orally QD
1753946|NCT00224445|Drug|Ritonavir|Ritonavir 100 mg capsule administered orally QD
1753947|NCT00224458|Drug|Truvada|
1753948|NCT00224458|Drug|efavirenz|
1753949|NCT00224471|Biological|GSK208141 vaccine|3 IM doses
1753950|NCT00224484|Biological|GSK208141|3 IM doses
1753951|NCT00224484|Biological|HavrixTM (investigational formulation)|3 IM doses
1753952|NCT00224484|Biological|Placebo|3 IM doses
1753953|NCT00224497|Drug|SB-742457|
1753954|NCT00224510|Drug|lamotrigine|
1753955|NCT00218972|Behavioral|Aerobic interval training|
1753956|NCT00218972|Behavioral|moderate intensity training|
1753957|NCT00218972|Behavioral|Recommendation of regular exercise|
1753958|NCT00218985|Behavioral|Exercise training|Intensity controlled exercise training before the scheduled bypass surgery
1753959|NCT00218998|Behavioral|exercise training|
1753960|NCT00219011|Drug|aliskiren|
1753961|NCT00219024|Drug|aliskiren|
1753962|NCT00219037|Drug|aliskiren|
1753963|NCT00219050|Drug|aliskiren|
1753964|NCT00219063|Drug|aliskiren|
1753965|NCT00219076|Drug|aliskiren|
1753966|NCT00219089|Drug|aliskiren|
1753967|NCT00219102|Drug|aliskiren|
1753968|NCT00219115|Drug|aliskiren|
1753969|NCT00219128|Drug|aliskiren|
1753970|NCT00224523|Drug|GW685698X|
1753971|NCT00224523|Drug|mometasone furoate|
1753972|NCT00224536|Procedure|Intracoronary bone marrow cell transfer|
1753973|NCT00224549|Drug|irbesartan, amlodipine and hydrochlorothiazide|irbesartan, amlodipine and hydrochlorothiazide
1956669|NCT02749630|Drug|UTTR1147A|Escalating doses of intravenously administered UTTR1147A
1753975|NCT00224575|Other|diagnosis reassessment|Strategy of diagnosis reassessment following a decision tree.
1753976|NCT00224575|Other|Diagnosis strategy and subsequent therapeutic reassessment|Performed by geriatricians, following a decision tree, based on medical history, electrocardiogram, cardiac echotomography and stress scintigraphy
1753977|NCT00224588|Drug|Ketamine (or placebo : isotonic saline solution)|
1753978|NCT00224601|Procedure|Colonoscopy with chromoscopy|
1753979|NCT00224614|Procedure|Allogenic transplantation|
1753980|NCT00224627|Procedure|Capsule GIVEN IMAGING LTD|
1753981|NCT00224640|Drug|Iron chelating intervention|Iron chelating intervention
1753982|NCT00224653|Procedure|Mechanical Ventilation|
1753983|NCT00224666|Device|Cortex stimulation|
1753984|NCT00224679|Drug|Aspirin|
1753985|NCT00224692|Drug|Low dose ketamine|
1753986|NCT00224705|Device|Molecular Adsorbent Recirculating System (MARS®)|
1753987|NCT00224718|Procedure|Endovascular repair (with endograft)|An endovascular stent graft is a tube composed of fabric supported by a metal mesh called a stent. It can be used for a variety of conditions involving the blood vessels, but most commonly to reinforce a weak spot in an artery called an aneurysm. Over time, blood pressure and other factors can cause this weak area to bulge like a balloon and eventually enlarge and rupture. The stent graft seals tightly with your artery above and below the aneurysm. The graft is stronger than the weakened artery and allows blood to pass through it without pushing on the bulge. Physicians typically use endovascular stent grafting to treat abdominal aortic aneurysms (AAAs).
1753988|NCT00224718|Procedure|Open repair|Conventional repair consist in open repair. Different types of surgery can be done : minimal incision aortic surgery (MIAS), transperitoneal approach (TPA), retroperitoneal repair, or conventional median laparotomy.
1753989|NCT00224744|Device|ultracision|Surgery by Ultracision
1753990|NCT00224744|Device|classical lymphadenectomy|classical lymphadenectomy
1753991|NCT00224757|Procedure|Transoesophageal echocardiography|TEE
1753992|NCT00224770|Drug|MIS+Cathflo Activase (drug)|MIS+Cathflo Activase (drug): The intervention is a comparison of the safety and preliminary effectiveness of investigational minimally invasive surgery to place a catheter into an intracerebral hemorrhage blood clot and subsequent administration in sequential tiers of 0.3 or 1.0mg of rt-PA, CathFlo® through the catheter once every eight hours for up to 72 hours, in addition to best medical care.
1753993|NCT00224770|Procedure|Intraoperative stereotactic CT-Guided Endoscopic Surgery|Mechanical intracerebral hemorrhage removal via an endoscope utilizing the same operative targeting arm as MISTIE arm. No rt-PA administered, and in addition to best medical care.
1753994|NCT00224783|Biological|CAIV-T|Trivalent cold adapted temperature sensitive attenuated Types A and Type B influenza virus live vaccine (CAIV-T)
1753995|NCT00224783|Biological|Placebo|0.2 mL of 0.01 mol/L potassium phosphate buffer containing 0.85% sodium chloride (pH 7.2).
1753996|NCT00224796|Device|V.A.C. ® System|
1753997|NCT00224809|Drug|Angiotensin-Converting Enzyme Inhibitors|
1753998|NCT00224809|Procedure|Coronary Artery Bypass Graft|
1753999|NCT00224809|Drug|Angiotensin Receptor Blockers|
1754000|NCT00224809|Drug|Spironolactone|
1754001|NCT00224809|Drug|Aspirin|
1754002|NCT00224809|Drug|Clopidogrel|
1754003|NCT00224809|Procedure|Surgical Ventricular Restoration|
1754004|NCT00224822|Drug|Aripiprazole|
1754005|NCT00224835|Behavioral|Mindfulness Based Stress Reduction Class|Subjects randomized to this condition will attend 120 minute weekly sessions, plus a 7 hour retreat, for training in mindfulness meditation methods.
1754006|NCT00224835|Behavioral|Cardiac Education Class|"Subjects in the disease education control condition will attend 8 weekly 60 minute sessions, plus a 7 hour special experience session, all of which will provide information about CAD in a didactic format."
1754007|NCT00224848|Behavioral|Palm-Pilot Intervention|"Both groups received guideline dissemination, patient activation materials, continuing education (CE) and feedback based on baseline chart audit. The intervention included academic detailing (AD) and a hand-held computerized decision support tool that provided patient-specific, ATPIII-based risk stratification and treatment recommendations. CE sessions offered information relevant to ATPIII and JNC7 and focused on the evidence base. AD offerings focused on strategies to apply concepts to practice and were specific to the randomized arm. Investigators visited each practice at baseline to educate physicians about the guideline and evidence supporting prevention of CVD, and to provide training on use of the Palm tool. Visits were conducted as lunch and learn sessions. The tool was a modified version of NHLBI's PDA decision support program and indicates specific drug therapies and dosages needed to achieve cholesterol reduction and prints documentation. A user's manual was developed."
1754008|NCT00225212|Drug|Rituximab 375 mg/m2|
1754009|NCT00225225|Drug|Rosiglitazone|
1754010|NCT00225225|Behavioral|dietary recommendation for weight maintenance|
1754011|NCT00225238|Drug|esomeprazole (PPI)|
1754012|NCT00225251|Drug|bupropion XL|Antidepressant medication
1754013|NCT00225251|Other|Placebo|Placebo
1754014|NCT00225264|Drug|Pioglitazone|Pioglitazone 15 mg titrated up to 45 mg, tablets, orally, once daily and glimepiride placebo-matching capsules, orally, once daily for up to 72 weeks.
1754015|NCT00225264|Drug|Glimepiride|Pioglitazone placebo-matching tablets, orally, once daily and glimepiride 1 mg titrated up to 4 mg, capsules, orally, once daily for up to 72 weeks.
1754016|NCT00225277|Drug|Pioglitazone|Up to 45 mg pioglitazone (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
1754017|NCT00225277|Drug|Glimepiride|Up to 4 mg of glimepiride (optimized for glucose control), tablets, orally, once daily for up to 72 weeks.
1754018|NCT00225290|Drug|Thalidomide(Thado)|
1754019|NCT00225303|Drug|TMC125|
1754020|NCT00225316|Procedure|Acupuncture|See Detailed Description.
1754021|NCT00225329|Procedure|Labour assessment and support|
1754022|NCT00225342|Drug|Rosiglitazone|
1754023|NCT00225342|Drug|Gliclazide (Comparison drug)|
1754024|NCT00225355|Drug|Rosiglitazone|
1754025|NCT00225368|Device|Insecticide treated bednets|
1754026|NCT00225381|Device|connection of measuring device to anesthesia circuit|same as name
1754027|NCT00225381|Procedure|drawing of blood sample through an arterial line, placed according to clinical criteria by primary anesthesia team|same
1754028|NCT00225381|Procedure|changing operating room bed position (head down and up position)|same
1754029|NCT00225381|Procedure|adding PEEP during anesthesia|same
1754030|NCT00225381|Procedure|placement of esophageal Doppler for cardiac output measurements|same
1754031|NCT00225381|Device|Humidity sensor|Small conventional anesthesia T piece including tiny 2 thermometer inside
1754032|NCT00225381|Device|A mixing chamber (bymixer)|2 mixing chambers (bymixers) composed of 2 arms where one arm serves as a mixing (passive) arm for the measurement of mixed gas fraction. The bymixer is made of conventional anesthesia supplies and does not influence dead space nor circuit resistance.
1754033|NCT00225381|Device|Pneumotachometer cuvette|The pneumotachometer cuvette is used by many anesthesia monitors to measure gas flow.
1754102|NCT00226096|Drug|Phentolamine mesylate|
1754103|NCT00226096|Drug|Nicardipine|
1754104|NCT00226096|Drug|Urapidil|
1754034|NCT00225381|Device|Mass spectrometer sampling port|Designed for the anesthesia tubing and connected at the airway opening. it has small volume (3 mL) and do not influence circuit resistance.
1754035|NCT00225407|Drug|Smoking of cannabis cigarettes (different strength)|
1754036|NCT00225420|Drug|docetaxel|Docetaxel will be administered per the designated cohort starting at 10 mg/m2 intravenously over 1 hour weekly for eight weeks, for a total of eight treatments.
1754037|NCT00225420|Drug|leuprolide acetate|Leuprolide acetate will be administered at 22.5 mg IM and will be initiated 2 to 3 months prior to radiotherapy and chemotherapy with docetaxel.
1754038|NCT00225420|Radiation|radiation therapy|The total dose will be 7800 cGy in 200 centigray (cGy) per fraction for a total of 39 treatments.
1754039|NCT00225433|Drug|follitropin beta|Follitropin beta
1754040|NCT00225433|Drug|ganirelix acetate|Ganirelix acetate
1754041|NCT00225446|Device|MicronTracker|MicronTracker is a Third Generation Optic Repositioning System in orthognatic surgery.
1754042|NCT00225472|Device|Modified Viaspan|
1754043|NCT00225485|Drug|Effexor XR|
1754044|NCT00225498|Drug|ziprasidone vs risperidone or olanzapine|ziprasidone target dose is 160 mg/day risperidone target dose is 4 mg/day olanzapine target dose is 20 mg/day
1754045|NCT00225511|Drug|Effexor XR|
1754046|NCT00225511|Drug|Milnacipran|
1754047|NCT00225524|Drug|Effexor XR|
1754048|NCT00225537|Drug|4-Methylumbelliferone (Heparvit®)|
1754049|NCT00225550|Drug|ADH -1 (Exherin™)|
1754051|NCT00225576|Other|Electronic Health Record Implementation|Intervention subjects implemented electronic prescribing as part of an electronic health record implementation
1754052|NCT00225589|Drug|Rosuvastatin calcium|
1754053|NCT00225602|Behavioral|Assertive Community Treatment|
1754054|NCT00225602|Behavioral|Treatment in Community Mental Health Center|
1754055|NCT00225615|Drug|sapropterin dihydrochloride|
1754056|NCT00225628|Behavioral|Computerized Reminders Medications Monitoring|
1754057|NCT00225628|Behavioral|Computerized Test Results Management Application|
1754058|NCT00225628|Behavioral|Computerized Reminders Hypertension Management|
1754059|NCT00225628|Behavioral|Computerized Reminders Osteoporosis Screening and Mgt|
1754060|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 1: 6, 12, 18, 24 and 36 months after surgery
1754061|NCT00225641|Procedure|CT-scan, CEA, X-ray of lungs|Arm 2: 12 and 36 months after surgery
1754062|NCT00225654|Device|coronary stent|
1754063|NCT00225667|Drug|Irbesartan|
1754064|NCT00225680|Device|drug eluting coronary stent|
1754065|NCT00225693|Device|drug eluting coronary stent|
1754066|NCT00225706|Drug|Caldolor|
1754067|NCT00225719|Drug|rHDL|
1754068|NCT00225732|Other|Normal saline as placebo comparator|250 ml normal saline as a placebo comparator was administered every 6 hours for a total of eight doses over the first 48 hours. Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)
1754069|NCT00225732|Drug|Intravenous ibuprofen|"800 mg intravenous ibuprofen diluted in 250 milliliters of normal saline was administered every 6 hours for a total of eight doses over the first 48 hours.
Those patients who received the initial eight doses could continue to receive additional doses as needed through the end of the treatment period (day 5)"
1754070|NCT00225745|Procedure|Blood draw|One blood draw prior to first treatment
1754071|NCT00225758|Drug|Lapatinib|1500 mg po daily for 26 weeks or longer
1754072|NCT00225784|Drug|Cetuximab/Gemcitabine|Once weekly Cetuximab, twice weekly Gemcitabine for six weeks
1754073|NCT00225784|Procedure|Radiotherapy|Daily radiotherapy for 28 days
1754074|NCT00225797|Drug|Oxymorphone Extended Release|
1754075|NCT00225810|Drug|Crohn's Disease|
1754076|NCT00225823|Drug|GW685698X|
1754078|NCT00225849|Drug|Aspirin|
1754079|NCT00225862|Drug|ropinirole|
1754080|NCT00225875|Drug|Mabthéra|
1754081|NCT00225888|Behavioral|Digital Photography of meals/snacks and group discussion|Digital Photography of meals/snacks and group discussion
1754082|NCT00225901|Drug|Recombinant human hepatocyte growth factor|
1754083|NCT00225914|Drug|Paroxetine|Paroxetine CR 12.5 mg/day; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability
1754084|NCT00225914|Drug|placebo|Subjects enter into a six-week, double blind phase, randomized in a 1:1 ratio to paroxetine CR 12.5 mg/day or matching placebo pill; dosing may be adjusted up to 25 mg/day after two weeks, based on treatment response and tolerability.
1754085|NCT00225927|Procedure|radioguided seed localization for nonpalpable breast cancers|radio-labelled (I-125) titanium seed inserted via needle into nonpalpable breast lesion and gamma probe used to guide surgery
1754086|NCT00225966|Device|Device Medtronic InterStim Tined Leads Models 3889 and 3093|
1754087|NCT00225979|Drug|Octreotide LAR|
1754088|NCT00225992|Drug|Arsenic Trioxide|
1754089|NCT00226005|Drug|PTK787/ZK222584|One arm: administered orally, twice daily: after enrollment - first week 250 BID, second week 500 BID, then 750 BID thereafter.
1754090|NCT00226018|Device|Hand Adapter (Organon, Oss, the Netherlands)|Randomization of acceleromyography with or without Hand Adapter to dominant or non-dominant arm. Contralateral neuromuscular transmission is measured with mechanomyography (The gold standard of neuromuscular monitoring)
1754091|NCT00226018|Device|Placebo|placebo
1754092|NCT00226031|Procedure|Educational Material and Reminder|Family practices were randomly assigned to intervention or usual care. The intervention was a mailed reminder with a summary of osteoporosis screening and treatment guidelines sent to the GP and a letter and educational package for the women.
1754093|NCT00226044|Drug|Omeprazole suppository|
1754094|NCT00226057|Drug|Raptiva|
1754095|NCT00226070|Procedure|interview and advising|
1754096|NCT00226070|Behavioral|3 follow up interviews and personal advising|
1754097|NCT00226070|Procedure|interview SF-36 self rated health|
1754098|NCT00226096|Drug|Labetalol Hydrochloride|
1754099|NCT00226096|Drug|Metoprolol tartrate|
1754109|NCT00226109|Drug|spironolactone|100 mg once daily. Can be reduced to 50 mg a day still maintaining the doubled-blinded status
1754110|NCT00226122|Drug|Indomethacin|Indomethacin capsules 50 mg
1754111|NCT00226135|Drug|lithium or lamotrigine|
1754112|NCT00226148|Procedure|Use of a membrane to cover bonedefects around implant|
1754113|NCT00226148|Device|Use of bonechips to fill up defects around implant|
1754114|NCT00226148|Procedure|Use of membrane and bonechips to manage defects|
1754115|NCT00226161|Procedure|Inguinal herniorrhaphy|
1754116|NCT00226174|Drug|Curcuminoids|
1754117|NCT00226187|Procedure|Supplement of fatty acid (DHA and AA)|
1754118|NCT00226200|Drug|Omalizumab|
1754119|NCT00226213|Procedure|Peripherally Inserted Central Catheter Placement|
1754120|NCT00226226|Procedure|Peripherally Inserted Central Catheter Placement|
1754121|NCT00226239|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV over 1 hour, day 1
1754122|NCT00226239|Drug|Cisplatin|Cisplatin 75 mg/m^2 IV over 1-2 hours, day 1, 1 hour following completion of cetuximab infusion.
1754123|NCT00226239|Drug|Cetuximab|Cetuximab dose will be 250 mg/m^2 IV over 60 minutes weekly on ALL subsequent administrations (days 8 and 15 of cycle 1 and days 1,8,15 of cycles 2 and 3).
1754124|NCT00226239|Procedure|Radiation Therapy|Photon energies of 1.25 to 6 MV and/or appropriate electron energies for boosting the nodes are allowed. Photon energies>6 MV may be utilized when appropriate to boost target localized centrally.
1754125|NCT00226252|Procedure|Instruction Only|Video details an individual propelling a manual wheelchair with biomechanically correct propulsion technique.
1754126|NCT00226252|Procedure|Instruction and Feedback|Individuals will watch video of correct propulsion technique and will receive real-time feedback from the SMART Wheel as they push their wheelchair to help optimize their propulsion technique.
1754127|NCT00226278|Drug|ORG 34517|
1754128|NCT00226291|Other|Synthesized evidence report|Each consultation response included a documented bibliographic search strategy with corresponding references, a targeted list of full-text articles, and a written synthesis and critique of the relevant research materials.
1754129|NCT00226317|Drug|Aripiprazole|
1754130|NCT00226330|Drug|Tesaglitazar|(0.5 or 1 mg)
1754131|NCT00226330|Drug|Pioglitazone|(15, 30 or 45 mg)
1754132|NCT00226343|Drug|Depakote-ER|
1754133|NCT00226356|Drug|Supplements of L-methionine, betaine and folate|
1754134|NCT00226369|Drug|CY-1503|
1754135|NCT00226382|Drug|Pegylated Interferon-alfa-2a|Pegasys once weekly
1754136|NCT00226395|Drug|Oxymorphone immediate release|
1754137|NCT00226408|Drug|Interferon-alpha-2b|
1754138|NCT00226421|Drug|Oxymorphone Extended Release|
1754139|NCT00226434|Procedure|Early antiretroviral treatment|The ARV treatment is started 2 weeks after the diagnosis and the start of the anti-tuberculosis treatment
1754140|NCT00226434|Procedure|Late antiretroviral treatment|The ARV treatment is started 8 weeks after the diagnosis and the start of the anti-tuberculosis treatment
1754141|NCT00226447|Drug|Pegylated Interferon|
1754142|NCT00226447|Drug|Lamivudine|
1754143|NCT00226460|Drug|Fetal porcine cells, Neurocell-PD|
1754144|NCT00226473|Drug|Cisplatin, Vindesine, Dacarbazine (drugs)|
1754145|NCT00226486|Other|multifactorial intervention|Identification of medical, cardiovascular, physical risk factors for falls; e.g. vision, drug-use, depression, carotid sinus syndrome, orthostatic hypotension, etc. Individual intervention; treatment of disease, drug review, pacemaker, exercises, new glasses, all if indicated.
1754146|NCT00226486|Other|Usual care|No intervention, but ususal care after an accidental fall.
1754150|NCT00226512|Drug|Campath-1H /ATG|
1754151|NCT00226525|Procedure|skin sensitivity test|
1754152|NCT00226538|Drug|Phenytoin|
1754153|NCT00226538|Drug|Rifampicin|
1754154|NCT00226538|Drug|Diclophenac|
1754155|NCT00226538|Drug|Fluconazole|
1754156|NCT00226551|Drug|Isoproterenol|
1754157|NCT00226564|Drug|Alfentanil|
1754158|NCT00226577|Drug|Gemcitabine|Gemcitabine (GemzarR) 1500 mg/m2
1754159|NCT00226577|Drug|Pemetrexed|Pemetrexed (AlimtaR) 500 mg/m2
1754160|NCT00226577|Procedure|Surgery|When the chemotherapy treatment is completed, the patient's tumor response will be evaluated by a CT scan, pulmonary function test, and another PET scan between days 50 and 63 (during weeks 8 and 9). If there is no growth or spread of the cancer on any of these tests, patients will then proceed to have surgery by week 10 to remove the cancer.
1754161|NCT00226590|Drug|Gemcitabine|Induction Chemotherapy.
1754162|NCT00226590|Drug|Carboplatin|Induction Chemotherapy. Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
1754163|NCT00226590|Drug|Paclitaxel|Weekly Carboplatin and Paclitaxel During Thoracic Radiation Therapy.
1754164|NCT00226590|Procedure|Radiation|Radiation Therapy will begin on day 57 if there has been adequate hematologic recovery from Induction Chemotherapy.
1754165|NCT00226603|Behavioral|Specific training programme (behavior)|
1754166|NCT00226616|Drug|Zinc|
1754167|NCT00226629|Procedure|Endovascular vs Open Repair|
1754168|NCT00226642|Drug|Sertralin|
1754169|NCT00226642|Behavioral|Cognitive-behavioral therapy|
1754170|NCT00226642|Drug|Placebo|
1754171|NCT00226642|Behavioral|Non-specific supporting group therapy|
1754172|NCT00226655|Drug|hCRF [XERECEPT (corticorelin acetate injection)]|2mg/day
1754173|NCT00226668|Drug|hCRF|hCRF 2mg/day; dexamethasone 4mg/day along with any open-label dexamethasone they may be taking
1754174|NCT00226668|Drug|placebo hCRF|placebo hCRF 2mg/day, dexamethasone 4mg/day and any open-label dexamethasone they may be taking
1754175|NCT00226681|Behavioral|Nursing Telephone Support Protocol|
1754176|NCT00226681|Behavioral|Usual Care|
1754177|NCT00226694|Drug|Citalopram|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
1754178|NCT00226694|Other|Placebo|Subjects receive provocative tests with citalopram, dexamethasone/corticotropin-releasing hormone and placebo on 3 separate, counterbalanced occasions at monthly intervals.
1754179|NCT00226707|Drug|Pimecrolimus Cream 1%|
1754180|NCT00226720|Procedure|Outpatient detoxification program|Outpatient detoxification program
1754181|NCT00226733|Behavioral|Exercise training|Interval exercise training with high intensity five days per week for four weeks.
1754182|NCT00226733|Behavioral|Exercise training|Exercise training with moderate intensity, five days per week for four weeks.
1754183|NCT00226746|Drug|Paclitaxel and gemcitabine|
1754184|NCT00226746|Procedure|Hyperfractionated external beam irradiation|
1754185|NCT00226759|Drug|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours.
1754186|NCT00226759|Drug|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
1754187|NCT00226772|Drug|OMS103HP|Maximum of 39 liters of OMS103HP irrigation solution over a maximum of 2 hours
1754188|NCT00226772|Drug|Vehicle|Maximum of 39 liters of vehicle irrigation solution over a maximum of 2 hours
1754189|NCT00226785|Drug|Dexmedetomidine|
1754190|NCT00226798|Drug|Capecitabine (Xeloda)|
1754191|NCT00226811|Drug|Sunitinib|50mg daily, taken by mouth for 28 days followed by 2 weeks of drug free period was one cycle. Cycles were repeated until progression of disease or unacceptable toxicity was observed
1754192|NCT00226824|Drug|galantamine|
1754193|NCT00226837|Drug|Nitrous oxide|nitrous oxide by inhalation during induction
1754194|NCT00226850|Behavioral|hypnosis|
1754195|NCT00226863|Behavioral|meditation plus education|
1754196|NCT00226863|Behavioral|group psychotherapy with hypnosis plus education|
1754197|NCT00226863|Behavioral|education|
1754198|NCT00226889|Drug|bosentan|
1754199|NCT00226902|Procedure|Changing hemoglobin concentration|
1754200|NCT00226915|Drug|Paclitaxel+Carboplatin|Paclitaxel 180mg/m2＋CBDCA AUC6 q21 days x 6-9cycles
1754201|NCT00226915|Drug|Paclitaxel+Carboplatin|Paclitaxel 80mg/m2 weekly ＋CBDCA AUC6 q21 days x 6-9cycles
1754202|NCT00226928|Behavioral|Supportive-Expressive Group Therapy plus education|
1754203|NCT00226928|Behavioral|Education|
1956670|NCT02749435|Other|Use of digital disease management tool in participants with T2DM|The purpose of this study is to evaluate if the provision of a digital disease management tool in addition to standard care for T2DM, will improve glycaemic control. The impact of the tool will be assessed in comparison to a Control group who will receive standard care alone. All participants will complete the PRO assessments. This is a real-world study carried out at the point of care intended to assist health care practitioners and managed care providers to make evidence-based decisions about how to improve participant self-management of their diabetes.
1754207|NCT00226954|Drug|zoledronic acid|
1754208|NCT00226967|Drug|Sandostatin|Calculated per patient
1754209|NCT00226980|Drug|Thalidomide|
1754210|NCT00226980|Drug|Capecitabine|
1754211|NCT00226993|Drug|CPG 7909|
1754212|NCT00227006|Behavioral|Behavioral lifestyle/weight-loss intervention|
1754213|NCT00227019|Drug|Bevacizumab|15 mg/kg, IV over 10 minutes every 3 weeks
1754214|NCT00227019|Drug|Pemetrexed|500 mg/m²; IV over 10 minutes every 3 weeks
1754215|NCT00227019|Drug|Vitamin B12|1000 micrograms, IM injection 1-2 weeks prior to treatment and repeated every 9 weeks until last dose of pemetrexed
1754216|NCT00227019|Drug|Folate|350 to 1000 micrograms 1 week prior to treatment and 3 weeks after last pemetrexed dose
1754217|NCT00227019|Drug|Dexamethasone|4 mg; oral, twice a day at the following times: the day before, of and after each dose of pemetrexed
1754218|NCT00227032|Drug|erlotinib hydrochloride|"300 mg, per day for subjects taking EIAEDs
150 mg, per day for those NOT taking EIAEDs"
1754219|NCT00227058|Drug|Orotic acid and Glutathione-(Nutritional Supplements)|
1754220|NCT00227071|Behavioral|exercise|
1754221|NCT00227084|Drug|Arista AH hemostasis powder|
1754222|NCT00227097|Behavioral|Education Notebook for anticoagulant treatment|
1754223|NCT00227110|Drug|Pioglitazone|30 mg/d for 8 weeks and titrated to 45 mg/d until completing 6 months of treatment.
1754224|NCT00227110|Drug|Placebo|Placebo is given to match pioglitazone.
1754225|NCT00227123|Drug|quetiapine, risperidone|Flexible dose titrations to 'treat-to-symptoms'
1754226|NCT00227136|Drug|5-Hydroxy-Tryptamine|
1754227|NCT00227162|Behavioral|Group 1|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive positive affect intervention.
1754228|NCT00227162|Behavioral|Group 2|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive the self-affirmation intervention.
1754229|NCT00227162|Behavioral|Group 3|Patients set a physical activity goal and were assigned to one of four groups. Patients were assigned to receive both positive affect and self-affirmation intervention.
1754230|NCT00227175|Behavioral|Semi-structured, open ended interview|
1754231|NCT00227188|Drug|Pneumococcal 7-valent conjugate vaccine Prevnar|
1754232|NCT00227201|Behavioral|Self-affirmation intervention|
1754233|NCT00227253|Procedure|Determination of growth hormone status|Growth hormone stimulating testing using Arginine and Clonidine, Corticotrophin releasing hormone stimulation test
1754234|NCT00227253|Procedure|Measurement of growth, thyroid and sex hormone levels|Gonadotrophin releasing hormone stimulation test Thyroid testing - T4, TSH, T3 uptake, and anti-thyroidal antibodies baseline sample - no medication administered
1754235|NCT00227253|Procedure|Behavior and neuropsychometric evaluations|evaluation by neuropsychologist, standardized testing geared to study participant's age, abilities and past medical history
1754236|NCT00227253|Procedure|Audiological and ear, nose and throat examination|neurotological exam, behavioral audiometry, immittance audiometry, assessment of the function of the inner ear using otoacoustic emissions, Auditory brain responses
1754237|NCT00227253|Procedure|Magnetic resonance imaging of the brain|MRI of the brain - standard clinical procedure
1754288|NCT00227591|Drug|lenalidomide|Given orally (PO)
1754238|NCT00227253|Procedure|Dysmorphology evaluation|Genetic evaluation with picture and measurements, physical exam
1754239|NCT00227253|Procedure|Neurology examination|physical examination including observation of balance, coordination and reflexes.
1754240|NCT00227253|Procedure|Dental evaluation|Visual detal inspection with panorex X-ray of the entire mouth
1754241|NCT00227253|Procedure|Speech pathology evaluation|Standardized speech & language tests and naturalistic assessment procedures.
1754242|NCT00227253|Procedure|Psychiatric evaluation|Psychiatric interview about history of psychiatric and medical illnesses, family psychiatric and medical history, demographic info also obtained
1754243|NCT00227253|Procedure|Orthopedic evaluation|Physical exam by orthopedic surgeon and a dysplasia series of radiographs including AP and lateral radiographics of the feet, APs of the knees, pelvis, thoracic lumbar spine and chest, laterals of thoracic lumbar and cervical spine, lateral of the skull, AP and lateral of the forearm, bone age evaluation with radiograph of left hand
1754244|NCT00227253|Procedure|Ophthalmologic evaluation|exam will determine visual acuity using one of the following: Snellen chart, Allen acuity, target acuity, optokinetic nystagmus (OKN), or Teller acuity depending on study participants ability level. Motility/alignment will also be determined using cover/uncover test. Pupils examined using slit lamp. Dilated fundus exam and cycloplegic refraction which will require dilating drops in both eyes. Cyclogen 1% and NeuSynephrine 2.5% are using. In children less than 6 months old, less potent mydriatrics and cycloplegics are used Cyclogel 0.5% or Tropicamide 1%. Intraocular pressure will be measured in adults and cooperative teens using applanation tonometry. A topical anesthetic will be used to perform this measurement.
1754245|NCT00227253|Procedure|Gastrointestinal evaluation|physical exam and medical history by board certified gastroenterologist.
1754246|NCT00227266|Drug|Valproic Acid and Levocarnitine|VPA,sprinkle cap; Levocarnitine, syrup; dosage is by weight
1754247|NCT00227266|Drug|Placebo|
1754248|NCT00227279|Biological|ALK Grass tablet|Tablets, 75,000 SQ-T or matching placebo. Daily administration for 3 years
1754249|NCT00227292|Drug|Escitalopram|Escitalopram 10mg per day for the first week, then 20mg per day till the end of study.
1754250|NCT00227292|Drug|Placebo|Placebo 10mg per day for the first week, then 20mg per day till the end of study.
1754251|NCT00227305|Drug|quetiapine fumarate|Oral dosing, flexible dosing
1754252|NCT00227318|Drug|ATACAND|
1754253|NCT00227331|Drug|Oral amoxicillin|
1754254|NCT00227344|Device|RF ablation|Catheter ablation with NAVISTAR® THERMOCOOL® Catheter in conjunction with CARTO™ EP Navigation System
1754255|NCT00227344|Drug|Antiarrhythmic drugs|Best antiarrhythmic drug according to local practice (amiodarone suggested) throughout the study
1754256|NCT00227357|Drug|On-site - buprenorphine/naloxone (Suboxone)|Tablet, sub-lingual, 8/2 mg, 1-3 daily
1754257|NCT00227357|Drug|Off-site - methadone or no agonist|
1754258|NCT00227370|Drug|valganciclovir|valgan 900mg QD x 9 months post lung transplant
1754259|NCT00227370|Other|Placebo|
1754260|NCT00227383|Device|Electroacupuncture (device)|
1754261|NCT00227409|Drug|calcium disodium EDTA (edetate calcium disodium)|
1754262|NCT00227422|Biological|Mencevax ACWY|
1754263|NCT00227435|Drug|val-mCyd|
1754264|NCT00227448|Drug|intravenous saline|
1754265|NCT00227448|Drug|intravenous phenylephrine|
1754266|NCT00227448|Drug|intravenous levophed|
1754267|NCT00227448|Drug|oral midodrine|
1754268|NCT00227461|Drug|Levetiracetam|Levetiracetam 250 mg orally twice daily for 7 days. This will increase to 500 mg oral twice daily for 7 days the following week. If this dose is tolerated, it will then be increased to 750 mg orally twice daily for another 7 days and then increased to 1000 mg orally twice daily for 7 days.
1754269|NCT00227461|Drug|Levetiracetam|subjects with aphasia will take levetiracetam and we will evaluate their speech, language, and memory in an ABAB design
1754270|NCT00227474|Drug|recombinant modified vaccinia Ankara-5T4 vaccine|
1754271|NCT00227474|Procedure|adjuvant therapy|
1754272|NCT00227474|Procedure|recombinant viral vaccine therapy|
1754273|NCT00227487|Other|Stool collection|Stool sample will be obtained by parent at home to prevent sample dilution during the cleanout
1754274|NCT00227487|Other|Administration of carbohydrate solution during clinically indicated endoscopy|"A carbohydrate solution (lactulose + rhamnose dissolved in tap water) will be administered during the procedure (upper endoscopy) through a catheter directly into the duodenum to allow for intestinal permeability analysis.
Clinically indicated pinch biopsies will then be obtained.
The endoscopy procedures will take at least 1 - 1 ½ hours.
Children will then typically recover in the endoscopy suite for 2 - 2½ hours or less, if the child is medically cleared to leave the endoscopy suite sooner.
Urine for intestinal permeability analysis will be collected during 5 hours after carbohydrate solution administration. If the child has not voided, an additional 60 minutes will be allowed for the child to void. If the child is not continent for urine, a bag will be applied to catch the specimen."
1754275|NCT00227487|Other|Questionnaires|Parents/legal guardians of subjects will be asked to complete five (5) questionnaires: the Gastrointestinal Symptoms Inventory; a Developmental Screening for Autism - based on the child's age, either the Checklist for Autism in Toddlers (CHAT), Modified Checklist for Autism in Toddlers (M-CHAT), or the Social Communication Questionnaire (SCQ); the Behavior and Sensory Interest Questionnaire (BSI), the Behavior Problems Inventory (BPI), and the Aberrant Behavior Checklist (ABC). It should take parents/guardians no longer than eighty-five (85) minutes to complete all 5 surveys. Results from these questionnaires will be correlated with documented gastrointestinal and/or neurological diagnostic information from subject medical records and with research study test results.
1754276|NCT00227500|Drug|Pravastatin|
1754277|NCT00227513|Drug|bortezomib|Given IV
1754278|NCT00227513|Drug|vorinostat|Given orally
1754279|NCT00227526|Behavioral|Prehabilitation|
1754280|NCT00227539|Drug|cisplatin|
1754281|NCT00227539|Drug|pemetrexed disodium|
1754282|NCT00227539|Procedure|adjuvant therapy|
1754283|NCT00227539|Procedure|therapeutic conventional surgery|
1754284|NCT00227539|Radiation|fludeoxyglucose F 18|
1754285|NCT00227565|Drug|carboplatin|
1754286|NCT00227565|Drug|pemetrexed disodium|
1754287|NCT00227565|Radiation|radiation|
1754289|NCT00227591|Drug|prednisone|Given PO
1754290|NCT00227591|Other|laboratory biomarker analysis|Correlative studies
1754291|NCT00227617|Biological|bevacizumab|5mg/kg IV q 2 wk on day 1. Initial study drug dose will be delivered over 90 +/- 15 minutes x1. If the first infusion is tolerated without fever/chills, the second infusion may be delivered over 60 +/- 10 minutes. If 60 minutes infusion is well tolerated, all subsequent infusions maybe be delivered over 30 +/- 10 minutes.
1754292|NCT00227617|Drug|5-fluorouracil|2400mg/m2 CIV over 46-48 hours D1-2 q2 weeks.
1754293|NCT00227617|Drug|leucovorin|200mg/m2 IV q2 wk on day 1 over a 2-hour period.
1754294|NCT00227617|Drug|oxaliplatin|200mg/m2 IV q 2 wk on day 1 over a 2-hour period
1754295|NCT00227630|Drug|cisplatin|
1754296|NCT00227630|Drug|pemetrexed disodium|
1754297|NCT00227630|Procedure|adjuvant therapy|
1754298|NCT00227630|Procedure|conventional surgery|
1754299|NCT00227630|Procedure|neoadjuvant therapy|
1754300|NCT00227630|Radiation|radiation therapy|
1754301|NCT00227656|Biological|PEG-interferon alfa-2a|Once a week subcutaneous injection for 21 days, beginning at 180 mcg per week. Repeated for additional 21 days to begin at the same time as repeat 21 day Capecitabine cycle.
1754302|NCT00227656|Drug|Capecitabine|1000 mg/m^2 twice daily during first 14 days of each 3-week cycle (2 weeks on, 1 week rest).
1754303|NCT00227669|Drug|docetaxel|
1754304|NCT00227669|Drug|gemcitabine hydrochloride|
1754305|NCT00227682|Dietary Supplement|ascorbic acid|
1754306|NCT00227682|Drug|arsenic trioxide|
1754307|NCT00227682|Drug|dexamethasone|
1754308|NCT00227682|Drug|thalidomide|
1754309|NCT00227695|Biological|rituximab|comparing two maintenance schedules of Rituximab
1754310|NCT00227708|Drug|docetaxel|
1754311|NCT00227708|Procedure|quality-of-life assessment|
1754312|NCT00227721|Drug|Docetaxel|40 mg/m2, 30 minute IV infusion, Days 1 and 8, Every 21 days
1754313|NCT00227721|Drug|Gemcitabine hydrochloride|800mg/m2, 30 minute IV infusion, Days 1 and 8, every 21 days
1754314|NCT00227734|Drug|capecitabine and oxaliplatin + cetuximab|cetuximab
1754315|NCT00227734|Drug|capecitabine and oxaliplatin|capecitabine and oxaliplatin without cetuximab
1754316|NCT00227747|Drug|capecitabine|
1754317|NCT00227747|Drug|oxaliplatin|
1754318|NCT00227747|Procedure|conventional surgery|
1754319|NCT00227747|Procedure|neoadjuvant therapy|
1754320|NCT00227747|Radiation|radiation therapy|
1754321|NCT00227760|Drug|Cediranib Maleate|Given PO
1754322|NCT00227760|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
1754323|NCT00227760|Other|Laboratory Biomarker Analysis|Correlative studies
1754324|NCT00227760|Other|Pharmacological Study|Correlative studies
1754325|NCT00227773|Drug|octreotide acetate|
1754326|NCT00227773|Drug|vatalanib|
1754327|NCT00227773|Procedure|anti-cytokine therapy|
1754328|NCT00227773|Procedure|antiangiogenesis therapy|
1754329|NCT00227773|Procedure|biological therapy|
1754330|NCT00227773|Procedure|endocrine therapy|
1754331|NCT00227773|Procedure|enzyme inhibitor therapy|
1754332|NCT00227773|Procedure|growth factor antagonist therapy|
1754333|NCT00227773|Procedure|hormone therapy|
1754334|NCT00227773|Procedure|protein tyrosine kinase inhibitor therapy|
1754335|NCT00227773|Procedure|somatostatin analogue therapy|
1754336|NCT00221962|Drug|Aripiprazole|Open label
1754337|NCT00227786|Behavioral|smoking cessation intervention|
1754338|NCT00227786|Other|counseling intervention|
1754339|NCT00227812|Drug|Bupropion|
1754340|NCT00227825|Behavioral|Motivational interviewing|
1754341|NCT00227838|Behavioral|Behavior Therapy|
1754342|NCT00227864|Behavioral|Behavior Therapy|
1754343|NCT00227864|Other|Treatment as Usual|
1754345|NCT00227890|Behavioral|MI/CBT|
1754346|NCT00227890|Behavioral|RT/TU|
1754347|NCT00227903|Behavioral|MI-CBT|Motivationally-enhanced cognitive behavioral skills counseling
1754348|NCT00227903|Behavioral|Brief Advice|Advice and education
1754349|NCT00227916|Behavioral|Behavior Therapy|
1754350|NCT00227929|Procedure|Care Management|
1754351|NCT00227942|Drug|Estrogen Replacement Therapy|17-b-Estradiol Patch, .05 mg/day; applied for 7 days
1754352|NCT00227942|Drug|Zolpidem|10 mg/day, po qhs
1754353|NCT00227942|Drug|placebo|placebo
1754354|NCT00227955|Drug|Imipramine|
1754355|NCT00227955|Behavioral|Interpersonal Psychotherapy|
1754356|NCT00227968|Behavioral|Interpersonal Social Rhythm Therapy (IPSRT)|
1754357|NCT00227968|Behavioral|Clinical Status and Symptom Response Therapy (CSSRT)|
1754358|NCT00227981|Behavioral|Interpersonal Psychotherapy|
1754359|NCT00227981|Drug|Fluoxetine|
1754360|NCT00227994|Drug|Galantamine|Participants assigned to receive galantamine will receive 4 mg twice a day for 4 weeks, 8 mg twice a day for the next 4 weeks, and 12 mg twice a day for the remainder of the study.
1754361|NCT00227994|Drug|Donepezil|Participants assigned to receive donepezil will receive 5 mg twice a day for 6 weeks, and then 10 mg twice a day for the next 6 weeks.
1754362|NCT00228007|Drug|Antidepressant Medication|
1754363|NCT00228020|Drug|basiliximab, MMF(mycophenolate mofetil), cyclosporine, prednisone (or equivalent)|
1754364|NCT00228020|Drug|MMF, cyclosporine, steroids|
1754365|NCT00228033|Drug|Elemental calcium (as carbonate)|
1754366|NCT00228046|Drug|Divalproex Sodium|
1754367|NCT00228046|Drug|Methylphenidate|
1754368|NCT00228046|Drug|Dextroamphetamine|
1754369|NCT00228046|Drug|Mixed Amphetamine Salts|
1754370|NCT00228046|Behavioral|Family Counseling|
1754371|NCT00228046|Behavioral|Behavior Management Training with Parents|
1754372|NCT00228059|Drug|Licarbazepine|
1754373|NCT00228072|Procedure|Suction-curettage|
1754374|NCT00228098|Behavioral|Smoking cessation|
1754375|NCT00228280|Procedure|Mineral Trioxide Aggregate (MTA)|retrograde rootfilling with MTA or smoothening of the orthograde root-filling, gutta-percha
1754376|NCT00228293|Device|investigational monitor/defibrillator with CPR feedback|
1754377|NCT00228306|Behavioral|Rehabilitation exercise|Rehab therapy is delivered for 8 weeks.
1754378|NCT00228319|Dietary Supplement|Oral Ascorbic Acid|4 grams per day for 12 months
1754379|NCT00228319|Drug|Paclitaxel|Six cycles
1754380|NCT00228319|Drug|Carboplatin|Six cycles
1754381|NCT00228319|Drug|Sodium Ascorbate|Intravenous infusion at 0.5 gram/min twice weekly over 1-2 hours at a dose to achieve levels of 400 mg/dl for 12 months
1754382|NCT00228319|Dietary Supplement|Oral Mixed natural Carotenoids with Vitamin A|Capsule containing mixed carotenoids and vitamin A. Participant to take 1 daily for 12 months
1754383|NCT00228319|Dietary Supplement|Vitamin E|500 IU per capsule and participant to take 1 capsule daily for 12 months
1754384|NCT00228332|Drug|Administration of zinkgluconaat or placebo|
1754385|NCT00228345|Procedure|Optical coherence tomography,Fluorescein angiography|
1754386|NCT00228358|Drug|ex vivo-expanded HER2-specific T cells|Laboratory-expanded T cells, given IV
1754387|NCT00228358|Drug|cyclophosphamide|Given IV
1754388|NCT00228358|Biological|denileukin diftitox|Given IV
1754389|NCT00228358|Other|flow cytometry|Intracellular cytokine staining (correlative study)
1754390|NCT00228358|Other|immunoenzyme technique|ELIspot assay (correlative study)
1754391|NCT00228371|Device|Neurostimulation|High frequency neurostimulation of subthalamic nucleus : quadrupolar electrode, type 3389, n° : I7 02 08 39709 158, Medtronic, Minneapolis, USA
1754392|NCT00228384|Device|GORE VIABAHN Endoprosthesis|Implantation
1754393|NCT00228384|Device|Bare Nitinol Stent|Implantation
1754394|NCT00228397|Drug|CCI-779|
1754395|NCT00228410|Drug|Tigecycline|
1754396|NCT00228410|Drug|vancomycin with aztreonam|
1754397|NCT00228423|Drug|Clopidogrel 75 mg daily|Daily dose of 75 mg Clopidogrel
1754398|NCT00228423|Drug|water pill daily|Daily dose of water pill (placebo)
1754399|NCT00228436|Drug|peginesatide|
1754400|NCT00228449|Drug|peginesatide|
1754401|NCT00228462|Drug|Seroquel (quetiapine)|
1754402|NCT00228475|Drug|Pulmicort (budesonide) Turbuhaler|
1754403|NCT00228488|Drug|Gefitinib|
1754404|NCT00228514|Drug|Rosuvastatin|
1754405|NCT00228514|Procedure|Positron emission tomography|
1754406|NCT00228527|Drug|Esomeprazole (Nexium)|
1754407|NCT00228540|Drug|Modafinil|
1754408|NCT00228553|Drug|Armodafinil 100 to 250 mg/day|Armodafinil 100-250 mg: once daily in the morning for patients with obstructive sleep apnea/hypopnea syndrome (OSAHS) or narcolepsy, once daily only on nights worked for patients with shift worker sleep disorder (SWSD).
1754409|NCT00228566|Drug|Armodafinil|
1754410|NCT00228592|Drug|HepeX-B|
1754411|NCT00228592|Drug|Hepatitis B Immune Globulin (HBIg)|
1754412|NCT00228605|Drug|OraVescent Fentanyl|
1754413|NCT00228657|Drug|4% Albumin / 0.9% Sodium Chloride|
1754414|NCT00228683|Procedure|Biology Study and Tissue Banking|Collection of specimens from Hepatoblastoma patients.
1754415|NCT00228696|Other|none, screening only|Screening protocol with no intervention
1754416|NCT00228813|Drug|Granulocyte Colony Stimulating Factor|"FILGRASTIM: G-CSF (NEUPOGEN®) is administered as a short IV infusion over 30 minutes or subcutaneously. It is given beginning on day -3 for 3 days to the donor prior to the bone marrow harvest.
Drug Information: FILGRASTIM: G-CSF (Neupogen®) Formulation: G-CSF is available as a preservative-free solution for injection in 1.0 ml and 1.6 ml vials containing 300 mcg/ml.
Administration: G-CSF 5 mcg/kg/d will be given subcutaneously or as a short I.V. infusion over 30 minutes.
Recombinant GM-CSF at the dose of 250 mcg/m2 will be given intravenously from day +7 to help white counts recovery. The drug will be diluted in NS at a concentration of at least 10 mcg/ml.
Drug Information: Sargramostim (Leukine) Formulation: 250 mcg, 500 mcg lyophlized powder for injection"
1754417|NCT00228839|Drug|Infliximab|
1754418|NCT00228852|Drug|Busulfan, Fludarabine and ATG|
1754419|NCT00228865|Procedure|Pulsatile IV insulin therapy|Diabetic pts are given pulsatile iv insulin on a weekly basis determined by weekly phys orders based on pt response and insulin resistance. Cognitive testing is performed quarterly to track progress
1754420|NCT00228865|Procedure|Effects of Pulsatile IV Insulin on Cognitive functions|Diabetic patients receive weekly treatment of Pulsatile Intravenous Insulin therapy. Dosage is determined each week by the patient's Endocrinologist based upon the patient's response and insulin resistance.
1754421|NCT00228878|Procedure|Effects of Pulsatile IV insulin on Diabetic Quality of Life|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment and their insulin resistance.
1754422|NCT00228891|Procedure|Effect of Pulsatile IV insulin on diabetic neuropathy|Control patients with diagnosed diabetic neuropathy will have objective testing at baseline and every six months to compare and measure results to patients receiving pulsatile intravenous insulin therapy.
1754423|NCT00228891|Procedure|Effect of Pulsatile IV Insulin on diabetic neuropathy|Patients diagnosed with diabetic neuropathy will be treated with pulsatile intravenous insulin on a weekly basis. Patient's Endocrinologist will determine the dosage of intravenous insulin to be given each week based upon the patient's response and insulin resistance.
1754424|NCT00228904|Procedure|Placebo|Control patients diagnosed with diabetic neuropathy are tested at baseline and every six months thereafter to compare to patients treated with pulsatile intravenous insulin therapy
1754425|NCT00228904|Procedure|Pulsatile IV insulin delivery (humalog, humulin, novolog)|Patients with diagnosed diabetic neuropathy have objective testing and questionnaires performed at baseline and every six months thereafter to evaluate and analyze progress of diabetic neuropathy after start of treatment of pulsatile intravenous insulin therapy
1754426|NCT00228917|Biological|Tritanrix-HepB/Hiberix|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B, Haemophilus influenzae Type b Vaccine
1754427|NCT00228917|Biological|Trianrix-Hepb|Combined Diphtheria, Tetanus, Whole Cell Pertussis, Hepatitis B Vaccine
1754428|NCT00228917|Biological|Mencevax-ACWY|Meningococcal Serogroups A, C, W-135 and Y Vaccine
1754429|NCT00228917|Biological|Hib-MenAC-TT|Haemophilus influenzae type b, Meningococcal Serogroups A and C -Tetanus toxoid conjugate vaccine
1754430|NCT00228930|Drug|Tamoxifen (pharmacodynamic analysis)|Tamoxifen 20mg po daily
1754431|NCT00228943|Dietary Supplement|Acute tryptophan depletion|L-alanine (5.5g), L-arginine (4.9g), L-cysteine (2.7g), glycine (3.2g), L-histidine (3.2g), L-isoleucine (8.0g), L-leucine (13.5g), L-lysine (11.0g), L-methionine (3.0g), L-phenylalanine (5.7g), L-proline (12.2g), L-serine (6.9g), L-threonine (6.9g), L-tyrosine (6.9g), L-valine (8.9g)
1754432|NCT00228943|Dietary Supplement|Half-strength tryptophan depletion (Control)|L-alanine (1.4g), L-arginine (1.2g), L-cysteine (0.7g), glycine (0.8g), L-histidine (0.8g), L-isoleucine (2.0g), L-leucine (3.4g), L-lysine (2.8g), L-methionine (0.8g), L-phenylalanine (1.4g), L-proline (3.1g), L-serine (1.7g), L-threonine (1.7g), L-tyrosine (1.7g), L-valine (2.2g), and fillers (7.95g).
1754433|NCT00228956|Drug|pharmacodynamic analysis|Exemestane 25mg po daily or Letrozole 2.5mg po daily
1754434|NCT00228969|Drug|RWJ-333369|
1754435|NCT00228982|Drug|Ceftobiprole medocaril|
1754436|NCT00228982|Drug|Vancomycin|
1754437|NCT00228995|Drug|epoetin alfa|
1754438|NCT00229008|Drug|ceftobiprole plus placebo|ceftobiprole 500 mg every 8 hours as a 120 minute intravenous infusion and placebo administered every 12 hours as a 60-minute intravenous infusion for 7 to 14 days
1754439|NCT00229008|Drug|linezolid plus ceftazidime|linezolid 600 mg every 12 hours as a 60-minute intravenous infusion plus ceftazidime 2 g every 8 hours as a 120-minute intravenous infusion for 7 to 14 days
1754440|NCT00229021|Drug|doripenum|
1754441|NCT00229060|Drug|doripenem|
1754442|NCT00229073|Drug|dapoxetine|
1754443|NCT00229086|Device|Gatekeeper Reflux Repari System (Device)|
1754444|NCT00229099|Drug|GerEPO|
1754445|NCT00229112|Drug|MK0826, ertapenem sodium / Duration of Treatment - 24 weeks|
1754446|NCT00229112|Drug|Comparator: Piperacillin/Tazobactam / Duration of Treatment - 24 weeks|
1754447|NCT00229125|Drug|Gabapentin|
1754448|NCT00229125|Drug|Lorazepam|
1754449|NCT00229138|Drug|EC-MPS, Tacrolimus|
1754450|NCT00229151|Behavioral|Sleep deprivation and sleep phase advancement|Total sleep deprivation from 0800 to 1700 next day, and three day sleep phase advancement following sleep deprivation.
1754451|NCT00229151|Other|usual treatment|Treatment as usual in the psychiatric ward. Patients in this group will be offered treatment with sleep deprivation and sleep phase advancement after five weeks if they still meet inclusion criteria
1754452|NCT00229164|Device|Transcutaneous Electric Nerve Stimulation (TENS)|
1754453|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 12/mg/kg/hr for 7 days
1754454|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 0 mg/kg/hr for 7 days
1754455|NCT00229177|Drug|ONO-2506|Once daily one-hour intravenous infusion at 8 mg/kg/hr for 7 days
1754456|NCT00229190|Procedure|Nasal lavage|
1754457|NCT00229190|Procedure|Allergy skin testing|
1754458|NCT00229190|Procedure|Peak nasal inspiratory flow|
1754459|NCT00229190|Procedure|Acoustic rhinometry|
1754460|NCT00229190|Procedure|Nasal examination|
1754461|NCT00229190|Procedure|Quality of Life Questionnaire|
1754462|NCT00229190|Procedure|Physical examination|
1754463|NCT00229203|Drug|Plitidepsin|3-hour infusion every 2 weeks alone or in combination with dexamethasone
1754464|NCT00229216|Drug|Tinidazole|
1754465|NCT00229229|Other|Low glycemic load diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
1754466|NCT00229229|Other|Canada Food Guide Diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
1754467|NCT00229229|Other|Low glycemic index diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
1754468|NCT00229229|Other|Low carbohydrate diet|A/A for 6 months intensive dietary intervention followed by a visit 1 year from enrolment
1754469|NCT00229242|Drug|Diuretic-Based or Non-Diuretic Based Hypertension Therapy|
1754470|NCT00229255|Other|high frequency of meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
1754471|NCT00229255|Other|twice a day meals|high carbohydrate diet i.e. 65% carbohydrate, 15% protein, 20% fat for 4 weeks.
1754472|NCT00229281|Behavioral|Group therapy|
1754473|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|20 minutes exposure
1754474|NCT00229307|Behavioral|Prolonged Exposure (PE) therapy|40 minutes exposure
1754475|NCT00229320|Behavioral|Group therapy|
1754477|NCT00229372|Behavioral|Prolonged Exposure (PE) therapy|
1754478|NCT00229385|Drug|Ziprasidone|40-80 mg BID
1754479|NCT00229411|Behavioral|simulation training|
1754480|NCT00229424|Drug|Lafutidine|Oral administration of lafutidine by 20mg/day along with famotidine placebo
1754481|NCT00229424|Drug|Famotidine|Oral administration of famotidine by 40mg/day along with lafutidine placebo
1754482|NCT00229424|Other|Placebo|Oral administration of lafutidine placebo along with famotidine placebo
1754483|NCT00229437|Drug|TAK-128|TAK-128 5 mg, tablets, orally, once daily for up to 6 months.
1754484|NCT00229437|Drug|TAK-128|TAK-128 50 mg, tablets, orally, once daily for up to 6 months.
1754485|NCT00229437|Drug|TAK-128|TAK-128 100 mg, tablets, orally, once daily for up to 6 months.
1754486|NCT00229437|Drug|Placebo|TAK-128 placebo-matching tablets, orally, once daily for up to 6 months.
1754487|NCT00229450|Drug|estrogen|
1754488|NCT00229476|Drug|sertraline (Zoloft)|
1754489|NCT00229515|Other|abciximab followed by implantation of bare metal stent|Patients will receive infusion of abciximab at standard regimen before undergoing intervention for STEMI and then bare metal stent implantation in the culprit lesion
1754621|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine dosage by 2 extra tablets of their current dose per week
1754490|NCT00229515|Other|abciximab and Sirolimus eluting stent|Patients will receive abciximab infusion at standard regimen followed by implantation of sirolimus-eluting stent in the culprit lesion
1754491|NCT00229515|Other|tirofiban and bare metal stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with bare metal stent implantation
1754492|NCT00229515|Other|tirofiban and sirolimus-eluting stent|Patients will receive tirofiban infusion at high loading dose followed by standard infusion for 18-24 hours and subsequently they will be treated with sirolimus-eluting stent implantation
1754493|NCT00229528|Drug|Paxil-CR|
1754494|NCT00229541|Procedure|Counselling and 3-week medical in-patient rehabilitation|Counselling and 3-week medical in-patient rehabilitation in IG
1754495|NCT00229567|Drug|Lidocaine infusion plus ketamine injection|
1754496|NCT00229580|Behavioral|3 session brief intervention with health behavior feedback|
1754497|NCT00229580|Other|treatment as usual|
1754498|NCT00229593|Drug|Nestorone gel|2 to 8 mg Nestorone gel daily for 3 weeks depending on treatment group assignment
1754499|NCT00229593|Drug|Testosterone Gel|100 mg Testosterone gel daily for 3 weeks
1754500|NCT00229619|Drug|Rituximab|Rituximab (Rituxan) 375mg/m2 intravenous infusion. The infusion will be once every week for a total of 4 doses.
1754502|NCT00229645|Drug|Quetiapine Fumarate (Seroquel®)|
1754503|NCT00229658|Drug|pramlintide acetate|Subcutaneous injection prior to each major meal
1754505|NCT00229684|Drug|Tesaglitazar|2 mg once daily in oral form
1754506|NCT00229684|Drug|pioglitazone|45 mg once daily in oral form
1754507|NCT00229697|Drug|Gefitinib|
1754508|NCT00229697|Drug|Tamoxifen|
1754509|NCT00229710|Drug|Tesaglitazar|0.5 in combination with insulin (with or without other oral antidiabetic drugs)
1754510|NCT00229723|Drug|gefitinib (Iressa)|250 mg oral tablet
1754511|NCT00229723|Drug|cisplatin|intravenous infusion
1754512|NCT00229723|Radiation|radiotherapy|radiation therapy
1754513|NCT00229723|Drug|Gefitinib (Iressa)|500 mg oral tablet
1754514|NCT00229736|Genetic|AAV-hAADC-2|9 x 10^10 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
1754515|NCT00229736|Genetic|AAV-hAADC-2|3 x 10^11 vector genomes (vg) of AAV-hAADC-2 in a single dose of 200 µL bilaterally infused over 4 striatal targets
1754516|NCT00229749|Drug|AVI-4065 Injection|
1754517|NCT00229762|Behavioral|phone call from nurses - informational only|
1754518|NCT00229775|Drug|artemether/lumafantrine vs chloroquine/sulfadoxine-pyrimethamine|
1754519|NCT00229801|Radiation|MRI|
1754520|NCT00229840|Procedure|Functional MRI, Diffusion Tensor Imaging|
1754521|NCT00229918|Drug|triamcinolone acetonide|
1754522|NCT00229931|Drug|Triamcinolone acetonide|4mg of intravitreal triamcinolone at time of cataract surgery with option to repeat at one month if no response
1754523|NCT00229931|Procedure|laser|Laser treatment 1 month after cataract surgery with option to repeat once if no improvement.
1754524|NCT00229944|Drug|Azithromycin|
1754525|NCT00229957|Behavioral|Occupational therapy|
1754526|NCT00229957|Behavioral|Physiotherapy|
1754527|NCT00229957|Behavioral|Self-management|
1754528|NCT00229970|Drug|montelukast sodium|7 mg or 14 mg single injection
1754529|NCT00229970|Drug|Comparator: Placebo|Placebo single injection
1754530|NCT00229983|Behavioral|Motivational Enhancement Therapy|Three 60 minute counseling sessions using a structured, developmentally appropriate approach to identification of drug- and alcohol- related risks and problems, and establishment of goals for behavioral change.
1754531|NCT00229996|Drug|Oral Contraceptive|
1754532|NCT00229996|Drug|Depot-Leuprolide/Norethindrone|
1754533|NCT00230009|Behavioral|Brief motivational intervention|
1754534|NCT00230022|Behavioral|Brief computer-delivered intervention|20-minute interaction with voice-enabled software that could provide reflections, images, text, etc.
1754535|NCT00230035|Procedure|Leukapheresis|
1754536|NCT00230035|Procedure|Non-myeloablative high dose immunosuppressive therapy conditioning (HDIT)|
1754537|NCT00230035|Procedure|Autologous CD34+HPC transplantation (HSCT)|
1754538|NCT00230035|Procedure|Plasmapheresis|
1754539|NCT00230035|Drug|Rabbit anti-thymocyte globulin|
1754540|NCT00230035|Drug|Methylprednisolone|
1754541|NCT00230035|Drug|Growth colony stimulating factor (G-CSF)|
1754542|NCT00230035|Drug|Corticosteroids|
1754543|NCT00230035|Drug|Mycophenolate mofetil|
1754544|NCT00230035|Drug|Azathioprine|
1754545|NCT00230035|Drug|Intravenous immunoglobulin|
1754546|NCT00230035|Drug|Methotrexate|
1754547|NCT00230035|Drug|Rituximab|
1754548|NCT00230035|Drug|Leflunomide|
1754549|NCT00230048|Behavioral|Brief computer-delivered intervention|Brief (20-minute) computer delivered intervention, plus two subsequent non-tailored mailings.
1754550|NCT00230061|Biological|HBVAXPRO, Hepatitis B (Recombinant) vaccine, 10 mcg/ml|
1754551|NCT00230074|Drug|TCH346|
1754552|NCT00230087|Procedure|blood donation|phlebotomy until iron depleted
1754622|NCT00230802|Drug|levothyroxine|patients will increase levothyroxine by 3 extra tablets of their current dose per week.
1754623|NCT00230815|Device|Follitropin alfa injected by Pen device|Follitropin alfa will be injected subcutaneously by Pen device at a dose of 75 International Unit (IU) and 150 IU in subjects aged 18-34 and 35-40 years, respectively, for 5 days. Dose will be adjusted on stimulation Day 6 until ovulation triggering criteria will met.
1754761|NCT00234923|Drug|lopinavir/ritonavir|400 mg lopinavir/ 100 mg ritonavir, BID
1754880|NCT00235976|Drug|Gantacurium Chloride for Injection (AV430A)|
1754553|NCT00230100|Behavioral|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance abuse antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
1754554|NCT00230100|Behavioral|mixed-gender Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
1754555|NCT00230113|Dietary Supplement|Omega-3 fatty acid diet supplementation|4 gm fish oil per day
1754556|NCT00230113|Dietary Supplement|safflower oil|4 gm per day safflower oil
1754557|NCT00230126|Drug|erlotinib|Arm A: 150 mg/day cycles 1 - 3. Arm B: Cycle 1 - 175 or 200 mg/day depending on body weight; Cycle 2 - if rash developed, then 150 mg/day; if no rash, then 175 mg/day; Cycle 3 - if rash developed, then 175 mg/day; if no rash, then 200 mg/day.
1754558|NCT00230139|Device|SPECT/CT|
1754559|NCT00230152|Device|Imaging|
1754560|NCT00230178|Drug|Rasburicase (SR29142)|30-min IV infusion
1754561|NCT00230178|Drug|Allopurinol|Oral administration
1754562|NCT00230191|Drug|RK-0202|
1754563|NCT00230204|Procedure|Serum antibodies to infectious agents using the BioPlex 2200 and complementary EIA kits|
1754564|NCT00230217|Drug|Rasburicase (SR29142)|
1754565|NCT00230230|Drug|SCH 486757|
1754566|NCT00230269|Procedure|PET-CT|
1754567|NCT00230282|Drug|Alemtuzumab|3 to 30 mg, IV
1754568|NCT00230282|Drug|Fludarabine|[(2R,3R,4S,5R)-5-(6-amino-2-fluoro-purin-9-yl)- 3,4-dihydroxy-oxolan-2-yl]methoxyphosphonic acid
1754569|NCT00230282|Drug|Cytoxan|(RS)-N,N-bis(2-chloroethyl)-1,3,2-oxazaphosphinan-2-amine 2-oxide
1754570|NCT00230295|Procedure|IMR LAG|
1754571|NCT00230321|Drug|Darbepoetin alfa|During the induction phase, the investigational agent DARBEPOETIN ALFA will be initiated at a dose of 4.5 ug/kg/week subcutaneously.If patients do not achieve a major erythroid response by 6 weeks, the dose of DARBEPOETIN ALFA will be doubled to 9.0 ug/kg/week.
1754572|NCT00230334|Drug|Gleevec|
1754573|NCT00230347|Procedure|Stereotactic radiosurgery|
1754574|NCT00230373|Drug|imiquimod 5% cream (Aldara)|
1754575|NCT00230386|Device|MRI|
1754576|NCT00230399|Drug|Celecoxib|
1754577|NCT00230399|Drug|Capecitabine|
1754578|NCT00230399|Drug|Irinotecan|
1754579|NCT00230438|Procedure|External Beam Radiotherapy|
1754580|NCT00230451|Procedure|Radiation|
1754581|NCT00230451|Drug|Paclitaxel|
1754582|NCT00230451|Drug|Cisplatin|
1754583|NCT00230451|Drug|5-Fluorouracil|
1754584|NCT00230464|Drug|LAF 237|
1754585|NCT00230477|Drug|Hepsera|
1754586|NCT00230477|Drug|Hepsera and lamivudine|
1754587|NCT00230490|Drug|pradefovir mesylate|
1754588|NCT00230490|Drug|adefovir dipivoxyl|
1754589|NCT00230503|Drug|pradefovir mesylate|
1754590|NCT00230503|Drug|adefovir dipivoxyl|
1754591|NCT00230516|Drug|Nexium|
1754592|NCT00230516|Drug|Prevacid|
1754593|NCT00230529|Drug|infliximab|
1754594|NCT00230542|Drug|Carboplatin|Given intravenously following pemetrexed over 30-45 minutes once every three weeks for 6 cycles (18 weeks)
1754595|NCT00230542|Drug|Pemetrexed|Given intravenously over 30 minutes once every three weeks for 6 cycles (18 weeks)
1754596|NCT00230555|Behavioral|professional support model|
1754597|NCT00230568|Drug|Aricept|
1754598|NCT00230581|Drug|DDP225|
1754599|NCT00230594|Drug|desmopressin|desmopressin 120 mcg melt tablet; 120 mcg, 240 mcg or 360 mcg administered once daily before bedtime
1754600|NCT00230594|Drug|placebo|placebo melt tablet; 1 to 3 placebo melt tablets administered once daily before bedtime
1754601|NCT00230607|Drug|agalsidase beta|Pharmaceutical form: powder for reconstitution Route of administration: intravenous
1754602|NCT00230646|Behavioral|Exercise counseling|
1754603|NCT00230659|Other|Blood sample to be taken.|Blood sample to be taken.
1754604|NCT00230698|Drug|topiramate|
1754605|NCT00230711|Behavioral|Physical activity counseling|
1754606|NCT00230724|Behavioral|Exercise Counseling|
1754607|NCT00230737|Drug|Melatonin 0.4 mg|
1754608|NCT00230737|Drug|Melatonin 4.0 mg|
1754609|NCT00230737|Drug|Placebo|
1754610|NCT00230750|Biological|Influenza A/H5N1 Vaccine|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 90-mcg/mL. Dosages: 45 mcg or 90 mcg administered intramuscularly.
1754611|NCT00230750|Drug|Placebo|Saline placebo.
1754612|NCT00230763|Procedure|GSS questionnaire|D0, D30 and D84
1754613|NCT00230763|Procedure|IOP|D0, D30 and D84
1754614|NCT00230763|Drug|LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION|in the evening during 84 days
1754615|NCT00230763|Procedure|Visual acuity|D0 and D84
1754616|NCT00230776|Drug|pregabalin|
1754617|NCT00230776|Drug|placebo|
1754618|NCT00230789|Drug|Tolterodine ER 4 mg QD|
1754619|NCT00230789|Behavioral|OAB Patient Behavioral Training Material|
1754620|NCT00230802|Drug|Anticipatory dose increase of levothyroxine|as it is know that levothyroxine requirement increases in pregnancy, both study arms will increase levothyroxine dose, though by different amounts.
1754828|NCT00235469|Drug|SPM 927|
1754829|NCT00235482|Drug|Coxsackievirus A21|
1754624|NCT00230815|Device|Recombinant Human Choriogonadotropin (r-hCG)|Recombinant Human Choriogonadotropin (r-hCG) injection will be administered as a single dose of 250 microgram subcutaneously when at least 1 follicle, but not more than 3 follicles, reached a mean diameter greater than or equal to (>=)17 mm and estradiol levels are approximately 150 picogram per milliliter (pg/mL) per mature follicle.
1754625|NCT00230828|Drug|bifeprunox|
1754626|NCT00230841|Device|nebulized humidity|
1754627|NCT00230854|Drug|EMZ702|
1754628|NCT00230867|Device|iontophoretic acyclovir|
1754629|NCT00230880|Behavioral|follow-up phone counseling|9 calls over 12 months
1754630|NCT00224861|Behavioral|Self-Management|
1754631|NCT00224861|Behavioral|Adherence|
1754632|NCT00224874|Drug|Etanercept|Etanercept [25 mg subcutaneously twice weekly for up to 4 weeks; discontinue if in complete response by 4 weeks].
1754633|NCT00224874|Drug|Mycophenolate Mofetil|Mycophenolate mofetil (MMF) [20 mg/kg (maximum 1 gm) orally or intravenously twice daily; continue through prednisone taper, then taper MMF over 4 weeks].
1754634|NCT00224874|Drug|Denileukin Diftitox|Denileukin Diftitox (ONTAK®) [9 mcg/kg intravenously Days 1, 3, 5, 15, 17, 19].
1754635|NCT00224874|Drug|Pentostatin|Pentostatin [1.5 mg/m2 daily for 3 days; Days 1-3 and repeat Days 15-17
1754637|NCT00224913|Procedure|Neuromuscular electrical stimulation|
1754638|NCT00224913|Procedure|Voluntary exercise|
1754639|NCT00224926|Procedure|Scalp Brushing|sterile, soft-head toothbrush massaged on scalp
1754640|NCT00224939|Drug|Potassium Chloride|
1754641|NCT00224952|Other|No intervention; Urine Collection|Urine collected from children receiving carbamazepine or valproic acid as part of their clinical management
1754642|NCT00224965|Behavioral|Behavior Therapy|
1754643|NCT00224978|Drug|Chloroquine|
1754644|NCT00224991|Procedure|Intensive systematic information (osteoporosis school)|
1754645|NCT00225004|Procedure|DEXA scan|orto
1754646|NCT00225017|Drug|Atazanavir|atazanavir 400 mg once daily
1754647|NCT00225017|Drug|current antiretroviral regimen|Continue current antiretroviral regimen for 24 weeks, single or RTV-boosted PI plus > 2 NRTIs
1754648|NCT00225030|Drug|antihypertensive drugs according to current guidelines|
1754649|NCT00225043|Drug|Epinephrine/phenylephrine|
1754650|NCT00225056|Drug|docetaxel and capecitabine|
1754651|NCT00225069|Procedure|Level of sympathectomy|T2 sympathectomy or T2-T3 sympathectomy
1754652|NCT00225082|Drug|Nucleoside analogue switch|stavudine switched to tenofovir
1754653|NCT00225095|Drug|Mesenchymal Stem Cells|
1754654|NCT00225095|Drug|Hyaluronan|
1754655|NCT00225108|Drug|Tinzaparin|
1754656|NCT00225121|Drug|PF-00299804|investigational drug by oral route (escalating doses depending on safety) administered until progression
1754657|NCT00225147|Drug|Recombinant Human C1 Inhibitor|IV
1754658|NCT00225147|Drug|placebo|saline solution
1754659|NCT00225160|Drug|acetyl L-carnitine|
1754660|NCT00225173|Drug|Doxorubicin|Doxorubicin 25 mg/m2 IV w 1,3,5,7,9,11
1754661|NCT00225173|Drug|Vinblastine|Vinblastine 6 mg/m2 IV w 1,3,5,7,9,11
1754662|NCT00225173|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV w 1, 5, 9
1754663|NCT00225173|Drug|Etoposide|Etoposide2 60 mg/mg2 x 2 IV w 3, 7,11
1754664|NCT00225173|Drug|Vincristine|Vincristine1 1.4 mg/m2 IV w 2,4,6,8,10,12 (cap @ 2mg)
1754665|NCT00225173|Drug|Bleomycin|Bleomycin 5 u/m2 IV w 2,4,6,8,10,12
1754666|NCT00225173|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 IV w 13,15,17,19
1754667|NCT00225173|Drug|Vinorelbine|Vinorelbine 25 mg/m2 IV w 13,15,17,19
1754668|NCT00225173|Drug|Prednisone|Prednisone 40 mg/m2 PO qod w 1-10, taper
1754669|NCT00225186|Drug|Visanne (SH T00660AA , BAY86-5258)|Daily long-term drug treatment (12 months), and post-treatment observation (6 months) in a subgroup of patients
1754670|NCT00225199|Drug|Visanne (BAY86-5258, SH T00660AA)|orally once daily
1754671|NCT00225199|Drug|Placebo|orally once daily
1754672|NCT00230906|Procedure|Haemodialysis with either low or high flux membranes|
1754673|NCT00230919|Behavioral|Diet counseling|
1754674|NCT00230945|Behavioral|education and support intervention|The patient-oriented education and support intervention (PES) is based on the Arthritis Self-Management Program, a group intervention that consists of 6 weekly 2 hour sessions shown to successfully reduce pain severity and depressive symptomatology and to enhance a sense of efficacy in managing arthritis pain and other symptoms. The couple-oriented education and support intervention (CES) is a group education and support intervention that consisted of 6 weekly 2 hour sessions attended by individuals with OA and their spouses. All components of the PES are covered in the CES using the standard format, and topics are framed as couples' issues whenever possible.
1754675|NCT00230958|Drug|Viramidine|
1754676|NCT00230958|Drug|Ribavirin|
1754677|NCT00230958|Drug|pegylated interferon alfa-2b|
1754678|NCT00230971|Drug|tigecycline|every 12 hours IV (an initial dose of 100 mg followed by 50 mg every 12 hours)
1754679|NCT00230971|Drug|ceftriaxone plus metronidazole|Ceftriaxone sodium 2 g once daily intravenously plus metronidazole 1 g to 2 g daily given in divided doses intravenously. Test article should be administered for a minimum of 4 days and up to 14 days at the discretion of the investigator.
1754680|NCT00230984|Behavioral|education|
1754681|NCT00230984|Drug|Oral dietary supplements (563 kcal/d), RESPIFOR|
1754682|NCT00230984|Behavioral|exercises on an ergometric bicycle 3 to 5 times a week|
1754683|NCT00230984|Drug|160 mg/d of oral testosterone undecanoate in men, 80 mg/d in women|
1754684|NCT00230997|Drug|Galantamine|
1754685|NCT00231023|Drug|Peribulbar Triamcinolone Acetonide|
1754686|NCT00231049|Drug|AG-707|
1754687|NCT00231062|Device|Sinuplasty|
1754688|NCT00231075|Drug|Paraplatin|
1754689|NCT00231075|Drug|Paclitaxel|
1754690|NCT00231101|Drug|Quetiapine|
1754691|NCT00231114|Device|Alair System|Treatment of airways with the Alair System
1754692|NCT00231114|Device|Alair System|Sham treatment of airways with the Alair System
1754693|NCT00231140|Drug|Thalidomide (drug)|
1754879|NCT00235963|Drug|Simvastatin|
1754694|NCT00231153|Drug|Omiganan 1% gel|Patients randomized to omiganan group will receive an application of omiganan gel around the catheter insertion site following catheter insertion. Every 3 days the dressing will be changed and patients will receive a new application of Omiganan 1% gel.
1754695|NCT00231153|Drug|Povidone-Iodine 10%|All CVC sites will be disinfected using a 10% povidone-iodine scrub for a minimum of 2 minutes prior to catheter insertion. Patients randomized to the povidone-iodine group will receive no further antiseptic treatment after catheter insertion until dressing changes. Every three days the dressing will be changed and the catheter site will be sterilized with povidone-iodine.
1754696|NCT00231166|Drug|HCD122|
1754697|NCT00231179|Behavioral|Home visiting professional support model|Home visits and telephone calls keyed to well child visits.
1754698|NCT00231179|Other|Control|The control group received an information booklet on child/family services upon enrollment and transportation for the follow-up evaluations. They were called every 4 months to maintain contact information
1754699|NCT00231192|Drug|Repaglinide and Insulin|
1754700|NCT00231205|Procedure|Revascularization|
1754701|NCT00231218|Drug|dietary supplement--echinacea, propolis, and vitamin c|
1754702|NCT00231231|Device|-PRECISE Nitinol Stent System (5F, 5.5F and 6F)|
1754703|NCT00231231|Device|ANGIOGUARD™ XP Emboli Capture Guidewire (ECGW)|
1754704|NCT00231244|Device|CYPHER Sirolimus-Eluting Coronary Stent|CYPHER Sirolimus-Eluting Coronary Stent
1754705|NCT00231257|Device|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent|Sirolimus-Eluting Bx Velocity® Balloon Expandable Stent
1754706|NCT00231257|Procedure|Brachytherapy|Brachytherapy
1754707|NCT00234377|Drug|Seroquel SR|
1754708|NCT00234390|Drug|Pulmicort (budesonide) pMDI|
1754709|NCT00234403|Drug|gefitinib and fulvestrant|
1754710|NCT00234416|Drug|Gefitinib|
1754711|NCT00234416|Drug|Gemcitabine|
1754712|NCT00234429|Drug|Gefitinib, raltitrexed|
1754713|NCT00234442|Drug|Iressa (Gefitinib)|
1754714|NCT00234455|Device|drug eluting-stent|PCI
1754715|NCT00234455|Device|drug-eluting stent|PCI
1754716|NCT00234468|Drug|Iressa (Gefitinib)|
1754717|NCT00234481|Drug|XL844|
1754718|NCT00234494|Drug|Cisplatin|Cisplatin 70 mg/m2, day 1
1754719|NCT00234494|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, day 1 and 8
1754720|NCT00234494|Drug|Bevacizumab|Bevacizumab 15mg/kg, day 1
1754721|NCT00234507|Drug|Botulinum toxin type A (Dysport®)|
1754723|NCT00234546|Drug|Botulinum toxin type A (Dysport®)|1 injection, 500 U at day 0. The study will last for 6 months in each patient.
1754724|NCT00234546|Other|Placebo|1 injection at day 0. The study will last for 6 months in each patient.
1754725|NCT00234559|Device|VAC® Therapy System|
1754726|NCT00234572|Drug|Lanreotide (Autogel formulation)|
1754727|NCT00234585|Device|Renal Artery Stent with Protective Device/Drug|
1754728|NCT00234598|Procedure|Toothbrushing only|Toothbrushing three times per 24 hours without chlorhexidine
1754729|NCT00234598|Procedure|Chlorhexidine only|Chlorhexidine oral rinse twice per 24 hours without toothbrushing
1754730|NCT00234598|Procedure|Toothbrushing and Chlorhexidine|Toothbrushing three times per 24 hours plus chlorhexidine twice per 24 hours.
1754731|NCT00234611|Procedure|Echocardiogram guided left ventricular lead placement|
1754732|NCT00234637|Drug|Rivastigmine, memantine|
1754733|NCT00234650|Procedure|Colonoscopy|
1754734|NCT00234663|Drug|PTC124|
1754735|NCT00234676|Drug|Premarin ®|Premarin ® 0.625 mg per day orally
1754736|NCT00234689|Drug|Naltrexone|
1754737|NCT00234702|Drug|Lanthanum carbonate|Lanthanum carbonate 750mg/day, T.I.D. for 2 weeks; titrated at the next 3 weekly visits in order to achieve target serum phosphorus levels, up to a maximum dose of 3000mg/day; 4-week maintenance period where subject receives the final titrated daily dose established during the titration period.
1754738|NCT00234702|Drug|Placebo|Placebo
1754739|NCT00234728|Device|Occlusive dressing|
1754740|NCT00234741|Drug|STA-5326 mesylate|
1754741|NCT00234754|Procedure|TVT Surgery TOT Surgery|TVT surgery and TOT surgery
1754742|NCT00234767|Device|Pulmonary Artery Catheter|
1754743|NCT00234767|Behavioral|Protocolized Fluid Management|
1754744|NCT00234780|Procedure|pediatric nursing used in home to avoid hospitalization|
1754745|NCT00234793|Behavioral|Problem-Solving Skills Training|
1754746|NCT00234806|Other|Health-e-Access|telemedicine intervention
1754747|NCT00234819|Drug|Bazedoxifene/Conjugated Estrogen|
1754748|NCT00234832|Drug|Sibutramine hydrochloride|One 10 mg tablet QD plus country-specific standard care for weight management. (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
1754749|NCT00234832|Drug|Placebo|1 tablet QD plus country-specific standard care for weight management (During the Treatment Period, the dose could have been titrated up to 15 mg at the investigator's discretion.)
1754750|NCT00234832|Drug|Sibutramine hydrochloride|10 mg tablet QD during the 6-week Lead-in Period plus country-specific standard care for weight management
1754751|NCT00234845|Drug|adalimumab|
1754752|NCT00234845|Drug|methotrexate|
1754753|NCT00234858|Drug|trandolapril/verapamil|2/180 mg QD with titration if needed at Week 4 to 4/240 mg QD
1754754|NCT00234858|Drug|(Hyzaar) losartan/hydrochlorothiazide|50/12.5 mg QD with titration if needed at Week 4 to 100/25 mg QD
1754755|NCT00234871|Drug|trandolapril/verapamil|2/180 mg QD with forced titration after 4 weeks to 4/240 mg QD
1754756|NCT00234871|Drug|Lotrel (amlodipine/benazepril)|5/10 mg QD with forced titration after 4 weeks to 10/20 mg QD
1754757|NCT00234884|Biological|adalimumab|commercial adalimumab as prescribed by the rheumatologist in a normal clinical setting and in accordance with the Summary of Product Characteristics (SmPC)
1754758|NCT00234897|Drug|adalimumab|
1754759|NCT00234910|Drug|Tenofovir DF|TDF 300mg QD for 72 wks
1754760|NCT00234910|Drug|lopinavir/ritonavir with 2 Nucleoside RTIs|LPV/rSGC 400/100mg BID + 2 nucleoside RTIs as prescribed by the Investigator for 72 wks
1754762|NCT00234923|Drug|lamivudine/zidovudine|300mg lamivudine/150mg zidovudine, BID
1754763|NCT00234936|Drug|Adalimumab|
1754764|NCT00234936|Drug|Methotrexate|
1754765|NCT00234949|Drug|cefdinir|
1754766|NCT00234949|Drug|cephalexin|
1754767|NCT00234962|Drug|Lopinavir/Ritonavir|
1754768|NCT00234975|Drug|Lopinavir/Ritonavir|400 mg/ 100 mg BID. Both arms use Kaletra 400/100 mg BID, plus NRTI chosen by the investigator
1754769|NCT00234988|Drug|sibutramine hydochloride monohydrate|10 mg QD with the option to increase dose to 15 mg QD up until Week 4
1754770|NCT00235001|Drug|trandolapril/verapamil|180/2 mg QD
1754771|NCT00235014|Drug|trandolapril|2 mg QD
1754772|NCT00235014|Drug|trandolapril/verapamil|180/2 mg QD
1754773|NCT00235014|Drug|placebo|1 tablet QD
1754774|NCT00235014|Drug|verapamil|SR 240 mg QD
1754775|NCT00235027|Other|Adverse Drug Event Monitoring|The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
1754776|NCT00235040|Behavioral|Smart Form|Computer Decision Support System
1754777|NCT00235053|Drug|fluticasone/salmeterol DISKUS 250/50|
1754778|NCT00235066|Device|PCI|PCI with Cypher Sirolimus-Eluting Stent
1754779|NCT00235079|Drug|Colchicine|Colchicine 0.5mg BID (>70Kg) or 0.5 once daily for 6 months
1754780|NCT00235079|Drug|Placebo|Placebo comparator
1754781|NCT00235092|Device|Cypher Sirolimus-Eluting Stent|
1754782|NCT00235092|Device|Taxus Paclitaxel-Eluting Stent|
1754783|NCT00235105|Drug|Adalimumab 40 mg sc every other week|
1754784|NCT00235118|Device|Cordis AAA Bilateral Device|
1754785|NCT00235131|Device|Smart Stent|Cordis S.M.A.R.T.™ CONTROL™ Nitinol Stent System
1754786|NCT00235131|Device|Luminexx Stent|Bard® Luminexx™ 6F Vascular Stent
1754787|NCT00235144|Device|sirolimus-coated Bx Velocity stent|drug-eluting stent
1754788|NCT00235144|Device|uncoated Bx Velocity stent|bare-metal stent
1754789|NCT00235157|Device|Sirolimus-eluting Palmaz Genesis peripheral stent|treatment of renal artery stenosis with a renal stent
1754790|NCT00235170|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary stent
1754791|NCT00235183|Other|plasma|transfusion of more than 15 mL/Kg of plasma
1754792|NCT00235196|Device|Collagen ORC Antimicrobial Matrix (CAM)|
1754793|NCT00235209|Device|Collagen ORC Antimicrobial Matrix (CAM)|
1754794|NCT00235222|Drug|stavudine|
1754795|NCT00235235|Procedure|Biopsy|core biopsy
1754796|NCT00235235|Procedure|Serum Collection|serum collection
1754797|NCT00235235|Procedure|Urine Collection|urine collection
1754798|NCT00235235|Drug|Doxorubicin|Doxorubicin 60 mg/m2 day 1 of every 21-day cycle
1754799|NCT00235235|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 day 1 of every 21-day cycle
1754800|NCT00235235|Drug|Capecitabine|Capecitabine 1000 mg/m2 bid days 1-14 of every 21-day cycle
1754801|NCT00235235|Drug|Vinorelbine|Vinorelbine 25mg/m2 days 1, 8, 15 of every 28-day cycle
1754802|NCT00235235|Drug|Gemcitabine|Gemcitabine 1000mg/m2 days 1, 8, 15 of every 28-day cycle
1754803|NCT00235248|Drug|Warfarin|Warfarin
1754804|NCT00235248|Drug|Clopidogrel-aspirin|Clopidogrel-aspirin
1754805|NCT00235261|Drug|Pregabalin|
1754806|NCT00235261|Drug|Dexamethasone|
1754807|NCT00235274|Drug|Subcutaneous Secretin|
1754808|NCT00235287|Drug|Candesartan and enalapril|24 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), where Enalapril is added in incremental doses (5,10 and 20 mg)the last 8 weeks.
1754809|NCT00235287|Drug|candesartan and enalapril|24 weeks of treatment with Enalapril in incremental doses (5, 10, 20 mg), where Candesartan is added in incremental doses (4,8,16 mg) in the last 8 weeks.
1754810|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Candesartan in incremental doses (4,8,16 mg), followed by 8 weeks of treatment with Enalapril in incremental doses (/5,10,20 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan in incremental doses (4,8,16 mg) and Enalapril 20 mg.
1754811|NCT00235287|Drug|candesartan and enalapril|8 weeks of treatment with Enalapril in incremental doses (5,10,20 mg), followed by 8 weeks of treatment with Candesartan (4,8,16 mg). The treatment in the last 8 out of the 24 weeks is a combination of Candesartan 16 mg and Enalapril in incremental doses (5,10,20 mg)
1754812|NCT00235300|Biological|Thymoglobulin [Anti-thymocyte Globulin (rabbit)]|1.5 mg/kg per day, for a maximum of 5 doses
1754813|NCT00235300|Drug|Simulect (basliximab)|20 mg per day on 2 days
1754814|NCT00235313|Procedure|Dose adjustment of nicotine replacement therapies|Dose adjustment of nicotine replacement therapies
1754815|NCT00235313|Drug|nicotine patch|normal following with a nicotine patch
1754816|NCT00235339|Behavioral|Exercise training|Standard exercise training at the hospital, two times per week for twelve weeks
1754817|NCT00235339|Behavioral|Exercise training|Interval exercise training with high intensity on treadmill. Subjects exercise two times per week for twelve weeks
1754818|NCT00235352|Drug|CX516 (Ampakine)|
1754819|NCT00235365|Behavioral|meta-cognitive therapy|Meta-cognitive therapy
1754820|NCT00235365|Other|waiting list|waiting list control
1754821|NCT00235391|Drug|Deferasirox|125 mg, 250 mg and 500 mg tablets. Dosage was calculated based on participant's body weight. Tablets were dispersed in water, orange or apple juice and taken orally once a day.
1754822|NCT00235404|Other|Multicomponent treatment|Specialized care in preparing recharge to home
1754823|NCT00235404|Other|usual care|Usual recharge directly from hospital to home
1754824|NCT00235417|Procedure|Bone marrow transplantation|
1754825|NCT00235443|Drug|lacosamide|Open-label treatment (two times per day) with film-coated tablets include 100mg/day, 200mg/day, 300mg/day, 400mg/day, 500mg/day, and 600mg/day throughout individual study period.
1754826|NCT00235456|Procedure|Perioperative supplemental oxygen|Patients were assigned to 80% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
1754827|NCT00235456|Procedure|Standard oxygen|Patients were assigned to 30% fraction of inspired oxygen (FIO2) intraoperatively and for 6 hours after surgery. Anesthetic treatment and antibiotic administration were standardized.
1754830|NCT00235495|Biological|human serum albumin infusion|human albumin, 25%, 2.0g/kg intravenously (or equivalent volume of saline control), infused over 2 h, commencing within 5 hours of stroke onset
1754831|NCT00235495|Drug|placebo|equivalent volume of saline control
1754832|NCT00235508|Drug|Eszopiclone (Lunesta)|Escitalopram oxalate 10 mg at bedtime; Eszopiclone 3 mg at bedtime
1754833|NCT00235521|Drug|aerosolized iloprost|
1754834|NCT00235534|Behavioral|Immediate initiation of OCPs|
1754835|NCT00235534|Behavioral|Delayed initiation of OCPs|
1754836|NCT00235547|Behavioral|timing of initiation of transdermal patch after an abortion|the initiation of the patch after abortion is dictated by the study as opposed to offering several options (i.e. first Sunday of period). For this arm it is to place the patch in the clinic with clinic staff before leaving the clinic
1754837|NCT00235560|Drug|rapamycin|sirolimus
1754838|NCT00235573|Dietary Supplement|Vitamin B12|After taking a fasting blood sample, all subjects were given a light breakfast plus 9 micrograms of vitamin B12. Two more doses of vitamin B12, 9 micrograms each, were administered 6 hours apart.
1754839|NCT00235586|Procedure|10 vit. D deficient subjects take vit. D for 3 months.|
1754840|NCT00235599|Procedure|IGFBP-3 Stimulation Test|
1754841|NCT00235625|Drug|Curcuminoids C3 Complex®|
1754842|NCT00235651|Drug|Amphotericin B|
1754843|NCT00235664|Procedure|Collection of stool and endotracheal aspirate samples|collection of samples
1754844|NCT00235677|Procedure|Endoscopic gastroplication|
1754845|NCT00235690|Procedure|Blood draws|PK samples obtained around a clinical dosing of colistin
1754846|NCT00235690|Other|Blood draw|PK blood samples will be obtained around a clinical dosing of colistin
1754847|NCT00235703|Device|Antimicrobial Prescribing Decision Support|
1754848|NCT00235716|Drug|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
1754849|NCT00235716|Drug|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
1754850|NCT00235716|Drug|dl-alpha-tocopherol|"Alpha-tocopherol will be given as an oral dose of 1000 IU twice a day (morning and evening). The form of vitamin E that will be used in this study will be hard gel capsules of dl-alpha-tocopheryl acetate (synthetic) vitamin E."
1754851|NCT00235716|Drug|Memantine|A moderate-affinity NMDA antagonist. Memantine will be titrated over four weeks to a maintenance dose of 10 mg twice a day. During week 1 patients will take one 5-mg memantine tablet in the morning. During week 2 patients will take one 5-mg memantine tablet in the morning and one in the evening. During week 3 patients will take two 5-mg memantine tablets in the morning and one 5-mg tablet in the evening. Beginning with week 4, participants will take four 5-mg tablets daily, two in the morning and two in the evening.
1754852|NCT00235716|Drug|Placebo|Matching placebos for dl-alpha-tocopherol and memantine.
1754853|NCT00235729|Drug|Lofexidine|Lofexidine is an alpha2-adrenergic-agonist with mild to moderate antihypertensive actions. It is mainly used in the alleviation of opioid withdrawal signs and symptoms.
1754854|NCT00235729|Drug|Placebo|Placebo is an exact match of lofexidine, less the active ingredient.
1754855|NCT00235755|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 3, patients will enter a 12 week maintenance phase.
1754856|NCT00235755|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 5, patients will enter a 12 week maintenance phase.
1754857|NCT00235755|Drug|Placebo|Oral tablet.
1754858|NCT00235781|Drug|Thymoglobulin|
1754859|NCT00235794|Drug|temsirolimus|
1754860|NCT00235807|Procedure|Tinnitus Masking|Sound therapy with Tinnitus Masking is intended to produce immediate relief from the discomfort caused by tinnitus (Vernon, 1977; 1987; Vernon, 1988). If maskers or combination units are used, the masking sound can be set at any level the patient chooses to attain maximum relief. Relief using masking noise can be accomplished using the external sound of the masker, which is generally a more acceptable sound than the tinnitus.
1754861|NCT00235807|Procedure|Tinnitus Retraining Therapy (TRT)|The TRT procedure adheres as closely as possible to the methodology described by Dr. Pawel Jastreboff. For TRT, sound therapy is used to facilitate long-term habituation to tinnitus (Jastreboff, 1999b).
1754862|NCT00235807|Procedure|Tinnitus Education (TED)|TED represents tinnitus treatment that would typically be provided by audiologists using hearing aids and counseling (although for this study the counseling has been structured and expanded to be equivalent in length to the other two groups).
1754863|NCT00235820|Drug|adalimumab|40 mg every other week following an 80 mg dose
1754864|NCT00235820|Drug|MTX|MTX 7.5 to 25 mg once weekly
1754865|NCT00235820|Drug|placebo adalimumab, placebo MTX|placebo injections once every other week after 2 injections at Baseline (adalimumab) placebo capsules once weekly (MTX)
1754866|NCT00235833|Biological|adalimumab|40 mg every other week (eow), subcutaneous (sc)
1754867|NCT00235846|Procedure|vein harvest|Conventional open vein harvest or endoscopic vein harvest
1754868|NCT00235859|Drug|adalimumab|
1754869|NCT00235859|Drug|methotrexate|
1754870|NCT00235872|Biological|adalimumab|40 mg eow, sc
1754871|NCT00235885|Drug|adalimumab|
1754872|NCT00235898|Drug|CoFactor|
1754873|NCT00235898|Drug|5-FU|
1754874|NCT00235898|Drug|Leucovorin|
1754875|NCT00235911|Drug|budesonide/formoterol Turbuhaler|
1754876|NCT00235924|Drug|soy isoflavone|
1754877|NCT00235937|Drug|Anastrozole and goserelin|
1754878|NCT00235950|Drug|Rosuvastatin or atorvastatin or simvastatin and clopidogrel|
1754881|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c.(subcutaneous) every other day
1754882|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|250 mcg administered s.c. every other day (for patients having received 500 mcg before)
1754883|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day
1754884|NCT00235989|Drug|Interferon beta 1b (Betaseron, BAY86-5046)|500 mcg administered s.c. every other day (for patients having received 250 mcg before)
1754885|NCT00236002|Drug|Alendronate|Alendronate 70mgm once a week for one year
1754886|NCT00236015|Drug|Gabitril|
1754887|NCT00236028|Drug|Infliximab|
1754888|NCT00236041|Drug|ACTIQ®|
1754889|NCT00236054|Drug|Gabitril|
1754890|NCT00236067|Drug|Gabitril|
1754891|NCT00236080|Drug|PROVIGIL 200 mg|PROVIGIL 200 mg/day
1754892|NCT00236080|Drug|Armodafinil 250 mg|Armodafinil 250 mg/day
1754893|NCT00236080|Drug|Armodafinil 200 mg|Armodafinil 200 mg/day
1754894|NCT00236080|Drug|Armodafinil 150 mg|Armodafinil 150 mg/day
1754895|NCT00236080|Drug|Placebo|Matching placebo tablets
1754896|NCT00236093|Drug|ACTIQ (Oral Transmucosal Fentanyl Citrate [OTFC])|
1754897|NCT00236106|Drug|tacrolimus ointment 0.1%|
1754898|NCT00236106|Drug|mometasone furoate 0.1%|
1754899|NCT00236119|Drug|CEP-701 20mg|Dosages of oral CEP-701 20mg will be given twice daily. Escalation to the next higher dosage, CEP-701 40mg, may occur once the first 8 patients at the current dosage have completed 8 weeks of treatment without adverse events or laboratory abnormalities. Patients who remain in Cohort 1 will continue on the 20mg dosage until study completion.
1754900|NCT00236119|Drug|CEP-701 40mg|Dosages of oral CEP-701 40mg will be given twice daily.Escalation to the next higher dosage, CEP-701 60mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 2 will continue on the 40mg dosage until study completion.
1754901|NCT00236119|Drug|CEP-701 60mg|Dosages of oral CEP-701 60mg will be given twice daily. Escalation to the next higher dosage, CEP-701 80mg, may occur once 8 weeks of treatment at the current dosage is completed without adverse events or laboratory abnormalities. Patients who remain in Cohort 3 will continue on the 60mg dosage until study completion.
1754902|NCT00236119|Drug|CEP-701 80mg|Dosages of oral CEP-701 80mg will be given twice daily. Patients who have moved to Cohort 4 will continue on the 80mg dosage until study completion.
1754903|NCT00236145|Drug|ACTIQ (Oral transmucosal fentanyl citrate)|
1754904|NCT00236158|Device|AAIR/DDDR pacemaker|Pacemaker with single lead or dual lead
1754905|NCT00236171|Drug|Protopic, Advantan|
1754906|NCT00236171|Procedure|Blood and Urine Test|
1754907|NCT00236171|Procedure|coherence tomography|
1754908|NCT00236184|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
1754909|NCT00236184|Other|Placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
1754910|NCT00236197|Drug|rabeprazole sodium|Following a one week single-blind, placebo run-in phase, patients will receive rabeprazole 10 mg orally,placebo once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
1754911|NCT00236197|Drug|placebo|Following a one week single-blind, placebo run-in phase, patients will receive placebo orally, once daily, for 14 days during the double-blind, randomized treatment phase. This will be followed by a one week single-blind placebo follow-up phase.
1754912|NCT00236210|Behavioral|Action Score|Improvement in a novel 100-point score summarizing cardiovascular risk.
1754913|NCT00236210|Behavioral|VIP program|Risk assessment, lifestyle counselling, exercise program
1754914|NCT00236223|Drug|Gabapentin + dexamethasone + ketamine|Comparing analgesic effect of gabapentin 1200 mg + dexamethasone 8 mg + ketamine 0.15 mg/kg
1754915|NCT00236223|Drug|Placebo|Matching placebo
1754916|NCT00236236|Device|Cardiac Resynchronization Therapy|
1754917|NCT00236249|Drug|Lidocaine|
1754918|NCT00236262|Device|ventilatory strategies with pressure|
1754919|NCT00236275|Drug|Fluoro-L-thymidine-(18F)|Fluoro-L-thymidine-(18F)
1754920|NCT00236288|Drug|Bupropion and intensive behavioral therapy|To prescribe bupropion and behavioral therapy to patients and/or their families, who are currently receiving radiation.
1754921|NCT00236301|Drug|CLIMASTON (drug)|CLIMASTON(drug)
1754922|NCT00236301|Drug|17 Beta-estradiol (2mg/day)and (1mg/day)|17 Beta-estradiol (2mg/day)and (1mg/day)
1754923|NCT00236301|Drug|placebo|placebo
1754924|NCT00236327|Drug|fentanyl|
1754925|NCT00236340|Device|syringe aspiration|
1754926|NCT00236340|Device|Wall suction|
1754927|NCT00236353|Drug|risperidone|
1754928|NCT00236366|Drug|fentanyl|
1754929|NCT00236379|Drug|Olanzapine|Target oral dose of 20 milligrams per day for 6 months
1754930|NCT00236379|Drug|Risperidone|Target oral dose of 6 milligrams per day for for 6 months
1754931|NCT00236392|Drug|rabeprazole|
1754932|NCT00236405|Drug|epoetin alfa|
1754933|NCT00236418|Drug|topiramate|
1754934|NCT00236431|Drug|Galantamine hydrobromide|
1754935|NCT00236444|Drug|risperidone|
1754936|NCT00236457|Drug|risperidone|
1754937|NCT00236470|Drug|risperidone|
1754938|NCT00236483|Drug|tramadol hydrochloride + acetaminophen|
1754939|NCT00236496|Drug|topiramate|
1754940|NCT00236509|Drug|topiramate|
1754941|NCT00236522|Drug|levofloxacin|
1754942|NCT00236535|Drug|tramadol HCl + acetaminophen; hydrocodone bitartrate + acetaminophen; placebo|
1754943|NCT00236548|Drug|risperidone|
1754944|NCT00236561|Drug|topiramate, propranolol|
1754945|NCT00236574|Drug|Galantamine hydrobromide|
1754946|NCT00236587|Drug|risperidone|
1754947|NCT00236600|Drug|topiramate|
1754948|NCT00236613|Drug|topiramate|
1754956|NCT00236717|Drug|Topiramate; Carbamazepine; Valproate|
1754957|NCT00236730|Drug|topiramate|
1754958|NCT00236743|Drug|topiramate|
1754959|NCT00236756|Drug|topiramate|
1754960|NCT00236769|Drug|norelgestromin + ethinyl estradiol|
1754961|NCT00236782|Drug|norelgestromin + ethinyl estradiol; mercilon|
1754962|NCT00236795|Drug|norelgestromin + ethinyl estradiol; triphasil.|
1754963|NCT00236808|Drug|levofloxacin|
1754964|NCT00236821|Drug|levofloxacin|
1754965|NCT00236834|Drug|levofloxacin; imipenem/cilastitin|
1754966|NCT00236847|Drug|topiramate|
1754967|NCT00236860|Drug|topiramate|
1754968|NCT00236873|Drug|topiramate|
1754969|NCT00236886|Drug|topiramate|
1754970|NCT00228150|Drug|SR57667B|
1754971|NCT00228163|Drug|teriflunomide (HMR1726)|tablet, oral administration once daily.
1754972|NCT00228176|Drug|Rimonabant|Tablet, oral administration
1754973|NCT00228176|Drug|Placebo (for Rimonabant)|Tablet, oral administration
1754974|NCT00228189|Biological|CEA-loaded dendritic cell vaccine|Carcinoembryonic antigen (either peptide or mRNA) loaded dendritic cells.
1754975|NCT00228215|Behavioral|TIPS Intervention|A behavioral-educational sleep intervention and support from a nurse in the immediate postpartum
1754976|NCT00228228|Biological|T cell vaccination|
1754977|NCT00228241|Device|AAI vs. DDD vs. BIV pacing in different patients groups|
1754978|NCT00228254|Drug|Zinc (12.5 mg/day)|
1754979|NCT00228254|Drug|vitamin A 10,000 IU per week|
1754980|NCT00228267|Drug|Propofol|
1754981|NCT00236899|Drug|Gemcitabine|"Arm A: 1000 mg/m², 30 minute (min) intravenous (IV) infusion on Days 1 and 8, repeated every 21 days for 10 cycles for complete responders (CRs=disappearance of all target lesions) or partial responders (PRs≥30% decrease in sum of longest diameter of target lesions); 6 cycles for stable disease (SD=small changes that do not meet the above criteria); or until progressive disease (PD≥20% increase in sum of longest diameter of target lesions).
Arm B: 1250 mg/m², 30 min IV infusion on Days 1 and 8, repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Arm C: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 21 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Arm D: 800 mg/m², 30 min IV infusion on Days 1, 8, and 15 repeated every 28 days for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
1754982|NCT00236899|Drug|Docetaxel|"Arm A: 75 milligram per square meter (mg/m²), 60 min IV infusion on Day 1 only, to be given 30 min prior to Gemcitabine, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Arm C: 30 mg/m², 30-60 min IV infusion on Days 1, 8, and 15, to be given 30 min prior to Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
1754983|NCT00236899|Drug|Paclitaxel|"Arm B: 175 mg/m², IV infusion over approximately 3 hours, followed by Gemcitabine, on Day 1, repeated every 21 days (tri-weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD.
Arm D: 80 mg/m², IV infusion over approximately 1 hour, Days 1, 8, and 15, followed by Gemcitabine, repeated every 28 days (weekly) for 10 cycles for CRs or PRs; 6 cycles for SD; or until PD."
1754984|NCT00236912|Drug|levofloxacin; metronidazole|
1754985|NCT00236925|Drug|Low dose Hydrocortisone|Hydrocortisone 10 mg daily
1754986|NCT00236925|Drug|Placebo|Placebo
1754987|NCT00236938|Drug|Venofer and stable erythropoietin (EPO) regimen|Fixed dose of erythropoietin (EPO) and Venofer (300mg) administered intravenous infusion over 1.5 hours on Days 1 and 15, and Venofer (400mg) administered intravenous infusion over 2.5 hours on Day 29.
1754988|NCT00236938|Drug|stable erythropoietin (EPO) regimen|Stable erythropoietin (EPO) dose and no supplemental iron.
1754989|NCT00236951|Drug|iron sucrose injection USP|
1754990|NCT00236951|Drug|stable erythropoietin therapy|
1754991|NCT00236964|Drug|Iron Sucrose + Erythropoietin|
1754992|NCT00236964|Drug|Ferrous Sulfate + Erythropoietin|
1754993|NCT00236977|Drug|Venofer|iron sucrose injection; 500 mg intravenous (IV) infusion administered over 3.5-4 hours on Days 0 and 14, or 200 mg injections administered over 2-5 minutes on 5 different occasions from Day 0 to Day 14.
1754994|NCT00236977|Drug|Ferrous Sulfate|oral iron tablets; 325 mg three times a day orally for 56 days
1754995|NCT00236990|Drug|pentosan polysulfate sodium|
1754996|NCT00237003|Behavioral|motivational interviewing|Assessment plus motivational interview condition -- two motivational interview sessions are conducted during the first month of this six month study participation.
1754997|NCT00237016|Drug|doxycycline treatment|
1754998|NCT00237042|Behavioral|Self Management|Two 1.5-hour in-person sessions and 6 10-15-minute telephone calls delivered by a dental hygienist, trained and supervised by a clinical psychologist. Structured, manual-based treatment based on standard cognitive-behavioral pain therapies and self-management interventions for chronic TMD pain. Sessions included education about the biopsychosocial model of chronic pain, TMD etiology and treatments, and the rationale for self-management; relaxation and stress management training; discussion of the role of stress and emotions as potential factors exacerbating and maintaining TMD symptoms; instruction and practice in self-monitoring of symptoms to identify factors that might be helpful to modify through self-care methods; practice of dentist-prescribed self-care treatments; and discussion of strategies to maintain gains and prevent relapse.
1754999|NCT00237042|Behavioral|Targeted Self Management|Self management as described above. However, the intervention also included education about the potential effects of hormones on TMD pain, instructions to monitor the association of pain and other symptoms with menstrual cycle changes, and planning for times in participants' menstrual cycles when symptoms might increase. Participant contacts were timed according to each participant's menstrual cycle.
1755000|NCT00237042|Drug|20 mcg ethinyl estradiol and 100 mcg levonorgestrel|Combination pill (20 mcg ethinyl estradiol and 100 mcg levonorgestrel) taken daily for 6 months.
1755001|NCT00237068|Drug|Lansoprazole; Solutab|15 and 30 mg doses of dissolvable tablet, 2 tablets daily for one year
1755002|NCT00237094|Behavioral|Nurse Practitioner led multidisciplinary team approach|
1755003|NCT00237107|Procedure|Curretage|
1755004|NCT00237120|Drug|Imatinib|
1755005|NCT00237133|Drug|Letrozole|1 tablet of Letrozole 2.5 mg orally adminnistered once a day
1755006|NCT00237146|Drug|Zoledronic acid|
1755007|NCT00237159|Drug|Zoledronic acid|
1755008|NCT00237172|Drug|Imatinib Mesylate|once daily
1755009|NCT00237185|Drug|Imatinib mesylate|Participants were randomized 1:1 to receive imatinib mesylate 400 mg/day or 600 mg/day. Upon unsatisfactory treatment effect on the starting dose of 400 mg/day or 600 mg/day imatinib mesylate, in the opinion of the treating physician, a dose increase up to 600 mg/day or 800 mg/day, was allowed provided that the participant continued to benefit from the treatment and in the absence of safety concerns.
1755010|NCT00237198|Drug|Letrozole|
1755011|NCT00237211|Drug|Letrozole|
1755012|NCT00237224|Drug|Letrozole|
1755013|NCT00237237|Drug|vildagliptin|
1755014|NCT00237328|Drug|Heparin|Heparin will be used as the intra-operative anticoagulant
1755015|NCT00237341|Drug|fentanyl|
1755016|NCT00237354|Drug|PV-10 (rose bengal disodium 10%)|PV-10 ablation of study lesion
1755017|NCT00237367|Drug|rabeprazole and pantoprazole|
1755018|NCT00237380|Drug|PTC124|
1755019|NCT00237393|Drug|Quetiapine|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
1755020|NCT00237393|Drug|Placebo|Dosage initiated at 25 mg HS with gradual titration to target dose of 400 mg HS, up to maximum of 800 mg HS.
1755021|NCT00237406|Procedure|interactive voice response|
1755022|NCT00237419|Drug|infliximab|Infliximab infusions 5 mg/kg body-weight each 6 to 8 weeks
1755023|NCT00237445|Drug|telithromycin|
1755024|NCT00237445|Drug|azithromycin|
1755025|NCT00237458|Drug|Lacosamide|"Dosage: Lacosamide up to 400 mg/day;
Dosage form: Film-coated tablets;
Dosage Frequency and Duration: Two times per day; 9.5 years"
1755026|NCT00237471|Drug|Insulin (tight blood glucose control)|
1755027|NCT00237484|Drug|Induction dose of (a) infliximab followed by combination of (b) pegylated interferon alfa-2b and (c) ribavirin|"Powder for intravenous infusion (100 mg strength), intravenous, single dose of 5 mg/kg, at Day -7, prior to initiation of the following combination therapy:
powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
1755028|NCT00237484|Drug|Combination of (a) pegylated interferon alfa-2b and (b) ribavirin|"Powder for injection in vials or Redipen (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
200 mg capsules, oral, dose of 800-1400 mg (weight based dosing as per PEGETRON Product Monograph), daily for up to 48 weeks"
1755029|NCT00237497|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 28 nights.
1755030|NCT00237497|Drug|Zopiclone|Zopiclone 7.5 mg, tablets, orally, once daily for up to 28 nights.
1755031|NCT00237497|Drug|Placebo|Placebo-matching tablets, orally, once daily for up to 28 nights.
1755032|NCT00237510|Drug|terazosin|
1755033|NCT00237523|Drug|IoGen (molecular iodine)|
1755034|NCT00237536|Drug|Lonidamine|
1755035|NCT00237549|Procedure|optimised treatment|"The intervention targeted individual patients and the Primary Care Team. Practitioners were trained in a target driven, intensive multifactorial approach including lifestyle advice (smoking cessation, physical activity 30 min./day and healthy diet) and pharmacological treatment with the aim of reducing the complications of diabetes as described in protocol.
The training included meetings, practice visiting, written feed back reports and reminders on controls."
1755036|NCT00237562|Procedure|Large loop electrosurgical excision|
1755037|NCT00237575|Drug|gemcitabine|
1755038|NCT00237575|Drug|cisplatin|
1755039|NCT00237575|Drug|sargramostim|
1755040|NCT00237575|Drug|filgrastim|
1755041|NCT00237588|Drug|Amlodipine 10 mg or Losartan 100 mg + Amlodipine 5 mg|
1755042|NCT00237601|Other|obstetric care|
1755043|NCT00237614|Drug|intravenous and oral N-acetylcysteine|
1755044|NCT00237627|Drug|PS-341|PS-341 will be administered as an intravenous push into a side arm of either a peripheral or central intravenous line infusing normal saline at 100 ml/hr. Patients will be treated twice weekly for two weeks, followed by a one week rest period, such that the typical days of treatment will be days 1, 4, 8, 11 of each three-week cycle. The initial dose level for PS-341 will be 0.9 mg/m2/dose intravenously, while subsequent dose levels will be determined according to a modified Fibonacci schema
1755045|NCT00237627|Drug|Doxil|Doxil will be administered at a dose of 30 mg/m2 as a 1 hour infusion through either a peripheral or central intravenous line every 3 weeks (on day 4 of each 21 day cycle)
1755046|NCT00237627|Drug|Velcade|Velcade will be adminstered intravenously at 1.3 mg/m2 days 1, 4, 8, 11 every 3 weeks
1755047|NCT00237640|Drug|Cinnamon or placebo 500 mg capsule twice daily|Cinnamon 500 mg capsule twice daily or placebo capsule twice daily
1755048|NCT00237653|Drug|Valganciclovir|
1755049|NCT00237666|Drug|Ziprasidone|Ziprasidone 20-60 mg BID, taken orally.
1755050|NCT00237679|Behavioral|Neuromuscular Electrical Stimulation|Through low voltage current delivered through the skin, motor nerves are excited, causing muscle contraction.
1755051|NCT00237679|Behavioral|Unstimulated|No current is generated.
1755052|NCT00237692|Behavioral|Nurse Behavioral intervention with Home BP Telemonitoring|Nurse-administered behavior intervention
1755053|NCT00237692|Behavioral|Nurse Medication Management with Home BP Telemonitoring|Nurse administer medication management according to hypertension decision support
1755054|NCT00237692|Behavioral|Nurse Combined intervention with Home BP Telemonitoring|Combination of the nurse administered tailored behavioral & medication management
1755055|NCT00237705|Drug|metoclopramide|
1755056|NCT00237718|Drug|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 6 months
1755057|NCT00237718|Drug|Alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 6 months
1755058|NCT00237718|Drug|Placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 6 months
1755059|NCT00237718|Drug|Placebo|placebo for alpha lipoic acid; 2 pills daily for 6 months
1755060|NCT00237731|Drug|morphine|morphine 0.05
1755061|NCT00237731|Drug|morphine|morphine 0.10
1755062|NCT00237744|Device|Robotics training for shoulder elbow.|training utilizing a robot to assist with movement practice
1755063|NCT00237744|Device|Surface Functional Neuromuscular Stimulation|training utilizing FNS to assist with movement practice
1755064|NCT00237744|Other|whole arm motor learning|intervention utilizing motor learning training principles to perform part and whole task practice of meaningful everyday functional tasks.
1755065|NCT00237757|Behavioral|Information feedback|The experimental arm consisted of a six month staff training period. The core of the intervention consisted of a concentrated 2.5 day workshop in Atlanta for 29 rehabilitation team leaders from 15 VA hospitals. Several weeks after the workshop, participants received a custom action plan developed on issues discussed in the workshop. The experimental arm also received a summary of results of the initial survey along with comparative data from all other sites. During the subsequent 5 months after the workshop, research staff maintained regular contact with research participants through telephone and videoconferencing. The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes.
1755066|NCT00237757|Behavioral|Information feedback|The comparison arm (staff on 16 teams) completed the identical summary of staff, hospital, and team characteristics. The local PIs at the Comparison sites received summaries of the survey findings, comparative data from other participating VA sites, and suggestions on how this information could be used to improve patient outcomes. In addition, participants in the comparison arm were invited to contact the research staff for help in interpreting data or to set-up a process improvement initiative.
1755067|NCT00237770|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
1755068|NCT00237770|Procedure|Head-up Tilt maneuver|Participant will be placed onto tilt table and brought to 15 degrees of head up tilt for 60 minutes (intravenous infusion time). After this time, a progressive increase to 45 degrees will be completed with a 10 degree increase every 5 minutes. Participant will remain at 45 degrees for 45 minutes or until symptom onset.
1755069|NCT00237783|Drug|dialysate sodium (140 mmol/L)|
1755070|NCT00237783|Drug|individualized dialysate sodium|individualized dialysate sodium (same concentration as the average pre-HD serum sodium during the baseline period)
1755071|NCT00237796|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|Thought challenging, social communication skills, and problem solving skills are trained in group therapy 2 hours per week for 9 months.
1755072|NCT00237796|Behavioral|Goal Focused Supportive Contact (GFSC)|Active goal setting and supportive contact in group therapy 2 hours per week for 9 months.
1755073|NCT00237809|Drug|D-serine|D-serine (30 mg/kg)
1755074|NCT00237809|Behavioral|Cognitive Retraining (CRT)|Cognitive retraining therapy (CRT)
1755075|NCT00237809|Drug|Placebo|Placebo D-serine Drug
1755076|NCT00237809|Behavioral|Cognitive Retraining Placebo|Cognitive retraining therapy (CRT) control
1755080|NCT00237848|Drug|D-serine|
1755081|NCT00237848|Behavioral|Cognitive retraining|
1755082|NCT00237861|Drug|risperidone|
1755083|NCT00237861|Drug|olanzapine|
1755084|NCT00237861|Drug|quetiapine|
1755085|NCT00237874|Drug|Aripiprazole|
1755086|NCT00237887|Drug|adalimumab|
1755087|NCT00237900|Drug|Gefitinib, 5-fluorouracil, leucovorin and radiotherapy|
1755088|NCT00237913|Drug|Aripiprazole|Tablets, Oral, 10 - 30 mg, Once daily, 26 weeks.
1755089|NCT00237913|Drug|Olanzapine or Quetiapine or Risperidone|Olanzapine: Tablets, Oral, 5-20 mg, Once daily, 26 weeks. OR Quetiapine: Tablets, Oral, 100-800 mg, Once daily, 26 weeks. OR Risperidone: Tablets, Oral, 2-8 mg, Once daily, 26 weeks.
1755090|NCT00237926|Behavioral|Exercise|aerobic or resistance training
1755091|NCT00237939|Drug|Aripiprazole|
1755092|NCT00237952|Drug|EDTA chelating agents|
1755093|NCT00237965|Behavioral|Mole Mapping Diagram|
1755094|NCT00237978|Drug|Adapalen|
1755095|NCT00237978|Radiation|VIS and wIRA|
1755096|NCT00237991|Biological|Hepatitis A|
1755097|NCT00238004|Drug|Nicotinic acid|
1755098|NCT00238017|Drug|amodiaquine-artesunate versus amodiaquine|
1755099|NCT00238030|Drug|L-thryoxine|2 mcg/kg iv or 2 mcg/kg po at time of enrollment
1755100|NCT00238030|Drug|iv thryoxine|thyroxine 2 mcg/kg iv
1755101|NCT00238043|Drug|Biogeneric Epoetin|
1755102|NCT00238056|Drug|domperidone Drug|
1755103|NCT00238069|Device|CPAP machine as a result of sleep study|
1755104|NCT00238082|Drug|HFA-134A Beclomethasone DIpropionate (QVAR)|
1755105|NCT00238108|Drug|Melatonin|2,5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
1755106|NCT00238108|Drug|Placebo|Placebo
1755107|NCT00238121|Drug|sorafenib tosylate|Given orally
1755108|NCT00238147|Drug|capecitabine|
1755109|NCT00238147|Drug|carboplatin|
1755110|NCT00238147|Drug|docetaxel|
1755111|NCT00238147|Procedure|conventional surgery|
1755112|NCT00238147|Procedure|neoadjuvant therapy|
1755113|NCT00238147|Radiation|radiation therapy|
1755114|NCT00238160|Drug|cisplatin|
1755115|NCT00238160|Drug|fluorouracil|
1755116|NCT00238160|Procedure|adjuvant therapy|
1755117|NCT00238160|Procedure|chemotherapy|
1755118|NCT00238160|Procedure|conventional surgery|
1755119|NCT00238160|Procedure|hepatic arterial infusion|
1755120|NCT00238160|Procedure|surgery|
1755121|NCT00238173|Biological|filgrastim|
1755122|NCT00238173|Drug|acetylcysteine|administered i.v. over 30 to 60 minutes
1755123|NCT00238173|Drug|carboplatin|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.a. over 10 minutes, in 50-180 cc of normal saline.
1755124|NCT00238173|Drug|cyclophosphamide|(330 mg/m2/day; total dose 660 mg/m2) will be infused i.v. in 25-50 cc of normal saline, over approximately 10 minutes.
1755125|NCT00238173|Drug|etoposide phosphate|(200 mg/m2/day; total dose 400 mg/m2) will be infused i.v. in 25-100 cc of normal saline, over approximately 10 minutes, immediately following the cyclophosphamide.
1755268|NCT00239278|Drug|budesonide/formoterol, 2x 200/6 microgram. 4 times daily|
1755269|NCT00239278|Drug|prednisolone, 30 mg once daily and placebo|
1755126|NCT00238173|Drug|mannitol|(25%) delivered i.a. at a pre-determined flow rate over 30 seconds. The flow rate will be determined by iodinated contrast injection and fluoroscopy as the lowest infusion rate in which there is retrograde flow from the arterial catheter. The rate and volume of mannitol infused will be approximately 4-12 cc/sec x 30 seconds.
1755127|NCT00238173|Drug|sodium thiosulfate|STS is available as a 25% (250 mg/ml) solution. The dose of STS administered 4 hours after carboplatin is 16 gm/m2. The dose of STS administered 8 hours after carboplatin is 16 gm/m2. Actual dose to be administered will be determined and mixed with an equivalent amount of sterile water (1 ml:1 ml) for infusion.
1755128|NCT00238199|Dietary Supplement|calcitriol|
1755129|NCT00238199|Drug|docetaxel|
1755130|NCT00238212|Drug|sorafenib tosylate|Given orally
1755131|NCT00238212|Other|laboratory biomarker analysis|Correlative studies
1755132|NCT00238225|Dietary Supplement|calcitriol|
1755133|NCT00238225|Drug|dexamethasone|
1755134|NCT00238225|Drug|ketoconazole|
1755135|NCT00238238|Biological|rituximab|Given IV
1755136|NCT00238238|Drug|lenalidomide|Given orally
1755137|NCT00238251|Drug|gefitinib|Once daily during days 1-28
1755138|NCT00238251|Drug|temozolomide|Once daily on days 1-21
1755139|NCT00238251|Radiation|radiation therapy|Whole brain radiotherapy
1755140|NCT00238264|Radiation|radiation therapy|Undergo 3D-CRT Undergo proton radiation therapy Undergo IMRT
1755141|NCT00238277|Drug|temozolomide|
1755142|NCT00238277|Procedure|adjuvant therapy|
1755143|NCT00238277|Procedure|chemotherapy|
1755144|NCT00238277|Procedure|radiation therapy|
1755145|NCT00238290|Drug|Trastuzumab + Letrozole|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes once in weeks 1-3 OR once in week 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity. Patients experiencing disease progression after 9 weeks receive trastuzumab as before and oral letrozole once daily in the absence of further disease progression or unacceptable toxicity.
1755146|NCT00238303|Drug|vorinostat|Given orally
1755147|NCT00238303|Procedure|conventional surgery|Patients undergo surgery to remove tumor
1755148|NCT00238316|Drug|letrozole|2.5 mg PO daily for 1 year
1755149|NCT00238316|Other|Placebo|2.5 mg PO daily for one 1 year
1755150|NCT00238329|Biological|PEG-interferon alfa-2b|
1755151|NCT00238329|Drug|thalidomide|
1755152|NCT00238342|Genetic|proteomic profiling|
1755153|NCT00238342|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
1755154|NCT00238342|Procedure|biopsy|
1755155|NCT00238355|Drug|caspofungin acetate|70 mg iv x 1 on day 1 (loading dose), followed by 50 mg iv daily on day 2 through day 84.
1755156|NCT00238355|Drug|voriconazole|6mg/kg iv q12 hours x 2 doses OR 400mg po q12hours on day 1 (loading doses. Maintenance doses on day 2 through day 84 may be either 4 mg/kg iv q12 hours, or 200 mg po q12 hours (at least one hour before or after meals).
1755157|NCT00238368|Biological|filgrastim|
1755158|NCT00238368|Biological|rituximab|
1755159|NCT00238368|Drug|busulfan|
1755160|NCT00238368|Drug|cisplatin|
1755161|NCT00238368|Drug|cyclophosphamide|
1755162|NCT00238368|Drug|cytarabine|
1755163|NCT00238368|Drug|doxorubicin hydrochloride|
1755164|NCT00238368|Drug|etoposide|
1755165|NCT00238368|Drug|methylprednisolone|
1755166|NCT00238368|Drug|prednisone|
1755167|NCT00238368|Drug|vincristine sulfate|
1755168|NCT00238368|Procedure|autologous bone marrow transplantation|
1755169|NCT00238368|Procedure|peripheral blood stem cell transplantation|
1755170|NCT00238368|Procedure|positron emission tomography|
1755171|NCT00238368|Radiation|fludeoxyglucose F 18|
1755172|NCT00238368|Radiation|radiation therapy|
1755173|NCT00238381|Procedure|5 cm colon-J-pouch|5 cm colon-J-pouch with/without temporary protective ileostomy
1755174|NCT00238381|Procedure|side-to-end anastomosis|side-to-end anastomosis with/without temporary protective ileostomy
1755175|NCT00238381|Procedure|straight coloanal anastomosis|straight coloanal anastomosis with/without temporary protective ileostomy
1755176|NCT00238394|Drug|cediranib maleate|Given orally
1755177|NCT00238394|Other|laboratory biomarker analysis|Correlative studies
1755178|NCT00238407|Drug|Docetaxel and Cisplatin|Patients receive docetaxel IV over 30-60 minutes and cisplatin IV over 1 hour on days 1, 22, 43, 50, 57, 64, and 71.
1755179|NCT00238407|Radiation|Radiotherapy|Beginning on day 43 (week 7) of chemotherapy, patients undergo radiotherapy once daily, 5 days a week, for 7 weeks.
1755180|NCT00238420|Drug|Paclitaxel|50 mg/m2 intravenously on days 1, 8, 15, 22, 29, 36, and 43 of radiation therapy
1755181|NCT00238420|Biological|Trastuzumab|Intravenously 4 mg/kg on day 1 of radiation therapy, then 2 mg/kg on days 8, 15, 22, 29, 36, and 43 of radiation therapy.
1755182|NCT00238420|Radiation|Radiation Therapy|Once daily fractions of 1.8 Gy to small pelvic fields 5 days per week for 22 fractions, then once daily fractions of 1.8 Gy to reduced fields 5 days per week for 8 fractions, for a total of 64.8 Gy in 36 fractions.
1956678|NCT02748122|Device|MMT 723|Subjects will have the insulin pump inserted. With the aid of a small needle, the catheter (tube) of the insulin pump will be inserted through the skin into fatty tissue and will be taped in place. The subject will be required to wear the pump for three (3) months.
1755189|NCT00238446|Drug|EC-MPS|
1755270|NCT00239291|Drug|Gefitinib, radiotherapy|
1755271|NCT00239304|Drug|Gefitinib|
1755272|NCT00239304|Drug|Cisplatin|
1755190|NCT00238459|Drug|Patients elected to take licensed drugs. The vaccine was not provided for evaluation|Note:In August 2007 we were notified by the manufacturer that the experimental vaccine was no longer being made and would no longer be available for this study. Too few participants have received the vaccine or placebo to conclude anything about potential efficacy
1755191|NCT00238459|Drug|multiple licensed drugs not randomized|
1755192|NCT00238459|Drug|multiple licensed antiretroviral drugs; not randomized|
1755193|NCT00238459|Other|Intended vaccine not provided, Licensed drugs provided, but were not investigated|
1755194|NCT00238472|Drug|nateglinide|
1755195|NCT00238485|Drug|Licarbazepine|
1755196|NCT00238498|Drug|vildagliptin|
1755197|NCT00238511|Drug|SPM 927|
1755198|NCT00238524|Drug|SPM 927|
1755199|NCT00238537|Drug|Alteplase t-PA|
1755200|NCT00238550|Drug|Cannabis based medicine extract (CBME)|
1755201|NCT00238563|Drug|Triamcinolone injection, sub-tenon|
1755202|NCT00238602|Procedure|Stereotactic radiosurgery|
1755203|NCT00238615|Drug|Docetaxel|20 mg/m2, 75 mg/m2 infusion
1755204|NCT00238615|Drug|Carboplatin|AUC of 2 and 6 infusion
1755205|NCT00238615|Procedure|Radiation therapy|NEOADJUVANT RADIOTHERAPY Radiation therapy will be concurrent with the chemotherapy. Radiation therapy will begin within 24 hours of chemotherapy. CONSOLIDATION RADIOTHERAPY Patients with positive surgical margins or incomplete resection (tumor shaved from spine or great vessels) will receive an additional boost of radiotherapy 3 to 6 weeks after surgery. This will be a 16 Gy boost given with concurrent weekly chemotherapy as during the neoadjuvant period.
1755206|NCT00238615|Procedure|Surgical resection|All patients will be taken to surgical excision, unless they have developed a condition other than progressive disease, which would make surgery unsafe.
1755207|NCT00238628|Drug|Bexarotene|
1755208|NCT00238628|Drug|Iressa|
1755209|NCT00238641|Drug|Botulinum Toxin type B|
1755210|NCT00238667|Drug|Antiplatelet (Aspirin, Dipyridamole, clopidogrel)|
1755211|NCT00238667|Drug|Anticoagulant (Unfractionated Heparin, LMW Heparin, Warfarin)|
1755212|NCT00238680|Behavioral|Bladder rehabilitation|
1755213|NCT00238680|Behavioral|Bladder rehabilitation with programmable timer|
1755214|NCT00238706|Device|Radiofrequency ablation|
1755215|NCT00238719|Drug|Venlafaxine ER|
1755216|NCT00238732|Drug|Bazedoxifene/Conjugated Estrogen|
1755217|NCT00238745|Drug|Bazedoxifene|
1755218|NCT00238745|Drug|Placebo|
1755219|NCT00238758|Drug|Omega-3 Polyunsaturated Fatty Acids|
1755220|NCT00238784|Drug|Budesonide/formoterol Turbuhaler|
1755221|NCT00238797|Drug|Gefitinib|
1755222|NCT00238836|Behavioral|Self-management of chronic illness|
1755223|NCT00238849|Drug|Oxaliplatin|
1755224|NCT00238862|Procedure|Amniotic membrane transplantation|
1755225|NCT00238862|Drug|Autologous serum/BSS 20%|
1755226|NCT00238875|Procedure|stereotactic body radiation therapy|Procedure/Surgery: stereotactic body radiation therapy
1755227|NCT00238888|Procedure|asthma control awareness|Repeated assessments of the child's asthma control using the Asthma Quiz for Kidz, with recommendation for asthma education and medical visit
1755228|NCT00238888|Procedure|Usual care|Recommendation for asthma education and/or follow-up at the physician's discretion
1755229|NCT00238901|Drug|Basiliximab|
1755230|NCT00238914|Drug|Naltrexone|50mg of oral naltrexone daily
1755231|NCT00238914|Behavioral|Behavioral Naltrexone Therapy (BNT)|a hybrid of Relapse Prevention, the Community Reinforcement Approach, and Network Therapy
1755232|NCT00238914|Behavioral|Compliance Enhancement (CE)|a controlled therapy intended to simulate outpatient psychiatric care.
1755233|NCT00238927|Drug|inhaled fluticasone 750 mcg/day twice daily until 2 days without symptoms (maximum 15 consecutive days)|
1755234|NCT00238940|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1755235|NCT00238953|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1755236|NCT00238966|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1755237|NCT00238979|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1755238|NCT00238992|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
1755239|NCT00239005|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1755240|NCT00239005|Drug|Mycophenolate Mofetil (MMF)|
1755241|NCT00239018|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1755242|NCT00239031|Drug|Enteric-Coated Mycophenolate Sodium|Enteric-Coated Mycophenolate Sodium
1755243|NCT00239044|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
1755244|NCT00239057|Drug|Enteric-Coated Mycophenolate Sodium|
1755245|NCT00239070|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1755246|NCT00239083|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1755247|NCT00239096|Drug|losartan (drug)|
1755248|NCT00239109|Drug|Ziprasidone|
1755249|NCT00239109|Drug|Olanzapine|
1755250|NCT00239109|Procedure|Scales|
1755251|NCT00239109|Procedure|measures of the body (Weight...)|
1755252|NCT00239109|Procedure|Serum analysis|
1755253|NCT00239122|Behavioral|Recovery Therapy (Cognitive Behaviour Therapy for psychosis)|
1755254|NCT00239135|Drug|PEP005|
1755255|NCT00239148|Drug|E1 and G1|
1755256|NCT00239161|Drug|Levofloxacin|
1755257|NCT00239174|Drug|SR147778|
1755258|NCT00239187|Drug|E1 and G1|
1755259|NCT00239200|Drug|Lapatinib|
1755260|NCT00239213|Drug|catechin extracts (health food)|
1755261|NCT00239226|Procedure|IAS pacing - study group|site of implant and permanent pacing
1755262|NCT00239226|Procedure|IAS pacing control group|site of implant and permanent pacing
1755263|NCT00239226|Procedure|Pacing RAA study group|site of implant and permanent pacing
1755264|NCT00239226|Procedure|Pacing RAA control group|site of implant and permanent pacing
1755265|NCT00239239|Drug|Darbepoetin alfa|darbepoetin alfa SC dosing 0.45 mcg/kg 3 times per week through study day 40. Optional extended treatment period: 200 mcg Q2W through study day 110
1755266|NCT00239252|Drug|Interferon alfacon-1|
1755278|NCT00239356|Drug|Aripiprazole|Tablets, Oral, 10 - 30 mg, once daily, greater than 52 weeks depending upon Aripiprazole approval in respective country
1755279|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 25 mg|
1755280|NCT00239369|Drug|Fixed dose combination telmisartan 80 mg + HCTZ 12.5 mg|
1755281|NCT00239382|Drug|Meloxicam ampoule|
1755282|NCT00239382|Drug|Meloxicam tablet|
1755283|NCT00239395|Drug|Meloxicam ampoule|
1755284|NCT00239395|Drug|Meloxicam tablet|
1755285|NCT00239408|Device|Pulmonary function Testing|
1755286|NCT00239408|Drug|tiotropium bromide|
1755287|NCT00239421|Drug|Test: Tiotropium 18 µg per day (one inhalation capsule) plus 12 µg formoterol twice daily (two times one inhalation capsule)|
1755288|NCT00239421|Drug|Reference: Salmeterol MDI 50 µg (2 puffs of 25 µg each) b.i.d., plus fluticasone propionate MDI 500 µg (2 puffs of 250 µg each) b.i.d.|
1755289|NCT00239434|Drug|tiotropium inhalation powder capsule|
1755290|NCT00239434|Drug|ipratropium bromide Metered Dose Inhaler|
1755291|NCT00239447|Drug|Tiotropium|
1755292|NCT00239447|Device|HandiHaler|
1755293|NCT00239447|Device|Respimat SMI|
1755294|NCT00239460|Drug|Tiotropium|
1755295|NCT00239473|Device|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
1755296|NCT00239473|Device|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
1755297|NCT00239486|Drug|Pramipexole|
1755298|NCT00239499|Drug|Tiotropium|
1755299|NCT00239499|Drug|Salmeterol plus Fluticasone|
1755300|NCT00239512|Drug|Indomethacin and Ibuprofen|
1755301|NCT00239525|Device|3-D ultrasound scanner|The availability of color flow Doppler combined with effective ultrasound contrast agents in transcranial sonography serves as a low cost, bedside method for evaluation and management of patients with cerebrovascular disease in spite of the image degrading properties of the skull.
1755302|NCT00239525|Drug|Perflutren Protein-Type A Microspheres for injection|Activated DEFINITY® (Perflutren Lipid Microsphere) Injectable Suspension is indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border.Bolus: The recommended dose for activated DEFINITY® is 10 microliters (μL)/kg of the activated product by intravenous bolus injection within 30-60 seconds, followed by a 10 mL saline flush. If necessary, a second 10 microliters (μL)/kg dose followed by a second 10 mL saline flush may be administered 30 minutes after the first injection to prolong contrast enhancement. Infusion: The recommended dose for activated DEFINITY® is via an IV infusion of 1.3 mL added to 50 mL of preservative-free saline. The rate of infusion should be initiated at 4.0 mL/minute, but titrated as necessary to achieve optimal image enhancement, not to exceed 10 mL/minute.
1755303|NCT00239538|Drug|telmisartan combined with hydrochlorothiazide (80/12.5 mg)|
1755304|NCT00239538|Drug|valsartan combined with hydrochlorothiazide (160/12.5mg)|
1755305|NCT00239551|Drug|Prevacid|Effect of Prevacid on prostaglandin levels at 8 weeks; EGD (esophagogastroduodenal endoscopy) with biopsy at day 1 & EGD with biopsy at 8 weeks
1755306|NCT00239564|Drug|IPX054 100 mg|IPX054 containing 25 mg carbidopa and 100 mg levodopa
1755307|NCT00239564|Drug|IPX054 150 mg|IPX054 containing 37.5 mg carbidopa and 150 mg levodopa
1755308|NCT00239564|Drug|IPX054 200 mg|CD-LD CR containing 50 mg carbidopa and 200 mg levodopa
1755309|NCT00239564|Drug|IPX054 250 mg|CD-LD CR containing 62.5 mg carbidopa and 250 mg levodopa
1755310|NCT00239564|Drug|IPX054 300 mg|CD-LD CR containing 75 mg carbidopa and 300 mg levodopa
1755312|NCT00239590|Drug|Testosterone undecanoate|
1755313|NCT00239603|Device|OV-Watch|
1755314|NCT00239616|Drug|iron sucrose injection USP|
1755315|NCT00239629|Drug|Teriparatide|
1755316|NCT00239629|Drug|Strontium ranelate|
1755317|NCT00239629|Procedure|Transiliac bone biopsy|
1755318|NCT00239642|Drug|Venofer (iron sucrose injection)|0.5 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
1755319|NCT00239642|Drug|Venofer (iron sucrose injection)|1.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
1755320|NCT00239642|Drug|Venofer (iron sucrose injection)|2.0 mg/kg of Venofer (iron sucrose) up to 100 mg administered intravenously
1755321|NCT00239655|Drug|MK0812|
1755322|NCT00239681|Drug|Rosuvastatin|Oral
1755323|NCT00239681|Other|Placebo|Oral
1755326|NCT00239707|Drug|GIP|One-time 20 ng/kg/min infusion over 3 hours
1755327|NCT00239707|Drug|Modified GIP|One-time infusion over 3 hours; dose to maintain desired biological effect of below 140 mg/dl
1755328|NCT00239707|Drug|Normal Saline|one-time infusion over 3 hours
1755329|NCT00239720|Drug|hOKT3gamma1(Ala-Ala)|Escalating dose given IV over 5 days (1mg, 2mg, 4mg on days 3-5) of each 28 day cycle
1755330|NCT00239720|Drug|Placebo|Intravenous dose of placebo given over 5 days of each 28 day cycle
1755331|NCT00239733|Drug|Anti-D|30-minute infusion administered in an outpatient setting
1755332|NCT00239746|Drug|Ibuprofen|200mg taken orally daily for 6-12 weeks
1755333|NCT00239746|Drug|Placebo|200mg matched placebo taken orally daily for 6-12 weeks
1755334|NCT00239772|Behavioral|Cognitive Processing Therapy|
1755335|NCT00239772|Behavioral|Prolonged Exposure Therapy|
1755336|NCT00239785|Drug|FTY720|
1755337|NCT00239798|Drug|FTY720|
1755338|NCT00239811|Drug|FTY720|
1755339|NCT00239824|Behavioral|Strength training of the pelvic floor muscles|"Group A followed a pelvic floor muscle exercise course consisting of intensive pelvic floor muscle training with follow up instructions (training group or DVD instructions)by a physiotherapist;3 x 10 contractions daily.
Group B were instructed to train the pelvic floor muscles 3 x 10 contractions daily without follow up instructions by a physiotherapist."
1755340|NCT00239824|Behavioral|strength training of the pelvic floor muscles with or without follow up instructions by a physiotherapist|
1755392|NCT00232258|Drug|Nolpitantium besylate|
1755393|NCT00232271|Drug|Clexane|
1755341|NCT00239837|Behavioral|Middle School Success Intervention (MSS)|This is a 10-month, psychosocial intervention for foster parents and girls, with administration of the intervention beginning the summer before entry into middle school. The intervention consists of: (1) six summer Pride groups for the girls, (2) six summer parenting intervention sessions for the foster parents; (3) weekly foster parent training and support sessions for foster parents during the first year of middle school; and (4) weekly individual skills training for the girls during the first year of middle school.
1755342|NCT00239850|Behavioral|lifestyle changes|
1755343|NCT00239863|Drug|FTY720|
1755344|NCT00231842|Drug|Ifosfamide|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IVSS bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333mg/IVSS bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles.
1755345|NCT00231842|Procedure|Radiation Therapy|Ifosfamide 1.2gm/m2/day for 5 days. Mesna 400mg/IVSS bolus at each ifosfamide dosing followed by 1200mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles. After 3 cycles, RT. After RT, Ifosfamide 1.0gm/m2/day for 5 days. Mesna 333mg/IVSS bolus at each ifosfamide dosing followed by 1000mg IV divided in 3L/day x 5 days. Repeat q21 days x 3 cycles.
1755346|NCT00231855|Drug|Topotecan and Taxotere|
1755347|NCT00231868|Drug|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
1755348|NCT00231868|Procedure|Carboplatin and Paclitaxel and Pelvic Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
1755349|NCT00231868|Drug|Carboplatin and Paclitaxel and Radiation Therapy|Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=6.5) Repeat q 21 days x 3 cycles followed by RT followed by Paclitaxel 175 mg/m2/3 hour & Carboplatin (AUC=5.0)Repeat q 21 days x 3 cycles
1755353|NCT00231907|Biological|FluMist|Live attenuated influenza vaccine (LAIV) containing approximately 10^7 TCID50 of each of the 3 influenza strains. 0.5 mL total dose volume administered intranasally via spray applicator (approximately 0.25 mL into each nostril). Administration of Flumist in children under 5 years of age is investigational.
1755354|NCT00231907|Biological|Fluzone|Trivalent inactivated vaccine (TIV), licensed Fluzone preservative free pediatric dose, 0.25 mL administered intramuscularly to the anterolateral thigh muscle or deltoid muscle.
1755355|NCT00231920|Biological|Fluzone|
1755356|NCT00231933|Behavioral|Person-centered planning (PCP)|PCP aids participants in discovering a vision of a desirable future and developing a plan for achieving that goal. Techniques include providing direction in the planning process, involving significant others, generating focus on assets and capacities, identifying and providing access to integrated community settings, and promoting acceptance of set backs as part of the path to success.
1755357|NCT00231933|Behavioral|Community integration (CI)|CI includes recovery group sessions and community integration activities.
1755358|NCT00231933|Behavioral|Illness management recovery (IMR)|IMR focuses on nine topic areas: recovery strategies; facts about psychosis; a stress-vulnerability model; building social support; reducing relapses; effective use of medications; coping with stress; coping with problems or symptoms; and meeting health care needs.
1755359|NCT00231946|Drug|VP4896|
1755360|NCT00231959|Drug|Pramipexole (Mirapex)|pramipexole 0.5mg tablets qd and titrated per protocol
1755361|NCT00231959|Drug|Placebo|sugar pill
1755362|NCT00231972|Behavioral|Project Enhance|The behavioral intervention will be administered by a trained medical social worker on an individual basis. It will include an education component, as well as motivational and behavioral skills enhancement. Treatment will occur for only the first 3 months, after which follow-up sessions will be held every 3 months for the remainder of the year.
1755363|NCT00231972|Behavioral|Standard prevention case management (PCM)|Participants will receive standard PCM for HIV prevention.
1755364|NCT00231985|Behavioral|Habit reversal therapy|Habit reversal therapy consists of awareness training, relaxation training, self-monitoring, and competing response training.
1755365|NCT00231985|Behavioral|Supportive therapy|Supportive therapy focuses on educating participants about tics: how tics present themselves, the causes of tics, the common conditions that may occur along with tics, and environmental factors that may affect their tics (e.g. family, social, school, stress).
1755366|NCT00231998|Drug|Pimecrolimus|Pimecrolimus cream 1 %
1755367|NCT00232011|Drug|Pimecrolimus Cream 1%|Pimecrolimus cream 1 %
1755368|NCT00232024|Drug|Tegaserod|
1755369|NCT00232037|Drug|Tegaserod|
1755370|NCT00232050|Drug|Omalizumab|
1755371|NCT00232063|Drug|ciclosporin|
1755372|NCT00232076|Drug|ciclosporin|
1755373|NCT00232089|Drug|Tegaserod|
1755374|NCT00232102|Drug|Tegaserod|
1755375|NCT00232115|Drug|Pimecrolimus|Pimecrolimus cream 1 %
1755376|NCT00232115|Drug|Placebo|Vehicle cream (placebo)
1755377|NCT00232128|Procedure|Radiofrequency Ablation of pulmonary neoplasms|
1755378|NCT00232141|Drug|pregabalin|75mg BID (can be titrated up to 150mg BID on day 4 based on individual response and up to 300mg BID at the end of week 1, visit 3 and end of week 2, visit 4)
1755379|NCT00232141|Drug|Placebo|Placebo
1755380|NCT00232154|Drug|Zithromax&#153; (azithromycin) 500mg tablets|
1755381|NCT00232154|Procedure|Endoscopic Sinus Surgery|
1755382|NCT00232154|Procedure|Blood sampling for hematology|
1755383|NCT00232154|Procedure|Blood sampling for plasma chemistry profile|
1755384|NCT00232154|Procedure|Serum pregnancy test (for women of child-bearing potential)|
1755385|NCT00232167|Drug|Indiplon|
1755386|NCT00232167|Drug|Sertraline|
1755387|NCT00232180|Drug|Eplerenone|Eplerenone administered on top of background standard heart failure therapy
1755388|NCT00232206|Drug|Neoadjuvant Therapy with Cisplatin Plus Docetaxel|
1755389|NCT00232219|Drug|Fish oil|
1755390|NCT00232232|Drug|Fish oil|
1755394|NCT00232284|Drug|sertraline|RCT of sertraline/placebo for those young people who fail to respond within first 4 weeks of study entry
1755395|NCT00232284|Behavioral|Cognitive Behavioural Therapy|An integrated 10-week CBT program for depression/anxiety and comorbid substance use
1755396|NCT00232297|Drug|SSR149744C|
1755397|NCT00232310|Drug|CELIVARONE (SSR149744C)|
1755398|NCT00232323|Behavioral|simulation training|
1755399|NCT00232336|Drug|quetiapine|
1755400|NCT00232349|Drug|galantamine|open label galantamine, dosed at 4-12 mg/b.i.d., with a target dose of 12 mg/b.i.d.
1755401|NCT00232362|Drug|Pioglitazone (Actos)|
1755402|NCT00232362|Drug|Anti-diabetic agent other than pioglitazone or rosiglitazone|
1755403|NCT00232375|Drug|Insulin|
1755404|NCT00232388|Procedure|Blood draw|
1755405|NCT00232414|Drug|Quetiapine|
1755406|NCT00232427|Procedure|Hemodynamic monitoring system PiCCO|
1755407|NCT00232440|Device|BodyFIX|
1755408|NCT00232453|Procedure|Combined Radiation and Chemotherapy|
1755409|NCT00232466|Procedure|Vertebroplasty|"Procedure:
The treatment consists of a transpedicular injection of polymethylmethacrylate bone cement into the collapsed vertebral body (maximal 2 vertebrae in 1 treatment session) using fluoroscopic guidance. The procedure is performed under the use of local anesthetics and the patient can be discharged the same day or after 1 night of hospital stay."
1755410|NCT00232479|Drug|trastuzumab, docetaxel and carboplatin in dose dense regimen|trastuzumab 4 mg/kg day 1 and then 2 mg/kg/week x 11, carboplatin 6 mg AUC Day 1, 15, 29, 43, docetaxel 75 mg/meter squared Days 1, 15, 29, 43, neulasta 6 mg Day 2, 16, 30, 44
1755411|NCT00232492|Drug|Placebo males|Intravenous saline bolus (Placebo-control) males
1755412|NCT00232492|Drug|Ketamine 0,1 mg/kg males|0,1 mg/kg ketamine iv bolus males
1755413|NCT00232492|Drug|Ketamine 0,3 mg/kg males|0,3 mg/kg ketamine iv bolus males
1755414|NCT00232492|Drug|Ketamine 0,5 mg/kg males|0,5 mg/kg ketamine iv bolus males
1755415|NCT00232492|Drug|Placebo females|Intravenous saline bolus (Placebo-control) females
1755416|NCT00232492|Drug|Ketamine 0,1 mg/kg females|0,1 mg/kg iv bolus ketamine females
1755417|NCT00232492|Drug|Ketamine 0,3 mg/kg females|0,3 mg/kg iv bolus ketamine females
1755418|NCT00232492|Drug|Ketamine 0,5 mg/kg females|0,5 mg/kg iv bolus ketamine females
1755419|NCT00232505|Biological|cetuximab|Given IV
1755420|NCT00232505|Drug|carboplatin|Given IV
1755421|NCT00232518|Procedure|Infection with hookworm larvae|
1755422|NCT00232531|Drug|Niaspan|
1755423|NCT00232544|Device|Telecommunications system|The telecommunications system is designed to improve patient adherence with prescribed positive airway pressure.
1755424|NCT00232557|Device|TLC-Asthma|Telephone-linked communication (TLC) designed to improve asthma self-management by enhancing compliance with preventive medication regimens
1755425|NCT00232557|Device|TLC-health education|A telephone-linked communication system (TLC) to provide general health education.
1755426|NCT00232570|Drug|quetiapine|
1755427|NCT00232583|Drug|Metformin|Metformin 1000mg/BID
1755428|NCT00232583|Drug|Insulin|Insulin Novolg 70/30 per protocol titration
1755429|NCT00232583|Drug|Metfomin|Metformin 1000mg/BID
1755430|NCT00232583|Drug|Pioglitazone|Pioglitazone 45mg
1755431|NCT00232583|Drug|glyburide|Glyburide per protocol titration
1755432|NCT00232596|Drug|Retigabine|Oral tablet. The starting daily dose will be 300 mg/day administered orally in three equally divided doses. This dosage will be increased by 150 mg/day (50 mg/dose) at 1-week intervals (titration phase). At the beginning of Week 7, patients will enter a 12 week maintenance phase
1755433|NCT00232596|Drug|Placebo|Oral tablet.
1755434|NCT00232609|Device|GameCycle Exercise System|
1755435|NCT00232622|Drug|Streptokinase|Accelerated infusion of streptokinase
1755436|NCT00232622|Drug|Streptokinase|Standard dose streptokinase
1755437|NCT00232635|Drug|A-60444|
1755438|NCT00232648|Drug|Pulmicort (budesonide) Respules|
1755439|NCT00232661|Drug|ARIMIDEX (anastrazole)|
1755440|NCT00232661|Drug|NOLVADEX (tamoxifen)|
1755441|NCT00232674|Drug|Pulmicort (budesonide) Turbuhaler|
1755442|NCT00232687|Drug|Aripiprazole|Tablets, Oral, 15 mg fixed dose (week 1-5) flexible dose 10-30 mg (week 6-12), once daily, 12 weeks.
1755443|NCT00232687|Drug|Aripiprazole|Tablets, Oral, Uptitration: 5 mg (week 1), 10 mg (week 2 and 3), 15 mg(week 4 and 5) flexible 10-30mg from week 6-12, once daily, 12 weeks.
1755444|NCT00232700|Drug|Escitalopram|
1755445|NCT00232726|Drug|CP-4055 (ELACYT)|
1755446|NCT00232739|Device|CYPHER Sirolimus-eluting Coronary Stent|2.25 Cypher Sirolimus-eluting Coronary Stent
1755447|NCT00232752|Device|4.0 CYPHER Sirolimus-Eluting Coronary Stent|4.0 CYPHER Sirolimus-Eluting Coronary Stent
1755448|NCT00232765|Device|CYPHER Sirolimus-Eluting Stent|CYPHER Sirolimus-Eluting Stent
1755449|NCT00232765|Device|Uncoated BX VELOCITY Balloon-Expandable Stent|Uncoated BX VELOCITY Balloon-Expandable Stent
1755450|NCT00232778|Device|GAMMA-Iridium-192 catheter|
1755451|NCT00232791|Device|Cypher Select|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
1755452|NCT00232791|Device|Cypher|CYPHER™ Sirolimus-eluting Coronary Stent
1755453|NCT00232804|Device|Bx Cypher stent|
1755454|NCT00232817|Drug|Nicotine (drug)|nicotine nasal spray (3mg) before surgery
1755455|NCT00232830|Device|drug-eluting stent|Cypher Sirolimus-eluting Coronary Stent
1755456|NCT00232830|Device|bare-metal stent|any bare-metal stent brand
1755457|NCT00232843|Device|stent|Cordis SMART™ nitinol self-expanding stent.
1755458|NCT00232843|Device|angioplasty|balloon angioplasty
1755459|NCT00232856|Device|drug-eluting stent|PCI
1755460|NCT00232869|Device|drug-eluting stent|Sirolimus Coated Cordis SMART™ nitinol selfexpandable stent
1755461|NCT00232869|Device|bare-metal stent|SMART™ bare-metal stent
1755462|NCT00232882|Drug|Candesartan Thiazide|Candesartan 16 mg for 4 weeks then added hydrochlorothiazide for 4 weeks
1755463|NCT00232882|Drug|Atenolol Thiazide|Atenolol 100 mg for 4 weeks followed by atenolol 100 mg + hydrochlorothiazide 12.5 mg for 4 weeks
1755523|NCT00233415|Device|Stereotactic Radiosurgery (Cyberknife)|
1755464|NCT00232882|Drug|Thiazide Candesartan|Thiazide 25 mg for 4 weeks then added with Candesartan 16 mg
1755465|NCT00232895|Drug|lipuro propofol|
1755466|NCT00232895|Drug|standard formulation propofol|
1755467|NCT00232908|Drug|ARV regimen|As prescribed
1755468|NCT00232908|Drug|enfuvirtide [Fuzeon]|90mg sc bid for 12 weeks
1755469|NCT00232921|Drug|caudal volume 1|
1755470|NCT00232921|Biological|caudal volume 2|
1755471|NCT00232921|Drug|caudal volume 3|
1755472|NCT00232934|Drug|Thalidomide|
1755473|NCT00232947|Biological|Influenza virus vaccine (Fluviral)|
1755474|NCT00232947|Biological|Influenza virus vaccine (Fluzone)|
1755475|NCT00232960|Procedure|Radiotherapy 50 Gy|
1755476|NCT00232973|Drug|ICXP007|
1755477|NCT00232999|Drug|Nebulized IVX-0142|
1755478|NCT00233012|Drug|Topiramate|
1755479|NCT00233025|Drug|Duloxetine|
1755480|NCT00233025|Drug|Placebo|
1755481|NCT00233038|Procedure|Ethanol injection into a cyst|
1755482|NCT00233051|Drug|Salmeterol or Salmeterol/Fluticasone|
1755483|NCT00233064|Biological|Lyophilized Palivizumab|Patients will receive 15 mg/kg of lyophilized palivizumab administered intramuscularly every 30 days for a total of 5 injections.
1755484|NCT00233064|Biological|Liquid Palivizumab|Patients will receive 15 mg/kg of liquid palivizumab administered intramuscularly every 30 days for a total of 5 injections.
1755485|NCT00233077|Behavioral|Patient Assistance|Patients will be surveyed to assess their knowledge about cancer & its treatment, experience with & access to health care system, trust, depression, social support & self-efficacy. A Brief Screening Needs Assessment will be done to ascertain practical, informational or psychosocial needs; based on their responses, an individualized action plan to connect with patient assistance programs will be created for the intervention group. We will ask intervention patients if they connected with any programs in their action plan. For those who didn't connect, we will give their name to an outreach worker. The outreach worker will call patients and identify reasons for not contacting the assistance programs.
1755486|NCT00233077|Behavioral|Information only|Control patients will be sent a pamphlet about breast cancer & its treatment. We will call all patients 2 weeks later and ask if they received the packet. If they didn't, we will send the packet again.
1755487|NCT00233090|Drug|Modafinil|single dose of 200 mg. a day of modafinil for four weeks
1755488|NCT00233090|Drug|Placebo|daily dose of placebo for four weeks.
1755489|NCT00233103|Drug|Sertraline|Sertraline arm
1755490|NCT00233103|Drug|Placebo|Placebo
1755491|NCT00233129|Behavioral|Top Down|Six months
1755492|NCT00233129|Other|cognitive rehabilitation day treatment program|six months
1755493|NCT00233142|Behavioral|Expressive writing|Writing as therapeutic intervention
1755494|NCT00233142|Behavioral|Neutral writing|Non-expressive writing
1755495|NCT00233155|Drug|Capsaicin Dermal Patch|
1755496|NCT00233168|Behavioral|Adherence Program|14 counseling sessions focusing on INH adherence conducted over 6 months, starting once per week and decreasing in frequency to once a month.
1755497|NCT00233168|Behavioral|Life Skills and Self-Esteem Training Program (Attention Control Arm)|Peer counseling session covering life skills (e.g., communication skills, goal setting, self-esteem) training, 14 sessions over 6 months beginning once per week and decreasing in frequency over time to once per month.
1755498|NCT00233181|Behavioral|Home-based adherence monitoring|
1755499|NCT00233194|Procedure|Observational follow-up study of adenotonsillectomy|Studies of sleep, behavior, cognition, and daytime sleepiness
1755500|NCT00233207|Drug|IC14|
1755501|NCT00233220|Behavioral|Multicomponent, multi-level intervention targeted at physicians and patients|The patient intervention will include an innovative patient education approach known as Self-Paced Programmed Instruction that will be used to educate patients on knowledge of HTN; behavioral counseling by trained C/MHC dieticians on lifestyle modification; and home BP monitoring to activate patients in their own care. The physician intervention comprises online continuing medical education (CME) courses on management of HTN based on the Joint National Committee-7 (JNC-7) guidelines; online HTN rounds or case conferences with HTN specialists; and feedback to physicians on clinical performance measures via computerized decision support systems. The intervention will be delivered to patients every 3 months during regular office visits for 12 months, while the physician intervention will occur every month for the duration of the trial.
1755502|NCT00233220|Behavioral|Usual Care|Patients will receive usual care.
1755503|NCT00233233|Behavioral|Standardized Asthma Education Program|
1755504|NCT00233246|Procedure|FFP Infusion|
1755505|NCT00233259|Behavioral|Mediterranean Diet|Mediterranean dietary program
1755506|NCT00233259|Behavioral|Physical Activity|Physical activity program
1755507|NCT00233259|Behavioral|Stress Management|Stress management program
1755508|NCT00233259|Behavioral|Social Support|Social support
1755509|NCT00233259|Behavioral|Smoking Cessation|Smoking cessation program
1755510|NCT00233259|Other|Control group|Usual Diabetes Care Control group
1755515|NCT00233337|Drug|Co-artemether|
1755516|NCT00233350|Device|use of navigated 3D ultrasound during surgery|
1755517|NCT00233363|Drug|Rebamipide|
1755518|NCT00233376|Procedure|Access to an antibiotic decision support system|
1755519|NCT00233376|Behavioral|Distribution of local antibiotic guidelines|
1755520|NCT00233389|Drug|Rebamipide|
1755521|NCT00233402|Drug|Hexvix|Single Instillation, Transurethral Resection of the Bladder
1755522|NCT00233402|Procedure|Standard white light cystoscopy|
1755524|NCT00233428|Procedure|Blood Draw|
1755525|NCT00233441|Drug|CELIVARONE (SSR149744C)|
1755526|NCT00233454|Drug|Midostaurin|Midostaurin is a broad-spectrum protein kinase inhibitor, acting on conventional PKC isoforms (α, β, γ); PDFRβ; VEGFR2; Syk; PKCη; Flk-1; Flt3; Cdk1/B; PKA; c-Kit; c-Fgr; c-Src; VEGFR1; and EGFR
1755527|NCT00233480|Drug|atorvastatin|atorvastatin 10mg PO QD
1755528|NCT00233480|Drug|placebo|matched placebo Qd x 3 months
1755529|NCT00233506|Drug|CpG 7909|
1755530|NCT00233519|Drug|SomatoKine/IPLEX|"Cohort 1: self-administered subcuteanous injections of 0.5 mg/kg/day of iPlex for 8 weeks, followed by 1.0 mg/kg/day of iPlex for 16 weeks.
Cohort 2: consecutive 8 week treatments of 0.5, 1.0, and 2.0 mg/kg/day of iPlex for a total of 24 weeks by self-administered subcuteanous injection."
1755531|NCT00233532|Drug|Trandolapril|0.5, 1,2,4mg/once daily/ for 26 weeks (If BP was not controlled, dose was escalated to the next higher dosage every 4-5 weeks).
1755532|NCT00233545|Drug|miltefosine|
1755533|NCT00233545|Drug|antimony|
1755534|NCT00233558|Drug|adalimumab (up to 9 months exposure)|
1755535|NCT00233558|Drug|methotrexate|
1755536|NCT00233571|Biological|Adalimumab 40 mg subcutaneous (SC) every other week (EOW)|
1755537|NCT00233584|Procedure|Pulmicort (budesonide) pMDI|
1755538|NCT00233597|Drug|ferumoxytol or oral iron|
1755539|NCT00233610|Drug|Bicalutamide|
1755540|NCT00233610|Drug|Tamoxifen|
1755541|NCT00233623|Drug|Iressa (Gefitinib)|
1755542|NCT00233623|Drug|Irinotecan|
1755543|NCT00233623|Drug|5Fluorouracil|
1755544|NCT00233623|Drug|Leucovorin|
1755545|NCT00233636|Drug|Iressa (Gefitinib)|
1755546|NCT00233636|Procedure|Radiotherapy|
1755547|NCT00233662|Drug|Alefacept|
1755548|NCT00233675|Drug|GABITRIL (tiagabine hydrochloride; CEP-6671)|
1755549|NCT00233688|Device|QUANTUM LP™ STENT GRAFT SYSTEM|Stent Graft System for the Treatment of Abdominal Aortic Aneurysms
1755550|NCT00233688|Procedure|Open surgical repair|Open surgical repair
1755551|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Single dose Sirolimus-Eluting coronary stent
1755552|NCT00233714|Device|CYPHER Sirolimus-Eluting Coronary Stent|Double-dose Sirolimus-Eluting coronary stent
1755553|NCT00233727|Procedure|HPV DNA Testing + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing HPV DNA testing of clinician-collected cervical samples, followed by cryosurgery of screen positive women."
1755554|NCT00233727|Procedure|VIA + Cryosurgery|"Patients will undergo a Screen and Treat program utilizing visual inspection of the cervix with acetic acid (VIA), followed by cryosurgery of screen positive women."
1755555|NCT00233740|Device|OPTEASE Vena Cava Filter|
1755556|NCT00233753|Device|Cordis Neurovascular Self-Expanding Stent|
1755557|NCT00233766|Device|Bx VELOCITY Stent containing 45% and 70% of Sirolimus dose|
1755558|NCT00233779|Device|SIROLIMUS-ELUTING, HEPARIN-COATED CoCr BALLOON-EXPANDABLE STENT|
1755559|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - fast release|
1755560|NCT00233792|Device|sirolimus coated Bx VELOCITY stent - slow release|
1755561|NCT00233805|Device|Sirolimus coated Bx Velocity™|drug-eluting stent
1755562|NCT00233805|Device|Bare metal Bx Velocity™|bare-metal stent
1755563|NCT00233818|Device|Sirolimus-coated Bx VELOCITY Stent|
1755564|NCT00233831|Device|Generator of electromagnetic millimeter waves|
1755565|NCT00233844|Procedure|"Venipuncture with cough-trick"|
1755566|NCT00233857|Procedure|Auricular acupuncture|
1755567|NCT00233870|Drug|Agalsidase beta (recombinant form)|agalsidase beta 1.0 mg/kg body weight infused every 2 weeks as an intravenous infusion
1755568|NCT00233883|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 4 weeks
1755569|NCT00233883|Drug|enfuvirtide [Fuzeon]|"90mg sc bid by 27G1/2 needle/syringe for 4 weeks"
1755570|NCT00233896|Drug|Oral beclomethasone dipropionate (drug)|
1755571|NCT00233909|Drug|Zosuquidar|
1755572|NCT00233909|Drug|gemtuzumab ozogamicin|
1755573|NCT00233922|Device|Osteosheet(r)|
1755574|NCT00233935|Other|placebo|Given PO
1755575|NCT00233935|Drug|defined green tea catechin extract|Given PO
1755576|NCT00233948|Drug|nelfinavir mesylate|Given orally
1755577|NCT00233948|Procedure|biopsy|Correlative studies
1755578|NCT00233948|Other|laboratory biomarker analysis|Correlative studies
1755579|NCT00233948|Other|pharmacological study|Correlative studies
1755580|NCT00233948|Genetic|gene expression analysis|Correlative studies
1755581|NCT00233948|Genetic|western blotting|Correlative studies
1755582|NCT00233948|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
1755583|NCT00233948|Other|immunoenzyme technique|Correlative studies
1755584|NCT00233961|Biological|filgrastim|
1755585|NCT00233974|Procedure|PET (positron emission tomography)|Following conventional segmental mastectomy with or without needle localization, the patient will then undergo intraoperative PET-probe evaluation
1755586|NCT00233987|Drug|carmustine|150 mg/m^2 IV over 2 hours 4, 5, and 6 days before transplant.
1755587|NCT00233987|Drug|cyclophosphamide|100 mg/kg IV 2 days before transplant.
1755588|NCT00233987|Drug|etoposide|60 mg/kg IV over 4 hours 4 days before transplant.
1755589|NCT00233987|Drug|melphalan|150 mg/m^2 IV 1 day before transplant.
1755590|NCT00233987|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|2.0 x 10^6 CD34+ cells, beginning at least 24 hours after melphalan infusion.
1755591|NCT00233987|Radiation|radiation therapy|150 centigray (cGy) total body irradiation given b.i.d on days 5-8 before transplant.
1755592|NCT00234000|Drug|arsenic trioxide|Each 28-day treatment cycle will include dosing for 2 days per week of ATO. Subjects will recieve 1 mg/mL each dosing day.
1755593|NCT00234000|Drug|azacitidine|Each 28-day treatment cycle will include dosing the first five days of cycle with Azacitidine. Cohorts of three to six patients will each receive 25, 50, and 75 mg/m2/d injected subcutaneously.
1755594|NCT00234026|Drug|gemcitabine hydrochloride|
1755595|NCT00234039|Drug|gemcitabine hydrochloride|
1755818|NCT00243048|Dietary Supplement|soy protein isolate|
1755596|NCT00234052|Biological|bevacizumab|5 mg/kg administered intravenously over 90 minutes on day 1 of each cycle (cycle = 3 weeks)
1755597|NCT00234052|Drug|carboplatin|Administered intravenously at a dose of AUC=6 over 30 minutes on day 1 of each cycle (1 cycle = 3 weeks)
1755598|NCT00234052|Drug|pemetrexed|Administered intravenously at a dose of 500 mg/m2 over 10 minutes on day 1 of each cycle (1 cycle = 3 weeks)
1755599|NCT00234065|Drug|Cilostazol|oral tablet, 100 mg twice a day and placebo of aspirin once a day, 1 to 5years
1755600|NCT00234065|Drug|Aspirin|oral tablet, placebo of cilostazol twice a day and 81 mg once a day, 1 to 5 years
1755601|NCT00234078|Drug|0.5% OPC-12759|
1755602|NCT00234078|Drug|1% OPC-12759|
1755603|NCT00234078|Drug|2% OPC-12759|
1755604|NCT00234078|Drug|placebo|
1755605|NCT00234091|Drug|Abacavir|8 mg/kg (up to 300 mg/dose) take orally twice daily
1755606|NCT00234091|Drug|Efavirenz|200 to 600 mg taken orally once daily
1755607|NCT00234091|Drug|Lamivudine|4 mg/kg (up to 150 mg/dose) taken orally twice daily
1755608|NCT00234091|Drug|Lopinavir/Ritonavir|230 mg/57.5 mg/m^2 body surface area taken orally twice daily with food
1755609|NCT00234091|Drug|Nelfinavir|45-55 mg/kg taken orally twice daily with food
1755610|NCT00234091|Drug|Nevirapine|120 mg/m^2 once daily for first 14 days, tehn 200 mg/m^2 (up to 400 mg/day) twice daily
1755611|NCT00234091|Drug|Zidovudine|180-240 mg/m^2 every 12 hours (up to 300 mg/dose)
1755612|NCT00234104|Drug|OPC-41061(Tolvaptan)|
1755613|NCT00234117|Drug|Rabeprazole|
1755614|NCT00234130|Procedure|nocturnal vs conventional dialysis|
1755615|NCT00234143|Behavioral|Darbepoetin and Filgrastim|Aranesp and Neupogen G-CSF (Neupogen) 300 mcg s.c. twice a week, 3-4 days apart and EPO (Aranesp) 500 mcg s.c. once every 2 weeks until week 24, titrate depending of response
1755616|NCT00234143|Drug|Darbepoetin|Aranesp EPO (Aranesp) 500 mcg s.c. once every 2 weeks until 24 weeks, titrate depending of response
1755617|NCT00234156|Procedure|oral fructose and high fat diet|"High fat diet: The composition will be: 35% of energy as fat, 50% carbohydrate, 15% protein (~1.3 g/kg), sat:mono:poly 1:3:1, cholesterol 200 mg/d, 30% starch,15% sugar, 3% fructose, and 25 gm fiber/d. This relatively high fat diet, which falls within the recommendations by the National Kidney Foundation for hemodialysis patients, will suppress fatty acid synthesis in normal volunteers.
Fructose in 360 ml water will be orally administered as 1.4 g/kg (~100 g or 400 kcal for a 70 kg person), divided into 30 mL (1 ounce) doses given every 1/2h for 6 hours."
1755618|NCT00234169|Drug|VTP195183|"VTP195183: 60mg/m2 orally daily G-CSF: 10mcg/kg/day subcutaneously Provision is made for dose reduction of VTP195183 in the event of unexpected dose-limiting toxicities G-CSF10mcg/kg/day will commence on day 1 and will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first.
Patients will be treated with VTP195183 alone at 60mg/m2/day from day 1 to day 7. On day 8 VTP195183 will be continued and G-CSF10mcg/kg/day will be added. VTP195183 plus G-CSF will continue until the peripheral blood (PB) CD34+ count falls below baseline, or below 5 x 106/L, whichever happens first."
1755619|NCT00234182|Drug|Interferon alpha-2b|
1755620|NCT00234195|Drug|bupropion extended release (Wellbutrin XL)|
1755621|NCT00234208|Procedure|Medical thoracoscopy|
1755622|NCT00234208|Procedure|Simple chest tube drainage|
1755623|NCT00234221|Behavioral|Strengths Based Case Management|
1755624|NCT00234221|Behavioral|Motivational Enhancement Therapy|
1755625|NCT00234221|Behavioral|Brief Informational Feedback|
1755626|NCT00234234|Drug|Adalimumab|
1755627|NCT00234247|Other|Long Term Follow-Up|Extended and enhance the follow-up of the NHLBI iNO RCT by assessing the effects of iNO use on: 1.) long term clinical and childhood developmental outcomes; 2.) family impact, and; 3.) healthcare costs of prematurity-associated respiratory failure.
1755628|NCT00234273|Procedure|Rehabilitation programme in Adapted Physical Activity (APA)|
1755629|NCT00234273|Behavioral|Therapeutic education primarily focused on dietary|
1755630|NCT00234286|Behavioral|Comfort care education intervention|Comfort care education intervention, consisting of intensive, on-site staff training together with an electronic order set for palliative care and educational materials
1755631|NCT00234299|Drug|Aspirin|325mg, one tablet orally, six months
1755632|NCT00234299|Drug|Placebo|325mg, one tablet orally every day, 6 months
1755633|NCT00234312|Drug|escitalopram and sertraline|
1755634|NCT00239876|Drug|FTY720|
1755635|NCT00239889|Drug|Salmon calcitonin|
1755636|NCT00239902|Drug|FTY720|
1755637|NCT00239915|Drug|Pagoclone|
1755638|NCT00239928|Drug|pegaptanib sodium|1 drop per dosed eye per protocol.
1755639|NCT00239954|Drug|Escitalopram|
1755640|NCT00239967|Drug|Rimonabant (SR141716)|
1755641|NCT00239967|Drug|Placebo|
1755642|NCT00239980|Drug|dalteparin|50, 100, 150 IU/kg administered subcutaneously once daily for 3 cycles of chemotherapy
1755643|NCT00239993|Drug|glatiramer acetate|
1755644|NCT00239993|Procedure|Warm compress prior to injection of glatiramer acetate|
1755645|NCT00240006|Procedure|Shared Solutions® plus MS Center v. Shared Solutions®|Copaxone
1755646|NCT00240019|Drug|Addition of furosemide 20 mg oral bid to baseline regimen|
1755647|NCT00240032|Drug|glatiramer acetate injection with oral cetirizine hydrochloride|Copaxone® injection 20 mg, Oral Zyrtec® 10 mg tablet
1755648|NCT00240032|Drug|glatiramer acetate with placebo|Copaxone® injection 20 mg, oral placebo
1755649|NCT00240045|Drug|Midodrine, albumin, octreotide LAR|
1755650|NCT00240045|Drug|midodrine, octreotide, albumin|midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly
1755651|NCT00240058|Drug|Regional phenylephrine arterial infusion, Nitric Oxide Clamp|
1755652|NCT00240071|Drug|Avastin|All patients will received Avastin 15 mg/kg IV every three weeks. The first evaluation will be done at Week 6. Patients with objective response or stable disease will continue therapy with restaging every 6 weeks until evidence of disease progression. Patients with progression of disease will be taken off study.
1755653|NCT00240071|Drug|Hormonal therapy|aromatase inhibitor (letrozole 2.5mg/d PO, anastrazole 1mg/d PO, or exemestane 25mg/d PO)or SERM (tamoxifen 20mg/d PO)
1755654|NCT00240084|Drug|nesiritide (Natrecor(TM))|administration of IV nesiritide
1755655|NCT00240097|Drug|Intervention A: Irinotecan; Oxaliplatin; Neulasta|Irinotecan (I.V.) 150-200 mg/m2; Day 1 (every 5 weeks) Oxaliplatin (I.V.) 85 mg/m2; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 1 (every 5 weeks)
1755656|NCT00240097|Drug|Intervention B: Etoposide; Carboplatin; Neulasta|Etoposide (I.V.) 100 mg/m2; Day 1, 2, 3 (every 5 weeks) Carboplatin (I.V.) AUC 6; Day 1 (every 5 weeks) Neulasta (subcutaneous) 6 mg; Day 4 (every 5 weeks)
1755657|NCT00240110|Drug|Valproate|Valproate with dose titration to achieve blood levels within the therapeutic range
1755658|NCT00240110|Drug|Placebo|Control arm
1755659|NCT00240110|Drug|Lithium Carbonate|All participants were started and stabilized on lithium carbonate as a standard treatment for bipolar disorder
1755660|NCT00240123|Drug|Benadryl versus Placebo|
1755661|NCT00240149|Drug|Regular Insulin via Insulin-Glucose Algorithm|
1755662|NCT00240162|Drug|PTK787/ZK 222584|
1755663|NCT00240175|Other|No Intervention|No Intervention
1755664|NCT00240188|Procedure|Open mesh repair of ventral incisional hernia|For the open procedure, the technique, as described by Chevrel and others was adopted.
1755665|NCT00240188|Procedure|Laparoscopic mesh repair of ventral incisional hernia|For the laparoscopic repair, the method of Gagner was adopted
1755666|NCT00240214|Drug|sirolimus|Tablet, dosage is determined by trough level
1755667|NCT00240227|Drug|Prazosin|FDA approved medication for hypertension
1755668|NCT00240227|Drug|placebo|
1755673|NCT00241852|Behavioral|Asthma: It's a Family Affair!|Intervention families will receive a comprehensive program with two complementary components: (1) a school-based intervention to empower middle school students to manage their asthma and (2) parent training to teach their caregivers childrearing skills that support the youth's growing autonomy and need to self-manage their disease. The student component is comprised of 6, 60 minute group workshops; the caregiver component consists of 5, 90-minute group workshops.
1755674|NCT00241852|Behavioral|Asthma and Stress Comparator|Caregivers assigned to the Asthma and Stress Comparator group will receive a single educational workshop focusing on the developmental changes adolescents experience, how these changes may cause stress, and ways to cope with stress. The children will also participate in a single school-based session on similar topics. Both caregivers and students will learn basic asthma facts.
1755675|NCT00241878|Behavioral|Teacher-Delivered Weight Control Intervention|The teacher-delivered weight control intervention (TD-WCI) is implemented over 14 weeks with three lessons per week. Many lessons include the use of colorful, friendly, hand-made puppets that represent the seven food groups of the food pyramid (Miss Grain, Miss Fruit, Mr. Vegetable, Mr. Protein, Miss Dairy, Mr. Fat and Miss Sugar). Please see Appendix IX for complete curriculum and pictures of puppets. There are three 40-minute lessons per week that consist of a 15-20 minutes interactive healthy eating and exercise didactic session and then 20 minutes of ongoing physical activity (5 minutes warm-up, 15 minutes aerobic activity composed of a number of games and dances with music, 5 minutes cool-down). In addition to the child-based curriculum the WCI has parent newsletters. These newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
1755676|NCT00241878|Behavioral|Teacher-Delivered General Health Intervention|The teacher-delivered general health intervention (TD-GHI) serves as the control group in the proposed study. TD-GHI is a general health intervention that is similar in structure and length to TD-WCI. Topics include those related to general health and safety, such as car safety, being a good friend, poison safety, disease prevention, etc. An example of an activity is the 911 emergency call. The children learn what 911 is and what would be an appropriate call. They then practice calling 911 on play telephones and relating the important information: nature of the emergency, their name, their address, etc. They learn also to stay on the phone with the 911 dispatcher until someone comes to help them. In addition to the child-based curriculum the GHI has parent newsletters. Like TD-WCI these newsletters are distributed on a weekly basis and provide information that parallels the children's curriculum
1755677|NCT00241891|Behavioral|Single behavior intervention|Focused on changing beverage choices which may have a significant impact on weight.
1755678|NCT00241891|Behavioral|Multiple behavior interventions|Focused on multiple behaviors (nutrition, beverages, physical activity, and sedentary lifestyle) which may have a significant impact on weight.
1755679|NCT00241891|Behavioral|Control Intervention unrelated to weight|Focused on standard intervention strategies unrelated to weight including bullying prevention.
1755680|NCT00241904|Behavioral|Lifestyle Changes|Nutrition counseling, smoking cessation counseling, medication compliance counseling, exercise
1755681|NCT00241904|Drug|Antiplatelet Agents|Aspirin 81 mg q day
1755682|NCT00241904|Drug|Beta Blocker|Oral medication
1755683|NCT00241904|Drug|ACE Inhibitors|Oral medications, received 1-2 times per day
1755684|NCT00241917|Behavioral|Hepatitis C educational video|
1755685|NCT00241917|Other|Video|Prevention education video about hepatitis C
1755686|NCT00241930|Behavioral|Integrating drug treatment into HIV services|
1755687|NCT00241943|Procedure|Hepatitis C educational video|
1956689|NCT02744898|Drug|Carboplatin AUC|
1755819|NCT00243048|Radiation|radiation therapy|
1755820|NCT00243061|Drug|cediranib maleate|Given orally
1956690|NCT02744898|Drug|Abraxane|100mg/m2
1956694|NCT02742441|Drug|122-0551 Foam|Topical Foam containing active drug
1956695|NCT02742441|Drug|Vehicle Foam|Topical Foam containing no active drug
1755690|NCT00241982|Drug|long-circulating liposomal prednisolone|
1956696|NCT02742623|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Treatment with rivaroxaban for DVT and/ or PE and/ or prevention of recurrent DVT and PE according to local label
1755692|NCT00242008|Drug|Rotigotine|
1755693|NCT00242021|Behavioral|Fatty acid composition of a margarine (spread)|
1755694|NCT00242034|Procedure|CT and MRI with contrast|
1755695|NCT00242047|Biological|Japanese (Tokyo) 172 Bacille Calmette Guerin (BCG).|
1755696|NCT00242060|Procedure|MRI|
1755697|NCT00242073|Procedure|MRI Prostate|
1755698|NCT00242086|Procedure|CT, PET and MRI|
1755699|NCT00242099|Procedure|Monitoring - blood samples drawn to test for HHV-6 and HHV-7|
1755700|NCT00242112|Procedure|MRI Prostate|
1755701|NCT00242138|Behavioral|Erectile Dysfunction|
1755702|NCT00242164|Drug|Dialysate Magnesium (Concentration)|
1755703|NCT00242177|Drug|ACTOS (Pioglitazone)|
1755704|NCT00242190|Drug|oxaliplatin|
1755705|NCT00242190|Drug|gemcitabine|
1755706|NCT00242190|Procedure|radiation therapy|
1755707|NCT00242203|Drug|Zometa|
1755708|NCT00242203|Drug|Epirubicin|
1755709|NCT00242203|Drug|Docetaxel|
1755710|NCT00242203|Drug|Trastuzumab|ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH
1755711|NCT00242203|Radiation|External beam radiation|
1755712|NCT00242203|Procedure|Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection|
1755713|NCT00242216|Drug|ritonavir-boosted atazanavir|100 mg ritonavir plus 300 mg atazanavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
1755714|NCT00242216|Drug|ritonavir-boosted fosamprenavir|100 mg ritonavir plus 1,400 mg fosamprenavir in combination with tenofovir-emtricitabine fixed dose combination given once daily.
1755715|NCT00242229|Drug|DVS-233 SR|
1755716|NCT00242268|Drug|Simvastatin|
1755717|NCT00242281|Drug|APC-111 MP Tablet, 775 mg|
1755718|NCT00242294|Drug|Roflumilast|
1755719|NCT00242307|Drug|Roflumilast|
1755720|NCT00242320|Drug|Roflumilast|to investigate the effect of 500 µg Roflumilast tablets once daily versus placebo
1755721|NCT00242320|Drug|Placebo|
1755722|NCT00242333|Drug|AD 237|
1755723|NCT00242346|Drug|candesartan cilexetil|
1755724|NCT00242359|Drug|omalizumab|
1755725|NCT00242372|Drug|Tesaglitazar 0.5|
1755726|NCT00242372|Drug|Insulin at least 30 units/day|
1755727|NCT00242385|Biological|Dose of 60 mg/kg Fraction IV-1 Alpha1-Proteinase Inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
1755728|NCT00242385|Biological|Dose of 60 mg/kg alpha1-proteinase inhibitor|Subjects meeting the eligibility criteria were randomized to receive either single dose ARALAST alpha1-proteinase inhibitor 60 mg/kg or single-dose ARALAST alpha1-proteinase inhibitor Fr. IV-1 60 mg/kg at 0.2 mL/kg/min during the first treatment period with crossover to the alternate study product during the second treatment period, with a minimum of 7 days between the two treatment periods.
1755729|NCT00242398|Device|AN69 ST|
1755730|NCT00242411|Drug|Budesonide/Formoterol Turbuhaler|
1755731|NCT00242411|Drug|Conventional Best Asthma Therapy|
1755732|NCT00242424|Biological|2005-2006 trivalent inactivated influenza vaccine|Children enrolled at 6-12 weeks to receive first dose, 0.25 ml of trivalent inactivated influenza vaccine, 2005-6 pediatric Fluzone formulation (sanofi pastuer), with concomitant routine pediatric vaccines. Second dose administered 4 weeks later.
1755733|NCT00242437|Device|Hemostatic matrix|
1755734|NCT00242437|Device|bovine thrombin|
1755735|NCT00242450|Drug|Metoclopramide|
1755736|NCT00242463|Drug|Nandrolone (anabolic steroid)|
1755737|NCT00242463|Drug|Placebo|
1755738|NCT00242476|Drug|MK0822A|
1755739|NCT00242489|Drug|MK0663, etoricoxib / Duration of Treatment: Part I (6 weeks), Part II (8 weeks)|
1755740|NCT00242489|Drug|Placebo;Diclofenac 50mg(tid)/Duration of Treatment: Part I (Placebo) 6 weeks;Part II (Diclofenac) 8 weeks|
1755741|NCT00242502|Drug|Bevacizumab (Avastin)|10 mg/kg IV every 14 days, repeat cycle every 28 days
1755742|NCT00242502|Drug|Erlotinib|150 mg orally every day continuous dosing, repeat cycle every 28 days
1755743|NCT00242515|Procedure|CD8+ T-cell depleted donor lymphocyte infusion|
1755744|NCT00242528|Drug|Zoledronic acid|
1755745|NCT00242541|Drug|Octreotide acetate|
1755746|NCT00242554|Drug|Zoledronic acid|
1755747|NCT00242567|Drug|Zoledronic Acid|"Zoledronic acid was provided by Novartis in vials containing 4 mg/5 mL liquid concentrate. Prior to administration, the liquid concentrate from one vial was to be further diluted with 100 mL of calcium-free infusion solution (0.9 % weight by volume sodium chloride solution or 5 % weight by volume glucose solution). If refrigerated, the solution had to be allowed to reach room temperature before administration.
After addition of the liquid concentrate to the infusion media, the infusion solution was to be used as soon as practicable to reduce the risk of microbiological hazard. If storage of the solution was necessary, it had to be refrigerated at temperatures between 2-8 degrees C and was to be used within 24 hours.
The infusion solution containing 4 mg zoledronic acid was to be administered every 4 weeks as an i.v. infusion over no less than 15 minutes."
1755748|NCT00242567|Drug|Androgen Deprivation Therapy (ADT)|Androgen deprivation therapy (ADT) was to be administered according to institutional protocols, in accordance with relevant prescribing information. The type and duration of androgen deprivation was at the discretion of the treating specialist, and could include orchiectomy where this would normally have been performed. Androgen deprivation therapy was provided by the investigational center, or obtained by the patient from usual sources. Anti-androgen monotherapy and intermittent ADT were excluded in the first 12 months of the study.
1755821|NCT00243074|Drug|cediranib maleate|Given orally
1755822|NCT00243074|Other|laboratory biomarker analysis|Correlative studies
1755749|NCT00242580|Drug|Verteporfin photodynamic therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
1755750|NCT00242580|Drug|Pegaptanib|Pegaptanib sodium 0.3 mg administered by intravitreal injection.
1755751|NCT00242580|Drug|Triamcinolone acetonide|Triamcinolone acetonide administered by intravitreal injection.
1755752|NCT00242593|Drug|Rosiglitazone|4 mg twice daily oral rosiglitazone or placebo pill for 18 months
1755753|NCT00242606|Drug|Lamotrigine|titrate to 200mg over 10 weeks and maintained until end of week 26
1755754|NCT00242606|Drug|Levetiracetam|titrate to 2000mg/day over 22 days, maintain until the end of week 26
1755755|NCT00242619|Drug|rosiglitazone|Rosiglitazone was administered at two different doses over the 12-week period.
1755756|NCT00242632|Drug|Namenda|Namenda has already been shown to offer cognitive benefits to patients suffering from Alzheimer's disease, but it's potential for treating those at risk for cognitive decline without Alzheimer's disease or other dementia has yet to be evaluated. It is possible that memantine may offer neurocognitive benefits to this population, as well. Participants are asked to take medication for six months, complete neuropsychological testing, and one blood draw.
1755757|NCT00242645|Behavioral|Health Information|
1755758|NCT00242645|Behavioral|Preventive Services|
1755759|NCT00242645|Behavioral|Computer tailored information|
1755760|NCT00242658|Behavioral|Tailored Physical Activity Intervention|Tailored physical activity computer reports will be provided to patients and physicians.
1755761|NCT00242671|Procedure|Isocapnic Hyperponea|
1755762|NCT00242697|Procedure|spinal analgesia and anesthesia for coronary artery surgery|
1755763|NCT00242710|Drug|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
1755764|NCT00242710|Drug|Bazedoxifene/Conjugated Estrogen|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
1755765|NCT00242710|Drug|CE 0.45 mg/MPA 1.5mg|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
1755766|NCT00242710|Other|Placebo|Subjects will take 1 capsule orally, once daily, at approximately the same time each day continuously for the duration of the study.
1755767|NCT00242736|Drug|Esomeprazole|
1755768|NCT00242749|Drug|Gefitinib, Cisplatin and Radiotherapy|
1755769|NCT00242762|Drug|ZD1839 (IRESSA™)|
1755770|NCT00242762|Drug|Docetaxel|
1755771|NCT00242762|Drug|Cisplatin|
1755772|NCT00242775|Drug|Budesonide/formoterol Turbuhaler|
1755773|NCT00242775|Drug|Salmeterol/fluticasone Diskus|
1755774|NCT00242788|Drug|Gefitinib and capecitabine|
1755775|NCT00242801|Drug|Gefitinib|
1755776|NCT00242814|Drug|Micardis|
1755777|NCT00242814|Drug|Amlodipine|
1755778|NCT00242814|Procedure|Abdominal biopsy|
1755779|NCT00242827|Drug|Oral CEP-701|
1755780|NCT00242840|Drug|No intervention; Observational study|
1755781|NCT00242853|Procedure|Power doppler ultrasonography|
1755782|NCT00242853|Procedure|High frequency ultrasonography|
1755783|NCT00242853|Procedure|Exhaled nitric oxide assessment|
1755786|NCT00242879|Drug|Physician determined comparator PI + ritonavir|
1755787|NCT00242879|Drug|GW640385 + ritonavir|
1755788|NCT00242892|Procedure|Intra coronary measures of pressure|Intra coronary measures of pressure
1755789|NCT00242905|Behavioral|Study of memory using MRI|Study of memory using MRI
1755790|NCT00242918|Drug|docetaxel|
1755791|NCT00242918|Drug|ZD1839|
1755792|NCT00242931|Other|Nonmyeloablative stem cell conditioning regimen|"Conditioning:
Fludarabine 30 mg/m2/day x 3, day -4 to day -2 TBI 200 cGy x 1, day 0
Hematopoeitic Stem Cell Transplantation:
Infusion of peripheral blood stem cells, day 0
Immunosuppression:
For related donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For related donors: mycophenolate mofetil (MMF) 15 mg/kg p.o. q 12 hours, day 0 to day +27, then stop
For unrelated donors: cyclosporine (CSP) 5 mg/kg p.o. bid, day -3 to day +56, then taper by 20% every 5 days to be completed by day +81 For unrelated donors: mycophenolate mofetil (MMF) 15 mg/kg tid day +0 to day +29, 15 mg/kg bid day +30 to day +149, and then taper by 25% per week from day +150 to day +180. Discontinue by day +181."
1755793|NCT00242944|Drug|Pitavastatin|Pitavastatin 4mg per day
1755794|NCT00242944|Drug|Atorvastatin|Atorvastatin 20mg per day
1755795|NCT00242957|Behavioral|Intervention with Microfinance for AIDS and Gender Equity|
1755796|NCT00242970|Device|3-Dimensional Color Scanning|Color imaging of the face and neck.
1755797|NCT00242983|Procedure|quality-of-life assessment|
1755798|NCT00242996|Biological|filgrastim|
1755799|NCT00242996|Biological|rituximab|
1755800|NCT00242996|Biological|sargramostim|
1755801|NCT00242996|Drug|carmustine|
1755802|NCT00242996|Drug|cyclophosphamide|
1755803|NCT00242996|Drug|etoposide|
1755804|NCT00242996|Procedure|adjuvant therapy|
1755805|NCT00242996|Procedure|bone marrow ablation with stem cell support|
1755806|NCT00242996|Procedure|peripheral blood stem cell transplantation|
1755807|NCT00243009|Drug|cyclosporine|
1755808|NCT00243009|Drug|fludarabine phosphate|
1755809|NCT00243009|Drug|mycophenolate mofetil|
1755810|NCT00243009|Procedure|allogeneic bone marrow transplantation|
1755811|NCT00243009|Procedure|peripheral blood stem cell transplantation|
1755812|NCT00243009|Radiation|radiation therapy|
1755813|NCT00243022|Drug|Boswellia serrata extract|given orally
1755814|NCT00243022|Dietary Supplement|cyanocobalamin|given orally
1755815|NCT00243035|Drug|bortezomib|Given IV
1755816|NCT00243035|Drug|tipifarnib|Given orally
1755817|NCT00243035|Other|laboratory biomarker analysis|Correlative studies
1755824|NCT00243100|Drug|vorinostat|Given orally
1755825|NCT00243100|Drug|gemcitabine hydrochloride|Given IV
1755826|NCT00243113|Drug|docetaxel|
1755827|NCT00243113|Radiation|radiation therapy|
1755828|NCT00243126|Behavioral|Family-Based Risk Reduction Intervention|The intervention module topics include five modules and each module is 2 hours in length. The intervention will focus on the elements critical to HIV risk behavior change. These include: risk education (practical understanding of factors responsible for risk and behavior changes needed to reduce risk); threat personalization (accurate appraisal of personal risk based on behavior); self-efficacy (belief that one can implement risk reduction behavior changes and that if changes are made they will have protective value); skills acquisition (e.g., condom use, safer sex guidance, negotiation); cognitive problem-solving skills; and reinforcement.
1755829|NCT00243139|Device|Mandibular advancement device (activator)|
1755831|NCT00243165|Behavioral|Lifemel honey intake every day|
1755832|NCT00243178|Drug|clopidogrel (SR25990C)|75 mg once daily in combination with aspirin
1755833|NCT00243191|Drug|imatinib mesylate|400 mg orally twice a day for 10 - 14 days
1755834|NCT00243204|Drug|talabostat mesylate|
1755835|NCT00243204|Drug|docetaxel|
1755836|NCT00243217|Drug|SPM 936|
1755837|NCT00243230|Drug|Vicriviroc maleate 20 mg|Two tablets of vicriviroc maleate 10 mg and one tablet of placebo once daily for 48 weeks. Then, for subjects who meet applicable criteria, one tablet of vicriviroc maleate 30 mg once daily, if appropriate, until the sponsor terminates the clinical development of vicriviroc.
1755838|NCT00243230|Drug|Vicriviroc maleate 30 mg|Three tablets of vicriviroc maleate 10 mg once daily for 48 weeks. Then, for subjects who meet applicable criteria, one tablet of vicriviroc maleate 30 mg once daily, if appropriate, until the sponsor terminates the clinical development of vicriviroc.
1755839|NCT00243230|Drug|Placebo|Three tablets of placebo once daily for 48 weeks. Then, for subjects who meet applicable criteria, one tablet of vicriviroc maleate 30 mg once daily, if appropriate, until the sponsor terminates the clinical development of vicriviroc
1755840|NCT00243243|Drug|Recombinant Factor VIIa|intravenous infusion of Factor VIIa
1755841|NCT00243243|Drug|Placebo|intravenous infusion of placebo (sterile water)
1755842|NCT00243256|Drug|Cholecalciferol|
1755843|NCT00243269|Behavioral|Acupressure expectancy enhancement|"This study hypothesizes that patients receiving efficacy enhancing information about the acupressure bands will expect less treatment-related nausea, which will subsequently result in less treatment-related nausea compared to patients who do not receive such information.
This study extends prior research by utilizing a randomized controlled trial in a clinical environment to examine the efficacy of an intervention that is specifically designed to reduce patients' response expectancies concerning nausea development from cancer treatments, and, thereby, reduce nausea."
1755844|NCT00243282|Behavioral|Relaxation Response (instruction, pocket practice card prov)|
1755845|NCT00243282|Behavioral|Mindfulness training using model developed from UMass|
1755846|NCT00243295|Drug|rhBMP-2/CPM|
1755848|NCT00243321|Procedure|high dose-rate brachytherapy|High dose-rate brachytherapy
1755849|NCT00243321|Procedure|intensity-modulated radiation therapy|intensity-modulated radiation therapy
1755850|NCT00243334|Other|Integration of advanced clinical decision support with ambulatory computerized physician order entry|Actiobable Reminders related to medication monitoring, preventive care and chronic disease management, and test result follow-up are administered either during the visit or between visits.
1755851|NCT00243347|Drug|AZD2171|oral tablet
1755852|NCT00243360|Behavioral|diagnostic and treatment clinical algorithms|
1755853|NCT00243373|Device|Barcode technology/eMAR|
1755854|NCT00243386|Drug|Antihemophilic factor, recombinant, manufactured protein-free|Standard prophylaxis: 20-40 IU/kg every 48+/-6 hours, actual dose determined by investigator
1755855|NCT00243386|Drug|Antihemophilic factor, recombinant, manufactured protein-free|PK-driven prophylaxis: 20-80 IU/kg every 72+/-6 hours, actual dose determined by Baxter using an algorithm and the patient´s pharmacokinetic data
1755856|NCT00243399|Drug|Oxandrolone|Subjects will be started on a dose of oxandrolone 0.04 mg/kg/day orally, once/day. After 16 weeks, patients will be assessed for hematologic improvement. If this criteria is not met after 16 weeks, the dose will be escalated to 0.08 mg/kg/day. If no improvement is noted after 16 weeks on the escalated dose, oxandrolone therapy will be discontinued.
1755857|NCT00243412|Drug|folate|Minimum of 1 mg/day oral (or folinic acid 5 mg/week)
1755858|NCT00243412|Drug|methotrexate|15-25 mg/week oral or parenteral (10-14 mg/week if intolerant)
1755859|NCT00243412|Drug|methylprednisolone|100 mg intravenous (IV) prior to each rituximab infusion (For Arm B, for the Months 6 and 18 cycles, IV saline was administered prior to each placebo infusion)
1755860|NCT00243412|Drug|Placebo|To maintain the blind, patients in Arm B (Rituximab 1000 mg) received placebo infusions at Months 6 and 18.
1755861|NCT00243412|Drug|Rituximab|500 mg or 1000 mg IV*2.
1755862|NCT00243425|Procedure|Standard Quality Improvement|
1755863|NCT00243425|Procedure|Patient-centered Intervention|
1755864|NCT00243438|Device|Multilink Vision™ Stent (CE-labeled)|Patients who have diabetes and/or complex lesions and who have had a Multilink Vision™ Stent placed.
1755865|NCT00243451|Other|PET scan & fMRI|Subjects will be screened and if applicable for the study will be scheduled for an MRI. At the third visit they will complete the PET scan. They will return at 6, 12, 24, and 36 months and complete another PET scan at the last visit.
1755866|NCT00243464|Drug|Calcipotriol plus betamethasone dipropionate (LEO80185 gel)|
1755867|NCT00243477|Drug|Escitalopram|Escitalopram 10mg or placebo once a day
1755868|NCT00243490|Procedure|Photodynamic therapy using Photosan and LumaCare™ Lamp Model LC-122M|
1755869|NCT00243503|Drug|SU011248/Trastuzumab|SU011248 will be administered orally, starting dose of 37.5 mg daily on a continuous regimen. Trastuzumab will be administered weekly (loading dose 4 mg/kg followed by weekly 2mg/kg) or every 3 weeks (loading dose 8 mg/kg followed by 6mg/kg q3w). Study treatment should continue until progression, withdrawal for other reasons, or for up to 18 months following which patients requiring continued access will be offered SU011248 on a separate protocol.
1755871|NCT00243529|Biological|autologous dendritic cell vaccine|
1755872|NCT00243542|Drug|ACZONE Gel, 5%|
1755873|NCT00243542|Drug|Vehicle|
1755874|NCT00243555|Procedure|allergy skin testing|
1755875|NCT00243555|Procedure|venepuncture|
1755876|NCT00243568|Drug|Vicriviroc|
1755877|NCT00243581|Behavioral|Dean Ornish Heart Disease Reversing Program|
1755878|NCT00243594|Biological|Peptide-pulsed dendritic cells|peptide-pulsed dendritic cells
1755879|NCT00243607|Other|hydrotherapy according to Kneipp rules|2-5 applications of hydrotherapy according to Kneipp rules (self application) per day
1755880|NCT00243620|Device|Vacuum therapy (device)|
1755881|NCT00243633|Procedure|Real-time contrast-enhanced ultrasound sonography|
1755882|NCT00243646|Radiation|External beam radiation|All patients will receive a 5-week course of external beam radiation therapy to the pelvis and a Pd-103 brachytherapy implant
1755883|NCT00243646|Drug|Lupron|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
1755884|NCT00243646|Drug|Casodex|9 months of an LHRH agonist and 4 months of an anti-androgen) is optimal for securing long-term biochemical control (a stable, non-rising PSA).
1755885|NCT00243659|Biological|ReFacto AF|
1755886|NCT00243672|Drug|Atorvastatin|
1755887|NCT00243672|Drug|Gemfibrozil|
1755888|NCT00243685|Other|Laboratory Assay|Chemotherapy
1755889|NCT00243685|Other|Mick Assay|Chemotherapy doctor determined from results
1755890|NCT00243698|Drug|SonoVue (sulphur hexafluoride microbubbles)|One contrast enhanced ultrasonography using sonovue / 4.8 ml per injection (maximum of 3 injections)
1755891|NCT00243711|Drug|Carboxymethylcellulose sodium and Glycerin|
1755892|NCT00243724|Drug|Esomeprazole|
1755893|NCT00243737|Drug|Artesunate-Mefloquine|
1755894|NCT00243750|Drug|Methotrexate|
1755895|NCT00243763|Drug|TKI258|
1755896|NCT00243789|Drug|Pentoxifylline|"Participants will be randomized to receive either pentoxifylline or placebo in addition to their stable steroid therapy. Active drug and placebo preparations will be supplied as gel capsules of identical size, appearance and taste. Active drug capsules will contain one 400 mg time-release pentoxifylline tablet and inert filler. Placebo capsules will contain inert filler.
Based on weight at screening, <30 mg will receive 1 400 capsule/day; 30-49 kg will receive two 400 capsules/day; 50 kg or greater will receive three 400 mg capsules/day."
1755897|NCT00243815|Drug|ibuprofen|
1755898|NCT00243828|Device|Total Face Mask|
1755899|NCT00243841|Radiation|Stereotactic Body Radiation|Arm A: Childs A - receive 3 fractions. Arm B: Childs B - receive 5 fractions.
1755900|NCT00243854|Drug|Tarceva|Tarceva: 100mg/day x 2 weeks (Days 1-14) +
1755901|NCT00243867|Drug|Taxoprexin|6. Other events that, based upon appropriate medical judgement, may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes
1755902|NCT00243880|Drug|lovastatin|investigators will treat the patients within 24 hours of symptom onset with short term high-dose lovastatin at escalating dosage. The escalating dosage levels will be 1, 3, 6, 8, and 10 mg/kg per day for 3 days.
1755903|NCT00243893|Drug|minocycline|Take minocycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
1755904|NCT00243893|Drug|doxycycline|Take doxycycline 50mg BID x2 years. Labs drawn at baseline, then every-6 months. MRI is done at baseline and completion of study.
1755905|NCT00243906|Drug|Recombinant tissue plasminogen activator|Low-dose IV rt-PA (0.6 mg/kg) followed by delivery of additional IA rt-PA (up to 22 mg).
1755906|NCT00243906|Procedure|Low-intensity ultrasound|Delivery of additional IA rt-PA (up to 22 mg) in the setting of low-energy ultrasound via the EKOS microinfusion catheter at the site of IA occlusion in acute ischemic stroke patients with large strokes (NIHSS >/= 10) treated within 3 hours of symptoms onset.
1755907|NCT00243919|Behavioral|Early locomotor training program|The early locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 2 months post-stroke.
1755908|NCT00243919|Behavioral|Late locomotor training program|The late locomotor training program is an out-patient program of locomotor training for 36 sessions, 3 times per week, using a body weight support system and stepping on a treadmill and overground training beginning at 6 months post-stroke.
1755909|NCT00243919|Behavioral|Home Exercise Program|Participants in the early home exercise group will receive a non-specific low intensity exercise program beginning at 2 months post stroke.
1755910|NCT00243932|Drug|coenzyme Q10|antioxidant and mitochondrial cofactor, given in capsules three times daily
1755911|NCT00243932|Drug|Placebo|Placebo capsules, indistinguishable from CoQ10 capsules, given three times daily
1755912|NCT00243945|Drug|Rotigotine|
1755913|NCT00243971|Drug|SPM 962|
1755914|NCT00243984|Drug|topiramate|
1755915|NCT00243997|Behavioral|Becoming Parents Program|Couple focused educational program for couples adding a new baby to the family-21 hours of workshops during pregnancy with two three hour workshops after the baby is born.
1755916|NCT00244010|Device|Allogeneic stem cell transplant|Participants will receive a reduced intensity conditioning regimen consisting of fludarabine, thiotepa, melphalan, and OKT3 followed by an infusion of haploidentical stem cells. Rituximab will be administered within 24 hours of the infusion in an effort to prevent posttransplant lymphoproliferative disorder LPD. In addition to T-cell depletion of the donor product, participant will receive mycophenolate mofetil for prophylaxis of GVHD.
1755917|NCT00244023|Drug|Testosterone gel|one sachet of 50 mg applied once a day, possibly titrated to two sachets if insufficient improvement of erectile function
1755918|NCT00244023|Drug|testosterone|testosterone gel, one sachet of 50 mg applied once a day, possibly titrated to 100 mg if insufficient effect
1755919|NCT00244023|Other|placebo gel|one sachet of placebo gel once a day possibly titrated to 2 sachets if insufficient efficacy
1755920|NCT00244049|Behavioral|counseling|Physicians discussed high-risk/binge drinking with college-aged individuals in a health care setting.
1755921|NCT00244049|Other|Brief Intervention|Physicians discussed effects of high-risk/binge drinking with college-aged individuals in a health care setting.
1755922|NCT00244062|Behavioral|counseling|
1755923|NCT00244075|Dietary Supplement|nutritional supplement|either oral nutritional formula (Nepro) or intravenous IDPN solution will be administered during hemodialysis; Nepro has a total calorie amount as well as protein, carbohydrate and fat content that are comparable to that of IDPN, and will be provided at four equal amounts with 1-hour intervals throughout the study (150 ml for a total of 600 ml over 4 hours of hemodialysis); IDPN consists of 225 ml of amino acids at a concentration of 15%, 112.5 ml of dextrose at 50% and 112.5 ml of lipids at 20%, will be given at a rate of 150 ml/hr, and will provide 209 kcal/hr
1755924|NCT00244075|Drug|recombinant human growth hormone (rcGH)|subcutaneous administration of 75 micrograms/kg/day of rcGH for 3 consecutive days
1755925|NCT00244075|Behavioral|exercise|either dual leg press (3 sets of 8-12 repetitions) beginning 30 minutes prior to hemodialysis, or modified stepper (minimum of 15 minutes up to a maximum of 90 minutes, depending upon the patient's tolerance) beginning 15 minutes post initiation of hemodialysis
1755926|NCT00244101|Drug|PS Group|Intubation, prophylactic surfactant administration shortly after delivery, and subsequent stabilization on ventilator support.
1755927|NCT00244101|Device|NCPAP Group|Early stabilization on nasal continuous positive airway pressure (NCPAP) with selected intubation and surfactant administration for clinical indications.
1755928|NCT00244101|Drug|ISX Group|Intubation, prophylactic surfactant administration shortly after delivery, and rapid extubation to nasal CPAP.
1755929|NCT00244114|Drug|blood draw|Single blood sample collected to perform histamine release assay.
1755930|NCT00244114|Procedure|Blood draw|Single blood sample collected to perform histamine release assay.
1755931|NCT00244127|Drug|Cyclophosphamide, oncovin, myocet, prednisone & rituximab (R-COMP)|
1755932|NCT00244140|Drug|Iopromide 370 mg I/mL|Iopromide (Ultravist 370 mg I/mL) administered intravenously
1755933|NCT00244140|Drug|Iopromide 300 mg I/mL|Iopromide (Ultravist 300 mg I/mL) administered intravenously
1755934|NCT00244153|Drug|intraarticular morphine|
1755935|NCT00244153|Drug|intraarticular dexamethasone|
1755936|NCT00244166|Drug|prednisolone|
1755937|NCT00244179|Drug|interferon-gamma|
1755938|NCT00244179|Drug|infliximab|
1755939|NCT00244179|Drug|dmard|
1755940|NCT00244192|Drug|infliximab (Remicade)|
1755941|NCT00244205|Procedure|Identifying genes methylated in urine|
1755942|NCT00244218|Drug|tetrahydrobiopterin (BH4)|Either placebo or BH4, 10mg/kg/day will be given for three months. Then the patient will be given three additional months of open label BH4 at the same rate.
1755943|NCT00244231|Drug|Nidadd|
1755944|NCT00244244|Drug|arimoclomol|
1755945|NCT00244257|Biological|GMA161|0.1 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
1755946|NCT00244257|Biological|GMA161|0.3 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
1755947|NCT00244257|Biological|GMA161|0.6 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
1755948|NCT00244257|Biological|GMA161|1.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
1755949|NCT00244257|Biological|GMA161|3.0 mg/kg, IV infusion on Day 0 and monitored for 7 days with collection of blood samples
1755950|NCT00244270|Device|totally implantable vascular access device|totally implantable vascular access device
1755951|NCT00244283|Drug|Sevoflurane|
1755952|NCT00244283|Procedure|High thoracic epidural analgesia|
1755953|NCT00244296|Drug|Duloxetine hydrochloride|
1755954|NCT00244296|Drug|placebo|
1755955|NCT00244309|Drug|tamsulosin and/or dutasteride|
1755956|NCT00244322|Drug|LY450139 dihydrate|
1755957|NCT00244322|Drug|placebo|
1755958|NCT00231270|Device|Cordis Nitinol Stent|
1755959|NCT00231270|Device|PRECISE tapered stent|
1755960|NCT00231270|Device|ANGIOGUARD XP Emboli Capture Guidewire (ECGW)|
1755961|NCT00231283|Device|CYPHER NxT SES ON BX SONIC OTW STENT DELIVERY SYSTEM (SDS)|CYPHER NxT Sirolimus-eluting Coronary Stent on the BX SONIC Over-the-wire Stent Delivery System
1755962|NCT00231296|Device|Cardiac CryoCor Cryoablation System|Treatment with CryoCor Cardiac Cryoablation system
1755963|NCT00231296|Drug|Medical management|Medical management- treatment with standard medical therapy, which includes anti-arrhythmic medications
1755964|NCT00231309|Drug|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor
1755965|NCT00231322|Drug|praziquantel|
1755966|NCT00231335|Drug|escitalopram|
1755967|NCT00231348|Drug|Nefazodone|
1755968|NCT00231374|Procedure|Myelogram|
1755969|NCT00231387|Drug|rosiglitazone|
1755970|NCT00231413|Biological|Novel HPV vaccine|
1755971|NCT00231426|Device|ICD|
1755972|NCT00231439|Drug|IvIg|
1755973|NCT00231452|Drug|Sulfadoxine-pyrimethamine (SP) + Artesunate (AS)|Monthly chemoprophylaxis with SP (Fansidar® 500/25 mg) plus Artesunate (AS, Arsumax® 50 mg) or placebo (provided by Roche and Sanofi-Aventis) was administered according to the following age-based dosing schedule: ½ tablet of SP or placebo and ½ tablet of AS or placebo on the first day and ½ tablet of AS or placebo on the second and third days.
1755974|NCT00231465|Drug|docetaxel (Taxotere®)|Taxotere® will be administered to patients a maximum of 2 cycles, after a maximal response is achieved, and then discontinued.
1755975|NCT00231465|Drug|ZD1839|ZD1839 will be continued until progression, or until trial closure, whichever comes first.
1755976|NCT00231478|Drug|granisetron|20 micrograms intravenously (iv) 15 min prior to end of surgery
1755977|NCT00231478|Drug|granisetron|40 micrograms intravenously (iv) 15 min prior to end of surgery
1755978|NCT00231491|Drug|Botulinum Toxin A (Botox )|
1755979|NCT00231504|Procedure|Blood samples|Blood samples
1755980|NCT00231517|Drug|topical opiod|
1755981|NCT00231517|Drug|morphine sulphate in intrasite gel|
1755982|NCT00231530|Drug|topiramate|
1755983|NCT00231543|Procedure|Laparoscopic fundoplication|
1755984|NCT00231543|Procedure|open Nissen fundoplication|
1755985|NCT00231556|Drug|topiramate|
1755986|NCT00231569|Drug|ISIS 301012 or Placebo|30 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
1756112|NCT00245440|Drug|Azithromycin|250 mg tablets; 2 tablets once daily (500 mg) for 3 days
1755987|NCT00231569|Drug|ISIS 301012 or Placebo|100 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
1755988|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
1755989|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
1755990|NCT00231569|Drug|ISIS 301012 or Placebo|400 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, and 29
1755991|NCT00231569|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
1755992|NCT00231569|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injection on days 1, 8, 10, 12, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
1755993|NCT00231582|Drug|epirubicin|epirubicin
1755994|NCT00231582|Procedure|high-dose and autologous stem cell transplantation|high-dose and autologous stem cell transplantation
1755995|NCT00231582|Drug|paclitaxel|paclitaxel
1755996|NCT00231582|Drug|etoposide|etoposide
1755997|NCT00231582|Drug|ifosfamide|ifosfamide
1755998|NCT00231582|Drug|carboplatin|carboplatin
1755999|NCT00231595|Drug|topiramate|
1756000|NCT00231608|Drug|topiramate|
1756001|NCT00231621|Drug|topiramate|
1756002|NCT00231634|Drug|topiramate|
1756003|NCT00231647|Drug|topiramate|
1756004|NCT00231660|Drug|topiramate|
1756005|NCT00231673|Drug|Topiramate|Increasing dosing of topiramate gradually to 200 mg daily by mouth, dose maintenance for 12 weeks, then decreasing dose until stopped over 12 weeks
1756006|NCT00231686|Behavioral|Supervised aerobic training|
1756007|NCT00231686|Behavioral|Supervised strength training|
1756008|NCT00231686|Behavioral|Unsupervised training|
1756009|NCT00231699|Procedure|Plastic wrap (study group) and cotton (control group) wrap.|
1756010|NCT00231725|Drug|insulin lispro injection [rDNA origin] Low Mix|
1756011|NCT00231738|Drug|Eicosapentaenoic acid ethyl ester(EPADEL Capsule 300 TM)|
1756012|NCT00231764|Drug|daclizumab|
1756013|NCT00231777|Drug|Comparator: MK0517|a single administration of 40 mg MK0517 by IV immediately prior to surgery
1756014|NCT00231777|Drug|Comparator: ondansetron|a single administration of 4 mg ondansetron by IV immediately prior to surgery
1756015|NCT00231790|Drug|MK-0634 50 mg|one capsule orally, once daily in morning
1756016|NCT00231790|Drug|MK-0634 125 mg|one or three capsules orally, once daily in morning
1756017|NCT00231790|Drug|Placebo for MK-0634|one, two, three or four capsules orally once daily in morning
1756018|NCT00231803|Procedure|Combined CKD and CVD Prevention|
1756019|NCT00231803|Procedure|Cardiovascular Disease prevention|
1756020|NCT00231803|Procedure|Treatment of Chronic Kidney Disease complications|
1756021|NCT00231816|Biological|ZOSTAVAX™ (concomitant)|a single administration of 0.65 mL subcutaneous injection of zoster vaccine live on Day 1 and placebo at Week 4
1756022|NCT00231816|Biological|Comparator: Influenza Vaccine|a single administration of 0.5 mL intramuscular injection of influenza vaccine (inactivated) at Day 1
1756023|NCT00231816|Biological|ZOSTAVAX™ (Nonconcomitant)|Placebo injection on Day 1 and a single administration of 0.65 mL subcutaneous injection of zoster vaccine live at Week 4
1756024|NCT00231829|Drug|Celecoxib|
1756025|NCT00237250|Drug|vildagliptin|
1756026|NCT00237263|Drug|Entacapone|
1756027|NCT00237276|Procedure|colonoscopy|
1756028|NCT00237289|Drug|topiramate|
1756029|NCT00237302|Drug|topiramate|
1756030|NCT00244348|Drug|Oxaliplatin (via HAI)|
1756031|NCT00244348|Drug|5 Fluorouracil (systemic)|
1756032|NCT00244361|Drug|rituximab|
1756033|NCT00244374|Biological|Hepatitis A & B vaccine|Each subject will receive a total of 4 immunizations over 6 months on a 0-1-2-6 month schedule. At the initial visit, subjects>18 years of age will receive the Twinrix vaccine and subjects<18 years of age will receive the Engerix-B vaccine. Cohort subjects>18 years found to have HAV antibody at screening will receive Engerix-B for their remaining 3 immunizations. All subjects will receive: an immunization record with the first vaccine dose entered and the dates the next doses are due; helpful hints for remembering vaccine appointments; and written instructions on where and how to get immunized outside of SF.
1756034|NCT00244374|Behavioral|Outreach|Outreach worker vaccine adherence support: Half of cohort subjects will be assigned to outreach worker vaccine adherence support and will meet with their outreach workers from Haight Ashbury Youth Outreach Team (HAYOT) and Glide Health Services on the day of vaccine cohort study enrollment. Intensive vaccination tracking and in-person outreach support will begin one week before the second and third vaccine doses are due, and again two weeks before the fourth dose is due.
1756035|NCT00244374|Behavioral|AIC|The Adult Immunization Clinic (AIC) is a public low-cost vaccine clinic located centrally at 101 Grove Street in the lobby of the San Francisco Department of Public Health (SFDPH). The clinic is open from Monday-Friday 9 a.m. to 4 p.m. Nurses at the AIC will be available 40 hours/week to administer free immunizations to study subjects.
1756036|NCT00244374|Behavioral|SEP|Subjects randomized to a set of syringe exchange programs for administration of viral hepatitis immunizations at Month 1, 2, 6. Research nurses will provide 16 hours/week of vaccine administration services at SEPs well attended by young IDU. The San Francisco Needle Exchange (SFNE) serves primarily youth and young adults on Mondays, Wednesdays, and Fridays from 5-7 p.m. in an indoor location in the Haight-Ashbury district. A study nurse will be at SFNE for a total of 6 hours per week. HIV Prevention Project (HPP) sites also operate for 2 hrs each (Tues, Thu, Fri, Sat). Medical services are provided either in a clinic setting at indoor sites (6th Street) or at outdoor sites (Hemlock Alley, Duboce). A study nurse will attend each of these 5 weekly sites for a total of 10 hours/week.
1756037|NCT00244387|Drug|SPM 962|
1756038|NCT00244426|Drug|indobufen|Indobufen capsules 100 and 200mg
1756039|NCT00244426|Drug|aspirin|Acetylsalicylic acid capsules 300mg
1756040|NCT00244439|Drug|MALG|30 minute application
1756041|NCT00244439|Drug|Ovide (malathion) lotion 0.05%|8-12 hour application
1756042|NCT00244439|Drug|Permethrin 1%|10 minute application
1756043|NCT00244452|Drug|Cetrorelix|
1756113|NCT00245440|Drug|Telithromycin|400 mg tablets; 2 tablets once daily (800 mg) for 5 days
1756114|NCT00245453|Drug|azithromycin|250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
1756044|NCT00244478|Dietary Supplement|Soy Protein Dietary Supplement|The soy-based meal replacements will contain 20 g soy protein and 161.2 mg isoflavones, 220-240 kcal, 31-36 g total carbohydrates, 0-2 g dietary fiber, 500 mg calcium, and 2.0-2.5 g total fat per serving.
1756045|NCT00244478|Dietary Supplement|Placebo|The control shake will have 20 g casein substituted for soy protein, and will be otherwise identical to the soy shakes. The shakes will be available in two flavors: chocolate and vanilla.
1756046|NCT00244491|Behavioral|Care Transitions Intervention|
1756047|NCT00244504|Drug|moxonidine|moxonidine 0.2 mg/d starting the morning of surgery until day 4 after surgery
1756048|NCT00244517|Drug|TTE measurements under anesthesia with sevoflurane, isoflurane, desflurane, and remifentanyl|TTE measurements were performed during remifentanil 2 ng/ml TCI end-organ concentration, 1 MAC of either anesthetic gas under spontaneous ventilation and 1 MAC of either anesthetic under IPPV
1756049|NCT00244517|Drug|Sevoflurane, Isoflurane, Desflurane|1 MAC
1756050|NCT00244530|Drug|Nifedipine|
1756051|NCT00244543|Drug|R89674 (generic name not yet established)|
1756052|NCT00244556|Drug|Methotrexate plus ENBREL or ENBREL alone|
1756053|NCT00244569|Drug|13C-Methacetin|
1756054|NCT00244569|Device|Breath ID Machine|
1756055|NCT00244595|Drug|candsartan cilexetil|
1756056|NCT00244608|Drug|Budesonide/Formoterol Turbuhaler|
1756057|NCT00244608|Drug|Budesonide Turbuhaler (Pulmicort)|
1756058|NCT00244608|Drug|Terbutaline Turbuhaler|
1756059|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.05 mg/kg once daily oral liquid dose
1756060|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.20 mg/kg once daily oral liquid dose
1756061|NCT00244621|Drug|candesartan cilexetil (Atacand)|0.40 mg/kg once daily oral liquid dose
1756062|NCT00244634|Drug|candsartan cilexetil|
1756063|NCT00244647|Drug|RESTEN-MP|
1756064|NCT00244660|Procedure|Frequent blood pressure measurements|
1756065|NCT00244660|Behavioral|Education|
1756066|NCT00245102|Drug|sorafenib tosylate|Given orally
1756067|NCT00245115|Biological|filgrastim|
1756068|NCT00245115|Drug|busulfan|
1756069|NCT00245115|Drug|cyclophosphamide|
1756070|NCT00245115|Procedure|in vitro-treated bone marrow transplantation|
1756071|NCT00245115|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1756072|NCT00245128|Drug|imatinib mesylate|Once daily oral administration of Imatinib Mesylate at a dose of 600mg for 12 months.
1756073|NCT00245141|Biological|dactinomycin|
1756074|NCT00245141|Drug|cyclophosphamide|
1756075|NCT00245141|Drug|vincristine sulfate|
1756076|NCT00245141|Radiation|radiation therapy|
1756077|NCT00245154|Drug|carboplatin|Given IV
1756078|NCT00245154|Drug|cediranib maleate|Given orally
1756079|NCT00245154|Drug|paclitaxel|Given IV
1756080|NCT00245154|Other|placebo|Given orally
1756081|NCT00245167|Procedure|Tracheal Aspirate Fluid|
1756082|NCT00245180|Behavioral|Diet|
1756083|NCT00245180|Behavioral|Exercise|
1756084|NCT00245193|Behavioral|Motivationally-Enhanced Interpersonal Psychotherapy|
1756085|NCT00245206|Drug|Aripiprazole|Participant will take aripiprazole. Dosing will be determined by each participant's psychiatrist.
1756086|NCT00245206|Drug|Olanzapine|Participant will take olanzapine. Dosing will be determined by each participant's psychiatrist.
1756087|NCT00245206|Drug|Risperidone|Participant will take risperidone. Dosing will be determined by each participant's psychiatrist.
1756088|NCT00245219|Behavioral|Education|The education group meetings focused on providing patients with information about their disease as well as methods to manage their illness and its side effects. Facilitators emphasized the theme of perceived control during all sessions, discussing how participants are in control of their illness experience and can have more control of their lives. A different topic was addressed in each session. Weekly homework assignments asked patients to write down something new they had learned from the session regarding how to take control of their lives. Meeting topics were as follows: Overview of breast cancer, treatment types and side effects, nutrition and diet management, exercise, body image, communication issues, relationships, and sexuality.
1756089|NCT00245219|Behavioral|Peer support|The peer support group meetings focused on fostering purpose in life by providing participants with opportunities to support and care for one another. Patients completed a weekly diary of critical experiences or current life problems as homework, and were then encouraged to share these experiences in the group meetings. The group facilitator encouraged participants to help one another with these issues, and share how they had dealt with similar problems.
1756090|NCT00245232|Behavioral|Cognitive Therapy|
1756091|NCT00245232|Behavioral|Cognitive Processing Therapy|
1756092|NCT00245232|Behavioral|Written Exposure|
1756093|NCT00245245|Drug|recombinant porcine coagulation factor VIII (OBI-1)|
1756094|NCT00245258|Drug|Sildenafil Citrate|
1756095|NCT00245271|Drug|OMS103HP|Maximum of 13 bags of OMS103HP irrigation solution over a maximum of 2 hours
1756096|NCT00245271|Drug|Vehicle|Maximum of 13 bags of BSS irrigation over a maximum of 2 hours.
1756097|NCT00245297|Drug|Kogenate FS, reconstituted in a suspension of liposomes|
1756098|NCT00245310|Procedure|Indocyangreen (ICG) clearance|
1756099|NCT00245323|Behavioral|Smoking status as a routine vital sign|
1756100|NCT00245336|Biological|rThrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
1756101|NCT00245336|Drug|bovine thrombin|1000 U/mL applied topically in combination with absorbable gelatin sponge
1756102|NCT00245349|Procedure|F-18 Fluorothymidine|
1756103|NCT00245362|Biological|CG 8020 and CG 2505|
1756104|NCT00245375|Drug|Tylenol #3|
1756105|NCT00245375|Drug|Combination Tylenol and Ibuprofen|
1756106|NCT00245388|Drug|Muraglitazar|
1756107|NCT00245401|Device|CYPHERTM Sirolimus-Eluting Coronary Stent|
1756108|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 48 weeks
1756109|NCT00245414|Drug|Pegasys®|180μg for s.c./week for 24 weeks
1756110|NCT00245427|Drug|all macrolide antibiotics|Varies based on antibiotic
1756111|NCT00245427|Drug|all beta-lactam antibiotics|Varies based on antibiotic
1756115|NCT00245453|Drug|telithromycin|400 mg tablets; 2 tablets once daily (QD) for 5 days
1756116|NCT00245453|Drug|Clarythromycin|500 mg extended release tablets; 2 tablets QD for 7 days
1756117|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
1756118|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
1756119|NCT00245466|Drug|Degarelix|Given as a subcutaneous injection once every 4 weeks.
1756120|NCT00245479|Drug|Primary nocturnal enuresis|Desmopressin
1756121|NCT00245492|Procedure|Chromocolonoscopy|Indigocarmine dye applied to entire colon to highlight mucosal detail and enhance detection of flat lesions.
1756122|NCT00245505|Drug|Mesalazine (Mesalamine)|Pentasa (mesalazine) sachets 2 g morning + 2 g evening during 12 weeks treatment
1756124|NCT00245544|Drug|MK0759|
1756125|NCT00245557|Drug|Sertraline|"Oral Sertraline Dosage started at 25 mg a day, with increases up to maximum dosage strength of 200 mg a day.
Duration of treatment was 12 weeks."
1756126|NCT00245570|Drug|Comparator: Montelukast|1 dose montelukast 10 mg tablet given orally in one of three treatment periods
1756127|NCT00245570|Drug|Comparator: Salmeterol|1 dose of 50 ug salmeterol given by inhalation in one of three treatment periods
1756128|NCT00245570|Drug|Comparator: Placebo (montelukast)|1 dose matching-image placebo to montelukast tablet in two of three treatment periods
1756129|NCT00245570|Drug|Comparator: Placebo (salmeterol)|1 dose matching-image placebo of salmeterol 50 ug inhalation in two of three treatment periods
1756130|NCT00245583|Drug|topiramate (Topomax)|
1756131|NCT00245596|Drug|sildenafil|
1756132|NCT00245609|Drug|Pregabalin|
1756133|NCT00245609|Drug|Alprazolam|
1756134|NCT00245609|Drug|Placebo|
1756135|NCT00245622|Biological|Tovaxin Autologous T cell vaccine|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
1756136|NCT00245622|Biological|Placebo|subcutaneous injections administered by healthcare provider at weeks 0, 4, 8, 12, and 24
1756137|NCT00245635|Drug|Fluoxetine|Tablets varying between 10mg and 80mg on a fixed/flexible dosing schedule based on the subjects' weight and side effects score.
1756138|NCT00245635|Drug|Placebo|Placebo tablets will be given 1x/day for the duration of the study at a fixed/flexible dosing schedule similar to that for the drug fluoxetine based off of subjects' weight and side effects score.
1756139|NCT00245648|Drug|fibrinolytic therapy or combination reduced fibrinolytic therapy|
1756140|NCT00245661|Drug|Temazepam|
1756141|NCT00245674|Drug|amisulpride|
1756142|NCT00245687|Device|Tiger Tube|
1756143|NCT00245713|Drug|levetiracetam|
1756144|NCT00245726|Device|FES Cycle|Subjects will use electrical stimulation of the leg muscles to pedal a cycle for 1 hour / 3x week
1756145|NCT00245726|Device|ES therapy|Subjects will electrically stimulate the leg muscles for 1 hour/ 3x week
1756146|NCT00245726|Device|Passive (Motor Assist) Cycle|Subjects will use a cycle that moves the legs for 1 hour/3x per week
1756147|NCT00245739|Drug|TMC-114|600/100 mg tablets of TMC114/rtv BID until commercial available to the subject
1756148|NCT00245752|Device|acupuncture|acupuncture in points bilaterally: BL 67, LI 4, SP6, one in GV20.
1756149|NCT00245765|Drug|CDP870 (Certolizumab pegol)|
1756150|NCT00245791|Drug|Levofloxacin|
1756151|NCT00245817|Behavioral|HINCAB|Psycho-educative intervention performed 2 and 4 weeks after surgery
1756152|NCT00245830|Procedure|Ischemic Preconditioning|Experimental: Hepatic Ischemic Preconditioning blood flow to the liver will be cut off by hilar clamping for ten minutes followed by release of the clamp prior to removal of the liver from the donor.
1756153|NCT00245843|Behavioral|Mother Infant Transaction Program (MITP)|Psychosocial intervention. 11-session one hour standardized intervention program. The aim of the MITP is to help parents to appreciate their infant's unique characteristics,temperament and developmental potential.
1756154|NCT00245856|Drug|Dalteparin sodium injection|200units/kg subcutaneous daily for one month, followed by 150units/kg subcutaneous daily for two additional months or 200 units/kg subcutaneously daily for 5 days followed by warfarin.
1756155|NCT00245856|Drug|Warfarin|Titrated to INR 2-3 through study month 3
1756156|NCT00245869|Procedure|Contrast-enhanced Ultrasound|
1756157|NCT00245882|Behavioral|Care Coordination|Care coordination with monthly follow-up by a diabetes nurse educator
1756158|NCT00245882|Behavioral|Home Telemedicine|Active care management by a nurse practitioner using home telemedicine
1756159|NCT00245895|Drug|Aranesp|Aranesp
1756160|NCT00245908|Drug|azithromycin|
1756161|NCT00245921|Drug|Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg|
1756162|NCT00245934|Drug|Enbrel|
1756163|NCT00245947|Drug|ERB-041|
1756164|NCT00245960|Drug|etanercept|Group A: Period 1: 50mg BIW. Period 2: 50 mg QW. Group B: Period 1 and 2: 50mg QW.
1756165|NCT00245973|Drug|Bifeprunox|
1756166|NCT00245986|Procedure|Blood draw|
1756167|NCT00246012|Drug|Intetumumab|Intetumumab will be administered at the dose of 3 milligram per kilogram (mg/kg) as intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) over a period of 2 hours (hr) (± 15 minutes) once every 3 weeks until the occurrence of dose limiting toxicities (DLTs). In Phase 2, intetumumab (5 mg/kg or 10 mg/kg) will be administered for 8 cycles until no evidence of disease progression or unacceptable toxicity. If a participant responds to therapy with stable disease (SD) or better, the participant will be eligible to receive up to 8 cycles of extended administrations.
1756168|NCT00246012|Drug|Dacarbazine|Commercially available dacarbazine will be administered intravenously over a 60-minute period (+30 minutes/-30 minutes) and prior to the intetumumab/placebo infusion. In case participants are unable to tolerate dacarbazine even after 2 dose reductions, they will be given the option to continue on intetumumab alone.
1756169|NCT00246012|Drug|Placebo|Placebo will be administered intravenously over a period of 2 hours (+15 minutes/-15 minutes).
1756170|NCT00246025|Drug|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, once a day, oral administration
1756171|NCT00246025|Drug|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, once a day, oral administration
1756172|NCT00246025|Drug|Dabigatran Etexilate|Dabigatran etexilate 220 mg capsule, once a day, oral administration
1756173|NCT00246025|Drug|placebo|matching placebo capsule, once a day, oral administration
1756174|NCT00246038|Device|Boston Scientific ENOVUS AAA Endograft|
1756175|NCT00246051|Behavioral|Sleep Hygiene Education|An education program, consisting of materials from experts in the field of fatigue management, will be provided to all police officers in the intervention group. Videotapes, slides, handouts and other educational material will be compiled to create a variety of information sources for police officers. Examples of materials to be incorporated into this training program would be the Operation Healthy Sleep Training Video, powerpoint created by the Harvard Work Hours, Health and Safety Group and pamphlets provided by the American Academy of Sleep Medicine.
1756176|NCT00246051|Other|Expert-Led Sleep Disorders Screening and Treatment|"Expert-led sleep disorder screening and treatment will consist of visiting police stations and presenting an information session about Operation Healthy Sleep. The session will take place during work time. During the session, we will invite officers to take the Operation Healthy Sleep survey. All subjects that answer the survey indicating that they are at high risk on the Berlin Questionnaire will be contacted to arrange an initial appointment at our OSA research clinic. If they don't meet the criteria they will be disempanelled.
Positive on the Berlin Questionnaire
Clinic visit, exam with a physician, given a home diagnostic device (HDD)
High risk on HDD, seen by physician, given a CPAP machine
Follow up visit after 2-3 weeks, CPAP data downloaded and reviewed
Contacted by a sleep health clinic at 3, 6, 12 months
After 12 months subject will be referred to their primary care physician"
1756177|NCT00246051|Other|Online Sleep Disorders Screening|Online sleep disorder screening will be available to all police officers nation-wide through the Operation Healthy Sleep survey. All subjects that answer the survey questions indicating that they are at high risk of a sleep disorder will be notified either online following the completion of the survey or by email or a letter. Treatment and follow up will not be conducted for individuals who screen positive on the online version of the Operation Healthy Sleep survey.
1756178|NCT00246064|Drug|infliximab|
1756179|NCT00246090|Drug|E7389|E7389 1.4 mg/m^2 intravenous bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
1756180|NCT00246103|Drug|Valproic acid|Beginning Dose, Level 1: 15 mg/kg/day.
1756181|NCT00246103|Drug|Epirubicin|Beginning Dose, Level 1: 75 mg/m^2.
1756182|NCT00246103|Drug|5-fluorouracil|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: 5-fluorouracil 500 mg/m^2.
1756183|NCT00246103|Drug|Cyclophosphamide.|For breast cancer participants treated at MTD of Valproic acid and Epirubicin: cyclophosphamide 500 mg/m^2.
1756184|NCT00246116|Procedure|Functional Imaging of Treatment Effects|PET & VQ Scans
1756187|NCT00246142|Drug|Botulinum type A toxin (Dysport)|
1756188|NCT00246155|Drug|Botulinum toxin type A (Dysport)|
1756189|NCT00246168|Drug|tramadol hydrochloride + acetaminophen|
1756190|NCT00246181|Procedure|radiation therapy|Patients will receive 3 fractions
1756191|NCT00246194|Drug|risperidone (RISPERDAL CONSTA)|Long-acting injectable of risperidone given as per the prescription from the prescribing physician.
1756192|NCT00246207|Drug|CONCERTA (OROS methylphenidate hydrochloride)|
1756193|NCT00246220|Drug|methylphenidate hydrochloride|
1756194|NCT00246233|Drug|methylphenidate|
1756195|NCT00246246|Drug|risperidone|
1756196|NCT00246259|Drug|Risperidone long-acting injection (LAI)|Risperidone LAI 25 mg, 37.5 mg or 50 mg intramuscular injection will be administered every 2 weeks as per Investigator's discretion.
1756197|NCT00246259|Drug|Oral Antipsychotic|Oral antipsychotic (new or current treatment) will be administered in which daily dose range permitted will be risperidone 6 mg; olanzapine 20 mg; quetiapine 800 mg.
1756198|NCT00246272|Drug|risperidone|
1756199|NCT00246285|Drug|risperidone|
1756200|NCT00246298|Drug|epoetin alfa|
1756201|NCT00246324|Drug|Interferon beta 1a, oral doxycycline|Patients took intramuscular interferon beta 1a, 30 micrograms, for 3 months then added oral doxycycline, 100 daily with the interferon for 4 months.
1756202|NCT00246337|Drug|Comparator: Placebo|Placebo to match assigned treatment arm; one orally-administered dose
1756203|NCT00246337|Drug|MK0974|MK0974 25 mg; one orally-administered dose
1756204|NCT00246337|Drug|MK0974|MK0974 50 mg; one orally-administered dose
1756205|NCT00246337|Drug|MK0974|MK0974 100 mg; one orally-administered dose
1756206|NCT00246337|Drug|MK0974|MK0974 200 mg; one orally-administered dose
1756207|NCT00246337|Drug|MK0974|MK0974 300 mg; one orally-administered dose
1756208|NCT00246337|Drug|MK0974|MK0974 400 mg; one orally-administered dose
1756209|NCT00246337|Drug|MK0974|MK0974 600 mg; one orally-administered dose
1756210|NCT00246337|Drug|Rizatriptan|Rizatriptan 10 mg; one orally-administered dose
1756211|NCT00246350|Procedure|massage|8 light massage treatments and hot pack
1756212|NCT00246350|Procedure|massage|16 light massage treatments and hot packs
1756213|NCT00246350|Procedure|spinal manipulation|8 high velocity, low amplitude spinal manipulation treatments and hot pack
1756214|NCT00246350|Procedure|Spinal manipulation|16 high velocity, low amplitude spinal manipulation treatments and hot pack
1756215|NCT00246363|Drug|Silymarin|Silymarin (milk thistle)
1756216|NCT00246363|Drug|Placebo|Placebo
1756217|NCT00246376|Behavioral|Diet|ATP-III diet
1756218|NCT00246376|Behavioral|Exercise|Supervised exercise in study gym
1756219|NCT00246376|Drug|Niacin|Niaspan, titrated up to 2 grams per day
1756220|NCT00246376|Drug|Fenofibrate|Tricor, 120 mg per day
1756221|NCT00246376|Other|Placebos|Placebos for Niaspan and Tricor
1756222|NCT00246389|Drug|cyclobenzaprine hydrochloride|
1756223|NCT00246402|Drug|Acipimox|
1756224|NCT00246415|Drug|Memantine|
1756225|NCT00246428|Behavioral|Motivational Interviewing|Experimental manipulations will be evaluated 6, 9, and 12 months
1756226|NCT00246441|Drug|Paroxetine|16 weeks treatment; dosing will start at 20 mg/day paroxetine and will increase gradually to a maximum dose of 60 mg/day
1756419|NCT00240955|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
1756227|NCT00246441|Drug|Placebo|treatment phase will last 16 weeks; dosing will start at 20 mg/day (placebo) and will increase gradually to a maximum dose of 60 mg/day.
1756228|NCT00246467|Biological|Alhydrogel|
1756229|NCT00246467|Biological|rF1 and rV protein antigens|
1756230|NCT00246506|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
1756231|NCT00246506|Procedure|in vitro fertilization|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
1756232|NCT00246519|Drug|Hydrochlorothiazide|atenolol 50 or 100 mg hydrochlorothiazide 12.5 or 25 mg
1756233|NCT00246519|Drug|Atenolol|atenolol 50 mg, then 100 mg if BP < 120/70, then add HCTZ 12.5 mg if BP < 120/70, then HCTZ 25 mg if BP < 120/70
1756234|NCT00246532|Drug|Morphine|Patients will be given morphine sulfate oral medication until their back pain is adequately controlled.
1756235|NCT00246532|Drug|Placebo|Patients will receive placebo tablets.
1756236|NCT00246545|Behavioral|exercise|
1756237|NCT00246571|Drug|SU011248|SU011248 capsules administered orally, daily in a continuous regimen, 3-week cycles, starting dose of 37.5 mg daily. 1-week treatment rests and dose reductions allowed for dose-limiting toxicity. Dose escalate SU011248 to 50-mg daily if minimal toxicities . Study will continue until disease progression. Patients randomized to or crossed over to SU011248 may continue beyond the time of Response Evaluation Criterion in Solid Tumors (RECIST) -defined progression at the discretion of the investigator in the case of clinical benefit.
1756238|NCT00246571|Drug|Chemotherapy|"The choice of chemotherapy will be at the discretion of the investigator within the limits outlined below.
Capecitabine - 1000-1250 mg/m2 twice daily days 1-14 every 3 weeks
Vinorelbine - 25-30 mg/m2 rapid intravenous infusion or 60-80 mg/m2 oral weekly, expressed in 3-week cycles
Docetaxel - 75-100 mg/m2 every 3 weeks
Paclitaxel - 175-200 mg/m2 every 3 weeks
Paclitaxel - 80-90 mg/m2 weekly, in a continuous regimen expressed in 3-week cycles or administration of 3 weeks of treatment followed by 1 week of rest. Use of the 3/1 regimen will require extra care in scheduling disease assessments.
Gemcitabine - 800-1250 mg/m2 Days 1 and 8 every 3 weeks Study will continue until disease progression or it is in the best interest of the patient to discontinue based on achievement of maximum benefit or tolerability issues. At the time of progression patients randomized to chemotherapy will be offered crossover to single agent SU011248."
1756239|NCT00246584|Drug|SPP100|
1756240|NCT00246597|Drug|epoetin alfa|
1756241|NCT00246610|Drug|Nelfinavir mesylate, 625 mg|Nelfinavir 625 mg [dosed orally as 1250 mg BID (two 625 mg tablets given orally BID)] plus Combivir (lamivudine 150 mg plus zidovudine 300 mg BID dosed orally) administered with food. Subjects will start treatment at their baseline visit. Subjects will be treated for up to 26 weeks during pregnancy plus 6 weeks postpartum.
1756242|NCT00246623|Drug|Exubera (inhaled insulin)|
1756243|NCT00246623|Procedure|8-point glucose diary (to assess pre- and post prandial glucoses)|
1756244|NCT00246623|Procedure|Meal Tolerance Test|
1756245|NCT00246623|Procedure|24-hour continuous glucose monitoring (at select sites)|
1756246|NCT00246623|Procedure|Pulmonary Function Testing|
1756247|NCT00246623|Procedure|Hypoglycemic Event Monitoring|
1756248|NCT00246623|Procedure|Laboratory Assessments|
1756249|NCT00246623|Behavioral|Nutritional Counseling and Diabetes Education|
1756252|NCT00246649|Procedure|Ex vivo expansion of mafosfamide purged marrow or mobilized stem cells with growth factors (rhSCF and rhTPO)|
1756253|NCT00246662|Drug|Vosaroxin|All patients receive vosaroxin Injection
1756254|NCT00246675|Drug|Frusemide|
1756255|NCT00246688|Drug|Sagopilone (BAY86-5302 , ZK219477)|10.5 mg lyophilized sagopilone per vial
1756258|NCT00246714|Drug|repeated injections of endotoxin during 5 days|
1756259|NCT00246727|Drug|Selected Vegetable and Herb Mix|The phytomix consists of 19 vegetable and herbs in a highly concentrated form. These vegetables and herbs were selected based on their anti-cancer and immune-enhancing activities. Each batch of raw materials has gone through a very strict quality control (QC) scheme to make sure the product meets our QC standards and devoid of deleterious contaminations, such as heavy metals, pesticides, aflatoxin, and microorganisms. The manufacturing process is tightly controlled to ensure batch-to-batch consistency. The final product, a 20 gram freeze-dried powder, is sealed in a pouch. In our previous studies, patients who ingested phytomix daily for 17-60 months showed no clinical sign of adverse effect.
1756261|NCT00246753|Drug|lapatinib ditosylate|1500 mg, daily until disease progression
1756262|NCT00246779|Procedure|Modified ultrafiltration|
1756263|NCT00246792|Behavioral|Group treatment|
1756264|NCT00246805|Device|Vitatron pacemaker C20 SSIR or T20 SSIR models|VRS: special function that automatically adapts pacing rate to regularize cardiac cycles
1756265|NCT00246818|Procedure|Tai Chi Chuan|
1756266|NCT00246883|Procedure|Exercise|
1756267|NCT00246896|Behavioral|care management|
1756268|NCT00246909|Drug|Pantoprazole|
1756269|NCT00246922|Drug|Roflumilast|
1756270|NCT00246935|Drug|Roflumilast|
1756271|NCT00246948|Procedure|Active conservative treatment of sciatica|
1756272|NCT00246974|Drug|Gemcitabine|intravenous
1756273|NCT00246974|Drug|Cisplatin|intravenous
1756274|NCT00246974|Drug|Gefitinib|oral
1756275|NCT00246987|Drug|Muraglitazar|
1756276|NCT00247000|Device|Routine Care in a HF clinic vs Home Telehealth Care for HF|
1756277|NCT00247013|Behavioral|Breast Cancer Screening Compliance|
1756278|NCT00247026|Drug|curcumin; coenzyme q10|
1756279|NCT00247039|Dietary Supplement|Solgar Israel|Dietary Supplement: garlic natural compound one pill, 450 mg active garlic extract (Solgar, Israel), bid.
1756280|NCT00247039|Other|Placebo capsules|placebo capsules
1756281|NCT00247052|Drug|diclofenac|diclofenac 50 mg bid versus placebo bid
1756282|NCT00247052|Drug|diclofenac|diclofenac 100 mg per day for 14 days
1756283|NCT00247052|Drug|matching placebo|
1756284|NCT00247078|Biological|widow spider antivenom|3 vials of antivenom capable of neutralizing 600 LD50 of L. mactans
1756285|NCT00247078|Biological|Placebo|
1756286|NCT00247091|Biological|standard-titer measles vaccine|
1756287|NCT00247104|Drug|Cranberries - Vaccinium macrocarpon|
1756288|NCT00247117|Drug|Metformin|
1756289|NCT00247130|Drug|Omeprazole|
1756290|NCT00247130|Drug|Ranitidine|
1756291|NCT00247143|Drug|Kaletra (drug)|
1756292|NCT00247156|Procedure|Acupressure treatments and NAET treatments|
1756293|NCT00247169|Drug|progesterone|Micronized progesterone 400mg 1x daily for 10 days/month from menstrual cycle day 16-25
1756294|NCT00247182|Behavioral|Step 1: Minimal Intervention|All participants will receive Step 1, a 15-minute minimal intervention including a discussion of the referral incident and the provision of a booklet containing advice to reduce drinking. Participants will be assessed six weeks later. All students will complete 3, 6, and 9 month follow-up assessments
1756295|NCT00247182|Behavioral|Step 2: Brief Motivational Intervention|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
1756296|NCT00247182|Behavioral|Alcohol Assessment|Participants continuing to exhibit risky alcohol use will receive Step 2, randomization to: (a) a 60-90 minute brief motivational intervention (BMI) or (b) an assessment-only control. All students will complete 3, 6, and 9 month follow-up assessments.
1756297|NCT00247195|Behavioral|Culturally Congruent Assessment and Treatment|Referral, engagement, and treatment is done following the cultural formulation model in DSM-IV in which patients' views and expectations about depression treatment are included in the assessment and treatment process.
1756298|NCT00247208|Device|Taxus polymer-based paclitaxel-eluting stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
1756299|NCT00247208|Device|Express 2 bare metal stent|Two different types of stents (paclitaxel-eluting and a similar bare metal stent) are being compared in saphenous vein graft lesions.
1756300|NCT00247221|Behavioral|MI/Family Check-up|The experimental intervention integrates an individual Motivational Interview (MI) for the adolescent with a brief family intervention, the Family Check-Up. Follow-up interviews will be conducted at 3, 6, and 12 months after the baseline intervention.
1756301|NCT00247221|Behavioral|MI only|An individual motivational interview (IMI only) will be conducted at 3, 6, and 12 months after the baseline intervention to assess outcome.
1756302|NCT00247234|Behavioral|Schema Therapy|group based schema therapy
1756303|NCT00247234|Behavioral|standard care|standard psychiatric out-patient care
1756304|NCT00247247|Drug|Comtess®|
1756305|NCT00247260|Device|32P BioSilicon|
1756306|NCT00247273|Drug|risedronate|tablet, 5 mg risedronate, once a day for 2 years
1756307|NCT00247273|Drug|risedronate|oral, 150 mg risedronate, once a month for 2 years
1756308|NCT00247286|Behavioral|weighted vaginal cones|
1756309|NCT00247286|Behavioral|Biofeedback|Pelvic floor muscles exercises performed with a biofeedback machine
1756310|NCT00247299|Device|IPL Quantum Product manufactured by Luminis Ltd.|
1756311|NCT00247312|Radiation|Pd-103|
1756312|NCT00247325|Drug|Iodixanol(Drug)|
1756313|NCT00247338|Drug|low calorie, low nitrogen parenteral nutrition for patient with NRS score 3|
1756314|NCT00247351|Procedure|Cryoablation|
1756315|NCT00247364|Drug|Levetiracetam (Keppra)|
1756316|NCT00247377|Procedure|Gastric bypass surgery|in order to meet health requirements for patient, gastric bypass surgery was undergone
1756317|NCT00247377|Procedure|Lap-Band|in order to meet health requirements for patient, gastric band surgery was undergone
1756318|NCT00247390|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 42 weeks.
1756319|NCT00247390|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 42 weeks.
1756320|NCT00247403|Drug|2-deoxyglucose (2DG)|Addition of 2DG to stereotactic radiosurgery. Dose escalation study.
1756321|NCT00247416|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 intravenously over 30 minutes on days 5 and 12.
1756322|NCT00247416|Drug|Dexamethasone|16 mg bid for 4 days prior to each chemotherapy start.
1756323|NCT00247416|Drug|Carboplatin|AUC 6.0 intravenously over 30 minutes on day 5.
1756324|NCT00247442|Behavioral|Decision aid|
1756325|NCT00247455|Drug|Low fibre breakfast cereal (puffed rice/cornflakes)|
1756326|NCT00247455|Drug|High fibre cereal (All Bran/Bran Flakes)|
1756327|NCT00247468|Procedure|Strict Glucose Control|
1756328|NCT00247481|Drug|Gefitinib|
1756329|NCT00247481|Drug|Docetaxel|
1756330|NCT00247494|Drug|mycophenol mofetil (MMF, Cellcept®) 500 mg BID|
1756331|NCT00247507|Drug|acetylcysteine|
1756332|NCT00247520|Drug|topical nasal rEV131|
1756333|NCT00247533|Procedure|Digital subtraction angiography and 24-hour simultaneous recorder of electrocardiograph|
1756334|NCT00247546|Behavioral|Multifactorial prevention|
1756335|NCT00247559|Drug|Botulinum type A toxin (BoNT-A)|
1756336|NCT00247572|Drug|NRP104|
1756337|NCT00247585|Drug|Ethanol (Bourbon or Vodka)|
1756338|NCT00247611|Behavioral|LifeWindows Intervention Sessions|At each clinical care visit, intervention arm participants use the full LifeWindows program, which includes welcome and assessment surveys and also includes the active intervention modules. ART adherence promotion intervention activities are tailored to the participant's assessment responses. Participants select which activities he or she wishes to use which culminates in an adherence specific goal.
1756416|NCT00240916|Biological|MMR-II (Measles-Mumps-Rubella Virus Live Vaccine, 0.5ml subcutaneous)|
1756417|NCT00240929|Drug|MEDI-493|Active Comparator
1756339|NCT00247611|Other|Control|At each clinical care visit, control arm participants use the portion of the LifeWindows software program that provides a welcome from the avatar and collection of assessment items/surveys.
1756340|NCT00240253|Drug|pramlintide acetate|Clear, colorless, sterile solution for SC injection
1756341|NCT00240266|Drug|Rosuvastatin|
1756342|NCT00240279|Drug|Rosuvastatin|
1756343|NCT00240279|Procedure|aortic pulse wave velocity measurements|
1756344|NCT00240292|Drug|Rosuvastatin|
1756345|NCT00240305|Drug|Rosuvastatin|
1756346|NCT00240318|Drug|Rosuvastatin calcium|
1756347|NCT00240331|Drug|10mg Rosuvastatin|
1756348|NCT00240331|Drug|Placebo|
1756349|NCT00240357|Procedure|Lifestyle Regulation|
1756350|NCT00240370|Drug|Muraglitazar|
1756351|NCT00240383|Drug|Muraglitazar|
1756352|NCT00240396|Drug|Narcotics alone|
1756353|NCT00240396|Drug|Narcotics and NSAIDS|
1756354|NCT00240409|Drug|Pramipexole|
1756355|NCT00240409|Drug|Bromocriptine|
1756356|NCT00240422|Drug|Telmisartan|
1756357|NCT00240422|Drug|Ramipril|
1756358|NCT00240435|Device|5 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
1756359|NCT00240435|Device|10 mcg once daily tiotropium inhalation solution delivered by the Respimat inhaler|
1756360|NCT00240448|Drug|telmisartan 80 mg/hydrochlorothiazide 25 mg|
1756361|NCT00240448|Drug|valsartan 160 mg/hydrochlorothiazide 25 mg|
1756362|NCT00240448|Drug|placebo|
1756363|NCT00240461|Dietary Supplement|COLD-fX natural health product|200 mg/COLD-fX natural health product - 2 capsules twice daily for 6 months
1756364|NCT00240461|Dietary Supplement|COLD-fX|400 mg COLD-fX natural health product 2 times daily for 6 months
1756365|NCT00240461|Other|Placebo|crystalline substance 200 mg twice daily for 6 months
1756366|NCT00240474|Drug|Telmisartan 80 mg + hydrochlorothiazide 12.5 mg|
1756367|NCT00240474|Drug|Amlodipine 10 mg + hydrochlorothiazide 12.5 mg|
1756368|NCT00240487|Drug|Nitric Oxide|Subjects will receive inhaled Nitric Oxide at a dose of 10 parts per million (ppm) for a 4 hour study period. Blood gases will be collected once an hour.
1756369|NCT00240487|Other|No Intervention|Subjects will receive no intervention (i.e., no nitric oxide treatment) for a 4 hour study period. Blood gases will be collected once an hour. During this time, all subjects will receive standard clinical care.
1756370|NCT00240500|Biological|Engerix™-B|In the primary study, subjects received HBV (10 milligram) vaccine according to a 0, 1 and 2 month schedule with a booster dose at Month 12. Subjects in the 5-dose vaccination regimen received a booster dose of HBV vaccine at Month 60.
1756371|NCT00240513|Drug|Minocycline|100 mg capsules OD for 3 months
1756372|NCT00240513|Drug|Minocycline plus tretinoin|100mg OD Minocycline for 12 weeks plus OD Topical tretinoin 0.01% for 12 weeks Followed by topical tretinoin 0.01% OD for 12 weeks alone
1756373|NCT00240526|Biological|Engerix™ -B|3 (Groups A and C) or 4 (Groups B and D) intramuscular injections during the primary study
1756374|NCT00240526|Biological|Hepatitis B immunoglobulin (HBIg)|1 intramuscular injections at birth (primary study)
1756375|NCT00240539|Procedure|Blood sampling|A blood sample will be taken yearly at each long-term follow-up time point (i.e. Year 16 through Year 20) after the first dose of Engerix-B™ vaccine.
1756376|NCT00240552|Drug|fosamprenavir|
1756377|NCT00240552|Drug|Telzir®|
1756378|NCT00240565|Drug|Tositumomab 450 mg|Unlabeled TST
1756379|NCT00240565|Drug|Tositumomab 35 mg|TST labeled with 185 megaBecqueral (mbq) of iodine 131
1756380|NCT00240604|Drug|Rosiglitazone|4 mg rosiglitazone per day
1956701|NCT02740322|Procedure|Hum Test|The subject will be brought into an exam room. The subject will then be asked to hum for a few seconds in a low pitch. They will then be asked if the nose was heard more so in one ear compared to the other. The subject will then be asked to hum for a few seconds in a high pitch. They will then be asked again if the noise was heard more so in one ear compared to the other.
1756386|NCT00240656|Drug|spironolactone captopril carvedilol|
1756387|NCT00240669|Device|Resorbable device PLLA/PGA|
1756388|NCT00240669|Device|Titanium device|
1756389|NCT00240682|Drug|cetuximab|Dosage form: bottles of 50 ml, 2 mg/ml; Dosage:400 mg/m2 initial dose followed by 250 mg/m2 by infusion every week; Number of Cycles : until progression or unacceptable toxicity develops.
1756390|NCT00240695|Drug|galantamine hydrobromide|
1756391|NCT00240708|Drug|risperidone|
1756392|NCT00240721|Drug|topiramate|
1756393|NCT00240734|Drug|Epoetin alfa|
1756394|NCT00240747|Drug|Synercid|
1756395|NCT00240760|Drug|Memantine Hydrochloride|
1756396|NCT00240773|Drug|acetaminophen|4 grams daily for six months
1756397|NCT00240773|Drug|naproxen|750 mg daily for 12 months
1756398|NCT00240773|Drug|acetaminophen|4 grams daily for 12 months
1756399|NCT00240773|Drug|naproxen|750 mg daily for six months
1756400|NCT00240786|Drug|acetaminophen extended release|
1756401|NCT00240799|Drug|acetaminophen extended release|
1756402|NCT00240799|Drug|placebo|
1756403|NCT00240812|Drug|ibuprofen; pseudoephedrine HCl|
1756404|NCT00240825|Drug|Ibuprofen|
1756405|NCT00240825|Drug|Placebo|
1756406|NCT00240825|Drug|Acetaminophen|
1756407|NCT00240838|Drug|acetaminophen extended release caplets|
1756408|NCT00240851|Drug|acetaminophen extended release|
1756409|NCT00240864|Drug|placebo|
1756410|NCT00240864|Drug|acetaminophen|
1756411|NCT00240864|Drug|ibuprofen|
1756412|NCT00240877|Biological|AV024|0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
1756413|NCT00240877|Other|Placebo|Placebo mist consisting of normal allantoic fluid. 0.5 mL total dose volume administered intranasal by spray applicator (approximately 0.25 mL into each nostril).
1756414|NCT00240903|Biological|Influenza A/Vietnam/1203/2004 (H5N1; sanofi pasteur)|
1756415|NCT00240916|Biological|Attenuvax (Measles Virus Live Vaccine, 0.5ml subcutaneous)|
1756418|NCT00240942|Drug|Letrozole|
1756420|NCT00240968|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|A monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit¿¿dose vials containing either 30-mcg/mL A/H5N1 HA or 90-mcg/mL A/H5N1 HA. Subjects will receive 1 of 4 dose levels of vaccine (7.5, 15, 45, or 90 mcg) administered intramuscularly.
1756421|NCT00240981|Drug|Topical testosterone gel 1% (active formulation)|Starting dose 10 g/day; increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
1756422|NCT00240981|Drug|Topical gel (placebo formulation)|Starting dose 15 g/day (3 tubes), applied to upper arms and shoulders each day.
1756423|NCT00240994|Drug|Alemtuzumab|Administered intravenously over a period of 2-3 hours. Two doses total, the first will be one day before transplant and the second will be on the day following transplantation. Pre-medication with methylprednisolone, acetaminophen, and Benadryl will be administered before each dose.
1756424|NCT00240994|Drug|Tacrolimus|Administered orally at a dose of 0.05-0.1 mg/kg twice daily, beginning 1-3 days following transplantation and continuing until weeks 8-12. Tacrolimus will be discontinued and a treatment regimen with sirolimus will be initiated between weeks 8-12 but some overlap with these medications is possible.
1756425|NCT00240994|Drug|Mycophenolate mofetil|Per recommendation
1756426|NCT00240994|Drug|Sirolimus|Administered by either liquid or tablet every 12 hours from month 6 until month 24. Dosage will vary throughout the treatment course.
1756427|NCT00241007|Drug|VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE|
1756428|NCT00241020|Drug|Octreotide|
1756429|NCT00241046|Drug|Letrozole|
1756430|NCT00241059|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1756431|NCT00241072|Drug|valsartan|24 WEEKS OF TREATMENT WITH VALSARTAN (80 MG - 320 MG)
1756432|NCT00241085|Drug|valsartan|
1756433|NCT00241098|Drug|valsartan|
1756434|NCT00241111|Drug|zoledronic acid|
1756435|NCT00241124|Drug|valsartan|
1756436|NCT00241124|Drug|lisinopril|
1756437|NCT00241137|Drug|valsartan|
1756438|NCT00241150|Drug|VALSARTAN|
1756439|NCT00241163|Procedure|Fibrinogen (human) + thrombin (human) (TachoSil)|
1756440|NCT00241176|Drug|Aripiprazole|Baseline Visit 2: Subjects btw 25-50kg start on 1.25mg/day, btw 50-70kg start on 2.5mg/day, greater than 70kg start on 5mg/day Visit 3: Titrated based on YGTSS & CGI-TS ratings at investigator discretion. Subjects who show evidence of response (reduction in CGI-TS by 1-2 points) may remain on same dose. Subjects who show no response may increase as follows: btw 25-50kg increase to 2.5mg/day, btw 50-70kg increase to 3.75mg/day, greater than 70kg increase to 7.5mg/day Visit 5: Subjects who show no response may increase as follows: btw 25-50kg increase to 3.75mg/day, btw 50-70kg increase to 5mg/day, greater than 70kg increase to 10mg/day Visit 6: Subjects who show no response may be increase as follows: btw 25-50kg increase to 5mg/day, btw 50-70kg increase to 7.5mg/day, greater than 70kg increase to 12.5mg/day Visit 7: Subjects who how no response may be increase as follows: btw 25-50kg increase to 7.5mg/day, btw 50-70kg increase to 10mg/day, greater than 70kg increase to 15mg/day
1756441|NCT00241189|Drug|rapamycin|
1756442|NCT00241189|Drug|methotrexate|
1756443|NCT00241202|Behavioral|Symptom Management Manual|Participants receive the Symptom Management Manual, and are shown an example. They are given the Manual to take home with them and use.
1756444|NCT00241215|Drug|Botulinum toxin serotype A|
1756445|NCT00241228|Device|Venovenous haemofiltration (renal replacement therapy)|High Volume ultra filtration (70 ml/kg/h)
1756446|NCT00241228|Device|Venovenous haemofiltration (renal replacement therapy)|Conventional Volume (35 ml/kg/h)
1756447|NCT00241241|Drug|pegylated interferon-alfa 2a|
1756448|NCT00241254|Drug|Cyclophosphamide (drug)|IV cyclophosphamide infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
1756449|NCT00241254|Drug|Methylprednisolone (drug)|Control group : IV methylprednisolone infusion administered every 4 weeks during 1 year and every 8 weeks during 1 year.
1756450|NCT00241267|Device|Dedicated ultrasonographic probe during bronchoscopy|
1756451|NCT00241280|Device|etafilcon A|
1756452|NCT00241280|Device|galyfilcon A|
1756453|NCT00241319|Drug|R89674 (generic name not yet established)|
1756454|NCT00241332|Drug|fentanyl|
1756455|NCT00241345|Drug|Valganciclovir|
1756456|NCT00241345|Drug|Ganciclovir|
1756457|NCT00241358|Drug|AMD3100|
1756458|NCT00241358|Procedure|Stem Cell Transplant|
1756459|NCT00241371|Drug|Clofarabine|
1756460|NCT00241384|Procedure|External beam radiation|
1756461|NCT00241384|Procedure|Pd-103|
1756462|NCT00241410|Biological|OralvacB2MPL|Comparison of different dosages of drug
1756463|NCT00241423|Drug|exenatide|subcutaneous injection, 5mcg twice a day for one week; then 10 mcg twice a day for one week
1756464|NCT00241423|Drug|Placebo|subcutaneous injection, equivalent volume to 5 mcg exenatide twice a day for one week; then equivalent volume to 10 mcg exenatide twice a day for one week
1756465|NCT00241436|Drug|Anastrozole (ARIMIDEX™)|
1756466|NCT00241449|Drug|Fulvestrant|intramuscular injection 250 mg
1756467|NCT00241449|Drug|Tamoxifen|20 mg oral tablet
1756468|NCT00241475|Drug|Gefitinib|
1756469|NCT00241488|Drug|Rosuvastatin|
1756470|NCT00241501|Drug|Esomeprazole (Nexium)|
1756471|NCT00241514|Drug|Esomeprazole|
1756472|NCT00241527|Drug|Esomeprazole|
1756473|NCT00241540|Drug|Esomeprazole|
1756474|NCT00241553|Drug|Esomeprazole|
1756475|NCT00241566|Device|implantation of stimulator|
1756476|NCT00241579|Drug|Smoked Cannabis|
1756477|NCT00241592|Drug|Cannabis|
1756478|NCT00241605|Drug|rosiglitazone/metformin|
1756479|NCT00241618|Drug|Pegylated interferon alpha 2|
1756480|NCT00241618|Drug|Ribavirin|
1756481|NCT00241631|Drug|fluticasone|500 mg b.d.
1756482|NCT00241631|Drug|placebo|
1756483|NCT00241644|Biological|Rotarix™|Two or Three doses, oral administration
1756484|NCT00241644|Biological|Placebo|One or three doses, oral administration.
1756485|NCT00241657|Biological|BCG|
1756486|NCT00241670|Drug|5-aminolevulinic acid (5-ALA)|1.5 grams 5-ALA dissolved in 50 ml water, single dose, orally, 2-4 hours prior to surgery
1756487|NCT00241722|Drug|Alvimopan|
1756488|NCT00241722|Drug|Placebo|
1756489|NCT00241813|Behavioral|Mindfulness Meditation (MM) Program|Participants will take part in a mindfulness meditation (MM) program.
1756490|NCT00241813|Behavioral|Health Education Control Program (CTL)|Participants will take part in a health education control program (CTL)
1756491|NCT00241813|Behavioral|Lifeskills Program (LP)|Participants will take part in a lifeskills program (LP).
1756492|NCT00241826|Procedure|Magnetic Resonance Angiography|Participants will undergo magnetic resonance angiography.
1756493|NCT00241826|Procedure|Magnetic Resonance Venography|Participants will undergo magnetic resonance venography.
1956702|NCT02740322|Procedure|Weber Test|Using a 512 Hz tuning fork, the tuning fork will be vibrated and placed on the subject's glabella (forehead landmark). The subject will then be asked if the vibration was heard more so in one ear compared to the other.
1956703|NCT02740322|Device|Audiogram|A standard audiogram will be administered by an audiologist.
1756497|NCT00247650|Drug|Zoledronic Acid; Letrozole|
1756498|NCT00247663|Drug|Letrozole|
1756499|NCT00247676|Drug|Sunitinib (SU011248)|Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
1756500|NCT00247702|Drug|warfarin|
1756501|NCT00247715|Drug|algeldrate/magnesium oxide|
1756502|NCT00247715|Drug|ranitidine|
1756503|NCT00247715|Drug|pantoprazole|
1756505|NCT00247741|Drug|spinal administration of articaine|
1756506|NCT00247741|Drug|spinal administration of lidocaine|
1756507|NCT00247754|Behavioral|Cognitive Behaviour Treatment|
1756508|NCT00247780|Procedure|Pulmonary vein isolation and cavotricuspid ishtmusblock|
1756509|NCT00247793|Drug|Oral Impact (preoperative enteral nutritional supplement)|
1756510|NCT00247819|Procedure|Blood draw|
1756511|NCT00247832|Behavioral|Self-directed motivation|Post-lobectomy patients are provided with a booklet that outlines expected physical activities (sitting up, walking arm exercises) to aim for each day after surgery. It also provides room for the patients to record what they have accomplished.
1756512|NCT00247832|Behavioral|Personal motivational interviewing|Post-lobectomy patients receive daily visits from a study coordinator aimed to motivate the patient to complete various physical activities each day after surgery. The study coordinator goes through the same booklet that is given to Group 2 and helps patients set goals and record their accomplishments.
1756513|NCT00247897|Drug|Skin antisepsis|See Detailed Description
1756514|NCT00247910|Drug|Hydrochlorothiazide|Not recorded in detailed description.
1756515|NCT00247923|Procedure|Hysteroscopic resection of endometrial polyps. (TCRP)|
1756516|NCT00247936|Procedure|Laparoscopic Esophagectomy|Laparoscopic Esophagectomy
1756517|NCT00247962|Drug|etanercept|50 mg
1756518|NCT00247962|Drug|sulphasalazine (SSZ)|Sulphasalazine: The target dose for SSZ is 1.5 g (3 tablets) twice daily orally. Subject start the oral TA at 0.5 g daily for the first week and increase by 0.5 g every week until a daily dose of 3 g. Is achieved by the start of study week 5 of the study.
1756526|NCT00249483|Drug|Venlafaxine|Venlafaxiine 300mg/day
1756527|NCT00249483|Drug|Placebo|Placebo
1756528|NCT00249496|Behavioral|Contingency management|Participants in the Contingency Management group will be employed for one year in a Therapeutic Workplace business and will have to provide drug-free urine samples to work and earn salary.
1756529|NCT00249496|Behavioral|Employment Only|Employment Only participants will be offered employment for one year, but these participants will not have to provide drug-free urine samples to work.
1756530|NCT00249509|Drug|Nefazodone|
1756531|NCT00249509|Drug|Bupropion|
1756532|NCT00249522|Behavioral|Contingency management|
1756533|NCT00249535|Behavioral|Contingency management|Rewards (prizes) for abstinence
1756534|NCT00249548|Behavioral|Contingency management|
1756535|NCT00249561|Behavioral|Recovery by Choice|"The experimental condition, the modified TC, was a 6- to 9-month program located in a separate 72-bed housing unit within the prison. Inmates progressed through four program stages with upper level inmates functioning as peer mentors for newer members. The modified, comprehensive TC treatment program focused on increasing awareness and understanding of female roles and relationships as they relate to addiction and drugs used and abused, and emotional and behavioral coping skills. Program elements addressed issues of substance abuse, relapse prevention, mental health, criminal thinking and behavior, coping with trauma and abuse, and parenting skills. All treatment staff received special training related to working with women exposed to trauma and abuse, making the program trauma informed and trauma sensitive."
1756665|NCT00250718|Drug|Levofloxacin|Levofloxacin will be administered at 500 mg PO qd.
1756536|NCT00249561|Behavioral|The Intensive Outpatient Program (IOP)|The control condition, known at the prison as the Intensive Outpatient Program (IOP), was designed to address substance abuse and criminality, with a focus on prevention of relapse and recidivism. The IOP substance abuse treatment curriculum, designed for delivery over 15 weeks, consisted of a 90-hour manual-driven course (Strategies for Self-Improvement and Change, Wanburg & Milkman, 1998), which employed a cognitive behavioral format to address underlying issues of substance use/abuse and criminal behavior.
1756537|NCT00249574|Drug|Buprenorphine/naloxone|Human subjects HIV, HCV
1756538|NCT00249574|Drug|pegInterferon|intervention drug 1. buprenorphine/naloxone. street-recruited heroin users induced on bup/naloxone for period of 3-6 months, after which the second intervention is offered. intervention drug 2: pegInterferon/ribavirin. subjects interested in initiation treatment for HCV are offered pegInterferon, 180ug SQ/wk and ribavirin, 800-1200 mg daily for the standard duration of HCV treatment as dictated by genotype.
1756539|NCT00249587|Drug|Methadone|dosed to effect, every six hours
1756540|NCT00249600|Behavioral|Contingency management|
1756541|NCT00249613|Behavioral|Women-Only|Gender-responsive treatment for women only
1756542|NCT00249626|Behavioral|Contingency management|Rewards (prizes) for abstinence
1756543|NCT00249639|Behavioral|Contingency management|Rewards valued $1-$100
1756544|NCT00249652|Behavioral|TAP|12-session motivational interviewing-based telephone intervention.
1756545|NCT00249652|Other|TAU|The usual care group will receive the same medical services they would otherwise receive if they were not in this study.
1756546|NCT00249678|Behavioral|Behavior Therapy|
1756547|NCT00249691|Drug|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
1756548|NCT00249691|Drug|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
1756549|NCT00249704|Drug|Vitamin D + Sham Exercise|1000 IU per day of Vitamin D + Sham (equivalent to placebo) Exercise
1756550|NCT00249704|Procedure|Vitamin D Placebo + Exercise|Vitamin D placebo + Exercise
1756551|NCT00249704|Procedure|Vitamin D Placebo + Sham Exercise|Vitamin D placebo + Sham (equivalent to placebo) Exercise
1756552|NCT00249704|Drug|Vitamin D + Exercise|1000 IU per day of Vitamin D + Exercise
1756553|NCT00249717|Behavioral|Contingency management|Receive rewards (prizes) abstinence and attendance
1756554|NCT00249730|Drug|Sildenafil|
1756555|NCT00249743|Device|FallSaver (formerly called NOCwatch)|
1756556|NCT00249756|Behavioral|Re-entry Modified Therapeutic Community (Re-entry MTC)|In general, the MTC program model applies three fundamental adjustments — increased flexibility, decreased intensity, and greater individualization. The central TC feature is retained; the MTC, like all TC programs, seeks to develop a subculture where clients learn through self-help and affiliation with the community to foster change in themselves and others. From this base (as elaborated below), further adaptations for the population of offenders with MICA disorders were incorporated to include an emphasis on modifying criminal thinking and behavior; on recognizing and responding to the interrelationship of substance abuse, mental illness, and criminality (triple recovery); and on using strategies for symptom management.
1756557|NCT00249756|Behavioral|Parole Supervision and Case Management|Recognizing the complexity of issues facing offenders returning to the community, and the importance of continuity of care, the CDOC established a system of aftercare substance abuse services for offenders on parole or placed in Community Corrections facilities. The statewide treatment options for the offenders consist of a network of community-based clinics and halfway houses throughout Colorado that provide substance abuse services and mental health services. Parole officers and Community Corrections case managers monitor treatment compliance to support participation in prescribed services.
1756558|NCT00249769|Biological|Japanese Encephalitis Live Attenuated SA 14-14-2 Vaccine|
1756559|NCT00249782|Drug|Vehicle control, 2x/day|
1756560|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 2x/day|
1756561|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day|
1756562|NCT00249782|Drug|MetroGel® (metronidazole gel), 1.0% 1x/day|
1756563|NCT00249782|Drug|ACZONE (dapsone) Gel, 5%, 1x/day (AM) + MetroGel (metronidazole gel), 1.0%, 1x/day (PM)|
1756564|NCT00249795|Drug|Irbesartan|oral administration (tablets) once daily
1756565|NCT00249795|Drug|placebo|oral administration (tablets) once daily
1756567|NCT00249821|Drug|Saizen®|Saizen® [somatropin (recombinant deoxyribonucleic acid [rDNA] origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
1756568|NCT00249821|Drug|Saizen®|Saizen® [somatropin (rDNA origin) for injection], a r-hGH, is indicated for the treatment of children with growth failure due to inadequate secretion of endogenous growth hormone.
1756570|NCT00249847|Drug|Paroxetine controlled-release|2-12.5 mg tablets, orally, every day for 4 weeks
1756571|NCT00249847|Drug|Conjugated equine estrogen|0.625 mg tablet, orally, every day for 4 weeks
1756572|NCT00249860|Drug|Interferon-beta-1a|Interferon-beta-1a will be administered subcutaneously at a dose of 44 microgram (mcg), three times a week up to Week 24
1756573|NCT00249860|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 12 weeks. The placebo responders will continue the study off-treatment after Week 12 up to Week 24
1756574|NCT00249860|Drug|Ribavirin plus Interferon-beta-1a|Placebo non-responders at Week 12 will receive ribavirin at a dose of 1000 milligram (mg) or 1200 mg orally once daily in combination with Interferon-beta-1a, administered subcutaneously at a dose of 44 mcg three times a week, from Week 16 up to Week 24
1756575|NCT00249873|Drug|clopidogrel (SR25990C)|oral administration (tablets)
1756576|NCT00249873|Drug|placebo|oral administration (tablets)
1756577|NCT00249886|Drug|Citalopram|
1756578|NCT00249899|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
1756579|NCT00249899|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
1756580|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
1756581|NCT00249912|Drug|Lapaquistat acetate and rosuvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
1756582|NCT00249912|Drug|Rosuvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable Rosuvastatin therapy (10 or 20 mg) for up to 24 weeks.
1756583|NCT00249925|Behavioral|Home-Based Intervention|
1756584|NCT00249925|Behavioral|Multi-component home-based intervention|
1756585|NCT00249938|Drug|Minute Maid Heart Wise orange juice|
1756586|NCT00249938|Drug|Welchol|
1756587|NCT00249951|Drug|Alkaline citrate|Prophylactic alkaline citrate medication during the first 8 weeks of life versus placebo solution to prevent nephrocalcinosis of prematurity.
1756588|NCT00249964|Drug|Combination Treatment - Cohort 1|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.
Temozolomide at 75 mg/m2 per day from day 2 to day 6."
1756589|NCT00249964|Drug|Combination Treatment - Cohort 2|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.
Temozolomide at 100 mg/m2 per day from day 2 to day 6."
1756590|NCT00249964|Drug|Combination Treatment - Cohort 3|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.
Temozolomide at 125 mg/m2 per day from day 2 to day 6."
1756591|NCT00249964|Drug|Combination Treatment - Cohort 4|"Paclitaxel at 175 mg/m2 intravenously + Carboplatin at AUC 5 intravenously on day 1.
Temozolomide at 150 mg/m2 per day from day 2 to day 6."
1756592|NCT00249977|Drug|Capecitabine in Combination with Cisplatin and Irinotecan|"Cisplatin 50 mg/m2 on day 1 (course 1) or day 11 (subsequent courses) Irinotecan 50 mg/m2 on day 1, 8, and 15 (course 1) or day 11, 18 and 25 (subsequent courses).
Capecitabine will be administered from day 1 to day 10 PO starting on course 2."
1756593|NCT00249990|Drug|9-NC in aerosol reservoir|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks (45-47).
1756594|NCT00250003|Behavioral|Preventive home visits|
1756595|NCT00250029|Drug|Oxaliplatin|"Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2 hour intravenous infusion on day 1 of a three week cycle, prior to the 1st dose of capecitabine. 5-HT3 antagonists with or without dexamethasone premedication are strongly recommended. Oxaliplatin may be infused either through a peripheral vein or a central venous line. The infusion lines must be adequately flushed with 5% dextrose solution (D5W) between oxaliplatin infusion & the administration of any other drug.
Capecitabine is to be administered orally within 30 mins. after the end of a meal. Tablets should be swallowed with approximately 200 mL water (not fruit juices). The first dose of each cycle will be administered as the evening dose on day 1 & the last dose of each cycle is scheduled the morning of day 15, followed by a 7 day rest period. This provides for a total of 28 single doses per cycle over 15 calendar days."
1756596|NCT00250042|Drug|Gleevec and Arsenic Trioxide|Pts. who fit the inclusion criteria, & were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) & then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
1756597|NCT00250055|Procedure|Colposcopy, Spectroscopy, and Biopsy|During the colposcopy or LEEP (Loop Electrical Excision Procedure) procedure, or during pelvic exams before surgery after the doctor applies 3% acetic acid to the cervix, the doctor then positions the colposcope to take pictures of the patient's cervix. Digital pictures are taken of the patient's cervix under white light using a colposcopy imaging system. These pictures are annotated by the doctor during the appointment to mark the spectroscopy sites.
1756598|NCT00250068|Drug|Liposomal 9-Nitrocamptothecin|Dose: 0.4 mg/ml of 9-NC in aerosol reservoir for 60 minutes (= daily dose of 0.52 mg/m2/day) per day X5 every week, X8 weeks, then observe for 2 weeks. One course = 10 weeks
1756599|NCT00250081|Procedure|Upper Extremity Tendon transfer|
1756600|NCT00250081|Procedure|Botulinum Toxin injections in Upper Extremity|
1756601|NCT00250081|Procedure|Regularly ongoing therapy|
1756602|NCT00250094|Drug|Topotecan and VP16|"Course 1A: On day 1 treatment will start with a continuous infusion of TPT at 0.4 mg/m2/day for 21 days. A pump will be used to deliver the TPT. The bag in the pump will be replaced every week for sterility precautions.
Course 1B: On day 28, if ANC is >1,500 and platelets > 100,000, VP-16 will be administered orally at 50 mg/day for 14 days."
1756603|NCT00250120|Drug|L9NC: Liposomal 9-Nitro-20 (S)-Camptothecin|delivery mode: inhalation
1756604|NCT00250133|Procedure|Blood draws|
1756605|NCT00250146|Behavioral|Gluten (behaviour)|
1756606|NCT00250172|Drug|[C-11](R)-rolipram|
1756607|NCT00250185|Drug|Sodium Nitrate|
1756608|NCT00250185|Drug|Acetylcholine|
1756609|NCT00250198|Drug|STA-5326|
1756610|NCT00250211|Procedure|Functional MRI imaging and tomotherapy|
1756611|NCT00250224|Device|Radiotherapy stent|
1756612|NCT00250237|Drug|Haloperidol|Haloperidol 1mg twice daily during 72hours
1756613|NCT00250237|Drug|placebo|Placebo 1mg twice daily during 72hours
1756614|NCT00250250|Drug|ZOMACTON|
1756615|NCT00250263|Drug|(agent for immunotherapy) Staloral|"Immunotherapy agent for sublingual daily use. First week (vial containing the concentration 10 IR/ml) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures
Second week (300 IR/ml) (vial containing the concentration 300 IR/ml) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures
Maintenance phase Day 12 to 364 - 8 pressures daily
The first year will be followed by a second year open label period (optional)- 8 pressures daily"
1756616|NCT00250263|Drug|Placebo|"Matching placebo for sublingual use. Same schedule used for the intervention ACTIVE group.
First week (vial containing placebo) Day 1 - 1 pressure Day 2 - 2 pressures Day 3 - 4 pressures Day 4 - 6 pressures Day 5 - 8 pressures Day 6 - 10 pressures
Second week (300 IR/ml) (vial containing placebo) Day 7 - 1 pressure Day 8 - 2 pressures Day 9 - 4 pressures Day 10 - 6 pressures Day 11 - 8 pressures
Maintenance phase Day 12 to 364 - 8 pressures daily"
1756617|NCT00250276|Biological|Cervarix™|GSK Biologicals' vaccine against human papillomaviruses 16 and 18.
1756618|NCT00250289|Device|a mucosal sticker with herbal formula|
1756619|NCT00250302|Procedure|autologous mesenchymal stem cells implantation|
1756620|NCT00250315|Drug|Dobutamine|
1756621|NCT00250328|Device|LapCAC Laparoscopic Compression Anastomosis Clip|
1756622|NCT00250341|Drug|QVAR|480 mcg
1756623|NCT00250341|Drug|Advair|250/50 mcg
1756624|NCT00250341|Drug|Servent Diskus|50 mcg
1756625|NCT00250354|Drug|Risperidone oral solution|
1756626|NCT00250367|Drug|risperidone|
1756627|NCT00250393|Drug|Istradefylline (KW-6002)|
1756628|NCT00250406|Device|Ureteral Stent|triclosan-eluting ureteral stent
1756629|NCT00250406|Device|Ureteral Stent|Percuflex Plus Stent as the control
1756630|NCT00250419|Biological|V930|
1756631|NCT00250432|Drug|caspofungin acetate|Caspofungin acetate 50 mg IV infusion (diluted with 9% saline) (following a 70-mg IV loading dose on Day 1); Caspofungin acetate 150 mg IV infusion (diluted with 9% saline) administered daily, over the course of ~2 hrs. Duration of Treatment - 14-90 days.
1756632|NCT00250445|Drug|MK0663, etoricoxib|
1756633|NCT00250445|Drug|Comparator: Diclofenac sodium|
1756634|NCT00250458|Drug|Comparator: Rizatriptan|One dose Rizatriptan 10 mg orally disintegrating tablet / oral lyophilisate to treat one migraine attack.
1756635|NCT00250458|Drug|Comparator: Placebo|One dose matching placebo to Rizatriptan to treat one migraine attack.
1756636|NCT00250471|Procedure|Percutaneous Coronary Intervention (PCI)|
1756639|NCT00250497|Behavioral|New Moves|The New Moves intervention is an all girls physical education class that provides a supportive environment for girls. Girls participate in noncompetitive physical activities. They also receive lessons on nutrition and social support. After the class is over, girls continue to receive intervention messages through weekly lunch meetings. Girls meet individually with a personal coach.
1756640|NCT00250510|Behavioral|Simulated insurance reimbursement|Participants were told they would have the possibility of being reimbursed 50% ($150) of their initial fee ($300) if they: 1) paid the fee in advance or committed 3 monthly payments in advance, 2) attended 10 of 12 class sessions, and 3) lost at least 6% of their current body weight during the program.
1756641|NCT00250536|Drug|nandrolone decanoate|
1756642|NCT00250536|Behavioral|resistance exercise training|
1756643|NCT00250549|Behavioral|Post test video|We compared the educational effectiveness of a 15-minute posttest counseling video with the normal practice of a session with an HIV counselor.Patients in the experimental group watched an HIV posttest educational video.
1756644|NCT00250562|Drug|valsartan plus hydrochlorothiazide|
1756645|NCT00250575|Drug|Clozapine|
1756646|NCT00250588|Behavioral|Problem solving skills training|See description in Results
1756647|NCT00250588|Behavioral|Asthma care coordination|See description in Results
1756648|NCT00250588|Other|Usual Care|Usual clinical care
1756649|NCT00250601|Drug|Saredutant succinate (SR48968C)|
1756650|NCT00250614|Drug|Saredutant succinate (SR48968C)|
1756651|NCT00250627|Drug|Saredutant succinate (SR48968C)|
1756652|NCT00250640|Drug|Iloprost (Ventavis, BAYQ6256)|The recommended dose is 2.5 micrograms or 5.0 micrograms of inhaled iloprost (as delivered at the mouthpiece of the nebuliser). Dosing should follow the recommendations of the current package leaflet
1756653|NCT00250653|Drug|Saredutant succinate (SR48968C)|
1756654|NCT00250666|Procedure|PCT measurement|Peripheral blood samples were collected in the morning, using vacuum tubes (BD Vacutainer SST II Plus plastic tubes; Becton Dickinson Diagnostic Systems, Allschwil, Switzerland). Circulating plasma PCT levels were measured with a time-resolved amplified cryptate emission technology assay (Kryptor PCT; Brahms AG, Hennigsdorf, Germany), with an assay sensitivity of 0.06 mg/L, approximately fourfold above mean normal levels. Measurements were performed 7 days a week.
1756655|NCT00250679|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 ųg BID by nebulization
1756656|NCT00250679|Drug|Arformoterol 25 ųg BID|Arformoterol 25 ųg BID by nebulization
1756657|NCT00250679|Drug|Formoterol 12 ųg BID|Formoterol fumarate 12 ųg BID via aerolizer/DPI
1756658|NCT00250679|Drug|Placebo|Placebo nebule or placebo aerolizer
1756659|NCT00250692|Drug|Nitrous Oxide|
1756660|NCT00250705|Drug|Aripiprazole|The initial dose depending on the weight of the patient will be as follows: < 25 kg = 1 mg/d; 25-50 kg = 2 mg/d; 50-70 kg = 5 mg/d; > 70 kg = 10 mg/d (Data on File, 2003, Bristol-Myers Squibb). Thereafter the dose will be flexible based on response and tolerance for the duration of the 6 week study. All subjects initially received either a 5 or 10 mg/d (7.0 ± 2.6 mg/d) dose of aripiprazole. Thereafter the dose was individualized based on response and tolerance. Maximum dose was 20 mg.
1756661|NCT00250718|Drug|Vincristine|Vincristine should be administered intravenously through a freely-running IV.
1756662|NCT00250718|Drug|VP-16|The VP-16 is optional for the first cycle if the patient has delays in obtaining the drug.
1756663|NCT00250718|Drug|Rituximab|"The total amount of rituximab needed for a patient's entire infusions (one course) will be determined at study entry. A single dose of 375 mg/m2 will be based upon the patient's actual body surface area calculated during the baseline evaluation. The dose level of rituximab will not be adjusted.
Patients will only receive rituximab if their tumors are CD20 positive CLL or NHL.
Rituximab will only be administered to patients if they have previously had less than 8 doses. If a patient is treated with rituxan they should have at least 4 doses"
1756664|NCT00250718|Drug|Dexamethasone|Dexamethasone will be administered at 200mg q 14 days. Dexamethasone should be administered over a 1 hour infusion.
1756666|NCT00250731|Behavioral|telephone support and behavior change|Diabetes self-management education provided over the telephone either for individuals or couples
1756667|NCT00250731|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
1756668|NCT00250744|Drug|Aprepitant vs. Gabapentin|Gabapentin 300mg PO QHS day -2; 300mg PO BID day -1; 300mg PO TID days 0 through +5.
1756669|NCT00250744|Drug|Aprepitant vs. Gabapentin|Aprepitant 125mg PO 60 minutes prior to chemotherapy on day 0; 80 mg PO QAM on days +1 and +2.
1756670|NCT00250796|Drug|Thalidomide, alpha interferon|If the patient SSR status is negative, patients will not be given subcutaneous injections of octreotide (Sandostatin LAR) but will receive the thalidomide and alfa interferon only.
1756671|NCT00250796|Drug|Thalidomide, interferon, Octreotide|If SSR status is positive or unknown, patients will receive oral doses of thalidomide starting at 200mg a day and increasing to 800mg at increments of 200 per week depending on tolerance. They will also receive injections three times a week of alpha interferon and monthly injections of octreotide (Sandostatin LAR) 30 mg into their buttocks muscle..
1756672|NCT00250809|Procedure|Placement of a central venous catheter|Placement of a central venous catheter
1756674|NCT00250835|Other|Chemotherapy, Celecoxib, and Radiation|Enrolled rectal cancer patients are treated with concurrent chemoradiation and celecoxib pre-operatively for at least 14 days. Definitive surgery is performed within 6 weeks from the end of treatment.
1756675|NCT00250861|Drug|Rituximab|
1756676|NCT00250861|Drug|Aldesleukin|
1756677|NCT00250874|Drug|Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab|
1756678|NCT00250887|Drug|Gefitnib|
1756679|NCT00250900|Behavioral|Prescription Fill Status|
1756680|NCT00250913|Behavioral|Telephone-based physical activity counseling program|
1756681|NCT00250926|Drug|Bortezomib|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
1756682|NCT00250926|Drug|Dexamethasone|Given intravenously on days 1, 4, 8, and 11 of a 21-day cycle for 8 cycles
1756683|NCT00250926|Drug|Rituximab|Given intravenously after bortezomib and dexamethasone on day 11 of a 21-day cycle for 8 cycles
1756684|NCT00250939|Biological|Myozyme|20 mg/kg qow
1756685|NCT00250952|Drug|Botox Cosmetic™|
1756686|NCT00250965|Drug|intravenous magnesium|Subjects will be randomized prior to surgery (1:1) to receive 5 g magnesium or placebo (saline) bolus by the anaesthesiologist upon removal of the crossclamp. On postoperative days 1 through 4, subjects will receive either IV MgSO4 (5g in 250 ml normal saline) or IV placebo (250 ml normal saline) infusion over 4 hours daily.
1756687|NCT00250978|Drug|bevacizumab with chemotherapy, Pleur-XTM catheter placement|After Pleur-XTM catheter placement patients will receive bevacizumab 15mg/kg IV x 1 dose as a single agent.Three weeks later, chemotherapy will be initiated according to routine clinical practice along with continued use of bevacizumab.
1756688|NCT00250991|Drug|activase|
1756689|NCT00250991|Drug|integrilin|
1756690|NCT00251004|Drug|Everolimus|oral, bis in diem/twice a day (bid)
1756691|NCT00251004|Drug|Mycophenolic Acid (MPA)|2 oral capsules of mycophenolic acid 360mg administered bid
1756692|NCT00251004|Drug|Cyclosporine A (CsA)|CsA dose adjustments were based on CsA trough levels (C0).
1756693|NCT00251004|Drug|Basiliximab|All patients received two 20 mg doses of basiliximab administered intravenously. The first dose was to be given within 2 hours prior to transplant surgery and the second dose was to be administered on day 4, or each dose could have been administered according to local practice.
1756694|NCT00251004|Drug|Corticosteroids|Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
1756695|NCT00251017|Procedure|Vancomycin|Two hour creatinine clearance before and after vancomycin
1756696|NCT00251017|Procedure|DNA are extracted from the whole blood of subjects|
1756697|NCT00251030|Drug|Nelfinavir and Omeprazole|
1756698|NCT00251043|Behavioral|Interpersonal psychotherapy for depression in pregnancy|IPT-P will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn ways to address emotional stressors associated with childbirth.
1756699|NCT00251043|Behavioral|Parenting education program (PEP)|PEP will include 45-minute weekly sessions for 12 weeks. During sessions, participants will learn about the stages of pregnancy, childbirth, and early infant development.
1756700|NCT00251056|Drug|mannitol|120mg BD
1756701|NCT00251056|Drug|mannitol|40 mg BD
1756702|NCT00251056|Drug|mannitol|240mg BD
1756703|NCT00251056|Drug|mannitol|400mg BD
1756704|NCT00251069|Drug|Glucosamine sulphate|
1756705|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|0.5 Mg Estradiol and 2.5 Mg Dydrogesterone
1756706|NCT00251082|Drug|continuous combined estradiol and dydrogesterone|1 Mg Estradiol and 5 Mg Dydrogesterone
1756707|NCT00251082|Drug|Placebo|Placebo
1756708|NCT00251095|Drug|Taxol|
1756709|NCT00251095|Drug|TOCOSOL Paclitaxel|100 mg/m2/week
1756710|NCT00251108|Procedure|Cardiorespiratory fitness training|
1756711|NCT00251121|Other|Mini-invasive electrophysiological study|Transvenous pacing in right heart atrium
1756712|NCT00251121|Other|Atrial pacing|Diagnostic pacing in right heart atrium in order to unmask reentry tachycardia
1756713|NCT00251134|Drug|Zodin (drug)|1 gram omega-3-acid ethyl esters 90 daily for a period of 12 months
1756714|NCT00251134|Drug|Olive oil (placebo)|1 gram olive oil daily for a period of 12 months
1756741|NCT00251355|Drug|Gemcitabine|Gemcitabine, IV bolus administered weekly (weeks 1-6) at least 4 hours before that day's radiation therapy.
1756742|NCT00251355|Drug|5-Fluorouracil|5-FU via continuous IV infusion.
1756743|NCT00251355|Procedure|Radiation Therapy|External Beam Radiotherapy (weeks 1-6), Monday through Friday.
1756744|NCT00251368|Drug|9-Aminocamptothecin (9-AC)|
1756745|NCT00251381|Drug|Cetuximab|
1756746|NCT00251394|Drug|Rituxan|Given intravenously once weekly for four weeks.
1756790|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
1756715|NCT00251147|Procedure|Open acromioplasty with rotator cuff repair|A standard vertical incision was made over the anterolateral aspect of the acromion. The deltoid muscle was split and stripped off the anterior aspect of the acromion. The anterior and inferior aspect of the acromion was removed. The coracoacromial ligament was excised. Repair of the tear in the cuff tendon(s) was accomplished by suturing leading edge of the tear into the greater tuberosity of the humerus at or near the original site of insertion of the cuff to bone. Trans-osseous sutures, suture anchors and tendon to tendon suture repair techniques were employed for a secure repair with the arm at the side. The surgeon was allowed to use whatever method(s) to create a secure repair. The deltoid was securely reattached to the acromion with the deltoid fascia repaired down the split.
1756716|NCT00251147|Procedure|Arthroscopic acromioplasty with mini-open repair|A standard arthroscopic gleno-humeral arthroscopy was performed followed by an arthroscopic acromioplasty. Three standard arthroscopic portals were used. The lateral portal was centered in line with the cuff tear, and incorporated into the mini-open incision. Initially, a partial bursectomy was performed to improve visualization. The inferior surface of the anterior acromion and the coracoacromial ligament were removed. Following the arthroscopic acromioplasty, a 3-4cm lateral incision was performed in the area of the lateral portal. The deltoid muscle was split longitudinally to expose the tear in the rotator cuff. The tear was repaired in a similar manner to the open repair with tendon to tendon sutures, trans-osseous sutures and with suture anchors.
1756717|NCT00251160|Procedure|Electrothermal arthroscopic capsulorrhaphy (ETAC)|The Oratec Vulcan Generator electro-thermal system (Oratec Interventions Inc., Menlo Park, CA, USA) delivers heat at 75C and 40 watts. An anterior portal is established above the superior border of the subscapularis tendon. For MDI patients, the heat probe is introduced through the posterior portal. The capsule is shrunk using a grid pattern until excess volume is diminished. The extent of the heat probe application is identical to the landmarks used for the open ICS. Care is taken to avoid applying heat to the capsule in the region from 5-7 o'clock within 1cm of the glenoid rim to avoid the axillary nerve. The method of heat application utilizes a grid pattern, which is less likely to cause dissolution of the capsule and subsequent catastrophic capsular loss.
1756718|NCT00251160|Procedure|Open inferior capsular shift (ICS)|MDI: lateral capsule released antero-superiorly from rotator interval to equator, posteriorly on the humeral neck. MDL-AII: release from the rotator interval to 7 o'clock (Right) or 5 o'clock (Left) position on humeral neck, to tighten the 2 bands of the inferior GH ligaments, middle GH ligament and rotator interval. Bone adjacent to the articular surface on the surgical neck of the humerus is roughened to create a bleeding bony bed. With the arm in 0deg flexion, 30deg abduction, 30deg external rotation, the inferior leaflet of the capsule is shifted superiorly and slightly laterally, and sutured to the rim of the capsule using a non-absorbable suture. Superior leaflet is shifted inferiorly and sutured. Subscapularis is repaired at its anatomic length using interrupted sutures.
1756719|NCT00251173|Behavioral|Strengths Based Case Management (SBCM)|
1756720|NCT00251173|Behavioral|Motivational Enhancement Therapy (MET)|
1756721|NCT00251173|Behavioral|Brief Informational Feedback (BIF) session|
1756722|NCT00251186|Drug|Capecitabine and Cetuximab|
1756723|NCT00251199|Drug|VX-950|
1756724|NCT00251199|Drug|peginterferon|
1756725|NCT00251212|Behavioral|Adapted Motivational Interviewing & Skills Training|Single session, 45 minute brief intervention during Emergency Department Visit
1756726|NCT00251225|Drug|Gleevec|Imatinib-400mg po qd for 10 days to commence on day 3. On day 0, Docetaxel 60mg/m^2 administered IV
1756727|NCT00251225|Drug|Docetaxel|60 mg/m^2 administered IV on day 0
1756728|NCT00251238|Drug|Ginkgo biloba extract EGb 761|daily Ginkgo biloba extract EGb 761
1756729|NCT00251251|Device|Optimal Medical Therapy plus ICD|ICD vs CRT/ICD
1756730|NCT00251251|Device|Optimal Medical Therapy plus CRT/ICD|ICD vs CRT/ICD
1756731|NCT00251264|Procedure|Open stabilization|"Following examination under anesthesia, a 5cm standard deltopectoral incision is made. Dissection is continued exploiting the deltopectoral internervous plane. The conjoined tendon is retracted medially. The underlying subscapularis tendon is identified and incised horizontally or split vertically in its midsubstance. If required for adequate exposure, the subscapularis split may be extended by incising the inferior component of the subscapularis tendon near its insertion on the lesser tuberosity. The shoulder is entered by performing a T shaped arthrotomy with retractors for full exposure of the glenoid. Shoulder pathology is addressed with suture anchor repair of any capsulolabral detachment (ie.Bankart lesion) and/ or a capsular plication for repair of capsular redundancy."
1756732|NCT00251264|Procedure|Arthroscopic stabilization|With the examination under anesthesia completed, the arthroscope is introduced through a standard posterior arthroscopy portal. A diagnostic arthroscopy is performed and the intraarticular pathology identified and documented. Any labral detachment (i.e. Bankart lesion) is repaired using suture anchor fixation and arthroscopic tying techniques. Capsular redundancy is addressed with the use of thermal electrocapsulorrhaphy or arthroscopic suture repair of the redundant capsule. With the repair complete, 40 cc of 0.5% Bupivicaine is introduced into the joint. A sterile dressing is applied over the wounds and the operated shoulder placed in a shoulder immobilizer.
1756733|NCT00251277|Drug|Rituximab|Rituximab will be administered immediately after pheresis to minimize the amount of Rituximab that is removed by the subsequent days pheresis. The guidelines will be that 12 hours must elapse between the end of the first infusion of study drug and the next pheresis. Subsequent infusions would be weekly (plus or minus 2 days) with an attempt made to give study drug infusions after a pheresis that might be the last in a series, i.e. when no pheresis would be scheduled for at least the next day.
1756734|NCT00251290|Procedure|auto-titrating continuous positive airway pressure|Continuous positive Airway pressure (CPAP) use for 90 days post TIA
1756735|NCT00251303|Drug|Riluzole|Active drug put into 10-mg capsules by NIH Clinical Center Pharmacy. Matched placebo capsules were also prepared by NIH Clinical Center Pharmacy. Dose up to 120 mg daily, divided into bid dosages.
1756736|NCT00251303|Drug|Placebo|Capsules matched active drug in appearance.
1756737|NCT00251316|Drug|Lithium Carbonate|30 mCi of 131I
1756738|NCT00251316|Drug|Placebo|Patients recently diagnosed with papillary or follicular thyroid cancer who have had their thyroid gland removed and whose cancer has not spread beyond the thyroid may be eligible for this study. Participants in this arm receive placebo (look-alike capsules with no active ingredient).
1756739|NCT00251329|Drug|neoadjuvant chemotherapy|
1756740|NCT00251342|Procedure|Edinburgh Postnatal Depression Scale|
1756747|NCT00251394|Drug|1018 ISS|Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
1756748|NCT00251407|Drug|Taxotere|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
1756749|NCT00251407|Drug|Cisplatin|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
1756750|NCT00251407|Drug|CPT-11|Given intravenously on days 1 and 8 of a 21-day cycle. Participants can continue to receive study drug as long as there disease does not worsen and they do not experience serious side effects.
1756751|NCT00251420|Procedure|writing about disease|writing about physical or emotional consequences of pulmonary disease
1756752|NCT00251433|Drug|lapatinib, docetaxel, trastuzumab|The phase I part of the study will include cohorts of 3 patients to investigate doses of lapatinib (750mg, 1000mg, 1250mg, 1500mg) with 75mg/m2 3- weekly docetaxel plus standard weekly doses of trastuzumab with prophylactic use of growth factors in all patients. Further cohorts may be explored with prophylactic use of growth factors at the doses stipulated in the phase I dose escalation schema
1756753|NCT00251433|Drug|Docetaxel, trastuzumab|For Phase II, subjects will be pre-stratified for Eastern Cooperative Oncology Group (ECOG) performance (0 vs. 1; see Appendix 4 ) and site of disease (visceral vs. non-visceral). Subjects will then be randomised in a 2:1 ratio to receive either the triplet regimen or the docetaxel and trastuzumab combination.
1756754|NCT00251446|Drug|Vinflunine|320 mg/m2 as a 20-minute IV infusion
1756755|NCT00251459|Drug|rhuFab V2 (ranibizumab)|
1756756|NCT00251472|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension|125mg/m2 by 30-minute IV infusion, once a week.
1756757|NCT00251485|Drug|Cetuximab|Cycle 1: 400 mg/m2 (given as a 2-hour infusion) on Day 1, then 250 mg/m2, Day 8 (given as a 1-hour infusion) subsequent cycles:250 mg/m2, Day 1 and Day 8 (given as a 1-hour infusion)
1756758|NCT00251498|Drug|Cetuximab|Cycle 1:400 mg/m2, administered as a 120-minute iv infusion on Day 1 and 250 mg/m2 administered as a 60-minute iv infusion on Days 8 and 15, subsequent cycles:250 mg/m2 administered as a 60-minute iv infusion on Days 1, 8, 15
1756759|NCT00251511|Drug|Arsenic Trioxide|
1756760|NCT00251524|Drug|Bevacizumab, Oxaliplatin, Pemetrexed|Avastin 15 mg/kg IV, Alimta 500 mg/m2 IV given over 10 minutes, Eloxatin 120 mg/m2 IV given over 2 hours
1756761|NCT00251537|Drug|LTB4|
1756762|NCT00251550|Drug|Pemetrexed|
1756763|NCT00251550|Drug|Cisplatin|
1756764|NCT00251576|Drug|A-Phase: tirofiban; Z-Phase simvastatin|
1756765|NCT00251576|Drug|Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years|
1756766|NCT00251576|Drug|Comparator: A-Phase: low molecular weight heparin, unfractionated heparin|
1756767|NCT00251576|Drug|Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours|
1756768|NCT00251576|Drug|Duration of Treatment: Z-Phase, 2 years.|
1756769|NCT00251589|Drug|Vorinostat|Vorinostat 200 mg twice a day for 3 days a week.
1756770|NCT00251589|Drug|Vorinostat|Vorinostat 300 mg once a day for 3 days a week.
1756771|NCT00251589|Drug|Vorinostat|Vorinostat 300 mg twice a day for 3 days a week.
1756772|NCT00251589|Drug|Vorinostat|Vorinostat 400 mg once a day for 21 out of 28 days.
1756773|NCT00251589|Drug|erlotinib|erlotinib 150 mg once a day.
1756774|NCT00251602|Drug|Atropine|One-time 10 mcg/kg infusion over 30 minutes, followed by a 10 mcg/kg bolus
1756775|NCT00251602|Drug|Propranolol|One-time 0.8mg/kg/hr infusion (maximum dose not to exceed 20mg) over 20 minutes, followed by either atropine or normal saline
1756776|NCT00251602|Drug|Normal Saline|One-time 0.25 ml/min infusion over 30 minutes
1756777|NCT00251628|Other|Standard Care|standard care
1756778|NCT00251628|Other|ATC Dosing|ATC dosing of a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours around-the-clock for the first 3 days following surgery
1756779|NCT00251628|Other|Structured Pain Management Program|The structured pain management program consisted of a nurse coaching intervention which included an evaluation of the child's current condition, review of the pain intensity scores, verification that the child was taking the pain medication, re-education regarding the rationale for ATC dosing, review of strategies to facilitate medication administration, and re-education about potential side effects associated with analgesic administration.
1756780|NCT00251628|Other|As needed dosing|"As needed analgesic dosing with a weight-appropriate dose of a nonopioid/opioid combination analgesic, every 4 hours as needed for pain."
1756781|NCT00251641|Drug|infliximab|The infliximab dose will be prepared according to the subject's weight (5 mg/kg). Each intravenous (IV) infusion will be administered over a period of not less than 2 hours. The infusion must be given via a separate line using the administration set with a 1.2 micron filter. Subjects will be infused at Weeks 0, 2, 6, 14, and 22.
1756782|NCT00251641|Drug|methotrexate|Methotrexate will be supplied as 2.5 mg tablets. Subjects are to take 15 mg/week orally for the first 6 weeks of the study. Subjects will be advised to take their MTX as a single dose (weekly) on the same day of the week. If subjects randomized to MTX 15 mg/week experience a <25% reduction in PASI score at Week 6 (Visit 4) as compared with Baseline, their MTX dose will be increased to 20 mg/week. Subjects will be treated for 22 weeks.
1756783|NCT00251654|Procedure|perineural block (anesthesia)|continuous peripheral regional anesthesia ropivacaine 0.33% for 3 to 5 days
1756784|NCT00251680|Drug|Lapaquistat acetate and lipid-lowering therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
1756785|NCT00251680|Drug|Lipid-lowering therapy|Lapaquistat acetate placebo-matching tablets, tablets, orally, once daily and stable lipid-lowering therapy for up to 24 weeks.
1756786|NCT00251693|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily (QD) for up to 8 weeks.
1756787|NCT00251693|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
1756788|NCT00251693|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
1756789|NCT00251706|Drug|amiodarone|
1756953|NCT00252863|Drug|Theophylline 200 mg|
1756791|NCT00251719|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 8 weeks.
1756792|NCT00251719|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
1756793|NCT00251732|Drug|Standard dose (once daily) PPI plus low-dose antidepressant|20 mg. rabeprazole plus low dose tricyclic antidepressant(TCA)
1756794|NCT00251732|Drug|Double dose PPI plus evening placebo|20 mg. twice daily with a placebo
1756795|NCT00251732|Drug|Rabeprazole , placebo, placebo|20 mg rabeprazole(PPI) once daily -a.m. placebo -p.m. placebo -bedtime
1756796|NCT00251745|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
1756797|NCT00251745|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
1756798|NCT00251745|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
1756799|NCT00251758|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
1756800|NCT00251758|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for 4 weeks.
1756801|NCT00251758|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
1756802|NCT00251771|Procedure|catheter-directed venous thrombolysis|catheter-directed continuous intravenous infusion of alteplase 0.01mg/kg/h and low-dose heparin. Max dose 20mg/24 h and up to 96 hrs.
1756803|NCT00251784|Drug|Sildenafil|
1756804|NCT00251797|Drug|Irinotecan|Irinotecan: 300 to 350 mg/m2 mixing with 250 cc. Dextrose injection. IV infusion over 90 minutes D1 and repeat every 21 days
1756805|NCT00251797|Drug|Thalidomide|Thalidomide 50 mg capsule starting from 4 tablets per day Oral D 3 to D 19 of each cycle
1756806|NCT00251810|Device|Cerebral State Monitor|All patients monitored with BIS and CSM, results hidden for the anesthesiologist.
1756807|NCT00251823|Drug|Eptifibatide facilitated PCI|
1756808|NCT00251836|Procedure|Laparoscopic hand-assisted donor nephrectomy|
1756809|NCT00251849|Drug|Rifalazil|
1756810|NCT00251862|Behavioral|Web-based decision aid plus personalized risk assessment|Patients review a computer-based decision aid that discuss the pros and cons of of 5 recommended CRC screening options and provides personalized 10-year estimates of CRC risk prior to meeting with their provider to discuss CRC screening.
1756811|NCT00251862|Behavioral|Web-based decision aid alone|Patients review a computer-based decision aid that discuss the pros and cons of the 5 recommended CRC screening options prior to meeting with their provider to discuss CRC screening.
1756812|NCT00251862|Behavioral|Generic website|Patients review a generic website that discuss ways to reduce overall cancer risk.
1756813|NCT00251875|Device|online health information journal|
1756814|NCT00251888|Drug|campto (irinotecan)|
1756815|NCT00251888|Drug|cisplatin (cisplatyl)|
1756816|NCT00251901|Drug|Esomeprazole|
1756817|NCT00251914|Drug|Esomeprazole|
1756818|NCT00251927|Drug|esomeprazole|40 mg oral tablet administered daily
1756819|NCT00251927|Procedure|Laparoscopic fundoplication (surgery)|Surgery
1756820|NCT00244673|Biological|DTP3/4+OPV+MV versus OPV+MV or DTP4+OPV4 versus OPV4|Trial of not providing 3. and/or 4. DTP together with or after MV at 9 to 18 month of age.
1756821|NCT00244686|Drug|Mepolizumab|open label investigational product
1756822|NCT00244699|Behavioral|MI Alone or Plus Mindfulness-Based Skills Training|
1756823|NCT00244712|Drug|emtricitabine/tenofovir|The intervention is an active comparator regimen containing tenofovir/emtricitabine + abacavir/lamivudine placebo + lopinavir/ritonavir.
1756824|NCT00244712|Drug|abacavir/lamivudine|The experimental intervention is a regimen containing abacavir/lamivudine + tenofovir/emtricitabine placebo + lopinavir/ritonavir.
1756825|NCT00244725|Drug|Odiparcil|
1756826|NCT00244725|Drug|Warfarin|
1756827|NCT00244725|Drug|Coumadin|
1756828|NCT00244738|Dietary Supplement|Castor oil|Patients who received castor oil for labor induction
1756829|NCT00244738|Dietary Supplement|Sunflower oil|Patients who received sunflower oil as a placebo
1756831|NCT00244764|Drug|GW786034|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
1756832|NCT00244764|Drug|Placebo|All patients receive GW786034. At week 12, some subjects will be randomized based on response (SD) and the others will remain on drug. After the interim analysis, the design was changed to an open label, single arm study with all subjects receiving pazopanib.
1756833|NCT00244777|Drug|Hypo-osmolar ORS|
1756834|NCT00244790|Behavioral|Diet|crossover low vs high protein diet before and after weight loss
1756835|NCT00244816|Drug|Taxoprexin|
1756836|NCT00244829|Drug|imatinib mesylate|
1756837|NCT00244829|Procedure|adjuvant therapy|
1756838|NCT00244842|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg po BID
1756839|NCT00244842|Drug|Placebo|Placebo
1756840|NCT00244855|Other|pharmacological study|Correlative studies
1756841|NCT00244855|Biological|rituximab|Given IV
1756842|NCT00244855|Drug|dexamethasone|Given IV
1756843|NCT00244855|Other|laboratory biomarker analysis|Correlative studies
1756844|NCT00244868|Other|counseling intervention|
1756845|NCT00244868|Other|educational intervention|
1756846|NCT00244881|Drug|cediranib maleate|Given orally
1756847|NCT00244881|Other|laboratory biomarker analysis|Correlative studies
1756848|NCT00244894|Procedure|acupuncture therapy|Acupuncture treatments will be administered by a qualified practitioner twice a week for the first four weeks and once per week for an additional 6 weeks. Sterile, disposable Seirin needles will be placed bilaterally at the point Gallbladder 34, and along the spine at Bladder 15, Bladder 23, and Bladder 32. Low intensity electrostimulation at 2 Hz will be used for both Bladder 23 and Bladder 32. Points will also be placed unilaterally at Governing vessel 20, Heart 7, Pericardium 6, Liver 2, and Spleen 6
1756849|NCT00244894|Procedure|fatigue assessment and management|Patients will utilize the Pittsburgh Sleep Quality Index (PSQI) to assess if the patient is an overall good sleeper or a poor sleeper.
1756954|NCT00252863|Drug|Theophylline 300 mg|
1756850|NCT00244894|Procedure|hot flashes attenuation|Patients will be asked to report hot flash frequency and severity daily using the hot flash diary (HFD) and hot flash severity guidelines (HFSG) throughout the treatment period.
1756851|NCT00244894|Procedure|management of therapy complications|Short Form Health Survey (SF-36) will be used to assess the patient's overall vitality.
1756852|NCT00244894|Procedure|quality-of-life assessment|Hot Flash Related Daily Interference Scale (HFRDIS)will be used to self-report hot flash related quality of life.
1756853|NCT00244907|Dietary Supplement|Genistein vs Risedronate|Gensitein (100 gm) from soy protein isolate Risedronate (5 mg)
1756854|NCT00244920|Drug|bicalutamide|
1756855|NCT00244920|Drug|leuprolide acetate|
1756856|NCT00244920|Drug|squalamine lactate|
1756857|NCT00244920|Procedure|adjuvant therapy|
1756858|NCT00244920|Procedure|antiandrogen therapy|
1756859|NCT00244920|Procedure|antiangiogenesis therapy|
1756860|NCT00244920|Procedure|conventional surgery|
1756861|NCT00244920|Procedure|neoadjuvant therapy|
1756862|NCT00244920|Procedure|releasing hormone agonist therapy|
1756863|NCT00244933|Dietary Supplement|genistein|Novasoy Orally-100 mg 2 times/day for 7 days; 2 times/day on Days 1-21 every 21 days.
1756864|NCT00244933|Drug|gemcitabine|Gemcitabine IV-1000mg/m2: Days 1 & 8 every 21 days
1756865|NCT00244933|Procedure|Tumor biopsy|Biopsy of tumor prior to dose of genistein (Novasoy)
1756866|NCT00244946|Biological|therapeutic autologous lymphocytes|Lymphocytes collected by standard apheresis technique either prior to or post stem cell mobilization and collection
1756867|NCT00244946|Drug|carmustine|
1756868|NCT00244946|Drug|cytarabine|
1756869|NCT00244946|Drug|etoposide|
1756870|NCT00244946|Drug|melphalan|
1756871|NCT00244946|Procedure|peripheral blood stem cell transplantation (PBSCT)|
1756872|NCT00244959|Drug|anastrozole|1 mg orally daily for 12 months
1756873|NCT00244959|Procedure|adjuvant therapy|treatment received after breast cancer surgery
1756874|NCT00244972|Other|Laboratory Biomarker Analysis|Correlative studies
1756875|NCT00244972|Drug|Sorafenib Tosylate|Given PO
1756876|NCT00244972|Drug|Tipifarnib|Given PO
1756877|NCT00244985|Biological|rituximab|IV
1756878|NCT00244985|Drug|pegylated liposomal doxorubicin hydrochloride|IV
1756879|NCT00244998|Drug|fulvestrant|IM
1756880|NCT00245011|Biological|filgrastim|Filgrastim will be administered post post chemotherapy until target WBC (white blood cell) count is achieved.
1756881|NCT00245011|Drug|ifosfamide|Ifosfamide administered IV.
1756882|NCT00245011|Procedure|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation is done 14 days after 2nd dose of Samarium is delivered
1756883|NCT00245011|Radiation|Sm-EDTMP (low dose)|Sm-EDTMP (low dose) administered after autologous stem cell collection
1756884|NCT00245011|Radiation|sm-EDTMP (higher dose)|Upon blood cell count recovery from Sm-EDTMP (low dose), Sm-EDTMP (higher dose) is administered followed in 14 days by peripheral blood stem cell transplantation.
1756885|NCT00245024|Drug|sulindac|
1756886|NCT00245024|Other|laboratory biomarker analysis|
1756955|NCT00252863|Drug|Singulair 10 mg|
1956721|NCT02729896|Drug|Atezolizumab [TECENTRIQ]|Atezolizumab will be administered by intravenous (IV) infusion at a flat dose of 1200 milligram (mg) every 3 weeks (Q3W) on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and 1680 mg every 4 weeks (Q4W; 840 mg Days 1 and 2 every month) during maintenance or consolidation treatment (1 cycle=21 days; infusion rate starts with 60 minutes (min) and decreases to 30 min).
1956722|NCT02729896|Drug|Obinutuzumab|Obinutuzumab will be administered by IV infusion at a flat dose of 1000 mg on Days 1, 8, and 15 of Cycle 1, and on Day 1 of Cycles 2-6, given in 21-day cycles during induction treatment, and on Day 1 of every other month during maintenance treatment (1 cycle=21 days; infusion rate starts at 50 mg/hour (hr) and increases every 30 min to a maximum of 400 mg/hr).
1956723|NCT02729896|Drug|Polatuzumab Vedotin|Polatuzumab vedotin will be administered by IV infusion. For relapsed or refractory FL either 1.4 mg/kilogram (kg) or 1.8 mg/kg (dose-escalation phase) and at RP2D (dose-expansion phase) on Day 1 of Cycles 1-6 will be given in 21-day cycles during induction treatment. For relapsed or refactory DLBCL, 1.8 mg/kg will be given during run-in phase and either 1.8 mg/kg or 1.4 mg/kg during the expansion phase (1 cycle=21 days; infusion rate starts with 90 min and decreases to 30 min).
1956724|NCT02729896|Drug|Rituximab|Rituximab will be administered by IV infusion at 375 mg/m˄2 on Day 1 of Cycles 1-6 during induction treatment and on Day 1 of every other month during consolidation treatment for DLBCL (1 cycle-21 days; infusion rate starts with 50 mg/hr and increases every 30 min to a maximum of 400 mg/hr).
1756897|NCT00245050|Dietary Supplement|pyridoxine hydrochloride|Arm I: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral pyridoxine twice 100 mg daily on days 1-28.
1756898|NCT00245050|Drug|Placebo|Arm II: Patients receive doxorubicin HCl liposome IV 40 mg/m2 over 1 hour on day 1 and oral placebo 100 mg twice daily on days 1-28.
1756899|NCT00245050|Drug|doxorubicin HCL liposome|IV, 40mg/m2
1756900|NCT00245063|Drug|cediranib maleate|Given PO
1756901|NCT00245063|Other|laboratory biomarker analysis|Correlative studies
1756902|NCT00245063|Other|pharmacogenomic studies|Optional correlative studies
1756903|NCT00245076|Behavioral|smoking cessation intervention|
1756904|NCT00245076|Other|internet-based intervention|
1756905|NCT00245089|Biological|dactinomycin|
1756906|NCT00245089|Drug|cyclophosphamide|
1756907|NCT00245089|Drug|vincristine sulfate|
1756908|NCT00251940|Drug|Tesaglitazar 0.5 or 1 mg|
1756909|NCT00251940|Drug|Glibenclamide 2.5, 5, 10 or 15 mg|
1756910|NCT00251953|Drug|Tesaglitazar|
1756911|NCT00251953|Drug|Metformin|
1756912|NCT00251966|Drug|Esomeprazole|
1756913|NCT00251979|Drug|Esomeprazole|
1756914|NCT00251992|Drug|Esomeprazole|
1756915|NCT00252005|Drug|Apixaban|
1756916|NCT00252018|Behavioral|Daily intake of broccoli sprouts|
1756917|NCT00252031|Behavioral|Dialectical Behavioral Therapy|
1756918|NCT00252044|Drug|Pergolide|
1756919|NCT00252057|Behavioral|Re-Engineered Hospital Discharge|"The Re-engineered Hospital Discharge (Project RED) intervention provides a set of 11 discrete, mutually reinforcing components provided by a Discharge Advocate and re-enforced by a telephone call after discharge by a clinical pharmacist."
1756920|NCT00252070|Behavioral|Functional Exercise for People with Arthritis (FEPA)|
1756921|NCT00252083|Behavioral|Popular Opinion Leader|
1756922|NCT00252096|Device|Nucleic acid amplification test|
1756923|NCT00252109|Behavioral|Popular Opinion Leader|Popular opinion leaders of social networks are identified and attend 4 sessions to prepare them to have casual conversations with persons in the social networks that are meant to shift social norms to embrace safer behaviors (e.g., increased condom use, fewer sexual partners)
1756924|NCT00252122|Drug|Ketamine|Ketamine. 0.2 mg/kg, intravenously
1756925|NCT00252148|Biological|ADMVA|experimental HIV vaccine, MVA vector expressing HIV clade C env, gag, pol, nef, and tat
1756926|NCT00252161|Procedure|Gastrectomy with more than D2 dissection|Gastrectomy with more than D2 dissection
1756927|NCT00252161|Drug|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy|Neoadjuvant chemotherapy(TS-1+CDDP) followed by gastrectomy
1756928|NCT00252174|Drug|Stage 1 Active Methylenedioxymethamphetamine|"Dosage form: capsule
Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):
Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
1756929|NCT00252174|Drug|Stage 1 Low dose Methylenedioxymethamphetamine|"Drug:
Dosage form: capsule
Dosage frequency and duration for the control arm (4 subjects):
Session 1: 25 mg followed 2.5 hours later with optional 12.5 mg for total of 37.5 g Session 2 (two to three weeks later): 25 mg followed 2.5 hours later with optional 12.5mg for total of 37.5mg."
1756930|NCT00252174|Behavioral|Psychotherapy|Psychotherapy conducted with low or active dose MDMA
1756931|NCT00252174|Drug|Stage 2 Active Methylenedioxymethamphetamine|"Administered open label Dosage form: capsule
Dosage frequency and duration for the treatment arm (8 subjects in Stage 1 and the other 4 subjects in Stage 1 who may continue into Stage 2):
Session 1: 83.3mg followed 2.5 hours later with optional 41.7 mg for total of 125mg Session 2 (two to three weeks later): 125mg followed 2.5 hours later with optional 62.5mg for total of 187.5 mg."
1756932|NCT00252187|Drug|B-type Natriuretic Peptide (BNP)|BNP hormone self-administered subcutaneously twice daily for 8 weeks at 10 mcg/kg.
1756933|NCT00252187|Other|Placebo|Placebo self-administered subcutaneously twice daily for 8 weeks.
1756934|NCT00252200|Drug|Neseritide|Dose of Nesiritide infusion will be 0.005 ug/Kg/min
1756935|NCT00252213|Drug|Human BNP|
1756936|NCT00252226|Drug|Quetiapine|
1756937|NCT00252239|Drug|tenecteplase|This study will compare 3 different doses of tenecteplase to tPA.
1756938|NCT00252239|Drug|tissue plasminogen activator, tPA|To date, tissue plasminogen activator (tPA) is the only scientifically-proven and FDA-approved treatment for acute stroke.
1756939|NCT00252252|Device|VPAP non-invasive ventilator|
1756940|NCT00252252|Device|AutoVPAP non-invasive ventilator|
1756941|NCT00252278|Drug|atomoxetine|
1756942|NCT00252850|Genetic|CERE-120: AAV2-NTN|
1756943|NCT00252863|Drug|Symbicort, used twice daily (b.i.d) and as needed (prn)|
1756944|NCT00252863|Drug|Budesonide Turbuhaler 200 µg|
1756945|NCT00252863|Drug|Fluticasone Discus 250 µg|
1756946|NCT00252863|Drug|Formoterol Turbuhaler 4.5 µg|
1756947|NCT00252863|Drug|Terbutaline Turbuhaler 0.5 mg|
1756948|NCT00252863|Drug|Salbutamol pressurized metered dose inhaler (pMDI) 100 µg|
1756949|NCT00252863|Drug|Salmeterol Discus 50 µg|
1756950|NCT00252863|Drug|Budesonide/Formoterol Turbuhaler 160/4.5 µg|
1756951|NCT00252863|Drug|Fluticasone/Salmeterol Discus 250/50 µg|
1756952|NCT00252863|Drug|Fluticasone/Salmeterol Discus 500/50 µg|
1756957|NCT00252889|Drug|Topotecan and pegylated doxorubicin|Doxil 40 mg/m2 day 1 and topotecan was to be escalated in cohorts of patients
1756958|NCT00252902|Behavioral|Behavior change counseling|
1756959|NCT00252915|Biological|GM-CSF (verum)|sagramostim
1756960|NCT00252928|Other|Sodium dichloroisocyanurate (NaDCC) tablets|Intervention arm receives NaDCC tablets to use for to disinfect their household water for use for 20L of water. Ideally, disinfection occurs every day.
1756961|NCT00252928|Other|Placebo|Placebo
1756962|NCT00252941|Device|Memokath 028SW Urethral Stent|
1756963|NCT00252954|Drug|Levetiracetam|Tablets 2000-3000 mg per day
1756964|NCT00252967|Drug|Atorvastatin|80 mg of Atorvastatin
1756965|NCT00252967|Drug|Placebo|
1756966|NCT00252980|Behavioral|Psychotherapy|
1756967|NCT00252993|Drug|DDP225|
1756968|NCT00253006|Procedure|Tissue examination for protein- and mRNA-expression of NO|
1756969|NCT00253032|Device|PRIMA|
1756970|NCT00253045|Behavioral|Motivational groups|Motivational interviewing in group format
1756971|NCT00253058|Drug|Cetirizine Dry Syrup|
1756972|NCT00253071|Behavioral|Prophylactic combined medical and psychological treatment|"Medical treatment is naturalistic and evidence based according to international recommendations.
Psychological treatment is either group psychoeducation or group cognitive behavioural therapy."
1756973|NCT00253084|Drug|IPX054 200 mg|IPX054 containing 50 mg carbidopa and 200 mg levodopa
1756974|NCT00253084|Drug|CD-LD IR|CD-LD IR containing 25 mg carbidopa and 100 mg levodopa
1756975|NCT00253084|Drug|IPX054 Placebo|Placebo to match IPX054 200 mg
1756976|NCT00253084|Drug|CD-LD IR Placebo|Placebo to match CD-LD IR
1756977|NCT00253097|Behavioral|Intervention|Patients allocated to the intervention group have 4 visits by a study nurse. She will measure patient's blood pressure (BP) by standardized meathods, inform the patient about the target BP, stress the importance of lowering the BP and in case of elevated BP she advices the patient to go the the GP for further control. She advises about smoking cessation, reduction of alcohol consumption, loss of excess body weigt and stresses the importance of physical activity as appropriate
1756978|NCT00253110|Drug|risperidone|
1756979|NCT00253110|Drug|haloperidol|
1756980|NCT00253123|Drug|risperidone|
1756981|NCT00253136|Drug|risperidone|
1756982|NCT00253149|Drug|risperidone|
1756983|NCT00253162|Drug|risperidone|
1756984|NCT00253175|Drug|topiramate|
1756985|NCT00253188|Drug|galantamine hydrobromide|
1756986|NCT00253201|Drug|galantamine hydrobromide|
1756987|NCT00253214|Drug|galantamine hydrobromide|
1756988|NCT00253227|Drug|galantamine hydrobromide|
1756989|NCT00253240|Procedure|Screening|
1756990|NCT00253240|Procedure|Management|
1756991|NCT00253266|Drug|Venlafaxine|Venlafaxine XR up to 450 mg/d during the complete trial (8 weeks)
1756992|NCT00253266|Drug|Quetiapine|Quetiapine up to 200 mg/d for four weeks
1756993|NCT00253279|Procedure|PET Scans|Healthy volunteers will undergo one PET Scan; bur patients will undergo a maximum of 3 PET scans over 2 years after injury; a maximum of 2 will be done while inpatient; one after d/c.
1756994|NCT00253305|Drug|Organogel of naftifine, 2%|
1756995|NCT00253305|Drug|Organogel of terbinafine, 2%|
1756996|NCT00253305|Drug|Organogel of naftifine, 6%|
1756997|NCT00253305|Drug|Organogel of terbinafine, 6%|
1756998|NCT00253318|Drug|Docetaxel|40 mg/m^2 IV over 1 hour on Day 1.
1756999|NCT00253318|Drug|RAD001|30 mg orally on Days 1 and 8.
1757000|NCT00253318|Drug|Dexamethasone|8 mg orally twice daily for 3 days, starting 24 hours prior to the administration of Docetaxel.
1757001|NCT00253331|Drug|topical organogel with nitroglycerin|
1757002|NCT00253344|Drug|docetaxel|Docetaxel IV over 1 hour on day 1. Courses repeat every 21 days until disease progression or unacceptable toxicity.
1757003|NCT00253344|Drug|lenalidomide|Oral lenalidomide on days 1-14. Courses repeat every 21 days until disease progression or unacceptable toxicity.
1757004|NCT00253370|Drug|BAY 43-9006|Given orally
1757005|NCT00253370|Drug|docetaxel|Given IV
1757006|NCT00253370|Drug|cisplatin|Given IV
1757007|NCT00253383|Other|counseling intervention|
1757008|NCT00253383|Other|educational intervention|
1757009|NCT00253383|Procedure|psychosocial assessment and care|
1757010|NCT00253383|Procedure|quality-of-life assessment|
1757011|NCT00253396|Drug|Unfractionated heparin|
1757012|NCT00253396|Drug|Enoxaparin|
1757013|NCT00253409|Drug|chemotherapy|
1757014|NCT00253409|Procedure|adjuvant therapy|
1757015|NCT00253409|Procedure|conventional surgery|
1757016|NCT00253409|Procedure|neoadjuvant therapy|
1757017|NCT00253409|Radiation|radiation therapy|
1757018|NCT00253422|Drug|anastrozole|
1757019|NCT00253422|Drug|exemestane|
1757020|NCT00253422|Drug|fulvestrant|
1757021|NCT00253435|Biological|Filgrastim|Filgrastim 5 micrograms/kg/day S.C. or IV will be given daily beginning on Day 0. The first dose should begin four hours after the stem cell infusion is completed. Filgrastim will continue daily until the ANC >=1500/uL for three consecutive days.
1757022|NCT00253435|Drug|Carboplatin|"The carboplatin will be administered as a continuous IV infusion Day - 7 through Day - 4, with dosing based upon pretreatment GFR levels. The carboplatin should be diluted to a concentration of 0.3 mg/ml in D5W 0.45NS and infused concomitantly with etoposide through the same central venous catheter using a Y connector; a controlled rate infusion pump is used for each arm of the Y."
1757023|NCT00253435|Drug|Etoposide|The etoposide shall be administered day -7 through day -4 via continuous intravenous infusion over 96 hours. For patients with a corrected GFR >= 100 ml/min/1.72 m^2, a dose of 300 mg/m^2/day (10 mg/kg/day if child is < 12 kg) shall be given. For patients with a corrected GFR 60-99 ml/min/1.72 m^2, the etoposide will be administered at a dose of 160 mg/m^2/day (5.3 mg/kg/day). The etoposide will be diluted in D5W 0.45%NS at a concentration of < 0.4 mg/ml. Etoposide should not be mixed with carboplatin, but administered using a Y-connector.
1757092|NCT00253669|Procedure|management of therapy complications|
1757322|NCT00248131|Drug|Octreotide acetate in microspheres|
1757024|NCT00253435|Drug|Melphalan|For patients in either the normal GFR strata (>=100 ml/min/1.73 m^2), or reduced GFR strata (60-99 ml/min/1.73m^2), melphalan shall be administered at a dose of 60 mg/m^2/day (2 mg/kg/day if child is < 12 kg) on day -7, -6, and -5 of study. The melphalan should be infused at a rate of less than 10 mg/minute, and should complete within 1 hour of reconstitution each day. The melphalan should be diluted in 0.9% NaCl at a concentration < 2 mg/ml. The total dosage of melphalan to be administered will be 180 mg/m^2.
1757025|NCT00253435|Procedure|Peripheral blood stem cell infusion|Stem cells or marrow will be infused on day 0 of study therapy. Where the DMSO concentration in the stem cell product would exceed accepted level for infusion within a 24 hour period, stem cell products may be infused over two days to meet this standard. For purged PBSC: A minimum of 2.0 x 10^6 viable CD34+ cells/kg must be available. For unpurged PBSC, a minimum of 2.0 x 10^6 viable CD34+ cells/kg must be available. Having a back-up of 2.0 x 10^6 viable CD34+ cells/kg purged or unpurged PBSC is recommended but not required. For purged bone marrow, a minimum of 1.5 x10^8 mononuclear cells/kg must be available.
1757026|NCT00253435|Radiation|131I-MIBG|Therapeutic 131I MIBG will be synthesized by Draximage Canada.with specific activity between 15 and 25mCi/ml. Radiopurity will be initially determined by Draximage, prior to shipment to participating centers. Free radioiodide content must then be rechecked at the treating center prior to infusion using HPLC or Sep-Pac methodology.
1757027|NCT00253435|Radiation|Radiation therapy|Local irradiation is to be given to previously non-irradiated primary and metastatic sites of disease. Local irradiation should not start till the patient is medically stable, has an ANC > 1000/uL, platelets > 30,000 / uL, and is > 42 days post transplant. Recommended radiation guidelines consist of 2160 cGy total, given over 12 days using a single 180 cGy fraction/day. Any delay in local radiation that would extend treatment beyond day +84 should be discussed with the study chair. Local radiation will be administered at a participating NANT member site.
1757028|NCT00253448|Radiation|radiation therapy|No more than 2 weeks later, patients undergo conventional radiotherapy once daily, 5 days a week, for 6 weeks.
1757029|NCT00253448|Radiation|stereotactic radiosurgery|stereotactic radiosurgery to high-risk areas of active tumor determined by MR-spectroscopy
1757030|NCT00253461|Procedure|computed tomography|Within 4 weeks after initial imaging, patients also undergo a CT scan.
1757031|NCT00253461|Procedure|positron emission tomography|"Phase I: IV over 10 minutes followed immediately by a 1-2 hour positron emission tomography (PET) scan.
Phase II: fludeoxyglucose F 18 IV and, 1 hour later, undergo a PET scan."
1757032|NCT00253461|Radiation|11C topotecan|Phase I and II: IV over 10 minutes
1757033|NCT00253461|Radiation|fludeoxyglucose F 18|Phase II: fludeoxyglucose F 18 IV
1757034|NCT00253474|Biological|PEG-interferon alfa-2a|
1757035|NCT00253487|Drug|O6-benzylguanine|
1757036|NCT00253487|Drug|busulfan|
1757037|NCT00253487|Drug|temozolomide|
1757038|NCT00253487|Procedure|adjuvant therapy|
1757039|NCT00253487|Procedure|autologous bone marrow transplantation|
1757040|NCT00253487|Procedure|conventional surgery|
1757041|NCT00253487|Procedure|peripheral blood stem cell transplantation|
1757042|NCT00253487|Radiation|radiation therapy|
1757043|NCT00253500|Biological|pegfilgrastim|6 mg in a syringe
1757044|NCT00253500|Drug|epirubicin hydrochloride|120 MG q 2 weeks for 4 cycles
1757045|NCT00253500|Procedure|conventional surgery|to remove small piece of cancer
1757046|NCT00253513|Drug|fludarabine|30 mg/m2, IV for 5 days
1757047|NCT00253513|Drug|treosulfan|12 or 14 g/m2, IV for 5 days
1757048|NCT00253513|Procedure|allogeneic blood or bone marrow transplantation|bone marrow or peripheral blood stem cells
1757049|NCT00253526|Drug|bevacizumab|
1757050|NCT00253526|Drug|gemcitabine hydrochloride|
1757051|NCT00253526|Procedure|adjuvant therapy|
1757052|NCT00253526|Procedure|anti-cytokine therapy|
1757053|NCT00253526|Procedure|antiangiogenesis therapy|
1757054|NCT00253526|Procedure|antibody therapy|
1757055|NCT00253526|Procedure|biological therapy|
1757056|NCT00253526|Procedure|chemotherapy|
1757057|NCT00253526|Procedure|conventional surgery|
1757058|NCT00253526|Procedure|growth factor antagonist therapy|
1757059|NCT00253526|Procedure|monoclonal antibody therapy|
1757060|NCT00253526|Procedure|surgery|
1757061|NCT00253539|Drug|arzoxifene hydrochloride|Given orally
1757062|NCT00253539|Drug|tamoxifen citrate|Given orally
1757063|NCT00253539|Other|placebo|Given orally
1757064|NCT00253552|Biological|filgrastim|
1757065|NCT00253552|Drug|busulfan|
1757066|NCT00253552|Drug|cyclophosphamide|
1757067|NCT00253552|Drug|cyclosporine|
1757068|NCT00253552|Drug|etoposide|
1757069|NCT00253552|Drug|methotrexate|
1757070|NCT00253552|Procedure|allogeneic bone marrow transplantation|
1757071|NCT00253552|Radiation|radiation therapy|
1757072|NCT00253565|Drug|capecitabine|
1757073|NCT00253565|Drug|imatinib mesylate|
1757074|NCT00253578|Drug|sorafenib tosylate|Given PO
1757075|NCT00253578|Other|laboratory biomarker analysis|Correlative studies
1757076|NCT00253591|Drug|cisplatin|
1757077|NCT00253591|Drug|vinorelbine tartrate|
1757078|NCT00253591|Radiation|radiation therapy|
1757079|NCT00253617|Drug|porfimer sodium|
1757080|NCT00253617|Procedure|adjuvant therapy|
1757081|NCT00253617|Procedure|laser therapy|
1757082|NCT00253617|Procedure|photodynamic therapy|
1757083|NCT00253617|Procedure|phototherapy|
1757084|NCT00253630|Other|Laboratory Biomarker Analysis|Correlative studies
1757085|NCT00253630|Drug|Vorinostat|Given PO
1757086|NCT00253643|Dietary Supplement|green tea catechin extract|Given orally 2 times/day
1757087|NCT00253643|Dietary Supplement|fish oil|Given orally 3 times/day
1757088|NCT00253643|Other|placebo|Given olive oil placebo orally 3 times/day
1757089|NCT00253643|Other|placebo|Given green tea placebo orally 2 times/day
1757090|NCT00253669|Other|laboratory biomarker analysis|
1757091|NCT00253669|Other|physiologic testing|
1757150|NCT00254163|Drug|Cyclophosphamide|
1757093|NCT00253695|Device|Wrist Actigraphy|Wrist actigraph will record participants' sleeping patterns.
1757094|NCT00253708|Procedure|management of therapy complications|
1757095|NCT00253708|Procedure|massage therapy|
1757096|NCT00253708|Procedure|pain therapy|
1757097|NCT00253708|Procedure|psychosocial assessment and care|
1757098|NCT00253708|Procedure|quality-of-life assessment|
1757099|NCT00253721|Drug|Melphalan|"All levels: Every 4 weeks for up to one year
Dose Escalation Plan:
Level 1: 4mg/m2/day x 2 days
Level 2: 6mg/m2/day x 2 days
Level 3: 8mg/m2/day x 2 days
Level 4: 10mg/m2/day x 2 days
Level 5: 12mg/m2/day x 2 days"
1757100|NCT00253734|Biological|Fluzone® (IM)|15, 9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by the standard intramuscular route.
1757101|NCT00253734|Biological|Fluzone®|9, 6, or 3 mcg of standard trivalent inactivated influenza vaccine (TIV) administered by intradermal route (Mantoux technique).
1757102|NCT00253747|Drug|Osmotic-Release Methylphenidate|OROS-MPH dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
1757103|NCT00253747|Drug|Placebo|OROS-MPH (placebo) dosing strategy will start with 18 mg/day for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). And, nicotine patch dosing schedule will be 21 mg/day during weeks 4-11; 14 mg/day during weeks 12-13; and 7 mg/day in week 14.
1757104|NCT00253760|Drug|dietary amino acids; cysteine and methionine|
1757105|NCT00253773|Drug|acetominophen, sulfer amino acids; cysteine and methionine|
1757106|NCT00253786|Drug|ACE inhibitors,ARB, HMG-CoA reductase inhibitors, vitamins|
1757107|NCT00253786|Behavioral|Compliance, antismoking, and nutrition instruction|
1757108|NCT00253799|Device|Hylan GF-20|
1757109|NCT00253812|Procedure|flexible sigmoidoscopy|
1757110|NCT00253825|Device|mCIMT combined with or without eye patching|
1757111|NCT00253838|Procedure|Restoration HA stem|The Restoration hip stem, is made from titanium alloy, a different type of metal that has a roughened surfacing and allows for a hydroxylapatite (HA) coating to be applied to the entire length of the stem.
1757112|NCT00253838|Procedure|Solution stem|The Solution stem is made from Cobalt Chrome, a type of metal, and does not have a hydroxylapatite (HA) coating.
1757113|NCT00253851|Drug|unfractionated heparin|Five minutes prior to tourniquet inflation, patients will receive 0.1 ml/kg/minute of intravenous (IV) unfractionated heparin (1000 units/ml) or placebo (normal saline solution). Five minutes will be allowed to elapse to ensure complete systemic heparinization. The operated limb will then be elevated and exsanguinated using an Esmarch bandage. Following cuff inflation, the contents of a second syringe will be administered IV over a 5 minute period. The second syringe will contain either protamine sulfate (1.0 mg/kg) to reverse the systemic heparin for patients in the treatment group, or normal saline for the control group. Study drugs will be administered by the anaesthesiologist via a peripheral IV. This new method of intraoperative regional heparinization has been used in two previous studies (Giachino et al., 2001; Giachino et al., 1985) with no adverse effects noted.
1757114|NCT00253877|Device|Hip Resurfacing System|All patients received the Conserve Plus Hip Resurfacing System, manufactured by Wright Medical Technology
1757115|NCT00253890|Drug|Trazodone|50 mg 1-3 capsules at bedtime for 3 months
1757116|NCT00253890|Drug|Placebo|1-3 at bedtime
1757117|NCT00253903|Drug|eplivanserin (SR46349)|oral administration
1757118|NCT00253903|Drug|placebo|oral administration
1757119|NCT00253916|Behavioral|Aerobic cardiovascular exercise program|Aerobic cardiovascular exercise program
1757120|NCT00253916|Behavioral|Resistance Exercise Program|Resistance Exercise Program
1757121|NCT00253929|Drug|Intra-arterial infusion of adenosine|
1757122|NCT00253929|Drug|intra-arterial infusion of caffeine|
1757123|NCT00253929|Drug|intra-arterial infusion of acetylcholine|
1757124|NCT00253929|Drug|intra-arterial infusion of sodium nitroprusside|
1757125|NCT00253929|Procedure|Occlusion of arm-circulation by inflation of upper-arm cuff to 200mmHg for 2, 5 and 13 minutes|
1757126|NCT00253942|Procedure|Injecting bee venom as a treatment for OA|
1757127|NCT00253955|Drug|Levofloxacin|
1757128|NCT00253955|Drug|Piperacillin/Tazobactam|
1757129|NCT00253968|Drug|Eplivanserin|oral administration
1757130|NCT00253968|Drug|placebo|oral administration
1757131|NCT00253981|Device|Monochromatic Near-Infrared Light Energy (MIRE)|Subjects randomized to the intervention group (Monochromatic Near-Infrared Light Energy), received treatment three times a week for a total of four weeks.
1757132|NCT00253994|Procedure|Acupuncture|
1757133|NCT00254007|Drug|citalopram (celexa)|20(1 tablet)-50(2 1/2 tablets) mg/day for a period of 6 or 10 weeks
1757134|NCT00254020|Drug|Citalopram|Patients who are found to have major depression will be referred to a psychologist
1757135|NCT00254033|Drug|Dextroamphetamine|
1757136|NCT00254033|Drug|Methylphenidate|
1757137|NCT00254046|Drug|TMC125|2 X100 mg tablets b.i.d.96 weeks
1757138|NCT00254046|Drug|Placebo|2 tablets b.i.d.96 weeks
1757139|NCT00254059|Procedure|Ambulatory diagnosis and titration with nasal CPAP using over night oxymetry and auto CPAP and vs conventional diagnosis and titration using polysomnography|
1757140|NCT00254072|Procedure|3.5 mm vs 4.8 mm Stapler During Laparoscopic Gastric Bypass|The procedure consists of a creation of a small gastric pouch and rerouting the small bowel to bypass the stomach and duodenum. There are two anastomoses in this procedure: the gastrojejunostomy and the jejunojejunostomy.
1757141|NCT00254085|Drug|Insulin Aspart|
1757142|NCT00254111|Device|Ultra Probe Laser System|
1757143|NCT00254124|Device|The Diet Plate (R) TM portion control plate and bowl|
1757144|NCT00254137|Drug|capecitabine|
1757145|NCT00254137|Drug|irinotecan|
1757146|NCT00254137|Drug|oxaliplatin|
1757147|NCT00254137|Drug|cetuximab|
1757148|NCT00254150|Procedure|Increase oxygen extraction rate|
1757149|NCT00254163|Drug|Fludarabine|
1956732|NCT02726009|Drug|Degarelix|
1757155|NCT00254189|Drug|Levonorgestrel|
1757156|NCT00254189|Drug|Ethinyl Estradiol|
1757157|NCT00254202|Drug|iloperidone|
1757158|NCT00254202|Drug|active comparator|
1757159|NCT00254202|Drug|placebo|
1757160|NCT00254215|Behavioral|high protein & low glycemic index diets|
1757161|NCT00254228|Device|Electrotactile sensory substitution|
1757162|NCT00254241|Drug|Seroquel and Risperidone|
1757163|NCT00254254|Drug|Exenatide - Exenatide - Placebo|Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose, followed by placebo 0.02 mL, single dose. All are subcutaneous injections.
1757164|NCT00254254|Drug|Exenatide - Placebo - Exenatide|Exenatide 2.5 mcg, single dose, followed by placebo 0.02 mL, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
1757165|NCT00254254|Drug|Placebo - Exenatide - Exenatide|Placebo 0.02 mL, single dose, followed by Exenatide 2.5 mcg, single dose, followed by Exenatide 5 mcg, single dose. All are subcutaneous injections.
1757166|NCT00254267|Drug|AMG 706|AMG 706 125mg, oral, once a day
1757167|NCT00254280|Procedure|Intense Pulsed Light + paring versus paring alone|
1757168|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
1757169|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC Solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
1757170|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
1757171|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
1757172|NCT00254293|Drug|Abatacept or Placebo (both as IV & SC solution)|Abatacept & Placebo as IV & SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
1757173|NCT00254293|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
1757174|NCT00254319|Drug|Avastin, Alimta|
1757175|NCT00254345|Procedure|coating a dental restoration material ,polymethylmethacrylate, with liquid polish resin|
1757176|NCT00254371|Procedure|Androgen Replacement|
1757177|NCT00254384|Drug|Erlotinib|150 mg by mouth daily for 1 year.
1757178|NCT00254384|Drug|Cisplatin|80 mg/m^2 IV over a 30 minutes - 1 hour infusion every 3 weeks (21 day cycle) for 3 cycles before surgery.
1757179|NCT00254384|Drug|Docetaxel|75 mg/m^2 IV over a 1 hour infusion every 3 weeks (21 day cycle) for 3 cycles before surgery.
1757180|NCT00254397|Drug|Leuprolide|A 3-month 11.25 mg sustained-release formulation will be administrated intramuscularly at time 0, and approximately 12 weeks (2 injections).
1757181|NCT00254397|Biological|GP100: 209-217(210M) Peptide|1.0 ml subcutaneous injection in extremities.
1757182|NCT00254397|Biological|MAGE-3 Peptide|1.0 ml subcutaneous injection in extremities.
1757183|NCT00254410|Drug|Fludarabine|Fludarabine 25 mg/m2 on Days 2,3,4 i.v. 5-30 mins for course 1, and on Days 1 - 3 for courses 2 - 6
1757184|NCT00254410|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 on Day 2,3,4 i.v. 5-30 mins for course 1, and on Days1 - 3 for courses 2 - 6.
1757185|NCT00254410|Drug|Mitoxantrone|Mitoxantrone 6 mg/m2 on Day 2 i.v. 30-60 mins for course 1, and on Day 1 for courses 2 - 6.
1757186|NCT00254410|Drug|Rituximab|Rituximab 375 mg/m2 on Day 1 i.v. 2-6 hours for course 1 and 500 mg/m2 on Day 1 for courses 2 - 6.
1757187|NCT00254410|Drug|Filgrastim|Pegylated Filgrastim - 6 mg on Day 4,s.c. for course 1 and on Day 3 for courses 2 - 6.
1757188|NCT00254423|Drug|Dasatinib (BMS-354825)|"Arm A: Starting dose 100 mg orally daily
Arm B: Starting dose of 50 mg orally twice daily"
1757189|NCT00254436|Drug|Procrit (epoetin alfa)|Weekly dose
1757190|NCT00254449|Drug|NGX-4010|
1757191|NCT00254462|Drug|Atomoxetine|Participants will receive atomoxetine for 8 weeks up to a maximum of 1.8 mg/kg/day. Dosed once daily in capsule formulation.
1757192|NCT00254462|Drug|Placebo|Participants will receive placebo for 8 weeks. Dosed once daily, capsule formulation.
1757193|NCT00254462|Behavioral|Parent Training|All children will receive parent training for the duration of the study.
1757194|NCT00254475|Drug|simvastatin|
1757195|NCT00254475|Drug|valsartan|
1757196|NCT00254488|Drug|Lithium (LI)|The starting LI dose will be 150 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma LI level ranges between 0.40 and 0.99 mEq/L (target 0.80 to 0.99 mEq/L).
1757197|NCT00254488|Drug|Divalproex (DV)|Dosage of DV will be 250 mg in the morning and evening. The dose of medication will be adjusted to achieve plasma DV level ranges between 40 and 99 mcg/mL (target 80 to 99 mcg/ml).
1757198|NCT00254501|Behavioral|Pharmacist Counseling|Patients were scheduled for free counseling with pharmacists including medication, diet, and other self-management items. Patients also received waiver of out-of-pocket expenses for diabetes care.
1757199|NCT00254501|Behavioral|Educational materials|Patients received educational materials (handouts) in the mail. This was assumed to be of minimal effectiveness. Patients also received waiver of out-of-pocket expenses for diabetes care.
1757200|NCT00254514|Drug|somatropin|
1757201|NCT00254540|Drug|SU011248 capsule|50mg, PO on day 28 of each 42 day cycle, until progression or unacceptable toxicity develops
1757202|NCT00254553|Drug|Testim 1% (testosterone gel)|Testim_ 100 mg: two tubes of 50 mg of Testim_per day
1757203|NCT00254553|Drug|Placebo|two tubes of placebo per day
1757204|NCT00254566|Other|Moxifloxacin Placebo|1 capsule once daily for 5 days
1757205|NCT00254566|Drug|Moxifloxacin|1 X 400mg capsule once daily for 5 days
1757206|NCT00254566|Other|Azithromycin SR Placebo|single dose, oral.
1757207|NCT00254566|Drug|Azithromycin SR|single dose 2.0 g oral
1757208|NCT00254579|Drug|CP-675,206|15 mg/kg Q12W dosing regimen
1757209|NCT00254592|Drug|Doxorubicin|60 mg/m2 IV, bolus once a day every 14 days x 2-4 cycles
1757210|NCT00254592|Drug|Cyclophosphamide|600 mg/m2 IV once a day every 14 days x 2-4 cycles
1757211|NCT00254592|Drug|Carboplatin|AUC 2 IV weekly for 9-12 doses beginning two weeks after completion of last AC dose
1757212|NCT00254592|Drug|Nab-paclitaxel|100 mg/m2 IV over 30 min weekly for 9-12 doses beginning two weeks after completion of last AC dose
1757213|NCT00254592|Drug|GM-CSF|250 μg/mL IV or on day 4-13 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
1757214|NCT00254592|Drug|Trastuzumab|4mg/kg, and then2 mg/kg q wk IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
1757215|NCT00254592|Drug|Bevacizumab|10mg/kg q 2 wks
1757216|NCT00254618|Drug|mesalamine|oral tablet, 30 mg mesalamine/day for 28 days
1757217|NCT00254618|Drug|mesalamine|oral tablet, 60 mg mesalamine/day for 28 days
1757218|NCT00254618|Drug|mesalamine|oral tablet, 90 mg mesalamine/day for 28 days
1757219|NCT00254631|Drug|Oxycodone hydrochloride|
1757220|NCT00254644|Procedure|Morphological and functional MRI|one time
1757221|NCT00254657|Drug|Levetiracetam|Started with one 500 mg tablet/day and titrated upward as tolerated over 6 weeks by 500 mg/week to a maximum dose of 3000 mg/day.
1757222|NCT00254657|Drug|Placebo|
1757223|NCT00254670|Drug|Naltrexone|
1757225|NCT00254696|Drug|Extended-Spectrum-Lactamases (ESBLs)|
1757226|NCT00254709|Drug|Sirolimus|
1757227|NCT00254722|Procedure|Autologous bone marrow precursor cell harvest and transplant|Bone marrow harvest (3 ml/kg of body weight) performed between 12 and 30 hours post injury, followed by single intravenous infusion of bone marrow progenitor cells - target dose is 6x10^6 mononuclear cells/kg body weight, administered within 36 hours of injury
1757228|NCT00254735|Drug|quetiapine fumarate|
1757229|NCT00254735|Drug|SSRI/Clomipramine|
1757230|NCT00254748|Drug|Quetiapine fumarate|flexible doses from 200 mg to 600 mg
1757231|NCT00254748|Drug|Placebo|placebo
1757232|NCT00254761|Drug|Cannabis|
1757233|NCT00254774|Drug|quetiapine fumarate or valproate|
1757234|NCT00254787|Drug|IR (Immediate-Release) quetiapine fumarate (drug)|
1757235|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
1757236|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
1757237|NCT00254800|Drug|ethinyl estradiol and levonorgestrel; exenatide|Oral contraceptive is ethinyl estradiol (30 μg) and levonorgestrel (150 μg) one time daily, per 28-day treatment period; Study drug (exenatide 10 mcg) is subcutaneously injected twice daily
1757238|NCT00254813|Drug|Quetiapine|
1757239|NCT00254826|Biological|YF-VAX® plus saline|YF-VAX® plus saine
1757240|NCT00254826|Biological|17D YF Vaccine plus Ig,|17D YF Vaccine plus Ig, one vaccine on day 0
1757241|NCT00254852|Procedure|Posterior Lateral Fusion (PLF)|Posterior lateral fusion (PLF) of the lumbar spine
1757242|NCT00254852|Procedure|Anterior Lumbar Interbody Fusion (ALIF)|Anterior lumbar interbody fusion (ALIF)
1757243|NCT00254852|Procedure|Transforaminal lumbar interbody fusion (TLIF)|Transforaminal lumbar interbody fusion (TLIF)
1757244|NCT00254852|Procedure|Posterior lumbar interbody fusion (PLIF)|Posterior lumbar interbody fusion (PLIF)
1757245|NCT00254852|Procedure|Extreme lateral interbody fusion (XLIF)|Extreme lateral interbody fusion (XLIF)
1757246|NCT00254865|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.75 mg of ethinyl estradiol (versus CILEST® tablets).|
1757247|NCT00254878|Drug|Methylphenidate hydrochloride|
1757248|NCT00254891|Drug|PF-3512676 + Paclitaxel + Carboplatin|"PF-3512676: 0.2 mg/kg subcutaneously Days 8 and 15 of each 21 day cycle x 6 cycles then weekly as maintenance until disease progression or unacceptable toxicity.
Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.
Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
1757249|NCT00254891|Drug|Paclitaxel + Carboplatin|"Paclitaxel: 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles.
Carboplatin: AUC 6 intravenously Day 1 of each 21 days cycle x 6 cycles."
1757250|NCT00254904|Drug|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
1757251|NCT00254904|Drug|Gemcitabine|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
1757252|NCT00254904|Drug|PF-3512676|PF-3512676 0.2 mg/kg subcutaneously days 8 and 15 x 6 cycles and then weekly until disease progression or unacceptable toxicity
1757253|NCT00254904|Drug|Cisplatin|Cisplatin 75 mg/m2 intravenously on day 1 of each 21 day cycle x 6 cycles
1757254|NCT00254904|Drug|Gemcitabine + Cisplatin|Gemcitabine 1250 mg/m2 intravenously on days 1 and 8 of each 21 cycle x 6 cycles
1757255|NCT00254917|Biological|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
1757256|NCT00254917|Biological|Diphteria, Tetanus, Polio, Acellular Pertussis, Hib vaccine|0.5 mL, IM
1757257|NCT00254930|Drug|risperidone|
1757258|NCT00254956|Drug|ciclesonide (XRP1526)|
1757259|NCT00254969|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, Im
1757260|NCT00254982|Biological|Infliximab|Infliximab 5 mg/kg was given as an induction regimen at week 0, 2, and 6 weeks after the first infusion and then at week 14.
1757261|NCT00254995|Biological|None administered in this study|N/A in this study
1757262|NCT00255008|Biological|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
1757263|NCT00255008|Drug|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks
1757264|NCT00255008|Biological|peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
1757265|NCT00255008|Drug|ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
1757266|NCT00255021|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib Vac|0.5 mL, IM
1757267|NCT00255034|Biological|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
1757268|NCT00255034|Biological|Peginterferon alfa-2b|Powder for injection in Redipen (50, 80, 100, 120 and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
1757269|NCT00255034|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 weeks
1757270|NCT00255034|Drug|Ribavirin|200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 48 weeks
1757271|NCT00255047|Biological|DAPTACEL®. (DTaP), IPOL®., and ActHIB®.|0.5 mL, Intramuscular
1757272|NCT00255047|Biological|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
1757273|NCT00255047|Biological|DTaP-IPV and ActHIB®|0.5 mL, Intramuscular
1757274|NCT00255047|Biological|Pentacel®: DTaP-IPV/Hib combined|0.5 mL, Intramuscular
1757275|NCT00255073|Drug|baclofen|
1757276|NCT00255086|Drug|Memantine|10mg Memantine
1757277|NCT00255086|Drug|Placebo pill|10mg placebo pill
1757278|NCT00255099|Drug|TMC125|2 x 100 mg tablets b.i.d. / 96 weeks
1757279|NCT00255099|Drug|Placebo|2 tablets b.i.d. / 96 weeks
1757280|NCT00255112|Behavioral|family based cognitive behavior therapy|newly developed family based cognitive behavior therapy for children with separation anxiety disorder over 5 years old
1757281|NCT00255125|Drug|Soy Supplement|Soy protein supplement will be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
1757282|NCT00255125|Drug|Placebo|Placebo will consist of a capsule without the soy protein added to be taken for 2-4 weeks until surgery to remove the prostate or start of radiation treatment. Patient will receive 4 capsules twice a day (8 capsules) daily to be taken with water or juice (except grapefruit juice).
1757283|NCT00255138|Drug|Atomoxetine|
1757284|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
1757285|NCT00255151|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
1757286|NCT00255151|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
1757287|NCT00255164|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to six months.
1757288|NCT00255164|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to six months.
1757289|NCT00255164|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
1757290|NCT00255177|Drug|VGX-410 (Mifepristone)|VGX-410 tablets taken daily or twice daily for 28 days
1757291|NCT00255177|Drug|Placebo|Placebo for VGX-410 tablets taken daily or twice daily for 28 days
1757292|NCT00255190|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 12 months.
1757293|NCT00255190|Drug|Dexlansoprazole MR|Dexlansoprazole MR 90 mg, capsules, orally, once daily for up to 12 months.
1757294|NCT00255216|Drug|Policosanol supplement (oral capsule) vs. placebo|
1757295|NCT00255229|Drug|Glutamine|Glutamine 10 g four times daily starting two days before treatment for six days in total
1757296|NCT00255229|Other|Placebo|Glutamine placebo
1757297|NCT00255242|Drug|Simvastatin treatment for 28 days|40 mg / day
1757298|NCT00255255|Drug|Budesonide/Formoterol|
1757299|NCT00255268|Drug|Goserelin|
1757300|NCT00255268|Drug|Bicalutamide|
1757301|NCT00255281|Drug|AZD7009, no generic name available|
1757302|NCT00255294|Drug|Cellulose sulfate vaginal gel|
1757303|NCT00255307|Drug|CVT-E002 ginseng extract|
1757304|NCT00255320|Drug|VIP|
1757305|NCT00255333|Drug|INNO-105|
1757306|NCT00255346|Drug|Dasatinib (BMS-354825)|70 mg orally twice daily
1757307|NCT00255359|Drug|XTL-2125|
1757308|NCT00255372|Drug|PEG 4000 (Forlax®)|Powder for oral solution. 2 sachets of 4g, from baseline every two weeks over a 4 week treatment period.
1757309|NCT00255372|Drug|Lactulose active and Lactulose placebo|Powder for oral solution. 1 sachet of 3.3g lactulose active and 1 sachet of lactulose placebo. From baseline every two weeks over a 4 week treatment period.
1757310|NCT00247975|Drug|L-carnitine|Patients will be randomized to L-carnitine therapy or placebo. Patients in the treatment group will receive oral L-carnitine (3 grams daily) for 3 days prior to chemotherapy, 1 gram of intravenous L-carnitine (5 cc over 5 minutes, prior to chemotherapy) on the day of chemotherapy and oral L-carnitine (3 grams daily) for 3 days after chemotherapy.
1757311|NCT00247988|Drug|Weekly Taxotere with weekly carboplatin|
1757312|NCT00248014|Device|Mandibular Advancement Via A Functional Appliance|Functional appliance
1757316|NCT00248053|Drug|curcumin|curcumin 500 mg by mouth, three times a day for 9 months
1757317|NCT00248066|Drug|RESTEN-MP|
1757318|NCT00248079|Device|Coronary Artery Stenting|Initial implant of drug eluting stent (zotarolimus)
1757319|NCT00248092|Drug|NRP104|
1757320|NCT00248105|Behavioral|Lifestyle Physical Activity Management|Lifestyle Physical Activity Promotion as given by Physical Activity Advocates. Advocates will meet with participants at baseline and every 3 months throughout the study to promote increase in lifestyle physical activity reached through goal setting and Motivational Interviewing (MI)
1757321|NCT00248118|Drug|Bupropion|During treatment phase, participants will take 300 mg bupropion or placebo daily.
1757324|NCT00248157|Drug|Octreotide acetate in microspheres|
1757325|NCT00248170|Drug|Letrozole|2.5 mg tablets
1757326|NCT00248170|Drug|Anastrozole|1 mg tablets
1757327|NCT00248183|Drug|PRX-00023|
1757328|NCT00248196|Device|Reprieve Endovascular Temperature Therapy System|
1757329|NCT00248209|Drug|Wellbutrin XL|Patients randomized to the bupropion treatment group will receive bupropion XL150 mg in the AM for 7 days increasing to 300mg/day (single daily dose). The investigator can increase the dose to 450mg per day at Day 28 if clinically indicated.
1757330|NCT00248222|Behavioral|Supervised aerobic training|
1757331|NCT00248235|Behavioral|Exercise|
1757332|NCT00248248|Drug|liposomal doxorubicin|Doxil at 50mg/m2 infused over one hour every 3 or 4 weeks for 3-6 cycles
1757333|NCT00248261|Drug|ziprasidone, sertraline|
1757334|NCT00248287|Drug|Irinotecan + Carboplatin|irinotecan 90 mg/m2 and carboplatin AUC=2.0 on Days 1 and 8 of each 21-day cycle
1757335|NCT00248287|Drug|irinotecan + Carboplatin + erbitux|irinotecan 90mg/m2, carboplatin AUC=2.0 on Days 1 and 8 of each 21- day cycle plus Erbitux 400 mg/m2
1757336|NCT00248300|Other|Chlorhexidine|Chlorhexidine, 5 ml swab to the oral cavity within 12 hours of endotracheal tube intubation
1757337|NCT00248313|Drug|Rapamune®|
1757338|NCT00248339|Drug|Peginterferon-alpha-2b (PEG-Intron)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD
PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
1757339|NCT00248339|Drug|Ribavirin|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus ribavirin ~13.3 mg/kg QD
PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
1757340|NCT00248339|Drug|Epoetin-alpha (Procrit)|"PEG-interferon-alpha-2b 1.5 μg/kg QW plus standard dose ribavirin, ~13.3 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week.
PEG-interferon-alpha-2b 1.5 μg/kg QW plus high dose ribavirin, ~15.2 mg/kg QD, plus erythropoetin (PROCRIT®) 40,000 U/week."
1757341|NCT00248352|Behavioral|Consultation with Endocrinologist|
1757342|NCT00248352|Behavioral|Counseling from Dietician|
1757343|NCT00248352|Behavioral|Counseling from Diabetes Educator|
1757344|NCT00248365|Biological|Theralux extracorporeal photochemotherapy|
1757345|NCT00248378|Drug|Smoked Cannabis|
1757346|NCT00248391|Behavioral|upright feeding|
1757347|NCT00248404|Drug|NB1011|
1757348|NCT00248430|Biological|aldesleukin|
1757349|NCT00248430|Biological|therapeutic allogeneic lymphocytes|
1757350|NCT00248430|Drug|melphalan|
1757351|NCT00248430|Procedure|bone marrow ablation with stem cell support|
1757352|NCT00248430|Procedure|peripheral blood stem cell transplantation|
1757353|NCT00248443|Procedure|Fiberoptic bronchoscopy and bronchoalveolar lavage|
1757354|NCT00248456|Drug|Calcipotriol plus betamethasone dipropionate ointment|
1757355|NCT00248469|Behavioral|In-school Sexual Health Education|
1757356|NCT00248469|Behavioral|Youth-friendly health services|
1757357|NCT00248469|Behavioral|Youth condom promotion & distribution|
1757358|NCT00248469|Behavioral|Community activities related to adolescent sexual health|
1757359|NCT00248482|Drug|Cisplatin|Cisplatin 60mg/m2 IV day 1 every 21 days x 4 cycles
1757360|NCT00248482|Drug|Gleevec™|Gleevac 400 mg po BID (800mg/day)- fo patients with objective response or stable disease.
1757361|NCT00248482|Drug|irinotecan|Irinotecan: 65 mg/m2 IV days 1, 8 every 21 days x 4 cycles
1757362|NCT00248495|Drug|cisplatin|Given IV
1757363|NCT00248495|Drug|pemetrexed disodium|Given IV
1757364|NCT00248495|Procedure|adjuvant therapy|Metastasis prevention/control
1757365|NCT00248495|Procedure|conventional surgery|Undergoing tissue removal
1757366|NCT00248495|Procedure|neoadjuvant therapy|Tumor Reduction
1757367|NCT00248521|Drug|alvespimycin hydrochloride|
1757371|NCT00248547|Drug|aprepitant|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
1757372|NCT00248547|Drug|dexamethasone|For Cyclophosphamide Total Body Irradiation(CyTBI) patients: Dexamethasone study drug 1 capsule PO daily, 1 hour prior to chemotherapy with aprepitant on total body irradiation(TBI) and cyclophosphamide chemotherapy days; For Busulfan Cyclophosphamide(BuCy) patients: Dexamethasone 1 capsule orally once daily, discontinue after last dose of chemotherapy.
1757373|NCT00248547|Drug|ondansetron|For CyTBI patients: Ondansetron 8 mg orally evert 12 hours, begin 1 hour prior to first TBI dose and discontinue after last dose; then Ondansetron 8 mg IV every 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy; For BuCy patients: Ondansetron 8 mg orally every 6 hours, begin 1 hour prior to first busulfan dose and discontinue after last busulfan dose is given. then: Ondansetron 8 mg IV Q 12 hours X 4 doses, begin 30 minutes prior to first cyclophosphamide chemotherapy
1757374|NCT00248547|Drug|placebo|Loading dose of 125 mg capsule once a day for one day, then maintenance dose of 80 mg capsule daily through Day +4 of Bone Marrow Transplant
1757375|NCT00248560|Drug|docetaxel|Gemcitabine hydrochloride given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine hydrochloride.
1757376|NCT00248560|Drug|gemcitabine hydrochloride|Gemcitabine hydrochloride given 3000 mg/m2 IV over 30 minutes and Docetaxel given 60mg/m2 IV over 60 minutes. The Docetaxel should be administered after the Gemcitabine hydrochloride.
1757378|NCT00248612|Drug|Venlafaxine|Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine. The treatments will conclude with a 2-week medication taper.
1757480|NCT00255606|Drug|prednisone|Given in 3- or 4- week courses
1757481|NCT00255619|Device|Baxter’s UltraBag® and FMC Andy·Disc®|
1757482|NCT00255658|Drug|sorafenib tosylate|Given orally
1757379|NCT00248612|Behavioral|CBT|CBT is Cognitive Behavioral Therapy. Participants will be assigned to a 12-week treatment condition; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial. The treatments will conclude with a 2-week medication/placebo taper.
1757380|NCT00248612|Other|Progressive muscle relaxation therapy (PMR)|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
1757381|NCT00248612|Other|Placebo medication|For patients with comorbid alcohol-use and anxiety disorders, CBT and pharmacotherapy will be contrasted with relaxation training and placebo medication; all treatment conditions will begin with a 1-week placebo run-in, after which participants will begin a trial of venlafaxine or placebo.
1757382|NCT00248625|Drug|N-acetylcysteine|The study drug is administered as a continuous infusion at a dose of 150 mg/kg/day for up to 7 days following entry into the study. The infusion is discontinued at the time of death, liver transplant or discharge.
1757383|NCT00248625|Drug|Placebo|Eligible children were adaptively allocated within strata defined by age (less than 2 years of age or at least 2 years old) and hepatic encephalopathy (grade 0-1 or 2-4) to receive N-acetylcysteine (150 mg/kg/d) in 5% dextrose (D5W) and water or placebo consisting of an equal volume of D5W alone. Volumes were adjusted for small children. Study medications were infused over 24 hours for up to 7 consecutive days in a dedicated line without other medications. Treatment was stopped earlier than 7 days in the case of hospital discharge, liver transplantation, or death within 7 days of randomization.
1757384|NCT00248638|Drug|Glutamine dipeptide with 15% Clinisol|Subjects randomized to AG-PN will receive PN containing 0.5 g/kg/day of L alanyl L GLN (AG) dipeptide (Dipeptiven 20%; Fresenius-Kabi) and 1.0 g/kg/day of 15% Clinisol (Baxter Inc., Deerfield, IL) AA solution (total = 1.5 g/kg/day, with AG replacing 1/3 of Clinisol AA). The amount of GLN dipeptide administered each day will be determined by daily PN volume intake data.
1757385|NCT00248638|Drug|15% Clinisol|Subjects randomized to STD-PN will receive 1.5 g/kg/day of 15% Clinisol. The amount of Clinisol administered each day will be determined by daily PN volume intake data.
1757386|NCT00248651|Drug|Amitriptyline|25 mg capsule by mouth at bedtime for two weeks, then 50 mg capsule by mouth at bedtime for 10 weeks. The drug will be provided in blister packs.
1757387|NCT00248651|Drug|Escitalopram|10 mg tablets by mouth at bedtime for 12 weeks. The drug will be provided in blister packs.
1757388|NCT00248651|Drug|Placebo|Placebo escitalopram and placebo amitriptyline will be manufactured to ensure all tablets and capsules will be indistinguishable, and provided in blister packs.
1757389|NCT00248677|Behavioral|Behavioral Family-Based Intervention|Behavioral family intervention
1757390|NCT00248677|Behavioral|Behavioral Parent-Based Intervention|Behavioral Parent-Only Intervention
1757391|NCT00248690|Device|ICP mean wave amplitude|Appropriate measures when ICP mean wave amplitude is to high, e.g. CSF drainage
1757394|NCT00248729|Drug|Etomidate (20mg) or Midazolam (7mg)|
1757395|NCT00248742|Behavioral|Psychological behavioral intervention|3x3 hours group intervention followed by 6-9 hours individual psychotherapy based on cognitive behavioral methods
1757396|NCT00248755|Procedure|mucociliary clearance scan|
1757397|NCT00248768|Device|Transcranial magnetic Stimulator|a device which produces intense magnetic fields in the brain and activates cerebral neurons
1757398|NCT00248781|Device|Telecommunications system|
1757399|NCT00248781|Device|attention control|health education
1757400|NCT00248794|Behavioral|Cognitive Rehabilitation Therapy (CRT) + Skill Training (SDG)|CRT is a one on one cognitive skills training and Skill training is a group intervention to develop concrete skills of daily living.
1757401|NCT00248794|Behavioral|Individual Computer Based Cognitive Rehabilitation (ICBCR) and Skills Training (SDG)|ICBCR is a computerized cognitive skills training program and Skill training is a group intervention to develop concrete skills of daily living.
1757402|NCT00248794|Behavioral|Skills Group (SDG)|Skill training is a group intervention to develop concrete skills of daily living. This is augmented with the opportunity to receive up to 5 hours of individual staff contact.
1757403|NCT00248807|Drug|1.25 mg enalaprilat IV|an angiotensin converting enzyme (ACE) inhibitor given to lower blood pressure (BP) and measure cerebral blood flow (CBF)
1757404|NCT00248807|Other|Head up tilt (HUT)|45 degree head-up tilt to lower blood pressure and measure cerebral blood flow.
1757405|NCT00248820|Procedure|Contrast-enhanced ultrasound|Contrast enhanced ultrasound using Sonovue / 2.4 ml per injection - one or two injections (maximum of 9.6 ml).
1757407|NCT00248846|Behavioral|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their physical activity level. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
1757408|NCT00248872|Behavioral|Intervention Group|During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.
1757483|NCT00255658|Drug|temsirolimus|Given IV
1757484|NCT00255658|Other|laboratory biomarker analysis|Correlative studies
1757862|NCT00261001|Biological|Intramuscular mode of administration|
1757409|NCT00248885|Procedure|Regulating Mean Arterial Pressure during cardiopulmonary bypass|Patients were randomized to one of two groups. In the first group (Low) the goal was to maintain MAP between 50-60 mm Hg during CPB. In the second group (High), the goal was to maintain MAP between 80-100 mm Hg. In both groups, CPB flow was held constant at 1.6 L/min/M2 (cool) and 2.4 L/min/M2 (warm) and vasoactive drugs (nitroglycerin or phenylephrine) were used to maintain MAP in the desired range. MAP was controlled in this fashion from the onset of CPB through separation from CPB began.
1757410|NCT00248898|Procedure|Cardiac Surgery|Coronary artery bypass graft surgery, aortic valve replacement, mitral valve replacement, aortic aneurysm repair
1757411|NCT00248911|Behavioral|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
1757412|NCT00248924|Behavioral|Social Services|
1757413|NCT00248937|Behavioral|Positive affect and self-affect induction|
1757414|NCT00248950|Behavioral|Positive affect induction and /or self affirmation induction|
1757415|NCT00248963|Drug|Levonorgestrel 90 mg and Ethinyl Estradiol 20 mg|
1757416|NCT00248976|Behavioral|Net-present value of individual health behaviors in years|
1757417|NCT00248989|Drug|Dehydroepiandrosterone|3.0 ml of 0.3% DHEA cream applied on the skin twice daily.
1757418|NCT00248989|Drug|Placebos|3.0 ml of placebo cream applied on the skin twice daily.
1757419|NCT00249002|Drug|ABI-007|
1757420|NCT00249015|Behavioral|Physical exercise|perform exercise program 3 days per week and 5 minutes of warm-up and cool-down exercises before and after the main exercise component
1757421|NCT00249041|Drug|50 mg Etanercept|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
1757422|NCT00249041|Drug|Enbrel liquid|50 mg Etanercept liquid injected SC once weekly using prefilled syringes
1757423|NCT00249054|Device|ASR hip prosthesis|Implantation of resurfacing prosthesis
1757424|NCT00249054|Device|ReCap hip prosthesis|Implantation of resurfacing prosthesis
1757425|NCT00249093|Drug|oxygen|
1757426|NCT00249106|Biological|ADVAX|
1757427|NCT00249119|Drug|risperidone|
1757428|NCT00249132|Drug|risperidone|
1757429|NCT00249145|Drug|risperidone|
1757430|NCT00249158|Drug|Risperidone|
1757431|NCT00249171|Drug|risperidone|
1757432|NCT00249197|Drug|levofloxacin|
1757433|NCT00249210|Drug|levofloxacin|
1757434|NCT00249223|Drug|Risperidone Long acting injectable|
1757435|NCT00249236|Drug|Risperidone, oral tablets|
1757436|NCT00249249|Drug|Pitavastatin|
1757437|NCT00249249|Drug|Atorvastatin|
1757438|NCT00249262|Drug|Taxoprexin|
1757439|NCT00249275|Device|spectacles|
1757440|NCT00249288|Drug|Folate|Folic acid taken as 2, 1mg capsule daily for 12 weeks
1757441|NCT00249288|Drug|Placebo|Placebo taken as 2, 1mg capsule daily for 12 weeks
1757442|NCT00249301|Drug|MLN8054|MLN8054 will be administered orally in multiple divided daily doses for 7 days to 21 consecutive days. A 14-day recovery period will follow each dosing period, regardless of its duration. MLN8054 will be supplied in capsules of 5 mg or 25 mg with dose strength expressed as the milligrams of active drug (free acid). MLN8054 will be given on an empty stomach. Patients will be instructed to take nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose.
1757443|NCT00249327|Behavioral|education|
1757444|NCT00249340|Behavioral|Weight Watchers|
1757445|NCT00249340|Behavioral|brief behavioral weight loss treatment|
1757446|NCT00249340|Behavioral|brief behavioral + Weight Watchers combined treatment|
1757447|NCT00249353|Drug|methylphenidate hydrochloride|
1757448|NCT00249366|Drug|Lorazepam (drug)|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
1757449|NCT00249366|Drug|Lorazepam|Lorazepam administered orally or IV for treatment of alcohol withdrawal in hospitalized patients
1757450|NCT00249379|Drug|Acamprosate|Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence
1757451|NCT00249405|Drug|Citalopram + MI|14-week citalopram treatment + Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
1757452|NCT00249405|Behavioral|Placebo + MI|placebo + single Motivational Interview (MI) and 9 brief sessions of a manual-guided Compliance Enhancement Therapy; post-treatment follow-up assessments will be conducted at 4, 12 and 24 weeks.
1757453|NCT00249418|Behavioral|Contingency management|Rewards (prizes) for abstinence
1757454|NCT00255385|Drug|Micronutrient (Zinc and Iron) fortification|
1757455|NCT00255385|Drug|Pre and Probiotic fortification|
1757456|NCT00255424|Drug|ferumoxytol or oral iron|
1757457|NCT00255437|Drug|ferumoxytol or oral iron|
1757458|NCT00255450|Drug|ferumoxytol or placebo|
1757459|NCT00255463|Drug|Anastrazole|
1757460|NCT00255463|Drug|Gefitinib|
1757461|NCT00255476|Drug|gefitinib|
1757462|NCT00255476|Drug|cisplatin|
1757463|NCT00255476|Drug|5-flourouracil|
1757464|NCT00255489|Drug|Gefitinib|
1757465|NCT00255489|Procedure|palliative thoracic radiotherapy|
1757466|NCT00255502|Drug|metoprolol succinate|
1757467|NCT00255515|Drug|Quetiapine fumarate|oral
1757468|NCT00255515|Drug|conventional treatment for schizophrenia|various standard therapies
1757469|NCT00255528|Drug|metoprolol succinate|
1757470|NCT00255541|Drug|Tesaglitazar|
1757471|NCT00255541|Drug|Glibenclamide|
1757472|NCT00255554|Behavioral|Dialectical Behavioral Therapy|
1757473|NCT00255554|Drug|Escitalopram|
1757474|NCT00255567|Drug|Sodium Stibogluconate|Sodium Stibogluconate 20mg/kg/day for 30 days
1757475|NCT00255567|Drug|Paromomycin sulphate|Paromomycin sulphate
1757476|NCT00255567|Drug|SSG and Paromomycin sulphate|SSG and Paromomycin Sulphate 17 days
1757477|NCT00255580|Drug|Smoked cannabis|
1757478|NCT00255593|Drug|rituximab|
1757479|NCT00255606|Drug|docetaxel|Given in 3- or 4- week courses
1757485|NCT00255671|Other|Questionnaire|Patients complete questionnaires about the side effects they experience from radiosurgery. The questionnaires are completed at baseline and at 1 week, 1 month, and 2 months after radiosurgery.
1757486|NCT00255684|Biological|graft-versus-tumor induction therapy|
1757487|NCT00255684|Drug|cyclophosphamide|
1757488|NCT00255684|Drug|cyclosporine|
1757489|NCT00255684|Drug|fludarabine phosphate|
1757490|NCT00255684|Drug|mycophenolate mofetil|
1757491|NCT00255684|Procedure|umbilical cord blood transplantation|
1757492|NCT00255684|Radiation|radiation therapy|
1757493|NCT00255697|Procedure|psychosocial assessment and care|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
1757494|NCT00255697|Procedure|quality-of-life assessment|Patients undergo a 45-minute interview in person or by phone to provide demographic data and to complete quality of life questionnaires, including Functional Assessment of Cancer Therapy (FACT), Spiritual tool, Quality and Satisfaction with Treatment (QUEST), and Profile of Mood State (POMS), at baseline and at 3 and 12 months. Caregivers undergo a 20- to 30-minute interview in person or by phone to provide demographic data and complete quality of life questionnaires, including the Caregiver Reaction Assessment (CRA), Quest, and POMS, at baseline and at 3 and 12 months. Caregivers complete the Quality of Death and Dying (QODD) questionnaire 2-3 months after the patient's death.
1757495|NCT00255710|Biological|filgrastim|
1757496|NCT00255710|Drug|cyclophosphamide|
1757497|NCT00255710|Drug|fludarabine phosphate|
1757498|NCT00255710|Drug|mycophenolate mofetil|
1757499|NCT00255710|Drug|tacrolimus|
1757500|NCT00255710|Procedure|allogeneic bone marrow transplantation|
1757501|NCT00255710|Procedure|peripheral blood stem cell transplantation|
1757502|NCT00255710|Radiation|radiation therapy|
1757503|NCT00255723|Drug|carboplatin|Given IV
1757504|NCT00255723|Drug|etoposide|Given IV
1757505|NCT00255723|Drug|ifosfamide|Given IV
1757506|NCT00258401|Dietary Supplement|dietary intervention|At the onset of diarrhea symptoms, patients are instructed to eat a low-residue diet. Patients continue on this diet for 2-4 weeks.
1757507|NCT00258401|Procedure|management of therapy complications|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
1757508|NCT00258401|Procedure|quality-of-life assessment|Interviewed weekly for up to 6 weeks to monitor dietary intake, bowel symptoms, diarrhea events, FI-QOL, and changes in CTC scores.
1757509|NCT00258427|Biological|anti-thymocyte globulin|Given 15 mg/kg/day intravenously every 12 hours on Days -5 through -1.
1757510|NCT00258427|Biological|filgrastim|given 5 mcg/kg/day intravenously on Day 1 (continue until absolute neutrophil count (ANC) ≥2.5 x 10^9/L)
1757511|NCT00258427|Drug|busulfan|Busulfan 0.8 mg/kg intravenously (IV) every 12 hours on Days -7 and -6 (1.0 mg/kg IV if <4 years old)
1757512|NCT00258427|Drug|cyclophosphamide|10 mg/kg intravenously (IV) on Days -5 through -2.
1757513|NCT00258427|Drug|fludarabine phosphate|35 mg/m^2 intravenously (IV) on Days -5 through -2.
1757514|NCT00258427|Drug|methylprednisolone|1 mg/kg intravenously (IV) every 12 hours on Days -5 through -1.
1757515|NCT00258427|Biological|Hematopoietic stem cell transplantation|Infused on Day 0 - Donor bone marrow or umbilical cord blood will be collected in the usual sterile manner using established parameters determined by the National Marrow Donor Program.
1757516|NCT00258440|Drug|Weekly procrit dosing|The dose is standard of care, the investigational piece is the dosing schedule itself. Either weekly or Interval-dosing schedule subjects will get the study drug once every week until hematocrit is greater than 36% or Hemoglobin reaches a value of 12 g/dl, then they will get study drug once every other week.
1757517|NCT00258440|Drug|Interval Dosing|The dosing of Procrit is standard of care, it is the schedule that is the investigational piece.
1757518|NCT00258453|Other|metabolic assessment|
1757519|NCT00258453|Other|physiologic testing|
1757520|NCT00258453|Procedure|biopsy|
1757521|NCT00258453|Procedure|computed tomography|
1757522|NCT00258453|Procedure|conventional surgery|
1757523|NCT00258453|Procedure|magnetic resonance imaging|
1757524|NCT00258453|Procedure|management of therapy complications|
1757525|NCT00258453|Procedure|psychosocial assessment and care|
1757526|NCT00258453|Procedure|quality-of-life assessment|
1757527|NCT00258453|Radiation|radiation therapy|
1757528|NCT00258466|Radiation|radiation therapy|
1757529|NCT00258479|Drug|ModafinilNicotine Replacement Therapy|A dose escalation design includes eight dose conditions across a 12-day study (nicotine low-high, modafinil low-high and 4 combinations). After day 1 placebo dose, placebo sessions occur in random order during low dose, high dose, and dose-combination testing. Modafinil and nicotine are tested alone with subjects exposed to low active doses prior to higher doses. Dose interactions will be determined with low doses tested in combination followed by low-high dose combinations then high-high dose combination. Doses are administered under double-blind, double dummy procedures. A nicotine patch (0, 7 or 14 mg doses) is applied at 7 am. Modafinil doses are prepared in size 00 opaque capsules. The modafinil dose (0, 100, 200 mg) is administered at 5 PM.
1757530|NCT00258479|Drug|Modafinil|See Modafinil Intervention Description above.
1757531|NCT00258492|Behavioral|Aerobic exercise|
1757532|NCT00258505|Procedure|Procedure: intracranial monitoring up to 9 days after injury|
1757533|NCT00258518|Procedure|mechanical ventilation/CT Scan|evaluation of pleural effusion and respiratory mechanics, CT scan
1757534|NCT00258531|Device|Olympus ScopeGuide®, 3-dimentional magnetic imager|
1757535|NCT00258557|Drug|LPV/RTV|400/100 mg twice daily or 800/200 mg daily depending on the country for max. 192 weeks
1757733|NCT00260416|Procedure|Primary angioplasty with stent and abciximab|
1757536|NCT00258557|Drug|TMC-114/RTV|two 400 mg tablets of TMC114 + one 100 mg capsule of RTV daily for max. 192 weeks
1757537|NCT00258596|Device|sirolimus-eluting stent|
1757538|NCT00258609|Drug|Botulinum Toxin type A (Dysport ® ) IM/SC 6-sites pericranial injection|
1757539|NCT00258622|Drug|NS1209|
1757540|NCT00258622|Drug|Lidocaine|
1757541|NCT00258635|Biological|RagweedMATAMPL|
1757542|NCT00258661|Procedure|Osteopathic Manipulative Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized OMT protocol + 5-minute nonstandardized component was performed twice daily for the duration of hospitalization.
1757543|NCT00258661|Procedure|Light-touch Treatment|In addition to conventional treatment for pneumonia, a 10-minute standardized light-touch protocol (designed to mimic OMT standardized protocol) + 5-minute auscultation of carotid bruits, heart, and lungs was performed twice daily for the duration of hospitalization.
1757544|NCT00258661|Procedure|Conventional Care Only|No intervention specific to the research study provided. Only conventional treatment as per attending physician orders.
1757545|NCT00258674|Other|Medicare Claims Feedback|Physician practices received periodic feedback on their performance on selected diabetes quality of care measures as reflected by the Medicare claims data for their patients.
1757546|NCT00258674|Other|Medical Record Review|Physician practices received period feedback on their performance on selected diabetes quality of care measures, as reflected by data collected from their patients' medical records. These data were compiled by trained nurse abstractors using a standardized data collection tool developed for this study.
1757547|NCT00258674|Other|Diabetes Resource Nurse|Diabetes Resource Nurses (DRNs) were registered nurses with 3-5 years of experience as certified diabetes educations who performed initial patient assessments, developed plans of care, administered screening tools, and monitored clinical outcomes. Physicians at the practices randomised to this intervention had could access the DRN's services for their diabetes patients, but neither physicians nor patients had to take advantage of this resource.
1757548|NCT00258687|Biological|GVAX|4 vaccines every two weeks
1757549|NCT00258700|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
1757550|NCT00258713|Drug|voclosporin|voclosporin 0.2, 0.3, or 0.4 mg/kg BID
1757551|NCT00258726|Biological|MMR-II|
1757552|NCT00258726|Biological|Pro-Quad|
1757553|NCT00258726|Biological|Varivax|
1757554|NCT00258739|Drug|Docetaxel + carboplatin + radiotherapy + docetaxel + gemcitabine|Docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy. Further on, 2 Docetaxel cycles and gemcitabine according to arm 2.
1757555|NCT00258739|Other|Docetaxel + gemcitabine + carboplatin + radiotherapy|Docetaxel 40 mg/ m² days 1, 8, 21 and 28 with gemcitabine 1200 mg/ m² days 1, 8, 21 and 28 followed by concomitant treatment with docetaxel 20 mg/m²/week with carboplatin AUC 2/week and concomitant radiotherapy up to 60 Gy (2 Gy/day, 5 days per week and for 6 weeks).
1757556|NCT00258752|Behavioral|IPT-AST|IPT-AST is a school based group treatment program that focuses on prevention, psychoeducation, and interpersonal skill building.
1757557|NCT00258752|Other|Enhanced IPT-AST|Enhanced IPT-AST entails IPT-AST plus three parent-adolescent sessions.
1757558|NCT00258752|Other|School counseling|Usual care consists of standard treatments, including individual counseling with guidance counselor.
1757559|NCT00258765|Drug|Zoledronic Acid|
1757560|NCT00258765|Drug|Docetaxel|
1757561|NCT00258778|Drug|Human Glucocerebrosidase (prGCD)|
1757562|NCT00258791|Drug|Ibuprofen|
1757563|NCT00258804|Drug|Insulin glargine|
1757564|NCT00258817|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0 and Day 28)
1757565|NCT00258817|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (Day 0)
1757566|NCT00258830|Biological|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
1757567|NCT00258830|Biological|Fluzone®: Influenza Virus Vaccine|0.5 mL, Intramuscular
1757568|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, intramuscular (IM)
1757569|NCT00258843|Biological|Inactivated Poliomyelitis vaccine|0.5 mL, IM
1757570|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
1757571|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
1757572|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
1757573|NCT00258856|Biological|Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL, Intramuscular
1757574|NCT00258882|Biological|Tetanus Toxoid, acellular pertussis, diphtheria toxoid|0.5 mL, Intramuscular
1757575|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
1757576|NCT00258895|Biological|DAPTACEL®: DTaP|0.5 mL, Intramuscular
1757577|NCT00258908|Biological|Diphteria, tetanus, and Acellular Pertussis vaccine|0.5 mL, Intramuscular
1757578|NCT00258934|Biological|Inactivated, split-virion influenza vaccine|0.1 mL single annual dose
1757579|NCT00258934|Biological|Inactivated, split-virion, influenza virus|0.5 mL single annual dose
1757580|NCT00258947|Biological|Smallpox vaccine, LISTER strain, from chick embryo cells|
1757581|NCT00258960|Drug|Liposomal Doxorubicin|
1757582|NCT00258960|Drug|Cyclophosphamide|
1757583|NCT00258960|Drug|Trastuzumab|
1757584|NCT00258973|Procedure|Carotid Ultrasound performed in office practice|
1757585|NCT00258986|Procedure|Living donornephrectomy|
1757586|NCT00258999|Device|Skin Cholesterol Testing|
1757587|NCT00259012|Drug|pantoprazole sodium enteric-coated spheroid suspension|pediatric suspension taken daily x 7 days
1757588|NCT00259025|Drug|lipid emulsion with a high content of n-3 fatty acids|
1757589|NCT00259038|Drug|Carperitide|
1757590|NCT00259038|Drug|Placebo|
1757591|NCT00259051|Drug|Omeprazole|
1757592|NCT00259064|Drug|Gefitinib|
1757593|NCT00259064|Other|Placebo|
1757594|NCT00259077|Drug|Omeprazole|
1757595|NCT00259090|Drug|Fulvestrant|500 mg intramuscular injection
1757596|NCT00259090|Drug|Anastrazole|oral tablet
1757597|NCT00259103|Drug|Serelaxin|
1757598|NCT00259103|Drug|Placebo|
1757599|NCT00259116|Drug|Relaxin|
1757863|NCT00261027|Drug|Exemestane|
1757600|NCT00259129|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice a day (bid) (2 x 200 mg tablets)
1757601|NCT00259142|Drug|Chloroquine, sulphadoxine-pyrimethamine|
1757602|NCT00259155|Drug|Rifaximin|
1757603|NCT00259168|Drug|Nateglinide|
1757604|NCT00259181|Procedure|saturation of polymethylmethacrylate with chlorhexidine gluconate to reduce in vivo plaque formation|
1757605|NCT00259194|Behavioral|Moving|The patients are allowed to lift their head, arms and legs during the 2 hours.
1757606|NCT00259194|Behavioral|No Moving|The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
1757607|NCT00259207|Procedure|Pulmonary valve insertion|Pulmonary valve insertion
1757608|NCT00259207|Procedure|medical surgery hybride|medical surgery hybride
1757609|NCT00259220|Drug|erythomycin|erythomycin
1757610|NCT00259220|Procedure|gastric lavage alone|gastric lavage alone
1757611|NCT00259220|Procedure|erythromycine and gastric lavage|erythromycine and gastric lavage
1757612|NCT00259233|Drug|peripheral Peptide YY administration|
1757613|NCT00259246|Drug|Peptide YY infusion|
1757614|NCT00259259|Behavioral|SALATRIM|
1757615|NCT00259272|Drug|olanzapine|5 to 20 mg (flexible dose) administered orally as disintegrated tablets, daily for 24 weeks.
1757616|NCT00259285|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
1757617|NCT00259285|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 3 cycles
1757618|NCT00259298|Drug|teriparatide|Subcutaneous, 20 microgram (mcg)/day, 18 months
1757619|NCT00259311|Drug|LY2422347|
1757620|NCT00259311|Drug|placebo|
1757621|NCT00259324|Behavioral|Diet and Activity|Diet and Activity
1757622|NCT00259337|Biological|Diphteria/Tetanus/Polio/Acellular Pertussis/Hib vaccine|0.5 mL, IM
1757623|NCT00259350|Drug|Skin disinfection|
1757624|NCT00259363|Drug|Oxaliplatin|oxaliplatin 60/mg/m2/15 days, 5-FU 225 mg/m2/day 5 weeks during radiotherapy (RT) 45 Gys/25 days
1757625|NCT00259376|Drug|Dronedarone (SR33589)|oral administration
1757626|NCT00259376|Drug|placebo|oral administration
1757627|NCT00259389|Behavioral|Directly observed therapy (DOT)|
1757628|NCT00259402|Drug|Oxaliplatin + cisplatin + 5-Fluorouracil (5-FU)|OXALIPLATIN 60 mg/m2/d, CISPLATIN 55 mg/m2/d, 5-FU 600 mg/m2/d with dose range and followed by radiotherapy
1757629|NCT00259415|Behavioral|Caregiver support via telephone|
1757630|NCT00259428|Drug|Dronedarone (SR33589)|oral administration
1757631|NCT00259428|Drug|placebo|oral administration
1757632|NCT00259441|Drug|Simvastatin|
1757633|NCT00259454|Behavioral|In-home intervention|occupational therapy techniques to reduce caregiver stress
1757634|NCT00259467|Behavioral|Home-Based Behavorial Intervention|
1757635|NCT00259480|Behavioral|Home Based Intervention|occupational therapy
1757636|NCT00259493|Procedure|Off-Pump Coronary Artery Bypass Graft Surgery|
1757637|NCT00259506|Behavioral|Mindfulness-Based Cognitive Therapy (MBCT)|
1757638|NCT00259519|Procedure|Induction of delivery|Induction of delivery
1757639|NCT00259532|Procedure|Ultrasound and contrast agent|contrast-enhanced ultrasound combined with the gastrointestinal hormones Secretin and Cholecystokinin, which triggers the enzyme production of pancreas
1757640|NCT00259545|Drug|Retarded Release Phosphatidylcholine (rPC)|
1757641|NCT00259558|Drug|retarded release phosphatidylcholine|
1757642|NCT00259571|Drug|retarded release phosphatidylcholine|2g daily, given orally QTD
1757643|NCT00259584|Behavioral|Management and Outcome of SVCO|
1757644|NCT00259597|Procedure|breast ductal lavage|breast ductal lavage and nipple aspiration done once
1757645|NCT00259610|Drug|methotrexate|varies
1757646|NCT00259610|Drug|sulfasalazine|varies
1757647|NCT00259610|Drug|hydroxychloroquine|varies
1757648|NCT00259610|Drug|etanercept|varies
1757649|NCT00259623|Device|Radiofrequency ablation|
1757650|NCT00259636|Drug|zonisamide|zonisamide 100 mg -300 mg daily vs placebo
1757651|NCT00259649|Drug|eletriptan|oral eletriptan 20 mg three times a day beginning 2 days before the expected onset of menstrual flow and continued for a total of 6 days
1757652|NCT00259662|Drug|atorvastatin|
1757653|NCT00259675|Drug|carboplatin/gemcitabine, carboplatin/taxol|
1757654|NCT00259688|Device|CPAP therapy for subjects diagnosed with sleep apnea|CPAP therapy is being offered to women who are diagnosed on Polysomnogram with sleep apnea. However, this is not an intervention study and treatment is not part of the study protocol.
1757655|NCT00259701|Device|Laser Doppler Flowmetry with topical acetylcholine and nitroglycerin|
1757656|NCT00259714|Drug|dialysate sodium individualization|"Dialysate sodium level prescribed matches the subject's average pre-dialysis serum sodium (individualized)."
1757657|NCT00259714|Drug|standard dialysate sodium|The prescribed dialysate sodium is 140 mEq/L
1757658|NCT00259740|Drug|DENOSUMAB|120 mg administered subcutaneously on study days 1, 8, 15, and 29 and every 28 days thereafter. Each dose will be administered in two separate injections of 60 mg (1.0 mL) each.
1757659|NCT00259753|Drug|Bevasiranib|
1757660|NCT00259766|Drug|Budesonide|
1757661|NCT00259766|Drug|Formoterol|
1757662|NCT00259766|Drug|Terbutaline|
1757663|NCT00259779|Drug|budesonide/formoterol|
1757664|NCT00259779|Drug|Prednisolone|
1757665|NCT00259792|Drug|Budesonide/formoterol Turbuhaler|
1757666|NCT00259805|Drug|Rituximab|375 mg/m2 given as an IV infusion once weekly for four doses
1757667|NCT00259818|Drug|EM-1421|
1757668|NCT00259831|Drug|CVT-E002 (Cold-FX); a natural health product|
1757669|NCT00259844|Biological|TroVax|
1757734|NCT00260429|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500/placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
1757735|NCT00260442|Behavioral|Resistance Training|12 weeks, 3 times a week whole body resistance training
1757736|NCT00260442|Behavioral|Sedentary|Absence of physical activity
1757670|NCT00259857|Drug|Alendronate|Group-1/Year-1:Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight, for 12 months. Group-1/Year-2:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-1:Placebo, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months. Group-2/Year-2: Alendronate, pill, 35mg or 70mg, weekly; calcium, pill, 500mg or 1000mg daily; vitamin D, liquid, 800IU, daily, depending upon the body weight for 12 months.
1757671|NCT00259870|Drug|SB-773812|
1757672|NCT00259870|Drug|Olanzapine|
1757674|NCT00259896|Drug|exenatide|
1757675|NCT00259922|Drug|Placebo|Placebo
1757676|NCT00259922|Drug|Alvimopan|0.5 mg QD
1757677|NCT00259922|Drug|Alviompan|0.5 mg BID
1757678|NCT00259935|Drug|topotecan|
1757679|NCT00259948|Procedure|Aerobic exercise training|
1757680|NCT00259961|Procedure|open fundoplication|
1757681|NCT00259961|Procedure|laparoscopic fundopliaction|
1757682|NCT00259974|Drug|Rituximab|Rituximab
1757683|NCT00259987|Drug|Lapatinib (GW572016) oral tablets|
1757684|NCT00260000|Drug|5,6,7,8-tetrahydrobiopterin|
1757685|NCT00260013|Procedure|program of care delivery|
1757686|NCT00260026|Drug|Docetaxel|
1757687|NCT00260026|Drug|Jin Fu Kang|
1757688|NCT00260039|Biological|Comparator: Gardasil|0.5 mL intramuscular injection administered at Day 1, Month 2 and Month 6
1757689|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 1|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
1757690|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 2|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
1757691|NCT00260039|Biological|Comparator: octavalent HPV Vaccine - dose formulation 3|0.5 mL octavalent HPV vaccine - intramuscular injection administered at Day 1, Month 2 and Month 6
1757692|NCT00260052|Drug|Erythropoietin administration|
1757693|NCT00260065|Drug|Decitabine|20mg/m^2, IV on days 1-5 of each 28 day cycle; until progression, death or unacceptable toxicity develops.
1757694|NCT00260078|Drug|Atazanavir|200 mg to 400 mg orally daily
1757695|NCT00260078|Drug|Darunavir|300 mg or 600 mg orally twice daily
1757696|NCT00260078|Drug|Efavirenz|Dosage dependent on participant
1757697|NCT00260078|Drug|Nevirapine|Dosage dependent on participant
1757698|NCT00260078|Drug|Ritonavir|50 mg or 100 mg orally twice daily
1757699|NCT00260078|Drug|Tenofovir disoproxil fumarate|300 mg orally daily
1757700|NCT00260078|Procedure|Pharmacokinetic Study|Intensive PK study will occur at least once. This will require a 24-hour inpatient visit.
1757701|NCT00260091|Procedure|intrauterine insemination|An assisted reproduction technique which deposits washed sperm directly into the uterus, bypassing the cervix, and allowing the sperm to enter the fallopian tubes where fertilization normally occurs.
1757702|NCT00260091|Procedure|infertility|This procedure involves stimulating the ovaries, retrieving released eggs, fertilizing the eggs, growing the embryos in a laboratory, and then implanting the embryos in the woman's uterus to develop naturally.
1757703|NCT00260117|Behavioral|Exercise|Referal to a website
1757704|NCT00260130|Other|food in fluid form|dietary intake of fluid forms of vegetables
1757705|NCT00260130|Other|food in solid form|dietary intake of solid forms of vegetables
1757706|NCT00260143|Drug|testosterone enanthate|
1757707|NCT00260156|Drug|vildagliptin|
1757708|NCT00260156|Drug|placebo|
1757709|NCT00260169|Behavioral|Collaborative care treatment|Patients receiving collaborative care treatment choose 12 weeks of CBT and/or medication management (antidepressants prescribed by patients' primary care provider) from the study depression care specialist (DCS).
1757710|NCT00260169|Behavioral|Enhanced usual care|Usual care participants are assigned to a 16-week wait-list for the study treatment, during which they are free to receive treatment elsewhere. A letter is given to participants' primary care providers (PCP) that indicates they screened positive for depression. In addition, patients receive an information booklet about depression and a community resource list.
1757711|NCT00260195|Behavioral|School-based cognitive behavioral support group|
1757712|NCT00260208|Drug|Cyclosporine A|Initial dose of 10-15mg/kg/day either orally, via a nasogastric (NG) tube or intravenously (i.v.) within the first 24 hours post-transplantation.
1757713|NCT00260208|Drug|Tacrolimus|Tacrolimus was administered within the first 24 hours post-transplantation at an initial dose of 0.1-0.15 mg/kg/day in 2 divided doses either orally or via a nasogastric (NG) tube or intravenously (i.v).
1757714|NCT00260221|Behavioral|using VR hypnosis/distraction and audio hypnosis|a between subject comparison using VR hypnosis and VR distraction and audio hypnosis for pain control
1757715|NCT00260234|Biological|Allogeneic Cultured Islet Cells (human); Encapsulated|
1757716|NCT00260247|Drug|carbamazepine oxcarbazepine|
1757717|NCT00260260|Drug|Oxycodone|
1757718|NCT00260273|Behavioral|Cognitive Behaviour Therapy|therapy
1757719|NCT00260286|Behavioral|Energy availability|
1757720|NCT00260312|Biological|Inactivated Polio Vaccine given at an accelerated schedule|
1757721|NCT00260325|Drug|valdecoxib|
1757723|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.1 mL, ID (TRC regimen)
1757724|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ZAGREB regimen)
1757725|NCT00260351|Biological|Purified Verocell Rabies Vaccine|0.5 mL, IM (ESSEN regimen)
1757726|NCT00260364|Drug|Gemcitabine 1000 mg/m2 iv days 1, 8, 15 of a 28 day cycle|
1757727|NCT00260364|Drug|Capecitabine orally days 1 -21|
1757728|NCT00260364|Drug|Erlotinib 100 mg orally days 1-28|
1757729|NCT00260364|Drug|Bevacizumab 5 mg/kg intravenously every 2 weeks|
1757730|NCT00260377|Procedure|Coronary artery bypass surgery|
1757731|NCT00260390|Drug|Testoviron|
1757732|NCT00260403|Procedure|Photodynamic therapy versus Transpupillary thermotherapy|
1757737|NCT00260468|Other|Clinical examination program|Psychiatric/clinical interview MRI scan Blood samples Saliva samples Eye examination
1757738|NCT00260481|Drug|Prometa|Medication protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient medications for 39 days
1757739|NCT00260481|Drug|Placebo|Placebo protocol includes 2 infusion periods of 3 and 2 days, respectively and outpatient placebo medications for 39 days.
1757740|NCT00260494|Other|acupuncture|standardized acupuncture intended to improve blood flow and reduce edema to lower extremity.
1757741|NCT00260494|Other|sham acupuncture|standardized sham acupuncture at same sites as acupuncture.
1757742|NCT00260520|Drug|Dalteparin|
1757743|NCT00260533|Drug|atomoxetine|Flexible dose, up to 50 mg per day
1757744|NCT00260533|Drug|placebo|placebo (matching to atomoxetine)
1757745|NCT00260546|Procedure|AV-node ablation|Patients that are randomized to AV node ablation will have their AV-node ablated using a transfemoral approach. Concurrently,a back-up pacing lead will temporarily be placed in the right ventricle.
1757746|NCT00260559|Procedure|Questionnaires|Quality of life and heartburn assessment questionnaires are administered preoperatively and at set intervals postoperatively.
1757747|NCT00260572|Behavioral|Questionnaires to evaluate QOL|Questionnaire to evaluate QOL administered preoperatively and postoperatively at set intervals.
1757748|NCT00260572|Behavioral|Questionnaires to evaluate heartburn and quality of life|Questionnaires to evaluate heartburn and quality of life administered preoperatively and at set intervals postoperatively.
1757749|NCT00260572|Behavioral|Questionnaire to evaluate satisfaction with treatment|Questionnaire administered postoperatively at set intervals.
1757750|NCT00260572|Behavioral|Questionnaire to evaluate presence or absence of pain|Questionnaire administered preoperatively and at set intervals postoperatively.
1757751|NCT00260585|Procedure|Survey of client health, personal habits, family history|A questionnaire is administered at the time of consent.
1757752|NCT00260585|Procedure|Blood specimen for non-DNA and DNA parts|Blood specimen is collected intraoperatively.
1757753|NCT00260585|Procedure|Biopsy of esophageal/stomach tissue, lymph nodes, tumor|Tissue from the biopsies is collected intraoperatively.
1757754|NCT00260585|Procedure|Biopsies from routine clinical surveillance endoscopies|Tissue from the biopsies is collected intraoperatively.
1757755|NCT00260598|Procedure|LIFE Bronchoscopy|The first LIFE Bronchoscopy is performed at least 6 months following surgical resection of primary NSCLC. Timing of subsequent bronchoscopies is dependent on pathology from first bronchoscopy.
1757756|NCT00260611|Drug|Oxaliplatin|
1757757|NCT00260611|Drug|Taxotere|
1757758|NCT00260624|Drug|Escitalopram (Lexapro)|
1757759|NCT00260637|Procedure|Acupuncture|
1757760|NCT00260650|Behavioral|Heart PACT Program|patient activation intervention
1757761|NCT00260663|Procedure|Group hearing aid fittings|
1757762|NCT00260663|Procedure|Group hearing aid follow-up|
1757764|NCT00260689|Biological|Anti-thymocyte globulin (rabbit)|
1757765|NCT00260689|Biological|Anti-thymocyte globulin (horse)|
1757766|NCT00260689|Drug|Cyclosporine|
1757767|NCT00260689|Drug|Alemtuzumab|
1757768|NCT00260702|Drug|Omalizumab (Xolair)|
1757769|NCT00260715|Behavioral|Community-Popular Opinion Leader Model|
1757770|NCT00260715|Behavioral|Diffusion of Innovations|
1757771|NCT00260728|Device|vascular access graft implantation|vascular access graft implantation
1757772|NCT00260741|Drug|Smoked Cannabis|
1757773|NCT00260754|Behavioral|Community-Popular Opinion Leader Model|
1757774|NCT00260754|Behavioral|Diffusion of Innovations|
1757775|NCT00260767|Drug|HEC placebo gel|
1757776|NCT00260780|Behavioral|The MISTERS Intervention for Post Jail Release Men|
1757777|NCT00260793|Drug|Ropinirole Hydrochloride|
1757778|NCT00260819|Drug|Bosentan|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
1757779|NCT00260819|Drug|Bosentam TRACLEER|Single dose administration of 250 mg bosentan (2 pills Tracleer 125 mg) or placebo
1757780|NCT00260832|Drug|Cytarabine or Supportive Care|Patient's choice with physician's advice of either supportive care (IV fluids, nutrition, and antibiotics as needed) or cytarabine 20 mg/m^2 subcutaneously once daily for the first 10 consecutive days of each 28 day cycle, until progression or unacceptable toxicity develops. (These represent one invervention.)
1757781|NCT00260832|Drug|Dacogen (decitabine) only|20mg/m^2, 1 hour intravenous (IV) for 5 consecutive days of each 28 day cycle. Cycles continue until disease progression or unacceptable toxicity develops.
1757782|NCT00260858|Drug|Test Meal: Reference food (glucose or white bread)|
1757783|NCT00260858|Drug|Test Meal: Pirate's Booty|
1757784|NCT00260858|Drug|Test Meal: Ceaprove wafer|
1757785|NCT00260858|Drug|Test Meal: Stretch Island Strawberry Fruit Leather|
1757786|NCT00260884|Behavioral|conventional gastrectomy or radical lymph node dissection|
1757787|NCT00260923|Drug|aliskiren|
1757788|NCT00252291|Drug|Aridol|
1757789|NCT00252291|Drug|Methacholine|
1757790|NCT00252291|Procedure|Exercise challenge|
1757791|NCT00252304|Drug|Zinc (zinc sulphate)|Dissolvable zinc tablet 10 mg elemental zinc per day for infants 20 mg elemental zinc per day for children 12 to 35 months
1757792|NCT00252304|Drug|Placebo|Placebo
1757793|NCT00252317|Drug|Captopril and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
1757794|NCT00252317|Drug|Captopril Test Dose and Trandolapril|Caps Captopril 6.25 mg test dose and Caps Trandolapril 0.5mg or 1.0mg or 2.0 mg (depending on symptoms ie. hypotension)
1757795|NCT00252330|Drug|SR58611A|
1757796|NCT00252343|Drug|SR58611A|
1757797|NCT00252356|Drug|SR58611A|
1757798|NCT00252369|Drug|Infliximab|
1757799|NCT00252369|Procedure|Instillation of fibrin glue|
1757860|NCT00260988|Drug|Innohep (tinzaparin)|175 IU/kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
1757861|NCT00261001|Biological|Transcutaneous mode of administration|
1757800|NCT00252382|Drug|SNS-595 Injection|Vosaroxin (formerly voreloxin or SNS-595) is a first in class anticancer quinolone derivative, non anthracycline topoisomerase II inhibitor. It induces replication dependent DNA damage by intercalating DNA and inhibiting topoisomerase II, leading to apoptosis.
1757801|NCT00252395|Device|PDA-based Electronic Prescribing Software|
1757802|NCT00252408|Drug|Hormone replacement therapy|
1757803|NCT00252421|Drug|Nitroglycerin ointment 15 mg/day daily for 24 month|Nitroglycerin ointment 15 mg/day applied daily for 24 mth
1757804|NCT00252421|Drug|Placebo ointment daily for 24 month|Placebo ointment applied daily for 24 mth
1757805|NCT00252434|Behavioral|Cognitive Behavioral Therapy Development for Methamphetamine Abuse|
1757806|NCT00252447|Procedure|Pre-Operative Conformal Radiotherapy|
1757807|NCT00252460|Device|Computed Tomography Scan and Magnetic Resonance Imaging|
1757808|NCT00252473|Device|MedTec S-frame Immobilization Masks|
1757809|NCT00252486|Drug|Flax oil|Flax oil and olive oil placebo were analyzed for quality and purity; sufficient bioactivity was confirmed for the flax oil independently at the University of Massachusetts mid-way through the study. Each capsule of omega -3 fatty acid concentrate contained 550 mg of α-linolenic acid (α-LNA) from flax seed oil.A stepped but flexible dose-titration schedule was carried out with doses increased by 1-2 grams at each visit as tolerated, to an attempted total dose of 6 capsules twice per day, as requested by the FDA (up to 6.6 grams of daily α-linolenic acid).
1757810|NCT00252499|Drug|rosiglitazone|PPAR-gamma agonist, insulin sensitizer
1757811|NCT00252499|Drug|fenofibrate|PPAR-alpha agonist, reduces triglycerides
1757812|NCT00252499|Drug|placebo for rosiglitazone|placebo tablets that are matched to look like rosiglitazone
1757813|NCT00252499|Drug|placebo for fenofibrate|placebo matched to look like fenofibrate tablets
1757814|NCT00252512|Behavioral|Contingency Management|Participants complete urine and breath screens 2 times per week for 8 weeks. If urine and breath screens are both negative, the participant receives a chance to draw tokens from a bowl. Some tokens are social reinforcement (Good Job!). Other have monetary value ($1, $20, or $80 canteen voucher).
1757815|NCT00252512|Other|Placebo|Participants complete urine and breath screens 2 times per week for 8 weeks with no reinforcement for negative results.
1757816|NCT00252551|Procedure|Osteosynthesis|
1757817|NCT00252551|Procedure|Simple surgery|Surgery without device
1757818|NCT00252564|Drug|Bevacizumab|5 mg/kg over 30 minutes on Days 1 and 15
1757819|NCT00252564|Drug|Oxaliplatin|85 mg/m2 on Days 1 and 15
1757820|NCT00252564|Drug|Leucovorin|400 mg/m2 on Days 1 and 15
1757821|NCT00252564|Drug|Fluorouracil|400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
1757822|NCT00252564|Drug|Cetuximab|400 mg/m2 over 2 hours (Cycle 1 Day 1 only) All subsequent doses (Day 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 other cycles)250 mg/m2 over 1 hour
1757823|NCT00252577|Drug|Lithium treatment|Lithium is a standard treatment for bipolar disorder. Patients will be stabilized on lithium monotherapy over a 3 month period, observed for one month, and then followed every 2 months in maintenance phase for 2 years
1757824|NCT00252590|Behavioral|Health Motivational Feedback|Personalized feedback on health status
1757825|NCT00252590|Behavioral|Health Education|Generalized health education related to alcohol use
1757826|NCT00252590|Behavioral|Control - treatment as usual|Control group with no additional intervention
1757827|NCT00252603|Drug|Galantamine|
1757828|NCT00252616|Behavioral|trophic enteral feeds|10cc/hr
1757829|NCT00252629|Other|Nasal CPAP treatment during sleep|After documenting sleep disordered breathing, GWS subject gets randomized to receive either a therapeutic nasal CPAP or a sham nasal CPAP treatment during sleep, GWS symptoms ( fatigue, pain, and cognitive dysfunction) were assessed by a baseline questionnaires and at 3 week period whether on sham or therapeutic CPAP. The change of symptoms in each group will be compared.
1757830|NCT00252642|Drug|Peginterferon Alpha-2a|
1757831|NCT00252655|Drug|Rapamune and Prograf|
1757832|NCT00252668|Drug|Etanercept|
1757833|NCT00252668|Drug|Methotrexate|
1757834|NCT00252681|Procedure|laparotomy|
1757835|NCT00252681|Procedure|primary peritoneal drainage|
1757836|NCT00252694|Drug|candesartan|32 mg oral tablet
1757837|NCT00252707|Drug|Gefitinib or Docetaxel|
1757838|NCT00252720|Drug|candesartan|32 mg oral tablet
1757839|NCT00252733|Drug|candesartan cilexetil|32 mg once daily oral tablet given over 60 months
1757840|NCT00252746|Drug|ZD6474 (vandetanib) 100mg|once daily oral dose
1757841|NCT00252746|Drug|ZD6474 (vandetanib) 200mg|once daily oral dose
1757842|NCT00252746|Drug|ZD6474 (vandetanib) 300mg|once daily oral dose
1757843|NCT00252772|Drug|Tesaglitazar|
1757844|NCT00252772|Behavioral|Dietary and Lifestyle counseling|
1757845|NCT00252785|Drug|Budesonide/Formoterol|
1757846|NCT00252785|Drug|Budesonide|
1757847|NCT00252785|Drug|Theophylline|
1757848|NCT00252798|Drug|Gefitinib|
1757849|NCT00252798|Drug|Carboplatin|
1757850|NCT00252798|Drug|Paclitaxel|
1757851|NCT00252798|Procedure|Radiation|
1757852|NCT00252811|Drug|Gefitinib|
1757853|NCT00252824|Drug|Budesonide/formoterol Turbuhaler vs Conventional Best Asthma Therapy|
1757854|NCT00252837|Drug|Tesaglitazar|
1757855|NCT00252837|Behavioral|Dietary and Lifestyle counseling|
1757856|NCT00260949|Procedure|Arthroscopic repair of rotator cuff tear|Patients will undergo arthroscopic shoulder surgery in the standard fashion
1757857|NCT00260962|Drug|Olanzapine|After a 2-week baseline period, olanzapine was administered for 10 weeks (weeks 3-12 of the study). Olanzapine was prescribed according to a flexible dose regimen, starting at the minimum dose of at 2.5 mg/day and titrated slowly by increments of 2.5 mg/week to a maximum dose of of 10 mg/day.
1757858|NCT00260962|Behavioral|Day Hospital|Day hospital program involved attendance 4 days a week from 9:00 am to 6:00 pm for 12 to 14 weeks, and supervised meals and group therapy.
1757859|NCT00260988|Drug|Fragmin (dalteparin)|200 IU/Kg/Day administered subcutaneously for three days prior to but not including the day of the surgery
1757866|NCT00261053|Drug|i.v. recombinant human C1 inhibitor|
1757867|NCT00261079|Drug|Fexofenadine|
1757868|NCT00261092|Drug|Oxaliplatin|
1757869|NCT00261105|Drug|telithromycin|
1757870|NCT00261118|Drug|Rituximab|Rituximab 1g in 500 mls Normal Saline Placebo 500 mls Normal Saline
1757871|NCT00261131|Drug|Botulinum Toxin A|
1757872|NCT00261144|Drug|Collagenase|One 0.58mg injection every two weeks for six weeks (total three 0.58mg injections)
1757873|NCT00261144|Biological|Biological|Collagenase injection
1757874|NCT00261157|Device|InTouch Telerounding Robot|
1757875|NCT00261170|Drug|bupropion|150 mg daily for the first 3 days, then 150 mg twice daily for 7 weeks
1757876|NCT00261170|Other|placebo|1 pill daily for the first 3 days, then one pill twice daily for 7 weeks
1757877|NCT00261183|Drug|Melatonin|
1757878|NCT00261196|Drug|Collagenase|
1757879|NCT00261209|Drug|Collagenase|Collagenase injection into adhesion restricting tendon gliding
1757880|NCT00261209|Drug|Collagenase injection|injection of collagenase into adhesion restricting tendon gliding
1757881|NCT00261222|Drug|Amodiaquine|
1757882|NCT00261235|Behavioral|Supported Employment|
1757883|NCT00261235|Behavioral|Using Strengths in Employment System (USES)|
1757884|NCT00261248|Biological|Immunization with inactivated bacteria|
1757885|NCT00261261|Behavioral|ADVANCE|
1757886|NCT00261261|Drug|Midazolam|
1757887|NCT00261261|Procedure|Parental presence|
1757888|NCT00263770|Device|soft palate implant|
1757889|NCT00263770|Other|Positive airway pressure (PAP)|which is air delivered by a mask worn over the nose during sleep
1757890|NCT00263783|Drug|MEDI-522|MEDI-522 will be administered at doses of 1.0, 2.0, 4.0, 6.0, 8.0, and 10.0 mg/kg. [As a 30 minute IV infusion initially as a single dose (single-dose treatment period) and 2 to 5 weeks later as weekly doses (multiple-dose treatment period) for up to 1 year.]
1757891|NCT00263796|Drug|Oxytocin|10 international units = 1 cc, IV over 4 hours
1757892|NCT00263796|Drug|Placebo|Normal Saline, IV over 4 hours
1757893|NCT00263809|Device|Pathogen Reduction Technology|
1757894|NCT00263822|Drug|erlotinib hydrochloride|
1757895|NCT00263835|Behavioral|Empowerment|
1757896|NCT00263861|Procedure|management of therapy complications|Patients undergo an interview and clinical evaluation to measure demographic data, cutaneous sensation, gait and balance, vibration, lower extremity muscle strength, orthostatic blood pressure, and glycemic control.
1757897|NCT00263874|Drug|UK-500,001|
1757898|NCT00263887|Drug|Alpha1-Proteinase Inhibitor (Human)|Weekly infusion of 60 mg/kg body weight for 2 years
1757899|NCT00263887|Drug|Albumin (Human) 20%, United States Pharmacopeia (USP)|Weekly infusion for 2 years. Albumin (Human) 20% will be diluted with 5% glucose to a final concentration of 2.0%.
1757900|NCT00263900|Device|RSV respi-strip and Quick-vue influenza|Assessments of 2 quick diagnostic tests in the emergency unit during children's care
1757901|NCT00263926|Biological|wasp venom|
1757902|NCT00263939|Behavioral|Homing in on Health|A peer (non-health professional) delivered intervention to enhance patient self-efficacy for chronic disease self-management. Developed as a modification of the Stanford Chronic Disease Self-Management Program.
1757903|NCT00263952|Biological|bee venom|
1757904|NCT00263965|Drug|Tesaglitazar|
1757905|NCT00263965|Drug|Metformin|
1757906|NCT00263965|Behavioral|Dietary and lifestyle modification counseling|
1757907|NCT00263978|Drug|Defibrotide|
1757908|NCT00263991|Device|EEC-techniques|
1757909|NCT00264004|Drug|AZD2171|30 mg & 45 mg oral tablet
1757910|NCT00264030|Device|Angioguard distal protection device|PTCA with the Angioguard distal protection device.
1757911|NCT00264030|Other|PTCA|PTCA
1757912|NCT00264043|Device|emboli capturing guidewire device combined with stent|AngioGuard™ device and Bx Velocity™ stent
1757913|NCT00264056|Device|hyperthermia|
1757914|NCT00264069|Drug|antipsychotic|as prescribed
1757915|NCT00264069|Drug|antidepressants|as prescribed
1757916|NCT00264082|Drug|Zometa(drug)|
1757917|NCT00264095|Procedure|Oncological surgery|surgery is primary observed intervention and blood loss is between 500-3000 ml
1757918|NCT00264108|Drug|Darbepoetin alfa|Either 150 ug once weekly or 500 ug once every 3 wks, variable treatment length.
1757919|NCT00264108|Drug|Epoetin alfa|40,000 IU once weekly, variable treatment length.
1757920|NCT00264134|Drug|Docetaxel|
1757921|NCT00264134|Drug|Irinotecan|
1757922|NCT00264134|Drug|Carboplatin|
1757923|NCT00264147|Drug|etoricoxib|Period I: Arm 1: etoricoxib 10 mg tablet once daily. 12 weeks of treatment.
1757924|NCT00264147|Drug|etoricoxib|Period I: Arm 2: etoricoxib 30 mg tablet once daily. 12 weeks of treatment.
1757925|NCT00264147|Drug|etoricoxib|Period I: Arm 3: etoricoxib 60 mg tablet once daily. 12 weeks of treatment.
1757926|NCT00264147|Drug|etoricoxib|Period I: Arm 4: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
1757927|NCT00264147|Drug|Comparator: placebo|Period I: Arm 5: Pbo tablet once daily. 12 weeks of treatment.
1757928|NCT00264147|Drug|etoricoxib|Period II: Arm 1: etoricoxib 90 mg tablet once daily. 12 weeks of treatment.
1757929|NCT00264147|Drug|Comparator: diclofenac|Period II: Arm 2: diclofenac 75 mg tablet twice daily. 12 weeks of treatment.
1757930|NCT00264160|Drug|AMN107|
1757931|NCT00264173|Drug|Valproate sodium|
1757932|NCT00264186|Drug|LPS 2 ng/kg intravenous (IV) bolus|
1757933|NCT00264186|Drug|rhSOD 82,000 IU (8.2 mg)/min intraarterially|
1757934|NCT00264186|Drug|Norepinephrine 60, 120, 240 pmol/min intraarterially over 5 min/dose level (two times; pre-dose and +3.5 hrs)|
1757935|NCT00264186|Drug|Acetylcholine 6.25, 12.5, 25 nmol/min intraarterially over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
1757936|NCT00264186|Drug|Glyceroltrinitrate (nitroglycerine) 4, 8, 16 nmol/min over 3 min/dose level (two times; pre-dose and +3.5 hrs)|
1757937|NCT00264199|Drug|GLP-1|iv. by weight (1.0 pmol/kg/min )
1757938|NCT00264199|Drug|placebo|same rate of infusion as GLP-1
1757939|NCT00264212|Drug|irbesartan and irbesartan-hydrochlorothiazide|
1757940|NCT00264225|Drug|Lamaline® , 3 different doses, Dafalgan codeine|
1757941|NCT00264238|Drug|Memantine|pharmacological dosing of memantine as adjunctive therapy for treatment-resistant obsessive-compulsive disorder
1757942|NCT00264251|Behavioral|Weight loss through diet and exercise|
1757943|NCT00264251|Drug|Rosiglitazone insulin sensitizing agent|
1757944|NCT00264264|Procedure|Closure Device|
1757945|NCT00264264|Procedure|Direct Compression|
1757946|NCT00264277|Drug|Vitamin K antagonist (Coumarin anticoagulants)|
1757947|NCT00264290|Drug|Valganciclovir|900mg PO qd x 8 weeks followed by 4 weeks of observation on background antiretroviral (ARV) regimen alone.
1757948|NCT00264290|Drug|Placebo|Placebo designed to resemble Valganciclovir
1757949|NCT00264303|Drug|Levocetirizine|5mg oral capsules, once daily, 4 week duration
1757950|NCT00264303|Drug|Desloratadine|5mg oral capsules, once daily, 4 week duration
1757951|NCT00264316|Procedure|bone marrow-derived stem cell transfer|
1757952|NCT00264329|Other|Transitional Case Management Study|In an effort to address problems involved in parole re-entry, the Transitional Case Management (TCM) intervention tested a model of strengths-based case management consisting of (1) completion by the inmate of a strengths and goals assessment as part of discharge planning, (2) a telephone conference call that included the inmate and people central to the inmate's aftercare plan (including the parole officer), and (3) strengths case management for 12 weeks in the community to promote treatment participation and increase the client's access to needed services.
1757953|NCT00264355|Drug|cyclosporine A|
1757954|NCT00264368|Drug|intravenous (IV) ganciclovir|
1757955|NCT00264381|Drug|Dalteparin sodium injection|Experimental group: dalteparin sodium 200units/kg subcutaneous on day one, followed by 10,000 units subcutaneous daily for six days plus placebo tablets taken orally three times daily for seven days. Control group: Ibuprofen 800mg orally three times daily for seven days plus placebo injection subcutaneous daily for seven days.
1757956|NCT00264394|Behavioral|Updated CHD risk profiles|Provision of computer generated CHD risk profiles
1757957|NCT00264394|Behavioral|Guidelines|provision of guidelines for CHD risk factor management only
1757958|NCT00264407|Drug|Hormone Replacement Therapy - HRT|
1757959|NCT00264420|Drug|zoledronic acid|At baseline 4 mg IV zoledronic acid over 15 min. every 4 weeks for 6 months plus radiation therapy 30 Gy in 10 fractions (5 times per week for first two weeks)
1757960|NCT00264433|Drug|ADH -1 (Exherin™)|
1757961|NCT00264446|Drug|ADH300004|
1757962|NCT00264459|Biological|Grass pollen formulation|"Solution for sublingual application containing allergen extracts of 6 grass pollen species (Holcus lanatus, Dactylus glomerata, Lolium perenne, Phleum pratense, Poa pratensis, Festuca pratensis) pollen allergen extract.
The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter."
1757963|NCT00264459|Other|Comparator|Solution for sublingual application containing Placebo. The study solution was applied sublingually, kept under the tongue for 3 minutes, and swallowed thereafter.
1757964|NCT00264472|Drug|ADH300004|5 mg
1757965|NCT00264485|Drug|E-TRANS Fentanyl hydrochloride; Morphine|
1757966|NCT00264498|Drug|Gefitinib|oral tablet
1757967|NCT00264498|Drug|Gemcitabine|intravenous injection
1757968|NCT00264498|Drug|Carboplatin|intravenous injection
1757969|NCT00264511|Procedure|Hyperbaric Oxygenation|Subjects in the HBO treatment group will receive a course of hyperbaric oxygen therapy (HBO) in addition to normal trauma and general care. A total of 12 HBO sessions will be delivered over approximately 8 days. HBO treatment will be provided at 2.4 atmospheres absolute (ATA) pressure for approximately 90 minutes of oxygen therapy. Treatments should be twice daily for the first three days. Minor variability will be allowed with respect to timing and profile of each session.
1757970|NCT00264524|Procedure|venipuncture to withdraw patient's blood|
1757971|NCT00264537|Drug|Placebo injections|SC injections
1757972|NCT00264537|Drug|Placebo capsules|Placebo capsules will be filled with microcrystalline cellulose (Avicel PH 102).
1757973|NCT00264537|Drug|Methotrexate capsules|Methotrexate capsules will be filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg methotrexate tablet.
1757974|NCT00264537|Biological|Golimumab 50 mg injections|SC injections
1757975|NCT00264537|Biological|Golimumab 100 mg injections|SC injections
1757976|NCT00264550|Drug|Golimumab 100 mg|Participants will receive subcutaneous (SC) injections of golimumab 100 mg every 4 weeks.
1757977|NCT00264550|Drug|Golimumab 50 mg|Participants will receive subcutaneous (SC) injections of golimumab 50 mg every 4 weeks.
1757978|NCT00264550|Drug|Methotrexate|Participants will receive methotrexate capsules weekly.
1757979|NCT00264550|Drug|Placebo injection|Participants will receive subcutaneous (SC) injections of placebo every 4 weeks.
1757980|NCT00264550|Drug|Placebo capsules|Participants will receive placebo capsules weekly
1757981|NCT00264563|Behavioral|Increasing the level of awareness to Iatrogenesis|Increasing the level of awareness to Iatrogenesis
1757982|NCT00264563|Behavioral|Increasing awareness .|Increasing awareness to Iatrogenesis and active daily recordings
1757983|NCT00264576|Biological|Influenza Virus Vaccine|
1757984|NCT00264589|Behavioral|8 weeks individualized training program|no drugs added
1757985|NCT00264602|Drug|Near Infrared Imaging|Dye injected into or around tumor at the time of surgery
1757987|NCT00264628|Drug|GW679769|
1757988|NCT00264641|Drug|Human insulin|Hyperinsulinaemic induced hypoglycaemia
1757989|NCT00264654|Drug|BRL29060A|
1757990|NCT00264654|Drug|paroxetine hydrochloride hydrate|
1757991|NCT00264667|Drug|GW677954|
1757994|NCT00264706|Drug|Nona-L-arginine|
1757995|NCT00264719|Drug|Metoclopramide (Maxolon)|Mothers will be given metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10 and once a day from 11th to 12th day
1757996|NCT00264719|Drug|placebo|placebo 10 mg
1757997|NCT00264732|Drug|Amolimogene|1-dose amolimogene Group: Two intramuscular (IM) injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM placebo injections (approximately 1 mL 0.9% sterile saline) at Weeks 3 and 6 in alternating quadriceps.
1757998|NCT00264732|Drug|Amolimogene|3-dose amolimogene Group: Two IM injections (100 micrograms ZYC101a per injection), one in each quadriceps, at Treatment Initiation. Single IM injections of 100 micrograms ZYC101a at Weeks 3 and 6 in alternating quadriceps.
1757999|NCT00264732|Other|Placebo|Placebo Group: Two IM placebo injections at Treatment Initiation (1 injection in each quadriceps). Single placebo injections at Weeks 3 and 6 in alternating quadriceps. Each placebo injection consists of approximately 1 mL 0.9% sterile saline.
1758000|NCT00264745|Behavioral|TASK intervention|The Telephone Assessment and Skill-building Kit (TASK) is an individualized 8-week intervention program geared toward reducing depression and improving general health in stroke caregivers.
1758001|NCT00264745|Behavioral|Attention Control|Minimal intervention beyond initial hospital visit.
1758002|NCT00264758|Device|Conventional hemodialysis|Three times per week in-center hemodialysis
1758003|NCT00264758|Device|Frequent hemodialysis|Six times per week in-center hemodialysis
1758004|NCT00264797|Drug|Methylphenidate (OROS-MPH)|Participants will be scheduled for weekly medication (OROS-MPH) and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
1758005|NCT00264797|Drug|Methylphenidate (OROS-MPH) - Placebo|Participants will be scheduled for weekly medication and research assessment visits (approximately 45 minutes to 1 hour in length). A forced titration dosing strategy will be used starting with 18 mg/day OROS-MPH placebo for 3 days, increasing to 36mg/day for the next three days; increasing to 54 mg/day in week two, and to 72 mg/day in week three through the remainder of the study (as tolerated). Participants will also attend weekly CBT sessions (approximately 1 hour in length) targeting their drug use.
1758006|NCT00264810|Procedure|RNS® System implantation|Using standard neurosurgical techniques the surgical team implants the RNS® System, which includes the RNS® Neurostimulator and intracranial NeuroPace® Leads. Up to 4 Leads (Cortical Strips and/or Depth Leads) are placed in or near the epileptogenic focus/foci. The Neurostimulator is placed in the skull and connected to up to 2 Leads. At first the Neurostimulator is programmed to record brain activity (electrographic patterns). The neurologist or neurosurgeon reviews the recorded electrographic patterns and identifies abnormal (epileptiform, or seizure-like) activity. The Neurostimulator is then programmed to detect the abnormal activity.
1758007|NCT00264810|Device|RNS® System responsive stimulation|The RNS® System is programmed to provide responsive stimulation (stimulation is ON or enabled). Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal (epileptiform, or seizure-like) activity, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
1758008|NCT00264823|Behavioral|Use of Memory Aids to take medications|Experimental participants will receive an integrated intervention tailored to the communication and comprehension of the individual, and will include memory aid devices, education regarding side effects and other treatment aspects, and active community outreach. For those who fail to adhere using the basic intervention, a treatment cascade that increases in intensity will be implemented. Using 80% adherence as a target, the cascade will include involvement of family and significant others in prompting participants through use of beepers, cellphones, and for those who still fall short of 80% adherence, directly observed therapy.
1758009|NCT00264849|Drug|Omalizumab|Omalizumab administered by subcutaneous injection. The dosage received was individualized based on body weight and serum IgE level.
1758010|NCT00264849|Other|Optimized asthma therapy|Optimized asthma therapy (OAT) according to Global Initiative for Asthma (GINA) 2004 guidelines during the first 4 weeks of the run-in period of the study.
1758011|NCT00264862|Procedure|DynaCT|
1758012|NCT00264875|Drug|pregabalin|75mg BID, titrated up to 300mg according to individual response and tolerability
1758013|NCT00264888|Drug|PTC124|
1758014|NCT00264901|Drug|insulin detemir|
1758015|NCT00264914|Drug|SR121463B|
1758016|NCT00264927|Drug|SR121463B|
1758017|NCT00264953|Drug|Adriamycin|
1758018|NCT00264953|Drug|Bleomycin|
1758019|NCT00264953|Drug|Vinblastine|
1758020|NCT00264953|Drug|DTIC|
1758021|NCT00264953|Drug|Etoposide|
1758022|NCT00264953|Drug|Procarbazine|
1758023|NCT00264953|Drug|Prednisone|
1758024|NCT00264953|Drug|Vincristine|
1758025|NCT00264953|Radiation|radiation therapy|20 or 30Gy IF-RT
1758026|NCT00264966|Drug|ASM8|
1758027|NCT00264979|Procedure|Simultaneous surgery|Simultaneous surgery of colorectal cancer and synchronous liver metastases
1758028|NCT00264979|Procedure|Sequential surgery|Sequential surgeries of colorectal cancer and synchronous liver metastases: the metastases surgery will be programmed 12 to 14 weeks after the primary tumour exeresis.
1758029|NCT00265005|Drug|alteplase|Iv administration of 1 mg/ml up to two times and 2 mg/ml if needed.
1758030|NCT00265018|Drug|Adriamycin|
1758031|NCT00265018|Drug|Bleomycin|
1758032|NCT00265018|Drug|Vinblastine|
1758033|NCT00265018|Drug|DTIC|
1758034|NCT00265018|Radiation|30 Gy IF-RT|
1758035|NCT00265018|Radiation|20 Gy IF-RT|
1758036|NCT00265031|Drug|Cyclophosphamide|
1758037|NCT00265031|Drug|Adriamycin|
1758038|NCT00265031|Drug|Etoposide|
1758039|NCT00265031|Drug|Procarbazine|
1758040|NCT00265031|Drug|Prednisone|
1758041|NCT00265031|Drug|Vincristine|
1758042|NCT00265031|Drug|Bleomycin|
1758043|NCT00265031|Procedure|radiation therapy|
1758044|NCT00265044|Behavioral|Provider Education|
1758045|NCT00265044|Behavioral|Hypertension Alert|
1758046|NCT00265044|Behavioral|Patient Education|
1758047|NCT00265057|Drug|ADH -1 (Exherin™)|
1758048|NCT00265070|Drug|Gefitinib|250 mg tablet oral daily dose
1758049|NCT00265083|Biological|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
1758050|NCT00265083|Biological|Golimumab (CNTO 148); placebo|SC injections every 4 wks thru wk 20 (unless early escape at wk 16);golimumab - if early escape, 50mg sc inj every 4wks from wk 16 up to 5yrs ;golimumab -50mg sc injection beginning wk 24 up to 5 yrs (unless early escape); golimumab- Dr's discretion after unblinding, dose adjust from 50 to 100mg
1758051|NCT00265083|Biological|golimumab|50 mg sc injs every 4wks from wk 0 thru 5yrs (unless early escape at wk 16); golimumab - If early escape, 100mg sc injections every 4 wks beginning wk 16 up to 5 yrs ; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
1758052|NCT00265096|Biological|golimumab|50 mg sc injs every 4 wks from wk 0 thru 5 yrs (unless early escape at wk 16); golimumab - if early escape, 100mg sc injection every 4 wks beginning wk 16 up to 5 yrs; golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100mg
1758053|NCT00265096|Biological|Placebo; golimumab|SC injections ever 4 wks thru Wk 20 (unless early escape at wk 16); golimumab - if early escape, 50mg sc injection from wk 16 up to 5 yrs; golimumab -50mg sc injection beginning Wk 24 up to 5 yrs (unless early escape); golimumab - Dr's discretion after unblinding, dose adjust from 50 to 100 mg
1758054|NCT00265096|Biological|golimumab|100 mg sc injections every 4 wks from wk 0 up to 5 yrs
1758055|NCT00265109|Drug|Levetiracetam|The initial levetiracetam dose will be 250 mg/day, which will be increased to 250 mg BID after 1 week. The dose will then be increased by 500 mg/day each week (given in BID dosing) to a maximum of 3,000 mg/day. The dose will be raised more slowly or the maximum dose will not be reached if response occurs at a lower dose or side effects are problematic. Subjects who are unable to tolerate at least 500 mg a day of levetiracetam will be withdrawn from the study.
1758056|NCT00265122|Drug|Ustekinumab 90 mg|one 90 mg SC injection each week for 4 weeks (Weeks 0-3 during Intervention Period 1 or Weeks 8-11 during Intervention Period 2 for Population 1 or Weeks 0-3 during Intervention Period 1 for Population 2)
1758057|NCT00265122|Drug|Ustekinumab 4.5 mg/kg|one IV infusion of 4.5 mg/kg over a period of not less than 2 hours at Week 0 in Intervention Period 1 or Week 8 in Intervention Period 2 for Population 1 or at Week 0 in Intervention Period 1 for Population 2
1758058|NCT00265122|Drug|Placebo SC|one SC injection each week for 4 weeks (Weeks 0-3 in Intervention Period 1 or Weeks 8-11 in Intervention Period 2 for Population 1 or at Weeks 0-3 in Intervention Period 1 for Population 2)
1758059|NCT00265122|Drug|Placebo IV|one IV infusion over a period of not less than 2 hours at Week 0 in Intervention Period 1 for Population 1 and Population 2 or at Week 8 in Intervention Period 2 for Population 1
1758060|NCT00265135|Drug|CNTO 328|Patients will receive CNTO 328 at dose levels ranging from 1, 3, 6, and 12 mg/kg in Part 1 of the study to determine the maximum tolerated dose for Part 2 of the study. Patients will receive 2 well tolerated dose levels of CNTO 328 from Part 1 of the study every 3 weeks in Part 2 of the study. Patients will receive 6 mg/kg of CNTO 328 every 2 weeks in Part 3 of the study.
1758063|NCT00265200|Drug|zoledronic acid|3.0-4.0 mg by IV (in the vein), once a month for 6 months
1758064|NCT00265226|Biological|Intra-dermal administration of Mycobacterium w|Mw Vaccine is given as oral suspension. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
1758065|NCT00265239|Drug|edaravone|intravenous administration of 30mg Edaravone just before reperfusion therapy
1758067|NCT00265265|Drug|Atomoxetine|
1758068|NCT00265278|Drug|Modafinil|
1758069|NCT00265291|Drug|fluoxetine or desipramine|fluoxetine 5-40 mg/day desipramine 50-150 mg/day
1758070|NCT00265304|Drug|Ketoprofen|
1758071|NCT00265317|Drug|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
1758072|NCT00265317|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
1758073|NCT00265317|Drug|erlotinib|erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
1758074|NCT00265317|Drug|placebo|Placebo daily by oral capsule in a continuous regimen plus erlotinib 150 mg daily by tablets in a continuous regimen, until progression or unacceptable toxicity
1758075|NCT00265330|Drug|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid .
1758076|NCT00265343|Drug|asenapine|5-10 mg sublingually twice daily for 26 weeks
1758077|NCT00265343|Drug|olanzapine|5-20 mg by mouth once daily for 26 weeks
1758078|NCT00265356|Procedure|PET diagnostic imaging|PET diagnostic imaging
1758079|NCT00265369|Drug|Spores of Bacillus Clausii Probiotic Strain|
1758080|NCT00265382|Drug|Ziprasidone oral capsules|Study medications will include oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 20mg bid to a maximum dose range of 80 mg bid.
1758081|NCT00265395|Drug|Combination of pegylated interferon alfa-2b (PEG-Intron®) and ribavirin (Rebetol®)|"Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks
200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
1758082|NCT00265395|Drug|Combination of pegylated interferon alfa-2b and ribavirin|"Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strength), subcutaneous, dose of 1.5 micrograms/kg, weekly for 72 weeks.
200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 72 weeks"
1758083|NCT00265408|Drug|aspirin|
1758084|NCT00265408|Drug|warfarin|
1758085|NCT00265421|Procedure|Suture technique for perineal repair after delivery|
1758086|NCT00265434|Drug|Pulmozyme|
1758087|NCT00265447|Behavioral|Strength training|3 months of strength training
1758088|NCT00265447|Behavioral|Aerobic conditioning|3 months of aerobic conditioning
1758089|NCT00265447|Behavioral|Delayed exercise|delayed exercise control group
1758090|NCT00265460|Drug|Oliwer Twist smokeless tobacco (tobacco)|
1758091|NCT00265473|Biological|Allogeneic Islets of Langerhans|Intraportal infusion of islets of Langerhans
1758092|NCT00265486|Drug|Recombinant human Erythropoietin|Adm 100 U/kg sc 1 hour before completing exercise in protocol
1758093|NCT00265499|Procedure|Skeletonization of the internal thoracic artery|
1758094|NCT00265512|Behavioral|Telephone Case Monitoring|Telephone Case Monitoring involves telephone delivery of continuing care treatment post intensive outpatient SUD treatment. It includes brief weekly phone calls with a counselor for up to 6 months.
1758095|NCT00265512|Behavioral|Continuing Care as Usual|Continuing Care as Usual will include standard group outpatient SUD treatment.
1758096|NCT00265525|Behavioral|CardioFit|CardioFit is a 26-week tailored web-based physical activity coaching service for individuals with Coronary Artery Disease (CAD). It has been designed to help patients develop personalized exercise programs based on their medical history, personal goals and preferences. Access to Cardio-fit is through a secured website. The cardio-fit website contains physical activity advice and heart health educational information. Each patient is assigned an on-line coach, whose role is to assist in creating safe an effective physical activity program, and to answer any questions that patients may have throughout the program.
1956742|NCT02721901|Behavioral|iEAT Manual Intervention|The iEAT manual guides caretakers in increasing the volume of food consumed by the child. The manual involves a touch screen application that collects and stores data on key behaviors and provides the feeder with direction for structuring treatment meals. Sessions will be 45 minutes long and occur biweekly for 10 sessions over 5 months. Two meals each day will be completed at home as part of the treatment of the feeding problems.
1956743|NCT02721901|Behavioral|Control group|The psychoeducation condition will involve 6 appointments (once monthly for 5 months and 1 session during the post-treatment assessment). Each appointment will include curriculum related to feeding concerns such as the etiology of feeding problems, meal structure, appropriate food selection, mealtime problem behaviors, and generalization of appropriate feeding behaviors. Each session will last approximately 45 minutes.
1758099|NCT00265551|Drug|SCA-136 (200 mg)|
1758100|NCT00265551|Drug|SCA-136 (400 mg)|
1758101|NCT00265551|Drug|olanzapine (15 mg)|
1758102|NCT00265551|Drug|placebo|
1956744|NCT02720757|Drug|Spiolto Respimat|Tiotropium bromide + Olodaterol
1758105|NCT00265603|Procedure|Extracorporeal Photochemotherapy With Transimmunization|The photopheresis apparatus and procedure will be identical to that currently used. Patients will receive intravenous 8-MOP (UVADEX®) directly into the photopheresis apparatus, to yield a concentration of 50-200 ng/ml of drug. The blood will be leukapheresed to obtain a buffy coat and will then be passed through the contiguous closed circuit ultraviolet A exposure device, delivering the desired 1-2 joules/cm2 of ultraviolet A energy. In this manner 2-4 molecules of 8-MOP will be induced to bind covalently to thymines of the leukocyte DNA. At that point, the single variation from the standard treatment will be initiated. Instead of returning the patient's cells and the saline to the patient, the bag will be detached from the apparatus. KLH (depyrogenated, endotoxin-free; Calbiochem-Novabiochem Corp., San Diego, CA) will be added at a concentration of 10 g/ml to the DC-rich leukocyte culture prior to overnight culture.
1758106|NCT00265616|Drug|propofol|liquid, mg/kg.h, titrated after EEG
1758107|NCT00265616|Drug|thiopental/pentobarbital|liquid, mg/kg.h, titrated after EEG
1758108|NCT00265629|Device|RF catheter ablation|RF ablation using mesh device
1758109|NCT00265642|Drug|Irbesartan|one tablet of 150 mg/d during 2 years
1758110|NCT00265642|Drug|placebo|one tablet per day during 2 years
1758111|NCT00265655|Drug|Satraplatin|Patients will receive 80mg/m2 Satraplatin on Days 1-5 of Cycles 1 and 2. A cycle consists of 21 days.
1758112|NCT00265681|Behavioral|Phone counseling and written materials|
1758113|NCT00265694|Drug|vinorelbine, gemcitabine and carboplatin|
1758114|NCT00265707|Device|Blood pressure measurement|
1758115|NCT00265720|Other|Control|Written materials only
1758116|NCT00265720|Other|Reduced out of pocket expense|Reimbursed up to $500 out of pocket expense for CRC screening
1758117|NCT00265720|Behavioral|one on one education|one on one education with a health educator
1758118|NCT00265720|Behavioral|Group education|Education in a small group
1758119|NCT00265733|Drug|capecitabine|
1758120|NCT00265733|Drug|paclitaxel poliglumex|
1758121|NCT00265746|Drug|Metformin|
1758122|NCT00265746|Behavioral|Lifestyle intervention - diet, physical activity|
1758123|NCT00265759|Drug|anastrozole|Given PO
1758124|NCT00265759|Drug|exemestane|Given PO
1758125|NCT00265759|Drug|letrozole|Given PO
1758126|NCT00265759|Procedure|Therapeutic Conventional Surgery|Undergo partial or radical mastectomy or lumpectomy with or without lymph node dissection
1758127|NCT00265772|Drug|MODULEN IBD (R) (specific Enteral Nutrition)|
1758128|NCT00265772|Drug|prednisolon|
1758129|NCT00265785|Drug|pemetrexed|Pemetrexed 500 mg/m^2 intravenous (IV) over 10 min every 21 days until any of the following criteria is met: (1) Progression of disease or symptomatic deterioration; (2) Unacceptable toxicity; (3) Treatment delay ≥ 3 weeks, for any reason; (4) The patient may withdraw from the study at any time for any reason; (5) Physician's discretion.
1758130|NCT00265798|Drug|Sorafenib Tosylate|
1758131|NCT00265811|Drug|Folfox + Cetuximab|
1758132|NCT00265811|Drug|Folfox|
1758133|NCT00265824|Drug|bevacizumab|bevacizumab 7.5mg/kg every 3 weeks until disease progression or limiting toxicity
1758134|NCT00265824|Drug|bevacizumab, erlotinib|bevacizumab 7.5mg/kg and oral erlotinib 150 mg/day continuously Cycles every 3 weeks until disease progression or limiting toxicity
1758135|NCT00265837|Biological|graft versus host disease prophylaxis/therapy|
1758136|NCT00265837|Procedure|allogeneic bone marrow transplantation|
1758137|NCT00265837|Procedure|in vitro-treated bone marrow transplantation|
1758138|NCT00265850|Biological|bevacizumab|Given IV
1758139|NCT00265850|Biological|cetuximab|Given IV
1758140|NCT00265850|Drug|FOLFOX or|Patients receive oxaliplatin 85 mg/m^2 IV infused over two hours followed by leucovorin 400 mg/m^2 IV over 2 hours followed by 5-FU 400 mg/m^2 IV bolus, then 2400 mg/m^2 continuous IV infusion over 46-48 hours
1758319|NCT00256828|Drug|didanosine + lamivudine + efavirenz|
1758141|NCT00265850|Drug|FOLFIRI|Patients receive irinotecan 180 mg/m^2 IV infused over 90 minutes followed by leucovorin 400 mg/m^2 IV over 2 hours followed by 5-FU 400 mg/m^2 IV bolus following leucovorin then 2400 mg/m^2 continuous IV infusion over 46-48 hours.
1758142|NCT00265863|Drug|mitomycin C|Mitomycin C is infused into the abdominal cavity by hyperthermic perfusion over 60 minutes.
1758143|NCT00265876|Drug|AZD0530|Taken daily every 4 weeks
1758144|NCT00265876|Drug|gemcitabine hydrochloride|1000mg/m2 IV weekly
1758145|NCT00265889|Biological|filgrastim|480 mcg beginning day +5
1758146|NCT00265889|Drug|busulfan|11.2 mg/kg; 0.8 mg/kg IV q6h X 14 doses
1758147|NCT00265889|Drug|cyclophosphamide|60 mg/kg IV over 2 hours x 2 days
1758148|NCT00265889|Drug|etoposide|60 mg/kg, IV
1758149|NCT00265889|Drug|melphalan|150mg/m2 in NS at a concentration of 0.4mg/cc infused over 60 minutes.
1758150|NCT00265889|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|autologous-autologous tandem hematopoietic stem cell transplantation
1758151|NCT00265889|Radiation|radiation therapy|radiation therapy
1758152|NCT00265902|Procedure|diagnostic imaging|
1758153|NCT00265915|Biological|rituximab|
1758154|NCT00265915|Biological|sargramostim|
1758155|NCT00265928|Drug|bortezomib|
1758156|NCT00265928|Drug|rituximab|
1758157|NCT00265928|Procedure|antibody therapy|
1758158|NCT00265928|Procedure|biological therapy|
1758159|NCT00265928|Procedure|enzyme inhibitor therapy|
1758160|NCT00265928|Procedure|monoclonal antibody therapy|
1758163|NCT00265954|Behavioral|internet, in-person and internet+in-person|All participants receive an 18 month behavioral weight loss program that meets weekly for the first 6 months and monthly for the next year.
1758164|NCT00265967|Drug|Irbesartan|Irbesartan 150-300 mg/d for 8 weeks
1758165|NCT00265980|Drug|Placebo|twice daily iinjections of saline in the same volume as will be used for B-2 leptin injections
1758166|NCT00265980|Drug|Leptin|Leptin will be given as twice daily subcutaneous injections in doses titrated to replicate 8AM circulating leptin concentrations measured in the same subjects prior to weight loss.
1758167|NCT00265980|Drug|placebo|Subjects will receive a once daily oral placebo that looks identical to the tri-iodothyronine administered in arm C-2.
1758168|NCT00265980|Drug|Tri-iodothyronine|Subjects will receive a once daily oral dose of T3 which will be titrated until 8AM T3 levels are similar to those measured in the same subjects prior to weight loss.
1758169|NCT00265993|Drug|enoxaparin|"All patients will be treated with enoxaparin 1.5 mg/kg, once a day, subcutaneously for up to 10 days.
Long-term oral anticoagulation will be started in all patients after 24 hours of initiation of enoxaparin treatment and continued at least for 3 months."
1758170|NCT00266006|Drug|eptacog alfa (activated)|
1758171|NCT00266019|Behavioral|Weight Management (diet, exercise, and behavior modification)|
1758172|NCT00266032|Drug|Flexible (extended) treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days intended treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate (EE20) plus 3 mg drospirenone (DRSP) followed by a 4 day tablet-free interval. If 3 consecutive days of bleeding and/or spotting occurred during the 120 day treatment period, a 4 day tablet free interval was advised. The minimum period between 2 tablet free intervals was 24 days. After each 4 day tablet free interval, a new 120 day intended treatment period was to be restarted, resulting in a minimum of 3 and maximum of 13 withdrawal bleeding episodes during one year of treatment.
1758173|NCT00266032|Drug|Fixed extended treatment of EE20/DRSP (YAZ, BAY86-5300)|3 cycles of treatment, each cycle comprising 120 days uninterrupted treatment with one tablet daily of 20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone followed by a 4 day tablet free interval, 3 withdrawal bleeding episodes during one year of treatment were expected.
1758174|NCT00266032|Drug|Standard 24+4 treatment of EE20/DRSP (YAZ, BAY86-5300)|13 cycles of treatment, each cycle comprising an intake of one tablet daily with 24 days of active tablets (20µg ethinyl estradiol as betadex clathrate plus 3 mg drospirenone) followed by 4 days of placebo tablets, 13 withdrawal bleeding episodes during one year of treatment were expected.
1758175|NCT00266058|Drug|Lopinavir/Ritonavir, Efavirenz, Artemether/lumefantrine|participants receive a total of 6 doses of artemether(80mg)/lumefantrine(480mg)for baseline PK evaluation. This is followed by a 26-day course of either efavirenz(600mg) once daily or lopinavir/ritonavir (400mg/100mg) twice daily and additional 6 doses of artemether/lumefantrine to determine the pharmacokinetics of the antimalarial medications in the context of antiretrovirals. The participants undergo at least a 14 day washout period (between the last baseline PK blood draw and the initiation of antiretrovirals)
1758176|NCT00266071|Behavioral|Cutaneous response|
1758177|NCT00266097|Drug|erlotinib hydrochloride|Cohort (-1) = 50 mg daily Cohort 1 = 50mg daily Cohort 2= 75 mg daily Cohort 3 = 100mg daily Cohort 4 = 100mg daily Cohort 5 = 150mg daily
1758178|NCT00266097|Drug|gemcitabine hydrochloride|Gemcitabine will be given at a dose of 100 mg/m2 for the first cohort and escalated to a fixed dose of 200 mg/m2 for the remaining 3 cohorts
1758179|NCT00266097|Drug|oxaliplatin|Oxaliplatin will be given at 30 mg/m2 weekly for the first two cohorts and then will be dose-escalated to 45 mg/m2 and 60 mg/m2 for the next 2 in cohorts
1758180|NCT00266097|Radiation|radiation therapy|5040 cGy, every week, up to 6 weeks
1758181|NCT00266097|Drug|gemcitabine hydrochloride|Given weekly at a starting dose of 100mg/m2 in the first 3 cohorts and dose escalated to 200 mg/m2 for the remaining 2 cohorts
1758182|NCT00266097|Drug|Oxaliplatin|The Part II dose of oxaliplatin will be determined by Part I of the study. The dose for Part II will be one dose level increase from the MTD determined in Part I.
1758183|NCT00266110|Biological|sargramostim|All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.
1758184|NCT00266110|Biological|therapeutic autologous dendritic cells|patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.
1758320|NCT00256841|Drug|Chemotherapy|
1758185|NCT00266110|Biological|trastuzumab|Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration. If the subject has previously received Trastuzumab within 30 days and has no adverse history with the drug, the infusion will be given over 30 minutes. If the subject is currently receiving Trastuzumab, the first study infusion will be given at 4mg/kg over 30 minutes. Subsequently, Trastuzumab will be infused at 4 mg/kg in the side-port of a freely flowing IV over 30 minutes.
1758186|NCT00266110|Drug|vinorelbine ditartrate|Vinorelbine 25 mg/m2 will be administered IV over six to ten minutes into the side port of a freely flowing IV line.
1758187|NCT00266123|Drug|Sirolimus|
1758188|NCT00266136|Drug|Cytarabine|see protocol
1758189|NCT00266136|Drug|Thioguanine|see protocol
1758190|NCT00266136|Drug|Daunorubicin|see protocol
1758191|NCT00266136|Drug|Cyclophosphamide|see protocol
1758192|NCT00266136|Drug|G-CSF|see protocol
1758193|NCT00266136|Procedure|Autologous stem cell transplantation|for details see protocol
1758194|NCT00266136|Procedure|Allogeneic stem cell transplantation|for details see protocol
1758195|NCT00266149|Drug|Oral contraception|
1758196|NCT00266149|Drug|Lamotrigine|
1758197|NCT00266162|Drug|Bosentan administration|
1758198|NCT00266214|Drug|lidocaine patch 5%|1 patch applied topically to the volar aspect of each affected wrist daily, 2-4 hours before bedtime
1758199|NCT00266227|Drug|placebo|Intravenous repeating dose
1758200|NCT00266227|Drug|rituximab|Intravenous repeating dose
1758201|NCT00266227|Drug|methotrexate|Oral or parenteral repeating dose
1758202|NCT00266227|Drug|folate|Intravenous repeating dose
1758203|NCT00266240|Drug|GK Activator (2)|Escalating doses po bid
1758204|NCT00266240|Drug|Placebo|po bid
1758205|NCT00266253|Drug|GK Activator (2)|Escalating doses, po bid or qd for 12 weeks.
1758206|NCT00266253|Drug|Metformin|As prescribed, for 12 weeks
1758207|NCT00266279|Drug|Oxaliplatin, Capecitabine|"Agent, DOSE AND SCHEDULE (28-days cycle):
Oxaliplatin 85 mg/m2 IV on days 1 and 15 Capecitabine 1500 mg PO BID on days 1-7 and 15-21"
1758208|NCT00266292|Behavioral|Fish oil (Bio-Marine, Pharma Nord)|
1758209|NCT00266292|Behavioral|n-6 PUFA intake (Margarine+sunflower oil vs. butter product+rapeseed oil)|
1758210|NCT00255905|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|
1758211|NCT00255905|Behavioral|Clinician monitoring|
1758212|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 150 mg immediate release followed by DMXB-A 75 mg 2 hours after the intiial dose
1758213|NCT00255918|Drug|Placebo|Placebo dosed to match active medication
1758214|NCT00255918|Drug|Dimethoxybenzylidene anabaseine (DMXB-A)|DMXB-A 75 mg immediate release followed by DMXB-A 37.5 mg 2 hours after the intiial dose
1758215|NCT00255931|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy and Relaxation/biofeedback
1758216|NCT00255931|Behavioral|Attention Placebo|Untrained relaxation
1956747|NCT02717832|Drug|hyperinsulinemic-euglycemic clamp|
1758219|NCT00255957|Drug|HES administration|
1758220|NCT00255957|Drug|Hydroxy Ethyl Starch administration to stroke patients|
1758221|NCT00255970|Other|DFDBA|Demineralized Freeze Dried Allograft bone
1758222|NCT00255970|Device|Regenafil|Demineralized Freeze Dried Bone in a porcine gel carrier
1758223|NCT00255983|Drug|Faropenem medoxomil|600 mg BID for 5 days
1758224|NCT00255983|Drug|placebo|placebo tablets BID for 5 days
1758225|NCT00255996|Drug|linezolid|
1758226|NCT00256009|Drug|Cytotec|
1758227|NCT00256022|Drug|Lactobacillus Probiotic|
1758228|NCT00256022|Other|Lactose Powder|
1758229|NCT00256035|Procedure|Measuring IL-4 levels|
1758230|NCT00256048|Procedure|Nasojejunal feeding|
1758231|NCT00256074|Procedure|Enteral feeding formula|
1758232|NCT00256087|Drug|Probiotic Lactobacillus|
1758233|NCT00256087|Other|Lactose Powder|
1758234|NCT00256100|Drug|Fondaparinux Sodium|The active group of the study will be given fondaparinux 10mg/24 hours for haemofiltration anticoagulation
1758235|NCT00256113|Drug|Saredutant succinate (SR48968C)|
1758237|NCT00256139|Drug|Raptiva|
1758238|NCT00256152|Device|AF Suppression Pacing Algorithm|
1758239|NCT00256165|Device|Tissue valve|Aortic valve replacement
1758240|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
1758241|NCT00256178|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
1758242|NCT00256178|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable simvastatin therapy for up to 24 weeks.
1758243|NCT00256191|Drug|TPI 287 Injection|
1758244|NCT00256204|Drug|Rasagiline Mesylate|tablet, 1mg once daily
1758245|NCT00256204|Drug|Rasagiline Mesylate|tablet, 2mg once daily
1758246|NCT00256204|Other|Placebo|Placebo
1758247|NCT00256217|Drug|Anastrozole|1 mg. oral every day for 2 - 4 weeks
1758248|NCT00256230|Drug|Disulfiram (DSF)|DSF pills at 250 mg will be given orally, two times a day. If this dose is tolerated, the dose will be escalated until the maximum tolerated dose is reached. Treatment will continue every day for 3 months or longer unless the disease gets worse, the side effects are too dangerous for the subject, or the subject decides to discontinue treatment.
1758249|NCT00256243|Drug|Doxorubicin|60 mg/m2 IV, bolus once every 14 days x 2-4 cycles
1758250|NCT00256243|Drug|Cyclophosphamide|600 mg/m2 IV once every 14 days x 2-4 cycles
1758251|NCT00256243|Drug|Paclitaxel|80 mg/m2 IV over 1 hour once weekly for 9-12 doses beginning two weeks after completion of last AC dose
1758252|NCT00256243|Drug|Carboplatin|Area under the concentration curve (AUC) 2 IV once weekly for 9-12 doses beginning two weeks after completion of last AC dose
1758253|NCT00256243|Drug|GM-CSF|250 μg/mL IV on day 5-14 of each subcutaneous cycle of doxorubicin and injection cyclophosphamide
1758254|NCT00256243|Drug|Trastuzumab|AUC 2 IV weekly for 12-16 doses beginning two weeks after completion of last AC dose
1758255|NCT00256256|Drug|glucagon-like-peptide-1|Dose: 1.2pmol/kg/min for 6 hours
1758261|NCT00256295|Drug|Gemcitabine|1000 mg/m2 IV over 100 minutes Every 21 days
1758262|NCT00256295|Drug|Oxaliplatin|65 mg/m2 IV over 120 minutes immediately following gemcitabine Every 21 days
1758268|NCT00256334|Drug|Resveratrol|Patients were randomly assigned to one of four dose cohorts: plant-derived resveratrol tablets (purchased through the Life Extension Foundation, Scottsdale, AZ) at a dose of 80 mg/day, plant-derived resveratrol tablets at a dose of 20 mg/day, Grape Powder (GP) dissolved in water and taken orally (supplied by the California Table Grape Commission) at a dose of 120 g/day, and GP at a dose of 80 g/day.
1758269|NCT00256347|Drug|intramuscular injections of morphine|
1758270|NCT00256360|Drug|dose dense with neulasta|
1758271|NCT00256373|Procedure|Mod. functional restoration-Individ. dynamic back-muscle|
1758272|NCT00256386|Device|Electronic Medical Record (EMR) to clinician's in-basket|
1758273|NCT00256386|Device|Automated Voice Message (AVM) reminder to patient's phone|
1758274|NCT00256386|Procedure|Pharmacy Team phone call-letter followup|
1758275|NCT00256399|Drug|Alfuzosin 10 mg|
1758276|NCT00256412|Drug|Eicosapentaenoic acid (EPA) 0.7 grams/day or 1.5 grams/day|Placebo and Omega 3 capsules. All participants receive 4 capsules with either 0, 2, or 4 capsules containing omega 3.
1758277|NCT00256412|Drug|Placebo|4 capsules of placebo each day
1758279|NCT00256438|Device|Transcranial Direct Current Stimulation|
1758284|NCT00256464|Behavioral|Multi-component Yoga Intervention|
1758285|NCT00256477|Behavioral|Sudarshan KRIYA Breathing Technique|
1758286|NCT00256490|Procedure|PET/CT 20 days after the first cycle of chemotherapy|
1758287|NCT00256503|Behavioral|Cognitive-Behavioral Therapy for Insomnia|Insomnia Subjects receive CBT-I
1758288|NCT00256516|Other|Eco-Atkins diet (high vegetable protein and vegetable fat)|
1758289|NCT00256516|Other|NCEP diet|
1758290|NCT00256529|Procedure|EGD with biopsies|All subjects presenting with dysphagia will undergo an EGD with distal and proximal biopsies of the esophagus.
1758291|NCT00256542|Drug|Alkalinized Lidocaine-Heparin|
1758292|NCT00256555|Drug|Nutropin AQ|
1758293|NCT00256568|Behavioral|reporting system|Nurses and office staff were asked to report all communications with community pharmacists regarding prescription problems
1758294|NCT00256581|Procedure|Additional rest and stress image sets on new camera|
1758296|NCT00256620|Procedure|Mean arterial pressure during cardiopulmonary bypass 80 mmHg vs. customized|
1758297|NCT00256646|Drug|Rosiglitazone|ROSIGLITAZONE (roe si GLI ta zone) helps to treat type 2 diabetes. It helps to control blood sugar. Treatment is combined with diet and exercise.
1758298|NCT00256659|Behavioral|Early assessment and referral to ancillary care services vs. standard care|
1758299|NCT00256672|Device|Thoraco-Lumbar-Sacral-Orthoses (TLSO) / Flex-Foam|TLSO back brace, Flex-Foam (Posterior Opening)
1758300|NCT00256685|Drug|DVS-233 SR|
1758301|NCT00256698|Drug|Fulvestrant|intramuscular injection 250 mg loading dose (LD) regimen
1758302|NCT00256698|Drug|Anastrozole|1 mg oral tablet
1758303|NCT00256711|Drug|Gefitinib|
1758304|NCT00256711|Drug|Vinorelbine|
1758305|NCT00256724|Device|Impedance Threshold Device|Active impedance threshold device
1758306|NCT00256724|Device|sham ITD|sham impedance threshold device
1758307|NCT00256737|Drug|Omeprazole|
1758311|NCT00256776|Drug|Velcade (Bortezomib)|
1758312|NCT00256776|Drug|Thalidomide|
1758313|NCT00256776|Drug|Dexamethasone|
1758314|NCT00256789|Procedure|Radiation|
1758315|NCT00256789|Drug|Chemotherapy|
1758316|NCT00256802|Device|MR-angiography, GTN|
1758317|NCT00256815|Drug|chemotherapy|
1758318|NCT00256815|Procedure|Radiation|
1758474|NCT00258271|Biological|filgrastim|
1758321|NCT00256841|Procedure|Radiation Therapy|
1758324|NCT00256880|Drug|GW786034|
1758325|NCT00256893|Drug|ropinirole|
1758326|NCT00256919|Drug|GW856553|
1758327|NCT00256932|Drug|alvimopan|0.5 mg
1758328|NCT00256932|Drug|Placebo|
1758329|NCT00256945|Procedure|dental restorative material surface preparation|
1758330|NCT00256958|Procedure|total knee replacement|
1758331|NCT00256971|Procedure|meniscectomy|
1758332|NCT00256984|Procedure|Stapled Transanal Resection (STARR) with Transtar (PROXIMATE®) 33 mm Circular Stapler|
1758333|NCT00256997|Drug|Risperidone long-acting injection (LAI)|Risperidone LAI 25 milligram (mg), 37.5 mg or 50 mg intramuscular (injection of a substance into a muscle) injection will be administered every 2 weeks as per Investigator's discretion. An oral atypical antipsychotic will also be administered in the first 3 weeks following the dose increase. Duration of treatment will be 24 months.
1758334|NCT00256997|Drug|Oral atypical Antipsychotic|Oral atypical antipsychotic will be administered as per local label practice for 24 months. Participants will be switched to another atypical oral therapy as per Investigator's discretion.
1758335|NCT00257010|Drug|Almotriptan Malate|Patients will take one 12.5 mg almotriptan malate tablet by mouth after the onset of migraine headache pain
1758336|NCT00257023|Drug|paliperidone|
1758337|NCT00257036|Drug|levofloxacin|
1758338|NCT00257049|Drug|levofloxacin|
1758339|NCT00257062|Drug|Levofloxacin|
1758340|NCT00257075|Drug|Risperidone, oral tablets|
1758341|NCT00257088|Behavioral|whole day first grade program|
1758342|NCT00257101|Behavioral|self-medication monitoring|
1758343|NCT00257114|Drug|bortezomib|
1758344|NCT00257127|Biological|Pneumococcal 7-valent conjugate vaccine|0.5 mL administered intramuscularly
1758345|NCT00257127|Biological|Pneumococcal polysaccharide vaccine|0.5 mL administered intramuscularly
1758346|NCT00257127|Biological|Hepatitis B vaccine|0.5 mL administered intramuscularly
1758347|NCT00257127|Biological|Measles, mumps, and rubella virus vaccine, live|0.5 mL administered subcutaneously
1758348|NCT00257140|Drug|levofloxacin|
1758349|NCT00257153|Device|Coronary thrombus aspiration catheter|
1758350|NCT00257166|Drug|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
1758351|NCT00257166|Drug|placebo oral capsules|Oral placebo capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength administered BID.
1758352|NCT00257192|Drug|placebo|Placebo matching the oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
1758353|NCT00257192|Drug|Ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength or matching placebo. Subjects will be dosed daily for 6 weeks using a flexible dose design with a minimal dose range of 40mg BID to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
1758354|NCT00257205|Drug|dacarbazine|decarbazine 1000 mg/m2 IV Q 21 days x 12
1758355|NCT00257205|Drug|CP-675,206|CP-675,206 15 mg/kg IV Q 90 days x 4
1758356|NCT00257205|Drug|temozolomide|temozolomide 200 mg/m2 orally on Days 1-5 every 28 days x 12
1758357|NCT00257218|Behavioral|Life style modification|
1758358|NCT00257257|Drug|Rimonabant (SR141716)|
1758359|NCT00257270|Drug|gabapentin|
1758360|NCT00257283|Drug|Omega-3-acid ethyl esters 90|
1758361|NCT00257296|Procedure|Screening Protocol for Intimate Partner Violence|
1758362|NCT00257296|Procedure|Intervention Protocol for Intimate Partner Violence|
1758363|NCT00257309|Drug|Tenecteplase + UFH (+ clopidogrel, since 01/97)|
1758364|NCT00257309|Procedure|Primary angioplasty|
1758365|NCT00257322|Drug|GM-CSF|250ug/m^2 SQ QD with a cap of 500mcg SQ QD
1758366|NCT00257335|Procedure|IMRT|
1758367|NCT00257348|Drug|Capecitabine|
1758368|NCT00257348|Drug|Docetaxel|
1758369|NCT00257361|Drug|D-Cycloserine|
1758370|NCT00257374|Drug|Gatorade, Pedialyte and New Solution|
1758371|NCT00257387|Drug|Cyclosporine|
1758372|NCT00257400|Behavioral|Interpersonal Psychotherapy (IPT)|Interpersonal Psychotherapy
1758373|NCT00257400|Behavioral|Individual Psychotherapy|Individual Psychotherapy
1758374|NCT00257413|Procedure|Transplantation of autologous endothelial progenitor cells|
1758375|NCT00257426|Drug|octreotide acetate|200mcg,3 times per day, 7 days per week, up to 36 weeks
1758376|NCT00257452|Drug|tiotropium 18 mcg or 54 mcg qd|
1758377|NCT00257452|Drug|placebo matching tiotropium qd|
1758378|NCT00257452|Drug|moxifloxacin 200 mg|
1758379|NCT00257465|Biological|Autologous, DNP-modified vaccine (M-Vax)|5.0, 2.5, 0.5, or 0 cells
1758380|NCT00257465|Biological|Autologous, DNP-Modified Melanoma Vaccine|5 million cells
1758381|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|2.5 million cells
1758382|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0.5 million cells
1758383|NCT00257465|Biological|Autologous, DNP-Modified Vaccine|0 cells
1758384|NCT00257478|Drug|YM155|
1758385|NCT00257491|Drug|Telmisartan|
1758386|NCT00257491|Drug|Telmisartan/HCTZ|
1758387|NCT00257530|Drug|Imiquimod|
1758388|NCT00257543|Procedure|Alternative donor bone marrow and cord blood|bone marrow transplant - alternative donors for bone marrow and cord blood transplants
1758389|NCT00257556|Drug|Menotrophin|150 IU Menotrophin daily subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
1758390|NCT00257556|Drug|Follitropin alfa|150 IU follitropin alfa daily by subcutaneous injection for a maximum of 13 days. In the event of hyperstimulation, the dose was reduced to 75 IU daily.
1758391|NCT00257569|Drug|Cetirizine Dry Syrup|
1758392|NCT00257582|Drug|Cetirizine Dry Syrup|
1758393|NCT00257595|Drug|Cetirizine Dry Syrup|
1758394|NCT00257608|Drug|bevacizumab|Intravenous repeating dose
1758395|NCT00257608|Drug|placebo|Oral repeating dose
1758396|NCT00257608|Drug|erlotinib HCl|Oral repeating dose
1758397|NCT00257621|Drug|GW640385|
1758398|NCT00257621|Drug|Ritonavir|
1758399|NCT00257634|Drug|dexamethasone to injury site|
1758400|NCT00257647|Other|SV40 vectors carrying siRNA|in vitro only use of gene therapy
1758401|NCT00257660|Drug|Botulinum type A toxin (Dysport®)|500 units
1758402|NCT00257660|Drug|Placebo|500 units
1758403|NCT00257673|Drug|MEM 1003|30 mg twice a day
1758404|NCT00257673|Drug|MEM 1003|90 mg MEM 1003 twice a day
1758405|NCT00257673|Drug|Placebo for MEM 1003|Placebo twice a day
1758406|NCT00257686|Drug|Pitavastatin|
1758407|NCT00257686|Drug|Pravastatin|
1758408|NCT00257699|Drug|Metronidazole placebo|
1758409|NCT00257699|Drug|ciprofloxacin placebo|
1758410|NCT00257699|Drug|ciprofloxacin|500 mg bid po
1758411|NCT00257699|Drug|metronidazole|250 mg bid po / 250 mg tid po / 500 mg bid po depending on body weight
1758414|NCT00257738|Biological|MAGE-A3|Three dose levels of MAGE-A3 vaccine will be tested : 500ug, 1000 ug and 1500 ug
1758415|NCT00257738|Biological|HPV-16 vaccine|Three dose levels of HPV- 16 vaccine will be tested : 500ug, 1000 ug and 1500 ug
1758416|NCT00257751|Procedure|Aprotinine|
1758417|NCT00257764|Behavioral|behavioral swallowing exercises/ strategies|
1758418|NCT00257777|Procedure|Myocardial protection techniques|
1758419|NCT00257790|Drug|Tobramycin once a day|
1758420|NCT00257803|Drug|Oxytocin|See detailed description
1758421|NCT00257803|Drug|Saline solution|See detailed description
1758424|NCT00257829|Drug|Methazolamide|
1758425|NCT00257829|Drug|Cisplatin|
1758427|NCT00257855|Drug|Lamotrigine|
1758428|NCT00257868|Drug|Rivastigmine prevention of delirium|
1758429|NCT00257881|Drug|CMD-193|
1758430|NCT00257894|Drug|Baclofen|Dosing taken orally for a total of 12 days: 40mg/day vs. 0mg/day (placebo tabs). The 40mg condition will receive 15mg/day the first 3 days(Days 1,2,3), 30mg/day for 3 days(Days 4,5,6), and 40mg/day for 3 days(Days 7,8,9). Downward titration: 40mg/day condition will receive 40mg/day(Day 10), 20mg/day(Day 11), and 10mg/day(Day 12).
1758431|NCT00257894|Drug|Placebo|Matched placebo capsules containing inert filler taken orally for a total of 12 days
1758432|NCT00257920|Drug|Zemplar® injection|6 mcg QOD
1758433|NCT00257920|Drug|Hectorol® injection|3.6 mcg QOD
1758434|NCT00257933|Drug|Prednisolone high dose|4 mg/kg/day orally divided every 6 hours (maximum 30 mg per dose)
1758435|NCT00257933|Drug|Prednisolone lower dose|2 mg/kg/day orally divided q 12 (maximum 30mg/dose) alternating with placebo
1758436|NCT00257946|Procedure|Repair of CDH w/SIS Gold|
1758437|NCT00257946|Procedure|Repair of CDH w/Alloderm|
1758438|NCT00257959|Drug|amiodarone beta blocker sotalol|
1758439|NCT00257972|Drug|aripiprazole|
1758440|NCT00257985|Drug|GTN|
1758441|NCT00257998|Procedure|Mobilization|manualtherapy techniques
1758442|NCT00258011|Biological|Aldurazyme (Recombinant Human Alpha-L-Iduronidase)|0.58 mg/kg every week
1758443|NCT00258024|Drug|IPT-sulphadoxinepyrimethamine|
1758444|NCT00258037|Behavioral|Pelvic Floor Muscle training|
1758445|NCT00258050|Drug|GW572016 oral tablets|
1758446|NCT00258063|Drug|EVRA® transdermal contraceptive patch containing 6 mg of norelgestromin and 0.60 mg of ethinyl estradiol (versus CILEST® tablets).|
1758447|NCT00258076|Drug|EVRA transdermal contraceptive patch 6 mg NGMN and 0.75 mg EE|
1758448|NCT00258089|Drug|Levofloxacin|
1758449|NCT00258102|Drug|Levofloxacin|
1758450|NCT00258115|Drug|salsalate|
1758452|NCT00258141|Drug|Rupatadine|
1758453|NCT00258141|Drug|Placebo|
1758454|NCT00258154|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|3 doses of rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
1758455|NCT00258154|Biological|Comparator: placebo|3 doses of placebo to rotavirus vaccine live, oral, pentavalent on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
1758456|NCT00258154|Biological|Comparator: Infanrix(tm) Hexa|3 doses of oral Infanrix(tm) Hexa on Day 1, 28 to 42 days post dose 1 and 28 to 42 days post dose 2
1758457|NCT00258167|Behavioral|"filling the Experience of Caregiving Inventory"|8 weeks of group therapy for family members
1758460|NCT00258193|Drug|MD-1100 Acetate|
1758461|NCT00258206|Biological|rituximab|
1758462|NCT00258206|Drug|cyclophosphamide|
1758463|NCT00258232|Drug|capecitabine|
1758464|NCT00258232|Drug|celecoxib|
1758465|NCT00258232|Drug|irinotecan hydrochloride|
1758466|NCT00258245|Dietary Supplement|ascorbic acid|Ascorbic Acid (Vit C)- 1000 mg IVPB after Arsenic Trioxide [ATO] days 1, 4, 8, 11
1758467|NCT00258245|Drug|arsenic trioxide|Arsenic Trioxide (Trisenox)- 0.10→0.15→0.25 mg/kg/dose IVPB days 1, 4, 8, 11
1758468|NCT00258245|Drug|bortezomib|Bortezomib (Velcade)- 0.7→1.0 mg/m2 IVP days 1, 4, 8, 11
1758469|NCT00258245|Drug|dexamethasone|Dexamethasone (Decadron)- 40 mg/days IVPB or PO d 1, 4, 8, 11
1758470|NCT00258245|Drug|thalidomide|Thalidomide (Thalomid) - 50 mg/day by mouth (PO)
1758471|NCT00258245|Drug|Aspirin|Aspirin - 325 mg by mouth (PO) every day
1758472|NCT00258258|Drug|paricalcitol|
1758473|NCT00258258|Drug|zoledronic acid|
1758478|NCT00258284|Drug|capecitabine|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
1758479|NCT00258284|Drug|docetaxel|Patients receive docetaxel IV over 30 minutes on days 1, 8, and 15 and oral capecitabine twice daily on days 5-18. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients achieving a complete response (CR) receive 2 additional courses of therapy beyond CR
1758480|NCT00258297|Drug|gefitinib|
1758481|NCT00258297|Procedure|conventional surgery|
1758482|NCT00258297|Procedure|enzyme inhibitor therapy|
1758483|NCT00258297|Procedure|neoadjuvant therapy|
1758484|NCT00258297|Procedure|protein tyrosine kinase inhibitor therapy|
1758485|NCT00258297|Procedure|surgery|
1758486|NCT00258310|Drug|capecitabine|Capecitabine 1000mg/day for one year
1758487|NCT00258310|Procedure|Surgery, chemotherapy and/or radiotherapy|Surgery, chemotherapy and/or radiotherapy
1758488|NCT00258323|Drug|cisplatin|20mg/m2d/IV continuous infusion x days
1758489|NCT00258323|Drug|fluorouracil|1000mg/m2/d IV continuous infusion x 4 days
1758490|NCT00258323|Drug|Iressa|250mg po qd days 1-28 then x 2 years
1758491|NCT00258323|Procedure|conventional surgery|conventional surgery
1758492|NCT00258323|Radiation|radiation therapy|150 cGy bid
1758493|NCT00258336|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
1758494|NCT00258336|Biological|rituximab|
1758495|NCT00258336|Biological|sargramostim|
1758496|NCT00258349|Drug|vorinostat|Given orally
1758497|NCT00258349|Drug|trastuzumab|Given IV
1758498|NCT00258362|Drug|carboplatin|Dose = Area-under-the-curve 6 on Day 1 every 3 weeks for 3 cycles.
1758499|NCT00258362|Drug|docetaxel|75 mg/m^2 on Day 1 of each course
1758500|NCT00258362|Radiation|radiation therapy|Weekly, 5 days/week over 6-7 weeks (tailored 4500 cGy)
1758501|NCT00258375|Drug|custirsen sodium|
1758502|NCT00258375|Drug|docetaxel|
1758503|NCT00258388|Drug|custirsen sodium|"640mg IV for 2 hours - Cycle 1: Days -7, -5, -3, 1, 8, 15 (4 week cycle)
Subsequent cycles:
weekly on days 1, 8, 15 (3 week cycles)"
1758504|NCT00258388|Drug|docetaxel|75mg/m2 IV for 1 hour - Day 1 every 3 weeks (3 week cycles)
1758505|NCT00258388|Drug|prednisone|5mg PO BID
1758506|NCT00266305|Behavioral|Fish oil (Dry n-3, BASF)|5 g/oil daily for the first four month of lactation
1758507|NCT00266318|Drug|Interferon Alfacon-1 and Ribavirin|
1758508|NCT00266331|Drug|Reduced glutathione|
1758509|NCT00266344|Drug|MK0928, gaboxadol / Duration of Treatment 3 Weeks|
1758510|NCT00266344|Drug|Placebo / Duration of Treatment 3 Weeks|
1758511|NCT00266357|Drug|MK0928, gaboxadol / Duration of Treatment: 6 days for treatment periods (2 days/dose)|
1758512|NCT00266357|Drug|Placebo / Duration of Treatment: 2 days for screening period|
1758513|NCT00266396|Behavioral|Recommend full weight-bearing|The full weight-bearing group is trained in 4-point gait with crutches and is recommended to put as much weight as tolerated on the leg on which surgery has been performed, immediately after surgery
1758514|NCT00266396|Behavioral|Recommend parital weight-bearing|The partial weight-bearing group is trained in 3-point gait with crutches and is instructed to limit weight-bearing of the affected leg to 20kg for a period of six-weeks. Scales are used to train these participants not to exceed 20kg
1758515|NCT00266409|Drug|Niravam|
1758516|NCT00266409|Drug|SSRI/SNRI|Selective Serotonin Reuptake Inhibitor or Selective Norepinephrine Reuptake Inhibitor
1758517|NCT00266448|Drug|Chlorhexidine solution 4%|
1758518|NCT00266461|Drug|Daikenchuto Extract Granules (TU-100)|
1758519|NCT00266474|Other|Assessment of upper and lower airway colonization, sinonasal symptoms, history, rhinoscopy and rhinomanometry.|
1758520|NCT00266487|Drug|Folic acid|
1758521|NCT00266487|Drug|Vitamin B12|
1758522|NCT00266487|Drug|Vitamin B6|
1758523|NCT00266526|Biological|Recombinant birch pollen|
1758524|NCT00266539|Drug|E-TRANS Fentanyl hydrochloride; Morphine|
1758525|NCT00266552|Drug|risperidone|
1758526|NCT00266565|Drug|Mepolizumab|10mg/kg (max 750 ml) once a month for 3 months
1758527|NCT00266578|Drug|Fluticasone Propionate|Flovent vs. placebo daily for 3 months
1758528|NCT00266591|Drug|topiramate|
1758529|NCT00266604|Drug|Topiramate|
1758530|NCT00266617|Drug|epoetin alfa|
1758531|NCT00266630|Drug|olanzapine|oral, daily
1758532|NCT00266630|Drug|lithium|Dose adjusted according to local package insert
1758533|NCT00266630|Drug|valproate|Dose adjusted according to local package insert
1758534|NCT00266630|Drug|carbamazepine|Dose adjusted according to local package insert
1758535|NCT00267670|Drug|Pentoxifylline|400mg PO TID
1758536|NCT00267670|Drug|Placebo|1 pill PO TID
1758537|NCT00267683|Drug|insulin aspart|
1758538|NCT00267683|Drug|glibenclamide|
1758539|NCT00267696|Drug|Bevacizumab|Bevacizumab(Avastin)=10mg/kg on day 1, day 15 of a 28 day cycle.
1758540|NCT00267696|Drug|Gemcitabine|A regimen consisting of gemcitabine 1000 mg/m2 will be administered on day 1 and day 15 of a 28 day cycle
1758541|NCT00267696|Drug|Carboplatin|
1758542|NCT00267709|Drug|Visilizumab|
1758543|NCT00267722|Drug|Visilizumab|
1758544|NCT00267735|Behavioral|Use of Computerized Decision Aid on Childbirth|
1758545|NCT00267748|Drug|Sunitinib Malate Continuous Daily Dosing|Sunitinib malate starting dose 37.5 mg daily continuous daily regimen.
1758546|NCT00267748|Drug|Sunitinib Malate Schedule 4/2|Sunitinib malate starting dose 50 mg per day for four weeks, followed by a two week off-drug period. This six week cycle is repeated.
1758547|NCT00267774|Device|Fractional flow reserve|
1758548|NCT00267774|Procedure|Angio-guided PCI|
1758549|NCT00267787|Other|genetic analysis|standard of care
1758550|NCT00267813|Drug|Bupropion (Zyban)|1 tablet a day increasing to 2 tablets a day after a week
1758613|NCT00268437|Procedure|conventional surgery|
1758551|NCT00267826|Drug|Rituximab|Intravenous infusion of 1000mg Rituximab (anti-CD20) on days 1 and 15 to patients with atopic dermatitis
1758552|NCT00267839|Behavioral|physical exercise, wellness|
1758553|NCT00267852|Other|as clinical practice|Dosage, form, frequency and duration as per ordinary clinical practice
1758557|NCT00267917|Device|Berodual Respimat|
1758558|NCT00267917|Device|Berodual HFA-MDI|
1758559|NCT00267930|Drug|Vernakalant (oral)|
1758560|NCT00267930|Drug|Placebo comparator|
1758561|NCT00267943|Drug|telmisartan 80 mg + hydrochlorothiazide 25 mg|
1758562|NCT00267956|Drug|CNTO 1275 63 mg|The patients will receive 90 mg (or 63 mg after filtration) subcutaneous injection on Weeks 0, 1, 2, and 3; Placebo subcutaneous injection on Weeks 12 and 16.
1758563|NCT00267956|Drug|Placebo|The patients will receive placebo subcutaneous injection on Weeks 0, 1, 2, and 3; At weeks 12 and 16 the patients will receive CNTo1275 90 mg (or 63 mg after filtration) subcutaneous injection
1758564|NCT00267969|Drug|ustekinumab|Type = exact number, Form = solution for injection, Number = 45 and 90, Unit = mg, Route = subcutaneous (SC) administered at Weeks 0, 4 and 16. Both treatments (45 mg and 90 mg) administered every 12 weeks after Week 16 depending on clinical response.
1758565|NCT00267969|Drug|placebo|Form = solution for injection, route = SC administered at Weeks 0 and 4. At Weeks 12 and 16, placebo will be crossed over to receive ustekinumab 45 mg or 90 mg.
1758566|NCT00268125|Device|Acupression's bracelet|
1758567|NCT00268125|Behavioral|Hygiene and dietetic advices|
1758568|NCT00268138|Drug|elmex gel|elmex gel once a week
1758569|NCT00268151|Drug|Oxaliplatin|
1758570|NCT00268151|Drug|Capecitabine|
1758571|NCT00268164|Drug|lactobacilus acidophilus & bifidobacterium animalis/lactis|
1758572|NCT00268177|Drug|Salmeterol/fluticasone propionate 50/500mcg Diskus|
1758573|NCT00268203|Biological|Iodine I 131 Tositumomab Therapeutic Regimen|Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) which has been trace-labeled with 5 mCi of Iodine-131 (dosimetric dose). Whole body counts using a gamma camera will be obtained 3 times between Days 0 and 7 following the dosimetric dose to determine a patient-specific mCi dose of Iodine-131 calculated to deliver the desired total body dose of radiation (either 65 cGy or 75 cGy). The therapeutic dose is administered 7-14 days after the dosimetric dose. Patients will receive unlabeled Tositumomab (450 mg) followed by Tositumomab (35 mg) labeled with the patient-specific dose of Iodine-131 (median dose in previous studies was approximately 85 mCi). Patients who are obese will be dosed based upon 137% of their calculated lean body mass. Patients will be treated with thyroid blocking medication at least 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
1758574|NCT00268216|Drug|Salmeterol 50mcg/ Fluticasone Propionate 500mcg|
1758575|NCT00268229|Drug|cytarabine|300 mg/m2/day
1758576|NCT00268229|Drug|daunorubicin hydrochloride|45 mg/m2/day
1758577|NCT00268229|Drug|imatinib mesylate|dose escalation (300 mg/day to 800 mg/day).
1758578|NCT00268242|Drug|Gemcitabine Hydrochloride|10 mg/m2/ min IV for 12 hours
1758579|NCT00268242|Drug|Mitoxantrone Hydrochloride|12 mg/m2/day IV (administer over 30-60 minutes) on Day 1, 2 and 3
1758580|NCT00268255|Drug|gefitinib|
1758581|NCT00268255|Procedure|adjuvant therapy|
1758582|NCT00268255|Procedure|enzyme inhibitor therapy|
1758583|NCT00268255|Procedure|neoadjuvant therapy|
1758584|NCT00268255|Procedure|protein tyrosine kinase inhibitor therapy|
1758585|NCT00268255|Procedure|radiation therapy|
1758586|NCT00268255|Procedure|radiosensitization|
1758587|NCT00268281|Device|Left Ventricular Capture Management Software|
1758588|NCT00268294|Device|Cardiac Resynchronization Therapy|
1758589|NCT00268307|Drug|Autologous, Unfractionated Bone Marrow Mononuclear Cells|Intracoronary infusion of Autologous, Unfractionated Bone Marrow Mononuclear Cells. Dose is 100,000,000 cells. One time infusion over 20 minutes.
1758590|NCT00268320|Device|Cardiac Resynchronization Therapy+Implantable Cardioverter Defibrillator|
1758591|NCT00268333|Drug|fluorouracil|
1758592|NCT00268333|Drug|leucovorin calcium|
1758593|NCT00268333|Drug|oxaliplatin|
1758594|NCT00268333|Procedure|neoadjuvant therapy|
1758595|NCT00268346|Drug|ZD1839|ZD1839 treatment will be taken once a day PO, every day about the same time
1758596|NCT00268359|Biological|bevacizumab|
1758597|NCT00268359|Drug|irinotecan hydrochloride|
1758598|NCT00268372|Drug|cisplatin|
1758599|NCT00268372|Drug|docetaxel|
1758600|NCT00268372|Drug|5-fluorouracil|
1758601|NCT00268372|Procedure|surgery|
1758602|NCT00268372|Radiation|radiation therapy|
1758607|NCT00268398|Drug|oxaliplatin, folinic acid, fluorouracil|folinic acid 200 mg/m² (day 1&2) oxaliplatin 85 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1&2) continuous 5FU 600mg/m² (day 1 to 2)
1758608|NCT00268398|Drug|oxaliplatin, irinotecan, folinic acid, fluorouracil|"FOLFOX7 folinic acid 400 mg/m² (day 1) oxaliplatin 130 mg/m² (day 1) continuous 5FU 3000mg/m² (day 1 to 2)
FOLFIRI folinic acid 400 mg/m² (day 1) irinotecan 180 mg/m² (day 1) bolus 5FU 400 mg/m² (day 1) continuous 5FU 2400mg/m² (day 1 to 2)"
1758609|NCT00268411|Drug|gemcitabine hydrochloride|
1758610|NCT00268411|Drug|oxaliplatin|
1758611|NCT00268437|Drug|carboplatin|carboplatin is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
1758612|NCT00268437|Drug|Pemetrexed|Pemetrexed is to be given on days 1 and 22 of the 5 ½ weeks of radiation treatment.
1758614|NCT00268437|Procedure|neoadjuvant therapy|
1758615|NCT00268437|Radiation|radiation therapy|Radiation therapy begins day 1 and continues for 5 ½ weeks (45 Gy in 22-25 fractions of 1.8 Gy to extended field; 50.4 Gy in 28 fractions within boost field).
1758616|NCT00268450|Biological|bevacizumab|
1758617|NCT00268450|Drug|cisplatin|
1758618|NCT00268450|Drug|gemcitabine hydrochloride|
1758619|NCT00268450|Drug|paclitaxel|
1758620|NCT00268450|Procedure|adjuvant therapy|
1758621|NCT00268450|Procedure|conventional surgery|
1758622|NCT00268450|Procedure|neoadjuvant therapy|
1758623|NCT00268463|Drug|capecitabine|"Oral capecitabine 850 mg/m2 twice daily on days 1-14 every 21 days for 8 cycles: Arm 1
Oral capecitabine 850 mg/m2 twice daily on days 22-35 every 42 days for 4 cycles and then on days 1-14 every 21 days for 4 cycles: Arm 2"
1758624|NCT00268463|Drug|floxuridine|Continuous hepatic arterial infusion of floxuridine 0.2 mg/kg on days 1-14 every 42 days for 4 cycles
1758625|NCT00268463|Drug|oxaliplatin|"Oxaliplatin 130 mg/m2 IV over 2 hours on day 1 every 21 days for 8 cycles: Arm 1
Oxaliplatin 130 mg/m2 IV over 2 hours on day 22 every 42 days for 4 cycles and then on day 1 every 21 days for 4 cycles: Arm 2"
1758626|NCT00268476|Drug|Celecoxib|
1758627|NCT00268476|Drug|Docetaxel|
1758628|NCT00268476|Drug|Prednisolone|
1758629|NCT00268476|Drug|ADT|
1758630|NCT00268476|Drug|Zoledronic Acid|
1758631|NCT00268476|Drug|Abiraterone|
1758632|NCT00268476|Procedure|Orchiectomy|
1758633|NCT00268476|Radiation|Radiotherapy to the prostate|
1758634|NCT00268476|Drug|Enzalutamide|
1758635|NCT00268476|Drug|Metformin|
1758636|NCT00268476|Drug|Transdermal Oestradiol|
1758637|NCT00268489|Biological|bevacizumab|
1758638|NCT00268489|Drug|pemetrexed disodium|
1758639|NCT00268502|Other|study of socioeconomic and demographic variables|
1758640|NCT00268502|Procedure|fatigue assessment and management|
1758641|NCT00268502|Procedure|management of therapy complications|
1758642|NCT00268502|Procedure|psychosocial assessment and care|
1758643|NCT00268502|Procedure|quality-of-life assessment|
1758644|NCT00268515|Drug|cyclosporine|
1758645|NCT00268515|Drug|tacrolimus|
1758646|NCT00268515|Drug|prednisone|
1758647|NCT00268515|Drug|azathioprine|
1758648|NCT00268528|Behavioral|compliance monitoring|
1758649|NCT00268528|Other|study of socioeconomic and demographic variables|
1758650|NCT00268528|Drug|mercaptopurine tablet|Given orally
1758651|NCT00268528|Drug|methotrexate|Given orally
1758652|NCT00268541|Behavioral|Physical activity|
1758653|NCT00268554|Drug|dipyridamole|
1758654|NCT00268554|Drug|caffeine|
1758655|NCT00268567|Drug|leflunomide combined with prednisone|
1758656|NCT00268580|Behavioral|Asthma Care Pathway|Asthma care provided using standardized asthma care pathway
1758657|NCT00268593|Drug|PI-88|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
1758658|NCT00268593|Drug|docetaxel|Subcutaneous injection administered 7 days/week for 130 mg PI-88 and 4 days/week for 250 mg PI-88; patients to be treated until progression or withdrawal from study.
1758659|NCT00268593|Drug|prednisone|5 mg twice a day orally
1758660|NCT00268606|Behavioral|cognitive-behavioral therapy|
1758661|NCT00268619|Drug|Ramipril|
1758662|NCT00268632|Drug|risedronate|
1758663|NCT00268645|Drug|Insulin Glargine|
1758664|NCT00268658|Device|SmartStep(tm) biofeedback device|
1758665|NCT00268671|Drug|Docetaxel|
1758666|NCT00268684|Drug|Erlotinib, Temozolomide|
1758667|NCT00268697|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 24 weeks.
1758668|NCT00268697|Drug|Lapaquistat acetate and ezetimibe|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
1758669|NCT00268697|Drug|Ezetimibe|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable ezetimibe therapy for up to 24 weeks.
1758670|NCT00268710|Drug|docetaxel|
1758671|NCT00268723|Drug|Levalbuterol tartrate HFA MDI|levalbuterol MDI 90 mcg QID
1758672|NCT00268723|Drug|Placebo|Placebo MDI QID
1758673|NCT00268749|Drug|glycine|0.8 g/kg/day
1758674|NCT00268762|Drug|argatroban|Argatroban IV Infusion at 1mcg/kg/min for 48 hours.
1758675|NCT00268775|Behavioral|training and follow-up of pharmacists|
1758676|NCT00268775|Behavioral|patient-directed discontinuation letter|
1758677|NCT00268788|Drug|Subcutaneous immunoglobulin|Individually dosed, given twice a week.
1758678|NCT00268788|Drug|Intravenous immunoglobulin|Individual dose and frequency
1758679|NCT00268814|Drug|Diacetylmorphine|Diacetylmorphine (i.v.), daily
1758680|NCT00268814|Behavioral|Psycho-education and Counselling|Psycho-educational group therapy and individual counselling
1758681|NCT00268814|Drug|Methadone|Methadone (p.o.), daily
1758682|NCT00268814|Behavioral|Case management and Motivational interviewing|Individual Case Management combined with Motivational interviewing
1758683|NCT00268827|Drug|Kaletra soft-gel capsules switched to Kaletra tablets|
1758684|NCT00268827|Device|MOS-HIV Health and Medication Satisfaction Survey, Global Conditioning Improvement and Therapy Preference Questionnaire|
1758685|NCT00268840|Drug|Docetaxel|Docetaxel 50 mg/m2 ou 35 mg/m² (suivant le bilan hépatique) à J1 et J15 toutes les 4 semaines
1758686|NCT00268840|Drug|Gemcitabine|Gemcitabine 1200 mg/m2 à J1 et J15 toutes les 4 semaines
1758687|NCT00268853|Drug|CPOP-R|Cyclophosphamide 750 mg/m2, pixantrone 150 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
1758688|NCT00268853|Drug|CHOP-R|Cyclophosphamide 750 mg/m2, doxorubicin 50 mg/m2, vincristine 1.4 mg/m2, rituximab 375 mg.m2 on Day 1 of a 21 day cycle, for 8 cycles Prednisone 100 mg/day on Day 1-5 of a 21 day cycle for 8 cycles
1758689|NCT00268866|Behavioral|Education|
1758690|NCT00268879|Drug|Renzapride|Placebo Renzapride 4 mg QD Renzapride 2 mg BID
1758691|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).
Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
1758692|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).
Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
1758693|NCT00268892|Drug|Degarelix|"Participants who completed the main study initially continued with the same dose in the FE200486 CS15A extension study. A protocol amendment changed the dosage to 360 mg (60 mg/mL) or 480 mg (60 mg/mL).
Drug supplied as a powder to be dissolved in the solvent for solution for injection. Degarelix given by subcutaneous injection every 3 months until the end of the study."
1758694|NCT00268905|Drug|E7389 + carboplatin AUC 5|Patients will receive E7389 before (Schedule A) or after (Schedule B) carboplatin AUC 5 infusion. E7389 will be administered as a 2-5 minute intravenous (IV) bolus infusion at a starting dose of 0.7 mg/m^2 on Days 1 and 8 every 21 days. Carboplatin 5 AUC will be administered as a 30-minute IV infusion on Day 1 every 21 days. Dose escalation will be performed in cohorts of three patients per dose level per schedule.
1758695|NCT00268905|Drug|E7389 + carboplatin AUC 6|"After MTD is reached with carboplatin AUC 5, dose escalation of E7389 in combination with carboplatin at AUC 6 will begin at one dose level below MTD, using the preferred schedule (A or B).
If carboplatin AUC 6 with E7389 is tolerated, the MTD reached will be used to enroll 20 additional patients with Stage IIIB or IV non-small cell lung cancer (NSCLC). If carboplatin AUC 6 is not tolerated, these patients will be enrolled at the MTD determined with the combination of E7389 and carboplatin AUC 5."
1758696|NCT00268905|Drug|E7389+carboplatin AUC 6|In a population of patients who had generally received multiple prior chemotherapies, the eribulin MTD has been determined to be 1.1 mg/m2 in combination with carboplatin at an AUC of 6. The first-line NSCLC patients in the extension arm may tolerate a higher dose of eribulin, because they have not been exposed to the toxicity of other chemotherapies. To investigate this possibility, the dose of eribulin will be increased to 1.4 mg/m2 for subsequent patients, if the first six of these patients do not experience a DLT during their first cycle of eribulin at 1.1 mg/m2 and carboplatin at AUC 6 combination therapy. If no more than one of the first six patients experience a DLT during the first cycle with the 1.4 mg/m2 dose of eribulin, then the 1.4 mg/m2 dose will be considered the recommended dose for front-line NSCLC therapy and the remaining patients will be treated using this dose.
1758697|NCT00268918|Drug|Docetaxel|Participants may continue receiving study drug as long as their disease does not worsen
1758698|NCT00268918|Drug|PTK787|Participants may continue receiving study drug as long as their disease does not worsen
1758699|NCT00268931|Behavioral|Movement Training|This group of infants underwent specific movement training activities two times per day with their parents.
1758700|NCT00268931|Behavioral|Social Training|This group underwent special social interactions with their parents two times each day.
1758701|NCT00268944|Biological|Myozyme|20 mg/kg qow
1758702|NCT00268957|Drug|Sevelamer carbonate (Renvela®)|sevelamer carbonate powder dosed once per day with largest meal
1758703|NCT00268957|Drug|Sevelamer hydrochloride (Renagel®)|Sevelamer hydrochloride tablets dosed three times a day with meals
1758704|NCT00268970|Drug|Satraplatin in combination with Paclitaxel|Paclitaxel 200 mg/m2 IV over 3 hours on day 1. Satraplatin 60 mg/m2 administered by mouth once daily for 5 consecutive days (days 1-5). Satraplatin will be administered within 2 hours following paclitaxel infusion on day 1. Subsequent doses on days 2-5 will be taken at approximately 24 hour intervals.
1758705|NCT00268983|Biological|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric dose: 450 mg Tositumomab infused over 1 hour followed by 5 mCi I 131 Tositumomab infused over 20 minutes
Therapeutic dose: 450 mg Tositumomab infused over 1 hour followed by Individualized mCi activity of I 131 Tositumomab (35 mg) infused over 20 minutes."
1758706|NCT00268983|Biological|Rituximab|Rituximab 375 mg/m2 given as an IV infusion once weekly for four weeks.
1758709|NCT00269009|Behavioral|CHERL|
1758710|NCT00269022|Drug|SB-705498|
1758711|NCT00269035|Drug|SB773812|SB-773812 tablets will be available with dose strength of 60 mg
1758712|NCT00269035|Drug|Risperidone|Risperidone tablets will be available with dose strength of 3 and 6 mg
1758713|NCT00269048|Drug|SB-480848|SB-480848
1758714|NCT00269048|Drug|placebo|placebo
1758715|NCT00269061|Drug|pioglitazone|
1758716|NCT00269074|Drug|IDEA-070|
1758718|NCT00269113|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv monthly for 8 cycles
1758719|NCT00269113|Drug|Standard chemotherapy|As prescribed
1758720|NCT00269126|Drug|fluticasone propionate/salmeterol combination DISKUS|
1758721|NCT00269126|Drug|salmeterol xinafoate|
1758722|NCT00269139|Behavioral|Crisis resolution|
1758723|NCT00269152|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 4 cycles
1758724|NCT00269152|Drug|cisplatin|75 mg/m^2, intravenous (IV), every 21 days x 4 cycles
1758725|NCT00269152|Drug|carboplatin|area under the curve (AUC) 5 milligrams per milliliter*minute (mg/ml*min), intravenous (IV), every 21 days x 4 cycles
1758726|NCT00269165|Procedure|Balloon Aortic Valvuloplasty|
1758727|NCT00269165|Procedure|External Beam Radiation|
1758728|NCT00269178|Behavioral|Peer Health Education Programme|
1758729|NCT00269191|Drug|MK0663, etoricoxib / Duration of Treatment 12 Weeks|
1758730|NCT00269191|Drug|Placebo or Ibuprofen / Duration of Treatment 12 Weeks|
1758731|NCT00269204|Drug|niacin (+) laropiprant|Duration of Treatment - 24 weeks
1758732|NCT00269204|Drug|ER-niacin|Duration of Treatment - 24 weeks
1758733|NCT00269217|Drug|niacin (+) laropiprant (+) simvastatin|Duration of Treatment 12 Weeks
1758837|NCT00270036|Drug|epoetin alfa|
1758734|NCT00269217|Drug|Comparator: niacin (+) laropiprant|Duration of Treatment 12 Weeks
1758735|NCT00269217|Drug|Comparator: simvastatin|Duration of Treatment 12 Weeks
1758736|NCT00269230|Device|Pacing Lead|Left ventricular pacing lead
1758737|NCT00269243|Drug|Quinapril|
1758738|NCT00269269|Drug|antihypertensive drug|
1758739|NCT00269269|Behavioral|placebo|
1758740|NCT00269282|Behavioral|Self-Management Training|Asthma education and self-monitoring strategies
1758741|NCT00269282|Behavioral|Motivational Interviewing (MI)|Motivational Interviewing (MI) is a promising interventional approach that uses a client-centered, non-directive approach for enhancing motivation to change health behaviors.
1758742|NCT00269295|Biological|Ty800|Live attenuated Ty800 S typhi oral vaccine is co-administered with a sodium bicarbonate buffer solution. Dosages: 5 X 10^7 cfu, 5 X 10^8 cfu, and 5 X 10^9 cfu.
1758743|NCT00269295|Drug|Placebo|150 mL of the prepared sodium bicarbonate buffer solution. Placebo will look and taste essentially like the study product.
1758744|NCT00269308|Procedure|Chiropractic Manual treatment + home exercise ( procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation and mobilization with light soft tissue massage as indicated to facilitate the manual therapy.
Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
1758745|NCT00269308|Procedure|Supervised rehabilitative exercise + home exercise|"The rehabilitative exercise program will consist of 20, 1 hour small-group sessions. It is a modification of exercise protocols used in previous studies by the investigators and others and incorporates recommendations of leading rehabilitative exercise specialists. The program will include exercises that reduce joint stiffness and relax elastic structures resulting in lower joint loads during movements.
Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active"
1758746|NCT00269308|Behavioral|Home exercise|Patients will attend 4, 1-hour small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about neck pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
1758747|NCT00269321|Procedure|Chiropractic Manual treatment + home exercise (procedure+behavior)|"The number of treatments will be determined by the individual chiropractor. Chiropractic manual treatment will be limited to gentle spinal manipulation, mobilization and flexion-distraction therapy with light soft tissue massage as indicated to facilitate the manual therapy.
Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
1758748|NCT00269321|Procedure|Supervised rehabilitative exercise+home exercise|"The rehabilitative exercise program will consist of 20, 1-hour sessions. It is a modification of exercise protocols used in previous studies by the investigators and incorporates recommendations of leading rehabilitative exercise specialists.
Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active."
1758749|NCT00269321|Behavioral|Home exercise|Patients will attend 4, 45-minute small-group sessions at weeks 1, 2, 4 and 8. At the first two sessions they will be given information about low back pain and shown exercises to perform at home. Emphasis will be placed on the importance of staying active.
1758750|NCT00269334|Drug|Using Citalopram(drug) or Paroxetine(drug)|
1758751|NCT00269347|Procedure|Chiropractic Spinal Manipulation|
1758752|NCT00269347|Procedure|Exercise|
1758753|NCT00269347|Behavioral|Self-care|
1758754|NCT00269360|Procedure|Chiropractic + Supervised Rehabilitative Exercise|"Chiropractic care will include manual spinal manipulation, with light soft tissue massage as indicated to facilitate the spinal manipulative therapy. The spinal levels treated will be determined by the individual chiropractors by static and/or motion palpation.
Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises."
1758755|NCT00269360|Procedure|Supervised Rehabilitative Exercise|Patients will attend 20, 1 hour sessions of rehabilitative exercises for the neck and upper body. Each session will begin with a 10-minute aerobic warm-up of the upper body and five minutes of light stretching to prepare for the strengthening exercises.
1758756|NCT00269360|Behavioral|Self-care education|Self-care education will be provided by the therapist trained in the study protocol. Two, one-hour sessions will be given regarding self-care measures and ergonomics relative to work and activities of daily living. These will include postural instructions and practical demonstrations of proper body mechanics performed with patient participation.
1758757|NCT00269373|Procedure|PET-CT|no drugs included
1758758|NCT00269386|Drug|Clarithromycin|Clarithromycin S/R 1g once daily April 2004 - Clarithromycin S/R (Klaricid XL) ceased to be abailable and subsequent patients will receive standard Clarithromycin 500mg bd
1758759|NCT00269386|Drug|Placebo|
1758760|NCT00269399|Drug|Rifaximin (Xifaxan)|
1758761|NCT00269412|Drug|Rifaximin|
1758762|NCT00269425|Behavioral|American Heart Association Step 2 diet|Low fat diet with patient education and diet analysis
1758763|NCT00269425|Behavioral|Mediterranean diet|Mediterranean style diet with patient education and diet analysis
1758764|NCT00269438|Drug|5 ASA, enemas, suppositories, corticosteroids|
1758765|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1758766|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1758767|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1758768|NCT00269477|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1758769|NCT00269490|Behavioral|Yoga Nidra|
1758770|NCT00269503|Procedure|Prone Distraction|
1758771|NCT00269503|Procedure|Side-Posture Manipulation|
1758838|NCT00270049|Drug|epoetin alfa|
1758772|NCT00269503|Procedure|Side-Posture Manipulation & Prone Distraction|
1758773|NCT00269503|Procedure|Usual Care (Control Group)|
1758774|NCT00269516|Drug|pardoprunox|fixed dose 6 mg
1758775|NCT00269516|Drug|Pardoprunox|fixed dose 12 mg
1758776|NCT00269516|Drug|Pardoprunox|12-42mg
1758777|NCT00269516|Drug|Placebo|Placebo
1758778|NCT00269529|Procedure|femoral nerve block|
1758779|NCT00269529|Procedure|knee infiltration and injection via catheter|
1758780|NCT00269542|Drug|Zinc and iron folic acid - Intervention|The intervention group tablet contained 10 mg of elemental zinc, 12.5 mg of iron and 50 micrograms of folic acid.
1758781|NCT00269542|Drug|Iron Folic Acid alone - Placebo|The control group tablets were similar in composition, appearance and taste except it contained placebo for zinc.
1758782|NCT00269555|Drug|Genistein Combined Polysaccharide (GCP)|
1758783|NCT00269568|Drug|mifepristone and misoprostol|
1758784|NCT00269581|Other|Educational CD-rom|Educational CD-Rom
1758785|NCT00269581|Other|Headstrong CD-rom|Headstrong CD-rom
1758786|NCT00269594|Drug|Lamictal (lamotrigine)|
1758787|NCT00269607|Drug|Implantation of naltrexone implants|
1758788|NCT00269620|Drug|ethinyl estradiol/etonogestrel vaginal ring|vaginal ring for cyclic use (3 weeks in, 1 week out)
1758789|NCT00269620|Drug|ethinyl estradiol/norelgestromin transdermal contraceptive|contraceptive patch worn for 7 days and replaced for use for 3 consecutive weeks followed by a one-week patch free interval
1758790|NCT00269633|Device|Blue Light Box 467 nm|467 nm Blue LED Light
1758791|NCT00269633|Device|Red Light Box 657 nm|657 nm Red LED Light
1758792|NCT00269646|Behavioral|Low-carbohydrate and high-carbohydrate diets|Each subject will consume two different ad libitum diets, each for four weeks, with a 4-week washout period inbetween each diet.
1758793|NCT00269672|Biological|13-valent Pneumococcal Conjugate Vaccine|
1758794|NCT00269685|Drug|vasopressin|
1758795|NCT00269724|Drug|OROS® oxybutynin|
1758796|NCT00269737|Drug|Fentanyl Transdermal Therapeutic System (TTS)|
1758797|NCT00269750|Drug|OROS® oxybutynin or Ditropan®|
1758798|NCT00269763|Drug|Fentanyl Transdermal Therapeutic System (TTS)|
1758799|NCT00269776|Drug|Placebo|Treatment C: Three OROS placebo tablets once daily + 1 placebo capsule 3x times/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
1758800|NCT00269776|Drug|OROS (methylphenidate HCl)|Treatment A: 1, 2, or 3 OROS methylphenidate 18-mg tablets + 0, 1, or 2 OROS placebo tablets (3 tablets in total) once daily + 1 placebo capsule 3x/day for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
1758801|NCT00269776|Drug|Ritalin (methylphenidate)|Treatment B: 5, 10, or 15-mg tablets (encapsulated/single capsule) 3 times a day + 3 OROS placebo tablets once daily for 7 days. Each patient will be randomized to 1 of 9 treatment sequences each consisting of 3 7-day treatment periods of Treatment A, B, and C.
1758802|NCT00269789|Drug|Ritalin|
1758803|NCT00269789|Drug|OROS Methylphenidate HCl|
1758804|NCT00269789|Drug|Placebo|
1758805|NCT00269802|Drug|OROS methylphenidate HCl|
1758806|NCT00269802|Drug|Ritalin|
1758807|NCT00269802|Drug|Placebo|
1758808|NCT00269815|Drug|methylphenidate HCl|
1758809|NCT00269828|Drug|paclitaxel|
1758810|NCT00269828|Drug|paclitaxel poliglumex|
1758811|NCT00269841|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
1758812|NCT00269841|Drug|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
1758813|NCT00269841|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
1758814|NCT00269854|Drug|Infliximab 5 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 10 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2 and 6.
1758815|NCT00269854|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 5 mg/kg will be administered as infusion at Week 0, 2 and 6.
1758816|NCT00269854|Drug|Infliximab 20 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 20 mg/kg will be administered as infusion at Week 0, 2 and 6.
1758817|NCT00269854|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2 and 6.
1758818|NCT00269867|Drug|Placebo|Matching placebo will be adminstered at Week 0, 2, 6 and every 4 weeks up to Week 54.
1758819|NCT00269867|Drug|Infliximab 3 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
1758820|NCT00269867|Drug|Infliximab 10 mg/kg|Infliximab (anti-TNF chimeric monoclonal antibody [cA2]) 3 milligram per kilogram (mg/kg) will be administered as infusion at Week 0, 2, 6 and every 8 weeks or every 4 weeks up to Week 52.
1758821|NCT00269880|Drug|Placebo|Placebo is administered as bolus or 12 hour infusion prior to index percutaneous coronary intervention.
1758822|NCT00269880|Drug|Heparin|Heparin is administered as either high dose (100 units/kg of body weight) or low dose (70 units/kg of body weight) boluses.
1758823|NCT00269880|Drug|Abciximab|Abciximab is administered as bolus followed by 12 hour infusion prior to index percutaneous coronary intervention.
1758824|NCT00269893|Drug|Abciximab|0.25 mg/kg of body weight of abciximab either bolus or infusion.
1758825|NCT00269893|Drug|Placebo|Matching Placebo soulution either bolus or infusion.
1758826|NCT00269906|Drug|Abciximab|
1758827|NCT00269906|Drug|Placebo|
1758828|NCT00269919|Drug|Risperidone Long-Acting Injectable (RLAI)|The RLAI 25 mg or 37.5 mg or 50 mg will be administered intramuscularly depending on Investigator's discretion every 2 weeks for 2 years.
1758829|NCT00269932|Drug|levofloxacin|
1758830|NCT00269945|Drug|epoetin alfa|
1758831|NCT00269958|Drug|epoetin alfa|
1758832|NCT00269971|Drug|epoetin alfa|
1758833|NCT00269984|Drug|Epoetin alfa|
1758834|NCT00269997|Drug|epoetin alfa|
1758835|NCT00270010|Drug|epoetin alfa|
1758836|NCT00270023|Drug|epoetin alfa|
1758846|NCT00270153|Drug|enalapril|5mg enalapril vs placebo pill po daily for 6 months
1758847|NCT00270166|Drug|epoetin alfa|
1758848|NCT00270179|Drug|epoetin alfa|
1758849|NCT00270192|Behavioral|individual lactation counseling and educational material|
1758850|NCT00270192|Behavioral|educational material alone|
1758851|NCT00270192|Behavioral|routine antenatal care without educational intervention|
1758852|NCT00270205|Biological|LC002 standard vaccination|0.1 mg DNA/participant, 0.8 ml total administered subcutaneously
1758853|NCT00270205|Biological|LC002 high-dose vaccination|0.4 mg DNA/participant, 3.2 ml total administered subcutaneously
1758854|NCT00270205|Biological|LC002 placebo vaccination|Placebo vaccination administered subcutaneously
1758855|NCT00270218|Biological|VRC-HIVADV014-00-VP|HIV-1 recombinant adenoviral vector vaccine given as a 1 mL intramuscular injection in the deltoid
1758856|NCT00270218|Biological|VRC-HIVDNA009-00-VP|HIV-1 DNA plasmid vaccine given as a 1 mL intramuscular injection in the deltoid
1758857|NCT00270218|Biological|FFB|Adenoviral vector FFB given as a 1 mL intramuscular injection in the deltoid
1758858|NCT00270218|Biological|PBS|phosphate buffered saline
1758859|NCT00270231|Drug|Naltrexone|"All participants took naltrexone during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo; all study medication periods were separated by a 5-7 day washout period.
Dosing of the naltrexone was the same for all participants: Day 1: 12.5mg, Day 2: 25mg, Days 3 and 4: 50mg."
1758860|NCT00270231|Drug|Placebo|"All participants took a placebo (sugar pill) during one of the two 4-day study medication periods. Both 4-day study medication periods were randomized and counterbalanced between naltrexone and placebo.
Placebo capsules matched the naltrexone in color, weight and inactive ingredients. The only difference the lack of active naltrexone in each capsule."
1758861|NCT00270244|Behavioral|Group interpersonal psychotherapy for depressed adolescents (IPT-AG)|Participants assigned to IPT-AG will attend two to three, 40-minute individual pre-group sessions, followed by 12, 90-minute group therapy sessions and two additional individual sessions—one midway through the group sessions and another upon completion of group therapy. Sessions will focus on problems in interpersonal relationships.
1758862|NCT00270244|Behavioral|Treatment as usual (TAU)|TAU will consist of counseling sessions as regularly conducted by the school clinic social worker and/or referral to another agency.
1758863|NCT00255827|Biological|HyperAcute-Pancreatic Cancer Vaccine|
1758864|NCT00255840|Behavioral|Monitoring by an HIV-trained medical doctor|Participants will receive care from an HIV-trained medical doctor
1758865|NCT00255840|Behavioral|Monitoring by an HIV-trained primary care nurse|Participants will receive care from an HIV-trained primary care nurse
1758866|NCT00255840|Drug|Efavirenz|600 mg tablet taken orally daily
1758867|NCT00255840|Drug|Lamivudine|150 mg tablet taken orally daily
1758868|NCT00255840|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100mg ritonavir tablet taken orally twice daily
1758869|NCT00255840|Drug|Nevirapine|200 mg tablet taken orally for 14 days before taking a 200 mg tablet orally twice daily
1758870|NCT00255840|Drug|Stavudine|Tablet taken orally daily. Dosage depends on weight.
1758871|NCT00255866|Behavioral|Skills training for the care of dementia patients|
1758872|NCT00255879|Drug|Quetiapine|
1758873|NCT00255879|Drug|Risperidone|
1758874|NCT00255879|Drug|Olanzapine|
1758875|NCT00261274|Procedure|Enzyme converted ECO red blood cells|
1758876|NCT00261287|Drug|Ciclesonide|
1758877|NCT00261300|Drug|Pantoprazole|Long term Pantoprozole trial
1758878|NCT00261313|Drug|Neulasta|6mg Neulasta to be given approximately 24 hours afer each cycle of chemotherapy
1758879|NCT00261313|Drug|Aranesp|If Hb drops below 110, 300mcg Aranesp will be administered.
1758882|NCT00261339|Drug|Pantoprazole|
1758883|NCT00261352|Drug|Tesaglitazar|
1758884|NCT00261352|Drug|Metformin|
1758885|NCT00261352|Drug|Fenofibrate|
1758886|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 3 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
1758887|NCT00261365|Drug|Ipilimumab|Solution, Intravenous, 10 mg/kg, 3 weeks, 12 - 48 weeks depending on the response.
1758888|NCT00261378|Device|Transarterialchemoembolisation (TACE)|
1758889|NCT00261378|Device|DC Bead with Doxorubicin|
1758890|NCT00261391|Drug|Marimastat|
1758891|NCT00261404|Drug|TNFerade™|
1758892|NCT00261417|Drug|Tesaglitazar|
1758893|NCT00261430|Behavioral|GAIN Acceptance Approach|
1758894|NCT00261443|Drug|Lithium or Valproate with placebo (PBO)|"Tablets, Oral, once daily
lithium 250-2100 mg/day
valproate 250-2500mg/day
Placebo once daily"
1758895|NCT00261443|Drug|Lithium or Valproate with Aripiprazole|"Tablets, Oral, once daily, 52 weeks post randomization (Pre-Randomization Phases 13-24 weeks)
lithium 250-2100 mg/day
valproate 250-2500mg/day
aripiprazole 15-30 mg/day"
1758896|NCT00261456|Behavioral|PSA test|Patients tested for their level of Prostate Specific Antigen.
1758897|NCT00261456|Procedure|Prostate Biopsy|A Prostate biopsy is given as an option to the patient if their PSA level is raised or at the end of 5 years screening.
1758898|NCT00261469|Drug|topiramate|
1758899|NCT00261482|Drug|norelgestromin + ethinyl estradiol|
1758900|NCT00261495|Drug|OROS hydromorphone HCl|8 to 32 mg once daily for 52 weeks (flexible dosing)
1758901|NCT00261495|Drug|Oxycodone|10, 20, or 40 mg twice a day for 52 weeks (flexible dosing)
1758902|NCT00261508|Drug|risperidone|
1758903|NCT00261521|Drug|epoetin alfa|
1758904|NCT00261547|Drug|Rituximab|All subjects will be treated with Rituximab 1000 mg (1 g) intravenously on days 1 and 15.
1758905|NCT00261560|Drug|acetaminophen|
1758906|NCT00261573|Drug|galantamine hydrobromide|
1758907|NCT00261586|Drug|aspirin, acetaminophen, ibuprofen, naproxen, celecoxib, rofecoxib|
1758908|NCT00261599|Drug|AQUAVAN® (fospropofol disodium) Injection|
1758909|NCT00261599|Drug|Midazolam HCI|
1758910|NCT00261612|Drug|bortezomib|
1758911|NCT00261612|Drug|rituximab|
1758913|NCT00261612|Procedure|treatment protocol|
1758914|NCT00261625|Drug|alendronate|
1758915|NCT00261664|Device|telehomecare|
1758916|NCT00261677|Drug|epoetin alfa|
1758917|NCT00261690|Behavioral|Virtual Reality Distraction|Using virtual reality distraction during a procedure
1758918|NCT00261703|Drug|Docetaxel, Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Docetaxel 75 mg/m2, Day 1 of the cycle + Cisplatin 75 mg/m2 Day 1 + 5-FU 750 mg/m2/day in 24-h continuous infusion for 5 days. 3 cycles will be administered, every 21 days, before the local-regional treatment (same as control group)
1758919|NCT00261703|Drug|Cisplatin, 5-fluorouracil (5-FU), radiotherapy|Cisplatin 100 mg/m2 Day 1, 5-FU 1000 mg/m2/day in 24-h continuous infusion for 5 consecutive days. 3 cycles will be administered every 21 days, before the local-regional treatment (same as control group)
1758920|NCT00261703|Other|Cisplatin + radiotherapy|Cisplatin 100 mg/m2 on days 1, 22 and 43 simultaneously with radiotherapy (2 Gy x 1/day, 5 days per week for 7 weeks-tumor- and 2 Gy x 1/day, 5 days per week for 6 weeks- lymph nodes)
1758921|NCT00261716|Behavioral|IPS|Individual Placement and Support Evidence based supported employment
1758922|NCT00261716|Behavioral|IE|Four sessions of manualized illness education about schizophrenia/schizoaffective disorder (tailored to the participant diagnosis) prior to each course of a job search
1758923|NCT00261716|Behavioral|VOMI|Four sessions of manualized motivational interviewing oriented to employment goals and concerns prior to each course of a job search
1758924|NCT00261729|Drug|Paroxetine|paroxetine 20 mg
1758925|NCT00261729|Drug|Prazosin|Prazosin
1758926|NCT00261729|Drug|placebo|placebo capsules
1758927|NCT00261742|Drug|Penicillin versus cefuroxim per os|
1758928|NCT00261755|Procedure|Acupuncture|Based on international experiences and experiences from the pilot project 34 specified acupuncture points could be used.Treatment was individualised according to the woman's mobility and localization of pain. Needles were sterile stainless steel acupuncture needles in three lengths: 0.20 x 15 mm, 0.30 x 30 mm and 0.35 x 50 mm. No electric stimulation was used. The duration of needling could vary from 30 minutes to two hours and could be repeated. The needles were removed if the patient felt uncomfortable or in cases with obstetric pathology.
1758929|NCT00261755|Other|TENS|The Transcutaneous Electric Nerve Stimulation (TENS treatment) was carried out using a B.C - TENS 120Z unit. Two to four electrodes were placed on the skin of the lower back. The units were set in constant mode, initially with a pulse width of 60 micro-seconds and a pulse rate of 100 pulses per second. The treatment lasted from 20 to 45 minutes and could be repeated. The intensity of stimulation could be adjusted by the woman or the midwife.
1758930|NCT00261755|Other|Traditional Group|All analgesic methods available (Sterile water papules, nitro oxygen, bath tub, pethidine and epidural analgesics (EDA)). A specific analgesic was chosen by the woman and the midwife after informed choice.
1758931|NCT00261768|Behavioral|Digital noise reduction|
1758932|NCT00261781|Behavioral|Treadmill training|Walking on a treadmill 3 times per week for 6 weeks
1758933|NCT00261794|Behavioral|computer-assisted cognitive remediation (CACR)|36 individual computer sessions with a staff clinician. computer activities consist of commercially available educational software designed for use in the classroom.
1758934|NCT00261794|Behavioral|manualized computer control condition (RC).|36 sessions of a manualized computer control condition.
1758935|NCT00261807|Drug|Daptomycin 6mg/kg/day|
1758936|NCT00261820|Drug|tacrolimus|
1758937|NCT00261820|Drug|mycophenolate mofetil|
1758938|NCT00261820|Drug|methylprednisolone|
1758939|NCT00261820|Drug|prednisolone|
1758940|NCT00261820|Drug|sirolimus|
1758941|NCT00261833|Biological|Alpha1-proteinase inhibitor|60 mg/kg body weight/week intravenous
1758942|NCT00261833|Other|Placebo|Lyophilized preparation: 60 mg/kg body weight/week intravenous
1758943|NCT00261846|Drug|Bosutinib|"Part 1, starting dose 400 mg oral, daily dosing in the dose-escalation component.
Part 2, 500 mg oral, continuous, daily dosing."
1758944|NCT00261859|Behavioral|BNI|behavioral- brief intervention
1758945|NCT00261872|Drug|Methylphenidate|
1758946|NCT00261898|Procedure|Increase sleep|
1758947|NCT00261911|Drug|sibutramine|
1758948|NCT00261924|Device|Transfusion of Pathogen Inactivated Platelets stored for 6-7 days|pathogen inactivation of platelets for transfusion
1758949|NCT00261937|Drug|Inhaled Furosemide vs Placebo (Normal Saline)|
1758950|NCT00261950|Drug|Sensipar (Cinacalcet HCl)|All enrolled subjects receive study medication at a starting dose of 30 mg cinacalcet once daily beginning on day 1. Possible sequential doses are 30 mg, 60mg, 90mg, 120mg, 180 mg taken once daily. During the study, dose adjustment (dose increase/decrease/withholding) is based upon iPTH, serum calcium, and subject safety information. Subjects swallowed tablets whole without biting or chewing. Subjects were dispensed investigational product every 4 weeks starting from Day 1 through to Week 48.
1758951|NCT00261963|Device|ultraviolet light|
1758952|NCT00261976|Drug|Infliximab (Remicade)|This is an non-interventional study. Participants took the study product as part of their medical routine.
1758953|NCT00262002|Biological|MenACWY Ad- (MenACWY-CRM, non adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated without adjuvant was injected IM (intramuscularly) in the anterolateral area of the right thigh.
1758954|NCT00262002|Biological|MenACWY Ad+ (MenACWY-CRM, adjuvanted formulation)|MenACWY-CRM conjugate vaccine formulated with adjuvant was injected IM in the anterolateral area of the right thigh.
1758955|NCT00262002|Biological|MenACWY PS (MenACWY-CRM, polysaccharide vaccine)|MenACWY polysaccharide vaccine was injected in the anterolateral area of the right thigh.
1758956|NCT00262002|Biological|HBV (Hepatitis B vaccine)|Hepatitis B vaccine at 2, 4, 6 months of age administered IM in the anterolateral area of the left thigh.
1758957|NCT00262002|Biological|Prevnar (pneumococcal polysaccharide serotypes 4, 9V, 14, 18C, 19F, 23F & 6B conjugated to the CRM197)|Prevnar was administered IM in the anterolateral area of the left thigh.
1758958|NCT00262002|Biological|MMR (Measles, Mumps and Rubella vaccine)|MMR at 12 month of age, administered in the left arm.
1758959|NCT00262002|Biological|DTaPHibIPV (Diphtheria, Tetanus, acellular Pertussis, H. Influenzae type b, Inactivated Poliovaccine)|DTaPHibIPV at 2, 3, 4 months of age, administered IM in the anterolateral area of the left thigh.
1759013|NCT00262470|Drug|Indomethacin|Indomethacin 25-50 mg PO x 1 dose
1758960|NCT00262002|Biological|Menjugate (Men C conjugated vaccine)|Menjugate was injected IM in the anterolateral area of the right thigh.
1758961|NCT00262015|Biological|· Meningococcal C conjugate vaccine; Meningococcal A/C Polysaccharide vaccine (partial dose)|
1758962|NCT00262028|Biological|MenACWY-CRM Vaccine|
1758963|NCT00262028|Biological|MenACWY-PS Vaccine|
1758964|NCT00262041|Biological|MenACWY-CRM conjugate vaccine, adjuvanted|
1758965|NCT00262041|Biological|MenACWY-CRM conjugate vaccine, unadjuvanted|
1758966|NCT00262041|Biological|MenACWY polysaccharide vaccine|
1758967|NCT00262054|Drug|Bivalirudin|bivalirudin to be administered as an intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure.
1758968|NCT00262054|Drug|Un-fractionated heparin|UFH is given as an intravenous bolus of 140 units/kg followed by infusion of placebo 1.75 mg/kg per hour for the duration of the procedure.
1758969|NCT00262067|Drug|Bevacizumab|Patients received bevacizumab until disease progression, treatment limiting toxicity, or death due to any cause up to a maximum treatment duration of 48 months. The dose of bevacizumab was based on the patient's weight at either screening or baseline and remained the same throughout the blinded treatment phase of the study. The initial dose was delivered over 90±10 minutes. If there were no infusion related adverse events (fever and/or chills), the second infusion was delivered over 60±10 minutes. If the 60 minute infusion was well tolerated, all subsequent infusions were delivered over 30±10 minutes.
1758970|NCT00262067|Drug|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody.
1758971|NCT00262067|Drug|Chemotherapy|"The chemotherapy was selected by the investigator prior to randomization. Chemotherapy treatment continued until disease progression, unacceptable toxicity, investigator/patient decision, or death, whichever occurred first, except for the anthracycline-based regimens, which had a maximum treatment duration of 8 cycles.
Taxanes - 1 of the following 2 taxanes on Day 1 of every 21-day cycle
Docetaxel 75-100 mg/m^2 IV
Paclitaxel protein-bound particles (Abraxane®) 260 mg/m^2 IV
Anthracyclines - 1 of the following 4 anthracycline-based regimens on Day 1 of every 21-day cycle
5-fluorouracil 500 mg/m^2 IV + epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV
5-fluorouracil 500 mg/m^2 IV + doxorubicin 50 mg/m^2 IV + cyclophosphamide 500 mg/m^2 IV
Doxorubicin 50-60 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV
Epirubicin 90-100 mg/m^2 IV + cyclophosphamide 500-600 mg/m^2 IV
Capecitabine: 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day cycle"
1758972|NCT00262080|Drug|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
1758973|NCT00262080|Drug|Phosphate Buffer Saline (PBS),|given as three 1mL subcutaneous injections.
1758974|NCT00262106|Drug|PRO 2000/5|Gel
1758975|NCT00262106|Drug|Placebo|Placebo
1758976|NCT00262119|Device|Pacemaker Medtronic EnRhythm|Pacemaker specific programming
1758977|NCT00262132|Drug|Mycophenolate|
1758978|NCT00262145|Drug|tea extracts|
1758979|NCT00262184|Drug|Soy Isoflavone|
1758980|NCT00262197|Behavioral|Customized Physician Intervention|
1758981|NCT00262197|Behavioral|Customized Patient Intervention|
1758982|NCT00262210|Drug|Cyclophosphamide Epirubicin Etoposide Prednisolone|
1758983|NCT00262223|Behavioral|Seeking Safety|Seeking Safety cognitive-behavioral treatment intervention for comorbid PTSD and substance use disorders
1758984|NCT00262223|Drug|Sertraline|An anti-depressant medication, selective serotonin reuptake inhibitor (SSRI) type
1758985|NCT00262223|Drug|Pill placebo|
1758986|NCT00262236|Drug|Aliskiren|
1758987|NCT00262249|Drug|somatropin|
1758988|NCT00262262|Drug|Levetiracetam (drug)|The starting dose of levetiracetam was 500 mg/day and the dose was increased with 500 mg every other day to 6 tablets of 500 mg (Keppra, UCB, Belgium), divided into two doses daily corresponding to 3000 mg/day. The dose was kept at this level throughout the remaining treatment period - 4 weeks total. Six placebo tablets with identical appearance were dosed similarly to levetiracetam in the placebo phase.
1758989|NCT00262275|Drug|Aspirin, Clopidogrel|
1758990|NCT00262288|Drug|i.v. recombinant human C1 inhibitor|
1758991|NCT00262301|Drug|recombinant human C1 inhibitor|IV
1758992|NCT00262301|Drug|Placebo|IV
1758993|NCT00262327|Drug|Antangiogenesis|
1758994|NCT00262327|Genetic|endostatin gene|
1758995|NCT00262340|Other|Non invasive measurement of airway inflammation|Airway inflammation will be assessed non-invasively using induced sputum and exhaled nitric oxide. In the active group the results of these tests will be used to determine if asthma treatment should be changed. In the comparator group treatment changes will be based according to conventional symptom based management
1758996|NCT00262353|Device|Dialysis with different artificial devices|
1758997|NCT00262366|Device|Comparison of automatic CPAP versus fixed CPAP|
1758998|NCT00262379|Drug|epoetin beta (NeoRecormon®)|• Prescription of the epoetin beta : when blood concentration of hemoglobin is lower or equal to 12 g/dL in male or lower or equal to 11 g/dL in female
1758999|NCT00262392|Drug|Pamidronate (AREDIA)|Pamidronate (AREDIA) vs radiation
1759000|NCT00262405|Drug|zileuton|
1759001|NCT00262405|Drug|azathioprine/prednisone|
1759002|NCT00262418|Drug|Administration of ivermectin or permethrin|
1759003|NCT00262431|Procedure|Tracheostomy on day 3-5 in early group and 10-12 in late group|Upon admission to ICU, acute respiratory failure patients requiring at least 3 days of mechanical ventilation and defined by a SAPS II score between 35 and 65, will be randomly assigned to either arm A or B of the study.
1759004|NCT00262444|Procedure|Different turning frequencies|
1759005|NCT00262457|Device|Implanted gluteal electrical stimulation system|Implanted electrical stimulation system incorporating BION microstimulators
1759006|NCT00262470|Drug|Acetazolamide|250 mg PO x 1
1759007|NCT00262470|Drug|Atomoxetine|10-40 mg PO x 1 dose
1759008|NCT00262470|Other|NO Drug|No intervention - just monitoring
1759009|NCT00262470|Drug|Clonidine|Clonidine 0.05-0.3 mg PO x 1 dose
1759010|NCT00262470|Drug|Entacapone|Entacapone 200-400 mg PO x 1 dose
1759011|NCT00262470|Drug|Entacapone & Propranolol|Entacapone 200-400 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
1759012|NCT00262470|Drug|Atomoxetine & Propranolol|Atomoxetine 10-40 mg PO x 1 dose AND propranolol 20 mg PO x 1 dose
1759014|NCT00262470|Drug|Mecamylamine|mecamylamine 1.25-5 mg PO x 1 dose
1759015|NCT00262470|Drug|Isosorbide Dinitrate|Isosorbide dinitrate 5-20 mg PO x 1 dose
1759016|NCT00262470|Dietary Supplement|Melatonin|melatonin 3 mg PO x 1 dose
1759017|NCT00262470|Drug|Midodrine|midodrine 2.5-10 mg PO x 1 dose
1759018|NCT00262470|Drug|Modafinil|modafinil 100-200 mg PO x 1 dose
1759019|NCT00262470|Drug|Octreotide|octreotide 12.5-50 mcg Subcutaneous x 1 dose
1759020|NCT00262470|Radiation|Placebo|lactose tablet x 1 pill
1759021|NCT00262470|Drug|Propranolol|Propranolol 10-80 mg PO x 1-2 dose
1759022|NCT00262470|Drug|Modafinil & Propranolol|Modafinil 100-200 mg PO x 1 dose AND Propranolol 20 mg PO x 1 dose
1759023|NCT00262470|Drug|Sertraline|sertraline 25-50 mg PO x 1 dose
1759024|NCT00262470|Procedure|IV Saline|1 liter IV over 2 hours
1759025|NCT00262470|Other|Drinking Water|16 fluid ounces
1759026|NCT00262470|Device|Breathing Device|Breathing through a dead space tube
1759027|NCT00262470|Drug|memantine|memantine 5-20 mg PO x 1 dose
1759028|NCT00262470|Device|Abdominal binder|Using large blood pressure cuffs linked together, they are wrapped around the subjects abdomen and inflated to generate increased pressure to below tolerably threshold.
1759029|NCT00262483|Drug|VX-950|
1759030|NCT00262483|Drug|ribavirin|
1759031|NCT00262483|Drug|peginterferon alfa-2a|
1759032|NCT00262496|Drug|Botox|
1759033|NCT00262509|Device|Egress Badge|Egress Badge is worn by subjects who are asked to use the badge to exit the building. The badge indicates the direction of each exit sign on route to an exit.
1759034|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once daily (QD) tablet + emtricitabine (FTC) 200 mg QD + tenofovir disoproxil fumarate (TDF) 300 mg QD
1759035|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg QD soft gel capsule (SGC) + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 800/200 mg QD Tablet + FTC 200 mg QD + TDF 300 mg QD
1759036|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice daily (BID) tablet + FTC 200 mg QD + TDF 300 mg QD
1759037|NCT00262522|Drug|lopinavir/ritonavir (LPV/r) (tablet or capsule) with nucleoside reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg BID SGC + FTC 200 mg QD + TDF 300 mg QD (8 weeks) followed by LPV/r 400/100 mg BID Tablet + FTC 200 mg QD + TDF 300 mg QD
1759038|NCT00262548|Drug|Rosuvastatin; improvement of lipid profile|
1759039|NCT00262561|Drug|Aspirin|The effect of Aspirin on platelet function was assessed.
1759040|NCT00262574|Drug|Nesiritide,|PCI
1759041|NCT00262587|Drug|Seretide|Combination of inhaled corticosteroids (250 microgr) and inhaled long-acting beta2-agonists (25 microgr)
1759042|NCT00262587|Drug|Placebo|Inhaled sugar powder in a placebo inhaler
1759043|NCT00262600|Drug|warfarin|once a day
1759044|NCT00262600|Drug|Dabigatran dose 1|twice daily
1759045|NCT00262600|Drug|Dabigatran dose 2|twice a day
1759046|NCT00262613|Drug|sodium pyruvate in 0.9% sodium chloride solution|
1759047|NCT00262626|Drug|Intraocular pressure reduction|
1759048|NCT00262626|Procedure|Argon laser trabeculoplasty|
1759049|NCT00262626|Procedure|Trabeculectomy|
1759050|NCT00262639|Drug|Flumazenil and Gabapentin|2 mg flumazenil for infusion given slowly over 20 minutes given day 1 and day 2 gabapentin 300 mg increasing to 1200 mg over 4 days and continuing to day 30. Gabapentin 900 mg Day 31 to Day 33 gabapentin 600 mg Day 34 to 36 and gabapentin 300 mg Day 37 to 39.
1759051|NCT00262639|Drug|Placebo|20 mg Saline infused slowly over 20 minutes. Placebo 1 capsule Day 1, 2 capsules Day 2, 3 capsules Day 3, 4 capsules days 4 to 30; 3 capsules Day 31 to 33; 2 capsules day 34 to 36 and 1 capsule 37 to 39.
1759052|NCT00262652|Drug|sodium pyruvate|
1759053|NCT00262665|Drug|ORG 24448|flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
1759054|NCT00262665|Drug|Placebo|matching placebo pill - flexible regimen starting at 250mg once a day, increasing to maximum of 750mg twice a day.
1759056|NCT00262704|Behavioral|Simulated case-based customized learning|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback
1759057|NCT00262704|Behavioral|Simulated case based customized learning + leader feedback|Formal Analysis of Diabetes Practice Style, Using SimCare cases with Process Trace Feedback + Physician Opinion Leader Feedback Tailored to Provider's Specific Practice Style
1759058|NCT00262717|Device|HIV drug resistance tests based upon genotype testing|
1759059|NCT00262730|Drug|poly ICLC|20 mcg/kg 3x each week (Maintenance cycles)
1759060|NCT00262730|Drug|temozolomide|daily 75mg/m2 6wks concomitant therapy Wk 1 - days 1-5 150-200 mg/m2 maintenance cycles (adjuvant)
1759061|NCT00262730|Radiation|radiation therapy|RT: 60 Gy (6 weeks) concomitant therapy
1759062|NCT00262743|Biological|Polyphenon E|"Phase I Dose Escalation:. 400 mg orally twice a day to 2000 mg orally twice a day
Phase II: 2000 mg orally twice a day"
1759063|NCT00262769|Drug|cisplatin|25 mg/m2 in 1000 mls 0.9% saline given over 1 hour followed by 500 mls 0.9% saline over 90 mins
1759064|NCT00262769|Drug|gemcitabine hydrochloride|1000mg/m2 in 250-500mls 0.9% saline over 30 mins by intravenous infusions on day 1, 8 and 15 (Arm A only) of each 28 (Arm A) or 21 (Arm B) day cycle.
1759065|NCT00262782|Drug|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
1759066|NCT00262795|Drug|Fludarabine|Fludarabine i.v. (25 mg/m2/d, d1-5) q28d; max 6 cycles
1759067|NCT00262795|Drug|Chlorambucil|Chlorambucil p.o. (0,4 mg - max. 0,8 mg/kg/d, d1) q15d, max. 12 month
1759068|NCT00262808|Biological|sargramostim|
1759069|NCT00262808|Drug|fluorouracil|
1759070|NCT00262808|Drug|leucovorin calcium|
1759071|NCT00262808|Drug|oxaliplatin|
1759072|NCT00262808|Procedure|adjuvant therapy|
1759073|NCT00262808|Procedure|conventional surgery|
1759074|NCT00262808|Procedure|neoadjuvant therapy|
1759075|NCT00262821|Drug|cisplatin|Given IV
1759076|NCT00262821|Drug|tirapazamine|Given IV
1759077|NCT00262834|Drug|vorinostat|Given orally
1759078|NCT00262834|Other|conventional surgery|Undergo surgery
1759079|NCT00262847|Biological|Bevacizumab|Given IV
1759080|NCT00262847|Drug|Carboplatin|Given IV
1759081|NCT00262847|Other|Laboratory Biomarker Analysis|Correlative studies
1759082|NCT00262847|Drug|Paclitaxel|Given IV
1759083|NCT00262847|Other|Placebo|Given IV
1759084|NCT00262847|Other|Quality-of-Life Assessment|Ancillary studies
1759085|NCT00262860|Drug|bortezomib|
1759086|NCT00262860|Drug|gemcitabine hydrochloride|
1759087|NCT00262873|Drug|bortezomib|
1759088|NCT00262886|Biological|anti-thymocyte globulin|
1759089|NCT00262886|Biological|graft-versus-tumor induction therapy|
1759090|NCT00262886|Biological|therapeutic allogeneic lymphocytes|
1759091|NCT00262886|Drug|cyclophosphamide|
1759092|NCT00262886|Drug|fludarabine phosphate|
1759093|NCT00262886|Drug|mycophenolate mofetil|
1759094|NCT00262886|Drug|tacrolimus|
1759095|NCT00262886|Procedure|allogeneic bone marrow transplantation|
1759096|NCT00262886|Procedure|peripheral blood stem cell transplantation|
1759097|NCT00262899|Behavioral|counseling intervention|
1759098|NCT00262899|Other|educational intervention|
1759099|NCT00262899|Procedure|psychosocial assessment and care|
1759100|NCT00262925|Biological|alemtuzumab|Given subcutaneously
1759101|NCT00262925|Drug|asparaginase|Given IM
1759102|NCT00262925|Drug|methotrexate|Given IV or orally
1759103|NCT00262925|Drug|dexamethasone|Given orally
1759104|NCT00262925|Drug|leucovorin calcium|Given IV
1759105|NCT00262925|Drug|mercaptopurine|Given orally
1759106|NCT00262925|Drug|vincristine|Given IV
1759107|NCT00262938|Behavioral|behavioral dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
1759108|NCT00262938|Other|counseling intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
1759109|NCT00262938|Other|educational intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
1759110|NCT00262938|Other|preventative dietary intervention|Patients undergo weekly contact with a dietitian; exercise intervention for 6 months; and physician counseling at baseline and at 3, 6, and 12 months. Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
1759111|NCT00262938|Procedure|quality-of-life assessment|Patients undergo quality of life assessments and clinical assessments at baseline and at 3, 6, and 12 months.
1759112|NCT00262951|Biological|recombinant interferon alfa|administered subcutaneously (SQ)at a dose of 3 million units Day 1,3, and 5 each week in Cycle 1
1759113|NCT00262951|Drug|cisplatin|administered at a dose of 30 mg/m2 intravenously (IV) day 1 each week in Cycle 1
1759114|NCT00262951|Drug|fluorouracil|administered at a dose of 175 mg/m^2/day continuous infusion (CI) for 38 days in Cycle 1 and then 500 mg/m^2 intravenously (IV) each week for 6 weeks followed by a 2 week rest (1 cycle = 8 weeks)in Cycle 2 and 3
1759115|NCT00262951|Radiation|radiation therapy|5040 cGy total, in 28 fractions, at 180 cGy/fraction daily, Monday -Friday, for 5½ weeks (days 1-5, 8-12, 15-19, 22-26, 29-33, 36-38).
1759116|NCT00262951|Procedure|Resection of tumor|After Cycle 1 treatment (if resectable)- In the absence of metastatic disease, special emphasis will be paid to the local tumor. Evaluation of the growth/regression of the tumor will be made as it relates to resectability. Surgical exploration will start with a diagnostic laparoscopy. If no evidence of carcinomatosis, liver metastases or other evidence of metastatic disease is encountered, then a laparotomy will be performed. In the absence of clear technical unresectability, a radical pancreaticoduodenectomy, distal or total pancreatectomy (and resection of any involved structures) will be performed as mandated by tumor anatomy.
1759117|NCT00262964|Drug|Niacin|Subjects randomized to Niacin therapy will be treated with Niacin at night for 16 wks to reduce plasma free fatty acid concentrations. The dose of medication will be gradually increased: 500 mg/day during week 1, 1000 mg/day during week 2, 1500 mg/day during week 3, and 2000mg/day during weeks 4-16.
1759118|NCT00262964|Drug|fenofibrate|Subjects randomized to fenofibrate will be treated with 200 mgs per day for eight weeks.
1759119|NCT00262964|Drug|placebo|Subjects randomized to placebo will be treated with one placebo pill per day for eight weeks.
1759120|NCT00262977|Behavioral|Electronic prompt plus patient-directed intervention|
1759121|NCT00262977|Behavioral|Electronic prompt to clinician to prescribe aspirin|
1759122|NCT00262990|Drug|EPO906 (Patupilone)|
1759123|NCT00262990|Drug|doxorubicin|
1759124|NCT00263003|Drug|Irbesartan/hydrochlorothiazide|
1759125|NCT00263003|Drug|Irbesartan|
1759126|NCT00263016|Drug|Docetaxel|
1759127|NCT00263029|Drug|Oxaliplatin|60mg/m² as a 2-hour intravenous infusion every week for 5-6 week
1759128|NCT00263029|Drug|Capecitabine|500mg tablets and 150mg tablets. 750mg/m² bd given approximately 12 hours apart
1759129|NCT00263029|Radiation|Radiotherapy|Planned total dose of 45-50.4Gy (with cone down) in 25-28 fractions
1759130|NCT00263042|Drug|Rimonabant|Tablet, oral administration
1759131|NCT00263042|Drug|Placebo (for Rimonabant)|Tablet, oral administration
1759132|NCT00263055|Drug|oxaliplatin|
1759133|NCT00263068|Drug|Rotigotine|"Transdermal Patch 1 per day for 24 hours containing:
1.125mg/day 2.25mg/day 4.5mg/day 6.75mg/day"
1759134|NCT00263081|Drug|Lapaquistat acetate and current lipid-lowering treatment|"Cohort 1: Weight is less than 50 kg:
Lapaquistat acetate 50 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
Cohort 2: Weight is more than 50 kg:
Lapaquistat acetate 100 mg, tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks."
1759326|NCT00271869|Procedure|Extracorporeal photoimmunotherapy|
1759135|NCT00263081|Drug|Current lipid-lowering treatment|Lapaquistat acetate placebo-matching tablets, orally, once daily and current lipid-lowering treatment for up to 12 weeks.
1759136|NCT00263094|Drug|Rofecoxib|
1759137|NCT00263107|Procedure|telerounding versus bedside rounding|
1759138|NCT00263120|Behavioral|Pain Questionnaire|
1759139|NCT00263133|Drug|Sertraline|
1759140|NCT00263146|Procedure|recruitment maneuver|
1759141|NCT00263159|Procedure|Pharmaceutical care for asthma patients|
1759142|NCT00263172|Behavioral|behavior modification for weight loss|
1759143|NCT00263185|Dietary Supplement|Vitamin D|
1759144|NCT00263185|Dietary Supplement|Calcium carbonate|
1759145|NCT00263185|Drug|Vitamin D|
1759146|NCT00263185|Other|Placebo|
1759147|NCT00263198|Drug|PTK787/ZK222584|
1759148|NCT00263198|Drug|Letrozole|
1759149|NCT00263211|Drug|Plavix|
1759150|NCT00263211|Drug|Aspirin|
1759151|NCT00263237|Drug|STA-5326|
1956759|NCT02712034|Behavioral|MAT + A-CHESS|"Subjects randomized to MAT + A-CHESS will receive MAT plus the A-CHESS recovery support system which provides:
Self-directed, interactive modules that teach basic recovery support, harm-reduction, and psychosocial functioning skills.
The latest information about addiction and recovery support, monitoring prompts, and peer and family support.
Advice on where to go for help and on how to make the best use of health and human services; and
A way to talk with experts in the area of addiction and other study participants by sending anonymous messages in the A-CHESS discussion groups.
A way to keep your health care team up to date through reports based on information entered into A-CHESS (i.e. alcohol and drug use, depression, MAT side effects)."
1759153|NCT00263263|Device|sirolimus-eluting stent|
1759154|NCT00263263|Device|bare metal stent|
1759155|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 2.5 mg, Once daily, 12 weeks.
1759156|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 5 mg, Once daily, 12 weeks.
1759157|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 10 mg, Once daily, 12 weeks.
1759158|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 20 mg, Once daily, 12 weeks.
1759159|NCT00263276|Drug|dapagliflozin|Tablets, Oral, 50 mg, Once daily, 12 weeks.
1759160|NCT00263276|Drug|placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks.
1759161|NCT00263276|Drug|metformin|Tablets, Oral, >/= 1500 mg, Once daily, 12 weeks.
1759162|NCT00263289|Procedure|preprocedural fasting|
1759163|NCT00263302|Drug|dexamethasone|
1759164|NCT00263315|Drug|nebulised liposomal amphotericin B|
1759165|NCT00263328|Drug|Tacrolimus|Standard of care
1759166|NCT00263328|Drug|CP-690,550|CP-690,550 5 mg BID
1759167|NCT00263328|Drug|CP-690,550|CP-690,550 10 mg BID
1759169|NCT00263354|Drug|Oxaliplatin|
1759170|NCT00263367|Other|Hyperbaric Oxygen|Hyperbaric Oxygen at 1.3 ATA for one hour
1759171|NCT00263393|Drug|ASA, Atenolol, hydrochlorothiazide, ACE inhibitor, Statin|The first intervention was a clinical algorithm designed to enhance the identification and treatment of high-risk individuals compared to continued usual care. The algorithm was designed to be used by either physician or non-physician health care workers.
1759172|NCT00263393|Behavioral|Health Promotion|The second intervention was a health promotion program designed to increase knowledge of cardiovascular risk factors compared to continued usual practices.
1759173|NCT00263406|Drug|Administration of an ACE-inhibitor or not|
1759174|NCT00263419|Behavioral|Mindfulness Based Stress Reduction|8 weeks mindfulness based stress reduction (MBSR) based on body and meditation practices that aims at cultivation of openness, awareness of the present moment and acceptance of all internal and external experiences. It is assumed that this allows to act more reflectively rather than impulsively.
1759175|NCT00263432|Procedure|Human allogenic chondrocytes|Implantation of fresh human allogenic chondrocytes in human knee cartilage injuries
1759176|NCT00263458|Other|Integrated office-based buprenorphine treatment for opioid dependence in an HIV primary care setting|Eligible opioid-dependent HIV-infected patients are randomly assigned to receive buprenorphine opioid agonist treatment for 12 months either in an integrated HIV primary care setting (intervention group) versus a non-integrated substance use treatment clinic setting (comparison group).
1759178|NCT00263484|Drug|dexamethasone|20 mg, PO (orally) on days 1-4, 8-11 and 15-18 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
1759179|NCT00263484|Drug|thalidomide|100 mg, PO (orally) on days 1-21 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
1759180|NCT00263484|Drug|zoledronic acid|4 mg, IV (in the vein) on day 1 of each 21 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
1759181|NCT00263497|Device|Temporary tuber-ischii bearing prosthesis|Tuber ischii-bearing holster is connected by hinged metal bars to foot device to enable immediate postoperative mobilization of transtibial amputees. No other medical interventions or pharmaceutical treatment.
1759182|NCT00263523|Drug|[11C] (-)-RWAY|
1759183|NCT00263536|Procedure|Interpersonal Psychotherapy|
1759184|NCT00263549|Biological|House dust mite Novo Helisen Depot|
1759187|NCT00263588|Drug|lapatinib|tyrosine kinase inhibitor
1759188|NCT00263601|Biological|Allergovit 6-grasses|Subcutaneous injections
1759189|NCT00263601|Other|Placebo|Subcutaneous injections
1759190|NCT00263627|Biological|Birch pollen allergoid|Subcutaneous injections were applied in the upper arm. Vials with three different concentrations were used: Strength A (1000 TU/mL), strength B (10 000 TU/mL) and strength 0 (100 TU/mL) by dilution of strength A.
1759191|NCT00263627|Other|Placebo|Sterile aluminium hydroxide suspension for subcutaneous injection were applied in the upper arm. Vials with strength A contained 0.0125 mg/mL and with strength B 0.125 mg/mL histamine-dihydrochloride and strength 0 was produced by dilution of strength A. The vials containing the placebo solution were identical in their outer appearance with the active study preparation of the birch pollen allergoids.
1759192|NCT00263640|Biological|Acaroid|The drug tested in this study (aluminium hydroxide-adsorbed house dust mite (D. pteronyssinus) allergoid preparation) was given as a subcutaneous injections of increasing doses.
1759193|NCT00263640|Drug|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection. Patients were treated according the same dosing schedule of active group. Children received lifestyle counselling.
1759194|NCT00263653|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
1759195|NCT00263666|Biological|Rotarix|Oral vaccination
1759196|NCT00263666|Biological|Placebo|Oral administration
1759197|NCT00263666|Biological|TritanrixTM-HB+Hib|Concomitant routine vaccination, IM administration
1759198|NCT00263666|Biological|SabinPolioTM vaccine|Oral administration, concomitant routine vaccination
1759199|NCT00263679|Biological|Prophylaxis: Diphtheria, tetanus and pertussis|
1759200|NCT00263692|Biological|Prophylaxis: Diphtheria, tetanus, pertussis, poliovirus type 1, type 2 and type 3|
1759201|NCT00263705|Drug|Adjuvant capecitabine|Capecitabine 2000 mg/m² daily six cycles
1759202|NCT00263705|Drug|capecitabine in aduvant setting|capecitabine in aduvant setting in ederly with breast cancer
1759203|NCT00263718|Drug|Calcipotriol plus betamethasone dipropionate (LEO 80185) gel|
1759204|NCT00263731|Other|13-C-glucose|"10 grams of 13-C-glucose intravenously, as a 30-minute piggyback infusion, 2 to 6 hours prior to scheduled surgical resection of primary lung cancer."
1759205|NCT00263744|Biological|MEDI 517|Vaccine is supplied in single use vials containing 0.75 mL of MEDI-517 at a concentration of 40 mg/0.5 mL formulated with SBAS4 adjuvant.
1759206|NCT00263744|Other|Aluminum hydroxide|Aluminum hydroxide supplied in single use vials containing 0.75 mL of aluminum hydroxide at a concentration of 0.5 mg of aluminum in the form of aluminum hydroxide per 0.5 mL.
1759207|NCT00263757|Device|Adaptive Servo-Ventilation|Adaptive Servo-Ventilation provides positive expiratory airway pressure and inspiratory pressure support, which is servocontrolled based on the detection of central sleep apnea.
1759208|NCT00263757|Other|Usual Care|Subjects randomized to this arm received medical management as prescribed by their cardiologist.
1759209|NCT00270257|Drug|Buprenorphine/Naloxone|Oral tablet
1759210|NCT00270270|Drug|epoetin alfa|
1759211|NCT00270283|Drug|epoetin alfa|
1759212|NCT00270296|Drug|Trizivir|300 mg abacavir sulfate/150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
1759213|NCT00270296|Drug|Lamivudine/Zidovudine|150 mg lamivudine/300 mg zidovudine tablet taken orally twice daily
1759214|NCT00270296|Drug|Lopinavir/Ritonavir|400 mg lopinavir/100 mg ritonavir tablet taken orally twice daily
1759215|NCT00270296|Drug|Nevirapine|200 mg tablet taken orally daily for the first 14 days before receiving 200 mg tablet taken orally twice daily
1759216|NCT00270309|Behavioral|Self-management|
1759217|NCT00270322|Drug|Marcaine 0.166% + Fentanyl 3.33 mcg/ml|
1759218|NCT00270322|Drug|Morphine sulphate|
1759219|NCT00270335|Drug|Propofol|
1759220|NCT00270348|Drug|ciclesonide|
1759221|NCT00270361|Drug|nesiritide|
1759222|NCT00270361|Drug|usual long term cardiac medications|
1759223|NCT00270361|Drug|nesiritide|
1759224|NCT00270374|Drug|nesiritide|
1759225|NCT00270387|Drug|Natrecor (nesiritide)|
1759226|NCT00270400|Drug|nesiritide|
1759227|NCT00270413|Drug|SU11248|sutent 50 mg daily 4w on 2w off
1759228|NCT00270426|Drug|Benazepril|
1759229|NCT00270439|Procedure|removal of omentum|patients with type 2 diabetes had their omentum removed
1759230|NCT00270452|Drug|WT1 and PR1 Peptide Vaccine|
1759231|NCT00270465|Drug|VRC-HIVDNA016-00-VP|
1759232|NCT00270465|Drug|VRC-HIVADV014-00-VP|
1759233|NCT00270478|Drug|Erythropoietin and Hydroxyurea|
1759234|NCT00270491|Drug|Paclitaxel|
1759235|NCT00270491|Drug|Capecitabine|
1759236|NCT00270504|Device|Memokath stenting|Urethral Stenting
1759237|NCT00270517|Drug|EDP-420 / Duration of Treatment – 3 days|
1759238|NCT00270517|Drug|Telithromycin / Duration of Treatment – 7 days|
1759239|NCT00270530|Drug|Sulfadoxine-pyrimethamine (Fansidar)|
1759240|NCT00270543|Drug|Taxotere, Fluorouracil, Leucovorin|
1759241|NCT00270556|Drug|tenofovir disoproxil fumarate|
1759242|NCT00270556|Drug|Abacavir|
1759243|NCT00270569|Drug|PhyxolTM, Cisplatin|
1759244|NCT00270582|Drug|Taxotere, Cisplatin, Gemcitabine|
1759246|NCT00271206|Drug|Progesterone|compared to placebo
1759247|NCT00271206|Drug|sugar pill|Compared to progesterone
1759248|NCT00271219|Drug|Methadone|daily oral dosing 20-140 mg
1759249|NCT00271219|Drug|Buprenorphine|sl daily 2-32 mg
1759250|NCT00271232|Device|Cardiac resynchronization therapy|
1759251|NCT00271245|Dietary Supplement|200 µg selenium as selenate|200 µg selenium as selenate
1759252|NCT00271245|Dietary Supplement|400 µg selenium as selenate|400 µg selenium as selenate
1759253|NCT00271245|Dietary Supplement|200 µg selenium as selenomethionine|200 µg selenium as selenomethionine
1759254|NCT00271245|Dietary Supplement|Placebo|Placebo
1759255|NCT00271258|Drug|SODIUM DIVALPROATE|
1759256|NCT00271271|Drug|oxaliplatine / gemcitabine / Vinorelbine|
1759257|NCT00271284|Drug|insulin glulisine / insulin glargine|insulin glargine administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
1759258|NCT00271284|Drug|insulin glulisin / insulin detemir|insulin detemir administered subcutaneously by the patient once a day, in the evening, between 18.30 and 24.00
1759259|NCT00271297|Behavioral|Pelvic floor muscle training|
1759260|NCT00271310|Drug|hypertonic saline|
1759261|NCT00271323|Drug|docetaxel and cisplatin|Docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles, followed by concurrent chemo-radiotherapy with docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy.
1759325|NCT00271856|Behavioral|HIV-education and self-management workshop|8-week group covering a variety of educational topics about managing HIV infection.
1759262|NCT00271323|Radiation|radiotherapy|Docetaxel (20 mg/m2, IV) and cisplatin (20 mg/m2) weekly for 6 weeks + radiotherapy 2 Gy/day, 5 days per week to a total dose of 66 Gy followed by docetaxel (75 mg/m2, IV, Day 1) and cisplatin (40 mg/m2, IV, Day 1, 2) every 3 weeks for 2 cycles.
1759263|NCT00271336|Drug|Pentoxifylline|
1759264|NCT00271349|Drug|Budesonide|
1759265|NCT00271362|Behavioral|Amputation rehabilitation exercise program|participants will be physically exercised with a full array of exercise methodologies.
1759266|NCT00271362|Procedure|Osteomyoplasty vs. routine long posterior flap|participants enrolled randomly in one of two surgical procedures.
1759267|NCT00271375|Behavioral|Caring For You, Caring For Me|5-week Education and Support Program for Caregivers of older adults.
1759268|NCT00271375|Behavioral|Caring for you, caring for me + social worker|5-week Education and Support Program for Caregivers of older adults.+ augmentation with social worker
1759269|NCT00271375|Behavioral|Control|Control group usual care
1759270|NCT00271388|Device|Transcutaneous current to the vestibular nerve|Delivery of randomly oscillating low level current
1759271|NCT00271401|Other|Angioplasty|
1759272|NCT00271401|Other|Intracoronary Stent|
1759273|NCT00271401|Drug|Abxicimab|
1759274|NCT00271401|Drug|Heparin|
1759275|NCT00271401|Drug|Placebo|
1759276|NCT00271414|Drug|Duragesic® (fentanyl) Transdermal Therapeutic System (TTS)|
1759277|NCT00271427|Drug|L-Selenomethionine|
1759278|NCT00271440|Procedure|skin cleansing with chlorhexidine (0.25%, 0.5%, 1%)|
1759279|NCT00271453|Drug|Durogesic® (fentanyl transdermal drug delivery system)|
1759280|NCT00271466|Drug|DuragesicÂ® (fentanyl) Therapeutic Transdermal System (TTS)|
1759281|NCT00271479|Biological|A, C, Y, W135 meningococcal polysaccharide vaccine|
1759282|NCT00271492|Drug|Atrasentan|1 10mg capsule to be taken daily for 6 month study period.
1759283|NCT00271492|Drug|Atrasentan|1 10mg capsule per day for the 6 month study period.
1759284|NCT00271492|Drug|atrasentan|One 10 mg capsule per day for 6 month study period
1759285|NCT00271505|Drug|Bevacizumab (Avastin)|15 mg/kg intravenously (IV) every 3 weeks
1759286|NCT00271505|Drug|Carboplatin|AUC 6 IV every 3 weeks
1759287|NCT00271505|Drug|Docetaxel|75 mg/m2 IV every 3 weeks
1759288|NCT00271518|Drug|growth hormone (somatropin)|dosing regimen is weight based.
1759289|NCT00271544|Device|Pacing Lead|implant and follow-up of study device
1759290|NCT00271557|Drug|nesiritide|
1759291|NCT00271570|Drug|Infliximab (Remicade)|Remicade was 5 mg/kg IV (single dose)
1759292|NCT00271570|Biological|Intravenous immunoglobulin (IVIG)|2nd dose of IVIG (2g/kg)
1759293|NCT00271583|Drug|CDB-2914|
1759294|NCT00271583|Drug|levonorgestrel|
1759295|NCT00271596|Drug|20mg daily citalopram|a selective serotonin reuptake inhibitor (SSRI) treatment administered over 16 weeks
1759296|NCT00271596|Drug|Placebo|a daily matching placebo administered over 16 weeks
1759297|NCT00271609|Drug|Bevacizumab|10 mg/kg intravenously over 90 minutes every 2 weeks on a 28 day cycle. First dose is given over 90 minutes and subsequent doses are given over 30 minutes.
1759298|NCT00271635|Drug|Placebo|Placebo 4 capsules b.i.d. during 1 year
1759299|NCT00271635|Drug|ascorbic acid|Ascorbic acid 1000 mg (4 capsules of 250 mg) b.i.d. during 1 year
1759300|NCT00271674|Device|Q-switched YAG laser|
1759301|NCT00271687|Behavioral|Exercise training|
1759302|NCT00271700|Behavioral|Order Set, Education, Feedback|
1759303|NCT00271713|Drug|ibandronate, calcium and vitamin D|1: 150 mg ibandronate monthly plus 500mg calcium and 800 UI vitamin D daily or
1759304|NCT00271713|Drug|placebo,calcium and vitamin D|2: placebo monthly plus 500mg calcium and 800 UI vitamin D daily
1759305|NCT00271726|Procedure|Osteosynthesis with palmar locking plate|
1759306|NCT00271726|Procedure|Osteosynthesis with external fixator|
1759307|NCT00271726|Procedure|Osteosynthesis with Kirschner wires|
1759308|NCT00271739|Device|Telemedicine Unit (HTU)|This study involves the deployment of a home telemedicine unit (HTU). The HTU provides 3 critical functions for patients: videoconferencing, access to information resources and e-mail through a web-enabled workstation, and medical data acquisition through an electronic device interface. The HTUs also included a glucometer and a blood pressure cuff interfaced directly with the HTU.
1759309|NCT00271739|Other|usual care|usual diabetes care, as provided by primary care providers
1759310|NCT00271752|Procedure|Earlier therapeutic changes regarding infection|For every day Procalcitonin levels increase in the intervention group, antibiotics, surgery, diagnostic imaging and microbiologic testing is intensified
1759311|NCT00271765|Drug|INO-1001|
1759312|NCT00271778|Procedure|mastoidotympanoplasty and tympanoplasty|
1759313|NCT00271791|Drug|Prednisone|PO, 1 mg/kg body weight, 5 days Short tapering regimen: daily reductions in the dose, 12 days
1759314|NCT00271791|Drug|Prednisone|PO, Placebo, 17 days
1759315|NCT00271804|Drug|bortezomib|
1759316|NCT00271817|Drug|Comparator: ezetimibe/simvastatin + niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be ~24 weeks
1759317|NCT00271817|Drug|Comparator: Placebo to ezetimibe/simvastatin|ezetimibe/simvastatin (Pbo) tablet. Treatment time will be ~24 weeks.
1759318|NCT00271817|Drug|Comparator: niacin (ER) tablet|niacin (ER) tablet, titrating to 2g, po qd. Treatment time will be ~24 weeks
1759319|NCT00271817|Drug|Comparator: ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be ~24 weeks.
1759320|NCT00271817|Drug|Comparator: Placebo to Niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be ~24 weeks.
1759321|NCT00271817|Drug|Comparator: ezetimibe/simvastatin and niacin (ER)|ezetimibe/simvastatin 10/20mg tablet + niacin (ER) tablet 2g, po qd. Treatment time will be ~40 additional weeks for a total of 64 weeks
1759322|NCT00271817|Drug|Comparator: ezetimibe and simvastatin|ezetimibe/simvastatin 10/20mg tablet. Treatment time will be ~40 additional weeks for a total of 64 weeks
1759323|NCT00271817|Drug|Comparator: Placebo to niacin (ER)|Niacin (ER) (Pbo) tablet. Treatment time will be ~40 additional weeks for a total of 64 weeks
1759324|NCT00271856|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|8 week MBSR course
1759327|NCT00271908|Behavioral|Community Mobilization|"ATN 040b is the evaluation sub-study for ATN 040, Phase III of C2P. Phase III is a community mobilization intervention aimed at reducing HIV rates among youth via community structural change. ATN 040b involves annual anonymous data collection with two cohorts per participating ATN/C2P site. Both cohorts will represent the site's target population, or population of focus."
1759328|NCT00271921|Behavioral|Calorie controlled diet|
1759329|NCT00271934|Biological|Immune ablation and hematopoietic stem cell support.|Autologous hematopoietic stem cell transplant
1759330|NCT00271947|Biological|Autologous Stem Cell Transplantation|Autologous Stem Cell Transplantation will be performed after conditioning regimen
1759331|NCT00271960|Behavioral|CenteringPregnancy|Following the initial intake into obstetric care in the usual manner, participants will be invited to join with 8 to 12 other women/couples/teens with similar due dates, meeting together regularly during their pregnancy.
1759332|NCT00271960|Behavioral|CenteringPregnancyPlus|CenteringPregnancyPlus is a modified program that integrated HIV/STD prevention components with the group prenatal care model. Participants will learn skill-building in the areas of efficacy, risk assessment, negotiation skills and prevention.
1759333|NCT00271960|Behavioral|Usual care|Participants will receive usual prenatal care.
1759334|NCT00271973|Drug|Oxycodone|
1759336|NCT00272012|Drug|Insulin glulisine|
1759337|NCT00272025|Drug|Escitalopram|10mg to 20mg tablet daily for 6 weeks
1759338|NCT00272025|Drug|placebo|
1759339|NCT00272038|Drug|Tarceva|150mg QD
1759340|NCT00272051|Drug|SR57746A|
1759341|NCT00272064|Drug|Insulin glulisine|individualized, once daily, dose aiming at 2h post-prandial plasma glucose goal < 140 mg/dl (7.8 mmol/l) in the optimized treatment phase, since visit 3, subcutaneous
1759342|NCT00272064|Drug|Insulin glargine|individualized, once daily, dose to reach mean fasting plasma glucose (FPG) <= 126 mg/dl (7.0 mmol/l), since randomization, subcutaneous
1759343|NCT00272064|Drug|Metformin|1000 mg b.i.d, since the qualification phase, oral
1759344|NCT00272077|Drug|Insuline glargine|
1759345|NCT00272090|Drug|Insulin glargine|
1759346|NCT00272103|Drug|Itopride (drug)|
1759347|NCT00272116|Drug|Zinc and vitamin A single dose at enrollment|10 mg/day of elemental zinc as zinc gluconate to infants and 20 mg/day to older children
1759348|NCT00272116|Drug|Placebo and vitamin A single dose at enrollment|Placebo was plain glucose. Vitamin A 100,000 IU to infants and 200,000 IU to older children
1759349|NCT00272142|Drug|Zinc|
1759350|NCT00272142|Drug|Placebo|
1759351|NCT00272155|Behavioral|Educational intervention|Educational outreach visits to the CME-groups, work-shops, audit and feedback
1759352|NCT00272155|Behavioral|Educational intervention program|The 433 recruited GPs had a total of 1336 717 office consultations of which 171 679 (12.8%) were RTIs encounters for 118 621 different patients. The GPs participated in peer continuing medical education (CME) groups in southern Norway. A multifaceted intervention was tailored, where key components were educational outreach visits to the CME-groups, work-shops, audit and feedback. Prescription Peer Academic Detailers conducted the educational outreach visits. During these visits, evidence-based recommendations of antibiotic prescriptions for RTIs were presented and software handed out for installation in participants PCs, enabling collection of prescription data. These data was linked to corresponding data from the Norwegian Prescription Database (NorPD). Main outcomes are baseline proportion of inappropriate antibiotic prescriptions for RTIs and change in prescription patterns compared to baseline one year after the initiation of the tailored pedagogic intervention.
1759353|NCT00272168|Behavioral|Maryland Program for Vocational Effectiveness|psychosocial intervention that combines elements of cognitive-behavioral therapy (CBT) with work-related social skills training and basic problem solving training (SST)
1759354|NCT00272168|Other|Supportive Treatment for SMI|Sessions are interactive, supportive, flexible, and unstructured, and are intended to help patients adjust to their new jobs and understand how working affects their lives. The therapist stance is non-directive, and there is an emphasis on having patients share with one another, rather than having the therapists dictate the content of group sessions. The primary goals of the therapists are to engage patients in treatment and to generate discussion among members.
1759355|NCT00272181|Drug|Proxinium|Intratumoral administration of Proxinium directly to target tumors.
1759356|NCT00272194|Device|Ambu Laryngeal Mask|
1759357|NCT00272194|Device|Aintree Exchange Catheter|
1759358|NCT00272194|Device|Laryngeal Mask Airway|
1759359|NCT00272207|Drug|Nabilone|Oral nabilone, 0.5 mg x7 days, increased to 0.5 mg t.i.d x 2 weeks if patient tolerates, then increase if patient tolerating to 0.5 in am and 1.0 mg at hs x 1 week, then if patient tolerating, increase to 1.0 mg b.i.d x 1 week.
1759360|NCT00272220|Behavioral|modified directly observed therapy (mDOT)|Peers individually administered the 6-week mDOT intervention at the Beira Day Clinic to mDOT participants during their morning weekday dose. Evening and weekend doses were not observed. Nighttime and weekend doses were self-administered. As part of the daily interaction with participants, peers provided social support, information about the benefits and side effects of HAART, how to address stigma's effect on adherence, and encouragement to participate in community support groups. The peers also provided an important link between the individual and other members of the HIV clinic team and the community.
1759361|NCT00272246|Procedure|deep brain stimulation of the internal globus pallidus|
1759362|NCT00272259|Procedure|Participants will interact with up to two small robots and a visual display|
1759363|NCT00272272|Behavioral|Music Therapy|Listening to Music while standing
1759364|NCT00272285|Drug|Ramosetron|IV, concomitant administration with dexamethasone
1759365|NCT00272285|Drug|Granisetron|IV, concomitant administration with dexamethasone
1759366|NCT00272311|Drug|Aspirin|Dosage
1759367|NCT00272324|Drug|Aspirin|
1759368|NCT00272324|Drug|Folate|
1759369|NCT00272337|Drug|Aspirin|Dosage
1759370|NCT00272350|Drug|Steroids|
1759371|NCT00272350|Drug|ZD6474|
1759372|NCT00272402|Behavioral|Cognitive Behavioral Intervention|Intervention consists of simulated case based learning for physicians.
1759513|NCT00273611|Behavioral|Pharmacist Education about Vitamin D|
1759373|NCT00272402|Behavioral|Office System Redesign Intervention|Intervention consists of clinical decision support within the electronic medical record.
1759374|NCT00272415|Drug|INO-1001|Intravenous repeating dose
1759375|NCT00272415|Drug|temozolomide|Oral repeating dose
1759376|NCT00272428|Behavioral|ascorbic acid, vitamin E, beta carotene, selenium, zinc|
1759377|NCT00272441|Drug|inhaled corticosteroids|
1759378|NCT00272454|Drug|Cilostazol|
1759379|NCT00272454|Drug|Aspirin|
1759380|NCT00272467|Drug|Rebamipide|"Brand name: Mucosta® Tab.
Generic name: Rebamipide.
Chemical name:
(±)-2-(4-chlorobenzoylamino)-3-[2(1H)-quinolinon-4-yl]propionic acid.
Formulation: Tablet (White, film-coated tablet).
Strength: One tablet contains rebamipide 100mg.
Storage condition: 15℃~25℃.
Manufacturer: Korea Otsuka Pharmaceuticals"
1759381|NCT00272467|Drug|Omeprazole|"Brand name: Losec® Cap.
Generic name: Omeprazole.
Chemical name:
5-melthoxy-2-{{{4-melthoxy-3.5-dlmethyl2-pyridinyl}methyl}sulp- hinyl}-1H-benzimidazole sodium. 4) Formulation: Capsule. 5) Strength: One capsule contains omeprazole 20mg. 6) Storage condition: 15℃~25℃. 7) Manufacturer: AstraZenaca Korea."
1759382|NCT00272480|Drug|Zidovudine/lamivudine|
1759383|NCT00272493|Biological|Hepatitis B virus vaccine with GM-CSF adjuvant|Arm B participants will receive 40 mcg of HBV vaccine and 250 mcg of GM-CSF at study entry, Week 4, and Week 12.
1759384|NCT00272493|Biological|Hepatitis B virus vaccine|Arm A participants will receive 40 mcg of HBV vaccine at study entry, Week 4, and Week 12.
1759385|NCT00272506|Drug|inhaled corticosteroid|
1759386|NCT00272506|Drug|long-acting beta2-agonist|
1759387|NCT00272519|Behavioral|Life Skills Intervention|Developed to promote life skills among young adolescents perinatally infected with HIV
1759388|NCT00272532|Drug|Thiocolchicoside|
1759389|NCT00272545|Behavioral|Normalization of Eating (NOE)|The NOE is a 6-week program based on principles of CBT. Participants will receive individual therapy, as well as take part in group and family therapy sessions. In addition, participants will be supervised while eating meals.
1759390|NCT00272545|Behavioral|Treatment As Usual (TAU)|Treatment as usual will include standard care for a person with an eating disorder.
1759391|NCT00272558|Drug|Carboplatin and Vinorelbine|
1759392|NCT00272571|Procedure|External counter pulsation therapy|
1759393|NCT00272584|Drug|Risperidone|
1759394|NCT00272597|Drug|Risperidone|See Detailed Description.
1759395|NCT00272610|Drug|0.4% Retinol Cream|
1759396|NCT00272623|Procedure|Seldinger technique or venous cut-down for port placement|
1759397|NCT00272636|Procedure|Radiofrequency catheter ablation|
1759398|NCT00272636|Drug|Amiodarone and cardioversion|
1759399|NCT00272649|Biological|AGS-003|Dendritic cell, autologous cellular immunotherapy. (Arcelis platform)
1759400|NCT00272662|Drug|peginesatide|
1759401|NCT00272675|Drug|Chlorhexidine gluconate (drug) vs placebo|
1759402|NCT00272688|Drug|Levodopa (drug), intraduodenal administration|
1759403|NCT00272701|Drug|Esomeprazole|
1759404|NCT00272701|Drug|Other PPI marketed in Sweden|
1759405|NCT00272714|Drug|Afimoxifene (0.057%) in hydroalcoholic gel|
1759406|NCT00272727|Behavioral|Dialog tool for caregivers|
1759407|NCT00272740|Drug|Fulvestrant|
1759408|NCT00272753|Drug|budesonide/formoterol Turbuhaler|
1759409|NCT00272753|Drug|formoterol Turbuhaler|
1759410|NCT00272753|Drug|salbutamol|
1759411|NCT00272766|Drug|pegaptanib sodium|
1759412|NCT00272779|Drug|ATV|300mg Oral capsules for 96 weeks
1759413|NCT00272779|Drug|RTV|100mg Oral Capsules for 96 weeks
1759414|NCT00272779|Drug|Tenofovi-Emtricitabine (TDF/FTC) tablet|One tablet with 300 mg - 200 mg once a day for 96 weeks.
1759415|NCT00272779|Drug|LPV|400 mg (3 133mg capsules) BID for 96 weeks
1759416|NCT00272792|Drug|Sapropterin Dihydrochloride|Phenoptin, provided in tablets containing 100 mg of sapropterin dihydrochloride each, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4-8 oz (120-240 mL) of water or apple juice for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
1759417|NCT00272792|Drug|Placebo|Placebo, provided as tablets similar to Phenoptin tablets, was administered orally once daily in the morning as the number of tablets equivalent to a 20mg/kg/day dose dissolved in 4 8 oz (120-240 mL) of water or apple juice. for 6 weeks. A follow-up call or visit was made 4 weeks later during this double-blind, placebo-controlled study.
1759418|NCT00272805|Drug|carvedilol|
1759419|NCT00272831|Drug|Cilostazol|Cilostazol 100 mg twice daily
1759420|NCT00272831|Drug|Placebo|1 tablet twice daily
1759422|NCT00272857|Genetic|Retrovirus Construct|This study will use an experimental gene transfer procedure performed in a laboratory to insert a new FA gene into the participant's bone marrow cells. The gene-corrected bone marrow cells will then be re-infused into the participant and participants will be observed for successful gene transfer
1759423|NCT00272870|Drug|06Benzylguanine|120 mg/m2/day; given Day 1-5 for up to 6 courses in Block 3
1759424|NCT00272870|Genetic|MGMT P140K|Gene manipulated cells, patients are not expected to receive greater than approximately 10 x 10e6 transduced CD34+ cells/kg
1759425|NCT00272870|Device|Meltenyi CliniMacs|Device used for CD34+ cell separation of peripheral collection
1759426|NCT00272896|Drug|Vasoactive intestinal peptide|
1759427|NCT00272909|Drug|piclozotan low dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
1759428|NCT00272909|Drug|placebo|Continuous IV infusion over a period of up to 72 hours of placebo.
1759429|NCT00272909|Drug|piclozotan high dose|Continuous IV infusion over a period of up to 72 hours of piclozotan
1759430|NCT00272922|Device|hernia repair|
1759431|NCT00272935|Drug|Cenestin 0.3 mg Tablets|1 tablet daily
1759432|NCT00272935|Other|Placebo|1 tablet daily
1759433|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d
1759727|NCT00276393|Drug|Basal insulin|
1759434|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv in 4 doses beginning at day of conditioning until day +30 or until discharge from inpatient care (with a minimum treatment of 14 days) if VOD does not occur.
1759435|NCT00272948|Drug|Defibrotide|Defibrotide 25 mg/kg/d iv therapeutically when patients fulfil modified Seattle criteria
1759436|NCT00272961|Drug|Placebo|placebo tablet once daily for 12 weeks
1759437|NCT00272961|Drug|TBC3711|10 mg tablets once daily for 10 weeks
1759438|NCT00272961|Drug|TBC3711|50 mg tablet once daily for 10 weeks
1759439|NCT00272961|Drug|TBC3711|100 mg tablet once daily for 10 weeks
1759440|NCT00272961|Drug|TBC3711|200 mg tablet once daily for 10 weeks
1759441|NCT00272974|Behavioral|Clinic-based counseling|
1759442|NCT00272987|Drug|lapatinib|(GW572016) 1000 mg QD
1759443|NCT00272987|Drug|paclitaxel|80 mg/m2 IV weekly for three weeks
1759444|NCT00272987|Drug|trastuzumab|4 mg/kg loading dose and 2 mg/kg weekly IV
1759445|NCT00273000|Drug|GLP-2|
1759448|NCT00273026|Drug|salmeterol xinafoate/fluticasone propionate|
1759450|NCT00273052|Drug|Carvedilol Phosphate modified release formulation|
1759451|NCT00273052|Drug|metoprolol succinate|
1759452|NCT00273065|Drug|Neosaxitoxin|
1759453|NCT00273091|Device|ICD with CRT therapy|permanently CRT pacing
1759454|NCT00273104|Procedure|Bariatric surgery|Bariatric surgery as a part of public health service offered treatment seeking morbidly obese patients.
1759455|NCT00273104|Behavioral|Intensive lifestyle intervention|Intensive lifestyle intervention as a part of public health service offered treatment seeking morbidly obese patients.
1759456|NCT00273117|Procedure|transnasal gastroscopy|
1759457|NCT00273130|Procedure|transnasal endoscopy|
1759458|NCT00273130|Procedure|transoral thin endoscopy|
1759459|NCT00273156|Behavioral|Telephone quitline|
1759460|NCT00273182|Device|InSync Model 8040|Subjects with sucessful implants of InSync Model 8040.
1759461|NCT00273182|Device|InSync III Model 8042|Subjects with successful implants of InSync III Model 8042
1759462|NCT00273195|Device|Implantable Cardioverter Defibrillator|
1759463|NCT00273208|Behavioral|10 week behavioral intervention program|
1759464|NCT00273221|Procedure|Glaucoma Implant Surgery|
1759465|NCT00273221|Procedure|trabeculectomy|
1759466|NCT00273221|Procedure|phacoemulsification|
1759467|NCT00273234|Procedure|Autologous Platelet Gel (APG)|
1759468|NCT00273247|Drug|Interferon alpha-2b|
1759469|NCT00273260|Behavioral|individualised bone density feedback and education|
1759470|NCT00273273|Procedure|blood draw|
1759471|NCT00273286|Behavioral|family diabetes management intervention|a clinic-integrated, low intensity, multi-component behavioral intervention
1759472|NCT00273299|Drug|valsartan plus hydrochlorothiazide|
1759473|NCT00273312|Drug|Patupilone|Patupilone was in dosage strength of 10 mg/4 mL as a clear, colorless concentrate for solution for injection in individual 10 mL glass vials
1759474|NCT00273338|Drug|calcitriol|
1759475|NCT00273338|Drug|docetaxel|
1759476|NCT00273351|Drug|[123I]B-CIT|Subjects will receive up to 6 mCi of [123I] B-CIT injected intravenously
1759477|NCT00273364|Procedure|Hematopoietic Stem Cell Therapy|After mobilization and harvest of stem cells, stem cells will be infused following conditioning regimen
1759478|NCT00273364|Drug|Standard treatment with a conventional drug|Standard treatment with a conventional drug is the treatment with one of the following drugs: Avonex (interferon beta 1a), Betaseron (interferon beta 1b), Copaxone (glatiramer acetate), Aubagio (teriflunomide), Tysabri (natalizumab), or GILENYATM (fingolimod)
1759479|NCT00273377|Other|Mild intraoperative hypercapnia (50 mmHg vs. 30 mmHg)|
1759480|NCT00273377|Other|Supplemental oxygen (80% vs. 30%)|
1759481|NCT00273377|Drug|Dexamethasone|4 mg
1759482|NCT00273377|Drug|Placebo|placebo
1759483|NCT00273390|Drug|Remicade (infliximab)|
1759484|NCT00273403|Behavioral|Maintenance in Care Services|
1759485|NCT00273403|Behavioral|Access to Care Services|
1759486|NCT00273416|Drug|PF-00592379|
1759487|NCT00273416|Drug|Sildenafil 100mg|
1759488|NCT00273429|Drug|timolol maleate 0.5%|
1759489|NCT00273429|Drug|dorzolamide/timolol maleate fixed combination|
1759490|NCT00273429|Drug|latanoprost 0.005%|
1759491|NCT00273429|Drug|placebo|
1759492|NCT00273442|Drug|timolol maleate|
1759493|NCT00273442|Drug|dorzolamide/timolol maleate fixed combination|
1759494|NCT00273455|Drug|bimatoprost 0.03%|
1759495|NCT00273455|Drug|dorzolamide 2%/timolol maleate 0.5% fixed combination|
1759496|NCT00273455|Drug|placebo|
1759497|NCT00273468|Drug|Granisetron|
1759498|NCT00273481|Drug|dorzolamide 2%/timolol maleate 0.5% fixed combination|
1759499|NCT00273481|Drug|latanoprost 0.005%/timolol maleate 0.5% fixed combination|
1759500|NCT00273481|Drug|timolol maleate 0.5%|
1759501|NCT00273481|Drug|placebo|
1759502|NCT00273494|Procedure|Surgery|
1759503|NCT00273507|Drug|Carboplatin and Paclitaxel|
1759504|NCT00273520|Drug|Telithromycin|
1759505|NCT00273533|Drug|Ramipril|
1759506|NCT00273546|Drug|XRP6976 (Docetaxel/Taxotere)|
1759507|NCT00273559|Drug|prednisone|group 2 will remain on 5 mg of prednisone for at least 90 days post transplant.
1759508|NCT00273572|Other|Moderate Lifestyle Intervention|Two educational group meetings with a dietitian in the first month of intervention; One individual counselling session with a dietitian at baseline, and at 6-month and 12-month follow-up
1759509|NCT00273572|Other|Intensive lifestyle intervention|A monthly individual counselling session with a dietitian; A monthly group session with a dietitian; Bi-monthly group sessions with a physical activity instructor
1759510|NCT00273585|Device|Personally-tailored educational software program|
1759514|NCT00273624|Drug|Olanzapine|10 mg Olanzapin concurrent to antidepressive medication
1759515|NCT00273624|Drug|Placebo|placebo
1759516|NCT00273650|Drug|methylcobalamin|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
1759517|NCT00273650|Other|saline placebo|Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
1759518|NCT00273663|Device|TCES|
1759519|NCT00273676|Procedure|Conversion to oral antibiotic treatment after 3 days of intravenous antibiotic treatment|
1759520|NCT00273689|Drug|montelukast vs pretreatment with albuterol|montelukast 5 or 10 mg once daily for 3 days vs albuterol 2 puffs, 15 minutes before exercise
1759521|NCT00273689|Drug|montelukast|Montelukast 5 or 10 mg once daily for 3 days vs Albuterol inhlare 2 puffs, 15 minutes before exercise
1759522|NCT00255749|Biological|epoetin alfa|
1759523|NCT00255762|Drug|carboplatin|Given IV
1759524|NCT00255762|Drug|paclitaxel|Given IV
1759525|NCT00255762|Biological|bevacizumab|Given IV
1759526|NCT00255762|Other|laboratory biomarker analysis|Correlative studies
1759527|NCT00255775|Dietary Supplement|broccoli sprout extract|
1759528|NCT00255775|Procedure|complementary or alternative medicine procedure|
1759529|NCT00255788|Drug|everolimus|
1759532|NCT00255814|Radiation|radiation therapy|
1759533|NCT00266643|Drug|duloxetine hydrochloride|
1759534|NCT00266656|Drug|Humatrope|According to investigator's clinical practice and guided by the approved package insert
1759535|NCT00266669|Drug|Topical organogel with nitroglycerin|
1759536|NCT00266682|Device|Pacing Lead|
1759537|NCT00266695|Drug|Ruboxistaurin|32-milligram (mg) tablet, orally, once daily (QD) for up to 2 years.
1759538|NCT00266708|Drug|risedronate 35 mg weekly vs placebo|
1759539|NCT00266721|Drug|Pancrelipase (Creon) 2 tablets with each meal|
1759540|NCT00266734|Device|RPS Adeno Detector|
1759541|NCT00266747|Drug|SR58611A|
1759542|NCT00266773|Behavioral|Chronic pain therapeutic interactive voice response (TIVR) system|Therapeutic Interactive Voice Response as a daily self monitoring and relapse prevention tool with didactic reviews and practices of recorded skills and monthly feedback based on daily calls
1759543|NCT00266786|Drug|Intranasal Ketorolac Tromethamine|Intranasal at 30mg
1759544|NCT00266786|Drug|Intranasal Placebo|Intranasal Placebo
1759545|NCT00266799|Drug|Pegylated liposomal doxorubicin (SCH 200746)|pegylated liposomal doxorubicin (50 mg/m^2 q 28 days) was administered intravenously until disease progression or unacceptable toxicity
1759546|NCT00266799|Drug|Capecitabine|capecitabine (1250 mg/m^2 BID x 14 days q 21 days) in tablets of 150 mg and 500 mg was administered orally, until disease progression or unacceptable toxicity
1759547|NCT00266812|Drug|Temozolomide and radiotherapy|Oral temozolomide 75mg/m2/day for 14 days, during radiation treatment, and later on temozolomide 100 mg/m2/day at 14 days on/14 days off, until unacceptable toxicity or evidence of disease progression for up to 6 cycles from initial treatment. Radiotherapy (as in Intervention 2).
1759548|NCT00266812|Procedure|Whole brain radiotherapy|2 regimens are allowed: a) 20 fractions of 2 Gray each, administered on days 1 to 5, 8 to 12, 15 to 19, and 22 to 26; b) 10 fractions of 3 Gray each, administered on days 1 to 5 and 8 to 12.
1759549|NCT00266825|Drug|DHA|600 mg DHA
1759550|NCT00266825|Other|Placebo capsule|Placebo capsule
1759551|NCT00266838|Drug|Maxidex; Lacrystat|6 times daily, for 20 weeks.
1956760|NCT02712034|Other|MAT|"Patients will receive treatment consisting of a recovery plan, appropriate pharmacology, routine urine screens, and regularly scheduled behavioral interventions, such as monthly group counseling sessions or sessions with a recovery coach. Appropriate pharmacology may include methadone; naltrexone; buprenorphine; and in the case of overdose, naloxone; and other medications and combinations of medications as part of the patient's standard clinical care."
1759558|NCT00266929|Procedure|surgical|surgical treatment of odontoid fractures
1759559|NCT00266929|Procedure|conservative treatment|conservative stabilization of fractures
1759560|NCT00266981|Device|APOS - exercise component|
1759561|NCT00267007|Drug|PROCRIT 40,000 IU QW|Epoetin alpha (PROCRIT) 40,000 IU every week (QW) for 18 weeks (IV or SC)
1759562|NCT00267007|Drug|Placebo|Equivalent volume to PROCRIT (1 mL) administered (QW) for 18 weeks (IV or SC)
1759563|NCT00267020|Drug|enzastaurin|1200 mg loading dose then 500 mg, oral, daily, six 28 day cycles
1759564|NCT00267020|Drug|gemcitabine|1000 mg/m2, IV, days 1, 8 and 15 per cycle, six 28 day cycles
1759565|NCT00267033|Procedure|injection of orthopaedic cement into vertebral bodies|injection of orthopaedic cement into vertebral bodies
1759566|NCT00267046|Drug|Palifermin|180 mcg/kg 3 days prior to chemotherapy
1759567|NCT00267046|Drug|Placebo|Single dose 3 days prior to chemotherapy
1759568|NCT00267046|Drug|Adriamycin (Doxorubicin)|30 mg/m^2 IV continuous infusion for 72 hours; days 0, 1, 2 (infusion completing on day 3) (total dose = 90 mg/m^2).
1759569|NCT00267046|Drug|Ifosfamide|2.5 g/m^2 IV bolus over 3 hours, days 0,1, 2, 3 (total dose = 10 g/m^2); for patients receiving the AI Regimen.
1759570|NCT00267046|Drug|Vincristine|2 mg IV on day 0, for patients with small cell histology receiving the AI Regimen.
1759571|NCT00267046|Drug|Cisplatin|120 mg/m^2 on day 0, for patients receiving the AP Regimen.
1759572|NCT00267059|Drug|Lenalidomide|10 mg/day, orally once a day for 28 days
1759573|NCT00267085|Biological|Synthetic Tumor-Specific Breakpoint Peptide Vaccine|CML vaccine, Imatinib mesylate, subcutaneously every 2 weeks x 4 weeks, then every three weeks x 1 week, then monthly for 10 months
1759574|NCT00267098|Device|Cardiac Resynchronization Therapy (CRT)|Biventricular pacing
1759575|NCT00267098|Device|Cardiac Resynchronization Therapy (CRT)|Right ventricular pacing
1759576|NCT00267111|Drug|Eucerin plus|1g, single application
1759577|NCT00267111|Drug|Amethocaine gel 4%|1 g, single application
1759578|NCT00267137|Device|Pacing Algorithms|
1759579|NCT00267150|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Experimental
1759580|NCT00267163|Drug|donepezil|
1759581|NCT00267163|Drug|Placebo|
1759582|NCT00267176|Drug|lumiracoxib|
1759583|NCT00267189|Drug|Everolimus|1.5 mg bid adjusted in order to achieve a trough level between 3 and 8 ng/mL while in combination with CNI and between 6 and 12 ng/mL after CNI discontinuation
1759584|NCT00267189|Drug|Calcineurin inhibitors (CNI)|
1759585|NCT00267189|Drug|Mycophenolate acid (MPA)/ Azathioprine (AZA)|
1759586|NCT00267189|Drug|Steroids|
1759587|NCT00267202|Drug|Placebo|Doses of placebo were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
1759588|NCT00267202|Drug|Omalizumab|Doses of omalizumab were administered subcutaneously every 2 to 4 weeks according to the US product label, depending on the patient's body weight and baseline serum IgE.
1759589|NCT00267202|Drug|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
1759590|NCT00267202|Drug|Immunotherapy|"Customized allergen extracts were prepared centrally for each patient based on his/her specific skin test results. Four vials containing dilutions of the patient's extract were provided. Investigators initiated dosing according to the protocol for the cluster dosing titration regimen, beginning with vial #4 (the most dilute) and progressing to vial #1, which was the most concentrated or maintenance solution. Each dose was administered subcutaneously into the deltoid region as a single injection. During study visits that required multiple IT injections, each injection was to be given at least 30 minutes apart. During weeks that required multiple visits for IT injections, each visit was to be separated by at least 48 hours."
1759591|NCT00267215|Drug|Lumiracoxib|
1759592|NCT00267241|Other|Mechanical Ventilation|Four different types of assisted ventilation (pressure support, pressure support plus sigh, BIPAP, variable ventilation)
1759593|NCT00267254|Drug|torcetrapib/atorvastatin|
1759594|NCT00267254|Drug|simvastatin|
1759595|NCT00267267|Drug|torcetrapib/atorvastatin|
1759596|NCT00267267|Drug|ezetimibe/simvastatin|
1759597|NCT00267280|Drug|torcetrapib/atorvastatin|
1759598|NCT00267280|Drug|simvastatin|
1759599|NCT00267293|Drug|Acetaminophen|Given for fever control 15mg/kg
1759600|NCT00267293|Drug|Ibuprofen|Given for fever control 10 mg/kg
1759601|NCT00267306|Drug|Visilizumab|
1759602|NCT00267319|Drug|Glatiramer acetate|
1759603|NCT00267332|Drug|Modafinil|
1759604|NCT00267358|Drug|RC-1291 HCl|
1759605|NCT00267358|Drug|Placebo|
1759606|NCT00267371|Device|PFO Closure with Premere investigational device.|PFO Closure with Premere investigational device.
1759607|NCT00267371|Drug|Medical management/current medications per standard of care by personal physician.|Medical management with current medications per standard of care by personal physician.
1759608|NCT00267384|Drug|Oral N-Acetylcysteine|
1759609|NCT00267410|Behavioral|Healthy Relationships|"Healthy Relationships, grounded in the social cognitive theory, is a five-session, group-level intervention originally designed for HIV-positive heterosexual individuals seeking skills-building and support around risk reduction, as well as disclosure of status and sexual preference. Through clip media and active role-plays, the intervention promotes the development of decision-making and problem-solving tools, empowering participants to make voluntary and informed decisions around disclosure and safer sex practices. This model was formally disseminated to AIDS Service Organizations as part of CDC's strategic plan - Advancing HIV Prevention, New Strategies for a Changing Epidemic - which focused on innovative strategies to recruit individuals into HIV testing, as well as a movement towards secondary prevention efforts."
1759610|NCT00267436|Behavioral|Community PROMISE|The Community PROMISE begins with a community assessment to identify HIV risk factors. Once risk factors have been identified, individuals from the targeted at-risk community are recruited and trained to be peer advocates. Trained peer advocates interview members of the community about their behavior. Role model stories are written based on the interviews. Role model stories are personal accounts from individuals in the target population which explain how and why they took steps to practice HIV risk-reduction behaviors and the positive effects the choice has had on their lives. Each week, peer advocates distribute role model stories and supplies, such as condoms, to 10 to 20 members of their social networks.
1759611|NCT00267449|Device|SoftScan Optical Breast Imaging System|
1759612|NCT00267488|Drug|topotecan|
1759613|NCT00267514|Drug|sevelamer carbonate (Renvela®) sevelamer hydrochloride (Renagel ®)|sevelamer carbonate powder dosed TID with meals for four weeks followed by sevelamer hydrochloride tablets dosed TID with meals for four weeks
1759614|NCT00267514|Drug|sevelamer hydrochloride (Renagel ®) sevelamer carbonate (Renvela®)|sevelamer hydrochloride tablets dosed TID with meals for four weeks followed by sevelamer carbonate powder dosed TID with meals for four weeks
1759615|NCT00267527|Drug|CJC 1295|
1759616|NCT00267540|Behavioral|cholecalciferol (D3) (vitamin)|
1759617|NCT00267553|Drug|Atamestane|
1759618|NCT00267553|Drug|toremifene|
1759619|NCT00267553|Drug|letrozole|
1759620|NCT00267566|Behavioral|Strongest Families (formerly Family Help Program): Anxiety Program|Evidence-based psychological and behavioural distance intervention
1759621|NCT00267579|Behavioral|Strongest Families (formerly Family Help Program): Behaviour Disorder Program|Evidence-based psychological and behavioural Distance Intervention
1759622|NCT00267592|Drug|Talampanel|Talampanel administered orally TID beginning the first day and continued until there is talampanel-related toxicity or tumor progression.
1759623|NCT00267592|Radiation|Radiation Therapy (RT) 5 days a week +|
1759624|NCT00267592|Drug|temozolomide(TMZ) 75mg|temozolomide(TMZ) 75mg 3 times daily (TID) for 6 weeks
1759625|NCT00267592|Drug|adjuvant TMZ 200mg|adjuvant TMZ 200mg TID for 5 consecutive days each month for a total of 6 months.
1759626|NCT00267605|Behavioral|FHPADHD|Evidence-based psychological and behavioural distance intervention
1759627|NCT00267605|Behavioral|ADHD Standard Care|
1759628|NCT00267618|Behavioral|FHP Pain|Evidence-based psychological and behavioural Intervention
1759629|NCT00267657|Drug|Reserpine|
1759630|NCT00273702|Drug|N-Acetyl Cysteine|
1759631|NCT00273715|Procedure|Surgical wound closure techniques|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
1759632|NCT00273715|Procedure|Surgical wound closure techniques (Comparator)|Subjects will be randomized to either receive sutures or staples during the surical procedure to close the incision
1759633|NCT00273728|Drug|hydroxy-ethyl starch (MW 130; 0.4) vs. normal saline|hydroxy-ethyl starch together with ringer's lactate versus physiologic saline together with saline
1759634|NCT00273741|Drug|methylphenidate|methylphenidate per os 20mg per day 7 days, 20mg or 40mg per day 7 days and 20, 40 or 60mg per day 14 days
1759635|NCT00273741|Drug|placebo comparator|placebo capsules
1759636|NCT00273754|Drug|Caffeine|Children in group one will receive caffeine benzoate 20 mg/kg i.v., which is equal to a 10 mg/kg caffeine base.
1759637|NCT00273754|Drug|Placebo|Children in group two will receive an amount of normal saline equal to Caffeine
1759638|NCT00273767|Drug|epoetin beta|800UI/kg in 60ml of Nacl IV slow 1 to 3 hours before surgery
1759639|NCT00273767|Drug|placebo|60ml of NaCl IV slow
1759640|NCT00273780|Behavioral|Adherence counseling|Three adherence counseling sessions will be given to participants in the trial. Two sessions will occur prior to initiation of antiretroviral medications and one session will be given one month after drug administration.
1759641|NCT00273780|Device|Alarm device|This pocket alarm device will be set to ring at designated times during the day that the participant should take their antiretroviral medication.
1759642|NCT00273793|Behavioral|Contingency Management|incentives are available for reduced smoking on each study visit which occur each weekday.
1759643|NCT00273806|Behavioral|Intervention for 4 behavioral risks by medical assistants.|
1759644|NCT00273819|Procedure|CT angiography|
1759645|NCT00273832|Procedure|coronary artery computed tomography angiogram|
1759646|NCT00273832|Procedure|single photon emission computed tomography|
1759647|NCT00273845|Behavioral|Motivational interviewing|One session
1759648|NCT00273845|Behavioral|Strengths-Based Case Management|5 sessions
1759649|NCT00273858|Other|There is no Intervention. The study is observational.|The study is observational and the prescription follows the SmPC of etanercept.
1759650|NCT00273871|Drug|Cyclosporin or tacrolimus|
1759651|NCT00273884|Drug|Amonafide L-Malate|
1759652|NCT00273884|Drug|Cytarabine|
1759653|NCT00273897|Device|Phoresor II|
1759654|NCT00273910|Drug|gp100:209-217 (210M)|
1759655|NCT00273910|Drug|Montanide ISA-51|
1759656|NCT00273910|Drug|Imiquimod|Apply imiquimod 5% cream to the skin at the site of injection daily for 5 days
1759657|NCT00273936|Drug|AVN-944 capsules for oral administration|
1759658|NCT00273949|Drug|lactulose|
1759659|NCT00273962|Drug|ipratropium plus salbutamol UDV|
1759660|NCT00273962|Drug|salbutamol UDV|
1759661|NCT00273975|Drug|Nevirapine|
1759662|NCT00273975|Drug|Lamivudine|
1759663|NCT00273975|Drug|Zidovudine|
1759664|NCT00273988|Drug|nevirapine|
1759665|NCT00274001|Drug|Nevirapine|
1759666|NCT00274014|Drug|Tiotropium|
1759667|NCT00274027|Drug|tiotropium bromide|
1759668|NCT00274040|Drug|Tiotropium|
1759669|NCT00274040|Drug|Ipratropium|
1759670|NCT00275743|Procedure|MRI|
1759671|NCT00275756|Drug|Timolol (drug)|Timolol (0.5%, non-selective beta-blocker, Timoptic®, Merck Sharp & Dohme, Haarlem, Netherlands), dose 1 drop in one eye twice daily for two weeks
1759672|NCT00275756|Drug|dorzolamide (drug)|Dorzolamide (2%, carbonic anhydrase inhibitor, Trusopt®, Laboratoires Merck Sharp & Dohme - Chibret, France), dose: 1 drop in one eye twice daily for two weeks
1759673|NCT00275756|Drug|brimonidine (drug)|Brimonidine (0.2%. alpha-2 adrenergic agonist, Alphagan®, Allergan Pharmaceuticals, Westport, Ireland), dose: 1 drop in one eye twice daily for two weeks
1759674|NCT00275756|Device|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head, in total 4x 9 minutes on 2 study days
1759675|NCT00275756|Device|Goldmann applanation tonometer|intraocular pressure measurements, in total 2x 5 measurements on two study days
1759676|NCT00275756|Procedure|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus; 4x 8 minutes on 2 study days
1759677|NCT00275769|Device|Pacemaker|
1759678|NCT00275795|Procedure|NAET Procedures|
1759679|NCT00275821|Drug|Ranibizumab 0.3 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.3 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
1759728|NCT00276406|Drug|Pyridostigmine|Pyridostigmine will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
1759729|NCT00276406|Drug|Placebo|If subject is randomized to placebo, placebo pills will be started at (60mg) tid, increased over 10 days to 120 mg tid, and maintained at that dose for 7 days.
1759680|NCT00275821|Drug|Ranibizumab 0.5 mg - 3 times monthly, then quarterly|Subjects received intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. They were treated monthly for 3 consecutive months and then quarterly for the remainder of the study. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
1759681|NCT00275821|Drug|Ranibizumab 0.3 mg monthly|Subjects received monthly intravitreal injections (in the study eye) of ranibizumab 0.5 mg over a duration of 12 months. On those months when ranibizumab was not administered, patients received a sham injection to preserve the masking of the treatment arms.
1759682|NCT00275834|Drug|Zonisamide|zonisamide 400 mg, 200 mg, or placebo
1759683|NCT00275912|Drug|Oxcarbazepine|
1759684|NCT00275925|Drug|Oxcarbazepine|
1759685|NCT00275938|Drug|interferon alpha 2b plus ribavirin|
1759686|NCT00275938|Drug|interferon alpha 2b plus placebo|
1759687|NCT00275951|Drug|Cetuximab Plus P-HDFL|Cetuximab 400 mg/m2, IV, day 1 of cycle 1; then weekly IV 250 mg/m2. Cisplatin 24-hour IV infusion 35 mg/m2/day, plus HDFL (5-FU 2,000 mg/m2 and leucovorin 300 mg/m2), day 1 and day 8. HDFL IV, day 15.
1759688|NCT00275964|Drug|TMN-1|
1759689|NCT00275977|Procedure|Coronary catherization and stem cell infusion|
1759690|NCT00275990|Device|rheolytic thrombectomy with direct stenting|
1759691|NCT00275990|Device|direct stenting|
1759692|NCT00276003|Drug|Gemcitabine, Irinotecan, Allopurinol.|Gemcitabine - 1000mg/m2; IV; d1, 8; q 21 days Irinotecan - 100mg/m2; IV; d1, 8; q 21 days Allopurinol - 300 mg; PO; day 1-5; 1st cycle
1759693|NCT00276016|Drug|phenylephrine|immediate-release 12 mg capsules for oral administration
1759694|NCT00276016|Drug|pseudoephedrine|60 mg immediate-release tablets for oral administration
1759695|NCT00276016|Drug|placebo|placebo capsules
1759696|NCT00276029|Drug|Etanercept|
1759697|NCT00276042|Drug|Faropenem Medoxomil|
1759698|NCT00276055|Drug|Gemcitabine, Docetaxel and Bevacizumab|During the treatment phase, pts. will receive the drug combination of gemcitabine, docetaxel, and bevacizumab every 2 weeks for a period of 4 weeks. This 4-week period is called a cycle of treatment. The treatment consists of receiving docetaxel IV over a 60-minute period and gemcitabine IV over a 30-minute period. Pts. will then receive bevacizumab IV over a 30-minute period. Pts. will receive this treatment once every 2 weeks. Pts. will receive at least 2 cycles of treatment unless you have progression of your disease or unmanageable side effects. As long as the size of pts.'s tumor stays the same or gets smaller, pts may continue receiving treatment
1759699|NCT00276068|Drug|topical lidocaine + oral desipramine, and/or placebo|
1759700|NCT00276081|Drug|Gabapentin, Estrogen and placebo administration|
1759701|NCT00276094|Drug|Ospemifene 30 mg|1 tablet (dose 30 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
1759702|NCT00276094|Drug|Ospemifene 60 mg|1 tablet (dose 60 mg/day) taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
1759703|NCT00276094|Drug|Placebo|1 tablet taken each morning with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12).
1759704|NCT00276094|Drug|Nonhormonal vaginal lubricant|Subjects should apply the vaginal lubricant as needed and record the usage in the medication diary.
1759705|NCT00276107|Biological|Prevenar|
1759706|NCT00276133|Drug|Effects of atorvastatin versus probucol on small dense LDL|
1759707|NCT00276146|Drug|oral dipyridamole, oral magnesium, or a combination of both|
1759708|NCT00276159|Drug|852A|Subcutaneous injection 0.6 mg/m2 2 times/week/12 weeks, may increase by 0.2 mg/m2 up to 1.2 mg/m2.
1759709|NCT00276172|Drug|Natalizumab|Natalizumab 300 mg by IV infusion, every 4 weeks, for up to 24 months
1759710|NCT00276185|Drug|Time delay treatment of botulinum toxin|
1759711|NCT00276198|Dietary Supplement|Sprinkles|Daily dosage of fat coated iron (desote fumarate) 12.5 mg, zinc 5mg, vitamin A 300 micrograms, folic acid 150 micrograms, ascorbic acid 50 mg.
1759712|NCT00276198|Dietary Supplement|Ferripel-3, Vitamins A&D drops|Daily dosage of Iron tonic 15mg, vitamins A 300 micrograms, vitamin D 10 micrograms once a day from age 6 months up to age 12 months
1759713|NCT00276224|Drug|ferrous sulphate (drug)|
1759714|NCT00276250|Drug|Efalizumab|Efalizumab was a medication approved for use in psoriasis which was being explored to determine efficacy with immunosuppression following organ transplantation. Efalizumab was administered subcutaneously on a weekly basis. Upon efalizumab being withdrawn from the US market, the protocol was amended to alter the immunosuppressive regimen to abatacept for the study participants.
1759715|NCT00276250|Drug|Abatacept|Abatacept is drug used to treat autoimmune diseases. Abatacept is administered intravenously, monthly, in weight-based doses and is given for as long as transplanted islets are functioning.
1759716|NCT00276250|Drug|Belatacept|Belatacept is a medication to provide extended graft survival while limiting the toxicity generated by standard immune suppressing regimens. Belatacept is administered intravenously. The protocol for this study was amended to substitute belatacept for abatacept for all newly enrolling participants (current participants remained on abatacept).
1759717|NCT00276263|Drug|Sarcosine (N-methylglycine)|Randomization to two treatment groups. One group treated with sarcosine 2 g/day for 16 weeks, the other group treated with placebo 2 g/day for 16 weeks.
1759718|NCT00276276|Drug|topotecan|
1759719|NCT00276289|Drug|Spironolactone|
1759720|NCT00276302|Drug|IPI-504|"IV administration of IPI-504 for 21-day cycles. Two different schedules of treatment will be tested. On Schedule A, doses occur on Days 1, 4, 8, and 11 followed by 10 days with no study drug administration. On Schedule B, doses occur on Days 1, 4, 8, 11, 15, and 18, or twice weekly for 3 weeks continuously.
For both Schedule A and B doses will be administered ≥ 72 hours apart."
1759721|NCT00276315|Drug|Botulinum type A toxin (Dysport®) - one single injection|
1759722|NCT00276328|Drug|Diosmectite (Smecta®)|
1759723|NCT00276341|Drug|EGb 761® (Tanakan®)|
1759724|NCT00276354|Drug|PEG 4000 (Forlax ®)|
1759730|NCT00276419|Drug|Diclofenac|Compounded topical diclofenac cream applied to the skin three times daily for 10 weeks
1759731|NCT00276419|Drug|Placebo|Placebo for Diclofenac in topical cream applied to the skin three times daily for 10 weeks
1759732|NCT00276432|Device|iSTAT point of care analyzer|
1759733|NCT00276445|Drug|beta-1,3-glucan|
1759734|NCT00276458|Drug|Comparator: atorvastatin|Atorvastatin 40mg tablet po qd (by mouth, once a day) for 6 weeks
1759735|NCT00276458|Drug|Comparator: Placebo|Atorvastatin 20mg Pbo and ezetimibe 10mg Pbo tablets po qd (by mouth, once a day). for 6 weeks
1759736|NCT00276458|Drug|Comparator: ezetimibe|Atorvastatin 20mg and ezetimibe 10mg tablets po qd (by mouth, once a day). for 6 weeks.
1759737|NCT00276458|Drug|Comparator: Placebo.|Atorvastatin 40mg Pbo tablets po qd (by mouth, once a day). for 6 weeks.
1759738|NCT00276471|Device|Implantable pulse generator and electrodes|
1759739|NCT00276484|Drug|atorvastatin|Atorvastatin 80 mg tablet by mouth, once a day for 6 weeks
1759740|NCT00276484|Drug|atorvastatin|Atorvastatin 40 mg by mouth, once a day for 6 weeks
1759741|NCT00276484|Drug|ezetimibe|Ezetimibe 10 mg tablets by mouth, once a day for 6 weeks.
1759742|NCT00276497|Drug|Pioglitazone|
1759743|NCT00276510|Drug|EGb 761® (Tanakan®)|120 mg, 1 tablet twice a day, oral route, during 5 years.
1759744|NCT00276510|Other|Placebo|1 tablet twice a day, oral route, during 5 years.
1759745|NCT00276523|Biological|PEG-interferon alfa-2b|Study medication begins on Day 1 and taken subcutaneously once each week with the last dose being taken within 1 week prior to surgery or biopsy.
1759746|NCT00276523|Procedure|Conventional surgery|Participants on the control arm may undergo surgery at anytime within 3 weeks of randomization, and those randomized to PEG-Intron will undergo surgery on Days 16-22 following initiation of treatment.
1759747|NCT00276523|Procedure|Neoadjuvant therapy|
1759748|NCT00276536|Biological|recombinant interferon alpha-1b|interferon
1759749|NCT00276536|Drug|IFN|IFN daily
1759750|NCT00276549|Drug|docetaxel|docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
1759751|NCT00276549|Drug|gemcitabine hydrochloride|IV over 30 minutes on days 1 and 8 followed by docetaxel IV over 60 minutes on day 8. Treatment repeats every 3 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.
1759752|NCT00276575|Biological|bevacizumab|
1759753|NCT00276575|Drug|erlotinib hydrochloride|
1759754|NCT00276575|Drug|everolimus|
1759755|NCT00276588|Drug|carboplatin|
1759756|NCT00276588|Drug|gemcitabine hydrochloride|
1759757|NCT00276588|Drug|paclitaxel|
1759758|NCT00276601|Drug|arsenic trioxide|
1759759|NCT00276601|Drug|cytarabine|
1759760|NCT00276601|Drug|daunorubicin hydrochloride|
1759761|NCT00276601|Drug|mercaptopurine|
1759762|NCT00276601|Drug|methotrexate|
1759763|NCT00276601|Drug|tretinoin|
1759764|NCT00276614|Drug|bortezomib|
1759765|NCT00276627|Behavioral|communication lecture|lecture on communication skills with oncology patients
1759766|NCT00276627|Behavioral|lecture plus CD-ROM|Interactive CD-ROM about responding to patients' negative emotions. The CD-ROM included tailored feedback on the oncologists' own recorded conversations.
1759767|NCT00276640|Drug|vincristine, carboplatin|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21
carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21"
1759768|NCT00276640|Drug|vincristine, carboplatin, etoposide|"vincristine: 1,5 mg/m² i.v., week 1,2,3,4,5,6,7,8,9,10,13,17,21
carboplatin: 550 mg/m² i.v., week 1,4,7,10,13,17,21
etoposide: 100 mg/m² i.v., week 1,4,7,10"
1759769|NCT00276640|Radiation|radiation therapy|"intracranial tumor site: 30 fractions, dose per fraction: 1.8 Gy, total dose: 54 Gy, duration 6 weeks
spinal tumor site: 28 fractions, dose per fraction: 1.8 Gy, total dose: 50.4 Gy duration 5 1/2 weeks"
1759770|NCT00276666|Drug|cisplatin|
1759771|NCT00276666|Drug|lomustine|
1759772|NCT00276666|Drug|vincristine sulfate|
1759773|NCT00276666|Procedure|adjuvant therapy|
1759774|NCT00276666|Radiation|radiation therapy|
1759775|NCT00276679|Drug|temozolomide|
1759776|NCT00276692|Drug|irinotecan hydrochloride|
1759777|NCT00276705|Drug|cisplatin|
1759778|NCT00276705|Drug|cyclophosphamide|
1759779|NCT00276705|Drug|doxorubicin hydrochloride|
1759780|NCT00276705|Drug|thalidomide|
1759781|NCT00276705|Procedure|adjuvant therapy|
1759782|NCT00276705|Procedure|conventional surgery|
1759783|NCT00276705|Procedure|neoadjuvant therapy|
1759784|NCT00276718|Biological|bleomycin sulfate|
1759785|NCT00276718|Drug|carboplatin|
1759786|NCT00276718|Drug|etoposide|
1759787|NCT00276718|Procedure|conventional surgery|
1759788|NCT00276731|Drug|carboplatin|
1759789|NCT00276731|Drug|cisplatin|
1759790|NCT00276731|Drug|cyclophosphamide|
1759791|NCT00276731|Drug|etoposide|
1759792|NCT00276731|Drug|vincristine sulfate|
1759793|NCT00276731|Procedure|conventional surgery|
1759794|NCT00276731|Procedure|neoadjuvant therapy|
1759795|NCT00276731|Radiation|radiation therapy|
1759796|NCT00276744|Biological|cetuximab|
1759797|NCT00276744|Drug|bortezomib|
1759798|NCT00276744|Drug|capecitabine|
1759799|NCT00276744|Drug|docetaxel|
1759800|NCT00276744|Drug|erlotinib hydrochloride|
1759801|NCT00276744|Drug|gemcitabine hydrochloride|
1759802|NCT00276744|Drug|irinotecan hydrochloride|
1759803|NCT00276744|Drug|mitomycin C|
1759804|NCT00276744|Drug|sirolimus|
1759805|NCT00276744|Drug|thalidomide|
1759806|NCT00276744|Other|antitumor drug screening assay|
1759807|NCT00276744|Procedure|conventional surgery|
1759808|NCT00276757|Drug|leucovorin calcium|
1759809|NCT00276757|Drug|methotrexate|
1759810|NCT00276757|Drug|prednisolone|
1759811|NCT00276757|Drug|vinblastine sulfate|
1759812|NCT00276770|Other|fluorine F 18 fluorothymidine|
1759813|NCT00276770|Procedure|positron emission tomography|
1759814|NCT00276783|Drug|pemetrexed|Administered intravenously at a dose of 900 mg/m2 every 21 days until disease progression.
1759815|NCT00276796|Drug|cisplatin|
1759816|NCT00276796|Drug|paclitaxel|
1759817|NCT00276796|Drug|topotecan hydrochloride|
1759818|NCT00276809|Biological|alemtuzumab|
1759819|NCT00276809|Biological|filgrastim|
1759820|NCT00276809|Drug|carmustine|
1759821|NCT00276809|Drug|cyclophosphamide|
1759822|NCT00276809|Drug|cytarabine|
1759823|NCT00276809|Drug|dexamethasone|
1759824|NCT00276809|Drug|etoposide|
1759825|NCT00276809|Drug|fludarabine phosphate|
1759826|NCT00276809|Drug|melphalan|
1759827|NCT00276809|Procedure|autologous bone marrow transplantation|
1759828|NCT00276809|Procedure|peripheral blood stem cell transplantation|
1759829|NCT00276809|Radiation|radiation therapy|
1759830|NCT00276822|Other|communication intervention|Patient Education Programs to include surveys, questionnaires, interviews, and videos.
1759831|NCT00276835|Biological|High-dose interleukin-2|Administered days 1-5, and 15-19; the patient will receive 600,000 IU/kg IL-2 by intravenous infusion over 15 minutes every 8 hours (on day 1 and day 15, patients will receive a maximum of 2 doses per day; on all other days in the cycle patients will receive a maximum of 3 doses per day)
1759832|NCT00276835|Dietary Supplement|genistein|Starting on day 10 and continuing through day 19, genistein will be administered orally at a dose of 600mg/day in two divided doses (i.e. 300mg po bid x 10 days)
1759833|NCT00276848|Drug|Fludarabine plus Cyclophosphamide|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, plus cyclophosphamide dosed at 250 mg/m2, administered intravenously daily over 30 minutes for 3 days, repeated every 28 days for a maximum of 6 courses
1759834|NCT00276848|Drug|Fludarabine|fludarabine at a dose of 25 mg/m2, administered intravenously daily over 30 minutes for 5 days, or fludarabine dosed at 30 mg/m2, administered intravenously daily over 30 minutes for 3 days, , repeated every 28 days for a maximum of 6 courses
1759835|NCT00276861|Drug|gemcitabine hydrochloride|
1759836|NCT00276861|Drug|oxaliplatin|
1759837|NCT00276874|Drug|Aripiprazole|Aripiprazole; 0-30 mg; oral; daily
1759838|NCT00276874|Drug|Placebos|Placebo; 0 mg; oral; daily
1759839|NCT00276887|Behavioral|Cognitive Behavior Therapy|
1759840|NCT00276887|Behavioral|Psychiatric Consultation Letter|
1759841|NCT00276900|Drug|Sertraline|
1759842|NCT00276913|Drug|STA-5312|
1759843|NCT00276926|Drug|STI571|
1759844|NCT00276939|Behavioral|Low-fat, low-Glycemic Index, vegan diet|
1759845|NCT00276952|Drug|Gonyautoxin|
1759846|NCT00276965|Drug|Sertraline|Sertraline or placebo for sertraline starting at 25 mg per day, up to maximum of 200 mg per day
1759847|NCT00276965|Drug|Lithium carbonate|Lithium or placebo for lithium starting at 150 mg per day; target dose of 900mg per day. Maximum dose based on clinical response and serum levels (maximum serum level of 1.2 mEq/L).
1759848|NCT00276978|Drug|Aripiprazole|Addition of Aripiprazole 10 mg to concurrent medication
1759849|NCT00276991|Drug|"Kallunk oxide (Immunotherapy) "|"The study was assigned only one Arm >450 cu/mm^3 of baseline CD + T cells. HIV type-1 subjects were received one drug, a daily regimen of Kallunk oxide(Immunotherapy) + Long Pepper, that is a combination of a traditional alternative medicine(Complementary and Alternative Medicine CAM) as Kallunk oxide and appropriate drug carrier antidote. The drug assigns to 0.100 mg and 0.200 mg Kallunk oxide molecules with 199.900 mg, and 499.800 mg Antidote( This antidote was used as a carrier of Kallunk oxide molecules), respectively, for children and adults. Dosage: 200 mg for children and 500 mg for adults. This powder form sample size product was administered once daily dose on 5 days treatment. The Botanical name of the antidote is Piper Longum."
1759850|NCT00277017|Drug|5-Flourouracil, Interferon-a, IL-2 and Thalidomide|"Patients will receive oral dosages of Thalidomide at 200mg/day to start, with dosage gradually increasing up to a max of 1200mg/day. This will be taken in combination with:5-fluorouracil, given by continuous IV infusion over 24 hours (Day 1) every week for 4 weeks.
Interferon-α, given subcutaneously on Day 1, 3 and 5 of every week for 4 weeks. Interleukin-2, given by continuous IV infusion Days 2-5, every week for 4 weeks.
Treatment will be followed by 2 weeks of rest then repeated."
1759851|NCT00277030|Drug|Surfactant|
1759852|NCT00277030|Device|Nasal CPAP|
1759853|NCT00277043|Drug|paclitaxel, docetaxel, taxane|1 mg paclitaxel or docetaxel test dose is prepared in 3 ml of normal saline and administered over two to five minutes IV push at least 30 minutes after prescribed IV and PO pre-medications. If no discernable adverse reaction ensues, the balance of the taxane dose is prepared and administered as per standard or specific chemotherapy protocol.
1759854|NCT00277043|Drug|taxane|The full taxane dose is prepared and administered as per standard or specific chemotherapy protocol, at least 30 minutes after prescribed IV and PO pre-medications.
1759855|NCT00277069|Drug|Carboplatin|Carboplatin given at 300mg/m2 IV over 30 minutes day 1, q 21 days
1759856|NCT00277069|Device|Capecitabine|Capecitabine is administered at 1500mg/m2 PO qd in 2 divided doses day 1-14 q 21 days
1759857|NCT00277069|Drug|Vinorelbine|Vinorelbine: 25mg/m2 IV over 10 minutes day 1, 8 q 21 days
1759858|NCT00277082|Drug|9-NC in aerosol reservoir|Samples will be minced or centrifuged and L9NC extracted by chromatography. L9NC will be measured by HPLC or mass spectrometry
1759859|NCT00277095|Device|ProACT (Adjustable Continence Therapy)|Implantable device to reduce urinary stress incontinence
1759860|NCT00277108|Drug|Escitalopram (Lexapro)|
1759861|NCT00277147|Drug|BB IND 6989|
1759862|NCT00277160|Drug|Neulasta (pegfilgrastim)|Commercial pegfilgrastim 6mg single subcutaneous fixed-dose
1759863|NCT00277173|Behavioral|Adoption of Crew Resource Management approach|
1759864|NCT00277186|Other|New Care Continuum|Patient experience surgery through newly designed arthroplasty continuum
1759865|NCT00277199|Drug|Abatacept|
1759866|NCT00277212|Drug|Lamotrigine + Aripiprazole|"Tablets, Oral, once daily, Phase 1 (all subjects) - up to 24 weeks; Phase 2 - up to 52 weeks
Lamotrigine 100-200 mg/day
Aripiprazole 10-30 mg/day"
1760171|NCT00281957|Drug|temsirolimus|Given IV
1759867|NCT00277212|Drug|Lamotrigine + Placebo|"Tablets, Oral, once daily, Phase 2 - up to 52 weeks
Lamotrigine 100-200 mg/day
placebo 0 mg/day"
1759868|NCT00277225|Drug|Abatacept|
1759869|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
1759870|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
1759871|NCT00277238|Drug|Control|Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks
1759872|NCT00277238|Drug|CPG10101|CPG10101, subcutaneous, 0.5mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks
1759873|NCT00277251|Drug|Alendronate|
1759874|NCT00277264|Drug|Tiotropium (Spiriva®)|
1759875|NCT00277277|Behavioral|Healthium|
1759876|NCT00277290|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at 2.4 mg/kg as a 4 hour intravenous (IV) infusion. Subjects received a XL999 infusion once a week for 8 weeks of treatment unless drug-related toxicity required a dosing delay
1759877|NCT00277303|Drug|XL999|XL999 will be administered at 2.4 mg/kg as a 4-hour intravenous (IV) infusion. Subjects will receive XL999 infusions weekly for 8 weeks of treatment unless drug-related toxicity requires dosing delay. In the absence of progressive disease and unacceptable toxicity, subjects may receive XL999 treatment weekly for up to a year on this study. After 8 weeks, at the discretion of the investigator, one dose of four may be omitted for a subject's convenience.
1759878|NCT00277316|Drug|XL999|Treatment was administered on an outpatient basis. XL999 was administered at a dose of 2.4 mg/kg given as a 4 hour IV infusion.
1759879|NCT00277329|Drug|XL999|• The Study Treatment Period, in which subjects received a once-weekly, 4-hour intravenous (IV) infusion of XL999 at 2.4 mg/kg as outpatients for 8 weeks. Treatment was to be stopped at the occurrence of disease progression or unacceptable toxicity.
1759880|NCT00277342|Procedure|measurement of lipid-induced hepatic insulin resistance|
1759881|NCT00277355|Drug|minocycline|Minocycline: Oral; minocycline 100 mg capsules administered twice a day with the morning and evening meal (~ 8 hours apart)
1759882|NCT00277355|Drug|Matching placebo|Matching placebo 1 capsule twice daily, 18 months treatment duration.
1759883|NCT00277368|Other|A structured questionnaire for seizure-related headache|A structured questionnaire for seizure-related headache
1759884|NCT00277381|Behavioral|Automated feedback regarding drug adherence|
1759885|NCT00277394|Drug|innohep®|175 anti-Xa IU/kg administered subcutaneously (SC) once daily
1759886|NCT00277394|Drug|Heparin|Heparin 50 IU /kg followed by a total dose of 400 to 600 IU/kg/day divided into two SC injections daily.
1759887|NCT00277407|Procedure|NAET with acupressure and/or chiropractic procedures|
1759888|NCT00277420|Behavioral|Comprehensive weight management|
1759889|NCT00277433|Other|Buccal Swab|collection of buccal swab
1759890|NCT00277446|Drug|Soy isoflavones|
1759891|NCT00277472|Drug|Valsartan/Hydrochlorothiazide|160/12.5 mg taken once daily orally
1759892|NCT00277472|Drug|HCTZ|25 mg taken once daily orally
1759893|NCT00277498|Drug|Xalacom|
1759894|NCT00277498|Drug|Xalatan|
1759895|NCT00277498|Drug|Timolol|
1759896|NCT00277511|Drug|Levofloxacin|
1759897|NCT00277537|Drug|Mannitol|320mg BD 12 weeks followed by 40 weeks open label
1759898|NCT00277537|Drug|placebo|BD for 12 weeks
1759899|NCT00277550|Drug|Tegaserod and Placebo|
1759900|NCT00277563|Device|reduction of pain scores by magnetic energy|
1759901|NCT00277576|Biological|ppdpSC18 administered by PMED|
1759902|NCT00277589|Drug|Levothyroxin-Na|1 tablet 30 minutes before breakfast
1759903|NCT00277589|Drug|Levothyroxine-Na + iodide|1 tablet 30 minutes before breakfast
1759904|NCT00277589|Drug|Iodide|1 tablet 30 minutes before breakfast
1759905|NCT00277589|Drug|Placebo|1 tablet 30 minutes before breakfast
1759906|NCT00277602|Drug|Riluzole|
1759907|NCT00277641|Drug|Lamotrigine|25 mg or 100 mg
1759908|NCT00277641|Drug|placebo|identical tablets to study drug
1759909|NCT00277654|Drug|Risperidone|risperidone 0.5mg up to 4mg daily vs. placebo
1759910|NCT00277667|Drug|Quetiapine|Oral dosing: 50mg (Day 1), 100mg (Day 2), 150mg (Day 3), 200mg (Day 4), followed by flexible dosing from 50mg to 800mg through day 56.
1759911|NCT00277680|Procedure|Laparoscopic bilateral occlusion of uterine artery|
1759912|NCT00277680|Procedure|Radiological embolization (UFE)|
1759913|NCT00277693|Drug|Spironolactone (drug)|
1759914|NCT00277706|Procedure|Periodontal surgery|
1759915|NCT00277706|Drug|FORTEO|parathyroid hormone; self-administration for 6 weeks
1759916|NCT00277706|Drug|Placebo|placebo; self administration for 6 weeks
1759917|NCT00277706|Dietary Supplement|Vitamin D and Calcium|PO, QD, for six weeks
1759918|NCT00277732|Procedure|Pharmaceutical care at baseline and follow-up visits over 6 months|
1759919|NCT00277745|Device|miniaturized microfluidic system|Subjects will provide appropriate periodontal treatment as needed.
1759920|NCT00277758|Biological|Interleukin 2|Interleukin-2 at 1.2 mU/M2 administered subcutaneously daily
1759921|NCT00277758|Drug|Ribavirin|Ribavirin @ 800 mg daily (< 65 kg body weight), 1000 mg (65-85 kg), and 1200 mg (> 85 kg)
1759922|NCT00277758|Biological|Pegylated Interferon Alpha|Pegylated-Interferon-alpha 1.5 ug/kg weekly subcutaneously.
1759923|NCT00277758|Biological|Inteleukin-2|Interleukin-2 administered as a daily subcutaneous injection at 1.2 mU/M2 BSA
1759924|NCT00277758|Drug|Ribavirin + Pegylated interferon-alpha|Pegylated interferon-alpha administered 1.5 ug/kg weekly. Ribivirin 800 mg daily for body weight <65 kg, 1000 mg for body weight 65-85 kg, and 1200 mg for body weight >85 kg.
1759925|NCT00277771|Behavioral|Standard behavioral treatment (SBT) for weight loss|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Standard paper diaries are used for self-monitoring.
1759926|NCT00277771|Behavioral|SBT for weight loss using a PDA|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants (PDAs) are used for self-monitoring.
1759927|NCT00277771|Behavioral|SBT for weight loss using a PDA with feedback messages|Participants attend group sessions where they learn about healthy eating and exercise. They are asked to self-monitor all calories consumed (food and drink) and all calories expended through exercise. Personal Digital Assistants with a customized feedback program are used for self-monitoring.
1759928|NCT00277784|Procedure|Ultrasound examination|one ultrasound examination
1759929|NCT00277797|Device|Biowave Targeted Non-Invasive Electronic Pain Control Device|"This device is a non-invasive non-pharmacologic treatment for pain. It sends a premixed modulated envelope of two high frequency electronic wave forms (Feed Signals) between two electrodes."
1759930|NCT00277797|Device|TENS (Transcutaneous Electrical Nerve Stimulation) device|This device features a bisourced, biphasic waveform. The combined constant voltage, constant-current waveform provides a strong stimulus that allows the clinician to prescribe a treatment program.
1759931|NCT00277810|Drug|lecozotan SR (SRA-333)|one of 3 doses of lecozotan sr dose for 6 months as an extesnion to a 6 month study with patients required to be on a cholinesterase inhibitor 2, 5, or 10 mg of lecozotan sr
1759932|NCT00277823|Drug|DVS-SR 50 mg|
1759933|NCT00277823|Drug|DVS-SR 100 mg|
1759934|NCT00277823|Drug|Placebo|
1759935|NCT00277836|Drug|MST-997|
1759936|NCT00277862|Drug|Pegylated IFN- alpha 2b|
1759937|NCT00277862|Drug|Ribavirin|
1759938|NCT00277875|Drug|ALT-711 (alagebrium chloride)|
1759939|NCT00277888|Procedure|Femoral route for hemodialysis|
1759940|NCT00277888|Procedure|Jugular route for hemodialysis|
1759941|NCT00277914|Drug|Flibanserin|flibanserin flexible dosing
1759942|NCT00278018|Procedure|Immunotherapy treatment for solid tumors|
1759943|NCT00278044|Procedure|blood sampling and medical records|
1759944|NCT00278057|Drug|dialysisis with and without glucose in the dialysis|
1759945|NCT00278070|Drug|vinorelbine oral formulation|Patients will take three times a week [Monday, Wednesday and Friday] by mouth, a standard dose of soft capsules of vinorelbine given at dose ascribed by randomization procedure
1759946|NCT00278083|Drug|Study drug administration|
1759947|NCT00278083|Procedure|Tuberculin intradermal skin test|
1759948|NCT00278083|Procedure|Lung function test for FEV1|
1759949|NCT00278083|Procedure|Asthma symptom scores diary|
1759950|NCT00278083|Procedure|Quality of life diary|
1759951|NCT00278083|Procedure|Breath nitric oxide|
1759952|NCT00278083|Procedure|Breath condensate|
1759953|NCT00278083|Procedure|Sputum induction|
1759954|NCT00278083|Procedure|Blood sampling|
1759955|NCT00278083|Procedure|Urinalysis|
1759956|NCT00278096|Behavioral|occupational therapy|
1759957|NCT00278109|Drug|cyclophosphamide|chemotherapy
1759958|NCT00278109|Drug|doxorubicin hydrochloride|chemotherapy
1759959|NCT00278109|Procedure|adjuvant therapy|chemotherapy
1759960|NCT00278109|Radiation|radiation therapy|chemotherapy
1759961|NCT00278122|Biological|sargramostim|
1759962|NCT00278122|Drug|paclitaxel|
1759963|NCT00278135|Dietary Supplement|DHA (nutritional supplement) or placebo|oral 900mg/day
1759964|NCT00278148|Drug|carboplatin|AUC2 weekly x 3 weeks
1759965|NCT00278148|Drug|Tarceva|Daily
1759966|NCT00278148|Drug|paclitaxel|50mg/m2/weekly x 3 weeks
1759967|NCT00278148|Procedure|conventional surgery|conventional surgery
1759968|NCT00278148|Radiation|radiation therapy|150 cGy bid
1759969|NCT00278161|Biological|pegfilgrastim|
1759970|NCT00278161|Biological|rituximab|
1759971|NCT00278161|Drug|cyclophosphamide|
1759972|NCT00278174|Biological|recombinant interferon alpha-1b|
1759973|NCT00278187|Biological|volociximab|
1759974|NCT00278187|Drug|erlotinib hydrochloride|
1759975|NCT00278200|Biological|autologous Epstein-Barr virus-transformed B-lymphoblastoid cell vaccine|
1759976|NCT00278213|Biological|alemtuzumab|
1759977|NCT00278213|Drug|cyclophosphamide|
1759978|NCT00278213|Drug|fludarabine phosphate|
1759979|NCT00278213|Drug|mitoxantrone hydrochloride|
1759980|NCT00278226|Behavioral|smoking cessation intervention|
1759981|NCT00278226|Other|educational intervention|
1759982|NCT00278239|Procedure|cognitive assessment|
1759983|NCT00278239|Procedure|psychosocial assessment and care|
1759984|NCT00278239|Procedure|quality-of-life assessment|
1759985|NCT00278252|Drug|etoposide|
1759986|NCT00278252|Procedure|conventional surgery|
1759987|NCT00278265|Drug|MTX followed by fludarabine|MTX should be administered with 10-20mg weekly, calculated according to the body weight. Fludarabine should be administered with 25mg/m2 on day 1-3 of 28 days, up to 4 cycles
1759988|NCT00278278|Drug|cisplatin|Given IV
1759989|NCT00278278|Drug|etoposide|Given IV
1759990|NCT00278278|Drug|ifosfamide|Given IV
1759991|NCT00278278|Drug|lomustine|Given IV
1759992|NCT00278278|Drug|methotrexate|Given IV
1759993|NCT00278278|Drug|prednisone|Given IV
1759994|NCT00278278|Drug|vincristine sulfate|Given IV
1759995|NCT00278304|Radiation|brachytherapy|
1759996|NCT00278304|Radiation|radiation therapy|
1759997|NCT00278330|Drug|alvocidib|Given by infusion
1759998|NCT00278330|Drug|vorinostat|Given orally
1759999|NCT00278343|Drug|cediranib maleate|30mg given PO, daily
1760000|NCT00278343|Other|laboratory biomarker analysis|Correlative studies
1760001|NCT00278369|Biological|aldesleukin|The IL-2 is given as a 15-minute infusion through an intravenous catheter (I.V.), a small plastic tube that is put into your vein for the time you are receiving the study treatment. IL-2 is given through the I.V. once every 8 hours for 5 days (days 1-5). A second 5 day cycle of IL-2 will begin on the 15th day (days 15-19). This is one complete cycle (days 1-19) of IL-2 treatment
1760002|NCT00278369|Biological|denileukin diftitox|Denileukin diftitox will be administered once daily as a 15 to 60 minute infusion for 3 consecutive days.
1760003|NCT00278382|Drug|sorafenib tosylate|Given orally
1760004|NCT00278382|Other|laboratory biomarker analysis|Correlative studies
1760005|NCT00278395|Drug|Vorinostat|Given orally
1760006|NCT00270608|Procedure|Quantitative Computed Tomography of the tibia and spine|a single time 1 minute procedure
1760007|NCT00270608|Procedure|MRI of the spine and the right knee|a single time 45 minutes procedure
1760008|NCT00270608|Procedure|Blood test|A single time procedure to check lipid profile and hemoglobin A1C
1760009|NCT00270621|Behavioral|FHP Night time ENuresis Intervention|Urine alarm/evidence-based psychological Intervention
1760010|NCT00270634|Drug|Voclosporin|voclosporin 0.4, 0.6, 0.8 mg/kg po BID
1760011|NCT00270634|Drug|tacrolimus|tacrolimus 0.05 mg/kg po BID
1760012|NCT00270647|Dietary Supplement|Vitamin E|400 IU synthetic alpha-tocopherol or its placebo on alternate days (provided by BASF)
1760013|NCT00270647|Dietary Supplement|Vitamin C|500 mg synthetic ascorbic acid or its placebo daily (provided by BASF)
1760014|NCT00270647|Dietary Supplement|Multivitamin|Centrum Silver or its placebo daily (provided by Pfizer (formerly Wyeth, American Home Products, and Lederle))
1760015|NCT00270647|Dietary Supplement|Beta-carotene|50 mg Lurotin or placebo on alternate days (provided by BASF)
1760016|NCT00270660|Behavioral|biopsy, audiometry, ET function test, ear swab culture, DNE|
1760017|NCT00270673|Procedure|Early lactate-directed therapy|
1760018|NCT00270699|Biological|rDEN4delta30-200,201|Live attenuated dengue 4 vaccine (one of three doses)
1760019|NCT00270699|Biological|Placebo|Placebo for rDEN4delta30-200,201
1760020|NCT00270738|Procedure|Indirect training of the PFMs via transversus abdominis|Individual visit: twice a month for 4 months. Exercise regimen: diaphragmatic breathing, tonic activation, muscle strengthening, functional expiratory patterns, and impact activities.
1760021|NCT00270738|Procedure|pelvic floor muscle training|Individual visit: twice a month for 4 months. Exercise: intensive pelvic floor muscle training
1760022|NCT00270738|Procedure|home exercise|PFM exercise at home: at least six high-intensity (near-maximum) contractions 3 times per day at home, with an aim at holding each muscle contraction for 10 seconds, with at least a 10-second rest between contractions.
1760023|NCT00270751|Procedure|1 apical pleurectomy|
1760024|NCT00270751|Procedure|2 pleural abrasion + minocycline pleurodesis|
1760025|NCT00270777|Drug|adrenaline, promethazine, hydrocortisone|
1760026|NCT00270790|Drug|Amifostine|Amifostine will be given at dose of 500 mg IV within one hour before radiation
1760027|NCT00270790|Drug|Carboplatin|Carboplatin for 100 mg/m2 and will be administered after the taxol infusion
1760028|NCT00270790|Drug|Taxol|Taxol will be given at a dose of 40 mg/m2 as a 3 hour infusion dose
1760029|NCT00270790|Device|Radiotherapy|Radiation will be given at a dose of 1.8 Gy. for a total of 70.2 Gy
1760030|NCT00270803|Drug|Tetra Hydro Cannabinol (THC)|Oral THC 13mg and 17mg smoked in low nicotine cigarettes
1760031|NCT00270816|Drug|Interferon-ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months
1760032|NCT00270816|Drug|Interferon ß-1b|250 micrograms (8 MIU) administered subcutaneously (sc) every other day
1760033|NCT00270829|Drug|nesiritide|Drug given intrarenally or placebo
1760034|NCT00270842|Behavioral|Tai Chi|This intervention is a 10 week Tai Chi group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
1760035|NCT00270842|Behavioral|Functional Balance|This intervention is a 10 week Functional Balance group exercise class designed specifically for persons with Peripheral Neuropathy, having difficulty feeling their feet.
1760036|NCT00270842|Behavioral|Education Control group|This control group participated in 10 weeks of general health education classes.
1760039|NCT00270868|Procedure|Double guide wire technique|
1760040|NCT00270868|Procedure|Standard bile duct cannulation|
1760041|NCT00270881|Procedure|Cord blood transplantation|unrelated cord blood transplantation
1760042|NCT00270881|Radiation|TBI|Total body irradiation (TBI) 12Gy
1760043|NCT00270881|Drug|cyclophosphamide|cyclophosphamide 120mg/kg
1760044|NCT00270881|Drug|cytarabine|cytarabine 3g/m2x4
1760045|NCT00270894|Drug|epirubicin|epirubicin (100 mg/m^2) every 2 weeks for 4 cycles
1760046|NCT00270894|Drug|cyclophosphamide|cyclophosphamide (600 mg/m^2) every 2 weeks for 4 cycles
1760047|NCT00270894|Drug|docetaxel|docetaxel (75 mg/m^2) every 2 weeks for 4 cycles
1760048|NCT00270894|Drug|trastuzumab|trastuzumab (6 mg/kg [loading dose] once then 4 mg/kg [maintenance dose]) every 2 weeks for 4 treatments
1760049|NCT00270907|Drug|CT-2103|135 mg/m^2 IV on Day 1.
1760050|NCT00270907|Drug|Gemcitabine|1000 mg/m^2 IV on Day 1 and 8.
1760051|NCT00270920|Behavioral|Lactation counseling|
1760052|NCT00270933|Device|Registry|
1760053|NCT00270946|Device|Bilayered Cellular Matrix (OrCel)|
1760054|NCT00270959|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
1760055|NCT00270959|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
1760056|NCT00270959|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
1760057|NCT00270959|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors.
1760058|NCT00270972|Device|Bilayered Cellular Matrix (OrCel)|
1760172|NCT00281970|Drug|cisplatin|
1760059|NCT00270985|Behavioral|Almonds in a calorie controlled diet|Prescribed daily dose of Almonds in calorie controlled diet for adults with pre-type 2 diabetes
1760060|NCT00270985|Behavioral|Nut free diet|Calorie controlled diet free of nuts for adults with pre-type 2 diabetes
1760061|NCT00270998|Behavioral|Behavioral Therapy|Pelvic muscle training and exercises
1760062|NCT00270998|Device|Intravaginal Pessary|Intravaginal pessary
1760063|NCT00270998|Device|Pessary combined with behavioral therapy|Intravaginal pessary and behavioral therapy
1760064|NCT00271011|Drug|Mitomycin C|Patients will receive mitomycin C 7 mg/m2 as a bolus infusion on day -1 of each 28 day cycle.
1760065|NCT00271011|Drug|Cetuximab|Patients will receive cetuximab 400 mg/m2 loading dose over 90 minutes cycle 1, day 1. All subsequent weekly cetuximab treatments will be 250 mg/m2 as a 60 minute infusion days 1, 8, 15, and 22 of each 28 day cycle.
1760066|NCT00271011|Drug|Irinotecan.|Patients will receive irinotecan 140 mg/m2 as a 90 minute infusion on days 1 and 15 of each 28 day cycle after cetuximab infusion. Patients found to be homozygous for UGT1A1*28 allele will receive irinotecan 110 mg/m2.
1760067|NCT00271024|Drug|Naltrexone (drug)|50 mg q.d. for 13 weeks
1760068|NCT00271024|Drug|Placebo (for Naltrexone)|Sugar pill manufactured to mimic Naltrexone tablet
1760069|NCT00271037|Procedure|Colpocleisis prolapse repair surgery|
1760070|NCT00271037|Procedure|sling or other to treat or prevent stress incontinence|
1760071|NCT00271050|Other|external beam radiotherapy plus 90-Y ibritumomab tiuxetan|combination of EBRT followed by radioimmunotherapeutic 90-Y ibritumomab tiuxetan
1760072|NCT00271063|Drug|Liposomal Annamycin|3-day IV infusion
1760073|NCT00271076|Procedure|IVUS|
1760074|NCT00271076|Device|CAS|
1760075|NCT00271076|Procedure|CEA|
1760076|NCT00271089|Procedure|PBSC Collection|
1760077|NCT00271089|Procedure|Bone Marrow Harvest|
1760078|NCT00271089|Device|CliniMacs Cell Selection System|
1996772|NCT02382224|Behavioral|Worry Exposure for GAD|WE is an optimized protocol that incorporates elements of CBT, without the addition of other miscellaneous methods of treatment. A therapist manual will be used and followed at all times to ensure standardized delivery of the program. Interventions that uniquely focus on addressing GAD symptoms will include confronting physical or imagined stimuli through in vivo exposure and WE respectively. Avoidance behaviors will be monitored and reduced systematically, an outcomes will be assessed at baseline, during the 12-week intervention, and at 6-month follow-up.
1760081|NCT00271115|Behavioral|Kangaroo Holding|Mothers will be asked to Kangaroo hold their infants two times during the first week of life.
1760082|NCT00271154|Device|Cardiac Resynchronization Therapy (CRT) Device or Implantable Cardioverter Defibrillator (ICD) with CRT|All randomized patients will be implanted with a market-released Medtronic CRT or CRT/ICD device.
1760083|NCT00271167|Drug|INO-1001|
1760084|NCT00278408|Biological|filgrastim|
1760085|NCT00278408|Biological|rituximab|
1760086|NCT00278408|Drug|cyclophosphamide|
1760087|NCT00278408|Drug|doxorubicin hydrochloride|
1760088|NCT00278408|Drug|prednisone|
1760089|NCT00278408|Drug|vincristine sulfate|
1760090|NCT00278408|Radiation|radiation therapy|
1760091|NCT00278421|Biological|rituximab|
1760092|NCT00278421|Drug|cyclophosphamide|
1760093|NCT00278421|Drug|doxorubicin hydrochloride|
1760094|NCT00278421|Drug|prednisone|
1760095|NCT00278421|Drug|vincristine sulfate|
1760096|NCT00278434|Drug|zoledronic acid|
1760097|NCT00278447|Behavioral|Chronic Disease Management for substance abuse|Referral to primary medical care & longitudinal, multidisciplinary care for persons with substance dependence.
1760098|NCT00278447|Behavioral|Standard care|Referral to primary medical care for persons with substance dependence.
1760099|NCT00278460|Drug|docetaxel|40 milligrams per meter squared infused over 30 minutes on day 1 and 8, repeated every 21 days
1760100|NCT00278460|Drug|gemcitabine hydrochloride|800 milligrams per meter squared intraveneously for two consecutive weeks followe by one week of no treatment then repeated.
1760101|NCT00278473|Behavioral|Meta-Cognitive Therapy|Cognitive Behavioral Group Treatment
1760102|NCT00278473|Behavioral|Supportive Therapy|Social Support Problem-Solving Group Treatment
1760103|NCT00278486|Biological|Hematopoietic stem cell transplantation.|Autologous hematopoietic stem cell transplantation will be performed.
1760104|NCT00278499|Behavioral|Cross-sectional surveys|Cross-sectional surveys will occur at study entry, Month 6, and Month 12. Every fourth participant enrolled in the FSW cross-sectional survey, all FSWs found to be HIV infected, and all FSWs who are intravenous drug users will participate in a substudy lasting 12 months.
1760105|NCT00278499|Behavioral|Questionnaire/counseling|An initial questionnaire and counseling will occur once in addition to post-test counseling.
1760108|NCT00278525|Drug|standard of care|standard of care medication will be given
1760109|NCT00278525|Procedure|stem cell transplantation|The following is intervention: stem cell transplantation after conditioning regimen
1760110|NCT00278538|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
1760111|NCT00278551|Biological|Immune ablation and hematopoietic stem cell transplant|Autologous Hematopoietic Stem Cell Transplant
1760113|NCT00278577|Biological|Immune Ablation and Hematopoietic Stem Cell Support|Autologous Hematopoietic Stem Cell Transplant
1760114|NCT00278590|Biological|Allogeneic Stem Cell Transplantation|Allogeneic stem cell transplantation will be performed.
1760115|NCT00278603|Biological|Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Injection
1760116|NCT00278616|Biological|Stem Cell Transplantation|Autologous Stem Cell Transplantation
1760117|NCT00278629|Biological|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
1760118|NCT00278642|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
1760119|NCT00278655|Biological|Hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
1760173|NCT00281970|Drug|docetaxel|
1760174|NCT00281970|Procedure|adjuvant therapy|
1760175|NCT00281983|Biological|alemtuzumab|
1760120|NCT00278681|Drug|Zinc and ORS|"One strip containing 14 dispersible zinc tablets (20 mg each) along with 2 ORS packets were prescribed to all children aged 1 month to 5 years visiting that channel with diarrhea.
Infants aged less than 6 months were advised half a zinc tablet in a teaspoonful of breast milk; older children were advised 1 tablet in breast milk or clean water."
1760121|NCT00278694|Drug|Oxaliplatin|
1760122|NCT00278694|Drug|Chemoradiation|
1760123|NCT00278694|Drug|5-FU|
1760124|NCT00278694|Radiation|Preoperative chemoradiation|
1760125|NCT00278694|Procedure|Pelvic surgery|
1760126|NCT00278694|Drug|Neoadjuvant oxaliplatin|
1760127|NCT00278707|Drug|GTA: Glyceryltriacetate|
1760128|NCT00278733|Behavioral|Brief intervention (physician advice)|
1760129|NCT00278746|Drug|Zinc and ORS|Government and private providers and village health workers were trained to prescribe zinc and ORS for use in diarrheal episodes in 1 month to 5 years old children in intervention communities
1760130|NCT00278746|Drug|ORS only|Promoted routine management of diarrhea in underfive with ORS
1760131|NCT00281866|Drug|erlotinib hydrochloride|
1760132|NCT00281879|Biological|anti-thymocyte globulin|Intravenous, 1.5 mg/kg of body weight daily for 7 to 14 days The first dose should be administered over a minimum of 6 hours and over at least 4 hours on subsequent doses through a high-flow vein.
1760133|NCT00281879|Biological|filgrastim|"Will be given IV at 5 µg/kg/day. The first injection will be administered on day +7, i.e. 7 days after the hematopoietic stem cells are infused.
Will be administered until the ANC is 1500 / µl for 2 days. Dose and schedule of G-CSF administration is left to each center's discretion."
1760134|NCT00281879|Drug|busulfan|Patients who take the drug PO, busulfan will be administered at 1 mg/kg/ dose given by mouth every 6 hours for 16 consecutive doses. Pediatric patients who receive busulfan IV continuous infusion will receive a dose of 3.0 mg/kg/IBW if under the age of 2.Pediatric patients over the age of 2 will receive busulfan at a dose of 0.8 mg/kg/dose.
1760135|NCT00281879|Drug|carmustine|300mg/m2 IV dissolved in 500 cc NS infused over 2 hours into right atrial catheter on day -6.
1760136|NCT00281879|Drug|cyclophosphamide|For transplantation, the drug is diluted in 250 to 500 cc of NS or D5W and administered IV over 2 hours.
1760137|NCT00281879|Drug|cyclosporine|Initial doses will be administered IV at a starting dose of 1.5 mg/kg BID. The infusion will vary from 2-24hr depending on the incidence of side-effects.
1760138|NCT00281879|Drug|cytarabine|400 mg/m2 dissolved in 200cc D5W and infused over 30 minutes into right atrial catheter on days -5, -4, -3, -2.
1760139|NCT00281879|Drug|etoposide|"Etoposide administration 200 mg /m2 dissolved in 1 liter NS and infused over 2 hours into right atrial catheter. Infusion to begin after cytarabine administration on days -5, -4, -3, -2.
Etoposide administration 50 mg/kg IV over 24 hours, divided into 3 doses. Dilute in normal saline at a concentration of 0.4 mg/ml (Observe for precipitation). Administered IV with continuous infusion over 24 hours. Diuretics may be given for fluid overload."
1760140|NCT00281879|Drug|fludarabine phosphate|"Fludarabine administered at 30 mg/m2 IVPB infused over 30 minutes into right atrial catheter on days -4, -3, -2.
Fludarabine administered at 40 mg/m2 IVPB infused over 30 into the right atrial catheter on days -5, -4, -3, and -2."
1760141|NCT00281879|Drug|melphalan|140 mg /m2 in concentration of 0.45 mg/ml of NS infused over 30 minutes into right atrial catheter on day -1.
1760142|NCT00281879|Drug|methotrexate|Administered on days +1, +3, and +7.
1760143|NCT00281879|Drug|methylprednisolone|Methyl-prednisolone is administered IV as a rapid infusion.
1760144|NCT00281879|Drug|mycophenolate mofetil|Mycophenolate may be used as a substitute for Methotrexate
1760145|NCT00281879|Drug|tacrolimus|A drug used to decrease the risk of graft versus host disease (GvHD).
1760146|NCT00281879|Procedure|peripheral blood stem cell transplantation|The stem cells will be given to you by intravenous injection (through your vein) using a catheter that was placed prior to beginning chemotherapy. The stem cell infusion takes 1-6 hours.
1760147|NCT00281879|Procedure|umbilical cord blood transplantation|The patient will receive ATG to improve the changes of engraftment and decrease their risk of graft versus host disease. The patient may receive ATG 3 times during their transplant regimen on days -3 through days -1
1760148|NCT00281879|Radiation|radiation therapy|Radiation will be given to you 2 times a day for 3 or 4 days.
1760149|NCT00281892|Biological|Fludarabine plus Darbopoetin|Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles and 500 mcg of darbepoetin alfa subcutaneously every 3 weeks
1760150|NCT00281892|Drug|Fludarabine mono|"Group 1 - Patients with an initial Hb-value of less than 12 g/dl receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles with no additional growth factor support.
Group 2 - Patients with an initial Hb-value more than 12 g/dl start to receive fludarabine (30 mg/m² intravenously on day 1, 3, 5; repeated every 28 days for 6 cycles . Patients of group 2 will be eventually randomized at later timepoints, if the Hb-value drops below 12 g/dl. Randomized patients will receive either 500 mcg darbepoetin alfa subcutaneously every 3 weeks or continue therapy with fludarabine without additional administration of darbepoetin alfa."
1760151|NCT00281905|Drug|carboplatin|
1760152|NCT00281905|Drug|cisplatin|
1760153|NCT00281905|Drug|cyclophosphamide|
1760154|NCT00281905|Drug|methotrexate|
1760155|NCT00281905|Drug|vincristine sulfate|
1760156|NCT00281905|Radiation|radiation therapy|
1760157|NCT00281918|Drug|Rituximab|Intravenous repeating dose
1760158|NCT00281918|Drug|Cyclophosphamide|Intravenous repeating dose
1760159|NCT00281918|Drug|Fludarabine Phosphate|Intravenous repeating dose
1760160|NCT00281931|Biological|rituximab|
1760161|NCT00281931|Drug|cyclophosphamide|
1760162|NCT00281931|Drug|fludarabine phosphate|
1760163|NCT00281944|Drug|oxaliplatin|Given IV
1760164|NCT00281944|Drug|fluorouracil|Given IV
1760165|NCT00281944|Drug|leucovorin calcium|Given IV
1760166|NCT00281944|Other|pharmacological study|Correlative studies
1760167|NCT00281944|Procedure|positron emission tomography|Undergo PET scan
1760168|NCT00281944|Procedure|computed tomography|Undergo PET/CT scan
1760169|NCT00281957|Drug|sorafenib tosylate|Given orally
1760170|NCT00281957|Drug|tipifarnib|Given orally
1760176|NCT00281983|Biological|anti-thymocyte globulin|
1760177|NCT00281983|Biological|filgrastim|
1760178|NCT00281983|Biological|rituximab|
1760179|NCT00281983|Biological|therapeutic allogeneic lymphocytes|
1760180|NCT00281983|Drug|busulfan|
1760181|NCT00281983|Drug|cyclophosphamide|
1760182|NCT00281983|Drug|cyclosporine|
1760183|NCT00281983|Drug|fludarabine phosphate|
1760184|NCT00281983|Drug|methotrexate|
1760185|NCT00281983|Drug|mycophenolate mofetil|
1760186|NCT00281983|Procedure|peripheral blood stem cell transplantation|
1760187|NCT00281983|Radiation|radiation therapy|
1760188|NCT00281996|Drug|Gemcitabine|Administered intravenously over 30 minutes on days 1 and 8 of a 21-day cycle starting at a dose of 700 mg/m2 and increasing to 1000mg/m2 by cohorts
1760189|NCT00281996|Drug|Imatinib mesylate|Administered orally once daily with 8 ounces of water at a starting dose of 300 mg/day and increased to 600 mg/day according to cohort.
1760190|NCT00282009|Behavioral|Basic Internet|Basic Internet control intervention
1760191|NCT00282009|Behavioral|Enhanced Internet|enhanced Internet cessation intervention
1760192|NCT00282009|Behavioral|Enhanced Internet + phone|enhanced Internet plus proactive telephone counseling
1760193|NCT00282022|Drug|laromustine|
1760194|NCT00282035|Radiation|3D-CRT APBI|Accelerated partial breast irradiation utilizing 3D-CRT
1760195|NCT00282035|Radiation|WBI|Whole breast irradiation
1760196|NCT00282048|Drug|AG-013736 (axitinib)|AG-013736 5 mg twice daily [bid] continuous dosing in 28 day cycles.
1760197|NCT00282061|Drug|Melatonin|
1760198|NCT00282074|Procedure|laparoscopic bilateral hernia repair|
1760199|NCT00282087|Drug|gemcitabine, docetaxel, doxorubicin|Cycles = 28 days
1760200|NCT00282100|Drug|Iressa|
1760201|NCT00282113|Dietary Supplement|ProBioPlus|ProBioPlus is advertised as containing Lactobacillus acidophilus, Bifidobacterium longum, Bifidobacterium infantis, and Bifidobacterium bifidum plus inulin. The dose given was 5 x 10e8 twice daily.
1760202|NCT00282113|Dietary Supplement|Culturelle|Culturelle is advertised as containing Lactobacillus rhamnosus GG. The dose was 5 x 10e8 twice daily.
1760203|NCT00282113|Other|Placebo|A dilute preparation of pregestimil powder formulated to have a similar appearance to the probiotic products
1760204|NCT00282126|Dietary Supplement|Potassium citrate|kcitrate
1760205|NCT00282139|Drug|Aripiprazole|
1760206|NCT00282152|Device|B-STN DBS|Deep brain stimulation (DBS) of both the right and left sub-thalamic nucleus (STN) is an FDA approved treatment for advanced PD. In mid- and advanced stage Parkinson's disease, using DBS in this area of the brain lessens symptoms and allows patients to take less drug to control the disease. Dosage and frequency are not applicable to the DBS. Once the DBS is placed, unless deemed necessary, it will not be removed.
1760207|NCT00282152|Drug|Optimal drug therapy|The drugs used on this study are not investigational. They are drugs for Parkinson's disease that are standard of care. The drug form, dosage, frequency and duration will vary. Examples of drugs used include carbidopa/levodopa, pramipexole, ropinirole, and selegiline.
1760208|NCT00282165|Drug|naratriptan|four weeks double blind experimental treatment using oral naratriptan
1760209|NCT00282165|Drug|placebo|four weeks double blind placebo treatment
1760210|NCT00282178|Drug|Hydrochlorothiazide|25-50 mg once daily
1760211|NCT00282178|Drug|Placebo|Once daily
1760212|NCT00282178|Drug|Candesartan|16-32 mg once daily 12 weeks
1760213|NCT00282204|Behavioral|antenatal hypnosis + audio compact disc on hypnosis|
1760214|NCT00282204|Behavioral|Audio compact disc on hypnosis|
1760215|NCT00282217|Drug|Sirolimus|
1760216|NCT00282230|Drug|FK778|
1760217|NCT00282243|Drug|tacrolimus modified release (MR)|Oral
1760218|NCT00282243|Drug|tacrolimus|Oral
1760219|NCT00282256|Drug|tacrolimus modified release (MR)|Oral
1760220|NCT00282256|Drug|tacrolimus|Oral
1760221|NCT00282269|Procedure|Induced Hypothermia|Induced Hypothermia within 6 hours of injury and maintained for a minimum of 72 hours
1760222|NCT00282282|Drug|tacrolimus|Given orally just prior to and following stem cell transplant
1760223|NCT00282282|Drug|sirolimus|Given orally just prior to and following stem cell transplant
1760224|NCT00282282|Drug|fludarabine|Given once daily over 30 minutes for 4 days
1760225|NCT00282282|Drug|busulfex|Given intravenously over 3 hours for 4 days
1760226|NCT00282295|Biological|Boostrix®|GlaxoSmithKline (GSK) Biologicals' registered tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed, containing 0.3 mg aluminum.
1760227|NCT00282295|Biological|Menactra™|Aventis Pasteur's me ningococcal polysaccharide diphtheria toxoid conjugate vaccine containing Neisseria meningitidis serogroups, A, C, Y and W-135.
1760228|NCT00282308|Drug|Rituximab|Rituximab was supplied in single-use vials.
1760229|NCT00282308|Drug|Methotrexate|
1760230|NCT00282308|Drug|Methylprednisone|Patients received methylprednisolone 100 mg intravenously before each infusion of rituximab.
1760231|NCT00282308|Biological|C. albicans|Patients received an intradermal injection of C. albicans (0.1 mL) on the volar surface of the forearm.
1760232|NCT00282308|Biological|Tetanus toxoid adsorbed booster vaccine|Patients received an intramuscular injection of the tetanus toxoid adsorbed booster vaccine (1 mg in 0.5 mL) in the deltoid muscle.
1760233|NCT00282308|Biological|23-valent pneumococcal polysaccharide vaccine|Patients received an intramuscular injection of the 23-valent pneumococcal polysaccharide vaccine (0.5 mL) in the deltoid muscle.
1760234|NCT00282308|Biological|Keyhole limpet hemocyanin|Patients received a subcutaneous injection of keyhole limpet hemocyanin (1 mg)
1760235|NCT00282321|Behavioral|High Protein diet|
1760236|NCT00282321|Behavioral|High carbohydrate diet|
1760237|NCT00282334|Device|Telemedical blood pressure monitoring|Measurement of home blood pressure, three times per week for three months and once a week for three months.
1760238|NCT00282347|Drug|Rituximab|Rituximab was provided as a sterile solution for injection.
1760239|NCT00282347|Drug|Placebo|Placebo was provided as a sterile solution for injection.
1760240|NCT00282347|Drug|Mycophenolate mofetil|
1760247|NCT00282386|Drug|MK0966; Rofecoxib / Duration of Treatment: 156 weeks|
1760248|NCT00282386|Drug|Placebo/ Duration of Treatment: 156 weeks|
1760249|NCT00282399|Drug|Subcutaneous Decitabine|
1996773|NCT02382224|Behavioral|12-week Waitlist|Those who are randomized to the waitlist condition will wait for 12 weeks before beginning the worry exposure.
1760251|NCT00282425|Biological|Hematopoietic stem cell transplantation|Allogeneic Hematopoietic stem cell transplantation
1760252|NCT00282438|Biological|Autologous hematopoietic stem cell transplantation|Autologous hematopoietic stem cells will be injected after conditioning
1760253|NCT00282438|Biological|Allogeneic stem cell transplantation|Allogeneic stem cells will be injected after conditioning
1760254|NCT00282451|Drug|biphasic insulin aspart|
1760255|NCT00282451|Drug|insulin aspart|
1760256|NCT00282464|Drug|Placebo|Subjects will start on placebo and remain on placebo for six weeks. All cards for the Placebo arm will be 0 mg bid.
1760257|NCT00282464|Drug|Geodon (Ziprasidone)|Ziprasidone flexible dosing treatment arm (20-80 mg bid). For the Ziprasidone arm, the Baseline card will contain 20 mg bid (one 20 mg capsule) for days 1-2 and 40 mg bid (two 20 mg capsules) for days 3-6. Cards A, B, C, and D will contain either 20 mg bid (one 20 mg capsule), 40 mg bid (two 20 mg capsules), 60 mg bid (one 60 mg capsule), or 80 mg bid (one 60 mg capsule and one 20 mg capsule).
1760258|NCT00282490|Device|Nerve stimulator|
1760259|NCT00282503|Drug|Methoxsalen+ECP, Methylprednisolone|"Those patients randomized to the ECP Treatment arm will receive ECP treatments by the following regimen:
Weeks 1 through Week 3 - 3 times within each week. (Treatments do not have to be performed on consecutive days but should be completed within the 7-day period),
Weeks 4 through 12 - 2 times each week. (It is preferable that patients receive ECP treatments on consecutive days within a week, but there should never be > 4 days between the ECP treatments within a week.)
Methylprednisolone will be started at 2mg/kg daily dose and may be tapered by reducing dose each week at the following reductions:
Daily Dose (mg/kg)
1 1.5 2 1.0 3 0.70 4 0.50 5 0.40 6 0.30 7 0.20 8 0.10"
1760260|NCT00282503|Procedure|Ecp|ECP or Extra Corporeal Phototherapy will be used with UVADex
1760261|NCT00282516|Procedure|In-home telemonitoring of pediatric patients with persistent asthma|
1760262|NCT00282529|Device|High Risk Lymphedema Education and Device Intervention|
1760263|NCT00282542|Procedure|Hepatocyte Infusion|
1760264|NCT00282555|Drug|S-Tenatoprazole-Na (STU-Na)|
1760265|NCT00282568|Drug|Tacrolimus Modified Release (MR)|Oral
1760266|NCT00282568|Drug|tacrolimus|Oral
1760267|NCT00282581|Biological|MVA Smallpox Vaccine|0.5mL of MVA3000 Smallpox Vaccine, 2 doses, separated by 28 days.
1760268|NCT00282594|Drug|Novolin R (human recombinant Insulin)|
1760269|NCT00282607|Drug|DA-8159|
1760270|NCT00282620|Drug|Magnesium L-lactate|
1760271|NCT00282633|Device|Dermabond|
1760272|NCT00282646|Procedure|intraarterial stem cell therapy|catheter delivery of stem cells
1760273|NCT00282646|Other|Stem cells|intraarterial application of bone marrow mononuclear cells versus placebo
1760274|NCT00282659|Drug|magnesium L-lactate|
1760275|NCT00282672|Device|Ablation System plus anti-secretory medication|Treatment group subjects undergo up to 4 ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI).
1760276|NCT00282672|Device|Sham procedure plus anti-secretory medication|The Sham Control group undergo an upper endoscopy procedure with sizing of the esophageal diameter (a component of the ablation procedure steps, deemed the sham procedure) plus standard anti-secretory drug therapy (Proton pump inhibitor, PPI)
1760277|NCT00282685|Procedure|Intraarterial bone marrow progenitor cell transplantation|catheter delivery of stem cells
1760278|NCT00282698|Drug|Insulin infusion with a goal|
1760279|NCT00282724|Drug|Liarozole|
1760280|NCT00282750|Device|Bar coded sponge and scanner|
1760281|NCT00282763|Drug|MK0686|
1760282|NCT00282776|Behavioral|Care Management for Postpartum Depression|Depression Care Manager calls postpartum women and encourages women to seek appropriate depression care. In this context the depression care manager helps the women to identify barriers to appropriate care, her preferred method of care, and resources available. Calls are made initially at 2 calls per month, followed by one call per month and calls every other month for women who are doing well. Women assigned to this group receive research assessments at 3, 6, and 12 months postpartum. They also receive information about community and health plan resources available for women with depression.
1760283|NCT00282776|Behavioral|TAU|Participants receive treatment as usual for postpartum depression. Women assigned to this arm receive research assessments at 3, 6, and 12 months postpartum. At the baseline home visit where diagnostic assessments are completed women are given information about community and health plan resources if they choose to seek care for depression symptoms. Women are also given phone contact numbers for the research program.
1760284|NCT00282789|Device|bilevel positive airway pressure|
1760285|NCT00282789|Device|bilevel positive airway pressure (Device)|
1760286|NCT00282815|Device|continuous positive airway pressure or CPAP|RemStar Pro (Respironics, Inc.) The CPAP is applied through a nasal mask during the hours of sleep. Positive air pressure holds the naso-oro-pharyngeal airway open during sleep.
1760287|NCT00282815|Device|sham CPAP|sham CPAP
1760288|NCT00282828|Drug|Sertraline|
1760289|NCT00282828|Drug|Venlafaxine|
1760290|NCT00282828|Drug|Placebo|
1760291|NCT00282828|Drug|Clonazepam|
1760293|NCT00282867|Drug|IV glucose insulin and potassium, GIK|The treatment intervention includes glucose, insulin, potassium infusion or standard therapy.
1760294|NCT00282867|Other|standard care|usual care
1760295|NCT00282893|Procedure|transluminal ballooning|
1760296|NCT00282893|Other|currently existing therapies for the treatment of vasospasm|
1760297|NCT00282906|Device|hybrid PET-CT imaging system|15 mCi of FDG
1760298|NCT00282919|Drug|Azithromycin plus chloroquine|dose of 2000 mg Azithromycin plus 600 mg chloroquine base
1760299|NCT00282932|Drug|Detrol LA|
1760300|NCT00282945|Drug|Rosiglitazone|
1760302|NCT00282958|Drug|Botulinum Toxin type a (Botox)|
1760303|NCT00282971|Other|Standard of Care|Standard of Care: All licensed diabetes drugs can be prescribed per discretion of investigators
1760304|NCT00282971|Drug|Inhaled Insulin (Exubera)|Addition of inhaled insulin to pre-existing oral diabetes therapy.
1760305|NCT00282984|Drug|placebo|1 mg placebo twice daily by mouth for 12 weeks
1760306|NCT00282984|Drug|Varenicline|1 mg twice daily by mouth for 12 weeks
1760307|NCT00282997|Drug|pregabalin|
1760308|NCT00283010|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
1760309|NCT00283010|Other|Educational DVDs|
1760310|NCT00283023|Procedure|Oligodendrocyte progenitor cell culture/craniotomy|Oligodendrocyte progenitor cell culture protocol of Rajavithi Hospital will be apply
1760311|NCT00283036|Drug|Irbesartan|
1760312|NCT00283049|Drug|Insulin Glargine|Insulin glargine administered subcutaneously once daily.
1760313|NCT00283049|Drug|Insulin Glulisine|Insulin glulisine will be added after Week 12 or later for those subjects needing prandial insulin therapy (HbA1c >6.5%)
1760314|NCT00283062|Drug|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m^2 docetaxel administered intravenously over 1 hour on Day 1 every three weeks (q3w) for 6 cycles. The first cycle was to be administered within 8 days after randomization.
Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
1760315|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 8 days after randomization.
1760316|NCT00283062|Drug|Docetaxel (TAXOTERE®) Chemotherapy|"75 mg/m^2 docetaxel administered IV over 1 hour on Day 1 q3w for 6 cycles. The first cycle was to be administered within 30 days after progression was confirmed.
Corticosteroid pre-medication was mandatory. The following schedule was recommended - 8 mg Dexamethasone orally for 6 doses given - the night before chemotherapy, the morning of chemotherapy, 1 hour before docetaxel infusion, the night of chemotherapy, the morning of the day after chemotherapy and the night of the day after chemotherapy."
1760317|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed (on Day 1 of docetaxel administration).
1760318|NCT00283062|Drug|Leuprolide acetate ( ELIGARD®) Hormonal Therapy|22.5 mg leuprolide acetate injection administered subcutaneously (SC) every 3 months for 18 months. The first injection was to be administered within 30 days after progression is confirmed.
1760319|NCT00283075|Biological|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kg
1760320|NCT00283088|Procedure|hypothermia|"Hypothermia with or without tPA for stroke. Hypothermia is induced using the Celsius Control™ System.
Subjects are stratified by time to six groups."
1760321|NCT00283088|Drug|tissue plasminogen activator|tPA is a naturally occurring protein that opens blocked arteries by dissolving blood clots
1760322|NCT00283101|Drug|SGN-40 (anti-huCD40 mAb)|1-8 mg/kg IV; Days 1, 4, 8, 15, 22, 29 of Cycle 1 and Days 1, 15, 29 and 43 of Cycles 2-6.
1760323|NCT00283114|Drug|lintuzumab|1.5 - 8 mg/kg IV (in the vein) on Days 1, 8, 15, 22 and 29 of Cycle 1; 1.5 - 8 mg/kg IV (in the vein) every other week for all subsequent cycles
1760324|NCT00283127|Procedure|Home sampling (urine test) for uro-genital C.trachomatis.|
1760325|NCT00283153|Behavioral|Facial Affect Recognition Training|A series of pictures of faces displaying various emotions are presented one at a time using a computerized training program.Participants are taught to recognize how emotions affect facial features such as the mouth and eyes.Participants are also taught how to recognize their own emotions.
1760326|NCT00283153|Other|Stories of Emotional Inference|Participants are presented with a series of short stories one at a time. Each story presents various contextual cues regarding the emotions the characters are likely to experience. Participants learn to connect the cues to specific emotions.
1760327|NCT00283166|Behavioral|Tailored Education and Coaching|A: Patients receive one-on-one counseling and education about pain management and improving doctor-patient communication B: Patients receive booklet on cancer pain control
1760328|NCT00283179|Drug|Aripiprazole|
1760329|NCT00283179|Drug|Risperidone|
1760330|NCT00283192|Drug|Sertraline|
1760331|NCT00283205|Behavioral|Yoga|
1760332|NCT00283218|Drug|NovoRapid, NovoMix 30, Bifasisk Insulin Aspart 50, BIAsp70|
1760333|NCT00283231|Behavioral|Paced Respiration|
1760334|NCT00283244|Drug|erlotinib hydrochloride|given orally
1760335|NCT00283244|Drug|gemcitabine hydrochloride|given IV
1760336|NCT00283257|Behavioral|Patients and caregivers are taught problem solving skills|
1760337|NCT00283270|Behavioral|Brief counselling|
1760338|NCT00283270|Behavioral|Behavior|
1760340|NCT00283296|Device|Endeavor|Collapsible, forward folding manual wheelchair
1760341|NCT00283309|Drug|Memantine|
1760342|NCT00283309|Drug|Riluzole|
1760343|NCT00283322|Other|blood samples (2)|Two blood samples were obtained from patients and tested for heparin antibodies.
1760344|NCT00283335|Drug|gemfibrozil|
1760345|NCT00283335|Other|Placebo|Matching placebo tablets taken once per day
1760346|NCT00283361|Drug|ZP120|
1760347|NCT00283361|Procedure|I.v. catherization|
1760348|NCT00283361|Procedure|6-minutes walk performance|
1760349|NCT00283361|Behavioral|Dyspnea severity assessment|
1760350|NCT00283361|Procedure|Blood sampling for laboratory tests|
1760351|NCT00283361|Procedure|ECG|
1760352|NCT00283361|Procedure|Physical examination|
1760353|NCT00283374|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
1760354|NCT00283387|Drug|Betaine|Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
1760473|NCT00284271|Drug|Erythropoietin beta|
1760355|NCT00283387|Drug|Placebo|Subjects received oral lactose placebo, in two doses daily, for 2 months.
1760356|NCT00283400|Drug|25% human albumin|25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
1760357|NCT00283413|Device|Covered Stent System|Self-expanding, polytetrafluoroethylene(PTFE)-covered, stent system
1760358|NCT00283413|Device|Bare metal stent|Any commercially available bare metal stent for coronary indication
1760359|NCT00283426|Drug|Soluble beta-1,3/1,6-glucan|
1760360|NCT00283439|Biological|AMG 531|"Planned Cohorts:
100 mcg,
300 mcg,
700 mcg,
1000 mcg;
Optional Cohorts:
cohort expansion,
schedule change,
new dose"
1760361|NCT00283452|Behavioral|Phone counseling with written materials|Participation in phone/mail counseling to maintain physical activity
1760362|NCT00283465|Drug|Epoetin alfa|
1760363|NCT00283478|Drug|Iscar Quercus|
1760364|NCT00283478|Drug|Gemcitabine|
1760365|NCT00283491|Behavioral|Active Lactobacillus plantarum 299v|10^11 cfu/meal in 2 meals on 2 consecutive days
1760366|NCT00283491|Dietary Supplement|Inactive Lactobacillus plantarum 299v|Inactive form of the active treatment but with the fermentation products in the same concentration
1760367|NCT00283504|Drug|ANTI-IGE THERAPY (XOLAIR)|
1760368|NCT00283517|Drug|antipsychotics|as prescribed
1760369|NCT00283530|Procedure|Tumor biopsy|
1760370|NCT00283543|Drug|Gliadel Wafer|
1760371|NCT00283543|Drug|Temozolomide|
1760372|NCT00283543|Procedure|Limited field radiation|
1760373|NCT00283556|Drug|Irinotecan (Camptosar, CPT-11)|"Cohort #1--Irinotecan 750 mg/m2 IV over 90 minutes Q 3 weeks x 15 patients; Cohort #2--Irinotecan 500 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients; Cohort #3--Irinotecan 600 mg/m2 IV over 90 minutes Q 2 weeks x 3 patients.
Additional increments of 50 mg/m2 for subsequent cohorts until MTD is reached."
1760374|NCT00283569|Other|Mouth Swab, Toe Nail Clippings, Questionnaires|The objective of this study is to establish a clinic based case control study for examination of potential risk factors for primary adult brain tumors.
1760375|NCT00283582|Drug|rhTPO|
1760376|NCT00283595|Drug|Recombinant Human Growth Hormone|Dosage increased in steps for first four weeks. Self injection qd x 12 weeks
1760377|NCT00283595|Drug|Placebo for Recombinant Human Growth Hormone|Administered as Arm 1, rHGH active Injection qd x 12 weeks Dosage increase over four weeks
1760378|NCT00283608|Genetic|Single nucleotide polymorphism (SNP)|Evaluating SNP association with traits.
1760379|NCT00283608|Other|high performance liquid chromatography|analysis of plasma concentrations of drugs
1760380|NCT00283608|Other|measurements by DXA|determine bone mineral density (BMD)
1760381|NCT00283608|Other|questionnaire administration|determine attitude changes
1760382|NCT00283621|Drug|Aranesp (darbepoetin alfa)|
1760383|NCT00283621|Drug|Neulasta (pegfilgrastim)|
1760384|NCT00283621|Drug|Adriamycin|
1760385|NCT00283621|Drug|Ifosfamide|
1760386|NCT00283634|Drug|erlotinib and bortezomib|
1760387|NCT00283660|Dietary Supplement|10 mg zinc oxide|10 mg zinc oxide
1760388|NCT00283660|Other|Placebo|Placebo pill taken five days a week for six months.
1760389|NCT00283673|Behavioral|Exercise|
1760390|NCT00283686|Drug|Lisinopril|Lisinopril titrated to 5mg, 10mg, 20mg, 40mg
1760391|NCT00283686|Drug|Telmisartan|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
1760392|NCT00283686|Drug|Placebo|Telmisartan/Placebo titrated to 40mg and 80mg, as tolerated by participants
1760393|NCT00283686|Other|Standard Blood Pressure Control|Achieve standard blood pressure control of 120-130/70-80 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
1760394|NCT00283686|Other|Low Blood Pressure Control|Achieve low blood pressure control of 95-110/60-75 mm Hg using step dosing specified in protocol of lisinopril, study drug, hydrochlorothiazide, metoprolol, or non-dihydropyridine and dihydropyridine calcium channel blockers (diltiazem), clonidine, minoxidil, hydralazine at the discretion of the investigator
1760395|NCT00283699|Drug|albendazole|Active drug or placebo dosed bid p o for 8days
1760396|NCT00283699|Other|placebo|an inactive substance
1760397|NCT00283712|Drug|Infliximab|Chimeric IgG monoclonal antibody that binds to TNF-alpha, generally used to treat Crohn's disease, given in a dosage of 5 mg/kg at Study entry and Weeks 2, 6, and 14
1760398|NCT00283712|Drug|Prednisone|Systemic corticosteroid at therapeutic levels. Dosage may be tapered by approximately 15% every 2 weeks if no new lesions are observed as determined by clinical assessment of the investigator.
1760399|NCT00283712|Other|Placebo|Placebo given in place of infliximab for control group
1760400|NCT00283725|Other|No intervention|Patients will be prescribed either galantamine or no AD treatment (ie, neither an acetylcholinesterase inhibitor [AChEI] nor memantine).
1760401|NCT00283738|Device|BioSTAR Septal Repair Implant System|PFO Closure
1760402|NCT00283738|Procedure|Sham Procedure|Catheterization
1760403|NCT00283751|Drug|insulin detemir|
1760404|NCT00283751|Drug|insulin glargine|
1760405|NCT00283764|Drug|Xalatan|
1760406|NCT00283777|Drug|Chromium Picolinate|
1760407|NCT00283790|Drug|zolpidem tartrate|
1760411|NCT00283816|Drug|Metformin|Metformin 500 mg. tabs 2 tabs BID for duration of study
1760412|NCT00283816|Drug|Oral Contraceptive Pill|"Yasmin, drospirenone and ethinyl estradiol 28 tablets
1 tab daily for duration of study"
1760413|NCT00283816|Behavioral|Lifestyle Management Program|Subjects and a parent/guardian will participate in a series of classes for training in diet, exercise & behavior modification skills on a regular weekly basis over the 24 week study
1760414|NCT00283816|Behavioral|Quality of Life Questionnaire|Quality of Life questionnaire designed for women with Polycystic Ovary Syndrome. Questions concern health and health related issues Performed twice during study, at baseline and conclusion
1760474|NCT00284284|Device|Use of a rehabilitation brace|
1760415|NCT00283816|Procedure|Oral Glucose Tolerance Test|"Insulin response to a glucose challenge in an oral glucose tolerance test (OGTT), as measured by area under the curve (AUC). In this study we will administer an OGTT and calculate the AUC as a measure of insulin resistance.
Performed twice during study, at baseline and conclusion"
1760416|NCT00283816|Procedure|Blood work|Initial and conclusion blood draws include; comprehensive metabolic profile, CBC and platelet,hormonal assessment and lipids.
1760417|NCT00283816|Procedure|Abdominal Ultra Sound|"transabdominal transducer, which contains integrated software for volume calculation will be used to assess ovarian volume.
Performed twice during study, at baseline and conclusion"
1760418|NCT00283816|Procedure|Dual-energy x-ray absorptiometry (DEXA scan)|Dual-energy x-ray absorptiometry (DEXA) will be used to assess percent body fat Performed twice during study, at baseline and conclusion
1760419|NCT00283816|Drug|placebo|placebo capsules, two capsules BID
1760420|NCT00283829|Drug|docetaxel|chemotherapy
1760421|NCT00283829|Drug|IL2|immunotherapy
1760422|NCT00283842|Drug|DVS SR|
1760423|NCT00283842|Drug|Placebo|
1760424|NCT00283855|Behavioral|Online Self-Management|Online Self-Management
1760425|NCT00283920|Drug|[(11)C] PBR28|
1760426|NCT00283933|Drug|AT1001 (migalastat hydrochloride)|
1760427|NCT00283946|Drug|Zolpidem MR|Oral
1760428|NCT00283946|Drug|Zolpidem|Oral
1760429|NCT00283959|Drug|AT1001 (migalastat hydrochloride)|administered every other day
1760430|NCT00283972|Device|LAP-BAND System|
1760431|NCT00283985|Drug|Kidrolase|6000 u/ m2 IM at J2, J4 and J6 and J8. 3 to 6 cycles.
1760432|NCT00283985|Drug|Methotrexate|3 gr/m2 at J1
1760433|NCT00283985|Drug|Dexamethasone|40 mg/ per os at J1, J2 and J4.
1760434|NCT00283985|Drug|Erwinase|"In case of allergy to Kidrolase
20000 u/m2 en IM at J2, J4, J6 et J8. 3 to 6 cycles"
1760435|NCT00283998|Procedure|surgical versus conservative treatment|Surgical treatment of fractures versus conservative stabilization
1760436|NCT00284011|Dietary Supplement|SAMe|800 mg dose daily for 4 weeks.
1760437|NCT00284011|Other|Placebo|2 placebo pills daily for 4 weeks.
1760438|NCT00284024|Drug|domperidone|
1760439|NCT00284037|Device|continuous positive airway pressure therapy|
1760440|NCT00284050|Drug|Ranibizumab 0.3 mg|6 mg/ml ranibizumab solution for intravitreal injection
1760441|NCT00284050|Drug|Ranibizumab 0.5 mg|10 mg/ml ranibizumab solution for intravitreal injection
1760442|NCT00284050|Drug|Sham injection|Non-treatment control for sham intravitreal injection.
1760443|NCT00284063|Procedure|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic low back spinal manipulation, and a second 15 minute MRI in neutral position.
1760444|NCT00284063|Procedure|Low back adjustment and MRI|Subjects received a 15 minutes MRI in neutral position, a chiropractic spinal manipulation to the low back, and a second 15 minute MRI in a side posture position.
1760445|NCT00284063|Procedure|MRI|Subjects received a 15 minute MRI in neutral position and a second 15 minute MRI in neutral position.
1760446|NCT00284076|Drug|L-arginine|
1760447|NCT00284089|Drug|Ranibizumab|Ranibizumab was administered by intravitreal injection in the study eye. Intravitreal injection was performed by the investigator following slitlamp examination.
1760448|NCT00284102|Procedure|Mechanical ventilation|measurement of gas exchange, dead space, respiratory mechanics 5, 15, 30, 60 minutes from PEEP change (5 and 15 cmH2O)
1760449|NCT00284115|Device|Gait trainer|Mechanical gait repetitive training
1760450|NCT00284115|Device|Conventional rehabilitation|Physiotherapeutic conventional rehabilitation
1760451|NCT00284128|Drug|AVE7688|oral administration (capsules)
1760452|NCT00284128|Drug|Losartan-potassium|oral administration (capsules)
1760453|NCT00284141|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over a period of at least 1 hour once every 2 weeks.
Aflibercept could be reduced by 1 dose level (to 3.0 mg/kg) or 2 dose levels (to 2.0 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
1760454|NCT00284154|Drug|Vinflunine|320mg/m2 every 21 days as a 15-20 minute infusion
1760455|NCT00284167|Behavioral|tailored web-based weight management intervention|
1760456|NCT00284180|Drug|Vinflunine|Novel second generation vinca alkaloid
1760457|NCT00284180|Drug|Trastuzumab|Anti-HER2 monoclonal antibody
1760458|NCT00284193|Drug|rFVIIa-FEIBA therapy for hemophilia A inhibitors|DOses tailored per ex vivo spiking thrombin generation
1760459|NCT00284193|Drug|FEIBA- Activated Prothrombin Complexes|
1760460|NCT00284206|Drug|long-acting injectable risperidone|
1760461|NCT00284219|Device|Transcranial Magnetic Stimulation 10Hz|3. rTMS subjects will receive 20 trains of rTMS at a rate of 10 Hz for 6 seconds (1200 pulses/session). Pulses will be administered over the left dorsolateral prefrontal cortex, defined as 5 cm anterior and in a parasagital plane to the point of maximum stimulation of the abductor pollicis muscle. Pulse intensity will be set at 100% motor threshold.
1760462|NCT00284219|Device|Magnetic stimulation using a special sham coil|Sham stimulation will be given at the same location as the active, with special sham coil.
1760463|NCT00284232|Behavioral|Use and interpretation of blood glucose results|
1760464|NCT00284232|Drug|Insulin dosing based on SMBG chart and education|
1760465|NCT00284258|Drug|CPT-11 and TS-1|TS-1 was administered orally at 40-60 mg twice daily for 14 days with a rest period of 14 days as one course. CPT-11 was administered intravenously 125 mg per square meter at day1 and day14 in 4 weeks as one course.
1760466|NCT00284258|Drug|CPT-11, 5-FU and l-LV|Patients were administered FOLFIRI every 2 weeks in one course. FOLFIRI:CPT-11 150 mg per square meter on day1 with l-LV 200 mg per square meter administered as a 2-hour infusion before 5-FU 400 mg per square meter administered as an intravenous bolus injection, and 5-FU 2400 mg per square meter as a 46-hour infusion immediately after 5-FU bolus injection on day1 in 2 weeks.
1760467|NCT00284271|Drug|Cyclophosphamide|
1760468|NCT00284271|Drug|Adramycin|
1760469|NCT00284271|Drug|Procarbacine|
1760470|NCT00284271|Drug|Prednisone|
1760471|NCT00284271|Drug|Vincristine|
1760475|NCT00284297|Procedure|History taken and clinical examination|History is taken and clinical examination is followed
1760476|NCT00284310|Procedure|Anamnesis and clinical examination|Anamnesis and clinical examination to follow.
1760477|NCT00284323|Drug|Adenosine|
1760478|NCT00284336|Drug|Caelyx|
1760479|NCT00284336|Drug|endoxan|
1760480|NCT00284349|Device|Use of a rehabilitation brace instead of a plaster|
1760481|NCT00284362|Procedure|Arthroscopic or open surgery for hallux rigidus|
1760482|NCT00274053|Drug|tiotropium|
1760483|NCT00274066|Drug|Tiotropium + placebo|
1760484|NCT00274066|Drug|Tiotropium + ipratropium|
1760485|NCT00274066|Drug|Tiotropium + fenoterol|
1760486|NCT00274079|Drug|SPIRIVA|
1760487|NCT00274092|Drug|tiotropium inhalation capsules (18 mcg once daily)|
1760488|NCT00274092|Drug|Atrovent MDI (2 puffs of 20 mcg(q.i.d.) in patients|
1760489|NCT00274105|Drug|telmisartan|
1760490|NCT00274105|Drug|Placebo|
1760491|NCT00274118|Drug|telmisartan|
1760492|NCT00274118|Drug|enalapril|
1760493|NCT00274131|Drug|Pramipexole 0.125 mg tablets|
1760494|NCT00274131|Drug|Pramipexole 0.5 mg tablets|
1760495|NCT00274144|Drug|telmisartan 40 mg|
1760496|NCT00274144|Drug|placebo 40 mg|
1760497|NCT00274157|Behavioral|Behavior|
1760498|NCT00274157|Behavioral|diet control, smoking cessation, exercize|
1760499|NCT00274170|Drug|Octreotide|
1760500|NCT00274196|Procedure|ultrasound examination|a single time 10 minutes procedure within the first week after the injury
1760501|NCT00274196|Procedure|MRI scan|a single time 30 minutes procedure, performed always after the ultrasound scan
1760502|NCT00274209|Procedure|Chromoendoscopy with magnification|A blue dye (indigo carmine) will be sprayed prior to imaging the bowel lining using a zoom colonoscope. The dye is not absorbed and is safe for human use.
1760503|NCT00274235|Drug|sulfadoxine-pyrimethamine / mefloquine|
1760504|NCT00274248|Drug|MLN518|
1760505|NCT00274261|Drug|C31G|The subject will insert one applicator of C31G prior to each episode of vaginal intercourse during her participation in the study.
1760506|NCT00274261|Drug|nonoxynol-9 (N-9)|The subject will insert one applicator of Conceptrol® vaginal gel (nonoxynol-9) prior to each episode of vaginal intercourse during her participation in the study.
1760507|NCT00274274|Drug|insulin detemir|
1760508|NCT00274274|Drug|insulin aspart|
1760509|NCT00274287|Drug|GM-CSF (Leukine)|250 ug/m2 daily for 2 weeks followed by 2 weeks of rest
1760510|NCT00274300|Biological|pPJV7630 administered by PMED|
1760511|NCT00274313|Drug|552-02|
1760512|NCT00274326|Drug|SR121463B|
1996778|NCT02377219|Other|hormonal and blood analysis|
1760516|NCT00274365|Procedure|videoconference|
1760517|NCT00274378|Device|ALLOMATRIX injectable putty in distal radius fractures|
1760518|NCT00274391|Drug|7% NaCl|
1760519|NCT00274391|Drug|Amiloride HCl|
1760520|NCT00274404|Drug|valacyclovir|
1760521|NCT00274417|Drug|dutasteride|
1760522|NCT00274430|Drug|dexamethasone 8 mg bid|
1760523|NCT00274430|Drug|tadalafil 10mg bid|
1760524|NCT00274443|Drug|ABI-007 (Abraxane) and Carboplatin|ABI-007 plus Carboplatin will be administered intravenously over 30 minutes in cycles of 3 weeks
1760525|NCT00274456|Drug|ABI-007|ABI-007 administered by intravenous infusion over 30 minutes at one of three different dosing levels (100, 150 or 300 mg/m^2) with a treatment cycle length of either 3 or 4 weeks depending upon treatment arm assignment.
1760526|NCT00274456|Drug|Docetaxel|Docetaxel dosed q3w at 100 mg/m^2
1760527|NCT00274469|Drug|fulvestrant|500 mg intramuscular injection
1760528|NCT00274469|Drug|anastrozole|1 mg oral tablet
1760529|NCT00274495|Drug|Rosiglitazone and Pegasys/Ribavirin|
1760530|NCT00274508|Drug|tiotropium bromide|
1760531|NCT00274521|Drug|Tiotropium|
1760532|NCT00274534|Drug|Tiotropium|
1760533|NCT00274534|Drug|Salmeterol|
1760534|NCT00274547|Drug|Tiotropium|
1760535|NCT00274560|Drug|Tiotropium|
1760536|NCT00274560|Drug|Salmeterol|
1760537|NCT00274573|Drug|Tiotropium bromide|
1760538|NCT00274586|Drug|Aggrenox® modified release capsules|
1760539|NCT00274586|Drug|Aggrenox® modified release capsules matching placebo|
1760540|NCT00274599|Drug|Telmisartan|
1760541|NCT00274599|Drug|Ramipril|
1760542|NCT00274612|Drug|Telmisartan|
1760543|NCT00274612|Drug|Ramipril|
1760544|NCT00274625|Device|Surgisis Gold Graft|Surgisis Gold Graft is placed as an underlay following open bariatric surgery.
1760545|NCT00274625|Procedure|Control|Incision is closed without the placement of a graft material (standard of care control)
1760546|NCT00274638|Drug|Telmisartan & Hydrochlorothiazide|
1760547|NCT00274638|Drug|Losartan & Hydrochlorothiazide|
1760548|NCT00274638|Procedure|ABPM|
1760549|NCT00274651|Drug|belinostat|
1760550|NCT00274664|Device|6 hours occlusion by patching|
1760551|NCT00274664|Device|12 hours occlusion by patching|
1760552|NCT00274677|Drug|Placebo|Experimental treatment arm
1760553|NCT00274677|Drug|lamotrigine|Experimental treatment
1760554|NCT00274690|Drug|GW679769|
1760555|NCT00274703|Drug|mepolizumab|
1760556|NCT00274716|Drug|MK0736|
1760557|NCT00274716|Drug|MK0916|
1760558|NCT00274716|Drug|Placebo|
1760559|NCT00274729|Behavioral|Mono Unsaturated Fatty Acids in Obesity|
1760560|NCT00274742|Biological|Blinatumomab (MT103)|Doses from 0.5 to 120 µg/m^2/24hours by continuous intravenous infusion
1760561|NCT00274755|Drug|chemotherapy|
1760562|NCT00274755|Procedure|conventional surgery|
1760563|NCT00274755|Procedure|magnetic resonance imaging|
1760564|NCT00274755|Procedure|magnetic resonance spectroscopic imaging|
1760565|NCT00274755|Radiation|radiation therapy|
1760566|NCT00274768|Drug|capecitabine|
1760567|NCT00274781|Drug|arsenic trioxide|Arsenic trioxide will be administered at a dose of 0.25 mg/kg/day IV over 1-2 hours for 5 consecutive days during the first week. Subsequently, arsenic trioxide will be given at a dose of 0.25mg/kg/day twice a week for 11 additional weeks (weeks 2-12).
1760568|NCT00274781|Drug|gemtuzumab ozogamicin|Gemtuzumab ozogamicin consists of a 2 hr infusion at a dose of 3mg/m2 on day 8 of each 12-week cycle. Gemtuzumab ozogamicin should be administered at a minimum of one hour after the completion of the arsenic trioxide infusion
1760569|NCT00274794|Biological|filgrastim|10mcg/kg/d subcutaneously, beginning 48 hours after completion of Etoposide
1760570|NCT00274794|Biological|rituximab|375 mg/m2, IV, Once per week for 3 weeks.
1760571|NCT00274807|Biological|filgrastim|
1760572|NCT00274807|Drug|cytarabine|
1760573|NCT00274807|Drug|etoposide|
1760574|NCT00274807|Drug|mitoxantrone hydrochloride|
1760575|NCT00274820|Dietary Supplement|ascorbic acid|The dose of ascorbic acid will be 1000 mg PO 2-3 hours prior to ATO infusion. The treatment will follow the same schedule as arsenic trioxide.
1760576|NCT00274820|Drug|arsenic trioxide|Treatment consists of a loading period of five 0.25 mg/kg ATO doses in the first week, followed by maintenance dosing with 0.25 mg/kg ATO twice weekly for 11 weeks. Loading is usually done Monday through Friday of the first treatment week. Maintenance should be started either 72 or 96 hours after the last loading dose. Thereafter, dosing is twice weekly, following an alternating pattern of 72 and 96 hours. For example, maintenance dosing may be done on Mondays and Thursdays, Tuesdays and Fridays, etc. The same pattern should be followed for the entire maintenance dosing period.
1760577|NCT00274820|Drug|dexamethasone|Dexamethasone will be given at a dose of 4mg PO daily for five days every four weeks (i.e., days 1-5, 29-33, 57-61, 84-88, etc.).
1760578|NCT00274820|Drug|thalidomide|The dose of thalidomide will be 50 mg PO daily starting day 1. The dose will be increased to 100mg PO daily after two weeks if tolerated and only if patients experience < grade 1 thalidomide-attributed toxicity using CTC criteria.
1760579|NCT00274833|Drug|erlotinib hydrochloride|Erlotinib is available as 25 mg, 100 mg, and 150 mg tablets. It should be administered orally once daily at the prescribed dose specified in the clinical study protocol per dose escalation schema. Preferably, erlotinib should be taken in the morning with up to 200 mL of water at least 1 hour before or 2 hours after a meal.
1760580|NCT00274833|Drug|temozolomide|TMZ is supplied in white opaque, preservative-free, two piece hard gelatin capsules of the following sizes: 100mg capsules, 20mg capsules, and 5mg capsules. TMZ will be a once a day orally administered (75 mg/m2 x BSA x 42 days)set of capsules taken at least two hours after and one hour before a meal.
1760581|NCT00274833|Radiation|radiation therapy|Concomitant focal RT will be delivered once daily at 2 Gy per fraction, 5 d/wk, for a total of 60 Gy. (6 weeks) as mentioned in therapeutic modalities.
1760582|NCT00274846|Biological|aldesleukin|10 million units three times a week for a total of 6 doses. For any subject less than 45 kilograms the IL-2 will be given at 5 million units per meter squared three times weekly for a total of 6 doses
1760583|NCT00274846|Biological|therapeutic allogeneic lymphocytes|Cells infused per kg. 1.5-8.0 x 10^7/kg Total cells infused(for 70 kg. adult) 1.05 - 5.6 x 10^9
1760584|NCT00274846|Drug|cyclophosphamide|Days -5 and -4: 60 mg/kg
1760585|NCT00274846|Drug|fludarabine phosphate|Days -5 through -2: 25 mg/m^2
1760586|NCT00274846|Procedure|in vitro treated peripheral blood stem cell transplantation|Day 0 infuse natural killer cells
1760587|NCT00274859|Drug|gemcitabine hydrochloride|
1760588|NCT00274859|Drug|oxaliplatin|
1760589|NCT00274872|Drug|fluorouracil|
1760590|NCT00274872|Drug|leucovorin calcium|
1760591|NCT00274872|Drug|oxaliplatin|
1760592|NCT00274885|Drug|oxaliplatin|
1760593|NCT00274885|Procedure|management of therapy complications|
1760594|NCT00274898|Drug|celecoxib|
1760595|NCT00274898|Drug|docetaxel|
1760596|NCT00274898|Procedure|adjuvant therapy|
1760597|NCT00274898|Radiation|radiation therapy|
1760598|NCT00274911|Drug|cisplatin|
1760599|NCT00274911|Drug|lomustine|
1760600|NCT00274911|Drug|vincristine sulfate|
1760601|NCT00274911|Procedure|adjuvant therapy|
1760602|NCT00274911|Radiation|radiation therapy|
1760603|NCT00274924|Biological|filgrastim|Given subcutaneously or intravenous bolus.
1760604|NCT00274924|Biological|rituximab|Given IV
1760605|NCT00274924|Drug|carboplatin|Given IV
1760606|NCT00274924|Drug|cyclophosphamide|Given IV
1760607|NCT00274924|Drug|doxorubicin hydrochloride|Given IV
1760608|NCT00274924|Drug|etoposide|Given IV
1760609|NCT00274924|Drug|ifosfamide|Given IV
1760610|NCT00274924|Drug|prednisone|Taken orally
1760611|NCT00274924|Drug|vincristine|Given IV
1760612|NCT00274937|Drug|amifostine trihydrate|Given subcutaneously
1760613|NCT00274937|Drug|fluorouracil|Given IV
1760614|NCT00274937|Drug|cisplatin|Given IV
1760615|NCT00274937|Other|laboratory biomarker analysis|Correlative studies
1760616|NCT00274937|Radiation|radiation therapy|Undergo radiotherapy
1760617|NCT00274950|Biological|bleomycin sulfate|
1760618|NCT00274950|Drug|carboplatin|
1760619|NCT00274950|Drug|cisplatin|
1760620|NCT00274950|Drug|etoposide|
1760621|NCT00274950|Drug|ifosfamide|
1760622|NCT00274950|Drug|vinblastine sulfate|
1760623|NCT00274950|Procedure|adjuvant therapy|
1760624|NCT00274950|Procedure|conventional surgery|
1760625|NCT00274963|Drug|bendamustine hydrochloride|
1760626|NCT00274963|Drug|mitoxantrone hydrochloride|
1760627|NCT00274976|Biological|alemtuzumab|
1760628|NCT00274989|Drug|Bendamustine|"First-Line Therapy: Bendamustine i.v. 90 mg/m² day 1-2, q4wks, cycle 1 to 6
2nd to 4th -Line Therapy: Bendamustine i.v. 70 mg/m² day 1-2 q4wks, cycle 1 to 6"
1760700|NCT00275353|Behavioral|Individualized Symptom Education|
1760629|NCT00274989|Biological|Rituximab|"First-Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6
2nd to 4th -Line Therapy: Rituximab i.v. 375 mg/m² day 0, q4wks, cycle 1; Rituximab i.v. 500 mg/m² day 1, q4wks, cycle 2-6"
1760630|NCT00275002|Drug|O6-benzylguanine|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. O6-Benzylguanine, 120 mg/m^2, will be administered as a one-hour intravenous (IV) infusion, daily for 5 days. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses of therapy.
1760631|NCT00275002|Drug|temozolomide|Dosing is based on the body surface area (BSA) calculated at the beginning of each course of therapy. Temozolomide, 75 mg/m^2 (rounded to the nearest 5 mg, the size of the smallest capsule) will be given orally, 30 minutes following the completion of each infusion of O6-Benzylguanine. Four consecutive weeks will constitute one course. Courses will be repeated every 4 weeks for up to 12 courses.
1760632|NCT00275015|Biological|filgrastim|
1760633|NCT00275015|Drug|carmustine|
1760634|NCT00275015|Drug|cyclophosphamide|
1760635|NCT00275015|Drug|cytarabine|
1760636|NCT00275015|Drug|dexamethasone|
1760637|NCT00275015|Drug|etoposide|
1760638|NCT00275015|Drug|fludarabine phosphate|
1760639|NCT00275015|Drug|melphalan|
1760640|NCT00275015|Procedure|bone marrow ablation with stem cell support|
1760641|NCT00275015|Procedure|peripheral blood stem cell transplantation|
1760642|NCT00275015|Radiation|radiation therapy|
1760643|NCT00275028|Drug|cediranib maleate|Given orally
1760644|NCT00275041|Biological|cetuximab|
1760645|NCT00275041|Drug|irinotecan hydrochloride|
1760646|NCT00275054|Drug|Fludarabine|cycles 1-6: 25 mg/m² i.v., d2-4, q28d
1760647|NCT00275054|Drug|Cyclophosphamide|cycles 1-6: 250 mg/m² i.v., d2-4, q28d
1760648|NCT00275054|Biological|Rituximab|"cycle1: 375 mg/m² i.v., d1, q28d
cycles 2-6: 500 mg/m² i.v., d1, q28d"
1760649|NCT00275067|Drug|arsenic trioxide|Arsenic trioxide administered intravenously at a dose of 0.20mg/kg Daily x 5 week then twice per week
1760650|NCT00275067|Drug|temozolomide|Temozolomide administered orally once per day 1 hour prior to radiation therapy at a dose of 75 mg/m2 x 42 days; at a dose of 200mg/m2 for 5 days every cycle (1 cycle = 28 days) after radiation therapy
1760651|NCT00275067|Radiation|radiation therapy|All patients will receive 5940-6120 cGy of radiation therapy as 28-33 treatments/fractions (180-200 cGy/treatment) depending on whether they receive standard 3-D conformal radiation therapy or intensity modulated radiation therapy.
1760652|NCT00275080|Drug|vorinostat|Given orally
1760653|NCT00275080|Drug|decitabine|Given IV
1760654|NCT00275093|Drug|temsirolimus|Given IV
1760655|NCT00275093|Other|laboratory biomarker analysis|Correlative studies
1760656|NCT00275093|Other|pharmacological study|Correlative studies
1760657|NCT00275106|Drug|asparaginase|
1760658|NCT00275106|Drug|cyclophosphamide|
1760659|NCT00275106|Drug|cytarabine|
1760660|NCT00275106|Drug|daunorubicin hydrochloride|
1760661|NCT00275106|Drug|dexamethasone|
1760662|NCT00275106|Drug|doxorubicin hydrochloride|
1760663|NCT00275106|Drug|leucovorin calcium|
1760664|NCT00275106|Drug|mercaptopurine|
1760665|NCT00275106|Drug|methotrexate|
1760666|NCT00275106|Drug|prednisolone|
1760667|NCT00275106|Drug|thioguanine|
1760668|NCT00275106|Drug|vincristine sulfate|
1760669|NCT00275106|Procedure|radiation therapy|
1760670|NCT00275119|Drug|fluorouracil|
1760671|NCT00275119|Drug|gemcitabine hydrochloride|
1760672|NCT00275119|Drug|oxaliplatin|
1760673|NCT00275119|Radiation|radiation therapy|
1760674|NCT00275132|Drug|erlotinib hydrochloride|Tarceva (OSI-774, erlotinib) PO 150 mg daily
1760675|NCT00275132|Drug|Matched placebo|Matched placebo PO daily
1760676|NCT00275145|Behavioral|Resistance Training|Lifting weights 3 times per week; 8 different exercise each time; for each exercise, do three sets = lifting an appropriate weight between 8-12 for each set; rest 45 seconds (at least) between sets
1760677|NCT00275145|Behavioral|Aerobic Exercise|Exercise at 75% of maximal capacity for approximately 2 hours per week
1760678|NCT00275145|Behavioral|Combo|Lift weights (as described in RT group) and do aerobic exercise (as described in Aerobic group
1760679|NCT00275145|Behavioral|Continued Sedentary lifestyle|No changes
1760680|NCT00275158|Drug|L-Arginine Supplementation|
1760681|NCT00275171|Drug|Recombinant human thyrotropin (Thyrogen)|0.1 mg rhTSH administered intramuscularly
1760682|NCT00275171|Drug|recombinant human TSH|0.1 mg rhTSH administered intramuscularly
1760683|NCT00275171|Other|isotonic saline = placebo|0.1 mg isotonic saline injected intramuscularly
1760684|NCT00275184|Drug|Senna|
1760685|NCT00275184|Drug|Citramag powder|
1760686|NCT00275184|Drug|Metoclopramide|
1760687|NCT00275197|Drug|Sertraline and Elzasonan Combination|
1760688|NCT00275197|Drug|Sertraline|
1760689|NCT00275197|Drug|Placebo|
1760690|NCT00275210|Drug|Oxaliplatin (SR96669)|
1760691|NCT00275236|Drug|Rotigotine|
1760692|NCT00275249|Drug|levorphanol|
1760693|NCT00275262|Drug|Leuprolide acetate depot (LAD) 11.25 mg 3 Month|LAD intramuscular injection 11.25 mg, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
1760694|NCT00275262|Drug|Matched placebo|Matched placebo intramuscular injection, 3 month duration. To stimulate immune response, a subcutaneous key limpet hemocyanin (KLH) vaccination injection (1 mg) was administered at Month 6.
1760695|NCT00275275|Drug|Requip PR|Requip 24-Hour once a day for one month
1760696|NCT00275275|Drug|Mirapex|All subjects started the study on Mirapex. They were all then switched to Requip PR based on a conversion factor of 1:3, 1:4 or 1:5.
1760697|NCT00275301|Drug|olanzapine|Olanzapine 2.5mg by mouth at bedtime x2 weeks, then Olanzapine 5mg by mouth at bedtime x2 weeks, then Olanzapine 7.5mg by mouth at bedtime x4 weeks.
1760698|NCT00275314|Drug|Valganciclovir|
1760699|NCT00275340|Other|Peer Support|
1760703|NCT00275392|Behavioral|Vestibular rehabilitation|vestibular adaptation and substitution exercises
1760704|NCT00275392|Behavioral|Placebo|placebo vestibular exercises
1760705|NCT00275405|Drug|Garlic Oil Macerate|
1760706|NCT00275418|Drug|beta carotene from Dunaliella algae|
1760707|NCT00275431|Drug|AT-101|Oral
1760708|NCT00275444|Drug|Tipranavir|
1760709|NCT00275457|Drug|pramipexole|
1760710|NCT00275483|Device|Vital-band (R)|
1760711|NCT00275496|Procedure|Sentinel Lymph Node Dissection|Subject has wide excision and sentinel lymph node dissection for primary melanoma.
1760712|NCT00275496|Procedure|Complete Lymph Node Dissection|Subject has wide excision, sentinel lymph node dissection, and complete lymph node dissection (if positive sentinel node found) for primary melanoma.
1760713|NCT00275496|Procedure|Wide Excision|Subject has wide excision only for primary melanoma.
1760714|NCT00275509|Drug|Thymoglobulin|
1760715|NCT00275522|Drug|Sirolimus|
1760716|NCT00275535|Drug|Anti-thymocyte globulin|Thymoglobulin 1.5 mg/kg/d (days 0,1,2,4,6)
1760717|NCT00275535|Drug|Mycophenolate mofetil|Mycophenolate mofetil 750 mg p.o. b.i.d.- maintenance
1760718|NCT00275535|Drug|Prednisone|Prednisone 500 mg/day initially, tapered to 5 mg/day by day 92
1760719|NCT00275535|Drug|Tacrolimus|Tacrolimus - maintain trough levels of 6-8 ng/ml (whole blood Imx assay)
1760720|NCT00275535|Drug|Sirolimus|Rapamycin 3 to 5 mg/day; adjust to the high-performance liquid chromatography (HPLC) blood level 15 to 20 ng ml
1760721|NCT00275548|Drug|Pegasys|135-180 micrograms administered sc once weekly
1760722|NCT00275548|Drug|Copegus|400-1200 mg/day for 48 weeks
1760723|NCT00275561|Drug|Fluticasone|Aerosolized swallowed fluticasone 880 mg twice a day
1760724|NCT00275561|Drug|Placebo|Placebo inhaler swallowed twice a day for 6 weeks
1760725|NCT00275574|Procedure|acupuncture|acupuncture
1760726|NCT00275600|Drug|Vitamin E, Evening Oil of Primrose, and Placebo|
1760727|NCT00275613|Drug|Rituximab|The Rituximab dose is 1000 mg (1 gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15)
1760728|NCT00275639|Drug|Cozaar|
1760729|NCT00275652|Drug|LdT (Telbivudine) and lamivudine|
1760730|NCT00275665|Drug|Valganciclovir|
1760731|NCT00275678|Procedure|Blood stem cell versus bone marrow transplant|"Cyclophosphamide and Total Body Irradiation (CY-TBI)-based regimens that include at least 120 mg/kg cyclophosphamide and at least 1200 cGy of fractionated TBI.
Busulfan and cyclophosphamide (BU-CY)-based regimens that include at least 14 mg/kg busulfan orally or 11.2 mg/kg busulfan intravenously (14 x 0.8 correction factor) or a targeted busulfan dosing strategy aimed at a serum concentration greater than 600 ng/mL at steady state and at least 120 mg/kg cyclophosphamide.
Fludarabine and melphalan (Flu-Mel)-based regimens that include a fludarabine dose of least 120 mg per m2 and a melphalan dose of at least 140 mg per m2.
Fludarabine, busulfan, and ATG (Flu-Bu-ATG)-based regimens that include a fludarabine dose of at least 120 mg/m2, at least 8 mg/kg busulfan orally or 250 mg/m2 busulfan intravenously, and at least 40 mg/kg equine ATG or 4 mg/kg rabbit ATG. Institutional standards should be followed for targeting plasma levels."
1760732|NCT00275704|Drug|Flaxseed|
1760733|NCT00275730|Drug|indometacine (drug) effect on ocular blood flow|
1760734|NCT00284375|Procedure|Registration of all big toe prostheses in Ghent University Hospital|Registration of all big toe prostheses in Ghent University Hospital.
1760735|NCT00284388|Procedure|Simultaneous controlled power measurement|
1760736|NCT00284388|Procedure|Surface EMG measurement|
1760737|NCT00284401|Procedure|Evaluation of the placement of the Delta prosthesis|
1760738|NCT00284414|Procedure|Ultrasonography or MRI|
1760739|NCT00284427|Drug|vitamin C|IV Vitamin C given 2-3 times a week
1760740|NCT00284453|Procedure|Peripheral blood sampling|blood samples will be collected within 72 hours of subjects receiving >2, 1-2(low level) or inappropriate therapies, device data and repeat bloodwork in 3 months(+/- 4weeks).
1760741|NCT00284466|Procedure|MS-CT Coronary Angiography|MS-CT Coronary Angiography done
1760742|NCT00284479|Behavioral|Walking 45 mins 2x p.w.|
1760743|NCT00284492|Procedure|Traditional chinese medicine type acupuncture|10 acupuncture sessions
1760744|NCT00284492|Behavioral|Self Care|Lifestyle advice on diet, physical activity
1760745|NCT00284505|Drug|thalidomide|
1760746|NCT00284518|Biological|botulinum toxin Type A|Botulinum toxin Type A 300 U, 200 U or 100 U transperineal or transrectal injection on Day 1.
1760747|NCT00284518|Drug|normal saline|Normal Saline (Placebo) transperineal or transrectal injection on Day 1.
1760748|NCT00284531|Drug|Daclizumab|
1760749|NCT00284557|Behavioral|Group-based behavioral intervention|"The group-based behavioral intervention targets eating behaviors, physical activity, and screen time, and is delivered to participating children and their parent/caregiver over the course of 4 weeks. Maintenance sessions occur every 3 months thereafter."
1760750|NCT00284583|Drug|Injection of Steroid into Foot|
1760751|NCT00284583|Drug|Injection of Alcohol into Foot|
1760752|NCT00284583|Drug|Injection of Lidocaine into Foot|
1760753|NCT00284596|Procedure|High tibial osteotomy|HTO
1760754|NCT00284609|Behavioral|Group based non-pharmacological rehabilitation|"6 x 1.5 hours education program in group classes taught by nurse, physiotherapist, dietitian and chiropodist.
24 x 1.5 hours training program (both aerobic and anaerobic exercise) in group classes supervised by a physiotherapist.
3 x 3 hours cooking sessions in group classes supervised by a dietitian.
Intervention period: 6 month"
1760755|NCT00284609|Behavioral|Individual non-pharmacological rehabilitation|"Individual counseling in Outpatient Clinic, including patient education, physical activity and diet instruction.
4 x 1 hour with a diabetes nurse,
3 x 0.5 hour with a dietitian and
1 hour with a chiropodist.
Intervention period: 6 month"
1760756|NCT00284622|Procedure|Arthroscopy|HTO with pre-scope
1760757|NCT00284635|Procedure|Fast track vs conventional|
1760758|NCT00284648|Procedure|Surgical repair Achilles tendon rupture|
1760759|NCT00284648|Procedure|Non-surgical repair Achilles tendon rupture|
1760760|NCT00284661|Procedure|FAST FIX|Fast fix repair of a meniscal tear
1760761|NCT00284661|Procedure|Meniscal suturing|standard suturing of meniscal tear
1760762|NCT00284674|Device|Hip prosthesis (re-cap, m2a-magnum and C2a-taper)|
1760763|NCT00284687|Drug|Artesunate|PO Artesunate
1760764|NCT00284700|Drug|Iron|
1760765|NCT00284713|Procedure|intracoronary infusion of BMC|catheter delivery of stem cells
1760766|NCT00285168|Behavioral|Bone Density Decision Aide|Absolute 10-year Fracture Risk Report
1760767|NCT00285181|Drug|Simvastatin|
1760768|NCT00285194|Drug|Allogeneic Islets of Langerhans|
1760769|NCT00285194|Drug|hOKT3γ1 (Ala-Ala)|
1760770|NCT00285207|Drug|placebo|5 days of 28 day cycle for 2 cycles
1760771|NCT00285207|Drug|A007|5 days of 28 day cycle
1760772|NCT00285220|Procedure|Laparoscopic Truncal Vagotomy|
1760773|NCT00285233|Biological|Allogeneic islets of Langerhans transplant|Allogeneic islets of Langerhans transplant
1760774|NCT00285259|Biological|VCL-CB01|5 mg/mL, Intramuscular (IM.) 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
1760775|NCT00285259|Other|Phosphate-buffered Saline (PBS)|1 mL, IM. 3 vaccinations for donors; 1 vaccination pretransplant, up to 3 vaccinations after transplant for recipients
1760776|NCT00285285|Device|Point of Care Device; i-Stat Analyzer|
1760777|NCT00285298|Drug|Pentoxifylline|
1760778|NCT00285298|Drug|Placebo|
1760780|NCT00285350|Drug|mycophenolate mofetil|
1760781|NCT00285376|Drug|vilazodone|titration to 40mg tablets qd for 8 weeks
1760782|NCT00285389|Drug|Adriblastin|
1760783|NCT00285389|Drug|dexamethasone|
1760784|NCT00285389|Drug|Chlorambucil|
1760785|NCT00285389|Drug|rituximab|
1760786|NCT00285389|Drug|cyclophosphamide|
1760787|NCT00285389|Drug|alkeran|
1760788|NCT00285389|Procedure|Total body irradiation (8Gy/4fr)|
1760789|NCT00285389|Drug|vincristine|0,4 mg/day day 1 to day 4
1760790|NCT00285402|Drug|AST-726 Low dose|
1760791|NCT00285402|Drug|AST-726 High dose|
1760792|NCT00285402|Drug|AST-726 Placebo|
1760793|NCT00285415|Drug|Docetaxel and Carboplatin|docetaxel (75 mg/m2) + carboplatin (AUC 6) IV every 3 weeks X 6 cycles
1760794|NCT00285428|Drug|hA20-humanized anti-CD20 antibody|once weekly iv dosing for 4 weeks
1760795|NCT00285454|Procedure|Retrograde coronary venous delivery of cells.|
1760796|NCT00285467|Drug|doxercalciferol|form of vitamin D that is already in active form.
1760797|NCT00285467|Drug|Cholecalciferol|from of vitamin D that requires cells in the body to make active
1760798|NCT00285493|Drug|Antibiotics|
1760799|NCT00285519|Drug|Doxazosin (drug)|
1760800|NCT00285558|Behavioral|CBT with peer-enhanced activities|
1760801|NCT00285558|Behavioral|CBT with supervised aerobic exercise|
1760802|NCT00285571|Behavioral|Controlled Feeding Intervention|
1760803|NCT00285584|Drug|Bupropion|Participants initially received bupropion, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage of bupropion allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
1760804|NCT00285584|Drug|Placebo|Participants initially received placebo, 150 mg, once daily, to be taken in the morning. Dosage was increased to 150 mg twice daily within one month. Return visits were conducted monthly from study Months 1 through 6 to review medication dosage, ascertain side effects and evaluate depression severity. At the end of Moth 6, subjects were tapered to 150 mg/day over a period of 4 - 7 days. The final 150 mg/day dosage allowed referral for pharmacotherapy without unblinding subjects or staff regarding bupropion/placebo assignment. Subjects were followed through Month 9 to permit evaluation of the durability of intervention effects.
1760805|NCT00285597|Drug|Ursodeoxycholic Acid|
1760806|NCT00285623|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|treatment in surgery for improvement of haemostasis where standard techniques are insufficient
1760807|NCT00285649|Other|HVLA-SM|HVLA-SM, Experimental, high-velocity low amplitude spinal manipulation
1760808|NCT00285649|Other|LVVA-SM|LVVA-SM, Experimental, low velocity variable amplitude spinal manipulation
1760809|NCT00285649|Other|Usual Medical Care|Arm: Active Comparator: Usual Medical Care Usual Medical Care, Active Comparator, advice, exercises and medications (Celebrex, Aleve, Bextra, Naptoxen)
1760810|NCT00285662|Drug|Amodiaquine/sulphadoxine-pyrimethamine, Artesunate/sulphadoxine-pyrimethamine or placebo|Children will get 25mg/1.25mg/kg of SP as a single dose, 4 mg/kg for 3 days of Artesunate and 10 mg/kg for 3 days of Amodiaquine in their respective arms
1760811|NCT00285675|Drug|DN-101 (calcitriol) - Drug|
1760812|NCT00285688|Procedure|gastroscopic examination|gastroscopic examination for tissue biopsy and real time PCR for gene study
1760813|NCT00285701|Drug|hexaminolevulinate|
1760814|NCT00285714|Procedure|3D stereophotogrammetric imaging|
1760815|NCT00285714|Procedure|3D CT-imaging with cone-beam CT|
1760816|NCT00285714|Procedure|Case report form|
1760817|NCT00285727|Drug|Ropinirole CR|
1760818|NCT00285740|Behavioral|Cognitive Behavioral Therapy (CBT) in a Group Format|
1760819|NCT00285753|Behavioral|support groups|cognitive behavioral intervention with psychoeducation
1760820|NCT00285766|Drug|Selegiline Transdermal System|
1760821|NCT00285779|Drug|Etanercept|etanercept 50 mg twice weekly for 12 weeks
1760822|NCT00285779|Drug|Placebo|
1760823|NCT00285792|Behavioral|Physical Activity|
1760824|NCT00285805|Drug|Rosiglitazone versus placebo|
1760825|NCT00285805|Drug|response (sodium excretion) to amiloride infusion|
1760826|NCT00285805|Drug|response (sodium excretion) to furosemide infusion|
1760827|NCT00285818|Drug|Mifepristone|Mifepristone is a glucocorticoid receptor antagonist.
1760828|NCT00285818|Drug|Placebo Oral Capsule|Placebo is a capsule without a pharmacological active ingredient
1760831|NCT00285857|Drug|Lovastatin|"Lovastatin 80 mg/day as 40 mg orally twice daily.
Lovastatin is approved by FDA as a cholesterol-lowering agent."
1760832|NCT00285883|Drug|Invirase|
1760833|NCT00285883|Drug|Norvir|
1760834|NCT00285896|Drug|Glucagon-like-peptide-1 (7-36) amide|Continuous, subcutaneous GLP-1 at a dose of 4.8 pmol/kg/min for 51 hours
1760835|NCT00285896|Drug|Placebo|continuous subcutaneous placebo infusion at a dose of 4.8 pmol/kg/min for 51 hours
1760836|NCT00285909|Behavioral|Alcohol: 25 gday (white wine)|
1760837|NCT00285935|Drug|Treatment with SSRI|"Participants who enroll in this phase are treated with an FDA-approved SSRI in an open-label treatment-as-usual manner, in accordance with clinical practices and at a titration rate no more rapid than the manufacturer's recommendations. The duration of the treatment phase is 8 weeks.
Other Name: fluoxetine (Prozac®), Sertraline (Zoloft®), paroxetine (Paxil®), citalopram (Celexa®), escitalopram (Lexapro®)"
1760838|NCT00285948|Device|Primary Birmingham hip resurfacing arthroplasty using a metal-on-metal couple|
1760839|NCT00285961|Device|Cork splint materials (instead of plaster splint)|
1760840|NCT00285974|Device|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis|metal-on-metal total hip prosthesis versus ceramic-on-ceramic total hip prosthesis
1760841|NCT00285987|Procedure|Reconstruction of the cruciate ligament|
1760842|NCT00286000|Drug|Administration of high dose simplified folfiri|
1760843|NCT00286013|Drug|Association of gemcitabine, oxaliplatin and radiotherapy|
1760844|NCT00286026|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg. One dose vs 2 doses given 30 days apart.
1760845|NCT00286039|Procedure|Blood sampling|Blood sampling is used.
1760846|NCT00286052|Drug|Low Dose Naloxone|
1760847|NCT00286065|Drug|AeroLEF|
1760848|NCT00286078|Device|Precision|Implantable neurostimulator
1760849|NCT00286091|Biological|Denosumab|Administered by subcutaneous injection
1760850|NCT00286091|Biological|Placebo|Same volume subcutaneous injection
1760851|NCT00286104|Device|Antibiotics-impregnated ventricular catheter (Bactiseal®)|Antibiotics-impregnated ventricular catheter (Rifampicin- and Clindamycin-impregnated)
1760852|NCT00286104|Device|Plain ventricular catheter (Codman EDS II/III)|Plain ventricular catheter
1760853|NCT00286117|Drug|Anastrozole|oral
1760854|NCT00286117|Drug|Tamoxifen|oral
1760855|NCT00286130|Drug|Cetuximab, Oxaliplatin, Leucovorin, 5FU, Irinotecan|
1760856|NCT00286130|Drug|FOLFOX 6|"FOLFOX 6:
Oxaliplatin 100 mg/m² d1 concurrent with
Leucovorin 400 mg/m², followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks:"
1760857|NCT00286130|Drug|FOLFIRI|"FOLFIRI:
Irinotecan 180 mg/m² day 1 concurrent with
Leucovorin 400 mg/m² followed by
Bolus 5FU 400 mg/m², followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks"
1760858|NCT00286143|Drug|Fentanyl|Fentanyl is added to epidural Bupivacaine to be administered to neonates having thoracotomy for lung resections.
1760859|NCT00286156|Drug|Rapamune|Group 1- doses of Rapamune aimed at maintaining trough levels 5-8ng/ml Group 2 - doses of Rapamune aimed at maintaining trough levels 2-5ng/ml Group 3- Standard Care
1760860|NCT00286169|Drug|Amrubicin Hydrochloride|
1760861|NCT00286182|Drug|Erythropoietin alpha|Erythropoietin alpha is administered weekly by subcutaneous injection using a pre-specified dosing algorithm. The dosing algorithm is designed to make adjustments based on the rate of rise (ROR) of the hemoglobin over a one week period, as well as the absolute hemoglobin value. Subjects initially received active treatment with 7,500 units of erythropoietin given weekly by subcutaneously injection. Subjects are carefully monitored (e.g. every week) to avoid rapid increases in hemoglobin/hematocrit and/or increasing blood pressure control. Dose adjustments are made if the hemoglobin rises too rapidly (greater than 0.3 g/dL) in any given weekly interval.
1760862|NCT00286182|Drug|Placebo|Placebo
1760863|NCT00286195|Device|Multi-Link Frontier Coronary Stent System|Bare metal stent
1760864|NCT00286208|Drug|Mifepristone, misoprostol|
1760865|NCT00286221|Drug|PCA fentanyl|"PCA fentanyl 0.5 ug/kg with a dosing interval (lockout) of 15 minutes and a maximal permitted dosage of 4 demand doses per hour, according to their randomized preoperative assignment. The PCA pump (CADD-Solis Ambulatory Infusion Pump; Smiths Medical, Dublin, OH) had a preprogrammed dose limit of 50 ug fentanyl, and this was the maximal PCA dose permitted"
1760866|NCT00286221|Drug|PRN fentanyl|IV fentanyl 25 to 50 ug every 30 minutes PRN (the maximal routine dose permitted in our Neurosciences Critical Care Unit (NCCU))
1760867|NCT00286234|Drug|omega-3 acid ethyl esters|4 q qd
1760868|NCT00286234|Drug|extended release niacin|2 g qpm
1760869|NCT00286234|Drug|placebo|omacor placebo plus niaspan placebo
1760870|NCT00286234|Drug|omega-3 acid ethyl esters|4 g qd
1760871|NCT00286234|Drug|combined treatment|omega-3 acid ethyl esters 4 g qd and extended release niacin, titrate up to 2 g Qpm
1760872|NCT00286247|Genetic|INGN 201|
1760873|NCT00286260|Drug|levetiracetam|Levetiracetam tablet 500 mg, daily dose titrated to 3000 mg, 6 weeks
1760874|NCT00286273|Drug|trisodium citrate|for regional anticoagulation of the extracorporeal CVVH circuit
1760875|NCT00286273|Drug|nadroparin|for anticoagulation of the extracorporeal CVVH circuit
1760876|NCT00286286|Device|Intraperitoneal Aerosolization System, IntraMyst|
1760877|NCT00286299|Other|Aerobic high-intensity interval training (AIT)|The AIT group trains 4x4 minute interval training on a treadmill at 85-95 % HRpeak interspersed with 3 minutes of active resting periods at a work load corresponding to 70% HRpeak between each interval. All training sessions are monitored and start with a 6 minute warm-up and end with a 5 minute cool-down period at a work load corresponding to 70% HRpeak. Intervals are performed walking or running on a treadmill with a minimum of 5% inclination, 3 times per week for 8 weeks.
1760926|NCT00286689|Procedure|Whole body Protein turnover|
1760927|NCT00286689|Procedure|DEXA scan|
1760928|NCT00286702|Device|hand splint|
1760929|NCT00286728|Behavioral|Intensive referral to dual-focused self-help|4 group sessions to introduce patients to dual focused groups
1760998|NCT00287430|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
1760878|NCT00286299|Other|Computer game training (CG)|The CG spend the same amount of time (36 minutes), training to improve their ability in the computer game, Tetris. Tetris is a game where small shapes called Tetraminoes fall from the top of the Playfield to the bottom. Players must rotate the Tetraminoes as they fall and fit them together to complete lines. When the player fills an entire line with blocks, that line is removed from the screen. If the player cannot complete lines, the blocks will eventually rise past the top of the screen, and the game ends.
1760879|NCT00286299|Other|Maximal strength training|Training starts with a 10 minute warm-up on the treadmill. Maximal strength training is then performed in an inclined leg press machine. The subject lifts 4 maximal repetitions that are repeated 4 times after a 2 minute rest period. Subjects are instructed to lift the weight with an intention of maximal mobilization of force. Training load is increased each time the subject manage to perform 4x4 maximal repetitions. Training is carried out 3 times per week in 8 weeks.
1760880|NCT00286312|Drug|Atorvastatin|
1760881|NCT00286325|Drug|Rituximab|Infusion of 1000 mg of rituximab on day 0 and day 14
1760882|NCT00286351|Drug|Combined treatment with Arimidex and Zoladex before IVF|
1760883|NCT00286364|Drug|Downregulation and androgen priming by use of GnRH antagonist, aromatase inhibitor and hCG before COH|
1760884|NCT00286377|Drug|prosaptide|
1760885|NCT00286390|Procedure|Acupuncture|
1760886|NCT00286403|Drug|Fenoldopam Mesylate and/or MESNA|
1760887|NCT00286416|Drug|omalizumab (Xolair)|
1760888|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 12.5 mg, tablets, orally, once daily and insulin for up to 26 weeks.
1760889|NCT00286429|Drug|Alogliptin and insulin|Alogliptin 25 mg, tablets, orally, once daily and insulin for up to 26 weeks.
1760890|NCT00286429|Drug|Insulin|Alogliptin placebo-matching tablets, orally, once daily and insulin for up to 26 weeks.
1760891|NCT00286442|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin for up to 26 weeks.
1760892|NCT00286442|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin for up to 26 weeks.
1760893|NCT00286442|Drug|Metformin|Alogliptin placebo-matching tablets, orally, once daily and metformin for up to 26 weeks.
1760894|NCT00286455|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 26 weeks.
1760895|NCT00286455|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 26 weeks.
1760896|NCT00286455|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 26 weeks.
1760897|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 12.5 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
1760898|NCT00286468|Drug|Alogliptin and glyburide|Alogliptin 25 mg, tablets, orally, once daily and glyburide for up to 26 weeks.
1760899|NCT00286468|Drug|Glyburide|Alogliptin placebo-matching tablets, orally, once daily and glyburide for up to 26 weeks.
1760900|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
1760901|NCT00286481|Drug|Lapaquistat acetate and simvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
1760902|NCT00286481|Drug|Simvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable dose of simvastatin for up to 12 weeks.
1760903|NCT00286494|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
1760904|NCT00286494|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
1760905|NCT00286494|Drug|Pioglitazone|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone 30 mg or 45 mg, tablets, orally, once daily for up to 26 weeks
1760906|NCT00286507|Procedure|Vitrectomy, post hyaloid detachment and gas injection with or without ILM peel.|Combined cataract surgery (phacoemulsification and intraocular lens implantation) and pars plana vitrectomy with postoperative intraocular tamponade with gas, with or without ILM peeling
1760907|NCT00286520|Procedure|Transanal irrigation with Peristeen Anal Irrigation|
1760908|NCT00286533|Procedure|Clinical examination (implant stability, gingiva condition, etc.)|Clinical examination (implant stability, gingiva condition, etc.) to follow
1760909|NCT00286533|Procedure|Questionnaires|Questionnaires are used.
1760910|NCT00286559|Drug|SonoVue|
1760911|NCT00286559|Drug|Optison|
1760912|NCT00286585|Drug|Inhalational anesthetic|Sevoflurane, dosage according to the physician in charge
1760913|NCT00286585|Drug|Intravenous anesthetic, propofol|Propofol, dosage according to the physician in charge
1760914|NCT00286598|Behavioral|Feet First|Phase 1: (enrollment to 3 months) 8 sessions with a physical therapist learning leg strengthening and balance exercises, and initiating a walking program Phase 2: Motivational enhancement calls from a nurse every 2 weeks.
1760915|NCT00286611|Procedure|Blood and salivary sampling of amifostine|Sampling of blood and saliva to test for amifostine levels.
1760916|NCT00286624|Biological|Allogeneic Islets of Langerhans|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. First infusion to contain at least 5,000 islet equivalents/kg body weight. Subsequent infusions to contain at least 3,000 islet equivalents/kg body weight.
1760917|NCT00286624|Drug|Everolimus|Loading dose of 3 mg PO on day -2 relative to transplant, followed at least 12 hours later by dose of 1.5 mg PO BID. The daily dose will be adjusted according to the whole blood 12-hr trough to target 3-15 ng/ml for the first 3 months and 3-12 ng/ml thereafter.
1760918|NCT00286624|Drug|anti-thymocyte globulin|A total of 6 mg/kg IV over 12 hours on days -2, -1, 0, +1, and +2. The dose will be 0.5 mg/kg on day -2, 1.0 mg/kg on day -1, and 1.5 mg/kg on days 0, +1, and +2.
1760919|NCT00286624|Drug|Cyclosporine|Cyclosporine started on day +1 relative to the first islet transplant. Initial dose of 3 mg/kg/day administered in 2 divided doses; then adjusted to maintain target levels of 400 (350-500) ng/mL for the first three months following islet transplant and 300 (200-350) ng/mL thereafter.
1760920|NCT00286650|Procedure|3rd molar teeth extraction|
1760921|NCT00286676|Drug|Nutropin|
1760922|NCT00286676|Procedure|Oral Glucose Tolerance Test|
1760923|NCT00286676|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
1760924|NCT00286676|Procedure|Computed Tomography (CT) Scan|
1760930|NCT00286741|Other|Diabetes Group Management Visits|Patients meet in groups and receive education about diabetes, reinforcing each other with their own experiences. Each patient also gets medication management by a physician and pharmacist.
1760931|NCT00286754|Behavioral|SMI|Stage-matched intervention
1760932|NCT00286754|Behavioral|HEI|Health Education Intervention
1760933|NCT00286754|Behavioral|UC|Usual Care
1760934|NCT00286754|Behavioral|SMI|Stage-matched intervention
1760935|NCT00286754|Behavioral|HEI|Health Education Intervention
1760936|NCT00286754|Behavioral|UC|Usual Care
1760937|NCT00286780|Drug|AT-101|80 mg of AT-101 once daily for three days every other week, 375 mg/m2 of rituximab weekly for up to 12 weeks
1760938|NCT00286793|Drug|AT-101|Oral
1760939|NCT00286806|Drug|AT-101|
1760940|NCT00286819|Drug|the FEC75 and 95 regimen|"Fluorouracil 500mg/m2 by i.v. bolus or infusion. Epirubicin 75mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion. All three drugs will be administered intravenously on Day 1 of each 14-day cycles.
Arm B: the FEC90 regimen will be given at the following doses:
Fluorouracil 500mg/m2 by i.v. bolus or infusion.Epirubicin 90mg/m2 by 30 minutes i.v infusion and Cyclophosphamide 500mg/m2 by i.v bolus or infusion.
All three drugs will be administered intravenously on Day 1 of each 14-day cycles.
Pegfilgrastim fixed dose of 6mg as a single subcutaneous injection will be given in both arms on Day 2 of each cycle.
Six cycles of adjuvant chemotherapy will be administered in both arms (A + B"
1760941|NCT00286832|Procedure|PET scan|One extra PET scan after 1 cycle of treatment.
1760942|NCT00286845|Drug|Standard Chemotherapy|physician determined
1760943|NCT00286858|Device|Insignia Ultra and Insignia AVT|Regular AV-Delay increase to allow for intrinsic AV conduction, if present.
1760944|NCT00286871|Drug|Neoral|
1760945|NCT00286871|Drug|Tacrolimus|
1760946|NCT00286884|Procedure|Monitoring of heart rate variability|
1760947|NCT00286897|Drug|E2007|
1760948|NCT00286923|Drug|Topiramate|
1760949|NCT00286936|Drug|Zolpidem|
1760950|NCT00286949|Drug|Atomoxetine|Open Label uncontrolled active Drug intervention
1760951|NCT00286962|Device|MIP 2007C implantable insulin pump|Intraperitoneal insulin infusion delivered by an implantable pump: MIP 2007c
1760952|NCT00286962|Device|continuous subcutaneous insulin infusion (CSII) or MDI|
1760953|NCT00286975|Behavioral|Leadership development program educational intervention|
1760954|NCT00286988|Drug|Topiramate|
1760955|NCT00287001|Device|Cold air cooling|
1760956|NCT00287027|Drug|Risperdal Long Acting Injectable Antipsychotic Medication|
1760957|NCT00287040|Behavioral|Tailored, interactive intervention for mammography screening|Follow ups will occur at 6-, 12-, and 21-months in order to determine effectiveness of intervention as well as cost effectiveness and variation based on participant characteristics to facilitate a more effective program for mammography screenings
1760958|NCT00287053|Drug|divalproex sodium|Divalproex sodium vs. placebo
1760959|NCT00287066|Drug|Inhaled Human Insulin|
1760960|NCT00287066|Drug|Regular Human Insulin|
1760961|NCT00287079|Drug|Rebif®|44 microgram (mcg) IFN beta-1a sc once a week (qw) for 96 weeks
1760962|NCT00287079|Other|No Treatment|No treatment for 96 weeks
1760963|NCT00287092|Biological|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
1760964|NCT00287092|Biological|Infanrix® -IPV+Hib|0.5 mL, IM
1760967|NCT00287131|Procedure|Procedure - Adoptive cell transfer|Procedure - Adoptive cell transfer
1760968|NCT00287157|Drug|Sublingual Tizanidine HCl|
1760969|NCT00287170|Drug|Delayed Release 6MP or Calcitriol vs. Purinethol|
1760970|NCT00287183|Drug|PF-04494700 (TTP488)|60 mg/day for 6 days followed by 20 mg/day for 175 days vs placebo, oral medication
1760971|NCT00287183|Other|Placebo|Placebo
1760972|NCT00287196|Radiation|Radiotherapy|48 Gy reference dose in 20 fractions at 5 fractions per week, with a maximum overall treatment time of 30 days.
1760973|NCT00287209|Drug|Amiodarone|
1760974|NCT00287222|Drug|Bevacizumab|15 mg/KG I.V. every 21 days
1760975|NCT00287222|Drug|Erlotinib|150 mg orally every day
1760976|NCT00287235|Device|MARS|
1760977|NCT00287235|Drug|Standard Medical Therapy|
1760978|NCT00287248|Drug|[123I] IMPY & SPECT Imaging|Subjects will be injected with 7mCi of [123I]IMPY, followed by SPECT imaging
1760979|NCT00287261|Drug|zoledronic acid|4 mg IV every 3 weeks for 36 weeks
1760980|NCT00287274|Device|computerized physician order entry|
1760981|NCT00287287|Drug|Lenalidomide|Initial dose is 25 mg/day dose will be adjusted accordingly as needed. Dose range for the study is 5 to 25 mg/day
1760982|NCT00287300|Drug|Sulfadoxine-Pyrimethamine|
1760983|NCT00287300|Drug|Azithromycin|
1760984|NCT00287300|Drug|Artesunate|
1760985|NCT00287313|Drug|Vitamin K|
1760986|NCT00287326|Drug|Bupivacaine, Clonidine, Morphine|
1760987|NCT00287339|Drug|Esomeprazole|40mg capsule BID for 12 weeks
1760988|NCT00287339|Drug|Placebo|placebo capsule BID for 12 weeks
1760989|NCT00287352|Drug|Olanzapine, Amantadine|Olanzapine continuing as clinically indicated, Amantadine 100 mg tid
1760990|NCT00287352|Drug|Olanzapine and placebo|Olanzapine continuing as clinically indicated
1760992|NCT00287378|Drug|omalizumab|omalizumab as per weight and IgE
1760993|NCT00287391|Drug|Rabeprazole|
1760994|NCT00287417|Device|echography|
1760995|NCT00287417|Other|blood sample|
1760996|NCT00287430|Drug|Growth Hormone|
1760997|NCT00287430|Procedure|Whole body Protein Turnover Study|
1760999|NCT00287443|Procedure|Oral Glucose tolerance test|
1761000|NCT00287443|Procedure|Whole body protein turnover|
1761001|NCT00287443|Procedure|IV glucose tolerance test|
1761002|NCT00287443|Procedure|Indirect Calorimetry|
1761003|NCT00287443|Procedure|Dual Energy X-ray Absorptiometry (DEXA)|
1761004|NCT00287443|Procedure|Growth Hormone Stimulation Test|
1761005|NCT00287456|Device|Insulin Pump|
1761006|NCT00287456|Drug|Insulin|
1761007|NCT00287456|Procedure|Oral Glucose Tolerance Test|
1761008|NCT00287456|Procedure|Whole body Protein Turnover|
1761009|NCT00287469|Biological|Hepatitis E vaccine, recombinant (Sar 56 kDa)|
1761010|NCT00287482|Drug|Essiac|
1761012|NCT00287508|Device|Carotid artery stenting with filter (interventional)|
1761013|NCT00287521|Drug|AL-37807 Ophthalmic Suspension, 1.0%|One drop in the study eye(s) once daily for 28 days
1761014|NCT00287521|Drug|Latanoprost, 0.005% (Xalatan)|One drop in the study eye(s) once daily for 28 days
1761015|NCT00287521|Other|AL-37807 Vehicle|One drop in the study eye(s) once daily for 28 days
1761016|NCT00287521|Drug|Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%|One drop in the study eye(s) once daily for 28 days
1761017|NCT00287534|Drug|Anastrozole|oral
1761018|NCT00287534|Drug|Tamoxifen|oral
1761019|NCT00287547|Drug|CTLA4Ig / Abatacept|
1761020|NCT00287560|Drug|propofol (drug)|
1761021|NCT00287573|Device|TAXUS Express2|Paclitaxel-Eluting Coronary Stent System
1761022|NCT00287573|Procedure|Brachytherapy (beta source)|Brachytherapy (beta source)
1761023|NCT00287586|Drug|Testosterone Gel (Androgel)|7.5 g of 1% testosterone gel to achieve a nominal delivery of 75 mg testosterone daily for 3 years
1761024|NCT00287586|Drug|Placebo|Placebo-matching testosterone gel daily for 3 years
1761025|NCT00287612|Procedure|Lap. Fundo. with Mobilization of the Esophageal Junction|Complete mobilization of the esophageal junction
1761026|NCT00287612|Procedure|Lap. Fundo. without Mobilization of the Esophageal Junction|phrenoesophageal membrane left intact
1761027|NCT00287625|Procedure|Pulmonary rehabilitation|Pulmonary rehabilitation
1761028|NCT00287638|Device|CPAP|Continuous positive pressure device with a time clock
1761029|NCT00287638|Device|placebo|no CPAP
1761030|NCT00287651|Procedure|Pulsatile IV Insulin|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
1761031|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Control Patients are not given pulsatile intravenous insulin therapy during the study.
1761032|NCT00287651|Procedure|Effects of Pulsatile IV Insulin on Diabetic Retinopathy|Intravenous Insulin is provided in a pulsed manner based upon weekly physician orders the amount of insulin provided is dependent on patients level of insulin resistance.
1761033|NCT00287664|Drug|terlipressin|
1761034|NCT00287677|Biological|recombinant human Growth Hormone|Growth Hormone during 6 months (30UG/KG/DAY)
1761035|NCT00287677|Biological|Vaccination|Vaccination (Hepatitis A+B + tetanus toxoid) at week 16
1761036|NCT00287677|Drug|HAART|HAART all over the trial
1761037|NCT00279344|Drug|Fentanyl (Matrifen)|
1761038|NCT00279357|Procedure|Narrow Band Imaging|
1761039|NCT00279383|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|Intra-operatively treated patients with hemostatic supporting agents/techniques in addition to the standard surgical procedures
1761040|NCT00279409|Drug|aripiprazole|double blind capsules (abilify or placebo) taken once daily, up to 10mg.
1761041|NCT00279422|Drug|visilizumab|
1761042|NCT00279422|Drug|visilizumab|
1761043|NCT00279435|Drug|visilizumab|
1761044|NCT00279448|Drug|exemestane|On tablet of 25 mg per day during 5 years
1761045|NCT00279448|Drug|tamoxifen|Two tablets of tamoxifen 10 mg per day during 2.5 to 3 years followed by one tablet of exemestane 25 mg per day during 2 to 2.5 years for a total duration of 5 years of treatment
1761046|NCT00279461|Drug|Placebo in arm A and Vitamin D in arm B|Vitamin D3 at 2,000 units daily, all in one capsule, for 6 months and Placebo provided in matching capsule, one capsule daily, for 6 months
1761047|NCT00279461|Drug|vitamin D 3 for arm A ,and matching placebo for arm B|Arm A 2,000 units of Vitamin D3 in one capsule daily for 6 months. Arm B matching placebo capsule, one daily for 6 months
1761048|NCT00279474|Behavioral|cognitive-behavior groups|
1761049|NCT00279487|Drug|Gabapentin|
1761050|NCT00279487|Drug|Placebos|
1761052|NCT00279513|Drug|Traumeel S|
1761053|NCT00279539|Genetic|Vascular Endothelial Growth Factor (VEGF1)|
1761054|NCT00279552|Drug|Recombinant human intrinsic factor|
1761055|NCT00279565|Drug|buprenorphine|
1761056|NCT00279565|Drug|methadone|
1761057|NCT00279565|Drug|pegylated interferon alfa-2b plus ribavirin|
1761058|NCT00279578|Drug|ReFacto (Recombinant factor VIII) and Tranexamic acid|
1761059|NCT00279591|Device|Continuous blood pressure monitoring using (Dinamap) standard oscillometric blood pressure device|Continuous blood pressure monitoring of patients during med flight to hospital
1761060|NCT00279591|Device|Standard of care blood pressure monitoring|Patients received the standard of care for blood pressure monitoring while en route to the hospital via med flight.
1761061|NCT00279604|Behavioral|'Problem Profile Intervention' vs. WHO-Brief Intervention|
1761062|NCT00279617|Drug|levetiracetam|open label levetricetam
1761063|NCT00279630|Procedure|Orthoses and Exercise|orthrose and exercise - daily
1761064|NCT00279643|Procedure|Laser Hair Removal|
1761065|NCT00279656|Behavioral|Pharmaceutical care|
1761066|NCT00279669|Procedure|Ultrasound examination|contact ultrasound examination
1761067|NCT00279682|Behavioral|treatment guidelines and depression care management|
1761068|NCT00279695|Procedure|high frequency ultrasound examination|high frequency ultrasound examination of the eye
1761069|NCT00279708|Drug|Atorvastatin|Placebo vs. Atorvastatin
1761070|NCT00279708|Other|Placebo Oral Tablet|Placebo: Sham Therapy in an oral tablet formulation
1761071|NCT00279721|Procedure|IMRT|
1761072|NCT00279734|Drug|Tetanus + pnemococcal vaccines alone|0 mg + vaccines, Single dose, 28 days.
1761073|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 70 days.
1761074|NCT00279734|Drug|Abatacept + vaccines|Parenteral, IV, 750 mg abatacept + vaccines, Single dose, 56 days.
1761075|NCT00279734|Drug|Abatacept + Vaccines|parenteral, IV, 750 mg abatacept + vaccines, Single dose, 84 days.
1761076|NCT00279747|Drug|meloxicam 0.25 mg/kg|
1761077|NCT00279747|Drug|meloxicam 0.125 mg/kg|
1761078|NCT00279747|Drug|naproxen 10 mg/kg|
1761079|NCT00279760|Drug|Belatacept|
1761080|NCT00279760|Drug|Abatacept|
1761081|NCT00279773|Drug|TKI258|
1761082|NCT00279786|Procedure|Blood draw|blood drawn
1761083|NCT00279799|Behavioral|Afiya HIV Prevention Intervention|Group-based session plus individually tailored HIV prevention phone sessions
1761084|NCT00279799|Behavioral|Afiya HIV prevention intervention|Afiya group-based intervention + nutrition phone sessions (attention control)
1761086|NCT00279825|Drug|IPX054 200 mg|IPX054 tablet containing 50 mg carbidopa and 200 mg levodopa
1761087|NCT00279825|Drug|IPX054 250 mg|IPX054 tablet containing 62.5 mg carbidopa and 250 mg levodopa
1761088|NCT00279825|Drug|CD-LD IR|Active comparator containing 25 mg carbidopa and 100 mg levodopa
1761089|NCT00279825|Drug|CD-LD CR|Active comparator containing 50 mg carbidopa and 200 mg levodopa
1761090|NCT00279825|Drug|IPX054 200 mg Placebo|Placebo to match IPX054 200 mg
1761091|NCT00279825|Drug|IPX054 250 mg Placebo|Placebo to match IPX054 250 mg
1761092|NCT00279825|Drug|CD-LD IR Placebo|Placebo to match CD-LD IR
1761093|NCT00279825|Drug|CD-LD CR Placebo|Placebo to match CD-LD CR
1761094|NCT00279838|Procedure|Computer Assisted Navigation Knee Replacement|
1761095|NCT00279877|Procedure|Kyphoplasty|kyphoplasty
1761096|NCT00279890|Drug|Topical SR-01|
1761097|NCT00279903|Drug|Botulinum toxin type A (Btx-A)|Participants randomized to Btx-A will be given either a low dose of 100 units or a high dose of 200 units. The Btx-A dose (100U or 200U) will be resonstituted with 4 cc of sterile non-preserved 0.9% sodium chloride solution.
1761098|NCT00279903|Drug|Cortisone|1 cc of 40 mg/cc methylprednisolone will be drawn up in 22 gauge needles with 3 cc of sterile non-preserved 0.9% sodium chloride solution.
1761099|NCT00279916|Drug|Triamcinolone acetonide nasal spray|"Subjects aged 12 years or older received 2 metered sprays in each nostril once daily (55 micrograms/spray) (total daily dose 220 micrograms).
Subjects younger than 12 years old received received 1 metered spray in each nostril once daily (55 micrograms/spray) (total daily dose 110 micrograms)."
1761100|NCT00279916|Drug|Placebo nasal spray|"Subjects aged 12 years or older received an aqueous solution lacking triamcinolone, 2 metered sprays in each nostril once daily.
Subjects younger than 12 years old received received 1 metered spray of placebo solution in each nostril once daily."
1761101|NCT00279929|Procedure|DHEA Replacement|
1761102|NCT00279942|Dietary Supplement|Soy|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
1761103|NCT00279942|Other|Placebo|Drink a shake (vanilla and chocolate taste) once a day for 6 weeks.
1761104|NCT00279955|Device|Cardiac Resynchronization Therapy Device|Patients with an ICD indication, a CRT indication and symptomatic heart failure who are implanted with a Cardiac Resynchronization Therapy Device.
1761105|NCT00279968|Device|ICD|
1761106|NCT00279981|Device|Diagnostic|
1761107|NCT00279994|Procedure|Exercise therapy|
1761108|NCT00279994|Device|Accelerometer (PAM; Personal Activity Monitor)|
1761109|NCT00279994|Procedure|Oral Exercise Therapy advise|
1761110|NCT00280007|Drug|bevacizumab|bevacizumab 5 mg/kg i.v. every 14 days for 52 weeks
1761111|NCT00280020|Behavioral|Tai Chi Chih (TCC)|Participants will learn and practice 20 movements in 1 hour sessions twice per week for 16 weeks
1761112|NCT00280020|Behavioral|Cognitive Behavior Therapy (CBT)|For each 2-hour session held once a week for 16 weeks, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
1761113|NCT00280020|Behavioral|Sleep Seminar (SS)|Each 2-hour session, held once a week for 16 weeks, consists of a 60-minute video presentation followed by a 60-minute question-and-answer discussion.
1761114|NCT00280033|Biological|Aluminum hydroxide|Provided in vials that contain 0.8 mL volume per vial.
1761115|NCT00280033|Biological|Inactivated Influenza A/H5N1 Vaccine (Chiron)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in unit-dose vials containing 60 mcg/mL A/H5N1 HA as determined by single radial immunodiffusion. It may be formulated with MF59 or aluminum hydroxide. Dosages: 7.5 mcg, 15 mcg, 30 mcg, or 45 mcg.
1761116|NCT00280033|Biological|MF-59|Proprietary experimental adjuvant. Provided in vials that contain 0.7 mL volume per vial.
1761117|NCT00280033|Drug|Placebo|Saline placebo.
1761118|NCT00280046|Drug|biphasic insulin aspart|
1761119|NCT00280059|Drug|Pregabalin|dose 150-600 mg/day given BID
1761120|NCT00280059|Drug|Lamotrigine|dose 100-500 mg/day given BID
1761121|NCT00280072|Device|Renal Assist Device|
1761122|NCT00280085|Procedure|MR imaging|
1761123|NCT00280085|Procedure|Glucose clamp|
1761124|NCT00280085|Drug|Arginine|
1761125|NCT00280098|Drug|docetaxel|Docetaxel 75mg/m2/q3wx10 cycles with Prednisone 10mg/d/bid
1761126|NCT00280111|Biological|116E AGMK|Single dose of 116E 10^5 FFu
1761127|NCT00280111|Drug|I321|Single dose of I321 10^5 FFu
1761128|NCT00280111|Drug|Placebo|1 crystal of potassium permanganate dissolved in the bicarbonate buffer to colour match the vaccine
1761129|NCT00280150|Biological|bevacizumab|Given IV
1761130|NCT00280150|Drug|carboplatin|Given IV
1761131|NCT00280150|Drug|erlotinib hydrochloride|Given orally
1761132|NCT00280150|Drug|paclitaxel|Given IV
1761133|NCT00280150|Radiation|3-dimensional conformal radiation therapy|Given 5 days a week for 7 weeks
1761134|NCT00280176|Drug|bortezomib|0.7mg/m2 - 1.5mg.m2 given during Weeks 1, 2, 4 and 5 on a Monday/Thursday or Tuesday/Friday schedule, up to six weeks
1761135|NCT00280176|Drug|fluorouracil|225mg/m2 given weekly, up to 6 weeks
1761136|NCT00280176|Radiation|radiation therapy|180 cGy, every 5 days, up to six weeks
1761137|NCT00280189|Procedure|Radiofrequency ablation of pulmonary malignancies|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
1761138|NCT00280189|Behavioral|Quality of life assessment|Quality of life assessment is administered prior to the Radiofrequency ablation procedure and every 3 months for 1 year following the procedure.
1761139|NCT00280189|Behavioral|Assessment of pain|Pain scores are obtained prior to the procedure, daily X 7 starting on the day of surgery, and then every 3 months for 1 year.
1761140|NCT00280202|Procedure|Biopsy of the major carinal area|Biopsy performed intraoperatively
1761141|NCT00280202|Procedure|Biopsy of abnormal & suspicious areas of the bronchial tree|Biopsy performed intraoperatively
1761142|NCT00280202|Procedure|Evaluation of the tumor for DNA mutations|Tumor tissue is banked for future analysis.
1761143|NCT00280202|Procedure|Bronchoalveolar Lavage (BAL) for cytokine analysis|BAL performed intraoperatively
1761144|NCT00280202|Procedure|Correlation of flow cytometric & RT PCR for TNM stage|Tissues banked for future correlative studies
1761145|NCT00280202|Procedure|Analysis of lymph nodes|Tissues banked for future analysis
1761146|NCT00280215|Drug|ACEI / Angiotensin converting enzyme inhibitor|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker, Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
1761147|NCT00280215|Drug|ARB /Angiotensin Receptor Blocker|Patients will be randomized to a combination of Angiotensin Converting Enzyme Inhibitor and Angiotensin Receptor Blocker,Patients will be randomized to a combination of ARB(losartan 50 mg daily in adult patients, 0.7 mg/kg/day in patients < 40 kg) ACE-I (lisinopril 10 mg daily in adult patients, 0.15 mg/kg/day in pediatric patients < 40 kg) to be taken for 24 months.
1761148|NCT00280215|Drug|Placebo|Patients will receive placebo for 24 months
1761149|NCT00280228|Behavioral|Adolescent Skills Parent Management Parent-Adol Negotiation|Acute treatment for 12 weeks followed by three monthly booster sessions.
1761150|NCT00280228|Behavioral|Treatment as Usual|Standard outpatient treatment for behavioral problems and substance use
1761151|NCT00280241|Drug|Fludarabine|Fludarabine is usually administered by IV infusion over 30 minutes or longer.
1761152|NCT00280241|Drug|Cyclophosphamide|The dosage is a solution of 20 mg/mI. IV infusion over 1 hour.
1761153|NCT00280241|Drug|Rituximab|First Infusion: The rituximab solution for infusion should be administered intravenously at an initial rate of 50 mg/hr. Subsequent rituximab infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
1761154|NCT00280254|Procedure|Hemodynamically Oriented Echocardiography-based Strategy|
1761155|NCT00280267|Drug|Testosterone gel|
1761156|NCT00280280|Drug|intramuscular Botox versus oral baclofen|Each vial of Botox contains 100 units of Clostridium botulinum toxin type A, 0.5 mg albumin (human) and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. Botox placebo is sterile normal saline (without preservatives) for injection. Baclofen is supplied as 10 mg tablets for oral administration. Inactive ingredients include colloidal anhydrous silica, microcrystalline cellulose, magnesium stearate, povidone, wheat starch. Baclofen placebo tablets are composed of microcrystalline cellulose binder (99%), magnesium stearate 0.5%, and silica gel 0.5% and appear similar to commercial Baclofen tablets.
1761157|NCT00280293|Drug|Lamotrigine|Lamotrigine
1761158|NCT00280293|Drug|Placebo|Placebo
1761159|NCT00280306|Other|No interventions|No intervention
1761160|NCT00280319|Behavioral|interpersonal psychotherapy for groups|psychotherapy
1761161|NCT00280319|Behavioral|creative play therapy|consisted of play activities
1761162|NCT00280332|Procedure|colonoscopy|proform a follow up colonoscopy in the 5 year period from index colonoscopy
1761163|NCT00280345|Procedure|Trabeculectomy|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork
1761164|NCT00280345|Procedure|Trabeculectomy and cataract surgery|A surgical procedure used in the treatment of glaucoma to relieve intraocular pressure by removing part of the eye's trabecular meshwork and the removal of the cataract
1761165|NCT00280345|Procedure|Cataract surgery|Removal of the cataract from the eye
1761166|NCT00280358|Drug|Fluticasone Propionate|
1761167|NCT00280358|Drug|Formoterol Fumarate|
1761168|NCT00280371|Drug|Formoterol Fumarate|
1761169|NCT00280384|Drug|E2014 (Botulinum toxin type B)|A single-dose injection solution containing 20 units (U), 100 U, or 500 U/ 0.2 milliliters (mL) of E2014 was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
1761170|NCT00280384|Drug|E2014 (Botulinum toxin type B) Placebo|A single-dose injection solution of E2014 Placebo was administered to extensor digitorum brevis (EDB) muscle in the left lower limb to Japanese and Caucasian participants. Duration of treatment lasted for 12 weeks: from Day -1 to Week 12. Participants were hospitalized from a day before study treatment to Day 8 for 9 nights and 10 days, and visited at the medical institution on Days 10 and 14, and Weeks 4 and 12.
1761171|NCT00280397|Drug|E7080|E7080 is administered orally twice a day for 2 weeks to patients with solid tumors that are resistant to approved conventional therapies or for which no appropriate treatment is available.
1761172|NCT00280410|Drug|E7337|
1761175|NCT00280449|Behavioral|strengths-based case managed proactive service model|
1761217|NCT00280761|Radiation|Radiation therapy|Dosing and dose modification will be per current standard of care at the discretion of the treating Radiation Oncologist.
1761176|NCT00280462|Drug|Nifedipine (drug)|Nifedipine (Adalat®, Bayer, Leverkusen, Germany) dose: 15µg/kg bolus infusion over 5 minutes; 0.2 µg/(kg.min) maintenance dose infusion period 25 minutes
1761177|NCT00280462|Drug|L-Arginin (drug)|L-Arginin (Clinalfa AG, Läufelfingen, Switzerland) 30% sodium chlorid solution, dose: 1g/min over 30 minutes
1761178|NCT00280462|Drug|Placebo|Placebo
1761179|NCT00280475|Device|Whole brain radiation therapy arm|Whole brain radiation therapy arm
1761180|NCT00280475|Device|Salvage stereotactic radiosurgery arm|Salvage stereotactic radiosurgery arm
1761181|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
1761182|NCT00280488|Behavioral|Assessment|In the assessment-only condition, patients will receive only assessment of their drinking at baseline.
1761183|NCT00280488|Behavioral|Motivational Interview|Two intervention sessions timed to occur in the hospital, and 1 booster session, occurring 1 month following discharge.
1761184|NCT00280501|Drug|Quetiapine (drug)|Quetiapine (Seroquel 100mg-film-coated tablet, AstraZeneca Vienna, Austria) Dose: 100 mg tablet oral single dose
1761185|NCT00280501|Drug|Sulpiride (drug)|Sulpiride (Dogmatil 200mg-tablet, Synthélabo Groupe, Le Plessis Robinson, France) Dose: one half of 200 mg tablet oral single dose
1761186|NCT00280501|Drug|Placebo|Placebo
1761187|NCT00280514|Drug|cefpirome and moxifloxacin administration|
1761188|NCT00280540|Drug|Valsartan/Hydrochlorothiazide|
1761189|NCT00280553|Drug|bupivicaine|PCA and bupivicaine infusion for up to five days
1761190|NCT00280553|Other|Saline infusion|PCA and pump with saline infusion for up to five days
1761191|NCT00280566|Drug|Placebo|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID (twice a day) for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to placebo will be tapered off the open-label ziprasidone by 20 mg BID every 2 days (in a double-blinded manner) until they are completely off ziprasidone and are on matching placebo capsules for up to 24 weeks of double-blind treatment.
1761192|NCT00280566|Drug|Ziprasidone Oral Capsule|Oral capsule formulation: Patients will be treated initially with open-label ziprasidone in the range of 40-80 mg BID for at least 10 weeks and up to 16 weeks. Patients who achieve a stable treatment regimen and whose symptoms stabilize for 8 consecutive weeks by Week 16 (Week 10 at the earliest) will be randomized. Patients randomized to ziprasidone will continue to receive the same stable treatment regimen achieved during the open-label treatment, ie, either 40 mg BID, 60 mg BID or 80 mg BID for up to 24 weeks of double-blind treatment.
1761193|NCT00280592|Drug|Cranberry|Dry essence of cranberry presented as 18 mg of proanthocyanidines sachets of powdered cranberry. Cranberry juice is administered twice a day (in the morning and in the evening).
1761194|NCT00280592|Drug|Placebo|Placebo presented as sachets of powder. Placebo juice is administered twice a day (in the morning and in the evening).
1761195|NCT00280605|Drug|Alfuzosin|
1761196|NCT00280618|Drug|Oxaliplatin|
1761197|NCT00280631|Drug|Ezatiostat Hydrochlorine|Oral Tablets in 2 Divided Doses, Dose Escalation From 200 mg Per Day to 6000 mg Per Day on Days 1-7 of each 21 Day Cycle.
1761198|NCT00280644|Drug|Leflunomide|
1761199|NCT00280657|Drug|Valette|1 tablet 0.030 mg ethinylestradiol / 2 mg dienogest + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
1761200|NCT00280657|Drug|Diane|1 tablet 0.035 mg ethinylestradiol / 2 mg cyproterone acetate + 1 placebo tablet daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
1761201|NCT00280657|Drug|Placebo|2 placebo tablets daily for 21 days followed by a 7-day tablet-free interval, oral administration for 6 cycles
1761202|NCT00280670|Behavioral|Cognitive-behavioral therapy|Cognitive behavioral therapy for children with autism and anxiety.
1761203|NCT00280683|Drug|L-arginine|subjects will take matching 0.01 g/kg/day of L-arginine in divided doses for thre months.
1761204|NCT00280683|Drug|Placebo|Placebo tablets that match the L-arginine intervention tablets will be given for three months
1761205|NCT00280696|Drug|Levetiracetam 250 mg|"Active Substance: Levetiracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 250 mg
Route of Administration: Oral Use"
1761206|NCT00280696|Drug|Levetiracetam 500 mg|"Active Substance: Levetiracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 500 mg
Route of Administration: Oral Use"
1761207|NCT00280696|Other|Placebo|"Active Substance: Placebo
Pharmaceutical Form: Film-coated tablet
Concentration: 250 mg and 500 mg
Route of Administration: Oral Use"
1761208|NCT00280709|Device|"Nitinella ; SX-ELLA Stent Biliary (biliary metal stent)"|Nitinella covered (arm 1) or uncovered (arm 2) biliary metal stent. Maximum diameter 10 mm, length 52 or 72 mm
1761209|NCT00280722|Behavioral|patient information leaflet|
1761210|NCT00280735|Drug|carboplatin|Carboplatin will be given intravenously,once,every 3 weeks. The carboplatin area under curve (AUC) dose will be calculated using the Calvert Equation 19 as follows: Carboplatin dose (mg) = 6x (GFR + 25)
1761211|NCT00280735|Drug|docetaxel|75 mg/m² intravenously, once, every 3 weeks
1761212|NCT00280748|Drug|pemetrexed disodium|500 mg/m2 once every 21 days up to 126 days
1761213|NCT00280748|Radiation|radiation therapy|Patients will receive cranial irradiation at 2.5 Gy per fraction, 5 days a week, for 3 weeks to a total dose of 37.5 Gy
1761214|NCT00280761|Drug|capecitabine|Capecitabine administration (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist
1761215|NCT00280761|Drug|5-fluorouracil|Administration of 5-fluorouracil (where deemed appropriate by the treating medical oncologist) will commence on the second day of radiotherapy after the 24-hour biopsy has been performed. Dosing and dose modification will be per current standard of care at the discretion of the treating Medical, Radiation and Surgical Oncologist.
1761216|NCT00280761|Procedure|Surgical Resection|Surgery will occur approximately 2-6 weeks after chemoradiation depending on clinical factors (i.e. resectability, presence or absence of metastatic disease).
1761218|NCT00280774|Drug|Memantine|
1761219|NCT00280787|Drug|Paclitaxel|175 mg/m2 administered on Day 1, of a 21 day cycle. Subjects will receive 2 cycles
1761220|NCT00280787|Drug|Carboplatin|Area Under the Curve(AUC)=5 administered on Day 1 of a 21 day cycle. Subjects will receive 2 cycles.
1761221|NCT00280787|Drug|CPT-11|100 mg/m2 administered on Day 1 of each 21 day cycle. Subjects will receive 2 cycles.
1761222|NCT00280787|Drug|Pegfilgrastim|6 mg administered on Day 2 each each 21 day cylce. Subjects will receive 2 cycles of treatment.
1761223|NCT00280787|Radiation|Conformal radiotherapy|Radiation therapy will be administered with standard daily fractionation of 2.0 Gy per fraction, 5 days per week.The total dose of radiotherapy will be 74 Gy
1761226|NCT00280813|Behavioral|Supportive Treatment in Addiction Recovery (STAR)|
1761227|NCT00280826|Drug|Efalizumab|Participants who qualified for the study received weekly subcutaneous treatments of efalizumab, with the first dose being a test dose of 0.7 mg/kg and subsequent doses of 1 mg/kg (not to exceed 200 mg per dose), for a total treatment duration of 16 weeks.
1761228|NCT00280839|Drug|Topiramate|
1761229|NCT00280839|Drug|Placebo|
1761230|NCT00280865|Drug|Tesaglitazar|
1761231|NCT00280865|Drug|Pioglitazone|
1761232|NCT00280865|Behavioral|Dietary and Lifestyle Modification Counseling|
1761233|NCT00280878|Drug|gemcitabine|
1761234|NCT00280878|Drug|vinorelbine|
1761235|NCT00280878|Drug|ifosfamide|
1761236|NCT00280878|Drug|rituximab|
1761237|NCT00280904|Device|Shunt catheter|standard of care implantation of shunt (any brand). Subjects are followed for 90 days to obtain information about whether or not an infection occurred.
1761238|NCT00280917|Drug|CF101|
1761239|NCT00280930|Drug|Letrozole|
1761240|NCT00280943|Behavioral|Long-term care facilities in the intervention arm will receive education and feedback audit on performance|
1761241|NCT00280956|Drug|natalizumab|
1761242|NCT00280969|Drug|atazanavir arm|Patients are treated with ritonavir 100mg boosted atazanavir 300mg along with Epzicom.
1761243|NCT00280969|Drug|efavirenz|Patients are treated with efavirenz 300mg along with Epzicom.
1761244|NCT00280982|Biological|tumor lysate-loaded autologous dendritic cells|50x10e6 cells per vaccination, 3 times, 2 weeks interval
1761245|NCT00280995|Drug|ISIS 301012|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
1761246|NCT00280995|Drug|ISIS 301012|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
1761247|NCT00280995|Drug|ISIS 301012|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64,71, 78, and 85
1761248|NCT00280995|Drug|ISIS 301012|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
1761249|NCT00281008|Drug|ISIS 301012 or Placebo|50 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
1761250|NCT00281008|Drug|ISIS 301012 or Placebo|100 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
1761251|NCT00281008|Drug|ISIS 301012 or Placebo|200 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, and 36
1761252|NCT00281008|Drug|ISIS 301012 or Placebo|300 mg subcutaneous injections on days 1, 4, 8, 11, 15, 22, 29, 36, 43, 50, 57, 64, 71, 78, and 85
1761253|NCT00281021|Drug|Erlotinib plus Digoxin|Each subject will receive erlotinib and digoxin daily until progression.
1761254|NCT00281047|Drug|FP-10|
1761255|NCT00281060|Procedure|primary stenting|
1761256|NCT00281073|Device|Intra-Cardiac Echocardiography guided Cardioversion|Intracardiac Echo and TEE
1761257|NCT00281073|Device|Intracardiac Echo|Intracardiac Echo Viewmate
1761258|NCT00281073|Device|ICE|ICE or TEE
1761259|NCT00281099|Device|ICD (Implantable Cardioverter Defibrillator)|VVI 40 vs. MVP
1761260|NCT00281125|Drug|PTK787 and Pemetrexed with or without Cisplatin|
1761261|NCT00281177|Behavioral|Asthma Disparity Reduction Strategy|
1761262|NCT00281190|Procedure|Blood drawing|blood will be drawn at the time of starting the intravenous (IV) line for the procedure.
1761263|NCT00281190|Procedure|Bronchoalveolar lavage during indicated bronchoscopy|A small amount of liquid will be introduced and immediately sucked back out of portions of the lung, and the cells that are recovered will be analyzed in the laboratory. All test will be solely for research, and there will be no results reported to the subject from that fluid.
1761264|NCT00281203|Procedure|blood drawing|blood will be drawn on the entry visit and will starting the intravenous (IV) line on the day of bronchoscopy
1761265|NCT00281203|Procedure|fiberoptic bronchoscopy|A flexible instrument will be passed through the mouth and into the lungs. Portions of the lungs will be washed, by injecting and immediately suctioning out a small amount of fluid. The entire return will be used for research purposes, and no results will be reported to the participant. Bronchoscopy is performed once.
1761266|NCT00281242|Other|blood draw|All subjects undergo blood draws at study visits and at the time of COPD exacerbation visits.
1761267|NCT00281255|Drug|Allopurinol|
1761268|NCT00281255|Drug|Dobutamine|
1761269|NCT00281268|Procedure|pulmonary artery catheter|
1761270|NCT00281268|Procedure|central venous catheter|
1761271|NCT00281268|Procedure|fluid management|
1761272|NCT00281281|Drug|vancomycin|
1761273|NCT00281294|Drug|Fontolizumab|
1761274|NCT00281307|Drug|RRR-alpha-tocopherol 1,000 IU/mL|Intranasal application three times daily vs. placebo (inert excipient)
1761275|NCT00281320|Drug|Asenapine|Asenapine 2 mg twice daily (BID) on Days 1 and 2, 5 mg BID on Days 3 and 4, followed by 10 mg BID on Day 5 through the end of the trial (Week 6); or Asenapine 5 mg BID on Days 1 to 4 followed by 10 mg BID on Day 5 through the end of the trial (Week 6).
1761276|NCT00281333|Behavioral|"Karate exercises and strengthening exercises"|
1761277|NCT00281346|Procedure|Doppler echocardiography|Echocardiography
1761278|NCT00281359|Device|With heat|heat pad followed by dynamic splinting
1761279|NCT00281359|Device|No heat|No heat added to tissue prior to dynamic splinting
1761280|NCT00281385|Behavioral|traditional vs. lifestyle exercise|
1761281|NCT00281398|Behavioral|Questionnaire|
1761282|NCT00281411|Procedure|Computed Tomography Angiography|Computed Tomography Angiography
1761283|NCT00281411|Procedure|Magnetic Resonance Angiography|Magnetic Resonance Angiography
1761284|NCT00281424|Device|pedometer|gave pedometer and info
1761285|NCT00281437|Behavioral|choice of exercise program|
1761286|NCT00281450|Behavioral|Educational intervention|We developed a set of explicit criteria for pharmacological inappropriateness for Norwegian GPs' prescribing to elderly patients. The main purpose of the criteria was to serve as quality indicators during an educational intervention: the Prescription Peer Academic Detailing (Rx-PAD) Study, aimed at improving GPs' prescribing for elderly patients.
1761287|NCT00281463|Device|Pushrim Activated Power Assist|The PAPAW is an electrically-powered add-on unit for common manual wheelchairs. The unit automatically supplements the users manual pushrim input with additional rear-wheel torque for up to six kilometers/hour traveling velocity. The amount of added torque is provided proportional to the user input to the pushrims. Movement and braking assistance is provided for both forward and rearward travel. Several types and sizes are available based on users operating strength, needs and anthropometry. The PAPAWs to be tested during this study will be the JWII (Yamaha Motor Corporation).
1761288|NCT00281476|Drug|Simvastatine|
1761289|NCT00281489|Device|BIS Monitor guided algorithm|BIS guided algorithm (BIS target 40 to 60) during anesthesia. Alarms when BIS is outside this range.
1761290|NCT00281489|Behavioral|Volatile anesthetic guided algorithm|Volatile anesthetic guided algorithm. Target anesthetic concentration 0.7 to 1.3 minimum alveolar concentration during anesthesia. Alarms when anesthetic concentration not in this range.
1761291|NCT00281502|Drug|Rifaximin (drug)|Rifaximin 400mg three (3) times daily
1761292|NCT00281515|Drug|Lonafarnib|100mg/twice a day during chemotherapie,in maintenance phase 200 mg twice a day
1761293|NCT00281528|Drug|ABI-007 (Abraxane)|30 minute infusions
1761294|NCT00281528|Drug|bevacizumab|infusions
1761295|NCT00281541|Drug|YM155|
1761296|NCT00281554|Drug|RSD1235|IV
1761297|NCT00281567|Drug|Tiotropium|
1761298|NCT00281567|Device|Respimat SMI|
1761299|NCT00281567|Device|HandiHaler|
1761300|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
1761301|NCT00281580|Drug|Placebo|Placebo to Telmisartan and Amlodipine once daily for eight weeks
1761302|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
1761303|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
1761304|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
1761305|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
1761306|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
1761307|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
1761308|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
1761309|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
1761310|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5g once daily for eight weeks
1761311|NCT00281580|Drug|Telmisartan 20 mg|Telmisartan 20 mg once daily for eight weeks
1761312|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
1761313|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5mg once daily for eight weeks
1761314|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
1761315|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
1761316|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
1761317|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
1761318|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
1761319|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
1761320|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for two weeks
1761321|NCT00281580|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg once daily for eight weeks
1761322|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
1761323|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
1761324|NCT00281580|Drug|Amlodipine 5 mg|amlodipine 5g once daily for two weeks
1761325|NCT00281580|Drug|Amlodipine 5 mg|Amlodipine 5 mg once daily for eight weeks
1761326|NCT00281580|Drug|Telmisartan 40 mg|Telmisartan 40 mg once daily for eight weeks
1761327|NCT00281580|Drug|Telmisartan 80 mg|Telmisartan 80 mg once daily for eight weeks
1761328|NCT00281580|Drug|Amlodipine 10 mg|Amlodipine 10 mg once daily for six weeks
1761329|NCT00281593|Drug|Telmisartan|
1761330|NCT00281593|Drug|Ramipril|
1761331|NCT00281606|Drug|Different formulations of once-daily lopinavir/ritonavir|CCTG585 is a randomized, open-label, two arm cross-over study to compare the tolerability of once daily LPV/r liquid versus capsules
1761332|NCT00281619|Drug|CellCept (mycophenolate mofetil)|
1761333|NCT00281619|Behavioral|Dietary Monitoring|
1761334|NCT00281619|Behavioral|Drug Diary|
1761335|NCT00281619|Procedure|Blood Sampling|
1761336|NCT00281632|Drug|GW786034|800 mg GW786034 administered orally on a daily basis.
1761337|NCT00281645|Drug|Bicifadine|
1761338|NCT00281645|Drug|Standard of Care (pharmacological analgesic treatment)|
1761339|NCT00281658|Drug|lapatinib (GW572016) oral tablets|1500 mg oral daily continuously
1761340|NCT00281658|Drug|paclitaxel infusion|Paclitaxel 80 mg/m2 every 3 weeks, 4th week rest for minimum 6 months
1761341|NCT00281671|Drug|nesiritide|nesiritide 0.015 mcg/kg/hour x 10 hours
1991504|NCT00990665|Device|CRT-D and LV lead (Quartet™ lead and Promote Q® device system)|Promote Q CRT-D and Quartet LV lead
1996779|NCT02377193|Drug|Simulect|"Simulect IV 40 mg/day D0 and D4
and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg"
1761346|NCT00281697|Drug|Bevacizumab|The dose of bevacizumab was based on a patient's weight at baseline and remained the same throughout the study.
1761347|NCT00281697|Drug|Placebo|
1761412|NCT00287950|Drug|vincristine sulfate|
1761413|NCT00287950|Procedure|adjuvant therapy|
1761348|NCT00281697|Drug|Standard chemotherapy|"Patients received one of the following four standard chemotherapies for metastatic breast cancer.
Taxane - Paclitaxel (Taxol) 90 mg/m^2 IV every week for 3 weeks followed by 1 week of rest; paclitaxel (Taxol) 175 mg/m^2 IV every 3 weeks, or paclitaxel protein-bound particles (Abraxane) 260 mg/m^2 IV every 3 weeks; or docetaxel (Taxotere) 75-100 mg/m^2 IV every 3 weeks.
Gemcitabine (Gemzar) 1250 mg/m^2 IV on Days 1 and 8 of each 3-week cycle.
Vinorelbine (Navelbine) 30 mg/m^2 IV every week of each 3-week cycle.
Capecitabine (Xeloda) 1000 mg/m^2 orally twice daily on Days 1-14 of each 3-week cycle."
1761349|NCT00281710|Drug|Methylprednisolone|
1761350|NCT00281723|Drug|Pro-Pe adhesive tablet|
1761351|NCT00281736|Drug|HPPH|Given IV
1761352|NCT00281749|Procedure|TELEPHONE CALL|
1761354|NCT00281788|Drug|capecitabine|
1761355|NCT00281788|Drug|carboplatin|
1761356|NCT00281788|Drug|paclitaxel|
1761357|NCT00281788|Radiation|radiation therapy|
1761358|NCT00281801|Procedure|psychosocial assessment and care|psychosocial assessment and care
1761359|NCT00281801|Procedure|Quality of Life Assessments|PACT Scale, Brief COPE, POMS Short Form and FACT BMT
1761360|NCT00281814|Procedure|psychosocial assessment and care|psychosocial assessment and care
1761361|NCT00281827|Drug|carboplatin|Day 1 of Cycles 1, 2 and 3 - intravenously (IV) 30 minutes (Area Under the Curve = 5.5)
1761362|NCT00281827|Drug|gemcitabine hydrochloride|Days 1 and 8 of Cycles 1, 2 and 3 - 30 minute IV, 1000 mg/m2.
1761363|NCT00281827|Drug|thalidomide|Oral administration: Cycle 1 - Day 1 50 mg, Day 2 100 mg, Day 3 150 mg, Day 4 and continuing until end of study treatment 200 mg.
1761364|NCT00281827|Procedure|conventional surgery|Resection - between 2 and 6 weeks following last dose of chemotherapy.
1761365|NCT00281840|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes once every 2 weeks for up to 1 year. Bevacizumab, which stops 8 weeks before surgery, may restart 4 weeks after surgery and continue for 9 months in the absence of disease progression or unacceptable toxicity.
1761366|NCT00281840|Drug|docetaxel|docetaxel IV over 1 hour once a week for 8 weeks
1761367|NCT00281840|Procedure|conventional surgery|8-10 weeks after the completion of chemoradiotherapy, patients may undergo neck dissection
1761368|NCT00281840|Radiation|radiation therapy|radiotherapy once daily, 5 days a week, for 8 weeks
1761369|NCT00281853|Procedure|management of therapy complications|Patients undergo a 1-hour peripheral nerve function assessment, including hearing, vibratory sensation, and blood pressure testing, at baseline and then at 4, 8, and 12 weeks during treatment with chemotherapy or biologic therapy.
1761370|NCT00287690|Drug|Genistein|Drink taken once daily
1761371|NCT00287690|Drug|Placebo|Drink taken once daily
1761372|NCT00287703|Device|Pulsating Electro-Magnetic Fields|5 days a week for 5 weeks 30 minutes
1761373|NCT00287703|Device|Pulsating Electro-Magnetic Fields sham|sham PEMF
1761374|NCT00287716|Drug|Pirfenidone|1197 or 2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
1761375|NCT00287716|Drug|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
1761376|NCT00287729|Drug|Pirfenidone|2403 mg/day given orally, and administered in divided doses three times daily with food, for the duration of the study.
1761377|NCT00287729|Drug|Placebo|Placebo equivalent, given orally, and administered in divided doses three times daily with food, for the duration of the study.
1761378|NCT00287742|Drug|risperidone|
1761379|NCT00287755|Drug|S-1|S-1 capsule at a dose of 80 mg/m2 b.i.d. for 4 weeks followed by 2 weeks rest.
1761380|NCT00287768|Drug|docetaxel + S-1|Docetaxel iv on day one and S-1 po days 1 to 14 every 3 weeks
1761381|NCT00287768|Drug|S-1|S-1 po days 1-28 every 6 weeks
1761382|NCT00287781|Drug|Lidocaine|
1761383|NCT00287794|Drug|diazepam, melatonin|Administration of diazepam or such drugs may improve the sleep disturbance of patients with RA.
1761384|NCT00287807|Behavioral|Self-monitoring of blood glucose (SMBG)|2 times a week (one in weekend and one during week) self measurement of blood glucose: fasting and three times post prandial
1761385|NCT00287820|Drug|Olanzapine|olanzapine 5-40 mg/day
1761386|NCT00287820|Drug|olanzapine|olanzapine 5-40 ,mg/day
1761387|NCT00287820|Drug|risperidone|risperidone 1-12 mg/day
1761388|NCT00287833|Other|placebo|Given orally
1761389|NCT00287833|Drug|Bowman-Birk inhibitor concentrate|Given orally
1761390|NCT00287846|Drug|imatinib mesylate|
1761391|NCT00287859|Drug|topotecan hydrochloride|intravenously (IV) over 30 minutes on days 1, 8, 15, 22, and 29.
1761392|NCT00287872|Drug|bortezomib|
1761393|NCT00287872|Drug|thalidomide|
1761394|NCT00287885|Drug|docetaxel|Three patients will be enrolled and dosed at each level; from dose level 1 of 2.9 mg/m^2/day up to dose level 6 of 6.4 mg/m^2/day
1761395|NCT00287898|Behavioral|Telephone Genetic Counseling|Participants will receive all genetic counseling via telephone
1761396|NCT00287898|Behavioral|Usual Care|subjects will receive standard in-person genetic counseling
1761397|NCT00287911|Drug|cisplatin|intravenously (IV) over 1 hour on days 1, 8, 15, 22, 29, and 36
1761398|NCT00287911|Drug|topotecan hydrochloride|intravenously continuously on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36 -Cohorts of 3-6 patients receive escalating doses of topotecan until the maximum tolerated dose (MTD) is determined
1761399|NCT00287911|Radiation|brachytherapy|Some patients may also undergo brachytherapy
1761400|NCT00287911|Radiation|radiation therapy|once daily on days 1-5, 8-12, 15-19, 22-26, 29-33, and 36
1761401|NCT00287924|Drug|methotrexate|
1761402|NCT00287924|Procedure|adjuvant therapy|
1761403|NCT00287937|Drug|vorinostat|Given orally
1761404|NCT00287937|Drug|paclitaxel|Given IV
1761405|NCT00287937|Drug|carboplatin|Given IV
1761406|NCT00287937|Other|laboratory biomarker analysis|Correlative studies
1761407|NCT00287937|Other|pharmacological study|Correlative studies
1761408|NCT00287950|Drug|carboplatin|
1761409|NCT00287950|Drug|cisplatin|
1761410|NCT00287950|Drug|cyclophosphamide|
1761411|NCT00287950|Drug|etoposide|
1761414|NCT00287950|Procedure|conventional surgery|
1761415|NCT00287950|Procedure|neoadjuvant therapy|
1761416|NCT00287950|Radiation|radiation therapy|
1761417|NCT00287963|Drug|topotecan hydrochloride|
1761418|NCT00287963|Drug|vinorelbine tartrate|
1761419|NCT00287976|Drug|irinotecan hydrochloride|
1761423|NCT00288002|Biological|trastuzumab|
1761424|NCT00288002|Drug|capecitabine|
1761425|NCT00288002|Drug|cyclophosphamide|
1761426|NCT00288002|Drug|docetaxel|
1761427|NCT00288002|Drug|epirubicin hydrochloride|
1761428|NCT00288002|Procedure|adjuvant therapy|
1761429|NCT00288002|Procedure|conventional surgery|
1761430|NCT00288002|Procedure|neoadjuvant therapy|
1761431|NCT00288015|Biological|Bevacizumab|Bevacizumab 15 mg/kg IV infusion given on day 1 every 21 days = (1 cycle).
1761432|NCT00288288|Procedure|Epicardial left ventricular lead placement|Epicardial left ventricular lead placement
1761433|NCT00288288|Procedure|Transvenous left ventricular lead implant|Transvenous left ventricular lead implant
1761434|NCT00288301|Behavioral|Weight loss intervention|weight loss intervention
1761435|NCT00288314|Procedure|Magnetic Resonance Imaging, Functional|Structural and functional MRI
1761436|NCT00288327|Behavioral|Lifestyle behavior change program|Intervention included a six-month intensive intervention of 2 individual counseling sessions, 3 group sessions, and 3 phone calls from a peer counselor followed by a maintenance phase (6 months) including 1 individual counseling session and 7 monthly peer counselor calls.
1761437|NCT00288327|Behavioral|Pamphlets|Nutritional and physical activity pamphlets from American Heart Association
1761438|NCT00288340|Device|functional magnetic resonance imaging|
1761439|NCT00288353|Drug|aripiprazole (Abilify)|active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
1761440|NCT00288353|Drug|ziprasidone (Geodon)|active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
1761443|NCT00288379|Drug|formoterol|
1761444|NCT00288379|Drug|budesonide/formoterol|
1761445|NCT00288392|Drug|Soluble beta-1,3/1,6-glucan|
1761446|NCT00288405|Device|Cordis Self Expanding Stent|
1761447|NCT00288418|Device|Central Venous Catheter|7-French x 20-cm, triple lumen, short-term CVC vs. 7-French x 20-cm, triple lumen, short-term CVC with an anti-infective polymer coating, applied to the outer surface that contains the active pharmaceutical ingredient 5-fluorouracil (5-FU). The Angiotech CVC uses a 50µg/linear cm dose of 5-FU
1761448|NCT00288431|Drug|ridaforolimus|Different schedules and routes of administration of AP23573 will be examined. For each schedule, AP23573 + Doxorubicin will be co-administered on Day 1 of a 3-week cycle. AP23573 will be given orally and will range in dose from 10-30 mg per dose.
1761449|NCT00288431|Drug|Doxorubicin|administered at 60 mg/m2 intravenously every 3 weeks
1761450|NCT00288444|Drug|Lonafarnib|
1761451|NCT00288444|Drug|Docetaxel|
1761452|NCT00288457|Device|Ureteral Stent|Ureteral stents are not investigatory but rather part of standard of care. In this study, we were interested in having patients fill out pre and post-operative questionnaires so that we could compare their symptoms with the length of their ureter and the stent placed.
1761453|NCT00288470|Device|Hylaform, Hylaform Plus (hylan B gel)|
1761454|NCT00288483|Drug|Policosanol|
1761455|NCT00288496|Drug|polyethylene glycol bowel lavage solution|
1761456|NCT00288509|Drug|abobotulinumtoxinA (Dysport) 250-1000 units|In this long-term extension study, a dose of 500 units Dysport was administered by intramuscular injection into the clinically indicated neck muscles in a single dosing session in the first treatment cycle. This was the same dose as given in the preceding study NCT00257660 (Y-47-52120-051). Based on individual safety & efficacy, subjects could then receive up to 3 subsequent injections with doses titrated in 250 unit steps, to a minimum of 250 units and a maximum of 1000 units. Retreatment occurred approximately 12-16 weeks after the previous injection, with the exact timing based on clinical need.
1761457|NCT00288522|Drug|Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days|
1761458|NCT00288535|Procedure|PCI of bifurcated coronary lesions using sirolimus coated stents in modified T-Stenting -Technique|
1761459|NCT00288548|Drug|Metoprolol|
1761460|NCT00288561|Drug|ranibizumab|
1761461|NCT00288574|Drug|Fluoxetine|
1761462|NCT00288574|Drug|Placebo|
1761463|NCT00288587|Drug|IV loop diuretic|Use of conventional diuretic therapy upon hospital admission for treatment of decompensated heart failure.
1761464|NCT00288587|Device|NxStage System One|Patients treated with Extracorporeal Ultrafiltration upon hospital admission for treatment of decompensated heart failure.
1761465|NCT00288600|Drug|Intravenous Immunoglobulin|Intravenous Immunoglobulin
1761466|NCT00288600|Drug|Normal saline solution|Normal saline solution 10 ml/Kg
1761467|NCT00288626|Drug|Granulocyte-colony stimulating factor (G-CSF) and prednisone|Growth factor regimen; occurs at study entry
1761468|NCT00288626|Drug|Carmustine, etoposide, cytarabine, and melphalan (BEAM)|High-dose chemotherapy; occurs seven or more days following collection of autologous graft
1761469|NCT00288626|Procedure|Autologous hematopoietic stem cell transplant|Occurs after growth factor regimen and collection of autologous graft
1761470|NCT00288639|Drug|Pregabalin|"Pregabalin treatment, given as 2 divided doses, is initiated at a dose of 150 mg/day (75 mg BID).
Based on individual subject response and tolerability, the dosage may be increased to 300 mg/day after 1 week (150 mg BID given as two 75-mg capsules BID). Based on subjects individual response and tolerability, dosage can be incrementally increased further after an additional week to 600 mg/day (300 mg BID given as four 75-mg capsules BID)."
1761472|NCT00288665|Device|Export catheter (Medtronic)|
1761473|NCT00288678|Procedure|Health Education|
1761474|NCT00288691|Drug|Asoprisnil (BAY86-5294)|5mg/day
1761475|NCT00288691|Drug|Asoprisnil (BAY86-5294)|10mg/day
1761476|NCT00288691|Drug|Asoprisnil (BAY86-5294)|25mg/day
1761477|NCT00288691|Drug|Placebo|Placebo
1761478|NCT00288704|Drug|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. On Day 1, subjects received two injections of rilonacept (for a total of 320 mg).
1761479|NCT00288704|Drug|Placebo|Subcutaneous injection of Placebo occurred during first 6 weeks of the study or during randomized withdrawal (weeks 15-24). On Day 1, subjects received two placebo injections.
1761480|NCT00288704|Drug|rilonacept 160 mg|Rilonacept was given by subcutaneous injection. It was administered weekly at the dose of 160mg. No loading dose was given for subjects who entered directly into the open-label.
1761481|NCT00288717|Drug|Candesartan|
1761482|NCT00288717|Drug|Telmisartan|
1761483|NCT00288730|Drug|nesiritide|
1761484|NCT00288743|Drug|to implement an insulin protocol with target blood glucose levels between 81-110 mg/dL.|
1761485|NCT00288756|Procedure|lv injection of contrast|
1761486|NCT00288769|Drug|daily sublingual tablets Vitamin B12 1000 mcg versus placebo|
1761487|NCT00288782|Drug|Mirtazapine|
1761488|NCT00288795|Other|Massage Therapy|Therapeutic Touch
1761489|NCT00288795|Other|Polarity Therapy|Use of energy fields to alleviate distress and achieve balance in the body
1761490|NCT00288808|Device|Hemosense (PT/InR point of care device)|
1761491|NCT00288834|Behavioral|dysphagia rehabilitation|
1761492|NCT00288860|Behavioral|Telephone monitoring|Three months of biweekly telephone monitoring and support
1761493|NCT00288860|Other|Treatment-As-Usual|Outpatient mental health Treatment As Usual (psychotherapy and/or medications)
1761494|NCT00288873|Drug|Ergocalciferol|
1761495|NCT00288873|Drug|Cholecalciferol|
1761496|NCT00288886|Behavioral|Contracting, Prompting and Reinforcement arm|Contracting, prompting and reinforcement of continuing care and abstinence.
1761497|NCT00288886|Behavioral|Control arm|Routine residential treatment and orientation to continuing care.
1761498|NCT00288899|Other|"Enhanced surgical iMedConsent process (with repeat back)"|"Consent process engages patient in discussion about why they are having procedure, risks, benefits, alternatives. Then provider asks patient to repeat backwhat they understand."
1761499|NCT00288899|Other|standard surgical iMedConsent process|Patients are consented in standard VA consent process, where are not necessarily asked to repeat back and no discussion is necessarily documented.
1761500|NCT00288912|Behavioral|Health Education|12-month intervention consisting of monthly phone calls about common health conditions and screening. Also includes written educational materials on these topics.
1761501|NCT00288912|Behavioral|Osteoarthritis Self-Management|12-month intervention consisting of monthly phone calls about topics related to self-care for osteoarthritis. Also includes written educational materials on these topics. Participants set goals and action plans, with assistance from health educator, about managing their osteoarthritis.
1761502|NCT00288925|Drug|Z-360|
1761503|NCT00288951|Drug|Travoprost 0.004% with and without BAK|
1761504|NCT00288964|Device|Hattler Respiratory Assist Catheter|
1761505|NCT00288977|Procedure|Islet Infusion|
1761506|NCT00289003|Drug|Soluble beta-1,3/1,6-glucan|
1761507|NCT00289016|Drug|Talimogene Laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
1761508|NCT00289029|Drug|Iopamidol 370 mgI/mL|
1761509|NCT00289042|Drug|Enoxaparin|
1761510|NCT00289055|Device|stent|Cordis SMART™ Nitinol Stent
1761511|NCT00289055|Device|angioplasty|balloon angioplasty
1761512|NCT00289068|Procedure|Phacoemulsification Sleeve surgery|Group 2.2 mm surgery setting
1761513|NCT00289068|Procedure|Phacoemulsification Sleeves surgery|Group 2.8 mm surgery setting
1761514|NCT00289068|Procedure|Phacoemulsification Sleeves|Group 3.0 mm surgery setting
1761515|NCT00289081|Device|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee implant
1761516|NCT00289081|Device|Total knee replacement|Rotating Platform (RP) Cruciate Substituting Knee implant.
1761517|NCT00289094|Device|Total Knee Replacement|Rotating Platform (RP) Cruciate Retaining Knee System
1761518|NCT00289094|Device|Total knee replacement|Fixed Cruciate Retaining Knee System
1761519|NCT00289107|Device|Total Knee Arthroplasty|Rotating Platform (RP) Cruciate Substituting Knee System
1761520|NCT00289107|Device|Total knee replacement|Fixed Cruciate Substituting Knee System
1761521|NCT00289120|Drug|Cola beverage|Subjects will be given 500cc of Cola beverage twice daily to be ingested with breakfast and dinner for six days while on a metabolic diet.There will be a three weeks interval before crossover to the other treatment arm.
1761522|NCT00289120|Drug|Deionized water|Subjects will be given 500cc of deionized water to be ingested twice daily with breakfast and dinner for three weeks while on a metabolic diet. There will be a three weeks interval before crossover to the other treatment arm
1761523|NCT00289133|Device|total knee arthroplasty|Gamma Vacuum Foil polyethylene tibial insert
1761524|NCT00289133|Device|total knee arthroplasty|cross-linked polyethylene tibial insert
1761525|NCT00289172|Biological|Live attenuated human rotavirus vaccine|
1761526|NCT00289185|Biological|RTS,S/AS02D|3-dose intramuscular injection in the thigh
1761527|NCT00289185|Biological|Engerix-B®|3-dose intramuscular injection in the thigh.
1761528|NCT00289185|Biological|TETRActHib™|3-dose intramuscular injection in the thigh.
1761531|NCT00289211|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
1761532|NCT00289211|Drug|Placebo (saline)|
1761592|NCT00289744|Biological|Engerix TM|If a subject has become seronegative for anti-HAV antibodies or lost anti-HBs seroprotection concentrations at the long-term blood sampling time point (i.e. Years 6, 7, 8, 9 or 10), he/ she will be offered an additional vaccine dose.
1761593|NCT00289757|Biological|Havrix™|2 doses at 6 months interval
1761533|NCT00289224|Biological|bivalent killed whole cell oral cholera vaccine|"Given as 1.5 mL dose, given orally in 2 doses 14 days apart, each dose contains:
V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
1761534|NCT00289224|Biological|Placebo|Heat Killed E. coli K12 in an optical turbidity identical to killed oral cholera vaccine, in 1.5 mL oral dose given twice, at least 14 days apart.
1761535|NCT00289237|Behavioral|Lifestyle intervention|
1761536|NCT00289250|Drug|Sulfadoxine-pyrimethamine|
1761537|NCT00289250|Drug|Sulfadoxine-pyrimethamine plus artesunate|
1761538|NCT00289263|Drug|Paclitaxel|
1761539|NCT00289276|Device|Fluid Status Monitoring (OptiVol™)|Thoracic Fluid Status Software downloaded on all subjects enrolled in the trial
1761540|NCT00289289|Device|Intervention Pacing Features|Intervention pacing features (atrial rate stabilization algorithm, atrial preference pacing algorithm, post mode switch overdrive pacing algorithm) in the pacemaker.
1761541|NCT00289302|Device|Cardiac resynchronization therapy device|
1761546|NCT00289341|Biological|vaccine vehicle only|Subcutaneous injection of vaccine vehicle only (5% DMSO in normal saline), followed by cross-over to Arm 1 design.
1761547|NCT00289341|Biological|DC/LNCaP|Subcutaneous injection of DC/LNCaP, DC/LNCaP-M1, DC/KLH
1761548|NCT00289354|Drug|Chromium Picolinate (600 mcg Cr) + biotin (2 mg)|
1761549|NCT00289367|Drug|Triiodothyronine|0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
1761550|NCT00289367|Drug|triiodothyronine|IV formulation - Triostat, 0.8 mcg/kg bolus loading dose followed by a six hour infusion of 0.8 mcg/kg/6hr.
1761551|NCT00289393|Behavioral|Perceived outcome by both patient and physician|
1761552|NCT00289406|Drug|S-amlodipine gentisate|
1761553|NCT00289406|Drug|Amlodipine besylate|
1761554|NCT00289419|Drug|Epidural Ropivacaine, morphine|Infusion rate 4 ml/h in 48 h Solution 200 ml Ropivacaine 2mg/ml added 1 ml morphine 10 mg/ml
1761555|NCT00289419|Drug|Ropivacaine, Ketorolac and Adrenaline|Wound infiltration: 100 ml Ropivacaine 2 mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml Bolus injection: 20 ml Ropivacaine 7,5mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml adrenaline 1 mg/ml
1761556|NCT00289432|Behavioral|Psychoeducative|The experimental group consists of five weekly 2-hours sessions, focusing on coping with diagnosis and treatment
1761557|NCT00289432|Other|Support group|Standard Hospital follow-up support group
1761558|NCT00289445|Drug|Mitomycin C|
1761559|NCT00289445|Drug|5-FU|
1761560|NCT00289445|Drug|Folinic acid|
1761561|NCT00289458|Behavioral|exercise|A community aquatic exercise program designed for older adults to improve balance, strength and mobility to decrease the risk of falls.
1761562|NCT00289458|Behavioral|2|Same as 1 with the addition of a 1/week educational group program to improve confidence in movement, learn about fall risk and fall prevention and the rationale for the exercises to decrease fall risk.
1761563|NCT00289458|Behavioral|Control|no exercise
1761564|NCT00289471|Other|No intervention delivered.|No intervention delivered.
1761565|NCT00289484|Drug|Omega-3 Polyunsaturated Fatty Acids|
1761566|NCT00289497|Device|TempTouch®|
1761567|NCT00289510|Biological|Inactivated influenza vaccine (whole virion, Vero cell-derived)|
1761568|NCT00289510|Biological|Inactivated influenza vaccine (egg derived) [licensed control vaccine]|
1761572|NCT00289549|Drug|forodesine hydrochloride (BCX-1777)|experimental, forodesine oral dose 200 mg administered daily.
1761573|NCT00289562|Drug|forodesine hydrochloride (BCX-1777)|
1761574|NCT00289575|Device|MBCP|
1761575|NCT00289588|Drug|Mupirocin (drug)|
1761576|NCT00289601|Drug|eptifibatide|
1761577|NCT00289614|Drug|Iopamidol 370 mgI/dL|
1761578|NCT00289627|Drug|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
1761579|NCT00289640|Drug|ipilimumab (MDX-010, BMS-734016)|IV solution, IV, 0.3mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
1761580|NCT00289640|Drug|Ipilimumab|IV solution, IV, 3 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
1761581|NCT00289640|Drug|Ipilimumab|IV solution, IV, 10 mg/kg, Q 3 wks for 12 wks then Q 12 wks, 48+ weeks depending on response.
1761583|NCT00289679|Device|Hip prosthesis revision|
1761584|NCT00289705|Procedure|Surgery|Laparoscopic Roux-en-Y gastric bypass
1761585|NCT00289718|Biological|Twinrix™ adult|Intramuscular administration
1761591|NCT00289744|Biological|TWINRIX™ ADULT|2 doses IM injection in primary study
1761594|NCT00289770|Biological|Twinrix™|Intramuscular injection, 3 doses
1991522|NCT00969553|Drug|BI 6727|Dose level 1
1761595|NCT00289783|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis 792014 vaccine|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
1761596|NCT00289783|Biological|ActHIB|3-dose intramuscular injection at 2, 4 and 6 months of age.
1761597|NCT00289783|Biological|PedvaxHIB|1 booster dose by intramuscular injection at 12 to 15 months of age.
1761598|NCT00289783|Biological|Pediarix|3-dose intramuscular injection at 2, 4 and 6 months of age.
1761599|NCT00289783|Biological|Prevnar|3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
1761600|NCT00289783|Biological|M-M-R II|1 booster dose by subcutaneous injection at 12 to 15 months of age.
1761601|NCT00289783|Biological|Varivax|1 booster dose by subcutaneous injection at 12 to 15 months of age
1761602|NCT00289796|Biological|DTPa-HBV-IPV/Hib|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus and Haemophilus influenzae type b conjugate vaccine
1761603|NCT00289809|Drug|combination of TLC D-99 and Ifosfamide|"TLC D-99: 40 mg/m2 Day 1 every 3 weeks;
Ifosfamide: 3000 mg/m2 Day 1, 2, 3 every 3 weeks"
1761604|NCT00289822|Drug|intracoronary infusion of progenitor cells|
1761605|NCT00289835|Device|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
1761606|NCT00289848|Drug|sitagliptin phosphate|Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.
1761607|NCT00289848|Drug|Comparator: placebo|placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
1761608|NCT00289861|Drug|Risperidone|
1761609|NCT00289861|Drug|placebo|
1761610|NCT00289874|Drug|montelukast sodium|montelukast 5 mg chewable tablet once daily. Up to 3 weeks of treatment.
1761611|NCT00289874|Drug|Comparator: Placebo|Placebo. Up to 3 weeks of treatment
1761612|NCT00289887|Drug|Comparator: losartan +/- HCTZ|Placebo to losartan once daily for 4 weeks in run-in period. Then, losartan 50 mg for 4 weeks, then titrate to losartan 100 mg at Week 4, then titrate to losartan 100 mg + hydrochlorothiazide (HCTZ) 12.5 mg at Week 8, and finally titrate to losartan 100 mg + HCTZ 25 mg at Week 12. Duration of treatment is approximately 16 weeks.
1761613|NCT00289887|Drug|Comparator: Placebo|Placebo to losartan once daily for 4 weeks in run-in period. Then, placebo to losartan or losartan/HCTZ once daily for approximately 16 weeks.
1761614|NCT00289900|Drug|MK-0524A|
1761615|NCT00289900|Drug|Atorvastatin|
1761616|NCT00289900|Drug|Simvastatin|
1761617|NCT00289913|Biological|Comparator: VAQTA™|"VAQTA™ (Hepatitis A Vaccine, Inactivated).
Two intramuscular 0.5-mL doses of VAQTA™ were administered 24 weeks apart, with the second dose being administered prior to 24 months of age."
1761618|NCT00289913|Biological|Comparator: Infanrix™|"Infanrix™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis
Vaccine Adsorbed, GlaxoSmithKline).
One intramuscular 0.5-mL injection of Infanrix™ was administered at the first study visit."
1761619|NCT00289913|Biological|Comparator: PedvaxHIB™|"PedvaxHIB™ (Haemophilus B Conjugate Vaccine [Meningococcal Protein Conjugate]).
One intramuscular 0.5-mL injection of PedvaxHIB™ was administered at the first study visit."
1761620|NCT00289926|Drug|dehydroepiandrosterone|dehydroepiandrosterone capsules 50.0 mg /capsule DHEA 248.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule
1761621|NCT00289926|Drug|placebo|Placebo capsules of 298.5 mg /capsule Microcrystalline Cellulose, NF 1.5 mg /capsule Magnesium Stearate, NF in a 60 mg Capsule manufactured to mimic the active DHEA capsule
1761622|NCT00289939|Behavioral|Motivational interviewing to reduce risk for HIV and DV|
1761623|NCT00289952|Drug|Valproic Acid|Oral valproic acid twice daily for 16 or 32 weeks. Dosage varies based on plasma levels.
1761624|NCT00289952|Drug|HAART|As per standard of care.
1761625|NCT00289965|Behavioral|Counselor-administered Brief Motivational Intervention (BMI)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
1761626|NCT00289965|Behavioral|Alcohol 101 Plus (interactive CD-ROM)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
1761627|NCT00289965|Behavioral|AlcoholEdu (Internet-based tutorial)|Students participate in a randomized study to evaluate 3 brief interventions: in-person brief motivational intervention, Alcohol 101plus (an interactive CD-ROM program), and AlcoholEdu (a Web-based tutorial). Participants will be followed over 12 months to determine changes in alcohol consumption and related problems.
1761628|NCT00289978|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
1761629|NCT00289978|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
1761630|NCT00289978|Drug|Placebo|Patients self-administered a fingolimod placebo capsule orally once daily.
1761631|NCT00289991|Drug|Itraconazole|Prophylaxis
1761632|NCT00289991|Drug|Vfend - voriconazole|Prophylaxis
1761633|NCT00290004|Drug|motexafin gadolinium|
1761634|NCT00290017|Drug|talabostat|
1761635|NCT00290017|Drug|pemetrexed|
1761636|NCT00290030|Drug|Alfuzosin|
1761637|NCT00290043|Drug|Insulin glulisine|
1761638|NCT00290056|Drug|Eicosapentanoic acid (EPA) and Docosahexanoic acid (DHA).|3.6 gram oral supplementation for 6 months.
1761639|NCT00290069|Drug|Tacrolimus|
1761640|NCT00290069|Drug|Rapamycin|
1761641|NCT00290082|Drug|loxapine, midazolam|agitated patients received loxapine 1 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 1 ml/ kg body weight ( midazolam 1mg/ml) if patients were still agitated 20 min after the first treatment, they received loxapine 0.5 ml/ kg body weight ( loxapine 25mg/ml) or midazolam 0.5 ml/ kg body weight ( midazolam 1mg/ml)
1761642|NCT00290082|Biological|blood sample|was evaluated in patients sedated, alcohol level, blood sugar
1761775|NCT00290745|Drug|letrozole|
1761643|NCT00290082|Other|patient monitoring|Till his coming out the emergency service, patient had an hemodynamic, respiratory and neurologic monitoring as well as an agitated score monitoring The occurence of a complication during the 15 days after leaving the emergency department was prospected.
1761644|NCT00290082|Drug|Loxapine|Loxapine 1 mL / 10 kg
1761645|NCT00290082|Drug|Midazolam|Midazolam 1 mL / 10 Kg
1761646|NCT00290108|Drug|Propofol|
1761647|NCT00290121|Drug|Olanzapine|
1761648|NCT00290134|Drug|Fispemifene once daily for 4 weeks|
1761649|NCT00290147|Biological|D1ME100 (dengue-1 premembrane/envelope DNA vaccine)|IM injection delivered by Biojector
1761650|NCT00290160|Behavioral|Protein supplementation|
1761651|NCT00290173|Drug|efficacy of oral ritodrine in maintaining uterine quiescence|
1761652|NCT00290186|Device|Hyperbaric Oxygen Treatment|100% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
1761653|NCT00290186|Device|Hyperbaric Air Treatment|14% oxygen at 1.5 ATA for 60 mins, Mon-Fri, 40 treatments total
1761654|NCT00290199|Device|Transcervical Foley catheter|Foley catheter placed through cervix for cervical ripening
1761655|NCT00290212|Drug|Natto capsules (food suppl.) cont. 360 microg. vit K2/day|
1761656|NCT00290212|Drug|Placebo capsules|
1761657|NCT00290225|Behavioral|Breath Water Sound Course and Traumatic Incident Reduction|
1761658|NCT00290238|Device|Vertis Percutaneous Neuromodulation Therapy (PNT)|"Ten PNT sessions in eleven weeks
On average, one PNT session per week
Ten lumbar Safeguide electrodes (three centimeters in length) deployed per lumbar montage
Forty-five minutes of electrical stimulation for each session
Electrical stimulation parameters:
Continuous 50 Hz current
Charge-balanced, biphasic (each phase is 200 microsec), rectangular waveform
Intensity to subject's tolerance for ten minutes then increased to a mildly uncomfortable level"
1761659|NCT00290238|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|"Ten TENS sessions in eleven weeks
On average, one TENS session per week
Four 2-inch (5.1 centimeters) diameter pads applied per TENS lumbar montage
Forty-five minutes of electrical stimulation for each session
Electrical stimulation parameters:
Current at 2 Hz—low frequency
Pulse trains delivered as asymmetric, biphasic, square waveform current, with pulse width lasting 20 microsec
Intensity titrated according to subject's sensory threshold
To maintain blinding, the treating physician or clinician will check on the subject after 10 minutes and dial the channels down just prior to the point of turning off the device."
1761660|NCT00290251|Drug|ulipristal acetate|ulipristal acetate at a daily dose of 20 mg, given once daily for three menstrual cycles or 90 - 102 days if amenorrheic
1761661|NCT00290251|Drug|ulipristal acetate|10 mg given daily for three menstrual cycles or 90 - 102 days
1761662|NCT00290251|Drug|placebo|placebo given once daily for 3 menstrual cycles or 90 - 102 days
1761663|NCT00290264|Drug|Budesonide/formoterol|
1761664|NCT00290277|Biological|HPV-16/18 L1/AS04|
1761665|NCT00290290|Drug|chlorhexidine-alcohol|Preoperative skin preparation with scrub and paint technique
1761666|NCT00290290|Drug|Povidone-Iodine|preoperative skin preparation with scrub and paint technique
1761667|NCT00290303|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
1761668|NCT00290316|Procedure|Endoscopy ultrasound|
1761669|NCT00290329|Biological|Mencevax ACWY|1 subcutaneous injection.
1956764|NCT02707367|Behavioral|Recovery Roadmap (RR)|"A web-based tool that provides guidance for implementing Person-Centered Recovery Planning. Participants in the RR intervention will use the tool in Year 2, Quarter 1 (Y2Q1), Y2Q2, and Y2Q3. There are 3 components:
Online module for service providers: A self-paced online module with interactive exercises, audio/video case studies, self-assessment, handouts, and collaborative materials designed for use with clients.
Online module for people in recovery: A self-paced online module with interactive exercises, case studies, self-assessment, informational handouts, and collaborative materials to be completed with providers.
Coaching & Support Center: A multimedia resource for providers with online coaching, a community of practice, and a resource library."
1956765|NCT02707367|Behavioral|Illness Management and Recovery (IMR)|IMR is an established evidence-based practice that helps people set meaningful goals for themselves, acquire information and skills to develop more mastery over their psychiatric illness, and make progress towards their own personal recovery. For this study, the IMR intervention will arise from established use of the intervention in enrolled programs.
1761675|NCT00290368|Procedure|Skin Prick Test|
1761676|NCT00290368|Procedure|Nasal allergen challenge|
1761677|NCT00290368|Procedure|Nasal filter paper placement|
1761678|NCT00290368|Procedure|Nasal lavage|
1761679|NCT00290368|Procedure|Nasal scrape|
1761680|NCT00290368|Procedure|Nasal symptoms score|
1761681|NCT00290381|Drug|Study drug administration|
1761682|NCT00290381|Procedure|Skin prick test|
1761683|NCT00290381|Procedure|12-lead ECG|
1761684|NCT00290381|Procedure|Laboratory safety samples|
1761685|NCT00290381|Procedure|Alcohol breath test|
1761686|NCT00290381|Procedure|Smokerlyzer test|
1761687|NCT00290381|Procedure|Urine drug test|
1761688|NCT00290381|Procedure|Blood test for drug concentrations|
1761689|NCT00290381|Procedure|Nasal allergen challenge|
1761690|NCT00290381|Procedure|Nasal filter paper placement|
1761691|NCT00290381|Procedure|Total nasal symptoms scores|
1761692|NCT00290394|Drug|rosiglitazone(drug), blood pressure lowering effect|
1761693|NCT00290407|Drug|Rituximab|375 mg/m2, IV (in the vein), once a week for 4 weeks
1761694|NCT00290407|Dietary Supplement|Beta-Glucan|250 mg, orally (tablet), three times a day for 9 weeks
1761695|NCT00290420|Drug|Chloroquine profilaxis|"Prevention:
Give a profilaxis with chloroquine once a week to prevent Plasmodium vivax malaria attacks and to prevent harmfull effect on birth outcomes"
1761704|NCT00290472|Drug|temsirolimus|
1761705|NCT00290485|Drug|Imatinib mesylate|
1761706|NCT00290498|Drug|Rituximab|Arm A: Rituximab 375 mg/m² by vein on day 1, Cycle 1 and alternating cycles. Arm B: Rituximab 375 mg/m² on day 1, Cycle 2 and alternating cycles.
1761776|NCT00290745|Drug|tamoxifen citrate|
1761707|NCT00290498|Drug|Cyclophosphamide|"Arm A: Cyclophosphamide 300 mg/m^2 by vein (IVPB) over 3 hours every 12 hours x 6 doses on Days 2-4, Cycle 1 and alternating cycles.
Arm B: Cyclophosphamide 750 mg/m² by vein day 1"
1761708|NCT00290498|Drug|Doxorubicin|Arm A: Doxorubicin 50 mg/m^2/day by vein over 15 minutes (12 hours after last dose of cyclophosphamide) on Day 5, Cycle 1 and alternating cycles.
1761709|NCT00290498|Drug|Vincristine|"Arm A: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12, Cycle 1 and alternating cycles.
Arm B: Vincristine 1.4 mg/m^2 (maximum 2 mg) by vein (IVPB) on Days 5 (1-24 hours after last cyclophosphamide) and on day 12 of each cycle."
1761710|NCT00290498|Drug|Dexamethasone|Arm A: Dexamethasone 40 mg by vein or by mouth daily x 4 on Days 2-5 and on days 12-15 of cycle 1 and alternating cycles.
1761711|NCT00290498|Drug|Methotrexate|Arm A: Methotrexate after finishing Rituximab, 200 mg/m2 by vein over 2 hours, then 800 mg/m2 by vein over 22 hours day 1 cycle 2.
1761712|NCT00290498|Drug|Cytarabine|Arm B: Cytarabine 3 g/m^2 by vein over 2 hours every 12 hours X 4 doses on days 3 & 4, cycle 2 and alternating cycles.
1761713|NCT00290498|Drug|Prednisone|Arm B: Prednisone 100 mg by mouth (as a pill, capsule, or tablet) once a day on Days 1-5, each cycle.
1761714|NCT00290511|Drug|Fludarabine|25 mg/m^2 intravenous (IV) over 5-30 minutes on Days 2-4.
1761715|NCT00290511|Drug|Mitoxantrone|10 mg/m^2 IV over 5-30 minutes on Day 2.
1761716|NCT00290511|Drug|Rituximab|375 mg/m^2 IV over 4-6 hours on Day 1 and 8; maintenance Rituximab = 375 mg/m^2 IV over 4-6 hours on Day 1 only, a single dose every other month for 12 months (6 doses total).
1761717|NCT00290511|Drug|Zevalin|0.3 mCi/kg IV after 4 cycles of R-FND.
1761718|NCT00290511|Drug|Dexamethasone|20 mg by mouth (PO) or IV daily on Days 2-6.
1761719|NCT00290524|Behavioral|Oral alimentation started 12 hours after colorectal surgery|
1761720|NCT00290537|Drug|ZD6474|ZD6474 alone: Cycles 1-3 = 300 mg PO Daily x 3 Weeks; ZD6474+Carboplatin+Paclitaxel = 300 mg oral (PO) Daily or 100 mg PO Daily plus Carboplatin and Paclitaxel Every 3 Weeks.
1761721|NCT00290537|Drug|Carboplatin|6 AUC IV Over 15-30 Minutes, Immediately After Paclitaxel
1761722|NCT00290537|Drug|Paclitaxel|200 mg/m^2 IV Over 3 Hours On Day 1
1761723|NCT00290550|Drug|MK0457|IV infusion at 10 mg/m2/hour; 5-day continuous infusion every 21 days
1761724|NCT00290563|Drug|MK0594|
1761725|NCT00290576|Dietary Supplement|Probiotics supplementation until weight reaches 1800g (Bifidobacterium Longum and Lactobacillus GG )|
1761726|NCT00290589|Drug|intramuscular methylprednisolone acetate|
1761727|NCT00290602|Drug|Methylprednisolone sodium succinate|
1761728|NCT00290615|Biological|bevacizumab|
1761729|NCT00290615|Biological|cetuximab|
1761730|NCT00290615|Drug|capecitabine|
1761731|NCT00290615|Drug|oxaliplatin|
1761732|NCT00290628|Drug|anti-thymocyte globulin|
1761733|NCT00290628|Drug|busulfan|
1761734|NCT00290628|Drug|cyclophosphamide|
1761735|NCT00290628|Drug|cyclosporine|
1761736|NCT00290628|Drug|filgrastim|
1761737|NCT00290628|Drug|melphalan|
1761738|NCT00290628|Drug|methylprednisolone|
1761739|NCT00290628|Drug|mycophenolate mofetil|
1761740|NCT00290628|Procedure|radiation therapy|
1761741|NCT00290628|Procedure|umbilical cord blood transplantation|
1761742|NCT00290641|Biological|filgrastim|
1761743|NCT00290641|Biological|graft-versus-tumor induction therapy|
1761744|NCT00290641|Drug|cyclophosphamide|
1761745|NCT00290641|Drug|cyclosporine|
1761746|NCT00290641|Drug|fludarabine phosphate|
1761747|NCT00290641|Drug|mycophenolate mofetil|
1761748|NCT00290641|Procedure|umbilical cord blood transplantation|
1761749|NCT00290641|Radiation|radiation therapy|
1761750|NCT00290654|Drug|Tamoxifen|Tamoxifen may be used postoperatively at the discretion of the treating physicians and patient
1761751|NCT00290654|Procedure|Lumpectomy|A standard lumpectomy will be performed with an attempt to remove at least 1 cm of gross margin around the DCIS.
1761752|NCT00290654|Radiation|brachytherapy|Treatment will be given in 10 fractions of 3.4 Gy per fraction twice a day, with a minimum of 6 hours between fractions. In general, brachytherapy will start between 2 - 5 days of implant. All treatments will be done using a commercially available HDR and 192Ir radioactive sources.
1761753|NCT00290667|Biological|pegfilgrastim|
1761754|NCT00290667|Biological|rituximab|
1761755|NCT00290667|Drug|cyclophosphamide|
1761756|NCT00290667|Drug|doxorubicin hydrochloride|
1761757|NCT00290667|Drug|prednisone|
1761758|NCT00290667|Drug|vincristine sulfate|
1761759|NCT00290667|Other|pharmacological study|
1761760|NCT00290667|Radiation|radiation therapy|
1761761|NCT00290680|Drug|bortezomib|
1761762|NCT00290680|Drug|celecoxib|
1761765|NCT00290706|Drug|bortezomib|Bortezomib 1.6mg/m2 on days 1 and 15 of each cycle, given over 3-5 seconds on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
1761766|NCT00290706|Drug|gemcitabine hydrochloride|Gemcitabine dose of 800 mg/m2 over 30 minutes on day 1 and day 15 of each cycle every 28 days for up to 8 cycles.
1761767|NCT00290719|Drug|cisplatin|
1761768|NCT00290719|Drug|gefitinib|
1761769|NCT00290719|Drug|irinotecan hydrochloride|
1761770|NCT00290719|Procedure|conventional surgery|
1761771|NCT00290719|Procedure|neoadjuvant therapy|
1761772|NCT00290719|Radiation|radiation therapy|
1761773|NCT00290732|Drug|Intraductal arm|Patients will receive PLD intraductally according to the dose escalation schema (Dose Level -1=1 mg, Dose Level 1=2 mg, Dose Level 2= 5mg, Dose Level 3=10 mg). The PLD dose will be diluted in 5% dextrose in water and will be mixed for a total volume of 5 ml. The PLD will be administered via a breast duct (i.e., intraductally) using a microcatheter
1761774|NCT00290732|Drug|Intravenous arm|Blood samples and a breast tissue biopsy collected to look at levels of doxorubincol from patients receiving intravenous pegylated liposomal doxorubin to compare to the group receiving drug intraductally.
1761777|NCT00290745|Procedure|conventional surgery|
1761778|NCT00290745|Procedure|neoadjuvant therapy|
1761779|NCT00290758|Drug|placebo|Given orally
1761780|NCT00290758|Drug|genistein|Given orally
1761781|NCT00290758|Other|laboratory biomarker analysis|Correlative studies
1761782|NCT00278759|Procedure|Nasopharyngeal washing for viral antigen detection by immunofluorescence initiated early in ED visit.|See Detailed Description.
1761783|NCT00278772|Drug|Divalproex|oral, 15mg/kg/day - 30mg/kg/day
1761784|NCT00278772|Other|Placebo|oral dose, placebo
1761785|NCT00278785|Behavioral|Brief Motivational Interview|10-20 minute brief motivational interview
1761786|NCT00278811|Procedure|mobile crisis team|
1761787|NCT00278824|Drug|Matrix Transdermal Fentanyl/CHADD Drug Delivery System|Patch applied every 3 days for 15 days
1761788|NCT00278824|Drug|Placebo Patch|Placebo patch applied every 3 days for 15 days
1761789|NCT00278837|Behavioral|Mindfulness based meditation program|Subjects will participate in an intervention consisting of group and individual instruction in a meditation-based practice of stress-reduction and cognitive-affective-behavioral learning.
1761790|NCT00278850|Behavioral|Educational|three 1 hour long educational seminars
1761791|NCT00278863|Drug|S-1|
1761792|NCT00278863|Drug|Capecitabine|
1761793|NCT00278876|Drug|Imatinib mesylate (Glivec)|Imatinib mesylate 400mg/day per oral (day 1-28) every 4 weeks
1761794|NCT00278889|Drug|AZD2171|oral tablet
1761795|NCT00278889|Drug|5-fluorouracil|intravenous infusion
1761796|NCT00278889|Drug|Leucovorin|intravenous infusion
1761797|NCT00278889|Drug|Oxaliplatin|intravenous infusion
1761798|NCT00278889|Drug|Bevacizumab|intravenous infusion
1761799|NCT00278902|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|Part 1: single dose and multiple dose, escalating; Part 2: multiple dose, single schedule
1761800|NCT00278915|Drug|Fulvestrant|intramuscular injection
1761801|NCT00278928|Drug|Liposyn III 20% (lipid infusion)|
1761802|NCT00278928|Drug|Intralipid 20% (lipid infusion)|
1761803|NCT00278941|Drug|Quetiapine Fumarate Sustained Release|
1761804|NCT00278954|Biological|Gammaplex (Intravenous immunoglobulin)|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously for 12 months.
1761805|NCT00278967|Drug|HalfLytely with Bisacodyl Tablets Bowel Prep Kit|
1761806|NCT00278967|Drug|HalfLytely - Reformulation|
1761807|NCT00278980|Drug|C-peptide|
1761808|NCT00278993|Drug|E7389|Intravenous 1.4 mg/m2 on a 3-week course.
1761809|NCT00279006|Procedure|Percutaneous coronary intervention|
1761810|NCT00279019|Drug|GSK233705|GSK233705 will be given orally with dosing strengths of 10, 50, 100 and 250 micrograms/blister via the DISKUS inhaler.
1761811|NCT00279019|Drug|Tiotropium|Tiotropium will be given orally as overfoiled strips of 5 capsules, each containing 18 micrograms of tiotropium (as bromide monohydrate) administered via a HandiHaler device.
1761812|NCT00279019|Drug|Placebo|Matching placebo will be given orally as overfoiled strips of 5 capsules, each containing lactose
1761813|NCT00279032|Drug|GW406381|
1761814|NCT00279045|Drug|Rosiglitazone|
1761815|NCT00279045|Drug|glyburide|
1761816|NCT00279045|Drug|metformin|
1761817|NCT00279058|Procedure|Immunotherapy treatment for melanoma|
1761818|NCT00279071|Device|Acupuncture og acupressure when diagnosed with dystocia|Acupuncture points: sp6 li4 ki3 ki6 bl60 Acupressure points: bl67
1761819|NCT00279084|Drug|GROUP A: if necessary, martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 110 to 129 g/L.|
1761820|NCT00279084|Drug|GROUP B: martial treatment and / or erythropoietin treatment to achieve the goal of haemoglobin level from 130 to 149 g/L|
1761821|NCT00279097|Device|High Frequency Chest Wall Oscillation|
1761822|NCT00279110|Behavioral|Directly administered antiretroviral therapy (DAART)|Participants are observed taking HIV medications on days when they receive opioid agonist therapy.
1761823|NCT00279123|Drug|pantoprazole infusion|
1761824|NCT00279123|Drug|pantoprazole bolus|
1761825|NCT00279123|Drug|no treatment|
1761826|NCT00279149|Procedure|Visio conference system connected to the Tele-stroke network|Visio conference system connected to the Tele-stroke network
1761827|NCT00279162|Drug|Calcipotriene/betamethasone gel and ointment|
1761828|NCT00279175|Biological|Intracoronary infusion of enriched bone marrow-derived progenitor cells|
1761829|NCT00279175|Biological|Placebo medium supplemented with autologous serum|
1761830|NCT00279188|Procedure|Guiding therapy by bronchial hyperrsponsiveness|
1761831|NCT00279201|Drug|Insulin glargine|Subcutaneous injection daily
1761832|NCT00279201|Drug|Lispro Low Mix|Subcutaneous injection twice daily.
1761833|NCT00279201|Drug|Lispro Mid Mix|Lispro Mid Mix subcutaneous injection 3 times daily.
1761834|NCT00279201|Drug|Lispro|Lispro subcutaneous injection 3 times daily.
1761835|NCT00279214|Drug|drotrecogin alfa (activated)|
1761836|NCT00279240|Drug|Metformin|
1761837|NCT00279253|Drug|clonidine (drug) intravenously|
1761838|NCT00279266|Drug|Thiamine|
1761839|NCT00279279|Device|Implanted Device|
1761840|NCT00279292|Procedure|Celiac Plexus Neurolysis|
1761841|NCT00279305|Drug|Anti-CD20 (rituximab)|
1761842|NCT00279305|Drug|Placebo Comparator|Placebo intravenous infusion
1761843|NCT00284726|Device|Celsior Cold Storage Solution|
1761844|NCT00284739|Drug|Alteplase|2mg or 4mg given twice daily for three days into loculated abscess
1761845|NCT00284739|Other|saline|saline injection twice daily for three days
1761846|NCT00284752|Drug|Abraxane|This is a Phase II single-arm study for first-line chemotherapy of patients with hormone refractory metastatic prostate cancer. Eligible patients will be chemotherapy naive and will receive weekly Abraxane 100mg/m2 IV over 30 minutes. These will be 4-week cycles with patients receiving Abraxane 100 mg/m2 weekly for 3 weeks and one week off for rest. Patients will continue on therapy until disease or PSA
1761847|NCT00284765|Procedure|flector|
1761848|NCT00284778|Drug|Alimta®|
1761849|NCT00284778|Drug|Taxotere®|
1761853|NCT00284804|Drug|MDX-060|anti-CD30 monoclonal antibody, i.v. weekly x 3 10 mg/kg
1761854|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
1761855|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
1761856|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
1761857|NCT00284817|Drug|MEDI-522|Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
1761858|NCT00284817|Drug|MEDI-522|The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
1761859|NCT00284830|Device|Implantable Pulse Generators|dual-chamber minimal ventricular pacing with the use of new pacemaker features designed to promote atrioventricular conduction, preserve ventricular conduction, and prevent ventricular desynchronization
1761860|NCT00284856|Drug|montelukast sodium|montelukast 10 mg tablet once daily, 6 month treatment period
1761861|NCT00284856|Drug|Comparator: Placebo|fluticasone propionate 250 mcg Placebo (Pbo) twice daily, 6 month treatment period
1761862|NCT00284856|Drug|Comparator: fluticasone|fluticasone propionate 250 mcg twice daily, 6 month treatment period
1761863|NCT00284856|Drug|Comparator: Placebo|montelukast 10 mg Pbo tablet once daily, 6 month treatment period
1761864|NCT00284869|Drug|LPS|
1761865|NCT00284908|Drug|S-Tenatoprazole-Na (STU-Na)|30 mg, 60 mg, 90 mg and 120 mg of STU-Na for 5 days every morning
1761866|NCT00284921|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
1761867|NCT00284934|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|
1761868|NCT00284934|Drug|Tacrolimus|
1761869|NCT00284934|Drug|Corticosteroids|At a dose of at least 5 mg/day.
1761870|NCT00284947|Drug|basiliximab|40 mg once every 28 days intravenously for 24 weeks
1761871|NCT00284947|Drug|MMF/EC-MPS|1g MMF or 720mg EC-MPS p.o twice daily
1761872|NCT00284947|Drug|Corticosteroids|Oral corticosteroids, equivalent to prednisone p.o, ≥ 5mg daily or ≥ 10mg on alternate days
1761873|NCT00284973|Biological|Plasmodium falciparum Chimeric Prot. 2.9 - Montanide ISA 720|
1761874|NCT00284986|Drug|Prochymal (TM)|
1761875|NCT00284999|Drug|Soothe|
1761876|NCT00284999|Drug|Refresh Tears|
1761877|NCT00285012|Drug|placebo|1mg (placebo) by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
1761878|NCT00285012|Drug|Varenicline Tartarate|1 mg by mouth twice daily for 12 weeks (first week is up titration schedule---0.5mg once daily for 3 days, 0.5mg twice daily for 4 days)
1761879|NCT00285025|Drug|SR57667B|
1761880|NCT00285051|Drug|inhaled delta-8-THC|
1761881|NCT00285064|Procedure|CT|
1761882|NCT00285077|Drug|SR57667B|
1761883|NCT00285090|Dietary Supplement|Calcium, Vitamin D|
1761884|NCT00285090|Dietary Supplement|Calcium,Vitamin D|
1761885|NCT00285090|Dietary Supplement|Calcium, VitaminD|
1761886|NCT00285090|Other|Sugar Pill|
1761887|NCT00285103|Drug|SPC2996|
1761888|NCT00285116|Procedure|Clinical examination and radiological evaluation|
1761889|NCT00285129|Device|ceramic-on-ceramic total hip replacement versus metal-on-metal hip resurfacing|
1761890|NCT00285142|Drug|rosiglitazone|
1761891|NCT00285155|Drug|Bupropion|
1761892|NCT00290771|Drug|Imatinib tablets|Imatinib was supplied as 100 and 400 mg tablets by Novartis.
1761893|NCT00290771|Drug|Hydroxyurea capsules|Hydroxyurea was supplied locally as 500 mg capsules.
1761894|NCT00290810|Biological|bevacizumab|Given IV
1761895|NCT00290823|Drug|Albendazole|400 mg tablet taken orally twice daily
1761896|NCT00290823|Drug|Dexamethasone|6mg or 8mg taken daily
1761897|NCT00290823|Drug|Omeprazole|20 mg tablet taken orally daily
1761898|NCT00290836|Drug|Human fibrinogen/thrombin and bovine aprotinin (TachoComb H)|
1761899|NCT00290849|Drug|Bivalirudin|
1761901|NCT00290875|Behavioral|Use of Xrays for diagnosis|
1761902|NCT00290888|Procedure|Acromioplasty|
1761903|NCT00290901|Drug|Tramadol Hydrochloride 50mg|
1761904|NCT00290901|Drug|Celebrex 200mg|
1761905|NCT00290914|Drug|Vilazodone|
1761906|NCT00290927|Drug|insulin glulisine|
1761907|NCT00290940|Drug|CS-917|
1761908|NCT00290940|Drug|metformin hydrochloride|
1761909|NCT00290940|Drug|pioglitazone|
1761910|NCT00290953|Drug|SR48692|
1761911|NCT00290966|Drug|XRP6976|
1761912|NCT00290979|Drug|insulin glulisine|
1761913|NCT00290992|Drug|rasburicase (SR29142)|
1761914|NCT00291005|Drug|ARD6562, Docetaxel|
1761915|NCT00291018|Device|Total Disc Replacement|Total Disc Replacement using ProDisc-C
1761916|NCT00291018|Device|ACDF|Anterior Cervical Discectomy and Fusion
1761917|NCT00291031|Behavioral|Imagery Rehearsal Therapy (IRT)|"Imagery Rehearsal Therapy is given by psychologists, psychotherapists or psychiatrists. The IRT therapists are all trained by Annette van Schagen, principal investigator.
IRT consists of six 1-hour sessions. The six sessions are given in a period of three months. Each session is described in the IRT Manual. The IRT Manual is devised by the principal investigator Annette van Schagen in colaboration with Victor Spoormaker PhD. There is a patient version of the IRT manual available for the patients, which includes descriptions of the IRT sessions and homework assignments."
1761918|NCT00291044|Other|testing for HSV 1 and 2 IgG type specific antibosy|
1761919|NCT00291057|Drug|MALG|30 minute application
1761920|NCT00291070|Drug|L-theanine|This study will examine the effects of L-theanine (an amino acid found in green tea) on the behavior, cognitive performance and sleep quality of boys with ADHD.
1761921|NCT00291109|Drug|letrozole 2.5 mg|
1761922|NCT00291122|Drug|celecoxib 400 mg BID|
1761923|NCT00294554|Drug|Memantine|Active memantine and placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
1761924|NCT00294554|Drug|Placebo Oral Tablet|Placebo, taken by mouth, will be titrated from 5mg a day to 20mg a day over 4 weeks. The subject will remain on 20mg (10mg twice a day) through week 24 unless unable to tolerate. The dose will be decreased as needed.
1761925|NCT00294567|Drug|Calcium channel blockers (amlodipine, azelnidipine)|Drug: amlodipine Drug: azelnidipine
1761926|NCT00294580|Drug|Maloprim|
1761927|NCT00294593|Drug|folinic acid|
1761928|NCT00294606|Drug|Comparison of Effects of Phenylephrine and Norepinephrine|
1761929|NCT00294619|Drug|growth hormone|subcutaneous injection, once-weekly
1761932|NCT00294645|Other|Transtelephonic monitoring (TTM)|TTM conducted at 2 month intervals. For patients with dual-chamber pacemakers, an in-office visit was required at 6 months (rather than TTM transmission for patients with single-chamber pacemakers). Follow-up frequency established to mimic best case standard of care when utilizing TTM for follow-up. A 12-month in-office visit completed the follow-up period.
1761933|NCT00294645|Other|Medtronic CareLink® Network|Remote pacemaker interrogation conducted at 3 month intervals. Follow-up frequency established to mimic best case standard of care when utilizing implantable cardioverter defibrillator (ICD) remote interrogation for follow-up. A 12-month in-office visit completed the follow-up period.
1761934|NCT00294658|Procedure|thymectomy plus prednisone|The thymectomy will be performed as soon as possible after randomization.
1761935|NCT00294658|Drug|prednisone alone|Prednisone regimen will be every other day, starting at 10mg. The dose will increase by 10mg every 2 days to a target dose.
1761936|NCT00294671|Drug|diflunisal|given twice daily for 24 months
1761937|NCT00294671|Other|placebo|an inactive substance given twice daily for 24 months
1761938|NCT00294684|Drug|Corticosteroids|"Schedule and dosing of corticosteroids following portoenterostomy in infants with biliary atresia are listed below.
Days 1-3: Methylprednisolone, IV-4mg/kg/day, divided BID Days 4-7: Prednisolone, PO-4mg/kg/day, divided BID Week 2: 4 mg/kg/day, divided BID Week 3: 2 mg/kg/day, divided BID Week 4: 2 mg/kg/day, divided BID Week 5: 1 mg/kg/day, once a day Week 6: 1 mg/kg/day, once a day Week 7: 0.8 mg/kg/day, once a day Week 8: 0.6 mg/kg/day, once a day Week 9: 0.4 mg/kg/day, once a day Week 10: 0.2 mg/kg/day, once a day Week 11: 0.1 mg/kg/day, once a day Week 12-13: 0.1 mg/kg/day, every other day Week 14: Stop"
1761939|NCT00294684|Drug|Placebo|"Schedule and dosing of placebo following portoenterostomy in infants with biliary atresia:
Days 1-3: IV - normal saline 4 mg/kg/day, divided BID Days 4-7: PO placebo 4 mg/kg/day, divided BID Week 2: PO placebo 4 mg/kg/day, divided BID Week 3: PO placebo 2 mg/kg/day, divided BID Week 4: PO placebo 2 mg/kg/day, divided BID Week 5: PO placebo 1 mg/kg/day, once a day Week 6: PO placebo 1 mg/kg/day, once a day Week 7: PO placebo 0.8 mg/kg/day, once a day Week 8: PO placebo 0.6 mg/kg/day, once a day Week 9: PO placebo 0.4 mg/kg/day, once a day Week 10: PO placebo 0.2 mg/kg/day, once a day Week 11: PO placebo 0.1 mg/kg/day, once a day Week 12-13: PO placebo 0.1 mg/kg/day, once a day every other day Week 14: Stop"
1761940|NCT00294710|Drug|Aliskiren|
1761941|NCT00294723|Drug|liraglutide|1.8 mg for s.c. (under the skin) injection
1761942|NCT00294723|Drug|glimepiride|8 mg capsule
1761943|NCT00294723|Drug|liraglutide|1.2 mg for s.c. (under the skin) injection
1761944|NCT00294723|Drug|placebo|Glimepiride placebo, 8mg capsule
1761945|NCT00294723|Drug|placebo|Liraglutide placebo, 200 mcl
1761946|NCT00294723|Drug|placebo|Liraglutide placebo, 300 mcl
1761947|NCT00294736|Drug|Tarceva|Dose Escalation: 150-350+ mg/day
1761948|NCT00294749|Drug|Ciprofloxacine|
1761949|NCT00294762|Drug|Tarceva|oral tablet
1761950|NCT00294762|Drug|carboplatin|IV
1761951|NCT00294762|Drug|paclitaxel|IV
1761952|NCT00294775|Drug|Candesartan|
1761953|NCT00294788|Biological|Fluvax|
1761954|NCT00294788|Drug|PCC® (Lactobacillus fermentum VRI 003)|
1761955|NCT00294801|Drug|flex-a-new (food supplement)|
1761956|NCT00294814|Device|Proximal anastomosis using Heartstring anastomotic device|
1761957|NCT00294827|Procedure|Liver transplantation and colo-rectal cancer|Liver transplantation
1761958|NCT00294840|Device|PET-CT|
1761959|NCT00294853|Procedure|MDCT calcium score|
1761961|NCT00294879|Procedure|pressure support ventilation at 0, 5, and 10% IRT|
1761962|NCT00294892|Drug|carbamazepine and nevirapine|Carbamazepine 400mg and Nevirapine 200mg are taken just before delivery during labor.
1761963|NCT00294892|Drug|Nevirapine|Nevirapine 200mg is taken prior to delivery during labor.
1761964|NCT00294905|Behavioral|Implementation of a combined smoking cessation strategy|
1761965|NCT00294918|Drug|Serostim®|Serostim® will be administered subcutaneously at a dose of 1 mg to subjects who had encountered toxicity during the antecedent protocol (Study 22388) whereas, other subjects will be randomized in 1:1 ratio, to receive either 2 milligram (mg) or 4 mg (on a weight adjusted basis) daily, starting from Day 1 of Week 1 up to Week 12 (Period 1). During Period 1, subjects who encounter toxicity will receive 1 mg Serostim® subcutaneously, daily for Period 2, starting from Day 1 of Week 13, whereas other subjects will be randomized in a 1:1 ratio to receive either 2 mg or 1 mg (on a weight adjusted basis) up to Week 36.
1761966|NCT00294931|Drug|irinotecan|
1761967|NCT00294931|Drug|carboplatin|
1761968|NCT00294931|Drug|bevacizumab|
1761969|NCT00294944|Drug|Idazoxan|
1761970|NCT00294996|Drug|Myocet|
1761971|NCT00295009|Device|ProDisc|Total disc replacement with ProDisc
1761972|NCT00295009|Procedure|Spinal Fusion|A circumferential fusion will be utilized as the control group in this study. The technique will consist of an interbody fusion procedure using commercially available femoral ring allograft. A posterior lateral fusion with autogenous iliac crest bone graft, combined with pedicle screw instrumentation.
1761976|NCT00295048|Behavioral|Computer Assisted Cognitive Remediation (CACR)|
1761977|NCT00295061|Drug|Alpha-1 MP|alpha-1 proteinase inhibitor (human), 60 mg/kg body weight
1761978|NCT00295061|Drug|alpha-1 proteinase inhibitor (human)|Prolastin
1761979|NCT00295074|Procedure|neuropsychologic testing|
1761980|NCT00295100|Drug|Tamoxifen|
1761981|NCT00295113|Procedure|EFR|
1761982|NCT00295126|Procedure|cellular therapy : Autologous platelet concentrate (APC)|
1761983|NCT00295139|Behavioral|Behavioral Treatment for Substance Abuse in SPMI (BTSAS)|Multifaceted treatment for substance abuse in dual disordered patients which contains 6 components: 1) a urinalysis contingency to enhance motivation to change and increase the salience of goals; 2) structured goal setting to identify realistic, short term goals for decreased substance use; 3) motivational interviewing to enhance motivation to reduce use; 4) social skills and drug refusal skills to enable development of relationships with people who do not use drugs, and to provide success experiences that can increase self-efficacy for change; 5) education about the reasons for substance use and the particular dangers of substance use for people with SPMI; and 6) relapse prevention training that focuses on behavioral skills for coping with urges and dealing with high risk situations and lapses. BTSAS is specifically structured to reduce the load on memory and attention, and minimize demands on higher level cognitive processes.
1761984|NCT00295139|Behavioral|Supportive Treatment in Addiction Recovery (STAR)|Manualized substance abuse treatment as usual
1761985|NCT00295139|Behavioral|Critical Time Intervention (CTI)|Case management component
1761986|NCT00295152|Behavioral|community occupational therapy in dementia|
1761987|NCT00295165|Drug|Sargramostim (Leukine)|Sargramostim 6 mcg/kg subcutaneously once daily
1761988|NCT00295165|Drug|Placebo|Placebo subcutaneously once daily
1761989|NCT00295178|Drug|Daptomycin|
1761990|NCT00295178|Drug|Vancomycin|
1761991|NCT00295191|Procedure|high-flux membrane|high-flux dialyser
1761992|NCT00295191|Procedure|low-flux membrane|low-flux dialyser
1761993|NCT00295191|Procedure|conventional dialysate|conventional dialysate
1761994|NCT00295191|Procedure|ultrapure dialysate|ultrapure dialysate
1761995|NCT00295217|Device|ExAblate 2000|
1761996|NCT00295230|Procedure|PSV+VG mode versus SIMV+VG mode|fully assisted mechanical ventilation versus assistance on only a select number of breaths
1761997|NCT00295243|Drug|Topotecan|
1761998|NCT00295256|Behavioral|nurse case manager|
1761999|NCT00295269|Drug|Mythylprednisolone|
1762000|NCT00295282|Drug|MDX-1100 (anti-CXCL10 human monoclonal antibody)|Patients will receive a single dose of MDX-1100 at 0.3, 1.0, 3.0 or 10 mg/kg as a 60 minute intravenous infusion. Patients who respond to treatment may receive up to an additional 3 doses of MDX-1100.
1762001|NCT00295295|Device|High frequency, low magnitude vibration|High frequency, low magnitude vibration at 30 Hz, 10 min/day using vibrating platform from Juvent Medical Inc.
1762002|NCT00295295|Other|Standing|Standing 10 min/day
1762003|NCT00295308|Drug|Clonidine|clonidine up to 0.3 mg/day oral
1762004|NCT00295308|Drug|Placebo|oral capsules daily
1762005|NCT00295334|Drug|alcohol|
1762006|NCT00295347|Drug|Spironolactone|
1762007|NCT00295347|Drug|fludrocortisone|
1762008|NCT00295347|Drug|escitalopram|
1762009|NCT00295360|Behavioral|no intervention, pathophysiological study|
1762010|NCT00295373|Drug|Rosuvastatin|
1762011|NCT00295373|Behavioral|Exercise Training|
1762012|NCT00295386|Behavioral|Cognitive behavior therapy (CBT)|
1762013|NCT00295386|Drug|Zopiclone|
1762014|NCT00295399|Device|The Jerusalem Telerehabilitation System|
1762015|NCT00295412|Drug|quetiapine (drug)|
1762016|NCT00295425|Drug|Cyclosporine A versus mycophenolate mofetil for psoriasis|
1762017|NCT00295438|Device|Robot-Based Tele-Echography (TER)|Robot-Based Tele-Echography, ultrasound performed by the radiologist
1762018|NCT00295438|Device|ultrasound method FAST|FAST,ultrasound performed by the emergency doctor
1762019|NCT00295464|Drug|Betamethasone sodium phos (drug)|
1762020|NCT00295477|Genetic|VRX496|In Step 1 of the protocol, each subject will receive up to 2 cycles of VRX496. Each treatment cycle consists of 3 infusions of VRX496.
1762021|NCT00295490|Drug|Devil Claw|Dose ranging study so will elucidate dose Frequency is four times daily
1762022|NCT00295490|Drug|Placebo|Placebo has same dosing freq as for active intervention and for same time period
1762023|NCT00295503|Drug|bevacizumab|15 mg/kg IV every 3 weeks
1762024|NCT00295503|Drug|cisplatin|75 mg/m2 IV every 3 weeks
1762025|NCT00295503|Drug|pemetrexed|500 mg/m2 every 3 weeks
1762026|NCT00295516|Procedure|Fetal Middle Cerebral Artery Doppler measurement|
1762027|NCT00295529|Behavioral|Multifaceted educational intervention|Educational materials available at end of study
1762028|NCT00295542|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
1762029|NCT00295542|Procedure|Chronotherapy, timing of antihypertensive medication|Comparison of effects of awakening versus bedtime dosing
1762030|NCT00295542|Drug|ACEI (including spirapril, enalapril, quinapril, lisinopril)|Treatment at awakening versus bedtime
1762031|NCT00295542|Drug|ARB (including valsartan, telmisartan, olmesartan)|Treatment at awakening versus bedtime
1762032|NCT00295542|Drug|beta blockers (including nebivolol, atenolol, carvedilol)|Treatment at awakening versus bedtime
1762033|NCT00295542|Drug|diuretics (torasemide, indapamide, HTCZ) and doxazosin|Treatment at awakening versus bedtime
1762034|NCT00295542|Procedure|Combination therapy in essential hypertension|Treatment at awakening versus bedtime
1762035|NCT00295555|Drug|Effects of doxazosin on morning surge in diabetic patients|
1762036|NCT00295581|Drug|PpPfs25/ISA51 & ScPvs25/ISA51|
1762037|NCT00295594|Drug|tacrolimus|Immunosuppression
1762038|NCT00295607|Drug|Tacrolimus|immunosuppression
1762039|NCT00295607|Drug|steroids, monoclonal anti-IL2R antibody|immunosuppression
1762040|NCT00295620|Drug|Anastrozole|1mg tablet daily
1762041|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (6 months ST, 12 months LT)
1762042|NCT00295633|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily (6 months ST, 12 months LT)
1762043|NCT00295633|Drug|Placebo|Tablets, Oral, 0 mg, Once daily (6 months ST, 12 months LT)
1762044|NCT00295633|Drug|pioglitazone|Tablets, Oral, 30 mg or 45 mg, once daily (6 months ST, 12 months LT)
1762045|NCT00295633|Drug|rosiglitazone|Tablets, Oral, 4 mg, once daily or 8 mg, either as once or twice daily (6 months ST, 12 months LT)
1762046|NCT00295633|Drug|metformin|Tablets, Oral, 500-2500 mg, as needed (12 months LT)
1762047|NCT00295646|Drug|tamoxifen|20 mg/d
1762048|NCT00295646|Drug|anastrozole|1 mg/d
1762049|NCT00295646|Drug|zoledronic acid|4 mg q6m
1762050|NCT00295672|Drug|Vinorelbine|
1762051|NCT00295685|Drug|Antacids|
1762052|NCT00295698|Drug|Diethylcarbamazine|
1762053|NCT00295711|Drug|Bicifadine|
1762054|NCT00295724|Drug|Bicifadine|
1762055|NCT00295737|Procedure|bronchoscopy, allergen/endotoxin instillation|
1762056|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 160 mg SC (by injection under the skin) given every 28 days for 364 days.
1762057|NCT00295750|Drug|Degarelix|Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 80 mg SC (by injection under the skin) given every 28 days for 364 days.
1762058|NCT00295750|Drug|Leuprolide 7.5 mg|Leuprolide (Lupron Depot) 7.5mg IM (in the muscle every 28 days starting at day 0.
1762059|NCT00295763|Drug|Thyrogen (thyrotropin alfa for injection)|"No reference therapy was given. All patients in this follow-up study received Thyrogen. Thyrogen 0.9 mg was administered intramuscularly (IM) in the buttock on 2 consecutive days.
For WBS and static neck imaging, each patient received 4 mCi (148 MBq) ± 0.4 mCi 131I PO."
1762060|NCT00295776|Drug|Lamictal in the treatment of Post-Herpetic Neuralgia|
1762061|NCT00295789|Drug|chemotherapy: Paclitaxel/Cisplatin|Drug: chemotherapy: Paclitaxel/Cisplatin
1762062|NCT00295789|Drug|chemotherapy: Paclitaxel/Carboplatin|Drug: chemotherapy: Paclitaxel/Carboplatin
1762063|NCT00295802|Device|Integrated Imaging High Intensity Focused Ultrasound|
1762064|NCT00295802|Device|Endocare CRYOcare Cryosurgical and Galil Medical CRYO-HIT Systems (cryotherapy)|Cryotherapy
1762065|NCT00295815|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 6 week cycles until PD
1762066|NCT00295815|Drug|lomustine|100-130 mg/m2, oral once, every 6 weeks until PD
1762067|NCT00295828|Other|Pegaptanib Sodium Injection/Panretinal Photocoagulation|Pegaptanib Sodium Injection is a single dose prefilled syringe and is formulated as a 3.47 mg/mL solution. Combined with an ocular laser procedure.
1762068|NCT00295828|Procedure|Panretinal Photocoagulation (PRP)|Ocular Laser Procedure
1762069|NCT00295841|Drug|clofarabine|
1762070|NCT00295841|Drug|cytarabine|
1762071|NCT00295854|Drug|MN-001 BID|Eligible patients received 500 mg MN-001 bid
1762072|NCT00295854|Drug|MN-001|Eligible patients received 500 mg MN-001 once daily (qd)
1762073|NCT00295854|Drug|Placebo|Eligible patients received placebo
1762075|NCT00295880|Procedure|umbilical cord blood transplantation|The graft will be given by slow injection into each posterior iliac crest.
1762076|NCT00295893|Biological|trastuzumab|Given IV
1762077|NCT00295893|Drug|carboplatin|Given IV
1762078|NCT00295893|Drug|cyclophosphamide|Given IV
1762079|NCT00295893|Drug|docetaxel|Given IV
1762080|NCT00295893|Drug|doxorubicin hydrochloride|Given IV
1762081|NCT00295893|Drug|paclitaxel|Given IV
1762082|NCT00295906|Other|educational intervention|
1762083|NCT00295906|Other|internet-based intervention|
1762084|NCT00295919|Drug|fenretinide lipid matrix|
1762085|NCT00295919|Drug|ketoconazole|
1762086|NCT00295919|Other|laboratory biomarker analysis|
1762087|NCT00295919|Other|pharmacological study|
1762088|NCT00295932|Biological|rituximab|Given IV
1762089|NCT00295932|Drug|bortezomib|Given IV
1762090|NCT00295932|Drug|cyclophosphamide|Given IV
1762091|NCT00295932|Drug|prednisone|Given orally
1762092|NCT00295945|Drug|fentanyl citrate|
1762093|NCT00295945|Drug|hydromorphone hydrochloride|
1762094|NCT00295945|Drug|ropivacaine hydrochloride|
1762095|NCT00295958|Biological|LMB-2 immunotoxin|
1762096|NCT00295958|Biological|MART-1 antigen|
1762097|NCT00295958|Biological|gp100 antigen|
1762098|NCT00295958|Biological|incomplete Freund's adjuvant|
1762099|NCT00295971|Biological|anti-thymocyte globulin|
1762100|NCT00295971|Biological|therapeutic allogeneic lymphocytes|
1762101|NCT00295971|Drug|fludarabine phosphate|
1762102|NCT00295971|Drug|thiotepa|
1762103|NCT00295971|Procedure|allogeneic bone marrow transplantation|
1762104|NCT00295971|Procedure|allogeneic hematopoietic stem cell transplantation|
1762105|NCT00295971|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1762106|NCT00295971|Radiation|total-body irradiation|
1762107|NCT00295984|Drug|nicotine|
1762108|NCT00295997|Biological|anti-thymocyte globulin|
1762109|NCT00295997|Biological|filgrastim|
1762110|NCT00295997|Biological|graft-versus-tumor induction therapy|
1762111|NCT00295997|Biological|therapeutic allogeneic lymphocytes|
1762112|NCT00295997|Drug|busulfan|
1762113|NCT00295997|Drug|cyclophosphamide|
1762114|NCT00295997|Drug|fludarabine phosphate|
1762115|NCT00295997|Drug|methotrexate|
1762116|NCT00295997|Drug|mycophenolate mofetil|
1762117|NCT00295997|Drug|tacrolimus|
1762118|NCT00295997|Procedure|allogeneic bone marrow transplantation|
1762119|NCT00295997|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1762120|NCT00295997|Procedure|peripheral blood stem cell transplantation|
1762121|NCT00296010|Drug|cyclophosphamide|cyclophosphamide 50 mg/day orally continuously for 16 weeks
1762122|NCT00296010|Drug|methotrexate|methotrexate 2.5 mg twice a day orally on days 1 and 4 of every week for 16 weeks
1762123|NCT00296010|Drug|pegylated liposomal doxorubicin hydrochloride|Caelyx (R) (Doxil (R)) 20 mg/m2 iv x 8 doses (delivered every 2 weeks)
1762124|NCT00296010|Procedure|adjuvant therapy|
1762125|NCT00296010|Radiation|radiation therapy|Radiation therapy should be used according to institutional accepted guidelines. Radiation therapy to the conserved breast is recommended. Radiation therapy to the chest wall following mastectomy is optional (if given, it may also include nodal fields). Radiation therapy may be given either during operation or after all chemotherapy.
1762126|NCT00296023|Biological|anti-thymocyte globulin|
1762127|NCT00296023|Biological|filgrastim|
1762128|NCT00296023|Biological|therapeutic allogeneic lymphocytes|
1762129|NCT00296023|Drug|busulfan|
1762130|NCT00296023|Drug|fludarabine phosphate|
1762131|NCT00296023|Drug|methotrexate|
1762132|NCT00296023|Drug|tacrolimus|
1762133|NCT00296023|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1762134|NCT00296023|Procedure|peripheral blood stem cell transplantation|
1762135|NCT00296036|Dietary Supplement|pyridoxine hydrochloride|Given orally
1762136|NCT00296036|Drug|urea/lactic acid-based topical cream|Applied topically
1762137|NCT00296036|Other|placebo|Given orally or applied topically
1762138|NCT00296049|Drug|daptomycin|
1762139|NCT00296049|Drug|vancomycin|
1762140|NCT00296062|Biological|bevacizumab|Phase II: IV over 30-90 minutes on days 1 and 15 of each course.
1762141|NCT00296062|Drug|capecitabine|Phase I: oral capecitabine twice daily on days 1-7 and 15-21.Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of capecitabine (during both odd- and even-numbered courses) until the maximum tolerated dose (MTD) is determined.Phase II:receive capecitabine (at the MTD determined in phase I(odd-numbered courses)
1762142|NCT00296062|Drug|irinotecan hydrochloride|Phase I: irinotecan hydrochloride IV over 90 minutes on days 1 and 15 during course 1 and all subsequent odd-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.Phase II: receive capecitabine (at the MTD determined in phase I) in combination with irinotecan hydrochloride (during odd-numbered courses)
1762143|NCT00296062|Drug|oxaliplatin|"Phase I: oxaliplatin IV over 2 hours on days 1 and 15 during course 2 and all subsequent even-numbered courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Phase II: oxaliplatin (during even-numbered courses) as in phase I"
1762144|NCT00296101|Behavioral|Physical Activity|
1762145|NCT00296114|Procedure|Serum and DNA Samples|To collect serum and DNA samples from subjects
1762146|NCT00296127|Drug|Celecoxib|
1762147|NCT00296140|Behavioral|self management of PSD symptoms|
1762148|NCT00296140|Procedure|screening and treatment of PSD|
1762149|NCT00296153|Drug|Omega-3-acid ethyl esters 90|Omacor capsule 1000mg x 4 per day. Duration 12 weeks
1762150|NCT00296166|Procedure|Catheter ablation|
1762151|NCT00296166|Procedure|Thoracoscopic epicardial ablation|
1762152|NCT00296179|Drug|zolpidem tartrate|
1762153|NCT00296192|Drug|Rotigotine nasal spray|Rotigotine- HCl 2.5mg/mL nasal spray, dosage per puff of 275µg per 110µg administered in up to 4 deliveries
1762154|NCT00296192|Other|Placebo|placebo nasal spray 1, 2 3, and 4 puffs
1762156|NCT00296218|Drug|Irbesartan|
1762157|NCT00296231|Other|Nasal high frequency ventilation|use of the high frequency ventilation mode of the Infant Star ventilator via a single nasopharyngeal prong.
1762158|NCT00296244|Drug|Steroids|Patients randomized to Control group shall be administered steroids as methylprednisolone (Solumedrol) 1000 mg IV during the anhepatic phase. Methylprednisolone will be continued according to the following taper schedule: 50 mg IV every 6 hrs on day 1; 40 mg IV every 6hrs on day 2; 30 mg IV every 6 hrs on day 3; 20 mg IV every 6 hrs on day 4; 20 mg IV every 12 hrs on day 5; and Prednisone 20 mg by mouth or Naso-gastric tube (NGT) on day 6. Prednisone shall be tapered slowly starting at 1 month post-OLT and weaned off completely by 6 months post-OLT.
1762159|NCT00296244|Drug|Basiliximab|Basiliximab shall be given as induction therapy at 20 mg IV bolus intra-operatively and on the 4th day after transplantation.
1762160|NCT00296244|Drug|Tacrolimus|Tacrolimus shall be used as the main maintenance immuno-suppressive drug. It will be given at a dose of 0.15mg/ kg/ day by mouth or through a naso-gastric tube (NGT), starting not earlier than 24 after the transplant but within 48 hrs after reperfusion. The dose shall be adjusted to achieve a trough level of 10-15 ng/ml during the first 30 days after transplantation and lowered to 5-10 ng/ml, thereafter.
1762161|NCT00296244|Drug|Enteric-coated Mycophenolic acid (EC-MPA)|This drug may be given in combination with calcineurin inhibitors (tacrolimus) and steroids for maintenance immuno-prophylaxis to prevent rejection. They are particularly useful in recipients with renal dysfunction and neurotoxicity, when there is a need to reduce dose or delay introduction of calcineurin inhibitors. This drug is given at 720 mg PO BID for 3 months.
1762162|NCT00296257|Drug|SMP-114|
1762163|NCT00296270|Behavioral|Memory for truth|
1762164|NCT00296283|Behavioral|integrative behavior couples therapy|
1762165|NCT00296296|Drug|Cyclosporin|Dose adjustment to pre-established targets
1762166|NCT00296296|Drug|Tacrolimus|Dose adjustment to pre-established targets
1762167|NCT00296296|Behavioral|'Diabetes Education / Management'|therapeutic adjustment to target ADA criteria
1762168|NCT00296309|Drug|Tacrolimus|Immunosuppression
1762169|NCT00296322|Drug|cisplatin, mitomycin-C, doxifluridine|"Mf: Mitomycin-C 20mg/m2 intravenously (3-6 weeks after surgery) Doxifluridine 460-600mg/m2/day per oral for 3 months (started 4 weeks after surgery)
iceMFP: Cisplatin 100mg with 1L of normal saline intraperitoneally for 2 hours during surgery Mitomycin-C 15mg/m2 intravenously (1 day after surgery) Doxifluridine 460-600mg/m2/day per oral(started at 4 weeks after surgery and administered a total of 12 months) Cisplatin 60mg/m2 intravenously monthly for 6 months (started at 4 weeks after surgery)"
1762170|NCT00296335|Drug|Mitomycin, doxifluridine and cisplatin|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28- day 336), Cisplatin 60mg/m2 intravenously (day 28, day 56, day 84, day 112, day 140, and day 168)
1762171|NCT00296335|Drug|Mitomycin and doxifluridine|Mitomycin-C 20mg/m2 intravenously (day 1), Doxifluridine 460-600mg/m2/day per oral (day 28-day 84)
1762172|NCT00296348|Drug|tacrolimus|immunosuppression
1762173|NCT00296348|Drug|mycophenolate mofetil|oral
1762174|NCT00296348|Drug|daclizumab|oral
1762175|NCT00296348|Drug|steroids|oral
1762176|NCT00296361|Drug|Tacrolimus|immunosuppression
1762177|NCT00296374|Drug|Rosuvastatin|10 mg oral dose administered once daily for 52 weeks
1762178|NCT00296374|Drug|Rosuvastatin|20 mg oral dose administered once daily for 4 weeks followed by 40 mg oral dose administered once daily for 48 weeks
1762179|NCT00296374|Drug|Atorvastatin|40 mg oral dose administered once daily for 4 weeks followed by 80 mg oral dose administered once daily for 48 weeks
1762180|NCT00296387|Drug|Rosuvastatin|
1762181|NCT00296387|Drug|Atorvastatin|
1762182|NCT00296400|Drug|Rosuvastatin|
1762183|NCT00296400|Drug|Atorvastatin|
1762184|NCT00296426|Procedure|New technology - PAML|
1762185|NCT00296439|Behavioral|Behavior|
1762186|NCT00296452|Behavioral|behavior|
1762187|NCT00296465|Drug|Pulsatile gonadotropin-releasing hormone (GnRH)|Dosages as specified, administered either subcutaneously (SC) or intraveneously (IV) as specified, via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
1762188|NCT00296465|Drug|Clomiphene Citrate|Oral clomiphene citrate (over encapsulated) for 5 days
1762189|NCT00296465|Drug|Placebo Pulsatile GnRH|Administered either intravenously or subcutaneously via portable infusion pump in a pulsatile fashion (every 90 minutes) for 4 weeks
1762190|NCT00296465|Drug|Placebo Clomiphene Citrate|oral placebo clomiphene citrate for 5 days
1762191|NCT00296478|Drug|Endometrin|Endometrin 100mg BID x 10weeks
1762192|NCT00296478|Drug|Endometrin|Endometrin 100mg TID x 10weeks
1762193|NCT00296478|Drug|Crinone|Crinone QD x 10weeks
1762194|NCT00296491|Drug|fluticasone propionate/salmeterol (FSC)|fluticasone propionate/salmeterol DISKUS combination
1762195|NCT00296491|Drug|montelukast (MON)|montelukast capsule
1762196|NCT00296491|Drug|fluticasone propionate (FP)|fluticasone propionate aqueous nasal spray
1762197|NCT00296491|Drug|placebo nasal|vehicle placebo nasal spray
1762198|NCT00296491|Drug|ADVAIR DISKUS|ADVAIR DISKUS
1762199|NCT00296491|Drug|placebo capsule|placebo capsule
1762200|NCT00296491|Drug|placebo DISKUS|placebo DISKUS
1762201|NCT00296504|Drug|fosamprenavir (GW433908)|
1762202|NCT00296504|Drug|ritonavir|
1762203|NCT00296517|Drug|323U66 (Bupropion Hydrochloride Sustained Release)|Subjects with Major Depressive Disorder who were randomized to take 100mg of Bupropion SR in the morning and placebo in the evening for one week. Week 2 subjects were given 100mg dose of Bupropion morning and evening. Weeks 3 thru 12 received 150mg dose morning and evening. Week 1=dose level 1, 100 mg. Week 2=dose level 2, 200 mg. Weeks 3 - 12=dose level 3, 300 mg.
1762204|NCT00296517|Drug|Placebo|Subjects with Major Depressive Disorder who were randomised to placebo to match Bupropion SR during the treatment period.
1762205|NCT00296530|Drug|fluticasone propionate/salmeterol|
1762206|NCT00296530|Drug|fluticasone propionate|
1762207|NCT00296530|Drug|montelukast|
1762208|NCT00296556|Drug|Rivenprost (drug)|
1762209|NCT00296569|Drug|MK0686|
1762210|NCT00296582|Behavioral|Gastric Motor Function Measurement|
1762211|NCT00296595|Behavioral|Nutrition|
1762212|NCT00296608|Drug|fluorouracil|
1762213|NCT00296608|Drug|leucovorin calcium|
1762214|NCT00296608|Procedure|conventional surgery|
1762215|NCT00296608|Radiation|radiation therapy|
1762216|NCT00296621|Drug|L-Glutamine|L-Glutamine
1762217|NCT00296621|Drug|placebo|placebo
1762218|NCT00296634|Drug|Aluminum hydroxide|Aluminum hydroxide adjuvant at 1200 mcg/mL.
1762219|NCT00296634|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur pre-adsorbed)|Inactivated monovalent subvirion influenza H5N1 vaccine produced with and without Aluminum hydroxide adjuvant. All formulations of the H5N1 vaccine are supplied in a unit dose (0.5 mL) vial as a sterile solution for intramuscular injection. Vaccine with adjuvant is a turbid liquid whitish-grey in color. Vaccine without adjuvant is essentially clear and slightly opalescent in color.
1762220|NCT00296647|Drug|nicotine patch|Decreasing dosages from 21 to 7 mg over 12 week period
1762221|NCT00296647|Drug|nicotine patch|Decreasing dosage from 21 to 7 mg over 12 weeks
1762222|NCT00296647|Drug|nicotine lozenge|4 mg nicotine lozenge: dosage according to package directions for 16 weeks
1762223|NCT00296647|Drug|bupropion|dosage according to prescription directions: 12 weeks
1762224|NCT00296647|Drug|patch + lozenge|dosage of each according to package insert directions (12 weeks patch, 16 weeks lozenge)
1762225|NCT00296647|Drug|bupropion + lozenge|dosage of each according to prescription or package insert (12 weeks bupropion, 16 weeks lozenge)
1762226|NCT00296673|Device|Rehabilitation device|
1762227|NCT00296686|Drug|Tranylcypromine|standard dose:60 mg/d for a minimum of 8 weeks, a maximum of 17 weeks; high dose for non-remitters: up to 120 mg/day for a maximum of 9 weeks.
1762228|NCT00296686|Drug|Dextroamphetamine|up to 40 mg/day for 9 weeks, in combination with high dose of tranylcypromine for patients not remitting on the standard or high doses of tranylcypromine alone.
1762229|NCT00296686|Drug|Triiodothyronine|For patients not remitting on higher dose of tranylcypromine plus dextroamphetamine: Up to 75 mg/day for 8 weeks(+/- dextroamphetamine) (max 8 weeks) in combination with highest does of tranylcypromine (up to 120mg/day).
1762230|NCT00296699|Drug|Duloxetine|"Day 1-7: 20 mg/d; day 8-24: 30 mg/d; day 15-28: 60 mg/d; day 29-56: 120 mg/d.
* dose raises will occur only if pt. is tolerating the previous dose and not remitting.; dose may be lowered or increased in 30 mg increments if pt. has difficulty tolerating."
1762231|NCT00296712|Drug|escitalopram + bupropion|same dosing as for monotherapy arms
1762234|NCT00296738|Device|SPECT/CT|GE INFINIA HAWKEYE
1762235|NCT00296751|Procedure|ECG recording|
1762236|NCT00296751|Procedure|Epidural catheter insertion|
1762237|NCT00296751|Drug|Intravenous meperidine injection|
1762238|NCT00296751|Drug|Epidural Bupivacaine and fentanyl injection|
1762239|NCT00296777|Drug|Escitalopram|8 weeks: up to 40 mg/day
1762240|NCT00296777|Drug|Bupropion|8 weeks: up to 450 mg/day (for patients without history of seizures or risk for developing seizures.
1762241|NCT00296777|Drug|Imipramine|"8 weeks: up to 300mg/day
*if patient does not have contraindication."
1762242|NCT00296790|Drug|zolpidem tartrate|
1762243|NCT00296803|Drug|clopidogrel|
1762244|NCT00296816|Drug|Bevacizumab (Avastin®)|15 mg/kg bevacizumab administered intravenously (IV) over 30 to 90 minutes on Day 1 of every 3 week cycle for 12 months or until disease progression or unacceptable toxicity
1762245|NCT00296816|Drug|Docetaxel (Taxotere®)|75 mg/m^2 docetaxel was administered IV over 1 hour on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
1762246|NCT00296816|Drug|Oxaliplatin (Eloxatin®)|85 mg/m^2 Oxaliplatin was administered IV over 2 hours on Day 1 of every 3 week cycle for 6 cycles or until disease progression or unacceptable toxicity
1762247|NCT00296829|Biological|Inactivated, split-virion influenza vaccine|
1762248|NCT00296842|Behavioral|Early psychological intervention|Psychoeducation, trauma narrative, provision of coping skills
1762249|NCT00296855|Drug|Vasovist (BAY86-5283, MS-325)|All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
1762250|NCT00296868|Drug|ascorbic acid (vitamin C) versus placebo|
1762251|NCT00296881|Device|PERIOWAVE|
1762252|NCT00296894|Drug|Adalimumab (40 mg sc every other week)|Adalimumab (40 mg sc every other week)
1762253|NCT00296894|Drug|Placebo|Placebo
1762254|NCT00296907|Behavioral|Brief psychological intervention|Psychoeducation, provision of medical knowledge, coping skills training
1762255|NCT00296920|Device|Deep Brain Stimulation|
1762256|NCT00296933|Drug|Escitalopram|
1762257|NCT00296933|Drug|Bupropion XL|
1762258|NCT00296946|Drug|ipratropium bromide (drug)|
1762259|NCT00296959|Drug|topiramate (drug)|
1762260|NCT00296972|Drug|peg interferon plus ribavirin|
1762261|NCT00296985|Device|Fresenius Cellsaver|
1762262|NCT00297011|Drug|valacyclovir+clobetasol gel|
1762263|NCT00297024|Procedure|MRI|Patients will be scanned while breathing in varying amounts of oxygen and carbon dioxide in varying amounts through a breathing device.
1762264|NCT00297037|Drug|Pimecrolimus 1% cream|pimecrolimus cream or matching placebo BID for 6 weeks
1762265|NCT00297050|Drug|Peramivir|
1762266|NCT00297063|Drug|Rosiglitazone|
1762267|NCT00288028|Drug|bortezomib|Dose of Bortezomib* Level 1: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 21 days; Level 2: 1.3 mg/m2 on Day 1, 4, 8, 11 - Every 28 days; Level 3: 1.0 mg/m2 on Day 1, 8, 15 - Every 28 days; Level 4: 1.0 mg/m2 on Day 1, 8, 15 - Every 35 days
1762268|NCT00288041|Drug|carboplatin|Given IV
1762269|NCT00288041|Drug|paclitaxel|Given IV
1762270|NCT00288041|Drug|bortezomib|Given IV
1762271|NCT00288054|Biological|cetuximab|"Cohorts 1 and 2: 400 mg/m2 (initial dose) 2 hour IV infusion on Day 1, Cycle 1 only.
250 mg/m2, 1 hour IV infusion on Days 8 , 15 and 22 during Cycle 1. 250 mg/m2 (subsequent doses), 1 hour IV infusion on Days 1, 8 , 15 and 22 during subsequent cycles."
1762272|NCT00288054|Drug|docetaxel|"Cohort 2 ONLY: 20 mg/m2 IV over 15 - 30 minutes on Days 8, 15 and 22 of Cycle 1. Concurrent with RT and cetuximab starting at Week 2.
20 mg/m2 IV over 15 - 30 minutes on Days 1, 8, 15 and 22 of Cycle 2."
1762273|NCT00288054|Radiation|radiation therapy|"Radiation therapy should begin on Day 8 of Cycle 1 and continue through the end of Cycle 2. Refer to Section 12.1 for Radiation Therapy Review.
RT prescription should be PTV (GTV + 2-cm margins on CT scan) to 6,480 cGy in 36 fractions given 5 days a week, 180 cGy per day. The dose is prescribed to the isocenter. The entire treatment should be planned prior to starting treatment to ensure that the plan meets protocol specifications."
1762274|NCT00288067|Drug|fenretinide|Given PO
1762275|NCT00288067|Drug|rituximab|Given IV
1762276|NCT00288080|Drug|Dexamethasone|Premedication of dexamethasone prior to docetaxel, per institutional standards.
1762277|NCT00288080|Drug|Prednisone|10 mg orally per day until day 21 of the last cycle of docetaxel, beginning 28 days after the completion of RT.
1762278|NCT00288080|Drug|docetaxel|75 mg/m2 i.v. over 1 hour (on day 1 of each cycle) every 21 days for 6 cycles, beginning 28 days after the completion of RT.
1762279|NCT00288080|Drug|Oral antiandrogen|Oral antiandrogen of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy. Treatment is discontinued at the end of radiation therapy.
1762280|NCT00288080|Radiation|Radiation therapy|46.8 Gy, using either three-dimensional conformal radiotherapy (3DCRT) or intensity-modulated radiation therapy (IMRT), will be given to the regional lymphatics followed by a 25.2-28.8 Gy boost to the prostate, to bring the total dose to the prostate to 72.0-75.6 Gy. Daily prescription doses will be 1.8 Gy per day, 5 days per week x 8-8.5 weeks, beginning 8 weeks after the initiation of androgen suppression.
1762281|NCT00288080|Drug|LHRH agonist|LHRH agonist of treating institution's choice to be given per package instructions for 8 weeks, then concurrent with radiation therapy, and then until 24 months from initiation of any treatment has been reached.
1762282|NCT00288093|Radiation|3-Dimensional Conformal Radiation Therapy|
1762283|NCT00288093|Drug|Triapine|
1762284|NCT00288106|Other|Follow-up|No additional drug was given; clinical observation of men diagnosed with prostate cancer who were previously randomized and treated on PCPT
1762330|NCT00297271|Other|Current treatment practice of each participating physician|Patients will be observed for the evaluation of current management strategies.
1762331|NCT00297284|Drug|Modafinil|
1762332|NCT00297297|Other|No intervention. Applying gene profiling on needle aspirates|
1762333|NCT00297310|Drug|tacrolimus|
1762334|NCT00297323|Drug|Topiramate|75 patients over the age of 2 years old with epilepsy.
1762335|NCT00297336|Drug|Topiramate|80 patients with diagnosed with migraine
1762336|NCT00297349|Drug|Topiramate|Individualization of the treatment should begin from 25 mg for 1 week.
1762285|NCT00288132|Behavioral|Intervention|A 12-month diabetes self-management intervention delivered via telemedicine, with opportunity to receive telemedicine-based screening eye exam, was conducted. The intervention goal was to achieve an A1c <7%, with secondary goals of 10% weight loss and increasing exercise to at least 30 minutes a day, 5 days a week. Participants attend 13 sessions, 2 in the first month (1 group, 1 individual), monthly thereafter (9 group, 2 individual). Three group sessions were conducted in-person, all others were conducted via telemedicine. The self-management education team consisted of an RN/CDE and an RD. Sessions were conducted remotely, with a trained facilitator (LPN) at the clinic site. Participants were given a notebook and new material was added at each session. Completion of self-monitoring logs, including blood sugar, diet and physical activity, was assigned daily followed by less frequently based on progress towards intervention goals.
1762286|NCT00288132|Behavioral|Usual Care|Upon randomization, received one 15-minute diabetes self-management individual session, using American Diabetes Association materials. Continued care, as usual, from their primary care provider throughout duration of active 12 month intervention period.
1762287|NCT00288145|Behavioral|WOW, Working On Wellness weight management|Treatment site, worksite-based health promotion activities such as self-directed campaigns, lectures, small group programs, online programs, environment interventions (food service and physical)--all with focus on nutrition, physical activity and/or weight management.
1762288|NCT00288158|Drug|Allopurinol|
1762289|NCT00288158|Drug|Probenecid|
1762290|NCT00288158|Drug|Placebo|
1762291|NCT00288171|Drug|Placebo|placebo capsule twice daily for one month
1762292|NCT00288171|Drug|Allopurinol|Allopurinol 200mg twice daily for one month
1762293|NCT00288184|Drug|Allopurinol|Allopurinol adminsitered one 200mg capsule by mouth twice daily. Placebo capsule once daily during crossover
1762294|NCT00288184|Drug|Placebo|
1762295|NCT00288197|Drug|voriconazole|
1762296|NCT00288210|Procedure|Primary angioplasty in acute myocardial infarction|
1762297|NCT00288223|Drug|Telithromycin|one daily intake of 800 mg (i.e. 2 x 400 mg tablets) per os in a single intake with a meal for 5 days.
1762298|NCT00288236|Drug|Rimonabant (SR141716)|
1762299|NCT00288236|Drug|Placebo|
1762300|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
1762301|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
1762302|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
1762303|NCT00288249|Drug|Sagopilone (BAY86-5302, ZK 219477)|22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
1762304|NCT00288262|Drug|melatonin 0.5 mg|
1762305|NCT00297076|Drug|GW873140|
1762306|NCT00297089|Drug|ABT-751|200 mg ABT-751 daily for 14 days every 21 days
1762307|NCT00297089|Drug|pemetrexed|Standard pemetrexed every 21 days
1762308|NCT00297089|Drug|placebo|Placebo daily for 14 days every 21 days
1762309|NCT00297102|Drug|Roflumilast|500 mcg, once daily, oral administration in the morning
1762310|NCT00297102|Drug|Placebo|once daily
1762311|NCT00297115|Drug|Roflumilast|500 mcg, once daily, oral administration in the morning
1762312|NCT00297115|Drug|Placebo|once daily
1762313|NCT00297128|Drug|Capecitabine|825 mg/m2 bid (on each therapy day of first 4 therapy weeks)
1762314|NCT00297128|Drug|Cetuximab|400mg/m2 week 1, 250mg/m2 week 2-4
1762315|NCT00297141|Drug|Capecitabine|chemotherapy oral use
1762316|NCT00297141|Drug|Oxaliplatin|chemotherapy intravenous use
1762317|NCT00297154|Behavioral|Lifestyle Modification (diet, exercise, and behavior)|
1762318|NCT00297167|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). The capsules could be opened and sprinkled on acidic food and half of the established dose was used with snacks. Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
1762319|NCT00297167|Drug|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
1762320|NCT00297167|Drug|Placebo|Placebo matched to EUR-1008 (APT-1008) microtablets or minitablets contained in a capsule will be given orally daily in first double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for first double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
1762321|NCT00297167|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) microtablets (5000 lipase units) or minitablets (10000, 15000 or 20000 lipase units) contained in a capsule will be given orally daily in second double-blind intervention period; at a dose based on investigator's discretion as achieved during dose titration and stabilization period (6 to 9 days). Treatment duration for second double-blind intervention period will be 2 days home treatment and 3 to 5 days hospital treatment.
1762323|NCT00297193|Procedure|Autologous haematopoietic stem cell transplant|All patients will be mobilised prior to randomisation. Those receiving early transplantation will be compared over the first year with those whose transplant has been delayed.
1762324|NCT00297206|Drug|Valaciclovir|Valaciclovir will be administered as an extemporaneously prepared suspension formulation. Valaciclovir oral suspension will be prepared by crushing marketed Valtrex Caplets 500 milligram (mg) and suspending the resultant powder in Suspension Structured Vehicle USNF with dose strength of 25 milligram per milliliter (mg/mL) or 50 mg/mL.
1762327|NCT00297232|Drug|Natalizumab|
1762328|NCT00297245|Drug|cognitive function|
1762329|NCT00297258|Drug|pazopanib|oral tablet
1762337|NCT00297362|Drug|Galantamine hydrobromide|247 patients with diagnosed mild to moderate Alzheimer disease.
1762338|NCT00297375|Drug|tramadol HCl/acetaminophen|
1762339|NCT00297388|Drug|Risperidone, long-acting injectable|
1762340|NCT00297401|Drug|ruboxistaurin|32 mg, QD, PO, up to 8 weeks
1762341|NCT00297401|Drug|placebo|QD, PO, up to 8 weeks
1762342|NCT00298194|Drug|Z-338|
1762343|NCT00298207|Behavioral|Walking (behavior)|
1762344|NCT00298220|Behavioral|Feedback about patients at risk|GPTs receive this feedback about their patient population; obtained through premeasurement results
1762345|NCT00298220|Behavioral|Dissemination guideline and patient information letters|
1762346|NCT00298220|Behavioral|Tailored educational training|for GP(T)s
1762347|NCT00298220|Behavioral|Tailored outreach based facilitator support|in the practices of the GPTs
1762348|NCT00298220|Behavioral|Facilitation of co-operation with local addiction services|
1762349|NCT00298220|Behavioral|Patient directed interventions|Like poster for the waiting room, self-help booklets, folders
1762350|NCT00298220|Behavioral|Reminder-card for GP's desk|
1762351|NCT00298220|Behavioral|Personal feedback to patients|Patients receive advise based on their premeasurement answers
1762352|NCT00298233|Drug|Oseltamivir|Oseltamivir is a sialic acid analogue that potently and specifically inhibits the viral neuraminidases by competitively and reversibly interacting with the active enzyme site of influenza A and B viruses. Oseltamivir will be administered orally in standard formulations (capsules for adults and children at least 15 years of age; suspension for children younger than 15 years).
1762353|NCT00298259|Procedure|operative fixation of fractured ribs|ORIFof fractured ribs in flail chest patients
1762354|NCT00298272|Biological|IDEC-C2B8 (rituximab)|Participants will receive 500 mg rituximab on Day 1 and Day 15
1762355|NCT00298272|Drug|Placebo|Participants will receive placebo on Day 1 and Day 15
1762356|NCT00298272|Drug|Methotrexate|Participants must have been treated with MTX ≥15 mg per week and ≤25 mg per week (dose may have been as low as 10 mg if unable to tolerate higher dose) for at least 12 weeks immediately prior to Day 1, at a stable dose for at least 4 weeks and was continued for the study duration.
1762357|NCT00298272|Drug|Etanercept|Participants must have been treated with etanercept at 50 mg per week (25 mg twice per week or 50 mg once per week).
1762358|NCT00298272|Drug|Adalimumab|Participants must have been treated with adalimumab at 40 mg every other week for at least 12 weeks immediately prior to Day 1.
1762359|NCT00298272|Drug|Methylprednisolone|Methylprednisolone 100 mg IV was administered by slow infusion to be completed at least 30 minutes prior to each infusion of rituximab or placebo.
1762360|NCT00298272|Dietary Supplement|Folate|All subjects also received a stable dose of folate (≥5 mg per week).
1762361|NCT00298285|Drug|enoxaparin|
1762362|NCT00298298|Biological|L-Vax: Autologous, DNP-Modified NSCLC Vaccine|autologous, DNP-modified NSCLC cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
1762363|NCT00298311|Behavioral|mci guidance peer support|12 weeks of home visits by peer mentor recovered from PPD and Keys to Caregiving (NCAST, 1990) program
1762364|NCT00298324|Drug|Myfortic|1440mg twice daily
1762365|NCT00298324|Drug|Prednisone and Cyclosporine|Prednisone and Cyclosporine given according to protocol. The drugs are tapered according to patient response
1762366|NCT00298337|Drug|Mixture of probiotic bacteria and prebiotic oligosaccharide|
1762367|NCT00298350|Drug|GS-9137 - A Novel HIV-1 Integrase Inhibitor|
1762368|NCT00298363|Drug|Tenofovir disoproxil fumarate (tenofovir DF; TDF)|300-mg tablet QD
1762369|NCT00298363|Drug|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC 200 mg/TDF 300 mg fixed-dose combination (FDC) tablet QD
1762370|NCT00298363|Drug|Entecavir (ETV)|0.5-mg or 1-mg tablet QD
1762371|NCT00298363|Drug|TDF placebo|Placebo to match TDF QD
1762372|NCT00298363|Drug|FTC/TDF placebo|Placebo to match FTC/TDF QD
1762373|NCT00298363|Drug|ETV placebo|Placebo to match ETV QD
1762374|NCT00298415|Drug|Paclitaxel + Carboplatin|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D29, 4 cycles) Carboplatin AUC 6 D1 (D1=D29, 4 cycles)
1762375|NCT00298415|Drug|Monotherapy (gemcitabine or vinorelbine)|Gemcitabine 1150 mg/m² D1 and D8 (D1=D22, 5 cycles) Vinorelbine 30 mg/m² D1 and D8 (D1=22, 5 cycles)
1762376|NCT00298428|Procedure|blood samples|blood samples before percutaneous coronary intervention (PCI) and at 4 months
1762377|NCT00298441|Drug|chondroitin sulfate-iron colloid|
1762378|NCT00298454|Drug|Furosemide|
1762379|NCT00298467|Drug|MDX-060|
1762380|NCT00298493|Procedure|Sedation management strategy|
1762381|NCT00298506|Drug|Multitherapy|Tacrolimus,4mg/d, MMF 1.0g/d
1762382|NCT00298532|Procedure|Advanced Life Support|
1762383|NCT00298545|Drug|placebo and Calcitriol|Placebo tablets twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
1762384|NCT00298545|Drug|Calcium and Calcitriol|Calcium twice daily together with an oral tablet of 1, 25 dihydroxy vitamin D3 (Calcitriol)
1762385|NCT00298558|Behavioral|Cognitive Training|Memory, Reasoning, or Speed of Processing cognitive training interventions
1762386|NCT00298571|Drug|.5% bupivacaine with epinephrine|
1762387|NCT00298584|Procedure|Percutaneous Suprapubic Aspiration|
1762388|NCT00298584|Procedure|Urethral Catheterization|
1762389|NCT00298597|Drug|granulocyte - colony stimulating factor (G-CSF)|
1762390|NCT00298597|Drug|erythropoetin (EPO)|
1762391|NCT00298610|Drug|Artesunate and Malarone|Intravenous Artesunate (2.4 mg/kg) once a day for three days and Malarone (proguanil/atovaquone) follow-on therapy (4 tablets once daily for three days)
1762392|NCT00298623|Drug|XP13512 (GSK1838262)|
1762393|NCT00298623|Other|placebo|
1762394|NCT00298636|Drug|adenosine|
1762395|NCT00298649|Behavioral|Lay Health Advisor|
1762396|NCT00298662|Drug|Interferon beta-1b and Tacrolimus|
1762397|NCT00298675|Drug|BSI-201 (iniparib)|BSI-201 administered intravenously (IV), 2x weekly
1762398|NCT00298675|Drug|irinotecan|Irinotecan administered weekly, IV.
1762399|NCT00298688|Drug|Gefitinib|
1762400|NCT00298701|Biological|ALK Grass tablet|
1762401|NCT00298714|Drug|Losartan|
1762402|NCT00298727|Behavioral|SHIPS|Stakeholder-Hosted Interactive Problem-based Seminars
1762403|NCT00298727|Behavioral|ePBL|Online Problem-Based Course
1762404|NCT00298740|Device|Aventis U-400 Insulin|
1762405|NCT00298753|Procedure|fluid restriction for 14 days (15ml fluid per kg weight)|
1762406|NCT00298766|Drug|VELCADE|"Once weekly at: 0.7, 1.0, 1.3 or 1.6 mg/m2
Or
Twice-weekly at: 0.7, 1.0, or 1.3 mg/m2"
1762407|NCT00298779|Drug|omeprazole and bortezomib|
1762408|NCT00298792|Behavioral|Cognitive Behavioral Treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety.
1762409|NCT00298792|Behavioral|Cognitive-behavioral treatment|Psychosocial treatment emphasizing teaching of coping skills to maintain sobriety
1762410|NCT00298831|Drug|sugammadex|"Each subject will receive an intravenous single bolus dose of 0.6 mg/kg rocuronium. If further neuromuscular block is required after endotracheal intubation, maintenance dose(s) of 0.15 mg/kg rocuronium may be administered.
At least 15 minutes after the intubation dose or the last maintenance dose of rocuronium, an intravenous single bolus dose of 4.0 mg/kg Org 25969 will be administered."
1762411|NCT00298857|Drug|Valproic acid|
1762412|NCT00298870|Drug|Isoniazid|Modified daily isoniazid dose : approx. 7.5 mg/kg, 5 mg/kg and 2.5 mg/kg for rapid, intermediate and slow acetylators, respectively
1762413|NCT00298870|Drug|isoniazed|Conventional standard daily isoniazid dose : approx. 5 mg/kg b.w. for all
1762416|NCT00298909|Behavioral|physical exercise|physical exercise
1762417|NCT00298909|Drug|niaspan (extended-release niacin)|niaspan (extended-release niacin)
1762418|NCT00298909|Drug|niacin|niacin extended-release
1762419|NCT00298909|Other|control|control
1762420|NCT00298922|Drug|Azithromycin|500 mg tablets orally thrice weekly for 24 weeks
1762421|NCT00298922|Drug|Placebo|tablet orally thrice weekly for 24 weeks
1762422|NCT00298935|Procedure|Osteopathic manipulative treatment (OMT)|
1762423|NCT00298961|Device|Videoconference equipment FALCON/IP|
1762424|NCT00298974|Drug|hydrocodone / acetaminophen extended release|2 tablets twice daily
1762425|NCT00298974|Drug|Placebo|2 tablets twice daily
1762426|NCT00298987|Drug|Dasatinib|Tablets, Oral, 70 mg, Twice daily, 2 months.
1762427|NCT00299000|Drug|Naglazyme|Weekly infusion for minimum of 52 weeks. Naglazyme is diluted in sterile 0.9% sodium chloride solution
1762428|NCT00299013|Drug|COLAL-PRED®|COLAL-PRED 40, 60 or 80mg oral capsule, once daily for 8 weeks.
1762429|NCT00299013|Drug|Prednisolone|Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
1762430|NCT00299026|Device|NIRx(TM) Paclitaxel-Coated Conformer Coronary Stent System|
1762431|NCT00299039|Drug|acetaminophen plus codeine|capsules four times daily until pain free or for a maximum of seven days
1762432|NCT00299039|Drug|acetaminophen plus ibuprofen|capsules four times daily until pain free or for a maximum of seven days
1762433|NCT00299052|Device|Grafton DBM|Grafton DBM will be mixed with bone reamings obtained during tibia IMN and place at the fracture site
1762434|NCT00299052|Biological|Reamings|Bone reamings obtained during tibia IMN will be placed at the fracture site
1762435|NCT00299065|Drug|Zileuton injection|
1762436|NCT00299091|Drug|Efavirenz capsules 200 mg and 600 mg|Modification of doses of efavirenz guided by its plasma concentration (therapeutic drug monitoring)
1762437|NCT00299104|Drug|folate|Intravenous repeating dose
1762438|NCT00299104|Drug|methotrexate|Oral or parenteral repeating dose
1762439|NCT00299104|Drug|methylprednisolone|Intravenous repeating dose
1762440|NCT00299104|Drug|placebo|Intravenous repeating dose
1762441|NCT00299104|Drug|rituximab|Intravenous repeating dose
1762442|NCT00299117|Behavioral|Brief preoperative smoking intervention|One counseling session of approximately 45 minutes duration 3-4 days preoperatively. The intervention is inspired by the principles of motivational interviewing and The Stages of Change Model.
1762443|NCT00299130|Drug|Folate|A stable dose, ≥ 5 mg/week given as either a single dose or as a divided weekly dose, orally.
1762444|NCT00299130|Drug|Methotrexate|A stable dose of between 10-25 mg/week, oral or parenteral, as prescribed by the treating physician.
1762445|NCT00299130|Drug|Methylprednisolone|Intravenous infusion
1762446|NCT00299130|Drug|Placebo|Placebo to rituximab intravenous infusion
1762447|NCT00299130|Drug|Rituximab|Intravenous infusion
1762448|NCT00299156|Drug|Clofarabine|Starting dose 10 mg (Group 1) or 20 mg (Group 2) as tablets once a day for 5 days in a row and repeated every 4-8 weeks. Each 4-8 week period is a cycle.
1762449|NCT00299169|Behavioral|N of 1 Trials|N of 1 Trials of statin therapy
1956784|NCT02701738|Dietary Supplement|Overeating Protocol|Subjects will ingest 30% more calories per day than their calculated daily energy requirements (~750kcals extra energy intake each day). All subjects will be instructed (and will be guided) to consume a diet containing approximately 50% carbohydrate, 35% fat, and 15% protein.
1956787|NCT02697734|Drug|osilodrostat|In the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg. Each strength has a unique size and color. The osilodrostat 1 mg, 5 mg, 10 mg and 20 mg film coated tablets are approximately 6 mm, 7 mm, 9 mm, and 11 mm respectively in diameter and pale yellow, yellow, pale orange brown and light brown respectively in color.
1991523|NCT00969761|Drug|BI-6727|Low to high dose (administered every 3 weeks). Depending on the toxicities observed, intermediary dose levels may be added
1991524|NCT00969761|Drug|BI 6727|low to high dose
1762459|NCT00299195|Drug|sulindac|Sulindac 150 mg po bid x 24 weeks
1762460|NCT00299195|Drug|Placebo|Placebo bid x 24 weeks
1762461|NCT00299208|Drug|Artesunate|
1762462|NCT00299208|Drug|Azithromycin|
1762463|NCT00299208|Drug|Quinine|
1762464|NCT00299221|Drug|Tacrolimus|tacrolimus
1762465|NCT00299221|Drug|combination therapy|MMF
1762466|NCT00299234|Drug|Atomoxetine|titration schedule: 0.5 to 1.5 mg/kg/day
1762467|NCT00299247|Drug|sulfadoxine/pyrimethamine|
1762468|NCT00299260|Biological|CMV gB vaccine|20 micrograms
1762469|NCT00299260|Drug|Placebo|normal saline
1762470|NCT00299273|Behavioral|Low calorie high fat/protein diet|6 weeks of caloric restriction (50%) on a high fat/protein diet
1762471|NCT00299286|Drug|Lapatinib|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).
Lapatinib tablets are dispensed as 250mg tablets. Patients should be advised to take all 6 tablets at once as one dose (total daily dose 1500mg). Tablets should be taken on an empty stomach either one hour before or one hour after a meal at the same time each day and according to the instructions on the bottle."
1762472|NCT00299286|Drug|Lapatinib-Placebo|"In order for patients to take their study medication for 14 days only, treatment should commence on the 14th day prior to the day before scheduled surgery (i.e. if surgery is scheduled for the 15th of the month, tablets should be taken from the 1st to the 14th of that month).
Lapatinib-placebo tablets will be composed of lactose, cellulose, starch, magnesium stearate, and coated with Opadryl orange and look the same as the active treatment. The patients should take all 6 tablets at once as one dose."
1762473|NCT00299325|Drug|Rimonabant|Tablet, oral administration
1762474|NCT00299325|Drug|Placebo (for Rimonabant)|Tablet, oral administration
1762475|NCT00299325|Other|Mild hypocaloric diet|Calculated by the dietitian based on the estimated basal metabolism rate and the physical activity
1762476|NCT00299338|Drug|SP01A|
1762477|NCT00299351|Drug|Depsipeptide|
1762478|NCT00299364|Drug|Black Cohosh (iCR) or tibolone|
1762479|NCT00299377|Drug|Abciximab i.v.|
1762480|NCT00299377|Drug|Abciximab i.c.|
1762481|NCT00299390|Drug|Sagopilone (BAY86-5302, ZK 219477)|Sagopilone; 16 mg/m2 (maximum 32 mg) as 3 hour i.v. infusion
1762482|NCT00299403|Procedure|Right prefrontal lowfrequency ( 1 hz) rTMS.|"Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes
Arms: 2"
1762483|NCT00299403|Procedure|Electroconvulsive therapy (ECT)|9 ECT ( 3 each week) during 3 weeks
1762484|NCT00299416|Drug|Caffeinol|Infusion of caffeinol (9mg/kg caffeine + 0.4g/kg ethanol) over 2 hours.
1762485|NCT00299416|Procedure|hypothermia|External or internal cooling for 24 hours and rewarming over 12 hours.
1762486|NCT00299429|Procedure|Stenting and minimally invasive bypass surgery|
1762487|NCT00299442|Behavioral|Self-help Triple P Behavioural Family Intervention|10-week self-help workbook and videos
1762488|NCT00299455|Drug|amoxicillin-clavulanate|Amoxicillin clavulanate 40 mg/kg/day divided into two daily doses for 7 days. Capsules will be produced by pulverizing amoxicillin clavulanate tablets (Augmentin 875 mg; manufacturer Glaxo SmithKline Beecham; ATC Code: J01CR02) and mixing that with lactose monohydrate. Each capsule will contain Augmentin tablet powder 68 mg and lactose monohydrate 572 mg. This means amoxicillin 40 mg and clavulanate 5,7 mg respecting the dose per 2 kg.
1762489|NCT00299455|Drug|Placebo|Placebo twice a day for 7 days. Placebo capsules contain lactose monohydrate 640 mg.
1762490|NCT00299468|Behavioral|Patient Activation Measure Intervention Package|
1956788|NCT02697734|Drug|osilodrostat Placebo|Matching Placebo in the form of filmcoated tablets for oral administration, in the following dose strengths: 1 mg, 5 mg, 10 mg, and 20 mg. Each strength has a unique size and color.
1762495|NCT00299507|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 3 or 6 month intervals
1762496|NCT00299507|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL posterior juxtascleral depot injection at 6 month intervals
1762497|NCT00299507|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6 month intervals
1762498|NCT00299520|Drug|intravenous iclaprim or intravenous linezolid|
1762499|NCT00299533|Drug|Fish oil (Super Omega-3, 4 caps/d) vs. placebo|
1762500|NCT00299546|Drug|Placebo|SC injections
1762501|NCT00299546|Biological|Golimumab 50 mg|SC injections
1762502|NCT00299546|Biological|Golimumab 100 mg|SC injections
1762503|NCT00299559|Drug|smart textiles containing menthol, camphor, cineol|application to skin
1762504|NCT00299572|Drug|alendronate (Fosamax)|
1762505|NCT00299585|Procedure|"using PD VitalOs Cement with dental implants"|supporting dental implants with Vitalos bone cement
1762506|NCT00299598|Device|alkylated polyethylenimine nanoparticles antibacterial evaluation|
1762507|NCT00299611|Drug|Sertraline|Tablets, 50mg each, (1-3TABLETS/DAY) during the Open-label phase for first 8 wks.
1762508|NCT00299611|Drug|Levetiracetam|Tablets, dosage 500mg each tablet (1-4tablets/day)for 8 wks during the 2nd phase of the study.
1762509|NCT00299611|Drug|Placebo|Tablets, No active ingredient, (1-4tablets/day) for 8 wks during the 2nd phase of the study.
1762510|NCT00299650|Drug|cisatracurium|
1762511|NCT00299650|Drug|Placebo|physiological serum infusion
1762512|NCT00299650|Drug|Cisatracurium besilate|Cisatracurium besilate infusion (900mg/day)
1762513|NCT00299676|Drug|Galantamine (Reminyl)|Use of Reminyl according to approved NZ data sheet
1762514|NCT00299689|Drug|Denileukin diftitox|12 mcg/kg IV (in vein) over 30 minutes on days 1 through 4 of each 21 day cycle for 4 cycles.
1762515|NCT00299702|Drug|Abilify|10-30 mg once daily for 104 weeks
1762516|NCT00299702|Drug|Risperidal Consta|25mg, 37.5mg, or 50mg every 2 weeks for 104 weeks
1762517|NCT00299715|Drug|Paliperidone extended-release|
1762518|NCT00299728|Biological|NY-ESO-1 protein with CpG 7909 and Montanide|
1762519|NCT00299741|Drug|Sunitinib|Sunitinib 50 mg daily, 4/2 schedule
1762520|NCT00299754|Drug|Misoprostol|
1762521|NCT00299767|Procedure|sequential cord blood transplantation|Infused on Day 0
1762522|NCT00299780|Drug|Stem cell mobilization|
1762523|NCT00299806|Drug|Aliskiren|
1762524|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
1762525|NCT00299819|Biological|MEDI 545|0.3 mg/kg IV (n=6) at Study Day 0
1762526|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
1762527|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
1762528|NCT00299819|Biological|MEDI-545|0.3 mg/kg IV (n=6) at Study Day 0
1762529|NCT00299832|Drug|Aliskiren|
1762530|NCT00299845|Drug|Lansoprazole|
1762531|NCT00299858|Drug|Theophylline|"Patients assigned to study group, will receive slow-release theophylline at a dose of 10 mg/kg, titrated to blood levels between 55-110 umol/L, for a period of 4 weeks.
Patients assigned to placebo group will receive identical-appearing placebo tablets for the same period of time."
1762532|NCT00299871|Drug|LIXISENATIDE (AVE0010)|
1762533|NCT00299884|Drug|Lipitor 20 mg|A/A for 6 weeks
1762534|NCT00299884|Drug|Combination Ezetrol 10 mg and Lipidil Supra 160 mg|a/a for 6 weeks
1762535|NCT00299897|Drug|SP01A|
1762536|NCT00299910|Drug|Montelukast|
1762537|NCT00299923|Drug|Peginterferon alfa-2a, Ribavirin, Amantadine|
1762538|NCT00299936|Drug|Ribavirin, PEG-Intron|
1762539|NCT00299962|Biological|Adenoviral-mediated Interferon-beta|BG00001 at doses 1.5 x 10e12 and 3 x 10e12 viral particles Days 1 and 8
1762540|NCT00299962|Biological|SCH 721015|Comparison of different doses and frequency of investigational agent
1762541|NCT00299975|Drug|MaZiRenWan (MZRW) Low dose|Dissolved MaZiRenWan (MZRW) granule (2.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
1762542|NCT00299975|Drug|MaZiRenWan (MZRW) Median dose|Dissolved MaZiRenWan (MZRW) granule (5.0g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
1762543|NCT00299975|Drug|MaZiRenWan (MZRW) High dose|Dissolved MaZiRenWan (MZRW) granule (7.5g/sachet) in 150 ml hot water, take orally twice daily for 8 weeks
1762544|NCT00299988|Drug|Intravenous Immunoglobulin|
1762545|NCT00300014|Procedure|Intravitreal triamcinolone injection|
1762546|NCT00300014|Procedure|Air-fluid exchange|
1762547|NCT00300027|Drug|BMS-582664|
1762548|NCT00300040|Drug|Hemoglobin glutamer 250 - bovine|intravenous - 250ml/dose - 32.5g Hb (Concentration 13 +/- 1g/dL)
1762549|NCT00300040|Drug|6% Hydroxyethylstarch|250ml for intravenous infusion
1762551|NCT00300079|Drug|brinzolamide 1.0%|
1762552|NCT00300092|Drug|Cepahlexin (drug)|Cephalexin 50 mg/kg divided 3 times daily for 7 days
1762553|NCT00300105|Drug|Tesaglitazar|
1762554|NCT00300118|Drug|budesonide|9 mg
1762555|NCT00300118|Drug|mesalazine|4.5 g
1762556|NCT00300131|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation stent in the treatment of coronary artery disease
1762557|NCT00300157|Device|Percutaneous coronary intervention with Taxus stent|
1762558|NCT00300196|Biological|Ancrod (Viprinex)|0.167 IU/kg/hr IV for 2-3 hours
1762559|NCT00300196|Drug|Placebo|0.6 mL/kg/hr
1762560|NCT00300222|Drug|NGX-4010|
1762561|NCT00300261|Behavioral|Telehealth monitoring|Experimental group receives telehealth monitoring equipment in their homes for the duration of home care. Equipment includes blood pressure cuff, scale, and pulse oximeter, or glucometer as needed. Two home care nurses provide video visits with subjects on the days when the home care nurse does not visit. Patients use the equipment daily and the results are downloaded to the nurse's computer at the home care agency where they are checked daily. The nurse acts on any abnormal readings by calling the patient, the home care nurse, or the physician.
1762562|NCT00300274|Drug|everolimus|Everolimus supplied as 0.75 mg tablets. Everolimus was also supplied in 0.25 mg and 0.5 mg tablets for dose adjustments.
1762563|NCT00300274|Drug|mycophenolate mofetil|Mycophenolate mofetil supplied as 500 mg tablets.
1762564|NCT00300274|Drug|cyclosporine|Cyclosporine reduced dose in the everolimus arms (approximately half of the standard dose) and standard dose in the mycophenolate mofetil arm.
1762565|NCT00300274|Drug|corticosteroids|Corticosteroids standard dose.
1762566|NCT00300287|Drug|Vildagliptin|
1762567|NCT00300300|Procedure|Computer-assisted surgery|no description
1762568|NCT00300313|Drug|Escitalopram|10 to 20 mg / day
1762569|NCT00300313|Drug|Placebo|1-2 capsules
1762570|NCT00300326|Procedure|Computer assist|same implant using a computer-assisted surgical technique.
1762571|NCT00300339|Drug|SL650472, Clopidogrel|
1762572|NCT00300352|Drug|Folic Acid|
1762573|NCT00300365|Drug|Pioglitazone|Pioglitazone, initially 30 mg, then titrated to 45 mg/day
1762574|NCT00300365|Other|Placebo|Pioglitazone placebo
1762575|NCT00300365|Drug|Niacin ER|Niacin ER 2.0 g/day
1762576|NCT00300365|Drug|Aspirin|asprin 325 mg/day
1762577|NCT00300378|Drug|desvenlafaxine 50 mg|
1762578|NCT00300378|Drug|desvenlafaxine 100 mg|
1762581|NCT00300404|Drug|daraprim|
1762582|NCT00300404|Drug|pyrimethamine|
1762583|NCT00300404|Drug|folinic acid|
1762584|NCT00300417|Drug|VRC-WNVDNA020-00-VP|
1762585|NCT00300430|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg plus rosuvastatin calcium daily, 52 weeks
1762586|NCT00300430|Drug|ABT-335 and atorvastatin calcium|ABT-335 135 mg plus atorvastatin calcium daily, 52 weeks
1956794|NCT02692755|Drug|Palbociclib + Letrozole or Fulvestrant|Palbociclib x 21 days with a 7 day rest plus 2.5 mg Letrozole QD (no break) or Fulvestrant 500mg IM every 2 weeks for 3 doses and then every 4 weeks until progression or maximum of 12 months
1762587|NCT00300430|Drug|ABT-335 and simvastatin|ABT-335 135 mg plus simvastatin daily, 52 weeks
1762588|NCT00300443|Drug|bimatoprost|
1762589|NCT00300456|Drug|ABT-335|135 mg, daily, 12 weeks
1762590|NCT00300456|Drug|Simvastatin|daily, 12 weeks, see Arm Description for dosage information
1762591|NCT00300456|Drug|Placebo|Daily, 12 weeks, see Arm Description for placebo information
1762592|NCT00300469|Drug|ABT-335|135 mg, daily, 12 weeks
1762593|NCT00300469|Drug|Atorvastatin|Daily, 12 weeks, see Arm Description for dosage information
1762594|NCT00300469|Drug|Placebo|daily, 12 weeks, see Arm Description for placebo information
1762595|NCT00300482|Drug|ABT-335|135 mg, daily, 12 weeks
1762596|NCT00300482|Drug|Rosuvastatin Calcium|Daily, 12 weeks, see Arm Description for dosage information
1762597|NCT00300482|Drug|Placebo|Daily, 12 weeks, see Arm Description for information regarding placebo type
1762598|NCT00300495|Drug|Amiodarone|Perioperative orally administered
1762599|NCT00300495|Other|Control arm, standard care|Control
1762600|NCT00300508|Drug|Anastrozole|
1762601|NCT00300521|Genetic|ADV-TK (adenovirus-thymidine kinase enzyme) gene therapy|
1762602|NCT00300534|Device|Abbott Laboratories Determine test for syphilis|
1762603|NCT00300534|Device|Investigational syphilis immunochromatographic strip test|
1762604|NCT00300547|Procedure|MR colonography|Altered planned surgical procedure if MR colonoscopy reveals synchronous cancer or larger polyps
1762605|NCT00300560|Drug|Colistin|
1762606|NCT00300573|Drug|Dexelvucitabine|nucleoside inhibitor of HIV Reverse Transcriptase
1762607|NCT00300586|Drug|observation|observation, second line chemotherapy if progression
1762608|NCT00300586|Drug|gemcitabine|1250 mg/m² D1, D8 q21 days
1762609|NCT00300586|Drug|erlotinib|150 mg daily
1762610|NCT00300599|Device|Continuous Positive Airway pressure|Continuous positive pressure device with a time clock
1762611|NCT00300599|Other|Placebo|Placebo
1762612|NCT00300612|Biological|HyperAcute-Melanoma Vaccine|Cells will be injected intradermally every two weeks for twelve vaccinations. If the patient completes all twelve vaccinations, dosage will vary from a total of 1.3 x 109 to 3.8 x 109 HyperAcute™-Melanoma Vaccine cells administered.
1762613|NCT00300625|Procedure|Application of the San Francisco Syncope Rule|
1762614|NCT00300638|Procedure|Magnetic Resonance Imaging (MRI)|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
1762615|NCT00300638|Behavioral|Interviews, cognitive tests, and emotional measurements|We present emotional words and pictures on a computer screen, and using MRI scans, we observe how the brain works when people purposefully respond to the words and pictures. Additionally, we are comparing brain structure and activation patterns in men and women, because there may be gender differences in responses to emotional stimuli.
1762616|NCT00300651|Behavioral|Cognitive Behavioral Therapy|
1762617|NCT00300664|Drug|Human Growth hormone|
1762618|NCT00300677|Drug|voriconazole|Multiple oral doses of voriconazole at 400 mg loading twice daily followed by 200 mg maintenance twice daily
1762619|NCT00300690|Device|6 mm Uni-graft® (B-Braun)|
1762620|NCT00300690|Device|6 mm Gore-Tex® (WL Gore)|
1762621|NCT00291135|Drug|letrozole|Letrozole 2.5 mg daily
1762622|NCT00291148|Drug|paroxetine|
1762623|NCT00291148|Drug|pregabalin|
1762624|NCT00291161|Behavioral|Partners in Dementia Care|"Partners in Dementia Care is facilitated by the VA Dementia care coordinator (VA DCC) that is with the study. The role of the VA DCC includes conducting initial assessments with the subject and caregiver that leads to:
Arranging for further assessment or attention from VA health care system/providers about dementia related concerns or about co-morbid health issues; for example: VA driving evaluation, congestive heart failure medication adherence; Ensuring education is provided about particular health, safety issues; Following up with patient/caregiver on health promoting activities he/she is committed to do; and Sharing care plan actions/outcomes with other VA providers as agreed upon by patient."
1762625|NCT00291187|Drug|20 mg VEC-162|20 mg VEC-162
1762626|NCT00291187|Drug|50 mg VEC-162|50 mg VEC-162
1762627|NCT00291187|Drug|100 mg VEC-162|100 mg VEC-162
1762628|NCT00291187|Drug|Placebo|Placebo
1762629|NCT00291213|Drug|levetiracetam|
1762630|NCT00291213|Drug|placebo|
1762631|NCT00291226|Drug|Glycine|Glycine 0.4 g/kg bid
1762632|NCT00291226|Drug|Placebo|Placebo
1762633|NCT00291239|Behavioral|partial sleep deprivation|
1762634|NCT00291304|Procedure|MRI|pre-surgery
1762635|NCT00291317|Device|RT 300-P FES Cycle|Participants exercised using functional electrical stimulation cycling (FES) using the RT 300-P FES cycle (Restorative Therapies, Baltimore, MD). Children were scheduled to attend three cycling sessions per week on non-consecutive days for up to 30 minutes per session over a 9 month period. The intervention was provided at Children's Specialized Hospital in Mountainside, and families were required to provide their own transportation. During the study, the participants continued to participate in their standard, primary rehabilitation program.
1762636|NCT00291330|Drug|dabigatran etexilate 150 mg|twice daily
1762637|NCT00291330|Drug|warfarin (INR 2-3)|prn to maintain INR (2-3)
1762638|NCT00291343|Biological|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
1762639|NCT00291343|Biological|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 24 months
1762640|NCT00291343|Biological|Mencevax™ ACWY|One full subcutaneous dose in subjects aged 24 to 30 months or 1/5th of a dose intramuscular in subjects aged 30 to 36 months
1762643|NCT00291369|Drug|Interleukin-2|
1762644|NCT00291369|Drug|Interferon alfa|
1762645|NCT00291369|Drug|medroxyprogesterone acetate|
1762646|NCT00291382|Drug|Salmeterol/fluticasone propionate combination|
1762647|NCT00291395|Drug|PGI2|
1762648|NCT00291408|Procedure|Skin Prick Test|
1762649|NCT00291408|Procedure|Impulse Oscillometry|
1762650|NCT00291408|Procedure|Exhaled Nitric Oxide|
1762651|NCT00291408|Procedure|Spirometry|
1762652|NCT00291408|Procedure|Reversibility|
1762653|NCT00291408|Procedure|Exhaled Breath Condensate|
1762654|NCT00291408|Procedure|Sputum Induction|
1762655|NCT00291902|Drug|SB-681323|
1762656|NCT00291915|Drug|Adalimumab|
1762657|NCT00291915|Drug|Methotrexate|
1956795|NCT02692742|Drug|Myelo001|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
1956796|NCT02692742|Drug|Placebo|Intake of study drug once daily per os for a maximum of 28 days in addition to Epirubicin and Cyclophosphamide treatment
1762660|NCT00291941|Biological|Henogen HBV vaccine|20µg, Month 0, 2 and 6
1762661|NCT00291941|Biological|FENDRIX|20 µg,Months 0, 1, 2 and 6
1762662|NCT00291954|Biological|HB-AS02V|HB-AS02V (20µg HBsAg) will be administered at Month 0 and 1
1762663|NCT00291954|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0 and 1
1762664|NCT00291967|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
1762665|NCT00291980|Biological|HB-AS02V vaccine|HB-AS02V (20µg HBsAg) will be administered at Month 0
1762666|NCT00291980|Biological|HBVAXPRO vaccine|HBVAXPRO vaccine (40µg HBsAg) will be administered at Month 0
1762667|NCT00292006|Device|Computerized tomography|
1762668|NCT00292019|Procedure|Laparoscopic|Patients with prostate cancer who are eligible for a radical prostatectomy will have their surgery conducted with the aid of surgical robots.
1762669|NCT00292045|Biological|NY-ESO-1 protein/CpG|
1762670|NCT00292058|Device|Videoconference equipment (telepsychiatry)|
1762671|NCT00292071|Drug|caspofungin acetate|(50 mg/m²/day and 70 mg/m²/day) Caspofungin will be given for a minimum of 4 days (or at least 2 separate days of 7-point plasma sampling). Patients will be administered caspofungin for a maximum of 28 days.
1762672|NCT00292084|Drug|Celgosivir|
1762673|NCT00292097|Procedure|Early tracheostomy|early conversion - less than or equal to 72 hours
1762674|NCT00292097|Procedure|Late tracheostomy|Late conversion (10-14 days)
1762675|NCT00292110|Drug|Methadone|100 mg/day orally
1762676|NCT00292110|Behavioral|Contingency Management|Incentives given for cocaine abstinence
1762677|NCT00292110|Drug|Methadone dose|flexible methadone dosing to 190 mg/day daily orally
1762678|NCT00292110|Behavioral|Contingency Management/Noncontingent Incentives|Incentives given independent of drug use
1762679|NCT00292123|Drug|Methadone|
1762680|NCT00292123|Behavioral|Contingency Management|
1762681|NCT00292162|Procedure|radiofrequency ablation|isolation of the pulmonary veins with radiofrequency ablation (RFA)
1762682|NCT00292162|Drug|ACE inhibitor - ramipril, enalapril, captopril, perindopril, lisinopril|Evidence based treatment for heart failure. Dose and type will depend on patient tolerability.
1762683|NCT00292162|Drug|Beta Blocker (BB) - metoprolol, bisoprolol, carvedilol|Evidence based treatment for heart failure. Dose and type will depend on patient tolerance.
1762684|NCT00292162|Drug|Aldosterone Antagonists - spironolactone|Evidence based treatment for heart failure. Dose and type will depend on patient to treatment.
1762685|NCT00292175|Procedure|Narrow Band Imaging|
1762686|NCT00292175|Procedure|colonoscopy|
1762687|NCT00292188|Drug|pregabalin|pregabalin
1762688|NCT00292188|Drug|Placebo|placebo
1762689|NCT00292201|Drug|Atorvastatin|The treatment group will receive Atorvastatin 80 mg po once per day for 4 weeks. The placebo group will receive an identical placebo pill po once per day for 4 weeks.
1762690|NCT00292214|Drug|Paracetamol (acetaminophen)|
1762691|NCT00292227|Drug|Rotigotine|"Rotigotine patch applied once daily for a 24-hour period.
Rotigotine dose schedule (patch application days):
Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
1762692|NCT00292227|Other|Placebo|"Placebo patch applied once daily for a 24-hour period. Size and number of patches matching to rotigotine dose schedule (patch application days):
Day 1 through Day 7: 9.0 mg/day; Day 8 through Day 14: 18.0 mg/day; Day 15 through Day 21: 27.0 mg/day; Day 22 through Day 28: 36.0 mg/day; Day 29 through Day 35: 45.0 mg/day; Day 36 through Day 42: 54.0 mg/day; Day 43 through Day 44: 45.0 mg/day; Day 45 through Day 46: 36.0 mg/day; Day 47 through Day 48: 27.0 mg/day; Day 49 through Day 50: 18.0 mg/day; Day 51 through Day 52: 9.0 mg/day;"
1762693|NCT00292227|Drug|Moxifloxacin infusion|Moxifloxacin 400 mg/250 mL iv solution infused over 1h once either on Day 32 or on Day 39
1762694|NCT00292227|Other|Placebo infusion|Placebo saline solution 250 mL infused over 1h once either on Day 32 or on Day 39
1762695|NCT00292227|Other|Placebo infusion|Placebo saline solution 250 mL infused over 1h once on both Day 32 and on Day 39
1762696|NCT00292240|Behavioral|Brief motivational substance use intervention|
1762697|NCT00292253|Device|Rebif® via Rebiject™Mini|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with Rebiject™Mini, an auto-injection device for 3 months.
1762698|NCT00292253|Device|Rebif® via manual injections|Rebif® will be administered subcutaneously at a dose 44 mcg three times a week with manual injections for 3 months.
1762699|NCT00292266|Drug|Rebif®|Rebif® injection will be administered subcutaneously at a dose of 44 mcg, three times per week, up to 72 weeks.
1762700|NCT00292266|Drug|Avonex®|Avonex® injection will be administered intramuscularly at a dose of 30 mcg, once weekly, up to 72 weeks.
1762701|NCT00292279|Drug|Omega-3 fish oil emulsion (Omegaven )|Patients of the treatment group received 0.2 g fish oil (10% Omegaven, Fresenius Kabi, Bad Homburg, Germany) and 1.0 g soy bean oil per kg BW per day
1762702|NCT00292279|Drug|long-chain triglyceride|the control group received 1.2 g soy bean oil (Intralipid, Sino-Swed,Wuxi,China)
1762703|NCT00292292|Device|Lumbar Artificial Disc|Insertion of the Kineflex Lumbar ArtificialDisc
1762704|NCT00292292|Device|Charite Artificial Disc|Insertion of the Charite
1762705|NCT00292305|Procedure|Percutaneous coronary intervention|Implantation of coronary stent in bifurcation lesions
1762706|NCT00292318|Behavioral|Biofeedback Therapy for Fecal Incontinence: A Randomized Control Study|Patients who have more than one episode per week of fecal incontinence would be enrolled and randomized into either the control group (medical counseling and exercises) or study group (biofeedback therapy, medical counseling, and sphincter exercises) for seven sessions to assist with their medical problem.
1762707|NCT00292318|Behavioral|control group|Medical counseling and ano-sphinctal exercises.
1762708|NCT00292331|Procedure|cyanoacrylate injection to treat gastric variceal hemorrhage|
1762709|NCT00292344|Drug|Rifaximin and loperamide|
1762710|NCT00292357|Procedure|Application of autologous bone marrow|
1762711|NCT00292370|Drug|Open Label (OL) Paroxetine|Open-label Paroxetine
1762712|NCT00292370|Drug|Placebo|Double-blind placebo taken with OL paroxetine
1762713|NCT00292370|Drug|Quetiapine|Double-blind quetiapine taken with OL paroxetine
1762714|NCT00292383|Procedure|Leads to be implanted according randomization on specified sites. Vitatron pacemakers to be implanted: T60 DR, T70 DR, T20 SR, C60 DR|
1762715|NCT00292396|Drug|Anti IL-12 monoclonal antibody/ABT-874|Please see Arm Description for intervention description and details.
1762716|NCT00292396|Drug|placebo|12 doses
1762717|NCT00292409|Drug|Aripiprazole|
1762718|NCT00292422|Drug|BG9924|
1762719|NCT00292435|Drug|Read vine leaf extract (AS 195)|
1762720|NCT00292448|Drug|Ba 679 BR Respimat|
1762721|NCT00292448|Drug|Tiotropium (Spiriva) inhalation capsule 18 ug|
1762722|NCT00292461|Drug|Zonisamide|Tablet once or twice daily orally for 16 weeks
1762723|NCT00292461|Drug|Lamotrigine|Tablet once daily orally for 16 weeks
1762724|NCT00292474|Device|percutaneous coronary intervention|
1762725|NCT00292487|Drug|Iopamidol 370 mgI/mL|
1762726|NCT00292500|Device|Automated distal anastomotic device|CABG
1762727|NCT00292513|Device|standard suture (5-0 prolene), topical skin adhesive (dermabond), absorbable suture (5-0 Chromic gut)|
1762728|NCT00292526|Drug|Enalapril|enalapril orally administered
1762729|NCT00292539|Device|Any pacemaker with right ventricular pacing option|
1762730|NCT00292552|Other|Novel endpoint determination|Novel endpoint determination
1762731|NCT00292578|Procedure|NAET Testing Modalities|
1762732|NCT00292591|Drug|cholecalciferol (vitamin D3)|randomized control trial of three vitamin D doses: 400, 2000 and 4000 IU/day
1762733|NCT00292591|Drug|cholecalciferol|comparing vitamin D requirements of pregnant women and their fetuses from 12 weeks' gestation through pregnancy
1762734|NCT00292656|Procedure|NAET|
1762735|NCT00292695|Other|VP-16, Cisplatin, Ifosfamide, Dexamethosone, Mesna, IF-RT|"IF-RT 50.4 Gy/28 Fractions, DEP: (Q4W, CCRT) X 2 Dexamethosone 20 mg/m2/d iv D1-3 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-3 Cisplatin 75 mg/m2 ivd 4 hr D1
DVIP: (Q4W, POST-RT) X 2 Dexamethosone 20 mg/m2/d iv D1-4 VP-16 (etoposide) 75 mg/m2 iv 1 hr D1-4 Ifosfamide 1.2 gm/m2/d ivd 2 hr D1-4 Mesna 240 mg/m2/d iv at 0, 4, 8 hr D1-4 Cisplatin 20 mg/m2 ivd 1 hr D1-4 G-CSF 250ug subcut D 9-12"
1762736|NCT00292708|Drug|Cefmetazole (drug)|
1762737|NCT00292721|Drug|Celecoxib|celecoxib: loading and maintenance for 6 months
1762738|NCT00292734|Drug|Zolpidem|
1762739|NCT00292747|Drug|Drotaverine|
1762740|NCT00292747|Drug|Drotaverine Placebo|
1762741|NCT00292747|Drug|Ibuprofen|
1762742|NCT00292747|Drug|Ibuprofen Placebo|
1762743|NCT00292760|Drug|Alemtuzumab|
1762744|NCT00292760|Drug|Methyprednisolone|
1762745|NCT00292773|Procedure|weight reduction minimal access surgery|Patients will be offered laparoscopic gastric bypass surgery by Mr Roger Ackroyd, in line with the current recommendation for gastric surgery according to NICE guidelines i.e. patients with a BMI over 40 or a BMI over 35 with at least one co-morbidity. Patients will be reviewed monthly for six months.
1762746|NCT00292786|Behavioral|Walking Practice with Functional Electrical Stimulation|
1762747|NCT00292786|Behavioral|Walking Practice|
1762748|NCT00292799|Drug|Orlistat Vs Metformin|
1762749|NCT00292812|Drug|Nutritional supplementation (nucleotides)|
1762750|NCT00292825|Device|Pacemaker treatment, pacemaker programmed as active = CLS|Pacemaker treatment with closed loop function(CLS)
1762751|NCT00292825|Device|Pacemaker, programmed as passive = VVI 30 beats per minute (bpm)|pacemaker treatment as VVI 30 bpm
1762752|NCT00292838|Drug|fluticasone 25, 50, 100, 200 mcg|
1762753|NCT00292864|Drug|SNS-032 Injection|
1762754|NCT00292877|Drug|SB-240563 (Mepolizumab)|
1762755|NCT00292890|Device|insulin needle|
1762756|NCT00292903|Behavioral|Brief interpersonal psychotherapy|IPT-B sessions include evaluation of participants' level of depression, identification of any difficulties or problems that participants may be experiencing, and review of how to manage these problems using skills learned during treatment.
1762757|NCT00292903|Behavioral|Facilitated referral for treatment as usual|F-TAU includes providing verbal and written information regarding depressive symptoms and a referral for treatment at a behavioral health clinic.
1762758|NCT00292916|Behavioral|whole body vibration|
1762759|NCT00292916|Behavioral|resistance exercise|
1762760|NCT00292916|Behavioral|"wellness"|
1991538|NCT00942162|Biological|Immunotherapeutic GSK2132231A|Intramuscular administration
1991539|NCT00940446|Device|Insorb staples|absorbable staples required for wound closure
1762763|NCT00292955|Drug|Cetuximab|monotherapy (day 1), then weekly thereafter along with radiation. dose is at 200mg/m2.
1762764|NCT00292968|Behavioral|Computer based care|
1762765|NCT00292968|Behavioral|Telephone counseling|
1762766|NCT00292968|Behavioral|Group visits|
1762767|NCT00292968|Behavioral|Usual care|
1762768|NCT00292981|Drug|C1 Esterase Inhibitor|Lyophilisate containing approximately 500 U C1-INH to be reconstituted with 10 mL water for injection; Single Dose: 20 U/kg b.w. iv
1762769|NCT00292994|Behavioral|Exercise|
1762770|NCT00292994|Behavioral|Weight Loss|
1762771|NCT00293020|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, 1200 mcg fentanyl; up to 4 times daily
1762773|NCT00293046|Biological|ALK Grass tablet - use of compliance device|
1762774|NCT00293059|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|2 days of 3 mg estradiol valerate (EV);5 days of 2 mg EV + 2 mg dienogest (DNG);17 days of 2 mg EV + 3 mg DNG;2 days of 1 mg EV;2 days of placeboA blister card consists of 28 pills taken orally once a day for 28 days (one cycle)
1762775|NCT00293059|Drug|Placebo|Matching placebo to be taken orally daily.
1762776|NCT00293072|Drug|Rituximab|
1762777|NCT00293085|Drug|Docetaxel|
1762778|NCT00293085|Drug|Docetaxel|"Docetaxel (Taxotere) 75 mg/m² as a 1 hour i.v. infusion, followed immediately by cisplatin 75 mg/m² as a 1 hour i.v. infusion, on day 1 every 21 days for 6 cycles.
Dose reductions and/or treatment delays or discontinuation of treatment are planned for arm A in case of severe haematological and/or non haematological toxicities.
Premedication:
Dexamethasone 8 mg p.o. (or any other steroid commonly used) will be given -12 h, -3 h, -1 h before start of docetaxel infusion, then + 12 h, +24 h and + 36 h post infusion.
All patients should receive a prophylactic antiemetic premedication to prevent nausea and vomitus, which includes a 5-HT3 antagonist prior to start of each docetaxel infusion.
Hyperhydration Patients will require intravenous hydration according to institutional guidelines."
1762779|NCT00293098|Drug|deferiprone|oral administration of 75 mg/kg/day in three divided doses, usually in combination with deferoxamine therapy
1762780|NCT00293111|Drug|SDX-101 (R-Etodolac)|
1762781|NCT00293124|Drug|Glivec|400mg p.o./day in a population of patients with locally advanced (=not amenable to surgery with curative intent) or metastatic malignant GIST. Glivec® may be increased to 600 mg p.o./day and then 800 mg p.o./day (400 mg b.i.d.) if the patient is progressing
1762782|NCT00293150|Drug|Eplerenone|
1762783|NCT00293163|Device|Hylaform, Hylaform Plus (hylan B gel)|
1762784|NCT00293176|Drug|Donepezil Hydrochloride|Subects will receive a starting dose of 5 mg orally. Dose-escalation from 5 mg to 10 mg will occur at the Week 9 Visit.
1762785|NCT00293176|Drug|Placebo|Subjects will receive matching placebo tablets.
1762786|NCT00293202|Drug|Etanercept|Hemodialysis patients having a serum albumin of less than or equal to 3.8 g/dl and a CRP greater than or equal to 0.8 mg/dL will receive either etanercept at a dose of 25 mg by subcutaneous injection twice a week or a placebo for a period of 48 weeks. The outcome is an increase in serum albumin and pre-albumin in the treated group.
1762787|NCT00293202|Drug|Saline|Saline will be injected subcutaneously twice a week
1762788|NCT00293215|Drug|111-Indium-CMD-193|
1762789|NCT00293215|Drug|CMD-193|
1991540|NCT00940446|Device|metal staples (Ethicon metal stapler)|wound closure with metal staples
1991541|NCT00939497|Drug|Risperidone|
1762792|NCT00293241|Device|Managed Ventricular Pacing programmed ON/OFF|Device programming
1762793|NCT00293254|Drug|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
1762794|NCT00293254|Drug|Comparator: placebo|Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
1762795|NCT00293267|Drug|raltegravir potassium|Raltegravir 400 mg twice daily (b.i.d.) by mouth (p.o.) with optimized background therapy. Treatment period of 48 weeks.
1762796|NCT00293267|Drug|Comparator: Placebo|Placebo b.i.d. p.o. with optimized background therapy. Treatment period of 48 weeks.
1762797|NCT00293280|Drug|lomustine|
1762798|NCT00293293|Other|healing touch|The practitioner performed a structured interview with the patient both a verbal assessment and an energy/physical assessment using pendulum and hand scan techniques. The practitioner will then provide the intervention which will consist of: chakra connection, magnetic passes (hands still and in motion), magnetic clearing.
1762799|NCT00293293|Other|massage therapy|Standard massage techniques will be employed over the head, neck, shoulders, back, hands, and/or feet areas. The intensity and rapidity of massage movements will be individualized to the patient's comfort level.
1762800|NCT00293293|Other|hypnosis|Steps: 1) begins with a progressive relaxation induction; 2) suggestions for deepening are then provided; 3) offered suggestions to increase comfort with medical procedures; 4) suggestion for enhanced capacity for coping will be given as an ego strengthening suggestion, with a post-hypnotic suggestion for increasing comfort/success in coping each time.
1762801|NCT00293293|Drug|Standard chemotherapy|Patients will receive 6 cycles of taxane and platinum therapy as prescribed by their treating physician. Chemotherapy treatment is not part of this study.
1762802|NCT00293319|Biological|filgrastim|
1762803|NCT00293319|Radiation|iobenguane I 131|
1762804|NCT00293332|Biological|bevacizumab|Neoadjuvant therapy with 15 mg/kg, IV on Day 1 of each 21 day cycle for the first 2 cycles.
1762805|NCT00293332|Drug|carboplatin|Neoadjuvant therapy, AUC 6, IV on day 1 of each 21 day cycle for 3 cycles.
1762806|NCT00293332|Drug|docetaxel|Neoadjuvant therapy, 75 mg/m2, IV on day 1 of each 21 day cycle for 3 cycles.
1762807|NCT00293332|Procedure|conventional surgery|Standard surgery after 3 cycles of neoadjuvant therapy with docetaxel, carboplatin, and bevacizumab. Bevacizumab is given for the first 2 cycles only.
1762808|NCT00293345|Drug|gemcitabine hydrochloride|
1762809|NCT00293345|Drug|triapine|
1762810|NCT00293358|Drug|carboplatin|
1762811|NCT00293358|Drug|cisplatin|
1762812|NCT00293358|Drug|etoposide phosphate|
1762813|NCT00293358|Drug|ifosfamide|
1762814|NCT00293358|Procedure|adjuvant therapy|
1762815|NCT00293358|Procedure|conventional surgery|
1762816|NCT00293358|Procedure|neoadjuvant therapy|
1762817|NCT00293358|Radiation|radiation therapy|
1762818|NCT00293371|Drug|docetaxel|
1762819|NCT00293371|Drug|prednisone|
1762820|NCT00293371|Drug|vatalanib|
1762821|NCT00293384|Drug|Aprepitant|Aprepitant 80mg once daily in the morning on days 2 and 3
1762822|NCT00293384|Drug|Cyclophosphamide|Cyclophosphamide 4 gm/m2 I.V. over 90-120 minutes
1762823|NCT00293384|Drug|Dexamethasone|Dexamethasone orally 10 mg 1 hour prior to cyclophosphamide administration.
1762824|NCT00293384|Drug|Granisetron hydrochloride|Kytril 1 mg orally or I.V., 1 hour prior to cyclophosphamide administration.
1991542|NCT00940238|Drug|Citalopram Hydrobromide|
1762826|NCT00293410|Drug|clofarabine|
1762827|NCT00293410|Drug|cyclophosphamide|
1762828|NCT00293423|Biological|HSPPC-96|25 mcg ID
1762829|NCT00293423|Procedure|conventional surgery|craniotomy
1762830|NCT00293436|Drug|celecoxib|
1762831|NCT00293436|Drug|erlotinib hydrochloride|
1762832|NCT00293436|Procedure|adjuvant therapy|
1762833|NCT00293462|Biological|sargramostim|
1762834|NCT00293462|Other|oral salt and soda mouthwash|Patients receive oral salt and soda mouthwash, holding it and swallowing it in intervals over 1 hour once daily.
1762835|NCT00293475|Drug|Carboplatin|Given IA
1762836|NCT00293475|Other|Laboratory Biomarker Analysis|Correlative studies
1762837|NCT00293475|Drug|Mannitol|Given IA
1762838|NCT00293475|Drug|Methotrexate|Given IA
1762839|NCT00293475|Other|Quality-of-Life Assessment|Ancillary studies
1762840|NCT00293475|Biological|Rituximab|Given IV
1762841|NCT00293475|Drug|Sodium Thiosulfate|Given IV
1762842|NCT00293488|Drug|polyamine analogue PG11047|
1762843|NCT00293501|Drug|tinzaparin sodium|
1762844|NCT00293514|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|
1762845|NCT00293527|Drug|Interferon Alpha-2b|
1762846|NCT00293540|Procedure|oophorectomy|Excision of an ovary
1762847|NCT00293540|Drug|Tamoxifen|20 mg orally every day
1762848|NCT00293553|Procedure|Electronic Barostat|
1762849|NCT00293579|Drug|Pemetrexed|500 mg/m2 IV every 3 weeks for 6 cycles
1762850|NCT00293592|Drug|Dexamethasone|1 mg per kg as a single dose before initiation of cardiopulmonary bypass
1762851|NCT00293605|Procedure|Total Hip Replacement|Implantation of one of 3 stem designs
1762852|NCT00293618|Device|Automatic Risk Presentation in the operating room|Automatic calculation and presentation of a patient's individual predicted PONV risk by the anesthesia information management system during the entire procedure
1762853|NCT00293618|Other|Education|Specific information is provided to the intervention group: about PONV, about the prediction model. While the Usual Care group only receives information about the study purposes
1762854|NCT00293618|Other|Feedback|Feedback about the physician's personal performance on prevention of PONV
1762855|NCT00293631|Drug|Lornoxicam 8 mg|
1762856|NCT00293631|Drug|Lornoxicam 16 mg|
1762857|NCT00293631|Drug|Ketorolac 30 mg|
1762858|NCT00293631|Drug|Placebo|
1762859|NCT00293644|Drug|Diclectin®|Participants will begin with an initial dose of 20mg (2 tablets), taken at bedtime. The dose of Diclectin® will be adjusted to match symptoms.
1762860|NCT00293657|Drug|Lornoxicam 8 mg|
1762861|NCT00293657|Drug|Lornoxicam 16 mg|
1762862|NCT00293657|Drug|Placebo|
1762863|NCT00293670|Drug|Goserelin (Zoladex)|
1762864|NCT00293683|Device|Insorb absorbable skin staple|
1762865|NCT00293696|Drug|bicalutamide (Casodex), goserelin (Zoladex)|
1762866|NCT00293709|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
1762867|NCT00293722|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
1762868|NCT00293735|Drug|labetalol (seizure prevention)|"20mg IV (can be increased to an escalating dose of maximum of 80 mg (20mg, 40 mg, 80 mg q 20min) Cumulative max of 240 mg.
20mg labetalol PO every 6 hours"
1762869|NCT00293735|Drug|MgSO4 (seizure prevention)|4-6g bolus over 20 minutes; 1-2 grams/hr Discontinued 24 hours after delivery.
1762870|NCT00293761|Drug|Travoprost, Investigational|One drop in study eye once daily for 13 days
1762871|NCT00293761|Drug|Travoprost (TRAVATAN)|One drop in study eye once daily for 13 days
1762872|NCT00293787|Drug|Travoprost 0.004% / Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
1762873|NCT00293787|Other|Timolol Vehicle|Placebo
1762874|NCT00293787|Drug|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
1762875|NCT00293787|Drug|Timolol Maleate Ophthalmic Solution 0.5%|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
1762876|NCT00293800|Drug|Travoprost 0.004%/Timolol 0.5% Ophthalmic Solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
1762877|NCT00293800|Drug|Latanoprost 0.005% Ophthalmic Solution (XALATAN)|Commercially marketed ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
1762878|NCT00293800|Drug|Timolol 0.5% Ophthalmic Solution|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension
1762879|NCT00293800|Other|Timolol Vehicle|Placebo
1762880|NCT00293813|Drug|Alendronate|Alendronate 70 mg PO QW
1762881|NCT00293813|Drug|Denosumab|denosumab 60 mg SC q 6 mos
1762882|NCT00293813|Drug|Placebo|Placebo for alendronate and placebo for denosumab
1762883|NCT00293826|Drug|AMG 108|50mg via SC (subcutaneous) injection every 4 weeks
1762884|NCT00293826|Drug|AMG 108|250mg via SC (subcutaneous) injection every 4 weeks
1762885|NCT00293826|Drug|AMG 108|125mg via SC (subcutaneous) injection every 4 weeks
1762886|NCT00293826|Drug|Placebo|Placebo via SC (subcutaneous) injection every 4 weeks
1762887|NCT00293839|Drug|oxybutynin chloride|
1762888|NCT00293852|Procedure|Outpatient clinic follow-up|
1762889|NCT00293865|Procedure|sentinel node|detection of the sentinel node in breast cancer
1762890|NCT00293865|Procedure|GAS|
1762891|NCT00293878|Drug|Disodium Ascorbyl Phytostanol Phosphate (FM-VP4)|
1762892|NCT00293891|Drug|Tacrolimus Cream|
1762893|NCT00293904|Biological|CYT005-AllQbG10|
1762894|NCT00293917|Drug|Tacrolimus Cream|
1762895|NCT00293930|Drug|Tacrolimus|
1762896|NCT00293943|Procedure|Pulmonary vein ablation|
1762897|NCT00293969|Drug|Morphine 0.1mg/kg versus morphine 0.15 mg/kg|
1762898|NCT00293982|Behavioral|Physician knowledge of parental expectations for the visit|
1762998|NCT00301028|Drug|Paclitaxel|135 mg/m^2 weekly for 6 courses.
1762899|NCT00293995|Procedure|Laparaoscopic repair, with closure of contralateral patent processus vaginalis|
1762900|NCT00293995|Procedure|open repair|
1762901|NCT00294008|Drug|Risperdal Consta|flexible dosage for 24 months
1762902|NCT00294034|Device|Pacemaker|
1762903|NCT00294047|Biological|Cervarix|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
1762904|NCT00294047|Biological|Placebo control|Subjects were planned to receive three doses of the control vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
1762905|NCT00294073|Procedure|Fascia Iliaca Block|
1762906|NCT00294073|Procedure|Femoral Block (with stimulating catheter)|
1762907|NCT00294073|Procedure|Femoral Block (without stimulating catheter)|
1762908|NCT00294086|Drug|valsartan 160 mg|
1762909|NCT00294086|Drug|valsartan 160 mg BID|
1762910|NCT00294099|Biological|Aluminum hydroxide|Aluminum hydroxide adjuvant.
1762911|NCT00294099|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated monovalent subvirion influenza H5N1 vaccine. Supplied in 0.5 mL unit dose vials as a sterile solution for IM injection. Dosages: 45 mcg, 15 mcg, 7.5, mcg, or 3.75 mcg administered with or without aluminum hydroxide adjuvant on Days 0 and 28.
1762912|NCT00294112|Drug|Prochymal™ adult human mesenchymal stem cells|Cells in plasmalyte and containing dimethylsulfoxide
1762913|NCT00294112|Drug|adult human mesenchymal stem cells|two infusions, one week apart, each comprising adult human mesenchymal stem cells
1762914|NCT00294125|Drug|Flavocoxid|Daily flavocoxid for 12 weeks
1762915|NCT00294125|Drug|Placebo|Daily placebo for 12 weeks
1762916|NCT00294151|Procedure|Vertebroplasty|
1762917|NCT00294164|Drug|Serostim®|Serostim® will be administered subcutaneously (daily or given on alternate days with matched placebo), at a dose based on body weight measured at Baseline, with a maximum daily dose of 4 mg up to Week 24.
1762918|NCT00294164|Drug|Placebo|Matching placebo will be administered subcutaneously (daily or given on alternate days with Serostim®), up to Week 24.
1762919|NCT00294177|Device|atomic force microscopy|
1762920|NCT00294177|Device|dual polarisation interferometry|
1762921|NCT00294190|Drug|Topotecan|Topotecan 6mg/m2 IV weekly x 6 consecutive weeks followed by a 2 week break.
1762922|NCT00294203|Drug|Epoetin Alfa group|Patients enrolled in the study will be randomized to receive either 40,000 units of epoetin alfa on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
1762923|NCT00294203|Other|Placebo group|Patients enrolled in the study will be randomized to receive either 40,000 units of placebo (saline) on day 1 and day 8. Hemoglobin, hematocrit, reticulocyte count, reticulocyte hemoglobin, and immature reticulocyte count will be measured on days 1, 4, 8, and once between post-operative days 20 and 30. Pre-operatively and between post-operative days 20 and 30 patients will complete a quality of live assessment tool (FACT-An) to assess their fatigue related to anemia.
1762924|NCT00294216|Drug|Omega-3-acid ethyl ester 90 (n-3 PUFA)|
1762925|NCT00294229|Procedure|manipulative therapy|
1762926|NCT00294242|Procedure|membrane sweeping|
1762927|NCT00294255|Drug|Risperidone|risperidone will be administered 1-3mg pills, each night, for up to 20 weeks
1762928|NCT00294268|Behavioral|cognitive behavioural therapy|20 weekly sessions of CBT integrated with motivational enhancement strategies
1762929|NCT00294281|Device|Vagus Nerve Stimulation (VNS) Therapy|The VNS Therapy System Pulse Generator is an implantable, multi-programmable bipolar pulse generator. The pulse generator will deliver electrical signals to the vagus nerve via bipolar leads. A programming wand and software system enable non-invasive programming, functional assessments, interrogation, and data retrieval.
1762930|NCT00294294|Biological|Prevenar|
1762931|NCT00294294|Biological|Infanrix hexa|
1762932|NCT00294307|Behavioral|Augmented Standard Care (ASC)|Standard hospital care and, if referred, home care plus early identification of CI during the patients' hospitalization by trained research assistants with immediate verbal feedback and documentation to patients' primary nurses, attending physicians and discharge planners [low intensity];
1762933|NCT00294307|Behavioral|Resource Nurse Care (RNC)|Standard hospital and, if referred, home care plus early identification of CI during the patient's hospitalization (ASC) and hospital care by RNs trained in the use of expert clinical guidelines developed to enhance the care management of hospitalized cognitively impaired elders and to facilitate their transition from hospital to home [medium intensity];.
1762934|NCT00294307|Behavioral|Advanced Practice Nurse Care (APNC)|Standard hospital care plus ASC and transitional care starting in the hospital and substituting for standard home care and provided by Advanced Practice Nurses (APNs) with advanced training in the management of CI patients using an evidence-based protocol designed specifically for this patient group and their caregivers [high intensity].
1762935|NCT00294320|Drug|Aldara (Imiquimod)|250mg of Imiquimod cream for application once daily 3 times per week.
1762936|NCT00294320|Other|Vehicle cream|250mg vehicle cream for application once daily 3 times per week.
1762937|NCT00294346|Drug|AV608|
1762938|NCT00294359|Drug|Mitomycin C; Capecitabine; Bevacizumab|
1762939|NCT00294372|Drug|BILR 355 BS|
1762940|NCT00294372|Drug|Placebo|
1762941|NCT00294385|Drug|Docetaxel|
1762942|NCT00294385|Drug|Gemcitabine, Docetaxel|Arm A (concomitant arm), Gemcitabine 1000 mglm2 will be administered intravenously on Days 1 and 8, repeated on Day 22. Docetaxel 75 mg/m2 will be given on Day 8 (before Gemcitabine), repeated on Day 22. This 3-week schedule defines a cycle of treatment for this arm. Overall 8 cycles will be administered.
1762943|NCT00294385|Drug|Docetaxel|rm B (sequential arm) four cycles of Docetaxel 100 mg/m2 an Day 1, repeated an Day 22, followed by four cycles of Gemcitabine 1250 mg/m2 an a Day 1 and 8, repeated an Day 22, will be given. Both drugs will be administered in a 3-week schedule.
1762999|NCT00301028|Procedure|Conventional Surgery|Following induction in second part of study.
1763000|NCT00301028|Radiation|Radiation Therapy|Following induction in second part of study.
1762944|NCT00294398|Other|ICS Prescription + Standard Asthma ED Discharge Therapy|"Subjects are given a prescription for a 30 day supply of an inhaled corticosteroid based on age:
1-4 year olds Budesonide 0.5mg via nebulizer once daily; 5-11 year olds Fluticasone propionate 44mcg 2 puffs via spacer twice daily; 12-18 year olds Fluticasone propionate 110mcg 2 puffs via spacer twice daily"
1762945|NCT00294398|Other|Standard Asthma ED Discharge Therapy|Subjects are instructed to use albuterol as needed (up to every 4 hours), may be prescribed prednisone and to follow-up with their primary doctor in 3-5 days. All view an educational video about asthma control and are provided a home nebulizer if needed.
1762946|NCT00294411|Procedure|elective cesarean section|
1762947|NCT00294424|Procedure|Short waiting time|
1762948|NCT00294424|Procedure|Non-fixed waiting time|
1762949|NCT00294437|Drug|Zometa|Zometa® (zoledronic acid) in 100ml of calcium free solution i.v. as a 15 minute infusion every 3 months
1762950|NCT00294450|Device|Fistula Pouching System|3 different sizes of fistula pounching system
1762951|NCT00294463|Drug|Tibolone|
1762952|NCT00294463|Drug|Estradiol|
1762953|NCT00294463|Drug|Estradiol + Medroxy Progesterone Acetate|
1762954|NCT00294476|Drug|IVIG|
1762955|NCT00294476|Procedure|Biological Therapy|
1762956|NCT00294502|Drug|Gentamycin/citrate, Minocycline/EDTA|
1762957|NCT00294515|Drug|Valganciclovir|900 mg orally daily for up to 100 days
1762958|NCT00294515|Drug|Valganciclovir|900 mg orally daily for up to 200 days
1762959|NCT00294528|Device|Nexgen LPS-flex and AGC|
1762960|NCT00294541|Drug|ICA-17043|
1762961|NCT00300716|Drug|Memantine|
1762962|NCT00300729|Drug|Celecoxib|Celecoxib 400 mg twice daily, orally, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
1762963|NCT00300729|Drug|Placebo|One capsule twice daily, starting on the same day as palliative chemotherapy. Maximum duration of treatment is one year. Treatment should be terminated earlier in case of disease progression, unacceptable toxicity, or if the patient wants to stop treatment.
1762964|NCT00300742|Drug|Topiramate|Topiramate up to 300 mg per day.
1762965|NCT00300755|Drug|pantoprazole sodium enteric-coated spheroid|pediatric spheroids taken daily x 8 weeks
1762966|NCT00300768|Drug|2 mg moxidectin|Single-dose, tablet encapsulated for blinding
1762967|NCT00300768|Drug|ivermectin 150 mcg/kg|Single-dose, tablets encapsulated for blinding
1762968|NCT00300768|Drug|4 mg moxidectin|Single dose, tablets encapsulated for blinding
1762969|NCT00300768|Drug|8 mg moxidectin|single dose, tablets encapsulated for blinding
1762970|NCT00300781|Drug|neratinib|
1762971|NCT00300794|Drug|Ketamine|
1762972|NCT00300807|Drug|XTL 6865|
1762973|NCT00300833|Drug|Tirofiban|pci
1762974|NCT00300846|Drug|aripiprazole|Tablets, Oral, 5 mg, 10 mg, 15 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional).
1762975|NCT00300846|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks followed by 12 weeks of Open-Label extension phase (optional)
1762976|NCT00300859|Behavioral|brief motivational intervention|
1762977|NCT00300872|Device|Continuous positive airway pressure (CPAP)|Continuous positive airway pressure (CPAP) - Horizon LT 8001 Continuous positive airway pressure (CPAP) device.
1762978|NCT00300872|Device|Sham Continuous positive airway pressure (CPAP)|Sham Continuous positive airway pressure (CPAP) - Continuous positive airway pressure (CPAP) units set to the lowest pressure (4 cm of water pressure) and 6 extra 4mm holes will be inserted in the collar of the main tubing at the end of the mask to allow air escape and to prevent carbon dioxide rebreathing.
1762979|NCT00300885|Drug|Nexavar (Sorafenib, BAY43-9006) + carboplatin + paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib (Nexavar, BAY43-9006), [400 mg orally, twice daily] on Study Days 2-19 and paclitaxel (P) (200 mg/m2, intravenous (IV)) and carboplatin (C) (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib 400 mg orally twice daily was administered on Days 1-21 of each 21-day cycle.
1762980|NCT00300885|Drug|Carboplatin plus Paclitaxel|Chemotherapy Phase up to 6 cycles: Sorafenib Placebo (2 tablets orally twice daily] on Study Days 2-19 and paclitaxel (200 mg/m2, intravenous (IV)) and carboplatin (area under the curve (AUC) =6 mg/ml*min-1, IV) on Study Day 1. The cycle duration 21 days. Maintenance Phase: Sorafenib Placebo 2 tablets orally twice daily was administered on Days 1-21 of each 21-day cycle.
1762981|NCT00300898|Procedure|Nucleoplasty|
1762982|NCT00300898|Procedure|Percutaneous decompression|
1762983|NCT00300898|Procedure|Intervertebral electrothermal disc decompression (IDET)|
1762984|NCT00300898|Behavioral|Conservative treatment|
1762985|NCT00300911|Drug|Rosiglitazone(drug), cardiac adverse effects|
1762986|NCT00300924|Drug|Rizatriptan co-administered with Acetaminophen|
1762987|NCT00300937|Dietary Supplement|Coenzyme Q10|100 mg oral BID starting at week 20 until delivery
1762988|NCT00300950|Biological|GI-4000|Heat-killed yeast cell transfected with target ras mutation.
1762989|NCT00300950|Drug|Gemcitabine|Chemotherapy
1762990|NCT00300963|Drug|Talnetant|
1762991|NCT00300976|Behavioral|Lifestyle consultation: weight control, diet, exercise|"Behavioral: Lifestyle modification including weight control, with the goal of BMI 22.
Drug: Drugs are added in a stepwise manner to control blood glucose, blood pressure and lipid metabolism, using mainly hypoglycemic drugs, ACEI/ARB and statins, respectively. Management goals are: HbA1c < 6.2%, BP < 120/75 mmHg, HDL-C 40 mg/dL , LDL-C < 80 mg/dL, TG < 120 mg/dL.
Follow-up study (Not provided)"
1762992|NCT00300976|Behavioral|Lifestyle consultation: weight control, diet, exercise|"Behavioral and Drug: The physician in charge is to administer appropriate therapy in accordance with the Guidelines.
Follow-up study (Not provided)"
1762993|NCT00300989|Device|Inion OTPS Biodegradable Fixation System|
1762994|NCT00301002|Drug|Alefacept|
1762995|NCT00301015|Device|Rapid diagnostic test for malaria|We used Paracheck Pf® (Orchid Biomedical Systems, India) as rapid diagnostic test in this trial
1762996|NCT00301028|Biological|Cetuximab|Beginning weekly dose 400 mg/m^2 IV over 1-2 hours, and 250 mg/m^2 weeks 2-6.
1762997|NCT00301028|Drug|Carboplatin|AUC 2 weekly for 6 courses.
1763001|NCT00304161|Drug|Atomoxetine|40 to 80 mg orally once daily for 8 weeks
1763002|NCT00304161|Drug|Placebo|40 to 80 mg orally once daily for 8 weeks
1763003|NCT00304174|Behavioral|Motivation to eat|Participants will use a computer program to earn food (a yogurt shake) by tapping on the keyboard. More taps on the keyboard will result in a larger amount of food earned by the end of the day. Once experimentation is complete on Day 1, participants will be instructed to eat as much as they can. On Days 2 and 3, participants will be given a small serving of the yogurt shake prior to beginning the computer task. Following the computer task, they will be instructed to either eat until they are comfortable (without restricting or binging), or eat as much as they can.
1763006|NCT00304200|Drug|Temozolomide and SU11248|First Cohort: Temozolomide 100 mg/m2 orally week 1 and week 3 of a 28-day cycle; SU11248, 25 mg/day orally on weeks 2, 3, and 4 or a 28 day cycle.
1763007|NCT00304213|Drug|Testosterone|
1763008|NCT00304226|Drug|valsartan|
1763009|NCT00304226|Drug|amlodipine|
1763010|NCT00304239|Procedure|Photodynamic therapy with methyl aminolevulinate cream|
1763011|NCT00304252|Drug|Interferon beta-1a|
1763012|NCT00304265|Biological|COVAXIS™: Tetanus, diphtheria, acellular 5-component pertussis, or + inactivated poliovirus vaccine (REPEVAX®)|0.5 mL, Intramuscular
1763013|NCT00304278|Drug|Erlotinib (Tarceva)|150 mg daily X 7 weeks
1763014|NCT00304278|Drug|Intra-arterial Cisplatin (PLAT)|1 dose (150 mg/sq) per week X 4 weeks
1763015|NCT00304278|Radiation|Radiation Therapy (RAD)|5 days per week X 7 weeks
1763016|NCT00304291|Drug|Mitoxantrone|
1763017|NCT00304304|Behavioral|Asthma education|Research assistant worked with CCC staff on asthma prevention
1763018|NCT00304317|Drug|celecoxib|Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.
1763019|NCT00304317|Other|Placebo|Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.
1763021|NCT00304369|Drug|Metronidazole|
1763022|NCT00304382|Biological|Prevnar|0.5 ml IM into each deltoid muscle one time (or two in group PCV-PCV)
1763023|NCT00304382|Biological|Pneumovax|0.5 ml IM one time
1763024|NCT00304421|Drug|rabeprazole|
1763025|NCT00304421|Drug|pantoprazole|
1763026|NCT00304434|Drug|Oseltamivir|
1763027|NCT00304434|Drug|Probenecid|
1763028|NCT00304447|Drug|Mylotarg|
1763029|NCT00304460|Biological|aldesleukin|
1763030|NCT00304473|Drug|Quetiapine fumarate|
1763031|NCT00304499|Drug|Oxybutynin|
1763032|NCT00304512|Drug|AT1001 (migalastat hydrochloride)|25mg capsules every other day for 12 weeks
1763033|NCT00304525|Drug|RAF265|A liquid nonaqueous oral formulation. Switched to a tablet formulations with was 60% bioavailable, relative to the liquid at 50mg dose. The liquid dose will be multiplied by a factor of 1.67 to achieve a comparable tablet dose. Tablets are available in 10mg and 50mg strengths.
1763034|NCT00304538|Drug|very low dose (VLD) glucagon|
1763035|NCT00304551|Drug|peginterferon alfa-2a 180μg|180μg（s.c.）/week for 48 weeks
1763036|NCT00304551|Drug|peginterferon alfa-2a 90μg|90μg(s.c.)/week for 48 weeks
1763037|NCT00304551|Drug|ribavirin|600, 800, or 1,000 mg X 2(p.o.)/day
1763038|NCT00304564|Behavioral|Music Listening|subjects listen to music
1763039|NCT00304577|Procedure|Bilateral recession|
1763040|NCT00304577|Procedure|Unilateral recession and resection|
1763041|NCT00304590|Drug|XL999|Treatment consisted of 8 weekly infusions of 2.4 mg/kg of XL999 with each infusion given over 4 hours, unless drug-related toxicity required a dosing delay or adjustment. In the absence of progressive disease and unacceptable toxicity, subjects may have received XL999 treatment weekly for up to 1 year on this study.
1763042|NCT00304603|Other|No intervention|No treatment was given to the patients as this is an observational study.
1763043|NCT00304616|Drug|Aripiprazole, Solian, Olanzapine, Seroquel, Risperidone|
1763044|NCT00304629|Drug|galantamine|
1763045|NCT00304642|Drug|dapivirine (TMC120) vaginal gel|
1763046|NCT00304655|Drug|Aripiprazole|
1763047|NCT00304668|Drug|dapivirine (TMC120) vaginal gel|
1763048|NCT00304681|Drug|OROS*-Methylphenidate|
1763049|NCT00304707|Drug|Bupropion|300 mg QD
1763050|NCT00304707|Drug|placebo|placebo
1763051|NCT00304720|Drug|Tacrolimus and MMF|
1763052|NCT00304733|Device|cast vs. shoe|
1763053|NCT00304746|Drug|Testosterone gel|AndroGel 2.5g and 5g sachets at doses ranging from 10g/day for duration of trial.
1763054|NCT00304746|Drug|Placebo|Placebo
1763055|NCT00304759|Procedure|7800 cGy/39 fractions in 8 weeks|see above
1763056|NCT00304759|Procedure|6000 cGy/20 fractions in 4 weeks|see above
1763057|NCT00304772|Drug|Fluconazole|400mg/day
1763058|NCT00304772|Drug|Micafungin|150mg/day
1763059|NCT00304785|Drug|latanoprost 0.005%|
1763060|NCT00304785|Drug|Fotil|
1763061|NCT00304785|Drug|placebo|
1763062|NCT00304798|Behavioral|Hospital admission|
1763063|NCT00304811|Drug|Vancomycin|
1763064|NCT00304811|Drug|Vancomycin plus Gentamicin|
1763065|NCT00304811|Drug|Vancomycin plus Rifampin|
1763066|NCT00304811|Drug|Vancomycin plus Gentamicin plus Rifampin|
1763067|NCT00304837|Genetic|pVGI.1 (VEGF-2)|
1763068|NCT00304850|Behavioral|polyamine-free diet|Polyamine-free diet in the 7 days befor surgery
1763069|NCT00304850|Drug|Ketamine or placebo|Peroperative and post operative (48h) ketamine injection
1763070|NCT00304863|Drug|Lactobacillus GG|This arm will receive the additional probiotic of lactobacillus GG
1763135|NCT00305539|Drug|adalimumab|40 mg sc / for 3 months
1763136|NCT00305539|Drug|placebo|placebo
1763137|NCT00305552|Drug|THALIDOMIDE|THALIDOMIDE
1763138|NCT00305565|Device|VNS Therapy|Received output current of 0.25 milliamps (mA)
1763139|NCT00305565|Device|VNS Therapy|Received output current of 0.5-1.0 mA
1763071|NCT00304915|Behavioral|Collaborative Care Interventions|Patients in the intervention group will be supported by a depression collaborative care team that will include a depression nurse care manager, clinical pharmacist, and psychiatrist. The depression nurse care manager will evaluate depression symptom severity, antidepressant side effects, depression and HIV medication adherence every two weeks over the phone during the acute phase of treatment and will record these results in CPRS. After a 50% improvement in depression severity, the intervention subject will move into the continuation phase of treatment and the patient will be contacted every four weeks by the depression nurse case manager.
1763072|NCT00304954|Drug|Intravenous Daclizumab|Participants randomly assigned to intravenous (IV) daclizumab received 8 mg/kg of IV daclizumab at baseline, then 4 mg/kg of IV daclizumab at Week 2 and then 2 mg/kg of IV daclizumab monthly for the rest of the 6-month study.
1763073|NCT00304954|Drug|Intravenous Infliximab|Participants randomized to IV infliximab received 3 mg/kg of IV infliximab monthly for 6 months.
1763074|NCT00304954|Other|Observation|Participants randomly assigned to the observation group were given injections of either bevacizumab (1.25 mg/0.05 mL or 2.5 mg/0.1 mL) or ranibizumab (0.5 mg) if they presented with recurrence of intraretinal or subretinal fluid as seen on Stratus Optical Coherence Tomography.
1763075|NCT00304954|Drug|Oral Rapamycin|Participants randomly assigned to rapamycin received 2 mg in capsule form every other day for 6 months.
1763076|NCT00304980|Drug|ARTEMETHER + LUMEFANTRINE VS. SULFADOXINE + PYRIMETHAMINE|
1763077|NCT00304993|Drug|fenofibrate|
1763078|NCT00304993|Drug|niacin|
1763079|NCT00304993|Drug|rosiglitazone|
1991544|NCT00939835|Drug|Citalopram Hydrobromide|
1763082|NCT00305019|Drug|clevudine|
1763083|NCT00305032|Procedure|gastric balloon insertion|patient would be offered endoscopic gastric balloon insertion
1763084|NCT00305045|Device|Repetitive Transcranial Magnetic Stimulation|Magnetic pulses to specified brain structures.
1763085|NCT00305058|Drug|Morphine 0.05 mg/kg Intravenous|
1763086|NCT00305058|Drug|Hydromorphone 0.0075 mg/kg intravenous|
1763087|NCT00305071|Drug|compound cranberry extract tablet|
1763088|NCT00305084|Drug|NGR-hTNF|0.2, 0.4, 0.8 and 1.6 μg/m²as 60-minute intravenous infusion every 3 weeks
1763089|NCT00305084|Drug|Doxorubicin|75 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion)
1763090|NCT00305097|Behavioral|Decaffeinated coffee|5 cups per day for 8 weeks
1763091|NCT00305097|Behavioral|caffeinated coffee|5 cups per day for 8 weeks
1763092|NCT00305110|Drug|Hydromorphone 2mg intravenous|
1763093|NCT00305149|Procedure|interim therapy scintigraphy study gallium scan or PET/CT|
1763094|NCT00305149|Procedure|"interim gallium or PET/CT"|
1763095|NCT00305162|Drug|Cangrelor (P2Y12 inhibitor)|IV bolus (30 mcg/kg) & infusion (4 mcg/kg/min) initiated prior to PCI, as soon as possible following randomization (after need for PCI is confirmed) but not more than 30 minutes prior to placement of arterial access. Infusion is to continue for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion).
1763096|NCT00305162|Drug|clopidogrel (oral P2Y12 inhibitor)|600 mg active clopidogrel administered as soon as possible following randomization (after need for PCI confirmed), but not more than 30 minutes prior to the placement of the arterial access.
1763097|NCT00305162|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
1763098|NCT00305162|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
1763099|NCT00305162|Drug|Placebo capsules - as soon as possible after randomization|Placebo capsules given as soon as possible after randomization to mimic 600mg clopidogrel dosing
1763100|NCT00305188|Drug|Xaliproden (SR57746A)|oral administration
1763101|NCT00305188|Drug|Placebo|oral administration
1763102|NCT00305188|Drug|Oxaliplatin|IV administration
1763103|NCT00305188|Drug|5-Fluorouracil|IV administration
1763104|NCT00305188|Drug|Leucovorin|IV administration
1763105|NCT00305201|Drug|pravastatin|
1763106|NCT00305214|Procedure|T Wave Alternans Test|
1763107|NCT00305227|Drug|Lactin-V|
1763108|NCT00305227|Drug|Placebo|
1763109|NCT00305240|Procedure|T Wave Alternans Test|
1763110|NCT00305253|Device|Non-pneumatic Anti-shock Garment (NASG)|In the Post-Intrevention phase of the study, the NASG will be used when a patient meets the study criteria.
1763111|NCT00305266|Drug|intravenous gammaglobulin|individual dose
1763112|NCT00305279|Other|Dietary|Dietary
1763113|NCT00305279|Other|Dietary|Dietary
1763114|NCT00305279|Other|Dietary|Dietary
1763115|NCT00305292|Drug|Modafinil-Alcohol Interactions|
1763116|NCT00305331|Drug|Domperidone (drug)|
1763117|NCT00305344|Procedure|Autologous Umbilical Cord Blood Transfusion|Cord Blood infusion
1763118|NCT00305344|Biological|Cord blood|Develop Cord blood vaccine
1763119|NCT00305370|Drug|Aripiprazole|
1763120|NCT00305383|Drug|Viramidine|
1763121|NCT00305383|Drug|Peginterferon alfa-2b|
1763122|NCT00305396|Drug|Sirolimus|
1763123|NCT00305409|Drug|Synbiotic (Synergy I / B.longum)|
1763124|NCT00305422|Drug|Quetiapine fumarate|
1763125|NCT00305422|Drug|Risperidone|
1763126|NCT00305435|Drug|Romiplostim (AMG-531)|Romiplostim (AMG-531)
1763127|NCT00305448|Drug|Fulvestrant|250 intramuscular injection
1763128|NCT00305448|Drug|Fulvestrant|500 mg intramuscular injection
1763129|NCT00305461|Drug|Ciclesonide|Effect of Ciclesonide on Quality of Life
1763130|NCT00305474|Drug|Risperidone|Risperidone will be given in low dosage to a random sample of family members of Schizophrenic patients
1763131|NCT00305487|Drug|Ciclesonide nasal spray|
1763132|NCT00305500|Drug|escitalopram|
1763133|NCT00305513|Procedure|The phasic alerting treatment|
1763134|NCT00305526|Device|Contak Renewal (CRT-D)|
1991546|NCT00939926|Drug|Risperidone|
1763140|NCT00305565|Device|VNS Therapy|Received output current of 1.0-1.5 mA
1763141|NCT00305578|Drug|Memantine|Memantine will be given orally. Subjects will be started at a dose of 5 mg for the first week and then increased by 5 mg every week up to a maximum of 20 mg depending on response and tolerance and will be kept at that level for the rest of the study. This is an 8 week study.
1763142|NCT00305578|Drug|Placebo|No active medication, only placebo
1763143|NCT00305591|Drug|l-ornithine l-aspartate|
1763144|NCT00305604|Drug|sitagliptin phosphate|Once daily (q.d.) administration of sitagliptin 100 mg tablet (or 50 mg based on creatinine clearance). For up to a 24-wk treatment period.
1763145|NCT00305604|Drug|Comparator: Placebo|sitagliptin matching placebo for up to a 24-wk treatment period.
1763146|NCT00305617|Other|antitumor drug screening assay|
1763147|NCT00305630|Drug|Periocular injection of triamcinolone acetonide 40mg|
1763148|NCT00305643|Drug|Capecitabine|Initial dose of 750-1500 mg/m^2 orally twice a day for each 21 day cycle.
1763149|NCT00305643|Drug|Celecoxib|200 mg given orally twice a day for each 21 day cycle.
1763150|NCT00305643|Procedure|Radiation Therapy|Some patients may undergo radiation therapy 5 days a week for 5-6 weeks, and receive oral capecitabine twice daily 5 days a week. Following completion of radiotherapy, patients may continue oral capecitabine once daily on days 1-14.
1763151|NCT00305643|Drug|Placebo|Oral placebo twice daily on days 1-21
1763152|NCT00305656|Drug|cediranib maleate|Given orally
1763153|NCT00305669|Biological|sargramostim|
1763154|NCT00305669|Other|immunohistochemistry staining method|
1763155|NCT00305669|Other|immunological diagnostic method|
1763156|NCT00305669|Other|laboratory biomarker analysis|
1763157|NCT00305669|Procedure|conventional surgery|
1763158|NCT00305669|Procedure|neoadjuvant therapy|
1763159|NCT00305682|Biological|anti-thymocyte globulin|Equine ATG dose is 15 mg/kg intravenously (IV) every 12 hours for 6 doses on days -6, - 5, and -4.
1763160|NCT00305682|Drug|cyclophosphamide|Cyclophosphamide 50mg/kg x 1 to be administered IV over 2 hours with high volume fluid flush on day -6.
1763161|NCT00305682|Drug|Fludarabine|Fludarabine 40 mg/m2/day or 30 mg/m2/day intravenously (IV) as one hour infusion x 5 days, on day -6 to -2.
1763162|NCT00305682|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) 3 gram/day for patients who are ≥ 40 kg divided in 2 or 3 doses. Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours.
1763163|NCT00305682|Procedure|umbilical cord blood transplantation|One or 2 UCB units may be infused to achieve the required cell dose.
1763164|NCT00305682|Radiation|total body irradiation|Administered Day -1, 200 cGy
1763165|NCT00305682|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL. Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
1763166|NCT00305695|Other|Laboratory Biomarker Analysis|Correlative studies
1763167|NCT00305695|Drug|Zoledronic Acid|Given IV
1763168|NCT00305708|Biological|anti-thymocyte globulin|
1763169|NCT00305708|Drug|busulfan|
1763170|NCT00305708|Drug|fludarabine phosphate|
1763171|NCT00305708|Procedure|allogeneic bone marrow transplantation|
1763172|NCT00305708|Procedure|peripheral blood stem cell transplantation|
1763173|NCT00305708|Procedure|umbilical cord blood transplantation|
1763174|NCT00305708|Radiation|radiation therapy|
1763175|NCT00305734|Drug|bortezomib|Given IV
1763176|NCT00305734|Drug|gemcitabine hydrochloride|Given IV
1763177|NCT00305734|Other|laboratory biomarker analysis|Correlative studies
1763178|NCT00305747|Drug|BR-DIM|75 mg orally (po) twice daily. May continue treatment for 12 months, however patients will be taken off study if their disease progresses, or have intolerable side effects.
1763179|NCT00305760|Drug|Cetuximab|Cetuximab will be administered at an initial dose of 400 mg/m2, followed by weekly doses of 250 mg/m2 for a total of 6 cycles that last 3 weeks each.
1763180|NCT00305760|Biological|Pancreatic tumor vaccine|Vaccine will be administered one day after cyclophosphamide (day 1) every three weeks for 6 cycles.
1763181|NCT00305760|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m2 will be administered one day prior to vaccination (day 0) every three weeks for 6 cycles.
1763182|NCT00305773|Drug|vorinostat|Given orally once daily
1763183|NCT00305773|Drug|vorinostat|Given orally three times daily
1763184|NCT00305786|Drug|gemcitabine hydrochloride|
1763185|NCT00305786|Drug|oxaliplatin|
1763186|NCT00305799|Procedure|management of therapy complications|Patients will complete three self-reported questionnaires including the Peripheral Neuropathy Scale, Hearing Handicap Inventory for Adults, and Dizziness Handicap Inventory. Patients will also be asked a series of questions regarding symptoms or complaints about hearing changes, tinnitus, and dizziness that they may have experienced prior to, during, and after completion of chemotherapy. Patients will also undergo a hearing test.
1763187|NCT00305812|Drug|dexamethasone|
1763188|NCT00305812|Drug|lenalidomide|
1763189|NCT00305812|Drug|melphalan|
1763190|NCT00305825|Biological|bevacizumab|
1763191|NCT00305825|Drug|letrozole|
1763192|NCT00305838|Drug|tamoxifen citrate|
1763193|NCT00305838|Other|diagnostic laboratory biomarker analysis|
1763194|NCT00305851|Procedure|music therapy (books on tape)|
1763195|NCT00305851|Procedure|psychosocial assessment and care|
1763196|NCT00305851|Procedure|quality-of-life assessment|
1763197|NCT00305851|Behavioral|Music Video|Song writing, recording the song with a digital accompaniment track, completing a video layout worksheet (determining the contents of the video), taking photos or making drawings for the video, and viewing clip art and pictures on a computer.
1763198|NCT00305864|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
1763199|NCT00305864|Drug|temozolomide|Given orally
1763200|NCT00305864|Drug|motexafin gadolinium|Given IV
1763201|NCT00305877|Biological|cetuximab|Given IV
1763202|NCT00305877|Drug|gemcitabine hydrochloride|Given IV
1763203|NCT00305877|Drug|capecitabine|Given orally
1763204|NCT00305877|Radiation|radiation therapy|Undergo radiation therapy
1763205|NCT00305877|Biological|bevacizumab|Given IV
1763206|NCT00305877|Other|laboratory biomarker analysis|Correlative studies
1763207|NCT00305890|Behavioral|Lifestyle Behavioral Weight Management Program|The lifestyle behavioral weight management program will focus on lifestyle, exercise, attitudes, relationships, and nutrition. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
1763208|NCT00305890|Behavioral|Pain-Coping Skills Training|The pain-coping skills training will focus on minimizing maladaptive over-reactions and enhancing adaptive strategies to control and decrease pain. Participants will attend 12 weekly group sessions, followed by 6 every-other-week group sessions.
1763209|NCT00305890|Other|Standard Care|Standard care will include routine medical care.
1763210|NCT00305903|Drug|Rivastigmine, memantine|
1763211|NCT00305916|Procedure|Multislice spiral computed tomography coronary angiography|
1763212|NCT00305916|Procedure|conventional coronary angiography|
1763213|NCT00305929|Drug|Treatment with Tookad VTP|
1763214|NCT00305929|Drug|Treatment with Tookad VTP|Tookad 2 mg/kg
1763215|NCT00305929|Drug|Treatment with Tookad VTP|2 mg/kg
1763216|NCT00305942|Drug|Topotecan|Topotecan 4mg/m2 IV on days 1, 8.
1763217|NCT00305942|Drug|carboplatin|Carboplatin AUC=5 IV day 1 only .
1763218|NCT00305955|Device|Spectacles|optimal spectacle correction
1763219|NCT00305968|Behavioral|patient education|Patient education group
1763220|NCT00306020|Drug|topical morphine|
1763221|NCT00306033|Drug|Intravenous ImmuneGlobulin|
1763222|NCT00306046|Drug|Bisphosphonate treatment|
1763223|NCT00306059|Procedure|Early goal directed therapy during 6 hours after occurence of the early phase of acute kidney injury|Directed therapy during 6 hours after occurence of the early phase of acute kidney injury.
1763224|NCT00306072|Drug|nutritional herbal extract from Salacia oblonga|
1763225|NCT00306085|Genetic|Autologous bone marrow cells|
1763227|NCT00306111|Drug|pegfilgrastim|Single dose (6mg) one day after chemotherapy
1763228|NCT00306124|Drug|Levodopa|
1763229|NCT00306137|Drug|Trasylol (Aprotinin, BAYA0128)|"Subjects successfully meeting all screening criteria will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The aprotinin was supplied in infusion vials of 200mL solution containing 2,000,000 KIU (10,000 KIU/mL) in 0.9% sodium chloride.
Subjects will be stratified into one of the 4 following strata:
Stratum 1: complete primary pneumonectomy
Stratum II: decortication or completion pneumonectomy
Stratum III: esophagectomy by transhiatal approach
Stratum IV: esophagectomy by transthoracic approach"
1763230|NCT00306137|Drug|Placebo|Placebo solution was supplied in identical vials and will consist of 200mL of 0.9% sodium chloride.
1763231|NCT00306150|Drug|Trasylol (Aprotinin, BAYA0128)|Subjects will be randomized to receive an infusion of aprotinin (a test dose followed by a loading dose of 2 million KIU before skin incision followed by 500,000 KIU/hour until the end of surgery) or matching placebo. The maximal dose of aprotinin, that can be administered is 7,000,000 KIU, regardless of the duration of the operation. When a total of 7 million has been reached the administration of aprotinin must be discontinued.
1763232|NCT00306150|Drug|Placebo|Placebo is used according to the description of Arm 1
1763236|NCT00306189|Drug|100 mg AMG 162|100 mg AMG 162 (denosumab) SC every 6 months
1763237|NCT00306189|Drug|60 mg AMG 162|60 mg AMG 162 (denosumab) SC every 6 months
1763238|NCT00306189|Drug|14 mg AMG 162|14 mg AMG 162 (denosumab) SC every 6 months
1763239|NCT00306189|Drug|Placebo|Placebo SC every 6 months
1763240|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. Once daily (QD), as long as clinical benefit was maintained.
Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after end-of-treatment (EOT)."
1763241|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose Level 2 of 80 mg/m^2. QD, as long as clinical benefit was maintained.
Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
1763298|NCT00291525|Device|On-X Valve with Standard warfarin Therapy|Valve replacement with standard dosage warfarin
1763299|NCT00291538|Drug|bortezomib|
1763300|NCT00291551|Device|Placement of the PVSS Implant|Implant is placed on epicardial surface of the heart surrounding both the right and left ventricles, to provide mechanical support to the ventricular walls.
1763301|NCT00291564|Device|Cardiac Resynchronization Therapy Device|
1763302|NCT00291577|Drug|Sunitinib (Sutent)|Sunitinib (Sutent) 37.5 mg in schedule 2/1; Sunitinib (Sutent) 37.5 mg in continuous dosing (post discontinuation of axotere) and in accordance with Investigator decision
1763303|NCT00291577|Drug|Taxotere|Taxotere 75 mg/m2 iv, once every 3 weeks
1763242|NCT00306202|Drug|Dasatinib|"Tablets, Oral, If necessary in participants who could not swallow, tablets were dispersed into 30 cc of 100% fruit juice with no preservatives (minute maid lemonade or orange juice or apple juice). Starting Dose Level of 60 mg/m^2; Escalated/Dose level 2 of 80 mg/m^2, Escalated/Dose level 3 of 100 mg/m^2, and Escalated/Dose level 4 of 120 mg/m^2. QD, as long as clinical benefit was maintained.
Intra-participant dose escalation was allowed based on tolerance and on individual response. The starting dose for subsequent participants in a stratum may have been escalated depending on safety, assessed by prior intra-participant dose-escalation, and lack of efficacy in previous participants. Treatment courses were defined as 3 weeks (21 days plus any required delay); for participants who stayed on treatment > 12 months, courses after 12 months were defined in quartiles of 13 weeks. Participants were to be followed until death or up to 5 years after EOT."
1763243|NCT00306215|Drug|CCX282-B|CCX282-B or placebo capsules
1763244|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with no infusion of tirofiban 120 minutes after fibrinolysis
1763245|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a bare-metal stent with infusion of tirofiban 120 minutes after fibrinolysis
1763246|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with no infusion of tirofiban 120 minutes after fibrinolysis
1763247|NCT00306228|Procedure|Postfibrinolysis percutaneous coronary intervention|implantation of a paclitaxel eluting-stent with infusion of tirofiban 120 minutes after fibrinolysis
1763248|NCT00306241|Biological|HPV-16/18 L1 VLP AS04|
1763249|NCT00306254|Drug|PD 0348292|
1763250|NCT00306254|Drug|Enoxaparin|
1763251|NCT00306267|Drug|epoetin alfa|
1763252|NCT00306280|Device|Phototherapy|
1763254|NCT00306306|Device|Reprieve Endovascular Temperature Therapy System|
1763255|NCT00306319|Drug|moxifloxacin|
1763256|NCT00306332|Procedure|T-cell and B-cell depletion|
1763257|NCT00306345|Behavioral|Outreach|
1763258|NCT00306358|Drug|Vitamin B12 (Cyanocobalamin)|
1763259|NCT00306371|Device|1450nm diode laser|
1763260|NCT00306384|Drug|Alogliptin|Alogliptin tablets.
1763261|NCT00306397|Drug|Rapamycin|Sirolimus perorally following kidney transplantation, randomisation after protocol biopsy at months three to a) Sirolimus - MF- or b) low dose tacrolimus - sirolimus -MMF -
1763262|NCT00306410|Drug|colecalciferol|
1763263|NCT00306423|Procedure|Other: Exercise|exercise 3 times per week for 12 weeks
1763264|NCT00306436|Procedure|comprehensive management|
1763265|NCT00306449|Behavioral|Small group seminar-based educational intervention|
1991550|NCT00924729|Drug|Moxifloxacin 0.5% ophthalmic solution|Administer moxifloxacin study drug prior to cataract surgery.
1991551|NCT00924729|Drug|Besifloxacin 0.6% ophthalmic suspension|Administer besifloxacin study drug prior to cataract surgery.
1763268|NCT00306475|Drug|divalproex sodium ER|divalproex sodium ER1000 mg
1763269|NCT00306475|Drug|placebo|placebo identical in appearance to active comparator
1763270|NCT00306488|Drug|OT-551 antioxidant eye drop|0.45% concentration of OT-551 eye drops were given three times a day on participants with geographic atrophy area for up to three years. Participants had one eye randomized to receive the eye drop and the fellow eye was observed.
1763271|NCT00306501|Procedure|Swallowing Training|Swallowing Training with press of button
1763272|NCT00306514|Biological|CYT004-MelQbG10|
1763273|NCT00306527|Biological|Cell culture derived influenza vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
1763274|NCT00306527|Biological|egg-derived influenza subunit vaccine|as a single IM injection of 0.5 ml in the deltoid muscle, preferably of the non-dominant arm
1763275|NCT00306540|Drug|Quetiapine Fumarate|oral flexible dose
1763276|NCT00306540|Drug|quetiapine fumarate placebo|oral 0 mg
1763277|NCT00306553|Biological|CYT004-MelQbG10|
1763278|NCT00306566|Biological|CYT004-MelQbG10|
1763279|NCT00306592|Biological|BG00002 (natalizumab)|
1763280|NCT00306605|Behavioral|Questionnaire|Participants will be asked to complete a questionnaire 3 times throughout the first 5 weeks after their infant's birth / hospitalization
1763281|NCT00306618|Drug|Panzem Nanocrystal Colloidal Dispersion|Panzem NCD suspension, 100 mg/mL, four times daily continuous dosing
1763282|NCT00306631|Drug|MKC-1|Oral capsules, 30 mg and 100 mg capsule strengths; administered twice daily for 14 days in a 28 day cycle
1763283|NCT00306644|Drug|Rosiglitazone|study drug
1763284|NCT00306657|Procedure|Optic nerve sheath fenestration|
1763285|NCT00306670|Drug|Rituxan|Acquired Hemophilia A Patients Who Have Developed Anti-Factor VIII Antibodies
1763286|NCT00306670|Drug|prednisone|<30 mg/day
1763287|NCT00306683|Drug|DIAZOXIDE|
1763288|NCT00291447|Drug|ch806|
1763289|NCT00291447|Drug|111-Indium-ch806|
1763290|NCT00291460|Device|inspiratory muscle training|
1763291|NCT00291473|Drug|CHP-HER2, CHP-NY-ESO-1|
1763292|NCT00291486|Drug|Capecitabine|Capecitabine will be administered at doses between 1000 and 1250 mg/m2/day depending on assigned dose level for 14 days per 21 day cycle. Daily doses may be rounded to the nearest 150mg.
1763293|NCT00291486|Drug|131I-huA33 (131-Iodine on humanised monoclonal antibody A33)|All patients will receive a scout dose of 5 mg huA33 conjugated to 5-8 mCi 131I. The therapy dose of 131I-huA33 will comprise a constant protein dose of 10 mg/m2 huA33 regardless of dose level. The 131I therapy dose will be determined by the assigned dose level (i.e. 20, 30 or 40 mCi/m2 131I).
1763294|NCT00291499|Drug|Chondroitin 4&6 sulfate (Condrosulf)|800 mg/day for 6 months
1763295|NCT00291499|Other|Placebo|800 mg placebo/day for 6 months
1763296|NCT00291512|Behavioral|Theory-based counseling program|
1763297|NCT00291525|Device|On-X valve using reduced anticoagulation|Valve replacement with antiplatelet agents or lowered warfarin
1763304|NCT00291590|Behavioral|DHEP|
1763305|NCT00291603|Device|FX-class of dialyser|
1763306|NCT00291616|Drug|Pegylated Interferon-alpha2a|180 microgram s.c. injection weekly
1763307|NCT00291616|Drug|Thymosin alpha1 & Pegylated Interferon-alpha2a|Pegylated interferon 180 microgram s.c. injection weekly Thymosin 1.6 mg s.c. injection twice per week
1763308|NCT00291629|Drug|G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
1763309|NCT00291629|Procedure|collection of mobilized peripheral blood stem cells|
1763310|NCT00291629|Procedure|Intracoronary infusion of mobilized cells|
1763312|NCT00291655|Drug|Levetiracetam|500 mg oral tablets,1000 - 3000 mg/day, twice a day (BID), duration of the study
1763313|NCT00291668|Biological|Certolizumab Pegol|"Active Substance: Certolizumab Pegol
Pharmaceutical Form: Solution for injection in pre-filled syringe
Concentration: 200 mg/mL
Route of Administration: Subcutaneous use"
1763314|NCT00291668|Other|Placebo|"Active Substance: isotonic sodium chloride solution
Pharmaceutical Form: Solution for injection
Concentration: 1 mL
Route of Administration: Subcutaneous use"
1763315|NCT00291694|Drug|celecoxib|Celecoxib 400 mg BID
1763316|NCT00291694|Other|placebo|placebo
1763317|NCT00291707|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. The infusion rate of cetuximab must never exceed 5 mL/min.
1763318|NCT00291707|Drug|Pemetrexed|• Pemetrexed 350-500 mg/m2 IV over 10 minutes (see dose escalation design. Dose will be decreased to 200 mg/m2, if the first dose level of 350 mg/m2 is not tolerable) on days 1 and 22, (and 43 if >6000 cGy to be delivered)
1763319|NCT00291707|Procedure|radiation therapy|• Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1. Radiation will be given M-F for 6-7 consecutives weeks
1763320|NCT00291720|Drug|Spironolactone|All patients receive a 4 week open labeled run in phase of 25mg spironolactone daily after which they are randomized to continue or receive matched placebo for 8 months.
1763321|NCT00291720|Drug|Placebo|matching placebo
1763322|NCT00291733|Drug|Levetiracetam|500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
1763323|NCT00291733|Drug|Placebo|Placebo tabl
1763324|NCT00291746|Drug|Esomeprazole|
1763325|NCT00291746|Procedure|Bravo technique|
1763326|NCT00291759|Drug|Tamoxifen|
1763327|NCT00291759|Drug|Anastrozole|
1763328|NCT00291772|Drug|Pramlintide|Basal and bolus pramlintide subcutaneous infusion
1763329|NCT00291785|Drug|CT-2106|CT-2106 as 10 minute infusion on days 1, 15 & 29 of each 42-day cycle
1763330|NCT00291785|Drug|Folinic acid|Folinic acid 200 mg IV 1 hour after CT-2106 infusion on days 1, 2, 15, 16, 29 and 30
1763331|NCT00291785|Drug|5-FU (fluorouracil)|5-FU following CT-2106 and folinic acid infusions @ 400 mg/m² IV bolus then 5-FU 600 mg/m² as a 22 hour IV infusion on Days 1, 2, 15, 16, 29, and 30.
1763332|NCT00291798|Procedure|rate of remission|
1763333|NCT00291811|Drug|AMD3100 + G-CSF|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
1763334|NCT00291824|Behavioral|Cardiovascular risk factors and willingness to change|
1763335|NCT00291837|Drug|CT-2106|
1763336|NCT00291850|Drug|Paclitaxel, Cisplatin, Pegfilgrastim|
1763337|NCT00291863|Drug|Simvastatin|
1763338|NCT00291876|Biological|Havrix™|2 doses at 12 months interval
1763339|NCT00291889|Biological|Mtb72F/AS02.|
1763340|NCT00297414|Other|No intervention|No study drug was administered to the patients. Data on vital status was obtained for patients with mild cognitive impairment who were treated with galantamine or placebo in previous 3 clinical studies.
1763341|NCT00297427|Procedure|Acupuncture|Acupuncture twice weekly for 6 weeks.
1763342|NCT00297427|Other|Sham acupuncture|Twice a week for 6 weeks
1763343|NCT00297440|Behavioral|Cognitive-behavioral treatment|
1763344|NCT00297440|Behavioral|Exercise|
1763345|NCT00297453|Behavioral|Internet-based smoking treatment|All participants have access to an Internet-based self-help intervention that includes social support through message boards. All participants have access to 10 weeks of nicotine replacement treatment.
1763346|NCT00297453|Behavioral|Individual Counseling|Six individual counseling sessions are provided over a 12 week treatment period. Participants also have access to a 10-week nicotine replacement treatment.
1763347|NCT00297453|Behavioral|self-help|Participants receive a self-help manual and have access to a 10 nicotine replacement treatment.
1763348|NCT00297466|Drug|transdermal nicotine patches|
1763349|NCT00297466|Behavioral|Motivational interview|
1763350|NCT00297479|Behavioral|MBAT Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) using a Mindfulness-Based Addiction Treatment for nicotine dependence
1763351|NCT00297479|Drug|Nicotine|6 weeks of nicotine patch therapy
1763352|NCT00297479|Behavioral|Group Therapy|In-person group therapy/counseling (8 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
1763353|NCT00297479|Behavioral|Individual Therapy|In-person individual counseling (4 sessions over 8 weeks) based upon Treating Tobacco Use and Dependence Clinical Practice Guideline
1763354|NCT00297492|Behavioral|Reduction Phone Counseling|Counseling of smokers to undergo gradual reduction in cigarettes per day prior to quit date. This includes 5 counseling calls: 3 calls focused on reduction prior to the quit date, 1 call two days prior to the quit date to discuss common strategies for preparing to quit, and 1 call two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges during reduction and after the quit date.
1763355|NCT00297492|Behavioral|Abrupt Phone Counseling|Counseling of smokers to set a quit date and not change cigarettes per day prior to quit date. This includes 5 counseling calls: 1 to set a quit date, 1 two days prior to the quit date to discuss common strategies for preparing to quit, and 3 after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
1763356|NCT00297492|Behavioral|Minimal Abrupt Phone Counseling|Minimal counseling to mimic intervention at a primary care office. This includes 2 counseling calls: 1 to set a quit date and 1 two days after the quit date to discuss relapse prevention. Telephone counseling also discusses the proper use of nicotine lozenges after the quit date.
1763357|NCT00297492|Drug|Pre-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.
4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.
Replace each forgone cigarette during reduction with one lozenge. Use additional lozenges to combat cravings to smoke."
1763358|NCT00297492|Drug|Post-Quit Nicotine Lozenges|"2 mg lozenges for participants usually smoke their first cigarette more than 30 minutes after awaking.
4 mg lozenge for participants who usually smoke their first cigarette less than 30 minutes after awaking.
Replace each forgone cigarette while abstinent with one lozenge. Use additional lozenges to combat cravings to smoke."
1763359|NCT00297505|Drug|citalopram|
1763360|NCT00297518|Device|PerioWave|
1763361|NCT00297518|Procedure|Scaling and Root Planing|
1763362|NCT00297531|Device|PerioWave|
1763363|NCT00297531|Procedure|Scaling and Root Planing|
1763364|NCT00297544|Drug|Viagra|
1763365|NCT00297570|Drug|Pegylated Interferon and Imatinib|
1763366|NCT00297583|Drug|Insulin Glulisine|
1763367|NCT00297596|Drug|Trastuzumab|Trastuzumab will be administered as an 8 mg/kg loading dose by intravenous (IV) infusion over 90 minutes on day 1 of cycle 1. Subsequent doses will be administered as a 6 mg/kg IV dose over 30 minutes.
1763368|NCT00297596|Drug|Oxaliplatin|"Oxaliplatin will be administered at a dose of 130 mg/ m2 over 120 minutes on day 1 of each cycle, following standard antiemetic premedications. 21 day cycles.
For the first cycle, trastuzumab will be administered before oxaliplatin; however for subsequent cycles, oxaliplatin will be infused prior to trastuzumab"
1763369|NCT00297635|Device|GlucoDYNAMIX™ intervention system|
1763370|NCT00297635|Device|GlucoMON™ telemetry device|
1763371|NCT00297648|Biological|Certolizumab pegol|Certolizumab pegol (CDP870) 400 mg administered subcutaneously (sc) at Weeks 0, 2 and 4 (induction doses), then every 4 weeks (Q4W) until Week 52. Investigators can escalate dosage to CDP870 400 mg 2-weekly (Q2W) at any time after Week 10 for lack of response/remission. After Week 52 patients can continue to receive treatment until study drug end, either Q4W or Q2W, according to their administration frequency at Week 52.
1763372|NCT00297661|Device|Sirolimus-eluting stent|
1763373|NCT00297661|Device|Paclitaxel-eluting stent|
1763374|NCT00297674|Drug|Intravenous Clarithromycin|
1763375|NCT00297687|Biological|MnB rLP2086|
1763376|NCT00297700|Behavioral|Active referral|
1763377|NCT00297713|Drug|ALTU-238|
1763378|NCT00297726|Behavioral|Self-Management Program|
1763379|NCT00297739|Drug|Risperidone|
1763380|NCT00297752|Drug|ceriumnitrate silversulfadiazine (flammacerium)|
1763381|NCT00297752|Drug|silversulfadiazine (flammazine)|
1763382|NCT00297765|Drug|Tacrolimus, Prograf®|
1763383|NCT00297778|Drug|Pramipexole|Dopamine agonist
1763384|NCT00297778|Other|Placebo|
1763385|NCT00297791|Procedure|surgery|randomized to open or laparoscopic technique
1763386|NCT00297804|Device|TAXUS Express Paclitaxel-Eluting Coronary Stent System|Paclitaxel-Eluting Coronary Stent System
1763387|NCT00297804|Device|Control stent|control stent
1763388|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
1763389|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the study vaccine following a 0,2,6 vaccination schedule.
1763390|NCT00297817|Biological|serogroup B meningococcal vaccine|0.5mL doses in pre-filled syringes. All subjects will receive the placebo following a 0,2,6 vaccination schedule.
1763391|NCT00297830|Drug|Zoledronic acid|Drug is administered through 5 mg intravenous infusion over 20 minutes
1763392|NCT00297830|Drug|Alendronate|Alendronate 70 mg will be taken once a week in the morning at least 30-60 minutes before first meal
1763393|NCT00297830|Other|Placebo Zoledronic Acid|Infusion of placebo zoledronic acid during the first 5 weeks after transplantation
1763394|NCT00297830|Other|Placebo Alendronate|Placebo alendronate 70 mg once weekly
1763395|NCT00297843|Procedure|allergen challenge (grass pollen), nasal lavage|
1763396|NCT00297856|Biological|Boostrix®|Single dose
1763397|NCT00297856|Biological|Td (Tetanus diphtheria) vaccine|Single dose
1763398|NCT00297869|Procedure|Computer-Assisted Decision Support|Electronic warnings when providers prescribe a potentially inappropriate medication or an excessively dosed medication (based on estimated creatinine clearance)
1991553|NCT00925002|Drug|Tafamidis|20 mg oral Fx-1006A daily
1763400|NCT00297895|Procedure|Completion Lymphadenectomy|complete lymph node dissection of lymph node basin with positive node
1763401|NCT00297895|Procedure|Monitoring with nodal ultrasound|serial ultrasound monitoring of SLND positive basin. If recurrence detected, subject has CLND.
1763402|NCT00297921|Drug|tandutinib|
1763403|NCT00297934|Device|Pro-adjuster mechanical spinal manipulative device|
1763404|NCT00297947|Drug|quetiapine|Participant will receive 1200 mg/day of quetiapine in twice daily dosing for 8 weeks.
1763405|NCT00297947|Drug|quetiapine|Participant will receive 600 mg/day of quetiapine for 8 weeks.
1763406|NCT00297960|Drug|ziprasidone or olanzapine|
1763407|NCT00297960|Procedure|hyperinsulinaemic euglycaemic clamp|
1763408|NCT00297960|Procedure|microdialysis (skeletal muscle)|
1763409|NCT00297973|Procedure|Blood pressure measurements|
1763410|NCT00297973|Procedure|Blood samples|
1763411|NCT00297986|Device|Helmet|Evaluation of different interfaces for NPPV
1763412|NCT00298012|Drug|Methotrexate|
1763413|NCT00298025|Drug|Cetrotide®|Cetrotide® will be administered subcutaneously as 3 mg injection when the lead follicle is >=14 mm till r-hCG day. If the subject did not achieve follicular maturation and did not receive r-hCG within 4 days, then the Cetrotide® will be administered at dose of 0.25 mg subcutaneously on successive days until r-hCG day.
1763414|NCT00298025|Drug|Antagon ™|Antagon™ will be administered subcutaneously at a dose of 0.25 mg once daily when the lead follicle is >=14 mm until r-hCG day.
1763415|NCT00298025|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered at a starting dose of 225 international unit (IU) subcutaneously once daily from S1 up to Stimulation Day 5 (S5). Beginning on Stimulation Day 6 (S6), the r-hFSH dose will be individualized to the subject. The minimum and maximum daily doses are 75 IU and 450 IU, respectively until r-hCG day.
1763416|NCT00298025|Drug|Human Menopausal Gonadotropin (hMG)|Human menopausal gonadotropin (hMG) will be administered subcutaneously daily at a dose of 75 IU till r-hCG day. The total daily dose of r-hFSH and hMG combined is not to exceed 450 IU (375 IU r-hFSH and 75 IU hMG).
1763417|NCT00298025|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250 microgram (mcg) subcutaneously when there is at least one follicle of >=18 mm and two additional follicles of >=16 mm with an appropriate plasma estradiol levels for the number and size of the existing follicles. The r-hCG will be administered within 36 hours after the last dose of the r-hFSH/hMG.
1763418|NCT00298038|Drug|Rifaximin|550 mg tablets BID
1763419|NCT00298051|Procedure|Delayed umbilical cord clamping|
1763420|NCT00298064|Genetic|Tissue Repository|
1763421|NCT00298090|Device|StO2 monitoring|placement of the StO2 device/ external noninvasive
1763422|NCT00298129|Device|Ambulatory blood pressure monitoring|
1763423|NCT00298142|Procedure|Usual Care provided by a medical doctor (GP or Neurologist)|
1763424|NCT00298142|Procedure|Usual care plus Physio-/ Manual Therapy|
1763425|NCT00298155|Drug|goserelin with dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd; continue bicalutamide for one more week.
1763426|NCT00298155|Drug|goserelin with bicalutamide and dutasteride|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot) and begin dutasteride 3.5 mg qd.
1763427|NCT00298155|Drug|goserelin with bicalutamide and dutasteride and ketoconazole|Bicalutamide 50 mg qd for one week, inject goserelin 10.8 mg (3-month depot), begin dutasteride 3.5 mg qd and ketoconazole 200 mg tid (with hydrocortisone 30 mg).
1763428|NCT00298168|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
1763429|NCT00298168|Drug|placebo|0.9% normal saline administered IV as a single bolus infusion with 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
1763430|NCT00298168|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion of 1 mg/kg with 10 mg YSPSL in 200 mL Lactated Ringer's for Injection USP total volume administered as an ex vivo flush intra-arterially to donor organ prior to implantation
1763431|NCT00298181|Drug|YSPSL|YSPSL administered intravenously (IV) as a single bolus infusion open-label at 0.07, 0.22, 0.7 or 2.2 mg/kg
1763432|NCT00306696|Drug|Rosiglitazone|
1763433|NCT00306696|Drug|spironolactone|
1763434|NCT00306696|Drug|hydrochlorothiazide|
1763435|NCT00306696|Drug|frusemide|
1763436|NCT00306709|Behavioral|culturally adapted behavior change|Behavior change strategies which have been modified to include spirituality, AA cultural materials and examples woven into the lesson plans, and sustained peer support.
1763437|NCT00306722|Drug|AQUAVAN® (fospropofol disodium) Injection|
1763438|NCT00306735|Drug|Palonosetron|
1763439|NCT00306748|Drug|MD-1100 Acetate|
1763440|NCT00306761|Device|Dynamic Wheelchair Seating System|
1763441|NCT00306774|Dietary Supplement|Vitamin D (cholecalciferol)|2,000 IU vitamin D capsule per day for 2 years
1763442|NCT00306774|Dietary Supplement|Placebo|Placebo capsule per day for 2 years
1763443|NCT00306787|Drug|Famciclovir|Famciclovir 500 mg tablet
1763444|NCT00306787|Drug|Valacyclovir|Valacyclovir 500 mg capsule
1763445|NCT00306787|Drug|Placebo matching famciclovir|Famciclovir placebo, matching in size, color and forms of famciclovir tablet.
1763446|NCT00306787|Drug|Placebo matching valacyclovir|Valacyclovir placebo, matching in size, color and forms of valacyclovir capsule.
1763447|NCT00306800|Procedure|Photodynamic therapy with methyl aminolevulinate cream|
1763448|NCT00306813|Drug|Revlimid|
1763449|NCT00306826|Drug|pioglitazone|
1763450|NCT00306826|Drug|simvastatin|
1763451|NCT00306826|Drug|pioglitazone + simvastatin|
1763452|NCT00306839|Procedure|standardized Lichtenstein technique|
1763453|NCT00306852|Procedure|Baerveldt implant|Patients will be randomized to receive a 350 mm^2 Baerveldt glaucoma implant or a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes)
1763454|NCT00306852|Procedure|Trabeculectomy with mitomycin C|Patients will be randomized to receive either a Trabeculectomy (guarded filtration surgery) with mitomycin C (0.4 mg/ml for 4 minutes) or a 350 mm^2 Baerveldt glaucoma implant
1763455|NCT00306878|Drug|Abatacept|
1763456|NCT00306891|Drug|Cediranib|45 mg oral dose
1763457|NCT00306891|Drug|Cediranib 30 - 90 mg|oral tablet dose escalation
1763458|NCT00306904|Drug|bevasiranib|
1763459|NCT00306917|Device|non-coated femoral hip stem|total hip replacement
1763460|NCT00306917|Device|coated femoral hip stem|total hip replacement
1763461|NCT00306930|Device|Acetabular cup|Acetabular cup replacement
1763462|NCT00306943|Biological|Influsplit SSW®|
1763463|NCT00306956|Behavioral|offer a pacifier|To offer a pacifier to normal newborn infants at 15 days of age
1763464|NCT00306969|Drug|bexarotene|
1763465|NCT00306969|Device|photopheresis|
1763466|NCT00306982|Biological|Fluarix|
1763474|NCT00307008|Biological|Pneumovax 23™|Single dose intramuscular injection
1763475|NCT00307021|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|3-dose intramuscular injection, 2 different formulations
1763476|NCT00310921|Drug|Misoprostol|
1763477|NCT00310934|Drug|methadone|
1763478|NCT00310934|Drug|buprenorphine / methadone sequence|
1763479|NCT00310934|Behavioral|Relapse prevention|
1763480|NCT00310934|Behavioral|Contingency management|
1763481|NCT00310973|Behavioral|Social Network Intervention|
1763482|NCT00310986|Behavioral|Breathing Meditation|
1763483|NCT00310999|Device|Shikani Optical Stylet|
1763484|NCT00311012|Drug|Aliskiren|
1763485|NCT00311025|Procedure|intensive endurance, strength and balance exercises|
1763486|NCT00311038|Drug|ONO-1101|
1763487|NCT00311051|Drug|ramatroban|
1763488|NCT00311051|Drug|montelukast|
1763489|NCT00311064|Behavioral|physical activity|
1763490|NCT00311077|Drug|Insulin Glulisine|
1763491|NCT00311090|Drug|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg
Subcutaneous injection"
1763492|NCT00311090|Drug|Idraparinux sodium|"0.5 mL pre-filled syringe for 2.5 mg
Subcutaneous injection"
1763493|NCT00311090|Drug|Avidin|"100 mg in 10 mg/mL solution
Intravenous infusion for 30 minutes"
1763494|NCT00311090|Drug|Placebo (for Avidin)|"Avidin matching powder in 10 mg/mL solution
Intravenous infusion for 30 minutes"
1763495|NCT00311103|Procedure|Specific clinical care program|The rheumatologists acted as principal care providers in regular visits, home visits and phone contacts. The visits were structured following specific proceedings for the different diagnoses based on previously demonstrated approaches. Such protocols included education and promotion of independence, pharmacological and no pharmacological treatment, and timing of diagnostic tests in a stepwise manner. The program also incorporated administrative duties such as the prescription of medication for the patients. Patients were seen as often as necessary according to the medical rheumatologist decision (until the episode of disability was medically resolved).
1763496|NCT00311116|Drug|Vitamin E|
1763497|NCT00311129|Drug|Fludarabine Phosphate (Fludara)|Injection of rituximab on Day 1 along with 5-consecutive day oral dosing of fludarabine phosphate from Day 1 to Day 5, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
1763498|NCT00311129|Drug|Rituximab|Injection of rituximab on Day 1, followed by an observation period from Day 6 to Day 28 as 1 treatment cycle, 6 cycles will be given. As for patients who has been observed with partial response (PR) or better antitumor effect, any treatment shall not be provided in principle until the status comes to progressive disease (PD)
1763499|NCT00311155|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|Olmesartan medoxomil oral tablets 20 mg for 4 weeks followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 12.5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 5 mg for 4 weeks, followed by, if necessary: Olmesartan medoxomil oral tablets 20 mg + hydrochlorothiazide oral tablets 25 mg + amlodipine oral tablets 10 mg for 4 weeks. All study medications are to be taken once daily. The subject's participation completes when blood pressure goals are achieved.
1763500|NCT00311168|Procedure|VIP On vs VIP Off|
1763501|NCT00311181|Device|Implantable Cardioverter Defibrillator (ICD), Cardiac Resynchronization Therapy (CRT-D)|Patients that are indicated for an ICD or CRT-D receive one of these devices.
1763502|NCT00311194|Behavioral|6 months readmission rate to hospital|
1763503|NCT00311220|Drug|tuberculin for skin test|
1763505|NCT00311259|Drug|Melatonin (drug)|
1763506|NCT00311259|Drug|Laktose|
1763507|NCT00311272|Biological|MelCancerVac|
1763508|NCT00311285|Device|Electrogram (EMG), heart rate variability (HRV), salivary cortisol, goniometry, inclinometry|
1763509|NCT00311298|Dietary Supplement|Multimicronutrients|Randomised, double-blind trial among pulmonary TB patients, except those who are found to be sputum positive and HIV positive. Both arms received a daily biscuit weighing 30 g (4.5 g protein, 615 kJ). The biscuit given to the No micronutrient-arm contained no additional micronutrients. The biscuit given to the Micronutrient-arm contained the following micronutrients: vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg. The intervention was given for 60 days during initial TB treatment.
1763510|NCT00311298|Dietary Supplement|Energy and proteins|Randomised, single-blind trial among sputum-positive HIV-coinfected pulmonary TB patients. Both arms received a daily for biscuit weighing 30 g (4.5 g protein, 615 kJ), with micronutrients (vitamin A 5000 IU, vitamin B1 20 mg, vitamin B2 20 mg, vitamin B6 25 mg, vitamin B12 50 microg, folic acid 0.8 mg, niacin 40 mg, vitamin C 200 mg, vitamin E 60 mg, vitamin D3 5 µg / 200 IU, selenium 0.2 mg, copper 5 mg, and zinc 30 mg). The experimental arm received an additional 5 biscuits without additional micronutrients. Thus, both arms received the same amount of micronutrients. However, the intervention arm received 3690 kJ and 27 g protein per day, while the control arm received 615 kJ and 4.5 g protein. The intervention was given for 60 days during initial TB treatment.
1763511|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. The target trough level of TAC will be maintained at 3-10 ng/mL through to the end of the study.
1763541|NCT00311545|Biological|CNTO 328|Anti-IL-6 chimeric monoclonal antibody
1763542|NCT00311558|Biological|recombinant interferon alfa-2b|SSG x 5 week
1763512|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
1763513|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
1763514|NCT00311311|Drug|sirolimus|"The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol.
On study Day 1 Conversion, the daily dose of TAC will not be taken, and SRL is initiated as a single 5-10 mg loading dose, followed by 3 mg/day on subsequent days, adjusted to maintain a SRL target trough level of 8-15 ng/mL through to month 24 post-transplant, then 5-12 ng/mL to the end of month 36 post-transplant."
1763515|NCT00311311|Drug|tacrolimus|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol TAC should be initiated within 24 hours before or after transplantation or within 14 days of transplantation as per local standard of care and tapered to a target trough level of 3-10 ng/mL by the Pre-Conversion visit at month 3-4 post-transplantation. Reintroduction of TAC or introduction of CsA is not permitted in the SRL Therapy group.
1763516|NCT00311311|Drug|mycophenolate mofetil|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol MMF or MPS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum oral dose of MMF ≥ 500 mg/day or MPS ≥ 360 mg/day by the Pre-Conversion visit at month 3-4 post-transplantation. At the discretion of the investigator, MMF may be changed to MPS, or MPS may be changed to MMF. MMF is to be continued at ≥ 500 mg/day dose or MPS is to be continued at ≥ 360 mg/day dose through to the end of study.
1763517|NCT00311311|Drug|prednisone|The daily dosage and formulation for each study treatment will be chosen by the investigator as medically appropriate for each individual subject, in order to achieve the target levels specified in the protocol CCS should be initiated within 24 hours before or after transplantation or within 14 days of transplantation per local standard of care and tapered to a minimum of 5 mg/day of prednisone orally or the alternate day equivalent by the Pre-Conversion visit at month 3-4 post-transplant. Continue administration of prednisone as per local standard of care to a minimum dose of 2.5 mg/day or alternate day equivalent dose to the end of the study. Withdrawal of CCS is prohibited.
1763518|NCT00311324|Behavioral|Special Intervention|
1763519|NCT00311324|Behavioral|Delayed Intervention|
1763520|NCT00311337|Drug|bortezomib|
1763521|NCT00311350|Drug|MOA-728|
1763522|NCT00311363|Drug|GEn (XP13512)|1200 mg GEn (XP13512) orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
1763523|NCT00311363|Drug|GEn (XP13512)|1200 mg GEn (XP13512), orally, once daily for 24 weeks followed by either 1200 mg GEn (XP13512) or placebo, orally, once daily for an additional 12 weeks
1763524|NCT00311363|Drug|Placebo|Placebo, orally, once daily for 12 weeks following single blind 24-week phase
1763525|NCT00311376|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
1763526|NCT00311376|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U (tx 1) followed by botulinum toxin Type A 300 U (tx 2); injections into detrusor, at > 12 weeks interval
1763527|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (200U)|Placebo (tx 1) followed by botulinum toxin Type A 200 U (tx 2); injections into detrusor, at > 12 weeks interval
1763528|NCT00311376|Other|Normal Saline (Placebo); botulinum toxin Type A (300U)|Placebo (tx 1) followed by botulinum toxin Type A 300 U (tx 2), injections into detrusor, at > 12 weeks interval
1763529|NCT00311389|Drug|Travoprost 0.004%/Timolol maleate 0.5% ophthalmic solution|Investigational ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
1763530|NCT00311389|Drug|Latanoprost 0.005%/Timolol 0.005% ophthalmic solution|Commercially marketed ophthalmic solution intended for the treatment of open-angle glaucoma or ocular hypertension
1763531|NCT00311402|Drug|Aggrenox capsule|extended-release dipyridamole 200 mg plus ASA 50 mg in a capsule, 2 capsules twice daily
1763532|NCT00311402|Other|Acetylsalicylic Acid (ASA)|Acetylsalicylic Acid (ASA) 81 mg, 1 tablet once daily
1763533|NCT00311415|Biological|Meningococcal C conjugate vaccine|"Meningococcal conjugate vaccine, active comparator.
Groups 1 to 3 were given a booster dose in the second year of life at 12-16 months of age"
1763534|NCT00311428|Biological|Influenza|
1763535|NCT00311441|Biological|Tick-Borne Encephalitis vaccine|
1763536|NCT00311454|Drug|T.R.U.E.Test|
1763537|NCT00311467|Drug|Capecitabine, Interferon, Interleukin|"Capecitabine orally from day 1 to 14 at a dose of 1000 mg/m2 twice daily every 21 days.
Interferon-alpha subcutaneously on days 1 + 3 + 5 weeks 1 + 2 +6 + 7,11+12 at a dose of 6 MIU/d.
Interleukin-2 subcutaneously on days 1 to 4 in weeks 3 + 4 +8 + 9,13+14 at a dose of 4.5 MIU/day.
Group B
Patients randomized to group B will receive treatment according to the same treatment schedule and at the same dosages without capecitabine.
Efficacy evaluations will be performed every 14 weeks of treatment in both groups"
1763538|NCT00311480|Biological|Influenza vaccine surface antigen adjuvanted with MF59|
1763539|NCT00311493|Biological|Tick-Borne Encephalitis vaccine|
1763540|NCT00311519|Drug|Hylenex|
1763543|NCT00311558|Drug|sodium stibogluconate|SSG & IFN
1763544|NCT00311558|Drug|SSG & interferon|1 arm study with SSG & interferon
1763545|NCT00311571|Drug|Ethidronate|
1763546|NCT00311571|Behavioral|Physical training|
1763547|NCT00311584|Drug|irinotecan hydrochloride|Given IV
1763548|NCT00311584|Drug|temozolomide|Given IV
1763549|NCT00311597|Procedure|Radiosurgery|single fractionated radiation therapy
1763550|NCT00311610|Drug|SN-38 liposome|38 mg/sq m IV infusion over 30 min q 21 days (1 cycle) until progression
1763551|NCT00311623|Drug|sirolimus|
1763552|NCT00311623|Other|immunohistochemistry staining method|
1763553|NCT00311623|Procedure|neoadjuvant therapy|
1763554|NCT00311636|Drug|cyclophosphamide|
1763555|NCT00311636|Drug|docetaxel|
1763556|NCT00311636|Drug|doxorubicin hydrochloride|
1763557|NCT00311636|Drug|epirubicin hydrochloride|
1763558|NCT00311636|Drug|fluorouracil|
1763559|NCT00311636|Drug|methotrexate|
1763560|NCT00311636|Drug|paclitaxel|
1763561|NCT00311636|Drug|triptorelin|
1763562|NCT00311636|Procedure|adjuvant therapy|
1763563|NCT00311649|Biological|Inactivated Influenza A Vaccine A/H5N1|
1763564|NCT00311662|Drug|Tonabersat|Tablet 40mg daily for 12 weeks
1763565|NCT00311662|Drug|Placebo|Tablet once daily for 12 weeks
1763566|NCT00311675|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Monovalent subvirion H5N1 vaccine (HA of A/Vietnam/1203/04) provided in single-dose vials containing 90-mcg/mL A/H5N1 HA. Dosage is two 90 mcg doses administered intramuscularly separated by approximately 28 days.
1763567|NCT00311688|Drug|Interleukin-2|Biological response modifier in liquid form; dosage of drug will vary by study
1763568|NCT00311714|Drug|CS-8958 formulated as dry powder|
1763569|NCT00311714|Other|Placebo|
1763570|NCT00311727|Biological|Influenza A/H5N1|232 subjects receive Influenza A/H5N1 vaccine as part of DMID protocols 04-063 and 04-076.
1763571|NCT00311740|Drug|Valsartan|
1763572|NCT00311740|Drug|Hydrochlorothiazide|
1763573|NCT00311753|Drug|Certoparin|Low-molecular-weight heparin, Certoparin (3000 U anti-Xa once daily) treatment period of 10 ± 2 days
1763574|NCT00311753|Drug|Heparin|7500 IU of unfractionated heparin administered twice daily during the treatment period of 10 ± 2 days
1763575|NCT00311766|Drug|Thymosin Beta 4|Topical administration, 0.01%, 0.03%, and 0.1% Thymosin Beta 4 gel, qd up to 56 days
1763576|NCT00311766|Drug|Placebo|Topical administration, 0.00% Thymosin Beta 4 gel qd up to 56 days
1763577|NCT00311779|Drug|Spinosad Creme Rinse|
1763578|NCT00311792|Behavioral|LapSimGyn training until expert proficiency level is reached|Two consecutive simulations reaching predefined expert level
1763579|NCT00311792|Behavioral|Traditional clinical education|
1763580|NCT00311805|Biological|Autologous Stem Cells (CD34+)|Intramuscular Injections
1763581|NCT00311818|Drug|Insulin glargine|
1763582|NCT00311831|Behavioral|Standard gastroenteritis education|Subjects in this arm of the study will receive an educational handout on gastroenteritis education.
1763583|NCT00311831|Behavioral|Extensive gastroenteritis education|Subjects in this arm of the study will receive an gastroenteritis educational handout as well a home visitation from a trained counselor.
1763584|NCT00311844|Drug|desloratadine|
1763585|NCT00311857|Drug|Cetuximab|
1763586|NCT00311857|Drug|Temozolomide|
1763587|NCT00311857|Procedure|Radiation therapy|
1763588|NCT00311870|Drug|nisoldipine|
1763589|NCT00311870|Drug|lisinopril|
1763590|NCT00311883|Drug|hydroxychloroquine|
1763591|NCT00311896|Drug|Bemiparin|
1763592|NCT00311896|Drug|Placebo|
1763593|NCT00311909|Device|Thalamic deep brain stimulation|
1763594|NCT00311922|Behavioral|Literacy/Numeracy oriented educational intervention|Comprehensive educational Intervention
1763595|NCT00311922|Behavioral|Control Group|Receives comprehensive education that is not literacy/numeracy sensitive
1763596|NCT00311935|Procedure|method of hernia repair|
1763597|NCT00311948|Behavioral|Telephone counseling + interactive website = more abstinence|
1763598|NCT00311948|Behavioral|Behavioral: interactive website|
1763599|NCT00311961|Drug|Intravenous prednisolone|
1763600|NCT00311961|Drug|Oral prednisolone|
1763601|NCT00311974|Drug|Dihydralazine|
1763602|NCT00311987|Drug|3,5-Diiodothyropropionic acid (DITPA) therapy|
1763603|NCT00312000|Drug|capecitabine-irinotecan|"st line capecitabine 1250 mg/m2 orally b.i.d. on day 1-14
nd line q 3 w irinotecan 350 mg/m2 IV infusion on day 1"
1763604|NCT00312000|Drug|capecitabine+irinotecan (1st line)|q 3 w irinotecan 250 mg/m2 IV infusion in 30 minutes on day 1 2 hours after discontinuation of the infusion followed by capecitabine 1000 mg/m2 orally b.i.d. on day 1-14
1763606|NCT00312026|Drug|efalizumab|
1763607|NCT00312039|Drug|elvucitabine|Elvucitabine 10 mg QD for 14days
1763608|NCT00312039|Drug|Lamivudine|Lamivudine 300 mg QD for 14 days
1763609|NCT00312052|Drug|E5555|50 mg or 100 mg E5555 tablets
1763610|NCT00312052|Drug|Placebo|50 mg and/or 100 mg placebo tablets
1763611|NCT00312065|Device|Application of reflective heat shield to thermistor probe|
1763612|NCT00312078|Dietary Supplement|Yogurt Supplementation|
1763613|NCT00312091|Drug|Lamivudine, nevirapine, and stavudine fixed-dose tablet|7 mg d4T, 30 mg 3TC, 50 mg NVP tablet
1763614|NCT00312091|Drug|Lamivudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
1763615|NCT00312091|Drug|Nevirapine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
1763616|NCT00312091|Drug|Stavudine|Dosage dependent on weight. More information on this criterion can be found in the protocol.
1763622|NCT00312143|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
1763623|NCT00312156|Drug|insulin detemir|
1763624|NCT00312156|Drug|insulin NPH|
1763625|NCT00312156|Drug|insulin aspart|
1763626|NCT00312182|Drug|Nelfinavir|
1763627|NCT00312195|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
1763628|NCT00312195|Drug|Placebo to match BTDS|Placebo to match buprenorphine transdermal patch applied for 7-day wear.
1763629|NCT00312208|Drug|docetaxel, doxorubicin, cyclophosphamide|TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.
1763630|NCT00312208|Drug|Docetaxel,doxorubicin, cyclophosphamide|AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.
1763631|NCT00312221|Drug|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
1763632|NCT00312221|Drug|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
1763633|NCT00312221|Drug|oxycodone immediate-release|Oxycodone immediate-release 40 mg (two 5-mg capsules every 6 hours).
1763634|NCT00312234|Behavioral|Aerobic exercise|
1763635|NCT00312234|Behavioral|Qigong exercise|
1763636|NCT00312260|Drug|Gabapentin|Gabapentin will be prescribed at 900mg/d (300mg tid). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
1763637|NCT00312260|Drug|Amitriptyline|Amitriptyline will be prescribed at a dose of 10mg (qhs). A dose escalation schedule will be followed: one pill taken at night (~2000h) for the first 3 days, one pill at night and one pill in the morning (~0800h) for the second 3 days and finally, one pill at night, one in the morning and one mid-afternoon (~1400h) for the reminder of the trial.
1763638|NCT00312273|Drug|Aminophylline (250mg IV +/- a second dose of 250mg IV)|
1763639|NCT00312286|Drug|851B|851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
1763640|NCT00312286|Drug|851B|851B 1.5% formulation, gel, topically, twice a week for 1 cycle.
1763641|NCT00312286|Drug|851B|851B 1.5% formulation, gel, topically, twice a week for 2 cycles.
1763642|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, once a week for 1 cycle.
1763643|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, once a week for 2 cycles.
1763644|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, twice a week for 1 cycle.
1763645|NCT00312286|Drug|851B|851B 3.0% formulation, gel, topically, twice a week for 2 cycles.
1763646|NCT00312286|Drug|851B|851B placebo-matching gel, topically, once a week for 1 cycle.
1763647|NCT00312286|Drug|851B|851B placebo-matching gel, topically, twice a week for 1 cycle.
1763648|NCT00312286|Drug|851B|851B placebo-matching gel, topically, once a week for 2 cycles.
1763649|NCT00312286|Drug|851B|851B placebo-matching gel, topically, twice a week for 2 cycles.
1763650|NCT00312299|Device|Square edge PMMA IOL|Arm 1 A - Square edge PMMA IOL
1763651|NCT00312299|Device|Round edge PMMA IOL|Round edge PMMA IOL
1763652|NCT00312299|Device|Acrysof IOL|Acrysof IOL
1763653|NCT00312299|Device|square Edge PMMA IOL|Square edge PMMA intra ocular lens
1763654|NCT00312299|Device|Square Edge PMMA IOL|Square Edge PMMA IOL lens
1763655|NCT00312312|Biological|Specific immunotherapy|
1763656|NCT00312325|Drug|Prednisolone|
1763657|NCT00312338|Drug|VIGAMOX|1 drop of VIGAMOX® ophthalmic solution 0.5% in both eyes TID for 7 days
1763658|NCT00312351|Drug|Pegaptanib sodium|
1763659|NCT00312364|Drug|MRE0094|
1763660|NCT00312377|Drug|Docetaxel|infusion
1763661|NCT00312377|Drug|Vandetanib|oral
1763662|NCT00312390|Procedure|Flicker|
1763663|NCT00312390|Procedure|Retinal Vessel Diameter|
1763664|NCT00312390|Procedure|Retinal Blood Flow|
1763665|NCT00312403|Procedure|Blood Sample|A single venous blood sample will be taken (10 ml).
1763666|NCT00312416|Drug|Clonidin|
1763667|NCT00312416|Drug|Brimonidine|
1763668|NCT00312429|Procedure|Stem Cell Transplantation|Allogeneic umbilical cord blood stem cell transplant
1763669|NCT00312442|Drug|Treatment with WST09 Vascular Photodynamic therapy|
1763670|NCT00312455|Drug|Pro-eicosapentaenoic acid (EPA)|450 mg 5x/day
1763671|NCT00312455|Drug|Pro-docosapentaenoic acid (DPA)|100mg 5x/day
1763672|NCT00312455|Drug|Placebo|5 capsules/day
1763673|NCT00312481|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|Split dose, 1-litre solution in the evening prior to colonoscopy and second dose in the morning prior to colonoscopy
1763674|NCT00312481|Drug|NA picosulfate magnesium citrate|150 ml solution before 8am on day prior to colonoscopy and 150ml solution 6 to 8 hours later.
1763675|NCT00312494|Drug|Placebo|Placebo with mood stabilizer (either lithium or divalproex)
1763676|NCT00312494|Drug|Ziprasidone|Flexible dosing, 20-40mg BID, with a mood stabilizer (either lithium or divalproex)
1763677|NCT00312494|Drug|Ziprasidone|Flexible dosing, 60-80mg BID, with a mood stabilizer (either lithium or divalproex)
1763678|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by lavage)|
1763679|NCT00312507|Drug|Bovine Lipid Extract Surfactant (administered by bolus)|
1763680|NCT00312520|Drug|prednisolone|
1763681|NCT00312520|Drug|methylprednisolone|
1763682|NCT00312533|Drug|Hylan F- 20|
1763683|NCT00312546|Drug|Enfuvirtide|90 mg subcutaneously twice daily
1763684|NCT00312546|Drug|Valproic acid|500 to 750 mg, taken orally twice daily
1763685|NCT00312559|Behavioral|Yoga Training|
1763686|NCT00312572|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
1763687|NCT00312585|Procedure|Acupuncture|
1763688|NCT00312585|Procedure|Sham comparator|
1763689|NCT00312598|Drug|Aripiprazole|
1763690|NCT00312611|Device|Transcend II Implantable Gastric Stimulator (IGS), Model 8848|
1763691|NCT00312624|Procedure|contrast-enhanced cardiac MRI|MRI of heart with delayed enhancement
1763692|NCT00312637|Procedure|Magnetic Resonance Spectroscopy|
1763693|NCT00312650|Drug|liposomal doxorubicin and gemcitabine|
1763695|NCT00312676|Procedure|Rapid versus slow conversion|
1763697|NCT00312728|Drug|bevacizumab|15 mg/kg intravenously (IV) on the first day of each 21- to 28-day cycle (± 4 days); the interval between infusions could not be < 17 days, but could extend beyond 28 days if chemotherapy was delayed to allow recovery from toxicity.
1763698|NCT00312728|Drug|First-Line Chemotherapy Agents|"Carboplatin, cisplatin, paclitaxel, docetaxel, gemcitabine, vinorelbine, pemetrexed, or erlotinib administered on Day 1 of every 21-day cycle except gemcitabine, which was administered on Days 1 and 8 of every cycle. Agents were administered as a platinum doublet, or erlotinib alone, at the investigator's discretion. Chemotherapy was administered for a total of 6 planned cycles (up to 8 cycles with prior approval from the Medical Monitor), followed by single-agent bevacizumab therapy. The chemotherapy regimen was to be consistent throughout the study. Erlotinib was administered orally daily.
All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
1763699|NCT00312728|Drug|Second-Line Chemotherapy Agents|"Erlotinib, pemetrexed, docetaxel, or chemotherapy at the investigator's discretion. Erlotinib was administered orally daily; pemetrexed and docetaxel were administered IV on Day 1 of every 21-day cycle. Single-agent bevacizumab therapy could be continued at the investigator's discretion if the second-line agent was discontinued.
All agents were dosed and administered per institutional standards using the respective package insert as a guideline."
1763700|NCT00312741|Procedure|empirical versus microbiological guided treatment|
1763701|NCT00312754|Drug|Atazanavir|
1763702|NCT00312767|Drug|Fabrazyme (agalsidase beta)|
1763703|NCT00312780|Drug|XL784|XL784 softgel capsules (100 mg per capsule) orally administered at a dose of 200 mg/day (or placebo softgel capsules)
1763704|NCT00312793|Device|stimulation of the quadriceps muscle with Myospare|
1763705|NCT00312806|Drug|Pantoprazole|Pantoprazole 40 mg o.d.
1763706|NCT00312819|Drug|chemotherapy +/- disulfiram|
1763707|NCT00312832|Drug|switching; dose reduction|
1763708|NCT00312845|Drug|Bortezomib + Rituximab|VELCADE for Injection will be administered weekly on Days 1,8,15, and 22 of a 35-day cycle in combination with 4 doses of rituximab once a week on Days 1,8,15, and 22 of Cycle 1 and in combination with a single dose of rituximab on Day 1 of Cycles 2 to 5.
1763709|NCT00312845|Drug|Rituximab|rituximab once a week on Days 1,8,15, and 22 of Cycle 1, and as a single dose on Day 1 of Cycles 2 to 5 (for a total of 8 doses).
1763710|NCT00312858|Biological|Comparator: VAQTA™ (Hepatitis A vaccine)|VAQTA™ 0.5 mL injection
1763711|NCT00312858|Biological|Comparator: ProQuad™ (Measles, Mumps, Rubella and Varicella vaccine)|ProQuad™ 0.5 mL injection
1763712|NCT00312858|Biological|Comparator: Prevnar™ (Pneumococcal 7-Valent Conjugate vaccine)|Prevnar™ 0.5 mL injection
1763713|NCT00312871|Drug|Epoetin alfa|
1763714|NCT00312884|Device|HomMed Telemonitoring System|The HomMed telemonitoring system allows for patients to monitor their weight, blood pressure, oxygen saturation and symptoms of dyspnoea on a daily basis from their home
1763717|NCT00312910|Drug|Probiotics-Bio-plus|
1763718|NCT00312923|Drug|Policosanol|20 mg of policosanol in capsular form daily
1763719|NCT00312923|Dietary Supplement|Placebo|Two capsules of 10 mg of microcrystalline cellulose daily
1763720|NCT00312936|Behavioral|Mindfulness-based Stress Reduction (MBSR)|8 week program
1763721|NCT00312949|Behavioral|Interactive Website on management of schizophrenia|Participants in the web-user group will sit with a laptop computer, answer questions about themselves and their treatment, receive feedback on care that may be inconsistent with current recommendations, and receive suggestions on how to discuss this with their physicians.
1763722|NCT00312949|Behavioral|Written materials and video on management of schizophrenia|Participants in the written materials/video group will be given the reading material and will watch a 20-minute video.
1763723|NCT00312962|Behavioral|Targeted cognitive training (TCT)|TCT includes cognitive remediation exercises that participants practice 1 hour per day, 5 days per week, for 20 weeks. TCT exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal and visuo-spatial targets.
1763724|NCT00312962|Behavioral|Computer games|The control treatment involves commercially available computer games that participants practice 1 hour per day, 5 days per week, for 20 weeks.
1763725|NCT00312975|Drug|CP-675,206|Given intravenously every 3 months
1763726|NCT00312975|Drug|best supportive care|As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
1763727|NCT00312988|Drug|Hycamtin|
1763728|NCT00312988|Drug|Gemcitabine|
1763729|NCT00313001|Drug|biphasic insulin aspart|
1763730|NCT00313001|Drug|exenatide|
1763731|NCT00313014|Drug|Buprenorphine|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
1763732|NCT00313014|Drug|Buprenorphine|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
1763733|NCT00313014|Drug|Oxycodone Immediate-Release|Oxycodone HCl immediate-release 40 mg (two 5-mg capsules every 6 hours).
1763734|NCT00313027|Radiation|PET scan|
1763735|NCT00313040|Behavioral|Brief Consultation with Health Counselor, workbook|
1763736|NCT00313040|Behavioral|Usual Care wait list|
1763737|NCT00313053|Drug|Human mAb 216|Two treatment courses of mAb infusion will be given, with the same dose of antibody administered on Day 0 and on Day 7.
1763738|NCT00313053|Drug|Vincristine|Vincristine 1.5 mg/m2/dose (max dose = 2 mg) IVP on weekly x 4 doses (Days 7, 14, 21, 28)
1763739|NCT00313079|Drug|MAb 216|Dosage: 1.25mg/kg intravenous with dose escalation
1763740|NCT00313079|Drug|Vincristine|Dosage: 1.5mg/m2 intravenous weekly X 4
1763808|NCT00301782|Drug|vincristine sulfate|
1763741|NCT00313092|Device|nCPAP treatment|treatment with positive air pressure during night
1763742|NCT00313105|Drug|Smokeless tobacco (Oliver Twist pellets)|individual visits with counseling
1763743|NCT00313105|Behavioral|smoking cessation counseling|individual visits
1763744|NCT00313131|Drug|tinidazole+fluconazole vs metronidazole+clotrimazole|
1763745|NCT00313144|Drug|ARALAST Alpha1-Proteinase Inhibitor|Weekly ARALAST infusions for 2 years, dose and mode of administration as prescribed by the physician
1763746|NCT00313157|Drug|Metoprolol|
1763747|NCT00313157|Drug|Diltiazem|
1763748|NCT00313157|Drug|Verapamil|
1763749|NCT00313157|Drug|Carvedilol|
1763750|NCT00313170|Drug|Fulvestrant|intramuscular injection 250 mg & 500 mg
1763751|NCT00313183|Drug|pramlintide acetate|single subcutaneous doses of 15mcg and 30mcg
1763752|NCT00313196|Drug|bosentan|Oral Initial dose: 62.5 mg b.i.d. for 4 weeks for all patients, maintenance dose: 125 mg
1763753|NCT00313209|Drug|Roflumilast|500 µg, once daily, oral administration in the morning
1763754|NCT00313209|Drug|Placebo|once daily
1763755|NCT00313222|Drug|bosentan|
1763756|NCT00313235|Biological|DC Vaccine and Cyclophosphamide|"Autologous dendritic cells (DC) are derived from PBMC, cultured with cytokines, pulsed ex vivo with irradiated allogeneic (Colo 829) melanoma cells. About 15 x 10^6 dendritic cells will be injected subcutaneously, in 3 separate sites (3.3 ml/site).
Patients will receive a total of 7 doses of the vaccination. Each individual dose will be administered at weeks: 0, 2, 4, 6, 11, 14, and 18. Patients with SD, PR according to RECIST criteria may receive 4 more vaccines at 36, 48, 60 and 72 weeks. Patients with CR will receive 4 additional vaccines at 36, 48, 72, and 96 weeks.
CPA will be administered 300mg/m2, intravenously over a 2-hour infusion 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7. Frequency of CPA administration might be increased based on their T cell measure."
1763757|NCT00313248|Drug|Sagopilone (ZK 219477)|All patients will receive ZK-Epo at a dose of 16mg/m2 as an intravenous infusion. Chemotherapy for recurrent breast cancer.
1763758|NCT00313248|Drug|Sagopilone (ZK 219477)|Patients will receive 22mg/m2 as intravenous infusion.
1763759|NCT00313261|Drug|Clevudine|
1763760|NCT00313274|Drug|Clevudine|
1763761|NCT00313287|Drug|clevudine|
1763762|NCT00313300|Drug|Apixaban|Tablets, Oral, 2.5 mg, twice daily, 26 weeks
1763763|NCT00313300|Drug|Apixaban|Tablets, Oral, 10 mg, once daily, 26 weeks
1763764|NCT00313300|Drug|Placebo|Tablets, Oral, 0, twice daily, 26 weeks
1763765|NCT00313300|Drug|Apixaban|Tablets, Oral 10 mg, twice daily, 26 weeks
1763766|NCT00313313|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Daily AM, (24 weeks short-term [ST], 12 months long-term [LT])
1763767|NCT00313313|Drug|Saxagliptin|Tablets, Oral, 5 mg, Daily AM (24 weeks ST, 12 months LT).
1763768|NCT00313313|Drug|Glyburide|Capsules, Oral, OL, 7.5 mg, Daily, AM (24 weeks ST, 12 months LT)
1763769|NCT00313313|Drug|Placebo|Tablets, Oral, 0 mg, Daily AM/PM, (24 weeks ST, 12 months LT)
1763770|NCT00313313|Drug|Glyburide|Capsules, Oral, DB Glyburide, 2.5 mg titrated to 7.5 mg + 7.5 mg OL, Daily AM/PM (24 weeks ST, 12 months LT)
1763771|NCT00313313|Drug|Metformin|Tablets, Oral, OL, 500 - 2500 mg, 1 or 2 times per day (12 months LT)
1763772|NCT00313326|Procedure|Adaptative Support Ventilation|Adaptive Support Ventilation (ASV) is a new protocol of weaning of the tracheal prosthesis after surgery which maintains a preset ventilation by an operator, and this whatever the activity of the patient
1763773|NCT00313339|Drug|Intra-coronary infusion|In our study there will be four dosing cohorts (5, 10, 20 and 30 x 106) of CD34+ cells.
1763774|NCT00313365|Procedure|Surgical Lavage (Arthrotomy)|
1763775|NCT00313365|Procedure|Arthrocentesis (Serial needle aspiration)|
1763776|NCT00313378|Drug|Hypothetica|
1763777|NCT00301535|Drug|HBOC-201 (hemoglobin glutamer-250 bovine)|HBOC-201 is an investigational solution of purified, glutaraldehyde-polymerized bovine hemoglobin with a concentration of hemoglobin of 13 ± 1 g/dL
1763778|NCT00301548|Drug|perioperative chemotherapy|
1763779|NCT00301561|Procedure|Simplified follow-up approach of ARV treatment|"Simplify treatment follow-up :
some clinical consultations will be performed by nurses under the physicians' responsibility ;
the CD4 cell count and HIV-1 viral load will not be available for the management of patients ;
the biologic assessment for tolerability will be limited"
1763780|NCT00301561|Procedure|Standard follow-up approach of ARV treatment|"Standard treatment follow-up :
all clinical consultations will be performed by physicians ;
the CD4 cell count and HIV-1 viral load will be available for the patients management routinely ;
the biologic assessment for tolerability will be available as needed"
1763781|NCT00301574|Drug|galantamine|
1763782|NCT00301587|Drug|Norgestimate-ethinyl estradiol, with or without folic acid|
1763783|NCT00301600|Drug|Mycophenolate mofetil|MMF,1.0g/d
1763784|NCT00301613|Drug|Mycophenolate mofetil|MMF,1.0g/d
1763785|NCT00301626|Behavioral|smoking reduction intervention (including NRT)|
1763786|NCT00301639|Drug|OROS methylphenidate hydrochloride|
1763787|NCT00301639|Drug|methylphenidate hydrochloride|
1763788|NCT00301652|Drug|mycophenolate mofetil|MMF,1.0g/d
1763789|NCT00301665|Drug|Botulinum toxin type A|
1763790|NCT00301678|Behavioral|behavioral dietary intervention|
1763791|NCT00301678|Other|educational intervention|
1763792|NCT00301678|Other|preventative dietary intervention|
1763793|NCT00301691|Behavioral|behavioral dietary intervention|
1763794|NCT00301691|Other|educational intervention|
1763795|NCT00301691|Other|preventative dietary intervention|
1763796|NCT00301730|Biological|aldesleukin|
1763797|NCT00301730|Biological|therapeutic tumor infiltrating lymphocytes|
1763798|NCT00301730|Biological|trastuzumab|
1763799|NCT00301730|Drug|paclitaxel|
1763800|NCT00301730|Procedure|conventional surgery|
1763801|NCT00301756|Drug|Belinostat|Given IV
1763802|NCT00301756|Other|Laboratory Biomarker Analysis|Correlative studies
1763803|NCT00301769|Drug|SJG-136|Given IV
1763804|NCT00301782|Biological|bleomycin sulfate|
1763805|NCT00301782|Drug|carboplatin|
1763806|NCT00301782|Drug|cisplatin|
1763807|NCT00301782|Drug|etoposide phosphate|
1763809|NCT00301795|Biological|oblimersen sodium|Given IV
1763810|NCT00301795|Biological|rituximab|Given IV
1763811|NCT00301795|Other|laboratory biomarker analysis|Correlative studies
1763812|NCT00301808|Drug|Cisplatin|Cisplatin 75 mg/m2 every 3 weeks on days 1, 22, and 43
1763813|NCT00301808|Drug|Docetaxel|Docetaxel 75 mg/m2 on day 1 of each cycle
1763814|NCT00301808|Drug|Pemetrexed disodium|Pemetrexed 500 mg/m2 every 3 weeks on days 1, 22, and 43
1763815|NCT00301808|Radiation|Radiation therapy|Radiation therapy will begin within 24 hours of the first cycle of chemotherapy.
1763816|NCT00301821|Biological|epratuzumab|
1763817|NCT00301821|Biological|rituximab|
1763818|NCT00301821|Drug|cyclophosphamide|
1763819|NCT00301821|Drug|doxorubicin hydrochloride|
1763820|NCT00301821|Drug|prednisone|
1763821|NCT00301821|Drug|vincristine sulfate|
1763822|NCT00301834|Biological|alemtuzumab|
1763823|NCT00301834|Drug|busulfan|
1763824|NCT00301834|Drug|cyclosporine|
1763825|NCT00301834|Drug|fludarabine phosphate|
1763826|NCT00301834|Drug|methotrexate|
1763827|NCT00301834|Drug|methylprednisolone|
1763828|NCT00301834|Procedure|allogeneic bone marrow transplantation|
1763829|NCT00301834|Procedure|allogeneic hematopoietic stem cell transplantation|
1763830|NCT00301834|Procedure|peripheral blood stem cell transplantation|
1763831|NCT00301834|Procedure|umbilical cord blood transplantation|
1763832|NCT00301847|Drug|sorafenib tosylate|
1763833|NCT00301860|Biological|anti-thymocyte globulin|
1763834|NCT00301860|Biological|filgrastim|
1763835|NCT00301860|Biological|therapeutic allogeneic lymphocytes|
1763836|NCT00301860|Drug|cyclosporine|
1763837|NCT00301860|Drug|fludarabine phosphate|
1763838|NCT00301860|Drug|melphalan|
1763839|NCT00301860|Drug|methotrexate|
1763840|NCT00301860|Procedure|allogeneic hematopoietic stem cell transplantation|
1763841|NCT00301860|Procedure|peripheral blood stem cell transplantation|
1763842|NCT00301873|Drug|IV Zometa|Zometa will be given at 4 mg intravenously over 15 minutes every 3 months for 1 year.
1763843|NCT00301886|Drug|ibandronate|
1763844|NCT00301886|Drug|zoledronate|
1763845|NCT00301886|Procedure|quality-of-life assessment|
1763846|NCT00301899|Biological|pertuzumab|
1763847|NCT00301899|Biological|trastuzumab|
1763848|NCT00301912|Biological|filgrastim|
1763849|NCT00301912|Drug|busulfan|
1763850|NCT00301912|Drug|fludarabine phosphate|
1763851|NCT00301912|Drug|methotrexate|
1763852|NCT00301912|Drug|tacrolimus|
1763853|NCT00301912|Procedure|allogeneic bone marrow transplantation|
1763854|NCT00301912|Procedure|allogeneic hematopoietic stem cell transplantation|
1763855|NCT00301912|Procedure|peripheral blood stem cell transplantation|
1763856|NCT00301925|Biological|pegfilgrastim|
1763857|NCT00301925|Drug|capecitabine|
1763858|NCT00301925|Drug|cyclophosphamide|
1763859|NCT00301925|Drug|epirubicin hydrochloride|
1763860|NCT00301925|Drug|fluorouracil|
1763861|NCT00301925|Drug|methotrexate|
1763862|NCT00301925|Procedure|adjuvant therapy|
1763863|NCT00301938|Drug|7-hydroxystaurosporine|Given IV
1763864|NCT00301938|Drug|perifosine|Given orally
1763865|NCT00301938|Other|pharmacological study|Correlative studies
1991568|NCT00853112|Drug|PF-00489791|tablet form, 1 mg, single dose (Day 1)
1763873|NCT00301964|Biological|bevacizumab|Given IV
1763874|NCT00301964|Other|laboratory biomarker analysis|Correlative studies
1763875|NCT00301990|Biological|aldesleukin|
1763876|NCT00301990|Biological|bevacizumab|
1763877|NCT00302003|Radiation|radiation therapy|Undergo radiation therapy
1763878|NCT00302003|Drug|doxorubicin hydrochloride|Given IV
1763879|NCT00302003|Drug|vincristine sulfate|Given IV
1763880|NCT00302003|Drug|prednisone|Given orally
1763881|NCT00302003|Drug|cyclophosphamide|Given IV
1763882|NCT00302003|Drug|ifosfamide|Given IV
1763883|NCT00302003|Drug|vinorelbine tartrate|Given IV
1763884|NCT00302003|Drug|dexamethasone|Given IV
1763885|NCT00302003|Drug|etoposide phosphate|Given IV
1763886|NCT00302003|Drug|cisplatin|Given IV
1763887|NCT00302003|Drug|cytarabine|Given IV
1763888|NCT00302003|Biological|filgrastim|Given IV or subcutaneously
1763889|NCT00302016|Drug|AMN107|
1763890|NCT00302042|Behavioral|Brief counseling plus group diabetes prevention in community|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk, Group diabetes prevention in community: 16 weekly group lifestyle behavior change visits followed by monthly group lifestyle behavior change visits.
1763891|NCT00302042|Behavioral|Brief Counseling for pre-diabetes alone|Brief counseling at measurement visits: education about diabetes and the importance of medical follow-up for determining the most appropriate strategies to decrease this risk.
1763892|NCT00302055|Behavioral|Clinical referral to diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
1763893|NCT00302055|Behavioral|Clinical referral to group diabetes prevention lifestyle|16 one-hour lifestyle program sessions (diet and physical activity skill building and problem solving) delivered about once weekly over 20-24 weeks, followed by monthly lifestyle maintenance sessions
1763894|NCT00302068|Behavioral|Supervised Aerobic Exercise|Supervised aerobic exercise, three times per week, for 16 weeks.
1763895|NCT00302068|Drug|Sertraline|Sertraline (Zoloft), daily, for 16 weeks.
1763896|NCT00302068|Drug|Placebo Pill.|Placebo pill, daily, for 16 weeks.
1763897|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 24 weeks
1763898|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.0 mcg/kg QW SC for 24 weeks
1763899|NCT00302081|Biological|peginterferon alfa-2b (SCH 54031)|1.5 mcg/kg QW SC for 16 weeks
1763900|NCT00302081|Drug|ribavirin (SCH 18908)|800-1200 mg daily for 24 weeks
1763901|NCT00302081|Drug|ribavirin (SCH 18908)|800-1200 mg daily for 16 weeks
1763902|NCT00302107|Drug|Mirtazapine|Mirtazapine initiated at 15mg qhs and titrated in 15mg increments to a maximum of 45 mg qhs as tolerated.
1763903|NCT00302107|Drug|Placebo|Look-a-like placebo tablets under double-blind conditions
1763904|NCT00302120|Procedure|Contrast-enhanced MR mammography|
1763905|NCT00302133|Drug|Naltrexone hydrochloride|Naltrexone hydrochloride 50 mg capsule daily for 12 weeks
1763906|NCT00302133|Other|Placebo|Placebo arm
1763907|NCT00302159|Procedure|adjuvant therapy|
1763908|NCT00302159|Drug|Temozolomide|Orally 75mg/m^2 first day of radiation until completion. Restart 4 weeks post radiation.
1763909|NCT00302159|Drug|Valproic Acid|Orally 25mg/kg/day twice a day concurrently with radiation therapy and temozolomide.
1763910|NCT00302159|Radiation|Radiation therapy|External beam radiation Monday-Friday in 2 Gy fractions to 60 Gy total.
1763911|NCT00302172|Drug|ARQ 197|"Patients in this trial will receive ARQ 197 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 20 mg/day (first cohort) and escalate until the RP2D or MTD is determined. Patients enrolled under a previous amendment will continue to receive ARQ 197 twice daily for 14 days followed by 7 days without therapy. Any patient enrolled under Amendment 3 will take ARQ 197 twice daily for 21 days where cycles will be repeated every three-weeks (21 days).
Patients enrolled under Amendment 4 will receive dose of 360 mg bid (720 mg daily) continuously for 21 days, and cycle will be repeated every three weeks.
All patients will remain on study until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment is permitted."
1763912|NCT00302185|Procedure|Acupuncture|Insertion of sterile, single-use acupuncture needles at 10-20 points including PC.6, HT.7, St.36, SP.6, and LR.3. Needles were connected to an electrical stimulator to mimick traditional manual stimulation with alternating patterns of stimulation for 20 minutes.
1763913|NCT00302185|Behavioral|Nurse-led supportive care|20-30 minutes of supportive attention from an experienced palliative nurse.
1763914|NCT00302198|Behavioral|ALS Registry|
1763915|NCT00302211|Drug|Iloprost Inhalation Solution (Ventavis)|iloprost inhalation solution (Ventavis) (5 mcg) 6×/day
1763916|NCT00302211|Drug|Iloprost Inhalation Solution (Ventavis)|iloprost inhalation solution (Ventavis) (5 mcg) 4×/day
1763917|NCT00302211|Drug|Inhaled Placebo|inhaled placebo 6×/day (5 mcg)
1763918|NCT00302211|Drug|Sildenafil|oral sildenafil (dosage between 60 and 300 mg/day)
1763919|NCT00302211|Drug|Bosentan|oral bosentan (dosage between 62.5 and 125 mg BID)
1763920|NCT00302224|Drug|2S, 4R Ketoconazole (DIO-902)|
1763921|NCT00302237|Device|RX ACCULINK, RX ACCUNET Embolic Protection System|1) To provide an ongoing post-market surveillance mechanism to document clinical outcomes. 2) To provide additional information that the RX ACCULINK™ and RX ACCUNET™ can be used safely by a wide range of physicians under commercial use conditions. 3) To evaluate the adequacy of Abbott Vascular's physician training program.
1763922|NCT00302250|Drug|ALT-711 (alagebrium chloride)|
1763923|NCT00302263|Drug|Metobes-compound|
1763924|NCT00302276|Drug|Metobes-compound|
1763925|NCT00302289|Drug|tyrosine, green tea, caffeine|
1763926|NCT00302302|Drug|L-arabinose|
1763927|NCT00302315|Device|transcutaneous electrical nerve stimulation|
1763928|NCT00302328|Procedure|macular hole operation|macular hole surgery with either no peeling, indocyanine green (ICG) assisted peeling or trypan blue (tb) peeling
1763929|NCT00302341|Drug|Pafuramidine maleate (DB289)|Oral tablet, 100 mg bid, 14 days
1763930|NCT00302341|Drug|Trimethoprim-Sulfamethoxazole (TMP-SMX)|15 mg/kg, oral tablet split tid X 21 days
1763931|NCT00302354|Drug|OROS methylphenidate HCl|
1763932|NCT00302354|Drug|SODAS methylphenidate HCl|
1763933|NCT00302367|Drug|OROS methylphenidate hydrochloride|
1763934|NCT00302367|Drug|immediate release methylphenidate hydrochloride|
1763935|NCT00302380|Radiation|PET imaging using C-11 altropane as the ligand.|A one-injection protocol will be used for the study. C-11 Altropane will be injected manually as an intravenous bolus.
1763936|NCT00302393|Drug|OROS methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of OROS MPH will be 36 mg which will be supplied as one 36 mg capsules. Study treatments will be administered with water following an overnight fast of at least 8 hours.
1763937|NCT00302393|Drug|methylphenidate hydrochloride|Subjects will be administered a first dose of one of the study treatments at hour 0 and then a second dose of one of the study treatments at hour 4 at each of the four treatment days in a crossover fashion, so that each subject will have received doses of each combination of treatments during the study. Each dose of IR MPH will be 20 mg which will be supplied as one 20 mg capsule. Study treatments will be administered with water following an overnight fast of at least 8 hours.
1763938|NCT00302406|Drug|methylphenidate hydrochloride|
1763939|NCT00302406|Drug|OROS methylphenidate hydrochloride (CONCERTA)|
1763940|NCT00302419|Drug|intracoronary infusion,|streptokinase, 250,000 units
1763941|NCT00302419|Procedure|primary percutaneous coronary angioplasty|
1763942|NCT00302432|Behavioral|Behavior therapy, cigarette holders, Flowers Menthol|
1763943|NCT00302445|Drug|Efalizumab|
1763944|NCT00302445|Device|Narrow Band Phototherapy|
1763945|NCT00302458|Drug|OROS-Methylphenidate|Each dose of OROS MPH will be 72 mg which will be supplied as two 36 mg overencapsulated capsules
1763946|NCT00302458|Drug|Immediate Release Methylphenidate|Each dose of IR MPH will be 40 mg which will be supplied as two 20 mg overencapsulated capsules
1764065|NCT00303524|Drug|Goserelin acetate|injection 10.8 mg every 3 months
1763947|NCT00302458|Drug|Placebo|Placebo will be administered during the first part of the day, and again during the second part of the day.
1763948|NCT00302471|Drug|Comparator: MK0429|"Part 1 - MK3328 of 1600 mg twice a day for 4 weeks given to men with hormone refractory prostate cancer and metastatic bone.
Disease."
1763949|NCT00302471|Drug|Comparator: MK0429|Part 2- MK3328 of 200 mg twice a day for 4 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
1763950|NCT00302471|Drug|Comparator: MK0429|Part 1- MK3328 of 800mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
1763951|NCT00302471|Drug|Comparator: MK0429|Part 2 - MK3328 of 400 mg twice a day for 8 weeks to men with hormone refractory prostate cancer and metastatic bone disease.
1763952|NCT00302484|Drug|Zoledronate|
1763953|NCT00302497|Drug|basiliximab|
1763954|NCT00302510|Procedure|immunoadsorption|immunoadsorption
1763955|NCT00302523|Drug|Tacrolimus|FK506,0.1mg/kg/d
1763956|NCT00302536|Drug|Tacrolimus|Tacrolimus
1763957|NCT00302549|Drug|FK506|FK506,0.1mg/kg/d
1763958|NCT00302575|Behavioral|Collaborative Behavioral Management|
1763959|NCT00302575|Procedure|Integrated parole and outpatient addiction treatment|
1763960|NCT00302601|Procedure|Scintigraphic interpretation|Not relevant
1763961|NCT00302627|Drug|Pamidronate|60mg or 90mg given at baseline, 6,12,18, and 24 months
1763962|NCT00302627|Drug|vitamin D|baseline, 6,12 months
1763963|NCT00302627|Drug|calcium supplement|baseline, 6,12 months
1763964|NCT00302640|Drug|Alinia (nitazoxanide)|
1763965|NCT00302653|Drug|Rasburicase|Rasburicase 0,20mg/Kg/Day once a day 3-7 days
1763966|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive extended cycles
1763967|NCT00302666|Drug|Valette (Dienogest/EE30, BAY86-5038)|Oral contraceptive conventional cycles
1763968|NCT00302692|Drug|Esmolol|
1763969|NCT00302692|Drug|Metoprolol|
1763970|NCT00302705|Drug|Valsartan, Enalapril|160 mg valsartan versus 10-20 mg enalapril
1763971|NCT00302705|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
1763972|NCT00302705|Procedure|Missing one dose|Patients skip the dose the second day of monitoring
1763973|NCT00302718|Behavioral|Physician-level financial incentives|Enrolled physician participants are eligible to receive financial incentives and audit and feedback reports based on their performance during a 4-month interval on the hypertension care study outcomes.
1763974|NCT00302718|Behavioral|Practice-level financial incentives|Enrolled practices (physician physicians and non-physician primary care personnel) are eligible to receive financial incentives and audit and feedback reports based on the performance of the practice during a 4-month interval on the hypertension care study outcomes.
1763975|NCT00302718|Behavioral|Physician- and practice-level financial incentives|Enrolled participants are eligible to receive financial incentives and audit and feedback reports based on performance during a 4-month interval on the hypertension care study outcomes. This arm tests the effect of combined financial incentives (physician-level incentives and practice-level incentives).
1991569|NCT00853112|Drug|PF-00489791|tablet form, 2 mg, single dose (Day 1)
1991570|NCT00853112|Drug|PF-00489791|tablet form, 4 mg, single dose (Day 1)
1991571|NCT00853112|Drug|PF-00489791|tablet form, 10 mg, single dose (Day 1)
1991572|NCT00853112|Drug|PF-00489791|tablet form, 20 mg, single dose (Day 1)
1763980|NCT00302744|Drug|Psilocybin (drug)|One placebo session (niacin) and one active drug session (.2 mg/kg). Treatment sessions are six hours.
1763981|NCT00302757|Drug|Radioimmunotherapy|
1763982|NCT00302757|Procedure|allogeneic hematopoietic cell transplantation|
1763983|NCT00302770|Drug|quetiapine|
1763984|NCT00302783|Behavioral|Multi-Source Feedback: including self-assessment & coaching|
1763985|NCT00302796|Drug|Bioclavid|500 + 125 mg times 3 or 6
1763986|NCT00302796|Drug|Placebo|
1763987|NCT00302809|Dietary Supplement|Concord Grape Juice|Approximately 16 oz of grape juice or placebo
1763988|NCT00302822|Drug|enfuvirtide|from week 0 to 24
1763989|NCT00302822|Drug|emtricitabine/tenofovir|1 pill/day
1763990|NCT00302822|Drug|lopinavir or efavirenz|investigator choice
1763991|NCT00302835|Drug|non-phenacetin containing analgesics|
1763992|NCT00302848|Drug|Drospirenone|
1763993|NCT00302848|Drug|Levonorgestrel|
1763994|NCT00302848|Drug|Other progestin containing oral contraceptive|
1763995|NCT00302861|Biological|MyVax|
1763996|NCT00302874|Behavioral|Implementation of a protocol for treatment of hyperglycemia|
1763997|NCT00302887|Device|combined ultrasound therapy|
1763998|NCT00302887|Procedure|connective tissue manipulation|
1763999|NCT00302900|Behavioral|Pre-Donation Water Consumption|Consumption of 500 ml of bottled water 30 minutes prior to donating
1764000|NCT00302900|Behavioral|Muscle Tensing Exercise During Donation|Alternating leg lifts at 10-second intervals during donation
1764001|NCT00302900|Behavioral|Muscle Tensing Exercise Prior to Donation|Alternating leg lifts at 10-second intervals prior to insertion of the donation needle
1764002|NCT00302913|Drug|Adjustment of clopidogrel dose|
1764003|NCT00302926|Procedure|energy restriction and maintenance|
1764004|NCT00302952|Drug|Lovastatin|Two 40 mg lovastatin tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
1764005|NCT00302952|Drug|Placebo|Two placebo tablets orally once daily for a total of 12 weeks in a blinded (masked) fashion
1764006|NCT00302965|Drug|Frozen Plasma|
1764007|NCT00302978|Behavioral|Behavior therapy|
1764008|NCT00303004|Drug|Bosentan and Sildenafil|
1764009|NCT00303017|Dietary Supplement|flavocoxid|flavonoid mixture
1764010|NCT00303017|Drug|Naproxen|non-steroidal anti-inflammatory drug
1764011|NCT00303030|Procedure|1. Anal injection|Submucosal injection just above the linea dentata in the anal canal of 4 x 1 ml of dextranomere.
1764066|NCT00303537|Drug|metformin|
1764067|NCT00303550|Drug|Intravenous iclaprim|
1991573|NCT00853112|Drug|placebo|tablet form, single dose (Day 1)
1764012|NCT00303030|Procedure|2. Biofeedback|Training under the guidance of a physiotherapist with the help of a biofeedback device with an anal probe.
1764013|NCT00303043|Procedure|Mixed venous saturation monitoring|Mixed venous saturation monitoring
1764014|NCT00303056|Drug|HOE140 Icatibant|
1764015|NCT00303069|Biological|V710|Single dose of V710 (at dosages of 5 μg, 30 μg, or 90 μg) intramuscularly
1764016|NCT00303069|Biological|Comparator: Placebo|Single dose of saline placebo intramuscularly
1764017|NCT00303082|Drug|Lactobacillus rhamnosus GR1 and Lactobacillus reuteri RC-14|
1764018|NCT00303108|Drug|Pegylated liposomal doxorubicin|30 mg/m2 IV on Day 1 of each 28 day cycle
1764019|NCT00303108|Drug|Carboplatin|AUC=5 on Day 1 of each 28 day cycle
1764020|NCT00303108|Drug|trastuzumab|4 mg/kg on Days 1 and 15 of each cycle(loading dose of 8 mg/kg on Day 1 of Cycle 1 only)
1764021|NCT00303134|Procedure|Islet Cell Transplantation|
1764022|NCT00303147|Behavioral|Expressive Writing|
1764023|NCT00303160|Drug|vitamin C & E supplements|
1764024|NCT00303173|Behavioral|Guided Imagery|
1764025|NCT00303199|Drug|ZIO-101 (Darinaparsin)|IV zio-101 (Darinaparsin) give for 5 consecutive days to be repeated every 28 days for up to 6 months
1764026|NCT00303212|Other|Telemonitoring|Participants in the intervention group are instructed to make a daily toll-free call to an automated telemonitoring system being provided by Pharos Innovations® (Chicago, IL) for 6 months.On each call patients hear a pre-recorded voice that goes through a series of questions about symptoms and the patient's daily weight. Information from the telemonitoring system is automatically downloaded to a secure Internet site for review by clinicians at each practice site.
1764027|NCT00303225|Drug|Vaccine: SIGA-246|
1764028|NCT00303238|Drug|Rose hips extract + blueberry/blackberry extract + resveravine|
1764029|NCT00303238|Drug|Rose hips extract + blueberry/blackberry extract + Aframomum melegueta extract|
1764030|NCT00303238|Drug|Rose hips extract + resveravine + Aframomum melegueta extract|
1764031|NCT00303251|Drug|TKI258|
1764032|NCT00303264|Drug|dexloxiglumide|
1764033|NCT00303264|Drug|Nexium (esomeprazole)|
1764034|NCT00303277|Drug|simvastatin|simvastatin 40 mg tablets once per day for 12 weeks
1764035|NCT00303277|Drug|pravastatin|pravastatin 80 mg tablets once per day for 12 weeks
1764036|NCT00303290|Drug|Peg Interferon Alpha 2b (Peg Intron)|4.5 micrograms/kg once a week
1764037|NCT00303290|Drug|Ara-C (cytosine arabinoside)|10 mg under the skin daily
1991574|NCT00853112|Drug|sildenafil|tablet form, 20 mg, single dose (Day 1)
1991575|NCT00847522|Drug|Fluorescein|Fluorescein is an orange-red powdered compound, designated by the formula C20H12O5, which exhibits intense greenish-yellow fluorescence in alkaline solution. It has been used extensively in surgery and medicine for decades for diagnostic purposes. Topical fluorescein is routinely used in ophthalmology to assess corneal lesions. Intravenous fluorescein is used in vascular surgery to measure vascular perfusion and in skin and melanoma surgery to assess the viability of skin flaps.
1764041|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
1764042|NCT00303316|Biological|DTaP-IPV//PRP~T combined vaccine|0.5 mL, Intramuscular
1764043|NCT00303329|Drug|Deferasirox|Deferasirox available as 125 mg, 250 mg or 500 mg tablets
1764044|NCT00303342|Behavioral|mind body treatment|regulation of attention, respiration and posture
1764045|NCT00303342|Behavioral|desensitization|mentation on insomnia behaviors and cognitive activity
1764046|NCT00303381|Drug|Interferon-beta-1a, 44 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 44 mcg, three times a week up to Week 8.
1764047|NCT00303381|Drug|Placebo|Matching Placebo will be administered subcutaneously, three times a week up to Week 8.
1764048|NCT00303381|Drug|Interferon-beta-1a, 66 microgram|Interferon-beta-1a will be administered subcutaneously at a dose of 66 mcg, three times a week up to Week 8.
1764049|NCT00303394|Drug|IL-1Ra|
1764050|NCT00303407|Drug|nadroparin|
1764051|NCT00303420|Drug|"Alteplase push protocol"|alteplase 2 mg / lumen. Instill and wait 10 minutes, instill 0.3 ml normal saline, wait 10 minutes, instill 0.3 ml of normal saline, wait 10 minutes and aspirate.
1764052|NCT00303420|Drug|alteplase dwell arm|alteplase 2 mg / lumen. Instill and let it dwell for 30 minutes. Assess catheter and allow to dwell for a total of 2 hours if necessary
1764053|NCT00303433|Drug|Namenda|
1764054|NCT00303446|Drug|Dutasteride|Dutasteride 0.5 mg/day
1764055|NCT00303446|Drug|Placebo|Matched placebo
1764056|NCT00303459|Drug|bosentan|bosentan/62.5 mg tablet/b.i.d. for 4 weeks then bosentan/125 mg tablet/b.i.d.
1764057|NCT00303459|Drug|placebo|Matching bosentan placebo/b.i.d.
1764058|NCT00303472|Drug|Romiplostim|
1764059|NCT00303485|Drug|Placebo|po monthly for 6 months
1764060|NCT00303485|Drug|Vitamin D and calcium supplementation|As prescribed
1764061|NCT00303485|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
1764062|NCT00303498|Drug|Sitaxsentan sodium|sitaxsentan 100 mg (target dose) 0rally once daily. A 10-week Run-In Phase was conducted where dosing commenced at 25 mg daily for 2 weeks, and then was stepped up to 50 mg daily for 2 weeks, to 75 mg daily for 2 weeks and then to 100 mg daily for 2 weeks, with an additional 2-week stabilization period (10 weeks total) to a target study dose of 100 mg daily. During the Run-In Phase, if a subject was not able to tolerate upward dose titration to the target dose of 100 mg, the investigator may have elected to continue at the current dosage or reduce the dosage of sitaxsentan or placebo to the subject's immediate prior dose. During the Maintenance Phase, subjects received the highest titrated dose reached of study drug and continued it through the last day of Week M24 of the Maintenance Phase (14 weeks)- total study drug treatment duration= 6 months
1764063|NCT00303498|Drug|Placebo|placebo identical to the study drug in description, dose and duration
1764064|NCT00303524|Drug|Goserelin acetate|Injection 3.6 mg monthly
1991578|NCT00843518|Drug|LY451395|3 mg BID oral 12 weeks. May be reduced to 1 mg if unable to tolerate
1764068|NCT00303550|Drug|Intravenous linezolid|
1764069|NCT00303563|Drug|P38 Inhibitor (4)|50mg po qd
1764070|NCT00303563|Drug|P38 Inhibitor (4)|150mg po qd
1764071|NCT00303563|Drug|P38 Inhibitor (4)|300mg po qd
1764072|NCT00303563|Drug|Placebo|po qd
1764073|NCT00303576|Drug|dapivirine (TMC120) vaginal gel|
1764074|NCT00303589|Drug|Standard care|As prescribed
1764075|NCT00303589|Drug|beta-lactam|750mg iv q8h
1764076|NCT00303589|Drug|beta-lactam|1500mg iv q8h
1764077|NCT00303602|Drug|Sublingual orally disintegrating olanzapine (SODO)|5 to 20mg dose, supplied in 5mg tablet strength, tablet should be placed under tongue for at least 60 seconds, daily for 16 weeks.
1764078|NCT00303602|Drug|Oral olanzapine|5 to 20mg dose, supplied in 5mg tablet strength, oral administration (tablets swallowed), daily for 16 weeks.
1764079|NCT00303615|Drug|Fluoxymesterone 10 mg|
1764080|NCT00303615|Drug|Anastrozole 1 mg|
1764081|NCT00303628|Drug|oxaliplatin|Given IV
1764082|NCT00303628|Drug|fluorouracil|Given IV
1764083|NCT00303628|Drug|leucovorin calcium|Given IV
1764084|NCT00303628|Drug|bevacizumab|Given IV
1764085|NCT00303641|Device|Medtronic Resting Heart Bypass System|
1764086|NCT00303654|Procedure|biopsy|
1764087|NCT00303654|Procedure|therapeutic conventional surgery|
1764088|NCT00303667|Biological|aldesleukin|Administered subcutaneously (SQ) 9 million units every other day beginning Day -12 through -2 (evening of natural killer cell infusion) for a total of 6 doses.
1764089|NCT00303667|Biological|natural killer cells|Infusion given on Day -12; The targeted infused cell dose of CD3- CD19- selected NK product is within the range of 2-3 x 10^7 cells/kg.
1764090|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Day -15
1764091|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 40 mg/m^2 on Days -18 through -14
1764092|NCT00303667|Procedure|allogeneic hematopoietic stem cell transplantation|On day 0, patients will receive an allogeneic transplant using pool cells from the day -1 and day 0 PBSC which will be CD34+ selected as the donor graft. The graft will be infused over 15-60 minutes.
1764093|NCT00303667|Radiation|total body irradiation|Administered on Day -13, 200 cGy two times.
1764094|NCT00303667|Biological|Thymoglobulin|intravenous (IV) 3 mg/kg on Day 0 (day of donor CD34 cell infusion)
1764095|NCT00303667|Drug|Cyclosporin A|1.5 mg/kg by mouth or intravenously for target dose range of 150-250; day -15 through day -8.
1764096|NCT00303667|Drug|cyclophosphamide|Administered intravenously (IV) 50 mg/kg on Days -16 and -15
1764097|NCT00303667|Drug|fludarabine phosphate|Administered intravenously (IV) 35 mg/m^2 on Days -18 through -14
1764098|NCT00303706|Procedure|Endoscopic Radial Artery Harvest|
1764107|NCT00303732|Drug|RAD001 (everolimus)|
1764108|NCT00303732|Drug|PTK787 (vatalanib)|
1764109|NCT00303745|Drug|capecitabine|
1764110|NCT00303745|Drug|irinotecan hydrochloride|
1764111|NCT00303758|Drug|cisplatin|
1764112|NCT00303758|Drug|fluorouracil|
1764113|NCT00303758|Drug|gemcitabine hydrochloride|
1764114|NCT00303758|Drug|leucovorin calcium|
1764115|NCT00303771|Drug|fluorouracil|
1764116|NCT00303771|Drug|irinotecan hydrochloride|
1764117|NCT00303771|Drug|leucovorin calcium|
1764118|NCT00303784|Drug|Goserelin|3.6mg implant, in pre-filled syringe
1764119|NCT00303784|Drug|Estradiol|Each patch contains 3 mg of estradiol hemihydrate in a patch size of 30 cm2, releasing 100 micrograms of estradiol per 24 hours.
1764120|NCT00303797|Drug|17-N-allylamino-17-demethoxygeldanamycin/bortezomib|
1764121|NCT00303797|Drug|sorafenib tosylate|
1764122|NCT00303810|Drug|carboplatin|
1764123|NCT00303810|Drug|cisplatin|
1764124|NCT00303810|Drug|cyclophosphamide|
1764125|NCT00303810|Drug|etoposide phosphate|
1764126|NCT00303810|Drug|high-dose chemotherapy|
1764127|NCT00303810|Drug|lomustine|
1764128|NCT00303810|Drug|methotrexate|
1764129|NCT00303810|Drug|thiotepa|
1764130|NCT00303810|Drug|vincristine sulfate|
1764131|NCT00303810|Radiation|radiation therapy|
1764132|NCT00303823|Drug|placebo|Given orally
1764133|NCT00303823|Dietary Supplement|defined green tea catechin extract|Given orally
1764134|NCT00303823|Other|laboratory biomarker analysis|Correlative studies
1764135|NCT00303836|Drug|cyclophosphamide|Given IV
1764136|NCT00303836|Drug|fludarabine phosphate|Given IV
1764137|NCT00303836|Biological|therapeutic autologous lymphocytes|Given IV
1764138|NCT00303836|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo in vitro-treated peripheral blood stem cell transplantation
1764139|NCT00303836|Biological|gp100 antigen|Given SC
1764140|NCT00303836|Biological|MART-1 antigen|Given SC
1764141|NCT00303836|Biological|incomplete Freund's adjuvant|Given SC
1764142|NCT00303836|Biological|filgrastim|Given SC
1764143|NCT00303836|Biological|aldesleukin|Given IV
1764144|NCT00303849|Drug|Carboplatin|Given IA
1764145|NCT00303849|Drug|Etoposide Phosphate|Given IV
1764146|NCT00303849|Other|Laboratory Biomarker Analysis|Correlative studies
1764147|NCT00303849|Drug|Mannitol|Given IA
1764148|NCT00303849|Drug|Melphalan|Given IA
1764149|NCT00303849|Other|Quality-of-Life Assessment|Ancillary studies
1764150|NCT00303849|Drug|Sodium Thiosulfate|Given IV
1764151|NCT00303862|Drug|cediranib maleate|Given orally
1764152|NCT00303862|Other|laboratory biomarker analysis|Correlative studies
1764153|NCT00303875|Behavioral|behavioral dietary and exercise intervention|
1764154|NCT00303888|Drug|docetaxel|Given IV
1764155|NCT00303888|Drug|idronoxil|Given orally
1764156|NCT00303888|Other|placebo|Given orally
1764157|NCT00303901|Procedure|cryosurgery|
1764158|NCT00303901|Procedure|positron emission tomography|
1764159|NCT00303914|Procedure|assessment of therapy complications|
1764160|NCT00303914|Procedure|cognitive assessment|
1764161|NCT00303914|Procedure|psychosocial assessment and care|
1764162|NCT00303927|Drug|capecitabine|
1764163|NCT00303940|Drug|carboplatin|
1764164|NCT00303940|Drug|talabostat mesylate|
1764165|NCT00303940|Drug|temozolomide|
1764166|NCT00303940|Other|pharmacological study|
1764167|NCT00303953|Drug|belinostat|Given IV
1764168|NCT00303966|Drug|sorafenib tosylate|Given orally
1764169|NCT00303992|Biological|trastuzumab|
1764170|NCT00303992|Drug|irinotecan hydrochloride|
1764171|NCT00304005|Drug|laromustine|
1764172|NCT00304018|Biological|anti-thymocyte globulin|
1764173|NCT00304018|Biological|sargramostim|
1764174|NCT00304018|Drug|busulfan|
1764175|NCT00304018|Drug|etoposide|
1764176|NCT00304018|Drug|fludarabine phosphate|
1764177|NCT00304018|Drug|prednisone|
1764178|NCT00304018|Drug|tacrolimus|
1764179|NCT00304018|Procedure|allogeneic hematopoietic stem cell transplantation|
1764180|NCT00304018|Procedure|umbilical cord blood transplantation|
1764181|NCT00304031|Drug|Concurrent temozolomide|Daily oral temozolomide (75 mg/m2) up to 49 doses.
1764182|NCT00304031|Radiation|Concurrent radiation therapy|60 Gy in 2 Gy fractions
1764183|NCT00304031|Drug|100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle|Oral temozolomide on days 1-5 of a 28-day cycle. Dose starts at 150mg/m2 for first cycle, increases to 200mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
1764184|NCT00304031|Drug|75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle|Oral temozolomide on days 1-21 of a 28-day cycle. Dose starts at 75mg/m2 for first cycle, increases to 100mg/m2 for subsequent cycles if no unacceptable toxicity. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity. Patients with responding disease may receive up to 6 more courses of temozolomide.
1764185|NCT00304070|Drug|doxorubicin hydrochloride|Given IV
1764186|NCT00304070|Procedure|conventional surgery|Patients undergo surgery
1764187|NCT00304070|Drug|cisplatin|Given IV
1764188|NCT00304070|Drug|mitotane|Given orally
1764189|NCT00304070|Drug|etoposide|Given IV
1764190|NCT00304070|Biological|filgrastim|Given subcutaneously
1764191|NCT00304083|Biological|filgrastim|Given subcutaneously
1764192|NCT00304083|Drug|doxorubicin hydrochloride|Given IV
1764193|NCT00304083|Drug|etoposide|Given IV
1764194|NCT00304083|Drug|ifosfamide|Given IV
1764195|NCT00304083|Procedure|conventional surgery|Patients undergo surgery
1764196|NCT00304083|Radiation|radiation therapy|Patients undergo radiotherapy
1764197|NCT00304096|Biological|synthetic breast cancer peptides-tetanus toxoid-Montanide ISA-51 vaccine|
1764198|NCT00304135|Drug|cisplatin|
1764199|NCT00304135|Drug|gemcitabine hydrochloride|
1764200|NCT00304135|Drug|oxaliplatin|
1764201|NCT00313391|Drug|Risperdal Consta|
1764202|NCT00313404|Biological|Safety tested norovirus inoculum|This is a safety tested live infectious norovirus inoculum that has been placed in groundwater that meets EPA drinking water standards
1764203|NCT00313417|Dietary Supplement|Creatine monohydrate|Up to 10 grams
1764204|NCT00313417|Other|Placebo|Placebo will be given in the same way and appearance as the active treatment
1764205|NCT00313443|Procedure|Fat tissue needle aspiration|Small fat tissue sampling performed by needle aspiration.
1764206|NCT00313456|Drug|Satraplatin|Satraplatin is an oral platinum analogue that has shown promising activity in multiple tumor settings. Satraplatin (40 to 80 mg/m2/day) will be administered orally on days 1 to 5 of a 21 day cycle.
1764207|NCT00313482|Drug|Sargramostim|250 mcg/m2 SC days 2-15 of each cycle
1764208|NCT00313482|Drug|Docetaxel|75 mg/m2 IV over 1 hour on Day 1 of each cycle
1764209|NCT00313482|Drug|Prednisone|5 mg orally BID on Day 1 continuously
1764210|NCT00313508|Biological|Autologous Dendritic Cells (DC)|Given intranodally
1764211|NCT00313508|Drug|Fludarabine|Fludarabine will be administered intravenously (IV) over 30 minutes, daily for 5 consecutive days.
1764212|NCT00313508|Biological|Autologous Lymphocyte Infusion (ALI)|Infusion
1764213|NCT00313521|Drug|thiotepa|
1764214|NCT00313521|Procedure|adjuvant therapy|
1764215|NCT00313521|Radiation|radiation therapy|
1764216|NCT00313534|Drug|masoprocol|
1764217|NCT00313547|Drug|Quinapril 40 mg|
1764218|NCT00313547|Drug|Quinapril 10 mg and amlodipine 5 mg|
1991579|NCT00843518|Drug|Placebo|BID oral 12 weeks
1764221|NCT00313573|Procedure|management of therapy complications|
1764222|NCT00313573|Procedure|pain therapy|
1764223|NCT00313573|Procedure|psychosocial assessment and care|
1764224|NCT00313573|Procedure|quality-of-life assessment|
1764225|NCT00313586|Drug|Azacitidine|Given SC
1764226|NCT00313586|Drug|Entinostat|Given PO
1764227|NCT00313586|Other|Laboratory Biomarker Analysis|Correlative studies
1764228|NCT00313599|Drug|lapatinib|
1764229|NCT00313599|Drug|paclitaxel|
1764230|NCT00313612|Drug|oxaliplatin|Given IV
1764231|NCT00313612|Drug|topotecan|Given IV
1764232|NCT00313625|Drug|busulfan|
1764233|NCT00313625|Drug|melphalan|
1764234|NCT00313625|Drug|methotrexate|
1764235|NCT00313625|Drug|tacrolimus|
1764236|NCT00313625|Procedure|allogeneic hematopoietic stem cell transplantation|
1764237|NCT00313625|Procedure|peripheral blood stem cell transplantation|
1764238|NCT00313690|Drug|Bortezomib, Docetaxel and Cisplatin|
1764239|NCT00313716|Drug|recombinant human erythropoietin, rhEpo|The study design is 2x2 factorial with randomization to erythropoietin or placebo and to transfusion trigger 10 gm/dl or 7 g/dl. Erythropoietin or placebo was initially dosed daily for 3 days and then weekly for 2 more weeks (first 74 patients, Epo1 dosing regimen), and then the 24- and 48-hour doses were stopped for the remainder of the patients (remaining 126 patients, Epo2 dosing regimen).
1764240|NCT00313716|Other|placebo|an inactive substance
1764241|NCT00313729|Drug|temozolomide|Chemotherapy
1764242|NCT00313742|Drug|insulin detemir|
1764243|NCT00313742|Drug|insulin glargine|
1764244|NCT00313742|Drug|insulin NPH|
1764245|NCT00313755|Procedure|Narrow Band Imaging|
1764246|NCT00316849|Other|pharmacological study|
1764247|NCT00316849|Procedure|adjuvant therapy|
1764248|NCT00316849|Radiation|3-dimensional conformal radiation therapy|
1764249|NCT00316849|Radiation|intensity-modulated radiation therapy|
1764250|NCT00316849|Drug|temsirolimus|Given IV
1764251|NCT00316849|Drug|temozolomide|Given orally
1764252|NCT00316862|Drug|cisplatin|Given IV
1764253|NCT00316862|Drug|irinotecan hydrochloride|Given IV
1764254|NCT00316862|Procedure|therapeutic conventional surgery|Undergo Surgery
1764255|NCT00316862|Radiation|radiation therapy|Undergo radiation
1764256|NCT00316875|Drug|lapatinib ditosylate|1500 mg orally daily for as long as patients remain on trial (up to 8 cycles).
1764257|NCT00316875|Drug|Doxil|Administered intravenously (IV) every 4 weeks in a dose-escalating fashion according to a set schedule
1764258|NCT00316888|Biological|cetuximab|Given IV
1764259|NCT00316888|Drug|cisplatin|Given IV
1764260|NCT00316888|Drug|fluorouracil|Given IV
1764261|NCT00316888|Radiation|radiotherapy|Given once daily 5 days a week for 5 weeks
1764262|NCT00316901|Procedure|computed tomography|
1764263|NCT00316901|Procedure|positron emission tomography|
1764264|NCT00316901|Radiation|fludeoxyglucose F 18|
1764265|NCT00316914|Drug|calcium gluconate|Given IV
1764266|NCT00316914|Drug|magnesium sulfate|Given IV
1764267|NCT00316914|Other|placebo|Given IV
1764268|NCT00316927|Drug|acetylsalicylic acid|
1764269|NCT00316927|Drug|dexamethasone|
1764270|NCT00316927|Drug|diethylstilbestrol|
1764271|NCT00316940|Drug|bortezomib|
1764272|NCT00316940|Radiation|samarium Sm 153 lexidronam pentasodium|
1764273|NCT00316953|Drug|dasatinib|Given orally
1764274|NCT00316953|Other|pharmacological study|Correlative studies
1764275|NCT00316953|Other|laboratory biomarker analysis|Correlative studies
1764276|NCT00316966|Behavioral|Multidisciplinary dietary intervention|
1764278|NCT00316992|Drug|Ramelteon and Placebo|Ramelteon 8 mg, tablets, orally, one night only and Ramelteon placebo-matching tablets, orally, one night only.
1764279|NCT00317005|Drug|folate treatment|
1764280|NCT00317018|Behavioral|Evidence-Based Quality Improvement|The implementation intervention is known as Evidence-Based Quality Improvement (EBQI). EBQI is an adaptation of the Plan-Do-Study-Act cycles of Continuous Quality Improvement that emphasizes empirical evidence and the involvement of clinical and implementation experts (i.e., researchers). In the EBQI implementation intervention, both researchers (clinical and implementation experts) and local staff participate fully in the quality improvement process, with the researchers facilitating rather than dictating implementation efforts. Using EBQI methods, researchers and local staff adapt evidence-based practices for local resources, needs and preferences while maintaining fidelity to the evidence-base. PDSA cycles are used to continuously revise the adapted evidence-based practice based on feedback during pilot tests.
1764281|NCT00317031|Drug|Acamprosate or Naltrexone|mg&d 90 days
1764282|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg twice daily
1764283|NCT00317044|Drug|Esomeprazole|Esomeprazole 40 mg once daily
1764284|NCT00317044|Drug|Placebo|Placebo twice daily
1764285|NCT00317057|Procedure|Patient education and disease management|
1764286|NCT00317070|Drug|dimethyl sulfoxide|intravesical installation 50 ml
1764287|NCT00317070|Drug|IC Cocktail|"Heparin 10,000 units
Gentamicin 80 mg
Hydrocortisone sodium succinate (Solucortef) 100 mg
Lidocaine hydrochloride 1% 10 ml
Sodium Bicarbonate 8.4% 5 ml"
1764288|NCT00317083|Procedure|Cough reflex test|
1764289|NCT00317096|Procedure|FCM|Active comparator: Chemotherapy
1764290|NCT00317096|Procedure|R-FCM|experimental: Chemotherapy with additional rituximab
1764291|NCT00317096|Drug|rituximab maintenance|2 courses of rituximab maintenance after completion of salvage therapy
1764292|NCT00317096|Other|observation only|no Intervention after completion of FCM or R-FCM
1764293|NCT00317109|Biological|Tritanrix™- HepB|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
1764294|NCT00317109|Biological|Hiberix™|One intramuscular dose during the booster vaccination study in subjects aged 15 to 18 months
1764295|NCT00317109|Biological|Mencevax™ ACW|One subcutaneous dose during the booster vaccination study in subjects aged 24 to 30 months
1764296|NCT00317122|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
1764297|NCT00317135|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
1764298|NCT00317148|Drug|Placebos|Placebo capsule
1764299|NCT00317148|Drug|DHEA capsule|One capsule of DHEA
1764300|NCT00317161|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
1764301|NCT00317174|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
1764302|NCT00317187|Biological|DTPw-HBV/Hib-MenAC conjugate vaccine|
1764303|NCT00317200|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV infusion over 1 hour, days 1, 8 and 15 of 28 day cycle.
1764304|NCT00317200|Drug|Bevacizumab|Bevacizumab 10 mg/kg, days 1 and 15 of 28 day cycle
1764305|NCT00317213|Drug|LIBERTAL- a phospholipid mixture|
1764306|NCT00317226|Drug|Ferric Carboxymaltose (FCM)|maximum dose of 1,000 mg over 15 minutes IV administered within 7 days of the qualifying visit
1764307|NCT00317239|Drug|Ferrous Sulfate tablets|325 mg/TID x 8 weeks
1764308|NCT00317239|Drug|Ferric Carboxymaltose (FCM)|A maximum dose of 1,000 mg of FCM over 15 minutes on day 0, and a maximum dose of 500 mg of FCM over 15 minutes on days 17 and 31 based on Ferritin and TSAT values.
1764309|NCT00317252|Drug|Hold ACEI or ARB|Angiotensin converting enzyme inhibitor or angiotensin receptor blocker held at least 24 hours pre-cardiac catheterization and restarted 48-96 hours post-catheterization (after creatinine measurement)
1764310|NCT00317265|Procedure|Coronary bypass surgery|
1764311|NCT00317278|Other|massage therapy|massage therapy to stable preterm infants
1764312|NCT00317278|Other|Sham|Sham (placebo) provided to the control group
1764313|NCT00317291|Procedure|Acupuncture/Moxibustion|
1764314|NCT00317304|Behavioral|Mindfulness-based stress reduction|MBSR is an 8-week group-based program of training in mindfulness and its application to the stresses and challenges of everyday life
1764315|NCT00317317|Procedure|Acupuncture|4 acupuncture treatments will be conducted during the IVF cycle. The 1st one is at the beginning of egg stimulation, the 2nd one is before the egg retrieval, the 3rd and 4th one are before and after the embryo transfer
1764316|NCT00317330|Drug|Isoniazid|
1764317|NCT00317330|Drug|Pyrazinamide|
1764318|NCT00317330|Drug|Rifampin|
1764319|NCT00317343|Drug|Bivalirudin (thrombin specific anticoagulant)|Percutaneous Coronary Intervention
1764320|NCT00317356|Drug|OPC-6535(Tetomilast)|
1764321|NCT00317369|Drug|OPC-6535(Tetomilast)|
1764322|NCT00317382|Device|Ultrasound|Ultrasound used to visualize spine to determine best location for lumbar puncture.
1764323|NCT00317395|Drug|Otamixaban (XRP0673)|intravenous administration
1764324|NCT00317395|Drug|unfractionated heparin|intravenous administration
1764325|NCT00317395|Drug|eptifibatide|intravenous administration
1764326|NCT00317408|Biological|anti-thymocyte globulin|
1764327|NCT00317408|Drug|busulfan|
1764328|NCT00317408|Drug|carboplatin|
1764329|NCT00317408|Drug|carmustine|
1764330|NCT00317408|Drug|cyclosporine|
1764331|NCT00317408|Drug|cytarabine|
1764332|NCT00317408|Drug|dexamethasone|
1764333|NCT00317408|Drug|etoposide phosphate|
1764334|NCT00317408|Drug|idarubicin|
1764335|NCT00317408|Drug|ifosfamide|
1764336|NCT00317408|Drug|leucovorin calcium|
1764337|NCT00317408|Drug|lomustine|
1764338|NCT00317408|Drug|melphalan|
1764339|NCT00317408|Drug|methotrexate|
1764340|NCT00317408|Drug|mitoxantrone hydrochloride|
1764341|NCT00317408|Drug|prednisolone|
1764342|NCT00317408|Drug|thiotepa|
1764343|NCT00317408|Drug|vinblastine sulfate|
1764344|NCT00317408|Drug|vindesine|
1764345|NCT00317408|Procedure|allogeneic hematopoietic stem cell transplantation|
1764346|NCT00317408|Procedure|autologous hematopoietic stem cell transplantation|
1764347|NCT00317408|Procedure|peripheral blood stem cell transplantation|
1764348|NCT00317408|Radiation|total-body irradiation|
1764349|NCT00317421|Drug|Sildenafil citrate|
1764350|NCT00317434|Drug|lapatinib|
1764351|NCT00317447|Drug|Oral Prednisone|
1764352|NCT00317460|Other|Physician Management|Standard physician care
1764353|NCT00317460|Behavioral|Counseling|Physician Management and Counseling
1764354|NCT00317473|Biological|FMP1/AS02A Malaria vaccine|Subjects vaccinated with FMP1/AS02 vaccine
1764355|NCT00317473|Biological|Imovax Rabies vaccine|Subjects vaccinated on corresponding FMP1/AS02A vaccination days
1764356|NCT00317486|Drug|bosentan|
1764357|NCT00317499|Other|Placebo|Placebo
1764358|NCT00317499|Drug|Etanercept|Etanercept
1764359|NCT00317512|Procedure|Percutaneous Coronary Revascularization|
1764360|NCT00317512|Drug|Hemoglobin-Based Oxygen Carrier-201 (HBOC-201)|
1764361|NCT00317512|Drug|Voluven|
1764362|NCT00317525|Device|Spectacle Lenses|
1764363|NCT00317538|Drug|infliximab, etanercept|
1764364|NCT00317551|Device|Aberration controlled contact lens|
1764365|NCT00317551|Behavioral|Vision training|
1764366|NCT00317577|Drug|brimonidine, timolol|
1764367|NCT00317590|Device|Rapid Diagnostic Test for Malaria (Paracheck®)|
1764368|NCT00317603|Biological|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
1764369|NCT00317629|Drug|controlled nitric oxide releasing patch|daily nitric oxide patch application during 20 days
1764370|NCT00317629|Drug|meglumine antimoniate|20mg/kg daily during 20 days
1764371|NCT00317642|Drug|clofarabine (IV formulation)|clofarabine (IV formulation) infusion 40mg/m^2 / day up to 3 cycles
1764372|NCT00317642|Drug|placebo|placebo (sodium Chloride) 1-hour IV infusion
1764373|NCT00317642|Drug|cytarabine|cytarabine IV infusion 1g/m^2/day for up to 3 cycles
1764374|NCT00317655|Drug|Glucosamine sulphate|
1764375|NCT00317655|Drug|Ginger|
1764376|NCT00317655|Drug|Ginger-Avocado-Soya|
1764377|NCT00317655|Drug|Ginger-ibuprofen|
1764378|NCT00317681|Drug|Tacrolimus ointment|
1764379|NCT00317694|Drug|Fermagate|Film coated tablet 500mg
1764380|NCT00317694|Drug|Placebo|Oral administration, film coated tablet, 0mg
1764381|NCT00317707|Drug|N-3 Polyunsaturated Fatty Acids|Each subject assigned to active treatment group will receive 1g/day capsule of n-3 PUFA
1764382|NCT00317707|Drug|Placebo: Olive oil|Each subject assigned to the control group will receive 1 g/day capsule of olive oil.
1764383|NCT00317720|Drug|Trastuzumab|"Loading dose = 8 mg/kg daily; maintenance dose = 6 mg/kg once per 21 day cycle.
If participant on trastuzumab at time of registration, loading dose deferred and received maintenance dose (6 mg/kg every 3 weeks). If the last trastuzumab dose was given 1 week (for participants receiving 2 mg/kg/week), or 3 weeks before registration (for participants receiving 6 mg/kg every 3 weeks), a loading dose (8 mg/kg) was given followed by maintenance dose."
1764384|NCT00317720|Drug|RAD001|Starting dose 10 mg by mouth daily. Phase I dose finding from two dose levels of daily RAD001 (5 and 10 mg).
1764385|NCT00317733|Drug|Ketoprofen in Transfersome|
1764386|NCT00317746|Drug|Citalopram|
1764387|NCT00317746|Drug|Placebos|
1764388|NCT00317759|Biological|therapeutic autologous lymphocytes|
1764389|NCT00317759|Drug|fludarabine phosphate|
1764392|NCT00317785|Drug|cyclophosphamide|
1764393|NCT00317785|Drug|cyclosporine|
1764394|NCT00317785|Drug|methotrexate|
1764395|NCT00317785|Drug|mycophenolate mofetil|
1764396|NCT00317785|Drug|sirolimus|
1764397|NCT00317785|Drug|tacrolimus|
1764398|NCT00317785|Other|pharmacological study|
1764399|NCT00317785|Procedure|allogeneic bone marrow transplantation|
1764400|NCT00317785|Procedure|allogeneic hematopoietic stem cell transplantation|
1764401|NCT00317785|Procedure|peripheral blood stem cell transplantation|
1764402|NCT00317785|Radiation|total-body irradiation|
1764403|NCT00317798|Biological|anti-thymocyte globulin|Escalating doses of rATG,intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
1764404|NCT00317798|Drug|sirolimus|escalating doses of rATG, intravenously, starting at 6 mg/kg to a maximum of 14.5 mg/kg. Rapamycin is given orally, starting at a dose of 1 mg daily beginning on day 1 and terminating on day 30. The dose of rapamycin was adjusted to maintain a constant blood level of 4-6 ng/ml in all subjects
1764405|NCT00317811|Dietary Supplement|ascorbic acid|
1764406|NCT00317811|Drug|bortezomib|
1764407|NCT00317811|Drug|melphalan|
1764408|NCT00317837|Procedure|Unipolar Hemiarthroplasty of the hip joint|Unipolar Hemiarthroplasty of the hip joint
1764409|NCT00317837|Procedure|bipolar hemiarthroplasty|bipolar hemiarthroplasty
1764410|NCT00317850|Drug|Gabapentin (Neurontin)|
1764411|NCT00317876|Drug|cyclophosphamide|
1764412|NCT00317876|Drug|cyclosporine|
1764413|NCT00317876|Drug|methotrexate|
1764414|NCT00317876|Procedure|allogeneic bone marrow transplantation|
1764415|NCT00317876|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1764416|NCT00317889|Procedure|Bone preparation technique: compaction|
1764417|NCT00317889|Procedure|Bone preparation technique: broaching|
1764418|NCT00317902|Drug|Epoetin alfa|
1764419|NCT00317915|Drug|Irbesartan treatment|
1764420|NCT00317928|Drug|Metformin|
1764421|NCT00317941|Drug|Betaferon/Betaseron|250ug administrated with Betaject
1764422|NCT00317941|Drug|Rebif|44ug administered with Rebiject II
1764423|NCT00317941|Drug|Betaferon/Betaseron|250ug administrated with Betaject light
1764424|NCT00317954|Drug|Spironolactone|
1764425|NCT00317967|Drug|Atorvastatin|80 mg pills daily
1764426|NCT00317967|Drug|Placebo|80 mg pills daily
1764427|NCT00317980|Drug|Meglumine antimoniate|Meglumine antimoniate 5mg/kg/d for 20 days
1764428|NCT00317980|Drug|Meglumine antimoniate|Meglumine antimoniate 15 mg/kg/d for 20 days
1764429|NCT00317993|Drug|ezetimibe|
1764430|NCT00317993|Drug|simvastatin|
1764431|NCT00317993|Drug|ezetimibe plus simvastatin|
1764432|NCT00318006|Procedure|saline irrigation|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
1764433|NCT00318006|Procedure|saline spray|subjects were instructed in the technique of nasal lavage (irrigation group) or nasal saline spray (spray group) and were asked to do the assigned treatment twice daily for 8 weeks. They were provided with an 8-week supply of materials (Sinus Rinse irrigations from NeilMed Products Inc, and Deep Sea nasal saline spray distributed by Major Pharmaceuticals, Livonia, Michigan).
1764434|NCT00318019|Dietary Supplement|OPC Factor(TM)|Evervescent poweder containing oligomeric proanthocyanidins (OPCs)and other nutrients.
1764435|NCT00318019|Other|Placebo|Effervescent powder similar in taste and appearance to the intervention but without the OPCs and nutrients.
1764436|NCT00318032|Drug|multi-factorial intervention|
1764437|NCT00318045|Device|Eyeglass lenses|
1764438|NCT00318058|Biological|influenza vaccine Fluarix, Adjuvanted Fluarix|
1764439|NCT00318071|Device|Merci Retriever|"For patients eligible to participate in the trial, the operating physician initiated treatment with the Merci L5 Retriever to remove large vessel thrombotic occlusion and recanalization of the vessel. Subsequent treatment could be made with Merci X6 or X5 Merci Retrievers.
Large vessel arteries are defined as internal carotid, middle cerebral M1/M2 segments, basilar, and vertebral arteries.
Recanalization was defined as TIMI II or TIMI III per angiography."
1764440|NCT00318084|Drug|Esomeprazole|
1764441|NCT00318084|Procedure|Ambulatory 24-hour esophageal pH-monitoring|
1764442|NCT00318110|Procedure|NST using MUD for metastatic renal cell carcinoma|"Preparative regimen:
Fludarabine 25 mg/m2 IV once a day x 5 days (-6,-5,-4,-3,-2) Melphalan 70 mg/m2 IV once a day x 2 days (-3,-2) Donor Stem Cell Infusion: Stem cells will be infused on day 0 GVHD prophylaxis: Tacrolimus and methotrexate 5 mg/m2 IV day 1, 3, 6 and 11"
1764443|NCT00318123|Drug|Kivexa|abacavir 600mg + lamivudine 300mg in one tablet QD
1764444|NCT00318136|Drug|Bevacizumab|15 mg/kg administered intravenously on Day 1 of each 21- to 28-day cycle, beginning on Cycle 3
1764445|NCT00318136|Drug|Carboplatin|Dose based on Calvert formula, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
1764446|NCT00318136|Drug|Paclitaxel|Dose based on patient's body surface area, on Day 1 of each 21- to 28-day cycle for a total of 6 cycles
1764448|NCT00318162|Drug|low dose naltrexone|
1764449|NCT00318175|Drug|Bosentan (Tracleer)|
1764450|NCT00318188|Procedure|standardized reeducation and readaptation program|
1764451|NCT00318201|Drug|Erythromycin|
1764452|NCT00318201|Drug|Diltiazem|
1764453|NCT00318214|Drug|MRE0094|Gel, 500 mcg/g once each day
1764454|NCT00318214|Drug|Vehicle gel|Gel administered once per day
1764455|NCT00318227|Procedure|Blood Transfusion|Blood transfusion will be administered when the transfusion trigger is met.
1764456|NCT00318240|Device|High Intensity Focused Ultrasound|Treatment of Radiation failure in Prostate Cancer
1764457|NCT00318253|Procedure|cranberry juice|
1764458|NCT00318266|Device|Nuclear Matrix Protein 22 Urine sample kit|Urine sample obtained from patient will be tested with the NMP22 sample kit to see if it can detect bladder cancer.
1764459|NCT00318279|Device|Surgical simulator to practice vascular anastomosis|
1764460|NCT00318292|Drug|bupivacaine and epinephrine|20 ml of 0.5% bupivacaine with 1:200,000 epinephrine paracervical injection.
1764461|NCT00318292|Drug|Placebo|20 ml normal saline injection.
1764462|NCT00318318|Drug|Premarin|
1764463|NCT00318331|Drug|Glutamine|Group A patients will receive 0.5g/kg/day of enteral glutamine daily while they are receiving tube feeds or at the end of 28 days (whichever comes first)
1764464|NCT00318344|Drug|Atuna Racemosa|
1764465|NCT00318357|Device|Medtronic CRT InSync® family devices|Implantation of CRT device and medical treatment according normal hospital routine.
1764466|NCT00318370|Drug|Farletuzumab|Weekly Farletuzumab infusions Dose dependent on dosing group
1764467|NCT00318370|Drug|Chemo Plus Far|Chemo+Far: paclitaxel 175 mg/m2 (or docetaxel, 75 mg/m2) plus carboplatin area under the concentration-time curve (AUC) 5-6 intravenously (IV) on Day 1 of a 21-day cycle plus farletuzumab, 100 mg/m2.
1764468|NCT00318383|Biological|NicVAX conjugate vaccine|200 mcg or 400 mcg IM in 4 doses over 6 months; 200 mcg or 400 mcg IM in 5 doses over 6 months; 200 mcg (formulation 2) IM in 5 doses over 6 months; All are adsorbed onto Alhydrogel
1764469|NCT00318383|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 4 or 5 doses over 6 months
1764470|NCT00318396|Procedure|Bone preparation technique: compaction|The bone is pressed very hard together before implantation of femoral component.
1764471|NCT00318396|Procedure|Bone preparation technique: conventional technique|Bone is broached before implantation of femoral component.
1764472|NCT00318409|Drug|Bupropion|
1764473|NCT00318409|Drug|Placebo|
1764474|NCT00318422|Drug|liraglutide|
1764475|NCT00318422|Drug|rosiglitazone|
1764476|NCT00318422|Drug|glimepiride|
1764477|NCT00318435|Device|Stent or stent-graft deployment|
1764478|NCT00318448|Drug|Zolpidem (SL800750)|
1764479|NCT00318461|Drug|liraglutide|0.6 mg for s.c. (under the skin) injection.
1764480|NCT00318461|Drug|metformin|1.5-2.0 g tablets
1764481|NCT00318461|Drug|glimepiride|4 mg tablets
1764482|NCT00318461|Drug|placebo|Glimepiride placebo 1 mg and 2 mg tablets
1764483|NCT00318461|Drug|placebo|Liraglutide placebo 1-3 mL for s.c. (under the skin) injection
1764484|NCT00318461|Drug|liraglutide|1.2 mg for s.c. (under the skin) injection
1764485|NCT00318461|Drug|liraglutide|1.8 mg for s.c. (under the skin) injection
1764486|NCT00318474|Drug|Mycophenolate Mofetil (MMF)|Oral administration of MMF; dose based on body size (between 25mg/kg/day and 36ng/kg/day); maximum dose 1gm BID.
1764487|NCT00318474|Drug|MMF Placebo|Placebo only, oral administration
1764488|NCT00318474|Drug|ACEi|Administer same as pre-treatment regimen.
1764489|NCT00318474|Drug|FOS|Administer same as pre-treatment regimen
1764490|NCT00318487|Procedure|Bilateral sinus augmentation with immediately loaded dental implants|Bilateral sinus augmentation with immediately loaded dental implants will be used.
1764491|NCT00318500|Drug|ERB-041|
1764492|NCT00318513|Drug|Bevacizumab|
1764493|NCT00318539|Drug|Quetiapine|
1764494|NCT00318552|Drug|Meropenem|
1764495|NCT00318565|Device|RF energy delivery for treatment of Typical Atrial flutter|Navistar ThermoCool catheter
1764496|NCT00318591|Device|SpeediCath|hydrophilic coated urinary intermittent catheter
1764497|NCT00318591|Device|Conveen Uncoated|Uncoated urinary intermittent catheter
1764498|NCT00318617|Drug|GW510516X|
1764499|NCT00318630|Drug|Rosiglitazone|Rosiglitazone will be given as immediate release tablet of 4 milligrams administered orally for 28 days.
1764500|NCT00318630|Drug|Placebo|Subjects will also receive placebo oral tablet.
1764501|NCT00318643|Drug|Chemophase|
1764502|NCT00318643|Drug|Mitomycin C|
1764503|NCT00318656|Drug|rosiglitazone-metformin fixed dose combination|
1764504|NCT00318656|Drug|metformin + glimepiride|
1764506|NCT00318682|Device|FIBROSCAN|diagnostic examination of the hepato fibrosis
1764507|NCT00318695|Dietary Supplement|Probiotics|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
1764508|NCT00318695|Other|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
1764509|NCT00318708|Drug|clarithromycin|clarithromycin 500 mg twice daily (Biaxin)
1764510|NCT00318708|Drug|fluticasone propionate|fluticasone propionate 88 mcg twice daily (Flovent® HFA 44 mcg two puffs twice daily)
1764511|NCT00318708|Drug|placebo clarithromycin|placebo clarithromycin twice daily
1764512|NCT00318721|Device|Long Lasting Impregnated Nets (LLIN)|Distribution of LLIN in selected clusters
1764513|NCT00318747|Drug|Amb a 1-immunostimulatory oligodeoxyribonucleotide conjugate (AIC)|
1764514|NCT00318760|Drug|Clonidine|0.1 or 0.2 mg oral, one dose
1764515|NCT00318760|Drug|Placebo|oral capsule 1 dose
1764516|NCT00318773|Drug|sertraline|50 - 100 mg daily for 2 weeks before each menses for 4 months or 12 months and then switched to placebo.
1764517|NCT00318786|Drug|biphasic insulin aspart|
1764518|NCT00318799|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|per cycle (28 days): Days 1-2: 3.0 mg EV; Days 3-7: 2.0 mg EV + 2.0 mg DNG; Days 824: 2.0 mg EV + 3.0 mg DNG; Days 25-26: 1.0 mg EV; Days 27-28: Placebo
1764519|NCT00318799|Drug|SH D01155E|per cycle: Days 1-21: 0.03 mg EE + 0.15 mg LNG; Days 22-28: Placebo
1764520|NCT00318812|Drug|Heme Iron Polypeptide (Proferrin)|Heme iron polypeptide 11mg po tid for 6 months
1764521|NCT00318812|Drug|Iron sucrose (Venofer)|Iron sucrose infusion IV q month x 6 months
1764522|NCT00318825|Drug|Nitrous oxide|
1764523|NCT00318838|Drug|Azimilide dihydrochloride|125 mg azimilide tablet every 12 hours for 3 days followed by 125 mg azimilide tablet every 24 hours for three days
1764524|NCT00318838|Drug|Placebo|Placebo tablet every 12 hours for 3 days followed by placebo tablet every 24 hours for three days
1764525|NCT00318851|Device|Carotid Stent with Distal Protection Device|Carotid Stent Placement with Distal Protection
1764526|NCT00318864|Behavioral|Cognitive behavioral therapy|
1764527|NCT00318877|Behavioral|After school team sports program|
1764528|NCT00318877|Behavioral|After school health education program|
1764529|NCT00318890|Drug|Cisplatin|Cisplatin is given at a dose of 75 mg/m2 intravenously for three cycles on Days 1, 21, and 43.
1764530|NCT00318890|Drug|Docetaxel|Docetaxel is given at a dose of 75 mg/m2 intravenously on Days 1, 21, and 43 and continued at variable doses for 4 weeks with standard radiotherapy.
1764531|NCT00318890|Procedure|Radiotherapy|Radiation therapy will be given 5 days each week for 4 weeks plus a concomitant boost in the last 2 weeks of treatment to deliver 54 Gy in 30 fractions. Radiotherapy will follow the induction chemotherapy with docetaxel and cisplatin.
1764532|NCT00318890|Drug|Amifostine|Amifostine will be administered as a subcutaneous injection on a daily basis during radiotherapy.
1764533|NCT00318903|Drug|Irinotecan (drug)|50 mg/m2 of Irinotecan will be administered intravenously over 60-90 minutes following a Taxotere infusion each week for 3 weeks. After a break, Irinotecan will then be given for 3 consecutive weeks at 45 mg/m2 in conjunction with radiotherapy.
1764534|NCT00318903|Drug|Taxotere (drug)|Taxotere at 35 mg/m2 is given intravenously over 1 hour each week for three consecutive weeks. After a one-week break, patients will receive Taxotere at a 25 mg/m2 dose for the first three weeks of a 5-6 week radiotherapy regimen.
1764535|NCT00318903|Procedure|Radiotherapy (procedure)|Radiotherapy will be given in 28 fractions over 5-6 weeks at 1.8 Gy per fraction for a total of 50.4 Gy. This will begin concurrently with chemotherapy on Day 29 of treatment.
1764536|NCT00318903|Procedure|Esophagectomy (procedure)|After approximately 14 weeks of treatment, the patient will be evaluated for surgery. Only those who have achieved a good response will be eligible.
1764537|NCT00318929|Drug|Divalproex Sodium Extended-Release Tablets|Once a day dosing
1764538|NCT00318942|Drug|Crystalloids|Isotonic or hypertonic saline or Ringer Lactate or any other crystalloids, at the necessary dose to restore hemodynamic for all ICU stay
1764539|NCT00318942|Drug|Colloids|Gelatines, Albumine, Starch, or any other colloids, at the necessary dose to restore hemodynamic (starch cumulative daily dose should not exceed 35/40 ml/kg), for all ICU stay
1764540|NCT00318942|Drug|Crystalloids|Any crystalloids given for correction of hypovolemia during all ICU stay
1764541|NCT00318942|Drug|Colloids|Any colloids given for correction of hypovolemia during all ICU stay
1764542|NCT00318955|Drug|Dexmedetomidine|
1764543|NCT00318955|Drug|Propofol|
1764544|NCT00318968|Drug|Esomeprazole|
1764545|NCT00318981|Drug|Concerta|
1764546|NCT00318994|Drug|Meropenem|
1764547|NCT00319007|Drug|Sulindac (drug)|
1764548|NCT00319007|Drug|VSL#3 (probiotic)|
1764549|NCT00319007|Drug|Inulin (probiotic)|
1764550|NCT00319020|Drug|Bosentan|32-mg dispersible and breakable tablet. The body weight-adjusted dose of the dispersible tablet was dispersed in a teaspoon of water (not mixed with food) before being administered orally
1764551|NCT00319033|Drug|bosentan|
1764552|NCT00319046|Drug|miglustat|miglustat oral capsules 100mg three times daily (TID)
1764553|NCT00319059|Drug|systemic administration of 99mTc-HYNIC-Annexin A5|
1764554|NCT00319059|Behavioral|10 minutes of ischemic handgripping|
1764555|NCT00319072|Behavioral|TalkToYourDoc(sm) hormone therapy module|
1764556|NCT00319085|Procedure|Total hip replacement (Preheating of femur stem)|Total hybrid hip arthroplasty, cementation of femural component, preheating, radiostereometry, DEXA
1764557|NCT00319098|Biological|Adjuvanted pandemic influenza candidate vaccine|2 doses, intramuscular injection
1764558|NCT00319098|Biological|Fluarix|One intramuscular injection
1764559|NCT00319098|Biological|Placebo|One intramuscular injection
1764560|NCT00319111|Drug|bosentan|"Oral bosentan
Initial dose: 62.5 mg twice a day (b.i.d.) for 4 weeks for all patients
Maintenance dose: 125 mg b.i.d. (62.5 mg b.i.d. if weight < 40 kg)"
1764561|NCT00319137|Drug|GW274150|
1764562|NCT00319150|Drug|erythropoietin|Decrease dosage by 12.5% q 2 weeks according to an algorithm.
1764563|NCT00319163|Drug|levonorgestrel/ethinyl estradiol|
1764564|NCT00319189|Drug|Nateglinide|
1764565|NCT00319202|Drug|Candesartan|32 mg/d for 6 months
1764566|NCT00319202|Drug|Placebo|Placebo administration for 6 months
1764567|NCT00319215|Drug|Ramelteon 8 mg|
1764568|NCT00319215|Drug|Zopiclone 7.5 mg|
1764569|NCT00319228|Drug|Plasma-derived AT-III concentrate|"Segment I: A single dose IV infusion of 50 IU/kg of ATIII-DAF/DI will be administered to each patient.
Segment II: A single dose or multiple doses depending on the subject's ATIII plasma levels and patient's specific treatment plan."
1764570|NCT00319241|Behavioral|Parenting Intervention|
1764571|NCT00319254|Drug|SKI-606 (Bosutinib)|SKI-606 (Bosutinib) 400mg once daily, for as long as tolerated or until disease progression.
1764572|NCT00319267|Drug|Bosentan|Pediatric oral formulation of bosentan, i.e., 32 mg dispersible and breakable tablets
1764573|NCT00319280|Procedure|bonesubstitution (Calcibon, Iliac Crest Bonegraft, control)|Osteotomysite are filled with Calcibon (an injectable calcium phosphate cement) or Minced Iliac Crest Bonegraft og local graft as control
1764574|NCT00319293|Drug|Metformin|
1764575|NCT00319306|Drug|Budesonide/formoterol|
1764576|NCT00319306|Device|Symbicort® Turbohaler®|
1764577|NCT00319319|Drug|Mecamylamine hydrochloride (Inversine)|
1764578|NCT00319332|Drug|Ibritumomab Tiuxetan|
1764579|NCT00319332|Drug|Iodine I 131 Tositumomab|
1764580|NCT00319345|Drug|Mannitol, Sodium-Lactate|
1764581|NCT00301041|Other|laboratory biomarker analysis|
1764582|NCT00301041|Procedure|adjuvant therapy|
1764583|NCT00301041|Radiation|radiation therapy|
1764584|NCT00301054|Drug|Ferrous sulphate|
1764585|NCT00301054|Drug|Sulphadoxine-Pyrimethamine|
1764586|NCT00301067|Dietary Supplement|calcitriol|The patient will receive calcitriol in capsule form by mouth on Days 1 and 15 of every cycle
1764587|NCT00301067|Drug|temozolomide|The patient will receive temozolomide in capsule form by mouth on Days 2-8 and 16-22 of each 28 study treatment cycle
1764588|NCT00301080|Drug|D-cycloserine|
1764589|NCT00301080|Other|Placebo|
1764590|NCT00301093|Biological|GM-K562 cell vaccine|Once weekly for 3 vaccination, then every other week for 3 vaccinations, and then every month for 3 vaccinations until the participant has received a total of 9 vaccinations
1764591|NCT00301093|Drug|imatinib mesylate|Participants will continue on current dose
1764592|NCT00301106|Biological|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/
1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
1764593|NCT00301145|Behavioral|smoking cessation intervention|
1764594|NCT00301145|Drug|varenicline|
1764595|NCT00301145|Other|counseling intervention|
1764596|NCT00301145|Other|internet-based intervention|
1764597|NCT00301158|Behavioral|exercise intervention|
1764598|NCT00301158|Other|counseling intervention|
1764599|NCT00301158|Other|educational intervention|
1764600|NCT00301158|Procedure|complementary or alternative medicine procedure|
1764601|NCT00301171|Drug|Inhaled Fluticasone|
1764602|NCT00301184|Biological|pGA2/JS7 DNA|DNA Vaccine
1764603|NCT00301184|Biological|Modified vaccinia Ankara/HIV62|Recombinant Modified Ankara Vaccine
1764604|NCT00301197|Behavioral|Behavioral Skills Maintenance|
1764605|NCT00301197|Behavioral|Social Facilitation Maintenance|
1764606|NCT00301210|Drug|Tramadol|oral doses four times per day
1764607|NCT00301223|Drug|Pregabalin|
1764608|NCT00301236|Drug|Dexmethylphenidate HCl extended-release capsules|
1764609|NCT00301262|Drug|Viagra (Sildenafil citrate)|
1764610|NCT00301288|Procedure|Autologous stem cell transplant|
1764611|NCT00301301|Drug|Gemcitabine|
1764612|NCT00301301|Drug|Cisplatinum|
1764613|NCT00301301|Drug|Rituximab|
1764614|NCT00301314|Procedure|Autologous stem cell transplant|
1764615|NCT00301327|Drug|Summers 5% L.A.|
1764616|NCT00301340|Drug|5% Lice Asphyxiator lotion - Summers Laboratories, Inc.|
1764617|NCT00301353|Drug|Isoflavones-enriched foods|
1764618|NCT00301366|Drug|alpha-1 proteinase inhibitor (human)|60 mg/kg weekly for 20 weeks
1764619|NCT00301379|Other|Observation data collection study.|This is a data collection study where the main purpose is to collect information about the treatments patients receive for their unresectable cholangiocarcinoma.
1764620|NCT00301392|Other|life-style intervention|As the life-style interventions aiming to reduce the major risks of developing diabetes mellitus, instruct the following four items:(1)set diet right, (2)maintain normal weight,(3)improve physical activity,(4)normalize smoking and alcohol drinking.
1764621|NCT00301392|Drug|Life style interventions plus concomitant use of pitavastatin.|Once-daily dosing of pitavastatin 1 mg(1 tablet of Livalo Tab 1 mg), or 2mg(2 tablets of Livalo Tab 1mg or 1 tablet of Livalo Tab 2mg);Dosing period of pitavastatin should be 60 months.(max.84 months).
1764622|NCT00301405|Drug|Thalidomide|Open label drug
1764623|NCT00301418|Drug|Erlotinib|Tarceva®: Will be given at a starting dose of 150mg QD dose for the first cycle which is 28 days. This will be followed by 14 days of 100mg PO on a bid schedule and 150mg PO on a bid schedule for the final 14 days of the second cycle. Assuming no dose limiting toxicity, 150 mg PO tid will be continued for up to 10 more cycles. This is an outpatient regimen, in which the drug is admininistered orally. Tumor response will be assessed after every 2nd treatment cycle. Patients may receive a maximum of 12 cycles of treatment under this research protocol.
1764624|NCT00301431|Drug|DVS-233|
1764625|NCT00301444|Device|mirror-box treatment|
1764626|NCT00301444|Behavioral|Mental visualization|
1764627|NCT00301457|Drug|Anastrozole|1 mg once daily oral dose
1764628|NCT00301470|Device|MR urography|undergoing both renal scintigraphy and MR within a month
1764667|NCT00307255|Drug|paclitaxel albumin-stabilized nanoparticle formulation|260 mg/m2 to 340 mg/m2 (dose will depend on when subject enters the study). Paclitaxel will be given on day 1 of each 21 day cycle (every 3 weeks)
1764668|NCT00308399|Drug|Itopride|
1764669|NCT00308412|Biological|rHPIV3cp45|Placebo for rHPIV3cp45 vaccine is 1X L-15.
1764670|NCT00308412|Biological|Placebo|Placebo for rHPIV3cp45 vaccine
1764629|NCT00301483|Drug|Hemoglobin-based oxygen carrier-201 (HBOC 201)|HBOC-201 is an investigational solution of sterile, ultrapurified, glutaraldehyde polymerized, modified bovine hemoglobin (Hb) in a balanced electrolyte solution. HBOC-201 has an Hb concentration of 12-14g/dL. HBOC-201 is an isosmotic solution that is stable for at least 36 months at 2-30ºC. It requires no reconstitution and can be administered directly into a peripheral or central vein. Blood typing is not required because all other cellular components, including the RBC membranes that carry the blood group antigens, have been removed.
1764630|NCT00301483|Other|Standard of Care|Standard Therapy
1764631|NCT00301496|Device|Coban 2 Layer Compression System|
1764632|NCT00301509|Drug|peginterferon and ribavirin|
1764633|NCT00301522|Device|TAXUS Paclitaxel-Eluting Coronary Stent, Slow-Formulation|Paclitaxel-Eluting Coronary Stent, Slow-Formulation
1764634|NCT00301522|Device|Express2|Coronary Stent System
1764635|NCT00307034|Biological|GSK Biologicals' 10-valent pneumococcal conjugate vaccine.|Intramuscular injection, 3 or 4 doses (2-4-11 or 2-3-4-11 months of age schedule).
1764636|NCT00307034|Biological|Infanrix hexa.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
1764637|NCT00307034|Biological|Infanrix-IPV/Hib.|Intramuscular injection, 3 doses (2-4-11 months of age schedule).
1764638|NCT00307047|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
1764639|NCT00307047|Device|TAXUS™ EXPRESS2™ Paclitaxel Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
1764640|NCT00307060|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 6 weeks|
1764641|NCT00307060|Drug|losartan / Duration of Treatment: 6 weeks|
1764642|NCT00307073|Device|Implantable Pulse Generator|
1764643|NCT00307086|Drug|Bortezomib|the maximum tolerated dose (MTD) of bortezomib in combination with high-dose melphalan as a conditioning regimen for autologous stem cell transplant
1764644|NCT00307086|Drug|Melphalan|Day -4 melphalan 100 mg/m2 intravenously over 30 minutes, Day -3 melphalan 100 mg/m2 intravenously over 30 minutes
1764645|NCT00307086|Procedure|PBSCT|PBSCT #1 Day 0 PBSCT #2 Day 0 (approx 90 days =/- 15 days after PBSCT #1)
1764646|NCT00307099|Drug|Meropenem|Meropenem 1 gram intravenously every 8 hours for 3 days (9 doses), then an additional 5 days if the Clinical Pulmonary Infection Score is greater than 6.
1764647|NCT00307099|Drug|Standard antibiotic therapy|Standard intravenous antibiotic therapy for a minimum of 8 days.
1764648|NCT00307125|Drug|Rituximab plus immunosuppression|"Genetically engineered monoclonal antibody directed against the CD20 antigen on B cells and is known to deplete B cells when administered intravenously. Generally used in the treatment of non-Hodgkin's lymphoma
Standard immunosuppression is site-specific."
1764649|NCT00307125|Drug|Placebo plus immunosuppression|"Placebo dosing: Adult Dosing (Subjects >18 years): 1000 mg on days 0 and 14; Pediatric Dosing (Subject <\=18 years): 375 mg/m^2/dose (maximum 500 mg/dose) in 4 doses, once per week (Days 0, 8, 15 and 22).
Standard immunosuppression is site-specific."
1764650|NCT00307138|Drug|hetastarch|
1764651|NCT00307151|Drug|Lamivudine|4 mg/kg twice daily
1764652|NCT00307151|Drug|Lopinavir/ritonavir|16/4 mg/kg twice daily for participants 2 months of age to less than 6 months of age; 12/3 mg/kg twice daily for participants at least 6 months of age and weighing less than 15 kg; 10/2.5 mg/kg twice daily for participants at least 6 months of age and weighing between 15 kg and 40kg; 400/100 mg twice daily for participants weighing more than 40 kg
1764653|NCT00307151|Drug|Nevirapine|Initially: 4 mg/kg for 14 days, then 7 mg/kg twice daily. In protocol version 2.0, Letter of Amendment 1 (September 2007), NVP dose increased to conform with WHO guidelines to: 160 to 200 mg/m^2/dose to max 200 mg once daily for 14 days, then 160 to 200 mg/m^2/dose to max 200 mg twice daily
1764654|NCT00307151|Drug|Zidovudine|180 mg/m^2 twice daily
1764655|NCT00307164|Drug|NucleomaxX|36 g sachet taken orally three times daily
1764656|NCT00307164|Drug|NucleomaxX placebo|36 g placebo sachet taken orally three times daily
1764657|NCT00307177|Biological|Trivalent inactivated influenza vaccine|Standard Trivalent inactivated influenza vaccine, licensed. Arm A receives standard dose of 15 mcg IM on day 0.
1764658|NCT00307177|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Trivalent Baculovirus-expressed influenza HA vaccine (Recombinant rHA0): Arms B, C and D receive 15 mcg, 45 mcg or 135 mcg IM dose on Day 0.
1764659|NCT00307203|Drug|bupropion SR|Participants were randomly assigned to receive bupropion SR 150 mg or placebo, once daily for 7 days, then twice daily for 11 weeks.
1764660|NCT00307203|Behavioral|Cognitive Behavioral Group Therapy|Participants attended a 12-session, 1-hour, weekly smoking cessation group program with 3 to 7 participants led by a psychologist with tobacco treatment specialist training. Subjects set a quit date, and nicotine patches (Habitrol) and nicotine polacrilex gum (Nicorette) were initiated in the fourth week.
1764661|NCT00307203|Drug|nicotine replacement therapy|Nicotine patch was dosed at 21 mg/d for 4 weeks, 14 mg/d for 2 weeks, and 7 mg/d for 2 weeks, then discontinued. Nicotine gum (2 mg) was distributed for use as needed for craving up to 18 mg/d.
1764662|NCT00307216|Behavioral|Graduated Recovery Intervention Program (GRIP)|GRIP is a manual-based comprehensive psychosocial intervention for people recovering from an initial episode of nonaffective psychosis. The purpose of GRIP is to improve occupational functioning after first-episode psychosis and promote goal pursuit and effective illness self-management. Participants assigned to receive TAU plus GRIP will attend therapy sessions weekly for up to 36 weeks, in addition to routine appointments. GRIP includes four phases, each of which focuses on one of the following topics: engagement and wellness management, substance use, persistent symptoms, and functional recovery.
1764663|NCT00307216|Behavioral|Treatment as usual (TAU)|Participants receiving TAU will meet with their case-manager and health care providers on an as-needed basis.
1764664|NCT00307229|Biological|adenoviral vector encoding rat Her-2/neu|Group 1 1 x 10'7 pfu (2.5 X 10'6 pfu per injection site)(1.6 x 10'9 particles) Group 2 5 x 10'7 pfu (1.25 X 10'7 pfu per injection site)(8.0 x10'9 particles) Group 3 1 x 10'8 pfu (5 x 10'7 pfu per injection site)(1.6 x10'10 particles)
1764665|NCT00307242|Drug|Adefovir Dipivoxil|
1764666|NCT00307255|Drug|gemcitabine hydrochloride|1000 mg/m2 on days 1 and 8 of each 21 day cycle
1764671|NCT00308425|Drug|Enteric-coated Mycophenolate sodium (EC-MPS), valsartan|
1764915|NCT00310128|Procedure|antibody therapy|
1764672|NCT00308438|Drug|Teduglutide (ALX-0600)|0.1 mg/kg injected subcutaneously daily
1764673|NCT00308451|Drug|Chromium Picolinate (600 mcg Cr+3) + biotin (2 mg)|
1764674|NCT00308464|Drug|PHA-794428|
1764675|NCT00308477|Drug|dexamethasone|
1764676|NCT00308490|Drug|iron sucrose|
1764677|NCT00308503|Drug|eplivanserin (SR46349)|oral administration
1764678|NCT00308503|Drug|placebo|oral administration
1764679|NCT00308516|Drug|5-Fluorouracil|"Combined Modality Treatment:
fluorouracil 225mg/m2 IV continuous infusion days 1-42
Systemic Treatment:
5-fluorouracil 400 mg/m2 bolus 5-fluorouracil 2400 mg/m2 over 46 hours days 1 and 15"
1764680|NCT00308516|Drug|Bevacizumab|"Combined Modality Treatment:
bevacizumab 5mg/kg IV infusion days 1, 15, and 29
Systemic Treatment:
bevacizumab 5 mg/kg days 1 and 15"
1764681|NCT00308516|Procedure|Radiation Therapy|radiation 1.8 Gy/day or 28 fractions weeks 1-6
1764682|NCT00308516|Drug|Oxaliplatin|"Systemic Treatment:
oxaliplatin 85 mg/m2 days 1 and 15"
1764683|NCT00308516|Drug|Leucovorin|"Systemic Treatment:
leucovorin 350 mg prior to FU on days 1 and 15"
1764684|NCT00308529|Drug|irinotecan|
1764685|NCT00308529|Drug|carboplatin|
1764686|NCT00308529|Drug|bevacizumab|
1764687|NCT00308529|Procedure|Radiation Therapy|
1764688|NCT00308542|Drug|dexamethasone|
1764689|NCT00308555|Drug|Cannabis|
1764690|NCT00308568|Behavioral|Mailed educational brochure|
1764691|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q4W, administered 4-weekly
1764692|NCT00308581|Biological|Certolizumab pegol|400mg Certolizumab Pegol, Q2W, administered 2-weekly
1764693|NCT00308581|Other|Placebo|placebo administered 4-weekly in Active 1
1764694|NCT00308594|Drug|Dexamethasone|
1764695|NCT00308607|Drug|Bevacizumab (Avastin)|
1764696|NCT00308607|Drug|dacarbazine|
1764697|NCT00308607|Drug|interferon-alfa-2a (Roferon-A)|
1764698|NCT00308620|Drug|chloroquine phosphate|250mg or 500mg PO (by mouth) QDay
1764699|NCT00308620|Drug|Placebo|Placebo once daily for 8 weeks
1764700|NCT00308659|Procedure|FOB protected distal microbiological samplings|
1764701|NCT00308685|Drug|Albuterol 90mcg|
1764702|NCT00308685|Drug|Placebo|Placebo
1764703|NCT00308711|Drug|Misoprostol vaginal insert 100 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
1764704|NCT00308711|Drug|Misoprostol vaginal insert 50 mcg|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
1764705|NCT00308711|Drug|Dinoprostone vaginal insert (Cervidil)|Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
1764706|NCT00308724|Behavioral|Cognitive Behavior Therapy|8 to 10 in person CBT sessions up to 60 minutes in duration within a 12 week time period
1764707|NCT00308724|Behavioral|Telephone check-in|Biweekly telephone calls to monitor symptom severity, an enhanced Usual Care condition
1764708|NCT00308737|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
1764709|NCT00308737|Drug|Usual Care|Subjects will receive antidiabetes treatment at the discretion of their physicians
1764710|NCT00308750|Drug|enzastaurin|1125-1200 mg loading dose then 500 mg, oral, daily, until disease progression
1764711|NCT00308750|Drug|pemetrexed|500 mg/m2, IV, q 21 days, six 21 day cycles or progressive disease
1764712|NCT00308750|Drug|docetaxel|75 mg/m2, IV, q 21 days, six 21 day cycles or progressive disease
1764713|NCT00308750|Drug|carboplatin|AUC 6, IV, q 21 days, six 21 day cycles or progressive disease
1764714|NCT00308763|Drug|Nicotine Patch|"After determining that it is appropriate to dispense study medication to a participant, the dosing regimen will be determined. Participants who report smoking more than 20 cigarettes each day will be initially placed on the 21 mg patch; participants who report smoking 10 - 19 cigarettes each day will be initially placed on the 14 mg patch; participants who report smoking 5 - 9 cigarettes will be initially placed on the 7 mg patch.
If a participant is initially placed on the 21 mg patch, the following dosing schedule will occur: 21 mg patch for 4 weeks, 14 mg patch for 4 weeks, 7 mg patch for 2 weeks, and then off. If a participant is initially placed on the 14 mg patch, the following dosing schedule will occur: 14 mg patch for 6 weeks, 7 mg patch for 4 weeks, and then off. If a participant is initially placed on the 7 mg patch, the following dosing schedule will occur: 7 mg patch for 10 weeks, and then off."
1764715|NCT00308763|Drug|Sustained Release Bupropion|Participants will receive the sustained-release bupropion 150 mg tablet in the morning for four days. If this dose is well-tolerated, then the dose will be increased to a 150 mg tablet twice daily, with at least 8 hours between the two doses. The sustained-release bupropion medication will begin at the randomization visit (RV) which is approximately one week before the quit date. At the RV, the participant should be dispensed enough of the 150 mg tablets of the sustained-release bupropion or placebo to return for the first follow-up visit with instructions on use. Participants will be evaluated by telephone on their quit date approximately one week after the RV to assess safety. We will discontinue the sustained-release bupropion at the second follow-up visit, at which time participants will have received sustained-release bupropion for approximately 11 weeks.
1764716|NCT00308776|Procedure|Cholecystokinin (CCK) infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline plus CCK.
1764835|NCT00309751|Drug|Pitavastatin|Pitavastatin 4 mg QD
1764836|NCT00309751|Drug|Atorvastatin|Atorvastatin 20 mg
1764837|NCT00309764|Behavioral|Telemedicine|
1764717|NCT00308776|Procedure|Saline infusion|Participants will begin infusion with a normal saline solution. After 10 minutes of saline infusion, participants will eat a small bowl of tomato soup, followed 20 minutes later by a 15-minute infusion of saline only.
1764718|NCT00308789|Procedure|Biphasic Infant flow NCPAP|Biphasic Nasal continuous positive airway pressure
1764719|NCT00308789|Procedure|CPAP|Continuous positive airway pressure
1764720|NCT00308802|Procedure|Kidney transplantation|Participants in this study will have had a kidney transplant
1764721|NCT00308815|Device|Automatic CPR machine|
1764722|NCT00308841|Drug|Lidocaine (drug)|
1764723|NCT00308854|Procedure|Photodynamic Therapy|
1764724|NCT00308867|Procedure|Photodynamic Therapy|
1764725|NCT00308867|Procedure|Cryosurgery|
1764726|NCT00308880|Drug|Transamin|
1764727|NCT00308893|Genetic|Genetic analysis|Compare BDNF polymorphism among responders and non-responders
1764728|NCT00308906|Drug|aminoglycoside|Aminoglycosides will be administered and monitored as part of the routine standard of care for the subject.
1764729|NCT00308919|Drug|WST09|Treatment with WST09 Vascular Photodynamic therapy
1764730|NCT00308932|Drug|HFA FP MDI|
1764731|NCT00308945|Drug|travoprost 0.004% (drug)|local drop application
1764732|NCT00308945|Drug|latanoprost 0.005% (drug)|local drop application
1764733|NCT00308958|Device|High frequency chest wall oscillator|
1764734|NCT00308971|Drug|Alpha, gamma, beta, and delta (mixed) tocopherols|approximately 666 IU daily (1 pill) for 4 months
1764735|NCT00308971|Drug|alpha lipoic acid|600 mg daily (2 pills 300 mg each) for 4 months
1764736|NCT00308971|Drug|placebo|placebo for alpha, gamma, beta, and delta (mixed) tocopherols; 1 pill daily for 4 months
1764737|NCT00308971|Drug|placebo|placebo for alpha lipoic acid; 2 pills daily for 4 months
1764738|NCT00308997|Device|1-hertz Repetitive Transcranial Magnetic Stimulation|Sham stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
1764739|NCT00308997|Device|Active 1-Hertz Repetitive transcranial magnetic stimulation|Active stimulation given to Wernicke's area or a right homologous area for 16 minutes per day x 5 days for week I, the same for week II with switch from right to left or left to right, and 5 more stimulation sessions (16 minutes per session) to the side producing greater benefit for week III.
1764740|NCT00309023|Drug|BMS-663513|mg/kg, intravenous (IV), 0.3, 1, 3, 6, 10 or 15 mg/kg, once every 3 weeks (q 3 wks), 12 weeks depending on response
1764741|NCT00309036|Biological|Recombinant grass pollen|
1764742|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of IV oral and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
1764743|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral IV and oral dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
1764744|NCT00309049|Drug|Ixabepilone|Capsules / IV formulation, Oral/IV, 15 mg IV and 30 mg Oral (3 capsules) in cycle 1 with a sequence of oral oral and IV dosage and 40 mg IV dose every 3 weeks on cycle 2 onwards, 3 times in cycle 1 (21 days) and every 3 weeks from cycle 2 onwards, 48-96 weeks depending on response.
1764745|NCT00309062|Biological|Recombinant birch pollen|
1764746|NCT00309075|Drug|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
1764747|NCT00309088|Drug|tacrolimus|oral
1764748|NCT00309088|Drug|placebo|oral
1764749|NCT00309101|Drug|tacrolimus|Oral
1764750|NCT00309114|Procedure|bacterial interference|
1764751|NCT00309127|Behavioral|Multidisciplinary team care|
1764752|NCT00309140|Drug|enzastaurin|500 mg, oral, daily, six 42 day cycles
1764754|NCT00309179|Drug|E7820 plus cetuximab|Escalating doses from 40 mg/m^2 irinotecan plus E7820 in combination with cetuximab.
1764755|NCT00309192|Drug|Triamcinolone Acetonide 4 mg intravitreal injection|
1764756|NCT00309192|Procedure|ETDRS grid laser technique|
1764757|NCT00309205|Drug|dapivirine (TMC120) vaginal gel|
1764758|NCT00309218|Drug|methylprednisolone|withdrawal of methylprednisolone in arm A and continuous Steroid Treatment in arm B
1764759|NCT00309231|Procedure|Islet Allotransplantation|Clinical islet transplantation using the Edmonton protocol, steroid free immunosuppression using sirolimus and tacrolimus and basilixumab induction therapy
1764760|NCT00309244|Drug|Technosphere® Insulin Inhalation Powder|Inhalation, 15U/30U
1764761|NCT00309244|Drug|70% insulin aspart protamine suspension and 30% insulin aspart injection (rDNA origin)|BPR 70/30, which is a premix of intermediate acting and rapid acting insulin given sc
1764762|NCT00309257|Drug|ACE I, ATA II and Statins|
1764763|NCT00309257|Drug|Benazepril, Valsartan and Fluvastatin|"Patients will be given a low dose of Benazepril, 10 mg/die,that, if tolerated, will be up-titrated, after a week,to 20 mg/day.
Patients will be given Valsartan, 80 mg/die,up-titrated after a week to 160 mg/die. Fluvastatin will be started at 40 mg/die.If tolerated, will up-titrated to 80 mg/die. In case of liver, muscular or renal toxicity, fluvastatin will be back-titrated to 40 mg or withdrawn as deemed appropriate."
1764764|NCT00309270|Drug|Campath-1H|
1764765|NCT00309283|Drug|Long-acting somatostatin|Patients randomized to treatment will be given intramuscularly long-acting somatostatin (Sandostatin-LAR, Novartis, Basel) at the dose of 40 mg every 28 days (in two intragluteal 20 mg injections).
1764766|NCT00309283|Other|Saline solution|Patients randomized to placebo will be given intramuscularly the same volume of solvent used to dissolve somatostatin every 28 days (in two intragluteal injections).
1764838|NCT00309777|Drug|Pitavastatin|Pitavastatin once daily
1764839|NCT00309777|Drug|Simvastatin|Simvastatin once daily
1764840|NCT00309790|Drug|sildenafil|
1764841|NCT00309803|Device|FiberNet Embolic Protection Device|
1764842|NCT00309816|Drug|sildenafil|
1764767|NCT00309296|Behavioral|smoking cessation|This was a randomized controlled trial to compare long-term smoking cessation outcomes between Longitudinal Care (LC) and Usual Care (UC) treatment groups. The LC group received smoking cessation treatment (combined behavioral and pharmacological therapies) for one-year period. This treatment recommended repeat quit attempts or smoking reduction for those who failed to quit after the initial attempt. The UC group received evidence-based treatment that lasted 8 weeks.
1764768|NCT00309309|Drug|Rosiglitazone|
1764769|NCT00309322|Drug|Phentolamine Mesylate (NV-101)|
1764770|NCT00309335|Drug|Phentolamine Mesylate (NV-101)|
1764771|NCT00309348|Other|Weekly measurement of graft flow|
1764772|NCT00309361|Drug|Phentolamine Mesylate (NV-101)|
1764773|NCT00309374|Drug|LPS 2ng/kg intravenous bolus|
1764774|NCT00309374|Drug|Simvastatin 80mg; administered daily p.o. over 5 days|
1764775|NCT00309374|Drug|Rosuvastatin 40mg; administered daily p.o. over 5 days|
1764776|NCT00309387|Dietary Supplement|Centrum|Multivitamin/mineral supplement containing US RDA levels of nutrients. 1 tablet a day for the expected duration of follow-up (on average 10 yrs).
1764777|NCT00309387|Other|Placebo|placebo tablets manufactured to mimic Centrum tablets.
1764778|NCT00309413|Drug|Placebo/Cannabidiol|600 mg/day, oral, capsules, 2 weeks, than cross-over
1764779|NCT00309413|Drug|Cannabidiol/Placebo|600 mg/day, oral, capsules, 2 weeks, than cross-over
1764780|NCT00309439|Procedure|ALA-rich diet|
1764781|NCT00309452|Behavioral|Cognitive Behavioral Group Therapy|once per week
1764782|NCT00309452|Behavioral|Cognitive remediation|as needed
1764783|NCT00309452|Drug|Medications|Individualized prescription of psychotropic medications including but not restricted to antipsychotic, antidepressant and mood stabilizers.
1764784|NCT00309452|Behavioral|MFG|Multi-Family psychoeducation Group based on the model published by McFarlane et al.
1764785|NCT00309452|Behavioral|Assertive case management|Meetings with an individual clinician (social work or nursing) who provides supportive psychotherapy, helps assist with vocational and educational supports.
1764786|NCT00309452|Other|Treatment as Usual in the community|Subjects randomized to this arm either return to their existing outpatient psychiatrist or, if they do not have one yet, are referred by the clinic to preferred providers in the community. The nature of the interventions provided is variable and is being monitored by the research clinic.
1764787|NCT00309465|Drug|Lantus|Patients in Group 1 will administer 80% of their usual insulin glargine dose.
1764788|NCT00309465|Other|Insulin|Group 2 patients will contact their own diabetes care physician and follow those recommendations for the dose
1764789|NCT00309465|Drug|Lantus|Group 3 patients will take 50%, 80%, or 100% of their usual insulin glargine dose. Which of those three percentages will be determined by the midpoint of the patient's usual self-reported fasting blood sugar (FBS) range and whether the patients is also taking a rapid-acting insulin.
1764790|NCT00309478|Drug|cyclophosphamide|
1764791|NCT00309478|Drug|Methotrexate|
1764792|NCT00309478|Drug|Fluorouracil|
1764793|NCT00309478|Drug|Goserelin|
1764794|NCT00309478|Drug|Tamoxifen|
1764795|NCT00309491|Drug|Tamoxifen alone|2 x 20 mg tamoxifen daily, start of therapy within 4 weeks after surgery; therapy duration 5 years
1764796|NCT00309491|Drug|Tamoxifen + Aminoglutethimide|"2 x 20 mg tamoxifen daily (5 years) plus Aminoglutethimide daily (first 2 years)
1st therapy week:125mg/-/125mg Aminoglutethimide daily
2nd therapy week: 125mg/-/250mg Aminoglutethimid daily
as of 3rd therapy week: 250mg/-/250mg Aminoglutethimid daily"
1764797|NCT00309517|Drug|Fluourouracil|
1764798|NCT00309517|Drug|Leucovorin|
1764799|NCT00309517|Drug|MAb 17-1A|
1764800|NCT00309530|Drug|5-fluorouracil, levamisol, interferon|
1764801|NCT00309543|Drug|Fluorouracil|
1764802|NCT00309543|Drug|Leucovorin|
1764803|NCT00309556|Drug|Epirubicin|6 cycles 75mg/m2 i.v. day 1 q3w
1764804|NCT00309556|Drug|Docetaxel|6 cycles 75mg/m2 i.v. day 1 q3w
1764805|NCT00309556|Drug|Capecitabine|6 cycles 1000mg/m2 oral, day 1-14 q2d
1764806|NCT00309556|Drug|Trastuzumab|cycle 1: 8mg/kg i.v. day 1 cycle 2-6: 6mg/kg i.v. day 1 (=6 cycles q3w)
1764807|NCT00309569|Drug|Cyclophosphamide|
1764808|NCT00309569|Drug|Methotrexate|
1764809|NCT00309569|Drug|Fluorouracil|
1764810|NCT00309569|Drug|Epirubicine|
1764811|NCT00309595|Device|stent|Cordis SMART™ Nitinol Stent System
1764812|NCT00309595|Device|balloon|balloon angioplasty
1764813|NCT00309608|Drug|Linagliptin|Linagliptin medium dose tablet once daily
1764814|NCT00309608|Drug|Linagliptin|Linagliptin high dose tablet once daily
1764815|NCT00309608|Drug|Linagliptin|Linagliptin low dose tablet once daily
1764816|NCT00309608|Drug|Placebo|Placebo tablets once daily
1764817|NCT00309608|Drug|Glimepiride|Glimepiride tablets once daily
1764818|NCT00309621|Drug|alitretinoin|
1764819|NCT00309634|Biological|4 adjuvanted pandemic influenza candidate vaccines|
1764820|NCT00309634|Biological|4 non-adjuvanted pandemic influenza candidate vaccines|
1764821|NCT00309647|Biological|Influenza Monovalent Whole virus (H5N1) adjuvanted vaccine|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
1764822|NCT00309647|Biological|Influenza Monovalent Whole virus (H5N1)|2 doses administered intramuscularly at the deltoid region of the non-dominant arm at Days 0 and 21
1764823|NCT00309660|Drug|Rosiglitazone|
1764824|NCT00309673|Drug|lidocaine / Prilocaine|
1764825|NCT00309686|Drug|Paliperidone ER|
1764826|NCT00309699|Drug|Placebo|Daily for 3 weeks
1764827|NCT00309699|Drug|Quetiapine|400 to 800 mg daily, initially titrated and flexibly dosed, for 12 weeks
1764828|NCT00309699|Drug|Paliperidone ER|3 to 12 mg daily, flexibly dosed, for 12 weeks
1764829|NCT00309712|Drug|fenofibrate 160 mg and placebo|
1764830|NCT00309712|Drug|simvastatin 20 mg and placebo|
1764831|NCT00309712|Drug|fenofibrate 160 mg and simvastatin 20 mg|
1764832|NCT00309725|Drug|galantamine|
1764833|NCT00309738|Drug|pitavastatin|
1764834|NCT00309738|Drug|simvastatin|
1764843|NCT00309842|Biological|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenously(IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days.
1764844|NCT00309842|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna (MT(S) 9006) at 10:00am, or per institutional routine, on days-7 and -6 after fludarabine. Cyclophosphamide 60mg/kg/day intravenous (IV) x 2 days, total dose 120 mg/kg (days -7 and -6) Dosing is calculated based on Actual BodyWeight (ABW) unless ABW > 30 kg above Ideal BodyWeight (IBW), in which case the dose should be computed using adjusted body weight.
1764845|NCT00309842|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of > 200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
1764846|NCT00309842|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -8 to -6);
1764847|NCT00309842|Drug|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -3. Patients ≥ 40 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
Pediatric patient (<40 kilograms) will receive MMF at the dose of 15 mg/kg three times a day."
1764848|NCT00309842|Procedure|umbilical cord blood transplantation|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
1764849|NCT00309842|Radiation|total-body irradiation|The recommended TBI is 165 cGy given twice daily for a total dose of 1320 cGy (days -4 to -1).
1764850|NCT00309855|Drug|Placebo|im and orally
1764851|NCT00309855|Drug|Testosterone|injections
1764852|NCT00309855|Drug|Anastrazole|orally x 21 days
1764853|NCT00309855|Drug|Dutasteride|orally x 21 days
1764854|NCT00309868|Drug|neseritide|
1764855|NCT00309881|Biological|rituximab|
1764856|NCT00309881|Drug|cyclophosphamide|
1764857|NCT00309881|Drug|doxorubicin hydrochloride|
1764858|NCT00309881|Drug|prednisone|
1764859|NCT00309881|Drug|vincristine sulfate|
1764860|NCT00309894|Biological|sargramostim|
1764861|NCT00309894|Drug|ketoconazole|
1764862|NCT00309894|Drug|therapeutic hydrocortisone|
1764863|NCT00309907|Biological|etanercept|Given IV and subcutaneously
1764864|NCT00309907|Drug|methylprednisolone|Given IV and orally
1764865|NCT00309920|Biological|darbepoetin alfa|
1764866|NCT00309920|Drug|cyclophosphamide|
1764867|NCT00309920|Drug|docetaxel|
1764868|NCT00309920|Drug|doxorubicin hydrochloride|
1764869|NCT00309920|Drug|epirubicin hydrochloride|
1764870|NCT00309920|Drug|fluorouracil|
1764871|NCT00309933|Procedure|cognitive assessment|
1764872|NCT00309933|Procedure|psychosocial assessment and care|
1764873|NCT00309933|Procedure|quality-of-life assessment|
1764874|NCT00309946|Drug|cediranib maleate|Given orally
1764875|NCT00309959|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1764876|NCT00309959|Other|Laboratory Biomarker Analysis|Correlative studies
1764877|NCT00309972|Drug|Control arm (SEQ):|Four cycles of cisplatinum/vinorelbine given in a 21 day cycle followed by radical radiotherapy, 55 Gy in 20 once daily fractions in four weeks (2.75 Gy/day).
1764878|NCT00309972|Drug|Experimental arm (CON):|concurrent chemo-radiotherapy [55 Gy in 20 daily fractions in 4 weeks (2.75 Gy/day) with cisplatinum given concurrently with fractions 1-4 and 16-19, and vinorelbine prior to fractions 1, 6, 15 and 20] followed by two cycles of cisplatinum/vinorelbine.
1764879|NCT00309985|Drug|androgen-deprivation therapy|LHRH analogs are administered with a variety of techniques such as subcutaneously, intramuscularly, or insertion, while antiandrogens (flutamide and bicalutamide) were given orally.
1764880|NCT00309985|Drug|docetaxel|Given IV
1764881|NCT00309998|Biological|bevacizumab|
1764882|NCT00309998|Drug|vinorelbine tartrate|
1764883|NCT00310011|Drug|cisplatin|
1764884|NCT00310011|Drug|gemcitabine hydrochloride|
1764885|NCT00310011|Drug|paclitaxel|
1764886|NCT00310011|Procedure|conventional surgery|
1764887|NCT00310024|Drug|bortezomib|Given IV
1764888|NCT00310024|Drug|vorinostat|Given orally
1764889|NCT00310024|Other|laboratory biomarker analysis|Correlative studies
1764890|NCT00310024|Other|pharmacological study|Correlative studies
1764892|NCT00310050|Drug|pemetrexed disodium|500 milligrams per meter squared day 1,15,29 for 14 days for three cycles
1764893|NCT00310063|Procedure|acupressure therapy|Acupressure wristband
1764894|NCT00310063|Procedure|sham intervention|Sham wristband
1764895|NCT00310076|Drug|thalidomide|Patients will receive thalidomide orally each evening for 24 months or until tumor progression is detected.
1764896|NCT00310076|Procedure|surgery|Cytoreductive Surgery with Intraperitoneal Hyperthermic Chemotherapy
1764897|NCT00310089|Biological|filgrastim|
1764898|NCT00310089|Biological|pegfilgrastim|
1764899|NCT00310089|Drug|cediranib maleate|
1764900|NCT00310089|Drug|cyclophosphamide|
1764901|NCT00310089|Drug|docetaxel|
1764902|NCT00310089|Drug|doxorubicin hydrochloride|
1764903|NCT00310089|Other|laboratory biomarker analysis|
1764904|NCT00310089|Procedure|conventional surgery|
1764905|NCT00310089|Procedure|neoadjuvant therapy|
1764906|NCT00310115|Behavioral|Smoking Prevention Usual Care|Usual care of self-help materials and advice for staying cigarette free
1764907|NCT00310115|Behavioral|Counseling Intervention|6 x 30 minute counseling sessions over the telephone
1764908|NCT00310115|Behavioral|Counseling Intervention|2 in-person counseling sessions
1764909|NCT00310128|Drug|cisplatin|
1764910|NCT00310128|Drug|cytarabine|
1764911|NCT00310128|Drug|etoposide|
1764912|NCT00310128|Drug|methylprednisolone|
1764913|NCT00310128|Drug|rituximab|
1764914|NCT00310128|Drug|yttrium Y 90 ibritumomab tiuxetan|
1764916|NCT00310128|Procedure|biological therapy|
1764917|NCT00310128|Procedure|chemotherapy|
1764918|NCT00310128|Procedure|monoclonal antibody therapy|
1764919|NCT00310128|Procedure|radiation therapy|
1764920|NCT00310128|Procedure|radioimmunotherapy|
1764921|NCT00310128|Procedure|radioisotope therapy|
1764922|NCT00310141|Behavioral|Smoking cessation intervention|6 weeks of computer delivered treatment for quitting smoking
1764923|NCT00310141|Other|Counseling intervention|In-person counseling (5 sessions)
1764924|NCT00310141|Drug|Nicotine patch|6-week supply of the nicotine patch
1764925|NCT00310154|Drug|docetaxel|
1764926|NCT00310154|Drug|gefitinib|
1764927|NCT00310154|Other|laboratory biomarker analysis|
1764928|NCT00310154|Radiation|radiation therapy|
1764929|NCT00310167|Radiation|radiation therapy|
1764937|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intradermally (ID); doses: 3 or 9 micrograms.
1764938|NCT00310206|Biological|Inactivated Influenza A Vaccine A/H5N1|Monovalent subvirion H5 vaccine (HA of A/Vietnam/1203/04), inactivated A/H5N1 vaccine administered intramuscularly (IM); doses: 15 or 45 micrograms.
1764939|NCT00310219|Procedure|computed tomography|
1764940|NCT00310219|Procedure|positron emission tomography|
1764941|NCT00310232|Drug|Epoetin Alfa|
1764942|NCT00310245|Procedure|STI (structured Treatment Interruption)|
1764943|NCT00310258|Behavioral|Drug use prevention intervention|
1764944|NCT00310271|Biological|pPJV7630 with pPJV2012 administered by PMED|
1764945|NCT00310284|Behavioral|Computerized delivery of cognitive-behavioral treatment of insomnia|
1764946|NCT00310284|Behavioral|Self-help manual to improve insomnia symptoms|
1764947|NCT00310297|Drug|Insulin Glulisine|
1764948|NCT00310310|Behavioral|Sleep Apnea Self-Management Program|Sleep apnea self-management program - 4 sessions, group-based.
1764949|NCT00310310|Behavioral|Usual care|Usual sleep apnea and cpap care
1764950|NCT00310323|Drug|Dextromethorphan|0.5 mg/kg (maximum 30 mg)
1764951|NCT00310323|Drug|Caffeine|Administered as 4 ounces of Coca-Cola
1764952|NCT00310336|Drug|S-adenosyl-L-methionine|
1764953|NCT00310336|Drug|betaine|
1764954|NCT00310336|Drug|pegylated interferon alpha2b|
1764955|NCT00310336|Drug|ribavirin|
1764956|NCT00310349|Biological|23 valent pneumococcal polysaccharide vaccine|
1764957|NCT00310362|Behavioral|Use of IVR system to improve adherene to GI appointments and prep procedures|Interactive voice response system calls patients 7 or 3 days prior to their appointment. Information available in the IVR system is based on the same template nurses use in usual care and includes an appointment reminder, preparation instructions, basic information about the procedure, and answers to commonly asked questions.
1764958|NCT00310375|Drug|Ezogabine: USAN Retigabine (International Nonproprietary Name)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patient receives between 600 and 1200 mg of retigabine per day. The duration will be until the trial concludes or the patient leaves the trial.
1764959|NCT00310388|Drug|Retigabine (INN), Ezogabine (USAN)|Film-coated tablets containing 50 mg, 100 mg, or 300 mg of retigabine per tablet. Dosage and frequency will be specific to each patient so long as the patients receives between 600 and 1200 mg of retigabine per day. The duration will be until the completion of the trial, or until the patient withdraws from the trial.
1764962|NCT00310427|Drug|LY686017|50 mg administered orally on a daily basis
1764963|NCT00310427|Drug|Placebo|Administered on a daily basis
1764964|NCT00310440|Device|P-15 Synthetic osteoconductive bone substitute|Safety and efficacy of synthetic bone substitute used for fusion in spinal surgery
1764965|NCT00310440|Other|Autologous bone|Local autologous bone will be harvested, milled and placed into the cavity of the structural allograft ring
1764966|NCT00310453|Biological|ALK Grass tablet|
1764967|NCT00310466|Biological|Sublingual immunotherapy|once daily intake of sublingual drops
1764968|NCT00310466|Biological|Placebo|once daily intake of sublingual drops
1764969|NCT00310479|Device|Magnetic Resonance Spectroscopy (3Tesla)|
1764970|NCT00310492|Biological|subcutaneous immunotherapy|Updosing by 16 injections to 100,000 SQ-U
1764971|NCT00310505|Drug|Amphotericin B deoxycholate given as daily administration|
1764972|NCT00310518|Drug|ARQ 501|
1764973|NCT00310531|Drug|Menostar (Estradiol, BAY86-5435)|Menostar (estradiol transdermal delivery system (SHP00577E), 0.014 mg/day)
1764974|NCT00310531|Drug|Raloxifene|Raloxifene tbl. (60 mg/day)
1764975|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period1:Magnevist 0.1 mmol/kg body weightperiod 2: Magnevist 0.2 mmol/kg body weight
1764976|NCT00310544|Drug|Magnevist (Gadopentetate dimeglumine, BAY86-4882)|One intravenous injection per period. Period 1 and 2 are separated by 4 to 14 days.period 1: Magnevist 0.2 mmol/kg body weightperiod 2: Magnevist 0.1 mmol/kg body weight
1764977|NCT00310557|Drug|Gadopentetate dimeglumine (Magnevist)|Approximately 0.1mmol/kg body weight, single intravenous administration on the study day
1764978|NCT00310570|Device|Circumferential thermoplastic thimble splint|
1764979|NCT00310570|Device|"dorsal aluminium foam Mexican Hat splint"|
1764980|NCT00310570|Device|stack splint (control)|
1764981|NCT00310583|Drug|Pregabalin|
1764982|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,1mmol/kg at 10 mL/15 sec
1764983|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 1 at bolus rate (2mL/sec)
1764984|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|0,3mmol/kg at 10 mL/15 sec
1764985|NCT00310596|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|same dose as arm 3 at bolus rate (2mL/sec)
1764986|NCT00310596|Drug|Moxifloxacin (BAY12-8039)|400 mg at 0,07 mL/sec over 60 min
1764987|NCT00310596|Drug|Placebo|0,9% saline at 0,6mL/kg at bolus rate
1764988|NCT00310609|Drug|Gadopentetate dimeglumine (Magnevist)|Gadopentetate dimeglumine (Magnevist Injection), approximately 0.1mmol/kg body weight, single intravenous administration on the study day
1764990|NCT00310635|Biological|Meningococcal C conjugate vaccine|
1764991|NCT00310648|Biological|Influenza vaccine|
1764992|NCT00310661|Drug|Sarizotan|The dose of sariztan HCI for each patient in the drug arm will be given 2mg b.i.d. orally during the first 4 weeks of treatment. If efficacy is inadequate and there are no safety concerns, the option to raise the dose to 5mg b.i.d is given. After 8 weeks of treatment, the option to raise the dose to 7mg bid is given. Dose may remain the same or may be decreased again to the previous dose.
1764993|NCT00310661|Other|Placebo|Placebo for each patient randomized to the placebo arm will be given placebo (oral, twice daily) in a pill form for 12 weeks
1764994|NCT00310674|Biological|Meningococcal C Conjugate Vaccine|
1764995|NCT00310687|Procedure|BLOOD DRAW|
1764996|NCT00310700|Biological|Meningococcal C conjugate vaccine|
1764997|NCT00310713|Biological|Meningococcal C conjugate vaccine|Group 1: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 3 post immunization) Group 2: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 5 post immunization) Group 3: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 7 post immunization) Group 4: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 9 post immunization) Group 5: Meningococcal C conjugate vaccine dose boost on Visit 6 (day 0), blood sample on Visit 7 (day 10 post immunization)
1764998|NCT00310726|Other|abrupt weaning at 4 months|abrupt weaning at 4 months
1764999|NCT00310726|Other|Continued exclusive breastfeeding|Continued exclusive breastfeeding
1765000|NCT00310752|Device|DermaStream(tm) application and Streaming of Saline|
1765001|NCT00310765|Drug|Pregabalin|First 7 weeks 75 or 150 mg of pregabalin po BID. Start at 75 mg and increase to 150 mg po BID if no improvement after 3 days
1765002|NCT00310765|Drug|Pregabalin|75 mg po BID
1765003|NCT00310778|Drug|high sodium diet|high sodium diet
1765004|NCT00310778|Drug|low sodium diet|low sodium diet
1765005|NCT00310778|Drug|ramipril 10 mg|ramipril 10 mg
1765006|NCT00310778|Drug|valsartan 160 mg|valsartan 160 mg
1765007|NCT00310778|Drug|candesartan 8 mg|candesartan 8 mg
1765008|NCT00310778|Drug|atenolol 50 mg|atenolol 50 mg
1765009|NCT00310791|Drug|Hormone replacement therapy (estrogen/progestin)|Hormone replacement therapy (estrogen/progestin). 0.3 mg conjugated estrogens x 3 months, followed by 9 months of oral contraceptive (20 mg ethinyl estradiol + 0.1 mg levonorgestrel)
1765010|NCT00310791|Other|Placebo (Sugar Pill)|Placebo (sugar pill)
1765011|NCT00310791|Drug|Dehydroepiandrosterone (DHEA)|50 mg tablet, 1 daily
1765012|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 1 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 1
1765013|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 2 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 2
1765014|NCT00310804|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine Lot 3 (cTIV)|One single 0.5ml intramuscular injection of Cell Derived Trivalent Subunit Influenza Vaccine (cTIV) from Lot 3
1765015|NCT00310804|Biological|Egg-Derived Trivalent Subunit Influenza Vaccine (TIV)|One single 0.5ml intramuscular injection of Egg Derived Trivalent Subunit Influenza Vaccine (TIV).
1765016|NCT00310817|Biological|MenACWY-CRM conjugate vaccine, adjuvanted|
1765017|NCT00310817|Biological|MenACWY polysaccharide vaccine|
1765018|NCT00310817|Biological|MenACWY-CRM conjugate vaccine, unadjuvanted|
1765019|NCT00310830|Drug|Bosentan|Oral, Initial dose: 62.5 mg b.i.d. for 4 weeks, maintenance dose: 125 mg b.i.d.
1765020|NCT00310843|Drug|Nevirapine|Patients with HIV-1 infection who have taken or are currently taking nevirapine
1765021|NCT00310856|Biological|MenACWY-CRM|Subjects received the full dose (0.5 mL) of MenACWY-CRM, obtained by extemporaneous mixing of lyophilized MenA powder component and the MenCWY suspension, administered by IM injection into the anterolateral area of the right thigh.
1765022|NCT00310856|Biological|MenC-CRM|One dose (0.5 mL) of MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized MenC component and a saline solvent, administered by IM injection into the arm region.
1765023|NCT00310856|Biological|DTaP-Hib-IPV|
1765024|NCT00310856|Biological|PC7|One dose (0.5 mL) of PC7, supplied in pre-filled syringe, administered by IM injection into the anterolateral area of the left thigh.
1765025|NCT00310856|Biological|MMR|
1765026|NCT00310856|Biological|Varicella|
1765027|NCT00310869|Behavioral|Individualized Developmental Care in the NICU|Newborn Individualized Developmental Care and Assessment Program (NIDCAP) utilizes close observation of each infant's thresholds of moving from organization to disorganization and stress, as exhibited by the infant's behavior. Care and environment are then continuously and dynamically adjusted to increase the infant's self-regulation and organization and decrease the infant's stress. This individualized model of NICU care provides an opportunity to investigate the modifiability of very early born infants' brain function and structure and the possibility of reducing or altogether eliminating the disruption and disturbance of fetal brain development in the NICU.
1765028|NCT00310895|Drug|Imetelstat Sodium (GRN163L)|Dose increase by 25% if tolerated infused over 2 hours
1765029|NCT00310908|Drug|Tramadol Hcl|Active Comparator
1765030|NCT00319358|Dietary Supplement|Antioxidants|600microgm selenium, 0.54g vitamin C, 9000IU beta-carotene, 270IU vitamin E, 2g methionine per day, daily, in divided doses for 6 months
1765031|NCT00319358|Dietary Supplement|Placebo|placebo
1765032|NCT00319384|Device|Ultrafiltration therapy|
1765033|NCT00319397|Behavioral|Exercise-Training Program|
1765034|NCT00319410|Procedure|vaginoscopic hysteroscopy|
1765036|NCT00319436|Behavioral|Mentalizing Therapy for Substance Using Mothers|This 12 session individual therapy aims to enhance maternal reflective functioning and soften harsh and distorted mental representations about the child. The intervention adopts a developmental progression based on attachment theory, supporting the mother in her parenting role and offering assistance with basic needs. Mothers are encouraged to reflect on their thoughts and feelings and how they affect behavior. The therapist assists mother's thinking about representations of herself as a parent and encourages her to explore opportunities for new understanding of her emotional needs. Therapist and mother explore representations of her child and their relationship in detail in order to understand their meaning and promote more balanced representations and affect regulation. Therapist and mother also explore child's emotional experiences underlying behavior. The goal is to support the mother in becoming more aware of her child's emotional needs.
1765037|NCT00319436|Behavioral|Standard Parent Education for Substance Using Mothers|This 12 session comparison was designed to match the experimental intervention on time spent with the counselor and maternal expectations for help with parenting. PE counselors helped mothers get connected to services (e.g. medical and pediatric care, child guidance services, housing assistance, vocational training), solve problems of daily living and make parenting-related decisions. PE mothers also received a pamphlet each week on a parenting topic of their choice. Pamphlets focused on common issues in caring for infants (e.g., soothing a crying baby, managing bedtime routines, and establishing routines ) and toddlers (e.g., helping toddlers dress, managing bedtime battles, managing difficult behavior in public, and setting limits without using punishment). Pamphlets provided behavioral guidance at a 5th grade reading level without reference to underlying mental states or emotional needs.
1765038|NCT00319449|Drug|Ezetimibe|10 mg ezetimibe, orally, daily for 6 weeks, added to ongoing treatment with 10 mg atorvastatin
1765039|NCT00319449|Drug|Placebo|10 mg/day matching placebo to ezetimibe, orally, daily for 6 weeks, added to ongoing 10 mg atorvastatin
1765040|NCT00319449|Drug|Atorvastatin 10 mg|10 mg/day atorvastatin, orally, (ongoing treatment in participants)
1765041|NCT00319462|Device|hemoclip|
1765042|NCT00319475|Procedure|AAA or AF/IB (end-to-end) in patients with Leriche Syndrome|
1765043|NCT00319488|Drug|Inhaled Corticosteroid (Budesonide)|Participants will receive inhaled corticosteroid for 7 days, at the first sign of RTI-associated symptoms.
1765044|NCT00319488|Drug|Leukotriene Receptor Antagonist (Montelukast Sodium)|Participants will receive leukotriene receptor antagonist for 7 days, at the first sign of RTI-associated symptoms.
1765045|NCT00319488|Drug|Inhaled Albuterol|All participants will receive inhaled albuterol treatments four times a day.
1765046|NCT00319501|Drug|Placebo|Intramuscular autoinjector; administered at onset of an episode
1765047|NCT00319501|Drug|Vanquix Auto-Injector (Diazepam Injection)|Intramuscular autoinjector: 5, 10, 15, or 20 mg (based on participant's age and weight); administered at the onset of an episode
1765048|NCT00319514|Drug|Docetaxel|
1765049|NCT00319540|Behavioral|Control with depression course (CWD)|
1765050|NCT00319553|Biological|ADACEL®:Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
1765051|NCT00319553|Biological|BOOSTRIX®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
1765052|NCT00319566|Drug|Premarin .625 mg daily plus medroxyprogesterone 2.5 mg daily|
1765053|NCT00319592|Biological|ChimeriVax™-JE vaccine|0.5 mL, subcutaneously
1765054|NCT00319592|Biological|JE-VAX® vaccine|1.0 mL, subcutaneously
1765055|NCT00319605|Drug|Levetiracetam|
1765056|NCT00319618|Drug|Gefitinib|
1765057|NCT00319618|Drug|Docetaxel|
1765058|NCT00319644|Device|Bronchoalveolar lavage|Using catheter to obtain respiratory sample
1765059|NCT00319657|Device|Immune tolerance|"Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for at least 6 months. Immunosuppressive drugs are stopped at 6 to 12 months if stable mixed chimerism achieved and there is no rejection of the transplant kidney.
The IDE used in this study is the column used for hematopoietic cell sorting."
1765060|NCT00319670|Drug|MiraLax|
1765061|NCT00319683|Drug|ADH300004|
1765062|NCT00321659|Behavioral|Aerobic|3x/week of walking and cycling
1765063|NCT00321659|Behavioral|Strength training|3x/week of resistance training activities
1765064|NCT00321659|Behavioral|Combination|3x/week of aerobic and strength training activities
1765065|NCT00321659|Behavioral|FSHC|Biweekly group education group meetings
1765066|NCT00321672|Drug|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm^2 each were applied to the feet (2 per foot) for 60 minutes.
1765067|NCT00321672|Drug|0.04% capsaicin patch|Up to 4 control patches of 280 cm^2 each were applied to the feet (2 per foot) for 60 minutes.
1765068|NCT00321672|Drug|NGX-4010, 8% capsaicin patch|Up to 4 NGX-4010 patches of 280 cm^2 each were applied to the feet (2 per foot) for 30 minutes.
1765069|NCT00321672|Drug|0.04% capsaicin patch|Up to 4 control patches of 280 cm^2 each were applied to the feet (2 per foot) for 30 minutes.
1765077|NCT00321698|Radiation|Intensity-Modulated Radiation Therapy (IMRT)|Group 1=radiation only; All men in all Arms/Groups receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)
1765173|NCT00322309|Other|Placebo|Placebo for days 1-4 Placebo for days 5-9 Placebo for days10-78 Placebo for days 79-81 Placebo for days 82-84
1765174|NCT00322309|Drug|Mirtazapine|Days 1-4 15mg Days 5-9 30 mg Days 10-78 45mg Days 79-81 30mg Days 82-84 15mg
1765078|NCT00321698|Drug|Docetaxel+IMRT|"Group 2=IV over 30mins, 10mg/m2; weekly x 5 weeks starting on day one of radiation; Group 3=IV over 30mins, 20mg/m2; weekly x 5 weeks starting on day one of radiation; Group 4=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation; Phase II with no phase I dose-limiting toxicities=IV over 30mins, 30mg/m2; weekly x 5 weeks starting on day one of radiation
Radiation: All men receive same radiation treatment protocol. External Beam, 45 Gy (1.8 Gy fractions), 5 per week (daily) x 5 weeks (25 fractions)"
1765079|NCT00321711|Drug|Placebo|Subjects in the control group will receive a placebo subcutaneous injection on a weekly basis during the 4 cycle treatment period.
1765080|NCT00321711|Biological|AMG 531 (Romiplostim)|AMG 531 (Romiplostim) will be administered weekly by subcutaneous injection at a dose of 500 or 750 μg during Part A and 750 μg during Part B for the 4 cycle treatment period, depending on randomization.
1765081|NCT00321711|Drug|Azacitidine|hypomethylating agent
1765082|NCT00321711|Drug|Decitabine|hypomethylating agent
1765083|NCT00321724|Drug|cediranib maleate|Given orally
1765084|NCT00321724|Other|laboratory biomarker analysis|Correlative studies
1765085|NCT00321737|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to six months.
1765086|NCT00321737|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, orally, once daily for up to six months.
1765087|NCT00321737|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for up to six months.
1765088|NCT00321750|Drug|1% pimecrolimus cream|
1765089|NCT00321763|Biological|Candidate Influenza Vaccine GSK1247446A - 3 different formulations|Single dose, Intramuscular injection
1765090|NCT00321763|Biological|Fluarix TM|Single dose, Intramuscular injection
1765091|NCT00321789|Behavioral|spouse-assisted intervention|Couples assigned to this arm received nine monthly phone calls from a nurse. The patient created monthly goals and action plans related to diet, exercise, patient-provider communication, or medication adherence. The spouse created plans to support patient goal achievement.
1765092|NCT00321802|Drug|Simvastatin|Patients take 40 mg of simvastatin per day for 6 months.
1765093|NCT00321802|Drug|Placebo|Placebo
1765094|NCT00321815|Drug|PF-3512676 + Erlotinib|"PF-3512676 0.2 mg/kg subcutaneously on days 1, 8 and 15 of each 21 day cycle until disease progression or unacceptable toxicity.
Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity"
1765095|NCT00321815|Drug|Erlotinib|Erlotinib 150 mg orally daily (21 day cycles) until disease progression or unacceptable toxicity
1765096|NCT00321828|Biological|bevacizumab|bevacizumab 5 mg/kg IV on day 1 every 14 days until excessive toxicity or disease progression
1765097|NCT00321828|Drug|fluorouracil|5-FU 400 mg/m2 IV bolus over 2-4 minutes then 2400 mg/m2 IV continuous infusion over 46 hours on day 1 every 14 days until excessive toxicity or disease progression
1765098|NCT00321828|Drug|leucovorin|leucovorin 400 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
1765099|NCT00321828|Drug|oxaliplatin|Oxaliplatin 85 mg/m2 IV on day 1 every 14 days until excessive toxicity or disease progression
1765100|NCT00321854|Drug|pramipexole|
1765101|NCT00321867|Procedure|Graft augmented posterior repair|Posterior repair with graft
1765102|NCT00321867|Procedure|Control|Native tissue repair
1765103|NCT00321880|Procedure|therapeutic touch|administration of healing touch in 30 minute sessions
1765104|NCT00321893|Drug|Budesonide|Inhaled Budesonide 800 micrograms (ug) twice daily for one year.
1765105|NCT00321893|Other|Placebo|Inhaled placebo twice daily for one year.
1765106|NCT00321906|Drug|azathioprine|azathioprine 2mg/kg
1765107|NCT00321906|Drug|sirolimus|sirolimus 2-4mg daily
1765108|NCT00321919|Drug|epoetin beta [NeoRecormon]|Participants in the early treatment group immediately started epoetin beta treatment to reach a target Hb level of 13-15 g/dL at the end of the correction phase.
1765109|NCT00321919|Drug|epoetin beta [NeoRecormon]|Participants in the late treatment Group started epoetin beta treatment once a decline in Hb level to <10.5 g/dL had occurred.
1765110|NCT00321932|Dietary Supplement|calcium|All randomized patients (control and study drug) will take 1000 mg of calcium and 400 - 500 International Units (IU) of vitamin D orally each day, beginning as soon as possible after study enrollment. These supplements may be taken either in the morning or in the evening with food. Participants will continue taking the supplements on a daily basis until the final study visit (approximately 12 months after the transplant date).
1765111|NCT00321932|Dietary Supplement|cholecalciferol|Given orally
1765112|NCT00321932|Drug|zoledronic acid|Zoledronic acid (Zometa®) will be administered after randomization (but within 28 days prior to transplant) and at 3 and 6 months after the transplant for a total of 3 doses. The dose of Zometa will be 4 mg intravenous in 100 ml of sterile 0.9% sodium chloride, United States Pharmacopeia (USP), or 5% dextrose, USP infused over a minimum of 15 minutes for patients with a calculated creatinine clearance of ≥60 mL/min. The drug may be administered through a peripheral or a central intravenous line.
1765113|NCT00321945|Procedure|ACE-Inhibitors and Angiotensin Receptor Blockers|Retrospective study - no intervention as part of study.
1765114|NCT00321958|Device|CSA System (CryoSpray AblationTM System)|10 second spray times
1765115|NCT00321958|Device|CryoSpray Ablation|10 second spray times
1956802|NCT02688660|Other|MRI Scans|
1765118|NCT00321984|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for 4 weeks.
1765119|NCT00321984|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for 4 weeks.
1765120|NCT00321984|Drug|Placebo|Dexlansoprazole placebo-matching capsules, orally, once daily for 4 weeks.
1765121|NCT00321997|Drug|Pegaptanib sodium|
1765175|NCT00322322|Drug|L-Carnitine|L-Carnitine
1956803|NCT02689206|Drug|GSK1278863|GSK1278863 will be supplied as a round, biconvex, 10 millimeter (mm) white film coated tablet with the unit dose strength of 5 mg and 25 mg.
1956804|NCT02689206|Drug|GSK1278863 matching Placebo|GSK1278863 matching placebo will be supplied as a round, biconvex, 10 mm white film coated tablet.
1765122|NCT00322010|Procedure|early PT OT|"Passive range of motion exercises for all limbs in patients who remain unresponsive despite sedative interruption (ten repetitions in all cardinal directions).
Sessions began with active assisted and active range of motion exercises in the supine position.
If tolerated, treatment is advanced to bed mobility activities, including transferring to upright sitting.
Sitting balance activities are followed by participation in activities of daily living (ADLs) and exercises that encourage increased independence with functional tasks.
The session progresses to transfer training, and finally pre-gait exercises and ambulation.
Progression of activities is dependent on patient tolerance and stability.
Therapy intervention continues on a daily basis throughout the patient's hospital stay until he/she returns to prior level of function or is discharged."
1765124|NCT00322036|Drug|MPC-7869|Oral 800 mg BID
1765125|NCT00322036|Drug|MPC-7869|Oral BID dosing
1765126|NCT00322049|Biological|Tetravalent live attenuated dengue vaccine|"DEN candidate vaccine: One dose of the tetravalent, live attenuated DEN vaccine candidate, F17, contains dengue serotype 1, 2, 3 and 4 vaccines. This formulation contains 50 mcg/mL neomycin base, 5.5% lactose, and 1.9 g/dL human serum albumin; for subcutaneous injection.
Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
All infants subsequently received an inactivated JE vaccine approximately one and 1.5 months following dengue vaccine dose 2. The licensed JE vaccine in liquid form, was dosed at 0.25 ml for subcutaneous injection.
A booster dose of DEN vaccine was given to all subjects previously vaccinated with DEN vaccine in Dengue -001. The booster dose was administered approximately 42 months after dose 2 (at the Year 3 visit)."
1765127|NCT00322049|Biological|Varicella vaccine and Haemophilus influenzae Type b Conjugate vaccine|Infants received dengue vaccine at study months 0 and 6 or control vaccine (varicella vaccine at study month 0 and Haemophilus influenzae Type b Conjugate vaccine at study month 6). Both control vaccines are licensed for use in Thailand.
1765128|NCT00322062|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|2L gut lavage solution
1765129|NCT00322062|Drug|Sodium Phosphate Solution|1 x 45ml solution, BID
1765130|NCT00322075|Drug|insulin glargine|
1765131|NCT00322101|Radiation|total-body irradiation|Radiation
1765132|NCT00322101|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
1765133|NCT00322101|Drug|cyclophosphamide|Given IV
1765134|NCT00322101|Drug|mycophenolate mofetil|Given orally
1765135|NCT00322101|Drug|busulfan|Given IV or orally
1765136|NCT00322101|Drug|cyclosporine|Given IV or orally
1765137|NCT00322101|Drug|fludarabine phosphate|Given IV
1765138|NCT00322101|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
1765139|NCT00322101|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
1765140|NCT00322101|Other|laboratory biomarker analysis|Correlative studies
1765141|NCT00322101|Genetic|cytogenetic analysis|Correlative studies
1765142|NCT00322101|Other|flow cytometry|Correlative studies
1765143|NCT00322101|Genetic|fluorescence in situ hybridization|Correlative studies
1765144|NCT00322101|Other|pharmacological study|Correlative studies
1765145|NCT00322101|Genetic|polymorphism analysis|Correlative studies
1765146|NCT00322101|Drug|tacrolimus|Given IV or orally
1765147|NCT00322101|Drug|methotrexate|Given IV
1765148|NCT00322114|Dietary Supplement|lycopene|Given orally
1765149|NCT00322114|Other|placebo|Given orally
1765151|NCT00322140|Drug|CDDO|
1765152|NCT00322153|Drug|memantine ER|28mg(7mg capsules) once daily and oral administration for 24 weeks.
1765153|NCT00322153|Drug|Placebo|Matching placebo oral administration once daily.
1765154|NCT00322166|Other|Sunlight|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week.
1765155|NCT00322166|Other|Sunlight and calcium|Subjects in the intervention groups will be asked to undergo exposure of approximately 15% of their body (ie the face, hands and arms) usually between 9.30am - 10am daily during the year, 5 days per week. In the calcium and sunlight arm, calcium supplements (Caltrate, 600mg elemental calcium, Whitehall) will be administered to the whole group via the Blister/ Webster packs.
1765156|NCT00322166|Other|control|Subjects in the control group will be provided with a brochure about vitamin D deficiency and how to treat it. They will receive their usual routine care and nutrition.
1765157|NCT00322192|Behavioral|Conventional UK Physical therapy|
1765158|NCT00322192|Behavioral|Increased intensity of UK conventional physical therapy|
1765159|NCT00322192|Behavioral|UK conventional physical therapy plus functional strength training|
1765160|NCT00322205|Drug|zyban|
1956806|NCT02683161|Drug|Varenicline|Varenicline will be administered as clinically indicated and will begin approximately 4-6 weeks prior to surgery. All participants will receive a 1-week dose induction period before transitioning to a full maintenance dose.
1765163|NCT00322231|Biological|zoster vaccine live (ZOSTAVAX™)|1 dose 0.65 mL/dose subcutaneous injection of zoster vaccine live
1765164|NCT00322231|Biological|Comparator: Placebo|1 dose 0.65 mL/dose subcutaneous injection of placebo.
1765165|NCT00322244|Procedure|Massage Therapy|
1765166|NCT00322257|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
1765167|NCT00322257|Drug|insulin detemir|Injection s.c., 50% of daily dose
1765168|NCT00322257|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
1765169|NCT00322270|Drug|Alfimeprase|single-dose of alfimeprase, 10 mg.administered intracatheter to an occluded CVAD
1765170|NCT00322283|Drug|Oglemilast|Oglemilast, 15mg once per day, oral administration
1765171|NCT00322283|Drug|Placebo|Dose-marched placebo, once per day, oral administration
1765172|NCT00322296|Drug|Bexarotene 1% gel|
1765218|NCT00322621|Drug|Duloxetine|
1765176|NCT00322335|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (group HibMenC) and as booster dose at 14 months of age (groups HibMenC and group NeisPoo).
1765177|NCT00322335|Biological|Infanrix™ penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
1765178|NCT00322335|Biological|Infanrix™ hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and/or 6 months of age (groups NeisPoo and MenCCRM) and/or as booster dose at 14 months of age (group MenCCRM).
1765179|NCT00322335|Biological|Engerix-B|Intramuscular injection into the thigh as a birth dose
1765180|NCT00322335|Biological|NeisVac-C™|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age.
1765181|NCT00322335|Biological|Infanrix™ IPV/HIB|Intramuscular injection into the thigh as primary vaccination at 4 months of age
1765182|NCT00322335|Biological|Meningitec™|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age
1765183|NCT00322348|Drug|Goserelin acetate|3.6 mg intramuscular depot injection given every 4 weeks
1765184|NCT00322348|Drug|Goserelin acetate|10.8 mg intramuscular depot injection given every 12 weeks
1765185|NCT00322361|Biological|Comparator: RECOMBIVAX HB™|RECOMBIVAX HB™ 3 x 5-mcg regimen administered via intramuscular injection.
1765186|NCT00322361|Biological|Comparator: Modified process Hepatitis B Vaccine|Modified Process Hepatitis B 3 x 5-mcg regimen administered via intramuscular injection.
1765187|NCT00322374|Drug|Ixabepilone|Infusion, intravenous (IV), Cycle = 21 days. Dose escalation study.
1765188|NCT00322374|Drug|Epirubicin|Infusion, intravenous (IV): 75 mg/m^2. Cycle = 21 days, up to 10 cycles or cumulative dose of 800 mg/m².
1765189|NCT00322387|Drug|G-CSF and plerixafor|G-CSF and plerixafor were administered as described in the treatment arms.
1765190|NCT00322400|Drug|Docetaxel|Subjects assigned to Arm B, cohorts will receive 75 or 100 mg/m2 of docetaxel (based on cohort assignment) on Day 1 repeated every 21 days (1 cycle). AMG 706 will be administered concurrently on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond.
1765191|NCT00322400|Drug|Paclitaxel|Subjects assigned to Arm A will receive 90 mg/m2 of paclitaxel on Days 1, 8 and 15 repeated every 28 days (1 cycle). On Arm A, AMG 706 will be concurrently administered on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond.
1765192|NCT00322400|Drug|AMG 706|"Subjects assigned to Arm A will receive AMG 706 at 50, 75, 100 or 125 mg daily (based on cohort assignment) on Days 3-28 of Cycle 1, and Days 1-28 of Cycle 2 and beyond in combination wth paclitaxel 90 mg/m2. Paclitaxel will be administered on Days 1, 8 and 15 every 28 days.
Subjects assigned to Arm B will receive AMG 706 at 50, 75, 100 or 125 mg daily(based on cohort assignment) on Days 3-21 of Cycle 1, and Days 1-21 of Cycle 2 and beyond in combination with docetaxel. Docetaxel will be administered at either 75 mg/m2 or 100 mg/m2 on Day 1 every 21 days."
1765193|NCT00322413|Drug|Epoetin|
1765194|NCT00322426|Device|Sensory Cueing Device|
1765195|NCT00322439|Drug|Etanercept|Observational study - no drug administered
1765196|NCT00322452|Drug|Gefitinib|oral tablet
1765197|NCT00322452|Drug|Carboplatin|IV
1765198|NCT00322452|Drug|Paclitaxel|IV
1956807|NCT02683161|Behavioral|Contingency Management|Contingency Management payments will begin on the target quit date (week 2) and will be in place for 5 weeks or until surgery (whichever is sooner). Participants will receive monetary incentives for biochemical evidence of smoking abstinence.
1765203|NCT00322478|Behavioral|Automated informatics driven education and social networking|The patient uses a self-contained wireless accessory to a standard blood glucose meter. This device manages the meter to ensure accurate time stamps and transmits the data to a centralized data management system. The system is then configured to assess the data and take automated steps to derive relevant diabetes education and/or send reports to a registered and authorized team.
1765204|NCT00322478|Behavioral|Blood Glucose Notifications to Remote Caregivers|When children with type 1 diabetes are at school they will connect their blood glucose meter to the GlucoMON appliance. The data from the meter is then transmitted to the central system followed by the most recent blood sugar being sent to the primary caregiver's email address(es) as a plain text message. The investigator is interested to better understand the behaviors that accompany the expectation of the message and actions taken subsequent to receipt of the message by the patient-centric team.
1765205|NCT00322478|Behavioral|Frequency of Pattern Management|The behavioral intervention being studied involves the assessment of frequency of self-care in relation to the primary and secondary outcomes including overall blood sugar control and patient satisfaction.
1765206|NCT00322491|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
1765207|NCT00322504|Procedure|Accupuncture|
1765208|NCT00322517|Drug|SU014813|100 mg capsule/day for 6 cycle of 21 days
1765209|NCT00322530|Procedure|Renal replacement therapy|ICU patients with acute renal failure were prospectively randomized to either CVVHD or SLED
1765210|NCT00322543|Device|Corio™ Pimecrolimus-eluting stent|
1765211|NCT00322556|Drug|Immunoglobulins Intravenous (Human)|Liquid formulation; treatment schedule every 3 or 4 weeks using an individualized regimen with a dose of 0.2 - 0.8 g IgG per kg bw
1765212|NCT00322569|Device|Corio™ Pimecrolimus-Eluting Coronary Stent System|Drug-eluting stent
1765213|NCT00322569|Device|SymBio™ Pimecrolimus/Paclitaxel-Eluting Coronary Stent System|Drug-eluting stent
1765214|NCT00322569|Device|Costar ™ Paclitaxel-Eluting Coronary Stent System|Drug-eluting Stent
1765215|NCT00322595|Drug|Quetiapine fumarate|
1765216|NCT00322595|Drug|Paroxetine|
1765217|NCT00322608|Drug|NPI-2358|Treatment on Days 1, 8 and 15 in a 28 day cycle
1765220|NCT00322673|Drug|XL999|XL999 was administered at a dose of 2.4 mg/kg given as a 4-hour IV infusion weekly for 4 weeks. In the absence of progressive disease and unacceptable toxicity, subjects were to receive XL999 treatment weekly for up to 1 year on this study
1765221|NCT00322686|Drug|Oglemilast|Oglemilast, 15mg oral administration, once per day and then dose-matched placebo
1765222|NCT00322686|Drug|Placebo then Oglemilast|Dose-matched placebo and then Oglemilast, 15mg, oral administration, once per day.
1765223|NCT00322699|Procedure|Whole bladder laser light treatment as an alternative to radical cystectomy|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
1765224|NCT00322699|Drug|Photofrin|The drug,Photofrin,at the dose of 1.5 mg/kg is infused intravenously two days prior to performing whole bladder laser light (630 nm) treatment.
1765225|NCT00322751|Drug|Topotecan|The starting dose for the first cohort will be 2 mg/m2/week. Increment between cohorts will be by 1 mg/m2/week if no toxicity related to topotecan occurs. All members of a dose cohort must have safely completed all radiotherapy and topotecan dosing prior to beginning enrollment in the next higher dose cohort. Increments will be reduced to 0.5 mg/m2 if mild to moderate toxicity occurs (grades 1 or 2). The escalation will continue until the maximum dose of 4 mg/m2/week is reached. Therefore the minimum number of dose levels (cohorts) is 3 to reach the goal of 4 mg/m2/week, and the maximum is 5.
1765226|NCT00322764|Drug|Uridine|
1765227|NCT00322777|Behavioral|Spirituality Teaching Program|The Spirituality Teaching Program is a home study program delivered through audio CDs over an 8-week period. The program consists of weekly 90 minute teaching sessions, based on the content of a workshop developed to assist users in developing a more spiritual outlook on life and coping resources. Using didactic comment and storytelling, the following spiritual concepts are addressed in the sessions: self-transcendence, connectedness, forgiveness, self-acceptance, detachment, compassion and gratitude. Each session concludes with a relevant guided visualization practice. In addition, a 15-minute progressive relaxation exercise is included that is to be used on a daily basis. The presented content is nondenominational to ensure compatibility with any beliefs participants may hold.
1765228|NCT00322803|Drug|ELB139|
1765229|NCT00322842|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
1991584|NCT00828009|Biological|bevacizumab|
1765231|NCT00322881|Drug|Paclitaxel|
1765232|NCT00322881|Drug|Carboplatin|
1765233|NCT00322907|Drug|Cotrifazid vs mefloquine or quinine+SP|
1765234|NCT00322920|Drug|Topotecan|
1765235|NCT00322920|Drug|Cisplatin|
1765236|NCT00322933|Procedure|renal replacement therapy (intermittent or continuous)|
1765237|NCT00322946|Biological|rDEN4delta30-4995|Live attenuated rDEN4delta30-4995 vaccine (one of three doses)
1765238|NCT00322946|Biological|Placebo|Placebo for rDEN4delta30-4995
1765239|NCT00322972|Drug|Mass treatment with oral azithromycin to an entire community|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. For study arm C and D, nasopharyngeal swabs will be collected from 10 randomly selected children among the 60 participants under 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
1765240|NCT00322985|Drug|Lenalidomide|25 mg/day, orally for 21 days with 7 days rest (28 day cycle). Dosing will be in the morning at approximately the same time each day.
1765241|NCT00323011|Drug|Fragmin, 5-Fluorouracil, Folinic Acid, irinotecan, bevacizumab|
1765242|NCT00323024|Drug|NX1011|
1765243|NCT00323037|Drug|carvedilol controlled release|Carvedilol controlled release (10, 20, 40 or 80 mg) and placebo taken in the morning. Two placebos taken in the evening. A total of 4 pills will be taken PO daily.
1765244|NCT00323037|Drug|carvedilol immediate release|Carvedilol immediate release (3.125, 6.25, 12.5 or 25 mg) and placebo, taken PO, twice-daily.
1765245|NCT00323050|Biological|Haemophilus influenzae type b- and meningococcal (vaccine)|
1991585|NCT00828009|Biological|emepepimut-S|
1991586|NCT00828009|Drug|carboplatin|
1765248|NCT00323076|Drug|18F-FAZA PET Imaging|"Phase I: 110-600 MBq per injection. A single injection of 18F-FAZA and PET scan will be permitted per patient.
Phase II: 110-600 MBq per injection. Up to three separate injections of 18F-FAZA and PET scans will be permitted per patient."
1765249|NCT00323089|Procedure|microcoil insertion and excision|The objective of this study is to determine if subcentimetre pulmonary nodules can be accurately and safely excised by endoscopic stapling devices after they have been localized using CT and marked with a microcoil device.
1765250|NCT00323102|Drug|Multihance|
1765251|NCT00323115|Biological|Autologous Dendritic Cell|Vaccine given by cervical lymph node injection 3 times every other week
1765252|NCT00323115|Drug|Temozolomide|Radiotherapy (RT) with concurrent temozolomide (TMZ) for 6 weeks before vaccine is SOC
1765253|NCT00323115|Procedure|Radiotherapy|RT is standard of care (SOC) post surgery
1765254|NCT00323115|Biological|Dendritic Cell Vaccine|Vaccine given cervical lymphnode injection 3 times every other week
1765255|NCT00323128|Procedure|Calculation of inuline clearance|Calculation of inuline clearance.
1765256|NCT00323128|Procedure|Measuring serum creatinine|Measuring serum creatinine.
1765257|NCT00323141|Device|Ventralex versus Leight Weight Vypro II prothesis|Ventralex and Leight Weight Vypro II prothesis are compared.
1765258|NCT00323154|Drug|Nalbuphine|
1765259|NCT00323193|Behavioral|MOVE!|group based psychoeducation, motivation and support
1991587|NCT00828009|Drug|cyclophosphamide|
1765260|NCT00323206|Biological|IL-12p DNA|Plasmid IL-12 will be administered as an intratympanic (IT) injection.
1765261|NCT00323206|Procedure|Intratumoral Electroporation|The electroporation apparatus with the electrical contacts will be placed around the tumor site and activated.
1765262|NCT00323219|Drug|Cefazolin and Moxifloxacin|See Detailed Description.
1765263|NCT00323232|Device|2 Versus 4 Hole DHS|See Detailed Description.
1765264|NCT00323245|Behavioral|Physiotherapy for urinary incontinence|See Detailed Description.
1765265|NCT00323258|Behavioral|oral education & written tips for remembering medications|Clinical pharmacist will review purpose of medications of interest (beta-blockers, statins, Angiotensin Converting Enzyme Inhibitor (ACEI)/Angiotensin Receptor Blocker (ARB), aspirin, and other anti-platelets) with the subject. A written list of tips for remembering medications will be provided and reviewed.
1765266|NCT00323258|Device|pill box|Subject is provided a pill box and briefly instructed on how to use the box.
1765267|NCT00323258|Device|pocket medication card|Subject is provided with a card that contains space for prescription and non-prescription medications. If desired the clinical pharmacist-investigator will complete the card for the subject.
1765268|NCT00323258|Behavioral|sharing information with community pharmacist|A fax is sent to the designated community pharmacy at the time of the subject's discharge from the hospital. The fax contains the subject's medications of interest, barriers to medication adherence, and physicians' contact information.
1765269|NCT00323258|Behavioral|Medication use evaluations by community pharmacist|The community pharmacist will assess use of medications of interest at time of first medication fill and by reviewing the subject's computerized medication profile at the pharmacy. Assessments occur at first visit to pharmacy, 6-weeks, 12-weeks, 18-weeks, and 24-weeks. If there are issues with any medications of interest the subject will be called. If needed, the subject's health care team will be notified.
1765270|NCT00323258|Behavioral|informing physician if patient has stopped a medication|The community pharmacist or clinical pharmacist-investigator will fax the subject's physician to notify that a medication has been stopped.
1765271|NCT00323258|Behavioral|Routine discharge counseling|Both groups received routine discharge counseling performed by the patient-care nurse.
1765272|NCT00323258|Other|Letter to physician/discharge summary|A letter/discharge summary from the hospital physician to the community physician listing the discharge medications, procedures, and recommendations.
1765273|NCT00323271|Behavioral|Cognitive-behavior therapy|CBT: The components of CBT include (1) identification of idiosyncratic beliefs about pain and pain treatment, as well as reconceptualization of the pain experience as subject to personal control (sessions 1-2), (2) instruction in specific cognitive (e.g., distraction) and behavioral (e.g., change in activity patterns such as alternating activity with periods of rest) skills (sessions 3-8), and (3) consolidation of cognitive/behavioral skills through activities such as role playing (sessions 9-11).
1765274|NCT00323271|Other|Interventional|Educational intervention: Session topics will include information on the etiology of MS, MS subtypes and disease progression, common symptoms of MS, medical management of MS, rehabilitation approaches to management of MS-related symptoms, exercise, sick day management, stress management, psychosocial adjustment, family involvement, and appropriate use of the health care system.
1765275|NCT00323284|Device|iStent plus Cataract Surgery|ab interno trabecular bypass stent surgery
1765276|NCT00323284|Procedure|Cataract surgery only|Cataract surgery only
1765277|NCT00323297|Drug|Bosentan|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
1765278|NCT00323297|Other|Placebo|Bosentan + Placebo for 12 weeks of the study (double blind), then 12 months open label phase (bosentan + sildenafil)
1765279|NCT00323297|Drug|Bosentan|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
1765280|NCT00323297|Drug|Sildenafil Citrate|Bosentan + Sildenafil for 12 weeks of the study (double blind), then 12 months open label phase
1765281|NCT00323310|Drug|gadobenate dimeglumine|A dose of 0.10 mmol/kg (i.e., 0.2 mL/kg) of 0.5 molar MultiHance was injected intravenously at a rate of 2 mL/sec as a single dose.
1765282|NCT00323323|Drug|CHOP|CHOP will be given 60-120 minutes following SQ administration of Alemtuzumab as follows: cyclophosphamide 750 mg/m2 IV on day 1, doxorubicin 50 mg/m2 IV on day 1, vincristine 1.4 mg/m2 (maximum dose = 2 mg) IV on day 1, and prednisone 100 mg PO on days 1-5.
1765283|NCT00323323|Drug|Alemtuzumab|Single agent Alemtuzumab given subcutaneously (SQ) on week #1. Dose escalation will occur during the first week of therapy, starting with 3 mg of Alemtuzumab administered SQ on day 1. If well tolerated, this will be followed by 10 mg SQ on day 3 and 30 mg (split into 2 injection sites) on day 5.
1765284|NCT00323323|Procedure|Plasma Samples|Plasma samples will be obtained for Alemtuzumab pharmacokinetics (PK) during the first week of single agent Alemtuzumab stepped up dosing and subsequently before and after the 5th and the 8th Alemtuzumab/CHOP dose.
1765285|NCT00323349|Procedure|Oral Glucose Tolerance Testing|
1765286|NCT00323349|Behavioral|Education tailored to learning style preferences|
1765287|NCT00323362|Drug|gemcitabine hydrochloride|1000 mg/m2 given intravenously at a FDR of 10 mg/m2/min on Days 3 and 10, every 21 days.
1765288|NCT00323362|Drug|imatinib mesylate|400 mg/day orally, given Days 1-5 and 8-12 every 21 days
1765289|NCT00323375|Drug|AQ-13 and Chloroquine|
1765290|NCT00323401|Other|Antenatal classes|3 sessions of 3 hours each
1765291|NCT00323401|Other|Antenatal classes|antenatal programme
1765292|NCT00323401|Other|Educational programme|3 times, 3 hours intervention programme
1765293|NCT00323401|Other|Educational programme|no programme are offered
1991588|NCT00828009|Drug|paclitaxel|
1991589|NCT00828009|Radiation|radiation therapy|
1765296|NCT00323427|Behavioral|The Living Well with Hearing Loss Workshop|Interactive group session modeled on Patient-Centered medicine and Adult Learning principles; the participants are partners with the Group Facilitator who is a hearing rehabilitation professional
1765297|NCT00323427|Device|hearing aid services|Standard VA audiological hearing aid dispensing services
1765298|NCT00323453|Device|Alexis Wound Retractor use in open appendectomy|
1765410|NCT00307489|Drug|tenofovir DF|300 mg tablet, once daily (QD)
1765299|NCT00323466|Procedure|IMRT versus conventional radiotherapy|Comparing MRT versus conventional radiotherapy
1765300|NCT00323479|Drug|Anastrozole|1mg/Day oral
1765301|NCT00323492|Drug|Truvada|Truvada + NNRTI or PI.
1765302|NCT00323492|Drug|Current HAART regimen|Maintain baseline regimen
1765303|NCT00323505|Drug|Pegylated Interferon|
1765304|NCT00323505|Drug|Interferon-alpha2a|
1765305|NCT00323518|Drug|velafermin|administered intravenously as 100mL single dose over 15 minutes on day 1
1765306|NCT00323518|Drug|placebo|administered intravenously as 100mL single dose over 15 minutes on day 1
1765307|NCT00323531|Procedure|Chest tube with tPA infusion for 3 days|fibrinolysis through the chest tube
1765308|NCT00323531|Procedure|VATS decortication|thoracoscopic decortication
1765309|NCT00323544|Drug|zidovudine and lamivudine (Combivir®)|
1765310|NCT00323544|Drug|emtricitabine and tenofovir DF|
1765311|NCT00323557|Drug|Sargramostim (GM-CSF)|Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.
1765312|NCT00323557|Biological|Pneumococcal Vaccine|Subcutaneously on Day 0
1765313|NCT00323570|Drug|activated recombinant human factor VII|
1765314|NCT00323583|Drug|paclitaxel|
1765315|NCT00323583|Drug|oxaliplatin|
1765316|NCT00323583|Drug|leucovorin|
1765317|NCT00323583|Drug|5-fluorouracil|
1765318|NCT00323583|Drug|glutathione|
1765319|NCT00323583|Drug|calcium and magnesium|
1765320|NCT00323583|Procedure|Chemotherapy|
1765321|NCT00323583|Procedure|Chemoprotection|
1765322|NCT00323583|Procedure|Complementary and alternative therapy|
1765323|NCT00323596|Behavioral|physical activity program of strength and balance retraining|Unspecified
1765324|NCT00323609|Procedure|Vertebroplasty|Vertebroplasty involves placement of a needle into the vertebral body. Cement is injected into the vertebral body.
1765325|NCT00323609|Procedure|Kyphoplasty|Balloon Kyphoplasty involves two inflatable bone tamps placed into the vertebral body in the spine. After the tamps are removed, the void is filled with viscous bone cement.
1765326|NCT00323622|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|IM injection in the deltoid muscle
1765327|NCT00323622|Biological|Engerix™-B|IM injection in the deltoid muscle
1765328|NCT00323622|Biological|Hiberix®|IM injection in the deltoid muscle
1765329|NCT00323622|Biological|Prevnar™|IM injection in the deltoid muscle
1765330|NCT00323622|Drug|sulfadoxine-pyrimethamine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
1765331|NCT00323622|Drug|amodiaquine|1 dose orally per day for 3 days, 4 weeks prior to onset of surveillance
1765332|NCT00323635|Drug|tolterodine|tablet, 4 mg, daily, 1 month
1765333|NCT00323648|Drug|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis|Whether or not giving postoperatively antibiotics to patients with an uncomplicated acute cholecystitis.
1765334|NCT00323661|Device|Rate-adaptive pacemaker: accelerometer|Accelerometer based pacing rate adaptation
1765335|NCT00323661|Device|Rate-adaptive pacemaker: Closed Loop Stimulation|Closed Loop Stimulation (CLS) is a unique concept in rate-adaptive pacing that uses the natural cardiovascular control loop to determine the appropriate pacing rate. Closed Loop Stimulation is the only rate-adaptive system responding to mental stress and thereby assuring optimal cerebral perfusion in everyday activity.
1765336|NCT00323674|Device|Polysoft Mesh|Polysoft Mesh is used.
1765337|NCT00323674|Device|Light Weight Mesh|Light Weight Mesh is used.
1765338|NCT00323687|Drug|Truvada|300mg / 200 mg QD tenofovir DF and Emtricitabine Fixed Dose Combination (FDC) Tablet (oral)
1765339|NCT00323713|Behavioral|Very low protein diet|0.3 g of proteins per kilo of body weight per day, supplemented with a mixture of essential aminoacids and chetoacids
1765340|NCT00323713|Behavioral|Low protein diet|0.6 g of protein per kilo of body weight per day
1765341|NCT00323739|Drug|bevacizumab|Bevacizumab 10mg/kg, IV infusion, every 2 weeks
1765342|NCT00323739|Drug|RAD001|RAD001 10 mg by mouth daily
1765343|NCT00323752|Procedure|rHuEpo|Subjects will be randomly assigned to either participate in the PAD program or receive the rHuEpo treatment. Subjects in the PAD group will donate 1 unit of blood at -14 and -7 days prior to surgery. A dose of 500 IU of rHuEpo will be administered subcutaneously to subjects in the rHuEpo group at -21, -14, and -7 days prior to surgery.
1765344|NCT00323778|Drug|Hyalgan|
1765345|NCT00323791|Drug|gemcitabine hydrochloride|
1765346|NCT00323791|Drug|imatinib mesylate|
1765347|NCT00323791|Genetic|gene expression analysis|
1765348|NCT00323791|Genetic|protein expression analysis|
1765349|NCT00323791|Other|immunohistochemistry staining method|
1765350|NCT00323791|Other|laboratory biomarker analysis|
1765351|NCT00323804|Biological|Peginterferon alfa-2b|PegIFN alfa 2b in addition to ribavirin or ribavirin-placebo, from day 0 to M36
1765352|NCT00323804|Drug|Ribavirin|Ribavirin in addition to PegIFN alfa 2b, from day 0 to M36
1765353|NCT00323804|Drug|Ribavirin-Placebo|Ribavirin-placebo in addition to PegIFN alfa 2b, from day 0 to M36
1765354|NCT00323817|Drug|Z-338|
1765355|NCT00323830|Drug|Capecitabine, cisplatin, Radiotherapy (+/-)|Capecitabine, cisplatin + Radiotherapy (randomized)
1765356|NCT00323843|Drug|Isoproterenol|
1765357|NCT00323856|Drug|Alphanate SD/HT|Plasma-derived preparation of Factor VIII
1765358|NCT00323869|Drug|Bevacizumab|Murine humanized anti-vascular endothelial growth factor A (VEGF-A) monoclonal antibody
1765359|NCT00323869|Drug|Gemcitabine|Nucleoside analog
1765360|NCT00323869|Drug|Carboplatin|Alkylating agent
1765361|NCT00323882|Drug|MDX-010|selected dose administered IV every 3 weeks
1765362|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
1765646|NCT00315900|Drug|Depakote ER|depakote ER
1765363|NCT00323895|Device|drug-eluting stent and balloon angioplasty|CYPHER Select ™ Sirolimus-eluting Stent and any balloon brand
1765364|NCT00323895|Device|drug-eluting stent|CYPHER Select ™ Sirolimus-eluting Stent
1765365|NCT00323921|Device|dermatological infrared laser|
1765366|NCT00323934|Drug|MGCD0103|Oral dosage 2 times weekly.
1765367|NCT00323947|Drug|Extended Release Methylphenidate (OROS-Methylphenidate)|"Participants will first take either immediate release MPH or placebo A for 1 day. On Day 2 of treatment, participants assigned to receive XR-MPH will begin taking it, and participants assigned to receive placebo will switch to placebo B. This treatment phase will continue for 6 days to 4 weeks, depending on weight, and will then be followed by a 1-week medication washout period. Target dose depends on the weight of the participant. Possible dose forms include 18, 36, 54 mg OROS-MPH."
1956808|NCT02683161|Behavioral|Behavioral Counseling|All participants will complete a 3-session behavioral counseling intervention with a trained member of our study staff during 3 of the pre-surgical study visits. This brief counseling intervention provides participants with information about the experience of quitting smoking, including a benefits/disadvantage analysis, functional analysis of craving/risk periods, and skills-building exercises to prevent lapse and relapse.
1765371|NCT00323973|Drug|Bisoprolol|10 mg qd
1765372|NCT00323986|Drug|azithromycin (drug)|
1765373|NCT00323999|Procedure|Hysteroscopic resection of fibroids, polyps and endometrium.|
1765374|NCT00324012|Drug|cisplatin, taxotere|cisplatin 75 mg/m2 Taxotere 75 mg/m2
1765375|NCT00324025|Drug|Mycograb|
1765376|NCT00324025|Drug|placebo|
1765377|NCT00324038|Drug|Buprenorphine|buprenorphine transdermal system 5, 10 and 20 mg
1765378|NCT00324038|Drug|Codeine paracetamol|combination tablet of codeine and paracetamol taken orally 3 or 4 times daily. Dosage form ranges from 8/500, 15/500 and 30/500
1765379|NCT00324051|Drug|olanzapine therapy|
1765380|NCT00324064|Procedure|GHRH/arginine stimulation testing|GHRH(Geref) 1mcg/kg IVP followed by Arginine 10% solution 0.5mg/kg (maximum of 30 Gm) infused over 30 minutes. Labs drawn 6 times over 2 hours.
1765381|NCT00324077|Drug|Dasatinib in combination with imatinib|
1765382|NCT00324090|Behavioral|High and low glycemic index|
1765383|NCT00324103|Drug|Structured Treatment Interruptions|
1765384|NCT00324116|Drug|pegaptanib sodium (Macugen)|0.3 MG/eye pegaptanib IB sodium by intravitreous injection given every 6 weeks for 54 weeks.
1765385|NCT00324129|Drug|MGCD0103|MGCD0103 given orally three times per week.
1765386|NCT00324142|Drug|Oral tinidazole|
1956812|NCT02680756|Drug|Ferric Maltol|
1956813|NCT02680756|Drug|Ferric Carboxy Maltose|
1765390|NCT00324168|Drug|Antibiotics|moxifloxacin 0.5% every one hour for 48 hours while awake and then every 2 hours until re-epithelialization
1765391|NCT00324168|Drug|Topical corticosteroid|prednisolone phosphate 1% with preservative four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
1765392|NCT00324168|Drug|Placebo|0.9% NaCl and preservative (same as in steroid) four times a day for 1 week, then twice a day for 1 week, and finally once a day for 1 week
1765393|NCT00307294|Drug|Thalidomide|100 mg PO q day and escalation will occur bt 50 mg every 4 weeks to a maximum of 200mg
1765394|NCT00307294|Drug|Doxil|On day 1 of each cycle 40 mg/m2 IV over 1 hr every 28 days
1765395|NCT00307307|Drug|Niacin/simvastatin compared to simvastatin alone at 2 doses|
1765396|NCT00307320|Behavioral|Relaxation Training|Relaxation techniques training
1765397|NCT00307333|Device|HeRO heart rate characteristics monitor|24 hour continuous HRC monitoring with display
1765398|NCT00307398|Drug|Anecortave Acetate (AL-3789) sterile suspension, 15 mg or 30 mg|One 0.5 mL injection of 30 mg/mL (AA 15 mg) or one 0.5 mL injection of 60 mg/mL (AA 30 mg) into a posterior juxtascleral depot (PJD) at 6-month intervals.
1765399|NCT00307398|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals. Syringe containing AA vehicle was not inserted into the eye.
1765400|NCT00307411|Drug|Growth hormone|
1765401|NCT00307424|Device|AutoCPAP|
1765402|NCT00307424|Device|FixCPAP|
1765403|NCT00307437|Drug|Placebo; Ustekinumab (CNTO 1275) 45 or 90 mg|Placebo at Weeks 0 and 4 and blinded SC injections of ustekinumab, 45 or 90 mg, at Weeks 12 and 16; followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
1765404|NCT00307437|Drug|Ustekinumab (CNTO 1275) 45 mg|Ustekinumab, 45 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
1765405|NCT00307437|Drug|Ustekinumab (CNTO 1275) 90 mg|Ustekinumab, 90 mg, at Weeks 0 and 4 and every 12 weeks for Weeks 16 to 28. Followed by a dosing regimen to be determined by patient's response status for Weeks 28 to 52; followed by unblinded dosing that may be adjusted at the investigator's discretion for Weeks 52 to 264
1765406|NCT00307450|Drug|Levetiracetam|up to 200 mg per day in two dosages per day.
1765407|NCT00307463|Procedure|strict volume control policy|strict volume control by UF and dietary salt restriction
1765408|NCT00307463|Procedure|antihypertensive drugs administration|continue antihypertensive medications
1765409|NCT00307476|Device|Rusch Nasopharyngeal Airway|
1765647|NCT00315900|Drug|Seroquel|seroquel
1765411|NCT00307489|Drug|emtricitabine /tenofovir DF|emtricitabine 200 mg/tenofovir DF 300 mg once daily (combination tablet)
1765412|NCT00307502|Drug|Nevirapine|tablets 200 mg, 400 mg/day
1765413|NCT00307502|Drug|Efavirenz|tablets 600 mg, 600 mg/day
1765414|NCT00307502|Drug|Indinavir/ritonavir|"Indinavir: capsules 400 mg, 1600 mg/day
Ritonavir: capsules 100 mg, 200 mg/day"
1765415|NCT00307502|Drug|Nelfinavir|tablets 250 mg, 2500 mg/day
1765416|NCT00307502|Drug|Saquinavir/ritonavir|"Saquinavir: tablets 500 mg, 2000 mg/day
Ritonavir: tablets 100 mg, 200 mg/day"
1765417|NCT00307502|Drug|Lopinavir/ritonavir|tablets lopinavir 200 mg + ritonavir 50 mg, 800/200 mg/day
1765418|NCT00307502|Drug|Atazanavir|capsules 200 mg, 400 mg/day
1765419|NCT00307502|Drug|Atazanavir/ritonavir|"Atazanavir: capsules 150 mg, 300 mg/day
Ritonavir: capsules 100 mg, 200 mg/day"
1765420|NCT00307502|Drug|Fos-amprenavir/ritonavir|"Fos-amprenavir: capsules 700 mg, 1400 mg/day
Ritonavir: capsules 100 mg, 200 mg/day"
1765421|NCT00307502|Drug|Tipranavir/ ritonavir|"Tipranavir: tablets 250 mg, 1000 mg/day
Ritonavir: capsules 100 mg, 400 mg/day"
1765422|NCT00307502|Drug|Darunavir/ritonavir|"Darunavir: tablets 300 mg, 1200 mg/day
Ritonavir: capsules 100 mg, 200 mg/day"
1765423|NCT00307515|Drug|Fibrin Sealant 2 (FS2)|FS2 Surgical Sealant Kit: Biological Active Component containing Human Fibrinogen 55-85 mg/mL and Thrombin containing Thrombin 800-1200 IU/mL and Calcium Chloride 5.6-6.2 mg/mL
1765424|NCT00307515|Device|Oxidized Regenerated Cellulose (Surgicel)|Commercially available Surgicel used within label.
1765425|NCT00307528|Biological|Pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Five different formulations, each administered to one Group
1765426|NCT00307528|Biological|Pneumovax 23™|Single dose intramuscular injection.
1765427|NCT00307541|Biological|Pneumococcal (vaccine)|
1765428|NCT00307554|Biological|Pneumococcal (vaccine)|
1765429|NCT00307567|Biological|Pneumococcal (vaccine)|
1765430|NCT00307580|Drug|Cathflo Activase (Alteplase)|
1765431|NCT00307593|Drug|Infliximab|Infliximab
1765432|NCT00307593|Drug|Rituximab|Rituximab
1765433|NCT00307606|Drug|Solu-medrol 125 mg|
1765434|NCT00307619|Drug|topiramate|
1765435|NCT00307632|Drug|Norelgestromine (NLGM)/ethinyl estradiol (EE)|Participants will apply a 20 centimeter square (cm^2) contraceptive transdermal patch on the skin for 1 full week, and then apply a fresh patch for Week 2, and a third patch for Week 3. The fourth week will be patch-free. Each patch delivers 150 microgram (mcg) of NLGM and 20 mcg of EE per day. The treatment duration is of 6 cycles (4 weeks each).
1765436|NCT00307645|Drug|Cyclophosphamide|
1765437|NCT00307645|Drug|Mycophenolate mofetil|
1765438|NCT00307645|Drug|Azathioprine|
1765439|NCT00307645|Drug|Prednisone (and methylprednisolone)|
1765440|NCT00307658|Drug|Intravenous immunoglobulins (human immunoglobulins G)|
1765441|NCT00307671|Drug|prednisone, methylprednisolone,cyclophosphamides|treatment conventional
1765442|NCT00307671|Drug|Cyclophosphamide, Azathioprine,prednisone,methylprednisolone|reduction dose
1765443|NCT00307671|Drug|Mycophenolate mofetil,methotrexate|in the treatment conventional and in the reduction dose
1765444|NCT00307684|Drug|double blind placebo|matching placebo tablets once daily for 4 weeks
1765445|NCT00307684|Drug|double blind PR OROS methylphenidate|18, 36, 54,72 or 90 mg/day once daily for 4 weeks
1765446|NCT00307684|Drug|open label PR OROS methylphenidate|Flexible dosage MPH (18 to 90 mg/day) for 72 weeks (108 weeks for Germany)
1765447|NCT00307697|Procedure|receipt of copy of psychiatic assessment letter|
1765448|NCT00307710|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Receive either standard inactivated influenza vaccine or one of three doses of the experimental vaccine, vaccine dose 15, 45 or 135 μg HA per virus, intramuscular injection.
1765449|NCT00307723|Drug|bevacizumab|Intravenously on days 1, 15 and 29 of the first cycle. Intravenously on days 1, 15 of each 28-day cycles for cycles 2-5.
1765450|NCT00307723|Drug|5-Fluorouracil|Continuous infusion on days 1-5, 8-12, 15-19, 22-26, 29-33 and 36-38 of cycle one.
1765451|NCT00307723|Drug|Oxaliplatin|Intravenously on dasy 1, 8, 15, 22, 29, 36 of cycle one.
1765452|NCT00307723|Drug|gemcitabine|Intravenously on days 1, 8, 25 of every 28-day cycle for cycles 2-5.
1765453|NCT00307723|Procedure|External Beam Radiation Therapy|Monday through Friday ending on day 38 of cycle 1
1765454|NCT00307736|Drug|5-fluorouracil|Given as a 24-hour infusion on days 1-14 of each 14-day cycle for a total of 3 cycles.
1765455|NCT00307736|Drug|bevacizumab|Given intravenously on day 1 of each 14-day cycle for a total of 3 cycles.
1765456|NCT00307736|Drug|erlotinib|Taken orally on days 1-14 of each 14-day cycle for a total of 3 cycles.
1765457|NCT00307736|Procedure|External beam radiation therapy (EBRT)|Given on days 1-5 and 8-12
1765458|NCT00307749|Drug|Placebo|once daily for 24 weeks
1765459|NCT00307749|Drug|MCC-257|20mg, once daily for 24 weeks
1765460|NCT00307749|Drug|MCC-257|40mg, once daily for 24 weeks
1765461|NCT00307749|Drug|MCC-257|80mg, once daily for 24 weeks
1765462|NCT00307762|Behavioral|intensified gait trainer|Intensity and type of rehabilitation after stroke. Gait trainér + or overground walking + other gait-oriented physioteharpy. The third group (control patients) received traditional (ordinary) physiotherapy witn o efforts to intensify it.
1765463|NCT00307775|Drug|oestradiol|
1765464|NCT00307788|Procedure|acupuncture|acupuncture
1765465|NCT00307801|Drug|Estradiol valerate/Dienogest (Natazia, Qlaira, BAY86-5027)|1 pill per day taken orally over 7 cycles of 28 pills per cycle
1765466|NCT00307801|Drug|Placebo|1 pill per day taken orally over 7 cycles of 28 pills per cycle
1765467|NCT00307814|Drug|Epoetin Alfa|
1765468|NCT00307827|Drug|Visilizumab|Visilizumab administered intravenously once per day for two days
1765469|NCT00307840|Drug|paricalcitol|
1765470|NCT00307853|Drug|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
1765471|NCT00307853|Other|Traumeel S|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
1765472|NCT00307853|Other|Placebo|All patients will receive an intra-operative injection of either Traumeel S or placebo solution. Afterwards, verum or indistinguishable placebo tablets, PO, two tablets five times daily from day 0 to 6 post-operatively, and two tablets three times daily from day 7 until day 21. To the extent possible, administration of tablets should be equally spaced between morning and evening (e.g. every 6 hours) at the same time every day.
1765473|NCT00307866|Procedure|Resovist (BAY86-4884, SH U 555 A)|Single bolus injection, followed by MRI
1765474|NCT00307879|Drug|Drug: G-CSF (Dong-A pharmaceutical, Seoul, Korea)|
1765475|NCT00307879|Procedure|collection of mobilized peripheral blood stem cells|
1765476|NCT00307879|Procedure|Intracoronary infusion of mobilized cells|
1765477|NCT00307892|Drug|Traumeel S: intra-operative irrigation + oral ingestion|homeopathic remedy
1765478|NCT00307892|Drug|Placebo|placebo remedy
1765479|NCT00307905|Drug|Traumeel S|homeopathic remedy
1765480|NCT00307905|Drug|Placebo remedy|identical size, shape and taste of treatment medication
1765481|NCT00307918|Device|acupuncture|
1765482|NCT00307931|Biological|Certolizumab pegol|"certolizumab pegol 400 mg (lyophilized product) administered as 2 x 200 mg subcutaneous injections at Weeks 0, 2, 4, 8 and 12.
Treatment duration: 12 weeks."
1765483|NCT00314379|Drug|Vitamin E 400IU/day|
1765484|NCT00314392|Behavioral|Information (behavior)|
1765485|NCT00314405|Drug|Methylene blue (1%)|
1765486|NCT00314405|Drug|Rhenium sulfure|
1765487|NCT00314405|Procedure|Surgical procedure|
1765488|NCT00314405|Procedure|Anatomo-pathologic procedure|
1765489|NCT00314418|Procedure|Colonoscopy in the prone position|
1765490|NCT00314431|Procedure|Care coordination by telephone contacts with a nurse|
1765491|NCT00314457|Drug|Bupivacaine|Patients receive either normal saline or Bupivacaine in normal saline that infuses intraarticularly for 48 hours.
1765492|NCT00314483|Drug|Mesenchymal Stem Cell Infusion|
1765493|NCT00314509|Drug|Ciclesonide/Formoterol Combination|
1765494|NCT00314548|Drug|PGE1 (prostacyclin)|alprostadil nebulization
1765495|NCT00314548|Drug|normal saline|nebulize for 30 mins
1765496|NCT00314561|Drug|Pioglitazone, Rosiglitazone|
1765497|NCT00314574|Drug|omalizumab (Xolair)|Omalizumab (Xolair) was administered by subcutaneous (SC) injection every 2 or 4 weeks. Xolair was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that were reconstituted with Sterile Water for Injection (SWFI), USP.
1765498|NCT00314574|Drug|placebo|Placebo was administered by subcutaneous (SC) injection every 2 or 4 weeks. Placebo contained the same ingredients as the lyophilized formulation of Xolair,excluding omalizumab.
1765499|NCT00314574|Drug|corticosteroids|Minimum dose of 500 µg of fluticasone dry-powder inhaler or its equivalent ex-valve dose twice a day.
1765500|NCT00314574|Drug|long-acting beta-agonists|50 µg salmeterol twice daily or 12 µg formoterol twice daily.
1765501|NCT00314587|Procedure|1 or 2 elastic stable intramedullary nails|
1765502|NCT00314600|Device|above and below elbow cast|
1765503|NCT00314613|Drug|Antipsychotic/Risperidone Consta|
1765504|NCT00314626|Drug|efavirenz|Efavirenz
1765505|NCT00314626|Drug|Abacavir+lamivudine|Abacavir+lamivudine
1765506|NCT00314639|Drug|modafinil|Modafinil OR Placebo 100mg orally (on the morning) from day 0 to day 14 and 200mg orally (on the morning) from day 15 to day 28. AND REVERSE : Modafinil OR Placebo 100mg orally (on the morning) from day 42 to day 56 and 200mg orally (on the morning) from day 57 to day 70.
1765507|NCT00314652|Drug|Buprenorphine transdermal delivery system|
1765508|NCT00314665|Drug|Thalidomide|
1765509|NCT00314678|Drug|Topotecan|
1765510|NCT00314678|Drug|Cisplatin|
1765511|NCT00314678|Drug|Paclitaxel|
1765512|NCT00314691|Genetic|Blood samples|
1765513|NCT00314704|Drug|dopamine versus norepinephrine|
1765514|NCT00314717|Behavioral|Control diet|
1765515|NCT00314717|Behavioral|Low GI diet|
1765516|NCT00314730|Device|handheld Personal Digital Assistant (PDA)|
1765517|NCT00314743|Drug|Ondansetron|
1765518|NCT00314743|Drug|Dexamethasone|
1765519|NCT00314743|Drug|Aprepitant|
1765520|NCT00314756|Drug|imiquimod|
1765521|NCT00314782|Drug|ZD4054 (Zibotentan)|oral tablet
1765522|NCT00314782|Drug|Docetaxel|intravenous infusion
1765523|NCT00314782|Drug|Placebo|
1765525|NCT00314808|Drug|Dronabinol|Oral route, 5mg PO 2x daily before and during 2 cycles of chemotherapy,2.5mg PO every night when not on chemotherapy
1765526|NCT00314821|Drug|ropinirole|
1765527|NCT00314834|Drug|Intradialytic parenteral nutrition|
1765528|NCT00314847|Device|Extra-Corporeal Life Support -Impella 2.5|Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
1765530|NCT00314873|Drug|Gleevec (imatinib)|Imatinib 600mg po qd X 21 days.
1765531|NCT00314886|Drug|Diet|
1765532|NCT00314912|Drug|Tramiprosate (3APS)|
1765533|NCT00314925|Drug|Seneca Valley Virus (biological agent)|Dose escalation (starting at 1 × 10^7 vp/kg), IV (in the vein) over 1 hour in a single administration
1765534|NCT00314938|Drug|PHA-794428|
1765535|NCT00314951|Drug|Fidaxomicin|200 mg oral capsules two times daily (q12h regimen)
1765536|NCT00314951|Drug|Vancomycin|125 mg capsules q6hr (4 times a day)
1765537|NCT00314951|Drug|Matching Placebo to Fidaxomicin|Matching Placebo to Fidaxomicin administered two times daily (intermittently with fidaxomicin dosing)
1765538|NCT00314964|Drug|PD-0299685|
1765539|NCT00314977|Drug|Doxorubicin|doxorubicin (arm A:60 mg/m2) and arm B: 50 mg/m2)
1765761|NCT00316784|Drug|IDEA-033 (and rescue medication)|
1765540|NCT00314977|Drug|Cyclophosphamide|Cyclophosphamide: (arm A; 6000 mg/m2) an (arm B: 500 mg/m2)
1765541|NCT00314977|Drug|Docetaxel|Docetaxel: (arm A: 100 mg/m2) and (arm B: 75 mg/m2)
1765542|NCT00314990|Drug|5 mg folic acid, 50 mg pyridoxine and 0.4 mg cyanocobalamin|
1765543|NCT00315003|Drug|Telithromycin|
1765544|NCT00315003|Drug|Azithromycin|
1765545|NCT00315016|Drug|eplerenone|active comparator
1765546|NCT00315016|Drug|fosinopril|doubling of fosinopril dose
1765547|NCT00315016|Drug|placebo|placebo (double dummy)
1765548|NCT00315029|Behavioral|evidence based decision aid|evidence based decision aid
1765549|NCT00315029|Behavioral|Possible reimbursement 4th IVF/ICSI cycle when necessary|Potential reimbursement 4th IVF/ICSI cycle when necessary
1765550|NCT00315042|Drug|Telithromycin (HMR3647)|
1765551|NCT00315042|Drug|Penicillin|
1765552|NCT00315055|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, Intramuscular (IM)
1765553|NCT00315055|Biological|DTaP-IPV//PRP~T combined|0.5 mL, IM
1765554|NCT00315055|Biological|Hepatitis B vaccine|0.5 mL, IM
1765555|NCT00315081|Drug|Bromocriptin|
1765556|NCT00315094|Behavioral|Caregiving support interventions (FamTechCare)|One set of combined interventions to be tested in this study are nursing interventions for the prevention of catheter-related infection, reactive depression, and HPN home care problem-solving. The other set of combined interventions are for increasing social support and use of a short nap to reduce daily fatigue. Information about all the interventions were incorporated into Internet formats as a booster for reinforcement.
1765557|NCT00315107|Drug|Alesse|
1765558|NCT00315120|Procedure|A. Active OMT and active UST|Active osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
1765559|NCT00315120|Procedure|B. Sham OMT and active UST|Sham osteopathic manipulation (OMT) and active ultrasound physical therapy (UST)
1765560|NCT00315120|Procedure|C. Active OMT and sham UST|Active osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
1765561|NCT00315120|Procedure|D. Sham OMT and sham UST|Sham osteopathic manipulation (OMT) and sham ultrasound physical therapy (UST)
1765562|NCT00315133|Procedure|Immunosuppression and autologous stem cell transplantation|Immunosuppression and autologous stem cell transplantation: Mobilization of hematopoietic stem cells (HSC) with cyclophosphamide (2 g/m2) and granulocyte-colony stimulating factor (G-CSF, 10 ug/kg/d), followed by collection and cryopreservation of unselected HSC and conditioning with cyclophosphamide (200 mg/kg) plus rabbit anti-thymocyte globulin (ATG 4.5 mg/kg).
1765563|NCT00315146|Drug|Pioglitazone|
1765564|NCT00315146|Behavioral|Resistance exercise training to maximize muscle power|
1765565|NCT00315146|Behavioral|Hypocaloric diet|
1765566|NCT00315146|Drug|Placebo|
1765567|NCT00315159|Procedure|Sentinel Node Biopsy|Inguinal sentinel node biopsy will be performed.
1765568|NCT00315172|Procedure|Non-Exercise Activity Thermogenesis (NEAT)|
1765569|NCT00315185|Drug|Cetuximab|
1765570|NCT00315198|Device|Eye Patch|2 hours daily patching
1765571|NCT00315198|Procedure|Near activities|near visual activities while patching
1765572|NCT00315198|Procedure|Distance activities|distance visual activities while patching
1765573|NCT00315211|Drug|Intravenous Topotecan|Topotecan 3 mg/m2 IV over 30 minutes on Days 1 and 8 every 21 days
1765574|NCT00315211|Drug|Intravenous Docetaxel|Docetaxel 30 mg/m2 IV over 60 minutes on Days 1 & 8 of a 21 day cycle
1765575|NCT00315224|Behavioral|heart-rate controlled 12 week exercise program|
1765576|NCT00315237|Drug|vinflunine and best supportive care|solution for injection, IV, 280/320 mg/m2, every 3 wks variable duration
1765577|NCT00315250|Drug|[123I]β-CIT|"Single Photon Emission Computed Tomography
SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI."
1765578|NCT00315276|Drug|Modafinil|
1765579|NCT00315289|Procedure|Nasolacrimal balloon catheter duct dilation|
1765580|NCT00315289|Procedure|Nasolacrimal intubation|
1765581|NCT00315289|Procedure|Simple Nasolacrimal duct probing|
1765582|NCT00315302|Drug|Atropine|Atropine 1% once each weekend day
1765583|NCT00315302|Device|Plano Lens|Plano lens for the sound eye
1765584|NCT00315315|Procedure|Nasolacrimal balloon catheter dilation|Balloon catheter nasolacrimal duct dilation consists of punctal dilation of at least one punctum and the passage into the nose of a semi-flexible wire probe with an inflatable balloon on the tip.
1765585|NCT00315315|Procedure|Nasolacrimal intubation|Nasolacrimal duct intubation consists of punctal dilation of at least one punctum with the passage of a flexible lacrimal probe into the nose and the placement of a temporary stent in the nasolacrimal duct.
1765586|NCT00315315|Procedure|Nasolacrimal duct probing|Simple nasolacrimal duct probing consists of punctal dilation of at least one punctum and the passage of a probe into the nose.
1765587|NCT00315328|Drug|Atropine|Atropine 1% each weekend day in the sound eye
1765588|NCT00315328|Device|Patching|Patching 2 hours per day
1765589|NCT00315328|Procedure|Near activities|near visual activities for at least one hour per day
1765590|NCT00315341|Drug|Buprenorphine/naloxone|Participants receive up to 16 mg BUP/4 mg NX on day 1 and up to 32 mg BUP/8 mg NX on day 2. It is recommended that dose changes be made in 2 to 8 mg increments, with the range of allowable daily doses between 2 mg and 32 mg starting on day 3 and thereafter according to clinical impression and depending upon the participant's clinical need.
1765648|NCT00315913|Drug|Propranolol|IV Propranolol 1mg/min for a total of 2 minutes. Total dose 2mg
1765649|NCT00315913|Other|IV Placebo|IV Saline Solution
1765650|NCT00315926|Drug|Melatonin|Melatonin 50 mg during surgery and 10 mg every night for 3 nights
1765651|NCT00315926|Drug|Placebo|a mixture of ethanol and physiological saline
1765591|NCT00315341|Drug|Methadone|Participants will receive a maximum of 30 mg for the first dose and a maximum of 40 mg on Day 1. It is recommended that participants receive a dose on day 2 that is 10 mg higher than their total day 1 dose, and a dose on day 3 that is 10 mg higher than their total day 2 dose, unless, in the clinical judgment of the physician, a slower induction is needed. Doses will be adjusted on Day 4 and thereafter according to clinical impression and depending upon the participant's clinical need with no specific upper limit.
1765592|NCT00315354|Other|Low glycemic index diet|Feeding protocol, all foods prepared in a metabolic kitchen
1765593|NCT00315354|Other|Low fat diet|Feeding protocol, all foods prepared in a metabolic kitchen
1765594|NCT00315354|Other|Very low carbohydrate diet|Feeding protocol, all foods prepared in a metabolic kitchen
1765595|NCT00315367|Drug|Donepezil HCI (drug)|
1765596|NCT00315432|Drug|Pegylated Interferon and Ribavirin|
1765597|NCT00315445|Drug|Buprenorphine transdermal patch|Buprenorphine 5, 10, or 20 mcg/hour patch applied transdermally for 7-day wear.
1765598|NCT00315445|Drug|Placebo oxycodone/acetaminophen tablets|Placebo oxycodone/acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
1765599|NCT00315445|Drug|OXY/APAP|5 mg oxycodone / 325 mg acetaminophen tablets; 1, 2, or 3 tablets taken four times/day.
1765600|NCT00315445|Drug|Placebo transdermal patch (TDS)|Placebo transdermal patch 5, 10, or 20 applied transdermally for 7-day wear
1765601|NCT00315458|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied for 7-day wear.
1765602|NCT00315458|Drug|Placebo transdermal patch|Placebo to match buprenorphine transdermal patch 10 or 20.
1765603|NCT00315484|Drug|Epoetin alfa and Darbepoetin alfa|
1765604|NCT00315510|Drug|Rosuvastatin|
1765605|NCT00315523|Drug|Levocetirizine|
1765606|NCT00315536|Drug|Administration of remifentanil and glycopyrrolate|2 mg, intravenius use
1765607|NCT00315549|Drug|Telithromycin|
1765608|NCT00315549|Drug|Penicillin|
1765609|NCT00315562|Procedure|carotid endarterectomy|
1765610|NCT00315575|Procedure|BOLD and Perfusion brain MRI|Blood oxygenation and perfusion functional MRI performed twice, two weeks apart; each scan lasts 1 hour
1765611|NCT00315588|Drug|Islet Transplantation|Islet Transplantation in subjects with a previous kidney transplant.
1765612|NCT00315601|Drug|Telithromycin|800 mg once a day for 5 days
1765613|NCT00315601|Drug|azithromycin|500 mg on day 1, and then 250 mg once-daily on days 2 through 5
1765614|NCT00315601|Procedure|bronchoalveolar lavage|One bronchoscopy with bronchoalveolar lavage with each drug administration
1765615|NCT00315601|Drug|Telithromycin|Telithromycin 800 mg once a day
1765616|NCT00315614|Biological|Islet Transplantation and Bone Marrow|Islet transplantation and CD34 Bone Marrow infusion in subjects with type 1 diabetes.
1765617|NCT00315627|Drug|Islet transplantation|Islet transplantation
1765618|NCT00315640|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
1765619|NCT00315640|Drug|Anecortave Acetate Suspension Depot, 30 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
1765620|NCT00315640|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
1765621|NCT00315640|Other|Anecortave Acetate Vehicle|One 0.5 mL anterior juxtascleral depot (AJD) injection in the study eye
1765622|NCT00315666|Drug|memantine|
1765623|NCT00315679|Drug|Pentoxifylline (also known as oxpentifylline)|
1765624|NCT00315692|Device|Biomarker Assay (CA125 and HE4)|
1765625|NCT00315705|Drug|clofarabine|Clofarabine 20‑40 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle as the first of the three IV interventions administered. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
1765626|NCT00315705|Drug|Etoposide|Etoposide 75-100 mg/m²/day 2 hour intravenous (IV) infusion daily for 5 days of a 28 day cycle following clofarabine therapy. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
1765627|NCT00315705|Drug|Cyclophosphamide|Cyclophosphamide 340‑440 mg/m²/day as 30-60 minute intravenous (IV) infusion daily for 5 days of a 28 day cycle following the other two interventions. Maximum of 8 cycles given in both the phase 1 and phase 2 study periods.
1765628|NCT00315718|Drug|Extract from Hintonia latiflora bark|
1765629|NCT00315731|Biological|Follicular Lymphoma|For subjects with previously untreated or relapsed follicular or transformed follicular non-Hodgkin's
1765633|NCT00315757|Biological|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
1765634|NCT00315757|Biological|Mapatumumab|20 mg/kg IV (in the vein), on day 1 of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
1765635|NCT00315757|Drug|Bortezomib|1.3 mg/m^2 IV (in the vein), twice weekly for two weeks (Days 1, 4, 8, and 11) of each 21-day cycle. Number of cycles: Treatment will continue for up to 17 cycles, or until disease progression or unacceptable toxicity.
1765636|NCT00315770|Procedure|weight loss diets for young adults|
1765637|NCT00315796|Device|Biophilic Nature Scene and Sound|
1765638|NCT00315822|Other|80% oxygen|Supplemental oxygen will be administered during surgery
1765639|NCT00315822|Other|30% oxygen|Subjects undergoing surgery will receive routine administration of oxygen
1765640|NCT00315835|Drug|Buprenorphine transdermal delivery system|
1765641|NCT00315848|Drug|Buprenorphine transdermal delivery system|
1765642|NCT00315861|Drug|pemetrexed|
1765643|NCT00315861|Drug|topotecan|
1765644|NCT00315874|Drug|Buprenorphine transdermal delivery system|
1765645|NCT00315887|Drug|Buprenorphine transdermal delivery system|
1765652|NCT00315939|Device|Integrated Biobehavioral Monitoring & Feedback - 1 (IBMF-1)|Integrated Biobehavioral Monitoring & Feedback-1 (IBMF-1): a hand-held computer (HHC) was given to the subjects, programmed to estimate HbA1c, risk for hypoglycemia (Low BG Index), and glucose variability (Average Daily Risk Range) using previously published algorithms. The subjects were asked to carry the HHC and enter all their self-monitored blood glucose (SMBG) readings. The estimates of HbA1c were updated weekly, and the estimates of risk for hypoglycemia and glucose variability were updated at each SMBG entry. Detailed instructions were provided on the meaning of these different types of glucose feedback; the study staff was available to answer any questions.
1765653|NCT00315939|Device|Integrated Biobehavioral Monitoring & Feedback - 2 (IBMF-2)|Integrated Biobehavioral Monitoring & Feedback-2 (IMBF-2) retains IMBF-1, but the HHC asked subjects to provide symptom ratings when blood glucose (BG) was low and at an equal number of matching euglycemic readings. From these data, the HHC estimated a set of potentially significant symptoms of hypoglycemia for each individual, using an iterative algorithm following a previously published symptom significance estimation procedure. The patient manual for the HHC program is provided in supplementary data of published manuscript.
1765654|NCT00315952|Drug|Exubera|
1765655|NCT00315965|Drug|Nitric oxide, Carbon monoxide, Helium|
1765656|NCT00315978|Device|Heart-to-Heart Decision Aid|
1765657|NCT00315991|Behavioral|Blood Glucose Awareness Training for Parents|
1765658|NCT00316004|Drug|7.5% Hypertonic Saline in 6% Dextran-70 (HSD)|250 ml intravenous bolus administration of 7.5% saline/6% dextran 70 administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
1765659|NCT00316004|Drug|7.5% Hypertonic Saline (HS)|250 ml intravenous bolus administration of 7.5% hypertonic saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
1765660|NCT00316004|Drug|0.9% Normal Saline (NS)|250 ml intravenous bolus administration of 0.9% saline administered as a one-time bolus fluid for initial resuscitation to injured patients with suspected severe traumatic brain injury in the out-of-hospital setting.
1765661|NCT00316017|Drug|7.5% hypertonic saline/6% Dextran-70 (HSD)|250 cc dose given as a one-time intravenous (IV) bolus in the pre-hospital setting.
1765662|NCT00316017|Drug|7.5% hypertonic saline (HS)|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
1765663|NCT00316017|Drug|0.9% normal saline|250 cc dose given as a one-time IV bolus in the pre-hospital setting.
1765664|NCT00316030|Drug|Bexarotene|
1765665|NCT00316043|Behavioral|Written information for parents|
1765666|NCT00316043|Behavioral|Distance learning package for General Practitioners|
1765667|NCT00316043|Behavioral|Distance learning package for practice assistants|
1765668|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 2.5 mg, QAM, Daily (6 months ST, 12 months LT)
1765669|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 2.5 mg titrated to 5mg, QAM, Daily (6 months ST, 12 months LT)
1765670|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 5mg, QAM, Daily, (6 months ST, 12 months LT)
1765671|NCT00316082|Drug|Saxagliptin|Coated tablets, Oral, 5mg QPM, Daily (6 months ST, 12 months LT)
1765672|NCT00316082|Drug|Placebo|Coated tablets, Oral, 0mg, Daily (6 months ST, 12 months LT)
1765673|NCT00316082|Drug|metformin|Tablets, Oral, 500-2000 mg, as needed (12 months LT)
1765674|NCT00316095|Drug|telmisartan|
1765675|NCT00316095|Drug|simvastatin|
1765676|NCT00316108|Device|WALLSTENT® Endoprosthesis™|Carotid Artery Stent
1765677|NCT00316121|Device|HEALOS and Leopard Cage|Placement in interbody space
1765678|NCT00316121|Device|Leopard Cage and Autograft|Placement in the interbody space
1765679|NCT00316134|Procedure|Procedure/Surgery|Diagnostic and/or therapeutic procedure to remove pleural fluid.
1765680|NCT00316147|Biological|DTPa-HBV-IPV/Hib vaccine|
1765681|NCT00316160|Drug|Bupropion Hydrochloride Extended-release|
1765682|NCT00316160|Drug|Extended-release Venlafaxine|
1765683|NCT00316173|Drug|topotecan|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
1765684|NCT00316173|Drug|CARBOPLATIN|HYCAMTIN at a dose of 2.0 mg/m2 on Days 1 and 8 every 21 days followed by carboplatin at AUC 5 on Day 1
1765685|NCT00316186|Drug|topotecan|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
1765686|NCT00316186|Drug|carboplatin|Hycamtin and Carboplatin as first-line treatment of chemonaive subjects with EX-SCLC.
1765687|NCT00316199|Drug|gemcitabine|1250 mg/m2, intravenous (IV), day 1 and day 8 every 21 days until disease progression
1765688|NCT00316199|Drug|paclitaxel|175 mg/m2, intravenous (IV), every 21 days until disease progression
1765689|NCT00316212|Drug|INS50589 Intravenous Infusion|
1765690|NCT00316225|Drug|pemetrexed|500 milligrams per meter squared (mg/m^2) IV every 21 days for 6 cycles
1765691|NCT00316238|Drug|olanzapine-RAIM|
1765692|NCT00316238|Drug|placebo|
1765693|NCT00316251|Device|Vibration Plate Therapy|
1765694|NCT00316264|Biological|Motavizumab, palivizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
1765695|NCT00316264|Biological|Palivizumab, motavizumab|Palivizumab was provided in sterile vials containing 100 mg of palivizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine, and 1.6 mM glycine.
1765696|NCT00316264|Biological|Motavizumab|Motavizumab was provided in sterile vials containing 100 mg of motavizumab in 1 mL of a sterile preservative-free liquid product at pH 6.0, formulated with 25 mM histidine-HCl.
1765697|NCT00316277|Behavioral|Standard Medical Management (SMM) of Prescription Opiate Abuse|Standard Medical Management in Phase 1 will consist of one hour-long initial visit; one individual 15-20 minute visit later in Week 1; one individual 15-20 minute visit per week through the end of Week 4; one 15-20 minute SMM visit at Week 6 and at Week 8. And in Phase 2, one 30-60 minute initial visit; one 15-20 minute follow-up visit later in Week 1; one individual session (15-20 minutes) per week through Week 12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
1765698|NCT00316277|Behavioral|Enhanced Medical Management (EMM) of Prescription Opiate Abuse|Enhanced Medical Management in Phase 1 will consist of SMM plus two individual sessions with a counselor per week (45 minutes each) through Weeks 1-4, and one 45-minute counseling visit at Week 6 and at Week 8. And in Phase 2, EMM will consist of the SMM plus two individual sessions with a counselor per week (45 minutes each) during Weeks 1-6 and one individual session with a counselor per week (45 minutes each) during Weeks 7-12. In addition, participants in Phase 1 will receive BUP/NX at between 8 to 32mg/day; tapering to zero between weeks three and four. Those referred to Phase 2 will receive up to 32 mg/day for three months tapering to zero during month four.
1765699|NCT00316290|Behavioral|Integrated Parent Training|Treatment will include behavioral parent training, a course on coping with depression, and cognitive-behavioral therapy targeted at coping with stressful parenting situations. Treatment will include weekly 2-hour sessions for 14 weeks.
1765700|NCT00316290|Behavioral|Behavioral Parent Training|Parents will receive behavioral training. Treatment will include weekly 2-hour sessions for 14 weeks.
1765701|NCT00316303|Drug|Twinrix|This vaccine will be given in three parts: at entry and after 3 and 6 months.
1765702|NCT00316303|Behavioral|Enhanced treatment as usual|Participants will receive comprehensive mental health services provided at each study site, education about blood-borne diseases, and referral to a local community health provider for blood testing, HAV and HBV immunizations, and any necessary treatments.
1765703|NCT00316316|Behavioral|Motivational interviewing plus exposure and response prevention (MI plus EX/RP)|Participants will receive 18 sessions of MI plus EX/RP.
1765704|NCT00316316|Behavioral|Exposure and response prevention (EX/RP)|Participants will receive 18 sessions of EX/RP.
1765705|NCT00316329|Drug|Artesunate + Amodiaquine|
1765706|NCT00316342|Device|Back supports|
1765707|NCT00316355|Behavioral|Traditional CBT|CBT with EX/RP is a psychosocial treatment that incorporates exposure with ritual prevention.
1765708|NCT00316355|Behavioral|Stepped-Care CBT|In the CBT stepped-care program, patients are first provided with a less expensive, less intrusive, and more accessible option that resembles quality community care (e.g., self-administered EX/RP combined with counseling to address medication issues, life stress, and motivational enhancement). Patients who fail to respond to this initial treatment progress to a more intensive treatment (e.g., therapist-administered EX/RP).
1765709|NCT00316368|Device|Ethicon TPW32 60 cm (pacing wires x 2)|
1765710|NCT00316381|Procedure|Autologous bone marrow-derived stem cells|
1765711|NCT00316394|Device|Preventive Care Checklist Form|
1765712|NCT00316407|Drug|lapatinib (GW572016)|1000 mg po qd
1765713|NCT00316407|Drug|Carboplatin|AUC 2 weekly x 3 of 4 week cycle
1765714|NCT00316407|Drug|Paclitaxel|60 mg/m2 weekly x 3 of 4 week cycle
1765715|NCT00316420|Drug|Capecitabine (Xeloda)|650 mg/m2 po bid Days 1-14 750 mg/m2 po bid Days 1-14 850 mg/m2 po bid Days 1-14 950 mg/m2 po bid Days 1-14
1765716|NCT00316420|Drug|Gemcitabine|750 mg/m2 IV Days 1 & 8 q 21 days
1765717|NCT00316433|Drug|Irinotecan (CPT-11)|
1765718|NCT00316433|Drug|Oxaliplatin (Eloxatin)|
1765719|NCT00316459|Drug|ERB-041|
1765720|NCT00316472|Drug|Niacinamide|
1765721|NCT00316498|Drug|OGT918|
1765722|NCT00316511|Drug|Aroplatin|
1765723|NCT00316524|Biological|MVA-BN® (IMVAMUNE)|2 immunizations: 1 x 10E8_TCID
1765724|NCT00316524|Biological|IMVAMUNE|1x 10E8_TCID50, 1x Placebo
1765725|NCT00316524|Biological|IMVAMUNE|2 x Placebo
1765726|NCT00316524|Biological|IMVAMUNE|1x 10E8_TCID50
1765727|NCT00316537|Drug|ATG002 (study drug)|
1765728|NCT00316550|Drug|AV608|
1765729|NCT00316563|Drug|Marinol (Dronabinol)|Intervention description: Marinol (drug) is being used as an appetite stimulant for treatment of cancer-induced anorexia.
1765730|NCT00316563|Other|Placebo|
1765731|NCT00316576|Procedure|Blood sampling for PCR|
1765732|NCT00316589|Biological|IMVAMUNE (MVA-BN)|2 immunizations, four weeks apart: 1 x 10E8 TCID50, subcutaneous
1765733|NCT00316602|Biological|MVA-BN® (IMVAMUNE)|x
1765734|NCT00316602|Biological|IMVAMUNE|x
1765735|NCT00316615|Biological|influenza vaccine|
1765736|NCT00316628|Biological|influenza vaccine|
1765737|NCT00316641|Drug|Lipid-lowing Tea|
1765738|NCT00316654|Biological|Meningococcal C conjugate vaccine|
1765739|NCT00316680|Biological|Diphtheria, tetanus, pertussis, hepatitis B, Hib vaccine|
1765740|NCT00316693|Biological|HPV-16/18 vaccine (Cervarix™)|Intramuscular injection, 3 doses
1765741|NCT00316693|Biological|Aimmugen™|Intramuscular injection, 3 doses
1765742|NCT00316706|Biological|GSK Biologicals' HPV-16/18 Vaccine (Cervarix™)|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule
1765743|NCT00316706|Biological|Havrix™|Three doses of vaccine administrerd intramuscularly according to 0, 1, 6 month schedule.
1765744|NCT00316719|Drug|LAM group|Subjects took one LAM 100mg tablet orally once daily and one ADV placebo tablet orally once daily.
1765745|NCT00316719|Drug|ADV group|Subjects took one ADV 10mg tablet orally once daily and one LAM placebo tablet orally once daily.
1765748|NCT00316745|Drug|Campto, Topotesin|100 mg/m2, IV (in the vein) on day 1,15 of each cycle.
1765749|NCT00316745|Drug|TS-1|S-1 Day1~14, everyday P.O.(Day 15~28 rest)
1765750|NCT00316745|Drug|L-Plat|Oxaliplatin (85mg/m2) Day 1, 15
1765751|NCT00316745|Drug|Isovorin|l-leucovorin (200mg/m2) Day 1, 15
1765752|NCT00316745|Drug|5-FU|400 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle. 2400 mg/m2, CIV (in the vein) on day 1~3 (48 hours) of each 28 day cycle.
1765753|NCT00316758|Drug|GK Activator (2)|Escalating doses bid
1765754|NCT00316758|Drug|Metformin|As prescribed, in patients who were in study BM18249
1765755|NCT00316771|Drug|P38 Inhibitor (4) 150mg|150mg po qd
1765756|NCT00316771|Drug|P38 Inhibitor (4) 25mg|25mg po bid
1765757|NCT00316771|Drug|P38 Inhibitor (4) 300mg|300mg po qd
1765758|NCT00316771|Drug|P38 Inhibitor (4) 50mg|50mg po qd
1765759|NCT00316771|Drug|P38 Inhibitor (4) 75mg|75mg po bid
1765760|NCT00316771|Drug|Placebo|po bid
1765762|NCT00316797|Drug|123-I INER|Serial whole body planar imaging in the anterior and posterior projection will be performed at 1 min, 30 min, 1 h, 2h, 3h, 4h, 5h, 6h, 7h, 8h, and 18-24h following injection of 5 mCi of 123-I INER. Venous blood data will be acquired at each imaging time point. In addition a 24 hour urine collection will commence following radiotracer injection and urine sampled in five collections every 4 hours collection for first sixteen hours (4 collections), then one collection from 16 to 24 h. Whole body and source organs uptake will be analyzed on anterior and posterior images for calculating the radiation absorbed doses to organs using the MIRD method as described previously (Seibyl, et al, 1993). Plasma and urine metabolites will be characterized and safety assessments obtained.
1765763|NCT00316810|Drug|Alemtuzumab|Day 0: Campath 30 mg i.v. infusion over 3-6 hours
1765764|NCT00316810|Drug|Rabbit Anti-Human Thymocyte Globulin|Day O: Single shot of a polyclonal antilymphocyte preparation (ATG-Fresenius - 8 mg/kg, or IMTIX-Sangstat ATG 4 mg/kg/day).
1765765|NCT00316823|Genetic|gene expression analysis|
1765766|NCT00316823|Genetic|polymerase chain reaction|
1765767|NCT00316823|Genetic|reverse transcriptase-polymerase chain reaction|
1765768|NCT00316823|Other|diagnostic laboratory biomarker analysis|
1765769|NCT00316823|Other|immunohistochemistry staining method|
1765770|NCT00316823|Procedure|needle biopsy|
1765771|NCT00316836|Procedure|mammography|
1765772|NCT00324194|Drug|MGCD0103|MGCD0103 oral dose given 2 times per week.
1765773|NCT00324220|Drug|MGCD0103|MGCD0103 Oral administration 3 times per week.
1765774|NCT00324233|Device|Intermittent catheter|SpeediCath catherter (SC) for intermittent catherisation
1765775|NCT00324233|Device|Compact intermittent catheter|SpeediCath Compact Male catheter (SCCM) is a compact intermittent catheter for males
1765776|NCT00324259|Drug|Estradiol|
1765777|NCT00324272|Drug|Fibrin Sealant (Tisseel) used in the Experimental Arm.|"For patients in the Experimental (Treatment) Arm, 4 ml of Tisseel fibrin sealant were instilled into the wound using the Duploject™ spray delivery system prior to wound closure. Tisseel™ fibrin sealant was provided by Baxter Healthcare Ltd., Newbury, Berkshire, UK.
For patients in the Active Comparator (Control) Arm, no fibrin sealant was used during wound closure (with the surgical procedure being identical in all other respects)."
1765778|NCT00324285|Drug|Amylase resistant starch added ORS|
1765779|NCT00324298|Biological|bleomycin sulfate|
1765780|NCT00324298|Drug|cisplatin|
1765781|NCT00324298|Drug|etoposide|
1765782|NCT00324298|Procedure|management of therapy complications|
1765783|NCT00324311|Drug|DGD|Lyophilized, sterile mixture of proteolyzed enzymes; mixed with gel,for topical application.
1765784|NCT00324324|Drug|moxifloxacin hydrochloride|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
1765785|NCT00324324|Drug|Placebo|Moxifloxacin/Placebo 400 mg capsule orally once a day through D+100 after bone marrow transplant, then discontinue
1765786|NCT00324350|Drug|hypoglycemic agents, hydroxymethylglutaryl-CoA Reductase inhibitors, hypertensive agents|type 2 diabetes treatments, per standard of care
1765787|NCT00324363|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day for 16 weeks
1765788|NCT00324363|Drug|Placebo|subcutaneous injection twice daily in volumes equal to exenatide
1765789|NCT00324376|Drug|Sevelamer hydrochloride|
1765790|NCT00324389|Drug|Interferon alpha|
1765791|NCT00324415|Biological|cetuximab|400 mg/m2 IV Day -7 (1 week before the cycle 1, Day 1 cisplatin/5-FU and RT), then 250 mg/m2 IV Days 1, 8, 15, 22, 29, 36 and 43 (a minimum of 6 and a maximum of 8 doses of cetuximab will be administered, including the loading dose)
1765792|NCT00324415|Drug|cisplatin|75 mg/m2 IV on Day 1 (cycle 1) and Day 29 (cycle 2)
1765793|NCT00324415|Drug|fluorouracil|1000 mg/m2/day by continuous intravenous infusion on Days 1-4 (cycle 1) and Days 29-32 (cycle 2)
1765794|NCT00324415|Radiation|radiation therapy|Irradiation to tumor site and inguinal nodes beginning on cycle 1, Day 1 cisplatin/5-FU (minimum 45.0 Gy [5 weeks if given on schedule and without interruption], maximum 54.0 Gy [6 weeks if given on schedule and without interruption). IMRT may be used at the discretion of the treating physician.
1765795|NCT00324428|Procedure|Transcranial Magnetic Stimulation|1Hz repetitive transcranial magnetic stimulation for 10 days 26 minutes each day
1765796|NCT00324441|Device|Iratherm® 1000|
1765797|NCT00324454|Biological|Levetiracetam|Levetiracetam 1500 mg BID
1765798|NCT00324467|Drug|Cyclophosphamide|"Dose: 750 mg/m^2 Administration: IV infusion day 1 over 20-60 minutes Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)
* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
1765799|NCT00324467|Drug|Doxorubicin|"Dose: 50 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)
* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
1765800|NCT00324467|Drug|Vincristine|"Dose: 1.4 mg/m^2 Administration: IV Push day 1 Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)
* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
1765801|NCT00324467|Drug|Prednisone|"Dose: 45 mg/m^2 Administration: IV infusion day 1 (or day 2) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4, 5*, 6* (Week 1, 4, 7, 10, 14, 17)
* Cycles 5 and 6 of R-CHOP will be administered only to patients with a negative mid-treatment PET scan"
1765802|NCT00324467|Drug|Ondansetron|Premedication for R-CHOP Dose: 8 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
1765803|NCT00324467|Drug|Dexamethasone|Premedication for R-CHOP Dose: 12 mg Route: PO Schedule: 15 min pre-CHOP chemotherapy
1765804|NCT00324467|Drug|Diphenhydramine|Premedication for R-CHOP Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
1765805|NCT00324467|Drug|Acetaminophen|Premedication for R-CHOP Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
1765806|NCT00324467|Drug|Ifosfamide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3, over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
1765807|NCT00324467|Drug|Mesna (IV)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5000 mg/m^2 (total dose per cycle) Administration: In 3 equally divided doses IV infusion days 1,2,3 (with ifosfamide) over 2 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
1765808|NCT00324467|Drug|Mesna (oral)|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 2 g Administration: PO 2h and 4h after ifosfamide infusion on days 1,2,3 Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
1765809|NCT00324467|Drug|Carboplatin|"R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 5 x (25+CrCl*) (maximum dose 800 mg) Administration: IV infusion day 1 over 1 hour Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
*Carboplatin is dose via the Calvert formula with an AUC of 5, maximum dose 800 mg per cycle.
Estimate Creatinine Clearance (CrCl)"
1765810|NCT00324467|Drug|Etoposide|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 100 mg/m^2 Administration: IV infusion day 1,2,3 over 30 minutes Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
1765811|NCT00324467|Drug|Rituximab|R-ICE Chemotherapy Schedule (cycles repeated every 3 weeks) Dose: 375 mg/m^2 Administration: IV infusion day 1 (or day 2 or day 3) over 90 minutes-8 hours Schedule: Cycle 1, 2, 3, 4 (Week 14, 16, 20, 23)
1765812|NCT00324467|Drug|Ondansetron|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
1765813|NCT00324467|Drug|Dexamethasone|Premedication for R-ICE Dose: 8 mg Route: PO Schedule: 15 min pre-chemotherapy daily
1765814|NCT00324467|Drug|Diphenhydramine|Premedication for R-ICE Dose: 50 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
1765815|NCT00324467|Drug|Acetaminophen|Premedication for R-ICE Dose: 650 mg Route: PO Schedule: Prior to rituximab and then q 4h during rituximab infusion
1765816|NCT00324467|Other|PET Scan|Investigations: 18F-FDG-PET scan Timing: After 4 cycles of R-CHOP (days 21-28) and after 4 cycles of R-ICE (days 28-35)
1765817|NCT00324480|Drug|alvocidib|Given IV
1765818|NCT00324480|Drug|vorinostat|Given orally
1765819|NCT00324480|Other|pharmacological study|Correlative studies
1765821|NCT00324519|Device|Foley bulb|
1765822|NCT00324519|Drug|misoprostol|
1765823|NCT00325468|Drug|AMG 162|AMG 162; 60 mg/mL of Denosumab given to all subjects at Screening/Day 1, Month 6, Month 12, Month 18, Month 24, Month 30, Month 36 and Month 42
1765824|NCT00325481|Drug|FluMist|
1765825|NCT00325494|Drug|MORAb-009|Each dose of investigational product will be given as a continuous infusion ranging from 12.5 mg/m^2 up to 400 mg/m^2.
1765827|NCT00325533|Behavioral|Baseline BP Screening|Barbers in the barbershops in the experimental arm will be trained to accurately measure and interpret blood pressure (BP). Each barber will offer a BP check to customers with each haircut, complete an encounter form after each haircut, discuss the BP reading with the customer, identify customers with elevated BP, and refer customers with elevated BP to a regular physician or other primary provider for long-term BP management. Each time a customer with elevated BP goes to a regular medical provider, he receives a free haircut, and the referring barber receives a monetary bonus.
1765828|NCT00325533|Other|Intensive 10-week Blood Pressure Screening|Intensive 10-week Blood Pressure Screening
1765829|NCT00325546|Drug|Rimonabant (SR141716)|
1765830|NCT00325546|Drug|Placebo|
1765831|NCT00325559|Procedure|Normoinsulinemic eu- or hyperglycemic clamp|
1765832|NCT00325572|Biological|oral zinc and vitamin C supplements|Each child will be provided separate suspensions containing zinc and vitamin C to be taken twice per day. The dose will be based on the child's weight and be titrated by checking copper/zinc ratio at 6 weeks of treatment. Monitoring of liver, renal functions and CBC will occur at the end of supplementation
1765833|NCT00325585|Behavioral|Couples HIV counseling and testing|
1765834|NCT00325585|Behavioral|Women's relationship-focused HIV counseling and testing|
1765835|NCT00325598|Radiation|Partial Breast Irradiation (PBI)|
1765836|NCT00325611|Behavioral|Multidisciplinary palliative care team met with patient|
1765837|NCT00325624|Device|Bluetooth-enabled Glucometer|blood glucose information provided to health care providers
1765838|NCT00325637|Drug|cilnidipine|Cilnidipine 10~20mg, qd, po for 4 weeks.
1765839|NCT00325650|Drug|Rimonabant|Tablet, oral administration
1765840|NCT00325650|Drug|Placebo (for Rimonabant)|Tablet, oral administration
1765841|NCT00325663|Procedure|Acupuncture|
1765842|NCT00325676|Drug|Pantoprazole|
1765843|NCT00325689|Drug|Quetiapine or Risperidone + Aripiprazole|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Aripiprazole 2-15 mg/day, Flexible, 16 weeks.
1765844|NCT00325689|Drug|Quetiapine or Risperidone + placebo|Tablets, Oral, Quetiapine 400-800 mg/day or Risperidone (4-8 mg/day) + Placebo, Flexible, 16 weeks.
1765845|NCT00325702|Behavioral|community-level intervention for young MSM|The community-level intervention includes small media in the form of role model stories, peer outreach and web-based intervention
1765846|NCT00325715|Drug|AGN 201904|
1765847|NCT00325715|Drug|esomeprazole|
1765848|NCT00325728|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 8 weeks.
1765849|NCT00325728|Drug|Placebo|Ramelteon placebo matching tablets, orally, once nightly for up to 8 weeks.
1765850|NCT00325741|Procedure|Hematopoietic Cell Transplantation|1200 cGy total lymphoid irradiation (TLI) are administered on day -11 through -7 and days -4 through -1 pretransplantation; rabbit ATG at 1.5 mg/kg i.v. on days -11 through -7 pretransplantation; one single infusion of donor CD34+ cells plus selected T cell add back on completion of TLI (day 0); mycophenolate mofetil (MMF) is begun on day 0 at a dose of 15 mg/kg bid and stopped on day +28; cyclosporine (CSP) at initial dose of 6.25 mg/kg and adjusted to maintain trough blood levels of 350-500 ng/ml is begun on day -3 to complete withdrawal by 6 months post-transplantation.
1765851|NCT00325754|Device|E-Cylinder|Portable Oxygen Therapy Delivered Via An E-Cylinder Mounted On A Wheeled Cart
1765852|NCT00325754|Device|Lightweight Cylinder|Ambulatory Oxygen Therapy Delivered Via A Carbon-Wrapped Aluminum Cylinder
1765853|NCT00325767|Drug|nebulized albuterol (2.5 mg/3ml/dose)|
1765854|NCT00325767|Drug|nebulized levalbuterol (1.25 mg/3ml/dose)|
1765855|NCT00325767|Drug|nebulized placebo (3ml/dose)|
1765856|NCT00325780|Drug|Pitavastatin|Pitavastatin 4 mg once daily
1765858|NCT00325806|Drug|Ramipril|
1765861|NCT00325832|Device|BpTRU|
1765862|NCT00325832|Device|Conventional mercury sphygmomanometry|
1765863|NCT00325845|Procedure|Synvisc viscosupplementation|
1765864|NCT00325858|Drug|Tramadol HCl ER|
1765865|NCT00325871|Procedure|concurrent chemoradiation|
1765866|NCT00325897|Drug|Macrolide Antibiotic (Azithromycin)|Azithromycin (daily capsule, 250 mg for 12 months)
1765867|NCT00325897|Drug|Placebo|Placebo taken on a daily basis
1765868|NCT00325910|Drug|Metformin|
1765869|NCT00325923|Behavioral|Decision aid|
1765870|NCT00325936|Drug|Cilnidipine|10~20mg, qd, po for 3 months or 12 months.
1765871|NCT00325949|Drug|Extended release hydrocodone and acetaminophen (Vicodin CR)|2 tablets BID
1765872|NCT00325949|Drug|hydrocodone/acetaminophen extended release (Vicodin CR)|1 tablet BID
1765873|NCT00325949|Drug|placebo|2 tablets BID
1765874|NCT00325962|Drug|6R-BH4 (sapropterin dihydrochloride)|
1765875|NCT00326001|Device|Gold tip catheter|Radiofrquency ablation using gold tip catheter
1765876|NCT00326001|Device|Platinum-iridium tip catheter|Radiofrequency ablation using platinum-iridium tip catheter
1765877|NCT00326014|Device|iStent|Glaucoma Surgery
1765878|NCT00326027|Drug|Pantoprazole|Efficacy of Pantoprazole
1765879|NCT00326040|Device|Glaucoma Surgery|
1765880|NCT00326053|Drug|Budesonide/formoterol|
1765881|NCT00326066|Device|Glaucoma Surgery|Comparing the effect in reducing IOP with two Trabecular Bypass Microstents Versus none in patients undergoing cataract surgery, with early open angle glaucoma or ocular hypertension.
1765882|NCT00326066|Procedure|cataract surgery only|Subjects will undergo routine cataract surgery only (no stent implant).
1765883|NCT00326079|Device|Stent|implantation of 1 Glaukos iStent versus 2 Glaukos iStents
1765884|NCT00326092|Drug|Brinzolamide/Timolol|
1765885|NCT00326105|Drug|Quetiapine fumarate|
1765886|NCT00326118|Biological|Haemophilus influenzae type b and meningococcal serogroup C (vaccine)|One intramuscular dose at 12-18 months of age
1765887|NCT00326118|Biological|Priorix™|One subcutaneous dose at 12-18 months of age
1765888|NCT00326118|Biological|Hiberix™|One intramuscular dose at 12-18 months of age.
1765889|NCT00326118|Biological|Meningitec™|One intramuscular dose at 12-18 months of age
1765890|NCT00326131|Drug|Oral Taxane|
1765891|NCT00326144|Drug|Quetiapine fumarate|
1765892|NCT00326157|Drug|AmBisome|3mg/kg/day three times a week until day 22 (21 days after transplantation day) and 7 mg/kg weekly from day 29 to the end of treatment (day 50-8th Week) of AmBisome®, IV administration
1765893|NCT00326170|Drug|5-Azacytidine (5-aza)|Start at 75 mg/m^2 subcutaneously daily for 7 days.
1765894|NCT00326170|Drug|Valproic Acid|50 mg/kg daily by mouth for 7 days, same days as 5-aza.
1765895|NCT00326170|Drug|All-Trans Retinoic Acid (ATRA)|45 mg/m^2 orally daily (in two divided doses) for 5 days starting on day 3 of the administration of 5-aza and VPA.
1765896|NCT00326183|Biological|VAQTA®|0.5 ml injection VAQTA®; 2nd 0.5 ml injection VAQTA® 24 week period of treatment.
1765897|NCT00326183|Biological|ProQuad|0.5 ml injection ProQuad; 2nd 0.5 ml injection ProQuad®. 24 week period of treatment.
1765898|NCT00326196|Device|Percutaneous coronary intervention (PCI)|percutaneous coronary stenting with drug eluding stents
1765899|NCT00326196|Procedure|Coronary artery bypass graft (CABG)|coronary bypass
1765900|NCT00326209|Drug|Mesalamine pellets|subjects receive 4 capsules each morning of 375mg MG each (total of 1.5g QD)
1765901|NCT00326222|Behavioral|Lifestyle counseling|Self-management group education
1765902|NCT00326235|Drug|Buspirone|
1765903|NCT00326248|Drug|GW679769 (casopitant)|
1765904|NCT00326261|Procedure|Ultrasound compared to dual-endpoint nerve stimulator guided approach.|
1765905|NCT00326261|Procedure|Ultrasound|
1765906|NCT00326274|Drug|Helioblock® SX Cream|
1765907|NCT00326287|Drug|Ceftobiprole medocaril|
1765908|NCT00326287|Drug|Ceftriaxone with or without Linezolid|
1765909|NCT00326300|Drug|methylphenidate hydrochloride extended-release tablets|
1765910|NCT00326326|Drug|CP-778,875|
1765911|NCT00326339|Drug|R788|R788 50 mg, 100 mg, or 150 mg PO bid
1765912|NCT00326339|Drug|Placebo|Placebo PO bid
1765913|NCT00326352|Drug|Sedation with propofol and remifentanil|
1765914|NCT00326365|Drug|Kali bichromicum 10-60 (C30)|
1765915|NCT00326378|Drug|consolidation chemotherapy with Docetaxel plus cisplatin|definitive CCRT, and followed by consolidation chemotherapy with three cycles of docetaxel plus cisplatin
1765916|NCT00326378|Drug|CCRT arm without consolidation chemotherapy|definitive CCRT with weekly Docetaxel/CDDP #6 without consolidation chemotherapy
1765917|NCT00326391|Drug|methylphenidate hydrochloride extended-release tablets|
1765918|NCT00326404|Drug|Desogestrel-Ethinyl Estradiol 21 tablets|The participants in the continuous study arm will be given 4 packs of Marvelon-21, so that they can take the pills continuously for 84 days followed by no medication for 7 days. During these 7 days, the participant will have a withdrawal bleed. This sequence is repeated by the participant for a total of 12 months. Each patient in the continuous arm will have 4 withdrawal bleeds per year.
1765919|NCT00326404|Drug|Desogestrel-Ethinyl Estradiol 28 tablets|The participants in the cyclical arm of the study will be given 3 packs of Marvelon-28 and asked to take all the pills in the packet, including the placebo pills. During the week of placebo pills, these participants will have a withdrawal bleed. Each patient in the cyclical arm will have 12 withdrawal bleeds per year. The duration of study drug treatment for both arms is 12 months.
1765924|NCT00326430|Behavioral|Cognitive Therapy, Interpersonal Therapy|
1765925|NCT00326443|Biological|CVD 909|5 X 10^9 CFU of oral S. Typhi vaccine strain CVD 909 with buffer administered on Day 0.
1765926|NCT00326443|Drug|Placebo|Buffer placebo administered on Day 0.
1765927|NCT00326443|Biological|Vi Polysaccharide|25 micrograms (0.5 ml) of licensed purified Vi polysaccharide vaccine on Day 21.
1765928|NCT00326456|Drug|liposomal doxorubicin|30 mg/m2 gieven intravenously on day 1 every 3 weeks
1765929|NCT00326456|Drug|carboplatin|AUC 5 intravenously on day 1 every 3 weeks
1765930|NCT00326456|Drug|paclitaxel|175 mg/m2 intravenously on day 1 every 3 weeks
1765931|NCT00326469|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for up to 24 months or until disease progression.
1765932|NCT00326495|Drug|Cetuximab|Cetuximab is a recombinant human/mouse chimeric monoclonal antibody which binds specifically to the extracellular domain of the epidermal growth factor receptor (epidermal growth factor receptor (EGFR), human epidermal growth factor receptor 1 (HER1), c-ErbB) in normal and tumor cells, and competitively inhibits the binding of epidermal growth factor (EGF) and other ligands, such as transforming growth factor-alpha.
1765933|NCT00326495|Drug|BAY 43-9006|Is a potent inhibitor of proto-oncogene c-Raf (c-raf), and wild-type and mutant proto-oncogene b-Raf (b-raf) in vitro
1765934|NCT00326508|Drug|Daclizumab|
1765935|NCT00326560|Procedure|Pterygium excision and conjunctival autograft|
1765936|NCT00326573|Behavioral|Motivational Interviewing|
1765937|NCT00326586|Drug|AR Antagonist (BMS-641988)|Tablets, Oral, 6 Patients will be randomized in a 1:1 ratio and in a double-blinded fashion to achieve a single dose of the study drug or Placebo on C1D1. Once daily, at least 3 cycles until the disease progresses
1765938|NCT00326599|Drug|carboplatin|Given IV
1765939|NCT00326599|Drug|cediranib maleate|Given orally
1765940|NCT00326599|Drug|gemcitabine hydrochloride|Given IV
1765941|NCT00326612|Drug|Midazolam|Intranasal Midazolam 0.2 mg/kg given once for seizures longer than 5 minutes.
1765942|NCT00326612|Drug|Diazepam|Rectal Diazepam (Diastat) given once for seizure greater than 5 minutes.
1765943|NCT00326625|Drug|40 mg glatiramer acetate|parenteral drug
1765944|NCT00326625|Drug|Placebo|
1765945|NCT00326638|Radiation|Arm B: Helical Tomotherapy Intensity Modulated Radiotherapy|"IMRT using Helical Tomotherapy* 7800 cGY/39 Fractions once daily Monday to Friday for 8 weeks
Initial IMRT to Nodes/Prostate + Seminal Vesicles 4,600 cGy/23
Boost IMRT to Prostate 3,200 cGy/16"
1765946|NCT00326638|Other|Arm A: 3D-Conformal Radiation|"3DCRT 7800 cGY/39 Fractions/ STD Technique* once daily Monday to Friday for 8 weeks
Initial 4F 3DCRT to Nodes/ Prostate + Seminal Vesicles 4,600 cGy/23
Boost 6 F 3DCRT to Prostate 3,200 cGy/16"
1765947|NCT00326664|Drug|Cediranib Maleate|Given orally
1765948|NCT00326677|Behavioral|Problem Solving Therapy|6 to 8 Problem Solving Therapy sessions over the course of 6 to 16 weeks followed by 3 booster PST sessions over the course of 2 years
1765949|NCT00326677|Behavioral|Dietary Education|6 to 8 Diet Education sessions over the course of 6 to 16 weeks followed by 3 booster Diet Education sessions over the course of 2 years
1765950|NCT00326690|Device|Blue Egg Device|
1765951|NCT00326703|Procedure|Hypobaric hypoxia|
1765952|NCT00326716|Drug|Atazanavir + Ritonavir + Combivir|Capsules, tablets, Oral, initially ATV 300 mg + RTV 100 mg + ZDV/3TC 300/150 mg, dose escalated to ATV 400 mg + RTV 100 mg + ZDV/3TC 300/150 mg, ATV and RTV once daily, lamivudine (ZDV) / zidovudine (3TC) twice daily (BID), up to 36 weeks
1765953|NCT00326742|Behavioral|Trier Social Stress Test|
1765954|NCT00326768|Drug|Telmisartan 40 mg/HCTZ 12.5 mg|
1765955|NCT00326768|Drug|Telmisartan 40 mg|
1765956|NCT00326768|Drug|Telmisartan 80 mg/HCTZ 12.5 mg|
1765957|NCT00326781|Drug|Nicoderm Transdermal Patch|The dosing schedule is as follows: 4 weeks of 21mg per 24 hours, 2 weeks of 14mg per 24 hours, and 2 weeks of 7mg per 24 hours. Treatment lasted 8 weeks.
1765958|NCT00326781|Drug|Nicotine Nasal Spray|8 weeks of self-administered nicotine nasal spray at 40 recommended doses per day, tapering by 1/3 for the last 4 weeks. Nasal spray dosing was 0.5 mg spray per nostril (1 mg) for a maximum of 5 doses per hour and 40 doses per day. This dosing schedule is based on the average nicotine intake per cigarette of 1 mg per cigarette. Treatment lasted 8 weeks.
1765959|NCT00326794|Procedure|mobilisation (rehabilitation)|
1765960|NCT00326807|Drug|Naltrexone|
1765961|NCT00326820|Drug|ibandronate sodium|
1765962|NCT00326820|Drug|zoledronic acid|
1765963|NCT00326820|Drug|Zolendronic Acid|Zoledronic acid 4 mg by intravenous infusion every 4 weeks.
1765964|NCT00326833|Drug|vitamin B12|9 µg vitamin B12 three times daily for two days (CobaSorb)
1765965|NCT00326859|Drug|remifentanil|
1765966|NCT00326872|Drug|Cediranib Maleate|
1765967|NCT00326885|Drug|catumaxomab|Catumaxomab is administered intraperitoneally via an indwelling catheter (or port) as a 3-hour infusion 4 times (Days 0, 3, 7, and 10) in ascending doses (10 mcg, 20 mcg, 50 mcg, and 150 mcg, respectively).
1765968|NCT00326898|Other|Placebo|Given PO
1765969|NCT00326898|Drug|Sorafenib|Given PO
1765970|NCT00326898|Drug|Sunitinib|Given PO
1765971|NCT00326911|Biological|cetuximab|I.V. infusion of 400 mg/m2 (over 120 minutes) on day 1 of cycle 1
1765972|NCT00326911|Biological|bevacizumab|10 mg/kg (over 60 minutes) on day 1 and repeated every 2 weeks.
1765973|NCT00326911|Drug|gemcitabine|1000 mg/m2 administered intravenously at 10 mg/m2/minute over 100 minutes weekly x 3 of 4 weeks.
1765974|NCT00326911|Biological|cetuximab|I.V.infusions of 250 mg/m2 (over 60 minutes) weekly
1765976|NCT00326950|Drug|E7389|E7389 will be administered intravenously on Days 1 and 8 of a 21 day cycle. The initial dose level will be 0.7 mg/m2, with planned dose levels of 1.0, 1.4, 2.0 mg/m2.
1765977|NCT00326963|Drug|Background ARVs|As prescribed
1765978|NCT00326963|Drug|PI|As prescribed
1765979|NCT00326963|Drug|enfuvirtide [Fuzeon]|90mg sc bid
1765980|NCT00326976|Drug|FX06|400 mg as intravenous injection in two divided boluses
1765981|NCT00326976|Procedure|Percutaneous coronary intervention|
1765982|NCT00326989|Procedure|intracoronary stem cell therapy|extracorporal shock waves prior to intracoronary cell therapy
1765984|NCT00327015|Drug|Saxagliptin|Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)
1765985|NCT00327015|Drug|Saxagliptin|Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)
1765986|NCT00327015|Drug|Metformin|Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)
1765987|NCT00327015|Drug|Placebo|Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)
1765988|NCT00327015|Drug|pioglitazone|Tablets, Oral, 15-45 mg, as needed (12 months LT)
1765989|NCT00327028|Drug|Diphenine|
1765990|NCT00327054|Drug|Nigella sativa seed|
1765991|NCT00327080|Procedure|MRI|
1765992|NCT00327080|Drug|L-NMMA|
1765993|NCT00327080|Drug|Acetylcholine|
1765994|NCT00327093|Drug|cetuximab|indication : second intention treatment
1765995|NCT00327093|Drug|bevacizumab|Indication: first intention treatment
1765996|NCT00327106|Drug|Tranexamic acid (Exacyl)|15 mg/kg IV (in the vein), just before surgery and 3 hours after surgery
1765997|NCT00327106|Drug|Placebo|NaCl 9‰, 0,15 ml/kg IV (in the vein), just before surgery and 3 hours after surgery.
1765998|NCT00327119|Drug|ABX-EGF (panitumumab)|
1765999|NCT00327132|Drug|Omeprazole, Amoxicillin, Clarithromycin|
1766000|NCT00327145|Drug|valsartan|
1766001|NCT00327145|Drug|hydrochlorothiazide|
1766002|NCT00327145|Drug|amlodipine|
1766003|NCT00327158|Procedure|Transesophageal transducer|One time use of reamer during surgery
1766004|NCT00327158|Procedure|echocardiography|takes photos of right atrium during the reaming processes
1766005|NCT00327171|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 4.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.
Aflibercept could be reduced by 1 dose level ( to 2.0 mg/kg) or 2 dose levels (to 1.0 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
1766006|NCT00327171|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|"Aflibercept 2.0 mg/kg administered intravenously (IV) over 1 hour once every 2 weeks.
Aflibercept could be reduced by 1 dose level (to 1.0 mg/kg) or 2 dose levels (to 0.5 mg/kg) in case of uncontrolled hypertension or urinary protein >3.5 g/24 hours. Intrapatient dose escalation was not to be permitted. Participants requiring more than 2 dose level reductions would be withdrawn from study treatment."
1766007|NCT00327184|Biological|Haemophilus influenzae type b- and meningococcal serogroup C (vaccine)|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
1766008|NCT00327184|Biological|Infanrix Penta|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age.
1766009|NCT00327184|Biological|Infanrix hexa|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
1766010|NCT00327184|Biological|Neis-Vac-C|Two primary vaccination doses at 3 and 5 months of age and a booster dose at 11 months of age
1766011|NCT00327197|Drug|Prednisolone|Subjects will be administered oral prednisolone at a dose of 0.5 mg/kg, up to a maximum of 40 mg per day for 14 days.
1766012|NCT00327197|Procedure|Bronchoscopy|All subjects will undergo bronchoscopy assessments which will involve insertion of a standard bronchoscope.
1766013|NCT00327210|Behavioral|Blood Glucose Awareness Training|
1766014|NCT00327223|Drug|imexon|
1766015|NCT00327249|Drug|imexon|
1766016|NCT00327262|Drug|Imatinib|
1766017|NCT00327275|Behavioral|strength training|
1766018|NCT00327288|Drug|imexon|IV variable dosages, days 1-5 every 21 days for duration of study
1766019|NCT00327288|Drug|docetaxel|IV once every 21 days for duration of study
1766020|NCT00327314|Procedure|Transplantation|
1766021|NCT00327314|Procedure|Hematopoietic cell transplantation|
1766022|NCT00327327|Drug|imexon|30-60 minutes IV, days 1,8,15 every 28 days
1766023|NCT00327327|Drug|gemcitabine|30 minutes IV, days 1,8,15 every 28 days
1766024|NCT00327340|Drug|custirsen (OGX-011)/mitoxantrone|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to-1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21-day cycle.
Mitoxantrone was administered IV on Day 1 of each cycle at a planned dose of 12 mg/m² infused over 30 minutes.
Patients could receive a maximum of 9 cycles of treatment."
1766025|NCT00327340|Drug|custirsen (OGX-011)/docetaxel|"All subjects began treatment with oral prednisone (5 mg twice daily, 10 mg/day) continued through completion of the final treatment cycle. Three IV administrations of OGX-011 (640 mg) were given as 2 hr infusions during the loading dose period (Days-9 to -1). Subjects were premedicated with either ibuprofen (400 mg) or acetaminophen (650 mg) 30 to 60 minutes prior to and every 4-6 hours for 24 hours following each of the three doses of OGX-011 during the loading dose period only. After the loading dose period, OGX-011 was given weekly on Days 1, 8, and 15 of each 21 day cycle.
Docetaxel was administered IV on Day 1 of each cycle at a planned dose of 75 mg/m² infused over 60 minutes.
Patients could receive a maximum of 9 cycles of treatment."
1766026|NCT00327353|Drug|formoterol (TURBOHALER)|
1766027|NCT00327353|Drug|Salmeterol (DISKUS)|
1766028|NCT00327366|Procedure|Light therapy|
1766029|NCT00327379|Drug|Trasylol (Aprotinin, BAYA0128)|Infusion of aprotinin (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
1766030|NCT00327379|Drug|Placebo|Infusion of placebo (loading dose of 2 million KIU (Kallikrein Inhibitor Units) followed by 500,000 KIU/hour until the end of surgery)
1766031|NCT00327392|Drug|AQUAVAN® (fospropofol disodium) Injection|
1766032|NCT00327418|Drug|Atorvastatin|
1766033|NCT00327431|Genetic|Cheek swab samples for DNA|
1766034|NCT00327444|Drug|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
1766035|NCT00327444|Drug|Placebo|Placebo was administered intravenously (IV) over 1 hour once every 2 weeks in the DB period.
1766036|NCT00327444|Drug|aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg aflibercept was administered intravenously (IV) over 1 hour once every 2 weeks in the OL period.
1766037|NCT00327457|Behavioral|Help with physician office and patient management|
1766038|NCT00327457|Behavioral|Tailored physician recommendation letter|
1766039|NCT00327470|Drug|Pegaptanib Sodium 0.3 mg|Pegaptanib Sodium dosed every 6 weeks in affected eye.
1766040|NCT00327483|Behavioral|Internet based education software|
1766041|NCT00327496|Biological|DC vaccine|
1766042|NCT00327522|Biological|pneumococcal vaccine|
1766043|NCT00327535|Drug|Darbepoetin alfa|According to the approved local label (6.75 micrograms/kg every 3 weeks, or 2.25 micrograms/kg every week)
1766044|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|6.3 micrograms/kg every 3 weeks
1766045|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|9 micrograms/kg every 3 weeks
1766046|NCT00327535|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|12 micrograms/kg every 3 weeks
1766047|NCT00327548|Behavioral|guided imagery|
1766048|NCT00327561|Procedure|Intensive periodontal therapy|
1766049|NCT00327561|Procedure|Community based periodontal therapy|
1766050|NCT00327574|Behavioral|Home heath education +/_ GP training|
1766051|NCT00327587|Drug|Valsartan + amlodipine|
1766052|NCT00327587|Drug|Valsartan + HCTZ|
1766053|NCT00327587|Drug|Amlodipine + HCTZ|
1766054|NCT00327587|Drug|Valsartan + amlodipine + HCTZ|
1766055|NCT00327600|Drug|imexon|
1766056|NCT00327600|Drug|DTIC|
1766057|NCT00327626|Drug|ISIS 113715|
1766058|NCT00327652|Drug|CRS-100|Live-attenuated Listeria monocytogenes
1766059|NCT00327665|Biological|11-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection. Each group receiving one of the 3 formulations
1766060|NCT00327665|Biological|Pneumo 23™|Single-dose intramuscular injection.
1766061|NCT00327665|Biological|Placebo|1 intramuscular injection.
1766062|NCT00327665|Biological|10-valent pneumococcal vaccine GSK513026|Two-dose intramuscular injection
1766063|NCT00327678|Drug|Rituximab|
1766064|NCT00327678|Drug|Imatinib Mesylate|
1766065|NCT00327691|Drug|Atorvastatin|
1766066|NCT00327704|Drug|albumin|albumin 20% 100 ml/8 hours for 3 days
1766067|NCT00327704|Drug|saline|saline 100 ml/8hours for 3 days
1766068|NCT00327717|Drug|Zonisamide|Patients entered a 4-week titration period, during which zonisamide dosing began at 100 mg/day for the first 2 weeks, increased to 200 mg/day for the 3rd week, and to 300 mg/day for the 4th week, reaching 300 mg/d at the end of the titration period. 300 mg/d was the target dose in the titration period and must be reached. Dose increment was continued to 400 mg/d if this was tolerated by the patient.
1766069|NCT00327717|Drug|Placebo|Patients in placebo group were titrated with placebo in the same way as in zonisamide group.
1766070|NCT00327730|Drug|Eperisone|
1766071|NCT00327743|Drug|larotaxel|IV infusion on Day 1 of a 21-day cycle
1766072|NCT00327743|Drug|capecitabine|oral, twice daily, Day 1-Day 14 of a 21-day cycle
1766073|NCT00327756|Drug|Coenzyme Q10|
1766074|NCT00327769|Drug|Fulvestrant|250 mg intramuscular injection
1766075|NCT00327769|Drug|Anastrozole|1 mg tablet
1766076|NCT00327808|Drug|TPI-1020|600 mcg BID x 14 days followed by 1200 mcg BID x 7 days
1766077|NCT00327808|Drug|budesonide|400 mcg BID x 14 days then 800 mcg/day x 7 more days
1766078|NCT00327821|Behavioral|calorie controlled diet|
1766079|NCT00327834|Drug|atomoxetine|
1766080|NCT00327847|Drug|Oral Vitamin D Supplementation|
1766081|NCT00327873|Other|Oxygen|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
1766082|NCT00327873|Other|Medical Air|2L/min for 15 hours or greater per day via concentrator and nasal cannulae for 7 days
1766083|NCT00327912|Procedure|Laparoscopic Biliopancreatic diversion with Duodenal switch|
1766084|NCT00327912|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|
1766085|NCT00327925|Procedure|Find Cancer Associated Antibodies|
1766086|NCT00327938|Device|Measuring of skin conductance|
1766087|NCT00327938|Procedure|Tetanic stimuli|
1766088|NCT00313833|Drug|Buprenorphine transdermal delivery system|
1766089|NCT00313846|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear.
1766090|NCT00313846|Drug|Placebo|Placebo to match BTDS 5, 10, or 20 mcg/h applied for 7-day wear.
1766091|NCT00313859|Drug|simvastatin|
1766092|NCT00313872|Drug|DP|D1 Taxotere 75 mg/m2 + D5W 200 mL IV over 1 hr D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr Pre & Post medication Dexamethasone 8mg PO D0 Night (X1) D1 immediately upon waking in the morning, 1 hour before infusion Taxotere, Night (X3) D0 NS 1500 mL IV overnight hydration D1 DNK2 1000 mL IV over 2 hours, pre & post hydration (if Mg <WNL, mix MgSO4 1 amp) 20% Mannitol 70 mL IV full dripping, 30 mins before cisplatin D2-D3 Dexamethasone 8 mg PO bid, D4-D5 Dexamethasone 4 mg PO bid every 3 weeks
1766093|NCT00313872|Drug|FOLFIRI|FOLFIRI regimen D1 Irinotecan 150 mg/m2 + D5W 500mL MIV over 90 min D1 Leucovorin 100 mg/m2 + D5W 500mL MIV over 2hrs D1-2 5-FU 1500 mg/m2 + D5W 1000 ml CIV over 24 hrs (total 2doses) D1 atropine 0.3mg SQ before irinotecan
1766094|NCT00313885|Drug|eplivanserin (SR46349)|oral administration
1766095|NCT00313885|Drug|placebo|oral administration
1766096|NCT00313898|Drug|sildenafil (viagra)|
1766097|NCT00313911|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
1766098|NCT00313911|Biological|Tritanrix-HepB/Hib|0.5 mL, Intramuscular
1766099|NCT00313924|Drug|DETRUSITOL|
1766100|NCT00313937|Drug|Insulin glargine|
1766101|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, intramuscular (IM) (HAV Day 0 and 168); 0.5 mL, IM (MMR Day 28)
1766102|NCT00313950|Biological|Attenuated Measles Mumps Rubella; Inactivated Hep A vaccine|0.5 mL, IM (MMR, Day 0); 0.5 mL, IM (HAV Day 28 and 168)
1766103|NCT00313950|Biological|Inactivated Hep A vaccine; Attenuated Measles Mumps Rubella|0.5 mL, IM (HAV Day 0 and 168); 0.5 mL, IM (MMR, Day 0)
1766104|NCT00313963|Drug|Magnesium Sulfate|Intravenous Magnesium Sulfate (100 mg/Kg, Max 2 gram/dose) 8 hourly.
1766105|NCT00313963|Drug|Normal Saline|Intravenous Placebo (Normal Saline in equivalent amount to magnesium sulfate 100 mg/Kg, Max 2 gram/dose) 8 hourly.
1766106|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|250 micrograms every other day, subcutaneously for 104 weeks
1766107|NCT00313976|Drug|Interferon beta-1b (Betaferon/Betaseron, BAY86-5046)|2x250 micrograms every other day, subcutaneously for 104 weeks
1766108|NCT00313989|Procedure|Evaluation of the success rate of implants|Evaluation of the success rate of implants
1766109|NCT00314002|Device|Mechanical Thrombectomy|
1766110|NCT00314015|Procedure|Evaluation of the success rate of implants|Evaluation of the success rate of implants will be followed.
1766111|NCT00314015|Procedure|Questionnaires|Questionnaires will be used
1766112|NCT00314028|Behavioral|Focus on the Future|Focus on the Future is an educational program designed to promote proper condom use.
1766113|NCT00314028|Other|Control standard of care treatment|Standard of care treatment is the normal treatment that someone would receive for the particular sexually transmitted disease or virus.
1766114|NCT00314041|Biological|Meningococcal C|
1766115|NCT00314041|Biological|DTP/Hib|
1766116|NCT00314054|Drug|HCV-796|HCV-796 1000mg single dose
1766117|NCT00314067|Procedure|Online Comprehensive Quality Management System (CQM) of alcohol-related disorders in primary care|
1766118|NCT00314067|Procedure|Physician training|
1766119|NCT00314067|Procedure|Practice team training|
1766120|NCT00314080|Drug|Botulinum AntiToxin|
1766121|NCT00314080|Procedure|neuro-electrophysiologic study, repetitive nerve stimulation|
1766122|NCT00314080|Procedure|Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
1766123|NCT00314093|Drug|RFT5pdgA|
1766124|NCT00314106|Biological|Melanoma Reactive TIL|
1766125|NCT00314106|Drug|Cyclophosphamide|60 mg/kg/ day x 2 days intravenous
1766126|NCT00314106|Biological|IL-2|720,000 IU/kg/dose every 8 hours for up to 15 doses
1766127|NCT00314106|Drug|Fludarabine|25 mg/m^2/day intravenous x 5 days
1766128|NCT00314106|Radiation|1200 total body irradiation (TBI)|1200 cGY total body radiation
1766129|NCT00314132|Biological|ChimeriVax-JE, Japanese Encephalitis vaccine|0.5 mL, Subcutaneous
1766130|NCT00314132|Biological|0.9% Saline|0.5 mL, Subcutaneous
1766131|NCT00314145|Biological|ChimeriVax™-JE|0.5 mL, Subcutaneous (ChimeriVax™-JE); 1.0 mL, (Saline)
1766132|NCT00314145|Biological|JE-VAX®|0.5 mL, Subcutaneous (JE-Vax®); 1.0 mL, (Saline)
1766133|NCT00314158|Drug|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop twice daily in each study eye for six months
1766134|NCT00314158|Drug|Brinzolamide 10 mg/ml (AZOPT) eye drops, suspension|One drop twice daily in each study eye for six months
1766135|NCT00314158|Drug|Timolol 5 mg/ml eye drops, solution|One drop twice daily in each study eye for six months
1766136|NCT00314171|Drug|Brinzolamide 10 mg/ml + Timolol 5 mg/ml eye drops, suspension|One drop in the study eye(s) twice daily for 12 months
1766137|NCT00314171|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (COSOPT)|One drop in the study eye(s) twice daily for 12 months
1766138|NCT00314184|Drug|quetiapine fumarate|
1766139|NCT00314197|Behavioral|Telephone Linked Care - Behavior Change Counseling System|
1766140|NCT00314197|Behavioral|Telephone-linked behavioral counseling|
1766141|NCT00314210|Drug|Quetiapine SR|
1766142|NCT00314236|Device|BST-CarGel with Microfracture|Microfracture performed with BST-CarGel added to the treated defect
1766143|NCT00314236|Procedure|Microfracture without BST-CarGel|Microfracture performed without BST-CarGel added to the treated defect.
1766144|NCT00314249|Drug|Placebo|Placebo, oral administration, twice daily for 12 weeks
1766145|NCT00314249|Drug|Milnacipran 100mg|Milnacipran 100mg per day (50mg BID [twice a day])
1766146|NCT00314262|Drug|Erlotinib & Celecoxib|"Erlotinib given orally, once daily (dose escalation from 50 mg, 75 mg, or 100 mg) continuously for 6 months in the phase I portion.
Celecoxib given 400 mg orally BID continuously for 6 months."
1766147|NCT00314275|Device|Coronary Artery Stenting|Drug eluting stent
1766148|NCT00314275|Device|Endeavor|Drug eluting stent
1766149|NCT00314288|Drug|Sarizotan HCl|
1766150|NCT00314301|Device|loaded sit-to-stand training|
1766151|NCT00314314|Drug|Intranasal Insulin|Intranasal spray; 40 IU qid; 8 weeks
1766152|NCT00314314|Drug|Diluent|Intranasal spray; 8 weeks
1766153|NCT00314327|Drug|long-acting injectable risperidone|One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
1766154|NCT00314340|Behavioral|Markers of Abuse Liability, Neuropsych Testing, and Cue Reactivity|The first dose of the study medication was taken following collection of baseline measurements, and subsequent measurements were taken hourly thereafter. Respiration, heart rate, arterial oxygen saturation (pulse oximetry), and blood pressure were also monitored at these intervals to insure the safety of subjects.
1766155|NCT00314340|Drug|ER Morphine|
1766156|NCT00314340|Drug|hydrocodone plus acetaminophen|
1766157|NCT00314340|Drug|placebo|
1766158|NCT00314353|Drug|Bevacizumab|"7.5 mg/kg IV Day 1 every 21 days for eight cycles*
*For patients with stable or responding disease after 8 cycles, continue bevacizumab at the same dose levels until disease progression."
1766159|NCT00314353|Drug|Oxaliplatin|130 mg/m2 IV Day 1 every 21 days for eight cycles
1766160|NCT00314353|Drug|Capecitabine|"850 mg/m2 po BID Days 1-14 every 21 days for eight cycles*#
*For patients with stable or responding disease after 8 cycles, continue capecitabine at the same dose levels until disease progression.
#For patients with baseline calculated creatinine clearance of 30-50 mL/min, the starting dose will be reduced to 650 mg/m2 BID"
1766161|NCT00314353|Drug|Irinotecan|200 mg/m2 IV Day 1 every 21 days for eight cycles
1766162|NCT00314366|Biological|Stem Cell Therapy|Cells are injected under electromechanical guidance and delivered by the Myostar catheter after NOGA mapping.
1766163|NCT00314366|Other|Control (plasma)|Placebo patients receive an injection of plasma (control) containing 5 % albumin the the same quantity as the stem cell arm. A total of 15 injections of 0.2 ml to total 3.0 ml.
1766164|NCT00319696|Drug|bosentan|Initial dose: bosentan 62.5 mg tablets b.i.d. for 4 weeks Maintenance dose: bosentan 125 mg tablets b.i.d.
1766165|NCT00319709|Drug|SR58611A|
1766166|NCT00319735|Procedure|Radiation Therapy|External beam radiation therapy, beginning on day 1, 4500 cGy to esophagus with boost of 540 cGy at 180 cGy per fraction for 6 weeks
1766167|NCT00319735|Procedure|Surgery|Surgical resection of primary tumor and adjacent mediastinal and/or celiac lymph nodes by a transthoracic approach after satisfactory hematologic and functional recovery within 8 weeks of completion of radiation therapy
1766168|NCT00319735|Procedure|Tissue Sample|For patients who give their consent, fresh frozen tissue will be obtained per EUS at baseline, per EUS 2 weeks after the initiation of chemotherapy, and at the time of surgery for pathology submission
1766169|NCT00319748|Drug|852A|0.2% 852a subcutaneous injection, 2 times per week for 12 weeks (24 doses) starting at 0.6 mg/m2; subsequent dose escalation for additional courses may be increased by 0.2 mg/m2 not to exceed 1.2 mg/m2.
1766170|NCT00319761|Drug|Calcitriol|
1766171|NCT00319774|Device|Hemocontrol Biofeedback System|
1766172|NCT00319787|Drug|Iressa|
1766173|NCT00319800|Drug|Gefitinib|
1766174|NCT00319800|Drug|Irinotecan|
1766175|NCT00319813|Behavioral|Education|
1766176|NCT00319826|Other|No intervention|This is an observational study with no intervention
1766179|NCT00319852|Biological|DTaP-IPV combined vaccine|0.5 mL, IM
1766180|NCT00319852|Biological|DTaP vaccine|0.5 mL, IM
1766181|NCT00319865|Drug|Velcade|
1766182|NCT00319865|Drug|Thalidomide|
1766183|NCT00319865|Drug|Adriamycin|
1766184|NCT00319865|Drug|Dexamethasone|
1766185|NCT00319878|Drug|Sirolimus|"Oral loading dose followed by a once daily dose:
Cohort 1: Loading Dose - 1.2 mg; Daily Dose - 0.4 mg
Cohort 2: % Dose Increase - 100%; Loading Dose - 2.4 mg; Daily Dose - 0.8 mg
Cohort 3: % Dose Increase - 67%; Loading Dose - 3.9 mg; Daily Dose - 1.3 mg
Cohort 4: % Dose Increase - 50%; Loading Dose - 6.0 mg; Daily Dose - 2.0 mg"
1766186|NCT00319878|Drug|Cyclosporine|Dose of 5 mg/kg divided as a twice daily oral dose
1766187|NCT00319891|Procedure|Computer-based Cognitive Training|
1766188|NCT00319917|Drug|tacrolimus|oral
1766189|NCT00319917|Drug|placebo|oral
1766190|NCT00319930|Drug|CNF1010 (17-AAG)|
1766191|NCT00319943|Procedure|Computer-based training for Mild Cognitive Impairment (MCI)|
1766194|NCT00319969|Drug|Amrubicin|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
1766195|NCT00319969|Drug|Topotecan|Topotecan 1.5mg/m<2> IV days 1, 2, 3, 4, 5 of each 21-day cycle until disease progression.
1766196|NCT00319982|Drug|Diltiazem|Sustained release formulation titrated to a target dose of 360 mg daily, or a maximum of 5 mg/kg/day in pediatric subjects for the duration of the study period
1766197|NCT00319982|Drug|Placebo|Placebo comparator (double-blind allocation of study medication)
1766198|NCT00319995|Drug|loratadine; montelukast|
1766199|NCT00320008|Behavioral|Diet|
1766200|NCT00320008|Behavioral|Exercise|
1766201|NCT00320008|Behavioral|Stop smoking|
1766202|NCT00320008|Drug|Glucose lowering therapy|
1766203|NCT00320008|Drug|Blood pressure lowering therapy|
1766204|NCT00320008|Drug|Lipid lowering therapy|
1766205|NCT00320021|Drug|Pyridorin (pyridoxamine dihydrochloride)|
1766206|NCT00320034|Drug|R-albuterol, S-albuterol|
1766207|NCT00320047|Drug|Baclofen|Participants will take baclofen 3 times a day, before meals, for 10 weeks. Baclofen dosages will be low to begin, followed by a gradual increase over a 2-week period. Upon reaching the maximum tolerated dose of baclofen, participants will continue at this dosage level until Week 11, at which time the dose will be gradually decreased. If any serious side effects occur, baclofen dosage will be decreased to the previous tolerated dosage level.
1766208|NCT00320060|Drug|Pyridorin (pyridoxamine dihydrochloride)|
1766209|NCT00320073|Drug|erlotinib hydrochloride|75 mg to 150mg
1766210|NCT00320073|Drug|pemetrexed disodium|Pemetrexed is administered intravenously over 10 minutes, every 21 days
1766211|NCT00320073|Drug|vinflunine|Vinflunine is administered intravenously over 20 minutes and should be given after pemetrexed, every 21 days
1766212|NCT00320099|Drug|recombinant human insulin|intensive insulin therapy as a continuous infusion to maintain blood glucose levels between 4 and 6 mmol/l
1766213|NCT00320099|Drug|hydrocortisone|50 mg as iv bolus every 6 hours for 7 days
1766214|NCT00320099|Drug|fludrocortisone|50 µg once a day via a nasogastric tube for seven days
1766215|NCT00320099|Drug|Hydrocortisone|hydrocortisone 50mg q6 for 7 days
1766216|NCT00320112|Behavioral|Reciprocal Diabetes Peer Support Program|participants are paired with another age-matched participation. Paired peer partners were encouraged to talk weekly using a telephone platform that recorded call frequency and duration and provided automated reminders promoting peer contact.
1766217|NCT00320112|Behavioral|Nurse Case management|patients are not paired in the NCM arm attended a 1.5 hour session to receive education on care manager services and diabetes educational materials and be assigned to a nurse care manager with whom they were encouraged to follow-up regularly.
1766218|NCT00320112|Behavioral|group outpatient counseling visits|Participants in the peer group were also offered three optional 1.5 hour patient-driven group sessions at month 1, 3, and 6
1766219|NCT00320125|Dietary Supplement|Orange juice plus calcium|> 1,200mg Ca (four glasses of orange juice plus calcium)per day
1766220|NCT00320125|Dietary Supplement|Dairy products|> 1,200mg Ca (by consuming milk, yogurt, and cheese)
1766221|NCT00320138|Procedure|Acupuncture, using Chinese Medicine methodology|4 weeks of 2/week treatments (8 total); 4 standardized and 4 individualized treatments
1766222|NCT00320190|Drug|Imatinib|Imatinib tablets administered orally at a dose of 400 mg twice daily. Each 400- mg dose to be taken with a meal and a large glass of water.
1766223|NCT00320190|Drug|Dasatinib|Dasatinib tablets administered orally at a dose of 100 mg once daily.
1766224|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|Single injection, anterior juxtascleral depot (AJD)
1766225|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single injection, anterior juxtascleral depot (AJD)
1766226|NCT00320203|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single injection, anterior juxtascleral depot (AJD)
1766227|NCT00320203|Other|Anecortave Acetate Vehicle|Single injection, anterior juxtascleral depot (AJD)
1766228|NCT00320216|Drug|Ustekinumab|Patients will receive subcutaneous injections of ustekinumab (45 or 90 mg).
1766229|NCT00320216|Drug|Placebo|Patients in the placebo group will receive placebo medication.
1766230|NCT00320229|Drug|abciximab|
1766231|NCT00320242|Device|1 mo baseline before visual cue|Laser Cane with Laser Accessory and/or U-Step Walker with Laser Accessory
1766232|NCT00320255|Drug|Apixaban|Oral tablets administered once daily in 5-, 10-, or 20-mg dose
1766233|NCT00320255|Drug|Placebo|Oral tablets administered once daily
1766234|NCT00320268|Drug|Quetiapine fumarate|
1766235|NCT00320281|Drug|botulinum toxin A|Injection of BTXA into cervical and upper back muscles based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit.Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
1766236|NCT00320281|Other|placebo|Injection of normal saline into cervical and upper back muscles was also based on treatment plan prescribed for each participant individually based on muscle soreness and tightness. Injections occured on one single clinic visit. Both the saline and BTXA were dosed in 25 cc syringes and looked the same for the physician performing the injections to ensure both participant and study physician remained blinded.
1766237|NCT00320294|Drug|irinotecan|
1766238|NCT00320294|Drug|cisplatin|
1766239|NCT00320307|Drug|abacavir|
1766240|NCT00320320|Drug|Irinotecan|
1766241|NCT00320333|Procedure|pulmonary rehabilitation programme|
1766242|NCT00320346|Biological|Pandemic Influenza Vaccine|
1766243|NCT00320359|Drug|Intravenous topotecan/cisplatin|"Topotecan 1 mg/m2 should be administered intravenously over a period of 30 minutes on days 1-5. Then a 30 minute saline flush should be administered followed by the cisplatin on day 5.
Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 5 after topotecan."
1766244|NCT00320359|Drug|Intravenous etoposide/cisplatin|"Cisplatin 75 mg/m2 given as an intravenous infusion at the rate of 1 mg/min on day 1. Cisplatin should be given simultaneously to post-hydration to ensure a high volume fluid.
Etoposide 100 mg/m2 should be administered after cisplatin intravenously over a period not less than 30 minutes on days 1 -3."
1766245|NCT00320385|Drug|Lapatinib|oral lapatinib once daily
1766246|NCT00320385|Biological|Trastuzumab|IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose
1766248|NCT00320411|Drug|lapatinib|Lapatinib 1500mg QD
1766251|NCT00320463|Biological|DTPa-HBV-IPV/Hib vaccine|
1766252|NCT00320476|Drug|Velcade|
1766253|NCT00320489|Drug|olanzapine|10 milligrams (mg), oral tablets, once daily for 4 weeks followed by 5-20 mg flexible dosing, oral tablets, once daily, for 100 weeks, for a total treatment duration of 104 weeks.
1766254|NCT00320489|Drug|olanzapine pamoate depot|405 milligrams (mg), intramuscular injection, followed 4 weeks later by 150-405 mg flexible dosing, intramuscular injection, every 4 weeks thereafter for 96 weeks, for a total treatment duration of 104 weeks.
1766255|NCT00320502|Drug|BXT-51072|
1766256|NCT00320515|Drug|pemetrexed|"Phase 1 - dose escalating: 600 mg/m2 level 1, 700 mg/m2 level 2, 800 mg/m2 level 3, 900 mg/m2 level 4, intravenous (IV), every 21 days, until disease progression
Phase 2 - 700 mg/m2, intravenous (IV), every 21 days, until disease progression"
1766257|NCT00320515|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days, until disease progression
1766258|NCT00320528|Drug|atomoxetine|0.5 milligrams per kilogram per day (mg/kg/day), by mouth (PO) for 1 week then 1.2 mg/kg/day, PO for 11 weeks followed by up to 1.4 mg/kg/day, PO for up to 12 additional weeks
1766259|NCT00320541|Drug|gemcitabine|1500 mg/m2, IV day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
1766260|NCT00320541|Drug|paclitaxel|90 mg/m2, IV, day 1, day 8 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
1766261|NCT00320541|Drug|bevacizumab|10 mg/kg, IV, day 1 and day 15 every 28 days until complete response, disease progression or unacceptable toxicity
1766262|NCT00320554|Behavioral|Durometer analysis|
1766263|NCT00320567|Drug|norgestimate/ethinyl estradiol|
1766264|NCT00320580|Drug|norelgestromin/ethinyl estradiol|
1766265|NCT00320593|Device|Progressive Addition Lenses (PALs)|Varilux Ellipse progressive addition lenses (PALs) with a +2.00 D addition
1766266|NCT00320593|Device|Single Vision Lenses (SVLs)|Single vision lenses
1766267|NCT00320606|Drug|Gradual withdrawal of immunosuppressive medication|With high dose, daily dose reduction by 25% for 8 weeks. With low dose, daily dose reduction by 25% for 4 weeks.
1766268|NCT00320619|Drug|Epsilon-Aminocaproic Acid (EACA)|Participants will receive EACA intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
1766269|NCT00320619|Drug|Placebo|Participants will receive placebo intravenously during surgery and for 8 hours following surgery in the intensive care unit (ICU).
1766270|NCT00320632|Drug|Desipramine|
1766271|NCT00320658|Biological|MSP1 42-C1/Alhydrogel|Recombinant MSP1 42-C1/Alhydrogel vaccine (one of two doses)
1766272|NCT00320658|Biological|CPG 7909|Adjuvant
1766273|NCT00320671|Drug|Aripiprazole|The dosage for aripiprazole will be 5 mg to 30 mg per day in capsule form. The dose of aripiprazole will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks and then every 2 weeks until the 12th week and then monthly until study end.
1766274|NCT00320671|Drug|Risperidone|The dosage for risperidone will be 1 mg to 6 mg per day in capsule form. The dose of risperidone will be based on the participant's clinical improvement and side effects, which will be evaluated weekly for the first 4 weeks, then every 2 weeks until the 12th week, and then monthly until the study end.
1766275|NCT00320697|Drug|bupropion + nicotine patch + nicotine gum or lozenges|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
1766276|NCT00320697|Drug|Placebo pill + placebo patch|Subjects eligible for bupropion were randomized to receive either nicotine patch and bupropion or placebo patch and pill added to CBT for 44 weeks.
1766277|NCT00320710|Drug|Zoledronic acid|4mg IV
1766278|NCT00320710|Drug|Placebo|Placebo to zoledronic acid
1766279|NCT00320723|Drug|bupropion, transdermal nicotine patch|
1766280|NCT00320736|Drug|galantamine|
1766281|NCT00320749|Drug|Capecitabine|Will be give on days 8-21
1766282|NCT00320749|Drug|Docetaxel|Will be given on days 1 and 8,
1766283|NCT00320749|Drug|Gemcitabine|A fixed dose rate will be give on days 8 and 15.
1766284|NCT00320762|Device|OculusGen Biodegradable Collagen Matrix Implant|
1766285|NCT00320775|Drug|VEGF Trap|"Part A: Six successive cohorts of 3-6 patients each with neovascular AMD will receive a single intravitreal (ITV) injection of 0.05, 0.15, 0.5, 1.0, 2.0, or 4.0 mg of VEGF Trap into the study eye.
Part B: Up to 30 subjects will be randomly assigned in a 1:1 ratio to receive a single of 2.0 mg/eye VEGF Trap followed by 1 sham injection six weeks later, or an initial dose of 0.3 mg pegaptanib sodium into the study eye, followed by a second dose six weeks later.
Part C: Approximately 30 subjects will be randomly assigned in a 1:1 ratio to receive up to two ITV injections of either 0.15 or 4.0 mg/eye VEGF Trap.
After completion of Visit 8 (Day 57), patients from all parts of the study, may be eligible to continue in Open-label Extension and will receive 4.0 mg of VEGF Trap."
1766286|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
1766287|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 0.5 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
1766288|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 4 week intervals through Week 12
1766289|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 2.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
1766290|NCT00320788|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received 4.0 mg of aflibercept injection (VEGF Trap-Eye, BAY86-5321) at 12 week intervals through Week 12.
1766291|NCT00320801|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
1766292|NCT00320801|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
1766293|NCT00320814|Drug|VEGF Trap-Eye|single IVT injection of 4.0 mg of VEGF Trap-Eye into the study eye on Day 1
1766294|NCT00320827|Drug|CS-1008 (humanized anti-DR5 antibody)|
1766295|NCT00320853|Drug|Vitamin D|
1766296|NCT00320866|Device|syringe driver|
1766297|NCT00320879|Drug|irbesartan|
1766298|NCT00320892|Drug|Atropine Sulphate 1% ophthalmic drops|Atropine Sulphate 1% ophthalmic drops will be used, by Fisher Pharmaceutical Labs, at a dose of 2 drops per administration
1766299|NCT00320905|Behavioral|Observational|No intervention
1766301|NCT00320957|Device|OculusGen Biodegradable Collagen Matrix Implant|
1766302|NCT00320970|Drug|Candesartan|
1766303|NCT00320983|Drug|Topotecan|Topotecan
1766304|NCT00320983|Drug|Cisplatin|Cisplatin
1766305|NCT00321009|Drug|Enoxaparin|
1766306|NCT00321022|Behavioral|Accelerated Diagnostic Protocol Emergency Department Observational Unit|
1766307|NCT00321035|Device|OculusGen Biodegradable Collagen Matrix Implant|
1766308|NCT00321048|Device|Active Breathing Coordinator|A SPECT scan will be used to determine if the active breathing device reduces radiation toxicities.
1766309|NCT00321061|Drug|VRC-HIVDNA016-00, VRC-HIVADV014-00|
1766310|NCT00321074|Drug|TACROLIMUS|Immunosuppression
1766311|NCT00321087|Drug|T2000|Dose escalation from 600 to 1000 mg
1766312|NCT00321087|Drug|T2000|Placebo followed by T2000 dose escalation from 600 to 1000 mg
1766313|NCT00321087|Drug|T2000|Placebo followed by dose escalation from 600 to 1000
1766314|NCT00321100|Drug|bevacizumab|Bevacizumab 7.5mg/kg IV day 1 of each 21 day cycle
1766315|NCT00321100|Drug|Cetuximab|Cetuximab 250mg/m2 IV weekly each 21 day cycle
1766316|NCT00321100|Drug|Oxaliplatin|Oxaliplatin 130mg/m2 IV day 1 every 21 days
1766317|NCT00321100|Drug|Capecitabine|Capecitabine 850mg/m2 PO every 12 hours days 1-14 of each 21 day cycle
1766318|NCT00321113|Drug|tacrolimus|immunosuppression
1766319|NCT00321113|Drug|mycophenolate mofetil|oral
1766320|NCT00321113|Drug|steroids|oral
1766321|NCT00321126|Drug|Children in the zinc group received 20 mg of elemental zinc as acetate per day in a twice-daily dose for two weeks.|
1766322|NCT00321152|Other|6(S)-5-MTHF (a Medical Food)|The study consists of 8 visits over a period of 8 weeks or 60 days. Eligible participants will be randomized to double-blind treatment with placebo or Deplin (6(S)-5-MTHF). Participants will have a greater than 50% chance of receiving active medication (Deplin) at some point in the 8 week study. At the end of the double-blind phase, both responders and non-responders who have completed the 8 week study will have the option of receiving free, open-label adjunctive treatment with either 7.5 mg or 15 mg of 6(S)-5-MTHF for 12 months. Subjects who agree to receive open-label treatment with 6(S)-5-MTHF for 12 months will be assessed every three (3) months until the end of the follow-up phase.
1766323|NCT00321165|Drug|taurolidine|
1766324|NCT00321178|Drug|SR4 - switch to CR4|switch to oral treatment after 4 weeks SR 'standard' therapy
1766326|NCT00321191|Drug|Administration of N2O|
1766327|NCT00321204|Procedure|TZD reducing the incidence of atrial arrhythmias|
1766328|NCT00321230|Drug|macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate|
1766329|NCT00321243|Behavioral|Visual clues|
1766330|NCT00321256|Procedure|human pancreatic islet transplantation|
1766331|NCT00321269|Behavioral|Single Illness Management|8 week nursing intervention addressing Congestive Heart Failure
1766332|NCT00321269|Behavioral|Comorbid Illness Management|8 week nursing intervention to address Congestive Heart Failure and emotional coping
1766333|NCT00321282|Procedure|Atrial Fibrillation|
1766334|NCT00321295|Device|Atrial synchronous bi-ventricular pacing|
1766335|NCT00321308|Drug|pemetrexed|500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
1766336|NCT00321308|Drug|pemetrexed + PF-3512676|pemetrexed 500 mg/m2 intravenously Day 1 of each 21 day cycle until disease progression or unacceptable toxicity
1766337|NCT00321321|Drug|Sulfonylurea|
1766338|NCT00321334|Procedure|Chemotherapy+Surgery|Docetaxel:75mg/m2 on D1 cycle,3 cycles Carboplatin:AUC=5 on D1 cycle,3 cycles
1766339|NCT00321347|Drug|Lidocaine|
1766340|NCT00321360|Drug|Propofol|
1766341|NCT00321360|Device|Patient maintained sedation|
1766342|NCT00321373|Biological|Candidate Influenza Vaccine GSK1247446A - 2 different formulations|Single dose, Intramuscular injection
1766343|NCT00321373|Biological|FluarixTM|Single dose, Intramuscular injection
1766344|NCT00321412|Drug|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
1766345|NCT00321425|Procedure|brachial plexus block|
1766346|NCT00321425|Procedure|ultrasound guidance|
1766347|NCT00321425|Procedure|electrical nerve stimulation|
1766348|NCT00321451|Behavioral|Cognitive behavioral therapy for insomnia|4 biweekly outpatient sessions with sleep psychologist
1766349|NCT00321451|Behavioral|Pseudo-desensitization procedure|4 biweekly outpatient visits with sleep psychologist
1766350|NCT00321451|Other|Usual care|3 outpatient visits with study physician
1766351|NCT00321464|Biological|Denosumab|Q4W 120 mg denosumab SC injection and 4 mg zoledronic acid (Zometa) placebo IV over a minimum of 15 minutes
1766352|NCT00321464|Drug|Zoledronic Acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
1766354|NCT00321490|Drug|Quetiapine fumarate|
1766355|NCT00321490|Drug|Duloxetine|
1766356|NCT00321516|Drug|aripiprazole|Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
1766357|NCT00321529|Device|motion analysis by durometer|
1766358|NCT00321542|Other|Imaging study, No intervention|Imaging with coronary computed tomographic angiography
1766360|NCT00321581|Drug|Cediranib, AZD2171, RECENTIN|
1766361|NCT00321594|Drug|belinostat|Given IV
1766362|NCT00321620|Drug|zoledronic acid|Q4W 4 mg zoledronic acid IV over minimum 15 minutes and 120 mg denosumab placebo SC
1766363|NCT00321620|Biological|denosumab|Q4W 120 mg denosumab SC and 4 mg zoledronic acid placebo IV over a minimum of 15 minutes
1766364|NCT00321633|Drug|carboplatin|
1766365|NCT00321633|Drug|docetaxel|
1766366|NCT00321646|Drug|Bevacizumab|Bevacizumab (marketed as Avastin, Genentech) is an antibody to all isoforms of vascular endothelial growth factor and is the first putative anti-angiogenic agent approved by the Food and Drug Administration (FDA) for the treatment of cancer.All subjects will be treated with intravenous docetaxel and bevacizumab for 5 cycles, followed by docetaxel alone for Cycle 6. Bevacizumab will be given first, at a starting dose of 15 mg/kg. Bevacizumab will be given once every 21 days in the infusion center.
1766367|NCT00321646|Drug|Docetaxel|Docetaxel will be given intravenously once every 21 days in the infusion center. The starting dose is 70mg/square meter.
1766368|NCT00327990|Drug|Ibandronate|
1766369|NCT00327990|Drug|Alendronate|
1766370|NCT00328016|Behavioral|Guided Breathing|The participant will engage in daily 15 min sessions of meditative relaxation that involves quiet attention to breathing pattern with no attempt to manipulate breathing pattern
1766371|NCT00328016|Device|RESPeRATE|The participant will be trained to perform a guided breathing task that involves a chest expansion sensor, battery-powered microcomputer, and earphones
1766372|NCT00328029|Drug|busulfan|5mg/kg/day (oral route : 4 doses/day for 4 days)
1766373|NCT00328029|Procedure|respiratory function tests|respiratory function tests before allograft or autograft and at several times in the follow up (3, 6, 12, 18 and 24 months).
1766374|NCT00328029|Procedure|pharmacokinetics, done during the treatment|"12 blood collections :
after 1st Busulfan taken : t0; t0 + 30 mn; t0 + 1h; t0 + 2h ; t0 + 3h ; t0 + 4h ; t0 + 5 h.
3 hours after 2nd taken of Busulfan
3 hours after 3rd taken of Busulfan
3 hours after 4th taken of Busulfan
3 hours after 5th taken of Busulfan
3 hours after 6th taken of Busulfan."
1766375|NCT00328042|Behavioral|Self-Management Workshop|The workshop is a once per week 2.5 hour group that meets for six weeks.
1766376|NCT00328042|Behavioral|Information Only|This is an individual self-paced at home study program.
1766377|NCT00328055|Behavioral|AD-Easy (Advance Directive-Easy)|
1766378|NCT00328055|Behavioral|AD-Standard (Advance Directive-Standard)|
1766379|NCT00328094|Drug|continuous intravenous insulin infusion|Tight glucose control versus standard of care
1766380|NCT00328107|Biological|Influenza Vaccine, recombinant Hemagglutinin|0.5mL dose for IM injection
1766381|NCT00328120|Drug|Fulvestrant|500 mg intramuscular injection
1766382|NCT00328146|Other|Observation of sternal reentry|Observation of sternal reentry
1766383|NCT00328159|Drug|Oil special 107 and MYGLIOL 810|
1766384|NCT00328172|Drug|Placebo|Placebo matching BI 1356
1766385|NCT00328172|Drug|BI 1356 dose 3 once daily|BI 1356 dose 3 once daily
1766386|NCT00328172|Drug|BI 1356 dose 2 once daily|BI 1356 dose 2 once daily
1766387|NCT00328172|Drug|BI 1356 dose 1 once daily|BI 1356 dose 1 once daily
1766388|NCT00328172|Drug|Metformin|Metformin
1766389|NCT00328198|Biological|Alemtuzumab|"Alemtuzumab is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg, 10mg, and 30mg administered subcutaneously (SC) (if tolerated). When escalation to 30 mg is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 18 weeks.
Part 1 of the study: The first 20 patients will be randomized to either Arm 1 (dose escalation) or Arm 2 (no escalation). Part 1 of the study has been completed; no additional patients will be enrolled in Part 1. An assigned review panel has reviewed the safety data from Part 1 and determined that all patients will be enrolled and treated under a no escalation schedule for Part 2 of the study."
1766390|NCT00328198|Biological|Alemtuzumab|"Alemtuzumab treatment is started immediately at the 30mg dose (with no escalation period), administered SC at alternating injection sites 3 times per week for up to 18 weeks.
Part 2 of the study: All patients are currently being enrolled under the no escalation schedule for Part 2 of the study. All patients in Part 2 will be treated with 30mg of alemtuzumab (with no escalation period) administered SC (at alternating injection sites) 3 times per week (e.g., Monday, Wednesday, Friday) for up to 18 weeks. Alemtuzumab is to be administered in a supervised medical setting on an outpatient basis for the first three weeks, after which some study centers may allow a home administration option, with one weekly clinic visit. Under the home administration option, alemtuzumab may be administered by the patient or care giver if the patient meets conditions specified in the protocol guidelines for home administration."
1766391|NCT00328211|Dietary Supplement|Bile Acids (Cholic, Ursodeoxycholic, Chenodeoxycholic)|15 mg/kg/day for 18 days
1766392|NCT00328211|Dietary Supplement|Sphingomyelin|1000mg/day for 19 days
1766393|NCT00328211|Drug|Pluronic F-68|"Pluronic F-68 is a detergent and potent inhibitor of cholesterol absorption. Dose = 0.5%-1.0% by weight of the diet."
1766394|NCT00328211|Other|C13 Stable isotope of Cholesterol|Food provided for 3 days and one time dose of 113mg of C13 Cholesterol.
1766395|NCT00328237|Procedure|Cord Blood Transplant|
1766396|NCT00328250|Behavioral|Cognitive behavioral treatment (CBT) delivered over the Internet|CBT delivered over the Internet for insomnia targets maladaptive behaviors and dysfunctional thoughts that perpetuate sleep problems. Treatment includes through educational, behavioral, and cognitive strategies.
1766397|NCT00328263|Dietary Supplement|Lactobacillus acidophilus CL1285 and Lactobacillus casei|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
1766398|NCT00328263|Dietary Supplement|placebo|One bottle daily 2 hours before or after antibiotic administration and for 5 days following the termination of antibiotic regimen.
1766399|NCT00328276|Drug|Sarcosine|
1766400|NCT00328289|Device|transcutaneous muscle stimulation, treadmill|
1766401|NCT00328302|Drug|Candesartan|
1766402|NCT00328302|Drug|Placebo|
1766403|NCT00328666|Behavioral|Iyengar yoga|
1766404|NCT00328666|Behavioral|Enhanced nutritional care classes|
1766405|NCT00328679|Device|in vitro and in vivo allergy testing|Patch Test: food to be tested is suspended in sterile saline, placed on the skin of the back using a Finn Chamber secured with surgical tape and left in place for 48 hours.
1766406|NCT00328692|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
1766407|NCT00328692|Drug|Comparator: Placebo (unspecified)|rolofyline Pbo 30 mg IV QD; 3 days
1766408|NCT00328705|Device|Implantable Cardioverter Defibrillator|
1766409|NCT00328718|Drug|montelukast (5mg QD)|
1766410|NCT00328718|Drug|Salmeterol/Fluticasone propionate Inhalation Powder (50/100mcg BID)|
1766411|NCT00328731|Procedure|Procedure|
1766412|NCT00328744|Behavioral|Standard|18-month standard behavioral weight loss intervention
1766413|NCT00328744|Behavioral|Limited Variety|Two chosen snack foods
1766414|NCT00328757|Behavioral|Regular diet as the first postoperative meal|
1766415|NCT00328770|Drug|Sirolimus|Sirolimus given intravenously or orally to achieve target levels of 12-20ug/l
1766416|NCT00328783|Device|Active Breathing Coordinator (ABC)|The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.
1766417|NCT00328783|Radiation|Radiation Therapy|
1766418|NCT00328796|Procedure|acupuncture in 6 specific points|
1766419|NCT00328796|Drug|lidocaine 10mg/ml|
1766420|NCT00328809|Drug|spironolactone|spironolactone administered to ESRD patients at low dose
1766421|NCT00328822|Drug|Quetiapine|
1766422|NCT00328822|Drug|placebo|
1766423|NCT00328835|Procedure|Brief Elevation of IOP|
1766424|NCT00328848|Behavioral|Behavioral|Group Treatment(patient education, self management support, caregiver support)
1766425|NCT00328848|Behavioral|behavioral|patient education, self management support, caregiver support
1766426|NCT00328861|Drug|Natural Killer (NK) Lymphocytes|Thirty minutes infusion of natural killer (NK) cells 2 days after last dose of chemotherapy.
1766427|NCT00328861|Biological|IL-2|IL-2 720,000 IU/kg/intravenous every 8 hours for up to 5 days.
1766428|NCT00328861|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day intravenous on days -8 and -7.
1766429|NCT00328861|Drug|Fludarabine|Fludarabine 25 mg/m^2 day intravenous on days -6 through -2.
1766430|NCT00328874|Drug|Coenzyme Q10|
1766431|NCT00328887|Genetic|CD40 Gene Transfer|gene transfer, intratumoral administration
1766434|NCT00328913|Drug|5-hydroxytryptophan (food supplement)|
1766435|NCT00328926|Drug|Luveris® 75 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 75 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and estradiol [E2] levels). Total duration will be of 3 treatment cycles.
1766436|NCT00328926|Drug|Luveris® 25 IU|Recombinant human luteinizing hormone (r-hLH, lutropin alfa, Luveris®), 25 IU will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
1766437|NCT00328926|Drug|Placebo|Placebo will be administered subcutaneously once daily. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
1766438|NCT00328926|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Fixed dose of recombinant human follicle stimulating hormone (r-hFSH, follitropin alfa) 75 to 150 IU will be administered subcutaneously for 7 days. After 7 days of treatment, if the subject response will suboptimal, based on follicular growth and serum E2 levels, follitropin alfa dose adjusted to maximal dose of 225 IU. Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
1766439|NCT00328926|Drug|Recombinant human chorionic gonadotropin (r-hCG)|When the follicular response will adequate, ovulation will be triggered by a single 250 microgram subcutaneous injection of recombinant human chorionic gonadotropin (r-hCG, choriogonadotropin alfa). Duration of treatment cycle will be up to 14 days, or maximum of 21 days (if follicular maturation is imminent, based upon follicular growth and E2 levels). Total duration will be of 3 treatment cycles.
1766440|NCT00328939|Drug|ARIXTRA infusion|
1766441|NCT00328939|Drug|Enoxaparine infusion|
1766442|NCT00328965|Drug|Lacidipine|Lacidipine 2, 4, 6mg
1766443|NCT00328978|Drug|Quetiapine|
1766444|NCT00328991|Device|duct tape occlusion therapy|
1766445|NCT00329004|Drug|BMS-690514|Tablets, Oral, up to 300 mg, once daily, up to 24 mos
1766446|NCT00329017|Procedure|Fine needle aspiration|Fine needle aspiration
1766447|NCT00329030|Drug|Autologous transplantation using rituxan/BEAM|Rituxan 375 mg/m2 (Day -19 and Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
1766448|NCT00329030|Drug|Autologous transplantation using Bexxar/BEAM|Bexxar dosimetric dose 5 mCi (Day -19); Bexxar therapy dose 75 cGy TBD (Day -12); BCNU 300 mg/m2 (Day -6); Etoposide (VP-16) 100 mg/m2 twice a day (Days -5 to -2); Cytarabine 100 mg/m2 twice a day (Days -5 to -2); Melphalan 140 mg/m2 (Day -1); Followed by autologous transplantation
1766449|NCT00329043|Drug|LHRH Agonist|Intramuscular injection either monthly for 3 months or in a single 3-month dose.
1766450|NCT00329043|Drug|Sunitinib Malate|25 to 37.5 mg/day once daily for 30 days (= 1 cycle), up to 3 cycles.
1766451|NCT00329043|Procedure|Radical Prostatectomy|Radical prostatectomy after completion of Sunitinib and LHRH agonist.
1766452|NCT00329056|Drug|MitoQ|Two doses will be compared to placebo: 40 or 80 mg of MitoQ once daily for a period of 12 months.
1766453|NCT00329069|Drug|atorvastatin (drug)|
1766454|NCT00329082|Drug|LY2062430|"100mg QW IV for 12 weeks
100mg Q4W IV for 12 weeks
400mg QW IV for 12 weeks
400mg Q4W IV for 12 weeks"
1766455|NCT00329082|Drug|Placebo|5: Placebo QW IV for 12 weeks
1766456|NCT00329095|Drug|travoprost, latanoprost, or bimatoprost|
1766457|NCT00329095|Drug|Additional ocular hypotensive medication|
1766458|NCT00329108|Drug|ziprasidone hydrochloride|Ziprasidone will be initiated at 80 mg/day on Day 1 and titrated to 120 mg/day from Day 3. From Day 7 the dosage may be adjusted on the basis of clinical status between 120 and 160 mg/day.
1766459|NCT00329108|Drug|olanzapine|Olanzapine will be started at 15 mg/day on Day 1 until Day 7. The dosage will then be adjusted on the basis of clinical status between 15 and 20 mg/day.
1766460|NCT00329121|Drug|PEP005|
1766461|NCT00329134|Drug|Administration of quinine sulphate taste-masked pellets|
1766462|NCT00329147|Drug|desvenlafaxine SR|
1766463|NCT00329147|Drug|desipramine|
1766464|NCT00329147|Drug|paroxetine|
1766465|NCT00329160|Drug|Rosuvastatin|2.5-20 mg
1766466|NCT00329160|Drug|HMG CoA inhibitor|3-hydroxy-3-methylglutaryl-coenzyme A
1766467|NCT00329173|Drug|Rosuvastatin|
1766468|NCT00329173|Drug|Atorvastatin|
1766469|NCT00329186|Drug|desvenlafaxine SR|
1766470|NCT00329186|Drug|venlafaxine ER|
1766471|NCT00329199|Behavioral|Attachment-Based Family Therapy|
1766472|NCT00329212|Drug|San Huang Xie Jin Tang|
1766473|NCT00329225|Drug|rosiglitazone|
1766474|NCT00329238|Drug|Dabigatran|Dabigatran 150 mg BID (twice daily)
1766475|NCT00329238|Drug|Warfarin|Warfarin dosed individually to maintain INR 2.0-3.0
1766476|NCT00329251|Biological|Hepatitis A|
1766477|NCT00329251|Biological|Hepatitis B|
1766478|NCT00329251|Biological|Influenza|
1766479|NCT00329251|Biological|Pneumococcal|
1766480|NCT00329251|Biological|Tetanus-diphteria|
1766481|NCT00329251|Biological|Varicella|
1766482|NCT00329251|Biological|Measles-Mumps-Rubella|
1766483|NCT00329264|Drug|Quetiapine fumarate|
1766484|NCT00329277|Procedure|perimetry|
1766485|NCT00329303|Drug|Certolizumab pegol (cimzia®)|
1766486|NCT00329316|Drug|Crinone Gel 8%|
1766487|NCT00329329|Drug|satraplatin and capecitabine|satraplatin and capecitabine dose escalated per the dosing scheme
1766488|NCT00329342|Behavioral|Occupational ergonomic training|Adequate postural habits in activities of daily living
1766489|NCT00329355|Drug|sumatriptan succinate/naproxen sodium|
1766490|NCT00329368|Biological|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously, weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
1766491|NCT00329368|Biological|GPI-0100|3.0mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first treatment cycle, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
1766492|NCT00329368|Drug|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks followed by 2 observation weeks for each cycle.
1766493|NCT00329368|Drug|Interleukin-2|Low dose (7-12 MIU) IL-2 administered subcutaneously three times per week (MWF) for 3 consecutive weeks during the first cycle, 4 consecutive weeks during cycle 2 and additional cycles
1766598|NCT00330148|Drug|melarsoprol 1.8 mg/kg/d, 10d + eflornithine 400 mg/kg/d, 7d|
1766599|NCT00330148|Drug|nifurtimox 15/20 mg/kg/d 10d + eflornithine 400 mg/kg/d 7d|
1766494|NCT00329368|Drug|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (MWF) for 3 consecutive weeks during the first cycle of treatment, then 3.0 MIU administered subcutaneously 3 times per week (MWF) for 4 weeks for cycle 2 and additional cycles.
1766495|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
1766496|NCT00329381|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
1766497|NCT00329394|Drug|ketamine|Evaluate the analgesic effectiveness of the systemic ketamine on the control of pain in the alcohol-dependent patient
1766498|NCT00329407|Drug|Topiramate (Topamax)|Medication Dosing Schedule: Days 1-3 50 mg q PM Days 4-7 50 mg BID Days 8-11 50 mg q AM & 100 mg q PM Days 12-15 100mg BID Days 16-19 100 mg q AM & 150 mg q PM Days 20-23 150 mg BID Days 24-27 150 mg qAM & 200 mg q PM Days 28-70 200 mg BID Days 71-77 150 mg BID Days 78-84 100mg BID Days 85-87 50 mg BID Days 88-91 50 mg qPM
1766499|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
1766500|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
1766501|NCT00329420|Biological|Certolizumab pegol|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 10, 12, 16, 20, 24, 28 and 32 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Certolizumab pegol (CZP) 400 mg at Weeks 0, 2 and 4.
1766502|NCT00329433|Drug|Desirudin (Iprivask™)|Patients who are randomized to the desirudin (study) group will receive 15 mg of subcutaneous desirudin twice a day (at 0900 and 2100). These patients will also receive an injection of normal saline placebo at 1300 so that patients in both groups will receive three injections at the same time points.
1766503|NCT00329433|Drug|Heparin|The patients who are randomized to the Heparin (standard of care) group will receive subcutaneous injections of heparin three times a day (0900, 1300 and 2100).
1766504|NCT00329446|Drug|Quetiapine Fumarate|
1766505|NCT00329446|Drug|Escitalopram oxylate|
1766506|NCT00329459|Drug|sumatriptan succinate/naproxen sodium|
1766507|NCT00329459|Drug|placebo|placebo to match
1766508|NCT00329472|Drug|gemcitabine, cisplatin|
1766509|NCT00329485|Drug|CORvalen (D-Ribose)|
1766510|NCT00329498|Drug|L-Ascorbic Acid|
1766511|NCT00329511|Drug|methyldopa vs. clonidine|Comparison of compliance
1766512|NCT00329511|Drug|clonidine patch|methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
1766513|NCT00329524|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS will initially be targeted to asymmetric cortical activation in one hemisphere, as defined by PET-CT imaging. TMS will then be optimized by identifying the area of maximal tinnitus suppression, within the area of asymmetry, by delivering single 1-Hz pulses of TMS at the MT. The area of maximal tinnitus suppression, as reported by the patient, will then be targeted for treatment with rTMS at 1-Hz frequency, delivering 1800 pulses at 110% MT on each of 5 consecutive treatment days.If no area of maximal tinnitus suppression can be found in the hemisphere initially targeted for treatment based on PET, we will perform the optimization procedure in a homologous region of the opposite cerebral hemisphere to determine if a maximal area of suppression can be found there. Each group will then crossover to sham and active stimulation conditions, respectively, 7 days following the completion of the first treatment session.
1766514|NCT00329537|Drug|Sargramostim (Leukine)|Self-subcutaneous injection
1766515|NCT00329537|Drug|Placebo|Self-subcutaneous injection
1766516|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received Placebo at Weeks 0, 2 and 4.
1766517|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol (CZP) 200 mg at Weeks 0, 2 and 4.
1766518|NCT00329550|Biological|Certolizumab pegol (CZP)|Certolizumab pegol (CZP) 400 mg administered subcutaneously in a liquid formulation at Weeks 8, 12, 16, 20 and 24 relative to the start of the 6-week double-blind main study C87037 (NCT00291668) where subjects received certolizumab pegol 400 mg at Weeks 0, 2 and 4.
1766519|NCT00329563|Drug|Up to 2 liter infusion of cold 4 degree C normal saline|Patients randomized to field cooling will receive up to 2 liters of 4oC normal saline. Control patients will receive standard of care following resuscitation.
1766520|NCT00329576|Biological|Hepatitis B vaccine|
1766521|NCT00329589|Drug|Velcade (bortezomib)|
1766522|NCT00329602|Drug|Placebo|Matching Placebo
1766523|NCT00329602|Drug|Ropinirole|Ropinirole IR 0.25mg/day to 4mg/day for RLS
1766524|NCT00329615|Drug|Insulatard, flexpen|
1766525|NCT00329628|Drug|Rivaroxaban (BAY59-7939)|10 mg OD tablet of rivaroxaban administered for 36 +/- 4 days
1766526|NCT00329628|Drug|Enoxaparin|Syringe of Enoxaparin active substance at a dose of 40 mg administered for 13 +/- 2 days
1766527|NCT00329641|Drug|carboplatin|Given IV
1766528|NCT00329641|Drug|paclitaxel|Given IV
1766529|NCT00329641|Drug|sorafenib tosylate|Given orally
1766530|NCT00329654|Procedure|Phototherapy with the Embar® light therapy or sham irradiation|Phototherapy with the Embar® light therapy or sham irradiation is followed.
1766531|NCT00329667|Device|EPIC|Surgical replacement of a diseased, damaged, or malfunctioning native or prosthetic aortic and/or mitral heart valves
1766600|NCT00330161|Drug|vorinostat|Given orally
1991602|NCT00810888|Drug|recombinant activated factor VII|Participants will receive rFVIIa at 80 mcg/kg (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg).
1766534|NCT00329693|Drug|Norprolac|Placebo
1766535|NCT00329693|Drug|Norprolac|Quinagolide
1766536|NCT00329693|Drug|Norprolac|Quinagolide
1766537|NCT00329693|Drug|Norprolac|Quinagolide
1766538|NCT00329706|Procedure|FDG-PET brain scan|The difference in the two arms' interventions is the time at which the FDG-PET brain scan information is available for the subjects' managing physicians. Experimental arms will have an immediate release of the PET report, while the Active Comparator arms will have a delayed release of 2 years.
1766539|NCT00329719|Drug|sorafenib tosylate|Given PO
1766540|NCT00329719|Drug|temsirolimus|Given IV
1766541|NCT00329719|Procedure|conventional surgery|Undergo surgery
1766542|NCT00329732|Drug|0.5% bupivicaine and 2% lidocaine|The injectors will infiltrate an area of 2cm along the occipital ridge centering around the occipital artery or around the site 1/3 from the mastoid to the inion. If the subject has a bilateral headache or the headache is known to switch sides then the block will be performed bilaterally. If the headache is strictly unilateral, the block will be performed only on the side of the headache
1766543|NCT00329732|Drug|Saline placebo|matching volume of saline (placebo)
1766544|NCT00329745|Biological|Rotarix™|Oral administration, 2 doses
1766545|NCT00329745|Biological|Placebo|Oral administration, 2 doses
1766546|NCT00329758|Drug|rosuvastatin|20 mg oral, during 10 days
1766547|NCT00329758|Drug|Placebo|
1766548|NCT00329771|Other|No intervention: We are testing for the presence of allodynia|We are testing for the presence of abnormal sensation (allodynia) during a migraine attack.
1766549|NCT00329784|Biological|Peanut Consumption Group|Peanut-containing snack. Children are to consume 2 g of peanut protein in three servings per week (total of 6 g) over 3 servings.
1991603|NCT00810888|Drug|placebo|An inactive substance (maximum dose volume 21.3 mL, equivalent to maximum weight of 160 kg)
1766562|NCT00329810|Drug|Aripiprazole|Tablets, oral, 15 mg, once daily, 12 weeks.
1766563|NCT00329823|Drug|Etanercept sc 50mg per week for 12 weeks|
1766564|NCT00329836|Other|There are no interventions in the observational study. The symptom of allodynia was measured.|No intervention. Description of allodynia testing appears elsewhere in this document
1766565|NCT00329849|Biological|Meningococcal ACWY-CRM conjugate vaccine|MenACWY-CRM vaccine was obtained by extemporaneous mixing of the lyophilized MenA component to be resuspended with the liquid MenCWY component. One dose (0.5 mL) was administered by IM injection in the deltoid area of the arm without a BCG scar.
1766566|NCT00329849|Biological|Meningococcal ACWY-PS polysaccharide vaccine|MenACWY-PS vaccine was supplied as a single dose (one vial of vaccine and one vial of diluent). One dose (0.5 mL) of MenACWY-PS vaccine was administered by SC injection in the deltoid area of the arm without a BCG scar.
1766567|NCT00329862|Procedure|Laparoscopic Truncal Vagotomy|
1766568|NCT00329888|Procedure|Endoscopic papillary balloon dilatation|
1766569|NCT00329888|Procedure|Endoscopic sphincterotomy|
1766570|NCT00329901|Biological|Meningococcal ACWY conjugate vaccine (MenACWY-CRM)|
1766571|NCT00329901|Biological|Combined tetanus, reduced diphtheria and acellular pertussis vaccine (Tdap)|
1766572|NCT00329901|Biological|saline placebo|4.5 mg sodium chloride per 0.5 ml dose
1766573|NCT00329914|Drug|Progesterone|Vaginal pessaries, 200 mg/day
1766574|NCT00329914|Drug|Placebo|Placebo pessaries containing peanut oil
1766575|NCT00329927|Biological|Surface Antigen, Inactivated, (Adjuvanted with MF59C.1), form. 2006-07|
1766576|NCT00329940|Drug|Letrozole|
1766577|NCT00329966|Biological|Surface Antigen, Inactivated, Influenza (form.2006-07)|
1766578|NCT00329979|Behavioral|vascular access site|Randomized vascular access site
1766579|NCT00329992|Behavioral|Brief Eclectic Psychotherapy for PTSD|16 weekly sessions (50min) of Brief Eclectic Psychotherapy for PTSD
1766580|NCT00330005|Behavioral|Group Psychotherapy|
1766581|NCT00330018|Drug|Valganciclovir|Valganciclovir
1766582|NCT00330018|Drug|Acyclovir|Acyclovir
1766583|NCT00330044|Drug|Premetrexed (Alimta)|
1766584|NCT00330044|Drug|Carboplatin|
1766585|NCT00330070|Drug|IPL512,602 20 mg once daily|
1766586|NCT00330070|Drug|IPL512,602 Matching Placebo once daily|
1766587|NCT00330083|Biological|ALK Ragweed Tablet|
1766588|NCT00330096|Drug|Hesperidin|
1766589|NCT00330096|Other|Placebo|
1766590|NCT00330109|Procedure|MRS Imaging|Performed on a 3.0 Tesla Philips Intera MRI Unit (Best, Netherlands). Scout views and T2 transverse images are obtained to locate the tumor in conjunction with any previous diagnostic images.
1766591|NCT00330109|Procedure|PET Scanning|Using an Allegro scanner, the patient will be scanned for approximately 20-30 minutes. All emission scan data is processed by a multi-step procedure.
1766592|NCT00330109|Procedure|Diffusion Tensor Imaging|Subjects will be scanned with a 3T Philips Intera MRI scanner for approximately 26 minutes for anatomical and DTI imaging. Total DTI acquisition time will be 6:06 minutes with 40 contiguous axial slices for full brain coverage.
1766593|NCT00330122|Procedure|fore locked plate|
1766594|NCT00330122|Procedure|external radiocarpal fixer|
1766595|NCT00330135|Drug|Sodium hyaluronate|Sodium hyaluronate 2.5 ml - 1 injection
1766596|NCT00330135|Drug|placebo injection|placebo injection - 1 injection
1766597|NCT00330148|Drug|melarsoprol 1.8 mg/kg/d, 10d + nifurtimox 15/20 mg/kg/d, 10d|
1766601|NCT00330161|Other|laboratory biomarker analysis|Correlative studies
1766602|NCT00330174|Drug|Acamprosate|2 333mg tablets three times daily
1766603|NCT00330187|Drug|Bupropion SR|
1766604|NCT00330187|Behavioral|Contingency Management|
1766605|NCT00330200|Drug|ISIS 113715|
1766606|NCT00330213|Behavioral|red wine and cognac consumption|
1766607|NCT00330239|Drug|Paroxetine CR|
1766608|NCT00330252|Drug|Rituximab|Given intravenously on day 1 of every week for eight weeks (or 16 weeks)
1766609|NCT00330252|Drug|Alemtuzumab|Drug: Alemtuzumab Dosage will vary during Phase I of trial: Given intravenously on days 1, 3, and 5 for weeks one and two, on days 1 and 4 for weeks three and four and on day 1 for weeks five through eight. Participants may receive either one eight-week course of treatment or two eight-week courses of treatment (16 weeks).
1766610|NCT00330265|Device|KC-002|Determine the safety and effectiveness of a device (the KC-002 interactive wound dressing) in the promotion of healing in diabetic foot ulcers as compared with a conventional wound therapy regimen for subjects with Type 1 or Type 2 diabetes mellitus.
1766611|NCT00330265|Other|Conventional Wound Therapy|Normal Saline Dressings
1766612|NCT00330278|Drug|Cefazolin|
1766613|NCT00330291|Drug|Xyrem|
1766614|NCT00330304|Drug|Isoniazid|isoniazid 10mg/kg orally, daily, for study period
1766615|NCT00330304|Drug|Cotrimoxazole|Cotrimoxazole given 3 times a week or daily, orally, for study period
1766616|NCT00330304|Drug|isoniazid|Isoniazid, 10mg/kg daily for study period
1766617|NCT00330304|Other|placebo|Placebo tablet identicle in appearance to intervention: isoniazid table
1766618|NCT00330317|Drug|letrozole|2.5mg letrozole once-daily
1766619|NCT00330330|Drug|ISIS 113715|
1766620|NCT00330343|Drug|naloxone|continuous infusion of naloxone administered in escalating dosing from 0.05 mcg/kg/hr to 1.65 mcg/kg/hour
1766621|NCT00330356|Behavioral|Low Salt Diet versus High salt diet|
1766622|NCT00330369|Drug|Darusentan|Darusentan administered orally once daily
1766623|NCT00330369|Drug|Darusentan Placebo|Placebo to match darusentan administered orally once daily
1766624|NCT00330382|Drug|Bowman-Birk inhibitor concentrate|Given orally
1766625|NCT00330382|Other|placebo|Given orally
1766626|NCT00330382|Other|laboratory biomarker analysis|Correlative studies
1766627|NCT00330395|Drug|caspofungin acetate|Duration of Treatment 28 Days
1766628|NCT00330408|Behavioral|GP training|
1766629|NCT00330421|Drug|sorafenib tosylate|Given PO
1766630|NCT00330421|Procedure|therapeutic conventional surgery|Undergo surgery
1766631|NCT00330421|Other|laboratory biomarker analysis|Correlative studies
1766632|NCT00330421|Other|pharmacological study|Correlative studies
1766633|NCT00330421|Procedure|computed tomography|Correlative studies
1766634|NCT00330421|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative studies
1766635|NCT00330434|Drug|Bupropion|
1766636|NCT00330434|Drug|Chlorzoxazone|
1766637|NCT00330434|Drug|Ethanol|
1766638|NCT00330460|Drug|Alendronate|ALN; 70 mg; oral; once weekly
1766639|NCT00330460|Drug|Denosumab|60 mg; SC; every 6 months
1766640|NCT00330473|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 9 months ( if patient chooses Human Insulin Inhalation Powder option)
1766641|NCT00330473|Drug|Insulin|patient specific dose, oral or injectable, before meals and/or as needed, 9 months. ( patients and investigator determine standard option therapy)
1766642|NCT00330486|Drug|Acamprosate|
1766643|NCT00330499|Drug|Cisplatin|Weekly Cisplatin 35mg/m2 x 6 doses, IV administration
1766644|NCT00330499|Radiation|External beam radiation treatment|64Gy reference dose in 32 fractions over 6.5 weeks
1766645|NCT00330525|Drug|sibutramine|
1766650|NCT00330564|Drug|SU011248|50 mg/day orally for 4 weeks, no treatment for 2 weeks (6 weeks = 1 cycle).
1766651|NCT00330577|Drug|timolol maleate 0.5%|
1766652|NCT00330577|Drug|latanoprost/timolol fixed combination|
1766653|NCT00330577|Drug|placebo (artificial tears)|
1766654|NCT00330603|Procedure|Serial exhaled breath collections|collect breath for 5 minutes on 8 occasions
1766655|NCT00330616|Drug|323U66 SR|
1766656|NCT00330629|Behavioral|Standard Behavioral Treatment|Participants in this condition will receive the standard behavioral treatment (SBT) described above. Food tastings will be held at the sessions and will focus on fat modified food products.
1766657|NCT00330629|Behavioral|SBT+LOV|The focus will be on the elimination of meat products as a means to reduce fat intake.
1766658|NCT00330655|Drug|memantine|
1766659|NCT00330668|Drug|rh IGF-1 (mecasermin)|Patients from untreated arm for prior study MS301 (NCT00125164) were randomized to a dose of either 80 or 120 mcg/kg twice daily. For patients receiving active treatment in previous study MS 301 (NCT00125164), they started on a dose of 80 or 120 mcg/kg twice daily based on the dose reached at end of the previous study. Following a protocol amendment in May 2009, all patients were switched to once daily doses of 160 µg/kg, escalated to a targeted maximum dose of 240 µg/kg.
1766660|NCT00330681|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
1991609|NCT00802464|Biological|Herpes zoster vaccine GSK1437173A|2 vaccinations at Months 0 and 2 with GSK1437173A (different formulations)
1991610|NCT00802464|Biological|Placebo|2 vaccinations at Months 0 and 2 with placebo
1991612|NCT00788697|Drug|SonoVue-enhanced ultrasound|Contrast-enhanced ultrasound (CE-US) examination of the target lesion. Drug: SonoVue® Dose of 2.4 mL bolus injection administered intravenously. Maximum of 2 injections (4.8 mL)
1991613|NCT00788697|Other|Unenhanced ultrasound|-Unenhanced: Gray scale and Doppler (color or power imaging) ultrasound investigations of the target lesion. Drug: None
1766661|NCT00330681|Drug|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
1766662|NCT00330694|Other|ParkNet|Development of a network of dedicated physiotherapist with specific expertise in Parkinson's Disease and structured referrals to these ParkNet therapists by neurologists.
1766663|NCT00330694|Other|Usual Care|No altered organisation of physiotherapy care in Parkinson's Disease
1766664|NCT00330707|Drug|Bacillus Calmette Guerin and interferon alpha|
1766665|NCT00330720|Device|Emergency Response System (Device)|
1766666|NCT00330733|Drug|Salsalate|Salsalate therapy
1766667|NCT00330733|Drug|Placebo|Matching placebo
1766668|NCT00330746|Drug|cetuximab|400 mg/m2 first dose then weekly at 250 mg/m2 until disease progression
1766669|NCT00330746|Drug|gemcitabine|1200 mg/m2 days 1 and 8 every 3 weeks for a maximum of 6 cycles
1766670|NCT00330746|Drug|gemcitabine|1200 mg/m2 IV days 1 and 8 every 3 weeks for a maximum of 6 cycles
1766671|NCT00330746|Drug|cetuximab|400 mg/m2 first dose followed by 250 mg/m2 weekly
1766672|NCT00330759|Biological|Denosumab|120 milligrams by subcutaneous injection every 4 weeks
1766673|NCT00330759|Drug|Zoledronic Acid|4 milligrams intravenous Zoledronic Acid over minimum 15 minutes every 4 weeks
1766674|NCT00330772|Drug|Aspirin|
1766675|NCT00330772|Drug|Clopidogrel|
1766676|NCT00330785|Drug|Amlodipine/Atorvastatin|
1766677|NCT00330798|Drug|nepafenac 0.1%|Nepafenac 0.1% randomly assigned to one eye, with ketorolac 0.4% in the fellow eye for contralateral post-surgical use.
1766678|NCT00330798|Other|ketorolac 0.4%|Keterolac 0.4% randomly assigned to one eye, with nepafenac 0.1% in the fellow eye for contralateral post-surgical use.
1766679|NCT00330824|Drug|antibiotic/steroid combination|1gtt, 4x/d, 15 days
1766680|NCT00330824|Drug|moxifloxacin/dexamethasone|1gtt, 4x/days, 15 days
1766681|NCT00330850|Drug|PRO-513|
1956820|NCT02675634|Device|Coloplast Test A|Test A is a new 1-piece ostomy appliance developed by Coloplast A/S
1956821|NCT02675634|Device|Coloplast Test B|Test B is a new 1-piece ostomy appliance developed by Coloplast A/S
1956822|NCT02675634|Device|Subjects own product|The comparator product is the ostomy appliance product that the subject normally uses. This could include products like SenSura , SenSura Mio, Confidence Natural, Moderma Flex and many more. data from the subject own product will be pooled so they appear as one comparator group.
1766689|NCT00330876|Drug|Pitavastatin|
1766690|NCT00330902|Drug|sulfadoxine-pyrimethamine (SP) plus artesunate (AS)|sulfadoxine-pyrimethamine (SP) plus three daily doses of artesunate (AS)
1766691|NCT00330902|Drug|primaquine (PQ) plus SP+AS|single dose of primaquine on day 4
1766692|NCT00330915|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 3 cycles
1766693|NCT00330928|Device|Near Infrared Spectroscopy (NIRS) Imaging|Near infrared spectroscopic imaging of the coronary artery with an intravascular spectroscopy catheter.
1766694|NCT00330928|Device|intravascular ultrasound (IVUS)|Ultrasound coronary catheter is positioned on a guidewire that has been placed in the coronary artery.Ultrasound imaging provides structural information about the vessel wall and blockages contained. It takes approximately 5 minutes to prepare, position, and to collect data with the catheter.
1766695|NCT00330941|Drug|lidocaine|
1766696|NCT00330967|Drug|20% Intralipid|lipid infusion
1766697|NCT00330980|Drug|40 mg Pravastatin (Pravachol)|Participants will receive 40 mg of pravastatin for 6 months.
1766698|NCT00330980|Drug|20 mg Simvastatin|Participants will receive 20 mg of simvastatin for 6 months.
1766699|NCT00330980|Drug|Placebo|Participants will receive placebo for 6 months.
1766700|NCT00330993|Drug|mifepristone, misoprostol|
1766701|NCT00331006|Drug|Rituximab|Rituximab by slow intravenous infusion; for participants greater than or equal to 10 kg, 375 mg per m^2 BSA weekly for 4 weeks; for participants less than 10 kg, 12.5 mg/kg weekly for 4 weeks
1766702|NCT00331032|Drug|3% w/w SPL7013 Gel|Twice-daily vaginal application of 3.5 g of VivaGel™ (Carbopol®-based gel with 3% w/w SPL7013) in single use pre-filled applicators.
1766703|NCT00331032|Drug|Placebo|Placebo gel (Carbopol®-based formulation alone) in single use pre-filled applicators.
1766704|NCT00331045|Drug|alvimopan|0.25 mg/day
1766705|NCT00331045|Drug|Placebo|
1766706|NCT00331045|Drug|Alvimopan 0.5 mg/day|
1766707|NCT00331045|Drug|Alvimopan 1 mg/day|
1766708|NCT00331058|Procedure|Bronchoscopsy|Healthy and Asthmatic Volunteers
1766709|NCT00331058|Procedure|Prednisolone|Asthmatic Volunteers
1766710|NCT00331071|Drug|Monophasic or triphasic Oral contraceptive tablet|fourth week is patch free
1766711|NCT00331071|Drug|Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE|worn for 1 week and replaced for 3 consecutive weeks
1766712|NCT00331084|Drug|antibiotic/steroid combination|1 gtt, 4x/day, 15 days
1766713|NCT00331084|Drug|moxifloxacin / dexamethasone|1 gtt 4x/day, 15 days
1766714|NCT00331097|Drug|docetaxel|35 mg/m2 intravenously on days 1, 8, and 15 every 28 days
1766715|NCT00331097|Drug|cyclophosphamide|600 mg/m2 intravenously days 1, 8 every 28 days
1766716|NCT00331097|Drug|methotrexate|40 mg/m2 intravenously days 1 and 8 every 28 days
1766717|NCT00331097|Drug|5-fluorouracil|600 mg/m2 intravenously days 1 and 8 every 28 days
1766718|NCT00331110|Device|Laterally-Wedged Insole with Ankle Strapping|
1766719|NCT00331110|Device|Laterally-Weged Insole|
1766720|NCT00331123|Drug|Testosterone Transdermal System|testosterone patch, 300mcg/day, changed every 3-4 days for up to 52 weeks
1766721|NCT00331123|Drug|Placebo|placebo patch,changed every 3-4 days for 24 weeks during double blind phase
1766722|NCT00331136|Drug|Pyronaridine-Artesunate|once a day for 3 days
1766725|NCT00331162|Drug|Alemtuzumab|30 mg/100ml NS intraoperatively. Start after dexamethasone administration and prior to reperfusion of the allograft. Infuse over a minimum of 2 hours.
1766726|NCT00331162|Drug|Anti-Thymocyte Globulin|"1.5 mg/kg per dose through a central line intraoperatively and on POD# 2 and 4, then continue on alternate days until a therapeutic tacrolimus(or cyclosporine) level is achieved, or until the SCr < 3-4 mg/dL.
Give first dose over 6 hours, subsequent doses over 4 hours.
Premedication to be given with the first 3 doses:
Tylenol 650mg PO/PR Benadryl 25-50mg PO/IV Daily scheduled corticosteroid dose or other corticosteroid as deemed appropriate.
Hold infusion if temperature > 100.5ºF; Adjust dose for low WBC or Plt count Peripheral Thymoglobulin administration: Prepare dose in 500cc NS; Add heparin 1,000 units and hydrocortisone 20mg to the bag; Infuse over a minimum of 6 hours"
1766727|NCT00331175|Drug|Peptide YY3-36|
1766728|NCT00307944|Drug|Pantoprazole|
1766729|NCT00307957|Device|Pillar Palatal Implants|
1766730|NCT00307970|Drug|HFA FP MDI|
1766731|NCT00307970|Device|conventional chamber/mask; anti-static chamber/mask|
1766732|NCT00307996|Drug|Coenzyme Q10 (drug)|
1766733|NCT00308009|Procedure|Vaginal Repair for prolapse, TVT procedure|"TVT at the time of Vaginal Repair
TVT 3 months after Vaginal Repair"
1766734|NCT00308009|Procedure|TVT and Prolapse surgery|"TVT at the time of Prolapse surgery
TVT 3 months after Prolapse Surgery"
1766735|NCT00308022|Device|High Frequency Percussive Ventilation|
1766736|NCT00308048|Drug|Pegylated Interferon alfa 2b and ribavirin|
1766737|NCT00308061|Biological|FMP1/AS02A|FMP1 antigen contained 62.5 ug of lyophilized protein with 3.1 percent lactose as cryoprotectant. It's reconstituted in approx. 600 uL AS02A adjuvant manufactured by GSK. AS02A contains 50 ug MPL and 50ug QS21, 250uL of SB62 (oil/water emulsion) in phosphate buffered saline (PBS) per volume of 0.5 mL. All AS02A vials contained 0.65 to 0.75 mL of liquid.
1766738|NCT00308061|Biological|Imovax Rabies Vaccine|Sterile, stable, freeze-dried suspension of rabies virus prepared from the strain PM-1503-3M, obtained from the Wistar Inst. in Philadelphia. Each 1 mL dose of vaccine contained 100 mg of human albumin, <150g of neomycin sulfate, and >2.5 IU of rabies antigen.
1766739|NCT00308074|Drug|Aripiprazole|open-label, flexible-dosing
1766740|NCT00308087|Drug|Sargramostim (Leukine)|Sargramostim 250 μg, administered subcutaneously (SC) 3 times weekly for 8 weeks, beginning at least 1 hour before the first dose of rituximab
1766741|NCT00308087|Drug|Rituximab|Four doses of rituximab 375 mg/m2, administered intravenously (IV) once weekly for 4 weeks
1766742|NCT00308100|Drug|Hydroxyethylstarch 130/0.4|HES 130/0.4, administered intra- and perioperatively, max. daily dose: 33ml/kg BW; if needed, additionally albumin is administered (ratio crystalloid to colloid= 1:1)
1766743|NCT00308100|Drug|5% Albumin|5% albumin, administered intra- and perioperatively
1766744|NCT00308113|Drug|Prednisone|Prednisone 0/75 mg/kg/day.
1766745|NCT00308113|Dietary Supplement|Coenzyme Q10|serum levels of greater or equal to 2.5 micrograms/mL.
1766746|NCT00308126|Drug|Hydroxyethyl Starch 130/0.4 (Voluven)|
1766747|NCT00308139|Drug|exenatide, long acting release|
1766748|NCT00308139|Drug|exenatide|
1766749|NCT00308152|Drug|Infusion of 1 litre of normal saline before colonoscopy|Prehydration with normal saline
1766750|NCT00308165|Procedure|Convection-Enhanced Delivery|microinfusion pumps to deliver chemotherapy directly into brain tumors
1766751|NCT00308165|Drug|Topotecan|chemotherapeutic drug for the treatment of brain tumors
1766752|NCT00308178|Drug|Abraxane|Following 4 cycles (8 weeks) of adjuvant chemotherapy (adriamycin and cytoxan), abraxane will be give every 2 weeks for 4 cycles(8 weeks)
1766753|NCT00308191|Drug|Formoterol Fumarate|
1766754|NCT00308191|Drug|Tiotropium Bromide|
1766755|NCT00308204|Drug|Raptiva (efalizumab)|
1766756|NCT00308230|Procedure|Six minute walk test|
1766757|NCT00308230|Behavioral|Minnesota Living with Heart Failure Questionnaire|
1766758|NCT00308243|Drug|Sodium Pyruvate in 0.9% Sodium Chloride Solution|
1766759|NCT00308256|Behavioral|nurse-counselling|Phone calls performed by nurse 15 days after each monthly visit
1766760|NCT00308269|Drug|Vintafolide IV Bolus|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
1766761|NCT00308269|Drug|Vintafolide IV Infusion|Vintafolide is a folic acid desacetylvinblastine hydrazide conjugate
1766762|NCT00308282|Drug|LY2127399|30 mg, 60 mg or 160 mg, IV (in the vein)in weeks 0, 3 and 6. Treatment duration: 6 weeks.
1766763|NCT00308282|Drug|Placebo|IV (in vein) in weeks 0,3 and 6. Treatment duration: 6 weeks.
1766764|NCT00308295|Drug|Fish oil capsules|
1766765|NCT00308295|Drug|matched placebo capsules|
1766766|NCT00308308|Drug|Technosphere Insulin|Inhalation, 15U/30U
1766767|NCT00308308|Drug|Active comparator|sc injectable insulin
1766768|NCT00308321|Drug|long term tapering of prednisolone|60mg/m2/day (0-4 weeks); 60mg/m2 alternate days (5-6 weeks); 50mg/m2 alternate days (week 7-8); 40mg/m2 alternate days (week 9-10); 30mg/m2 alternate days (week 11-12); 20mg/m2 alternate days (week 13-14); 10mg/m2 alternate days (week 15-16)
1766769|NCT00308321|Drug|standard prednisolone treatment|60mg/m2/day week 0-4; 40mg/m2 on alternate days week 5-8
1766770|NCT00308334|Drug|Domperidone|10 mg po TID X 14 days
1766771|NCT00308334|Drug|Placebo- Sugar pill|placebo po TID x 14 days
1766772|NCT00308347|Drug|MK0954, losartan / Duration of Treatment: mean 3.4 years|
1766773|NCT00308347|Drug|Placebo / Duration of Treatment: mean 3.4 years|
1766774|NCT00308360|Drug|Risperidone, divalproex|
1766775|NCT00308373|Drug|Metformin vs Thiazolidinedione (Pioglitazone)|
1766776|NCT00308386|Behavioral|Nurse Case Management intervention|Intervention is meeting with nurse case managers
1766777|NCT00313768|Drug|paclitaxel + carboplatin + bevacizumab|paclitaxel 200 mg/m2 intravenously Day 1 of each 21 day cycle x 6 cycles
1766778|NCT00313768|Drug|carboplatin + paclitaxel + bevacizumab + PF-3512676|carboplatin AUC 6 intravenously on Day 1 of each 21 day cycle x 6 cycles
1766779|NCT00313781|Drug|CP-751,871|CP-750,871 is administered intravenously at a dose of 20 mg/kg on day 1 of each 21-day cycle (for patient convenience and logistical management, the dose of CP-751,871 may be deferred up to 7 days).
1766780|NCT00313781|Drug|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
1766781|NCT00313781|Drug|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
1766977|NCT00332813|Behavioral|HIV Risk Behavior Intervention|
1766782|NCT00313781|Drug|docetaxel|Docetaxel is administered IV on day 1 of each 21-day cycle, at a dose of 75 mg/m2.
1766783|NCT00313781|Drug|prednisone|Prednisone is administered at a dose of 5 mg twice daily.
1766784|NCT00313794|Drug|CP-675,206|15 mg/kg IV q 3 months for 4 cycles in the absence of disease progression or unacceptable toxicity.
1766785|NCT00313807|Drug|Amino Acid|7% amino acid infusion
1766786|NCT00313807|Drug|Placebo|0.9% Saline Infusion
1766787|NCT00313820|Drug|Pregabalin|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
1766788|NCT00313820|Drug|Placebo|Eligible subjects with post-stroke central pain will be randomized to receive double blinded treatment using pregabalin or matched placebo. The effects of pregabalin as compared to placebo on pain pain symptoms will be compared over the 13 week clinical trial. At baseline following pain ratings and clinical measures, subjects randomized to pregabalin receive instructions to take 75mg twice a day for 7days. The dosing of pregabalin or matching placebo will be titrated over the first 4 weeks (based on tolerability and pain scores). (Range 150-600mg) After the 4th week, the dose of medication will be maintained until week 12 (when tapering of medication begins) Ratings of Pain severity, review of pain/sleep diaries as well as medication tolerance occur bi-weekly throughout the study. Tapering off med occurs from week 12-13.
1766789|NCT00324532|Drug|ProBactrix|
1766790|NCT00324545|Behavioral|Medium-intensity Minimally-directive Counseling|
1766791|NCT00324558|Drug|Bemiparin|subcutaneous administration (sc) of Bemiparin (3,500 UI/day) for 26 weeks, starting on the first day of chemotherapy (CT)
1766792|NCT00324571|Drug|Sevelamer hydrochloride|
1766793|NCT00324571|Drug|Calcium-based phosphate binder|
1766794|NCT00324584|Device|Telemonitoring of glucose values using GlucoNet device|
1766795|NCT00324597|Drug|gemcitabine hydrochloride|
1766796|NCT00324597|Drug|motesanib diphosphate|
1766797|NCT00324597|Other|pharmacological study|
1766798|NCT00324610|Drug|capecitabine|
1766799|NCT00324623|Biological|Melan-A VLP vaccine, IMP321 adjuvant|
1766800|NCT00324623|Biological|adoptive immunotherapy|
1766801|NCT00324623|Biological|therapeutic autologous lymphocytes|
1766802|NCT00324623|Drug|cyclophosphamide|
1766803|NCT00324623|Drug|fludarabine phosphate|
1766804|NCT00324649|Drug|Truvada|Truvada once daily with continuation of the current NNRTI or PI at randomization.
1766805|NCT00324649|Drug|Zidovudine/lamivudine|Continuation of the zidovudine + lamivudine containing regimen plus the current NNRTI or PI at randomization.
1766806|NCT00324662|Device|Implantable cardioverter-defibrillator|
1766807|NCT00324675|Drug|Rosiglitazone|4 mg tablets, bid, 12 months
1766808|NCT00324675|Drug|Placebo|2 tablets per day
1766809|NCT00324688|Drug|Viread|
1766810|NCT00324701|Behavioral|Telepsychology|therapy done at patients house
1766811|NCT00324701|Behavioral|Face-to-face therapy|therapy delivered at the VAMC
1766812|NCT00324714|Drug|risedronate sodium|
1766813|NCT00324714|Other|diagnostic laboratory biomarker analysis|
1766814|NCT00324727|Drug|melphalan|Given throug isolated hepatic artery infusion
1766815|NCT00324727|Drug|regional chemotherapy|Patients receive the best alternative therapy
1766816|NCT00324727|Drug|systemic chemotherapy|Patients receive the best alternative therapy
1766817|NCT00324727|Procedure|hepatic artery embolization|Patients receive the best alternative therapy
1766818|NCT00324740|Drug|vorinostat|Given orally
1766819|NCT00324740|Drug|isotretinoin|Given orally
1766822|NCT00324766|Drug|levosimendan|1 h infusion, 0.2 microgs/kg/min, 24 h infusion,0.1 microgs/kg/min
1766823|NCT00324766|Drug|placebo,|24 h, infusion
1766824|NCT00324779|Biological|rituximab|
1766825|NCT00324792|Drug|intensive insulin therapy|
1766826|NCT00324805|Biological|Bevacizumab|Given IV
1766827|NCT00324805|Drug|Cisplatin|Given IV
1766828|NCT00324805|Drug|Docetaxel|Given IV
1766829|NCT00324805|Drug|Gemcitabine Hydrochloride|Given IV
1766830|NCT00324805|Other|Laboratory Biomarker Analysis|Correlative studies
1766831|NCT00324805|Drug|Pemetrexed Disodium|Given IV
1766832|NCT00324805|Other|Questionnaire Administration|Ancillary studies
1766833|NCT00324805|Drug|Vinorelbine Tartrate|Given IV
1766834|NCT00324818|Drug|metronidazole and azithromycin|
1766835|NCT00324831|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
1766836|NCT00324831|Drug|cyclophosphamide|
1766837|NCT00324831|Drug|doxorubicin hydrochloride|
1766838|NCT00324831|Drug|prednisone|
1766839|NCT00324831|Drug|rituximab|
1766840|NCT00324831|Drug|sargramostim|
1766841|NCT00324831|Drug|vincristine|
1766842|NCT00324831|Procedure|Intervention/procedure|
1766843|NCT00324831|Procedure|antibody therapy|
1766844|NCT00324831|Procedure|biological therapy|
1766845|NCT00324831|Procedure|chemotherapy|
1766846|NCT00324831|Procedure|colony-stimulating factor therapy|
1766847|NCT00324831|Procedure|cytokine therapy|
1766848|NCT00324831|Procedure|monoclonal antibody therapy|
1766849|NCT00324831|Procedure|non-specific immune-modulator therapy|
1766850|NCT00324831|Procedure|therapeutic procedure|
1766851|NCT00324831|Procedure|tumor cell derivative vaccine|
1766852|NCT00324831|Procedure|vaccine therapy|
1766853|NCT00324857|Behavioral|Decision Aid Video|"The research interventionist will show the participant the Dartmouth Knee OA Decision Aid video entitled Treatment Choices for Knee Osteoarthritis. The video gives a detailed explanation of 1) the damage to the knee joint caused by OA; 2) treatment options including lifestyle changes, medications, injections, complementary therapy, and surgery; 3) the risks, benefits, and known efficacy of each treatment option."
1766854|NCT00324857|Behavioral|Motivational Interviewing|The research intervention will conduct the fact-to-face MI session with the participant. The MI session will do the following things: 1) Assessing Readiness, Importance, and Confidence; 2) Eliciting Barriers, Concerns and Positive Motivational; 3) Summarizing Pros and Cons; 4) Assess Patient Values and Goals; 5) Provide a Menu of Options.
1766855|NCT00324857|Behavioral|MI plus Decision aid|Patient viewed the video and then underwent MI.
1766856|NCT00324857|Other|Attention control|patients received a booklet.
1766857|NCT00324870|Drug|vorinostat|Given orally
1766858|NCT00324870|Drug|bevacizumab|Given IV
1766861|NCT00324909|Drug|Hyperbaric Oxygen Therapy|
1766862|NCT00324922|Drug|trimethoprim-sulfamethoxazole|trimethoprim/sulfamethoxazole 320/1600 mg po bid
1766863|NCT00324922|Drug|vancomycin|1g iv bid
1766864|NCT00324948|Drug|Topical alprostadil (PGE-1)|
1766865|NCT00324961|Drug|adefovir dipivoxil tablets|adefovir dipivoxil once daily 10 mg orally
1766866|NCT00324974|Drug|Lansoprazole microgranules suspension|"Lansoprazole microgranules 0.2-0.3 mg/kg/day suspension, orally, once daily for up to 28 days for infants less than 10 weeks;
Lansoprazole microgranules 1.0-1.5 mg/kg/day suspension, orally, once daily for up to 28 days for infants greater than 10 weeks."
1766867|NCT00324974|Drug|Placebo|Lansoprazole placebo-matching suspension, orally, once daily for up to 28 days.
1766868|NCT00324987|Biological|Bevacizumab|Given IV
1766869|NCT00324987|Drug|Imatinib Mesylate|Given PO
1766870|NCT00324987|Other|Laboratory Biomarker Analysis|Correlative studies
1766871|NCT00324987|Other|Pharmacological Study|Correlative studies
1766872|NCT00325000|Behavioral|Interpersonal Psychotherapy|
1766873|NCT00325000|Drug|sertraline or amitriptyline|
1766874|NCT00325013|Drug|Docosahexaenoic Acid (DHA)|800mg twice a day for 1 year
1766875|NCT00325026|Drug|Misoprostol|
1766876|NCT00325026|Device|Foley bulb|
1766877|NCT00325039|Procedure|retropubic mid-urethral sling (TVT)|This trial is a comparison of two types of mid-urethral slings. The retropubic mid-urethral mesh sling is used for treatment of stress incontinence; this procedure was less invasive than the fascial sling procedures that were reference standards at the start of the study. Specifically, a synthetic tape is passed transvaginally at the midurethral level through the retropubic space.
1766878|NCT00325039|Procedure|transobturator mid-urethral sling (TVT-O and the Monarc)|This trial is a comparison of two types of mid-urethral slings. The transobturator mid-urethral sling is used for treatment of stress incontinence; this procedure was developed to minimize the potential for bladder and bowel injuries associated with the retropubic sling, since the sling is passed through the obturator canal, avoiding the pelvic organs in the retropubic space.
1766879|NCT00325078|Drug|Infliximab|
1766880|NCT00325104|Procedure|Parathyroid hormone testing|
1766881|NCT00325104|Procedure|Serum calcium testing|
1766882|NCT00325117|Drug|Vildagliptin|
1766883|NCT00325130|Biological|Comparator: Quadrivalent Human Papillomavirus (HPV) vaccine|"Quadrivalent HPV vaccine was provided by the SPONSOR in single-dose vials containing a volume of 0.75 mL. The vaccine was administered as a
0.5-mL intramuscular dose at Day 1, Month 2, and Month 6."
1766884|NCT00325130|Biological|Comparator: Menactra™ (Concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Day 1
1766885|NCT00325130|Biological|Comparator: Adacel™ (Concomitant)|a single administration of 0.5 mL intramuscular injection administered in a limb opposite that of quadrivalent HPV injection at Day 1
1766886|NCT00325130|Biological|Comparator: Menactra™ (Non-concomitant)|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
1766887|NCT00325130|Biological|Comparator: Adacel™|A single administration of 0.5 mL intramuscular injection in a limb opposite that of quadrivalent HPV injection at Month 1
1766888|NCT00325143|Biological|DTPa-HBV-IPV/Hib|1 intramuscular injection (3rd study vaccine dose)
1766889|NCT00325143|Biological|DTPa-IPV/Hib vaccine|3 intramuscular injections (1st, 2nd and 4th vaccine dose)
1766890|NCT00325156|Biological|GSK Biologicals' combined DTPa-IPV/Hib vaccine|4 intramuscular injections
1766891|NCT00325169|Drug|Tiotropium + SERETIDE 50/500|
1766892|NCT00325182|Drug|Levetiracetam|
1766893|NCT00325182|Other|Historical controls|
1766894|NCT00325195|Other|placebo|placebo by intravenous infusion every 2 weeks
1766895|NCT00325195|Biological|pegloticase|8 mg pegloticase by intravenous infusion
1766896|NCT00325208|Device|partial-vacuum milk bottle|
1766897|NCT00325208|Device|anti-vacuum milk bottle|
1766898|NCT00325221|Device|HM on|Home Monitoring activated after implantation
1766899|NCT00325221|Device|HM Off|Home Monitoring activated 9 months after implantation
1766900|NCT00325234|Drug|Pemetrexed|600 mg/m^2, administered intravenously (IV) every 21 days until disease progression or unacceptable toxicity.
1766901|NCT00325234|Drug|Carboplatin|AUC 5 mg*min/mL, administered IV every 21 days until disease progression or unacceptable toxicity.
1766902|NCT00325234|Drug|Gemcitabine|1200 mg/m^2 gemcitabine, administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
1766903|NCT00325234|Drug|Vinorelbine|30 mg/m^2 vinorelbine administered IV on day 1 and day 8 every 21 days until disease progression or unacceptable toxicity.
1766904|NCT00325247|Drug|ZINC|
1766905|NCT00325260|Biological|Influvac; subunit influenza vaccine|
1766906|NCT00325273|Dietary Supplement|Lactobacillus rhamnosus GG|use Lactobacillus rhamnosus GG in pregnant women from gestational 26 weeks till newborn 6 months
1766978|NCT00332826|Drug|Technosphere Insulin|
1767048|NCT00333294|Procedure|Radiation therapy|
1766908|NCT00325299|Drug|Magnesium|
1766909|NCT00325312|Drug|carbon dioxide, subcutaneous application|
1766910|NCT00325325|Drug|everolimus and tacrolimus|
1766911|NCT00325338|Biological|Ragweed MATAMPL|
1766912|NCT00325351|Drug|Sagopilone (ZK 219477) + carboplatin|Chemotherapy for recurrent ovarian cancer
1766913|NCT00325364|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 months
1766914|NCT00325364|Drug|Injectable insulin|patient specific dose, injectable, before meals, 24 months
1766915|NCT00325377|Procedure|MME Procedure|
1766916|NCT00325390|Drug|clopidogrel (SR25990C)|
1766917|NCT00325403|Drug|Oral treprostinil (UT-15C) Sustained Release Tablets|Sustained release oral tablet, twice daily
1766918|NCT00325403|Other|Placebo|Placebo oral tablet twice daily
1766919|NCT00325416|Drug|melphalan|(Days -4,-3,-2) 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2)
1766920|NCT00325416|Drug|topotecan (TPT)|"Phase I Dose Escalation: Level 1 - 20 mg/m^2; Level 2 - 30 mg/m^2; Level 4 - 54 mg/m^2; Level 5 - 72 mg/m^2; Level 6 - 96 mg/m^2; Level 7 - 127.8 mg/m^2; Level 8 - 170.1 mg/m^2
Phase II: Treatment at maximum tolerated dose (MTD)"
1766921|NCT00325416|Procedure|Autologous Stem Cell Rescue|Day 0
1766922|NCT00325429|Drug|Vildagliptin|
1766923|NCT00325442|Drug|Oral treprostinil (UT-15C) sustained release tablets|UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
1766924|NCT00325442|Drug|Placebo|Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
1766925|NCT00325455|Drug|MK0859|
1766926|NCT00331188|Drug|Sanvar® (vapreotide)|
1766927|NCT00331201|Drug|SAFEstart|
1766928|NCT00331214|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day), patch changed twice a week for six months
1766929|NCT00331214|Drug|placebo patch|placebo patch replaced every 3-4 days for 6 months
1766930|NCT00331227|Drug|Isotonix OPC-3 (flavonoid supplement)|
1766931|NCT00331240|Drug|travoprost/timolol fixed combination|
1766932|NCT00331240|Drug|placebo (artificial tears)|
1766933|NCT00331253|Procedure|Indocyanine Green-Mediated Photothrombosis|
1766934|NCT00331279|Drug|Oral Cinnamon Extract|A purified aqueous abstract of cinnamon in a 500mg tablet will be taken by each patient before lunch and dinner, making a total of one gram per day for eight weeks.
1766935|NCT00331279|Drug|Placebo|Placebo pills in likeness of the cinnamon extract
1766936|NCT00331305|Behavioral|Supervised Exercise|
1766937|NCT00331305|Behavioral|Home-Based Exercise|
1766938|NCT00331305|Drug|Sertraline (Zoloft)|
1766939|NCT00331305|Drug|Placebo Pill|
1766943|NCT00331370|Behavioral|GP training and Health Education|
1766946|NCT00331422|Drug|carboplatin|Carboplatin dose (milligrams (mg)) - Target Area Under the Curve (AUC) 6 x (Glomerular Filtration Rate+25) - Calvert Formula, given intravenously (IV) for 30 minutes.
1766947|NCT00331422|Drug|paclitaxel|Paclitaxel dose = 175 milligrams per meter squared (mg/m2) over 3 hours.
1766948|NCT00331422|Procedure|cytoreductive surgery|Surgery - tumor specimen collected for extreme drug resistant assay (EDR) and A1 assays for analysis
1766949|NCT00331435|Procedure|Ocular photodynamic therapy with verteporfin|Ocular photodynamic therapy with 6 mg per meter squar of body sarface of verteporfin with PDT lazer application for 83 seconds
1766950|NCT00331474|Biological|BCG delayed|early (birth) and delayed (14 weeks) intradermal BCG vaccination
1766951|NCT00331487|Drug|Pioglitazone|Pioglitazone 30 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to pioglitazone 45 mg, capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks
1766952|NCT00331487|Drug|Rosiglitazone|Rosiglitazone 4 mg capsules, orally, once daily and placebo-matching capsules, orally, once daily for up to 12 weeks; increasing to rosiglitazone 4 mg, capsules, orally, twice daily for up to 12 weeks
1766953|NCT00331500|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
1766954|NCT00331500|Drug|Olopatadine Hydrochloride Ophthalmic Solution Vehicle|Inactive ingredients used as a placebo comparator
1766955|NCT00331513|Drug|vorinostat|Given orally
1766956|NCT00331513|Drug|idarubicin|Given IV
1766957|NCT00331513|Other|laboratory biomarker analysis|Correlative studies
1766958|NCT00331513|Other|pharmacological study|Correlative studies
1766959|NCT00331526|Biological|aldesleukin|
1766960|NCT00331526|Biological|therapeutic autologous lymphocytes|
1766961|NCT00331526|Procedure|adjuvant therapy|
1766962|NCT00331526|Procedure|conventional surgery|
1766963|NCT00331539|Device|Cochlear Implant|
1766964|NCT00331552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
1766965|NCT00331552|Drug|cyclophosphamide|Given orally
1766966|NCT00331552|Biological|trastuzumab|Given IV
1766967|NCT00331565|Procedure|Bariatric surgery|Gastric bypass, duodenal switch and sleeve surgery
1766968|NCT00332735|Drug|spinal administration of articaine|
1766969|NCT00332735|Drug|spinal administration of bupivacaine|
1766970|NCT00332748|Drug|Oral Taxane|
1766971|NCT00332761|Drug|Caduet|
1766972|NCT00332774|Drug|Nepafenac ophthalmic solution 0.1%|1 drop 4 times daily for 90 days
1766973|NCT00332774|Drug|Ketorolac Tromethamine ophthalmic solution 0.4%|1 drop 4 times daily for 90 days
1766974|NCT00332774|Other|Nepafenac ophthalmic suspension vehicle|
1766975|NCT00332787|Drug|Fluoxetine|
1766976|NCT00332800|Drug|Nutritional Supplementation|
1766979|NCT00332839|Drug|Everolimus|Participants, switching from the CsA based treatment, initially received everolimus 1.5 mg/day and then from day 7, 3 mg/day, and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml). Participants, switching from the tacrolimus based treatment, initially received 3 mg/day and then from day 14, the dose was based on the participants' blood level (6-10 ng/ml).
1766980|NCT00332839|Drug|Cyclosporin A (CsA)|The dose was based on the participants' blood level of C0h (80-150 ng/ml).
1766981|NCT00332839|Drug|Tacrolimus|The dose was based on the participants' blood level of C0h (5-10 ng/ml).
1766982|NCT00332839|Drug|Enteric Coated - Mycophenolate Sodium (EC-MPS)|The dose was ≥ 720 mg/day.
1766983|NCT00332839|Drug|Corticosteroids|Corticosteroids were given according to local standard and/or the Investigators' discretion.
1766984|NCT00332852|Drug|Letrozole|2.5 mg/day - oraly
1766985|NCT00332865|Behavioral|Swallowing Exercises|Daily exercises
1766986|NCT00332878|Behavioral|Stepping Stones|a comprehensive sexual and reproductive health promotion programme lasting about 50 hours comprising 13 content sessions of about 3 hours duration and 4 meetings of peer groups
1766987|NCT00332878|Behavioral|stepping Stones short|3 hour intervention on HIV and safer sex
1766988|NCT00332891|Drug|SR58611A|
1766989|NCT00332904|Drug|propranolol|tablet 80 mg pr. day in a period of 3 weeks, evt. dose adjustment
1766990|NCT00332904|Drug|spironolactone|tablet 200 mg pr. day in 3 weeks, evt. dose adjustment
1766991|NCT00332917|Drug|Pardoprunox|12-42 mg
1766992|NCT00332930|Biological|recombinant fowlpoxvirus (rFPV) expressing HIV gag-pol antigens|
1766993|NCT00332930|Biological|HIV gag-pol antigens and interferon-gamma (IFN-y)|
1766994|NCT00332943|Procedure|MR colonography with fecal tagging|
1766995|NCT00332956|Biological|rFIV vaccine|rF1V vaccine 80 mcg given by intramuscular (IM) injection into the arm on study Days 0, 28, 182
1766996|NCT00332956|Biological|rF1V vaccine|rF1V 80 mcg vaccine given by intramuscular (IM) injection into the arm on study Days 0, 56, 182
1766997|NCT00332956|Biological|rF1V vaccine|rF1V 160 mcg vaccine given by intramuscular (IM) injection into the arm on Study Days 0, 28, 182
1766998|NCT00332956|Biological|rF1V vaccine 160 mcg given on Study Days 0, 56, 182|rF1V 160 mcg vaccine given by Intramuscular (IM) injection into the arm on Study days 0. 56, 182
1766999|NCT00332969|Drug|Octreotide|
1767000|NCT00332982|Behavioral|Focused knowledge translation strategies|
1767001|NCT00332995|Drug|dapivirine (TMC120) vaginal ring|
1767002|NCT00333008|Drug|Doxil|
1767003|NCT00333008|Drug|Cyclophosphamide|
1767004|NCT00333008|Drug|Vincristine|
1767005|NCT00333008|Drug|Prednisone|
1767006|NCT00333008|Drug|Rituximab|
1767007|NCT00333008|Drug|Pegfilgrastim|
1767008|NCT00333021|Drug|Fondaparinux sodium|
1767009|NCT00333021|Drug|GSK576428|
1767010|NCT00333034|Drug|Etanercept|
1767011|NCT00333047|Drug|Letrozole|
1767012|NCT00333060|Drug|OT-551 ophthalmic solution|
1767013|NCT00333073|Device|Bulkamid|initial injection with option for second (if required)
1767014|NCT00333086|Drug|Letrozole|
1767015|NCT00333099|Dietary Supplement|Impact (R) Enteral Nutrition|mucositis frequency, treatment tolerance
1767016|NCT00333099|Other|impact|"1500 calories every day :
-5 days before the begining of the chemoradiotherapy and until the last day of the treatment"
1767017|NCT00333112|Drug|solifenacin succinate|Oral
1767018|NCT00333112|Drug|tamsulosin|oral
1767019|NCT00333112|Drug|placebo|oral
1767020|NCT00333125|Drug|Travoprost 40 mcg/ml + Timolol 5 mg/ml eye drops, solution (DuoTrav)|One drop in the study eye(s) once daily, 9 PM, for 6 weeks
1767021|NCT00333125|Drug|Dorzolamide 20 mg/ml + Timolol 5 mg/ml eye drops, solution (Cosopt)|One drop in the study eye(s) twice daily for 6 weeks
1767022|NCT00333125|Other|Timolol Vehicle|One drop in the study eye(s) once daily for 6 weeks
1767023|NCT00333138|Drug|FTY720|FTY720 capsule was taken orally once a day
1767024|NCT00333138|Drug|Placebo|Placebo 1.25 mg capsule was given once daily
1767025|NCT00333151|Drug|liraglutide|
1767026|NCT00333151|Drug|rosiglitazone|
1767027|NCT00333151|Drug|metformin|
1767028|NCT00333164|Drug|Asprin, Cilostazol|
1956835|NCT02667236|Drug|A-101 Solution|Active Drug
1956836|NCT02667236|Other|Vehicle Solution|Placebo
1956837|NCT02666950|Drug|Cytarabine|Given SC
1767034|NCT00333190|Device|CD+8 T cell depletion|CD8 depleted product Given through central line after treatment with fludarabine and busulfex intravenously for 4 days
1767035|NCT00333203|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
1767036|NCT00333203|Other|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
1767037|NCT00333216|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Posterior juxtascleral administration of suspension
1767038|NCT00333216|Drug|Anecortave Acetate Sterile Suspension, 60 mg/ML|Posterior juxtascleral administration of suspension
1767039|NCT00333216|Other|Anecortave Acetate Vehicle|Sham posterior juxtascleral administration of suspension
1767040|NCT00333229|Drug|Zoledronic Acid|4 mg zoledronic acid in 5 mL concentrate solution. Plastic vials.
1767041|NCT00333229|Drug|Placebo|Matching Placebo
1767042|NCT00333242|Drug|dextromethorphan|dextromethorphan PO titrated to 480 mg/day x 5 weeks
1767043|NCT00333255|Drug|Nepafenac Ophthalmic Suspension, 0.1%|
1767044|NCT00333268|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
1767045|NCT00333268|Drug|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
1956838|NCT02666950|Other|Laboratory Biomarker Analysis|Correlative studies
1956839|NCT02666950|Other|Pharmacological Study|Correlative studies
1956840|NCT02666950|Other|Quality-of-Life Assessment|Ancillary studies
1767051|NCT00333307|Drug|recombinant human relaxin|
1767052|NCT00333320|Procedure|postconditioning|patients were treated by repeated cycles of cycles of reperfusion/ischemia at the end of the procedure within the first minute after reperfusion
1767053|NCT00333320|Procedure|Control group|Percutaneous coronary interventions were performed following international guidelines. No additional intervention was performed in the control group.
1767054|NCT00333333|Procedure|Cord blood|Cord blood will be obtained at the time of delivery.
1767055|NCT00333346|Drug|Administration of tramadol intravenously|
1767056|NCT00333359|Drug|XP13512 (GEn)|1200 mg XP13512, orally, once daily for 52 weeks
1767057|NCT00333372|Drug|Z-338|
1767058|NCT00333385|Drug|ceftazidime|
1767059|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine - Thimerosal-free|CSL influenza vaccine-prefilled syringe presentation (thimerosal-free) 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
1767060|NCT00333398|Biological|CSL Trivalent Inactivated Influenza Vaccine with Thimerosal|CSL influenza vaccine-multiple dose vial presentation (thimerosal-containing) containing 15 mcg per dose of each of the hemagglutinins of H1N1, H3N2, and B strains (total of 45 mcg of hemagglutinins). Single dose of 0.5 mL administered on study day 0.
1767061|NCT00333398|Biological|Placebo with Thimerosal|Phosphate buffered isotonic saline solution containing thimerosal. Single dose of 0.5 mL administered on study day 0.
1767062|NCT00333411|Drug|BIRT 2584 XX|
1767063|NCT00333411|Drug|Placebo|
1767064|NCT00333424|Biological|pHIS-HIV-AE (DNA vaccine) prime and rFPV-HIV-AE (recombinant fowlpox virus boost) vaccine|6mg pHIS-HIV-AE at weeks 0, 4 and 8; 3 x 10e8 pfu/mL rFPV-HIV-AE at week 12
1767065|NCT00333437|Drug|Mycophenolate mofetil|
1767066|NCT00333450|Biological|Pneumococcal vaccine|
1767067|NCT00333463|Behavioral|Intervention|The intervention group watched an educational video, reviewed current barriers to drop-taking and possible solutions with a study coordinator, received regular phone call reminders, and had audible and visible reminders activated on their DA devices.
1767068|NCT00333476|Drug|MSI-1256F (Squalamine Lactate)|
1767069|NCT00333489|Drug|valsartan|
1767070|NCT00333502|Drug|Camptothecin (CPT) conjugated to a linear, cyclodextrin-based polymer|Subjects who meet inclusion/exclusion criteria will receive CRLX101 every other week.
1767075|NCT00333541|Behavioral|Using internet/E-mail for follow-up|follow-up via email link to survey
1767076|NCT00333554|Dietary Supplement|DHA Treatment|DHA study treatment given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food) depending on age of child.
1767077|NCT00333554|Dietary Supplement|Placebo for DHA|Study placebo given on daily basis to nursing mother (breast milk) or baby as either formula, or capsules (removing content and mixing with food)depending on age of child.
1767078|NCT00333567|Drug|Lumiracoxib|
1767079|NCT00333593|Device|Large pore dialyser|
1767080|NCT00333593|Device|Standard dialyser|
1956841|NCT02666950|Other|Questionnaire Administration|Ancillary studies
1767082|NCT00333619|Behavioral|Nonpharmacological sleep intervention|The intervention combines: 1) structured sleep assessment, 2) environmental interventions (efforts to increase bright light exposure, decrease daytime in-bed time, and provide a structured bedtime routine), and 3) elements of cognitive-behavioral strategies
1767083|NCT00333619|Behavioral|Active control|Daily 15-minute social visit from a research assistant. The visits include structured activities to facilitate social interaction (e.g., memory games, current event discussions).
1767084|NCT00333632|Drug|Dexmedetomidine|
1767085|NCT00333632|Drug|Propofol|
1767086|NCT00333632|Drug|Midazolam|
1767087|NCT00333632|Drug|Fentanyl|
1767088|NCT00333632|Drug|Isoflurane|
1767089|NCT00333645|Drug|Caspofungin|
1767090|NCT00333658|Behavioral|Goal setting and work feedback group|Goal setting and feedback using WBI
1767091|NCT00333671|Drug|Glycerol|
1767092|NCT00333684|Device|BIO-ALCAMID SOFT TISSUE ENDOPROSTHESIS|prosthetic bioalcamid was injected- amounts determined by the plastic surgeon and depended individual needs
1767093|NCT00333697|Other|Comprehensive Duplex Ultrasound (diagnostic study)|A sigle duplex ultrasound examination of the deep venous system of the leg(s) suspected of deep vein thrombosis. Deep veins of the leg are examined for evidence of thrombosis from the inguinal ligament to the level of the malleolus.
1767094|NCT00333710|Behavioral|Individual psychotherapy|Individual face-to-face contact with educational and goal setting components
1767095|NCT00333710|Behavioral|Telehealth Intervention|Individual telephone contact with educational and goal setting components
1767097|NCT00333736|Device|Biojector|All patients received biojector to use with BID enfuvirtide doses
1767098|NCT00333749|Biological|Drinking or rinsing the mouth 2-3 times for 1 day|
1767099|NCT00333749|Biological|Pasturlized cow milk|Drinking or rinsing the mouth 2-3 times for one day.
1767100|NCT00333762|Device|Smart Power Assistance Module (SPAM)|Experimental Power wheelchair utilized to traverse prescribed course
1767101|NCT00333762|Device|Smart Wheelchair Component System (SWCS)|Experimental power wheelchair utilized to traverse prescribed course
1767102|NCT00333775|Drug|Docetaxel|Docetaxel was supplied in 2 vials, 1 containing docetaxel and 1 containing a solvent, for intravenous infusion.
1767103|NCT00333775|Drug|Placebo to bevacizumab|Placebo to bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
1767104|NCT00333775|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid for intravenous infusion in single-use vials.
1767105|NCT00333788|Biological|Certolizumab pegol (CDP870)|400 mg subcutaneous (sc) injection of Certolizumab pegol (CDP870) every 2 (Q2W) or 4 (Q4W) weeks
1767106|NCT00333801|Behavioral|Vocational Rehabilitation Program (VRP)|Vocational Rehabilitation Program (VRP) is a treatment-as-usual method using traditional train-place approaches, such as prevocational work skills training , compensated work therapy, or transitional work experience, which consists of temporary employment in a brokered-job with time-limited support from the VRP specialist
1767107|NCT00333801|Behavioral|Individual Placement and Support (IPS)|Individual Placement and Support (IPS) is an evidence--based model of supported employment that emphasizes rapid job search within client preferences, community job development, placement in a competitive job, on-the-job training, time-unlimited follow-along supports, and integration of the IPS specialist within the treatment team.
1767108|NCT00333814|Drug|Dexamethasone|Dexamethasone 350 µg; injection drug delivery system at Day 0
1767109|NCT00333814|Drug|dexamethasone|Dexamethasone 700 µg injection drug delivery system at Day 0
1767110|NCT00333814|Drug|Sham injection|Sham injection at Day 0
1767111|NCT00333827|Drug|optimal therapy for cardiaca failure|optimal therapy for cardiaca failure
1767112|NCT00333827|Procedure|cell|stem cell
1767113|NCT00333840|Drug|imatinib mesilate|imatinib supplied as 100 mg and 400 mg tablets or 100 mg capsules.
1767114|NCT00333840|Drug|interferon-alpha (INF-a)|interferon-alpha (IFN-a) subcutaneous (SC) injections escalated over 4 weeks to achieve a target dose of 5 MU/m^2/day.
1767115|NCT00333840|Drug|cytarabine (ARA-C)|cytarabine 20 mg/m^2/day (max 40 mg) SC for 10 days every month.
1767116|NCT00333853|Device|OneTouch(r) UltraSmart(r)|
1767117|NCT00333866|Drug|pregabalin|600mg/day
1767118|NCT00333866|Drug|pregabalin|450mg/day
1767119|NCT00333866|Drug|pregabalin|300mg/day
1767120|NCT00333866|Drug|placebo|placebo
1767121|NCT00333879|Device|Virtual Sound System|Virtual Sound System is tested for efficacy in its ability to realistically simulate Street Crossings sounds in a safe indoor environment. If efficacious, Blind students will be able to practice crossing streets in safety indoors.
1767122|NCT00333892|Procedure|leukapheresis|pack of cells as per protocol
1767123|NCT00333905|Procedure|Ischemic exercise training|
1767124|NCT00333918|Drug|bromfenac ophthalmic solution|
1767125|NCT00333918|Drug|placebo comparator|
1767126|NCT00333931|Drug|Phenytoin|
1767127|NCT00333931|Behavioral|Cognitive Behavioral Therapy|
1767128|NCT00333944|Drug|Pralidoxime(drug)|
1767129|NCT00333970|Behavioral|cognitive remediation|individual cognitive training
1767130|NCT00333983|Device|Robotic Upper Extremity Neurorehabilitation|Upper extremity exercise using a planar robot Upper extremity exercise using a planar and vertical robot
1767131|NCT00333983|Other|Traditional Upper Extremity Exercise Group|Upper extremity stretching, skateboard reaching activities, and arm ergometer
1767132|NCT00333996|Drug|Dexamethasone|
1767133|NCT00334022|Drug|enfuvirtide|1ml BID
1767134|NCT00334035|Drug|Quetiapine|
1767135|NCT00334048|Drug|Ropinirole (Requip)|1 mg extended release formulation given once per day to a maximum of 4 per day
1767136|NCT00334061|Device|Penumbra System|
1767137|NCT00334074|Drug|Clofarabine and Cytarabine|Phase II Trial of Clofarabine and Cytarabine in Relapsed Standard-Risk AML and Untreated High-Risk MDS in Adult Patients, and Untreated AML in selected Elderly Patients at high risk of anthracycline toxicity
1767138|NCT00334087|Behavioral|feeding habits|
1767139|NCT00334100|Behavioral|Exercise|Treadmill exercise
1767140|NCT00334113|Behavioral|TLC-PED|Telephone-Linked Care - Promoting Exercise for Diabetes (TLC-PED), a method that uses interactive voice response and speech recognition technologies, will be developed to provide individualized and personalized motivational messages using automated telephone calls for veterans with Type 2 diabetes who participate in a home based walking program.
1767141|NCT00334126|Drug|paliperidone ER tablets, quetiapine tablets, placebo - all over encapsulated|
1767142|NCT00334139|Drug|Zoledronic Acid|every 4 weeks for 4 months
1956842|NCT02666950|Drug|WEE1 Inhibitor AZD1775|Given PO
1767144|NCT00334165|Procedure|Auricular acupuncture (procedure)|
1767145|NCT00334178|Drug|Laxymig ER (drug)|
1767146|NCT00334191|Drug|Sodium Bicarbonate|
1767147|NCT00334191|Drug|Placebo|
1767148|NCT00334204|Device|measuring Platelet Function Analyser-100 (PFA-100) platelet function before kidney biopsy|measuring Platelet Function Analyser (PFA) -100 platelet function before kidney biopsy
1767149|NCT00334217|Behavioral|Cognitive Remediation|PSS Cogrehab
1767150|NCT00334243|Drug|Microflare protocol for IVF|
1767151|NCT00334243|Drug|Antagonist protocol for IVF|
1767152|NCT00334243|Drug|Demi-halt protocol for IVF|
1767153|NCT00334256|Drug|Tenofovir (TDF)|
1767154|NCT00334256|Drug|Emtricitabine (FTC)|
1767155|NCT00334269|Behavioral|Health messaging at weekly home visits by health counsellor|
1767156|NCT00334269|Behavioral|Weekly home delivery of bottled spring water|
1767157|NCT00334269|Behavioral|Weekly afterschool physical activity program for 5-18y.o.|
1767158|NCT00334269|Behavioral|Cooking classes and grocery store tours with dietician|
1767159|NCT00334269|Behavioral|Pedometers to track/increase weekly physical activity|
1767160|NCT00334282|Drug|Pazopanib|Oral pazopanib tablet 800 mg once daily continuously
1767161|NCT00334282|Drug|placebo|matching placebo (800 mg tablet) once daily
1767162|NCT00334295|Drug|Fulvestrant|A monthly intramuscular application of 250 mg Fulvestrant as a 1st line endocrine therapy in patients with recurrent or metastatic endometrial carcinoma.
1767163|NCT00334308|Procedure|Barley protein bread or control (casein) bread|
1767164|NCT00334321|Radiation|IMRT|
1767165|NCT00334321|Radiation|Intracavitary vaginal brachytherapy|
1767166|NCT00334321|Drug|Paclitaxel|
1767167|NCT00334321|Drug|Carboplatin|
1767168|NCT00334334|Biological|Pneumococcal (vaccine)|
1767169|NCT00334347|Drug|Depakote ER|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
1767170|NCT00334347|Drug|Depakote DR|The starting doses will be 25 mg/kg and 20 mg/kg. The dose you get will depend on how much you weigh.
1767250|NCT00334815|Radiation|radiation therapy|Undergo thoracic radiotherapy
1767171|NCT00334360|Drug|dexmedetomidine|Dexmedetomidine (delivered by a computer-controlled IV infusion to target a plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
1767172|NCT00334360|Drug|buspirone|Buspirone, 60 mg orally, will be given during controlled hypothermia.
1767173|NCT00334360|Drug|Bus and Dex|the combination of 60 mg buspirone and dexmedetomidine (target plasma concentration of 0.6 ng/mL) will be given during controlled hypothermia
1767174|NCT00334360|Drug|Control|No drugs given during controlled hypothermia
1767175|NCT00334373|Procedure|Post conditioning|4 cycles of balloon inflation /deflation (post-conditioning) within first minute of opening up artery in primary PCI for STEMI vs usual balloon inflation sequence
1767176|NCT00334386|Drug|Torasemide Prolonged Release (loop diuretic)|
1767177|NCT00334386|Drug|Torasemide Immediate Release (loop diuretic)|
1767178|NCT00334399|Drug|Miglitol|
1767179|NCT00334412|Drug|Ambisome|
1767180|NCT00334412|Drug|caspofungin|
1767181|NCT00334425|Drug|MENOPUR; GONAL-F|
1767182|NCT00334438|Biological|rituximab|250mg/m2, IV, Days 1 and 8
1767183|NCT00334438|Drug|bortezomib|dose escalation 1.0, 1.3, or 1.5, IVP; Days 4, 8, 11, 15
1767184|NCT00334438|Radiation|yttrium Y 90 ibritumomab tiuxetan|Dose dependant upon platelet count (0.4mCi/kg) not to exceed 32mCi; Day 8
1767185|NCT00334438|Radiation|Indium 111 ibritumomab tiuxetan|5cmCi; IV day 1
1767186|NCT00334464|Drug|Standard of care or genotyping dosing of warfarin dosing|
1767187|NCT00334477|Drug|tadalafil|
1767188|NCT00334490|Drug|Sildenafil|12.5 mg Sildenafil once with optional second dose
1767189|NCT00334490|Drug|Sildenafil|12.5 mg orally once with optional second dose
1767190|NCT00334490|Drug|Placebo|Oral Placebo in 5 mls distilled water
1767191|NCT00334503|Drug|Miglitol|
1767192|NCT00334529|Drug|Oseltamivir|
1767193|NCT00334542|Drug|simvastatin|24-28 weeks of simvastatin
1767194|NCT00334555|Other|different methods of partner notification|comparing patient referral, partner delivered medications and field intervention to treat sex partners
1767195|NCT00334555|Other|partner delivered meds|patient given meds to give to her partner
1767196|NCT00334555|Other|field intervention|health worker finds partners
1767197|NCT00334568|Drug|Rosiglitazone XR (extended release) oral tablets|Rosi XR tablets
1767198|NCT00334568|Drug|Placebo|Placebo
1767199|NCT00334581|Drug|Irbesartan|Administration throughout the study period
1767200|NCT00334581|Drug|Irbesartan|Administration throughout the study period
1767201|NCT00334594|Drug|Cisplatin|Cisplatin 75 mg/m2 i.v. over approximately 2 hours on day 1 every 21 days
1767202|NCT00334594|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 every 21 days
1767203|NCT00334594|Procedure|Therapeutic conventional surgery|Extrapleural pneumonectomy
1767204|NCT00334594|Radiation|Radiotherapy|CTV1 will receive 45 or 46 Gy. CTV2 will be treated up to a total dose of 55,9 to 56,2 Gy.
1767205|NCT00334607|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
1767206|NCT00334620|Procedure|15 radon(+CO2) baths vs 15 CO2 baths; beside rehabilitation|
1767207|NCT00334633|Drug|tinidazole, metronidazole|Tinidazole 500 mg bid; Tinidazole 1mg bid; Metronidazole 500mg bid
1767208|NCT00334646|Drug|Oral GW679769|150mg oral, once daily on days 1-3
1767209|NCT00334646|Drug|IV Cyclophosphamide 500-700mg/m2|IV Cyclophosphamide 500-700mg/m2 on day 1 of each cycle
1767210|NCT00334659|Drug|apricitabine|
1767211|NCT00334672|Biological|anti-thymocyte globulin|
1767212|NCT00334672|Drug|busulfan|
1767213|NCT00334672|Drug|cyclophosphamide|
1767214|NCT00334672|Drug|cyclosporine|
1767215|NCT00334672|Drug|dexamethasone|
1767216|NCT00334672|Drug|etoposide|
1767217|NCT00334672|Drug|methotrexate|
1767218|NCT00334672|Drug|mycophenolate mofetil|
1767219|NCT00334672|Drug|therapeutic hydrocortisone|
1767220|NCT00334672|Other|laboratory biomarker analysis|
1767221|NCT00334672|Procedure|allogeneic hematopoietic stem cell transplantation|
1767222|NCT00334672|Procedure|biopsy|
1767223|NCT00334685|Drug|[S,S]-Reboxetine|
1767224|NCT00334698|Drug|Cetirizine|
1767225|NCT00334698|Drug|Pseudoephedrine|
1767226|NCT00334698|Drug|Cetirizine with Pseudoephedrine|
1767227|NCT00334711|Drug|Sulfonylurea|
1767228|NCT00334724|Procedure|Home blood pressure measurement|Blood pressure controlled based on home blood pressure measurement
1767229|NCT00334724|Procedure|Office blood pressure measurement|Blood pressure controlled based on office blood pressure measurement
1956843|NCT02666638|Other|Control Volunteers|MRI on up to a 7T scanner without contrast.
1956844|NCT02666638|Other|Clinical Volunteers|One-hour MRI on up to a 7T scanner without contrast + 10 minutes of research development imaging using radio frequency (RF) coils
1767233|NCT00334750|Other|There is no intervention in this study.|This study is collecting information on the presence of risk factors in new diagnosed OH and OAG patients in Canada.
1767234|NCT00334763|Biological|bevacizumab|
1767235|NCT00334763|Drug|carboplatin|
1767236|NCT00334763|Drug|chemoprotection|
1767237|NCT00334763|Drug|paclitaxel|
1767238|NCT00334763|Radiation|radiation therapy|
1767239|NCT00334776|Biological|MART-1 antigen|
1767240|NCT00334776|Biological|gp100:209-217(210M) peptide vaccine|
1767241|NCT00334776|Biological|therapeutic autologous dendritic cells|
1767242|NCT00334776|Biological|tyrosinase peptide|
1767246|NCT00334802|Drug|gemcitabine|"Phase 1: 1000 mg/m2, intravenous (IV), day 1 and day 8 x 2 cycles (dose escalation)
Phase 2: dose determined by phase 1"
1767247|NCT00334802|Drug|paclitaxel|"Phase 1: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles
Phase 2: 175 mg/m2, intravenous (IV), every 21 days x 2 cycles"
1767248|NCT00334815|Drug|cisplatin|Given IV
1767251|NCT00334815|Biological|bevacizumab|Given IV
1767252|NCT00334815|Drug|docetaxel|Given IV
1767253|NCT00334815|Biological|filgrastim|Given SC
1767254|NCT00334815|Biological|pegfilgrastim|Given SC
1767255|NCT00334828|Drug|eritoran tetrasodium|Intravenous infusion at a total dose of 105 mg.
1767256|NCT00334828|Drug|Placebo|Matching placebo; intravenous infusion.
1767257|NCT00334854|Drug|doxorubicin hydrochloride|
1767258|NCT00334854|Drug|ifosfamide|
1767259|NCT00334854|Procedure|adjuvant therapy|
1767260|NCT00334854|Procedure|conventional surgery|
1767261|NCT00334854|Procedure|neoadjuvant therapy|
1767262|NCT00334854|Radiation|radiation therapy|
1767263|NCT00334867|Drug|cyclophosphamide|Given IV
1767264|NCT00334867|Drug|dexrazoxane hydrochloride|Given IV
1767265|NCT00334867|Drug|doxorubicin hydrochloride|Given IV
1767266|NCT00334867|Drug|etoposide|Given IV
1767267|NCT00334867|Drug|ifosfamide|Given IV
1767268|NCT00334867|Drug|topotecan hydrochloride|Given IV
1767269|NCT00334867|Drug|vincristine sulfate|Given IV
1767270|NCT00334867|Procedure|conventional surgery|Patients undergo surgery in week 18
1767271|NCT00334867|Procedure|radiation therapy|Patients undergo radiation therapy in week 19
1767272|NCT00334880|Drug|NRP104|
1767273|NCT00334893|Drug|eribulin mesylate|Given IV
1767274|NCT00334906|Drug|memantine HCl|
1767275|NCT00334919|Behavioral|Diet (Anti-Inflammatory or standard diabetic diet)|6 weeks standard ADA diet, then randomized to either ADA or antiinflammatory (AI) diet for 6 weeks
1767276|NCT00334932|Drug|bortezomib|
1767277|NCT00334932|Drug|melphalan|
1767278|NCT00334932|Drug|pegylated liposomal doxorubicin hydrochloride|
1767279|NCT00334958|Drug|Placebo|BID for 12-day Titration Phase and 12-week Maintenance Phase.
1767280|NCT00334958|Drug|Rufinamide|400 mg twice daily (BID) orally uptitrated every 3 days in 400 mg BID increments up to 1600 mg BID (total daily dose of 3200 mg/day) over 12-day Titration Phase; followed by 1600 mg BID over 12-week Maintenance Phase.
1767281|NCT00334971|Procedure|Follicle Aspiration|Follicles will be aspirated using a transvaginal ultrasound guided needle.
1767282|NCT00334984|Drug|glutamine|
1767283|NCT00334984|Procedure|chemoprotection|
1767284|NCT00334984|Procedure|management of therapy complications|
1767285|NCT00334984|Procedure|therapeutic nutritional supplementation|
1767286|NCT00334997|Procedure|endoscopic surgery|
1767287|NCT00334997|Procedure|laser surgery|
1767288|NCT00334997|Radiation|radiation therapy|
1767289|NCT00335010|Drug|Nitroglycerin|
1767290|NCT00335023|Other|Red blood cell transfusion|At least one unit of red blood cells will be administered. The target Hb value after transfusion is at least 8.7 g/dL.
1767291|NCT00335036|Device|ICD lead implant|Randomization of ICD lead type at implant
1767292|NCT00335036|Device|Thin leads|Thin (less than or equal to 7 French introducer) isodiametric ICD leads
1767293|NCT00335049|Device|progressive addition spectacle lens (bifocal)|Progressive addition lenses (PAL) with a +2.00 D add.
1767294|NCT00335049|Device|Single Vision Lenses (SVLs)|Single vision spectacle lenses.
1767295|NCT00335075|Drug|Temozolomide|Temozolomide orally for 5 consecutive days (Day 1 through Day 5) every 28 days, at a dose of 150 mg/m2/day for subjects previously treated with chemotherapy, or 200 mg/m2/day for subjects who have not received previous chemotherapy.
1767296|NCT00335075|Drug|Semustine|Semustine orally once every 28 days at a dose of 150 mg/m2/day.
1767298|NCT00335101|Drug|Iodixanol, Ioversol, Iopromide|
1767299|NCT00335114|Drug|cyclosporine ophthalmic emulsion|
1767300|NCT00335140|Biological|Rituximab|Rituximab is administered intravenously. The initial rate is 50 mg/hr for the first hour. If no toxicity is seen, the rate may be escalated gradually in 50 mg/hour increments at 30-minute intervals to a maximum of 300 mg/hr. If the first dose is well tolerated, the initial rate for subsequent dose is 100 mg/hr, increased gradually in 100 mg/hr increments at 30-minute intervals, not to exceed 400 mg/hr.
1767301|NCT00335140|Drug|Cytarabine|3 g/m2/day in 500 cc D5W IV over 2 hrs. x 2 doses 24hrs. apart, Weeks 11, 14
1767302|NCT00335140|Drug|Dexamethasone|16mg (week 1) PO daily Weeks 1, 2, 3, 4, 5, 6 Taper by 4 mg/wk, weeks 2, 3, by 2 mg/wk week 4, 5, 6
1767303|NCT00335140|Drug|Leucovorin|25 mg PO/IV every 6 hrs. x 12 doses, Weeks 1, 3, 5, 7, 9 For patients with meningeal involvement additionally 10 mg PO every 12 hrs. x 8 doses, Weeks 2, 4, 6, 8, 10
1767304|NCT00335140|Drug|Methotrexate|"3.5 g/m2In 500 cc D5W + 25 mEq NaHCO3 IV over 2 hours, Weeks 1, 3, 5, 7, 9
For patients with meningeal involvement additionally:
12 mg Intrathecally, in preservative-free sterile .9NS Weeks 2, 4, 6, 8, 10 Via Ommaya or lumbar puncture"
1767305|NCT00335140|Drug|Procarbazine|100 mg/m2 PO daily x 7 days Weeks 1, 5, 9
1767306|NCT00335140|Drug|Vincristine|1.4 mg/m2 IV push, Weeks 1, 3, 5, 7, 9 2m2 (2.8 mg) dose cap
1767307|NCT00335153|Drug|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
1767308|NCT00335153|Device|CADD-Legacy® 1400 ambulatory infusion pump|
1767309|NCT00335153|Device|PEG tube|percutaneous endoscopic gastrostomy tube
1767310|NCT00335153|Device|J-tube|jejunal tube
1767311|NCT00335166|Drug|Pardaprunox|12-42 mg
1767312|NCT00335166|Drug|pramipexole|1.5-4.5 mg
1767313|NCT00335166|Drug|Placebo Comparator|Placebo
1767314|NCT00335179|Drug|Aldara (imiquimod 5% cream)|Imiquimod 5% cream containing 12.5 mg of imiquimod per 250 mg of cream
1767315|NCT00335179|Drug|Vehicle cream|Vehicle cream in 250 mg
1767316|NCT00335192|Drug|Patients in treatment with 3TC + TDF + LPV/rtv, stop tenofovir during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h) + Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
1767317|NCT00335192|Drug|Patients in treatment with ABV + TDF + LPV/rtv, stop tenofovir during 4 weeks|ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h)
1767448|NCT00335868|Other|pharmacological study|
1767449|NCT00335881|Biological|hepatitis B vaccine|
1767318|NCT00335192|Drug|Patients in treatment with 3TC + ABV + TDF+ LPV/rtv, stop TDF during 4 weeks|3TC (300 mg/24 h, 1 tablet/24 h)+ ABV (300 mg/12 h, 1 tablet/12 h)+ Lopinavir/ritonavir (400 mg/12 h, 3 tablets/12 h).
1767319|NCT00335205|Drug|ropinirole|
1767320|NCT00328367|Drug|aripiprazole|aripiprazole augmentation of clozapine
1767321|NCT00328367|Drug|placebo|placebo
1767322|NCT00328380|Drug|Rifaximin|
1767323|NCT00328393|Drug|Pioglitazone|45 mg 8 weeks
1767324|NCT00328393|Drug|Placebo|Placebo
1767325|NCT00328419|Device|photoprotected bags, tubing, syringes|use of photoprotected parenteral nutrition device
1767326|NCT00328419|Device|standard tubing and bags|Use of standard (transparent) parenteral nutrition device
1767327|NCT00328432|Drug|celecoxib 400 mg bid|
1767328|NCT00328445|Behavioral|Positive Action|See publications
1767329|NCT00328458|Drug|EPO906 (epothilone B)|
1767330|NCT00328471|Behavioral|care management|
1767331|NCT00328484|Behavioral|Lifestyle Activity Program|The lifestyle activity program will consist of 35 exercise and counseling sessions spaced over 11 months. This program will use cognitive-behavioral strategies to encourage physical activity at home. Participants will receive information on how to deal with COPD symptoms (including shortness of breath), goal-setting, social support, and motivation. Participants will also receive follow-up telephone calls from the program staff for additional support.
1767332|NCT00328484|Behavioral|Exercise Program|The 3-month exercise program will consist of 36 1-hour exercise training sessions, conducted 3 times a week for 12 weeks.
1767333|NCT00328497|Drug|Panzem (2-methoxyestradiol) NCD, Avastin (Bevacizumab)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days bevacizumab 5 mg/kg intravenous bolus on Day 1 and Day 15
1767334|NCT00328510|Device|GTC frame|
1767335|NCT00328510|Device|Thermoplastic facemask|
1767336|NCT00328510|Radiation|Stereotactic radiation therapy|
1767337|NCT00328523|Drug|MK-0653, ezetimibe|
1767338|NCT00328523|Drug|Duration of Treatment: 3 months|
1767339|NCT00328536|Drug|Omacor|
1767340|NCT00328549|Drug|Pegylated Interferon and Ribavirin|
1767341|NCT00328562|Drug|ZD1839 (Iressa)|
1767342|NCT00328562|Radiation|Thoracic Radiotherapy|
1767343|NCT00328575|Radiation|Intensity-Modulated Radiotherapy (IMRT)|"The duration of radiation therapy will be total of 3 weeks. During the first week, all patients will be treated initially with whole brain radiation therapy (WBRT) at 2.5Gy per fraction daily 5 days a week to a dose of 12.5Gy. This will be delivered through parallel-opposed fields to cover the entire cranial contents.
For the remaining 2 weeks, patients will be treated using intensity-modulated radiation therapy (IMRT) technology such that a higher dose can be delivered to the tumor. IMRT is capable of generating complex 3-D dose distribution to conform closely to the target volume by modulating the radiation beam. This process is based on the inverse method of treatment planning to optimize radiation dose to tumor target coverage and normal tissue sparing."
1767344|NCT00328588|Drug|YM155|IV
1767345|NCT00328601|Drug|Thioctic Acid|
1767346|NCT00328614|Drug|Samarium-153|Samarium-153 will be administered as a single dose after one month of hormonal therapy. The dose level of Samarium-153 may change to determine maximum tolerated dose (MTD).
1767347|NCT00328614|Drug|Total Androgen Suppression (TAS) with Bicalutamide|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
1767348|NCT00328614|Drug|Total androgen suppression (TAS) with Goserelin Acetate|Patients will receive 5 months of total androgen suppression (TAS) consisting of Zoladex and Casodex. Total androgen suppression will begin 3 months prior to initiation of irradiation.
1767349|NCT00328614|Device|Radiation Therapy|Radiation therapy will begin 3 months following the initiation of hormone administration. Daily tumor doses will be given 5 days per week for 7-8 weeks.
1767350|NCT00328627|Drug|Alogliptin|Alogliptin tablets.
1767351|NCT00328627|Drug|Alogliptin placebo|Alogliptin placebo-matching tablets.
1767352|NCT00328627|Drug|Pioglitazone|Pioglitazone tablets.
1767353|NCT00328627|Drug|Pioglitazone placebo|Pioglitazone placebo-matching tablets.
1767354|NCT00328640|Drug|Optimal treatment|
1767355|NCT00328653|Drug|cyclosporine|
1767356|NCT00335218|Drug|Climodien / Lafamme (BAY86-5027)|1 tablet daily (2 mg EV + 2 mg DNG)
1767357|NCT00335218|Drug|Placebo|1 tablet daily
1767358|NCT00335231|Drug|gatifloxacin ophthalmic (ZYMAR)|
1767359|NCT00335244|Drug|L-citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass followed by continuous infusion of 9mg/kg/hr IV, starting 4 hours post bolus administration and ending at 48 hours continuous infusion or discharge from the PCCU
1767360|NCT00335244|Drug|Placebo of intravenous L-citrulline|Placebo of intravenous L-citrulline
1767361|NCT00335270|Drug|fos-amprenavir calcium, ritonavir|
1767362|NCT00335270|Drug|abacavir/lamivudine as Epzicom|
1767363|NCT00335283|Drug|Lansoprazole Tablet|40 mg bid x 16 weeks
1767364|NCT00335283|Procedure|PH and impedence testing|24 hour ph monitoring
1767365|NCT00335283|Procedure|manometry|done prior to pH probe to measure length of esophagus
1767366|NCT00335283|Drug|lansoprazole|40mg bid
1767367|NCT00335283|Drug|placebo|one tablet bid
1767368|NCT00335296|Device|PFx catheter|
1767369|NCT00335309|Procedure|Maxillary Sinus Irrigation|Twice a day irrigation with 100cc saline for 4 days
1767370|NCT00335309|Drug|IV Amoxicillin and Clavulanate acid|IV Amoxycillin and Clavulanate 1 Gram TID for 4 days.
1767371|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine) + Stocrin (efavirenz)|Truvada (tenofovir 300mg qd + 200mg qd) once daily Efavirenz 600mg qd once daily
1767372|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine)+ ritonavir/atazanavir (r/ATV)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily ritoanvir/atazanavir 100mg/300mg qd once daily (taken with food)
1767373|NCT00335322|Drug|Truvada (fixed dose combination of tenofovir + emtricitabine) + zidovudine (ZDV) + abacavir (ABC)|Tuvada (tenofovir 300mg qd + 200mg qd) once daily zidovudine 250mg/300mg qd (taken in two equal doses approximately 12 hours apart) Abacavir 600mg qd
1767374|NCT00335335|Drug|iodixanol|
1767450|NCT00335894|Drug|hMG-IBSA|
1767375|NCT00335348|Drug|Bortezomib|Induction- 1.3mg/m2 IV days 1,4,8,11 every 3 weeks up to 8 cycles Consolidation- 1.3mg/m2 IV days 1,8,15,22 every 5 weeks up to 3 cycles Maintenance- 1.3mg/m2 IV days 1,15 every 4 weeks
1767376|NCT00335348|Drug|Dexamethasone|Induction- 20mg orally days 1,2,4,5,8,9,11,12 every 3 weeks up to 8 cycles Consolidation- 20mg orally days 1,2,8,9,15,16,22,23 every 5 weeks up to 3 cycles Maintenance- 20mg orally days 1,2,15,16 every 4 weeks
1767377|NCT00335361|Device|Intra Vas Device (IVD)|
1767378|NCT00335374|Drug|Pardoprunox|12 -42 mg
1767379|NCT00335400|Drug|Anesthetic Dilating Gel|
1767380|NCT00335413|Drug|Spironolactone|
1767381|NCT00335426|Procedure|Spinal manipulative therapy|
1767382|NCT00335439|Drug|ketorolac tromethamine 0.5% (Acular®)|
1767383|NCT00335452|Drug|Clopidogrel|oral administration
1767384|NCT00335452|Drug|acetylsalicyclic acid (ASA)|oral administration
1767385|NCT00335465|Drug|Insulin glargine|once a daily, sc injection, 100IU/ml
1767386|NCT00335478|Drug|Daptomycin|daptomycin 6 mg/kg over 30 minutes every 24 hours until patient is afebrile and ANC is >500 cells/mm^3.
1767387|NCT00335491|Behavioral|exercise intervention|12 weeks of 3x/week training on a recumbent eccentric stepper
1767388|NCT00335491|Procedure|complementary or alternative medicine procedure|12 weeks of 3x/week training on the eccentron
1767389|NCT00335491|Procedure|fatigue assessment and management|The visual analog scale will be used to assess muscle soreness from the previous exercise session
1767390|NCT00335491|Procedure|physical therapy|12 weeks of 3x/week training on the eccentron
1767391|NCT00335504|Drug|oligofructose-enriched inulin|Given orally
1767392|NCT00335504|Drug|sulindac|Given orally
1767393|NCT00335504|Drug|placebo|Given orally
1767394|NCT00335504|Drug|atorvastatin calcium|Given orally
1767395|NCT00335504|Other|laboratory biomarker analysis|Correlative studies
1767396|NCT00335517|Drug|DepoDur|An epidural catheter will be placed under direct vision at the conclusion of surgery. The catheter will be advanced at least 4cm to L1 level prior to injection. Two mililiters of air will be injected through the catheter to ensure patency. Aspiration will be done to ensure no intradural injections. Then the undiluted (1 or 1.5 cc) DepoDur will be injected.
1767397|NCT00335543|Drug|cisplatin|
1767398|NCT00335543|Drug|gemcitabine hydrochloride|
1767399|NCT00335543|Procedure|adjuvant therapy|
1767400|NCT00335543|Procedure|conventional surgery|
1767401|NCT00335543|Procedure|neoadjuvant therapy|
1767402|NCT00335543|Radiation|radiation therapy|
1767403|NCT00335556|Drug|Doxorubicin Hydrochloride|Given IV
1767404|NCT00335556|Drug|Irinotecan Hydrochloride|Given IV
1767405|NCT00335556|Procedure|Conventional Surgery|Patients undergo resection
1767406|NCT00335556|Drug|Cyclophosphamide|Given IV
1767407|NCT00335556|Drug|Etoposide|Given IV
1767408|NCT00335556|Drug|Carboplatin|Given IV
1767409|NCT00335556|Biological|Dactinomycin|Given IV
1767410|NCT00335556|Drug|Vincristine Sulfate|Given IV
1767411|NCT00335556|Radiation|Radiation Therapy|Undergo radiotherapy
1767412|NCT00335556|Other|Laboratory Biomarker Analysis|Correlative studies
1767413|NCT00335569|Drug|hCG-IBSA|
1767414|NCT00335673|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet a day per os.
1767415|NCT00335686|Drug|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h|Lopinavir-rtv (Kaletra): 3 capsules (600 mg)/12 h
1767416|NCT00335686|Drug|Nevirapine (Viramune): 1 comp (200mg)/12h|Nevirapine (Viramune): 1 comp (200mg)/12h
1767417|NCT00335699|Drug|Rosuvastatin|
1767418|NCT00335712|Drug|ONO-5129|
1767419|NCT00335725|Drug|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
1767420|NCT00335725|Drug|Follicle Stimulating Hormone|subcutaneous injection of FSH. Starting dose: 225 IU.
1991614|NCT00788892|Drug|CPX-351|CPX-351 at 100u/m2 will be administered on study days 1, 3 and 5 as a 90 minute infusion
1991615|NCT00788892|Drug|Cytarabine|Cytarabine at a dose of 100mg/m2/day for 7 days
1767424|NCT00335751|Procedure|positron emission tomography computed tomography (PET/CT)|The first PET/CT scan will be performed as part of clinical evaluation of sarcoma; The second PET/CT scan will be performed 6 weeks after the start of chemotherapy treatment OR 6 weeks after the end of radiation therapy, to monitor response of sarcoma to treatment.
1991616|NCT00788892|Drug|Daunorubicin|Daunorubicin at dose of 60mg/m2 for 3 days
1991617|NCT00787176|Procedure|Lactated Ringers bolus of 1000 ml|Lactated Ringers bolus of 1000 ml initiated at patient positioning for epidural placement
1767429|NCT00335777|Drug|Migranal nasal spray|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
1767430|NCT00335777|Drug|Migranal nasal spray|Migranal® 4 mg. will be self administered by each subject in the following manner: one spray in each nostril, wait 15 minutes then follow with one spray in each nostril. This will deliver the desired 4 mg. dose.
1767431|NCT00335790|Procedure|Hyperbaric Therapy|
1767432|NCT00335816|Drug|fluorouracil|Given IV
1767433|NCT00335816|Drug|leucovorin calcium|Given IV
1767434|NCT00335816|Drug|oxaliplatin|Given IV
1767435|NCT00335816|Procedure|conventional surgery|Patients undergo surgery
1767436|NCT00335816|Radiation|radiation therapy|Patients undergo radiotherapy
1767437|NCT00335816|Other|laboratory biomarker analysis|Correlative studies
1767438|NCT00335816|Genetic|DNA analysis|Correlative studies
1767439|NCT00335816|Genetic|polymerase chain reaction|Correlative studies
1767440|NCT00335816|Other|immunohistochemistry staining method|Correlative studies
1767441|NCT00335829|Biological|bevacizumab|
1767442|NCT00335829|Drug|chemotherapy|
1767443|NCT00335829|Drug|embolization therapy|
1767444|NCT00335829|Procedure|hepatic artery infusion|
1767445|NCT00335855|Device|Auto-injector for IM/SC vaccine administration|
1767446|NCT00335868|Drug|danusertib|
1767447|NCT00335868|Other|laboratory biomarker analysis|
1767451|NCT00335907|Procedure|Fluid and Vasopressor Protocol|A Physician Ordered, Nurse Administered Fluid and Vasopressor Protocol
1767452|NCT00335920|Drug|Dexamethasone-dihydrogenphosphate (4mg/ml)|
1767453|NCT00335933|Drug|Gabapentin extended-release tablets|
1767454|NCT00335946|Device|HANS non-needle acupuncture|
1767455|NCT00335946|Procedure|Stimulation of two acupuncture points bi-lateral|
1767456|NCT00335959|Drug|capecitabine|850 mg/m2/dose PO q 12 hours Days 1-14 and 22-35. 650 mg/m2/dose PO q 12 hours Days 43-77.
1767457|NCT00335959|Drug|oxaliplatin|130 mg/m2 by 2-hour infusion Days 1 and 22
1767458|NCT00335959|Procedure|conventional surgery|Distal subtotal gastrectomy, total gastrectomy, or proximal gastrectomy
1767459|NCT00335959|Radiation|radiation therapy|Beginning Day 43, patients will be treated 5 days/week at 180 cGy/day times 25 fractions to a total dose of 4,500 cGy.
1767460|NCT00335972|Drug|Remifentanil|Remifentanil will be infused throughout surgery at a rate of 0.1-0.2 µg/kg/min. Propofol will be titrated to maintain a BIS value as close to 45 as clinically practical
1767461|NCT00335972|Drug|Dexmedetomidine|Dexmedetomidine, 0.5-1 µg/kg, will be infused over 20 minutes, immediately followed by an infusion at a rate of 0.2 µg/kg/hr until the end of surgery (For patients in renal failure, the loading dose will be 0.2 µg/kg). The infusion rate will be reduced as necessary to maintain acceptable blood pressure and heart rate. Propofol will be titrated to maintain BIS as close to 45 as clinically practical.
1767462|NCT00335985|Drug|GB-0998|8 mL (400 mg of GB-0998)/kg per day is intravenously administered for five successive days
1767463|NCT00335985|Drug|Placebo of GB-0998|8 mL/kg per day is intravenously administered for five successive days
1767464|NCT00335998|Drug|triapine|Given IV
1767465|NCT00335998|Other|laboratory biomarker analysis|Correlative studies
1767466|NCT00335998|Radiation|external beam radiation therapy|Undergo external beam radiation therapy
1767467|NCT00335998|Radiation|brachytherapy|Undergo intracavitary or interstitial brachytherapy
1767468|NCT00335998|Drug|cisplatin|Given IV
1767469|NCT00335998|Other|pharmacological study|Correlative studies
1767470|NCT00336011|Device|Magnetic resonance imaging|
1767471|NCT00336024|Drug|etoposide|Given IV
1767472|NCT00336024|Drug|cyclophosphamide|Given IV
1767473|NCT00336024|Drug|cisplatin|Given IV
1767474|NCT00336024|Biological|filgrastim|Given IV or SC
1767475|NCT00336024|Drug|carboplatin|Given IV
1767476|NCT00336024|Drug|thiotepa|Given IV
1767477|NCT00336024|Drug|methotrexate|Given IV
1767478|NCT00336024|Drug|leucovorin calcium|Given IV or orally
1767479|NCT00336024|Drug|vincristine sulfate|Given IV
1767480|NCT00336024|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSC transplantation
1767481|NCT00336024|Other|laboratory biomarker analysis|Correlative studies
1767482|NCT00336024|Procedure|quality-of-life assessment|Ancillary studies
1767487|NCT00336076|Other|Collection of blood and bone marrow|5-8 cc blood or bone marrow was additionally collected for analysis during diagnostic procedures. No assigned interventions.
1767488|NCT00336089|Behavioral|exercise intervention|
1767489|NCT00336089|Other|educational intervention|
1767490|NCT00336089|Procedure|complementary or alternative medicine procedure|
1767491|NCT00336089|Procedure|fatigue assessment and management|
1767492|NCT00336089|Procedure|management of therapy complications|
1767493|NCT00336089|Procedure|pain therapy|
1767494|NCT00336089|Procedure|quality-of-life assessment|
1767495|NCT00336102|Other|physiologic testing|Markers of thyroid function including thyroid stimulating hormone (TSH), Free thyroxine (free T4) and Thyroid peroxidase antibody (TPO Ab). These will be performed at baseline, in 12 months and again 24 months after enrollment. All thyroid function marker assays will be performed by LabCorp.
1767496|NCT00336102|Procedure|fatigue assessment and management|Fatigue Symptoms Inventory (FSI) survey
1767497|NCT00336102|Procedure|management of therapy complications|If baseline testing results suggest hyperthyroidism or hypothyroidism, the enrolling center will give test results to participants for follow-up with their primary healthcare provider. Participants with hypothyroidism, who are not started on thyroid hormone, will continue on study, given the TSH level is below 10. Those with hypothyroidism who have treatment initiated will not continue on study. Participants who develop hypothyroidism during the study will not continue on-study if replacement therapy is initiated or if the TSH level is 10 or higher. Work up the next control nominated by the patient or contact the patient for the name of another control
1767498|NCT00336115|Biological|Tetanus and Diphtheria Toxoids Adsorbed Combined with Acellular Pertussis (Adacel)|
1767499|NCT00336128|Behavioral|attitude change|TigerKids: setting based prevention program to reduce obesity risk factors in children
1767500|NCT00336128|Behavioral|adiposity prevention program|The behavioral intervention aimed at modifying physical activity and food and drink choices at the kindergarten setting
1767501|NCT00336141|Drug|Suberoylanilide hydroxamic acid|400 mg QD (every day) for five days, followed by 9 days of no vorinostat
1767502|NCT00336154|Drug|tetracyclin|
1767504|NCT00336180|Behavioral|HealthWise South Africa curriculum|18 classroom lessons
1767505|NCT00336193|Behavioral|Home visitation|Home visitation to improve maternal health and well-being and parenting practices
1767506|NCT00336206|Drug|Alemtuzumab|
1767507|NCT00336219|Drug|Pantoprazole|Symptom Assessment after treatment with Pantoprozole 40 mg
1767508|NCT00336232|Drug|Vitamin K|phylloquinone (vitamin K1) 500 mcg daily in third month
1767509|NCT00336245|Device|Copper T Intrauterine Contraceptive Device|
1767510|NCT00336245|Drug|Hormonal Contraception|
1767511|NCT00336284|Other|Home Monitoring|Home Monitoring programmed on. In-office and Home Monitoring evaluation at 3 and 15 months post ICD implant. Home Monitoring evaluation only at 6, 9, and 12 months post ICD implant.
1767512|NCT00336284|Other|In-Office Conventional Follow-up|Home Monitoring programmed off. In-office evaluations at 3, 6, 9, 12, and 15 months post ICD implant.
1767513|NCT00336297|Procedure|Woman Abuse Screening Tool|
1767514|NCT00336297|Procedure|Partner Violence Screen|
1767515|NCT00336297|Procedure|Computerized screening|
1767516|NCT00336297|Procedure|Face to face screening|
1767517|NCT00336297|Procedure|Written screening on forms|
1767518|NCT00336310|Drug|Repaglinide|
1767519|NCT00336323|Procedure|Laser Photocoagulation|Laser photocoagulation at baseline; If edema present at 12 weeks, can be treated with 2 intravitreal injections of 1.25 mg bevacizumab spaced 6 weeks apart
1767520|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline and 6 weeks
1767521|NCT00336323|Drug|Bevacizumab|2.5 mg intravitreal injection of bevacizumab at baseline and 6 weeks
1767522|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline (sham injection at 6 weeks)
1767523|NCT00336323|Drug|Bevacizumab|1.25 mg intravitreal injection of bevacizumab at baseline, laser photocoagulation at 3 weeks, and intravitreal injection of 1.25 mg bevacizumab at 6 weeks
1767524|NCT00336336|Drug|n-3 PUFA|1 g die per os
1767525|NCT00336336|Drug|Rosuvastatin|10 mg die per os
1767526|NCT00336336|Drug|Placebo|1 gram c. per os
1767527|NCT00336336|Drug|Placebo|10 mg c. per os
1767528|NCT00336349|Drug|Botulinum Toxin Type A|Botulinum Toxin Type A
1767529|NCT00336362|Drug|Hydroxyurea|"Hydroxyurea: Subjects will be treated for one month with hydroxyurea at a starting dose of 10 mg/kg orally (closest approximation to 500 mg capsule, alternate day dosing, e.g. 500 alternating with 1000 to achieve 750 mg average daily dose), once daily, with a gradual dose escalation up to 20 mg/kg (in non-splenectomized patients) and up to 25 mg/kg (in splenectomized patients).
G-CSF: G-CSF will be administered subcutaneously. In general, G-CSF will be administered at 10μg/kg/day (5μg/kg on a twice a day schedule) for at least 4-5 days before leukapheresis and for 1-2 additional days during collections. For the splenectomized patients who are not receiving HU pretreatment, and for the splenectomized patients who receive HU pretreatment who have greater than or equal to 12,000 WBCs before G-CSF, G-CSF will start at a lower dose (for example, 1.5 or 2.5 µg/kg); the next doses will be adjusted by the Principal Investigator based on the observed degree of leukocytosis."
1767530|NCT00336375|Drug|artemether-lumefantrine|All treatment doses given either accompanied or not-accompanied with intake of fatty food.
1767531|NCT00336388|Device|Paracheck Device|
1767532|NCT00336401|Drug|Sevoflurane or Propofol|
1767533|NCT00336414|Drug|cyclophosphamide-prednisone-azathioprine|
1767534|NCT00336453|Biological|Influenza Vaccination|0.5mL dose for intramuscular injection
1767535|NCT00336453|Biological|Influenza Vaccination|0.25mL dose for intramuscular injection
1767536|NCT00336466|Drug|Human recombinant erythropoietin|
1767537|NCT00336479|Drug|Telaprevir|tablet
1767538|NCT00336479|Drug|Ribavirin|tablet
1767539|NCT00336479|Drug|Pegylated Interferon Alfa 2a|Solution for injection
1767540|NCT00336479|Other|Placebo|matching placebo tablet
1767541|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 12 wks through week 42; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 42; infliximab - Could receive infusion of 5mg/kg every 8 weeks up to week 42
1767542|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6 followed by every 8 wks through week 46; infliximab - Could receive infusion of 10mg/kg every 8 weeks up to week 46
1767543|NCT00336492|Biological|infliximab|infliximab - Could receive infusion of 10 mg/kg every 8 weeks up to week 42
1767544|NCT00336492|Biological|infliximab|infusion of 5mg/kg at weeks 0, 2, 6, then every 12 wks through week 42
1767545|NCT00336505|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
1767546|NCT00336505|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
1767547|NCT00336518|Drug|peginterferon alfa-2a|
1767548|NCT00336518|Drug|ribavirin|
1767549|NCT00336531|Drug|itraconazole|2.5 mg/kg twice daily for the first two days --> once daily
1767550|NCT00336544|Drug|Cethromycin|Cethromycin 300 mg once per day (QD) for 7 days, administered orally
1767551|NCT00336544|Drug|Clarithromycin|Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
1767552|NCT00336557|Procedure|NAbs testing|blood drawn for a Binding Antibody (BAb) and Neutralizing Antibody (NAb) test.
1767553|NCT00336583|Drug|Oxaliplatin|Oxaliplatin, 130 mg per square meter, on day 1
1767554|NCT00336596|Procedure|transcranial ultrasound in patients treated with iv t-PA|
1767555|NCT00336622|Device|Splint fabricated by an OT versus an off-the-shelf splint|"Experimental:
Custom-made splint and tendon-nerve gliding exercises Custom-made splint and no tendon-nerve gliding exercises
Control:
Control: Off-the-shelf splint and tendon-nerve gliding exercises Off-the-shelf splint and no tendon-nerve gliding exercises"
1767556|NCT00336635|Biological|cell-culture derived smallpox vaccine|
1767557|NCT00336648|Drug|Avastin (Bevacizumab)|10mg/kg by vein (IV) on Days 1, 2, 15 and 29 the adjuvant therapy every two weeks starting approximately 6 weeks after surgery for three months.
1767558|NCT00336648|Drug|Gemcitabine|400 mg/m2 IV once a week on Days 1, 2, 8,15, 22, 29, 36 +/-2 days (Saturdays)
1767559|NCT00336648|Procedure|Radiation Therapy|Day 3 +/-2 days (Monday) Start Radiation therapy, Mon -Fri x 28 days; 50.4 Gy prescribed to the 95% isodose at 1.8 Gy/fraction (28 fractions)
1767560|NCT00336661|Device|PerioWave|
1767561|NCT00336674|Biological|Intranasal insulin|440IU Insulin
1767562|NCT00336674|Other|Placebo|Placebo insulin carrier solution containing benzalkonium chloride and glycerol
1767563|NCT00336700|Drug|Gemcitabine|1500mg/m2 IV over 150 min IV q 2 weeks 4 months
1767564|NCT00336700|Drug|Erlotinib|150 mg/d Daily, oral 12 months
1767565|NCT00336713|Drug|Saredutant (SR48968C)|oral administration (capsules)
1767566|NCT00336713|Drug|Placebo|oral administration (capsules)
1767567|NCT00336739|Drug|cinacalcet|
1767568|NCT00336752|Procedure|non operative treatment|non operative treatment -casting for 6 weeks
1767569|NCT00336752|Procedure|operative treatment of ankle fractures|operative treatment of ankle fractures
1767570|NCT00336765|Drug|XL647|Tablets supplied in 50-mg strength administered orally daily
1767571|NCT00336778|Drug|3TC, TDF, NLV|3TC 300 mg PO once daily+ TDF 300 mg PO once daily+ NLV 1250 mg PO twice daily (after 12 week lead-in period)
1767572|NCT00336791|Drug|5-Fluorouracil|"FEC Chemotherapy: 500 mg/m^2 IV on day 1 of 21 day cycle.
FAC Chemotherapy: 500 mg/m^2 IV on day 1 and day 4 of 21 day cycle."
1767573|NCT00336791|Drug|Cyclophosphamide|"FAC and FEC Chemotherapy:
500 mg/m^2 IV on day 1 of 21 day cycle."
1767574|NCT00336791|Drug|Doxorubicin|FAC Chemotherapy: 50 mg/m^2 IV on day 1 over 72 hour continuous infusion or IV bolus.
1767575|NCT00336791|Drug|Paclitaxel|80 mg/m^2 by vein (IVPB) over 1 hour every week for 12 weeks
1767576|NCT00336791|Drug|Epirubicin|FEC: 100 mg/m^2 IV on day 1 of 21 day cycle.
1767577|NCT00336817|Drug|Myfortic|Myfortic 360mg or 720 mg BID for 90 days
1767578|NCT00336817|Drug|CellCept|CellCept 500mg or 1000mg BID for 90 days
1767579|NCT00336830|Behavioral|MD-endorsed Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program with signature and strong recommendation from attending physician.
1767580|NCT00336830|Behavioral|Standard Cardiac Rehabilitation referral|Note to patient with general description of the Cardiac Rehabilitation program without signature or recommendation from attending physician.
1767581|NCT00336843|Drug|Zevalin-BuCyE|rituximab (IV, 250 mg/m2 on days −21 and −14) single dose of 90Y-ibritumomab (IV, 0.4 mCi/kg on day −14) Busulfan (IV, 0.8 mg/kg every 6 h from day −7 to day −5) Cyclophosphamide (IV, 50 mg/kg on days −3 and −2) Etoposide (IV, 200 mg/m2 every 12 h on days −5 and −4) Autologous stem cells infusion on day 0
1767582|NCT00336856|Drug|Cetuximab|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
1767583|NCT00336856|Drug|Irinotecan|The treatment will include cetuximab 500 mg/m² IV for 120 minutes followed by irinotecan 180 mg/m² or 60 minutes. The starting dose of irinotecan for patients who are 70 years old or greater, or who have had radiation therapy to the abdomen or pelvis, or whose level of functioning is poor (performance status of 2) will have a starting dose of 150 mg/m2 for irinotecan. All subsequent treatments will include cetuximab 500 mg/m² IV over 60 minutes and irinotecan 150 mg/m² or 180 mg/m2 intravenously over 60 minutes every 2 weeks.
1767584|NCT00336882|Drug|Propofol|Propofol at a dose of 1 mg/kg/hour with a dose increase of 1 mg/kg until therapeutic effect (with a maximum dose of 5 mg/kg/hour)
1767585|NCT00336882|Drug|Midazolam|Midazolam at a dose of 0,03 mg/kg/hour with dose increasing of 0,02 mg/kg/hour until therapeutic effect.
1767586|NCT00336895|Drug|Myfortic|Myfortic 360mg or 720 mg BID for 90 days.
1767587|NCT00336908|Drug|a combination of MCT, LCT , and Fish Oil|
1767588|NCT00336921|Drug|Alfuzosin|Once daily
1767589|NCT00336921|Drug|Placebo|Once daily
1767590|NCT00336934|Dietary Supplement|pomegranate juice|Given orally daily.
1767591|NCT00336934|Other|placebo|Given orally daily.
1767592|NCT00336947|Drug|tegafur-gimeracil-oteracil potassium|
1767593|NCT00336947|Drug|tegafur-uracil|
1767594|NCT00336947|Procedure|adjuvant therapy|
1767595|NCT00336960|Drug|celecoxib|twice daily beginning 5 days prior to radiotherapy and continuing until completion of radiotherapy
1767596|NCT00336960|Drug|fluorouracil|Patients receive concurrent fluorouracil IV continuously for 5 weeks.
1767597|NCT00336960|Procedure|conventional surgery|4-10 weeks after completion of chemoradiotherapy
1767598|NCT00336960|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 5 weeks
1767599|NCT00336960|Procedure|tumor biopsy|at baseline and then at the time of surgical resection
1767600|NCT00336960|Other|laboratory biomarker analysis|blood and urine collected at baseline, 5 days after initiation of celecoxib, 7 days after initiation of celecoxib in combination with fluorouracil and radiotherapy, and at the time of surgical resection. specimens are evaluated for COX-2 expression, eicosanoid production, and gene and protein expression using immunohistochemistry, microarray, and mass spectrometry.
1767601|NCT00336973|Drug|efalizumab|Subcutaneous repeating dose
1767602|NCT00336986|Drug|recombinant interleukin-21|
1767603|NCT00337038|Drug|N-acetylcystein(drug)|p.O t.Siran 200mg x1 during one weak
1767604|NCT00337051|Drug|Sevoflurane|General anesthesia using Sevoflurane (inhalation) as hypnotic
1767605|NCT00337051|Drug|Propofol|General anesthesia with propofol TCI
1767606|NCT00337064|Procedure|Radiation Therapy|
1767607|NCT00337077|Drug|eribulin mesylate|Given IV
1767608|NCT00337090|Drug|YM178|
1767609|NCT00337103|Drug|Eribulin Mesylate|1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days
1767610|NCT00337103|Drug|Capecitabine|Capecitabine 2.5 g/m^2/day administered orally twice daily in two equal doses on Days 1 to 14 every 21 days
1767611|NCT00337116|Drug|iso sorbide dinitrate iv bolus or s/l|
1767612|NCT00337129|Drug|eribulin mesylate|1.4 mg/m2 by IV bolus on Days 1 and 8 of an every 21-day cycle.
1767613|NCT00337155|Drug|Radium-223 dichloride (BAY88-8223)|3 doses of radium-223 at different dose levels, 25, 50 or 80 kBq/kg b.w.given as injection.
1767614|NCT00337168|Drug|clofarabine|Induction: 40mg/m2/d; IV over 1 hr; days 1-5 Re-induction (if necessary): 40mg/m2/d; IV over 1 hr; days 1-5 Consolidation: 40mg/m2/d; IV over 1 hr; days 1-4
1767615|NCT00337168|Drug|cytarabine|Induction: 1g/m2/d; IV over 2 hrs; days 1-5 Re-induction (if necessary): 1g/m2/d; IV over 2 hrs; days 1-5 Consolidation: 1g/m2/d; IV over 2 hrs; days 1-4
1767616|NCT00337194|Biological|monoclonal antibody SGN-30|Given IV
1767617|NCT00337194|Other|placebo|Given IV
1767618|NCT00337194|Drug|vinorelbine tartrate|Given IV
1767619|NCT00337194|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
1767620|NCT00337194|Drug|gemcitabine hydrochloride|Given IV
1767621|NCT00337194|Other|laboratory biomarker analysis|Correlative studies
1767622|NCT00337194|Other|pharmacological study|Correlative studies
1767623|NCT00337207|Biological|bevacizumab|Bevacizumab 15 mg/kg every 3 weeks over 30 to 90 minutes. One cycle = 3 weeks. Treatment continues until progressive disease or unacceptable toxicity.
1767624|NCT00337233|Procedure|yoga therapy|10 week yoga class
1767625|NCT00337246|Biological|rituximab|
1767626|NCT00337246|Drug|cyclophosphamide|
1767627|NCT00337246|Drug|fludarabine phosphate|
1767628|NCT00337246|Drug|mitoxantrone hydrochloride|
1767629|NCT00337259|Drug|gemcitabine|D1 and 8, Gemcitabine 1250mg/m2 + NS 100ml MIV over 30min, every 3 weeks
1767630|NCT00337272|Drug|Placebo|Placebo taken 30 minutes before bedtime days 1-28 of treatment period
1767631|NCT00337272|Drug|Ramelteon|8 mgs daily for days 1-28 of treatment period
1767632|NCT00337285|Drug|Vyvanse (lisdexamfetamine dimesylate), NRP104|NRP104 capsule once-a-day orally beginning at 30mg/day and titrated by 20 mg per day at weekly intervals up to a maximum daily dose of 70 mg
1767633|NCT00337298|Drug|Amlodipine|1 (5mg) tablet daily, given 14 days totally before measure of outcome.
1767634|NCT00337298|Drug|Lisinopril|Lisinopril 10 mg given daily for 14 days and then outcome was measured.
1767635|NCT00337324|Device|Frequency-modulated electromagnetic neural stimulation|
1767636|NCT00337337|Behavioral|Multiple grain|
1767637|NCT00337337|Behavioral|Ordinary Asian- rice|
1767638|NCT00337350|Drug|rosiglitazone|Rosiglitazone 4mg, one capsule per day for eight weeks
1767639|NCT00337350|Drug|placebo|matched placebo for rosiglitazone 4mg/day
1767640|NCT00337376|Drug|Rapamune|Dose escalation as follows: 5mg PO, 10mg PO, 20mg PO, 40mg PO
1767641|NCT00337376|Drug|Abraxane|intravenous administration of 100mg/m2 Abraxane over 30 minutes, weekly for three out of four consecutive weeks.
1767642|NCT00337389|Drug|5- Fluorouracil (5-FU)|
1767643|NCT00337389|Drug|bevacizumab (Avastin)|
1767644|NCT00337389|Drug|Leucovorin|
1767645|NCT00337389|Drug|CoFactor (ANX-510)|
1767646|NCT00337415|Drug|MK0354|
1767647|NCT00337428|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Current Manufacturing Facility (CMF)|GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the current manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
1767648|NCT00337428|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant (qHPV) Vaccine from Future Manufacturing Facility (FMF)|GARDASIL™ (quadrivalent human papillomavirus [types 6, 11, 16, 18] virus-like particle [VLP] vaccine, referred to as qHPV vaccine) made at the future manufacturing facility was administered as 0.5-mL intramuscular dose at Day 1, Month 2, and Month 6.
1767649|NCT00337428|Biological|Comparator: REPEVAX™ (Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Day 1 in a limb opposite that of quadrivalent HPV injection.
1767650|NCT00337428|Biological|Comparator: REPEVAX™ (Non-Concomitant)|REPEVAX™ (diphtheria, tetanus, pertussis [acellular, component] and poliomyelitis [inactivated] vaccine, Sanofi Pasteur, Swiftwater, PA U.S.A) was administered as a single 0.5-mL intramuscular dose at Month 1 in a limb opposite that of quadrivalent HPV injection.
1767651|NCT00337441|Drug|Epoetin Alfa (drug)|
1767652|NCT00337454|Drug|Dasatinib|Tablets, Oral, 50mg BID, once daily, 24 weeks.
1767653|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
1767654|NCT00337454|Drug|Dasatinib|Tablets, Oral, 90mg BID, once daily, 24 weeks.
1767655|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 24 weeks.
1767656|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
1767657|NCT00337454|Drug|Dasatinib|Tablets, Oral, 70mg BID, once daily, 12 weeks.
1767658|NCT00337467|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg + RTV 100mg, once daily, 96 weeks
1767659|NCT00337480|Behavioral|education|education of acute coronary syndrome patients, mostly about nicotinic weaning, weight loss and physical activity
1767660|NCT00337493|Drug|mycophenolate mofetil [CellCept]|Concentration-controlled
1767661|NCT00337493|Drug|mycophenolate mofetil [CellCept]|1g po bid
1767662|NCT00337493|Drug|Cyclosporine or tacrolimus|Reduced
1767663|NCT00337493|Drug|Cyclosporine or tacrolimus|Standard, as prescribed
1767664|NCT00337506|Drug|Dexamethasone|
1767665|NCT00337506|Drug|velcade|
1767666|NCT00337519|Procedure|allogeneic stem cell transplantation|see detailed description
1767667|NCT00337519|Drug|Alemtuzumab|alemtuzumab is given as cytoreductive pre-treatment with the last application of alemtuzumab scheduled for day 14
1767668|NCT00337532|Drug|Paclitaxel|Sterile solution mixed with 0.9% saline or 5% glucose solution 500mL, 3-hour Continuous infusion, Level 0: 175 mg/m2, Level 1: 140 mg/m2, Level 2: 105 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
1767669|NCT00337532|Drug|cisplatin|solution mixed with 0.9% saline 500mL, 30 to 90 min intravenous infusion, Level 0: 75 mg/m2, Level 1: 60 mg/m2, Level 2: 45 mg/m2 (dose reduction in function of toxicity), Day 1 of each cycle, max of 3 cycles; each cycle of 21 days ± 3 days.
1767670|NCT00337545|Drug|RAD001|
1767671|NCT00337558|Drug|Solifenacin succinate|tablet
1767672|NCT00337558|Behavioral|Simplified bladder training|Instructions
1767673|NCT00337571|Drug|Aripiprazole|Tablets, Oral, once daily, 8 weeks
1767674|NCT00337571|Drug|Placebo|Tablets, Oral, once daily, 8 weeks
1767675|NCT00337584|Procedure|Pre-surgical screening|
1767676|NCT00337597|Other|Glucose 5%|
1767677|NCT00337597|Other|NaCl 0.9%|
1767678|NCT00337610|Drug|sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive blinded sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
1767679|NCT00337610|Drug|comparator: placebo to match sitagliptin 100 mg q.d./metformin ≥ 1500 mg/day|Patients will receive placebo to match sitagliptin 100 mg q.d. and open-label metformin ≥ 1500 mg/day for up to 30 weeks. Sitagliptin 100 mg q.d. and metformin ≥ 1500 mg/day will be administered as oral tablets.
1767680|NCT00337623|Drug|Prednisolone|
1767681|NCT00337636|Procedure|Surgery to implant human CNS stem cells (HuCNS-SC)|single dose
1767682|NCT00337636|Drug|Medication to suppress the immune system|Immunosuppression for 12 months post transplant
1767683|NCT00337649|Drug|Epothilone D|<100mg/m2 iv on days 1, 8 and 15 every 4 weeks
1767684|NCT00337649|Drug|Herceptin|4mg/kg iv loading dose followed by 2mg/kg iv weekly
1767685|NCT00337662|Drug|olanzapine|10-20 milligrams (mg), oral, daily, 10 weeks.
1767686|NCT00337662|Drug|risperidone|2-6 mg, oral, daily, for 10 weeks.
1767687|NCT00337662|Drug|risperidone|2-6 mg, oral, daily, 10 weeks
1767688|NCT00337675|Drug|montelukast sodium|Montelukast 4 mg (or 5 mg, depending on age of patient) qd + episode driven supplemental Pbo qd for 12 days for a 52-wk treatment period.
1767689|NCT00337675|Drug|Comparator: Placebo (unspecified)|Placebo (Pbo) qd + episode driven supplemental Pbo for 12 days for a 52-wk treatment period.
1767690|NCT00337675|Drug|montelukast sodium|Pbo qd + episode driven supplemental Montelukast 4 mg (or 5 mg, depending on age of patient) qd for 12 days for a 52-wk treatment period.
1767691|NCT00337688|Device|isometric joystick|isometric joystick
1767692|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by Biojector 2000 NFID for 8 weeks
1767693|NCT00337701|Drug|enfuvirtide [Fuzeon]|90mg sc bid by standard needle and syringe for 4 weeks, followed by 90mg sc bid by Biojector 2000 NFID for 4 weeks.
1767694|NCT00337714|Procedure|CVC impregnated with silver nanoparticles (AgTive®)|insertion of medicated silver nanoparticles CVC
1767695|NCT00337714|Procedure|CVC cannulation|placement of conventional trilumen CVCs
1767696|NCT00337727|Drug|aprepitant|aprepitant 125 mg capsule; aprepitant 80 mg capsule Three day treatment period.
1767697|NCT00337727|Drug|Comparator: ondansetron|Ondansetron 8 mg capsule Three day treatment period.
1767698|NCT00337727|Drug|Comparator: dexamethasone|dexamethasone 12 mg tablets; 20 mg tablets Three day treatment period.
1767699|NCT00337727|Drug|Comparator: fosaprepitant dimeglumine|fosaprepitant dimeglumine 115 mg
1767700|NCT00337727|Drug|Comparator; Placebo (unspecified)|dexamethasone 12mg Pbo tablets.
1767701|NCT00337727|Drug|Comparator; Placebo (unspecified)|Aprepitant 80 mg & 125 mg Pbo capsules.
1767702|NCT00337740|Procedure|endoscopic variceal banding|
1767703|NCT00337740|Drug|propranolol|
1767704|NCT00337753|Behavioral|Cognitive Behavioral Therapy|5-weeks of Cognitive Behavioral Therapy
1767705|NCT00337753|Behavioral|Wait-list|subjects assigned to wait-list condition for six-weeks
1767706|NCT00337766|Drug|Desmopressin (DDAVP)|
1767707|NCT00337766|Drug|Placebo|
1767708|NCT00337779|Drug|Glatiramer Acetate (GA) 40 mg|Glatiramer Acetate Injection 40 mg/ml Daily subcutaneous injection for 12 months
1767709|NCT00337779|Drug|glatiramer acetate 20 mg|Glatiramer Acetate Injection 20 mg/ml Daily subcutaneous injection for 12 months
1767710|NCT00337792|Drug|oxycodone + lorazepam versus fentanyl + midazolam|
1767711|NCT00337805|Other|Pentaspan|When fluids are indicated either pentaspan or saline are given in a double blind randomized assignment
1767712|NCT00337818|Biological|Cervarix™|Three doses of vaccine according to a 0, 1, 6 month schedule (during the primary study)
1767713|NCT00337831|Procedure|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration|Performance of predilution hemofiltration, predilution hemodiafiltration or postdilution hemodiafiltration is followed.
1767714|NCT00337870|Behavioral|PAT|Cognitive-Behavioral/Relaxation Intervention
1767715|NCT00337883|Drug|Erlotinib HCl (OSI-774)|
1767716|NCT00337909|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
1767717|NCT00337909|Other|Educational DVDs|
1767718|NCT00337922|Drug|Lamivudine / Abacavir Sulfate|
1767719|NCT00337935|Drug|Epoetin Alfa|Epoetin alfa administered at 20,000 IU subcutaneously every 2 weeks for a period of 26 weeks
1767720|NCT00337935|Other|Standard of care|
1767721|NCT00337948|Drug|Epoetin alfa|
1767722|NCT00337961|Procedure|Optic Nerve Sheath Fenestration|
1767723|NCT00337974|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
1767724|NCT00337974|Other|Educational DVDs|
1767725|NCT00337987|Drug|Ontak|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
1767726|NCT00337987|Drug|CHOP (cyclophosphamide (C), adriamycin (H), vincristine (O), and prednisone (P)) chemotherapy|ONTAK ( denileukin diftitox) is given at 18 mcg/kg/d (Days 1,2) plus CHOP therapy (Day 3) q 21 days x 6 cycles (cyclophosphamide 750 mg/m²IV, doxorubicin 50 mg/m²IV day, vincristine 1.4 mg/m²IV day, and prednisone 100 mg q day PO days #3-7) plus, G-CSF support beginning on Day 4 to prevent neutropenia
1767727|NCT00338000|Drug|Epoetin alfa|
1767728|NCT00338026|Drug|ECO-4601|Continuous IV infusion for 14 days with 7 days recovery (21 day cycle)
1767729|NCT00338039|Drug|Cetuximab|500 mg/m^2 IV/week +/-1 day continued throughout induction chemotherapy, chemoradiation and maintenance chemotherapy.
1767730|NCT00338039|Drug|Gemcitabine|"Induction Therapy: 1 gm/m^2 over 100 minutes every 2 weeks +/-1 day for 4 doses.
Chemotherapy Maintenance: 1 gm/m^2/week over 100 minutes weekly for 3 weeks then 1 week off."
1767731|NCT00338039|Drug|Oxaliplatin|Induction Chemotherapy: 100 mg/m^2 over 120 minutes every 2 weeks +/-1 day for 4 doses.
1767732|NCT00338039|Drug|Capecitabine|Chemoradiation (to start 2-3 weeks post completion of oxaliplatin and gemcitabine): 825 mg/m^2 by mouth (PO) twice daily Monday-Friday throughout radiation.
1767733|NCT00338039|Radiation|Radiotherapy|Conformal radiation therapy to gross disease, total dose = 50.4 Gy delivered in 28 fractions.
1767734|NCT00338052|Drug|Norethindrone 1 mg / ethinyl estradiol 20 mcg|
1767735|NCT00338065|Behavioral|Postural change|Intraocular pressures, blood pressures, and retinal thicknesses are measured with postural changes
1767736|NCT00338065|Behavioral|Water drinking|Intraocular pressures, blood pressures, and retinal thicknesses are measured with water drinking.
1767737|NCT00338078|Device|nocturnal oxygen treatment from oxygen concentrators|
1767738|NCT00338091|Drug|Benazepril|
1767739|NCT00338091|Drug|Losartan|
1767740|NCT00338104|Drug|insulin glargine|Insulin glargine given at 40% of prior stable drip rate.
1767741|NCT00338104|Drug|insulin glargine|Insulin glargine given at 60% of prior stable drip rate.
1767742|NCT00338104|Drug|insulin glargine|Insulin glargine given at 80% of prior stable drip rate.
1767743|NCT00338117|Drug|Galantamine hydrobromide|
1767744|NCT00338130|Drug|AZD6244|Oral liquid or Capsule
1767745|NCT00338130|Drug|Temozolomide|oral
1767746|NCT00338143|Drug|efalizumab|
1767747|NCT00338182|Drug|AZD1152 part A|48-hour continuous intravenous infusion
1767748|NCT00338182|Drug|AZD1152 part B|2-hour intravenous infusion
1767749|NCT00338195|Behavioral|Individualized caffeine cessation instructions|Intervention is described in the protocol
1767750|NCT00338208|Behavioral|Training in the Use of Low Vision Devices|
1767751|NCT00338221|Drug|alanyl-glutamine|
1767752|NCT00338221|Drug|glycine|
1767753|NCT00338247|Drug|lapatinib + capecitabine|Experimental
1767754|NCT00338260|Drug|MK0954, /Duration of Treatment : 5 Years|
1767755|NCT00338260|Drug|Comparator : atenolol /Duration of Treatment : 5 Years|
1767756|NCT00338273|Drug|Aripiprazole|Tablets, Oral, 5 - 30 mg, Once daily, 8 weeks.
1767757|NCT00338273|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 8 weeks.
1767758|NCT00331578|Device|Excel drug-eluting coronary artery stent|
1767759|NCT00331604|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
1767760|NCT00331604|Drug|insulin detemir|Injection s.c., 50% of daily dose.
1767761|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
1767762|NCT00331604|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. After 2 years.
1767763|NCT00331630|Drug|lapatinib ditosylate|Oral lapatinib is taken once daily on days 1-21 of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
1767764|NCT00331630|Drug|paclitaxel albumin-stabilized nanoparticle formulation|30 patients receive Abraxane IV over 30 minutes on day 1 each of each treatment cycle. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
1767765|NCT00331643|Drug|ixabepilone|Given IV
1767766|NCT00331656|Device|Non-invasive positive pressure mask ventilators|
1767767|NCT00331656|Device|Extrathoracic biphasic cuirass ventilator (RTX, Hayek)|
1767768|NCT00331669|Procedure|deep brain stimulation|high frequency stimulation
1767769|NCT00331682|Drug|alvocidib|Given IV
1767770|NCT00331682|Drug|docetaxel|Given IV
1767771|NCT00331695|Drug|17 alpha-hydroxyprogesterones caproate|17 alpha-hydroxyprogesterones caproate
1767772|NCT00331708|Drug|Artesunate plus sulfadoxine-pyrimethamine|
1767773|NCT00331721|Drug|Enecadin|Dose escalating
1767774|NCT00331721|Drug|Placebo|Placebo comparator
1767775|NCT00331747|Drug|Glatiramer acetate|
1767776|NCT00331760|Drug|cisplatin|
1767777|NCT00331760|Radiation|intensity-modulated radiation therapy|
1767778|NCT00331773|Radiation|Conventional 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 1.8 Gy per fraction, for 41 fractions and a total dose of 73.8 Gy
1767779|NCT00331773|Radiation|Hypofractionated 3D-CRT or IMRT|Radiation therapy will be given once daily, five days a week, at 2.5 Gy per fraction, for 28 fractions and a total dose of 70 Gy.
1767780|NCT00331786|Drug|nitric oxide-releasing acetylsalicylic acid derivative|
1767781|NCT00331786|Other|laboratory biomarker analysis|
1767782|NCT00331786|Procedure|biopsy|
1767783|NCT00331799|Drug|Duloxetine|Open label treatment with Duloxetine for 8 wks. Dose 30-60 mg.
1767784|NCT00331812|Procedure|Mitochondrial functions and oxidative stress|
1767785|NCT00331825|Drug|Risperidone and Olanzapine|
1767786|NCT00331838|Drug|Semuloparin sodium|"0.8 mL solution in Type I amber glass vials
Subcutaneous injection"
1767787|NCT00331838|Drug|Placebo (for Enoxaparin sodium)|"0.4 mL solution in ready-to-use prefilled syringe strictly identical in appearance containing the same volume but without active component
Subcutaneous injection"
1767788|NCT00331838|Drug|Enoxaparin sodium|"0.4 mL solution in ready-to-use pre-filled syringe
Subcutaneous injection"
1767789|NCT00331838|Drug|Placebo (for Semuloparin sodium)|"0.8 ml solution in type I amber glass vials strictly identical in appearance containing the same volume but without active component
Subcutaneous injection"
1767790|NCT00331851|Drug|liraglutide|
1767791|NCT00331851|Drug|insulin glargine|
1767792|NCT00331851|Drug|metformin|
1767793|NCT00331851|Drug|glimepiride|
1767794|NCT00331864|Drug|Ranibizumab|
1767795|NCT00331877|Procedure|family conference with bereavement information leaflet|
1767796|NCT00331890|Drug|Citicoline|1g/12h iv during 3 days and then orally until complete 6 weeks of treatment
1767797|NCT00331890|Drug|Placebo|As active drug
1767798|NCT00331916|Drug|quinolone|
1767799|NCT00331929|Device|Minato A 500 AS spirometer|Spirometry at rest
1767800|NCT00331955|Drug|doxorubicin hydrochloride|Given IV
1767801|NCT00331955|Drug|vorinostat|Given orally
1767802|NCT00331955|Other|pharmacological study|Correlative studies
1767803|NCT00331955|Other|laboratory biomarker analysis|Correlative studies
1767804|NCT00331981|Drug|Amisulpride|
1767805|NCT00331994|Drug|Bacillus clausii|3 bacillus clausii vials/day for one month
1767806|NCT00331994|Drug|Metronidazole|3 Metronidazole tablets/day for one week
1767807|NCT00332007|Drug|Tonabersat|two tablets once daily
1767808|NCT00332007|Drug|Placebo|two tablets once daily
1767809|NCT00332020|Drug|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 35 +/- 4 days
1767810|NCT00332020|Drug|Enoxaparin|40 mg enoxaparin syringe administered for 12 +/- 2 days
1767811|NCT00332033|Drug|Pirfenidone|
1767812|NCT00332046|Drug|GW679769|
1767813|NCT00332059|Drug|bimatoprost/timolol fixed combination|
1767814|NCT00332072|Drug|bimatoprost/timolol fixed combination|
1767815|NCT00332085|Drug|Chromium Picolinate|
1767816|NCT00332098|Behavioral|Family-Focused Treatment Plus Pharmacotherapy|Participants assigned to FFT will take part in weekly treatment sessions with their families for 12 weeks, biweekly for 12 weeks, monthly for 3 months, and then trimonthly until Month 24. Medications used for the pharmacotherapy portion of the study will include mood stabilizers, such as lithium or divalproex sodium, and atypical antipsychotics, such as quetiapine. Participants will also receive anti-anxiety medications, psychostimulants, or antidepressants as needed.
1767817|NCT00332098|Behavioral|Enhanced Care Plus Pharmacotherapy|Participants assigned to Enhanced Care will take part in weekly brief psychoeducation sessions for 3 weeks. The pharmacotherapy treatment will be the same as for the FFT participants.
1767818|NCT00332124|Drug|Choline|900 mg every day until birth of infant
1767819|NCT00332124|Dietary Supplement|Placebo|Corn oil every day in place of choline
1767820|NCT00332137|Drug|Tolterodine|
1767821|NCT00332163|Biological|Panitumumab|Administered by intravenous infusion
1767822|NCT00332163|Drug|Irinotecan|Recommended dosage regimen and administration of irinotecan was based on local standard of care, the package insert, and institutional guidelines.
1767823|NCT00332163|Drug|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
1767824|NCT00332163|Drug|Pre-emptive Skin Treatment|Pre-emptive skin treatment included a skin moisturizer (eg, Lubriderm), sunscreen (free of paraaminobenzoic acid (PABA), skin protection factor (SPF) 15 or higher, ultraviolet-A (UV-A), and UV-B protection), topical steroid (1% hydrocortisone cream) and oral antibiotic (doxycycline, 100 mg twice daily).
1767825|NCT00332163|Drug|Reactive Skin Treatment|Treatment was based on symptoms and severity and may have included an emollient (eg, Lubriderm, Vaseline), sunscreen (SPF ≥ 15), oral antibiotic (eg, doxycycline, ciprofloxacin, cefadroxil, amoxicillin/clavulanic acid), topical steroid (hydrocortisone cream), topical antibiotic (clindamycin), oral systemic steroid, topical medical treatment (eg, silver sulfadiazine, Silvadene), topical antihistamine or oral antihistamine (hydroxyzine)
1767826|NCT00332176|Drug|Celgosivir|400mg qd + standard of care for 12 weeks
1767827|NCT00332176|Drug|Celgosivir|600mg qd + standard of care for 12 weeks
1767828|NCT00332176|Drug|Peginterferon alfa 2b + ribavirin|Standard of care for 12 weeks
1767829|NCT00332189|Drug|sapropterin dihydrochloride|5-20mg/kg/day orally, dose may be adjusted up or down as needed at the discretion of the investigator in increments of 5mg/kg/day.
1767830|NCT00332202|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or maximum of 3 years
1767831|NCT00332202|Drug|placebo|oral, daily
1767832|NCT00332215|Drug|Inhaled Sodium Pyruvate|
1767833|NCT00332228|Drug|depot naltrexone|long-acting depot parenteral formulation of naltrexone
1767834|NCT00332228|Behavioral|Compliance enhancement (CE)|Compliance enhancement (CE), simulating standard treatment with oral naltrexone
1767835|NCT00332228|Drug|BNT|behavioral therapy with oral naltrexone maintenance for the treatment of heroin addiction
1767836|NCT00332241|Drug|Aripiprazole|Tablets, Oral, 5, 10, or 15 mg, once daily, 8 weeks
1767837|NCT00332241|Drug|Placebo|Tablets, Oral, once daily, 8 weeks
1767838|NCT00332254|Drug|Anakinra|150 mg IL1Ra ia x1 vs saline ia x1
1767839|NCT00332267|Procedure|Endotoxin infusion, Normobaric hypoxia|
1767840|NCT00332280|Drug|AMT2003|
1767841|NCT00332293|Drug|Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
1767842|NCT00332293|Drug|Moxifloxacin hydrochloride ophthalmic solution 0.5% as base|1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
1767843|NCT00332306|Drug|Didanosine, Lamivudine, Efavirenz|Didanosine 250mg patients <60kg, 400mg patients > 60kg once daily Lamivudine 300 mg once daily Efavirenz 600 mg once daily All drugs will be given for 24 months
1767844|NCT00332306|Drug|Didanosine, Lamivudine, Nevirapine|Didanosine 250 mg once daily for patients < 60kg, 400 mg OD patients > 60kg Lamivudine 300 mg once daily Nevirapine 400 mg once daily All drugs will be given for 24 months
1767846|NCT00332332|Biological|etanercept|etanercept subcutaneous injection
1767847|NCT00332345|Drug|brimonidine/timolol fixed combination|
1767848|NCT00332371|Device|CPFA (Coupled Plasma Filtration Adsorption)|"CPFA is a specific method for the treatment of sepsis.
It consists of:
a plasma-filter (polyethersulfone 0.45 m2 with a cutoff of approx 800 kDa)
a hemofilter (polyethersulfone 1,4 m2)
a cartridge (contains approximately 140 ml of hydrophobic styrenic resin)
The kit is lodged in the Bellco Lynda machine (Bellco Mirandola, Italy). The treatment consists of the separation of plasma from the whole blood with adsorption of the inflammatory mediators and cytokines from the plasma, and a subsequent purification step by way of a hemofilter."
1767849|NCT00332384|Drug|brimonidine/timolol fixed combination|
1767850|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, Cypher stent will be implanted
1767851|NCT00332397|Device|Zotarolimus-eluting Stent|due to randomization, Endeavor stent will be implanted
1767852|NCT00332397|Device|Rapamycin-eluting Stent|due to randomization, rapamycin-eluting stent will be implanted
1767853|NCT00332436|Drug|brimonidine/timolol fixed combination|
1767854|NCT00332462|Drug|Cyclosporine (Sandimmun® i.v.)|Cyclosporine (Sandimmun® i.v.) intravenous given 2 times daily as an infusion over four hours staring at a dose of 2 X 200 mg/day for 7 days. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
1767855|NCT00332462|Drug|Cyclosporine (Sandimmun® Optoral)|Sandimmun® Optoral microemulsion oral capsule twice daily starting at an initial daily dose of 8-12 mg/kg/day. Dosages were adjusted based on blood levels at two hours to achieve protocol specified target levels.
1767856|NCT00332488|Drug|Technosphere Insulin|Inhalation, 15U/30U, prandial
1767857|NCT00332488|Drug|Metformin & Secretagogues|Metformin tablets,Secretagogues supplied as any of the currently marketed brands and formulations.
1767858|NCT00332488|Drug|Technosphere Insulin & Metformin|Technosphere Insulin Inhalation Powder 15U/30U, Metformin tablets
1767859|NCT00332514|Behavioral|telephone call by a pharmacist|
1767860|NCT00332540|Drug|bimatoprost/timolol fixed combination|
1767861|NCT00332553|Drug|Raloxifene|
1767862|NCT00332553|Drug|medroxyprogesterone acetate|
1767863|NCT00332553|Drug|estrogen|
1767864|NCT00332553|Drug|17 beta estradiol|
1767865|NCT00332566|Biological|DTPw-HBV/Hib Kft vaccine GSK323527A|Intramuscular injection, 1 dose
1767866|NCT00332566|Biological|Tritanrix™-HepB/Hiberix™|Intramuscular injection, 1 dose
1767867|NCT00332579|Drug|Naltrexone|daily
1767868|NCT00332579|Drug|Placebo|daily
1767869|NCT00332605|Drug|Naltrexone plus N-Acetyl Cysteine|daily
1767870|NCT00332605|Drug|Placebo|daily
1767871|NCT00332618|Device|OXYGENATED GLYCEROL TRIESTERS|
1767872|NCT00332631|Drug|N-acetylcysteine|
1767873|NCT00332631|Drug|Placebo|
1767874|NCT00332644|Drug|nicotine patch|used according to FDA package label
1767875|NCT00332644|Drug|nicotine lozenge|used according to FDA-approved package directions
1767876|NCT00332644|Drug|nicotine patch + nicotine lozenge|dosage of both according to FDA-approved dosing schedule
1767877|NCT00332644|Drug|bupropion|dosage according to FDA-approved instructions
1767878|NCT00332644|Drug|bupropion + lozenge|dosage according to FDA approved standard instructions
1767879|NCT00332644|Drug|placebo|dosage same as active drug conditions
1767880|NCT00332657|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
1767881|NCT00332657|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|One 0.5 mL injection into the PJD at 6-month intervals for 42 months
1767882|NCT00332657|Other|Anecortave Acetate Vehicle|One 0.5 mL sham injection at 6-month intervals for 42 months. Syringe and vehicle were not inserted into the eye.
1767883|NCT00332670|Procedure|10.000lux blue 1 hour every day during three weeks|10.000lux during 60 minutes, starting 1 hour after wake-up, during 3 weeks
1767884|NCT00332670|Procedure|50lux dim red 1 hour every day during three weeks|50 lux red light, 60 minutes every morning, starting 1 hour after wake-up, during three weeks
1767885|NCT00332683|Procedure|Maintaining low (15mmHg) ETT cuff pressure|Manipulation of the ETT cuff pressure to hold a lower pressure of 15 mmHg
1767886|NCT00332683|Procedure|Maintaining a normal pressure in the ETT cuff|No manipulation to maintain a low pressure of 15 mm Hg in the ETT cuff
1767887|NCT00332696|Drug|Octreotide LAR|Octreotide long-acting release (LAR) 30 mg intramuscular injection.
1767888|NCT00332696|Drug|Octreotide (Immediate release)|Immediate-release Octreotide supplied in 100 µg/mL ampules.
1767889|NCT00332696|Drug|methylprednisolone|methlylpredinisolone 3-4 mg/kg per day (IV bolus for 1 hour or 2 subcutaneous injections).
1767890|NCT00332696|Drug|Placebo|Physiologic saline solution
1767891|NCT00332709|Drug|Letrozole|2.5 mg/day for 3 years
1767892|NCT00332709|Drug|Zoledronic acid|4 mg every 6 months
1767893|NCT00332722|Procedure|Cervical facet joint nerve blocks|
1767894|NCT00338286|Other|Standard supportive care (packed RBC transfusion)|Per doctor prescription
1767895|NCT00338286|Drug|epoetin alfa + packed RBC transfusion|40,000 IU SC once a week.
1767896|NCT00338299|Drug|Epoetin alfa|
1767897|NCT00338312|Drug|Testosterone Transdermal System|testosterone patch (300 mcg/day) patch changed 2 times/week, for one year
1767898|NCT00338312|Drug|Placebo patch|placebo patch changed twice a week for one year
1767899|NCT00338325|Behavioral|Reading program|Reading of children's story/picture books preoperatively
1991618|NCT00787176|Procedure|No additional fluid|Regular maintenance infusion of Lactated Ringers @ 125 ml/hr; no additional fluids
1767902|NCT00338351|Biological|Pneumococcal (vaccine)|
1767903|NCT00338364|Behavioral|PAT|Coping and Distraction Intervention
1767904|NCT00338377|Biological|Dendritic Cell Immunization|1x10^7 to 2.5x10^8 MART-1 peptide-pulsed Dendritic Cells given by vein over 20-30 minutes approximately 4 hrs after receiving T cells.
1767905|NCT00338377|Drug|Cyclophosphamide|60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
1767906|NCT00338377|Drug|Fludarabine|25 mg/m^2 by vein daily over 30 minutes on Days -5 to -1 before T cell infusion.
1767907|NCT00338377|Biological|T-Cells|On Days 0, up to 1.5 x 10^11 T-cells by vein infusion over 30-60 minutes.
1767908|NCT00338377|Biological|Interleukin-2|12-16 hours after completing the T cell infusion, all will receive high dose IL-2 on an inpatient basis at the standard dose of 720,000 IU/kg as an intravenous bolus over approximately a 15 minute period every 8-16 hours for up to 15 doses on Days 1-5 and 22-26 (+/- 7 days), as tolerated.
1767909|NCT00338377|Drug|Mesna|60 mg/kg with D5W or NS at 125 ml/hr infused intravenously over 24 hours on Day -7 and -6.
1767910|NCT00338377|Biological|Intrathecal T-Cells|5.0x10^9 T-cells administered on Day 1, and 10x10^9 T-cells on Day 15. 1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated.
1767911|NCT00338377|Biological|Intrathecal Interleukin-2|1.2 MIU of IL- 2 on Day 2, 4, 9, 11, 16 and 18 as tolerated. Then, patient receives twice weekly IL-2 that will be gradually changed to weekly IL-2. After 4-6 weeks patients switched to IL-2 maintenance.
1767912|NCT00338390|Drug|Abacavir|Change tenofovir to abacavir
1767913|NCT00338390|Drug|Didanosine|Increase didanosine dose to 400 mg/day if weight is > 60 Kg. or to 250mg/day if weight is < 60 kg.
1767914|NCT00338390|Drug|Abacavir+Lamivudine|Change tenofovir and didanosine to abacavir + lamivudine (600mg+300 mg/day in one single tablet).
1767915|NCT00338403|Procedure|Continuous positive airway pressure (CPAP) at -5, 0, 5 and 10 cm of water|
1767916|NCT00338416|Drug|Epoetin alfa|
1767917|NCT00338429|Behavioral|FHP Sleep Program|Cognitive-Behavioral Intervention
1767918|NCT00338442|Drug|VariZIG™|Biological / Vaccine
1767919|NCT00338455|Drug|Natrecor (nesiritide)+Standard Care+dobutamine or milrinone|3-hour 0.005 mcg/kg/min, may be titrated to 0.015 mcg/kg/min
1767920|NCT00338455|Drug|Placebo+Standard Care+dobutamine or milrinone|28-day continuous infusion, no bolus
1767921|NCT00338468|Drug|epoetin alfa|
1767922|NCT00338481|Drug|Morphine p.o.|"Morphine p.o. in red morphine drops calculated as 1/12 of the 24 hours opioid consumption converted to morphine p.o., max. 24 mg morphine p.o.and isotonic sodium chloride s.c."
1767923|NCT00338481|Drug|Morphine s.c.|"False red morphine drops without morphine p.o. and 60% of 1/12 of the 24 hours opioid consumption converted to morphine p.o. but given s.c., max. 14,4 mg"
1767924|NCT00338494|Drug|Clofarabine|The starting dose of clofarabine will be 10 mg/m2 once a week for 3 weeks repeated every 4 weeks with dose escalations to 15, 20 , 30 and 40 mg/m2/week.
1767925|NCT00338507|Drug|Erdosteine|
1767926|NCT00338533|Device|endoscopic goniotomy|The goninotomy is performed through an endoscope; allowing the physician a better view of the structure within the eye
1767927|NCT00338546|Drug|Cocaine hydrochloride|
1767928|NCT00338546|Drug|Dexmedetomidine|
1767929|NCT00338546|Procedure|Microneurography|
1767930|NCT00338546|Procedure|Laser doppler velocimetry|
1767931|NCT00338572|Behavioral|Exercise Program|Participants in the exercise group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day.
1767932|NCT00338572|Behavioral|Combined Exercise and Diet Program|Participants in this group will receive a 12-week membership to the YMCA and will meet with a personal trainer twice a week. They will be encouraged to exercise on their own for an additional 3 to 4 days per week. Participants will also be provided with a pedometer, which will track the number of steps they take each day. They will meet with a dietician and will be encouraged to reduce their caloric intake by incorporating low-fat, high-fiber foods into their diet.
1767933|NCT00338585|Drug|alfimeprase|
1767934|NCT00338598|Drug|Glycine|Glycine, 0.8 gr per kg given in two daily doses
1767935|NCT00338598|Drug|placebo|
1767936|NCT00338611|Behavioral|Home-based Pencil Push-Up Therapy|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose
1767937|NCT00338611|Behavioral|Home-based Pencil Push-ups with Computer Vision Therapy/Orthoptics|Exercise in which patients visually followed a small letter on a pencil as they moved the pencil closer to the bridge of their nose combined with additional computer vision therapy
1767938|NCT00338611|Behavioral|Office-based Vision Therapy/Orthoptics|Weekly hour-long sessions of office-based vision therapy with a trained therapist and performed at-home reinforcement exercises
1767939|NCT00338611|Behavioral|Placebo Office-based Vision Therapy/Orthoptics|Vision activities designed to simulate office-based therapy
1767940|NCT00341055|Drug|Epoetin alfa|
1767941|NCT00341224|Behavioral|Group-mentoring intervention|Group mentoring used to teach social skills to middle school students
1767942|NCT00341250|Drug|AMA1-C1/Alhydrogel Malaria Vaccine|
1767943|NCT00341328|Biological|Intradermal injection of Mycobacterium w|Mw Vaccine is given as intradermal administration. Total 6 doses are given 0.2 ml at baseline and then 0.1 ml after interval of 2 weeks upto 8 weeks
1767944|NCT00341354|Behavioral|Prolonged Mechanical Ventilation|
1767945|NCT00341432|Behavioral|Nicotine Replacement Therapy|
1767946|NCT00341445|Behavioral|Effect of Cockroach Allergen|
1767947|NCT00341471|Procedure|Risk Behavior Prevention Intervention Program|
1767948|NCT00341614|Behavioral|3-month Exercise Training and Diet Education|
1767949|NCT00341640|Procedure|Blood testing|
1767950|NCT00342108|Behavioral|cross-modal sensory stimulation|comparison of participant response to unimodal visual stimulation and to bimodal sensory stimulation
1767951|NCT00342134|Procedure|Stem Cell Transplanataion|
1767952|NCT00342316|Procedure|Reduced Intensity Conditioning Stem Cell Transplantation|"One of the following conditioning regimens:
Busulphan (orally or IV), fludarabine
Fludarabine, carmustine, melfalan
Cyclophosphamide, fludarabine"
1767953|NCT00342355|Drug|Zidovudine|600 mg once daily
1767954|NCT00342355|Drug|Stavudine|40 mg once daily
1767955|NCT00342355|Drug|Didanosine|<60 kg/125 mg twice daily or >60kg/200 mg twice daily
1767956|NCT00342355|Drug|Lamivudine|300 mg once daily
1767957|NCT00342355|Drug|Efavirenz|600 mg once daily
1767958|NCT00342355|Drug|Lopinavir/Ritonavir|r/LPV 400mg/100mg twice daily
1767959|NCT00342368|Procedure|CPAP delivered by an Helmet|continuous positive airway pressures delivered through an helmet
1767960|NCT00342381|Drug|3,4-diaminopyridine|Single dose 3,4 diaminopyridine
1767961|NCT00342381|Drug|Placebo|Single dose placebo treatment
1767962|NCT00342563|Drug|mecamylamine|mecamylamine 10mg/day
1767963|NCT00342563|Drug|Placebo|Placebo
1767964|NCT00342628|Biological|Vi-rEPA conjugate vaccine for typhoid fever|Vi-rEPA contains a 25 ug/dose of Vi (Sanofi-Pasteur Lot 130) and rEPA in 0.2 N NaCl, 10 mM phosphate PH 7.2 and 0.01% thimerosal.
1767965|NCT00342628|Biological|Hib-TT|Hib-TT is Hemophilus influenzae type b-tetanus toxoid conjugate vaccine (ActHib, NDC#49281-545-05 Sanofi-Pasteur, France) in single-dose vials containing 10 ugof Hib CP conjugated to 24 ug of tetanus toxoid
1767966|NCT00342628|Biological|DTP|DTP, diphtheria, tetanus toxoid and pertussis vaccine were from the Ministry of Health, Vietnam for routine infant immunization
1767967|NCT00342706|Procedure|Community based intervention|
1767968|NCT00342836|Procedure|Akt levels|
1767969|NCT00342849|Drug|Succimer|Succimer (2,3-meso-dimercaptosuccinic acid) is an orally active dithiol compound that is a relatively specific chelating agent for heavy metals, especially lead, arsenic and mercury. The drug undergoes limited absorption in the gastrointestinal tract and then is rapidly metabolized to mixed disulfides which are eliminated in the urine. Blood levels decline slowly with an apparent elimination half-life of about 48 hours in adults.
1767970|NCT00342849|Drug|Placebo|
1767971|NCT00342862|Drug|Amevive exposure|Observational
1767972|NCT00342940|Biological|influenza surface antigen inactivated vaccine|
1767973|NCT00343005|Biological|AMA1-C1|
1767974|NCT00343005|Drug|AMA1-C1/alhydrogel Malaria Vaccine|
1767975|NCT00343044|Drug|Topotecan|Topotecan administered days 1, 8, and 15 of each 28 day cycle. Dose was 4 mg/m2 administered IV.
1767976|NCT00343044|Drug|Bevacizumab|bevacizumab administered IV 10 mg/kg, days 1 and 15 of 28 day cycle.
1767977|NCT00343057|Other|Patients' questionnaire|
1767978|NCT00343070|Drug|Oral administration of escitalopram during 8 weeks|
1768058|NCT00343460|Drug|Palonosetron Hydrochloride|Given IV
1768059|NCT00343460|Other|placebo|Given subcutanously or IV
1768060|NCT00343486|Drug|Solabegron|
1768061|NCT00343499|Drug|valsartan|
1767979|NCT00343083|Drug|Erbitux, Paclitaxel & Carboplatin|"Paclitaxel, 40 mg/m2/week,
1-hour infusion (weeks 2-9.Paclitaxel will be administered on a weekly schedule at a dose of 40mg/m2 IV by 1-hour infusion prior to cetuximab dose.
Cetuximab: 400 mg/m2 IV (initial dose) week 1 then 250 mg/m2 IV weekly for 8 weeks weeks 2-9). Cetuximab will be administered 400mg/m2 IV on Day 1, then the first 250 mg/m2 IV dose will be given on day 8 (week 2) prior to carboplatin dose.
Carboplatin, AUC=2/week as a 30 minute infusion after cetuximab infusion (weeks 2-9)Carboplatin will be administered at a dose of AUC = 2/week IV bolus each week and will be administered prior to head and neck irradiation dose. (Carboplatin: AUC=2/week x 8 weeks (weeks 2-9)"
1767980|NCT00343083|Radiation|Radiation|XRT=Radiotherapy 1.8 Gy radiation/day, 5 days a week for a total of 70.2 Gy.(weeks 2-9) - IMRT is allowed
1767981|NCT00343096|Drug|Lorazepam|All doses 0.1mg/kg once, repeat after 10 minutes x1
1767982|NCT00343109|Biological|HER-2/neu intracellular domain protein|Given ID
1767983|NCT00343109|Procedure|leukapheresis|Optional correlative studies
1767984|NCT00343109|Other|laboratory biomarker analysis|Correlative studies
1767985|NCT00343109|Biological|sargramostim|Given ID
1767986|NCT00343109|Other|immunologic technique|Correlative studies
1767987|NCT00343109|Biological|synthetic tumor-associated peptide vaccine therapy|Given ID
1767988|NCT00343122|Procedure|echocardiography for intrapulmonary vasodilatation|
1767989|NCT00343135|Drug|amoxicillin/clavulanate potassium 1gm|amoxicillin/clavulanate potassium 1gm
1767990|NCT00343148|Drug|AVI-4126 Injection (RESTEN-NG®)|
1767991|NCT00343161|Drug|esomeprazole|
1767992|NCT00343161|Drug|Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)|
1767993|NCT00343174|Drug|Ancrod|
1767994|NCT00343187|Drug|ACZONE (dapsone) Gel, 5%|
1767995|NCT00343187|Drug|Vehicle Control|
1767996|NCT00343200|Drug|Placebo|Placebo tablet orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 8 weeks (DB phase). In 4-week OL phase, subjects received sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period.
1767997|NCT00343200|Drug|Viagra (sildenafil citrate)|Sildenafil 50 mg or 100mg orally approximately 1 hour before sexual activity, with no more than 1 dose in a 24-hour period, for a total of 12 weeks (8-week DB phase and 4-week OL phase).
1767998|NCT00343213|Procedure|colposcopy|
1767999|NCT00343226|Drug|Basiliximab|
1768000|NCT00343239|Drug|Docetaxel|"Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 75 mg/m2"
1768001|NCT00343239|Drug|Cisplatin|"Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 75 mg/m2"
1768002|NCT00343239|Drug|Fluorouracil|"Formulation: infusion solution
Route of administration: IV infusion on the first day of each 21-day cycle
Dose regimen: 750 mg/m2/day for 5 days"
1768003|NCT00343252|Drug|teriparatide|20 ug/day, subcutaneous, 18 months
1768004|NCT00343252|Drug|risedronate|35 mg/once weekly, oral, 18 months
1768005|NCT00343252|Drug|placebo|once weekly, oral, 18 months
1768006|NCT00343252|Drug|placebo|daily, subcutaneous, 18 months
1768007|NCT00343265|Drug|Vaginal progesterone gel|Vaginal gel once daily
1768008|NCT00343265|Drug|Placebo gel|once daily
1768009|NCT00343278|Drug|Valaciclovir Hydrochloride|
1768010|NCT00343291|Biological|Cetuximab|Administered intravenously
1768011|NCT00343291|Biological|Bevacizumab|Administered intravenously
1768012|NCT00343291|Drug|Paclitaxel|Administered intravenously
1768013|NCT00343291|Drug|Carboplatin|Administered intravenously
1768014|NCT00343304|Device|Robot|
1768015|NCT00343304|Device|Ergometer|
1768016|NCT00343317|Drug|Intrapartum Cefoxitin (2g) vs. placebo|
1768017|NCT00343343|Device|NovoFine® needle 6 mm|
1768018|NCT00343343|Device|NovoFine® needle 4 mm|
1768019|NCT00343356|Drug|Trement|
1768020|NCT00343369|Drug|asparaginase|
1768021|NCT00343369|Drug|cyclophosphamide|
1768022|NCT00343369|Drug|cytarabine|
1768023|NCT00343369|Drug|daunorubicin hydrochloride|
1768024|NCT00343369|Drug|dexamethasone|
1768025|NCT00343369|Drug|doxorubicin hydrochloride|
1768026|NCT00343369|Drug|mercaptopurine|
1768027|NCT00343369|Drug|methotrexate|
1768028|NCT00343369|Drug|pegaspargase|
1768029|NCT00343369|Drug|prednisolone|
1768030|NCT00343369|Drug|teniposide|
1768031|NCT00343369|Drug|thioguanine|
1768032|NCT00343369|Drug|vincristine sulfate|
1768033|NCT00343369|Radiation|radiation therapy|
1768034|NCT00343382|Drug|pilocarpine hydrochloride|Given orally
1768035|NCT00343382|Other|placebo|Given orally
1768036|NCT00343395|Drug|AVANDAMET|2/500 mg
1768037|NCT00343408|Drug|cediranib maleate|
1768038|NCT00343408|Drug|cisplatin|
1768039|NCT00343408|Drug|fluorouracil|
1768040|NCT00343408|Drug|gemcitabine hydrochloride|
1768041|NCT00343408|Drug|leucovorin calcium|
1768042|NCT00343408|Drug|oxaliplatin|
1768043|NCT00343421|Biological|PEDIACEL® and Prevenar®|0.5 mL each, IM (opposite thigh)
1768044|NCT00343421|Biological|Infanrix®-IPV+Hib and Prevenar®|0.5 mL each, IM (opposite thigh)
1768045|NCT00343434|Behavioral|behavioral dietary intervention|
1768046|NCT00343434|Behavioral|exercise intervention|
1768047|NCT00343434|Dietary Supplement|soy isoflavones|
1768048|NCT00343434|Dietary Supplement|soy protein isolate|
1768049|NCT00343434|Other|counseling intervention|
1768050|NCT00343434|Other|educational intervention|
1768051|NCT00343434|Procedure|psychosocial assessment and care|
1768052|NCT00343434|Procedure|quality-of-life assessment|
1768053|NCT00343447|Biological|autologous tumor cell vaccine|
1768054|NCT00343447|Biological|rituximab|
1768055|NCT00343447|Drug|cyclophosphamide|
1768056|NCT00343460|Drug|APF530|Given subcutanously
1768057|NCT00343460|Drug|dexamethasone|Given IV and orally
1768062|NCT00343512|Drug|docetaxel|Docetaxel 75 mg/m2 IV (1-hour infusion) on day 1 of each cycle (cycle = 2 weeks) x 4 cycles
1768063|NCT00343512|Genetic|protein expression analysis|protein expression analysis
1768064|NCT00343512|Other|laboratory biomarker analysis|laboratory biomarker analysis
1768065|NCT00343512|Procedure|biopsy|biopsy
1768066|NCT00343512|Procedure|conventional surgery|conventional surgery
1768067|NCT00343512|Procedure|neoadjuvant therapy|neoadjuvant therapy
1768068|NCT00343525|Drug|bavituximab|
1768069|NCT00343551|Drug|Aliskiren|
1768070|NCT00343564|Drug|SB-743921|Phase 1: I.V. dose on Days 1 and 15 of a 28 day cycle starting at 2mg/m2 and increasing by 1 mg/m2 with possible prophylactic granulopoietic support until unacceptable toxicity develops.
1768071|NCT00343564|Drug|SB-743921|Phase 2: I.V. dose and regimen will be determined based on Phase 1 findings.
1768072|NCT00343590|Device|Whole Body Vibration machine|
1768073|NCT00335582|Drug|clonidine hydrochloride|One hour prior to surgery, patients randomized to the treatment arm will receive clonidine as both a 0.2 mg oral tablet and 0.2 mg/day transdermal patch patch will be removed on postoperative day 4 (or hospital discharge, whichever is earlier)
1768074|NCT00335595|Drug|XELOXA|XELOXA Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 One cycle every 3 weeks
1768075|NCT00335595|Drug|XELOXA-A|"XELOXA-A Bevacizumab: 7,5 mg/kg, day 1 Oxaliplatino: 130 mg/m2 ; day 1 Capecitabine: 1000 mg/m2 bid, oral, day 1-14 during 6 cycles followed by Bevacizumab until disease progression or premature drop out of study.
One cycle every 3 weeks"
1768076|NCT00335621|Drug|Inhaled Tiotropium|
1768077|NCT00335647|Drug|fluphenazine hydrochloride|
1768078|NCT00335660|Drug|AV608|
1768079|NCT00343616|Procedure|cognitive assessment|Cognitive function will be assessed using the CogState battery and the Cognitive Failures Questionnaire.
1768080|NCT00343616|Procedure|fatigue assessment and management|Fatigue will be evaluated using the Brief Fatigue Inventory.
1768081|NCT00343616|Procedure|psychologic distress|Psychologic distress will be evaluated using the General Health Questionnaire after cognitive testing.
1768082|NCT00343616|Procedure|quality-of-life assessment|Quality of life will be assessed using global linear analogue self-assessment (LASA) indicators for physical well-being, mood, coping effort (PACIS), perceived social support and subjective health estimation.
1768083|NCT00343629|Drug|sulindac|
1768084|NCT00343629|Other|pharmacological study|
1991619|NCT00787176|Procedure|Routine oxytocin|per regular oxytocin protocols
1991620|NCT00787176|Procedure|Half-dose oxytocin|The dose of oxytocin currently being administered will be halved and not increased until after 60 minutes after initiation of labor analgesia
1768088|NCT00343655|Drug|Atorvastatin|
1768089|NCT00343668|Drug|S-1, irinotecan|S-1, 40 mg/m2 PO twice daily, days 1-14 irinotecan, 150 mg/m2 IV, day 1
1768090|NCT00343681|Biological|Inactivated influenza vaccine (split virion)|0.5 mL, Intramuscular
1768091|NCT00343707|Drug|vestipitant|
1768092|NCT00343707|Drug|paroxetine|
1768093|NCT00343720|Drug|VELCADE|
1768094|NCT00343720|Drug|Alimta|
1768095|NCT00343733|Drug|OraVescent Fentanyl|
1768096|NCT00343759|Drug|Lapatinib|Patients will take 14 days of Lapatinib prior to definitive surgery.
1768097|NCT00343785|Drug|cyclophosphamide|Given IV
1768098|NCT00343785|Biological|anti-thymocyte globulin|Given IV
1768099|NCT00343785|Drug|cyclosporine|Given IV or PO
1768100|NCT00343785|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic bone marrow transplantation
1768101|NCT00343785|Drug|methotrexate|Given IV
1768102|NCT00343785|Genetic|DNA analysis|Correlative studies
1768103|NCT00343785|Other|flow cytometry|Correlative studies
1768104|NCT00343785|Genetic|polymorphism analysis|Correlative studies
1768105|NCT00343785|Other|laboratory biomarker analysis|Correlative studies
1768106|NCT00343798|Drug|cyclophosphamide|Given IV
1768107|NCT00343798|Drug|fludarabine phosphate|Given IV
1768108|NCT00343798|Drug|cyclosporine|Given IV
1768109|NCT00343798|Drug|mycophenolate mofetil|Given IV or PO
1768110|NCT00343798|Other|ex-vivo umbilical cord blood expansion|Undergo double-unit umbilical cord blood transplantation
1768111|NCT00343798|Procedure|double-unit umbilical cord blood transplantation|Undergo double-unit umbilical cord blood transplantation
1768112|NCT00343798|Procedure|biopsy|Optional correlative studies
1768113|NCT00343798|Other|immunologic technique|Correlative studies
1768114|NCT00343798|Other|diagnostic laboratory biomarker analysis|Correlative studies
1768115|NCT00343811|Drug|Modafinil|
1768116|NCT00343824|Procedure|aquacel AG hydrofiber versus acticoat burn dressing|Aquacel AG hydrofiber versus acticoat burn dressing will be compared.
1768117|NCT00343850|Drug|Asacol (mesalamine)|
1768118|NCT00343863|Drug|palonosetron hydrochloride|Given IV
1768119|NCT00343863|Drug|cyclophosphamide|Given orally
1768120|NCT00343863|Drug|dexamethasone|Given orally or IV
1768121|NCT00343863|Drug|doxorubicin hydrochloride|Given IV
1768122|NCT00343863|Procedure|quality-of-life assessment|Ancillary studies
1768123|NCT00343863|Procedure|nausea and vomiting therapy|Given IV
1768124|NCT00343863|Procedure|management of therapy complications|Given IV
1768125|NCT00343863|Drug|ondansetron hydrochloride|Given IV
1768126|NCT00343863|Other|survey administration|Ancillary studies
1768127|NCT00343876|Drug|aspirin|
1768128|NCT00343876|Drug|clopidogrel|
1768129|NCT00343889|Biological|DTaP-HB-PRP~T vaccine + OPV|0.5 mL, Intramuscular
1768130|NCT00343889|Biological|Tritanrix-HepB/Hib™ + OPV vaccine|0.5 mL, Intramuscular
1768131|NCT00343889|Biological|Oral Polio Vaccine|Oral co-administered with study vaccine
1768132|NCT00343902|Drug|Crataegus Special Extract WS 1442|
1768133|NCT00343915|Biological|Engerix™-B (thiomersal-free) 20µg|In the primary study: 2 deep intramuscular injections (Months 0, & 6)
1768134|NCT00343915|Biological|10 μg Engerix™-B (preservative-free)|In the primary study: 3 deep intramuscular injections (months 0, 1 & 6)
1768135|NCT00343915|Biological|placebo|In the primary study: 1 deep intramuscular injection (month 1)
1768136|NCT00343928|Other|Branched-chain amino acids|Participants will spend approximately 2 weeks in each phase over a 9-week period, during which they will receive an amino acid mixture and the placebo control condition.
1768137|NCT00343941|Drug|Tucaresol tablets 25 mg|
1768138|NCT00343954|Drug|L-citrulline tablets, 1000 mg|
1768139|NCT00343980|Drug|rosiglitazone|Tablets, 4 mg once or twice a day.
1768140|NCT00343980|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
1768141|NCT00343980|Drug|glimepiride|Tablets, 4 mg/day.
1768142|NCT00344474|Behavioral|PRE-Venture: Personality Risk Education|Motivational and Cognitive-Behavioural interventions targeting four personality risk factors for substance misuse. Two, 90-minute group sessions conducted at school with personality-matched peers and trained psychologists/councellors and co-facilitators.
1768143|NCT00344487|Drug|Lopinavir/Ritonavir|Dosing of Kaletra will be per package insert and BID with food. A three-drug standard of care antiretroviral regimen will be used in this study. Subjects will enter the study already on an effective, virally-suppressive treatment regimen. One of these drugs will be substituted for Lopinavir/ritonavir (Kaletra®). However, the nucleoside/nucleotide backbone drugs that the subject is already on will remain the same.
1768144|NCT00344500|Behavioral|Behavioral Weight Loss Program|"Patients randomized to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient
Be given a 7% weight loss goal
Be assisted in obtaining a 500 calorie reduction per day
Exercise for at least 30 min/day, at least 5 days a week
Maintain weekly food and exercise diaries
Be quizzed on their knowledge of healthy eating habits and nutrition"
1768145|NCT00344513|Drug|Beta-blockers including Carvedilol|
1768146|NCT00344513|Drug|ACE inhibitors|
1768147|NCT00344526|Drug|Melphalan|
1768148|NCT00344526|Drug|Dexamethasone|
1768149|NCT00344526|Procedure|Autologous stem cell transplantation|
1768150|NCT00344539|Biological|AMA1-C1/Alhydrogel®|AMA1-C1/Alhydrogel malaria vaccine, cloudy suspension, 0.5 mL dose containing up to equivalent of 377 mcg of aluminum as Alhydrogel® (800 mcg of aluminum hydroxide gel per dose) onto which 20 mcg or 80 mcg of recombinant AMA1-C1 is bound. Dosages: 20 mcg and 80 mcg administered via the deltoid muscle by IM injection
1768151|NCT00344539|Biological|CPG 7909 Oligodeoxynucleotide (VaxImmune®)|CPG 7909 is an investigational agent and is supplied in sterile vials at 10mg/mL in phosphate buffered saline for intramuscular administration. Dosage 500 mcg.
1768152|NCT00344552|Drug|Paclitaxel|Injection solution, IV, 100mg/sqm, once weekly, 7 weeks and over
1768153|NCT00344565|Drug|Modafinil|During the first lead-in week, participants will attend the clinic 3 times per week, participate in one session of neuropsychological assessment and receive motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP). At the end of the first lead-in week participants will be randomized to modafinil or placebo stratified by the levels of cocaine use, and whether or not abstinence was achieved. Participants will then be followed for 11 weeks with measures of cocaine cravings and withdrawal, and drug use outcome, and will receive CBT-RP.
1768154|NCT00344565|Behavioral|Cognitive Behavioral Therapy--Relapse Prevention|Once weekly individual session of motivational interviewing and Cognitive Behavioral Therapy--Relapse Prevention (CBT-RP)
1768155|NCT00344578|Device|Restor IOL|
1768156|NCT00344591|Behavioral|Structured Ecosystems Therapy (SET)|
1768157|NCT00344591|Behavioral|Individually tailored intervention|
1768158|NCT00344604|Behavioral|Role of psychosocial and quality of life parameters prior to and following LASIK.|
1768159|NCT00344617|Drug|Bevacizumab (tradename: Avastin)|
1768160|NCT00344630|Device|TAXUS Stent and Cypher Stent|
1768161|NCT00344643|Device|Silicone Hydrogel Soft Contact Lenses|
1768162|NCT00344669|Drug|Albendazole 400 mg, given 6 monthly|
1768163|NCT00344682|Drug|memantine|memantine 5mg - 20mg PO daily
1768164|NCT00344682|Drug|Placebo|5mg - 20mg PO daily over 8 weeks
1768165|NCT00344695|Drug|bupropion SR|
1768166|NCT00344708|Procedure|Transplantation of Tissue-Cultured Human Amniotic Epithelial Cells|
1768167|NCT00344721|Drug|Essential fatty acid supplement|
1768168|NCT00344734|Drug|Ng-monomethyl-L-arginine (drug)|
1768169|NCT00344747|Behavioral|dietary, behavioral, physical activity|
1768170|NCT00344760|Drug|Enfuvirtide|subcutaneously twice a day
1768171|NCT00344760|Drug|Efavirenz, lamivudine, and tenofovir|Efavirenz -600mg once daily, lamivudine- 300mg once daily, and tenofovir 300mg once daily
1768172|NCT00344773|Drug|Gefitinib|250mg tablet oral tablet once daily
1768173|NCT00344786|Drug|CNF2024 (BIIB021)|"Dose starting at 12.5 mg/d, p.o. as a once-daily dose for 21 days followed by a 1-week rest period.
Dose escalation will proceed according to the predetermined scheme until the maximum tolerated dose (MTD) is reached due to dose limiting toxicities (DLT) during the first course of treatment."
1768174|NCT00344812|Drug|LAAM. buprenorphine and methadone|
1768175|NCT00344825|Drug|Alemtuzumab (MabCampath, BAY86-5045) and Fludarabine Phosphate (Fludara, BAY86-4864)|"Descriptive statistical methods applied for the whole study cohort and for subgroups according to QoL and the correlation of the following parameters: Age, Sex, Stage of disease, Time from first B-CLL diagnosis, number of previous B-CLL treatments, Reason of starting of the new B-CLL treatment (progression disease, relapse, no-response to the previous treatment, previous treatment toxicity), Therapeutic Regimen (Day Hospital, Hospital Admission, etc.), Type of Centre, B-CLL treatment lasting, Response to B-CLL treatment.
QoL at baseline, Change in QoL over time evaluated using an analysis of Variance."
1768176|NCT00344838|Device|Comparison of LADAR CustomLasik and VISX Wavefront System custom laser ablation devices|
1768177|NCT00344851|Drug|metformin, exenatide or combined (metformin & exenatide )|
1768178|NCT00344864|Device|LADARWave|
1768179|NCT00344890|Procedure|Anterior Cervical Discectomy and Fusion|1,2,3,or 4 level surgery
1768180|NCT00344916|Drug|Ng-monomethyl-L-arginine (drug)|
1768181|NCT00344942|Drug|triamcinolone acetonide|220µg/day or a double spray into each nostril once daily for 12 weeks'treatment
1768182|NCT00344942|Drug|placebo|a double spray into each nostril once daily
1768183|NCT00344955|Drug|HMG-CoA reductase inhibition (atorvastatin)|
1768184|NCT00344968|Drug|fluocinolone acetonide|0.5 mg fluocinolone acetonide intravitreal insert
1768185|NCT00344968|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
1768186|NCT00344968|Procedure|Standard of care laser photocoagulation|Laser photocoagulation
1768187|NCT00344981|Drug|Tenofovir|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir.
1768188|NCT00344981|Drug|Hydroxyurea|Half of the 20 volunteers will be randomized to the Tenofovir 300 mg qd/Hydroxyurea 500mg qd arm and those subjects will have Hydroxyurea added to their current screening regimen for 4 weeks prior to de-intensifying to Hydroxyurea and Tenofovir. Volunteers will continue on this regimen for 48 weeks. Patients will be monitored for immunological and virological parameters as well as the incidence of toxicity and side effects during the study. If a patient's viral load reaches >400 copies/ml on 3 consecutive measurements over a 6 week period, they will be terminated from the study and started back on their HAART.
1768189|NCT00344994|Drug|pramipexole|PO, 0.25mg, 0.50mg, or 0.75mg QHS
1768190|NCT00345007|Procedure|Scleral buckling|
1768191|NCT00345020|Procedure|Deep Lamellar Endothelial Keratoplasty: Small Incision Technique|
1768192|NCT00345033|Drug|Aripiprazole|15-mg dose once a day for 8 weeks
1768193|NCT00345033|Drug|Placebo|1 tablet placebo dose once a day for 8 weeks
1768194|NCT00345046|Drug|Pred Forte|Four drops daily decreasing to once daily over four weeks.
1768195|NCT00345046|Drug|EconoPred Plus|Prednisolone Acetate four times daily decreasing to once daily over four weeks.
1768196|NCT00345046|Drug|Prednisolone Acetate|Dosed four times daily decreasing to once daily over four weeks.
1768197|NCT00345059|Drug|docetaxel|
1768198|NCT00345059|Drug|vinorelbine|
1768199|NCT00345059|Drug|gemcitabine|
1768200|NCT00345059|Drug|capecitabine|
1768201|NCT00345072|Device|Web-based decision aid system|
1768202|NCT00345085|Device|Wavefront and Contrast Sensitivity|
1768203|NCT00345098|Drug|SR58611A|
1768204|NCT00345111|Procedure|Clinical visual outcomes of bilateral implantation of Restore Intra Ocular Lens.|
1956850|NCT02667275|Drug|A-101 Solution|
1768207|NCT00345137|Drug|Ng-monomethyl-L-arginine (drug)|
1768208|NCT00345150|Drug|Ng-monomethyl-L-arginine (drug)|
1768209|NCT00345163|Drug|bevacizumab|Intravenous repeating dose
1768210|NCT00345163|Drug|irinotecan|Intravenous repeating dose
1768211|NCT00345176|Dietary Supplement|Lutein/zeaxanthin|10 mg lutein and 2 mg zeaxanthin (1 tablet) Placebo-DHA/EPA (2 soft-gel capsules)
1768212|NCT00345176|Dietary Supplement|DHA/EPA|Placebo-lutein/zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
1768213|NCT00345176|Drug|Lutein/zeaxanthin and DHA/EPA|10 mg lutein and 2 mg zeaxanthin (1 tablet) 350 mg DHA and 650 mg EPA (2 soft-gel capsules)
1768214|NCT00345189|Drug|CNF2024|"CNF2024 capsules administered orally following 2 schedules:
starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or
starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).
Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment."
1768215|NCT00345202|Drug|HMG-CoA reductase inhibition (atorvastatin)|
1956851|NCT02667275|Other|Vehicle Solution|Placebo
1768218|NCT00345241|Drug|Systane Ocular Drops (OTC)|
1768219|NCT00345241|Drug|Placebo - Saline Drops|
1768220|NCT00345254|Procedure|severing cord|The cord was cut intentionally after delivery of the anterior shoulder and prior to extraction of the body.
1768221|NCT00345267|Device|Integrated Care Pathway|
1768222|NCT00345280|Procedure|impression cytology, obtain the tear fluid|Vitamin A
1768223|NCT00345293|Biological|autologous dendritic cell vaccine (DC/PC3)|ex vivo generated autologous dendritic cells pulsed with apoptotic PC3 cells and pulsed with apoptotic PC3-M1 cells(control apoptotic cells) and pulsed with KLH (control antigen). maximum dose of DC/PC3 that we are able to generate from their initial leukaphereses product, up to a maximum of 10 x 106 DCs. Doses in the range of 105 to 10 x 106 DCs have been used clinically without toxicity
1768224|NCT00345306|Drug|Comparison between two different progesterone administration|
1768225|NCT00345319|Biological|rabies vaccine|Administration of PCECV according to ESSEN regimen
1768226|NCT00345332|Drug|Botox|Injected
1768227|NCT00345332|Drug|Placebo|Injected
1768231|NCT00345371|Drug|Topiramate|
1768232|NCT00345371|Drug|Placebo Oral Tablet|
1768233|NCT00345384|Drug|Dexmedetomidine|Dexmedetomidine titrated over 24 hours
1768234|NCT00345384|Other|Placebo (Normal Saline)|
1768235|NCT00345397|Device|Percutaneous endoscopic colostomy (PEC) tube|PEC placement for antegrade enemas uses commercially available PEG tubes
1768236|NCT00345410|Drug|AVE1625 B|
1768238|NCT00345462|Biological|Trivalent virosomal influenza vaccine|
1768239|NCT00345501|Drug|Iloprost|Iloprost 1ng/kg/min IV starting 1 hour before the procedure and continuing for 4 hours after its end
1768240|NCT00345501|Drug|Placebo|Placebo IV (Normal saline) starting 1 hour before the procedure and continuing for 4 hours after its end
1768241|NCT00345514|Behavioral|Behavioral Intervention Arm|The arm emphasized individual provider behavior (interactive CME, feedback at the provider, clinic and program levels, expert modeling, academic detailing and opinion leaders)
1768242|NCT00345514|Behavioral|Organizational Interventions Arm|Leadership, team building, benchmarking at the clinic and program level
1768243|NCT00345527|Behavioral|Emotion and Behaviour Regulation Treatment (EBRT)|
1768244|NCT00345527|Behavioral|Cognitive Behavioural Therapy|
1768245|NCT00345540|Drug|NOV-002|60 mg / mL / day / 20-23 Days
1768246|NCT00345540|Drug|Carboplatin|AUC 5 following IV bolus administration of NOV-002
1768247|NCT00345566|Procedure|Nutrition composition|
1768248|NCT00345579|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined 792014|3-dose intramuscular injection
1768249|NCT00345579|Biological|ActHIB|3-dose intramuscular injection
1768250|NCT00345579|Biological|Pediarix/Infanrix Penta|3-dose intramuscular injection
1768251|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|The devices automatically applies therapy (shock) for atrial fibrillation, when atrial fibrillation is confirmed.
1768252|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|In hospital application of anti arrhythmic therapies via the device
1768253|NCT00345592|Device|Dual (atrial and ventricular) implantable defibrillator|Therapy for atrial arrhythmias will be delivered from the device through command of the physician and in a hospital environment
1768254|NCT00345605|Drug|Sodium Phenylbutyrate|None will be administered during the washout period; 500 mg/kg/day or 10 grams/m2 will be administered during the first one week treatment period in addition to arginine
1768255|NCT00345605|Drug|Arginine|Standard therapeutic dose of 500 mg/kg/day or 10 grams/2 will be administered during the washout periods, during the first one week treatment period when receiving arginine plus Buphenyl, 100 mg/kg/day or 2 grams/m2 will be administered, during the second treatment week, when receiving arginine alone, 500 mg/kg/day or 10 grams/m2 will be administered
1768256|NCT00345618|Drug|Idrabiotaparinux sodium|"0.5 mL pre-filled syringe for 3.0 mg
Subcutaneous injection"
1768257|NCT00345618|Drug|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)
Oral administration"
1768258|NCT00345618|Drug|Placebo (for idrabiotaparinux sodium)|"0.5 mL pre-filled syringe
Subcutaneous injection"
1768259|NCT00345618|Drug|Avidin|"100 mg in 10 mg/mL solution
Intravenous infusion for 30 minutes"
1768260|NCT00345618|Drug|Placebo (for warfarin)|"Warfarin matching capsules
Oral administration"
1768261|NCT00345618|Drug|Enoxaparin|"Prefilled syringes as locally registered
Subcutaneous injection"
1768262|NCT00345631|Other|Manual Compression|Manual compression
1768263|NCT00345631|Device|Vascular Closure Device|Investigational vascular closure device
1768264|NCT00345644|Drug|risedronate|risedronate sodium 35 mg tablets (once a week dose)
1768265|NCT00345644|Drug|risedronate placebo|placebo for risedronate tablets (once a week dose)
1768266|NCT00345657|Drug|Niacin Extended Release/Lovastatin|
1768267|NCT00345670|Biological|MEDI-534|10:4 TCID50 of MEDI-534 intranasal spray Study Day 0
1768268|NCT00345670|Biological|MEDI-534|10:5 TCID50 of MEDI-534 intranasal spray Study Day 0
1768269|NCT00345670|Biological|MEDI-534|10:6 TCID50 of MEDI-534; intranasal spray
1768270|NCT00345683|Biological|GSK Biologicals' Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine combined (792014)|Booster dose by intramuscular injection
1768271|NCT00345683|Biological|PedvaxHIB|Booster dose by intramuscular injection
1768272|NCT00345683|Biological|Prevnar|Booster dose by intramuscular injection
1768273|NCT00345683|Biological|M-M-R II|Single dose by subcutaneous injection
1768274|NCT00345683|Biological|Varivax|Single dose by subcutaneous injection
1768275|NCT00345696|Drug|Bevacizumab|5 mg/Kg intravenous, 90-60-30 minutes, every 2 weeks.
1768276|NCT00345696|Drug|Capecitabine|600 mg/m2, orally, every 12 hours, continuous.
1768277|NCT00345696|Drug|Oxaliplatine|85 mg/m2, intravenous, 2 hours infusion, every 2 weeks
1768278|NCT00345709|Behavioral|Questionnaire|65 page questionnaire that contains questions about your ovarian cancer diagnosis, gynecologic history, family history, general medical history, and health risk factors.
1768279|NCT00345722|Procedure|strawberry dietary intervention|
1768280|NCT00345735|Drug|Fentanyl|
1768281|NCT00345748|Drug|Abatacept|Injection, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
1768282|NCT00345748|Drug|Placebo|Injectio, IV Infusion, Day 1, 15, 29 and every 28 days for 24 weeks
1768283|NCT00345761|Drug|Bevacizumab|7.5 mg/kg(i.v.) on Day 1 of 1 cycle(3 weeks)
1768284|NCT00345761|Drug|Oxaliplatin|130 mg/m2(i.v.) on Day 1 of 1 cycle(3 weeks)
1768285|NCT00345761|Drug|Capecitabine|2000 mg/m2/day(p.o.) for 14 days in 1 cycle(3 weeks)
1768286|NCT00345774|Drug|PRX-08066|
1768287|NCT00345787|Drug|Placebo|Corresponding placebo is applied for 12weeks
1768288|NCT00345787|Drug|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20mg/patch is applied for 12weeks
1768289|NCT00345800|Drug|Sodium Oxybate (Xyrem)|Active Substance: Sodium Oxybate Pharmaceutical form: Oral Solution Concentration: 500 mg/mL oral solution from 4.5 to 9 g/day divided into two equal doses during 12 weeks Route of administration: Oral
1768290|NCT00345813|Dietary Supplement|soy isoflavones|Given orally
1768291|NCT00345813|Dietary Supplement|soy protein isolate|Given orally
1768292|NCT00345813|Other|placebo|Given orally
1768293|NCT00345826|Drug|dasatinib|
1768294|NCT00345839|Drug|Cinacalcet|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg daily (QD), once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
1768295|NCT00345839|Drug|Placebo|Possible doses: 30, 60, 90, 120, and 180 mg using tablet strengths of 30, 60, or 90 mg. Sequential titration starting at 30 mg QD, once every 4 weeks for the first 20 weeks and once every 8 weeks after Week 20. Titration increases or decreases based on PTH values, serum calcium, and safety. Daily dosing unless temporary hold criteria or withdrawal criteria is met, or until study completion; estimated 2.5 to 4 years of intervention.
1768296|NCT00345852|Procedure|Fetoscopic Selective Laser Photocoagulation|
1768297|NCT00345865|Drug|carmustine|Day -6, 300 mg/m^2 over 2 hour
1768298|NCT00345865|Drug|cyclophosphamide|"NHL with radiation: Cyclophosphamide 60 mg/kg intravenous (IV) over two hours daily x 2 days.
HL without radiation: Cyclophosphamide, Days - 6 through -3, 1.5 gm/m^2 over 2 hours daily x 4 days.
Cyclophosphamide will be dosed based on actual body weight (ABW) unless the patient is 20% or more of ideal body weight (IBW). If more than 20% of ideal body weight, an adjusted ideal body weight (AIBW) will be used for dosing."
1768299|NCT00345865|Drug|etoposide|"NHL without radiation and cyclophosphamide: Etoposide 100 mg/m2 IV over 2 hours twice daily on Day -5 through -2.
HL without radiation: 150 mg/m^2 intravenously over 4 hours every 12 hours for 6 total doses on Days -6 through -4."
1768300|NCT00345865|Procedure|peripheral blood stem cell transplantation|Day 0 infuse PBSC. All patients will have PBSC collected by leukapheresis. Mobilization will be done with G-CSF alone (filgrastim) or using ifosfamide/carboplatin/etoposide and with or without rituximab. Leukapheresis is to begin on Day 5.
1768301|NCT00345865|Radiation|irradiation therapy|"Patients undergo total body irradiation (TBI) twice daily on days -4 to -1.
> 1000 cGy to whole lung, kidney, or abdominal bath.
> 3000 cGy to spinal cord, myocardium, mediastinum, lumbar periaortic lymph nodes.
> 3600 cGy to whole brain."
1768302|NCT00345865|Biological|G-CSF|"Day 5: Begin G-CSF 5μg/kg/day subcutaneously (SQ) rounded to the nearest vial size.
Continue G-CSF until absolute neutrophil count (ANC) > 1500/μl x 3 consecutive days.
If ANC falls <1000/μL, restart G-CSF."
1768303|NCT00345865|Drug|Cytarabine|100 mg/m^2 over one hour BID on days -6 through -2 of BEAM conditioning regimen.
1768304|NCT00345878|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
1768305|NCT00345878|Biological|HPV-16/18 L1 VLP AS04 (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
1768306|NCT00345891|Behavioral|Coping-focused counseling telephone calls|
1768307|NCT00345904|Biological|Fluarix|
1768312|NCT00345956|Biological|Human rotavirus liquid vaccine|
1768315|NCT00345982|Drug|Serdolect|16 mg, 12 weeks
1768316|NCT00345982|Drug|placebo|placebo
1768317|NCT00346008|Genetic|mutation analysis|
1768318|NCT00346008|Other|high performance liquid chromatography|
1768319|NCT00346008|Other|laboratory biomarker analysis|
1768320|NCT00346008|Other|questionnaire administration|
1768321|NCT00346021|Behavioral|Increasing hat use|Sun protection intervention that address sun protection knowledge, attitudes, social norms, and perceived behavioral controls. Intervention also provides free wide brimmed hats
1768322|NCT00346034|Drug|Pregabalin|150 to 600mg/day
1768323|NCT00346047|Drug|Placebo|Corresponding placebo is applied for 12weeks
1768324|NCT00346047|Drug|Buprenorphine Transdermal System|Buprenorphine Transdermal System 5, 10 or 20 mg/patch is applied for 12weeks
1768325|NCT00346060|Device|Retinal transplantation instrument|
1768326|NCT00346060|Device|Fetal tissue.|
1768328|NCT00346086|Drug|AIC (Amb a 1 Immunostimulatory Conjugate)|
1768329|NCT00346099|Drug|Panitumumab with capecitabine and oxaliplatin (CAPOX) followed by|
1768330|NCT00346099|Drug|Panitumumab with capecitabine and radiation|
1768331|NCT00346112|Procedure|psycho-educational|
1768332|NCT00346125|Biological|pegfilgrastim|will be given at 6 mg subcutaneously (SC) at the end of the mesna infusion
1768333|NCT00346125|Drug|doxorubicin hydrochloride|65 mg/m^2 by continuous intravenous (IV) infusion over 7 days beginning on day 1
1768334|NCT00346125|Drug|ifosfamide|9 g/m^2 by continuous intravenous (IV) infusion over 6 days beginning on day 1 with mesna 10.5 g/m^2 by continuous IV infusion over 7 days beginning on day 1
1768335|NCT00346125|Drug|pegylated liposomal doxorubicin hydrochloride|45 mg/m2 intravenous (IV) Day 1, repeat every 28 days.
1768336|NCT00346125|Procedure|conventional surgery|The surgical procedure will be decided by the treating physician and independent of study participation
1768337|NCT00346125|Radiation|fludeoxyglucose F 18|FDG is a radioactive sugar equal to a uniform whole-body exposure of approximately 1.5 rem for each scan. Post-operative radiation therapy may be given according to institutional guidelines in patients felt to have close surgical margins.
1768338|NCT00346138|Procedure|Corneal transplantation|
1768339|NCT00346151|Drug|Belatacept|10 mg/kg given intravenously (IV) on transplant (day 1), day 5, and at weeks 2, 4, 8 and 12, then 5 mg/kg IV every 4 weeks
1768340|NCT00346151|Drug|Sirolimus|4 mg/day (oral tablet) at transplant (day 1), then dose adjusted to maintain serum trough level of 8-12 ng/mL for at least 1 year
1768341|NCT00346151|Drug|Anti-thymocyte globulin|1.5 mg/kg given IV daily on days 1 through 4. Subjects are premedicated with glucocorticoids, acetaminophen 650 mg by mouth, and diphenhydramine 25- 50 mg by mouth prior to each dose.
1768342|NCT00346151|Drug|methylprednisolone|500 mg given IV at transplant (day 1), then given 250 mg IV on day 2 and given 0.5 mg/kg IV or prednisone 0.5 mg/kg given by mouth on days 3 and 4
1768343|NCT00346164|Drug|doxorubicin hydrochloride|Given IV
1768344|NCT00346164|Other|clinical observation|Patients undergo observation
1768345|NCT00346164|Procedure|therapeutic conventional surgery|Patients undergo surgery
1768346|NCT00346164|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
1768347|NCT00346164|Drug|ifosfamide|Given IV
1956857|NCT02658734|Drug|Trastuzumab emtansine|3.6 mg/kg intravenously (IV) over 30-90 minutes on day 1 of 21 day cycle, repeated every 3 weeks
1956858|NCT02658214|Drug|paclitaxel + carboplatin|IV infusion
1768348|NCT00346177|Biological|Autologous Stem Cells|Intramyocardial injections
1768349|NCT00346190|Drug|Alendronate|
1768350|NCT00346216|Drug|celecoxib|100 to 200 mg twice daily, taken by mouth
1768351|NCT00346216|Drug|Ibuprofen|ibuprofen 600 mg to 800 mg three times daily, taken by mouth
1768352|NCT00346216|Drug|Naproxen|naproxen 375mg to 500 mg twice daily, taken by mouth
1768353|NCT00346229|Biological|filgrastim|
1768354|NCT00346229|Biological|pegfilgrastim|
1768355|NCT00346229|Drug|lyso-thermosensitive liposomal doxorubicin(Thermodox)|
1768356|NCT00346229|Procedure|hyperthermia treatment|
1768357|NCT00346242|Drug|Zoledronic Acid|
1768358|NCT00346255|Drug|BB-10901|dose escalation study, doses will vary per cohort. patients will receive an IV infusion weekly for two weeks every three weeks.
1768359|NCT00346268|Drug|Morphine, Parecoxib|Parecoxib 40 milligrams (mg) administered intravenously immediately post surgery, followed 20 mg every 12 hours until 48 hours post surgery, total 5 doses. Participants also received Patient-Controlled Analgesia (PCA) 1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA.
1768360|NCT00346268|Drug|Morphine, Placebo|Matching placebo administered intravenously immediately post surgery and every 12 hours until 48 hours post surgery, total 5 doses. Participants also received PCA (1 mg per dose, maximum 40 mg/4 hours, and if necessary, bolus (2 to 5 mg) before or after enabled PCA
1768361|NCT00346281|Device|32P BioSilicon|
1768362|NCT00346294|Other|Etanercept|Intervention type was to study the drug delivery method.
1768363|NCT00346320|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy, 60 Gy in once daily 4 Gy fractions (Monday to Friday) over 3 weeks
1768364|NCT00346333|Drug|Lutein|12mg/d
1768365|NCT00346333|Dietary Supplement|Cornstarch control|Daily intake of cornstarch control plus 15,000 IU/d Vitamin A palmitate
1768366|NCT00346359|Biological|anti-thymocyte globulin|
1768367|NCT00346359|Drug|busulfan|
1768368|NCT00346359|Drug|fludarabine phosphate|
1768369|NCT00346359|Drug|methotrexate|
1768370|NCT00346359|Drug|tacrolimus|
1768371|NCT00346359|Procedure|allogeneic hematopoietic stem cell transplantation|
1768372|NCT00346359|Procedure|peripheral blood stem cell transplantation|
1768373|NCT00346385|Drug|BB-10901|dose escalation study, dose will vary per cohort. patients will receive an IV infusion once every three weeks.
1768374|NCT00346398|Biological|Oral mucosal immunoprophylaxis (OMIP)|OMIP consists of a mixture of allergen extracts including 0.2 milliliters (mL) timothy grass, 0.2 mL cat, and 0.2 mL house dust mite for a total daily dose of 0.6 mL.
1768375|NCT00346398|Biological|Placebo|The placebo consists of three 0.2 mL vials of solution mixed together for a total daily dose of 0.6 mL.
1768376|NCT00346424|Drug|Alfimeprase|
1768377|NCT00346437|Genetic|Ad5FGF-4 vs. Placebo|Intracoronary infusion
1768378|NCT00346450|Procedure|Cultivated conjunctival transplantation|
1768379|NCT00346463|Drug|Allopurinol|
1768380|NCT00346489|Drug|5-fluorouracil|
1768381|NCT00346489|Drug|Mitomycin C|
1768382|NCT00346502|Drug|20% betulinic acid ointment|
1768383|NCT00346502|Drug|BA|20% Betulinic Acid Ointment
1768384|NCT00346515|Device|FiberNet Emboli Protection System|
1768385|NCT00346528|Drug|Next Generation Ophthalmic Irrigating Solution (NGOIS)|Volume sufficient to irrigate adequately during cataract surgery
1768386|NCT00346528|Drug|BSS Plus|Volume sufficient to irrigate adequately during cataract surgery
1768387|NCT00346567|Drug|Zidovudine and Lamivudine (Combivir)|
1768388|NCT00346567|Drug|Emtricitabine and Tenofovir (Truvada)|
1768389|NCT00346580|Drug|Nelfinavir|
1768390|NCT00346593|Device|Silicone hydrogel contact lens|
1768391|NCT00346606|Drug|Denosin® and Xyzal®|
1768392|NCT00346619|Drug|Nelfinavir|
1768393|NCT00346632|Drug|KW-2449|Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).
1768394|NCT00346645|Drug|Bortezomid (VELCADE®)|
1768395|NCT00346658|Drug|magnesium|
1768396|NCT00346671|Other|Rest|30 min supine rest
1768397|NCT00346671|Other|Sham|30 min session with Sham practitioner
1768398|NCT00346671|Other|Reiki|30 min session with Reiki practitioner
1768399|NCT00346684|Drug|Rituximab|
1768400|NCT00346697|Drug|Omega-3 fatty acid administration|LOVAZA 1 gram capsules, 4 capsules daily
1768401|NCT00346697|Drug|Placebo|Corn-oil placebo
1768402|NCT00346723|Biological|Influvac® subunit influenza vaccine for i.m./deep s.c.injection|
1768403|NCT00346736|Procedure|Acupuncture (Procedure)|
1768404|NCT00346749|Drug|Salmeterol|
1768405|NCT00346749|Drug|Fluticasone Propionate/Salmeterol Combination Product|
1768406|NCT00346762|Behavioral|Education|HIV prevention education and risk reduction counselig
1956859|NCT02658214|Drug|carboplatin + etoposide|IV infusion
1956860|NCT02658214|Drug|gemcitabine + carboplatin|IV infusion
1768409|NCT00346788|Procedure|Surgical approach for total knee arthroplasty|total knee arthroplasty surgery using minimally invasive surgery or standard technique.
1768410|NCT00346801|Drug|Celecoxib|100 mg by mouth (PO) twice daily for 5 days before beginning radiation therapy; continued 7 days per week throughout radiation treatment (about 7 weeks).
1768411|NCT00346801|Drug|Cisplatin|25 mg/m^2 IV over 60 minutes on Day 1, Weeks 2-8
1768412|NCT00346801|Drug|CPT-11|30 mg/m^2 IV over 90 minutes on Day 1, Weeks 2-8, followed by cisplatin which will be infused for 60 minutes.
1768413|NCT00346801|Radiation|Concurrent Thoracic Radiation Therapy|63 Gy at 1.8 Gy/Fx in 35 Fractions over 7 weeks starting 2nd week of celebrex.
1768414|NCT00346814|Drug|intravitreal injection|
1768415|NCT00346827|Drug|Apomorphine Nasal Powder|
1768416|NCT00346840|Drug|Misoprostol vaginal insert 25 mcg|One hydrogel polymer vaginal insert for up to 24h
1768417|NCT00346840|Drug|Misoprostol vaginal insert 50 mcg|One hydrogel polymer vaginal insert for up to 24h
1768418|NCT00346840|Drug|Misoprostol vaginal insert 100 mcg|One hydrogel polymer vaginal insert for up to 24h
1768419|NCT00346840|Drug|Misoprostol vaginal insert 200 mcg|One hydrogel polymer vaginal insert for up to 24h
1768420|NCT00346853|Drug|4-Methylpyrazole|15 mg/kg dose
1768421|NCT00346853|Other|saline|
1768422|NCT00346866|Drug|anecortave acetate|
1768423|NCT00346879|Drug|fondaparinux|Single 2.5 mg dose of fondaparinux or weight-based 0.03 mg/Kg dose of fondaparinux
1768424|NCT00346892|Biological|Rotavirus (vaccine)|
1768425|NCT00346905|Drug|Enteryx|
1768426|NCT00346918|Drug|Sirolimus|Standard plus Sirolimus
1768427|NCT00346918|Other|Standard|Standard
1768428|NCT00346931|Procedure|Phacoemulsification, implantation of intraocular lens|
1768429|NCT00346931|Procedure|Phacoemulsification, Implantation of IOL, trabeculotomy|
1768430|NCT00346944|Procedure|Removal of dental amalgam restorations|Removal of dental amalgam restorations by patient's own dentist. Fillings will be replaced with e.g. resin based filling material, metalloceramic restorations, and ceramic materials. Rubber dam will be used during removal of amalgam restorations.
1768431|NCT00346957|Drug|Anecortave acetate 30 mg|0.5ml administered onto the sclera once every six months for 24 months
1768432|NCT00346957|Drug|Anecortave Acetate 15 mg|0.5ml administered onto the sclera once every six months for 24 months
1768433|NCT00346957|Drug|Anecortave Acetate 3 mg|0.5ml administered onto the sclera once every six months for 24 months
1768434|NCT00346957|Other|Anecortave Acetate Vehicle|0.5ml administered onto the sclera once every six months for 24 months
1768435|NCT00346970|Drug|Extended-Release Niacin|Extended-Release Niacin tablets week 1-4 500 mg/d week 4-8 1000 mg/d week 9-12 1500 mg/d
1768436|NCT00346970|Drug|Placebo|Placebo tablets
1768437|NCT00346983|Drug|Pegaptanib sodium|0.3mg/0.1ml intravitreal injection, every 6 weeks, up to a total of 3 injections
1768438|NCT00346983|Drug|Control|Sham injection, every 6 weeks, up to a total of 3 sham injections
1768439|NCT00338624|Drug|oxybutynin chloride extended release|
1768440|NCT00338637|Device|APOS shoe kit|
1768441|NCT00338650|Drug|adalimumab|
1768442|NCT00338663|Device|knee immobilization splint|
1768443|NCT00338689|Dietary Supplement|Lower protein formula; Higher protein formula|During the intervention phase of the study, which is from inclusion in the study (latest age 2 weeks) until age 12 months, two experimental infant formulae with different protein content are fed to the enrolled infants; Lower protein formula and Higher protein formula. Additional a breastfed observational group without any intervention is included.
1768444|NCT00338702|Procedure|Autologous Platelet Gel|
1768445|NCT00338715|Device|PVI with Medtronic's Cardioblate BP2 radiofrequency catheter|Ablation of the right and left pulmonary veins
1768446|NCT00338728|Drug|Imatinib Mesylate|400 mg orally twice daily
1768447|NCT00338728|Drug|Letrozole|2.5 mg orally once daily
1768448|NCT00338754|Drug|Human anti-TNF monoclonal antibody adalimumab/ up to 24 weeks|
1768449|NCT00338767|Behavioral|Directly Observed Therapy (DOT)|DOT includes storefront directly observed therapy of prescribed anti-depressants. Participants will meet with a study psychiatrist, who will prescribe an appropriate antidepressant medication. Subsequent meetings with the psychiatrist will occur weekly for the first 3 weeks, and then monthly for the duration of the study. Additionally, participants will have DOT visits every weekday morning for 1 month to take their antidepressant medications. After the first month, DOT visits will occur weekly or biweekly, depending on the medication regimen.
1768450|NCT00338767|Drug|Fluoxetine|Medication treatment includes flouxetine for treatment of depression.
1768451|NCT00338780|Drug|Lamivudine/ Placebo 100mg daily|
1768452|NCT00338793|Drug|prednisolone|
1768453|NCT00338806|Behavioral|Interpersonal psychotherapy for prevention with adolescents|Individual interpersonal psychotherapy with the adolescents will be conducted over 12 weeks and will include a family psychoeducation component.
1768454|NCT00338806|Behavioral|Educational clinical monitoring|Educational clinical monitoring will include two individual sessions of psychoeducation on mood disorders with the adolescent followed by monthly (and if needed bimonthly) meetings with therapist. If more sessions are required, a referral will be made.
1768455|NCT00338832|Behavioral|Physically Ready for Invigorating Movement Every Day (PRIME)|The PRIME program is a lifestyle intervention focused on increasing physical activity. The intervention is cognitive/behaviorally based, 24-weeks in length, and a lifestyle PA intervention known to be effective in the general population of adults. The program has been modified based on theory and empirical findings about this special subgroup. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks. PRIME sessions will focus on learning about PA, setting PA-related goals, and assessing short- and long-term goals. Goals may include early-stage process-oriented goals, such as reading about PA benefits or finding a walking partner.
1768456|NCT00338832|Behavioral|Program for Activity, Leisure Skills, and Socialization (PALSS)|PALSS sessions will focus on motivating participants to engage in leisure and social activity. Sessions will include interactive, structured activity that will be led by a therapist, as well as unstructured leisure activities, such as board games, cards, general socialization, and viewing a travel video. Social and communication skills will not be explicitly taught or practiced. All participants will attend 90-minute sessions weekly for the first 16 weeks, then biweekly for the remaining 8 weeks.
1768457|NCT00338845|Behavioral|Share Safer Sex program|The Share Safer Sex intervention will consist of a single, 30 to 40 minute, one-on-one counseling session designed to increase personal awareness of the participant's current unsafe behaviors and the associated risks, help her understand her motivation to change, and increase her knowledge about how to practice safe sex. Demonstrations and practice exercises will be used to improve participants' attitudes about, as well as intentions to practice, condom use. The counseling session will include the following activities: assessing readiness for change; building motivation for change; and performing exercises in decisional balance, identification of problem and problem-solving, and knowledge and skill-building.
1768458|NCT00338845|Behavioral|Standard didactic safer-sex counseling program|The standard counseling program will be based on a sexual risk reduction counseling program developed by the Centers for Disease Control and Prevention, and will focus on personal risk assessment and strategies for risk reduction. Additionally, it will incorporate risk reduction materials provided by CENSIDA, Mexico's National Center for AIDS Studies.
1768459|NCT00338858|Other|walking and balance performance evaluation|
1768460|NCT00338858|Procedure|muscle strength, walking and balance performance|HHD- muscle strength, Balance performance - TUG, FRT, Walking performance- gaiterite and 2 min walk test
1768461|NCT00338871|Procedure|home exercise|
1768462|NCT00338884|Drug|Sunitinib malate|Sunitinib malate starting dose 37.5 mg daily continuous daily schedule
1768463|NCT00338897|Drug|SR123781A|
1768464|NCT00338910|Drug|Budesonide 2 single doses, Metronidazole multiple-dose|Budesonide 3 mg single oral dose on Day 1 and Day 9. Metronidazole 750 mg b.i.d. from Day 2 until Day 8, Metronidazole 750 mg once daily (in the morning) on Day 9.
1768465|NCT00338923|Drug|HO/03/03|
1768466|NCT00338936|Drug|Valsartan + Hydrochlorothiazide|
1956861|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + carboplatin|IV infusion
1956862|NCT02658214|Drug|oxaliplatin + 5-fluorouracil (5FU) + leucovorin (calcium folinate/folinic acid)|IV infusion and bolus administration
1768469|NCT00338962|Drug|paroxetine|paroxetine (40mg/day)
1768470|NCT00338962|Drug|desipramine|200 mg per day
1768471|NCT00338962|Drug|Naltrexone|50 mg per day
1768472|NCT00338962|Drug|Placebo|placebo
1768473|NCT00338975|Behavioral|Cognitive Behavioral Social Skills Training (CBSST)|There are 36 weekly group sessions, each session is 2 hours in length, with a half-hour break after the first hour. The intervention integrates CBT and SST techniques and neurocognitive compensatory aids. All participants are asked to identify a goal. The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. The CBT components are based on techniques developed for CBT in general and techniques developed specifically for patients with schizophrenia. Cognitive therapy is combined with role-play practice of communication skills and problem-solving training.
1768474|NCT00338975|Behavioral|Goal-focused supportive contact (GFSC)|"There are 36 weekly group sessions, each 2 hours in length, with a half-hour break after the first hour. GFSC has a number of specific goals and interventions, including providing a safe environment where the patient can discuss her/his feelings and concerns; to validate these feelings and concerns; and to provide support and guidance to the client so that she/he can make progress to solving problems or alleviating concerns and worries. Psychotic symptoms and cognition are not directly targeted. Therapists utilize non-specific therapeutic techniques, including providing unconditional positive regard, reflective listening, encouraging, paraphrasing, and summarizing. Therapists do not develop a formulation or teach skills."
1768475|NCT00338975|Behavioral|Social Skills Training|The SST components are based, in part, on a pre-packaged SST intervention available from Psychiatric Rehabilitation Consultants. Participants engage in role plays and problem solving.
1768476|NCT00338975|Behavioral|Goal Setting|All participants are asked to identify a personally meaningful goal as soon as possible in therapy. Over the 36 weeks, participants in CBSST learn skills related to goal attainment, while participants in GFSC do not receive skills aimed at goal attainment, but are encouraged to discuss their goals .
1768477|NCT00338988|Drug|Capecitabine|1500 mg/m^2 PO twice daily x 14 days.
1768478|NCT00338988|Drug|Oxaliplatin|130 mg/m^2 IV over 2 hours on day 1 of cycle.
1768479|NCT00339001|Drug|erythropoietin and early iron supplements|
1768480|NCT00339014|Drug|Zonisamide CR and Bupropion SR|Zonisamide SR and Bupropion SR
1768481|NCT00339014|Other|Placebo|Identical placebo
1768482|NCT00339040|Biological|Quadrivalent human papillomavirus (types 6, 11, 16, 18) L1 virus-like particle (VLP) or Quadrivalent human papillomavirus vaccine (QHPV)|QHPV at week 0, 8, 24 and 96.
1768483|NCT00339040|Other|Placebo/QHPV|Placebo at week 0, 8, 24 and QHPV at week 96, 104, 120.
1768484|NCT00339053|Drug|Immunonutrition ( Impact)|
1768485|NCT00339066|Drug|Sertraline|
1768486|NCT00339079|Drug|Fluoxetine|Each patient will receive fluoxetine in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter. The maximum dose for patients who are age 60 or older will be 60 mg/day. The study psychiatrist will have the option of not increasing or lowering the dose if hypochondriacal symptoms have resolved nearly completely for the last two weeks or adverse effects thought to be due to fluoxetine have occurred.
1768487|NCT00339079|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT is based upon the cognitive and perceptual model of hypochondriasis and incorporates established behavioral techniques. There will be six 60-minute individual sessions conducted at weekly intervals. Booster sessions of 20 to 30 minutes will be conducted at Weeks 8 and 12. The introduction of boosters will make the CBT alone and medication alone arms identical in length.
1768488|NCT00339079|Other|Supportive Therapy|The supportive therapy component of the treatment is similar to what might occur in a family physician's office. Participants will meet with the same psychiatrist throughout the study, who will offer general encouragement; review the participant's illness, physical symptoms and, adverse effects over the previous week; and monitor medication dosage accordingly. Patients will be seen at Weeks 1, 2, 3, 4, 6, 8, 10, and 12, for medication adjustment. Visits with the psychiatrist will last 30 minutes.
1768489|NCT00339079|Drug|Placebo|Each patient will receive placebo in 10 or 20 mg pills given according to the following schedule: 10 mg/day for two weeks, 20 mg/day for two weeks, 40 mg/day for two weeks, 60 mg/day for two weeks, and 80 mg/day thereafter.
1768490|NCT00339092|Behavioral|Modified Directly Observed Therapy|Treatment includes storefront modified directly observed therapy (MDOT) of prescribed antiretrovirals. Participants in the MDOT program will report to the study site each morning for 3 months, Monday through Friday, to take their HIV medication and any other medications prescribed by their primary care doctors. At the end of 3 months, participants will no longer attend the study site for medication assistance. Participants will then attend Action Point, a county program that helps participants adhere to taking medication, for an additional 3 months.
1768491|NCT00339092|Behavioral|Standard Care|Participants assigned to standard care will report to the study site once a month for 9 months, but will not receive any assistance with taking HIV medications. Information about medication adherence, housing, income, use of health services, drug use, sexual practices, and mental health services will be collected at each visit.
1768492|NCT00339118|Drug|doxorubicin, cytoxan|
1768493|NCT00339131|Drug|Ultratrace iobenguane I 131|
1768494|NCT00339144|Drug|Dasatinib|tablets, Oral, 100 mg, once daily for 4 weeks
1768671|NCT00349180|Drug|Enoxaparin sodium|
1956863|NCT02658214|Biological|durvalumab|IV infusion
1768495|NCT00339144|Drug|Dasatinib|tablets, Oral, 150 mg, once daily, 4 weeks
1768496|NCT00339144|Drug|Dasatinib|tablets, Oral, 200 mg, once daily for 4 weeks
1768497|NCT00339157|Drug|Anakinra|
1768498|NCT00339157|Biological|Pneumo23|
1768499|NCT00339170|Behavioral|Computer-Based Cognitive Enhancement Training Program|Participants in the cognitive enhancement training program will receive feedback on their cognitive strengths and weaknesses based on the outcomes of the baseline assessment. The training component will be comprised of 150 computer-based exercises that focus on improving memory, attention, and organizational skills. Participants will attend two weekly meetings: one will focus on providing feedback regarding goal-setting and problem-solving, and the other will focus on improving verbal skills and social information processing.
1768500|NCT00339170|Behavioral|Work Therapy Program|Participants in the work therapy program will attend two non-cognitive discussion groups per week.
1768501|NCT00339183|Drug|Panitumumab|Panitumumab was administered by IV infusion on Day 1 of each 14-day cycle, just before administration of FOLFIRI chemotherapy.
1768502|NCT00339183|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m^2, leucovorin 400 mg/m^2 racemate (or 200 mg/m^2 I-leucovorin), 5-FU bolus 400 mg/m^2, 5-FU infusion 2400 mg/m^2.
1768503|NCT00339196|Drug|5 azacytidine - VALPROIC acid- Retinoic acid|5 azacytidine - VALPROIC acid- Retinoic acid
1768504|NCT00339365|Behavioral|Promoting First Relationships Program|Participants assigned to PFR will receive ten weekly home visits that will focus on promoting the development of a secure attachment between foster parents and infants.
1768505|NCT00339365|Behavioral|Early Education Support Program|EES will consist of three monthly home visits, during which infants will be assessed and referred for additional care if necessary. EES participants will not receive any training.
1768506|NCT00339417|Drug|Albendazole|
1768507|NCT00339417|Drug|Ivermectin|
1768508|NCT00339456|Drug|HAART|
1768510|NCT00339586|Drug|Erlotinib|
1768511|NCT00339625|Other|low fat, high fiber, high fruit and vegetable eating plan|Participants were randomized to a low fat, high fiber, high fruit and vegetable (intervention arm) or their usual diet (control arm)
1768512|NCT00339690|Other|MITE-T-FASTtest kit|The primary objective of this randomized intervention trial is to determine if the use of an inhome test kit, as an adjunct to education, results in greater reductions in dust mite allergen levels than the use of educational materials alone.
1768514|NCT00339833|Drug|Salsalate|The intervention was salsalate (3g/day) for 7 days.
1768515|NCT00339833|Drug|Placebo|Identical placebo for 7 days.
1768516|NCT00339872|Drug|IMA-638|
1768517|NCT00340054|Other|questionnaire administration|
1768518|NCT00340054|Procedure|study of high risk factors|
1768520|NCT00340093|Behavioral|Managing Diabetes|
1768521|NCT00340106|Behavioral|Counseling|
1768522|NCT00340184|Drug|paclitaxel, carboplatin|
1768523|NCT00340314|Procedure|Circumferential Pulmonary Vein Ablation|
1768524|NCT00340314|Drug|Antiarrhythmic Drug Therapy|
1768525|NCT00340327|Drug|IMA-638|
1768526|NCT00340379|Drug|Ziprasidone|Target dosage 120-160mg/day based on tolerance
1768527|NCT00340379|Drug|Sertraline|Target dosage 150-200mg/day based on tolerance.
1768528|NCT00340379|Drug|Haloperidol|Target dosage 6-8mg/day based on tolerance.
1768529|NCT00340431|Drug|MSP1(42)-FVO & MSP1(42)-3D7|
1768530|NCT00340470|Behavioral|Driver Education|
1768531|NCT00340483|Behavioral|Smoking cessation|
1768532|NCT00340574|Drug|AMA1-C1/Alhydrogel + CpG 7909|
1768533|NCT00340613|Drug|glargine insulin|
1768534|NCT00340678|Drug|Losartan|Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.
1768535|NCT00340678|Drug|Placebo|Treatment with placebo corresponding to each dose of losartan.
1768536|NCT00340691|Drug|Doxycycline|
1768537|NCT00340704|Drug|tamsulosin hydrochloride|oral
1768538|NCT00340834|Drug|Fingolimod 1.25 mg|"Core: Patients self-administered fingolimod 1.25 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.
Extension: Patients self-administered fingolimod 1.25 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
1768539|NCT00340834|Drug|Fingolimod 0.5 mg|"Core: Patients self-administered fingolimod 0.5 mg capsules orally once daily. In addition, they self-administered an interferon β-1a placebo intramuscular (im) injection once weekly.
Extension: Patients self-administered fingolimod 0.5 mg capsules orally once daily."
1768540|NCT00340834|Drug|Interferon β-1a 30 µg|"Core: Patients self-administered interferon β-1a 30 μg in an intramuscular (im) injection once weekly. In addition, they self-administered a fingolimod placebo capsule orally once daily.
Extension: Patients self-administered either fingolimod 1.25 mg or 0.5 mg capsules orally once daily until switched to 0.5 mg capsules upon study protocol amendment."
1768542|NCT00346996|Drug|insulin levemir / aspart|for subcutaneous injection
1768543|NCT00346996|Drug|human insulin /insulin isophane|for subcutaneous injection
1768544|NCT00347009|Drug|adefovir dipivoxil|10mg once daily
1768545|NCT00347022|Drug|Xenetix|300 mg of iodine/ml
1768546|NCT00347022|Drug|Visipaque|270 mg of iodine/ml
1768547|NCT00347035|Drug|brimonidine|
1768548|NCT00347048|Drug|tacrolimus|oral
1768549|NCT00347048|Drug|Placebo|oral
1768550|NCT00347061|Drug|afuzosin|
1768551|NCT00347087|Drug|Irbesartan|up-titration over 4 weeks to target dose 300 mg od
1768552|NCT00347100|Drug|Insulin Glargine|Throughout study period
1768553|NCT00347100|Drug|Glyburide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
1768554|NCT00347100|Drug|Glyclazide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
1768555|NCT00347100|Drug|Glimiperide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
1768556|NCT00347100|Drug|Glipizide|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
1768557|NCT00347100|Drug|Metformin|Combination throughout the study period. Titrate to FPG ≤ 100 mg/dl.
1768558|NCT00347113|Drug|Albendazole and praziquantel|
1956864|NCT02658214|Biological|tremelimumab|IV infusion
1956865|NCT02658214|Drug|nab-paclitaxel (paclitaxel-albumin) + gemcitabine|IV infusion
1768561|NCT00347152|Drug|Divalproex|Divalproex, 8-20% taper
1768562|NCT00347152|Drug|Divalproex|Divalproex, 8-20% taper
1768563|NCT00347165|Drug|bevacizumab intravitreal injection|
1768564|NCT00347178|Procedure|Laser Peripheral Iridotomy|
1768565|NCT00347204|Drug|ketorolac (Acular LS)|
1768566|NCT00347204|Drug|Nepafenac (Nevanac)|
1768567|NCT00347230|Device|Intacs intracorneal ring insertion for the treatment of keratoconus|
1768568|NCT00347243|Procedure|phacoemulsification (cataract surgery)|
1768569|NCT00347256|Drug|cisplatin|
1768570|NCT00347256|Procedure|targeted radiation therapy|
1768571|NCT00347256|Procedure|tumor resection|
1768572|NCT00347269|Behavioral|Cognitive-behavioral therapy|Participants in CALM will choose to receive CBT, medication, or both for the treatment of their anxiety. CBT includes computer-assisted CBT with an anxiety clinical specialist.
1768573|NCT00347269|Drug|Psychotropic medication optimization|For those participants in CALM who choose medication, the ACS will facilitate the delivery of, and adherence to, anti-anxiety medication which will be prescribed by the participants' PCP.
1768574|NCT00347269|Behavioral|Treatment as Usual|Participants in the control group will receive standard treatment from their PCP.
1768575|NCT00347295|Drug|Brotizolam|
1768576|NCT00347295|Drug|Estazolam|
1768577|NCT00347308|Behavioral|Eyebrow Position|Photography of brow positions
1768578|NCT00347321|Procedure|Dilatational Percutaneous tracheostomy|Dilatational Percutaneous tracheostomy
1768579|NCT00348478|Behavioral|water and health education program to improve hygiene|
1768580|NCT00348491|Drug|Lumiracoxib|
1768581|NCT00348504|Drug|levosimendan|
1768582|NCT00348504|Drug|dobutamine|
1768583|NCT00348517|Other|Systane Free Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
1768584|NCT00348517|Other|Refresh Liquigel Lubricant Eye Drops|1-2 drops per eye four times per day for 42 days
1768585|NCT00348530|Drug|Verapamil|
1768586|NCT00348543|Procedure|laser treatment|
1768587|NCT00348556|Drug|Nesiritide|Nesiritide 0.005 ug/kg/min IV for 6 hours, then to 0.01 ug/kg/min for 6 hours then to 0.02ug/kg/min for 6 hours then to 0.03 ug/kg/min for the last 6 hours.
1768588|NCT00348569|Device|64 Channel VCT|
1768589|NCT00348582|Drug|Ketorolac, Nepafenac|
1768590|NCT00348595|Drug|Revlimid|one 5 mg/day capsule or one 25 mg/day capsule with matched placebo capsule day 1-21 (28 day cycle)
1768591|NCT00348608|Drug|iodixanol|
1768592|NCT00348621|Procedure|Visual impairment intervention program|enhanced access to eye care services
1768593|NCT00348634|Drug|Tegaserod|
1768594|NCT00348647|Behavioral|physical training program to prevent injuries|
1768595|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 10 mg BID, 30 mg BID, 100 mg BID or 500 mg QD for 7 days
1768596|NCT00348673|Drug|UK-453,061|Placebo BID, Placebo QD, UK-453,061 100 mg QD, 500 mg BID or 750 mg QD for 7 days
1768597|NCT00348686|Drug|Candesartan|16 mg once daily in oral tablet form
1768598|NCT00348686|Drug|Candesartan|32 mg once daily in oral tablet form
1768599|NCT00348686|Drug|Felodipine|5 mg once daily in oral tablet form
1768600|NCT00348686|Drug|Felodipine|10 mg once daily in oral tablet form
1768601|NCT00348699|Drug|AFP464|Given IV
1768602|NCT00348699|Other|pharmacological study|Correlative studies
1768603|NCT00348699|Other|laboratory biomarker analysis|Correlative studies
1768604|NCT00348712|Drug|rosiglitazone|Tablets, 4 mg once or twice daily.
1768605|NCT00348712|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
1768606|NCT00348712|Drug|metformin|Tablets, 2000 mg/day.
1768607|NCT00348725|Drug|fenofibrate and metformin fixed combination (drug)|
1768608|NCT00348738|Drug|Erythropoietin|Administration of 10.000 I.U Erythropoeitin SQ 3x/week, two weeks prior to radiation therapy until a haemoglobin concentration of >14g/dl, <15g/dl is reached or until the end of the radiation therapy.
1768609|NCT00348751|Device|CholGate|
1768610|NCT00348764|Drug|lauromacrogol|
1768611|NCT00348777|Drug|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
1768612|NCT00348777|Drug|3 days access to watering place at 6 months|access to watering place for movement in swimming pool, sauna and hammam.
1768613|NCT00348790|Drug|vatalanib|
1768614|NCT00348816|Drug|docetaxel|Docetaxel 20mg/m2/week IV every week during standard of care radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
1768615|NCT00348816|Drug|prednisone|Docetaxel 20mg/m2/week IV every week during radiation treatment (7 cycles). Post radiation: docetaxel 75mg/m2 IV every 21 days for 4 cycles plus prednisone 5mg PO BID QD.
1768616|NCT00348829|Procedure|mitral valve repair|surgical mitral valve repair
1768617|NCT00348842|Procedure|Newcastle Virus|
1768672|NCT00349193|Drug|laquinimod 0.3|laquinimod 0.3mg
1768618|NCT00348855|Other|Cardiovascular drugs strategies|Implementation of drug strategies according to guidelines to try to reach goals proposed in these guidelines.
1768619|NCT00348855|Behavioral|Compliance|Discussion about compliance and questionnaire to assess compliance at inclusion, Year 1 and Year 2.
1768620|NCT00348855|Behavioral|Exercise|Discussion with the patient on necessity to have regular exercise. Assessment of exercise by questionnaire at inclusion, year 1 and year 2.
1768621|NCT00348855|Behavioral|Stop Smoking|Minimal intervention
1768622|NCT00348855|Behavioral|Diet|Discussion with the patient on his (her) alimentation during each of the six consultations and assessment of daily diet at inclusion, year 1 and year 2.
1768623|NCT00348855|Other|Feed Back|Feed back on results in the intervention group at baseline, Year 1 ans Year 2.
1768624|NCT00348868|Behavioral|enhanced behavioral motivation counseling|
1768625|NCT00348868|Behavioral|Motivational counseling|
1768626|NCT00348868|Behavioral|Standard counseling|
1768627|NCT00348881|Biological|DTaP-HB-PRP~T combined vaccine|0.5 mL, Intramuscular
1768628|NCT00348881|Biological|Tritanrix-HepB/Hib™ vaccine|0.5 mL, Intramuscular
1768629|NCT00348881|Biological|Oral poliomyelitis vaccine (OPV)|Oral co-administered with study vaccine.
1768630|NCT00348894|Drug|[S,S]-Reboxetine|[S,S]-reboxetine
1768631|NCT00348894|Drug|Any|Any standard of care treatment for DPN
1768632|NCT00348907|Drug|thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam
1768633|NCT00348907|Drug|late thermal cure|thermal cure of 18 days including movement in swimming pool, mud-bath, shower, massage and thermal steam at 2 years
1768634|NCT00348920|Procedure|High Spinal and General Anesthesia|Spinal bupivacaine 0.75% in dextrose, 6 mls (45mg) and preservative free morphine 3 mcg/kg (to a maximum of 300 mcg).
1768635|NCT00348933|Drug|Betaine|100-200 mg per kg per day by mouth with a maximum of 6 grams divided in two daily doses
1768636|NCT00348933|Drug|Creatine|200 mg per kg per day with a daily maximum of 5 grams divided in two daily doses
1768637|NCT00348933|Drug|Metafolin|0.5 mg per kg per day by mouth with a maximum of 8 milligrams divided in two daily doses
1768638|NCT00348933|Drug|Vitamin B12|1 mg by mouth per day for all weights and ages
1768639|NCT00348946|Drug|androgen oxandrolone|Oxandrolone or placebo capsule, .06 >mg/kg/day, orally, for 2 years
1768640|NCT00348946|Other|placebo|an inactive substance
1768641|NCT00348959|Behavioral|'Open Window' Project|"Open Window' is an entirely art based intervention comprising a multimedia system that uses a combination of video projectors, audio speakers and bespoke software to make images appear as a 'virtual window' on the wall of the patients' room. Artists use mobile phone cameras and camcorders to record the images that are sent to the unit over the internet and via mobile phone networks. Original music composed for the project may also accompany the images as they appear.
Artists are commissioned to create work for the 'Open Window' project and are aware of the nature of the viewer and the context in which the art will be shown. The art in 'Open Window' encourages the viewer to think about and engage in what they see from their own personal frame of reference."
1768642|NCT00348972|Drug|Lantus® (insulin glargine)|
1768643|NCT00348985|Drug|belinostat|
1768644|NCT00348985|Drug|bortezomib|
1768645|NCT00348985|Other|pharmacological study|
1768646|NCT00348998|Biological|bevacizumab|
1768647|NCT00348998|Drug|bicalutamide|
1768648|NCT00348998|Drug|goserelin acetate|
1768649|NCT00348998|Radiation|radiation therapy|
1768650|NCT00349011|Procedure|Personalized risk assessment|
1768651|NCT00349011|Procedure|genetic counseling intervention|
1768652|NCT00349024|Drug|polyvinylpyrrolidone-sodium hyaluronate gel|
1768653|NCT00349037|Biological|Trivalent DNA vaccine with and without pPJV2012 administered by PMED|
1768654|NCT00349050|Device|laboratory pain assessment|Participants will record their pain experiences every day for 2 weeks before receiving the first of 5 laboratory pain assessments. The laboratory pain assessment uses a small device, controlled by a computer and attached to the underside of the forearm, to produce different temperature stimulations. As the device reaches a level considered painful to the participant, he/she can push a button to return to a level of comfort.
1768655|NCT00349050|Procedure|transcranial magnetic stimulation|"There will be two, 20-minute, 3-day TMS treatment sessions. Participants will be randomly assigned to one of two groups. Group A will receive real TMS for the first 3-day treatment and sham TMS (which does not involve real stimulation) for the second treatment. Group B will receive sham TMS for the first treatment, and real TMS for the second treatment. Regardless of the group, participants will receive both real and sham TMS."
1768656|NCT00349063|Device|soft contact lens|
1768657|NCT00349063|Drug|Soft contact lens multipurpose disinfection regimen|
1768658|NCT00349076|Drug|5-FU and oxaliplatin|"Preoperative radiochemotherapy:
Oxaliplatin: 50 mg/m² i.v., days 1, 8, 22 und 29; 5-Fluorouracil: 250 mg/m²/d continuous infusion, days 1-14 and 22-35
Adjuvant Chemotherapy:
Oxaliplatin: 100 mg/m² i.v. on day 1; Calciumfolinate: 400 mg/m² on day 1; 5-Fluorouracil: 2400 mg/m² continuous infusion for 46 hours repeat day 15, 8 cycles"
1768659|NCT00349076|Drug|5-FU|"Preoperative radiochemotherapy:
5-Fluorouracil: Days 1-5 and 29-33: 120h-continuous infusion 1000 mg/m²/d
Adjuvant Chemotherapy: 5-Fluorouracil: 500 mg/m² on 5 consecutive days (day 1-5) i.v. bolus fot 2-5 minutes; repeat day 29, 4 cycles"
1768660|NCT00349089|Drug|Pemetrexed|Pemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
1768661|NCT00349089|Drug|Cisplatin|"PPemetrexed 500 mg/m2 d1 and Cisplatin 75 mg/m2 d1; q d22
Comparator:
Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29 Cisplatin 50 mg/m2 d1, 8; q d29"
1768662|NCT00349089|Drug|Vinorelbine|Vinorelbine 25 mg/m2 d1, 8, 15, 22; q d29
1768663|NCT00349102|Radiation|Free breathing|Free breathing during conformal radiation
1768664|NCT00349102|Radiation|Breath holding|Breath holding during conformal radiation
1768665|NCT00349115|Drug|Thalidomide|
1768666|NCT00349128|Drug|fenofibrate and metformin combination (drug)|
1768667|NCT00349141|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|
1768668|NCT00349167|Drug|PR-104|
1768669|NCT00349167|Other|laboratory biomarker analysis|
1768670|NCT00349167|Other|pharmacological study|
1768673|NCT00349193|Drug|laquinimod 0.6|laquinimod 0.6mg
1768674|NCT00349193|Other|Placebo|Blinded Placebo
1768675|NCT00349206|Drug|sorafenib tosylate|Given orally
1768676|NCT00349206|Drug|temsirolimus|Given IV
1768677|NCT00349219|Drug|erlotinib|erlotinib 150 mg taken orally daily until disease progression
1768678|NCT00349219|Drug|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks given in second-line therapy
1768679|NCT00349219|Drug|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks, given in second-line
1768680|NCT00349219|Drug|cisplatin|cisplatin 80 mg/m2 IV day 1 every 3 weeks for 6 cycles
1768681|NCT00349219|Drug|gemcitabine|gemcitabine 1200 mg/m2 IV days 1 and 8 every 3 weeks for 6 cycles
1768682|NCT00349219|Drug|erlotinib|erlotinib 150 mg orally taken daily as second line therapy (after disease progression on chemotherapy)
1768683|NCT00349232|Behavioral|lifestyle intervention (diet and physical activity)|
1768684|NCT00349245|Drug|Remifentanil|
1768685|NCT00349245|Drug|Dexmedetomidine|
1768686|NCT00349258|Drug|Leuprolide acetate|
1768687|NCT00349271|Procedure|Stem cell|Stem cell
1768688|NCT00349271|Drug|Filgrastime (G-CSF)|Filgrastime (G-CSF)
1768689|NCT00349271|Drug|Standart therapy|All drug with clinical evidence of benefical effect in Chagas disease
1768690|NCT00349284|Drug|Combination of 145 mg fenofibrate and 10 mg ezetimibe|
1768691|NCT00349310|Drug|Pramipexole|
1768692|NCT00349323|Behavioral|Community directed treatment|
1768693|NCT00349336|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
1768694|NCT00349336|Drug|XELOX|As prescribed
1768695|NCT00349336|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
1768696|NCT00349336|Drug|FOLFOX-4|As prescribed
1768697|NCT00349349|Drug|ofatumumab|Intravenous infusion
1768698|NCT00349362|Drug|Testosterone|Sustanon- 200mg intramuscular testosterone
1768699|NCT00349362|Drug|0.9% saline|Saline intramuscular injection every two weeks
1768700|NCT00349375|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate 145mg and Simvastatin 20mg
1768701|NCT00349375|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
1768702|NCT00349375|Drug|Simvastatin|Simvastatin 40 mg
1768703|NCT00349388|Drug|Asacol|Asacol is given once a day versus twice or three times a day
1768704|NCT00349401|Drug|ketorolac|
1768705|NCT00349401|Drug|morphine|
1768706|NCT00349414|Procedure|Micropulse Transscleral Cyclophotocoagulation|
1768707|NCT00349414|Procedure|Conventional Transscleral Cyclophotocoagulation|
1768708|NCT00349427|Drug|Rosiglitazone 4 mg|
1768709|NCT00349440|Drug|Cyclosporine, Refresh Plus|"Cyclosporine 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily.
Refresh Plus 0.4ml (in the eye) on for 3 months instill one drop in randomized eye twice daily."
1768710|NCT00349453|Drug|Deferiprone (L1)|50-100 mg/kg body weight daily
1768711|NCT00349453|Drug|Deferiprone (L1)|75 mg/kg body weight daily
1768712|NCT00349453|Drug|Desferrioxamine|35-50 mg/kg body weight on 2 or more days per week
1768713|NCT00349466|Drug|CF101|Orally CF101 1mg
1768714|NCT00349466|Drug|Placebo|Orally matching Placebo
1768715|NCT00349479|Behavioral|Barrier assessment / interactive educational intervention|"Intervention hospitals received a barrier assessment - interactive educational intervention (BA-IEI) which included: on-site barrier assessment, annual stroke champions meetings, stroke center telephone access, quarterly mock stroke codes, and ongoing feedback and education."
1768716|NCT00349492|Drug|IP|irinotecan+cisplatin
1768717|NCT00349505|Procedure|hyper thermic chemo + surgery|
1768718|NCT00349518|Drug|Dasatinib|
1768719|NCT00349531|Drug|Pramipexole|
1768720|NCT00349557|Drug|bevacizumab, bicalutamide and goserelin|
1768721|NCT00349557|Procedure|intensity modulated radiation therapy (IMRT)|
1768722|NCT00349570|Device|Xtract Aspiration Catheter|
1768723|NCT00349583|Drug|Topical Cyclosporine, Tears|
1768724|NCT00349596|Drug|Decitabine|Administered intravenously (IV) over 1 hour at 10 mg/m2 daily x 5 days every other week.
1768725|NCT00349622|Drug|ceftriaxone|"Participants will be randomly assigned to receive treatment with ceftriaxone or placebo for at least 12 months. Two thirds of participants will receive ceftriaxone and one third will receive placebo. This is a blinded study, so neither participants nor study staff will know which treatment a participant is receiving.
Ceftriaxone is approved by the U.S. Food and Drug Administration (FDA) for treating bacterial infections but not for treating ALS. Also, ceftriaxone has not been given to people over a long period of time, such as months or years."
1768726|NCT00349622|Other|placebo|an inactive substance
1768727|NCT00349635|Drug|Metformin and Metformin + Fenofibrate|
1768728|NCT00349648|Procedure|acromioplasty|
1768729|NCT00349661|Drug|impact on VASP test|
1768730|NCT00349674|Drug|Azathioprine: 2 mg/kg/day|
1768731|NCT00349674|Drug|methotrexate 0.3 mg/kg/week, to a maximum and optimal dose of 25 mg/week|
1768732|NCT00349687|Behavioral|self-control practice|
1768733|NCT00349700|Procedure|Compression: 2 weeks four layer bandages, then stockings|
1768734|NCT00349700|Procedure|debridement|
1768735|NCT00349700|Procedure|Actisorb plus (r) + Trionic(r)/ Allevyn (r)|
1768736|NCT00349713|Biological|FMP2.1/AS02A|FMP2.1 in GSK Biologicals' AS02A
1768737|NCT00349713|Biological|Rabies vaccine (RabAvert)|RabAvert Rabies vaccine
1768738|NCT00349726|Drug|Inositol lower volume|60 mg/kg (1.2ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
1768739|NCT00349726|Drug|Inositol higher volume|120 mg/kg (2.4ml/kg) of myo-inositol 5% given intravenously over 20 minutes.
1768740|NCT00349726|Drug|Placebo lower volume|60 mg/kg (1.2ml/kg) of glucose 5% given intravenously over 20 minutes.
1768741|NCT00349726|Drug|Placebo higher volume|120 mg/kg (2.4ml/kg) of glucose 5% given intravenously over 20 minutes.
1768742|NCT00349739|Drug|Anecortave Acetate|Dosage: 0.5ml of 30mg/ml(15 mg) or 60mg/ml(30mg) Duration of action: 159-180 days
1768798|NCT00350220|Other|transfusion strategy|For the High Hb group; transfusions will be given to keep the Hb >13.0 g/dl
1768743|NCT00349752|Biological|certolizumab pegol 400 mg|Certolizumab pegol 400 mg provided in solution for subcutaneous injection (2 x 200 mg/mL) in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
1768744|NCT00349752|Other|Placebo|Placebo (commercially available sodium chloride 0.9% (preservative free)) provided for subcutaneous injection in single-use vials for administration at Weeks 0, 2, 4 and then every 4 weeks until Week 36. Two vials will be required for each dosing.
1768745|NCT00349765|Behavioral|higher fat, high polyunsaturated fat diet|
1768746|NCT00349765|Behavioral|higher fat, high saturated and trans fat diet|
1768747|NCT00349765|Behavioral|lower fat diet|
1956866|NCT02658214|Drug|cisplatin + 5-fluorouracil (5FU)|IV infusion
1768751|NCT00349791|Drug|Testosterone Transdermal System|testosterone (300 mcg/day) patch replaced twice a week for two years
1768752|NCT00349791|Drug|Placebo patch|placebo patch replaced twice a week for two years
1768753|NCT00349804|Other|cool dry air|cool dry air (0.22-0.28 m3/min at 15-18 Degrees C)
1768754|NCT00349817|Behavioral|web-based learning, didactic lecture and role-play|
1768755|NCT00349830|Procedure|blood draw|
1768756|NCT00349843|Device|Soft contact lens|
1768757|NCT00349843|Drug|Marketed soft lens multipurpose disinfection regimen|
1768758|NCT00349856|Device|Biofinity|Soft contact lens
1768759|NCT00349869|Behavioral|yoga|8-week yoga program.
1768760|NCT00349882|Device|soft contact lens|
1768761|NCT00349882|Drug|Marketed multipurpose disinfection regimen|
1768762|NCT00349895|Device|Coronary stent implantation|Percutaneous Coronary Intervention
1768763|NCT00349908|Device|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE used to treat symptomatic stenosis in intracranial arteries.
1768764|NCT00349908|Device|Cordis Neurovascular ENTERPRISE Self Expanding Stent System|Implantation of the device ENTERPRISE to treat wide-necked aneurysms
1768765|NCT00349921|Drug|clonidine|Clonidine—a drug commonly used to treat high blood pressure—has been shown to effectively treat neuropathic pain, is FDA-approved for administration via epidural (an injection given in the lower back), and is the third most commonly prescribed drug for chronic intrathecal (an injection into the cerebrospinal fluid) use in people with chronic pain.
1768766|NCT00349921|Drug|adenosine|Adenosine—a drug commonly administered intravenously (into a vein) to treat certain types of abnormal heart rhythms—has been found to reduce areas of allodynia (pain caused by a stimulus that does not normally cause pain) after intrathecal, but not intravenous administration in people with neuropathic pain.
1768767|NCT00349921|Drug|placebo|inactive substance
1768768|NCT00349921|Drug|placebo|inactive substance
1768769|NCT00349934|Biological|IMP321|"This study is an open label, non-randomized, fixed dose-escalation phase I study, performed in ambulatory setting with patients receiving as a first line chemotherapy for metastatic breast carcinoma the standard 6 cycles of paclitaxel (80 mg/m² at D1, D8 and D15 of every 4-week cycle).
Three IMP321 dose levels (250 µg, 1,250 µg and 6,250 µg) will be evaluated in three cohorts of 8 patients. At any given dose level the patients will be administered one dose every two weeks for a total of 24 weeks (12 s.c. injections in total), separated by 13-day intervals free of IMP321 administration.
The repeated single doses will be administered on D2 and D16 of the 4-week cycles, on the day which follows chemotherapy."
1768770|NCT00349947|Behavioral|Exercise Program|Participants who live within 15 miles of the Palo Alto VA Hospital will take part in a supervised aerobic exercise program 3 days a week. Participants who live farther than 15 miles from the hospital will receive a detailed exercise plan and will exercise on their own while wearing a heart rate and activity tracking device. They will also attend monthly study visits for review of their progress. All participants assigned to the exercise program will be encouraged to increase their daily exercise. Each day they will wear a pedometer; twice a month they will wear a global positioning system (GPS) and heart rate monitor.
1768771|NCT00349960|Drug|NeoRecormon SC once-weekly versus once-every-other-week|
1768772|NCT00349973|Drug|Dipyridamole|Week 1- 50 mg bid Week 2- 50 mg am and 100 mg pm Weeks 3-6 100 mg am and 100 mg pm
1768773|NCT00349973|Other|Olanzapine|Week 1- 5 mg BID Week 2- 5 mg am and 10 mg pm Weeks 3-6 10 mg am and 10 mg pm
1768774|NCT00349986|Drug|Insuline glargine|
1768775|NCT00350025|Drug|Cetuximab|Cetuximab 250mg/m2 IV weekly for each 28 day cycle.
1768776|NCT00350025|Drug|Paclitaxel|Paclitaxel 80mg/m2 IV weekly for each 28 day cycle.
1768777|NCT00350038|Drug|Irbesartan|
1768778|NCT00350038|Drug|Ciprofibrate|
1768779|NCT00350051|Drug|Sagopilone (ZK 219477) + prednisone|Chemotherapy for hormone refractory prostate cancer; 16mg/m2 (up to 32mg/m2 max) IV on day 1 or each 21 day cycle for 6 cycles or until progression or unacceptable toxicity.
1768780|NCT00350064|Behavioral|Exercise Training|16 weeks of aerobic exercise training at two different intensities
1768781|NCT00350077|Drug|Intravenous Vitamin C|vitamin C IV during 24 hour period following burn
1768782|NCT00350077|Drug|Vitamin C|IV vitamin C
1768783|NCT00350090|Drug|Epoetin Alfa|
1768784|NCT00350103|Drug|SPM 929|
1768785|NCT00350116|Drug|topical vitamin B12|
1768786|NCT00350142|Radiation|Stereotactic Body Radiotherapy|Stereotactic Body Radiotherapy will be performed using Trilogy Linear Accelerator
1768787|NCT00350142|Drug|Gemcitabine|Weekly Gemcitabine will be administered at 1000mg/m2 over 100 minutes
1768788|NCT00350142|Other|4D pancreatic protocol CT scan|Patients will undergo this imaging procedure prior to treatment for planning purposes.
1768789|NCT00350142|Radiation|FDG PET scan|Patients will have this imaging procedure along with a CT scan to map the tumor and facilitate treatment planning.
1768790|NCT00350155|Drug|Lumiracoxib|
1768791|NCT00350168|Drug|valsartan + amlodipine|
1768792|NCT00350181|Drug|Sirolimus|
1768793|NCT00350181|Drug|Mycophenolate Mofetil|
1768794|NCT00350194|Dietary Supplement|Omega-3 fatty acids|Total of 1.8 grams of EPA +DHA in the form of fish oil capsules (3/day)
1768795|NCT00350207|Drug|Tiotropium bromide|
1768796|NCT00350207|Drug|Placebo|
1768797|NCT00350207|Drug|Salmeterol xinafoate|
1768905|NCT00344110|Drug|Aliskiren|
1768799|NCT00350220|Other|Low Hb transfusion group|RBCs will not be transfused unless the Hb < 9.0 g/dl
1768800|NCT00350233|Device|ExAblate 2000|
1768801|NCT00350246|Procedure|Laser Refractive Surgery|
1768802|NCT00350272|Drug|elvucitabine|elvucitabine 10 mg orally daily
1768803|NCT00350272|Drug|Lamivudine|lamivudine 300 mg orally daily
1768804|NCT00350272|Drug|Tenofovir|tenofovir open-label 300 mg orally daily
1768805|NCT00350272|Drug|Efavirenz|efavirenze open-label 600 mg orally daily
1768806|NCT00350285|Behavioral|Motivational enhancement therapy|Personal feedback with counselor using motivational interviewing strategies.
1768807|NCT00350285|Behavioral|Marijuana education|Information about health and behavioral effects of marijuana use.
1768808|NCT00350298|Biological|GS-CDA1|one dose IV
1768809|NCT00350298|Biological|MDX-1388|one dose IV
1768810|NCT00350298|Biological|normal saline|200ml IV once
1768811|NCT00350311|Drug|nicotine transdermal patch/lozenge|
1768813|NCT00350350|Device|oxygenated oil|oxygenated oil in spray versus product reference (artificial saliva) dosage : one to two spray 5 times a day
1768814|NCT00350350|Device|medical device. Spray containing essentially oxygenated oil|"protective oral spray containing :
94.4% of oxygenated oil
Silicium dioxide
aspartame artificial flavoring"
1768815|NCT00350363|Drug|Zymar|zymar qid
1768816|NCT00350389|Behavioral|Outdoor use of plain distance glasses with counselling|Provision of single lens glasses, glasses aids, counselling, updated multifocal glasses if required
1768817|NCT00350402|Behavioral|Respiratory muscle strength training|The Muscle Stength Training (MST)device is a mouthpiece that the participant uses to inspire against controlled resistance; Intervention involves use of this device for breathing exercises over 4 week period, 5 days a week, approximately 20 minutes/day.
1768818|NCT00350415|Drug|Mesalamine|"Asacol 400g/day (400 mg tablet), oral, for 6 weeks
OR
Asacol 4,8 g/day (800 mg table), oral, for 6 weeks"
1768819|NCT00350428|Procedure|Laser Preipheral Iridotomy and phacoemulsification|
1768820|NCT00350441|Drug|Sildenafil Citrate|
1768821|NCT00350454|Device|rapamycin-eluting Stent with permanent polymer|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
1768822|NCT00350454|Device|rapamycin-eluting stent with biodegradable polymer|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
1768823|NCT00350454|Device|polymer-free, rapamycin-eluting stent|due to randomization, polymer-free.rapamycin-eluting stent will be implanted
1768824|NCT00350467|Drug|ER OROS paliperidone and Olanzapine|
1768825|NCT00350480|Drug|Provera|
1768826|NCT00350480|Drug|Combination Birth Control pills|
1768827|NCT00350506|Device|64 Channel VCT|
1768828|NCT00350519|Drug|Epoetin alfa|Participants will receive epoetin alfa 300 IU/kg once daily subcutaneously for 10 days prior to surgery, on the day of surgery, and for four days after surgery.
1768829|NCT00350519|Drug|Standard of Care|Participants will receive standard of care based on the Institution's treatment policy.
1768830|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
1768831|NCT00350532|Drug|clonidine|Patients will receive intrathecal clonidine (or clonidine injected into cerebrospinal fluid)
1996780|NCT02377193|Drug|ATG Fresenius|Simulect IV 40 mg/day D0 and D4 and oral use Tacrolimus 0.1 mg/ kg/ day + Myfortic 720 to 1440mg + Corticosteroids 5mg
1768836|NCT00350571|Behavioral|brief (behavioral therapy)|up t 3 sessions of phone or office based counseling sessions to promote re-engagement in treatment.
1768837|NCT00350571|Behavioral|Drop out re-engagement motivational intervention|Up to 3 phone or office based counseling sessions to promote reengagement in treatment
1768838|NCT00350571|Behavioral|standard care follow up|routine counselor phone calls and letters
1768839|NCT00350584|Behavioral|Mindfulness Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on learning mindfulness skills.
1768840|NCT00350584|Behavioral|Psychoeducation Telehealth Intervention|Two in-person sessions and six telephone sessions with a therapist. Focus is on education about PTSD.
1768841|NCT00350597|Drug|Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)|
1768842|NCT00350610|Other|Treatment as usual (TAU)|Standard treatment as usual in a community based treatment setting
1768843|NCT00350610|Behavioral|CBT for CBT|Standard treatment as usual (TAU) plus computer based therapy using CBT
1768844|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 4 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
1768845|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 8 x 10^9 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
1768846|NCT00350623|Biological|MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose (V520)|3-dose regimen of 1.0-mL intramuscular injections of MRKAd5 HIV-1 gag/pol/nef 1.5 x 10^10 Ad5 vg/dose, 3 doses administered at Day 1, Week 4, and Week 26.
1768847|NCT00350636|Drug|Oxybutynin topical gel|1 application daily to skin for 12 weeks
1768848|NCT00350636|Other|Placebo topical gel|1 application daily to skin for 12 weeks
1768849|NCT00350649|Behavioral|Standard CBT|Manualized delivery of CBT by trained clinicians
1768850|NCT00350649|Behavioral|CBT+CM/adherence|CBT and Clinical Management for attendance and completing homework
1768851|NCT00350649|Behavioral|CM/abstinence|Contingency Management
1768852|NCT00350649|Behavioral|CM/abstinence+CBT|Contingency Management for abstinence in addition to manualized CBT delivered by a trained clinician
1768853|NCT00350662|Drug|Deferiprone (L1)|75 mg/kg body weight daily
1768854|NCT00350662|Drug|Desferrioxamine|In combination with deferiprone: 40-50 mg/kg body weight 2-times weekly As single agent: 40-50 mg/kg body weight 5- to 7-times weekly
1768855|NCT00350688|Radiation|Helical tomotherapy IMRT|Helical tomotherapy IMRT
1768856|NCT00350701|Drug|androgel|androgel 5g
1768857|NCT00350701|Drug|androgel 10g|androgel 10g
1768858|NCT00350701|Drug|placebo|placebo
1768859|NCT00350714|Other|MBT and BreathID|75 mg methacetin (c13 labelled) dissolved in 150 cc water ingested and breath collected before and after ingestion.
1768860|NCT00350727|Drug|pazopanib|Pazopanib is a novel compound being developed for the treatment of various cancers.
1768861|NCT00350727|Drug|lapatinib|Lapatinib is a novel compound being developed for the treatment of various cancers.
1768862|NCT00350753|Drug|Erlotinib and bevacizumab|Erlotonib 150 mg daily bevacizumab 10 mg/kg every 14 days
1768863|NCT00350766|Procedure|Autologous Bone Marrow Mononuclear Cells (ABMMC) Transplantation|Catheter based stem cells delivery of 100 million cells resuspended in a 10 ml solution of saline with autologous serum. About 100 ml of Bone Marrow aspirate were harvested from iliac crest between the fifth and seventh day after myocardial infarction. ABMMC were isolated by density gradient centrifugation on Ficoll-PaqueTM plus (Amersham Biosciences) and manipulated under aseptic conditions for injection, after being filtered through 100 um nylon mesh to remove cell aggregates.
1768864|NCT00350779|Drug|sitagliptin|Sitagliptin 100mg tablet each day for 54 weeks. All subjects will be given placebo to sitagliptin for a 2 week period.
1768865|NCT00350779|Drug|Comparator: Placebo|Placebo to sitagliptin 100mg tablet each day for 54 weeks.
1768866|NCT00350779|Drug|rosiglitazone|Subjects taking 4mg or greater rosiglitazone at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 4mg/day or no rosiglitazone at screening will be titrated to a stable dose of at least 4mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
1768867|NCT00350779|Drug|metformin|Subjects taking 1500mg or greater metformin at screening will enter a 6 week stable dose period followed by a 54 week treatment period. Subjects who are taking less than 1500mg/day or no metformin at screening will be titrated to a stable dose of at least 1500mg over a a maximum of 8 weeks followed by a dose stable period of up to 12 weeks then a 54 week treatment period. Total treatment will be up to 77 weeks.
1768868|NCT00350779|Drug|glipizide|Subjects not meeting specific glycemic controls during the 54-week treatment period will use glipizide as rescue therapy. Glipizide will be titrated in 5mg doses up to a maximum 40mg each day. (In Canada, the rescue therapy will be a sulfonylurea agent marketed in that country.)
1768869|NCT00350792|Drug|pemetrexed|500 milligrams per square meter (mg/m^2), intravenous (IV), every 21 days x 6 cycles
1768870|NCT00350792|Drug|carboplatin|Area Under the Curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
1768871|NCT00350805|Procedure|EEG|One 20 minutes session
1768872|NCT00350818|Drug|Azacitidine|8 mg/m^2 Subcutaneously Once Daily for 5 Days
1768873|NCT00350831|Drug|XL820|
1768874|NCT00350844|Drug|Hydroxyurea|20 mg/kg/day and dose escalating every 2 months until maximum tolerated dose.
1768875|NCT00350857|Drug|Extended-Release Carbamazepine|
1768876|NCT00350870|Drug|disulfiram|250mg per day of Disulfiram plus CBT
1768877|NCT00350870|Drug|Placebo|Placebo plus CBT
1768878|NCT00350870|Behavioral|Placebo plus Contingency Management|Placebo plus Contingency Management for cocaine abstinence and medication compliance in addition to CBT
1768879|NCT00350870|Drug|Disulfiram plus Contingency Management|250mg of Disulfiram plus Contingency Management for cocaine abstinence and medication compliance plus CBT.
1768880|NCT00350883|Behavioral|Cognitive Therapy|Goal-oriented talk therapy
1768881|NCT00350883|Other|Treatment as Usual|Keep getting usual care
1768882|NCT00350896|Device|Thumb orthoses|
1768883|NCT00350909|Behavioral|brief intervention (cognitive-behavioral therapy)|Consists of 60 minute individual sessions delivered with a therapist using a motivational interviewing (MI) style. Session 1 focuses on eliciting information about the students' substance use and related consequences based on the assessment, their perception of level of willingness to change, examining the cause and benefits of change using the decisional balance exercise, and discussing what goals for change the student would like to select and pursue. Session 2 reviewed the students' progress with the agreed upon goals, identifying high risk situations associated with clients difficulty in achieving the goals, discussing strategies to address barriers toward goal attainment, reviewing where the client is in the stage of change process, and negotiating either the continuation of goals or advancing to more ambitious goals of substance use reduction. Session 3 involved delivering the same MI interviewing style to the primary parent or guardian (student is not present).
1768884|NCT00350922|Behavioral|Psychoeducation|
1768885|NCT00350935|Procedure|fMRI|One 30 minute session
1768886|NCT00350948|Drug|Telcyta|Day 1 of 28 day Cycle.
1768887|NCT00350948|Drug|Liposomal Doxorubicin|Day 1 of 28 Day Cycle. 50 mg/m2
1768888|NCT00350961|Drug|Gemcitabine|
1768889|NCT00350961|Drug|Oxaliplatin|
1768890|NCT00350961|Drug|Capecitabine|
1768891|NCT00350987|Behavioral|a strategy based on PCT guided AB therapy|In this study a strategy based on PCT guided AB therapy with enforced guideline implementation will be compared.
1768892|NCT00351000|Drug|Ziprasidone|
1768893|NCT00343993|Device|noninvasive positive pressure ventilation|
1768894|NCT00344006|Drug|chlorproguanil-dapsone-artesunate|
1768895|NCT00344006|Drug|artemether-lumefantrine|
1768896|NCT00344019|Drug|Placebo Oral Tablet|placebo pre-PCI for ACS
1768897|NCT00344019|Drug|Atorvastatin 80mg|atorvastatin 80 mg pre-angio/PCI
1768898|NCT00344019|Other|Screening|Patients signed consent to be screened for eligibility for randomization to placebo vs. study drug (atorvastatin)
1768899|NCT00344032|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
1768900|NCT00344032|Biological|HPV-16/18 VLP/AS04 Vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
1768901|NCT00344045|Drug|Paracetamol|IV Solution, Intravenous, 100 mL (10 mg/mL), 4 times at 6-hour intervals, 24 hours
1768902|NCT00344045|Drug|Placebo|IV Solution, Intravenous, 100 mL (0 mg/mL), 4 times at 6-hour intervals, 24 hours
1768903|NCT00344058|Drug|abbreviation of magnesium sulfate therapy (12 hours versus the traditional 24 hours after delivery)|
1768904|NCT00344097|Procedure|Soy protein|
1768906|NCT00344123|Drug|Tipranavir/Ritonavir|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).
On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r."
1768907|NCT00344123|Drug|Rosuvastatin|"On Day 1, subjects will receive a single 10 mg dose of rosuvastatin. Beginning on Day 3, subjects will receive a combination of TPV 500mg/RTV 200 mg twice daily for 11 days (Days 3-13).
On Day 12, subjects will receive a single 10 mg dose of rosuvastatin co-administered with TPV/r.."
1768908|NCT00344149|Drug|Rituximab (Mabthera)|I.V infusion of Rituximab 375 mg/m2 per week for 4 weeks
1768909|NCT00344175|Drug|pitavastatin|
1768910|NCT00344175|Drug|simvastatin|
1768911|NCT00344201|Device|Tisseel fibrin adhesive|Intraoperative application to scleral bed and graft
1768912|NCT00344214|Behavioral|Tri-focal cognitive behavioral therapy - social skills training (CBTSS) counseling program|This condition is a Theory-Based Counseling Program. The program will involve nine 90-minute face-to-face counseling sessions that use CBT and strategies associated with social cognitive theory. The theory addresses three treatment domains, including mood regulation, reduction/cessation of meth use, and reduction of high risk sexual practices.
1768913|NCT00344214|Behavioral|Standard care|Standard care involves nine weekly, face-to-face individual counseling sessions that provide standard care in relation to sexual risk, methamphetamine use, and depression. The sexual risk component is a modified version of Project RESPECT 1 (CDC, Atlanta) that focuses on educational materials and personal risk appraisal. The meth component is a modified version of the 12-step drug abstinence program developed by the National Institute of Alcohol Abuse and Alcoholism (NIAAA) (Project MATCH). The depression component is an educational approach based primarily on materials provided by the National Alliance on Mental Illness (NAMI) and the National Institute of Mental Health (NIMH).
1768914|NCT00344227|Drug|Lucentis (Ranibizumab)|
1768915|NCT00344240|Behavioral|Functional circuit training with lifestyle behavior|
1768916|NCT00344253|Drug|Interferon beta|
1768917|NCT00344253|Drug|Methotrexate|
1768918|NCT00344305|Biological|Trivalent influenza virus vaccine live, intranasal|A single, intranasal dose of 0.2 mL (approximately 0.1 mL in each nostril) FluMist trivalent influenza virus vaccine live on Day 0 of the study. Each dose of FluMist vaccine contained 10^7 FFU of three influenza virus strains.
1768925|NCT00344370|Drug|Pitavastatin|Pitavastatin 4 mg QD
1768926|NCT00344370|Drug|Atorvastatin|Atorvastatin 40 mg
1768927|NCT00344383|Drug|Norgestimate/Ethinyl Estradiol tablet|
1768928|NCT00344409|Drug|darbepoetin alfa|
1768929|NCT00344422|Drug|Vincristine, DOXIL (doxorubicin HCl liposomal injection), and Dexamethasone (VDD) vs. Vincristine, Doxorubicin and Dexamethasone (VAD)|
1768930|NCT00344448|Drug|Raptiva|During the first phase of the study, subjects are randomized in a double blind fashion to receive weekly subcutaneous injections of efalizumab (Raptiva) or placebo (weeks 0-12). The second 12 weeks long phase is open label with all subjects receiving weekly subcutaneous injections of efalizumab.
1768932|NCT00351013|Other|Malaria Tropica Nosode D200|5 pellets every four months
1768933|NCT00351026|Drug|Methadone|short-term methadone maintenance
1768934|NCT00351039|Drug|Bevacizumab|Treatment Regimen Item 1: Bevacizumab 10 mg/Kg I. V. Day 1 and Day 15. Repeat cycles every 28 days.
1768935|NCT00351039|Drug|Erlotinib|Treatment Regimen Item 2: Erlotinib 150mg Per Orally (PO) Once Daily (QD) for 7 days starting day 2 and day 15. Repeat cycles every 28 days.
1768936|NCT00351039|Drug|Pemetrexed|Treatment Regimen Item 3: Premetrexed 500mg/m2 I.V. Day 1 and Day 15. Repeat cycles every 28 days.
1768937|NCT00351052|Drug|Pimecrolimus|Pimecroliums cream 1 % bid.
1768938|NCT00351052|Drug|Placebo|Vehicle control (placebo) bid.
1768939|NCT00351065|Drug|SK3530|
1768940|NCT00351078|Drug|PTC124|
1768941|NCT00351091|Drug|RISEDRONATE|
1768942|NCT00351104|Drug|Ketoprofen Topical Patch 20%|
1768943|NCT00351117|Drug|St. John's Wort|SJW in capsule form 300 mg PO TID
1768944|NCT00351117|Drug|Lactose|lactose in gelatin capsule that same as St. John's wort
1768945|NCT00351130|Drug|valsartan|
1768946|NCT00351130|Drug|amlodipine|
1768947|NCT00351143|Drug|salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training|Salmeterol/fluticasone propionate 50/250 µg + 3 training sessions of compliance enhancement training will be provided to intervention group in Period 2.
1768948|NCT00351143|Drug|salmeterol/fluticasone propionate 50/250 µg|Salmeterol/fluticasone propionate 50/250 µg will be administered to control group in Period 2
1768949|NCT00351156|Procedure|Blood sample|
1768950|NCT00351169|Drug|Quetiapine SR|
1768951|NCT00351169|Drug|Escitalopram|
1768952|NCT00351182|Drug|Telithromycin|
1768953|NCT00351182|Drug|Doxycycline|
1768954|NCT00351195|Drug|Etoposide|
1768955|NCT00351195|Drug|Oxaliplatin|
1768956|NCT00351195|Drug|Capecitabine|
1768957|NCT00351208|Device|Medtronic Manufactured Spinal Cord Stimulators|
1768959|NCT00351234|Drug|Carnitine (drug)|Oral L-carnitine will be obtained from Sigma Tau Pharmaceuticals. Supplementation will be initiated at 50mg/kg body weight and increased to 100mg/kg body weight after one week.
1768960|NCT00351247|Procedure|Postconditioning|
1768961|NCT00351260|Procedure|Coronary Angioplasty|
1768962|NCT00351273|Drug|Doxycycline and Rifampin|doxycycline 100mg daily; rifampin 300mg daily (both for 6 months)
1769165|NCT00352898|Biological|MeMuRu-OKA (study vac)|
1768963|NCT00351273|Drug|Azithromycin and Rifampin|Azithromycin 500mg daily for 5 days and then twice weekly; Rifampin 300mg daily (both for 6 months)
1768964|NCT00351273|Drug|Placebo|Methylcellulose
1768965|NCT00351286|Drug|L-citrulline tablets, 1000 mg|
1768966|NCT00351286|Drug|Placebo tablets matching L-citrulline tablets|
1768967|NCT00351286|Drug|Background simvastatin at a stable dose of 40 mg qHS|
1768968|NCT00351299|Drug|Dexmedetomidine|dexmedetomidine infusion titrated to effect
1768969|NCT00351299|Other|Standard of Care|Standard of care per treating physician preference
1768971|NCT00351325|Drug|BMS-663513|mg/kg, IV, 0.3, 1, 3, 10 mg/kg, q 3 wks, up to 24 weeks
1768972|NCT00351455|Behavioral|smoking cessation|
1768973|NCT00351455|Behavioral|tighter diabetic control|
1768974|NCT00351455|Behavioral|diet and exercise program|
1768975|NCT00351468|Drug|eltrombopag olamine (SB-497115-GR)|Eltrombopag with starting dose of 50mg daily, max dose of 75mg daily and min dose of 25mg daily or less frequently. Modifications were given to maintain platelet count in range of 50 to 200 Gi/L.
1768976|NCT00351494|Procedure|contrast enhanced ultrasonography|"Three contrast-enhanced ultrasonography : before embolization, after one day and after 6 months.
Abdominal route 2.4 ml sonovue per injection / bolus"
1768977|NCT00351494|Procedure|embolization|Intervention is described in the case report form for each patient
1768978|NCT00351507|Drug|Vildagliptin|
1768979|NCT00351520|Drug|Miltefose|
1768980|NCT00351533|Drug|Fish oil (eicosapentaenoic acid and docosahexanoic acid)|Liquid fish oil 7.5cc enterally every 6 hours
1768981|NCT00351546|Drug|Vildagliptin|
1768982|NCT00351559|Device|AlloMap molecular expression testing|
1768983|NCT00351559|Procedure|Right ventricular endomyocardial biopsy|
1768984|NCT00351572|Procedure|Cell Search Assay|
1768985|NCT00351585|Drug|Vildagliptin|
1768986|NCT00351598|Radiation|Definitive Radiotherapy|60Gy in 6 weeks, 50Gy in 4 weeks. Each individual fraction should not exceed 2.5Gy.
1768989|NCT00351624|Behavioral|DHA|
1768990|NCT00351624|Behavioral|placebo|
1768991|NCT00351637|Drug|Sublingual Methadone|
1768992|NCT00351663|Drug|Enoxaparine|"Patients considered eligible will be divided into 2 groups- those receiving vasopressor support and those not receiving vasopressor support at the time of inclusion. The patients in each group will be randomized to receive enoxaparin in accordance with one of the following DVT prophylaxis protocols:
Intravenous Enoxaparine according to their weight (0.5mg/kg x 1/day)
Subcutaneous Enoxaparine according to their weight (0.5mg/kg x 1/day)
Subcutaneous Enoxaparine 40mg x1/day"
1768993|NCT00351676|Behavioral|Integration of a team based clinical pharmacist|
1768994|NCT00351676|Drug|Optimizing therapeutic treatments|
1768995|NCT00351676|Behavioral|Optimizing processes of care|
1768996|NCT00351689|Behavioral|dietary supplement|
1768997|NCT00351702|Drug|Isoniazid with Ethambutol|Isoniazid (300mg) with Ethambutol (800mg) daily for 6 months
1768998|NCT00351715|Drug|Sublingual Methadone|
1768999|NCT00351741|Device|Ventilation - High Frequency Percussive Ventilation|Ventilatory support delivering high frequency percussive ventilation using the Volumetric Diffusive Respirator
1769000|NCT00351741|Device|Ventilation - ARDSnet|Respiratory support with a conventional mode of ventilation using a conventional ventilator (Draeger Evita XL)
1769001|NCT00351754|Drug|Isovue|
1769002|NCT00351767|Drug|placebo|Topically applied
1769003|NCT00351767|Drug|telbermin|Topically applied
1769004|NCT00351780|Device|FFR measurement, side branch angioplasty|
1769005|NCT00351793|Device|Knee Implant|Total knee replacement with Genesis II posterior stabilized knee
1769006|NCT00351806|Drug|Erigeron breviscapus injection|
1769007|NCT00351806|Drug|hua tuo zai zao wan (a herbal medicine pill)|
1769008|NCT00351806|Drug|Compound stroke herbal medicine (8 herbal)|
1769009|NCT00351819|Drug|AndroGel|5g gel, applied once daily to the upper arms, upper back or shoulders.
1769010|NCT00351819|Other|Placebo|5g gel, applied once daily to the upper arms, upper back or shoulders.
1769011|NCT00351832|Drug|Vildagliptin|
1769012|NCT00351845|Behavioral|Low carbohydrate diet (behavior)|
1769013|NCT00351858|Drug|ertumaxomab|
1769014|NCT00351871|Drug|PEG-Intron Plus REBETOL|
1769015|NCT00351884|Drug|Vildagliptin AM|
1769016|NCT00351884|Drug|vildagliptin pm|
1769017|NCT00351884|Drug|placebo|
1769018|NCT00351897|Device|pulsed dye (585nm) laser therapy|
1769019|NCT00351910|Drug|Quetiapine|
1769020|NCT00351910|Drug|Amitriptyline|
1769021|NCT00351910|Drug|Bupropion|
1769022|NCT00351910|Drug|Citalopram|
1769023|NCT00351910|Drug|Duloxetine|
1769024|NCT00351910|Drug|Escitalopram|
1769025|NCT00351910|Drug|Fluoxetine|
1769026|NCT00351910|Drug|Paroxetine|
1769027|NCT00351910|Drug|Sertraline|
1769028|NCT00351910|Drug|Venlafaxine|
1769029|NCT00351923|Biological|MeMuRu-OKA (study vaccine)|
1769030|NCT00351936|Drug|Aripiprazole|
1769031|NCT00351936|Drug|placebo|
1769032|NCT00351949|Biological|IMP321|subcutaneous injections of IMP321 every 14 days for three months (6 injections. Doses tested: 50, 250, 1,250, 6,250 or 30,000 µg
1769033|NCT00351962|Procedure|Fractionated Stereotactic Radiotherapy|
1769034|NCT00351975|Drug|Belinostat|Given IV
1769035|NCT00351975|Drug|Azacitidine|Given SC
1769036|NCT00351975|Other|Laboratory Biomarker Analysis|Correlative studies
1769037|NCT00351988|Behavioral|Phenomenological Interviews|Part 1 will collect phenomenologic data to understand the meaning of caregiver burden, and the positive experiences faced when caring for a underserved patient with advanced lung cancer.
1769038|NCT00351988|Behavioral|Quantitative Interviews|Part 2 will collect quantitative data to determine the prevalence and severity of symptoms experienced by caregivers and their contribution to caregiver burden.
1769041|NCT00352027|Drug|Adriamycin®|Given IV on Day 1 of weeks 1, 3, 5, 7, 9 and 11.
1769042|NCT00352027|Drug|Vinblastine|Given IV, Day 1 of weeks 1, 3, 5, 7, 9 and 11.
1769043|NCT00352027|Drug|Nitrogen Mustard|Given IV, Day 1 of weeks 1, 5 and 9. Cyclophosphamide may be substituted if nitrogen mustard is unavailable.
1769044|NCT00352027|Drug|Cyclophosphamide|May be substituted if nitrogen mustard is unavailable. Given on Day 1 of weeks 1, 5 and 9.
1769045|NCT00352027|Drug|Vincristine|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
1769046|NCT00352027|Drug|Bleomycin|Given IV on Day 1 of weeks 2, 4, 6, 8, 10 and 12.
1769047|NCT00352027|Drug|Etoposide|Given IV on Days 1 and 2 of weeks 1-10.
1769048|NCT00352027|Drug|Prednisone|Given PO every other day of weeks 1-12.
1769049|NCT00352027|Biological|G-CSF|Given subcutaneously days 3-13, 16-26, 29-39, 42-52, 55-65, and 68-78 (as clinically indicated).
1769050|NCT00352027|Procedure|Radiotherapy|Participants receive radiotherapy after completion of 12 weeks of Stanford V chemotherapy.
1769051|NCT00352053|Drug|Tenofovir DF|Tenofovir DF 300-mg tablet, administered orally, daily + OBR
1769052|NCT00352053|Drug|Placebo|Tenofovir DF Placebo administered orally, daily + OBR
1769053|NCT00352066|Drug|apricitabine|
1769054|NCT00352079|Biological|BCG vaccine|"Intravesical BCG:
Induction:
q weekly x 6 (cycle 1)
Maintenance:
q weekly x 3 at 3, 6, 12, 18, 24, 30, 36 months post- 2 randomization (cycles 2 - 8)"
1769055|NCT00352079|Drug|gefitinib|Iressa® 250 mg PO Daily for 12 weeks starting on day 1 of each cycle of intravesical BCG therapy (cycles 1 - 8)
1769056|NCT00352079|Procedure|quality-of-life assessment|Each cycle and at 3 and 6 months after treatment discontinuation
1769057|NCT00352092|Drug|calcineurin inhibitor|
1769058|NCT00352092|Drug|sirolimus|
1769059|NCT00352092|Drug|mycophenolate mofetil|
1769060|NCT00352105|Drug|cisplatin|20mg/m2/d IV continuous infusion x4 days
1769061|NCT00352105|Drug|fluorouracil|1000mg.m2/d IV continuous x 4 days
1769062|NCT00352105|Drug|Iressa|250mg/PO qd x 2 years
1769063|NCT00352105|Radiation|hyperfractionated radiation therapy|120cGy bid
1769064|NCT00352118|Biological|filgrastim|subcutaneously on Days 5-14, repeating every 3 weeks for 2 courses.
1769065|NCT00352118|Biological|pegfilgrastim|If applicable on day 5, repeating every 3 weeks for 2 courses.
1769066|NCT00352118|Drug|cisplatin|Intravenous over 1 hour on day 1, every 3 weeks for 3 courses.
1769067|NCT00352118|Drug|docetaxel|Intravenous over 1 hour on day 1.
1769068|NCT00352118|Drug|fluorouracil|Intravenous continuously on days 1-4.
1769069|NCT00352118|Procedure|conventional surgery|As appropriate, neck dissection.
1769070|NCT00352118|Radiation|radiation therapy|60 Gy 5 days/week x 6 weeks with cisplatin
1769071|NCT00352131|Drug|HuC242-DM4|Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.
1769072|NCT00352144|Drug|Eszopiclone|Eszopiclone 3 mg
1769073|NCT00352144|Drug|Placebo|Placebo tablet
1769074|NCT00352157|Behavioral|Revival Soy Dietary Supplement|
1769075|NCT00352170|Dietary Supplement|calcium supplementation|calcium carbonate 1500 mg/day
1769076|NCT00352170|Dietary Supplement|calcium and vitamin D3 supplementation|calcium carbonate 1500 mg/day vitamin D3 1000 IU/day
1769077|NCT00352170|Dietary Supplement|Placebo|calcium and vitamin D3 placebo
1769078|NCT00352183|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40mg
1769079|NCT00352183|Drug|Simvastatin|Simvastatin 40mg
1769080|NCT00352196|Drug|Risperidone|12 weeks of treatment with risperidone 0.25 to 11 mg per day.
1769081|NCT00352196|Other|Magnetic Resonance Spectroscopy|Subjects will receive a standard MRS to assess the concentrations and ratios of brain metabolites N-acetylaspartate, creatine, phosphocreatine, and choline.
1769082|NCT00352222|Device|stent implantation|
1769083|NCT00352235|Drug|KRN7000|
1769084|NCT00352248|Procedure|Tongue Acupuncture (Procedure)|
1769085|NCT00352261|Drug|Esomeprazole|
1769086|NCT00352261|Drug|Lansoprazole|
1769087|NCT00352287|Drug|Recombinant human growth hormone; pioglitazone|
1769088|NCT00352300|Procedure|Adjuvant Therapy|
1769089|NCT00352300|Drug|Carboplatin|Given IV
1769090|NCT00352300|Drug|Paclitaxel|Given IV
1769091|NCT00352300|Biological|Pegfilgrastim|Given IV
1769092|NCT00352313|Drug|ATN-161|Given IV
1769093|NCT00352313|Drug|carboplatin|Given IV
1769094|NCT00352326|Device|reprogramming assisted communication device interface|The subjects were required to touch targets on the iPad® screen with the index finger of their preferred (less-affected) arm. The experimental task consisted of 180 targets divided in 4 blocks: 45 targets each block with a 1-minute interval between trials to avoid fatigue. Targets appeared at 1 of 9 different locations on the screen, and subjects moved their finger sequentially from one target to the next.
1769095|NCT00352339|Drug|Rispridoen and Aripiprazole|Start with risperidone and switch it to aripiprazole. Flexible dose
1769096|NCT00352339|Drug|Risperidne|Start with risperidne and keep it through the end of study. Risperidne:flexible dose
1769097|NCT00352339|Drug|Abilify|Start with abilify and keep it through the end of study
1769098|NCT00352352|Procedure|Tongue Acupuncture (Procedure)|
1769099|NCT00352365|Drug|lenalidomide|Given orally
1769100|NCT00352378|Drug|Anthracycline, Cyclophosphamide, Docetaxel, Capecitabine|"Patients will be randomized to receive regimen A (AC) and regimen B(TX),preoperatively as follows:
Regimen A (AC): Intravenous infusion of Adriamycin 60mg/m2 , over 30 min, onD1 and Intravenous infusion of cyclophosphamide 600 mg/m2 over 30 min on D1. Regimen B(TX): Intravenous infusion of Taxotere 75 mg/m2 over 1 hr, on D1, and Xeloda 1000mg/m2.p.o. BID x 14days on D1-D14"
1996781|NCT02376803|Drug|Warfarin|Morning vs Evening administration
1769101|NCT00352391|Other|Assessments|At Months 6, 12, 18, 24, 30, and 36, complete medical history will be recorded, and a physical exam will be performed by either a doctor or a nurse. At each of these visits, blood will be drawn for routine tests (about 3 teaspoons) and for research purposes (about 4 teaspoons). Also, a chest x-ray and a chest CT will be done at these visits.
1769102|NCT00352404|Device|Endomicroscope|
1769103|NCT00352417|Drug|VIA-2291|100 mg, oral dosing, 1 time daily for 12 weeks
1769104|NCT00352417|Drug|Placebo|oral dosing, 1 time daily for 12 weeks
1769105|NCT00352430|Drug|Nitric Oxide/INP Pulse Delivery|
1769106|NCT00352430|Drug|Nitric Oxide/INO Pulse Delivery|
1769107|NCT00352443|Drug|everolimus|part 1: dose assigned by ETx online system PO days 1-28 daily part 2: cohort a: 5 mg PO days 1-28 part 2: cohort a: 1250 mg PO days 8-28 (cycle 1) days 1-28 (subsequent cycles)
1769108|NCT00352443|Drug|lapatinib ditosylate|dose assigned by ETx online system PO days 1-28 daily part 2 cohort a: 1250 mg PO d 8-28 (cycle 1) days 1-28 (subsequent cycles) part 2 cohort b: 120 mg PO days 1-28 daily
1769110|NCT00352482|Drug|Sildenafil (50 mg)|
1769111|NCT00352495|Drug|carboplatin|
1769112|NCT00352495|Drug|vinblastine sulfate|
1769113|NCT00352508|Behavioral|Dietary advice|
1769114|NCT00352521|Drug|bevacizumab|
1769115|NCT00352521|Drug|irinotecan|
1769116|NCT00352521|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1769117|NCT00352534|Procedure|therapeutic conventional surgery|Undergo surgery
1769118|NCT00352534|Drug|vincristine sulfate|Given IV
1769119|NCT00352534|Biological|dactinomycin|Given IV
1769120|NCT00352534|Drug|doxorubicin hydrochloride|Given IV
1769121|NCT00352534|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
1769122|NCT00352560|Drug|Irbesartan|Tablets, Oral, 300 mg, once daily, 30 days.
1769123|NCT00352560|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 30 days.
1769124|NCT00352599|Drug|Lovastatin|
1769125|NCT00352599|Drug|Lovastatin|Lovastatin capsules daily for 14 weeks (titrated up from 10 mg to 40 mg)
1769126|NCT00352599|Drug|placebo pill|
1769127|NCT00352612|Drug|clindamycin|clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
1769128|NCT00352612|Drug|cephalexin|cephalexin suspension or tablets, 40mg/kg/day, given by mouth, divided TID, for 7 days
1769129|NCT00352625|Drug|Ketoprofen Topical Patch 20%|
1769130|NCT00352638|Other|counseling intervention|
1769131|NCT00352638|Other|educational intervention|
1769132|NCT00352638|Other|study of socioeconomic and demographic variables|
1769133|NCT00352651|Drug|Pregabalin|
1769134|NCT00352664|Drug|Donepezil|5 mg once a day by mouth for 7 day cycle. After evaluation on Day 8, all participants will be offered donepezil every day for 7 days.
1769135|NCT00352664|Drug|Placebo|Placebo tablet once a day by mouth for one 7 day cycle. After evaluation on day 8, all participants offered donepezil every day for 7 days.
1769136|NCT00352677|Drug|INNO-406|Oral, twice daily self-administration of 10 mg and/or 50 mg tablets
1769137|NCT00352690|Drug|Paclitaxel poliglumex|
1769138|NCT00352690|Drug|Carboplatin|
1769139|NCT00352690|Radiation|External beam radiation therapy|
1769140|NCT00352703|Drug|Kepivance (Palifermin)|
1769141|NCT00352716|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
1769142|NCT00352729|Device|ACell dressing|dressing
1769143|NCT00352742|Drug|ATN-224 + bortezomib|ATN-224 and bortezomib dose to be determined in Phase I portion of study
1769144|NCT00352755|Procedure|Surgical debulking with peritonectomy|
1769145|NCT00352755|Drug|Intraperitoneal 5FU|
1769146|NCT00352755|Drug|FOLFOX|
1769147|NCT00352768|Drug|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
1769148|NCT00352768|Drug|Placebo|Placebo
1769149|NCT00352781|Drug|nicotine replacement therapy|nicotine transdermal patches as per product monograph
1769150|NCT00352781|Behavioral|behavioural intervention|Smoking cessation counselling and relapse prevention
1769151|NCT00352794|Drug|Lenalidomide|Oral 10 mg daily/days 1-21 of 28 day cycle
1769152|NCT00352794|Drug|Prednisone|Starting dose oral 30 mg/day during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
1769153|NCT00352807|Drug|Brimonidine Purite|
1769154|NCT00352820|Behavioral|Interview|Recorded face-to-face session.
1769155|NCT00352820|Behavioral|Questionnaire|Written survey lasting approximately 30 minutes.
1769156|NCT00352833|Drug|catumaxomab|
1769157|NCT00352846|Drug|Zoledronic Acid|4 mg/m^2 by vein over 30 Minutes at baseline and 6 months.
1769158|NCT00352846|Drug|Vitamin D|400 mg by mouth daily
1769159|NCT00352846|Drug|Calcium Carbonate|1200 mg by mouth daily
1769160|NCT00352859|Drug|Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon|Continue sorafenib with addition of gemcitabine or interferon
1769161|NCT00352859|Drug|Gemcitabine or Interferon (only)|Discontinue Sorafenib and receive Gemcitabine or Interferon only
1769162|NCT00352885|Drug|Escitalopram|Participants will begin medication approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 10 mg per day. If 10 mg is well tolerated by the participant, the dosage will be increased to 20 mg per day. The dosage for the remainder of the study will be 20 mg per day.
1769163|NCT00352885|Drug|Placebo|Participants will begin the placebo approximately 2 weeks before their first scheduled IL-2 treatment. The dosage for the first week will be 1 pill per day, if 1 pill is well tolerated by the participant the dosage will be increased to 2 pills per day. Two pills per day will be the dosage for the reminder of the study.
1769164|NCT00352885|Drug|IL-2|IL-2 is a 12-week treatment regimen with intravenous (IV) IL-2. There will be one cycle every 3 weeks for a total of four cycles. One cycle is 720,000 units/kg every 8 hours for 5 days.
1769166|NCT00352898|Biological|MMR, Varicella vacc (control)|
1769167|NCT00352911|Drug|VGX-410 (Mifepristone)|
1769168|NCT00352911|Drug|Placebo for VGX-410 (Mifepristone)|
1769169|NCT00352950|Drug|AMG 954/Panitumumab|
1769170|NCT00352963|Biological|Study vaccines: IH+Hib-MenC/NVC; Control: IH+Meningitec|
1769171|NCT00352976|Drug|Cyclophosphamide|Day -5 through Day -2, subjects will receive chemotherapy of Cyclophosphamide via central line (i.e. Hickman or Broviac),10 mg/kg intravenously (IV)
1769172|NCT00352976|Drug|Fludarabine|Day -5 through Day -2 prior to transplant; subjects will receive chemotherapy of Fludarabine via central line (i.e. Hickman or Broviac),35 mg/m^2 intravenous (IV)
1769173|NCT00352976|Procedure|Total Body Irradiation|total body irradiation (300 cGy) with thymic shielding will be given six days before the stem cells are given (day -6). Thymic shielding is done by placing a piece of lead on the chest during the irradiation treatment so that the irradiation beams do not go to the thymus.
1769174|NCT00352976|Procedure|Bone Marrow Transplantation|A target of 5 * 10^6/kg and a minimum of 4 * 10^6 CD34+ cell/kg recipient weight will be collected by apheresis and used for transplant. In most cases this dose will be recovered in a single apheresis; however, a second or rarely third apheresis performed on the following days may be required to achieve the minimum dose.
1769175|NCT00352976|Drug|Mycophenolate Mofetil|Patients will receive MMF therapy beginning on day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute graft-versus-host disease (GVHD). Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 * 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours by mouth(to a maximum dose of 1 gram).
1769176|NCT00352976|Drug|Sirolimus|Sirolimus will be administered starting at day -3 with 8mg-12mg mg oral loading dose followed by single dose 4 mg/day with a target serum concentration of 3 to 12 mg/mL by high-performance liquid chromatography (HPLC). Levels are to be monitored 3 times/week in the first 2 weeks, weekly until day +60, and as clinically indicated until day +100 post-transplantation. In the absence of acute GVHD sirolimus may be tapered starting at day +100 and eliminated by day +180 post-transplantation.
1769177|NCT00352989|Drug|Smecta (Diosmectite), duration of treatment - 7 days|
1769178|NCT00353002|Drug|Ametop (4% Amethocaine cream )|
1769179|NCT00353002|Drug|Maxilene (4% Liposomal Lidocaine)|
1769180|NCT00353015|Drug|Cisplatin|Cisplatin 25 mg/m2 IV days 1, 8 of a 21-day cycle
1769181|NCT00353015|Drug|Irinotecan|Irinotecan 65 mg/m2 IV days 1, 8 of a 21-day cycle
1769182|NCT00353028|Drug|Fluvoxamine maleate|Test product: Fluvoxamine maleate 25mg tablet. In case that the daily dose is one tablet, the study medication will orally be administered once daily, at bedtime. In case that the daily dose is two tablets or higher (maximam:6 tablets), the study mmedica
1769183|NCT00353028|Drug|Placebo|Placebo
1769184|NCT00353041|Drug|lidocaine topical|
1769185|NCT00353054|Drug|Caltrate® 600 + D|
1769186|NCT00353054|Behavioral|Weight loss intervention|
1769187|NCT00353067|Drug|veliflapon (DG-031)|
1769188|NCT00353080|Drug|risedronate (HMR4003)|
1769189|NCT00353093|Procedure|Ultrasonography of the deep vein system of the legs|
1769190|NCT00353106|Behavioral|Interview|30-minute interviews of participating patients and their caregiver(s).
1769191|NCT00353106|Behavioral|Questionnaire|Questionnaires that will take approximately 5 minutes to complete.
1769192|NCT00353119|Drug|Placebo comparator|Patients received placebo subcutaneously twice weekly
1769193|NCT00353119|Drug|Etanercept|Patients received etanercept 50 mg subcutaneously twice weekly
1769194|NCT00353145|Drug|Gemcitabine (Gemox)|1000 mg/m^2, infused at 10 mg/m^2/min on Day 1 repeated every 14 days (one cycle).
1769195|NCT00353145|Drug|Oxaliplatin|100 mg/m^2 by vein infused on Day 2 over two hours, repeated every 14 days (one cycle).
1769196|NCT00353145|Behavioral|Questionnaire|Quality of Life Surveys
1769199|NCT00353184|Drug|Montelukast 5-mg orally added to standard therapy|
1769200|NCT00353223|Behavioral|Interpersonal and behavioral psychotherapy|Participants will receive a combined intervention of interpersonal and behavioral psychotherapy designed for people with heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours. The psychotherapy sessions will allow participants to discuss how they are coping with their illness and loss of functioning. They will also aim to help participants with heart failure to develop new recreational activities in keeping with their new level of functioning.
1769201|NCT00353223|Behavioral|Attention control (AC) condition|The AC group will not receive therapy. Instead, a clinician will ask them questions about their depression and heart failure. Participants will attend 12 sessions, 9 of which will be 30-minute to 1-hour sessions over the phone. The remaining 3 will be in-home visits, lasting 1 to 2 hours.
1769202|NCT00353249|Behavioral|Adapted cognitive behavioral therapy (CBT)|Adapted CBT is a group treatment for PTSD and will occur two times per week for 4 weeks. The sessions will last 90-minutes and will be led by a therapist and co-therapist.
1769203|NCT00353262|Drug|Avastin|7.5mg/kg iv (cycle 3 only)
1769204|NCT00353262|Drug|Oxaliplatin|130mg/m2 iv (cycles 1, 2 and 3)
1769205|NCT00353262|Drug|capecitabine [Xeloda]|1000mg/m2 po bid (cycles 1, 2 and 3)
1769206|NCT00353275|Drug|Strict Glycemic control|Blood glucose target range is 80-110 mg/dL.
1769207|NCT00353275|Drug|Conventional Glycemic Control|Blood glucose target range is 110-140 mg/dL.
1769208|NCT00353288|Biological|MeMuRu-OKA (study vacc)|
1769209|NCT00353288|Biological|MMR, Varicella vacc (control)|
1769210|NCT00353301|Drug|Erlotinib hydrochloride|Patients will receive single-agent Tarceva, 150 mg/day
1769211|NCT00353301|Drug|Sirolimus|Patients will receive a loading dose of 6 mg of Rapamune seven days after beginning treatment with Tarceva™ followed by a dose of 2mg/day.
1769212|NCT00353327|Procedure|Plasma infusion|
1769213|NCT00353340|Drug|n acetylcysteine|
1769216|NCT00353353|Procedure|consumption of fortified bread|
1769217|NCT00353366|Biological|Rotarix|Two doses of the oral vaccine
1769218|NCT00353366|Other|Data collection|Safety evaluation: recording of adverse events by using diary cards and by non-leading questioning.
1769219|NCT00353379|Drug|Guanfacine|Participants will take guanfacine for 6 weeks. Guanfacine dosages will not exceed 2 mg per day.
1769220|NCT00353379|Drug|Placebo|Participants will take placebo for 6 weeks.
1769221|NCT00353392|Device|Laser Therapy|
1769222|NCT00353405|Behavioral|Social Skills Training|Social skills training includes two 8-hour sexual health skills building sessions conducted in the community.
1769223|NCT00353405|Behavioral|Mass media|Mass media provides messages that support sexual health skills.
1769224|NCT00353405|Behavioral|Control|Control group received no social skills training and no media mass media messages.
1769225|NCT00353418|Drug|Peginterferon alfa-2a|180 µg subcutaneously weekly for 48 weeks
1769226|NCT00353418|Drug|Ribavirin|800 mg orally daily for 48 weeks
1769227|NCT00353418|Drug|Ribavirin|1000 mg or 1200 mg (based on patient weight of < 75 kg or ≥ 75 kg, respectively) orally daily for 48 weeks
1769228|NCT00353431|Drug|Novorapid ®, Novo Nordisk, Denmark|Comparison of a sliding scale with an intensive s.c. scale
1769229|NCT00353457|Drug|Capecitabine, Oxaliplatin and Cetuximab|Capecitabine 825mg/m2 po BID D1-15 of 21 x2 cycles (Cyle 1 and 2), Capecitabine 825mg/m2 po BID weekly Sun PM-Fri AM x2 cycles (cycle 3 and 4), Capecitabine 825mg/m2 po BID D1-15 of 21 x4 cycles (cycle 5,6,7,8) Oxaliplatin 130mg/m2 IV Day 1 every 3 weeks x2 cycles (Cycle 1 and 2), Oxaliplatin 50mg/m2 IV weekly every Monday x2 cycles (Cycle 3 and 4), Oxaliplatin 130mg/m2 IV day 1 every 3 weeks x4 cycles (Cycles 5,6,7,8) Cetuximab 400mg/m2 IV cycle 1 day1, Cetuximab 250mg/m2 Day 1,8,15 of 21 for cycles 1-8
1769230|NCT00353457|Radiation|Radiation|45 Gy in 25 fractions, 3-fraction boost 5.4 Gy
1769231|NCT00353470|Behavioral|Cognitive behavioral therapy|CBT for panic disorder will include 19 to 24 sessions over 12 weeks.
1769232|NCT00353470|Behavioral|Applied relaxation training (ART)|ART with exposure protocol will include 19 to 24 sessions over 12 weeks.
1769233|NCT00353470|Behavioral|Panic focused psychodynamic psychotherapy (PFPP)|PFPP will include 19 to 24 sessions over 12 weeks.
1769234|NCT00353483|Procedure|Peripheral blood draw|
1769235|NCT00353483|Procedure|Breast tissue collection|
1769236|NCT00353483|Procedure|Bone marrow biopsy|
1769237|NCT00353496|Drug|lanreotide (Autogel formulation)|120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
1769238|NCT00353496|Drug|Placebo|Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks.
1769239|NCT00353509|Device|Device Closure of a Septal Defect|
1769240|NCT00353522|Drug|Placebo|po daily for 24 weeks
1769241|NCT00353522|Drug|dalcetrapib|900mg po daily for 24 weeks
1769242|NCT00353535|Procedure|Total Lymphoid irradiation|
1769243|NCT00353561|Drug|Boric|Gelatin capsules filled with 600 mg of boric acid
1769244|NCT00353561|Drug|Fluconazole|150 mg oral fluconazole gives once in 14 days
1769245|NCT00353574|Drug|Darusentan|Darusentan capsules administered orally once daily
1769246|NCT00353587|Drug|MBX-102|MBX-102 200 mg once daily for 16 weeks
1769247|NCT00353587|Drug|MBX-102|MBX-102 400 mg once daily for 16 weeks
1769248|NCT00353587|Drug|MBX-102|MBX-102 600 mg once daily for 16 weeks
1769249|NCT00353587|Drug|Placebo|MBX-102 Placebo once daily for 16 weeks
1769250|NCT00353587|Drug|Actos|Actos 30 mg once daily for 16 weeks
1769251|NCT00353613|Behavioral|Package of targeted interventions to reduce error|Interventions will include changes in administration of antibiotics and the improved monitoring of blood glucose and body temperature peri-operatively.
1769252|NCT00353652|Drug|Chlorthalidone|12.5-25 mg taken orally, once daily
1769253|NCT00353652|Drug|Spironolactone|50-75 mg taken orally, once daily
1769254|NCT00353652|Drug|Eplerenone|50-100 mg taken orally, once daily
1769255|NCT00353652|Drug|Quinapril|20 mg taken orally, once daily
1769256|NCT00353652|Drug|Irbesartan|150 mg taken orally, once daily
1769257|NCT00353665|Drug|Memantine (Ebixa)|10 mg bid
1769258|NCT00353665|Drug|riluzole|riluzole 50 mg bid
1769259|NCT00353665|Drug|Placebo|
1769260|NCT00353678|Drug|YM150|
1769261|NCT00353691|Drug|glimepiride|
1769262|NCT00353691|Drug|metformin|
1769263|NCT00353704|Drug|pregabalin|capsule 150 mg x 1 per orally one hour before surgery
1769264|NCT00353704|Drug|Placebo|One capsule of saccharose (placebo) was administered about one hour before surgery
1769265|NCT00353704|Drug|morphine|All patients were equipped with a PCA (patient controlled analgesia) for 24 hours after surgery. The sum of morphine used was registered (milligram).
1769266|NCT00353717|Drug|cetuximab paclitaxel|weekly iv paclitaxel 80 mg/m2 and cetuximab 250 mg /m2
1769267|NCT00353743|Drug|placebo|placebo
1769268|NCT00353743|Drug|doxycycline plus metronidazole|doxycycline 200mg/day plus metronidazole 500mg/day up to 10 days of treatment (additional to the hospital treatment)
1769269|NCT00353756|Drug|C326, IL-6 Inhibitory Avimer protein|
1769270|NCT00353769|Procedure|Hair Apposition Technique|
1769271|NCT00353795|Procedure|MR Imaging of the Coronary Arteries|
1769272|NCT00353808|Drug|[S,S]-Reboxetine|
1769273|NCT00353834|Drug|Exenatide|Exenetide 5ug twice daily for 4 weeks, then 10ug twice daily for 8 weeks
1769274|NCT00353834|Drug|Glargine Insulin|Glargine insulin 10-20 units once daily and subsequently adjusted per protocol to achieve a fasting glucose of 100mg/dl and avoid hypoglycemia.
1769275|NCT00353847|Device|Acupuncture|
1769276|NCT00353860|Device|SOLEX 300i Stem Cell Selection|
1769277|NCT00353873|Drug|Fluticasone propionate|200μg twice daily
1769278|NCT00353873|Drug|Fluticasone propionate/salmeterol|50/100μg twice daily
1769279|NCT00353886|Procedure|TONI-3|
1769280|NCT00353886|Procedure|WRAT-3|
1769281|NCT00353886|Procedure|Connor's Rating Scales PRS & TRS|
1769282|NCT00353886|Procedure|Peabody Picture Vocabulary Test|
1769283|NCT00353886|Procedure|Children's Memory Scale|
1769285|NCT00353886|Procedure|Behavioral Assessment System for Children PRS & TRS|
1769286|NCT00353912|Drug|valsartan + amlodipine|
1769287|NCT00353938|Drug|3,4-methylenedioxymethamphetamine 125 mg|Participants will receive an initial dose of 125 mg MDMA orally and, if investigator and participant deem appropriate, 2-2.5 hours later they receive 62.5 mg MDMA orally.
1769288|NCT00353938|Drug|3,4-methyelendioxymethamphetamine 25 mg|Participants will receive a 25 mg MDMA and if investigator and participant agree, 2 to 2.5 hours later a dose of 12.5 mg MDMA.
1769289|NCT00353938|Behavioral|Psychotherapy|Psychotherapy performed by a team of two co-therapists
1769290|NCT00353964|Drug|rEV131|
1769291|NCT00353964|Drug|Prenisolone sodium phosphate 1.0%|
1769292|NCT00353964|Drug|rEV131 vehicle|
1769293|NCT00347334|Behavioral|infant home positioning|
1769294|NCT00347360|Drug|lisinopril|
1769295|NCT00347360|Drug|carvedilol controlled release formulation|
1769296|NCT00347373|Drug|Tonalin Conjugated linoleic acid (dietary supplement)|
1769297|NCT00347386|Drug|Drug: Zinc (zinc sulphate)|Dissolvable tablet 10 mg. Once daily during the illness
1769298|NCT00347386|Drug|Placebo|Placebo tablet, once daily
1769299|NCT00347399|Drug|bevacizumab intravitreal injection|
1769300|NCT00347399|Procedure|verteporfin photodynamic therapy|
1769303|NCT00347425|Drug|Aripiprazole|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
1769304|NCT00347425|Drug|Olanzapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
1769305|NCT00347425|Drug|Risperidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
1769306|NCT00347425|Drug|Quetiapine|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
1769307|NCT00347425|Drug|Ziprasidone|Abrupt discontinuation of prior anti-psychotic med after a successful eight-day up titration of bifeprunox
1769308|NCT00347425|Drug|Aripiprazole|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
1769309|NCT00347425|Drug|Olanzapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
1769310|NCT00347425|Drug|Risperidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
1769311|NCT00347425|Drug|Quetiapine|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
1769312|NCT00347425|Drug|Ziprasidone|Cross-tapering during which prior anti-psychotic med will be tapered off at the same time while bifeprunox is being titrated up within 8 days
1769313|NCT00347438|Drug|Capecitabine|Capecitabine twice daily for 14 days followed by 7 days without taking drug (1 cycle). This schedule is followed for 8 cycles (about 24 weeks).
1769314|NCT00347477|Drug|HyperHAES vs. RA-solution/NaCl|
1769315|NCT00347490|Drug|Enoxaparine|
1769316|NCT00347503|Drug|ketorolac 0.4%, bromfenac 0.09%|
1769317|NCT00347516|Procedure|IOL calculation formula|
1769318|NCT00347529|Biological|pPML7789 with and without pPJV2012 administered by PMED|
1769319|NCT00347542|Drug|Vitamin D|
1769320|NCT00347555|Biological|Aluminum Phosphate|1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant; dosage 500 micrograms.
1769321|NCT00347555|Drug|Placebo|0.5 mL normal saline placebo. Sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride).
1769322|NCT00347555|Biological|EBA-175 RII-NG Malaria Vaccine|White, translucent, cloudy, nonparticulate liquid suspension. Recombinant Plasmodium falciparum erythrocyte-binding antigen 175 kDa Region II-nonglycosylated (EBA-175 RII-NG) absorbed to aluminum phosphate adjuvant; dosage levels 5, 20, 80, and 160 micrograms.
1769323|NCT00347568|Device|TX-plore|PI has terminated at institution and there is no one available to report.
1769324|NCT00347581|Procedure|Base-in prism glasses for reading|
1769325|NCT00347581|Procedure|Placebo reading glasses|
1769326|NCT00347594|Device|Next Generation Diagnostic Instrument (NGDI)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
1769327|NCT00347594|Device|Zyoptix Diagnostic Workstation (ZDW)|Measurement of the aberrations, corneal surface topography, and pachymetry of normal human eyes
1769328|NCT00347607|Behavioral|community surveillance and re-treatment|
1769329|NCT00347620|Device|spectacles|
1769330|NCT00347620|Procedure|Cataract Surgery|
1769331|NCT00347646|Drug|Plasmin|27 mg of human-derived plasmin to be reconstituted with of 0.9% Sterile Sodium Chloride for a single intravitreal injection
1769332|NCT00347659|Drug|BLVR System|Treatment is administered in a single treatment session.
1769446|NCT00354107|Other|laboratory biomarker analysis|Correlative studies
1769447|NCT00354120|Drug|Alentuzumab|Alentuzumab
1769333|NCT00347672|Biological|H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca)|Live, attenuated recombinant H5N1 (6-2) AA ca Recombinant (A/VietNam/1203/2004 x A/AnnArbor/6/60/ca) vaccine (one of three doses)
1769334|NCT00347685|Drug|tramadol ER|
1769335|NCT00347698|Drug|intravitreal injection of bevacizumab|
1769336|NCT00347698|Procedure|panretinal photocoagulation|
1769337|NCT00347711|Drug|Intravitreal injection|
1769338|NCT00347724|Drug|Tramadol HCl ER|
1769339|NCT00347737|Drug|teriparatide|Teriparatide
1769340|NCT00347750|Drug|Lopinavir pharmacokinetic/pharmacodynamic analysis|
1769341|NCT00347763|Procedure|10% permethrin in water applied as low volume spray|
1769342|NCT00347776|Drug|azithromycin|oral antibiotic
1769343|NCT00347776|Drug|topical tetracycline|
1769344|NCT00347789|Procedure|Glaucoma surgery- Bleb revision|
1769345|NCT00347802|Drug|Bimatoprost 0.03%, Travoprost 0.004%|
1769346|NCT00347815|Drug|Buprenorphine|
1769347|NCT00347828|Drug|Moxifloxacin ophthalmic solution 0.5%|
1769348|NCT00347828|Drug|Gatifloxacin ophthalmic solution 0.3%|
1769349|NCT00347841|Drug|Bimatoprost 0.03%, Latanoprost|
1769350|NCT00347854|Other|Systane Free lubricant eye drops|
1769351|NCT00347854|Other|Visine Tears Lubricant Eye Drops|
1769352|NCT00347854|Other|Refresh Liquigel Lubricant Eye Drops|
1769353|NCT00347854|Other|Refresh Plus Lubricant Eye Drops|
1769354|NCT00347867|Drug|Viagra administration in IUGR/PET pregnancies|
1769355|NCT00347893|Procedure|Selective laser trabeculoplasty|
1769356|NCT00347906|Procedure|laser treatment|
1769357|NCT00347919|Drug|pazopanib (GW786034) 400 mg|400 mg administered orally once daily
1769358|NCT00347919|Drug|lapatinib (GW572016) 1500 mg|1500 mg administered orally once daily.
1769359|NCT00347919|Drug|lapatinib (GW572016) 1000 mg|1000 mg administered orally once daily
1769360|NCT00347919|Drug|pazopanib (GW786034) 800 mg|800 mg administered orally once daily
1769361|NCT00347932|Drug|ISV-403|Subjects with bacterial conjunctivitis were randomized to receive 0.6% ISV-403 eye drops three times a day (TID) for 5 days.
1769362|NCT00347932|Drug|Vehicle|Subjects with bacterial conjunctivitis were randomized to receive vehicle eye drops three times a day (TID) for 5 days.
1769363|NCT00347945|Procedure|Pencil Push-ups|
1769364|NCT00347945|Procedure|Office-based Vision Therapy|
1769365|NCT00347945|Procedure|Placebo Office-based Vision Therapy|
1769366|NCT00347958|Biological|Tetanus-diphtheria-acellular pertussis (Tdap) vaccine|0.5mL, Intramuscular (IM)
1769367|NCT00347971|Drug|recombinant human interleukin 21 and rituximab|rIL-21 (30, 100, 150 ug/kg) IV rituximab (375 mg/m2) IV
1769368|NCT00347984|Other|Systane Lubricant eye drops|
1769369|NCT00347997|Device|217z Laser|LASIK correction of myopia and myopic astigmatism
1769370|NCT00348010|Drug|Tramadol HCl ER|
1769371|NCT00348023|Drug|Bimatoprost 0.03%, Travoprost 0.004%, Timolol 0.5%|
1769372|NCT00348036|Behavioral|Group Intervention for Interpersonal Trauma|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences. Groups will be comprised of three components at each meeting: psycho-education, current relationship issues, and coping skills. Each group session will focus on a different aspect of education. Next, relationship difficulties typically associated with the symptoms discussed in that module will be addressed, and there will be group discussion about participants' relationship difficulties. Each group will end with the therapist teaching a coping skill that fits with the issues discussed earlier.
1769373|NCT00348036|Other|Information only|Participants will receive information about PTSD and depression, in the form of a brochures and a DVD about trauma and its emotional consequences.
1769374|NCT00348049|Procedure|Laser in Situ Keratomileusis (LASIK)|
1769375|NCT00348049|Procedure|Photorefractive Keratectomy (PRK)|
1769376|NCT00348062|Drug|Bimatoprost|
1769377|NCT00348075|Device|Neurovision|
1769378|NCT00348101|Drug|Combined therapy with enoximone and esmolol|
1769379|NCT00348114|Procedure|Transplantation of cultivated limbal epithelium|
1769380|NCT00348127|Device|Neurovision|
1769381|NCT00348140|Drug|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
1769382|NCT00348140|Drug|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
1769383|NCT00348140|Other|Placebo|Placebo
1769384|NCT00348153|Drug|Adalimumab|
1769385|NCT00348166|Drug|cyclopentolate|
1769386|NCT00348179|Procedure|Measurement of vascular function per SphymgnoCor equipment|Pressure tonometer will be used on various vessels, non-invasive.
1769387|NCT00348192|Drug|SB-742457|
1769388|NCT00348192|Drug|donepezil|
1769389|NCT00348205|Device|Technolas 217z Zyoptix Laser|Technolas 217z Zyoptix System with Treatment Planner Customized Treatment Calculation Software for the wavefront-guided LASIK treatment of hyperopia and hyperoptic astigmatism.
1769390|NCT00348218|Device|NeuroVision|
1769391|NCT00348231|Drug|dual-action insulin analog|
1769392|NCT00348244|Drug|Ketorolac, Prednisolone Acetate|
1769393|NCT00348257|Device|Hair removal by laser/IPL device|
1769394|NCT00348270|Device|Tecnis Z9000 intraocular lens|
1769395|NCT00348270|Device|MA60 intraocular lens|
1769396|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab 40 mg eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
1769448|NCT00354120|Drug|Globulina antilinfocitaria|Globulina antilinfocitaria
1769449|NCT00354133|Device|Kinetra and Soletra (neurostimulator, Medtronic)|Arm I: Implantation of stimulation electrodes in the STN and best medical treatment Arm II: Best medical treatment only
1769450|NCT00354146|Drug|tipifarnib (R115777)|
1769497|NCT00354393|Procedure|conventional surgery|
1769397|NCT00348283|Biological|placebo|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8.
1769398|NCT00348283|Biological|adalimumab|At Baseline (Week 0), subjects received an OL dose of 160 mg adalimumab SC followed by an OL dose of 80 mg adalimumab SC at Week 2 (induction dose). At Week 4, subjects were randomized to either adalimumab 40 mg SC eow or placebo SC eow. Adalimumab or placebo SC eow dosing through blinded portion of study, which continued through Week 52. While all subjects began blinded study drug (placebo or adalimumab), subjects could have switched to an OL dose of adalimumab upon disease flare or non-response at or after Week 8. In the Open-Label arm, interventions were either adalimumab 40 mg SC eow or adalimumab 40 mg SC weekly. There was no placebo intervention post Week 52.
1769399|NCT00348296|Drug|High-dose intravenous immunoglobulin (Venoglobulin-IH)|
1956874|NCT02656225|Drug|Ejiao compound|20ml,twice daily, orally after breakfast Duration:4 weeks
1956875|NCT02656225|Drug|Niferex|one tablet,once daily, orally after breakfast Duration:4 weeks
1769404|NCT00348322|Drug|Systane Free Lubricant Eye Drops|
1769405|NCT00348335|Drug|Cyclosporine 0.05%|
1769406|NCT00348335|Drug|Ocular lubricant|
1769407|NCT00348348|Drug|Besifloxacin|Besifloxacin hydrochloride ophthalmic suspension, 0.6% as base, administered TID for 5 days
1769408|NCT00348348|Drug|Moxifloxacin solution|Moxifloxacin hydrochloride ophthalmic solution 0.5% administered TID for 5 days.
1769409|NCT00348361|Drug|Fluticasone Propionate|
1769410|NCT00348374|Drug|Insulin Lispro|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
1769411|NCT00348374|Drug|Exubera|Weight based initiation dose, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to insulin glargine and oral agents.
1769412|NCT00348387|Biological|Poliomyelitis Vaccine inactivated|0.5 mL, Intramuscular
1769413|NCT00348387|Biological|Poliomyelitis Vaccine in Dragee Candy (Human Diploid Cell)|1g dragee, oral
1769414|NCT00348400|Drug|Brimonidine Purite 0.15%, Dorzolamide 2%, Latanoprost|
1769415|NCT00348413|Drug|Intravenous Methylprednisolone + Oral Methotrexate vs Intravenous Methylprednisolone + Placebo|
1769416|NCT00348426|Drug|Botulinum AntiToxin|
1769417|NCT00348426|Procedure|neuro-electrophysiologic study, repetitive nerve stimulation|
1769418|NCT00348426|Procedure|: Protocol early weaning ventilator after recovery of repetitive nerve stimulation and stable negative inspiratory pressure|
1769419|NCT00348439|Drug|Plasmin|27 mg of human-derived plasmin to be reconstituted with 0.9% Sterile Sodium Chloride for a single intravitreal injection.
1769420|NCT00348439|Drug|Vehicle|Plasmin formulation, without active ingredient to be reconstituted in 0.9% Sterile Sodium Chloride and administered in a single intravitreal injection.
1769421|NCT00348452|Drug|tramadol HCl ER; celecoxib|
1769422|NCT00348465|Procedure|Brachytherapy with Iodine-125 seeds|Brachytherapy of the prostate, and measurements of the prostate volume using CT scan and TURS
1769423|NCT00353977|Biological|ALVAC-CMV (vCP260)|"ALVAC-pp65 (vCP260), an attenuated canary pox-based vaccine (Aventis Sanofi Pasteur, Lyon, France), 3 doses (1.0 ml each) delivered intramuscularly in the deltoid muscle.
Sero-negative subjects will receive a total of 3 immunizations to be given day 0, 5 and 10.
Sero-positive subjects will receive a total of 2 immunizations to be given day 0 and 5. (Protocol amendment after findings from the 9/6/2006 interim analysis demonstrated that in the sero-positive group, only 2 vaccinations were required to generate maximum immune response.)"
1769424|NCT00353990|Drug|Insulin Aspart|
1769425|NCT00354003|Behavioral|A series of questionnaires|Research participants who previously underwent ß-CIT imaging will be contacted by the staff at IND to enquire whether they would like to receive their ß-CIT scan data. After signing a Research Participant Information and Consent Form, all research participants will be asked to complete a questionnaire prior to receipt of their imaging data. Those research participants requesting imaging data will be sent their data by IND and may review their data with IND (by phone) and/ or with their study investigator. All research participants will be asked to respond to a second questionnaire after receiving their imaging data and to a third study questionnaire approximately six weeks following receipt of their imaging data.
1769426|NCT00354016|Biological|preservative free inactivated split influenza vaccine using the strain composition 2006/2007|
1769427|NCT00354029|Drug|S (+) Ketamine|0,35 mg/kg bolus after induction of anaesthesia; 5 ug/kg/min. continuous until the end of surgery
1769428|NCT00354029|Drug|Placebo|isotonic saline
1769429|NCT00354042|Drug|GW597901X|
1769430|NCT00354068|Drug|imatinib mesylate|
1769431|NCT00354068|Drug|temozolomide|
1769432|NCT00354068|Other|pharmacological study|
1769433|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin), vitamin B6 (pyridoxine)|folic acid 0.8 mg plus vitamin B12 0.4 mg and vitamin B6 40 mg, in a capsule, taken orally once a day
1769434|NCT00354081|Drug|folic acid, vitamin B12 (cyanocobalamin)|folic acid 0.8 mg plus vitamin B12 0.4 mg, in a capsule, taken orally once a day
1769435|NCT00354081|Drug|vitamin B6 (pyridoxine)|vitamin B6 40 mg, in a capsule, taken orally once a day
1769436|NCT00354081|Drug|placebo|placebo, in a capsule, taken orally once a day
1769437|NCT00354094|Drug|[S,S]-Reboxetine|
1769438|NCT00354107|Biological|monoclonal antibody SGN-30|Given IV
1769439|NCT00354107|Drug|therapeutic hydrocortisone|Given IT
1769440|NCT00354107|Drug|ifosfamide|Given IV
1769441|NCT00354107|Drug|carboplatin|Given IV
1769442|NCT00354107|Drug|etoposide|Given IV
1769443|NCT00354107|Drug|methotrexate|Given IT
1769444|NCT00354107|Drug|cytarabine|Given IT
1769445|NCT00354107|Other|pharmacological study|Correlative studies
1769451|NCT00354159|Device|Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)|Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.
1956885|NCT02651194|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
1956886|NCT02650141|Drug|ziyinxiehuo Granules|"Ziyinxiehuo granules Herbs (1 bag ): shengdi 5g, xuanshen 3g, zexie 3g, zhimu3g, huangpai 3g, zhiguiban 2g, maiya 6g,tiandong 3g, zhigancao 2g Therapeutic Principle: Nourishing Yin, removing Fire Usage: administered after dissolved, 3 times per day after breakfast and supper"
1956887|NCT02650141|Drug|zishenqinggan Granules|"Zishenqinggan granules Herbs (1 bag ): Shengdi 5g, baishao 3g, huangqin 3g, fuling 4g, danpi 3g, maiya 6g, shanzha 3g, zhebei 3g, zhigancao 2g Therapeutic Principle: replenishing Kidney, Clearing Liver Usage: administered after dissolved, 3 times per day after breakfast and supper"
1769462|NCT00354185|Drug|tanespimycin|Given IV
1769463|NCT00354185|Drug|belinostat|Given IV
1769464|NCT00354185|Other|laboratory biomarker analysis|Correlative studies
1769465|NCT00354185|Other|pharmacological study|Correlative studies
1769466|NCT00354198|Drug|pentoxifylline|intravenous pentoxifylline (0.33-0.66 mg/kg/h from days 1 to 7) followed by oral pentoxifylline 400-800 mg/day (from days 8-90). The dose of intravenous pentoxifylline will be determined by estimated GFR, patients whose GFRs are 30-59 ml/min/1.73 m2 will be given 0.66 mg/kg/h, and those below 30 ml/min/1.73 m2 will be given 0.33 mg/kg/h. The oral dose of pentoxifylline will also be determined by estimated GFR. Patients whose estimated GFRs are between 30-59 ml/min/1.73 m2 will be given 800 mg/day, and those below 30 ml/min/1.73 m2 will be given 400 mg/day.
1769467|NCT00354198|Drug|corticosteroids|intravenous methylprednisolone (15 mg/kg/day or a maximum of 1 g/day) x 3 days + oral prednisolone (0.5-1.0 mg/kg/day) for 27 days] x 3 courses
1769468|NCT00354211|Device|minimally invasive cardiac output system consisting of arterial line sensor and cardiac output bedside monitor (device)|
1769469|NCT00354224|Drug|capecitabine|
1769470|NCT00354224|Drug|oxaliplatin|
1769471|NCT00354237|Other|Conventional antidiabetic treatment|No intensive treatment
1769472|NCT00354237|Other|Intensive insulin treatment|Intensive insulin treatment
1769473|NCT00354250|Drug|ispinesib|Given IV
1769474|NCT00354263|Biological|IMP321|This study is a single centre, single blind, placebo (step 1) or reference (step 2) randomised study. Healthy young male volunteers will receive single ascending dose of IMP321 in each step (4 doses tested: 3, 10, 30 and 100 µg). In step 1, IMP321 will be given alone and tested versus placebo (physiological saline). In step 2, the association IMP321 + Agrippal (commercially available flu vaccine) will be tested versus Agrippal alone.
1769475|NCT00354263|Biological|saline|saline injected alone in step 1 or mixed with Aggripal in step 2
1769476|NCT00354276|Drug|cytarabine|
1769477|NCT00354276|Drug|laromustine|
1769478|NCT00354302|Dietary Supplement|calcium carbonate|
1769479|NCT00354302|Dietary Supplement|calcium citrate|
1769480|NCT00354302|Dietary Supplement|cholecalciferol|
1769481|NCT00354302|Drug|alendronate sodium|
1769482|NCT00354302|Drug|calcium gluconate|
1769483|NCT00354302|Drug|risedronate sodium|
1769484|NCT00354302|Other|laboratory biomarker analysis|
1769485|NCT00354302|Procedure|dual x-ray absorptometry|
1769486|NCT00354315|Behavioral|Continuous medical education (CME)|The intervention will be held over a 6 months period. DECISION+ is a multifaceted intervention program that includes: Interactive workshops (3x180 min), reminders of expected behaviours and feedback.
1769487|NCT00354341|Drug|Epoetin beta|
1769488|NCT00354354|Drug|Combivent|Nebulized Combivent (4 mL) or saline solution (0.9% NaCl) (4 mL) will be administered once only to subjects.
1769489|NCT00354367|Drug|Certolizumab pegol|
1769490|NCT00354380|Drug|Methylene blue|
1769491|NCT00354380|Drug|Artesunate|
1769492|NCT00354380|Drug|Amodiaquine|
1769493|NCT00354393|Drug|cisplatin|
1769494|NCT00354393|Drug|methotrexate|
1769495|NCT00354393|Drug|vinorelbine ditartrate|
1769496|NCT00354393|Procedure|adjuvant therapy|
1956888|NCT02649166|Device|Deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, thalamic leads to be implanted in the ventral intermediate nucleus (Vim), and subdural cortical strips. The deep brain stimulation system will be set to provide continuous stimulation for the 6 months following surgery. Subjects will be seen monthly for evaluation as a part of normal clinical care for deep brain stimulation. At 6 months, the investigators will determine whether or not the subject is a candidate for closed-loop deep brain stimulation. Qualifying subjects will have the option to have their settings changed in order to participate in the RBS stimulation intervention. These subjects will been seen every 6 months for evaluation as part of normal clinical care for deep brain stimulation.
1956889|NCT02649166|Device|Closed-loop deep brain stimulation|The deep brain stimulation system includes an implantable neurostimulator, Vim thalamic leads, and subdural strips. Six months post-surgery, the deep brain stimulation system will be set to provide responsive stimulation for the duration of the study. Subjects will be seen every 6 months for evaluation as a part of normal clinical care for deep brain stimulation. Data gathered from the subject during the first 6 months will be used to determine if this intervention is applicable for each individual subject. Subjects who do not qualify will continue to receive the other study intervention.
1769498|NCT00354393|Procedure|neoadjuvant therapy|
1769499|NCT00354393|Radiation|3-dimensional conformal radiation therapy|
1769500|NCT00354393|Radiation|intensity-modulated radiation therapy|
1769501|NCT00354406|Drug|abciximab|standard i.v. bolus of abciximab is administered at time of randomization in arm A, and at time of primary angioplasty in arm B.
1769502|NCT00354419|Radiation|total-body irradiation|Undergo radiotherapy
1769503|NCT00354419|Drug|cyclophosphamide|Given IV
1769504|NCT00354419|Biological|anti-thymocyte globulin|Given IV
1769505|NCT00354419|Drug|cyclosporine|Given IV
1769506|NCT00354419|Procedure|umbilical cord blood transplantation|Undergo transplantation
1769507|NCT00354419|Drug|mycophenolate mofetil|Given IV or orally
1769508|NCT00354419|Procedure|bone marrow aspiration|Correlative study
1769509|NCT00354419|Genetic|DNA analysis|Correlative study
1769510|NCT00354419|Biological|filgrastim|Given IV or SC
1769511|NCT00354432|Dietary Supplement|oral soy protein/isoflavones powder|Soy protein powder (20gm) orally 160 mg of total isoflavones isocaloric supplement of casein protein
1769512|NCT00354432|Drug|Venlafaxine|Patients receive oral venlafaxine 75mg.
1769513|NCT00354432|Dietary Supplement|Placebo Powder|Placebo powder (20gm casein protein) orally 0 mg of total isoflavones
1769514|NCT00354432|Drug|Placebo Pill|Patients receive oral placebo pill.
1769515|NCT00354445|Drug|pegaptanib sodium (Macugen)|
1769516|NCT00354458|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
1769517|NCT00354458|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
1769518|NCT00354471|Procedure|Uterine Artery Embolization|
1769519|NCT00354484|Drug|Ferric Carboxymaltose (FCM)|Up to a maximum cumulative dose of 2,500 mg administered IV based on iron-deficit calculations; the calculated dose was given in divided doses of up to 1,000 mg weekly.
1769520|NCT00354484|Drug|Ferrous Sulfate tablets|325 mg of ferrous sulfate 3 times daily (TID) x 6 weeks.
1769521|NCT00354497|Other|physiologic testing|
1769522|NCT00354497|Other|study of socioeconomic and demographic variables|
1769523|NCT00354497|Procedure|evaluation of cancer risk factors|
1769524|NCT00354497|Procedure|mutation carrier screening|
1769525|NCT00354497|Procedure|study of high risk factors|
1769526|NCT00354510|Drug|GW842470X cream|
1769527|NCT00354523|Drug|Capecitabine (Xeloda)|Starting Dose 500 mg/m^2 twice a day Days 1-14 of 21 Day Cycle.
1769528|NCT00354523|Drug|DTIC-Dome (Dacarbazine)|Starting Dose 250 mg/m^2 a day on Days 1-3 of 21 Day Cycle.
1769529|NCT00354523|Drug|Gleevec (Imatinib Mesylate)|Starting Dose 400 mg a day on Days 1-21 of 21 Day Cycle.
1769530|NCT00354536|Drug|GSK716155 subcutaneous injections|albiglutide subcutaneous injection
1769531|NCT00354536|Biological|placebo injection|placebo injection
1769532|NCT00354549|Drug|bevacizumab + erlotinib hydrochloride|Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
1769533|NCT00354549|Drug|gemcitabine hydrochloride + cisplatin or carboplatin|Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
1769534|NCT00354562|Drug|ABT-751|200mg ABT-751 daily for 14 days every 21 days
1769535|NCT00354562|Drug|Placebo|Placebo daily for 14 days every 21 days
1769536|NCT00354562|Drug|Docetaxel|Standard Docetaxel every 21 days
1769537|NCT00354575|Drug|Chinese Herb: CCH1|1.5/3.0/4.5gm powder per day for mild/moderate/severe constipation
1769538|NCT00354601|Drug|capecitabine|oral capecitabine twice daily on days 1-21
1769539|NCT00354601|Drug|docetaxel|docetaxel IV over 30 minutes on days 1, 8, and 15
1769540|NCT00354614|Device|ApneaLink Sleep Screener|Device used to evaluate for the presence of OSA
1769541|NCT00354627|Drug|TMC125|200 mg b.i.d. till commercially available.
1769542|NCT00354640|Drug|anastrozole|1 milligram tablet PO QD for 14 days
1769543|NCT00354640|Drug|simvastatin|40 milligram tablet PO QD for 14 days
1769544|NCT00354640|Other|pharmacological study|laboratory analysis
1769545|NCT00354640|Procedure|adjuvant therapy|laboratory analysis
1769546|NCT00354653|Drug|LAMIVUDINE|
1769547|NCT00354666|Drug|GSK159797|
1769548|NCT00354679|Biological|bevacizumab|
1769549|NCT00354679|Drug|cisplatin|
1769550|NCT00354679|Drug|irinotecan hydrochloride|
1769551|NCT00354679|Genetic|proteomic profiling|
1769552|NCT00354679|Other|diagnostic laboratory biomarker analysis|
1769553|NCT00354679|Other|mass spectrometry|
1769554|NCT00354679|Procedure|adjuvant therapy|
1769555|NCT00354679|Procedure|neoadjuvant therapy|
1769556|NCT00354679|Procedure|therapeutic conventional surgery|
1769557|NCT00354679|Radiation|radiation therapy|
1769558|NCT00354692|Drug|Sodium Ferric Gluconate and Iron sucrose|
1769559|NCT00354705|Behavioral|Questionnaire|Two questionnaires taking 30 minutes to complete.
1769560|NCT00354731|Drug|pentoxifylline|Oral pentoxifylline 1,200 mg/day (for estimated GFR ≧60 ml/min) or 800 mg/day (estimated GFR 59-30 ml/min) x 6 months, followed by stepwise reduction (800 mg/day x 6 M, 400 mg/day x 6 M and discontinued at 18 M
1769561|NCT00354731|Drug|Corticosteroid|Oral prednisolone (1 mg/kg/day) x 3 M, followed by gradual tapering (0.5 mg/kg/day at 6 M, 0.25 mg/day at 12 M, and discontinued at 18 M
1769562|NCT00354744|Biological|dactinomycin|"Age based dosage: ≥ 1 year 0.045 mg/kg IV x 1(maximum dose 2.5 mg), < 1 year 0.025 mg/kg.
Day 1 of Weeks 35, 38, 41 and 44.
Given IV"
1769563|NCT00354744|Drug|cyclophosphamide|"Age based dosage: ≥ 3 years 1200 mg/m2, <3 years 40 mg/kg.
Day 1 of weeks 7, 11, 15, 28, 32, 35, 38, 41 and 44.
Given IV"
1769564|NCT00354744|Drug|doxorubicin hydrochloride|"Age based dosage: ≥ 1 year: 37.5mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis. Total dose 75 mg/m².
Days 1 and 2 of weeks 7, 11, 15, 28 and 32.
Given IV"
1769565|NCT00354744|Drug|etoposide|"Age based dosage: ≥ 1 year: 100 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.
Days 1-5 of weeks 9, 13, 17, 26 and 30.
Given IV"
1769566|NCT00354744|Drug|ifosfamide|"Age based dosage: ≥ 1 year: 1800 mg/m²/day, < 1 year: treat with 50% doses calculated on a m2 basis.
Days 1-5 of weeks 9, 13, 17, 26 and 30.
Given IV"
1769567|NCT00354744|Drug|irinotecan hydrochloride|"Dosage 50 mg/m2-max dose 100 mg/day.
Days 1-5 of weeks 1, 4, 20, 23, 47 and 50.
Given IV"
1769568|NCT00354744|Drug|vincristine sulfate|"Age based dosage: ≥ 3 years 1.5 mg/m2 (max dose 2 mg), ≥ 1 year and < 3 years 0.05 mg/kg (max dose 2 mg), < 1 year 0.025 mg/kg.
Days 1-5 of weeks 1, 2, 3, 4, 5, 7, 8, 11, 12, 15, 16, 20, 21, 22, 23, 24, 28, 29, 32, 33, 35, 38, 41, 42, 43, 44, 47, 48, 50, and 51.
Given IV"
1769569|NCT00354744|Procedure|conventional surgery|"Resection of the primary tumor with a surrounding envelope of normal tissue"
1769570|NCT00354744|Radiation|radiation therapy|Radiotherapy beginning at Week 20 to the primary tumor and to the metastatic sites excepting those with parameningeal tumors with intracranial extension (direct extension into the brain) and those requiring emergency radiotherapy
1769571|NCT00354744|Biological|filgrastim|"5 micrograms/kg/day (max 300 micrograms) beginning 24-36 hours after the last dose of chemotherapy. Continue at least 7 days, or until the ANC ≥750/μL whichever comes last.
Given subcutaneously."
1769572|NCT00354757|Drug|rabeprazole|
1769573|NCT00354770|Drug|Placebo|daily
1769574|NCT00354770|Drug|N-Acetyl Cysteine|600mg capsules in varying doses for 12 weeks.
1769576|NCT00354822|Drug|Zevalin|Yttrium-90 (90Y) ibritumomab tiuxetan 0.4 mCi/kg is delivered to patient achieving at least a partial remission (PR) after chemotherapy as a single dose for patients with baseline platelet counts>150x10^9/L or 0.3 mCi/kg for patients with baseline platelet counts of 100 to 149x10^9/L. Rituximab 250mg/sqm is given prior to therapeutic radiolabeled antibodies.
1769577|NCT00354835|Drug|Irinotecan Hydrochloride|Given IV
1769578|NCT00354835|Biological|Dactinomycin|Given IV
1769579|NCT00354835|Drug|Cyclophosphamide|Given IV
1769580|NCT00354835|Drug|Vincristine Sulfate|Given IV
1769581|NCT00354835|Radiation|Radiation Therapy|Undergo radiotherapy
1769582|NCT00354835|Other|Laboratory Biomarker Analysis|Correlative studies
1769583|NCT00354835|Other|Questionnaire Administration|Ancillary studies
1769584|NCT00354861|Biological|hepatitis B antigen (without alum) plus IMP321|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with IMP321
1769585|NCT00354861|Biological|hepatitis B antigen alone (without alum)|hepatitis B antigen (10 µg HbsAg, subtype adw, without alum) with physiological saline
1769586|NCT00354861|Biological|Engerix B|20 µg hepatitis B antigen absorbed on alum
1769587|NCT00354874|Drug|GW642444|drug
1769588|NCT00354874|Drug|Placebo|placebo
1769589|NCT00354874|Drug|salmeterol 50mcg|salmeterol
1769590|NCT00354887|Drug|Capecitabine|Oral capecitabine 750 mg/m^2 twice daily (total daily dose 1500 mg/m^2) on Days 1-14 in 21 Day Cycle.
1769591|NCT00354887|Drug|Oxaliplatin|130 mg/m^2 by vein Day 1 over 2 hours in 21 Day Cycle
1769592|NCT00354900|Drug|Aprotinin|
1769593|NCT00354913|Drug|hydroxyurea|Hydroxyurea is administered orally twice a day. The dose will be set at 500 mg twice a day for all patients. If vomiting occurs not additional trial medication should be taken that day in an effort to replace the material that has been vomited. It is recommended that patients take their prescribed hydroxyurea at the same time that they take their prescribed imatinib mesylate, however, a 30-60 minute interval between agents is acceptable, if required for practical or other compliance issues.
1769594|NCT00354913|Drug|imatinib mesylate|"Imatinib administered orally on daily, continuous basis. Imatinib doses of 400mg/600mg administered once daily, whereas daily doses of 800mg/greater administered as equally divided dose taken twice day.
Dose for Imatinib:
Patients receiving p450-inducing antiepileptic drugs:500mg twice day Patients not receiving p450-inducing antiepileptic drugs:400mg/day.
If patients who were not on Cytochrome P450, family 3, subfamily A (CYP3A) enzyme-reducing anti-epileptic drug (EIAED) when originally enrolled must initiate CYP3A enzyme-inducing anti-epileptic drug while on study, study regimen will remain same for minimum of 2 wks before pt transitions to dosing as specified for patients on anti-epileptic drug. If patients originally enrolled must discontinue all EIAEDs while on study, in interest of patient safety, dosing of study regimen will transition to that of patients not on anti-epileptics immediately."
1769595|NCT00354926|Biological|AME-133v (LY2469298)|IV 4X weekly X 4
1769596|NCT00354939|Drug|Insulin glargine|
1769597|NCT00354952|Drug|Macrolides (azithromycin or clarithromycin)|
1769598|NCT00354965|Drug|amoxicillin/clavulanate potassium|amoxicillin/clavulanate potassium
1769599|NCT00354978|Drug|5-Fluorouracil|"400 mg/m^2 injection by vein Day 1 of 14 day cycle immediately after completion of leucovorin infusion.
2.4 g/m^2 by vein over 46 hours over Days 1-3 of 14 day cycle immediately after completion of 400 mg/m^2 injection."
1769600|NCT00354978|Drug|Bevacizumab|"5 mg/kg over 90 minutes on Day 1 of first 14 day cycle as initial dose, administered alone without other drugs.
5 mg/kg by vein on Day 1 of 14 day cycle."
1769601|NCT00354978|Drug|Leucovorin|400 mg/m^2 over 2-4 minutes by vein on Day 1 of 14 day cycle.
1769602|NCT00354978|Drug|Irinotecan|180 mg/m^2 by vein over 90 minutes on Day 1 of 14 day cycle.
1769603|NCT00354991|Drug|losartan potassium (+) hydrochlorothiazide|Patients took losartan 50 mg /HCTZ 12.5 mg orally once daily for 13 weeks. At Weeks 0, 4 and 8 if the blood pressure goal was not reached then the losartan/HCTZ combination will be titrated upwards according to the following scheme: losartan 50/HCTZ 12.5 to losartan 100/HCTZ 12.5 to losartan 100/HCTZ 25.
1769604|NCT00355004|Other|counseling intervention|
1769605|NCT00355004|Procedure|fecal occult blood test|
1769606|NCT00355004|Procedure|screening colonoscopy|
1769607|NCT00355017|Procedure|BNP-guided care in addition to multidisciplinary management|
1769608|NCT00355030|Drug|somatropin|0.05 mg/kg/day
1769609|NCT00355030|Drug|leuprorelin|11.25 mg/3 months
1769610|NCT00355043|Drug|Zinc sulphate 20 mg|
1770346|NCT00364247|Drug|CG5503 IR;tapentadol|
1769613|NCT00355069|Behavioral|electronic (computer based) provider feedback tool|All sites received a Basic Pediatric Chronic Care Model; 2x2 factorial design allocated the additional Medication Assessment Prompt and family education across the four sites as well.
1769614|NCT00355082|Drug|lamotrigine, 300 mg/day|300 mg/day
1769615|NCT00355082|Drug|lamotrigine, 250 mg/day|250 mg/day
1769616|NCT00355095|Drug|Erythropoietin|intravenous daily 3.3 *10^4 Units, duration 3 days
1769617|NCT00355108|Drug|tranexamic acid|2 3-month-periods in cross-over: placebo or 3g/day of tranexamic acid
1956896|NCT02640664|Drug|Ranibizumab|0.2 mg Intravitreal administration Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections
1769621|NCT00355134|Drug|Fingolimod|Fingolimod capsules for oral administration
1769622|NCT00355134|Drug|Placebo|Matching placebo capsules for oral administration.
1769623|NCT00355147|Behavioral|Physician stroke guideline adherence|Provided clinicians with Secondary Stroke Prevention Guidelines/Posted near workstations for Discharge Planning and Provided Clinicians with Seminar on Motivational Interviewing and Goal Setting to Modify Patient Health Behaviors
1769624|NCT00355147|Behavioral|Stroke Self Management|Provided Post Stroke Guidelines on Secondary Prevention to Clinicians Preparing Discharge Plans; Provided Secondary Stroke Self-Management and Stroke Peer Support to Veteran Patients with Stroke/TIA
1769625|NCT00355173|Device|Lubo cervical collar|
1769626|NCT00355186|Procedure|intracoronary bone marrow cells infusion|"intracoronary bone marrow cell infusion via a OTW balloon; Stop-flow-technique as previously described"
1769627|NCT00355199|Drug|Rituximab-HDS|Rituximab-HDS
1769628|NCT00355199|Drug|Rituximab-CHOP|Rituximab-CHOP
1769629|NCT00355212|Procedure|percutaneous ablation of hepatocellular carcinoma|
1769630|NCT00355225|Procedure|ITN distribution channel|
1769631|NCT00355238|Drug|brivanib (active)|Tablet, Oral, Brivanib 800 mg, once daily, until progression
1769632|NCT00355251|Drug|Atorvastatin 40 mg/Atorvastatin 80 mg|Atorvastatin 40 mg/80 mg
1769633|NCT00355264|Drug|Phenoptin|5mg/kg/day orally, dose may be adjusted to between 5-20 mg/kg/day by investigator at week 6 to control blood Phe levels
1769634|NCT00355277|Drug|Amitriptyline|
1769635|NCT00355290|Behavioral|Changes on Oral Vitamin K Intake|
1769636|NCT00355303|Drug|Misoprostol|Vaginal application of Misoprostol tablets at 4 hrly interval with maximumof five doses
1769637|NCT00355303|Drug|PGE2 gel|PGE2 gel will be applied in poaterior fornix at six hrly interval with maximum of 2 doses
1769638|NCT00355316|Other|Blood draw|
1769639|NCT00355329|Procedure|Tongue Acupuncture (Procedure)|
1956897|NCT02640664|Drug|Ranibizumab|0.1 mg Intravitreal administration Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections
1956898|NCT02639637|Drug|Sitagliptin|Subjects will receive sitagliptin 100 mg daily for 7 days prior to one of the study days.
1769642|NCT00355355|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) slowly administered (3-5 min.) in a free flowing intravenous drip at a dose of 1 mg/kg.
1769643|NCT00355355|Device|Interstitial Light Emitting Diodes|200 J/cm per Light Source at 20 mW/cm light energy
1769644|NCT00355355|Procedure|Percutaneous placement of device in the liver|Litx™ treatment group undergo CT or Ultrasound guided percutaneous placement of a single, two, three, or four Light Sources depending on their tumor characteristics. No more than 4 Light Sources will be used at a single treatment. The Light Source(s) may be used in a single lesion or in multiple lesions.
1769645|NCT00355355|Procedure|Standard Care|The standard of care could include any one of the following treatment options: Percutaneous Ethanol Injection (PEI), Transcatheter Arterial Chemoembolization (TACE), Radio Frequency Ablation (RFA), Cryotherapy, Systemic Chemotherapy, or other modalities that may be used at a particular institution.
1769646|NCT00355368|Drug|Succinylcholine|1mg/kg iv
1769647|NCT00355368|Drug|Rocuronium|0.6mg/kg iv
1769648|NCT00355381|Behavioral|Information Services (IRx)|Information services tailored to the needs of individual patients. The information prescription (IRx)or service is defined for this study as a combination of: 1)An evidence-based web site for use by patients and their families; 2) A reference interview and assistance in locating relevant general information in response to patient information needs; 3) Documentation of the questions and the information service provided in response to these in the patient's Electronic Patient Record for review by providers as needed; and, 4) Triage of patient's/parents clinical questions to providers.
1769649|NCT00355394|Drug|Metoclopramide|Intravenous bolus administration.
1769650|NCT00355394|Other|Placebo|Standard care including intravenous fluid, but no metoclopramide.
1769651|NCT00355407|Drug|Darbepoetin alfa|
1769652|NCT00355433|Procedure|Urodymanics|
1769653|NCT00355446|Drug|Bimatoprost 0.03%|
1769654|NCT00355459|Drug|Tetracycline: Doxycycline analog|
1769655|NCT00355472|Drug|KW-0761|IV administration at 4 escalating dose levels.
1769656|NCT00355485|Device|microdermabrasion|"Device: Bellamed microdermabrasion system produced by Bella products or the Altair Diamondtome System.
Subjects will receive a series of microdermabrasion treatment sessions (up to 6) spaced one to two weeks apart."
1769657|NCT00355511|Behavioral|education: disease, medication, self-care, diet|education on heart failure self care; medication initiation and titration, frequent follow-up
1769658|NCT00355524|Drug|TMC114|TMC114 will be administered as oral tablets (75 milligram [mg] or 300 mg) twice daily at a dose ranging from 300-600 mg up to 48 weeks.
1769659|NCT00355524|Drug|Ritonavir|Ritonavir will be administered as oral capsules (100 mg) or liquid (80 mg/mL) twice daily at a dose ranging from 50 mg (0.625 mL)-100 mg up to 48 weeks.
1769660|NCT00355537|Drug|Testosterone|Sustanon- intramuscular testosterone 200mg every 2 weeks
1769661|NCT00355537|Drug|0.9% saline|Saline injection intramuscular every 2 weeks
1769662|NCT00355550|Drug|Ketasyn|
1769663|NCT00355563|Device|PAS-Port Automated Proximal Anastomosis System|
1769664|NCT00355576|Drug|Celecoxib|Celecoxib 400 mg BID with creatine 10 g BID if randomized to the Celecoxib + Creatine study arm.
1769665|NCT00355576|Drug|Creatine|10 g BID for either study arm
1770347|NCT00364260|Drug|epoetin alfa|
1769666|NCT00355576|Drug|Minocycline|Minocycline 100 mg BID with creatine 10 g BID if randomized to the Minocycline + Creatine study arm
1769667|NCT00355589|Drug|Ramipril and hydrochlorothiazide|
1769668|NCT00355602|Drug|Cefuroxime|
1769669|NCT00355602|Drug|Ciprofloxacin|
1769670|NCT00355602|Drug|Clarithromycin|
1769671|NCT00355602|Drug|Cotrimoxazole|
1769672|NCT00355602|Drug|Coamoxiclav|
1769673|NCT00355602|Drug|metronidazole|
1769674|NCT00355602|Drug|neomycin|
1769675|NCT00355602|Drug|rifaximin|
1769676|NCT00355602|Drug|Vancomycin|
1769677|NCT00355602|Drug|Doxycycline|
1769678|NCT00355615|Drug|Rosuvastatin|oral
1769679|NCT00355615|Drug|Placebo|oral
1769680|NCT00355628|Drug|KW-2246 (fentanyl citrate)|KW-2246
1956899|NCT02639637|Drug|Placebo|Subjects will receive a placebo capsule daily for 7 days prior to one of the study days.
1769682|NCT00355654|Biological|DT5aP-IPV-Hib 5-component Pertussis vaccine|0.5 mL, IM
1769683|NCT00355654|Biological|DT3aP-HBs-IPV|0.5 mL, IM
1769684|NCT00355667|Drug|furosemide|Patients with chronic heart failure receive furosemide and other standard treatment/
1769685|NCT00355667|Drug|azosemide|Patients with chronic heart failure receive azosemide and other standard treatment.
1769686|NCT00355680|Device|Green Laser (Aurolas, Aurolab)|Green laser developed by Aurolab
1769687|NCT00355680|Device|Green Laser (Iridex)|Already available green laser
1769688|NCT00355693|Device|Pump for propofol delivery|
1769689|NCT00355706|Procedure|Thoracic facet joint nerve blocks|Thoracic medial branch blocks
1769690|NCT00355719|Drug|Atazanavir (Reyataz)|Atazanavir (Reyataz): capsules 150 mg (2 capsules/24h)
1769691|NCT00355719|Drug|Ritonavir (Norvir)|Ritonavir (Norvir): capsules 100 mg (1 capsule/24h)
1769692|NCT00355719|Drug|Nevirapine (Viramune)|Nevirapine (Viramune): tablets 200 mg (1 tablet/12h*)
1769693|NCT00355732|Procedure|Weaning from mechanical ventilation|
1769694|NCT00355745|Device|Ultrasound breast scanning|breast scanning
1769695|NCT00355771|Drug|Levocetirizine|Intake of 1 tablet of Levocetirizine 5mg OD for 8 weeks
1769696|NCT00355771|Drug|Placebo|1 tablet OD in the morning for 8 weeks
1769697|NCT00355784|Other|overfeeding|overfeeding 2000kcals/day above energy requirements for 14d
1769698|NCT00355784|Drug|growth hormone treatment|growth hormone administrated for 2 weeks (dose = 1.0 mg/m2/d)
1769699|NCT00355797|Device|Closed Loop Stimulation (CLS)|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the Closed Loop Stimulation (DDD-CLS or VVI-CLS) pacing mode for the long-term follow-up portion of this study.
1769700|NCT00355797|Device|Standard Rate Adaptive (R) Technology|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the standard are adaptive pacing mode (DDDR or VVIR) for the long-term follow-up portion of this study.
1769701|NCT00355797|Device|Non-rate adaptive (DDD) pacing|Comparison of different pacing modes available on the Cylos pacemaker device. In this intervention group, subjects were programmed to the non-rate adaptive pacing mode (DDD or VVI) for the long-term follow-up portion of this study.
1769702|NCT00355810|Dietary Supplement|placebo followed by Lactobacillus plantarum MF 1298|placebo during 3 weeks, washout period 4 weeks, Lactobacillus plantarum MF1298 during 3 weeks
1769703|NCT00355810|Dietary Supplement|Lactobacillus plantarum MF1298 followed by placebo|Lactobacillus plantarum MF1298 during 3 weeks, washout period 4 weeks, placebo during 3 weeks
1769704|NCT00355836|Behavioral|Mental Imagery|
1769705|NCT00355849|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 52 weeks
1769706|NCT00355849|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 52 weeks
1769707|NCT00355862|Drug|CNI, MMF, Steroids, Aza etc. (mTOR inhibitor free)|center specific therapeutic regimen without mTOR inhibition
1769708|NCT00355862|Drug|Sirolimus|Sirolimus based immunosuppression
1769709|NCT00355875|Procedure|titration of oxygen during resuscitation|
1769710|NCT00355888|Drug|MBP-426|Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
1769711|NCT00355901|Drug|Visilizumab (Nuvion®; HuM291)|
1769712|NCT00355914|Procedure|Lumbar Facet Joint Nerve Block|Lumbar Facet Joint Nerve Block
1769713|NCT00355927|Procedure|Sedation with IV propofol|Propofol(50 microgram/kg/min.), I.V. for 5-10 minutes, Until a level of light sedation is achieved
1769714|NCT00355940|Device|Technological Methods|"Usage of technological methods and devices to improve intravascular navigation during endovascular aortic repair.
In this arm we first use an optical pointer to allocate the femoral artery ramification (point of incision) and the lower renal artery (upper confinement of stent graft). Later we use an electromagnetically tracked catheter to find and enter the opening in the main stent graft before placing the second limb. For both optical and electromagnetic tracking we use a custom made navigation system based on 3 dimensional CT images"
1769715|NCT00355940|Device|Regular Fluoroscopy|Usage of conventional fluoroscopy and angiography for intravascular navigation. In this arm standard endovascular aortic repair is performed. The only means of navigation are fluoroscopy and angiography with overlay function (standard).
1769716|NCT00355953|Drug|Genistein|
1769717|NCT00355966|Drug|Misoprostol|In one group of women immediate induction of labour will be done by intravaginal misoprostol 25 microgram 4 hourly , a maximum of 5 doses .
1769718|NCT00355966|Drug|PGE2 gel|In other group immediate induction of labour will be done by intravaginal application of PGE2 gel 0.5 mg at an interval of 6 hours , a maximum of 2 doses.
1769719|NCT00355979|Device|intragastric balloon|
1769720|NCT00356005|Drug|azithromycin plus artesunate|
1769721|NCT00356005|Drug|Artesunate|
1769722|NCT00356018|Behavioral|Compliance|
1769723|NCT00356031|Drug|Bevacizumab|Bevacizumab 5mg/kg given intravenously every 2 weeks for a total of 4 doses
1769724|NCT00356031|Radiation|Radiation Therapy|External beam radiation given two weeks after the first bevacizumab infusion and delivered 5 days a week at 1.8 Gy per day, over 6 weeks. Total radiation dose is 50.4 Gy. For patients with tumors in the retroperitoneum or pelvis, intraoperative radiation therapy (10-20 Gy) may be given for close or positive margins at the discretion of the radiation oncologist and surgeon. For patients with tumors in the extremity or trunk, post-operative external beam radiation therapy (10-20 Gy) will be given for close or positive margins assuming wound healing is good.
1769725|NCT00356031|Procedure|Surgery|Surgical resection is performed 6-7 weeks after completion of neoadjuvant therapy.
1769726|NCT00356044|Procedure|Coronary angioplasty|
1769727|NCT00356057|Device|Protos DR/CLS and Stratos LV CRT pacemakers|Protos DR/CLS is a dual chamber pacemaker with CLS rate adaption, Stratos LV is a biventricular pacemaker with accelerometer based rate adaption
1769728|NCT00356070|Drug|Strattera|
1769729|NCT00356083|Drug|Methadone|
1769730|NCT00356096|Drug|pramipexole|
1769731|NCT00356109|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
1769732|NCT00356109|Drug|Injectable insulin|patient specific dose, injected, before meals, 6 months
1769733|NCT00356109|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 6 months
1769734|NCT00356122|Drug|Docetaxel|70 mg/m^2 administered intravenously (IV) on Day 1 for Cycles 1-6 (the treatment cycle is 3 weeks)
1769735|NCT00356122|Drug|Oxaliplatin|100 mg/m^2 administered IV on Day 1 for Cycles 1-6
1769736|NCT00356122|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and every 3 weeks during maintenance therapy for a total treatment of one year, until disease progression or death due to any cause, whichever occurs first.
1769737|NCT00356135|Drug|prasugrel 10 mg|10 mg tablet taken orally
1769738|NCT00356135|Drug|clopidogrel|75 mg tablet taken orally
1769739|NCT00356135|Drug|prasugrel placebo|oral, as blinding mechanism.
1769740|NCT00356135|Drug|prasugrel 60 mg|60 mg (six 10-mg tablets) taken orally
1769741|NCT00356135|Drug|clopidogrel placebo|oral, as blinding mechanism
1769742|NCT00356148|Drug|Ampicillin/Sulbactam|Ampicillin/Sulbactam 1 gr, once within onr hour before surgery
1769743|NCT00356161|Device|interventionally implanted hepatic arterial port catheter|
1769744|NCT00356187|Drug|Propranolol|
1769745|NCT00356200|Drug|Fluphenazine Decanoate|"Fluphenazine decanoate marketed by APP Pharmaceuticals (25 mg/mL, 5 mL vial) was used in this study. This was an ascending dose study with the first cohort of 5 subjects dosed at 10 µg/mL, followed by 5 subject dosed in the second cohort at 100 µg/mL. Note: APP Pharmaceuticals is the name of the pharmaceutical company; APP is not an acronym."
1769746|NCT00356200|Drug|Placebo|The sterile placebo (sesame oil with 1.2% (w/v) benzyl alcohol) was prepared at the University of Iowa, Division of Pharmaceutical Services, a FDA registered pharmaceutical manufacturing facility.
1769747|NCT00356213|Procedure|sleeve gastrectomy|laparoscopic sleeve gastrectomy
1769748|NCT00356213|Procedure|Roux-Y-gastric bypass|laparoscopic gastric bypass
1769749|NCT00356226|Drug|clonidine|
1769750|NCT00356252|Drug|mixed carotenoids|
1769751|NCT00356265|Drug|Procedure: Regional phenylephrine arterial infusion|
1769752|NCT00356278|Drug|D-Cycloserine|D-Cycloserine doses will be 50 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
1769753|NCT00356278|Drug|Alprazolam|Alprazolam doses will be 0.25 mg. There will be 5 pills total during study, each given 30 minutes prior to each VRE session.
1769754|NCT00356278|Behavioral|Virtual Reality Exposure Therapy|VRE includes viewing scenes of virtual Iraq via a head mounted display. Other stimuli presented include sounds, smells and vibration. Each session will be 60 minutes with approximately 30 to 45 minutes of that wearing head mounted display.
1769755|NCT00356278|Drug|Placebo|Placebo will be administered in the same manner as the active drugs.
1769756|NCT00356291|Behavioral|Skill-Building (SB) plus Motivational Interviewing|SB is a 4 to 5 session individually-based psychoeducational intervention. Participants meet weekly with an interventionist for 3 to 4 weeks and then receive a booster session 3 months after baseline. The traditional Skill-Building intervention will be augmented with Motivational Interviewing techniques.
1769757|NCT00356291|Behavioral|Skill-Building (SB)|SB is a 4-session individually-based psychoeducational HIV risk reduction intervention. Participants meet weekly with an interventionist for 3 weeks and then receive a booster session 3 months after baseline.
1769758|NCT00356304|Behavioral|Motivational interviewing|Participants assigned to motivational interviewing will attend two 1-hour sessions of motivational interviewing over 2 consecutive weeks, followed by a third session 8 weeks later. Motivational interviewing is a type of counselling. Each session is of approximately 1 hour duration.
1769759|NCT00356304|Behavioral|Treatment as usual|Participants will continue with their normal treatment regimen as usual.
1769760|NCT00356317|Behavioral|Culturally informed therapy for schizophrenia (CIT-S)|This family therapy consists of 15 video-taped, therapy sessions, each lasting approximately 75 minutes. The 15-session treatment will be broken down into five segments (each lasting approximately three sessions) with the following goals: 1) Fortify a strong sense of family unity; 2) educate about schizophrenia; 3) foster adaptive use of cultural, spiritual and/or existential beliefs in conceptualizing and coming to terms with schizophrenia; 4) teach effective communication training techniques; and 5) and teach useful problem solving strategies.
1769761|NCT00356317|Behavioral|Psychoeducation treatment as usual|This family therapy consists of three weekly sessions focusing on education about schizophrenia.
1769762|NCT00356343|Device|NMES Strength Training|Subjects will complete 12 weeks of NMES isometric strength training using implanted electrodes in bilateral quadriceps and triceps surae muscles.
1769763|NCT00356343|Other|Volitional Strength Training|Subjects will complete 12 weeks of volitional isometric strength training of bilateral quadriceps and triceps surae muscles.
1769764|NCT00356356|Drug|Etanercept|Etanercept 50 mg/wk administered as 2-25 mg SQ injections at separate injection sites
1956900|NCT02639637|Drug|Neuropeptide Y|During the study days, neuropeptide Y will be infused through an intra-arterial line. There will be four doses of neuropeptide Y used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
1769767|NCT00356382|Drug|Lactobacillus (L.) casei|
1769768|NCT00356395|Drug|ramipril, candesartan|
1769769|NCT00356408|Biological|Certolizumab pegol|"Certolizumab pegol (CDP870), an anti-tumor necrosis factor (TNF)α, humanized antibody Fab' fragment - polyethylene glycol conjugate, solution for injection, in 10 mM sodium acetate buffer and 125 mM sodium chloride, pH 4.7, supplied in 3 mL vials with a fill of 1.4 mL (an extractable volume of 1 mL corresponds to a dose of 200 mg).
Dosing is every 4 weeks from Week 2 until Week 34, or until CDP870 is available for a Crohn's disease indication in the patient's country. Subjects who were Non-completers of C87059 (COSPAR I, NCT00349752) receive an additional CDP870 400 mg dose at Week 2."
1769770|NCT00356421|Drug|Inhaled Human Insulin (Exubera®)|Preprandial inhaled insulin regimen and administration of insulin glargine QD
1769771|NCT00356421|Drug|Insulin lispro (Humalog)|Subcutaneous insulin regimen of pre-prandial insulin lispro and administration of insulin glargine QD.
1769772|NCT00356434|Device|Kendall A-V foot impulse pump, model 6060|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
1769773|NCT00356434|Device|Kendall sequential compression device, model 9525|Will wear device for DVT prevention and receive questionnaire about compliance and comfort. Will also undergo random checks to confirm compliance with instructions and use
1769774|NCT00356447|Drug|Estradiol/DRSP (Angeliq, BAY86-4891)|Drospirenone (DRSP) 2mg and Estradiol 1mg. One cycle consists of 28 days. One tablet daily for 28 days given for a total of 4 cycles. Oral administration.
1769775|NCT00356447|Drug|Placebo|Same administration.
1769776|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.1 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.1 mg/kg IV (one dose every 14 days)
1769777|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 0.3 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 0.3 mg/kg IV (one dose every 14 days)
1769778|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 1.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 1.0 mg/kg IV (one dose every 14 days)
1769779|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 3.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 3.0 mg/kg IV (one dose every 14 days)
1769780|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 10.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 10.0 mg/kg IV (one dose every 14 days)
1769781|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
1769782|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ ) Monoclonal Antibody|1 dose of 15.0 mg/kg IV followed by a 28 day observation period and then 3 additional doses of 15.0 mg/kg IV (one dose every 14 days)
1769783|NCT00356460|Biological|GC1008 Human Anti Transforming Growth Factor _Beta (TGFβ) Monoclonal Antibody|1 dose of 15.0 or 10.0 mg/kg IV (based on safety profile of part 2, cohort 1) followed by a 28 day observation period and then 3 additional doses of 15.0 or 10.0 mg/kg IV (one dose every 14 days)
1769784|NCT00356473|Drug|Atorvastatin|
1769785|NCT00356486|Drug|Peginterferon alfa-2a, Ribavirin, epoetin-β|Peginterferon alfa-2a(270 µg/week) + Ribavirin (1600 mg/day) + epoetin-β (450 UI/kg/week) for 4 weeks. Peginterferon alfa-2a (180 µg/week) + Ribavirin(1000-1200 mg/day) for 8 weeks
1769786|NCT00356486|Drug|Peginterferon alfa-2a + Ribavirin for 12 weeks|Peginterferon alfa-2a (40 KD) (180 µg/week) subcutaneous + Ribavirin(1000-1200 mg/day) oral/day for 12 weeks
1769787|NCT00356525|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
1769788|NCT00356525|Drug|gemcitabine|1500 mg/m2, intravenous (IV), every 14 days x 6 cycles or until disease progression
1769789|NCT00356525|Drug|carboplatin|area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles or until disease progression
1769790|NCT00356525|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles or until disease progression
1769791|NCT00356551|Behavioral|Family Spirit curriculum|
1769792|NCT00356564|Biological|hepatitis B vaccine|
1769793|NCT00356590|Biological|Etanercept|Etanercept (TNFR:Fc) will be administered 50 mg per week as two 25 mg subcutaneous injections at separate sites, given either on the same day or 3 or 4 days apart.
1769795|NCT00356616|Drug|Trizivir (AZT+3HT+Abacavir) twice daily|Trizivir (AZT+3HT+Abacavir) twice daily
1769796|NCT00356616|Drug|Viread (300 mg Tenofovir disoproxil fumarate) once daily|Viread (300 mg Tenofovir disoproxil fumarate) once daily
1769797|NCT00356642|Drug|GW842470X|GW842470X will be available as a yellow smooth water-in-oil cream.
1769798|NCT00356642|Drug|Placebo|GW842470X matching placebo will be available as a yellow smooth water-in-oil cream.
1769799|NCT00356655|Behavioral|Psychoeducation|
1769800|NCT00356668|Device|High Flow Nasal Cannula|30 minute blocks on varying flows of high flow nasal cannula
1769801|NCT00356681|Drug|AMG 706 placebo|Blinded placebo
1769802|NCT00356681|Drug|Bevacizumab|Bevacizumab is a recombinant, humanized anti-VEGF monoclonal antibody.
1769803|NCT00356681|Drug|AMG 706|AMG 706 is a small organic molecule that has been shown in preclinical pharmacology and PK studies to be a potent, oral, multi-kinase inhibitor with anti-angiogenic and anti-tumor activity achieved by selectively targeting all known VEGF, PDGF and Kit receptors.
1769804|NCT00356681|Drug|Paclitaxel|Paclitaxel is an antineoplastic agent that acts by promoting and stabilizing the polymerization of microtubules.
1769805|NCT00356720|Drug|Azithromycin|
1769806|NCT00356733|Drug|Erythropoietin administration|50 IU/kg/week EPO to a target haemoglobin level of 13.7 g/dL for men and 13.4 g/dL for women (group A) or to a target comparable to starting hemoglobin level (group B)
1769808|NCT00356772|Drug|Azithromycin|
1769809|NCT00356785|Behavioral|health education|
1769810|NCT00356785|Behavioral|food supplementation|
1769811|NCT00356785|Behavioral|food supplementation combined with physical activity program|
1769812|NCT00356798|Biological|an inactivated whole virion H5N1 vaccine, adjuvanted|
1769813|NCT00356811|Drug|Lapatinib oral tablets|Lapatinib will be given as tablets contain 410 mg of lapatinib ditosylate monohydrate, equivalent to 250 mg lapatinib free base per tablet. Subjects will be given a 4 week supply of lapatinib tables and instructed to take 6 tablets daily (1500 mg daily dose) orally at the same time each day. Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent.
1769814|NCT00356811|Drug|Paclitaxel infusion|Subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle). Subjects will be treated with paclitaxel for at least 6 months, and may continue on paclitaxel at the discretion of the Investigator, or discontinued sooner if the subject has disease progression, an unacceptable toxicity or withdraws consent.
1769815|NCT00356824|Drug|Amodiaquine|200 mg oral tablet taken daily for 3 days under direct supervision at study clinic
1769816|NCT00356824|Drug|Artesunate|50 mg oral tablet taken daily for 3 days under direct supervision at study clinic
1769817|NCT00356837|Procedure|Ultrasound|use ultrasound to confirm diagnosis of extremity fractures
1769818|NCT00356850|Drug|Azithromycin|
1769819|NCT00356863|Behavioral|Increasing awareness to cardiac rehabilitation programs|Before coronary artery bypass grafting (CABG) surgery patients received a face-to-face explanation on their right to participate in cardiac rehabilitation programs (CRPs) under the Israeli Basket of Health Services; they were also provided with a brochure on the benefits of CRP participation and the availability of CRPs throughout the country.
1769820|NCT00356889|Drug|erlotinib hydrochloride|Given orally, 150 mg, once daily.
1769821|NCT00356889|Biological|bevacizumab|Given IV, 5mg/kg on days 1 and 15 every cycle
1769822|NCT00351351|Device|Cyberwand|FDA approved - dual probe intracorporeal lithotrite
1769823|NCT00351351|Device|single probe ultrasonic|FDA-approved - single probe ultrasonic
1769824|NCT00351364|Drug|Montelukast Sodium|100 mg P.O. One time only
1769825|NCT00351377|Drug|Enteric-coated Mycophenolate Sodium|Enteric-coated Mycophenolate Sodium (EC-MPS) 180 mg and 360 mg tablets were administered orally in divided doses twice daily.
1769826|NCT00351390|Other|Drug therapy for HF|Titration of HF meds in an aggressive out patient manner following guideline direction
1769827|NCT00351390|Other|NT-proBNP guided HF therapy|Standard of care drug therapy following guideline direction, plus adjustment of medication titrated to achieve NT-proBNP <1000 pg/mL
1769828|NCT00351403|Drug|Ribavirin|Rebetol 200 mg: applied as hard capsule
1769829|NCT00351403|Drug|Peginterferon alfa 2b|PegIntron (50/80/100/120/150 microgram): applied by injection
1769830|NCT00351416|Drug|Letrozole|Letrozole 20 mg orally one time
1769831|NCT00351416|Drug|NAL-GLU GnRH antagonist|5 mcg/kg of the NAL-GLU GnRH antagonist subcutaneously
1769832|NCT00351429|Device|Polyglycolic acid suture|PGA suture used in Trabeculectomy surgery
1769833|NCT00356902|Procedure|titration of oxygen during resuscitation|
1769834|NCT00356915|Drug|Itraconazole 100mg capsules|Subjects took two 100mg capsules once per day after a full meal. The dose dose was taken the day before the Week 12 visit.
1769835|NCT00356915|Drug|Itraconazole 200mg tablets|Subjects took one 200mg tablet once per day after a full meal. The last dose was taken the day before the Week 12 visit.
1769836|NCT00356915|Drug|Placebo tablets|Placebo tablets are the same as the Itraconazole tablets but without the active drug included. Subjects took one tablet once per day after a full meal. The last tablet was taken the day before the Week 12 visit.
1769837|NCT00356928|Biological|donor lymphocytes|
1769838|NCT00356928|Biological|therapeutic allogeneic lymphocytes|
1769839|NCT00356928|Drug|cyclophosphamide|
1769840|NCT00356941|Drug|docetaxel|60 mg/m2 on day 1 of each week during radiation therapy
1769841|NCT00356941|Drug|oxaliplatin|Escalating dose per assignment: 20-50 mg/m2 on day 2 of each week during radiation therapy
1769842|NCT00356941|Procedure|radiation therapy|2 Gy Days 1-5 each week, total dose of 70Gy
1769843|NCT00356954|Drug|N-acetylcystein|
1769844|NCT00356954|Drug|ascorbic acid|
1769845|NCT00356967|Drug|dianicline|
1769846|NCT00356980|Biological|colloidal gold-bound tumor necrosis factor|
1769847|NCT00356980|Other|pharmacological study|
1769848|NCT00356993|Drug|Nicotine Replacement Therapy|transdermal nicotine patch, nicotine gum, nicotine inhaler, nicotine lozenge
1769849|NCT00356993|Behavioral|behavioural intervention|Smoking cessation counselling, relapse prevention strategies
1769850|NCT00357006|Drug|Estradiol|100 mcg adjunctive transdermal estradiol
1769851|NCT00357006|Drug|Estradiol|200 mcg adjunctive transdermal estradiol
1769852|NCT00357006|Other|placebo|adjunctive transdermal placebo
1769853|NCT00357019|Drug|N-acetyl-aspartyl-glutamate (NAAXIA Sine)|
1769854|NCT00357032|Drug|belinostat|Given IV
1769855|NCT00357032|Other|laboratory biomarker analysis|Correlative studies
1769856|NCT00357045|Drug|Paroxetine|
1769857|NCT00357084|Drug|methotrexate|
1769858|NCT00357084|Drug|methylprednisolone|
1769859|NCT00357084|Drug|prednisone|
1769860|NCT00357097|Drug|Ropinirole|
1769861|NCT00357110|Drug|Fulvestrant|intramuscular injection
1769862|NCT00357110|Drug|Anastrozole|1 mg oral tablet
1769863|NCT00357123|Drug|Rosuvastatin|20 mg 10 days daily since abdominal sepsis diagnosis
1769864|NCT00357136|Behavioral|password usage|
1769865|NCT00357149|Drug|Docetaxel, cisplatin and 5-FU treatment followed by concomitant cisplatin, 5-FU and radiotherapy|
1769866|NCT00357149|Drug|Concomitant cisplatin, 5-FU and radiotherapy|
1769867|NCT00357162|Drug|belinostat|Given IV
1769868|NCT00357188|Drug|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 10 days.
1769869|NCT00357188|Drug|Atazanavir Sulphate + Ritonavir + Efavirenz|Capsules/Tablets, oral, ATV 400 mg + RTV 100 mg + EFV 600 mg, once daily, 14 days.
1769870|NCT00357201|Drug|Food supplement (T1675)|
1769871|NCT00357214|Dietary Supplement|Potassium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
1769872|NCT00357214|Dietary Supplement|Sodium Bicarbonate|67.5 mmol/d given as three tablets after each meal, with a full glass of water
1769873|NCT00357214|Dietary Supplement|Potassium Chloride|67.5 mmol/d given as three tablets after each meal, with a full glass of water
1769874|NCT00357214|Dietary Supplement|placebo (microcrystalline cellulose)|Given as three tablets after each meal, with a full glass of water
1769875|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
1769876|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
1769877|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 300/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
1769878|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in PM + once daily in AM, 7 days.
1769879|NCT00357240|Drug|Atazanavir|Capsules, Oral, 400 mg, once daily, 6 days.
1769880|NCT00357240|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, once daily, 10 days.
1769881|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in AM, 7 days.
1769882|NCT00357240|Drug|Atazanavir/Ritonavir+Omeprazole|Capsules/capsules + Capsules, Oral, 400/100 mg + 20 mg, once daily in AM + once daily in PM, 7 days.
1769883|NCT00358644|Drug|Decitabine|20 mg/m^2, IV on days 1-5 of each 28 day cycle; until death, progression or unacceptable toxicity develops.
1769884|NCT00358657|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplantation
1769885|NCT00358657|Drug|Cyclophosphamide|Given IV
1769886|NCT00358657|Drug|Fludarabine Phosphate|Given IV
1769887|NCT00358657|Other|Laboratory Biomarker Analysis|Correlative studies
1769888|NCT00358657|Drug|Mycophenolate Mofetil|Given PO
1769889|NCT00358657|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic bone marrow transplantation
1769890|NCT00358657|Drug|Sirolimus|Given PO
1769891|NCT00358657|Drug|Tacrolimus|Given IV or PO
1769892|NCT00358657|Radiation|Total-Body Irradiation|Undergo total-body irradiation
1769893|NCT00358670|Biological|infliximab|"Infliximab maintenance therapy
intravenous (IV) infusion every 8 weeks, 5 mg/kg body weight (first infusion at Week 4/Visit 2)."
1769894|NCT00358670|Biological|infliximab|"Infliximab intermittent therapy:
Paricipants will receive no infliximab treatment until the Week 26 improvement in PASI from Baseline (original Study P04271 [NCT00251641] Baseline) is reduced by more than 50%. At that time, participants will receive an infliximab infusion, 5 mg/kg body weight. Participants may receive additional infusions at 0, 2, 6, and 14 weeks after the first infusion of the cycle (ie, a maximum of 4 infusions in each infusion cycle) as needed until they respond, defined as a >=75% improvement in PASI from the original Baseline in Study P04271. Subjects will receive no further treatment until they relapse again (ie, improvement in PASI from Baseline is reduced by more than 50%), at which time participants will receive another infusion cycle of up to 4 infusions, as described above. Throughout the study, intermittent treatment infusion cycles will be repeated whenever participants relapse."
1769895|NCT00358683|Drug|Certolizumab pegol|
1769896|NCT00358696|Drug|tenofovir|See Detailed Description.
1769897|NCT00358709|Behavioral|Cognitive-Behavioral therapy and Symptom Management|A group cognitive-behavioral therapy approach to lessening psychotic symptoms of individuals with a first episode of psychosis, and comparison its effects to a known skills training approach and a control group.
1769898|NCT00358722|Drug|Fermagate|Film coated tablet 500mg
1769899|NCT00358735|Device|ActiveCare CECT device|Patients will be treated with the ActiveCare+ CECT device starting after the induction of anesthesia, throughout the surgery and for 10-12 days after surgery. Baby aspirin (81 mg) QD can be added (depending on surgeon preference) 12-24 hours after surgery. Post discharge prophylaxis is the same for the remainder of the 10-12 days. Patients will wear the device to the duplex ultrasound when it will be discontinued by nurse.
1769900|NCT00358735|Drug|Enoxaparin|Patients will be treated with Enoxaparin (Lovenox) for a total of 10 days beginning with 30mg BID starting 12-24 hours after surgery and continued until hospital discharge. Post discharge prophylaxis will be Enoxaparin 40mg QD for the remainder of the 10 days.
1769901|NCT00358748|Drug|Hydrocortisone|See detailed description above.
1769902|NCT00358774|Procedure|homeopathic nasal spray|
1769903|NCT00358787|Procedure|Crossed K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by crossed K wire percutaneous pinning.
1769904|NCT00358787|Procedure|Lateral K-wiring of supracondylar fracture of the humerus|Closed reduction of the fracture followed by lateral K wire percutaneous pinning.
1769905|NCT00358800|Device|REMStar Auto with C-Flex|
1769906|NCT00358813|Drug|Casopitant|Casopitant oral tablets will be available with a dose of 50 milligrams.
1769907|NCT00358826|Drug|VIA-2291|oral dosing, 1 time daily for 12 or 24 weeks
1769908|NCT00358826|Drug|Placebo|oral dosing, 1 time daily for 12 or 24 weeks
1769909|NCT00358839|Drug|CGRP|
1769910|NCT00358852|Other|No intervention|This is an observational study. The data will be collected of patients suffering from schizophrenia and schizoaffective disorder / schizophreniform.
1769911|NCT00358878|Drug|Satavaptan|oral administration once daily
1769912|NCT00358878|Drug|placebo|oral administration once daily
1769913|NCT00358917|Drug|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 800/200 mg once-daily (QD) tablet
1769914|NCT00358917|Drug|lopinavir/ritonavir (LPV/r) tablet with nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs)|LPV/r 400/100 mg twice-daily (BID) tablet
1769915|NCT00358930|Drug|ARQ 501|
1769916|NCT00358956|Drug|ZD6474 (vandetanib)|100 mg once daily oral tablet
1769917|NCT00358969|Drug|guanfacine (Tenex)|
1769918|NCT00358982|Drug|MGCD0103|MGCD0103 administered orally three times per wek
1769953|NCT00359281|Drug|simvastatin|Simvastatin 20 mg and AEGR-733 10 mg or 60 mg
1769954|NCT00359281|Drug|ezetimibe|Ezetimibe 10 mg and AEGR-733 10 mg
1769955|NCT00359281|Drug|fenofibrate|Micronized Fenofibrate 145 mg and AEGR-733 10 mg
1769956|NCT00359281|Drug|dextromethorphan|Dextromethorphan 30 mg and AEGR-733 10 mg
1769957|NCT00359281|Drug|Extended Release Niacin|1000 mg ER niacin and AEGR-733 10 mg
1769919|NCT00358995|Behavioral|Cognitive Behavioral Therapy|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
1769920|NCT00358995|Behavioral|Stress Management Therapy (SMT)|Participants will be randomly assigned to either immediate treatment or delayed treatment (three month delay). Participants will then be again be randomly assigned to either Cognitive Behavior Therapy (CBT) or Stress Management Therapy (SMT). The delayed participants (wait list control) will be randomly assigned to either of the two active treatment groups in three months time. Both active treatment conditions involve one hours, individual treatment sessions for 12 consecutive weeks by one of the treating psychologists. All participants will also be asked to complete a package of psychometric questionnaires before treatment.
1769921|NCT00359021|Drug|TMC125|200 mg twice daily until commercially available
1769922|NCT00359047|Behavioral|Documentation|Participants will receive written educational material for themselves as well as the Guidelines document for their physician (same written material as in the Educational Video Group). They will be asked to revisit their physician and provide written documentation inviting him/her to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada
1769923|NCT00359047|Behavioral|Video|Participants will receive a 15-minute educational video on osteoporosis. They will also receive written educational material for themselves and a Guidelines document for their physician. They will be asked to revisit their physician and provide the written documentation inviting her/him to consider a complementary investigation and an adequate treatment according to the 2002 Clinical Practice Guidelines for the Diagnosis and Management of Osteoporosis in Canada. Should participants wish to obtain additional information on osteoporosis, they will be provided with a toll-free number (1-866-571-ROCQ) to contact
1769924|NCT00359060|Behavioral|Physical activity|
1769927|NCT00359086|Drug|MGCD0103|MGCD0103 given orally three times per week
1769928|NCT00359112|Drug|metformin|
1769929|NCT00359112|Drug|sulphonylurea|
1769930|NCT00359112|Drug|Avandamet|
1769931|NCT00359125|Drug|mifepristone (RU-486)|RU-486, 600 mg/day for 1 week.
1769932|NCT00359125|Other|Placebo|Placebo, 600 mg/day for 1 week.
1769933|NCT00359138|Drug|desloratadine|5 mg tablet once daily
1769934|NCT00359138|Drug|levocetirizine|5 mg capsule once daily
1769935|NCT00359138|Drug|Desloratadine placebo tablet|once daily
1769936|NCT00359138|Drug|Levocetirizine placebo capsule|once daily
1769937|NCT00359151|Drug|Celecoxib|7 days pre-surgery (excluding day of surgery): 1 celecoxib 200 mg capsule or matching placebo QD; Day of surgery: 2 celecoxib 200 mg capsules or matching placebo within 2 hours prior to surgery, and 1 celecoxib 200 mg capsule or matching placebo following surgery; Post-surgery: starting the day after surgery, 1 celecoxib 200 mg capsule or matching placebo BID for the duration of the study.
1769938|NCT00359151|Drug|Placebo|Placebo once daily (QD) for 7 days pre-surgery (excluding the day of surgery); Placebo within 2 hours prior to surgery; and post surgery on the same day of the surgery; Placebo twice daily (BID) following the day of surgery and for the duration of the study.
1769939|NCT00359164|Drug|Verteporfin Photodynamic Therapy (Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (300 mW/cm2 delivered for 83 seconds [light dose of 25 J/cm2]) Photodynamic Therapy.
Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
1769940|NCT00359164|Drug|Verteporfin Photodynamic Therapy (Very Low Fluence) and bevacizumab|"Bevacizumab 1.25 mg with verteporfin at Low Fluence (150 mW/cm2 delivered for 83 seconds [light dose of 12.5 J/cm2]) Photodynamic Therapy.
Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
1769941|NCT00359164|Drug|Verteporfin Photodynamic Therapy (SHAM) and bevacizumab|"Bevacizumab with SHAM (150 mW/cm2 delivered for 83 seconds [light dose of 12.5 J/cm2]) Photodynamic Therapy.
Treatment at Baseline visit, followed by an as needed basis. Assessments monthly for bevacizumab and at 3-month intervals for combination therapy with verteporfin or sham."
1769942|NCT00359177|Drug|GW679769|GW679769 will be available in dose strength of 50 mg tablets. Subjects will receive two tablets of 50 mg orally once daily in the morning
1769943|NCT00359190|Drug|lapatinib|
1769944|NCT00359203|Device|Dual chamber pacemeker|
1769945|NCT00359216|Drug|Mometasone furoate nasal spray|MFNS, 50 mcg/spray. Each subject to take 200 mcg (4 sprays) once daily in the morning.
1769946|NCT00359216|Drug|Placebo|Placebo nasal spray. Each subject to take 4 sprays once daily in the morning.
1769947|NCT00359229|Drug|Zolpidem|Administration of Zolpidem 5mg
1769948|NCT00359242|Behavioral|Infant Sleeping and Soothing|Soothing and Calming instructions given to parents at a home visit when their infant is approximately 2 weeks old.
1769949|NCT00359242|Behavioral|Repeated Food Exposure|Instructions given to parents on introduction of solid foods and repeated exposure when the infant is approximately 4 to 6 months of age.
1769950|NCT00359255|Behavioral|Education manual|The control arm was given education on stroke, the affected arm post strooke, bone health, and healthy living. This information was given in a booklet format and administered once weekly by the site coordinator.
1769951|NCT00359255|Behavioral|An inpatient homework based exercise program for the upper limb post stroke|"The experimental arm was given arm exercises graded based on motor impairment and administered by the site coordinator. The exercises were given in a booklet with written and photographic instructions. These exercises were monitored on a twice-weekly basis.
The intervention was to be completed once daily for 45 minutes, 5 days per week, and supervised by the site coordinator. Exercises consisted of range of motion, strengthening, and use of the arm in daily activites such as buttoning, pouring and throwing."
1769952|NCT00359281|Drug|atorvastatin|Atrovastatin 20 mg and AEGR-733 10 mg or 60 mg
1769959|NCT00359320|Procedure|pancreaticojejunostomy|
1769960|NCT00359333|Drug|Gemcitabine , Docetaxel|Gemcitabine 800 mg/m2 IV over 80 minutes on day 1 and day 8, and Docetaxel 60 mg/m2 IV over 60 minutes on day 1 of a 21-day cycle
1769961|NCT00359359|Drug|Sagopilone (BAY86-5302, ZK 219477)|Phase 1: dose escalation/deescalation, starting dose 12mg/m² Sagopilone, Phase 2: MTD or RPIID
1769962|NCT00359359|Drug|Cisplatin|75 mg/m² as a 1 h infusion after the sagopilone infusion on Day 1
1769963|NCT00359385|Drug|Alendronate 70mg weekly|70mg weekly
1769964|NCT00359398|Procedure|Platelet rich plasma sequestration|Venesection of blood (14 ml/kg) and separation to red cells and platelet rich plasma.
1769965|NCT00359424|Drug|IV rt-PA alone|Intravenous (IV) recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy; Group one will receive the standard dose of IV rt-PA given over an hour.
1769966|NCT00359424|Other|endovascular therapy|Group two will receive a lower dose or the standard dose of IV rt-PA and then undergo an angiogram test (cerebral angiography) right after the medicine is given to check for blood clots. If a clot is not seen then no more treatment will be given. If a clot is seen, the neurointerventionalist will then choose a protocol approved endovascular treatment given directly in the brain artery that will be most effective in reopening the blocked artery. Endovascular therapy can be implemented with or without interarterial rt-PA use.
1769967|NCT00359437|Drug|Satavaptan|oral administration once daily
1769968|NCT00359437|Drug|placebo|oral administration once daily
1769969|NCT00359450|Drug|BMS-275183 (oral taxane)|
1769970|NCT00359463|Drug|eltrombopag|
1769971|NCT00359476|Drug|Vinflunine|solution for injection, IV, 280/320 mg/m2, every 3 wks, variable duration
1769972|NCT00359489|Device|cardiac echosonography|
1769973|NCT00359554|Biological|VAXIGRIPPE|
1769974|NCT00359567|Drug|palonosetron|intravenous injections of 0.75 mg palonosetron (5 mL) and then granisetron placebo before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
1769975|NCT00359567|Drug|granisetron hydrochloride|intravenous injections of palonosetron placebo and then 40μg/kg granisetron hydrochloride before administration of highly emetogenic chemotherapy, concomitantly administered with corticosteroids.
1769976|NCT00359593|Behavioral|Knowledge translation intervention package|
1769977|NCT00359606|Drug|5-Fluoro-2-Deoxycytidine (FdCyd)|Given PO and IV
1769978|NCT00359606|Other|Laboratory Biomarker Analysis|Correlative Studies
1769979|NCT00359606|Other|Pharmacological Study|Correlative Studies
1769980|NCT00359606|Drug|Tetrahydrouridine (THU)|Given PO and IV
1769981|NCT00359619|Biological|CervarixTM|Subjects were administered three doses of HPV vaccine
1769982|NCT00359619|Biological|HPV investigational vaccine GSK568893A, different formulations|Subjects were administered three doses of HPV investigational vaccine
1769983|NCT00359632|Drug|Zyvox - linezolid|Observation and testing in patients for whom their treating physician has determined linezolid is an appropriate therapy. Eye tests performed for subjects who have received linezolid for at least 6 weeks and matching controls who have received other antibiotics for similar types of infections.
1769984|NCT00359632|Drug|Matched control|Matched controls received an antibiotic other than linezolid for at least 6 weeks prior to baseline visit. The control group had only a baseline visit and there were no post baseline study visits.
1769985|NCT00359645|Procedure|Screening by head and neck clinical examination with a fiberoptic nasolaryngoscopy and an oesopharyngeal brush biopsy annually during 3 years|
1769986|NCT00359658|Drug|prednisolon|prednisolon withdrawal: reduction of maintenance dosage, 0,5 mg of the daily dose every week till withdrawal
1769987|NCT00359658|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: start doses 250 mg, increase of the daily dose about 250 mg every week till reaching 2 g/daily
1769988|NCT00359658|Drug|Cyclosporin A|Cyclosporin A reduction: 8 weeks after starting prednisolon withdrawal and Mycophenolatmofetile administration reduction of Cyclosporin A trough level till a range from 50 to 90 ng/ml
1769989|NCT00359671|Drug|MK6592|MK6592 delivered as a 48-hour CIV as monotherapy in Cycle 1; 48-hour CIV of MK6592 in Cycle 2 and subsequent cycles.
1769990|NCT00359671|Drug|comparator: docetaxel|docetaxel, delivered as a standard IV infusion.
1769991|NCT00359684|Drug|Cysteamine|Cystine-depleting agent
1769992|NCT00359697|Drug|Hypertonic Saline, Mannitol|
1769993|NCT00359723|Drug|methylphenidate|
1769995|NCT00359762|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
1769996|NCT00359762|Drug|glimepiride|oral tablet (titrated to maximally tolerated dose), once daily
1769997|NCT00359775|Behavioral|Coping Skills Training|6 session behavioral program
1769998|NCT00359788|Drug|tiotropium|
1769999|NCT00359788|Drug|Combivent (Ipratropium/Albuterol)|
1770000|NCT00359801|Drug|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use Exubera. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice). Enrolling physicians are provided with the approved local label for Exubera to guide prescribing and treatment decisions.
1770001|NCT00359801|Drug|Randomization to Exubera (insulin human [rDNA origin] inhalation powder) or Usual Diabetes Care|Subjects are randomized to use usual diabetes care. Following initial use of randomized treatment, physicians and subjects are free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
1770002|NCT00359814|Drug|Mycophenolatmofetile|Mycophenolatmofetile administration: was started with 250 mg/daily at day 1, the start dose was increased about 250 mg/daily every week till 2 g/daily
1770003|NCT00359814|Drug|Cyclosporin A|Cyclosporin A reduction: Cyclosporin A trough level reduction started after week 8. The new target range was 50 to 90 ng/ml
1770004|NCT00359840|Drug|darbepoetin alfa|
1770005|NCT00359853|Drug|Oral norfloxacin|
1770006|NCT00359866|Radiation|IMRT with tomotherapy|
1770283|NCT00363714|Drug|AGN211745|100microgram single intravitreal injection
1770007|NCT00359879|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before lunch and dinner)
1770008|NCT00359879|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day (before breakfast and dinner)
1770009|NCT00359892|Drug|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
1770010|NCT00359905|Drug|Silodosin|8 mg daily for 12 weeks
1770011|NCT00359905|Drug|Tamsulosin|0.4 mg daily for 12 weeks
1770012|NCT00359905|Drug|Placebo|once daily for 12 weeks
1770013|NCT00359918|Drug|fibrinolysis|
1770014|NCT00359944|Drug|AC-3933|5mg twice daily
1770015|NCT00359944|Drug|AC-3933|AC-3933, 20 mg twice daily
1770016|NCT00359944|Other|Sugar Pill|Sugar Pill twice daily
1770017|NCT00359957|Behavioral|Pediatric Obesity Intervention (STANDARD)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
1770018|NCT00359957|Behavioral|Pediatric Obesity Intervention + High Activity (ADDED)|14 weekly behavioral intervention visits with parent and child; individual family sessions (25-30 minutes) and separate parent and child groups (40 minutes)
1770019|NCT00359970|Drug|Azithromycin 500 mg|A single 500 mg dose at the start of treatment
1770020|NCT00359970|Drug|Azithromycin 1000 mg|A single 1000 mg dose at the start of treatment
1770021|NCT00359970|Drug|Loperamide|A single 4 mg loading dose at the start of treatment and then 2 mg after each loose stool
1770022|NCT00359970|Other|Placebo|A single loading dose at the start of treatment and then a dose after each loose stool
1770023|NCT00359983|Biological|MenHibrix (Hib-MenCY-TT)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
1770024|NCT00359983|Biological|Hib conjugate vaccine (ActHIB)|First three doses: 3 intramuscular doses Fourth dose: 1 intramuscular dose
1770025|NCT00359996|Behavioral|health disparities collaborative|The HDC incorporates rapid quality improvement (QI), a chronic care model, and best practices. This study determines if the HDC improves diabetes care and whether more intensive interventions with additional learning sessions for health centers, provider training in behavioral change, and patient empowerment materials enhance care further.
1770026|NCT00359996|Other|No additional educational sessions|
1770027|NCT00360009|Procedure|DBS of the STN|Patients undergo Deep Brain Stimulation (DBS) of the subthalamic nucleus (STN) to treat Parkinson's Disease, using a Medtronic 3387 device.
1770028|NCT00360009|Procedure|DBS of the GPI|Patients undergo Deep Brain Stimulation (DBS) of the globus pallidus interna (Gpi) to treat Parkinson's disease, using a Medtronic 3387 device.
1770029|NCT00360022|Other|Joint visits|Both the pediatric GI specialist and the adult GI specialist will see the patient together at 2 different visits. The first joint visit is lead by the pediatric MD and the second joint visit is lead by the adult MD.
1770030|NCT00360035|Drug|Obatoclax mesylate (GX15-070MS)|60 mg q2wks
1770031|NCT00360048|Drug|oxytocin|
1770032|NCT00360061|Behavioral|Cognitive Behaviour Therapy|
1770033|NCT00360074|Drug|Thyroxin, Triiodothyronine|
1770034|NCT00360087|Drug|Bosentan|
1770035|NCT00360100|Drug|Zmax|
1770036|NCT00360126|Drug|lamotrigine|
1770037|NCT00360139|Device|Sculptra Injection|
1770038|NCT00360152|Procedure|Fine needle aspiration biopsy (FNAB)|
1770039|NCT00360152|Procedure|Sentinel Lymph Node Biopsy|
1770040|NCT00360178|Drug|Valsartan plus Hydrochlorothiazide|
1770041|NCT00360178|Drug|Candesartan plus Hydrochlorothiazide|
1770042|NCT00360178|Drug|Amlodipine|
1770043|NCT00360191|Drug|Buspirone|
1770044|NCT00360191|Procedure|Motivational enhancement therapy|
1770045|NCT00360204|Behavioral|Home Nurse Visit|Home nurse visit by maternal child health nurse within first 24-48 after post-partum hospital discharge.
1770046|NCT00360217|Drug|docosahexanoic acid (DHA)|
1770049|NCT00360243|Drug|flibanserin|Experimental: flibanserin 25 mg b.i.d
1770050|NCT00360243|Drug|flibanserin|Experimental: flibanserin 50mg qhs
1770051|NCT00360243|Drug|flibanserin|Experimental: flibanserin 50mg b.i.d.
1770052|NCT00360243|Drug|placebo|placebo
1770053|NCT00360269|Drug|Atomoxetine|25 to 100 mg daily
1770054|NCT00360269|Procedure|Motivational enhancement therapy|Three sessions
1770055|NCT00360269|Drug|Placebo|25 to 100 mg daily
1770056|NCT00360282|Drug|Rizatriptan|10 mg Rizatriptan in an unlabeled pill given once on one of two visits
1770057|NCT00360282|Other|Placebo|In an unlabeled pill given once on one of two visits.
1770058|NCT00360295|Drug|Azithromycin SR|
1770059|NCT00360308|Drug|Placebo|
1770060|NCT00360308|Drug|E2007|
1770061|NCT00360308|Drug|E2007|
1770062|NCT00360334|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
1770063|NCT00360334|Drug|insulin glargine|subcutaneous injection, titrated to target blood glucose level, once a day
1770064|NCT00360347|Drug|C.E.R.A.|
1770065|NCT00360360|Drug|paclitaxel|Paclitaxel 175mg/m2, 1-3 hour IV infusion,Day 1
1770066|NCT00360360|Drug|carboplatin|Carboplatin AUC 6.0 IV Day 1
1770067|NCT00360360|Drug|bevacizumab|Bevacizumab 15mg/kg IV infusion,Day 1
1770068|NCT00360360|Drug|erlotinib|Erlotinib 150 mg by mouth daily
1770069|NCT00360386|Drug|Clopidogrel|
1770070|NCT00360399|Drug|Escitalopram|Escitalopram 10 to 20 mg per day for 12 weeks
1770071|NCT00360399|Drug|Duloxetine|Duloxetine 30 to 60 mg per day for 12 weeks
1770072|NCT00360399|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 16 one-hour sessions provided over 12 weeks.
1770073|NCT00360412|Drug|E2007|
1770074|NCT00360425|Drug|ferumoxytol|
1770075|NCT00360425|Drug|moxifloxacin|
1770076|NCT00360425|Drug|placebo|
1770077|NCT00360438|Drug|Rasburicase|0.15mg/kg intravenously over 30 minutes once per day for 5 consecutive days.
1770284|NCT00363714|Drug|AGN211745|200microgram single intravitreal injection
1770078|NCT00360451|Behavioral|Adolescent only Penn Resiliency Program (Adolescent PRP)|In adolescent PRP, students learn both cognitive skills (recognizing the link between beliefs and emotions, challenging negative beliefs with evidence, making accurate attributions for events, and accurately assessing the ramifications of negative events) and behavioral problem-solving skills (decision making, assertiveness and negotiation, social skills, and relaxation).
1770079|NCT00360451|Behavioral|Parent Penn Resiliency Program (Parent PRP)|Parent PRP teaches parents to model and reinforce the skills taught in the adolescent program.
1770080|NCT00360464|Drug|Azithromycin SR|
1770081|NCT00360477|Procedure|Floseal|Bioglue that seals the kidney
1770082|NCT00360477|Procedure|Cope Loop|Nephrostomy tube for fluid drainage from the kidney
1770083|NCT00360477|Procedure|Fascial Stitch|Stitch that closes the kidney
1770084|NCT00360490|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Initial release rate of 20µg Levonorgestrel IUS (Mirena, BAY86-5028) per day for 6 cycles.
1770085|NCT00360490|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate (MPA, Provera), oral, 10mg per tablet on 10 consecutive days of each cycle for 6 cycles.
1770086|NCT00360516|Behavioral|metabolic (nutrient controlled) diet|metabolic (nutrient controlled) diet
1770087|NCT00360529|Drug|flibanserin|flibanserin placebo versus 50 mg qhs versus 100 mg qhs
1770088|NCT00360555|Drug|flibanserin|flibanserin 25 mg b.i.d
1770089|NCT00360555|Drug|flibanserin 50mg|flibanserin 50mg qhs/b.i.d.
1770090|NCT00360555|Drug|flibanserin 100mg|flibanserin 50 mg b.i.d/100mg qhs
1770091|NCT00360555|Drug|placebo|placebo comparator
1770092|NCT00360568|Drug|Levodopa-carbidopa intestinal gel|Infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour).
1770093|NCT00360568|Device|CADD-Legacy® 1400 ambulatory infusion pump|
1770094|NCT00360568|Device|PEG tube|percutaneous endoscopic gastrostomy tube
1770095|NCT00360568|Device|J-tube|jejunal tube
1770096|NCT00360581|Behavioral|Yoga|
1770097|NCT00360581|Behavioral|Yoga and Cognitive Behavioral Therapy|
1770098|NCT00360594|Drug|Acamprosate|3 pills (666 mg) for 1998mg/day
1770099|NCT00360594|Drug|Placebo|3 pills (666mg) for 1998mg/day
1770100|NCT00360607|Drug|Magnex (Sulbactam Sodium/Cefoperazone Sodium 1:1) Pfizer Ltd.|
1770101|NCT00360607|Drug|Fortum (Ceftazidime for injection USP) Glaxo Smith Kline Pharmaceuticals Limited|
1770102|NCT00360607|Drug|Metrogyl (Metronidazole Injection IP) J.B.Chemicals & Pharmaceuticals Ltd.|
1770103|NCT00360607|Drug|Mikacin (Amikacin Sulphate Injection IP) Aristo Pharmaceuticals Ltd.|
1770104|NCT00360659|Device|Continuous Positive Airway Pressure|
1770105|NCT00360672|Drug|Revlimid|25 mg/day, orally for 21 days with 7 days rest (28 day cycle).
1770106|NCT00360685|Drug|Tac+MTX|Tacrolimus- 0.03mg/kg/24h IV beginning day-3 Methotrexate- 15mg/m2 IV day +1 then 10mg/m2 IV on days 3, 6, 11 post transplant.
1770107|NCT00360685|Drug|TAC + MMF|Tacrolimus- 0.03 mg/kg/24h as a continuous IV infusion, beginning day -3. Mycophenolate Mofetil- 30 mg/kg/day IV in 2 divided doses (q12 hours) beginning day 0 at least 2 hours after the end of the hematopoietic stem cell transplant
1770108|NCT00360698|Drug|Insulin Glargine|One daily injection at bedtime
1770109|NCT00360698|Drug|Glimepiride|At same dosage as during the run-in period
1770110|NCT00360698|Drug|Insulin Glulisine|One bolus given before the main meal
1770111|NCT00360698|Drug|Metformin|At same dosage as during the run-in period
1770112|NCT00360724|Drug|Duloxetine (Cymbalta)|duloxetine medication up to dose of 120 mg/day
1770113|NCT00360737|Biological|Botulinum Antitoxin Heptavalent (A B C D E F G) - (EQUINE)|Biological/Vaccine NP-018 Experimental with 8 Cohorts of 5 Subjects each evaluating 2 Dosage levels of 1 or 2 vials of NP-018 administered intravenously.
1770114|NCT00360750|Drug|carboplatin|
1770115|NCT00360750|Drug|cytarabine|
1770116|NCT00360750|Drug|etoposide|
1770117|NCT00360750|Drug|vincristine sulfate|
1770118|NCT00360750|Other|clinical observation|
1770119|NCT00360750|Procedure|adjuvant therapy|
1770120|NCT00360750|Radiation|radiation therapy|
1770121|NCT00360763|Drug|candesartan cilexetil|
1770122|NCT00360776|Drug|tipifarnib|Given orally
1770123|NCT00360776|Other|laboratory biomarker analysis|Correlative studies
1770124|NCT00360789|Behavioral|Conventional UK physical therapy|
1770125|NCT00360789|Behavioral|Increased intensity of UK conventional physical therapy (PT)|
1770126|NCT00360789|Behavioral|UK conventional PT plus functional strength training|
1770127|NCT00360802|Behavioral|Cognitive Behavioral Treatment|Behavioral treatment to reduce pain in chronic back pain patients
1770128|NCT00360802|Behavioral|Mindfulness Based Stress Reduction|Behavioral treatment to reduce pain in chronic back pain patients
1770129|NCT00360815|Behavioral|Insulin|
1770130|NCT00360828|Drug|Irinotecan Hydrochloride (HCI) Treatment|Irinotecan injections. Irinotecan hydrochloride [CPT-11; CAMPTOSAR] is an antineoplastic agent of the topoisomerase I inhibitor class. The drug is supplied in amber vials and appears as a pale yellow transparent aqueous solution. Two vial sizes are available: 2 mL vials containing 40 mg of drug and 5 mL vials containing 100 mg of drug. A treatment cycle was 21 days. Patients were treated for a minimum of 3 cycles (doses) of CPT-11 or until their disease progressed.
1770131|NCT00360828|Drug|Continued Irinotecan Hydrochloride (HCI) Treatment|For patients responding to treatment, therapy could have continued beyond 18 cycles.
1770132|NCT00360841|Procedure|Auricular acupuncture|Subjects will be randomized to one of these arms. The subjects in arm A and B will receive auricular acupuncture. Before subjects receive chemotherapy within one day, they will be treated by auricular acupuncture, sham acupuncture, or control group.
1770133|NCT00360841|Procedure|Sham auricular acupuncture|
1770134|NCT00360854|Drug|erlotinib hydrochloride|
1770135|NCT00360854|Genetic|mutation analysis|
1770136|NCT00360854|Genetic|polymorphism analysis|
1770137|NCT00360854|Other|laboratory biomarker analysis|
1770138|NCT00360854|Other|pharmacological study|
1770139|NCT00360854|Radiation|radiation therapy|
1770559|NCT00357292|Drug|Azithromycin (T1225)|
1770140|NCT00360867|Drug|AMG 706|The dose of AMG 706 will be administered at the same dose level and schedule received at the conclusion of the previous study but will be no greater than 125 mg QD or 75 mg BID.
1770141|NCT00360906|Drug|Triomar™ (omega-3 fatty acids)|
1770142|NCT00360919|Behavioral|cheese ingestion|"On study day 1, approximately half of the participants will consume a breakfast of fruits and vegetables, whereas the other half of participants will consume a meal consisting of 9 oz. of cheese.
Blood samples will be collected from participants immediately prior to consumption of the meals, and then again at regular intervals for up to 8 hours following the meals.
At least 3 days later, participants will return for study Day 2. The participants will receive the second meal. Blood samples will then be collected immediately prior to consumption of the test meal and for up to 8 hours after the meal."
1770143|NCT00360932|Device|SCULPTRA (poly-L-lactic acid injection)|Subjects will be treated with SCULPTRA® according to the investigator's judgment, and in accordance with the SCULPTRA® package insert. Details of the exact amount and the time of administration of SCULPTRA® (date, amount, location) will be documented in the CRF at each protocol and non-protocol visit.
1770144|NCT00360945|Drug|cisplatin|
1770145|NCT00360945|Drug|temozolomide|
1770146|NCT00360945|Genetic|fluorescence in situ hybridization|
1770147|NCT00360945|Genetic|loss of heterozygosity analysis|
1770148|NCT00360945|Other|immunohistochemistry staining method|
1770149|NCT00360945|Other|laboratory biomarker analysis|
1770150|NCT00360945|Radiation|radiation therapy|
1770151|NCT00360958|Procedure|ultrafiltration|
1770152|NCT00360971|Biological|palifermin|Four doses of palifermin, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
1770153|NCT00360971|Drug|cisplatin|Patients will receive cisplatin (100 mg/m2) administered intravenously on days 1, 22, and 43 of the treatment course.
1770154|NCT00360971|Other|placebo|Four doses of placebo, 180ųg/kg, administered as an i.v. bolus injection over 30-60 seconds. Starting on day -3 (Friday) prior to radiation therapy / chemotherapy and then once weekly, on days 5, 12, and 19.
1770155|NCT00360971|Procedure|neck dissection|A neck dissection is required for patients with persistent nodal disease, any stage, if a palpable abnormality or worrisome radiographic abnormality persists in the neck 8-9 weeks after completion of therapy. A neck dissection is optional for patients with multiple positive lymph nodes or with lymph nodes exceeding 3 cm in diameter at pre-treatment (N2a, N2b, N3) who achieve a complete clinical and radiographic response in the neck. All patients will be assessed at approximately 8 weeks post-treatment with CT scan or MRI by the same technique used at baseline.
1770156|NCT00360971|Radiation|radiation therapy|A radiation dose of 70 Gy with at least 66 Gy to at least 2 mucosal sites of the oral cavity/oropharynx mucosa. Radiation therapy can be given with 3D conformal (3D-CRT) or with intensity modulated RT (IMRT) techniques; however, the chosen modality must be used for the entire course of treatment.
1770157|NCT00360984|Drug|insulin glargine|
1770158|NCT00360984|Device|continuous subcutaneous insulin infusion|
1770159|NCT00360997|Behavioral|Conventional UK physical therapy (Con UK PT)|
1770160|NCT00360997|Behavioral|Con UK PT + 30 minutes/day Mobilisation & Tactile Stimulation (MTS)|
1770161|NCT00360997|Behavioral|Con UK PT + 60 minutes a day MTS|
1770162|NCT00360997|Behavioral|Con UK PT + 120 minutes a day MTS|
1770163|NCT00361010|Drug|Levetiracetam|
1770164|NCT00361023|Drug|losartan|
1770165|NCT00361036|Device|Uterine fibroid embolization BeadBlock™|Intervention with BeadBlock Microspehere
1770166|NCT00361036|Device|Uterine fibroid embolization Embosphere®|Embosphere - control arm
1770167|NCT00361049|Biological|graft versus host disease prophylaxis/therapy|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
1770168|NCT00361049|Genetic|fluorescence in situ hybridization|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
1770169|NCT00361049|Other|immunoenzyme technique|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
1770170|NCT00361049|Other|immunohistochemistry staining method|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
1770171|NCT00361049|Other|laboratory biomarker analysis|Tissue specimens are examined by CD45 immunohistochemistry and fluorescent in situ hybridization to detect hematopoietic and nonhematopoietic cells.
1770172|NCT00361049|Procedure|in vitro-treated bone marrow transplantation|Within 72 hours after the initiation of medical therapy (e.g., corticosteroids, cyclosporine) for graft-vs-host disease, patients undergo donor MSC infusion over 10-15 minutes.
1770173|NCT00361049|Procedure|management of therapy complications|Patients will be evaluated for clinical signs and symptoms of GVHD weekly for up to 28 days.
1770174|NCT00361062|Behavioral|comparative computer simulation|comparative computer simulation assessing the level of aggressiveness before and after the beginning of SSRI treatment.
1770175|NCT00361075|Drug|transdermal estradiol patch (Vivelle), oral estrogen (Estrace), progesterone (Prometrium)|
1770176|NCT00361088|Drug|PS-341|Phase I and II: 1.3mg/m2 iv days 1,4,8,11
1770177|NCT00361088|Drug|R11577|"Phase I: 100mg po BID days 1014 for Cohort 1, 200mg po BID days 1014 for Cohort 2, 300mg po BID days 1014 for Cohort 3.
Phase II: Maximum Tolerated Dose (MTD)"
1770178|NCT00361101|Drug|AMD11070|200 mg PO BID (by mouth two times per day) for 10 days.
1770179|NCT00361114|Drug|sulphadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
1770180|NCT00361114|Drug|Chlorproguanil/dapsone|Chlorproguanil/ dapsone (CD) given daily for 3 days per manufacturers recommendations (tablets chlorproguanil 15mg/ dapsone 18.75 mg; 5-7.9Kgs 1 tablet, 8-11.9 Kg 1 ½ tablets, 12-15.9 2 tablets, 16-20.9 Kgs 2 ½ tablets, 21- 40Kg 5 tablets).
1770285|NCT00363714|Drug|AGN211745|400microgram single intravitreal injection
1770286|NCT00363714|Drug|AGN211745|800microgram single intravitreal injection
1770181|NCT00361114|Drug|Sulfadoxine/pyrimethamine|Sulfadoxine/pyremethamine (SP) given as a single dose per manufacturers recommendation (tablets 500mg sulphadoxine and 15mg pyremethamine; child's body weight 5-10Kgs ½ tablet, 11-20Kgs 1 tablet, 21-30 Kgs 1 ½ tablets)
1770182|NCT00361127|Drug|isotonic saline infusion|
1770183|NCT00361140|Drug|Busulfan|"Bu IV (BusulfexR) over 3 hours on days -6, -5, -4, and -3. Day -6 and -5 doses for patients on Level 1 will be 170mg/m2. This dose is based on the dose used by DeLima (2004) adjusted proportionately to achieve an AUC of 6000uM-min. Subsequent daily doses for patients on Level 1 will be adjusted to achieve an average AUC of 6000uM-min.
Day -6 and -5 doses for patients on Level 2 will be based on the mean dose required on Level 1 to achieve target AUC then adjusted proportionally for new target AUC.
Subsequent daily doses will be adjusted to achieve target AUCs."
1770184|NCT00361140|Drug|Fludarabine|Fludarabine 40mg/m2 IV over 1 hour on days -6, -5, -4, and -3
1770185|NCT00361153|Drug|Colesevelam hydrochloride|Welchol tablet 625mg
1770186|NCT00361153|Drug|placebo|placebo
1770187|NCT00361166|Drug|ACP-103|
1770188|NCT00361192|Procedure|biopsy of temporal artery|
1770189|NCT00361205|Device|Electronic Monitoring cap|
1770190|NCT00361218|Drug|open-label selective serotonin reuptake inhibitor (SSRI)|Duration is 8 weeks. For escitalopram, starting dose is 10mg po qd,which can be increased up to 30mg po qd per clinical discretion. For citalopram, starting dose is 20mg po qd, which can be increased up to 60mg po qd per clinical discretion.
1770191|NCT00361231|Drug|Bevacizumab|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
1770192|NCT00361231|Drug|Gemcitabine|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
1770193|NCT00361231|Drug|Oxaliplatin|Given intravenously on days 1 and 15 of each 28-day cycle. Participants may continue to receive study treatment as lond as their disease does not progress and they do not experience any serious side effects.
1770194|NCT00361244|Drug|SU011248|Given orally in the morning for two weeks followed by a one week rest period (one cycle equals 21 days). Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
1770195|NCT00361244|Drug|Irinotecan|Given intravenously on days 1 and 8 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
1770196|NCT00361244|Drug|Cetuximab|Given intravenously on days 8 and 15 of each 21-day cycle. Participants may continue to receive study treatment as long as their disease does not progress and they do not experience any serious side effects.
1770197|NCT00361257|Drug|Minocycline|Tetracycline antibiotic, 100 mg taken orally every 12 hours
1770198|NCT00361257|Drug|Placebo (Tetracycline)|Tetracycline antibiotic placebo, orally every 12 hours
1770199|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
1770200|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
1770201|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
1770202|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
1770203|NCT00361270|Behavioral|Hyp-2 w recordings|2 weeks of 1-hour sessions of therapist-guided hypnosis + 6 weeks of daily home practice with hypnosis CDs
1770204|NCT00361270|Behavioral|Hyp-8|8 weekly 1-hour sessions of therapist-guided hypnosis
1770205|NCT00361270|Behavioral|Hyp-8 w recordings|8 weekly 1-hour sessions of therapist-guided hypnosis + daily home practice with hypnosis CDs
1770206|NCT00361270|Behavioral|BIO|8 weekly 1-hour sessions of EMG Biofeedback without hypnotic suggestion
1770207|NCT00361283|Drug|Atorvastatin|atorvastatin 80mg tablets given by mouth once daily for 16 weeks with follow-up visits every 4 weeks
1770208|NCT00361296|Biological|GM-K562 cell vaccine|
1770209|NCT00361309|Drug|SU011248|Patients will receive SU011248 37.5 mg/day for 4 weeks continuously followed by 2 weeks of rest per cycle (each cycle = 6 weeks).
1770210|NCT00361322|Drug|clindamycin phosphate|
1770211|NCT00361322|Drug|salicylic acid|
1770212|NCT00361335|Drug|Golimumab|2mg/kg or 4mg/kg will be administered as an IV infusion over 30 minutes
1770213|NCT00361335|Drug|Methotrexate|Active MTX capsules, filled with microcrystalline cellulose (Avicel PH 102) and a 2.5 mg MTX tablet, will be administered at the same dose as before the study entry.
1770214|NCT00361335|Drug|Placebo|Placebo solution will be administered through IV infusion in Group V and oral placebo capsules (sham MTX) filled with microcrystalline cellulose (Avicel PH 102) will be administered in Group II and IV.
1770215|NCT00361348|Drug|Palifermin|
1770216|NCT00361348|Drug|Heparin|
1770217|NCT00361361|Device|Excimer Laser Therapy|excimer laser is a UV 308nm laser. repeated sessions (10 sessions) needed. once per week.
1770218|NCT00361374|Dietary Supplement|eicosapentaenoic acid|1 gram/day
1770219|NCT00361374|Dietary Supplement|docosahexaenoic acid|1 gram/day
1770220|NCT00361374|Drug|Placebo|980 milligram/day
1770221|NCT00361387|Drug|d-methylphenidate|oral dosing for 8 weeks then cross over to placebo in random order
1770222|NCT00361413|Drug|Alefacept (AMEVIVE®)|Alefacept
1770223|NCT00361413|Drug|control group|these patients will receive the same treatment as group A, without alefacept
1770224|NCT00361426|Device|Earlysense vital sign monitor|The system is a contactless system that measures heart and respiratory rates and other parameters via a contactless sensor that is placed under the patient mattress
1770225|NCT00361439|Drug|Mometasone|2 puffs in each nostril once daily of nasal spray
1770226|NCT00361439|Drug|Placebo|2 puffs in each nostril once daily of nasal spray
1770227|NCT00361452|Drug|nebulized epinephrine and nebulized albuterol|
1770287|NCT00363714|Drug|AGN211745|1200microgram single intravitreal injection
1770288|NCT00363714|Drug|AGN211745|1600microgram single intravitreal injection
1770290|NCT00363740|Drug|GW685698X Aqueous Nasal Spray|
1770228|NCT00361465|Other|EMG and Kinematics recording|"The experimental protocol envisages the recording of the movement and the bilateral recording of activity EMG during three types of tasks:
discrete driving tasks: movements of inflection and extension of the wrist car-generated, or produced in answer to an imperative stimulus try driving repetitive: sequence of inflection-extension of the wrist unilateral, bilateral in phase and bilateral in opposition of phase.
try driving complexes: movement of inflection and extension of the wrist with concurrent realization of a driving task controlatérale different, or of a cognitive task.
For the Parkinsonian patients, these various tests will be carried out twice: without antiparkinsonian treatment (off) and under treatment (one)."
1770229|NCT00361478|Behavioral|Exercise and education|Weekly exercise and education program for 8 weeks
1770230|NCT00361478|Behavioral|Education|Written educational material
1770231|NCT00361491|Drug|SSR149415|
1770232|NCT00361504|Drug|Oxycodone CR|Oxycodone CR 10 mg oral tablet BID administered for first 3 days, 20 mg oral tablet BID administered for next 4 days, 20 to 50 mg oral tablet BID administered for the next 51 weeks.
1770233|NCT00361504|Drug|Tapentadol (CG5503) ER|Tapentadol (CG5503) ER 50 mg oral tablet BID administered for first 3 days, 100 mg oral tablet BID administered for next 4 days, 100 to 250 mg oral tablet BID administered for the next 51 weeks.
1770234|NCT00361517|Behavioral|Galactomannan antigen monitoring, Aspergillus PCR|There will be blood draws twice weekly for monitoring GM antigen and once a week for Aspergillus PCR.
1770235|NCT00361517|Other|blood draws|Blood is drawn for monitoring of Galactomannan antigen in the blood
1770236|NCT00361517|Other|blood draws for GM monitoring|blood samples will be taken twice weekly for monitoring of GM antigen levels in the blood and once a week for Aspergillus PCR.
1770237|NCT00361517|Drug|Amphotericin-B deoxycholate|1-1.5mg/kg, i.v, once a day
1770238|NCT00361517|Other|blood test|Blood will be tested twice a week for the presence of Galactomannan.
1770239|NCT00361517|Other|Blood test|Blood will be drawn twice a week and it will be tested for the presence of GM(a component of the cell wall of the mold Aspergillus which is released during growth)
1770240|NCT00361530|Drug|Statin|
1770241|NCT00361543|Drug|Raloxifene hydrochloride|120 mg per capsule (1 tablet daily)
1770242|NCT00361543|Other|Lactose Capsules|1 tablet daily for 12 weeks
1770243|NCT00361556|Behavioral|The Back Book|A book on how to prevent back pain
1770244|NCT00361556|Behavioral|The Back Guide|A guide for the prevention of back pain.
1770245|NCT00361556|Behavioral|General health book|A book on general health
1770246|NCT00363415|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
1770247|NCT00363415|Drug|etoposide|100 mg/m2, intravenous (IV), days 1-3 x 6 cycles
1770248|NCT00363415|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
1770249|NCT00363428|Behavioral|exercise intervention|life style
1770250|NCT00363428|Behavioral|smoking cessation intervention|Life style
1770251|NCT00363428|Other|counseling intervention|life style
1770252|NCT00363428|Other|educational intervention|life style
1770253|NCT00363428|Procedure|conventional surgery|life style
1770254|NCT00363428|Procedure|pulmonary complications management/prevention|life style
1770255|NCT00363441|Procedure|Intensity Modulated Radiotherapy|
1770256|NCT00363454|Drug|Triciribine Phosphate Monohydrate|8 Cycles @ 28 days. Level 1: 15 mg/m^2; Level 2: 25 mg/m^2; 35 mg/m^2; 45 mg/m^2.
1770257|NCT00363467|Drug|G-CSF|"Mobilization Option 1:Twenty-four to 48 hours following completion of consolidation chemotherapy, patients will begin to receive G-CSF at 10 mcg/kg twice daily subcutaneously.
Mobilization Option 2: If patients have recovered hematologically from consolidation chemotherapy, they may receive G-CSF at 10 mcg/kg twice daily subcutaneously."
1770258|NCT00363467|Drug|Leukapheresis|leukapheresis
1770259|NCT00363467|Drug|Busulfan|Busulfan IV daily x 4 days (transplantation days -5,-4,-3,-2). The day -5 and -4 dose will be 130mg/m2
1770260|NCT00363467|Procedure|Stem cell reinfusion|autologous stem cell transplant
1770262|NCT00363506|Behavioral|Serotona Plus and dietary behavior management|
1770263|NCT00363519|Drug|Placebo|Double-blind period (12 wk); placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
1770264|NCT00363519|Drug|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
1770265|NCT00363532|Drug|infusion of calcitonin gene related peptide (CGRP)|
1770266|NCT00363545|Biological|Lyophilized formulation of HRV vaccine|Lyophilized formulation of HRV vaccine
1770267|NCT00363545|Biological|Liquid formulation of HRV vaccine|Liquid formulation of HRV vaccine
1770268|NCT00363571|Drug|GTN, Diamox|
1770269|NCT00363584|Drug|capecitabine|
1770270|NCT00363584|Other|clinical observation|
1770271|NCT00363584|Procedure|adjuvant therapy|
1770272|NCT00363597|Device|in vitro and in vivo permeability testing|single oral dose, 2 mL/kg (maximum 100 mL) of Sugar Absorption Solution containing 5 gm lactulose, 2 gm mannitol and 40 gm sucrose dissolved in demineralized water.
1770273|NCT00363610|Drug|Oncaspar & Gemzar; advanced and/or solid tumors and lymphoma|
1770274|NCT00363623|Device|Silicone hydrogel contact lens|
1770275|NCT00363636|Drug|Galiximab in combination with rituximab|Galiximab (500mg/m2 IV) in combination with Rituximab (375 mg/m2 IV), weekly x 4
1770276|NCT00363636|Drug|Rituximab in combination with placebo|Rituximab (375 mg/m2 IV) in combination with placebo, weekly x 4
1770277|NCT00363649|Biological|GM-K562 cell vaccine|Given by injection
1770278|NCT00363649|Biological|recombinant interferon alfa|Given by injection
1770279|NCT00363649|Biological|sargramostim|Given by injection
1770280|NCT00363675|Behavioral|Functional hand tests|Chilren were tested after healed hand burns for functional ability.
1770281|NCT00363688|Drug|Penicillin test and challenge|
1770282|NCT00363701|Drug|esomeprazole|
1770291|NCT00363753|Drug|aspirin versus clopidogrel|
1770292|NCT00363766|Drug|LY573636|A loading dose to target 380 micrograms/ml Cmax followed by a lower chronic dose to maintain Cmax within this target range, IV, every 21 days until disease progression.
1770293|NCT00363779|Drug|Cyclosporine|An oral preparation given every 12 hours, 5-10 mg/kg/day in divided doses. Doses are adjusted to maintain a therapeutic level between 200-400 ng/ml. Levels will be checked twice weekly and once the patient has achieved steady state levels they shall be monitored once every 2 weeks. These therapeutic levels shall be maintained for 3 months.
1770294|NCT00363779|Genetic|Gene expression analysis|A permutation test will be performed to examine whether the overall expression profile changes due to treatment. This will be done by comparing the number of significant genes to the distribution of this number if in fact there is no difference between pre-treatment and post-treatment gene expression.
1770295|NCT00363779|Genetic|Microarray analysis|Gene expression profiling will be carried out on Affymetrix microarrays to compare pretreatment and posttreatment samples.
1770296|NCT00363779|Other|Laboratory biomarker analysis|Analysis of differential gene expression profiles in patients with LGL leukemia treated with cyclosporine.
1770297|NCT00363792|Drug|Glyceryl trinitrate, azetazolamide|
1770298|NCT00363805|Dietary Supplement|green tea|Given orally
1770299|NCT00363805|Drug|Polyphenon E|Given orally
1770300|NCT00363805|Other|placebo|Given orally
1770301|NCT00363831|Drug|Oxaliplatin|130mg/m² infusion day 1, repeat every 21 days
1770302|NCT00363844|Drug|Sitagliptin phosphate|50 mg QD or 100 mg QD for 12 months
1770303|NCT00363857|Drug|Ropinirole|
1770304|NCT00363870|Biological|Fluarix vaccine|
1770305|NCT00363883|Drug|vorinostat|Given orally
1770306|NCT00363883|Other|laboratory biomarker analysis|Correlative studies
1770307|NCT00363896|Drug|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation via the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
1770308|NCT00363896|Drug|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
1770309|NCT00363909|Drug|citalopram hydrobromide|
1770310|NCT00363909|Other|placebo|
1770311|NCT00363922|Behavioral|Rehabilitation in institution|Rehabilitation in institution for four weeks. Subjects follow standard rehabilitation in the center.
1770312|NCT00363922|Behavioral|Rehabilitation at home|Subjects get a written prescription of exercise training, diet, etc. to follow at home.
1770313|NCT00363922|Behavioral|Out-patient rehabilitation at the hospital|This intervention was removed. We never got time to randomize subjects into this category. We had planned to randomize patients from one hospital to either Rehabilitation in institution (rehab center) or rehabilitation at the hospital (out patient). And also patients from another hospital to either rehabilitation in institution (rehab centre) or rehabilitation at home. We have only managed to start the study in this second hospital so far (due to maternity leave and limited time to finish a PhD)
1770314|NCT00363935|Drug|Dexmedetomidine|
1770315|NCT00363948|Drug|Placebo|Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
1770316|NCT00363948|Drug|Sitagliptin phosphate|Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
1770317|NCT00363961|Behavioral|Resistance exercise|resistance exercise vs sham comparison
1770318|NCT00363974|Drug|XIAP antisense|2 days loading dose followed by weekly 2hr infusion
1770319|NCT00363987|Drug|Ketosteril®|1 tablet Ketosteril/5kgBW/d
1770320|NCT00363987|Other|diabetic diet|Energy 30-35 Kcal/kg BW/d + protein 0.8 g/kg BW/d
1770321|NCT00364000|Drug|Calcium acetate|Calcium acetate in 240 chronic HD patients
1770322|NCT00364000|Drug|Sevelamer|label sevelamer (RenagelR) 800 mg tablets
1770323|NCT00364013|Drug|Panitumumab|Panitumumab 6 mg/kg over on Day 1 of each 14-day cycle, just prior to the administration of chemotherapy.
1770324|NCT00364013|Drug|FOLFOX regimen|The FOLFOX regimen consisted of oxaliplatin 85 mg/m^2 intravenous (IV) infusion on Day 1, leucovorin, 200 mg/m^2 (racemate) on Days 1 and 2 and 5-fluorouracil 400 mg/m^2 IV bolus followed by 600 mg/m^2 IV infusion over 22 hours on Days 1 and 2. Each cycle was 14 days.
1770325|NCT00364026|Drug|darusentan|
1770326|NCT00364039|Drug|AV650|
1770327|NCT00364052|Drug|oral Valganciclovir vs oral Ganciclovir|
1770328|NCT00364065|Device|Ferris PainWrap|
1770329|NCT00364091|Drug|R89674 0.025% ophthalmic solution|
1956901|NCT02639637|Drug|Enalaprilat|Ninety minutes after the last dose of neuropeptide Y, enalaprilat will be infused through the intra-arterial line at 0.33 µg/min/100mL of forearm volume. After 30 minutes, a second infusion of neuropeptide Y will begin. Similar to the previous neuropeptide infusion, four doses of neuropeptide Y will be used (0.1, 0.3, 1.0, and 3.0 nmol/min) and each dose will be infused for 10 minutes.
1956902|NCT02639637|Drug|Valsartan 160mg|Valsartan 160 mg/d for 7 days prior to one of the study days.
1770334|NCT00364117|Behavioral|Timely Discharge (Remote Presence Technology)|
1770335|NCT00364130|Device|Low magnitude mechanical stimulus|10 minute daily treatment sessions standing on the low magnitude mechanical stimulus device
1770336|NCT00364130|Device|Placebo (inactive) low magnitude mechanical stimulus|10 minute daily treatments standing on a placebo version of a low magnitude mechanical stimulus device
1770337|NCT00364143|Drug|IHL-305 (irinotecan liposome injection)|
1770338|NCT00364156|Drug|Standard Patch Treatment|8-weeks of nicotine patch + 16-weeks of placebo
1770339|NCT00364156|Drug|24-weeks of nicotine patch|24-weeks of 21mg nicotine patch
1770340|NCT00364169|Procedure|Degree of constipation|
1770341|NCT00364182|Drug|Recombinant Coagulation Factor IX (BeneFIX)|100 IU/kg once weekly then crossover to 50 IU/kg twice weekly
1770342|NCT00364182|Drug|Recombinant Coagulation Factor IX (BeneFIX)|50 IU/kg twice weekly then crossover to 100 IU/kg once weekly
1770343|NCT00364195|Drug|Tesmilifene (YMB1002)|
1770344|NCT00364221|Drug|Rosiglitazone|
1770345|NCT00364234|Device|Low magnitude mechanical stimuli|20 minutes standing on low magnitude high frequency vibrating platform
1770348|NCT00364273|Drug|GSK159802|GSK159802 will be available with dosing strengths of 75 microgram per blister and 300 microgram per blister administered using DISKUS inhaler.
1770349|NCT00364273|Drug|Placebo|Subjects will receive placebo administered using DISKUS inhaler.
1770350|NCT00364273|Drug|Salmeterol|Salmeterol will be available with dosing strength of 50 micrograms per blister administered using DISKUS inhaler.
1770351|NCT00364286|Drug|Dasatinib (BMS-354825)|50mg Orally twice daily
1770352|NCT00364299|Device|Automatic control of tracheal tube cuff pressure|
1770353|NCT00364312|Behavioral|diet and physical activity|
1770354|NCT00364325|Other|Acute Decompensated Heart Failure|Standard of Care
1770355|NCT00364338|Behavioral|gourment cooking workshop|
1770356|NCT00364351|Drug|Vandetanib|once daily oral tablet
1770357|NCT00364351|Drug|Erlotinib|oral dose
1770358|NCT00364364|Drug|Radiolabeled humanized PAM4 IgG|
1770359|NCT00364377|Drug|Sitagliptin|100 mg once daily
1770360|NCT00364377|Other|Placebo|once daily for duration of the study
1770361|NCT00364390|Drug|Anginera, a human tissue replacement therapy|
1770362|NCT00364403|Behavioral|Low glycemic load|Provision of foods and dietary counseling to promote a low glycemic load diet
1770363|NCT00364403|Behavioral|Low fat diet|Provision of foods and dietary counseling to promote a low fat diet
1770364|NCT00364416|Other|Any treatment used to treat CHF|Clinical Outcomes of Chronic Decompensated Heart Failure patients
1770365|NCT00364429|Drug|[123]I-CNS 1261|Study Drug
1770366|NCT00364429|Drug|Lorazepam|Study Drug
1770367|NCT00364429|Drug|Risperidone|Study Drug
1770368|NCT00364442|Drug|fluticasone propionate/salmeterol|investigational drug
1770369|NCT00364455|Drug|Epoetin alfa|
1770370|NCT00364468|Drug|pegfilgrastim|
1770371|NCT00364481|Drug|omeprazole|
1770372|NCT00364481|Behavioral|Tongue exercises|
1770373|NCT00364494|Procedure|Different timing of red blood cells transfusion (substudy 1); Acute hemodilution versus no hemodilution (substudy 2)|Subgroup 1,with Ht<21% receive an hemotransfusion before or after CEC;subgroup 2,with Ht>25% bleed or not
1770374|NCT00364520|Other|Shanghai workers|
1770375|NCT00364533|Drug|Tapentadol IR (CG5503)|Fixed Dose 50, 75, & 100 mg BID for 3 days
1770376|NCT00364533|Drug|Placebo|Fixed Dose Matching placebo for 3 days
1770377|NCT00364533|Drug|Oxycodone HCL IR|Fixed Dose 10 mg BID for 3 days
1770378|NCT00364533|Drug|Tapentadol IR (CG5503)|Flexible Dose q4-6 hr Tapentadol IR 50 & 100 mg BID for 9 days
1770379|NCT00364546|Drug|CG 5503;tapentadol|
1770380|NCT00364559|Drug|Rosuvastatin|20 mg 10 days daily
1770381|NCT00364572|Drug|epidural injection of etanercept|2 injections of etanercept 2 weeks apart with doses ranging from 2 mg to 6 mg
1770382|NCT00364572|Drug|placebo (control procedure)|Two injections of epidural saline 2 weeks apart
1770383|NCT00364585|Device|GreenLight Model 120 Laser System|
1770384|NCT00364598|Drug|Anginera, a human tissue replacement therapy|
1770385|NCT00364611|Drug|Bevacizumab|"Bevacizumab (Avastin) 15 mg/kg will be administered prior to chemotherapy on
On Day 1 of the 1st cycle over 120 minutes
On Day 1 of the 2nd cycle over 90 minutes, if no reaction on the first dose
On Day 1 of 3rd cycle over 60 minutes, if no reaction on previous doses
On Day 1 of subsequent cycles over 30 minutes, if no reaction on previous doses"
1770386|NCT00364611|Drug|Docetaxel|Docetaxel 75 mg/m^2 IV infused over 60 minutes after completion of Bevacizumab infusion q3w
1770387|NCT00364611|Drug|Trastuzumab|"A loading dose of 8 mg/kg Trastuzumab (Herceptin) IV will be infused over 90 minutes on Day 2 of Cycle 1.
For all subsequent cycles 6 mg/kg trastuzumab will be administered on Day 1 one hour following completion of docetaxel infusion"
1770388|NCT00364637|Drug|Sevoflurane (Volatile Anesthetic)|
1770389|NCT00364637|Drug|Total intravenous anesthesia|
1770390|NCT00364650|Drug|Probiotic Supplement|2 capsules twice daily
1770391|NCT00364650|Other|Placebo|placebo
1770392|NCT00364676|Drug|VLI|Patients are dosed on Day 1 and Day 8 of a 21-day cycle.
1770393|NCT00364676|Drug|VLI|Patients are dosed on Day 1 of a 21-day cycle.
1770394|NCT00364689|Drug|Rifaximin alone, Rifaximin combined with Lactulose|
1770395|NCT00364702|Drug|methylphenidate|
1770396|NCT00364741|Drug|Oxygen|During and 2 hours after surgery
1770397|NCT00364754|Drug|Tesmilifene (YMB 1002)|
1770398|NCT00364767|Dietary Supplement|A|Alcohol consumption (32 g/day) for 4 weeks
1770399|NCT00364767|Dietary Supplement|B|Water
1770400|NCT00364780|Drug|XL647|XL647 will be administered orally as a single agent. XL647 will be supplied as 50 mg tablets. Subjects in the Intermittent 5 & 9 cohort will receive XL647 at a dose of 350 mg on a 5 days on and 9 days off cycle every 2 weeks for 8 weeks. Subjects in the Daily Dosing cohort will receive XL647 administered daily as a single oral dose of 300 mg. In the absence of progressive disease (PD) and unacceptable XL647-related toxicity, subjects may continue to receive XL647 treatment on their assigned dosing schedule for up to 1 year on this study. Subjects who reach 1 year of treatment with no evidence of disease progression may, with the concurrence of the investigator and the sponsor, continue to receive therapy.
1770401|NCT00364793|Drug|Efavirenz (EFV) + Didanosine (ddI) + Emtricitabine (FTC)|"Oral Solution, Capsules or Tablets, Oral, once daily
Efavirenz (EFV) per weight-based dosing nomogram (max 720 mg)
Didanosine (ddI) 240 mg/m2 (max 400 mg)
Emtricitabine (FTC) 6 mg/kg (max 200 mg)
Where EFV oral solution is commercially available: 48 weeks or until 3rd birthday (whichever is longer);
Where EFV oral solution NOT commercially available: until 7th birthday or until able to swallow EFV capsules (whichever occurs first)"
1770402|NCT00364806|Drug|Prochlorperazine|
1770403|NCT00364806|Drug|Metoclopramide|
1770404|NCT00364819|Drug|rituximab|rituximab 1000 mg IV day 1 and 15, given over 5 - 6 hours
1770405|NCT00364832|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
1770406|NCT00364845|Drug|Darbepoetin alfa|Starting dose was calculated at 0.75 micrograms per kilogram (μg/kg) body weight at randomization, rounded to nearest prefilled syringe dose unit. Dose was titrated incrementally. Monthly dose was initially double the every 2 week dose at time of conversion.
1770407|NCT00364845|Drug|Placebo|Prefilled syringe placebo, to match active arm
1770408|NCT00364858|Drug|Cerezyme|Cerezyme doses of 20-60U/kg every 2 weeks (Q2 Arm) or 40-120 U/kg every 4 weeks (Q4 Arm).
1770409|NCT00364871|Drug|naltrexone and bupropion SR|naltrexone 16, 32 or 48 mg/day and bupropion SR 400 mg/day
1770410|NCT00364884|Drug|ketoaminoacid|
1770413|NCT00364923|Drug|Pralatrexate Injection|Pralatrexate 30 mg/m2 via IV push over 3-5 minutes for 6 weeks in a 7 week cycle.
1770414|NCT00364936|Procedure|Palliative care service|
1770415|NCT00364975|Behavioral|gourmet cooking workshop|
1770416|NCT00364988|Drug|pioglitazone+losartan|Pioglitazone (30 mg/daily) losartan (100 mg daily)
1770417|NCT00364988|Drug|losartan|losartan (100 mg daily)
1770418|NCT00365001|Drug|tocilizumab [RoActemra/Actemra]|10mg/kg iv on day 8
1770419|NCT00365001|Drug|Methotrexate|10-25mg po/week
1770420|NCT00365001|Drug|Simvastatin|40mg po on days 1, 15 and 43
1770421|NCT00365027|Procedure|Delayed embryo transfer|
1770422|NCT00365040|Procedure|Prk with mitomycin vs Lasik|
1770423|NCT00365053|Drug|belinostat|Given IV
1770424|NCT00365053|Other|laboratory biomarker analysis|Correlative studies
1770425|NCT00365092|Procedure|Insertion of tympanostomy tubes|
1770426|NCT00365105|Dietary Supplement|Calcium|At least 500 mg of calcium (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
1770427|NCT00365105|Dietary Supplement|Vitamin D|400 IU of vitamin D (1 pill) by mouth daily until the study doctor thinks it is in their best interest to stop.
1770428|NCT00365105|Drug|zoledronic acid|4 mg of Zoledronic acid intravenously once a month until the study doctor thinks it is in their best interest to stop.
1770429|NCT00365105|Drug|Sm-153|Single dose intravenously 1 mCi/kg body weight.
1770430|NCT00365105|Radiation|Sr-89|Single dose intravenously 4 mCi.
1770431|NCT00365118|Device|Pulsed dye laser (Candela), Intense pulsed light (Palomar)|
1770432|NCT00365131|Drug|Cerezyme (imiglucerase for injection)|
1770433|NCT00365144|Biological|bevacizumab|
1770434|NCT00365144|Drug|erlotinib hydrochloride|
1770435|NCT00365144|Other|laboratory biomarker analysis|
1770439|NCT00365170|Drug|human insulin|
1770440|NCT00365170|Drug|insulin aspart|
1770441|NCT00365183|Drug|Motexafin gadolinium and pemetrexed|1 dose of MGd 15 mg/kg and pemetrexed 500 mg/m2 once during the first week of every 3-week treatment cycle for a maximum of 12 cycles
1770442|NCT00365196|Behavioral|CBT Hostility Reduction Program|
1770443|NCT00365209|Other|laboratory biomarker analysis|Correlative studies
1770444|NCT00365209|Other|pharmacological study|Correlative studies
1770445|NCT00365209|Drug|curcumin|Given orally
1770446|NCT00365222|Drug|Temozolomide|temozolomide 75 mg/m2 /d
1770447|NCT00365248|Drug|Fibrinogen human (TachoSil)|Resection of the liver with or without segmental liver transplantation
1770448|NCT00365261|Drug|Eszopiclone|eszopiclone 2 to 3 mg po at bedtime
1770449|NCT00365261|Drug|Placebo|placebo 2 to 3 mg po at bedtime
1770450|NCT00365274|Drug|Cyclophosphamide|Given IV 750 mg/m^2 day 1
1770451|NCT00365274|Drug|Doxorubicin hydrochloride|Given 50 mg/m^2 IV day 1
1770452|NCT00365274|Drug|vincristine sulfate|Given 1.4 mg/m^2 IV
1770453|NCT00365274|Drug|prednisone|100 mg orally daily days 1 - 5
1770454|NCT00365274|Drug|SGN-30|12 mg/kg weekly IV over 2 hours once weekly for 3 weeks.
1770455|NCT00365287|Drug|anti-thymocyte globulin|
1770456|NCT00365287|Drug|cyclophosphamide|
1770457|NCT00365287|Drug|cyclosporine|
1770458|NCT00365287|Drug|fludarabine phosphate|
1770459|NCT00365287|Drug|mycophenolate mofetil|
1770460|NCT00365287|Procedure|radiation therapy|
1770461|NCT00365287|Procedure|umbilical cord blood transplantation|
1770462|NCT00365300|Drug|pantoprazole|
1770463|NCT00365300|Drug|Placebo|
1770464|NCT00365313|Drug|celecoxib, esomeprazole|
1770465|NCT00365326|Procedure|catheter-based intracoronary injection|
1770466|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir|Cap/Cap/Tablet, Oral, 300/100/300 mg, QAM/QAM/QAM, 10 days.
1770467|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 coadmin, 7 days.
1770468|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/20 mg, QAM/QAM/QAM/Q12 2 hr post, 7 days.
1770469|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/QPM 12 hr post, 7 days.
1770470|NCT00365339|Drug|Atazanavir+Ritonavir+Tenofovir+Famotidine|Cap/Cap/Tablet/Tablet, Oral, 300/100/300/40 mg, QAM/QAM/QAM/Q12 2 hr post,7 days.
1770471|NCT00365352|Drug|XP13512 600MG|XP13512 600MG ONCE DAILY
1770472|NCT00365352|Drug|XP13512 1200MG|XP13512 1200MG ONCE DAILY
1770473|NCT00365352|Drug|PLACEBO|PLACEBO ONCE DAILY
1770474|NCT00365365|Drug|Doxorubicin and cyclophosphamide (AC) + bevacizumab|"For every 3-week cycle
bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by
doxorubicin 60 mg/m^2 IV push or infusion followed by cyclophosphamide 600 mg/m^2 IV push or infusion
Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
1770475|NCT00365365|Drug|Docetaxel (T) + bevacizumab|"For every 3-week cycle
bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by
docetaxel 100 mg/m^2 IV
Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy
Note: The starting dose of docetaxel was reduced to 75 mg/m^2 if toxicity occurred that met the criteria for doxorubicin dose reduction"
1770476|NCT00365365|Drug|Docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab|"For every 3-week cycle
bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by
doxorubicin 50 mg/m^2 IV push or infusion followed by cyclophosphamide 500 mg/m^2 IV push or infusion followed by docetaxel 75 mg/m^2
Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
1770477|NCT00365365|Drug|Docetaxel, carboplatin, trastuzumab (TCH) + bevacizumab|"For every 3-week cycle
bevacizumab 15 mg/kg infused intravenously (IV) on Day 1 followed by
docetaxel in 75 mg/m^2 IV followed by carboplatin AUC 6 mg/mL/min IV followed by
trastuzumab 6 mg/kg by IV infusion (For the first cycle 1 only a loading dose of trastuzumab 8 mg/kg IV was infused on Day 2)
Prophylactic G-CSF was administered within 24 hours following each cycle of chemotherapy but no greater than 72 hours after chemotherapy"
1770478|NCT00365365|Drug|Bevacizumab and trastuzumab maintenance therapy|"bevacizumab 15 mg/kg was infused IV followed by
trastuzumab 6 mg/kg IV
Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
1770479|NCT00365365|Drug|Bevacizumab maintenance therapy|"- bevacizumab 15 mg/kg was infused IV
Treatment was every 3 weeks for 52 weeks from the date of the first administration regardless of the number of doses received or missed."
1770480|NCT00365378|Biological|Comparator: HPV 16 L1 Vaccine|A 0.5 intramuscular injection given at Day 1, Month 2, and Month 6
1770481|NCT00365378|Biological|Comparator: Placebo|A 0.5 intramuscular placebo injection given at Day 1, Month 2, and Month 6
1770482|NCT00365391|Biological|bevacizumab|Given IV, 10 mg/kg, days 1 and 15 in every cycle
1770483|NCT00365391|Drug|erlotinib hydrochloride|Given orally, 150 mg, every day during each cycle.
1770484|NCT00365404|Behavioral|Diet and exercise promotion|
1770485|NCT00365417|Drug|Bevacizumab|15 mg/kg IV every 21 days x 4 cycles, then after clinical response assessment, 15 mg/kg IV every 21 days x 2 cycles, then following surgery, 15 mg/kg every 21 days x 10 cycles
1770486|NCT00365417|Drug|Doxorubicin|60 mg/m^2 IV every 21 days x 4 cycles
1770487|NCT00365417|Drug|Cyclophosphamide|600 mg/m^2 IV every 21 days x 4 cycles
1770488|NCT00365417|Drug|Capecitabine|Following clinical response assessment, 650 mg/m^2 twice a day (orally), days 1-14 every 21 days x 4 cycles
1770489|NCT00365417|Drug|Docetaxel|Following clinical response assessment, 75 mg/m^2 IV every 21 days x 4 cycles
1770490|NCT00365430|Behavioral|safety program|Education, patient involvement, tailored implementation and a computerized registration system
1770491|NCT00365443|Biological|V502|
1770492|NCT00365456|Drug|Parathyroid Hormone (PTH)|Self-administered (100 μg in a volume of 71.4 μL) daily as a subcutaneous injection in the abdomen using the Preotact pen.
1770493|NCT00365456|Drug|Risedronate|Orally once weekly as one 35 mg tablet.
1770494|NCT00365469|Dietary Supplement|Probiotic|Bifidobacterium longum [BL999] and Lactobacillus rhamnosus [LPR]
1770495|NCT00365469|Other|Placebo|Commercially available cow's milk based infant formula without probiotic supplementation
1770496|NCT00365495|Procedure|Physical training (aerobic training)|
1770497|NCT00365508|Drug|nicotine lozenge|nicotine lozenge
1770498|NCT00365508|Drug|nicotine patch|transdermal nicotine patch
1770499|NCT00365521|Procedure|Photodynamic Therapy|
1770500|NCT00365534|Procedure|MEI|
1770501|NCT00365547|Biological|bevacizumab|Will be given by intravenous (IV) infusion at the dose of 10 mg/kg on days 1 and 15 after topotecan administration until disease progression or for another reason.
1770502|NCT00365547|Drug|topotecan hydrochloride|Topotecan 4 mg/m^2 intravenously (IV) will be given as a 30-minute intravenous infusion on days 1, 8, and 15 with a rest on day 22. Treatment will be repeated every 28 days until disease progression or for another reason.
1770503|NCT00365560|Drug|tiotropium|
1770504|NCT00365560|Drug|placebo|
1770505|NCT00365586|Drug|Ketoprofen Topical Patch , 20%|
1770506|NCT00365599|Drug|suberoylanilide hydroxamic acid (SAHA, Vorinostat)|Vorinostat will be used to potentiate the effects of tamoxifen or overcome tamoxifen resistance. All patients will receive vorinostat at 400 mg by mouth (po) daily for 3 out of 4 weeks. Responses will be assessed after 2 cycles (8 weeks + 4 days).
1770507|NCT00365599|Drug|tamoxifen citrate (Tamoxifen)|Tamoxifen will be given once daily at 20 mg. Tamoxifen will be given continuously. Responses will be assessed after 2 cycles (8 weeks + 4 days).
1770508|NCT00365612|Drug|Efavirenz (EFV), Emtricitabine (FTC), Tenofovir DF (TDF)|
1770509|NCT00365638|Drug|simvastatin|
1770510|NCT00365651|Procedure|Youth Soccer|
1770511|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving Aspheric algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
1770512|NCT00365677|Device|The Bausch & Lomb Zyoptix Tissue Saving algorithm|Used with LASIK treatment for the correction of myopia and myopic astigmatism.
1770513|NCT00365690|Behavioral|Telephone-administered coping improvement therapy|Telephone-administered coping improvement therapy is aimed to improve coping in older adults living with HIV/AIDS. Participants will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. Cognitive behavioral principles will be used to evaluate stressor severity, develop problem- and emotion-focused coping skills, determine the relationship between coping strategies and stressor controllability, and optimize coping through use of social support resources. Between weekly sessions, participants will also work to improve coping abilities on their own.
1770514|NCT00365690|Behavioral|Telephone-administered supportive-expressive therapy|Telephone-administered supportive-expressive therapy is aimed to improve relationships with friends, family members, and health care providers. Participants in will partake in 12 weekly conference calls lasting approximately 90 minutes each. Six to eight participants and two group facilitators will be connected via telephone each week. Separate conference call groups will be conducted for men who have sex with men, heterosexual men, and women. The first 60 minutes of each session will focus on discussing topics believed to be of interest to older adults with HIV and providing up-to-date information related to living with HIV/AIDS. The last 30 minutes of each session will be devoted to discussing topics raised by the group.
1770560|NCT00357305|Drug|vorinostat|Given orally
1770561|NCT00357305|Drug|cytarabine|Given IV
1770562|NCT00357305|Drug|etoposide|Given IV
1770515|NCT00365690|Behavioral|Individual therapy|Participants will receive no active treatment, but will have access to community-based support services that are commonly available to people living with HIV/AIDS. Additionally, participants who experience pronounced periods of emotional crisis and request assistance will be provided with brief, individual, telephone-based therapy by study clinicians.
1770516|NCT00365703|Procedure|Feeding tube insertion|"Orogastric feeding tube
Nasogastric feeding tube"
1770517|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 20/40/40/20|20/40/40/20 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
1770518|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 40/40/40/40|40/40/40/40 formulation of quadrivalent human papillomavirus (HPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
1770519|NCT00365716|Biological|Quadrivalent HPV (Types 6,11,16,18) L1 VLP Vaccine 80/80/40/80|80/80/40/80 formulation of quadrivalent human papillomavirus (qHPV) (Types 6, 11, 16, 18) L1 Virus-Like Particle (VLP) vaccine at Day 1, Month 2, and Month 6.
1770520|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant)225|placebo containing 225 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
1770521|NCT00365716|Biological|Placebo (mcg) (Aluminum Adjuvant) 450|placebo containing 450 mcg of aluminum adjuvant per dose at Day 1, Month 2, and Month 6.
1770522|NCT00365729|Behavioral|Smear and biopsy testing for HPV-types and viral load|Smear and biopsy testing for HPV-types and viral load
1770523|NCT00365742|Drug|simvastatin|
1770524|NCT00365742|Drug|red yeast rice|
1770525|NCT00365742|Drug|pharmaceutical grade fish oil|
1770526|NCT00365742|Behavioral|therapeutic lifestyle changes|
1770527|NCT00365755|Drug|carboplatin|
1770528|NCT00365755|Drug|cisplatin|
1770529|NCT00365755|Drug|cyclophosphamide|
1770530|NCT00365755|Drug|etoposide|
1770531|NCT00365755|Drug|melphalan|
1770532|NCT00365755|Drug|vincristine sulfate|
1770533|NCT00365755|Procedure|autologous bone marrow transplantation|
1770534|NCT00365755|Procedure|conventional surgery|
1770535|NCT00365768|Drug|Glutamine|Administered orally twice daily for 21 days
1770536|NCT00365768|Other|Placebo|Administered orally twice daily for 21 days
1770537|NCT00365781|Drug|ISIS 113715|
1770539|NCT00365807|Behavioral|Positively Fit|12-week group intervention for children with obesity and their parents/caregivers
1770540|NCT00365807|Other|Brief Family Intervention (Primarily education)|3 hours of contact with registered dietician for education and nutritional counseling.
1770541|NCT00365820|Drug|Tegaserod|
1770542|NCT00365846|Drug|Campath-1H|
1770543|NCT00365859|Drug|Aripiprazole|Tablets, Oral, 2, 5, 10, or 15 mg, once daily, 52 weeks
1770544|NCT00365872|Biological|Dendritic Cell (DC) Injections|"DCs (10^7 cells) were injected intratumorally three times on the second, third, and fourth Friday during the course of radiation.
One additional DC injection was given before surgery to assess DC migration
Patients were assigned to one of three cohorts:
Group 1 - DC injection # 4 given 24 hours prior to surgery Group 2 - DC injection # 4 given 48 hours prior to surgery Group 3 - DC injection # 4 given 72 hours prior to surgery"
1770545|NCT00365872|Procedure|Radiation therapy|Radiation was delivered 5 days per week (Monday-Friday).
1770546|NCT00365872|Procedure|Complete Resection - Surgery for tumor removal|Tumors were surgically resected 3-6 weeks after the completion of EBRT.
1770547|NCT00365885|Other|Computer-based clinical decision support.|computer decision support system that generates notifications about sentinel health events and communicates this information via electronic mail to care managers, feedback reports to clinical managers, and letters to patients
1770548|NCT00365898|Drug|Hydromorphone Hydrochloride Extended-Release|
1770549|NCT00365911|Procedure|Taking blood sample|A blood sample will be taken.
1770550|NCT00365924|Drug|Forteo|Open label single arm study with Forteo as an intervention
1770551|NCT00365937|Biological|Immunological peptides and immunological adjuvants|
1770552|NCT00365937|Biological|HLA-A2 peptides|Tyrosinase.A2: lyophilized powder, 326 mcg, 5 injections every 3 weeks MAGE-C2.A2: lyophilized powder, 320 mcg, 5 injections every 3 weeks NY-ESO-1b.A2: lyophilized powder, 290 mcg, 5 injections every 3 weeks MAGE-4.A2: lyophilized powder, 299 mcg, 5 injections every 3 weeks MAGE-3.A2: lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-1.A2: lyophilized powder, 298 mcg, 5 injections every 3 weeks NA17.A2 (GnTV): lyophilized powder, 300 mcg, 5 injections every 3 weeks MAGE-10.A2: lyophilized powder, 309 mcg, 5 injections every 3 weeks
1770553|NCT00365937|Biological|Montanide ISA51|Oil emulsion (W/O: droplet test S57 IN 001), conductivity less than 10mcs.cm-1, viscosity: 1500 mPas (brookfield DVI - spindle 2- Speed 30). For human applications. Injected 5 times every 3 weeks.
1770554|NCT00365937|Biological|IMP321|"Official name of the LAG-3 molecule is CD223. Chemical structure: hLAG-3Ig is a soluble human recombinant LAG-3 protein comprising the extra-cellular Ig-like domains.
The IMP321 drug product is composed of a soluble recombinant protein at a 1.18 mg/ml concentration, in PBS (Na2HPO4 2H2O 8.1mM, KH2PO4 1.47mM, NaCl 137mM, KCl 2.68mM, PH 7.2). Batch number: S017/LC1/041011.IMP321 will be provided in 250mcl aliquots in brosilicate siliconized vials."
1770555|NCT00357253|Drug|capecitabine|This is a dose escalation study. 375, 500, 650, or 850 mg/m2 capecitabine RDT is given orally daily in two divided doses approximately 12 hours apart beginning at the start of radiation therapy and continuing for 9 weeks. After a two week break, patients receive twice daily oral capecitabine, either 900 mg/m2 or 1250 mg/m2, approximately 12 hours apart for 14 days followed by a 7-day rest period for a total of 3 courses.
1770556|NCT00357253|Radiation|radiation therapy|Participants receive local radiation once daily, 5 days/week for 9 weeks for a total dose of 5580 cGy.
1770557|NCT00357279|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution, three times daily for six months during the double-blind portion of the study. Subsequently, denufosol 60 mg is administered for an additional six months during the open label safety extension.
1770558|NCT00357279|Drug|Placebo - 0.9% w/v sodium chloride solution|4.2 mL of solution, allowing delivery of approximately 4 mL into the nebulizer cup for nebulization, three times daily for six months.
1770563|NCT00357305|Other|pharmacological study|Correlative studies
1770564|NCT00357305|Other|laboratory biomarker analysis|Correlative studies
1770565|NCT00357318|Drug|sunitinib malate|Given PO
1770566|NCT00357318|Biological|bevacizumab|Given IV
1770567|NCT00357318|Other|pharmacological study|Correlative studies
1770568|NCT00357318|Other|laboratory biomarker analysis|Correlative studies
1770569|NCT00357331|Drug|potassium citrate|20 meq by mouth in capsule form twice daily
1770570|NCT00357357|Drug|HF0220|comparison of different dosages of drug
1770571|NCT00357370|Drug|Dapagliflozin|Tablets, Oral, once daily, up to 12 weeks
1770572|NCT00357370|Drug|Placebo|Tablets, Oral, 0 mg, once daily, up to 12 weeks
1770573|NCT00357383|Drug|Azithromycin (T1225)|
1770574|NCT00357396|Biological|graft versus host disease prophylaxis/therapy|
1770575|NCT00357396|Drug|busulfan|
1770576|NCT00357396|Drug|melphalan|
1770577|NCT00357396|Drug|thiotepa|
1770578|NCT00357396|Procedure|allogeneic bone marrow transplantation|
1770579|NCT00357396|Procedure|allogeneic hematopoietic stem cell transplantation|
1770580|NCT00357396|Procedure|peripheral blood stem cell transplantation|
1770581|NCT00357422|Procedure|Operation|No drug needed
1770582|NCT00357422|Procedure|Percutaneous ethanol injection therapy|99% ethanol, 2-4cc per one session, two to three sessions per single procedure for one week
1770583|NCT00357448|Biological|denileukin diftitox|Given IP at 3 dose levels: 5mcg/kg of ONTAK, 15mcg/kg of ONTAK, or 25mcg/kg of ONTAK
1770584|NCT00357448|Procedure|intraperitoneal administration|After completion of I.P. normal saline infusion, the I.P. catheter will be capped and patients will be turned/rotated for 1 hour to help facilitate I.P. bathing w/ONTAK; patients will be turned/rotated every 15 minutes in 4 different positions for a total of 1 hour
1770585|NCT00357448|Other|laboratory biomarker analysis|Correlative studies
1770586|NCT00357448|Other|enzyme-linked immunosorbent assay|Correlative studies
1770587|NCT00357448|Other|flow cytometry|Correlative studies
1770588|NCT00357461|Biological|gp100:209-217(210M) peptide vaccine|
1770589|NCT00357461|Biological|gp100:280-288(288V) peptide vaccine|
1770590|NCT00357461|Biological|incomplete Freund's adjuvant|
1770591|NCT00357461|Biological|ipilimumab|
1770592|NCT00357474|Procedure|Transarterial chemoembolization|lipiodol, adriamycin and/or mitomycin
1770593|NCT00357474|Procedure|Percutaneous ethanol injection therapy|99% ethanol 2-4cc per one session, two to three sessions per single procedure for one week
1770594|NCT00357487|Device|peroperative scintillating probe|
1770595|NCT00357487|Device|operative gamma camera|
1770596|NCT00357500|Drug|celecoxib|
1770597|NCT00357500|Drug|cyclophosphamide|
1770598|NCT00357500|Drug|etoposide|
1770599|NCT00357500|Drug|fenofibrate|
1770600|NCT00357500|Drug|thalidomide|
1770601|NCT00357526|Drug|OCPs|
1770602|NCT00357526|Device|vaginal ring|
1770603|NCT00357539|Drug|Azithromycin (T1225)|
1770604|NCT00357552|Drug|Emtricitabine/Tenofovir disoproxil fumarate|Once daily
1770605|NCT00357552|Drug|Lopinavir/Ritonavir|Twice daily
1770606|NCT00357565|Biological|filgrastim|All patients will receive G-CSF 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight IV beginning on day +1 after umbilical cord blood (UCB) infusion. G-CSF will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
1770607|NCT00357565|Drug|busulfan|Administered 1.1 mg/kg if <12 kg intravenous (IV) every 6 hours (0.8 mg/kg if >12 kg IV every 6 hours on Days -8 through -5.
1770608|NCT00357565|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -3 maintaining a level of >200 ng/mL. For children < 40 kg the initial dose will be 2.5 mg/kg intravenous (IV) over 2 hours every 8 hours.
1770609|NCT00357565|Drug|fludarabine phosphate|Administered 25 mg/m^2 intravenous (IV) over 60 minutes on Days -4 through -2.
1770610|NCT00357565|Drug|melphalan|Administered 60 mg/m^2 intravenous (IV) over 30 minutes on Days -4 through -2.
1770611|NCT00357565|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3. Patients <45 kilograms will receive MMF at the dose of 15 mg/kg/dose every 8 hours (max dose 1gm/dose) orally or intravenously (PO or IV).
1770612|NCT00357565|Procedure|umbilical cord blood transplantation|The product is infused via IV drip directly into the central line without a needle, pump or filter on Day 0.
1770613|NCT00357591|Device|Continuous Aortic Flow Augmentation|1.0-1.5 lpm augmented blood flow
1770614|NCT00357604|Drug|Ortho Tri-Cyclen (ethinyl estradiol + norgestimate)|Tablets, Oral, 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 28 days.
1770615|NCT00357604|Drug|Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days|Tablets + Capsules/Capsules, Oral, (25 mcg of EE + 0.18/0.215/0.25 mg of NGM) + 300/100 mg then 35 mcg of EE + 0.18/0.215/0.25 mg of NGM, once daily, 21 days.
1770616|NCT00357617|Drug|celecoxib|
1770617|NCT00357617|Genetic|microarray analysis|
1770618|NCT00357617|Genetic|protein expression analysis|
1770619|NCT00357617|Other|immunoenzyme technique|
1770620|NCT00357617|Other|immunohistochemistry staining method|
1770621|NCT00357617|Other|laboratory biomarker analysis|
1770622|NCT00357617|Procedure|biopsy|
1770623|NCT00357617|Procedure|conventional surgery|
1770624|NCT00357617|Procedure|neoadjuvant therapy|
1770625|NCT00357630|Drug|gemcitabine hydrochloride|
1770626|NCT00357630|Procedure|quality-of-life assessment|
1770627|NCT00357643|Drug|Calcium 500 mg/day and vitamin D 700 IU/day|
1770684|NCT00358033|Behavioral|Counseling|
1770685|NCT00358033|Behavioral|Interactive Education|
1770686|NCT00358033|Behavioral|Group Support|
1770687|NCT00358033|Procedure|Pharmacologic case management|Provided by clinical pharmacists
1770688|NCT00358046|Drug|ILY101|
1770689|NCT00358059|Behavioral|Behavioral Family Systems Therapy for Diabetes|
1770630|NCT00357669|Drug|Brivaracetam 25 mg|"Active Substance: Brivaracetam
Pharmaceutical Form: Tablet
Concentration: 25 mg
Route of Administration: Oral use"
1770631|NCT00357669|Drug|Brivaracetam 50 mg|"Active Substance: Brivaracetam
Pharmaceutical Form: Tablet
Concentration: 50 mg
Route of Administration: Oral use"
1770632|NCT00357669|Other|Placebo|"Active Substance: Placebo Pharmaceutical Form: Tablet
Concentration: 25 mg and 50 mg
Route of Administration: Oral use"
1770633|NCT00357682|Drug|Esomeprazole|20mg per day
1770634|NCT00357682|Drug|Esomeprazole|80mg per day
1770635|NCT00357682|Drug|Aspirin|300mg per day
1770636|NCT00357708|Drug|decitabine|Given IV
1770637|NCT00357708|Drug|vorinostat|Given orally
1770638|NCT00357708|Other|laboratory biomarker analysis|Correlative studies
1770639|NCT00357708|Other|pharmacological study|Correlative studies
1770640|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 200 mg, twice daily, 7 days.
1770641|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 300 mg, twice daily, 8 days.
1770642|NCT00357721|Drug|Atazanavir Sulphate|Capsules, Oral, 400 mg, twice daily, 9 days.
1770643|NCT00357734|Drug|Gefitinib|ZD1839 at a daily dose of 250 mg or 500 mg depending on final dose in parent trial
1770644|NCT00357747|Drug|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
1770645|NCT00357747|Drug|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
1770646|NCT00357760|Biological|VEGF Trap|Given IV
1770647|NCT00357773|Drug|Azithromycin (T1225)|
1770648|NCT00357786|Drug|Replagal agalsidase alfa|
1770649|NCT00357786|Drug|Replagal|
1770650|NCT00357799|Device|VeinViewer|Using the VeinViewer, IV attempts will be made
1770651|NCT00357825|Drug|[S,S]-Reboxetine|
1770652|NCT00357851|Drug|Aprotinin|
1770653|NCT00357864|Drug|carbachol|
1770654|NCT00357877|Drug|10% w/v chlorhexidine acetate coating FDA IND #45466|Dental coating topically applied by dental professional supragingivally to the full dentition
1770655|NCT00357877|Other|Placebo|
1770656|NCT00357890|Device|Pump therapy (CSII)|CSII initiated within 1 month of dx
1770657|NCT00357890|Drug|Multiple daily injections (MDI) using insulin glargine + rapid acting analog|MDI as control
1770658|NCT00357903|Biological|Etanercept|Adult Rheumatoid Arthritis (RA) patients on etanercept (TNFR:Fc) with well controlled arthritic symptoms will continue on the etanercept (TNFR:Fc) dose administered in their original protocol of enrollment. All other adults will receive 50 mg per week as two 25 mg subcutaneous (SC) injections at separate sites, either on the same day or 3 or 4 days apart. Pediatric patients ages 4 to 17 years will receive a 0.8 mg/kg per week dose (up to a maximum of 50 mg per week).
1770659|NCT00357916|Drug|PEP005 Topical Gel (0.01% concentration)|
1770661|NCT00357942|Drug|morphine solution for injection|morphine solution for injection 2 mg/ml, 50 microg/kg bodyweight, every 3 hour for 24 hours and placebo mouthwash
1770662|NCT00357942|Drug|Placebo|Placebo mouthwash
1770663|NCT00357942|Drug|morphine mouthwash|morphine mouthwash 2 mg/ml, 50 microg/kg bodyweight every 3 hour for 24 hours and placebo solution for injection
1770664|NCT00357942|Drug|Placebo|Placebo solution for injection every 3 hour for 24 hours
1770665|NCT00357955|Behavioral|Behavioral counseling and peer support|Multidisciplinary education and diabetes intervention for cardiac risk reduction - pharmacist led group intervention
1770666|NCT00357955|Behavioral|Interactive Education|interactive lectures with hands-on learning
1770667|NCT00357955|Behavioral|Role modeling|learning from peers with similar disease and problems
1770668|NCT00357955|Procedure|Pharmacologic case management|provided by clinical pharmacists following pre-established algorithms
1770669|NCT00357968|Drug|Prasugrel|Administered orally
1770670|NCT00357968|Drug|Clopidogrel|Administered orally
1770671|NCT00357968|Drug|Placebo for Prasugrel|Administered orally
1770672|NCT00357968|Drug|Placebo for Clopidogrel|Administered orally
1770673|NCT00357981|Drug|ORTHO EVRA, the contraceptive patch|
1770674|NCT00357994|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa per/hour)
1770675|NCT00357994|Drug|Placebo gel|
1770676|NCT00357994|Drug|Levodopa carbidopa (LC) oral encapsulated immediate release (IR) tablets|
1770677|NCT00357994|Drug|Placebo (PBO) oral capsules|
1770678|NCT00357994|Device|CADD-Legacy® 1400 ambulatory infusion pump|
1770679|NCT00357994|Device|PEG tube|percutaneous endoscopic gastrostomy tube
1770680|NCT00357994|Device|J-tube|jejunal tube
1770681|NCT00358007|Device|PTV Reduction|The margin around the area to be treated with radiation is decreased due the image guidance of the cone beam CT
1770682|NCT00358020|Drug|THALIDOMIDE|
1770683|NCT00358020|Drug|BORTEZOMIB|
1770690|NCT00358072|Behavioral|Postremission consolidation based on MRD status|Application of combination chemotherapy aimed to reduce MRD burden in unselected patients, followed by MRD-adjusted therapy that range from maintenance chemotherapy (MRD-negative patients) to allogeneic SCT (MRD-positive patients) or high-dose therapy with autologous blood stem cell support (MRD-positive patients without compatible donor for allogeneic SCT)
1770691|NCT00358085|Procedure|Endovascular Repair of Abdominal Aortic Aneurysm|
1770692|NCT00358085|Procedure|Conventional open repair of Abdominal Aortic Aneurysm|
1770693|NCT00358111|Device|Luma Cervical Imaging System|Colposcopy using LUMA Cervical Imaging System
1770694|NCT00358124|Drug|insulin glargine|
1770695|NCT00358124|Drug|rosiglitazone|
1770696|NCT00358124|Drug|metformin|
1770697|NCT00358137|Behavioral|Aerobic Conditioning Program|
1770698|NCT00358137|Behavioral|Strength Training Program|
1770699|NCT00358150|Drug|Eliglustat tartrate|Eliglustat (Genz-112638) capsule as single 50 mg dose on Day 1 then eliglustat 50 mg twice daily (BID) from Day 2 to Day 19, then either eliglustat 50 mg BID (if Genz-99067[active moiety of eliglustat in plasma] trough plasma concentration was greater than or equal to [>=]5 nanogram per milliliter [ng/mL] on Day 10) or eliglustat 100 mg BID(if Genz-99067 trough plasma concentration was less than [<] 5 ng/mL), from day 20 to Year 4. After primary completion date (Week 52) participants underwent treatment interruption period of approximately 2 weeks before continuing same treatment through study completion (Year 9). Participant receiving 100 mg BID could be considered for further dose increase to 150 mg BID at Week 24 if they met certain criteria (for example, had been on treatment for at least 24 months, had not reached therapeutic goals established for participants receiving Cerezyme, and if all other causes for lack of treatment effect had been evaluated and ruled out).
1770700|NCT00358163|Drug|PTK787/ZK 222584|Taken in tablet form daily
1770701|NCT00358163|Drug|paclitaxel|Given as a 3-hour infusion once every 21 days
1770702|NCT00358176|Drug|Risedronate (HMR4003)|
1770703|NCT00358189|Device|Deep Brain Stimulation|
1770704|NCT00358202|Drug|cefepime|cefepime hydrochloride 1gm IM q24h
1770705|NCT00358202|Drug|ceftriaxone|ceftriaxone 1 gm IM q24h
1770706|NCT00358215|Drug|Darbepoetin alfa|Administered by subcutaneous injection
1770707|NCT00358215|Drug|Placebo|Placebo subcutaneous injection
1770708|NCT00358228|Drug|Rimonabant|
1770709|NCT00358241|Procedure|Nerve block|
1770710|NCT00358267|Procedure|Partial Resection of Inferior Turbinates (PRIT)|PRIT involves surgically removing a small piece off the turbinate, which also reduces its size.
1770711|NCT00358267|Procedure|Radiofrequency Ablation (RFA)|RFA involves inserting a special needle into the inferior (lower) turbinate that releases high frequency energy, which produces heat. The energy and heat cause tissue denaturation (protein damage) and vaporization. The vaporization reduces tissue volume, and denaturation causes healing with scar tissue formation and contraction of surrounding tissue. This procedure can be done under local anesthesia at the doctor's office.
1770712|NCT00358280|Drug|Ropivacaine|
1770713|NCT00358280|Drug|Bupivacaine|
1770714|NCT00358293|Drug|Tizanidine (sublingual or oral)|
1770715|NCT00358319|Drug|Karenitecin|
1770716|NCT00358319|Drug|Valproic Acid|
1770717|NCT00358332|Biological|FMP2.1/AS02A|FMP2.1 will be reconstituted in AS02A adjuvant. Dosages: 10, 25, or 50 mcg of FMP2.1 or 0.1, 0.25 or 0.5 mL of FMP2.1/AS02A administered by intramuscular injection.
1770718|NCT00358332|Biological|Rabies vaccine (RabAvert)|RabAvert, white, freeze-dried vaccine for reconstitution with diluent. Dosage: 1.0 mL of rabies vaccine.
1770719|NCT00358358|Drug|Fluticasone Propionate/Salmeterol 500/50mcg combination|
1770720|NCT00358358|Drug|Fluticasone Propionate 500mcg|
1770721|NCT00358358|Drug|Salmeterol 50mcg|
1770722|NCT00358371|Drug|flucloxacillin 250 mg|Subjects will be randomized to receive single oral dose of 250 mg flucloxacillin capsule and 250 mg Intravenous dose
1770723|NCT00358371|Drug|flucloxacillin 500 mg|Subjects will be randomized to receive single oral dose of 500 mg flucloxacillin capsule and 500 mg Intravenous dose
1770724|NCT00358384|Drug|pazopanib (GW786034)|
1770725|NCT00358397|Drug|Clostridium novyi-NT spores|TBD
1770726|NCT00358410|Drug|GW679769 oral tablets|2x GW679769 60mg tablets
1770727|NCT00358410|Drug|Placebo|Placebo oral tablets to match experimental intervention
1770728|NCT00358423|Drug|Pegaptanib Sodium|0.3 mg/0.1 ml intravitreal injection, every 6 weeks, up to a total of 3 injections
1770729|NCT00358423|Drug|Control|Sham injections, every 6 weeks, up to a total of 3 sham injections
1770730|NCT00358436|Drug|Aclidinium bromide|Aclidinium bromide 200 μg once-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning for 52 weeks
1770731|NCT00358436|Drug|Placebo|Placebo once-daily via inhalation: 1 puff in the morning for 52 weeks
1770732|NCT00358449|Drug|mepolizumab|Participants received mepolizumab 0.55 milligrams (mg)/kilogram (kg), 2.5 mg/kg , or 10 mg/kg by intravenous (IV) infusion for 30 minutes on Day 1, Week 4 and Week 8.
1770733|NCT00358462|Drug|Azithromycin|two 500mg tablets or four 250mg tablets administered as a single dose
1770734|NCT00358462|Drug|Doxycycline|one 100mg capsule administered twice daily for seven days
1770735|NCT00358475|Drug|GW685698|
1770740|NCT00358501|Drug|Defibrotide|Defibrotide 6.25 mg/kg i.v. administered four times a day via 2 hour continuous infusion. Minimum duration 21 days.
1770741|NCT00358514|Device|Continuous Compartment Pressure Monitoring|See Detailed Description.
1770742|NCT00358527|Drug|Mometasone Furoate Nasal Spray (MFNS)|MFNS 50 mcg/spray: self-administered, two sprays per nostril (ie, 200 mcg QD), once daily (each morning), for 28 days.
1770743|NCT00358527|Other|Placebo|Matching placebo nasal spray: 2 sprays per nostril once daily for 28 days
1770744|NCT00358540|Drug|eltrombopag|Dosing of sarcoma subjects with eltrombopag after treatment with Adriamycin and Ifosfamide.
1770745|NCT00358553|Drug|Insulin|
1770967|NCT00373100|Drug|Placebo|Placebo
1770746|NCT00358566|Biological|GV1001|0.56mg GV1001 day 1, 3, 5, 8, 15, 22, week 6 and every 4 weeks thereafter. When gemcitabine is add it is given in cycles of once a week for 3 weeks and 1 week. Gemcitabine is dosed as per the SmPC.
1770747|NCT00358566|Drug|Gemcitabine (Chemotherapy)|Gemcitabine is given as per the Burris regime and the SmPC, i.e. 7 weeks, followed by cycles of 1 weeks rest and 3 weeks chemotherapy.
1770748|NCT00358579|Drug|Adrenaline|1 mg
1770749|NCT00358579|Drug|Vasopressin|40 IU
1770750|NCT00358592|Device|Mobius™ retractor|
1770751|NCT00358592|Device|traditional metal retraction instruments|
1770752|NCT00358605|Device|The Klearway™ oral appliance|See Detailed Description.
1770753|NCT00358618|Drug|Propofol|See Detailed Description.
1770754|NCT00358631|Drug|SSR149415|
1770755|NCT00365950|Drug|Duration of anticoagulation|
1770756|NCT00365950|Drug|Warfarin duration|
1770757|NCT00365963|Device|Comprehensive Health Enhancement Support System|computer based support and education
1770758|NCT00365976|Drug|Eszopiclone|Eszopiclone 3 mg po nightly for duration of study blind phase.
1770759|NCT00365976|Drug|Placebo|Placebo nightly over duration of double blind study phase
1770760|NCT00365989|Device|ExAblate 2000|
1770761|NCT00366002|Drug|Darifenacin|Darifenacin 7,5 mg tablets once daily with the possibility to up-titrate to 15 mg once daily
1770762|NCT00366015|Procedure|Robotic-assisted Coronary Surgical Revascularization|Robotic assistance of coronary artery bypass grafting using the DaVinci surgical robotic console
1770763|NCT00366015|Procedure|PCI- Drug Eluting Stents|Drug eluting stents performed by cardiologist within the same operating theatre following robotic assisted coronary artery bypass surgery
1770764|NCT00366028|Behavioral|Organization Model|The organizational model contains three components: leadership support, a multidisciplinary redesign team, and management structures and processes to link the two.
1770765|NCT00366028|Behavioral|Data Feedback Model|The research team will periodically interview the facilities and provide them with reported hand hygiene data.
1770766|NCT00366041|Drug|Dermal substrate cellularised LG002 (10x10cm)|application depending on burn injury surface
1770767|NCT00366041|Device|Dermal substrate uncellularised LG002 (10x10 cm)|depending on burn injury surface
1770768|NCT00366067|Drug|Phenytoin|
1770770|NCT00366093|Drug|Eszopiclone|eszopiclone 3 mg
1770771|NCT00366093|Drug|Placebo|placebo tablet
1770772|NCT00366106|Drug|bortezomib|Patients will be treated with bortezomib at 1.3mg/m^2 on Days 1, 4, 15, and 18 every 28 days (cycle).
1770773|NCT00366106|Drug|dexamethasone|Dexamethasone tablets will be given at 20mg daily on Days 1, 2, 4, 5, 15, 16, 18, and 19 every 28 days (cycle).
1770774|NCT00366106|Drug|doxorubicin HCl liposome|Patients will receive intravenous doxorubicin HCl liposome injection given at 30 mg/m^2 on Day 4 every 28 days (cycle).
1770775|NCT00366119|Drug|Ramipril|
1770776|NCT00366132|Device|Extracorporeal Shockwaves|
1770777|NCT00366145|Biological|Mesenchymal Stem Cells|2 million cells/kg twice a week for 4 weeks
1770778|NCT00366145|Biological|placebo|2 infusions a week for 4 weeks
1770779|NCT00366158|Device|Device: St. Jude Medical Victory dual-chamber pacemaker|Pacemaker implant
1770780|NCT00366158|Device|Ventricular Intrinsic Preference|Programming of pacemaker
1770781|NCT00366171|Drug|Bifeprunox|
1770782|NCT00366210|Behavioral|Constraint-Induced Movement (CI) Therapy|
1770783|NCT00366210|Behavioral|Stretching, Relaxation, & Biofeedback|Passive stretching of both arms, EMG biofeedback for more-impaired arm
1770784|NCT00366236|Drug|Nitazoxanide|
1770785|NCT00366249|Drug|Tigecycline|150 mg Tigecycline once-daily IV infusion for up to 28 days, or 42 days for the substudy wth osteomyelitis
1770786|NCT00366249|Drug|Ertapenem|Ertapenem 1g IV infusion every 24 hours +/- vancomycin depending on culture results and at the discretion of investigator (for coverage of Methicillin-resistant Staphylococcus aureus (MRSA), coagulase-negative staphylococci (CNS) or enterococci coverage).
1770787|NCT00366262|Drug|PLA-695|
1770788|NCT00366262|Drug|Naproxen|
1770789|NCT00366262|Drug|Placebo|
1770790|NCT00366275|Procedure|Immunochemotherapy, in vivo purging and autrotransplant|2-4 courses every 3 weeks with rituximab 375 mg/m^2 on day 1, vincristine 1.4 mg/m^2 on day 2 and cyclophosphamide 400 mg/m^2 on days 2-6. Courses were started if granulocytes >1.5 · 10^9/l. The phase of peripheral blood stem cells (PBSC) mobilization coupled rituximab 375 mg/m^2 on days 1 and 9 with high-dose cytarabine (AraC) 2 g/m^2 every 12 hours on days 2 and 3. Granulocyte colony-stimulating factor (G-CSF)(5 mcg/kg/day subcutaneously) was administered from day 6. High-dose chemotherapy with autotransplant consisted of BEAM [carmustine (BCNU), etoposide, Cytarabine (AraC), melphalan] followed by the infusion of in vivo purged peripheral blood stem cells (PBSC) + 2 consolidation doses of rituximab 375 mg/m^2 on days +14 and +21 after autotransplant.
1770791|NCT00366288|Drug|PAZ-417|2.5 mg, 5, 10, 25, 50 mg - fasted in healthy young 10 mg - food effect in healthy young 5 and 25 mg -fasted healthy elderly.
1770792|NCT00371839|Procedure|Audiological Evaluation|Tests of hearing, cognition, and speech perception
1770793|NCT00371852|Drug|lactoserum|
1770794|NCT00371865|Behavioral|Cognitive-behavioral therapy|8 group-administered sessions of Cognitive-Behavioral Therapy; includes relaxation, cognitive restructuring, and problem-solving
1770795|NCT00371865|Behavioral|Acceptance-based therapy|8 group-administered sessions of Acceptance-based therapy; includes mindfulness, values, and committed action
1770796|NCT00371878|Biological|7-valent pneumococcal conjugate vaccine (Prevnar)|
1770797|NCT00371891|Procedure|Multidetector Computed Tomography Coronary Angiography|1 Multidetector Computed Tomography Coronary Angiography
1770798|NCT00371904|Drug|Rituximab|Single dose (375 mg/m2) of rituximab to be given intravenously (IV) 14 days prior to transplantation
1770799|NCT00371904|Drug|Standard Care|Standard care
1770800|NCT00371930|Procedure|application of a dye suspension followed by a laser intervention|
1770801|NCT00371943|Procedure|band ligation|
1770802|NCT00371956|Drug|raloxifene|60mg/day
1770803|NCT00371956|Drug|placebo|tab 1 daily
1771026|NCT00373503|Drug|Marijuana|marijuana intoxication, withdrawal and relapse assessed
1770804|NCT00371969|Behavioral|Enhanced Motivational Interview|The intervention consists of a brief motivational interview, which is combined with daily alcohol monitoring through the use of an interactive voice response system IVR (automated telephone system).
1770805|NCT00371969|Behavioral|Standard Motivational Interview or viewing DVD|Brief motivational interview, viewing a DVD on HIV self-care.
1770806|NCT00371982|Drug|Fish oil (Maxepa)|
1770807|NCT00371995|Drug|Liposomal amphotericin B and Miltefosine|"Liposomal amphotericin B administered intravenously as single dose on day 1, Dosage: 5 mg/kg.
Miltefosine administered orally (50 mg capsules) for 14 days (on days 2-15)"
1770808|NCT00372008|Drug|Testosterone|
1770809|NCT00372021|Procedure|optic nerve neurotomy|
1770810|NCT00372034|Device|Temporary Collagen Inserts|
1770811|NCT00372047|Device|multiphoton laser imaging|
1770812|NCT00372060|Drug|sitagliptin phosphate|Sitagliptin (MK0431) 50 or 100 mg once daily for 52 weeks
1770813|NCT00372060|Drug|Comparator: sitagliptin phosphate (MK0431)|Sitagliptin (MK0431) 50 or 100 mg once daily for 40 weeks
1770814|NCT00372060|Drug|Comparator: pioglitazone|pioglitazone once daily for 52 weeks
1770815|NCT00372060|Drug|Comparator: placebo (unspecified)|Placebo once daily for 12 weeks
1770816|NCT00372073|Drug|seliciclib|1200 mg bid x 3 days every 2 weeks
1770817|NCT00372073|Drug|placebo|1200 mg bid x 3 days every 2 weeks
1770818|NCT00372086|Drug|Rosiglitazone|
1770819|NCT00372099|Drug|Salmon calcitonin|nasal salmon calcitonin 200UI/day during 2 years
1991641|NCT00736515|Drug|Gliclazide MR and Insulin Glargine Injection|Combination therapy of oral administration of 60-120mg Gliclazide Modified Release Tablet once daily before breakfast and subcutaneous injection of Insulin Glargine Injection once daily before dinner (initial dosage 0.2U/KG/D) for 3 months
1770822|NCT00372125|Drug|Norditropin SimpleXx|0.3-0.4 mg/day placebo or GH for 4 weeks. Thereafter 0.6-0.8 mg/day placebo or GH for 11 months. During the following 24 months open phase doses will be individually titrated.
1770823|NCT00372138|Procedure|PRP + autologous thrombin|simultaneous perioperative PRP and autologous thrombin in the aneurysm sac, during the endovascular treatment of unruptured abdominal aortic aneurysms
1770824|NCT00372151|Dietary Supplement|L-Theanine|400 mg/day, caps.
1770825|NCT00372151|Other|Placebo|caps.
1770826|NCT00372164|Procedure|American Society of Interventional Pain Physician Guidelines|
1770827|NCT00372177|Radiation|Fab-fragment of Anti-human CD4|Sterile lyophilized Powder for Preparation of a Solution and sterile labelling Buffer labelling with Tc99m-Pertechnetat Intravenous injection
1770828|NCT00372190|Device|Tensionfree vaginal mesh kit (Prolift)|Insertion of a tension free vaginal mesh using a Prolift mesh kit
1770829|NCT00372190|Procedure|classic vaginal prolapse surgery (fascia plication)|classic vaginal prolapse surgery (fascia plication) to correct Pelvic Organ prolapse
1770830|NCT00372203|Procedure|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy|Endobronchial Ultrasound Guided Transthoracic Needle Biopsy of mediastinal lymph nodes at the time of the mediastinoscopy.
1770831|NCT00372216|Drug|Clopidogrel (Iscover/Plavix)|Pre-hospital loading-dose of 600 mg Clopidogrel as early as possible
1770834|NCT00372242|Behavioral|Prospective Longitudinal Interventional Stury|
1770835|NCT00372255|Biological|Influsplit SSW® 2005/2006|
1770836|NCT00372268|Device|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and wet nebulization of either saline solution or ropivacaïne 0.75% (Naropeine) during the surgical procedure.
1770837|NCT00372268|Device|Aeroneb® Pro (Nektar® Company)|The Aeroneb® Pro (Nektar® Company) permits cold and dry nebulization without saline solution neither ropivacaïne (Naropéine) during the surgical procedure.
1770838|NCT00372281|Drug|Cliavist|Injection of 0,9 mL (weight < 60kg) or 1,4 mL (weight > 60kg) of Cliavist (ferucarbotran) by direct intraveinous way, 48 h following the MRI done with gadolinium.
1770839|NCT00372294|Drug|pyrimethamine-sulfadiazine + prednisolone|Administration of pyrimethamine-sulfadiazine + prednisolone
1770840|NCT00372294|Drug|Clindamycin+Dexamethasone|Intravitreal injection of Clindamycin+Dexamethasone
1770841|NCT00372307|Drug|Application of pimecrolimus|
1770844|NCT00372333|Drug|IDEA-033|
1770845|NCT00372346|Procedure|Transplantation of autologous endothelial progenitor cells|
1770846|NCT00372372|Drug|risedronate|
1770847|NCT00372385|Drug|Ribavirin|tablet
1770848|NCT00372385|Drug|Pegylated Interferon Alfa 2a|Solution for injection
1770849|NCT00372385|Drug|Placebo|tablet
1770850|NCT00372385|Drug|Telaprevir|tablet
1770851|NCT00372411|Device|Robot-Assisted Therapy - MIT-MANUS System|The MIT-MANUS robot consists of four modules to train the entire upper limb: module A: shoulder-elbow; module B: anti-gravity; module C: wrist, and module D: hand-unit. Training will be given for 12 weeks and is divided into 4 consecutive blocks, with 9 training sessions per block.
1770852|NCT00372411|Other|Intensive Comparison Therapy|The intensive comparison therapy protocol being used in CSP#558 was developed and field-tested at the Burke Rehabilitation Hospital. It exposes the patient to the identical number of treatments, time, and intensity that robot treated patients will receive (12 weeks, 3 times per week). Therapy sessions can be conducted on back-to-back days if needed and on more than 3 days a week (with approval from the Study Chairman) over a treatment period of up to 14 weeks in order to complete the 36 treatment sessions. During each 1-hour session, subjects participate in therapy in four successive stages: 1) warm-up and assisted stretching; 2) active arm treatments; 3) goal-directed planar reaching, and 4) functionally based Neurodevelopment Techniques (NDT)/Bobath arm training (Bobath, 1979).
1770853|NCT00372411|Other|Usual Care|The usual chronic stroke care as delivered at each participating medical center
1770854|NCT00372424|Drug|Herceptin|Trastuzumab will be administered intravenously on Day 1 before docetaxel - loading dose of 4 mg/kg over 90-minute on Day 1 followed by weekly maintenance doses of 2 mg/kg on Days 1, 8, 15 given as 30-minute infusions if the initial loading dose was well tolerated. Loading dose of 8 mg/kg over 90-minute on Day 1 followed by 3-weekly maintenance doses of 6 mg/kg given as 90-minute infusions. The administration of 6 mg/kg will be repeated on Day 1 every 3 weeks.
1771027|NCT00373516|Drug|Vehicle (Placebo) applied BID|
1770855|NCT00372424|Drug|Sunitinib|SU011248 will be administered at 37.5 mg once daily for 2 weeks every 3 weeks (Schedule 2/1) starting from Day 2, when in combination with docetaxel. SU011248 will be administered at the starting dose of 37.5 mg daily in a continuous regimen when docetaxel is discontinued.
1770856|NCT00372424|Drug|Taxotere|The starting dose of docetaxel will be 75 mg/m2 every 3 weeks, administered on Day 1 of each cycle as a 1-hour IV infusion.
1770857|NCT00372437|Drug|MGCD0103|MGCD0103 as an oral dose three times per week.
1770858|NCT00372437|Drug|Gemcitabine|Gemcitabine 1000mg/m<2> intravenously days 1, 8, 15 of a 28 day cycle.
1770859|NCT00372450|Procedure|management of therapy complications|
1770860|NCT00372450|Procedure|quality-of-life assessment|
1770861|NCT00372463|Behavioral|6-week Online Diabetes Self-Management Educational Program|
1770862|NCT00372476|Drug|Imatinib and Vinorelbine|
1770863|NCT00372489|Drug|peginesatide|Participants received the same initial peginesatide dose as was administered at the end of the previous peginesatide treatment study (NCT00228449) in which the participant was enrolled. The median first dose at study start was 0.087 milligram per kilogram (mg/kg) with an interquartile range of 0.064 to 0.123 mg/kg. Each participant was to receive peginesatide as an injection administered intravenously once every 4 weeks for approximately 54 months in this trial.
1770864|NCT00372502|Procedure|Modified EGDT|Early goal directed therapy with lactate clearance
1770865|NCT00372502|Procedure|Standard EGDT|Early goal directed therapy
1770866|NCT00372515|Drug|Gefitinib|On days 1-14 gefitinib will be taken orally daily at either 750, 1000, or 1250mg (depends upon when subject entered trial). If medication is tolerated well, subject will take 500mg daily on days 15-28 of each 28-day cycle. Cycles (higher dose followed by lower dose) will be repeated as long as subject's cancer does not worsen and they do not experience any serious side effects.
1770867|NCT00372528|Drug|pregabalin (LYRICA)|150 mg up to a maximum of 600 mg per day bid or tid as required
1770868|NCT00372541|Drug|ceftriaxone|
1770869|NCT00372567|Drug|sunitinib malate|37.5 mg daily
1770870|NCT00372567|Drug|imatinib mesylate|800mg daily
1770871|NCT00372580|Procedure|blood test|
1770872|NCT00372593|Drug|asparaginase|Given intramuscularly
1770873|NCT00372593|Drug|cytarabine|Given IV
1770874|NCT00372593|Drug|daunorubicin hydrochloride|Given IV over 6 hours
1770875|NCT00372593|Drug|etoposide|Given IV over 1-4 hours
1770876|NCT00372593|Drug|gemtuzumab ozogamicin|Given IV over 2 hours
1770877|NCT00372593|Drug|mitoxantrone hydrochloride|Given IV over 1 hour
1770878|NCT00372606|Behavioral|Online MiDieta Diet and Weight Management Program for Hispanics|
1770879|NCT00372619|Drug|clofarabine|Given IV for 5 days
1770880|NCT00372619|Drug|cytarabine|Given IV
1770881|NCT00372619|Drug|methotrexate|Given intrathecally or IT age based dosage
1770882|NCT00372619|Other|laboratory biomarker analysis|
1770883|NCT00372632|Drug|Sulfadoxine-Pyrimethamine|The intervention group receives 1500mg of sulfadoxine and 75mg of pyrimethamine at enrollment and in the third trimester.
1770884|NCT00372632|Drug|placebo|The control group receives placebo similar in taste and appearance to to the experimental arm
1770885|NCT00372645|Dietary Supplement|Folic acid (supplement)|200 µg folate per day from supplemental folic acid
1770886|NCT00372645|Dietary Supplement|Metafolin (supplement)|200 µg folate per day from supplemental Metafolin®
1770887|NCT00372645|Drug|Placebo|Placebo
1770888|NCT00372645|Other|Folate rich foods|200 µg folate per day from folate-rich foods
1770889|NCT00372658|Drug|1% Lidocaine intracervical injection|
1770890|NCT00372671|Behavioral|Survey|
1770891|NCT00372671|Behavioral|Survey and videotape|
1770892|NCT00372684|Genetic|with severe malaria hospitalized in ICU|with severe malaria hospitalized in ICU
1770893|NCT00372684|Genetic|with uncomplicated malaria|with uncomplicated malaria
1770894|NCT00372697|Drug|Octreotide acetate 30 mg suspension|Each vial of study medication contained octreotide acetate 30 mg in a microencapsulated biodegradable polymer, poly (DL-lactide-co-glycolide) (D-(+)glucose), with 17% w/w mannitol in an approximate octreotide:polymer ratio of 1:20. The vehicle contained 0.5% sodium carboxymethylcellulose.
1770895|NCT00372710|Drug|Zoledronic acid|
1770896|NCT00372723|Drug|Remicaide (infliximab)|a single dose infusion of 5mg/kg Remicade (Infliximab)
1770897|NCT00372736|Drug|AEG35156|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
1770898|NCT00372736|Drug|docetaxel|After a recommended phase II dose (RPTD) of AEG35156 has been determined with docetaxel 75 mg/m2, patients will be accrued to the RPTD-1 plus docetaxel 100 mg/m2, and possibly RPTD plus docetaxel 100 mg/m2, to determine the RPTD of AEG35156 in combination with docetaxel 100 mg/m2 given every three weeks.
1770899|NCT00372736|Genetic|protein expression analysis|Cycle 1: Pre-dose on Days -2, 1, 8 and 15; repeat every 2-4 days if LFTs > 5 x ULN1 Cycle 2: Prior to each infusion; repeat every 2-4 days if LFTs > 5 x ULN1
1770900|NCT00372736|Genetic|reverse transcriptase-polymerase chain reaction|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
1770901|NCT00372736|Other|flow cytometry|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
1770902|NCT00372736|Other|immunoenzyme technique|Data will be summarized by descriptive statistics relevant to each of the proposed pharmacodynamic studies.
1770903|NCT00372736|Other|immunohistochemistry staining method|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
1770904|NCT00372736|Other|laboratory biomarker analysis|The plasma concentration/ time data will be analysed using non-compartmental methods. The pharmacokinetic parameters to be determined for AEG35156 include the maximum observed plasma concentration (Cmax), the half-life (T1/2), and mean residence time (MRT).
1770905|NCT00372749|Behavioral|Aversive reaction during alcohol cue exposure|Aversive reaction during alcohol cue exposure
1770906|NCT00372762|Drug|Furosemide|Current dose of furosemide will be maintained and equivalent dose bumetanide will be used following crossover
1770907|NCT00372762|Drug|Bumetanide|Equivalent dose to pre-existing furosemide will be used
1770908|NCT00372762|Drug|furosemide|20mg to 80mg orally once or twice daily
1770909|NCT00372762|Drug|bumetanide|0.5mg to 2mg orally once or twice daily
1770910|NCT00372775|Drug|Sunitinib|Sunitinib 37.5 mg daily by oral capsule in a continuous regimen until progression or unacceptable toxicity
1770911|NCT00372788|Drug|AZD6244|oral vial
1770912|NCT00372788|Drug|Pemetrexed|oral
1770913|NCT00372801|Drug|Ibuprofen|
1770914|NCT00372814|Behavioral|Intensive Home-Based Family Therapy|Multisystemic Therapy (MST): Adolescents receiving MST will receive home-based, family psychotherapy sessions 2-3 times a week, lasting 60 minutes in duration from a pediatric mental health worker for six months. The purpose of the therapy sessions are to improve the youths' ability to complete their dilay diabetes illness management tasks, reduce average blood glucose levels and improve metabolic control.
1770915|NCT00372814|Behavioral|Supportive Telephone Calls|Telephone Support Calls: Adolescents receiving TS will receive weekly 30 minute phone calls from a pediatric mental health worker for six months. The purpose of the call is to provide emotional support regarding the adolescent's chronic medical condition, assess adherence to the prescribed regimen and to help the adolescent brainstorm solutions to any barriers they identify to completion of diabetes care.
1770916|NCT00372827|Drug|Brinzolamide 1% added to Travoprost 0.004%|
1770917|NCT00372840|Other|educational intervention|
1770918|NCT00372840|Procedure|psychosocial assessment and care|
1770919|NCT00372840|Procedure|quality-of-life assessment|
1770920|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
1770921|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 37.5mg/day every day.
1770922|NCT00372853|Drug|CP-675,206|CP-675,206 administered intravenously every 3 months. Escalating doses from 6mg/kg to 15mg/kg will be tested.
1770923|NCT00372853|Drug|SU011248|SU011248 administered at a dose of 50mg/day for 4 weeks followed by 2 weeks off, repeated every 6 weeks.
1770924|NCT00372879|Dietary Supplement|Vitamin E|Vitamin E 800IU bid
1770925|NCT00372892|Drug|Rituximab|375mg/m2 per week for 4 consecutive weeks
1770926|NCT00372892|Drug|Placebo|Saline IV placebo once per week for 4 consecutive weeks
1770927|NCT00372905|Drug|rituximab|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
1770928|NCT00372905|Drug|bortezomib|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
1770929|NCT00372905|Drug|Ibritumomab tiuxetan|Induction therapy will last 28 days. Bortezomib will be given on days 1, 8, 15, and 22. Rituximab will be given on days 8 and 15 along with 111-indium-ibritumomab tiuxetan. During consolidation therapy, Bortezomib will be given intravenously on days 1, 8, and 15 of each cycle for a maximum of 3 cycles. Rituximab or Y-90-ibritumomab tiuxetan will not be given during consolidation therapy.
1770930|NCT00372918|Procedure|Transnasal Esophagoscopy|fiberoptic exam of esophagus thru nares
1770931|NCT00372931|Drug|AL-37807|
1770932|NCT00372944|Drug|AZD6244|oral capsule
1770933|NCT00372944|Drug|capecitabine|oral tablet
1770935|NCT00372970|Drug|Botulinum toxin A|200 U given by injection into the pylorus.
1770936|NCT00372970|Drug|Placebo|saline injection into pylorus.
1770937|NCT00372983|Drug|NOV-205|
1770938|NCT00372996|Drug|CP-751,871|CP-751,871 given at 20 mg/kg IV on day 1 of each 21 day cycle.
1770939|NCT00372996|Drug|exemestane|Exemestane given at 25 mg orally once a day.
1770940|NCT00372996|Drug|exemestane|Exemestane given at 25 mg orally once a day. Treatment until progression or toxicity
1770941|NCT00372996|Drug|Fulvestrant|Used for salvage therapy and administered according to the local label and standard clinical practice.
1770942|NCT00373009|Behavioral|Traditional Army training|As usual training for Soldiers
1770943|NCT00373009|Behavioral|Core stabilization exercise only|Core stabilization exercise
1770944|NCT00373009|Behavioral|Psychosocial education class only|Psychosocial education class
1770945|NCT00373009|Behavioral|Core stabilization and psychosocial education|Includes both core stabilization training and psychosocial education class
1770946|NCT00373022|Behavioral|exercise intervention|
1770947|NCT00373022|Other|flow cytometry|
1770948|NCT00373022|Other|laboratory biomarker analysis|
1770949|NCT00373022|Procedure|management of therapy complications|
1770950|NCT00373022|Procedure|psychosocial assessment and care|
1770951|NCT00373022|Procedure|quality-of-life assessment|
1770952|NCT00373035|Genetic|proteomic profiling|
1770953|NCT00373035|Other|immunological diagnostic method|
1770954|NCT00373035|Other|laboratory biomarker analysis|
1770955|NCT00373035|Other|mass spectrometry|
1770956|NCT00373035|Procedure|biopsy|
1770957|NCT00373035|Procedure|ultrasound imaging|
1770958|NCT00373048|Drug|mefloquine|tablet, once weekly
1770959|NCT00373048|Drug|placebo|tablet, once weekly
1770960|NCT00373061|Drug|Xolair®|This being an observational study, the study protocol does not specify any dose regimen.
1770961|NCT00373074|Other|Epidural Blood Patch|Use 15 cc of blood
1770962|NCT00373074|Other|Epidural Blood Patch|Inject 20 cc of blood into epidural space
1770963|NCT00373074|Other|Epidural Blood Patch|Inject 30 cc of autologous blood
1770964|NCT00373087|Drug|entacapone|entacapone
1770965|NCT00373087|Drug|l dopa versus placebo|l dopa versus placebo
1770966|NCT00373100|Drug|Zinc acetate|
1770968|NCT00373113|Drug|Capecitabine|1250 mg/m^2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
1770969|NCT00373113|Drug|Sunitinib malate|37.5 mg daily, continuous dosing
1770970|NCT00373126|Drug|transdermal nicotine patch|
1770971|NCT00373152|Procedure|Lumpectomy|Standard lumpectomy or mastectomy will be performed 1 to 21 days after the post-RFA MRI.
1770972|NCT00373152|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Dynamic-contrast enhanced breast images will be visualized with parametric image maps to assist in identifying regions with residual cancer.
1770973|NCT00373152|Procedure|radiofrequency ablation|RFA is accomplished by placing a multi-array needle within a tumor. The tines of the needle are advanced and opened like an inverted umbrella. High frequency, alternating current moves from the tip of an electrode into the surrounding tissue. Oscillating ions generate frictional heat within the tumor. Cell death occurs at sustained temperatures above 45-50 degrees C. The multi-array configuration creates an egg-shaped ablation zone up to 5 cm in diameter.
1770974|NCT00373152|Radiation|gadopentetate dimeglumine|Injected at baseline MRI and post radiofrequency ablation MRI.
1770975|NCT00373165|Drug|Ganciclovir|
1770976|NCT00373178|Drug|rosiglitazone|
1770977|NCT00373178|Drug|metformin|
1770978|NCT00373178|Drug|Anti-diabetic medications|
1770979|NCT00373191|Drug|chemotherapy|N/A- not dictated by study
1770980|NCT00373191|Drug|endocrine therapy|N/A- not dictated by study
1770981|NCT00373191|Genetic|DNA methylation analysis|laboratory analysis
1770982|NCT00373191|Genetic|protein analysis|laboratory analysis
1770983|NCT00373191|Other|laboratory biomarker analysis|laboratory analysis
1770984|NCT00373191|Other|questionnaire administration|questionnaire
1770985|NCT00373191|Procedure|adjuvant therapy|N/A- not dictated by study
1770986|NCT00373191|Procedure|conventional surgery|N/A- not dictated by study
1770987|NCT00373191|Radiation|radiation therapy|N/A- not dictated by study
1770988|NCT00373204|Drug|Motexafin Gadolinium|"On Day 1 of each 3 week cycle for up to 12 cycles:
MGd 10 mg/kg infused over approximately 30 to 60 minutes, followed ≥ 30 minutes later by Docetaxel 75 mg/m2 administered IV over approximately 1 hour."
1770989|NCT00373217|Biological|MAGE-A1, Her-2/neu, FBP peptides ovarian cancer vaccine|Given intradermally or subcutaneously
1770990|NCT00373217|Biological|tetanus toxoid helper peptide|Given intradermally or subcutaneously
1770991|NCT00373217|Drug|carboplatin|Given IV
1770992|NCT00373217|Drug|paclitaxel|Given IV
1770993|NCT00373217|Procedure|conventional surgery|Patients undergo primary optimal cytoreductive surgery
1770994|NCT00373230|Behavioral|telemedicine|One year behavioral modification weight control program comparing in-person consultations (monthly) to a computer based telemedicine system (available 24/7).
1770995|NCT00373243|Drug|GW406381|GW406381 will be available as 10 mg hard gelatin capsules. Subjects will receive two capsules of 10 mg to make 20 mg dose.
1770996|NCT00373256|Drug|Sunitinib|Sunitinib 25 mg daily by oral capsules with titration up to 37.5 mg,
1770997|NCT00373256|Drug|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
1770998|NCT00373256|Drug|bevacizumab|Bevacizumab 10 mg/kg IV every 2 weeks.
1770999|NCT00373256|Drug|paclitaxel|Paclitaxel 90 mg/m2 IV, 3 weekly doses every 28 days until progression or unacceptable toxicity.
1771000|NCT00373282|Drug|Triamcinolone acetonide|
1771001|NCT00373295|Drug|Baclofen|Baclofen (60mg/day or 90 mg/day): Packaged medication in size 00 opaque capsules with riboflavin filler. Study capsules (0, 20, 30mg) were administered 3 times per day (0900, 1530, 2200).
1771002|NCT00373295|Drug|Marijuana|Marijuana: Participants each received a single marijuana cigarette (provided by the National Institute on Drug Abuse) at each smoking occasion. Marijuana cigarettes were stored frozen in an airtight container and humidified at room temperature for 24 h prior to use.
1771003|NCT00373295|Drug|Placebo|
1771004|NCT00373334|Drug|nizatidine (axid)|nizatidine (axid)
1771005|NCT00373334|Drug|nizatidine (axid)|nizatidine (axid)
1771006|NCT00373334|Drug|placebo|placebo
1771007|NCT00373360|Drug|treprostinil sodium|rapid switch from intravenous epoprostinol to intravenous remodulin on the CADD ambulatory pump
1771008|NCT00373373|Drug|Sorafenib|2 x 400 mg/d
1771009|NCT00373373|Drug|Placebo|Chemotherapy + Placebo
1771012|NCT00373412|Biological|VCL CT02 pDNA vaccine|
1771013|NCT00373412|Biological|Towne CMV vaccine|
1771014|NCT00373425|Drug|Erlotinib|150 mg tablet
1771015|NCT00373425|Drug|Placebo|Placebo tablet
1771016|NCT00373438|Procedure|Fetoscopic tracheal balloon occlusion|Maternal local anesthesia, percutaneous ultrasound-guided fetal analgo-sedation and relaxation, percutaneous ultrasound-guided access into amniotic cavity with trocar, fetoscopic tracheal ballon occlusion, removal of fetoscope and trocar, maternal abdominal closure, skin-to-skin time 30 minutes
1771017|NCT00373451|Drug|Abciximab + UFH|Abciximab (0.25 mg/kg of body weight bolus, followed by a 0.125 µg/kg/minute [maximum of 10 µg/minute] infusion for 12 hours)
1771018|NCT00373451|Drug|Bivalirudin|Bivalirudin (intravenous bolus of 0.75 mg/kg prior to the start of the intervention, followed by infusion of 1.75 mg/kg per hour for the duration of the procedure)
1771019|NCT00373451|Drug|Heparin|i.v. bolus of 70 units/kg/body weight of unfractionated heparin
1771020|NCT00373464|Drug|etoricoxib|
1771021|NCT00373477|Procedure|Generalist Care Manager vs Usual Care|
1771022|NCT00373490|Drug|Vorinostat|600 mg daily (300 mg twice daily [b.i.d.]) for 3 consecutive days followed by 4 days of rest.
1771023|NCT00373490|Drug|Vorinostat|400 mg once daily (400 mg q.d.) continuous daily dosing for 21 days.
1771024|NCT00373503|Drug|Lofexidine|alpha 2 adrenergic agonist, hypothesized to decrease noradrenergic activity
1771025|NCT00373503|Drug|dronabinol|cannabinoid agonist hypothesized to decrease MJ withdrawal
1771028|NCT00373516|Drug|QRX-101 75 mcg/g ointment applied QD|
1771029|NCT00373516|Drug|QRX-101 75 mcg/g ointment applied BID|
1771030|NCT00373529|Drug|clofarabine|"Induction cycle 1: cycle 1 of clofarabine 30 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days.
Reinduction (cycle 2) and/or Consolidation cycles (cycles 2-6): cycles repeated minimally every 28 days, of clofarabine 20 mg/m^2/day as a 1-hour intravenous infusion for 5 consecutive days."
1771032|NCT00373555|Procedure|Bronchoscopy|
1771033|NCT00373568|Drug|miltefosine: 2.5 mg/kg/day for 42 days|
1771034|NCT00373581|Drug|Vigabatrin|
1771035|NCT00373581|Drug|Cocaine|
1771036|NCT00373594|Drug|Rituximab|
1771037|NCT00373594|Drug|Fludarabine|
1771038|NCT00373607|Drug|Dihydroartemisin-piperaquine|Dihydroartemisin-piperaquine (Artekin) manufactured by Hualijian Pharmaceutical Co. Ltd., Guangzhou, China. Each tablet contains 40mg of dihydroartemisinin and 320mg piperaquine
1771039|NCT00373607|Drug|Mefloquine + Artesunate|Mefloquine + Artesunate (MAS3). The regimen is artesunate 4 mg/kg/day once daily for 3 days plus mefloquine 24 mg/kg given as a three day regimen of 8mg/kg/day
1771040|NCT00373620|Drug|paclitaxel|
1771041|NCT00373633|Procedure|Thoracic Epidural|Gold standard for post thoracotomy pain
1771042|NCT00373633|Procedure|Extrapleural Intercostal Catheter|Continuous extra-pleural intercostal local anesthesia
1771043|NCT00373646|Drug|Thalidomide, Pharmion|200 mg p.o. daily
1771044|NCT00373659|Drug|Ranibizumab (Lucentis)|
1771047|NCT00373685|Drug|Celecoxib|open-label
1771048|NCT00373685|Drug|Any commercially available NSAID with the indication for osteoarthritis|dosing as per USPI label related to the chosen commercially marketed NSAID
1771049|NCT00373698|Behavioral|Three Component Model of Collaborative Care|Patients randomized to 3CM will receive telephone care management along with usual care by VA clinicians.
1771050|NCT00373711|Drug|Iodine-124|2 mCi, oral
1771051|NCT00373711|Drug|Iodine-123|2 mCi, oral
1771052|NCT00373711|Drug|F-18 FDG|10-15 mCi, iv
1771053|NCT00373724|Procedure|radiofrequency denervation|
1771054|NCT00373750|Procedure|Family Spirit Intervention|The Family Spirit Intervention was developed over a decade through community-based participatory research.The intervention content included 43 structured lessons and followed a culturally congruent format.
1771055|NCT00373763|Procedure|Fetoscopic tracheal balloon occlusion|
1771056|NCT00373776|Drug|miltefosine 2.5 mg/kg/day for 28 days|
1771057|NCT00373789|Drug|Botulinum Toxin A, bladder detrusor muscle injection|200 U provided as a total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices.
1771058|NCT00373789|Drug|Vehicle saline as placebo|A total of 6 cc of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization. Injections will be spread out to equally cover the entire dome of the bladder, but spare the bladder trigone and ureteral orifices
1771059|NCT00373802|Drug|Phenylephrine|
1771060|NCT00373815|Drug|Everolimus|
1771061|NCT00373867|Behavioral|Standard physical therapy|Treatment-based classification physical therapy
1771062|NCT00373867|Behavioral|Graded exercise|Graded exercise increases an individual's tolerance to activity over time
1771063|NCT00373867|Other|Graded exposure|Graded exposure places the individual in fearful situations and gradually increases their exposure to such situations.
1771064|NCT00373880|Drug|Aripiprazole + Cocaine|Participants received aripiprazole (15mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
1771065|NCT00373880|Drug|Placebo + Cocaine|Placebo (0 mg/day) in conjunction with a dose-response of cocaine (0, 12, 25, 50 mg).
1771066|NCT00373893|Drug|Lidoderm Patch|
1771067|NCT00373906|Drug|Bortezomib (Velcade)|
1771068|NCT00373919|Drug|intravenous (IV) administration of erythromycin|
1771069|NCT00373932|Behavioral|Coached exercise persistence intervention|Collaborative symptom and exercise monitoring and weekly reinforcement for exercise persistence from nurse coach via a mobile device and telephone.
1771070|NCT00373932|Behavioral|Self-Monitored exercise persistence intervention|Self-monitoring of symptoms and exercise using a mobile device
1771071|NCT00373945|Drug|Observational Study|
1771072|NCT00373958|Biological|13 valent pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
1771073|NCT00373958|Biological|7vPnc pneumococcal conjugate vaccine|1 single 0.5 mL dose together with a concomitant dose of Pediarix and ActHIB at the 2-, 4-, and 6-month visits and ProQuad, PedvaxHIB, and VAQTA at the 12-15 month visit.
1771074|NCT00373971|Behavioral|Involving the patients in their own nutritional care|
1771075|NCT00373997|Procedure|Esophageal and Laryngeal biopsies|one day procedure
1771076|NCT00373997|Procedure|egd with biopsy|standard of care procedure with biopsy
1771077|NCT00374010|Behavioral|Patient-Centered Advance Care Planning|"The PC-ACP is a scheduled interview with the dyad, delivered by a trained nurse facilitator. It consists of 5 stages and lasts about an hour:
Representational assessment (10 - 15 minutes);
Exploring concerns related to planning for future medical decision-making (10 - 15 minutes);
Creating conditions for conceptual change (5 minutes);
Introducing replacement information using a disease-specific Statement of Treatment Preferences document (15 minutes); and
Summary (3 - 5 minutes)"
1771078|NCT00374023|Drug|Zinc, or Vitamin A or both|
1771079|NCT00374036|Drug|ECC|capecitabine
1771080|NCT00374036|Drug|FOLFIRI|Irinotecan
1771081|NCT00374049|Drug|MUC_1|Pretreatment with Poly-ICLC alone week 1 &2 (50 ug/kg 3 days/week) Weeks 3-7 Poly-ICLC, 2 days/week; MUC-1 vaccine (100ug) admixed with GM-CSF (100ug), administered subcutaneously at weeks 3, 5 and 7 Tetanus toxoid, administered via intramuscular injection, 1x at week 3 GM-CSF 100ug, administered subcutaneously on days 2-4
1771082|NCT00374062|Behavioral|relaxation therapy 1|relaxation therapy 1
1771083|NCT00374062|Behavioral|relaxation therapy 2|relaxation therapy 2
1771084|NCT00374062|Behavioral|relaxation therapy 3|relaxation therapy 3
1771085|NCT00374075|Drug|Valproic Acid|
1771086|NCT00374088|Drug|N-acetylcysteine|"Loading dose: Subjects randomized to IV NAC will receive a total loading dose of 100 mg/kg of 10% (100 mg/mL) solution. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the loading dose will be 1 mL/kg, anticipated to be 2.5-5 mL in our patient population. The loading dose will be administered over 1 hr beginning 1 hr prior to the patient's OR time. Subjects in the placebo group will receive 1 mL/kg of D5W over 1 hr.
Maintenance infusion: Subjects randomized to IV NAC will receive an infusion of 10 mg/kg/hr of 10% (100 mg/mL) solution for 24 hrs, starting in the OR after weaning from CPB. Acetadote is supplied as a 20% solution (200 mg/mL) and will be diluted 1:1 with an equal volume of D5W. The volume of the maintenance infusion will be 0.1 mL/kg/hr, anticipated to be 0.25-0.5 mL/hr in our patient population. Subjects in the placebo group will receive 0.1 mL/kg/hr of D5W for 24 hrs."
1771087|NCT00374088|Drug|Placebo|D5W bolus prior to surgery and D5W infusion after surgery in an equal volume to the drug arm.
1771088|NCT00374101|Drug|omeprazole|
1771089|NCT00374101|Drug|pantoprazole|
1771090|NCT00374114|Procedure|cervical conization|
1771091|NCT00374114|Procedure|ultrasonic surgical aspiration of the cervix|
1771092|NCT00374127|Drug|Marijuana blunt|Blunts were fabricated by cutting the bottom third off a Dutch Master® cigar, removing all of the cigar tobacco, and replacing it with all of the marijuana contained in a NIDA marijuana cigarette (ca. 800 mg).
1771093|NCT00374127|Drug|marijuana cigarette|Marijuana cigarettes were provided by the National Institute on Drug Abuse.
1771095|NCT00374153|Behavioral|Feedback|Online personal feedback report
1771096|NCT00374153|Behavioral|Motivational Interview with Feedback|In-person Motivational Interview with personal feedback report
1771097|NCT00374153|Behavioral|Motivational Interview|In-person Motivational Interview only (without a personal feedback report)
1771098|NCT00374166|Drug|SSR149415|Oral administration (capsules of 50 and 100 mg)
1771099|NCT00374166|Drug|Placebo|Oral administration (capsules)
1771100|NCT00374166|Drug|Paroxetine|Oral administration (capsules)
1771101|NCT00374179|Drug|CT-322|IV solution, weekly or bi-weekly
1771102|NCT00374192|Drug|Eszopiclone|3 mg per day
1771103|NCT00374192|Drug|Placebo|Placebo
1771104|NCT00374205|Drug|Artesunate plus Amodiaquine|Artesunate 50 mg and Amodiaquine 153 mg co-blister tablets: 3 days once daily weight-adjusted dosing according to manufacturer
1771105|NCT00374205|Drug|Artemether-Lumefantrine|Artemether 20 mg/Lumefantrine 120mg fixe-dose-combination tablets: 3 days twice daily weight-adjusted dosing according to manufacturer
1771106|NCT00374218|Drug|High Fructose Corn Syrup|
1771107|NCT00374218|Drug|Sucromalt|
1771108|NCT00374231|Drug|tacrolimus|Tacrolimus is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
1771109|NCT00374231|Drug|mycophenolate mofetil|Mycophenolate mofetil is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
1771110|NCT00374231|Drug|Prednisone|Prednisone is a pill taken orally. Dose, frequency and duration will be decided by the study doctor on a case-by-case basis.
1771111|NCT00374244|Drug|Pimozide|half of the subjects are randomized to the active drug group
1771112|NCT00374244|Drug|placebo|half of the subjects are randomized to placebo group
1771113|NCT00374257|Procedure|Narrow-Band UVB Phototherapy|Performed either two or three times per week for a total of 24 treatments
1771114|NCT00374270|Behavioral|Lifestyle Counselling; Opinion Leader Influence Statements|
1771115|NCT00374296|Drug|MGCD0103|MGCD0103 administered orally three-times per week
1771116|NCT00374309|Drug|VRC-EBOADV018-00-VP|
1771117|NCT00374322|Drug|lapatinib|Lapatinib 1500 mg (6 tablets) daily for 12 months
1771118|NCT00374322|Other|placebo|6 tablets daily for 12 months
1771119|NCT00374335|Procedure|abdominal ultrasound|abdominal ultrasound to detect hepatic hemangiomas
1771120|NCT00374335|Other|Dermatologic Examination|Complete dermatologic examination
1771121|NCT00374348|Drug|Aripiprazole|Abilify, 5mg; 10mg; 15mg; 20mg; 30mg
1771122|NCT00361569|Drug|DR-2041a|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
1771123|NCT00361569|Drug|DR-2041b|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
1771124|NCT00361569|Other|Placebo|1 gram administered vaginally daily for the 1st 7 days then twice a week thereafter
1771125|NCT00361569|Other|Placebo|2 grams administered vaginally daily for the 1st 7 days then twice a week thereafter
1771126|NCT00361582|Drug|CG5503 IR; tapentadol|
1771127|NCT00361595|Drug|zoledronic acid|5 mg zoledronic acid administered in a single 15 minute IV
1771128|NCT00361608|Device|EarlySense ES 16|
1771129|NCT00361621|Drug|bortezomib|Given intravenously on day 1 and day 4 of a 21-day cycle for 6 cycles
1771130|NCT00361621|Drug|Rituximab|Given intravenously on day 1 of a 21-day cycle for 6 cycles
1771131|NCT00361621|Drug|Cyclophosphamide|Given intravenously on day 1 of a 21-day cycle for 6 cycles
1771132|NCT00361621|Drug|Doxorubicin|Given intravenously on day 1 of a 21-day cycle for 6 cycles
1771133|NCT00361621|Drug|Vincristine|Given intravenously on day 1 of a 21-day cycle for 6 cycles
1771134|NCT00361621|Drug|Prednisone|Taken orally on days 2, 3, 4 and 5 or a 21-day cycle for 6 cycles
1771135|NCT00361621|Radiation|Radiation therapy|After 6 cycles of chemotherapy there will be 3 weeks of radiation therapy
1771136|NCT00361634|Drug|Etanercept|
1771137|NCT00361647|Procedure|Diagnostic screening for occult malignancy|
1771138|NCT00361660|Behavioral|functional task practice - distributed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday, Wednesday, and Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
1771139|NCT00361660|Behavioral|functional task practice - condensed|This functional task practice is modeled after Constraint-Induced Movement Therapy in which participants wear a mitt on the non-paretic arm for up to 90% of waking hours and then attend therapy for 3 hours a session Monday through Friday in which they practice various functional tasks, such as tracing a stencil, placing toothbrushes in toothbrush holders, etc.
1771140|NCT00361686|Drug|tramadol|
1771141|NCT00361686|Drug|remifentanyl|
1771142|NCT00361686|Device|patient contolled analgesia|
1771143|NCT00361699|Drug|Statin|
1771145|NCT00361738|Drug|AVE2268|
1771146|NCT00361751|Drug|fenofibrate|
1771147|NCT00361790|Drug|Escitalopram on days -7 to day 14; Aripiprazole dosed starting Day 1 to day 14: 3 days at 10 mg, 4 days at 15 mg and 7 days at 20 mg|Tablets, Oral, Escitalopram: 10 mg; Aripiprazole: 10, 15, 20 mg, once daily, 14 days.
1771148|NCT00361803|Drug|topotecan|
1771149|NCT00361842|Drug|CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection|CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
1771150|NCT00361855|Drug|NX-CP105|
1771151|NCT00361868|Drug|fenofibrate (F) + metformin (M) hydrochloride fixed combination|First period: F80mg/M500mg - per os - twice a day during 2 weeks and F80mg/M850mg - per os - twice a day during 10 weeks - Second period: F54mg/M850mg - per os - three times a day during 12 weeks
1771152|NCT00361868|Drug|Rosiglitazone|First period: 4 mg - per os - daily during 12 weeks - Second period: 4 mg - per os - twice a day during 12 weeks
1771153|NCT00361881|Drug|ME-609|Cream, dose 5 times daily during 5 days.
1771154|NCT00361881|Drug|acyclovir in ME-609 vehicle|Dose 5 times daily for 5 days
1771155|NCT00361881|Drug|Vehicle|Dose 5 times daily for 5 days
1771156|NCT00361894|Drug|Rivaroxaban (BAY59-7939)|10 mg rivaroxaban (tablet) once daily administered for 13 +/- 2 days
1771157|NCT00361894|Drug|Enoxaparin|Syringe of enoxaparin at a dose of 40 mg for 13 +/- 2 days
1771158|NCT00361907|Procedure|Effect of Pulsatile IV insulin on diabetic pt blood markers|Diabetic patients are given pulsatile intravenous insulin on a weekly basis determined by weekly physician order based on pt response and insulin resistance.
1771159|NCT00361907|Procedure|Effect of Pulsatile IV Insulin on blood markers|Circulating blood markers are performed at baseline and every twelve months to compare and measure against diabetic patients receiving pulsatile intravenous insulin.
1771160|NCT00361907|Procedure|Effect of Pulsatile IV insulin on diabetic pt blood markers|Blood markers will be performed on diabetic patients enrolled as control patients at baseline and every twelve months to measure and compare against diabetic patients treated with Pulsatile intravenous insulin therapy
1771161|NCT00361920|Drug|prednisone|
1771162|NCT00361933|Drug|Valganciclovir|valganciclovir open label, two 450mg tablets orally, twice a day
1771163|NCT00361959|Drug|Tiotropium bromide 18mcg|
1771164|NCT00361959|Drug|Fluticasone propionate/ salmeterol combination 50/500mcg|
1771165|NCT00361972|Drug|lansoprazole|30 mg of lansoprazole twice daily for 6 weeks
1771166|NCT00361972|Drug|placebo|placebo comparator to lansoprazole 30 mg, twice daily for 6 weeks
1771167|NCT00361985|Drug|Esomeprazole|Esomeprazole 40mg once daily orally.
1771168|NCT00361985|Drug|Esomeprazole|Esomeprazole 40mg once daily orally
1771169|NCT00361998|Drug|NITROFURANTOIN MACROCRYSTALS|
1771170|NCT00362011|Behavioral|Salba diet|
1771171|NCT00362024|Drug|MK0952|
1771172|NCT00362024|Drug|Comparator: Placebo|
1771173|NCT00362037|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide one per day per os.
1771174|NCT00362050|Drug|Treatment with 3 dose groups of RBx11160 over 7 days|
1771175|NCT00362063|Drug|growth hormone (Nutropin)|growth hormone (Nutropin), 0.3mg/kg/week administered subcutaneously daily.
1771176|NCT00362089|Dietary Supplement|Marinol D-40|Marinol D-40, three capsules per day, from 15th week of gestation until 4th month of lactation
1771177|NCT00362102|Drug|Cetuximab|
1771178|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 5 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
1771179|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 10 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
1771180|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
1771181|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 40 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
1771182|NCT00362115|Drug|Azilsartan Medoxomil|Azilsartan medoxomil 80 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
1771183|NCT00362115|Drug|Olmesartan|Olmesartan 20 mg and comparator matching placebo tablets, orally, once daily for up to 8 weeks.
1771184|NCT00362115|Drug|Placebo|Matching placebo tablets, orally, once daily for up to 8 weeks.
1771185|NCT00362141|Drug|levetiracetam (add-on)|
1771186|NCT00362180|Drug|mipomersen|200 mg subcutaneous injections
1771187|NCT00362180|Drug|Placebo|subcutaneous injections
1771188|NCT00362193|Behavioral|Telephonic diabetes care|
1771189|NCT00362206|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 20mg
1771190|NCT00362206|Drug|Fenofibrate/Simvastatin|Combination of Fenofibrate and Simvastatin 40 mg
1771191|NCT00362206|Drug|Pravastatin|Pravastatin 40 mg
1771192|NCT00362219|Other|Placebo|Gel with no active ingredient.
1771193|NCT00362219|Drug|Morphine - .25 mg|gel with 0.25 mg morphine per 100cm2 square of wound.
1771194|NCT00362219|Drug|Morphine|Gel with 0.75 mg morphine per 100cm2 square of wound.
1771195|NCT00362219|Drug|Morphine|Gel with 1.25 mg morphine per 100cm2 square of wound.
1771196|NCT00362232|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban (Xarelto, BAY59-7939) 10 mg tablet administered once daily (od) in the evening.
1771197|NCT00362232|Drug|Enoxaparin|Syringes of enoxaparin active substance 30 mg twice a day administered once in the morning and once in the evening.
1771198|NCT00362232|Drug|Placebo: tablet of Rivaroxaban|Placebo tablet of rivaroxaban administered once daily in the evening.
1771199|NCT00362232|Drug|Placebo: syringes of Enoxaparin|Placebo syringes of enoxaparin twice a day (bid) administered once in the morning and once in the evening.
1771200|NCT00362245|Drug|Systemic and Intra-Thecal Amikacin Therapy|
1771201|NCT00362258|Drug|Irbesartan (Aprovel)|Aprovel (150 & 300mg) & CoAprovel (300/12.5mg hydrochlorothiazide) one tablet/day per os.
1771202|NCT00362271|Drug|Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.|Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
1771203|NCT00362284|Behavioral|NYUCI-AC|Approximately six individual and family consultation sessions (2 individual, 3 family, 1 individual) within the first 4 months with adult child caregivers and/or their family members; support group participation (recommended at least once a month) after the completion of the individual and family consultation sessions for the duration of the project (up to 3 years after the intake interview); ad hoc consultation (ongoing in-person, telephone, or email support on an as-needed basis) for the duration of the project (up to 3 years after the intake interview); New York University Caregiver Intervention
1771204|NCT00362297|Drug|acyclovir|800 mg orally three times daily for 7 weeks
1771205|NCT00362297|Drug|valacyclovir|500 mg orally once daily for 7 weeks
1771206|NCT00362310|Drug|indinavir|
1771207|NCT00362323|Drug|fenofibrate (F) + metformin (M) hydrochloride fixed combination|F80mg/M500mg - per os - twice a day during 24 weeks / or / F80mg/M850mg - per os - twice a day during 24 weeks /or / F54mg/M850mg - per os - three times a day during 24 weeks
1771208|NCT00362323|Drug|Metformin|500mg - per os - twice a day during 24 weeks /or / 850mg - per os - twice a day during 24 weeks /or / 850mg - per os - three times a day during 24 weeks
1771209|NCT00362336|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular (IM)
1771210|NCT00362336|Biological|CombAct-HIB®|0.5 mL, IM
1771211|NCT00362336|Biological|Engerix B® Pediatric|0.5 mL, IM
1771212|NCT00362349|Drug|IgNextGen 10%|"Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:
Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.
Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days"
1771213|NCT00362375|Behavioral|Healthy Love Workshop|The Healthy Love Workshop is a single-session intervention lasting 3-4 h that is typically delivered to groups of 4-15 women; however, SisterLove facilitators can accommodate larger groups if needed. The intervention is designed to increase consistent use of condoms and other latex barriers, reduce unprotected sex with male partners, and reduce the number of sex partners. HLW also promotes sexual abstinence, HIV testing, and receipt of test results.
1771214|NCT00362375|Behavioral|HIV/AIDS 101 Workshop|The comparison workshop (named HIV101) was also delivered as a single session lasting 2-3 h, to groups of women about the same size and in settings similar to those used for the HLW. The HIV101 workshop consists of an opening, one module containing the same three HIV/STD-related components as the HLW (HIV/AIDS facts, STI facts, and the Look of HIV) and a closing. However, the presentation of this information used a didactic, lecture-style format, as opposed to the interactive approach used to deliver the HLW.
1771215|NCT00362388|Procedure|Intramyocardial injection of autologous bone marrow cells|
1771216|NCT00362414|Drug|Dual Growth Factor|"10,000 IU Beta-hCG IV on days 1, 3, and 5 of study participation
30,000 IU Erythropoietin IV on days 7, 8 and 9 of study participation"
1771217|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM
1771218|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 Ml, 4 doses, IM
1771219|NCT00362427|Biological|Hybrid 5 component DTaP, Vero IPV, Hep B and PRP-OMPC|0.5 mL, 4 doses, IM with concommitant vaccines
1771220|NCT00362440|Drug|Leptin|
1771221|NCT00362440|Drug|Pioglitazone or metformin|
1771222|NCT00362440|Drug|Placebo|
1771223|NCT00362453|Behavioral|Tai Chi versus Attention Control|60 minutes, twice a week for 12 weeks.
1771224|NCT00362466|Drug|Dasatinib|Tablets, Oral, Once daily, 5-7 years
1771225|NCT00362466|Drug|Imatinib|Tablets, Oral, Once daily, 5-7 years
1771226|NCT00362479|Drug|DR-1021|1 tablet daily
1771227|NCT00362492|Procedure|Bilateral ultrasound examination 7+/- 2 after surgery|
1771228|NCT00362505|Drug|Clevudine|
1771229|NCT00362518|Dietary Supplement|Study Arm A|Control: no vitamins (placebo only). This study will provide baseline metabolic and surrogate marker changes that are caused by the high fat meal. Study arms B, C, and D will be statistically compared to this study.
1771230|NCT00362518|Dietary Supplement|Study Arm B|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a low dosage form of vitamin C is administered (250 mg) and Vitamin E (200 IU).
1771231|NCT00362518|Dietary Supplement|Study Arm C|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a medium dosage form of vitamin C administered (500 mg)and Vitamin E (400 IU).
1771232|NCT00362518|Dietary Supplement|Study Arm D|This study arm will provide information on the response of atherogenic surrogate markers to a high fat supper when a high dosage form of vitamin C is administered (1000 mg) and Vitamin E (800 IU).
1771233|NCT00362531|Drug|tacrolimus combined with prednisone|
1771234|NCT00362544|Drug|Ambisome|
1771235|NCT00362557|Device|MRI|Magnetic resonance imaging
1771236|NCT00362570|Drug|Temozolomide|"p.o.(by mouth), 150 mg/m2/d x days 1-7 and 15-21, given every 28 days [i.e., 7 days on/7 days off] using a standardized dosing range.
Administration: Temozolomide will be administered on an empty stomach (i.e., 1 hour before or 2 hours after any oral intake)."
1771237|NCT00362583|Drug|Fentanyl|
1771238|NCT00362596|Drug|acyclovir|
1771239|NCT00362609|Drug|pantoprazole|
1771240|NCT00362635|Drug|Clevudine|
1771241|NCT00362648|Biological|RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent|2.0 mL oral dose of RotaTeq™. 14 week treatment period
1771242|NCT00362648|Biological|Comparator: Placebo|Arm 2: Placebo. 14 week treatment period
1771243|NCT00362661|Drug|Cortisol|Cortisol 10 mg/d for 3 months
1771244|NCT00362687|Drug|Truvada (TDF+FTC) alone|tenofovir DF 300 mg and emtricitabine 200 mg in a fixed dose tablet formulation
1771245|NCT00362687|Drug|FTC alone|emtricitabine 200 mg
1771246|NCT00362687|Procedure|No HAART|No HAART
1771247|NCT00362700|Drug|Clevudine|
1771248|NCT00362713|Drug|Ipilimumab|Intravenous Solution, Intravenous, One dose every 3 weeks for four weeks, followed through Week 24
1771249|NCT00362726|Drug|Rosiglitazone maleate|Tablets, Oral, RGZ 4 mg, once daily, 1 day.
1771250|NCT00362726|Drug|Atazanavir Sulphate|Capsules, Oral, ATV 400 mg, once daily, 5 days.
1771251|NCT00362726|Drug|Atazanavir Sulphate + Rosiglitazone maleate|Capsule, Oral, ATV 400 mg + RGZ 4 mg, once daily, 1 day.
1771252|NCT00362726|Drug|Atazanavir Sulphate + Ritonavir|Capsules, Oral, ATV 300 mg + RTV 100 mg, once daily, 14 days.
1771253|NCT00362726|Drug|Atazanavir Sulphate + Ritonavir + Rosiglitazone maleate|Capsules/Tablets, Oral, ATV 300 mg + RTV 100 mg + RGZ 4 mg, once daily, 1 day.
1771254|NCT00362752|Drug|Norfloxacin|400 mg po bid
1771255|NCT00362752|Drug|Placebo|Placebo 400 mg po bid
1771256|NCT00362765|Drug|Fenofibrate|160 mg
1771257|NCT00362765|Drug|Metformin|2000 mg
1771258|NCT00362765|Drug|Placebo|Placebo
1771259|NCT00362778|Drug|Insulin|intravenous continuous insulin infusion for 48 hours
1771260|NCT00362791|Behavioral|"Enhanced HIV/STD Counseling: 4 face-to-face, interctive counseling sessions based on the Theory of Reasoned Action & Health Belief Model"|
1771261|NCT00362791|Behavioral|"Brief Counseling (aka client-centered counseling): 2 brief, face-to-face interactive sessions targeted a patient-identified risk behavior"|
1771262|NCT00362791|Behavioral|"HIV Prevention Education: 2 brief, didactic sessions informing the patient about HIV/STD prevention strategies"|
1771263|NCT00362804|Drug|Tetrabenazine|The initial TBZ dose will be 12.5 mg and the dose will be increased to 25 mg at Week 2. Thereafter, the dose can be decreased to 12.5 mg or increased in 12.5 mg increments at weekly intervals, depending on clinical response and tolerability, to a maximum of 75 mg/day. For 37.5 and 50 mg daily, administration will be BID i.e., 25 mg QAM, 12.5 or 25 mg QHS. For 62.5 or 75 mg daily, a TID dosing will be employed i.e., 25 mg QAM, 12.5 or 25 mg QPM, 25 mg QHS
1771264|NCT00362817|Drug|carboplatin|IA carboplatin 200 mg/m2/day for each arterial injection on days 1 and 2.
1771265|NCT00362817|Drug|temozolomide|150 mg/m2/day orally Days 1-5. Treatment cycles to be repeated every 4 weeks.
1771266|NCT00362830|Drug|vinflunine + ixabepilone|solution for injection, IV, vinflunine: 250 to 320 mg/m2 + ixabepilone: 30 to 40 mg/m2, every 3 wks, variable duration
1771267|NCT00362856|Drug|larazotide acetate|capsule
1771268|NCT00362856|Drug|Placebo|capsule
1771269|NCT00362869|Drug|Levofloxacin|Administered at a dose of 500 mg once a day for 3 days
1771270|NCT00362869|Drug|Placebo|Sodium bicarbonate solution
1771271|NCT00362869|Biological|Enteroaggregative E. coli (EAEC)|Dosages: 1X10^9, 5X10^9, 1X10^10, and 5X10^10 cfu; given in a sodium bicarbonate solution
1771272|NCT00362882|Drug|docetaxel|Given IV
1771273|NCT00362882|Drug|bortezomib|Given IV
1771274|NCT00362882|Other|laboratory biomarker analysis|correlative study
1771275|NCT00362882|Other|immunoenzyme technique|correlative study
1771276|NCT00362882|Other|immunohistochemistry staining method|correlative study
1771277|NCT00362882|Other|pharmacological study|correlative study
1771278|NCT00362895|Drug|Tobramycin 0.3% / Dexamethasone 0.033% ophthalmic suspension|One drop in the study eye, single dose
1771279|NCT00362895|Drug|Tobramycin 0.3% / Dexamethasone 0.1% ophthalmic suspension (TOBRADEX)|One drop in the study eye, single dose
1771282|NCT00362921|Drug|Gliadel wafers in combination with O6-benzylguanine|
1771283|NCT00362934|Drug|fenofibrate / simvastatin|Combination of fenofibrate and simvastatin 20 mg and 40 mg
1771284|NCT00362934|Drug|Atorvastatin|Atorvastatin 10 mg and 20mg
1771285|NCT00362947|Drug|LMWH parnaparin subcutaneously|
1771286|NCT00362960|Drug|Olmesartan medoxomil|
1771287|NCT00362960|Drug|Losartan|
1771288|NCT00362973|Other|laboratory biomarker analysis|
1771289|NCT00362973|Procedure|needle biopsy|
1771290|NCT00362973|Procedure|positron emission tomography|
1771291|NCT00362973|Procedure|radionuclide imaging|
1771292|NCT00362973|Radiation|fludeoxyglucose F 18|
1771293|NCT00362986|Drug|sunscreen|
1771294|NCT00362986|Other|placebo|
1771295|NCT00363012|Biological|HER-2/neu intracellular domain protein|300mcg (100mcg/peptide) of the HER2 ICD peptide mixture per skin test. This will be injected intradermally on the back at 6 months post active immunization.
1771296|NCT00363012|Other|flow cytometry|This is a laboratory test used to assess the antigen specific T cell population.
1771297|NCT00363012|Other|immunohistochemistry staining method|This is a laboratory test used to identify CD3+, CD4+, CD45R0+, CD8+, and DC1a+ present in the skin biopsy.
1771298|NCT00363012|Procedure|biopsy|A 3mm punch biopsy is taken of the vaccine site. This is taken for laboratory analysis for immunohistochemical staining.
1771299|NCT00363012|Other|Sterile water placement|100mcg of sterile water will be administered intradermally on the back and serves as a negative control for the laboratory analysis. This will be injected intradermally on the back at 6 months post active immunization.
1771300|NCT00363025|Procedure|Two post-remission strategies|
1771301|NCT00363025|Drug|Idarubicin versus daunorubicin|
1771302|NCT00363038|Drug|Petrolatum United States Pharmacopeia (USP)|Topical formation applied to bruise twice daily for 2 weeks.
1771303|NCT00363038|Drug|Vitamin K and retinol ointment|Topical formation applied to bruise twice daily for 2 weeks.
1771304|NCT00363038|Drug|Arnica ointment|Topical formation applied to bruise twice daily for 2 weeks.
1771305|NCT00363038|Drug|Vitamin K ointment|Topical formation applied to bruise twice daily for 2 weeks.
1771306|NCT00363051|Drug|Everolimus 10 mg|Participants took two 5 mg tablets of Everolimus orally with a glass of water, once daily (preferably in the morning) in a fasting state or after no more than a light, fat-free meal. Dosing was to occur at the same time each day. If vomiting occurred, the vomited dose was not to be replaced.
1771308|NCT00363077|Biological|GSK1247446A Group|Low dose influenza vaccine adjuvanted with AS03 compared
1771309|NCT00363077|Biological|Fluarix™|GlaxoSmithKline (GSK) Biologicals' inactivated influenza split vaccine.
1771310|NCT00363090|Biological|alemtuzumab|
1771311|NCT00363090|Drug|cyclophosphamide|
1771312|NCT00363090|Drug|doxorubicin hydrochloride|
1771313|NCT00363090|Drug|prednisone|
1771314|NCT00363090|Drug|vincristine sulfate|
1771315|NCT00363090|Other|flow cytometry|
1771316|NCT00363090|Other|pharmacological study|
1771317|NCT00363116|Drug|Daclizumab|daclizumab 1 mg/kg/dose every 14 days for 5 doses
1771318|NCT00363129|Dietary Supplement|vitamin E|Given orally
1771319|NCT00363129|Other|placebo|Given orally
1771320|NCT00363142|Drug|Half-boosted Fosamprenavir|Once daily, reduced dose ritonavir-boosted fosamprenavir
1771321|NCT00363142|Drug|Full Boosted Fosamprenavir|Full ritonavir-boosted fosamprenavir
1771322|NCT00363155|Drug|KRN7000|
1771323|NCT00363168|Drug|Ranibizumab|0.3 mg/0.05 ml dose
1771324|NCT00363168|Drug|Ranibizumab|0.5 mg/0.05 ml dose
1771325|NCT00363194|Drug|Pazopanib (GW786034)|
1771326|NCT00363233|Drug|flax lignans|
1771327|NCT00363259|Drug|Peginterferon alfa-2b|
1771328|NCT00363259|Drug|Ribavirin|
1771329|NCT00363272|Drug|ispinesib|Given IV
1771330|NCT00363272|Other|laboratory biomarker analysis|Correlative studies
1771331|NCT00363272|Other|pharmacological study|Correlative studies
1771332|NCT00363285|Biological|gonadotrophin releasing hormone|
1771333|NCT00363285|Drug|cyproterone acetate|
1771334|NCT00363285|Procedure|quality-of-life assessment|
1771335|NCT00363298|Drug|dextro-amphetamine|dextro-amphetamine dosage form: 15 mg capsules, in Bottles A and B. Dosage: One capsule from Bottle A and one capsule from bottle B each morning. Frequency: once daily. Duration: 5 weeks.
1771336|NCT00363298|Drug|Sham Comparison|caffeine dosage form: capsules identical to those in dextro-amphetamine arm, but containing 200 mg caffeine in Bottle A and 100 mg caffeine in Bottle B. Frequency: once daily. Duration: 5 weeks
1771337|NCT00363311|Drug|Dutasteride|Dutasteride 0.5mg
1771338|NCT00363311|Drug|Matching placebo|Matching placebo
1771339|NCT00363324|Procedure|intracoronary injection of bone marrow cells|
1771340|NCT00363337|Drug|aripiprazole|open label treatment with aripiprazole
1771341|NCT00363350|Drug|rituximab (anti-CD20)|2 infusions of 1000 mg
1771342|NCT00363363|Behavioral|Physical Activity|Children in this arm of the study will be provided with specific activities to be completed on most days of the week. The selected activities will be based on the child's interests and results of the baseline measures of health-related PA, MVPA and gross motor skill. The resources and facilities available to the family and season of the year will also influence the choice of activities. The frequency and duration of the required activities will be gradually increased until the child's baseline MVPA has been increased by a minimum of 30 minutes per day, most days of the week. Once that increase is achieved, the activities will be modified to maintain and reinforce the higher PA level.
1771343|NCT00363363|Behavioral|Education|Children in this arm of the study will be provided with puzzles, stories and games to be completed each week. The selected activities will be based on the child's interests and designed to increase the child's knowledge of activity options, perceptions of activity benefits, self-confidence for activity participation and motivation for daily activity. The activities introduced will vary with the resources available to the family and the season of the year, and will include information about healthy eating, injury prevention, and healthy lifestyle options.
1771344|NCT00363376|Drug|zonisamide|Zonisamide will be administered at an initial dose of 100 mg/d for 7 days. Subsequently, zonisamide may be increased, based on clinical response and tolerability, by 100mg/d every 7 days to a maximum of 600 mg/d by the end of the sixth week of treatment. The maximum amount of zonisamide allowed during the study will be 600 mg/day. The minimum amount of zonisamide allowed during the study will be 100 mg/d. Zonisamide will initially be given as a single pm dose, but alterations in dosing will be permitted to reduce side effects (e.g., as BID dosing to reduce nausea).
1771345|NCT00363376|Drug|olanzapine|olanzapine will be administered open-label at 5-20 mg/d titrated to optimize response and minimize side effects
1771346|NCT00363376|Drug|Zonisamide|zonisamide ranging from 100mg to 600mg daily
1771347|NCT00363376|Drug|Sugar Pill (placebo)|sugar pill (placebo) for zonisamide
1771348|NCT00363389|Drug|misoprostol and cervical ripening|
1771349|NCT00363402|Procedure|PET-CT|
1771350|NCT00374374|Behavioral|Administration of probiotic|
1771351|NCT00374387|Drug|Nuvaring|
1771352|NCT00374387|Drug|low-dose combination pill|
1771353|NCT00374387|Drug|minipill|
1771354|NCT00374413|Device|Artificial disk|Implant
1771355|NCT00374413|Device|Artificial disc|Implant
1771356|NCT00374426|Drug|sertraline|
1771357|NCT00374439|Behavioral|Cognitive-behavioral|Cognitive-behavioral approach
1771358|NCT00374439|Behavioral|Interpersonal Therapy|Interpersonal therapy approach
1771360|NCT00374465|Drug|Verapamil|
1771361|NCT00374465|Drug|Carvedilol|
1771362|NCT00374478|Drug|Scopolamine|
1771363|NCT00374517|Drug|Pimonidazole hydrochloride|
1771364|NCT00374530|Drug|PGE2|
1771365|NCT00374543|Drug|Ziprasidone|Ziprasidone, flexibly dosed from 40 to 160 mg/day, for 8 weeks.
1771366|NCT00374543|Drug|Placebo|Placebo administered daily for 8 weeks
1771368|NCT00374569|Procedure|Gymnastic Routine|A combination of gymnastic movements are performed
1771429|NCT00375661|Drug|interferon-alfa-2b and ribavirin|Interferon, pnce per week plus daily ribavirin
1771488|NCT00376103|Procedure|Brachytherapy|60 Gy to 1 cm
1771489|NCT00376103|Procedure|External Beam Radiation Therapy|60 Gy
1771371|NCT00374621|Drug|Misoprostol with or without isosorbide mononitrate|Misoprostol 50 micrograms orally then 100 micrograms every 4 hours for up to four doses until modified Bishop score of 8 or higher was observed vs. the same misoprostol dosing plus isosorbide mononitrate 40 mg vaginally every 6 hours up to two doses total until a modified Bishop sore of at least 8 was observed
1771372|NCT00374634|Drug|rFSH drug dose|"Individual rFSH dose (50, 75 or 100 IU rFSH/day)"
1771373|NCT00374634|Drug|"Standard rFSH dose"|"Standard rFSH dose was 75 IU/day"
1771374|NCT00374647|Drug|mycophenolate mofetil|
1771375|NCT00374647|Drug|sirolimus|
1771376|NCT00374660|Drug|Irofulven + oxaliplatin|"Oxaliplatin will be administered in a 2-hour infusion on Days 1 and 15 of a 28-day cycle. Starting dose 40 mg/m^2, dose escalation 50, 60, 70, and 80 mg/m^2 every 28 days if no dose-limiting toxicity.
Thirty minutes after completion of oxaliplatin infusion, irofulven will be administered in a 30-minute infusion on Days 1 and 15 of a 28-day cycle. Starting dose 0.30 mg/kg, dose escalation to 0.40 mg/kg every 28 days if no dose-limiting toxicity."
1771377|NCT00374673|Device|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation of the motor cortex (10 Hz) every day during 5 days then every week for 3 weeks then every two weeks for 2 months then every month for 3 additional months
1771378|NCT00374686|Drug|Valganciclovir|
1771379|NCT00375115|Drug|Sambucol|
1771380|NCT00375128|Biological|FP9-PP (FP9 polyprotein)|
1771381|NCT00375128|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
1771382|NCT00375141|Device|Pulsed dye laser, Intense pulsed light|
1771383|NCT00375154|Device|Noninvasive Positive-Pressure Ventilation (NPPV)|
1771385|NCT00375193|Drug|Amrubicin|Amrubicin 40mg/m<2> IV days 1, 2, 3 of each 21-day cycle until Cycle 6 or no longer beneficial
1771386|NCT00375206|Biological|Trivalent DNA Vaccine (PIA0601) with or without DEI-LT (pPJV2012)|
1771388|NCT00375232|Drug|Administration of montelukast or placebo|
1771389|NCT00375245|Drug|Rapamycin (sirolimus)|Weekly oral doses, dose is assigned at the time of study entry
1771390|NCT00375245|Other|Grapefruit Juice|Daily oral doses starting during the second week on study.
1771391|NCT00375258|Drug|Tranexamic acid|Loading dose of 1 gram then 1 gram by infusion over 8 hours
1771392|NCT00375258|Drug|Sodium Chloride 0.9%|Visual matched placebo
1771393|NCT00375271|Procedure|perioperative hemodynamic optimization protocol|
1771394|NCT00375284|Drug|Pramipexole|
1771395|NCT00375297|Drug|sildenafil|
1771396|NCT00375310|Drug|Gemcitabine, Sorafenib|"Gemcitabine is given IV
Sorafenib is given orally of varying doses:
Sorafenib 200 mg po qd ( during combination therapy)
Sorafenib 400 mg po qd ( during combination therapy)
Sorafenib 400 mg po bid ( during combination therapy)"
1771397|NCT00375310|Procedure|Radiotherapy|1.8 Gy CTV daily for 5 weeks
1771398|NCT00375323|Drug|NovoSeven|
1771399|NCT00375349|Procedure|Ultrasound to demonstrate existence of fatty liver|
1771400|NCT00375362|Drug|Nitroderm patch|
1771401|NCT00375375|Drug|Lactulose|
1771402|NCT00375388|Drug|Metformin on top of intensive insulin therapy|
1771403|NCT00375401|Drug|CP-945,598 Treatment A|Arm includes CP-945,598 Treatment A plus Dietary, Physical Activity, and Weight Loss Counseling
1771404|NCT00375401|Drug|CP-945,598 Treatment B|Arm includes CP-945,598 Treatment B plus Dietary, Physical Activity, and Weight Loss Counseling
1771405|NCT00375401|Drug|Placebo|Arm includes Placebo plus Dietary, Physical Activity, and Weight Loss Counseling
1771406|NCT00375414|Procedure|PEG-Gastropexy|
1771407|NCT00375427|Drug|Zoledronic acid|Zoledronic acid as a 15-minute (at least) intravenous (i.v.) infusion. The dose of study drug will be the same administered before the study entry, that is 4 mg or a reduced dose, i.e. 3.5 mg, or 3.3 mg or 3.0 mg.
1771408|NCT00375440|Drug|Tranexamic Acid|
1771409|NCT00375453|Drug|SH U04722|
1771410|NCT00375466|Drug|Tranexamic acid|Tranexamic acid 10 mg/kg as a bolus dose followed by an infusion of 1 mg/kg/hour. Bolus given before start of surgery, infusion continued during surgery.
1771411|NCT00375466|Drug|placebo|0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
1771412|NCT00375492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
1771413|NCT00375492|Drug|placebo|subcutaneous injection, volume equivalent to exenatide dose, twice a day
1771414|NCT00375505|Drug|Zoledronic acid|
1771415|NCT00375505|Drug|Placebo|Placebo
1771416|NCT00375518|Drug|Atorvastatin|Atorvastatin 40 mg once a day beginning 7 days before the operation. Surgical procedures will be as planned and unaffected by this study. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
1771417|NCT00375518|Drug|Placebo|Placebo given beginning 7 days before the operation. Starting from the day after surgery, patients will be given their study drug for an additional 7 days.
1771418|NCT00375531|Behavioral|Mindfulness Meditation (MfM)|
1771419|NCT00375544|Device|Low level light therapy|
1771420|NCT00375557|Drug|Divalproex ER|Divalproex ER will be initiated on 250 mg/day, dosed once daily. The daily dose of Divalproex ER will be titrated up 250 mg each day based on patients' response and tolerability, not to exceed a maximum of 2000 mg/day.
1771421|NCT00375557|Drug|Quetiapine|Quetiapine will be initiated in 25 mg/day, with a variable dosing frequency (QD-TID). The daily dose of Quetiapine will be titrated up by 25-50 mg each day based on patients' response and tolerability, not to exceed a maximum of 750 mg/day.
1771422|NCT00375570|Drug|ME-609|Topical treatment 5 times daily for 5 days
1771423|NCT00375583|Drug|DEC/Albendazole|
1771424|NCT00375596|Drug|Ketotifen/vasoconstrictor|
1771426|NCT00375622|Drug|Tamoxifen|
1771427|NCT00375635|Procedure|mFPSA treatment|
1771428|NCT00375648|Drug|Zoledronic acid|
1771430|NCT00375674|Drug|Sunitinib malate|sunitinib malate 50 mg PO on schedule 4/2: 4 weeks on, 2 weeks off for 1 year or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent.
1771431|NCT00375674|Other|Placebo|Placebo PO for 1 year on schedule 4/2: 4 weeks on, 2 weeks off or until disease recurrence or occurrence of a secondary malignancy, significant toxicity, or withdrawal of consent
1771432|NCT00375687|Drug|Triptorelin|
1771433|NCT00375700|Dietary Supplement|Nutritional Supplement|
1771434|NCT00375713|Drug|Levocetirizine|1 Levocetirizine 5mg tablet per day before bedtime for 14 days
1771435|NCT00375713|Drug|Cetirizine|1 Cetirizine 10mg tablet per day before bedtime for 14 days.
1771436|NCT00375713|Drug|Placebo-Levocetirizine|1 Placebo-Levocetirizine tablet per day before bedtime for 14 days
1771437|NCT00375713|Drug|Placebo-Cetirizine|1 Placebo-Cetirizine tablet per day before bedtime for 14 days
1771438|NCT00375713|Drug|Standard topical steroid (1% hydrocortisone) ointment|1% hydrocortisone ointment, applied 2-3 times a day to all affected areas
1771439|NCT00375726|Biological|rDEN3/4delta30(ME)|Live attenuated rDEN3/4delta30(ME) vaccine (one of three doses)
1771440|NCT00375726|Biological|Placebo|Placebo for rDEN3/4delta30(ME)
1771441|NCT00375739|Drug|PEP005|
1771444|NCT00375765|Drug|Dutasteride|
1771445|NCT00375778|Drug|memantine (drug)|
1771446|NCT00375791|Drug|perifosine|100 - 150 mg daily
1771447|NCT00375791|Drug|dexamethasone|20 mg twice weekly
1771448|NCT00375817|Procedure|Myoblasts injection with MyoCath catheter|
1771449|NCT00375830|Procedure|Positron Emission Tomography|Undergo 18F NaF PET/MRI
1771450|NCT00375830|Procedure|Magnetic Resonance Imaging|Undergo 18F NaF PET/MRI
1771451|NCT00375830|Radiation|Fludeoxyglucose F-18|105851-17-0, 18FDG, 2-Deoxy-2-(18F)Fluoro-D-Glucose, 2-F18-Fluoro-2-deoxy-D-glucose, 2-F18-Fluoro-2-deoxyglucose, 723398, FDG, fludeoxyglucose F 18, FLUDEOXYGLUCOSE F-18, Fludeoxyglucose F-18, Fludeoxyglucose F-18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18
1771452|NCT00375830|Radiation|Fluorine F 18 Sodium Fluoride|Undergo 18F NaF PET/MRI
1771453|NCT00375843|Drug|Escitalopram|Level 1 of the study involves open-label treatment with escitalopram, up to 30 mg/day for up to 12 weeks.
1771454|NCT00375843|Drug|Sertraline|Level 2 of the study involves open-label treatment with sertraline, up to 200 mg/day for up to 12 weeks.
1771455|NCT00375856|Device|DePuy P.F.C.® Sigma Rotating Platform Knee|no details
1771456|NCT00375869|Drug|Darbeopoetin|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
1771457|NCT00375869|Drug|Normal Saline (Placebo)|The treatment group, comprised of ten patients, will receive an intravenous dose of 200 mcg (1 ml) of darbepoetin (Aranesp®). Patients will be randomly assigned to either the treatment group, or the control group in a 2:1 ratio. The treatment group will be given 200 mcg of darbepoetin intravenously. The control group will be given a matching placebo of 1 mL of normal saline.
1771458|NCT00375882|Procedure|hypothermia|
1771459|NCT00375882|Procedure|cochlear implantation with mild hypothermia|
1771460|NCT00375895|Drug|ciclosporin|ciclosporin administered orally twice a day, at the initial dosing of 2.5 mg/kg/d, adjusted to obtain a C2 concentration of 600 ng/ml associated with the usual ribavirin and PEGinterferon bitherapy.
1771461|NCT00375934|Drug|diclofenac potassium (XP21L)|25 mg capsule, every 6 hours
1771462|NCT00375934|Drug|Placebo|Oral placebo capsule, every 6 hours
1771463|NCT00375947|Other|Hand Exercise|
1771464|NCT00375947|Other|sham hand cream|placebo intervention
1771465|NCT00375960|Drug|V3381|
1771466|NCT00375960|Drug|Placebo|
1771467|NCT00375973|Drug|Duloxetine|Duloxetine po 60-120 mg/day for 12 weeks
1771468|NCT00375973|Drug|Placebo|Sugar pill dose comparable to duloxetine
1771469|NCT00375986|Procedure|Manual placental removal at Cesarean delivery|
1771470|NCT00375986|Procedure|Spontaneous placental removal at Cesarean delivery|
1771471|NCT00375999|Drug|Docetaxel and epirubicin|
1771472|NCT00376012|Drug|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 4 months.
1771473|NCT00376012|Drug|Anti-TB drugs (Ethambutol, Isoniazid, Rifampicin and Pyrazinamide)|Arm 1 is a standard six-month intermittent regimen consisting of Ethambutol, Isoniazid, Rifampicin and Pyrazinamide given thrice weekly for 2 months followed by Rifampicin and Isoniazid given thrice-weekly for 7 months.
1771474|NCT00376025|Dietary Supplement|Biological Antioxidant Supplementation|Supplementation of affected population with the Phytochemical antioxidant, Garcinia Mangostata in addition to sodium selenate.
1771475|NCT00376038|Drug|GSK189075 oral tablets|
1771476|NCT00376038|Drug|metformin tablets|
1771477|NCT00376051|Drug|Citalopram|Titrates from 10mg/day to 40mg/day, increases 10mg per week.
1771478|NCT00376064|Drug|Octreotide acetate and cabergoline/Octrotide and Somavert|
1771479|NCT00376077|Drug|Methylprednisolone and IVIG|Combination therapy (IV MP (Solu-Medrol®, Upjohn) 30 mg/kg (max. 1 g) over 1 hour followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous [Human], 10%; Bayer)* x 1 dose
1771480|NCT00376077|Drug|Placebo and IVIG|Placebo followed by IVIG 1 g/kg (Gamunex Immune Globulin Intravenous [Human], 10%; Bayer)* x 1 dose
1771487|NCT00376103|Drug|temozolomide|75 mg/m2/day
1956914|NCT02631538|Drug|Belimumab|Belimumab will be provided as a 200 mg sterile, liquid product in a prefilled syringe. Each syringe contains 1.0 mL of 200 mg/mL belimumab. Each syringe will be a single use.
1771490|NCT00376116|Device|Cardiac resynchronisation therapy|
1771491|NCT00376116|Device|Implantable cardioverter-defibrillator|
1771492|NCT00376129|Drug|Alefacept|15 mg i.m. once weekly for 12 weeks
1771493|NCT00376142|Behavioral|Psychological theory-based behaviour change interventions|
1771494|NCT00376155|Drug|sulfadoxine /pyrimethamine plus amodiaquine|
1771495|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks for 9 months
1771496|NCT00376168|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every 2 weeks for 9 months
1771497|NCT00376181|Drug|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 20 mg combination tablets, orally, once daily for up to 24 weeks.
1771498|NCT00376181|Drug|Pioglitazone and Azilsartan|Pioglitazone 45 mg and Azilsartan 40 mg combination tablets, orally, once daily for up to 24 weeks.
1771499|NCT00376181|Drug|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily for up to 24 weeks.
1771500|NCT00376194|Drug|DMSA|
1771501|NCT00376207|Behavioral|Physical exercise|
1771502|NCT00376220|Drug|Riluzole|Initially dispensed 50 mg capsules to take twice a day (BID). At two weeks, increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules in the morning (qAM), two capsules in the evening (qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as Montgomery Asberg Depression Rating Scale (MADRS) < 12) the dose will not be increased further unless clinical symptoms recur.
1771503|NCT00376220|Other|Placebo|Initially dispensed 50mg capsules to take BID. At two weeks increase dose to 50 mg/100 mg. At four weeks increase to 100 mg BID (two capsules qAM, two capsules qHS). If significant side effects occur (at any time), titration can be slowed and doses can be reduced to a minimum daily dose of 50 mg/day, after which titration may resume by no more than 50 mg a week. Subjects who are unable to tolerate the minimal daily dose permitted in the study will be discontinued from further participation. In addition, if clinical remission is observed at a lower dose of study medication (defined as MADRS < 12) the dose will not be increased further unless clinical symptoms recur.
1771504|NCT00376246|Drug|Ezetimibe|
1771505|NCT00376259|Drug|telbivudine|600mg/day oral tablet for 96 weeks
1771506|NCT00376259|Drug|adefovir dipivoxil|10 mg of adefovir by mouth once daily
1771507|NCT00376272|Drug|Valsartan|
1771508|NCT00376272|Drug|Placebo|
1771509|NCT00376285|Drug|CP-742,033|
1771510|NCT00376285|Drug|Fenofibrate|
1771511|NCT00376311|Drug|oral salmon calcitonin|
1771512|NCT00376324|Drug|Tigecycline|Each subject will receive 3 IV doses of tigecycline, as 30-minute infusions: Dose 1 = 100 mgDose 2 = 50 mgDose 3 = 50 mg The doses of tigecycline will be administered to the subjects at approximately 12-hour intervals.
1956915|NCT02631538|Drug|Rituximab|Rituximab will be provided as a 100 mg concentrated solution for infusion. It is a clear, colorless liquid.
1771515|NCT00376350|Procedure|Spinal Manipulation|5 minutes high velocity, low amplitude lumbar thrust
1771516|NCT00376350|Procedure|Light Massage|light pressure massage of the low back.
1771517|NCT00376350|Procedure|Pulsed Ultrasound|5 minutes pulsed ultrasound
1771518|NCT00376363|Device|Ahmed implant|placement of glaucoma drainage device to control intraocular pressure
1771519|NCT00376363|Device|Baerveldt implant|placement of glaucoma drainage device to control intraocular press
1771520|NCT00376376|Drug|levofloxacin at 250, 500, 750, and 1000 mg doses|
1771521|NCT00376402|Biological|H5N1 Pandemic Influenza Vaccine|
1771522|NCT00376415|Drug|Lessertia Fructescens|Participants received 400mg lessertia fructescens leaf powder capsules twice daily for 3 months.
1771523|NCT00376415|Drug|Placebo|Participants received an identical placebo capsule twice daily for 3 months.
1771524|NCT00376428|Drug|Gentamicin|
1771525|NCT00376441|Procedure|Vaginal Surgery|patients undergoing vaginal surgery
1771526|NCT00376454|Drug|GW493838|
1771527|NCT00376467|Drug|Imatinib|
1771528|NCT00376480|Biological|anti-thymocyte globulin|
1771529|NCT00376480|Biological|peripheral blood lymphocyte therapy|
1771530|NCT00376480|Drug|fludarabine phosphate|
1771531|NCT00376480|Drug|methylprednisolone|
1771532|NCT00376480|Drug|thiotepa|
1771533|NCT00376480|Procedure|allogeneic hematopoietic stem cell transplantation|
1771534|NCT00376480|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1771535|NCT00376480|Radiation|total-body irradiation|
1771536|NCT00376493|Drug|metronidazole and doxycycline|use of metronidazole 500mg/day and doxycycline 200mg/day up to 10 days
1771537|NCT00376506|Device|Neurostimulation device for dysphagia|A neurostimulation device that is surgically implanted in the swallowing muscles.
1771538|NCT00376506|Device|External vibrotactile device|A vibrotactile device that is placed on the neck during swallowing.
1771539|NCT00376519|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush and mesna (MT(S)9006) on day -8 and -7 one hour after fludarabine infusion.
1771540|NCT00376519|Drug|cyclosporine|Will be administered beginning on day -3 and adjusted to maintain a level of >200. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours.
1771541|NCT00376519|Drug|fludarabine phosphate|Fludarabine 25 mg/m^2/day will be administered as a 1 hour intravenous infusion on days -9 through -7.
1771542|NCT00376519|Drug|mycophenolate mofetil|All patients will begin mycophenolate mofetil (MMF) on day -3, at the dose of 3 grams/day divided into 2 or 3 doses (every 12 or 8 hours).
1771543|NCT00376519|Procedure|Treg cell infusion|On day -1 prior to UCB transplantation, Treg cells will be infused IV without in-line filtration. A semi-log dose escalation of CD4+CD25+ Treg cells is scheduled with 3 patients at each step. Doses will be 0.1 x 10^6/kg, 0.3 x 10^6/kg, 1 x 10^6/kg and 3 x 10^6/kg weight (determined on the day prior to administration of the preparative therapy).
1771603|NCT00376935|Drug|Palifermin|Keratinocyte growth factor administered via injection
1771544|NCT00376519|Procedure|umbilical cord blood transplantation|Following the administration of the preparative therapy, all subjects will undergo UCB transplantation. The UCB will be administrated by IV infusion without in-line filtration.
1771545|NCT00376519|Radiation|total-body irradiation|Radiotherapy: 165 cGy will be administered on day -5 through -2 two fractions each day.
1771546|NCT00376558|Behavioral|Community Reinforcement Approach|Community Reinforcement Approach (CRA): The community reinforcement treatment program will be carried out in accordance with NIDA's therapy manual (13).During weeks 13 through 24, patients will meet once per week with their therapists. Sessions will focus on promoting continued change in the life areas addressed in the first 12 weeks of treatment or new components are added as needed.
1771547|NCT00376571|Procedure|Percutaneous coronary intervention|"Comparing treatment of either no side branch treatment versus stenting of main vessel and side branch treatment"
1771548|NCT00376584|Drug|MK-0524A|
1771549|NCT00376584|Drug|ER Niacin|
1771550|NCT00376584|Drug|Placebo|
1771551|NCT00376597|Other|quality of life assessment|Ancillary studies
1771552|NCT00376597|Other|educational intervention|Receive lymphedema educational materials
1771553|NCT00376597|Procedure|Physical therapy|Complete physical therapy-focused intervention
1771554|NCT00376610|Device|ASR/Re-cap|
1771555|NCT00376623|Drug|BI 2536|
1771556|NCT00376636|Drug|SPP635 (drug)|
1771557|NCT00376649|Behavioral|lifestyle changing workshop|
1771558|NCT00376662|Drug|Hormone Replacement Therapy and Etidronate|
1771559|NCT00376675|Drug|methylphenidate hydrochloride|Given orally
1771560|NCT00376675|Other|placebo|Given orally
1771563|NCT00376701|Drug|Avastin (Bevacizumab)|Avastin 1.25 mg intravitreal
1771564|NCT00376701|Drug|Bevacizumab|Intravitreal 1.25 mg
1771565|NCT00376701|Drug|Bevacizumab|Intravitreal 1.25 mg
1771566|NCT00376701|Drug|Bevacizumab|Intravitreal Avastin 1.25 mg and sham reduced fluence PDT
1771567|NCT00376714|Drug|GSK233705|
1771568|NCT00376727|Biological|cetuximab|Dose level 0: cetuximab 400 mg/m2 week 1, 250 mg/m2 weekly; Dose level 1: cetuximab 400 mg/m2 week 1, 300 mg/m2 weekly; Dose level 2: cetuximab 400 mg/m2 week 1, 350 mg/m2 weekly; Dose level 3: cetuximab 400 mg/m2 week 1, 400 mg/m2 weekly
1771569|NCT00376727|Genetic|molecular diagnostic method|Tissue and Blood Specimens; IHC Methodology; IHC Scoring; K-RAS Mutation Analysis
1771570|NCT00376727|Other|immunologic technique|Peripheral Blood Mononuclear Cells (PBMC)
1771571|NCT00376727|Other|laboratory biomarker analysis|Cetuximab Pharmacodynamics
1771572|NCT00376740|Drug|zoledronic acid|Zoledronic acid 4 mg IV every 6 months up to 2.5 years after the start of letrozole treatment.
1771573|NCT00376766|Drug|levetiracetam|
1771574|NCT00376779|Biological|Infanrix hexa Vaccine|
1771575|NCT00376792|Drug|docetaxel|
1771576|NCT00376792|Other|active surveillance|
1771577|NCT00376792|Procedure|adjuvant therapy|
1771578|NCT00376805|Drug|Fludarabine|administered intravenously 25 mg/m^2 times 5 doses
1771579|NCT00376805|Drug|Cyclophosphamide|administered intravenously 60 mg/kg days times 2 doses.
1771580|NCT00376805|Radiation|Total body irradiation|200 cGy (gray) on day -1
1771581|NCT00376805|Other|Natural killer cell infusion|Infused cell dose is within the range of 1.5-8.0 x 10^7/kg. Cell counts are based on total cells infused after the activation culture and washing determined on the morning of infusion.
1771582|NCT00376805|Biological|Interleukin-2|administered subcutaneously (10 MU) 3 times per week for 6 doses
1771583|NCT00376818|Behavioral|exercise intervention|All participants will convene once per week for 8 weeks for a 90-minute session that will be based on yoga principles for a stress reduction.
1771584|NCT00376818|Other|educational intervention|A 15-minute educational session on a particular topic (mind-body connection; fight or flight response; relaxation response; the science and philosophy of yoga; the science of meditation; sleeping well; mindfulness; the healer within - how to harness your innate healing potential).
1771585|NCT00376818|Other|physiologic testing|Both patients and family caregivers will complete Perceived Stress Scale (PSS) and Beck Anxiety Inventory (BAI) questionnaires.
1771586|NCT00376818|Other|management of therapy complications|Brain Cancer module-20 questionnaire to assesses problems specific to brain tumor.
1771587|NCT00376818|Behavioral|mind-body intervention procedure|"Meditation practice in this study will consist of 15 minutes of body scan to completely relax the body from head to toe and will be followed by 15 minute silence during which the study participants will maintain awareness of their breath, bodily sensations and thoughts as they spontaneously arise. The remainder of the class will be devoted to a group discussion of personal reflections and challenges."
1771588|NCT00376818|Procedure|Measurement of stress-related hormones|Measurements of stress-related hormones: Stress hormones cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin will be measured in saliva because their levels in saliva accurately reflect blood levels (Carlson et al, 2004). The non-invasive saliva collection method by cotton swabs (Salivette® by Sardstedt Inc.) will be used in this study.
1771589|NCT00376831|Drug|Midazolam, Fentanyl|fentanyl 0.07 mcg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
1771590|NCT00376831|Drug|KETAMINE, MIDAZOLAM|Ketamine 0.25 mg/kg + midazolam 0.05 mg/kg if needed adding midazolam up to a total of 0.1 mg/kg
1771591|NCT00376844|Radiation|External Beam Radiation Therapy|
1771592|NCT00376844|Radiation|Vaginal Brachytherapy|
1771593|NCT00376857|Drug|Surgery with and without the aid of Indocyanine Green (ICG)|
1771594|NCT00376870|Drug|Pioglitazone|pioglitazone 30 mg/d
1771595|NCT00376870|Drug|Placebo|Placebo 30 mg/d
1771596|NCT00376883|Drug|pamidronate|
1771597|NCT00376896|Drug|GW876008 200mcg|GW876008
1771598|NCT00376896|Drug|GW876008 20mcg|GW876008 20mcg
1771599|NCT00376896|Other|Placebo|placebo
1771600|NCT00376909|Other|educational intervention|
1771601|NCT00376909|Other|study of socioeconomic and demographic variables|
1771602|NCT00376922|Procedure|music therapy|music played for patient during bone marrow biopsy collection
1771604|NCT00376935|Drug|Palifermin placebo|Keratinocyte growth factor placebo administered via injection
1771605|NCT00376948|Dietary Supplement|genistein|
1771606|NCT00376948|Drug|erlotinib hydrochloride|
1771607|NCT00376948|Drug|gemcitabine hydrochloride|
1771608|NCT00376961|Biological|rituximab|375 mg/m^2 on day 1 for cycles 1-6.
1771609|NCT00376961|Drug|bortezomib|1.3 mg/m^2 on days 1, 4 of cycles 1-6 and on days 1, 4, 8, 11 of cycles 7-14.
1771610|NCT00376961|Drug|cyclophosphamide|750 mg/m^2 on day 1 of cycles 1-6.
1771611|NCT00376961|Drug|doxorubicin hydrochloride|50 mg/m^2 on day 1 of cycles 1-6.
1771612|NCT00376961|Drug|prednisone|100 mg on days 1-5 of cycles 1-6.
1771613|NCT00376961|Drug|vincristine sulfate|1.4 mg/m^2 on day 1 of cycles 1-6.
1771614|NCT00376974|Behavioral|American Academy of Ophthalmology Glaucoma Educational Tape|
1771615|NCT00376987|Dietary Supplement|zinc oxide|Oral daily dietary supplement containing 80 mg Zinc oxide
1771616|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% gel pump|
1771617|NCT00377000|Drug|clindamycin 1% / benzoyl peroxide 5% tube|
1771618|NCT00377026|Behavioral|lifestyle intervention|Lifestyle modification including individual sessions with an interventionist to discuss dietary intake and exercise. Group sessions with other participants randomized to the lifestyle intervention to discuss lifestyle modification and group exercise.
1771619|NCT00377039|Drug|AD 337|
1771620|NCT00377052|Drug|bortezomib|1.0 mg/m2 IV; injection bolus (3-5 sec) Twice weekly x 2 weeks every three weeks
1771621|NCT00377052|Drug|gemcitabine hydrochloride|1000 mg/m2 IV; injection 30 minute infusion Once weekly x 2 weeks every three weeks
1771622|NCT00377065|Drug|raltegravir|raltegravir 400 mg P.O. bid tablet twice daily for 12 weeks
1771623|NCT00377078|Drug|recombinant human lactoferrin|
1771624|NCT00377091|Drug|Fondaparinux|
1771625|NCT00377104|Drug|alvocidib|Given IV
1771626|NCT00377104|Other|pharmacological study|Correlative studies
1771627|NCT00377104|Other|laboratory biomarker analysis|Correlative studies
1771628|NCT00377117|Procedure|Management|
1771629|NCT00377117|Procedure|Screening|
1771630|NCT00377130|Other|Self Administered Stress Management|"The SSMT kit includes a DVD and booklet will discuss the sources and manifestations of stress during chemotherapy and the potential benefits of stress management training. The videotape/DVD and booklet will also include brief instruction in paced breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements as well as recommendations for practicing the techniques before the start of chemotherapy and using them after the start of treatment. The exercise combines abbreviated progressive muscle relaxation training with use of relaxing mental imagery. The positive thinking exercise provides participants with brief instruction in the use of coping self-statements using techniques borrowed from stress inoculation training."
1771631|NCT00377143|Drug|Warfarin Dosing|
1771632|NCT00377156|Radiation|radiation therapy|Patients undergo radiation therapy 5 days a week for 2.5 weeks
1771633|NCT00377156|Radiation|stereotactic radiosurgery|
1771634|NCT00377182|Drug|Copegus|1000/1200mg po daily for 4 weeks
1771635|NCT00377182|Drug|PEGASYS|180 micrograms sc weekly for 4 weeks
1771636|NCT00377182|Drug|RO5024048 1500mg|1500mg po bid for 4 weeks
1771637|NCT00377182|Drug|RO5024048 3000mg|3000mg po bid for 4 weeks
1771638|NCT00377195|Radiation|Involved Field Radiotherapy|"The prescribed dose will be 30 Gy in 15-20 fractions, unless the orbit is to be treated, in which case the dose will be 24 Gy in 1.5 to 2 Gy fractions.
Daily fractions of 1.5-2.0 Gy will be employed. Treatment will be given 5 days per week with the planned duration of treatment not exceeding 28 days."
1771639|NCT00377208|Behavioral|Web-Based Intervention|"My Expert Doctor is a web-based program that helps patients to ask the right questions regarding specific tests and treatments during their doctor visits. Upon entering medication and treatment information into the web site, patients are provided with individualized feedback and recommended questions to ask their doctor."
1771640|NCT00377234|Drug|Risedronate|35mg po weekly for 12 weeks
1771641|NCT00377234|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 3 months
1771642|NCT00377247|Biological|autologous monocyte-derived dendritic cells (DC) transfected with DNA|The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area (e.g., to inguinal LN)
1771643|NCT00377260|Drug|amoxicillin-clavulanate|Augmentin ES-600™: Amoxicillin-clavulanate potassium (600/42.9 mg per 5 mL), administered at a dose of 90/6.4 mg/kg/day in 2 divided doses for 10 days with strawberry cream flavor.
1771644|NCT00377260|Drug|Placebo|Same base formulation of the licensed product Augmentin ES-600™, with the same strawberry cream flavor.
1771645|NCT00377273|Drug|fluorouracil cream 0.5%|
1771646|NCT00377286|Dietary Supplement|Glucosamine (a dietary supplement)|1500 mg in 16 oz lite lemonade, once per day for 6 months
1771647|NCT00377286|Other|16 oz lite lemonade|16 oz lite lemonade 1 time daily for 6 months
1771648|NCT00377299|Drug|Citicoline|Citicoline is an over the counter supplement that may have neuroprotective properties and may have antidepressant effects. Citicoline or placebo (identical in appearance) add-on therapy was given beginning at one tablet (500mg/day) with an increase to two tablets (1000 mg/day) at week 2, three tablets (1500 mg/day) at week 4 and four tablets (2000 mg/day) at week 6. Doses were decreased, if needed, due to side effects.
1771649|NCT00377299|Drug|Placebo|Placebo matching active medication in all other physical aspects
1771650|NCT00377312|Drug|Parathyroid Hormone (1-34)|PTH(1-34) IV given over a one week period
1771651|NCT00377325|Drug|Cyclosporine|4 mg/Kg/day; daily; liquid form; 6 months
1771652|NCT00377364|Drug|Drug: Acetaminophen, Drug: Placebo|Acetaminophen: Participants will be given acetaminophen (two 500 mg tablets) four times daily for 7 days, not exceeding 4,000 mg/day. Placebo: Participants will be given placebo(two 500 mg tablets) four times daily for 7 days
1771653|NCT00377377|Drug|EP1572 (ghrelin agonist) oral and duodenal application|
1771654|NCT00377390|Biological|Omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standardized asthma care for 60 weeks, beginning with the Randomization Visit, as a part of ICATA (ICAC-08, NCTNCT00377572).
1772173|NCT00379041|Drug|mechlorethamine hydrochloride|
1771655|NCT00377403|Drug|Acetaminophen|"Symptomatic treatment:
Dose: 500mg every 4 to 6 hours for pain or fever"
1771656|NCT00377403|Drug|Amoxicillin|"Intervention drug:
Dose: 500mg tid for 10 days"
1771657|NCT00377403|Drug|Dextromethorphan hydrobromide with guaifenesin|"Symptomatic treatment:
Dose: 10mls every 4 to 6 hours for cough"
1771658|NCT00377403|Drug|Guaifenesin|"Symptomatic treatment:
Dose: 600mg every 12 hours to thin secretions"
1771659|NCT00377403|Drug|Pseudoephedrine Sustained Action|"Symptomatic treatment:
Dose: 120mg every 12 hours for nasal congestion"
1771660|NCT00377403|Drug|Saline spray (0.65%)|"Symptomatic treatment:
Dose: 2 squeezes per nostril as needed for nasal congestion"
1771661|NCT00377416|Genetic|rAAV2-CB-hAAT Gene Vector|Participants will attend a 5-day inpatient visit, during which they will receive a series of injections consisting of one of four different doses of rAAV2-CB-hAAT.
1771662|NCT00377429|Drug|catumaxomab|Catumaxomab administered as four 3-hour, constant-rate, intraperitoneal (IP) infusions of 10, 20, 50, 150 microgram (mcg).
1771663|NCT00377442|Drug|GK Activator (2)|100mg po
1771664|NCT00377442|Drug|Simvastatin|80mg po
1771665|NCT00377455|Drug|Bosentan|62.5 mg by mouth (PO) twice daily (Bid) for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
1771666|NCT00377455|Drug|Placebo|62.5 mg PO Bid for 1 month, followed by 125 mg PO Bid thereafter, for a total of 16 weeks
1771667|NCT00377468|Drug|Delta9-Tetrahydrocannabinol|
1771668|NCT00377481|Drug|darbepoetin alfa|30 micrograms sc weekly (2 doses)
1771669|NCT00377481|Drug|epoetin beta [NeoRecormon]|6000 IU sc weekly (2 doses)
1771670|NCT00377494|Biological|MVA-CSO Vaccine|
1771671|NCT00377494|Biological|PfCSP DNA (VCL-2510) Vaccine|
1771672|NCT00377507|Dietary Supplement|catechin extracts|catechin extracts solution
1771673|NCT00377520|Drug|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
1771674|NCT00377533|Device|wheelchair rear anti-tip device|assistive device
1771675|NCT00377546|Drug|Nepafenac|
1771676|NCT00377546|Drug|Ketorolac LS, Bromfenac|
1771677|NCT00377559|Drug|Non pegylated liposomal doxorubicin and docetaxel|max. 6 courses
1771678|NCT00377572|Biological|omalizumab|Subcutaneous injections of omalizumab will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
1771679|NCT00377572|Biological|omalizumab placebo|Subcutaneous injections of placebo will be administered every 2 or 4 weeks along with standard of care for asthma for 60 weeks, beginning with the Randomization Visit. Dosage is dependent on participant's individual characteristics.
1771680|NCT00377585|Biological|Fluarix|
1771681|NCT00377585|Biological|adjuvanted influenza vaccine|
1771682|NCT00377598|Drug|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 8 weeks
1771683|NCT00377598|Drug|TAK-583|TAK-583 25 mg, tablets, orally, once daily for up to 8 weeks
1771684|NCT00377598|Drug|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 8 weeks
1771685|NCT00377598|Drug|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 8 weeks
1771686|NCT00377598|Drug|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 8 weeks
1771688|NCT00369304|Drug|pharmacokinetic (how the body absorbs and eliminates) interaction|
1771689|NCT00369317|Drug|asparaginase|Given IM
1771690|NCT00369317|Drug|daunorubicin hydrochloride|Given IV
1771691|NCT00369317|Drug|cytarabine|Given IV or IT
1771692|NCT00369317|Drug|thioguanine|Given orally
1771693|NCT00369317|Drug|etoposide|Given IV
1771694|NCT00369317|Other|laboratory biomarker analysis|Correlative studies
1771695|NCT00369330|Device|external electrical cardioversion|
1771696|NCT00369343|Drug|Desvenlafaxine administered as a succinate salt in a sustained-release form (DVS SR)|DVS-SR 50-200mg, daily (QD), tablet form, treatment period up to 34 weeks
1771697|NCT00369343|Drug|Placebo|Placebo, daily (QD), tablet form, treatment period up to 8 weeks
1771698|NCT00369356|Drug|Prednisone|Bare metal stenting with administration of oral prednisone as described in the protocol
1771699|NCT00369356|Device|Drug eluting coronary stent|Stenting with DES (Cypher or Taxus)
1771700|NCT00369356|Device|Bare metal coronary stent|Stenting with BMS only
1771701|NCT00369382|Drug|cyclosporine or tacrolimus|Cyclosporine and tacrolimus are provided by the sites and dosed to achieve a target trough level determined by the investigator; therefore, form, dosage, and frequency are site and patient specific. Duration should be 52 weeks on-therapy.
1771702|NCT00369382|Drug|sirolimus|Oral (1 and 2 mg) tablets, dosing should be once daily to achieve a target trough level of 7- 15 ng/mL. Duration should be 52 weeks on-therapy.
1771703|NCT00369395|Drug|volociximab|Volociximab, 15 mg/kg, IV infusion once a week for 8 weeks. Subjects who achieved SD or better at Day 50 ± 2 days (Week 8) were eligible to continue receiving weekly infusions of volociximab until disease progression.
1771704|NCT00369408|Drug|Naltrexone|naltrexone (50 mg orally) for 12-week treatment period; 3 and 6 months post-treatment follow-up
1771705|NCT00369408|Drug|placebo|placebo for 12-week treatment period; 3 and 6 months post-treatment follow-up
1771706|NCT00369434|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|
1771707|NCT00369447|Procedure|External radiotherapy|Radiotherapy for first 2 weeks, 10 daily fractions of 30Gy 2 additional fractions to be added if desirable
1771708|NCT00369447|Biological|nimotuzumab|weekly dose until disease progression
1771709|NCT00369460|Other|physiologic testing|Weight, body mass index, age, ECOG performance status, gait speed, concomitant medications, CA19-9, and total lymphocyte count measured before start of cancer treatment of the patient's choosing. Patients will be re-assessed at approximately 2 months, 4 months, 6 months, and with any change in tumor burden.
1771710|NCT00369473|Drug|AMG 108|125 mg via SC (subcutaneous) injection every 4 weeks
1771711|NCT00369473|Drug|AMG 108|250 mg via SC (subcutaneous) injection every 4 weeks
1771712|NCT00369486|Procedure|Focal laser photocoagulation|Focal laser photocoagulation (modified Early Treatment Diabetic Retinopathy Study technique)
1771713|NCT00369486|Drug|40mg triamcinolone|Posterior peribulbar injection of 40 mg triamcinolone (Kenalog)
1771714|NCT00369486|Drug|20mg triamcinolone|Anterior peribulbar injection of 20 mg triamcinolone
1771715|NCT00369486|Drug|40mg triamcinolone + laser|Posterior peribulbar injection of 40 mg triamcinolone followed after one month by laser
1771716|NCT00369486|Drug|20mg triamcinolone + laser|Anterior peribulbar injection of 20 mg triamcinolone followed after one month by laser
1771717|NCT00369499|Device|PFO Closure|
1771718|NCT00369512|Drug|Erlotinib|Erlotinib therapy for 2 weeks (150 mg po qd)(for those who are enrolled before surgery is done), surgery/biopsy up to 8 weeks recovery, radiation/Erlotinib therapy for 6 weeks (150mg po qd).
1771719|NCT00369538|Drug|losartan, hydrochlorothiazide|Two administrations of losartan per day,up to 100mg per day, during 2 months, followed by a wash-out during 1 month, and then one administration of hydrochlorothiazide, 25 mg per day during 2 months
1771720|NCT00369538|Drug|hydrochlorothiazide, losartan|One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
1771721|NCT00369551|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal radiation therapy
1771722|NCT00369551|Drug|paclitaxel|Given IV
1771723|NCT00369551|Biological|bevacizumab|Given IV
1771724|NCT00369551|Drug|carboplatin|Given IV
1771725|NCT00369551|Other|laboratory biomarker analysis|Correlative studies
1771726|NCT00369564|Drug|glutamic acid|Given orally 3 times daily
1771727|NCT00369564|Other|placebo|Given orally 3 times daily
1771729|NCT00369590|Biological|ziv-aflibercept|Given IV
1771730|NCT00369590|Other|pharmacological study|correlative studies
1771731|NCT00369590|Other|laboratory biomarker analysis|correlative studies
1771732|NCT00369603|Drug|Razadyne ER|4-weeks 8mg. Razadyne ER, then 4-weeks 16mg. Razadyne ER, and a subsequent 4-weeks of 24mg. Razadyne ER
1771733|NCT00369603|Drug|Aricept|8-weeks 5mg. Aricept and a subsequent 4-weeks of 10mg. Aricept
1771734|NCT00369616|Biological|CYT002-NicQb|
1771735|NCT00369629|Drug|Gemcitabine|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of gemcitabine will be 800 mg/m^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 1200 mg/m^2.
1771736|NCT00369629|Drug|Pemetrexed|Patients will be treated in cohorts of 3-6 per cohort. The starting dose of pemetrexed will be 400 mg/m^2 given as an intravenous (IV) infusion on days 1 and 15 of each 28-day cycle. The dose will be escalated for each subsequent cohort of patients, up to a maximum of 500 mg/m^2.
1771737|NCT00369642|Behavioral|Cognitive-behavioral therapy|
1771738|NCT00369655|Biological|ziv-aflibercept|
1771739|NCT00369668|Behavioral|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving their paretic arm at the same time as they move their non-paretic arm in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 4 times per week for 2 weeks.
1771740|NCT00369668|Behavioral|Bilateral movements and neuromuscular electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Neuromuscular electrical stimulation triggered by the participants' own contracting muscles is provided to the paretic arm during the movements. Training period was 2 times per week for 2 weeks.
1771741|NCT00369668|Behavioral|Bilateral movements and sham electrical stimulation|Participants practice moving both their paretic and non-paretic arms at the same time in the same movement patterns. Sham electrical stimulation (low level electrical stimulation that can be felt but is insufficient to trigger a muscle contraction) is provided to the paretic arm during the movement. Training period was 2 times per week for 2 weeks.
1771742|NCT00369681|Biological|bleomycin|
1771743|NCT00369681|Biological|rituximab|
1771744|NCT00369681|Drug|ABVD regimen|
1771745|NCT00369681|Drug|dacarbazine|
1771746|NCT00369681|Drug|doxorubicin|
1771747|NCT00369681|Drug|vinblastine|
1771748|NCT00369681|Genetic|DNA methylation analysis|
1771749|NCT00369681|Other|laboratory biomarker analysis|
1771750|NCT00369681|Radiation|fludeoxyglucose F 18|
1771751|NCT00369694|Drug|Terlipressin|2 mg Terlipressin stat, then 1 mg q6h for total of 72 hours
1771752|NCT00369694|Drug|Terlipressin & then Dummy|2 mg Terlipressin stat then 1 mg q6 hours for 24 hours, then a Dummy of Terlipressin q6 hours for the next 48 hours.
1771753|NCT00369707|Drug|Rituximab|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
1771754|NCT00369707|Drug|bortezomib|On days 1, 8, 15 and 22 of the 1st cycle, bortezomib will be administered intravenously (through a vein) over 3-5 seconds followed by an intravenous infusion of rituximab. How long it will take to infuse the dose of rituximab is dependent upon your weight and how well you tolerate the infusion; it is estimated this first infusion may take between 3-4 hours. During subsequent cycles, bortezomib will again be given on days 1, 8, 15 and 22. However, rituximab will only be given on day 1 of each cycle.
1771755|NCT00369720|Procedure|Titration of oxygen in delivery room|
1771756|NCT00369733|Drug|Darbepoetin alfa|Darbepoetin alfa adminstered SC every other week to acheive a Hb not to exceed 12 g/dL
1771757|NCT00369746|Drug|citalopram|tablets, 60 mg maximum, daily, 12 weeks
1771758|NCT00369759|Other|Emergency Dept. Subjects with LRI or Apnea|No intervention; Epidemiological Study
1771759|NCT00369772|Drug|darbepoetin alfa|
1771760|NCT00369785|Drug|donepezil hydrochloride|Weeks 1-6: One tablet Donepezil 5 mg given daily Weeks 7-24: Two Donepezil 5 mg tablets given daily
1771761|NCT00369785|Drug|Placebo|Weeks 1-6: One tablet per day Weeks 7-24: Two tablets per day
1771762|NCT00369798|Procedure|PET scan|
1771763|NCT00369798|Drug|Rolipram|
1771764|NCT00369811|Drug|Oxycodone, fentanyl|
1771765|NCT00369824|Biological|Different formulations of GSK Biologicals' HPV vaccine (580299)|Three doses of vaccine administered intramuscularly, with the second and third dose given one month and six months after the first dose respectively
1771766|NCT00369824|Biological|Menactra TM|One dose of vaccine administered intramuscularly
1771767|NCT00369824|Biological|Boostrix TM|One dose of vaccine administered intramuscularly
1771768|NCT00369837|Drug|clevidipine|Clevidipine was required to be administered continuously for a minimum of 18 hours and a maximum of 96 hours and was not to exceed a rate of 32.0 mg/h at any time. Use of an additional or alternative intravenous antihypertensive agent was allowed if the blood pressure target range was not achieved or maintained. If transition to an oral antihypertensive agent is required, then approximately 1 hour prior to the anticipated cessation of clevidipine infusion, but no less than at the 18-hour time point, an oral antihypertensive agent was allowed to be administered as clevidipine was down-titrated or terminated as needed in order to achieve the desired blood pressure level..
1771769|NCT00369850|Other|laboratory biomarker analysis|Biomarkers (C-telopeptide, osteocalcin and skeletal alkaline phosphatase) will be assessed in serum.
1771770|NCT00369850|Procedure|Dual energy X-ray absorptiometry (DEXA)|Mone mineral density measurements of L2-L4 and hip will be performed using DEXA.
1771771|NCT00369850|Procedure|Spine X-ray|Thoracic and lumbar X-ray (T4-L4, lateral projection) will be performed.
1771772|NCT00369863|Drug|Triamcinolone acetonide|
1771773|NCT00369889|Drug|bevacizumab|iv every 21 days
1771774|NCT00369889|Drug|Erlotinib|oral daily
1771775|NCT00369902|Procedure|acupuncture|
1771776|NCT00369915|Drug|Scopolamine|
1771777|NCT00369915|Drug|Scopolamine|
1771778|NCT00369928|Drug|PG-760564|100 mg BID, of oral PG-760564
1771779|NCT00369928|Drug|Placebo dose|placebo, BID, oral for 12 weeks
1771780|NCT00369928|Drug|PG-760564|25 mg BID, of oral PG-760564
1771781|NCT00369941|Drug|MK-0518|400 mg MK-0518 tablet taken by mouth (PO) twice a day (b.i.d.) for up to 240 weeks
1771782|NCT00369941|Drug|Comparator: efavirenz|600 mg efavirenz tablet taken by mouth (PO) every night (q.h.s.) for up to 240 weeks
1771783|NCT00369941|Drug|Comparator: Truvada|One tablet Truvada once a day (q.d.) for up to 240 weeks (one tablet contains 200 mg emtricitabine and 300 mg tenofovir)
1771784|NCT00369941|Drug|Comparator: Placebo to MK-0518|Placebo to MK-0518 PO b.i.d., taken for up to 240 weeks
1771785|NCT00369941|Drug|Comparator: Placebo to efavirenz|Placebo to efavirenz PO every night (q.h.s.), taken for up to 240 weeks
1771786|NCT00369954|Drug|carboplatin|
1771787|NCT00369954|Drug|gemcitabine hydrochloride|
1771788|NCT00369967|Drug|NuvaRing|Initiation of NuvaRing for contraception
1771789|NCT00369993|Drug|fluticasone propionate/salmeterol|
1771790|NCT00370006|Biological|Towne CMV vaccine|
1771791|NCT00370019|Drug|Estradiol/Medroxyprogesterone acetate|
1771792|NCT00370032|Drug|alosetron|
1771793|NCT00370045|Drug|Bivalirudin with and without eptifibatide|
1771794|NCT00370058|Procedure|ECT treatment|
1771795|NCT00370071|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b 250 μg (8 MIU) subcutaneously (sc) every other day (e.o.d.)
1771796|NCT00370084|Drug|Itopride|oral, three times daily
1771797|NCT00370084|Other|Placebo|oral, three times daily
1771798|NCT00370097|Drug|FLOVENT (fluticasone propionate) HFA|FLOVENT HFA consists of a white to off-white suspension of FP (micronized) in a liquefied hydrofluoroalkane propellant, 1,1,1,2-tetrafluoroethane. Subject will receive FP HFA using an Aerochamber Plus with Infant Mask.
1771799|NCT00370097|Drug|Placebo HFA|Subjects will receive FP-matched placebo using an Aerochamber Plus with Infant Mask.
1771800|NCT00370110|Drug|Itopride 100 mg|100 mg three times daily
1771801|NCT00370110|Other|Placebo|
1771802|NCT00370110|Drug|Itopride 200 mg|200 mg three times daily
1771803|NCT00370136|Drug|ultrasound contrast|
1771804|NCT00370149|Device|Antibiotic-impregnated Catheters (M/R)|Patients randomized to this arm will have the antibiotic-impregnated catheters inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
1771805|NCT00370149|Device|Non-impregnated Catheters (C/S)|Patients randomized to this arm will have the central venous catheter inserted intra-operatively. The catheters are sized to accommodate children in different size ranges.
1771806|NCT00370162|Drug|lactoserum|
1771807|NCT00370188|Drug|Topiramate|
1771808|NCT00370201|Drug|colchicine|
1771809|NCT00370227|Biological|10 valent pneumococcal conjugate (vaccine)|
1771810|NCT00370240|Drug|Chlorhydrate de Ropivacaine|The Ropivacaïne group received 3mg/kg of 0.375% ropivacaïne(0.75% ropivacaïne, Astra, mixed with saline)
1771811|NCT00370240|Other|placebo|The PCB group received saline solution in equal volume.
1771812|NCT00370253|Drug|Terlipressin|1mg/4 h per day
1771813|NCT00370253|Drug|Noradrenalin|0,1 mcg/kg/min
1771814|NCT00370266|Drug|Triamcinolone|
1771815|NCT00370279|Procedure|scleral buckling, primary vitrectomy|Four different surgical techniques were performed(one in each arm); 1- scleral buckling, 2- primary vitrectomy without encircling band, 3- primary vitrectomy with encircling band, 4- triamcinolone assisted vitrectomy
1771816|NCT00370292|Drug|Pemetrexed - Before Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 14 days x 8 cycles or disease progression, unacceptable toxicity or patient decision to discontinue
1771817|NCT00370292|Drug|Pemetrexed - After Protocol Amendment|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 6 cycles or disease progression, unacceptable toxicity or patient decision to discontinue.
1771818|NCT00370305|Drug|rosiglitazone|
1771819|NCT00370318|Biological|10 valent pneumococcal conjugate vaccine|
1771820|NCT00370318|Biological|Infanrix Hexa|
1771821|NCT00370318|Biological|Rotarix|
1771822|NCT00370318|Drug|Paracetamol|
1771823|NCT00370331|Drug|eltrombopag|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down.
1771872|NCT00370799|Drug|Caudal epidural injection|group 1: Caudal epidural injection local anesthetics only
1771824|NCT00370331|Drug|Placebo|Subjects will initiate treatment with either 50 mg eltrombopag or matching placebo once daily. Based upon the subjects platelet count at each visit, the dose of eltrombopag may be adjusted either up or down
1771825|NCT00370344|Procedure|Laparoscopic cholecystectomy|Operation by experts in laparoscopy. The operation may be performed as laparoscopic or converted to an open operation.
1771826|NCT00370344|Procedure|Small-incision open cholecystectomy|Operation by experts in small-incision open cholecystectomy.
1771827|NCT00370357|Drug|3% w/w SPL7013 Gel (VivaGel™)|
1771828|NCT00370370|Drug|bevacizumab|Injection of intravitreal bevacizumab
1771829|NCT00370370|Drug|bevacizumab + triamcinolone acetonide|Injection of bevacizumab + triamcinolone acetonide
1771830|NCT00370383|Drug|Erlotinib|erlotinib 150 mg/day once daily
1771831|NCT00370383|Drug|Satraplatin|"satraplatin 100 mg/m2 orally once daily for 5 consecutive days (days 1-5)followed by erlotinib 150mg/day for 14 consecutive days (days 8-21).
Satraplatin JM-216, bis-aceto-ammine dischlorocyclohexylamine platinum)is a third-generation platinum analogue with activity following oral administration. The molecular formula for satraplatin is C10H22N2Cl2O4Pt, which is structured as an octahedral platinum compound."
1771833|NCT00370409|Procedure|Cryotherapy|Cryotherapy of both sides of sclerotomy sites was done for 6 seconds after complition of operation.
1771834|NCT00370422|Drug|Triamcinolone, Bevacizumab|
1771835|NCT00370435|Drug|GW274150|
1771836|NCT00370448|Behavioral|school-based social support system|Training gatekeeper recruited from students and tutors and counselors for group 1; training counsellors for group 2; No special intervention for group 3
1771837|NCT00370474|Device|Bi-ventricular lead placement|
1771838|NCT00370500|Drug|Quetiapine fumarate|Dosage and frequency are judged by the study physician. The dosage must not excess 800mg/d.
1771839|NCT00370513|Drug|pazopanib|Pazopanib is a potent, multi-target receptor tyrosine kinase inhibitor of VEGFR.
1771840|NCT00370526|Procedure|Acute hemodynamic assessment using PV Loops (CD Leycom, The Netherlands) during LV lead placement|
1771841|NCT00370539|Drug|verteporfin, bevacizumab, triamcinolone acetonide|
1771842|NCT00370552|Drug|Ixabepilone, 16 mg/m^2 + Bevacizumab, 10 mg/kg|Ixabepilone,16 mg/m^2, administered as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
1771843|NCT00370552|Drug|Ixabepilone, 40 mg/m^2 + Bevacizumab, 15 mg/kg|Ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle until disease progression or unacceptable toxicity (After Cycle 4, dose reduction to 32 mg/m^2 was to be implemented for all subsequent cycles.) Bevacizumab, 15 mg/kg, administered as IV infusion every 3 weeks. Bevacizumab to be infused over 90 minutes for the first dose, and if well tolerated for 60 minutes, for the second dose. Then if still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
1771844|NCT00370552|Drug|Paclitaxel, 90 mg/m^2 + Bevacizumab, 10 mg/kg|Paclitaxel, 90 mg/m^2, given as a 1-hour IV infusion on Days 1, 8, and 15 of a 28-day cycle until disease progression or unacceptable toxicity. Bevacizumab, 10 mg/kg, administered as IV infusion every 2 weeks. Bevacizumab infused over 90 minutes for the first dose, and if well tolerated, over 60 minutes for the second dose. If still tolerated, over 30 minutes for subsequent infusions. Bevacizumab was to be dosed until disease progression or unacceptable toxicity.
1771845|NCT00370565|Drug|Inhaled Human Insulin|
1771846|NCT00370578|Device|repeated thrombus aspiration during primary PCI|
1771847|NCT00370591|Drug|Salmeterol/fluticasone propionate and fluticasone propionate|
1771848|NCT00370604|Device|19g Tuohy-type epidural needle, 23g catheter|Patients in the experimental group will receive a 23g 90cm adult length epidural catheter placed via a 19g Tuohy epidural needle (SIMS Portex, Hythe, UK). The 19g Tuohy needle is a standard 3½ inch length.
1771849|NCT00370604|Device|=> 18g Tuohy-type needle|Patients in the control arm will receive a traditional large gauge (16g, 17g or 18g Tuohy or Hustead) epidural needle and a traditional epidural catheter. Two control needles and two control catheters will be designated apriori by each institution for use in the study.
1771850|NCT00370617|Drug|metformin|
1771851|NCT00370630|Drug|Avastin (Bevacizumab) and triamcinolone|
1771852|NCT00370643|Drug|human regular insulin|
1771853|NCT00370656|Drug|Pregabalin|capsule, 150mg bd, 300mg bd
1771854|NCT00370656|Drug|Duloxetine|Capsule, 60mg on, 60mg bd
1771855|NCT00370656|Drug|Amitriptyline|Capsule. 25 mg bd, 25 mg om and 50 mg on
1771856|NCT00370669|Drug|bevacizumab|
1771857|NCT00370669|Drug|triamcinolone acetonide|
1771858|NCT00370682|Biological|T-DEN F17|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
1771859|NCT00370682|Biological|T-DEN F-19|A single dose of 0.5 mL of the dengue vaccine was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
1771860|NCT00370682|Other|Placebo Comparator|A single dose of 0.5 mL of the placebo sterile solution of buffer identical in appearance to vaccine)was injected subcutaneously into the upper-outer triceps/deltoid area of the non-dominant arm at Day 0 and at 6 months.
1771861|NCT00370695|Device|Precision Spinal Cord Stimulation System|Stimulation turned on from implant throughout the Study
1771862|NCT00370708|Procedure|Oral Intake following admittance to the postpartum ward|
1771863|NCT00370721|Drug|bevacizumab|
1771864|NCT00370734|Drug|Botulinum toxin A injection|
1771865|NCT00370747|Drug|Ecabet|ophthalmic solution 2.83%
1771866|NCT00370747|Drug|Ecabet|ophthalmic solution 3.70%
1771867|NCT00370747|Drug|Placebo|
1771868|NCT00370760|Drug|oral colchicine, dexamethasone, low molecular weight heparin, 5-FU|
1771869|NCT00370760|Drug|placebo|
1771870|NCT00370773|Device|Precision Spinal Cord Stimulation System|
1771871|NCT00370786|Drug|bevacizumab|
1772174|NCT00379041|Drug|prednisone|
1771873|NCT00370799|Drug|Caudal Epidural Injection with generic Celestone|Group 2. Caudal Epidural Injection local anesthetic with 6mg of non-particulate Celestone
1771874|NCT00370799|Drug|Caudal Epidural Injection with Celestone|Group 3. Caudal Epidural Injection with local anesthetic with 6 mg of brand name Celestone
1771875|NCT00370799|Drug|Caudal Epidural Injection with DepoMedrol|Group 4. local anesthetic with 40 mg of alcohol-free DepoMedrol
1771876|NCT00370812|Procedure|amniotic membrane transplantation|AMT with conventional medical therapy (group A) or medical treatment only (group B). AMT will be performed within 24h of presentation. Amniotic membrane will remain in place for 7-14 days.
1771877|NCT00370825|Drug|Combination therapy with AmBisome and miltefosine|
1771878|NCT00370838|Drug|Levetiracetam|The initial dose of levetiracetam was 10 mg/kg/day, divided twice daily (rounded to the closest unit of 250 mg). The dose was increased weekly by 5-10 mg/kg/day, to a maximum dose of 50 mg/kg/day (or 2,500 mg/day), if deemed necessary for tic suppression. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
1771879|NCT00370838|Drug|Clonidine|The initial dose of clonidine was 0.05 mg, twice daily. If needed for tic suppression, the dose was increased weekly by 0.05-0.1 mg, with a maximum dose of 0.4 mg per day. In any individual, dose escalation may have proceeded more slowly, or the dose may have been reduced as necessary. No changes in dosage occurred during the final week of either treatment phase.
1771880|NCT00370851|Drug|Avastin (Bevacizumab)|Intravitreal injection of 125 mg Avastin
1771881|NCT00370864|Biological|H5N1 pandemic influenza vaccine|
1771882|NCT00370877|Drug|rFVIIa|The patients included in this arm of the study will recieve standard care for post-partum hemorrhage plus a slow intravenous injection (2ml/min) of rFVIIa (60µg/kg)
1771883|NCT00370877|Procedure|Standard Care|Patients will recieve standard care for post partum hemorrhage according to current recommendations.
1771885|NCT00370916|Behavioral|Physician-initiated medication reconciliation|Physician house staff performed and documented medication reconciliation after hospital admission with the assistance of a CPRS template
1771886|NCT00370916|Behavioral|Pharmacist-initiated medication reconciliation|Pharmacist performed and documented medication reconciliation
1771887|NCT00370929|Behavioral|Meditation|
1771888|NCT00370942|Drug|GW823093C A|A=45 mg
1771889|NCT00370942|Drug|GW823093C B|B=30 mg
1771890|NCT00370942|Drug|GW823093C C|C=25 mg
1771891|NCT00370955|Procedure|phacoemulsification using either high vacuum or low vacuum techniques|All surgeries were performed using Sovereign phacoemulsification system (AMO) using Whitestar technology.
1771892|NCT00370968|Drug|Zinc sulphate|
1771893|NCT00370981|Drug|pagoclone|
1771894|NCT00370994|Procedure|Caudal epidural injection|Caudal epidural injection with catheterization
1771895|NCT00370994|Procedure|Percutaneous adhesiolysis|Percutaneous adhesiolysis with hypertonic saline neurolysis
1771896|NCT00371007|Drug|MK0431, sitagliptin phosphate / Duration of Treatment: 12 Weeks|
1771897|NCT00371007|Drug|Comparator : placebo (unspecified) / Duration of Treatment: 12 Weeks|
1771898|NCT00371020|Drug|low molecular weight heparin, 5-FU|
1771899|NCT00371033|Drug|Pregabalin|dosage
1771900|NCT00371033|Drug|Placebo|dosage
1771901|NCT00371046|Procedure|Transvaginal ultrasound cervical length|
1771902|NCT00371046|Procedure|Cervicovaginal fetal fibronectin|
1771903|NCT00371059|Drug|Memantine|Memantine 10mg BD
1771904|NCT00371059|Drug|Placebo|Placebo 10 mgs BD
1771905|NCT00371072|Procedure|trabeculectomy with mitomycin-C|
1771906|NCT00371085|Behavioral|education|Video-based educational program for heart failure focus on daily weights, medication taking, and salt restriction
1771907|NCT00371098|Biological|Influenza vaccination: Influvac (SolvayPharma)|
1771908|NCT00371098|Biological|placebo influenza vaccine|
1771909|NCT00371111|Drug|Intravitreal injection of Triamcinolone|4 mg of Triamcinolone
1771910|NCT00371111|Drug|Intravitreal injection of Avastin|Injection of 1.25 mg of Avastin and
1771911|NCT00371124|Drug|Atropine Eye drops|
1771912|NCT00371137|Drug|Xyrem®|two doses
1771913|NCT00371137|Drug|Placebo|Oral Solution
1771914|NCT00371150|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily, up to 52 weeks
1771915|NCT00371176|Behavioral|Exposure therapy|A manualized form of treatment that involves vividly visualizing indexed trauma with the guidance of a therapist
1771916|NCT00371176|Drug|D-Cycloserine|A partial NMDA agonist that has been shown in human trials to facilitate and strengthen extinction with CBT.
1771917|NCT00371176|Other|Placebo pill|
1771918|NCT00371189|Drug|Placebo|Normal saline.
1771919|NCT00371189|Biological|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Adenovirus Type 35 Circumsporozoite Malaria Vaccine (Ad35.CS.01); administered at 0, 1, and 6 months; dosage levels: 10^8 viral particles (vp)/mL, 10^9 vp/mL, 10^10 vp/mL and 10^11 vp/mL.
1771920|NCT00371202|Procedure|keratoplasty|
1771921|NCT00371215|Biological|rThrombin|1000 U/mL applied topically
1771922|NCT00371228|Procedure|Delay of umbilical cord clamping|Umbilical cord delayed until pulsation stops.
1771923|NCT00371254|Drug|Dasatinib|Tablets, Oral, 100 mg, twice daily as long as the patient benefits (avg <6 months)
1771924|NCT00371254|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily as long as the patient benefits (avg <6 months)
1771925|NCT00371267|Behavioral|Telephone-delivered Cognitive Behavior Therapy|Telephone-delivered cognitive behavior therapy for pain management
1771926|NCT00371267|Other|Telephone-delivered Patient Education|Telephone-delivered patient education regarding chronic pain
1771927|NCT00371280|Procedure|orbital implant|Implantation of pegged versus unpegged hydroxyapatite orbital implants
1771928|NCT00371293|Behavioral|Weight Loss Program|Participants in the weight loss program will receive weekly dietary counseling and will be encouraged to decrease caloric intake and increase physical activity.
1772169|NCT00379028|Drug|Budesonide/Formoterol Turbuhaler|
1771929|NCT00371293|Device|CPAP therapy|Participants receiving CPAP therapy will use a CPAP machine each night while they sleep.
1771930|NCT00371306|Drug|Insulin versus glucovance (glyburide/metformin)|
1771931|NCT00371319|Drug|tacrolimus|0.06-0.1 mg/kg/day
1771932|NCT00371319|Drug|mycophenolate mofetil|2-3 gm/day
1771933|NCT00371332|Drug|Minocycline HCL Microspheres|
1771934|NCT00371345|Drug|Dasatinib|Tablets, Oral, 70 mg, twice daily, as long as the participant benefits (average <6 months)
1771935|NCT00371345|Drug|Dasatinib 100 mg|Tablets, Oral, 100mg, twice daily, as long as the participant benefits (average <6 months)
1771936|NCT00371371|Procedure|Bone marrow punction|A total volume of 100 ml bone marrow will be aspirated from the iliac crest under local anaesthesia (lidocaine) according to local routine. To maximise the patients comfort, 5-10 mg midazolam and 50 ug fentanyl will be administered intravenously.
1771937|NCT00371371|Procedure|BM-MNC infusion|Repeated intra-arterial infusion of autologous BM-MNC into the common femoral artery
1771938|NCT00371371|Procedure|Placebo infusion|Repeated intra-arterial infusion of placebo (PBS/4% HAS/heparin, coloured with autologous erythrocytes to match the colour of BM-MNC suspension) into the common femoral artery.
1771940|NCT00371397|Behavioral|Hatha Yoga Classes|Iyengar yoga, the form of hatha yoga used in this study, emphasizes the use of props to help students achieve precise postures safely and comfortably according to their particular body types and needs. The yoga activity sessions were directed by four experienced yoga teachers following a script. The poses used were (in order) Supta Baddha Konasana (Reclining Bound Angle Pose), Adho Mukha Svanasana (Downward Facing Dog), Supported Uttanasana (Intense Forward Stretch), Parsvotanasana (Intense Side Stretch Pose), Prasarita Padottanansana (Wide-Legged Forward Bend), Janu Sirsasana (Head to Knee Pose), Bharadvajasana (Simple Seated Twist Pose), Viparita Karani (Restful Inversion), Supported Setu Bandha Sarvanagasana (Bridge Pose), and Savasana (Corpse Pose). Blood draws occurred during the last two minutes of Supta Baddha Konasana (pose held 10 minutes), Viparita Karani (10 minutes), and Savasana (15 minutes).
1771941|NCT00371397|Behavioral|Movement Control|Walking on a treadmill at .5 miles per hour was used to control for general physical movement/cardiovascular expenditure because it best approximated the heart rates during the restorative yoga session. To match the lower heart rate, women also rested supine on a bed for several minutes after walking, before and after getting their blood drawn.
1771942|NCT00371410|Procedure|vitrectomy|
1771943|NCT00371410|Drug|intravitreal triamcinolone acetonide|
1771944|NCT00371410|Procedure|macular focal laser photocoagulation|
1771945|NCT00371423|Device|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
1771946|NCT00371423|Device|TAXUS Liberté™-SR|Paclitaxel-Eluting Coronary Stent System
1771947|NCT00371436|Procedure|Progressive Audiologic Tinnitus Management|The five levels of progressive intervention are: (1) triage; (2) audiologic evaluation; (3) group education; (4) tinnitus evaluation; and (5) individual management.
1771948|NCT00371436|Procedure|Usual Care|Typical audiologic care that would be received in a VA Audiology Clinic.
1771949|NCT00371462|Behavioral|Use of PDA + support to reduce weight and pain|participants will attend the MOVE! group, record their food, activity, mood, pain, and weight daily via a PDA. Participants will be assigned a coach to help them set physical activity and calorie goals in order to produce a weight loss of .5%-1% per week on average over the course of 6 months. Participants will continue to log using the PDA during the 2nd 6-months for follow-up. They will also be asked to attend assessments at 3, 6, 9, and 12 months.
1771950|NCT00371462|Behavioral|MOVE! level 2 group weight loss counseling|Participants will attend the MOVE! group and will be asked to complete assessments at 3, 6, 9, and 12 months.
1771951|NCT00371475|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary 38 mm Stent
1771952|NCT00371475|Device|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
1771953|NCT00371488|Drug|GW572016 oral tablets|Tablets contain 405mg of lapatinib ditosylate monohydrate, equivalent to 250mg lapatinib free base per tablet. Oval, orange, film-coated tablets.
1771954|NCT00371501|Drug|Rosuvastatin|10mg/day
1771955|NCT00371501|Drug|placebo|one tablet/day
1771956|NCT00371501|Drug|aspirin|80mg/day
1771957|NCT00371501|Drug|placebo|placebo
1771958|NCT00371527|Drug|ipratropium|
1771959|NCT00371540|Other|Home visit by community care coordinators|Decrease in patient visits to the clinic from the standard of once per month to every 3 months with home visits monthly.
1771960|NCT00371553|Drug|SU011248 (Sunitinib)|
1771961|NCT00371566|Drug|Lapatinib oral tablets|
1771962|NCT00371566|Drug|Placebo|
1771963|NCT00371579|Drug|rosuvastatin|
1771964|NCT00371592|Drug|Acyclovir|800 mg tablet taken orally twice daily
1771965|NCT00371592|Drug|Acyclovir placebo|800 mg placebo tablet taken orally twice daily
1771966|NCT00371618|Procedure|Fluoroscopy|
1771967|NCT00371631|Biological|Insertion of urinary catheters coated with E. coli 83972|All patients in this pilot study were in the treatment arm, which consisted of receiving a urinary catheter that had been pre-coated with a biofilm of E. coli.
1771968|NCT00371644|Behavioral|Cognitive Processing Therapy|CPT is a cognitive therapy based on information processing theory and includes components which help the client to (a) access her or his memory of the event, (b) identify and experience her or his emotions until they have been extinguished, and (c) identify and challenge beliefs about the event itself and beliefs about self and the world which have been altered because of the rape.
1771969|NCT00371644|Behavioral|Present-Centered Therapy|PCT consists of general support and education focused on current issues in the patient's life. It emphasizes the focus on the individual's current life, and conceptualizes the problems addressed as manifestations of PTSD that, in some cases, may have been present for long periods of time. Emphasis is on problem solving and improving relationships. Connections are made between current problems and PTSD symptoms. PCT provides the emotional support for the trauma patient that is thought to help in recovery and helps the victim gain a better understanding of the nature of the patient's problems and connection with PTSD.
1771970|NCT00371670|Drug|balicatib (AAE581)|
1771971|NCT00371683|Drug|Enoxaparin + Placebo|Syringes + tablets, Subcutaneous + Oral, 30mg, twice daily, 12 day treatment period
1772170|NCT00379028|Drug|Salmeterol/Fluticasone Diskus|
1771972|NCT00371683|Drug|Apixaban + Placebo|Tablet + Syringes, Oral + subcutaneous, 2.5 mg, twice daily, 12 day treatment period
1771973|NCT00371696|Drug|diclofenac|
1771974|NCT00371696|Drug|paracetamol|
1771975|NCT00371696|Device|heat retaining knee support|
1771976|NCT00371696|Device|standard knee support|
1771977|NCT00371709|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent System
1771978|NCT00371709|Device|TAXUS™ Express|Paclitaxel-Eluting Coronary Stent System
1771979|NCT00371722|Procedure|Appendectomy|
1771980|NCT00371735|Drug|chlorproguanil-dapsone-artesunate|
1771981|NCT00371735|Drug|chlorproguanil-dapsone|
1771982|NCT00371748|Device|TAXUS Liberté-SR|Paclitaxel-Eluting Coronary Stent, 2.25 mm
1771983|NCT00371748|Device|TAXUS™ Express2|Paclitaxel-Eluting Coronary Stent System
1771984|NCT00371748|Device|Express2|Coronary Stent System
1771985|NCT00371761|Biological|Pegylated interferon alfa-2b (PegIntron)|Powder for injection in vials ( 100, and 120 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
1771986|NCT00371761|Drug|Adefovir dipivoxil (adefovir)|10 mg adefovir dipivoxil (equivalent to 5.4.5 mg adefovir) tablets, oral, dose of 1 tablet per day for up to 48 weeks
1771987|NCT00371787|Device|Soft contact lens|Soft contact lens
1771988|NCT00371800|Drug|cinnamon|
1771989|NCT00371813|Drug|Varenicline tartrate|
1771990|NCT00371813|Drug|Placebo|
1771991|NCT00371826|Drug|Everolimus (RAD001)|
1771992|NCT00371826|Drug|Cyclosporine (Calcineurin Inhibitor (CNI))|
1771993|NCT00371826|Drug|Methylprednisone/prednisone|
1771994|NCT00371826|Drug|Mycophenolate sodium (MPA)|
1771995|NCT00377624|Drug|sodium hyaluronate|
1771996|NCT00377637|Drug|Mycophenolate mofetil (MMF)|Supplied as 500 mg tablets taken orally twice a day (BID). Dose specific for each arm. Dosing started at 500 mg BID for the first week, increasing by 500 mg in subsequent weeks until the final target dose was reached.
1771997|NCT00377637|Drug|Cyclophosphamide|"Intravenous cyclophosphamide (IVC) was administered every four weeks (monthly) to a total of six infusions.
Dosing was started at 0.75 g/m^2 of body surface area for the first month, with subsequent doses at 0.5-1.0 g/m^2. The target dose was 1.0 g/m^2, but doses were titrated by 0.25 g/m^2 increments to maintain nadir leukocyte count between 2500-4000/mm^3."
1771998|NCT00377637|Drug|Azathioprine|2 mg/kg/day orally, provided as 50 mg capsules to be taken after meals.
1771999|NCT00377637|Drug|Placebo to Azathioprine|Placebo capsules matching Azathioprine taken orally once a day.
1772000|NCT00377637|Drug|Placebo to Mycophenolate mofetil|Placebo tablets matching Mycophenolate mofetil taken orally twice daily.
1772001|NCT00377637|Drug|Corticosteroid|Oral prednisolone (or equivalent) starting at a dose of 0.75-1.0 mg/kg/day (maximum 60 mg/day) tapered to 10 mg/day.
1772002|NCT00377650|Device|Percutaneous thrombectomy|
1772003|NCT00377663|Behavioral|AsthmaNet|The AsthmaNet Web site will provide parents of children in the AsthmaNet group with individualized clinical information regarding their child's asthma care and with decision-making aids that they can share with their child's doctor. The web site will also prompt parents to make additional doctor appointments, as needed, to discuss their child's condition.
1772004|NCT00377676|Drug|Cycloset|Usual diabetes therapy plus Cycloset
1772005|NCT00377676|Drug|Usual Diabetes Therapy plus placebo|Placebo tablet taken orally once in the morning, beginning with one tablet daily, titrated up by 1 tablet each week to a maximum of 6 tablets daily
1772006|NCT00377689|Behavioral|high intensity functional exercise|high intensity functional exercise
1772007|NCT00377715|Drug|Dimebon|
1772008|NCT00377715|Drug|Placebo|
1772010|NCT00377741|Drug|valganciclovir [Valcyte]|900mg po
1772011|NCT00377767|Behavioral|To change structure and roles of primary care teams to optimize prevention of obesity|
1772012|NCT00377780|Drug|Non pegylated liposomal doxorubicin, trastuzumab, docetaxel|max. 6 courses
1772013|NCT00377793|Drug|Levitra (Vardenafil, BAY38-9456)|
1772014|NCT00377793|Drug|Placebo|
1772015|NCT00377806|Drug|Diclofenac gel|
1772016|NCT00377819|Drug|alendronate|70 mg oral QW
1772017|NCT00377819|Drug|Denosumab (AMG 162)|60 mg SC q 6 mos
1772018|NCT00377832|Drug|Acetaminophen 975 mg|Acetaminophen 975 mg by mouth once only
1772019|NCT00377845|Procedure|Regular Tampax used in 3 hours|
1772020|NCT00377858|Drug|Insulin lispro mid mixture (MM)|Patient specific adjusted dose, three times a day (TID), subcutaneous (SC) injection x 36 weeks
1772021|NCT00377858|Drug|Insulin glargine|Patient specific adjusted dose, every day (QD), subcutaneous (SC) injection x 36 weeks
1772022|NCT00377871|Device|biological heart valve prosthesis|Two heart valve designs
1772023|NCT00377897|Procedure|cell therapy|Injection of Bone-Marrow mononuclear cells in the muscles of the calf.
1772024|NCT00377910|Drug|Aethoxysclerol|2 ml Aethoxysclerol 10 mg/ml 2 ml. lidocaine 10mg/ml
1772025|NCT00377923|Drug|Progesterone|
1772026|NCT00377936|Drug|Gemcitabine alone|Gemcitabine monotherapy 1000 mg/m2 weekly
1772027|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 11 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
1772028|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 22 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
1772029|NCT00377936|Drug|EndoTAG-1 and Gemcitabine|EndoTAG-1 44 mg/m2 twice weekly + Gemcitabine 1000 mg/m2 weekly
1772030|NCT00377975|Drug|Ephedrine|
1772031|NCT00377975|Drug|Pioglitazone|
1772032|NCT00377975|Drug|Caffeine|
1772033|NCT00377988|Drug|Transdermal Contraceptive System|In each 4-week period, exposed subjects will wear a transdermal patch containing 6 mg norelgestromin and 0.75 mg EE worn for each of 3 consecutive weeks with no patch the 4th week.
1772034|NCT00377988|Drug|Norgestimate-containing oral contraceptives with EE|NGM-OCs with 34 mcg of EE taken during each 4 week period for 21 consecutive days, then no pill or a drug-free pill 7 days.
1772035|NCT00378001|Drug|FSH-IBSA|
1772036|NCT00378001|Drug|GONAL-F|
1772171|NCT00379041|Biological|bleomycin sulfate|
1772172|NCT00379041|Drug|doxorubicin hydrochloride|
1772037|NCT00378014|Drug|everolimus|Start dose of everolimus was 1.5 mg in the morning followed by 1.5 mg in the evening. After one week, the dose was adjusted to achieve trough levels between 5-12 ng/mL. Once trough levels were above 5ng/mL, the CNI dose was reduced to 70%. At week 8 post-baseline (latest at week 16 post baseline), CNI was completely discontinued. For patients receiving Ciclosporin A (CiA) as CNI, the everolimus dosage was adjusted to achieve a trough level of 8-12 ng/mL, prior to discontinuation of CiA. After discontinuation of CNI, everolimus was maintained at a trough level of 5-12 ng/mL.
1772038|NCT00378014|Drug|basiliximab|All patients who met the eligibility criteria were treated with 2 doses of basiliximab on Day 0 (transplantation) and Day 4.
1772039|NCT00378014|Drug|CNI|Patients who met the screening eligibility received CNI-based immunosuppressive therapy for 1 month. Then at week 4 (or week 8 at maximum), patients randomized to the CNI arm continued on CNI-based immunosuppressive therapy.
1772040|NCT00378027|Drug|Fondaparinux|Administer Fondaparinux Risk Stratify
1772041|NCT00378066|Drug|Bevacizumab|Bevacizumab, Capecitabine, Oxaliplatin
1772042|NCT00378079|Other|Counseling Only|Counseling only in prison, with passive referral to drug abuse treatment upon release
1772043|NCT00378079|Drug|Counseling + Transfer|Counseling only in prison, with opportunity to enter methadone maintenance upon release
1772044|NCT00378079|Drug|Counseling + Methadone|Counseling and methadone maintenance in prison, with opportunity to continue that treatment upon release
1772045|NCT00378092|Drug|Oral risperidone|Oral risperidone 1 mg or 2 mg or 3 mg will be administered for 21 days from the first dose of RLAI (until RLAI injection becomes effective) and then taper off over the next 5 days. Thereafter, oral risperidone can be administered at the discretion of the Investigator if additional antipsychotic medication will be required due to acute exacerbation of symptoms between visits.
1772046|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|RLAI 25 mg to 50 mg will be administered, intramuscularly which will be tapered and discontinued over a period of up to 6 weeks.
1772047|NCT00378092|Drug|Risperidone Long-Acting Injection (RLAI)|Participants who will experience a disease relapse, will receive RLAI 25 mg, 37.5 mg, or 50 mg, every 2 weeks as an intramuscular injection in the gluteus for up to 24 months.
1772048|NCT00378105|Drug|Bortezomib|Intravenously on days 1, 4, 8 and 11 of a 21 day cycle for a minimum of 8 cycles (dosage will vary depending upon when the participant enters the trial)
1772049|NCT00378105|Drug|Lenalidomide|Taken orally twice a day for 2 weeks (days 1-14) of each 21-day cycle for a minimum of 8 cycles (dosage will vary depending upon when participant enters trial).
1772050|NCT00378105|Drug|dexamethasone|Taken orally on days 1,2,4,5,8,9,11 of a 21-day cycle for a minimum of 8 cycles.
1772051|NCT00378118|Other|Abbott-rapid HIV antibody test|Abbott will be used to test serum or whole blood
1772052|NCT00378118|Other|OraQuick Rapid HIV-1/2 Antibody test|OraQuick for oral fluid HIV antibody testing
1772053|NCT00378131|Drug|RC-1291|
1772054|NCT00378131|Drug|placebo|
1772055|NCT00378144|Drug|Pseudoephedrine/Paracetamol|Fixed oral tablet doses, 2 tablets 3 times a day for 5 days with at least 4 hours between each treatment (morning-noon-evening) and last dose not later than 2 hours before bedtime [Paracetamol (500 mg) and Pseudoephedrine (30 mg)]
1772056|NCT00378157|Behavioral|Joint attention intervention|Eight weeks with two daily sessions (20 minutes) with joint attention intervention in the pre-school.
1772057|NCT00378170|Device|intubation of patients undergoing elective surgery|
1772058|NCT00378183|Drug|risperidone|
1772059|NCT00378196|Drug|Ranibizumab|0.3 mg/0.05 ml dose
1772060|NCT00378196|Drug|Ranibizumab|0.5 mg/0.05 ml dose
1772061|NCT00378209|Drug|Bortezomib|Given intravenously on days 1,4,8 and 11 of a 21-day cycle for a minimum of 8 cycles.
1772062|NCT00378209|Drug|Lenalidomide|Taken orally once a day for 2 weeks (days 1-14) of a 21-day cycle for a minimum of 8 cycles
1772063|NCT00378209|Drug|Dexamethasone|Taken orally on days 1,2,4,5,8,9,11,and 12 of a 21-day cycle for a minimum of 8 cycles
1772064|NCT00378222|Procedure|Autologous Stem Cell Transplantation|
1772065|NCT00378235|Drug|IL13-PE38QQR|
1772066|NCT00378248|Behavioral|Combined psychotherapy|18 weeks day hospital treatment followed by long-term outpatient combined group-and individual psychotherapy
1772067|NCT00378248|Behavioral|Outpatient individual psychotherapy|Eclectic individual psychotherapy in private practice
1772068|NCT00378261|Procedure|Use of an Electronic Data Capture System by patients and physicians to assess patient-physician interactions & therapeutic decisions & outcomes in RA subjects.|
1772069|NCT00378274|Behavioral|Observation|
1772070|NCT00378287|Drug|rabeprazole sodium|
1772071|NCT00378300|Drug|Oral Probiotics|
1772072|NCT00378313|Drug|gemcitabine, epirubicin, paclitaxel|
1772073|NCT00378326|Drug|Tacrolimus|Tacrolimus at doses of 0.15- 0.3mg/kg/day in two divided oral doses, in conjunction with, initially, up to 60mg/day of oral prednisone
1772074|NCT00378339|Device|gold berlocks|
1772075|NCT00378352|Drug|Epoetin alfa|Randomized
1772076|NCT00378365|Procedure|Arsenic trioxide|Arsenic trioxide
1772077|NCT00378365|Procedure|ATRA|ATRA
1772078|NCT00378378|Drug|Mometasone Furoate Nasal Spray (MFNS)|100 mcg nasal spray
1772079|NCT00378378|Drug|Placebo nasal spray|One spray of placebo nasal spray in each nostril once daily for 4 months.
1772080|NCT00378404|Drug|Docetaxel|30 mg/m2 IV on days 1, 8, 15 every 28 days for 6 cycles
1772081|NCT00378404|Radiation|Radiation|50 - 80 cGy on days 1, 8, 15 every 28 days for 6 cycles
1772082|NCT00378417|Biological|7-valent pneumococcal-CRM197 conjugate vaccine|
1772083|NCT00378417|Biological|7-valent pneumococcal-OMPC conjugate vaccine|
1772084|NCT00378443|Drug|prednisone + Inhibace/Cozaar|
1772085|NCT00378443|Drug|Inhibace/Cozaar|
1772086|NCT00378456|Drug|Antioxidants- (Vitamins A,C,E Selenium and Zinc)|
1772087|NCT00378456|Drug|Folinic acid|
1772088|NCT00378456|Drug|Vitamins A,C,E Selenium and Zinc and Folinic acid.|
1772089|NCT00378456|Drug|Placebo|
1772090|NCT00378469|Behavioral|45 minute exercise on ergocycle|
1772091|NCT00378482|Drug|CP-675,206 (Tremelimumab)|15 mg/kg IV every 3 months as long as required
1772092|NCT00378495|Drug|Miltefosine: initially 2.5 mg/kg/day for 28 days|
1772288|NCT00379730|Drug|Prednisolone|
1772093|NCT00378508|Drug|mAb hOKT3gamma1(Ala-Ala), Teplizumab|This is a randomized, two-arm, double blind placebo controlled phase II trial in which 60 participants with recent-onset T1DM are randomized at a 1:1 ratio to receive Teplizumab or placebo over a 14 day treatment period. The course of Teplizumab comprises daily doses of 51 µg/m2, 103 µg/m2, 207 µg/m2, 413 µg/m2, and 10 of 826 µg/m2.
1772094|NCT00378508|Drug|Placebo Arm|
1772095|NCT00378521|Drug|MQX-503|
1772096|NCT00378534|Device|Miltenyi reagent system|Miltenyi Clinimax CD34 Reagent System for CD34 selectioni and delayed T cell depletion add back
1772097|NCT00378534|Drug|Fludarabine|Therapeutic
1772098|NCT00378534|Drug|Cyclosporine|Therapeutic
1772099|NCT00378534|Drug|Cyclophosphamide|Therapeutic
1772100|NCT00378547|Drug|paracetamol + placebo + placebo|Comparing the analgesic effect of combinations of paracetamol + placebo + placebo
1772101|NCT00378547|Drug|paracetamol + pregabalin + placebo|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + placebo
1772102|NCT00378547|Drug|paracetamol + pregabalin + dexamethasone|Comparing the analgesic effect of combinations of paracetamol + pregabalin 300 mg + dexamethasone 8 mg
1772103|NCT00378560|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
1772104|NCT00378560|Biological|Comparator: Placebo|Placebo 0.5 ml injection in 3 dosing regimen
1772105|NCT00378573|Drug|docetaxel|
1772106|NCT00378573|Drug|gemcitabine|
1772107|NCT00378573|Drug|bevacizumab|
1772108|NCT00378586|Procedure|Rectal biopsy|Rectal biopsy.
1772109|NCT00378586|Procedure|Measurement of inflammatory markers in the rectal mucosa|IL-6, TNF-alfa.
1772110|NCT00378586|Procedure|Measurement of rectal lactic acid|Equilibrium dialysis.
1772111|NCT00378599|Drug|Combination of (a) pegylated interferon alfa-2b and (b) rebetol|"Powder for injection in vials and Redipen (50, 80, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
200 mg capsules, oral, weight based dose of 400-1200 mg, daily for up to 48 weeks"
1772112|NCT00378612|Device|Cypher sirolimus eluting coronary stent|Cypher® sirolimus eluting coronary stent ranging in diameters 2.5 to 3.5 mm and available in length from 8 to 33 mm.
1772113|NCT00378625|Drug|Artesunate|
1772114|NCT00378638|Drug|bevacizumab combined with dose dense chemotherapy|
1772115|NCT00378651|Procedure|Neck Auscultation|
1772116|NCT00378664|Procedure|lumbar to sacral ventral nerve re-routing procedure|surgical nerve re-routing procedure
1772117|NCT00378677|Drug|Cyclosporine A dry powder inhalation (Drug)|
1772118|NCT00378690|Drug|leuprorelin acetate|LHRH antagonist
1772119|NCT00378703|Biological|Bevacizumab|Given IV
1772120|NCT00378703|Other|Laboratory Biomarker Analysis|Correlative studies
1772121|NCT00378703|Other|Pharmacological Study|Correlative studies
1772122|NCT00378703|Drug|Sorafenib Tosylate|Given PO
1772123|NCT00378703|Drug|Temsirolimus|Given IV
1772124|NCT00378716|Drug|5-fluorouracil|
1772125|NCT00378716|Drug|leucovorin calcium|
1772126|NCT00378716|Drug|tegafur|
1772127|NCT00378716|Drug|uracil|
1772128|NCT00378729|Drug|Metformin and FSHr|treatment for infertility
1772129|NCT00378729|Procedure|Ovarian drilling by FERTILOSCOPY|surgical ovarian drilling
1772130|NCT00378755|Drug|velcade|
1772131|NCT00378768|Biological|anti-thymocyte globulin|
1772132|NCT00378781|Drug|Heparin|Heparin flush solution into CVC once daily.
1772133|NCT00378781|Drug|Minocycline-EDTA|M-EDTA flush solution into CVC once daily.
1772134|NCT00378820|Behavioral|Whey without milk minerals|
1772135|NCT00378820|Behavioral|Whey with milk minerals|
1772136|NCT00378820|Behavioral|Casein without milk minerals|
1772137|NCT00378820|Behavioral|Casein with milk minerals|
1772138|NCT00378833|Drug|niacin (+) laropiprant|Duration of Treatment: 18 Weeks
1772139|NCT00378833|Drug|niacin|Duration of Treatment: 18 Weeks
1772140|NCT00378846|Procedure|infrared thermography|
1772141|NCT00378859|Behavioral|Skim milk|
1772142|NCT00378859|Behavioral|Lean meat|
1772143|NCT00378872|Drug|IV Tranexamic acid 10mg/kg pt body weight|
1772144|NCT00378872|Drug|Quixil topical sealant|
1772145|NCT00378885|Behavioral|Cognitive-behavioral tailored intervention|
1772146|NCT00378898|Device|BRAVO capsule|
1772147|NCT00378898|Procedure|Fluoroscopy|"one time xray to determine evacuation of bravo"
1772148|NCT00378898|Other|sham BRAVO capsule placement|
1772149|NCT00378911|Drug|sunitinib malate|Given orally
1772150|NCT00378937|Drug|acetaminophen|
1772151|NCT00378937|Drug|codeine phosphate|
1772152|NCT00378937|Drug|dextropropoxyphene hydrochloride|
1772153|NCT00378937|Drug|morphine sulfate|
1772154|NCT00378937|Drug|oxycodone hydrochloride|
1772155|NCT00378937|Procedure|management of therapy complications|
1772156|NCT00378937|Procedure|quality-of-life assessment|
1772157|NCT00378950|Behavioral|Teach to Goal (TTG)|The TTG program includes the Brief Educational Intervention (BEI) educational intervention, as well as education about diuretic self adjustment. In addition, follow-up phone calls are given to the TTG group to further reinforce the initial training and provide further training so participants will master the task.
1772158|NCT00378950|Behavioral|Brief Educational Intervention (BEI)|The BEI is a one hour educational session on CHF, symptom recognition, diet, exercise, and daily checkups.
1772159|NCT00378963|Device|ProAdjuster|
1772160|NCT00378976|Drug|valacyclovir|500 mg twice-daily oral
1772161|NCT00378976|Drug|matching placebo|twice daily as per experimental drug
1772162|NCT00378989|Behavioral|Consultation at the occupational health services|Consultation at the occupational health services
1772163|NCT00379015|Biological|trastuzumab|
1772164|NCT00379015|Drug|cyclophosphamide|
1772165|NCT00379015|Drug|docetaxel|
1772166|NCT00379015|Drug|epirubicin hydrochloride|
1772167|NCT00379015|Procedure|conventional surgery|
1772168|NCT00379015|Procedure|neoadjuvant therapy|
1772175|NCT00379041|Drug|procarbazine hydrochloride|
1772176|NCT00379041|Drug|vinblastine sulfate|
1772177|NCT00379041|Drug|vincristine sulfate|
1772178|NCT00379041|Radiation|radiation therapy|
1772179|NCT00379054|Behavioral|telephone based skills training intervention|
1772180|NCT00379067|Drug|Tamsulosin OCAS|Adrenoceptor antagonist
1772181|NCT00379067|Drug|Placebo|placebo
1772182|NCT00379080|Procedure|conventional surgery|Undergo surgery
1772183|NCT00379080|Drug|tandutinib|Given orally
1772184|NCT00379080|Other|pharmacological study|Correlative studies
1772185|NCT00379080|Other|Tissue samples|Correlative studies
1772186|NCT00379093|Behavioral|Brief advice|"The intervention will have the following components:
A) At the time of the recruitment visit, all intervention group patients will receive:
A personalized risk report;
An educational booklet titled Healthy Drinking as You Age;
A drinking diary;
Brief advice to reduce their drinking by their physicians;
B) After the recruitment visit, all intervention group patients will receive up to 3 telephone calls from a health educator. After each call, intervention group patients may choose to receive a letter updating their health risks.
Also, at the conclusion of their interaction with the health educator, they may choose to have a letter summarizing the calls sent to their physician."
1772187|NCT00379106|Procedure|Arm exercises.|Basic active exercise program at home.
1772188|NCT00379106|Procedure|Arm Exercises|Instruction in the same active exercise program along with additional exercises using exercise equipment and stretching exercises
1772189|NCT00379119|Other|diagnostic laboratory biomarker analysis|
1772190|NCT00379119|Other|flow cytometry|
1772191|NCT00379119|Other|physiologic testing|
1772192|NCT00379119|Procedure|computed tomography|
1772193|NCT00379132|Drug|131-I-TM-601 (chlorotoxin)|"Patients will be administered 1 - 3 (Test Doses A, B, and Dose C) escalating doses of 131I-TM601 by intravenous (IV) administration. Each dose will be administered as a single administration, scheduled at one-week intervals.
Test Dose A - 10 mCi (+/- 20%)/0.2 mg TM601 (131I-TM601) Test Dose B - 20 mCi (+/- 20%)/0.4 mg TM601 (131I-TM601) Dose C - 30 mCi (+/- 10%)/0.6 mg TM601 (131I-TM601)"
1772195|NCT00379158|Drug|Micronutrient supplements|
1772196|NCT00379171|Behavioral|Cow's milk with fish oil|
1772197|NCT00379171|Behavioral|Cow's milk without fish oil|
1772198|NCT00379171|Behavioral|Formula with fish oil|
1772199|NCT00379171|Behavioral|Formula without fish oil|
1772200|NCT00379197|Drug|naltrexone|Naltrexone 50 mg will be orally taken once daily for 28 day (cycle 1), and continues once daily for another 28 days (cycle 2) without interval.
1772201|NCT00379197|Procedure|PET scan|Patients will receive PET scan approximately one hour after being injected with 2-Deoxy-2-[18F]fluoro-D-Glucose (FDG). PET scans will be performed after the completion of cycle 1 and cycle 2 and during the 1 year follow-up.
1772202|NCT00379210|Behavioral|Mindfulness Meditation Training (MMT)|8-week training course in mindfulness meditation
1772203|NCT00379210|Behavioral|Nutrition Education course|8-week course in nutrition
1772204|NCT00379223|Procedure|vitrectomy with radial optic neurotomy|
1772205|NCT00379236|Device|EUFLEXXA™|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate (molecular weight 2.4-3.6 MD); sodium chloride, 17 mg; disodium hydrogen phosphate dodecahydrate, 1.12 mg; sodium dihydrogen phosphate dihydrate, 0.1 mg; enough water for injection to make 2.0 ml. EUFLEXXA™ is supplied in 2.25 ml nominal volume, disposable prefilled glass syringes containing 2 mL of EUFLEXXA™. Only the contents of the syringe are sterile. EUFLEXXA™ is nonpyrogenic. See package insert for further details.
1772206|NCT00379236|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Only the contents of the syringe are sterile.
1772207|NCT00379249|Drug|Rosuvastatin|
1772208|NCT00379262|Drug|Capecitabine|Dose:1000 mg/m2, BD, Day 1-Day 14 Interval: 21 days Cycles: 3 cycles
1772209|NCT00379262|Drug|Adjuvant chemotherapy using PF (5-Fluorouracil )|Cisplatin 80 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 96 hr every 28 days for 3 cycles
1772210|NCT00379262|Drug|Induction chemotherapy using PF (5-Fluorouracil)|Cisplatin 100 mg/m2 IV + 5-Fluorouracil 1000 mg/m2/day IV infusion for 120 hr every 21 days for 3 cycles
1772211|NCT00379288|Drug|mometasone furoate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
1772212|NCT00379288|Drug|mometasone furoate combination MDI 400/10 mcg BID|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 1 year
1772213|NCT00379288|Drug|Fluticasone/Salmeterol 250/50 mcg BID|F/SC 250/50 twice daily for 1 year
1772214|NCT00379288|Drug|Fluticasone/Salmeterol 500/50 mcg BID|F/SC 500/50 twice daily for 1 year
1772215|NCT00379301|Procedure|Radiofrequency ablation|Special catheters are inserted into blood vessels in the groin, then advanced into the left atrium of the heart. Radiofrequency (heat) energy is applied to small areas of heart tissue where electrical impulses that generate AF are found.
1772216|NCT00379314|Procedure|TVT and TVT-O minimally invasive surgical procedures|
1772217|NCT00379314|Procedure|Surgery for female stress urinary incontinence|
1772218|NCT00379327|Procedure|Acupuncture|Acupuncture administered in last three weeks of pregnancy
1772219|NCT00379327|Device|Non-puncturing Acupuncture Needle|Streitsberg non-Acupuncture Needle
1772220|NCT00379340|Drug|doxorubicin hydrochloride|Given IV
1772221|NCT00379340|Drug|liposomal vincristine sulfate|Given IV
1772222|NCT00379340|Procedure|conventional surgery|
1772223|NCT00379340|Radiation|3-dimensional conformal radiation therapy|
1772224|NCT00379340|Biological|dactinomycin|Given IV
1772225|NCT00379340|Drug|cyclophosphamide|Given IV
1772226|NCT00379340|Drug|etoposide|Given IV
1772227|NCT00379353|Drug|Thalidomide|100 mg capsules orally, once a day for 14 days.
1772228|NCT00379353|Drug|Placebo|Two placebo capsules orally, once a day for 14 days.
1772229|NCT00379366|Device|External ionizing radiations|14 Gy in one time
1772230|NCT00379379|Device|electroacupuncture|
1772231|NCT00379392|Behavioral|Mental Imagery only|Listening to an audio tape to enhance mental imagery of functional activities of the affected upper extremity
1772232|NCT00379392|Procedure|Mental Imagery and Constraint induced therapy|Listening to an audio tape to enhance mental imagery AND participation in constraint induced therapy
1772233|NCT00379405|Drug|Saquinavir/Ritonavir : 2 capsules (500 mg) / 12 hours|Saquinavir/Ritonavir: 2 capsules (500 mg) / 12 hours
1772234|NCT00379418|Drug|Abciximab|
1772235|NCT00379431|Drug|Administration of rituximab and methylprednisolone|"Rituximab:
Pharmaceutical form: Concentrate for solution for infusion. Maximum duration of treatment: 28 weeks Maximum dose allowed: 2000 mg (use of total dose) Route of administration: intravenous use."
1772236|NCT00379444|Behavioral|Standard intervention (counseling + self-help written materials)|counseling
1772237|NCT00379444|Behavioral|Enhanced Intervention (same as standard treatment plus 10-15 min of counseling and a culturally tailored video)|counseling
1772238|NCT00379457|Biological|dactinomycin|
1772239|NCT00379457|Drug|carboplatin|
1772240|NCT00379457|Drug|cyclophosphamide|
1772241|NCT00379457|Drug|doxorubicin hydrochloride|
1772242|NCT00379457|Drug|etoposide|
1772243|NCT00379457|Drug|ifosfamide|
1772244|NCT00379457|Drug|topotecan hydrochloride|
1772245|NCT00379457|Drug|vincristine sulfate|
1772246|NCT00379457|Drug|vinorelbine tartrate|
1772247|NCT00379457|Procedure|conventional surgery|
1772248|NCT00379457|Radiation|radiation therapy|
1772249|NCT00379470|Device|NovoTTF-100A|multiple four-week courses of continuous NovoTTF-100A treatment
1772250|NCT00379483|Drug|Deferasirox|
1772251|NCT00379496|Procedure|Antidepressants|
1772252|NCT00379496|Procedure|acupuncture|
1772253|NCT00379509|Drug|lapatinib ditosylate|Patients will be assigned in cohorts of 3. Dose levels of GW572106 will include 500mg, 1000mg,1500 mg (additional levels at 750 mg and 1250 mg will be added if needed). Lapatinib is an oral drug. It is taken every day.
1772254|NCT00379509|Genetic|TdT-mediated dUTP nick end labeling assay|Genetic analysis of tumor tissue
1772255|NCT00379509|Genetic|gene expression analysis|Genetic analysis of tumor tissue.
1772256|NCT00379509|Genetic|microarray analysis|Genetic analysis of tumor tissue.
1772257|NCT00379509|Other|immunohistochemistry staining method|Laboratory analysis of tumor tissue.
1772258|NCT00379509|Procedure|biopsy|Serial biopsies by skin punch or core biopsy or fine needle aspiration.
1772259|NCT00379509|Radiation|radiation therapy|Radiotherapy will be delivered at standard dose and fractionation. For patients who have not received previous locoregional radiotherapy, 50-56 Gy will be delivered to the regional lymph nodes and/or chest wall at a dose of 2 Gy per fraction, 5 days per week followed by a boost to the sites of gross involvement to a total dose of 60-70 Gy over a course of 6-7 weeks. For patients who have received adjuvant radiotherapy, a dose of 35-45 Gy will be delivered to sites of chest wall involvement at a dose of 1.8 Gy per fraction over 4-5 weeks. In either de novo or reirradiated settings, the total dose to the brachial plexus will not exceed 60 Gy.
1772260|NCT00379522|Drug|Vasopressin|10 minutes after standard shock treatment 10 IU arginine vasopressin will be injected; if shock persists for 5 minutes, another 10 IU arginine vasopressin will be injected; after 5 minutes persisting shock, the last 10 IU arginine vasopressin will be injected; Total duration: approx. 15 minutes; Dose per intravenous injection: 10 IU; max. dose: 30 IU arginine vasopressin
1772261|NCT00379522|Drug|Saline placebo|Placebo for arginine vasopressin
1772262|NCT00379535|Drug|potassium iodide|per os
1772263|NCT00379535|Drug|placebo|per os
1772264|NCT00379548|Behavioral|2 groups of population responding to 2 types of diets|Intervention groups include: Asian intervention and Caucasian intervention- both these groups switch from an Asian diet to a Western diet halfway through the study.
1772265|NCT00379561|Drug|PSA-Activated PSA-PAH1|
1772266|NCT00379574|Drug|Bortezomib|"Bortezomib:
For phase I, 3 dose levels (1.0, 1.3 or 1.6 mg/m2), days 1 and 4, every 2 weeks.
For phase II, suggested dose of Bortezomib through phase I, days 1 and 4, every 2 weeks."
1772267|NCT00379574|Drug|Cyclophosphamide|cyclophosphamide 750mg/m2 day 1, every 2 weeks
1772268|NCT00379574|Drug|Doxorubicin|doxorubicin 50 mg/m2 day 1, every 2 weeks
1772269|NCT00379574|Drug|Vincristine|vincristine 1.4 mg/m2 (max. 2 mg) day 1, every 2 weeks
1772270|NCT00379574|Drug|Prednisolone|prednisolone 100 mg days 1-5, every 2 weeks
1772271|NCT00379574|Drug|Lenograstim|Lenograstim 5 microgram/kg subcutaneously days 4-13 every 2 weeks
1772272|NCT00379587|Drug|Rituximab|Rituximab at months 3, 6, 9 and 12 post-transplant
1772273|NCT00379587|Drug|375 mg/m2 RRituximab|Rituximab 375 mg/m2 q3months
1772275|NCT00379613|Drug|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)
At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
1772276|NCT00379613|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: 1.2 mg/kg rocuronium (arms 2-6)
At 5 minutes after administration of rocuronium, the randomized single dose of sugammadex 2.0 to 16.0 mg/kg IV was administered"
1772277|NCT00379626|Drug|cognitive and hormone treatment|cognitive and hormone (Leuprorelin) treatment
1772278|NCT00379639|Drug|Romidepsin|7, 10 or 12 mg/m^2 via intravenous infusion over 4 hours on either Days 1, 8 and 15 or Days 1 and 15 of each 28-day cycle.
1772279|NCT00379639|Drug|Gemcitabine|800 or 1000 mg/m^2 via intravenous infusion over 30 minutes on either Days 1,8 and 15 or Days 1 and 15 of each 28 day cycle.
1772280|NCT00379652|Behavioral|Medical Practice Improvement|The details for the medical practice improvement intervention will be decided at a later date.
1772281|NCT00379652|Behavioral|Patient Education and Support|The details for the patient education and support intervention will be decided at a later date.
1772282|NCT00379652|Other|Combination Intervention to Include Medical Practice Improvement and Patient Education and Support|The details for this combination intervention will be decided at a later date.
1772283|NCT00379665|Drug|Cisplatin|1 mg/ml at a dosage of approximately 2 mg per cubic cm of tumor. Weekly up to 6 injections.
1772284|NCT00379691|Drug|phenylephrine|
1772285|NCT00379717|Drug|Cisplatinum|
1772286|NCT00379717|Drug|Docetaxel|
1772287|NCT00379717|Device|Tomotherapy|
1772289|NCT00379743|Behavioral|Health coordinator (or patient navigator)|Individuals randomized to receive the less intensive intervention receive educational materials only. Those randomized to the more intensive intervention are assigned a health coordinator (patient navigator) who delivers an enhanced, tailored educational intervention after review of the participant's screening history and knowledge gaps about cancer. The health coordinator also facilitate adherence to cancer screening and/or treatment services, by assisting in scheduling and keeping of appointments for cancer-related screening and/or treatment services.
1772290|NCT00379743|Behavioral|Educational materials only|A brochure is provided to the participant with information about preventive services covered by Medicare, and the frequency with which those services should be obtained.
1956916|NCT02631538|Drug|Placebo belimumab|The placebo control will be provided as a sterile liquid product in a prefilled syringe. Each syringe will be of a single use.
1956917|NCT02631538|Drug|Placebo rituximab|Placebo rituximab will be provided as solution for infusion. It is a clear, colorless liquid.
1772293|NCT00379769|Drug|Rosiglitazone|Rosiglitazone maximum 8 mg per day
1772294|NCT00379769|Drug|Sulfonylurea|Sulfonylurea (SU) maximum permitted daily dose
1772295|NCT00379769|Drug|Metformin|Metformin maximum permitted daily dose .
1772296|NCT00379782|Other|Navigation|Navigation and escourt
1772297|NCT00379795|Drug|Ranibizumab 0.5 mg|Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)
1772298|NCT00379808|Drug|montelukast|10 mg tablet (masked by capsule) daily for 1 month
1772299|NCT00379808|Drug|Placebo|1 lactose-containing capsule daily for 1 month
1956918|NCT02632110|Drug|ALA|20% ALA applied to face prior to light treatment
1956919|NCT02632110|Drug|Topical Solution Vehicle|Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face prior to light treatment
1956920|NCT02632110|Device|IBL 10 mW|10 J/cm2 blue light delivered at 10mW/cm2 for 16 minutes 40 seconds
1956921|NCT02632110|Procedure|Microneedle lesion preparation|Microneedling of all visible/palpable AK lesions prior to solution application.
1772304|NCT00379834|Drug|Cosopt|Cosopt twice daily in both eyes
1772305|NCT00379847|Drug|conivaptan|IV
1772306|NCT00379860|Drug|LXR-623|
1772307|NCT00379873|Device|ProAdjuster|
1772308|NCT00379886|Drug|Propofol Thiopental|
1772309|NCT00379899|Drug|cinacalcet|Low dose vitamin D with cinacalcet
1772310|NCT00379912|Drug|Azacitidine|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
1772311|NCT00379912|Drug|Erythropoietin|Erythropoietin 60,000IU subcutaneous injection weekly while on protocol therapy
1772312|NCT00379912|Drug|Azacitidine (Monotherapy)|Azacitidine 50 mg/m2 subcutaneously qod for two consecutive weeks every four weeks.
1772313|NCT00379925|Behavioral|Physical Activity and Dietary Health Promotion Program|Churches within the intervention group will receive a committee training and church cook training designed to teach them how to do a self-assessment of current practices and develop a plan for their program. The intervention is based on the structural model of health behavior and targets opportunities, mass media (within the church), guidelines and policies, and church environment. Intervention churches also receive monthly intervention mailings to support intervention implementation.
1772314|NCT00379938|Biological|VAI-VP705 (parvovirus B-19 vaccine)|Recombinant human parvovirus B-19 capsids at dose levels: 25 micrograms of VAI-VP705 with and without MF59 adjuvant and 2.5 micrograms with MF59 adjuvant.
1772315|NCT00379938|Drug|Placebo|Saline control
1772316|NCT00379938|Biological|MF-59|Adjuvant
1772317|NCT00379951|Drug|ertapenem sodium|ertapenem sodium as a single dose of 1gm I.V. was infused over a 30 min interval for a minimum of 3 days to a maximum of 14 days.
1772318|NCT00379964|Drug|caspofungin acetate|Cancidas 50 mg dose followed by 70 mg load on day 1 was administered in Indian adults with persistent fever and neutropenia for a maximum duration of empirical treatment from 28 days ((for patients without documented infection) to 90 days (for patients with documented baseline or emergent fungal infection). Patients were treated until the resolution of neutropenia (ANC>500/mm3), and for up to 72 hours later.
1772319|NCT00379977|Biological|diphtheria, tetanus, pertussis & Hib vaccine|
1772323|NCT00380003|Drug|EVT 201|
1772324|NCT00380016|Procedure|Percutaneous Transluminal Angioplasty|
1772325|NCT00380029|Drug|Erlotinib|Erlotinib will be given at a dose of 150 mg per day for 4 weeks before undergoing planned radical cystectomy. In addition, patients will continue on erlotinib daily at a dose of 150 mg per day (qd dosing) for up to 2 years after surgery (beginning within 12 weeks of surgery) or until evidence of disease recurrence or progression
1772326|NCT00380029|Procedure|Radical Cystectomy|Will occur 4 weeks prior to dosing with erlotinib
1772327|NCT00380042|Device|Cortical Stimulation|Cortical stimulation of prefrontal cortex
1772328|NCT00380042|Device|Sham|Sham stimulation
1772329|NCT00380055|Behavioral|Navigation Services|Navigators (community health workers) identify and assist in overcoming barriers to appropriate cancer care.
1772330|NCT00380055|Behavioral|Cancer education|Community health workers provide cancer education appropriate for Medicare participants.
1772331|NCT00380068|Drug|Ambrisentan|Oral tablets taken once daily.
1772332|NCT00380081|Drug|zolpidem tartrate sublingual tablet 3.5mg|Zolpidem tartrate sublingual tablet 3.5 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
1772333|NCT00380081|Drug|zolpidem tartrate sublingual tablet 1.75mg|Zolpidem tartrate sublingual tablet 1.75 milligram administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
1772334|NCT00380081|Drug|Placebo|Placebo sublingual tablet administered between 2:15 and 3:15 a.m. on Night 1 and 2 of each treatment period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
1772335|NCT00380120|Drug|sodium warfarin|dosage: as much as it is required to prolong the international normalized ratio, checked every 2-3 weeks, between 2.0 and 3.0
1772469|NCT00367744|Drug|Rosiglitazone|Rosiglitazone 4mg BID
1772336|NCT00380120|Drug|Sodium warfarin|As much drug as it is necessary to prolong the international normalized ratio between 2.0 and 3.0
1772337|NCT00380133|Drug|SB681323|5 mg and 2.5 mg tablets - The tablets will be round (9.0 mm in diameter) and white and provided in labelled bottles
1772338|NCT00380133|Drug|Prednisolone|5 mg size DB AA capsule shell (Swedish orange) with a powder backfill (lactose Anhydrous)
1772339|NCT00380133|Drug|Placebo|Tablets matched to SB681323 or prednisolone
1772340|NCT00380146|Drug|sulfadoxine-pyrimethamine|
1772341|NCT00380159|Drug|elvucitabine|elvucitabine 10 mg in combination with background ART
1772342|NCT00380159|Drug|Lamivudine|
1772343|NCT00380159|Drug|Emtricitabine|
1772344|NCT00380172|Device|Rheopheresis blood filtration|
1772345|NCT00380198|Drug|Apadenoson|
1772346|NCT00380211|Biological|Influenza vaccine (A/H3N2, A/H1N1, and B strains)|
1772347|NCT00380211|Biological|Fluarix|
1772348|NCT00380224|Drug|bifeprunox, olanzapine|
1772349|NCT00380237|Biological|H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca)|Live attenuated H9N2 (6-2) AA ca Reassortant (A/Chicken/Hong Kong/G9/97 x A/Ann Arbor/6/60 ca) vaccine
1772350|NCT00380250|Drug|Lubiprostone|
1772351|NCT00380250|Drug|Placebo|
1772352|NCT00380263|Drug|PACAP38|10 pmol/kg/min given one time
1772353|NCT00380276|Drug|MPC-7869|800 mg BID Oral dosing
1772354|NCT00380289|Drug|Thiazide and beta blocker|
1772355|NCT00380302|Drug|AVE1625|
1772356|NCT00380315|Drug|AG1321001(drug)|
1772357|NCT00380328|Drug|neratinib|HKI-272
1772358|NCT00380341|Procedure|Instrument-applied spinal manipulative therapy|
1956922|NCT02632110|Device|IBL 20 mW|10 J/cm2 blue light delivered at 20mW/cm2 for 8 minutes 20 seconds
1772360|NCT00380367|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent HPV vaccine (6, 11, 16, 18) given intramuscularly on Day 1, Month 2, and Month 6.
1772361|NCT00380380|Drug|Vildagliptin|
1772364|NCT00380406|Drug|Leuprolide acetate|
1772365|NCT00380419|Behavioral|Interpersonal Psychotherapy (IPT)|IPT sessions will address adjustment to pregnancy, concerns about interpersonal relationships, and parenting concerns. Sessions will be weekly, but may be determined by clinical desires of patient and therapist.
1772366|NCT00380445|Drug|Vildagliptin|
1772367|NCT00380458|Device|Coblation (radiofrequency-based device)|
1772368|NCT00380471|Device|Bath PUVA|
1772369|NCT00366301|Drug|Insulin glargine injection|Once daily for 14 weeks
1772370|NCT00366301|Drug|metformin|Up to 4 pils per day (2g per day) maximum
1772371|NCT00366301|Drug|Placebo pill|Up to 4 pills per day
1772372|NCT00366327|Drug|Bifeprunox|Flex dose (20 or 30 mg)tablet, QD for 1 year
1772373|NCT00366340|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
1772374|NCT00366340|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5mL dose given at 2, 3, 4 and 11 to 12 months of age
1772375|NCT00366353|Other|Sedation during SBT|
1772376|NCT00366353|Other|No sedation|
1772377|NCT00366366|Biological|Infanrix-Hexa|
1772378|NCT00366379|Drug|GK Activator (2)|25-200mg po bid for 20 weeks
1772379|NCT00366392|Device|Optical Aids|
1772380|NCT00366418|Drug|Rituximab|
1772381|NCT00366431|Drug|MOA-728|
1772382|NCT00366444|Drug|diclofenac potassium (XP21L)|25 mg every 6 hours
1772383|NCT00366444|Drug|Placebo|Placebo every 6 hours
1772384|NCT00366457|Drug|Bevacizumab|Given intravenously on days 1 and 25 of every 28-day cycle (one every 2 weeks). Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
1772385|NCT00366457|Drug|Erlotinib|Taken orally every day. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
1772386|NCT00366457|Drug|Gemcitabine|Given intravenously on days 1, 8 and 15 of each 28-day cycle. Participants may continue to receive study treatment as long as there is no disease progression or serious side effects.
1772387|NCT00366470|Drug|A. 100,000 IU Cholecalciferol per dose of 3.3ml|100,000 IU Cholecalciferol in 3.3ml Migliol (Carrier) oil, once every two weeks for 2 Months
1772388|NCT00366470|Other|B. Migliol Oil without Cholecalciferol|3.3 ml Migliol Oil, every two weeks for two months
1772389|NCT00366483|Drug|Lecozotan SR|
1772390|NCT00366496|Device|Acrysof single piece (SA60AT)|
1772391|NCT00366496|Device|Acrysof IQ (SN60WF)|
1772392|NCT00366522|Drug|LXR-623|
1772394|NCT00366548|Biological|13 valent pneumococcal conjugate vaccine with Polysorbate 80|
1772395|NCT00366548|Biological|13 valent pneumococcal conjugate vaccine without Polysorbate 80|
1772396|NCT00366574|Device|Amadeus Microkeratome|
1772397|NCT00366574|Device|IntraLase|
1772398|NCT00366587|Device|Cataract surgery and IOL implantation|
1772399|NCT00366600|Drug|neratinib|HKI-272
1772400|NCT00366613|Procedure|Cataract surgery with Perfect Capsule and Sodium Chloride|
1772401|NCT00366626|Drug|Naltrexone|Naltrexone (25 mg/day for days 1-2 and 50 mg/day for days 3-7)
1772402|NCT00366626|Drug|Placebo|Placebo for 7 days matched to Naltrexone
1772403|NCT00366639|Other|Acute Decompensated Heart Failure|Treatment & outcomes during hospital admission for Acute DHF
1772404|NCT00366652|Drug|desvenlafaxine SR|
1772405|NCT00366652|Drug|desipramine|
1772406|NCT00366652|Drug|duloxetine|
1772407|NCT00366665|Device|Legacy 20000|
1772408|NCT00366665|Device|Infinit system|
1772409|NCT00366678|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
1772410|NCT00366678|Biological|7-valent pneumococcal conjugate vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age.
1772468|NCT00367731|Drug|Highly Active Antiretroviral Treatment (combination of :NRTI, NNRTI,or PI)|
1772411|NCT00366678|Drug|Pentavac|The Pentavac was administered by intramuscular injection 0.5 ml into the anterolateral thigh muscle of the right leg at 2, 3, and 4 months (infant series) and 12 months of age (toddler dose).
1772412|NCT00366691|Drug|Acular LS|
1772413|NCT00366691|Drug|Lotemax|
1772414|NCT00366704|Drug|bifeprunox|.25mg titrate up to 20mg/day (week 1) then 30mg/day (weeks 2-8)
1772415|NCT00366704|Drug|risperidone|4mg, QD, 8 week treatment
1772416|NCT00367224|Procedure|6 to 9 ultraviolet B treatments|Treatments with ultraviolet B with gradually progressive doses
1772417|NCT00367224|Procedure|Skin biopsies|4 mm punch biopsies of the skin
1772418|NCT00367237|Drug|Infliximab + methotrexate (IFX + MTX)|Infliximab 5 mg/kg infusion at Weeks 0, 2, 6, 14 and oral methotrexate 15 mg/week for 16 weeks. Methotrexate dose can be increased to 20 mg/week at week 6.
1772419|NCT00367237|Drug|Methotrexate (MTX)|Oral methotrexate 15 mg/week for 15 weeks. Dose can be increased to 20 mg/week at Week 6.
1772420|NCT00367250|Drug|Cetuximab|weekly i.v.
1772421|NCT00367250|Drug|Trastuzumab|weekly i.v.
1772422|NCT00367263|Drug|Alvesco (Ciclesonide) 160 ug/day|
1772423|NCT00367276|Drug|Yasmin (30 µg EE, 3 mg Drospirenone, BAY86-5131)|Yasmin, SH T 470 FA; 30 µg ethinylestradiol and 3 mg drospirenone, oral administration over 6 treatment cycles, one tablet per day for 21 days followed by a 7 day pill-free interval.
1772424|NCT00367302|Drug|buprenorphine|maintenance
1772425|NCT00367302|Drug|methadone|maintenance
1772426|NCT00367315|Drug|Lumiracoxib|
1772427|NCT00367328|Device|1320nm Nd: YAG nonablative laser|a 4 mm piece of skin tissue (about the size of a pencil-head eraser) from the affected area. This procedure is called a punch biopsy and will be done to confirm your diagnosis. A culture swab similar to a Q-Tip will be used to wipe the affected areas during the first visit to determine any bacteria that may be present. A survey with questions will be given at the first visit, again after 3 months and at the last visit to measure the success of the treatment. Photographs will be taken prior to each treatment and one month following your last treatment. A laser, which is a very powerful light, will be used to treat half of the skin that is affected by your condition.
1772428|NCT00367341|Drug|escitalopram|Participants will receive treatment with escitalopram for 12 weeks.
1772429|NCT00367341|Behavioral|Cognitive Behavioral Therapy (CBT)|CBT will include 16 1 hour sessions provided over 12 weeks.
1772430|NCT00367367|Procedure|Hysteroscopy and Curettage|
1772431|NCT00367380|Other|413ABM|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 413ABM
1772432|NCT00367380|Other|414WRR|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 414WRR
1772433|NCT00367380|Other|418JAL|+/- 3 bites of Anopheles albimanus mosquitoes infected through membrane feeding with blood of the P. vivax infected volunteers 418JAL
1772434|NCT00367393|Drug|Pimecrolimus cream 1%|Pimecrolimus cream 1% bid, as needed
1772435|NCT00367406|Device|Gamma 3 nail versus ACE trochanteric nail|Comparing Gamma 3 nail versus ACE trochanteric nail
1772436|NCT00367419|Drug|Erythromycin|
1772437|NCT00367432|Drug|Levetiracetam|Levetiracetam 500 mg/day to 3000 mg/day , tablets twice daily (morning and evening orally) during the study period (until the time of approval granted).
1772438|NCT00367445|Drug|Inhaled Human Insulin (Exubera)|
1772439|NCT00367445|Drug|Insulin Glargine (Lantus)|
1772441|NCT00367471|Drug|lapatinib|Lapatinib (GW572016) is a potent small molecule, reversible inhibitor of both EGFR and ErbB2 tyrosine kinases
1772442|NCT00367471|Drug|carboplatin|An alkylating agent used in the treatment of ome cancers
1772443|NCT00367471|Drug|trastuzumab|A monoclonal antibody that interferes with the HER2/neu receptor
1772444|NCT00367471|Drug|paclitaxel|A mitotic inhibitor used in cancer treatment
1772445|NCT00367484|Biological|Rebif® (clone 484-39)|s.c. administered Rebif®
1772446|NCT00367497|Drug|Rituximab, Etoposide, Methylprednisolone, Cytarabine, Cisplatin|
1772447|NCT00367536|Drug|bazedoxifene/conjugated estrogens combination tablet|
1772448|NCT00367549|Dietary Supplement|Energy-containing soft drink|Commercial energy/sports drink
1772449|NCT00367562|Drug|ENALAPRIL VALSARTAN METHYLPREDNISONE|
1772450|NCT00367575|Procedure|Internet personalized alcohol feedback (PAF)|
1772451|NCT00367588|Behavioral|Low bacterial diet|
1772452|NCT00367601|Drug|Erlotinib|Erlotinib 150 mg qd days 1-21
1772453|NCT00367601|Drug|Bevacizumab|Bevacizumab 15 mg/kg IV, day 1
1772454|NCT00367614|Drug|pantoprazole|
1772455|NCT00367627|Drug|Albendazole|
1772456|NCT00367640|Drug|100 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
1772457|NCT00367640|Drug|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
1772458|NCT00367640|Drug|500 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
1772459|NCT00367640|Drug|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
1772460|NCT00367653|Drug|Azithromycin plus Chloroquine|Azithromycin 1000 mg by mouth (PO) (two 500 mg tablets) once daily (QD) for 3 days(Days 0, 1, 2) plus chloroquine 600 mg base PO once daily for 3 days (Days 0, 1, 2)
1772461|NCT00367653|Drug|Mefloquine|Mefloquine 1250 mg PO given as a split dose (750 mg [three 250 mg capsules]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
1772462|NCT00367666|Device|MRI, Digital Mammography, Ultrasound and Positron Emission Tomography (PET)|
1772463|NCT00367679|Drug|Pazopanib|Pazopanib is an oral, potent, multi-target receptor tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit. Subjects were to receive 800 mg oral pazopanib daily for a minimum of 2 weeks to a maximum of 6 weeks.
1772464|NCT00367692|Drug|PSI-697|
1772465|NCT00367705|Dietary Supplement|VSL#3®|1-2 sachets/day per os, 6 months
1772466|NCT00367705|Dietary Supplement|Placebo|1-2 sachets/day per os, 6 months
1772467|NCT00367718|Drug|Velcade|
1772470|NCT00367744|Drug|Placebo|Placebo for rosiglitazone
1772471|NCT00367757|Procedure|Ablate AF triggers via PVI|Trigger-based ablation guided by pulmonary vein antrum isolation
1772472|NCT00367757|Procedure|Substrate via CFAEs|Substrate-based ablation using an approach targeting CFAEs
1772473|NCT00367757|Procedure|Combined approach for AF ablation|Combined trigger and substrate based approach
1772474|NCT00367770|Drug|Tracleer®|Patients will receive up to 125 mg b.i.d. of Tracleer.
1772475|NCT00367783|Drug|CP-741,952|
1772476|NCT00367809|Behavioral|Mindfulness-Based Stress Reduction (MSBR)|Mindfulness-Based Stress Reduction (MBSR) is the intervention of primary interest. It is a psycho-educational program of 8-weekly classes, 2.5 hours long taught by a trained instructor. Over the course of the program participants receive training in several formal meditation techniques: a body-scan meditation, sitting meditation, walking meditation and mindful Hatha yoga that involves simple stretches and movements. Participants are requested to practice meditation at home and to integrate informal mindfulness practices into their daily lives. The content of MBSR is described in the book Full Catastrophe Living by Jon Kabat-Zinn.
1772477|NCT00367809|Behavioral|Health Education (HE)|The active control condition was a peer-led chronic disease self-management program comprised of 8 weekly, 2.5 hour meetings. Led by trained peer-leaders, groups of participants discussed health challenges and problem-solved using a technique called action-planning. The curriculum described by Lorig and colleagues in the book Living a Health Life was the core of this program, and transplant-specific issues were covered in two meetings to match MBSR for time and attention.
1772478|NCT00367809|Behavioral|Delayed Intervention|A temporary wait-list control group; after 6 months, those in the Delayed Intervention were randomized a second time, to one of the active treatment arms (MBSR or HE).
1772479|NCT00367822|Drug|Lisuride|
1772480|NCT00367822|Drug|Ropinirole|
1772481|NCT00367822|Drug|Placebo|
1772482|NCT00367835|Drug|SPD503 (Guanfacine hydrochloride)|Subjects will start at 1mg tablet each morning and will subsequently be titrated (in 1 mg weekly increments) to optimal dose based upon tolerance and response to investigational product (not to exceed 4 mg/day).
1772483|NCT00367835|Drug|Placebo|Placebo
1772484|NCT00367861|Drug|interruption of Glivec®|interruption of Glivec®
1772485|NCT00367874|Drug|Buprenorphine|
1772486|NCT00367874|Drug|Valproate|
1772487|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
1772488|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
1772489|NCT00367887|Drug|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
1772490|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
1772491|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
1772492|NCT00367887|Drug|HCV 796|Capsules, 500 mg, Q 12 hrs. daily, 48 weeks
1772493|NCT00367887|Drug|Peg-Intron|SC injection, weight based dosing, weekly, 48 weeks
1772494|NCT00367887|Drug|REBETOL|Capsules, weight based dosing, Q12 hrs daily, 48weeks
1772495|NCT00367913|Drug|Addition of clarithromycin to rifampicin and ethambutol|
1772496|NCT00367913|Drug|Addition of Ciprofloxacin to rifampicin and ethambutol|
1772497|NCT00367913|Biological|Vaccination with M.vaccae|
1772498|NCT00367926|Drug|American ginseng root / polysaccharides|
1772499|NCT00367939|Drug|valsartan + amlodipine|
1772500|NCT00367952|Drug|apricitabine|800mg apricitabine twice daily orally for 96 weeks
1772501|NCT00367965|Drug|Eszopiclone|eszopiclone 3 mg
1772502|NCT00367965|Drug|placebo|placebo tablet
1772503|NCT00367978|Drug|Amlodipine/benazepril|
1772504|NCT00367991|Drug|Recombinant human erythropoietin alfa (drug)|200 U/kg IV daily for 3 days vs. matched volume of normal saline IV daily for 3 days
1772505|NCT00367991|Drug|Placebo|Normal saline to match active drug (rHuEpo)
1772506|NCT00368017|Drug|pioglitazone|30 mg once a day for 12 weeks
1772507|NCT00368017|Drug|placebo|1 pill once a day for 12 weeks
1772508|NCT00368030|Drug|Eszopiclone|Eszopiclone 3 mg QD
1772509|NCT00368030|Other|Placebo|Placebo tablet
1772510|NCT00368056|Drug|Eszopiclone|eszopiclone 3 mg
1772511|NCT00368056|Drug|Placebo|Placebo tablet
1772512|NCT00368069|Drug|Keppra® extended release formulation - XR|500mg extended release oral tablet, 2 tablets once daily
1772513|NCT00368069|Drug|Placebo|oral tablets, 2 tablets once daily
1772515|NCT00368095|Behavioral|Intensive Education for Metabolic Syndrome Patients|Excercise, Intensive diatary program
1772516|NCT00368108|Drug|2 mg perampanel|2 mg perampanel
1772517|NCT00368108|Drug|4 mg perampanel|4 mg perampanel
1772518|NCT00368108|Drug|placebo comparator|placebo comparator
1772519|NCT00368121|Drug|Cetuximab +/- Dexamethasone|"Cetuximab dosing schedule:
• Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly over 16 weeks. Mode of administration: intravenous infusion
Dexamethasone dosing schedule:
• 20 mg administered on day 1-3, q1w, starting week 5 if evidence of tumor progression or week 9 if no PR or CR to Cetuximab alone.
Mode of administration: orally"
1772520|NCT00368134|Drug|Vildagliptin|
1772521|NCT00368160|Drug|Eszopiclone|eszopiclone 3 mg
1772522|NCT00368160|Drug|Placebo|Placebo tablet
1772524|NCT00368186|Biological|Pneumo 23|
1772525|NCT00368212|Behavioral|Relaxation response training|The control treatment is relaxation training or attention control. This will be taught in three, 1-hour sessions with a trained therapist.
1772526|NCT00368212|Behavioral|Psychoeducational counseling|Patients will receive five sessions of psychoeducational counseling from the nurse who works with the primary care physicians. Patients who are interested in continuing treatment or who have not responded to this first treatment step will then be referred for the second step, cognitive behavioral therapy (CBT), for more intensive treatment.
1772527|NCT00368238|Drug|Recombinant human erythropoietin alfa (drug)|
1772528|NCT00368238|Drug|Aspirin (drug)|
1772529|NCT00368238|Drug|Clopidogrel (drug)|
1772530|NCT00368251|Other|Placebo|"Pharmaceutical Form: Tablet
Concentration: 2.5 mg, 25 mg and 50 mg
Route of Administration: Oral use"
1772531|NCT00368251|Drug|BRV 2.5 mg|"Pharmaceutical Form: Tablet
Concentration: 2.5 mg
Route of Administration: Oral use"
1772532|NCT00368251|Drug|BRV 25 mg|"Pharmaceutical Form: Tablet
Concentration: 25 mg
Route of Administration: Oral use"
1772533|NCT00368251|Drug|BRV 50 mg|"Pharmaceutical Form: Tablet
Concentration: 50 mg
Route of Administration: Oral use"
1772534|NCT00368264|Drug|infliximab|azathioprine (2 mg/lkg) plus four infusions of infliximab (5mg/kg)
1772535|NCT00368264|Drug|placebo|azathioprine (2 mg/kg) plus four placebo infusions
1772536|NCT00368277|Drug|Aliskiren|Aliskiren 150 mg and 300 mg tablets taken orally, once a day in the morning
1772537|NCT00368277|Drug|Ramipril|Ramipril 5 mg and 10 mg capsules taken orally, once a day in the morning
1772538|NCT00368277|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg capsules taken orally, once a day in the morning
1772539|NCT00368277|Drug|Amlodipine|Amlodipine 5 mg or 10 mg tablets taken orally, once a day in the morning
1772540|NCT00368290|Drug|Modafinil|300mg a day for 8 weeks
1772541|NCT00368290|Drug|placebo|placebo pills for 8 weeks
1772542|NCT00368290|Behavioral|Cognitive Behavioral Therapy (CBT)|Weekly cognitive behavioral therapy sessions for a period of 8 weeks.
1772543|NCT00368303|Drug|Paroxetine CR|
1772544|NCT00368303|Drug|Paroxetine IR|
1772545|NCT00368316|Biological|Shigella conjugate vaccines|Shigella sonnei-rEPA and Shigella flexneri2a rEPA vaccines
1772546|NCT00368329|Drug|Capecitabine (Xeloda)|PO bid daily on RT days: 500mg & 150mg tabs for dose 825mg/m2 bid AM/PM (total daily dose 1650mg/m2)
1772547|NCT00368329|Drug|[18-F] Fluorodeoxyglucose (FDG)|5-10 mCi IV administration
1772548|NCT00368329|Drug|5-Fluorouracil (5-FU)|200mg/m2 continuous venous infusion
1772549|NCT00368329|Drug|Carboplatin|AUC 2, based onCalvert formula IV infusion
1772550|NCT00368342|Drug|Erythromycin, Azithromycin , Clarithromycin|
1772551|NCT00368355|Drug|Ara-C|"day-8 through day-5
3 g/m2 q 12 hours"
1772552|NCT00368355|Drug|Cyclophosphamide|"day-7 and day-6
45 mg/kg"
1772553|NCT00368355|Biological|Campath-1H|"day-3 through day-1
Dosing for children:
5 - 15kg : 3mg IV in 30ml NS
15.1 - 30kg : 5mg IV in 50ml NS
>30 kg : 10mg IV in 100ml NS
Adults will receive 10mg IV in 100ml NS"
1772554|NCT00368355|Radiation|Total Body Irradiation|"day-4 through day-1
175 cGy x 2 at 24 cGy/min"
1772555|NCT00368355|Procedure|Stem Cell Infusion|Stem cells are infused on day 0
1772556|NCT00368368|Drug|GK Activator (2)|100mg po
1772557|NCT00368381|Drug|Hydrocortisone|Patients randomized to this arm will receive hydrocortisone for the treatment of adrenal insufficiency secondary to sepsis.
1772558|NCT00368394|Drug|Insulin glulisine|
1772559|NCT00368407|Device|308-nm excimer laser|
1772560|NCT00368459|Drug|raloxifene|Raloxifene is a selective estrogen receptor modulator
1772561|NCT00368459|Drug|Placebo|Identical appearing placebo
1772562|NCT00368472|Drug|Perampanel|Perampanel 2 mg to 12 mg, once daily during the OLE study
1772563|NCT00368485|Device|Neurally Controlled Mechanical Ventilation|A new mode of mechanical ventilation controlled by the electrical activity of the diaphragm (NAVA) will be used before and after extubation.
1772564|NCT00368498|Drug|teicoplanin|
1772565|NCT00368511|Procedure|Music Listening|Listen to music and posture measurements
1772566|NCT00368524|Behavioral|contingency management and behavioral day treatment|
1772567|NCT00368537|Drug|Tigecycline|Treatment A: Tigecycline every 12 hours intravenous (IV) (an initial dose of 100 mg followed by 50 mg every 12 hours)
1772568|NCT00368537|Drug|ampicillin-sulbactam|"Ampicillin-sulbactam: 1.5 g (1 g ampicillin plus 0.5 g sulbactam) to 3 g (3 g ampicillin plus 1 g sulbactam) intravenous (IV) every 6 hrs or Amoxicillin-clavulanate: 1.2 g (1000 mg amoxicillin plus 200 mg clavulanate) IV every 6 to 8 hrs.
A glycopeptide antibiotic (either vancomycin 1 g IV every 12 hrs or teicoplanin IV loading dose of 400 mg the first day followed by a maintenance dose of 200 mg daily) may be added to the aminopenicillin/betalactamase inhibitor regimen if infection with methicillin-resistant staphylococcus aureus (MRSA) is suspected or confirmed within the first 72 hrs of enrollment. If culture results fail to show a resistant organism, use of the glycopeptide may be discontinued."
1772569|NCT00368550|Drug|Sertraline|Sertraline (to a maximum of 200 mg/day) for 14-week treatment period
1772570|NCT00368550|Drug|Placebo|Placebo for 14-week treatment period
1772571|NCT00368563|Drug|Helioblock SX|
1772572|NCT00368576|Drug|SB 480848, tablets|
1772573|NCT00368589|Drug|atorvastatin|
1772574|NCT00368602|Drug|Timoptic|Timoptic to be applied to the target wound daily for up to 12 weeks.
1772575|NCT00368602|Other|Placebo|Saline solution with no active ingredients to be applied to the target wound daily for up to 12 weeks.
1772576|NCT00368628|Procedure|continuous positive airway pressure|Continuous Positive Airway Pressure initiated within 48 hours of stroke onset and continued for 90 days.
1772577|NCT00368641|Drug|Extraneal|Periotneal Dialysis
1772578|NCT00368654|Drug|Methotrexate|Initial dose 5 mg, then 15 mg per week
1772579|NCT00368654|Drug|Raptiva|Raptiva, initial dose 0.7 mg/kg, then 1.0 mg/kg
1772580|NCT00368680|Device|Early Bubble CPAP|
1772581|NCT00368693|Device|Dermal - Living Skin Replacement (Dermal-LSR)|The only experimental procedure is the application of the study device, Dermal - Living Skin Replacement (Dermal - LSR), to the foot ulcer. All others are regular or standard procedures. Dermal - LSR is a gel containing living human skin cells. This gel is applied directly to ulcers to help repair the skin. The cells used in this study device have come from one foreskin (skin covering the tip of the penis) taken from a baby boy shortly after his birth for reasons unrelated to this study. All cells that will be used have been tested to be healthy and safe. The amount of the study device you will receive depends on the size of your ulcer at each treatment visit. You will receive less than a 1/4 teaspoon of Dermal - LSR for about every dime-size area of your ulcer as measured and calculated by the research investigator.
1772582|NCT00368706|Drug|solifenacin succinate|Oral
1772583|NCT00368706|Drug|tolterodine|oral
1772584|NCT00368719|Drug|Tacrolimus|Participants will be followed for 10 years to study the effects of Tacrolimus.
1772585|NCT00368745|Drug|Pregabalin|GAD subjects on stable dose of alprazolam will be randomized to double-blind pregabalin at starting dose of 75mg twice daily. Weekly assessments of tolerability, need for rescue medication, anxiety/withdrawal symptoms will guide flexible dose titration of pregabalin at dose range between 75 and 300mg twice daily. Subjects successful in discontinuation of alprazolam while treated with pregabalin will continue to be maintained on pregabalin for 6 weeks and assessed weekly for ability to remain in the study.
1772586|NCT00368745|Drug|Placebo|GAD subjects on stable dose of alprazolam will be randomized to double-blind placebo matching assessments and study medication titration as detailed under the pregabalin arm description. Subjects successful in discontinuation of alprazolam while treated with placebo will continue to be maintained on placebo for 6 weeks and assessed weekly for ability to remain in the study.
1772587|NCT00368758|Drug|Probiotic bacteria (Trevis R)|
1772588|NCT00368771|Behavioral|IBS Stress Management|If randomly assigned to this intervention, the session with the therapist will consist of training about IBS symptoms and their relationship to stress, as well as skills training in relaxation and ways of identifying and challenging mistaken thoughts about life events. The goal of this treatment is to lessen mental and physical stressful reactions to daily events, and therefore lessen IBS symptoms as a reaction to stress. The patient will be encouraged to apply relaxation skills to stressful situations.
1772589|NCT00368771|Behavioral|IBS Symptom Management|If assigned to this group, the therapist will discuss feelings, over-attention to IBS symptoms, and your fear of IBS symptoms. Patients will learn how to identify thoughts that may increase your IBS symptoms and will practice how to change these thoughts to ones that make them feel more comfortable. The sessions will focus on reactions to daily life that in turn result in IBS Symptoms.
1772590|NCT00368771|Behavioral|IBS Educational Training|Those assigned to this group will be given educational materials about IBS and will discuss the reading material with the therapist. The reading topics include information on gut disorders, anatomy and physiology of the gut, assessment procedures, and how to manage IBS symptoms. Sessions will also consist of weekly reviews of daily records and IBS symptoms. The goal of this intervention is to provide educational training about IBS.
1772591|NCT00368797|Drug|XRP0038 (NV1FGF)|
1772592|NCT00368823|Device|Electronic point-of-care delivery system|
1772594|NCT00368849|Drug|atomoxetine|This study utilizes a crossover design. Accordingly, half of the participants receive 40 milligram twice a day atomoxetine at arm one while the remaining half receive this intervention at arm two.
1772595|NCT00368849|Drug|Matching Placebo|This study utilizes a crossover design. Accordingly, half of the participants receive twice a day matching placebo at arm one while the remaining half receive this intervention at arm two.
1772596|NCT00368862|Drug|Ebixa (memantine hydrochloride)|
1772597|NCT00368862|Drug|Cipralex (escitalopram)|
1772598|NCT00368875|Drug|vorinostat|Given orally
1772599|NCT00368875|Drug|paclitaxel|Given IV
1772600|NCT00368875|Biological|bevacizumab|Given IV
1772601|NCT00368888|Device|Urine collection bag for infants|
1772602|NCT00368901|Drug|Darbepoetin alfa|Aranesp administered every other week SC titrated to not exceed Hb 12 g/dL
1772603|NCT00368914|Drug|sirolimus|
1772604|NCT00368914|Other|laboratory biomarker analysis|
1772605|NCT00368914|Other|pharmacological study|
1772606|NCT00368914|Procedure|biopsy|
1772607|NCT00368927|Drug|sulindac|Given orally
1772608|NCT00368927|Other|placebo|Given orally
1772609|NCT00368940|Behavioral|PATH|PATH utilizes a problem solving approach based on Problem Solving Therapy (PST) and identifies problems that interfere with everyday functions and that contribute to depression and disability. The treatment then provides compensatory strategies and environmental adaptations that are designed to bypass the person's cognitive limitations and to improve adaptive functioning in the home environment. PATH also incorporates caregiver involvement to help patient reduce depression and improve functioning.
1772610|NCT00368940|Behavioral|ST-CI|Supportive therapy focuses on the use of nonspecific or common factors of therapy, including facilitation of affect, helping the person feel understood, empathy, the treatment ritual, success experiences, and therapeutic optimism. In working with the participant, the therapist creates a supportive relationship and encourages the participant to consider his/her strengths and abilities rather than focusing on negative aspects of his/her character.
1772611|NCT00368953|Device|Yukon Choice stent system|coronary stent implantation
1772612|NCT00368953|Device|Taxus Liberté stent system|coronary stent implantation
1772613|NCT00368966|Biological|13-valent Pneumococcal Conjugate Vaccine|
1772614|NCT00368966|Biological|7-valent Pneumococcal Conjugate Vaccine|
1772615|NCT00368979|Drug|Dutasteride|once daily
1772616|NCT00368979|Drug|Placebo|once daily
1772617|NCT00368992|Biological|cetuximab|Given IV
1772618|NCT00368992|Drug|paclitaxel|Given IV
1772619|NCT00368992|Biological|bevacizumab|Given IV
1772620|NCT00369005|Procedure|Red blood cell transfusion guidelines|
1772621|NCT00369018|Drug|methyl aminolevulinate (MAL) and hexaminolevulinate (HAL)|MAL 1.2M, HAL 10mM and HAL 40mM solutions for 3 and 12 hours application
1772622|NCT00369031|Biological|Human Immunodeficiency Virus glycoprotein 140 (vaccine)|Human Immunodeficiency Virus glycoprotein 140 (vaccine) alone nasally
1772623|NCT00369031|Biological|HIV glycoprotein 140 + Labile Toxin mutant LTK63 adjuvant|Human Immunodeficiency Virus glycoprotein 140 (vaccine) + Labile Toxin mutant LTK63 adjuvant nasally
1772624|NCT00369031|Biological|Labile Toxin mutant LTK63 adjuvant|Labile Toxin mutant LTK63 adjuvant alone
1772625|NCT00369044|Drug|prednisone|
1772626|NCT00369070|Biological|Bevacizumab|15 mg/kg bevacizumab, delivered via intravenous (IV) infusion once every 3 weeks
1772627|NCT00369070|Drug|AMG 706|subjects in Arms A and B will take AMG 706 orally in one of two dosing regimens over each 21-day cycle: •Arm A: 125 mg once daily (QD) •Arm B: 75 mg twice daily every 12 ± approximately 1 hour for 5 days followed by a 2 day treatment free period every 7 days
1772865|NCT00385177|Drug|SN2310 Injectable Emulsion|Escalating doses given IV every three weeks
1772628|NCT00369070|Drug|Paclitaxel|All subjects will receive a paclitaxel chemotherapy regimen (paclitaxel 200 mg/m2) on day 1 of each 3-week cycle for a maximum of 6 cycles.
1772629|NCT00369070|Drug|Carboplatin|All subjects will receive carboplatin chemotherapy regimen (carboplatin at AUC of 6 mg/mL x min) on day 1 of each 3-week cycle for a maximum of 6 cycles.
1772630|NCT00369083|Procedure|Hospital at home treatment|
1772631|NCT00369096|Drug|bemiparin 3500 IU/day|
1772632|NCT00369109|Other|biologic sample preservation procedure|
1772633|NCT00369109|Other|immunohistochemistry staining method|
1772634|NCT00369109|Other|laboratory biomarker analysis|
1772635|NCT00369109|Procedure|biopsy|
1772636|NCT00369122|Radiation|external beam radiation therapy|Undergo EBRT
1772637|NCT00369122|Radiation|brachytherapy|Undergo brachytherapy
1772638|NCT00369122|Biological|bevacizumab|Given IV
1772639|NCT00369122|Drug|cisplatin|Given IV
1772640|NCT00369135|Procedure|combined intervention|
1772641|NCT00369148|Drug|nateglinide(drug) mitiglinide(drug)|
1772642|NCT00369161|Drug|Everolimus (RAD001)|
1772643|NCT00369161|Drug|Tacrolimus|
1772644|NCT00369161|Drug|Basiliximab|
1772645|NCT00369161|Drug|Corticosteroids|
1772646|NCT00369174|Drug|rosiglitazone maleate|Given orally
1772647|NCT00369174|Other|laboratory biomarker analysis|Correlative studies
1772648|NCT00369187|Drug|large protein molecule|
1772649|NCT00369200|Drug|AFP464|Given IV
1772650|NCT00369200|Other|laboratory biomarker analysis|Correlative study
1772651|NCT00369200|Other|pharmacological study|Correlative study
1772652|NCT00369213|Device|Additional spermicidal lubricant to condoms|
1772653|NCT00369226|Drug|Bortezomib (Velcade)|Infusion for a total of 3 doses
1772654|NCT00369226|Drug|Tacrolimus|Taken until Doctor determines it is not necessary any more
1772655|NCT00369226|Drug|Methotrexate|Infusion for a total of 4 doses
1772656|NCT00369226|Procedure|blood stem cell transplantation|Allogeneic Non-myeloablative peripheral blood stem cell transplantation
1772657|NCT00369239|Drug|risperidone long acting injectable|
1772658|NCT00369252|Drug|Nimotuzumab (TheraCIM h-R3)|
1772659|NCT00369265|Drug|Lansoprazole|Lansoprazole 30mg twice daily
1772660|NCT00369265|Dietary Supplement|Sugar pill|placebo twice daily
1772661|NCT00369278|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Tablets for oral administration
1772662|NCT00369291|Biological|keyhole limpet hemocyanin|KLH is a foreign protein to humans, it will be used to assess the immune response to a neo-antigen given as a single injection, 1 mg subcutaneously in the arm (per MT1999-06).
1772663|NCT00369291|Biological|tetanus toxoid|Tetanus toxoid booster 0.5 ml intramuscularly (IM) in the opposite arm (per MT1999-06)
1772664|NCT00374699|Drug|Velcade|
1772665|NCT00374725|Behavioral|Administration of probiotic (L. rhamnosus and L. acidophilus)|
1772666|NCT00374738|Behavioral|Guided Imagery for Trauma (GIFT)|Guided Imagery for Trauma (GIFT) - music and voice narration over a 12-week intervention. The control intervention included a relaxing music audio (the same music used in the guided imagery audio but without the narrative voiceover), PDA to log audio use, orientation and weekly phone consults, but did not have access to the patient advocate or to the guided imagery instructions provided on the GIFT audio.
1772667|NCT00374751|Drug|Samarium (153SM)|The Samarium is introduced into the vertebral cavity using a 2-way valve by the radiation oncologist. The cement is then introduced via the same 2-way valve into the vertebral cavity by the neurosurgeon.
1772668|NCT00374764|Drug|Risperidone|
1772669|NCT00374764|Behavioral|ABA|
1772670|NCT00374777|Drug|zolpidem MR|oral
1772671|NCT00374777|Drug|nitrazepam|oral
1772672|NCT00374777|Drug|placebo|oral
1772673|NCT00374790|Drug|Ferrous sulfate|
1772674|NCT00374803|Drug|Mycophenolic Acid (Myfortic)|"Group 1: Mycophenolic Acid (Myfortic) 1080 mg twice daily (2160 mg/day) for two weeks, followed by 720 mg twice daily (1440 mg/day) thereafter
Group 2: Mycophenolic Acid (Myfortic) 720 mg twice daily (1440 mg/day)."
1772675|NCT00374829|Behavioral|An IT-based patient follow-up and reminder system|
1772676|NCT00374842|Biological|Fluarix™|GlaxoSmithKline Biologicals' licensed influenza vaccine
1772677|NCT00374842|Biological|GSK1247446A|Low-dose GlaxoSmithKline Biologicals' GSK1247446A influenza vaccine
1772678|NCT00374855|Drug|PPAR alpha|
1772679|NCT00374855|Drug|Hydrochlorothiazide|
1772680|NCT00374855|Drug|Placebo|
1772681|NCT00374868|Drug|pemetrexed|"Phase 1: 300 mg/m^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles (dose escalation: 300 mg/m^2, 400 mg/m^2, and 500 mg/m^2)
Phase 2: phase 1 determined dose, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
1772682|NCT00374868|Drug|cisplatin|"Phase 1: 50 mg/m^2, intravenous (IV), days 1 and 15 every 28 days x 2 cycles
Phase 2: 50 mg/m^2, intravenous (IV), days 1 and 15 every 28 days until disease progression, unacceptable toxicity or patient decision to discontinue or 6 cycles of therapy"
1772683|NCT00374881|Drug|Morphine|Morphine
1772684|NCT00374881|Drug|Morphine|Morphine low dose
1772685|NCT00374881|Drug|Sorbitol+Phenylephrine|Sorbitol+Phenylephrine
1772686|NCT00374881|Drug|Sorbitol+Phenylephrine+Morphine|Sorbitol+Phenylephrine+Morphine
1772687|NCT00374881|Drug|Sorbitol low concentration+Phenylephrine+Morphine|Sorbitol low concentration+Phenylephrine+Morphine
1772688|NCT00374894|Drug|2,3-dimercaptosuccinic acid|
1772693|NCT00374920|Drug|MEM 1003|
1772866|NCT00385190|Drug|HCV-796|
1772867|NCT00385203|Drug|AZD2171|45 mg oral tablet once daily dose
1772868|NCT00385216|Drug|Nicotine|Nicotine nasal spray 3mg x 1 before surgery
1772694|NCT00374933|Drug|Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
1772695|NCT00374933|Drug|"Prophylactic delayed ADLI"|"Prophylactic ADLI after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
1772696|NCT00374933|Drug|"Prophylactic delayed activated donor lymphocyte infusion"|"Prophylactic delayed activated donor lymphocyte infusion (ADLI) after non-myeloablative conditioning and allogeneic peripheral blood cell stem cell transplantation"
1772697|NCT00374946|Device|THA|
1772698|NCT00374959|Drug|ceftriaxone|
1772699|NCT00374959|Device|Endotracheal tube for aspiration of subglottic secretions.|
1772700|NCT00374985|Drug|Docetaxel, Oxaliplatin|weekly doses
1772701|NCT00374985|Procedure|Radiotherapy|regular fractions
1772702|NCT00374998|Biological|FP9-PP (FP9 polyprotein)|
1772703|NCT00374998|Biological|MVA-PP (Modified Virus Ankara polyprotein)|
1772704|NCT00375024|Procedure|Patient Navigation|Inclusion of Patient Navigator in treatment plan.
1772705|NCT00375024|Procedure|Clinic Staff|Specific Patient Navigator will not be included in treatment plan. Existing clinical staff will work with the patients.
1772706|NCT00375037|Behavioral|feedback|
1772707|NCT00375037|Behavioral|Education|
1772708|NCT00375037|Other|usual care|
1772709|NCT00375050|Drug|Riluzole|
1772710|NCT00375050|Drug|Placebo|placebo
1772711|NCT00375063|Procedure|Percutaneous Coronary Intervention|
1772712|NCT00375063|Procedure|Coronary Artery Bypass Grafting|
1772713|NCT00375076|Drug|enoxaparin|
1772714|NCT00375089|Other|Group 1|Individuals with Prader-Willi syndrome. Monitoring every 6 months.
1772715|NCT00375089|Other|Group 2|Individuals with Early-onset Morbid Obesity.
1772716|NCT00375102|Procedure|Acupuncture|
1772717|NCT00375102|Behavioral|Relaxation Response|
1772718|NCT00380484|Drug|Budesonide|200µg daily
1772719|NCT00380484|Drug|Montelukast|5 mg daily
1772720|NCT00380497|Drug|PEG-Lyte®|
1772721|NCT00380497|Drug|Pico-Salax®|
1772722|NCT00380523|Drug|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
1772723|NCT00380536|Behavioral|Peer-Led Health Education Class|Participants will participate in group sessions once a week for 6 weeks. Sessions will focus on medical self-management, healthy behaviors, and effective use of the general medical system.
1772724|NCT00380549|Device|Blood ion levels|Blood ion levels
1772725|NCT00380562|Behavioral|Experience Corps|High intensity volunteering (15 hours a week or more) over a two year time period working with children in grades K-3 in Baltimore City Schools. Controls are assigned to usual activities for two years and then offered opportunity to volunteer with children at the end of two year.
1772726|NCT00380575|Drug|YM087|
1772727|NCT00380588|Drug|gemcitabine|1000 milligrams per square meter (mg/m2), intravenous (IV)
1772728|NCT00380588|Drug|cisplatin|25 milligrams per square meter (mg/m2), intravenous (IV)
1772729|NCT00380601|Drug|MRA(Tocilizumab)|8mg/kg/4 weeks
1772730|NCT00380614|Drug|Lamivudine|
1772731|NCT00380627|Drug|MK0663, Arcoxia, etoricoxib / Duration of Treatment: 3 Days|
1772732|NCT00380640|Drug|Trimethoprim|This group will receive the active intervention (trimethoprim) first, followed by the placebo.
1772733|NCT00380640|Drug|Trimethoprim|This group will start the study with placebo, followed by the active intervention (trimethoprim).
1772734|NCT00380653|Drug|sapacitabine|
1772735|NCT00380666|Procedure|PET/CT scan|
1772736|NCT00380679|Biological|Influenza vaccination|
1772737|NCT00380679|Biological|Pneumococcal polysaccharide vaccination|
1772738|NCT00380692|Drug|Atomoxetine|
1772739|NCT00380692|Drug|Placebo|
1772740|NCT00380705|Drug|MK0476, Singulair, montelukast sodium / Duration of Treatment: 8 Weeks|
1772741|NCT00380718|Drug|pemetrexed|"500 milligrams per square meter (mg/m2), intravenous (IV) in the first cycle. Acceptable toxicity* in cycle 1 determines dose increase to 1000 mg/m2 or dose decrease to 375 mg/m2 with unacceptable toxicity every 3 week in subsequent cycles till progression of disease.
*Toxicity acceptable if none of the following toxicities recorded at any time during Cycle 1: Platelets <50 x 10^9/L; absolute neutrophil count <1.0 x 10^9/L; Stomatitis/pharyngitis/esophagitis/diarrhea Grade >2; Skin Grade >2; Serum bilirubin >3.0 x upper limit of normal (ULN); alanine aminotransferase/aspartate aminotransferase >10 x ULN; Other non-hematologic toxicities Grade >2 (except nausea, vomiting)."
1772742|NCT00380731|Behavioral|Individual Cognitive Behavioral Therapy|CBT includes 16 weekly 60-minute individual CBT sessions for social anxiety disorder.
1772745|NCT00380757|Procedure|bystander CPR using 30:2 ratio vs 15:2 ratio|Participants will use 2 CPR techniques with different chest compression to ventilation ratios
1772746|NCT00380770|Drug|Generic HAART Triomune : d4T, 3TC, NVP|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks)
1772747|NCT00380770|Drug|Generic HAART Triomune : d4T, 3TC, NVP and chemotherapy ABV|Triomune® (Cipla, Mumbai) Stavudine 40mg b.d > 60 kg , 30mg bd <60kg Lamivudine 150mg b.d > 50 kg 2mg/kg < 50 kg Nevirapine 200mg b.d ( 200mg daily for first 2 weeks) Intramuscular Bleomycin 10 U/m2 ; Intravenous Vincristine 1.4mg/m2 maximum 2mg and Intravenous Doxorubicin 20mg/m2.
1772748|NCT00380783|Drug|AGN 203818|
1772749|NCT00380796|Drug|Collection of safety data for Cohort 1|Twice-yearly collection of information about cancer incidence and cause of death among patients who participated in clinical trials of infliximab in the treatment of COPD. The follow-up period is 5 years.
1772750|NCT00380809|Procedure|Rotational Atherectomy + PES|
1772751|NCT00380809|Procedure|Standard Treatment (PES without Rotational Atherectomy)|
1772752|NCT00384228|Drug|Nilotinib|
1772753|NCT00384241|Behavioral|Induced Stress|Participation in an active coping task by playing a video game against another participant.
1772754|NCT00384241|Procedure|Buccal Swab|One Buccal swab collected from each parent
1772755|NCT00384254|Behavioral|5 A|Dental providers are trained to provide Ask, Advise, Assess, Assist and Arrange to all tobacco using patients. Written materials are provided, including information on local cessation resources, pharmacotherapy and tobacco quitlines.
1772756|NCT00384254|Behavioral|3 A|Providers are trained to provide Ask, Advise and Arrange intervention to all tobacco using patients. Written materials, prescription for NRT and a Fax-to-Quit referral are provided.
1772757|NCT00384280|Drug|Rifampin|
1772758|NCT00384293|Drug|Comparator: niacin (+) laropiprant (MK0524A)|niacin (+) laropiprant (2 g) po qd.
1772759|NCT00384293|Drug|Comparator: placebo|niacin (+) laropiprant (2 g) placebo po qd.
1772760|NCT00384306|Drug|prednisolone|
1772761|NCT00384319|Device|ThermoSuit(R) System|The ThermoSuit device is used to cool patients using direct contact of the skin with cold water.
1772762|NCT00384332|Drug|orally-disintegrating olanzapine|5 to 20 mg (daily) orally disintegrating olanzapine for approx.8 weeks.
1772763|NCT00384332|Drug|regular olanzapine|5-20 mg. olanzapine daily for approximately 8 weeks.
1772764|NCT00384345|Device|Bright Light Therapy|
1772765|NCT00384345|Behavioral|Exercise|
1772766|NCT00384358|Drug|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
1772767|NCT00384358|Drug|rhBMP-2/CPM|one time injection of 3-5 mL test article at time of internal fracture fixation
1772768|NCT00384358|Other|surgical intervention alone|surgical internal fixation of fracture defines the standard of care group
1772769|NCT00384371|Drug|Botulinum Toxin A|Botulinum Toxin A
1772770|NCT00384371|Drug|Placebo|Placebo
1772771|NCT00384384|Drug|oral 18B Glycyrrhetinic acid versus placebo|
1772772|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular
1772773|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1772774|NCT00384397|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1772775|NCT00384410|Drug|Nabilone|
1772776|NCT00384423|Drug|PRX-03140|
1772777|NCT00384436|Drug|escitalopram|
1772778|NCT00384449|Drug|Ranibizumab|Consented, enrolled subjects will receive open-label intravitreal injections of 0.5 mg ranibizumab administered once a month for 3 months
1772779|NCT00384475|Drug|Ciclesonide Nasal Spray|
1772780|NCT00384488|Behavioral|Interactive Voice Response System (IVR)|
1772781|NCT00384501|Device|Intacs|
1772782|NCT00384514|Device|VesCell (TM)-Autologous EPCs/Angiogenic Cell Precursors|
1772783|NCT00384527|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet twice daily plus one vancomycin-placebo capsule four times daily for 10 days.
1772784|NCT00384527|Drug|Vancomycin|One vancomycin 125 mg capsule four times daily plus one nitazoxanide-placebo twice daily for 10 days.
1772785|NCT00384540|Procedure|Dobutamine stress echocardiography, coronarography, brachial arterial echography|DSE: cumulative doses of dobutamine (max = 40 µg/kg/min) and atropine (max = 1.5 mg), to reach a maximal heart rate under clinical, electrocardiographic and echocardiographic surveillancesCoronarography: invasive injection into coronary arteries of a radiological product showing a contrast visible on an x-ray. FMD: Flow-mediated dilatation of the brachial artery induced by 5-min forearm arterial occlusion
1772786|NCT00384553|Drug|Rituximab|
1772787|NCT00384553|Drug|DHAP|
1772788|NCT00384553|Drug|TEC|
1772789|NCT00384553|Drug|autologous stem cell transplantation|
1772790|NCT00384566|Drug|Carvedilol|anit hypertensive medication
1772791|NCT00384566|Drug|Metoprolol|Anti hypertensive medication
1772792|NCT00384579|Drug|Botulinum toxin B|Botulinum Toxin B
1772793|NCT00384579|Drug|Placebo|Placebo
1772794|NCT00384592|Drug|Esomeprazole|
1772795|NCT00384592|Procedure|Physical exam|
1772796|NCT00384592|Procedure|Pregnancy test if applicable|
1772797|NCT00384605|Drug|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
1772798|NCT00384605|Drug|placebo|Placebo capsule once daily. Treatment for 52 weeks.
1772799|NCT00384618|Drug|pravastatin|
1772800|NCT00384618|Drug|vitamin E|
1772801|NCT00384631|Other|subconjunctival normal saline|0.1cc normal saline injection in the subconjunctival space repeated twice at monthly intervals
1772802|NCT00384631|Drug|Avastin|intravitreal injection of avastin 2.5mg repeated twice at monthly intervals
1772804|NCT00384657|Drug|iron sucrose|"Patients in Group I will receive iv iron sucrose, as described in the study protocol.
Patient in Group II will receive conventional treatment for chronic heart failure."
1772805|NCT00384670|Biological|Dengue Vaccine Formulation 17|Tetravalent live attenuated DEN vaccine candidate. Containing dengue serotypes 1,2, and 3 vaccines produced at the Salk Institute and dengue serotype 4 produced at the WRAIR Pilot Bioproduction Facility. Dosage 1 mL administered via injection at Day 0 and Day 60.
1772806|NCT00384670|Biological|Licensed Japanese Encephalitis (JE) Vaccine|Produced by the Thailand GPO using a Beijing strain of JE in liquid form; dosed at 0.5 mL ot 7 and 7.5 months.
1772807|NCT00384696|Drug|Nicotine Replacement Therapy|4 Weeks of nicotine patch. Patch therapy for participants who smoke >10 cigarettes/day consists of 2 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches.
1772808|NCT00384696|Behavioral|Questionnaire|Survey taking 1 and 1/2 hours at each study visit.
1772809|NCT00384722|Device|EASYTRAK 3 Downsize Lead|EASYTRAK 3 Downsize Lead
1772810|NCT00384748|Behavioral|TR intervention|The 3 tele-visits will occur within 5 weeks post randomization. Telephone call visits will occur during weeks 2, 4, 6, 8 and 12. One additional tele-visit may be scheduled as needed. The first visit is devoted to mobility assessment, goal-setting. The second visit is to review the current exercise component. Visit 3 focuses on functional mobility using adaptive strategy component.
1772869|NCT00385216|Other|Placebo|Placebo nasal spray 0mg x 1 before surgery
1772870|NCT00385229|Drug|induction of labor|Misoprostol, Dinoprostone, amniotomy, Oxytocin
1772811|NCT00384748|Behavioral|In-home messaging device.|The purpose of this aspect of the intervention is to screen for unforeseen problems and to reinforce adherence to the recommended treatment. It will be used to interface with patients daily, but briefly. The in-home messaging device, which resembles a caller ID box is attached to the home telephone line and electrical outlet. Installation of the equipment involves connecting it to the phone line and plugging it into an electrical outlet. The teletherapist receives the clinical data from the in-home messaging device via the internet on a daily basis. It is used to screen for depression, lower extremity strength, self-care tasks and mobility, falls and exercise adherence.
1772812|NCT00384748|Behavioral|Usual care|Routine VA care.
1772813|NCT00384774|Drug|COL-144|
1772814|NCT00384787|Biological|VRC-HIVDNA009-00-VP|HIV DNA vaccine containing the HIV genes gag, pol, nef, and env A,B, and C. The HIV DNA vaccine will be given in three doses intramuscularly at study entry and Months 1 and 2
1772815|NCT00384787|Biological|VRC-HIVADV014-00-VP|Adenoviral vector HIV booster vaccine containing the HIV genes gag, pol, and env. The adenoviral vector HIV booster vaccine will be administered intramuscularly (Group 1), intradermally (Group 2), or subcutaneously (Group 3) at Month 6
1772816|NCT00384800|Drug|Thalidomide(THADO), Tegafur/Uracil(UFUR)|
1772817|NCT00384813|Behavioral|Project ASPIRE Home-Based Family Intervention|Home-based psychoeducational family intervention jointly conducted by psychology postdoctoral fellow and respiratory therapist over 4 months
1772818|NCT00384813|Behavioral|Project ASPIRE Enhanced Treatment As Usual|Psychoeducational family intervention addressing the written asthma action plan during a single home visit, conducted by a respiratory therapist
1772819|NCT00384826|Drug|erlotinib|Erlotinib 150 mg/day (until progression)
1772820|NCT00384826|Drug|paclitaxel + carboplatine|Paclitaxel 90 mg/m² D1, D8, D15 (D1=D28, until progression) Carboplatine AUC 6 D1 (D1=D28, 6 cycles)
1772822|NCT00384852|Drug|rhBMP-2/CPM|
1772823|NCT00384865|Drug|Simvastatin|Simvastatin 40 mg, taken orally, once a day for 6 months
1772824|NCT00384865|Drug|Aspirin|Aspirin 81 mg, taken orally, once a day for 6 months
1772825|NCT00384865|Drug|Placebo|Placebo, taken orally, once a day for 6 months
1772826|NCT00384878|Drug|Cetuximab, Cisplatin,5-Fluorouracil,Leucovorin|
1772827|NCT00384891|Device|Synergo + MMC|Combined bladder wall hyperthermia and intravesical instillation with cooled Mitomycin-C
1772828|NCT00384891|Drug|Bacillus Calmette-Guérin|Intravesical instillation with BCG (Bacillus Calmette-Guérin)
1772829|NCT00384904|Drug|Atazanavir/Ritonavir|Capsules/capsules, Oral, 300/100 mg, Once daily, 10 days.
1772830|NCT00384904|Drug|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 40 mg, Once daily + Twice daily, 7 days.
1772831|NCT00384904|Drug|Atazanavir/Ritonavir + Famotidine|Capsules/capsules + Tablets, Oral, 300/100 mg + 20 mg, Once daily + Twice daily, 7 days.
1772832|NCT00384904|Drug|Atazanavir/Ritonavir|Capsules/capsules + Tablets, Oral, 300/100 mg, Once daily, 10 days.
1772833|NCT00384904|Drug|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 40 mg, Once daily + Twice daily, 7 days.
1772834|NCT00384904|Drug|Atazanavir/Ritonavir + Tenofovir Disproxil Fumrarate + Famotidine|Capsules/capsules + Tablets + Tablets, Oral, 300/100 mg + 300 mg + 20 mg, Once daily + Twice daily, 7 days.
1772835|NCT00384917|Drug|Ketoconazole|
1772836|NCT00384930|Drug|tadalafil|2.5 mg tadalafil tablet by mouth once a day for twelve weeks.
1772837|NCT00384930|Drug|tadalafil|5 mg tadalafil tablet by mouth once a day for twelve weeks.
1772838|NCT00384930|Drug|tadalafil|10 mg tadalafil tablet by mouth once a day for twelve weeks.
1772839|NCT00384930|Drug|tadalafil|20 mg tadalafil tablet by mouth once a day for twelve weeks.
1772840|NCT00384930|Drug|placebo|Placebo tablet taken by mouth one a day for twelve weeks
1772841|NCT00384943|Behavioral|Moderate-intensity Exercise|
1772842|NCT00384956|Drug|Azacitidine|
1772843|NCT00384969|Drug|RAD001 and Sorafenib|RAD001 2.5mg to 10.0mg PO QD Sorafenib 400mg PO BID
1772844|NCT00384982|Procedure|Bone marrow-derived stem cells implantation|percutaneous BM-derived cell therapy
1772845|NCT00384995|Drug|0.9% (154 mEq/L) IV Sodium Chloride|Saline solution
1772846|NCT00384995|Drug|1/6 M (166 mEq/L) IV Sodium Bicarbonate|Bicarbonate solution
1772849|NCT00385021|Drug|5-Fluorouracil, leucovorin, oxaliplatin, avastin|
1772850|NCT00385034|Device|Interactive computer based health-risk survey before doctor's visit|
1772851|NCT00385047|Biological|Group A FMP2.1/AS01B|
1772852|NCT00385047|Biological|Group B FMP2.1/AS02A|
1772853|NCT00385086|Drug|TNF blocker|Treatment with TNF-alpha blocker
1772854|NCT00385086|Drug|Placebo|Treatment with placebo
1772856|NCT00385112|Procedure|Echocardiogram|2D echocardiogram with Doppler flow
1772857|NCT00385125|Drug|Bendamustine|
1772858|NCT00385125|Drug|Rituximab|
1772859|NCT00385138|Drug|Cangrelor|cangrelor bolus (30 mcg/kg) & cangrelor infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
1772860|NCT00385138|Drug|clopidogrel|clopidogrel capsules (600 mg) at end of PCI
1772861|NCT00385138|Drug|Placebo bolus & placebo infusion|placebo bolus (30 mcg/kg) & placebo infusion (4 mcg/kg/min) administered from randomization for at least 2 hours, or until the end of the PCI, whichever is longer with the option to extend up to 4 hours maximum (per investigator discretion)
1772862|NCT00385138|Drug|Placebo capsules - end of PCI|Placebo capsules given at the end of PCI to mimic 600mg clopidogrel dosing
1772863|NCT00385138|Drug|Placebo capsules - end of infusion|Placebo capsules given at the end of infusion to mimic 600mg clopidogrel dosing
1772864|NCT00385164|Procedure|PET/CT scan for RT planning|
1772935|NCT00385775|Drug|AEG35156|weekly IV solution infused over 2 hrs
1772871|NCT00385242|Procedure|Positron emission tomography: FDG viability imaging|FDG PET viability imaging
1772872|NCT00385242|Other|PET imaging|PET viability imaging
1772874|NCT00385268|Drug|acamprosate|1998 mg/dau fpr 8 weeks
1772875|NCT00385268|Drug|placebo|placebo pills
1772876|NCT00385268|Behavioral|Cognitive Behavioral Therapy|Weekly individual psychosocial treatment sessions.
1772877|NCT00385281|Biological|FluMist|
1772878|NCT00385307|Drug|amibegron (SR58611A)|
1772879|NCT00385320|Biological|HRV vaccine|
1772880|NCT00385333|Procedure|Feasibility Study - Imaging System|
1772881|NCT00385346|Behavioral|Expressive writing|Patients in the intervention group write on three day for 20 minutes about highly emotional topics In the control group patients write on three days for 20 minutes about topics with relatively low emotional involvement such as diet, time management and sport.
1772882|NCT00385359|Procedure|aerosol drug deposition strategies|
1772883|NCT00385359|Drug|Albuterol|
1772884|NCT00385372|Procedure|elimination diet|
1772885|NCT00385372|Procedure|provocation diet|
1772886|NCT00385385|Drug|Rifalazil|
1772887|NCT00385398|Drug|erlotinib hydrochloride|Erlotinib will be administered orally on at a dose of 200 mg/day on Days 1-23 of each 28 day cycle.
1772888|NCT00385398|Drug|temozolomide|Temozolomide will be administered orally at a dose of 150 mg/m2 on Days 1-5 for Cycle 1 then increased to 200 mg/m2 for Cycle 2 forward.
1772889|NCT00385398|Radiation|stereotactic radiosurgery|Stereotactic radiosurgery will be performed prior to chemotherapy.
1772890|NCT00385411|Drug|valproate microgranules|20 to 30 mg/kg/day
1772891|NCT00385437|Behavioral|Driving Simulator Testing|
1772892|NCT00385437|Drug|Mirtazapine Treatment|
1772893|NCT00385450|Drug|Nelfinavir/placebo|1250mg/twice each day/four days.
1772894|NCT00385463|Drug|Adding Advair Diskus 100/50mcg (FSC) BID and Singulair 10mg is added to placebo Diskus BID|
1772895|NCT00385476|Behavioral|PMKT Questionnaire|Patient Medication Knowledge Tool - Questionnaire entailing the medications the patient is currently taking.
1772896|NCT00385489|Drug|LXR-623|
1772897|NCT00385502|Drug|EcoNail™ (econazole 5%/SEPA® 18% nail lacquer)|nail lacquer applied daily for 48 weeks
1772898|NCT00385515|Drug|SNX-1012 (meclocycline sulfosalicylate)|tablets to be dissolved in water for oral swish and expectorate; 30 mg, 4 times daily for 10 days
1772899|NCT00385515|Drug|placebo|Tablets to be dissolved in water for oral swish and expectorate; placebo, 4 times daily for 10 days
1772900|NCT00385528|Behavioral|Multi-faceted psychiatric intervention|
1772901|NCT00385541|Drug|Morphine PCA|Morphine 1mg/mL, dose 1mL, lockout 6 minutes, max 10mL
1772902|NCT00385541|Drug|Hydromorphone PCA|hydromorphone PCA 0.2mg/lml, dose 1ml, lockout 6min, max 10ml
1772903|NCT00385554|Drug|UC-781 carbomer gel, 0.1% and 0.25%|
1772904|NCT00385567|Drug|PEHRG214|
1772905|NCT00385580|Drug|dasatinib|Tablets, Oral, 100 mg or 70 mg, twice daily, treatment may continue until disease progression
1772906|NCT00385580|Drug|dasatinib|Tablets, Oral, 100 mg, once daily (QD) treatment may continue until disease progression
1772907|NCT00385593|Drug|Symbicort (budesonide/formoterol) Turbuhaler|
1772908|NCT00385593|Drug|Conventional treatment|
1772909|NCT00385606|Drug|gemcitabine|
1772910|NCT00385606|Drug|prolonged continuous infusion gemcitabine|
1772911|NCT00385606|Drug|cisplatin|
1772912|NCT00385606|Drug|rofecoxib|
1772913|NCT00385632|Drug|Antiretroviral Regimens|Various antiretroviral therapy combinations already being administered to participants
1772914|NCT00385645|Drug|Combivir+Kaletra|
1772915|NCT00385645|Drug|Combivir+Reyataz|
1772916|NCT00385658|Drug|Fluvastatin extended release, fenofibrate|
1772917|NCT00385658|Drug|Fixed combination simvastatin/ezetimibe|
1772918|NCT00385671|Drug|duloxetine hydrochloride|Duloxetine (DLX) once daily (QD), orally (PO)
1772919|NCT00385671|Drug|pregabalin|Pregabalin (PGB) orally (PO)
1772920|NCT00385671|Drug|gabapentin|Stable Gabapentin (GAB) (participants will remain on the same dose of gabapentin at which they entered the study)
1772921|NCT00385684|Drug|hydrocodone/APAP w placebo PRN|Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid three times daily (TID). With liquid placebo available PRN.
1772922|NCT00385684|Drug|hydrocodone/APAP|Participants judged as responders during Phase A continue the same dose of study medication (hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid TID). Otherwise, moved to a higher dose (hydrocodone/acetaminophen 5/500mg TID or the most appropriate formulary alternative). Participant can also receive up to 2 PRN administrations at the same dose levels as listed above, but not to exceed 2.5g of acetaminophen.
1772923|NCT00385684|Drug|placebo with hydrocodone/APAP PRN|Liquid placebo PRN. Also available PRN is Hydrocodone/acetaminophen 2.5/167 mg per 5 ml liquid.
1772924|NCT00385697|Drug|Teplizumab|IV dosing daily for 14 days times 2 courses
1772925|NCT00385697|Other|Placebo|IV dosing daily for 14 days times 2 courses
1772926|NCT00385710|Drug|valproic acid|Depakine
1772927|NCT00385710|Drug|Placebo|Placebo
1772928|NCT00385723|Dietary Supplement|Omega 3 (Fish Oil) Supplementation|1.25 g or 2.496 g daily for 4 months
1772929|NCT00385723|Dietary Supplement|Placebo|matching placebo capsule daily for 4 months
1772930|NCT00385736|Biological|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 80 mg at Week 0, 40 mg at Week 2, and 40 mg every other week starting at Week 4.
1772931|NCT00385736|Biological|adalimumab|Prefilled syringe, 40 mg (loading dose then every other week dosing). 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week starting at Week 4.
1772932|NCT00385736|Biological|placebo|Placebo for 40 mg syringe. Matching placebo for loading dose and every other week dosing. Subjects received placebo at Weeks 0, 2, 4, and 6, followed by 160 mg adalimumab at Week 8, 80 mg adalimumab at Week 10, and 40 mg adalimumab eow thereafter (prior to Amendment 3) or 40 mg adalimumab eow starting at Week 8 (after Amendment 3).
1772933|NCT00385749|Device|RV apical vs RV septal defibrillation threshold testing|
1772934|NCT00385762|Drug|paroxetine|paroxetine 10-40mg daily x 5 weeks
1956933|NCT02626455|Drug|Copanlisib (BAY 80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. For patients on R-B dosing of copanlisib will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered and then rituximab followed by bendamustine. For patients on R-CHOP dosing of copanlisib will be administered on Days 1 and 8 of each 21-day cycle. Copanlisib will be administered before rituximab followed by cyclophosphamide, doxorubicin and vincristine infusions. Prednisone/prednisolone tablets to be taken for 5 days.
1956934|NCT02626455|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered as per copanlisib described above. Applies to the phase III part of the study only.
1772944|NCT00385801|Drug|Risperidone|
1772945|NCT00385801|Drug|Placebo|
1772946|NCT00385827|Drug|Mitoxantrone|Mitoxantrone 12 mg/m^2 intravenously as a 30 minute infusion on Day 1 of each 3-week cycle until disease progression or unacceptable toxicity or up to 10 cycles (a maximum cumulative dose of approximately 120 mg/m^2)
1772947|NCT00385827|Drug|Siltuximab|Siltuximab 6 mg/kg intravenously as a 2 hour infusion every 2 weeks until disease progression or unacceptable toxicity or up to a maximum of 1 year
1772948|NCT00385827|Drug|Prednisone|Prednisone 5 mg orally twice daily
1772949|NCT00385840|Biological|Influenza Vaccine GSK1247446A|Single dose, intramuscular injection
1772950|NCT00385840|Biological|FluarixTM|Single dose, intramuscular injection
1772951|NCT00385853|Drug|PTK787/ZK 222584|Twice daily for each 28-day cycle
1772952|NCT00385853|Drug|Temozolomide|Daily for each 28-day cycle
1772953|NCT00385853|Procedure|Radiation Therapy|For 7 weeks beginning on day 5 of the first treatment cycle
1772954|NCT00385866|Behavioral|cancer screening and health education|The control group will receive cancer screening and health education materials on a quarterly basis but will not have access to patient navigation services.
1772955|NCT00385866|Behavioral|facilitation of Services to improve cancer screening|The intervention group will receive cancer education and faciliation of services in the form of patient navigation
1772956|NCT00385879|Behavioral|Case management|
1772957|NCT00385892|Device|Abdominal binder|
1772958|NCT00385905|Device|Excel Drug-eluting stent|
1772959|NCT00385918|Device|Lokomat Training|The Lokomat is a robotically assisted partial weight suspension treadmill training device that has the potential to restore leg function in persons with incomplete leg paralysis.
1772960|NCT00385918|Other|Home stretching then Lokomat training|Patients will be instructed by a physical therapist on how to perform a home stretching protocol 3 times per week for 3 months. The stretching will be monitored via telephone by the study coordinator. This will be an active control arm. After 3 months the patients will be crossed over to Lokomat training for an additional 3 months. This training will be the same as given to the individuals originally randomized to the Lokomat treatment intervention.
1772961|NCT00385931|Drug|Valsartan and simvastatin|
1772962|NCT00385944|Drug|Prasugrel|Prasugrel 10-mg tablet taken orally as a daily maintenance dose for a 14-day treatment period.
1772963|NCT00385944|Drug|Clopidogrel|Clopidogrel two 75-mg tablets taken orally as a daily maintenance dose for a 14-day treatment period.
1772964|NCT00385957|Drug|AZT+3TC+IDV+RTV|
1772965|NCT00385957|Drug|AZT+3TC+EFV|
1772966|NCT00385970|Drug|Tegafur-uracil (UFT)|From within 9 weeks after surgery, 300 mg/m2, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
1772967|NCT00385970|Drug|Calcium folinate (LV)|From within 9 weeks after surgery, 75 mg, PO from day 1 to day 28 of each 35 day cycle. Number of Cycles: 5
1772968|NCT00385970|Drug|Krestin (PSK)|From within 9 weeks after surgery to 12 months after surgery, 3 g/day, PO every day
1772969|NCT00385983|Device|Harmonic Scalpel|
1772970|NCT00385996|Drug|Tarceva (Erlotinib)|Patients will receive daily erlotinib at 150 mg/day for 3 weeks followed by surgical resection at week 4 then daily Tarceva® at 150 mg/day for 2 years for those patients who had a response rate of at least 50% tumor volume reduction and/or have EGFR-positive tumor tissue determined by IHC and/or FISH.
1772971|NCT00386009|Drug|Tadalafil|20 mg tadalafil tablet taken by mouth once a day for 12 weeks.
1772972|NCT00386009|Drug|Placebo|Placebo tablet taken by mouth once a day for 12 weeks.
1772973|NCT00386022|Drug|GnRH|GnRH doses of 25, 75, 250 and 750 ng/kg will be given IV every 4 hr at baseline and after transdermal estradiol
1772974|NCT00386022|Drug|NAL-GLU GnRH antagonist|A single subcutaneous injection of the NAL-GLU GnRH antagonist at a dose of 150 mcg/kg before and after transdermal estradiol
1772975|NCT00386022|Drug|Estrogen patch|transdermal estrogen patches 0.05mg/day, changing the patch every 86 hr in second part of sequential study
1772976|NCT00386035|Drug|Delayed ART|Participants follow a drug conservation (DC) regimen in which ART is stopped or deferred until CD4 cell count dropped below 250 cells/mm3, initiated until CD4 cell count is at least 350 cells/mm3, and then are followed by episodic ART based on CD4 cell count.
1772977|NCT00386035|Drug|Continuous ART|Group 2 participants follow a viral suppression (VS) regimen in which ART was continued to keep viral loads as low as possible, regardless of CD4 cell count.
1772978|NCT00386048|Behavioral|Brief Cognitive-Behavioral Pain Management Training|Participants complete a manualized, single session of training which includes: (A) education about the causes of sickle cell pain, (B) education about how the nervous system processes pain signals, and (C) explanations of how one can use cognitive and behavioral treatment (CBT) strategies to decrease the extent of pain experienced (all based on how the nervous system processes pain). Four specific CBT skills are taught and practiced by the participant (Progressive muscle relaxation, Controlled Deep Breathing, Imagery, and Distraction). The protocol explicitly emphasizes the use of CBT as a complimentary pain management tool to use in addition to the standard of care methods.
1772979|NCT00386061|Drug|rimonabant (SR141716)|
1772980|NCT00386074|Drug|NaFeEDTA, Electrolytic Iron|
1772981|NCT00386087|Drug|Enzastaurin Hydrochloride|
1773023|NCT00386399|Drug|Mitomycin C|Mitomycin C, finds use as a chemotherapeutic agent by virtue of its antitumour antibiotic activity.
1772982|NCT00386100|Drug|Avandamet 6 mg/1500 mg (ttd)|One 2 mg/ 500 mg capsule will be taken in the AM with the morning meal Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal
1772983|NCT00386100|Drug|Avandamet 4 mg/1000 mg (ttd)|One 2 mg/500 mg capsule will be taken in the AM with the morning meal. One 2 mg/500 mg capsule will be taken in the PM with the evening meal.
1772984|NCT00386100|Drug|Avandamet 2 mg/500 mg (ttd)|one placebo capsule will be taken in the AM with the morning meal one 2 mg/ 500 mg capsule will be taken in the PM with the evening meal.
1772985|NCT00386100|Drug|Avandamet 8 mg/ 2000 mg (ttd)|Two 2 mg/ 500 mg capsules will be taken in the AM with the morning meal. Two 2 mg/ 500 mg capsules will be taken in the PM with the evening meal.
1772986|NCT00386100|Drug|Metformin 500 mg (ttd)|One placebo capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
1772987|NCT00386100|Drug|Metformin 1000 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. One 500 mg capsule will be taken in the PM with the evening meal.
1772988|NCT00386100|Drug|Metformin 1500 mg (ttd)|One 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsules will be taken in the PM with the evening meal.
1772989|NCT00386100|Drug|Metformin 2000 mg (ttd)|Two 500 mg capsule will be taken in the AM with the morning meal. Two 500 mg capsule will be taken in the PM with the evening meal.
1772990|NCT00386113|Biological|Fluarix and adjuvanted influenza vaccine|
1772991|NCT00386126|Drug|Iron Sucrose IV 200mg, once a week, for 5 weeks|
1772992|NCT00386126|Drug|Ferrous sulfate 200mg PO TID, for 8 weeks|
1772993|NCT00386139|Drug|Aliskiren/HCTZ|
1772994|NCT00386152|Drug|epoetin alfa|80,000 Units and 120,000 Units of epoetin alfa (PROCRIT) injected subcutaneously once every 3 weeks for up to 13 weeks
1772995|NCT00386152|Drug|darbepoetin alfa|500 mcg of darbepoetin alfa (ARANESP) injected subcutaneously the skin once every 3 weeks for up to 13 weeks
1772996|NCT00386165|Drug|larazotide acetate|larazotide acetate 4 mg capsules
1772997|NCT00386178|Drug|Vitamin E supplement rich in gamma tocopherol|daily dose of Vitamin E supplement rich in gamma tocopherol
1772998|NCT00386191|Drug|clopidogrel (SR25990C)|oral administration
1772999|NCT00386204|Device|Q-switched Ruby Laser|
1773000|NCT00386217|Behavioral|Telephone Survey|Telephone interview, about 90 minutes, covering demographic information, medical information, health-related quality of life, emotional distress, and stress related to interrupted childbearing.
1773001|NCT00386230|Drug|ZDV Short (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Sinfant)
1773002|NCT00386230|Drug|ZDV Short (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 35 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Smother-Linfant)
1773003|NCT00386230|Drug|ZDV Long (mother)-Short (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Three days of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Sinfant)
1773004|NCT00386230|Drug|ZDV Long (mother)-Long (infant): Comparison of zidovudine durations|Maternal ZDV treatment (300 mg, twice daily) starting at 28 weeks Gestational Age (GA) until the onset of labor, ZDV 300 mg at the onset of labor and then 300 mg every 3 hours until delivery. Six weeks of infant ZDV treatment (2 mg/kg, every 6 hours) starting at birth (Lmother-Linfant)
1773005|NCT00386243|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy is delivered by phone by a nurse care-manager 6 times over a 12-week period. Sessions last approximately 45 minutes and occur at weeks 14, 16, 18, 20, 22, and 24 of the study.
1773006|NCT00386243|Behavioral|Pain self-management program|The pain self-management program is delivered by a nurse care-manager during a 12-week period. Sessions are each 45 minutes long and phone-based. They occur at baseline, week 1, week 3, week 6, week 9, and week 12.
1773007|NCT00386243|Drug|Co-Analgesic Therapy|"Amitriptyline, start at 10-25, titrate to 100 mg Nortriptyline, start at 10-25, titrate to 100 mg
Gabapentin, titrate up to 900-1200 tid venlafaxine, carbemazepine, duloxetine, and/or pregabalin
Cyclobenzaprine, titrate to 10 mg TID fluoxetine, sertraline, citalopram"
1773008|NCT00386243|Drug|Opioid Analgesics|Tramadol 50 mg BID or TID and titrate to 100 mg QID Acetaminophen/codeine (300mg/30mg). Take 1 or 2 tablets qid prn pain Acetaminophen/hydrocodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Acetaminophen/oxycodone (500mg/5mg). Take 1 or 2 tablets qid prn pain Morphine SR (30mg). Start at 30 mg twice a day (titrate up to 240mg/day if needed) Methadone (5-10mg). Start at 5mg bid; titrate 10mg tid (max 20mg tid)
1773009|NCT00386256|Device|Health Buddy, Home telehealth technology|Exercise questions, educational messages, and clinical reminders have been programmed into the home telehealth technology and are administered daily via the Health Buddy(R) to evaluate the program's feasibility based on adherence rates, program completion rates, and safety.
1773010|NCT00386256|Other|Telephone counseling|
1773011|NCT00386269|Drug|Codeine Phosphate Analgesia|
1773012|NCT00386282|Drug|mifepristone-misoprostol treatment|200 mg mifepristone followed by 800 mcg buccal misoprostol 24-48 hours after the mifepristone.
1773013|NCT00386308|Drug|Tranexamic acid tablets|3900 mg/Day
1773014|NCT00386308|Drug|Placebo tablets|
1773015|NCT00386321|Drug|Yttrium 90 -labeled ibritumomab tiuxetan (Zevalin)|
1773016|NCT00386334|Drug|Eszopiclone|2 mg tablet once per day in the evening
1773017|NCT00386334|Drug|Placebo|Tablet one per day in the evening.
1773018|NCT00386347|Drug|GSK364735 oral solution and oral tablets|
1773019|NCT00386360|Drug|Placebo comparator|oral weekly for one year
1773020|NCT00386360|Drug|risedronate|35 mg risedronate, once a week for one year
1773021|NCT00386373|Drug|Imatinib Mesylate|Starting dose of 100 mg daily by mouth for first 100 days following bone marrow transplant (BMT) or stem cell transplant (SCT).
1773024|NCT00386412|Drug|Valganciclovir|900 mg/ 12 h oral, 2 weeks 900 mg/ 24 h oral, 2 weeks
1773025|NCT00386425|Drug|Drotrecogin alfa (activated)|intravenous
1773026|NCT00386438|Procedure|Honan balloon application|
1773027|NCT00386451|Device|Catheter locking systems|
1773028|NCT00386464|Device|noninvasive positive pressure ventilation|
1773029|NCT00386477|Procedure|Vaginal cleansing before cesarean delivery|Cleansing vagina with 1% betadine scrub before cesarean.
1773030|NCT00386490|Drug|larazotide acetate|capsule for oral administration
1773031|NCT00386503|Drug|Artesunate + Amodiaquine|
1773032|NCT00386516|Drug|GM-CT-01|GM-CT-01 at 280 mg/m2 given IV for 4 consecutive days in 28 days cycle until disease progression
1773033|NCT00386516|Drug|5-Fluorouracil|5-FU given IV by infusion for 30, at 600 mg/m2 in combination with GM-CT-01 for 4 consecutive days in 28 days cycle until disease progression
1773034|NCT00386529|Drug|Aspirin enteric coated pellests 100mg|
1773035|NCT00386542|Biological|Vaxigrip® trivalent inactivated influenza vaccine|See full description elsewhere in this record.
1773036|NCT00386542|Device|Intradermal spacer on Biojector® 2000 jet injector|See elsewhere in this record for full description.
1773037|NCT00386555|Drug|docetaxel|
1773038|NCT00386555|Drug|CP-868,596 + docetaxel|
1773039|NCT00386555|Drug|AG-013736 + docetaxel|
1773040|NCT00386555|Drug|CP-868,596 + AG-013736 + docetaxel|
1773041|NCT00386581|Drug|atomoxetine|
1773042|NCT00386581|Drug|placebo|
1773043|NCT00386594|Drug|852A|
1773044|NCT00386607|Drug|Aliskiren|Aliskiren 300 mg
1773045|NCT00386607|Drug|Valsartan|Valsartan 320 mg
1773046|NCT00386607|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide (HCTZ) 12.5-25 mg
1773047|NCT00386620|Behavioral|Questionnaire|45 minute survey about health, pain and relationships
1773048|NCT00386620|Behavioral|Interview|Feedback on use of handheld computer electronic diaries (ED).
1773049|NCT00386633|Biological|MVA-mBN32|3 immunizations; first study group: 10E7_TCID50
1773050|NCT00386633|Biological|MVA-mBN32|3 immunizations; second study group: 10E8_TCID50
1773051|NCT00386646|Drug|0.5% carboxymethylcellulose (CMC) with purite and CMC alone|
1773052|NCT00386659|Drug|tenofovir + abacavir + lopinavir/ritonavir|
1773053|NCT00386659|Drug|tenofovir + abacavir + efavirenz|
1773054|NCT00386672|Dietary Supplement|Reduced energy (lite) OJ fortified with Calcium and Vitamin D|Three 240ml servings of lite OJ fortified with 350mg Ca and 100U VitD per day.
1773055|NCT00386672|Behavioral|Nutrition Counseling|Individual and group nutritional counseling by a registered dietician.
1773056|NCT00386672|Dietary Supplement|Reduced energy (lite) OJ without Calcium and Vitamin D|Three 240ml servings of lite OJ without 350mg Ca and 100U VitD per day.
1773057|NCT00386685|Drug|larotaxel (XRP9881)|intravenous administration
1773058|NCT00386685|Drug|trastuzumab|intravenous administration
1773059|NCT00386698|Biological|Fluarix|
1773060|NCT00386698|Biological|adjuvanted influenza vaccine|
1773061|NCT00386711|Behavioral|training on identification of suicide risk and depression|
1773062|NCT00386724|Device|Precision Spinal Cord Stimulation System|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
1773063|NCT00386724|Device|Artisan Surgical Lead|Artisan paddle electrode is a 2 x 8 surgical lead approved for use as part of the Precision System.
1773064|NCT00386750|Drug|Artemether-lumefantrine|
1773065|NCT00386763|Drug|Artemether-lumefantrine|
1773066|NCT00366730|Drug|Nitazoxanide|
1773067|NCT00366743|Procedure|Conventional LASIK|
1773068|NCT00366743|Procedure|Wavefront-guided LASIK|
1773069|NCT00366769|Device|Wavefront-guided LASIK using CustomVue platform|
1773070|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^6 TCID50
1773071|NCT00366782|Biological|rB/HPIV3|Live attenuated rB/HPIV3 vaccine given at a dose of 10^5 TCID50
1773072|NCT00366782|Biological|Placebo|Placebo for rB/HPIV3 vaccine
1773073|NCT00366795|Drug|Satavaptan|oral administration once daily
1773074|NCT00366795|Drug|placebo|oral administration once daily
1773075|NCT00366808|Procedure|LASIK surgery|
1956935|NCT02626455|Drug|Rituximab|Rituximab is administered as an infusion at a dose of 375 mg/m2 body surface on Day 1 of each 28-day cycle for patients assigned to R-B and on Day 2 of each 21-day cycle for patients assigned to R-CHOP.
1773081|NCT00366860|Behavioral|Soy bread|
1773082|NCT00366873|Procedure|Calcium absorption|formula with or without prebiotics
1773083|NCT00366899|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 13vPnC given at 3, 5 and 11 months of age.
1773084|NCT00366899|Biological|7 valent pneumococcal conjugate vaccine|Single 0.5 mL dose of 7vPnC given at 3, 5 and 11 months of age.
1773085|NCT00366912|Device|non-invasive ventilation|
1773086|NCT00366925|Device|Adacolumn®|
1773087|NCT00366938|Drug|Lumiracoxib|
1773088|NCT00366951|Procedure|Foley catheter only|
1773089|NCT00366951|Procedure|Extraamniotic saline infusion|
1773090|NCT00366964|Device|Laser Treatment|The laser treatment involves the use of an FDA approved laser device (510K Clearance certificate) for hair removal and treatment of leg veins for females having skin types III - VI. The pulses are of appropriate energy and pulse duration based on the skin type.
1773091|NCT00366964|Device|Wave Light laser device for skin treatment|To determine efficacy of FDA approved Laser treatment for hair removal and leg veins. The Mydon Wavelight is a Long Pulsed Nd Yag Laser, Class IV 1064 nm 55W
1773092|NCT00366977|Behavioral|Multi-session telephone counseling|
1773093|NCT00366977|Drug|NRT patches|
1773094|NCT00366990|Behavioral|Low Sodium Diet|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics with a focus on lowering sodium intake.
1773194|NCT00389116|Drug|water|oral water ingestion
1773195|NCT00389129|Drug|acetylsalicylic acid|
1773095|NCT00366990|Behavioral|Regular Sodium Intake|Group sessions once a week for 16 weeks, bi-weekly for 16 weeks, and monthly for 16 weeks on behavioral & weight loss topics.
1773096|NCT00367003|Device|Deep Brain Stimulator, implantable|Deep Brain Stimulator
1773097|NCT00367016|Drug|Xolair (Omalizumab)|Xolair (Omalizumab) will be given by subcutaneous injection according to Ige level and weight calculation.
1773098|NCT00367016|Drug|Placebo|Placebo
1773099|NCT00367029|Behavioral|Individualized Print-Based Motivational Program|"Study researchers will develop individualized reports, manuals, and tip sheets that include feedback and strategies for increasing physical activity for each participant. Materials will be mailed to participants 14 times throughout the year.
Participants in the enhanced intervention will receive additional materials that focus on increasing social support, self regulation, and outcome expectations, as well as materials on how to effectively monitor physical activity levels. They will also attend one study visit to assess their goals with the research staff."
1773100|NCT00367042|Device|Scalpel for tissue scoring|During Mohs surgery we will compare the outcomes of scarring, to determine whether a mark (with a pen) or a score with a scalpel will receive the best scar.
1773101|NCT00367042|Device|Surgical marker for tissue marking|You will be asked to participate, examined, discuss participation have procedure and come in for follow up for photos and check up.
1773102|NCT00367055|Drug|rosiglitazone-metformin|
1773103|NCT00367055|Drug|Metformin|
1773104|NCT00367055|Drug|metformin+ gliclazide|
1773105|NCT00367068|Drug|baclofen, intrathecal|
1773106|NCT00367068|Device|infusion pump for intrathecal baclofen, Synchromed, Medtronic|
1773107|NCT00367081|Drug|TMX-SMX (Bactrim(R))|
1773108|NCT00367081|Drug|Pyrimethamine plus Sulfadiazine plus leucoverin|
1773109|NCT00367094|Drug|Benazepril plus hydrochlorothiazide|
1773110|NCT00367120|Drug|Azithromycin Extended Release|
1773111|NCT00367120|Drug|Amoxicillin/Clavulanate|
1773112|NCT00367133|Procedure|Standard of Care Group|Standard of care group: conventional treatment consisting of focal/grid photocoagulation.
1773113|NCT00367133|Drug|1mg triamcinolone acetonide|Intravitreal injection of 1mg of triamcinolone acetonide at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
1773114|NCT00367133|Drug|4mg triamcinolone acetonide|4mg intravitreal triamcinolone acetonide injection at baseline. At each 4-month interval visit, the investigator will assess whether persistent or recurrent DME is present that warrants retreatment with the randomization assigned treatment. Retreatment, when indicated, will be performed within four weeks after the follow-up visit. Retreatment should not be performed sooner than 3.5 months from the time of the last treatment.
1773115|NCT00367146|Drug|MMF|
1773116|NCT00367159|Procedure|endoscopic treatment of vesico-renal reflux|Autologous Adipocytes Graft (lipostructure)
1773117|NCT00367172|Behavioral|Directly Administered Antiretroviral Therapy|
1773118|NCT00367185|Drug|Thalidomide|
1773119|NCT00367198|Dietary Supplement|Pro-Stat|two separate oral ingestions of nutrition supplement (either 30 ml per serving or at 60 ml per serving) during the hemodialysis session
1773120|NCT00367211|Drug|PN 200 tablets (500 mg naproxen and 20 mg omeprazole)|
1773121|NCT00367211|Drug|Naproxen 500 mg tablets (PN 200 minus omeprazole)|
1773122|NCT00377962|Drug|Everolimus|0.75-1.5 mg twice daily. At the week 1 visit and thereafter, the dose was adjusted to target blood concentration in the range 3-8 ng/mL.
1773123|NCT00377962|Drug|Mycophenolic acid (MPA)/azathioprine (AZA)|In the standard CNI arm, all immunosuppressants including (MPA) and azathioprine (AZA) continued unchanged as per local practice.
1773124|NCT00377962|Drug|Calcineurin inhibitors (CNI)|Calcineurin inhibitors include cyclosporine, pimecrolimus, and tacrolimus.
1773125|NCT00377962|Drug|Steroids|Steroid treatment was according to local practice. If steroids were given, the baseline dose of prednisone or equivalent was to be kept unchanged for all treatment groups for the total study duration, unless a medical condition dictated a change.
1773126|NCT00386776|Other|Computer-based medical history|The intervention is a computer-based medical interview, which contains 232 primary questions that are asked of all respondents, and over 6000 frames (questions, explanations, suggestions, recommendations, and words of encouragement) that are available for presentation as determined by the patient's responses and the branching logic of the program.
1773127|NCT00386802|Drug|Antifungal drug. VORICONAZOL. (VFEND®)|I.V charge dose 6 mg/kg/12h (2 doses) Maintenance iv treatment 4 mg/kg/12h during 6 days, followed by oral treatment (200 mg/12h)
1773128|NCT00386815|Drug|pemetrexed|
1773129|NCT00386815|Drug|cisplatin|
1773130|NCT00386828|Drug|Bevacizumab:|
1773131|NCT00386841|Drug|Escitalopram|Escitalopram 10 mg p.o. per day
1773132|NCT00386841|Drug|Placebo|Placebo
1773133|NCT00386854|Behavioral|physical training|
1773134|NCT00386867|Drug|800 mcg misoprostol via oral or buccal administration|
1773135|NCT00386880|Other|Sounds|
1773136|NCT00386893|Procedure|simultaneous EEG/fMRI|fMRI/EEG recordings
1773137|NCT00386893|Device|fMRI|
1773138|NCT00386906|Procedure|Sentinel Lymph Node Mapping and Biopsy|Intraoperative lymphatic mapping, then biopsy/removal of the conjunctiva/eyelid tumor.
1773139|NCT00386919|Procedure|CyberKnife|
1773140|NCT00386945|Behavioral|Brief counseling (Ask, Advise, Arrange)|Providers are trained to provide Ask, Advise and Arrange (brief cessation counseling) to all tobacco using patients. A Fax-to-Quit referral to a tobacco quit line and written materials on local cessation resources and pharmacotherapy are provided.
1773141|NCT00386958|Drug|Povidone-Iodine|
1773142|NCT00386971|Dietary Supplement|L-carnitine|3 grams daily in liquid form by mouth
1773143|NCT00386971|Other|placebo|1 oz sweet tasting liquid daily by mouth
1773144|NCT00386984|Drug|Somatostatin (octreotide)|
1773145|NCT00386997|Drug|liposomal amphotericin B (AmBisome®)|
1773196|NCT00389155|Drug|Vinflunine|solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
1773146|NCT00387010|Drug|Fentanyl Buccal Tablets|"Fentanyl buccal tablets (FBT) placed in the buccal cavity above a rear molar until disintegrated, approximately 14-25 minutes.
Dose titration: Participants self-administered FBT, starting at 100, 200 or 400 mcg (depending on analgesic used pre-study) and titrated to 600 and 800 mcg as needed. For each breakthrough pain (BTP) episode, participants took a dose, and did not take further study drug if adequate pain relief was achieved. If pain was not controlled within 30 minutes, the same dose level was repeated. If pain relief was inadequate 30 minutes after the second dose, usual rescue medication was taken for that BTP episode. Doses were adjusted until pain relief was adequate and side effects were tolerated.
Open-label: Once the successful dose of FBT was identified (100, 200, 400, 600, or 800 mcg), participants were dispensed a 4-week supply at the successful dose. Participants were not to use FBT for more than 6 BTP episodes or take more than 8 FBT daily."
1773147|NCT00387023|Drug|Rituximab|250 mg/m^2 IV over 4-6 hours for 2 weeks.
1773148|NCT00387023|Drug|Zevalin|5 mCi/kg IV over 30 minutes for 1 week, followed by 0.3 mCi/kg or 0.4 mCi/kg 90Y-Zevalin based on platelet counts for 1 week.
1773149|NCT00387036|Drug|Fluticasone|fluticasone 250 µg/inhalation, 2 inhalations bid. 14 Days of treatment.
1773150|NCT00387036|Drug|Comparator: Placebo|Placebo /inhalation, 2 inhalations bid. 14 Days of treatment.
1773151|NCT00387049|Behavioral|Anxiety Sensitivity Program for Smoking Cessation|
1773152|NCT00387062|Device|Computer-based Cognitive Training|
1773153|NCT00387075|Procedure|[123I]β-CIT and SPECT imaging|This study is designed as a prospective cohort study to test the strategy of combining two biomarkers of parkinsonism, olfaction and brain imaging with a radioactively labeled drug, [123I]β-CIT , in a population of first-degree relatives of PD patients as a tool to establish an 'at risk' Parkinson disease cohort without motor symptoms of PD.
1773154|NCT00387075|Drug|[123I]β-CIT|PECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections),
1773155|NCT00387088|Device|Respimat|
1773156|NCT00387088|Drug|Tiotropium|
1773157|NCT00387101|Device|Dermal - Living Skin Replacement (Dermal - LSR)|
1773158|NCT00387114|Drug|Vitamin C|
1773159|NCT00388817|Behavioral|Pharmacist intervention|
1773160|NCT00388830|Procedure|Ultrasound|
1773161|NCT00388856|Drug|Vitamin C 1000mg and E 400IU|
1773162|NCT00388882|Drug|tiotropium|
1773163|NCT00388882|Drug|ipratropium bromide / albuterol|
1773164|NCT00388895|Drug|chemotherapy|
1773165|NCT00388895|Drug|Glivec|
1773166|NCT00388908|Behavioral|Reminders and opinion leader generated guidelines +/- leaflets and counselling|
1773167|NCT00388908|Other|Usual Care|
1773168|NCT00388921|Drug|Vitamin A|
1773169|NCT00388934|Device|Drug eluting stent|percutaneous intervention with implantation of drug eluting coronary stent
1773170|NCT00388947|Device|AMS Prolapse Product|AMS Apogee™ with IntePro (Synthetic) or InteXen (Biologic) Mesh implant for posterior wall pelvic organ prolapse AMS Straight-In™ with IntePro (Synthetic) Mesh implant for vaginal vault pelvic organ prolapse AMS Perigee™ with IntePro Mesh implant for anterior wall pelvic organ prolapse AMS Perigee™ with IntePro Mesh coated with PC AMS Elevate® Prolapse Repair System Family
1773171|NCT00388960|Drug|Amrubicin|"Amrubicin 45mg/m<2> IV days 1, 2 3 of each 21-day cycle until disease progression.
Amrubicin 40mg/m<2> IV days 1, 2, 3 plus cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression."
1773172|NCT00388960|Drug|Cisplatin|"Amrubicin 40mg/m<2> IV days 1, 2, 3 plus Cisplatin 60mg/m<2> day 1 of each 21-day cycle until disease progression.
Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression."
1773173|NCT00388960|Drug|Etoposide|Cisplatin 75mg/m<2> IV day 1 plus etoposide 100mg/m<2> IV day 1 and 200mg/m<2> orally days 2, 3 or etoposide 100mg/m<2> IV days 1, 2, 3 of each 21-day cycle until disease progression.
1773174|NCT00388973|Drug|Quetiapine|
1773175|NCT00388986|Drug|GK Activator (2)|100mg po bid
1773176|NCT00388986|Drug|Glyburide|10-20mg po daily
1773177|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
1773178|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
1773179|NCT00388999|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous (i.v.) administration for 4 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
1773180|NCT00389012|Procedure|exercise therapy|
1773181|NCT00389012|Procedure|walking rehabilitation|
1773182|NCT00389025|Drug|Olopatadine (generic name)|
1773183|NCT00389038|Behavioral|Coping Skills Training|Behavioral Treatment 1 (coping skills training)--Behavioral Treatment session 1 and 2: Doses are one session a week for 8 weeks, followed by one session a month for 2 months, followed by 1 session every three months for 1 year.
1773184|NCT00389038|Behavioral|Headache Education|Behavioral Treatment 2 (headache education)
1773185|NCT00389038|Drug|Amitriptyline|Amitriptyline: up to 1 mg/kg capsule taken once daily at bedtime. Taken up to Week 20. After Week 20 medications and doses may change with standard care.
1773186|NCT00389051|Drug|bendamustine hydrochloride|
1773187|NCT00389064|Drug|Quetiapine XR|Quetiapine XR 50 mg tablets orally administered in flexible doses of 50 to 300 mg quetiapine XR once daily, in the evening for a 9-week treatment period.
1773188|NCT00389064|Drug|Placebo|Matching placebo tablets orally administered in flexible doses of 50 to 300 mg once daily, in the evening for a 9-week treatment period.
1773189|NCT00389077|Drug|Perifosine Daily Dose|Daily Dose Perifosine
1773190|NCT00389077|Drug|Perifosine|Weekly Dose
1773191|NCT00389090|Drug|Temozolomide and O6-Benzylguanine|O6BG + Temozolomide
1773192|NCT00389103|Biological|MVA (smallpox vaccine)|0.5ml of MVA3000 Smallpox vaccine, administered twice separated by 28 days, subcutaneous injections
1773193|NCT00389116|Drug|gastrograffin|ingestion
1773197|NCT00389155|Drug|Gemcitabine|solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
1773198|NCT00389155|Other|Placebo|
1773199|NCT00389168|Drug|Irbesartan|Titrated to 300 mg od, 48 weeks.
1773200|NCT00389168|Drug|Atenolol|Titrated to 100 mg od, 48 weeks.
1773201|NCT00389181|Procedure|Interventional therapy|All interventional procedures are standard of care for the treatment of AVMs. They are not experimental. A patient randomized to interventional therapy is expected to begin interventional therapy within 3 months following randomization. Interventional therapy consists of endovascular attempts at occlusion of the nidus and feeding vessels, coiling or microsurgery for feeding artery aneurysms, microsurgery for BAVM itself, and radiosurgery, these alone or in various combinations and timings.
1773202|NCT00389181|Other|Medical management|Patients participating in the trial will receive the best medical management possible for the disorder being tested in the trial and for any general medical illnesses they are demonstrated to have. One important consideration in the medical management of patients in this trial is stroke risk factor reduction.
1773203|NCT00389194|Drug|continuing AZT+3TC or switching AZT+3TC to TDF+ FTC|
1773204|NCT00389207|Drug|nevirapine bid|nevirapine twice daily
1773205|NCT00389207|Drug|nevirapine qd|nevirapine once daily
1773206|NCT00389207|Drug|atazanavir|atazanavir once daily
1773207|NCT00389220|Device|Coronary stent placement|Coronary stent placement
1773208|NCT00389233|Drug|Macrogol3350 NA sulphate NACl KCl ascorbic acid NA ascorbate|"1 pack will consist of 2L NRL 994 - 4 (2 x PEG + E/P + 2 x Vitamin C/C) sachets for the 2L of 2 sachets (1 x P plus 1 x C) will be dissolved in 1L of water. Each litre will be drunk within 1 hour followed by at least 500ml of any additional clear fluid."
1773209|NCT00389233|Drug|Macrogol3350 Na sulphate Na bicarbonate NaCl KCl|"1 pack will consist of 4L PEG + E - contains 4 sachets for the 4L of PEG + E/P/E. Each sachet will be dissolved in 1L of water. Each litre will be drunk within 1 hour."
1773210|NCT00389246|Behavioral|Consultation without genetic information|
1773211|NCT00389246|Behavioral|Consultation with genetic information|
1773212|NCT00389259|Drug|Placebo|IV placebo q4h
1773213|NCT00389272|Drug|Ibuprofen, acetaminophen|
1773214|NCT00389285|Drug|rIL-21 only|Part 1: rIL-21, IV, Day 1-5 and 15-19 of each 6-week treatment course
1773215|NCT00389285|Drug|rIL-21 + sorafenib|Part 2: rIL-21 IV, Day 1-5 and 15-19 of each 6-week treatment course + sorafenib (up to 400 mg taken orally twice daily)
1773216|NCT00389298|Drug|VCH-759 (BCH-27759)|
1773217|NCT00389311|Drug|Normosol-R|
1773218|NCT00389311|Drug|Nonoxynol-9|
1773219|NCT00389311|Procedure|Gastrointestinal instrumentation|
1773220|NCT00389324|Biological|Immune Globulin Intravenous (Human)|This trial was an open-label, single-sequence, study. The enrolled subjects received IGIV-C via two routes of administration (IV for 4 -5 weeks and SC for 24 weeks) in order to compare the PK variables, safety and tolerability of SC administration of IGIV-C. Certain subjects required IV IGIV-C dosing during a Run-in Phase (3 - 4 months) for steady-state conditions prior to the IV phase. Subjects received two IV infusions of IGIV (between 200 - 600 mg based on the subject's previous IgG dosing regimen, 3 to 4 weeks apart) until a steady-state was reached at which time PK profiling was performed. Subjects began weekly SC administration (1.37 times the weekly equivalency of each subject's monthly IV dose) 1 week following last IV dose and followed for a period of six months.
1773221|NCT00389350|Drug|Extract of Green and Black Tea|
1773222|NCT00389363|Drug|ALK HDM tablet|
1773223|NCT00389376|Drug|Placebo|Placebo
1773224|NCT00389376|Drug|Silymarin|140 mg every 8 hours
1773225|NCT00389376|Drug|Silymarin|280 mg single dose
1773226|NCT00389376|Drug|Silymarin|280 mg single dose + every 8 hours
1773227|NCT00389376|Drug|Silymarin|560 mg single dose + every 8 hours
1773228|NCT00389376|Drug|Silymarin|560 mg single dose + every 8 hours
1773229|NCT00389376|Drug|Silymarin|280 mg every 8 hours
1773230|NCT00389376|Drug|Silymarin|700 mg single dose + every 8 hours
1773231|NCT00389389|Drug|AZD4877|intravenous infusion
1773232|NCT00389402|Drug|saquinavir/ritonavir|
1773233|NCT00389402|Drug|atazanavir/ritonavir|
1773234|NCT00389415|Drug|Vildagliptin|
1773235|NCT00389428|Drug|CPX-351 (Cytarabine:Daunorubicin) Liposome Injection|
1773236|NCT00389441|Drug|AG-013736|AG-013736, tablets 5 mg BID , treatment will continue until tumor progression or toxicity
1773237|NCT00389467|Device|Merci Retriever and Penumbra System|"The MERCI (Mechanical Embolus Removal in Cerebral Ischemia) Retriever consists of a flexible, nickel titanium (nitinol) wire with a helical-shaped distal tip. The helical distal tip is covered with a platinum radiopaque coil, which facilitates fluoroscopic visualization. The body of the MERCI Retriever is covered with a hydrophilic coating that helps facilitate device placement. The MERCI Retriever is available in 6 configurations (Merci Retrievers X6, L5, L4, L6, V series, DAC).
The Penumbra System uses a reperfusion catheter in parallel with a separator component and an aspiration source to achieve separation of the thrombus and subsequent aspiration of the occlusion from the vessel. The system is available in different sizes according to the target vessels (041 Reperfusion Catheter/Separator pair for use in vessels larger than 3mm, notably the ICA and M1; 032 Reperfusion Catheter/Separator pair for use in vessels 2mm - 3mm, notably the M2)."
1773238|NCT00389480|Drug|AR-67 (formerly DB-67)|infusion daily x 5 days, every 21 days
1773239|NCT00389493|Drug|Risperidone|Dosage of 0.5 mg to 4.0 mg per day as tolerated
1773240|NCT00389493|Behavioral|Exposure/ritual prevention therapy (EX/RP)|EX/RP is a form of cognitive behavioral therapy. Participants assigned to EX/RP will attend therapy sessions twice per week. In EX/RP, participants will be exposed to feared objects or ideas, and will be encouraged not to carry out a compulsive response.
1773241|NCT00389493|Drug|Placebo|Placebo capsules will be identical in appearance to those of risperidone.
1773242|NCT00389506|Biological|LMB-2 immunotoxin|
1773243|NCT00389506|Drug|cyclophosphamide|
1773244|NCT00389506|Drug|fludarabine phosphate|
1773245|NCT00389506|Other|pharmacological study|
1773246|NCT00389519|Drug|ramipril|once a day oral ramipril capsules given for 4 weeks
1773247|NCT00389519|Drug|placebo|once a day oral placebo capsule for 4 weeks
1773248|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
1773249|NCT00389532|Biological|Influenza Virus Vaccine (2006-2007 Fluzone® vaccine)|Influenza vaccine
1773250|NCT00389545|Procedure|Intracoronary infusion of autologous bone-marrow derived stem cells|
1773251|NCT00389558|Procedure|disinfection efficacy using Biseptine|Detersion and antiseptic application when changing catheter dressing
1773252|NCT00389558|Procedure|disinfection efficacy using Amukin|Detersion and antiseptic application when changing catheter dressing
1773253|NCT00389584|Drug|irinotecan hydrochloride|
1773254|NCT00389584|Procedure|cognitive assessment|
1773255|NCT00389584|Procedure|management of therapy complications|
1773256|NCT00389584|Radiation|radiation therapy|
1773257|NCT00389597|Device|Cervical Artificial Disc|Cervical artificial disc mechanical device
1773258|NCT00389610|Biological|allogenic GM-CSF plasmid-transfected pancreatic tumor cell vaccine|Given subcutaneously
1773259|NCT00389636|Device|TheraGauze|TheraGauze
1773260|NCT00389636|Drug|Regranex|Regranex + TheraGauze
1773261|NCT00389649|Device|heart rate setting|
1773262|NCT00389662|Device|"Wearing the Nike Free shoe"|
1773263|NCT00389675|Drug|Darusentan|Darusentan capsules at a dose of 50, 100, or 300 mg administered orally once daily
1773264|NCT00389675|Drug|Guanfacine|Guanfacine 1 mg capsules administered orally once daily
1773265|NCT00389688|Drug|cisplatin|
1773266|NCT00389688|Drug|pemetrexed disodium|
1773267|NCT00389688|Procedure|adjuvant therapy|
1773268|NCT00389688|Procedure|conventional surgery|
1773269|NCT00389688|Procedure|neoadjuvant therapy|
1773270|NCT00389701|Drug|bortezomib|
1773271|NCT00389701|Drug|dexamethasone|
1773272|NCT00389714|Device|dental restoration|
1773273|NCT00389727|Procedure|Radiotherapy|
1773274|NCT00389740|Drug|MK0217, /Duration of Treatment : 12 Months|
1773275|NCT00389740|Drug|Comparator : raloxifene hydrochloride /Duration of Treatment : 12 Months|
1773276|NCT00389753|Drug|Application of Aruba Aloë formula F-BC-096 or control|
1773277|NCT00389766|Drug|iodine I 131 metaiodobenzylguanidine|
1773278|NCT00389766|Drug|topotecan hydrochloride|
1773279|NCT00389766|Procedure|chemotherapy|
1773280|NCT00389766|Procedure|peripheral blood stem cell transplantation|
1773281|NCT00389766|Procedure|radioisotope therapy|
1773282|NCT00389766|Procedure|radionuclide imaging|
1773283|NCT00389766|Procedure|radiosensitization|
1773284|NCT00389766|Procedure|total-body irradiation|
1773285|NCT00389779|Drug|Darusentan|Darusentan capsules administered orally once daily
1773286|NCT00389779|Drug|Guanfacine|Guanfacine capsules administered orally once daily
1773287|NCT00389779|Drug|Darusentan Placebo|Placebo to match darusentan administered orally once daily
1773288|NCT00389792|Drug|ATI-2042|no intervention
1773289|NCT00389792|Drug|ATI-2042 200 mg|To stop the dosing of ATI-2042 for a designated time frame as determined by the medical monitor and Principal Investigator.
1773290|NCT00389805|Drug|bortezomib|
1773291|NCT00389805|Drug|pemetrexed disodium|
1773292|NCT00389805|Genetic|gene expression analysis|
1773293|NCT00389805|Genetic|mutation analysis|
1773294|NCT00389805|Genetic|protein expression analysis|
1773295|NCT00389805|Genetic|reverse transcriptase-polymerase chain reaction|
1773296|NCT00389805|Other|flow cytometry|
1773297|NCT00389805|Other|immunoenzyme technique|
1773298|NCT00389805|Other|immunohistochemistry staining method|
1773299|NCT00389818|Biological|filgrastim|Supportive therapy: GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
1773300|NCT00389818|Biological|pegfilgrastim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
1773301|NCT00389818|Biological|rituximab|375 mg/m2 IV Day 1 of each cycle
1773302|NCT00389818|Biological|sargramostim|GF therapy with G-CSF, GM-CSF, or pegfilgrastim will be used in all patients, beginning on Day 3 of each cycle, until post nadir of blood counts from each chemotherapy cycle.
1773303|NCT00389818|Drug|cyclophosphamide|750 mg/m2 IV Day 1 of each cycle
1773304|NCT00389818|Drug|pegylated liposomal doxorubicin hydrochloride|40 mg/m2 IV Day 1 of each cycle
1773305|NCT00389818|Drug|prednisone|100 mg PO Days 1-5 of each cycle
1773306|NCT00389818|Drug|vincristine sulfate|1.4 mg/m2 IV Day 1 (2.0 mg maximum) of each cycle
1773307|NCT00389818|Other|immunohistochemistry staining method|tissue specimen collected at baseline
1773308|NCT00389818|Other|laboratory biomarker analysis|tissue specimen collected at baseline
1773309|NCT00389831|Drug|Rotigotine Nasal Spray|Daily single dose of 62µg, 124µg, and 247µg rotigotine delivered as single puff of nasal spray solution
1773310|NCT00389831|Other|Placebo Nasal Spray|Daily single dose of placebo delivered as single puff of nasal spray solution
1773311|NCT00389844|Behavioral|Exercise Trainer component of the Exercise Plus Program|With the exception of the routine care group, the exercise trainers visited each of the participant in their homes twice a week for two months, once a week for four months, and once a month for six months.
1773312|NCT00389844|Behavioral|Plus component (motivation) of the Exercise Plus Program|Motivation only
1773313|NCT00389844|Behavioral|Exercise Plus Program (exercise + motivation)|Exercise plus motivation
1773314|NCT00389857|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
1773315|NCT00389857|Biological|Influenza Virus Vaccine (Fluzone®)|0.25 mL, Intramuscular (infant/children dose)
1773316|NCT00389870|Biological|panitumumab|
1773317|NCT00389870|Drug|cyclosporine|
1773318|NCT00389870|Drug|irinotecan hydrochloride|
1773319|NCT00389883|Drug|Comparison of two anesthetics protocol|Comparison of two anesthetics protocol
1773320|NCT00389896|Drug|MK0733 / Duration of Treatment: 18 Weeks|
1773451|NCT00390598|Drug|senna glycoside 36 mg and PEG (solution given 2 L)|
1773321|NCT00389896|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks|
1773322|NCT00389909|Drug|Doxapram|"Dosing comparison between fixed scheduled and sex related dosage.
Dosing related to weight only versus chart taking into account weight, age and gender."
1773323|NCT00389922|Drug|lapatinib ditosylate|Given orally for 28 days per dose level (Dose level 1: 250mg; Dose level 2: 500mg; Dose level 3: 1000mg; Dose level 4: 1250mg; Dose level 5: 1500mg; Dose level 6: 1500mg)
1773324|NCT00389922|Drug|vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 20mg/m2; Dose level 4: 20mg/m2; Dose level 5: 20mg/m2; Dose level 6: 25mg/m2)
1773325|NCT00389922|Genetic|comparative genomic hybridization|Molecular correlative study
1773326|NCT00389922|Genetic|cytogenetic analysis|Molecular correlative study
1773327|NCT00389922|Genetic|gene expression analysis|Molecular correlative study
1773328|NCT00389922|Genetic|mutation analysis|Molecular correlative study
1773329|NCT00389922|Genetic|polymerase chain reaction|Molecular correlative study
1773330|NCT00389922|Genetic|polymorphism analysis|Molecular correlative study
1773331|NCT00389922|Genetic|proteomic profiling|Molecular correlative study
1773332|NCT00389922|Genetic|reverse transcriptase-polymerase chain reaction|Molecular correlative study
1773333|NCT00389922|Other|immunohistochemistry staining method|Molecular correlative study
1773334|NCT00389922|Other|laboratory biomarker analysis|Molecular correlative study
1773335|NCT00389922|Drug|lapatinib ditosylate|Given orally on Days 2-5, 9-12 and 16-25 per dose level (Dose level 1: 1250mg; Dose level 2: 1500mg; Dose level 3: 1500mg; Dose level 4: 1700mg)
1773336|NCT00389922|Drug|Vinorelbine ditartrate|Given IV Days 1, 8 and 15 per dose level (Dose level 1: 20mg/m2; Dose level 2: 20mg/m2; Dose level 3: 25mg/m2; Dose level 4: 25mg/m2)
1773337|NCT00389935|Drug|Thalidomide|Thalidomide 50 - 200 mg once at nightime
1773338|NCT00389948|Drug|Lanzoprazole|
1773339|NCT00389974|Drug|sunitinib malate|Given PO
1773340|NCT00389987|Drug|MK0826, /Duration of Treatment : 8 Weeks|
1773341|NCT00389987|Drug|Comparator : piperacillin sodium (+) tazobactam sodium /Duration of Treatment : 8 Weeks|
1773342|NCT00390000|Drug|vatalanib|Given orally
1773343|NCT00390000|Drug|pemetrexed disodium|Given IV
1773344|NCT00390000|Other|pharmacological study|Correlative study
1773345|NCT00390000|Procedure|ultrasound imaging|Correlative study
1773346|NCT00390013|Drug|Gabapentin|"300 mg. capsules
Dosage schedule for weeks 1 and 2 and weeks 12 and 13:
day 1 you will take 1 capsule for the day
day 2 you will take 1 capsule 2 times for that day
days 3-6 you will take 1 capsule 3 times for those days
days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day
days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day
days 13-14 you will take 2 capsules 3 times each day
continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.
at completion of study treatment you will titrate off study drug over a weeks time."
1773347|NCT00390013|Drug|Placebo oral capsule|"Placebo capsules
Dosage schedule for weeks 1 and 2 and weeks 12 and 13:
day 1 you will take 1 capsule for the day
day 2 you will take 1 capsule 2 times for that day
days 3-6 you will take 1 capsule 3 times for those days
days 7-9 you will take 1 capsule in am and 1 capsule at noon, 2 capsules at bedtime each day
days 10-12 you will take 1 capsule in am and 2 capsules at noon and 2 capsules at bedtime each day
days 13-14 you will take 2 capsules 3 times each day
continue on 2 capsules 3 times each day for 6 weeks after maximum dose of 1800 mg is reached after weeks 2 and 13.
at completion of study treatment you will titrate off study drug over a weeks time."
1773348|NCT00390026|Drug|Bevacizumab (Avastin)|
1773349|NCT00390026|Drug|Verteporfin photodynamic therapy (PDT)|
1773350|NCT00390039|Drug|Intranasal Morphine|MNS075 7.5mg q1h PRN
1773351|NCT00390039|Drug|Placebo|IN Placebo q1h PRN
1773352|NCT00390039|Drug|IV morphine|IV morphine 7.5mg q3h PRN
1773353|NCT00390039|Drug|Placebo|IV Placebo q3h PRN
1773354|NCT00390039|Drug|Intranasal morphine|MNS075 15mg q3h PRN
1773355|NCT00390039|Drug|Placebo|IN Placebo q3h PRN
1773356|NCT00390052|Drug|triapine|Given IV and orally
1773357|NCT00390052|Other|pharmacological study|correlative study
1773358|NCT00390052|Procedure|laboratory biomarker analysis|Correlative study
1773359|NCT00390065|Drug|Nitric Oxide|Early low dose (5ppm) NO inhalation Placebo
1773360|NCT00390078|Biological|MVA-mBN32|3 immunizations: 1x 10E8_TCID50 MVA-mBN32
1773361|NCT00390078|Biological|IMVAMUNE|3 immunizations: 1x 10E8_TCID50 IMVAMUNE
1773362|NCT00390091|Drug|abetimus sodium (LJP 394)|
1773363|NCT00390117|Drug|CDKI AT7519|AT7519M (1 hour IV) on days 1, 4, 8 and 11 every 5 weeks.
1773364|NCT00390117|Other|laboratory biomarker analysis|Pharmacokinetic bioanalysis of the AT7519 plasma concentration data will be performed by BioDynamics Northhampton, U.K. The pharmacokinetic parameters for AT7519 will be determined by Astex Therapeutics as data permits.
1773365|NCT00390130|Drug|Pentacel (DPTaP+Hib)|
1773366|NCT00390130|Drug|Prevnar (conjugated pneumococcal vaccine)|
1773367|NCT00390143|Biological|Meningococcal vaccine 134612|One intramuscular dose during the primary study
1773368|NCT00390143|Biological|Mencevax™ ACWY|One subcutaneous dose during the primary study
1773369|NCT00390156|Biological|bevacizumab|5 mg/kg
1773370|NCT00390156|Drug|cyclophosphamide|Current dose 50 mg
1773371|NCT00390156|Drug|imatinib|Current dose 400 mg
1773372|NCT00390169|Behavioral|Mindfulness Meditation-Based Stress Reduction|
1773373|NCT00390169|Behavioral|Supportive-Expressive Group Therapy|
1773374|NCT00390182|Drug|Gemcitabine|"Gemcitabine will be given at 1250 mg per meter squared over 2 hours days 1 and 8 of a 21 day cycle for a total of 4 cycles.
Radiation:External Radiation Therapy The total dose would be 19.2 Gy divided over 32 fractions twice a day, on day 1 and day 8 after chemotherapy.
**Radiation is the experimental part of the study."
1773375|NCT00390195|Drug|RAD001 (everolimus)|Arm 1: 2.5, 5, 7.5 or 10 mg of RAD001 daily
1773376|NCT00390195|Drug|RAD001 (everolimus)|Arm 2: 20, 30, 50 or 70 mg of RAD001 daily
1773452|NCT00390611|Drug|Sorafenib|
1773453|NCT00390611|Drug|Paclitaxel|Paclitaxel
1956936|NCT02626455|Drug|Cyclophosphamide|Cyclophosphamide is administered as an infusion at a dose of 750 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
1956937|NCT02626455|Drug|Doxorubicin|Doxorubicin is administered as an infusion at a dose of 50 mg/m2 body surface on Day 2 of each 21-day cycle for patients assigned to R-CHOP
1773379|NCT00390221|Biological|BIIB019 (Daclizumab High Yield Process)|SC injection
1773380|NCT00390221|Drug|Placebo|Placebo SC injection
1773381|NCT00390234|Drug|ziv-aflibercept|Given IV
1773382|NCT00390247|Drug|thalidomide|
1773383|NCT00390260|Drug|MK0966 / Duration of Treatment: 1 Days|
1773384|NCT00390260|Drug|Comparator: acetaminophen (+) hydrocodone bitartrate / Duration of Treatment: 1 Days|
1773385|NCT00390260|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 1 Days|
1773386|NCT00390273|Drug|Metformin|
1773387|NCT00390299|Biological|Carcinoembryonic Antigen-Expressing Measles Virus|Given via injection into resection cavity or around tumor bed and/or IT
1773388|NCT00390299|Other|Laboratory Biomarker Analysis|Correlative studies
1773389|NCT00390299|Procedure|Therapeutic Conventional Surgery|Undergo en bloc resection
1773390|NCT00390312|Drug|Intranasal Placebo|Intranasal placebo
1773391|NCT00390312|Drug|Intranasal Morphine 15 mg|Intranasal Morphine 15 mg
1773392|NCT00390312|Drug|Immediate Release Oral Morphine 60 mg|Immediate Release Oral Morphine 60 mg
1773393|NCT00390312|Drug|Intravenous morphine|Intravenous morphine 7.5 mg
1773394|NCT00390312|Drug|Intranasal morphine 7.5 mg|Intranasal morphine 7.5 mg
1773395|NCT00390312|Drug|Oral placebo|Oral placebo
1773396|NCT00390312|Drug|Intravenous placebo|Intravenous placebo
1773397|NCT00390325|Other|Laboratory Biomarker Analysis|Correlative studies
1773398|NCT00390325|Other|Pharmacological Study|Correlative studies
1773399|NCT00390325|Drug|Sorafenib Tosylate|Given orally
1773400|NCT00390338|Biological|polarized dendritic cells|
1773401|NCT00390338|Biological|non-polarized dendritic cells|
1773402|NCT00390351|Device|optical coherence tomography|
1773403|NCT00390364|Drug|everolimus|
1773404|NCT00390364|Procedure|antiangiogenesis therapy|
1773405|NCT00390364|Procedure|biopsy|
1773406|NCT00390364|Procedure|diagnostic procedure|
1773407|NCT00390364|Procedure|gene expression analysis|
1773408|NCT00390364|Procedure|immunohistochemistry staining method|
1773409|NCT00390364|Procedure|laboratory biomarker analysis|
1773410|NCT00390364|Procedure|mutation analysis|
1773411|NCT00390364|Procedure|protein tyrosine kinase inhibitor therapy|
1773412|NCT00390364|Procedure|reverse transcriptase-polymerase chain reaction|
1773413|NCT00390377|Procedure|Cutting scalp hair|
1773414|NCT00390390|Drug|Lansoprazole|
1773415|NCT00390403|Drug|R-(-)-gossypol acetic acid|
1773416|NCT00390403|Drug|temozolomide|
1773417|NCT00390403|Genetic|gene expression analysis|
1773418|NCT00390403|Genetic|mutation analysis|
1773419|NCT00390403|Genetic|protein expression analysis|
1773420|NCT00390403|Other|laboratory biomarker analysis|
1773421|NCT00390403|Other|pharmacological study|
1773422|NCT00390403|Procedure|adjuvant therapy|
1773423|NCT00390403|Radiation|radiation therapy|
1773424|NCT00390416|Drug|Docetaxel, Cisplatin, Fluorouracil, Bevacizumab, Leucovorin|Bevacizumab 10mg/kg day 1 IV over 30 minutes Docetaxel 40mg/m2 day 1 IV over 1 hour Leucovorin 400mg/m2 day 1 IV over 30 minutes Fluorouracil 400mg/m2 IVP day 1 Fluorouracil 1000mg/m2 IVCI x 48 hours Cisplatin 40mg/m2 day 3 IV over 30 minutes
1773427|NCT00390442|Device|continuous positive airway pressure|
1773428|NCT00390455|Drug|Fulvestrant|Given IM
1773429|NCT00390455|Other|Laboratory Biomarker Analysis|Correlative studies
1773430|NCT00390455|Drug|Lapatinib Ditosylate|Given PO
1773431|NCT00390455|Other|Placebo|Given PO
1773432|NCT00390468|Drug|Tandutinib|500 mg twice daily every day with doses taken approximately 12 hours apart, 28 day cycle.
1773433|NCT00390481|Procedure|EC-IC Bypass in the COSS study|EC-IC Bypass surgery involves taking an artery from the scalp outside the skull, making a small hole in the skull, and then connecting the scalp artery to a brain artery inside the skull. In this way, the blockage of the carotid artery in the neck is bypassed and more blood can flow to the brain.
1773434|NCT00390494|Procedure|Hysterectomy|
1773435|NCT00390494|Procedure|Myomectomy|
1773436|NCT00390494|Procedure|Uterine Fibroid Embolization|
1773437|NCT00390507|Procedure|Post-tetanic count frequency|
1773438|NCT00390520|Drug|Vildagliptin|
1773439|NCT00390533|Drug|Saredutant|oral administration (capsules)
1773440|NCT00390533|Drug|Placebo|oral administration (capsules)
1773441|NCT00390546|Drug|Digoxin|
1773442|NCT00390546|Drug|Propranolol|
1773443|NCT00390559|Drug|nicotine transdermal system|21 mg nicotine transdermal system
1773444|NCT00390559|Drug|Nicotine transdermal system|Placebo nicotine patch
1773445|NCT00390559|Other|Nicotine containing cigarette|Nicotine containing cigarette
1773446|NCT00390559|Other|Placebo cigarette|Non nicotine containing cigarette
1773447|NCT00390572|Behavioral|Sleep Specialty Consultation|The Sleep Specialty Consultation (SSC) consisted of: (1) a thorough sleep disorders evaluation accomplished via a clinician-administered structured interview designed to assess specific symptoms of global sleep disorder categories, review of a sleep history questionnaire, and review of available (CPRS) medical/psychiatric electronic records; (2) education about the specific sleep disorders diagnoses and relevant treatment recommendations provided to the patients; and (3) standardized diagnostic information and treatment recommendations provided to the participants' primary care providers.
1773448|NCT00390585|Drug|Iodixanol 320|Iodixanol 320 is used as contrast media while coronary intervention.
1773449|NCT00390585|Drug|Iomeprol 350|Iomeprol 350 is used as contrast media while coronary intervention.
1773450|NCT00390598|Drug|PEG (solution given 4 L)|
1773454|NCT00390611|Drug|Carboplatin|Carboplatin
1773455|NCT00390624|Drug|URODILATIN (ULARITIDE, ATRIAL NATRIURETIC PEPTIDE)|
1773456|NCT00390624|Drug|MANNITOL|
1773457|NCT00390637|Behavioral|High or low Glycemic Index and high or low Protein Diet|
1773458|NCT00390650|Drug|Saredutant|
1773459|NCT00390663|Procedure|Nasal Cautery|
1773460|NCT00390676|Drug|ADH -1 and carboplatin|
1773461|NCT00390676|Drug|ADH -1 and docetaxel|
1773462|NCT00390676|Drug|ADH -1 and capecitabine|
1773463|NCT00390689|Drug|Pramipexole 0.125 mg tablet|
1773464|NCT00390689|Drug|Pramipexole 0.5 mg tablet|
1773465|NCT00390702|Device|transcatheter implantation of a VSD occluder (Nitinol coil)|transcatheter implantation, by first performing a arterial-venous loop through the defect
1773466|NCT00390715|Drug|chemotherapy|
1773467|NCT00390728|Drug|Insulin Glargine|
1773468|NCT00390741|Behavioral|Exercise Plus Program|Those assigned to the treatment group were visited by an exercise trainer three times a week for the first two months of the study, two times per week during months three and four, one time per week during months five and six, two times a month during months seven and eight, and one time a month during months nine through twelve. During months seven through twelve of the study the trainer contacted the participant by telephone once each week during the weeks that he or she did not go the participants' home.
1773469|NCT00390754|Behavioral|Education for pregnancy planning|Provision of free home pregnancy tests to women at risk for unintended pregnancy
1773470|NCT00390767|Biological|MultiGeneAngio|Escalating doses of MultiGeneAngio, one dose per patient administered as one treatment, infused intra-arterially
1773471|NCT00390780|Drug|miconazole Lauriad|50 mg buccal tablet once a day for 14 days
1773472|NCT00390780|Drug|Clotrimazole|10mg troches administered Five Times a Day for 14 days
1773473|NCT00390793|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2 & 3
1773474|NCT00390793|Drug|Vincristine|2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days
1773475|NCT00390793|Drug|Doxorubicin|50 mg/m^2 IV over 24 hours on day 4
1773476|NCT00390793|Drug|Dexamethasone|40 mg IV or by mouth days 1-4 +/- 2 days and days 11-14 +/- 2 days
1773477|NCT00390793|Drug|Dasatinib|100 mg by mouth (PO) daily on days 1-14; 70 mg PO daily continuously for Course 2 - 8.
1773478|NCT00390793|Drug|Methotrexate|200 mg/m^2 over 2 hours followed by 800 mg/m^2 over 22 hours on day 1.
1773479|NCT00390793|Drug|Ara-C|3 g/m^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
1773480|NCT00390806|Drug|HYCAMTIN, oral capsules|topotecan oral capsules 1.1 mg/m2
1773481|NCT00390806|Radiation|Radiation|Whole brain radiation
1773482|NCT00390832|Drug|Erythropoietin|33.333 IU of recombinant human erythropoietin beta are given at 3 time points (immediately, 24 hours and 48 hours after percutaneous coronary intervention) providing a cumulative dose of 100.000 IU
1773483|NCT00390832|Other|Placebo|Patients will receive placebo immediately, 24 hours and 48 hours after percutaneous coronary intervention.
1956938|NCT02626455|Drug|Vincristine|Vincristine is administered as an infusion at a dose of 1.4 mg/m2 body surface (maximum dose 2.0 mg) on Day 2 of each 21-day cycle for patients assigned to R-CHOP
1956939|NCT02626455|Drug|Bendamustine|Bendamustine is administered as an infusion at a dose of 90 mg/m2 body surface on Day 1 and Day 2 for patients assigned to R-B
1773486|NCT00390858|Drug|Deferasirox|Deferasirox in children from 1 to 18 years old was given orally once daily, 30 minutes prior to breakfast. An initial daily dose of 10 mg/kg was used during the 1-year core study. In this 4-year extension study dose modifications of ± 5 or 10 mg/kg were based on safety parameters and on increasing or decreasing Liver Iron Concentration (LIC), and serum ferritin. Deferasirox was available as 125 mg, 250 mg and 500 mg tablets.
1773489|NCT00390884|Biological|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
1773490|NCT00390884|Biological|Influenza Virus Vaccine, Fluzone®|0.25 mL, Intramuscular
1773491|NCT00390897|Drug|Glivec|
1773492|NCT00390897|Drug|Interferon|
1773495|NCT00390923|Drug|Selegiline + nicotine replacement therapy|Participants will begin selegiline once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
1773496|NCT00390923|Drug|placebo + nicotine replacement therapy|Participants will begin placebo once a day during Week 1, and dose will be graduated to full study dosage (10 mg/day) by adding an evening intake (a.m. and p.m. dosing) for Weeks 2-8. Day 15 of the trial represents target quit day and the transdermal nicotine patch (21 mg/24hr) will be applied at this time. Patches will be worn in conjunction with study medication for Weeks 3-8, after which the patch will be removed and study medication tapered throughout Week 9.
1773497|NCT00390936|Drug|Brivanib|Tablet, Oral, Brivanib 300 mg, 600 mg, 800 mg, 1000 mg, once daily (cycle 1: Day 1, Day 8 - 35), more than 5 weeks depending on response/toxicity
1773498|NCT00390949|Behavioral|Peer education among commercial sex workers and clients|
1773499|NCT00390949|Behavioral|Condom distribution and promotion|
1773500|NCT00390949|Procedure|Syndromic treatment of sexually transmitted infections|
1773501|NCT00390949|Procedure|Systemic counselling for STI patients|
1773502|NCT00390975|Drug|Tegaserod|
1773503|NCT00390988|Procedure|blood sampling|
1773504|NCT00391001|Drug|Taurine|double-blind, placebo-controlled, adjunctive medication
1773505|NCT00391014|Drug|liposomal Amphotericine B|"AML patients in induction chemotherapy treatment will received prophylaxis with nebulized liposomal amphotericin B (24 mg/week). It will be maintained during the intensification chemotherapy and in periods between cycles.
If patient required ALO-TPH, the prophylaxis should be followed."
1773506|NCT00391027|Drug|Insulin Glargine (Lantus®)|Patient will be randomized to Lantus® while remaining on pre-study oral hypoglycemic agents.
1773507|NCT00391027|Drug|Inhaled Human Insulin (Exubera®)|Patient will be randomized inhaled insulin while remaining on pre-study oral hypoglycemic agents.
1773508|NCT00391040|Behavioral|SGS education|
1773509|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
1773510|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
1773511|NCT00391053|Biological|High-Dose Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
1773512|NCT00391053|Biological|Inactivated, Split-Virion Influenza Vaccine|0.5 mL, IM
1773513|NCT00391066|Drug|FCR + Lumiliximab|Dose, schedule, and duration specified in the protocol
1773514|NCT00391066|Drug|FCR|Dose, schedule, and duration specified in protocol
1773515|NCT00391079|Drug|Sativex|"Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml, as extracts of Cannabis sativa L.
Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays (THC 32.5 mg: CBD 30 mg."
1773516|NCT00391079|Drug|Placebo|Containing colourants and excipients. Delivered in 100 µl actuations by a pump action oromucosal spray. Maximum dose within any 24-hour interval 12 sprays.
1773517|NCT00391092|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
1773518|NCT00391092|Drug|Docetaxel|100mg/m2 iv every 3 weeks
1773519|NCT00391092|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv every 3 weeks
1773520|NCT00391105|Drug|Remifentanil|
1773521|NCT00391118|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, six 21 day cycles or up to 3 years
1773522|NCT00391118|Drug|carboplatin|AUC 5, IV, q 21 days, six 21 day cycles
1773523|NCT00391118|Drug|paclitaxel|175 mg/m2, IV, q 21 days, six 21 day cycles
1773524|NCT00391118|Drug|placebo|oral, daily
1773525|NCT00391131|Drug|IgNextGen 16%|IgNextGen 16% administered subcutaneously on a weekly basis from visit 1 to 12
1773527|NCT00391157|Drug|Velcade/Dexamethasone|Velcade 1,3 mg/m2 on days 1, 4, 8 and 11
1773530|NCT00391183|Procedure|Biliary stenting|ERCP and stenting
1773531|NCT00391196|Drug|Placebo|Subjects receive placebo plus non-pharmacological weight loss program.
1773532|NCT00391196|Drug|CP-945,598|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
1773533|NCT00391196|Drug|CP-945,598 Treatment B|Subjects receive CP-945,598 plus non-pharmacological weight loss program.
1773534|NCT00391209|Drug|simplified diabetes regimen starting with a fixed dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,6 months
1773535|NCT00391209|Drug|intensive diabetes management starting with an adjusted dose of Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 6 months
1773536|NCT00391222|Drug|Olanzapine|Intramuscular injections of placebo every 2 weeks and oral olanzapine 10 mg daily
1773537|NCT00391222|Drug|Placebo|Intramuscular injections of placebo every 2 weeks and oral placebo daily
1773538|NCT00391222|Drug|Risperidone Long Acting Injectable (LAI)|Intramuscular injections of risperidone LAI (25, 37.5, or 50 mg) every 2 weeks and oral placebo daily
1773539|NCT00391248|Drug|Erlotinib|150 mg in a single daily dose, starting Day 1 through Day 22
1773540|NCT00391261|Drug|Metformin|open-label, flexible dosing
1773541|NCT00391274|Drug|pemetrexed|500 mg/m2, intravenous (IV) every 21 days until disease progression, death or 12 months after enrollment
1773542|NCT00391274|Drug|docetaxel|75 mg/m2, intravenous (IV), every 21 days until disease progression, death or 12 months after enrollment
1773543|NCT00391300|Procedure|bioelectric field imaging|
1773544|NCT00391300|Procedure|biopsy|
1773545|NCT00391300|Procedure|histopathologic examination|
1773546|NCT00391313|Drug|Chloroquine|
1773547|NCT00380822|Drug|miglitol|
1773548|NCT00380835|Drug|Amrubicin|
1773549|NCT00380848|Procedure|Hemodiafiltration|
1773550|NCT00380861|Device|Total knee replacement using the PFC Sigma RPF knee implant.|Total knee replacement
1773551|NCT00380861|Device|Total knee replacement using the PFC Sigma RP knee implant|Total knee replacement
1773552|NCT00380874|Drug|Pregabalin|150- 600 mg/day (double blind in divided doses)
1773553|NCT00380874|Drug|Placebo|Placebo
1773554|NCT00380887|Drug|Premarin|
1773555|NCT00380900|Drug|AGG-523|
1773556|NCT00380913|Drug|Cesamet™ (nabilone)|
1773557|NCT00380926|Drug|polyunsatturated fatty acids (fish oil)|
1773558|NCT00380939|Drug|Atorvastatin|
1773559|NCT00380939|Drug|Pravastatin|
1773560|NCT00380952|Device|Dune Device|
1773561|NCT00380965|Drug|Cesamet™ (nabilone)|
1773562|NCT00380978|Procedure|combined spinal epidural analgesia|Analgesia was initiated in the early group using a standard needle-through-needle technique with intrathecal fentanyl 25 mcg and an epidural test dose of lidocaine 15 mg/ml and epinephrine 5 mcg/ml in 3ml. At the second analgesia request, the cervix was examined. Epidural analgesia was initiated with a dilute bupivicaine/fentanyl solution if the cervix was less than 4 cm. If the cervix was 4 cm or more, epidural analgesia was initiated with bupivicaine 1.25 mg/ml. If no cervical exam was performed at the second request for analgesia, the cervix was assumed to be at least 4 cm dilated. Thereafter, analgesia was maintained in all participants in the early group with patient-controlled epidural analgesia.
1773563|NCT00380978|Procedure|late analgesia (systemic)|Analgesia was initiated in the late group with hydromorphone 1mg intramuscularly (IM) and 1 mg intravenously (IV). If the cervix was less than 4 cm at the second analgesia request, hydromorphone analgesia was repeated. Epidural analgesia was initiated with bupivicaine 1.25 mg/ml if the cervix was 4 cm or more. At the third analgesia request, epidural analgesia was initiated regardless of cervical dilation. Thereafter, epidural analgesia was maintained with patient controlled analgesia until delivery.
1773564|NCT00380991|Drug|lactoserum|
1773565|NCT00381004|Drug|Cyclophosphamide|Course 1: 250 mg/m^2 by vein over 5-30 minutes on Days 2, 3, and 4; Course 2 - 6: 250 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
1773566|NCT00381004|Drug|Fludarabine|Course 1: 25 mg/m^2 by vein over 5-30 minutes on Days 2,3, and 4; Course 2 - 6: 25 mg/m^2 by vein over 5-30 minutes on Days 1 - 3
1773567|NCT00381004|Drug|Sargramostim|Course 1: 250 mcg/m^2 subcutaneous (SQ) on Days -1 and Days 5 - 11; Course 2 - 6: 250 mcg/m^2 SQ on Days -1 and Days 4 - 10
1773568|NCT00381004|Drug|Rituximab|Course 1: 375 mg/m^2 by vein over 2-6 Hours on Day 1; Course 2 - 6: 500 mg/m^2 by vein over 2-6 Hours on Day 1
1773569|NCT00381017|Drug|Peg interferon alpha-2b|
1773570|NCT00381030|Drug|carvedilol plus nurse management|
1773571|NCT00381043|Drug|Acamprosate (Campral)|The study is a double-blind, randomized, placebo-controlled clinical trial in which participants will receive 333 mg t.i.d. oral acamprosate or matching placebo for a 12-week period. Each participant will also receive brief behavioral intervention at each visit.
1773572|NCT00381056|Behavioral|Labor and Delivery Team Coordination Course|
1773573|NCT00381069|Behavioral|Family & Community Recreation Center Intervention|The two year intervention involves changing the environment and policies in community recreation centers to promote physical activity and healthy eating choices. The Recreation Specialist will meet with recreation center staff monthly to create action plans that work towards this goal. Family Health Coaches will be in contact with intervention families twice a month either through a phone consultation, workshop at the recreation center,or home visit. Intervention families will receive a monthly mailing highlighting tips for healthy eating and physical activity. MOVE families will be encouraged to utilize the recreation center as a resource in supporting their child's physical activity and healthy eating behaviors.
1773574|NCT00381082|Drug|1) MOOV Head Lice Treatment (Ego Pharmaceutical).|
1773575|NCT00381082|Drug|Banlice Mousse Aerosol (Pfizer, Australia)|
1773576|NCT00381082|Drug|3) KP24 Medicated Foam (Nelson Laboratories)|
1773577|NCT00381095|Drug|Pregabalin|Capsule, Flexible-dosing, Double-blind. Treatment duration is 28 days at 100-600 mg/day administered BID+ taper (6 days).
1773578|NCT00381095|Drug|Placebo|Placebo
1956940|NCT02626455|Drug|Prednisone|Prednisone is given as 100 mg tablets daily from Day 2 to Day 6 for patients assigned to R-CHOP
1773581|NCT00381134|Drug|losartan 100 mg orally once daily|
1773582|NCT00381134|Drug|spironolactone 25 mg orally once daily|
1773583|NCT00381134|Drug|placebo once orally once daily|
1773584|NCT00381147|Drug|Clarithromycin|
1773585|NCT00381160|Behavioral|Reduction of sugar-sweetened beverage consumption|Multi-component intervention aimed at reducing sugar-sweetened beverage consumption. Components include delivery of non-caloric beverages to home in combination with behavioral modification (telephone counseling with parent; check in visit with participant).
1773586|NCT00381173|Drug|Cyclophosphamide & ZYC300 (ZYC300 with cyclophosphamide pre-dosing)|Patients who meet all entry criteria will be administered 600 mg/m^2 cyclophosphamide intravenously 3 days before each dose of ZYC300. ZYC300 will be administered at 400 micrograms DNA/total dose every two weeks for a maximum of six doses (6 cycles).
1773587|NCT00381186|Behavioral|diet- and exercise intervention|
1773588|NCT00381199|Drug|Amitriptyline Hydrochloride|
1773589|NCT00381199|Drug|Nabilone|
1773590|NCT00381212|Biological|AGS-004|Four intradermal injections of AGS-004-001 immunotherapeutic, 4 weeks apart.
1773591|NCT00381225|Procedure|Ultra-sound guided radio-frequency ablation|
1773592|NCT00381238|Drug|rosiglitazone|Extended Release Tablets
1773593|NCT00381251|Drug|Formulations A and B of Premarin/MPA 0.45 mg/0.5 mg and PREMPRO0.45 mg/0.5 mg|
1773594|NCT00381264|Drug|Cesamet™ (nabilone)|
1773595|NCT00381277|Drug|Gatorade|
1773596|NCT00381277|Drug|Performance|
1773597|NCT00381290|Behavioral|Diet|The prescribed diet will include traditional healthy food and up to two meal replacement supplements. Initially, the diet will be set to result in an overall loss of 800 to 1000 calories per day.
1773598|NCT00381290|Behavioral|Exercise|The program will consist of 60-minute exercise sessions per week for the duration of the study. The exercise sessions will incorporate aerobic exercise and resistance training. Participants will also be encouraged to exercise at home.
1773599|NCT00381303|Drug|darunavir|600mg bid for 48 wks
1773600|NCT00381303|Drug|ritonavir|100mg bid for 48 wks
1773601|NCT00381732|Drug|tadalafil|2.5 mg or 5 mg tadalafil tablet taken by mouth once a day for 24 weeks. Followed by an open label extension where all patients receive 5 mg doses.
1773602|NCT00381732|Drug|placebo|Placebo tablet taken by mouth once a day for 24 weeks. Placebo patient will receive 5 mg tadalafil tablet during the open label extension.
1773603|NCT00381758|Drug|Methylphenidate Extended Release Capsules|
1773604|NCT00381771|Behavioral|Conservative management for xerostomia|Active hydration (drinking more than 10 cups of water per day), Humidification, Oral gargle with a diluted (0.05% to 0.1%) chlorhexidine solution, Sugarless chewing gum, Saliva-stimulating sour juice (sugarless orange juice), Commercial artificial saliva, Nasal saline spray 3 to 4 times a day, Warm massage of the 4 major salivary glands.
1773605|NCT00381784|Behavioral|Printed materials|"Role model stories comprise the heart of printed materials distributed throughout the target community. The role model stories are brief publications that depict personal accounts from individuals in the population of focus who have made or are planning to make a risk-reducing behavioral change. Depending on the population they are meant to reach and what behavior they are trying to influence, the stories may include examples of people who now carry condoms with them, talked to a partner about condom use, use condoms consistently, avoid sharing needles, or exhibited other risk reduction behaviors."
1773606|NCT00381784|Behavioral|Peer advocates|"Core Element 1 Core group of young gay men and additional volunteers recruited from the community. The core group and volunteers comprise the peer advocates who design and carry out all program activities.
Core Element 2 Designated space where most social events and meetings are held; also serves as a drop in center where young men can meet and socialize during specified hours.
Core Element 3 Social events to attract young gay men and to promote safer sex. Core Element 4 Teams of young gay men go to locations frequented by young gay men to discuss and promote safer sex, deliver appealing informational literature on HIV risk reduction and distribute condoms.
Core Element 5 Meetings of eight to 10 young gay men to discuss factors contributing to unsafe sex among men. Men practice safer sex negotiation and correct condom use skills.
Core Element 6 Publicity campaigns that attract men to the program by word of mouth and through articles and advertisements in gay newspapers."
1773691|NCT00382252|Procedure|radiofrequency ablation|
1773610|NCT00381810|Drug|Rituximab|Rituximab will be supplied as a liquid for intravenous infusion.
1773611|NCT00381810|Drug|Methylprednisolone|
1773612|NCT00381810|Drug|Acetaminophen|
1773613|NCT00381810|Drug|Diphenhydramine|
1773614|NCT00381823|Behavioral|Cognitive Behavioral Therapy|
1773615|NCT00381836|Drug|Darbepoetin Alfa|
1773616|NCT00381849|Drug|Cystone|"Participants will take 2 pills, 2 times a day.
Each tablet of Cystone contains:
Shilapushpha (Didymocarpus pedicellata) 130 mg, Pasanabheda (Saxifraga ligulata Syn. Bergenia ligulata/cilata) 98 mg, Indian madder/ Manjishtha (Rubia cordifolia) 32 mg, Umbrella's edge/ Nagarmusta (Cyperus scariosus) 32 mg, Prickly chaff flower/ Apamarga (Achyranthes aspera) 32 mg, Sedge/ Gojiha (Onosma bracteatum) 32 mg, Purple fleabane/ Sahadeve (Veronoia Cinerea) 32 mg, Lime silicate calx/ Hajrul yahood Bhasma/ Badrashma bhasma) 32 mg, Shilajit 26 mg."
1773617|NCT00381849|Drug|Sugar Pill (Placebo)|Participants will take 2 pills, 2 times a day for 6 weeks.
1773618|NCT00381862|Drug|aprepitant|Aprepitant 125 mg by mouth (PO) on day 1 and 80 mg PO on days 2 and 3 of each chemotherapy cycle
1773619|NCT00381862|Drug|dexamethasone|Dexamethasone 12 mg PO on 1st day of study drug and 8 mg PO on days 2-4
1773620|NCT00381862|Drug|fluorouracil|as per institutional standard of care
1773621|NCT00381862|Drug|irinotecan hydrochloride|as per institutional standard of care
1773622|NCT00381862|Drug|leucovorin calcium|as per institutional standard of care
1773623|NCT00381862|Drug|oxaliplatin|as per institutional standard of care
1773624|NCT00381862|Drug|palonosetron hydrochloride|Palonosetron 0.25 mg IV push on day 1 only.
1773625|NCT00381862|Procedure|quality-of-life assessment|baseline
1773626|NCT00381875|Biological|E1M184V peptide vaccine|
1773627|NCT00381875|Biological|incomplete Freund's adjuvant|
1773628|NCT00381875|Biological|sargramostim|
1773629|NCT00381875|Other|immunoenzyme technique|
1773630|NCT00381888|Drug|fondaparinux sodium|Fondaparinux, 2.5 mg subcutaneous, Days 1-28 by mouth.
1773631|NCT00381901|Biological|trastuzumab|
1773632|NCT00381901|Genetic|polymorphism analysis|
1773633|NCT00381901|Procedure|adjuvant therapy|
1773634|NCT00381914|Drug|Vitamin D|400 IU vitamin D / day
1773635|NCT00381914|Drug|Vitamin D|800 IU vitamin D / day
1773636|NCT00381914|Drug|Vitamin D|1200 IU vitamin D / day
1773637|NCT00381927|Behavioral|Physician Counseling|
1773638|NCT00381940|Drug|ifosfamide|Given IV
1773639|NCT00381940|Drug|bortezomib|Given IV
1773640|NCT00381940|Drug|vinorelbine tartrate|Given IV
1773641|NCT00381940|Biological|filgrastim|Given IV or SC
1773642|NCT00381953|Drug|Peginterferon alfa-2a|
1773643|NCT00381953|Drug|Interferon alfa-2a|
1773644|NCT00381953|Drug|Ribavirin|
1773645|NCT00381966|Device|robotic placement device|this device is a robotic arm that utilizes a template as a guidance system to precisely inplant radioactive brachytherapy seeds directly to the prostate.
1773646|NCT00381979|Other|Supportive Expressive Therapy|
1773647|NCT00382018|Drug|chemotherapy|No administration details available
1773648|NCT00382031|Drug|Zalutumumab|Individual dose titration weekly i.v doses
1773649|NCT00382031|Other|Control|Best Supportive Care
1773650|NCT00382044|Drug|Eprex; Neorecormon; Aranesp|
1773651|NCT00382057|Drug|Testosterone|
1773652|NCT00382057|Drug|Anastrozole|
1773653|NCT00382057|Drug|Goserelin|
1773654|NCT00382070|Drug|Letrozole|Letrozole 2.5 mg taken orally once daily for 5 years
1773655|NCT00382070|Other|Placebo|Placebo tablet taken orally once daily for 5 years
1773656|NCT00382083|Drug|1000 mg acetaminophen|
1773657|NCT00382083|Drug|800 mg ibuprofen|
1773658|NCT00382083|Drug|1 oz 4% lidocaine gel|
1773659|NCT00382096|Drug|Vildagliptin|
1773660|NCT00382096|Drug|Metformin|
1773661|NCT00382096|Drug|Vildagliptin + Metformin|
1773662|NCT00382109|Drug|thiotepa|Given IV
1773663|NCT00382109|Drug|cyclophosphamide|Given IV
1773664|NCT00382109|Drug|tacrolimus|Given IV or orally
1773665|NCT00382109|Drug|methotrexate|Given IV
1773666|NCT00382109|Drug|sirolimus|Given orally
1773667|NCT00382109|Radiation|total body irradiation|Part of the transplant preparatory regimen
1773668|NCT00382135|Drug|tadalafil|20mg tadalafil tablet taken by mouth once a day for 40 weeks
1773669|NCT00382135|Drug|placebo|Placebo tablet taken by mouth once a day for 40 weeks
1773670|NCT00382148|Drug|omalizumab|SC repeating dose
1773671|NCT00382161|Drug|Fluvastatin-sodium|
1773672|NCT00382174|Drug|Placebo|Topical administration of 0.00% thymosin beta 4 qd up to 84 days
1773673|NCT00382174|Drug|Thymosin Beta 4|Topical Administration of 0.01, 0.02, and 0.1% thymosin beta 4 gel qd for up to 84 days
1773674|NCT00382187|Biological|MF59 adjuvanted H5N1 influenza vaccine|"MF59 adjuvanted (H5N1) influenza vaccine (Vietnam strain) containing 7.5 mg or 15 mg of H5N1
non-adjuvanted influenza vaccine containing 15 ug of H5N1"
1773675|NCT00382200|Drug|decitabine|
1773676|NCT00382200|Drug|tretinoin|
1773677|NCT00382200|Genetic|DNA methylation analysis|
1773678|NCT00382200|Genetic|cytogenetic analysis|
1773679|NCT00382200|Genetic|microarray analysis|
1773680|NCT00382200|Other|flow cytometry|
1773681|NCT00382200|Other|immunohistochemistry staining method|
1773682|NCT00382213|Drug|Olmesartan medoxomil|
1773683|NCT00382213|Drug|Placebo|
1773684|NCT00382226|Drug|Azopt|
1773685|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 10 mcg for 8 weeks
1773686|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 5 mcg for 4 weeks, then 5 mcg for 8 weeks
1773687|NCT00382239|Drug|exenatide (LY2148568)|subcutaneous injection twice daily, 2.5 mcg for 4 weeks, then 2.5 mcg for 8 weeks
1773688|NCT00382239|Drug|Placebo|subcutaneous injection twice daily, 0.02 mL to 0.04 mL
1773689|NCT00382252|Procedure|computed tomography|
1773690|NCT00382252|Procedure|positron emission tomography|
1773692|NCT00382265|Drug|tamsulosin|tamsulosin 0.4mg po qd for 28 days
1773693|NCT00382278|Procedure|Autologous bone marrow-derived mononuclear cells infusion|Under local anesthesia, 100 mL of bone marrow were aspirated from the posterior iliac crest. ABMMC were isolated by density gradient centrifugation in Ficoll-Hypaque gradient, 10% of the cells were labeled with SnCl2-99mTc, and a small fraction was used for cell counting and viability analysis. At least 100 millions of mononuclear-enriched BMC suspended in 20 mL of saline were delivered preferentially in the common hepatic artery by celiac trunk catheterism.
1773694|NCT00382291|Drug|Regular Titration|Sertraline will be administered in standard dosing. Treatment with sertraline will last 18 weeks.
1773695|NCT00382291|Drug|Placebo|The placebo will be administered in the same manner as sertraline. Treatment with placebo will last 18 weeks.
1773696|NCT00382291|Drug|Slow Titration|Sertraline will be administered in slow titration. Treatment with sertraline will last 18 weeks.
1773697|NCT00382304|Drug|tolevamer potassium-sodium (GT267-004)|
1773698|NCT00382317|Drug|Iobitridol|
1773699|NCT00382330|Drug|Ciclopirox|
1773700|NCT00382343|Drug|Sulfamethoxazole/trimethoprim|Sulfamethoxazole/trimethoprim prophylaxis
1773701|NCT00382356|Drug|Dutasteride|once daily dosing of 0.5mg Dutasteride for 12 months
1773702|NCT00382382|Other|diffusion tensor imaging (DTI)|Both groups will have a diffusion tensor imaging (DTI) perform.
1773703|NCT00382395|Device|SOLX Gold Shunt GMS-plus|Single use implant
1773704|NCT00382395|Device|Ahmed FP7 Glaucoma Valve|Single use implant
1773705|NCT00382408|Biological|DR-5001|All randomized subjects received a single tablet of both Type-4 and Type-7 ADV vaccines on Day 0. Both vaccine tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
1773706|NCT00382408|Other|Placebo|All randomized subjects received a single tablet each of the placebos matching Type-4 and Type-7 ADV vaccines on Day 0. Both placebo tablets were administered orally, kept in the mouth as briefly as possible and swallowed whole with water. Chewing the tablets was not permitted.
1773707|NCT00382421|Drug|bisoprolol|
1773708|NCT00382421|Drug|amlodipine|
1773709|NCT00382421|Drug|molsidomine|
1773710|NCT00382421|Drug|acetylsalicylic acid|
1773711|NCT00382434|Procedure|presence of an emergency pharmacist in the ED|
1773712|NCT00382447|Device|standard nebulizer|Standard small volume nebulizer for aerosolized medication delivery
1773713|NCT00382447|Device|breath actuated nebulizer|Nebulizer that dispenses medication only during the inspiratory phase
1773714|NCT00382460|Drug|PRAVASTATIN SODIUM|
1773715|NCT00382473|Behavioral|Aerobic exercise program - 8 weeks|No drugs. Regular aerobic exercise in structured prescription format
1773716|NCT00382486|Procedure|Reduce the risk of allograft rejection|
1773717|NCT00382499|Drug|Lidocaine Intravenous Infusion|1.5 mg/kg IV bolus on induction, 3 mg/kg/hr infusion from inducation until fascia closure
1773718|NCT00382512|Drug|Raptiva (efalizumab)|
1773719|NCT00382525|Device|Cardiac Rhythm Management device|
1773720|NCT00382538|Drug|Addition of mifepristone 200 mg 24 hours before induction|
1773721|NCT00382551|Behavioral|Moderate daily consumption of Red wine|
1773722|NCT00382551|Behavioral|Moderate daily consumption of beer|
1773723|NCT00382551|Behavioral|Moderate consumption of fruit juice rich in polyphenolics|
1773724|NCT00382577|Drug|Itopride|
1773725|NCT00382577|Drug|Placebo|
1773726|NCT00382590|Drug|5-Azacytidine|75 mg/m^2 daily for 7 days (days 1-7) via subcutaneous injection.
1773727|NCT00382590|Drug|Ara-C|20 mg twice daily via subcutaneous injection for 10 days.
1773728|NCT00382590|Drug|Valproic Acid (VPA)|50 mg/m^2 orally daily days 1-7.
1773729|NCT00382603|Device|OptiFree Multi-Purpose Disinfecting Solution|
1773730|NCT00382616|Drug|Phosphatidylserine-Omega3|
1773731|NCT00382629|Drug|BHT-3009 0.5 mg|
1773732|NCT00382629|Drug|BHT-3009 1.5 mg|
1773733|NCT00382629|Drug|Placebo|
1773734|NCT00382642|Drug|Ondansetron + Cognitive Behavioral Therapy|13 week outpatient trial
1773735|NCT00382642|Drug|Placebo + Cognitive Behavioral Therapy|13 week outpatient trial
1773736|NCT00382655|Procedure|Education and referral|
1773737|NCT00382668|Drug|Dasatinib|Tablets, Oral, 50 mg, once daily, for one day
1773738|NCT00382668|Drug|Dasatinib|Tablets, Oral, 20 mg, once daily for one day
1773739|NCT00382668|Drug|Dasatinib|Tablets, Oral, 70 mg, once daily for one day
1773740|NCT00382681|Device|FID 107027 Multi-Purpose Disinfecting Solution|Investigational, multi-purpose disinfecting solution intended for use in cleaning, rinsing, conditioning, disinfecting, and storing soft contact lenses.
1773741|NCT00382681|Device|ReNu MultiPlus Multi-Purpose Solution No Rub Formula|Commercially marketed product indicated for cleaning, rinsing, disinfecting, and storing soft contact lenses.
1773742|NCT00382694|Drug|Fludarabine|
1773743|NCT00382707|Device|cortical magnetic stimulation provided by an eight-shaped coïl placed upon the skull.|
1773744|NCT00382720|Drug|Docetaxel + Oxaliplatin|"Dose level 1 (non-optimal dose):
Docetaxel 75 mg/m² as an 1-hour intravenous (IV) infusion on day 1 followed by Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1
Dose level 2 (optimal dose):
Docetaxel 75 mg/m² as an 1-hour IV infusion on day 1 followed by Oxaliplatin 130 mg/m² as a two to six-hour IV infusion on day 1"
1773745|NCT00382720|Drug|Docetaxel + Oxaliplatin + 5-FU|"Dose level 1 (non-optimal dose):
Docetaxel 40 mg/m² as a 1-hour intravenous (IV) infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m2 as a 46-hour continuous infusion day 1.
Dose level 2 (optimal dose):
Docetaxel 50 mg/m² as a 1-hour IV infusion day 1; Oxaliplatin 85 mg/m² simultaneously with folinic acid 400 mg/m² as a 2-hour IV infusion, followed by 5-FU 2400 mg/m² as a 46-hour continuous infusion day 1."
1773746|NCT00382720|Drug|Docetaxel + Oxaliplatin + Capecitabine|"Dose level 1 (optimal dose):
Docetaxel 50 mg/m² as a 1-hour intravenous (IV) infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m2 two times a day continuously.
Dose level 2 (non-optimal dose):
Docetaxel 65 mg/m² as a 1-hour IV infusion on day 1, Oxaliplatin 100 mg/m² as a two to six-hour IV infusion on day 1, Capecitabine 625 mg/m² two times a day continuously."
1773747|NCT00382733|Drug|Oral Topotecan|Topotecan will be received in one of the five dose levels:0.25mg/day,0.5mg/day, 0.75mg/day, 1.0mg/day, and 1.25mg/day.
1773748|NCT00382746|Device|EarlySense monitoring device|
1773749|NCT00382759|Procedure|stem cell transplant|
1773750|NCT00382772|Biological|2-dose oral live attenuated G1P[8] human rotavirus vaccine|
1773751|NCT00382785|Behavioral|moderated support|one 12-week online support group led by a professional healthcare provider
1773752|NCT00382785|Behavioral|peer-led|12-week online support in a peer-led format
1773753|NCT00382798|Drug|RO5024048|
1773754|NCT00382811|Drug|phenoxodiol|400mg phenoxodiol three times daily in 28 day cycles.
1773755|NCT00382811|Drug|carboplatin|AUC=2 weekly in 28 day cycles
1773756|NCT00382811|Drug|placebo|every 8 hours daily in 28 day cycles
1773758|NCT00382837|Drug|Epratuzumab|
1773759|NCT00382850|Procedure|Nissen fundoplication|
1773760|NCT00382863|Device|HeartNet Ventricular Support System|The HeartNet Implant is placed on the epicardial surface of the heart surrounding both the left and right ventricles.
1773761|NCT00382863|Drug|Optimal Medical/Device Therapy|Optimal Medical/Device Therapy - For the purpose of the PEERLESS-HF study, optimal medical therapy is defined as the use of ACE inhibitors and Beta blockers in the highest tolerable doses for three months prior to study enrollment, and Optimal device therapy is defined as CRT or CRT-D for at least three months prior to study enrollment, when indicated.
1773762|NCT00382889|Drug|beclomethasone/salbutamol combination|
1773763|NCT00382889|Drug|beclomethasone|
1773764|NCT00382889|Drug|salbutamol|
1773765|NCT00382902|Device|OptiFree Multi-Purpose Disinfecting Solution|
1773766|NCT00382915|Device|CReSSmicro handheld topography device|The CReSS micro device represents the state-of-the-art technology for measurements of ambulatory puff topography taken in the smoker's natural environment. Although all topography measurements are limited, at least to some degree, by the artificial act of smoking while using a device, or smoking through a mouthpiece, this small, lightweight and portable device is easy to use outside of the laboratory setting to capture more naturalistic smoking behavior and allows for less intrusion from the research team and research environment.
1773767|NCT00382928|Device|Defibrillation of pulseless VT/VF by AECD|In case of cardiac arrest caused by shockable rhythms the automatic external cardioverter defibrillator (AECD) will automatically deliver defibrillation. Automated External Cardioverter Defibrillator (AECD; The PowerHeart CRM, Cardiac Science Inc., Seattle, WA) is a device attached to the chest wall by pads, monitors the electrocardiogram, and is capable of automatically delivering electric countershock to appropriate rhythms without operator intervention. The device will deliver only one shock of 150 Joules for pulseless ventricular tachycardia and ventricular fibrillation.
1773768|NCT00382941|Device|Red and near infrared LED phototherapy device|
1773769|NCT00382954|Drug|Velcade|velcade (4 original dosing levels with 3 modified dosing levels) I.V. on days 1, 4, 8, 11, 15, 18, 22, and 25 for 4 weeks concurrent with the Idarubicin
1773770|NCT00382954|Drug|Idarubicin|I.V., 8, or 10 or 12 mg/m^2 weekly (days 1, 8, 15, and 22) for 4 weeks
1773771|NCT00382967|Procedure|DaTSCAN SPECT imaging|A single intravenous injection of DaTSCAN with a total activity of 111-185 MBq (volume of 2.5 or 5.0 mL). SPECT scanning to be performed 3 to 6 hours after DaTSCAN injection.
1773772|NCT00382980|Biological|Aluminum hydroxide|Adjuvant administered with A/H5N1 vaccine dosages 7.5 mcg and 15 mcg.
1773773|NCT00382980|Biological|Inactivated Vero cell based whole virus influenza A/H5N1|Inactivated Vero cell-grown, whole virus, influenza A/H5N1 vaccine at dosages 7.5 mcg and 15 mcg of hemagglutinin (HA) per 0.5 mL, each dosage with and without aluminum hydroxide adjuvant; 45 mcg HA/0.5 mL without adjuvant.
1773774|NCT00382980|Drug|Placebo|Saline injected into the deltoid muscle. 2 identical dosages will be given approximately 28 days apart.
1773775|NCT00382993|Drug|Placebo|Matching placebo tablet
1773776|NCT00382993|Drug|Combination Product (sumatriptan succinate/naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in second layer.
1773777|NCT00383006|Behavioral|Skills for affect regulation (behavior)|
1773778|NCT00383019|Drug|Xalacom (KP2035)|
1773779|NCT00383019|Drug|Xalatan|
1773780|NCT00383032|Drug|mifepristone|
1773781|NCT00383045|Drug|Buprenorphine/Subutex|
1773782|NCT00383045|Drug|Naltrexone|
1773783|NCT00383045|Procedure|Drug counseling|
1773784|NCT00383058|Drug|the extract of green tea|
1773785|NCT00383071|Biological|H5N1 vaccine|Monovalent subvirion H5N1 vaccine (rgA/Vietnam/1203/2004) 90 mcg/mL Manufactured by Sanofi Pasteur Inc, Swiftwater, PA.
1773786|NCT00383071|Procedure|Apheresis|Once subjects achieved a high antibody titer (>1:160), they could begin apheresis to collect plasma.
1773787|NCT00383084|Behavioral|Lifestyle physical activity (LPA)|Bi-weekly, 60-minute group sessions spread over 12 weeks. Participants will receive education on how to increase their daily physical activity, goal setting, problem solving strategies to overcome barriers to being more physically active, and finding new ways to integrate short bouts of LPA into their daily lives.
1773788|NCT00383084|Behavioral|Fibromyalgia education|Participants will meet monthly for 1.5 to 2 hours for a total of 3 months. The sessions will be divided into three components: (1) education, (2) question and answer, and (3) social support.
1773789|NCT00383097|Genetic|LMP1 SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10^7 cells/m2, 1x 10^8 cells/m2, 3 x 10^8 cells/m2, 1 x 10^9 cells/m2
1773790|NCT00383097|Genetic|LMP2-SPECIFIC CYTOTOXIC T-LYMPHOCYTES|1 injection One of the following 4 dose levels: 2x 10^7 cells/m2, 1x 10^8 cells/m2, 3 x 10^8 cells/m2, 1 x 10^9 cells/m2
1773791|NCT00383123|Biological|Fluarix™|"Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children < 12 months.
*Only those subjects between the age of 6 months and < 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 & 1."
1773913|NCT00383786|Procedure|24-hour plasma sampling|
1773914|NCT00383786|Procedure|MRI|
1773915|NCT00383799|Drug|iv Amiodarone|
1773916|NCT00383799|Drug|iv Procainamide|
1773792|NCT00383123|Biological|Fluzone|"Subjects were administered 1 or 2 doses* intramuscularly, into the non-dominant upper arm for children > 12 months of age, in the anterolateral thigh for children < 12 months.
*Only those subjects between the age of 6 months and < 9 years, who had no history of prior influenza vaccination, received 2 doses at months 0 & 1."
1773793|NCT00383136|Drug|tirofiban high-bolus dose regimen|bolus of 25 mcg/kg of body weight, followed by 18 hours infusion of 0.15 mcg/kg/min.
1773794|NCT00383136|Drug|Abciximab|bolus of 0.25 mg/kg of body weight, followed by 12 hours infusion of 0.125 mcg/kg per minute
1773795|NCT00383149|Drug|Ixabepilone|Intravenous Infusion (IV), 32 mg/m^2 every 21 days.
1773796|NCT00383149|Drug|Cetuximab|Initial dose of 400 mg/m^2 intravenous (IV) over 2 hours) followed by a weekly lower dose of 250 mg/m^2 IV over 1 hour.
1773797|NCT00383162|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|Bilayer tablet containing 85mg sumatriptan (as 119mg sumatriptan succinate; fast disintegrating/rapid release formulation) active ingredient in one layer, and 500mg naproxen sodium active ingredient in the second layer.
1773798|NCT00383162|Drug|Placebo|Matching placebo tablet.
1773799|NCT00383175|Other|Autorefractor, standard clinical instrument|Autorefractor, standard clinical instrument was used to assess the children's focusing power at near.
1773800|NCT00383188|Drug|placebo|Capsule, once daily (QD) for 12 weeks
1773801|NCT00383188|Drug|PH-797804|Capsule, 0.5 mg of PH-797804, once daily (QD) for 12 weeks
1773802|NCT00383188|Drug|PH-797804|Capsule, 3 mg of PH-797804, once daily (QD) for 12 weeks
1773803|NCT00383188|Drug|PH-797804|Capsule, 6 mg of PH-797804, once daily (QD) for 12 weeks
1773804|NCT00383188|Drug|PH-797804|Capsule, 10 mg of PH-797804, once daily (QD) for 12 weeks
1773805|NCT00383201|Device|OptiFree Multi-Purpose Disinfecting Solution|
1773806|NCT00383214|Drug|Epratuzumab|360 mg/m2 or 720 mg/m2 delivered by slow intravenous infusion
1773807|NCT00383214|Other|Placebo|Intravenous
1773808|NCT00383227|Biological|Hepatitis B adjuvanted vaccine|
1773809|NCT00383240|Drug|mometasone furoate/formoterol fumarate combination MDI 200/10 mcg BID|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
1773810|NCT00383240|Drug|Mometasone furoate MDI (MF MDI) 200 mcg|MF 200 mcg via metered dose inhaler twice daily for 26 weeks
1773811|NCT00383240|Drug|formoterol fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
1773812|NCT00383240|Drug|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
1773813|NCT00383253|Behavioral|caloric restriction - 10%|Subjects maintained on 10% caloric restriction (caloric intake = 90% of baseline)
1773814|NCT00383253|Behavioral|caloric restriction - 25%|Subjects maintained on 25% caloric restriction (caloric intake = 75% of baseline)
1773815|NCT00383253|Behavioral|caloric restriction - 50%|Subjects maintained on 50% caloric restriction (caloric intake = 50% of baseline)
1773816|NCT00383253|Behavioral|caloric restriction - Control|Subjects maintained on their baseline caloric intake (caloric restriction = none)
1773817|NCT00383266|Drug|Pemetrexed|
1773818|NCT00383266|Drug|Carboplatin|
1773819|NCT00383279|Other|counseling intervention|
1773820|NCT00383279|Other|study of socioeconomic and demographic variables|
1773821|NCT00383292|Drug|LY573636|LY573636 dose is dependent on patient's height, weight, and gender and is adjusted to target a specific Cmax based on patient laboratory parameters. LY573636 is administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met.
1773822|NCT00383305|Device|Cool-Cap|
1773823|NCT00383318|Procedure|Gene mutation sample|
1773824|NCT00383331|Drug|Pemetrexed|"A: 500 mg/m2, intravenous (IV), every 21 days x 6 cycles
B: 500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
1773825|NCT00383331|Drug|Gemcitabine|"A: 1250 mg/m2, intravenous (IV) days 1 and 8, every 21 days x 6 cycles
B: 1500 mg/m2, intravenous (IV), every 14 days x 9 cycles"
1773826|NCT00383344|Procedure|FDG PET/CT|
1773827|NCT00383357|Drug|zolpidem|
1773828|NCT00383370|Drug|VEGF Trap|VEGF Trap formulation 1, ITV-1
1773829|NCT00383370|Biological|VEGF Trap|VEGF Trap formulation 2 at higher concentration in Open label cohort
1773830|NCT00383383|Biological|Hepatitis B adjuvanted vaccine|
1773831|NCT00383383|Biological|Engerix-B|
1773832|NCT00383396|Drug|Topical Cyclosporine|
1773833|NCT00383409|Drug|multivitamins|
1773834|NCT00383409|Drug|placebo|
1773835|NCT00383422|Drug|Arzoxifene|20 mg, oral, tablet, once a day for 52 weeks
1773836|NCT00383422|Drug|Raloxifene|60 mg, oral, tablet, once a day for 52 weeks
1773837|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
1773838|NCT00383435|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
1773839|NCT00383435|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
1773840|NCT00383435|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
1773841|NCT00383435|Drug|Placebo|Placebo MDI twice a day for 26 weeks
1956946|NCT02620046|Drug|Vedolizumab SC|Vedolizumab SC 108 mg injection QW
1773917|NCT00383812|Drug|Intravitreal Bevacizumab|
1773918|NCT00383825|Procedure|Anterior segment indocyanine green angiography|
1773919|NCT00383838|Behavioral|brief, voluntary substance use intervention|
1956948|NCT02617277|Drug|AZD1775|AZD1775 is available in capsules for oral administration.
1773850|NCT00383461|Behavioral|smoking cessation intervention|
1773851|NCT00383461|Other|counseling intervention|
1773852|NCT00383474|Drug|Bortezomib|Given IV
1773853|NCT00383474|Other|Laboratory Biomarker Analysis|Correlative studies
1773854|NCT00383474|Drug|Tipifarnib|Given orally
1773855|NCT00383487|Drug|Calcitriol|0.5 micrograms/kilogram q weekly
1773856|NCT00383487|Drug|Naproxen-n-butyl nitrate|400 mg BID, oral
1773857|NCT00383500|Device|Flexitouch|A standard of care intermittent pneumatic compression device (aka, lymphedema pump)
1773858|NCT00383500|Device|Class 1 compression garment|Manual lymphatic drainage therapy to provide lymphatic massage, using a Class 1 compression garment supporting the arm during heavy exercise or where the risk of trauma maybe increased (ie, flight, elevation, etc).
1773859|NCT00383513|Biological|Epratuzumab|360 mg/m^2 four consecutive 12-week maintenance cycles beginning with 2 consecutive weekly administrations each lasting ≤ 1 hour
1773860|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
1773861|NCT00383526|Biological|Inactivated, split-virion influenza vaccine|Vaccine
1773862|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 1
1773863|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 2
1773864|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Vaccine Lot 3
1773865|NCT00383539|Biological|Inactivated Split-virion influenza vaccine|Control Vaccine
1773866|NCT00383552|Drug|Mometasone Furoate/Formoterol Fumarate Combination MDI 100/10 mcg BID|MF/F 100/10 mcg via a metered dose inhaler (MDI) twice daily for 26 weeks
1773867|NCT00383552|Drug|Mometasone Furoate MDI (MF MDI)|MF 100 mcg via metered dose inhaler twice daily for 26 weeks
1773868|NCT00383552|Drug|Formoterol Fumarate 10 mcg|F via metered dose inhaler 10 mcg twice a day for 26 weeks
1773869|NCT00383552|Drug|Placebo|Placebo metered dose inhaler twice a day for 26 weeks
1773870|NCT00383565|Drug|romidepsin|Given IV
1773871|NCT00383578|Drug|Vildagliptin 100 mg qd|
1773872|NCT00383578|Drug|Metformin 1500 mg daily|
1773873|NCT00383591|Biological|Hepatitis B adjuvanted vaccine|
1773874|NCT00383591|Biological|Engerix-B|
1773875|NCT00383630|Biological|Intramyocardial injection of bone marrow mononuclear cells|6mL of bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
1773876|NCT00383630|Biological|Intramyocardial injection of CD34+ selected bone marrow mononuclear cells|6mL of CD34+ selected bone marrow mononuclear cells will be injected into the myocardium during LVAD implantation.
1773877|NCT00383630|Device|LVAD alone|LVAD implantation without any intramyocardial injection of bone marrow cells.
1773878|NCT00383643|Drug|zolpidem tartrate|
1773879|NCT00383643|Drug|sodium oxybate|
1773880|NCT00383643|Drug|Matching Placebos|
1773881|NCT00383656|Drug|GnRH|75 ng/kg GnRH IV
1773882|NCT00383656|Device|Pump|portable, infusion pump for GnRH
1773883|NCT00383669|Dietary Supplement|Multivitamins (including B, C and E)|One daily oral dose of 20 mg B1, 20 mg B2, 25 mg B6, 100 mg niacin, 50 μg B12, 0.8 mg folic acid, 500 mg C, and 30 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
1773884|NCT00383669|Dietary Supplement|Multivitamins B, C and E|One daily oral dose of 1.2 mg vitamin B1, 1.2 mg vitamin B2, 1.3 mg vitamin B6, 15 mg niacin, 2.4 μg vitamin B12, 0.4 mg folic acid, 80 mg vitamin C, and 15 mg vitamin E taken taken from randomization until the end of follow-up (24-28 months).
1773885|NCT00383682|Drug|morphine and mexiletine|
1773886|NCT00383695|Biological|cetuximab|
1773887|NCT00383695|Drug|capecitabine|
1773888|NCT00383695|Drug|oxaliplatin|
1773889|NCT00383695|Procedure|adjuvant therapy|
1773890|NCT00383695|Procedure|conventional surgery|
1773891|NCT00383695|Procedure|neoadjuvant therapy|
1773892|NCT00383695|Radiation|radiation therapy|
1956949|NCT02617277|Drug|MEDI4736|MEDI4736 will be administered by IV infusion.
1956950|NCT02616146|Drug|ENG-E2 125 μg/300 μg vaginal ring|Up to 13 cycles of ENG-E2 125 μg/300 μg administered intravaginally, each cycle consisting of 21 days of vaginal ring use followed by 7 vaginal ring-free days.
1773895|NCT00383721|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
1773896|NCT00383721|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks
1773897|NCT00383721|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 52 weeks
1773898|NCT00383721|Drug|Formoterol MDI|Formoterol 10 mcg via metered dose inhaler twice a day for 52 weeks
1773899|NCT00383721|Drug|Placebo|Placebo MDI twice a day for 26 weeks
1773900|NCT00383734|Device|Newfill|1 to 7 injections of drug
1773901|NCT00383734|Device|Eutrophill|1 to 7 injections of drug
1773902|NCT00383747|Drug|transdermal nicotine patch|14mg transdermal nicotine application
1773903|NCT00383747|Drug|Transdermal Nicotine Patch|14mg transdermal nicotine application
1773905|NCT00383773|Procedure|Retinal endo vascular surgery|
1773906|NCT00383786|Drug|NK1 Antagoist (GR205171)|
1773907|NCT00383786|Procedure|Psychophysiology (Trauma Script)|
1773908|NCT00383786|Procedure|Psychophysiology (Verbal Threat)|
1773909|NCT00383786|Procedure|Psychophysiology (Fear Conditioning)|
1773910|NCT00383786|Procedure|Psychophysiology (Affective Modulation)|
1773911|NCT00383786|Procedure|Psychophysiology (Heart rate variability)|
1773912|NCT00383786|Procedure|Lumbar Puncture|
1773922|NCT00383864|Drug|Pegylated interferon and ribavirin|
1773923|NCT00383877|Drug|insulin detemir|
1773924|NCT00383877|Drug|insulin NPH|
1773925|NCT00383890|Drug|Dexmedetomidine HCL Injection|
1773926|NCT00383890|Drug|Placebo|
1773927|NCT00383903|Biological|HRV vaccine|Two or three oral doses
1773928|NCT00383916|Drug|pantoprazole|
1773929|NCT00383929|Drug|Candesartan cilexetil|32mg oral
1773930|NCT00383929|Drug|Hydrochlorothiazide|12.5 mg oral
1773931|NCT00383929|Drug|Hydrochlorothiazide|25 mg oral
1773932|NCT00383942|Drug|Misoprostol|Misoprostol,25 micrograms every 4 hours.
1773933|NCT00383942|Device|Catheter|A catheter with extra amniotic saline infusion (EASI) is placed in the uterus and applies pressure to the cervix to cause it to ripen
1773934|NCT00383994|Drug|GM-CSF|250 micrograms subcutaneously 3 times a week for 4 weeks starting a day before the administration of Rituximab.
1773935|NCT00383994|Drug|Rituximab|375 mg/m^2 by vein followed by 1000 mg/m^2 weekly for 3 weeks for a total of 4 doses.
1773936|NCT00383994|Biological|NK Cell Infusion|NK cells will be infused one week after the fourth dose of Rituximab and GM-CSF.
1773937|NCT00384007|Procedure|Hydrodiscectomy with Spinejet|
1773938|NCT00384020|Drug|Paroxetine (Seroxat)|
1773939|NCT00384020|Drug|Escitalopram (Lexapro)|
1773940|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
1773941|NCT00384033|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|100 mg tablet, once daily dosing for 8 weeks
1773942|NCT00384033|Drug|Placebo|Matching placebo tablets and capsules, once daily dosing for 8 weeks
1773943|NCT00384033|Drug|Duloxetine 60 mg/day|60 mg capsule, once daily dosing for 8 weeks
1773944|NCT00384046|Drug|Testosterone|patch, 300 mcg/day testosterone, patch changed every 3-4 days, 24 weeks
1773945|NCT00384046|Drug|Placebo|patch, placebo, patch changed every 3-4 days, 24 weeks
1773946|NCT00384059|Biological|13-valent Pneumococcal Conjugate Vaccine|Single 0.5 mL dose given at 2, 3, 4, and 12 months of age
1773947|NCT00384059|Biological|7vPnC|Single 0.5 mL dose given at 2, 3, 4 and 12 months of age
1773948|NCT00384059|Biological|Pediacel|concommitant vaccine, both at arm 1 and at arm 2, at 2 months, 3 months and 4 months of age
1773949|NCT00384059|Biological|NeisVac-C|concomittant vaccine, both at arm 1 and at arm 2, at 2 months and 4 months of age
1773950|NCT00384059|Biological|Menitorix|concomitant vaccine, both at arm 1 and at arm 2, at 12 months of age
1773951|NCT00384072|Drug|bazedoxifene BZA-20|
1773952|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 1 injection per day
1773953|NCT00384085|Drug|Insulin Glargine|Subcutaneous injection once-a-day
1773954|NCT00384085|Drug|Premixed Insulin|Subcutaneous injection twice-a-day.
1773955|NCT00384085|Drug|Insulin Glulisine|Subcutaneous injection up to 3 injections per day.
1773956|NCT00384098|Drug|CTA018 cream|
1773959|NCT00384124|Drug|Imiquimod|Imiquimod application M-F for six weeks (total of 30 applications) followed by surgical excision of site
1773960|NCT00384137|Drug|Tacrolimus|Immunosuppression
1773961|NCT00384150|Drug|galiximab in combination with rituximab|galiximab (500 mg/m2 IV) in combination with rituximab (375 mg/m2 IV)once weekly for 4 weeks.
1773962|NCT00384176|Drug|Cediranib|oral tablet once daily
1773963|NCT00384176|Drug|Bevacizumab|intravenous infusion
1773964|NCT00384176|Drug|5-fluorouracil ( in FOLFOX)|intravenous infusion
1773965|NCT00384176|Drug|Leucovorin (in FOLFOX)|intravenous infusion
1773966|NCT00384176|Drug|Oxaliplatin (in FOLFOX)|intravenous infusion
1773967|NCT00384189|Drug|Ciclesonide|inhaled Ciclesonide
1773968|NCT00384189|Drug|Placebo|Ciclesonide placebo-matching inhaler
1773969|NCT00384189|Drug|Salbutamol|Salbutamol inhalation powder
1773970|NCT00384202|Drug|Tacrolimus|Immunosuppression
1773971|NCT00384215|Drug|insulin glargine [rDNA origin] injection|
1773972|NCT00391339|Drug|Bryophyllum p.|
1773973|NCT00391352|Drug|IFN-β-1a (Rebif®)|44 mcg Three times a week, subcutaneous injection
1773974|NCT00391365|Procedure|Gait analysis|Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.
1773975|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (infant dose)
1773976|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine|Vaccine (children dose)
1773977|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (infant dose)
1773978|NCT00391391|Biological|Split, Inactivated, Trivalent Influenza Vaccine ( Fluzone® 2006/2007 Formulation)|Vaccine (children dose)
1773979|NCT00391404|Drug|Alendronate|Alendronate 70 mg weekly (oral)
1773980|NCT00391404|Drug|Placebo|Placebo
1773981|NCT00391417|Drug|estradiol gel|
1773982|NCT00391430|Drug|Sertraline|Dosage: up to 100 mg/day; Frequency: once per day; Duration: 12 weeks
1773983|NCT00391430|Behavioral|Cognitive behavioral therapy (CBT)|CBT consists of sixteen 1-hour sessions during a period of 12 weeks.
1773984|NCT00391443|Drug|Bosentan|Bosentan 62.5 mg tablets twice daily (b.i.d.) for 4 weeks followed by bosentan 125 mg tablets b.i.d (if body weight > 40 kg) or bosentan 62.5 mg tablets b.i.d. (if body weight < 40 kg)
1773985|NCT00391443|Drug|Placebo|Placebo matching bosentan 62.5 mg tablets and 125 mg tablets
1773986|NCT00391456|Behavioral|Animal-assisted Therapy|
1774050|NCT00392509|Procedure|ALDH-br bone marrow cells vs. mononuclear bone marrow cells|Surgery
1774051|NCT00392522|Drug|50% Nitrous Oxide and 50% Oxygen (MEOPA)|
1773987|NCT00391469|Other|Rapid infusion of 2 liters of 4oC normal saline|Patients randomized to mild hypothermia will receive a rapid infusion of 2 liters of 4oC normal saline prior to arrival in the emergency room. Patients randomized to control will receive standard of care following resuscitation from cardiac arrest.
1773988|NCT00391469|Drug|Rapid infusion of cold normal saline|
1773989|NCT00391482|Behavioral|Peer Mentoring Intervention for HCV-Infected IDUs|
1773990|NCT00391495|Procedure|Blood drawing|
1773991|NCT00391521|Drug|AS703569|Regimen 1: 3 mg/m2 /day given orally on Days 1 and 8 during a 21-day cycle
1773992|NCT00391521|Drug|AS703569|Regimen 2: 2 mg/m2/day given orally on Days 1, 2, and 3 of a 21-day cycle
1773993|NCT00391521|Drug|AS703569|Regimen 3: 10 mg/m2/day given orally on Days 1, 2, 3 and Days 8, 9, 10 of a 21-day cycle
1773994|NCT00391534|Drug|modified release formulation of oxcarbazepine (OXC MR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC MR. Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
1773995|NCT00391534|Drug|immediate release formulation of oxcarbazepine (OXC IR)|Patients who are pre-treated with a total daily dose of exactly 900 or exactly 1200 mg or exactly 1500 mg oxcarbazepine (as OXC IR) will increase dosage of OXC by 300 mg to a daily dose of 1200 mg / 1500 mg / 1800 mg OXC IR (divided in two daily doses). Dosage will be titrated to a maximum tolerated total daily dose, maximally to 2700 mg in steps of 300 mg every 6th day.
1773996|NCT00391547|Drug|Frio Oral Rinse|
1773997|NCT00391560|Drug|perifosine|Perifosine Daily Dose
1773998|NCT00391573|Procedure|Polyglactin sutures for suturing of conjunctival autograft in pterygium surgery|
1773999|NCT00391573|Procedure|Nylon sutures for suturing of conjunctival autograft in pterygium surgery|
1774000|NCT00391586|Drug|Erlotinib|"Erlotinib will be administered for at least 2 cycles (6 weeks) and for a maximum of 8 months.
Upon progression or intolerance to erlotinib, standard of care platinum-based chemotherapy (per the choice of the treating physician) is administered every 3 weeks. Physicians can adjust dose, schedule, or supportive care to the benefit of the patient"
1774001|NCT00391586|Drug|Platinum-based chemotherapy|Intravenous chemotherapy combination per physician discretion every 3 weeks for at least 2 cycles
1774002|NCT00391599|Procedure|enema|
1774003|NCT00391612|Device|Exhale® Drug-Eluting Stent|Bronchoscopic procedure in which up to six Exhale Drug-Eluting Stents are placed in the lungs; total procedure time is 1 to 2 hours
1774004|NCT00391612|Device|Sham control|5-10 minute bronchoscopic procedure in which the lungs are examined and a bronchial lavage is performed; the bronchoscope is then retracted to a point above the carina and below the vocal folds for the remained of the time; total procedure time is about 1-2 hours
1774005|NCT00391625|Drug|GA-GCB|15-60 U/kg every other week via intravenous infusion
1774006|NCT00391638|Drug|TRUVADA (EMTRICITABINE + TENOFOVIR DF)|Truvada ® (200 mg tablet of 300 mg of emtricitabine + tenofovir DF) Dosage 1 tablet taken orally once a day
1774007|NCT00391638|Biological|PEGASYS 180μg (Interféron pégylé alpha -2a)|Pegasys ® injection 180μg Dosage: A subcutaneous injection per week
1774008|NCT00391651|Drug|Nitrofurantoin 100mg twice daily x 5 days|Nitrofurantoin 100mg twice daily x 5 days
1774009|NCT00391651|Drug|TMP/SMX DS twice daily x 3 days|TMP/SMX DS twice daily x 3 days
1774010|NCT00392288|Drug|Ciclesonide|Ciclesonide MDI 40 µg BID over twelve weeks
1774011|NCT00392288|Drug|Ciclesonide|Ciclesonide MDI 80 µg BID over twelve weeks
1774012|NCT00392288|Drug|Placebo|Placebo MDI over twelve weeks
1774013|NCT00392314|Other|PET/CT post 2 cycles of chemotherapy|sintigraphy with PET/CT following 2 cycles of chemotherapy on day 12-14 following chemotherapy
1774014|NCT00392327|Radiation|Radiation Therapy|Undergo radiation therapy
1774015|NCT00392327|Drug|Vincristine Sulfate|Given IV
1774016|NCT00392327|Drug|Carboplatin|Given IV
1774017|NCT00392327|Drug|Cisplatin|Given IV
1774018|NCT00392327|Drug|Cyclophosphamide|Given IV
1774019|NCT00392327|Biological|Filgrastim|Given IV or SC
1774020|NCT00392327|Drug|Isotretinoin|Given PO
1774021|NCT00392327|Other|Laboratory Biomarker Analysis|Correlative studies
1774022|NCT00392327|Other|Quality-of-Life Assessment|Ancillary studies
1774023|NCT00392340|Biological|filgrastim|
1774024|NCT00392340|Drug|doxorubicin hydrochloride|
1774025|NCT00392340|Drug|topotecan hydrochloride|
1774026|NCT00392340|Drug|vincristine sulfate|
1774031|NCT00392366|Device|MR-guided Laser Interstitial Thermal Therapy System|
1774032|NCT00392379|Drug|Nicotine Lozenges|Nicotine lozenges, 4 mg
1774033|NCT00392379|Drug|Placebo lozenge|Placebo lozenge
1774034|NCT00392392|Drug|nab-paclitaxel|ABI-007
1774035|NCT00392392|Drug|Bevacizumab|Bevacizumab
1774036|NCT00392392|Drug|Trastuzumab|Trastuzumab
1774037|NCT00392405|Drug|3 amps of sodium bicarbonate mixed in one liter of D5W|
1774038|NCT00392418|Drug|Multiple micronutrient supplement (iron)|
1774039|NCT00392431|Drug|amiodarone|
1774040|NCT00392444|Drug|sunitinib malate|Given orally
1774041|NCT00392457|Drug|ketoconazole|loading dose of 1g followed by a maintenance dose of 400 mg PO QID for 7 days
1774042|NCT00392457|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump titrated to reach normal serum testosterone levels)
1774043|NCT00392470|Biological|cetuximab|
1774044|NCT00392470|Drug|irinotecan hydrochloride|
1774045|NCT00392470|Procedure|conventional surgery|
1774046|NCT00392470|Procedure|neoadjuvant therapy|
1774047|NCT00392470|Radiation|3-dimensional conformal radiation therapy|
1774048|NCT00392470|Radiation|intensity-modulated radiation therapy|
1774049|NCT00392496|Drug|sunitinib malate|Given orally
1774052|NCT00392535|Drug|cyproterone acetate|
1774053|NCT00392535|Drug|releasing hormone agonist therapy|
1774054|NCT00392535|Radiation|hypofractionated radiation therapy|
1774055|NCT00392535|Radiation|intensity-modulated radiation therapy|
1774056|NCT00392561|Dietary Supplement|Selenium|200 ug Selenium daily
1774057|NCT00392561|Dietary Supplement|vitamin E|100 mg Vitamin E daily
1774058|NCT00392574|Drug|Prulifloxacin|Tablet
1774059|NCT00392574|Drug|Placebo|Tablet
1774060|NCT00392587|Drug|GW856553|
1774061|NCT00392613|Procedure|Strict versus lenient rate control|
1774062|NCT00392639|Procedure|Comparison of 2 cooling procedures|Comparison of 2 cooling procedures
1774063|NCT00392652|Drug|oral microencapsulated diindolylmethane|Given PO
1774064|NCT00392665|Drug|Bevacizumab|Given intravenously on day one of each 3 week cycle
1774065|NCT00392665|Drug|erlotinib|Given orally once a day
1774066|NCT00392665|Drug|Sulindac|Given orally twice a day
1774067|NCT00392678|Drug|Salsalate|Placebo and Salsalate 3.0 g/d; 3.5 g/d; 4.0 g/d orally, divided
1774068|NCT00392678|Drug|Placebo|
1774069|NCT00392691|Drug|ibritumomab tiuxetan|185 MBq (5mCi) of 111In-Zevalin will be used for radioimaging. and the dose is 14.8 MBq/kg (0.4 mCi/kg) total body weight of 90Y-Zevalin (max. 1184 MBq or 32 mCi at patients > 80kg) for imaging.
1774070|NCT00392691|Drug|rituximab|250 mg/m2
1774071|NCT00392691|Drug|melphalan|"Dose level 1: 100 mg/m2
Dose level 2: 140 mg/m2
Dose level 3: 170 mg/m2
Dose level 4: 200 mg/m2"
1774072|NCT00392691|Drug|vinorelbine tartrate / G-CSF|on day 1: 35 mg/m2 day 4-8 (longer if required) G-CSF 5 μg/kg s.c. morning and 5 μg/kg s.c. evening for at least 5 days
1774073|NCT00392691|Procedure|autologous hematopoietic stem cell harvesting and transplantation|"Optimal mobilization usually takes place on day 8. A minimum of 2.5x106 CD34+ cells/kg should be collected (optimal 5x106 CD34+ cells/kg). If not enough CD34+ cells can be collected on day 8, it is recommended to continue with G-CSF until a sufficient collection (a minimum of 2.5x106 CD34+ cells/kg) can be obtained.
Stem cells will be reinfused approximately 24 hours after the melphalan administration. The infusion will be performed with a minimum of 2.5x106 CD34+ cells/kg body weight according to local guidelines. G-CSF (5 μg/kg/d) will be given from day 5 and continued until neutrophils > 0.5x109/l for at least 2 consecutive days."
1774074|NCT00392704|Drug|Bevacizumab|"Induction Treatment:
Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.
Combined Modality Treatment:
Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
1774075|NCT00392704|Drug|Erlotinib|"Induction Treatment:
Paclitaxel 200mg/m2 by vein over 1-3 hours on Day 1 & Day 22 Carboplatin AUC 6.0 by vein over 1 hour on Days 1 and 22 Bevacizumab 15mg/kg by vein over 60-90 minutes on Days 1 and 22 5-FU 200mg/m2 as a 24 hour continuous infusion via pump on Days 1 through 43.
Combined Modality Treatment:
Radiation therapy is given daily, Monday through Friday for approximately 7 weeks. Erlotinib 150mg by mouth daily during the entire course of radiation (approximately 7 weeks) Paclitaxel 50mg/m2 by vein over 1-hour weekly for 6 weeks beginning Day 1 of radiation therapy Bevacizumab 15mg/kg by vein over 30-90 minutes on Days 50 and 71 at the same time of radiation therapy"
1774076|NCT00392704|Drug|Paclitaxel|"Neoadjuvant: 200 mg/m2 IV, 1-3 hour infusion, Days 1 and 22
Combined Modality: 50 mg/m2 IV, 1 hour IV infusion, weekly x6, beginning day 1 of radiation therapy"
1774077|NCT00392704|Drug|5-FU|Neoadjuvant: 200 mg/m2 24 hour continuous infusion days 1-43
1774078|NCT00392704|Radiation|Radiation Therapy|Combined Modality Therapy: 1.8 Gy/day, Monday-Friday, total dose 68.4 Gy
1774079|NCT00392717|Drug|Atorvastatin|
1774080|NCT00392717|Drug|Fish oils|
1774081|NCT00392730|Dietary Supplement|Remove Mn from PN if evidence of increased brain Mn on MRI|Withhold Mn-containing trace element cocktail and add zinc, copper and chromium individually to PN
1774082|NCT00392743|Procedure|pet/spect scan|
1774083|NCT00392756|Drug|gonadotropin releasing hormone (GnRH)|pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
1774084|NCT00392769|Drug|Cetuximab|Initial Dose = 400 mg/m^2 IV Over 120 Minutes, Followed by Weekly Infusions at 250 mg/m^2 IV Over 60 Minutes.
1774085|NCT00392782|Biological|anti-thymocyte globulin|Rabbit thymoglobulin will be given intravenously at a dose of 2.5 mg/kg on days -5,-4, -3, and -2. The first dose of thymoglobulin will be given over six (6) hours and subsequent doses over four (4) or more hours as tolerated or, per institutional anti-thymocyte globulin (ATG) administration guidelines.
1774086|NCT00392782|Drug|fludarabine phosphate|Fludarabine 40 mg/m^2/day intravenously (IV) over 30-60 minutes on days -7,-6,-5,-4,-3 (total dose 200 mg/m^2).
1774087|NCT00392782|Drug|thiotepa|Thiotepa 5 mg/kg/day intravenously (IV) over 4 hours on days -8, -7 (total dose 10 mg/kg).
1774088|NCT00392782|Procedure|peripheral blood stem cell transplantation|Peripheral Blood Stem Cell (PBSC) Infusion. All patients will receive granulocyte colony-stimulating factor (G-CSF)-mobilized PBSC on day 0 (or day+1 when available) following CD34 cell selection for ex vivo T cell removal. PBSC is infused via a central venous catheter using blood infusion tubing.
1774089|NCT00392782|Radiation|total-body irradiation|The total-body irradiation (TBI) will be given in 2 fractions of 400 cGy each administered on day -10 and -9 via anterior and posterior fields for a total dose of 800 cGy.
1774090|NCT00392808|Biological|conjugated polysaccharide menC vaccine|Booster vaccine dose at 14 to 18 months.
1774091|NCT00392821|Drug|Sorafenib|Sorafenib
1774092|NCT00392821|Drug|RAD001|RAD001
1774093|NCT00392834|Biological|filgrastim|given subcutaneously
1774094|NCT00392834|Biological|pegfilgrastim|given subcutaneously
1774095|NCT00392834|Biological|rituximab|given IV
1774096|NCT00392834|Drug|cyclophosphamide|given IV
1774097|NCT00392834|Drug|cytarabine|given intrathecally
1774098|NCT00392834|Drug|doxorubicin hydrochloride|given IV
1774099|NCT00392834|Drug|etoposide|given IV
1774100|NCT00392834|Drug|ifosfamide|given IV
1774101|NCT00392834|Drug|leucovorin calcium|given IV
1774102|NCT00392834|Drug|liposomal cytarabine|given intrathecally
1774103|NCT00392834|Drug|methotrexate|given intrathecally
1774104|NCT00392834|Drug|therapeutic hydrocortisone|given intrathecally
1774105|NCT00392834|Drug|vincristine sulfate|given IV
1774106|NCT00392847|Behavioral|Promoting Parental Skills and Enhancing Attachment|The first group will receive routine follow-up as currently provided by national community health and social services.
1774107|NCT00392847|Behavioral|had home visits by community workers during pregnancy|had home visits by community workers during pregnancy to the child's second birthday.
1774108|NCT00392860|Device|Natural-Fit|Ergonomic handrim for wheelchairs
1774109|NCT00392860|Device|PalmRim|Ergonomic handrim for wheelchair
1774110|NCT00392860|Device|Handrim Control Group|Participants were given a new standard handrim to test. This intervention group is the control group.
1774111|NCT00392873|Behavioral|EAMD+Calories|During the 12 month intervention, volunteers in the Increased calorie intake group will follow a modified dietary plan designed to achieve and maintain a target level of 20-30% above their previously determined baseline, in an effort to achieve a chronic energy surplus of +20-30% over their baseline energy requirements.
1774112|NCT00392886|Drug|carboplatin|Given IV
1774113|NCT00392886|Drug|cisplatin|Given IV
1774114|NCT00392886|Drug|cyclophosphamide|Given IV
1774115|NCT00392886|Drug|etoposide|Given IV and orally
1774116|NCT00392886|Drug|methotrexate|Given IV
1774117|NCT00392886|Drug|temozolomide|Given orally
1774118|NCT00392886|Drug|thiotepa|Given IV
1774119|NCT00392886|Drug|vincristine sulfate|Given IV
1774120|NCT00392886|Procedure|autologous bone marrow transplantation|Given on day 0
1774121|NCT00392886|Procedure|autologous hematopoietic stem cell transplantation|Given on day 0
1774122|NCT00392886|Procedure|peripheral blood stem cell transplantation|Given on day 0
1774123|NCT00392886|Radiation|radiation therapy|Some patients undergo radiation therapy once daily, 5 days a week for 4-6 weeks.
1774124|NCT00392899|Drug|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
1956951|NCT02616146|Drug|LNG-EE 150 μg/30 μg COC|Up to 13 cycles of LNG-EE 150 μg/30 μg administered orally, each cycle consisting of one tablet per day for 21 days, followed a 7-day tablet-free interval.
1774126|NCT00392925|Drug|pramlintide acetate 360 mcg|subcutaneous injection, twice a day, 360mcg
1774127|NCT00392925|Drug|metreleptin|subcutaneous injection, twice a day, 5mg
1774128|NCT00392925|Drug|placebo-pramlintide 600 uL|twice a day
1774129|NCT00392925|Drug|placebo-metreleptin 1 mL|twice a day
1774130|NCT00392925|Drug|Pramlintide acetate 180 mcg|subcutaneous injection twice a day, 180 mcg
1774131|NCT00392938|Drug|antiandrogen therapy|
1774132|NCT00392938|Drug|docetaxel|
1774133|NCT00392938|Diagnostic Test|C-11 acetate PET scan|
1774134|NCT00392938|Diagnostic Test|F-18 FDG PET scan|
1774135|NCT00392938|Diagnostic Test|Tc-99m bone scan|
1774136|NCT00392938|Diagnostic Test|CT scan of the chest, abdomen and pelvis|
1774138|NCT00392977|Dietary Supplement|remove Mn from PN if evidence of increased brain Mn on MRI|trace element cocktail will be withheld and zinc, copper and chromium added to PN individually.
1774139|NCT00392990|Drug|Regimen A|Cyclophosphamide (800 mg/m2 IV over 1 hour)+ vincristine (1.5 mg/m2 IV PUSH)+ doxorubicin (40 mg/m2 IV)+ high-dose methotrexate (2,700 mg/m2 IV over 23 hours)+ rituximab (500 mg/m2 IV)(R-CODOX-M) regimen
1774140|NCT00392990|Drug|Regimen B|Rituximab (500 mg/m2 IV once)+ Ifosfamide (1500 mg/m2 IV daily over 3 hours)+ Etoposide (60 mg/m2 IV daily over 1 hour), and Cytarabine (2 grams/m2 IV over 3 hours for 4 doses)
1774141|NCT00393003|Device|Closed-loop anesthesia system|
1774142|NCT00393029|Biological|anti-protein 53 or tumor protein 53 (p53) T-cell receptor transduced peripheral blood lymphocytes|Peripheral blood lymphocytes are harvested by lymphapheresis and engineered to express a T cell receptor that binds to P53.
1774143|NCT00393029|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours for up to 5 days
1774144|NCT00393029|Biological|filgrastim|Beginning on day 1 or 2, administered subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day); continue daily until neutrophil count > 1.0 x 10^9/L x 3 days or > 5.0 x 10^9/L.
1774145|NCT00393029|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenously in 250ml dextrose 5% in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour.
1774146|NCT00393029|Drug|fludarabine phosphate|25 mg/m2/day intravenously piggyback (IVPB) daily over 30 minutes for 5 days.
1774147|NCT00393042|Drug|Dexmethylphenidate|10, 20, 25-30 mg.
1774148|NCT00393042|Drug|Mixed Amphetamine Salts, ER|10, 20, 25-30
1774149|NCT00393042|Drug|placebo|randomized placebo week during each 4 week period
1774150|NCT00393055|Dietary Supplement|xylitol|1g xylitol lozenges to be dissolved in mouth. Five lozenges daily for three years
1774151|NCT00393055|Dietary Supplement|inactive lozenge|1g inactive lozenge, dissolved in mouth. Five/day for three years
1774152|NCT00393068|Drug|Erlotinib|Erlotinib
1774153|NCT00393068|Drug|Bevacizumab|Bevacizumab
1774154|NCT00393068|Drug|Paclitaxel|Paclitaxel
1774155|NCT00393068|Drug|Carboplatin|Carboplatin
1774156|NCT00393068|Drug|5-FU|5-FU
1774157|NCT00393068|Procedure|Radiation therapy|Radiation therapy
1774158|NCT00393068|Procedure|Surgery|Surgery
1774159|NCT00393094|Biological|Bevacizumab|10 mg/kg intravenous injection
1774160|NCT00393094|Drug|Irinotecan hydrochloride|125 mg/m^2 if patient is on a non-enzyme inducing anti-epileptic drugs 340 mg/m^2 if patient is on enzyme inducing anti-epileptic drugs every two weeks on a 4 week cycle
1774161|NCT00393107|Drug|rituximab|
1774162|NCT00393107|Drug|rituximab,fludarabine, cyclophosphamide|
1774163|NCT00393120|Drug|INCB009471|100mg SR (sustained release) orally once daily
1774164|NCT00393120|Drug|INCB009471|300mg SR (sustained release) orally once daily
1774165|NCT00393120|Drug|Placebo comparator|Orally once daily
1774167|NCT00393159|Device|Ear Popper|
1774168|NCT00393172|Behavioral|exercise|5 days per week exercise for 4 months
1774169|NCT00393185|Biological|Non-myeloablative Hematopoietic Stem Cell Transplantation|autologous Hematopoietic Stem Cell Transplantation
1774170|NCT00393198|Drug|Levonorgestrel (Mirena, BAY86-5028)|Removal of first MIRENA and insertion of the second MIRENA at entry visit. Removal of MIRENA (in vitro release rate 20 microgram/24h) at year 5 visit.
1774171|NCT00393198|Drug|Cytotec|Cytotec, single, sublingual dose of 400 microgram, 3 hours prior to the MIRENA removal and insertion procedure at entry visit
1774172|NCT00393198|Drug|Placebo|Placebo, single, sublingual dose, 3 hours prior to the MIRENA removal and insertion procedure at entry visit.
1774173|NCT00393211|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
1774174|NCT00393211|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
1774175|NCT00393250|Behavioral|Hypnosis|
1774176|NCT00393263|Drug|pimecrolimus and clobetasol|
1774177|NCT00393263|Drug|clobetasol 0.05% cream|twice daily for three months
1774178|NCT00393276|Biological|Twinrix|Combined hepatitis A and hepatitis B immunization
1774179|NCT00393276|Biological|Decavac|Diphtheria and tetanus toxoid vaccine
1774180|NCT00393289|Behavioral|Calcium controlled diet|
1774181|NCT00393302|Procedure|HIV screening in pregnancy|
1774182|NCT00393315|Device|paclitaxel coated balloon catheter|
1774183|NCT00393328|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as 2-150mg + RTV 100mg, single dose, 7 days washout crossed over to Treatment B.
1774184|NCT00393328|Drug|Atazanavir + Ritonavir|Capsules, Oral, ATV 300mg as single cap + RTV 100mg, single dose, 7 days washout.
1774185|NCT00393341|Procedure|Blood Draw|Blood sample will be drawn from a vein in the arm.
1774186|NCT00393354|Drug|MK0663, Etoricoxib / Duration of Treatment : 12 Weeks|
1774187|NCT00393354|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 12 Weeks|
1774188|NCT00393367|Drug|Budesonide inhalation suspension (0.5 mg/2mL) 2mg, albuterol (5mg/mL) 7.5 or 10mg|Patients randomized to budesonide inhalation suspension (BIS) receive 2 nebulized albuterol sulfate (5mg/mL) doses (2mL =10mg for patients over 20kg, 1.5mL =7.5mg for patients 10-20kg) mixed with 8mL (2mg) of BIS(0.5mg/2mL). The albuterol sulfate and BIS mixture is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
1774189|NCT00393367|Drug|Prednisolone, prednisone, or methylprednisolone|All patients are given 2mg/kg of systemic corticosteroids (max 60mg). Patients who can tolerate pills are given oral prednisone, those who cannot are given oral prednisolone, and those who cannot tolerate oral medications are given IV methylprednisolone.
1774190|NCT00393367|Drug|Albuterol, ipratropium bromide|While guardians are approached for possible participation, patients are given a single nebulized dose of albuterol sulfate (5mg/mL) mixed with ipratropium bromide (500mcg/2.5mL). Patients who weigh 10-20kg receive 3.75mg of albuterol. Patients over 20kg receive 5mg of albuterol. All patients receive 500mcg of ipratropium bromide. Albuterol sulfate and ipratropium bromide are delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM)with an oxygen flow rate of 8L/min via a tight-fitting face mask.
1774191|NCT00393367|Drug|Ipratropium bromide|500 mcg/2.5mL. All patients receive a final dose of ipratropium bromide after the intervention or placebo. The ipratropium bromide is delivered by a medium volume, high flow nebulizer (AirLife Mister FinityTM) with an oxygen flow rate of 8L/minute via a tight-fitting face mask.
1774192|NCT00393380|Drug|Parathyroid Hormone (teriparatide)|Day +1: PTH 40 mcg, Day +2: PTH 60 mcg, Day +3: PTH 80 mcg, Day +4 to Day +29 or until ANC>2000/microL: PTH 100 mcg
1774193|NCT00393393|Drug|intra-articular injection of Hylan G-F 20|
1774194|NCT00393419|Behavioral|Comprehensive pharmacy care program|
1774195|NCT00393445|Drug|GLP-1 control|intravenous infusion of GLP-1
1774196|NCT00393445|Drug|GLP-1 and Exendin(9-39) 300|intravenous infusion of exendin(9-39) at 300 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
1774197|NCT00393445|Drug|saline control|intravenous infusion of saline
1774198|NCT00393445|Drug|GLP-1 and Exendin(9-39) 600|intravenous infusion of exendin(9-39) at 600 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
1774199|NCT00393445|Drug|GLP-1 and Exendin(9-39) 900|intravenous infusion of exendin(9-39) at 900 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
1774200|NCT00393445|Drug|GLP-1 and Exendin(9-39) 1200|intravenous infusion of exendin(9-39) at 1200 pmol/kg/min during GLP-1 at 0.3 and 0.9 pmol/kg/min
1774201|NCT00393458|Drug|Indacaterol|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
1774202|NCT00393458|Drug|Formoterol|Formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
1774203|NCT00393458|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
1774204|NCT00393458|Drug|Placebo to formoterol|Placebo to formoterol was supplied in powder-filled capsules with the manufacturer's proprietary inhalation device (Aerolizer®).
1774205|NCT00393471|Drug|Etanercept|
1774206|NCT00393484|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (0-96 weeks) and (96-240 weeks)
1774207|NCT00393484|Drug|Lamivudine Placebo|Capsules, Oral, 0 mg, once daily (0-96 weeks)
1774208|NCT00393484|Drug|Lamivudine|"Capsules, Oral, 100 mg, once daily (0-96 weeks)
Tablets, Oral, 100 mg, once daily (96-240 weeks)"
1774209|NCT00393484|Drug|Entecavir Placebo|Tablets, Oral, 0 mg, once daily (0-96 weeks)
1774210|NCT00393497|Drug|bevacizumab|Bevacizumab 15 mg/kg IV every 21 days
1774288|NCT00394134|Behavioral|Interview|Interviews to describe the sun exposure and sun protection practices of patients and their children.
1774289|NCT00394147|Drug|pemetrexed|pemetrexed 500mg/m2 given on day 1 and day 15 of each 28 day cycle
1774290|NCT00394147|Drug|gemcitabine|gemcitabine 1500mg/m2 given on day 1 and day 15 of each 28 day cycle
1774211|NCT00393510|Drug|TCM|"The Decoction is taken orally, twice a day, treatment period is 24 weeks The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.
The formula consisted of 12 herbs, viz:
Radix astragali, Rhizoma atractylodis marcocephalae, Radix stephaniae tetrandrae, Radix polygoni multiflori, Radix rehmanniae, Radix smilax china, Fructus corni, Rhizoma dioscoreae, Cortex moutan, Rhizoma alismatis, Rhizoma smilacis glabrae, and Fructus schisandrae"
1774212|NCT00393510|Drug|Placebo|"Placebo taking orally, twice a day, 24 week treatment period The herbal formulation or a placebo was given as an adjuvant therapy for the treatment of the unhealing ulcers in these diabetic patients.
The placebo was made with starch and colouring materials."
1774213|NCT00393523|Biological|Comparator: Modified Process Hepatitis B Vaccine|Single dose 5 µg/0.5ml modified process hepatitis B vaccine
1774214|NCT00393523|Biological|Comparator: Comparator: ENGERIX-B|Single dose 10 µg/0.5ml ENGERIX-B
1774215|NCT00393536|Behavioral|Educational outreach visiting|
1774216|NCT00393549|Device|NeuroPath|
1774217|NCT00393562|Drug|modafinil|
1774218|NCT00393562|Drug|methylphenidate|
1774219|NCT00393575|Behavioral|Community Mobilization|The intervention will consist of guiding C2P coalitions through a strategic planning process that will result in the development and implementation of a local action plan. The action plan will focus on changing structural elements of the affected communities that are believed to be associated with youth HIV acquisition and transmission. Each coalition's plan will include: (1) identification of potential community structural changes and specific steps for how to effect such changes; and (2) the selection of a community-level Centers for Disease Control and Prevention (CDC)-endorsed HIV prevention program.
1774220|NCT00393614|Drug|levetiracetam|20 mg pr. kg a day
1774221|NCT00393627|Behavioral|Sleep Education Program|The Sleep Education Program (SEP) is conducted by a licensed MS- or PhD-level mental health professional experienced in working with persons with dementia and their caregivers. The therapist meets with the AFH owner/operator and staff for four weekly sessions at the AFH. The SEP content includes information about the causes of sleep problems in dementia, and provides staff with assistance in developing customized resident behavioral sleep plans focused on environmental (light and noise), dietary (eliminating caffeine and excessive nighttime fluids), and sleep scheduling (reducing afternoon/ evening napping; consistent, appropriate bed and rising times) factors that are commonly associated with resident nighttime awakenings. A written manual is used.
1774222|NCT00393640|Procedure|Early and regular breast milk expression|Breast pump given to be used on regular intervals
1774223|NCT00393653|Procedure|N-of-1 prescription method|
1774224|NCT00393679|Drug|amodiaquine-artesunate (ASAQ)|A fix-dose combination tablet containing artesunate-amodiaquine in three different dosages, to be used according to patient age and weight: 25mg/67.5mg; 50mg/135mg; 100mg/270mg
1774225|NCT00393679|Drug|dihydroartemisinin-piperaquine (DHAPQ)|DHAPQ tablets contain either 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively.
1774226|NCT00393679|Drug|artemether-lumefantrine (AL)|Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine.
1774227|NCT00393679|Drug|Lapdap (Chlorproguanil-Dapsone) + artesunate (AS)|"Lapdap tablets contain 15/18.75mg or 80/100mg of Chlorproguanil Hydrochloride and Dapsone, respectively. Arsumax® tablets contain 50mg Artesunate.
TO BE NOTED: following GlaxoSmithKline decision to discontinue the clinical development of the fixed-doses combination of Lapdap (Chlorproguanil-Dapsone) and artesunate, the Lapdap plus Artesunate arm was immediately discontinued in this study, on 17th February 2008. A formal amendment has been submitted to all the concerned ECs and competent authorities.The leading EC approval was obtained on 2nd June 2008."
1774228|NCT00393705|Drug|Insulin Biphasic Aspart 30/70|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
1774229|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, injected subcutaneously for 16 weeks - possibility of using instead of insulin lispro MM before evening meal if there is a risk of hypoglycemia after the dinner or high fasting glucose levels.
1774230|NCT00393705|Drug|insulin lispro MM|Participant adjusted dose, three times per day, injected subcutaneously for 16 weeks
1774231|NCT00393705|Drug|insulin lispro LM|Participant adjusted dose, twice daily, injected subcutaneously for 16 weeks
1774232|NCT00393718|Drug|liraglutide|0.9 mg/day. Injected s.c. (under the skin) once daily.
1774233|NCT00393718|Drug|glibenclamide|1.25-2.5 mg tablet. Given orally once or twice daily.
1774234|NCT00393718|Drug|placebo|liraglutide placebo. Injected s.c. (under the skin) once daily.
1774235|NCT00393718|Drug|placebo|glibenclamide placebo. Given orally once or twice daily.
1774236|NCT00393731|Drug|Misoprostol|
1774237|NCT00393731|Drug|oxytocin|
1774238|NCT00393744|Drug|pristinamycin|50 mg/kg/d in 2 doses for children, and 1g twice daily in adults for 4 days
1774239|NCT00393744|Drug|amoxicillin|50 mg/kg/d in 2 doses in children and 1 g twice daily in adults for 6 days
1774240|NCT00393770|Drug|L-acetylcarnitine|250-500 mg/kg/die.
1774241|NCT00393783|Biological|MAB HER 2 (HERCEPTIN)|Rat HER2 DNA will be delivered intramuscularly at four different dose levels (0.5mg, 1mg, 3mg, or 6mg) during weeks 1, 4, 7, 10 and 13 for five injections.
1774242|NCT00393796|Drug|SUTENT|"50 mg/PO once daily for four consecutive weeks with a two week rest period. Study participants who show evidence of disease progression (or are considered for removal from study for any other reason) will be unblinded. Participants receiving SU011248 will be removed from the study. Participants receiving placebo will be given the opportunity to crossover and receive SU011248."
1774243|NCT00393796|Other|Placebo|
1774244|NCT00393809|Drug|DTA-H19|
1774245|NCT00393822|Drug|palifermin|dose of 120 μg/kg, intravenous (IV) on day -3 for each cycle, for up to 6 chemotherapy cycles
1774246|NCT00393822|Drug|placebo|one bolus IV injection at 120 μg/kg/day of matched placebo
1774247|NCT00393835|Drug|Azithromycin SR|
1774248|NCT00393848|Drug|Essential amino acid supplement|15g of essential amino acid in capsule form three times daily during hospitalization, continued through 6 weeks after discharge.
1774249|NCT00393848|Drug|Ketoconazole|200mg ketoconazole twice daily; started night before surgery and continued through hospitalization.
1774250|NCT00393848|Drug|Placebo|Placebo for Ketoconazole
1774251|NCT00393861|Drug|Bevacizumab and Oxaliplatin|Oxaliplatin 85 mg/M2 IV over 2 hours plus Bevacizumab 10 mg/kg IV over 90 minutes
1774252|NCT00393874|Behavioral|Behavioral Sleep Intervention|Participants will receive a workbook with information related to the intervention. The three core components are presented and discussed during these sessions are:1) education about sleep and nightmares; 2) imagery rehearsal; 3) stimulus control and sleep restriction. Session 1 focuses on education on PDSD-related insomnia, nightmares, and sleep avoidance behaviors. The rationale for imagery rehearsal will then be presented, and the technique will be practiced once. Strategies for managing intrusive thoughts and images during the practice of imagery rehearsal will be discussed. Participants will be instructed to practice this technique at least three times each day for the duration of the treatment phase. During the second 45-minute session (Week 3), sleep schedules extracted from the pre-intervention sleep diary will be used to identify goals to reduce insomnia, i.e., for sleep restricted schedules, and activities to be performed out of bed when awake.
1774253|NCT00393874|Drug|Prazosin|Participants randomized to PRZ will take 4 capsules each night (PRZ dose complemented with placebo capsules ). The target dose of prazosin is 10 mg. Some individuals may require doses up to 15 mg, (Murray Raskind, M.D., personal communication, February 4, 2005). Prazosin will be administered in an initial oral dose of 1 mg (Week 1), with titration to a maximum of 15 mg. The first increment will be of 1 mg (Week 2: 2 mg), and subsequent weekly increments according to the following schedule: Week 3: 4 mg; Week 4: 6 mg; Week 5: 10 mg; Week 6: 15 mg; Week 7: 15 mg; Week 8: 15 mg. A maximum dose of 15 mg may be necessary. Medication will be administered in a single dose to be taken 30 minutes prior to bedtime because the onset of action occurs within 30 to 90 minutes after a single dose.
1774254|NCT00393874|Drug|Placebo|Participants randomized to PLA will take 4 capsules each night for eight weeks, all capsules will be identical to prazosin capsules. As for participants randomly assigned to PRZ, they will receive a one-week medication supplies in daily dose dispensers. Similarly, participants will also be instructed to be ready for bed at the time they take the medication, and not to engage in any activities that will prevent them from going to bed.
1774255|NCT00393887|Device|Biodesign IHM|Biodesign IHM is placed to reinforce the hernia repair
1774256|NCT00393887|Device|Polypropylene mesh|Polypropylene mesh is used to reinforce the hernia repair.
1774257|NCT00393913|Device|Continuous Positive Airway Pressure (CPAP)|Positive airway pressure delivered via a nasal mask titrated to a therapeutic level to eliminate all sleep disordered breathing to be used every night for 4-6 weeks.
1774258|NCT00393926|Device|TheraDrive Assistive Device|
1774259|NCT00393926|Procedure|Rote Therapy versus Fun Therapy|
1774260|NCT00393939|Drug|Sunitinib malate|Sunitinib 37.5 mg daily by oral capsule in schedule 2/1 with Docetaxel 75 mg/m2 every 3 weeks or 37. 5 mg daily in continuous dosing (in absence of docetaxel)
1774261|NCT00393939|Drug|Taxotere|Docetaxel 100 mg/m2 every 3 weeks in the comparator arm
1774262|NCT00393952|Drug|Fluticasone propionate/Formoterol fumarate 250/10|FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
1774263|NCT00393952|Drug|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
1774264|NCT00393952|Drug|Fluticasone propionate/Formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
1774265|NCT00393952|Drug|Fluticasone propionate 250|Fluticasone 250 is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
1774266|NCT00393952|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
1774267|NCT00393965|Drug|MPC-6827|2-hour IV infusion given once weekly for 3 consecutive weeks on a 28-day cycle.
1774268|NCT00393978|Drug|Quetiapine and placebo|placebo (titrated to 150-300 mg/day) in combination with quetiapine (titrated to 400-800 mg/day).
1774269|NCT00393978|Drug|Quetiapine and Topiramate|topiramate (titrated to 150-300 mg/day) in combination with Quetiapine (titrated to 400-800 mg/day).
1774270|NCT00393991|Drug|Fluticasone propionate/formoterol fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
1774271|NCT00393991|Drug|Fluticasone propionate 100|Fluticasone 100ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
1774272|NCT00393991|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
1774273|NCT00393991|Drug|Placebo|Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
1774274|NCT00394017|Behavioral|Reminder letters|3 mailed reminder letters
1774275|NCT00394030|Drug|GSK716155 subcutaneous injections|GSK716155 will be available as lyophilize uniform cake in 10 milliliter (mL) clear glass vials with 20 millimeter (mm) closure. Subjects will administer dose of either 16mg or 64mg of GSK716155 via subcutaneous injection(s). For dose of 16 mg 1 injection of 0.62 mL will be administered and for dose of 64 mg 3 injections of 0.82 mL each will be administered.
1774276|NCT00394043|Procedure|Osteopathic Manipulative Treatment|A protocol of specific Osteopathic manipulative techniques was used.
1774277|NCT00394043|Procedure|Placebo Sub-Therapeutic Ultrasound|Sub-therapeutic ultrasound was applied in a standardized method.
1774281|NCT00394069|Drug|MK-0476, montelukast sodium|Duration of Treatment: 14 Days
1774282|NCT00394082|Drug|ABI-007|125 mg/m^2 of ABI-007 administered by intravenously (IV) over 30 minutes on days 1, 8 and 15 of each 28 day cycle.
1774283|NCT00394082|Drug|Bevacizumab|Bevacizumab administered once every 2 weeks (10 mg/kg) by IV infusion after ABI-007 has been given. The first dose is one Day 1, cycle 1.
1774284|NCT00394095|Drug|Topiramate|Oral topiramate 300-400mg/day for 12 weeks
1774285|NCT00394095|Drug|Placebo|Matched placebo to Experimental arm
1774286|NCT00394108|Procedure|Determination of neuropsychological status|
1774287|NCT00394121|Drug|Fluticasone propionate/formoterol fumarate|
1774582|NCT00387933|Drug|hydroxyurea|
1774291|NCT00394160|Drug|MK0476, Montelukast Sodium /Duration of Treatment : 14 Days|
1774292|NCT00394173|Drug|DNK333|DNK333 25mg b.i.d. given orally for 4 weeks
1774293|NCT00394173|Drug|Placebo|Matching placebo
1774294|NCT00394186|Drug|GW427353|
1774295|NCT00394186|Drug|Placebo|
1774296|NCT00394199|Drug|Fluticasone propionate/Formoterol Fumarate 100/10|FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
1774297|NCT00394199|Drug|Fluticasone propionate 100|Fluticasone 100 is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
1774298|NCT00394199|Drug|Formoterol fumarate 10|Formoterol 10ug is a HFA pMDI that delivers 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
1774299|NCT00394212|Device|Transoral Suturing|suturing of anastomosis
1774300|NCT00394212|Other|Sham Endoscopy|suturing not performed
1774301|NCT00394225|Drug|Oxygen|
1774302|NCT00394225|Drug|Helium|
1774303|NCT00394238|Procedure|Ultrasonographic imaging|
1774304|NCT00394251|Drug|Adriamycin and Cytoxan (AC)|Adriamycin (doxorubicin) and Cytoxan (cyclophosphamide) make up the chemotherapy regimen known as AC. Adriamycin 60 mg/m^2 intravenous, plus Cytoxan 600 mg/m^2 intravenous on Day 1 of each of four 2-week cycles (weeks 1-8).
1774305|NCT00394251|Drug|ABI-007|260 mg/m^2 IV on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
1774306|NCT00394251|Drug|Taxol|175 mg/m^2 intravenously (IV) on day 1 of each of four 2-week cycle, representing treatment cycles 5-8 (weeks 9-16)
1774307|NCT00394251|Drug|Bevacizumab|10 mg/kg on day 1 of each of eight 2-week cycles (weeks 9-16), then 15 mg/kg on day 1 of each of ten three-week cycles (weeks 17-46).
1774308|NCT00394251|Drug|pegfilgrastim|6 mg subcutaneous (SC) on day 2 for each of the first four 2-week cycles (weeks 1-8). Pegfilgrastim 6 mg SC was administered on day 2 of cycles 6-8 (weeks 11-16) during taxane treatment only if necessary.
1774309|NCT00394264|Procedure|Soft Tissue|
1774310|NCT00394264|Procedure|Myofascial release|
1774311|NCT00394264|Procedure|Counterstrain|
1774312|NCT00394264|Procedure|Muscle energy|
1774313|NCT00394264|Procedure|Sacro-iliac articulation|
1774314|NCT00394264|Procedure|High-velocity, low amplitude|
1774315|NCT00394277|Drug|peginterferon alfa-2a|180 µg sc weekly for 48 weeks
1774316|NCT00394277|Drug|Ribavirin|1200 mg po daily for 48 weeks
1774317|NCT00394277|Drug|peginterferon alfa-2a|360 µg sc weekly decreasing to 180 µg sc weekly for 48 weeks
1774318|NCT00394277|Drug|Ribavirin|1400-1600 mg po daily for 48 weeks
1774319|NCT00394290|Device|Continuous Positive Pressure|Nighttime continuous positive pressure device, to be used every day
1774320|NCT00394303|Drug|Intraoperative continuous insulin infusion|Nomogram specified in appendix
1774321|NCT00394303|Other|Control|Glucose management according to the discretion of the anesthesiologist aimed to maintain glucose levels <200 mg.dl, reflecting current practice.
1774322|NCT00394316|Drug|Phagocyte Oxidase Subunit Transduced CD34 Hematopoietic Stem Cells|
1774323|NCT00394329|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) one puff bid
1774324|NCT00394329|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate HFA (QVAR® 40 mcg Inhalation Aerosol) rescue puffs as needed
1774325|NCT00394329|Drug|Albuterol sulfate|Albuterol sulfate HFA (ProAir® 90 mcg Inhalation Aerosol) rescue puffs as needed
1774326|NCT00394355|Drug|mometasone furoate dry powder inhaler|400 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
1774327|NCT00394355|Drug|mometasone furoate dry powder inhaler|200 mcg MF DPI via a breath-actuated, dry-powder inhaler and a placebo tablet given by mouth once daily in the evening for 1 year.
1774328|NCT00394355|Drug|fluticasone propionate hydrofluoroalkane (HFA)|250 mcg FP HFA given twice a day via a metered-dose inhaler and a placebo tablet given once daily in the evening for 1 year
1774329|NCT00394355|Drug|montelukast|10 mg given once daily in the evening by mouth for 1 year.
1774330|NCT00394368|Drug|beclomethasone dipropionate plus formoterol fumarate combination|
1774331|NCT00394368|Drug|fluticasone propionate plus salmeterol xinafoate combination|
1774332|NCT00394381|Procedure|Infusion of autologous CIK cells|Autologous CIK cells will be infused at timed intervals after autologous transplant for AML for group 1 patients, and with or without some cytoreduction treatment for group 2 patients
1774333|NCT00394394|Drug|Amiloride 2,5/d or Enalapril/d 10 mg|
1774334|NCT00394407|Drug|sliding scale regular insulin|SSRI acqhs
1774335|NCT00394407|Drug|glargine basal insulin and glulisine prandial insulin|glargine insulin once a day and glulisine insulin three times a day as long as patient eating
1774336|NCT00394420|Behavioral|Telephone Quitline|
1774337|NCT00394433|Drug|Bevacizumab|
1774338|NCT00394433|Drug|Docetaxel|
1774339|NCT00394433|Drug|Cisplatin|
1774340|NCT00394433|Drug|Irinotecan|
1774341|NCT00394446|Drug|MPC-6827|2-hour intravenous infusion given once weekly for 3 consecutive weeks on a 28 day cycle
1774342|NCT00394459|Device|Perifix Epidural Anaesthesia Catheter|Epidural Catheter
1774343|NCT00394459|Device|Perifix Standard|Perifix Standard
1774344|NCT00394459|Device|Perifix New|Perifix New
1774345|NCT00394472|Drug|AZD3355|
1774346|NCT00394485|Drug|Procaterol|
1774347|NCT00394485|Drug|Tiotropium|
1774348|NCT00394498|Drug|Granulocyte Colony Stimulating Factor|
1774349|NCT00394511|Procedure|low-LET photon therapy|
1774350|NCT00394524|Device|Glucommander|Computer-guided IV insulin infusion (Glucommander)
1774351|NCT00394524|Drug|Standard insulin infusion drip|Insulin infusion with glulisine per columnar algorithm
1774352|NCT00394524|Device|Glucommander|Glucommander computer assisted program to run glulisine insulin drip
1774353|NCT00394524|Drug|Glulisine drip using columnar algorithm|Apidra insulin per insulin infusion algorithm
1774354|NCT00394537|Drug|Labetalol 10mg iv|
1774583|NCT00387933|Drug|imatinib mesylate|
1774584|NCT00387933|Drug|vatalanib|
1774355|NCT00394550|Procedure|supraglottoplasty with laser|"Polysomnogram, fiberoptic flexible laryngoscopy, adenotonsillectomy, direct laryngoscopy, bronchoscopy, laser supraglottoplasty, general anesthesia, a proton-pump inhibitor ibuprofen, acetaminophen with codeine without alcohol, or other narcotic containing medication, antibiotic, possible use of other analgesics per anesthesia None of these procedures are new or experimental. Our investigation pertains to a broader use of the laser supraglottoplasty to include children with obstructive sleep apnea and laryngomalacia, as opposed to the more traditional use of laser supraglottoplasty for only severe laryngomalacia in young children"
1774356|NCT00394550|Procedure|supraglottoplasty with laser|laser excision of laryngomalacia (floppy tissue) on one side of the supraglottis
1774357|NCT00394563|Drug|RN624 (PF-04383119)|10 mcg/kg
1774358|NCT00394563|Drug|RN624 (PF-04383119)|25 mcg/kg
1774359|NCT00394563|Drug|RN624 (PF-04383119)|50 mcg/kg
1774360|NCT00394563|Drug|RN624 (PF-04383119)|100 mcg/kg
1774361|NCT00394563|Drug|RN624 (PF-04383119)|200 mcg/kg
1774362|NCT00394563|Drug|placebo|
1774363|NCT00394576|Behavioral|Internet-based nutrition module|usual care plus Internet-based nutrition module
1774364|NCT00394576|Behavioral|usual care|usual care
1774365|NCT00394589|Drug|Infliximab Increased Frequency|Continuing the same dose of 3 mg/kg infliximab, but at every 6 weeks for 24 weeks
1774366|NCT00394589|Drug|Infliximab Increased Dose|3 mg/kg infliximab + 1 extra vial (100 mg) infliximab every 8 weeks for 24 weeks
1774367|NCT00394589|Drug|Infliximab Control|Continuation of infliximab 3 mg/kg every 8 weeks for 24 weeks
1774368|NCT00394602|Behavioral|Interview|Interview regarding perceptions of side effects that are related to chemoradiation treatment.
1774369|NCT00394602|Other|Questionnaire|3 Questionnaires regarding quality of life given during and after treatment, each taking about 20 minutes to complete.
1774370|NCT00394615|Procedure|Metabolic Imaging|
1774371|NCT00394628|Drug|AQ4N|
1774372|NCT00394628|Drug|Temozolomide|
1774373|NCT00394628|Procedure|Radiotherapy|
1774374|NCT00394641|Behavioral|listening to music / stories via stereophonic headphones|
1774375|NCT00394654|Biological|MEDI-528 9 mg/kg|MEDI-528 at a single dose of 9 mg/kg administered as an intravenous infusion
1774376|NCT00394654|Other|Placebo|Placebo administered as a single intravenous infusion
1774377|NCT00394667|Drug|Tesofensine|
1774378|NCT00394693|Genetic|Adenovirus Interferon gamma|intra-tumoral injections, 1 dose per lesion, up to 6 simultaneous lesions.
1774379|NCT00394706|Device|Impedance Threshold Device (ITD)|Use of Impedance Threshold Device (ITD)
1774380|NCT00394706|Device|Sham ITD|Sham ITD
1774381|NCT00394706|Other|Analyze early|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, an assessment of the cardiac rhythm is done to determine whether a defibrillatory shock is required.
1774382|NCT00394706|Other|Analyze later|Upon EMS arrival at the scene of a non-traumatic cardiac arrest, three minutes of CPR is given prior to the assessment of the cardiac rhythm to determine whether a defibrillatory shock is required.
1774383|NCT00394732|Device|Total Disc Prosthesis|
1774384|NCT00394732|Behavioral|Multidisciplinary rehabilitation program|
1774385|NCT00394745|Drug|Valsartan|
1774386|NCT00394758|Procedure|CO2 laser surgery|
1774387|NCT00394758|Procedure|ultrasonic surgical aspiration|
1774388|NCT00394771|Drug|DR-1031|Active therapy cycle of 84 days taking combination tablets containing ascending doses of ethinyl estradiol (EE) and 150 mcg levonorgestrel (LNG), followed by a 7-day withdrawal cycle of 10 mcg EE. The total extended cycle was 91 days and participants were to complete two extended cycles. Active therapy dosage of EE varied by treatment arm.
1774389|NCT00394771|Drug|Seasonale®|84 days of combination active tablets, each containing 30 mcg EE and 150 mcg LNG, followed by 7 days of placebo tablets for two consecutive 91-day cycles.
1774390|NCT00394771|Drug|Portia®|Portia® 28 consists of 21 pink active tablets, each containing 0.15 mg of levonorgestrel and 0.03 mg of ethinyl estradiol, and seven white inert tablets. Portia was taken as a pre-study run-in medication.
1774391|NCT00394797|Procedure|mitral valve annuloplasty|
1774392|NCT00394810|Drug|Panzem® NCD|suspension, 100 mg/mL, four times daily continuous dosing
1774393|NCT00394823|Behavioral|Set of supportive tools/measures vs. standard care|
1774394|NCT00394836|Drug|Ofatumumab|Eight weekly infusions of ofatumumab. The first infusion of 300mg ofatumunab
1774395|NCT00394836|Drug|Ofatumumab|followed by 7 weekly infusions of 1000mg ofatumumab
1774396|NCT00394849|Procedure|suturing of tonsillar pillars after tonsillectomy|
1774397|NCT00381316|Drug|Technetium Tc99m Tetrofosmin injections|Single Isotope: be 555 to 888 MBq (15 to 24 mCi) MYOVIEW at Rest/i.v./bolus.
1774398|NCT00381316|Drug|Thallous Chloride T1-201|Myoview SPECT Imaging
1774399|NCT00381329|Behavioral|Motivational Interviewing (MI)|MI is an empirically supported, client-centered, directive method for matching counseling to an individual's readiness to change.
1774400|NCT00381329|Behavioral|Structured Brief Advice (SBA)|SBA includes the administration of scripted, brief cessation counseling that follows standard health care smoking cessation guidelines.
1774401|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day
1774402|NCT00381342|Drug|exenatide|Placebo subcutaneously injected twice daily as a lead-in followed by exenatide subcutaneously injected, 5 mcg, twice a day, then exenatide subcutaneous injection, 10 mcg twice a day
1774403|NCT00381342|Drug|placebo|subcutaneous injection, volume equivalent to appropriate dose of exenatide, twice a day
1774404|NCT00381355|Procedure|Written Action Plan for Acute Asthma|
1774405|NCT00381368|Drug|Ibandronic acid|
1774406|NCT00381381|Drug|Donepezil|2.5mg once daily for the first 7 days, 5mg once daily for the next 3 weeks, after then the dose can be increased 10mg once daily under the investigator's decision.
1774408|NCT00381407|Behavioral|Organizational Skills Training|Participants in the OST group attend twenty 1-hour sessions over 10 weeks. OST trains children to use a variety of techniques for improving their organizational skills. Both children and their parents attend every OST session.
1774409|NCT00381407|Behavioral|Contingency management (CM)|"Participants in the CM group will attend twenty 1-hour sessions over 10 weeks. CM trains parents and teachers to identify desired end behaviors and to increase the frequency of these behaviors through the use of a structured reward system. Both children and their parents attend every CM session, but the children's participation will be minimal."
1774410|NCT00381420|Device|drug-eluting stent|sirolimus-coated Bx VELOCITY Balloon-Expandable Stent
1774411|NCT00381420|Device|bare-metal stent|un-coated Bx VELOCITY Stent
1774412|NCT00381433|Drug|AVI-4065 Injection|
1774413|NCT00381446|Device|Marketed contact lens care products|
1774414|NCT00381472|Drug|Ropinirole|
1774415|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 400/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
1774416|NCT00381485|Drug|Mometasone furoate/formoterol (MF/F) combination|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 12 weeks
1774417|NCT00381485|Drug|Mometasone furoate MDI (MF MDI)|MF 400 mcg via metered dose inhaler twice daily for 12 weeks
1774418|NCT00381511|Drug|low molecular weight heparin|
1774419|NCT00381524|Behavioral|Increase condom use|Voluntary increase in condom use
1774420|NCT00381537|Drug|phenobarbitone|
1774421|NCT00381537|Drug|carbamazepine|
1774422|NCT00381550|Drug|fludarabine phosphate|Given IV
1774423|NCT00381550|Drug|triapine|Given IV
1774424|NCT00381550|Procedure|laboratory biomarker analysis|Correlative study
1774425|NCT00381563|Device|Patellofemoral realigning knee brace|Knee brace that changes the tracking of the patella over the femur bone
1774426|NCT00381563|Device|Non-aligning knee brace|Knee brace that does not change the tracking of the patella over the femur bone
1774427|NCT00381576|Behavioral|Resistance training|Intervention group: 12 weeks of resistance training for the lower extremity. Control group: No intervention - 12 weeks of normal daily living
1774428|NCT00381589|Drug|ipratropium bromide 0.03% spray|
1774429|NCT00381602|Drug|GHRP-1/AG 70 mg depot in ESRD|
1774430|NCT00381602|Other|Placebo|
1774431|NCT00381615|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
1774432|NCT00381615|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
1774433|NCT00381615|Biological|DTaP-Hib-IPV|Intramuscular (IM) injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2, 3 and 4 months in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
1774434|NCT00381615|Biological|PC7|IM injections of 3 doses of 0.5 mL each of PC7 supplied in prefilled syringe were administered at 2, 4 and 13 months of age in the anterolateral area of the left thigh (when given concomitantly with rMenB±OMV-NZ) or the right thigh.
1774435|NCT00381615|Biological|MenC-CRM|MenC-CRM was obtained by extemporaneous mixing just before injection of the lyophilized Men C component to be re-suspended with the saline solvent (aluminum hydroxide suspension) supplied. IM injection of 2 doses each of 0.5 mL were administered into the anterolateral area of the left thigh.
1774436|NCT00381615|Biological|MenC-Hib|MenC-Hib was obtained by extemporaneous mixing of powder and solvent just before injection. One dose (0.5 mL) of MenC-Hib was administered at 12 months of age as an IM injection into the anterolateral area of the thigh.
1774437|NCT00381615|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months of age in the anterolateral area of the left thigh.
1774438|NCT00381628|Procedure|epithelial cells and blood lymphocyte extraction|Nasal curettage will be performed from each nostril to obtain nasal epithelial cells. Venipuncture will be performed and up to 60-ml of blood will be obtained from which neutrophils will be isolated.
1774439|NCT00381641|Drug|Sunitinib Malate|Given PO
1774440|NCT00381654|Drug|AV-412|Solid oral dosage; 4 dosage strengths; 25, 50, 100, or 200 mg per capsule Dosing Frequency: Once daily dosing for 4 weeks (4 weeks equals 1 cycle)
1774444|NCT00381680|Drug|vincristine sulfate|Given IV
1774445|NCT00381680|Drug|prednisone|Given PO
1774446|NCT00381680|Drug|doxorubicin hydrochloride|Given IV
1774447|NCT00381680|Drug|pegaspargase|Given IM
1774448|NCT00381680|Drug|cytarabine|Given IT or IV
1774449|NCT00381680|Drug|methotrexate|Given IT or IV
1774450|NCT00381680|Drug|dexamethasone|Given PO
1774451|NCT00381680|Drug|etoposide|Given IV
1774452|NCT00381680|Drug|cyclophosphamide|Given IV
1774453|NCT00381680|Drug|leucovorin calcium|Given IV or PO
1774454|NCT00381680|Biological|filgrastim|Given IV or SC
1774455|NCT00381680|Drug|asparaginase|Given IM
1774456|NCT00381680|Drug|mercaptopurine|Given PO
1774457|NCT00381693|Drug|azacitidine|
1774458|NCT00381706|Biological|cetuximab|given IV
1774459|NCT00381706|Drug|ECF|epirubicin and 5-fluorouracil given IV
1774460|NCT00381706|Drug|IC|cisplatin and irinotecan given IV
1774461|NCT00381706|Drug|FOLFOX|oxaliplatin , leucovorin and 5-fluorouracil IV
1774462|NCT00381719|Drug|AGN 203818|3 mg Capsule twice daily for 4 weeks
1774463|NCT00381719|Drug|AGN 203818|20 mg Capsule twice daily for 4 weeks
1774464|NCT00381719|Drug|AGN 203818|60 mg Capsule twice daily for 4 weeks
1774465|NCT00381719|Drug|placebo capsule|Capsule twice daily for 4 weeks
1774466|NCT00387127|Drug|Lapatinib oral tablets|Lapatinib is administered orally once daily.
1774467|NCT00387127|Drug|radiotherapy|Radiotherapy is given either as conventional fractionation using Two-dimensional (2D) or conformal techniques, or as Intensity Modulated Radiation Therapy (IMRT). Radiation therapy will be standardised throughout the study. Radiation therapy is given only once daily, with a dose/fraction not exceeding 2.5Gy, to a total dose of 65 Gy (IMRT) or 70 Gy (2D or 3D RT) to the gross site of disease .
1774585|NCT00387946|Drug|SSR591813L (dianicline)|
1774468|NCT00387127|Drug|cisplatin chemotherapy|Cisplatin is administered intravenously at a dose of 100mg/m2 on days 1, 22 and 43 of radiotherapy (approximately Study Days 8, 29 and 50).
1774469|NCT00387140|Drug|MK2295|
1774470|NCT00387153|Drug|MPC-2130|MPC-2130 10 mg/mL administered by intravenous infusion over 1-2 hours
1774471|NCT00387179|Drug|Melatonin|5mg, pill, once
1774472|NCT00387179|Drug|Methylxanthine|2.9 mg/kg, pill, once
1774473|NCT00387179|Procedure|Light Therapy|Bright light exposure
1774474|NCT00387192|Drug|Optivate|Plasma-derived Factor VIII
1774475|NCT00387205|Drug|Pazopanib|Pazopanib monotherapy or in combination with lapatinib or other approved anti-cancer medications
1774476|NCT00387218|Behavioral|Exercise, Physical therapy|
1774477|NCT00387231|Procedure|Percutaneous coronary angioplasty/intervention (PCI)|
1774478|NCT00387231|Drug|Anti-ischemic drug therapy|
1774479|NCT00387244|Device|Precision for Spinal Cord Stimulation|Precision System aids in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with the following: failed back surgery syndrome, intractable back pain, and leg pain.
1774480|NCT00387257|Drug|Rilapladib (SB-659032)|
1774481|NCT00387270|Drug|Dimebon|Dimebon 10 or 20 mg TID x 7 days
1774482|NCT00387283|Drug|AVI-4020 Injection|
1774483|NCT00387296|Device|functional microarray|functional microarray application
1774484|NCT00387309|Drug|Methylnaltrexone (MOA-728)|
1774485|NCT00387322|Drug|erlotinib hydrochloride|Given orally
1774486|NCT00387322|Drug|pemetrexed disodium|Given IV
1774487|NCT00387335|Drug|sunitinib malate|Given orally
1774488|NCT00387348|Drug|escitalopram oxalate|escitalopram oxalate 10 mg once daily for 4 weeks
1774489|NCT00387348|Drug|Placebo|one placebo pill identical in appearance to the escitalpram pill once daily
1774490|NCT00387361|Procedure|Osteopathic Manipulative Treatment|20 minute post-operative osteopathic manipulation as described in the protocol
1774491|NCT00387374|Biological|bevacizumab|Given IV
1774492|NCT00387374|Drug|paclitaxel|Given IV
1774493|NCT00387374|Drug|carboplatin|Given IV
1774494|NCT00387374|Radiation|radiation therapy|Undergo radiotherapy
1774495|NCT00387387|Drug|pazopanib|
1774496|NCT00387400|Drug|everolimus|150 mg/m2/day PO Daily x 5, q 4 weeks
1774497|NCT00387400|Drug|temozolomide|2.5 mg PO Daily, beginning day 2 of cycle 1, q 4 weeks
1774498|NCT00387400|Genetic|microarray analysis|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
1774499|NCT00387400|Other|immunohistochemistry staining method|Tissue sections will be stained by immunohisto-chemistry using the following antibodies: EGFRvIII, PTEN, phospho-specific PKB/Akt Ser473; phosphor-mTORSer2448, p70S6K Thr389; S6 ribosomal protein Ser235/236. These antibodies are selected on the basis of providing a readout of upstream and downstream signaling through mTOR, and availability of antibodies that reliably stain paraffinembedded tissue.
1774500|NCT00387413|Drug|Duloxetine|Subjects will be receive hard gelatin capsules of Duloxetine at 30mg once daily for one week and 60mg once daily for the second week in Treatment Arm B.
1774501|NCT00387413|Drug|GSK189254|Subjects will receive film coated tablet of GSK189254 at 50 mcg once daily for a one week and 100 mcg once daily for the second week in Treatment Arm A.
1774502|NCT00387413|Drug|GSK189254 Placebo|Subjects will receive Placebo matching GSK189254 for 3 weeks in each period.
1774503|NCT00387413|Drug|Duloxetine Placebo|Subjects will receive Placebo matching Duloxetine for 3 weeks in each period.
1774504|NCT00387426|Drug|sunitinib malate|Given PO
1774505|NCT00387439|Behavioral|standard medical treatment + anoperineal physiotherapy.|
1774506|NCT00387439|Behavioral|Standard medical treatment|
1774507|NCT00387452|Behavioral|Aerobic Exercise and Strength Exercise|6 months of aerobic training exercise. regulated by heart rate; work up to 80% of maximal heart rate on treadmill or stationary bike; 3 hours a week, 90% attendance.
1774508|NCT00387452|Behavioral|Strength training|6 months of strength training exercise using weight machines involving legs and arms: 12-15 repetitions of weights per exercise; 3 hours a week, 90% attendance.
1774509|NCT00387465|Drug|Azacitidine|Given SC
1774510|NCT00387465|Drug|Entinostat|Given PO
1774511|NCT00387465|Other|Laboratory Biomarker Analysis|Correlative studies
1774512|NCT00387465|Other|Pharmacological Study|Correlative study
1774513|NCT00387478|Biological|Tree MATA MPL or Tree MATA|"4 injections of increasing dose strength for Tree MATA MPL or Tree MATA:
600 SU/0.5 ml
1600 SU/0.5 ml
4000 SU/0.5 ml
4000 SU/0.6 ml
4 injections of 0.5 mL of 2% w/v L-tyrosine for Placebo"
1774514|NCT00387491|Drug|MOA-728|
1774515|NCT00387504|Drug|fenretinide|4-HPR (Fenretinide) is given as a continuous intravenous infusion (CIV) for five consecutive days. Cycle is repeated every 3 weeks, if PR, CR or stable disease for 6 cycles.
1774516|NCT00387504|Other|pharmacological study|samples drawn per protocol
1774517|NCT00387517|Drug|Aliskiren/HCTZ|
1774518|NCT00387530|Drug|oral sodium phenylbutyrate|
1774519|NCT00387530|Drug|valganciclovir|
1774520|NCT00387530|Genetic|polymerase chain reaction|
1774521|NCT00387530|Genetic|protein expression analysis|
1774522|NCT00387530|Procedure|biopsy|
1774523|NCT00387556|Drug|Ondansetron|ondansetron (0.15 mg/kg/dose; maximum dose 4 mg)
1774524|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 20ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
1774525|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 60ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
1774526|NCT00387569|Biological|MnB vaccine rLP8026|MnB vaccine at 200ug dose (0,1,6 months) or control (Hepatitis A vaccine, placebo, Hepatitis A vaccine at 0,1,6 months, respectively)
1774527|NCT00387582|Drug|Ranibizumab (Lucentis)|Lucentis 0.5 mg monthly for the first three months and then per protocol for the duration of the trial.
1774528|NCT00387582|Procedure|Argon Laser|Argon laser at entry to trial and then per protocol for the duration of the study.
1774529|NCT00387608|Drug|veliparib|
1774530|NCT00387608|Other|pharmacological study|
1774531|NCT00387608|Procedure|biopsy|
1774532|NCT00387621|Drug|Nesiritide|The first 10 subjects in each group will receive a dose of 5 ug/kg and the next ten subjects will receive 10 ug/kg.
1774533|NCT00387621|Drug|Placebo|The pharmacy created a placebo subcutaneous injection volume to match the volume of the nesiritide dose.
1774534|NCT00387621|Drug|Saline|Normal saline 0.9% 0.25 ml/kg/min for 60 minutes
1774535|NCT00387634|Biological|TBE vaccine for adults|Serology blood draw.
1774536|NCT00387647|Drug|Azacitidine|Azacitidine given subcutaneously as outlined in treatment arm.
1774537|NCT00387660|Drug|carboplatin|Patients receive carboplatin IV over 15-30 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
1774538|NCT00387660|Drug|irinotecan|Patients receive irinotecan hydrochloride IV over 90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity.
1774539|NCT00387673|Behavioral|Somatosensory Stimulation and Massed Practice Training|a) somatosensory stimulation of the median, ulnar and radial nerves at the level of the wrist (2 hours/session); SS group b) somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); SS+ABT group and c) sham somatosensory stimulation of the median, ulnar and radial nerves at the wrist (2 hours/session) followed by an activity-based upper extremity training program (1 hour/session); ABT group then carry out training in the 3 subject groups simultaneously, each group consisting of 2 subjects at a time, with 2 sets of subjects/year over a 2-year period, yielding a target sample of 36 subjects.
1774540|NCT00387686|Drug|rhBMP-2/CPM|
1774541|NCT00387686|Drug|rhBMP-2/CPM|
1774542|NCT00387686|Drug|rhBMP-2/CPM|
1774543|NCT00387686|Drug|rhBMP-2/CPM|
1774544|NCT00387699|Biological|bevacizumab|
1774545|NCT00387699|Drug|cisplatin|
1774546|NCT00387699|Drug|etoposide|
1774547|NCT00387699|Radiation|radiation therapy|
1774548|NCT00387712|Other|Velocity based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill speed is gradually progressed to meet the training heart rate goals for moderate aerobic exercise, when hemiparetic gait velocity can no longer be progressed, incline is added to achieve heart rate training goals. Progression is also based on participant's tolerance, abilities and safety.
1774549|NCT00387712|Other|Duration based treadmill training|6 month of progressive treadmill walking with a safety harness and hand rail support to prevent falls. Treadmill duration is gradually progressed to meet the endurance goals for low aerobic intensity exercise, gait velocity and incline do not progress. Progression is based on participant's tolerance, abilities and safety.
1774550|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
1774551|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
1774552|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
1774553|NCT00387725|Biological|rLP2086|Vaccine administered at 0, 1, and 6 months
1774554|NCT00387738|Biological|Amb a 1 immunostimulatory oligodeoxyribonucleotide conjugate|Escalating doses, 6 weekly subcutaneous (under the skin) injections
1774555|NCT00387738|Biological|Histamine base|Escalating doses, 6 weekly subcutaneous (under the skin) injections
1774556|NCT00387751|Biological|Bevacizumab|Given IV
1774557|NCT00387751|Other|Laboratory Biomarker Analysis|Correlative studies
1774558|NCT00387751|Other|Pharmacological Study|Correlative studies
1774559|NCT00387751|Drug|Sorafenib Tosylate|Given orally
1774560|NCT00387764|Drug|pazopanib|800 mg daily dosing continously until progression
1774561|NCT00387777|Drug|Patch with centrally acting analgesic|
1774562|NCT00387777|Drug|Transtec(R) PRO (buprenorphine)|
1774563|NCT00387790|Drug|motexafin gadolinium|Given IV
1774564|NCT00387790|Radiation|3-dimensional conformal radiation therapy|Undergo focal cranial radiotherapy
1774565|NCT00387803|Device|Cardiac Resynchronization Therapy with Defibrillation|
1774566|NCT00387829|Device|DuraGen Plus Adhesion Barrier Matrix|Application of DuraGen Plus Adhesion Barrier Matrix in spine surgery
1774567|NCT00387842|Procedure|Laparoscopic surgery|
1774568|NCT00387842|Procedure|Conventional surgery|
1774569|NCT00387855|Behavioral|SOS program|screening and didactic programming to raise awareness of depression suicidality
1774570|NCT00387868|Drug|cisplatin and etoposide|Cisplatin: 50mg/m2 - administered on days 1,8,29&36 Etoposide: 50 mg/m2 - administered on days 1-5 & 29-33
1774571|NCT00387868|Procedure|Surgical Resection|Resection will take place 4-8 weeks after completion of radiotherapy.
1774572|NCT00387868|Radiation|Concurrent Radiotherapy|Preoperative External Beam Radiotherapy
1774573|NCT00387881|Drug|sumatriptan succinate / naproxen sodium|sumatriptan 85mg / naproxen sodium 500mg
1774574|NCT00387881|Drug|Placebo|Placebo to match Treximet tablets
1774575|NCT00387894|Drug|erlotinib hydrochloride|Tarceva will be self-administered in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients who are not receiving EIAED (Group A) will receive single-agent Tarceva, 150 mg/day. Patients on EIAED (Group B) will receive single-agent Tarceva, 600 mg/day. Tablets should be taken at the same time each day with 200 mL of water at least 1 hour before or 2 hours after a meal. Patients who are unable to swallow tablets may dissolve the tablets in distilled water for administration. The dose of Tarceva will be escalated after 14 days to 200 mg/day (Group A) or 650 mg/day (Group B) assuming no intolerable grade 2 rash, any grade 3 rash, or grade 2 diarrhea despite loperamide.
1774576|NCT00387907|Drug|larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
1774577|NCT00387907|Drug|trastuzumab|administered as a 90-minute IV infusion on Day 1 of every week (qw)
1774578|NCT00387920|Drug|sunitinib malate|Given orally
1774579|NCT00387920|Other|pharmacological study|Correlative studies
1774580|NCT00387920|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
1774581|NCT00387920|Other|laboratory biomarker analysis|Correlative studies
1774590|NCT00387959|Drug|fludarabine phosphate|
1774591|NCT00387959|Drug|mycophenolate mofetil|
1774592|NCT00387959|Procedure|allogeneic hematopoietic stem cell transplantation|
1774593|NCT00387959|Procedure|umbilical cord blood transplantation|
1774594|NCT00387959|Radiation|total-body irradiation|
1774595|NCT00387972|Drug|denagliptin (GW823093)|
1774596|NCT00387985|Drug|MOA-728|
1774597|NCT00387998|Other|AHRQ staying healthy booklet|educational booklet about prevention
1774598|NCT00387998|Other|Risk primer|Know your chances booklet
1774599|NCT00388011|Drug|Intranasal Morphine (MNS075) 3.75 mg|Intranasal Morphine (MNS075) 3.75 mg
1774600|NCT00388011|Drug|Intravenous Morphine 7.5 mg|Intravenous Morphine 7.5 mg
1774601|NCT00388011|Drug|Intranasal morphine (MNS075) 7.5 mg|Intranasal morphine (MNS075) 7.5 mg
1774602|NCT00388011|Drug|Intranasal morphine (MNS075) 15 mg|Intranasal morphine (MNS075) 15 mg
1774603|NCT00388011|Drug|Intranasal morphine (MNS075) 30 mg|Intranasal morphine (MNS075) 30 mg
1774604|NCT00388011|Drug|Intranasal placebo|Intranasal placebo
1774605|NCT00388037|Drug|sunitinib malate|Given PO
1774606|NCT00388037|Other|laboratory biomarker analysis|Correlative studies
1774607|NCT00388050|Behavioral|Diabetes Medication Choice decision aid|The decision aid covers five commonly prescribed anti-hyperglycemic medications and their attributes.
1774608|NCT00388050|Behavioral|Usual Care|Patients and clinicians in this arm will discuss anti-hyperglycemic agents in their usual manner.
1774609|NCT00388063|Drug|Atiprimod|oral, 14 days on / 14 days off; 30mg capsules
1774610|NCT00388076|Drug|Pazopanib|pazopanib in combination with paclitaxel in Part 1, paclitaxel and carboplatin in Part 2, and paclitaxel and lapatinib in Part 3
1774611|NCT00388076|Drug|Lapatinib|Lapatinib in combination with pazopanib and paclitaxel in Part 3
1774612|NCT00388076|Drug|paclitaxel|in combination with pazopanib
1774613|NCT00388076|Drug|carboplatin|in combination with pazopanib
1774614|NCT00388089|Drug|bortezomib|Dose level A: 1 mg/m2; Dose level B: 1.3 mg/m2; Dose level C: 1.6 mg/m2; Dose level D: 1.6 mg/m2
1774615|NCT00388089|Drug|topotecan hydrochloride|Dose level A: 3 mg/m2; Dose level B: 3 mg/m2; Dose level C: 3 mg/m2; Dose level D: 4 mg/m2
1774616|NCT00388089|Other|flow cytometry|No description
1774617|NCT00388089|Other|immunoenzyme technique|No description
1774618|NCT00388089|Other|immunohistochemistry staining method|No description
1774619|NCT00388089|Other|laboratory biomarker analysis|No description
1774620|NCT00388115|Procedure|conventional surgery|Standard of care lumpectomy or mastectomy following RFA
1774621|NCT00388115|Procedure|neoadjuvant therapy|Standard of care lumpectomy or mastectomy following RFA
1774622|NCT00388115|Procedure|radiofrequency ablation|A small diameter needle is inserted through the skin and directly into the tumor for the purpose of supplying RF current. Initial power of the RF generator will start at 5-10 watts. The power will increase by 5-10 watts every minute until impedance of the system automatically stops the RF treatment.
1774623|NCT00388128|Drug|Caffeine 6mg/kg|Capsules of caffeine 6 mg/kg, taken orally at each test. Before and after treadmill testing
1774624|NCT00388141|Behavioral|NIDCAP|Systematic care, where the mother and the nurses organize the caring on behalf of the preterm infants' ressources and developmental capacity such as the infant avoid over stimulation and distress
1774625|NCT00388154|Drug|Gemcitabine|900 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
1774626|NCT00388154|Drug|Cisplatin|30 mg/m^2 by vein over 1 hour on Day 1 and Day 8.
1774627|NCT00388167|Drug|Caspofungin|The patients are treated with 70 mg IV of caspofungin on day 1, followed by 50 mg/day IV during the rest of treatment
1774628|NCT00388180|Drug|GW501516|
1774629|NCT00388180|Drug|GW590735|
1774630|NCT00388193|Drug|RITUXIMAB|375 mg/m2/d day 1
1774631|NCT00388219|Drug|Transtec (R) PRO (buprenorphine)|
1774632|NCT00388245|Procedure|Percutaneous Coronary Intervention|
1774633|NCT00388245|Procedure|Coronary Artery Bypass Grafting|
1774634|NCT00388258|Drug|Alvimopan|
1774635|NCT00388271|Drug|Alfuzosin (Xatral)|standard treatment plus alfuzosin
1774636|NCT00388271|Drug|standard treatment|standard treatment
1774637|NCT00388284|Device|Arterial Sealing|
1774638|NCT00388297|Drug|Levothyroxine|Coded study drug is thyroxine encapsulated in a gel capsule; matching placebo contains only cellulose. Color of capsule corresponds to mcg dose level (100mcg or 25 mcg). Subjects in subclinical hypothyroidism stratum are started on 1 capsule of 100 mcg per day; subjects in hypothyroxinemia stratum are started on 2 capsules of 25 mcg per day. Thyroxine dosing adjustments for both strata are determined centrally, using an algorithm, based on results of monthly TSH or free-T4 assays. Subjects take study medication until delivery.
1774639|NCT00388297|Drug|Placebo for Levothyroxine|
1774640|NCT00388310|Procedure|Culture|Culture
1774641|NCT00388323|Other|blood and biopsies|blood and biopsies
1774642|NCT00388336|Drug|Epoetin Alfa|
1774643|NCT00388349|Drug|Gemcitabine|
1774644|NCT00388349|Drug|Vinorelbine|
1774645|NCT00388349|Drug|Carmustine|
1774646|NCT00388349|Drug|Etoposide|
1774647|NCT00388349|Drug|Cyclophosphamide|
1774648|NCT00388349|Procedure|Autologous HCT|
1774649|NCT00388362|Drug|Sirolimus|Patients will receive sirolimus at 2 mg/day orally with monitoring of trough drug levels weekly for 2 weeks to achieve trough drug levels 7-12 ng/ml. Along with prednisone therapy.
1774650|NCT00388362|Drug|Prednisone|Prednisone therapy will remain at the dose the patient received at the time sirolimus was begun. Withdrawal of prednisone will began after first evidence of improvement of chronic GVHD.
1774651|NCT00388375|Procedure|Ultrasound|limited ultrasound examination to evaluate the following areas: Examination of the subclavian and internal jugular veins to assess proper catheter placement PTX detection, using lung sliding and comet-tail artifact Visualization of the heart (right atrium and ventricle) and the inferior vena cava through the subcostal window
1774652|NCT00388388|Drug|losartan, hydrochlorothiazide|Losartan, 50-100 mg per day, once a day, for 6 months. Hydrochlorothiazide, 12.5-25 mg per day, once a day, for 6 months.
1774653|NCT00388401|Drug|Alvimopan|
1774656|NCT00388427|Drug|Dasatinib (BMS-354825)|100 mg, 150 mg, or 200 mg per dose escalation schedule; continuous oral dosing on Days 1-21 of each 21-day cycle until progression or unacceptable toxicity develops.
1774657|NCT00388427|Drug|Cetuximab (Erbitux, C225)|Loading dose of IV 400 mg/m^2 on Day 1 of Cycle 1; IV 250 mg/m^2 weekly thereafter each 21-day cycle until progression or unacceptable toxicity develops.
1774658|NCT00388440|Biological|MMR vaccine (Priorix)|
1774659|NCT00388453|Device|Dx-pH Probe|24 hour ph monitoring
1774660|NCT00388453|Procedure|Manometry|procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
1774661|NCT00388466|Device|GALILEO|
1774662|NCT00388479|Drug|Alvimopan|
1774663|NCT00388505|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder (TIP) capsules for inhalation.
1774664|NCT00388505|Drug|Tobramycin Solution for Inhalation|Tobramycin solution for inhalation (TOBI), supplied as 300 mg/5mL ampoules administered with a nebulizer
1774665|NCT00388518|Drug|Actos|45mg po daily
1774666|NCT00388518|Drug|Placebo|po daily
1774667|NCT00388518|Drug|aleglitazar|Administered po daily, at ascending doses with a starting dose (arm 1) of 0.05mg.
1774668|NCT00388531|Drug|Depocyte®|Depocyte® is a cytostatic drug
1774669|NCT00388544|Behavioral|Activity matched to interest|Recreational activities are tailored to subject's style of interest
1774670|NCT00388544|Behavioral|Activity matched to function|Recreational activities are tailored to subjects physical and cognitive functioning
1774671|NCT00388544|Behavioral|Activity matched to both interest and function|Recreational activities are tailored to both style of interest and physical and cognitive functioning.
1774672|NCT00388557|Drug|vinflunine + ketaconazole|vinflunine solution for injection, ketaconazole tablets, vinflunine IV, ketaconazole oral, vinflunine 80 to 320mg/m2 + ketaconazole 400 mg, vinflunine every 3 wks, ketaconazole C1 only, variable duration
1774673|NCT00388570|Device|The Aerocrine NIOX MINO® Airway Inflammation Monitor|
1774674|NCT00388583|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.1 mL, Intradermal
1774675|NCT00388583|Biological|Split, Inactivated, Trivalent Influenza Vaccine|0.5 mL, Intramuscular
1774676|NCT00388596|Drug|SB-751689|
1774677|NCT00388609|Drug|BMS-646256|Tablet, Oral, Once Daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
1774678|NCT00388609|Drug|Placebo|Tablet, Oral, Once daily, 12 weeks treatment followed by 20 week washout (ST); up to 190 weeks treatment (LT)
1774679|NCT00388622|Behavioral|Pharmacist intervention|
1774680|NCT00388635|Drug|Velcade|Phase I: Velcade, 1.0mg/m2-1.3mg/m2 in escalating doses every 6 weeks for 4 cycles Pase II: Velcade at optimal doses, twice a week (days 1, 4, 8, 11, 22, 25, 28 and 32) follow a rest period for 10 days (days 33 to 42)
1774681|NCT00388635|Drug|Melphalan|Melfalán 9mg/m2 days 1 to 4, V.O, follow by a rest period of 38 days in phse I and II
1774682|NCT00388635|Drug|Prednisone|Prednisone 60mg/m2 v.o days 1 to 4 follows by a rest period of 38 days (phase I and II)
1774683|NCT00388648|Drug|mixture of amino and keto acids|
1774684|NCT00388661|Drug|Melatonin tablet 3 mg once daily|Melatonin tablet 3 mg once daily
1774685|NCT00388661|Drug|Placebo comparator|Placebo comparator
1774688|NCT00388687|Drug|18F Fluoroazomycin Arabinoside (FAZA)|
1774689|NCT00388700|Drug|GM-CT-01|On Day 1 and 2 of each cycle, GM-CT-01 280 mg/m2 administered IV over 30 minutes with 5-FU (400 mg/m2), followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) with 5-FU (600 mg/m2 .)
1774690|NCT00388700|Drug|5-Fluorouracil, Leukovorin, bevacizumab|On Day 1 and 2 of each cycle, LV (200 mg/m2) will be administered IV over 2 hours, followed by 5-FU 400 mg/m2 in solution with GM-CT-01 280 mg/m2 administered over 30 minutes, followed by a 22-hour continuous infusion of GM-CT-01 (280 mg/m2) and 5-FU (600 mg/m2 ). on Day 3 Avastin® (5 mg/kg)will be given IV over 30 to 90 minutes per the package insert.
1774691|NCT00388713|Procedure|carotid intima-media thickening ultrasound|
1774692|NCT00388726|Drug|E7389|1.4 mg/m^2 intravenous (IV) infusion given over 2-5 minutes on Days 1 and 8 every 21 days.
1774693|NCT00388726|Drug|Physician's Choice|Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
1774694|NCT00388739|Drug|Pulmicort|
1774695|NCT00388739|Behavioral|TEDAS ED Educational Intervention|
1774696|NCT00388752|Procedure|Acupuncture|
1774697|NCT00388778|Drug|Doxycycline|
1774698|NCT00388791|Drug|Systane Free|
1774699|NCT00388804|Procedure|Radiation Therapy|Radiation treatment given over about 8 1/2 weeks; 42 treatments, 5 days per week with 2 days rest in between.
1774700|NCT00388804|Drug|Bicalutamide|50 mg By Mouth (PO) Daily
1774701|NCT00388804|Drug|Leuprolide|22.5 mg Intramuscularly (IM) Every 3 Months or 7.5 mg IM Every 1 Month
1774702|NCT00388804|Drug|Goserelin|10.8 mg Subcutaneously Every 3 Months or 3.6 mg Subcutaneously Every 1 Month
1774703|NCT00388804|Drug|Flutamide|250 mg by mouth three times daily on first 21-30 Days. May be used instead of Bicalutamide.
1774704|NCT00388804|Behavioral|Questionnaire|Questionnaires regarding health-related quality of life given before therapy begins, each taking about 15 minutes to complete.
1774705|NCT00394862|Drug|multivitamin|
1774706|NCT00394875|Procedure|Treated and educated by nurses specialized in diabetes.|
1774707|NCT00394888|Device|MRI|MRI of the spine.
1774708|NCT00394888|Device|MRI of head and neck|MRI of head and C-spine
1774709|NCT00394888|Other|Dermatological Examination|Complete dermatological examination to identify and characterize nature of dermatological anomalies
1774710|NCT00394888|Other|Cardiac examination|Complete cardiac examination
1774848|NCT00396747|Drug|Methotrexate + Infliximab|
1774711|NCT00394888|Device|Abdominal ultrasound|Abdominal ultrasound to detect hepatic hemangiomas
1774712|NCT00394901|Drug|Placebo|placebo, oral administration for 13 weeks (1 week titration and 12-week fixed dose).
1774713|NCT00394901|Drug|Pregabalin|Pregabalin 150mg/day (75mg BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
1774714|NCT00394901|Drug|Pregabalin|Pregabalin 300mg/day (150mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
1774715|NCT00394901|Drug|Pregabalin|Pregabalin 600 mg/day (300 mg/BID), oral administration for 13 weeks (1-week titration and 12-week fixed dose).
1774716|NCT00394914|Drug|Pleconaril|Pleconaril nasal suspension is supplied in a bottle containing 120 actuations. Each actuation contains 1.5 mg of pleconaril.
1774717|NCT00394914|Drug|Placebo to Pleconaril|Placebo nasal suspension
1774718|NCT00394953|Drug|Darbepoetin alfa|As prescribed, iv.
1774719|NCT00394953|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv / month, starting dose
1774720|NCT00394966|Drug|SCH 619734 Dose 1|SCH 619734 10 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
1774721|NCT00394966|Drug|SCH 619734 Dose 2|SCH 619734 25 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
1774722|NCT00394966|Drug|SCH 619734 Dose 3|SCH 619734 100 mg (2 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
1774723|NCT00394966|Drug|SCH 619734 Dose 4|SCH 619734 200 mg (4 capsules) x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
1774724|NCT00394966|Drug|Placebo|Matching placebo x 1 orally approximately 2 hours prior to the administration of the first chemotherapeutic agent on Day 1 of Cycle 1 and on Day 1 of all subsequent cycles (up to five additional cycles)
1774725|NCT00394992|Drug|oxaliplatin+capecitabine|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
1774726|NCT00394992|Drug|Oxaliplatin+capecitabine+bevacizumab|postoperatively oxaliplatin 130 mg/m2 i.v. day 1 plus bevacizumab 7.5 mg/kg on day 1 plus capecitabine 1000 mg/m2 b.i.d. on day 1-14, q3w
1774727|NCT00395018|Drug|entecavir|Tablets, Oral, 1 mg, once daily, up to 72 weeks
1774729|NCT00395044|Drug|Placebo|Placebo
1774730|NCT00395044|Drug|Gabapentin|
1774731|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 1000µg injection at Day 1, Month 1, Month 2
1774732|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 300µg injections, Day 1, Month 1, Month 2
1774733|NCT00395057|Drug|AGN 211745|AGN 211745 Solution 100µg injections, Day 1, Month 1, Month 2
1774734|NCT00395057|Drug|Ranibizumab 500µg|Ranibizumab 500µg injections at Day 1, Month 1, Month 2
1774735|NCT00395070|Biological|Allovectin-7®|Allovectin-7® 2 mg intralesional injection into a single lesion weekly for six consecutive weeks, repeated beginning after each 8th week.
1774736|NCT00395070|Drug|Dacarbazine (DTIC)|1000 mg/m2 intravenous infusion over 60 minutes, repeated every 28 days, OR
1774737|NCT00395070|Drug|Temozolomide (TMZ)|150 to 200 mg/m2 orally once daily for five consecutive days, repeated every 28 days.
1774738|NCT00395083|Behavioral|COPD Self-management Education|The comprehensive self-management intervention incorporates self-management education, development of an action plan, and case management. The intervention is designed using the social cognitive theory with the Precede-Proceed Model which has guided other successful patient education programs.
1774739|NCT00395109|Device|PET/CT|All study participates will be scanned with PET/CT scan before surgery.
1774740|NCT00395122|Device|Retinal nerve fiber layer and macular thickness measurements|
1774743|NCT00395148|Drug|rHDL|
1774744|NCT00395161|Drug|Metoclopramide|0.2 mg/kg/dose IV every 12 hours
1774745|NCT00395161|Drug|Zinc|one enteral dose daily of zinc chloride (10 mg/day elemental zinc for infants < or equal to one year of age, and 20 mg/day elemental zinc for patients > 1 year of age)
1774746|NCT00395161|Dietary Supplement|Glutamine|one enteral dose daily of glutamine 0.3 gm/kg/day
1774747|NCT00395161|Drug|Selenium|one enteral dose daily of selenium (40 μg for infants < 8 months of age, 60 μg for infants 8 to 12 months of age, 90 μg for children 1-3 years, 150 μg for children 4-8 years, 280 μg for children 9 to 13 years, and 400 μg for children > 13 years)
1774748|NCT00395161|Other|saline|equivalent volume of intravenous saline
1774749|NCT00395161|Other|sterile water|equivalent volume of sterile water
1774750|NCT00395161|Other|selenium|equivalent volume of sterile water
1774751|NCT00395161|Dietary Supplement|whey-protein|one enteral dose daily of whey-protein
1774752|NCT00395174|Biological|Influenza Vaccination|0.5mL dose for intramuscular injection
1774753|NCT00395187|Procedure|Photodynamic Therapy|
1774754|NCT00395200|Procedure|MSC Treatment|Intravenous administration of up to 2x10^6 autologous MSCs per kg
1774755|NCT00396045|Drug|Revlimid (CC-5013)|
1774756|NCT00396058|Drug|Methylphenidate|
1774757|NCT00396071|Drug|vildagliptin|vildagliptin 100 mg
1774758|NCT00396071|Drug|Placebo|matching placebo
1774759|NCT00396084|Drug|Gatifloxacin|Gatifloxacin 400 mg/day x 7 days.
1774760|NCT00396084|Drug|Levofloxacin|Levofloxacin 1000 mg/day x 7 days.
1774761|NCT00396084|Drug|Moxifloxacin|Moxifloxacin 400 mg/day x 7 days.
1774762|NCT00396084|Drug|Isoniazid|Isoniazid 300 mg/day x 7 days.
1774763|NCT00396084|Drug|Linezolid|Linezolid 600 mg/day x 7 days; Linezolid 600 mg every 12 hours x 7 days.
1774800|NCT00396370|Drug|Placebo (ID)|0.1 mL of sterile Sauton medium for intradermal administration.
1774849|NCT00396760|Drug|aprotinin or tranexamic acid|
1774764|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
1774765|NCT00396097|Drug|Genotropin|Compare daily injections of formula-based HGH treatment to daily injections of standard HGH treatment in subjects with Idiopathic Short Stature over 24 months period followed by an exploratory 24 months period.
1774766|NCT00396136|Device|Corox OTW Steroid Left Ventricular Lead|This is a registry: no study required interventions necessary.
1774767|NCT00396149|Biological|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
1774768|NCT00396149|Biological|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 50 to 300 µg rBet v 1.
1774769|NCT00396162|Drug|probiotic containing L.rhamnosus R0011 strain|500 million active cells of L rhamnosus R0011 strain per tablet bid for 4 weeks
1774770|NCT00396162|Other|Placebo|Placebo pill
1774771|NCT00396175|Drug|MK0906, finasteride / Duration of Treatment : 48 Weeks|
1774772|NCT00396175|Drug|Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks|
1774773|NCT00396201|Drug|G-CSF Plus Plerixafor|Randomized participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
1774774|NCT00396214|Drug|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 1 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
1774775|NCT00396214|Drug|Quetiapine|Fixed oral dose of quetiapine at 400 mg/day to be administered in divided doses (BID) utilizing a 5-day upward titration from 50 mg/day.
1774776|NCT00396214|Drug|Bifeprunox|52 weeks of fixed oral doses of bifeprunox at 30 mg/day administered as a single dose with 2 week upward titration from 0.25 mg/day dose. Placebo will be used for evening dose.
1774777|NCT00396227|Drug|vildagliptin|vildagliptin as add-on to metformin
1774778|NCT00396227|Drug|thiazolidinedione (TZD)|TZD add-on to metformin
1774779|NCT00396240|Drug|Rosuvastatin|
1774780|NCT00396240|Procedure|Initiatives to improve compliance|
1774781|NCT00396253|Drug|Tenecteplase|2 mL (2 mg) of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter.
1774782|NCT00396266|Drug|G-CSF Plus Plerixafor|Participants underwent mobilization with G-CSF 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 5 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
1774783|NCT00396279|Biological|Denosumab|Administered by subcutaneous injection
1774784|NCT00396279|Dietary Supplement|Calcium/Vitamin D|
1774785|NCT00396292|Drug|Oral iron tablets|325 mg tablets (65 mg elemental iron) with instructions to take 1 tablet by mouth (PO) TID with 8 ounces of tap water, 1 hour before meals from Day 0 until Day 42
1774786|NCT00396292|Drug|VIT-45|A maximum of 1,000 mg iron as IV VIT-45 given at weekly intervals until the the cumulative dose has been reached or a maximum of 2,500 mg has been administered
1774787|NCT00396305|Drug|Placebo|Sterile phosphate buffered saline solution.
1774788|NCT00396305|Biological|Trivalent Inactivated Influenza|The trivalent influenza vaccine is a sterile suspension prepared from the allantoic fluids of chicken embryos infected with a specific type of influenza virus. Each 0.5 mL dose of the vaccine contains 15 mcg hemagglutinin (HA) of 3 strains of virus (H1N1, H3N2, and B). The vaccine is a liquid preparation; as such, no diluent is required. It is essentially clear and slightly opalescent in color.
1774789|NCT00396318|Drug|tenecteplase|"2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC.
Patients weighing ≥ 30 kg received 2-mL instillations of tenecteplase (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of tenecteplase equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg)."
1774790|NCT00396331|Drug|G-CSF plus plerixafor|Participants underwent mobilization with granulocyte colony-stimulating factor (G-CSF) 10 µg/kg/day for 4 days, administered by subcutaneous injection (SC) injection each morning. On the evening of Day 4, participants received a dose of plerixafor 240 µg/kg, administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF 10 µg/kg and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor (within 60 minutes after administration of G-CSF). Participants continued to receive an evening dose of plerixafor followed the next day by a morning dose of G-CSF and apheresis for up to a maximum of 7 aphereses or until ≥ 2*10^6 CD34+ cells/kg were collected.
1774791|NCT00396344|Other|Çontrol|Intravenous saline
1774792|NCT00396344|Drug|Hydrocortisone|Intravenous stress dose of hydrocortisone
1774793|NCT00396344|Drug|Hydrocortisone|Intravenous pharmacologic hydrocortisone
1774794|NCT00396357|Drug|Vildagliptin|
1774795|NCT00396357|Drug|metformin|
1774796|NCT00396370|Biological|Connaught strain BCG|Connaught strain Bacillus Calmette-Guerin (BCG), 8-32 x 10^5 CFU vaccine for intradermal administration.
1774797|NCT00396370|Drug|Placebo (PO)|60 mL of sterile phosphate buffered saline (PBS) for oral administration.
1774798|NCT00396370|Biological|BCG (ID)|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 2-8 X 10^5 colony-forming units (CFU) intradermal in 100 microliters diluent.
1774799|NCT00396370|Biological|BCG (PO)|Bacillus Calmette-Guerin (BCG) strain Danish from the Statens Serum Institute (SSI BCG). 1.2 X 10^8 colony-forming units (CFU) oral (PO) in 60 mililiters phosphate buffered saline (PBS).
1774801|NCT00396383|Drug|plerixafor|Participants were given a 240 µg/kg dose of plerixafor by subcutaneous injection in the morning followed by apheresis 6 hours later. Daily treatment with plerixafor followed by apheresis was administered for up to 4 consecutive days or until 4*10^6 CD34+ cells/kg body weight had been collected.
1774803|NCT00396409|Drug|Depigoid|Administered in 4-week intervals using 0.5 ml of vial 2 (1000 DPP/mL)
1774804|NCT00396409|Drug|Omalizumab|anti-IgE (Omalizumab) given during the 2006 core study
1774805|NCT00396409|Drug|Placebo|Placebo given during the 2006 core study
1774806|NCT00396422|Drug|RWJ-445380|
1774807|NCT00396435|Drug|Neorecormon|Administration SC one a week in patients randomized in group A Administration SC if Hb below 10.5 g/dl in group B
1774808|NCT00396448|Drug|CP-945,598 Treatment B|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
1774809|NCT00396448|Drug|CP-945,598 Treatment A|Subjects receive CP-945,598 plus dietary, physical activity, and behavioral counseling.
1774810|NCT00396448|Drug|Placebo|Subjects receive placebo plus dietary, physical activity, and behavioral counseling.
1774811|NCT00396461|Drug|MCT/LCT (1:1)|Emulsion based on 20% MCT/LCT (50:50 ratio)
1774812|NCT00396461|Drug|MCT/LCT/omega-3 (5:4:1)|Emulsion based on 20% MCT/LCT/w3 (50:40:10 ratio), medium- and long-chain triglycerides and fish oil triglycerides.
1774813|NCT00396474|Other|post GH treatment observational study|Intravenous glucose tolerance test (IVGTT)
1774814|NCT00396487|Drug|Capecitabine, Irinotecan, 5-Fluorouracil+Calciumfolinat|
1774815|NCT00396500|Drug|Albendazole (400 mg) and/or Vitamin a|
1774816|NCT00396513|Drug|Simvastatin|
1774817|NCT00396513|Drug|Simvastatin and Metformin|
1774818|NCT00396513|Drug|Metformin|
1774819|NCT00396526|Drug|Oral Co-trimoxazole (8mg/kg/day trimithoprim) twice a day for five days vs. oral amoxycillin (20 mg/kg/day) thrice a day for three days.|
1774820|NCT00396552|Device|refractory transcranial magnetic stimulation (rTMS)|Bilateral rTMS will be delivered according to the following protocol: high frequency left (HFL) stimulation will initially be applied at 20 Hz, in 25 trains of 1.5 second duration with a 30 second interval between trains and at 100% of the RMT for a total of 25 minutes of stimulation. Following this HFR stimulation will be applied at the same parameters. Therefore a total of 50 minutes of stimulation will be delivered.
1774821|NCT00396552|Device|Sham condition|Sham stimulation will be made at the site of active treatment but with only the side edge resting on the scalp. It will be administered as HFL and HFR for 50 minutes but with the coil angled 45-90 degrees away from the skull in a single-wing tilt position. This method produces sound and some somatic sensation (e.g., contraction of scalp muscles) similar to those with active stimulation but with minimal direct brain effects. Participants will be unable to see the stimulating coil and therefore will remain blind to the treatment condition.
1774822|NCT00396565|Drug|ER OROS paliperidone|Type= exact number, unit= mg, number= 3, form= tablet, route= oral use. Two tablets once daily for 6 weeks.
1774823|NCT00396565|Drug|Placebo|Form= tablet, route= oral use. Two tablets once daily for 6 weeks.
1774824|NCT00396565|Drug|Olanzapine|Type= exact number, unit= mg, number= 2.5, form= tablet, route= oral use. Four tablets once daily for 6 weeks.
1774825|NCT00396578|Drug|aerosolized vancomycin or gentamicin|
1774826|NCT00396591|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4.0 mg/kg administered intravenously (IV) once every 2 weeks
1774827|NCT00396604|Drug|indacaterol maleate|
1774828|NCT00396617|Device|prothesis voice|The device may be used for patient using another type of voice prosthesis, of for patient undergoing total laryngectomy. This device is definitively placed in two parts:The first one is introduced in the puncture (TEP) through the esophagus (retrograde way). The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
1774829|NCT00396617|Procedure|total laryngectomy|The second part is then clipped on the first one through the tracheotomy orifice (anterograde way).A third part containing the valve can then be clipped in the prosthesis and easily removed in order to change it as often as necessary.
1774830|NCT00396630|Biological|Rotarix|Two-dose oral vaccination.
1774831|NCT00396630|Biological|Placebo|Two-dose oral administration.
1774832|NCT00396643|Drug|Omega 3 fatty acids|The active treatment is a supplement of yellow gelatin 0.5 g fish oil capsules. The daily dose of 4 (2x2) capsules provides 700 mg of eicosapentaenoic acid and 500 mg of docosahexaenoic acid, and 10 mg of Vitamin E. Placebo treatment comprises coconut oil capsules, carefully matched with the active treatment with respect to both appearance and flavor, also containing 10 mg Vitamin E, and 10 mg of fish oil to mimic taste. Coconut oil was chosen as placebo because it does not contain polyunsaturated fatty acids and has no impact on n-3 fatty acid metabolism. The intervention period is 12 weeks.
1774833|NCT00396656|Drug|Atenolol|100 mg tablets orally once a day (od) in the morning.
1774834|NCT00396656|Drug|Hydrochlorothiazide (HCTZ))|12.5 or 25 mg tablets orally once a day (od) in the morning.
1774835|NCT00396656|Drug|Valsartan|80 mg, 160 mg, or 320 mg tablets orally once a day in the morning
1774836|NCT00396669|Drug|Bupropion|We measure dopamine release at the striatum using 11 C Raclopride at baseline and after smoking a cigarette
1774837|NCT00396669|Drug|Bupropion|Brain imaging after treatment with Bupropion
1774838|NCT00396682|Drug|Cyclophosphamide|150 - 250 - 350 mg
1774839|NCT00396695|Procedure|Blood test|
1774840|NCT00396708|Device|myomo e100 neurorobotic elbow brace|
1774841|NCT00396721|Drug|ACE inhibitor + statin|sirolimus starting at 1 mg/d (target 3-6 ng/ml) plus enalapril starting at 5 mg/d to control blood pressure plus atorvastatin starting at 10 mg/d
1774842|NCT00396721|Drug|Sirolimus (study drug)+ACE inhibitor + statin|enalapril starting at 5 mg/d in order to control blood pressure. Atorvastatin starting at 10 mg/d
1774843|NCT00396734|Drug|Provigil (Modafinil)|Increase from 100mg to 400mg during 1 month of treatment
1774844|NCT00396734|Drug|Topamax (Topiramate)|Increase from 25mg to 200mg in one month (double every week)
1774845|NCT00396747|Drug|Infliximab, methylprednisolone, methotrexate|
1774846|NCT00396747|Drug|Methotrexate|
1774847|NCT00396747|Drug|Methotrexate + Methylprednisolone|
1774850|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 5 mg once daily plus placebo enoxaparin syringe
1774851|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 10 mg once daily plus placebo enoxaparin syringe
1774852|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 20 mg once daily plus placebo enoxaparin syringe
1774853|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 30 mg once daily plus placebo enoxaparin syringe
1774854|NCT00396786|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Rivaroxaban 40 mg once daily plus placebo enoxaparin syringe
1774855|NCT00396786|Drug|Enoxaparin|Enoxaparin 40 mg once daily plus Rivaroxaban placebo tablets
1774856|NCT00396799|Drug|bazedoxifene/conjugated estrogens|
1774857|NCT00396812|Drug|Rituximab|"Participants to receive an intravenous infusion of rituximab (1 gram ) fourteen days apart, at baseline (Day 0) and at Week 2.
Concomitant treatments to be administered at a dose and frequency prescribed per protocol include methotrexate (MTX) and folic or folinic acid."
1774858|NCT00396825|Behavioral|Video-based coping skills training with telephone coaching|Subjects will view the 10 modules of Williams LifeSkills Caregiver Video, do Workbook exercises for each module, and receive telephone coaching to enhance their ability to apply the skills taught in each module to caregiver situations.
1774859|NCT00396851|Drug|Gurmar|
1774860|NCT00396851|Drug|Metformin|
1774861|NCT00396864|Drug|NPI-0052|NPI-0052 IV injection at doses ranging from 0.0125 to 0.8 mg/m2 over 1 to 10 minutes on Day 1, Day 8, Day 15 of each 28-day Cycle; 11 dose cohorts during dose-escalation
1774862|NCT00396877|Drug|Clopidogrel (SR25990)|"Form: reconstituted solution using Clopidogrel powder
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight"
1774863|NCT00396877|Drug|placebo|"Form: reconstituted solution using matching placebo powder
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight"
1774864|NCT00396903|Device|catheter|
1774865|NCT00396916|Device|PET/CT imaging|
1774866|NCT00396929|Drug|local intracoronary dosis of Paclitaxel|
1774867|NCT00396955|Drug|PLA-695|
1774868|NCT00396968|Drug|AMD3100|
1774869|NCT00396968|Procedure|Allogeneic Stem Cell Transplantation|
1774870|NCT00396981|Device|Matrix 2® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
1774871|NCT00396981|Device|GDC® coils for endovascular aneurysm occlusion|endovascular aneurysm occlusion coil
1774872|NCT00396994|Device|Low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a vibrating platform set at 0.3 g and 30 Hz
1774873|NCT00396994|Device|Sham low magnitude mechanical stimulation|10 minutes per day of low magnitude mechanical stimulation using a sham vibrating platform
1774874|NCT00397007|Behavioral|Biofeedback-based cognitive-behavioural intervention|
1774877|NCT00397033|Drug|Paliperidone ER|6mg/day paliperidone er for 6 weeks
1774878|NCT00397033|Drug|Paliperidone ER|12mg/day paliperidone er for 6 weeks
1774879|NCT00397033|Drug|Placebo|Placebo for 6 weeks
1774881|NCT00397059|Drug|Escitalopram|
1774882|NCT00397072|Drug|ZK 219477|
1774883|NCT00397098|Drug|SR58611A|
1774884|NCT00397124|Device|PET/CT imaging|
1774885|NCT00397137|Procedure|Circular stapled anopexy|
1774886|NCT00397137|Procedure|Closed diathermy haemorrhoidectomy|
1774887|NCT00397150|Behavioral|Peer-support for exclusive breastfeeding|Counselling to support exclusive breastfeeding up to the age of 6 months of age by the use of peer-counsellors in the local community
1774888|NCT00397163|Procedure|Remote ischemic preconditioning|Blood pressure cuff inflation
1774889|NCT00397163|Procedure|Placebo|Deflated cuff on upper arm and thigh for 20 min
1774890|NCT00397176|Drug|desvenlafaxine succinate sustained release (DVS SR)|
1774891|NCT00397189|Drug|Circadin|Prolonged release melatonin 2 mg
1774892|NCT00397189|Drug|placebo circadin|placebo circadin tablets
1774893|NCT00397202|Device|Diva Cup TM|See Detailed Description.
1774894|NCT00397215|Biological|Pandemic influenza vaccine (GSK1562902A) (adjuvanted or not)|intramuscular injection
1774895|NCT00397215|Biological|Fluarix|Intramuscular injection. All subjects not vaccinated with an influenza vaccine for the 2006-2007 season received Fluarix NH 2006/2007 (i.e. interpandemic GSK's influenza vaccine) at least 3 weeks before administration of the first dose of H5N1 vaccine.
1774896|NCT00397228|Drug|ALTROPANE®|ALTROPANE® SPECT imaging
1774897|NCT00397241|Drug|Drug: dorzolamide/timolol|
1774898|NCT00397241|Drug|Drug: latanoprost/timolol|
1774899|NCT00397241|Drug|dorzolamide/timolol and latanoprost|
1774900|NCT00397241|Drug|placebo (artificial tears)|
1774901|NCT00397254|Drug|rizatriptan|10mg ODT 27 tablets
1774902|NCT00397254|Drug|rizatriptan|10mg ODT 9 tablets
1774903|NCT00397267|Drug|inhalation of corticosteroids|
1774904|NCT00397293|Drug|AT-101|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
1774905|NCT00397293|Drug|topotecan|40 mg of AT-101 (by mouth) on days 1-5 of each 21 day cycle with topotecan 1.25 mg/m2, IV (in the vein) on days 1-5 of each 21 day cycle for approx. 4 cycles or until progression or unacceptable toxicity develops.
1774906|NCT00397306|Device|Bioimpedance Analysis|
1774907|NCT00397319|Drug|Growth Hormone|
1774908|NCT00397332|Drug|Alefacept|IM Alefacept
1774909|NCT00397345|Biological|Trovax|1ml IM injection 2-8 weeks apart.
1774910|NCT00397358|Drug|Extraneal (7.5% icodextrin) Peritoneal Dialysis Solution|
1774911|NCT00397384|Drug|cetuximab|Given IV
1774912|NCT00397384|Drug|erlotinib hydrochloride|Given PO
1774913|NCT00397384|Other|laboratory biomarker analysis|Correlative studies
1774914|NCT00397410|Device|Hip protectors|
1774915|NCT00397423|Drug|Granulocyte Colony Stimulating Factor|Granulocyte Colony Stimulating Factor,5ug/kg/day iH Qd*5 days,3 months interval for 4 times
1774916|NCT00397423|Drug|NS|NS 1ml iH Qd*5 days, 3 months interval for 4 times
1774917|NCT00397436|Procedure|UV Irradiation|UV irradiation
1774918|NCT00397449|Biological|GMZ2 (GLURP + MSP3 Hybrid) (malaria vaccine)|
1774919|NCT00397462|Device|calf muscle pump stimulation|Micromechanical stimulation of the postural reflex arc to activate the soleus muscle to enhance lower limb fluid return to the heart
1774920|NCT00397475|Drug|Colecalciferol|
1774921|NCT00397488|Drug|sunitinib malate|
1774922|NCT00397501|Biological|trastuzumab|"Trastuzamab, 6mg/kg, within 48 hrs before BBBD
Then, Trastuzumab, 2mg/kg, weekly until next BBBD Then continue for 12 cycles"
1774923|NCT00397501|Drug|carboplatin|200mg/m2/day x 2 days; total dose 400mg/m2 Infused i.a. over 10 mins in 200ml of normal saline after MTX infusion
1774924|NCT00397501|Drug|methotrexate|2500 mg/day x 2 days; total dose 5000mg Infused over 10mins in 200ml saline beginning immediately after mannitol infusion
1774925|NCT00397501|Drug|sodium thiosulfate|STS dose admin i.v. over 15mins @ 4hrs post carboplatin = 20gm/m2; STS dose admin i.v. over 15mins @ 8hrs post carboplatin = 16gm/m2
1774926|NCT00397514|Procedure|Congenital Heart Surgery Patients|undergoing either Biventricular (BiV) pacing or Right Ventricular (RV) Pacing
1774927|NCT00397527|Drug|lactoserum|
1774928|NCT00397540|Procedure|PEIT|Percutaneous Ethanol Injection Therapy
1774929|NCT00397540|Procedure|RFTA|Radiofrequency Thermal Ablation
1774930|NCT00397553|Drug|Insulin glulisine|
1774931|NCT00397566|Drug|HIV Integrase Inhibitor (BMS-707035)|
1774932|NCT00397579|Drug|DT388IL3|Intravenously via a 3 cc plastic syringe as a 15 minute bolus infusion daily for five days.
1774933|NCT00397592|Drug|Growth Hormone|
1774934|NCT00397605|Drug|Synthetic cannabinoids (1:1 ratio of THC % CBD)|Randomized crossover study of 2 weeks of active study medication (maximum daily dosage of 60 mg) vs. 2 weeks of matching placebo.
1774935|NCT00397631|Drug|sitagliptin 100 mg q.d./pioglitazone 30 mg q.d|Patients will receive initial combination therapy with blinded sitagliptin 100 mg q.d. and open- label pioglitazone 30 mg q.d. for up to 24 Weeks. Sitagliptin 100 mg q.d. and pioglitazone 30 mg q.d. will be administered as oral tablets.
1774936|NCT00397631|Drug|Comparator: placebo to match sitagliptin 100 mg q.d./pioglitazone 30 mg q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open label pioglitazone 30 mg q.d. for up to 24 Weeks. Placebo to match sitagliptin 100 mg q.d.(blinded) and open-label pioglitazone 30 mg q.d. will be administered as oral tablets.
1774937|NCT00397644|Behavioral|Prompting (survey instrument/resources list) (behavior)|
1774938|NCT00397657|Drug|extended release niacin|Extended release niacin will be started at 1000mg and titrated to 2000mg once a day
1774939|NCT00397657|Drug|ezetimibe|Ezetimibe 10mg once daily
1774940|NCT00397670|Drug|Drug: BufferGel® with diaphragm|
1774941|NCT00397683|Drug|MK0822|
1774942|NCT00397696|Drug|[123I] 5-IA|All subjects will undergo written informed consent and a screening evaluation including baseline clinical laboratory testing, a baseline physical and neurological evaluation and baseline cognitive evaluations using the MMSE, the ANAM computerized cognitive battery, and other tests of executive function. All subjects will be evaluated with United Parkinson Disease Rating Scales (UPDRS) following an overnight withdrawal of anti-parkinson medication. Subjects will be asked to undergo an injection of [123I] 5-IA followed by SPECT imaging as described below. A second [123I] 5-IA and SPECT imaging study will be obtained for reliability testing between 2 weeks and 2 months following the initial [123I] 5IA imaging session.
1774943|NCT00397709|Drug|I ( isoniazid), II (isoniazid + rifampin )|
1774946|NCT00397735|Procedure|amniocentesis|Amniotic fluid will be retrieved for routine amniocentesis to rule-out or confirm intra-amniotic infection and /or inflammation. The amniocentesis procedure will be clinically indicated and the patient will undergo the procedure independent of our study.
1774947|NCT00397735|Drug|N-acetylcysteine or placebo|Only women with amniocentesis results consistent with infection/inflammation will be randomized
1774948|NCT00397761|Drug|capecitabine|
1774949|NCT00397761|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1774950|NCT00397761|Procedure|neoadjuvant therapy|
1774951|NCT00397774|Behavioral|Physical exercise|Physical exercise twice a week for 8 weeks, and best supportive care
1774952|NCT00397774|Other|best supportive care|
1774953|NCT00397787|Drug|sunitinib malate|Given PO
1774954|NCT00397800|Biological|rituximab|
1774955|NCT00397800|Drug|cyclophosphamide|
1774956|NCT00397800|Drug|fludarabine phosphate|
1774957|NCT00397800|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1774965|NCT00397826|Drug|MK0733|Duration of Treatment: 12 Weeks
1774966|NCT00397839|Drug|Ibandronate|Ibandronate orally (tablet) at a dose of 150 mg once per month
1774967|NCT00397839|Drug|placebo|Placebo orally (tablet) at a dose of 150 mg once per month
1774968|NCT00397852|Procedure|Kirschner-wires or not|
1774969|NCT00397865|Behavioral|Educational booklet|Parental perception of educational booklet and evaluating any change in child's weight.
1774970|NCT00397878|Drug|saracatinib|Given orally
1774971|NCT00397878|Other|laboratory biomarker analysis|Correlative studies
1774972|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
1774973|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
1774974|NCT00397891|Drug|bapineuzumab|The dose cohorts are as follows: 0.15 mg/kg AAB-001; 0.5 mg/kg AAB-001; 1.0 mg/kg AAB-001. Placebo is vehicle (all ingredients except active). In each dose cohort, designated as groups 1 to 3, study drug (AAB-001 or placebo) will be administered as an intravenous infusion over 1 hour.
1774975|NCT00397904|Biological|cetuximab|
1774976|NCT00397904|Drug|cisplatin|
1774977|NCT00397904|Drug|irinotecan hydrochloride|
1774978|NCT00397904|Other|immunohistochemistry staining method|
1774979|NCT00397904|Other|laboratory biomarker analysis|
1774980|NCT00397904|Procedure|biopsy|
1774981|NCT00397917|Drug|Folic acid: 4 mg versus 0.4 mg per day|Folic acid
1774982|NCT00397930|Procedure|Standard Care Control Condition|Cancer survivors assigned to this condition continued with the standard follow-up care provided by their treating oncologists as appropriate for individual diagnoses. Participants in the control condition were offered the 4-week YOCAS program gratis after completing all study requirements.
1774983|NCT00397930|Procedure|Yoga Intervention (YOCAS)|The Yoga for Cancer Survivors (YOCAS) intervention uses two forms of yoga: Gentle Hatha yoga and Restorative yoga. The YOCAS sessions are standardized, and each session includes physical alignment postures, breathing and mindfulness exercises. The intervention is delivered in an instructor taught, group format, twice a week for 75 minutes each time over 4 weeks for a total of eight sessions of yoga. All sessions were taught in community-based sites (eg. yoga studios, community centers, community oncology practices) with an average group size of 12 (range, 10-15) in the late afternoon or evening after 4pm.
1774988|NCT00397956|Drug|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
1774989|NCT00397969|Other|counseling intervention|
1774990|NCT00397969|Procedure|screening colonoscopy|
1774991|NCT00397982|Biological|Bevacizumab|Given IV
1774992|NCT00397982|Other|Laboratory Biomarker Analysis|Correlative studies
1774993|NCT00397982|Drug|Temsirolimus|Given IV
1774994|NCT00397982|Procedure|Therapeutic Conventional Surgery|Undergo tumor resection
1774995|NCT00397995|Procedure|above- or under elbow cast|
1774996|NCT00398008|Drug|Buprenorphine/Subutex|Opioid agonist medication to treat opiate dependence
1774997|NCT00398008|Drug|Naltrexone|Opioid antagonist medication to treat opiate dependence
1774998|NCT00398008|Behavioral|Drug counseling|DC-HIV: Drug Counseling that provides education about HIV, drug abuse and dependence; encourages medication adherence; uses motivational enhancement techniques; encourages life style changes; and teaches cognitive and behavioral coping skills to prevent relapse
1774999|NCT00398034|Drug|Testosterone Gel|
1775000|NCT00398047|Drug|Azacitadine and Hematopoietic Growth Factors|Combination of Azacitadine and Hematopoietic Growth Factors
1775001|NCT00398060|Behavioral|Cognitive-behavioral life-style counseling|
1775002|NCT00398073|Biological|mouse gp100 plasmid DNA vaccine|
1775003|NCT00398073|Device|The Dermal PowderMed® devices|
1775004|NCT00398073|Other|intramuscularly (IM injection)|
1775005|NCT00398086|Drug|Gemcitabine|Administered by intravenous infusion over 30 minutes.
1775006|NCT00398086|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion over 30 minutes.
1775007|NCT00398099|Drug|MK0826, ertapenem sodium / Duration of Treatment: 14 Days|
1775008|NCT00398112|Drug|sunitinib malate|Given orally
1775009|NCT00398112|Other|pharmacological study|Correlative studies
1775010|NCT00398112|Other|laboratory biomarker analysis|Correlative studies
1775011|NCT00398125|Drug|GSK364735|
1775012|NCT00398138|Biological|WT-1 analog peptide vaccine|
1775013|NCT00398138|Biological|incomplete Freund's adjuvant|
1775014|NCT00398138|Biological|sargramostim|
1775015|NCT00398138|Genetic|polymerase chain reaction|
1775016|NCT00398138|Other|flow cytometry|
1775017|NCT00398138|Other|immunoenzyme technique|
1775018|NCT00398151|Drug|MK0476, montelukast sodium / Duration of Treatment: 12 Weeks|
1775019|NCT00398190|Behavioral|Control|Standard anti-tobacco programming
1775020|NCT00398190|Behavioral|Media Literacy|Anti-smoking media literacy curriculum intervention
1775021|NCT00398203|Device|NaviAid™ BGE Device|NaviAid™ Balloon Guided Endoscopy Device
1775022|NCT00398216|Drug|DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor|
1775023|NCT00398229|Drug|s.c. human chorionic gonadotropin (Ovitrelle)|S.C. Ovitrelle 250 mcg once
1775024|NCT00398242|Device|above or below elbow cast for the last 3 weeks of treatment|
1775025|NCT00398255|Behavioral|self-management program|
1775026|NCT00398268|Procedure|Kirschner-wire fixation|
1775027|NCT00398281|Drug|dutasteride|Given orally
1775028|NCT00398281|Other|placebo|Given orally
1775029|NCT00398294|Drug|MK0733, simvastatin / Duration of Treatment: 12 Weeks|
1775030|NCT00398307|Drug|S-1/Cisplatin|"S-1 administration will be determined by degree of renal impairment as follows:
Group A (Control): 30 mg/m2 BID Group B (Mild renal dysfunction): 30 mg/m2 BID Group C (Moderate renal dysfunction): 20 mg/m2 BID Group D (Severe renal dysfunction): 20 mg/m2 QD
Pharmacokinetic Phase (Part 1):
On Days -2 and 14 of the Pharmacokinetic Phase, patients will receive a single dose of S-1 administered orally in the morning.
Treatment will be followed by 1 week of recovery (Days 15 through 21).
Extension Phase (Part 2):
S-1 will be administered orally for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
1775031|NCT00398320|Drug|Capecitabine|850 mg/m2 by mouth twice a day for days 1-14 oa a 21 day cycle
1775032|NCT00398320|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 21 day cycle
1775033|NCT00398320|Drug|Bevacizumab|7.5mg/kg Intravenous on day 1 of a 21 day cycle
1775034|NCT00398333|Dietary Supplement|Eicosapentaenoic acid enriched nutritional supplement|Oral intake of nutritional supplementation: a maximum of 480 mL or a minimum of 240 mL daily during the first 3 months of the study.
1775035|NCT00398359|Behavioral|Motivational Interviewing (physicians)|Identifying and referring children with BMI >93%.
1775036|NCT00398359|Behavioral|Behavior Modification (families)|Group meetings and individual family meetings based on behavior modification for healthy lifestyle changes.
1775037|NCT00398372|Drug|Rituximab|
1775038|NCT00398372|Drug|Epratuzumab|
1775039|NCT00398385|Drug|cisplatin|
1775040|NCT00398385|Drug|gemcitabine hydrochloride|
1775041|NCT00398385|Procedure|adjuvant therapy|
1775042|NCT00398385|Procedure|conventional surgery|
1775043|NCT00398385|Procedure|neoadjuvant therapy|
1775044|NCT00398398|Drug|Capecitabine, Oxaliplatin, Cetuximab|Xelox(Capecitbine, Oxaliplatin) and Cetuximab every three week; Capecitabine 1,000 mg/m2 was administered twice daily on days 1-14. Oxaliplatin 130 mg/m2 i.v. for 2 h was given on day 1 after cetuximab infusion. Cetuximab at an initial loading dose of 400 mg/m2 i.v. for 2 h and, thereafter, maintenance dose of 250 mg/m2 for 1 h every week.
1775045|NCT00398411|Drug|moxifloxacin|400 mg p.o. per day
1775046|NCT00398411|Drug|placebo|one tablet per day p.o.
1775047|NCT00398424|Drug|S-1/Cisplatin|"PK Phase (Part 1), Beginning on Day 1 of the Pharmacokinetic Phase, 30 mg/m2 S-1 will be administered orally BID for 14 days (Days 1 through 14), followed by a 1-week recovery period.
On Day -2 and Day 14 of the Pharmacokinetic Phase, all patients will receive a single dose of 30 mg/m2 S-1 administered orally.
Extension Phase, Patients will receive S-1 at the dose that they tolerated in the PK Phase. S-1 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
1775048|NCT00398437|Biological|trastuzumab|
1775049|NCT00398437|Drug|chemotherapy|
1775050|NCT00398437|Procedure|magnetic resonance imaging|
1775051|NCT00398450|Biological|recombinant interferon alfa-2b|
1775052|NCT00398450|Drug|azacitidine|
1775053|NCT00398463|Drug|Tirofiban|Tirofiban infusion given as high bolus dose plus standard 14-24 hour infusion
1775054|NCT00398463|Drug|Placebo|Saline infusion will be administered for 14-24 hours
1775057|NCT00398489|Biological|trastuzumab|
1775058|NCT00398489|Drug|anastrozole|
1775059|NCT00398489|Drug|cyclophosphamide|
1775060|NCT00398489|Drug|docetaxel|
1775061|NCT00398489|Drug|epirubicin hydrochloride|
1775062|NCT00398489|Drug|goserelin acetate|
1775063|NCT00398489|Drug|tamoxifen citrate|
1775064|NCT00398489|Procedure|adjuvant therapy|
1775065|NCT00398489|Procedure|conventional surgery|
1775066|NCT00398489|Procedure|neoadjuvant therapy|
1775067|NCT00398489|Radiation|radiation therapy|
1775068|NCT00398502|Drug|MOA-728|
1775069|NCT00398515|Drug|lenalidomide|Given orally
1775070|NCT00398515|Drug|temsirolimus|Given IV
1775071|NCT00398515|Other|pharmacological study|Correlative studies
1775072|NCT00398515|Other|laboratory biomarker analysis|Correlative studies
1775073|NCT00398528|Drug|Glatiramer acetate, (Copaxone®)|
1775074|NCT00398528|Drug|IFN-β-1a, (Avonex®)|
1775075|NCT00398541|Drug|losartan potassium (+) hydrochlorothiazide|losartan potassium (+) hydrochlorothiazide combination will be titrated upwards according to the following scheme: losartan potassium 50/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 12.5 then losartan potassium 100/hydrochlorothiazide 25
1775076|NCT00398554|Drug|cyclophosphamide|1250 mg/m2 i.v. 60 Min.-Inf. day 1 and 21
1775077|NCT00398554|Drug|doxorubicin hydrochloride|25mg/m²/day, 2 hours i.v.infusion on day 21
1775078|NCT00398554|Drug|etoposide|150 mg/m²/day, 2 hours i.v.infusion (intravenous drip) on days 1 - 3
1775079|NCT00398554|Drug|prednisone|40 mg/m2/day p.o. (intake by mouth)divided in 3 single doses daily from day 1 - 14 and day 21 - 34
1775080|NCT00398554|Drug|vinblastine sulfate|6 mg/m² i.v. bolus on day 1 and day 21
1775081|NCT00398554|Drug|vincristine sulfate|1,5 mg/m2 i.v. bolus max. single dose 2 mg (cap dose at 2 mg) on day 8 and day 29
1775082|NCT00398554|Radiation|radiation therapy|involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
1775089|NCT00391664|Behavioral|Psychosocial|
1775090|NCT00391677|Behavioral|Social skills training with attention shaping procedures|Social skills training with attention shaping procedures includes behavioral procedures to increase the frequency, intensity, and duration of attentive behaviors and to reduce the frequency of inattentive behaviors.
1775091|NCT00391677|Behavioral|Social skills training without attention shaping|Social skills training without attention shaping is based on the UCLA Basic Conversation Skills Training Module, used without attention shaping procedures.
1775092|NCT00391690|Drug|Zoledronic acid|In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.
1775093|NCT00391703|Behavioral|Electrostimulation programme: using a cycloergometer|Quadriceps electrostimulation programme performed prior to an endurance retraining program using a cycloergometer, for 6 weeks, 60 to 90 minutes by session, 5 to 6 sessions per week
1775094|NCT00391703|Behavioral|Usual sport activity|Usual sport activity performed prior to an endurance retraining program using a cycloergometer
1775095|NCT00391716|Drug|Gabapentin 900mg|900 mg gabapentin daily for 12 weeks
1775096|NCT00391716|Behavioral|behavioral counseling|The manual for standardized alcohol-related behavioral counseling was developed by Drs. Barbara Mason and Anita Goodman. The manual is available at alcoholfree.info.
1775097|NCT00391716|Drug|placebo|lactose capsule compounded to mimic gabapentin capsules
1775098|NCT00391716|Drug|gabapentin 1800mg|1800 mg gabapentin daily for 12 weeks
1775099|NCT00391729|Drug|ABT-089|Subjects will take 2 mg QD, 5 mg QD, 15 mg QD, 40 mg QD, 40 mg BID for 4-6 weeks
1775100|NCT00391729|Drug|Placebo|Subjects will take placebo QD, BID for 4-6 weeks
1775101|NCT00391742|Behavioral|Brief intervention|
1775102|NCT00391755|Drug|ramelteon|"ramelteon 8mg po qhs with sleep and headache diary
placebo 1 po qhs with sleep and headache diary"
1775103|NCT00391768|Drug|oseltamivir (Tamiflu®)|Oseltamivir is supplied as a white powder blend for constitution to a suspension. It is supplied in 100 ml amber glass bottles with 30 grams of powder for oral suspension, a plastic adapter, a plastic oral dispenser and a plastic measuring cup. Initially subjects in Cohort I received oseltamivir 30 mg orally twice daily for 5 days. The DSMB recommended on 05-Aug-2009 that weight based dosing of oseltamivir for subjects subsequently enrolled in Cohort I. Based on pharmacokinetic data available as of that date, the initial weight-based dose to be evaluated for Cohort I is 3.5 mg/kg twice a day. Cohort II and Cohort III will receive oseltamivir at 3.0 mg/kg/dose orally twice daily for 5 days. Cohorts IV and V will receive 3.0 mg/kg/dose orally twice daily for 5 days, this dose may be adjusted.
1775104|NCT00391781|Procedure|Temperature of contrast medium|
1775105|NCT00391794|Behavioral|Early Stage Memory Loss Support Group|8 week support group led by trained facilitators
1775106|NCT00391794|Behavioral|Educational Seminar|4 hour education session led by trained facilitators
1775107|NCT00391807|Drug|Norethindrone acetate/ethinyl estradiol|one tablet per day
1775108|NCT00391820|Drug|TD-5108|
1775109|NCT00391833|Drug|Panax Ginseng|
1775110|NCT00391846|Drug|Captopril|
1775111|NCT00391846|Drug|Enalapril|
1775112|NCT00391846|Drug|Lisinopril|
1775113|NCT00391846|Drug|Ramipril|
1775114|NCT00391846|Drug|Trandolapril|
1775115|NCT00391846|Drug|Bisoprolol|
1775116|NCT00391846|Drug|Carvedilol|
1775117|NCT00391846|Drug|Metoprolol succinate|
1775118|NCT00391846|Drug|Candesartan|
1775119|NCT00391846|Drug|Valsartan|
1775120|NCT00391846|Drug|Eplerenone|
1775121|NCT00391846|Drug|Spironolactone|
1775122|NCT00391846|Drug|Diuretics|
1775123|NCT00391846|Drug|HF treatment according to Swedish guidelines|
1775124|NCT00391846|Procedure|Blood samples|
1775125|NCT00391846|Procedure|The Kansas City Cardiomyopathy Questionnaire (KCCQ)|
1775126|NCT00391859|Procedure|Pharmacist-Initiated Intervention in OsteoArthritis (PhIT-OA)|See Detailed Description.
1775127|NCT00391872|Drug|Ticagrelor|Ticagrelor (AZD6140) 90 mg twice daily dose (BD)
1775128|NCT00391872|Drug|Clopidogrel|Clopidogrel 75 mg once daily dose (ODD)
1775129|NCT00391885|Device|Closed-loop anesthesia system|
1775130|NCT00391898|Drug|Levodopa/carbidopa/entacapone|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa/entacapone was available in 2 oral dosage forms: 100/25/200 or 150/37.5/200 mg encapsulated tablets.
1775131|NCT00391898|Drug|Levodopa/carbidopa|Patients were instructed to take the study medication at the same hours and the same levodopa dose they were taking prior to enrollment in this study. Levodopa/carbidopa was available in 2 oral dosage forms: One or one and one-half 100/25 mg encapsulated tablets.
1775132|NCT00391911|Drug|N-Acetylcysteine|Patients are assigned to either N-Acetylcysteine or placebo. Dose is weight based Placebo is normal saline or D5W
1775133|NCT00391911|Other|N-Acetylcystine and Non CRRT|Patients are assigned to N-Acetylcysteine and CRRT. The N-Acetylcysteine is blinded to everyone except pharmacy. The CRRT is open label as would be impossible to blind
1775134|NCT00391911|Other|Placebo and CRRT|Patients are assigned to Placebo and CRRT. The N-Acetylcysteine/Placebo is blinded to everyone except pharmacy. The CRRT is open label
1775135|NCT00391911|Other|Placebo and Non CRRT|Patients are assigned to Placebo and non-CRRT. The N-Acetylcysteine/placebo is blinded to everyone except pharmacy. The CRRT/non CRRT is open label as would be impossible to blind
1775136|NCT00391924|Drug|Dehydroepiandrosterone|
1775137|NCT00391937|Device|Articular Surface Replacement (ASR) hip prosthesis|a DePuy ASR™ primary resurfacing femoral and acetabular component (DePuy International Ltd, Leeds, UK). The cement that will be used is one dose of DePuy SmartSet® GHV 40 gram, a high-viscosity cement with gentamycin (DePuy CMW, Blackpool, UK). Instrumentation includes standard ASR™ instruments and Ci™ Software for DePuy ASR™ System1.0.
1775138|NCT00391950|Drug|Zoledronic acid|
1775139|NCT00391963|Device|Bispectral index, Entropy|
1775140|NCT00391976|Drug|Tobramycin solution for inhalation 300 mg|Tobramycin solution for inhalation was supplied in 5 mL liquid-filled low-density polyethylene ampoules containing 300 mg tobramycin. Patients used a nebulizer to inhale the contents of the ampoules.
1775141|NCT00391989|Drug|Dasatinib|
1775142|NCT00392002|Drug|Esomeprazole|
1775145|NCT00392028|Drug|ertapenem|
1775148|NCT00392054|Procedure|Pulmonary Vein Isolation performed by Catheter Ablation|Ablation will be done to achieve entrance block into all pulmonary veins.
1775149|NCT00392054|Drug|Conventional Antiarrhythmic Drug Therapy|Anti-Arrhythmic Drugs per ACC/AHA 2006 Guidelines for the Management of Patients with AF
1775150|NCT00392067|Drug|Calcipotriol and LEO80122 (LEO19123 cream)|
1775151|NCT00392080|Drug|CJ-023,423|75 mg BID
1775152|NCT00392080|Drug|placebo|placebo
1775153|NCT00392080|Drug|naproxen|naproxen
1775154|NCT00392093|Drug|Conjugated equine estrogens 0.625 mg/d + MPA 5 mg/d/10d|
1775155|NCT00392106|Drug|propafenone|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
1775504|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|5mg bid
1775156|NCT00392106|Drug|flecainide|Anti-arrhythmic drug prescribed for the treatment of Atrial fibrillation
1775157|NCT00392106|Drug|dofetilide|Anti-arrhythmic drug prescribed for treatment of atrial fibrillation
1775158|NCT00392106|Drug|sotolol|Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
1775159|NCT00392106|Device|Pulmonary vein ablation|Electrical isolation of pulmonary vein with high-intensity focused ultrasound
1775160|NCT00392106|Drug|Amiodarone|Anti-arrhythmic Drug prescribed for the treatment of Atrial Fibrillation
1775161|NCT00392119|Device|MR-guided Laser Interstitial Thermal Therapy System|
1775162|NCT00392145|Drug|Standard IV rehydration|A 20 mL/kg 0.9% normal saline bolus (maximum 999 mL) will be administered over 1 hour. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
1775163|NCT00392145|Drug|Rapid intravenous rehydration (RIVR)|A 60 mL/kg 0.9% normal saline bolus (maximum 999 mL) over 1 hour will be administered. This will be followed by D5-0.9% normal saline at a maintenance rate (maximum 55 mL/hr).
1775164|NCT00392158|Device|Closed-loop anesthesia system|
1775165|NCT00392171|Drug|Temozolomide|Subjects will receive temozolomide 50 mg/m^2 for cycles of 28 days for 12 months or until progression
1775166|NCT00392184|Procedure|Accelerated partial breast irradiation|
1775167|NCT00392197|Drug|Aripiprazole|1 or 2 times a day, p.o., 6 - 24mg a day
1775168|NCT00392210|Genetic|Voiding Trial|Post-void residual and uroflow study will be done twice
1775169|NCT00392223|Drug|Azithromycin microspheres|Azithromycin microspheres, powder for oral suspension, 2 g a week, in unique administration PO, repeated weekly for 8 weeks and minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
1775170|NCT00392223|Drug|minocycline-placebo capsules|minocycline-placebo capsules daily for 8 weeks plus minocycline placebo
1775171|NCT00392223|Drug|Azithromycin microspheres-placebo|Minocycline capsules, PO, 100 mg daily for 8 weeks and Azithromycin microspheres-placebo once a week for 8 weeks plus azithromycin placebo.
1775172|NCT00392223|Drug|Minocycline capsules,|Capsules, PO, 100 mg daily for 8 weeks.
1775175|NCT00392249|Behavioral|Supervised Treatment of Schizophrenia by a family member|
1775176|NCT00392262|Drug|valsartan + amlodipine|
1775177|NCT00392275|Drug|Ofloxacin 0.3%|
1775178|NCT00392275|Drug|Ciprofloxacin 0.3%|
1775179|NCT00392275|Drug|Levofloxacin 0.5%|
1775180|NCT00392275|Drug|Ofloxacin 400mg|
1775181|NCT00392275|Drug|Ciprofloxacin 400mg|
1775182|NCT00392275|Drug|Levofloxacin 250mg|
1991642|NCT00736515|Drug|Biosynthetic Human Insulin Injection|Monotherapy of subcutaneous injection of Biosynthetic Human Insulin Injection twice daily (before breakfast and before dinner) (initial dosage 0.4-0.6U/KG/D) for 3 months
1991643|NCT00736645|Dietary Supplement|selenomethionine|Given orally
1991644|NCT00736645|Drug|finasteride|Given orally
1991645|NCT00736645|Other|placebo|Given orally
1775187|NCT00398606|Drug|MK0217, alendronate sodium / Duration of Treatment : 2 Years|
1775188|NCT00398606|Drug|Comparator : calcium carbonate /Duration of Treatment : 2 Years|
1775189|NCT00398619|Drug|INCB13739|
1775190|NCT00398632|Drug|Duloxetine|dosage form: capsule. dosage: 60 mg. frequency: once daily, or twice daily if 120 mg/day is needed to control symptoms of major depression. duration: 12 weeks
1775191|NCT00398645|Drug|GW685698X 200mcg,GW685698X 200mcg and 400mcg|
1775192|NCT00398658|Drug|gentamycin and clindamycin|
1775193|NCT00398671|Device|Application of cool cap after primary successful CPR|
1775194|NCT00398684|Drug|Single dose nevirapine to the mother and to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant NVP (0.6 ml/6mg) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
1775195|NCT00398684|Drug|Single dose nevirapine to the mother and placebo to the child|One maternal 200 mg NVP dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
1775196|NCT00398684|Drug|Single dose placebo to the mother and to the child|One maternal placebo dose at the onset of labor, and one dose of infant placebo (0.6 ml) between 48-72 hours after birth. [Infants less than 2,500g received only 0.2mL/kg]
1775197|NCT00398697|Drug|Perifosine|
1775198|NCT00398697|Drug|Gemcitabine|
1775199|NCT00398710|Drug|Perifosine|100 - 150 mg daily
1775200|NCT00398723|Device|Narrowband UVB|Treatment three to seven times weekly for a total of 12 to 26 weeks (36 to 168 treatments). Dosing of NB-UVB will begin at 100-280 mJ/cm2, depending on tolerance and skin type, and will be titrated 10-20% per session until clinical efficacy or symptomatic erythema
1775201|NCT00398736|Procedure|sonographic measurement of inferior caval vein diameter|
1775202|NCT00398749|Drug|Epoetin alfa|40,000 IU once weekly, variable treatment length
1775203|NCT00398775|Procedure|antibiotic discontinuation|
1775204|NCT00398788|Drug|OROS® hydromorphone HCL; Dilaudid CR (controlled release); Dilaudid IR (immediate release) as rescue medicine|
1775205|NCT00398814|Drug|Perifosine|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
1775206|NCT00398814|Drug|Sorafenib|For the purposes of this study, one cycle of therapy will be defined as 4 weeks. Patients will take perifosine one to three times a day and will also receive sorafenib one to two times a day.
1775207|NCT00398827|Drug|Dexmedetomidine|
1775208|NCT00398827|Drug|Placebo|
1775209|NCT00398840|Drug|ARQ 171|
1775210|NCT00398853|Dietary Supplement|chromium picolinate 1000 mcg daily vs placebo|chromium picolinate 1000 mcg daily vs placebo
1775211|NCT00398853|Other|Placebo|Placebo
1775212|NCT00398866|Drug|Synvisc (Hylan G-F20; hyaluronan injection)|1 ml of hyaluronan (Synvisc) injected once a week for 2 consecutive weeks
1775213|NCT00398866|Drug|Bupivicaine (local anesthesia injection)|1 ml of bupivicaine 0.5% injected once a week for 2 weeks
1775214|NCT00398866|Drug|Kenalog (triamcinolone; corticosteroid injection)|1 ml (40mg) of triamcinolone (Kenalog) injected the first week, followed by a placebo injection of 1 ml 0.5% bupivacaine the second week; Kenalog is a non-suspension steroid preparation and is less likely to cause post-injection flares than a suspension preparation
1775215|NCT00398879|Drug|Perifosine in combination with capecitabine|Perifosine or Placebo 50 mg/d qd + Capecitabine 825 mg/m^2 BID days 1 - 14 q 3 weeks
1775216|NCT00398892|Drug|Lipoic acid|Lipoic acid capsules
1775217|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|2,5 mg twice daily (5 mg total daily dose)
1775218|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|5 mg twice daily (10 mg total daily dose)
1775219|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg twice daily (20 mg total daily dose)
1775220|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|20 mg twice daily (40 mg total daily dose)
1775221|NCT00398905|Drug|Rivaroxaban (Xarelto, BAY59-7939)|30 mg twice daily (60 mg total daily dose)
1775222|NCT00398905|Drug|Enoxaparin|40 mg once daily (40 mg total daily dose)
1775223|NCT00398918|Drug|zonisamide|zonisamide (100 mg)one time
1775224|NCT00398918|Drug|Placebo|Placebo Comparator
1775225|NCT00400452|Behavioral|wheelchair skills training|
1775226|NCT00400465|Procedure|Normal dressing|Normal dressing
1775227|NCT00400465|Procedure|Pressure dressing|Pressure dressing
1775228|NCT00400478|Drug|Rituximab|Rituximab 375mg/m2 i every 8 weeks for two years (12 infusions)
1775229|NCT00400491|Drug|Cholecalciferol (vitamin D)|Cholecalciferol capsule 20.000 IU twice per week for 6 months
1775230|NCT00400491|Drug|Placebo|Placebo capsule twice a week, identical to the cholecalciferol capsules
1775237|NCT00400543|Device|Continuous positive airway pressure (CPAP)|
1775238|NCT00400556|Drug|ATRA plus G-CSF (filgrastim, NEUPOGEN (R)) combination|
1775239|NCT00400569|Drug|Sunitinib Malate (SU011248)|For each 6 week cycle, patients will take SU011248 every day in the morning for 4 weeks followed by a 2 week rest period.
1775240|NCT00400582|Drug|Candesartan up to 32 mg daily|Candesartan 4 to 32 mg daily
1775241|NCT00400595|Drug|Mupirocin ointment|topical ointment (already in widespread clinical use)
1775242|NCT00400595|Drug|Polysporin Triple|
1775243|NCT00400608|Drug|ADVAIR HFA|
1775244|NCT00400608|Drug|ADVAIR DISKUS|
1775245|NCT00400621|Drug|acetaminophen|
1775246|NCT00400634|Genetic|CERE-120 (Adeno-Associated Virus Serotype 2 [AAV2]-Neurturin [NTN])|CERE-120 5.4 x 10^11 vg
1775247|NCT00400634|Procedure|Sham Surgery|Bilateral partial thickness burr holes placed, no intraparenchymal injections
1775248|NCT00400647|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|
1775249|NCT00400647|Drug|Mycophenolate mofetil|
1775250|NCT00400660|Drug|GSK615915A|GSK615915A inhaler will be given with a dose of 250 micrograms per metered actuation and 120 actuations per inhaler.
1775251|NCT00400660|Drug|Placebo|Subjects will also receive placebo inhaler.
1775252|NCT00400673|Behavioral|Two-step remission induction and risk-oriented consolidation|
1775253|NCT00400686|Biological|epoetin alfa|Epoetin alfa will be administered 80,000 u sc every week commencing on study day 1.
1775254|NCT00400699|Other|counseling intervention|
1775255|NCT00400699|Other|study of socioeconomic and demographic variables|
1775256|NCT00400699|Procedure|psychosocial assessment and care|
1775257|NCT00400712|Behavioral|physical rehabilitation|two weeks intensive physical rehabilitation
1775258|NCT00400725|Drug|Clobex Shampoo 0.05%|twice weekly
1775259|NCT00400725|Drug|clobex shampoo placebo|twice weekly
1775260|NCT00400738|Drug|Saquinavir, lopinavir, ritonavir|arm 1 = LPV/RTV 400/100 mg BID + SQV 1000 mg BID arm 2 = LPV/RTV 400/100 mg BID + SQV 600 mg BID arm 3 = LPV/RTV 266/66 mg BID + SQV 1000 mg BID arm 4 = LPV/RTV 266/66 mg BID + SQV 600 mg BID
1775261|NCT00400751|Behavioral|FAMCON (Family Consultation)|
1775262|NCT00400764|Drug|Dulanermin|Dulanermin was administered by intravenous (IV) infusion over 1 hour on days 1-5 of each 21-day cycle.
1775263|NCT00400764|Drug|Rituximab|Rituximab was administered by intravenous (IV) infusion at 375 mg/m^2 weekly for up to eight doses.
1775264|NCT00400777|Drug|Valsartan, hydrochlorothiazide and amlodipine|
1775265|NCT00400790|Drug|propofol|Propofol used as the primary anaesthetic agent
1775266|NCT00400790|Drug|desflurane|Desflurane used as the primary anaesthetic
1775267|NCT00400803|Drug|Gemcitabine, Carboplatin, Bevacizumab|Patients will be treated with Gemcitabine 2000mg/m^2 intravenously (IV) over 30 minutes, followed by Carboplatin AUC= 3 IV over 30 minutes and Bevacizumab 10 mg/kg IV over 90 minutes 1st infusion, 60 minutes 2nd infusion and 30 minutes for the following infusions. Cycles will be repeated every 2 weeks for a maximum of 6 cycles of therapy. Bevacizumab will continue to be given until disease progression.
1775268|NCT00400816|Drug|temozolomide|Schedule of Temozolomide administration: Temozolomide, 150 mg/m2/d x days 1-7 and 15-21, given every 28 days [i.e., 7 days on/7 days off]
1775269|NCT00400829|Drug|eribulin mesylate|Given IV
1775270|NCT00400842|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 7 days
1775271|NCT00400842|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 6 capsules/day for 7 days
1775272|NCT00400842|Drug|Placebo|Placebo
1775273|NCT00400855|Drug|Fluticasone propionate|Study drug
1775274|NCT00400868|Behavioral|psycho-educational Joint protection education|individualized psycho-educational joint protection education, 4-times over 3 weeks; one additional booster session 2 months later
1775331|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg
1775332|NCT00401245|Drug|Placebo|Tapering placebo
1775333|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, placebo
1775275|NCT00400881|Other|automatic tube compensation|new mode of ventilation during spontaneous breathing trial. It is a mode of the same device (mechanical ventilator) where the pressure applied by the ventilator varies according to calculations o fthe mechanical properties of the respiratory system automatically performed by the ventilator.
1775276|NCT00400907|Other|clinical observation|
1775277|NCT00400907|Procedure|management of therapy complications|
1775278|NCT00400933|Behavioral|psycho-education|six session psycho-educational group program for family members and close friends of persons with eating disorders and co-morbid personality disorders
1775279|NCT00400946|Drug|asparaginase|
1775280|NCT00400946|Drug|cyclophosphamide|
1775281|NCT00400946|Drug|cytarabine|
1775282|NCT00400946|Drug|dexamethasone|
1775283|NCT00400946|Drug|dexrazoxane hydrochloride|
1775284|NCT00400946|Drug|doxorubicin hydrochloride|
1775285|NCT00400946|Drug|etoposide|Given IV
1775286|NCT00400946|Drug|leucovorin calcium|
1775287|NCT00400946|Drug|mercaptopurine|Given orally
1775288|NCT00400946|Drug|methotrexate|
1775289|NCT00400946|Drug|methylprednisolone|
1775290|NCT00400946|Drug|pegaspargase|Given IV
1775291|NCT00400946|Drug|prednisolone|
1775292|NCT00400946|Drug|therapeutic hydrocortisone|
1775293|NCT00400946|Drug|vincristine sulfate|
1775294|NCT00400946|Radiation|radiation therapy|
1775295|NCT00400959|Procedure|cd133+cell intracoronary administration|
1775296|NCT00400972|Device|GlideScope videolaryngoscope|
1775298|NCT00400998|Drug|Fluticasone Propionate|"Subjects will receive the following treatment regimen over one of two dosing periods within each of the three study phases:
- Intranasal FPANS (Fluticasone Propionate aqueous nasal spray) 200 mcg once daily for 8 to 14 days i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL (microlitres) i.e. 50 mcg fluticasone propionate."
1775299|NCT00400998|Other|Matched FPANS placebo|"Subjects will receive the following placebo treatment regimen over one of two dosing periods within each of the three study phases:
Intranasal FPANS placebo once daily for 8 to 14 days (i.e. 4 actuations (2 per nostril) daily, where each actuation delivers a volume of 100 mcL."
1775300|NCT00401011|Drug|Perifosine|All patients will received perifosine qhs daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks.
1775301|NCT00401011|Drug|Bortezomib|All patients will received perifosine qhs daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks.
1775302|NCT00401011|Drug|Dexamethasone|All patients will received perifosine qhs daily and Bortezomib IV on days 1, 4, 8, and 11 q 21 days. Patients will be evaluated at q 3 weeks. If the patient shows progressive disease, dexamethasone 20 mg will be added on days 1, 2, 4, 5, 8, 9, 11, 12, 15, 16, 18, and 19 to perifosine qhs and bortezomib IV on days 1, 4, 8, and 11 q 21 days.
1775303|NCT00401024|Drug|imatinib mesylate|
1775304|NCT00401024|Other|pharmacological study|
1775305|NCT00401024|Procedure|conventional surgery|
1775306|NCT00401050|Procedure|chiropractic manipulative therapy|
1775307|NCT00401050|Procedure|knee exercises|
1775308|NCT00401050|Procedure|Graston Instrument Soft Tissue Mobilization (GISTM)|
1775309|NCT00401063|Device|Acupuncture|Acupuncture treatment twice a day for eight weeks
1775310|NCT00401076|Drug|SA-001|0.25 g of SA-001 pellets/capsule, 12 capsules/day for 52 weeks
1775311|NCT00401089|Drug|Panax Ginseng|The standardized extract of Panax Ginseng was formulated by Boehringer Ingelheim Pharmaton, Switzerland and fulfills the criteria of cGMP. Quality control and safety are monitored regularly by Boehringer Ingelheim Pharmaton.
1775312|NCT00401102|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|Open clinical trial of IPT-ASI for depressed and self-injuring adolescents, 12-18 years. Goal is to assess feasibility of using IPT-A protocol for teens with co-morbid depression and self-injury. All eligible participants receive 12 weeks of individual IPT-ASI with optional monthly booster sessions. IPT-ASI is a psychosocial intervention that focuses on the importance of interpersonal relationships in relation to psychological functioning. The first phase (4 weeks) includes a review of depression and self-injury symptoms, psycho-education about depression and self-injury, and a detailed assessment of the patient's important interpersonal relationships. The middle phase (weeks 5-9) involves interpersonal skill building, including communication skills, affect identification and expression, problem solving. The final phase ( weeks 10-12) involves review of skills, generalization of skills to other relationships, termination.
1775313|NCT00401115|Drug|MS-R001 (rapamycin)|Subconjunctival injection in various dosages
1775314|NCT00401115|Drug|MS-R001 (rapamycin)|Intraocular injection in various dosages
1775315|NCT00401128|Drug|gemcitabine hydrochloride|
1775316|NCT00401128|Drug|irinotecan hydrochloride|
1775317|NCT00401141|Procedure|Blood samples|
1775318|NCT00401154|Other|Stationary Cycling|Use of a stationary bicycle for exercise
1775319|NCT00401167|Drug|memantine|Following the baseline visit, subjects will receive memantine 5 mg OD for one week, followed by 5 mg BID for one week, followed by 10 mg QAM and 5 mg QPM for one week, followed by 10 mg BID for the following 9 weeks.
1775320|NCT00401180|Drug|docetaxel|administered weekly in 5 escalating doses of 25 to 35 mg/ m(2) as a one-hour bolus intravenous infusion for 3 consecutive weeks.
1775321|NCT00401180|Drug|temozolomide|administered orally daily for 3 weeks (escalating doses of 75 to 100 mg/m(2)). Cycles were repeated at 4 week intervals.
1775322|NCT00401193|Drug|Tranexamic acid tablets|3900 mg/Day
1775323|NCT00401193|Drug|Tranexamic acid tablets|1950 mg/Day
1775324|NCT00401193|Drug|Placebo tablets|
1775325|NCT00401206|Drug|dexmedetomidine|
1775326|NCT00401219|Drug|conjugated estrogens/progestin (MPA)|
1775327|NCT00401232|Procedure|Blood Collection|Blood Collection
1775328|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 100 mg
1775329|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 50 mg
1775330|NCT00401245|Drug|desvenlafaxine succinate sustained release|Titration 25 mg, 50mg
1775334|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg, 25 mg
1775335|NCT00401245|Drug|desvenlafaxine succinate sustained release|Tapering 50 mg QOD
1775336|NCT00401258|Drug|duloxetine|30mg oral duloxetine per day for one week, titrated up to 60mg per day at day 8, concluded by a one week taper period of 4 days of 30mg pills at the conclusion of the study, followed by 3 days on no medication (4+3 days=1 week), concluded with a post-taper follow-up appointment with a study physician.
1775337|NCT00401271|Drug|OPC-67683|
1775338|NCT00401271|Drug|Rifafour e-275|
1775339|NCT00401284|Drug|EVT 201|
1775340|NCT00401310|Drug|Comparator: Placebo|Placebo IV infusions 1hr/daily over 7 days.
1775341|NCT00401310|Drug|Comparator: MK0724|MK0724 8 mg/kg/hr 1 hr/daily over 7 days.
1775342|NCT00401323|Drug|docetaxel (XRP6976)|
1775343|NCT00401323|Drug|cisplatin|
1775344|NCT00401323|Drug|5-fluorouracil (5-FU)|
1775345|NCT00401336|Device|Magnetic resonance imaging multiecho gradient-echo sequence|Breath-hold gradient echo sequences with a single echo and a new multiple-echo gradient-echo sequence
1775346|NCT00401362|Drug|SC Methylnaltrexone|Dose 1
1775347|NCT00401362|Drug|SC Placebo|
1775348|NCT00401362|Drug|SC Methylnaltrexone|Dose 2
1775349|NCT00401375|Drug|Methylnaltrexone|Intravenous MNTX
1775350|NCT00401375|Drug|Placebo|Intravenous
1775351|NCT00401388|Drug|Perifosine|Perifosine is available in 50 mg tablets. Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
1775352|NCT00401388|Drug|Perifosine|Patients will take two perifosine 50 mg tablets orally once a day at bedtime with food.
1775353|NCT00401401|Drug|zalutumumab|Eight weekly infusions
1775354|NCT00401401|Drug|cisplatin|Infusions
1775355|NCT00401401|Procedure|Radiotherapy|Daily in the treatment period
1775356|NCT00401414|Drug|Warfarin|2 mg tablets take as directed by study staff (based on INR)
1775357|NCT00401427|Drug|trastuzumab|
1775358|NCT00401427|Drug|vinorelbine|
1775359|NCT00401440|Drug|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 6 hours with a maximum of 4 doses
1775360|NCT00401440|Drug|Misoprostol|400 microgram vaginal misoprostol tablet will be applied every 12 hours with a maximum of 4 doses
1775361|NCT00401453|Behavioral|Diet: carbohydrate days. (Name: oatmeal.)|Dietary intervention with two days of oatmeal compared to normal diabetes adapted diet in insulin resistant subjects.
1775362|NCT00401466|Device|Implantable Cardioverter Defibrillator|ICD with Biotronik Home Monitoring capability
1775363|NCT00401479|Drug|Placebo|
1775364|NCT00401479|Drug|Solabegron (GW427353)|
1775365|NCT00401492|Drug|gemcitabine prolonged continuous infusion|
1775366|NCT00401492|Drug|cisplatin|
1775367|NCT00401492|Drug|vinorelbine|
1775368|NCT00401518|Device|ACADIA® Facet Replacement System|Investigational ACADIA Facet Replacement System used for the treatment of lumbar spinal stenosis
1775369|NCT00401518|Device|Instrumented posterolateral fusion|Control treatment using an instrumented posterolateral fusion for the treatment of lumbar spinal stenosis
1775370|NCT00401531|Biological|DTaP-IPV-HB-PRP~T and Pneumococcal polysaccharide vaccines|0.5 mL, IM
1775371|NCT00401531|Biological|DTaP-HB-IPV and Pneumococcal polysaccharide vaccines|0.5 mL, IM
1775372|NCT00401544|Drug|darbepoetin alfa|Darbepoetin alfa administered by subcutaneous injection.
1775373|NCT00401544|Drug|IV iron dextran|Administered by intravenous (IV) injection.
1775374|NCT00401570|Drug|Volociximab|Volociximab: 10 mg/kg or 15mg/kg every week or every other week (qowk) via IV infusion for up to 104 weeks.
1775375|NCT00401570|Drug|Gemcitabine|Gemcitabine: Standard chemotherapy regime at 1 g/m2 once per week for 3 weeks via IV infusion, followed by one week with no treatment
1775376|NCT00401583|Drug|GW786034 (pazopanib)|
1775377|NCT00401596|Drug|Xolair (omalizumab)|
1775378|NCT00401609|Drug|gemcitabine|
1775379|NCT00401609|Drug|vinorelbine|
1775380|NCT00401609|Drug|cisplatin|
1775381|NCT00401609|Drug|etoposide|
1775382|NCT00401609|Drug|carboplatin|
1775383|NCT00401622|Behavioral|OneTouch® Ultra®2 System|Education and self-monitoring of blood glucose performed with OneTouch® Ultra®2 System that includes the Simple Start™ home-based education program
1775384|NCT00401622|Behavioral|Standard care|Standard education and self-monitoring of blood glucose performed with traditional meter systems
1775385|NCT00401635|Drug|liposomal doxorubicin|
1775386|NCT00401635|Drug|carboplatin|
1775387|NCT00401648|Drug|Brivaracetam|
1775388|NCT00401661|Drug|Alfuzosin|One tablet of 10mg once daily at the end of evening meal
1775389|NCT00401674|Drug|carboplatin|
1775390|NCT00401674|Drug|paclitaxel|
1775391|NCT00401687|Drug|Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension|The intervention for this study was that all patients received a slow bolus injection of diluted DEFINITY during the contrast-enhanced imaging study.
1775392|NCT00401713|Procedure|Transplantation of autologous RPE|RPE cell suspension
1775393|NCT00401713|Procedure|Translocation of autologous RPE and Choroid|RPE patch
1775394|NCT00401726|Drug|Venlafaxine ER|
1775395|NCT00401726|Behavioral|Dialogues Time to Talk Program|
1775396|NCT00401739|Drug|CSL360|Weekly IV Infusion. Dose escalation study.
1775397|NCT00401752|Drug|Esomeprazole|
1775398|NCT00401752|Drug|Ranitidine|
1775399|NCT00401765|Drug|CNTO 328|Patients will receive 6 mg/kg CNTO 328 in treatment phase of cohort 1A and cohort 1B; 9 mg/kg CNTO 328 in treatment phase of cohort 2; and 12 mg/kg CNTO 328 in treatment phase of cohort 3.
1775400|NCT00401765|Drug|Docetaxel|Patients will receive 75 mg/m2 docetaxel in run-in phase of cohort 1A, cohort 2, and cohort 3; and in treatment phase of cohort 1A, cohort 1B, cohort 2, and cohort 3.
1775401|NCT00401778|Drug|RAD001|Patients will be assigned to one of three treatment arms with RAD001 doses of 5, and 10 mg/day for 21-28 days sequentially taken orally in tablet form.
1775444|NCT00402129|Procedure|1064nm Nd:YAG laser at 12 J/cm2, 20 ms and 10mm spot size.|
1775445|NCT00402142|Biological|Dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
1775402|NCT00401791|Behavioral|Exercise|"Interval Exercise Training: Each interval training session will start with 10 minutes of warm up and will end with 10 minutes of cool down period at 40% VO2 peak. Training duration, intensity and number of exercise bout will increase with the progression of training period
Aerobic training: Each endurance training session will start with 5 minutes of warm up and will end with 5 minutes of cool down at 40% VO2 peak. Subjects will exercise at 70% VO2 peak for 45 minutes on day 3 and 5, for 55 minutes on day 8 and 10, and for 35 minutes on day 14 using a bicycle ergometer."
1775403|NCT00401804|Drug|Dexamethasone, Bortezomib, Doxorubicin|
1775405|NCT00401830|Drug|Lacosamide|Tablet 400mg daily (200mg twice daily) during 8-week maintenance phase following 4-week titration phase starting at 100mg/day and increasing to 400mg/day at weekly intervals of 100mg
1775406|NCT00401830|Other|Placebo|Matching placebo tablet administered twice daily
1775407|NCT00401843|Biological|Siltuximab|Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during cycle 1 in Part 1. Siltuximab 6 mg/kg will be administered as intravenous infusion once every 2 weeks during 42-day Treatment Phase and 35-day Maintenance Phase in Part 2.
1775408|NCT00401843|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus once every 2 weeks during cycle 1 in Part 1. Bortezomib 1.3 mg/m^2 will be administered as intravenous bolus on Days 1, 4, 8, 11, followed by a 10-day rest period; and on Days 22, 25, 29, and 32 followed by a 10-day rest period during 42-day treatment phase in Part 2. Bortezomib 1.3 mg/m2 will be administered as intravenous bolus on Days 1, 8, 15, 22 followed by a 13-day rest period (cycle Days 23 to 35) during 35-day Maintenance Phase in Part 2.
1775409|NCT00401843|Drug|Placebo|Matching placebo will be administered as intravenous infusion once every 2 weeks during 42-day treatment phase and 35-day maintenance phase in Part 2.
1775410|NCT00401843|Drug|Dexamethasone|Dexamethasone tablet will be administered in this study at the first occurrence of documented disease progression or if bortezomib was discontinued due to intolerable toxicity. Dexamethasone 40 mg/day will be administered on days 1-4, 9-12, and 17-20 for four 28-day cycles then 40 mg/day for Days 1-4 for all subsequent cycles in treatment phase and maintenance phase of Part 2.
1775411|NCT00401856|Drug|Eplerenone|50mg oral route
1775412|NCT00401856|Drug|Placebo|Placebo is identical to eplerenone but the active ingredient is absent
1775413|NCT00401869|Drug|Epoetin alfa|
1775414|NCT00401882|Drug|Epinephrine|Epinephrine (1 mg) IV additional doses
1775415|NCT00401882|Drug|Metoprolol|Metoprolol 5 mg IV (up to two times only) instead of epinephrine additional doses
1775416|NCT00401895|Device|TIPS created with 8 or 10 mm covered stent|creation of a shunt between hepatic vein and portal vein with PTFE-covered stents
1775417|NCT00401921|Drug|Minocycline|100 mg, 1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery
1775418|NCT00401921|Drug|Placebo oral capsule|1 capsule PO BID starting 36 hours prior to surgery. 2 capsules the morning of surgery.
1775419|NCT00401947|Drug|ACH-0137171|
1775420|NCT00401960|Drug|Daptomycin|daptomycin at a dose of 8 milligrams/kilogram/day in addition to the antibiotics they are already receiving for native valve enterococcal endocarditis
1775421|NCT00401973|Drug|olanzapine|5-20 milligrams (mg), oral, daily for 22 weeks.
1775422|NCT00401973|Drug|amantadine|Amantadine, 100 milligrams (mg), oral, 1 twice a day (BID). Patients who gained greater than 3 kilograms (kg) will switch to metformin. Patients who gained greater than 3 kg after switching to metformin will be switched to zonisamide.
1775423|NCT00401973|Drug|metformin|Metformin, 500 mg, oral, twice a day (BID) for 2 weeks titrated to 500mg three times a day (TID) thereafter. Patients who gain greater than 3 kilograms (kg) will be switched to amantadine. Patients who gained greater than 3 kg after switching to amantadine will be switched to zonisamide.
1775424|NCT00401973|Drug|zonisamide|Zonisamide, 100-400mg, oral, daily.
1775425|NCT00401973|Behavioral|Wellness education|weight management
1775427|NCT00402012|Drug|Pioglitazone|During the double-blind, 12 weeks treatment period, subjects will self-administer study medication (pioglitazone or equivalent volume of placebo) 30 mg/day each morning. The dose of pioglitazone will be increased to 45 mg/day after 4 weeks if the fasting plasma glucose is higher than 100mg/dl or the HbA1C is higher than 7%. This dose has proven tolerability, safety and efficacy for type 2 diabetes and has previously been used at the Pennington Center in studies on pioglitazone.
1775428|NCT00402025|Biological|Talimogene Laherparepvec|Talimogene laherparepvec administered by direct injection into pancreatic tumors using EUS-guided FNI, up to a maximum of 4 mL per treatment.
1775429|NCT00402038|Drug|SC Methylnaltrexone|Dose 1
1775430|NCT00402038|Drug|SC Placebo|
1775431|NCT00402051|Drug|Pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
1775432|NCT00402051|Drug|Cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
1775433|NCT00402051|Drug|Carboplatin|Area under the concentration curve (AUC) 5, intravenous (IV), every 21 days x 6 cycles
1775434|NCT00402077|Drug|pramlintide acetate|subcutaneous injection, three times a day, 120mcg
1775435|NCT00402077|Drug|sibutramine|oral tablet, once a day, 10mg
1775436|NCT00402077|Drug|phentermine|oral tablet, once a day, 37.5mg
1775437|NCT00402077|Drug|placebo|subcutaneous injection, three times a day
1775438|NCT00402103|Drug|Aliskiren|All patients received aliskiren 150 mg for the first two weeks; dose was then force-titrated to aliskiren 300 mg for 52 weeks duration
1775439|NCT00402103|Drug|Amlodipine|All patients received amlodipine 5 mg for the first two weeks; dose was then force-titrated to amlodipine 10 mg for 52 weeks duration
1775440|NCT00402103|Drug|Hydrochlorothiazide|Optional addition of Hydrochlorothiazide (HCTZ)of 12.5 mg with increase to 25 mg was allowed for patients not adequately controlled.
1775441|NCT00402116|Drug|enzastaurin|Phase 1 - 250 mg Cohort 1 with one dose escalation allowed to 500 mg for Cohort 2, oral, daily, 6 weeks then twelve 28 day cycles Phase 2 - Phase 1 established dose, oral, daily, 6 weeks then twelve 28 day cycles
1775442|NCT00402116|Drug|temozolomide|75 mg/m2, oral, daily, 6 weeks 200 mg/m2, oral, daily, twelve 28 day cycles
1775443|NCT00402116|Radiation|radiation|1.8-2.0 Gy x 30 fractions, 5 days/week, for 6 weeks
1775446|NCT00402142|Biological|non pulsed dendritic cell untreated patients|107 DC subcutaneous 3 doses every 2 weeks
1775447|NCT00402142|Biological|pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
1775448|NCT00402142|Biological|dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
1775449|NCT00402142|Biological|non pulsed dendritic cell vaccine|107 DC subcutaneous 3 doses every 2 weeks
1775450|NCT00402155|Behavioral|Stress on visual discomfort|Effects of visual discomfort are measured by contrast sensitivity, ERGs, and accommodative stability.
1775454|NCT00402181|Biological|Siltuximab|Siltuximab 6 mg/kg as intravenous infusion once every 2 weeks for 12 cycles and duration of each cycle is 28 days.
1775455|NCT00402181|Drug|Dexamethasone|Dexamethasone 40 mg tablet orally on Day 1 to 4, 9 to 12 and 17 to 20 for maximum 4 cycles after that on Day 1 to 4 up to 12 cycles and duration of each cycle is 28 days.
1775456|NCT00402194|Drug|Losartan|Tablet, 100mg, once per day for 3 months
1775457|NCT00402207|Drug|extrafine HFA-beclomethasone|
1775458|NCT00402207|Drug|HFA-fluticasone|
1775459|NCT00402220|Drug|TMS|Active Transcranial Magnetic Stimulation
1775460|NCT00402220|Device|Sham TMS|Sham Transcranial Magnetic Stimulation
1775461|NCT00402233|Drug|Pramipexole|
1775462|NCT00402233|Drug|Placebo|
1775463|NCT00402246|Other|Remote Management|"The Remote Management method of treating patients consists of 3 components:
CareAlerts: Device alerts that are triggered by either device integrity issues or arrhythmic issues with the patient (e.g. multiple shocks delivered for a ventricular arrhythmia, more than 12 hours of atrial arrhythmias occurring in a day)
Conexus: the device feature which allows the device to wirelessly transmit information (possibly triggered by a CareAlert) to a patient monitor that is hooked up a patient's phone line
CareLink: the Medtronic system which allows device data to be transmitted from a patient's monitor through the phone line to ultimately be displayed on a secure website for viewing by the patient's physician.
The combination of these 3 components allow the patient's device to transmit information relating to either a device issue or patient issue to be viewed by a clinician without the patient having to take direct action."
1775464|NCT00402246|Other|In-Office Care|Routine in-office care
1775465|NCT00402259|Drug|Esomeprazole IV|
1775466|NCT00402259|Drug|Omeprazole IV|
1775467|NCT00402272|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease.
1775468|NCT00402285|Dietary Supplement|lycopene supplement|
1775469|NCT00402285|Dietary Supplement|fish oil supplement|
1775470|NCT00402285|Other|Placebo|placebos for lycopene and fish oil.
1775471|NCT00402298|Drug|3,4-methylenedioxymethemphetmaine (MDMA_|Participants will receive an initial dose of 125 mg MDMA orally followed 2.5 hours later by 62.5 mg MDMA orally during the course of a day-long psychotherapy session.
1775472|NCT00402298|Drug|3,4-methylenedioxymethamphetamine|Participants will receive an initial dose of 25 mg MDMA orally followed 2.5 hours alter by a supplemental dose of 12.5 mg MDMA orally during the course of each of two day-long psychotherapy sessions.
1775473|NCT00402311|Procedure|DOC-PG: integrated multidisciplinary assessment|
1775474|NCT00402311|Procedure|Usual care: assessment by GP or one of the regional services|
1775475|NCT00402324|Drug|olanzapine|15mg, capsules, by mouth every evening, daily for minimum of one day, followed by 5-20mg, capsules, by mouth every evening, daily for remainder of study (6 weeks total).
1775476|NCT00402324|Drug|placebo|placebo, capsules, by mouth every evening, daily, for 6 weeks.
1775477|NCT00402324|Drug|divalproex|dose to maintain blood levels of 75-125 ug/mL, by mouth, twice a day, daily for 52 days (Study Period I and Study Period II).
1775478|NCT00402337|Drug|linaclotide acetate|oral, once daily.
1775479|NCT00402337|Drug|Matching placebo|oral, once daily
1775480|NCT00402350|Drug|Inhaled Placebo|Inhaled Staccato Placebo, same number of doses as active comparator in that arm
1775481|NCT00402350|Drug|Inhaled Fentanyl 25 mcg|Inhaled Staccato Fentanyl, 25 mcg x 1 dose
1775482|NCT00402350|Drug|Intravenous Fentanyl 25 mcg|Intravenous Fentanyl 25 mcg, single dose
1775483|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 2|Inhaled Staccato Fentanyl, 25 mcg x 2 doses
1775484|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 4|Inhaled Staccato Fentanyl, 25 mcg x 4 doses
1775485|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 6|Inhaled Staccato Fentanyl, 25 mcg x 6 doses
1775486|NCT00402350|Drug|Inhaled Fentanyl 25 mcg x 12|Inhaled Staccato Fentanyl, 25 mcg x 12 doses
1775487|NCT00402363|Drug|omega-3-acid ethyl esters|
1775488|NCT00402363|Drug|Placebo|
1775489|NCT00402376|Drug|Pravastatin, Carvedilol, Perindopril|
1775490|NCT00402376|Device|Biventricular assist device (Thoratec paracorporeal assist device)|
1775491|NCT00402389|Drug|Omega-3 Fatty Acids (EPA plus DHA)|Four capsules will be taken daily for 8 weeks.
1775492|NCT00402389|Behavioral|Supportive psychotherapy|Supportive psychotherapy will provide education to increase understanding of the condition, guidance on how to cope with depression, and methods on how to improve self-esteem.
1775493|NCT00402389|Drug|Placebo|Four capsules will be taken daily for 8 weeks.
1775494|NCT00402402|Procedure|Tuberculin skin test|
1775495|NCT00402402|Procedure|Quantiferon-TB Gold assay|
1775496|NCT00402415|Drug|Sunitinib malate|C1: 50 mg po days 1-15, 2 weeks off C2: 50 mg po x 4 weeks, 2 weeks off
1775497|NCT00402415|Drug|Rapamycin|"Dose escalation until MTD as follows:
C1: not given C2: 4 mg weekly, 8 mg weekly, 12 mg weekly, 20 mg weekly"
1775498|NCT00402428|Drug|albumin interferon alfa-2b|900 mcg or 1200mcg every two week for 48 weeks
1775499|NCT00402428|Drug|peginterferon alfa-2a|180 mcg once a week for 48 weeks
1775500|NCT00402428|Drug|Ribavirin|"1000 mg/day(for subjects <75kg) or 1200 mg/day (for subjects
=,> 75kg)"
1775501|NCT00402441|Drug|Risedronate (HMR4003)|
1775502|NCT00402454|Drug|isoniazid, rifampin + isoniazid or rifampin + pyrazinamide|
1775503|NCT00402467|Drug|Rivaroxaban (BAY59-7939)|2.5mg bid
1775505|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|10 mg bid
1775506|NCT00402467|Drug|Rivaroxaban, (BAY59-7939)|20mg bid
1775507|NCT00402467|Drug|Enoxaparine|30mg bid
1775508|NCT00402467|Drug|Enoxaparine|30mg bid
1775509|NCT00402480|Drug|Hydroxyurea|
1775510|NCT00402493|Drug|ibuprofen, latanoprost, brimonidine|to determine whether commonly used OTC non-steroidal anti-inflammatory agents taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
1775511|NCT00402493|Drug|Ibuprofen, brimonidine, latanoprost|to determine whether commonly used OTC non-steroidal anti-inflammatory agentsn(200mg ibuprofen) taken orally has any effect on the ability of either latanoprost or brimonidine to lower high eye pressure
1775512|NCT00402493|Drug|Ibuprofen|ibuprofen 200mg
1775513|NCT00402506|Drug|(MC-1) Pyridoxal 5'-phosphate|
1775514|NCT00402519|Radiation|Accelerated partial breast irradiation|APBI with PDR and HDR brachytherapy
1775515|NCT00402519|Radiation|External beam whole breast irradiation|Standard Whole breast irradiation
1775516|NCT00402532|Drug|Everolimus|Initial dosage 2 x 0.75 mg/d
1775517|NCT00402532|Drug|Mycophenolatmofetil|Initial dosage 2 x 500 mg/d intravenous
1775518|NCT00402545|Drug|Cetuximab|Given intravenously on days 1, 8 and 15 of each 21-day cycle for three cycles
1775519|NCT00402545|Drug|Docetaxel|Given intravenously on day 1 of each 21-day cycle for 3 cycles
1775520|NCT00402545|Drug|Cisplatin|Intravenously on day 1 of each 21-day cycle for 3 cycles
1775521|NCT00402545|Drug|5-Fluorouracil|Given by continuous infusion pump over a period of 96 hours(dosage wil vary depending upon when participant enrolls in trial)
1775522|NCT00402558|Drug|Thymoglobulin|1.5 mg/kg By Vein Daily x 3 Days
1775523|NCT00402558|Drug|Busulfan|130 mg/m^2 By Vein Over 3 Hours x 4 Days
1775524|NCT00402558|Drug|Fludarabine|40 mg/m^2 By Vein Over 30 Minutes x 4 Days
1775525|NCT00402558|Procedure|Alloreactive NK Infusion|Alloreactive NK infusion from haploidentical donor on Day -8. The alloreactive NK cell infusion given at one of 4 dose levels 10e6, 5 x 10e6, 3 x 10e7 cells/kg and 3 x10e7.
1775526|NCT00402558|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until absolute neutrophil count (ANC) is > 500 x 109/L for 3 consecutive days.
1775527|NCT00402558|Drug|Tacrolimus|Starting dose of 0.015 mg/kg as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present.
1775528|NCT00402558|Drug|Methotrexate|5 mg/m2 intravenously on Days 1, 3 and 6 and Day +11 post transplant.
1775529|NCT00402558|Drug|Interleukin-2|0.5 million units per day subcutaneously starting on Day -8 (day of the NK cell infusion) to Day -4 only to participants receiving fourth dose level of NK cells.
1775530|NCT00402571|Drug|acetaminophen|
1775531|NCT00402584|Drug|sibutramine|
1775532|NCT00402597|Drug|Rivaroxaban/Placebo|1 rivaroxaban tablet once daily (and 1 placebo tablet once daily) for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
1775533|NCT00402597|Drug|Placebo|1 placebo tablet twice daily for 6 months.
1775534|NCT00402597|Drug|Rivaroxaban|1 rivaroxaban tablet twice daily for 6 months. Safety at each dose level will be confirmed before additional patients are randomized to the next higher dose level.
1775535|NCT00402610|Drug|isoniazid, rifampin + isoniazid, rifampin + pyrazinamide or not treatment|
1775536|NCT00402623|Dietary Supplement|quercetin|1000 mg quercetin within 24 hours
1775537|NCT00402623|Other|placebo|
1775538|NCT00402636|Device|rapamycin plus 17beta estradiolvalerat-eluting stent|rapamycin plus 17beta estradiolvalerat-eluting stent was implanted due to randomisation
1775539|NCT00402636|Device|rapamycin-eluting stent|rapamycin-eluting stent was implanted due to randomisation
1775540|NCT00402649|Biological|Inactivated Influenza A/H5N1 Vaccine (sanofi pasteur)|Inactivated influenza A/H5N1 vaccine administered via intramuscular (IM) injection; dosage 45-mcg.
1775541|NCT00402662|Drug|everolimus|
1775542|NCT00402662|Drug|Imatinib|
1775543|NCT00402675|Procedure|Timing of percutaneous coronary intervention|Immediate, early or selective invasive angiography
1775544|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 2 weeks followed by 2 weeks of placebo.
1775545|NCT00402688|Drug|levofloxacin|750mg tablet once daily for 3 weeks followed by 1 week of placebo.
1775546|NCT00402688|Drug|levofloxacin|500mg tablet once daily for 4 weeks.
1775547|NCT00402701|Behavioral|Walking School Bus Program|Schoolwide promotion of walk to school. Facilitation of parent-led walking school bus routes.
1775548|NCT00402714|Procedure|extracorporeal photopheresis|Extracorporeal photopheresis (ECP) is the ex vivo exposure of the leukocyte rich fraction to ultraviolet light in the presence of 8-methoxypsoralen.
1775549|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
1775550|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
1775551|NCT00402714|Drug|Pentostatin|pentostatin 8mg/m2 over 48 hours by continuous infusion
1775552|NCT00402714|Radiation|Total Body Irradiation|600cGy TBI in 3 200cGy TBI fractions
1775553|NCT00402727|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY 12-8039) 400 mg intravenous (IV) once daily followed by Moxifloxacin 400 mg oral tablets once daily for a minimum of 7 days and a maximum of 21 days. Oral phase was not always mandatory.
1775554|NCT00402727|Drug|Piperacillin/Tazobactam & Amoxicillin/Clavulanic acid|Piperacillin/Tacobactam 4.0/0.5 g (PIP/TAZ) administered intravenous three times daily followed by Amoxicillin/Clavulanic acid (AMC) oral tablets 875/125 mg twice daily for a minimum of 7 days and a maximum of 21 days. Oral phase not always mandatory.
1775555|NCT00402740|Device|Xact Stent with either Emboshield Pro (Gen 5) or Emboshield (Gen 3)|All subjects will receive the Xact™ Rapid Exchange Carotid Stent System. The first 220 consecutively enrolled subjects will be treated with the investigational filter system, the Emboshield® Pro Rapid Exchange Embolic Protection System (Generation 5). The remaining subjects will be treated with the FDA approved Emboshield® BareWire™ Rapid Exchange Embolic Protection System (Generation 3).
1775556|NCT00402753|Behavioral|Ambulatory Physical Exercise Program|supervised exercise, 2 x / week
1775557|NCT00402766|Drug|Cisplatin|Starting Dose: 60 mg/m^2 by vein, Over 2 Hours
1775558|NCT00402766|Drug|Imatinib Mesylate|Starting Dose: 300 mg PO Daily
1775559|NCT00402766|Drug|Pemetrexed|Starting Dose: 500 mg/m^2 by vein, Over 40 Minutes
1775560|NCT00402766|Drug|Dexamethasone|20 mg by vein given prior to Pemetrexed therapy and 4 mg given orally on Day 2 of each cycle.
1775561|NCT00402779|Drug|Erlotinib|150 mg by mouth daily
1775562|NCT00402779|Drug|Placebo|Tablet by mouth daily
1775563|NCT00402792|Drug|Hydrocodone/Acetaminophen Extended-Release|1 tablet q 12 hours
1775564|NCT00402792|Drug|Hydrocodone/Acetaminophen Extended Release|2 tablets q 12 hours
1775565|NCT00402792|Drug|Placebo|2 tablets q 12 hours
1775566|NCT00402805|Biological|Trivalent Inactivated Influenza Vaccine|
1775568|NCT00402844|Device|Transvaginal mesh- PROLIFT®-system|
1775569|NCT00402857|Behavioral|Incredible Years Program|The Incredible Years Program is a 10-week group parenting intervention. Parent training sessions will take place once per week for 10 weeks, and will last approximately 2 hours each. Sessions will focus on teaching positive parenting skills, such as appropriate play and use of praise and rewards, as well as limit-setting techniques, such as ignoring, allowing children to experience the natural consequences of their actions, and assigning time-outs.
1775570|NCT00402870|Device|ProSeal LMA|ProSeal LMA vs Tracheal Tube
1775571|NCT00402870|Device|ProSeal LMA, Tracheal Tube|ProSeal LMA vs Tracheal Tube
1775572|NCT00402883|Drug|Bevacizumab|15mg/kg week 1, 4, 16, 19, 22, 25, 28, 31, 34, 37, 40, 43, 46, and 49.
1775573|NCT00402883|Drug|Pemetrexed|500mg/m2 week 1, 4, 16, 19 and 22.
1775574|NCT00402883|Procedure|Radiotherapy|1.8 Gy single daily fractions(Monday-Friday), to total dose 61.2 Gy (7 weeks)
1775575|NCT00402883|Other|Folic Acid|350 to 1,000 ug or equivalent supplementation administered orally beginning 1 to 2 weeks before the first dose of pemetrexed and continued daily until the patient discontinues study therapy.
1775576|NCT00402883|Other|vitamin B12|1,000ug administered by intramuscular injection 1 to 2 weeks before the first dose of study therapy and repeated every 9 weeks until the patient discontinues therapy.
1775577|NCT00402883|Drug|carboplatin|AUC=5 administered intravenously weeks 1 and 4.
1775578|NCT00402896|Drug|ZD6474|300 mg/day orally for 10 weeks.
1775579|NCT00402909|Drug|Nateglinide|
1775580|NCT00402935|Other|laboratory biomarker analysis|Patients undergo blood collection at the same time points for follicle-stimulating hormone, estradiol, and inhibin B levels.
1775581|NCT00402935|Procedure|fertility assessment and management|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
1775582|NCT00402935|Procedure|management of therapy complications|Patients are also asked to fill out questionnaires on estrogen-depletion symptoms at those times. Patients also keep a calendar of menstrual bleeding and hormonal medications.
1775583|NCT00402935|Procedure|ultrasound imaging|Patients undergo a transvaginal or transabdominal ultrasound to measure the ovarian volume and count the number of antral follicles.
1775584|NCT00395213|Drug|Selective serotonin reuptake inhibitor (SSRI) and serotonin-norepinephrine reuptake inhibitor (SNRI) medications|Treatment with SSRIs or SNRIs
1775585|NCT00395226|Drug|zinc sulfate|zinc sulfate 220 mg bis for 90 days
1775586|NCT00395226|Drug|placebo|placebo bid for 90 days
1775587|NCT00395239|Drug|inhaled corticosteroid|Fluticasone; Budesonide; Ciclesonide Dosage and frequency is patient dependant.
1775588|NCT00395252|Drug|Cetuximab (Erbitux®) and Gemcitabine|"Cetuximab:
Loading dose of 400 mg/m2, followed by weekly doses of 250 mg/m2. Cetuximab will be administered once weekly for up to 6 months (treatment duration: 24 weeks)
Gemcitabine:
1000 mg/m2 administered on days 1, 8, 15 Cycles will be repeated on day 29, up to 6 treatment cycles will be administered
Mode of administration:
Intravenous infusion"
1775589|NCT00395291|Drug|MK-0677|The dosage of the drug is 25mg, subjects will take one pill a day for about 30 days.
1775590|NCT00395291|Drug|Placebo|Placebo
1775591|NCT00395304|Drug|fluticasone propionate + montelukast|Dry-powder inhaler fluticasone 100 mcg bid (Flovent Diskus®, GlaxoSmithKline) plus Montelukast 5 or 10 mg qd (Singulair®, Merck)
1775592|NCT00395304|Drug|fluticasone propionate|Dry-powder inhaler fluticasone 250 mcg bid (Flovent Diskus®, GlaxoSmithKline)
1775593|NCT00395304|Drug|fluticasone propionate + salmeterol|Dry-powder inhaler fluticasone + salmeterol combination 100 mcg/50 mcg bid (Advair Diskus®, GlaxoSmithKline)
1956963|NCT02611830|Drug|Vedolizumab IV 300 mg|
1956964|NCT02611830|Drug|Placebo IV|
1956965|NCT02611830|Drug|Vedolizumab SC 108 mg|
1775597|NCT00395343|Drug|sitagliptin phosphate|sitagliptin 100 mg tablet qd for a 24-wk treatment period.
1775598|NCT00395343|Drug|Comparator : placebo (unspecified)|sitagliptin 100 mg Pbo tablet qd for a 24-wk treatment period.
1775599|NCT00395356|Behavioral|calorie controlled diet|
1775600|NCT00395369|Drug|intraoperative aprotinin administration|
1775601|NCT00395382|Drug|Alendronate|70mg weekly orally
1775602|NCT00395382|Drug|Placebo|weekly orally
1775603|NCT00395395|Drug|Oral salmon calcitonin, salmon calcitonin nasal spray|
1775604|NCT00395408|Drug|MK0476, montelukast sodium / Duration of Treatment : 56 Weeks|
1775605|NCT00395408|Drug|Comparator : beclomethasone dipropionate / Duration of Treatment : 56 Weeks|
1775606|NCT00395421|Drug|NM283 plus Peg-IFNα-2a|200 mg QD 180 µg QW
1775607|NCT00395434|Drug|Combretastatin A4 Phosphate (CA4P)|
1775608|NCT00395434|Drug|Bevacizumab (Avastin)|
1775609|NCT00395447|Procedure|Straight-forward Device Replacement|
1775610|NCT00395447|Procedure|Device Replacement with Upgrade|
1775611|NCT00395460|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|1,0M, intra venous injection at a dose of 0,1 ml/kg BW (= 0,1 mmol Gd/kg BW)
1775612|NCT00395460|Drug|Magnevist|0,5M, intra venous injection at a dose of 0,2 ml/kg BW (= 0,1 mmol Gd/kg BW)
1775613|NCT00395473|Drug|MK0653, ezetimibe / Duration of Treatment: 6 Weeks|
1775614|NCT00395486|Drug|Rosuvastatin|10mg
1775615|NCT00395486|Drug|Atorvastatin|10mg
1775616|NCT00395499|Drug|Risperidone|
1775617|NCT00395512|Drug|Alogliptin|Alogliptin tablets.
1775618|NCT00395512|Drug|Pioglitazone|Pioglitazone tablets.
1775619|NCT00395512|Drug|Placebo|Matching placebo tablets.
1775621|NCT00395551|Drug|ranibizumab|0.5mg intravitreal injection
1775622|NCT00395577|Drug|VX-702|
1775623|NCT00395603|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
1775624|NCT00395603|Drug|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
1775625|NCT00395616|Drug|Botox (drug)|
1775626|NCT00395629|Drug|Deferasirox (ICL670)|
1775627|NCT00395642|Device|Kronos LV-T, Lumax HF-T|Implanted CRT-device sends out device diagnostics (e.g. heart rate, device and lead integrity, patient activity) via CardioMessenger on daily basis. In addition, daily weight and blood pressure readings are taken; remote data are analyzed by investigational sites via the internet on a weekly basis.
1775628|NCT00395655|Drug|Hydralazine and magnesium valproate administration|
1775629|NCT00395655|Procedure|Core-needle biopsy of the breast|
1775630|NCT00395668|Device|TETRA (at lowest carrier freq, std TDMA pulse at 17,6 Hz).|
1775631|NCT00395681|Drug|Diprivan|Propofol 200 mg versus 350 mg
1775632|NCT00395694|Drug|lamictal|anti-epileptic drug
1775633|NCT00395707|Drug|Lucentis|0.3mg/0.05 ml or 0.5mg/0.05 ml
1775634|NCT00395707|Drug|Ranibizumab|0.3mg/0.05 ml or 0.5mg/0.05 ml
1775635|NCT00395707|Drug|Ranibizumab (Lucentis)|0.3mg/0.05 ml intravitreally
1775636|NCT00395707|Drug|Ranibizumab (Lucentis)|0.5mg/0.05 ml
1775637|NCT00395720|Biological|MVA85A (TB vaccine)|Intradermal vaccine
1775638|NCT00395720|Biological|MVA 85A|Intradermal vaccine
1775639|NCT00395733|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participant received a single intravenous injection with Gadobutrol (1.0 M) at a volume of 0.2 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.3 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
1775640|NCT00395733|Drug|Gadopentate dimeglumine (Magnevist, BAY86-4882)|Participant received a single intravenous injection with Gadopentate (0.5 M) at a volume of 0.4 mL/kg BW (dose = 0.2 mmol/kg BW) or up to 0.6 mL/kg BW when 3 Fields of View were imaged (up to dose = 0.3 mmol/kg BW)
1775641|NCT00395746|Drug|sulfonylurea|SU agent
1775642|NCT00395746|Drug|liraglutide|Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
1775643|NCT00395746|Drug|liraglutide|Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
1775644|NCT00395759|Drug|Optiva artificial tear by Allergan|
1775645|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 20 mg once daily (od) for 12 weeks
1775646|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 30 mg od for 12 weeks
1775647|NCT00395772|Drug|Xarelto (Rivaroxaban, BAY59-7939)|BAY59-7939 40 mg od for 12 weeks
1775648|NCT00395772|Drug|(LMW) Heparin + Vitamin K Antagonist|Low Molecular Weight (LMW) Heparin + Vitamin K Antagonist (VKA) for 5 days, then VKA only for the rest of 12 weeks
1775649|NCT00395785|Device|Carotid Stent Implantation|
1775650|NCT00395785|Device|Embolic Protection|
1775651|NCT00395798|Device|Soft or stiff cervical collar(device), neck school(behavior)|
1775652|NCT00395811|Procedure|Bone Marrow Stem Cell Therapy combined CABG|Bone Marrow Stem Cell inject into myocardium
1775653|NCT00395824|Procedure|anticoagulation procedure|
1775654|NCT00395837|Behavioral|Aerobic exercise|
1775655|NCT00395850|Drug|Disulfiram|Disulfiram at 0, 250, 375, or 500 mg/day for 12 weeks
1775656|NCT00395863|Drug|Multihance|0.5 M at a single injection
1775657|NCT00395863|Drug|Arm 2 - Magnevist|0.5 M Magnevist at a single dose injection
1775658|NCT00395876|Drug|placebo|2 mL of placebo instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of placebo). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
1775659|NCT00395876|Drug|tenecteplase|2 mL of reconstituted lyophilized tenecteplase instilled into lumen of dysfunctional CVC. Patients weighing ≥ 30 kg received 2-mL instillations of study drug (i.e., 2 mg of tenecteplase). Patients weighing < 30 kg received instillations of study drug equal to 110% of the internal lumen volume of the dysfunctional CVC. This dose was rounded to the nearest 0.1 mL and should not have exceeded 2 mL (2 mg).
1775660|NCT00395889|Procedure|Rehabilitation including structured exercise training|Rehabilitation of at least 8 weeks, for at least twice/week. This group will also receive the exercise counseling as a part of the rehabilitation program.
1775661|NCT00395889|Procedure|Physical Activity Counseling|Six exercise counseling sessions will be carried out during a 6-month period. This group will only receive the counseling and no formal structured exercise training sessions.
1775662|NCT00395902|Drug|Sensipar after Post Transplant|
1775663|NCT00395915|Drug|aripiprazole|
1775664|NCT00395941|Drug|Pioglitazone|
1775665|NCT00395967|Drug|G-CSF plus plerixafor|Mobilization with Granulocyte Colony Stimulating Factor (G-CSF) (10 µg/kg once a day) for 5 days. Patients received once daily plerixafor treatment (240 mg/kg) in the evening (10 to 11 hours prior to apheresis) for up to 3 days if peripheral blood CD34+ cell counts on Day 5 met the entry criteria. Morning doses of G-CSF (10 µg/kg) continued throughout apheresis.
1775666|NCT00395980|Device|surgical table pressure mat|
1775667|NCT00395993|Drug|Ferric Carboxymaltose (FCM)|Maximum of 1,000 mg of iron as IV FCM given at weekly intervals until the individual's calculated cumulative dose has been reached or a maximum of 2,500 mg has been administered
1775668|NCT00395993|Drug|Ferrous Sulfate tablets|325 mg tablets TID on Days 0 through Day 42
1956966|NCT02611830|Drug|Placebo SC|
1775671|NCT00396032|Drug|placebo|For the initial treatment, 2 mL of placebo instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
1775672|NCT00396032|Drug|tenecteplase|For the initial treatment, 2 mL of reconstituted lyophilized tenecteplase instilled into each lumen of the HD catheter; subsequent treatments were 2 mL of open-label tenecteplase
1775673|NCT00402948|Drug|TPI ASM8|0.25mg, 0.5mg for 14 days, daily dosage
1775674|NCT00402948|Drug|ASM8|inhalation 0.25mg daily for 14 days
1775675|NCT00402961|Other|Acupuncture|Acupuncture will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge.
1775676|NCT00402961|Other|Sham Acupuncture|Sham Acupuncture involves the acupuncturist tapping a plastic guiding tube on the surface of the true points to produce some discernible sensation and then immediately tapping a real needle sideways parallel to the skin surface without needle insertion. It will be given twice daily for a total of three days (Day 1 to 3). The two acupuncture sessions will be separated by at least 4 hours, preferably given in the morning and late afternoon. Each session will last approximately 30 minutes, starting from the moment the first needle is inserted and ending the moment the first needle is removed. The last treatment will be given at the end of Day 3 or day of discharge,
1775677|NCT00402974|Drug|menaquinone 7|
1775678|NCT00402987|Drug|celecoxib|dose 1 celecoxib 50 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
1775679|NCT00402987|Drug|celecoxib followed by placebo|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 placebo
1775680|NCT00402987|Drug|celecoxib|dose 1 celecoxib 100 mg followed 6-12 hours later by dose 2 celecoxib 50 mg
1775681|NCT00402987|Drug|placebo|dose 1 placebo followed 6-12 hours later by dose 2 placebo
1775682|NCT00403000|Drug|dutasteride|Oral
1775683|NCT00403013|Procedure|Positioning and anesthesia|Positioning during axillary plexus block
1775684|NCT00403026|Drug|Bevacizumab ( Avastin)|
1775685|NCT00403039|Drug|Ranibizumab (Lucentis )|
1775686|NCT00403052|Drug|1018 ISS immunostimulatory oligonucleotide|6 weekly subcutaneous (under the skin) injections
1775687|NCT00403065|Drug|dexamethasone|
1775688|NCT00403065|Procedure|quality-of-life assessment|
1775689|NCT00403065|Radiation|radiation therapy|
1775690|NCT00403091|Behavioral|Internet Intervention|Internet-based intervention aims to improve guideline adherence by rural physicians caring for adult patients with type 2 diabetes.
1775691|NCT00403091|Behavioral|Control|The comparison group will receive a text-based, non-interactive Internet posting of publicly available resources.
1775692|NCT00403104|Drug|ONO-2506PO|1200 mg QD / 18 months
1775693|NCT00403104|Drug|ONO-2506PO|0 mg QD / 18 months
1775696|NCT00403130|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
1775697|NCT00403130|Drug|Paclitaxel|Paclitaxel 80 mg/m2 by IV infusion, days 1, 8, and 15 in 28-day cycles
1775698|NCT00403130|Drug|Bevacizumab|Bevacizumab 10 mg/kg by IV infusion, days 1 and 15 in 28-day cycles
1775699|NCT00403143|Procedure|cataract surgery|
1775700|NCT00403156|Drug|Imatinib Mesylate /Ranibizumab|
1775702|NCT00403182|Drug|chemotherapy|
1775703|NCT00403182|Drug|letrozole|
1775705|NCT00403221|Genetic|RTVP-1 Gene|"Cohort Level #1 1.0 x 1010vp Cohort Level #2 5.0x1010vp Cohort Level #3 1.0 x 1011vp Cohort Level #4 5.0x1011vp Cohort Level #5 1.0 x 1012vp Cohort Level #6 5.0x1012vp
One dose only followed by a radical prostatectomy 4 weeks later."
1775706|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
1775707|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
1775708|NCT00403234|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patches 10 mcg/h and 20 mcg/h (total of 30 mcg/h) applied for 7-day wear.
1775709|NCT00403234|Drug|Placebo BTDS|Placebo to match BTDS transdermal 10 and 20 patches applied for 7-day wear.
1775710|NCT00403247|Dietary Supplement|Capsule with folate, Vitamin B12 & pyridoxine|
1775711|NCT00403247|Other|placebo|placebo capsule
1775712|NCT00403260|Drug|Pyronaridine artesunate|once a day for 3 days
1775713|NCT00403260|Drug|Mefloquine plus artesunate|once a day for 3 days
1775714|NCT00403273|Drug|Botulinum toxin A|100 units of Botulinum toxin A in 5 cc of normal saline in the Painful TKA at screening visit
1775715|NCT00403273|Drug|Normal Saline|Single Intra-articular Injection of 5 cc of normal saline in the Painful TKA at screening visit
1775716|NCT00403585|Drug|adefovir dipivoxil 10mg|
1775717|NCT00403611|Drug|Praziquantel 60 mg/kg|Praziquantel (Distocide) 60 mg/kg single oral dose
1775718|NCT00403611|Drug|Praziquantel 40 mg/kg|Praziquantel (Distocide) 40 mg/kg single oral dose
1775719|NCT00403624|Drug|OXALIPLATIN|
1775720|NCT00403637|Drug|indacaterol maleate|
1775721|NCT00403650|Drug|Iloprost|Iloprost 2.5-5 mg inhaled via nebulizer up to 6 times a day
1775722|NCT00403663|Drug|bupivacaine 0.75% with fentanyl and morphine|the following administered once, by spinal injection; 9-12 mg 0.75% hyperbaric bupivacaine 10 mcg fentanyl 100 mcg morphine
1775723|NCT00403676|Other|Follow up bu a nurse|Follow up bu a nurse
1775724|NCT00403676|Other|Follow up by a medical doctor|Follow up by a medical doctor
1775725|NCT00403689|Dietary Supplement|Beta-D-Glucan|1,5 g Beta-D-Glucan daily
1775726|NCT00403689|Dietary Supplement|placebo|1.5 g waxy maize starch daily
1775727|NCT00403702|Drug|Oxane HD [oil-RMN3-mixture]|
1775728|NCT00403702|Drug|Densiron [(F6H8)|
1775729|NCT00403715|Drug|diquafosol tetrasodium (INS365) Ophthalmic Solution|
1775730|NCT00403728|Drug|ciclosporine A|
1775731|NCT00403741|Behavioral|motivational interviewing|
1775732|NCT00403754|Drug|Indacaterol|In the morning, powder filled capsules inhaled using a single dose dry powder inhaler (SDDPI).
1775733|NCT00403754|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
1775734|NCT00403754|Drug|Salmeterol|Salmeterol 100 μg total dose taken on Day 1. 50 μg in the morning and 50 μg twelve hours post initial dose inhaled via Diskus®, an inhalation device for Salmeterol.
1775735|NCT00403767|Drug|Rivaroxaban|Type=exact number, unit=mg, number=20, form=tablet, route=oral use. One 20 mg tablet once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years (Patients with moderate renal impairment at screening willl have a dose adaptation to rivaroxaban 15 mg, orally, once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years)
1775736|NCT00403767|Drug|Warfarin|Type=exact number, unit=mg, number=1, 2.5, or 5 mg, form=tablet, route=oral use. Number of warfarin tablets to be determined based on target INR values once daily for an expected maximum treatment period of up to 32 months that may extend up to 4 years
1775737|NCT00403767|Drug|Matching placebo for Rivaroxaban arm (Warfarin placebo)|Form=tablet, route=oral. One warfarin placebo tablet taken orally once daily for up to an expected maximum treatment period of 32 months that may extend up to 4 years
1775738|NCT00403767|Drug|Matching placebo for Warfarin arm (Rivaroxaban placebo)|Form-tablet, Route=oral administration. Number of rivaroxaban placebo determined by the number of warfarin tablets taken. Duration of treatment is up to an expected maximum treatment period of 32 months that may extend up to 4 years
1775739|NCT00403780|Drug|pregabalin|"Capsule pregabalin 75 mg once or twice daily up to a total dose of 600mg daily (300mg twice daily) for a total of minimum 14 days and maximum 8 weeks.
Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily."
1775740|NCT00403780|Drug|placebo|Capsule placebo once or twice daily up to a total dose of 8 capsules(4 capsules twice daily) for a total of minimum 14 days and maximum 8 weeks. Dosage will be up titrated during first study week according to a prespecified scheme, starting with one capsule daily.
1775741|NCT00403793|Drug|etonogestrel with testosterone undecanoate|42 or 44 weeks with etonogestrel implant and testosterone undecanoate injections every 10 to 12 weeks
1775742|NCT00403793|Drug|Placebo|42 or 44 weeks with placebo implant and placebo injections
1775743|NCT00403806|Drug|dexamethasone|intravenous dexamethasone 0.05 mg per kg bodyweight
1775744|NCT00403806|Drug|Dexamethasone|Intravenous dexamethasone 0.15 mg per kg bodyweight
1775745|NCT00403806|Drug|dexamethasone|Intravenous dexamethasone 0.5 mg per kg bodyweight
1775746|NCT00403806|Drug|Saline|Intravenous saline
1775747|NCT00403819|Drug|Polyethylene glycol 3350 Na bicarbonate NaCl KCl (Movicol)|
1775748|NCT00403832|Device|intraocular lenses: Two foldable, acrylic, sharp edged IOLs: AcrySof™ (AcrySof SA60AT, Alcon), and Akreos adapt™ (Bausch & Lomb)|
1775749|NCT00403845|Drug|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
1775750|NCT00403845|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
1775751|NCT00403845|Drug|Placebo|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
1775752|NCT00403858|Drug|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
1775753|NCT00403858|Drug|Lactulose|
1775754|NCT00403884|Procedure|Selective RPE laser treatment|interventional SRT laser treatment
1775755|NCT00403897|Drug|Polyethylene glycol 3350 Na bicarbonate NaCl KCl|6.9g sachet, oral
1775756|NCT00403910|Drug|Canrenone|
1775757|NCT00403923|Dietary Supplement|Lactose in water|
1775758|NCT00403936|Procedure|OA decompression manipulation|
1775759|NCT00403949|Drug|Azelaic acid 15% gel|gel, applied once daily, for 6 weeks
1775760|NCT00403949|Drug|Non-active base from azelaic acid 15% gel|gel, apply once daily for six weeks
1775761|NCT00403962|Drug|vestipitant/paroxetine|
1775762|NCT00403975|Drug|diquafosol tetrasodium ophthalmic solution, 2%|
1775763|NCT00403988|Drug|Oxaliplatin|
1775764|NCT00403988|Drug|vinorelbine|
1775765|NCT00404001|Drug|MD-0727|
1775766|NCT00404014|Drug|AL-208|1 dose of 300 mg
1775767|NCT00404014|Drug|Placebo|1 dose of placebo
1775768|NCT00404040|Drug|Polyethylene glycol 3350 NA bicarbonate NaCl KCl (Movicol)|
1775769|NCT00404040|Drug|Lactulose|
1775770|NCT00404053|Drug|Clopidogrel|
1775779|NCT00404079|Drug|Glucosamine sulphate|Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months
1775780|NCT00404079|Drug|Placebo|Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months
1775781|NCT00404092|Drug|caspofungin|i.v.
1775782|NCT00404105|Procedure|PRK|
1775783|NCT00404105|Procedure|LASIK|
1775784|NCT00404131|Drug|diquafosol tetrasodium (INS365) Ophthalmic Solution|
1775785|NCT00404144|Device|Drug Eluting Balloon|PCI of small vessels single arm study
1775786|NCT00404157|Drug|Rituximab|
1775787|NCT00404170|Drug|B-CIT and SPECT imaging|Optional ongoing B-CIT SPECT imaging scans at follow-up visits
1775788|NCT00404183|Drug|Extended-Release Hydrocodone/Acetaminophen|2 tablets BID
1775789|NCT00404183|Drug|Placebo|2 tablets BID
1775790|NCT00404196|Drug|Calcipotriol and LEO80122 (LEO19123 cream)|
1775791|NCT00404209|Procedure|Vitrectomy|pressurized 23GA vitrectomy with a 3D system
1775792|NCT00404222|Drug|Hydrocodone/Acetaminophen Extended-Release|2 tablets x 1
1775793|NCT00404222|Drug|Hydrocodone/Acetaminophen Immediate Release (NORCO®)|1 tablet q 4 hours x 3
1775794|NCT00404222|Drug|Placebo|q 4 hours x 3
1775797|NCT00404248|Drug|terameprocol|terameprocol will be given IV 5 consecutive days every 28 days. Starting dose 750mg/day. Cohorts of 3pts. A Dose Limiting Toxicity (DLT) target rate of Less than or equal to 33%. Dose levels: 750, 1100, 1700, 2200, 3000, 4000, 5300, 7000, 9300 mg.
1775798|NCT00404248|Other|pharmacological study|All pts on both arms will have pks, blood collections. 5ml of blood will be drawn on Cycle 1 day 1, Cycle 1 Day 5, Cycle 2 day 1 and Cycle 2 day 5. A total of 10 samples will be drawn at each of these time points. 1hr pre-infusion, 15 min, 1hr, 1.15, 1.5, 2, 3,4,6 and 24hr post infusion.
1775800|NCT00404274|Drug|Casopitant (GW679769) oral tablets|Casopitant will be available in the dose strength of 20,30 or 50 mg
1775801|NCT00404274|Drug|Warfarin oral tablets|Warfarin will be available in the dose strength of 5 mg
1775802|NCT00404287|Drug|Fluvastatin|
1775803|NCT00404300|Drug|Optivate|Plasma-derived Factor VIII
1775804|NCT00404313|Drug|MK0633|Patients will receive 10 mg, 50 mg, or 100 mg MK0633 tablets once daily for 6 weeks. There will be 2 week period during which all patients will receive placebo to MK0633
1775805|NCT00404313|Drug|Comparator: placebo|Placebo to MK0633 10 mg, 50 mg, or 100 mg tablets once daily for 6 weeks
1775806|NCT00404326|Drug|Hydralazine and magnesium valproate|
1775807|NCT00404326|Procedure|Punch biopsy of the primary tumor|
1775808|NCT00404339|Biological|mutant p53 peptide pulsed dendritic cell vaccine|
1775809|NCT00404339|Biological|tetanus toxoid helper peptide|
1775810|NCT00404339|Procedure|adjuvant therapy|
1775811|NCT00404352|Drug|RNF|Single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months, or 36 months for patients enrolled in the OL extension.
1775812|NCT00404352|Drug|RNF|Single dose of RNF administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 24 months.
1775813|NCT00404352|Drug|Placebo|Placebo was supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 mL.
1775814|NCT00404365|Other|counseling intervention|
1775815|NCT00404365|Other|screening questionnaire administration|
1775816|NCT00404365|Other|study of socioeconomic and demographic variables|
1775817|NCT00404365|Procedure|psychosocial assessment and care|
1775818|NCT00404378|Drug|ketoconazole|Ketoconazole tablets will be available with dose strength of 200 mg. The dose of ketoconazole 400 mg will be comprised of two 200 mg tablets. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
1775819|NCT00404378|Drug|casopitant 100 mg|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive two 50 mg tablets for the dose of 100 mg. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time
1775820|NCT00404378|Drug|Casopitant 50 mg|Casopitant tablets will be available with dose strength of 50 mg and will receive single dose. On Day 4 of Treatment Period 2, the dose of casopitant and ketoconazole is to be taken at the same time.
1775821|NCT00404391|Drug|Hydrocodone/Acetaminophen Extended Release|1 tablet every 12 hours
1775822|NCT00404391|Drug|Hydrocodone/Acetaminophen Extended Release|2 tablets every 12 hours
1775823|NCT00404391|Drug|Placebo|2 tablets every 12 hours
1775824|NCT00404404|Biological|bevacizumab|
1775825|NCT00404404|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1775826|NCT00404417|Drug|Botulinum Toxin A / Placebo|Botulinum Toxin A at first injection / Placebo at second injection
1775827|NCT00404417|Drug|Botulinum Toxin A / Botulinum Toxin A|Botulinum Toxin A at first injection / Botulinum Toxin A at second injection
1775828|NCT00404417|Drug|Placebo / Botulinum Toxin A|Placebo at first injection / Botulinum Toxin A at second injection
1775829|NCT00404417|Drug|Placebo / Placebo|Placebo at first injection / Placebo at second injection
1775830|NCT00404443|Device|Acupuncture|Placebo-needles 17 will be used for those randomized to receive sham-acupuncture, which will be connected to the electrical current generator for the same duration and at the same acupuncture points without any current passing through, and intermittent non-specific manual twirling will also be applied. Patients are discouraged to communicate with each other before and after the treatment sessions to minimize bias.
1775831|NCT00404456|Drug|Melatonin|Melatonin 3 mg once-daily
1775832|NCT00404469|Procedure|peritendinous corticosteroid injections|1 ml of40mg/ml methylprednisolone acetate at 0 and 4 weeks. 2 week observational
1775833|NCT00404469|Procedure|eccentric decline squat training|eccentric decline unilateral squats performed twice daily. for 12 weeks
1775834|NCT00404469|Procedure|heavy slow resistance training|Heavy slow resistance training for knee extensors. 3/week. total of 12 weeks
1775835|NCT00404482|Drug|Cyclosporine A|
1775836|NCT00404495|Drug|Irinotecan|Irinotecan 10 mg/m^2 per day on days 1-5 and days 8-12 in repeated 3 week cycles
1775837|NCT00404495|Drug|Temozolomide|Temozolomide 100-125 mg/m^2 daily on days 1-5 in repeated 3 week cycles
1775838|NCT00404508|Drug|Hydralazine and magnesium valproate|
1775839|NCT00404521|Drug|PM02734|Administered every 3 weeks, intravenously, over 30 minutes
1775840|NCT00404534|Drug|Amoxicillin, Clarythromycin, Omeprazole for ten days|Amoxicillin 1000 mg BID, clarythromycin 500 mg BID for ten days in the experimental group and placebo of Amoxicillin 1000 mg BID and placebo of clarythromycin 500 mg BID in the placebo comparator. Both groups receive omeprazole 20 mg bid for 10 days.
1775843|NCT00404573|Drug|RGH-188|
1775844|NCT00404586|Drug|GW784568X|GW784568X will be delivered as a micronized suspension (50 or 100mcg/spray) via an aqueous nasal spray. Dose planned for treatment groups are 100, 200 and 400 mcg.
1775845|NCT00404586|Drug|Fluticasone propionate|Fluticasone propionate will be delivered 50 mcg/spray and planned dose is 200 mcg.
1775846|NCT00404586|Drug|Placebo|Matching Placebo to GW784568X as aqueous nasal spray.
1775847|NCT00404599|Drug|atrorvastatin 10mg|Atorvastatin 10 mg once a day
1775848|NCT00404599|Drug|simvastatin 40mg|simvastatin 40mg once a day
1775849|NCT00404612|Drug|Placebo|PO BID
1775850|NCT00404612|Drug|LX211|0.2 mg/kg, twice a day (BID)
1775851|NCT00404612|Drug|LX211|0.4 mg/kg, twice a day (BID)
1775852|NCT00404612|Drug|LX211|0.6 mg/kg, twice a day (BID)
1775853|NCT00404625|Behavioral|Risk factors for infections due to ESBL+ Enterobacteriaceae|
1775854|NCT00404625|Behavioral|Risk factors for inadequate initial antimicrobial therapy|
1775855|NCT00404625|Behavioral|Overall and 30-day mortality in bad first antibiotic therapy|
1775856|NCT00404638|Drug|Desmopresin|
1775857|NCT00404638|Behavioral|Paula Method of Circular Muscle Exercise|
1775858|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
1775859|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
1775860|NCT00404651|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, IM
1775861|NCT00404651|Biological|DTaP-HBV-IPV vaccine|0.5 mL, IM
1775862|NCT00404664|Behavioral|influenza vaccine, reminders letters, raffle prize|
1775863|NCT00404677|Other|deep inhalation|deep inhalation is comprised of an inhalation manoeuver from FRC to TLC
1775864|NCT00404690|Procedure|Bedside Silo|silo placed at bedside on admission
1775865|NCT00404690|Procedure|Operative attempt at closure|go the operating room to attempt closure
1775866|NCT00404703|Drug|bevacizumab [Avastin]|15mg iv on day 1 of each 3 week cycle
1775867|NCT00404703|Drug|Platinum-based chemotherapy|As prescribed
1775868|NCT00404716|Drug|Cilostazol|
1775869|NCT00404729|Drug|Cytidine-5’-diphosphocholine (Citicoline)|
1775870|NCT00404742|Drug|Placebo|PO BID
1775871|NCT00404742|Drug|LX211|0.2 mg/kg, twice a day (BID)
1775872|NCT00404742|Drug|LX211|0.4 mg/kg, twice a day (BID)
1775873|NCT00404742|Drug|LX211|0.6 mg/kg, twice a day (BID)
1775879|NCT00404781|Drug|cilostazol in addition to aspirin and clopidogrel|
1775880|NCT00404794|Drug|prednisolone and mycophenolate mofetil|
1775881|NCT00404794|Drug|prednisolone and tacrolimus|
1775882|NCT00404807|Device|CPAP(Continuous Positive Airway Pressure)|
1775883|NCT00404820|Drug|Zoledronic acid 5 mg solution|Zoledronic acid was supplied as a concentrate of 5.33 mg zoledronic acid monohydrate in a 100 ml solution. 5.33 mg zoledronic acid monohydrate equals 5 mg zoledronic acid.
1775884|NCT00404820|Drug|Alendronate 70 mg tablets|Patients received an alendronate 70 mg tablet once weekly with 200 ml of tap water in the morning on an empty stomach at least 30 minutes before the first meal.
1775885|NCT00404820|Drug|Calcium/Vitamin D|Combined elemental calcium / vitamin D chewable tablets. Participants took 2 tablets a day, for a daily dose of calcium 1200 mg/vitamin D 800 IU.
1775886|NCT00404833|Drug|prednisolone and mycophenolate mofetil|
1775887|NCT00404833|Drug|prednisolone and chlorambucil|
1775888|NCT00404846|Procedure|Hyperbaric Oxygenation Therapy|
1775889|NCT00404885|Drug|Placebo|PO BID
1775890|NCT00404885|Drug|LX211|0.2 mg/kg, twice a day (BID)
1775891|NCT00404885|Drug|LX211|0.4 mg/kg, twice a day (BID)
1775892|NCT00404885|Drug|LX211|0.6 mg/kg, twice a day (BID)
1775893|NCT00404911|Behavioral|MFG therapy|MFG includes 16 weekly group therapy sessions for families with children who have ODD or CD. Sessions will include adult caregivers and all children over age 6. Each session will follow the same procedures, and will proceed through the following stages: creating social networks; information exchange; group discussions; individual family practice; and homework assignment.
1775894|NCT00404911|Behavioral|Standard of Care|Participants assigned to standard care will receive treatment that is traditionally offered to outpatients. Participants in the MFG program will also receive standard care.
1775895|NCT00404924|Drug|ZD6474 (vandetanib)|once daily oral tablet
1775896|NCT00404924|Other|Best Supportive Care|standard of care
1775897|NCT00404937|Drug|Tobradex (Antibiotic steroid combination)|
1775898|NCT00404963|Drug|placebo|
1775899|NCT00404963|Drug|GSK376501|
1775900|NCT00405002|Procedure|Helium dilution technique, lung CT scan|Helium dilution technique and lung CT scan
1775901|NCT00405015|Drug|rosiglitazone|Rosiglitazone 4 mg bidaily for 8 weeks
1775902|NCT00405041|Dietary Supplement|Dietary supplement GVG 2|2.670 g/day for 14 days
1775903|NCT00405054|Drug|MK0457|IV infusion 32 mg/m2/hour; 5-day continuous infusion every 14 days
1775904|NCT00405067|Drug|BMS-201038 (AEGR-733)|
1775905|NCT00405067|Drug|Ezetimibe|
1775906|NCT00405080|Drug|GW679769 (Casopitant) oral tablets|Casopitant tablets will be available with dose strength of 50 mg. Subjects will receive three 50 mg tablets for the dose of 150 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
1775907|NCT00405080|Drug|Rifampin oral capsules|Rifampin capsules will be available with dose strength of 300 mg. Subjects will receive two 300 mg capsules for the dose of 600 mg. On Day 8 of Treatment Period 2, the dose of casopitant and rifampin is to be taken at the same time.
1775908|NCT00405119|Drug|AH23844 (lavoltidine)|
1775909|NCT00405119|Drug|NEXIUM (esomeprazole)|
1775910|NCT00405119|Drug|ZANTAC (ranitidine)|
1775911|NCT00405158|Procedure|Acupuncture treatment|
1775912|NCT00405158|Procedure|Administration of oxytocin nasal spray|
1775913|NCT00405158|Procedure|Improved breast milk removal|
1775914|NCT00405158|Procedure|Warmth applied to breasts|
1775915|NCT00405158|Procedure|Breast massage|
1775916|NCT00405158|Drug|Anti-pyretic medication, paracetamol|
1775917|NCT00405158|Drug|cefadroxil|
1775918|NCT00405158|Drug|penicillin|
1775919|NCT00405158|Drug|flucloxacillin|
1775920|NCT00405171|Drug|Nevirapine|
1775921|NCT00405184|Drug|IntragamP|IntragamP - dosage based on previous dose of IntragamP prior to study entry. One cycle (Cycle 0)only administered, with dosage calculation based on body weight on Day 1 of the study and must be between 0.2-0.8 g/kg body weight. IntragamP to be administered intravenously.
1775922|NCT00405184|Drug|Ig NextGen 10%|Ig NextGen 10% - dosage based on previous dose of IntragamP in Cycle 0. Dosage calculation to use body weight on Day 1 of Cycle 1 of the study and must be between 0.2-0.8 g/kg body weight. 7 cycles administered, and patients to be dosed at 3 to 4 week intervals (in accordance with previous dosage schedule with IntragamP). Ig NextGen 10% to be administered intravenously.
1775923|NCT00405197|Behavioral|Isocaloric diet high in MUFA or Mediterranean diet|
1775924|NCT00405210|Drug|sorafenib (200 or 400mg bid) and taxotere iv|200 mg BID, day 3-19 cycle 1, day 2-19 other cycles 200 mg BID, day 3-21 Cycle 1, day 1-21 other cycles 400 mg BID, day 3-19 cycle 1, day 2-19 other cycles 400 mg BID, day 3-21 cycle 1, day 1-21 other cycles
1775925|NCT00405236|Drug|tiotropium|
1775926|NCT00405249|Drug|elvucitabine|
1775927|NCT00405262|Drug|Ketorolac|0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
1775928|NCT00405262|Drug|Bupivacaine|0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
1775929|NCT00405262|Drug|ketorolac + bupivacaine|"0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.
For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter"
1775930|NCT00405275|Drug|Etanercept|etanercept, subcutaneous injection
1775931|NCT00405275|Drug|methotrexate|baseline methotrexate is maintained throughout the study and is not provided by the sponsor
1775932|NCT00405275|Drug|Sulfasalazine|sulfasalazine, oral
1775933|NCT00405275|Drug|Hydroxychloroquine|hydroxychloroquine, oral
1775934|NCT00405275|Drug|Placebo, triple|Participants in Etanercept arm (Arm 1) were given placebo hydroxychloroquine and sulfasalazine pills.
1775935|NCT00405275|Drug|Placebo, etanercept|Participants in triple arm (Arm 2) were given placebo etanercept injections.
1775936|NCT00405288|Drug|Proctofoam-HC®|Observational study of the exposure to Proctofoam-HC®
1775937|NCT00405301|Drug|Rifampicin(max dose 10 mg/kg/day), Isoniazide (max dose 5 mg/kg/day) and Pyrazinamide (max dose 25 mg/kg/day)|Patients who develop ATT drug induced hepatotoxicity will be divided into 3 arms .Arm 1,2,3 will be given drugs as described in detailed description of the title.
1775938|NCT00405314|Device|Continuous positive airway pressure ventilation mask|
1775939|NCT00405327|Biological|Tumor lysate-pulsed dendritic cell (DC) vaccine|Tumor lysate-pulsed dendritic cell vaccine
1775940|NCT00405327|Other|Hematopoietic stem cell transplantation (HSCT)|Hematopoietic stem cell transplantation (HSCT)
1775941|NCT00405340|Drug|Rituximab|Patients will received rituximab 4 weekly doses of rituximab 375 mg/m2 at baseline. Patients will be retreated at 6 months.
1775943|NCT00405366|Drug|sorafenib tosylate|Patients will receive treatment with 400mg of sorafenib, orally, twice daily, on a continuous basis as a single agent for at least 4 weeks, but not more than 8 weeks prior to their scheduled nephrectomy
1775944|NCT00405379|Device|Trabecular Metal Mesh Tibial Monoblock Knee Arthroplasty|new porous metal tibial component with potential to result in improved bone in-growth and implant integration with proximal tibia
1775945|NCT00405392|Drug|Ibandronate (SB743830HD)|
1775946|NCT00405405|Drug|Cisplatin|"Two cycles during neoadjuvant therapy
Response assessment at approximately day 36
Concurrent biochemoradiotherapy"
1775947|NCT00405405|Drug|Docetaxel|"Two cycles during neoadjuvant therapy
Response assessment at approximately day 36
Concurrent biochemoradiotherapy"
1775948|NCT00405405|Drug|Bevacizumab|"Two cycles during neoadjuvant therapy
Response assessment at approximately day 36
Concurrent biochemoradiotherapy"
1775949|NCT00405405|Drug|Erlotinib|"Two cycles during neoadjuvant therapy (dose escalation)
Response assessment at approximately day 36
Concurrent biochemoradiotherapy"
1775950|NCT00405405|Radiation|Radiotherapy|Radiotherapy begins as soon as possible following neoadjuvant chemotherapy, and continues for 7 weeks
1775951|NCT00405418|Drug|Insulin glargine|Subcutaneous injection, once a day in the evening
1775952|NCT00405418|Drug|Insulin Detemir|Subcutaneous injection, twice a day at breakfast and before dinner
1775953|NCT00405431|Drug|Restasis|1 drop in study eye twice a day X 6 months
1775954|NCT00405431|Drug|Endura (artificial tears)|1 drop in study eye twice a day X 6 months
1775955|NCT00405444|Drug|Fentanyl|The dose of fentanyl that each child will receive will be 2 mcg/kg based on the child's weight. The medication will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
1775956|NCT00405444|Drug|Sterile water|The dose of sterile water that each child will receive will be 2 mcg/kg based on the child's weight. It will be administered 10 minutes prior to the procedure and will be dropped into the unoccluded nares over 1-2 seconds.
1775957|NCT00405457|Drug|Restasis, Optive Tears|Restasis and Optive Tears use twice daily more frequently if needed
1775958|NCT00405470|Device|Advance Medial Pivot Knee Arthroplasty|medial pivot total knee arthroplasty tibial component vs standard posterior stabilized tibial component with post. Medial pivot provides a constrained medial condyle through shape of polyethylene and reduces amount of bone removal on femoral side that would otherwise be removed to accommodate PS post
1775959|NCT00405483|Procedure|Standard exposure|Minimal invasive vs standard exposure of the joint is the difference between a small incision, smaller equipment for less tissue damage vs large incision (standard is greater than 10cm)and subsequent more tissue damage.
1775960|NCT00405483|Procedure|Minimally Invasive|Minimally invasive surgical technique (minimal incision)
1775961|NCT00405496|Drug|Difluprednate Ophthalmic Emulsion|
1775962|NCT00405522|Drug|Propofol + Remifentanil|Patients in this arm of the study will receive 2.0 mg/kg propofol + 1.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
1775963|NCT00405522|Drug|Propofol + Remifentanil|Patients in this arm of the study will receive 4.0 mg/kg propofol + 0.5 ug/kg remifentanil. An anesthesiologist will inject propofol mixed with lidocaine, followed immediately by remifentanil, diluted with 0.9% saline to a volume of 3 ml and administered as a bolus.
1775964|NCT00405535|Drug|glycine|
1775965|NCT00405535|Other|placebo|
1775966|NCT00405548|Drug|BNP (nesiritide)|
1775967|NCT00405548|Drug|Placebo|
1775968|NCT00405561|Drug|AMT2003|
1775969|NCT00405574|Drug|ATN-224|ATN-224 high dose: 300mg ATN-224 low dose: 30mg
1775970|NCT00405587|Drug|PLX4032|Oral capsules administered BID
1775971|NCT00405600|Procedure|Device used in surgery with or without instrumentation|Infuse Bone Graft BMP-2, Large Kit will be used in all surgeries. Spine surgeries will be either instrumented or uninstrumented.
1775972|NCT00405613|Drug|Aspirin|
1775973|NCT00405626|Drug|Bellis Perenis ,Arnica montana|
1775974|NCT00405639|Drug|Nesiritide|Subjects randomized to this arm will receive 5 microgram/Kg subcutaneous (SQ) injection of nesiritide on Day 1. If after the first SQ injection the subject's systolic blood pressure is >90 mmHG and no symptoms of hypotension, then the second dose can be increased to 10 microgram/Kg. Subjects will self-administer the second dose 12 hours after the first dose, then self-administer the third dose 12 hours after the second dose. Subjects will be dismissed with instructions and supplies for 6 weeks of SQ administration twice a day. After 6 weeks, the subjects will return to the lab for assessments, and will be dismissed with supplies for 6 more weeks of SQ administration twice a day.
1775975|NCT00405639|Drug|Placebo|Normal saline will be used for placebo.
1775976|NCT00405652|Drug|Enteric-coated Mycophenolate sodium (EC-MPS)|experimental
1775977|NCT00405665|Drug|L-arginine|Group 1 will receive the active treatment followed by the inactive treatment. The active treatment phase will consist of L-arginine 250 mg/ml dispensed in 2.2 ml vials, from which the patient will take 2ml (500mg) and dilute with 3ml of sterile water to give 5ml of a 100mg/ml solution. Dosing in the inactive treatment phase will consist of a placebo of similar osmolarity and appearance will be formulated and dosed in a similar fashion. It will consist of 2.2ml vials of 1110mmol/L hypertonic saline. Again, the patient will take 2ml and dilute with 3ml of sterile water to give a 445mmol/L solution which has similar tonicity (10%) to the L-arginine. Both treatment phases will be administered by inhalation with a PARI eFLOW device.
1775978|NCT00405665|Drug|L-arginine|Group 2 will receive the inactive treatment followed by the active treatment.
1775979|NCT00405678|Behavioral|Exercise Training|Subjects receiving chemo with exercise training
1775980|NCT00405678|Behavioral|Chemo only|Subjects receiving chemo only
1775981|NCT00405691|Device|"TOPS System - Total Posterior Arthroplasty Implant"|
1775982|NCT00405704|Drug|Trimethoprim-Sulfamethoxazole|Cherry-flavored liquid suspension with 3 mg of trimethoprim plus 15 mg sulfamethoxazole per kilogram of body weight, taken once daily.
1775983|NCT00405704|Drug|Placebo|Cherry flavored liquid suspension matched to active comparator.
1775984|NCT00405717|Drug|atorvastatin,pravastatin|
1775985|NCT00405730|Drug|Nepafenac 1mg/ml eye drops, suspension|One drop in the study eye 3 times daily for 23 days
1775986|NCT00405730|Drug|Ketorolac Trometamol 5 mg/ml eye drops, solution|One drop in the study eye 3 times daily for 23 days
1775987|NCT00405730|Other|Nepafenac vehicle eye drops|One drop in the study eye 3 times daily for 23 days
1775988|NCT00405743|Drug|CP-4055|CP-4055 Continuous IV infusion
1775989|NCT00405743|Drug|CP-4055|CP4055 2 and 4 hour IV infusion
1775990|NCT00405756|Drug|Lenalidomide: Double-blind Induction|Double-blind Induction: the starting lenalidomide oral dosing regimen was 10 mg once daily on Days 1 through 21 of each 28 day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
1775991|NCT00405756|Drug|Melphalan|Double-blind Induction: the starting melphalan oral dosing regimen in all 3 treatment arms was 0.18 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
1775992|NCT00405756|Drug|Prednisone|Double-blind induction: the starting prednisone oral dosing regimen in all 3 treatment arms was 2 mg/kg daily on Days 1 through 4 of each 28-day cycle for up to 9 cycles. Dose was reduced if needed due to dose-limiting toxicity.
1775993|NCT00405756|Drug|Aspirin|"Double-blind induction: low-dose aspirin 75 mg to 100 mg daily for all treatment arms.
Double-blind maintenance: at the investigator's discretion"
1775994|NCT00405756|Drug|Placebo|"Double-blind induction: participants in treatment arm MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle for up to 9 cycles.
Double-blind maintenance: participants in treatment arms MPR+p and MPp+p received placebo once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression."
1775995|NCT00405756|Drug|Lenalidomide: Double-blind Maintenance|Single-agent oral lenalidomide 10 mg once daily on Days 1 through 21 of each 28-day cycle from cycle 10 to disease progression.
1775996|NCT00405756|Drug|Lenalidomide: Open-label|Any study participant who had progressive disease had the option of open-label lenalidomide up to 25 mg daily on Days 1 through 21 of each 28-day cycle.
1775997|NCT00405769|Drug|red yeast rice|600 mg 3 caps bid
1775998|NCT00405769|Drug|placebo|3 caps bid
1775999|NCT00405782|Behavioral|Moderate-Intensity Exercise|Exercise program designed by exercise physiologist
1776000|NCT00405795|Device|Envision® Patient Support System|
1776001|NCT00405808|Drug|Rimonabant|Once daily in the morning
1776002|NCT00405808|Drug|Placebo|Once daily in the morning
1776003|NCT00405821|Drug|Acyclovir|400mg twice daily for 24 months
1776004|NCT00405821|Drug|Placebo|Placebo tablet twice daily for 24 months
1776005|NCT00405834|Device|Envision® Patient Support System|
1776006|NCT00405847|Drug|Dexmedetomidine|
1776007|NCT00405860|Drug|CellCept (mycophenolate mofetil)|
1776008|NCT00405873|Drug|AMT2003|
1776009|NCT00405886|Drug|Neramexane|Oral tablets, duration: 16 weeks
1776010|NCT00405886|Drug|Placebo|Oral tablets, duration: 16 weeks
1776011|NCT00405912|Drug|Placebo|Placebo (inactive drug) given 3 times per day
1776012|NCT00405912|Drug|St. John's Wort-900 mg/day|St. John's Wort - 300 mg tables -3 times per day
1776013|NCT00405912|Drug|St. John's Wort-1800mg/day|St. John's Wort - 600 mg tables - 3 times per day
1776014|NCT00405925|Drug|Trizivir|
1776015|NCT00405925|Drug|zidovudine,lamivudine,abacavir|zidovudine 300 mg bid, lamivudine 150mg bid, abacavir 300mg bid
1776016|NCT00405938|Drug|Bevacizumab|Bevacizumab 10mg/kg IV every 2 weeks
1776017|NCT00405938|Drug|Anastrozole|anastrozole (1 mg orally daily)
1776018|NCT00405938|Drug|Fulvestrant|fulvestrant (500 mg IM on Day 1 of Cycle 1, followed by 250 mg IM of fulvestrant on Day 15 of Cycle 1. On Day 1 of Cycle 2 and the first day of all subsequent cycles thereafter, patients in this treatment arm will receive 250 mg IM of fulvestrant).
1776019|NCT00405951|Drug|Obatoclax mesylate 250 ml|
1776020|NCT00405951|Drug|Docetaxel|
1776021|NCT00405964|Drug|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 12 weeks
1776022|NCT00405964|Drug|Placebo tablet|Placebo tablet, once daily for 12 weeks
1776023|NCT00405977|Drug|Physiologic saline|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group and 1 ml per kg physiological saline. The infusion will be given with during 15 minutes.
1776024|NCT00405977|Drug|Magnesium sulphate|Intravenous infusion of the study solution, 1 ml per kg bodyweight, corresponding to MgSO4 60 mg kg-1 in the magnesium group. The infusion will be given during 15 minutes.
1776025|NCT00405990|Behavioral|Voluntary counselling and HIV testing in ANC for PMTCT|VCT for 30 minutes in ANC
1776026|NCT00405990|Behavioral|VCT|HIV VCT for PMTCT
1776027|NCT00406003|Drug|Paroxetine controlled release tablet|Paroxetine will be given as single dose, controlled release tablet with dosing strengths of 12.5, 25 and 37.5 milligrams in fasted state separated by a wash-out period of 10 days.
1776028|NCT00406016|Drug|ATI355|
1776029|NCT00406029|Drug|Preladenant|1 mg BID capsules
1776030|NCT00406029|Drug|Preladenant|2 mg BID capsules
1776031|NCT00406029|Drug|Preladenant|5 mg BID capsules
1776032|NCT00406029|Drug|Preladenant|10 mg BID capsules
1776033|NCT00406029|Drug|Placebo|BID capsules
1776034|NCT00406029|Drug|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
1776035|NCT00406029|Drug|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O-methyl transferase (COMT) inhibitor entacapone.
1776036|NCT00406042|Drug|prednisolone acetate 1%|
1776037|NCT00406055|Device|RX ACCULINK , RX ACCUNET , XACT , EMBOSHIELD and EMBOSHIELD Nav6|Provide an ongoing post-market surveillance mechanism for documentation of clinical outcomes and for possible extension of the Centers for Medicare and Medicaid Services (CMS) coverage to a broader group of patients.
1776038|NCT00406068|Drug|Mycobacterial cell wall-DNA complex|8 mg MCC, intravesical - Induction Phase (6 weekly intravesical instillations) and Maintenance Phase (3 weekly instillations at months 3, 6, 12, 18 and 24).
1776039|NCT00398931|Drug|MK0217, alendronate sodium / Duration of Treatment : 5 Years|
1776040|NCT00398931|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 5 Years|
1776041|NCT00398944|Device|Evaluation of the impact of a guideline based computerized decision support system.|
1776042|NCT00398957|Drug|OROS® Hydromorphone HCL; OROS® Dilaudid; Dilaudid SR (slow release); Naltrexone (an opioid antagonist).|
1776043|NCT00398970|Device|Endobronchial ultrasound miniprobe|Endobronchial ultrasound miniprobe is used to identify solid mass in lung parenchyma.
1776044|NCT00398983|Drug|Decitabine|20 mg/m^2 IV over 1 hour daily for 5 days
1776045|NCT00398996|Drug|Early versus intermediate versus late initiation of ART|Initiation of once daily ddI (400 / 250mg), 3TC (300mg) and EFV (600mg)during the intensive phase of TB therapy or during the continuation phase of TB therapy or once TB therapy has been completed
1776046|NCT00399009|Device|AutoSuture Premium Plus CEEA/Ethicon Proximate ILS|
1776047|NCT00399022|Drug|Duloxetine|
1776048|NCT00399035|Drug|Cediranib|oral tablet
1776049|NCT00399035|Drug|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
1776050|NCT00399035|Drug|XELOX (Capecitabine and Oxaliplatin)|intravenous oxaliplatin 130 mg/ m^2(day 1) followed by oral capecitabine 1,000 mg/ m^2twice daily (day 1 to day 15)
1776051|NCT00399035|Drug|Cediranib Placebo|oral tablet
1776052|NCT00399048|Drug|OROS hydromorphone HCL ; OxyContin|
1776053|NCT00399061|Drug|Systane, Optive, Restasis|Systane 30ml (in the eye) instill one drop twice a day in morning and evening Optive 15ml (in the eye) instill one drop twice a day in morning and evening Restasis 0.4ml (in the eye) instill one drop twice a day in morning and evening more frequently if needed
1776054|NCT00399074|Drug|sulfadoxine pyrimethamine|Monthly SP
1776055|NCT00399087|Drug|Perifosine|Perifosine oral administration
1776056|NCT00399087|Drug|Docetaxel|IV administration
1776057|NCT00399087|Drug|Prednisone|Oral administration
1776058|NCT00399100|Procedure|HBO - hyperbaric oxygen treatment|
1776059|NCT00399113|Drug|188Re-PTI-6D2|monoclonal antibody
1776060|NCT00399126|Drug|Perifosine|Perifosine oral dose
1776061|NCT00399126|Drug|Paclitaxel|Paclitaxel IV
1776062|NCT00399152|Drug|Perifosine|Perifosine Oral Dose
1776063|NCT00399152|Drug|Sunitinib Malate|Sunitinib oral dose
1776064|NCT00399165|Drug|Testosterone Enanthate|Oral Testosterone 400 mg orally for 28 days
1776065|NCT00399165|Drug|Testosterone Enanthate|Oral Testosterone 800 mg orally for 28 days
1776066|NCT00399165|Drug|Dutasteride|dutasteride 0.5 mg orally, once daily for 28 days
1776067|NCT00399165|Other|placebo sesame oil|placebo sesame oil
1776068|NCT00399165|Drug|Dutasteride|24.5 mg po once (Day 0)
1776069|NCT00399178|Drug|Transdermal delivery system|
1776070|NCT00399191|Drug|stable isotope of iron, dysprosium|
1776071|NCT00399204|Drug|Pioglitazone vs Metformin|
1776072|NCT00399217|Device|Subcutaneous Implantable Defibrillator (S-ICD) system|
1776073|NCT00399217|Device|ICD|
1776074|NCT00399230|Drug|Optive|
1776076|NCT00399256|Drug|Acetylcysteine|
1776077|NCT00399256|Drug|Zinc|
1776078|NCT00399269|Drug|Recombinant Human Erythropoietin alpha|
1776079|NCT00399282|Drug|Omega-3 and Vitamin E supplementation|
1776080|NCT00399295|Drug|Hydromorphone HCL 16mg; Dilaudid SR 16mg; Naltrexone (opioid antagonist) 50mg.|
1776081|NCT00399308|Device|Celaderm (Frozen Cultured Epidermal Allograft)|Four biweekly applications of Celaderm plus compression therapy
1776082|NCT00399308|Device|Celaderm (Frozen Cultured Epidermal Allograft)|Four weekly applications of Celaderm plus compression therapy
1776083|NCT00399308|Device|Control (compression bandaging)|Multi-layer compression bandaging
1776084|NCT00399334|Drug|antipsychotic medications|as prescribed
1776085|NCT00399360|Drug|Metformin|Starting at 500 mg twice daily and increasing to 850 mg twice daily after 3 Months
1776086|NCT00399360|Drug|Placebo|500 mg twice daily increasing to 850 mg twice daily after 3 Months
1776087|NCT00399360|Behavioral|Lifestyle Modification|Lifestyle Modification
1776088|NCT00399386|Procedure|EP|
1776089|NCT00399386|Procedure|ICD|
1776090|NCT00399386|Procedure|Ablation|
1776091|NCT00399399|Drug|azathioprine|
1776092|NCT00399399|Drug|cyclophosphamide|
1776093|NCT00399412|Device|subcutaneous ICD|
1776094|NCT00399425|Drug|bemiparin (low molecular weight heparin)|
1776095|NCT00399438|Drug|Placebo|Tablets, Oral, once daily, 2 weeks
1776096|NCT00399438|Drug|BMS-562086|Tablets, Oral, once daily, 2 weeks
1776097|NCT00399451|Drug|Polidocanol Sclerotherapy|
1776098|NCT00399464|Drug|alfuzosin|
1776099|NCT00399477|Drug|rasagiline mesylate|Azilect®
1776100|NCT00399477|Drug|Rasagiline mesylate plus Mirapex|Mirapex, Azilect®
1776101|NCT00399477|Drug|Rasagiline mesylate with Levodopa|Azilect®, Levodopa
1776102|NCT00399477|Drug|Rasagiline mesylate with Requip|Azilect®, Requip
1776103|NCT00399490|Drug|RN624 (PF-04383119)|50 mcg/kg
1776104|NCT00399503|Procedure|Spectral T Wave Alternans|
1776105|NCT00399503|Procedure|Modified Moving Average T Wave Alternans|
1776106|NCT00399503|Procedure|Baroreceptor Sensitivity|
1776107|NCT00399503|Procedure|Heart Rate Variability|
1776108|NCT00399503|Procedure|Heart Rate Turbulence|
1776109|NCT00399503|Procedure|Deceleration Capacity|
1776110|NCT00399503|Procedure|Signal Averaged ECG|
1776111|NCT00399516|Device|Precision|
1776112|NCT00399529|Biological|Allogeneic GM-CSF-secreting breast cancer vaccine|the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 108 cells for each patient and each vaccination cycle) on day 0.
1776113|NCT00399529|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody specific for the extracellular domain of HER-2/neu (Carter et al., 1992) that is now one component of the standard of care for both early and late stage HER-2/neu-overexpressing breast cancers. It exerts a pleiotropic antitumor effect by multiple mechanisms (Emens, 2005). The antibody decreases heterodimer formation with other members of the EGFR family, thereby indirectly inhibiting signaling through the ras/Raf/MAPK and PI3K/Akt pathways (Arteaga, 2003). It also inhibits tumor neovascularization (Izumi et al., 2002), and augments apoptosis both in vitro and in vivo (Lee et al., 2002; Chang et al., 2003). Trastuzumab prevents cleavage of the extracellular domain of HER-2/neu, thus abrogating the constitutive activation of the remaining membrane-associated intracellular domain.
1776114|NCT00399529|Drug|Cyclophosphamide|The doses of Cyclophosphamide are based on previously reported clinical experience as well as our own preclinical data demonstrating augmented vaccine efficacy with CY-modulated vaccination. In particular, 300 mg/m2
1776115|NCT00399542|Drug|Lubiprostone|
1776116|NCT00399542|Drug|Placebo|
1776117|NCT00399568|Drug|IV Acetaminophen|Intravenous acetaminophen 1 g/100 mL
1776118|NCT00399568|Drug|IV Placebo 100 mL solution|IV Placebo 100 mL solution dosed at same frequency as IV Acetaminophen every 6 hours (q6h)
1776119|NCT00399581|Procedure|High Frequency Oscillatory Ventilation-Hi|HFOV will be conducted with recruitment maneuvers and with a table of mPaw and FiO2s that include higher mPaw's.
1776120|NCT00399581|Procedure|High Frequency Oscillatory Ventilation-Lo|HFOV will be conducted without routine recruitment maneuvers and with a table of mPaw and FiO2s that include relatively low mPaw's.
1776121|NCT00399594|Procedure|A|LV lead placement in region of latest mechanical velocity (tissue doppler)
1776122|NCT00399594|Procedure|B|LV lead placement in standard (lateral / posterolateral) position.
1776123|NCT00399607|Procedure|Rectal biopsy during colonoscopy|Biopsies of rectal tissue will be obtained during the 3 or 5 year follow-up colonoscopy. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
1776124|NCT00399607|Procedure|Rectal biopsy at randomization|Biopsies of rectal tissue will be obtained at the time of randomization. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
1776172|NCT00400023|Drug|FT|During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
1776173|NCT00400036|Behavioral|Cod protein NCEP-diet|
1776125|NCT00399607|Procedure|Rectal biopsy at 1 year|Biopsies of rectal tissue will be obtained at the time of the one year follow-up visit. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
1776126|NCT00399607|Procedure|Rectal biopsy prior to colonoscopy|Biopsies of rectal tissue will be obtained 7-21 days prior to the 3 or 5 year colonoscopy. The collection of rectal biopsies involves inserting a tube—about as long and big around as a doctor's examining finger—through the anus into the rectum or lower colon to a depth of about 3-4 inches. At this spot, 4 - 6 tiny pinches of tissue one mm thick (less than 1/16 of an inch) will be taken. The procedure takes less than two minutes, is painless (the only discomfort is like that of having a rectal exam), and is very low risk—about like having blood drawn.
1776127|NCT00399607|Procedure|Biopsies during colonoscopy|Biopsies of the rectum, sigmoid colon and ascending colon will be obtained during the 3-5 year follow-up colonoscopy. The colonoscopy involves insertion of a flexible tube through the anus, which is then advanced the full length of the colon. Biopsies (tiny pinches of tissue less than 1/16 of an inch thick) will be taken as the colonoscopy tube is being removed. In total, 12-16 biopsies will be taken from the rectum (or lower colon about 3 - 4 inches up), sigmoid colon and ascending colon.
1776128|NCT00399620|Procedure|Gingival crevicular fluid samples (this procedure is added to the subject usual medical follow-up).|
1776129|NCT00399633|Drug|sumatriptan|
1776130|NCT00399646|Device|Metricath Gemini System|
1776131|NCT00399659|Drug|Tegaserod|
1776132|NCT00399672|Drug|Interferon injections and ribavirin|Weekly pegylated interferon injections will be administered by clinic staff and ribavirin will be dispensed in weekly medication pack.
1776133|NCT00399672|Drug|Interferon injections and ribavirin|Patients will be offered the option of self or nurse administered pegylated interferon injections on an appointment basis. Ribavirin will be dispensed biweekly. The treatment medication cannot be stored at the clinic; it must be the subjects responsibility.
1776134|NCT00399685|Drug|Ortho Tri-Cyclen LO|Tablets, oral, OTC Lo 1 tab/daily (no dosage units), once daily, 28 days.
1776135|NCT00399685|Drug|Ortho Cyclen|Tablet, oral, Ortho Cyclen 1 tab/daily (no dosage units), once daily, 28 days.
1776136|NCT00399685|Drug|Ortho Cyclen + Efavirenz|Tablet, oral, OC + EFV 600 mg, once daily, 14 days.
1776137|NCT00399685|Drug|Ortho Cyclen|Tablet, oral, OC 1 tab daily (no dosage units), once daily, 7 days.
1776138|NCT00399698|Drug|Risperdal|
1776139|NCT00399711|Drug|repaglinide and metformin combination tablet|
1776140|NCT00399711|Drug|rosiglitazone and metformin combination tablet|
1776141|NCT00399724|Drug|Insulin glargine|
1776142|NCT00399737|Drug|repeated intake of fermented milk followed by a single oral dose of an ACE inhibitor|
1776143|NCT00399750|Drug|oxaliplatin|
1776144|NCT00399750|Drug|fluoropyrimidine|
1776145|NCT00399750|Drug|bevacizumab|
1776146|NCT00399763|Drug|Atomoxetine|Half of participants are randomized to atomoxetine plus individual cognitive behavioral therapy targeting substance use disorder
1776147|NCT00399763|Drug|Placebo|Half of participants are randomized to placebo plus individual cognitive behavioral therapy targeting substance use disorder
1776148|NCT00399776|Radiation|Bone Density Test|Evaluating bone mineral content and bone metabolism in adolescents on antipsychotic therapy compared to healthy adolescents
1776149|NCT00399789|Drug|Perifosine|Perifosine will be tested in 3 dose forms
1776154|NCT00399828|Device|TRI-ACTIVE LASERDERMOLOGYTM (DEKA M.E.L.A., Itália)|
1776155|NCT00399841|Device|Precision for Spinal Cord Stimulation|During Trial Implant Period, stimulation from single lead initially turned on at the T7 or T8 level, then crossover. At time of permanent implant, subject chooses which level they want the stimulator turned on.
1776156|NCT00399854|Device|Dhermia® – Industra Mecânica Fina Ltda|
1776157|NCT00399867|Drug|Simvastatin|
1776158|NCT00399880|Behavioral|Health literacy intervention|Illustrated medication schedules, pill boxes, pharmacist counseling
1776159|NCT00399893|Drug|Octreotide|Octreotide to be administered by subcutaneous injection three times daily
1776160|NCT00399893|Drug|Placebo|Placebo to be administered by subcutaneous injection three times daily while on study
1776161|NCT00399906|Drug|BMS-582949|Tablets, Oral, Once daily, 12 weeks
1776162|NCT00399906|Drug|Placebo|Tablets, Oral, Once daily, 12 weeks
1776163|NCT00399919|Drug|Propionyl-L-Carnitine|2 grams per day for six months
1776164|NCT00399919|Drug|PLC|2 grams/day for six months
1776165|NCT00399945|Drug|Tobramycin|
1776166|NCT00399971|Procedure|Ex Vivo Immunotherapy|Allogeneic and autologous ex vivo activated immune cells are given intravenously at least once a week
1776167|NCT00399971|Drug|Ex vivo immunotherapy|i.v. infusions, once a week, at least 6 to 12 months
1776168|NCT00399984|Behavioral|Asthma Education Program|interactive seminars regarding daily inhaled corticosteroids
1776169|NCT00399997|Behavioral|Exercise on Prescription|
1776170|NCT00400010|Behavioral|Expert System Intervention|Questionnaires on motivation to change and alcohol consumption were assessed in a clinical interview. Data were entered in a Computer and a fully automatized feedback letter was generated by an expert system. The printed feedback letter was handed out to patients by study staff the following day.
1776171|NCT00400023|Drug|S-1|"During the Cross-Over PK Phase, S-1 will be administered as a 50 mg oral fixed dose and FT will be administered as an 800 mg oral fixed dose.
During the S-1 Extension Phase (Part 2), S-1 30 mg/m2 will be administered orally BID for 2 weeks (Day 1 through Day 14) followed by a 1-week recovery period (Day 15 through Day 21). This cycle will be repeated every 3 weeks."
1776176|NCT00400088|Drug|paroxetine|Start at 20 mg po od. Increase dose to 40 mg po od at week 4 if there is less than 20 % reduction in MADRS scores.
1776177|NCT00400088|Drug|lithium|start at 600mg po hs with dose to be flexibly titrated to a serum level of between 0.6 and 1.1 mmol/l.
1776178|NCT00400101|Biological|Virosome-formulated synthetic peptides (malaria vaccine)|
1776179|NCT00400114|Drug|Irinotecan|Irinotecan (50mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
1776180|NCT00400114|Drug|Cisplatin|Cisplatin (65mg/m2)once weekly in weeks 1, 2, 4, 5, 7, and 8
1776181|NCT00400114|Procedure|Radiation|Radiation 50 Gy (weeks 4-9)
1776182|NCT00400114|Procedure|Surgery|Esophagectomy
1776183|NCT00400114|Drug|sunitinib (Sutent)|sunitinib (Sutent), dose range of 12.5mg - 50mg OD x 1 year post op.
1776184|NCT00400127|Device|Silesian suspension belt|
1776185|NCT00400140|Device|Hyperopic lens|+3 D glasses
1776186|NCT00400153|Drug|Atrovent Respimat (20 mcg)|
1776187|NCT00400153|Drug|COMBIVENT MDI (36/206 mcg)|
1776188|NCT00400153|Drug|Combivent Respimat (20 mcg/100 mcg)|
1776189|NCT00400153|Drug|Placebo via corresponding inhaler for blinding purposes|
1776190|NCT00400166|Behavioral|Recovery Mentor|Provided Recovery Mentor services
1776191|NCT00400179|Drug|S-1/Cisplatin|"In Arm A, S-1 25 mg/m2 was taken orally two times daily for 21 days followed by a 7-day recovery period. The patient was instructed to have nothing by mouth (NPO 1 hour prior to and 1 hour after S-1 administration. S-1 was taken with approximately 8 ounces of water and prior to cisplatin infusion on Day 1.
Cisplatin 75 mg/m2 was administered as a 1- to 3-hour IV infusion after the morning dose of S-1 on Day 1 of each cycle. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin."
1776192|NCT00400179|Drug|5-FU/cisplatin|In Arm B, 5-FU 1000 mg/m2/24 hours was administered CIV on Days 1 through 5 following cisplatin 100 mg/m2 administered IV as a 1- to 3-hour infusion on Day 1. This regimen was repeated every 4 weeks with a maximum of 6 cycles of treatment for cisplatin.
1776193|NCT00400205|Drug|Taxotere|Docetaxel 75 mg/m2, intravenous infusion over 1 hour, mixed with normal saline per institutional standard, day 1 and then every 3 weeks.
1776194|NCT00400205|Drug|Cisplatin|Cisplatin 100 mg/m2, intravenous infusion over 30 minutes to 3 hours, day 1 and then every 3 weeks.
1776195|NCT00400205|Drug|5-fluorouracil|5-fluorouracil 1000 mg/m2/day, 24 hour continuous infusion over 4 days, every 3 weeks.
1776196|NCT00400218|Drug|MK0954A, hydrochlorothiazide (+) losartan potassium / Duration of Treatment: 12 Weeks|
1776197|NCT00400231|Drug|Study drugs: Metformin and fenofibrate|145mg fenofibrate once/day and 2000mg/day of metformin for arm 3.
1776198|NCT00400231|Drug|Study Drug: Metformin|2000mg/day
1776199|NCT00400231|Drug|Study Drug: fenofibrate|145mg/day of fenofibrate
1776200|NCT00400231|Drug|Metformin and Fenofibrate placebo|placebo metformin and fenofibrate
1776201|NCT00400244|Procedure|Wheelchair skills traing program|
1776202|NCT00400257|Behavioral|Early detection of heart failure|Early detection of heart failure
1776203|NCT00400270|Procedure|Breathing and relaxation exercises: the Papworth Method|
1776204|NCT00400283|Drug|NNC 55-0414|
1776205|NCT00400296|Drug|RG547|Administered iv on days 1 and 8 of a 3 week cycle at escalating doses to successive groups of patients until MTD is reached.
1776206|NCT00400309|Biological|REPEVAX® after REVAXIS®|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after tetanus, diphtheria, poliomyelitis (inactivated)
1776207|NCT00400309|Biological|REPEVAX® after Placebo|Tetanus, diphtheria, tetanus, pertussis (acellular, component) and poliomyelitis (inactivated) vaccine after placebo
1776208|NCT00400322|Drug|Valganciclovir (Valcyte)|
1776209|NCT00400335|Drug|Nanomilled testosterone|
1776210|NCT00400335|Drug|commercially available dutasteride|
1776211|NCT00400335|Drug|Nanomilled dutasteride|
1776212|NCT00400348|Drug|Panzem Nanocrystal Colloidal Dispersion (NCD)|Panzem NCD 1,000 mg, four times daily for 28 consecutive days
1776213|NCT00400361|Drug|RG1507|Administered iv, either weekly or 3 weekly, at escalating doses (with a starting dose of 1mg/kg) (7 cohorts).
1776214|NCT00400374|Drug|Erlotinib|Patients will be given Erlotinib (dose escalation from 50 mg, 75 mg, and 100 mg) once daily continuously for 6 months.
1776215|NCT00400374|Drug|Celecoxib|Celecoxib, 400 mg, daily for 6 months.
1776216|NCT00400387|Drug|Fragmin P Forte (dalteparin sodium)|subcutaneous injection, once daily supported by multivitamine supplement and close monitoring
1776217|NCT00400387|Dietary Supplement|Multivitamin supplement|general pregnancy support by multivitamin supplementation and close monitoring
1776218|NCT00400400|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|Enteric-coated mycophenolate sodium supplied as 180 mg tablets.
1776219|NCT00400400|Drug|Mycophenolate mofetil|Mycophenolate mofetil supplied as 250 mg capsules.
1776220|NCT00400400|Drug|Placebo to mycophenolate sodium|Placebo to mycophenolate sodium matching tablets.
1776221|NCT00400400|Drug|Placebo to mycophenolate mofetil|Placebo to mycophenolate mofetil matching capsules.
1776222|NCT00400413|Procedure|fMRI|
1776223|NCT00400426|Procedure|Radiotherapy|20 Gy in 4 fx
1776224|NCT00400439|Drug|dalcetrapib (RO4607381)|900mg po daily for 24 weeks
1776225|NCT00400439|Drug|placebo|po daily for 24 weeks
1776228|NCT00406107|Drug|pegaptanib sodium (Macugen)|Subjects were randomized 3:1 to intravitreous injections of pegaptanib 0.3mg or 1mg at baseline and at weeks 6 and 12 with subsequent injections at 6-week intervals at investigator discretion until week 48.
1776229|NCT00406120|Procedure|Fine needle aspiration biopsy|
1776230|NCT00406133|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor
1776231|NCT00406146|Drug|amodiaquine+artesunate/artemether-lumefantrine|
1776232|NCT00406159|Device|Hyperbaric Oxygen Therapy|
1776233|NCT00406172|Drug|Bevacizumab|
1776234|NCT00406198|Procedure|venovenous hemofiltration|
1776235|NCT00406211|Biological|MMRV|
1776236|NCT00406211|Biological|MMR (Priorix®)|
1776237|NCT00406211|Biological|Varicella (Varilrix®)|
1776238|NCT00406224|Drug|breathing 100% oxygen|
1776239|NCT00406237|Drug|tigecycline|Single intravenous dose of tigecycline 50 mg, as a 30-minute infusion
1776240|NCT00406250|Drug|intravitreal injection|1.25 mg in 0.05 cc of bevacizumab
1776241|NCT00406250|Drug|intravitreal injection|1.25 mg of bevacizumab intravitreally injected in a steril field
1776242|NCT00406263|Procedure|Scheimpflug crystalline lens photographs|scheimpflug photographs
1776243|NCT00406276|Drug|RAD001|RAD001 will be given at a dose of 5mg/day in combination with docetaxel
1776244|NCT00406276|Drug|Docetaxel|In combination with RAD001
1776245|NCT00406289|Procedure|18F-FDG-PET radiotherapy|
1776246|NCT00406302|Drug|Docetaxel|75mg/m², day 1,22
1776247|NCT00406302|Drug|oxaliplatin|40mg/m², d1,2,22,23
1776248|NCT00406302|Drug|cetuximab|400mg/m² (day1), 250mg/m² (day 8,15,22,29,36)
1776249|NCT00406302|Procedure|surgery|28 days after end of induction chemotherapy
1776250|NCT00406315|Drug|ziprasidone|Days 1-3: 40 mg twice a day (BID); Days 4-7: 60 mg BID; Day 8: 80 mg BID; Flexible dose between 40-80 mg BID (adjustable up to 40 mg daily/week) for the remainder of the 16-week treatment phase and continuing throughout the 16-week follow-up phase
1776251|NCT00406341|Drug|Difluprednate Ophthalmic Emulsion|
1776252|NCT00406354|Drug|Atomoxetine|Dosage form for the atomoxetine fast and slow titration arms consists of 2.5 mg, 10 mg, 20 mg, 25 mg, and 40 mg capsules. Double-blind treatment will consist of 3 capsules taken once per day for approximately 9 weeks.
1776253|NCT00406354|Drug|Placebo|Double-blind treatment will consist of 3 matching placebo capsules taken once per day by mouth for approximately 9 weeks.
1776254|NCT00406367|Drug|incobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection, up to 50 Units per eye; Mode of administration: intramuscular injection"
1776255|NCT00406367|Drug|Placebo|Placebo to incobotulinumtoxinA (Xeomin) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium chloride (NaCl), placebo volume corresponding to up to 50 Units per eye; Mode of administration: intramuscular injection
1776256|NCT00406380|Drug|Bevacizumab|
1776257|NCT00406380|Procedure|Intravitreal injection of Bevacizumab|
1776258|NCT00406393|Drug|Tacrolimus|"Adults and Children: Tacrolimus will be given at a dose of 0.02 mg/kg every 24 hours as a continuous intravenous infusion beginning on Day -3. An effort will be made to convert the tacrolimus to oral dosing at 2-3 times the total 24-hour intravenous dose, split into 2 doses given every 12 hours as soon as clinically feasible.
The target serum level for tacrolimus is 5-10 ng/mL."
1776259|NCT00406393|Drug|Methotrexate|Methotrexate will be given at a dose of 15 mg/m2 on Day 1 after transplantation, and at a dose of 10 mg/m2 on Days 3, 6 and 11 after transplantation.
1776260|NCT00406393|Drug|Sirolimus|"Adults: Sirolimus will be given in a loading dose of 12 mg on Day -3 followed by a daily oral dose of 4 mg per day. Doses may be repeated if the subject vomits within 15 minutes of an oral dose.
Children: Children aged < 12.0 years OR weighing < 40.0 kg will be given an oral loading dose of sirolimus of 3 mg/m2 followed by a daily oral dose of 1 mg/m2, rounded to the nearest full milligram.
The target serum level for sirolimus is 3-12 ng/mL."
1776261|NCT00406406|Drug|SKI-606|
1776262|NCT00406419|Drug|methotrexate|Oral repeating dose
1776263|NCT00406419|Drug|ocrelizumab|Intravenous repeating dose (200mg)
1776264|NCT00406419|Drug|ocrelizumab|Intravenous repeating dose (500mg)
1776265|NCT00406419|Drug|placebo|Intravenous repeating dose
1776267|NCT00407771|Drug|Tirofiban|
1776268|NCT00407784|Drug|eplerenone|
1776269|NCT00407797|Drug|Pregabalin|150 to 600 mg/day during 21 weeks
1776270|NCT00407823|Procedure|Central venous oxygen saturation continuous monitoring|
1776271|NCT00407836|Biological|T cell vaccination|Approximately 10-20 million glutaraldehyde fixed CD4 responsive autologous T cells in 1-2 ml, per vaccine injection.
1776272|NCT00407836|Biological|T cell vaccination|Approximately 10-20 million autologous CD4 reactive T cells per each vaccine injection
1776273|NCT00407849|Drug|triamcinolone acetonide|Intravitreal injection
1776274|NCT00407862|Drug|Telmisartan 80 mg|
1776275|NCT00407862|Drug|Losartan 50 mg|
1776276|NCT00407875|Procedure|Intensity Modulated External Beam Radiation Therapy|
1776277|NCT00407888|Drug|doxorubicin hydrochloride|Given IV
1776278|NCT00407888|Drug|cyclophosphamide|Given orally
1776279|NCT00407888|Biological|filgrastim|Given SC
1776280|NCT00407888|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1776281|NCT00407888|Biological|trastuzumab|Given IV
1776282|NCT00407888|Other|laboratory biomarker analysis|Correlative studies
1776283|NCT00407888|Procedure|quality-of-life assessment|Ancillary studies
1776284|NCT00407914|Device|Aquamid|Subcutaneous injection
1776285|NCT00407914|Device|Restylane|Injection in dermis
1776286|NCT00407927|Drug|Epinastine Nasal Spray|
1776287|NCT00407940|Device|Lower extremity Atherectomy and Cryoplasty|
1776288|NCT00407966|Drug|alvocidib|Given IV
1776289|NCT00407966|Drug|cytarabine|Given IV
1776290|NCT00407966|Drug|mitoxantrone hydrochloride|Given IV
1776291|NCT00407992|Device|Occipital nerve stimulation ON|Implant of an occipital nerve stimulator switched ON
1776292|NCT00407992|Device|Occipital nerve stimulation off|Implant of an occipital nerve stimulator switched OFF
1776309|NCT00408018|Drug|P276-00|Potent Cyclin dependent kinase (cdk) cdk4 D1, cdk1 B and cdk9 T inhibitor
1776310|NCT00408031|Drug|D-cycloserine|D-cycloserine (DCS , Seromycin) is a broad spectrum antibiotic, in use for over thirty years against tuberculosis, that acts as a partial agonist at the NMDAR-associated GLY site.
1776311|NCT00408044|Procedure|cardiac surgery with sternotomy|
1776312|NCT00408057|Other|no intervention|no intervenion
1776313|NCT00408070|Drug|Bevacizumab|cycle 2 (6 cycles re-evaluated and follow up)
1776314|NCT00408070|Drug|Carboplatin|cycle #1 and continuous through entire regimen; treated every 3 weeks
1776315|NCT00408070|Drug|Paclitaxel|cycle #1 and continuous through entire regimen; treated every 3 weeks
1776316|NCT00408083|Drug|MultiHance|0.5 mmol/kg as a single dose administration
1776317|NCT00408083|Drug|Magnevist|0.5 mmol/kg as a single dose administration
1776318|NCT00408096|Procedure|Copeland or Global CAP resurfacing prosthesis|Both Copeland and Global Cap are uncemented prostheses with titanium-sprayed, hydroxyapatite (HA)-coated bone-contact surfaces.
1776319|NCT00408109|Drug|VRC-AVIDNA036-00-VP|
1776320|NCT00408122|Procedure|PET/CT scan and EUS|
1776321|NCT00408135|Drug|telithromycin (HMR3647)|
1776322|NCT00408148|Drug|Placebo|Undistinguishable placebo tablets
1776323|NCT00408148|Drug|Rimonabant|White film-coated, for oral administration containing 20 mg of active rimonabant
1776324|NCT00408161|Behavioral|Contingency Management|prize contingency management (CM) -- 6-month treatment plus standard case management treatment and follow-ups at 9, 12, and 18 months after intake
1776325|NCT00408161|Behavioral|standard case management treatment|6-month treatment standard case management treatment, and follow-ups scheduled at 9, 12, and 18 months after intake.
1776326|NCT00408174|Drug|Balsalazide disodium|
1776327|NCT00408187|Drug|voclosporin|voclosporin 0.4 mg/kg po BID
1776328|NCT00408187|Drug|Ciclosporin|ciclosporin 1.5 mg/kg po BID
1776329|NCT00408187|Drug|Placebo|Placebo
1776330|NCT00408200|Drug|propafenone; flecainide; sotalol; dofetilide|Above drugs prescribed per established guidelines for treatment of AF
1776331|NCT00408200|Device|Radiofrequency catheter ablation|A special catheter that delivers radiofrequency (heat) energy is advanced into the heart and used to destroy small areas of heart tissue responsible for causing atrial fibrillation. All catheters / devices used in the study are FDA approved for human use and currently being used to perform the AF ablation procedure in the United Sates.
1776332|NCT00408213|Drug|mycophenolate mofetil [CellCept]|1g po bid
1776333|NCT00408213|Drug|Placebo|po bid
1776334|NCT00408226|Drug|MKC-1|capsules, twice daily for 14 days in 21 day cycle
1776335|NCT00408226|Drug|pemetrexed|standard dosing of 500 mg/m2 infused every 21 days
1776336|NCT00408239|Drug|YM150|Oral
1776337|NCT00408239|Drug|enoxaparin|Sub cutaneous
1776338|NCT00408252|Other|biopsies|No intervention, only biopsy for translational project
1776339|NCT00408252|Drug|SU011248|no intervention
1776340|NCT00408265|Behavioral|Contingency Management|
1776341|NCT00408278|Drug|ATRA|45 mg/m2 day until CR Consolidation: 3 cycles (45 mg/m2 days 1-15) Maintenance:15 days every 3 months
1776342|NCT00408278|Drug|Idarubicina|Induction: 12 mg/m2 days 2, 4, 6 and 8 Consolidation: 5 mg/m2 days 1-4 in cycle 1 and 12 mg/m2 day 1 in cycle 3.
1776343|NCT00408278|Drug|Mitoxantrone|Consolidation: Mitoxantrone 10 mg/m2 days 1-3 in cycle 2
1776344|NCT00408278|Drug|ARA-C|In high risk patients, consolidation with ara-C in cycles 1 and 3.
1776345|NCT00408291|Procedure|Winsta PH osteosynthesis device|The Winsta PH osteosynthesis device have been developed for use in treatment of proximal humerus fractures.
1776346|NCT00408304|Drug|omega-3 fatty acid|
1776347|NCT00408317|Drug|Ultrase® MT20|Ultrase® MT 20 capsules containing enteric-coated minitablets orally daily at a dose stabilized during the first stabilization period (4 days), as per investigator's discretion, for 6 to 7 days in either first intervention period or second intervention period.
1776348|NCT00408317|Drug|Placebo|Placebo matched to Ultrase® MT 20 capsules orally daily for 6 to 7 days in either first intervention period or second intervention period.
1776349|NCT00408330|Drug|Azelaic Acid 15% Gel|15% gel, topically applied daily for six weeks
1776350|NCT00408330|Drug|Inactive 15% gel base|placebo, topically applied daily for six weeks
1776352|NCT00408369|Drug|DB289|
1776353|NCT00408382|Drug|atorvastatin, Lipitor|
1776354|NCT00408395|Biological|Influenza vaccine|Seasonal Influenza Vaccine
1776355|NCT00408408|Biological|bevacizumab|15 mg/kg IV
1776356|NCT00408408|Drug|capecitabine|825 mg/m2 orally
1776357|NCT00408408|Drug|cyclophosphamide|600 mg/m2 IV
1776358|NCT00408408|Drug|docetaxel|100 mg/m2 IV
1776359|NCT00408408|Drug|doxorubicin hydrochloride (Adriamycin)|60 mg/m2 IV
1776360|NCT00408408|Drug|gemcitabine hydrochloride|1000 mg/m2 IV
1776361|NCT00408421|Drug|Duloxetine|
1776362|NCT00408421|Drug|placebo|
1776363|NCT00408434|Drug|CS-7017|CS-7017 0.05mg and 1.0mg tablets
1776364|NCT00408447|Drug|Busulfan|Busulfan 4 mg/kg/d x 4d
1776365|NCT00408447|Drug|Fludarabine|Fludarabine 30 mg/m2/d x 6d
1776366|NCT00408447|Drug|Alemtuzumab|Alemtuzumab 2mg/m2 x 1d, 6mg/m2 x 2 d, 20mg/m2 x 2d
1776367|NCT00408447|Procedure|Allogeneic stem cell transplant|Allogeneic stem cells will be given on day 0 (after chemotherapy conditioning)obtained either from a family donor (first degree relative) or sibling cord blood donor.
1776368|NCT00408460|Drug|imatinib mesylate|Given PO
1776369|NCT00408460|Drug|paclitaxel|Given IV
1776370|NCT00408473|Drug|Flecainide|
1776442|NCT00408967|Drug|Tucotuzumab celmoleukin (EMD 273066)|
1776443|NCT00408980|Behavioral|Fat and calorie controlled diet|
1776371|NCT00408499|Drug|cetuximab|Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
1776372|NCT00408499|Drug|erlotinib|Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
1776373|NCT00408512|Drug|thiazides|Up to 25 mg per day
1776374|NCT00408512|Procedure|Non thiazidic treatment|Amximum tolerated dosage as indicated from the label
1776375|NCT00408525|Drug|donepezil|donepezil 5 mg tablets, total dose per day 10 mg for 6 week duration of study. Taken once per day.
1776376|NCT00408538|Drug|UC-781 microbicide gel (0.1% and 0.25%)|
1776377|NCT00408538|Drug|placebo|
1776378|NCT00408551|Drug|floxuridine|Given IV
1776379|NCT00408551|Drug|fluorouracil|Given IV
1776380|NCT00408551|Drug|irinotecan hydrochloride|Given IV
1776381|NCT00408551|Drug|leucovorin calcium|Given IV
1776382|NCT00408551|Drug|oxaliplatin|Given IV
1776383|NCT00408564|Biological|cetuximab|
1776384|NCT00408564|Drug|capecitabine|
1776385|NCT00408564|Drug|oxaliplatin|
1776386|NCT00408564|Procedure|conventional surgery|
1776387|NCT00408564|Procedure|neoadjuvant therapy|
1776388|NCT00408564|Radiation|radiation therapy|
1776389|NCT00408564|Drug|Gemcitabine|
1776390|NCT00408577|Drug|L-arginine|
1776391|NCT00408590|Biological|carcinoembryonic antigen-expressing measles virus|
1776392|NCT00408590|Biological|oncolytic measles virus encoding thyroidal sodium iodide symporter|
1776393|NCT00408590|Genetic|reverse transcriptase-polymerase chain reaction|
1776394|NCT00408590|Other|laboratory biomarker analysis|
1776395|NCT00408603|Drug|Voreloxin Injection|All patients in initial dose level receive voreloxin injection at 48 mg/m2 administered once every 21 days up to 6 cycles. Subsequent levels are of 60 mg/m2 or 75 mg/m2 every 28 days up to 6 cycles if safety acceptable.
1776396|NCT00408616|Biological|Grazax-R|Grass tablet, 75.000 SQ per day for one year
1776397|NCT00408616|Biological|Grazax Placebo|Grazax Placebo, 0 SQ tablet per day for one year
1776398|NCT00408629|Biological|adalimumab|Prefilled syringe, 40 mg, 160 mg at Week 0, 80 mg at Week 2, and 40 mg every other week between Weeks 4 and 50.
1776399|NCT00408629|Biological|placebo|Matching Placebo for prefilled syringe, 40 mg,
1776400|NCT00408642|Behavioral|Enhanced adherence support|The enhanced adherence support intervention consists of 5 one-on-one, Information-Motivation-Behavioral Skills (IMB) theory-based counseling sessions, as well as a problem-solving card which summarizes key messages and strategies. The counseling sessions are given at key points post-initiation of therapy: at baseline, 2 weeks, 2 months, 3 months, and 6 months. Three brief weekly ART planning sessions are conducted post-initiation of therapy.
1776401|NCT00408642|Behavioral|Standard adherence support|The control arm receives the standard of care adherence support which consists of three group counseling adherence sessions conducted prior to initiation of therapy.
1776402|NCT00408655|Drug|paclitaxel|Given IV
1776403|NCT00408655|Drug|carboplatin|Given IV
1776404|NCT00408655|Drug|temsirolimus|Given IV
1776405|NCT00408668|Biological|PEV3A|
1776406|NCT00408668|Biological|FP9 ME-TRAP|
1776407|NCT00408668|Biological|MVA ME-TRAP|
1776408|NCT00408681|Drug|lithium carbonate|Given orally
1776409|NCT00408681|Other|laboratory biomarker analysis|Correlative studies
1776410|NCT00408694|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
1776411|NCT00408694|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1776412|NCT00408694|Biological|bevacizumab|Given IV
1776413|NCT00408694|Drug|cisplatin|Given IV
1776414|NCT00408694|Drug|fluorouracil|Given IV
1776415|NCT00408707|Procedure|local infiltration analgesia|
1776416|NCT00408733|Other|Medication Education Tool|Picture and Icon-based Customizable Educational Tool
1776417|NCT00408746|Behavioral|palatal development|Impressions of preterm and term palates.
1776418|NCT00408759|Behavioral|hypnosis|
1776419|NCT00408772|Biological|bevacizumab|
1776420|NCT00408772|Drug|capecitabine|
1776421|NCT00408772|Drug|oxaliplatin|
1776422|NCT00408772|Procedure|conventional surgery|
1776423|NCT00408772|Procedure|neoadjuvant therapy|
1776424|NCT00408772|Procedure|radiofrequency ablation|
1776427|NCT00408798|Drug|Intracutaneous injections of Botulinum Toxin A (Botox), 0.1 cc per injection site, which equals 10 units|See Detailed Description.
1776428|NCT00408850|Drug|Pioglitazone|15 mg per day for 6 weeks and 30 mg per day for further 6 weeks
1776429|NCT00408850|Drug|sugar pill|One capsule daily for 6 weeks followed by two capsules per day for next 6 weeks
1776430|NCT00408863|Drug|tibolone|tibolone 2.5 mg/day
1776431|NCT00408863|Drug|placebo|
1776432|NCT00408876|Drug|Duloxetine|
1776433|NCT00408876|Drug|Placebo|
1776434|NCT00408902|Drug|tandutinib|Given orally, 500 mg bid daily
1776435|NCT00408902|Other|laboratory biomarker analysis|Correlative studies
1776436|NCT00408915|Drug|Continuous Subcutaneous Lisuride Infusion|
1776437|NCT00408928|Drug|Bortezomib|Bortezomib at 1.3 mg/m2/dose given twice weekly for two weeks followed by a 10-day rest period. If patients have a complete response, they will receive additional cycles of bortezomib.
1776438|NCT00408941|Drug|Propofol|
1776439|NCT00408941|Drug|Prilocaine|
1776440|NCT00408954|Drug|UK-369,003|100 mg MR tablet once daily for 2 weeks
1776441|NCT00408954|Drug|UK-369,003|UK-369,003-100 mg MR formulation for 2 weeks
1776629|NCT00403455|Drug|Paroxetine|SSRI
1776444|NCT00408993|Drug|Duloxetine Hydrochloride|60 mg every day (QD) (morning or evening), by mouth (PO)
1776445|NCT00408993|Drug|Placebo|Placebo every day (QD), by mouth (PO)
1776446|NCT00409006|Drug|Pemetrexed|500 milligrams per meter squared (mg/m2), administered by intravenous (IV) infusion every 21 days for 4 cycles (1-4) or 500 mg/m2, IV, every 21 days until disease progression or unacceptable toxicity.
1776447|NCT00409006|Drug|Cisplatin|75 mg/m2, IV, every 21 days for 4 cycles (1-4) or 75 mg/m2, IV, every 21 days for 4 cycles with optional continuation for 2 additional cycles until disease progression or unacceptable toxicity
1776448|NCT00409006|Drug|Gefitinib|250 mg, administered orally once daily beginning at Cycle 5 until disease progression or unacceptable toxicity
1776449|NCT00409019|Drug|Telbivudine|Study cancelled: Withdrawn before enrollment of any participants
1776450|NCT00409019|Drug|Adefovir|
1776451|NCT00409019|Drug|Tenofovir|
1776452|NCT00409032|Drug|Strontium malonate|
1776453|NCT00409058|Behavioral|Teen Online Problem Solving|We will test the following hypotheses: 1) Children with TBI receiving TOPS will have fewer behavior problems, greater social competence, and better functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 2) Caregivers of children receiving TOPS will report less depression and psychological distress, less parent-child conflict, and better family functioning than those receiving IRC at both post-treatment and at a 6-month follow-up assessment. 3) Social resources will moderate treatment efficacy, such that children with limited social and economic resources will show greater improvements in the more comprehensive TOPS intervention. We hypothesize better teen problem solving and communication skills, fewer teen emotional/behavioral problems, less parental burden and distress, and less parent-teen conflict at follow-up among the TOPS group compared to the IRC group.
1776454|NCT00409071|Drug|Cocculine®|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
1776455|NCT00409071|Drug|placebo|12 tablets in 3 days at each of the CT courses: 2 on the day before evening of the CT courses; 2 on the morning, noon and evening of the CT courses; 2 on morning and noon of the day after the CT courses.
1776456|NCT00409084|Procedure|endoscopic variceal band ligation|endoscopic variceal band ligation
1776457|NCT00409097|Drug|Rosiglitazone|
1776458|NCT00409136|Behavioral|Human Alert|An alert from study staff informing a physician that his/her patient is at high risk for DVT and/or PE, but is not receiving any prophylaxis.
1776459|NCT00409149|Behavioral|CALM Approache|
1776460|NCT00409149|Behavioral|DASH approach|standard dietary DASH approach in hypertensive patients
1776461|NCT00409162|Device|Eraser TM device, with washing fluid|
1776462|NCT00409175|Drug|Fx-1006A|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
1776463|NCT00409175|Drug|Placebo|Fx-1006A 20mg or matched placebo once daily (at the same time each day) for a period of 18 Months
1776464|NCT00409188|Biological|Tecemotide (L-BLP25)|After receiving cyclophosphamide, participants will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 0, 1, 2, 3, 4, 5, 6, and 7 followed by maintenance vaccinations with 806 mcg of tecemotide (L-BLP25) at 6-week intervals, commencing at Week 13, until disease progression is documented.
1776465|NCT00409188|Drug|Single low dose cyclophosphamide|A single intravenous infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before first tecemotide (L-BLP25) vaccination.
1776466|NCT00409188|Drug|Placebo|A single infusion (IV) of 0.9% Saline solution instead of cyclophosphamide but in the same calculated dose will be given three days before first placebo vaccination. Subjects will then receive eight consecutive weekly subcutaneous vaccinations with placebo at weeks 0; 1; 2; 3; 4; 5; 6 and 7 followed by maintenance placebo vaccinations at 6-week intervals, commencing at week 13, until disease progression is documented.
1776467|NCT00409201|Drug|reboxetine adjuvant therapy|
1776468|NCT00409214|Drug|LS11 (talaporfin sodium)|
1776469|NCT00409214|Device|Light source (interstitial light emitting diodes)|
1776470|NCT00409214|Procedure|Intraoperative placement of device in glioma|
1776471|NCT00409227|Drug|Alpha blocker-alfuzosin|P.O. alfuzosin 10 mg once a day
1776472|NCT00409227|Drug|placebo|placebo once a day for 3 months or stone free
1776473|NCT00409240|Other|MEDIC|Multidisciplinary Education and Diabetes Intervention for Cardiac risk reduction (MEDIC; a pharmacist-led behavioral and pharmacologic intervention in groups.
1776474|NCT00409253|Drug|URAPIDIL (EUPRESSYL*)|Urapidil (Eupressyl*) :IV (PSE) 1 microg/kg/min° until reduction PAM 15 %. Reduction ¼ of the posology to obtain PAM between 105 and 125 mmHg with adjustment 0.25 microg/kg/min/15 min. Maximal dose = 30mg/h.
1776475|NCT00409253|Drug|NICARDIPINE|Nicardipine : IV 6.25 mg bolus until PAD >105 mm/Hg. Perfusion (PSE) 4 mg/h to obtain PAM between 105 and 125 mm/Hg with adjustment 2mg/h/5 min without overshoot 20 mg/h Maximal treatment duration : 7 days
1776476|NCT00409266|Device|Computer assisted navigation|
1776477|NCT00409279|Behavioral|Information, counseling and support|individual-family consultation, support group, and ad hoc consultation
1776478|NCT00409292|Drug|RAD001|Taken orally daily for as long as the participant continues to receive a benefit.
1776479|NCT00409305|Drug|Betahistine|
1776480|NCT00409305|Behavioral|Dietary counseling|
1776481|NCT00409318|Drug|Etanercept|50 mg SC q week
1776482|NCT00409318|Drug|Placebo|SC q week
1776483|NCT00409331|Drug|Amifostine|500 mg in two divided doses subcutaneously given 30-60 minutes prior to IMRT.
1776484|NCT00409331|Procedure|Intensity- Modulated Radiation Therapy|2.0 to 2.2 Gy delivered in 30 fractions
1776485|NCT00409344|Drug|Dexmedetomidine|A continuous infusion of dexmedetomidine will be started at a dose of 0.8mcg/kg/hr. This will continue for no longer than 24 hours. Four hours post extubation the study drug wii be discontinued using a standard tapering protocol: 0.6mcg/kg/hr for 4 hours then 0.4mcg/kg/hr for 4 hours, then 0.2 mcg/kg/hr for 4 hours and then 0.1mcg/kg/hr for 4 hours and then turned off.
1776486|NCT00409344|Other|Normal Saline|Normal Saline will be given as the placebo and will administered at 0.8mcg/kg/hr
1776487|NCT00409357|Drug|SL77.0499-10 (alfuzosin hydrochloride)|
1776488|NCT00409370|Device|SOMA safe enclosure|
1776489|NCT00409383|Drug|Genasense® (oblimersen)|Cohorts 1 and 2: Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 7 days (Week 1) and beginning again on Day 22 and continuing for 7 days (Week 4); Cohort 3: Genasense 900 mg as a 1-hour intravenous infusion on Day 1, 4, 8, and 11 (Weeks 1 and 2) and Day 22, 25, 29, and 32 (Weeks 4 and 5).
1776490|NCT00409383|Drug|Abraxane® (paclitaxel protein-bound particles for injectable suspension)|Cohorts 1 and 2: Abraxane 175 mg/m2 or 260 mg/m2 as a 30-minute intravenous infusion on Day 8 and Day 29 following end of Genasense continuous infusion; Cohort 3: Abraxane 175 mg/m2 as a 30-minute intravenous infusion on Day 4 and Day 25 following end of Genasense 1-hour infusion
1776491|NCT00409383|Drug|Temodar® (temozolomide)|Cohorts 1-3: Temodar 75 mg/m2/day orally on Days 1 through 42 (Week 1 through Week 6)
1776492|NCT00409396|Procedure|Urinary PGEm level|Level of PGEm in urine compared to CRP and fecal calprotectin levels in patients with ulcerative colitis.
1776493|NCT00409396|Procedure|fecal calprotectin|Level of fecal calprotectin in comparison to urinary PGEm and serum CRP levels.
1776494|NCT00409409|Drug|300 IR grass pollen allergen extract tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
1776495|NCT00409409|Drug|Placebo tablet|One sublingual tablet daily during 4 months before pollen season and during pollen season
1776496|NCT00409422|Behavioral|weight management program|
1776497|NCT00409435|Drug|pyridostigmine|one 180 mg capsule per day for 3 days
1776498|NCT00409435|Drug|Placebo|one capsule per day for 3 days
1776499|NCT00409448|Behavioral|Counselor-assisted problem solving (CAPS)|In CAPS, a trained counselor will guide families through a 6-month structured online problem-solving and skill-building program via one-on-one videoconference sessions.
1776500|NCT00409448|Behavioral|Internet-resource comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources, but not the CAPS website content.
1776501|NCT00409461|Drug|ATG-Sirolimus-Tacrolimus|
1776502|NCT00409487|Device|Continuous positive airway pressure (CPAP)|8 weeks of CPAP
1776503|NCT00409487|Drug|Valsartant treatment|8 weeks of Valsartant treatment (160 mg / day)
1776504|NCT00409500|Drug|AQW051|
1776505|NCT00409526|Drug|Inhaled Iloprost|50 micrograms for one hour followed by 100 micrograms for one hour
1776509|NCT00409552|Behavioral|Virtual Reality based distraction|Participants will undergo virtual reality based distraction using the head display while they go through the pain process.
1776510|NCT00409552|Behavioral|VR with flat projection display|VR with flat projection display
1776511|NCT00409552|Behavioral|non-interactive video with head display|non-interactive video with head display
1776512|NCT00409552|Behavioral|non-interactive video with with flat projection display|non-interactive video with with flat projection display
1776515|NCT00409578|Drug|Placebo|Placebo tablets and capsules. In order to adequately blind the study, patients were required to take a total of 1 tablet and 2 capsules during the first 4 weeks of the study. During the remainder of the study, patients were required to take 2 tablets and 2 capsules. Each dose was taken by mouth with water at approximately 8:00 AM with or without food.
1776516|NCT00409578|Drug|Aliskiren 300 mg|Following 1 week of treatment with 75 mg of aliskiren (tablets), patients in this arm were titrated up to 150 mg of aliskiren; 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
1776517|NCT00409578|Drug|Valsartan 320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
1776518|NCT00409578|Drug|Aliskiren/valsartan 300/320 mg|Following 1 week of treatment with 80 mg of valsartan (capsules), patients in this arm were titrated up to 160 mg of valsartan; 1 week later they were titrated up to 320 mg valsartan for the remainder of the study. Beginning with Week 4, in addition to 320 mg valsartan, patients were treated with 75 mg of aliskiren (tablets); 1 week later patients were titrated up to 150 mg of aliskiren and 1 week later they were titrated up to 300 mg aliskiren for the remainder of the study. If a patient was not up-titrated or required down-titration, the patient continued on that dose for the remainder of the study. If 2 down-titrations were required, they stopped study drug. In order to adequately blind the study, patients were required to take 1 tablet and 2 capsules during the first 4 weeks of the study and 2 tablets and 2 capsules for the remainder of the study. Each dose was taken by mouth with water at approximately 8:00 AM.
1776519|NCT00409591|Drug|Maternal and infant nevirapine|"In women, one NVP 200 mg tablet at onset of labor;
In neonates, NVP oral suspension 6 mg in the delivery room immediately"
1776520|NCT00409591|Drug|Maternal placebo and infant nevirapine|"In women, one placebo tablet at onset of labor;
In neonates, NVP oral suspension 6 mg in the delivery room immediately after birth plus a second dose between 48 and 72 hours
Comparison between Arms 1 and 2 is double-blinded."
1776521|NCT00409591|Drug|Maternal lopinavir+ritonavir|- In women, LPV/r 400/100 mg bid from 28 weeks' gestation until delivery
1776522|NCT00409591|Drug|zidovudine|In addition, all women and infants in the 3 arms will receive standard ZDV prophylaxis, as per Thai and WHO guidelines.
1776523|NCT00409604|Device|Temporary RV VVI pacing|temporary pacing at the onset of revascularisation
1776524|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Other Week dosing
1776525|NCT00409617|Biological|adalimumab|Adalimumab 40 mg Every Week dosing if participant experiences a disease flare or is not responding to treatment. A disease flare is defined as an increase of 3 points or more on the HBI compared to the Baseline score and a total HBI score of 7 or higher. Non-response is defined as a decrease by fewer than 3 points in the HBI compared to Baseline.
1776526|NCT00409630|Drug|fluticasone|
1776527|NCT00409643|Drug|valsartan+amlodipine combination|
1776528|NCT00409643|Drug|valsartan|
1776529|NCT00409643|Drug|amlodipine|
1776530|NCT00409656|Drug|Basiliximab|
1776531|NCT00409669|Device|Barraquer tonometer|barraquer tonometer
1776532|NCT00409682|Biological|Adalimumab|All subjects received an open-label adalimumab induction regimen. Subjects weighing greater than or equal to 40 kg at Baseline received 160 mg at Week 0 and 80 mg at Week 2. Subjects weighing less than 40 kg at Baseline received 80 mg at Week 0 and 40mg at Week 2.
1776533|NCT00409682|Biological|Adalimumab|Subjects randomized to the Low-Dose treatment group received either 20 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 10 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blind (DB) ew therapy they could be switched to open-label ew therapy.
1776534|NCT00409682|Biological|Adalimumab|Subjects randomized to the High-Dose treatment group received either 40 mg adalimumab every other week (eow) (if Week 4 body weight [BW] was greater than or equal to 40 kg) or 20 mg adalimumab eow (if Week 4 BW less than 40 kg). Starting at the Week 12 study visit, subjects who experienced a disease flare or were non-responders could be switched from blinded eow dosing to blinded every week (ew) dosing, continuing with the same blinded dose. If a subject continued to experience a flare or met the definition of non-response following an 8-week course of double-blinded (DB) ew therapy they could be switched to open-label ew therapy.
1776535|NCT00409695|Drug|Low Dose Thymoglobulin (ATG)|2.5 mg /kg by vein every other day for 3 doses (total dose = 7.5 mg/ kg).
1776536|NCT00409695|Drug|High Dose Thymoglobulin (ATG)|1.25mg/kg by vein every other day for 3 doses (total dose = 3.75mg/kg)
1776537|NCT00409708|Drug|Extended Release Methylphenidate (Ritalin LA ) plus Behavior Therapy|
1776538|NCT00409708|Behavioral|Behavior Therapy|
1776539|NCT00409721|Drug|Memantine|
1776540|NCT00409747|Drug|Minocycline|
1776541|NCT00409760|Drug|valsartan+amlodipine combination, valsartan, amlodipine|
1776542|NCT00409773|Drug|ezetimibe (+) simvastatin|Ezetimibe (+) simvastatin combination tablet at doses of 10/20 mg or 10/40 mg.
1776543|NCT00409773|Drug|Comparator: atorvastatin calcium|"Atorvastatin will be supplied in 10mg, 20mg and 40mg tablets.
Each patient will receive 1 active treatment dose & 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
1776544|NCT00409773|Drug|Comparator: Placebo (unspecified)|"Atorvastatin Placebo will be supplied in 10mg, 20mg and 40mg tablets.
ezetimibe/simvastatin Placebo will be supplied in 10/20mg and 10/40mg combination tablets.
Each patient will receive 1 active treatment dose & 2 Placebo doses at randomization according to a predetermined partial blinding schedule to reduce the number of pills from 5 to 3 per patient per day for 6 weeks."
1776545|NCT00409786|Behavioral|Virtual Lifestyle Management (VLM)|16 weekly lessons followed by monthly maintenance lessons
1776547|NCT00409825|Drug|17-OHPC|Intra-muscular injection of 250 mg 17-OHPC administered weekly between the second and third trimesters of pregnancy, until time of delivery.
1776548|NCT00409825|Procedure|Blood Draws|10 cc of blood will be drawn prior to the fifth weekly administration of 17-OHPC during second trimester of pregnancy, and then once daily for seven consecutive days post-dose. 10 cc of blood also will be drawn prior to weekly administration of 17-OHPC from sixth weekly dose in the second trimester until the last scheduled dose in the third trimester. Prior to this last scheduled dose, 10 cc of blood will be drawn, as well as once daily for seven consecutive days post-dose.
1776549|NCT00409838|Drug|Abatacept|Intravenous (IV) solution, - weight tiered (500 mg <60 kg); (750 mg 60-100 kg); (1 gram > 100 kg), Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
1776550|NCT00409838|Drug|Methotrexate|Tablets, Oral, ≥ 15 mg, weekly, 6 months
1776551|NCT00409838|Drug|Placebo|IV solution, Intravenous, D5W, Day 1, Day 15, Day 29; every 28 days thereafter, 6 months
1776552|NCT00409838|Drug|Abatacept|Solution, intravenous, 10 mg/kg, every 28 days
1776553|NCT00409838|Drug|Methotrexate|Tablets, oral, 15 mg weekly to be adjusted according to patient condition
1776554|NCT00409851|Drug|valsartan+amlodipine|
1776555|NCT00409864|Procedure|Endoscopic biliary stenting, Percutaneous biliary stenting|percutaneous 10 F stent, endoscopic 10 F stent insertion
1776556|NCT00409890|Drug|Hyoscine Butyl Bromide|
1776557|NCT00409903|Drug|Eprosartan|
1776558|NCT00409916|Device|BioZ Dx|
1776559|NCT00409929|Drug|AEB071|
1776560|NCT00409942|Drug|Torasemide Prolonged Release|Torasemide Prolonged release 10mg/day up to 40mg/day, treatment duration:8 months
1776561|NCT00409942|Drug|Furosemide|Furosemide 40mg/day up to 160mg/day, Treatment duration:8 months
1776562|NCT00409955|Procedure|Lamellar transplant with lyophilized corneas|
1776563|NCT00409968|Procedure|Tumor Biopsy|A sample of tumor tissue will be collected by either a CT-guided core biopsy, bronchoscopy, or other type of biopsy (such as subcutaneous, cutaneous, or lymph node).
1776564|NCT00409981|Device|paclitaxel coated balloon catheter (device with drug)|
1776565|NCT00409994|Drug|Rapamycin|dosis escalation: 2/4/6 mg rapamycin tablets, once daily during 13 days
1776566|NCT00410007|Behavioral|High Sodium Diet|250-350 mmol
1776567|NCT00410007|Behavioral|Low Sodium Diet|25-35 mmol
1776568|NCT00410020|Behavioral|Alpha-linolenic enriched diet|
1776569|NCT00410033|Drug|soluble human insulin|
1776570|NCT00410033|Drug|isophane human insulin|
1776571|NCT00410033|Drug|insulin aspart|
1776572|NCT00410046|Drug|Enbrel (etanercept)|Etanercept 50 mg SC injection once weekly
1776573|NCT00410059|Drug|Erlotinib|150 mg by mouth daily x 28 days
1776574|NCT00410072|Drug|Entecavir|Tablets, Oral, ETV = 0.5 mg, once daily, 100 weeks
1776575|NCT00410072|Drug|Entecavir + Tenofovir|Tablets, Oral, ETV = 0.5 mg + TFV = 300 mg, once daily, 100 weeks
1776576|NCT00410085|Drug|L-NMMA (N-mono.methyl-L-arginine)|
1776577|NCT00410098|Behavioral|Bikram Yoga|
1776578|NCT00410124|Drug|RAD001|The dose of RAD001 was 10 mg/day. Patients were instructed to take two tablets (5 mg each) by mouth every day.
1776579|NCT00410124|Drug|Placebo|
1776580|NCT00410150|Drug|Helium-oxygen-driven albuterol nebulizer|Subjects will be treated with continuous albuterol nebs with Heliox
1776581|NCT00410150|Drug|Oxygen|Subjects will be treated with continuous albuterol nebs in oxygen
1776582|NCT00410163|Drug|Ofatumumab 500mg|Ofatumumab 500mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
1776583|NCT00410163|Drug|Ofatumumab 1000mg|Ofatumumab 1000mg or should be diluted into 1000mL pyrogenefree saline and administered as an IV infusion.Duration of infusion will be approximately 6½ hours.Infusions should be given every 4 weeks until a total of 6 infusions has been given.
1776584|NCT00410163|Drug|Fludarabine|Fludarabine (25 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses
1776585|NCT00410163|Drug|Cyclophosphamide|Cyclophosphamide (250 mg/m2) should be administered as an IV infusion daily, Days 2 through 4 of Course 1, and Days 1 through 3 of Courses 2 through 6, every 4 weeks for 6 courses.
1776586|NCT00410176|Behavioral|sanitation and personal hygiene|
1776587|NCT00410189|Drug|ZD6474|300 mg by mouth daily for 28 Days.
1776588|NCT00410202|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 100 weeks
1776589|NCT00410202|Drug|Tenofovir|Tablets, Oral, 300 mg, once daily
1776590|NCT00410202|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 100 weeks
1776591|NCT00410202|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 100 weeks
1776592|NCT00410215|Drug|picosalax plus bisacodyl|10 mg bisacodyl three and two nights prior to colonoscopy, followed by two sachets picosalax
1776593|NCT00410215|Drug|picosalax|two sachets of picosalax taken orally the day prior to colonoscopy
1776594|NCT00410215|Drug|sodium phosphate|two 45 ml bottles of sodium phosphate the day prior to colonoscopy
1776595|NCT00410228|Drug|AHT956|
1776596|NCT00410254|Drug|HCV-796|
1776597|NCT00410254|Drug|midazolam|
1776598|NCT00410280|Biological|IMA-638 is a biologic|
1776599|NCT00410293|Procedure|NT-proBNP testing|
1776600|NCT00410306|Drug|Testosterone Undecanoate (Nebido, BAY86-5037)|Patients from routine practice
1776601|NCT00410319|Behavioral|Fear-reducing Information|
1776602|NCT00410319|Behavioral|Symptom-based exercise|
1776603|NCT00410332|Drug|Traumeel S|homeopathic remedy
1776604|NCT00410332|Drug|Placebo|placebo drug, identical in size, form and taste as treatment remedy
1776605|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation suspension for nebulization 1000/20 mcg bid for 2 weeks
1776606|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 1000/10 mcg bid for 2 weeks
1776607|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/20 mcg bid for 2 weeks
1776608|NCT00403286|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension for nebulization 500/10 mcg bid for 2 weeks
1776609|NCT00403286|Drug|Fluticasone Propionate|Inhalation Suspension for nebulization 1000 mcg bid for 2 weeks
1776610|NCT00403286|Drug|Formoterol Fumarate|Inhalation Solution for nebulization 20 mcg bid for 2 weeks
1776611|NCT00403286|Drug|Fluticasone Propionate/Salmeterol Xinafoate|Inhalation Powder delivered by Diskus device 250/50 mcg bid for 2 weeks
1776612|NCT00403286|Drug|Placebo|Inhalation Solution for nebulization 2 mL bid for 2 weeks
1776613|NCT00403299|Procedure|MDCT of the coronary arteries.|
1956986|NCT02601625|Drug|Anifrolumab SC injection (300mg)|300 mg of anifrolumab delivered as 2 separate 1 mL SC injections administered serially on Day 1
1956987|NCT02601625|Drug|Anifrolumab IV infusion (300mg)|300 mg of anifrolumab delivered as an IV infusion over 30 minutes on Day 1
1776617|NCT00403325|Drug|rhuFab V2 [ranibizumab] ( Lucentis )|
1776618|NCT00403338|Device|CYPHER® Bx Velocity™ stent (sirolimus-eluting)|
1776619|NCT00403364|Drug|Placebo amoxicillin pantoprazole clarithromycin tinidazole|
1776620|NCT00403377|Behavioral|Intervention|In the intervention arm, photographs are taken of the participants and they then receive sunscreen lotion and sunless tanning lotion and instructions and benefits for using both. Participants also receive an educational pamphlet regarding skin cancer.
1776622|NCT00403403|Drug|Bevacizumab|Bevacizumab 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
1776623|NCT00403403|Drug|Chemotherapy|Chemotherapy = cisplatin (or carboplatin) + etoposide. Cisplatin 75 mg/m² IV on Day 1 of each of the first four 21-day cycles OR carboplatin (area under the curve [AUC]=5 mg/mL/min, per Calvert formula) IV on Day 1 of each of the first four 21-day cycles; etoposide 100 mg/m² on Days 1-3 of each of the first four 21-day cycles.
1776624|NCT00403403|Drug|Placebo|Placebo 15 mg/kg by intravenous (IV) infusion on Day 1 of each of the first four 21-day cycles during chemotherapy, followed by single agent administration until disease progression, unacceptable toxicity, discontinuation from study, or death.
1776625|NCT00403416|Drug|AEB071|
1776626|NCT00403416|Drug|Mycophenolic Acid|
1776627|NCT00403429|Drug|capecitabine|
1776628|NCT00403442|Device|Verteporfin Therapy/ Drug: Bevacizumab|
1776630|NCT00403481|Drug|olmesartan medoxomil|Olmesartan medoxomil tablets, once daily
1776631|NCT00403481|Drug|Olmesartan medoxomil plus Hydrochlorothiazide|Olmesartan medoxomil and hydrochlorothiazide combination tablets, once daily, if necessary
1776632|NCT00403494|Drug|Placebo for 6R-BH4 (sapropterin dihydrochloride)|Placebo to be administered in the same manner as that of the investigational product for 24 weeks
1776633|NCT00403494|Drug|6R-BH4 (sapropterin dihydrochloride)|800 mg/day 6R-BH4 tablets, divided into two doses, administered orally for 24 weeks
1776634|NCT00403494|Drug|6R-BH4 (sapropterin dihydrochloride)|800 mg/day of 6R-BH4 tablets, divided into two doses, administered orally, plus 1000mg/day Vitamin C caplets, divided into two doses, administered orally for 24 weeks
1776635|NCT00403494|Drug|Placebo for 6R-BH4 (sapropterin dihydrochloride)|Placebo to be administered in the same manner as that of the investigational product, plus 1000mg/day Vitamin C, divided into two doses, for 24 weeks
1776636|NCT00403507|Behavioral|Participation in a monitored exercise program|No contact with control group during 20 weeks.
1776637|NCT00403507|Behavioral|Personalized aerobic and strength training.|Three-days per week for 20 weeks at hospital gym under supervision of exercise specialist.
1776638|NCT00403520|Drug|Experimental 1|Drug: Donepezil Hydrochloride 10 mg orally for 12 months
1776639|NCT00403520|Drug|Placebo Comparator|Drug: Placebo Matching placebo orally for 12 months
1776640|NCT00403533|Drug|20 mg of atorvastatin daily|
1776641|NCT00403546|Drug|Ziprasidone 80-160 mg/d|Participants will be instructed to take one study capsule of ziprasidone orally twice daily (80 mg/d). After the first week, the study drug will be increased to two capsules twice daily (160 mg/d).
1776642|NCT00403546|Drug|Placebo|Participants will be instructed to take one study capsule of matching placebo orally twice daily. After the first week, the matching placebo will be increased to two capsules twice daily.
1776643|NCT00403546|Drug|Ziprasidone 160 mg/d|Participants will be taking open-label ziprasidone 80 mg orally twice daily for a total dose of 160 mg/d from at least 3 weeks before randomization to end of study 8 weeks after randomization.
1956988|NCT02601625|Drug|Anifrolumab SC infusion (600mg)|600 mg of anifrolumab delivered as 4 mL SC by infusion pump on Day 1
1776645|NCT00410345|Drug|Mifepristone|
1776646|NCT00410358|Drug|Gimatecan|
1776647|NCT00410371|Drug|Lamotrigine|Lamotrigine
1776648|NCT00410371|Drug|GI267119|25 mg ODT
1776649|NCT00410384|Drug|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
1776650|NCT00410384|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy; belimumab 1 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
1776651|NCT00410384|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy; belimumab 10 mg/kg administered on Days 0, 14, 28, and every 28 days thereafter through 72 weeks.
1776652|NCT00410397|Procedure|Osteopathic Manipulative Medicine|Pelvic balancing, myofascial release of the anterior pelvis.
1776653|NCT00410397|Procedure|Sham Manipulation|Neutral positional, gentle palpation
1776654|NCT00410410|Drug|abatacept (ABA)|"Dextrose 5% in water, IV. Placebo on days IP-1, IP-15,IP-29, IP-57; 3 mg/kg on days IP-1, IP-15,IP-29, IP-57; 10 mg/kg on days IP-1, IP-15,IP-29, IP-57; or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57 (ABA 30/~10 mg/kg Group).
Induction Period 3 months
Maintenance Period 12 months"
1776655|NCT00410410|Drug|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.
Induction Period 3 months
Maintenance Period 12 months"
1776656|NCT00410410|Drug|abatacept|"~10 mg/kg, once monthly
Open- Label Extension Period until the drug is marketed for UC or the UC development program for abatacept is discontinued"
1956989|NCT02601625|Drug|Anifrolumab placebo SC injection (300mg)|300mg of placebo delivered as 2 separate 1 mL SC injections administered serially on Day 1
1776658|NCT00410436|Behavioral|Resistance Exercise|Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
1776659|NCT00410449|Drug|Alpha tocopherol|
1776660|NCT00410462|Drug|brostallicin|
1776661|NCT00410462|Drug|doxorubicin hydrochloride|
1776662|NCT00410488|Drug|Palonosetron - Single Dose|0.25 mg by vein for 1 dose (day 0).
1776663|NCT00410488|Drug|Palonosetron - Triple Dose|0.25 mg by vein for 3 doses (days 0, 2, 4).
1776664|NCT00410488|Drug|Adriamycin|75 mg/m2 as an IV bolus OR 75 mg/m2 as continuous IV infusion over 72 hours (without zinecard) on Day 0.
1776665|NCT00410488|Drug|Ifosfamide chemotherapy (AI)|Ifosfamide: 2.5 g/m2 IV bolus over 3 hours; days 0, 1, 2, 3 (total dose = 10 g/m2). Cycle is 3 weeks, up to 6 cycles.
1776666|NCT00410488|Drug|Zinecard|750 mg/m2 as an IV bolus.
1776667|NCT00410488|Drug|Mesna|500 mg/m2 given simultaneously with ifosfamide day 0; then 1500 mg/m2 over 24 hour for days 0, 1, 2, and 3 (infusion completing on day 4).
1776668|NCT00410488|Drug|Vincristine|"2 mg IV by rapid administration on day 0 (for patients with small cell histology).
For patients with certain types of sarcoma, vincristine will be given through the catheter by rapid infusion on Day 0 only."
1776669|NCT00410488|Drug|Dexamethasone|IV piggyback (IVPB) daily for 5 days (12 mg on day 0, and 8 mg on days 1-4) 30 minutes prior to chemotherapy.
1776670|NCT00410501|Drug|Indacaterol (QAB149)|
1776671|NCT00410514|Drug|Mirabegron|oral
1776672|NCT00410514|Drug|Placebo|oral
1776673|NCT00410527|Drug|Merrem|
1776674|NCT00410540|Drug|OROS hydromorphone HCL ; Morphine sulfate|
1776675|NCT00410553|Drug|Eribulin Mesylate|Given IV
1776676|NCT00410553|Drug|Gemcitabine Hydrochloride|Given IV
1776677|NCT00410566|Drug|rhASM|Single dose of 0.03mg/kg body weight IV
1776678|NCT00410566|Drug|rhASM|Single dose of 0.1mg/kg body weight IV
1776679|NCT00410566|Drug|rhASM|Single dose of 0.3mg/kg body weight IV
1776680|NCT00410566|Drug|rhASM|Single dose of 0.6mg/kg body weight IV
1776681|NCT00410566|Drug|rhASM|Single dose of 1.0mg/kg body weight IV
1776763|NCT00411138|Drug|carboplatin|carboplatin AUC 5, 4 cycles after completion of radiotherapy, 3 wks interval
1776822|NCT00411645|Other|placebo|twice daily for up to 12 weeks
1776682|NCT00410579|Other|Telephone interview|Telephone interview to assess generic health status, quality of life, comorbidity, impact of cancer, use of medical services, health rating, pain, fatigue, activities of daily living, demographics, functional well-being(C-06 only), and neurotoxicity (C-07 only)
1776683|NCT00410592|Drug|Esomeprazole 40mg|
1776684|NCT00410592|Drug|Pantoprazole 40mg|
1776685|NCT00410592|Drug|Lansoprazole 30mg|
1776686|NCT00410605|Biological|bevacizumab|Given IV
1776687|NCT00410605|Drug|lenalidomide|Given orally
1776688|NCT00410605|Drug|dexamethasone|Given orally
1776689|NCT00410618|Procedure|cognitive assessment|
1776690|NCT00410618|Procedure|magnetic resonance imaging|
1776691|NCT00410618|Procedure|management of therapy complications|
1776692|NCT00410631|Biological|filgrastim|
1776693|NCT00410631|Drug|carboplatin|
1776694|NCT00410631|Drug|cisplatin|
1776695|NCT00410631|Drug|cyclophosphamide|
1776696|NCT00410631|Drug|dacarbazine|
1776697|NCT00410631|Drug|doxorubicin hydrochloride|
1776698|NCT00410631|Drug|etoposide phosphate|
1776699|NCT00410631|Drug|ifosfamide|
1776700|NCT00410631|Drug|isotretinoin|
1776701|NCT00410631|Drug|melphalan|
1776702|NCT00410631|Drug|topotecan hydrochloride|
1776703|NCT00410631|Drug|vincristine sulfate|
1776704|NCT00410631|Drug|vindesine|
1776705|NCT00410631|Procedure|autologous hematopoietic stem cell transplantation|
1776706|NCT00410631|Procedure|conventional surgery|
1776707|NCT00410631|Procedure|peripheral blood stem cell transplantation|
1776708|NCT00410631|Radiation|iobenguane I 131|
1776709|NCT00410631|Radiation|radiation therapy|
1776710|NCT00410644|Drug|OROS Hydromorphone HCI|
1776711|NCT00410657|Biological|alemtuzumab|
1776712|NCT00410657|Drug|methylprednisolone|
1776713|NCT00410657|Drug|prednisone|
1776714|NCT00410657|Other|flow cytometry|
1776715|NCT00410657|Other|immunologic technique|
1776716|NCT00410657|Other|pharmacological study|
1776717|NCT00410826|Drug|erlotinib hydrochloride|Given orally
1776718|NCT00410826|Drug|cisplatin|Given IV
1776719|NCT00410826|Radiation|3-dimensional conformal radiation therapy|35 fractions
1776720|NCT00410826|Radiation|intensity-modulated radiation therapy|35 fractions
1776721|NCT00410826|Procedure|quality-of-life assessment|Ancillary studies
1776722|NCT00410839|Procedure|ALA rich diet|
1776723|NCT00410852|Procedure|Computer-assisted IV insulin infusion protocol (algorithm A)|Computer assisted insulin protocol (CAIP), with continuous intravenous insulin adjustments aiming blood glucose levels between 100 mg/dl and 130 mg/dl.
1776724|NCT00410852|Procedure|Leuven Strict glycemic control protocol (Algorithm B)|Leuven protocol: continuous intravenous insulin infusion aimiming blood glucose levels between 80mg/dl and 110mg/dl.
1776725|NCT00410852|Procedure|Conventional Intermittent Insulin Protocol (Algorithm C)|Conventional treatment: intermitent subcutaneous insulin according to a sliding scale, starting with blood glucose levels higher than 150mg/dl.
1776726|NCT00410865|Genetic|INGN 201|Mouth rinse given one time on the first day and two times on Days 2-5 of each course of INGN 201. The injection and rinse (first day of each cycle), or the two rinses (Days 2-5 of each cycle), will be separated by at least two hours.
1776727|NCT00410878|Drug|OROS Hydromorphone HCI (slow release)|
1776728|NCT00410891|Drug|gatifloxacin|
1776729|NCT00410904|Drug|cediranib maleate|
1776730|NCT00410904|Drug|pemetrexed disodium|
1776731|NCT00410930|Biological|Subcutaneous immunotherapy - Recombinant birch pollen|
1776732|NCT00410943|Drug|OROS Hydromorphone HCI SR (slow release)|
1776733|NCT00410956|Biological|bevacizumab|
1776734|NCT00410956|Drug|dexamethasone|
1776735|NCT00410956|Drug|floxuridine|
1776736|NCT00410956|Genetic|protein expression analysis|
1776737|NCT00410956|Other|flow cytometry|
1776738|NCT00410956|Other|immunoenzyme technique|
1776739|NCT00410956|Other|immunohistochemistry staining method|
1776740|NCT00410956|Other|immunologic technique|
1776741|NCT00410956|Other|laboratory biomarker analysis|
1776742|NCT00410956|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1776743|NCT00410969|Device|ThermoSuit(R) System|The LRS ThermoSuit System is used to cool patients using direct contact of the skin with cold water.
1776744|NCT00410982|Drug|Busulfan|Day -10 = 32 mg/m^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m^2 Intravenous
1776745|NCT00410982|Drug|Gemcitabine|Day -8 = 75 mg/m^2 Intravenous bolus; Day -3 = 75 mg/m^2 Intravenous bolus.
1776746|NCT00410982|Drug|Melphalan|Day -3 and Day -2 = 60 mg/m^2 Intravenous.
1776747|NCT00410982|Other|Hematopoietic Cell Transplantation|Infusion of stem cells on Day 0.
1776748|NCT00410982|Drug|Rituximab for Patients with B-Cell Malignancies|375 mg/m^2 Intravenous on Days 1 and 8.
1776749|NCT00410982|Drug|Palifermin|60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2
1776750|NCT00410995|Drug|Naproxen|
1776751|NCT00411021|Procedure|Pipelle (Endometrial Sampling)|
1776752|NCT00411034|Drug|OROS Hydromorphone HCI|
1776753|NCT00411047|Drug|gefitinib|oral drug taken daily around the same time
1776754|NCT00411073|Drug|Darapladib|
1776755|NCT00411086|Biological|Rituximab|375 mg/m^2 By Vein Weekly on Days 1, 8, 15, and 22.
1776756|NCT00411086|Biological|Sargramostim (GM-CSF)|250 mcg subcutaneously three times weekly for 8 weeks, starting at least 1 hour before first dose of rituximab.
1776757|NCT00411099|Drug|agomelatine|
1776758|NCT00411099|Drug|placebo|
1776759|NCT00411112|Procedure|blue and isotopic detection of sentinel lymph nodes|
1776760|NCT00411125|Drug|Oral salmon calcitonin|
1776761|NCT00411138|Radiation|Radiation Therapy|External beam pelvic radiotherapy (48.6 Gy in 1.8 Gy fractions) Vaginal brachytherapy boost in case of cervical involvement
1776762|NCT00411138|Drug|cisplatin|cisplatin 50 mg/m2 i.v., 2 cycles during radiotherapy, 3 wks interval
1776764|NCT00411138|Drug|Paclitaxel|paclitaxel 175 mg/m2, 4 cycles after completion of radiotherapy, 3 wks interval
1776765|NCT00411151|Drug|Sunitinib-Malate|Capsules of 50, 25 or 12,5 mg. Dosage 50 mg, 37.5 mg or 25 mg once daily until progression of disease or untolerable side effects
1776766|NCT00411164|Drug|OROS hydromorphone HCI (slow release)|
1776767|NCT00411177|Procedure|post-dilution on-line hemodiafiltration|post-dilution on-line hemodiafiltration, 3 times a week 4 hours
1776768|NCT00411177|Procedure|high flux hemodialysis|High-flux hemodialysis, 3 times a week 4 hours
1776769|NCT00411190|Drug|Relacatib|Subjects will administer 60 or 120 mg tablets in Session 2
1776770|NCT00411190|Drug|Acetaminophen|Acetaminophen will be administered orally
1776771|NCT00411190|Drug|Ibuprofen|Ibuprofen will be administered orally
1776772|NCT00411190|Drug|Atorvastatin|Atorvastatin will be administered orally
1776773|NCT00411203|Drug|Tamoxifen Citrate|
1776774|NCT00411203|Drug|Placebo|
1776775|NCT00411216|Other|Control exercises|saccadic eye movements against a plain background; no head movements
1776776|NCT00411216|Other|gaze stabilization exercises|adaptation and substitutin exercises encorporating retinal lsip and head movements
1776777|NCT00411229|Drug|Capecitabine|1,000 mg/m² twice daily. Film coated tablets of 500 mg, 150mg.
1776778|NCT00411229|Drug|Oxaliplatin|IV infusion, 130mg/m²
1776779|NCT00411242|Drug|agomelatine|
1776780|NCT00411242|Drug|placebo|
1776781|NCT00411255|Procedure|repetitive transcranial magnetic stimulation (rTMS)|Three arms on three different days 180 stimuli will be delivered to the AC with a sham coil, with the H-coil and with a standard circular coil in separate sessions.
1776782|NCT00411268|Drug|OROS hydromorphone HCI SR (slow release)|
1776783|NCT00411281|Drug|cytarabine|Given subcutaneously
1776784|NCT00411281|Procedure|observation|No intervention
1776785|NCT00411307|Drug|OROS hydromorphone HCI|
1776786|NCT00411320|Drug|oral steroid-dexamethasone|2 week steroid trial
1776787|NCT00411333|Drug|triamcinolone acetonide (Kenalog)|
1776788|NCT00411346|Procedure|Nurse-led telemonitoring|
1776789|NCT00411359|Behavioral|Cardiac rehabilitation|Phase III cardiac rehabilitation programme
1776790|NCT00411372|Drug|fluticasone propionate/salmeterol 250/50mcg combination, salmeterol 50mcg|
1776791|NCT00411385|Drug|albumin interferon alfa-2b|900 and 1200 micrograms Albumin Interferon Alpha 2a given subcutaneously once every two weeks for 24 weeks
1776792|NCT00411385|Drug|peginterferon alfa-2a|180 micrograms Pegasys given subcutaneaously once a week for 24 weeks
1776793|NCT00411385|Drug|Ribavirin|800mg/day for 24 weeks
1776794|NCT00411398|Drug|Namenda/Memantine|5mg tablets, 1-4 tabs by mouth per day
1776795|NCT00411411|Drug|Januvia|200 mg t.i.d
1776796|NCT00411411|Drug|Placebo|Placebo
1776797|NCT00411424|Drug|ASK8007|IV
1776798|NCT00411424|Drug|Placebo|IV
1776799|NCT00411437|Drug|Tolterodine ER|
1776800|NCT00411437|Drug|Oxybutynin ER|
1776801|NCT00411450|Biological|Panitumumab|Administered by intravenous infusion
1776802|NCT00411450|Drug|FOLFIRI|Chemotherapy consisting of irinotecan with infusional 5-fluorouracil and leucovorin. Recommended dosage regimen and administration of FOLFIRI was based on local standard of care, the package insert for each product, and institutional guidelines.
1776803|NCT00411463|Behavioral|Interpersonal and Social Rhythm Therapy (IPSRT-BPII)|"IPSRT is comprised of three components: psychoeducation, social rhythm therapy, and standard IPT as developed for unipolar depression.
Psychoeducation focuses on a) the illness and its consequences, b) treatment options and associated side effects, and c) prodromal symptoms/detection of early warning symptoms."
1776804|NCT00411463|Drug|Seroquel|"Subjects will be started at 100 mg/day titrated to a maximum of 800 mg /day
Day 1-BID doses totaling 100 mg/day, increased to 400 mg/day on Day 4 in increments of up to 100 mg/day in BID divided doses, by Day 6 begin titration up to a maximum dose of 800 mg/day in increments no greater than 200 mg/day.
This titration schedule may be adjusted based on the subject's response and ability to tolerate Seroquel.
Subjects who are unable to tolerate the study medications, or for whom the study medications are an inappropriate clinical choice, will be treated openly by a clinic physician according to the standard of care guidelines designated by the American Psychiatric Association (2002) for the treatment of bipolar disorder."
1776805|NCT00411489|Procedure|endolumenal surgery|
1776806|NCT00411515|Drug|Mycophenolate Mofetil 2x 1g|
1776807|NCT00411528|Drug|Patupilone|
1776808|NCT00411541|Drug|vincristine|
1776809|NCT00411541|Drug|dexamethasone|
1776810|NCT00411554|Drug|sitagliptin phosphate|sitagliptin 50 mg orally once daily QD. Duration of Treatment: 12 Weeks
1776811|NCT00411554|Drug|Comparator: voglibose|voglibose 0.2 mg orally three times daily TID. Duration of Treatment: 12 Weeks
1776812|NCT00411567|Drug|inhaled corticosteroid therapy|
1776813|NCT00411580|Biological|CAD106|
1776814|NCT00411580|Drug|Placebo|
1776815|NCT00411593|Drug|Bevacizumab|15 g/kg by vein every 3 weeks on day 1 of each cycle.
1776816|NCT00411593|Drug|Bortezomib|"Phase I Starting dose: 1.6 mg/m2 by vein on days 1, 8 of each 3 week cycle.
Phase II: MTD from Phase I."
1776817|NCT00411606|Procedure|Thermography|Subjects will have a picture of their face taken with a thermal camera
1776818|NCT00411619|Drug|Everolimus|Initial everolimus dosage will be 3 mg/m2/d taken daily or every other day, with titration to achieve a trough serum level of 5-15 ng/ml. Patients unable to tolerate levels in this range will have doses held or reduced 25% to achieve trough serum levels of 5-10 ng/ml. If trough serum level of 5-15 ng/ml is not achieved at a dosage of 3 mg/m2/d, then dosage escalation by 25% will be undertaken as tolerated. Everolimus will be similarly adjusted during the extension phase. If a subject misses more than 10 consecutive everolimus doses, additional days of everolimus treatment will be added so total duration of treatment is 6 months. If this occurs, dates of subsequent study events will be adjusted according to number of missed doses. This process will also be followed in the extension phase.
1776819|NCT00411632|Drug|Bexarotene|400 mg/m^2 by mouth daily x 28 Days
1776820|NCT00411632|Drug|Erlotinib|150 mg by mouth daily x 28 Days
1776821|NCT00411645|Drug|maribavir|100 mg twice daily for up to 12 weeks
1776823|NCT00411658|Device|Investigational Device|
1776824|NCT00411658|Device|Experimental|
1776825|NCT00411658|Other|Cryopreserved|
1776826|NCT00411671|Drug|Sorafenib|400 mg By Mouth Twice Daily for 28 Days.
1776827|NCT00411684|Drug|CDB-2914|
1776828|NCT00411697|Biological|Engerix™-B Kinder|Intramuscular injection, 1 dose
1776829|NCT00411723|Drug|RTL1000 (recombinant T cell receptor ligand)|Dosage form: IV infusion. Dosage: Single dose @ 2, 6, 20, 60, 100 or 200mg. Duration: 1 - 2 hours.
1776830|NCT00411723|Drug|RTL1000 Placebo|Dosage form: IV infusion. Dosage: Same volume as Experimental. Frequency: Single dose. Duration: 1 - 2 hours.
1776831|NCT00411736|Drug|Study medication, azithromycin or placebo|Granulate for syrup in the group under 8 years, 40 mg/ml. Dose: 5 mg/kg/day in one daily dose.
1776832|NCT00411736|Drug|Azithromycin or placebo tablets|Tablets of 250 mg, azithromycin or placebo. Dosage: 1 tablet every other day for participants with a weight less than 40 kg´s. 1 tablet every day for participants weighing 40 kg´s or more.
1776833|NCT00411749|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (V501)|V501; Gardasil, 0.5 ml injection in 3 dosing regimen
1776834|NCT00411749|Biological|Comparator: Placebo (unspecified)|Placebo 0.5 ml injection in 3 dosing regimen
1776835|NCT00411762|Drug|Capecitabine|
1776836|NCT00411762|Drug|PHY906|
1776837|NCT00411788|Drug|Rapamycin|oral rapamycin 6 mg daily
1776838|NCT00411788|Drug|Trastuzumab|Trastuzumab 4 mg/kg will be administered (intravenous) on day 1, and this will be followed by weekly dose of 2 mg/kg starting day 8.
1776839|NCT00411801|Biological|Uniplas|Uniplas will be provided frozen in sterile plastic bags.
1776840|NCT00411801|Biological|Cryosupernatant plasma|Cryosupernatant plasma will be provided frozen in sterile plastic bags.
1776841|NCT00411814|Drug|GSK679586|Active Drug
1776842|NCT00411814|Drug|Placebo|Saline
1776843|NCT00411827|Procedure|PRK with conjunctival impression cytology before and after surgery|
1776844|NCT00411827|Procedure|LASIK with conjunctival impression cytology before and after surgery|LASIK with conjunctival impression cytology before and after surgery
1776845|NCT00411840|Procedure|intraarterial and intramuscular injection of BMCs|
1776846|NCT00411853|Drug|Fermented Wheat germ extract|Fermented Wheat Germ powder, given orally, per os, 17 gram daily
1776847|NCT00411866|Drug|SB773812|SB-773812 20 mg will be available as white round film coated tablets.
1776848|NCT00411866|Drug|Ketoconazole|Ketoconazole will be available as 200mg tablets.
1776849|NCT00411879|Drug|Vasopressin, Epinephrine, and Steroids|During resuscitation, study group patients receive vasopresssin [20 IU IV maximum dose = 100 IU] and methylprednisolone (40 mg IV). Epinephrine is given to both groups according to guidelines for resuscitation 2005. In the study group, postresuscitation shock is treated with stress-dose hydrocortisone.
1776850|NCT00411879|Drug|Placebo, Epinephrine, Placebo|Epinephrine is given to both groups according to guidelines for resuscitation 2005. Control group patients receive placebo instead of vasopressin and steroids.
1776851|NCT00411892|Drug|pioglitazone|Tablets, 45 mg/day.
1776852|NCT00411892|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
1776853|NCT00411905|Drug|Bortezomib|
1776854|NCT00411931|Drug|Multihance|0.5M administered as a single injection
1776855|NCT00411957|Drug|Atazanavir|ATV/r 300/100mg OD vs ATV/r 200/100 mg OD
1776856|NCT00411970|Device|20- and 23 gauge vitreoretinal surgery systems|
1776857|NCT00411996|Drug|indinavir/ritonavir|IDV/r 600/100 mg BID + rifampicin OD for at least 2 weeks
1776858|NCT00412009|Procedure|Comprehensive package of activities|
1776859|NCT00412022|Drug|tamoxifen|20 mg daily for 5 years
1776860|NCT00412022|Drug|triptorelin|Premenopausal patients will receive triptorelin 3.75 mg IM at the beginning of therapy and every 4 weeks for 5 years or up to age 55
1776861|NCT00412022|Drug|letrozole|2.5 mg daily for 5 years
1776862|NCT00412022|Drug|zoledronic acid|4 mg every 6 months
1956990|NCT02601625|Drug|Anifrolumab placebo IV infusion (300mg)|600mg of placebo delivered as an IV infusion over 30 minutes on Day 1
1776865|NCT00412048|Procedure|fMRI to detect MCI patients who will convert to Alzheimer's disease|There is a fMRI to be realized in the 3 arms. No drug is administered
1776866|NCT00412061|Drug|Octreotide|Octreotide 30 mg intramuscularly (i.m.) every 28 days.
1776867|NCT00412061|Drug|Placebo|A 10-mg oral daily dosing regimen (two 5-mg tablets) of matching placebo.
1776868|NCT00412061|Drug|Everolimus|A 10-mg oral daily dosing regimen (two 5-mg tablets) of everolimus.
1776869|NCT00412074|Drug|400 IU Vitamin D3 (cholecalciferol)|400 IU vitamin D3/day given to lactating mother and 400 IU vitamin D3/day given as oral supplement to her infant
1776870|NCT00412074|Drug|2400 IU Vitamin D3 (cholecalciferol)|2400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
1776871|NCT00412074|Drug|6400 IU Vitamin D3 (cholecalciferol)|6400 IU vitamin D3/day given to lactating mother and 0 IU vitamin D3/day (placebo) given as oral supplement to her infant
1776872|NCT00412087|Drug|cholecalciferol (vitamin D3)|randomized to one of two treatments: 2000 or 4000 IU vitamin D3/day
1776873|NCT00412087|Drug|cholecalciferol|randomized to one of 2 treatment doses: 2000 vs. 4000 IU/day vitamin D3
1776874|NCT00412087|Drug|cholecalciferol|cholecalciferol at 2000 or 4000 IU/day to be taken througout pregnancy. This follows the initial run-in dosing of 2000 IU/day starting at 12-weeks' gestation.
1776875|NCT00412100|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
1776876|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 5 mg
1776877|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 10/20 mg
1776878|NCT00412113|Drug|Amlodipine besylate|Amlodipine besylate 10 mg
1776879|NCT00412113|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Amlodipine/atorvastatin single pill combination 5/20 mg
1776880|NCT00412126|Drug|Insulin|
1776881|NCT00412152|Drug|Oxycodone nalaxone prolonged release tablets (OXN)|
1777036|NCT00413413|Drug|Valsartan 80 mg|1 valsartan 80 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
1776882|NCT00412165|Behavioral|Cell Phone|The cell phone arm receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
1776883|NCT00412165|Behavioral|Weekly access to interactive web site|This group receives access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
1776884|NCT00412165|Behavioral|Group|The Group arm receives monthly face to face group sessions plus access to the website with weekly health ed materials and weekly case management via phone, mail, e-mail
1776885|NCT00412178|Device|telecommunication based glucose monitoring system|
1776886|NCT00412191|Drug|Lamotrigine|In treatment regimen A lamotrigine XR tablets will be available 100 and 200mg tablets, for regimen B and C of lamotrigine tablets 300 mg will be available.
1956991|NCT02601625|Drug|Anifrolumab placebo SC infusion (600mg)|600 mg of placebo delivered as 4 mL SC by infusion pump on Day 1
1776889|NCT00412217|Drug|Placebo|Participants will receive placebo tablets (matched to erlotinib) once daily.
1776890|NCT00412217|Drug|Erlotinib|Erlotinib will be given as 150 mg PO once daily.
1776891|NCT00412217|Other|Standard of care|Additional clinical management including surgical resection and chemoradiotherapy or radiotherapy alone will be at the discretion of the Investigator according to local standard of care.
1776892|NCT00412243|Drug|Clofarabine|40 mg/m^2 Daily for 3 Days
1776893|NCT00412243|Drug|Cyclophosphamide|Beginning dose 200 mg/m^2 every 12 hours for 3 days
1776894|NCT00412256|Drug|Omegaven (10% fish-oil emulsion; Fresenius-Kabi)|
1776895|NCT00412295|Device|Alcon Ladarvision (Wavefront-guided PRK)|Wavefront-guided PRK using Alcon Ladarvision
1776896|NCT00412308|Procedure|Tidal volume used in mechanical ventilation|
1776897|NCT00412321|Drug|CNTO 328|Patients will receive administrations of CNTO 328 with dose ranging from 3 mg/kg to 12 mg/kg weekly, every 2 or 3 weeks till Day 43 in cohorts 1 to 6. After cohort 6, if the clinical response is found to be suboptimal, the patients will receive 9 mg/kg or 12 mg/kg every 3 weeks in cohorts 7a. Participants in Cohort 7a who will experience intolerable toxicity after escalating to or receiving 12 mg/kg every 3 weeks will have the option of reverting to a dose of 9 mg/kg every 3 weeks if the investigator felt it was clinically indicated. In cohort 7b participants will receive 12 mg/kg CNTO 328 every 3 weeks.
1776898|NCT00412334|Drug|Copegus|1200-1600mg/day po
1776899|NCT00412334|Drug|Copegus|1000-1200mg/day po
1776900|NCT00412334|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc weekly
1776901|NCT00412334|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc twice weekly
1776902|NCT00412347|Drug|Insulin Drip Therapy|
1776903|NCT00412360|Biological|Single Umbilical Cord Blood Unit Transplant|Unrelated donor, single umbilical cord blood unit; conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
1776904|NCT00412360|Biological|Double Umbilical Cord Blood Unit Transplant|Unrelated donor, double umbilical cord blood unit; Conditioning regimen: TBI/cyclophosphamide/fludarabine; GVHD prophylaxis: cyclosporine/MMF
1776905|NCT00412360|Radiation|Total Body Irradiation|The TBI will be delivered from either a linear accelerator or cobalt source at a dose rate of between 4 and 26 cGy/minute using energies of between 1 and 25 MV.
1776906|NCT00412360|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day will be administered as a 2 hour intravenous infusion with a high volume fluid flush on Days -3 and -2.
1776907|NCT00412360|Drug|Fludarabine|Fludarabine 25 mg/m2/day will be administered over 30-60 minutes intravenous infusion on Days -10 through -8. Fludarabine will not be dose adjusted for body weight.
1776908|NCT00412360|Drug|Cyclosporine A|CSA will be administered beginning on Day -3 and doses will be adjusted to maintain a level of 200-400 ng/mL by TDX method (or 100-250 ng/mL by Tandem MS or equivalent level for other CSA testing methods). CSA can be administered per institutional practice.
1776909|NCT00412360|Drug|Mycophenolate Mofetil|MMF will be given at a dose of 1 gram IV q 8 hours if > 50 kg or 15 mg/kg IV q 8 hours if < 50 kg beginning the morning of Day -3.
1776910|NCT00412373|Drug|Placebo|for 6 weeks
1776911|NCT00412373|Drug|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
1776912|NCT00412373|Drug|Paliperidone ER|(3-12mg/day in 3 mg/day increments for 6 weeks)
1776913|NCT00412412|Drug|CNF2024|Oral doses of CNF2024 as specified in the protocol.
1776914|NCT00412412|Drug|CNF2024 + trastuzumab|Oral doses of CNF2024 as specified in the protocol Intravenous doses of trastuzumab as specified in the package insert.
1776915|NCT00412425|Drug|Palonosetron|0.25 mg IV (By Vein) Daily for 2 Days or 0.25 mg IV Daily for 3 Days.
1776916|NCT00412451|Drug|ocriplasmin|Intravitreal injection, single administration
1776917|NCT00412451|Other|Sham injection|Sham intravitreal injection
1776918|NCT00412464|Drug|Fondaparinux|Fondaparinux 0.1 mg/kg (up to 7.5 mg max initial dose) once daily for up to 21 days.
1776919|NCT00412477|Biological|HIV LFn-p24|HIV LFn-p24 is a combination of an Anthrax derived polypeptide Lethal factor (LFn), from which the toxin domain has been removed, and the HIV-1 gag p24 protein has been fused to LFn. Lfn-p24 is formulated in liquid form, and vialed at 200 µg/ml and 600 µglml. The product will be administered IM in doses ranging from 150µg to 450µg with Alhydrogel.
1776920|NCT00412490|Behavioral|Questionnaire|Written survey at 1 Month & 6 Months post surgery.
1776921|NCT00412490|Behavioral|Interview|One-on-One meeting lasting about one hour, at 1 Month & 6 Months post surgery.
1776922|NCT00412503|Drug|Topotecan, Temozolomide|
1776923|NCT00412516|Biological|Live attenuated SA 14-14-2 vaccine|Live attenuated SA 14-14-2 vaccine coadministered with live measles vaccine (experimental Group)
1776924|NCT00412529|Drug|Entecavir|Entecavir 0.5 mg once daily for 12 weeks.
1776925|NCT00412529|Drug|Telbivudine|Telbivudine 600 mg once daily for 12 weeks.
1776926|NCT00412542|Drug|Thalidomide|100 mg PO (by mouth) daily for 8 weeks
1776927|NCT00412542|Drug|CPT-11|125 mg/m^2 by vein weekly over 90 minutes for 4 weeks, followed by 2 weeks rest
1776928|NCT00412542|Procedure|MRI Scan|Dynamic MRI scan with dye injection through vein, every 6 weeks
1776929|NCT00412542|Procedure|Quantitative Sensory Tests (QST)|QST, every 12 weeks, to check for any nerve problems that may be present before starting treatment; by touching a small machine tests are done on feeling of touch, vibration, and temperature.
1776930|NCT00412555|Drug|oseltamivir [Tamiflu]|30-75mg po daily for 6 weeks
1776931|NCT00412568|Procedure|Photorefractive Keratectomy (PRK)|vision correction with PRK
1776932|NCT00412581|Drug|Lenalidomide|25 mg by mouth daily for 2 weeks, followed by 1 week of rest.
1776933|NCT00412581|Drug|Dacarbazine|600 mg/m^2 intravenously on Day 1 of every study cycle.
1776934|NCT00412594|Drug|Cladribine|5.6 mg/m^2 by vein over 2 hours daily for 5 days
1776935|NCT00412594|Drug|Rituximab|375 mg/m^2 by vein weekly x 8 starting on day 28 (plus or minus 4 days) following 2CDA treatment.
1776936|NCT00412607|Device|NAVISTAR® THERMOCOOL® Catheter|The primary objective is to provide additional, corroborative safety data for the NAVISTAR THERMOCOOL catheter for the treatment of subjects with sustained, monomorphic VT or incessant VT associated with coronary artery disease
1776937|NCT00412620|Drug|ABT-925|
1776938|NCT00412620|Drug|Placebo|
1776939|NCT00412633|Behavioral|Diet and physical activity interventions|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
1776940|NCT00412633|Behavioral|Computer technology to tailor, promote and sustain health behavior change & improve health care delivery.|Weekly web-based intervention that included goal setting, self-monitoring, weekly behavioral skills, nutrition and physical activity tips, and access to a health coach.
1776941|NCT00412646|Drug|TMC125|
1776942|NCT00412659|Procedure|Surgery for pilonidal disease, midline excision|A midline excision is made for the treatment of pilonidal sinus disease.
1776943|NCT00412659|Procedure|Surgery for pilonidal disease, Karydakis operation|A Karydakis operation is done for the treatment of pilonidal sinus disease.
1776944|NCT00412698|Drug|rimonabant|"Administration of one tablet containing 20 mg of active rimonabantonce daily in the morning.
White film-coated tablets, for oral administration containing 20 mg of active rimonabant"
1776945|NCT00412698|Drug|Placebo|Administration of one rimonabant placebo tablet once daily in the morning. Undistinguishable placebo tablets.
1776946|NCT00412737|Drug|Oseltamivir|Oseltamivir 30 mg to 75 mg capsule or suspension orally once daily for 12 weeks.
1776947|NCT00412737|Drug|Placebo|Placebo matched to oseltamivir capsule or suspension orally once daily for 12 weeks.
1776948|NCT00412750|Drug|Telbivudine (LdT)|600 mg orally once daily for 104 weeks.
1776949|NCT00412750|Drug|peginterferon alpha-2a|180 μg subcutaneous injection once a week for 52 weeks.
1776950|NCT00412763|Drug|Silymarin (Silybum marianum)|
1776951|NCT00412776|Drug|Proxinium|700 µg Proxinium, once weekly until complete resolution of all target tumours or radiographic tumour progression
1776952|NCT00412789|Drug|Patupilone|
1776953|NCT00412802|Drug|dose adaptation of Enoxaparin|A same initial dose of 1 mg/kg will be administrated to all patients. According to creatinine clearance, the next doses (every 12 hours subcutaneously) will be adjusted with a 25% dose reduction if creatinine clearance is comprised between 30 and 50 ml/min.
1776954|NCT00412802|Drug|normal injection of Enoxaparine|No dose adaptation of Enoxaparine
1776955|NCT00412815|Behavioral|Exercise training|
1776956|NCT00412828|Drug|CR011-vcMMAE|administered as an intravenous infusion of 250 mL over 90 min
1776957|NCT00412841|Drug|Atorvastatin|Atorvastatin 40mg vs placebo 40mg daily
1776958|NCT00412841|Procedure|MRI, Venipuncture|MRIs done baseline, four and nine months
1776959|NCT00412841|Drug|Placebo|Tablets identical to atorvastatin 40mg
1776960|NCT00412854|Biological|Infanrix™/Hib|
1776961|NCT00412854|Biological|Infanrix|
1776962|NCT00412854|Biological|Hiberix|
1776963|NCT00412867|Drug|Alteplase|0.6 mg/kg of Alteplase is intravenously administered
1776964|NCT00412880|Drug|BI 2536|
1776965|NCT00412893|Drug|Isavuconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
1776966|NCT00412893|Drug|Voriconazole|Loading doses were administered as IV infusion and maintenance doses were administered as IV infusion or oral (capsules).
1776967|NCT00412906|Drug|Escherichia Coli Endotoxin|
1776968|NCT00412919|Drug|Azacitidine|
1776969|NCT00412932|Drug|Olmesartan medoxomil|Tablets
1776970|NCT00412932|Drug|Olmesartan medoxomil/hydrochlorothiazide|Tablets
1776971|NCT00412958|Drug|Ocriplasmin 25µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 25µg of ocriplasmin.
1776972|NCT00412958|Drug|Ocriplasmin 75µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 75µg of ocriplasmin.
1776973|NCT00412958|Drug|Ocriplasmin 125µg|Intravitreal injection of 0.1 ml of ocriplasmin solution containing 125µg of ocriplasmin.
1776974|NCT00412958|Drug|Placebo|Intravitreal injection of placebo
1776975|NCT00412971|Drug|Hexvix|Single installation, TURB
1776976|NCT00412971|Other|Standard white light cystoscopy|
1776977|NCT00412984|Drug|warfarin|Oral tablets, 2.0 mg, adjusted to an INR of 2.5 (range 2.0 to 3.0)
1776978|NCT00412984|Drug|apixaban|Oral tablets, 5.0 mg or 2.5 mg, twice daily
1776979|NCT00412997|Drug|LBH589|
1776980|NCT00413010|Drug|pregabalin|pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
1776981|NCT00413010|Drug|placebo|placebo + concurrent GAD treatment from the open-label study period
1776982|NCT00413023|Drug|GW679769|
1776983|NCT00413036|Drug|lenalidomide|once daily oral capsule
1776984|NCT00413049|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet and 1 placebo capsule matching amlodipine 5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
1777037|NCT00413413|Drug|Valsartan 160 mg|1 valsartan 160 mg capsule, 1 placebo tablet to match valsartan/amlodipine 80/5 mg once daily
1777078|NCT00406757|Drug|Nelarabine injection 650mg/m2|Nelarabine 650mg/m2 will be administered once a day from Day 1 to Day 5.
1776985|NCT00413049|Drug|Amlodipine 5 mg|1 amlodipine 5 mg capsule and 1 placebo tablet matching valsartan/amlodipine 80/5 mg to be taken with water at approximately 8:00 a.m. once daily, except on the morning of every scheduled study visit, when study drug was taken after the completion of all other study procedures.
1776986|NCT00413062|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
1776987|NCT00413062|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
1776988|NCT00413075|Drug|oral belinostat|oral belinostat dosed once or twice daily at continuous and discontinuous dosing schedules.
1776989|NCT00413088|Drug|bemiparin|
1776990|NCT00413101|Drug|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/L
1776991|NCT00413114|Drug|Obatoclax mesylate (GX15-070MS)|
1776992|NCT00413127|Drug|lidocaine|administration of lidocaine intravenously or epidural or administration of placebo
1776993|NCT00413127|Drug|NaCl 0,9%|Administration of placebo i.v.
1776994|NCT00413153|Drug|atazanavir/ritonavir|atazanavir 300mg + ritonavir 100mg once daily
1776995|NCT00413153|Drug|lopinavir/ritonavir|patient remains on their pre-study dose of lopinavir/ritonavir
1776996|NCT00413166|Drug|All-Trans Retinoic Acid (ATRA)|Induction: 45 mg/m2 daily by mouth in 2 divided doses beginning day 1
1776997|NCT00413166|Drug|Arsenic Trioxide (ATO)|Induction: 0.15 mg/kg daily IV beginning day 1
1776998|NCT00413166|Drug|Idarubicin|"12 mg/m2 one dose only (may be given on day 1 to 5 of induction)
If either ATRA or ATO are discontinued due to toxicity, idarubicin 12 mg/m2 x 2 doses will be administered once every 4 to 5 weeks (depending on the recovery of counts) until 28 weeks has elapsed from the Complete Recovery date."
1776999|NCT00413179|Drug|Metformin|
1777000|NCT00413179|Drug|Clomiphene citrate|
1777001|NCT00413179|Drug|Placebo|
1777002|NCT00413192|Drug|E7389|1.4 mg/m^2 administered as an intravenous (I.V.) bolus infusion on Days 1 and 8 of every 21 days.
1777003|NCT00413205|Drug|Placebo|po daily
1777004|NCT00413205|Drug|RAR Gamma|5mg po daily
1777005|NCT00413218|Drug|Isavuconazole|Administered by intravenous infusion.
1777006|NCT00413218|Drug|Caspofungin|Administered by intravenous infusion.
1777007|NCT00413218|Drug|Voriconazole|Administered by intravenous infusion.
1777008|NCT00413231|Device|Valiant Thoracic Stent Graft System|Surgical procedure in which a device is implanted inside the aorta, isolating the diseased area (aneurysm).
1777009|NCT00413244|Drug|AndroGel 5 Grams|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.
Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
1777010|NCT00413244|Drug|Placebo|"Placebo (randomization will occur on a 2:1 drug to placebo). A total of 50 subjects will be randomized to receive Androgel 5 grams and 25 subjects will be randomized to receive placebo.
Androgel treatment/Placebo (after the treatment arm is assigned, subjects will be instructed to begin the study drug at 1 week post entry into the study and will continue to take the study drug for a total of 6 months. The study drug has to be applied to the skin once daily for 6 months."
1777011|NCT00413257|Drug|Nefopam|0,3mg/kg IV bolus preoperative and 65 µg/kg/h during H48 postoperative
1777012|NCT00413257|Drug|néfopam|bolus Néfopam (0,3mg/kg) during 10 min at the end of surgery and 65 µg/kg/h during postoperative H48
1777013|NCT00413257|Drug|Placebo comparator|bolus NaCl during 10 min at the end of surgery and during postoperative H48
1777014|NCT00413270|Drug|nilotinib|
1777015|NCT00413283|Biological|Romiplostim|Romiplostim is a thrombopoiesis recombinant protein that targets the thrombopoietin (TPO) receptor which results in increased platelet production.
1777016|NCT00413283|Drug|Placebo|Placebo subcutaneous injection.
1777017|NCT00413283|Drug|Gemcitabine|Intravenous infusion
1777018|NCT00413283|Drug|Carboplatin|Intravenous infusion
1777019|NCT00413283|Drug|Cisplatin|Intravenous infusion
1777020|NCT00413296|Drug|levetiracetam|Tablets, dosage 500 mg each ( 1-6 tablets/day)for20 wks
1777021|NCT00413296|Drug|Placebo|Placebo, Tablets, no active ingredient in the tablets, (1-6tablets/day)for 12 wks in the 2nd phase of the study.
1777022|NCT00413296|Drug|Levetriracetam|Tablets, 500 mg each (1-6 tablets/day) for 8 wks during the open label phase and for 12 wks during the 2nd phase of the study.
1777023|NCT00413309|Procedure|Video Capsule Endoscopy|Noninvasive pill endoscopy is undertaken after 90 days of Aspirin/Clopidogrel in patients who have had percutaneous coronary intervention with drug-eluting stents.
1777024|NCT00413322|Drug|belinostat|300, 600, or 1000 mg/m2 belinostat IV for 5 days every 21 days starting with cycle 1
1777025|NCT00413322|Drug|5-Fluorouracil (5-FU)|250, 500, 750, or 1000 mg/m2/d of 5-FU starting with cycle 2 onwards in combination with belinostat. Starting on day 2, 5-FU is administered as a continuous 96 hour infusion.
1777026|NCT00413335|Drug|Rosiglitazone|2mg to begin then 4mg, twice daily for 4 months
1777027|NCT00413335|Drug|Placebo|Subject receives placebo.
1777028|NCT00413348|Drug|Lactobacillus acidophilus NCFM|
1777029|NCT00413361|Drug|versus hydroxychloroquine|versus hydroxychloroquine
1777030|NCT00413374|Drug|Enoxaparin|Patient takes 1.5 mg per kilogram, once daily, subcutaneous injections until INR is therapeutic, then medication is stopped.
1777031|NCT00413387|Drug|beclomethasone dipropionate plus formoterol fumarate combination|100mcg beclomethasone diproprionate plus 6 mcg formoterol
1777032|NCT00413387|Drug|budesonide plus formoterol combination|200mcg budesonide plus 6 mcg formoterol
1777033|NCT00413400|Drug|Etanercept|50 mg one syringe sc 2X per week for three months followed by 50 mg one syringe sc 1X per week for three months
1777034|NCT00413400|Drug|Placebo|50 mg one syringe sc 2x per week for three months followed by 50 mg one syringe sc 1X per week for three months
1777035|NCT00413413|Drug|Valsartan/amlodipine 80/5 mg|1 valsartan/amlodipine 80/5 mg tablet, 1 placebo capsule to match valsartan once daily
1777038|NCT00406432|Drug|Paroxetine Controlled Release Tablet|Eligible subjects will receive paroxetine controlled release tablet with dose of 25 milligrams.
1777039|NCT00406458|Drug|SB-509|60 mg dose
1777040|NCT00406458|Other|Normal Saline|
1777041|NCT00406471|Drug|Ranibizumab (Lucentis)|500 microgram intravitreal injection for 8 months or 300 microgram intravitreal injection for 8 months
1777042|NCT00406484|Behavioral|Standard drug counseling|Individual drug counseling
1777043|NCT00406484|Behavioral|BDRC|Behavioral Drug and HIV Risk Reduction Counseling, individual once or twice weekly sessions
1777044|NCT00406497|Drug|Difluprednate Ophthalmic Emulsion|
1777045|NCT00406510|Drug|Optive, Systane|
1777046|NCT00406523|Device|JANUS Stent|
1777047|NCT00406536|Dietary Supplement|Lym-X-Sorb powder|Lym-X-Sorb is an organized matrix of lyso phosphatidylcholine (LPC), free fatty acid (FFA) and monoglyceride formulated at 20wt% with flour and sugar. A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
1777048|NCT00406536|Dietary Supplement|Placebo powder|The placebo is composed of soybean oil, sunflower oil, fully hydrogenated cottonseed oil and flax seed oil dispersed at 16wt% on flour and sugar. The placebo is >99% triglycerides with no trans fatty acids. The fatty acid composition and caloric content is designed to match the active supplement (Lym-X-Sorb). A dosage contains 32 grams of powder and is consumed with food twice a day (6 to 11.9 years old) or three times per day (12 to 17.9 years old) for 18 months.
1777049|NCT00406562|Biological|Boostrix|
1777050|NCT00406575|Drug|Placebo|Placebo was the diluent used for preparation of the 100 µg/kg/day dose of active study medication.
1777051|NCT00406575|Drug|Recombinant human relaxin (rhRlx)|Recombinant human relaxin (rhRlx) diluted for continuous IV infusion.
1777052|NCT00406588|Drug|Levodopa (Pardoprunox)|12-42mg
1777053|NCT00406588|Drug|Placebo Comparator|Placebo
1777054|NCT00406601|Drug|Sorafenib (BAY-43-9006)|800 mg/die orally on a continuous basis
1777055|NCT00406614|Behavioral|Health Literacy-Focused High Blood Pressure Intervention|Participants assigned to the intervention group will attend a weekly 2-hour educational session for 6 weeks that will cover topics such as learning medical terminology, understanding the content of prescription and appointment slips, and blood pressure (BP) management strategies. Upon completion of the educational sessions, participants will submit BP measurements via telephone monitoring system for 12 months and Community Health Worker (CHW) will conduct telephone counseling once every month during the same 12-month period for support and follow-up counseling. Participants will continue to monitor BP measurement by logging BP data on BP diary book for another 12 months. Control group participants will receive the same intervention education following the completion of the study.
1777056|NCT00406640|Drug|Desvenlafaxine succinate sustained-release (DVS SR)|flexible dose of DVS 50-100 or 200 mg every day during 56 days. Extension until 6 months.
1777057|NCT00406640|Drug|Escitalopram|Flexible dose of Escitalopram 10 or 20 mg every day during 56 days. Extension until 6 months.
1777058|NCT00406653|Drug|abatacept|"Dextrose 5% in water, intravenous (IV).
Placebo on days Induction Period (IP)-1, IP-15,IP-29, IP-57;
3 mg/kg on days IP-1, IP-15,IP-29, IP-57;
~10 mg/kg on days IP-1, IP-15,IP-29, IP-57,
or 30 mg/kg on days IP-1,IP-15 and ~10 mg/kg on days IP-29, IP-57.
Induction Period 3 months
Maintenance Period 12 months"
1777059|NCT00406653|Drug|placebo|"Normal saline, IV, 0 mg/kg, every 28 days.
Induction Period 3 months
Maintenance Period 12 months"
1777060|NCT00406653|Drug|abatacept|"~10 mg/kg, every 28 days.
Open- Label Extension Period until the drug is marketed for Crohn's Disease (CD)or the CD development program for abatacept is discontinued"
1777061|NCT00406679|Drug|Paracetamol (acetaminophen) solution experimental|1 gm IV
1777062|NCT00406679|Drug|paracetamol (acetaminophen) solution commercial|1 gm IV
1777063|NCT00406679|Drug|placebo|equivalent volume IV 0.9% sodium chloride (equivalent volume)
1777064|NCT00406692|Drug|Zonisamide|Week 1 (Wk1) -100 mg daily; Wk 2- 100 mg daily; Wk 3- 200 mg daily; Wk 4- 200 mg daily; Wk 5- 300 mg daily; Wk 6- 300 mg daily; Wk 7-11- 400 mg daily; Wk 12(Days 1-5) 300 mg daily; Wk 12 (Day 6-7) Week 13 (Days 1-3)- 200 mg daily; Week 13 (Days 4-7) - 100 mg daily.
1777065|NCT00406705|Behavioral|Helium-Hyperoxia|
1777066|NCT00406718|Behavioral|Med-eMonitor|Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.
1777067|NCT00406718|Behavioral|PharmCAT|Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.
1777068|NCT00406718|Behavioral|Treatment as Usual|Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
1777069|NCT00406731|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6 mg/kg over 5 minutes followed by a continuous intravenous infusion of 60 µg/kg/min over 12 minutes; twice on 1 study day
1777070|NCT00406731|Drug|Endothelin-1 (ET-1)|5 ng/kg/min intravenous infusion over 17 minutes; twice on 1 study day
1777071|NCT00406731|Drug|Physiologic saline solution (placebo control)|intravenous infusion over 20 minutes; twice on 1 study day
1777072|NCT00406731|Device|Laser Doppler flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
1777073|NCT00406731|Device|Goldmann applanation tonometer|Intraocular pressure measurements
1777074|NCT00406731|Device|HP-CMS patient monitor|blood pressure and pulse rate measurements
1777075|NCT00406731|Procedure|Suction cup method|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
1777076|NCT00406744|Drug|Intravitreal injection of Bevacizumab|
1777077|NCT00406757|Drug|Nelarabine injection 400mg/m2|"Cycle 1: Nelarabine 400mg/m2 will be administered once a day from Day 1 to Day 5.
Cycle 2 and subsequent Cycles: Nelarabine 650mg/m2 will be administered once daily from Day 1 to DAy 5."
1777079|NCT00406757|Drug|Nelarabine injection 1000mg/m2|"Cycle 1: Nelarabine 1000mg/m2 will be administered once a day on Days 1, 3 and 5.
Cycle 2 and subsequent Cycles: Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5."
1777080|NCT00406757|Drug|Nelarabine injection 1500mg/m2|Nelarabine 1500mg/m2 will be administered once a day on Days 1, 3 and 5.
1777081|NCT00406770|Device|Light therapy|
1777082|NCT00406783|Drug|5-mg Desloratadine|5-mg Desloratadine tablet, once daily for 15 days
1777083|NCT00406783|Drug|Placebo|Placebo tablet, once daily for 15 days
1777084|NCT00406796|Drug|Ranibizumab|0.3mg and 0.5mg dose of Ranibizumab 0.05ml administered intravitreally
1777085|NCT00406809|Drug|ABT-263|"Oral solution
Phase 1 dosing was under two different schedules: 14 days on drug, 7 days off or 21 days continuous dosing.
- 55 subjects with relapsed or refractory lymphoid malignancies. Enrollment is closed in Phase 1 of the study.
Oral solution and tablets
Phase 2a dosing under 21 day continuous dosing.
150 mg lead-in dose for 7-14 days followed by a 325 mg continuous once daily dose.
26 subjects in two arms: Arm A and Arm B. Enrollment is closed in Phase 2a of the study.
Oral tablets
Extension portion of the study is to allow Phase 2a subjects who remain active 1 year after the last subject enrolls or who have been on study approximately 1 year to continue receiving ABT-263 under 21 day continuous dosing."
1777086|NCT00406822|Device|OculusGen Biodegradable Collagen Matrix Implant|
1777087|NCT00406835|Procedure|Whole-Brain Radiation Therapy, Stereotactic Radiosurgery|
1777088|NCT00406848|Drug|duloxetine hydrochloride|Placebo for 1 week (double-blind placebo lead-in), then duloxetine 30 milligrams (mg) orally once daily (QD) for 1 week, followed by duloxetine 60 mg QD orally for 11 weeks. This double-blind acute treatment phase was followed by a double-blind 12 week continuation phase during which participants either remained on 60 mg QD or were eligible for dose escalation to 120 mg QD orally based on depression symptom severity.
1777089|NCT00406848|Drug|placebo|Placebo for 13 weeks (The first week was placebo lead-in). This double-blind acute phase was followed by a double-blind 12 week continuation phase during which participants either remained on placebo or were eligible for receiving duloxetine 60 milligrams (mg) orally once daily (QD), beginning with duloxetine 30 mg QD orally for 1 week followed by duloxetine 60 mg QD orally for the remainder of the study based on depression symptom severity.
1777090|NCT00406861|Drug|montelukast in treatment of ENL reaction|
1777091|NCT00406874|Drug|omega 3 fats|1,000 mg daily
1777092|NCT00406874|Drug|folic acid|800 micrograms daily
1777093|NCT00406887|Drug|Difluprednate Ophthalmic Emulsion|
1777094|NCT00406900|Procedure|Treatment of metastatic disease|
1777095|NCT00406913|Drug|mupirocin ointment|
1777096|NCT00406913|Other|SOC sterilization|
1777097|NCT00406926|Drug|Somatropin|
1777098|NCT00406939|Genetic|IL-12 gene|
1777099|NCT00406952|Procedure|electronic diary|
1777100|NCT00406952|Drug|Sertraline|
1777101|NCT00406952|Drug|Placebo|
1777102|NCT00406952|Procedure|voice acoustics|
1777103|NCT00406965|Drug|HAE1 (PRO98498)|
1777104|NCT00406978|Drug|Prednisone|Prednisone will be given orally at the dose of 1.5 mg/Kg for 4 days followed by a 31-day rest period (days 5 through 35)
1777105|NCT00406978|Drug|Melphalan|Melphalan will be given orally at the dose of 0.25 mg/Kg for 4 days,
1777106|NCT00406978|Drug|Thalidomide|Thalidomide will be administered orally at the initial dose of 50 mg/day p.o. once daily, with increment of 50 mg after a month to acceptable tolerance (maximum 100 mg), continuously for the entire 6 courses.
1777107|NCT00406978|Drug|Defibrotide|Lev - 1 Def = 10 mg/Kg (max 0.6 g) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Lev - 1 Def = 1.2 g p.o (400 mg every 8 hours) on days 1-4, followed by 1.2 g (400 mg every 8 hours) p.o. through day 35 Level + 1 Def = 17 mg/Kg (max 1.2 g) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 1 Def = 2.4 g p.o. (400 mg every 4 hours) on days 1-4, followed by 1.6 g p.o. (400 mg every 6 hours) through day 35 Lev + 2 Def = 34 mg/Kg (max 2.4 g) as a i.v. injection on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 2 Def = 4.8 g p.o. (800 mg every 4 hours) on days 1-4, followed by 3.2 g p.o. (800 mg every 6 hours) through day 35 Lev + 3 Def = 51mg/Kg (max 3.6 g) as a i.v. injection on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) through day 35 Lev + 3 Def = 7.2 g p.o.(1200 mg every 4 hours ) on days 1-4, followed by 4.8 g p.o. (1200 mg every 6 hours) given p.o. through day 35
1777108|NCT00406991|Drug|aspirin|
1777109|NCT00406991|Drug|clopidogrel|
1777110|NCT00407004|Device|MARS (Molecular Adsorbents Recirculating System)|
1777111|NCT00407004|Device|Prometheus (FPSA, Fractionated Plasma Separation and Adsorption)|
1777112|NCT00407017|Drug|Gatifloxacin|
1777113|NCT00407017|Drug|Ketorolac LS|
1777114|NCT00407017|Drug|Pred Forte|
1777115|NCT00407017|Drug|Moxifloxacin|
1777116|NCT00407017|Drug|Nepafenac|
1777117|NCT00407017|Drug|EconoPred Plus|
1777118|NCT00407030|Drug|incobotulinumtoxinA (Xeomin) (240 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (240 Units)"
1777119|NCT00407030|Drug|incobotulinumtoxinA (Xeomin) (120 Units)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (120 Units)"
1777120|NCT00407030|Drug|Placebo|Placebo
1777121|NCT00407043|Drug|Lotemax|
1777122|NCT00407043|Drug|Restasis|
1777123|NCT00407056|Drug|Difluprednate Ophthalmic Emulsion|
1777124|NCT00407082|Drug|fluocinolone acetonide intravitreal implant|Fluocinolone acetonide ocular implant 0.59mg
1777125|NCT00407082|Drug|Fluocinolone acetonide 2.1mg|Fluocinolone acetonide ocular implant 2.1mg
1777126|NCT00407095|Drug|Pardoprunox|12-42 mg/day
1777127|NCT00407108|Procedure|Vitrectomy|
1777128|NCT00407121|Drug|Bevacizumab|
1777129|NCT00407121|Procedure|Intravitreal Injection of Bevacizumab|
1777130|NCT00407134|Procedure|Different abdominal volumes and different glucose-concentrations during peritoneal dialysis|
1777131|NCT00407147|Device|Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor|"antibiotic treatment based on clinical decision making with traditional thought processes used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection."
1777132|NCT00407173|Drug|HCV-796|HCV-796 1000mg single dose
1777136|NCT00407199|Drug|quetiapine|
1777137|NCT00407212|Drug|TCH346 (dibenz[b,f]oxepin-10-ylmethyl-prop-2-ynyl-amine, hydrogen maleate salt)|
1777138|NCT00407225|Drug|Difluprednate Ophthalmic Emulsion|
1777139|NCT00407238|Device|Multi-purpose solutions (polyquaternium-1 and PHMB)|
1777140|NCT00407251|Drug|Patupilone|
1777141|NCT00407264|Drug|Fluticasone propionate|
1777142|NCT00407277|Drug|Nicotine patch|21 mg of nicotine via a dermal patch
1777143|NCT00407277|Other|placebo|placebo via a dermal patch
1777144|NCT00407277|Behavioral|smoking cessation group therapy|"a 9-week group based on the Freedom From Smoking program designed by the American Lung Association. The treatment was manualized and modified to meet the functional and cognitive capabilities of patients with psychotic disorders"
1777145|NCT00407290|Drug|neostigmine|
1777146|NCT00407303|Drug|Obatoclax mesylate|30 mg, 45 mg
1777147|NCT00407303|Drug|Bortezomib|1.0mg/m2, 1.3 mg/m2
1777148|NCT00407329|Procedure|transurethral resection of the prostate|resection of prostate
1777149|NCT00407342|Drug|Alefacept (drug)|alefaceptgiven iv
1777150|NCT00407342|Procedure|Narrowband UVB phototherapy|
1777151|NCT00407355|Drug|Intravitreal injection of ranibizumab .3 dose|PRN every 30 days withing retreatment criteria
1777152|NCT00407355|Drug|Intravitreal injection of Ranibizumab .5 dose|Intravitreal injection of Ranibizumab .5 dose every 30 days PRN with retreatment criteria
1777153|NCT00407368|Procedure|Blood Sample|
1777154|NCT00407381|Drug|Ranibizumab|Ranibizumab for intravitreal injection. .05ml dosing at 30 day intervals and pro re nata (PRN) with dosing criteria.
1777155|NCT00407381|Procedure|Laser photocoagulation|Laser photocoagulation in either focal or grid pattern as determined by investigator.
1777156|NCT00407394|Drug|Amoxycillin|
1777157|NCT00407407|Drug|ABI-007|80mg/m^2 to 150mg/m^2 IV every 3 weeks
1777158|NCT00407407|Drug|Carboplatin|6 AUC IV every 3 weeks on the same day as ABI-007
1777159|NCT00407420|Behavioral|mandometer|
1777160|NCT00407433|Drug|Gemcitabine (Gemzar®), Oxaliplatin (Eloxatin®)|
1777161|NCT00407446|Drug|sildenafil|
1777162|NCT00407459|Drug|Bevacizumab, Pemetrexed, Carboplatin|"Bevacizumab: 15 mg/kg intravenous infusion over 30 to 90 minutes, following chemotherapy, on Day 1 every 3 weeks
Pemetrexed: 500 mg/m2 intravenous infusion over 10 minutes on Day 1 every 3 weeks
Carboplatin: AUC 5 intravenous infusion over 1 hour on Day 1 every 3 weeks"
1777163|NCT00407472|Device|ATS-1 needle free device|
1777164|NCT00407485|Biological|ziv-aflibercept|Given IV
1777165|NCT00407485|Other|pharmacological study|Correlative studies
1777166|NCT00407498|Drug|P276-00|Starting dose of 9 mg/m2/day from day 1to 5 and day 8 to 12 in 21 day cycle.Protocol wa amended to dose the subjects for day 1 to5 in 21 day cycle after 34.4 mg/m2/day cohort.Maximum dose administered was 259 mg/m2/day
1777167|NCT00407511|Drug|Pregabalin|Pregabalin will be administered orally, twice a day for 12 weeks, including 4-week dose adjustment phase followed by 8-week maintenance phase. The minimum allowable pregabalin dose during the trial will be 75 mg BID (150 mg/day) and the maximum allowable dose will be 300 mg BID (600 mg/day).
1777168|NCT00407524|Drug|AKL 1|
1777169|NCT00407537|Drug|Amlodipine besylate/atorvastatin calcium single pill combination|Open label amlodipine besylate/atorvastatin calcium single pill combination at multiple doses: 5/10, 10/10, 5/20, 10/20 mg prescribed at the investigator's discretion
1777170|NCT00407550|Drug|gemcitabine HCL|1250 mg/m^2 administered through 250 cc NS (normal saline) IV (intravenous) infusion over 30 minutes at days 1 & 8 of each cycle (21 days) x6 cycles.
1777171|NCT00407550|Drug|pemetrexed disodium|500 mg/m^2 administered through 100 mL NS IV infusion over 10 minutes at day 1 of each cycle.
1777172|NCT00407550|Drug|gemcitabine HCL|1500 mg/m^2 administered through 250 cc NS IV infusion over 30 minutes at days 1 of each cycle (14 days) x9 cycles.
1777173|NCT00407563|Drug|Bevacizumab|Bevacizumab will be given via IV infusion at 10mg/kg given on days 1 and 15 of a 28-day cycle.
1777174|NCT00407563|Drug|Abraxane|Abraxane will be given via IV infusion at 100mg/m²over 30 minutes on days 1, 8, and 15 of a 28-day cycle.
1777175|NCT00407576|Drug|[11C]MeS-IMPY|
1777176|NCT00407589|Drug|BOL-303224-A|1 drop in each eye, TID for 5 days at approximately 6 h intervals, with a final, single dose on the morning of Visit 7 (Day 6).
1777177|NCT00407602|Device|Argus II Retinal Stimulation System|epiretinal implantation of device
1777178|NCT00407615|Device|Flex Pad/Static Magnet|
1777179|NCT00407641|Drug|Tinzaparin administration|Patients will receive tinzaparin during the HD session
1777180|NCT00407641|Drug|Heparin administration|Patients will receive Heparin as an anticoagulant during the HD session.
1777181|NCT00407654|Drug|aflibercept|Given intravenously
1777182|NCT00407667|Device|transcranial galvanic stimulation|for tDCS: Siemens Universal-Neuroton 826 for arm training: Bi-Manu-Track, Reha-Stim, Berlin
1777183|NCT00407680|Drug|Intensive therapy Valsartan,Fluvastatin|
1777184|NCT00407693|Drug|[C-11]PRB28|
1777185|NCT00407706|Procedure|blood test|
1777186|NCT00407719|Drug|Bevacizumab|
1777187|NCT00407732|Behavioral|psychosocial intervention|motivational enhancing case management intervention
1777188|NCT00407745|Drug|placebo|Placebo
1777189|NCT00407745|Drug|pregabalin|Pregabalin capsules taken twice daily up to 17 weeks (150-600 mg/day)
1777190|NCT00413426|Drug|Darifenacin (DAR328)|
1777191|NCT00413439|Drug|Isavuconazole|Intravenous solution or oral capsules
1777192|NCT00413452|Drug|Etanercept|50 mg once weekly
1777193|NCT00413465|Drug|Escherichia Coli Endotoxin|
1777194|NCT00413478|Drug|5-Azacytidine|Starting dose level: 75mg/m^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
1777195|NCT00413491|Procedure|MR mammography|MR mammography
1777196|NCT00413491|Procedure|MR|MR
1777197|NCT00413504|Drug|Fondaparinux|
1777198|NCT00413517|Procedure|Epi-Lasik|A vision correcting surgery
1777199|NCT00413543|Other|early pulmonary lung rehabilitation|early pulmonary rehabilitation, 10 days after discharge
1777200|NCT00413556|Biological|ALK Grass tablet|
1777201|NCT00413569|Procedure|cervical spine surgery|
1777202|NCT00413582|Drug|Epidural Analgesia|Upon arrival to the operating room, patients will have a thoracic epidural (T 6-9) placed while in the sitting position. All epidural catheters will be inserted 3-5 cm within the epidural space and will be placed by attending anesthesiologists. Patients will receive midazolam 0.025 - 0.05 mg/kg IV (max 5mg) and/or fentanyl 0.5 - 2 mcg/kg IV for comfort during the procedure. Once the epidural is placed, the patient will be positioned for surgery. The epidural catheter will be initially bolused with 0.3ml/kg of ropivacaine 0.10% (max 10 ml), fentanyl 1 - 1.2 mcg/kg and clonidine 1.8 - 2mcg/kg. An infusion of ropivacaine 0.10%, fentanyl 2mcg/ml and clonidine 1.5mcg/ml will be initiated immediately at the rate of 0.3ml/kg/hr (max 10ml/hr). Intraoperatively, patients will receive intravenous fentanyl if indicated.
1777203|NCT00413582|Drug|Patient-Controlled IV Analgesia|In the PCA arm, patients will receive fentanyl (3-6 mcg/kg) at anesthesia induction. Additional fentanyl may be administered intraoperatively as indicated. Patients who are > 35 Kg. (in keeping with current FDA approved labeling) will receive a clonidine 0.1 mg/day transdermal patch to the deltoid immediately after induction of anesthesia. Subjects in the epidural arm also receive clonidine. Upon arrival to the post anesthesia care unit, patients will be placed on a patient controlled analgesic (PCA) pump (hydromorphone: loading dose if needed; 5-6 mcg/kg continuous infusion; 5-6 mcg/kg six minute demand dose). An additional hydromorphone dose (8mcg/kg) will be available every 2 hours for pain scores of > 4/10 throughout the duration of PCA use.
1777204|NCT00413595|Other|No intervention|Observational, epidemiological, prognosis study; no drug tested; only laboratory analysis and diagnostic interventions done.
1777205|NCT00413608|Drug|Clopidogrel|Clopidogrel
1777206|NCT00413634|Drug|anagrelide hydrochloride|Anagrelide hydrochloride 0.5 mg per capsule; patients will be stable on an anagrelide treatment regimen and will take capsules from their own prescription except on the PK day when the patient specific anagrelide dose will be administered from a controlled study specific supply.
1777207|NCT00413647|Drug|CardioPET|
1777208|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
1777209|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
1777210|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
1777211|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
1777212|NCT00413660|Drug|CP-690,550|4 blinded tablets administered BID
1777213|NCT00413660|Drug|CP-690,550|Oral tablets
1777214|NCT00413660|Other|placebo|Placebo
1777215|NCT00413673|Procedure|PRK|PRK
1777216|NCT00413686|Drug|AZD7762|intravenous infusion
1777217|NCT00413686|Drug|Gemcitabine|weekly intravenous infusion
1777220|NCT00413712|Drug|Calcium Channel Blocker & Adenosine|
1777221|NCT00413725|Biological|MRKAd5 HIV-1 gag/pol/nef|Experimental Clade-B based Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine
1777222|NCT00413725|Other|Placebo|Placebo
1777223|NCT00413738|Device|Antiseptic-coated central venous catheters|
1777224|NCT00413751|Drug|Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)|
1777225|NCT00413764|Drug|tibolone|tibolone (2.5 mg) over 24 weeks
1777226|NCT00413764|Drug|estradiol-norethisterone|transdermal continuous combined E2-NETA (estradiol-norethisterone 50/140 mcg) over 24 weeks
1777227|NCT00414505|Device|Intradermal Acupuncture Treatment|
1777228|NCT00414518|Drug|Tenofovir disoproxil fumarate/Emtricitabine|300 mg Tenofovir disoproxil fumarate/ 200 mg emtricitabine tablet taken orally once daily
1777229|NCT00414518|Drug|Lopinavir/Ritonavir|Three 400 mg lopinavir/ 100 mg ritonavir soft gel capsules taken orally twice daily
1777230|NCT00414531|Drug|Atorvastatin|20 to 80 mg per day
1777231|NCT00414544|Device|CosmetaLife|Dermal filler
1777232|NCT00414544|Device|Restylane|Dermal filler
1777233|NCT00414557|Procedure|Quadriceps strengthening|
1777234|NCT00414570|Procedure|Positron-Emission Tomography (PET) 18F-FLT|
1777235|NCT00414583|Other|No intervention|Observational study, only laboratory analysis and diagnostic interventions done; no drug tested
1777236|NCT00414596|Device|DRX9000™|Device is designed to apply spinal decompressive forces.
1777237|NCT00414609|Drug|Aliskiren|Aliskiren was available in 75 mg tablet, 150 mg tablet
1777238|NCT00414609|Drug|placebo|Placebo tablets matching aliskiren for 36 weeks once daily in the morning for core period only.
1777240|NCT00414635|Drug|Intermitent Dosing|"Intermittent dosing treatment is the maintenance of the 5/2 schedule, where the regimen, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine is dosed for 5 consecutive days - typically Monday through Friday - followed by two days off of medication, 300 mg tenofovir td, 600 mg efavirenz, 200 mg emtricitabine. ."
1777241|NCT00414648|Drug|Sirolimus|A sirolimus dose of 2 mg will be given in the form of 2 tablets (1 mg/tablet) per day for 1 year.
1777242|NCT00414648|Drug|Placebo sirolimus|A placebo dose of 2 mg will be given in the form of 2 tablets (1 mg/tablet) per day for 1 year.
1777243|NCT00414661|Drug|CP-690,550|Subjects had to have received CP-690,550 or other blinded study drug in index study. No intervention in this long-term follow-up trial.
1777244|NCT00414687|Drug|Ventavis (Iloprost, BAYQ6256)|
1777245|NCT00414700|Drug|ChondroCelect implantation|"10.000 cells/µl cell suspension for implantation (Autologous Chondrocyte Implantation). ChondroCelect consists of characterised autologous cartilage-forming cells expressing a specific marker profile.
The dose depends on the size of the lesion. Recommended dose is 0.8 to 1.0 million cells/cm²."
1777246|NCT00414700|Procedure|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form scar tissue.
1777247|NCT00414713|Procedure|red blood cell transfusion|red blood cell transfusion
1777250|NCT00414739|Drug|Benzalkonium chloride|
1777251|NCT00414752|Drug|AFQ065|
1777252|NCT00414765|Drug|Aldesleukin|
1777253|NCT00414778|Drug|LHT344|
1777254|NCT00414804|Device|Precision SCS|Precision Spinal Cord Stimulation (SCS) Therapy
1777255|NCT00414804|Procedure|Nerve Blocks and PT|Pain therapy utilizing Nerve Blocks with Physical Therapy
1777256|NCT00414817|Behavioral|Automated Phone-Based Refill Reminders|The BREATHE EASY Medication Reminder Program uses interactive voice recognition phone technology to offer timely reminders to patients to refill their ICS medication, educational messages about ICS, and may offer to transfer them to a refill line or to speak with a pharmacist if they have questions.
1777257|NCT00414856|Drug|AFQ056|
1777258|NCT00414869|Drug|NCX-1000|500 mg powder sachets to be taken as 1, 2, or 4 sachets twice daily, PO x 16 days
1777259|NCT00414869|Drug|Placebo|Inactive powder matching NCX-1000
1777260|NCT00414908|Drug|Pancrelipase delayed release capsule|24,000 unit capsule
1777261|NCT00414908|Drug|Placebo Comparator|Placebo
1777262|NCT00414921|Drug|clonidine|Clonidine is FDA-approved for the treatment of hypertension in adults
1777263|NCT00414921|Drug|methylphenidate|Methylphenidate is known to safely and effectively treat many ADHD symptoms.
1777264|NCT00414921|Other|placebo|inactive substance
1777265|NCT00414947|Drug|Vildagliptin (LAF237)|
1777266|NCT00414960|Drug|enzastaurin|500 mg, daily, oral, 6 months
1777267|NCT00414960|Drug|placebo|oral, daily
1777268|NCT00414973|Drug|Teriparatide|Subcutaneous, 20 micrograms/day, 24 weeks
1777269|NCT00414973|Drug|Salmon Calcitonin|Intranasal, 200 International Units (IU)/day, 24 weeks
1777270|NCT00414986|Behavioral|Standard CQI intervention|In-practice change facilitator assists the practice in implementing a chronic disease registry
1777271|NCT00414986|Behavioral|Chronic Care Improvement (CCI) Intervention|An in-practice change facilitator will assist the Improvement Team in enhancing the relationship infrastructure of the practice and in implementing diabetes and depression office systems.
1777272|NCT00414986|Behavioral|Self-directed practice comparison|Practices will have access to all tools used in Arm 1 via a project website
1777273|NCT00414999|Drug|TG100801|
1777274|NCT00415025|Procedure|adjuvant therapy|
1777275|NCT00415025|Procedure|management of therapy complications|
1777276|NCT00415025|Procedure|quality-of-life assessment|
1777277|NCT00415025|Radiation|intensity-modulated radiation therapy|
1777278|NCT00415038|Drug|Rostafuroxin|1 capusle of 50 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
1777279|NCT00415038|Drug|Rostafuroxin|1 capusle of 150 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
1777280|NCT00415038|Drug|Rostafuroxin|1 capusle of 500 micrograms of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
1777281|NCT00415038|Drug|Rostafuroxin|1 capusle of 1.5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
1777282|NCT00415038|Drug|Rostafuroxin|1 capusle of 5 milligrams of Rostafuroxin or placebo per day in the morning before breakfast for 5 weeks followed by other 5 weeks with placebo or Rostafuroxin
1777283|NCT00415051|Biological|RVF MP-12|Administer 1 ml SQ
1777284|NCT00415064|Drug|Perifosine|Perifosine given in either 50 mg or 100 mg / day
1777285|NCT00415064|Drug|Lenalidomide|Lenalidomide given in either 15 or 25 mg / day
1777286|NCT00415064|Drug|Dexamethasone|Dexamethasone given in 20 mg / day
1777287|NCT00415077|Procedure|PRK|PRK
1777288|NCT00415077|Procedure|MMC PRK|mitomycin C PRK
1777289|NCT00415077|Procedure|LASEK|LASEK
1777290|NCT00415090|Drug|Nevirapine|Switch one of ARV drugs to Nevirapine
1777291|NCT00415103|Drug|Aprepitant|Aprepitant: 125 mg oral day 1, follows by 80 mg oral every 24 hours in next days
1777292|NCT00415103|Drug|Palonosetron|Palonosetrón: 0.25 mg iv every 48 hours, starting day 1
1777293|NCT00415103|Drug|Granisetron|Granisetrón : 3 mg iv day, all days the patient will be treated with chemotherapy, and Aprepitant placebo 125 mg oral, day 1, and 80 mg next days in chemotherapy treatment
1777294|NCT00415116|Drug|carboplatin|
1777295|NCT00415116|Drug|docetaxel|
1777296|NCT00415116|Drug|lenalidomide|
1777297|NCT00415129|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
1777298|NCT00415129|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5mL, Intramuscular
1777299|NCT00415142|Drug|saredutant (SR48968)|oral administration (capsules)
1777300|NCT00415142|Drug|placebo|oral administration (capsules)
1777301|NCT00415142|Drug|escitalopram|oral administration (capsules)
1777302|NCT00415155|Drug|LY2181308|"Phase 1: 250mg, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle. (dose escalation)
Phase 2: phase 1 recommended dose, maximum 750mg dose, IV, loading dose days 1-3 cycle 1 then weekly for six 28 day cycle."
1777303|NCT00415168|Drug|pemetrexed|700 milligrams/meters squared (mg/m2), intravenous (IV), every 21 days x 6 cycles
1777304|NCT00415168|Drug|cisplatin|75 mg/m2, IV, every 21 days x 6 cycles
1777305|NCT00415194|Drug|pemetrexed|500 mg/m^2, IV, every 21 days, six 21 day cycles
1777306|NCT00415194|Drug|cisplatin|75 mg/m^2, administered IV, every 21 days, six 21 day cycles
1777307|NCT00415194|Drug|placebo|Approximately 100 mL normal saline administered IV, every 21 days, six 21 day cycles
1777308|NCT00415220|Procedure|Spinal Manipulation, Microdiscectomy|
1777311|NCT00415246|Drug|Triptorelin (Decapeptyl®) - Treatment 8 months (pivotal study) followed by a treatment extension of 8 months (extension study)|
1777312|NCT00415259|Device|Laterally wedged shoe insoles|Full-length 5 degree lateral wedged insoles worn inside the shoes daily for 12 months
1777313|NCT00415259|Device|Control insole group|Flat control insoles worn inside the shoes daily for 12 months
1777314|NCT00415272|Behavioral|Pulmonary Rehabilitation|
1777315|NCT00415285|Drug|Docetaxel|
1777316|NCT00415285|Drug|Capecitabine|
1777317|NCT00415285|Drug|Docetaxel/Capecitabine|
1777318|NCT00415298|Drug|DACH polymer platinate AP5346|
1777319|NCT00415298|Drug|oxaliplatin|
1777320|NCT00415298|Genetic|gene expression analysis|
1777321|NCT00415298|Other|immunohistochemistry staining method|
1777322|NCT00415298|Other|pharmacological study|
1777323|NCT00415298|Procedure|biopsy|
1777324|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
1777325|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
1777326|NCT00415311|Drug|Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Intravenous(i.v.) administration for 8 weeks. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
1777327|NCT00415324|Drug|eribulin mesylate|Given IV
1777328|NCT00415324|Drug|cisplatin|Given IV
1777329|NCT00415324|Other|laboratory biomarker analysis|correlative study
1777330|NCT00415324|Other|pharmacological study|correlative study
1777331|NCT00415337|Procedure|endobronchial ultrasound|EBUS
1777332|NCT00415350|Drug|Azithromycin|Azithromycin Tablet 250 mg daily
1777333|NCT00415350|Other|Placebo|Placebo tablet 1 daily
1777334|NCT00415363|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
1777335|NCT00415363|Drug|placebo|oral, daily
1777336|NCT00415376|Drug|levetiracetam|
1777337|NCT00415376|Procedure|quality-of-life assessment|
1777338|NCT00415389|Behavioral|interactive educational program|2-session interactive stroke educational program
1777339|NCT00415389|Behavioral|usual medical care|standard educational materials and usual care
1777340|NCT00415402|Drug|Vitamin D3|
1777341|NCT00415428|Behavioral|Patient adherence to national educational guidelines.|
1777342|NCT00415441|Procedure|Physiotherapy program|
1777343|NCT00415441|Procedure|Placebo physiotherapy treatment|
1777344|NCT00415454|Genetic|Ad5-yCD/mutTKSR39rep-ADP|Single injection on day 1 at one of five dose levels
1777345|NCT00415467|Device|GliaSite Radiation Therapy System|Radiation delivery system that provides brachytherapy targeted to a specific site in the brain, to see its effects to the surrounding area where the tumor was located.
1777346|NCT00415493|Other|Cold-dry air provocation|15 minute exposure to cold-dry air by nasal mask
1777347|NCT00415493|Other|Warm-moist air provocation|15 minute exposure to warm-moist air by nasal mask
1777348|NCT00415506|Drug|Rituximab|Two 500 or 1000mg infusions over 2 weeks with the option of retreating after 6 months if initial improvement was seen.
1777351|NCT00415532|Drug|Medical Standard of Care for ITP|
1777352|NCT00415532|Biological|Romiplostim|
1777353|NCT00415545|Behavioral|Fluid Watchers LITE Educational Intervention|Patients in Fluid Watchers LITE will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written material, a diary, a scale and a telephone follow-up to answer any questions they might have about the educational session.
1777354|NCT00415545|Behavioral|Fluid Watchers PLUS Educational Intervention|Patients in Fluid Watchers PLUS will receive counseling about HF and self-monitoring, and coaching on seeking care. They will receive written materials, a diary, a scale, an audio tape of the session and telephone followup. Participants in the PLUS program will receive additional counseling, audio tapes, and follow-up telephone calls on a biweekly basis, as compared to participants in the LITE program.
1777355|NCT00415558|Device|Microwave Ablation System|
1777356|NCT00415571|Drug|Fispemifene (once daily for 8 weeks)|
1777357|NCT00415584|Drug|Cinacalcet HCl|
1777358|NCT00415597|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride ER)|capsules, available dosage strengths 20, 30, 40, 50, 60, 80, and 100 mg morphine sulfate with 4% by weight naltrexone hydrochloride given once or twice daily
1777359|NCT00415610|Drug|nicardipine|"Intravenous (IV) nicardipine infusion. It is expected that the treatment duration will vary between 18 and 24 hours.
Started at 5mg/h
Titrated by 2.5mg/hour every 15 minutes to bring systolic blood pressure in target range for the applicable Tier. Max dose 15mg/hour *Once target systolic blood pressure reached, dose decreased by 2.5mg/hour every 15 minutes until systolic blood pressure maintained in the target range or the medication is discontinued."
1777360|NCT00415623|Drug|Amlodipine|Amlodipine 5mg/ day
1777361|NCT00415623|Drug|Amlodipine|Amlodipine 10mg/ day
1777475|NCT00416455|Drug|ferumoxtran-10|Undergo femoxtran-10 MRI
1777362|NCT00415636|Drug|IC83/LY2603618|40 mg/m2 day 1 and day 9 cycle 1, day 2 of subsequent cycles, unlimited 21 day cycles. Dose finding study: dose is escalated after a minimum of 6 patients receive 40 mg/m2.
1777363|NCT00415636|Drug|pemetrexed|pemetrexed 500 mg/m2, IV, day 8 of cycle 1, day one of subsequent cycles, unlimited 21 day cycles
1777364|NCT00415649|Biological|VRC-HIVDNA016-00-VP|
1777365|NCT00415649|Biological|VRC-HIVADV014-00-VP|
1777366|NCT00415649|Biological|Vaccine placebo|Placebo comparator
1777367|NCT00415662|Device|Pulsed Signal Therapy (PST)|
1777368|NCT00415675|Procedure|Motion CT Scans|A total of up to 12 scanning sessions used to understand how the tumor and other organs move while breathing.
1777369|NCT00415688|Behavioral|Low carbohydrate, ketogenic diet|
1777370|NCT00415688|Behavioral|Low glycemic index, reduced calorie diet|
1777371|NCT00415701|Drug|Etomidate|Single induction dose of etomidate 0.2%; total dose 0.15 mg/kg
1777372|NCT00415701|Drug|Propofol|Single induction dose of propofol 2%; total dose 1.5 mg/kg
1777373|NCT00415701|Drug|Hydrocortisone|Hydrocortisone 100 mg/2 ml: day of operation 3x, POD 1 2x, POD 2 1x
1777374|NCT00415701|Drug|NaCl 0.9%|NaCl 0.9% 2 ml; day of operation 3x, POD 1 2x, POD 2 1x
1777375|NCT00415701|Other|Tetracosactin|Diagnostic test, Tetracosactin 250 microg iv
1777376|NCT00415714|Device|Portable Biofeedback|
1777377|NCT00415727|Device|auto Continuous Positive Airways Pressure (CPAP) with oxygen supplementation|
1777378|NCT00415740|Drug|ELC200 (carbidopa+levodopa+entacapone)|
1777379|NCT00415753|Behavioral|No antibiotics if se-procalcitonin is below stated limit|
1777380|NCT00415766|Drug|rHCG 250ug|Injection of 250 ug Ovitrelle to trigger final oocyte maturation
1777381|NCT00415766|Drug|uHCG 5000 IU|Injection of 5000 IU Pregnyl to trigger final oocyte maturation
1777382|NCT00415766|Drug|uHCG 7500 IU|Injection of 7500 IU Pregnyl to trigger final oocyte maturation
1777383|NCT00415779|Drug|docetaxel|given IV in subsequent cohorts of patients at 30, 40, or 50mg/m2
1777384|NCT00415779|Drug|zoledronic acid|2 mg IV every 2 weeks
1777385|NCT00415792|Drug|Arvekap, Pregnyl|
1777386|NCT00415805|Drug|Multihance|0.5 Molar, single injection at 0.2 mL/kg
1777387|NCT00415805|Drug|vasovist|0.25 molar single injection 0.03 ml/kg
1777388|NCT00415818|Biological|MVA-MUC1-IL2|"MVA-MUC1-IL2:
Dose of 10exp8 plaque forming units (pfu).
Chemotherapy:
Arm 1 and Arm 2 Intravenous CT: cisplatin (75mg/m² at Day 1) and gemcitabine (1250mg/m² at Days 1 and 8) every 3 weeks, for up to six cycles or until progressive disease, whichever occurred first."
1777389|NCT00415818|Drug|1st line Chemotherapy|
1777390|NCT00415831|Drug|ELC200 (carbidopa+levodopa+entacapone)|
1777391|NCT00415844|Drug|ELC200 (carbidopa+levodopa+entacapone)|
1777392|NCT00415857|Biological|Peptide Vaccine (PR1 Peptide)|PR1 peptide will be administered at a dose of 0.5 mg of PR1 on weeks 0, 3, 6 and 18 for a total of 4 doses.
1777393|NCT00415857|Drug|Peginterferon alfa-2b|Subcutaneous injection of interferon 0.5 microg/kg with each PR1 vaccination.
1777394|NCT00415857|Drug|Imatinib|Continue receiving imatinib by mouth at the same dose received during the last 6 months.
1777395|NCT00415857|Drug|GM-CSF|75 micrograms subcutaneously in the same area as the vaccine with every vaccination.
1777396|NCT00415870|Behavioral|Printed Material|Printed Material
1777397|NCT00415870|Behavioral|Weekly Weighing|Weekly Weighing
1777398|NCT00415870|Behavioral|Cell phone will serve as a self monitoring device|Cell phone will serve as a self monitoring device
1777399|NCT00415870|Device|Text Message|Text Message
1777400|NCT00415870|Behavioral|Diet Goals via Cell Phone|Diet Goals via Cell Phone
1777401|NCT00415870|Behavioral|Food Monitoring|Food Monitoring
1777402|NCT00415883|Drug|Valsartan|
1777403|NCT00415896|Device|positive pressure ventilation|
1777404|NCT00415909|Drug|Imatinib Mesylate (IM)|IM Therapy of (100 mg or 400 mg) tablets by mouth, same dose each day.
1777405|NCT00415909|Drug|TALL-104 cells|TALL-104 cells will be given intravenously over 1 hour at the dose of 109 cells daily for 4 days, on days 1 to 4 of the cycle, and then again on days 7, 10, 14, 17 and 21 of the cycle. One cycle is equal to 28 days. Patients will receive only one cycle of therapy with TALL-104 cells
1777406|NCT00415922|Drug|ELC200 (carbidopa+levodopa+entacapone)|
1777407|NCT00415935|Drug|methotrexate|
1777408|NCT00415948|Device|Biomarkers|
1777409|NCT00415961|Device|CoStar Paclitaxel Drug-Eluting Coronary Stent System|CoStar Paclitaxel Drug-Eluting Coronary Stent System
1777410|NCT00415974|Behavioral|Physician Counseling|Physician-patient visits will occur in the primary care setting and are scheduled at study onset (beginning of step 1) and at the end of the first year. An extra physician visit will occur for patients who do not progress from step 1 after two attempts. At study entry, physicians will discuss the purpose and importance of the intervention and encourage participation. Physicians will underline the value of attending all study visits and complying with study protocol and instructions. Subsequent physician visits will focus on weight loss progress and overcoming barriers.
1777411|NCT00415974|Behavioral|Health Educator|Health education sessions are held with teens and parents at the primary care setting. These include information on nutrition, physical activity, and weight loss. Behavioral approaches are used to enhance the home environment, food preparation, and planned physical activity to elicit weight loss, including discovery of perceived and actual barriers to modification of eating and physical activity behaviors. The Health Educator focuses on problem-solving and tailored selection of behavior change skills to help participants overcome difficulties. In addition to reviewing the assessment and generating solutions to barriers, sample meal plans (including strategies for restricting calories) and pedometers will be distributed at the initial health educator visit. Pedometers are encouraged to monitor progress with physical activity goals. An initial binder is distributed to teen and parent participants at the initial session and subsequent materials are added with each visit.
1777476|NCT00416455|Procedure|magnetic resonance imaging|Undergo femoxtran-10 MRI
1777477|NCT00416455|Procedure|diagnostic lymphadenectomy|Undergo extraperitoneal, laparoscopic, or trans-peritoneal lymphadenectomy
1777478|NCT00416455|Procedure|lymph node biopsy|Undergo pelvic and abdominal lymph node biopsy
1777479|NCT00416468|Drug|Aliskiren|
1777412|NCT00415974|Behavioral|Phone Counseling|Brief counseling calls will occur between PACE-PC participants and assigned counselors during all steps. In general, these calls occur on a bi-weekly to monthly basis in steps 1 and 2, and monthly in step 3. Such calls are intended to encourage continued goal attainment and progression and to promote healthy eating and physical activity behaviors. Counselors will review progress since the last clinical interaction (e.g., health educator visit, phone call, or physician visit) and help adolescents set new goals that are appropriate and attainable. Data from pedometers may be discussed during these sessions as an interim assessment of progress on physical activity behaviors between formal study measurement visits. After speaking with the adolescent, the counselor will talk with the parent (when feasible) to reinforce parental involvement and emphasize the importance of the healthy changes in the home environment to encourage goal attainment.
1777413|NCT00415974|Behavioral|Health promotion materials on physical activity and nutrition|PACE-PC adolescents and their families will receive information regarding healthy eating and physical activity behaviors on a weekly basis via mail. These behavioral-based materials will educate participants and their families on healthy behaviors that are necessary for successful weight management. Topics will coincide with the intervention goals and include supplemental information to enhance quality of life and improve body image. Topics will include realistic goal-setting and attainment, how to handle holidays and celebrations, eating fast food, grocery shopping and food preparation, and relapse prevention, etc.. Topics will include specific strategies related to the adolescent's readiness to change to reflect processes that are most appropriate. Content from these materials will be addressed by the phone counselors to ensure that participants received and understood intervention messages.
1777414|NCT00415987|Procedure|Hematopoietic Stem Cell Transplantation|
1777415|NCT00416026|Behavioral|Educational/Counseling/Training|
1777416|NCT00416039|Drug|Midazolam|0.2 mg/kg of sublingual midazolam and 0.5 mg/kg of morphine
1777417|NCT00416039|Drug|Placebo|placebo at 0.2 mg/kg and morphine 0.5 mg/kg
1777418|NCT00416065|Device|PET/CT imaging|
1777419|NCT00416078|Behavioral|caregiver website support|caregiver access to website support for 6 months embedded in one year of customary care
1777420|NCT00416078|Behavioral|caregiver brief supportive phone calls|caregiver brief supportive telephone calls for 6 months embedded in one year of customary care
1777421|NCT00416117|Procedure|Manual Physical Therapy and Exercise|
1777422|NCT00416117|Procedure|Minimal Intervention|
1777423|NCT00416130|Drug|Vorinostat|MK-0683 capsules, 100 mg, 400mg once a day, continuously (at dose level 0 - Phase 1 part of the study)
1777424|NCT00416143|Procedure|bed rest|
1777425|NCT00416143|Drug|prednisone - oral corticosteroid 1mg/kg/D for 1 week|
1777426|NCT00416156|Behavioral|Lifestyle modification|
1777427|NCT00416169|Drug|galantamine hydrobromide|
1777428|NCT00416182|Drug|Pulmozyme (dornase alfa)|2.5 mg/2.5 mL of Pulmozyme (dornase alfa) delivered via Sinustar nasal nebulizer device
1777429|NCT00416182|Drug|Placebo|2.5 mL of placebo delivered via Sinustar nebulizer device
1777430|NCT00416195|Drug|E2007|
1777431|NCT00416195|Drug|Placebo|
1777432|NCT00416208|Drug|Bortezomib|1.6 mg/m2 i.v. d1 d8 d15 d22 for 4 cycles each of 35 days
1777433|NCT00416221|Drug|Lexapro, an antidepressant medicine|
1777434|NCT00416221|Behavioral|Physical Activity|
1777435|NCT00416221|Behavioral|Mood Management Skills|
1777436|NCT00416221|Behavioral|Personalized support from a Family Nurse Practitioner|
1777437|NCT00416234|Procedure|Laparoendoscopic Rendez vous|intraoperative ERCP for CBD clearance during laparoscopic cholecystectomy
1777438|NCT00416234|Procedure|preoperative ERCP and CBD clearance|ERCP and CBD clearance followed by laparoscopic cholecystectomy
1777439|NCT00416247|Behavioral|Hypnosis|Hypnosis
1777440|NCT00416260|Other|High Frequency Oscillation and Tracheal Gas Insufflation|Intermittent combined use of High Frequency Oscillation and Tracheal Gas Insufflation until the PaO2/inspired oxygen fraction ratio remains above than 150 mm Hg for more than 24 hours.
1777441|NCT00416273|Drug|Bortezomib|Bortezomib will be administered as 1.6 mg/m2 per body surface area on the days 1, 8, 15, 22 for the duration of 4 therapy cycles.
1777442|NCT00416273|Drug|No intervention|Participants in the observation group will be observed and will not receive any consolidation therapy.
1777450|NCT00416325|Dietary Supplement|lycopene|
1777451|NCT00416325|Other|laboratory biomarker analysis|
1777452|NCT00416338|Device|film dressing by adhesive|
1777453|NCT00416351|Drug|clofarabine|
1777454|NCT00416377|Biological|bleomycin sulfate|
1777455|NCT00416377|Drug|chlorambucil|
1777456|NCT00416377|Drug|dacarbazine|
1777457|NCT00416377|Drug|doxorubicin hydrochloride|
1777458|NCT00416377|Drug|prednisolone|
1777459|NCT00416377|Drug|procarbazine hydrochloride|
1777460|NCT00416377|Drug|vinblastine sulfate|
1777461|NCT00416377|Drug|vincristine sulfate|
1777462|NCT00416377|Radiation|radiation therapy|
1777463|NCT00416390|Dietary Supplement|lycopene|
1777464|NCT00416390|Other|laboratory biomarker analysis|
1777465|NCT00416390|Procedure|biopsy|
1777466|NCT00416403|Drug|fluvastatin sodium|Given orally
1777467|NCT00416403|Procedure|Breast Cancer Surgery Only - Arm III|Breast Cancer Surgery
1777468|NCT00416429|Biological|aldesleukin|
1777469|NCT00416429|Biological|recombinant interferon alpha-2a|
1777470|NCT00416429|Drug|medroxyprogesterone|
1777471|NCT00416442|Drug|RSV604|
1777472|NCT00416455|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
1777473|NCT00416455|Procedure|positron emission tomography|Undergo FDG PET/CT
1777474|NCT00416455|Procedure|computed tomography|Undergo FDG PET/CT
1777481|NCT00416481|Behavioral|quality of life questionnaires|
1777482|NCT00416494|Biological|bevacizumab|10 mg/kg intravenously over 30-90 minutes on day 1
1777483|NCT00416494|Drug|oxaliplatin|85 mg/m2 intravenously over 2 hours on day 1.
1777484|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 1000 mg/m2 in initial cohort
1777485|NCT00416494|Drug|Capecitabine|Oral administration every 12 hours on days 1-5 and 8-12 850 mg/m2 in second cohort
1777486|NCT00416507|Drug|fluorouracil|
1777487|NCT00416507|Drug|gemcitabine hydrochloride|
1777488|NCT00416507|Drug|liposomal cisplatin|
1777489|NCT00416520|Drug|MCI-196 (Colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose and 4 weeks of double blind
1777490|NCT00416520|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
1777491|NCT00416520|Drug|Another phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
1777492|NCT00416533|Drug|docetaxel|
1777493|NCT00416533|Drug|doxorubicin hydrochloride|
1777494|NCT00416533|Drug|prednisone|
1777495|NCT00416546|Drug|AEB071|
1777496|NCT00416559|Other|clinical observation|
1777497|NCT00416572|Behavioral|Education Intervention|Sessions were led by two professionals with expertise in the topic. The sessions began a with presentation of informational material followed by guided discussion of related topics. The first session discussed what to say and not say to children about cancer and how to create a safe environment for them; the second session discussed carrying on with life after the diagnosis of breast cancer, including strategies for managing stress and anxiety and developing meaning in life; the third session talked about how to maintain closeness with a partner and ways to talk about breast cancer; the last session focused on the effects of treatment on reproductive status, and the genetic bases of breast cancer. Participants were also given related booklets and brochures to take home to read.
1777498|NCT00416572|Behavioral|Nutrition Education Intervention|The nutrition sessions were presented by a professional trained in nutritional science. Sessions included the presentation of information and guided discussion of related topics. The first session discussed information on choosing fruits, vegetables, and low-fat foods and incorporating them into a diet; the second session involved a demonstration of low-fat cooking methods; the third session provided information on the nutritional make-up of a healthy diet and how to shop for it; the last session included information on how to maintain a healthy, low-fat diet while eating out. Women were also asked to keep a four-day food diary, to focus them on their dietary intake and control over it.
1777499|NCT00416585|Drug|isotretinoin (Roaccutane)|
1777500|NCT00416598|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous bone marrow transplantation
1777501|NCT00416598|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplantation
1777502|NCT00416598|Drug|Busulfan|Given IV
1777503|NCT00416598|Drug|Cytarabine|Given IV
1777504|NCT00416598|Drug|Daunorubicin Hydrochloride|Given IV
1777505|NCT00416598|Drug|Decitabine|Given IV
1777506|NCT00416598|Drug|Etoposide|Given IV
1777507|NCT00416598|Biological|Filgrastim|Given SC
1777508|NCT00416598|Other|Laboratory Biomarker Analysis|Correlative studies
1777509|NCT00416598|Other|Pharmacological Study|Correlative studies
1777510|NCT00416611|Behavioral|Implementation of guidelines|
1777511|NCT00416624|Drug|darbepoetin alfa|
1777512|NCT00416624|Drug|epoetin alfa|
1777513|NCT00416624|Procedure|fatigue assessment and management|
1777514|NCT00416624|Procedure|quality-of-life assessment|
1777515|NCT00416637|Biological|Bevacizumab (Avastin)|
1777516|NCT00416650|Drug|erlotinib hydrochloride|All patients will receive 150 mg orally daily
1777517|NCT00416663|Procedure|Intracoronary administration of autologous ACPs|Stem cells type:ACPs. At least 1.5 million of ACPs per one time of treatment
1777518|NCT00416676|Drug|carboplatin|
1777519|NCT00416676|Drug|cisplatin|
1777520|NCT00416676|Drug|cyclophosphamide|
1777521|NCT00416676|Drug|etoposide|
1777522|NCT00416676|Drug|vincristine sulfate|
1777523|NCT00416676|Procedure|adjuvant therapy|
1777524|NCT00416676|Procedure|conventional surgery|
1777525|NCT00416676|Procedure|neoadjuvant therapy|
1777526|NCT00416676|Radiation|radiation therapy|
1777527|NCT00416689|Procedure|assessment of therapy complications|
1777528|NCT00416689|Procedure|quality-of-life assessment|
1777529|NCT00416702|Drug|QAB149|
1777530|NCT00416715|Drug|letrozole|Given PO
1777531|NCT00416715|Dietary Supplement|calcium carbonate|Given PO
1777532|NCT00416715|Other|laboratory biomarker analysis|Optional correlative studies
1777533|NCT00416715|Dietary Supplement|calcium citrate|Given PO
1777534|NCT00416715|Dietary Supplement|calcium glucarate|Given PO
1777535|NCT00416715|Drug|calcium gluconate|Given PO
1777536|NCT00416715|Dietary Supplement|cholecalciferol|Given PO
1777537|NCT00416715|Procedure|assessment of therapy complications|Ancillary studies
1777538|NCT00416715|Procedure|musculoskeletal complications management/prevention|Correlative studies
1777539|NCT00416728|Drug|Aliskiren|
1777540|NCT00416728|Drug|Valsartan|
1777541|NCT00416741|Behavioral|Implementation of guidelines|Attaining targets for LDL cholesterol, arterial blood pressure, fasting [plasma flucose
1777542|NCT00416754|Other|counseling intervention|subjects will receive genetic counseling
1777543|NCT00416767|Drug|fluorouracil|
1777544|NCT00416767|Drug|irinotecan hydrochloride|
1777545|NCT00416767|Drug|leucovorin calcium|
1777546|NCT00416780|Other|counseling intervention|
1777547|NCT00416780|Other|educational intervention|
1777548|NCT00416780|Procedure|psychosocial assessment and care|
1777549|NCT00416793|Drug|bortezomib|Given IV
1777550|NCT00416793|Drug|carboplatin|Given IV
1777551|NCT00416793|Other|laboratory biomarker analysis|Correlative studies
1777552|NCT00416819|Biological|filgrastim|
1777553|NCT00416819|Biological|rituximab|
1777554|NCT00416819|Drug|cytarabine|
1777555|NCT00416819|Drug|etoposide phosphate|
1777556|NCT00416819|Drug|leucovorin calcium|
1777557|NCT00416819|Drug|methotrexate|
1777558|NCT00416819|Drug|temozolomide|
1777559|NCT00416832|Drug|cyclophosphamide|
1777560|NCT00416832|Drug|dacarbazine|
1777561|NCT00416832|Drug|doxorubicin hydrochloride|
1777562|NCT00416832|Drug|etoposide|
1777563|NCT00416832|Drug|prednisone|
1777564|NCT00416832|Drug|procarbazine hydrochloride|
1777565|NCT00416832|Drug|vincristine sulfate|
1777566|NCT00416832|Radiation|radiation therapy|
1777567|NCT00416845|Drug|FTY720|
1777568|NCT00416858|Drug|cisplatin|
1777569|NCT00416858|Drug|fluorouracil|
1777570|NCT00416858|Procedure|adjuvant therapy|
1777571|NCT00416858|Procedure|conventional surgery|
1777572|NCT00416858|Procedure|neoadjuvant therapy|
1777573|NCT00416858|Radiation|radiation therapy|
1777574|NCT00416871|Biological|aldesleukin|
1777575|NCT00416871|Biological|recombinant interferon alfa|
1777576|NCT00416884|Drug|Campath|30 mg on day -8 over 5-6 hours
1777577|NCT00416884|Drug|Fludarabine|Fludarabine 30 mg/m^2 on day -4 through day -2
1777578|NCT00416884|Radiation|Total Body Irradiation (TBI)|Total body irradiation single fraction 200 cGy at 7 cGy per minute on day 0
1777579|NCT00416884|Other|T-Cell Deplete|Stem cells will be T cell depleted and given on day 0
1777580|NCT00416897|Drug|chemotherapy|
1777581|NCT00416897|Drug|dexamethasone|
1777582|NCT00416897|Procedure|plasmapheresis|
1777583|NCT00416910|Biological|Filgrastim|
1777584|NCT00416910|Drug|Fludarabine|
1777585|NCT00416910|Drug|Cyclophosphamide|
1777586|NCT00416910|Drug|Mitoxantrone|
1777587|NCT00416923|Biological|rituximab|
1777592|NCT00416962|Drug|amantadine hydrochloride|
1777593|NCT00416962|Drug|oseltamivir phosphate|
1777594|NCT00416975|Other|counseling intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
1777595|NCT00416975|Other|educational intervention|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
1777596|NCT00416975|Procedure|evaluation of cancer risk factors|Women in the intervention group will be offered breast cancer risk assessment at baseline. Computerized risk assessment is followed by personalized risk tailored health messages. The health messages will also include appropriate recommendations for genetic and psychosocial counseling. Baseline measurements from a questionnaire given prior to the intervention will capture current breast cancer screening practices (mammography, clinical breast exam and self exam), intentions to get mammograms, family discussion of breast cancer, risk perceptions, and breast cancer worry. Important demographic variables and breast cancer risk factors will also be measured. Participants will receive follow up telephone interviews at 1, 6, and 18 months to assess mammography use.
1777597|NCT00416988|Other|educational intervention|
1777598|NCT00417001|Procedure|Aroma therapy|
1777599|NCT00417014|Drug|chlorambucil|
1777600|NCT00417014|Drug|prednisolone|
1777601|NCT00417014|Drug|procarbazine hydrochloride|
1777602|NCT00417014|Drug|vinblastine sulfate|
1777603|NCT00417014|Radiation|radiation therapy|
1777604|NCT00417027|Procedure|Programmed Intermittent Epidural Bolus (PIEB)|A commercial pump that can be programmed to administer intermittent boluses and patient controlled boluses does not exist. Two pumps were prepared for each subject with the same epidural solution. One pump was programmed to administer the programmed intermittent epidural bolus(PIEB). The second pump was programmed to administer patient controlled epidural analgesia (PCEA)with a dose of 5 mL delivered with a lockout of every 10 minutes.
1777605|NCT00410683|Other|clinical observation|
1777606|NCT00410683|Procedure|adjuvant therapy|
1777607|NCT00410683|Radiation|3-dimensional conformal radiation therapy|
1777608|NCT00410696|Drug|Filgrastim|5 mcg/kg/day sc from day +1 after transplantation to hemopoietic reconstitution
1777609|NCT00410696|Drug|Pegfilgrastim|6 mg/day sc at day +1
1777610|NCT00410709|Drug|NatrOVA Creme Rinse (1%)|
1777613|NCT00410735|Drug|Placebo|0 mg BID for 12 weeks
1777614|NCT00410735|Drug|Pranlukast hydrate|225 mg BID for 12 weeks
1777615|NCT00410748|Drug|OROS hydromorphone HCI CR|
1777616|NCT00410761|Drug|ZD6474 (Vandetanib)|once daily oral tablet
1777617|NCT00410774|Biological|bevacizumab|
1777618|NCT00410774|Drug|gemcitabine hydrochloride|
1777619|NCT00410774|Procedure|adjuvant therapy|
1777620|NCT00410787|Drug|OROS hydromorphone HCI (slow release)|
1777621|NCT00410813|Drug|dasatinib|given orally
1777622|NCT00417040|Other|internet-based intervention|Use the STAR database system
1777623|NCT00417040|Other|assessment of therapy complications|Use the STAR database system
1777624|NCT00417040|Other|Questionnaire Administration|Ancillary studies
1777625|NCT00417053|Biological|filgrastim|
1777626|NCT00417053|Drug|busulfan|
1777627|NCT00417053|Drug|carboplatin|
1777628|NCT00417053|Drug|cyclophosphamide|
1777629|NCT00417053|Drug|doxorubicin hydrochloride|
1777630|NCT00417053|Drug|etoposide phosphate|
1777631|NCT00417053|Drug|melphalan|
1777632|NCT00417053|Drug|vincristine sulfate|
1777633|NCT00417053|Procedure|autologous bone marrow transplantation|
1777634|NCT00417053|Procedure|bone marrow ablation with stem cell support|
1777635|NCT00417053|Procedure|conventional surgery|
1777636|NCT00417053|Procedure|peripheral blood stem cell transplantation|
1777637|NCT00417053|Radiation|radiation therapy|
1777638|NCT00417066|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
1777639|NCT00417066|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
1777640|NCT00417079|Drug|cabazitaxel (XRP6258) (RPR116258)|25 mg/m^2 administered by intravenous (IV) route over 1 hour on day 1 of each 21-day cycle
1777641|NCT00417079|Drug|mitoxantrone|12 mg/m^2 administered by intravenous (IV) route over 15-30 minutes on day 1 of each 21-day cycle
1777642|NCT00417079|Drug|prednisone|10 mg daily administered by oral route
1777643|NCT00417092|Procedure|Postoperative Pacing|
1777644|NCT00417105|Procedure|hemodialysis|group 1: twice weekly, four hours
1777645|NCT00417105|Procedure|hemodialysis|group 2: twice weekly, eight hours
1777646|NCT00417105|Procedure|hemodialysis|group 3: every other day, eight hours
1777647|NCT00417105|Procedure|hemodialysis|group 4: six days a week, eight hours
1777648|NCT00417118|Drug|Saredutant|oral administration (capsules)
1777649|NCT00417118|Drug|Escitalopram|oral administration (capsules)
1777650|NCT00417118|Drug|Placebo|oral administration (capsules)
1777651|NCT00417144|Drug|Arvekap 0.1mg (Triptorelin, Ipsen, France)|
1777652|NCT00417144|Drug|Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)|
1777653|NCT00417157|Drug|recombinant FSH (Puregon, Organon, The Netherlands)|
1777654|NCT00417157|Drug|GnRH antag: Ganirelix (Orgalutran, Organon, The Netherlands)|
1777655|NCT00417157|Drug|hCG (Pregnyl, Organon, The Netherlands)|
1777656|NCT00417170|Drug|Aliskiren|Aliskiren 300 mg tablets taken orally once daily
1777657|NCT00417170|Drug|Amlodipine|Amlodipine 5 mg capsule taken orally once daily
1777658|NCT00417170|Drug|Placebo Aliskiren|Placebo Aliskiren taken orally once daily.
1777659|NCT00417170|Drug|Placebo Amlodipine|Placebo Amlodipine taken orally once daily
1777660|NCT00417183|Drug|Arvekap 0.1 mg (Triptorelin, Ipsen, France)|
1777661|NCT00417183|Drug|Ganirelix 0.25 (Orgalutran, Organon, The Netherlands)|
1777662|NCT00417196|Drug|QAX576|
1777663|NCT00417209|Drug|Larotaxel (XRP9881)|administered as a 1-hour IV infusion on Day 1 of every 3 weeks (q3w)
1777664|NCT00417209|Drug|5-Fluorouracil|administered as IV infusion from Day 1 to Day 4
1777665|NCT00417209|Drug|Capecitabine|administered orally from Day 1 to Day 14 q3w
1777666|NCT00417222|Drug|olmesartan medoxomil|5 to 40mg P.O. daily until the end of the study
1777667|NCT00417235|Device|Chlorhexidine Sponge (Biopatch TM)|dressing with chlorexidrine sponge versus dressing without chlorexidrine sponge
1777668|NCT00417235|Behavioral|7-day catheter dressing frequency|dressing changes every 7 days versus every classical change every 3 days
1777669|NCT00417248|Drug|Cisplatin|Cisplatin 50 mg/m2 IV, days 1 and 8 of 28 day cycle
1777670|NCT00417248|Drug|Etoposide|Etoposide 50 mg/m2 IV, days 1-5 of 28 day cycle
1777671|NCT00417248|Procedure|Radiotherapy|Concurrent chest radiation (planned dose is 5940 cGy with an additional, optional boost of 1080 cGy to a total allowed dose of 7020 cGy)
1777672|NCT00417248|Drug|Sorafenib|Maintenance therapy of Sorafenib 400 mg PO BID, to begin a minimum of 6 and maximum of 9 weeks from completion of chemo-radiotherapy until PD, intolerable toxicity, or up to 6 months
1777673|NCT00417261|Drug|ATF936|
1777674|NCT00417261|Drug|AXT914|
1777675|NCT00417274|Drug|Quinacrine|100 mg daily
1777676|NCT00417287|Drug|PX-12|3 hour intravenous infusion as a dose of either 54 mg/m2 or 128 mg/m2 daily for 5 days every three weeks.
1777677|NCT00417300|Behavioral|Prolonged exposure (PE) therapy for adolescents|PE is an individual therapy. The treatment involves talking about thoughts and feelings about the assault and confronting the memory of the assault. The therapy also involves doing homework outside of session.
1777678|NCT00417300|Behavioral|Client centered therapy (CCT)|CCT is an individual therapy. The therapist will talk to the adolescent and help her to discuss all of the thoughts and feelings she wishes to talk about. The therapist is an active listener and helps the child to clarify and understand her feelings and offer non-directive problem solving.
1777679|NCT00417313|Device|periosteal electro-acupuncture (osteopuncture).|
1777680|NCT00417326|Drug|ONO-5046Na|twenty four hour infusion at 0 mg/kg/hr for 14 days
1777681|NCT00417326|Drug|ONO-5046Na|twenty four hour intravenous infusion at 0.2 mg/kg/hr for 14 days
1777682|NCT00417339|Procedure|hemodialysis|individualised
1777683|NCT00417352|Device|Brace|
1777684|NCT00417352|Device|Added mass|
1777685|NCT00417365|Device|WaterWorks Douching Device|
1777686|NCT00419913|Dietary Supplement|Dehydroepiandrosterone|DHEA 25 mg tid
1777687|NCT00419926|Drug|Enteric-coated mycophenolate sodium (Myfortic)|1440 mg/day for the standard dose. 2880 mg/day for the initial intensified dosage, reduced to standard level in two steps,i.e. reduction to 2160 mg/day after 2 weeks of treatment and to 1440 mg/day after 6 weeks of treatment.
1777688|NCT00419926|Drug|Cyclosporine (Neoral)|cyclosporine microemulsion in galenic form capsules starting at twice a day for a dose of 8-10 mg/kg/day adjusted if necessary to achieve protocol specific target levels
1777689|NCT00419926|Drug|Prednisone|20 mg orally per day reduced according to center practice for a minimum dose of 5 mg/day.
1777690|NCT00419952|Drug|Budesonide/formoterol (SYMBICORT) pMDI|Symbicort pMDI 160/4.5 ug x 2 actuations twice daily (BID)
1777691|NCT00419952|Drug|Budesonide HFA pMDI|Budesonide HFA pMDI 160 ug x 2 actuations BID
1777692|NCT00419978|Procedure|Colectomy|
1777693|NCT00419991|Drug|Tigecycline|All patients will receive tigecycline infusions approximately every 12 or 24 hours. The usual regimen of tigecycline is (an initial intravenous (IV) dose of 100 mg followed by 50 mg approximately every 12 hours). Patients with severe hepatic dysfunction may, at the investigator's discretion with CPL Associates approval (call enrollment hotline) may be given a total daily dose of 50 mg (one 50 mg dose or 25 mg approximately every 12 hours). Tigecycline infusions will be administered over approximately 30 minutes in 100 mL of normal saline.
1777694|NCT00420004|Drug|LY2216684|3 mg - 12 mg once daily oral dose (tablets) with flexible titration for 8 weeks.
1777695|NCT00420004|Drug|Placebo|tablet and capsule equivalents to LY2216684 and escitalopram taken once daily for 8 weeks
1777696|NCT00420004|Drug|escitalopram|10 mg or 20 mg once daily oral dose (capsules) with flexible titration for 8 weeks
1777697|NCT00420017|Drug|Amiodarone|Intravenous amiodarone continuous infusion x 4 days
1777698|NCT00420017|Other|Control|No amiodarone
1777699|NCT00420030|Drug|Abciximab|Abciximab - IIb/IIIa GP inhibitor, dosage - bolus + continuous infusion
1777700|NCT00420043|Drug|imatinib|
1777701|NCT00420056|Drug|PD-0332991|125 mg, oral, Days 1-21 of a 28-day cycle
1777702|NCT00420069|Device|MRTX device|device for ventilation
1777703|NCT00420082|Drug|Bilastine|Encapsulated Bilastine 20 mg tablets Q.D.
1777704|NCT00420082|Drug|Fexofenadine|Encapsulated Fexofenadine 120 mg tablets Q.D.
1777705|NCT00420082|Drug|Cetirizine|Encapsulated Cetirizine 10 mg tablets Q.D.
1777706|NCT00420082|Drug|Placebo|Encapsulated Placebo tablets Q.D.
1777707|NCT00420095|Drug|Human insulin 30/70|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
1777708|NCT00420095|Drug|Insulin lispro low mix|Patient adjusted dose, twice daily (BID), injected subcutaneous (SC) x 12 weeks
1777709|NCT00420121|Procedure|laboratory analysis|blood withdrawal for laboratory analysis
1777710|NCT00420134|Procedure|injection of progenitor of hepatocyte drived from Mesenchymal stem cell|
1777711|NCT00420147|Device|wedged inshoe orthosis|Treatment subjects were prescribed an inshoe wedged orthosis
1777712|NCT00420147|Device|neutral inshoe orthosis|Control subjects were prescribed a neutral inshoe orthosis
1777713|NCT00420160|Behavioral|Smoking cessation treatment plus moderate intensity exercise|
1777714|NCT00420160|Behavioral|Smoking cessation treatment plus health education|
1777715|NCT00420173|Procedure|Laboratory analysis|blood withdrawal
1777716|NCT00420186|Drug|BMS-690514|Tablets / IV, Oral / IV, 100 to 300 mg / Paclitaxel (200 mg/m2) / Carboplatin dose (mg) = Target AUC (6) x (GFR + 25), Once daily Days 4-19, up to 24 mos
1777717|NCT00420199|Drug|Abatacept|Vials (250 mg/vial), intravenous (IV), 10 mg/kg, monthly infusion , 12 months of treatment
1777718|NCT00420199|Drug|Placebo|Intravenous (IV) bags, IV, 0 mg, monthly infusion, 12 months of treatment
1777719|NCT00420212|Drug|BG00012|
1777720|NCT00420212|Drug|Placebo|
1777721|NCT00420225|Device|Low-weight prolypropylene mesh|
1777722|NCT00420238|Drug|Etanercept (Enbrel)|50 mg injection once weekly
1777723|NCT00420238|Other|Placebo|placebo
1777724|NCT00420251|Drug|Genotropin|
1777725|NCT00420264|Device|Uterine Ablation|Uterine Ablation in the office setting to see if the procedure is tolerated w/o sedation
1777726|NCT00420277|Drug|Hemospan (MP4OX)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
1777727|NCT00420277|Drug|Voluven (HES 130/0.4)|250 mL unit dose, up to 500 mL total dose as needed at protocol-defined dosing triggers
1777728|NCT00420290|Drug|kineret|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
1777729|NCT00420290|Drug|placebo|100 mg administered subcutaneously every other day (3 days a week during hemodialysis) for 4 weeks
1777730|NCT00420303|Drug|Etanercept|50 mg injection once weekly
1777731|NCT00420303|Other|Placebo|placebo
1777732|NCT00420316|Biological|Rotarix (primary vaccination study)|GlaxoSmithKline Biologicals' oral live attenuated human rotavirus vaccine.
1777733|NCT00420316|Biological|Placebo (primary vaccination study)|Two liquid oral doses of placebo
1777734|NCT00420342|Drug|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 A -Active study medication encapsulated tablet
1777735|NCT00420342|Drug|Drospirenone/17ß-estradiol (Angeliq, BAY86-4891)|SH K 00641 B - Active study medication encapsulated tablet
1777736|NCT00420342|Drug|SH K 00641 C - Medroxyprogesterone acetate / conjugated equine (Prempro TM)|Active control encapsulated tablet
1777737|NCT00420355|Drug|atazanavir|Atazanavir 300 mg daily on Days 6-12.
1777738|NCT00420355|Drug|lopinavir/ritonavir|Lopinavir/ritonavir 400 mg/100 mg twice daily on Days 6-16, then 800 mg/200 mg daily on Days 17-21.
1777739|NCT00420368|Dietary Supplement|No food supplement|
1777740|NCT00420368|Dietary Supplement|Food supplement: fortified spread|
1777741|NCT00420368|Dietary Supplement|Food supplement: maize-soy flour|
1777742|NCT00420381|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until progressive disease
1777743|NCT00420394|Procedure|Chemotherapy|
1777744|NCT00420394|Procedure|surgery|
1777745|NCT00420394|Procedure|radiotherapy|
1777746|NCT00420407|Drug|normal saline control|no vasopressin added to bolus or 5 hour continuous infusion
1777747|NCT00420407|Drug|vasopressin|vasopressin bolus 4 units followed by continuous infusion 2.4units/hr for 5 hours
1777748|NCT00420420|Drug|MK0249|MK0249 two (2) 2.5 mg capsules quaque die (qd) for 28 day treatment period.
1777749|NCT00420420|Drug|Comparator: Placebo (unspecified)|MK0249 two (2) 2.5 mg Pbo capsules qd for a 28 day treatment period
1777750|NCT00420433|Procedure|Skeletal Scintigraphy|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
1777751|NCT00420433|Procedure|Radiography|Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
1777853|NCT00421252|Device|arterial access sheath|randomize to 5Fr vs 6Fr
1777752|NCT00420433|Procedure|CT Scan|CT scan will include your chest, abdomen, and pelvis. Performed before treatment and again at 3, 6, 9, and 12 months after starting anticancer therapy.
1777753|NCT00420446|Behavioral|Adjusted diet|
1777754|NCT00420459|Drug|Aripiprazole|All subjects will initially receive 2.5 mg/day of aripiprazole during the first week. The dosage may be increased to a maximum of 20 mg/day over 8 weeks.
1777755|NCT00420472|Drug|mycophenolate mofetil [CellCept]|
1777756|NCT00420485|Drug|gimatecan|
1777757|NCT00420498|Drug|Atomoxetine (Strattera™)|
1777758|NCT00420511|Drug|Sitagliptin|sitagliptin 100 mg once a day
1777759|NCT00420511|Drug|Placebo|placebo once a day
1777760|NCT00420511|Drug|metformin|metformin 1000 mg twice a day (bid) by mouth (po)
1777761|NCT00420524|Drug|Patupilone/EPO906|
1777762|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 100 and 150
1777763|NCT00420537|Drug|cyclosporine|cyclosporine trough levels between 40 and 90 ng/ml
1777764|NCT00420537|Drug|Mycophenolate mofetil|mycophenolate with low doses
1777765|NCT00420537|Drug|Everolimus|
1777766|NCT00420550|Behavioral|Relaxation Response using Guided Imagery|
1777767|NCT00420563|Drug|CYCLOPHOSPHAMIDE|50 mg x 2 /day , per os, nonstop until disease progression or toxicity or patient decision
1777768|NCT00420563|Drug|MEGESTROL|320 mg/day, per os, 2 pills of 160 mg one time, nonstop until disease progression or toxicity or patient decision
1777769|NCT00420576|Drug|DBT-Danggui Buxue Tang|Herbal Combination of Danggui (Radix Angelicae Sinensis) and Huangqi (Radix Astragali)in granules form, in 3 different dosage 6g/3g/1.5g, once time per day for 3 Months treatment
1777770|NCT00420589|Drug|taranabant|taranabant 0.5 mg capsule, 1 mg capsule, 2 mg capsule once daily. Treatment for 52 weeks.
1777771|NCT00420589|Drug|Comparator: placebo|Placebo capsules once daily. Treatment for 52 weeks
1777772|NCT00420602|Dietary Supplement|Over the counter DHA/EPA dietary supplementation|1000 mg/day DHA/EPA
1777773|NCT00420615|Drug|Patupilone and Omeprazole|
1777774|NCT00420615|Drug|Patupilone + Midalzolam|
1777775|NCT00420628|Drug|loteprednol etabonate/tobramycin opthalmic suspension|Topical ophthalmic drug: 0.5% loteprednol etabonate with 0.3% tobramycin 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
1777776|NCT00420628|Drug|vehicle|topical ophthalmic vehicle was applied 4 times a day (QID) days 1-7, 2 times a day (BID) days 8-14. Warm compresses were applied to affected eyes 2 times a day prior to application of study medication.
1777780|NCT00420654|Drug|Growth Hormone|1.25 mg, 6 months
1777781|NCT00420654|Drug|Placebo|Equivalent to 1.25 mg, 6 months
1777782|NCT00420654|Other|Healthy controls|Healthy controls
1777783|NCT00420667|Drug|Enoxaparin|
1777784|NCT00420680|Drug|Sugammadex|Sugammadex, 2.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium
1777785|NCT00420680|Drug|Sugammadex|Sugammadex, 4.0 mg/kg given as a reversal agent at reappearance of T2 after 0.6 mg/kg rocuronium.
1777786|NCT00420680|Drug|Placebo|Placebo given at reappearance of T2 after 0.6 mg/kg rocuronium
1777787|NCT00420693|Drug|sevoflurane|
1777788|NCT00420706|Drug|SCA-136|
1777789|NCT00420719|Device|Intramuscular diaphragm electrodes|Conditioning of the diaphragm
1777790|NCT00420732|Biological|HyperAcute-Lung Cancer Vaccine|300 million cells given intradermally every 3 weeks for up to a total of 12 vaccinations
1777791|NCT00420745|Biological|Rotarix™|Two-dose oral vaccination.
1777792|NCT00420745|Biological|Placebo|Two-dose oral administration
1777793|NCT00420758|Dietary Supplement|Food supplement: fortified spread|Provision of fortified spread
1777794|NCT00420758|Dietary Supplement|Food supplement: maize-soy flour|Provision of corn-soy blend (maize-soy flour)
1777796|NCT00420784|Drug|Telaprevir|tablet
1777797|NCT00420784|Drug|Ribavirin|tablet
1777798|NCT00420784|Drug|Pegylated Interferon Alfa 2a|Solution for injection
1777799|NCT00420784|Drug|Matching Placebo|Tablet
1777800|NCT00420797|Drug|10% Phenylephrine hydrochloride gel|
1777801|NCT00420810|Drug|MK0928 / Duration of Treatment : 8 Weeks|
1777802|NCT00420823|Drug|Taurine 4g|
1777803|NCT00420836|Drug|Tobramycin|
1777804|NCT00420849|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression, drug became commercially available or limited to 6 treatment cycles.
1777805|NCT00420849|Drug|Dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4. Beginning cycle 5, a maintenance dose of dexamethasone (40 mg QD) was administered on Days 1 to 4 of each 28-day cycle.
1777806|NCT00420862|Procedure|Spiral Computed Tomography|
1777807|NCT00420875|Device|TOPAZ MicroDebrider|The TOPAZ MicroDebrider will be used for patients that fail conservative care. Under sterile conditions in the operating room, patients will be given intravenous sedation (drugs that make you sleepy and unaware of your surroundings) in a hand vein and local anesthetic (drugs to numb the area where the surgical procedure will be done). Depending on the technique used the study doctor may or may not make an incision (cut) about 1 inch long on the side of your foot to expose your tendon. If the study doctor chooses to use the percutaneous method, an incision will not be made. The study doctor will put the tip of the TOPAZ MicroDebrider device (which is about 1/16th of an inch long) into the tendon. A current of energy will be applied on and around the tendon. Steri strips will be placed on the skin to close the area treated.
1777808|NCT00420888|Drug|ABR-217620/naptumomab estafenatox|10 mcg/kg or 15 mcg/kg, 5 minute bolus intravenous injection on 4 consecutive days / 8 week cycle repeated 3 times
1777809|NCT00420888|Drug|IFN-alpha|3 MIU, 6 MIU, and 9 MIU, subcutaneous or intramuscular injection 3 times / week
1777810|NCT00420901|Drug|sildenafil|
1777811|NCT00420914|Procedure|low dose of 2.25 x 10^11 platelets/transfusion (range 1.5 to 2.9)|
1777812|NCT00420927|Biological|adalimumab|Adalimumab 40 mg/0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
1777813|NCT00420927|Drug|methotrexate|Methotrexate 2.5 mg tablets administered orally once a week starting at 7.5 mg/week with dose escalation (weekly or every other week) by 2.5 mg intervals to 20 mg/week.
1777814|NCT00420927|Biological|placebo|Placebo for adalimumab 0.8 mL prefilled syringe injected subcutaneously (SC) every other week (eow)
1777817|NCT00420953|Drug|Cordarone|
1777818|NCT00420992|Drug|ALO-01 (Morphine Sulfate Plus Naltrexone Hydrochloride Extended Release)|capsules, up to 80 mg bid
1777819|NCT00420992|Drug|Placebo|capsules, bid
1777820|NCT00421005|Drug|fluvastatin|Fluvastatin 80 mg (Arm 1) vs. Fluvastatin 20 mg (Arm 2) increased according with LDL concentrations
1777821|NCT00421018|Drug|Single corticosteroid inhalers and Singulair|Treatment steps according to preset algorithm
1777822|NCT00421031|Drug|DVS-233 SR|
1777823|NCT00421044|Drug|Patupilone/EPO906|
1777824|NCT00421057|Behavioral|Combined Strength Training and Functional Endurance Exercise|Participants will be taught to stretch a Theraband as far as your arms or legs can stretch and the proper posture for walking for exercise. The Estimated Timed-Get-Up and Go test (ETGUPGo) and a 6-minute walk test will be performed to check your level of fatigue and physical ability.
1777825|NCT00421057|Behavioral|Questionnaire|Questionnaires taking approximately 30 minutes total to complete.
1777826|NCT00421070|Procedure|Massage therapy|A qualified massage therapist will administer a 20-minute standard massage procedure with the client sitting fully clothed in a special massage chair. The massage therapy session will consist of ; 1) long, broad stroking with light-moderate pressure to the back, compression to the back (parallel to spine) from the shoulders to base of spine, trapezius squeeze, finger pressure on the shoulder; 2) arms dropped to the side with arms kneaded from shoulder to lower arm and pressing down on upper and lower arms; 3) entire hands massaged and pulling of fingers, light kneading to area of cervical vertebrae, pressing down on trapezius with finger pressure and squeezing continuing down the arms.
1777827|NCT00421083|Drug|tadalafil|
1777828|NCT00421096|Drug|Gemcitabine|125 mg/m² at day 1, 8, 15, 21 and 28, 2 hours before radiotherapy.
1777829|NCT00421096|Procedure|Radiotherapy|"45Gy (5 x 1,8Gy/week) on pelvic area +/- boost (10 to 15Gy)
+/- 45Gy (5 x 1,8Gy/week)on lumbo-aortic area"
1777830|NCT00421096|Drug|Cisplatin|40 mg/m² at day 1, 8, 15, 21 and J28 before Gemcitabine and with a hyperhydration
1777831|NCT00421109|Drug|Bilastine|Encapsulated 20 mg Tablet. Once daily for 28 days
1777832|NCT00421109|Drug|Levocetirizine|Encapsulated 5 mg tablet. Once daily for 28 days
1777833|NCT00421109|Drug|Placebo|Encapsulated tablet. Once daily for 28 days
1777834|NCT00421122|Drug|budesonide/formoterol (Symbicort)|inhalation therapy
1777835|NCT00421122|Drug|budesonide (Pulmicort)|inhalation
1777836|NCT00421122|Drug|terbutaline sulfate (Bricasol)|inhalation therapy
1777837|NCT00421135|Drug|ZIO-201|ZIO-201 as a single dose given once every 21 days. This is a dose escalation arm.
1777838|NCT00421148|Drug|Sugammadex 0.5 mg/kg|Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 0.5 mg/kg sugammadex will be given.
1777839|NCT00421148|Drug|Sugammadex 1.0 mg/kg|Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 1.0 mg/kg sugammadex will be given.
1777840|NCT00421148|Drug|Sugammadex 2.0 mg/kg|Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 2.0 mg/kg sugammadex will be given.
1777841|NCT00421148|Drug|Sugammadex 4.0 mg/kg|Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of 4.0 mg/kg sugammadex will be given.
1777842|NCT00421148|Drug|Placebo|Each subject will receive an intravenous (i.v.) single bolus dose of 0.6 mg/kg rocuronium. At reappearance of T2, a single bolus dose of placebo will be given.
1777843|NCT00421161|Drug|olive oil and omega 3 in a combined cream|
1777844|NCT00421174|Drug|Etanercept|Etanercept will be given eight doses of study drug over a 4-week period. The initial dose of etanercept will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated.
1777845|NCT00421174|Drug|Placebo plus corticosteroid|"Patients will receive a total of eight doses of placebo over a 4-week period. The initial dose of placebo will be administered intravenously on Day 0, with subsequent doses administered subcutaneously (SQ). Dosing will be administered twice weekly over 4 consecutive weeks. The placebo will be the inert diluent used for the etanercept formulation.
Additionally, patients in both arms will receive corticosteroids (2 mg/kg/day) Day 0 through Day 7, with subsequent taper as clinically indicated."
1777846|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
1777847|NCT00421187|Drug|Liposomal amphotericin B (AmBisome®)|
1777848|NCT00421200|Drug|Hemospan (MP4OX)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
1777849|NCT00421200|Drug|Voluven (HES 130/0.4)|250 ml unit dose, up to 500 mL total dose, as needed at protocol-defined dosing triggers
1777850|NCT00421213|Drug|Darinaparsin|300mg/m2 of Darinaparsin given daily for five consecutive days to be repeated every 28 days for up to six months.
1777851|NCT00421226|Drug|ACZ885|
1777852|NCT00421252|Drug|clopidogrel 600 mg|Clopidogrel load > 2hrs pre-angiography
1777854|NCT00421278|Drug|MK0633|Single dose MK0633 100mg po in the fed state administered during a 4-wk study.
1777855|NCT00421291|Behavioral|Education|
1777856|NCT00421304|Biological|Motavizumab|Will receive a single dose of IV of Motavizumab (100mg/kg)
1777857|NCT00421304|Other|Biological/Vaccine: Motavizumab|A single IV dose of placebo (30 mg/kg).
1777858|NCT00421304|Other|Placebo|A single IV dose of placebo (30 or 100 mg/kg).
1777859|NCT00421317|Drug|Imatinib|800 mg/day until disease progression or toxicity
1777860|NCT00421330|Procedure|Open Aneurysm Repair|
1777861|NCT00421330|Procedure|Endovascular Aneurysm Repair|
1777862|NCT00421343|Drug|alendronate with cholecalciferol|alendronate 70mg /cholecalciferol 2800IU orally once weekly
1777863|NCT00421343|Drug|calcium carbonate with cholecalciferol|calcium carbonate 500mg /cholecalciferol 200IU orally twice daily
1777864|NCT00421343|Behavioral|Falls prevention measures|personalized exercises, home safety evaluation, referral to an eye doctor if needed, review of medications
1777865|NCT00421369|Drug|sertraline|
1777866|NCT00421369|Drug|triiodothyronine (T3)|
1777867|NCT00421369|Drug|reboxetine|
1777868|NCT00421395|Biological|90Y-hLL2|weekly dosing for either 2 or 3 weeks
1777869|NCT00421408|Dietary Supplement|Whey protein supplement|40-g whey protein supplement daily for 18 months
1777870|NCT00421408|Dietary Supplement|Placebo|Placebo supplement daily for 18 months
1777871|NCT00421421|Drug|Dutasteride|
1777872|NCT00421434|Drug|Nitazoxanide|One oral nitazoxanide 500 mg tablet with food twice daily for 48 weeks.
1777873|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
1777874|NCT00421434|Biological|Peginterferon alfa-2a|Weekly injections of 180 µg peginterferon alfa-2a for 48 weeks.
1777875|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 36 weeks.
1777876|NCT00421434|Drug|Ribavirin|Oral ribavirin 1000 mg (body weight <75 kg) or 1200 mg (body weight ≥75 kg) daily in two divided doses for 48 weeks.
1777877|NCT00421447|Drug|Anastrozole|Group of women with breast cancer
1777878|NCT00421460|Drug|Testosterone Undecanoate,1000mg|duration for 4 injections
1777879|NCT00421473|Drug|Atovaquone / Proguanil|
1777880|NCT00421486|Procedure|Oral swabs for HPV-typing and high-risk HPV-determination|Oral swabs for HPV-typing and high-risk HPV-determination
1777881|NCT00421499|Drug|dark chocolate|
1777882|NCT00421512|Drug|Bevacizumab and Sunitinib|On Cycle 1, Day 0, patients will begin treatment with bevacizumab. Sunitinib will begin on Day 1. The starting dose for sunitinib will be 25mg orally daily. sunitinib will be given in a four weeks on-two weeks off schedule. Bevacizumab will begin on Day 0 and will be administered every two weeks at 10mg/kg. A cycle of therapy is 6 weeks. The sunitinib dose escalation portion of the trial will be performed to determine the MTD of sunitinib given in combination with bevacizumab. Once the MTD has been determined, 10 additional patients will be treated at the MTD of sunitinib in combination with bevacizumab.
1777883|NCT00421525|Biological|milatuzumab|twice weekly dosing for 4 weeks, total of 8 doses
1777884|NCT00421538|Drug|nadroparine calcium|Once-daily injection of 171 U/Kg/day of nadroparine calcium for 6 weeks.
1777885|NCT00421538|Drug|Placebo|Once-daily injectable placebo (sterilized NaCL 0.9%) for 6 weeks
1777886|NCT00421551|Drug|Darunavir|during the 48 first weeks of the trial, (2x300mg) twice a day between W48 and W96, (2x400mg) once a day
1777887|NCT00421551|Drug|ritonavir|during the first 48 weeks, 100mg twice a day between W48 and W96, 100mg once a day
1777888|NCT00421564|Drug|DBT-Danggui Buxue Tang|
1777889|NCT00421590|Drug|SMC021|
1777890|NCT00421603|Drug|Adderall-XR and Topiramate|Adderall-XR 60mg/day and Topiramate 300mg/day
1777891|NCT00421603|Drug|Placebo|Placebo
1777892|NCT00421616|Behavioral|High protein diet study|
1777893|NCT00421629|Behavioral|After-sales service and supportive supervision (AfterSS)|
1777894|NCT00421629|Behavioral|Prospective reimbursement (PR)|
1777895|NCT00421629|Behavioral|Both (AfterSS and PR)|
1777896|NCT00421642|Drug|Adalimumab|The loading dose will be 160 mg. A dose of 80 mg will be given at Week 2 and 40 mg every other week starting at Week 4 until completion at Week 24. If it is found that they are not responding to 40 mg of adalimumab at Week 8 or later, the dose may be increased to 40 mg weekly.
1777897|NCT00421655|Drug|Grazax|Tablets 75,000 SQT and matching placebo. One tablet daily.
1777898|NCT00421668|Drug|Zinc|zinc
1777899|NCT00421668|Drug|Multivitamins|Vitamins C, E, B1, B2, niacin, B6, folate and B12
1777900|NCT00421668|Drug|Placebo|Placebo
1777901|NCT00421681|Behavioral|Fit and Strong! Exercise Program|Fit and Strong! is an 8-week (24 sessions) multi-component exercise and health education intervention, including flexibility, aerobic conditioning, strength training, and group discussion/problem solving for lifestyle change. Following participation in Fit and Strong!, all study participants are randomly assigned to one of 2 maintenance treatment follow-up groups.
1777902|NCT00421694|Drug|Bicalutamide|
1958301|NCT01783444|Drug|Capecitabine|Capecitabine, for oral use 1250 mg/m2 twice daily for 2 weeks followed by one week rest (3-week cycle). Capecitabine will be locally supplied by the Investigator.
1958302|NCT01783444|Drug|Exemestane|Exemestane tablets of 25 mg will be taken orally once per day. Dose modifications in the management of adverse events is allowed.
1777905|NCT00421720|Drug|Sufentanil|
1777906|NCT00421720|Drug|Remifentanil|
1777907|NCT00421733|Drug|Zemplar (paricalcitol ) capsules|Group 2 - paricalcitol 1 mcg capsules once daily (one paricalcitol 1 mcg capsule once daily and one matching placebo capsule once daily)
1777908|NCT00421733|Drug|Zemplar (paricalcitol) capsules|Group 3 - paricalcitol 2 mcg capsules once daily (two paricalcitol 1 mcg capsules once daily)
1777909|NCT00421733|Drug|Placebo|Group 1 - Placebo once daily (two placebo capsules once daily)
1777910|NCT00421746|Drug|Piboserod|
1777912|NCT00421785|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks.|
1777913|NCT00421811|Drug|ADH-1|4 gm IV Days 1 and 8
1778135|NCT00422721|Procedure|biomicroscopical test|
1777914|NCT00421811|Drug|melphalan|By Isolated Limb Infusion (ILI), Lower Extremity: 7.5 mg/L (Limb Volume), Day 1 or Upper Extremity: 10 mg/L (Limb Volume), Day 1
1777915|NCT00421824|Drug|Oxaliplatin, capecitabine|OXA 130 D1 + Capecitabine 2000 / day D1-D14 for 4 cycles. After 10 weeks of rest, XELOX-RT regimen x 5 weeks followed by surgery
1777916|NCT00421824|Drug|Oxaliplatin, capecitabine|XELOX-RT x 5 weeks followed by surgery and 4 cycles of adjuvant XELOX with the same scheme as arm A.
1777917|NCT00421850|Behavioral|UNITED Planned Care|
1777918|NCT00421863|Drug|Triatec 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
1777919|NCT00421863|Drug|Triatec HCT 5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
1777920|NCT00421863|Drug|Lasix 25|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
1777921|NCT00421863|Drug|Micardis 80 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
1777922|NCT00421863|Drug|Micardis plus 80/12.5|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
1777923|NCT00421863|Drug|Catapresan TTS 2|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
1777924|NCT00421863|Drug|Norvasc 10 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
1777925|NCT00421863|Drug|Triatec 5 mg|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
1777926|NCT00421863|Drug|Pluscor|Use and dosage according to physician judgement, concomitant treatment assumed and randomization arm (Intensive Strategy vs. Usual Strategy).
1777927|NCT00421876|Behavioral|multifactorial continued educational - behavioural programme|
1777928|NCT00421889|Drug|belinostat|
1777929|NCT00421889|Drug|Paclitaxel|
1777930|NCT00421889|Drug|Carboplatin|
1777931|NCT00421902|Procedure|Acupuncture|
1777932|NCT00421915|Drug|Enbrel (etanercept)|
1777933|NCT00421928|Drug|oxycodone|10, 20, 30, 40, 50mg twice a day (BID) during 15 weeks
1777934|NCT00421928|Drug|placebo|matching placebo twice a day (BID) during 15 weeks
1777935|NCT00421928|Drug|tapentadol (CG5503)|50, 100, 150, 200, 250mg twice a day (BID) during 15 weeks
1777936|NCT00421941|Procedure|Tube feeding|
1777937|NCT00421954|Drug|Ziprasidone|subjects will use ziprasidone
1777938|NCT00421967|Drug|Ropivacaine, Ketorolac, adrenaline|Infiltration: 150 ml Ropivacaine 2mg/ml added 1 ml Ketorolac 30 mg/ml and 0,5 ml Adrenaline 1 mg/ml Intraarticular infusion: 4 ml/h 384 mg Ropivacaine 60 mg Ketorolac
1777939|NCT00421967|Drug|Ropivacaine Ketorolac|Epidural infusion: 4 ml/h 384 mg Ropivacaine I.V. Ketorolac 90 mg
1777940|NCT00421980|Drug|Etanercept|
1777941|NCT00421993|Drug|Adapalene/Benzoyl Peroxide|Topical Gel, One application daily in the evening for 12 weeks
1777942|NCT00421993|Drug|Adapalene|Topical Gel,One application daily in the evening for 12 weeks
1777943|NCT00421993|Drug|Benzoyl Peroxide|Topical Gel, one application daily in the evening for 12 weeks
1777944|NCT00421993|Drug|Topical Gel Vehicle|Topical Gel Vehicle,one application daily in the evening for 12 weeks
1777945|NCT00422006|Procedure|biopsy of muscle, of liver, and of adipose tissue|biopsy of muscle, of liver, and of adipose tissue
1777946|NCT00422006|Procedure|clamp euglycemic - hyperglycemic|clamp euglycemic-hyperglycemic
1777947|NCT00422006|Behavioral|diet|diet
1777948|NCT00422006|Other|biopsies for biological and genetic analyses|biopsies for biological and genetic analyses
1777949|NCT00422019|Drug|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
1777950|NCT00422019|Drug|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
1777951|NCT00422032|Drug|Clofarabine|"Group A: 15 mg/m^2 IV over 1 hour daily for 5 days
Group B: 30 mg/m^2 IV over 1 hour daily for 5 days"
1777952|NCT00422045|Device|Low Level Laser Therapy|Low Level Laser Therapy done after surgery.
1777956|NCT00422084|Drug|Pyronaridine artesunate|once a day for 3 days
1777957|NCT00422084|Drug|Coartem® (artemether lumefantrine)|twice a day for 3 days
1777958|NCT00422097|Drug|Ixabepilone, 5 mg/d|Ixabepilone, 5 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
1777959|NCT00422097|Drug|Ixabepilone, 10 mg/d|Ixabepilone, 10 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
1777960|NCT00422097|Drug|Ixabepilone, 15 mg/d|Ixabepilone, 15 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
1777961|NCT00422097|Drug|Ixabepilone, 20 mg/d|Ixabepilone, 20 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
1778136|NCT00422721|Procedure|retinal imaging|
1778137|NCT00422721|Procedure|retinal autofluorescence|
1778138|NCT00422721|Procedure|genotyping|
1777962|NCT00422097|Drug|Ixabepilone, 25 mg/d|Ixabepilone, 25 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
1777963|NCT00422097|Drug|Ixabepilone, 30 mg/d|Ixabepilone, 30 mg, administered orally once daily on Days 1 through 5 every 21 days. Dose increased by 5 mg for each subsequent treatment group until disease progression, unacceptable toxicity, or participant refusal. No dose escalation within each treatment group. On all dosing days in Cycle 1, participants must fast at least 4 hours before and 4 hours after treatment.
1777964|NCT00422097|Drug|Ixabepilone, 25 mg, with famotidine|Participants crossed over from Cycle 1 to receive famotidine, 40 mg, in an oral dose given 2 hours before ixabepilone, 25 mg, on Day 1 of Cycle 2 only.
1777965|NCT00422097|Drug|Ixabepilone, 25 mg, with food|Participants consume a low-fat meal starting 30 minutes before dose administration on Day 1 of Cycle 2. Food consumed within 30 minutes. Administration of the total oral dose should not exceed more than 10 minutes from start to finish.
1777966|NCT00422110|Drug|Seletracetam|
1777967|NCT00422123|Drug|Quetiapine fumarate (Seroquel) SR|
1777968|NCT00422149|Drug|SUBLIVAC® Grasses/Placebo treatment|SUBLIVAC® Grasses/Placebo treatment
1777969|NCT00422149|Drug|SUBLIVAC® Grasses treatment|SUBLIVAC® Grasses treatment
1777970|NCT00422149|Drug|Placebo treatment|Placebo treatment
1777971|NCT00422162|Drug|Duloxetine hydrochloride|60 mg once or twice a day, by mouth
1777972|NCT00422162|Drug|Placebo|placebo capsule by mouth
1777973|NCT00422175|Drug|BAF 312|
1777974|NCT00422188|Drug|Deoxycholic Acid Injection|Administered via intralipomal injection.
1777975|NCT00422188|Drug|Placebo|Administered via intralipomal injection.
1777976|NCT00422201|Drug|Mifepristone|Singe dose
1777977|NCT00422214|Drug|Quetiapine fumarate (Seroquel) SR|
1777978|NCT00422227|Drug|Etanercept , Methotrexate|"Etanercept: 25 mg twice weekly over 16 weeks, SC
Methotrexate: > 7.5 mg/week and no more than 25 mg/week, PO"
1777979|NCT00422227|Drug|Methotrexate; sulfasalazine; hydroxychloroquine;leflunomide|"Methotrexate: at least 7.5 mg/wk and not more than 25 mg/wk.;PO
Sulfasalazine: Start treatment w/500 mg daily for 1 wk, thereafter increase dose by 1 tab each wk to a max of 3 g/day;PO
Hydroxychloroquine:400 mg daily in divided dose, may be reduced to 200 mg. Max: 6.5 mg/kg/day
Leflunomide: Initially, loading dose 100 mg daily for 3 days. Maintenance: 20 mg daily"
1777980|NCT00422240|Drug|Adapalene/Benzoyl Peroxide|
1777981|NCT00422253|Behavioral|dietary intervention|
1777982|NCT00422266|Drug|Omega 3 fatty acids and plant sterol enriched drink|
1777983|NCT00422266|Dietary Supplement|Omega 3 fatty acids and plant sterols|Capsules and Yoghurt based minidrink
1777984|NCT00422279|Device|Nobel Replace Tapered Groovy|Bone inductive implant placed in supralveoral position or extraction site
1777985|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, intramuscular (IM)
1777986|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 mL dose, IM
1777987|NCT00422292|Biological|Meningococcal Polysaccharide Diphtheria Conjugate Vaccine|0.5 Ml dose, IM
1777988|NCT00422292|Biological|Measles, Mumps, Rubella and Varicella|0.5 mL dose, SC
1777989|NCT00422318|Drug|Benzbromarone (drug)|
1777990|NCT00422331|Drug|Lithium Carbonate Capsule|
1777991|NCT00422344|Drug|RAD001, Sunitinib|Patients will start treatment with Sunitinib and RAD001 on Cycle 1, Day 1. Sunitinib will be given orally daily for 4 weeks followed by a 2 week rest period. RAD001 will be given orally daily or weekly in subsequent cohorts with the first treatment on day 1. DLT determination will be based on toxicities observed in Cycles 1 - a cycle being defined by Sunitinib dosing. Once the MTD for the combination has been identified, a total of 10 patients will be enrolled into the study at the highest dose level that allows for administration of multiple cycles and provides potentially therapeutic drug levels of both drugs
1777992|NCT00422357|Drug|Urtica Dioica (Tea bag)|
1777993|NCT00422370|Device|lipid based additives based on vegetable oil & lecithin|
1777994|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv in days 1 and 15, and 500mg iv on days 168 and 182
1777995|NCT00422383|Drug|rituximab [MabThera/Rituxan]|500mg iv on days 1 and 15, and 1000mg iv on days 168 and 182
1777996|NCT00422383|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15 and 1000mg iv (or placebo in UK)on days 168 and 182
1777997|NCT00422396|Drug|Fenofibrate (drug)|
1777998|NCT00422409|Procedure|Endoscopic stenting|
1777999|NCT00413777|Drug|Tolvaptan|Participants were titrated to either the tolvaptan 45/15 or 60/30 mg split-dose over a 2-month Titration Period. They received the titrated dose for 34 months during the Fixed-dose Period. Following a planned off-treatment period, participants had the option to enter an Extension Period for an additional 12 months. Tolvaptan was supplied as tablets.
1778000|NCT00413790|Drug|Darifenacin|Darifenacin tablets 15 mg once daily
1778001|NCT00413790|Drug|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
1778002|NCT00413790|Drug|Placebo|Placebo tablet once daily
1958303|NCT01783444|Drug|Everolimus|Everolimus will be centrally dispensed via IWRS. Everolimus will be taken as oral tablets for oral use 10 mg (2 × 5 mg) daily.
1778005|NCT00413829|Drug|Intravitreal ranibizumab with photodynamic therapy|Intravitreal injection, photodynamic therapy
1778006|NCT00413855|Procedure|laparoscopic appendectomy or not (surgery)|
1778007|NCT00413868|Procedure|LASIK|
1778008|NCT00413868|Procedure|PRK|
1778009|NCT00413868|Behavioral|Small target contrast sensitivity and disability glare|
1778010|NCT00413881|Procedure|WAVEFRONT- GUIDED LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using wavefront guided LADARvision 4000 excimer laser system
1778011|NCT00413881|Procedure|CONVENTIONAL LASIK ENHANCEMENT|Laser treatment to correct residual refractive error left over from initial LASIK correction using LADARvision 4000 excimer laser system.
1778012|NCT00413894|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv monthly, with starting dose based on previous dose of epoetin alfa or beta or darbepoetin alfa
1778308|NCT00424970|Drug|acetazolamide|
1778013|NCT00413920|Drug|Enteric-coated mycophenolate sodium (EC-MPS)|An initial dose of 1080 mg EC-MPS was administered immediately before transplantation. Then, during the first 6 weeks post-transplantation, EC-MPS was administered at a dose of 1080 mg twice a day 12 hours apart. From week 7 until the end of the study (month 6), EC-MPS was administered at standard dose of 720 mg twice a day.
1778014|NCT00413920|Drug|Prednisone|Oral tablets
1778015|NCT00413933|Procedure|Comprehensive Multidisciplinary Intervention|Comprehensive Multidisciplinary Intervention
1778016|NCT00413946|Drug|Recombinant human Erythropoietin|3 doses 3000 units (1 ml) of recombinant human erythropoietin per kg body weight
1778017|NCT00413946|Drug|saline|three doses of 1.0 ml saline per body weight
1778018|NCT00413959|Drug|VELCADE®|1.6 mg/m^2 of Velcade® given intravenously on days 1, 8, 15 and 22.
1778019|NCT00413959|Drug|Rituximab|375 mg/m^2 of Rituximab given intravenously on days 1, 8, 15 and 22 during the first cycle then on day 1 of each subsequent cycle.
1778020|NCT00413959|Drug|Cyclophosphamide|400 mg/m^2 of Cyclophosphamide given orally on days 1-4 of each cycle.
1778021|NCT00413959|Drug|Decadron|40 mg given orally on days 1, 2, 8, 9, 15, 16, 22 and 23
1778022|NCT00413972|Drug|ezetimibe with simvastatin|Ezetimibe 10 mg with Simvastatin 10 mg once daily for a total of eight weeks
1778023|NCT00413972|Drug|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 20 mg once daily for a total of eight weeks
1778024|NCT00413972|Drug|Ezetimibe with Simvastatin|Ezetimibe 10 mg with Simvastatin 40 mg once daily for a total of eight weeks
1778025|NCT00413972|Drug|Placebo|Placebo once daily for a total of eight weeks
1778026|NCT00413985|Drug|Nutrient-enriched human milk|
1778027|NCT00413998|Procedure|CABG + Mitral valve annuloplasty|Patients will receive a mitral annuloplasty ring in addition to coronary artery bypass grafting.
1778028|NCT00413998|Procedure|CABG|Patients will undergo coronary artery bypass grafting alone.
1778029|NCT00414011|Drug|Moxifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
1778030|NCT00414011|Drug|Gatifloxacin|1 drop 4 times daily for 1 week or until complete re-epithelization (usually 3-4 days) after surgery
1778031|NCT00414024|Drug|Tegaserod|
1778032|NCT00414037|Drug|Eszopiclone|
1778033|NCT00414037|Drug|Placebo|Placebo-treatment
1778034|NCT00414050|Biological|Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine given intramuscularly (IM) in 3 injections of 5 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 5 μg arm). Modified Process Hepatitis B Vaccine given IM in 3 Injections of 10 ug (micrograms)/0.5 mL each over 4 months (Modified Process Hepatitis B vaccine 10 μg arm).
1778035|NCT00414050|Biological|Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM in 3 Injections of 5 ug/0.5 mL each over 4 months.
1778036|NCT00414050|Biological|Hepatitis B Vaccine (Recombinant)|ENGERIX-B® (currently licensed product) given IM in 3 Injections of 10 ug/0.5 mL each over 4 months
1778037|NCT00414076|Drug|Letrozole|2.5 mg Tablet By Mouth Daily for 12 Weeks.
1778038|NCT00414089|Drug|90Y-ibritumomab tiuxetan (Zevalin)|
1778039|NCT00414102|Drug|Ramelteon|Ramelteon 8mg, tablets, orally, once nightly for up to 28 days.
1778040|NCT00414102|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 28 days.
1778041|NCT00414128|Drug|mycophenolate mofetil|2-3g/day for 3-6 months, in tablet, capsule or liquid form
1778042|NCT00414128|Drug|cyclophosphamide|intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
1778043|NCT00414141|Biological|Grass MATA MPL|4 subcutaneous injections
1778044|NCT00414141|Biological|Placebo|4 subcutaneous injections
1778045|NCT00414154|Behavioral|Group based multidisciplinary patient education programme|
1778046|NCT00414167|Drug|bupropion|300 mg per day for 8 weeks
1778047|NCT00414167|Other|Placebo|Placebo
1778048|NCT00414180|Drug|Bupropion SR|
1778049|NCT00414206|Drug|Mecamylamine|
1778050|NCT00414206|Drug|Placebo|
1778051|NCT00414219|Behavioral|Visual quality of patients with corneal eye injuries|Visual quality of patients with corneal eye injuries
1778052|NCT00414245|Drug|metformin|
1778053|NCT00414258|Procedure|breastfeeding|See detailed description.
1778055|NCT00414284|Drug|Increased dose of Kaletra|
1778056|NCT00414297|Device|ECP Therapy|application of ECP Therapy to CAD Patients
1778057|NCT00414310|Drug|Decitabine|20 mg/m^2 IV over 1 hour daily for 5 days.
1778058|NCT00414310|Drug|Valproic Acid|50 mg/kg orally daily for 7 days
1778059|NCT00414323|Drug|Duloxetine|
1778060|NCT00414323|Drug|Escitalopram|
1778061|NCT00414323|Drug|Placebo|
1778062|NCT00414336|Drug|AMA1-C1/Alhydrogel + CPG 7909 Vaccine|
1778063|NCT00414349|Drug|Topical analgesic|max. 3 plasters per day for PHN patients max. 4 plasters per day for DPN patients
1778064|NCT00414349|Drug|oral intake|300 to 600 mg per day taken orally
1778065|NCT00414349|Drug|Topical analgesic|3 plasters for PHN patients per day 4 plasters for DPN patients per day
1778066|NCT00414375|Procedure|Operation on Admission|Laparoscopic appendectomy on admission
1778067|NCT00414375|Procedure|Drainage and Interval Appendectomy|drainage with interval appendectomy
1778068|NCT00414388|Drug|Sorafenib|400mg twice daily
1778069|NCT00414401|Behavioral|Clinical Reminder|
1778070|NCT00414414|Drug|Prednisone|
1778071|NCT00414414|Drug|placebo|placebo
1778072|NCT00414427|Procedure|Intraarticular steroids|
1778073|NCT00414440|Drug|Placebo|placebo comparator
1778074|NCT00414440|Drug|Everolimus|experimental
1778075|NCT00414453|Drug|Lidocaine patch 5%|lidocaine 5% patch; 12 hours on, 12 hours off
1778076|NCT00414453|Drug|Extended-release oxycodone|extended-release oxycodone titrating schedule
1778077|NCT00414453|Drug|Placebo extended-release oxycodone pills|placebo pills with titrating schedule
1778078|NCT00414453|Drug|Placebo lidocaine patches|used with extended release oxycodone group; used with placebo pills/placebo patches
1778309|NCT00424983|Drug|Zoledronic acid|
1778079|NCT00414466|Drug|Intraspinal Gabapentin|Surgical implantation of a drug infusion system with intrathecal (spinal) delivery of active drug (1 of 3 possible dose levels) or placebo (saline) for 22 days followed by 7 days of infusion at half dose level. Subjects may then continue in open-label treatment with study drug. Dosage in open-label may be adjusted to meet subject needs.
1778080|NCT00414479|Drug|praziquantl, iron, ACT|
1778081|NCT00422422|Drug|Brivaracetam|"Oral solution
Evaluation period (3 weeks up-titration):
For subjects ≥8 years:
~0.4 mg/kg bid for Week 1
~0.8 mg/kg bid for Week 2
~1.6 mg/kg bid for Week 3
For subjects <8 years:
~0.5 mg/kg bid for Week 1
~1.0 mg/kg bid for Week 2
~2.0 mg/kg bid for Week 3
Down-titration period (up to 2 weeks):
For subjects ≥8 years:
~0.8 mg/kg bid for Week 4
~0.4 mg/kg bid for Week 5
For subjects <8 years:
~1.0 mg/kg bid for Week 4
~0.5 mg/kg bid for Week 5"
1778082|NCT00422435|Device|CoStar™ Paclitaxel-Eluting Coronary Stent with SRX catheter|Paclitaxel-Eluting Coronary Stent
1778083|NCT00422448|Genetic|To test the frequency of BRAF and NRAS mutations among nevi|Benign nevi excised for the study purpose where genetically analyzed for the presence/absence of BRAF and NRAS mutations
1778084|NCT00422461|Drug|PF-00489791|PF-00489791 4 mg, oral, tablets, once daily, for 28 days
1778085|NCT00422461|Drug|PF-00489791|PF-00489791 10 mg, oral, tablets, once daily, for 28 days
1778086|NCT00422461|Drug|PF-00489791|PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days
1778087|NCT00422461|Drug|placebo|placebo, oral, tablets, once daily, for 28 days
1778088|NCT00422487|Drug|MBX-2044|MBX-2044 1.5 mg one capsule daily for 14 days
1778089|NCT00422487|Drug|MBX-2044|MBX-2044 4.5 mg three 1.5 mg capsules daily for 14 days
1778090|NCT00422487|Drug|MBX-2044|MBX-2044 15 mg one capsule daily for 14 days
1778091|NCT00422487|Drug|MBX-2044|MBX-2044 30 mg two 15 mg capsules daily for 14 days
1778092|NCT00422487|Drug|MBX-2044|MBX-2044 60 mg one capsule daily for 14 days
1778093|NCT00422487|Drug|MBX-2044|MBX-2044 90 mg one 60 mg capsule and two 15 mg capsules daily for 14 days
1778094|NCT00422487|Drug|Placebo for MBX-2044|Placebo Intervention
1778095|NCT00422500|Behavioral|Questionnaire|Surveys about symptoms, mood, and quality of life.
1778096|NCT00422500|Behavioral|Telephone Interactive System|Automated telephone system call once a week during therapy, rating of severity of symptoms and daily life interference done with numeric key pad. Post therapy is complete, a call every two weeks for up to six months.
1778097|NCT00422500|Other|Blood Samples|For participating patients, 3 additional tablespoons of blood drawn at the beginning of each chemotherapy treatment (before treatment starts) and at the beginning of each cycle of treatment.
1778098|NCT00422513|Drug|methoxy polyethylene glycol-epoetin beta|120-360 micrograms intravenous (iv) monthly, starting dose
1778099|NCT00422513|Drug|Epoetin alfa|As prescribed, iv, 3 times weekly
1778100|NCT00422526|Drug|Micronised progesterone (Utrogestan)|
1778101|NCT00422539|Drug|70% trichloroacetic acid|
1778102|NCT00422552|Drug|Indacaterol (QAB149)|
1778103|NCT00422565|Device|Endeavor, Medtronic|Zotarolimus-eluting stent
1778104|NCT00422565|Device|Cypher, Cordis|Sirolimus-eluting stent
1778105|NCT00422565|Device|Taxus Liberte, Boston Scientific|Paclitaxel-eluting stent
1778106|NCT00422578|Drug|tadalafil|
1778107|NCT00422591|Drug|Cytarabine|1.5 g/m2 IV over 24 hours daily on day 1-4 (age <60 years) or days 1-3 (age > 60 years).
1778108|NCT00422591|Drug|Idarubicin|12 mg/m2 IV over 1 hour daily x 3 (days 1-3)
1778109|NCT00422604|Drug|salmeterol|
1778110|NCT00422604|Drug|tiotropium|
1778111|NCT00422604|Drug|GSK233705|
1778112|NCT00422617|Drug|Alefacept (Amevive)|
1778113|NCT00422630|Behavioral|The DASH diet|The DASH diet was originally conceived as the optimal diet for individuals with hypertension, based on epidemiologic and clinical trial data suggesting a beneficial effect of plant-based diets on blood pressure It is a diet rich in fruits, vegetables, whole grains, and low-fat dairy products, with moderate amounts of nuts, legumes, fish, and poultry. Consumption of red meat, sweets, and sugary beverages is limited. As a result, the DASH diet contains more potassium, magnesium, calcium, and fiber and less total fat, saturated fat, cholesterol, simple sugars, and sodium than the average American diet
1778114|NCT00422630|Behavioral|The low glycemic Index Diet|The carbohydrate content of a low GI diet can vary, but many advocates of low GL popular diets suggest a macronutrient profile that is 40% carbohydrate, 30% protein, and 30% fat. These low GL diets are lower in carbohydrate content and higher in protein content than the average American diet. Low GL diets typically contain ample amounts of fruits and vegetables, moderate quantities of nuts, legumes, lean meats, fish, and reduced-fat dairy products, and scant amounts of refined grains, potatoes, and sweets
1778115|NCT00422630|Behavioral|Reduced calorie American Diet|The reduced-calorie diets will provide at least the Recommended Daily Allowance (RDA) for protein (0.8 g/kg/day).
1778116|NCT00422643|Drug|Sodium hyaluronate (hyaluronic acid)|
1778117|NCT00422656|Drug|Perifosine|Taken orally every night for 6 back to back 28 day cycles. Participant may continue on treatment if there is no disease progression at the discretion of the treating investigator
1778118|NCT00422669|Device|Medtronic Dual-Chamber Pacemaker|A Medtronic market-approved dual-chamber implantable pulse generator (IPG)
1778119|NCT00422669|Device|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
1778120|NCT00422682|Drug|bsi-201 + topotecan|21 day cycle
1778121|NCT00422682|Drug|bsi-201 + temozolomide|28 day cycle
1778122|NCT00422682|Drug|bsi-201 + gemcitabine|28 day cycle
1778123|NCT00422682|Drug|bsi-201 + carboplatin/paclitaxel|21 day cycle
1778124|NCT00422708|Procedure|Local anesthesia|
1778125|NCT00422721|Procedure|realization of a family tree|
1778126|NCT00422721|Procedure|refractometry|
1778127|NCT00422721|Procedure|evaluation of the presence of a nystagmus|
1778128|NCT00422721|Procedure|ocular behavior|
1778129|NCT00422721|Procedure|test of baby vision|
1778130|NCT00422721|Procedure|test of keenness|
1778131|NCT00422721|Procedure|reading test|
1778132|NCT00422721|Procedure|visual field|
1778133|NCT00422721|Procedure|color vision|
1778134|NCT00422721|Procedure|electroretinographical activity|
1778139|NCT00422734|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day for 12 weeks
1778140|NCT00422734|Drug|Placebo|placebo tablet taken by mouth once a day for 12 weeks
1778141|NCT00422747|Drug|beclomethasondipropionate|2 x 100 ug dd for two months, via aerochamber
1778142|NCT00423839|Biological|MVA85A (Tuberculosis vaccine)|
1778143|NCT00423852|Biological|filgrastim|
1778144|NCT00423852|Drug|carboplatin|
1778145|NCT00423852|Drug|ifosfamide|
1778146|NCT00423852|Drug|paclitaxel|
1778147|NCT00423852|Procedure|autologous hematopoietic stem cell transplantation|
1778148|NCT00423852|Procedure|peripheral blood stem cell transplantation|
1778149|NCT00423865|Drug|cisplatin|cisplatin (20 mg/m2 intravenously on Days 1, 8, and 15)
1778150|NCT00423865|Drug|everolimus|escalating doses of daily RAD001 tablets (per oral or via percutaneous gastrostomy tube, Days 1 -21 of a 28-Day Cycle)
1778151|NCT00423865|Genetic|gene expression analysis|Each biopsy specimen will be formalin-fixed and paraffin-embedded for IHC, and analysis of p53 and p21 will follow methods previous reported by our group. The avidin-biotin immunoperoxidase technique will be employed.
1778152|NCT00423865|Other|immunohistochemistry staining method|After the phase 2 recommended dose is established in the phase I portion of the study (Part A), we plan to enroll an additional 6 patients for pharmacodynamic studies (Part B). Entry into Part B requires the patient have tumor tissue which is easily accessible for research biopsy. The patients will be asked to provide written informed consent for the research biopsies. Patients also will be asked to provide written informed consent to allow the use of their tissue for future research studies. The research biopsies are not mandatory for any patient. Patients who do not consent to the research biopsies or who withdraw consent for the research biopsies may still receive RAD001 + cisplatin in the study
1778153|NCT00423865|Other|laboratory biomarker analysis|Laboratory data (complete blood count, comprehensive metabolic panel including magnesium) regarding adverse events will be collected on each cisplatin treatment day. Additional adverse event data will be collected at regularly scheduled clinic visits at which history and physical are performed by the investigator (Cycle 1 - Days 1, 8, 15, and 21. Cycle 2 - Days 1 and 15. Cycle 3 and beyond - Day 1)
1778154|NCT00423865|Other|pharmacological study|For patients in Part A, research bloods for pharmacokinetics are drawn on Day 1 and Day 8.
1778155|NCT00423865|Procedure|biopsy|"Pre-treatment Research Biopsy: Within 14 days prior to treatment, research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be performed. Baseline labs should be drawn within 14 days of the research biopsy. The biopsy sample will be formalin-fixed and paraffin-embedded for immunohistochemistry. Post-treatment Research Biopsy: Research biopsy (of primary tumor, metastatic deposit, or involved lymph node) will be requested again for Day 15 of Cycle 1, prior to administration of RAD001 and cisplatin on that day."
1778156|NCT00423878|Drug|Risperidone|Continued treatment with the medication risperidone for schizophrenia for up to 6 months in study
1778157|NCT00423878|Drug|Olanzapine|Continued treatment with the medication olanzapine for schizophrenia for up to 6 months in study
1778158|NCT00423878|Drug|Quetiapine|Continued treatment with the medication quetiapine for schizophrenia for up to 6 months in study
1778159|NCT00423878|Drug|Aripiprazole|Switching medication to aripiprazole for schizophrenia for up to 6 months in study
1778160|NCT00423891|Drug|Entecavir|Tablets / Oral Solution, Oral, Naïve: 0.015 mg/kg up to 0.5 mg; Experienced: 0.030 mg/kg up to 1 mg, once daily, 48 - 120 weeks depending on response
1778161|NCT00423904|Behavioral|Brief intervention|
1778162|NCT00423917|Biological|bevacizumab|
1778163|NCT00423917|Drug|fulvestrant|
1778164|NCT00423930|Biological|bevacizumab|
1778165|NCT00423930|Drug|cisplatin|
1778166|NCT00423930|Procedure|conventional surgery|
1778167|NCT00423930|Radiation|intensity-modulated radiation therapy|
1778168|NCT00423943|Drug|modafinil|200 milligrams daily dose
1778169|NCT00423943|Drug|Placebos|capsule containing placebo
1778171|NCT00423969|Drug|Galantamine|
1778172|NCT00423969|Drug|Escitalopram|
1778173|NCT00423982|Drug|Rifampin-combination therapy|Rifampin 300 mg x 3 po and cloxacillin 2 g x 4 iv for two weeks. Then rifampin 300 mg x 3 po and cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, rifampin 300 mg x 3 po and vancomycin 1 g x 2 iv for 6 weeks.
1778174|NCT00423982|Drug|Monotherapy|Cloxacillin 2 g x 4 iv for two weeks, then cloxacillin 1 g x 4 po for 4 weeks. In case of methicillin resistance, vancomycin 1 g x 2 iv for 6 weeks.
1778175|NCT00423995|Drug|Loratadine/montelukast combination|
1778176|NCT00424008|Drug|Mometasone furoate/formoterol (MF/F) MDI|MF/F 200/10 mcg via a metered dose inhaler (MDI) twice daily for 52 weeks.
1778177|NCT00424008|Drug|Fluticasone propionate/salmeterol (F/SC) DPI|Fluticasone propionate 250 mcg and salmeterol 50 mcg fixed dose combination dry powder inhaler taken twice daily for 52 weeks.
1778178|NCT00424021|Drug|ambrisentan|1, 2.5, 5, and 10 mg ambrisentan given orally once daily
1778179|NCT00424034|Drug|GSK1325760A|
1778183|NCT00424060|Drug|sagopilone|
1778184|NCT00424060|Genetic|fluorescence in situ hybridization|
1778185|NCT00424060|Genetic|gene expression analysis|
1778186|NCT00424060|Other|immunohistochemistry staining method|
1778187|NCT00424060|Other|laboratory biomarker analysis|
1778188|NCT00424060|Other|pharmacological study|
1778189|NCT00424086|Biological|Inactivated seasonal influenza vaccine (split virus, vero cell derived)|
1778190|NCT00424086|Biological|Inactivated seasonal influenza vaccine (split virus, egg derived) [licensed control vaccine]|
1778191|NCT00424099|Drug|Methylphenidate|5 mg (one capsule) orally every two hours as needed up to a maximum of 20 mg per day for a period of 14 days.
1778192|NCT00424099|Behavioral|Nursing Telephone Intervention|Call from study nurse 3 times weekly to ask about side effects and other symptoms.
1778193|NCT00424099|Drug|Placebo|One capsule, orally every two hours as needed up to a maximum of 4 capsules per day for a period of 14 days.
1778194|NCT00424125|Behavioral|Enhanced Pharmacy Care|"Participants randomized to Enhanced Pharmacy Care will have their prescriptions electronically transmitted or faxed to one of the five participating pharmacies.
Pharmacists will then provide real-time, targeted education around the purpose and use of the new and refilled ICS medications to study participants and their families at each point of contact, including rationale for their use, device teaching, dosage review, and importance of compliance. Families randomized to enhanced care will also be contacted monthly by phone and mail with reminders to fill their controller medications prescriptions and to seek ongoing longitudinal asthma care with their primary care providers."
1778195|NCT00424125|Behavioral|Control|Usual care.
1778196|NCT00424138|Radiation|FDG|
1778197|NCT00424151|Drug|Rituximab|
1778198|NCT00424164|Drug|lapatinib ditosylate|
1778199|NCT00424164|Drug|tamoxifen citrate|
1778200|NCT00424164|Other|pharmacological study|
1778201|NCT00424177|Drug|eltrombopag|experimental
1778202|NCT00424190|Drug|IV Vancomycin plus IV Aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
1778203|NCT00424190|Drug|Ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
1778204|NCT00424203|Drug|AC regimen|
1778205|NCT00424203|Drug|cyclophosphamide|
1778206|NCT00424203|Drug|doxorubicin hydrochloride|
1778207|NCT00424203|Procedure|adjuvant therapy|
1778208|NCT00424203|Procedure|cognitive assessment|
1778209|NCT00424203|Procedure|management of therapy complications|
1778210|NCT00424203|Procedure|psychosocial assessment and care|
1778211|NCT00424203|Procedure|quality-of-life assessment|
1778212|NCT00424216|Procedure|DC Polarization|
1778213|NCT00424229|Drug|LENALIDOMIDE|
1778214|NCT00424242|Drug|Pemetrexed|Orally beginning at 500 mg/m2 every 3 weeks until disease progression
1778215|NCT00424255|Drug|Lapatinib|Dual ErbB1/2 inhibitor
1778216|NCT00424255|Radiation|Chemoradiation|Radiation plus platinum based chemotherapy
1778217|NCT00424255|Other|Placebo|Placebo
1778218|NCT00424268|Drug|Roflumilast|500 µg, once daily, oral administration in the morning
1778219|NCT00424268|Drug|Placebo|once daily
1778220|NCT00424281|Drug|Arixtra (fondaparinux), 2.5 mg/day-what is bioavailability|
1778221|NCT00424294|Drug|CP-195,543|CP-195543 is a potent and specific antagonist of the leukotriene B4 (LTB4) receptor.
1778222|NCT00424294|Drug|celecoxib|Celecoxib is a nonsteroidal anit-inflammatory drug (NSAID) marketed worldwide (in the United States [US] as Celeberex) and approved for the relief of signs and symptoms of osteoarthritis.
1778223|NCT00424294|Drug|Methotrexate|Methotrexate is a folate analogue that, based on it efficacy and safety in RA, is commonly used as frontline DMARD treatment in patients with moderate to severe disease who do not respond to NSAIDs alone.
1778224|NCT00424307|Device|HiResolution Bionic Ear System|
1778225|NCT00424320|Drug|Sodium bicarbonate|
1778226|NCT00424333|Drug|Inhaled human insulin|
1778227|NCT00424346|Drug|Canakinumab|
1778228|NCT00424346|Drug|Placebo|
1778229|NCT00424372|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
1778230|NCT00424385|Drug|Gleevec + Sorafenib|400 mg Sorafenib every day (QD) 300mg Gleevec QD
1778231|NCT00424398|Drug|Bepreve|sterile ophthalmic solution
1778232|NCT00424398|Drug|Placebo|sterile ophthalmic solution
1778233|NCT00424398|Drug|Bepotastine Besilate|sterile ophthalmic solution
1778234|NCT00424411|Drug|Inhaled human insulin (EXUBERA™)|
1778235|NCT00424424|Drug|MK0719|
1778236|NCT00424437|Drug|Inhaled human insulin|
1778237|NCT00424450|Procedure|lower limb artery bypass surgery|bypass of severe atherosclerotic vascular lesion
1778238|NCT00424450|Procedure|percutaneous angioplasty (PTA)|PTA of severe atherosclerotic lesion
1778241|NCT00424476|Drug|Placebo|Placebo IV plus standard therapy; placebo administered on Days 0, 14, 28, and every 28 days thereafter through Week 48.
1778242|NCT00424476|Drug|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
1778243|NCT00424476|Drug|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV plus standard therapy on Days 0, 14, 28, and every 28 days thereafter through Week 48.
1778245|NCT00424502|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
1778246|NCT00424502|Drug|Methotrexate|10-25mg po/week
1778247|NCT00424515|Drug|Imatinib|Imatinib was given at a dose of 400 mg orally daily (4 100mg pills). Patients received treatment up to 12 months as long as they were receiving clinical benefit. Dosage may have been increased to twice daily if disease worsened and patient was in otherwise good clinical condition.
1778248|NCT00424528|Drug|Arformoterol Tartrate Inhalation Solution|Arformoterol tartrate inhalation solution 15 mcg twice daily and placebo inhalation powder once daily.
1778249|NCT00424528|Drug|Tiotropium|Placebo inhalation solution twice daily and tiotropium inhalation powder 18 mcg once daily.
1778250|NCT00424528|Drug|Arformoterol and Tiotropium|Arformoterol tartrate inhalation solution 15 mcg twice daily and Tiotropium inhalation powder 18 mcg once daily.
1778251|NCT00424528|Drug|Placebo|Placebo inhalation solution and placebo inhalation powder
1778252|NCT00424541|Drug|SPP100 (aliskiren)|
1778310|NCT00425009|Drug|Berberine|
1778311|NCT00425009|Drug|Metformin|
1778254|NCT00424567|Procedure|Fracture surgery|
1778255|NCT00424567|Drug|Cultured Bone Marrow Tissue|
1778256|NCT00424580|Drug|Montelukast (10mg) and Desloratadine (5mg)|
1778257|NCT00424593|Drug|Duloxetine|30 mg, every day (QD), by mouth (PO) for 1 week followed by 60 mg, QD, PO, 6 weeks then 60 mg (responders) or 120 mg (non-responders), QD, PO, 6 weeks during the placebo-controlled phase, then 60 mg or 120 mg, QD, PO, 41 weeks during the extension phase
1778258|NCT00424593|Drug|Placebo|every day (QD), by mouth (PO), 13 weeks
1778259|NCT00424606|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 intravenously (IV) every 3 weeks for 4 consecutive cycles
1778260|NCT00424606|Drug|Epirubicin|Epirubicin at the dose of 90 mg/m2 IV every 3 weeks for 4 consecutive cycles
1778261|NCT00424606|Drug|Epirubicin|Epirubicin at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
1778262|NCT00424606|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV every 3 weeks for 6 consecutive cycles
1778263|NCT00424619|Drug|Vitamin D2|50 000 IU vitamin D2, one time bolus dose
1778264|NCT00424619|Drug|Vitamin D2|100 000 IU vitamin D2, one time bolus dose
1778265|NCT00424619|Drug|Placebo|Placebo, 1 time bolus dose
1778266|NCT00424632|Drug|PF-03814735|1, 5, and 25 mg gelatin capsules administered orally once a day from day 1 to day 5, or from day 1 to day 10 every 3 weeks until disease progression or unacceptable toxicity.
1778267|NCT00424645|Drug|Voraxaze (Glucarpidase)|50 units/kg IV within 12 hours of study eligibility being confirmed.
1778268|NCT00424645|Drug|Placebo|Administered by IV within 12 hours of study eligibility being confirmed.
1778269|NCT00424658|Procedure|SAHS diagnosis|
1778270|NCT00424671|Drug|Licarbazepine|
1778271|NCT00424684|Procedure|collection of blood sample|
1778272|NCT00424697|Drug|placebo|
1778273|NCT00424697|Drug|lorazepam|
1778274|NCT00424697|Drug|GW876008|
1778275|NCT00424710|Drug|ranibizumab intravitreal injection|liquid, 0.5 mg ranibizumab intravitreally, once a month for 1 year
1778276|NCT00424723|Drug|Pemetrexed|Given intravenously over 10 minutes every 21 days (21 days equals one cycle). Subjects will continue to receive pemetrexed as long as their disease does not worsen and they do not experience any serious side effects.
1778277|NCT00424736|Procedure|whole body CT scan|
1778278|NCT00424749|Drug|Rituximab|Patients received 4 weekly doses of rituximab 375 mg/m^2.
1778279|NCT00424749|Drug|Prednisone|Prednisone 1 mg/kg/day (not to exceed 80 mg/day) for 4 weeks followed by a taper to 0 mg by 6 months
1778280|NCT00424762|Drug|rosiglitazone|6 months of treatment of blinded study drug
1778281|NCT00424762|Drug|placebo|blinded treatment with matching placebo
1778282|NCT00424775|Drug|MK0683, vorinostat|vorinostat 300 mg or 400 mg once daily consecutive days (14 days) followed by 11 days of rest in the first cycle or 7 days of rest in the second or later cycle.
1778283|NCT00424788|Procedure|Plasma exchange|
1778284|NCT00424788|Drug|natalizumab treatment|
1778285|NCT00424801|Drug|Lercanidipine|Individual titration, max. dose 20 mg OD for 8 months
1778286|NCT00424801|Drug|Valsartan|Individual titration, max. dose 160 mg OD for 8 months
1778287|NCT00424801|Drug|Nicorandil|Individual titration, max. dose 20 mg BD for 8 months
1778288|NCT00424801|Drug|Doxazosin|Individual titration, max. dose 4 mg OD for 8 months
1778289|NCT00424801|Drug|Moxonidin|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 0,2 mg OD for 8 months
1778290|NCT00424801|Drug|Pindolol|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 10 mg OD for 8 months
1778291|NCT00424801|Drug|Amiloride, hydrochlorothiazide|Possible add-on therapy in case target blood pressure can not be reached with a combination of the other drugs in the Vasodilatory arm. Individual titration, max. dose 1 tbl. OD for 8 months
1778292|NCT00424814|Drug|Kaletra (lopinavir/ritonavir)|(200/50 mg x2)x 2/d= 2 pills twice daily
1778293|NCT00424814|Drug|Kaletra (lopinavir/ritonavir) + Combivir (zidovudine/lamivudine)|Kaletra (lopinavir/ritonavir): (200/50 mg x2)x 2/d= 2 pills twice daily Combivir (zidovudine/lamivudine): (300/150mg) x 2/d=1 pill twice daily
1778294|NCT00424827|Drug|Gemcitabine/Fluorouracil with External Beam Radiation|This protocol will assess the antitumor activity of gemcitabine (200 mg/m2 per week) and cetuximab (400mg/m2 loading dose followed by 250 mg/m2 weekly) when given with continuous infusion 5-FU (200 mg/m2/day/M-F) and daily concurrent external beam radiation therapy (50.4 Gy) in patients with non-metastatic, locally advanced pancreatic carcinoma.
1778296|NCT00424853|Drug|Docetaxel and cisplatin followed by gemcitabine|docetaxel 75 mg/m2 day 1 + cisplatin 75 mg/m2 day1 repeated every 21 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles
1778297|NCT00424853|Drug|docetaxel and cisplatin followed by gemcitabine|docetaxel 25 mg/m2 day 1,8,15 + cisplatin 25 mg/m2 days1,8,15 repeated every 28 days for 3 cycles followed by gemcitabine 1200 mg/m2 day 1,8 repeated every 21 days for 3 cycles.
1778298|NCT00424866|Drug|FGF-1|"Doses of FGF-1:
Vehicle: 0 µg/kg Low dose: 3.0 μg/kg Mid dose: 10 μg/kg High dose: 30 µg/kg"
1778299|NCT00424892|Drug|Desvenlafaxine Sustained Release|
1778300|NCT00424905|Drug|Bacillus clausii|2 Enterogermina vials/day for 12 to 17 days (i.e. during the 5 to 10-days antibiotic treatment and for 7 days thereafter.
1778301|NCT00424918|Behavioral|Physical Activity, reduced sedentary behavior|
1778302|NCT00424931|Drug|JNJ-17216498|50mg one time
1778303|NCT00424931|Drug|JNJ-17216498|10mg one time
1778304|NCT00424931|Drug|Modafinil|200 mg X 2
1778305|NCT00424944|Biological|GMZ2 (malaria vaccine)|100 micrograms of GMZ2 in each vaccination
1778306|NCT00424944|Biological|GMZ2 malaria vaccine|100 micrograms of GMZ2
1778307|NCT00424944|Biological|Verorab vaccine|Anti-rabies vaccine
1778313|NCT00425035|Drug|Panitumumab (ABX-EGF)|
1778314|NCT00425048|Procedure|wearing gloves|
1778315|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
1778316|NCT00425061|Biological|IMA-638|SC Injection, 12 weeks
1778317|NCT00425061|Other|placebo|placebo
1778318|NCT00425074|Drug|slow release acetyl salicylic acid|150 mg in capsules via oral, during 14 days.
1778319|NCT00425074|Drug|ASA|normal release acetylsalicylic acid
1778320|NCT00425074|Drug|SR-ASA|slow release acetylsalicylic acid 150 mg
1778321|NCT00425100|Drug|fesoterodine fumarate|12 weeks of study treatment: Subjects received fesoterodine tablets 4 mg once daily for 4 weeks; thereafter, daily dosage was maintained at 4 mg or increased to 8 mg based on subject's and physician's subjective assessment of efficacy and tolerability.
1778322|NCT00425113|Drug|Metronidazole|
1778323|NCT00425113|Procedure|Blood Draw|
1778324|NCT00425113|Procedure|CT Scan|
1778325|NCT00425113|Procedure|PET Scan|
1778326|NCT00425126|Drug|Epoetin Alfa|
1778327|NCT00425139|Behavioral|Re-Mission|
1778328|NCT00425152|Drug|fluorouracil|
1778329|NCT00425152|Drug|leucovorin calcium|
1778330|NCT00425152|Drug|levamisole hydrochloride|
1778331|NCT00425165|Drug|denufosol tetrasodium (INS37217) Inhalation Solution|Denufosol 60 mg is administered as an inhalation solution one time during the study.
1778332|NCT00425178|Drug|FGF-1|
1778333|NCT00425191|Drug|Docetaxel and Gemcitabine|Docetaxel: 40 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 8 immediately followed by Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8
1778334|NCT00425191|Drug|Docetaxel and Gemcitabine|Docetaxel: 50 mg/m², administered IV over 60 minutes (infusion drop by drop during the first five minutes) on day 1 and 15 immediately followed by Gemcitabine: 1600 mg/m2, administered IV over 30 minutes on day 1 and 15.
1778335|NCT00425191|Drug|Gemcitabine cisplatin followed by docetaxel|Gemcitabine: 1200 mg/m2, administered IV over 30 minutes on day 1 and 8 followed by Cisplatin 75 mg/m2, administered IV over 30-60 minutes on day 2
1778336|NCT00425204|Drug|Panitumumab (ABX-EGF)|Dose received in previous studies will be rolled over to this study. These regimens include: 2.5 mg/kg weekly; 6.0 mg/kg every 2 weeks; and 9.0 mg/kg every 3 weeks.
1778337|NCT00425217|Drug|Rituximab|
1778338|NCT00425230|Drug|Duloxetine|
1778339|NCT00425243|Drug|zolpidem-MR (SL800750)|
1778340|NCT00425256|Drug|Bremelanotide|
1778341|NCT00425269|Behavioral|lifestyle intervention (diet and physical activity)|The intervention will include a combination of individual counselling group sessions. The intervention groups will be divided into subgroups of 10-12 subjects. Each group will have 10 group sessions on diet/lifestyle in the 6 months the intervention period lasts, and will additionally have the possibility to join a culturally adapted exercise program of low intensity twice a week.
1778342|NCT00425282|Drug|RWJ-333369|
1778343|NCT00425295|Behavioral|Human Simulation Training|Fellows will undergo Human Simulation Training (HST) composed of one 1 hour session of high-fidelity simulation of crisis scenarios requiring management of critical care skills, including triage, Advanced Cardiac Life Support (ACLS), team management, and difficult airway management.
1778344|NCT00425308|Drug|Everolimus + Cyclosporine|
1778345|NCT00425308|Drug|Everolimus + Enteric-coated Mycophenolate Sodium (EC-MPS)|
1778346|NCT00425308|Drug|Steroids|
1778347|NCT00425321|Drug|RWJ-445380 100 mg|RWJ-445380 100 mg once daily for up to 12 weeks
1778348|NCT00425321|Drug|RWJ-445380 200 mg|RWJ-445380 200 mg once daily for up to 12 weeks
1778349|NCT00425321|Drug|RWJ-445380 300 mg|RWJ-445380 300 mg once daily for up to 12 weeks
1778350|NCT00425321|Drug|Placebo|Placebo once daily for up to 12 weeks
1778351|NCT00425334|Drug|Hemospan (MP4OX)|250 mL or 500 mL Hemospan (MP4OX)
1778352|NCT00425334|Drug|Ringer's lactate|250 mL or 500 mL Ringer's lactate USP
1778353|NCT00425347|Drug|HuLuc63|Not applicable for HuLuc63.
1778354|NCT00425360|Biological|sargramostim|
1778355|NCT00425360|Biological|telomerase peptide vaccine GV1001|
1778356|NCT00425360|Drug|capecitabine|
1778357|NCT00425360|Drug|gemcitabine hydrochloride|
1778358|NCT00425373|Drug|Valsartan + amlodipine 40/2.5 mg|Valsartan + amlodipine 40/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
1778359|NCT00425373|Drug|Valsartan + amlodipine 40/5 mg|Valsartan + amlodipine 40/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
1778360|NCT00425373|Drug|Valsartan + amlodipine 80/2.5 mg|Valsartan + amlodipine 80/2.5 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
1778361|NCT00425373|Drug|Valsartan + amlodipine 80/5 mg|Valsartan + amlodipine 80/5mg tablet plus 3 tablet and 2 capsule placebos taken once daily
1778362|NCT00425373|Drug|Valsartan 40 mg|Valsartan 40 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
1778363|NCT00425373|Drug|Valsartan 80 mg|Valsartan 80 mg tablet plus 3 tablet and 2 capsule placebos taken once daily
1778364|NCT00425373|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
1778365|NCT00425373|Drug|Amlodipine 5 mg|Amlodipine 5 mg capsule plus 4 tablet and 1 capsule placebos taken once daily
1778366|NCT00425373|Drug|Placebo|4 tablet and 2 capsule placebos taken once daily
1778367|NCT00425386|Drug|erlotinib hydrochloride|"Dose Level 0 = 50 mg/day, continuous daily; 0.5= 75 mg/day, continuous daily;
100 mg/day, continuous daily; 1.5= 125 mg/day, continuous daily;
150 mg/day, continuous daily"
1778368|NCT00425386|Drug|sunitinib malate|Will be administered at 50 mg daily, 4 weeks on, 2 weeks off
1778369|NCT00425386|Procedure|biopsy|Paraffin block (or unstained slides) of the primary tumor and/or metastatic lesions (as available) and a plasma sample for future correlative studies will be collected. A paraffin block (or at least 10 unstained slides, each of 10 micromillimeter thickness) from the original paraffin-embedded biopsy material taken at the diagnosis will be stored at 4 degrees Celsius.
1778370|NCT00425399|Procedure|Shiatsu|Shiatsu treatment provided in 40-minute sessions, twice a week for 4 weeks
1778371|NCT00425425|Biological|cetuximab|
1778372|NCT00425425|Drug|fluorouracil|
1778373|NCT00425425|Drug|oxaliplatin|
1778374|NCT00425425|Procedure|conventional surgery|
1778375|NCT00425425|Procedure|neoadjuvant therapy|
1778376|NCT00425425|Radiation|radiation therapy|
1778377|NCT00425438|Drug|Mycophenolate Mofetil|0.5 g PO BID from Day 0 to the end of Week 1, followed by 1.0 g PO BID from Weeks 2 through 24, and 0.75 g PO BID from Weeks 32 to 48
1778378|NCT00425438|Drug|Corticosteroids|0.75 to 1.0 mg/kg/d PO (up to 60 kg/day) from Weeks 1 through 4; reduced by 10 mg/day every 2 weeks until dose reaches 40 mg/day, followed by a reduction of 5 mg/day every 2 weeks until dose reaches 10 mg/day up to Week 48
1778379|NCT00425438|Drug|Azathioprine|100 mg PO daily for participants with a body weight of 50 to 70 kg,150 mg PO daily for subjects with a body weight of more than 70 kg up to Week 48
1778380|NCT00425438|Drug|Cyclophosphamide|0.75 g/m^2 IV every 4 weeks from Weeks 1 through 4, and 0.5-1.0 g/m^2 to maintain a minimum WBC count of ≥ 2500 per mm^3 from Weeks 5 through 24
1778381|NCT00425451|Drug|PerioChip Plus (Flurbiprofen +Chlorhexidine ), Flurbiprofen Chip, PerioChip (Chlorhexidine ) and Placebo Chip|
1778382|NCT00425464|Device|Standard Monofocal Intraocular Lens|"The control (active comparator) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a standard monofocal intraocular lens.
Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
1778383|NCT00425464|Device|Synchrony® Dual Optic Intraocular Lens|"The Synchrony® Dual Optic Intraocular Lens (experimantal) arm is comprised of patients who meet all study eligibility criteria and will be implanted with a Synchrony® Dual Optic Intraocular Lens.
Each study patient will undergo standard extracapsular cataract extraction through a clear corneal or limbal incision and circular continuous curvilinear capsulorhexis."
1778384|NCT00425477|Biological|sargramostim|
1778385|NCT00425477|Drug|bexarotene|
1778386|NCT00425477|Genetic|cytogenetic analysis|
1778387|NCT00425477|Genetic|fluorescence in situ hybridization|
1778388|NCT00425477|Other|flow cytometry|
1778389|NCT00425477|Other|laboratory biomarker analysis|
1778390|NCT00425477|Procedure|biopsy|
1778391|NCT00425490|Drug|sitagliptin|
1778392|NCT00425503|Drug|PS-341 (bortezomib)|PS-341 is a dipeptidyl boronic acid inhibitor with high specificity for the proteasome developed by Millennium Pharmaceuticals Inc. to treat human malignancies. It is the first member of this class of anti-tumor agents to come to human trials. Patients will receive PS-341 (1.6mg/m2/dose) by intravenous push weekly for 4 consecutive weeks followed by a 24-72 hour rest. This schedule consists of one treatment cycle. Upon the completion of 4 weeks of PS-341 followed by a 24-72 hour rest period, radical prostatectomy will be performed.
1778393|NCT00425516|Drug|Taxotere|
1778394|NCT00425516|Drug|5-Fluorouracil|
1778395|NCT00425516|Drug|Epirubicin|
1778396|NCT00425516|Drug|Cyclophosphamide|
1778397|NCT00425529|Device|Module AOX (attached to Sondalis ISO)|
1778398|NCT00425542|Other|Outpatient care (vs traditional inpatient care)|Patients randomized to the outpatient arm are discharged from the emergency department within 24 hours after randomization. Patients randomized to the inpatient arm are admitted to the hospital and are discharged based on the decision of the managing physician at the hospital.
1778399|NCT00425555|Drug|Panobinostat|
1778400|NCT00425568|Drug|AndroGel (Transdermal Testosterone Gel)|
1778401|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 1|
1778402|NCT00425594|Drug|HalfLytely and Bisacodyl Tablets - Formulation 2|
1778403|NCT00425594|Drug|NuLYTELY|
1778404|NCT00425607|Drug|Lonafarnib|Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.
1778405|NCT00425620|Drug|SinuNase|Lavage
1778406|NCT00425633|Drug|Homeopathic Potassium Dichromate|5 pellets under tongue q12h until extubation
1778407|NCT00425646|Biological|bevacizumab|
1778408|NCT00425646|Drug|imatinib mesylate|
1778409|NCT00425659|Device|home sleep study|different in algorithm arrangement for diagnosing sleep apnea
1778410|NCT00425659|Device|home CPAP titration (Autoset)|continuous positive airway pressure device for treatment of sleep apnea
1778411|NCT00425659|Device|CPAP|usual practice
1778412|NCT00425672|Biological|ONTAK|Given IV
1778413|NCT00425672|Other|flow cytometry|Correlative studies
1778414|NCT00425672|Other|immunohistochemistry staining method|Correlative studies
1778415|NCT00425672|Other|enzyme-linked immunosorbent assay|Correlative studies
1778416|NCT00425672|Other|laboratory biomarker analysis|Correlative studies
1778417|NCT00425672|Genetic|protein expression analysis|Correlative studies
1778418|NCT00425698|Drug|Recombinant erythropoietin alpha (rHuEPO alpha)|Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
1778419|NCT00425698|Drug|Placebo|Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation
1778420|NCT00425711|Drug|Acamprosate|Acamprosate 666 mg tid, or 333 tid in renal impairment, for 12 weeks
1778421|NCT00425724|Drug|Methylprednisolone pulses plus prednisone versus Cyclosporine A|The patients will be randomised to receive either MP pulses i.v. or cyclosporine A p.o. The MP pulses will consist of three doses of methylprednisolone 30 mg/kg i.v. given over a period of one week in hospital. On the intermediate days and for a month after the MP pulses, the patients will be given prednisone 30 mg/m2/day p.o., after which the prednisone medication will be gradually run down over 3 months. The patients randomised into the cyclosporine A group will receive an initial dose of 5 mg/kg/day, after which the dosage will be titrated to an optimal therapeutic level by monitoring the B-Cya concentration. The cyclosporine A treatment will be continued for 12 months.
1778422|NCT00425737|Biological|Rotarix|
1778423|NCT00425750|Drug|bortezomib|1.6 mg/m2 through a vein on days 1 and 8 of a 21-day cycle. The first dose is given as a single agent only on Day 1 of Cycle 1.
1778670|NCT00418938|Drug|Panitumumab|6mg/kg IV
1778424|NCT00425750|Drug|docetaxel|40 mg/m2 through a vein on days 1 and 8 of a 21-day cycle except the first dose is held only on Day 1 of Cycle 1.
1778425|NCT00425750|Other|laboratory biomarker analysis|Tissue and blood collection.
1778426|NCT00425750|Other|pharmacological study|Blood collection.
1778427|NCT00425763|Drug|AQAS|AQAS dosed by body weight, on days 0, 1, 2
1778428|NCT00425776|Device|acupuncture|
1778429|NCT00425776|Device|Sham acupuncture|
1778430|NCT00425789|Procedure|Treatment with Hyperbaric oxygen|
1778441|NCT00425815|Drug|Org 24448|Org 24448 is a moderate-potency selective AMPA positive modulator that enhances the glutamate system in the brain.
1778442|NCT00425815|Other|Placebo|Placebo comparison
1778443|NCT00425841|Drug|gemcitabine hydrochloride|
1778444|NCT00425841|Drug|oxaliplatin|
1778445|NCT00425841|Procedure|adjuvant therapy|
1778446|NCT00425841|Procedure|neoadjuvant therapy|
1778447|NCT00425841|Radiation|hypofractionated radiation therapy|
1778448|NCT00425841|Radiation|stereotactic radiosurgery|
1778449|NCT00425854|Drug|BIBW 2992|high dose once daily
1778450|NCT00425867|Behavioral|PAR1 polymoprhisms and placental invasion|
1778451|NCT00425893|Behavioral|hand hygiene|alcohol-based hand wash
1778452|NCT00425893|Other|health education|Proper nutrition, etc.
1778453|NCT00425893|Device|face masks|face masks
1778454|NCT00425906|Drug|nicotine|
1778455|NCT00425906|Other|Placebo|
1778456|NCT00425906|Procedure|Quality of life|
1778457|NCT00425919|Drug|PPM-204|
1778458|NCT00425932|Biological|Rituximab|At Week 24 or any time up to Week 48 if the Patient DAS 28 > 2.6 patients will be retreated with 1000 mg IV at Day and Day 15.
1778459|NCT00425945|Drug|Pine Bark Extract (Flavangenol®)|"Flavangenol 200 mg per day. Flavangenol is a brand of pine bark extract manufactured by Toyo Shinyaku of Saga, Japan.
Dosage delivered as four tablets, each containing 50 mg Flavangenol, all 4 tablets taken once per day orally for 12 weeks."
1778460|NCT00425971|Drug|BMEC-1217B|
1778461|NCT00425984|Procedure|Adult male circumcision|
1778462|NCT00425997|Drug|Valsartan/HCTZ|
1778463|NCT00425997|Drug|amlodipine|
1778464|NCT00425997|Drug|HCTZ|
1778465|NCT00426010|Drug|caffeine/placebo|caffeine or placebo, either overt or covert
1778466|NCT00426023|Drug|Cyclosporine A 0,05% eye drop|Cyclosporine A 0.05% eye drops will be administered 2 times daily for six months in the first year of the study and in the second year of the study in a cross-over manner(from March to September)
1778467|NCT00426023|Drug|ketotifen fumarate 0.025% eye drops|ketotifen fumarate 0.025% eye drops 2 times daily for 6 months in the first year of the study (from March to September) and 6 months in the same period in the second year of the study in cross over manner.
1778468|NCT00426036|Drug|Licarbazepine|
1778469|NCT00426049|Drug|Everolimus|
1778470|NCT00426075|Device|Elastic stockings|
1778471|NCT00426101|Drug|Dexamethasone|"10 mg/m2 daily wk 1-2 5 mg/m2 daily wk 3-4 2.5 mg/m2 daily wk 5-6 1.25 mg/m2 daily wk 7 Steroids tapered wk 8
If continuation:
Pulses every 2nd wk, 10 mg/m2 for 3 days"
1778472|NCT00426101|Drug|Etoposide|"150 mg/m2 iv twice/wk (wk 1-2) 150 mg/m2 iv once/wk (wk 3-8)
If continuation:
150 mg/m2 iv, every 2nd wk"
1778473|NCT00426101|Drug|Cyclosporin|"WK 1-8:
- Aim at around 200 microgram/L (trough value). Start: 6 mg/kg daily (divided in 2 daily doses) wk 1, if kidney function is normal.
If continuation:
- Aim for around 200 microgram/L. Monitor GFR."
1778474|NCT00426101|Procedure|Intrathecal therapy|"If at 2 wks there are progressive neurological symptoms or if an abnormal CSF (cell count and protein) has not improved, then give 4 wkly intrathecal inj. Be aware that some pat may have increased intracranial pressure.
Methotrexate: <1 yr 6 mg, 1-2 yrs 8 mg, 2-3 yrs 10 mg, >3 yrs 12 mg. Prednisolone: <1 yr 4 mg, 1-2 yrs 6 mg, 2-3 yrs 8 mg, >3 yrs 10 mg."
1778475|NCT00426101|Procedure|Stem cell transplant|The SCT procedure is up to the treating physician. However, a suggested regimen is provided.
1778476|NCT00426114|Drug|Administration of an IV glucose-injection|
1778477|NCT00426127|Drug|Docetaxel|
1778478|NCT00426127|Drug|Liposomal Doxorubicin|
1778479|NCT00426127|Drug|Enoxaparin|
1778480|NCT00426140|Drug|Patupilone|
1778481|NCT00426153|Drug|Octreotide|Participants received Octreotide LAR® Depot injections (up to 40 mg)intramuscularly every 28 days (+/- 5 days) for one year
1778482|NCT00426153|Drug|Placebo|Participants received an injection of placebo (sham) medication intramuscularly every 28 days (+/- 5 day) for one year
1778484|NCT00426179|Drug|Imatinib|
1778485|NCT00426192|Drug|i.v. mannitol|
1778486|NCT00426192|Procedure|hemofiltration|
1778487|NCT00426205|Biological|GM-CSF secreting leukemia vaccine|Vaccine given subcutaneously or intradermally on the leg, arm, or abdomen 6 times. The first three vaccines will be given once a week for three weeks. The last three vaccines will be given once every other week for three doses.
1778488|NCT00426218|Drug|ACZ885|
1778489|NCT00426231|Behavioral|Navigation by a health worker|Help provided by health worker to navigate medication access programs
1778490|NCT00426231|Behavioral|Information control|Information about medication access programs provided to the participant and their healthcare provider
1778491|NCT00426244|Other|Osteopathic Manipulative Treatment|OMT is a complementary and alternative body-based treatment method in which the patient is evaluated and treated including the musculoskeletal system to improve physiologic functioning and remove impediments to optimal health and functioning.
1778492|NCT00426244|Other|Placebo Ultrasound|"In addition to controlling for physician attention during the treatment visit, the SUT used a nonfunctional ultrasound therapy unit that was modified for research purposes to provide both visible and auditory cues that could potentially elicit a placebo response. The physician provided the SUT by placing the applicator head over the subject's clothing and applying sufficient pressure for tactile stimulation of the skin and underlying tissues in the same anatomical distributions as would generally be addressed if the subject were being treated with OMT.
The subjects assigned to the UOBC only group did not receive any study treatments beyond conventional obstetrical care; however, they were expected to complete data collection forms on the same schedule as all other trial subjects."
1778493|NCT00426257|Procedure|Secondary debulking|Secondary debulking
1778494|NCT00426257|Procedure|secondary debulking with intraperitoneal chemotherapy|secondary debulking with intraperitoneal chemotherapy
1778495|NCT00426270|Drug|Octagam 10%|Octagam 10% was supplied as a ready-to-use solution in glass bottles.
1778496|NCT00426283|Drug|Flovent|1760 mcg daily
1778497|NCT00426283|Other|Placebo|1760 mcg daily
1778498|NCT00426296|Drug|atazanavir (Reyataz)|
1778499|NCT00426296|Drug|ritonavir (Norvir)|
1778500|NCT00426322|Device|bovine bone mineral particles (Bio-Oss®)|bovine bone mineral particles used for sinus augmentation prior to dental implant placement
1778501|NCT00426348|Drug|Valsartan|Valsartan (80-160mg/day)
1778502|NCT00426348|Drug|Probucol|Probucol (750mg/day)
1778503|NCT00426348|Drug|Placebo|Placebo
1778504|NCT00426361|Biological|Boostrix ® Polio|One dose of vaccine administered intramuscularly
1778505|NCT00426361|Biological|GSK Biologicals' HPV-16/18 L1 AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly, with the second and third dose give one month and six months after the first dose respectively
1778506|NCT00426374|Procedure|echocardiography and blood test|
1778507|NCT00426400|Drug|The cessation of anti-aggregative treatment for 10 days|
1778508|NCT00417430|Drug|ICI 182,780 (Faslodex)|
1778509|NCT00417443|Drug|Clonidine|
1778510|NCT00417456|Other|Evisit|Asynchronous,remote care delivery via a secure web platform
1778511|NCT00417456|Other|Office visit|Conventional office-based care
1778512|NCT00417469|Device|NADGL|
1778513|NCT00417482|Drug|risperidone|Risperidone open label flexible dose 0.25 to 3 mg daily for first 16 weeks; dose at 16 weeks then fixed for randomized trial
1778514|NCT00417495|Behavioral|Sentinel Lymph Node Technique|
1778515|NCT00417508|Dietary Supplement|Sip feeding|Daily supplement with sip feeding, 2 packages(each package containing 200 ml,20 g protein and 300 kcal)
1778516|NCT00417508|Dietary Supplement|Dietary Advice|The patients will receive ordinary dietary advice with a recommendation of four meals per day or similar dietary advice and no daily sip feeding supplements.
1778517|NCT00417521|Behavioral|Family-Based Treatment|
1778518|NCT00417560|Biological|inactivated influenza A/H5N1 vaccine|
1778519|NCT00417573|Drug|IV Gamunex 10%|
1778520|NCT00417586|Device|Specialized Doppler Ultrasound Instrument|Patients with a reading of 140 cm/sec or higher will be referred for further duplex screening
1778521|NCT00417599|Behavioral|Lifestyle Intervention|lifestyle intervention .
1778522|NCT00417599|Other|control group|waiting list control group
1778523|NCT00417612|Drug|Paricalcitol|Paricalcitol given first as a dose of 2 capsules once per day. Dose titration as needed per biochemical results at outpatient visits.
1778524|NCT00417612|Other|Placebo|Placebo sugar pill
1778525|NCT00417638|Device|Endovascular cooling by the Celsius Control System|
1778526|NCT00417638|Other|Standard of care|
1778527|NCT00417664|Drug|dexmedetomidine|
1778528|NCT00417664|Drug|midazolam|
1778529|NCT00417664|Drug|propofol|
1778530|NCT00417677|Drug|Combination of Temsirolimus and Sunitinib|
1778531|NCT00417690|Drug|4-Aminosalicylic acid|Oral granules administered as one 4 g packet three times daily for two weeks followed by one 4 g packet two times daily for two weeks
1778532|NCT00417690|Drug|PASER placebo granules|Oral granules administered administered as one packet three times daily for two weeks followed by one packet two times daily for two weeks
1778533|NCT00417716|Drug|Intravitreal Bevacizumab|
1778534|NCT00417729|Drug|Acarbose|After an 8-week period of metformin monotherapy (500 mg t.i.d.), all patients were randomised to add on either acarbose or glibenclamide. The doses of acarbose and glibenclamide were 50 mg t.i.d. and 2.5 mg t.i.d., respectively, for 4 weeks and force-titrated to 100 mg t.i.d. and 5 mg t.i.d., respectively, for the last 12 weeks.
1778535|NCT00417742|Behavioral|Service delivery through a Headache Management Program|
1778536|NCT00417768|Drug|Tissue Plasminogen Activator|The dosage of tPA is determined by the volume of drainage obtained when abscess is first drained. The same dose will be repeated on day 1 and 2.
1778537|NCT00417768|Other|Normal Saline|Normal Saline will be used rather than Tissue Plasminogen Activator for the Sham arm.
1778538|NCT00417794|Drug|Strattera|escalating dosage: 0.5 mg/kg, 1.0 mg/kg, and 1.4 mg/kg titrated up or down according to adverse effects to therapy
1778539|NCT00417794|Drug|Placebo|0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with breakfast.
1778540|NCT00417807|Drug|Imatinib mesilate|
1778541|NCT00417820|Drug|BCT194|
1778542|NCT00417833|Drug|Intravitreal Bevacizumab|
1778543|NCT00417859|Device|Total knee arthroplasty: mobile bearing|Total knee arthroplasty: mobile bearing
1778544|NCT00417872|Drug|Nitazoxanide|
1778545|NCT00417872|Drug|Metronidazole|
1778546|NCT00417885|Drug|exemestane|25 mg, oral, daily dosing
1778547|NCT00417885|Drug|sunitinib malate|37.5 mg, oral, continuous dosing, daily
1778548|NCT00417898|Drug|Aspirin|
1778549|NCT00417911|Drug|bortezomib|Bortezomib 1,3 mg/sqm Days 1,4,8,11 for two 3-week cycles and then once a week for three weeks in 4 4-week cycles
1778550|NCT00417924|Behavioral|Patient education|
1778551|NCT00417937|Drug|azelaic acid 15% gel|15% gel, topically applied once daily for six weeks
1778552|NCT00417937|Drug|azelaic acid 15% gel|15% gel, topically applied twice daily for six weeks
1778553|NCT00417950|Drug|Acarbose|
1778554|NCT00417963|Device|Carotid Artery Stenting|placement of a bare metal stent at sites of stenosis in the carotid artery
1778555|NCT00417976|Drug|Gemcitabine|1000 mg/m2 over 100 minutes every 2 weeks.
1778556|NCT00417976|Drug|Bevacizumab|10 mg/kg every 2 weeks.
1778557|NCT00417976|Drug|Infusional 5-Fluorouracil|2400 mg/m2 over 48 hours every 2 weeks.
1778558|NCT00417989|Device|MiniMed Paradigm REAL-Time System|Paradigm 722 insulin pump Paradigm REAL-Time Transmitter Sensor ComLink Paradigm Link glucose meter
1778559|NCT00418002|Drug|AQW051|
1778560|NCT00418015|Procedure|Blood Draw|Blood for OPRM1 analysis
1778563|NCT00418054|Drug|Nitazoxanide plus peginterferon alfa-2b|
1778564|NCT00418054|Drug|Peginterferon alfa-2b|
1778565|NCT00418067|Device|Endeavor|Zotarolimus-eluting stent
1778566|NCT00418067|Device|Cypher|Sirolimus-eluting stent
1778567|NCT00418067|Device|Taxus Liberte|Paclitaxel-eluting stent
1778568|NCT00418080|Drug|bicalutamide|
1778569|NCT00418093|Drug|Gemcitabine|Given intravenously over 30 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
1778570|NCT00418093|Drug|Oxaliplatin|Given intravenously over 2 hours on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
1778571|NCT00418093|Drug|Bevacizumab|Given intravenously over 30-90 minutes on day 1 and day 15 of a 28-day cycle. Participants can continue study treatment as long as there is no disease progression.
1778572|NCT00418119|Drug|erythropoietin|
1778573|NCT00418132|Drug|Thalidomide|Thalidomide at a dose of 50 mg/day. The dose will be increased to 100 mg/day at Week 2, then to 200 mg/day at Week 4, and finally to 300 mg/day at Week 6.
1778574|NCT00418132|Drug|Placebo thalidomide|Participants will receive placebo thalidomide. The placebo dose will be increased through to Week 6.
1778575|NCT00418145|Drug|megadose oral methylprednisolone|1400 mg qd/5 days
1778576|NCT00418145|Drug|IV methylprednisolone|1000 mg/qd/5 days
1778577|NCT00418158|Behavioral|use of Airlife (therapy)|
1778578|NCT00418171|Drug|Ziprasidone|
1778579|NCT00418171|Drug|Olanzapine|
1778580|NCT00418184|Dietary Supplement|Phosphatidylserine-Omega3|Phosphatidylserine-Omega3 conjugate capsules. Weeks 0-15: 300 mg/day. weeks 16-30: 150 mg/day and a 150 mg/day one year follow-up.
1778581|NCT00418184|Other|Colored cellulose tainted with fishy odor|as arm 1
1778582|NCT00418197|Device|Total Facet Arthroplasty System® (TFAS®)|
1778583|NCT00418210|Radiation|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT)|Accelerated partial breast irradiation (APBI) to region of tumour bed using 3D conformal radiation therapy (3D CRT; 38.5 Gy in 3.85 Gy fractions bi-daily over 5 consecutive working days
1778584|NCT00418249|Drug|AS101|
1778585|NCT00418262|Drug|Atomoxetine|Titrating with oral administration of 0.25 mg/kg, 0.50 mg/kg, 1.0 mg/kg, or 1.4 mg/kg once each morning with food.
1778586|NCT00418275|Genetic|Recombinant Human Plasminogen Activator (HTUPA)|
1778587|NCT00418288|Drug|glucagon-like-peptide-1|intravenous infusion of 1.2pmol/kg/min for 7 hours
1778588|NCT00418288|Drug|placebo|intravenous infusion of 1.2pmol/kg/min
1778589|NCT00418301|Other|Precision Spinal Cord Stimulation and PET Scan|Imaging procedure to assess spinal Cord Stimulation.
1778590|NCT00418314|Device|Control|Empiric programming or one-time optimization using a non-IEGM method.
1778591|NCT00418314|Device|QuickOpt|Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
1778592|NCT00418327|Drug|Tarceva (Erlotinib Hydrochloride)|tablets of 25 mg, 100 mg and 150 mg 75 to 150 mg/m² Once daily
1778593|NCT00418340|Drug|probiotic (bacterial/dietary supplement)|
1778594|NCT00418353|Drug|Betamethasone(Celestone soluspan) and Dexamethasone|
1778595|NCT00418366|Drug|MK0431, sitagliptin phosphate / Duration of Treatment : 1 Days|
1778596|NCT00418379|Drug|300 IR (4M)|300 IR grass pollen allergen extract tablet starting 4 months before the pollen season
1778597|NCT00418379|Drug|300 IR (2M)|300 IR grass pollen allergen extract tablet starting 2 months before the pollen season
1778598|NCT00418379|Drug|Placebo|Placebo tablet
1778599|NCT00418392|Procedure|Simple aspiration with minocycline pleurodesis|Intrapleural instillation of 300mg minocycline within 5 min after simple aspiration
1778600|NCT00418392|Procedure|simple aspiration|Simple aspiration for primary spontaneous pneumothorax by pigtail catheter
1778601|NCT00418418|Procedure|Coronary bypass operation|Coronary bypass operation is performed via sternotomy during cardiac arrest.
1778602|NCT00418418|Procedure|Bone marrow aspiration (crista iliaca)|The bone marrow is aspirated from the iliac crest (100ml). During the operation the aspirate is transported to the stem cell laboratory, where the sample is centrifugated through Ficoll(Registered Trademark).
1778603|NCT00418418|Biological|Intramyocardial mesenchymal stem cell transplantation|During the cardiac arrest, stem cells are directly injected to myocardium. The amount of the cells varies individually (5-1000 x 10e6 cells), the cells are diluted in autologous serum (5 ml)
1778604|NCT00418418|Biological|Intramyocardial injection of autologous serum|Intramyocardial injection of autologous serum is injected during cardiac arrest
1778605|NCT00418431|Drug|Intravitreal injection of Bevacizumab|
1778606|NCT00418444|Behavioral|Group Therapy Intervention|
1778607|NCT00418457|Drug|General anesthesia and opioids|General anesthesia, usually with sevoflurane, and opioid analgesia
1778608|NCT00418457|Drug|Regional analgesia and propofol|Regional anesthesia and analgesia (either epidural or paravertebral), combined with deep sedation or general anesthesia
1778609|NCT00418470|Procedure|regular dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in regular NS volume
1778671|NCT00418938|Drug|Bevacizumab|Either 5mg/kg OR 10mg/kg IV
1778610|NCT00418470|Procedure|higher dilution of antibiotic in NS|IV administration of ceftazidime tid diluted in larger NS volume
1778611|NCT00418483|Biological|Plasmin (Human) 25 mg|Plasmin (Human) 25 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
1778612|NCT00418483|Biological|Plasmin (Human) 50 mg|Plasmin (Human) 50 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
1778613|NCT00418483|Biological|Plasmin (Human) 75 mg|Plasmin (Human) 75 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
1778614|NCT00418483|Biological|Plasmin (Human) 100 mg|Plasmin (Human) 100 mg
1778615|NCT00418483|Biological|Plasmin (Human) 125 mg|Plasmin (Human) 125 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
1778616|NCT00418483|Biological|Plasmin (Human) 150 mg|Plasmin (Human) 150 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
1778617|NCT00418483|Biological|Plasmin (Human) 175 mg|Plasmin (Human) 175 mg delivered via an infusion catheter into the thrombus over approximately 5 hours.
1778618|NCT00418496|Drug|Aldesleukin|600,000 IU/kg every 8 hours on days 1-5 (week 1) to a maximum of 12 doses. Another cycle of HD aldesleukin will be started on day 15 (week 3).
1778619|NCT00418496|Drug|Sorafenib|To be initiated at a dose of 200 mg orally. Once it is determined that no further HD aldesleukin therapy will be given, sorafenib may be given daily at the FDA approved dose of 400 mg twice daily until there is lack of clinical benefit or intolerable side effects develop.
1778620|NCT00418509|Drug|Mometasone furoate|
1778621|NCT00418509|Drug|Formoterol fumarate|
1778622|NCT00418522|Drug|Insulin glargine|Insulin glargine, label instruction initiation dose (10 units), and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
1778623|NCT00418522|Drug|Inhaled Insulin (Exubera)|Initiation dose of one mg per meal, and individually adjusted doses, per subject's blood glucose, over the six months study, in addition to oral agents.
1778624|NCT00418535|Drug|Concurrent Radiotherapy (RT)/cisplatin, VIPD|
1778625|NCT00418548|Drug|Etanercept|
1778626|NCT00418561|Drug|rhASA|intravenous infusion 25 U/kg,50 U/kg, 100U/kg or 200 U/kg every other week for 26 weeks
1778627|NCT00418574|Biological|Abagovomab|2 mg/ml SC (subcutaneously)
1778628|NCT00418574|Biological|Placebo|2 mg/ml SC (subcutaneously)
1778629|NCT00418587|Drug|Cholecalciferol|800 IU oral daily
1778630|NCT00418587|Drug|Cholecalciferol|2000 IU oral daily
1778631|NCT00418587|Drug|Cholecalciferol|4000 IU oral daily
1778632|NCT00418600|Drug|Hectorol® (doxercalciferol capsules)|Hectorol capsules at 1.0 times current injection dose
1778633|NCT00418600|Drug|doxercalciferol capsules, Hectorol®|Hectorol capsules at 1.5 times current injection dose
1778634|NCT00418600|Drug|doxercalciferol capsules, Hectorol® capsules|Hectorol capsules at 2.0 times current injection dose
1778635|NCT00418613|Drug|MK633|MK0633 100mg capsules qd for a 12-wk treatment period.
1778636|NCT00418613|Drug|Comparator: Placebo (unspecified)|MK0633 100mg Pbo capsules for a 12-wk treatment period
1778637|NCT00418626|Drug|Nilotinib|
1778638|NCT00418639|Drug|Nitazoxanide|
1778639|NCT00418652|Device|No TMS intervention|"In the no TMS condition, no simulation was given and no coil placed near participants' heads."
1778640|NCT00418652|Device|TMS over the PO3 EEG site|10Hz TMS over the dorsal stream (PO3 EEG site)
1778641|NCT00418652|Device|TMS over the vertex|10Hz TMS for over vertex.
1778642|NCT00418665|Biological|AMG 531|AMG 531 will be administered by subcutaneous injection at a dose of 500 or 750 μg.
1778643|NCT00418665|Drug|Placebo|Subjects in the control group will receive placebo via subcutaneous injection.
1778644|NCT00418678|Drug|Cesamet|2 mg BID on Days 2-5.
1778645|NCT00418691|Drug|IR Methylphenidate|10 mg by mouth (PO) twice daily x 4 Weeks
1778646|NCT00418691|Drug|Modafinil|200 mg PO Once Daily x 4 Weeks
1778647|NCT00418691|Drug|SR Methylphenidate|18 mg PO Once Daily x 4 Weeks
1778648|NCT00418704|Drug|Erlotinib|Tarceva (150 mg) is a pill you take once a day -- every day
1778649|NCT00418704|Drug|taxotere|Taxotere® (docetaxel) is given intravenously (I.V.) into the vein. Taxotere® chemotherapy treatment takes about one hour, and usually people receive treatments every three weeks.
1778650|NCT00418717|Drug|etanercept|Period A: Weeks 1-4: Etanercept 25mg (25mg vial)bi-weekly (BW); Period B: Weeks 5-12: Etanercept 50mg (50mg vial) weekly (QW)
1778651|NCT00418730|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, active comparator, placebo comparator) will be applied twice daily to the scalp for 112 days
1778652|NCT00418756|Drug|Nilotinib|Semi-synthetic antibiotic derivative of rifamycin B and is known to induce cytochrome P-450 (CYP) enzymes.
1778653|NCT00418769|Drug|Nilotinib|
1778654|NCT00418782|Drug|naproxen|
1778655|NCT00418782|Drug|CE-224535|
1778656|NCT00418782|Drug|placebo|
1778657|NCT00418795|Drug|recombinant human porphobilinogen deaminase (Porphozym)|
1778658|NCT00418821|Biological|Aldurazyme (laronidase)|dose of 0.58mg/kg body weight intravenously (IV) every week
1778659|NCT00418834|Drug|ezetimibe and atorvastatin|ezetimibe 10 mg and atorvastatin 10 mg daily for 12 weeks
1778660|NCT00418834|Drug|atorvastatin|Atorvastatin 20 mg daily for 6 weeks, and up-titrated to atorvastatin 40 mg daily for an additional 6 weeks
1778661|NCT00418834|Drug|Placebo (unspecified)|Placebo (unspecified) daily for 12 weeks
1778662|NCT00418847|Drug|miglustat|Target dose of 320 mg/m^2/day (divided in 3 doses) will be based on the Body Surface Area (BSA). For children with a BSA > 1.3, 200 mg TID will be administered. For children with a BSA of 0.8-1.3, 100 mg TID will be administered.
1778663|NCT00418860|Drug|Aspirin, Clopidogrel|Aspirin 100mg qd plus clopidogrel 75mg qd for 3 month after index procedure
1778664|NCT00418873|Drug|Zotepine|Oral
1778665|NCT00418873|Drug|Risperidone|Oral
1778666|NCT00418886|Drug|Vandetanib|oral once daily tablet
1778667|NCT00418886|Drug|Pemetrexed|intravenous infusion
1778668|NCT00418899|Behavioral|Questionnaire|Questionnaire, 30-40 minutes, about gliomas and its risk factors (such as environmental and genetic information).
1778672|NCT00418938|Drug|Leucovorin|400mg/m^2 IV (in the vein)
1778673|NCT00418938|Drug|Irinotecan|180mg/m^2 IV (in the vein)
1778674|NCT00418938|Drug|5-Fluorouracil|400mg/m^2 bolus IV (in the vein) over 2-4 min, followed by 2400mg/m^2 continuous IV over 46 hours for the first 2 cycles, increased to 3000mg/m^2 thereafter if no significant side effects
1778675|NCT00418951|Drug|Voriconazole|400 mg by mouth twice daily on day 1, followed by 200 mg by mouth twice daily
1778676|NCT00418951|Drug|Liposomal amphotericin B|3 mg/kg intravenously three times per week over 2 hours +/- 15 minutes
1778677|NCT00418951|Drug|Liposomal amphotericin B|9 mg/kg intravenously once per week over 2 hours +/- 15 minutes
1778678|NCT00418964|Procedure|Single bundle hamstring|Single bundle hamstring
1778679|NCT00418964|Procedure|Double bundle hamstring|Double bundle hamstring
1778680|NCT00418964|Procedure|Bone patellar tendon bone|Bone patellar tendon bone
1778681|NCT00418977|Behavioral|"Family-Based Therapy (Maudsley Method)"|The goal of FBT is to resolve the eating disorder and return the patient to healthy psychosocial and physiological development through active family involvement across three treatment phases. In Phase I, therapy is focused on the disordered eating. The therapist primarily makes careful, persistent requests for united parental action toward re-feeding and/or regulating eating habits and directs the discussion so as to create and reinforce a strong parental alliance around their efforts at feeding their child. In Phase II, the goal is to gradually transfer control over eating back to the participant, with the parents still maintaining general oversight and responsibility for continued progression toward healthy habits. In Phase III, the central goal is establishment of a healthy child or adolescent relationship with the parents where disordered eating is not the basis of interaction.
1778682|NCT00418977|Behavioral|Individual Supportive Psychotherapy|The goal of ISP is for the patient to understand and address the psychological issues underlying the origin and maintenance of the eating disorder. This work is done directly with the child/adolescent. In this treatment, eating disorders are seen as complicated (e.g., they tend to mask other underlying difficulties). In Phase I, the aims are to establish a sound therapeutic relationship, obtain a comprehensive description of the eating problem and its development, identify underlying problems that might be responsible for the disordered eating, and inform the patient about the dangers of eating disorders. Phase II encourages participants to explore underlying emotional problems, facilitates self-disclosure and expression of feelings, and fosters independence. Phase III focuses on how other underlying issues might affect future adjustment.
1778683|NCT00418990|Drug|Multivitamin/Mineral supplements|
1778684|NCT00419003|Drug|Lamotrigine|anticonvulsant medication
1778685|NCT00419003|Drug|Ketamine|subanesthetic dose of NMDAR antagonist
1778686|NCT00419003|Drug|Riluzole|glutamate release inhibitor
1778687|NCT00419029|Behavioral|telephone-administered motivational interviewing|telephone motivational interviewing
1778688|NCT00419029|Behavioral|control|brief telephone check-in (no motivational interviewing)
1778689|NCT00419042|Drug|TARCEVA|Tarceva (150 mg) is a pill you take once a day -- every day -- to help treat non-small cell lung cancer.
1778690|NCT00419042|Drug|Gemzar|GEMZAR by mixing it into a solution and giving it through a needle into a vein—called intravenous infusion (IV). This will take about 30 minutes
1778691|NCT00419055|Procedure|Early discharge after percutaneous coronary intervenntion|Eligible patients receive Bivalirudin at the standard dose during PCI and all have to be eligible for femoral access seal.
1778692|NCT00419068|Drug|Cholecalciferol|
1778693|NCT00419068|Drug|Migliol Placebo Oil|
1778694|NCT00419081|Drug|Forodesine Hydrochloride Sterile Solution, 5 mg/mL|
1778695|NCT00419081|Drug|Forodesine Hydrochloride Capsules (100 mg)|
1778696|NCT00419094|Drug|Keppra XR|Administered as two 500 mg tablets (1000 mg) and two placebo tablets once daily for 18 weeks
1778697|NCT00419094|Drug|Keppra XR|Administered as four 500 mg tablets (2000 mg) once daily for 18 weeks
1778698|NCT00419120|Biological|Autologous neo bladder construct|augmentation cystoplasty with autologous neo-bladder construct
1778699|NCT00419133|Biological|Killed bivalent whole cell oral cholera vaccine|"Each 1.5 mL dose, given orally, contains:
V. cholerae O1 Inaba El Tor strain Phil 6973 formalin killed, 600 Elisa units (EU) LPS V. cholerae O1 Ogawa classical strain Cairo 50 heat killed 300 EU LPS V. cholerae O1 Ogawa classical strain Cairo 50 formalin killed 300 EU LPS V. cholerae O1 Inaba classical strain Cairo 48 heat killed 300 EU LPS V. cholerae O139 strain 4260B formalin killed 600 EU LPS"
1778700|NCT00419133|Biological|Heat Killed E. coli Placebo|Heat Killed E.coli in an optical turbidity identical to cholera vaccine, given in a 1.5 mL oral dose.
1778701|NCT00419146|Drug|Ethyl-eicosapentaenoic acid (EPA)|Capsules, 2 g per day for 16 weeks
1778702|NCT00419146|Drug|Vitamins E + C|RRR-alpha-tocopherol 392 mg + slow-release ascorbic acid 1000 mg per day, for 16 weeks
1778703|NCT00419146|Other|Etyl EPA (placebo)|Paraffin oil. Capsules, each 0.5 g.
1778704|NCT00419146|Other|Vitamins E+C (placebo)|Tablets containing dicalciumphosphate
1778705|NCT00419159|Drug|Everolimus (RAD001)|Everolimus was supplied in 5 mg tablets in blister packs.
1778706|NCT00419172|Drug|Deferasirox|
1778707|NCT00419172|Drug|Rifampicin|
1778708|NCT00419185|Procedure|Delamination of the Internal limiting membrane|
1778709|NCT00419198|Procedure|Postconditioning|Postconditioning during angioplasty
1778710|NCT00419198|Procedure|standard angioplasty|standard angioplasty without postconditioning
1778711|NCT00419211|Behavioral|Exercise|Tailored exercise program
1778712|NCT00419224|Biological|inactivated split-virus influenza vaccine|
1778713|NCT00419237|Drug|GW685698X|
1778714|NCT00419250|Drug|lenalidomide|
1778715|NCT00419250|Drug|lenalidomide|
1778716|NCT00419250|Drug|lenalidomide|
1778717|NCT00419250|Drug|lenalidomide|
1778718|NCT00419250|Drug|lenalidomide|
1778719|NCT00419263|Drug|Peramivir 150 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (one injection of peramivir 150 mg and one injection of placebo).
1778720|NCT00419263|Drug|Peramivir 300 mg|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of peramivir 150 mg).
1778721|NCT00419263|Drug|Placebo|Single dose administered as bilateral 2-mL intramuscular injections in each gluteal muscle (2 injections of placebo).
1778722|NCT00419276|Procedure|Ambulatory continuous femoral nerve block for 100 hours|Treatment group: 100 hours of ropivacaine femoral perineural infusion. Standard-of-care group: overnight ropivacaine femoral perineural infusion followed by a normal saline infusion.
1778723|NCT00419289|Behavioral|follow-up rehabilitation of participants with COPD|
1778724|NCT00419302|Drug|Technosphere/Insulin|
1778725|NCT00419315|Behavioral|Alcohol Care Management|Care management for alcohol dependence with a focus on pharmacotherapy
1778726|NCT00419315|Behavioral|Usual Care|Usual care included a referral to a specialty addiction treatment program.
1778727|NCT00419328|Drug|NGR-hTNF|iv q3W escalating dose up 1.6 mcg/sqm
1778728|NCT00419341|Biological|Human Normal Immunoglobulin for Subcutaneous Administration|
1778730|NCT00419380|Drug|dornase alfa (Pulmozyme®)|This study will compare two treatment arms. Patients will be randomized to either traditional treatment (Ofloxin)or to experimental treatment [dornase alfa (Pulmozyme®)]. Each arm will have subjects instilling 5 drops twice daily for 7 days to the affected ear.
1778731|NCT00419393|Drug|Keppra XR (Levetiracetam XR)|500 mg tablets, 1000 - 3000 mg/day, flexible dosing for duration of the study (planned: approximately 6 months-3 years).
1778732|NCT00419406|Procedure|UVA1 phototherapy|
1778733|NCT00419406|Procedure|NB-UVB phototherapy|
1778734|NCT00419419|Drug|Topical AmphiMatrix with nitroglycerin (MQX-503)|
1778735|NCT00419432|Other|Routine Observational Analysis (prior to procedure)|Controls will undergo the standard orthopaedic surgery using the information from the physical examination and observational analysis of the gait alone.
1778736|NCT00419432|Other|Routine Observational analysis supplemented with Gait Lab Information (prior to procedure)|This experimental group will undergo standard orthopaedic surgery using the information from the physical examination, observational AND the gait laboratory analysis data
1778737|NCT00419445|Drug|GTS21/Placebo|
1778738|NCT00419458|Procedure|inspiratory muscle strength training|
1778739|NCT00419471|Drug|Escitalopram|Study medication will be provided as 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day, and matched placebo. The initial dose of escitalopram was 10mg/day generally, but 5mg/day for those aged 65 or over and with hepatic dysfunction. After the 2nd evaluation, the treatment doses are determined by the investigators' clinical decision considering the severity of depression and tolerability of drug. Drugs are taken once daily per orally within 30 min after the supper meal.
1778740|NCT00419471|Drug|Placebo|Placebo medication will be provided as matched 1 tablet of escitalopram 5mg/day or 1 or 2 tablets of escitalopram 10mg/day.
1778741|NCT00419484|Drug|pioglitazone|
1778742|NCT00419497|Behavioral|Paleolithic diet vs Mediterranean diet|Prudent diets with or without grains and dairy
1778743|NCT00419510|Behavioral|Culturally Tailored Genetic Counseling|
1778744|NCT00419536|Drug|LBH589|
1778745|NCT00419549|Drug|Glyceryl - trinitrate|Transdermal Patch once only
1778746|NCT00419549|Drug|Valdecoxib|Single parenteral administration
1778747|NCT00419562|Drug|Oral Insulin|7.5 mg oral insulin or placebo given before breakfast on a daily basis.
1778748|NCT00419601|Drug|Remifentanyl|Start dose:9 µg/kg/h Maximum dose: 30 µg/kg/h
1778749|NCT00419601|Drug|Fentanyl|start dose: 3 µg/kg/h Maximum dose: 10 µg/kg/h
1778750|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
1778751|NCT00419640|Device|Pacemaker implantation with RA lead in LAS position|Pacemaker implantation with RA lead placed in low atrial septal position
1778752|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
1778753|NCT00419640|Device|Pacemaker implantation with RA lead in RAA position|Pacemaker implantation with RA lead placed in right atrial appendage position
1778754|NCT00419653|Drug|Amisulpride|
1778755|NCT00419653|Drug|Olanzapine|
1778756|NCT00419653|Drug|Haloperidol|
1778757|NCT00419666|Drug|Calcitriol|BID
1778758|NCT00419679|Procedure|x-ray diffraction of human hair|
1778760|NCT00419705|Device|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
1778761|NCT00419718|Drug|inhaled human insulin|
1778764|NCT00419744|Drug|Budesonide/formoterol (SYMBICORT) pMDI|
1778765|NCT00419744|Drug|Formoterol Turbuhaler|
1778766|NCT00419757|Drug|Budesonide/formoterol (SYMBICORT) pMDI|SYMBICORT® pMDI 160/4.5 μg x 2 actuations twice daily
1778767|NCT00419757|Drug|Budesonide HFA pMDI|Budesonide Hydrofluoroalkane (HFA) pressurised metered dose inhaler (pMDI) 160 μg x 2 actuations twice daily
1778768|NCT00419770|Drug|deferasirox|20 mg/kg enterally per day
1778769|NCT00419770|Drug|Placebo|
1778770|NCT00419770|Drug|Liposomal amphotericin B|
1778771|NCT00419783|Drug|bilastine|20 mg tablets.
1778772|NCT00419783|Drug|Bilastine|100 mg (5 tablets of 20 mg)
1778773|NCT00419783|Drug|Bilastine & Ketoconazole|1 capsule containing bilastine 20 mg tablet + ketoconazole 400 mg tablet
1778774|NCT00419783|Drug|Moxifloxacin|1 capsule containing moxifloxacin 400 mg tablet
1778775|NCT00419783|Drug|Placebo|Placebo tablets
1778776|NCT00419796|Drug|Lumiracoxib|
1778777|NCT00419809|Drug|SB-681323 oral tablets|
1778778|NCT00419822|Procedure|Acupuncture|6 Acupuncture visits
1778779|NCT00419822|Procedure|Sham Acupuncture|6 Acupuncture visits with sham procedure
1778780|NCT00419822|Other|Patient to receive standard care without Acupuncture or Sham Acupuncture.|Standard care
1778781|NCT00419835|Drug|enalapril|
1778783|NCT00419848|Drug|Doxycycline|Cap 100mg- 100mg/daily
1778784|NCT00419848|Drug|Azithromycin|Azithromycin: Cap 250 mg- 500 mg single dose/daily - 3 times per week
1778785|NCT00419887|Drug|Vildagliptin (LAF237)|
1778786|NCT00419900|Procedure|diagnosis of breast cancer by x-ray diffraction of hair|
1778787|NCT00426413|Drug|pioglitazone|Obese AA subjects with DKA or severe hyperglycemia that are able to discontinue insulin at 12 weeks or less will be randomized (blinded fashion) to receive either placebo or pioglitazone qd. The subjects will be followed while in the study arm and beta-cell function will be assessed using OGTT at set intervals.
1778788|NCT00426426|Behavioral|Cognitive-Behavioural Therapy|12 sessions with Cognitive-Behavioural Therapy (CBT), and waiting list will be over 12 weeks, and then allocated into Meta-Cognitive Therapy.
1778789|NCT00426426|Behavioral|Meta-Cognitive Therapy|12 sessions with Meta-Cognitive Therapy (MCT), and waiting list will be over 12 weeks, and then allocated into Cognitive-Behavioural Therapy .
1778790|NCT00426426|Behavioral|Waiting list|
1778791|NCT00426439|Drug|Chloroquine|Chloroquine tablets gives as 50 mg/kg divided into 6 doses giver twice a day for 3 days.
1778792|NCT00426439|Drug|Artemether-lumefantrine (Coartem)|Will be dosed according to the recommendations of WHO. Will be given at time: 0 h, 8 h, 24 h, 36 h,48 h and 60 h. The dosage will be according to bodyweight of the child as follows: 5-14 kg: 1 tablet, 15-24 kg: 2 tablets, 25-34 kg: 3 tablets, < 34 kg: 4 tablets.
1778793|NCT00426452|Drug|Vatalinib|
1778794|NCT00426478|Drug|Valsartan plus Hydrochlorothiazide (80mg/12.5mg)|
1778795|NCT00426478|Drug|Amlodipine (5mg)|
1778796|NCT00426491|Drug|Misoprostol|400 ug Misoprostol or placebo will be placed in the posterior fornix of the vagina using a speculum under the direct visualization of the provider.
1778797|NCT00426504|Procedure|Radiotherapy|Helical Tomotherapy Intensity Modulated Radiotherapy (HT-IMRT) with the intend of delivering radical radiotherapy to a dose of 66-70 Gy to involved areas and at least 50 Gy to un-involved sites to be treated prophylactically.
1778798|NCT00426517|Drug|Fludarabine|For patients with inflammatory disorders or immunodeficiencies with a predominant inflammatory component, we may use Fludarabine instead of TBI to increase the immunosuppression induced by the regimen as well as to try to decrease the target cells responsible for the inflammatory symptoms
1778799|NCT00426517|Drug|Total Body Irradiation, Busulfan, Campath-1H, or h-ATG, Fludarabine|Conditioning regimen in various combination based on patient underlining immune deficiency disorder
1778800|NCT00426517|Drug|Sirolimus or equivalent based on response|post Transplantation immunosuppressants
1778801|NCT00426517|Drug|Granulocyte Colony Stimulating Factor (G-CSF)|For mobilization of sibling donors
1778802|NCT00426517|Other|hematopoietic progenitor cells|Allogeneic Stem Cells (sibling donor, Unrelated Donor (MUD) or Cord Blood Unit (CBU)
1778803|NCT00426530|Drug|everolimus (RAD001)|
1778804|NCT00426543|Drug|MabThera (rituximab)|1000 mg infusion twice with 14 days interval
1778805|NCT00426543|Drug|Rituximab, Mabthera|1000 mg Rituximab infusion in 500 ml isotonic sodiumchloride twice with 14 days interval
1778806|NCT00426556|Drug|Everolimus|Everolimus (RAD001) was supplied as tablets in 3 different dosage strengths, 2.5, 5, and 10 mg. The drug was packaged in blisters containing 10 tablets per blister. Blisters and packaging labels were compliant with local regulations and were printed in local language.
1778807|NCT00426556|Drug|Trastuzumab|Commercially-available trastuzumab was used in this study. A 4 mg/kg loading dose was administered, intra-venous (IV), over 90 minutes on Day 1 (if patient was not already receiving trastuzumab); this was followed by weekly trastuzumab 2 mg/kg IV administered over 30 minutes. For patients who continued to receive trastuzumab and everolimus after completion/discontinuation of chemotherapy in the core treatment phase, trastuzumab may have been administered once every 3 weeks at a dose of 6 mg/kg. PT = Paclitaxel & Trastuzumab
1778808|NCT00426556|Drug|Paclitaxel|Commercially-available paclitaxel was used in this study. Paclitaxel infusion was administered on Days 1, 8, and 15 of each 28-day cycle, after administration of trastuzumab. Paclitaxel (80 mg/m2) was administered as a 60-minute continuous IV infusion after standard premedication. Patients received paclitaxel for 6 cycles. At the investigator's discretion, treatment with paclitaxel could continue beyond 6 cycles.
1778809|NCT00426582|Drug|Patupilone|
1778810|NCT00426595|Drug|Administration of omeprazole suspension|
1778811|NCT00426595|Drug|omeprazole administered as a multi-unit-pellet system|
1778812|NCT00426608|Drug|metyrapone|Metyrapone will be available as 250 mg dose capsule.
1778813|NCT00426608|Drug|alprazolam|Alprazolam capsules will be available with dose strength of 0.25mg
1778814|NCT00426608|Drug|placebo|GSK561679 placebo tablets visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that visually matches active Alprazolam capsules.
1778815|NCT00426608|Drug|GSK561679|GSK561679 tablets will be available with dose strength of 50, 10 and 200 mg.
1778816|NCT00426621|Drug|Diclofenac Sodium Gel|4 grams per knee, 4 times per day, for 12 weeks
1778817|NCT00426621|Drug|Placebo|4 grams per knee, 4 times per day, for 12 weeks
1778818|NCT00426647|Drug|Buprenorphine|
1778819|NCT00426647|Drug|Tramadol|
1778820|NCT00426660|Drug|maraviroc|The nominal dose for maraviroc is 300 mg twice a day (BID). However, the dosage of maraviroc should be adjusted based on optimal background therapy (OBT) patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
1778821|NCT00426673|Drug|Brivaracetam (ucb34714)|
1778822|NCT00426712|Biological|1018 ISS immunostimulatory oligonucleotide with HBV surface antigen|Intramuscular (IM) injections on Day 0, Week 4 and Week 24, plus a placebo (salt solution) injection at Week 8
1778823|NCT00426712|Biological|Hepatitis B Vaccine (Recombinant)|IM (in the muscle) injections on Day 0, Week 4, Week 8 and Week 24
1778824|NCT00426725|Device|EasyLabour|According to the trial protocol
1778825|NCT00426751|Drug|Abciximab|Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
1778895|NCT00427557|Other|Peripheral Blood Stem Cell Infusion|Infusion of blood stem cells on Day 0.
1778896|NCT00427570|Biological|BCG vaccine|
1778826|NCT00426751|Drug|Eptifibatide|Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
1778827|NCT00427089|Drug|Macrogol 3350 Na sulphate NaCl KCl Ascorbic Acid Na Ascorbate|2L gut lavage solution
1778828|NCT00427089|Drug|Sodium Phosphate solution (NaP)|45 ml solution; BID
1778829|NCT00427102|Drug|Oral MRX-1024|
1778830|NCT00427102|Procedure|Standard Fractionation Radiation Therapy|
1778831|NCT00427102|Drug|High-Dose Cisplatin Chemotherapy|
1778832|NCT00427115|Behavioral|Multimodal exercise and psychosocial program|
1778833|NCT00427128|Drug|fluoxetine|10mg/day increased over 12 weeks to 20-80 mg/day; 20-80 mg/day maintained from week 13-36.
1778834|NCT00427128|Drug|placebo|Week 13-36.
1778835|NCT00427141|Drug|GSK580416|
1778836|NCT00427154|Drug|rosiglitazone|Tablets, 4 mg once or twice daily.
1778837|NCT00427154|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
1778838|NCT00427154|Drug|metformin|Tablets, 2000 mg/day.
1778839|NCT00427154|Drug|glimepiride|Tablets, 8 mg/day.
1778840|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Saline)|
1778841|NCT00427167|Biological|AMA1-C1/Alhydrogel + CPG 7909 (Phosphate)|
1778842|NCT00427167|Drug|AMA1-C1/Alhydrogel + CPG 7909|
1778843|NCT00427180|Device|Retinal Implant System (IRIS)|AIMD - Active Implantable Medical Device designed for artificial electrical neural stimulation of photoreceptor degenerated retina
1778846|NCT00427206|Drug|acetaminophen (4g/day)|
1778847|NCT00427206|Drug|placebo|
1778848|NCT00427219|Drug|Ozarelix/Placebo|Ozarelix 15 mg or placebo will be administered IM on Day 0 and Day 14
1778849|NCT00427219|Drug|Placebo|Eligible patients entered a placebo run-in phase in which placebo was administered twice over a 2 week period (Day -28 and Day -14) and patients were assessed to establish baseline values approximately 14 days following the second placebo injection
1778850|NCT00427232|Drug|BQ-123 and BQ-788|
1778851|NCT00427245|Drug|cyclophosphamide|
1778852|NCT00427245|Drug|goserelin acetate|
1778853|NCT00427245|Procedure|adjuvant therapy|
1778854|NCT00427245|Procedure|fertility assessment and management|
1778855|NCT00427245|Procedure|neoadjuvant therapy|
1778856|NCT00427258|Drug|MOA-728|
1778857|NCT00427271|Drug|aspirin|
1778858|NCT00427297|Drug|AZT/3TC/NVP (zidovudine/lamivudine/nevirapine)|First line regimen
1778859|NCT00427297|Drug|d4T/3TC/NVP (stavudine/lamivudine/nevirapine)|First line regimen
1778860|NCT00427297|Drug|AZT/3TC/ABC (zidovudine/lamivudine/abacavir)|First line regimen
1778861|NCT00427297|Drug|d4T/3TC/ABC (stavudine/lamivudine/abacavir)|First line regimen For children who have anaemia(Hb of<8g/dl), AZT will be substituted for d4T.
1778862|NCT00427297|Drug|ddI/ABC/LPV/r (didanosine/abacavir/lopinavir-ritonavir)|Second line regimen
1778863|NCT00427297|Drug|ABC/ ddI or TDF / NVP or EFV (abacavir / didanosine or tenofovir / nevirapine or efavirenz)|Second line regimen - Among children randomized to NVP sparing HAART, who will be initiated on a regimen containing lopinavir/ritonavir, zidovudine and lamivudine will be substituted with abacavir and didanosine or tenofovir (TDF) and lopinavir/ ritonavir will be replaced with nevirapine or efavirenz (EFV) in case of treatment failure of the LPV/r containing regimen.
1778864|NCT00427297|Drug|ABC/3TC/NVP (abacavir/lamivudine/nevirapine)|First line regimen
1778865|NCT00427310|Drug|fluorouracil|
1778866|NCT00427310|Other|Observation|
1778867|NCT00427310|Drug|sodium heparin|
1778868|NCT00427323|Procedure|light exposure|
1778869|NCT00427336|Drug|Fludarabine|30 mg/m^2 by vein daily over 30 minutes
1778870|NCT00427336|Drug|Cyclophosphamide|300 mg/m^2 by vein daily over 2 hours
1778871|NCT00427336|Drug|Antithymocyte Globulin|3.75 mg/kg by vein daily over 4 hours
1778872|NCT00427349|Drug|AMG 706|AMG 706 was administered on a flat scale of mg/day and not by weight or body surface area (BSA). AMG 706 was provided as a 25 mg tablet; the daily dose was 125 mg administered as five 25 mg tablets in the AM. AMG 706 was taken daily without breaks in treatment
1778873|NCT00427349|Drug|octreotide|One dose consisted of octreotide-LAR 30 mg administered IM on day 1 of each cycle. The first octreotide-LAR injection would correspond with the first day of AMG 706 and then on day 1 of subsequent cycles.
1778874|NCT00427362|Drug|Adalimumab|
1778875|NCT00427375|Procedure|local rectal excision|New surgical option in good responders after neoadjuvant treatment for low rectal cancer
1778876|NCT00427375|Procedure|total mesorectal excision|standard surgery
1778877|NCT00427388|Drug|Methylprednisolone|Given by IV in 2 doses (250 mg each dose for a total of 500 mg)
1778878|NCT00427388|Other|Placebo|Given in 2 IV doses (approximately 4 ml of 0.9% normal saline solution in each dose)
1778879|NCT00427401|Drug|PF-00915275|
1778880|NCT00427414|Drug|liposomal daunorubicin citrate|40 mg/m2 Days 1 and 15 every 28 days x 3 cycles
1778881|NCT00427427|Drug|Trastuzumab|
1778882|NCT00427440|Drug|AMG 102 at 20 mg/kg|AMG 102 at 20 mg/kg IV (in the vein) every 2 weeks
1778883|NCT00427440|Drug|AMG 102 at 10 mg/kg|AMG 102 at 10 mg/kg IV (in the vein) every 2 weeks
1778884|NCT00427453|Biological|MVA85A|
1778885|NCT00427466|Drug|Pemetrexed|
1778886|NCT00427492|Drug|Magnesia|Tablet magnesia 500mg. 2 tablet 2 times a day for a week
1778887|NCT00427492|Drug|Placebo|
1778888|NCT00427505|Drug|Deferasirox|
1778889|NCT00427531|Other|physiologic testing|
1778890|NCT00427544|Drug|PRA-027|
1778891|NCT00427557|Drug|Fludarabine|30 mg/m^2 by vein for 4 Days (Day -10 through Day -7).
1778892|NCT00427557|Drug|Melphalan|140 mg/m^2 by vein for 1 Day (Day -7).
1778893|NCT00427557|Procedure|Umbilical Cord Blood|1 UCB Unit by vein on Day -5.
1778894|NCT00427557|Drug|Rituximab|375 mg/m^2 by vein once weekly (Days -7, -1, +7, +14) for 4 Weeks (if appropriate).
1778897|NCT00427570|Biological|biological therapy|
1778898|NCT00427570|Drug|fluorouracil|
1778899|NCT00427570|Drug|semustine|
1778900|NCT00427570|Drug|vincristine sulfate|
1778901|NCT00427583|Drug|imatinib mesylate|
1778902|NCT00427596|Drug|Solabegron|
1778903|NCT00427609|Drug|Bicillin L-A|Bicillin L-A administered intramusculary in a dose of 2.4 million units every three weeks or normal saline injection administered intramusculary in a dose of 3 cc every three weeks
1778904|NCT00427622|Other|physiologic testing|
1778905|NCT00427635|Drug|Esomeprazole|
1778906|NCT00427648|Drug|alkalinized xylocaine|30 cc of 1% xylocaine and 10 cc of 0.9% sodium bicarbonate, dosed twice a week for three weeks
1778907|NCT00427648|Drug|placebo|normal saline
1778908|NCT00427661|Other|Busulfan; Fludarabine; cyclosporine A and MMF|Hematopoietic stem cell transplantation from a matched sibling or unrelated donor following a reduced intensity conditioning regimen
1778909|NCT00427674|Drug|[123I] mZINT injection and serial dynamic SPECT imaging|Following bolus intravenous injection of 5 mCi of 123-I mZINT over 15 seconds, serial dynamic SPECT brain acquisitions will be obtained to evaluate the regional brain uptake and washout of activity. Venous blood measures will be obtained with each acquisition and characterization of 123-I mZINT and metabolites will be assessed. Safety assessments will include vital signs, serum chemistries, CBC, urinalysis, and EKG.
1778910|NCT00427687|Drug|AGG-523|
1778911|NCT00427700|Drug|clomiphene citrate|100mg PO on days 5-9 of the menstrual cycle
1778912|NCT00427700|Drug|raloxifene|100mg PO on days 5-9 of the menstrual cycle
1778913|NCT00427713|Drug|capecitabine|
1778914|NCT00427713|Drug|oxaliplatin|
1778915|NCT00427713|Procedure|adjuvant therapy|
1778916|NCT00427713|Procedure|standard follow-up care|
1778917|NCT00427739|Procedure|Cardiac CT|64 slice spiral computerized tomography
1778918|NCT00427752|Procedure|Transgastric endoscopic peritoneoscopy.|Exploration of the abdominal area
1778919|NCT00427765|Drug|Busulfan|Test Dose = 32 mg/m^2 IV for 1 Day; 130 mg/m^2 IV for 4 Days
1778920|NCT00427765|Drug|Melphalan|70 mg/m^2 IV for 2 Days
1778921|NCT00427778|Device|incontinence ring|"Incontinence ring fitted to patient's anatomy (by choosing appropriate size). It is worn continually for the duration of the treatment period.
Intravaginal incontinence ring placed proximally in the posterior vaginal fornix. Knob located at mid-urethra."
1778922|NCT00427791|Drug|Etoposide|60 mg/kg IV Daily Over 4 Hours for 1 Day
1778923|NCT00427791|Radiation|Total Body Irradiation|3 Gy Daily for 4 Days
1778924|NCT00427791|Drug|Rituximab|375 mg/m^2 IV Weekly Over 4-8 Hours for 4 Weeks
1778925|NCT00427804|Drug|calcitriol|0.25 mcg PO BID for 1 week for low dose then 0.25 mcg PO BID for high dose
1778926|NCT00427830|Biological|MVA85A|
1778927|NCT00427843|Behavioral|home exercise program for the hip abductor muscles|"All patients with knee OA will be taught a home-based exercise program for the hip abductor muscles during the initial visit. Patients will be instructed in the following program: contraction of the gluteus medius muscle during functional activities (gait, stepping sideways up on a step and standing on one leg); and side lying isotonic hip abduction exercises using graded resistance elastic bands positioned around the distal thighs.
The program will be performed 3 times per week for 8 weeks and subjects will record exercise frequency and level of resistance on exercise calendars. Follow-up visits will occur at the end of week 1 and week 4 for review and progression of exercises. A telephone follow-up call will occur for support and participants will be encouraged to call with any questions or concerns."
1778928|NCT00427856|Drug|Obatoclax mesylate|Obatoclax mesylate 40mg, and 60mg
1778929|NCT00427856|Drug|Rituximab|Rituximab
1778930|NCT00427882|Drug|ALFUZOSIN|
1778931|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
1778932|NCT00427895|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered on day 1
1778933|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
1778934|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered on day 1
1778935|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
1778936|NCT00427895|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|0.5 mL dose administered 3-4 years after dose 1
1778937|NCT00427895|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL dose administered 3-4 years after dose 1
1778941|NCT00427921|Biological|adalimumab|160 mg loading dose, 80 mg at week 2, 40 mg every other week
1778942|NCT00427934|Drug|Maraviroc|300 mg (2- 150 mg tablets) are administered by mouth twice a day (BID) for 12 weeks.
1778943|NCT00427934|Drug|Maraviroc Placebo|Placebo tablets to match active drug. Two tablets are administered by mouth twice a day (BID) for 12 weeks.
1778944|NCT00427947|Drug|ropivacaine/placebo|Continuous sciatic nerve bloc
1778945|NCT00427960|Behavioral|Dietary advice|
1778946|NCT00427960|Drug|rosuvastatin|rosuvastatin 5 mg
1778947|NCT00427960|Drug|atorvastatin|atorvastatin 10 mg
1778948|NCT00427973|Drug|cediranib maleate|Given orally
1778949|NCT00427973|Other|laboratory biomarker analysis|Peripheral blood was obtained from all patients enrolled for studies of early changes in circulating proangiogenic and proinflammatory molecules and cells. Blood samples were collected in EDTA-containing tubes before and after cediranib therapy on days 1 and 14 of cycle 1. Circulating VEGF, placental growth factor (PlGF), sVEGFR1, basic fibroblast growth factor (bFGF), interleukin (IL)-6, IL-8, transforming growth factor a ((TNF-a), gamma interferon (IFN-g) were measured using multiplex ELISA plates from Meso-Scale Discovery. Hepatocyte growth factor (HGF), insulin-like growth factor 1 (IGF-1), sVEGFR2, angiopoietin 2 (Ang-2), sTie2, soluble c-KIT, carbon anhydrase 9 (CAIX), and stromal cell-derived factor-1a (SDF1a) were measured using ELISA kits from R&D Systems.
1778950|NCT00427973|Procedure|computed tomography|computed tomography (CT) every 8 weeks to evaluate response and progression.
1778951|NCT00427973|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Magnetic resonance imaging (MRI) every 8 weeks to evaluate response and progression.
1778952|NCT00427973|Other|pharmacological study|Blood samples to characterize the steady-state PK of cediranib were drawn from a peripheral vein shortly before patients received the dose on days 8 and 15 of cycle 1 and at the following times relative to dosing on day 1 of cycle 2: 5 min and 1, 2, 4, 6, 8, and 24 hours, with the last sample collected before taking the next daily dose.
1778954|NCT00427999|Drug|imatinib mesylate|
1778955|NCT00427999|Drug|Treosulfane|
1778956|NCT00427999|Drug|etoricoxib|
1778957|NCT00427999|Drug|pioglitazone|
1778958|NCT00427999|Drug|dexamethasone|
1778959|NCT00428012|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
1778960|NCT00428012|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
1778961|NCT00428025|Drug|diclofenac|100 mg diclofenac rectal suppository
1778962|NCT00428025|Drug|placebo|similar shape and size suppository
1778963|NCT00428051|Other|Surveillance|No study drug, only interventions are blood draws and Chest X-rays
1778964|NCT00428064|Drug|Sirolimus|
1778965|NCT00428064|Drug|cyclosporine|
1778966|NCT00428077|Biological|bcr-abl peptide vaccine|Patients will be vaccinated 15 times over 12 months with a vaccine comprised of native and synthetic break-point cluster region-Abelson murine leukemia(BCR-ABL) specific peptides and the immunologic adjuvants, Montanide ISA 51-VG.
1778967|NCT00428077|Genetic|reverse transcriptase-polymerase chain reaction|"A baseline reverse transcriptase-polymerase chain reaction(RT-PCR) transcript level of BCR-ABL will be determined after enrollment on study. This baseline will be used to measure response to the vaccine. Patients will have 3 quantitative RT-PCR tests for BCR-ABL transcript levels performed on their peripheral blood in the first month after enrolling on study. Peripheral blood samples will be drawn at approximately 1-month prior (about day -30), 2 weeks prior (about day -14), and the day of the first vaccination (day 0). Samples will be analyzed at a central lab and the three values will be averaged to determine a baseline circulating transcript level. During this one-month period, a peripheral blood sample will be analyzed to determine whether patients have a B3A2 or B2A2 junction."
1778968|NCT00428090|Drug|Rosiglitazone|XR (extended release) oral tablets
1778969|NCT00428103|Procedure|3 dimensional echocardiography|Lab tests: BNP, 6 minute walk test Transthoracic 3D echocardiogram
1778970|NCT00428116|Drug|HAART|Combination first line antiretrovirals as previously described.
1778971|NCT00428129|Drug|microplasmin|20mg with Trellis-8 15cm Treatment length 40mg with Trellis-8 30cm Treatment length
1778972|NCT00428142|Biological|rituximab|375mg/m2 day 1
1778973|NCT00428142|Drug|bortezomib|1.3mg/m2 days 1 & 8
1778974|NCT00428142|Drug|cyclophosphamide|750mg/m2 day 1
1778975|NCT00428142|Drug|prednisone|40mg/m2 days 1-5
1778976|NCT00428142|Drug|vincristine sulfate|1.4mg/m2 day 1 (dose capped at 2mg)
1778977|NCT00428155|Device|closure device placement|
1778978|NCT00428168|Drug|Betahistine|Betahistine 24mg BID
1778979|NCT00428181|Behavioral|Brief alcohol intervention|Brief alcohol intervention
1778980|NCT00428181|Behavioral|Brief alcohol intervention plus booster|Brief alcohol intervention plus booster in a later session
1778981|NCT00428194|Drug|cisplatin|40 mg/m^2 every 7 days during radiation
1778982|NCT00428194|Drug|erlotinib hydrochloride|Erlotinib escalating dose per schedule - 100, 125 and 150 mg/m^2 by mouth once a day beginning day 1.
1778983|NCT00428194|Procedure|radiation therapy|standard (fixed) doses of pelvic irradiation (as determined by their radiation oncologist)
1778984|NCT00428207|Drug|Insulin Aspart versus Insulin Lispro|Subjects will be randomly assigned to insulin aspart versus insulin lispro via random number generation. Half of the patients will begin with insulin aspart, and then will be crossed over to insulin lispro. The insulin sequence will be reversed for the other half of the patients.
1778985|NCT00428207|Drug|Insulin Lispro versus Insulin Aspart|Subjects will be randomly assigned to insulin lispro versus insulin aspart via random number generation. Half of the patients will begin with insulin lispro, and then will be crossed over to insulin aspart. The insulin sequence will be reversed for the other half of the patients.
1778986|NCT00428220|Drug|sunitinib|sunitinib
1778987|NCT00428233|Procedure|Leukemia cell harvest|Leukemia cells will be harvested either by: Blood draw, leukapheresis, bone marrow aspiration or surgery to remove the lymph node
1778988|NCT00428246|Drug|paricalcitol|1 mcg or 2 mcg for 4 weeks.
1778989|NCT00428246|Drug|Placebo|Placebo
1778990|NCT00428272|Drug|Lexatumumab alone|Dose escalation : 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
1778991|NCT00428272|Drug|Lexatumumab in combination|Dose escalation : 1mg/kg, 3mg/kg, 5mg/kg, 8mg/kg, 10mg/kg
1778992|NCT00428272|Drug|Interferon gamma 1b in combination|Dosing at the following for each lexatumumab dose level: .75mcg/m2/dose and 25mcg/m2/dose
1778993|NCT00428272|Drug|Gamma 1b potential expansion|Potential expansion (at 10mg/kg lexatumumab): 1.5mcg/m2/dose and 50mcg/m2/dose
1778994|NCT00428285|Procedure|Argon Plasma Coagulation|Argon Plasma Coagulation (APC) is a non-contact electrosurgical technique delivering a high-frequency electrical current through ionized argon gas i.e. the argon plasma. This current produces a zone of coagulation, desiccation, and devitalisation 2-3 mm deep. Patients will be offered up to 3 treatments if recurrence occur after the first two.
1778995|NCT00428298|Drug|Valacyclovir|Subjects take two 500 mg capsules twice daily for 16 weeks.
1778996|NCT00428298|Drug|Placebo|Subjects take two 500 mg capsules twice daily for 16 weeks.
1778997|NCT00428311|Drug|Metformin|
1778998|NCT00428311|Drug|Ethynyl-estradiol plus cyproterone acetate|
1778999|NCT00428337|Biological|EP-1233|DNA-HIV-recombinant vaccine
1779000|NCT00428337|Biological|MVA-mBN32|HIV-recombinant viral vaccine
1779001|NCT00428350|Drug|Quetiapine Fumarate (Seroquel)|
1779002|NCT00428363|Device|Cataract surgery with implantation of an intraocular lens|
1779003|NCT00428376|Device|Building Blocks|
1779004|NCT00428389|Drug|Rivastigmine 5 cm^2 transdermal patch|Rivastigmine 5 cm^2 patch size, loaded with 9 mg and providing 4.6 mg rivastigmine per 24 hours.
1779169|NCT00417391|Drug|RR110 (Tamibarotene)|1 mg RR110
1779005|NCT00428389|Drug|Rivastigmine 10 cm^2 transdermal patch|Rivastigmine 10 cm^2 patch size loaded with 18 mg and providing 9.5 mg rivastigmine per 24 hours.
1779006|NCT00428402|Behavioral|Focus Group Discussion|Focus groups meeting for up to 1 hour during the regular school day.
1779007|NCT00428415|Drug|Tesofensine|
1779008|NCT00428428|Drug|Isoproterenol|ISO 0.1 microgram/ml, 8 ml/min irrigation compared to saline irrigation
1779009|NCT00428441|Drug|Warfarin|tablets, based on INR levels, according to D-dimer levels
1779010|NCT00428454|Device|sirolimus-eluting stent, zotarolimus-eluting stent|PCI in chronically occluded coronary artery
1779011|NCT00428467|Procedure|LV Apex Compression|
1779012|NCT00428480|Behavioral|Daily reinforcement of walking speed (DRS)|Inpatients are encouraged to walk faster and given feedback on their walking speed during a daily 10-meter walk as part of their usual physical therapy.
1779013|NCT00428480|Behavioral|No reinforcement of walking speed (NRS)|Inpatients complete a 10-meter walk as part of their daily physical therapy but are not given any encouragement to walk faster or feedback on their walking speed.
1779014|NCT00428506|Drug|albumin 4 gr/L ascites removed|albumin 4 gr/L ascites removed
1779015|NCT00428506|Drug|albumin 8 gr/L ascites removed|albumin 8 gr/L ascites removed
1779016|NCT00428519|Drug|Placebo|Placebo for 14 days
1779017|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 125 mg daily for 14 days
1779018|NCT00428519|Drug|Aprepitant|Aprepitant at a dose of 250 mg daily for 14 days
1779019|NCT00428532|Drug|Licorice root extract or Pomegranate juice|
1779020|NCT00428545|Drug|Bevacizumab|Starting Dose 2.5 mg/kg By Vein On Day 1 Every 21 Days
1779021|NCT00428545|Drug|Bortezomib|Starting Dose 0.7 mg/m^2 By Vein On Days 1 and 8 Every 21 Days
1779022|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|A Phase 3 Trial of Systematic versus Response-adapted Timed-SEQUENTIAL Induction in Patients with Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)
1779023|NCT00428558|Drug|Chemotherapy (DAUNORUBICINE-CYTARABINE)|Chemotherapy induction sequential
1779024|NCT00428571|Procedure|laparoscopic gastric bypass surgery|Laparoscopic Gastric Bypass Surgery
1779025|NCT00428571|Procedure|laparoscopic adjustable gastric banding|laparoscopic adjustable gastric banding
1779026|NCT00428571|Procedure|Intensive Medical Management|lifestyle, diet, medication optimization
1779027|NCT00428584|Drug|New Formulation of rebif - human interferon beta-1a|New Formulation of rebif- 44 mcg, SC (sub-cutaneous) thrice weekly (tiw) injection.
1779028|NCT00428584|Drug|Interferon beta -1b|Betaseron - 250 mcg, SC (sub-cutaneous) every other day injection.
1779029|NCT00428597|Drug|sunitinib malate|"sunitinib malate oral starting dose 37.5 mg daily (continuous dosing).
Dose may be decreased to 25 mg daily in case of adverse events.
It may be increased to 50 mg daily if no response is seen after 8 weeks on treatment.
Dosing to continue until unacceptable toxicity, progression of disease, death, or study termination."
1779030|NCT00428597|Drug|Placebo|Placebo to match sunitinib taken daily (oral) on the same schedule as active agent below.
1779031|NCT00428610|Drug|LY573636|LY573636 dose is dependent on patient's height, weight, and gender and is adjusted to target a specific Cmax based on patient laboratory parameters. LY573636 is administered every 28 days until disease progression or other criteria for patient discontinuation are met.
1779032|NCT00428623|Procedure|wound dressing|
1779033|NCT00428636|Procedure|ileostomy|
1779034|NCT00428649|Dietary Supplement|20 µg selenium|20 µg selenium as selenomethionine
1779035|NCT00428649|Dietary Supplement|40 µg selenium|40 µg selenium as selenomethionine
1779036|NCT00428649|Dietary Supplement|60 µg selenium|60 µg selenium as selenomethionine
1779037|NCT00428649|Dietary Supplement|80 µg selenium|80 µg selenium as selenomethionine
1779038|NCT00428649|Dietary Supplement|100 µg selenium|100 µg selenium as selenomethionine
1779039|NCT00428649|Dietary Supplement|120 µg selenium|120 µg selenium as selenomethionine
1779040|NCT00428649|Dietary Supplement|placebo|placebo
1779041|NCT00428662|Device|drug eluting nonpolymeric nanoporous stent|
1779042|NCT00428701|Drug|Esomeprazole Sodium|
1779043|NCT00428714|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 28 day cycles until disease progression, unacceptable toxicity or 3 years
1779044|NCT00428727|Drug|Controlled nitric oxide releasing patch|daily application of nitric oxide patch during 90 days
1779045|NCT00428727|Drug|placebo patch|daily application during 90 days
1779046|NCT00428766|Drug|MORAb-003|
1779047|NCT00428779|Procedure|running during 24 hours without sleep|patients running during 24 hours without sleep
1779048|NCT00428779|Other|no sleeping|patients without sleep during 24 hours
1779049|NCT00428792|Drug|Methylphenidate 20 mg long-acting capsules|
1779050|NCT00428805|Behavioral|classroom curriculum|"classroom curriculum for 3 & 4 year old children includes activities to increase intake of fruits, vegetables, & whole grains; increase physical activity; decrease intake of fats and sugared drinks; and decrease screen time following monthly learning modules.
Teachers are trained to carry out the classroom curriculum."
1779051|NCT00428805|Behavioral|In-service training for Head Start teachers/aides|Teachers and teacher aides are trained quarterly by certified trainers and receive a certificate for participating in the training. Topics include the content as well as developmental concepts.
1779052|NCT00428805|Behavioral|Training for Head Start food service|Food service workers are trained (quarterly) to modify food ordering, food preparation, and food serving to match the aims of the study
1779053|NCT00428805|Behavioral|Family intervention component|Families receive the CHILE intervention quarterly at Family Events. These include family activities to increase intake of fruits, vegetables, whole grains, decrease intake of fats and sugared drinks, increase of physical activity and decrease screen time. Parenting skills are also included.
1779054|NCT00428805|Behavioral|Food source|The grocery store component includes field trips, self labeling, and taste testing of promoted foods.
1779055|NCT00428805|Behavioral|Health care providers|The health care provider component includes the health care providers presenting at the Family Events and reinforcing the CHILE intervention message in the practice setting when talking with families of head start children.
1779170|NCT00417391|Drug|RR110 (Tamibarotene)|4 mg RR110
1779056|NCT00428805|Behavioral|CHILE Head Start Intervention|There are six components of this transcommunity social-ecological intervention including a classroom curriculum, health care provider component, family component, training of Head Start teachers/aides, training of food service staff and grocery store component.
1779057|NCT00428818|Drug|trimethoprim-sulfamethoxazole or doxycycline|
1779058|NCT00428844|Drug|daptomycin|6 mg/kg
1779059|NCT00428844|Drug|daptomycin|8 mg/kg
1779060|NCT00428844|Drug|vancomycin|1 gram
1779061|NCT00428844|Drug|teicoplanin|6 mg/kg; used only at UK sites
1779062|NCT00428844|Drug|nafcillin|1-2 gram
1779063|NCT00428844|Drug|oxacillin|1-2 gram
1779064|NCT00428844|Drug|flucloxacillin|1-2 mg
1779065|NCT00428857|Procedure|non invasive ventilation|non invasive ventilation
1779066|NCT00428870|Procedure|Arthroscopic acromioplasty or arthroscopy alone (sham) or conservative treatment (rehabilitation)|
1779067|NCT00428883|Drug|N-acetylcysteine (NAC)|
1779068|NCT00428896|Drug|ZD1839|ZD1839 will be given at the dose of 250mg/day for a minimum of 3 months
1779069|NCT00428909|Drug|Imatinib/Acetaminophen|
1779070|NCT00428922|Drug|Trastuzumab|administered every three weeks on day 1, every 21 days. The dose given will be 6 mg/kg. The initial loading dose is 8mg/kg and is administered as a 90-minute infusion. Thereafter, the maintenance dose is 6mg/kg every three weeks administered as a 30 minute infusion (unless the treating physician indicates a longer infusion duration is warranted). Trastuzumab is given prior to bevacizumab. Trastuzumab is to be continued until disease progression or unacceptable toxicity.
1779071|NCT00428922|Drug|Bevacizumab|administered every three weeks on day 1, every 21 days. The dose given will be 15 mg/kg. The initial dose is administered over 90 minutes. If the first infusion is well tolerated, the second dose is given over 60 minutes, and if that is well tolerated, then subsequent doses may be given over 30 minutes. Avastin is given after trastuzumab and prior to docetaxel.
1779072|NCT00428922|Drug|Docetaxel|administered every three weeks on day 1, every 21 days. The dose given will be 75 mg/M². All doses of docetaxel are administered over 60 minutes. Docetaxel is given after trastuzumab and bevacizumab.
1779073|NCT00428935|Biological|rAAV2.5-CMV-minidystrophin (d3990)|Recombinant adeno-associated virus (AAV) carrying a truncated human dystrophin gene (mini-dystrophin) expressed from a cytomegalovirus (CMV) promoter.
1779074|NCT00428948|Drug|Tolvaptan|Tolvaptan was supplied as tablets.
1779075|NCT00428948|Drug|Placebo|Placebo was supplied as tablets.
1779076|NCT00428974|Drug|CF101|CF101 1 mg q12 hours for 12 weeks
1779077|NCT00428974|Drug|CF101|CF101 2 mg q12 hours for 12 weeks
1779078|NCT00428974|Drug|CF101|CF101 4 mg q12 hours for 12 weeks
1779079|NCT00428974|Drug|Placebo|Placebo tablets q12 hours for 12 weeks
1779080|NCT00429000|Device|thermospot|
1779081|NCT00429013|Device|Tongue Display Unit|lingual electric stimulation
1779082|NCT00429026|Drug|Fludarabine|25 mg/m^2 intravenous (IV) daily for 5 Days
1779083|NCT00429026|Drug|Melphalan|70 mg/m^2 IV Daily for 2 Days
1779084|NCT00429026|Drug|Cyclophosphamide|60 mg/kg IV Daily for 2 Days
1779085|NCT00429026|Procedure|Stem Cell Transplant|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation Using HLA-Matched Related Donor
1779086|NCT00429039|Drug|L-leucyl-L-leucine methyl ester (LLME)|
1779087|NCT00429065|Drug|Rituximab|
1779088|NCT00429078|Genetic|2nd Generation Designer T Cells|
1779089|NCT00429091|Drug|ABT-894|Subjects will take 1 mg QD, 2 mg QD, 4 mg QD, 4 mg BID for up to four weeks.
1779090|NCT00429091|Drug|atomoxetine|Subjects will take 40 mg BID or placebo for up to four weeks.
1779091|NCT00429091|Drug|placebo|Subjects will take BID for up to four weeks
1779092|NCT00429104|Drug|Herceptin|4 mg/kg IV Over 90 Minutes
1779093|NCT00429104|Drug|GM-CSF|250 mcg/m^2 Subcutaneously
1779094|NCT00429117|Behavioral|Survey|Internet survey lasting 30 to 40 minutes.
1779095|NCT00429143|Radiation|Total Body Irradiation (TBI)|TBI twice daily days 6-9 prior to transplant (HSCT)
1779096|NCT00429143|Biological|Donor Lymphocyte Infusion (DLI)|DLI given 6 days prior to transplant (HSCT).
1779097|NCT00429143|Drug|Cyclophosphamide (CY)|Cyclophosphamide given once daily at 60 mg/kg on days 2 and 3 prior to transplant (HSCT).
1779098|NCT00429143|Drug|Tacrolimus|Tacrolimus given one day prior to transplant (HSCT).
1779099|NCT00429143|Drug|Mycophenolate Mofetil (MMF)|MMF given one day prior to transplant (HSCT).
1779100|NCT00429143|Biological|Hematopoietic Stem Cell Transplant (HSCT)|CD34+ selected Hematopoietic Stem Cell Transplant (HSCT) is performed. This is the day of transplantation.
1779101|NCT00429156|Device|Home non-invasive ventilation|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home NIV for 1 year.
1779102|NCT00429156|Device|Home non-invasive ventilation (sham)|Continuation of home non-invasive ventilation after acute NIV for AHRF in COPD. Daily nocturnal treatment by home sham NIV (CPAP 5 cm H2O) for 1 year.
1779103|NCT00429169|Drug|Paroxetine|Dosage will be 25 mg every day for 2 weeks, then 37.5 mg every day for 2 weeks, and then optional increase to 50 mg every day for the remainder of treatment.
1779104|NCT00429169|Drug|Bupropion|Dosage will be 150 mg every day for 2 weeks, then 300 mg every day for 2 weeks, and then optional increase to 450 mg every day for the remainder of treatment.
1779105|NCT00429182|Drug|Carboplatin|Target Area Under the Curve (AUC) of 20, then divided into 4 doses given by vein (IV) days -6, -5, -4, -3 prior to stem cell infusion.
1779106|NCT00429182|Drug|Cyclophosphamide|1.5 gm/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
1779107|NCT00429182|Drug|Thiotepa|120 mg/m^2 by vein days -6, -5, -4, -3 prior to stem cell infusion.
1779108|NCT00429182|Procedure|Stem Cell Transplant|Stem Cell Transplant on Day 0.
1779109|NCT00429195|Behavioral|Dietary Fatty Acid Modification|
1779110|NCT00429208|Drug|Nicotine|
1779111|NCT00429221|Behavioral|Tailored Medication Messages for Parents|
1779112|NCT00429234|Drug|Dasatinib|Starting dose 70 mg by mouth daily for Week 1. Cycle is 28 days, except Cycle 1 which is 8 weeks.
1779171|NCT00417404|Drug|Aquasol A|IM Aquasol A 10,000IU three times weekly
1779172|NCT00417404|Drug|aquasol A|10,000 IU three times weeks, by intramuscular injection
1779113|NCT00429234|Drug|Gemcitabine|Starting dose of 800 mg/m^2 by vein once weekly over 30 minutes beginning Cycle 1 Day 1. All other cycles once weekly for 7 weeks on Days 8, 15, 22, 29, 36, and 43. Cycle is 28 days, except Cycle 1 which is 8 weeks.
1779114|NCT00429247|Drug|Trastuzumab|Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles
1779115|NCT00429260|Drug|Saredutant|
1779116|NCT00429273|Drug|Guanfacine|Week 1: 0.5 mg twice daily; Week 2: 1 mg twice daily; Week 3: 1.5 mg twice daily; Weeks 4 through 8: best dose as determined by efficacy measures
1779117|NCT00429273|Drug|Methylphenidate (MPH)|Participants less than 25 kg will receive 10 mg once daily for Week 5, 20 mg once daily for Week 6, and 30 mg once daily for Week 7. Subjects greater than 25 kg will receive 20 mg once daily for Week 5, 30 mg once daily for Week 6, 40 mg once daily for Week 7, and best doses as determined by efficacy measures for Week 8.
1779118|NCT00429286|Behavioral|Problem Solving Training|A systematic cognitive-behavioral intervention teaching problem solving skills for addressing functional impairment related to breast cancer and its treatment.
1779119|NCT00429299|Drug|lapatinib|Arm B 1250mg/d PO Arm C 750mg/d PO
1779120|NCT00429299|Biological|trastuzumab|First dose 4mg/kg in 60mins, then weekly 2mg/kg in 30 mins
1779121|NCT00429299|Drug|paclitaxel|80mg/sqm 1 hour infusion for 12 weeks
1779122|NCT00429299|Drug|fluorouracil|600mg/sqm iv day 1 q21 days for four coursess
1779123|NCT00429299|Drug|epidoxorubicin|75mg/sqm iv day 1 q21 days for four courses
1779124|NCT00429299|Drug|cyclophosphamide|600mg/sqm day 1 q21 days for four courses
1779126|NCT00429338|Procedure|AIR-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with an air-filled endorectal coil (AIR-MRSI).
1779127|NCT00429338|Procedure|PFC-MRSI|3T Magnetic Resonance Spectroscopic Imaging (MSRI) scan performed with a perfluorocarbon compound (PFC)-filled endorectal coil (PFC-MRSI).
1779128|NCT00429364|Drug|Losartan Potassium|Losartan .3 - 1.4 mg/kg
1779129|NCT00429364|Drug|Atenolol|Atenolol .5 - 4 mg/kg
1779130|NCT00429377|Drug|tacrolimus|
1779131|NCT00429390|Behavioral|Ramadan Fasting|
1779132|NCT00429403|Drug|Goserelin|3.6 mg subcutaneous injection 1 week before the start of chemotherapy, then once a month until 3 weeks after the last chemotherapy dose.
1779133|NCT00429416|Drug|L-leucyl-L-leucine Methyl Ester (LLME)|Infusion of L-leucyl-L-leucine methyl ester (LLME) treated donor white blood cells
1779134|NCT00429416|Drug|Fludarabine|Fludarabine 30 mg/m2 prior to HSCT infusion
1779135|NCT00429416|Drug|Cytarabine|Cytarabine 2gm/m2 prior to HSCT infusion
1779136|NCT00429416|Drug|Cyclophosphamide|Cyclophosphamide 1gm/m2 prior to HSCT infusion
1779137|NCT00429416|Drug|Tacrolimus|Tacrolimus given before and after HSCT infusion
1779138|NCT00429416|Drug|Mesna|Mesna 1gm/m2/day given prior to HSCT infusion.
1779139|NCT00429416|Biological|Granulocyte Macrophage Colony-Stimulating Factor (GM-CSF)|GM-CSF given post HSCT infusion
1779140|NCT00429416|Procedure|Hematopoietic stem cell transplantation (HSCT)|CD34 selected allogeneic stem cell infusion with 5x104/kg untreated T cells
1779141|NCT00429429|Procedure|Sublingual immunotherapy|Drops of peanut protein placed and held under the tongue for a specific time before swallowed.
1779142|NCT00429442|Drug|Simvastatin|80 mg once daily
1779143|NCT00429442|Drug|placebo|calcium tablets once daily
1779144|NCT00429455|Behavioral|Survey|3-Part Questionnaire
1779145|NCT00429468|Drug|Vicodin® CR (extended-release hydrocodone/acetaminophen)|
1779146|NCT00429481|Biological|Rotarix|
1779147|NCT00429494|Drug|Leuprolide Acetate|22.5 mg IM injection 2 months before transplant and 3 months post-transplant.
1779148|NCT00429494|Behavioral|Questionnaire|Questionnaires taking about 15 minutes to complete.
1779149|NCT00429494|Procedure|Hematopoietic Stem Cell Transplantation|Stem cell infusion on Day 0.
1779150|NCT00429507|Drug|153 Sm-EDTMP|Tracer dose = 30 mCi by vein On Day 1. If enough study drug goes to bones, will receive a higher dose of 153 Sm-EDTMP, called a therapy dose, 7-14 days after the tracer dose.
1779151|NCT00429507|Behavioral|Questionnaire|Questionnaires taking about 15 minutes to complete.
1779152|NCT00429507|Procedure|Stem Cell Transplant|Stem Cell Transplant on Day 0, about 14-21 days after Samarium 153-EDTMP.
1779153|NCT00429520|Drug|Hyaluronic acid filler/IMD1 basic|
1779154|NCT00429533|Drug|Dapsone|
1779155|NCT00429546|Behavioral|Teaching, Raising, and Communicating with Kids (TRACK)|TRACK is cognitive-behavioral treatment designed to improve mother-child communication and parenting skills and prepare caregiver for disclosure of HIV serostatus to child. The treatment consists of three 75-minute sessions that focus on exploring mothers' concerns, determining children's readiness to receive the news, planning for disclosure, and practicing disclosure.
1779156|NCT00429546|Other|Treatment as usual|Treatment as usual includes standard care for HIV infected mothers.
1779157|NCT00429559|Drug|Hycamptin|1.75mg/m2 IV on day 1 every week for 3 weeks in cycles of 4 weeks Number of cycles: until progression
1779158|NCT00429559|Drug|Gemcitabine|"Gemcitabine at starting dose of 700 mg/m 2 with increments of 100 mg/m2 IV on day 1 every week for 3 weeks in cycles of four weeks.
Number of cycles: until progression"
1779159|NCT00429572|Drug|Fludarabine|30 mg/m^2 intravenously Daily for 5 Days
1779160|NCT00429572|Drug|Melphalan|70 mg/m^2 intravenously Daily for 2 Days
1779161|NCT00429572|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
1779162|NCT00429585|Device|reamed, interlocking intramedullary nail|Standard of care device for tibia fracture repair; Randomized Treatment - Nail
1779163|NCT00429585|Device|locking periarticular plate|Standard of care device for tibia fracture repair; Randomized Treatment - Plate
1779164|NCT00429611|Procedure|Cardiac defibrillation at high energy vs low energy levels|Defibrillation with progressive high-energy biphasic shocks at 200J, 300J and 360J or low-energy biphasic shocks at 150J, 150J and 150J.
1779165|NCT00429624|Procedure|Chiropractic manipulation|
1779166|NCT00429624|Drug|acetaminophen|
1779167|NCT00417378|Device|Left Ventricular Assist Device Impella LP 2.5|Left Ventricular Assist Device
1779168|NCT00417378|Device|Intraaortic Balloon Pump|Counterpulsation
1779173|NCT00417404|Other|sham injection|sham injection
1779174|NCT00417417|Drug|Rilonacept|Lyophilized rilonacept will be supplied by Regeneron Pharmaceuticals at 160 mg/vial and reconstituted with 2.3 mL of sterile water for injection by the Clinical Center Pharmacy Intravenous Admixture Unit. The formulation contains 80 mg/mL rilonacept, histidine, citrate, PEG 3350, polysorbate 20, glycine, arginine, and sucrose (pH 6.5). Matching placebo in the identical formulation will also be supplied, and also reconstituted with 2.3 mL of sterile water for injection. Each administration of study drug will consist of two syringes containing 2.0 mL in each syringe (320 mg total drug).
1779175|NCT00417417|Drug|Placebo|Normal saline subcutaneously at each treatment visit.
1779176|NCT00422773|Drug|Cetuximab|Dose level Infusion time (h) Dose level unit 1 2 3 4 Cetuximab 2.0 mg/m² 500 500 500 500 Irinotecan, before oxaliplatin 1.0 mg/m² 95 125 165 180 Oxaliplatin, with folinic acid 2.0 mg/m² 85 85 85 85 Folinic acid, with folinic acid 2.0 mg/m² 400 400 400 400 5-FU Infusion 46.0 mg/m² 3200 3200 3200 3200
1779177|NCT00422786|Drug|CAP-232|Continuous IV infusion over 21 days at 0.48 mg/kg/day followed by a 7-day rest period
1779178|NCT00422799|Drug|Bortezomib|Once weekly for 3 weeks
1779179|NCT00422799|Drug|Rituximab|Intravenously once a week for the first and fourth weeks of a cycle
1779181|NCT00422825|Drug|imatinib|
1779182|NCT00422838|Procedure|fine-needle aspiration biopsy|aspiration of intrahepatic cells
1779183|NCT00422864|Drug|oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).
Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
1779184|NCT00422864|Drug|fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.
Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
1779185|NCT00422864|Drug|leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
1779186|NCT00422864|Procedure|External beam radiotherapy|Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy, Weeks 8-10: as per Weeks 3-5
1779187|NCT00422877|Drug|Taxoprexin|DHA-paclitaxel
1779188|NCT00422890|Drug|5-Azacytidin|in case of decreasing CD34 chimerism
1779189|NCT00422903|Drug|lapatinib|1500 mg administered orally daily
1779190|NCT00422903|Drug|letrozole|2.5 mg administered orally daily
1779191|NCT00422903|Other|placebo|1500 mg administered orally daily
1779192|NCT00422916|Behavioral|behavioral intervention|
1779193|NCT00422942|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
1779194|NCT00422942|Drug|Methotrexate|10-25mg po weekly
1779195|NCT00422955|Drug|rosiglitazone|
1779196|NCT00422968|Device|Percutaneous coronary intervention|Using silorimus eluting stent
1779197|NCT00422968|Procedure|coronary artery bypass graft|coronary artery bypass graft
1779198|NCT00422981|Drug|AL-108|5 mg QD
1779199|NCT00422981|Drug|AL-108|15 mg BID
1779200|NCT00422981|Drug|Placebo|Placebo
1779201|NCT00422994|Drug|ropinirole dosing for up to 28 days|
1779202|NCT00423007|Drug|Bromfenac|
1779203|NCT00423007|Drug|Placebo|
1779205|NCT00423046|Biological|GSK Biologicals HPV 16/18 vaccine 580299 (CervarixTM)|Three doses administered intramuscularly at months 0, 1 and 6
1779206|NCT00423046|Biological|Gardasil ® (Merck & Co. Inc)|Three doses administered intramuscularly at months 0, 2 and 6
1779207|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 1 to maintain blinding
1779208|NCT00423046|Biological|Placebo|One dose administered intramuscularly at month 2 to maintain blinding
1779209|NCT00423059|Drug|bevacizumab|
1779210|NCT00423085|Drug|Rivastigmine transdermal patch|"Rivastigmine transdermal patch was provided in the following sizes and doses:
2.5 cm^2 (4.5 mg), 5 cm^2 (9 mg), 7.5 cm^2 (13.5 mg), and 10 cm^2 (18 mg). The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day."
1779211|NCT00423085|Drug|Placebo|Placebo transdermal patch was provided in the following sizes: 2.5 cm^2, 5 cm^2, 7.5 cm^2 and 10 cm^2. The caregiver applied one patch on the back of a patient, placed alternately from the right to the left side at approximately the same time each day.
1779212|NCT00423098|Drug|Mycophenolate sodium|Mycophenolate sodium as administered orally for 2 weeks at 1440mg daily and then increased to 2160mg daily for 22 weeks.
1779213|NCT00423098|Drug|Prednisone|Oral prednisone or prednisone equivalent was started on Day 4 and subsequently tapered every 2 weeks according to the patient's weight.
1779214|NCT00423098|Drug|Methylprednisolone|All patients received bolus therapy with 0.5 g of intravenous Methylprednisolone per day for 3 consecutive days.
1779215|NCT00423124|Genetic|HSV-TK|Infusion of genetically modified lymphocytes (1x10^6-1x10^7 c/kg): first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
1779216|NCT00423137|Drug|BIBW 2948 BS|
1779217|NCT00423137|Drug|Placebo|
1779218|NCT00423150|Drug|Temozolomide|Temozolomide capsules 150 mg/m^2 daily on a 7-day on / 7-day off schedule for each 28-day cycle, until disease progression, intolerable toxicity, or withdrawal of consent.
1779219|NCT00423163|Drug|micafungin|
1779220|NCT00423163|Drug|voriconazole|
1779221|NCT00423176|Drug|MFNS and antibiotic|MFNS BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
1779222|NCT00423176|Drug|Matching Placebo nasal spray plus antibiotic|Matching placebo nasal spray BID for 29 days plus amoxicillin/clavulanic acid BID for 10 days
1779223|NCT00423189|Drug|Ranibizumab (Lucentis)|as needed, one intravitreal injection of 0.50mg ranibizumab
1779224|NCT00423189|Drug|0.5mg ranibizumab|as needed, one intravitreal injection of 0.50mg ranibizumab
1779226|NCT00423215|Drug|Insulin glargine (LANTUS)|"The patients will receive Lantus administered by subcutaneous injection, once daily at any time but at the same time each day.
Treatment duration: 4 months."
1779227|NCT00423228|Drug|ZT-1|Patients in the ZT-1 treatment group will receive ZT 1-1 mg capsules administered p.o. daily during the first month of treatment, followed by ZT-1 implants (9 mg) administered s.c. during the second month of treatment, followed by ZT-1 implants (12 mg) administered s.c. every 4 weeks during months 3 to 6 of treatment. Patients in the ZT-1 treatment group will receive dummy donepezil capsules during months 2 to 6 of the treatment period.
1779228|NCT00423228|Drug|Donepezil|Patients in the donepezil treatment group will receive donepezil 5 mg capsules administered p.o. during the first month of treatment, followed by donepezil 10 mg/day during months 2 to 6 of the treatment period. Patients in the donepezil treatment group will also receive s.c. injections of dummy ZT 1 implants every 4 weeks during months 2 to 6 of the treatment period.
1779229|NCT00423241|Device|SEMPERFLO Pain Management System|continuous infusion of 0.5% bupivacaine at 2mL per hour
1779230|NCT00423241|Device|ON-Q PainBuster Post-Op Pain Relief System|continuous infusion of 0.5% bupivacaine at 2mL per hour
1779231|NCT00423254|Biological|PSMA/PRAME|Low dose
1779232|NCT00423254|Biological|PSMA/PRAME|high dose
1779233|NCT00423267|Drug|Posaconazole|Posaconazole 400 mg orally (PO) (oral suspension 40 mg/mL) administered twice daily with meals or oral nutritional supplements for 12 months
1779234|NCT00423267|Drug|Fluconazole|Fluconazole 400 mg PO (given as two 200-mg oral encapsulated tablets) administered once daily for 12 months
1779235|NCT00423280|Drug|6R-BH4|6R-BH4 tablets 700mg/day, 6R-BH4 tablets 400mg/day or placebo
1779236|NCT00423293|Drug|fluorouracil|1000 mg/m^2/day 96-hour continous infusion (M-F) starting on day 1 and again on day 29 of radiation therapy.
1779237|NCT00423293|Drug|mitomycin C|10 mg/m^2 intravenous therapy on day 1 and day 29 of radiation therapy.
1779238|NCT00423293|Radiation|Intensity-modulated radiation therapy|"Prescription dose depends on tumor staging.
T2N0: The primary tumor PTV (planning target volume) (PTVA) receives 50.4 Gy in 28 fractions (fx) at 1.8 Gy/fx. The nodal PTVs receive 42 Gy in 28 fx at 1.5 Gy/fx. PTVA receive 50.4 Gy in 28 fractions at 1.8 Gy/fx. PTV42 receive 42 Gy in 28 fx at 1.5 Gy/fx and will include all nodal regions.
T3N0 or T4N0: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. The nodal PTVs will receive 45 Gy in 30 fx at 1.5 Gy/fx. PTVA will receive 54 Gy in 30 fx at 1.80 Gy/fx. PTV45 will receive 45 Gy in 30 fx electively at 1.5 Gy/fx and will include all nodal regions.
For N+ disease: The primary tumor PTV (PTVA) will receive 54 Gy in 30 fx at 1.8 Gy/fx. For involved nodes ≤ 3 cm in maximum dimension, the involved nodal PTV will receive 50.4 Gy in 30 fx at 1.68 Gy/fx. For involved nodes > 3 cm in maximum dimension, the involved nodal PTV will receive 54 Gy in 30 fx at 1.80 Gy/fx."
1779239|NCT00423306|Drug|Darinaparsin|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest, for up to 6 months
1779240|NCT00423319|Drug|Enoxaparin|Subcutaneous, 40 mg, once daily, 5 weeks
1779241|NCT00423319|Drug|Apixaban|Oral tablets, 2.5 mg, twice daily, 5weeks
1779242|NCT00423319|Drug|Enoxaparin-matching placebo|Administered as injection
1779243|NCT00423319|Drug|Apixaban-matching placebo|Administered as oral tablets
1779244|NCT00423332|Drug|Cediranib|45 mg oral tablet
1779245|NCT00423332|Drug|Cediranib Placebo|oral tablet
1779246|NCT00423358|Dietary Supplement|Vitamin D|Ergocalciferol 50,000 IU loading dose then twice monthly for one year
1779247|NCT00423358|Dietary Supplement|placebo|matching placebo
1779248|NCT00423371|Device|sodium hyaluronate|EUFLEXXA™ is supplied in a single-dose syringe containing 20 mg/2 ml of 1% sodium hyaluronate. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
1779249|NCT00423371|Device|placebo|Placebo is supplied in a disposable prefilled glass syringe. Each single-dose syringe will contain 2 mL of phosphate buffered saline. Each subject will receive three single dose injections into the target first CMC joint on study weeks 0, 2 and 4.
1779250|NCT00423384|Drug|Placebo|Placebo
1779251|NCT00423384|Drug|Ibandronate|I.v.
1779252|NCT00423397|Biological|PEG-interferon alfa-2a|
1779253|NCT00423397|Drug|gefitinib|
1779254|NCT00423410|Drug|EPC2407 (crinobulin)|IV infusion 1 to 4 hours
1779255|NCT00423436|Behavioral|Questionnaire|Questionnaires taking about 30-45 minutes to complete.
1779256|NCT00423436|Behavioral|Interactive Voice Response Telephone System|IVR Only = Phone calls twice weekly, each call lasting less than 5 minutes.
1779257|NCT00423436|Behavioral|IVR Plus Triage|"IVR system will triage, or sort, the symptom data by symptom severity, notifying health care professionals when a symptom is greater than the set threshold limit."
1779258|NCT00423449|Drug|vorinostat|Dose escalation study: vorinostat 300-500 mg capsules once daily for 7-14 days in continuous cycles of 21 days
1779259|NCT00423449|Drug|Gemcitabine|Dose escalation study: Gemcitabine 1000-1250 mg/m2 will be given for 2 days in each 21 day cycle
1779260|NCT00423449|Drug|Platinum-based agent|Cisplatin IV 75 mg/m2 will be given for 1 day in each 21 day cycle or carboplatin dosed according to renal function.
1779261|NCT00423462|Behavioral|Brief dynamic psychotherapy|
1779262|NCT00423475|Drug|goserelin acetate|
1779263|NCT00423475|Procedure|adjuvant therapy|
1779264|NCT00423475|Radiation|radiation therapy|
1779265|NCT00423488|Drug|Ezetimibe 10 mg|1 x 10-mg tablet, provided as blinded study treatment
1779266|NCT00423488|Drug|Simvastatin 20 mg|1 x 20-mg tablet, provided as open-label study treatment
1779267|NCT00423488|Drug|Ezetimibe Placebo|1 tablet matching ezetimibe 10-mg tablet, provided as blinded study treatment
1779268|NCT00423488|Drug|Simvastatin 20 mg|1 x 20-mg tablet, provided as blinded study treatment
1779269|NCT00423488|Drug|Simvastatin Placebo|1 tablet matching 20-mg simvastatin tablet, provided as blinded study treatment
1779270|NCT00423501|Drug|Placebo|sc weekly
1779271|NCT00423501|Drug|taspoglutide|20mg sc weekly
1779272|NCT00423501|Drug|taspoglutide|10mg sc every 2 weeks
1779273|NCT00423501|Drug|taspoglutide|5mg sc weekly
1779274|NCT00423501|Drug|taspoglutide|10mg sc weekly
1779275|NCT00423501|Drug|taspoglutide|20mg sc every 2 weeks
1779276|NCT00423514|Biological|filgrastim|
1779277|NCT00423514|Drug|clofarabine|
1779279|NCT00423514|Drug|mycophenolate mofetil|
1779280|NCT00423514|Drug|tacrolimus|
1779281|NCT00423514|Drug|thiotepa|
1779282|NCT00423514|Procedure|allogeneic bone marrow transplantation|
1779283|NCT00423514|Procedure|allogeneic hematopoietic stem cell transplantation|
1779284|NCT00423514|Procedure|peripheral blood stem cell transplantation|
1779285|NCT00423527|Drug|levetiracetam|Levetiracetam tablets 500 mg, total daily dose 3000 mg
1779286|NCT00423540|Drug|Intravenous Infusion of Magnesium Sulfate|See Detailed Description.
1779287|NCT00423566|Biological|MVA85A (Tuberculosis vaccine)|
1779288|NCT00423579|Drug|Ezetimibe/Simvastatin 10/20 mg|1 tablet containing 10 mg of ezetimibe and 20 mg of simvastatin per day for 6 weeks
1779289|NCT00423579|Drug|simvastatin 40 mg|1 tablet containing 40 mg of simvastatin per day for 6 weeks
1779290|NCT00423592|Drug|ambrisentan|All eligible subjects received 2.5 mg ambrisentan once daily for a period of 4 weeks before increasing the dose to 5 mg once daily. After Week 24, investigators were allowed to adjust the dose of ambrisentan as clinically indicated (available doses were 2.5, 5, and 10 mg).
1779291|NCT00423605|Drug|Xyrem®|flexible dosing
1779292|NCT00423618|Radiation|radiotherapy|radiotherapy as adjuvant treatment for adults with soft tissue sarcoma extremities
1779293|NCT00423631|Behavioral|Standard care and web|A static web site containing cognitive and behavioral self management instructions.
1779294|NCT00423631|Behavioral|Standard Care|Standard care delivered by the primary care provider.
1779295|NCT00423644|Drug|Darinaparson|420 mg/m2 of Darinaparsin given twice weekly for three weeks, followed by one week of rest for up to six months
1779296|NCT00423657|Drug|ceftaroline|600 mg parenteral infused over 60 minutes, every 12 hours for 5 to 14 days
1779297|NCT00423657|Drug|vancomycin plus aztreonam|vancomycin at 1 g parenteral infused over 60 minutes followed by aztreonam 1 g infused over 60 minutes, every 12 hours, for 5 to 14 days.
1779298|NCT00423657|Drug|Placebo|Ceftaroline fosamil 600 mg administered intravenously over 60 minutes every 12 hours, followed by placebo administered over 60 minutes every 12 hours.
1779299|NCT00423670|Drug|boceprevir (SCH 503034)|200 mg capsules taken as 800 mg orally three times daily (TID)
1779300|NCT00423670|Drug|peginterferon-alfa 2b (PegIntron)|1.5 μg/kg subcutaneously (SC) once weekly (QW)
1779301|NCT00423670|Drug|ribavirin|200 mg capsules in doses of 800 to 1400 mg/day (based on weight) taken orally divided twice daily
1779302|NCT00423670|Drug|ribavirin (low-dose)|200 mg capsules in doses of 400 to 1000 mg/day (based on weight) taken orally divided twice daily
1779303|NCT00423683|Drug|Arixtra alone|Arixtra subq injection 5mg dose (dose also dependent upon size and age of pt)
1779304|NCT00423683|Device|Arixtra + filter|Arixtra as daily injections similar to arm I and placement of Inferior Vena Cava (IVC) filter.
1779305|NCT00423696|Biological|bevacizumab|
1779306|NCT00423696|Drug|capecitabine|
1779307|NCT00423696|Drug|fluorouracil|
1779308|NCT00423696|Drug|irinotecan hydrochloride|
1779309|NCT00423696|Drug|leucovorin calcium|
1779310|NCT00423696|Procedure|quality-of-life assessment|
1779311|NCT00423709|Procedure|Allogeneic Blood Stem Cell Transplantation|
1779312|NCT00423709|Drug|Fludarabine|
1779313|NCT00423709|Drug|Melphalan|
1779314|NCT00423722|Drug|Saline|1,000 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
1779315|NCT00423722|Drug|Saline|100 ml of normal saline (0.9% sodium chloride) parenterally over 4 hours daily.
1779316|NCT00423735|Drug|Dasatinib|Given PO
1779317|NCT00423735|Other|Pharmacological Study|Correlative studies
1779318|NCT00423748|Drug|ambrisentan|
1779319|NCT00423761|Drug|midazolam|
1779320|NCT00423761|Drug|GW876008|
1779321|NCT00423774|Behavioral|Problem-Solving Education|
1779322|NCT00423787|Biological|Ragweed MATA MPL|"4 injections of increasing dose strength:
300 SU/0.5 ml
700 SU/0.5 ml
2000 SU/0.5 ml
6000 SU/0.5 ml"
1779323|NCT00423800|Drug|Combination of pegylated interferon alfa-2b (PEG) and ribavirin (RBV)|"Powder for Solution in Redipen® (pegylated interferon alfa-2b) (80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 or 48 weeks
200 mg ribavirin capsules, oral, weight-based dose of 800, 1000, or 1200 mg, daily for up to 24 or 48 weeks"
1779324|NCT00423813|Drug|placebo|Oral Solution
1779325|NCT00423813|Drug|Xyrem®|two doses
1779326|NCT00423826|Drug|Busulfan|3 mg/kg intravenously over 3 hours
1779327|NCT00423826|Drug|Cytarabine|Patients with previous history of CNS involvement will receive pre-transplant intrathecal Cytarabine (Ara-C) (30 mg/M2) therapy.
1779328|NCT00423826|Drug|Fludarabine phosphate|25 mg/M2/day IV
1779329|NCT00423826|Drug|mycophenolate mofetil|Orally at the dose of 1 gm every 8 hours.
1779330|NCT00423826|Drug|tacrolimus|0.015 mg/kg IV every 12 hours by continuous infusion.
1779331|NCT00423826|Procedure|allogeneic hematopoietic stem cell transplantation|10 days post drug intervention
1779332|NCT00423826|Procedure|umbilical cord blood transplantation|10 days post drug intervention
1779333|NCT00423826|Radiation|total-body irradiation|10 days post drug intervention
1779334|NCT00429650|Behavioral|increased exercise|Use prescribed number of minutes of exercise 5-6 days per week to maintain weight loss.
1779335|NCT00429650|Behavioral|diet|Use a prescribed diet to maintain weight loss
1779336|NCT00429650|Behavioral|Exercise and Diet|Use a combination of exercise and diet to maintain weight loss.
1779337|NCT00429663|Device|reamed, interlocking intramedullary nail|Standard of care device for femur fracture repair
1779338|NCT00429663|Device|locking periarticular plate|Standard of care device for femur fractures
1779339|NCT00429676|Drug|Haloperidol|
1779340|NCT00429689|Procedure|Saliva sample|
1779341|NCT00429702|Drug|Decadron®|Given IV
1779342|NCT00429702|Drug|Benadryl®|Given IV
1779343|NCT00429702|Drug|Ativan®|Given IV
1779344|NCT00429702|Drug|ondansetron hydrochloride|Given IV
1779345|NCT00429715|Biological|Alum-ALM + BCG|Alum precipitated autoclaved L. major
1779346|NCT00429715|Biological|Alum-ALM + BCG|Arm 1=Alum-ALM + BCG Arm 2=BCG Arm 3=Placebo comparator
1779347|NCT00429715|Biological|Alum-ALM + BCG|Alum-ALM + BCG
1779348|NCT00429728|Drug|GW876008|
1779349|NCT00429754|Drug|Aprepitant|
1779350|NCT00429780|Biological|Alum-ALM + BCG|Alum-ALM + BCG 200 ug per injection
1779351|NCT00429793|Drug|temsirolimus|Given IV
1779352|NCT00429806|Drug|DHEA|DHEA
1779353|NCT00429806|Drug|Placebo|Placebo
1779354|NCT00429832|Drug|Ondansetron|
1779355|NCT00429832|Drug|promethazine|
1779356|NCT00429845|Behavioral|Nutritional|
1779359|NCT00429871|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
1779360|NCT00429871|Drug|Capecitabine|Capecitabine 950 mg/m2 orally twice a day on days 1-14 every 3 weeks for 6 consecutive cycles
1779361|NCT00429871|Drug|Epirubicin|Epirubicin at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
1779362|NCT00429871|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
1779363|NCT00429897|Drug|Bendroflumethiazide 2.5mg - 5mg|
1779364|NCT00429897|Drug|Amiloride 20-40mg|
1779365|NCT00429897|Drug|Spironolactone 50-100mg|
1779366|NCT00429897|Drug|Frusemide 20-40mg|
1779367|NCT00429897|Drug|Bendroflumethiazide 1.25-2.5mg/ Amiloride 10-20mg combined|
1779368|NCT00429923|Drug|Difluprednate|
1779369|NCT00429923|Drug|Difluprednate|
1779370|NCT00429923|Drug|Placebo|
1779371|NCT00429936|Drug|Fenretinide|Once daily 30 minutes after the evening meal for 24 months
1779372|NCT00429949|Drug|Dasatinib|
1779373|NCT00429962|Drug|intravitreal ranibizumab|intraocular injection
1779374|NCT00429962|Drug|intravitreal ranibizumab & photodynamic therapy|intraocular injection photodynamic treatment (LASER) after intravenous injection
1779375|NCT00429975|Drug|levofloxacin|
1779376|NCT00429975|Drug|ceftriaxone|
1779377|NCT00433901|Behavioral|Targeted parental instruction for positive lifestyle change with follow-up calls.|
1779378|NCT00433914|Biological|rMenB|One dose (0.5 mL) of rMenB vaccine without OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
1779379|NCT00433914|Biological|rMenB+OMV|One dose (0.5 mL) of rMenB vaccine with OMV-NZ supplied as a full liquid formulation in a prefilled syringe was administered into the anterolateral area of the right thigh.
1779380|NCT00433927|Drug|5-FU|5-FU 400 mg/m² Bolus day 1 5-FU 2400 mg/m² iv over 46 h day 1-2
1779381|NCT00433927|Drug|folinic acid|Folinsäure (racemisch) 400 mg/m² iv, 120 min d 1
1779382|NCT00433927|Drug|irinotecan|Irinotecan 180 mg/m² iv, 30 - 90 min day 1
1779383|NCT00433927|Drug|cetuximab|Cetuximab initial 400mg/m² as 120 min infusion, than 250 mg/m² iv as 60 min infusion d 1 + 8
1779384|NCT00433927|Drug|bevacizumab|Bevacizumab 5 mg/kg iv over 30 to 90 minutes d 1
1779385|NCT00433940|Drug|Prednisolone|Oral prednisolone sodium phosphate suspension administered in dosage of 15mg/5mL. Medication administered every morning at a starting daily dose of 2.5mg/kg.
1779386|NCT00433953|Drug|Mycophenolate Mofetil (CellCept)|
1779387|NCT00433953|Behavioral|Dietary Monitoring|
1779388|NCT00433953|Behavioral|Drug Diary|
1779389|NCT00433953|Procedure|Blood Sampling|
1779394|NCT00433979|Drug|antiretroviral treatment|These antiretroviral drugs are a part of the participant's current drug regimen.
1779395|NCT00434005|Drug|N-acetylcysteine, ascorbate|NAC: 600mg twice daily for the day prior to exposure and 1x pre-exposure Ascorbate: 500mg twice daily for 7 days prior to exposure
1779396|NCT00434005|Drug|Placebo|matched appearance to acetylcysteine and ascorbate intervention
1779397|NCT00434018|Behavioral|Wheelchair Skills Training|Subjects are provided with five weeks of wheelchair skills training, tailored to meet their needs.
1779398|NCT00434018|Behavioral|Basic Health Education|Five sessions are held with subjects to provide them with educational information regarding health related issues - such as nutrition, proper hand hygiene, sports, etc.
1779399|NCT00434031|Drug|docetaxel|
1779400|NCT00434031|Drug|cyclophosphamide|
1779401|NCT00434031|Drug|trastuzumab|
1779402|NCT00434031|Drug|liposomal doxorubicin|
1779403|NCT00434044|Drug|Enbrel (etanercept)|
1779404|NCT00434057|Device|MelaFind(R)|Biopsy ratio comparison
1779405|NCT00434083|Drug|sumatriptan|
1779406|NCT00434083|Drug|naproxen sodium|
1779407|NCT00434096|Drug|rimonabant (SR141716)|oral administration once daily
1779408|NCT00434096|Drug|placebo|oral administration once daily
1779409|NCT00434109|Drug|Sunitinib malate|Sunitinib malate (Sutent) at a dose of 37.5mg will be administered orally once daily on days 1-28 in a 42-day cycle. Treatment with Sutent will begin no sooner than seven days after the first hepatic artery embolization. Subsequent embolizations (if necessary) will be scheduled during scheduled Sutent treatment breaks. No fewer than seven days shall separate treatment with Sutent and scheduling of hepatic artery embolizations.
1779410|NCT00434109|Procedure|Hepatic Artery Embolizations|1-3 selective hepatic artery embolizations will be performed at approximately 5-week intervals, based on the extent of hepatic involvement with tumor.
1779411|NCT00434122|Drug|Degarelix mid-luteal, 2.5 mg|Degarelix 2.5 mg will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak and on Stimulation Day 6. Placebo will be injected SC on Stimulation Day 1.
1779412|NCT00434122|Drug|Placebo|"Placebo will be injected subcutaneously (SC) 7 days after luteinizing hormone (LH) peak. Degarelix 2.5 mg will be injected SC on Stimulation Day 1 and Stimulation Day 6.
or Placebo will be injected SC 7 days after LH peak and on Stimulation Day 1. Ganirelix 0.25 mg will be injected SC daily from Stimulation Day 6 until the last stimulation day."
1779413|NCT00434135|Drug|gemcitabine plus pemetrexed, paclitaxel plus gemcitabine|gemcitabine 1,250 mg/sqm days 1&8 + pemetrexed 500 mg/sqm day 8 paclitaxel 120 mg/sqm + gemcitabine 1,000 mg/sqm days 1&8
1779414|NCT00434148|Drug|Pasireotide|
1779415|NCT00434161|Drug|Palifermin before only|One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 days before-high dose chemotherapy and one bolus IV injection at 60 μg/kg/day of matched placebo on days 0, 1 & 2 days after-high dose chemotherapy. Minimum of 4 days between before-chemotherapy and after-transplantation dosing.
1779416|NCT00434161|Drug|Placebo|"One bolus IV injection at 60 μg/kg/day of matched placebo on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).
Minimum of 4 days between pre-chemotherapy and post-transplantation dosing."
1779417|NCT00434161|Drug|Palifermin before and after|"One bolus IV injection at 60 μg/kg/day, on Days 6, 5 & 4 (before-high dose chemotherapy) and on Days 0, 1 & 2 (after-high dose chemotherapy).
Minimum of 4 days between before-chemotherapy and after-transplantation dosing."
1779418|NCT00434174|Drug|Everolimus|"RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. All proposed dose levels in this study can be given as a combination of these dose strengths.
Daily doses of 2.5, 5, 7.5 and 10 mg of RAD001 will be given alongside the standard 21-day cycle of pemetrexed."
1779419|NCT00434174|Drug|Pemetrexed|Pemetrexed was supplied to the sites in 500 mg/m2 was administered on Day 1 of each cycle as a 10-minute continuous i.v. infusion in 100mL normal saline
1779420|NCT00434187|Drug|ERB-041|
1779421|NCT00434200|Procedure|long-term intensive exercise|
1779422|NCT00434213|Drug|Daytrana|Methylphenidate Transdermal System (MTS)
1779423|NCT00434226|Drug|bevacizumab|Intravenously at a dose of 15mg/kg on the first day of each 21-day cycle
1779424|NCT00434226|Drug|sunitinib|25 mg/day for 2 weeks, followed by 1 week of rest
1779425|NCT00434226|Drug|carboplatin|On the first day of each cycle for 4 cycles
1779426|NCT00434226|Drug|paclitaxel|On the first day of each cycle for 4 cycles
1779427|NCT00434239|Drug|Lenalidomide + Ancestim|Dose level 1. Lenalidomide 10mg orally daily days 1-21/ 28 day cycle Ancestim 10mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle. Dose level 2 Ancestim 20mc/kg subcutaneously daily for 7 days for cycle 3 only 10mg orally daily days 1-21/ 28 day cycle
1779428|NCT00434252|Drug|bevacizumab|15 mg/kg by intravenous (IV) infusion on the first day of each 3-week cycle (dose was based on patient's weight at screening and remained the same throughout study)
1779429|NCT00434252|Drug|carboplatin|Dose based on patients' creatinine clearance (Calvert formula) and administered by intravenous (IV) infusion on the first day of each 3-week cycle, for a maximum of 10 cycles
1779430|NCT00434252|Drug|paclitaxel|175 mg/m^2 by IV infusion on the first day of each 3-week cycle (dose was based on patient's weight and could be adjusted for weight change)
1779431|NCT00434252|Drug|placebo|Administered by IV infusion on the first day of each 3-week cycle
1779432|NCT00434265|Behavioral|Physical training|
1779433|NCT00434278|Drug|Dornase alfa|2.5 mg inhalation dose twice daily for 14±2 days
1779434|NCT00434278|Drug|placebo|2.5 mg inhalation dose twice daily for 14±2 days
1779435|NCT00434291|Drug|TG-873870(Nemonoxacin)|
1779436|NCT00434304|Drug|Ropinirole prolonged release/extended release(PR/XR)|Subjects will take the investigational drug once daily at the same time each day, it is recommended that this is in the morning for optimal benefit. Investigational drug is taken for 52 weeks, starting on the next day of the Week 0 visit. One tablet of ropinirole PR/XR 2 mg tablets will be orally dosed as the initial dose. The dose will be titrated weekly by 2 mg/day, and increased to 8 mg/day in Week 4. From Week 5 up to 16, the dose will be increased at minimum intervals of one week between titration steps until sufficient efficacy is obtained, according to individual clinical response and tolerability (the dose may be titrated up to 16 mg/day). In Week 16 and further, treatment dose at Week 16 will be continuously administered up to Week 52. If insufficient efficacy is judged in a subject during treatment, or unable to maintain the dose due to adverse event, the treatment dose may be changed. The dose is down tapered according to the maintenance dose at Week 52 (or withdrawal).
1779437|NCT00434317|Drug|Zoledronic acid|
1779438|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 milligram per kilogram (mg/kg) for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously (SC) once every 4 weeks (Q4W) for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
1779439|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously (IV) once every 4 weeks for a total of 7 doses. No transition period between epoetin treatment and start of peginesatide treatment.
1779440|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
1779441|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.05, 0.075, or 0.1 mg/kg for participants on an epoetin (alfa or beta) dose of ≤100 Units/kg/week, >100 to 150 Units/kg/week, or >150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
1779442|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered subcutaneously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
1779543|NCT00435071|Procedure|Carpal Tunnel Release Surgery|Patient will have large incision size during carpal tunnel release surgery.
1779443|NCT00434330|Drug|peginesatide|Tiered peginesatide starting doses of 0.04 mg/kg or 0.075 mg/kg for participants with an epoetin (alfa or beta) dose of ≤100 Units/kg/week or 100 to 150 Units/kg/week, respectively. Doses were administered intravenously once every 4 weeks for a total of 7 doses. With transition period between epoetin treatment and start of peginesatide treatment.
1779444|NCT00434343|Procedure|Physical Therapy|
1779445|NCT00434356|Drug|bevacizumab|Intravenous repeating dose
1779446|NCT00434356|Drug|sunitinib|Oral repeating dose
1779447|NCT00434356|Drug|paclitaxel|Intravenous repeating dose
1779448|NCT00434369|Drug|CoFactor (ANX-510)|
1779449|NCT00434382|Drug|Sevoflurane|
1779450|NCT00434382|Drug|Isoflurane|
1779451|NCT00434382|Drug|Desflurane|
1779452|NCT00434382|Drug|Propofol|
1779453|NCT00434382|Drug|Fentanyl|
1779454|NCT00434382|Drug|Sufentanil|
1779455|NCT00434382|Drug|Alfentanil|
1779456|NCT00434382|Drug|Remifentanil|
1779457|NCT00434382|Device|Midlatency auditory evoked potentials|
1779458|NCT00434395|Drug|MOA-728|
1779459|NCT00434408|Behavioral|chx once|4.0% chlorhexidine cleansing of the cord applied once by a project worker visiting the newborn in the home as soon as possible after birth
1779460|NCT00434408|Behavioral|CHX x 7 days|4.0% chlorhexidine cleansing of the cord during home visits by project workers for the first 7 days after birth
1779461|NCT00434408|Behavioral|dry cord care|Household members are instructed to apply nothing to the newborn's umbilical cord stump.
1779462|NCT00434421|Drug|Glycerinated German cockroach allergenic extract|Initially each subject underwent a 1-day, 8-dose escalation (e.g., one dose of placebo, 0.14 milliliters [mL], followed by 7 escalating doses of Glycerinated German Cockroach Allergenic Extract until the Maximum Study Dose [0.42 mL, 1:10 wt/vol] or Maximum Tolerated Dose was achieved). This maximum dose became the daily dose - maintenance dose- of Glycerinated German Cockroach Allergenic Extract for the following 14 days.The maintenance dose of 0.42 mL was calculated to contain 3685 bioequivalent allergy units (BAU), with approximately 4.2 mg of German cockroach allergen Bla g 2 and 50 mg of Bla g 1 per dose. Route of administration: sublingual-oral route.
1779463|NCT00434421|Drug|Placebo|Placebo was administered only as the first dose (e.g., representing no Glycerinated German Cockroach bioequivalent allergy units) during the initial 1-day, 8-dose escalation, otherwise referred to as the Preliminary Dosing Visit. Refer to the Glycerinated German cockroach allergenic extract treatment for more details. Route of administration: sublingual-oral route.
1779464|NCT00434434|Drug|omalizumab|Aged Liquid; subcutaneous repeating dose
1779465|NCT00434434|Drug|omalizumab|Lyophilized; subcutaneous repeating dose
1779466|NCT00434434|Drug|placebo|Subcutaneous repeating dose
1779467|NCT00434447|Drug|Zoledronic acid|
1779468|NCT00434460|Behavioral|Education|Implementation of clinical practice guideline for ventilator associated pneumonia through education.
1779469|NCT00434473|Drug|A-001|A-001
1779470|NCT00434473|Other|Placebo|Placebo
1779471|NCT00434486|Drug|SKI-606|
1779472|NCT00434499|Drug|EGCG|EGCG 400 mg by mouth twice/daily for 4 weeks duration.
1779474|NCT00434525|Procedure|Laparoscopic restrictive procedure|Patients will receive laparoscopic sleeve gastrectomy with or without omentectomy
1779475|NCT00434525|Procedure|Sleeve gastrectomy|Sleeve gastrectomy
1779476|NCT00434538|Device|BST-DermOn|
1779477|NCT00434564|Procedure|Stress nuclear scan|
1991658|NCT00718549|Drug|cladribine|0.12mg/kg iv on days 2-4 of each cycle (induction phase)
1991659|NCT00718549|Drug|cyclophosphamide|250mg/m2 iv on days 2-4 (induction phase)
1779480|NCT00434590|Drug|Enteric coated mycophenolate sodium (Myfortic®)|
1779481|NCT00434603|Behavioral|Expressive Arts--Theatre Skills Training Program|The experimental intervention was an intensive theatre skills training program. The group of adolescent participants recovering from ABI met daily for four hours over a period of 4 weeks. During this 4 hour period, regular breaks were scheduled to provide the participants with a mental and physical break from therapy. Theatre training included voice work, breathing, movement, physical warm-up, character development, script analysis, writing skills, three-dimensional awareness, group dynamics, story development, mask work and clowning among others.
1779482|NCT00434616|Procedure|Autologous bone marrow cell concentrate transplantation|bone marrow aspiration (240 ml), processing and reinjection
1779483|NCT00434616|Biological|saline injection|saline injections
1779484|NCT00434629|Drug|Bexxar|"Day 0: Tositumomab, IV (in the vein) followed by test dose of 131I-Tositumomab, IV (in the vein) to determine treatment dose of 131I-Tositumomab.
1-2 weeks after Day 0: Tositumomab, IV (in the vein) followed by therapeutic dose 131I-Tositumomab (in the vein)."
1779485|NCT00434642|Drug|Carboplatin|Carboplatin was provided as commercially available drug.
1779486|NCT00434642|Drug|Gemcitabine|Gemcitabine was provided as commercially available drug.
1779487|NCT00434642|Drug|Bevacizumab|Bevacizumab was supplied as a clear to slightly opalescent, sterile liquid in glass vials (400 mg in 8 mL [25 mg/mL]) with a vehicle consisting of sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
1779488|NCT00434642|Drug|Placebo|Placebo consisted of the vehicle for bevacizumab without the antibody and contained sodium phosphate, trehalose, polysorbate 20, and Sterile Water for Injection, USP.
1779489|NCT00434655|Procedure|Laparoscopic restrictive procedure|Morbidly Obese VETERANS will receive one of two laparoscopic bariatric restrictive procedures.
1779490|NCT00434668|Drug|cisplatin/docetaxel|
1779491|NCT00434668|Drug|cisplatin/vinorelbine|
1779492|NCT00434681|Drug|paracetamol 4.8% paediatric oral suspension|
1779493|NCT00434694|Procedure|Pulmonary Vein Isolation (Radiofrequency Catheter Ablation)|
1779494|NCT00434720|Device|GlideScope Specific Stylet|
1779495|NCT00434733|Biological|Pandemic influenza vaccine|
1779496|NCT00434746|Drug|ILV-094|Single, ascending doses of 5, 15, 50, 100, 300, and 600 mg IV or SC dose of ILV-094 or placebo
1779497|NCT00434759|Behavioral|cognitive therapy|changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
1779498|NCT00434759|Behavioral|stepped care program based on cognitive therapy|starting with a digital-video-disk-based (DVD-based) self-help module (8 Sessions) followed by face-to-face-therapy including 8 or 16 sessions depending on remission status; including: changing safety behaviors, self-focused attention, and automatic negative thoughts in anxiety-provoking situations via cognitive techniques, for example role plays and behavioral experiments
1779499|NCT00434772|Drug|glucagon|
1779500|NCT00434785|Drug|AGG-523|
1779501|NCT00434798|Biological|Campylobacter jejuni strains CG8421 and BH-01-0142|Campylobacter jejuni strains CG8421 and BH-01-0142 at a single dose. Dosing will be based on attack rate, to achieve a 75% attack rate. Anticipate use of 10^6-10^9 CFU
1779502|NCT00434811|Biological|Allogeneic Pancreatic Islet Cells|200 ml suspension of allogenic human purified islets
1779503|NCT00434811|Biological|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the first islet transplant. ATG will continue to be given until Day 2 post-transplant.
1779504|NCT00434811|Drug|Sirolimus|Participants will begin receiving sirolimus 2 days prior to the first islet transplant and will be given for the duration of the study.
1779505|NCT00434811|Drug|Tacrolimus|On Day 1 post-transplant, participants will receive tacrolimus, which will also be taken for the duration of the study.
1779506|NCT00434811|Biological|Etanercept|Etanercept will be taken on the day of transplant and Days 3, 7, and 10 post-transplant.
1779507|NCT00434811|Procedure|Islet Transplantation|Transplantation of pancreatic islet cell
1779508|NCT00434811|Biological|Basiliximab|Basiliximab will be used in place of ATG for the second and third transplants, if they are necessary.
1779509|NCT00434824|Drug|Oral testosterone undecanoate (Andriol)|treatment for 12 months with oral TU 80 mg/d, oral TU 160 mg/d or oral TU 240 mg/d in divided doses
1779510|NCT00434824|Drug|Placebo|treatment for 12 months with placebo in divided doses
1779512|NCT00434850|Biological|Allogeneic Pancreatic Islet Cells|Preparation of allogeneic pancreatic islet cells injected into the portal vein of the liver
1779513|NCT00434850|Drug|Deoxyspergualin|An anti-inflammatory agent that blocks proinflammatory cytokine production and inhibits T-cells and B-cells and affects antigen presenting cells.
1779514|NCT00434850|Biological|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
1779515|NCT00434850|Biological|Daclizumab or basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
1779516|NCT00434850|Drug|Sirolimus|Maintenance immunosuppressive therapy
1779517|NCT00434850|Drug|Tacrolimus|Maintenance immunosuppressive therapy
1779518|NCT00434850|Biological|Etanercept|Blocks TNF-alpha which is toxic to islet cells
1779519|NCT00434863|Drug|botulinum toxin type A|
1779520|NCT00434876|Drug|Quetiapine XR|Quetiapine is a second generation antipsychotic medication, which has also recently shown to be associated with properties of mood stabilization in bipolar disorder.
1779521|NCT00434876|Drug|Placebo.|Inactive or inert pill which will be used as a comparator.
1779522|NCT00434915|Drug|DHEA|
1779523|NCT00434941|Other|Radiotherapy + Capecitabine|Experimetal treatment consists of administration of 825 mg/m2 x 2 daily p.o., for 7 days simultaneously with daily radiotherapy treatment.Capecitabine will be administered for 35 days as maximum.
1779524|NCT00434954|Drug|exenatide twice daily (BID)|subcutaneous injection (5 mcg or 10 mcg), twice a day
1779525|NCT00434954|Drug|premixed insulin aspart twice daily (BID)|subcutaneous injection (titrated appropriately), twice a day
1779526|NCT00434967|Drug|Candesartan cilexetil|32 mg oral tablet
1779527|NCT00434967|Drug|Hydrochlorothiazide|25 mg oral tablet
1779528|NCT00434967|Drug|Candesartan/HCT 32/25 mg|
1779529|NCT00434980|Behavioral|Family-Directed Cognitive Adaptation Program|
1779530|NCT00434993|Drug|Albuterol Sulfate|"Albuterol sulfate, USP, solution for inhalation will be diluted as follows:
The full dose of 5.0 mg will be diluted into 2.0 ml of sterile normal saline solution.
The reduced dose of 2.5 mg will be diluted into 2.5 ml of sterile normal saline solution.
A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization. The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
1779531|NCT00434993|Procedure|Mini-Bronchoalveolar Lavage (BAL)|The mini-BAL procedure involves blind specimen sampling from distal airspaces. Specimens are obtained with the Combicath (Plastimed) catheter. The procedure will be done on study days 0 and 3
1779532|NCT00434993|Drug|Placebo|"Placebo aerosol will consist of 3.0 ml of identical appearing sterile 0.9 % sodium chloride without preservative.
A high-efficiency small volume jet nebulizer (SVN) powered at a flow of 8 liters/minute from a 50 psi wall oxygen flow meter will be used for continuous nebulization (e.g.: throughout the inspiratory and expiratory cycle).
The study drug will be given every 4 hours (plus or minus one hour) for ten days following randomization or until 24 hours after extubation, whichever occurs first."
1779533|NCT00435019|Drug|insulin detemir|s.c. injection, once or twice daily.
1779534|NCT00435019|Drug|insulin NPH|s.c. injection, once or twice daily.
1779535|NCT00435019|Drug|insulin aspart|s.c. injection, at main meals.
1779536|NCT00435032|Procedure|early appendectomy|Appendectomy within 24 hours of admission
1779537|NCT00435032|Procedure|interval appendectomy|Initial antibiotic treatment followed by appendectomy at 6-8 weeks
1779538|NCT00435045|Drug|Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor] plus atorvastatin|Lovaza + atorvastatin
1779539|NCT00435045|Drug|atorvastatin|atorvastatin + placebo
1779540|NCT00435058|Drug|timolol maleate 0,5%|
1779541|NCT00435058|Drug|brimonidine tartrate 0,2%|
1779542|NCT00435058|Drug|travoprost 0,004%|
1779544|NCT00435071|Procedure|Carpal tunnel release surgery|Patient will have a small incision size during carpal tunnel release surgery.
1779545|NCT00435084|Drug|APO866|
1779546|NCT00435110|Procedure|standard ventilatory settings|
1779547|NCT00435110|Procedure|PEEP and FiO2|
1779548|NCT00435123|Dietary Supplement|Nutritional Supplement ProStat 64 twice a day|
1779549|NCT00435123|Dietary Supplement|Placebo supplement|Patients randomly assigned to Placebo for the first 3 months will receive open label Prostat for the last 3 months
1779550|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will be put in a splint after surgery.
1779551|NCT00435149|Procedure|Carpal tunnel release surgery|Patient will have carpal tunnel release surgery and will have a bandage placed over the incision site after surgery.
1779552|NCT00435162|Drug|Valsartan 0.25 mg/kg|once daily
1779553|NCT00435162|Drug|Valsartan 1.0 mg/kg|once daily
1779554|NCT00435162|Drug|Valsartan 4.0 mg/kg|once daily
1779555|NCT00435175|Drug|estradiol|
1779556|NCT00435188|Behavioral|Multi-component physical activity counseling program|A one-year high intensity physical activity counseling program with the following five components: (1) a baseline face-to-face counseling session by the health counselor, (2) follow-up telephone calls by the health counselor biweekly for 6 weekly and then monthly, (3) a one-time physician endorsement of the prescribed exercise regimen in a primary care clinic visit, (4) monthly automated tailored telephone calls from the primary care provider encouraging continued physical activity, and (5) quarterly mailed materials providing personalized feedback
1779557|NCT00435227|Biological|MEDI-524|30 mg/kg of MEDI-524
1779558|NCT00435227|Other|Placebo|30 mg/kg of Placebo
1779559|NCT00435240|Behavioral|Paleolithic diet|
1779560|NCT00435253|Biological|BLVR Treatment|BLVR Treatment, 10 mL Hydrogel
1779561|NCT00435266|Procedure|Remote ischemic preconditioning|Inflation of blood pressure cuff 4 x 5 minutes during transportation to primary PCI
1779562|NCT00435279|Drug|Eszopiclone|Eszopiclone 3 mg
1779563|NCT00435279|Drug|Placebo|Placebo
1779564|NCT00435279|Drug|Venlafaxine|Venlafaxine 75 mcg Weeks 1, 2, 29, and 30 Venlafaxine 150 mcg Weeks 3 through 28
1779565|NCT00435292|Drug|Naproxen|nonsteroidal anti-inflammatory drug
1779566|NCT00435292|Dietary Supplement|flavocoxid 250 mg|flavonoid mixture
1779567|NCT00435292|Dietary Supplement|flavocoxid 500 mg|flavonoid mixture
1779568|NCT00435305|Drug|Meropenem|
1779569|NCT00435305|Drug|Vancomycin|
1779570|NCT00435305|Drug|Linezolid|
1779571|NCT00435305|Drug|Piperacillin/Tazobactam|
1779572|NCT00435305|Drug|Cefepim|
1779573|NCT00435305|Drug|Ceftazidim|
1779574|NCT00435318|Procedure|Iontophoresis|
1779575|NCT00435331|Drug|sapropterin dihydrochloride (6R-BH4)|2.5 mg/kg/day for two weeks, 5 mg/kg/day for two weeks, 10 mg/kg/day for four weeks, then 20 mg/kg/day for two days
1779576|NCT00435344|Behavioral|Pediatric Practice-Based Smoking Intervention|
1779577|NCT00435357|Device|mobile-bearing TKA|
1779578|NCT00435357|Device|fixed- bearing TKA|
1779579|NCT00435370|Drug|Tropisetron|10 mg/day
1779580|NCT00435370|Drug|Placebo|placebo
1779581|NCT00435370|Drug|Risperidone|6mg/day
1779582|NCT00435396|Biological|GSK Biologicals' Recombinant CMV gB Vaccine GSK1492903A|Intramuscular injection, 3 doses
1779583|NCT00435409|Drug|Sunitinib + Capecitabine|"Sunitinib administered orally at a starting dose of 37.5 mg once a day on a continuous regimen.
Capecitabine administered orally at a starting dose of 2000 mg/m^2 per day [1000 mg/m^2 bid (twice daily)] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons."
1779584|NCT00435409|Drug|Capecitabine|Capecitabine administered orally at a starting dose of 2500 mg/m^2 per day [1250 mg/m^2 bid (twice daily)] from days 1-14 every 3 weeks. Study treatment should be given until progression or withdrawal from the study for other reasons. At the time of progression, patients may be eligible to crossover to single agent sunitinib, administered orally at a starting dose of 37.5 mg daily.
1779585|NCT00435422|Procedure|Stroke volume optimization|Stroke volume optimization
1779586|NCT00435435|Drug|Disulfiram|
1779587|NCT00435435|Drug|Acamprosate|
1779588|NCT00435435|Drug|Naltexone|
1779589|NCT00435448|Drug|Lonidamine|
1991660|NCT00718549|Drug|rituximab [MabThera/Rituxan]|375mg/m2 on day 1 of cycle 1 (induction phase)
1779591|NCT00435474|Procedure|Wound treatment|wound treatment (silver product, alginate and foam dressing)
1779592|NCT00435474|Procedure|wound treatment|wound treatment (honey product, alginate and foam dressing)
1779593|NCT00435474|Other|psycho-social support|psycho-social support (based on the structure in cognitive therapy)
1779594|NCT00435474|Other|relaxation therapy|relaxation therapy
1779595|NCT00435487|Drug|Dalteparin ( Fragmin)|Dalteparin will be administered at a dose of 120 IU/kg (international units per kilogram) total body weight subcutaneously (SC) every 12 hours up to a maximum dose of 10,000 IU/12 hours.
1779596|NCT00435487|Drug|Unfractionated heparin|Unfractionated heparin will be given intravenously according to a weight-adjusted nomogram (bolus of 60 U/kg [units per kilogram] and initial infusion of 12 U/kg/h [units per kilogram per hour]).
1779597|NCT00435500|Drug|Fluoride varnish|
1779598|NCT00435526|Biological|anti-CFA/I bovine IgG, and anti-CfaE bovine IgG|
1779599|NCT00435539|Drug|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 75µg of ocriplasmin.
1779600|NCT00435539|Drug|ocriplasmin|Intravitreal injection of ocriplasmin solution containing 125µg of ocriplasmin with up to 2 additional (open label) 125µg ocriplasmin injection at 1 month interval.
1779601|NCT00435539|Drug|Sham Comparator|Intravitreal sham injection
1779602|NCT00435552|Procedure|Ease-It Spray|
1779603|NCT00435578|Drug|Glufosfamide|
1779604|NCT00435591|Drug|Conivaptan|ampoule or premix bag
1779605|NCT00435591|Drug|placebo|ampoule or premix bag
1779606|NCT00435604|Drug|Hylenex|
1991661|NCT00718549|Drug|rituximab [MabThera/Rituxan]|500mg/m2 iv on day 1 of cycles 2-6 (induction phase)
1991662|NCT00718549|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 12 weeks (maintenance phase)
1779608|NCT00435630|Other|LapSim training|complete curriculum training on LapSim surgical simulator
1779609|NCT00435643|Procedure|nasal continuous positive airway pressure|After an average interval of three months, 10 patients with severe OSAS (AHI of more than 30 events per hour of sleep) treated with a mean nCPAP pressure of 11.2 ± 0.7 cm of H2O were reassessed and all mentioned measurements above were repeated
1779610|NCT00435669|Drug|Brivanib|Oral Solution, Oral, 800 mg, X1 on Day 1, 10 D for ADME
1779611|NCT00435669|Drug|Brivanib|Tablet, Oral, Brivanib 800 mg, QD, until progression
1779612|NCT00435682|Drug|Botox (Allergan Inc., US)|
1779613|NCT00435695|Drug|GSK163090|
1779614|NCT00435708|Behavioral|5 portions fruit and vegetables/day|Participants consume > = 5 portions fruit and veg per day
1779615|NCT00435721|Behavioral|Psychoeducation|
1779616|NCT00435734|Behavioral|obesity intervention|
1779617|NCT00435747|Drug|PARECOXIB SODIUM|
1779618|NCT00435760|Drug|Aclidinium bromide|200 micrograms, once daily, 1 day treatment
1779619|NCT00435760|Drug|Placebo Tiotropium|1 puff once daily, 1 day treatment
1779620|NCT00435760|Drug|Tiotropium|1 puff of 18 µg (22.5 µg tiotropium bromide monohydrate) in the morning between 8:00 and 10:00
1779621|NCT00435760|Drug|Placebo LAS34273|1 puff, 1 dat treatment
1779622|NCT00435773|Procedure|Single Leeching|
1779623|NCT00435773|Procedure|Repeated Leeching after 4 weeks|
1779624|NCT00435773|Procedure|Placebo Leeching|
1779625|NCT00435799|Procedure|corneal cross-linking (CCL)|
1779626|NCT00435799|Drug|Riboflavin/dextran eyedrops|
1779627|NCT00435799|Device|UV-X system|
1779628|NCT00435812|Biological|1018 ISS with HBsAg and Placebo|Intramuscular (IM) injections on Week 0, Week 4 and Week 24; placebo (saline) injection at Week 24
1779629|NCT00435812|Biological|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
1779630|NCT00435825|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms subcutaneous weekly for 24 weeks or 48 weeks.
1779631|NCT00435838|Drug|No Intervention -- Observational study|
1779632|NCT00435851|Drug|Thyrogen, thyroid hormone withdrawal, iode 131|
1779633|NCT00435864|Procedure|Blood test|The study of KIR and HLA genes will be performed on samples of cord blood or peripheral blood donor and recipient before transplant For grafts from placental cord blood, we do ask any additional samples.
1779634|NCT00435890|Behavioral|Triage Liaison Physician|triage liaison physician stationed with nurses at the triage desk of the Emergency Department.
1779635|NCT00435903|Device|Palm Pilot|
1779636|NCT00435916|Drug|SGN-40|1-8 mg/kg IV (in the vein) on Days 1, 4, 8, 15, 22 and 29 of Cycle 1; 8 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 for Cycles 2-12.
1779637|NCT00435929|Drug|Ritonavir|100mg po bid
1779638|NCT00435929|Drug|saquinavir [Invirase]|1000mg po bid
1779639|NCT00435942|Device|Relay Thoracic Stent-Graft|implant
1779640|NCT00435942|Procedure|Open Repair|Open surgery
1779641|NCT00435955|Procedure|High dose chemotherapy with autologous transplantation|
1779642|NCT00435955|Drug|Rituximab|
1779643|NCT00435968|Drug|CVT E002 (Cold-fX)|
1779644|NCT00435981|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|
1779645|NCT00435994|Drug|Inhaled primatene will be given as a breathing treatment|While the research subject is sedated an inhaled mist of primatene mist will be given to the patient.
1779646|NCT00435994|Other|Nasal Washing|1-3 mls of normal saline will be instilled into the infant's nose and then aspirated to obtain the nasal fluid, which will be analyzed for VEGF level by ELISA and viral antigens by immunoflourescence
1779647|NCT00436007|Biological|GSK 257049|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine
1779648|NCT00436007|Biological|Tritanrix™ HepB/Hib|GSK Biologicals' re-constituted diphtheria, tetanus, pertussis, hepatitis B vaccine (Tritanrix™ HepB) and Haemophilus influenzae type B vaccine (Hiberix™)
1779649|NCT00436007|Biological|Rouvax™|Aventis Pasteur's attenuated measles vaccine.
1779650|NCT00436007|Biological|Stamaril™|Aventis Pasteur's attenuated yellow fever vaccine.
1779651|NCT00436007|Biological|Polio Sabin™|GSK Biologicals' oral polio virus vaccine
1779652|NCT00436020|Device|TMS|Transcranial Magnetic Stimulation
1779653|NCT00436020|Device|Sham TMS|Sham Transcranial Magnetic Stimulation
1779654|NCT00436033|Drug|milnacipran|
1779655|NCT00436033|Drug|Placebo|
1779656|NCT00436046|Biological|Trivalent inactivated influenza virus vaccine (2006-2007 formulation)|Commercially available trivalent inactivated influenza virus vaccine without or with 1 of 2 dosages of commercially available type 1 interferon administered once by nasal instillation. Dosages: 0.6 ml of IVV or 0.7 ml of IVV.
1779657|NCT00436046|Biological|Type 1 interferon|Commercially available lyophilized IFN; dosages 1 M unit (Mu) of IFN; 10 M units (Mu) of IFN.
1779658|NCT00436059|Drug|bortezomib|
1779659|NCT00436072|Drug|ZD6474|Orally on a daily basis
1779660|NCT00436072|Drug|Cetuximab|Infusion once weekly
1779661|NCT00436072|Drug|Irinotecan|Infusion once the safe dose of ZD6474 and cetuximab is established
1779662|NCT00436085|Behavioral|Cognitive behavioral stress management training|
1779663|NCT00436098|Behavioral|Motorpedagogic exercise|physical training
1779664|NCT00436124|Drug|oseltamivir [Tamiflu]|
1779665|NCT00436137|Behavioral|Patient mailing|Patient will receive a mailing recommending colonoscopy, followed by telephone outreach
1779666|NCT00436150|Behavioral|Interpersonal therapy-based treatment|Participants assigned to receive interpersonal therapy-based treatment will focus on the psychological aspects of pregnancy and factors that may play a role in the development of postpartum depression in teenage mothers, such as poor social support, role transitions, and life stressors. Both groups will attend weekly 1-hour sessions for 5 weeks.
1779667|NCT00436150|Behavioral|Standard care|Participants assigned to receive standard care will focus more on the health issues associated with pregnancy and postpartum. Both groups will attend weekly 1-hour sessions for 5 weeks.
1779668|NCT00436163|Drug|Peginterferon alfa-2a|180 mcg subcutaneously once per week for 48 weeks.
1779734|NCT00427037|Drug|Placebo|identical placebo pill orally by mouth
1779735|NCT00427050|Drug|PEP005|
1779669|NCT00436176|Behavioral|Expanded Chronic Care Model|Intervention clinicians receive monthly performance feedback reports, cultural competency training, and health navigation training.
1779670|NCT00436189|Procedure|Blood Draw|
1779671|NCT00436202|Behavioral|Iron supplement|
1779672|NCT00436215|Drug|Bevacizumab|bevacizumab 5 mg/kg intravenous (IV) every two weeks
1779673|NCT00436215|Drug|BAY 43-9006|BAY 43-9006 200 mg po (by mouth) twice daily 5 out of 7 days each week (Mon-Fri)
1779674|NCT00436241|Drug|Oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
1779675|NCT00436241|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-10 of each 2 week cycle
1779676|NCT00436254|Biological|pNGVL3-hICD vaccine|Plasmid-based DNA vaccine, given intradermally
1779677|NCT00436254|Biological|sargramostim|Given intradermally
1779678|NCT00436254|Other|flow cytometry|Correlative studies
1779679|NCT00436254|Other|immunologic technique|Correlative studies
1779680|NCT00436254|Other|immunoenzyme technique|Undergo ELIspot (correlative studies)
1779681|NCT00436254|Genetic|protein expression analysis|Undergo ELISA (correlative studies)
1779682|NCT00436254|Procedure|biopsy|Undergo punch biopsy (correlative studies)
1779683|NCT00436267|Drug|fluorouracil|
1779684|NCT00436267|Radiation|selective external radiation therapy|
1779685|NCT00436267|Radiation|tomotherapy|
1779686|NCT00436267|Radiation|yttrium Y 90 glass microspheres|
1779687|NCT00436267|Radiation|yttrium Y 90 resin microspheres|
1779688|NCT00436280|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression or 3 years
1779689|NCT00436280|Drug|gemcitabine|1000 mg/m2, IV, once, every two weeks, four to eight 2 week cycles
1779690|NCT00436280|Drug|rituximab|375 mg/m2, IV, once every 2 weeks, four to eight 2 week cycles
1779691|NCT00436280|Drug|oxaliplatin|100 mg/m2, IV, once every two weeks, four to eight 2 week cycles
1779692|NCT00436293|Drug|Docetaxel|75 mg/m²
1779693|NCT00436293|Drug|Cisplatin|75 mg/m²
1779694|NCT00436306|Behavioral|Individualized Intervention|Individualized Intervention is a computer-based, stage-matched, tailored intervention to promote the use of dual methods of contraception for STD and unplanned pregnancy prevention.
1779695|NCT00436306|Behavioral|Computer-based contraceptive information|Contraceptive method information is provided on a computer.
1779696|NCT00436319|Procedure|Duration of GnRH agonist downregulation|"This is a randomized controlled trial. Patients will be randomized to two groups during the first consultation. GnRH agonist will be administrated according to the long luteal protocol. Down-regulation of the pituitary will be controlled on the first day of the menstrual period.
The purpose of this study is to compare the pregnancy rates between the two groups. In the eventuality that pituitary down-regulation has not been confirmed (down-regulation levels determined as Ε2<80 pg/ml and progesterone <1.6 ng/ml), the patient will be assigned to a third group (group 3) and ovarian stimulation will only be initiated after down-regulation has been confirmed.
The GnRH agonist that will be administrated is Buserelin Acetate. Recombinant FSH will be used for the ovarian stimulation and dose determination will be based on patient characteristics and previous history."
1779697|NCT00436332|Biological|bevacizumab|
1779698|NCT00436332|Drug|erlotinib hydrochloride|
1779699|NCT00436345|Drug|Remifentanil|analgesia in medical and post-surgical Intensive Care Unit subjects requiring mechanical ventilation
1779700|NCT00436345|Drug|Propofol|conventional sedation in medical and post-surgical Intensive Care Unit subjects requiring mechanical
1779701|NCT00436358|Other|Not applicable: none|Please refer to the detailed description section
1779702|NCT00436371|Drug|Amisulpride|Oral tablets
1779703|NCT00426764|Drug|Romidepsin|Romidepsin intravenously (through a vein) over 4 hours on Days 1, 8 and 15 of each 28-day cycle.
1779704|NCT00426777|Drug|risedronate|risedronate 35mg tablet, weekly for 12 months
1779705|NCT00426777|Drug|risedronate|35mg weekly
1779706|NCT00426777|Drug|Control|risedronate-matched placebo weekly
1779707|NCT00426790|Procedure|Positive end-expiratory pressure|
1779708|NCT00426803|Drug|activated recombinant human factor VII|
1779711|NCT00426829|Drug|Bevacizumab|10 mg/kg by vein every 14 days +/- 2 days, starting on day 1.
1779712|NCT00426829|Radiation|Proton Radiation Therapy|3 Gy dose/fraction x 20 fractions.
1779713|NCT00426842|Drug|Midodrine Hydrochloride|Alpha1-agonist, exerts its actions via activation of the alpha-adrenergic receptors of the arteriolar and venous vasculature, producing an increase in vascular tone and elevation of blood pressure.
1779714|NCT00426855|Drug|Bendamustine|starting with 60 mg/m^ 2, IV, dose escalation, weekly d1,8,15 q5w
1779715|NCT00426855|Drug|Bortezomib|weekly 1.5mg/m^2, IV, d1,8,15,22 q5w
1779716|NCT00426868|Other|Direct injection of ADRCs into the Left Ventricle|Dose escalation
1779717|NCT00426868|Other|Direct injection of placebo into the Left Ventricle|
1779718|NCT00426881|Behavioral|Exercise Training|Twice weekly resistance training for 52 weeks.
1779719|NCT00426881|Behavioral|Exercise training|Once weekly resistance training for 52 weeks.
1779720|NCT00426881|Behavioral|Exercise training|Twice weekly resistance training for 52 weeks.
1779721|NCT00426894|Procedure|samples from nostrils, mouth, axillas, perianal area and postoperative wound|
1779722|NCT00426907|Procedure|Unlimited postoperative weightbearing|Unlimited postoperative weightbearing
1779723|NCT00426920|Drug|Insulin|
1779724|NCT00426933|Drug|Daptomycin|
1779725|NCT00426933|Drug|Vancomycin|
1779726|NCT00426946|Drug|Reboxetine|
1779727|NCT00426959|Device|Image Guided Dynamic Dosimetry|Image Guided Dynamic Dosimetry
1779728|NCT00426972|Drug|estradiol (Zesteem)|
1779729|NCT00426985|Drug|Ketoprofen Topical Patch 20%|
1779730|NCT00426998|Drug|Verteporfin|
1779731|NCT00426998|Drug|Bevacizumab|
1779732|NCT00427011|Drug|E2007|E2007 2mg tablets. Dose (2mg, 4mg, 6mg or 8mg), is taken orally at nighttime.
1779733|NCT00427037|Drug|Cholecalciferol|50,000 IU weekly by mouth
1779872|NCT00438321|Other|Placebo|
1779736|NCT00427076|Drug|Cotrimoxazole|Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR<30.
1779737|NCT00427076|Drug|Vancomycin|intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR <10 1gr Q 4-7 days.
1779738|NCT00436384|Procedure|Monitoring-blood samples drawn for CMV testing|
1779739|NCT00436397|Radiation|radiation therapy|
1779740|NCT00436410|Biological|colloidal gold-bound tumor necrosis factor|
1779741|NCT00436410|Other|electron microscopy|
1779742|NCT00436410|Other|pharmacological study|
1779743|NCT00436410|Procedure|conventional surgery|
1779744|NCT00436423|Drug|gemcitabine, TS-1|
1779745|NCT00436436|Drug|O6-benzylguanine|
1779746|NCT00436436|Drug|temozolomide|
1779747|NCT00436449|Drug|Avotermin|
1779752|NCT00436501|Drug|docetaxel|25 mg/m^2 given intravenously (IV) over 1 hour (+/- 10 minutes) following VEGF Trap every 3 weeks starting cycle 1 (21 day cycles)
1779753|NCT00436501|Biological|ziv-aflibercept|Starting dose 2 mg/kg given IV Cycle 0. Phase I Group: Every 3 weeks beginning with Cycle 0 (Completed 03/14/2008); Phase II Group: Every 3 weeks starting cycle 1 (Opened 05/09/2008).
1779754|NCT00436501|Other|laboratory biomarker analysis|Correlative studies
1779755|NCT00436501|Other|pharmacological study|Correlative studies
1779756|NCT00436514|Behavioral|diet and absorption of ColoPEG|4l of PEG during 2 days
1779757|NCT00436514|Procedure|Colonoscopy with colic videocapsule|2x 10mg Motilium, 2 Fleet Phospho soda (one is facultative) and 1 dulcolax (facultative)
1779758|NCT00436514|Procedure|Standard colonoscopy|1l of PEG the morning just before colonoscopy
1779759|NCT00436527|Drug|Metronidazole gel 1%|Applied once to a test site on the right or left cheek (as determined by a randomization design)
1779760|NCT00436540|Drug|Clobetasol Propionate 0.05% Spray|Apply to affected areas twice daily
1779761|NCT00436540|Drug|Clobetasol Propionate 0.05% Foam|Apply to affected areas twice daily
1779762|NCT00436553|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 (Standard Fluence rate) or 25 J/cm^2 (Reduced Fluence rate) to the study eye, begun 15 minutes after the start of the infusion.
1779763|NCT00436553|Drug|Ranibizumab|Ranibizumab 0.5 mg administered as an intravitreal injection.
1779764|NCT00436553|Drug|Verteporfin Placebo|To maintain masking, as a placebo for verteporfin photodynamic therapy, patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
1779765|NCT00436553|Drug|Ranibizumab Placebo|To maintain masking, patients in the combination groups received sham intravitreal injections whenever retreatment with active Ranibizumab was not warranted based on the retreatment algorithm.
1779766|NCT00436566|Biological|trastuzumab|
1779767|NCT00436566|Drug|cyclophosphamide|
1779768|NCT00436566|Drug|doxorubicin hydrochloride|
1779769|NCT00436566|Drug|lapatinib ditosylate|
1779770|NCT00436566|Drug|paclitaxel|
1779771|NCT00436566|Genetic|gene expression analysis|
1779772|NCT00436566|Genetic|reverse transcriptase-polymerase chain reaction|
1779773|NCT00436566|Other|fluorophotometry|
1779774|NCT00436566|Other|laboratory biomarker analysis|
1779775|NCT00436566|Other|mass spectrometry|
1779776|NCT00436566|Procedure|adjuvant therapy|
1779777|NCT00436566|Procedure|quality-of-life assessment|
1779778|NCT00436579|Drug|sorafenib tosylate|Given orally
1779779|NCT00436579|Other|pharmacological study|
1779780|NCT00436579|Procedure|assessment of therapy complications|Ancillary studies
1779781|NCT00436579|Other|laboratory biomarker analysis|Correlative studies
1779782|NCT00436592|Device|NeuroFlo™ Catheter|45 minute Treatment
1779783|NCT00436605|Drug|dasatinib|
1779784|NCT00436618|Drug|Everolimus|Everolimus 10 mg orally daily for 4 week cycle. Repeat until progression, unacceptable toxicity, refusal, or alternative therapy at any time.
1779785|NCT00436631|Behavioral|Dietary management of seizures|Using the high-fat, low carbohydrate modified Atkins diet - 15 grams per day initially. This is a 3-month study of this diet.
1779786|NCT00436644|Drug|Lapatinib|1250 mg orally days 1 -28.
1779787|NCT00436644|Drug|Topotecan|3.2 mg/m2 IV over 30 min in 100mL D5W (5% dextrose in water) or 0.9% NS at days 1, 8 & 15.
1779788|NCT00436657|Drug|CHPP of Cisplatin|Starting dose of 100 mg/m^2 intraperitoneally delivered as Continuous Hyperthermic Peritoneal Perfusion (CHPP) over 90 minutes at a flow rate of 1.5L/min and a peritoneal temperature of 42.5°Celsius.
1779789|NCT00436657|Procedure|Abdominal Surgery|Surgical removal of abdominal tumors.
1779790|NCT00436670|Biological|AMG 317 75 mg|75 mg SC weekly injection
1779791|NCT00436670|Biological|AMG 317 150 mg|150 mg SC once weekly injection
1779792|NCT00436670|Biological|AMG 317 300 mg|300 mg weekly SC injection
1779793|NCT00436670|Biological|Placebo|Placebo SC once weekly injection
1779794|NCT00436683|Drug|Fermagate|Film coated tablet 500mg
1779795|NCT00436683|Drug|Sevelamer HCl|tablet 800mg
1779798|NCT00436709|Biological|bevacizumab|
1779799|NCT00436709|Biological|pegfilgrastim|
1779800|NCT00436709|Drug|cyclophosphamide|
1779801|NCT00436709|Drug|doxorubicin hydrochloride|
1779802|NCT00436709|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1779803|NCT00436709|Other|flow cytometry|
1779804|NCT00436709|Other|immunoenzyme technique|
1779805|NCT00436709|Other|immunologic technique|
1779806|NCT00436709|Other|laboratory biomarker analysis|
1779807|NCT00436709|Procedure|adjuvant therapy|
1779808|NCT00436709|Procedure|immunoscintigraphy|
1779809|NCT00437710|Procedure|cell therapy, bone marrow derived stem cell|
1779810|NCT00437723|Drug|epoetin beta [NeoRecormon]|At a dose to achieve and maintain an Hb level of 120-135g/dL.
1779811|NCT00437736|Drug|APO010|APO010 starting at 2.5 µg/m² IV on D1, D15, D22 and D29 followed by a two-week drug rest.
1779812|NCT00437749|Drug|CBT-1|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
1779813|NCT00437749|Other|Placebo|(50 mg caps) 500 mg/m2/day x 7 + paclitaxel 135 mg/m2 + carboplatin AUC 6
1779814|NCT00437762|Drug|Botulinum Toxin A Injection|Botulinum Toxin A Injection
1779815|NCT00437762|Drug|Placebo injection|Placebo Injection
1779816|NCT00437814|Drug|Ketamine, effect on intracranial pressure|
1779817|NCT00437827|Other|Star*D algorithm|Standard of care based upon the therapies selected in the Star*D study.
1779818|NCT00437827|Other|rEEG-guided therapy|An rEEG report is based upon a process that utilizes a patient's drug-free QEEG to predict successful treatment strategies.
1779819|NCT00437840|Drug|GSK598809|GSK598809 capsules will be available in dose strength of 5 and 25 mg. Subjects will receive single oral dose of GSK598809 n order to achieve the required dose.
1779820|NCT00437840|Drug|Placebo|Subjects will receive single oral dose of matching placebo tablet to GSK598809.
1779821|NCT00437853|Drug|Anastrozole|
1779822|NCT00437892|Drug|atorvastatin|tablets, 40 mg day, 3 months
1779823|NCT00437892|Drug|atorvastatin|tablets, 40 mg once daily
1779824|NCT00437892|Behavioral|diet|daily
1779825|NCT00437892|Behavioral|diet|daily diet
1779826|NCT00437905|Procedure|angioplasty|
1779827|NCT00437918|Drug|nateglinide|
1779828|NCT00437918|Drug|acarbose|
1779829|NCT00437957|Drug|Temozolomide|75 Mg/m2/day for all Cohorts
1779830|NCT00437957|Drug|Valproic Acid|Cohort 1: 20 mg/kg/day Cohort 2: 30 mg/kg/day Cohort 3: 40 mg/kg/day Cohort 4: 50 mg/kg/day
1779831|NCT00437957|Procedure|Whole Brain Radiation Therapy|Concurrently with Temozolomide and VPA
1779832|NCT00437970|Drug|Pioglitazone|15mg of Pioglitazone taken orally twice a day
1779833|NCT00437970|Drug|Metformin|500 mg of Metformin taken orally twice a day
1779834|NCT00437983|Dietary Supplement|PS-Omega3|Phosphatidylserine-Omega3 capsules 3x100mg/day 15 wk. Next, follow up phase, open label,1x100mg/day, 15 wk
1779835|NCT00437983|Dietary Supplement|Placebo|Placebo cellulose tainted with fishy odor capsules 3x100mg/day 15 wk
1779836|NCT00437996|Drug|Clonidine|
1779837|NCT00437996|Drug|Levobupivacaine|
1779838|NCT00437996|Drug|Sufentanil|
1779839|NCT00438009|Drug|Coxsackievirus A21|Two doses of drug, separated by 48 hours
1779840|NCT00438035|Procedure|ECG spectral|
1779841|NCT00438048|Procedure|pilocarpine|or secondary symptomatic SS with clinically significant dry mouth were randomized to receive either 5 mg oral Pilocarpine solution (5ml) or artificial saliva (5 ml) 3 times a day for 12 weeks
1779842|NCT00438048|Drug|Artificial Saliva|5ml 3 times daily
1779843|NCT00438061|Behavioral|Weight loss by dietary restriction|
1779844|NCT00438087|Drug|methylprednisolone|methylprednisolone administrated intra and post operatively
1779845|NCT00438100|Drug|Capecitabine|1600 mg/m2 orally bid daily for day 1 through day 21 followed by 7-day washout; repeat this as a course.
1779846|NCT00438100|Drug|S-1|80 mg/m2 orally bid daily for day 1 through day 28 followed by 14-day washout; repeat this as a course.
1779847|NCT00438113|Drug|Aggressive Blood Pressure control|Aggressive Blood Pressure therapy, alone or combination therapy, to reach a target BP equal to or less than 120/80 mmHg
1779848|NCT00438126|Behavioral|A lifestyle educational program|
1779849|NCT00438139|Drug|Dronabinol|
1779850|NCT00438152|Drug|Saquinavir (Invirase®)|Saquinavir 1000mg + Ritonavir 100mg Bd for 24 weeks
1779851|NCT00438152|Drug|Lopinavir/ritonavir (Kaletra®)|Lopinavir/ritonavir 400/100 mg BD 24 weeks
1779852|NCT00438165|Behavioral|home visitation|Home visitation by nurses from midway through pregnancy until child age 12
1779853|NCT00438178|Drug|Obatoclax mesylate (GX15-070MS)|
1779854|NCT00438204|Biological|bevacizumab|Bevacizumab 10mg/kg IV over 90 ± 15 minutes every 14 days
1779855|NCT00438204|Drug|gemcitabine hydrochloride|Gemcitabine 1200 mg/m2 intravenously over 30 minutes following the pemetrexed every 14 days
1779856|NCT00438204|Drug|pemetrexed disodium|Pemetrexed disodium 400 mg/m2 intravenously over 10 minutes every 14 days.
1779857|NCT00438217|Drug|Triptorelin (GnRH agonists)|
1779858|NCT00438217|Drug|Leuprolide (GnRH agonists)|
1779859|NCT00438230|Drug|Warfarin|
1779860|NCT00438243|Drug|Bromfenac (Xibrom)|1 drop to affected eye twice daily.
1779861|NCT00438243|Drug|Refresh Plus|1 drop in the affected eye twice daily
1779862|NCT00438256|Procedure|Proton Beam Radiation|Given over different schedules and duration
1779863|NCT00438256|Drug|Capecitabine|Given orally starting on day one of radiation therapy for 2 weeks
1779864|NCT00438269|Drug|Site-specific empiric regimens included: Meropenem|
1779865|NCT00438269|Drug|Piperacillin/tazobactam|
1779866|NCT00438269|Drug|Ciprofloxacin and cefazolin +/- metronidazole|
1779867|NCT00438282|Behavioral|home visitation|Home visitation from midway through pregnancy until child age 2. Group 2 is visitation by Paraprofessionals; group 3 is home visitation by Nurses.
1779868|NCT00438295|Procedure|temperature control|
1779869|NCT00438321|Drug|Zoladex|
1779870|NCT00438321|Drug|Testosterone gel|
1779871|NCT00438321|Drug|Anastrozole Pill|
1779873|NCT00438334|Device|Programmable directional/omni-directional hearing aid|
1779874|NCT00438347|Behavioral|Aerobic Exercise|One hour per day three times a week for one year
1779875|NCT00438347|Behavioral|Stretching and toning|One hour per day three times a week for one year
1779876|NCT00438360|Drug|Cyclosporine A microemulsion|Oral soft gelatin capsules of Cyclosporine 10 mg, 25 mg, 50 mg or 100 mg administered twice a week for 24 weeks at the dosage of 5 mg/Kg/day in two daily administrations
1779877|NCT00438360|Drug|Placebo|Oral soft gelatin capsules of placebo matching cyclosporine administered twice a week for 24 weeks in two daily administrations
1779878|NCT00438386|Drug|Aripiprazole|
1779879|NCT00438399|Drug|C. propionate - Corticosteroid 1|Twice daily application
1779880|NCT00438399|Drug|C. propionate- Corticosteroid 2|Twice daily application
1779881|NCT00438399|Drug|C. propionate -Corticosteroid 3|Twice daily application
1779882|NCT00438399|Drug|Corticosteroid 1- C. propionate|Twice daily application
1779883|NCT00438399|Drug|Corticosteroid 2 - C. propionate|Twice daily application
1779884|NCT00438399|Drug|Corticosteroid 3 - C. propionate|Twice daily application
1779885|NCT00438425|Dietary Supplement|Dietary Portfolio - Intensive|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 7 visits during a 6-month period with the study dietitian.
1779886|NCT00438425|Dietary Supplement|Dietary Portfolio - Routine|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) plus the combination of viscous fibers, soy protein, plant sterols and nuts. The portfolio diet plan will include foods which contribute 9.8 g/1000 kcal viscous fiber as B-glucan (oats, barley, oat bran breads and soups) and psylliium (cereal), 0.94 g plant sterol/1000 kcal diet (in sterol margarine), 22.5 g soy protein/1000 kcal (soy burgers, dogs, links, other meat analogues, milks, yogurts and cheese) and 22.5 g nuts/1000 kcal as part of a low fat vegetarian diet. Participants received 2 visits during a 6-month period with the study dietitian.
1779887|NCT00438425|Dietary Supplement|Control (low saturated fat therapeutic diet)|Dietitians advised participants to consume the following therapeutic diet components (<7% of energy saturated fat, <200 mg/d cholesterol) with a focus on low-fat dairy and whole grain cereals together with fruit and vegetables as part of a low fat vegetarian diet, and avoidance of the specific portfolio components.
1779888|NCT00438438|Behavioral|forced desynchrony protocol with sleep restriction|Subjects are scheduled to live on a non-24 hour day. This separates the sleep-wake schedule from the near-24 hour circadian rhythm. This allows assessment of how circadian rhythms and the length-of-time awake contribute to sleepiness, alertness, and cognitive performance.
1779889|NCT00438451|Drug|Levetiracetam|LEV 250 mg capusles: week 1 and 2 0-0-1, week 3 and 4 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (500 - 3000 mg)during maintenance.
1779890|NCT00438451|Drug|Carbamazepine|CBZ 100 mg capusles: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 per day (200 - 1200 mg) during maintenance depending on tolerance and efficacy.
1779891|NCT00438451|Drug|Lamotrigine|LTG 25 mg encapsulated: week 1 and 2: 0-0-1, week 3 and 4: 1-0-1, week 5: 1-0-2, week 6: 2-0-2. Patients may take 2 to 12 caps. per day (50 - 300 mg)during maintenance depending on tolerance and efficacy.
1779892|NCT00438464|Drug|Finasteride|Given PO
1779893|NCT00438464|Other|Placebo|Given PO
1779894|NCT00438464|Procedure|Prostatectomy|Undergo prostatectomy
1779895|NCT00438464|Other|Laboratory biomarker analysis|Correlative studies
1779896|NCT00438477|Drug|Isosulfan Blue|At time of surgery, breast injected with 3-5 cc of isosulfan blue in subareolar or peritumoral position.
1779897|NCT00438477|Procedure|Lymphangiography|2 lymphoscintigraphy images performed following peritumoral and subareolar injection of breast
1779898|NCT00438477|Radiation|Technetium Tc 99m sulfur colloid|"At least 2 days before scheduled surgery, receive technetium Tc 99m sulfur colloid by peritumoral injection; and again the day before surgery by subareolar injection.
At the time of surgery, patients receive isosulfan blue by subareolar injection."
1779899|NCT00438490|Drug|Recombinant Human Prolactin|
1779900|NCT00438503|Procedure|Procedure|
1779901|NCT00438516|Behavioral|nurse home visitation|Nurse home visits from midway through pregnancy to child age 2
1779902|NCT00438555|Behavioral|Parents and children group|3 months workshops of parents and children intervention, guided by dietician and phycologist
1779903|NCT00438555|Behavioral|Parent's group|3 months workshop of parents intervention, guided by dietician and phycologist
1779904|NCT00438568|Drug|Regular Insulin|administered intra-nasally twice a day for 16 weeks
1779905|NCT00438568|Drug|Placebo|administered intra-nasally twice a day for 16 weeks
1779906|NCT00438581|Drug|Yttrium 90 Ibritumomab Tiuxetan ( Zevalin )|
1779907|NCT00438594|Behavioral|home visitation|Home visits from mid-pregnancy until child age 2. Group 2 is visits by a paraprofessional; group 3 is visits by nurses.
1779908|NCT00438607|Drug|BIIB014|oral administration of BIIB014 at dose to be specified from Part A, given daily for 8 weeks
1779909|NCT00438607|Drug|Placebo|Matched placebo for MTD or MTD-1
1779910|NCT00438620|Behavioral|Home-based physical activity program|the role of physical activity as a Quality of Life intervention
1779911|NCT00438659|Drug|mometasone furoate|Applied to treatment area
1779912|NCT00438659|Other|placebo|Applied to treatment area
1779913|NCT00438672|Drug|Placebo Injection|Injection without steroid
1779914|NCT00438672|Drug|Steroid (dexamethasone) Injection|Injection with steroid (dexamethasone)
1779915|NCT00438685|Behavioral|Outpatient MST/OPTION-A|
1779916|NCT00438685|Behavioral|Usual Services|
1779917|NCT00438698|Other|Low Glycemic Index diet|Diet to emphasize carbohydrate foods low in glycemic index
1779918|NCT00438698|Other|High Cereal Fibre Diets|Diet to emphasize whole wheat carbohydrate cgoices
1779919|NCT00438724|Behavioral|Information, counseling and support|
1779920|NCT00438737|Biological|bevacizumab|
1779921|NCT00438737|Biological|cetuximab|
1779922|NCT00438737|Drug|fluorouracil|
1779923|NCT00438737|Drug|leucovorin calcium|
1779924|NCT00438737|Drug|oxaliplatin|
1779925|NCT00438737|Procedure|adjuvant therapy|
1779926|NCT00438737|Procedure|conventional surgery|
1779927|NCT00438737|Procedure|neoadjuvant therapy|
1779928|NCT00438750|Other|Independent Excercises|Subjects provided with wrist splint and instructions for independent exercises to perform at home on their own. Subjects were advised to perform exercises as often as possible, but at least three to four times a day for a minimum of thirty minutes. There was no formal strengthening program.
1779929|NCT00438750|Other|Occupational Therapy|Subjects were prescribed formal occupational therapy with supervised exercises to regain digit, wrist, and forearm motion and to strengthen the hand. The content, frequency, and duration of the rehabilitation program were at the discretion of the treating hand therapist.
1779930|NCT00438776|Drug|olanzapine|2.5mg to 15mg daily
1779931|NCT00438776|Drug|sugar pill|matching placebo to olanzapine
1779932|NCT00438789|Drug|eculizumab|600mg IV every week and 900mg IV every 2 weeks
1779933|NCT00438802|Drug|Alefacept|Dose escalation theme. 0.075mg/kg by IV Weekly x 8 to 0.30mg/kg IV Weekly x 8
1779934|NCT00438815|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
1779935|NCT00438828|Drug|dexamethasone|8mg Dexamethasone PO on days 0 (prior to radiation treatment), and days 1, 2, and 3 following radiation treatment.
1779936|NCT00438841|Drug|bortezomib|
1779937|NCT00438841|Drug|cyclophosphamide|
1779938|NCT00438841|Drug|dexamethasone|
1779939|NCT00438841|Drug|thalidomide|
1779940|NCT00438854|Drug|Dasatinib|Taken orally once daily. Participants may continue on study treatment as long as there is no disease progression or serious side effects.
1779941|NCT00438867|Genetic|Ad5FGF-4|Adenovirus serotype-5 mediated human fibroblast growth factor-4 gene transfer
1779942|NCT00438867|Genetic|Placebo|Control group
1779943|NCT00438880|Drug|Agatolimod Sodium|Given IV
1779944|NCT00438880|Radiation|Indium In-111 Ibritumomab Tiuxetan|Given IV
1779945|NCT00438880|Other|Laboratory Biomarker Analysis|Correlative study
1779946|NCT00438880|Procedure|Radionuclide Imaging|Undergo imaging scans
1779947|NCT00438880|Biological|Rituximab|Given IV
1779948|NCT00438880|Procedure|Single Photon Emission Computed Tomography|Undergo imaging scans
1779949|NCT00438880|Radiation|Yttrium Y-90 Ibritumomab Tiuxetan|Given IV
1779950|NCT00438893|Dietary Supplement|Dietary portfolio of cholesterol-lowering foods|A plant based dietary portfolio providing plant sterols (1.0g/1000 kcal), soy protein (22.5g/1000 kcal, viscous fibers 10 g/1000 kcal and almonds 22.5g/1000 kcal)
1779951|NCT00438906|Procedure|Biopsy, Fine Needle Aspiration (FNA)|If a pancreatic lesion of concern is identified, a small needle is inserted in the lesion in the pancreas and cells of the lesion are aspirated. Diagnosis of the lesion can typically occur with FNA.
1779952|NCT00438906|Drug|Secretin (human synthetic) - ChiRhoClin|Secretin is a synthetic human hormone that encourages the pancreas to create fluid. This will allow pancreatic juice to be collected via gentle suction in the duodenum where the pancreatic juice naturally flows.
1779953|NCT00438919|Device|drug-eluting stent|CYPHER SELECT™ Sirolimus-eluting Coronary Stent
1779954|NCT00438932|Drug|Lanthanum Carbonate|Lanthanum carbonate 1000mg 3x/day
1779955|NCT00438932|Dietary Supplement|Low Phosphorus Diet|Low phosphorus diet will consist of 800 mg of phosphorus per day.
1779956|NCT00438932|Dietary Supplement|Unrestricted Phosphorus Diet|Unrestricted diet will contain 1550 mg of phosphorus per day - 800 mg of which is dietary and 750mg of Neutraphos (3 packets/day); each packet is 250mg.
1779957|NCT00438932|Drug|Placebo|Lanthanum Carbonate placebo given three times a day with meals.
1779958|NCT00438945|Drug|Eprosartan|
1779959|NCT00438958|Biological|filgrastim|Given on day 0.
1779960|NCT00438958|Procedure|allogeneic bone marrow transplantation|Given on day 0
1779961|NCT00438958|Procedure|peripheral blood stem cell transplantation|Given on day 0
1779962|NCT00438971|Drug|Duloxetine|Treatment will be initiated at 30mg/day in the first week (week 0), and then increased to 60mg/day at week 1, with the option to increase to 90mg at week 4, and 120mg at week 6.
1779963|NCT00438984|Drug|cyclophosphamide|Given IV
1779964|NCT00438984|Biological|therapeutic autologous lymphocytes|Given IV
1779965|NCT00438984|Biological|aldesleukin|Given IV or SC
1779966|NCT00438984|Other|immunohistochemistry staining method|Correlative studies
1779967|NCT00438984|Procedure|biopsy|Optional correlative studies
1779968|NCT00438984|Other|laboratory biomarker analysis|Correlative studies
1779969|NCT00438984|Other|immunologic technique|Correlative studies
1779970|NCT00438984|Genetic|polymerase chain reaction|Correlative studies
1779971|NCT00439010|Drug|[123I] AV 39|
1779972|NCT00439023|Procedure|dialysis with glucose in dialysis water|
1779973|NCT00439036|Behavioral|Behavior Therapy|The Act-ODT intervention will consist of 24 50-minute sessions delivered weekly in the context of a methadone dose reduction program. Sessions will begin during the methadone run-up/stabilization period approximately 4 weeks prior to the onset of dose reduction and will continue through the 20 week detoxification.
1779974|NCT00439036|Behavioral|Drug Counseling|
1779975|NCT00439049|Drug|modafinil|400 mg daily
1779976|NCT00439049|Drug|d-amphetamine|60mg daily
1779977|NCT00439049|Drug|L-Dopa|800/200mg daily
1779978|NCT00439049|Drug|Naltrexone|50mg daily
1779979|NCT00439062|Drug|Roxithromycin|
1779980|NCT00439075|Procedure|CPAP|
1779981|NCT00439075|Drug|standard treatment|
1779982|NCT00439101|Drug|Megstrol Acetate|Megestrol acetatet 7.5 mg/kg/day orally (lemon-lime suspension) for 90 days.
1779983|NCT00439101|Other|Placebo|Placebo (lemon-lime suspension) taken orally for 90 days.
1779984|NCT00439140|Biological|botulinum toxin Type A|Botulinum toxin Type A injection into the detrusor.
1779985|NCT00439140|Drug|Normal Saline (Placebo)|Placebo (Normal Saline) injection into the detrusor.
1779986|NCT00439153|Device|Tourniquet instrument capable of measuring LOP in combination with tourniquet cuffs|See Detailed Description.
1779987|NCT00439166|Drug|doxycycline|capsule, 100 mg, b.i.d., daily for 1 year
1779988|NCT00439166|Drug|rifampicin|capsule, 300mg, o.d., daily for 11 months (administration starts in 2nd month of trial)
1779989|NCT00439166|Drug|Placebo matched to doxycycline|Doxycycline-matched - blue capsule, b.i.d.,daily for 12 months
1779990|NCT00439166|Drug|Placebo matched to Rifampin|Rifampin-matched - red capsule, o.d., daily for 11 months starting at month 2.
1779991|NCT00439179|Drug|cohort 1|Weekly gem + GW572016, 1000mg/day (combination)
1779992|NCT00439179|Drug|cohort 2|Weekly gem + GW572016, 1500 mg/day (combination)
1779993|NCT00439179|Drug|cohort 3|GEMOX + GW572016 1000 mg/day (combination)
1779994|NCT00439179|Drug|cohort 4|GEMOX + GW572016 1500 mg/day (combination)
1779995|NCT00439192|Drug|ELB245|
1779996|NCT00439192|Drug|Tolterodine|
1779999|NCT00439218|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD.
1780000|NCT00439231|Drug|Lenalidomide|Lenalidomide (Revlimid) regimen testing to determine efficacy for SLL/ CLL subjects
1780001|NCT00439244|Drug|Zoledronic acid|Zoledronic acid 5.0 mg in a ready-to-infuse plastic bottle with a total fill volume of 103 mL to allow an infusion of 100 mL total volume corresponding to 5 mg of zoledronic acid.
1780002|NCT00439244|Drug|Placebo|Zoledronic acid matched placebo as a 103 mL solution of sterile water (physiologic 0.9% normal saline) to allow an infusion of 100 mL total volume in a ready-to-infuse plastic bottle
1780003|NCT00439244|Drug|Teriparatide|"Teriparatide is supplied as sterile, colorless clear, isotonic solution in a glass cartridge which is pre-assembled into a disposable pen device for subcutaneous injection. Each pre-filled delivery device is filled with 3.3 mL to deliver 3 mL.
Each mL contains 250 μg teriparatide (corrected for acetate, chloride, and water content), 0.41 mg glacial acetate acid, 0.10 mg sodium acetate (anhydrous), 45.4 mg mannitol, 3.0 mg Metacresol, and water for injection. In addition, hydrochloric acid solution 10% and/or sodium hydroxide solution 10% may have been added to adjust the product to pH 4. Each cartridge pre-assembled into a pen device delivers 20 μg of teriparatide per dose each day for up to 28 days."
1780004|NCT00439270|Drug|Dasatinib|Tablets, Oral, 50, 70, 100, or 120 mg once daily; treatment may continue until disease progression
1780005|NCT00439270|Drug|Docetaxel|Infusion, 60 or 75 mg/m^2, administered every 3 weeks.
1780006|NCT00439283|Drug|infliximab|
1780007|NCT00439283|Drug|methotrexate|
1780008|NCT00439296|Drug|ABT-751|Oral capsule to be given daily for 21 days.
1780009|NCT00439296|Drug|dexamethasone|IV or Oral daily for 14 days
1780010|NCT00439296|Drug|PEG-asparaginase|Intramuscular injection
1780011|NCT00439296|Drug|doxorubicin|IV infusion
1780012|NCT00439296|Drug|cytarabine|Intrathecal dose on day 1
1780013|NCT00439296|Drug|methotrexate|Intrathecal dose
1780014|NCT00439296|Drug|cyclophosphamide|Intravenous dose
1780015|NCT00439296|Drug|6-thioguanine|Oral dose, course #2
1780016|NCT00439309|Device|Gelfoam/Thrombin|Gelfoam/Thrombin
1780017|NCT00439309|Device|VascuSeal|VascuSeal
1780018|NCT00439335|Biological|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intramuscular (IM) injection. Vaccine will be administered to each subject at Days 0 and 28.
1780019|NCT00439335|Biological|Inactivated Influenza A Vaccine A/H5N1|Inactivated influenza A/H5N1 vaccine formulated to a concentration of HA greater than or equal to 300 mcg/mL administered via intradermal (ID) injection. Vaccine will be administered to each subject at Days 0 and 28.
1780020|NCT00439335|Drug|Placebo (IM)|The placebo will be 0.1 mL of saline administered by the IM route.
1780021|NCT00439335|Drug|Placebo (ID)|The placebo will be 0.1 mL of saline administered by the ID route.
1780022|NCT00439348|Behavioral|Verbal advice|Patients receive verbal advice regarding specific over-the-counter medications.
1780023|NCT00439348|Behavioral|Prescription|Patients receive a prescription for a specific over-the-counter medication.
1780024|NCT00439361|Drug|Bortezomib|1.0 mg/m^2 by Vein Over 5 Seconds on Days 1 and 4
1780025|NCT00439361|Drug|Carboplatin|5 AUC by Vein Over 1 Hour On Day 1
1780026|NCT00439361|Drug|Etoposide|100 mg/m^2 By Vein Over 2 Hours On Days 1-3
1780027|NCT00439361|Drug|Ifosfamide|5 Gm/m^2 By Vein Continuous Infusion Over 24 Hours On Day 1
1780028|NCT00439361|Drug|Mesna|5 mg/m^2 IV continuous Infusion over 24 Hours On Day 1; 2 Gm/m^2 IV continuous infusion over 12 hours starting after completion of Ifosfamide + Mesna 24 hour continuous infusion
1780029|NCT00439374|Drug|17 alpha-hydroxyprogesterone caproate|Coded study medication is sterile solution containing 250 mg/mL of 17 alpha-hydroxyprogesterone caproate in castor oil with benzyl benzoate and benzyl alcohol as a preservative; placebo is same without the active ingredient. Study drug is administered as weekly 1 ml intramuscular injections until 36 week 6 days of gestation or delivery, whichever occurs first.
1780030|NCT00439400|Drug|doxycycline|
1780031|NCT00439400|Drug|placebo|
1780032|NCT00439413|Drug|Selegiline Transdermal Patch|Selegiline cm(2) via transdermal system
1780033|NCT00439413|Drug|Placebo|Matching placebo via transdermal system
1780034|NCT00439413|Behavioral|Smoking Cessation Counseling|Subjects were provided with on-site, individual smoking cessation counseling sessions 1x per week for 9 weeks
1780035|NCT00439426|Drug|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
1780036|NCT00439426|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
1780037|NCT00439439|Radiation|Beamer Ablation (Argon Plasma Coagulation)|APC-Beamerablation of heterotopic gastric mucosa
1780089|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
1780038|NCT00439452|Other|Telemedicine-Based Collaborative Care|Off-site depression care team (telephone nurse care manager, telephone pharmacist, tele-psychologist and tele-psychiatrist) works collaboratively with on-site primary care providers. Telephone nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response. Telephone pharmacist activities include documenting medication histories and conducting medication management. Tele-psychologist activities include providing cognitive behavioral therapy via interactive video. Tele-psychiatrist activities include conducting patient consultation via interactive video.
1780039|NCT00439452|Other|Practice Based Collaborative Care|One-site nurse care manager works collaboratively with on-site primary care providers. Nurse care manager activities include promoting patient activation and self management, assessing symptoms and comorbidities, and monitoring adherence, side-effects and treatment response.
1780040|NCT00439465|Biological|Autologous ex-vivo expanded effector cells|This trial will test if the combination of infusing ex vivo expanded cytotoxic effector cells with IL-2 and GM-CSF post-transplant will accelerate immune reconstitution, resulting in an effector cell-versus-myeloma effect and, possibly, improved clinical outcomes.
1780041|NCT00439478|Drug|Radioiodine|
1780042|NCT00439491|Behavioral|Hypocaloric diet|
1780043|NCT00439504|Drug|Lobeline|
1780044|NCT00439517|Drug|UFOX + Cetuximab|"Cetuximab infusion (400 mg/m^2 on day 1 of cycle 1 and 250 mg/m^2 at each subsequent day 1, as well as on days 8, 15 and 22)
Oxaliplatin infusion (85mg/m^2) on days 1 and 15 (every 2 weeks)
Oral UFT® (250mg/m^2 tegafur + 560 mg/m^2 uracil in 3 daily doses rounded to the nearest number of whole capsules) on days 1-21
Oral Folinic Acid (90 mg in 3 daily divided doses) on days 1-21"
1780045|NCT00439517|Drug|FOLFOX4 + Cetuximab|"Cetuximab infusion (400 mg/m^2 on day 1 of cycle 1 and 250 mg/m^2 at each subsequent day 1, as well as on days 8, 15 and 22)
Oxaliplatin infusion (85 mg/m^2) on days 1 and 15 (every 2 weeks)
5-FU bolus + infusions (400 mg/m^2) on days 1, 2, 15 and 16
Folinic Acid infusions (200 mg/m^2) on days 1, 2, 15 and 16"
1780046|NCT00439530|Drug|oseltamivir|
1780047|NCT00439530|Drug|probenecid|
1780048|NCT00439543|Drug|Iloprost inhalation|
1780056|NCT00439569|Drug|sodium phenylbutyrate|500 mg/kg/day, depending upon tolerability subsequent dosages may increase to 675, 900, or 1200 mg/kg/day to identify maximum tolerated dose (MTD) and then an additional 6 participants will enroll at the MTD
1780057|NCT00439582|Dietary Supplement|vaccenic acid enriched milk fat (VAMF) [Transfact1]|
1780058|NCT00439582|Dietary Supplement|hydrogenated oil|Partially hydrogenated vegetable oils (PHVO) and vegetable oils and fats
1780059|NCT00439595|Device|Hemocue 210 meter|Diagnostic device
1780060|NCT00439595|Device|Copack HBCS|
1780061|NCT00439608|Drug|Cetuximab,Paclitaxel, Carboplatin|IV treatment for 6 weeks
1780062|NCT00439621|Biological|RP 01|Active immunotherapy
1780063|NCT00439634|Drug|AVE1625|oral administration
1780064|NCT00439634|Drug|placebo|oral administration
1780065|NCT00439647|Drug|Zoledronic acid 5 mg iv|Zoledronic acid 5 mg iv given once a year.
1780066|NCT00439647|Drug|Placebo|Placebo intravenous (i.v.) once a year
1780067|NCT00439660|Biological|Oral Rotavirus Vaccine 116E Live Attenuated|
1780068|NCT00439673|Drug|5-Azacytidine|
1780069|NCT00439673|Drug|Valproic Acid|
1780070|NCT00439673|Drug|ATRA|
1780071|NCT00439686|Drug|ZIO-201|ZIO-201 given for 3 consecutive days to be repeated every 21 days for up to 6 months
1780073|NCT00439712|Drug|Levocetirizine|1 tablet of Levocetirizine 5 mg OD in the morning for 29+/-4 days
1780074|NCT00439712|Drug|Placebo|1 placebo tablet OD in the morning for 29+/-4 days
1780075|NCT00439725|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Patients randomized to rivaroxaban will receive rivaroxaban 20 mg once-daily.
1780076|NCT00439725|Drug|Placebo|Patients allocated to placebo will receive a matching placebo tablet once daily.
1780077|NCT00439738|Drug|HCTZ + Amlodipine|"12.5 mg HCTZ capsules
25 mg HCTZ capsules
5 mg amlodipine capsules
10 mg amlodipine capsules"
1780078|NCT00439738|Drug|Valsartan/HCTZ|"160 mg film-coated valsartan tablets
320 mg film-coated valsartan tablets
12.5 mg HCTZ capsules
25 mg HCTZ capsules"
1780079|NCT00439751|Drug|Goserelin Acetate|Continuous goserelin, 12 week (10.8 mg) depot, will be used as ADT for both study arms. It is supplied as a sterile syringe for subcutaneous use.
1780080|NCT00439764|Behavioral|General health talk|Routine clinical practice and talk on general health
1780081|NCT00439764|Behavioral|Handout of The Back Book|Talk on health of the back and handout of The Back Book
1780082|NCT00439764|Behavioral|Back exercise|Routine clinical practice, talk on back health, handout of The Back Book and back exercise
1780083|NCT00439777|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
1780084|NCT00439777|Drug|Enoxaparin overlapping with and followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 hr before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
1780085|NCT00439790|Procedure|Microneurography|Microneurography
1780086|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the IM route
1780087|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
1780088|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e7 IU given at T=0, 8, 24 weeks via the SC route
1780090|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the IM route
1780091|NCT00439803|Biological|AVX601|3 doses of placebo given at T=0, 8, 24 weeks via the IM route
1780092|NCT00439803|Biological|AVX601|3 doses of AVX601 at 1e8 IU given at T=0, 8, 24 weeks via the SC route
1780093|NCT00439803|Biological|Placebo|3 doses of placebo given at T=0, 8, 24 weeks via the SC route
1780094|NCT00439816|Behavioral|Group Visits|
1780095|NCT00439829|Drug|Gonal F|"450 IU Gonal-f (Serono Canada) subcutaneously daily (225 IU BID; injections to be given after bloodwork).
Dosing to begin on day 1 or day 4 (day 1=first day of menses), continuing until administration of human Chorionic Gonadotropin (hCG; see below).
Gonal-f dose may be further reduced, at the discretion of the study physician, to minimize the risk of OHSS."
1780096|NCT00439829|Drug|Luveris|"0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:
leading follicle is > 13 mm in diameter
if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L
Dosing to continue until administration of hCG (see below)."
1780097|NCT00439829|Drug|Cetrotide|"0.250 mg Cetrotide (Serono Canada) and 75 IU Luveris (Serono Canada) subcutaneously daily when one or more of the following conditions are met:
leading follicle is > 13 mm in diameter
if 6 or more follicles develop to > 10 mm and E2 > 1000 pmol/L
Dosing to continue until administration of hCG (see below)."
1780098|NCT00439829|Drug|hCG|"- 10,000 IU hCG (Pharmaceutical Partners of Canada Inc.) subcutaneously when:
o > 3 follicles are > 17 mm in diameter"
1780099|NCT00439842|Behavioral|Heart Failure Group Clinic Appointments|Self Management and Care of Heart Failure with Group Clinics (SMAC-HF)
1780100|NCT00439855|Drug|Enoxaparin i.v.|
1780101|NCT00439855|Drug|unfractionated heparin|
1780102|NCT00439868|Drug|WellbutrinXL|WELLBUTRIN XL tablets will be available with dose strength of 150 and 300 mg.
1780103|NCT00439868|Drug|placebo|Matching placebo tablets to WELLBUTRIN XL.
1780104|NCT00439881|Drug|SB-681323|
1780105|NCT00439894|Procedure|Blood draw|blood draw at baseline, week 12 and week 24
1780106|NCT00439907|Procedure|End-to-end repair of the external anal sphincter muscle|Surgical procedure: End-to-end repair of the external anal sphincter muscle
1780107|NCT00439907|Procedure|Overlap repair of the external anal sphincter muscle|Surgical procedure: Overlap repair of the external anal sphincter muscle
1780108|NCT00439920|Drug|High-dose anthracycline|
1780109|NCT00439933|Behavioral|low fat and polysaccharide rich diet|
1780110|NCT00439933|Behavioral|specific physical training program for obese children|
1780111|NCT00439946|Drug|treprostinil|rapid switch from intravenous epoprostenol on the CADD ambulatory pump to intravenous Remodulin on the Crono Five ambulatory pump
1780112|NCT00439946|Device|Crono Five ambulatory pump|Used for administration of IV Remodulin (treprostinil)
1780113|NCT00439959|Drug|GSK625433/placebo|
1780117|NCT00439985|Behavioral|Cognitive Behavioral Therapy|The treatment which incorporates cognitive restructuring and skill training, was designed to help children with diabetes and their families develop particular skills and optimistic/positive thinking style in order to facilitate better coping with the enduring demands and stress of diabetes management. The goal of the intervention was to improve the child's diabetes management both medically and psychologically by promoting optimism (positive outlook), mastery (problem-solving) and child-parent collaboration (team-work).
1780118|NCT00439998|Procedure|Ultrasound|ultrasound scan of the lumbar spine with 2-5 MHz curved array probe
1780119|NCT00440011|Drug|bimatoprost 0.03% eye drops|bimatoprost 0.03% 1 drop nightly for 3 months
1780120|NCT00440011|Drug|travoprost 0.004% eye drops|travoprost 0.004% 1 drop nightly for 3 months
1780121|NCT00440024|Drug|Tazorac|Tazarotene 0.1% cream applied to the face once daily before bed
1780122|NCT00440024|Drug|Dove Mild Cleanser|Ultra mild cleanser: Dove Non-foaming cleansing lotion
1780123|NCT00440024|Drug|Dove Facial Moisturizer|Moisturizing cream - Dove facial moisturizer with SPF 15
1780124|NCT00440037|Biological|AMG 531|AMG 531 will be administered by SC injection once per week from Week 1 (Day 1). The maximum permitted dose of AMG 531 is 10 μg/kg. AMG 531 will be supplied as a sterile, white, preservative-free, lyophilized powder in 5 mL glass vials containing 0.6 mg of protein per vial, and a protein concentration of 0.5 mg/mL when reconstituted with 1.2 mL of sterile water for injection.
1780125|NCT00440050|Drug|DHA (Docosahexaenoic Acid)|950 mg soft-gel capsules which contain approximately 510 mg DHA, 2 capsules twice a day for 18 months
1780126|NCT00440050|Drug|Placebo|2 placebo capsules twice a day for 18 months
1780127|NCT00440063|Drug|epoetin beta [NeoRecormon]|
1780128|NCT00440076|Drug|Velcade|
1780129|NCT00440089|Behavioral|Hands-on-Healing|
1780130|NCT00440102|Drug|Ketamine|Ketamine
1780131|NCT00440102|Drug|Etomidate|Etomidate
1780132|NCT00440115|Behavioral|High intensity disease management|Health education mailings, 6 motivation interviews/counseling
1780133|NCT00440115|Behavioral|Low intensity disease management|Health education mailings, one motivation interview/counseling
1780134|NCT00440115|Behavioral|Comparison group|Health education mailings
1780135|NCT00440115|Drug|Bupropion|Buproprion or Nicotine Replacement Therapy
1780136|NCT00440128|Drug|Docetaxel|Docetaxel
1780137|NCT00440128|Drug|Casopitant/Docetaxel|Casopitant/Docetaxel
1780405|NCT00433303|Behavioral|Correlation between early delivery and coital activity|
1780138|NCT00440141|Drug|latanoprost 0.005% eye drops and brimonidine 0.1% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months and brimonidine 0.1% three-times daily for 3 months
1780139|NCT00440141|Drug|latanoprost 0.005% eye drops and brinzolamide 1.0% eye drops|latanoprost 0.005% 1 drop nightly for 3 months AND brinzolamide 1.0% 1% three-times daily for 3 months
1780140|NCT00440154|Drug|AVE5530|
1780141|NCT00440154|Drug|placebo|
1780142|NCT00440154|Drug|ezetimibe|
1780143|NCT00440167|Drug|Gemcitabine|Gemcitabine 1000 mg/m², d 1, 8 , 15, q d28
1780144|NCT00440167|Drug|Capecitabine|"Capecitabine 2 x 1000 mg/m²/ d oral, d 1 - 14 followed by 7 days Pause (Flat Dosing)"
1780145|NCT00440167|Drug|Erlotinib|Erlotinib 150 mg/d oral, daily without break
1780146|NCT00440180|Drug|Anastrozole|1 mg qd for 4 months
1780147|NCT00440180|Drug|Placebo|Placebo Comparator
1780148|NCT00440193|Drug|Rivaroxaban (Xarelto, BAY59-7939)|During the first 3 weeks patients will receive 15 mg rivaroxaban twice-daily. Thereafter, patients will receive rivaroxaban 20 mg once-daily. Rivaroxaban will be administered orally and should be taken with food.
1780149|NCT00440193|Drug|Enoxaparin followed by VKA|Enoxaparin 1.0 mg/kg twice daily with a minimal duration of 5 days. This 5 days treatment could include the period up to 36 h before randomization if enoxaparin twice-daily was used. VKA should be started as soon as possible but not later than 48 hours after randomization.
1780150|NCT00431379|Drug|Tenecteplase|
1780151|NCT00431392|Drug|Phenylephrine|
1780152|NCT00431392|Drug|NG-Monomethyl-L-Arginine|
1780153|NCT00431392|Drug|Propanolol|
1780154|NCT00431392|Drug|Atropine|
1780155|NCT00431418|Drug|Sildenafil|Sildenafil oral solution
1780156|NCT00431418|Drug|Placebo|Placebo solution
1780157|NCT00431431|Drug|tibolone|2 years treatment with tibolone (1.25 mg Org OD-14)
1780158|NCT00431431|Drug|raloxifen|2 years treatment with raloxifene (60 mg)
1780159|NCT00431444|Drug|Raloxifene|
1780160|NCT00431444|Drug|Zoledronic acid|
1780161|NCT00431444|Drug|Placebo oral pills|
1780162|NCT00431444|Drug|Placebo intravenous (i.v.) infusion|
1780163|NCT00431457|Device|Implantation of an intracranial electrode|Implantation of an intracranial electrode will be followed.
1780164|NCT00431457|Procedure|amygddohyppocampertomy|Resective surgery
1780165|NCT00431470|Behavioral|Six classroom based character building education lessons|
1780166|NCT00431483|Behavioral|pharmaceutical consulting|to measure if information and advice by a pharmacist has an impact on quality and quantity of prescribed antibacterials
1780167|NCT00431496|Drug|Cinacalcet|Cinacalcet tablets
1780168|NCT00431509|Procedure|conventional vs. navigated total knee arthroplasty|
1780169|NCT00431522|Drug|Valproic acid, sodium salt|
1780170|NCT00431548|Drug|100% O2|
1780171|NCT00431561|Drug|AP 12009 10 µM|10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
1780172|NCT00431561|Drug|AP 12009 80 µM|80 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks
1780173|NCT00431561|Drug|temozolomide or PCV|temozolomide: capsules, up to 200 mg/sqm/day, 5 days per cycle; PCV (procarbazine, CCNU, vincristine): standard regimen
1780174|NCT00431561|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump with drug reservoir and infusion line. Main implanted parts are the port access system and the intratumoral catheter.
1780175|NCT00431561|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
1780176|NCT00431574|Procedure|dosing|
1780177|NCT00431600|Other|100% Oxygen|100% Oxygen- breathing over 30 minutes
1780178|NCT00431613|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 8 every 3 weeks for 2 cycles
1780179|NCT00431613|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 on days 1 and 8 every 3 weeks for 2 cycles
1780180|NCT00431613|Drug|Carboplatin|Carboplatin 6AUC IV on day 1 every 3 weeks for 3 cycles
1780181|NCT00431613|Radiation|Chemoradiotherapy|"After 21 days from the 2nd chemotherapy cycle definitive concurrent chemoradiotherapy will be started: daily fractions of 1.8 Gy for 5 days/week, for a total dose of 45 Gy.
During the radiotherapy docetaxel 25 mg/m2, IV, will be administered on days 1, 8, 15, 22, 29 and carboplatin 2AUC, IV , on days 4, 11, 18, 25, 32"
1780182|NCT00431613|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 for 3 cycles
1780183|NCT00431626|Drug|Dutasteride (Avodart)|
1780184|NCT00431626|Drug|Placebo|Placebo before and after treatment of TURP
1780185|NCT00431639|Behavioral|Animal Assisted Therapy|Every subject will be exposed to both treatment and comparison conditions.
1780186|NCT00431665|Drug|NG-monomethyl-L-Arginine (L-NMMA)|
1780187|NCT00431665|Drug|triglycerides (Intralipid 20%)|
1780188|NCT00431665|Drug|heparin|
1780189|NCT00431665|Drug|somatostatin|
1780190|NCT00431665|Drug|insulin|
1780191|NCT00431665|Drug|glucose|
1780192|NCT00431665|Drug|inulin|
1780193|NCT00431665|Drug|paraamino hippurate (PAH)|
1780194|NCT00431678|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential intravenous/oral (400/400 mg once daily for 7 to 14 days) of Avelox (Moxifloxacin, BAY12-8039)
1780195|NCT00431678|Drug|Levofloxacin + Ceftriaxone|Intravenous combination therapy of levofloxacin 500 mg twice daily and ceftriaxone (2 g once a day) followed by oral levofloxacin (500 mg twice a day for 7 to 14 days).
1780196|NCT00431691|Drug|vitamin and mineral supplement|"dose: 4 tablets daily for two weeks
vitamin A 7160 IU, vitamin C 113mg, vitamin E 100IU, zinc 17.4mg, copper 0.4mg"
1780197|NCT00431691|Drug|Escherichia coli Endotoxin (LPS)|dose: 2 ng/kg (corresponding to 20 IU/kg), intravenous bolus over 5 minutes on both study days
1780198|NCT00431691|Drug|100% O2|breathing for 30 minutes, 2 breathing periods on both study days
1780199|NCT00431691|Drug|nitroglycerin|dose: 0,8 mg sublingual, applied during FMD measurements on both study days
1780200|NCT00431704|Drug|vinorelbine|25 mg/m2 days 1 and 8 every 3 weeks for 6 cycles, or up to 9 cycles for responding patients
1780201|NCT00431704|Drug|carboplatin|AUC 5 intravenously every 3 weeks for 6 cycles, up to 9 cycles for responding patients
1780202|NCT00431704|Drug|trastuzumab|8 mg/kg IV day 1, then 6 mg/kg IV every 3 weeks until disease progression
1780203|NCT00431730|Procedure|flicker light stimulation|
1780204|NCT00431743|Drug|Hydroxyethylstarch 130/0,4|
1780205|NCT00431743|Drug|Lactated Ringer's solution|
1780206|NCT00431769|Drug|Bortezomib|Bortezomib will be given intravenously (into a vein) twice weekly, on Days 1, 4, 8 and 11 and then a 10-day (Days 12 to 21) rest period, of each 3-week cycle for up to a total of 8 cycles. The initial bortezomib dose is 1.0 or 1.3 milligram per meter square (mg/m^2) depending on the previous bortezomib-based treatment, up to a maximum dose of 1.3 mg/m^2. Participants will receive bortezomib in combination with or without dexamethasone, in accordance with the standard of care. The median total dose of dexamethasone per cycle ranges from 120 mg (Cycle 7) to 160 mg (Cycles 1 to 6 and 8).
1780207|NCT00431782|Drug|ATI-5923|
1780208|NCT00431795|Drug|Pegylated liposomal doxorubicin (Caelyx)|Pegylated liposomal Doxorubicin (Caelyx) at the dose of 50mg/m^2 IV every 4 weeks for 6 consecutive cycles
1780209|NCT00431795|Drug|Epirubicin|Epirubicin (Farmorubicin) at the dose of 90mg/m^2 IV every 3 weeks for 6 consecutive cycles
1780210|NCT00431808|Biological|Malaria vaccine AMA1 (PfAMA-1-FVO[25-545]|3 doses of AMA 1 vaccine
1780211|NCT00431808|Biological|AMA1|50 micrograms of AMA1
1780212|NCT00431821|Behavioral|Exercise|Home-based exercise prescriptions with weekly motivational telephone calls.
1780213|NCT00431821|Other|Stroke education|Stroke education program with matched attention phone calls
1780214|NCT00431834|Device|Cardioblate System Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
1780215|NCT00431834|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
1780216|NCT00431847|Procedure|Regional Anesthesia|Subject received regional anesthesia to affected limb(s) within 72 hours of traumatic event.
1780217|NCT00431847|Procedure|Standard Pain Management Protocol|Intermittent dosing of analgesics and anxiolytics instituted prior to continuous intravenously dosing which was individually titrated to patient care goals.
1780218|NCT00431860|Procedure|Coronary computed tomographic angiography|
1780219|NCT00431873|Drug|MGCD0103|MGCD0103 Administered orally three times per week.
1780220|NCT00431886|Procedure|64 multi-detector computed tomography|
1780221|NCT00431899|Behavioral|fish oil supplementation|
1780222|NCT00431912|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr for 4 consecutive days (96 hours), every 3 weeks for a total of 3 cycles
1780223|NCT00431951|Drug|ST-246|250 mg, 400 mg or 800 mg capsules given once daily for 21 days
1780224|NCT00431951|Drug|Placebo|Capsules to match experimental drug
1780225|NCT00431964|Drug|azithromycin 250 mg tablets|"One (1) tablet three times weekly for patients who weigh 40-79 lbs
Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
1780226|NCT00431964|Drug|placebo tablets|"One (1) tablet three times weekly for patients who weigh 40-79 lbs
Two (2) tablets three times weekly for patients who weigh greater than or equal to 80 lbs"
1780227|NCT00431977|Procedure|coronary computed tomography angiography|
1780228|NCT00431990|Drug|depsipeptide|Cohort 1. Dose escalation, IV, Weeklyx3 in a 4week cycle. Cohort 2A. 12mg/m2, IV, Weeklyx3 in a 4week cycle. Cohort 2B. 12mg/m2, IV, Weeklyx2 in a 3week cycle.
1780229|NCT00431990|Drug|bortezomib|Cohort 1 and 2A. 3.5mg/m2, IV, day 1, 4, 8, 11 in 28 day cycle. Cohort 2B. 3.5mg/m2, IV, day 1, 4, 8, 11 in 21 day cycle
1780230|NCT00431990|Drug|dexamethasone|20mg for 2 days with each dose of bortezomib
1780231|NCT00432016|Drug|zidovudine|
1780232|NCT00432016|Drug|amdoxovir|
1780233|NCT00432016|Procedure|pharmacokinetic sampling|
1780234|NCT00432029|Procedure|Forearm blood flow measurement, Flow mediated dilation (FMD)|Forearm blood flow measurement: baseline 1 min, 3 min after inflation of cuff, 4 min after 0.8mg Nitroglycerin
1780235|NCT00432029|Device|Zeiss Retinal Vessel Analyzer (RVA), Stimulation with Flicker-light|Stimulation with Flicker-light: 1 min, measurement without flickering light 4 min after 0.8 mg Nitroglycerin
1780237|NCT00432055|Drug|Botulinum toxin type A (Botox)|
1780238|NCT00432055|Drug|placebo (saline)|
1780239|NCT00432068|Drug|Octreotide pamoate|
1780240|NCT00432081|Drug|indomethacin|
1780241|NCT00432094|Drug|carboplatin|Days -6, -5, -4: 500mg/m2^/day intravenously (IV) over 60 minutes
1780242|NCT00432094|Drug|etoposide|600mg/m^2/day intravenously (IV) over 60 minutes on Days -6 through -3.
1780243|NCT00432094|Drug|ifosfamide|2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
1780244|NCT00432094|Drug|paclitaxel|225 mg/m^2 intravenous over 3 hours on Day -7.
1780245|NCT00432094|Drug|thiotepa|150mg/m^2/day intravenously IV over 30 minutes; Days -6, -5 and -4
1780246|NCT00432094|Procedure|autologous hematopoietic stem cell transplantation|Peripheral blood stem cell infusion (< 4 x 10^6 CD34+ cells/kg)
1780247|NCT00432094|Drug|Mesna|2500 mg/m^2/day continuous infusion intravenously on Days -6, -5 and -4.
1780248|NCT00432094|Biological|filgrastim|Beginning Day 5, G-CSF 5 μg/kg/day until absolute neutrophil count (ANC) ≥ 1500/UL for 3 consecutive days.
1780249|NCT00432107|Drug|APO866|APO866 is administered as 0.126 mg/m²/hr IV every 4 weeks for 4 consecutive days (96 hours) for a total of 3 cycles
1780250|NCT00432120|Drug|clopidogrel|To compare two different clopidogrel regimens on the outcomes of patients undergoing elective coronary angiography ± ad-hoc percutaneous coronary intervention
1780400|NCT00433238|Behavioral|Participants will be screened for depression and cognitive impairment, then receive screening results.|
1780401|NCT00433264|Procedure|peritoneal dialysis|individualised
1780251|NCT00432133|Behavioral|Protection Motivation Theory-Based Intervention|Targets perceptions of outcome severity and susceptibility, self-efficacy, response efficacy, response costs, and rewards of physical inactivity. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
1780252|NCT00432133|Behavioral|Environmenta|Targets increased awareness and use of local parks and trials near the home and work environments. Targets increased access by providing membership to a local fitness facility for 12 months. One computer interactive session is followed by 3 automated telephone counseling sessions and 4 tailored newletters spread over a 6 month period.
1780253|NCT00432146|Drug|lugol's solution|
1780256|NCT00432172|Drug|Standard treatment|EC x 4 -> Tx4
1780257|NCT00432172|Drug|Selective treatment|Postmenopausic patients: exemestane x 6 months; Premenopausic Patients: goserelin x 6 months + exemestane x 6 months
1780258|NCT00432172|Drug|Standard treatment|ECx4-> Tx4
1780259|NCT00432172|Drug|Selective treatment|EC x4->CBPT x4
1780260|NCT00432185|Drug|PEP005|0.25% PEP005 Gel
1780261|NCT00432198|Drug|Zolpidem (Myslee®)|Oral
1780262|NCT00432198|Drug|placebo|Oral
1780263|NCT00432211|Drug|Avotermin|"Complete Excision:- On Day 0,Following wound closure the two outer segments of the wound will receive either Juvista or placebo.100µl of vehicle containing 200ng of Juvista will be injected per linear centimetre into both margins of one segment of the wound,and 100µl of vehicle alone (placebo) will be injected per linear centimetre into the other segment of the wound. There will be a central area (at least 3cm) of untreated wound between the two segments.The treatments will be re-administered to each wound segment (A and B) 24 hours after the first administration.
Staged Excision On Day 0, the two end segments of the scar will be excised.Following wound closure each subject will receive 100µl of vehicle containing 200ng of Juvista per linear centimetre intradermally into one wound, and 100µl of vehicle alone (placebo) per linear centimetre into the other wound.The trial treatments will be re-administered to each wound 24 hours after the first administration."
1780264|NCT00432224|Procedure|photodynamic therapy|
1780265|NCT00432237|Drug|MK0974 50 mg|
1780266|NCT00432237|Drug|MK0974 150 mg|
1780267|NCT00432237|Drug|MK0974 300 mg|
1780268|NCT00432237|Drug|Comparator: Placebo|MK0974 50 mg soft gel capsule Placebo; MK0974 150 mg soft gel capsule Placebo; MK0974 300 mg soft gel capsule Placebo.
1780269|NCT00432250|Procedure|Cervical length ultrasound|
1780270|NCT00432263|Drug|Genotropin (PN-180,307) Somatropin|
1780271|NCT00432276|Drug|Alogliptin|Alogliptin tablets.
1780272|NCT00432276|Drug|Pioglitazone|Pioglitazone tablets.
1780273|NCT00432276|Drug|Metformin|Metformin HCl tablets (immediate-release, commercially available formulation) ≥1500 mg or maximum tolerated dose.
1780274|NCT00432276|Drug|Placebo|Matching placebo tablets.
1780275|NCT00432289|Procedure|Acupuncture|Acupunture treatment 3x per week for 6 weeks.
1780276|NCT00432302|Drug|Sagopilone (BAY 86-5302, ZK 219477)|First infusion only: 28 mg, containing 14 kBq/7.8 mcg [14C]-ZK 219477. Subsequent infusions: 16 mg/m2 ZK 219477 without radioactive label. IV infusion was given over a period of 30 min.
1780277|NCT00432315|Drug|Docetaxel + CDDP|"3 cycles chemotherapy : docetaxel + CDDP
Surgery (if no histologically proven R0-resection could be achieved,additional adjuvant radiotherapy should be considered)
3 cycles adjuvant chemotherapy docetaxel"
1780278|NCT00432315|Drug|docetaxel + CDDP|"3 cycles chemotherapy: docetaxel + CDDP
Radiochemotherapy
3 cycles adjuvant chemotherapy docetaxel"
1780279|NCT00432328|Drug|Avotermin|
1780280|NCT00432341|Biological|botulinum toxin type A|200 Units at Visit 1 (Day 1)
1780281|NCT00432341|Biological|botulinum toxin type A|500 Units at Visit 1 (Day 1)
1780282|NCT00432354|Drug|atorvastatin|
1780283|NCT00432367|Drug|Amodiaquine plus artesunate combination; sulphadoxine-pyrimethamine|"Eligible women will be allocated randomly to one of three groups and treated as follows:
Arm 1 (OptiMAL® antigen screening and treatment with SP plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment if her screening test is positive.
Arm 2 (OptiMAL® antigen screening and treatment with AQ+AS plus LLIN) - a woman in this will receive 300mg of AQ and 100mg co-administered two times a day for 3 days if her screening test is positive. The first dose is observed on enrolment day at the ANC.
Arm 3 (SP-IPTp plus LLIN group) - a woman in this will receive 1500mg/75mg (S/P) administered at the ANC as single dose on enrollment as recommended by national policy.
All enrolled women will be given one long lasting insecticide treated bed net each for use."
1780284|NCT00432380|Biological|Rotarix™|oral doses
1780285|NCT00432380|Biological|Placebo|oral dose
1780286|NCT00432393|Drug|levodopa-carbidopa|
1780287|NCT00432406|Drug|Infliximab|Infliximab 5 mg/kg given at day 1, week 2, week 6
1780288|NCT00432406|Drug|Etanercept|Etanercept 25 mg twice weekly
1780289|NCT00432419|Procedure|autologous peripheral blood cell transplantation|
1780290|NCT00432432|Drug|Infliximab and MTX|MTX 15mg weekly Infliximab 5mg/kg given at day 0, wk 2, wk6
1780291|NCT00432445|Radiation|Proton Beam Radiation Therapy|Radiation given daily for 5 days in a row each week (except for Saturdays, Sundays, and holidays). The whole treatment will take about 4-6 weeks.
1780292|NCT00432445|Procedure|Ophthalmic EUA|Ophthalmic examination under anesthesia including dilated eye exam, ocular fundus photography (Ret-Cam), ocular echography and neuro-radiologic assessment (as deemed necessary)
1780293|NCT00432458|Drug|Thalidomide|200 mg orally on days 1-28 of 28 day cycle
1780294|NCT00432458|Drug|zoledronic acid|4 mg^2 by IV on day 1 every 84 days for 1 year and once per year thereafter
1780295|NCT00432471|Procedure|Optical Imaging|Imaging using the multispectral digital microscope (MDM), a system that shines different colors of light on the skin and takes pictures of fluorescence and reflectance on the skin area.
1780402|NCT00433277|Drug|twice-daily dosage with 0.5% cyclosporine-A eyedrops|
1780406|NCT00433316|Drug|ropivacaine|1% ropivacaine
1780407|NCT00433316|Device|Aeroneb Pro Nezulizer, Aerogen, Ireland|Aeroneb Pro Nezulizer, Aerogen, Ireland
1780296|NCT00432484|Drug|Lingzhi and Sen Miao San|G lucidum and SMS were supplied as capsules, containing 4.0 gm of G lucidum extract, 2.4 gm of Rhizoma atractylodis (Cangzhu), 2.4 gm of Cotex phellodendri(Huangbai), and 2.4 gm of Radix achyranthes Bidentatae(Niuxi). Each patient took either 3 capsules twice daily as recommended by the TCM experts or identical-looking placebo.
1780297|NCT00432510|Drug|C1 esterase inhibitor [human] (C1INH-nf)|
1780298|NCT00432523|Biological|M-M-R™II manufactured with recombinant Human Albumin (rHA) and VARIVAX®|
1780299|NCT00432536|Other|Quality improvement intervention|determine the effectiveness of adopting quality improvement strategies to reduce embolization, hypotension and cerebral desaturation
1780300|NCT00432549|Drug|Almotriptan|
1780301|NCT00432549|Drug|Topiramate|
1780302|NCT00432562|Drug|Vinorelbine Tartrate|Subjects received one dose each of ANX-530 and NAVELBINE, each providing 30 mg/m2 vinorelbine. Study drugs will be infused into an arm vein over ten minutes.
1780303|NCT00432575|Drug|surinabant (SR147778)|oral administration
1780304|NCT00432575|Drug|placebo|oral administration
1780305|NCT00432588|Drug|misoprostol|
1780306|NCT00432588|Drug|dinoprostone|
1780307|NCT00432601|Behavioral|type of decision aid|We will be comparing two decision aids (MCC vs. NCCN) in terms of their impact on decision making and patient-physician communication.
1780308|NCT00432614|Drug|SR58611A|oral administration
1780309|NCT00432614|Drug|escitalopram|oral administration
1780310|NCT00432614|Drug|placebo|oral administration
1780311|NCT00432627|Drug|Deferasirox|one dose of 20 mg/kg/day
1780312|NCT00432640|Procedure|Endoscopic ultrasound staging|Endoscopic ultrasound staging with both EUS-FNA and EBUS-TBNA
1780313|NCT00432640|Procedure|Surgical staging|Surgical staging
1780315|NCT00432666|Drug|IncobotulinumtoxinA (Xeomin)|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kiloDalton), free from complexing proteins) (active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins) powder for solution for injection dose (Main Period only): one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl), up to five injections in the Open-Label Extension Period, up to 400 units at each injection visit; Mode of administration: intramuscular injection"
1780316|NCT00432666|Drug|Placebo|Placebo
1780318|NCT00432692|Procedure|Falls Prevention Program|
1780319|NCT00432705|Procedure|Checking stability of ankle|Flexing and walking
1780320|NCT00432718|Procedure|Saline Instillation before Tracheal Suctioning|
1780321|NCT00432731|Biological|VARIVAX®|
1780322|NCT00432731|Biological|M-M-RTM II|
1780323|NCT00432744|Drug|CoenzymeQ10|CoenzymeQ10 will be given in 10 mg/kg daily up to 400 mg. Then a draw of CoQ10 troughs every three months will be performed.
1780324|NCT00432744|Drug|Placebo|Placebo will be given in 10 mg/kg daily up to 400 mg. Then a draw of placebo troughs every three months will be performed. This treatment group will be treated as the active group.
1780325|NCT00432757|Drug|Ketotifen with a Contact Lens (generic name not yet established)|
1780326|NCT00432770|Drug|ARC1779|
1780327|NCT00432796|Drug|Dalteparin|5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0
1780328|NCT00432796|Other|Placebo|"patients will be randomized post-operative to receive either active treatment or placebo.
the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.
ie. 5,000 iu or 200 iu/kg"
1780329|NCT00432809|Procedure|Gastric bypass|Roux-en-Y gastric bypass
1780330|NCT00432809|Procedure|Sleeve Gastrectomy|Laparoscopic sleeve gastrectomy
1780331|NCT00432822|Drug|tetrahydrobiopterin (BH4)|
1780332|NCT00432835|Device|Gastric Electrical Stimulator, Enterra, Medtronics, Inc.|All patients received a GES electrode, endoscopically placed and connected to an external device at baseline. The device was turned ON to provide 72 continuous hours of active stimulation and OFF to deactivate stimulation
1780333|NCT00432861|Drug|PANCRECARB® (pancrelipase)|Capsules
1780334|NCT00432861|Drug|Placebo|Capsules
1780335|NCT00432874|Procedure|wound hydration method|Anterior vs lateral wound hydration
1780336|NCT00432887|Drug|caffeine administration|
1780337|NCT00432900|Radiation|[(11)C]PBR28|PET Ligand
1780338|NCT00432913|Drug|Eicosapentaenoic Acid (EPA)|Either 2 x 500mg EPA capsules in the morning and evening (2g per day EPA) or 1 x 500mg EPA and 1 x placebo in the morning and evening (1g per day EPA)
1780339|NCT00432913|Procedure|Endoscopy|At baseline, month 3 and month 6.
1780340|NCT00432913|Procedure|Biopsies taken|9 biopsies taken for measurement of apoptosis (3 biopsies), cell proliferation (3 biopsies) and fatty acid levels (3 biopsies) at baseline, month 3 and month 6.
1780341|NCT00432913|Procedure|Clinical chemistry|Full blood count at baseline, month 3 and month 6.
1780342|NCT00432913|Procedure|Haematology|Urea and electrolytes, liver function tests, clotting profile and CRP at baseline, month 3 and month 6.
1780343|NCT00432913|Procedure|Physical examination|Including cardio-respiratory and abdominal examination at baseline, month 3 and month 6.
1780344|NCT00432913|Procedure|Vital signs|Height, weight, heart rate, blood pressure and temperature at baseline, month 3 and month 6.
1780345|NCT00432913|Procedure|Urine pregnancy test|For subjects of child-bearing potential, urine pregnancy test at baseline, month 3 and month 6.
1780346|NCT00432913|Procedure|Completion of patient diary card|Subjects are requested to complete when study medication is taken and in any new or unusual symptoms are experienced on a daily basis for 6 months.
1780347|NCT00432926|Behavioral|EDGE counseling, no maintenance|Five-session behavior change intervention that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports).
1780403|NCT00433290|Drug|Duloxetine|duloxetine 30 mg every day (QD), by mouth (PO) for 1 week, then duloxetine 60 mg QD, PO for 6 weeks, followed by duloxetine 60 mg QD, PO for 6 weeks for responders or duloxetine 120 mg QD, PO for 6 weeks for non-responders
1780348|NCT00432926|Behavioral|EDGE counseling, plus maintenance|Five-session behavior change intervention (identical to Arm 1) that combines client-centered motivational interviewing and structured behavioral counseling (to address context of unsafe sex/drug use; condom use, safer sex negotiation; disclosure; and enhancement of social supports) PLUS eight group-format safer sex maintenance counseling sessions, which utilize clinical strategies from relapse prevention to identify high risk situations and develop effective coping strategies.
1780349|NCT00432926|Behavioral|Attention control|An attention-control condition that is time-equivalent to Arm 2, and addresses diet, exercise, and HIV.
1780350|NCT00432952|Behavioral|Intake of rainbow trout from different feeding conditions versus a control poultry meal|
1780352|NCT00432978|Drug|Bosentan administration|
1780353|NCT00432991|Drug|Ephedrine [Synonyms: Ephedra, Ephedrinum]|25 mg, IM (in the muscle), one time
1780354|NCT00432991|Drug|Saline Placebo|0.5 mL, IM (in the muscle), one time
1780355|NCT00433004|Drug|Plan B (Levonorgestrel)|PP TEENS ARE RANDOMIZED TO PLAN B + ROUTINE CONTRACETIVE CARE VS. ROUTINE CARE ALONE. QUESTIONNAIRES ON HEALTH STATUS, SEXUAL HISTORY, AND CONTRACEPTIVE USE ARE COMPLETED AT STATED INTERVALS.
1780356|NCT00433017|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, verteporfin was activated by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of the infusion.
1780357|NCT00433017|Drug|Ranibizumab|Ranibizumab 0.5 mg (0.05 mL of 10 mg/mL solution for injection) administered as an intravitreal injection
1780358|NCT00433017|Drug|Placebo|As a placebo for verteporfin photodynamic therapy (for masking purposes), patients were administered a 10-minute intravenous infusion of 5% dextrose solution, followed by light application of 50 J/cm^2 to the study eye, begun 15 minutes after the start of infusion.
1780359|NCT00433043|Drug|Beta blocker (carvedilol or metoprolol succinate)|Both groups get CRT. Group 1 is uptitrated to target dose beta blocker after CRT. Group 2 maintains their b-blocker dose from study entry.
1780360|NCT00433043|Procedure|CRT (cardiac resynchronization therapy)|Both arms
1780361|NCT00433056|Other|STI|CD4 guided treatment interruption
1780362|NCT00433056|Drug|stable HAART|continuous therapy
1780363|NCT00433069|Drug|Pioglitazone|Increase early virological response to pegylated interferon alpha plus ribavirin by increasing insulin sensitivity
1780364|NCT00433069|Drug|Interferon Alfa-2a|Standard of care for chronic hepatitis C
1780365|NCT00433069|Drug|Ribavirin|Standard of care for chronic hepatitis C
1780366|NCT00433082|Behavioral|Ramadan Fasting|
1780367|NCT00433095|Drug|Navelbine|
1780368|NCT00433095|Drug|Herceptin|
1780369|NCT00433095|Drug|Navelbine (oraly)|
1780370|NCT00433108|Drug|Mitoquinone mesylate (MitoQ)|
1780371|NCT00433121|Drug|Risperidone|
1780372|NCT00433121|Drug|Olanzapine|
1780373|NCT00433121|Drug|Haloperidole|
1780374|NCT00433121|Drug|Quetiapin|
1780375|NCT00433121|Drug|Escitalopram|
1780376|NCT00433121|Drug|Citalopram|
1780377|NCT00433121|Drug|Sertralin|
1780378|NCT00433134|Behavioral|Adherence|
1780379|NCT00433147|Drug|AT2101|AT2101 25 mg orally once a day (25 mg capsule), AT2101 150mg (six 25 mg capsules)once a day, AT2101 150mg once every fourth day, or AT2101 150 mg once per week for 28 days.
1780380|NCT00433160|Drug|Teriparatide|daily, subcutaneous
1780381|NCT00433160|Drug|Placebo|daily, subcutaneous
1780382|NCT00433173|Procedure|intravenous glucose tolerance test|The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
1780383|NCT00433173|Drug|testosterone|transdermal 7.5 g/per day for 3 months
1780384|NCT00433173|Drug|anastrozole|tablet (per oral) 10.0 mg/ daily 3 months
1780385|NCT00433173|Drug|goserelin acetate implant|single depot injection 10.8 mg 3 months
1780386|NCT00433173|Procedure|aerobic capacity (VO2 Max)|This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
1780387|NCT00433173|Procedure|MRI|1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
1780388|NCT00433173|Procedure|muscle biopsy|Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
1780389|NCT00433173|Procedure|measurement of resting metabolic rate (energy expenditure)|Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
1780390|NCT00433173|Procedure|Dual energy x-ray absorptiometry|Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
1780391|NCT00433173|Procedure|Fasting oral glucose tolerance test|To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
1780392|NCT00433186|Drug|Mycophenolate Mofetil|Mycophenolate 3000 mg each day
1780393|NCT00433199|Drug|Testosterone (T) Gel 1.62%|Testosterone gel 1.62% contains 1.62% testosterone gel as active ingredient.
1780394|NCT00433199|Drug|Placebo|Placebo Control
1780395|NCT00433212|Device|nCPAP|Deliver non-invasive respiratory support via ventilator with nCPAP device
1780396|NCT00433212|Device|NIPPV|Deliver non-invasive respiratory support via ventilator with NIPPV device
1780397|NCT00433225|Drug|Prednisolone Acetate|
1780398|NCT00433225|Drug|Ketorolac 0.4%|
1780399|NCT00433225|Drug|Gatifloxacin 0.3%|
1780404|NCT00433290|Drug|Placebo|placebo every day (QD), by mouth (PO) for 13 weeks
1780408|NCT00433329|Drug|Bosentan|Oral bosentan 62.5 mg BID first 4 weeks followed by 24 weeks of 125 mg BID if the 62.5 mg BID dose was well tolerated
1780409|NCT00433329|Drug|Sildenafil|Oral sildenafil 20 mg TID in patients who do not reach the 6-MWT distance threshold at Week 16
1780410|NCT00433342|Drug|Flucloxacillin|500 mg QD oral
1780411|NCT00433368|Drug|L-Ornithine L-Aspartate|
1780412|NCT00433381|Drug|irinotecan hydrochloride|Given IV
1780413|NCT00433381|Biological|bevacizumab|Given IV
1780414|NCT00433381|Drug|temozolomide|Given orally
1780415|NCT00433394|Procedure|cancer prevention intervention|
1780416|NCT00433394|Procedure|educational intervention|
1780417|NCT00433407|Biological|trastuzumab|
1780418|NCT00433420|Biological|pegfilgrastim|
1780419|NCT00433420|Drug|cyclophosphamide|
1780420|NCT00433420|Drug|epirubicin hydrochloride|
1780421|NCT00433420|Drug|fluorouracil|
1780422|NCT00433420|Drug|paclitaxel|
1780423|NCT00433420|Procedure|adjuvant therapy|
1780424|NCT00433433|Drug|ABVD q4 weeks|Doxorubicin 25 mg/m2 i.v. day 1 and 15; Bleomycin 10 mg/m2 i.v./i.m. day 1 and 15; Vinblastine 6 mg/m2 i.v. day 1 and 15; Dacarbazine 375 mg/m2 i.v. day 1 and 15
1780425|NCT00433433|Drug|BEACOPP escalated q3 weeks|Cyclophosphamide 1250 mg/m2 i.v. day 1; Doxorubicin 35 mg/m2 i.v. day 1; Vincristine 1.4 mg/m2 i.v.(max.2mg) day 8; Bleomycin 10 mg/m2 i.v./i.m. day 8; Etoposide 200 mg/m2/ i.v. day 1 to 3; Procarbazine 100 mg/m2 orally day 1 to 7; Prednisone 40 mg/m2 orally day 1 to 14; G-CSF 5 mcg/kg s.c. day 9 to recovery leukocytes>1.0x109/l
1780426|NCT00433433|Radiation|IN-RT 30 Gy (+ boost 6 Gy residual)|
1780427|NCT00433433|Procedure|FDG-PET scan|
1780428|NCT00433446|Biological|CNTO 328|
1780429|NCT00433459|Drug|cyclophosphamide|drug is used in first line treatment in combination (COPP or COPDAC)
1780430|NCT00433459|Drug|dacarbazine|drug is used in first line treatment in combination (COPDAC)
1780431|NCT00433459|Drug|prednisolone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
1780432|NCT00433459|Drug|prednisone|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
1780433|NCT00433459|Drug|procarbazine hydrochloride|drug is used in first line treatment in combination (COPP)
1780434|NCT00433459|Drug|vincristine sulfate|drug is used in first line treatment in combination (OEPA, COPP or COPDAC)
1780435|NCT00433459|Radiation|fludeoxyglucose F 18|used as a diagnostic marker for metabolically active tumour at staging and response assessment
1780436|NCT00433459|Radiation|radiation therapy|part of combination treatment (combined modality between chemo- and radiotherapy)
1780437|NCT00433472|Device|magnetic resonance imaging (MRI)|MRI scan to be complete to look at RSR13 on measurement of T2 and T2* on MRI
1780438|NCT00433485|Drug|sirolimus|
1780439|NCT00433485|Genetic|comparative genomic hybridization|
1780440|NCT00433485|Genetic|gene expression analysis|
1780441|NCT00433485|Genetic|microarray analysis|
1780442|NCT00433485|Genetic|protein expression analysis|
1780443|NCT00433485|Genetic|proteomic profiling|
1780444|NCT00433485|Other|laboratory biomarker analysis|
1780445|NCT00433485|Other|mass spectrometry|
1780446|NCT00433485|Procedure|biopsy|
1780447|NCT00433498|Drug|carboplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
1780448|NCT00433498|Drug|cisplatin|Should be given according to local practice but suggested doses and schedules are provided in the protocol.
1780449|NCT00433498|Drug|etoposide phosphate|Day 1: given by IV, days 2 and 3 given by IV or oral. Dose should be given according to local practice but suggested doses and schedules are provided in the protocol.
1780450|NCT00433498|Drug|pravastatin sodium|40mg daily oral tablet taken for a maximum of 2 years
1780458|NCT00433524|Procedure|computed tomography|
1780459|NCT00433537|Drug|bortezomib|Given IV
1780460|NCT00433537|Biological|rituximab|Given IV
1780461|NCT00433537|Drug|cyclophosphamide|Given IV
1780462|NCT00433537|Drug|doxorubicin hydrochloride|Given IV
1780463|NCT00433537|Drug|vincristine|Given IV
1780464|NCT00433537|Drug|dexamethasone|Given IV
1780465|NCT00433537|Biological|filgrastim|Given SC
1780466|NCT00433537|Biological|pegfilgrastim|Given SC
1780467|NCT00433537|Procedure|Autologous stem cell transplantation (ASCT)|
1780468|NCT00433550|Drug|capecitabine|given orally
1780469|NCT00433550|Drug|irinotecan hydrochloride|given IV
1780470|NCT00433550|Drug|oxaliplatin|given IV
1780471|NCT00433563|Radiation|Once daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + once daily radiotherapy
1780472|NCT00433563|Radiation|Twice daily radiotherapy|Standard of care chemotherapy (cisplatin/etoposide) + twice daily radiotherapy
1780473|NCT00433576|Drug|resveratrol|Given orally
1780474|NCT00433576|Other|pharmacological study|Correlative studies
1780475|NCT00433576|Other|laboratory biomarker analysis|Correlative studies
1780476|NCT00433589|Drug|anthracycline-based|
1780477|NCT00433589|Drug|docetaxel and capecitabine|
1780478|NCT00433602|Other|clinical observation|
1780479|NCT00433602|Procedure|management of therapy complications|
1780480|NCT00433602|Procedure|ultrasound imaging|
1780481|NCT00433615|Drug|R744|100μg(s.c./i.v.)/4 week for 8 weeks, then 25~400μg(s.c./i.v.)/4 week for 40 weeks
1780482|NCT00433615|Drug|R744|150μg(s.c./i.v.)/4 week for 8 weeks, then 25~400μg(s.c./i.v.)/4 week for 40 weeks
1780483|NCT00433641|Drug|sibutramine|placebo
1780484|NCT00433641|Drug|sibutramine|oral 15 mg sibutramine once per day
1780485|NCT00433641|Drug|sibutramine|oral sibutramine 10 mg once per day
1780486|NCT00433654|Device|Implantable Pulse Generator (IPG) and Pacing Leads (wires)|Pacer and leads
1780487|NCT00433654|Other|Magnetic Resonance Imaging (MRI) scan|One hour MRI scan on the head and lower back.
1780488|NCT00433667|Drug|RWJ-333369|
1780489|NCT00433680|Behavioral|Healthy Weight|4 weekly 1 hour meetings that encourage reductions in fat and sugar intake and increases in physical activity to decrease onset of obesity and body dissatisfaction.
1780490|NCT00433693|Drug|R744|50μg(i.v.)/2 week until Hb concentration reaches to 11.0g/dL or above, then 25~300μg(i.v.)/4 week
1780491|NCT00433706|Procedure|Control position by 3DOBI before the fraction|
1780492|NCT00433706|Procedure|Standard imaging|
1780493|NCT00433719|Drug|Combivir and efavirenz|Arm 1: Combivir and efavirenz for 12 months Arm 2: Placebo for 2 months then Combivir and efavirenz for 10 months
1780494|NCT00433732|Drug|sumatriptan|
1780495|NCT00433732|Drug|naproxen sodium|
1780496|NCT00433745|Drug|WT1 Peptide Vaccine|WT1 vaccination (9 doses of WT-1:126-134 peptide (in Montanide adjuvant) administered concomitantly with GM-CSF (Sargramostim)
1780497|NCT00433758|Device|GlucoTrack|GT
1780498|NCT00433771|Device|WallFlex™ Biliary Fully Covered Metal Stent placement|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is fully covered with a polymer to reduce the potential for tumor ingrowth into the stent.
1780499|NCT00433784|Drug|Clopidogrel|
1780500|NCT00433784|Procedure|Blood sampling - platelet aggregation|
1780501|NCT00433784|Procedure|Blood sampling - genotyping|
1780502|NCT00433797|Dietary Supplement|Prostate cancer, phytochemical and PUFA|Patients with localized prostate cancer are supplemented with either tomato or a multi-diet cinsisting of grape juice, pomegranate juice, tomato, green tea, black tea, soy, selenium and PUFAs for 3 weeks.
1780503|NCT00433823|Drug|Atorvastatin, Ezetimibe|
1780504|NCT00433836|Drug|Valsartan|Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.
1780505|NCT00433836|Drug|Enalapril|Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.
1780506|NCT00433849|Drug|R744|100μg(i.v./p.o.)/4weeks for 8 weeks, then 25~400μg(i.v./p.o.)/4weeks for 40 weeks
1780507|NCT00433849|Drug|R744|150μg(i.v./p.o.)/4weeks for 8 weeks, then 25~400μg(i.v./p.o.)/4weeks for 40 weeks
1780508|NCT00433875|Drug|AMG 714|
1780509|NCT00433888|Drug|R744|100μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
1780510|NCT00433888|Drug|R744|150μg/4 weeks for 8 weeks,then 25~400μg/4 weeks for 40 weeks
1780511|NCT00440219|Drug|Oral Prednisone|Prednisone 50 mg once daily for 10 days pre-op
1780512|NCT00440219|Drug|Placebo comparator|Placebo pill identical to Prednisone 10 days once daily pre-op
1780513|NCT00440232|Drug|Frovatriptan|Frovatriptan 5.0 mg orally one time at the start of the 20 hour fast
1780514|NCT00440232|Drug|Placebo|Inert tab identical in appearance to Frovatriptan
1780515|NCT00440245|Drug|salbutamol|200 micrograms salbutamol from MDI
1780516|NCT00440258|Drug|Cabergoline|
1780517|NCT00440258|Procedure|MR|
1780518|NCT00440258|Procedure|Ultrasound|
1780519|NCT00440258|Procedure|Blood Analysis|
1780520|NCT00440271|Drug|tipranavir|
1780521|NCT00440271|Drug|ritonavir|
1780522|NCT00440271|Drug|Optimized Background Regimen (OBR)|Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.
1780523|NCT00440284|Drug|conventional vs. flexible, intensive insulin therapy|
1780524|NCT00440297|Biological|Comparator: modified process hepatitis B vaccine|Modified process hepatitis B vaccine 40 ug/1.0 mL injection in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
1780525|NCT00440297|Biological|Comparator: ENGERIX-B™|ENGERIX-B™ two 20 ug/1.0 mL injections in a 4 dose regimen at months 0, 1, 6, and 8. Duration of treatment is 9 months.
1780526|NCT00440310|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
1780527|NCT00440310|Procedure|Percutaneous placement of device in liver metastases|Light Source placement will be conducted under placement imaging using ultrasound or CT guidance. No more than four Light Sources will be used at a single treatment session. The Light Sources may be used in a single lesion or in multiple lesions.
1780528|NCT00440310|Device|Interstitial light emitting diodes|200 J/cm per Light Source at 20 mW/cm light energy
1780529|NCT00440310|Drug|FOLFOX4 regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and oxaliplatin
1780530|NCT00440310|Drug|FOLFIRI regimen|Standard care chemotherapy regimen consisting of leucovorin, 5-FU and irinotecan
1780531|NCT00440323|Drug|SB-649868|SB-649868 tablets will be available with dose strength of 5 and 25 mg.
1780532|NCT00440323|Drug|Zolpidem|Zolpidem capsules will be available with dose strength of 10 mg.
1780533|NCT00440323|Drug|Placebo|Placebo tablet matching SB-649868 or Placebo capsule matching Zolpidem will be available.
1780534|NCT00440336|Drug|Cosopt|
1780535|NCT00440336|Drug|Xalatan|
1780536|NCT00440349|Drug|Tamoxifen|
1780537|NCT00440349|Drug|Prednisone|
1780538|NCT00440362|Biological|AVX502|1 dose at 2e8 IU given at t=0 via IM route
1780539|NCT00440362|Biological|AVX502|1 dose at 2e7 IU given at T=0 via the IM route
1780540|NCT00440362|Biological|AVX502|1 dose at 2e7 IU given at t=0 via the SC route
1780541|NCT00440362|Biological|AVX502|1 dose at 2e8 IU given at T=0 via the SC route
1780542|NCT00440362|Biological|AVX502|2 doses at 2e7 IU given at T=0 and 8 weeks via the IM route
1780543|NCT00440362|Biological|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the IM route
1780544|NCT00440362|Biological|AVX502|2 doses of 2e7 IU given at t=0 and 8 weeks via the SC route
1780545|NCT00440362|Biological|AVX502|2 doses at 2e8 IU given at T=0 and 8 weeks via the SC route
1780546|NCT00440362|Biological|Placebo|1 dose of placebo given at T=0 via the IM route
1780547|NCT00440362|Biological|Placebo|1 dose of placebo given at T=0 via the SC route
1780606|NCT00441662|Drug|Sub-Tenon triamcinolone 40mg|
1780548|NCT00440362|Biological|Placebo|2 doses of placebo given at T=0 and 8 weeks via the IM route
1780549|NCT00440362|Biological|Placebo|2 doses of placebo given at T=0 and 8 weeks via the SC route
1780550|NCT00440375|Drug|Rosiglitazone|
1780551|NCT00440388|Drug|AT-101|AT-101 30 mg orally for 21 of 56 days, every cycle. Cycle = 56 days; Max of 5 cycles.
1780552|NCT00440388|Drug|Rituximab|Rituximab 375mg/m2 IV once per week for four weeks during 1st cycle, 375mg/m2 IV once per cycle for cycles 2-5. Cycle = 56 days; Max of 5 cycles.
1780553|NCT00440401|Drug|fibrinogen (human) + thrombin (human)|
1780554|NCT00440401|Drug|Standard haemostatic treatment in cardiovascular surgery|Any haemostatic fleece material without additional active coagulation stimulating compounds (primarily Surgicel®)
1780555|NCT00440414|Drug|Erlotinib (Tarceva)|Erlotinib at the dose of 150 mg orally once a day continually until progression
1780556|NCT00440414|Drug|Pemetrexed (Alimta)|Pemetrexed at the dose of 500mg/m2 IV infusion every 3 weeks for 6 consecutive cycles
1780557|NCT00440427|Drug|Desvenlafaxine Sustained Release (DVS SR)|
1780558|NCT00440440|Drug|Testosterone gel|Testosterone gel to be applied daily, starting does 5g.
1780559|NCT00440440|Drug|placebo|placebo gel apply daily
1780560|NCT00440453|Other|Nutritional therapy|Nutritional therapy by dietician
1780561|NCT00440466|Drug|epoetin alfa|Continue pre-study once weekly dose of epoetin alfa for 36 weeks
1780562|NCT00440466|Drug|epoetin alfa|Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
1780563|NCT00440466|Drug|epoetin alfa|Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
1780564|NCT00440479|Drug|Bortezomib|dose as determined (observational study) by treating physician
1780565|NCT00440492|Drug|PLA-695|
1780566|NCT00440505|Drug|Placebo|Subjects applied a placebo patch (0 mg) in the morning and removed it at bedtime for one day.
1780567|NCT00440505|Drug|Nicotine (5 mg)|Subjects applied a nicotine patch (5 mg) in the morning and removed it at bedtime for one day.
1780568|NCT00440505|Drug|Nicotine (10 mg)|Subjects applied a nicotine patch (10 mg) in the morning and removed it at bedtime for one day.
1780569|NCT00440518|Drug|Lacosamide|Lacosamide 100mg immediate-release film-coated tablet (white,oval) oral administration twice daily 12 hours apart
1780570|NCT00440518|Other|Placebo|Immediate-release film coated tablet (white, oval), oral administration twice daily 12 hours apart
1780571|NCT00440518|Drug|Lacosamide|Lacosamide 300mg, immediate-release film coated tablet (white,oval), oral administration twice daily 12 hours apart.
1780572|NCT00440531|Biological|Comparator: RECOMBIVAX HB™ Hepatitis B Vaccine (Recombinant)|RECOMBIVAX HB™ (currently licensed product) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
1780573|NCT00440531|Biological|Comparator: Modified Process Hepatitis B Vaccine (Experimental)|Modified Process Hepatitis B Vaccine (Experimental) given IM (Intramuscular) in 3 doses of 10 mcg (micrograms)/1.0 mL each over 6 months.
1780574|NCT00440531|Biological|Comparator: ENGERIX-B™ (currently licensed product)|ENGERIX-B™ given IM (Intramuscular) in 3 doses of 20 mcg (micrograms)/1.0 mL each over 6 months.
1780575|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG naive subjects
1780576|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG naive subjects
1780577|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen in BCG immunized subjects
1780578|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|50 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
1780579|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen in BCG immunized subjects
1780580|NCT00440544|Biological|Ag85B-ESAT6 fusion protein H1|100 ug H1 antigen + LTK63 adjuvant 30 ug in BCG immunized subjects
1780581|NCT00441415|Drug|Adapalene BPO|
1780582|NCT00441428|Drug|solifenacin|
1780583|NCT00441441|Drug|fluticasone propionate|fluticasone propionate 100mcg HFA
1780584|NCT00441441|Drug|fluticasone propionate/salmeterol|fluticasone propionate/salmeterol 100/50mcg HFA
1780585|NCT00441454|Device|Transobturator Tension-free vaginal tape (TVT-O)|tension-free vaginal tape (TVT)
1780586|NCT00441454|Device|Retropubic Tension-free vaginal tape (TVT)|Retropubic Tension-free vaginal tape (TVT)
1780587|NCT00441467|Drug|Glufosfamide|5000 mg/m2 of glufosfamide on Day 1 of each three-week cycle for up to 6 cycles.
1780588|NCT00441480|Dietary Supplement|Plant sterols esters|1.6g phytosterols and 1.3g omega-3 fatty acids per day
1780589|NCT00441480|Dietary Supplement|placebo|4 gr of corn oil
1780590|NCT00441493|Drug|fluvastatin|
1780591|NCT00441506|Drug|daily interruption of sedatives|
1780592|NCT00441519|Drug|aspirin|
1780593|NCT00441519|Drug|omeprazole|
1780594|NCT00441532|Drug|Lidocaine|
1780595|NCT00441545|Drug|Fosrenol (Lanthanum Carbonate)|The starting dose is a total daily dose of 2250mg of Fosrenol (Lanthanum carbonate) to a maximum dose of 3000mg daily. Chewable tablets will be administered orally with meals in 750mg and 1000mg strength tablets.
1780596|NCT00441545|Drug|Sevelamer hydrochloride|The starting dose is a total daily dose of 4800mg of sevelamer hydrochloride up to a maximum of 6400 mg daily. Sevelamer hydrochloride 800mg tablets, administered orally with meals.
1780597|NCT00441558|Drug|Flibanserin|flexible dosing of either 50 or 100mg every evening, or 25 or 50mg twice daily.
1780598|NCT00441571|Drug|177Lu-CYT-500|
1780599|NCT00441584|Biological|PegIntron (peginterferon alfa-2b)|Powder for injection in vial or Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks
1780600|NCT00441584|Drug|Rebetol (ribavirin)|200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 48 weeks
1780601|NCT00441597|Drug|atorvastatin|atorvastatine 80mg, during 3 days
1780602|NCT00441610|Drug|Gimatecan|
1780603|NCT00441623|Behavioral|observational|effect of protein-bound uremic retention solutes
1780604|NCT00441636|Device|continuous positive airway pressure (CPAP)|CPAP (Respironics: RemStar plus M-series) machines for treatment of obstructive sleep apnea training for participant required by registered sleep technologist
1780605|NCT00441649|Drug|Methylphenidate|
1780607|NCT00441675|Procedure|Symptom Score|Symptom Score
1780608|NCT00441675|Procedure|Symptom Score and PD20|Symptom Score and PD20
1780610|NCT00441701|Drug|Navarixin 1 mg|Navarixin 1 mg capsules
1780611|NCT00441701|Drug|Navarixin 10 mg|Navarixin 10 mg capsules
1780612|NCT00441701|Drug|Placebo to match navarixin|Placebo to navarixin capsules
1780613|NCT00441701|Drug|Rescue medication|Salbutamol/albuterol - 2 puffs of salbutamol/albuterol approximately every 4 hours as needed for dyspnea relief
1780614|NCT00441714|Procedure|repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise|
1780615|NCT00441727|Drug|Esomeprazole 40 mg|Esomeprazole 40 mg once daily
1780616|NCT00441727|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
1780617|NCT00441727|Drug|Placebo|Placebo once daily
1780618|NCT00441740|Drug|Vinorelbine|Vinorelbine (oral) 70 mg/m2, on days 1 and 15 every 4 weeks for 6 cycles
1780619|NCT00441740|Drug|Gemcitabine|Gemcitabine 900 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
1780620|NCT00441740|Drug|Docetaxel|Docetaxel 75 mg/m2 intravenous on day 8 every 3 weeks for 6 cycles
1780621|NCT00441740|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 intravenous, on days 1 and 8 every 3 weeks for 6 cycles
1780622|NCT00441766|Drug|AGN 203818|Part A: 3 mg AGN203818 capsule every 12 hours for 4 weeks
1780623|NCT00441766|Drug|AGN 203818|Part A: 20 mg AGN203818 capsule every 12 hours for 4 weeks
1780624|NCT00441766|Drug|AGN 203818|Part A: 60 mg AGN203818 capsule every 12 hours for 4 weeks
1780625|NCT00441766|Drug|placebo|Part A: placebo capsule every 12 hours for 4 weeks
1780626|NCT00441792|Drug|Etomidate|Etomidate at induction dose based on weight
1780627|NCT00441792|Drug|midazolam|Midazolam at induction dose based on weight
1780628|NCT00441805|Device|Radio Frequency|
1780629|NCT00441818|Drug|TNX-650|
1780630|NCT00441844|Drug|Simvastatin|
1780631|NCT00441857|Behavioral|plant stanol consumption|
1780632|NCT00441870|Drug|EC0225, for Injection (Folic acid desacetylvinblastine hydrazide conjugate)|Dose escalation from a starting dose of 0.38mg IV bolus Monday Wednesday and Friday Weeks 1 and 3 of a 4 Week Cycle to the Maximum Tolerated Dose (MTD)
1780633|NCT00441870|Drug|99mTC-EC20 (Folic acid-technetium 99m conjugate)|20-25 mCi 99m Tc-EC20 administered IV 1-2 hours prior to imaging
1780634|NCT00441883|Drug|PF-03187207 and Latanoprost Vehicle|
1780635|NCT00441883|Drug|Latanoprost 0.005% and PF-03187207 Vehicle|
1780636|NCT00441896|Drug|Ganaxolone|
1780637|NCT00441909|Drug|UC-781|0.1% UC-781 Vaginal Gel
1780638|NCT00441909|Drug|UC-781 placebo|Vaginal Gel Placebo
1780639|NCT00441922|Drug|Docetaxel|Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
1780640|NCT00441922|Drug|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
1780641|NCT00441935|Device|Interstim Neuromodulation|Two stage procedure to implant an interstim device for neuromodulation.
1780642|NCT00441948|Device|Peterio|
1780643|NCT00441961|Drug|methotrexate|methotrexate
1780644|NCT00441974|Drug|adefovir dipivoxil|adefovir dipivoxil once daily one tablet 10mg orally
1780645|NCT00441987|Drug|GSI-953|
1780646|NCT00442000|Procedure|Prostatectomy|Patients undergoing prostatectomy.
1780647|NCT00442013|Drug|Lansoprazole|Participants less than 30 kg will receive 15 mg a day, by mouth; participants greater than or equal to 30 kg will receive 30 mg a day, by mouth.
1780648|NCT00442013|Drug|Matching placebo|Participants will receive a placebo pill on a daily basis. To maintain masking, there are two doses of the matching placebo provided to participants depending on participant body weight at randomization: 1.) less than 30kg will receive 15mg po once daily or 2.)greater or equal to 30kg 30mg po once daily.
1780649|NCT00442026|Drug|Docetaxel|Docetaxel at the dose of 30mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
1780650|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 900mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
1780651|NCT00442026|Drug|Gemcitabine|Gemcitabine at the dose of 1200mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
1780656|NCT00442052|Drug|aspirin|
1780657|NCT00442052|Drug|omeprazole|
1780658|NCT00442065|Device|Aorfix™ Stent Grafts (AAA endovascular procedure)|Endovascular treatment of AAA using the Aorfix™ Stent Graft and Delivery System
1780659|NCT00442078|Device|I-STOP TOMS male sling|Bulbus urethral compression with polypropylene mesh
1780660|NCT00442091|Drug|dandelion juice|10 ml bid for 20-30 days
1780661|NCT00442104|Drug|Ganaxolone|
1780662|NCT00442117|Drug|mometasone furoate dry powder inhaler|MF DPI 200 mcg, two puffs once daily PM (total of 400 mcg/day) for 12 weeks.
1780663|NCT00442117|Drug|Budesonide DPI|Budesonide (BUD) DPI 200 mcg, two puffs twice daily (total of 800 mcg/day) for 12 weeks.
1780664|NCT00442130|Biological|GM-K562 vaccine|The vaccine will be administered over 1 cycle of 7 weeks, that begins 1 month after stem cell transplant. The vaccine will be given 6 times over 2 months -- once a week for three weeks then every other week for 3 vaccines.
1780665|NCT00442130|Procedure|stem cell transplantation|Participants will be admitted to the hospital for approximately 8 days to receive chemotherapy and stem cell transplantation
1780666|NCT00442143|Procedure|Stem cell implantation|
1780734|NCT00442715|Procedure|Exercise chalenge test|
1957025|NCT02590757|Device|NIV-NAVA|Non-invasive neurally adjusted ventilatory assist
1957026|NCT02590757|Device|N-CPAP|Nasal-continuous positive airway pressure
1780667|NCT00442156|Procedure|Laser photocoagulation|modified ETDRS focal photocoagulation generally completed in a single sitting on the day of enrollment, but if little or no improvement, may be repeated at 16 weeks
1780668|NCT00442169|Biological|ChimeriVax-WN02 Low Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region.
1780669|NCT00442169|Biological|ChimeriVax-WN02 Medium Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
1780670|NCT00442169|Biological|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
1780671|NCT00442169|Biological|0.9% Saline solution|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
1780672|NCT00442169|Biological|ChimeriVax-WN02 High Dose|Single dose formulation given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
1780673|NCT00442169|Biological|0.9 % NaCl solution|Single dose given in a volume of 0.5 mL by subcutaneous injection to the deltoid region
1780674|NCT00442182|Drug|ITF2357|
1780675|NCT00442208|Drug|PN 200|
1780676|NCT00442221|Drug|Sumatriptan and Naproxen sodium|
1780677|NCT00442234|Drug|Monteplase|
1780678|NCT00442247|Device|Pelvicol|
1780679|NCT00442260|Drug|DOXIL|
1780680|NCT00442260|Drug|Abraxane|
1780681|NCT00442273|Drug|Umbilical cord serum eyedrops|
1780682|NCT00442273|Drug|Autologous serum eyedrops|
1780683|NCT00442286|Device|Rheos® Baroreflex Hypertension System|Electrical activation of the Carotid Baroreflex
1780685|NCT00442312|Drug|Combigan Ophthalmic Solutiom|
1780686|NCT00442325|Drug|Atorvastatin (Lipitor)|
1780687|NCT00442338|Drug|montelukast sodium|Montelukast 7 mg single injection (IV bolus administration) over 2-3 minutes
1780688|NCT00442338|Drug|montelukast sodium|Montelukast 14 mg single injection (IV bolus administration) over 5 minutes
1780689|NCT00442338|Drug|aminophylline hydrate|Aminophylline 250 mg IV drip infusion over 60 minutes
1780690|NCT00442351|Drug|Asmanex twisthaler|Asmanex Twisthaler 220 mcg provided once daily in the evening for 12 weeks
1780691|NCT00442351|Other|Placebo for Asmanex twisthaler|Placebo for Asmanex Twisthaler 220 mcg, once daily in the evening for 12 weeks
1780692|NCT00442364|Drug|Polidocanol (1%) Microfoam (Varisolve)|Varisolve polidocanol 1% microfoam, maximum of 20ml injected into affected great saphenous vein.
1780693|NCT00442364|Procedure|Endovenous Microfoam Occlusion|Varisolve® polidocanol microfoam injection under duplex guidance to fill proximal and distal great saphenous vein and varicose tributaries.
1780694|NCT00442377|Procedure|exposure to malaria sporozoites|
1780695|NCT00442390|Drug|hydrocortisone substitution therapy versus withdrawal|
1780696|NCT00442403|Drug|chloroquine|
1780697|NCT00442403|Drug|dehydroepiandrosterone sulphate|
1780698|NCT00442416|Drug|Epoetin alfa|As prescribed, SC
1780699|NCT00442416|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120-360 micrograms SC monthly, starting dose
1780700|NCT00442442|Device|mosquito coils|mosquito coil / night mosquito coil & LLIN / night
1780701|NCT00442442|Device|LLIN|Sleep under LLIN every night
1780702|NCT00442455|Drug|Erlotinib chlorhydrate|150 mg/day for 7 weeks
1780703|NCT00442455|Drug|Cisplatin|30 mg/m2 i.v. weekly for 7 weeks
1780704|NCT00442455|Procedure|Radiation therapy|63 Gy, five days a week, for 7 weeks
1780705|NCT00442468|Other|Non-interventional study.|This is a non-interventional (no drug treatment administered), prevalence (observational) study.
1780706|NCT00442481|Drug|Escitalopram|
1780707|NCT00442481|Procedure|A baseline overnight polysomnography (oPSG)|
1780709|NCT00442507|Drug|Erlotinib|
1780710|NCT00442507|Drug|Avastin|
1780711|NCT00442533|Drug|Indium-111 pentetreotide|4 cycles of 500 mCi treatments every 10-12 weeks
1780712|NCT00442546|Drug|pregabalin|150 milligram (mg)/ day (double blind)
1780713|NCT00442546|Drug|pregabalin|300 mg/day (double blind)
1780714|NCT00442546|Drug|Placebo|Placebo
1780715|NCT00442559|Drug|montelukast sodium|Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
1780716|NCT00442559|Drug|inhaled corticosteroid|Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months
1780717|NCT00442572|Drug|PEGASYS [peginterferon alfa-2a]|There were 4 treatment cycles of continuous intermittent treatment with Peginterferon alfa-2a. Each cycle consisted of 12 weeks injection treatment with Peginterferon alfa-2a 135 micrograms in 0.5 ml solution in prefilled syringes, applied once weekly subcutaneously and followed by 12 weeks period without treatment.
1780718|NCT00442585|Drug|S(+)-ibuprofen|
1780719|NCT00442598|Drug|Glufosfamide|
1780724|NCT00442650|Drug|Efalizumab|
1780725|NCT00442663|Device|Transcervical Foley Catheter|
1780726|NCT00442663|Device|Transcervical Foley Catheter with an EASI|
1780727|NCT00442676|Drug|Celecoxib|Capsule, 200 mg/day until 32 weeks of gestation
1780728|NCT00442676|Drug|Placebo|Gelatin capsules of lactose
1780729|NCT00442689|Drug|flutamide|250 mg twice daily
1780730|NCT00442689|Drug|ethinyl estradiol 35 mcg and drospirenone 3 mg|one active pill per day for three weeks and then 1 sugar pill per day for one week
1780731|NCT00442689|Other|placebo|
1780732|NCT00442702|Drug|Mircera|Starting dose of 120, 200 and 360 micrograms administered by subcutaneous injection once a month.
1780733|NCT00442702|Drug|Darbepoetin alfa|As prescribed, subcutaneous injection once every week, once every 2 weeks or once every month as per local labeling specifications.
1780735|NCT00442728|Device|ELECTRICAL STIMULATION|
1780736|NCT00442741|Drug|Patupilone|
1780737|NCT00442741|Drug|Patupilone + Omeprazole|
1780738|NCT00442754|Biological|Allogeneic Tumour Lysate (MelCancerVac)|subcutaneaus, /once weekly /4 wks then /4 weekly
1780739|NCT00442767|Drug|Pramlintide acetate|Pramlintide given before meal and insulin given after meal
1780740|NCT00442780|Drug|BIIB014|oral administration of BIIB014 per dose, schedule,and duration specified in protocol
1780741|NCT00442780|Drug|Placebo|Oral administration of placebo matched to BIIB014 dose level; placebo to follow same dosing schedule as BIIB014
1780742|NCT00442793|Drug|Epoetin beta|As prescribed, 3 times weekly
1780743|NCT00442793|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|0.4 micrograms/kg iv every 2 weeks
1780744|NCT00442806|Drug|Injection of ADRC's|ADRC's are injected
1780745|NCT00442806|Other|Injection of Placebo|Placebo is injected
1780746|NCT00442819|Procedure|Hemodialysis with Polymethylmethacrylate Artificial Kidney|
1780747|NCT00442832|Drug|TD-1792|TD-1792 2 mg/kg/day IV
1780748|NCT00442832|Drug|Vancomycin|Vancomycin 1 Gm IV q 12 hrs
1780749|NCT00442845|Drug|Atorvastatin (Lipitor)|
1780750|NCT00442871|Drug|eltrombopag|eltrombopag 50 mg oral
1780751|NCT00442884|Behavioral|Trier Social Stress Test (TSST)|
1780752|NCT00442897|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20mg, tablet, once daily, 12wks(sub group:24wks)
1780753|NCT00442897|Drug|Comparator: atorvastatin|atorvastatin 10mg, tablet, once daily, 12wks(sub group:24wks)
1780754|NCT00442910|Drug|3% SPL7013 Gel (VivaGel)|3% vaginal gel
1780755|NCT00442910|Drug|Placebo Gel|Placebo for SPL7013 gel
1780756|NCT00442910|Drug|HEC Placebo Gel|HEC Placebo gel intravaginally bd for 14 days
1780757|NCT00442923|Drug|Coreg|
1780758|NCT00442936|Drug|Telcagepant potassium 150 mg|Telcagepant 150 mg liquid-filled soft gel capsules
1780759|NCT00442936|Drug|Telcagepant potassium 300 mg|Telcagepant 300 mg liquid-filled soft gel capsules
1780760|NCT00442936|Drug|Zolmitriptan 5 mg|Zolmitriptan 5 mg tablets
1780761|NCT00442936|Drug|Placebo to telcagepant 150 mg|Placebo to match telcagepant 150 mg liquid-filled soft gel capsules
1780762|NCT00442936|Drug|Placebo to tecagepant 300 mg|Placebo to match tecagepant 300 mg liquid-filled soft gel capsules
1780763|NCT00442936|Drug|Placebo to zolmitriptan 5 mg|Placebo to match zolmitriptan 5 mg tablets
1780764|NCT00442936|Drug|Rescue medication|If moderate or severe migraine headache pain continues or recurs 2 hours after dose of study drug, participants are allowed to take an optional second dose of study drug or their own non-study rescue migraine medication, which may include analgesics (e.g., nonsteroidal anti-inflammatory drugs [NSAIDs] or opiates), anti-emetics, or zolmitriptan. Triptans other than zolmitriptan and ergot derivatives are prohibited for 24 hours following the last dose of study drug.
1780765|NCT00442949|Procedure|Catheterization immediate PCI|Catheterization immediate PCI
1780766|NCT00442949|Procedure|delayed PCI|delayed PCI
1780767|NCT00442962|Drug|Efavirenz|600-mg tablet taken orally daily
1780768|NCT00442962|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine/300-mg tenofovir disoproxil fumarate tablet taken orally once daily
1780769|NCT00442975|Biological|Fluarix|
1780770|NCT00443001|Device|Non invasive blood pressure monitor|Updated device and software to improve performance in patients with dysrhythmia
1780771|NCT00443014|Device|Cognitive, physical and social stimulation|Sessions of 30 minutes daily five days a week for one year
1780772|NCT00443027|Device|Vaginal Heat Wash-Out Device|No drug administered. Device tested three times with each subject.
1780773|NCT00443040|Drug|Asimadoline|Asimadoline was provided in coated tablets of 1.0 mg strength. Subjects were given 3 tablets of study drug 90 minutes prior to their operation and then 3 tablets b.i.d. for up to 10 post-operative doses. Subjects randomized to receive 3.0 mg of asimadoline received three 1.0 mg asimadoline tablets at each scheduled dose, while those randomized to receive 1.0 mg of asimadoline received two placebo tablets and one 1.0 mg asimadoline tablet at each scheduled dose.
1780774|NCT00443040|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets. Subjects were given 3 tablets of placebo 90 minutes prior to their operation and then 3 placebo tablets b.i.d. for up to 10 post-operative doses.
1780775|NCT00443053|Drug|Fondaparinux 2.5mg or placebo|Fondaparinux 2.5mg or matching placebo subcutaneously once daily up to day 45 day
1780776|NCT00443079|Drug|IdB 1016 (Siliphos)|1 pill 3 times daily x 3 months
1780777|NCT00443092|Other|proprietary cherry juice blend (food)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
1780778|NCT00443092|Other|control juice (kool aid blend)|2 bottles per day for 6 weeks, 1 in the morning and 1 in the evening
1780779|NCT00443105|Drug|Tacrolimus 0.03% ointment (Protopic)|
1780780|NCT00443118|Device|T-piece resuscitator Neopuff TM|Positive pressure ventilation will be performed with Neopuff® with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
1780781|NCT00443118|Device|Self Inflating Bag with PEEP|Positive pressure ventilation will be performed with Self Inflating Bag with PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
1780782|NCT00443118|Device|Self Inflating Bag without PEEP|Positive pressure ventilation will be performed with Self Inflating Bag without PEEP with face mask. For this study, an initial PIP 25 cm H2O and a 5 cm H2O PEEP will be used for resuscitation according to protocol.
1780783|NCT00443131|Biological|GSK Malaria vaccine 257049|Three-dose vaccination by slow intramuscular injection. Three different formulations of this vaccine are tested (without adjuvant, with adjuvant AS01B, with adjuvant AS02A).
1780784|NCT00443144|Drug|recombinant human growth hormone|
1780785|NCT00443157|Biological|Meningococcal B Vaccine NZ|
1780786|NCT00443170|Drug|GSK626616, placebo, midazolam|
1780787|NCT00443170|Drug|omeprazole, caffeine, flurbiprofen, rosiglitazone|
1780788|NCT00443183|Behavioral|Brief Negotiation Interview (BNI)|The Brief Negotiation Interview is a manual guided intervention using techniques based on motivational interviewing, brief advice, and behavioral contracting and is designed to be delivered in less than 10 minutes.
1780789|NCT00443183|Behavioral|Discharge Instructions|Used as a placebo comparator, scripted discharge instructions are to be read by emergency practitioner and designed to be less than 1 minute in length.
1780790|NCT00443196|Procedure|MiCK Assay|Physician determined treatment
1780791|NCT00443209|Drug|Telcagepant 300 mg soft gel capsules|One capsule taken orally at onset of migraine
1780792|NCT00443209|Drug|Telcagepant 280 mg tablets|One tablet taken orally at onset of migraine
1780793|NCT00443209|Drug|Rizatriptan 10 mg tablets|One tablet taken orally at onset of migraine
1780794|NCT00443209|Drug|Placebo to telcagepant capsules|One capsule taken orally at onset of migraine
1780795|NCT00443209|Drug|Placebo to telcagepant tablets|One tablet taken orally at onset of migraine
1780796|NCT00443209|Drug|Placebo to rizatriptan tablets|One tablet taken orally at onset of migraine
1780797|NCT00443222|Drug|Infliximab|
1780798|NCT00443235|Drug|Melphalan/Prednisone/Velcade|"One cycle:
Melfalan, 9 mg/m2 v.o days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4 Velcade, 1,3 mg/m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32) Five cycles: Melfalán, 9 mg/m2 vo, days 1 to 4 Prednisone, 60 mg/m2 v.o days 1 to 4, Velcade,1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
1780799|NCT00443235|Drug|Thalidomide/Prednisone/Velcade|"One cycle:
Thalidomide,day 1 cycle 1 v.o (50 mg). If toxicity < grade 2, dose will be increased to 100 mg on day 15 cycle 1 Prednisona, 60 mg/m2 vo, days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 4, 8, 11, 22, 25, 29 and 32)
Five cycles:
Thalidomide, 100 mg vo all days, Prednisone, 60 mg/m2 vo days 1 to 4, Velcade, 1,3 mg/ m2 iv (days 1, 8, 15 and 22)"
1780800|NCT00443248|Device|Vaginal Heat Wash-Out Device|No drug administered. Device tested twice with each subject.
1780801|NCT00443261|Drug|Azacitidine|SC azacitidine
1780802|NCT00443261|Drug|Cisplatin|cisplatin 75 mg/m^2 day 8 every 28 days
1780803|NCT00443274|Other|NBIR Placeholder|
1780804|NCT00443274|Device|410 Arm|
1780805|NCT00443274|Device|BIFs|
1780806|NCT00443287|Drug|ataciguat (HMR1766)|oral administration
1780807|NCT00443287|Drug|placebo|oral administration
1780808|NCT00443287|Drug|cilostazol|oral administration
1780809|NCT00443326|Drug|AMG 714|Dosing Regimen is 6 Doses over 3 Months
1780810|NCT00443339|Drug|Darbepoetin|
1780811|NCT00443352|Drug|duloxetine|Duloxetine: 120 mg. daily or maximum tolerated dose (minimum: 60 mg per day)
1780812|NCT00443365|Procedure|Mitral valve repair|mitral valve annuloplasty
1780813|NCT00443378|Behavioral|CARE+|CARE+ is a .NET based application on tablet computers that comprises risk assessment, medication monitoring, tailored feedback, stage-based skills-building videos, motivational interviewing counseling, an integrated health promotion plan, and printout with referrals. Evidence-based approaches (pharmacist education, self-efficacy/importance scaling exercises, and consequence-framing) are incorporated.
1780814|NCT00443391|Drug|ABT-089|Open label study, subjects will take up to 80mg daily for 24 months.
1780815|NCT00443404|Procedure|perioperative epidural catheter|Perioperative epidural catheter in groups 1-4. Pre- and postoperative epidural analgesia in group 1. Preoperative IV PCA Fentanyl and postoperative epidural analgesia in group 2. Perioperative IV PCA Fentanyl in groups 2,3. IM meperidine p.o. codeine/acetaminophen, IV acetaminophen and IV parecoxib in group 5 (control)
1780816|NCT00443417|Drug|SK-PC-B70M|dosage, frequency
1780817|NCT00443430|Drug|methotrexate|Methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus placebo etanercept and and placebo prednisolone
1780818|NCT00443430|Drug|methotrexate - etanercept - prednisolone arm|methotrexate 0.5 mg/kg given by sub cutaneous injection once per week, plus etanercept 0.8 mg/kg given by sub cutaneous injection once per week, plus prednisolone, by mouth daily with decreasing dose tapered over 16 weeks.
1780819|NCT00443456|Drug|Amlodipine|Two tablets of amlodipine 5 mg, Oral administration, Once daily for 44 weeks
1780820|NCT00443469|Device|magnetic stimulation|SMS was delivered with a repetitive magnetic stimulator connected to a figure of eight coil capable of delivering a maximum output of 2 Tesla per pulse. The coil measured 90 mm in each wing and was centered over the surface landmark corresponding to the cauda equina region. SMS was performed with the patient lying comfortably in the prone position and a soft pillow supported the lower abdomen. The coil was placed flat over the back with the handle pointing cranially. Each patient on active treatment received 200 trains of 5 pulses delivered at 10 Hz, at an interval of 5 s between each train. As this was a pilot study, each only received 1000 pulses in a single session.
1780821|NCT00443469|Device|Magnetic Stimulation with tilted coil|The placebo arm consisted of 'sham' SMS delivered with the coil angled vertically and one of the wing edges in contact with the stimulation point. As this coil type allows maximum magnetic flux at the center of the intersection, we believe minimum or no stimulation was effected at the edge of the coil in contact with the patient. Stimulation parameters and duration were unchanged in this arm.
1780822|NCT00443482|Drug|formoterol|
1780823|NCT00443495|Drug|Chitin microparticles by nasal route|
1780824|NCT00443508|Drug|adding Certican to therapy|
1780825|NCT00443508|Drug|reducing Tacrolimus|
1780826|NCT00443521|Drug|Triamcinolone Acetonide 4 mg intravitreal injection|
1780827|NCT00443521|Procedure|Panretinal photocoagulation|
1780828|NCT00443534|Drug|SU011248|Administered orally in doses ranging from 25 to 50 mg once daily; dosing schedule and dosage depends on the patients dosing from the prior protocol
1780829|NCT00443547|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Patient will receive the Vectra-T plate (Sized 1 to 4 levels)
1780830|NCT00443560|Other|Case controlled analysis of epidural labor analgesia patterns|A retrospective study utilizing the Obstetric Anesthesiology Database to identify parturients who received neuraxial labor analgesia initiated with a combined spinal epidural (CSE) technique and maintained with a continuous epidural infusion with patient controlled epidural analgesia boluses
1780831|NCT00443573|Drug|recombinant nematode anticoagulant protein c2 (rNAPc2)|escalating dose administered 2x/week sq.
1780832|NCT00443586|Behavioral|Developmental Screening|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at ages 12 and 24 months of age
1780875|NCT00443820|Drug|Placebo|Vehicle (placebo) once daily for 48 weeks
1780876|NCT00443820|Drug|terbinafine|Terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis once daily for 24 weeks
1780833|NCT00443586|Behavioral|Screening plus Transportation|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2.
1780834|NCT00443586|Behavioral|Screening, Transport, Prenatal Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy.
1780835|NCT00443586|Behavioral|Screen, Transport, Prenatal/Inf Visits|Child participants were screened for sensory and developmental problems and referred for further evaluation and treatment at 12 and 24 months of age; their mothers were provided with free transportation for prenatal and well-child care through child age 2, and were provided an average of 9 home visits by nurses during pregnancy and 23 during the child's first two years of life.
1780836|NCT00443599|Drug|Insulin|Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
1780837|NCT00443599|Other|Usual Care|Participants receive standard Cardiac ICU care without tight blood glucose control.
1780838|NCT00443612|Drug|Irbesartan/Hydrochlorothiazide|Administration of irbesartan 150 mg/day + hydrochlorothiazide 12.5 mg
1780839|NCT00443612|Drug|Irbesartan|Administration of irbesartan 150 mg/day
1780840|NCT00443625|Drug|SK3530|
1780841|NCT00443638|Behavioral|nurse home visitation|Nurse home visitation
1780842|NCT00443651|Drug|Rituximab|Rituximab was supplied as a concentrate for IV administration at a concentration of 10 mg/mL in 500 mg (50 mL) single-use vials.
1780843|NCT00443651|Drug|Anti-inflammatory drugs|Each rituximab infusion was preceded by methylprednisolone 100 mg IV. Use of stable doses of oral corticosteroids was permitted (≤ 10 mg of prednisone or equivalent per day) as were stable doses of nonsteroidal anti-inflammatory drugs (NSAIDs).
1780844|NCT00443664|Device|EXTERNAL MICROPULSE DIODE LASER TRANSSCLERAL TRABECULOPLASTY|
1780845|NCT00443677|Drug|COPPEBVCAD vs BEACOPP vs ABVD|
1780846|NCT00443690|Drug|rolofylline|rolofylline 30 mg IV QD; 3 days
1780847|NCT00443690|Drug|Comparator: Placebo (unspecified)|rolofylline Pbo 30 mg IV QD; 3 days
1780848|NCT00443703|Drug|MK0518 (raltegravir)|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
1780849|NCT00443703|Drug|Comparator: KALETRA™ (lopinavir (+) ritonavir )|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment.
1780850|NCT00443703|Drug|Comparator: placebo|MK0518 (raltegravir) 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
1780851|NCT00443703|Drug|Comparator: placebo|KALETRA™ (lopinavir (+) ritonavir ) 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment.
1780852|NCT00443716|Drug|estrogen|
1780853|NCT00443729|Drug|Comparator: raltegravir|raltegravir 400 milligram (mg) by mouth (PO) twice daily (b.i.d) for up to 48 weeks of treatment
1780854|NCT00443729|Drug|Comparator: placebo|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
1780855|NCT00443729|Drug|Comparator: lopinavir (+) ritonavir|lopinavir (+) ritonavir 400/100 mg by mouth (PO) twice daily (b.i.d.) for up to 48 weeks of treatment
1780856|NCT00443729|Drug|Comparator: placebo|raltegravir 400 mg by mouth (PO) twice daily (b.i.d.) Placebo for up to 48 weeks of treatment
1780857|NCT00443742|Procedure|Validation|
1780858|NCT00443755|Drug|metformin|To minimize side effects the metformin will be initiated at 500 mg twice daily with meals and increased to 1 gm twice daily with meals after two weeks and continue to a total of 3 months of dosing.
1780859|NCT00443755|Drug|pioglitazone|To minimize side effects, the pioglitazone will be initiated at 30 mg daily and increased to 45 mg daily after two weeks, and continue to a total of 3 months of dosing.
1780860|NCT00443755|Drug|Placebo|Placebo tablets matching the metformin and pioglitazone tablets are given in the same regimen as the active drug arm for 3 months.
1780863|NCT00443794|Drug|Thiazides|Capsule (blinded) oral administration once daily for 12 weeks
1780864|NCT00443794|Drug|Ramipril with Thiazide|Capsule (blinded) oral administration 12 weeks
1780865|NCT00443794|Drug|Thiazide plus atenolol|Caspule (blinded) for oral administration once daily for 12 weeks
1780866|NCT00443794|Drug|Ramipril plus atenolol|Capsule ( blinded) for oral administration once daily for 12 weeks
1780867|NCT00443794|Drug|Ramipril plus atenolol plus thiazide|Capsule (blinded) for oral administration once daily for 12 weeeks
1780868|NCT00443794|Drug|POLYCAP|Capsule for Oral Administration once daily for 12 weeks
1780869|NCT00443794|Drug|Thiazide + Ramipril+Atenolol+Aspirin|Capsule (Blinded) for oral administration once daily for 12 weeks
1780870|NCT00443794|Drug|Simvastatin|Capsule (Blinded) for oral administration once daily for 12 weeks
1780871|NCT00443794|Drug|aspirin|capsule (Blinded) for oral administration once daily for 12 weeks
1780872|NCT00443807|Device|On-line EEG monitoring during neurosurgery|Comparison of 2 ways of processing the EEG signal
1780873|NCT00443807|Device|EEGo vs BIS|comparison of two processed EEG monitors.
1780874|NCT00443820|Drug|terbinafine|Terbinafine hydrochloride (HCl) 10 % nail solution for onychomycosis (NSO) once daily for 48 weeks
1957032|NCT02586051|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) IV infusion.
1957033|NCT02586051|Drug|Intravenous Immunoglobulin|High dose (2 grams per kilogram [g/kg]) IVIG (maximum 140 grams).
1780877|NCT00443820|Drug|Placebo|Vehicle (placebo) once daily for 24 weeks
1780880|NCT00429988|Genetic|fluorescence in situ hybridization|
1780881|NCT00429988|Genetic|polymerase chain reaction|
1780882|NCT00429988|Genetic|proteomic profiling|
1780883|NCT00429988|Other|cytology specimen collection procedure|
1780884|NCT00429988|Other|immunohistochemistry staining method|
1780885|NCT00429988|Procedure|breast duct lavage|
1780886|NCT00430001|Drug|docetaxel|
1780887|NCT00430001|Drug|vinorelbine|
1780888|NCT00430001|Drug|trastuzumab|
1780889|NCT00430014|Drug|Atiprimod|Starting Dose of 60 mg/day orally for 14 days of 28 day cycle.
1780890|NCT00430027|Drug|Capecitabine|Given 650 mg/m^2 BID on days of ration therapy, 825 mg/m^2 day 1-14, day 15-20 off x 4
1780891|NCT00430027|Drug|Oxaliplatin|Oxaliplatin 30 mg/m^2, 130mg/m2 IV Q 21 days x 4
1780892|NCT00430027|Drug|Cetuximab|Initial Cetuximab 400 mg/m^2 IV starting no earlier than 8 weeks and no later than 10 weeks after surgical resection
1780893|NCT00430040|Drug|carvedilol|carvedilol
1780894|NCT00430040|Drug|lisinopril|lisinopril
1780895|NCT00430053|Genetic|gene rearrangement analysis|
1780896|NCT00430053|Genetic|polymerase chain reaction|
1780897|NCT00430053|Genetic|proteomic profiling|
1780898|NCT00430053|Other|flow cytometry|
1780899|NCT00430053|Other|immunohistochemistry staining method|
1780900|NCT00430053|Procedure|biopsy|
1780901|NCT00430066|Drug|Imatinib Mesylate|400 mg/die for 6 months
1780902|NCT00430079|Drug|etanidazole|Given IV
1780903|NCT00430079|Procedure|conventional surgery|Undergo surgery
1780904|NCT00430079|Other|pharmacological study|Correlative studies
1780905|NCT00430079|Other|laboratory biomarker analysis|Correlative studies
1780906|NCT00430092|Drug|Difluprednate|
1780907|NCT00430092|Drug|Difluprednate|
1780908|NCT00430092|Drug|Placebo|
1780909|NCT00430105|Drug|cyclophosphamide|
1780910|NCT00430118|Drug|asparaginase|
1780911|NCT00430118|Drug|cyclophosphamide|
1780912|NCT00430118|Drug|cytarabine|
1780913|NCT00430118|Drug|daunorubicin hydrochloride|
1780914|NCT00430118|Drug|dexamethasone|
1780915|NCT00430118|Drug|doxorubicin hydrochloride|
1780916|NCT00430118|Drug|etoposide|
1780917|NCT00430118|Drug|ifosfamide|
1780918|NCT00430118|Drug|mercaptopurine|
1780919|NCT00430118|Drug|methotrexate|
1780920|NCT00430118|Drug|prednisone|
1780921|NCT00430118|Drug|thioguanine|
1780922|NCT00430118|Drug|vincristine sulfate|
1780923|NCT00430118|Drug|vindesine|
1780924|NCT00430118|Radiation|radiation therapy|
1780925|NCT00430131|Procedure|Cognitive Orientation to Occupational Performance|
1780926|NCT00430131|Procedure|Contemporary Treatment Approach|
1780927|NCT00430144|Drug|Belotecan(CKD-602)|Belotecan was administrated at 0.5 mg/m(2)/day for 5 consecutive days every 3-week cycle
1780928|NCT00430157|Drug|GSK256066|
1780929|NCT00430170|Drug|Dipyridamole|Dipyridamole 2x200mg 7day per os
1780930|NCT00430170|Drug|caffeine|caffeine 4mg/kg iv
1780931|NCT00430183|Drug|docetaxel|75 mg/m^2 will be administered intravenously over one hour on Day 1 of each cycle, every 21 days
1780932|NCT00430183|Drug|LHRH agonist|Given intramuscularly
1780933|NCT00430183|Procedure|surgery|Patients undergo radical prostatectomy with staging pelvic lymphadenectomy.
1780934|NCT00430196|Drug|BOTOX®|
1780935|NCT00430196|Drug|Zanaflex®|
1780936|NCT00430235|Drug|BAY 43-9006|BAY 43-9006, 400 mg, PO, BID in a 28-day cycle(morning and evening) Bicalutamide 50 mg po Once daily in a 28-day cycle (morning)
1780937|NCT00430248|Drug|Febuxostat|Febuxostat 40 mg, capsules, orally, once daily for up to 6 months.
1780938|NCT00430248|Drug|Febuxostat|Febuxostat 80 mg, capsules, orally, once daily for up to 6 months.
1780939|NCT00430248|Drug|Allopurinol|"Allopurinol 200 mg or 300 mg, capsules, orally, once daily for up to 6 months.
Dose is dependent on the subject's renal function. Subjects with normal renal function or mild renal impairment received 300 mg once daily; subjects with moderate renal impairment received 200 mg once daily."
1780940|NCT00430261|Drug|sunitinib|50mg po qd x 4 weeks on followed by 2 weeks off for a 6 week cycle.
1780941|NCT00430300|Drug|UK-432,097|Formulated as a dry powder, supplied as capsules and administered using an atomizer device. Given as either 150mcg, 450mcg or 1350mcg BID.
1780942|NCT00430300|Drug|Placebo|Capsules containing 100% lactose administered BID using an atomizer device
1780943|NCT00430313|Procedure|Electro-Stimulation of Yongquan (K1) Acupoint|Electro-stimulation at an active (responsive) acupuncture site on the bottom of the foot.
1780944|NCT00430313|Procedure|Electro-Stimulation of Yongquan (K1) Acupoint|"Electro-stimulation at a inactive site on the bottom of the foot (a placebo site)."
1780945|NCT00430326|Drug|Avotermin|
1780946|NCT00430352|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 8 weeks
1780947|NCT00430365|Drug|lenalidomide|oral drug
1780948|NCT00430365|Drug|placebo|oral placebo
1780949|NCT00430378|Procedure|Acupuncture|Acupuncture for 20 minutes before the radiation therapy session, 3 days a week for 7 weeks.
1780950|NCT00430378|Other|Standard Care|No Acupuncture.
1780951|NCT00430391|Other|DVD Consent|Participants are randomized to DVD enhanced consent that is either high risk or low risk.
1780952|NCT00430391|Other|Routine Control|Participants are assigned to the routine, standard consent.
1780953|NCT00430404|Other|Collaborative care (Intervention)|Structured shared care with treatment protocol & support
1780954|NCT00430430|Procedure|High MUFA dietary portfolio|high monounsaturated fat background diet to dietary portfolio
1780955|NCT00430430|Procedure|Low MUFA dietary portfolio|low monounsaturated fat background diet to dietary portfolio
1780956|NCT00430443|Drug|Liposomal Annamycin|3-day IV infusion
1780957|NCT00430456|Procedure|Exercise|Treadmill Training
1780958|NCT00430469|Drug|human lactoferrin (hLF1-11)|intravenous 0.5mg in NaCl-solution
1780961|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 21 weeks.
1780962|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 21 weeks.
1780963|NCT00430495|Drug|Atacicept|Atacicept was administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
1780964|NCT00430495|Drug|Placebo matched to atacicept|Placebo matched to atacicept was administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
1780965|NCT00430508|Drug|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets and placebo|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) Tablet 40mg/0mg + 20mg/12.5mg matching placebo tablet once daily for 8 week
1780966|NCT00430508|Drug|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/12.5mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
1780967|NCT00430508|Drug|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 40mg/25mg + 20mg/12.5mg matching placebo tablet once daily for 8 weeks
1780968|NCT00430508|Drug|olmesartan medoxomil/hydrochlorothiazide tablets|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ) tablets 20mg/12.5mg + 40mg/0mg matching placebo tablet once daily for 8 weeks
1957038|NCT02583425|Drug|DFN-11 Injection|
1957039|NCT02582593|Device|MedX 1116 Rehab Console|This intervention makes use of transcranially applied near infrared light using light emitting diodes. Near infrared light will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
1780971|NCT00430534|Biological|EBV vaccine (268664)|
1780972|NCT00430547|Drug|Carbimazole, radio-active iodine (I131)|
1780973|NCT00430560|Behavioral|cognitive rehabilitation|computer training
1780974|NCT00430560|Procedure|work therapy|opportunity to work in carefully supervised hospital job
1780975|NCT00430560|Behavioral|work therapy|work therapy
1780976|NCT00430573|Drug|D-cycloserine|Single dosage prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
1780977|NCT00430573|Drug|Placebo|Single dosage prior to each of 6 sessions of CBT-IC treatment (sessions 5-10)
1780978|NCT00430586|Drug|Botulinum neurotoxin type A, free of complexing proteins|Single treatment with 10, 20 or 30 Units of NT 201 given as intramuscular treatment injections of equal amount to 5 sites on Day 0. The same volume of reconstituted study medication (0.6 mL per subject) was administered irrespective of the treatment group. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL study medication per injection site.
1780979|NCT00430586|Drug|Placebo|Single treatment with Placebo given as intramuscular treatment injections of equal amount to 5 sites on Day 0. A volume of reconstituted 0.6 mL per subject was administered. The total dose volume was administered in equal aliquots to the 5 injection sites. Thus, each of the 5 injection sites was injected with 0.12 mL Placebo per injection site.
1780980|NCT00430625|Biological|VPRIV ®,|Intravenous (IV) infusion, every other week via intravenous infusion for 12 months
1780981|NCT00430638|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|olmesartan medoxomil + hydrochlorothiazide, if necessary. Oral tablets administered for once daily for 12 weeks
1780982|NCT00430638|Drug|Placebo|Oral tablets administered for once daily for 12 weeks
1780983|NCT00430651|Drug|Docetaxel|Docetaxel 50 mg/m2 IV on days 1 and 15 every 28 days for 6 cycles
1780984|NCT00430651|Drug|Carboplatin|Docetaxel 50 mg/m2 IV over 1 hour followed by Carboplatin 4 AUC IV over 1 hour on days 1 and 15
1780985|NCT00430664|Procedure|Pleurodesis with either talc or iodopovidone|
1780986|NCT00430677|Drug|Corticosteroids (prednisone or prednisolone)|tablets, oral, 0.5-0.8 mg/kg, daily
1780987|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 30 mg/kg, every 28 days
1780988|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
1780989|NCT00430677|Drug|Mycophenolate mofetil (MMF)|tablets, oral, 1.5 to 2 g, daily
1780990|NCT00430677|Drug|Abatacept|intravenous solution, injectable, 10 mg/kg, every 28 days
1780991|NCT00430690|Procedure|acoustic startle testing|acoustic startle testing: listening to sounds through headphones while the eyeblink component of the acoustic startle reflex is recorded with small surface electrodes
1780992|NCT00430703|Behavioral|body weight support treadmill training|Gait training: Gait robot (Lokomat®, Hocoma, Switzerland) is adjusted to the patient/healthy volunteer individually with chest strap, pelvic straps, harness, leg cuffs and foot lifters. Weight is adjusted individually, so there is a minimum weight support (i.e. when one foot is standing on the treadmill the other foot lifts free from the treadmill thereby simulating normal gait). Gait speed is 1,7-2,3 km/hour (speed can be changed and adjusted that the normal step length is achieved).The duration of the training session is 20 minutes.Blood pressure and pulse are monitored.
1780993|NCT00430716|Drug|Sildenafil citrate|oral, 20 mg, tid
1780994|NCT00430716|Drug|Sildenafil citrate|oral 1 mg, tid
1780995|NCT00430716|Drug|Sildenafil citrate|oral 5 mg, tid
1780996|NCT00430716|Drug|Sildenafil citrate|oral 20 mg, tid
1780997|NCT00430729|Drug|Roflumilast|
1780998|NCT00430742|Drug|Taranabant|Taranabant 0.5 mg, 1 mg capsule, 2 mg capsule once daily Treatment for 52 weeks.
1780999|NCT00430742|Drug|Comparator: Placebo|Placebo capsule once daily. Treatment for 52 weeks.
1781066|NCT00431288|Behavioral|diet high in fruits, vegetables, and dairy|
1781067|NCT00431288|Behavioral|Routine nutrition care|
1781068|NCT00431327|Behavioral|Peer coach phone call|
1781069|NCT00431340|Drug|PXD101|
1781070|NCT00431353|Drug|Ganciclovir|5mg/kg iv bid for 21 days
1781071|NCT00431353|Drug|valganciclovir [Valcyte]|900mg po bid for 21 days
1781000|NCT00430755|Device|Computer-assisted history|"Methods The intervention was use of an expert system to acquire medical histories by direct interview of patients.
Description of the software program - The program tested in this study consisted of a data acquisition [history-taking] component and a data analysis component. The data acquisition component was constructed on the basis of established principles of pathophysiology. Medical knowledge was formalized as software algorithms that were machine-readable by representing the knowledge as branched chain decision trees."
1781001|NCT00430755|Procedure|physician taken history|Convential history taking by physicians
1781002|NCT00430755|Other|Computer-assisted history taking|
1781003|NCT00430768|Biological|rAAV1-CB-hAAT|
1781004|NCT00430781|Drug|pazopanib (GW786034)|
1781005|NCT00430781|Drug|lapatinib (GW572016)|
1781006|NCT00430794|Drug|Spironolactone|
1781007|NCT00430807|Drug|hydroxychloroquine/placebo|
1781008|NCT00430820|Procedure|per intervention|per intervention
1781009|NCT00430833|Drug|candesartan|
1781010|NCT00430846|Drug|SGN-35|Every 21 days. Dose Escalating. 0.1 - 3.6 mg/kg
1781011|NCT00430859|Drug|Alkaline Phosphatase|Intravenous over a period of 24 hours
1781012|NCT00430859|Drug|Placebo|Saline over a period of 24h
1781013|NCT00430872|Behavioral|Survey|Survey about the severity of certain symptoms lasting 10-15 minutes.
1781014|NCT00430885|Drug|Octagam (IVIG)|Intravenous immunoglobulin 0.4 g/kg given as infusion
1781015|NCT00430898|Drug|Basiliximab|3 doses of 40mg, IV at baseline, week 2, and week 4
1781016|NCT00430911|Drug|Radiotherapy|
1781017|NCT00430924|Drug|Eplerenone|Once daily administration for 8 weeks and 8 weeks control.
1781018|NCT00430937|Drug|Daptomycin|4 mg/kg intravenous once daily
1781019|NCT00430937|Drug|Vancomycin|1 g intravenous twice daily
1781020|NCT00430937|Drug|Teicoplanin|400 mg intravenous once daily following a loading dose of 400 mg administered at 0, 12, 24 hours on day one.
1957040|NCT02582593|Device|Sham MedX 1116 Rehab Console|This intervention makes use of sham transcranially applied near infrared light using light emitting diodes. Light emitting diodes (but not near-infrared light) will be applied to the scalp for a period of 1 hour at each session. A total of six session will be held.
1781023|NCT00430963|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|
1781024|NCT00430963|Drug|Placebo|
1781025|NCT00430976|Behavioral|Minds in Motion|
1957043|NCT02576054|Biological|V501|V501 (GARDASIL™, Quadrivalent HPV [Type 6, 11, 16 and 18] L1 Virus-Like Particle vaccine), 0.5 mL intramuscular injection on Day 1, Month 2, and Month 6
1781028|NCT00431002|Behavioral|Resistance training|See Detailed Description.
1781029|NCT00431015|Drug|IPI-504|IV Hsp90 inhibitor
1781030|NCT00431028|Device|slow delivery ciprofloxacin + triamcinolone|2 mg ciprofloxacin + 25mg triamcinolone
1781031|NCT00431041|Drug|solifenacin|Oral
1781032|NCT00431041|Drug|oxybutynin immediate release|Oral
1781033|NCT00431054|Drug|Perifosine|Loading Dose = 100 mg by mouth (PO) every 6 hours, followed by 50 mg by mouth (PO) daily
1781034|NCT00431054|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour every 4 weeks
1781035|NCT00431067|Drug|BIBW 2992|
1781036|NCT00431080|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
1781037|NCT00431080|Drug|Paclitaxel|Paclitaxel 175 mg/m2 as an IV infusion over 3hrs every two weeks for 4 cycles
1781038|NCT00431080|Drug|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
1781039|NCT00431080|Drug|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
1781040|NCT00431080|Drug|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
1781041|NCT00431080|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
1781042|NCT00431093|Drug|tibolone|uncoded tablets, at a dose of 2.5 mg per tablet; Subjects were to take 1 Livialâ tablet and 1 -matched Activelleâ placebo tablet, orally, once a day (preferably at the same time).
1781043|NCT00431093|Drug|low-dose estradiol/noresterone|"Activelleâ, estradiol (E2) 1 mg and norethisterone acetate (NETA) 0.5 mg per tablet, was supplied as uncoded tablets.
Subjects were to take 1 Activelleâ tablet and 1 Livialâ-matched placebo tablet, orally, once a day (preferably at the same time)."
1781044|NCT00431106|Drug|Gemcitabine|Gemcitabine at the dose of 1000 mg/m2 intravenously (IV) every 2 weeks for 12 consecutive cycles
1781045|NCT00431106|Drug|Capecitabine|Capecitabine at the dose of 1250 mg/m2 twice daily orally (os), from day 1 to day 14, every 3 weeks for 6 consecutive cycles
1781046|NCT00431106|Drug|Vinorelbine|Vinorelbine at the dose of 25 mg/m2 IV on day 1 every 2 weeks for 12 consecutive cycles
1781047|NCT00431119|Drug|Azathioprine or Mycophenolate mofetil|
1781048|NCT00431132|Drug|estradiol, 10 mcg|Tablets, administered intravaginally twice weekly
1781049|NCT00431145|Drug|Niacin|
1781050|NCT00431145|Drug|Niacin+Statin|
1781051|NCT00431158|Other|Different Mechanical Ventilation Protocols|"OLA Group: Open lung approach protocol and recruitment maneuvers
ARDSnet Group: ARDSnet protocol"
1781052|NCT00431171|Drug|Lithium carbonate|
1781053|NCT00431184|Drug|Pentazocine|see arms description
1781054|NCT00431184|Drug|Lorazepam|see arms description
1781055|NCT00431197|Drug|Ketoconazole, Dexamethesone, Androgel,GnRH|
1781056|NCT00431210|Biological|Epstein-Barr virus-specific adoptive T-cells immunotherapy|Given intravenously on Day 1 and Day 14
1781057|NCT00431223|Behavioral|Cognitive remediation therapy|36 sessions of computerized cognitive skills training over a 12 week duration. 7 patients were assigned to cognitive remediation therapy or CRT Group.
1781062|NCT00431249|Drug|Cilostazol|
1781063|NCT00431262|Drug|antabuse (disulfiram)|
1781064|NCT00431275|Drug|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
1781065|NCT00431275|Drug|CP-675,206|CP-675,206 15 mg/kg iv single dose on Day 1
1781072|NCT00436722|Drug|ATG (Fresenius Biotech)|ATG-Fresenius 9 mg/kg at induction
1781073|NCT00436748|Drug|Darbepoetin Alfa|Administered by subcutaneous or intravenous injection
1781074|NCT00436748|Drug|Placebo|Matching placebo solution for subcutaneous or intravenous injection to maintain the blind in the Q2W arm.
1781075|NCT00436761|Biological|anti-thymocyte globulin|
1781076|NCT00436761|Biological|graft-versus-tumor induction therapy|
1781077|NCT00436761|Biological|sargramostim|
1781078|NCT00436761|Drug|busulfan|
1781079|NCT00436761|Drug|cyclosporine|
1781080|NCT00436761|Drug|melphalan|
1781081|NCT00436761|Drug|methylprednisolone|
1781082|NCT00436761|Other|flow cytometry|
1781083|NCT00436761|Other|immunologic technique|
1781084|NCT00436761|Other|laboratory biomarker analysis|
1781085|NCT00436761|Procedure|allogeneic hematopoietic stem cell transplantation|
1781086|NCT00436761|Procedure|umbilical cord blood transplantation|
1781087|NCT00436774|Procedure|assessment of therapy complications|
1781088|NCT00436774|Procedure|quality-of-life assessment|
1781089|NCT00436787|Drug|Fondaparinux Sodium|
1781090|NCT00436800|Drug|Gemcitabine|1000mg/m² over 10mg/m²/min
1781091|NCT00436800|Drug|Oxaliplatin|100 mg/m² over 2 hours.
1781092|NCT00436826|Drug|Cladribine|Subjects will receive cladribine tablets orally as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the double blind (DB) period of 96 weeks. Subjects who will complete the DB period will to enter in open label (OL) extension period, if they meet the eligibility criteria they will be given total cladribine dose of 3.5 mg/kg over 48 weeks.
1781093|NCT00436826|Drug|Placebo|Subjects will receive matching placebo tablets orally as cumulative dose of 0.875 mg/kg over a course of 4-5 consecutive days at Week 1, 5, 48, and 52 resulting in total matching placebo dose of 3.5 mg/kg during the DB period of 96 weeks.
1781094|NCT00436826|Drug|Interferon-beta (IFN-beta)|Subjects will receive IFN-beta therapy (Rebif® new formulation [RNF] 44 microgram [mcg] three times a week, subcutaneously; Avonex® 30 mcg every week, intramuscularly; or Betaseron® 250 mcg every other day, subcutaneously) during both DB period of 96 weeks and OL extension period of 48 weeks.
1781095|NCT00436839|Drug|Docetaxel|75mg/m² intravenously (day 1) every 21 days
1781096|NCT00436839|Drug|Mitoxantrone|12mg/m² intravenously every 21 days
1781097|NCT00436839|Drug|Prednisone|10mg orally given daily
1781098|NCT00436852|Drug|ABT-751|Given orally
1781099|NCT00436852|Procedure|quality-of-life assessment|Ancillary studies
1781100|NCT00436865|Behavioral|Weight loss|
1781101|NCT00436878|Behavioral|Food portion size|Each of four experiments involves a 2 x 2 within-subjects factorial design, in which the first factor is the portion size of a food served to children: foods will be served in a reference amount (i.e. 250 g macaroni and cheese) or doubled in size(i.e. 500 g of macaroni and cheese). In the Experiment 1, the second factor of the 2 x 2 design is meal type: whether the food is consumed at a meal or a snack. In experiment #2, the second factor is food type: fruit vs. vegetable. In experiment #3, the second factor is entree energy density: a regular energy density or a 40% greater energy density. In experiment #4, the second factor is plate size: a 6 inch plate vs. a 10 inch plate.
1781102|NCT00436904|Drug|Alemtuzumab|30 mg Monday, Wednesday, and Friday x 5 weeks
1781103|NCT00436904|Drug|Rituximab|375mg/m2 IV weekly (Wednesday) x 4 weeks (weeks 2-5)
1781104|NCT00436917|Drug|zoledronic acid|zoledronic acid
1781105|NCT00436917|Procedure|Letrozole as adjuvant therapy|standard care
1781106|NCT00436930|Biological|autologous tumor cell vaccine|Given subcutaneously
1781107|NCT00436930|Biological|sargramostim|Given subcutaneously
1781108|NCT00436930|Biological|therapeutic autologous dendritic cells|Given subcutaneously
1781109|NCT00436943|Drug|nicotine replacement therapy and bupropion|3-6 months
1781110|NCT00436943|Behavioral|smoking cessation counseling and referrals|Organizational counseling and referrals
1781111|NCT00436956|Procedure|Magnetic Resonance Imaging (DCE-MRI)|Scans evaluate tumor tissue and blood flow.
1781112|NCT00436956|Drug|AZD2171|20 mg oral daily for 28 days
1781113|NCT00436956|Drug|Prednisone|10mg orally daily in combination with AZD2171 20mg daily.
1957047|NCT02569372|Biological|GC1102|GC1102(Recombinant Hepatitis B Human Immunoglobulin)
1781116|NCT00436982|Device|Cemented Triathlon total knee system|Orthopaedic implant
1781117|NCT00436982|Device|Duracon total knee system|Orthopaedic implant
1781118|NCT00436995|Drug|Darbepoetin Alfa|Administered IV or SC, Q2W at the following unit doses: 10, 15, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200 or 300ug. Initial Q2W dose calculated from pre-enrollment QW doses. Doses titrated to achieve target Hb.
1781119|NCT00437008|Drug|Benfotiamine 1050mg, 3 days|
1781120|NCT00437008|Behavioral|high-AGE vs. low-AGE meal|
1781121|NCT00437021|Drug|Placebo (subcutaneous)|0.9 percent (weight/volume) sodium chloride injection, United States Pharmacopeia [Sterile Saline Placebo (SSP)].
1781122|NCT00437021|Drug|Placebo (scarification)|Physiologic normal saline for injection.
1781123|NCT00437021|Biological|Dryvax®|Dryvax® Vaccinia Vaccine (~10^5 [plaque forming units (pfu)/dose] given via scarification, titer 10^8 pfu per mL after reconstitution).
1781124|NCT00437021|Biological|IMVAMUNE®|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route at titer 1X10^8 Tissue Culture Infections Dose50 per 0.5 mL dose.
1781125|NCT00437034|Biological|aflibercept|Given IV
1781126|NCT00437060|Procedure|Cognitive Assessment|Ancillary studies
1781127|NCT00437060|Procedure|Diffusion Tensor Imaging|Correlative studies
1781128|NCT00437060|Other|Laboratory Biomarker Analysis|Correlative studies
1781129|NCT00437060|Other|Pharmacological Study|Correlative studies
1781130|NCT00437060|Procedure|Psychosocial Assessment and Care|Ancillary studies
1781131|NCT00437073|Drug|capecitabine|capecitabine 2000mg/m2/day orally, Days 1-14, every 21 days
1781132|NCT00437073|Drug|topotecan|topotecan intravenous (IV, in the vien) 3.2mg/m2 Days 1, 8 and 15; every 28 days
1781133|NCT00437073|Drug|lapatinib|lapatinib administered 1250mg once daily orally
1781134|NCT00437086|Drug|PS-341|1.6 mg/m2 by IV; 4 out of 5 weeks
1781135|NCT00437099|Drug|Omacor®|arm 1: Omacor 1680 Arm 2: Omacor 3360
1781136|NCT00437099|Drug|Placebo|Placebo
1781137|NCT00437112|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals, 24 weeks
1781138|NCT00437112|Drug|Insulin Glargine|patient specific dose, injectable, before meals, 24 weeks
1781139|NCT00437125|Drug|Duloxetine hydrochloride|Duloxetine 30 milligram (mg) once daily (QD) orally (PO) for 1 week, then duloxetine 60 mg QD PO for 11 weeks
1781140|NCT00437138|Behavioral|Exposure to dilute diesel exhaust (300µg/m3) or filtered air|
1781141|NCT00437151|Other|More frequent than normal office visits|Mode of patient reminder
1781142|NCT00437151|Other|Electronic reminders (voice, e-mail, text messages)|Mode of patient reminder
1781143|NCT00437151|Other|Parenteral involvement / intervention reminders|Mode of patient reminder
1781144|NCT00437151|Other|No intervention or reminders|Mode of patient reminder
1781145|NCT00437164|Drug|Insulin|
1781146|NCT00437164|Drug|Oral GW677954 Capsules (15 mg)|
1781147|NCT00437177|Drug|apomorphine|Apomorphine 0.05 mg/kg subcutaneously at hospital admission and at discharge. Abstinent participants at 3 months will receive a third dose.
1781148|NCT00437177|Drug|[(123)I] iodobenzamide|[(123)I] iodobenzamide 185 MBq I.V., at discharge.
1781149|NCT00437190|Device|ATLANTIS™ Cervical Plate System and allograft|Control treatment is commercially available allograft (without bone matrix paste) used in conjunction with the Medtronic Safamor Danek ATLANTIS™ Cervical Plate System.
1781150|NCT00437190|Device|BRYAN Cervical Disc Prosthesis|The intent is to treat stable degenerative disc disease by implanting the BRYAN Cervical Disc Prosthesis to provide motion like the normal cervical functional spinal unit.
1781151|NCT00437203|Drug|PF-00477736|"Escalating doses of PF-00477736 will be administered intravenously on Days 2 and 9 and gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
If a patient is administered Cycle 0 - only PF-0047736 will be administered intravenously on Days 1 and 8 of a 21-day cycle for patients who have a 3-hour infusion and Days 1 and 8 of a 14-day cycle for patients who have a 24-hour infusion."
1781152|NCT00437203|Drug|gemcitabine|gemcitabine will be administered intravenously on Days 1 and 8 of a 21-day cycle (doses to be evaluated range from 750 to 1250 mg/m2 in three separated cohorts).
1781153|NCT00437216|Drug|Clobetasol Propionate, 0.05%|Apply twice daily for 2 or 4 weeks as monotherapy
1781154|NCT00437216|Drug|Clobetasol propionate, 0.05% Spray|Apply twice daily for 2 or 4 weeks as add-on therapy
1781155|NCT00437229|Drug|GW679769 Oral Tablets|
1781156|NCT00437229|Drug|dexamethasone oral tablets & intravenous|
1781157|NCT00437229|Drug|ondansetron oral tablets & intravenous|
1781158|NCT00437242|Drug|Odiparcil|
1781159|NCT00437255|Drug|Clobetasol Propionate, 0.05%|Topical, twice daily for 4 weeks
1781160|NCT00437255|Drug|Calcipotriene and betamethasone dipropionate ointment|Topical, once daily
1781161|NCT00437268|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral daily, 21 day cycles until progressive disease
1781162|NCT00437268|Drug|irinotecan|300 mg/m2, IV, day 1 every 21 days until progressive disease
1781163|NCT00437268|Drug|cetuximab|400 mg/m2, IV, day 1, 250 mg/m2 day 8, day 15 cycle 1 then 250 mg/m2, IV, day 1, 8 and 15 of each cycle, IV, 21 day cycles until progressive disease
1781164|NCT00437281|Drug|Placebo|Placebo
1781165|NCT00437281|Drug|Pregabalin|Orally-administered pregabalin
1781166|NCT00437294|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, 21 day cycles until progressive disease
1781167|NCT00437294|Drug|placebo|oral, daily, 21 day cycles until progressive disease
1781168|NCT00437294|Drug|capecitabine|1250 mg/m2, BID, days 1-14 of each 21 day cycle until progressive disease
1781169|NCT00437307|Drug|Topotecan|Topotecan: 0,75 mg/m²/d, day 1-3, and Carboplatin: AUC 5 (after Cockroft and Gault Formula) on day 3 after Topotecan, q 21d
1781170|NCT00437320|Procedure|Metvix PDT|Metvix PDT
1781171|NCT00437320|Procedure|placebo|placebo
1781172|NCT00437333|Drug|Metformin cloridrate|
1781173|NCT00437346|Procedure|Individualized and comprehensive information|Thorough verbal and written information about results of the tests. Individualized meals recommendation based on the results.
1781174|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
1781175|NCT00437346|Drug|Lanzo Melt|30mg, od, 1/2 h before meal
1781176|NCT00437359|Drug|Toremifene citrate|Toremifene citrate: 40-mg tablets by mouth once daily.
1781177|NCT00437359|Drug|Anastrozole|Anastrozole: 1-mg tablets by mouth once daily.
1781178|NCT00437372|Drug|Sunitinib|"The use of the FDA approved drug sunitinib, used in an off-label manner with external beam radiation therapy."
1781179|NCT00437372|Radiation|External Beam Radiation Therapy|Radiotherapy will be administered Monday through Friday for a maximum of 8 weeks. Total dose will depend on the patient's disease site.
1781180|NCT00437385|Drug|TCAs, SSRIs, NARIs, SNRIs, Lithium|Antidepressant, dosage, and duration are chosen due to the guidelines of the WFSBP (Bauer et al. 2002)
1781181|NCT00437385|Procedure|Electroconvulsive therapy|ECT treatment is administered three times per week on non-successive weekdays and according to existing standards. Treatment lasts for at least three weeks (nine ECT sessions). Psychopharmacological treatment is continued during ECT treatment. Patients receive ultrabrief pulse (0.3 ms), unilateral treatment at a frequency of 40-100 Hertz. Stimulation is applied to the non-dominant hemisphere, according to the d'Elia electrode positioning paradigm. All patients are initially treated with right unilateral stimulation and in case of non-response switched to bilateral treatment. Stimulus intensity is chosen according to individual seizure threshold and administered at 2.5 to 6-fold intensity. During the ECT session, patients are anesthetized, under the influence of a muscle relaxant, and monitored regarding their vital functions.
1781235|NCT00443963|Drug|Esomeprazole Magnesium|
1781236|NCT00443976|Drug|Aurora kinase inhibitor AT9283|The starting dose of AT9283 will be 1.5 mg/m2 given as a 24 hour IV infusion on Days 1 and 8 every three weeks.
1781237|NCT00444015|Drug|Erlotinib in combination with Dasatinib|6 Cycles @ 28 Days
1781239|NCT00444041|Drug|Bevacizumab|neoadjuvant therapy prior to elective surgery
1781182|NCT00437385|Behavioral|Cognitive behavioral group therapy|"The continuation-psychotherapy (continuation cognitive behavioral therapy, C-CBT) sample took part in a newly developed cognitive behavioral group therapy program called EffECTive. This therapy program was developed within the EffECT-project (Brakemeier et al. 2005), to fit the specific target group of patients finished with acute ECT-treatment. EffECTive is a group therapy that combines several aspects of existing cognitive-behavioral depression manuals with new elements (e.g., the situational analysis from CBASP, McCullough 2000), to fit the target group. Therapy sessions were held once a week and include approximately 15 sessions until follow-up."
1781183|NCT00437398|Biological|Islet Transplant|Purified pancreatic islets
1781184|NCT00437411|Behavioral|Affective Self-Awareness workshop|Affective Self Awareness intervention: 90 minute face-to-face consultation with the treating physician, then three 2-hour weekly small-group workshops involving education regarding Mind-Body connections, written emotional expression, meditation, and self-affirmation practices.
1781185|NCT00437424|Drug|Brivanib|Tablet, Oral, Brivanib 400 mg, based on Day 1 PK, QD, until progression
1781186|NCT00437437|Drug|Brivanib|Tablet, Oral, Brivanib 800 mg, QD after single dose Pk comparison of food effect, until progression
1781187|NCT00437450|Drug|Epoetin/Atra|
1781188|NCT00437463|Drug|Ramipril|2.5mg and increase to 5mg if patient do not develop symptomatic hypotension
1781193|NCT00437489|Drug|Inhaled Human Insulin (Exubera)|Initial dose (mg) as per weight based formula = 0.05 x body weight (kg) TID
1781194|NCT00437489|Drug|Inhaled Human Insulin (Exubera)|Initial dose of 1mg TID of inhaled human insulin
1781195|NCT00437502|Biological|tumor peptide vaccine|Cohort 1 low dose level of vaccine @ 0.3 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
1781196|NCT00437502|Biological|tumor peptide vaccine|Cohort 2 high dose vaccine @ 1 mg administered as x1 weekly injection given intradermally/subcutaneously into site assigned( same limb) for total number of study vaccine injections = 6.
1781197|NCT00437541|Device|Insulation retrofitted into house|
1781198|NCT00437554|Drug|Glimepiride|
1781199|NCT00437567|Dietary Supplement|Galacto-oligosaccharide (GOS)|Treatment group to receive 1.3 gm/kg/day GOS from initiation of enteral feeds until 35 weeks post-conceptual age.
1781200|NCT00437567|Other|Placebo|Similar quantity of sterile water to be added to milk
1781201|NCT00437580|Drug|Lactobacillus casei rhamnosus (strain Lcr 35 LC)|Patients will be blindly randomized to be assigned to a 5 weeks regimen with the probiotic or to a 5 weeks regimen with placebo.
1781202|NCT00437593|Procedure|ppVE, MP, ICG|surgery with ILM staining
1781203|NCT00437593|Procedure|ppVE, MP, MB|Surgery with ERM staining
1781204|NCT00437606|Drug|GK Activator (2)|100mg po
1781205|NCT00437606|Drug|Ethanol|40g po
1781206|NCT00437619|Drug|calcipotriol hydrate [Daivonex]|50 micrograms/g bid for 4 weeks (weeks 5-8) in patients who have shown a >50% response to Daivobet from weeks 0-4.
1781207|NCT00437632|Drug|GSK598809|GSK598809 will be available as 5 and 25 mg capsules. Subjects will receive GSK598809 capsules orally with water.
1781208|NCT00437632|Drug|Placebo|Subjects will receive matching placebo capsules to GSK598809 orally with water.
1781209|NCT00437632|Drug|Caffeine|Caffeine 100 mg will be available as oral solution or tablet and subjects will receive Caffeine 100 mg orally on -1 day. On Day 35 caffeine and GSK598809 will be co-administered.
1781210|NCT00437645|Drug|Valsartan 160 mg capsules|
1781211|NCT00437645|Drug|Amlodipine 5 mg capsules|
1781212|NCT00437645|Drug|placebo|capsules
1781213|NCT00437658|Drug|NBI-56418|NBI-56418 is a novel GnRH antagonist being studied for the management of pain associated with endometriosis.
1781214|NCT00437658|Drug|depo-subQ provera 104|Depo-subQ provera 104 is indicated for the management of pain associated with endometriosis.
1781215|NCT00437671|Drug|Tetanus Immune Globulin (Human)|Based on package insert recommendation and recommendations of WHO
1781216|NCT00437671|Biological|Diphtheria-Tetanus Toxoids Adsorbed|Based on package insert recommendations and recommendations of WHO
1781217|NCT00437684|Drug|LPV/r|200/50 mg 2 cpr bid monotherapy
1781218|NCT00437684|Drug|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week
1781219|NCT00437684|Drug|Ribavirin|Ribavirin 1-1.2 g/day
1781220|NCT00437684|Drug|NUCS|Nucleoside Reverse Transcriptase Inhibitors
1781221|NCT00437697|Drug|dalteparin|
1781222|NCT00443872|Drug|orally disintegrating selegiline (Zelapar)|1.25 mg once daily orally disintegrating selegiline for 6 weeks with an increase to 2.5 mg once daily orally disintegrating selegiline for remaining 6 weeks if tolerated
1781223|NCT00443898|Drug|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 48 weeks
1781224|NCT00443898|Drug|Placebo|vehicle (placebo) applied once daily for 48 weeks
1781225|NCT00443898|Drug|terbinafine|Active terbinafine hydrochloride (HCl) 10 % Nail Solution for Onychomycosis (NSO) once daily for 24 weeks
1781226|NCT00443898|Drug|Placebo|vehicle (placebo) applied once daily for 24 weeks
1781227|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for three days
1781228|NCT00443924|Drug|Placebo|One drop of placebo in each eye every 12 hours for three days
1781229|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #2 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
1781230|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #3 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
1781231|NCT00443924|Drug|INS115644 Ophthalmic Solution|One drop of Concentration #4 in one eye and one drop of placebo in the contralateral eye every twelve hours for three days
1781232|NCT00443937|Drug|enteric-coated mycophenolate sodium|oral
1781233|NCT00443937|Drug|everolimus|oral
1781234|NCT00443950|Drug|Etanercept|
1781240|NCT00444054|Behavioral|Very low carbohydrate diet (approximately 20 grams per day)|Very low carbohydrate diet for a duration of four weeks.
1781241|NCT00444067|Device|Spinal Sealant|Spinal Sealant System
1781242|NCT00444067|Other|Standard of Care|Standard of Care
1781243|NCT00444080|Procedure|Trabeculectomy|"Standard trabeculectomy procedure
Creation of a fornix or limbal based conjunctival flap in upper quadrants
Creation of a limbal-based scleral flap extending into clear cornea
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)
Creation of fistula 1mm x 2mm in size
Iridectomy
Suturing the scleral flap
Repositioning of conjunctiva with sutures After procedure, antibiotics & steroids are administered topically; eye is covered with a pad - patient is discharged."
1781244|NCT00444080|Device|Ex-PRESS mini shunt|"Ex-PRESS implantation procedure:
Creation of a fornix or limbal based conjunctival flap in upper quadrants
Creation of limbal-based scleral flap extending into clear cornea
Delicate application of MMC solution onto sclerectomy bed. (MMC concentration 0.4mg/ml for 1-3 minutes)
Penetration into anterior chamber using 23-25G needle, halfway between the white sclera and clear cornea (in the center of the grey zone);creation of track incision at limbus
Prior to implantation, a thorough mobility check should be performed
Implantation of Ex-PRESS implant loaded on its introducer, through that pre-incision
Withdrawal of introducer
Tucking plate under the scleral flap, and verification of its position
Suturing scleral flap After implantation procedure, antibiotics & steroids administered topically; eye is covered with a pad - patient is discharged."
1781245|NCT00444093|Drug|Tinctura opii|
1781246|NCT00444106|Drug|Artesunate-mefloquine|
1781247|NCT00444106|Drug|Atovaquone-proguanil|
1781248|NCT00444106|Drug|Artemether-lumefantrine|
1781249|NCT00444132|Drug|clopidogrel|
1781250|NCT00444145|Drug|Prevacid|30 mg bid for 3 months
1781251|NCT00444145|Procedure|Esophageal and Laryngeal Biopsies|repeat egd with biopsy after Prevacid 30 mg bid for 3 months
1781252|NCT00444158|Drug|MOA-728|
1781253|NCT00444171|Procedure|insulin infusion rate controled by computer algorithm|
1781254|NCT00444171|Procedure|insulin infusion rate guided by in-house glucose management protocol|
1781255|NCT00444184|Drug|Travoprost/timolol fixed combination, travoprost|
1781256|NCT00446849|Drug|MMX Mesalamine|MMX™ mesalamine 2.4g/day to 4.8g/day once-daily (QD) (two to four 1.2g tablets MMX™ mesalamine, dosed QD,respectively).
1781257|NCT00446862|Drug|enalapril and other angiotensin converting enzyme inhibitors; losartan and other angiotensin receptor blockers|10 mg by mouth every day; 25 mg by mouth every day
1781258|NCT00446875|Procedure|Administration of oral sucrose|
1781259|NCT00446888|Behavioral|Standardized Meals for Diet Stabilization|Subjects will eat prepared meals for 3 days prior to their study; or they will document their dietary intake over this period.
1781260|NCT00446888|Dietary Supplement|Forticare|400 ml of commercially-available nutritional supplement.
1781261|NCT00446888|Dietary Supplement|Product 4808|400 ml Forticare, to which has been added extra protein and the amino acid leucine.
1781262|NCT00446901|Dietary Supplement|Selenium|Selenized yeast, 300 ug/day
1781263|NCT00446914|Behavioral|Systems Change (High Blood Pressure Strategy)|
1781264|NCT00446940|Drug|rosuvastatin|
1781265|NCT00446940|Drug|atorvastatin|
1781266|NCT00446953|Drug|betamethasone|2x12 mg betamethazone c-section at 38 weeks
1781267|NCT00446953|Other|placebo|c-section at 39 weeks
1781269|NCT00446979|Drug|Placebo gel|HEC (hydroxyethyl cellulose) Control Gel applied vaginally twice daily for two weeks
1781270|NCT00446979|Drug|UC 781|UC 781 0.1% or UC 781 0.25%, applied vaginally twice daily for two intermenstrual weeks
1781271|NCT00446992|Drug|Olanzapine|16-week open trial of olanzapine. The patients were started on a dose of 15 mg/d by mouth, which could be adjusted to as low as 10 mg/d or as high as 40 mg/d, based on clinical response. The trial began while they were hospitalized and continued after discharge.
1781272|NCT00447005|Drug|Axitinib (AG-013736)|AG-013736 5mg twice daily [BID]
1781273|NCT00447018|Drug|20% mannitol|
1781274|NCT00447018|Drug|7.45% hypertonic saline solution|
1781275|NCT00447031|Drug|intravitreal bevacizumab and triamcinolone acetonide|
1781276|NCT00447044|Behavioral|Resistance Exercise|Subjects will lift weights with their legs.
1781277|NCT00447044|Dietary Supplement|diet orange soda|Subjects drink diet orange soda 3x day for 2 days.
1781278|NCT00447044|Dietary Supplement|essential amino acids|Subjects drink 15 grams of EAA mixed into diet orange soda 3x day for 2 days.
1781279|NCT00447057|Drug|Pemetrexed|500 mg/m² intravenous (iv) over 10 minutes on the first day of each 21-day cycle until disease progression (PD) or unacceptable toxicity
1781280|NCT00447057|Drug|Erlotinib|150 mg given orally (po), daily (QD), starting on the first day of the first cycle
1781281|NCT00447057|Drug|Pemetrexed|500 mg/m² iv over 10 minutes on the first day of each 21-day cycle until PD or unacceptable toxicity
1781282|NCT00447057|Drug|Erlotinib|150 mg given po, QD, starting on the first day of the first cycle
1781283|NCT00447070|Drug|ATAZANAVIR|
1781285|NCT00447096|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Repetitive transcranial magnetic stimulation (rTMS).
1781286|NCT00447109|Device|Closed system suction|
1781287|NCT00447122|Drug|gemcitabine and Lapatinib|
1781288|NCT00447148|Procedure|3-dimensional coronary angiography|3-dimensional coronary angiography
1781289|NCT00447161|Drug|Bacillus Clausii Multi ATB Resist|Twice daily dose of 1 vial of 1x10^9 of Bacillus clausii spores, orally suspension in water
1781290|NCT00447161|Drug|Placebo|Matched placebo
1781291|NCT00447174|Behavioral|Dyadic treatment for parental bereavement|
1781292|NCT00447187|Drug|LX201|"LX201 is a novel sustained-release silicone implant containing 30% cyclosporine A by weight.
LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant was 0.08 inch wide and 0.04 inch in height. The implants were flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
1781456|NCT00448357|Drug|methotrexate|5 mg/m^2 on days +1, +3 and +6
1781293|NCT00447187|Other|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
1781294|NCT00447200|Procedure|Esophagus Doppler monitoring|
1781295|NCT00447200|Procedure|Fluid optimization|
1781296|NCT00447213|Drug|Insulin glargine|Patient specific, injected, daily, 24 weeks
1781297|NCT00447213|Drug|Human Insulin Inhalation Powder|patient specific dose, inhaled, before meals,12 weeks
1781298|NCT00447213|Drug|Injectable Insulin|Patient specific dose,injected, before meals, 12 weeks
1781299|NCT00447226|Drug|Oral lapatinib tablets or placebo tablets|Subjects administered open label lapatinib, 1500 mg to be taken orally once a day, for 12 weeks. After 12 weeks, subjects with a partial or complete response per Response Evaluation Criteria in Solid Tumors (RECIST) will continue to receive open label lapatinib (1500 mg/day orally) until disease progression. Subjects who maintain stable disease will be randomized in a 1:1 ratio to enter stage 2 of the study and receive double blind therapy of either lapatinib 1500 mg/day orally or placebo. Subjects who progress on placebo will have the option to receive lapatinib 1500 mg/day orally until further progression. Those who progress on lapatinib will be withdrawn from the study.
1781300|NCT00447239|Procedure|glucontrol (insulin therapy)|
1781301|NCT00447265|Drug|Etanercept|1.) Immune suppressant. 2.) Tumor necrosis factor (TNF) inhibitor.
1781302|NCT00447265|Drug|Lupus Treatment- Standard of Care|Individualized standard of care treatment for lupus with corticosteroids and with mycophenolate mofetil (MMF), mycophenolic acid, or azathioprine (AZA)
1781303|NCT00447265|Drug|Placebo|
1781304|NCT00447278|Drug|Atomoxetine|0.5 mg/kg/day once a day (QD) or twice a day (BID) for 1 week then 1.2-1.8 mg/kg/day QD or BID for 6 months, up to an additional 6 months optional extension
1781305|NCT00447278|Drug|Other standard therapy for ADHD|Any treatment for ADHD as prescribed by investigator, 6 months, up to an additional 6 months extension
1781306|NCT00447291|Drug|Supplement: Omega-3 Fish Oil|
1781307|NCT00447291|Behavioral|Multi-Disciplinary Nutrition & Exercise program|
1781308|NCT00447304|Drug|moxifloxacin|
1781309|NCT00447304|Procedure|cholecystectomy|
1781310|NCT00447317|Behavioral|BalanceWise-PD|Dietary counseling based on Social Cognitive Theory, paired with PDA-based dietary self-monitoring
1781311|NCT00447317|Behavioral|Attention control|Standard peritoneal dialysis dietary education
1781312|NCT00447330|Drug|capecitabine (Xeloda), oxaliplatin and bevacizumab (Avastin)|"Capecitabine will be administered orally at a twice daily dose of 850 mg/m2 (equivalent to a total daily dose of 1700 mg/m2) given days 1-14 of the three week cycle.
Oxaliplatin will be administered at the dose of 130 mg/m2 given as a 2-hour intravenous infusion on day 1 of a three week cycle.
Bevacizumab will be administered at a dose of 15 mg/kg given as a 30-90 minute intravenous infusion on day 1 of a three week cycle following the administration of oxaliplatin."
1781313|NCT00447343|Procedure|Decompressive cervical spine surgery|"Treatment group (25 patients) will undergo decompressive anterior cervical spine surgery
Healthy volunteers will ONLY undergo two scans 6 months apart."
1781314|NCT00447343|Procedure|fMRI and MRS scan|A scan pre-op and 6 months post-op.
1781315|NCT00447356|Drug|recombinant interferon alfa|
1781316|NCT00447369|Drug|Pregabalin|
1781317|NCT00447369|Drug|sodium valproate|
1781318|NCT00447382|Drug|insulin detemir|NN304 injected s.c. (under the skin). Given as basal insulin.
1781319|NCT00447382|Drug|insulin aspart|Injected s.c. (under the skin). Given as bolus insulin.
1781320|NCT00447382|Drug|insulin detemir|NN729 injected s.c. (under the skin). Given as basal insulin
1781321|NCT00447408|Behavioral|Standard hemodialysis dietary instruction|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments.
1781322|NCT00447408|Behavioral|Behavioral counseling plus PDA-based self-monitoring of diet|Participants receive standard hemodialysis dietary instruction via a PowerPoint presentation delivered during routinely scheduled dialysis treatments. In addition they receive behavioral counseling paired with PDA-based self-monitoring of dietary sodium intake.
1781323|NCT00447421|Drug|pemetrexed|"Phase 1: 500 mg/m2 then 400 mg/m2, intravenous (IV), every 21 days x 4 cycles (dose escalation)
Phase 2: 500 mg/m2 then phase 1 determined dose, IV, every 21 days x 4 cycles"
1781324|NCT00447421|Drug|cisplatin|Phase 1 and Phase 2: 75 mg/m2, intravenous (IV), every 21 days x 4 cycles
1781325|NCT00447421|Radiation|radiation|Phase 1 and Phase 2: 50-62 Gy, 25-31 days, cycles 2-4
1781326|NCT00447434|Drug|Natto extract (Nattokinase)|
1781327|NCT00447460|Procedure|Mesenchymal stem cell (MSC)|
1781328|NCT00447473|Drug|GM-CSF|GM-CSF will be administered as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) on weeks 2 and 3 each 21 day cycle (total of 14 days).
1781329|NCT00447473|Drug|Ketoconazole|Ketoconazole will be administered daily at a dose of 400 mg po tid (either 1 hour before or 2 hours after meals), ascorbic acid 250 mg po tid (given with ketoconazole) and replacement doses of hydrocortisone (20 mg po in the morning and 10 mg po in the evening).
1781330|NCT00447473|Drug|Mitoxantrone|Mitoxantrone will be given at dose of 12 mg/m2 every 3 weeks, up to a maximum cumulative dose of 140 mg/m2
1781331|NCT00447486|Drug|GW842166|
1781332|NCT00447499|Drug|Somatuline Autogel (lanreotide acetate)|Injections
1781333|NCT00447499|Behavioral|Home administration|Questionnaire
1781334|NCT00447512|Drug|ghrelin|acylated ghrelin
1781335|NCT00447525|Biological|REVAXIS®|
1781336|NCT00447525|Biological|DT-Polio®|
1781337|NCT00447551|Drug|Poly-L-Lactic Acid|Deep dermal injection
1781338|NCT00447564|Drug|Probuphine|4 implants
1781339|NCT00447564|Drug|placebo|4 implants
1781340|NCT00447577|Drug|Loteprednol etabonate and tobramycin ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
1781341|NCT00447577|Drug|Tobramycin and dexamethasone ophthalmic suspension|Subjects will self-administer the study drug in the affected eye(s) 4 times a day (QID) for 14 days.
1781342|NCT00447590|Device|LAP-BAND System|Restriction of food intake
1781343|NCT00447603|Drug|hydrochlorothiazide (+) losartan potassium|losartan/hydrochlorothiazide 12.5mg tablet po qd; for a 4 week study period.
1781457|NCT00448383|Biological|adalimumab|40mg every other week
1781344|NCT00447603|Drug|losartan potassium|Losartan 50mg titrating up to Losartan 100mg tablet po qd; for a 4 week study period
1781345|NCT00447603|Drug|Placebo for Losartan|
1781346|NCT00447603|Drug|Placebo for Losartan/HCTZ|losartan/hydrochlorothiazide 12.5mg Pbo tablet po qd; for a 4 week study period.
1781347|NCT00447629|Drug|PPM-204|
1781348|NCT00447642|Drug|LX201|"LX201 was a novel sustained-release silicone implant containing 30% cyclosporine A by weight.
LX201 was available in two different lengths, 0.50 and 0.75 inch. Each implant is 0.08 inch wide and 0.04 inch in height. The implants are flat on one side (the posterior surface, which is applied to the episclera) and the anterior surface and ends were rounded."
1781349|NCT00447642|Other|Placebo|The placebo was a silicone implant 0.75 inch in length. It contained no cyclosporine A
1781350|NCT00447655|Behavioral|Self-management and peer support|
1781354|NCT00447681|Drug|ILV-094|
1781355|NCT00447694|Drug|Deferasirox|Oral deferasirox 30mg/kg/day once per day for 77 weeks.
1781356|NCT00447707|Behavioral|Positive Choice|
1781357|NCT00447720|Behavioral|PATH|We have chosen to translate two proven prevention programs for delivery to the SMI populations by their case managers. These interventions are the Brief Counseling intervention from the Project Respect program and the Community-Based Outreach Program (CBOM). Together we will translate them into ongoing case management for SMI persons who also abuse substances in the Preventing AIDS through Health Project (PATH). Consistent with other findings regarding HIV infections among the SMI, in our preliminary studies we found that these individuals are at much higher risk within the population of persons being served in Philadelphia.
1781358|NCT00447733|Behavioral|Integrated mental health and substance use treatment|Psychosocial and drug treatment targeting both the substance use disorder and the psychiatric disorder in an integrated and comprehensive way.
1781359|NCT00447733|Behavioral|Treatment as usual|Non-standardized psychiatric outpatient treatment
1781360|NCT00447746|Procedure|D1 or D2 lymphadenectomy for gastric cancer patients|
1781364|NCT00447798|Behavioral|Prevention Care Advocate|Prevention Care Advocate: 8 Session intervention combining cognitive-behavioral skill building & strengths based case management
1781365|NCT00447811|Drug|MOA-728|
1781366|NCT00447824|Procedure|Introduction of better conditions during blood sampling|
1781367|NCT00447837|Drug|SPRC-AB01|90 mg/3 mL BID, 180 mg/3 mL bid, placebo
1781368|NCT00447850|Procedure|endometrial biopsy|
1781369|NCT00447863|Drug|Levonorgestrel/Ethinyl Estradiol|
1781370|NCT00447876|Drug|Botulinum type A toxin (Dysport®)|Botulinum type A toxin (Dysport®): 200 Units injected at the root of the plantar fascia
1781371|NCT00447876|Other|Placebo|0.9% sodium chloride: 2 ml injected at the root of the plantar fascia
1781372|NCT00447889|Drug|gadoteric acid|
1781373|NCT00447902|Drug|tipranavir|
1781374|NCT00447902|Drug|ritonavir|
1781375|NCT00447915|Drug|ibandronic acid 0.5mg|0.5mg(i.v.)/month for 35 months
1781376|NCT00447915|Drug|RIS placebo|0 mg(p.o.)/day for 36 months
1781377|NCT00447915|Drug|1.0mg ibandronic acid|1.0mg(i.v.)/month for 35 months
1781378|NCT00447915|Drug|ibandronic acid placebo|0mg(i.v.)/month for 35 months
1781379|NCT00447915|Drug|2.5mg RIS|2.5 mg(p.o.)/day for 36 months
1781380|NCT00447915|Dietary Supplement|Calcium and Vitamine D3|Calcium 305 mg and Vitamine D3 200IU(p.o.)/day for 36 months
1781381|NCT00447928|Drug|OrthoDerm transdermal nitroglycerin patch|
1781382|NCT00447941|Drug|SCA-136|
1781383|NCT00447954|Drug|NT-501 implant|High Dose
1781384|NCT00447954|Drug|NT-501 implant|Low Dose
1781385|NCT00447954|Other|Sham Procedure|Sham Procedure
1781386|NCT00447967|Drug|Irinotecan|Irinotecan 200 mg/m2 IV on Day 1 every 3 weeks for 6 cycles
1781387|NCT00447967|Drug|Oxaliplatin|Oxaliplatin 80 mg/m2 IV on Day 2 every 3 weeks for 6 cycles
1781388|NCT00447967|Drug|Fluorouracil|Fluorouracil 400 mg/m2 infused over 10 min IV and Fluorouracil600 mg/m2 infused over 22 hours IV, Day 1 and 2 (De Grammont regimen)every 2 weeks for 12 cycles
1781389|NCT00447967|Drug|Leucovorin|Leucovorin 200 mg/m2 infused over 1 hour IV on day 1 and day 2 (De Grammont regimen) every 2 weeks for 12 cycles
1781390|NCT00447967|Drug|Oxaliplatin|Oxaliplatin 85 mg/m2 as a 4 hour IV infusion, Day 1 every 4 weeks for 6 cycles
1781391|NCT00447980|Drug|NT-501|High Dose
1781392|NCT00447980|Drug|NT-501|Low Dose
1781393|NCT00447993|Drug|NT-501|High Dose
1781394|NCT00447993|Drug|NT-501|Low Dose
1781395|NCT00448006|Device|Allium Biliary Stent|
1781396|NCT00448019|Drug|Fludarabine|25 mg/m^2 IV over 30 minutes daily for 3 days
1781397|NCT00448019|Drug|Cyclophosphamide|250 mg/m^2 IV over 30 minutes daily for 3 days
1781398|NCT00448019|Drug|Rituximab|375 mg/m^2 IV on Day 1 by prolonged infusion. All subsequent doses 500 mg/m^2 IV 30-minute infusion.
1781399|NCT00448019|Drug|Bevacizumab|10 mg/Kg IV on Day 3, course 1 over 30-90 minutes
1781400|NCT00448032|Drug|PPM-204|
1781401|NCT00448045|Behavioral|Manual and mechanical assisted cough|Individuals will be given a pulse oximeter and taught both manually assisted and mechanically assisted coughing techniques to maximize their cough. Manually assisted coughing consists of air stacking to deep insufflations. An abdominal thrust is then applied upon glottic opening to augment the cough. These subjects will also have rapid access to a mechanical in-exsufflator (CoughAssistTM) and will be trained on how to access and use this device. Mechanically assisted coughing (MAC) involves the use of the CoughAssistTM to expand the lungs and then quickly reverse the pressure to rapidly empty the lungs with expiratory (cough) flows of 600 L/m. An abdominal (manual) thrust is applied in conjunction with the negative pressure (exsufflation) to further increase cough.
1781458|NCT00448396|Drug|Patupilone|
1781402|NCT00448045|Behavioral|Incentive spirometry|These individuals will be given a pulse oximeter and an incentive spirometer (AirLife Company) and taught how to use them.
1958323|NCT01772472|Drug|trastuzumab|6 mg/kg intravenously every 3 weeks, 14 cycles
1781406|NCT00448071|Drug|MTR107|
1781407|NCT00448097|Drug|cetuximab|No verifiable data available, PI relocated
1781408|NCT00448097|Drug|docetaxel|No verifiable data available, PI relocated
1781409|NCT00448110|Drug|Intravenous Diclofenac (DIC075V)|Intravenous Diclofenac (DIC075V): 1 of 2 dosage levels
1781410|NCT00448110|Drug|Intravenous Ketorolac|Intravenous Ketorolac
1781411|NCT00448110|Drug|placebo|placebo
1781412|NCT00448123|Drug|Tamsulosin|Study Drug
1781413|NCT00448123|Drug|Placebo|Placebo
1781414|NCT00448136|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 every 3 weeks
1781415|NCT00448136|Drug|5 FU|400mg/m2/day iv on days 1-5 every 6 weeks
1781416|NCT00448136|Drug|Streptozotocin|500mg/m2/day iv on days 1-5 every 6 weeks
1781417|NCT00448136|Drug|Xeloda|1000mg/m2 po bid on days 1-14 every 3 weeks
1781418|NCT00448149|Drug|RAD001|RAD001 will be administered orally once a day, daily, without interruption per 4 wk cycle for 2 cycles. MTD is established in Phase I portion of trial (2.5, 5 or 10mg). If responding, additional therapy will be given.
1781419|NCT00448149|Drug|Sorafenib|A dose of 400mg of Nexavar® will be administered orally twice a day, daily, without an interruption per 4 week cycle for 2 cycles. If responding, additional therapy will be given.
1781420|NCT00448175|Device|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
1781421|NCT00448175|Drug|Tolterodine|
1781422|NCT00448188|Procedure|central venous catheter application|
1781423|NCT00448201|Biological|anti-thymocyte globulin|0.5 mg/kg on day -3, 2.5 mg/kg on day -2 (groups 2, 3 and 4) and 3 mg/kg on day -1 (group 4 only)
1781424|NCT00448201|Biological|sargramostim|GM-CSF 500 ug everyday (QD) subcutaneously will be given to recipients who remain with an Absolute neutrophil count (ANC) < 1000/microliter (uL) past day 20
1781425|NCT00448201|Biological|therapeutic allogeneic lymphocytes|A minimum total cluster of differentiation 34 (CD34)+ cell dose of 3 x 10^6 cells/kg and a maximum 8 x 10^6 cells/kg will be infused on day 0
1781426|NCT00448201|Drug|busulfan|6.4 mg/kg by continuous IV infusion over 48 hours on Days -6 and -5
1781427|NCT00448201|Drug|fludarabine phosphate|fludarabine 30 mg/m^2/day x 5 days IV piggyback (IVPB) over 30 minutes on Days -7 through -3
1781428|NCT00448201|Drug|methotrexate|Methotrexate 5 mg/m^2 per day on days +1, +3 and +6
1781429|NCT00448201|Drug|tacrolimus|Suggested starting dose is 0.03 mg/kg po bid starting on Day -1
1781430|NCT00448201|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0
1781431|NCT00448201|Procedure|peripheral blood stem cell transplantation|Minimum total CD34+ cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on Day 0
1781432|NCT00448214|Drug|YM150|Oral
1781433|NCT00448214|Drug|warfarin|Oral
1781434|NCT00448227|Drug|famciclovir|Administered orally as a single individualized dose between 25-200 mg based on body weight.
1781435|NCT00448240|Drug|Erlotinib|loading dose of 300 mg on Day 2 followed by 150 mg daily Days 3 - 17 of each cycle of paclitaxel and cisplatin/carboplatin
1781436|NCT00448253|Biological|NP-015|"Three Cohorts evaluating three dosage levels: 210, 420 or 840 units TNA, or placebo.
And a Fourth Cohort at 840 units TNA with 2 additional product lots."
1781437|NCT00448266|Drug|Intensified Cyclophophamide, Carboplatin and Thiotepa|2 courses of Intensified Cyclophophamide, Carboplatin and Thiotepa with PBPC support
1781438|NCT00448266|Drug|dose dense adriamycine and cyclophosphamide|dose dense adriamycine and cyclophosphamide, Q 2 weeks
1781439|NCT00448279|Drug|trastuzumab|2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks
1781440|NCT00448279|Drug|Chemotherapy|Schedule and dose at the investigator's discretion
1781441|NCT00448292|Drug|PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
1781442|NCT00448292|Drug|Placebo for PRX-00023|Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
1781443|NCT00448305|Drug|EndoTAG-1 + paclitaxel|EndoTAG-1 22 mg/m² + Paclitaxel 70 mg/m² weekly
1781444|NCT00448305|Drug|EndoTAG-1|EndoTAG-1 44 mg/m² twice weekly
1781445|NCT00448305|Drug|Paclitaxel|Paclitaxel 90 mg/m² weekly
1781446|NCT00448318|Procedure|Music Therapy|
1781447|NCT00448344|Behavioral|Family-supported|Group receives quit kit, option for nicotine replacement therapy, and 5 telephone counseling sessions with the goal of attaining social support during the process of quitting smoking
1781448|NCT00448344|Behavioral|Standard Telephone counseling|Group receives quit kit, option for nicotine replacement therapy, and 5 standard smoking cessation telephone counseling sessions
1781449|NCT00448357|Biological|rabbit anti-thymocyte globulin (ATG)|.5 mg/kg on day -3 and 2.5 mg/kg on day -2
1781450|NCT00448357|Biological|therapeutic allogeneic lymphocytes|minimum total cluster of differentiation (CD34+) cells of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on day 0
1781451|NCT00448357|Drug|busulfan|PK-targeted continuous IV infusion over 90 hours on Days -7 to -4.
1781452|NCT00448357|Drug|fludarabine phosphate|30 mg/m^2/day x 5 days intravenous piggyback (IVPB) over 30 minutes on Days -7 through -3
1781453|NCT00448357|Drug|tacrolimus|The suggested starting dose is 0.03 mg/kg po bid starting on day -1
1781454|NCT00448357|Procedure|allogeneic hematopoietic stem cell transplantation|A minimum total CD34+ cell dose of 3 x 10^6 cells/kg and maximum of 8 x 10^6 cells/kg will be infused on day 0
1781455|NCT00448357|Procedure|peripheral blood stem cell transplantation|minimum total CD34+ cell dose of 3 x 10^6 cells/kg and a maximum of 8 x 10^6 cells/kg will be infused on day 0
1781459|NCT00448409|Biological|TroVax|11 Intramuscular injection of TroVax® over 45 weeks. A single dose of 5 x 108 pfu/ml, will be given by an intramuscular injection into the deltoid muscle of the upper arm.
1781460|NCT00448409|Drug|GM-CSF|168 subcutaneous GM-CSF injections over 45 weeks. Administered every day as a subcutaneous injection at a dose of 250mcg/m2/d (maximum 500 mcg) in weeks 1 and 2 of each 28 day cycle (total of 14 days per cycle with a total of 12 cycles).
1781461|NCT00448422|Drug|prulifloxacin|Tablet
1781462|NCT00448435|Drug|GW815SF HFA MDI|salmeterol and fluticasone propionate combination
1781463|NCT00448435|Drug|salmeterol and fluticasone propionate|salmeterol + fluticasone propionate
1781464|NCT00448448|Device|Brace|Brace (TLSO) applied for at least 18 hours per day. Wear time measured using a temperature monitor. Clinical, radiographic, and self-report follow-up every 6 months.
1781465|NCT00448448|Other|Observation|Clinical, radiographic, and self-report follow-up every 6 months.
1781466|NCT00448461|Drug|heparin|comparison between heparin and bivalirudin
1781467|NCT00448461|Drug|bivalirudin|comparison between heparin and bivalirudin
1781468|NCT00448474|Behavioral|Mailed Arthritis Self-Management Education|
1781469|NCT00448513|Dietary Supplement|catechin extracts|comparison with placebo
1781470|NCT00448526|Behavioral|low protein diet|
1781471|NCT00448539|Drug|Rufinamide|400 mg tablet administered in two equally divided daily doses.
1781472|NCT00448539|Drug|Placebo|Subjects who had received placebo began receiving rufinamide at a dose of 800 mg/day at the start of the Transition Phase, with subsequent dose increases to 3200 mg/day over the 12-day Transition Phase.
1781473|NCT00448552|Drug|capecitabine|
1781474|NCT00448552|Drug|oxaliplatin|
1781475|NCT00448578|Drug|Quetiapine Fumarate|
1781476|NCT00448578|Drug|Lithium|
1781477|NCT00448591|Drug|bevacizumab [Avastin]|10mg/kg iv on day 1 of each 3 week cycle, or 15mg/kg iv on day 1 of each 2 week cycle
1781478|NCT00448591|Drug|Taxane-based chemotherapy|As prescribed
1781479|NCT00448630|Other|No intervention|Non-interventional study
1781480|NCT00448643|Radiation|Vaginal Brachytherapy|High-Dose Rate [HDR] or Low-Dose Rate [LDR], no earlier than during last cycle of Carboplatin/Taxol chemotherapy; or no later than 1 week before cisplation and WAR therapy
1781481|NCT00448643|Drug|Cisplatin|Weekly at 40 mg/m2 (maximum of 70 mg) for 6 weeks, start no later than 6 weeks from last cycle of standard of care carboplatin and taxol chemotherapy
1781482|NCT00448643|Radiation|Whole Abdominal Radiation [WAR] Therapy|Whole Abdominal Radiation Therapy, Dose Escalated [2-Levels]; 6 -8 hours after administration of Cisplatin chemotherapy
1781483|NCT00448656|Procedure|ablation of pulmonary veins by video assisted thoracic surgery|epicardial ablation using HIFU
1781486|NCT00448682|Drug|Docetaxel|
1781487|NCT00448682|Drug|Floxuridine|
1781488|NCT00448682|Drug|Leucovorin|
1781489|NCT00448682|Drug|Oxaliplatin|
1781490|NCT00448695|Procedure|MRI Targeted Focal Thermal Therapy of Prostate Cancer|The Interstitial Laser Thermal Therapy (LTT) procedure is similar to brachytherapy, with fibers and probes inserted trans-perineal using transrectal ultrasound guidance. Patients will be under general anesthetic, and the procedure is expected to last 3 hours. Patients will be able to return home the day of the procedure.
1781491|NCT00448708|Device|Vascular Wrap Paclitaxel-Eluting Mesh|0.9 µg/mm^2 paclitaxel
1781492|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
1781493|NCT00448708|Device|Lifespan® ePTFE Vascular Graft|vascular graft
1781494|NCT00448721|Drug|Perifosine|Patients will begin perifosine at 100 mg PO daily with food.
1781495|NCT00448734|Drug|Picoplatin|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.
Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
1781496|NCT00448734|Drug|docetaxel|"The treatment regimen will be the assigned dose of picoplatin plus docetaxel, 60 mg/m2 or 75 mg/m2, once every three weeks, plus prednisone (or prednisolone, if prednisone is not available), 5 mg orally twice daily beginning on day 1 and continuing daily until therapy is discontinued.
Docetaxel will be given intravenously over 60 minutes, followed 30 minutes later by picoplatin as a 1-2 hour intravenous infusion."
1781497|NCT00448747|Drug|AEZS-130 (formerly ARD-07)|A single oral administration of AEZS-130 as Growth Hormone Stimulation Test
1781498|NCT00448747|Drug|L-ARG+GHRH|A single administration of L-ARG+GHRH (iv bolus) followed by a 30min infusion of L-ARG as Growth Hormone Stimulation Test
1781499|NCT00448760|Drug|Docetaxel|Intravenously, 25 mg/m2, over 30 minutes, 2 cycles
1781500|NCT00448760|Drug|Floxuridine|Intravenuosly, 110mg/kg, continuous infusion over 24 hours, 2 cycles
1781501|NCT00448760|Drug|Leucovorin|Intravenuosly, 500mg/m2, continuous infusion over 24 hours, 2 cycles
1781502|NCT00448760|Drug|Oxaliplatin|Intravenously, 85 mg/m2, over 2 hours, 2 cycles
1781503|NCT00448760|Genetic|Microarray analysis|Analysis of tumor for pathologic response to protocol therapy
1781504|NCT00448760|Genetic|reverse transcriptase-polymerase chain reaction|Analysis of tumor for pathologic response to protocol therapy
1781505|NCT00448760|Procedure|Conventional surgery|Surgical removal of tumor for correlative studies
1781506|NCT00448773|Behavioral|Online education|
1781507|NCT00448786|Drug|AMG 706|Arm B - AMG 706 75 mg BID 2-weeks on and 1-week off
1781508|NCT00448786|Drug|AMG 706|Arm C - 75 mg BID 5-days on, 2-days off
1781509|NCT00448786|Drug|AMG 706|AMG 706 125 mg daily continuously (Arm A)
1781510|NCT00448799|Radiation|[123-I] AV-83 Injection and Imaging Procedures|Evaluation of [123I] AV83 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
1781511|NCT00448825|Drug|Topiramate + Cognitive Behavioral Therapy|Topiramate up to 300 mg per day
1781512|NCT00448825|Drug|Placebo + Cognitive Behavioral Therapy|Placebo twice a day
1781513|NCT00448838|Biological|Cetuximab|Cetuximab: an initial loading dose of 400 mg/m2 will be given followed by 250 mg/m2 administered weekly. Cetuximab will be given first followed by gemcitabine on the weeks the patient receives cytotoxic chemotherapy on day 1. Cetuximab will be given as a single agent on Day 8. The treatment will be given on two-week cycles.
1781514|NCT00448838|Drug|Gemcitabine Hydrochloride|Gemcitabine 1000 mg/m2 IV day 1. The treatment will be given on two-week cycles.
1781515|NCT00448838|Drug|Oxaliplatin|Oxaliplatin 100 mg/m2 IV day 2. The treatment will be given on two-week cycles.
1781516|NCT00448851|Biological|inhaled allergen challenge|Subjects will inhale gradually increasing concentrations of Dermatophagoides farinae until a 15% drop in FEV1 is noted
1781517|NCT00448864|Drug|Ecallantide|
1781518|NCT00448864|Drug|Placebo|
1781519|NCT00448877|Device|fNIR light emitting and sensing device|
1781520|NCT00448890|Drug|GSK729327|Tablets
1781521|NCT00448890|Drug|Placebo|GSK729327 Matching placebo - Tablets
1781522|NCT00448903|Drug|Bemiparin|Bemiparin sodium
1781523|NCT00448903|Drug|Placebo|Sodium Chloride 0,9%
1781524|NCT00448916|Drug|Pregabalin|Orally-administered pregabalin
1781525|NCT00448929|Device|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
1781526|NCT00448942|Behavioral|Daily bathing with Chlorhexidine based product|
1781527|NCT00448955|Drug|ARD-0403|ARD-0403
1781528|NCT00448981|Behavioral|Hand hygiene and educational material|
1781529|NCT00448981|Device|Mask, alcohol and hand sanitizer|
1781530|NCT00449007|Drug|fluoxetine|6 months
1781531|NCT00449007|Drug|bupropion|6 months
1781532|NCT00449020|Drug|Carboplatin|CARBOPLATIN (AUC=2) IV in 250 cc NS over 30 minutes, weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
1781533|NCT00449020|Drug|Docetaxel|DOCETAXEL 75 mg/m2 IV over one hour every three weeks for 3 cycles.
1781534|NCT00449020|Drug|irinotecan hydrochloride|IRINOTECAN 30 mg/m2 IV over 90 minutes weekly for seven weeks (Days #1, #8, #15, #22, #29, #36 and #43) along with radiation.
1781535|NCT00449020|Radiation|radiation therapy|Radiotherapy will start on the first day of scheduled chemotherapy. The daily administered dose will be 1.8 Gy, 5 days a week for 4.4 weeks, 22 fractions, ( 39.6 Gy) to the primary tumor and mediastinum (primary planning target volume: PPTV). After 39.6 Gy, the same targets will be treated by oblique fields at 1.8 GY for 3 fxs to a toal dose of 45 GY. Thereafter, the primary tumor and involved nodal metastasis (secondary planning target volume SPTV) will be boosted at 2 Gy per day to 18 Gy in 9 fractions. The total dose will be 63 Gy in 35 fractions over seven weeks.
1781536|NCT00449033|Drug|Sorafenib (Nexavar, BAY43-9006)|Multikinase inhibitor, Sorafenib 400 mg po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
1781537|NCT00449033|Drug|Placebo|Placebo 2 tablets po bid; applied in combination with chemotherapy components: Gemcitabine 1250 mg/m^2 IV, Cisplatin 75 mg/m^2 IV
1781538|NCT00449033|Drug|Gemcitabine|Chemotherapy component; Gemcitabine 1250 mg/m^2 IV
1781539|NCT00449033|Drug|Cisplatin|Chemotherapy component; Cisplatin 75 mg/m^2 IV
1781540|NCT00449046|Drug|GW815SF Salmeterol/Fluticasone propionate(HFA MDI)|
1781541|NCT00449059|Drug|acute infusion of nitroglycerine into the pulmonary artery|
1781542|NCT00449072|Other|Placebo|Placebo to TAA-AQ was administered once at the study site in each nostril during the baseline/screening period to demonstrate intranasal IP administration
1781543|NCT00449072|Other|Placebo|Placebo to TAA-AQ was administered intranasally once daily in each nostril during the double-blind period
1781544|NCT00449072|Drug|TAA-AQ, Nasacort® AQ|110 μg TAA-AQ was administered once daily intranasally (1 spray delivering 55 μg of TAA-AQ in each nostril) during the double-blind treatment period
1781545|NCT00449072|Drug|Claritin®|Participants were provided Children's Claritin® Syrup (5 mg of loratadine per 5 mL), as rescue medication for the relief of allergic rhinitis (AR) symptoms, and could be used throughout the study on an as needed basis according to the Food and Drug Administration-approved manufacturer's label
1781546|NCT00449085|Procedure|Electrophysiology|
1781547|NCT00449085|Device|CARTO™ XP EP Navigation System V9|
1781548|NCT00449098|Device|OculusGen Biodegradable Collagen Matrix Implant|Trabeculectomy with OculusGen Biodegradable Collagen Matrix Implant
1781549|NCT00449098|Drug|Trabeculectomy with MMC|Trabeculectomy with MMC
1781550|NCT00449111|Drug|MK0954, losartan potassium / Duration of Treatment - 12 weeks|
1781551|NCT00449124|Drug|Placebo|Injections of 0.5 mL of normal saline solution (0.9% NaCl).
1781552|NCT00449124|Biological|TG4040|Modified vaccinia virus Ankara encoding hepatitis C virus (HCV) proteins NS3, NS4, and NS5B administered by subcutaneous injection into the thigh. Dosages: TG4040 10^6 PFU, TG4040 10^7 PFU and TG4040 10^8 PFU.
1781553|NCT00449137|Drug|Arsenic trioxide|ATO will be administered at dose levels determined by the dose escalation scheme (section 4.2). Intra-venous (IV) infusion of ATO (mg/kg body weight) over 1-4 hours will be administered for 5 consecutive days (day 1 to day 5) during the first week, twice a week on weeks 2 and 3 (days 8, 11, 15, and 18), and only one day (day 22) of week 4. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
1781554|NCT00449137|Drug|Fluorouracil|Escalate 5-FU, starting at dose 1600 mg/m2. On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
1781555|NCT00449137|Drug|Leucovorin calcium|On day 8, 15, and 22 the assigned dose of 5 FU plus 500 mg/m2 of leucovorin will be administered over 24 hours intravenous infusion following the administration of arsenic trioxide. Treatment will continue for a maximum of 8 cycles, provided that the patient tolerates treatment and there is evidence of clinical benefit.
1781556|NCT00449137|Other|Plasma levels of elemental arsenic|Pre-Treatment and and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22
1781610|NCT00440726|Drug|methotrexate|Intrathecal administration
1781611|NCT00440726|Drug|vincristine|Intravenous push on days 1, 8, 15, 22
1781612|NCT00440739|Drug|etoricoxib|etoricoxib 120 mg
1781613|NCT00440739|Drug|flavoxate|flavoxate 200 mg 3 times
1781557|NCT00449137|Genetic|Peripheral Blood Mononuclear Cells (PBMC) for mRNA analysis|Peripheral blood samples (PAXgene Blood RNA tube, Qiagen, USA) will be obtained up to 2 weeks prior to start of treatment (same day as the first FNA) and one hour post ATO on days 1, 5, 8, 11,15, 18, and 22. Along with FNA an additional blood sample will be obtained on day 23 of every odd treatment cycle.
1781558|NCT00449137|Procedure|Tumor Biopsy (Fine-Needle Aspiration)|Pre-Treatment, Day 23 of Cycles 1, 3, 5, 7
1781559|NCT00449150|Drug|Cetrorelix|Cetrorelix 78 mg combining Week 0 and Week 2 + 78 mg combining Week 26 and Week 28
1781560|NCT00449150|Drug|Cetrorelix|Cetrorelix 78 mg combining Week 0 and Week 2 + 52 mg combining Week 26 and Week 28
1781561|NCT00449150|Drug|Placebo|Placebo at Week 0/2 and Placebo at Week 26/28
1781562|NCT00449163|Biological|Bevacizumab|
1781563|NCT00449163|Drug|Floxuridine|
1781564|NCT00449163|Drug|Irinotecan|
1781565|NCT00449163|Drug|Leucovorin|
1781566|NCT00449176|Drug|tapentadol (CG5503) ER|50, 100, 150, 200, 250 mg twice daily for 15 weeks
1781567|NCT00449176|Drug|oxycodone CR|10, 20, 30, 40, 50 mg twice daily for 15 weeks
1781568|NCT00449176|Drug|placebo|matching placebo twice daily for 15 weeks
1781569|NCT00449202|Drug|oleoyl-estrone (MP 101)|
1781570|NCT00449228|Procedure|-preoperative education and total hip replacement|-preoperative education and total hip replacement
1781571|NCT00449241|Device|Acupuncture|
1781572|NCT00449254|Drug|oleoyl-estrone (MP-101)|
1781573|NCT00449267|Device|Intraocular Lens|Phacoemulsification with in the bag implantation of the IOL
1781574|NCT00449280|Drug|Sorafenib|400mg BID (200 mg twice daily)
1781575|NCT00449280|Drug|Rapamycin|30mg once weekly
1781576|NCT00449280|Drug|Rapamycin|3mg once daily
1781577|NCT00449293|Behavioral|standard cognitive behavioral therapy|Standard therapy to help participants with smoking cessation.
1781578|NCT00449293|Behavioral|Mindfulness Based Cognitive Therapy|A novel mind body therapy that extends basic CT principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
1781579|NCT00449319|Procedure|Identification of appropriate therapies according to risks factors|
1781580|NCT00449319|Drug|Daunorubicine|
1781581|NCT00449319|Procedure|Transplant|
1781582|NCT00440557|Drug|Epoetin alfa 3 times weekly /once weekly|Epoetin alfa will be administered as a SC injections at initial dose of 50 IU/kg (3 times weekly for 22 weeks) and at initial dose of 10000 IU (once weekly for 22 weeks)
1781583|NCT00440557|Drug|Epoetin alfa once weekly|Epoetin alfa will be administered as a SC injection at initial dose of 10000 IU (once weekly for 44 weeks).
1781584|NCT00440557|Drug|Epoetin alfa once every two weeks|Epoetin alfa will be administered as a SC injection at initial dose of 20000 IU (once every 2 weeks for 44 weeks).
1781585|NCT00440570|Device|Low levels of amplitude-modulated electromagnetic fields|
1781586|NCT00440570|Device|Emitter of low levels of amplitude-modulated electromagnetic fields|
1781587|NCT00440583|Drug|chemotherapy followed by Zevalin|6 cycles of chemotherapy with CHOP (Cyclophosphamide iv 750 mg/m2 over 15-45 minutes; Doxorubicin iv 50 mg/m2 over 5-20 minutes; and Vincristine iv 1.4 mg/m2 over 5-15 minutes on day 1 and oral prednisone 40 mg/m2 on days 1-5 repeated every 21 days), followed by Zevalin
1781591|NCT00440622|Drug|Gemcitabine|Gemcitabine at the dose of 1250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
1781592|NCT00440622|Drug|Herceptin|Herceptin 8 mg/Kg (90 min IV) on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles over a 30 min IV
1781593|NCT00440622|Drug|Capecitabine (Xeloda)|Capecitabine at the dose of 1250 mg/m2 b.i.d p.o on day 1-14 every 3 weeks 6 cycles
1781594|NCT00440635|Drug|Bortezomib, tradename Velcade|
1781595|NCT00440648|Drug|sevelamer carbonate, sevelamer hydrochloride|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
1781596|NCT00440648|Drug|sevelamer hydrochloride, sevelamer carbonate|Starting dose individualized for each patient and fixed daily dose throughout both treatment periods
1781597|NCT00440661|Drug|Diacerhein|
1781598|NCT00440674|Device|CoStar Paclitaxel-eluting coronary stent system|
1781599|NCT00440687|Drug|Fluticasone 500mcg BD via accuhaler or identical placebo|
1781600|NCT00440700|Behavioral|Anxiety Self-Management, Patient preferred relaxing music|Experimental group randomized to patient-directed music intervention where subjects listened to tailored, self-selected music as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
1781601|NCT00440700|Behavioral|Control 1: Noise-cancelling headphones|Control group: noise-canceling headphones only where subjects wear headphones as desired (frequency and length determined by the individual subject) each day they are receiving mechanical ventilatory support.
1781602|NCT00440700|Behavioral|Control 2: Standard of Care|Usual ICU nursing care.
1781603|NCT00440713|Drug|Aripiprazole|
1781604|NCT00440713|Behavioral|Interpersonal Therapy|
1781605|NCT00440726|Drug|bortezomib (Velcade)|Intravenous at 1.3mg/m2 on days 1, 4, 8 and 11
1781606|NCT00440726|Drug|dexamethasone|Intravenous or oral administration for 14 days.
1781607|NCT00440726|Drug|PEG-asparaginase|Intramuscular injection
1781608|NCT00440726|Drug|doxorubicin|Intravenous infusion
1781609|NCT00440726|Drug|cytarabine|Intrathecal administration on day 1
1781614|NCT00440739|Drug|etoricoxib, flavoxate|etoricoxib 120 mg once and flavoxate 200 mg 3 times
1781615|NCT00440739|Drug|placebo|placebo once and placebo 3 times
1781616|NCT00440765|Drug|bortezomib|dose as determined (observational study) by treating physician
1781617|NCT00440778|Drug|Abciximab|100% abciximab bolus dose (0.3 mg/kg) ic or iv vs standard bolus (0.25 mg/kg) ic or iv plus 12-hr infusion
1781618|NCT00440791|Device|PillCam Colon capsule endoscopy|
1781619|NCT00440804|Drug|ibuprofen l-lysine iv solution (NeoProfen (R) )|
1781620|NCT00440817|Other|No intervention|All treatments are prescribed by a physician on the basis of usual clinical practice.
1781621|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10 or 15mg/day) applied to smokers
1781622|NCT00440830|Drug|nicotine patch|nicotine patch (0,5,10,or 15mg/day) applied to nonsmokers
1781623|NCT00440830|Drug|placebo|placebo patch applied to smokers
1781624|NCT00440830|Drug|placebo|placebo patch applied to nonsmokers
1781625|NCT00440843|Drug|Olanzapine (Zyprexa)|OLZ
1781626|NCT00440843|Drug|Typicals|Stay on typicals regimen
1781627|NCT00440856|Behavioral|Presentation of excised intervertebral disc fragments|
1781628|NCT00440869|Dietary Supplement|N-acetylcysteine|600 mg po bid
1781629|NCT00440869|Dietary Supplement|placebo|bid oral dosing
1781630|NCT00440895|Drug|Abciximab|Abciximab (bolus) i.c. or i.v. or placebo, bolus dose is calculated according to current dosage (0.25 mg/kg) followed by 12 h infusion at 0.125 µg/kg/min (max 10µg/min).
1781631|NCT00440921|Drug|Single donor Allogenous Fibrin Sealant|
1781632|NCT00440934|Device|Amplitude-modulated electromagnetic fields|
1781633|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV) + ritonavir (/r)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV)+ ritoanvir (/r) for 36weeks followed by ABC/3TC + ATV + /r for 48wks followed by optional treatment extension for 60 weeks on the same regimen
1781634|NCT00440947|Drug|Abacavir (ABC)/lamivudine (3TC) + atazanavir (ATV)|Abacavir (ABC)/lamivudine (3TC) FDC + atazanavir (ATV) + ritonavir (/r) for 36 weeks followed by ABC/3TC + ATV for 48wks followed by optional treatment extension for 60 weeks on the same regimen
1781635|NCT00440960|Drug|propofol|
1781636|NCT00440960|Drug|midazolam|
1781637|NCT00440960|Drug|alfentanil|
1781638|NCT00440960|Drug|lidocaine|
1781639|NCT00440973|Drug|Bevacizumab|monoclonal antibody with anti-angiogenesis properties used as chemotherapy
1781640|NCT00440973|Drug|Interleukin-2|immunotherapy - cytokine signaling molecule used as an immune system regulator to trigger T & B lymphocyte proliferation
1781641|NCT00440986|Procedure|Eritrocytoapheresis|
1781642|NCT00440999|Drug|Pyronaridine artesunate|
1781643|NCT00440999|Drug|Chloroquine|
1781644|NCT00441012|Biological|Comparator: Modified Process Vaccine|Modified process vaccine HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4 & 12 months of age. Duration of treatment is 11 months.
1781645|NCT00441012|Biological|Comparator: COMVAX™|COMVAX™ HBsAg 5 ug/0.5 mL and PRP [OMPC] 7.5 ug/0.5 mL in a 3-dose regimen at 2, 4, and 12 months of age. Duration of treatment is 11 months.
1781646|NCT00441025|Drug|Alemtuzumab|
1781647|NCT00441038|Behavioral|The Back Guide|Education on postural hygiene and handout of The Back Guide
1781648|NCT00441038|Behavioral|The Back Book|Education on active management and Handout of The Back Book
1781649|NCT00441038|Behavioral|Cardiovascular and general health|Education on cardiovascular and general health
1781650|NCT00441051|Drug|Diclofenac sodium 1mg/g|
1781651|NCT00441064|Drug|Aliskiren|
1781652|NCT00441077|Behavioral|Education|
1781653|NCT00441090|Drug|Placebo|Placebo Tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
1781654|NCT00441090|Drug|AKR-501 Tablets|AKR-501 Tablets 2.5, 5, 10 and 20 mg taken orally once daily for 28 days.
1781655|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week for 40 weeks.
1781656|NCT00441103|Drug|Placebo|Matching placebo will be administered subcutaneously three times a week for 16 weeks.
1781657|NCT00441103|Drug|Rebif® New Formulation (IFN-beta-1a, RNF)|RNF will be administered at a dose of 44 mcg subcutaneously three times a week from Week 17 to Week 40.
1781658|NCT00441116|Drug|Dutasteride 0.5mg oral tablets|Dutasteride
1781659|NCT00441129|Device|Minimed paradigm Real Time Sytem|
1781660|NCT00441142|Drug|ZD6474|Taken orally once a day (at 100 mg/day is the phase II dose; the MTD determined by the phase I portion of the trial) until disease gets worse or participants experience unacceptable side effects
1781661|NCT00441142|Drug|temozolomide|"During the 'Induction' phase: 75/mg/m2/day temozolomide will be given orally daily for 6 weeks (42 days) during radiation therapy, beginning either the night before or on the first day of the first fraction of radiation, including weekends and holidays. This is followed by a 4-6 week break.
During the 'Maintenance' phase: The first post-radiation temozolomide cycle will be administered at 150 mg/m2/day orally for 5 days (days 1-5) of a 28-day TMZ cycle. If 150 mg/m2/day is tolerated without difficulty and the investigator feels the patient can tolerate 200 mg/m2/day, then an increase to a maximum of 200 mg/m2/day for five days every 28 days may be given. This is given for 12 cycles."
1781662|NCT00441142|Radiation|Radiation Therapy|Radiotherapy must be given by external beam to a partial brain field in daily fractions of 180-200 cGy, to a planned total dose to the tumor of approximately 6000 cGy.
1781663|NCT00441155|Drug|Nilotinib, Imatinib|Nilotinib 50 mg and 200 mg gelatin capsules and Imatinib 100 mg and 400 mg film-coated tablets in bottles.. Medication labels for each study drug complied with the legal requirements of each country, were printed in the local language.
1781664|NCT00441168|Drug|adriamycin|adriamycin: 9mg/m² intravenous (IV) push on days 1 to 4
1781665|NCT00441168|Drug|bortezomib|bortezomib: 1.3 mg/m² intravenous (IV) bolus on days 1, 4, 8, and 11
1781666|NCT00441168|Drug|dexamethasone|dexamethasone: 40 mg daily days 1- 4/9-12/17-20 - cycle 1 / days 1-4/17-20 - subsequent cycle
1781667|NCT00441168|Drug|vincristine|vincristine: 0.4mg IV push on days 1 to 4
1781668|NCT00441181|Drug|Travoprost|
1781669|NCT00441194|Device|Visual Field (Octopus 311 and the HFA 700 series)|
1781670|NCT00441207|Drug|Ascorbic Acid|Delivered via IV Infusion.
1781671|NCT00441233|Device|Silicone hydrogel contact lens|
1781672|NCT00441246|Drug|Mucinex D (600 mg guaifenesin and 60 mg pseudoephedrine HCl extended-release bi-layer tablets)|
1781673|NCT00441259|Biological|ChimeriVax™-JE|One dose of 4.0 log10 PFU is given in a volume of 1 ml for children aged > 3 years and 0.5 ml to children and infants aged < 3 years administered subcutaneously
1781674|NCT00441259|Biological|Japanese Encephalitis Inactivated Mouse Brain Vaccine|Two doses of 1 ml reconstituted JE-MBDV is given to subjects aged > 3 years and 0.5 ml is given to children and infants aged < 3 years administered subcutaneously
1781675|NCT00441272|Drug|Pioglitazone|
1781676|NCT00441285|Drug|Praziquantel|- Praziquantel 50 mg / kg / d (up to 3600 mg / d ) for 10 days.
1781677|NCT00441285|Drug|Albendazole|"Albendazole 15 mg / kg / d ( up to 800 mg /d ) in Arm I for 10 days.
Albendazole at an increased dose, 22.5 mg / kg / d (up to 1200 mg / d ), in Arm II for 10 days."
1781678|NCT00441285|Drug|ABZ Placebo|- Placebo (of Albendazole ) 7.5 mg / kg / d in Arm I and II for 10 days.
1781679|NCT00441285|Drug|PZQ Placebo|- Placebo (of Praziquantel) 50 mg / kg / d in Arm II and III for 10 days.
1781680|NCT00441298|Drug|Tenofovir gel|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
1781681|NCT00441298|Drug|Placebo (Universal HEC placebo)|Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, placebo gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
1781682|NCT00441311|Behavioral|Academic Detailing|The academic detailing intervention will involve multiple components some of which are standardized across physicians (i.e. self-learning packets, newsletters). Detailing will also be customized to each physician, although the frequency of the detailing visits will be routinized across all participants to reduce cost and to maximize its potential for dissemination.
1781683|NCT00441324|Procedure|recombinant human LH|
1781684|NCT00441337|Biological|MDX-1106|patients will receive a single dose of MDX-1106 as a 60 minute infusion.
1781685|NCT00441350|Drug|OM 40|Initially patients were to be treated with Olmesartanmedoxomil (OM)40 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/12.5 mg and responders remained on the previous therapy for further 8 weeks.
1781686|NCT00441350|Drug|OM/HCTZ 40/12.5|Initially patients were to be treated with Olmesartanmedoxomil (OM) /Hydrochlorothiazide (HCTZ)40/12.5 mg tablets once daily for 8 weeks. After 8 weeks non-responders were to be uptitrated to OM/HCTZ 40/25 mg and responders remained on the previous therapy for further 8 weeks.
1781687|NCT00441363|Drug|Bromocriptine Mesylate|0.8 mg tablet
1781688|NCT00441376|Drug|ThermoDox|15 ml vial containing 2mg/ml Doxorubicin HCl, DPPC, MSPC, DSPE-MPEG 2000. Administered as single dose intravenously over 30 minutes. Dose is determined by dose cohort patient enters study.
1781689|NCT00449345|Procedure|Blood test for Quantiferon-GOLD assay|
1781690|NCT00449358|Procedure|apply methyl-ALA cream|
1781691|NCT00449384|Behavioral|Diagnostic Screening|
1781692|NCT00449397|Drug|Quetiapine Fumarate|
1781693|NCT00449410|Drug|Atorvastatin|
1781694|NCT00449410|Drug|ezetimibe|
1781695|NCT00449423|Drug|acipimox|
1781696|NCT00449436|Drug|TRIZIVIR|
1781697|NCT00449436|Drug|Non-nucleoside reverse transcriptase inhibitor|
1781698|NCT00449436|Drug|Boosted Protease Inhibitor|
1781699|NCT00449449|Drug|Pertubation with Lidocain Solution|
1781700|NCT00449462|Procedure|consumption of CLA enriched food|
1781701|NCT00449488|Drug|epoetin alfa|epoetin alfa 60.000 IU one i.v. bolus
1781702|NCT00449501|Drug|Budesonide/formoterol pMDI|
1781703|NCT00449501|Drug|Budesonide HFA pMDI|
1781704|NCT00449514|Drug|tamoxifen|
1781705|NCT00449514|Drug|clomiphene citrate|
1781706|NCT00449527|Drug|Budesonide/formoterol pMDI|
1781707|NCT00449527|Drug|Budesonide HFA pMDI|
1781708|NCT00449540|Device|Active Transcranial Magnetic Stimulation (TMS) Device|Transcranial Magnetic Stimulation Device treatment
1781709|NCT00449540|Device|Sham TMS Device|Simulated Sham treatment without TMS delivery
1781710|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 15 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
1781711|NCT00449553|Drug|Pioglitazone and sulphonylurea|Pioglitazone 30 mg, tablets, orally, once daily and stable sulphonylurea therapy for up to 24 months.
1781712|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 15 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
1781713|NCT00449553|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and stable metformin therapy for up to 24 months.
1781714|NCT00449579|Device|Excercise stress test with high frequency ECG recording (HyperQ™ System)|
1781715|NCT00449592|Drug|Zinc|Oral Zincol 1 Tab TID from day -6/-7 until discharge
1781716|NCT00449592|Drug|Placebo|Oral placebo 1 Tab TID from day -6/-7 until discharge
1781717|NCT00449605|Drug|Rimonabant|Tablet, oral administration
1781718|NCT00449605|Drug|Glimepiride|Tablet, oral administration
1781719|NCT00449605|Drug|Metformin|Metformin continued at stable dose as background therapy
1781720|NCT00449618|Drug|Aspirin 100 mg|dose of 100 mg administered on awakening or at bedtime
1781721|NCT00449618|Device|Ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
1781722|NCT00449618|Procedure|Chronotherapy, timing of medication|Dosing on awakening versus bedtime
1781723|NCT00449618|Drug|Placebo|Use of placebo on awakening versus bedtime
1781724|NCT00449644|Drug|TMC207|TMC207 400mg (4 tablets) once daily for 14 days, 200mg (2 tablets) three times a week for 6 or 22 weeks.
1781725|NCT00449644|Drug|Placebo|Placebo 4 tablets once daily for 14 days, 2 tablets three times a week for 6 or 22 weeks.
1781726|NCT00449644|Drug|Background regimen (BR) for MDR-TB (multi-drug resistant tuberculosis)|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as speciified in the protocol for up to 96 weeks.
1781727|NCT00449657|Drug|Taxol (paclitaxel)|paclitaxel 15mg/m2 Q am on Mon/Wed/Fri
1781728|NCT00449657|Procedure|Radiotherapy|"Off cord thoracic radiotherapy 200cGy (total dose 1000cGy). Mon/Wed/Fri: radiotherapy is delivered at least 6 hrs after chemotherapy. Tue/Thurs: radiotherapy is delivered 24 hrs or less from the paclitaxel dose the day before.
Off-cord and off-esophagus concomitant boost radiotherapy 100 cGy (total dose 500 cGy)Mon/Wed/Fri of week 5"
1781729|NCT00449657|Drug|Carboplatin|Carboplatin AUC 5mg/min/ml, prior to Gemcitabine on Wed of weeks 8 & 9
1781730|NCT00449657|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 at a fixed dose rate of 10mg/m2/min on Wed during week 8 & 9
1781732|NCT00449683|Drug|terazosin|off-label use of terazosin to treat antidepressant-induced sweating
1781733|NCT00449696|Device|Gel-200|Single intra-articular injection
1781734|NCT00449696|Device|Placebo|Single intra-articular injection
1781735|NCT00452608|Drug|amido pill|one pill of amido/d by mouth for 10 days
1781736|NCT00452608|Drug|atorvastatina|atorvastatina 80 mg/day by mouth for 10 days
1781737|NCT00452621|Procedure|blood draw|
1781738|NCT00452634|Drug|Irinotecan|Irinotecan 65mg/m2/iv over 90min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
1781739|NCT00452634|Drug|Cisplatin|Cisplatin 30mg/m2/iv over 30min on day 1 and 8, repeat Q 3weeks. until disease progression, unacceptable toxicity or patients' refusal.
1781740|NCT00452634|Drug|Simvastatin|simvastatin 40mg/QD, PO, daily, every 3 weeks
1781741|NCT00452660|Drug|Exjade|
1781742|NCT00452673|Drug|Dasatinib|Tablets, Oral, 50 mg or 70 mg twice a day (BID), 100 mg once per day (QD). Treatment may continue until disease progression
1781743|NCT00452673|Drug|Capecitabine|Tablets, Oral, 660 - 1250 mg/m^2 twice a day (BID). Treatment may continue until disease progression.
1781744|NCT00452686|Biological|Boostrix|
1781745|NCT00452686|Biological|Chinese DT vaccine|
1781746|NCT00452699|Drug|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
1781747|NCT00452699|Drug|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
1781748|NCT00452712|Procedure|All subjects will have their blood pressure measured in supine position (after 5 minute of rest) and after 3 minute of standing.|
1781749|NCT00452725|Drug|MAXOMAT ®, biosynthetic growth hormone|2 posologies according to age (children and adolescents) treatment is planned for a 2 year duration
1781750|NCT00452738|Behavioral|Therapy dog|
1781751|NCT00452738|Behavioral|Costumed character|
1781752|NCT00452738|Behavioral|Parents-only|
1781753|NCT00452751|Procedure|laparoscopy-assisted distal gastrectomy|
1781754|NCT00452751|Procedure|open distal gastrectomy|
1781755|NCT00452764|Behavioral|Withdrawal of medication|
1781756|NCT00452777|Drug|BVT.115959|
1781757|NCT00452777|Drug|Placebo|
1781758|NCT00452790|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
1781759|NCT00452790|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 6, 10, 14 weeks and 12 months of age
1781760|NCT00452803|Drug|chemotherapy|Paclitaxel 90mg/m2 + Cisplatin 40mg/m2 on D1 & 8 q 3weeks, Pre-OP & post-op : 2cycles (total 4 cycles)
1781761|NCT00452803|Drug|Concurrent chemoradiation therapy|Paclitaxel 50mg/m2 + Cisplatin 20mg/m2 on D1 & 8 q 3weeks, Pre-OP & post-op : 2cycles (total 4 cycles)
1781762|NCT00452803|Radiation|Concurrent chemoradiation therapy|Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx
1781763|NCT00452816|Behavioral|Workplace Solutions Consulting approach|"Consulting process includes:
baseline measure of best practices
gap analysis and recommendations reporting
delivery of solution set toolkits for each practice chosen for implementation"
1781764|NCT00452816|Behavioral|Delayed intervention|Abbreviated version of the Workplace Solutions Consulting process applied in the intervention group
1781765|NCT00452829|Drug|Folic Acid and inositol|Folic Acid and inositol
1781766|NCT00452829|Drug|Folic acid and placebo|Folic acid and placebo
1781767|NCT00452855|Procedure|Sevoflurane-remifentanil anaesthesia|
1781768|NCT00452868|Drug|Donepezil|Donepezil 5 milligrams a day for 6 weeks
1781769|NCT00452881|Drug|gemcitabine|Gemcitabine1250mg/m2 iv on day 1 and 15, every 4weeks, maximum 4 cycles
1781770|NCT00452881|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
1781771|NCT00452881|Drug|Cisplatin|Cisplatin 40mg/m2 iv on day 1 and 15, every 4 weeks, maximum 4 cycles
1781772|NCT00452894|Drug|varenicline tartrate|
1781773|NCT00452907|Drug|Artesunate|oad, per os, 3 days of treatment
1781774|NCT00452907|Drug|Artesunate + Sulfadoxine-Pyrimethamine|oad, per os
1781775|NCT00452907|Drug|arthemether + lumefantrine|bid, per os. Duration of treatment: 3 days
1781776|NCT00452920|Drug|docetaxel|
1781777|NCT00452920|Radiation|cesium Cs 137|
1781778|NCT00452920|Radiation|radiation therapy|
1781779|NCT00452972|Drug|Spinal Anesthesia|
1781780|NCT00452985|Drug|Docetaxel|60-75 mg/m²
1781781|NCT00452985|Drug|Carboplatin|AUC 5
1781782|NCT00452998|Procedure|Q-switched fd Nd:yag in Laser Iridotomy|
1781783|NCT00453011|Device|posterior chamber intraocular lens|
1781784|NCT00453011|Device|anterior chamber intraocular lens|
1781785|NCT00453024|Procedure|Pericardial graft & tissue glue|
1781786|NCT00453024|Procedure|scleral flap & sutures|
1781787|NCT00453037|Behavioral|structured educational program|structured education and evaluation of hypertensive patients in a design similar to the DAFNE study design. Behavioural intervention follows the Dusseldorf-educational program
1781788|NCT00453037|Behavioral|participation in the educational program after 6 months|Control group consisting of patients randomly assigned to participate in the educational program 6 months later than the active group
1781790|NCT00453050|Drug|indocyanine green solution|
1781791|NCT00453050|Other|flow cytometry|
1781792|NCT00453050|Other|immunologic technique|
1781793|NCT00453050|Other|laboratory biomarker analysis|
1781794|NCT00453063|Drug|mometasone furoate|50 mcg/spray, two sprays in each nostril once daily (ie, 200 mcg QD) in the morning
1781795|NCT00453063|Drug|Placebo|Two sprays in each nostril once daily in the morning
1781796|NCT00453076|Device|Paclitaxel eluting covered metal stent and control covered metal stent|Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique
1781797|NCT00453089|Drug|VG101|
1781798|NCT00453102|Drug|Rituximab|IV Infusion of 250mg/m² of Rituximab Within 4 hours on Days 1, 7, 8, 9 0.4 millicuries (mCi)/kilogram (kg) (14.8 megabecquerels (MBq)/kilogram (kg)) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³
1781799|NCT00453102|Drug|Ibritumomab Tiuxetan|"IV injection of Y-90 Zevalin® over 10 minutes on Days 1, 7, 8, 9:
0.4 mCi/kg (14.8 MBq/kg) for patients with normal platelet count 0.3 mCi/kg (11.1 MBq/kg) for patients with platelet count of 100,000-149,000 cells/mm³"
1781800|NCT00453115|Drug|Oxaliplatin|oxaliplatin 85mg/m2 iv on D1 and 15, every 4 weeks until disease progression
1781801|NCT00453115|Drug|Gemcitabine|gemcitabine 1250mg/m2 iv on day 1 and 15, every 4 weeks until disease progression
1781802|NCT00453141|Drug|dosing of Betamethasone|
1781803|NCT00453154|Drug|sunitinib malate|Given PO
1781804|NCT00453154|Drug|cisplatin|Given IV
1781805|NCT00453154|Drug|carboplatin|Given IV
1781806|NCT00453154|Drug|etoposide|Given IV
1781807|NCT00453154|Other|placebo|Given PO
1781808|NCT00453154|Other|laboratory biomarker analysis|Correlative studies
1781809|NCT00453167|Drug|Paclitaxel|Paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
1781810|NCT00453167|Drug|Gemcitabine|Gemcitabine 1000mg/m2 iv on day 1 and 8, every 3 weeks until disease progression
1958324|NCT01772472|Drug|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks, 14 cycles
1781813|NCT00453193|Drug|Pentostatin|4 mg/m^2 IV weekly for 4 weeks then every 2 weeks
1781814|NCT00453193|Drug|Alemtuzumab|30 mg IV three times weekly
1781815|NCT00453206|Procedure|allogeneic bone marrow transplantation|
1781816|NCT00453206|Procedure|allogeneic hematopoietic stem cell transplantation|
1781817|NCT00453206|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1781818|NCT00453206|Procedure|peripheral blood stem cell transplantation|
1781819|NCT00453219|Procedure|Screening evaluation|A detailed history will be taken and a physical examination performed along with a blood sample to verify ovulatory status in women with regular cycles and determine cause of anovulation in women with irregular or absent menstrual cycles.
1781820|NCT00453219|Procedure|Meal Response|The investigators are interested in how nutrition and metabolism can influence reproduction and they will look at how the body senses hunger and how it responses to food. Blood samples will be collected and questionnaires given to assess responses and feeling about hunger and food.
1781821|NCT00453219|Genetic|Blood Collection|A blood sample will be collected and used to check for genetic markers of stress vulnerability.
1781822|NCT00453219|Procedure|Functional MRI|research participants will have an functional MRI scan of their brain while reviewing word lists associated with body image and emotions. This procedure will last about 1 hour.
1781823|NCT00453219|Procedure|Endocrine Assessment|research participants will have a 30 hour inpatient hospital admission with every 15 minute blood sampling for 24 hours. Hormone measures of stress, reproduction, and appetite will be obtained.
1781824|NCT00453232|Biological|bleomycin sulfate|
1781825|NCT00453232|Biological|pegfilgrastim|
1781826|NCT00453232|Drug|cisplatin|
1781827|NCT00453232|Drug|etoposide|
1781828|NCT00453258|Other|Eye Examination|Subjects receiving eye examination
1781829|NCT00453271|Drug|NB-002|
1781830|NCT00453271|Drug|Vehicle control|
1781831|NCT00453297|Drug|MF101|
1781832|NCT00453310|Drug|sunitinib malate|
1781833|NCT00453323|Drug|Paclitaxel|paclitaxel 80mg/m2 iv on day 1 and 8, every 3 weeks
1781834|NCT00453323|Drug|Capecitabine|capecitabine 900mg/m2 bid po on day 1~14, 1 weeks rest, until disease progression
1781835|NCT00453336|Drug|Porfimer Sodium|Day 1 of Therapy. An IV access (of 20 gauge or larger) is started and 2 mg/kg of Porfimer Sodium (Photofrin®) is given intravenously. Once completed the patient puts on the light protective gear and is sent home.
1781836|NCT00453336|Procedure|Photodynamic Therapy|Laser Activation. The time of exposure and the power of the laser are computed based on the dosimetry in appendix A using a computed energy dose of 75 to 150 joules, depending on the depth of penetration desired.
1781837|NCT00453349|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin (Avelox, BAY12-8039) 400 mg by mouth (PO) once daily for 14 days
1781838|NCT00453349|Drug|Levofloxacin & Metronidazole|Levofloxacin 500 mg by mouth (PO) once daily for 14 days plus Metronidazole 500 mg (PO) twice daily for 14 days
1781839|NCT00453362|Other|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|FDG prepared in sterile buffered solution for intravenous injection. Dosage was based on the participant's weight not to exceed 15 mCi (millicurie).
1781840|NCT00453362|Other|3'-deoxy-3'-[18F]fluorothymidine (FLT)|FLT 7 mCi dose prepared in sterile buffered solution for intravenous injection.
1781841|NCT00453362|Drug|erlotinib HCl|Tablets taken orally 150 mg/day.
1781842|NCT00453375|Drug|BHT-3021|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
1781843|NCT00453375|Drug|BHT-Placebo|Evaluation of up to four dose levels will be given in weekly IM injections for 12 weeks.
1781844|NCT00453388|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
1781845|NCT00453388|Drug|Cyclophosphamide|Given IV
1781846|NCT00453388|Drug|Cyclosporine|Given IV or PO
1781847|NCT00453388|Drug|Fludarabine Phosphate|Given IV
1781848|NCT00453388|Other|Laboratory Biomarker Analysis|Correlative studies
1781849|NCT00453388|Drug|Mycophenolate Mofetil|Given PO
1781850|NCT00453388|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
1781851|NCT00453388|Radiation|Total-Body Irradiation|Undergo TBI
1781852|NCT00453401|Drug|NB-001|
1781853|NCT00453414|Drug|Iloprost Inhalation Solution (Ventavis)|
1781854|NCT00453427|Drug|Alemtuzumab (Campath-1H)|The investigational drug is alemtuzumab (Campath-1H). It is a recombinant humanized monoclonal antibody directed against the CD52 antigen on most (> 95%) normal lymphocytes and T-cell and B-cell lymphomas. Alemtuzumab binds to the CD52 antigen on the cell surface, activating antibody-dependent cellular cytotoxicity, complement binding, apoptosis, cellular opsonization, and anti-tumour T-cell activity.
1781855|NCT00453440|Procedure|Cheek swab & blood test|Cheek swab & blood test
1781856|NCT00453453|Drug|Nesiritide|Nesiritide given orally in the emergency department
1781857|NCT00453466|Behavioral|EBW group intervention to empower battered women|
1781859|NCT00453492|Drug|risedronate sodium|
1781860|NCT00453518|Device|FiberNet EPS used during SVG intervention.|The FiberNet EPS is indicated for use as a guide wire and embolic protection system to capture and remove embolic material produced while performing percutaneous transluminal interventional procedures in saphenous vein grafts.
1781861|NCT00453531|Procedure|Limb Ischemia|
1781862|NCT00453531|Drug|Acetylcholine|
1781863|NCT00453544|Other|Enhanced Consent Procedure|This is a procedure involving use of multimedia materials, as well as standard review with research staff, to see if the research consent procedure can be improved
1781864|NCT00453544|Other|Routine Consent Procedure|This is a procedure designed to be in accord with standard research consent practices (and lacks multimedia aids)
1781865|NCT00453557|Drug|rhGH|
1781866|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
1781867|NCT00453570|Biological|Diphtheria, Tetanus, Polio, Acellular Pertussis and Hib|0.5 mL, IM
1781868|NCT00453570|Biological|Diphtheria, Tetanus, & Acellular Pertussis Combined, Absorbed|0.5 mL, IM
1781869|NCT00453609|Drug|long-lasting injectable naltrexone|
1781870|NCT00453622|Device|Cardiac Resynchronization Therapy-Defibrillator|Implantation of a CRT-D device
1781871|NCT00453635|Drug|Docetaxel|Docetaxel at the dose of 75mg/m^2 IV on day 1 every 3 weeks for 6 consecutive cycles
1781872|NCT00453635|Drug|Carboplatin|Carboplatin at the dose of 5 AUC IV on day 1 every 3 weeks for 6 consecutive cycles
1781873|NCT00453635|Drug|Herceptin|Herceptin 8 mg/Kg on day 1 for the first cycle and 6 mg/Kg for the 5 remaining cycles, IV, every 3 weeks
1781874|NCT00453635|Drug|Vinorelbine|Vinorelbine at the dose of 60mg/m^2 per os,weekly
1781875|NCT00453648|Other|White-fleshed sweet potatoes|
1781876|NCT00453648|Other|Orange-fleshed sweet potatoes (boiled)|
1781877|NCT00453648|Other|Orange-fleshed sweet potatoes (fried)|
1781878|NCT00453648|Other|WFSP and capsule of retinyl palmitate|
1781879|NCT00453661|Behavioral|Questionnaire|"Intervention Group:
Cancer Screening Assessment (CSA) questionnaire 45-60 minutes annually for 4 years + Exit Questionnaire at end of study.
Comparison Group:
Exit Questionnaire only."
1781880|NCT00453661|Behavioral|Patient Navigator (PN)|Staff member, called patient navigator (PN), who assist with medical care and/or screenings, questionnaires.
1781881|NCT00453687|Drug|GSK233705|investigational drug
1781882|NCT00453700|Procedure|Trypanosoma cruzi serology|
1781883|NCT00453726|Procedure|Non invasive mechanical ventilation|
1781884|NCT00453765|Drug|montelukast|montelukast, 8 weeks, once daily, 10 milligrams
1781885|NCT00453765|Drug|placebo|placebo
1781886|NCT00453778|Drug|FLIXOTIDE Diskus 500 mcg (Fluticasone Propionate)|
1781887|NCT00453791|Drug|GW805858|GW805858 MDI will be given with dose of 150 micrograms per metered actuation and 120 actuations per inhaler. GW805858 MDI comprises a solution of GW805858 in a liquefied hydrofluoroalkane propellant (1,1,1,2-tetrafluoroethane) which is contained in an aluminium alloy can, internally coated with a specified fluoropolymer, fitted with a metering valve.
1781888|NCT00453791|Drug|Placebo|Placebo MDI will be given to the subjects.
1781889|NCT00453804|Drug|injectable naltrexone|
1781890|NCT00453804|Drug|oral naltrexone|
1781891|NCT00453817|Drug|ferucarbotran (iron-based MRI contrast agent)|islets will be incubated with ferucarbotran prior to transplantation, for imaging after transplantation
1781892|NCT00453817|Procedure|Islet transplantation|intraportal percutaneous islet transplantation
1781893|NCT00453817|Procedure|Magnetic resonance imaging|Magnetic resonance imaging of the liver before and after islet transplantation (6 days, 6 weeks, 6 months, 1 year)
1781894|NCT00453830|Procedure|laparoscopic sigmoid resection|a laparoscopic 5 trocars approach for left colon mobilization, sigmoid colon transsection and intracorporeal colorectal anastomosis
1781895|NCT00453843|Device|rehabilitation robotics|sequence of intervention
1781896|NCT00453843|Procedure|Movement therapy|sequence of intervention
1781897|NCT00453856|Drug|Sulfadoxine Pyrimethamine|
1781898|NCT00453869|Other|liver fibrosis evaluation|Evaluation of liver fibrosis with blood test
1781899|NCT00453882|Device|flostat (TM) System|
1781901|NCT00453908|Drug|Alfuzosin|
1781902|NCT00453921|Drug|Methylphenidate|Dosage dependent on weight
1781903|NCT00453921|Behavioral|Memory and Attention Training|Weekly Memory and Attention Training with at home practice.
1781904|NCT00453921|Other|Placebo as both treatments|Placebo capsules and Placebo Memory and Attention Training
1781905|NCT00453934|Device|h-Patch|
1781906|NCT00453947|Device|CPAP and Non Invasive Ventilation|
1781907|NCT00453960|Dietary Supplement|Genivis|54 mg/day daily for 6 months
1781908|NCT00453960|Drug|Norethisterone Acetate|tablets 10mg/day from day 16 to 25 of menstruation
1781909|NCT00453960|Other|placebo|tablets daily for 6 months
1781962|NCT00454350|Drug|Hectorol (doxercalciferol injection)|
1781963|NCT00454350|Drug|Zemplar (Paricalcitol injection)|
1781910|NCT00453973|Drug|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.044 milligram per kilogram (mg/kg) with an interquartile range of 0.028 to 0.076 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
1781911|NCT00453973|Drug|peginesatide|Participants received the same initial peginesatide dose via the same route, intravenously or subcutaneously, as was administered at the end of the previous peginesatide treatment study in which the participant was enrolled. The median first dose at study start was 0.024 mg/kg with an interquartile range of 0.017 to 0.035 mg/kg. Each participant was to receive peginesatide as an injection administered once every 4 weeks for approximately 54 months in this trial.
1781912|NCT00453986|Biological|Meningococcal vaccine GSK134612|One intramuscular dose
1781913|NCT00453986|Biological|Mencevax™ACWY|One subcutaneous dose
1781914|NCT00453986|Biological|Fluarix™|One intramuscular dose
1781915|NCT00453999|Drug|Peramivir 200 mg|Peramivir (200 mg in 100 mL of solution) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 mL) treatment
1781916|NCT00453999|Drug|Peramivir 400 mg|Peramivir (400 mg in 100 mL of solution ) intravenous infusion (over 15 minutes) and an orally administered oseltamivir placebo suspension (6.25 ml)
1781917|NCT00453999|Drug|Oseltamivir|Placebo peramivir infusion (over 15 minutes) and a 75-mg dose of oseltamivir suspension (6.25 mL)
1781918|NCT00454012|Procedure|biophysical profile|
1781919|NCT00454038|Device|HYPRO SORB F|resorbable, double layered, collagen membrane
1781920|NCT00454051|Drug|Omalizumab|Omalizumab was supplied as a sterile, freeze dried preparation, to be reconstituted to deliver 150mg of omalizumab. Each vial was reconstituted with 1.4ml of sterile water for injection. The appropriate dose and dosing frequency of omalizumab were determined by baseline total IgE and body weight. A dosing table was used following the European Summary of Product Characteristics (SmPC) of omalizumab.
1781921|NCT00454051|Drug|placebo|Placebo was a physiological salt solution, administered according to the same administration scheme to respect the same dosing frequency and injected volume.
1781922|NCT00454064|Behavioral|cognitive-behavioral treatment|
1781923|NCT00454077|Procedure|radioiodine therapy after rhTSH|
1781924|NCT00454090|Drug|AZD8330|oral tablet
1781925|NCT00454103|Drug|123I-Iodometomidate|
1781926|NCT00454116|Drug|Vandetanib|once daily oral tablet two doses
1781927|NCT00454116|Drug|FOLFIRI|Intravenous infusion
1781928|NCT00454129|Procedure|cholangiography via double-balloon enteroscopy|
1781929|NCT00454129|Procedure|MR cholangiography|
1781930|NCT00454142|Drug|pazopanib hydrochloride|Given PO
1781931|NCT00454142|Other|pharmacological study|Correlative studies
1781932|NCT00454142|Procedure|computed tomography|Correlative studies
1781933|NCT00454155|Drug|Opebacan|4 mg/kg continuous IV infusion for 30 minutes followed immediately by 6 mg/kg/day continuous IV infusion for 3 days
1781934|NCT00454168|Biological|PR1 leukemia peptide vaccine|Given subcutaneously
1781935|NCT00454168|Biological|sargramostim|Given subcutaneously
1781936|NCT00454168|Other|placebo|Given subcutaneously
1781937|NCT00454181|Drug|Interferon-alpha|500 IU interferon-alpha lozenges taken 3 times per day for 24 weeks
1781938|NCT00454181|Other|placebo|200 mg lozenges containing anhydrous crystalline maltose taken three times per day for 24 weeks
1781939|NCT00454194|Drug|pemetrexed disodium|given IV
1781940|NCT00454194|Drug|sorafenib tosylate|given orally
1781941|NCT00454207|Drug|sildenafil citrate (UK-92,480)|sildenafil citrate (UK-92,480)
1781942|NCT00454220|Other|Placebo|33 patients to placebo + 131-I arm
1781943|NCT00454220|Drug|MRrhTSH|33 patients to 0.01 mg MRrhTSH + 131-I arm
1781944|NCT00454220|Drug|MRrhTSH|33 patients to 0.03 mg MRrhTSH + 131-I arm
1781945|NCT00454233|Drug|YM543|Oral
1781946|NCT00454233|Drug|Metformin|Oral
1781947|NCT00454233|Drug|Placebo|oral
1781948|NCT00454246|Drug|methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta was provided as a sterile single-use injectable solution in a 1-mL prefilled syringe containing 0.3 mL or 0.6 mL solution. The methoxy polyethylene glycol-epoetin beta injectable solution was formulated in sodium phosphate, sodium sulfate, mannitol, methionine and poloxamer 188, pH 6.2 and did not contain any preservative. Participants received methoxy polyethylene glycol-epoetin beta subcutaneous once a month.
1781949|NCT00454246|Drug|epoetin alfa|Standard of care as prescribed, per individual participant, subcutaneous once per week. Subcutaneous injections were to be administered in the same part of the body (ie, thigh, abdomen or arm) throughout the study.
1781950|NCT00454246|Drug|darbepoetin alfa|Standard of care as prescribed, per individual participant, darbepoetin alfa subcutaneous once every two weeks. Subcutaneous injections were to be administered in the same part of the body (ie, thigh,abdomen or arm) throughout the study.
1781951|NCT00454259|Drug|Fentanyl/Placebo injection|Ultra low dose intravenous injection
1781952|NCT00454272|Drug|Teicoplanin|
1781953|NCT00454272|Drug|Vancomycin|
1781954|NCT00454285|Drug|Effect of Amoxicillin on bacteremia following a single-tooth extraction|Administer Amoxicillin 1 hour prior to single-tooth extraction.
1781955|NCT00454298|Drug|AGG-523 (Aggrecanase Inhibitor)|
1781956|NCT00454311|Procedure|Biopsy of Day 3 Embryo|
1781957|NCT00454311|Procedure|· day embryo biopsy|
1781958|NCT00454324|Drug|Carboplatin|Carboplatin will be given at a dose of target area under the concentration versus time curve in mg/mL•min (AUC)=6, on Day 1 of a 21 Day Cycle
1781959|NCT00454324|Drug|Abraxane|"Abraxane will be given at a dose of 240mg/m2 on Day 1 of a 21 Day Cycle (Arm A)
Abraxane will be given at a dose of 80mg/m2 on Days 1, 8, and 15 of a 21 Day Cycle (Arm B)"
1781960|NCT00454337|Drug|FTC/TDF + EFV or LPV/R +T20|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day) + enfuvirtide 90mg twice a day
1781961|NCT00454337|Drug|FTC/TDF + EFV or LPV/R|emtricitabine 200mg/TDF 300mg (1 pill per day) + efavirenz 600mg (1 pill per day) or lopinavir/ritonavir (3 pills twice a day)
1781964|NCT00454363|Other|Laboratory Biomarker Analysis|Correlative studies
1781965|NCT00454363|Drug|Pazopanib Hydrochloride|Given PO
1781966|NCT00454363|Other|Pharmacological Study|Correlative studies
1781967|NCT00454376|Other|questionnaire administration|
1781968|NCT00454376|Procedure|quality-of-life assessment|
1781969|NCT00454389|Device|Epi-Rad90™ Ophthalmic System|A single procedure using the Epi-Rad90™ Ophthalmic System plus 2 injections of Lucentis administered 1 month apart
1781970|NCT00454389|Drug|ranibizumab|Lucentis injection administered monthly for the first 3 injections followed by quarterly injections
1781971|NCT00454402|Drug|Alfuzosin|
1781972|NCT00454428|Procedure|pulsatile intra-aortic balloon pump|
1781973|NCT00454441|Drug|MF101|
1781974|NCT00454467|Procedure|Baseline Questionnaire|Patients will fill out a baseline questionnaire prior to surgery.
1781975|NCT00454467|Procedure|Operative Data|Type of prosthesis and other operative data will be uploaded into our database.
1781976|NCT00454467|Procedure|Intra-operative data will be collected post-operatively|Research assistants will post-operatively collect data from patient charts.
1781977|NCT00454467|Procedure|In-hospital post-operative data will be collected|Research assistants will collect information about hospital stay from patient charts.
1781978|NCT00454467|Procedure|Satisfaction data will be extracted from Press/Ganey and on follow-up questionnaires|Follow-up questionnaires will be mailed to participants.
1781979|NCT00454467|Procedure|Cost Data|Cost Data will be collected via hospital billing databases.
1781980|NCT00454467|Procedure|Follow-up questionnaires|Participants will be mailed follow-up questionnaires.
1781981|NCT00454480|Biological|alemtuzumab|
1781982|NCT00454480|Drug|arsenic trioxide|
1781983|NCT00454480|Drug|azacitidine|
1781984|NCT00454480|Drug|busulfan|
1781985|NCT00454480|Drug|clofarabine|
1781986|NCT00454480|Drug|cytarabine|
1781987|NCT00454480|Drug|daunorubicin hydrochloride|
1781988|NCT00454480|Drug|fludarabine phosphate|
1781989|NCT00454480|Drug|gemtuzumab ozogamicin|
1781990|NCT00454480|Drug|melphalan|
1781991|NCT00454480|Drug|tipifarnib|
1781992|NCT00454480|Genetic|DNA methylation analysis|
1781993|NCT00454480|Genetic|cytogenetic analysis|
1781994|NCT00454480|Genetic|gene expression analysis|
1781995|NCT00454480|Genetic|mutation analysis|
1781996|NCT00454480|Other|diagnostic laboratory biomarker analysis|
1781997|NCT00454480|Other|immunologic technique|
1781998|NCT00454480|Procedure|allogeneic hematopoietic stem cell transplantation|
1781999|NCT00454480|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1782000|NCT00454493|Drug|Omacor (omega-3-acid ethyl esters)|
1782001|NCT00454519|Procedure|cytoreductive surgery|the whole abdominal-pelvic cavity is explored and maximal cytoreductive surgery is performed to remove visible tumor burden as much as possible.
1782002|NCT00454519|Procedure|intraoperative peritoneal hyperthermic chemotherapy with cisplatin and mitomycin|Immediately after the cytoreductive surgery, cisplatin and mitomycin C dissolved in 12,000 ml of normal saline heated to 42 degrees celsius is infused into the abdominal cavity for a sustained hyperthermic intraperitoneal chemotherapy for 60 to 90 minutes.
1782003|NCT00454532|Drug|BZL101|Freeze dried powder mixed with liquid. Administered as a daily dose. Dosage to be determined in Phase 1 portion.
1782004|NCT00454545|Drug|Atorvastatin|
1782005|NCT00454558|Drug|Riociguat (Adempas, BAY63-2521)|Biweekly uptitration of BAY63-2521 (Oral sGC Stimulator) starting from 1.0 mg TID up to 2.5 mg TID in steps of +0.5 mg according to safety and tolerability.
1782006|NCT00454571|Drug|pazopanib hydrochloride|Given PO
1782007|NCT00454571|Drug|leuprolide acetate|
1782008|NCT00454571|Drug|goserelin acetate|
1782009|NCT00454584|Drug|CNTO 1275 45 mg|Type=exact number, number=45, unit=mg, form=injection, route=subcutaneous
1782010|NCT00454584|Drug|CNTO 1275 90 mg|Type=exact number, number=90, unit=mg, form=injection, route=subcutaneous
1782011|NCT00454584|Drug|Etanercept 50 mg|Type=exact number, number=50, unit=mg, form=injection, route=subcutaneous
1782012|NCT00454597|Procedure|omentectomy|surgery omentectomy
1782013|NCT00454610|Behavioral|FLOW|
1782014|NCT00454610|Behavioral|SelfHelp|
1782015|NCT00454623|Behavioral|drawing serum adiponectin level|
1782016|NCT00454636|Drug|Cisplatin|80 mg/m2/day, intravenous (IV), every 3 weeks
1782017|NCT00454636|Drug|Capecitabine|1,000 mg/m2, oral, twice daily for 2 weeks, followed by 1 week of rest in each cycle
1782018|NCT00454636|Drug|Epirubicin|50 mg/m2/day, IV, every 3 weeks
1782019|NCT00454636|Drug|Cisplatin|60 mg/m2/day, IV, every 3 weeks
1782020|NCT00454636|Drug|Capecitabine|625 mg/m2, oral, twice daily per 3-week cycle
1782021|NCT00454636|Drug|Oxaliplatin|130 mg/m2/day, IV, every 3 weeks
1782022|NCT00454636|Drug|Docetaxel|60 mg/m2/day, IV, every 3 weeks
1782023|NCT00454636|Drug|Capecitabine|825 mg/m2, oral, twice daily for 2 weeks
1782024|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 1)|Axitinib (AG-013736) 1 milligram (mg) tablet orally twice daily (BID) as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel [200 milligram/square meter (mg/m^2)] 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target area under the concentration-time curve (AUC) of 6.0 milligram*minute/milliliter (mg*min/mL) on Day 1 of Cycle 1 and all subsequent cycles.
1782025|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 2)|Axitinib (AG-013736) 3 tablets of 1 mg orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
1782065|NCT00454909|Biological|Menactra®|Single dose intramuscular injection.
1782066|NCT00454922|Behavioral|standard of care|no intervention
1782205|NCT00445237|Device|H1 and H2 deep TMS coils|
1782026|NCT00454649|Drug|Axitinib + Paclitaxel + Carboplatin (Cohort 3)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Paclitaxel (200 mg/m^2) 3-hour infusion followed by carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
1782027|NCT00454649|Drug|Axitinib + Paclitaxel (Cohort 4)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 25 of Cycle 1 (28 days) and then without interruption from Day 3 for Cycle 2 (28 days) and all subsequent cycles (28 days). Paclitaxel (90 mg/m^2) 60-minute infusion on Day 1, 8, and 15 of each cycle.
1782028|NCT00454649|Drug|Axitinib + Docetaxel + Carboplatin (Cohort 4a)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1 (21 days). Axitinib (AG-013736) 5 mg tablet orally BID from Day 3 to Day 18 of Cycle 1 and Day 3 to Day 20 of Cycle 2 (21 days) and all subsequent cycles (21 days). Docetaxel (75 mg/m^2) 60-minute infusion on Day 1 of every cycle. Carboplatin 30-minutes infusion at a dose to target AUC of 6.0 mg*min/mL on Day 1 of Cycle 1 and all subsequent cycles.
1782029|NCT00454649|Drug|Axitinib + Docetaxel (Cohort 5)|Axitinib (AG-013736) 5 mg tablet orally BID as lead in dose from Day -5, -4 or -3 through Day 2 of Cycle 1. Axitinib (AG-013736) 5 mg oral tablet BID administered from Day 3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Docetaxel (100 mg/m^2) 60-minute infusion on Day 1 of each cycle.
1782030|NCT00454649|Drug|Axitinib + Capecitabine (Cohort 6)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1000 mg/m^2) orally BID from Day 1 to Day 14 of each cycle.
1782031|NCT00454649|Drug|Axitinib + Capecitabine (Cohort 7)|Axitinib (AG-013736) 5 mg tablet orally BID from Day 1 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Capecitabine (1250 mg/m^2) orally BID from Day 1 to Day 14 of each cycle.
1782032|NCT00454649|Drug|Axitinib + Gemcitabine + Cisplatin (Cohort 8)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Gemcitabine (1250 mg/m^2) 30-minute infusion on Day 1 and Day 8 of Cycle 1 and all subsequent cycles followed by cisplatin (80 mg/m^2) infusion on Day 1 of each cycle.
1782033|NCT00454649|Drug|Axitinib + Pemetrexed + Cisplatin (Cohort 9)|Axitinib (AG-013736) 5 mg tablet orally BID from Day -5, -4 or -3 to Day 18 of Cycle 1 (21 days) and then without interruption from Day 3 of Cycle 2 and all subsequent cycles. Pemetrexed (500 mg/m^2) 10-minute infusion followed by cisplatin (75 mg/m^2) infusion on Day 1 of each cycle.
1782034|NCT00454662|Drug|olmesartan medoxomil / amlodipine or azelnidipine|AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine
1782035|NCT00454662|Drug|olmesartan medoxomil / low dose thiazide type drug|AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug
1782036|NCT00454688|Drug|Asimadoline|Asimadoline was provided in coated tablets of three dosages (0.15 mg, 0.5 mg, and 1.0 mg). All asimadoline tablets used in this trial were synthesized from the same batch of drug substance (Batch EF418492). Asimadoline was administered orally, BID for 12 weeks
1782037|NCT00454688|Drug|Placebo|Placebo was provided in coated tablets identical in appearance to asimadoline tablets.
1782038|NCT00454701|Drug|Alefacept exposure|Observational
1782039|NCT00454714|Drug|single dose Sildenafil|Application of a single dose Sildenafil
1782040|NCT00454714|Drug|Single dose placebo|Application of a single dose placebo
1782041|NCT00454740|Drug|solifenacin succinate|Oral
1782042|NCT00454753|Drug|Dasatinib|"tablet, Oral, 140mg/day, BID, until;
the time of reimbursement in Korea
the application for marketing authorization is withdrawn
the application for marketing authorization is denied"
1782043|NCT00454766|Behavioral|Questionnaire|Survey of two educational brochures with approximately the same information, but which vary in their health literacy (readability) level.
1782044|NCT00454779|Drug|Cisplatin|chemotherapy arm
1782045|NCT00454779|Drug|Panitumumab|experimental arm
1782046|NCT00454779|Drug|Docetaxel|chemotherapy arm
1782047|NCT00454779|Drug|Cisplatin|experimental arm
1782048|NCT00454779|Drug|Docetaxel|experimental arm
1782049|NCT00454792|Other|Exercise|Back exercise: At home every day. In groups once a week. Duration 10 weeks.
1782050|NCT00454792|Other|Restitution|Restitution: At home 2 times one hour. Meetings every 2 weeks. Duration 10 weeks.
1782051|NCT00454805|Drug|AZD2171|Oral tablet
1782052|NCT00454805|Drug|Fulvestrant|intramuscular injection
1782053|NCT00454818|Genetic|MYDICAR Phase 1 (Open-label, Serial Dose-Escalation Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
1782054|NCT00454818|Procedure|Placebo Infusion|Saline; epicardial coronary artery infusion
1782055|NCT00454818|Genetic|MYDICAR Phase 2 (Placebo-controlled, Randomized Study)|MYDICAR administered by antegrade epicardial coronary artery infusion
1782056|NCT00454831|Device|HEP-40 chitosan|Enzymatically Hydrolyzed Polychitosamine-40 kDa
1782057|NCT00454857|Other|Retrospective Chart Review|Retrospective chart review for up to 36 months of enrollment date.
1782058|NCT00454857|Other|Patient-reported Outcome Questionnaires|Quality of lige questionnaires as well as treatment satisfaction questionnaires are required monthly. Includes QOL, ITP-PAQ (immune thrombocytopenic purpura - patient assessment questionnaire), EQ-5D, and TSQM (Treatment Satisfaction Questionnaire for Medication).
1782059|NCT00454857|Other|Physician Survey|Physician characteristics to be collected include demographics, years of practice, medical specialty or primary treating physician, and the referral process.
1782060|NCT00454870|Drug|MEM 3454|
1782061|NCT00454883|Drug|ziprasidone|Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.
1782062|NCT00454896|Drug|VESIcare®|Oral
1782063|NCT00454896|Drug|placebo|Oral
1782064|NCT00454909|Biological|Meningococcal vaccine 134612|Single dose intramuscular injection.
1782206|NCT00445250|Drug|Calcipotriol|
1782067|NCT00454922|Other|education|meet with trained glaucoma educator 6 times over life of study
1782068|NCT00454948|Behavioral|Home-based nutrition sessions and play group exercise|
1782069|NCT00454948|Behavioral|Group-based nutrition sessions and mail-out activities|
1782070|NCT00454961|Drug|artemether-lumefantrine|
1782071|NCT00454974|Device|Wearable artificial kidney|
1782072|NCT00454987|Biological|Menitorix|Menitorix was only administered to subjects of the group NoBoost at 40 to 43 months of age.
1782073|NCT00454987|Biological|Infanrix IPV|Infanrix IPV was administered according to the manufacturer's instructions to UK subjects at 40 to 43 months of age.
1782074|NCT00455000|Biological|PF-04360365|Monoclonal antibody
1782075|NCT00455000|Drug|Placebo|Placebo
1957076|NCT02561091|Other|Placebo|
1782081|NCT00455026|Drug|remifentanil|target effect site concentration during induction
1782082|NCT00455039|Drug|GW572016|Dose: 1500 mg daily
1782083|NCT00455052|Drug|XMT-1001|XMT-1001 is administered as an IV infusion once every 21 days. This expansion of the Phase 1 study is to confirm the MTD.
1782084|NCT00455065|Behavioral|Whole Grain Foods|
1782085|NCT00455078|Procedure|esophagogastroduodenoscopy|EGD will be done pretransplant then again before 18mos post transplant.
1782086|NCT00455078|Other|Standard GER questionnaire (RDQ)|RDQ questionnaire will be done pretransplant then again before 18mos post transplant.
1782087|NCT00455078|Procedure|Scintigraphic evaluation of solid gastric emptying|Scintigraphic evaluation of solid gastric emptying will be done pretransplant then again before 18mos post transplant.
1782088|NCT00455078|Procedure|Twenty-four hour ambulatory pH testing|Twenty-four hour ambulatory pH testing will be done pretransplant then again before 18mos post transplant.
1782089|NCT00455078|Procedure|Esophageal manometry testing|Esophageal manometry testing will be done pretransplant then again before 18mos post transplant.
1782090|NCT00455091|Drug|Adefovir Dipivoxil and Lamivudine|Adefovir Dipivoxil 10mg/day x 36 months,Lamivudine 100 mg/day x 18 months#, when HBV DNA =/> 105 copies/mL and ALT > 2.0 x UNL
1782091|NCT00455104|Other|No intervention|This is an observational, voluntary registry.
1782092|NCT00455117|Drug|Intravenous Parecoxib ('Dynastat' Pfizer)|parecoxib or placebo
1782093|NCT00455130|Drug|Inhaled mannitol|
1782094|NCT00455143|Drug|Precedex (Dexmedetomidine)|Participants will be randomized to either dexmedetomidine or placebo which will be started prior to surgery and continued for 24 hours postoperatively. Patients will receive dexmedetomidine until discharge from the PACU.
1782095|NCT00444314|Drug|Panzem® NCD|NCD suspension, 1500 mg TID daily for 6 week cycles
1782096|NCT00444314|Drug|Sunitinib Malate|Sunitinib Malate, highest tolerated dose (patient's current dose), daily oral administration for 4 weeks, with 2 week break in 6 week cycle
1782097|NCT00444340|Drug|Enbrel (Etanercept)|
1782098|NCT00444353|Device|DL6049 (injectable poly-L-lactic acid)|
1782099|NCT00444379|Drug|Lopinavir/ritonavir plus Emtricitabine/Tenofovir versus Efavirenz plus Emtricitabine/Tenofovir|Lopinavir/ritonavir 200/50mg plus Emtricitabine/Tenofovir 200/300mg versus Efavirenz 600mg plus Emtricitabine/Tenofovir 200/300mg
1782100|NCT00444392|Behavioral|Calorie controlled diabetic diet for the control patients|Calorie controlled diabetic diet for the control patients
1957077|NCT02561091|Drug|AM-111 0.4 mg/ml|
1957078|NCT02561091|Drug|AM-111 0.8 mg/ml|
1957079|NCT02557152|Device|GentleWave System Treatment|
1782104|NCT00444431|Procedure|Pyeloplasty|
1782105|NCT00444457|Biological|13-valent Pneumococcal Conjugate Vaccine|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
1782106|NCT00444457|Biological|7vPnC|0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.
1782107|NCT00444470|Drug|Tranexamic acid|"Eligible patients who have consented to be in the study and have been randomised to be in Arm A will receive 10 mg/kg of tranexamic acid, and then a continuous infusion of 1 mg/kg/hr of tranexamic acid."
1782108|NCT00444470|Drug|Placebo|"Eligible patients who have consented to be in the study and have been randomised to be in Arm B will receive 10 mg/kg of placebo followed by a continuous infusion of 1 mg/kg/hr of placebo."
1782109|NCT00444483|Behavioral|Structured diabetes teaching and treatment program|
1782110|NCT00444509|Drug|GW685698X|GW685698X will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
1782111|NCT00444509|Drug|GW685698X containing magnesium stearate|GW685698X containing magnesium stearate will available with a unit dose strength of 400 mcg that will be inhaled via DISKUS
1782112|NCT00444522|Drug|Alprazolam thermal aerosol|
1782113|NCT00444535|Drug|lapatinib|1500 mg oral lapatinib (once daily)
1782574|NCT00456560|Drug|AV650|
1782114|NCT00444535|Drug|bevacizumab|10 mg/kg intravenous bevacizumab (every two weeks)
1782115|NCT00444548|Drug|[S,S]-Reboxetine|
1782116|NCT00444561|Drug|pramlintide acetate|Clear, colorless, sterile solution for SC administration
1782117|NCT00444574|Drug|Methylphenidate Transdermal System|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
1782118|NCT00444574|Drug|Placebo|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
1782119|NCT00444574|Drug|Concerta|The primary objective of this study was to evaluate, under controlled conditions, the safety and efficacy of MTS compared to placebo with reference to CONCERTA
1782120|NCT00444587|Drug|Second line chemotherapy|As prescribed
1782121|NCT00444587|Drug|trastuzumab [Herceptin]|6mg/kg iv every 3 weeks
1782122|NCT00444600|Drug|Triamcinolone Acetonide + laser|4 mg intravitreal triamcinolone at randomization plus focal photocoagulation 1 week post-injection, repeated every 16 weeks with sham injections at 4-week intervals in-between. Retreatment starting at 16 weeks depends on visual acuity and OCT.
1782123|NCT00444600|Drug|Ranibizumab + laser|0.5 mg intravitreal ranibizumab at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
1782124|NCT00444600|Drug|Sham injection + laser|Sham injection at randomization plus focal photocoagulation 1 week post-injection. Injections are repeated every 4 weeks with focal photocoagulation given post-injection every 16 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT.
1782125|NCT00444600|Drug|Ranibizumab + deferred laser|0.5 mg intravitreal ranibizumab at randomization, repeated every 4 weeks. Retreatment starting at 16 weeks depends on visual acuity and OCT. If improvement has not occured from injections alone, laser can be given starting at the 24 week visit.
1782126|NCT00444613|Drug|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 25 mg twice a week for 3.5 years.
1782127|NCT00444613|Drug|E0302 (mecobalamin)|Intramuscular injection, mecobalamin 50 mg twice a week for 3.5 years.
1782128|NCT00444613|Drug|Placebo|Intramuscular injection, placebo twice a week for 3.5 years.
1782129|NCT00444626|Device|Dermal Gel Extra (DGE)|Dermal Gel Extra (DGE) Injectable Gel contains hyaluronic acid with lidocaine. DGE was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of DGE to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
1782130|NCT00444626|Device|Restylane|Restylane was administered to nasolabial folds via the intradermal route. The Principal Investigator was instructed to inject a sufficient amount of Restylane to ensure full correction of the NLF wrinkles (i.e., to the optimal level of correction achievable). Up to 2 touch-up treatments were allowed in the Initial Treatment period.
1782131|NCT00444626|Drug|EMLA Cream|EMLA Cream (Eutectic Mixture of Local Anesthetics) is an FDA-approved topical anesthetic comprised of 2.5% each of lidocaine/prilocaine. EMLA Cream was applied in approximately equal amounts prior to all injections of DGE and Restylane.
1782132|NCT00444639|Drug|Triptorelin (Decapeptyl®)|Two injections of 11.25mg given every 12 weeks
1782133|NCT00444652|Drug|Enoxaparin|injection of enoxaparin a few time
1782134|NCT00444665|Drug|Travatan-Z|
1782135|NCT00444678|Drug|Cetuximab|500 mg/m2, IV every two weeks
1782136|NCT00444678|Drug|Oxaliplatin|85 mg/m2, IV, q 2 weeks
1782137|NCT00444678|Drug|Capecitabine|2500 mg, po bid x 7 days every two weeks
1782138|NCT00444691|Device|ultra-sonography|"o The ultrasonographic evaluation was performed on 38 joints: the 28 joints included in DAS28 (e.g. shoulderx2, elbowx2, wristx2, metacarpo-phalangeal (MCP)x10, proximal inter phalangeal (PIP)x10, kneex2) and also the metatarso-phalangeal (MTPx10). Systematic multiplanar gray-scale (mode B) and Power Doppler examination was carried out with commercially available real-time scanners using multi-frequency linear transducers (7-12 MHz).
The ultrasonographic evaluation was performed at baseline and 1, 2, 3, and 4 months after baseline."
1782139|NCT00444704|Drug|PRA-027|
1782140|NCT00444717|Drug|pitavastatin|Pitavastatin (2mg/day) was administered for 12 weeks
1782141|NCT00444730|Procedure|Radical Prostatectomy|Surgical procedure for prostate cancer.
1782142|NCT00444730|Procedure|InterStim Implantation|surgical placement of the interstim
1782143|NCT00444730|Procedure|Pelvic organ prolapse repair|Surgical pelvic organ prolapse repair
1782144|NCT00444743|Drug|MM-093|60 mg, administered subcutaneously, weekly
1782145|NCT00444743|Other|Placebo|Placebo
1782146|NCT00444756|Procedure|J-tip jet injection of 1% buffered lidocaine|
1782147|NCT00444769|Drug|GW842166|
1782148|NCT00444782|Biological|GV1001|
1782149|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
1782150|NCT00444795|Drug|Sunitinib malate|Sunitinib : dosing not pre-determined
1782151|NCT00444795|Drug|sunitinib malate|Sunitinib : dosing not pre-determined
1782152|NCT00444808|Drug|Intranasal calcitonin|
1782153|NCT00444821|Device|AneuRx AAA stent graft / Talent AAA stent graft|Catheter based stent graft inserted to seal off an abdominal aortic aneurysm
1782154|NCT00444834|Drug|Carvedilol|50 mg
1782155|NCT00444847|Device|Hyperbaric chamber|
1782156|NCT00444860|Biological|Zoster Vaccine, Live, (Oka-Merck)|A single dose of 0.65 ml of Zostavax injection was given to each study subject
1782157|NCT00444873|Drug|lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval|Six deep subcutaneous injections of Lanreotide Autogel, 24-56 week intervals.
1782158|NCT00444886|Drug|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
1782159|NCT00444886|Drug|Botulinum Toxin Type A injection (BOTOX)|Each subject will receive an injection under EMG guidance into the anterior and middle scalene muscles of either 75 units of BTX-A (experimental group), or normal saline (control group). Both groups will be provided with a stretching and strengthening exercise program.
1782160|NCT00444899|Behavioral|Intensive treatment|Subjects will be followed by the dietician in combination with his/her endocrinologist. Diet, physical activity, smoking cessation and drug prescriptions will be used to treat subjects.
1782161|NCT00444899|Other|Normal follow-up|Subject will continue to be followed by their endocrinologist and general practitioner as they already do.
1782162|NCT00444912|Drug|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (sc) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥ 5*10^6 CD34+ cells/kg were collected.
1782163|NCT00444912|Drug|G-CSF plus plerixafor|Participants underwent mobilization with G-CSF (7.5 µg/kg twice daily) for 4 days, administered by subcutaneous (SC) injection. On the evening of Day 4, participants received a dose of plerixafor (240 µg/kg), administered by SC injection. On Day 5, participants returned to the clinic and received a morning dose of G-CSF (7.5 µg/kg) and underwent apheresis approximately 10 to 11 hours after the dose of plerixafor. Participants were to continue to receive G-CSF twice daily and to receive the evening dose of plerixafor followed by apheresis the following morning for a maximum of 4 aphereses or until ≥5*10^6 CD34+ cells/kg were collected.
1782164|NCT00444912|Biological|rituximab|Participants were given a weekly dose of rituximab 375mg/m2 by intravenous infusion for 1 week prior to and continuing until 2 weeks after the first dose of G-CSF.
1782165|NCT00444925|Drug|fesoterodine fumarate|4 mg once daily (OD) for 1 week followed by a forced dose-escalation to 8 mg once daily (OD) for 11 weeks
1782166|NCT00444925|Drug|placebo|once daily (OD)for 12 weeks
1782167|NCT00444925|Drug|tolterodine tartrate|4 mg once daily (OD) for 12 weeks
1782168|NCT00444938|Device|H1 -coil TMS device|
1782169|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
1782170|NCT00444951|Biological|Mencevax®: Group A, C, W135 and Y polysaccharide meningococcal vaccine|0.5 mL, Subcutaneous
1782171|NCT00444951|Biological|Menactra®: Meningococcal A, C, Y, and W 135 Polysaccharide Diphtheria Toxoid Conjugate vaccine|0.5 mL, Intramuscular
1782172|NCT00444964|Drug|Nutropin AQ|
1782173|NCT00444977|Behavioral|Case-management linkage intervention|dental care
1782174|NCT00444990|Device|Magnetic Flex Pad|
1957086|NCT02551497|Drug|CNV1014802|
1782179|NCT00445016|Procedure|peripheral regional anesthesia|evaluation and description of adverse effects
1782180|NCT00445042|Drug|Sorafenib|The initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily. Intrapatient dose escalation will occur as defined in the protocol, providing no dose limiting toxicity (Grade 3 or 4) is observed.
1782181|NCT00445055|Drug|Droperidol|Intravenous injection
1782182|NCT00445068|Drug|LBH589|
1782183|NCT00445081|Drug|Prednisolone|
1782184|NCT00445081|Drug|Ciclosporine A|
1782185|NCT00445094|Drug|MK0787B, imipenem/cilastatin sodium / Duration of Treatment: 7 Days|
1782186|NCT00445094|Drug|Comparator: amikacin / Duration of Treatment: 3 Days|
1782187|NCT00445094|Drug|Comparator: tazocin / Duration of Treatment: 3 Days|
1782188|NCT00445094|Drug|Comparator: vancomycin / Duration of Treatment: 3 Days|
1782189|NCT00445107|Drug|MK0476, montelukast sodium / Duration of Treatment: 8 Weeks|
1782190|NCT00445120|Drug|Lactobacillus Rhamnosus GG|patients are treated with oral Lactobacillus Rhamnosus GG once daily for six months
1782191|NCT00445120|Drug|placebo (sugar)|Placebo will be administered to patients once daily for six months
1782192|NCT00445133|Device|Magnetic Sleep Pad|
1782193|NCT00445146|Drug|EVG|Elvitegravir (EVG) tablet administered orally once daily with food
1782194|NCT00445146|Drug|RTV|Ritonavir (RTV; /r) 100 mg capsule administered orally once daily with food
1782195|NCT00445146|Drug|ARV regimen|The components of the ARV regimen will be selected by the investigator without input from the sponsor. The antiretroviral regimen must consist of at least 2 agents, not including the non-nucleoside reverse transcriptase inhibitors (NNRTIs) efavirenz, nevirapine, or delavirdine; the protease inhibitors saquinavir, nelfinavir, or indinavir; or investigational agents (without sponsor approval).
1782196|NCT00445159|Drug|UT-15C SR (treprostinil diethanolamine) 1mg oral tablets|
1782197|NCT00445172|Drug|E0302 (mecobalamin)|Intramuscular injection, mecobalamin twice a week.
1782198|NCT00445185|Biological|Henogen HB vaccine|Month 12, 24 and 36
1782199|NCT00445185|Biological|Fendrix vaccine|Month 12, 24 and 36
1782200|NCT00445198|Drug|ABT-263|"Phase 1 dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.
- 50 patients with SCLC and non-hematologic malignancies. Enrollment is closed in this arm of the study.
Phase 2a dosing under two different schedules: 14 days on drug, 7 days off or continuous dosing.
- 40 patients with SCLC"
1782201|NCT00445211|Drug|Heparin|Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).
1782202|NCT00445211|Other|Without Heparin|Intra-Aortic balloon Pump (IABP) without Heparin.
1782203|NCT00445224|Other|Hip Progressive Resistive Exercise|Hip Progressive Resistance Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening hip abduction ad external rotation musculature.
1782204|NCT00445224|Other|Quad Progressive Resistive Exercises|Quad Progressive Resistive Exercise program will be carried out by subjects under supervision once a week and then performed at home 2 additional times at home without supervision. Exercises focus on strengthening quadriceps musculature with straight leg raises and quadriceps isometrics.
1782207|NCT00445263|Drug|TIROFIBAN|intravenous infusion
1782208|NCT00445263|Procedure|CORONAROGRAPHY|standard procedure of coronarography
1782209|NCT00445276|Drug|Diacerein|
1782210|NCT00445289|Device|SmartCare/PS|
1782211|NCT00445302|Drug|plerixafor|Single dose of plerixafor (240 µg/kg) administered by subcutaneous (SC) injection
1782212|NCT00445315|Drug|PF-00868554|300 mg BID
1782213|NCT00445315|Drug|PF-00868554|450 mg BID
1782214|NCT00445315|Drug|PF-00868554|100 mg BID
1782215|NCT00445315|Drug|PF-00868554|300 mg TID
1782216|NCT00445315|Drug|Placebo|Placebo
1782217|NCT00445328|Drug|Dalteparin (Fragmin)|Dalteparin 5000 IU once daily subcutaneously for 6-14 days.
1782218|NCT00445328|Drug|Unfractionated heparin|Unfractionated heparin 5000 IU thrice daily subcutaneously for 6-14 days.
1782219|NCT00445341|Drug|Flavopiridol|Flavopiridol 30 mg/m^2 is given weekly for 4 weeks followed by a 2 week break for up to 6 cycles. It is given through a vein as a 30 minute infusion followed by a 4 hour infusion.
1782220|NCT00445354|Drug|cinnamon|
1782221|NCT00445406|Drug|bevacizumab + doxorubin hydrochloride liposme|Patients receive bevacizumab IV over 30-90 minutes and doxorubicin hydrochloride liposome IV over 30-90 minutes on days 1 and 15. Treatment repeats every 4 weeks for up to 6 courses
1782222|NCT00445406|Drug|Bevacizumab|Patients then receive bevacizumab alone IV over 30-90 minutes on days 1 and 15. Courses with bevacizumab repeat every 4 weeks in the absence of disease progression or unacceptable toxicity
1782223|NCT00445419|Biological|PEV2A PEV2B|
1782224|NCT00445432|Biological|adalimumab|Subcutaneous injection of 40 mg adalimumab (0.8 mL/injection) every other week (eow)
1782225|NCT00445432|Other|Placebo|Subcutaneous injection of placebo (0.8 mL/injection) every other week (eow)
1782226|NCT00445445|Other|physiologic testing|Urine samples will be assessed for levels of bisphenol-A
1782227|NCT00445445|Other|screening questionnaire administration|Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
1782228|NCT00445445|Procedure|breast imaging study|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
1782229|NCT00445445|Procedure|radiomammography|Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis.
1782230|NCT00445445|Procedure|study of high risk factors|"Questionnaire: Patients and healthy participants complete a self-administered questionnaire providing detailed information on breast cancer risk factors, including demographics, behavioral and lifestyle factors, reproductive history, family history of breast cancer, comorbidities, medication and hormone replacement therapy use, and breast cancer screening history. This information is then cross-validated with documented data abstracted from medical records to provide a longitudinal and historical framework for assessing individual risk.
Mammographic density (MD) assessment: Patients and healthy participants are evaluated for patterns of longitudinal change in MD and subsequent breast cancer risk by retrospective review of screening mammograms performed prior to breast cancer diagnosis."
1957087|NCT02550652|Drug|Mycophenolate Mofetil/Mycophenolic Acid|MMF/MPA will be administered as per schedule specified in the respective arm.
1782234|NCT00445471|Behavioral|Mifne Approach to PDD|
1782235|NCT00445471|Behavioral|Treatment as usual|
1782236|NCT00445484|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
1782237|NCT00445484|Drug|lenalidomide|Given orally
1782238|NCT00445497|Drug|amoxicillin-clavulanate potassium|
1782239|NCT00445497|Drug|ciprofloxacin|
1782240|NCT00445497|Procedure|psychosocial assessment and care|
1782241|NCT00445497|Procedure|quality-of-life assessment|
1782242|NCT00445510|Drug|GSK256066|
1782243|NCT00445523|Biological|TroVax® (Immunological Vaccine Therapy)|16 Intramuscular injections of TroVax® over 47 weeks
1782244|NCT00445523|Drug|Interferon-alpha|36 subcutaneous IFN-α injections for 12 weeks. sc injection three times per week (5MU each)
1782245|NCT00445549|Drug|Vandetanib|300 mg daily dose, 28 day cycle
1782246|NCT00445562|Other|biologic sample preservation procedure|
1782247|NCT00445562|Other|informational intervention|
1782248|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
1782249|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
1782250|NCT00445575|Drug|risedronate|During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
1782251|NCT00445575|Drug|placebo|placebo and risedronate have exactly the same aspect. During two months courses, every 6 months : 30mg tablet/day for adults and 10mg/day or 20mg/day for children, according to the age and weight of the child.
1782252|NCT00445588|Drug|erlotinib hydrochloride|150mg Given orally once daily
1782253|NCT00445588|Drug|sorafenib tosylate|400mg Given orally twice daily
1782254|NCT00445588|Other|pharmacological study|Correlative studies
1782255|NCT00445601|Drug|gemcitabine hydrochloride|Given intravesically
1782256|NCT00445601|Other|placebo|Given intravesically
1782257|NCT00445614|Behavioral|Effects of trout on CVD risk markers and plasma proteome|
1782258|NCT00445679|Drug|DVS SR|Arm 1: 50mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 2: 100mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper Arm 3: 200mg DVS SR tablet, QD, 8 weeks treatment with 2 week taper
1782259|NCT00445679|Drug|Paroxetine|20 mg Paroxetine capsule, QD, 8 weeks treatment with 2 week taper
1957088|NCT02550652|Drug|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
1957089|NCT02550652|Other|Placebo|Placebo matching to obinutuzumab will be administered as per schedule specified in the respective arm.
1957090|NCT02550652|Drug|Methylprednisolone|Methylprednisolone IV will be administered as per schedule specified in the respective arm.
1782263|NCT00445705|Drug|placebo|Part A: Placebo every 12 hours for 4 weeks
1782264|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 3 mg every 12 hours for 4 weeks
1782265|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 20 mg every 12 hours for 4 weeks
1782266|NCT00445705|Drug|AGN 203818|Part A: AGN 203818 60 mg every 12 hours for 4 weeks
1782267|NCT00445718|Procedure|computed tomography|
1782268|NCT00445718|Procedure|3-Tesla magnetic resonance imaging|
1782269|NCT00445718|Procedure|Abdominal Sonogram|Sonogram of the abdomen area
1782270|NCT00445731|Behavioral|exercise intervention|
1782271|NCT00445731|Procedure|management of therapy complications|
1782272|NCT00445731|Procedure|observation|
1957091|NCT02550652|Drug|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
1957095|NCT02545127|Drug|merotocin|Merotocin nasal spray
1782283|NCT00445757|Procedure|conventional surgery|Two months after completion of radiotherapy, patients undergo preoperative assessment of tumor response followed by partial nephrectomy.
1782284|NCT00445757|Radiation|stereotactic radiosurgery|Patients undergo stereotactic radiotherapy to 1 tumor. Cohorts of 4-8 patients receive escalating doses of radiotherapy twice daily for 2 days until the maximum tolerated dose (MTD) or upper limit is reached.
1782285|NCT00445770|Drug|Etanercept|10 mg twice weekly, subcutaneous injection for 52 weeks
1782286|NCT00445770|Drug|Etanercept|25 mg, twice weekly, subcutaneous injection for 52 weeks
1782287|NCT00445770|Drug|Methotrexate|up to 8 mg per week, oral dosing for 52 weeks
1782288|NCT00445783|Genetic|gene expression analysis|
1782289|NCT00445783|Genetic|mutation analysis|
1782290|NCT00445783|Other|immunohistochemistry staining method|
1782291|NCT00445783|Other|laboratory biomarker analysis|
1782292|NCT00445783|Procedure|examination|
1782293|NCT00445783|Procedure|mutation carrier screening|
1782294|NCT00445783|Procedure|study of high risk factors|
1782295|NCT00445796|Drug|Artesunate|
1782296|NCT00445796|Drug|Amodiaquine|
1782297|NCT00445835|Other|Arterial doppler for screening asymptomatic and significant extracoronary arterial stenoses in all arterial beds|A strategy of systematic screening of these extra-coronary asymptomatic lesions combined with a specific treatment if needed and an aggressive secondary prevention pharmacological treatment of atherothrombosis
1782298|NCT00445835|Other|Conservative arm|Conservative medical approach
1782299|NCT00445848|Biological|bevacizumab|
1782300|NCT00445848|Drug|erlotinib hydrochloride|
1782301|NCT00445861|Biological|cetuximab + docetaxel + cisplatin|Chemoimmunotherapy: Patients receive cetuximab IV over 1-2 hours once weekly in weeks 1-3 and docetaxel IV over 1 hour and cisplatin IV over 1 hour once in week 1. Treatment repeats every 3 weeks for 2 courses.
1782302|NCT00445861|Biological|Treatment level 1|Treatment level 1: Patients receive cetuximab IV over 1 hour once weekly, cisplatin IV over 1 hour once weekly, and undergo radiotherapy once daily, 5 days a week, in weeks 7-11.
1782303|NCT00445861|Biological|Treatment level 2|Patients receive cetuximab, cisplatin, and radiotherapy as in treatment level 1. Patients also receive docetaxel IV over 1-2 hours once weekly in weeks 7-11.
1782304|NCT00445861|Procedure|conventional surgery|Between 4-8 weeks after completion of neoadjuvant chemoimmunotherapy and radiotherapy, patients undergo surgery.
1782305|NCT00445874|Drug|Ketotifen with a Contact Lens (no generic name)|
1782308|NCT00445900|Drug|cyclophosphamide|
1782309|NCT00445900|Drug|prednisone|
1782310|NCT00445900|Drug|thalidomide|
1782311|NCT00445900|Other|immunohistochemistry staining method|
1782312|NCT00445900|Other|laboratory biomarker analysis|
1782313|NCT00445900|Procedure|biopsy|
1782314|NCT00445913|Biological|Diabetes-suppressive dendritic cell vaccine|The dendritic cells will be treated ex vivo with the antisense oligonucleotides and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to the dendritic cell vaccine will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
1782315|NCT00445913|Biological|control dendritic cells|The dendritic cells will be treated ex vivo with vehicle and cryopreserved in aliquots for subsequent intradermal administration into sites closest to the physical location of the pancreas inside the body. Physiologic, biologic and immunologic responses to these control dendritic cells will be evaluated over the period of the trial. The first group of volunteers will receive autologous dendritic cells without any ex vivo treatment (7/15) and the second group will be administered iDC (8/15). If there is no evidence of toxicity or adverse events associated with the dendritic cell vaccine, and only upon FDA and IRB approval we will initiate a new study comparing efficacy of control DC and iDC in improving glycemia and reversing autoimmunity in new-onset patients.
1782316|NCT00445926|Device|deep TMS H-coil|
1782317|NCT00445939|Biological|adalimumab|160 mg at Week 0, 80 mg at Week 2
1782575|NCT00456560|Drug|Fluvoxamine|
1782318|NCT00445939|Biological|adalimumab|80 mg at Week 0, 40 mg at Week 2
1782319|NCT00445939|Biological|placebo|Placebo at Week 0 and Week 2
1782320|NCT00445952|Other|clinical observation|
1782321|NCT00445952|Procedure|management of therapy complications|
1782322|NCT00445965|Genetic|DNA analysis|
1782323|NCT00445965|Other|immunologic technique|
1782324|NCT00445965|Other|pharmacological study|
1782325|NCT00445965|Radiation|iodine I 131 monoclonal antibody 3F8|
1782326|NCT00445965|Radiation|131I-3F8|Patients will receive 10mCi intrathecal 131I-3F8 per week. Patients will be pre-medicated with dexamethasone to prevent possible meningeal inflammatory reaction, Liothyronine and SSKI to prevent thyroid accumulation, and acetaminophen and diphenhydramine in anticipation of possible allergic reaction and fever.
1782327|NCT00445978|Drug|6R-BH4 (sapropterin dihydrochloride)|Subjects will receive oral, once-daily (for 2.5, 5, 10mg/kg/day doses) or twice-daily (for the 20 mg/kg/day dose) of 6R-BH4 during a 16-week dose escalation phase, with dose levels increasing within subjects every 4 weeks as follows: 2.5, 5, 10, and 20 mg/kg/day. Subjects may continue in an optional extension phase at the highest tolerated dose for up to a total of 2 years.
1782328|NCT00446004|Drug|Imatinib Mesylate|Dosage form: tablets Dosage: 400 mg Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
1782329|NCT00446004|Drug|Omeprazole|Dosage form: capsules Dosage: 40 mg Frequency: On an 18-day schedule, once daily day 10 through day 16 (for Arm A); or once daily day -4 through day 1 (for Arm B)
1782330|NCT00446017|Drug|adrenaline|
1782331|NCT00446017|Drug|milrinone|
1782332|NCT00446030|Drug|Docetaxel|"75 mg/m^2 administered IV on Day 1 for Cycles 1-6
All participants received a prophylactic steroid regimen prior to each dose of docetaxel - Dexamethasone 8 mg orally 12 hours prior to docetaxel, dexamethasone 10 mg IV just prior the docetaxel infusion and 8 mg orally 12 hours after docetaxel administration. If a participant had not taken their oral dexamethasone the evening prior to receiving docetaxel, the dose of the pre-docetaxel infusion of dexamethasone was increased from 10 mg IV to 15 mg IV. A Dexamethasone 8 mg equivalent may have been used (dexamethasone 8 mg = methylprednisolone 40 mg = prednisone 50 mg = prednisolone 50 mg)."
1782333|NCT00446030|Drug|Doxorubicin|50 mg/m^2 administered IV on Day 1 for Cycles 1-6
1782334|NCT00446030|Drug|Carboplatin|6 mg/mL/min (target area under the curve [AUC] dose) administered IV on Day 1 for Cycles 1-6
1782335|NCT00446030|Drug|Cyclophosphamide|500 mg/m^2 administered IV on Day 1 for Cycles 1-6
1782336|NCT00446030|Drug|Trastuzumab|A single loading dose of 8 mg/kg administered IV on Day 2 for Cycle 1, and 6 mg/kg administered IV on Day 1 for Cycles 2-6 and for maintenance therapy
1782337|NCT00446030|Drug|Bevacizumab|15 mg/kg administered IV on Day 1 for Cycles 1-6, and for maintenance therapy
1782338|NCT00446043|Drug|Adapalene/Benzoyl Peroxide|
1782339|NCT00446056|Drug|MK0476, montelukast sodium / Duration of Treatment: 4 Weeks|
1782340|NCT00446056|Drug|Comparator: ketotifen / Duration of Treatment: 4 Weeks|
1782341|NCT00446069|Drug|Morphine Sulphate|Egalet® morphine, Controlled Release 30 mg Oral tablet once daily for 2 weeks and MST Continus® 15 mg twice daily for 2 weeks
1782342|NCT00446082|Drug|Pasireotide|
1782343|NCT00446095|Drug|fostamatinib|200 mg PO BID
1782344|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 20mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
1782345|NCT00446134|Drug|Taribavirin|Oral (200 mg) Tablet: 25mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
1782346|NCT00446134|Drug|Taribavirin|Oral (200mg)Tablet: 30mg/kg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
1782347|NCT00446134|Drug|Ribavirin|Oral (200mg)Tablet: 800 mg/day, 1000 mg/day, 1200 mg/day, or 1400 mg/day BID, patients will be treated for a total of 48 weeks. in addition, all patients will receive peginterferon alfa-2b (PEG-Intron) by weekly subcutaneous injection. Patients who complete treatment with study drug or discontinue treatment prematurely will enter a 24-week follow-up period.
1782348|NCT00446147|Drug|Pyridoxine|100mg BID/daily, Per oral
1782349|NCT00446147|Drug|Placebo|placebo 100mg BID/daily, Per oral
1782350|NCT00446173|Drug|Busulfan|130 mg/m^2 IV Daily Over 3 Hours x 4 Days
1782351|NCT00446173|Drug|Cyclophosphamide|60 mg/kg IV Daily Over 4 Hours x 2 Days
1782352|NCT00446173|Drug|G-CSF|10 mcg/kg Subcutaneously Once Daily
1782353|NCT00446173|Drug|GM-CSF|250 mcg/kg Subcutaneously Once Daily
1782354|NCT00446186|Drug|MK0476, montelukast sodium / Duration of Treatment: 2 Weeks|
1782355|NCT00446186|Drug|Comparator: placebo / Duration of Treatment: 2 Weeks|
1782356|NCT00446199|Drug|0.5mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.5mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
1782357|NCT00446199|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One tablet [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 3 cycles (28 days per cycle).
1782358|NCT00446199|Drug|Estradiol (E2 0.3mg)|One tablet [17β-estradiol (E2 0.3mg)] per day taken orally for 3 cycles (28 days per cycle).
1782359|NCT00446199|Drug|Placebo|Matching placebo tablet per day taken orally for 3 cycles (28 days per cycle).
1782360|NCT00446212|Drug|Propofol|target controlled infusion of propofol
1782361|NCT00446212|Drug|desflurane|Anaesthetic maintenance with desflurane
1782362|NCT00446225|Drug|Erlotinib (Tarceva)|150 mg/day
1782363|NCT00446225|Drug|Carboplatin // Gemcitabine // Docetaxel //Cisplatin|Cisplatin (75 mg/m2) / Docetaxel (75 mg/m2); Cisplatin (75 mg/m2) / Gemcitabine (1250 mg/m2; day 1 and 8); Docetaxel (75 mg/m2) /carboplatin (AUC=6); Gemcitabine (1000 mg/m2; day 1 and 8) / Carboplatin (AUC=5)
1782364|NCT00446238|Behavioral|Cognitive Behavioral Therapy|CBT enhanced with physical illness narrative, family education, and social skills components.
1782365|NCT00446238|Behavioral|Standard of Community Care Treatment|Treatment as usual for depression and related symptoms provided within the community.
1782366|NCT00446251|Drug|Rituximab|Rituximab dose is 1,000 mg given as an IV infusion every two weeks for 2 doses (days 1 and 15).
1782367|NCT00446251|Drug|Mycophenolate mofetil (MMF)|Cellcept is continued from prior study, taken 500 - 1,000 mg BID, P.O.
1782368|NCT00446264|Procedure|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
1782369|NCT00446264|Drug|daclizumab - sirolimus - tacrolimus|Immunosuppressive consisted of Tacrolimus, target through level at 3-6 ng/ml, Sirolimus, target through level at 12-15 ng/ml for three months and at 7-10 ng/ml thereafter. A five-dose induction course of Daclizumab 1mg/Kg was administered biweekly beginning one hour prior to the first infusion
1782370|NCT00446277|Procedure|cataract surgery|
1782371|NCT00446290|Drug|Docetaxel, Capecitabine and Oxaliplatin|
1782372|NCT00446303|Drug|Azacitidine|"Azacitidine 60mg/m2 /d for 5 days every 28 days, for 24 months (parallel study to the ongoing NMDSG study.
Extension of maintenance in responders after 24 courses until relapse or death."
1782373|NCT00446316|Drug|Antacids (Mg-Al-based)|the antacid (Maximum Strength Maalox®Max® Antacid/Anti-gas) at a dose level of 20 mL (equivalent to 1600 mg aluminum hydroxide and 1600 mg magnesium hydroxide).
1782374|NCT00446316|Drug|Imatimib Mesylate (Gleevec®)|Gleevec® will be administered at a dose of 400 mg. Half of the subjects will receive Gleevec® and antacid on day 15 and Gleevec® alone on day 1. The other half will be treated in reverse order, i.e., they will receive the combination of Gleevec® and antacid on day 1, and Gleevec® alone on day 15. The antacids will be administered 15 minutes before the Gleevec® dose.
1782375|NCT00446329|Drug|cinacalcet|Initiation dose of cinacalcet 30 mg/day. Titration every 2-3 weeks with a maximum dose of 180 mg/day.
1782376|NCT00446342|Drug|SNS-032 Injection|"Stage 1: Escalating doses of SNS-032 on days 1, 8 and 15 per 28 day cycle
Stage 2: Same as stage 1 except SNS-032 administered at the maximum tolerated dose established in stage 1"
1782377|NCT00446368|Drug|RAD001|Participant will take RAD001 (Everolimus) 10mg by mouth once a day.
1782378|NCT00446381|Drug|Macugen (pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively
1782379|NCT00446381|Drug|Macugen (Pegaptanib)|Pegaptanib 0.3 mg by intravitreal injection once pre-operatively.
1782380|NCT00446394|Behavioral|Resources and Activities for Life Long Independence (RALLI)|Strengthening exercises, encouragement to walk daily, pedometer reading, health promotion information for 1.5 hours weekly for 9 weeks
1782381|NCT00446394|Behavioral|Social Walking program (SW)|Group support for walking, pedometer reading, 1 hour weekly for 9 weeks
1782382|NCT00446407|Other|Collaborative Stepped Care Intervention|Psychoeducation, interpersonal therapy, fluoxetine (20-40 mg/d), adherence management
1782383|NCT00446407|Other|Enhanced Usual Care|Screening plus Antidepressants based on practice guidelines
1782384|NCT00446420|Drug|Propofol, midazolam, fentanyl|All drugs administered in doses according to anaesthetists' discretion during sedation for colonoscopy
1782385|NCT00446433|Drug|CC-5013|
1782386|NCT00446446|Drug|Panitumumab|Panitumumab was administered over a 1 hour intraveneous (IV) infusion at a dose of 9 mg/kg every 21 days.
1782387|NCT00446459|Drug|mycophenolate mofetil (CellCept)|500mg - 1,000mg, taken PO, twice daily.
1782388|NCT00446472|Drug|Regranex®|Regranex gel will be used for a total of 16 weeks
1782389|NCT00446472|Drug|Hydrogel|Placebo hydrogel will be applied for 16 weeks
1957096|NCT02545127|Drug|placebo|The placebo nasal spray is identical with the active product except that it does not contain merotocin
1782393|NCT00446498|Device|CPAP and Non Invasive Ventilation|
1782394|NCT00446511|Drug|Valsartan|Valsartan (80, 160, and 320 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
1782395|NCT00446511|Drug|Enalapril|Enalapril (10, 20, and 40 mg, weight stratified). All study medications were taken orally once daily, at approximately the same time each day, with or without food.
1782396|NCT00446511|Drug|placebo matched to enalapril|Placebo matched to enalapril. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
1782397|NCT00446511|Drug|placebo matched to valsartan|placebo matched to valsartan. All study medications were taken orally once daily, at approximately the same time each day, with or without food.
1782398|NCT00446524|Drug|Valsartan + Amlodipine besilate|During the run-in period, either Valsartan 80 mg or Amlodipine 5 mg tablet was given once daily. Throughout the Valsartan + Amlodipine treatment period, a Valsartan + Amlodipine tablet 80/5 mg was given once daily at around 8:00 AM in the morning.
1782399|NCT00446537|Procedure|Methylphenidate|
1782400|NCT00446550|Drug|AT2101|"Arm 1: AT2101 oral capsules, dose 1, regimen 1
Arm 2: AT2101 oral capsules, dose 1, regimen 2"
1782401|NCT00446563|Drug|Valsartan|160 mg film coated tablets taken orally once daily in the morning.
1782402|NCT00446563|Drug|Amlodipine|5 mg or 10 mg tablets taken orally once daily in the morning.
1782403|NCT00446563|Drug|Hydrochlorothiazide|12.5 mg or 25 mg tablets taken orally once daily in the morning.
1782404|NCT00446563|Drug|Losartan|100 mg tablets taken orally once daily in the morning.
1782405|NCT00446576|Drug|Epoetin Alfa|
1782406|NCT00446589|Drug|ibandronate|iv 1mg ibandronate monthly for one year
1782407|NCT00446589|Drug|teriparatide|sc injection using a pen like device during every hemodialysis session (thrice a week)
1782408|NCT00446602|Drug|Epoetin alfa|Type=exact, unit=units, number=80,000, form=solution for injection, route=subcutaneous use, once every week or once every 2 weeks.
1782409|NCT00446615|Behavioral|computer decision support tool|
1782410|NCT00446615|Behavioral|audit and feedback|
1782411|NCT00446615|Behavioral|group learning session|
1782412|NCT00446628|Behavioral|behaviors reducing spread of influenza|Non-pharmaceutical interventions for flu prevention
1782413|NCT00446641|Drug|Cilostazol|cilostazol 100mg twice a day for 4 weeks
1782414|NCT00446641|Drug|placebo|placebo 1 tablet twice a day matching for cilostazol
1782415|NCT00446654|Drug|CGC-11047|16.5 mg (3.3%) subconjunctival injection
1782416|NCT00446667|Drug|mannitol|400mg BD for 2 days
1782417|NCT00446680|Drug|Mannitol|400mg BD for 6 months followed by a 6 month open label period
1782418|NCT00446680|Drug|placebo|placebo BD for 6 months
1782419|NCT00446693|Device|EndoFast Reliant™ system for Pelvic Organ Prolapse repair|The EndoFast Reliant™ system is a new concept of reinforcing the vaginal wall with proprietary mesh and soft-tissue Fasteners in a minimally-invasive procedure.
1782420|NCT00446719|Drug|Rellidep|2000 mg P.O. daily for 8 weeks
1782421|NCT00446732|Device|UroSshield|Attachment of the UroShield device to the external part of the urinary catheter
1782422|NCT00446758|Dietary Supplement|Zinc|zinc effervescent tablets: 6.25mg to infants ≤12 months and 12.5 mg to children > 12 months.
1782423|NCT00446771|Drug|Mannitol|
1782424|NCT00446784|Drug|CE-224,535|
1782425|NCT00446784|Drug|Methotrexate|
1782426|NCT00446797|Drug|Non-selective NSAIDS|Non-selective NSAIDs administered at usual (standard) doses.
1782427|NCT00446797|Drug|Celecoxib|celecoxib with an initial loading dose of 400 mg followed by 200 mg twice daily (BID) for up to 7 days.
1782428|NCT00446810|Drug|Benfotiamine|
1782429|NCT00446810|Drug|Placebo|
1782430|NCT00446823|Device|XCell cellulose wound dressing|
1782431|NCT00446823|Device|Impregnated gauze dressing|
1782432|NCT00446836|Drug|Paclitaxel polyglumex (Xyotax)|biologically enhanced chemotherapeutic
1782433|NCT00455156|Drug|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR)|150 mg of Nestorone and 15 mg of ethinyl estradiol (150/15 NES/EE CVR), administered via vaginal ring, used on a 21/7 days in/out schedule for no more than one year.
1782434|NCT00455169|Biological|Trivalent Inactivated Influenza Vaccine|Influenza vaccine
1782435|NCT00455182|Procedure|Acupuncture|Standard medical care plus a single true acupuncture treatment.The needles are strategically inserted into the scalp, trunk, arms or legs (not near the surgical site) and manipulated. The needles are withdrawn between 5 minutes and 30 minutes after insertion.
1782436|NCT00455182|Procedure|Sham Acupuncture|Standard medical care plus sham acupuncture. A single treatment, using a maximum of 9 sham needles, which adhere to the skin but do not penetrate it. The sham needles are strategically placed on the scalp, trunk, arms or legs (not near the surgical site)
1782437|NCT00455182|Procedure|Standard medical care|Standard medical care at Woodwinds Hospital includes guided imagery, essential oils and massage.
1782438|NCT00455195|Biological|alglucosidase alfa|IV infusion of 20 mg/kg; every other week (qow)
1782439|NCT00455208|Drug|Cura-100|
1782440|NCT00455221|Biological|Bcr-abl multipeptide vaccine|The first three patients will receive the lower dose of both IL-12 and GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the lower dose of IL-12 plasmid and higher dose of GM-CSF plasmid. If this is well tolerated, then the next three patients will receive the higher dose of IL-12 and lower dose of GM-CSF plasmids. If this is well tolerated, then the next three patients will receive the higher dose of both IL-12 and GM-CSF plasmids. Once assigned to a dose, the patient will receive the same dose throughout their participation in this trial
1782441|NCT00455221|Genetic|Cytokine gene adjuvant|Cytokine gene adjuvant
1782442|NCT00455234|Drug|Intramuscular Olanzepine 10 mg|
1782443|NCT00455234|Drug|Intramuscular Haloperidol 5-10 mg + Promethazine 25-50 mg|
1782444|NCT00455247|Drug|Glutamine|
1782445|NCT00455260|Drug|hGH-ViaDerm™ System (hGH or somatropin)|transdermal patch; Group 1: 0.2 mg/day SC hGH during Period I, and 0.5 mg per transdermal patch during Period III (expected equivalent dose to SC 0.2 mg/day) Group 2: 0.4 mg/day SC hGH during Period I, and 2.0 mg per transdermal patch during Period III (expected equivalent dose to SC 0.4 mg/day) Group 3: 1.0 mg/day SC hGH during Period I, and 5.0 mg per transdermal patch during Period III (expected equivalent dose to 1.0 mg/day)
1782446|NCT00455260|Device|hGH-ViaDerm™ System|"The hGH-ViaDerm™ System is a transdermal delivery system for somatropin (hGH, rDNA origin).
The ViaDerm System™ consists of a medical device component and a printed dry hGH patch component. The device component is comprised of two primary elements: a reusable, computer mouse-like electronic controller and a disposable sterile array, which is inserted onto the base of the controller, delivers RF-current to ablate cells and creates microscopic throughways, termed RF-MicroChannels™, across the stratum corneum into the upper epidermis. The drug component consists of a unique circular transdermal dry hGH patch formulated specifically for use with the ViaDerm™ device. hGH is delivered by passive diffusion through the RF-MicroChannels™ into the systemic circulation system."
1782447|NCT00455286|Drug|Methotrexate|
1782448|NCT00455286|Drug|Methylprednisolone|
1782449|NCT00455286|Drug|Temozolomide|
1782450|NCT00455299|Procedure|Laparoscopic ventral hernia repair|
1782451|NCT00455312|Drug|Campath 1H|10, 9, 8, 7, and 6 days before transplant subjects will be given 1 dose of campath 1H given via catheter (0.2 mg/kg over 2 hours).
1782452|NCT00455312|Drug|Cyclophosphamide|7 days before the transplant, 1 dose of cyclophosphamide is given via catheter (50mg/kg IV over 2 hours).
1782453|NCT00455312|Drug|Fludarabine|6, 5, 4, 3, and 2 days before the transplant, 1 dose fludarabine is given via catheter (40 mg/kg IV over 1 hour)
1782454|NCT00455312|Procedure|Total Body Irradiation|1 day before the transplant one dose (200 cGy) of total body irradiation is given
1782455|NCT00455312|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
1782456|NCT00455312|Drug|antithymocyte globulin|ATG (rabbit) 3 mg/kg for 3 days.
1782457|NCT00455312|Drug|Methylprednisolone|2mg/kg IV is given before each dose of antithymocyte globulin (ATG).
1782458|NCT00455325|Drug|Placebo Comparator Limb 1|1 chloroquine placebo tablet for 3 weeks; euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
1782459|NCT00455325|Drug|Chloroquine|80mg chloroquine or placebo tablet weekly for Weeks 1-3;euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
1782576|NCT00456560|Drug|Paroxetine|
1782460|NCT00455325|Drug|Chloroquine|80mg tablet daily for 3 weeks; euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
1782461|NCT00455325|Drug|Chloroquine|250mg tablet daily for 3 weeks; euglycemic clamp procedure; 24 hour Ambulatory Blood Pressure; Oral Glucose tolerance Test; serum collection; 24 hour urine collection; collection of peripheral blood mononuclear cells
1782462|NCT00455338|Behavioral|Meal Composition|
1782463|NCT00455351|Drug|Vorinostat|Increasing dosing, phase I
1782464|NCT00455364|Drug|Voriconazole|
1782465|NCT00455390|Procedure|Post-immediate Psychotherapeutic Intervention|
1782466|NCT00455403|Drug|Chloroquine|One tablet of 80 mg of chloroquine on a daily basis for 12 months followed by 12 months off drug with 1 visit at month 24
1782467|NCT00455403|Drug|Placebo Comparator|Chloroquine Placebo tablet daily for 12 months followed by 12 months off drug with 1 visit at month 24
1782468|NCT00455416|Drug|Omega 3 fatty acids (EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid))|1000mgx5 daily
1782469|NCT00455416|Drug|Selenium (L-Selenomethionine),|100mcgx2 daily
1782470|NCT00455416|Drug|Garlic extract (Allicin)|6 garlic pearls daily
1782471|NCT00455416|Drug|Pomegranate juice (ellagic acid)|Pomegranate juice 100%, 660ml /495 ml every second day.
1782472|NCT00455416|Drug|Grape juice (resveratrol, quercetin)|Merlot grape juice 100%, 660ml /495 ml every second day
1782473|NCT00455416|Drug|Green Tea (Epigallocathechin gallate)|Green Tea. 2 cups daily
1782474|NCT00455429|Drug|Placebo|Matching placebo capsules to JNJ-26113100 (50 milligram [mg]) orally once daily or 100 mg orally once daily or 100 mg orally twice daily or 250 mg orally twice daily for 6 weeks.
1782475|NCT00455429|Drug|JNJ-26113100 (50 mg) once daily|JNJ-26113100 (50 mg) capsules orally once daily for 6 weeks.
1782476|NCT00455429|Drug|JNJ-26113100 (100 mg) once daily|JNJ-26113100 (100 mg) capsules orally once daily for 6 weeks.
1782477|NCT00455429|Drug|JNJ-26113100 (100 mg) twice daily|JNJ-26113100 (100 mg) capsules orally twice daily for 6 weeks.
1782478|NCT00455429|Drug|JNJ-26113100 (250 mg) twice daily|JNJ-26113100 (250 mg) capsules orally twice daily for 6 weeks.
1782479|NCT00455442|Drug|Mifepristone|
1782480|NCT00455455|Drug|Optifree RepleniSH Multipurpose Disinfecting Solution|lens care system
1782481|NCT00455455|Drug|ReNu Multiplus Multipurpose Solution|lens care system
1782482|NCT00455468|Procedure|Day-care treatment vs. hospital care|
1782483|NCT00455494|Drug|AQ-13|
1782484|NCT00455624|Drug|Androgen deprivation therapy|According to standard medical care
1782485|NCT00455637|Drug|Botulinum type A toxin (Dysport®)|
1782486|NCT00455650|Drug|Mecamylamine|A single dose of 10 mg of mecamylamine (via two 5 mg capsules) is given at the start of the mecamylamine arm of the study. This is the only administration of mecamylamine given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
1782487|NCT00455650|Drug|Varenicline|A single dose of 1 mg of varenicline (via two 0.5 mg capsules) is given at the start of the varenicline arm of the study. This is the only administration of varenicline given during the course of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance.
1782488|NCT00455650|Drug|Placebo|The placebo contains no active medication. The placebo dose is given via two capsules at the start of the placebo arm of the study. Participants' blood pressure and vitals are checked regularly for five hours after drug administration for monitoring and safety assurance. The placebo has no effects that last for any duration of time.
1782489|NCT00455663|Behavioral|Cognitive Adaptation Training|Environmental supports for all independent living skills
1782490|NCT00455663|Behavioral|Pharm-Cognitive Adaptation Training|Environmental supports for medication and appointment adherence
1782491|NCT00455663|Other|Treatment as usual|Medication follow-up and limited case management provided by local community mental health authority
1782492|NCT00455676|Procedure|Chevron osteotomy versus Scarf osteotomy|
1782493|NCT00455689|Drug|Leuprolide acetate (Lupron)|"Leuprolide acetate (Lupron Depot®) 3.75-mg intramuscular injection
Leuprolide is a widely used GnRH agonist that is manufactured by TAP Pharmaceutical Products. Leuprolide is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered once during the mid-luteal phase of the menstrual cycle at a dose routinely used for treatment of endometriosis and uterine fibroids in women."
1782494|NCT00455702|Drug|d-cycloserine|50mg dose d-cycloserine v placebo
1782495|NCT00455715|Drug|Sildenafil|1 capsule Sildenafil 50mg or Sildenafil 100mg or placebo taken at the time of study visit.
1782498|NCT00455754|Drug|Esomeprazole|
1782499|NCT00455767|Drug|EPI-hNE4|I.V. injection of 1mg/kg Depelestat (EPI-hNE4) 3 times daily for 7 days
1782500|NCT00455767|Drug|Placebo|Placebo
1782501|NCT00455780|Behavioral|Weight Loss Phase|Weight loss using CBT and meal replacements
1782502|NCT00455780|Behavioral|Continued CBT|Using CBT during weight loss maintenance
1782503|NCT00455780|Behavioral|reduced energy density education|Additional nutritional learning
1782504|NCT00455780|Behavioral|continued use of meal replacements|continued use of meal replacements during weight loss maintenance
1782505|NCT00455806|Drug|esomeprazole|
1782506|NCT00455806|Drug|moxifloxacin|
1782507|NCT00455806|Drug|amoxicillin|
1782508|NCT00455819|Procedure|home treatment|
1782509|NCT00455832|Procedure|peginterferon alpha and ribavirin|sperm collection
1957100|NCT02540811|Device|dCELL® ACL Scaffold|
1782511|NCT00455858|Drug|insulin detemir|Treat-to-target dose titration scheme, once daily, injected s.c. (under the skin).
1782818|NCT00450255|Other|pharmacological study|Correlative studies
1782512|NCT00455871|Drug|reduced fluence photodynamic therapy with Visudyne|reduced fluence photodynamic therapy with visudyne
1782513|NCT00455871|Drug|Lucentis|Lucentis intravitreal injection
1782517|NCT00455910|Drug|Thalidomide|
1782520|NCT00455936|Drug|Gefitinib|gefitinib 250mg tablet/ QD daily until Progression
1782521|NCT00455936|Procedure|chemotherapy|gemcitabine(1250mg/m2 iv on D1 & 8) plus Cisplatin (80mg/m2 iv on D1) every 3 weeks, maximum 9 cycles
1782522|NCT00455962|Drug|Estradiol steroid infusion|Estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr
1782523|NCT00455962|Drug|Progesterone steroid infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr
1782524|NCT00455975|Drug|Bevacizumab|Bevacizumab
1782525|NCT00456014|Drug|Escitalopram|Escitalopram will be administered at a dose of 10 mg daily for 4 weeks. If participants have not achieved response (greater than 50 % improvement in Hamilton Depression Rating Scale) by 4 weeks, the dose will be increased to 20 mg. Remission status is determined after an 8-week trial.
1782526|NCT00456014|Drug|Desipramine|Subsequent to escitalopram trial, non-remitters will be offered pharmacotherapy with desipramine. Desipramine will be initiated at a dose of 50 mg and titrated according to a treatment manual, with monitoring of therapeutic blood levels. Remission status is determined after an 8-week trial.
1782527|NCT00456027|Drug|rhGAD65 formulated in Alhydrogel® (Diamyd®)|20 micrograms of rhGAD65 formulated in Alhydrogel® administered subcutaneously twice 4 weeks apart
1782528|NCT00456053|Drug|FG2216|
1782529|NCT00456066|Device|Export Aspiration System|Patients scheduled for emergency angioplasty
1782530|NCT00456092|Drug|CC-10004|20mg CC-10004 twice a day orally following dose titration)
1782531|NCT00456092|Drug|CC-10004|40 mg CC-10004 QD following dose titration
1782532|NCT00456092|Drug|Matching Placebo|: Placebo identical to CC-10004 orally BID or QD following dose titration
1782533|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive standard diabetes care by their admitting physician|See Detailed Description.
1782534|NCT00456105|Behavioral|Subjects with diabetes who plan to undergo elective infrainguinal bypass surgery will receive diabetes care under the direction of the Diabetes Action Team|See detailed description.
1782535|NCT00456105|Behavioral|Subjects without diabetes will have their blood glucose levels monitored while in the hospital|See detailed description.
1782536|NCT00456131|Behavioral|Healthy Eating Behaviors Training|The intervention group (other group is a control without any intervention) involves 6 one-hour group sessions teaching healthy eating habits and weight gain prevention tools.
1782537|NCT00456144|Drug|Gonadotropin Releasing Hormone Agonist Therapy|Given either for 24 months and 6 months
1782538|NCT00456157|Drug|Intra-articular Injection of OP-1 to affected knee|
1782539|NCT00456170|Procedure|Performing Vaginal hysterectomy with Harmonic Scalpel|
1782540|NCT00456183|Biological|MVA 85A|
1782541|NCT00456222|Behavioral|Disrupting or changing the timing or the duration of sleep|Disrupting or changing the timing or the duration of sleep
1782542|NCT00456235|Drug|Mycophénolate Mofétil|
1782543|NCT00456235|Drug|Ciclosporine A|
1782544|NCT00456235|Drug|Tacrolimus|
1782545|NCT00456248|Drug|Infergen and ribavirin|Infergen 15 ug QD plus RBV for 36 weeks and Infergen 15 ug QD plus RBV for 48 weeks
1782546|NCT00456261|Drug|Pemetrexed|pemetrexed 500 mg/m2
1782547|NCT00456261|Drug|Gemcitabine|gemcitabine 1500 mg/m2
1782548|NCT00456261|Drug|Bevacizumab|bevacizumab 10mg/kg bevacizumab 15mg/kg
1782549|NCT00456261|Drug|Carboplatin|carboplatin AUC=5
1782550|NCT00456274|Procedure|Frequent baseline blood sampling|3 ml of blood sampled every 10 minutes for a total of 8-12 hours
1782551|NCT00456287|Device|CPAP (Continuous Positive Airway Pressure)|
1782552|NCT00456300|Drug|Exenatide|3 doses of exenatide will be tested in same group of patients
1782553|NCT00456313|Drug|FLIXOTIDE and SERETIDE|comparator
1782554|NCT00456339|Drug|Prednisolone and amoxicillin/clavulanate|Prednisolone 1mg/kg QD for 5 days Amoxicillin/clavulanate 45mg/Kg/d divided BID for 10 days
1782555|NCT00456352|Procedure|duodenal exclusion|
1782558|NCT00456378|Device|DIAM™ Spinal Stabilization System|Surgical procedure with implantation of the Investigational device
1782559|NCT00456378|Procedure|Conservative care|Six months of conservative care, to include: patient education, medications, physical therapy and spinal injections.
1782560|NCT00456391|Procedure|Medical history|
1782561|NCT00456391|Procedure|Brain CT scan|
1782562|NCT00456404|Drug|peppermint water|
1782563|NCT00456417|Procedure|123-I MNI-187 Injection and Imaging Procedures|
1782564|NCT00456430|Drug|Escitalopram|10 mg a day of escitalopram by mouth per day for 4 weeks. Dose may be increased to 20 mg a day after the 4th week depending on tolerance and treatment response.
1782565|NCT00456443|Procedure|Historical records|
1782566|NCT00456482|Drug|Fluocinolone Acetonide 0.59mg|Fluocinolone Acetonide Intravitreal Implant 0.59 mg
1782567|NCT00456482|Drug|Fluocinolone Acetonide 2.1mg|Fluocinolone Acetonide Intravitreal Implant 2.1 mg
1782568|NCT00456495|Drug|ranibizumab|Subconjunctival injection of drug every 2 to 4 weeks
1782569|NCT00456508|Drug|ecallantide|solution for SC injection, one 30 mg dose per HAE attack
1782570|NCT00456521|Drug|Naltrexone SR 32 mg/ bupropion SR 360 mg/ day|
1782571|NCT00456521|Drug|Placebo|
1782572|NCT00456521|Behavioral|Intensive group lifestyle modification counseling|
1782573|NCT00456547|Procedure|Blood Draw|Blood was obtained for coagulation studies at 2 hours following hysterectomy or cesarean delivery.
1782577|NCT00456573|Procedure|tonsillectomy|medically indicated tonsillectomy in subjects with and without OAS
1782578|NCT00456586|Drug|KW-6002 (istradefylline)|
1782579|NCT00456599|Drug|gemcitabine|Gemcitabine 1000mg/m2 will be infused over 30 minutes on days 1, 8, and 15 of a treatment cycle.
1782580|NCT00456599|Drug|oxaliplatin|Oxaliplatin 85mg/m2 will be infused following gemcitabine over approximately 90 minutes on days 1 and 15 of a treatment cycle.
1782581|NCT00456599|Procedure|Radiation|The total dose in a three week treatment block will be 30 Gy in 2.0 Gy fractions.
1782582|NCT00456612|Procedure|CyberKnife|Radiosurgery to enhancing high grade glioma in 5 fractions with escalating doses.
1782583|NCT00456625|Biological|Engerix™-B|Intramuscular injection, 1 dose
1782584|NCT00456638|Drug|Depodur|Depodur vs. traditional management
1782585|NCT00456651|Device|CPAP (Continuous Positive Airway Pressure)|
1782586|NCT00456664|Genetic|IE gene|
1782587|NCT00456677|Drug|minocycline|addition of antibiotic minocycline as antiinflammatory agent in addition to standard of care regimen.
1782588|NCT00456677|Drug|Placebos|Addition of oral placebo capsule in addition to standard of care regimen
1782589|NCT00456690|Other|Nutritional recommendations|Nutritional status assessment including complete endocrine and lipid laboratory profile and after one year of nutritional follow up a secondary assessment will be done
1782590|NCT00456703|Other|intraoperative fluid management|fluid restriction
1782591|NCT00456703|Other|fluid restriction|restriction of fluids
1782592|NCT00456716|Drug|sorafenib|400mg po bid
1782593|NCT00456729|Drug|Metronidazole|
1782594|NCT00456729|Procedure|Blood tests|
1782595|NCT00456755|Drug|Shi-Bi-Lin|4 weeks of treatment, dose of 1 g (two capsules), twice daily
1782596|NCT00456755|Other|Placebo|4 weeks of colormatched placebo capsules, dose of 1 g (two capsules), twice daily
1782597|NCT00456781|Device|Augmentation|Rotator Cuff Repair plus Graft Jacket
1782598|NCT00456781|Procedure|Rotator Cuff Repair without augmentation|Rotator Cuff Repair without augmentation
1782599|NCT00456794|Drug|Istradefylline (KW-6002)|
1782600|NCT00456807|Biological|Placebo|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
1782601|NCT00456807|Biological|Cervarix TM|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
1782602|NCT00456820|Drug|Wellbutrin XL|
1782603|NCT00456833|Drug|RAD001|
1782604|NCT00456833|Drug|erlotinib|
1782605|NCT00456846|Drug|ABI-007|100 mg/m^2 ABI-007 weekly for 3 weeks followed by 1 week rest
1782606|NCT00456859|Drug|Kremezin|
1782607|NCT00456872|Drug|lidocaine|
1782608|NCT00456885|Drug|exenatide|5 microgram twice a day for two week and then 10 mcg for remaining 15 weeks
1782609|NCT00456885|Drug|Placebo|Twice daily injection of placebo
1782610|NCT00456898|Drug|desvenlafaxine sustained release (DVS SR)|
1782611|NCT00456898|Drug|Paroxetine|
1782612|NCT00456898|Drug|Codeine|
1782613|NCT00456911|Behavioral|Fat and carbohydrate controlled diet|
1782614|NCT00456924|Drug|VA2914|
1782615|NCT00456937|Drug|Escitalopram|
1782616|NCT00456963|Behavioral|Diet|total fat < 5%, saturated fat < 10%, vegetables, fruit
1782617|NCT00456963|Behavioral|Moderate exercise|30 min at least 5 times/week
1782618|NCT00456963|Drug|enalapril tablets|one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
1782619|NCT00456963|Drug|placebo tablets|one Enalapril placebo tablet and one Losartan placebo tablet once daily until study end.
1782620|NCT00456963|Drug|Losartan Tablets|one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
1782621|NCT00456976|Drug|Selegiline|
1782622|NCT00456989|Drug|Taxotere|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Taxotere is administered on days 1, 8 and 15 (rate: 1 hour). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 25 and 30, respectively.
1782623|NCT00456989|Drug|Doxil|Treatment will be administered on an outpatient basis. Treatment will be repeated every 28 days. Doxil is administered on day 1 (rate: 1mg/min). Dose levels 1, 2 and 3 (mg/m2 i.v.) are 25, 30 and 30, respectively.
1782624|NCT00457002|Drug|Apixaban|"Apixaban: Twice daily, 30 days
Placebo: Once daily, 6-14 days"
1782625|NCT00457002|Drug|Enoxaparin|"Enoxaparin: Once daily, 6-14 days
Placebo: Twice daily, 30 days"
1782626|NCT00457015|Drug|ecallantide|dose of 30 mg (10 mg/ml) given as 3 subcutaneous injections.
1782627|NCT00457015|Drug|Phosphate Buffer Saline (PBS), pH 7.0|given as three 1mL subcutaneous injections.
1782628|NCT00457054|Drug|Lithium|starting dose 600 mg increase as tolerated
1782629|NCT00457067|Drug|Ranibizumab|
1782630|NCT00457080|Device|Alaris ETCO2 monitor - cont. resp. rate, & apnea events|
1782631|NCT00457093|Drug|glargine|
1782632|NCT00457093|Drug|detemir|
1782633|NCT00457106|Drug|Paroxetine|
1782634|NCT00457106|Drug|Risperidone|
1782635|NCT00457119|Drug|RAD001|5mg oral tablets of RAD001 - for the 5mg/daily arm, 10mg oral tablets x 3 of RAD001 - for the 30mg/weekly arm
1782636|NCT00457132|Device|APOS biomechanical gait system|
1782637|NCT00457145|Drug|Ranibizumab|
1782638|NCT00457158|Device|ALN optional filter|J1 : ALN optional filter M3 : ALN optional filter removed
1782639|NCT00457171|Drug|GI-270384|
1782640|NCT00457184|Procedure|Blood tests|
1782643|NCT00457210|Procedure|Brain Radiotherapy/Stereotactic Radiosurgery|
1782644|NCT00457223|Procedure|Amniotic membrane transplantation using fibrin glue|After pterygium excision, amniotic membrane was shaped and attached to bare scleral area using fibrin glue (Quixil®) in 16 eyes of 16 patients of FG group and continuous suture with nylon 10-0 in 16 eyes of 16 patients of SU group.
1782819|NCT00450268|Procedure|blood draw, skin shave biopsy|
1782645|NCT00457249|Biological|ADACEL®: Tetanus, Reduced Diphtheria and Acellular Pertussis Adsorbed|0.5 mL, IM
1782646|NCT00457249|Biological|DECAVAC®: Tetanus and Diphtheria Toxoids Adsorbed|0.5 mL, IM
1782647|NCT00457262|Procedure|soy consumption|
1782648|NCT00457275|Drug|MK0653, ezetimibe / Duration of Treatment: 4 Weeks|
1782649|NCT00457288|Drug|TF 002|
1782650|NCT00457301|Behavioral|HUI score card|Patients completed the HUI2 and HUI3 before the encounter with the clinician, the result was graphically represented in the HUI score card. Clinicians used the HUI score card as an extra tool to help them in the management of the patients
1782651|NCT00457314|Behavioral|Exercise|Regular exercise training
1782652|NCT00457327|Procedure|protective ileostomy|
1782653|NCT00457340|Drug|Atorvastatin 80mg|
1782654|NCT00457353|Drug|Bacillus Clausii|For 5 days
1782655|NCT00457353|Other|Oral rehydration therapy|For 5 days
1782658|NCT00457379|Behavioral|physical exercise|
1782659|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
1782660|NCT00457392|Drug|sunitinib|Sunitinib 37.5 mg daily by oral capsules in a continuous regimen
1782661|NCT00457392|Drug|erlotinib|plus erlotinib 150 mg daily by tablets in a continuous regimen until progression or unacceptable toxicity
1782662|NCT00457392|Drug|placebo|Placebo daily by oral capsules in a continuous regimen
1782663|NCT00457405|Drug|dipyridamole|dipyridamole 200mg twice daily
1782664|NCT00457418|Drug|PEG-Intron|
1782665|NCT00457431|Procedure|Mild therapeutic hypothermia|Mild therapeutic hypothermia will be performed by any methods applicable in the hospitals
1782666|NCT00457444|Drug|Pollen|
1782667|NCT00457457|Drug|Tamsulosin|Tamsulosin hydrochloride capsules, 0.4 mg. Tamsulosin hydrochloride is an antagonist of alpha1A adrenoceptors in the prostate
1782668|NCT00457457|Drug|UK-369,003|UK 369,003 is a highly selective and potent inhibitor of PDE5. It has increased selectivity for PDE5 over PDE6 (>80 fold) compared to sildenafil (~10 fold). Two recently completed trials have shown efficacy for UK-369,003 in treating subjects with ED
1782669|NCT00457470|Drug|AG-014699|
1782670|NCT00457483|Drug|hydrochlorothiazide|12.5 mg once-a-day
1782671|NCT00457483|Drug|valsartan, 80 mg once-a-day|80 mg once-a-day
1782672|NCT00457496|Behavioral|Cognitive, behavioral, exercise|Relaxation exercises once a day, visual feedback, exercises for neck and shoulder
1782673|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
1782674|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
1782675|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
1782676|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant|0.5 mL, Intramuscular
1782677|NCT00457509|Biological|A/H5N1 inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
1782678|NCT00457522|Behavioral|Nurse/community health worker telephone intervention|
1782679|NCT00457548|Behavioral|Brief Telephone Counseling for risky aclohol use|Two brief sessions (30-40 minutes) of brief counseling using a motivational interviewing approach. The counseling session are delivered by telephone and focus on the alcohol use of inuured ED patients who randomize into the treatment arm of the study. Patient who randomize into the controla rm of the study receive standard emergency department care only plus study assessments.
1782680|NCT00457574|Drug|GMX1777|
1782681|NCT00457600|Procedure|patient-driven health IT product|
1782682|NCT00457613|Drug|bolus injection, followed by a continuous infusion ( 24 h) (Alkaline phosphatase)|
1782683|NCT00457626|Drug|Valsartan|All patients started with dose 1 mg/kg once daily for first 2 weeks, up-titration to 2mg/kg (then to 4mg/kg) depending on MSSBP.
1782684|NCT00457639|Drug|Cholic Acid|Capsules of active Cholic Acid or matching placebo, total dose is 15 mg/kg per day, maximum dose of 1500 mg per day, taken PO, BID.
1782685|NCT00457652|Drug|Rosuvastatin|7 day treatment rosuvastatin 20mg
1782686|NCT00457665|Drug|Viracept versus Sustiva with stavudine and epivir|
1782687|NCT00457678|Drug|Visudyne|
1782688|NCT00457678|Drug|Lucentis|
1782689|NCT00457678|Drug|Dexamethasone|
1782690|NCT00457691|Drug|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
1782691|NCT00457691|Drug|irinotecan|180mg/m2 iv day 1 every 14 days
1782692|NCT00457691|Drug|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
1782693|NCT00457691|Drug|sunitinib|37.5mg of blinded therapy every day for 28 days followed by 14 days of blinded therapy free period
1782694|NCT00457691|Drug|5 fluorouracil|400mg/m2 bolus injection day 1 followed by 2400mg/m2 continuous infusion for 46 hours every 14 days
1782695|NCT00457691|Drug|irinotecan|180mg/m2 iv day 1 every 14 days
1782696|NCT00457691|Drug|levo- leucovorin|200mg/m2 iv; day 1 every 14 days
1782697|NCT00457691|Drug|placebo|37.5mg of blinded placebo therapy every day for 28 days followed by 14 days of blinded therapy free period
1782698|NCT00457717|Drug|0.25 % atropine|
1782699|NCT00457717|Drug|0.5 % atropine|
1782700|NCT00457717|Procedure|0.25 % atropine+auricular acupoints|
1782701|NCT00457730|Drug|Duloxetine|Patients will be randomly assigned to Duloxetine 30mg/d for 1 week, 60mg/d for 5 weeks and 30mg/d for 1 week or placebo for 7 weeks under double-blind conditions.
1782702|NCT00457730|Drug|Placebo|Subjects are randomized to either Duloxetine or Placebo
1782703|NCT00457743|Drug|Sunitinib malate (SU011248)|SU011248
1782704|NCT00457756|Dietary Supplement|BiosLife Complete|
1782705|NCT00457756|Dietary Supplement|Placebo|
1782706|NCT00457769|Drug|Donepezil|Aricept 5 mg PO qd for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
1782707|NCT00457769|Drug|Donepezil|Aricept 5 mg PO daily for 4 weeks followed by Aricept 10 mg PO qd for 8 weeks
1782708|NCT00457782|Drug|KW-2478|Daily intravenous KW-2478 for 5 days in 14-day cycles, ascending dose cohorts
1782709|NCT00457795|Drug|brimonidine 0.1% (Alphagan® P)|Brimonidine 0.1%, 1 drop three-times daily for 4 weeks
1782710|NCT00457808|Drug|Rapamycin, sirolimus|
1782711|NCT00457821|Drug|Ivacaftor 25 mg/75 mg|25 mg or 75 mg q12h for a total of 28 days (Part 1)
1782712|NCT00457821|Drug|Ivacaftor 75 mg/150 mg|75 mg or 150 mg q12h for a total of 28 days (Part 1)
1782713|NCT00457821|Drug|Ivacaftor 150 mg or 250 mg|150 mg or 250 mg of ivacaftor q12h for 28 days (Part 2)
1782714|NCT00457821|Drug|Placebo|Given q12h for 28 days each in Part 1 and Part 2 of the study
1782715|NCT00457834|Device|InSync III|Bi-ventricular pacing from leads in LV+RVA or LV+RVOT
1782716|NCT00457860|Drug|Immunotoxin therapy|
1782717|NCT00457860|Drug|CAT-8015 immunotoxin|
1782718|NCT00457860|Procedure|Biological therapy|
1782719|NCT00457873|Drug|0.9% saline in 5% dextrose (intravenous)|
1782720|NCT00457873|Drug|0.45% saline in 5% dextrose (intravenous)|
1782721|NCT00457899|Drug|Quetiapine IR (Immediate Release)|oral
1782722|NCT00457925|Drug|GSK221149A|
1782723|NCT00457938|Other|low-fat diet ( Still recruiting )|This study will compare 10% fat versus 35% fat diets in terms if effect on liver fat, triglycerides adn other metabolic parameters.
1782724|NCT00457938|Other|Diet|10 % versus 35 % fat in diet
1782725|NCT00457951|Drug|Open-Label|ODSH administered open-label
1782726|NCT00457951|Drug|Placebo Comparator: Placebo-Control Arm 0.9% Sodium Chloride|Placebo-Control Arm: Bolus infusion followed by a 96 hour continuous infusion of 0.9%Sodium Chloride
1782727|NCT00457951|Drug|ODSH|Randomized, Blinded, ODSH Arm
1782728|NCT00457964|Drug|RAD001|5 and 10 mg/day or 30, 50, 70mg/week
1782729|NCT00457977|Biological|Pneumovax (PPSV23)|Injection
1782730|NCT00457977|Biological|Prevnar (PCV7)|Injection
1782731|NCT00457990|Drug|Oral administration of ferrous sulphate|
1782732|NCT00458003|Drug|Ephedrine|Ephedrine concentration: 8 mg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP > 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP < 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
1782733|NCT00458003|Drug|Phenylephrine|Phenylephrine concentration: 100 mcg/mL. The infusion will be initiated immediately after completion of the spinal injection at a rate of 1 mL/min and continued for a minimum of 2 min after which the infusion will be stopped, continued or increased based on the SBP each minute. After each SBP measurement the infusion will be stopped if SBP > 80% baseline, and the infusion will be continued or restarted if the SBP is approximately equal to 80% baseline. The infusion will be increased by 1 mL/min if the SBP < 80% baseline. Each time there is hypotension the patient will receive a 1 mL IV bolus of the study solution and the infusion will be increased by 1 mL/min until delivery.
1782734|NCT00458016|Drug|MB07803|Daily oral administration
1782735|NCT00458016|Drug|Placebo|Daily oral administration
1782736|NCT00458029|Behavioral|integrated program of nutrition, activity, behavior, and promotion|implemented across 5 half-year periods: winter/spring 2007, fall 2007, winter/spring 2007, fall 2008, winter/spring 2008
1782737|NCT00458042|Drug|treprostinil sodium|
1782738|NCT00458055|Drug|Atorvastatin; Fenofibrate; Niacin|Atorvastatin 20 mg; Fenofibrate 200 mg; Niacin 2g used sequentially for 8 weeks, after 4 weeks washout.
1782739|NCT00458068|Drug|Oral administration of ferrous sulphate|
1782740|NCT00458081|Drug|Rimonabant|20 mg once per day + slightly reduced calorie diet
1782741|NCT00458081|Drug|Placebo|placebo once per day + slightly reduced calorie diet
1782742|NCT00458094|Behavioral|Physical activity intervention with peer support (PA+PS)|Participants in the PA+PS group will have three exercise sessions each week for 4 months, which will include group exercise classes and open gym hours for supervised individual exercise. They will also meet with a peer educator once a week for 15 minutes. Peer educators will provide emotional, informational, instrumental, and appraisal support that is aimed to motivate participants to partake in the exercise sessions.
1782743|NCT00458094|Behavioral|Physical activity intervention without peer support (PA)|Participants in the PA group will attend the three weekly exercise sessions for 4 months but will not attend meetings with the peer educator.
1782744|NCT00444197|Behavioral|Mentoring and violence prevention curriculum with parental monitoring|
1782745|NCT00444210|Device|DL6049 (injectable poly-L-lactic acid)|
1782746|NCT00444223|Procedure|fluorine F 18 FEQA + positron emission tomography|
1782747|NCT00444236|Drug|Nexium|nexium or placebo 40 mg twice a day for 10-12 weeks. Therapy will then be switched for another 10-12 weeks
1782748|NCT00444236|Drug|Placebo|matching placebo for active drug
1782749|NCT00444249|Procedure|White Alcon IOL|Implantation of white Alcon IOL
1782750|NCT00444249|Procedure|Yellow Alcon IOL|Implantation of yellow Alcon IOL
1782751|NCT00444249|Procedure|White Hoya IOL|Implantation of white Hoya IOL
1782752|NCT00444249|Procedure|Yellow Hoya IOL|Implantation of yellow Hoya IOL
1782753|NCT00444262|Procedure|hemodynamic optimisation guided using esophageal Doppler|hemodynamic optimisation guided using esophageal Doppler
1782754|NCT00444262|Drug|VOLUVEN and others solute|VOLUVEN and others solute
1782755|NCT00444275|Drug|esomeprazole (Nexium®)|"This randomized study was conducted on parallel groups and included two phases:
One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
1782820|NCT00450281|Genetic|chromogenic in situ hybridization|
1782821|NCT00450281|Genetic|gene expression analysis|
1782822|NCT00450281|Genetic|mutation analysis|
1782823|NCT00450281|Genetic|polymerase chain reaction|
1782824|NCT00450281|Genetic|polymorphism analysis|
1782756|NCT00444275|Drug|Xolaam®|"This randomized study was conducted on parallel groups and included two phases:
One initial phase during when the patients received once daily, either esomeprazole 20 mg or esomeprazole 40 mg, depending on the investigator's decision
One maintenance treatment phase, patients were randomized to one of the following three groups, either esomeprazole 20 mg once daily, or esomeprazole 20 mg on demand or antacid treatment as needed"
1782757|NCT00449709|Drug|GSK221149|
1782758|NCT00449722|Drug|mesalazine|
1782759|NCT00449748|Drug|RAD001 (Everolimus)|Oral RAD001 10 mg daily for 30 days
1782760|NCT00449761|Drug|panobinostat|LBH589
1782761|NCT00449774|Drug|Lamotrigine IR tablets|Lamotrigine IR tablets will be available in dose strength of 200 mg.
1782762|NCT00449774|Drug|Lamotrigine ODT tablets|Lamotrigine ODT tablets will be available in dose strength of 200 mg.
1782763|NCT00449787|Drug|Sumatriptan 100 mg|Sumatriptan 100mg tablet
1782764|NCT00449787|Drug|Naproxen|Naproxen 500mg tablet
1782765|NCT00449800|Drug|ceftriaxone|
1782766|NCT00449813|Drug|Pantoprazole|40 mg Pantoprazole
1782767|NCT00449826|Procedure|Computed Tomographic Angiography|CT scan
1782768|NCT00449839|Drug|Insulin Aspart|"A; CSII without bolus: 8 hours of constant insulin infusion. B; CSII with bolus: 8 hours of a constant insulin infusion starting with a s.c. bolus.
C; CSII with bolus, optional: 8 hours of a constant insulin infusion starting with a different bolus than period B. This period is optional and it will be evaluated after period A and B if period C is conducted."
1782769|NCT00449852|Behavioral|Interactive Voice Response|The IVR group will receive a telephone call from the IVR system three, 14, 30, 90, 120 and 150 days after hospital discharge.
1782770|NCT00449865|Drug|creatine|"Creatine, a widely used dietary supplement is thought to improve exercise performance. In animal models and human studies, creatine has been shown to be well tolerated and may have some ability to protect brain cells.
The study is comparing creatine 5 grams twice daily with placebo."
1782771|NCT00449865|Other|placebo|an inactive substance
1782772|NCT00449878|Drug|Liprotamase|Administered orally
1782773|NCT00449878|Drug|Placebo|Administered orally
1782774|NCT00449904|Drug|Liprotamase|Administered orally
1782775|NCT00449917|Drug|lutein|
1782776|NCT00449917|Drug|DHA|
1782777|NCT00449917|Drug|vitamins|
1782778|NCT00449930|Drug|sitagliptin phosphate|(1) sitagliptin 100mg tablet once daily (q.d.) for a 24-wk treatment period
1782779|NCT00449930|Drug|Comparator: metformin hydrochloride|(4) Metformin 500mg tablets once daily (q.d.) for a 24-wk treatment period.
1782780|NCT00449943|Procedure|Computed Tomographic Angiography|CT scan
1782781|NCT00449943|Procedure|Myocardial Perfusion Imaging Scan|SPECT
1782782|NCT00449956|Drug|dorzolamide hydrochloride (+) timolol maleate|Dorzolamide hydrochloride 1% + timolol 0.5%, 8-week
1782783|NCT00449956|Drug|Comparator: timolol maleate|timolol maleate 0.5%, 8-week
1782784|NCT00449956|Drug|Comparator: dorzolamide hydrochloride|dorzolamide hydrochloride 1%, 8-week
1782785|NCT00449969|Device|Zoll AED pro|Arm one (Extended feedback) offers full feedback guidance during CPR
1782786|NCT00449969|Device|Zoll AED pro|In arm two (limited feedback) feedback is modified lacking several elements of feedback
1782787|NCT00450099|Drug|bupivacaine|0.125% bupivacaine in a volume determined according to the biased coin up-down sequential allocation model, starting at 8mL.
1782788|NCT00450112|Device|Gel-200|Single Intra-articular Injection
1782789|NCT00450125|Other|Six-Minute Walk Test|Six-Minute walk tests at least one hour after vigorous exertion (such as exercise stress test) and at least 20 minutes in between the first and second six-minute walk tests
1782790|NCT00450125|Other|Exercise stress test|Scheduled gold standard exercise test, i.e. stress test, cycle ergometry with incremental workloads or oxygen consumption exercise studies
1782791|NCT00450138|Drug|ZD6474 (vandetanib)|once daily oral dose
1782792|NCT00450138|Drug|Cisplatin|intravenous infusion
1782793|NCT00450138|Radiation|Radiation|radiation of head and neck
1782794|NCT00450164|Procedure|esofagic varices ligation|
1782795|NCT00450164|Drug|Nadolol|
1782796|NCT00450164|Drug|Isosorbide mononitrate|
1782797|NCT00450164|Drug|Prazosin|
1782798|NCT00450177|Drug|Ferrous Sulfate 325 mg PO TID, or placebo|
1782800|NCT00450203|Biological|bevacizumab|7.5mg/kg IV Day 1 of each 21 cycle of chemotherapy (6 cycles) plus day 1 of each maintenance dose every 21 days for 6 doses.
1782801|NCT00450203|Drug|capecitabine|dose banded as based on patient BSA. Oral dose given twice a day during each 21 day cycle of chemotherapy (6 cycles in total)
1782802|NCT00450203|Drug|cisplatin|60mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
1782803|NCT00450203|Drug|Epirubicin|50mg/m2 IV day one of each 21 day cycle of chemotherapy (6 cycles in total)
1782804|NCT00450203|Procedure|adjuvant therapy|3 cycles of ECX chemotherapy post operatively
1782805|NCT00450203|Procedure|conventional surgery|Surgery undertaken after 3 cycles of pre-operative chemotherapy. Followed by 3 cycles of chemotherapy.
1782806|NCT00450203|Procedure|neoadjuvant therapy|3 cycles of pre-operative ECX chemotherapy.
1782807|NCT00450203|Drug|Lapatinib|1250mg/day Day 1-21 of each cycle of chemotherapy (6 cycles) plus day 1-21 of each maintenance course every 21 days for 6 doses.
1782808|NCT00450216|Drug|Ibuprofen/famotidine|HZT-501: Ibuprofen800mg/famotidine 26.6mg administered orally 3 times daily for 24 weeks
1782809|NCT00450216|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for 24 weeks
1782810|NCT00450229|Drug|diindolylmethane|Given PO
1782811|NCT00450229|Drug|placebo|Given PO
1782812|NCT00450229|Procedure|therapeutic conventional surgery|Undergo surgical resection
1782813|NCT00450229|Other|laboratory biomarker analysis|Correlative studies
1782814|NCT00450229|Other|pharmacological study|Correlative studies
1782815|NCT00450242|Drug|5% topical lidocaine ointment|Lidocaine 5% in hydrophilic petrolatum, dime-sized amount, applied nightly.
1782816|NCT00450242|Drug|Placebo cream|hydrophilic petrolatum, dime-sized amount, applied nightly.
1782817|NCT00450255|Biological|ziv-aflibercept|Given IV
1782825|NCT00450281|Other|fluorescent antibody technique|
1782826|NCT00450281|Other|immunohistochemistry staining method|
1782827|NCT00450281|Other|laboratory biomarker analysis|
1782828|NCT00450281|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
1782829|NCT00450281|Other|study of socioeconomic and demographic variables|
1782830|NCT00450281|Procedure|study of high risk factors|
1782831|NCT00450307|Biological|monoclonal antibody 3F8|
1782832|NCT00450307|Biological|sargramostim|
1782833|NCT00450320|Drug|sirolimus|The target rapamycin trough level will be 5-10 ng/mL. The initial dose will be dependent upon the type of HAART regimen. Subjects will continue on study protocol for six cycles as long as their KS is stable or continuing to respond to study medication. Treatment will be extended for up to six additional cycles if the subject has met criteria for a response. Subjects with no more than stable disease will have treatment discontinued after six cycles. Protocol treatment will be discontinued if the subject develops tumor progression, unacceptable toxicity or develops one of the protocol-defined reasons for treatment discontinuation at any time during the study.
1782834|NCT00450333|Drug|Dynepo (Epoetin delta)|subcutaneous, BIW for 24 weeks
1782835|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
1782836|NCT00450333|Drug|Dynepo|subcutaneous, QW for 24 weeks
1782837|NCT00450333|Drug|Dynepo|subcutaneous, Q2W for 24 weeks
1782838|NCT00450359|Procedure|breast imaging study|
1782839|NCT00450359|Procedure|comparison of screening methods|
1782840|NCT00450359|Procedure|radiomammography|
1782841|NCT00450372|Biological|ADI-PEG-20|There will be 6 cycles planned, each consisting of 4 weeks. During each cycle subjects will receive injections on days 1, 8, 15, and 22 + 2 days. All subjects may begin treatment with 160 IU/m2 on a weekly basis.
1782842|NCT00450372|Other|Pharmacology Studies|tissue blocks will be obtained from the initial biopsy of melanoma. Immunohistochemical staining for ASS and RT-PCR will be performed on the tumor tissue
1782843|NCT00450385|Drug|Rituximab|Rituximab 375 mg/m2 on day 1 for 6 to 8 cycles
1782844|NCT00450385|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 IV on day 1 for 6 to 8 cycles
1782845|NCT00450385|Drug|Doxorubicin|Doxorubicin 50 mg/m2 on day 1 for 6 to 8 cycles
1782846|NCT00450385|Drug|Prednisone|Prednisone 40 mg/m2 orally days 1-5, repeated every 21 days for 6 to 8 cycles.
1782847|NCT00450385|Drug|Vincristine|Vincristine 1.4 mg/m2 (maximum = 2 mg) IV on day 1 for 6 to 8 cycles
1782848|NCT00450398|Drug|YSPSL|YSPSL administered as an ex vivo flush (20 mg YSPSL in Viaspan® 200 mL total volume) into the portal vein prior to transplant at the back table; YSPSL 1 mg/kg administered IV to the transplant recipient prior to arterial reperfusion of the liver.
1782849|NCT00450398|Drug|Placebo|Ex vivo flush of placebo control (200 mL Viaspan®) into the portal vein prior to transplant and 0.1 mL/kg placebo control (saline) IV to the transplant recipient prior to arterial reperfusion of the liver.
1782853|NCT00450424|Other|counseling intervention|Participants in the Counseling intervention will meet with the study health educator who will provide the participant with the standard MSI informed consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. The patients will either sign (or not sign, if they do not consent to have the test, or wish to think further about the decision) after this discussion. Participants who have further questions will be referred to either the attending physician or the genetics counselor at each hospital site.
1782854|NCT00450424|Other|CD-ROM intervention|Participants who are randomized to the CD-ROM condition will complete the baseline interview and then meet with the health educator who will provide the participant with the standard MSI consent form and provide a brief, standardized explanation of the MSI test. At that time, the participant can ask any questions s/he wishes to ask. Next, the participant will be provided with the CD-ROM to view on a laptop computer in the clinic. Participants will also be given a copy of the CD-ROM to take home and keep for future reference. The CD-ROM patients will sign (or not sign, if they do not consent or wish to think further about the decision) the consent form after this discussion.
1782855|NCT00450437|Biological|MenACWY CRM|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered intramuscularly.
1782856|NCT00450437|Biological|Meningococcal ACWY Conjugate vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered intramuscularly.
1782857|NCT00450450|Procedure|allogeneic bone marrow transplantation|Patients undergo allogeneic BMT
1782858|NCT00450450|Other|laboratory biomarker analysis|Correlative studies
1782859|NCT00450450|Biological|filgrastim|Given IV
1782864|NCT00450476|Device|Hi-Lo Evac Endotracheal Tube|
1782865|NCT00450502|Drug|Batracylin|
1782866|NCT00450515|Drug|capecitabine|
1782867|NCT00450515|Drug|vinflunine|
1782868|NCT00450541|Behavioral|Questionnaire|Four questionnaires taking 15-20 minutes total to complete.
1782869|NCT00450541|Behavioral|Interview|Interview lasting about 30 minutes.
1782870|NCT00450567|Procedure|computed tomography|
1782871|NCT00450567|Procedure|positron emission tomography|
1782872|NCT00450567|Radiation|fludeoxyglucose F 18|
1783055|NCT00451893|Procedure|Lichtenstein operation with a heavy-weight mesh|Bard flat mesh, polypropylene, 7,5 x 15 cm, 90 g/m2
1782873|NCT00450580|Drug|fosamprenavir/ritonavir|Fosamprenavir (FPV, TELZIR) is currently licensed in Europe for twice daily (BID) dosing in combination with ritonavir (RTV, Norvir) as a boosting agent
1782874|NCT00450593|Genetic|gene expression analysis|
1782875|NCT00450593|Genetic|microarray analysis|
1782876|NCT00450593|Genetic|molecular genetic technique|
1782877|NCT00450593|Genetic|mutation analysis|
1782878|NCT00450593|Other|laboratory biomarker analysis|
1782879|NCT00450593|Procedure|mutation carrier screening|
1782880|NCT00450593|Procedure|study of high risk factors|
1782881|NCT00450606|Procedure|Balneotherapy and hydrotherapy|
1782882|NCT00450619|Radiation|Samarium Sm 153 lexidronam pentasodium|1 mCi/Kg given intravenous (IV)over 1 minute on day 8.
1782883|NCT00450619|Biological|Sargramostim|100 mcg/injection x 4 days given subcutaneously
1782884|NCT00450619|Biological|Recombinant vaccinia-TRICOM vaccine|2 x 10^8 PFU given subcutaneously on day 1.
1782885|NCT00450619|Biological|Recombinant fowlpox-TRICOM vaccine|1 x 10^9 PFU given subcutaneously on days 15 and 29
1782886|NCT00450645|Drug|low molecular weight heparin|LMWH were continued for additional 6 months after detection of residual vein thrombosis (6 months after the index deep vein thrombosis) in patients randomized to group A. LMWH are stopped in patients randomized to group B or in those patients without residual vein thrombosis after 6 months from the index DVT. Dosage of LMWH are 75% of the therapeutic dosage (almost 1 mg/Kg every 12 hours)
1782887|NCT00450658|Drug|HZT-501|HZT-501: Ibuprofen 800mg/famotidine 26.6mg orally 3 times daily for 24 weeks
1782888|NCT00450658|Drug|Ibuprofen|Ibuprofen 800mg orally 3 times daily for 24 weeks
1782889|NCT00450671|Procedure|Collagen Plug Placement|
1782890|NCT00450671|Procedure|Seton placement|
1782891|NCT00450684|Device|Implantation and testing of CRT|Biventricular pacing for 12 weeks (CRT ON) followed by automatic rhythmicity or the original, conventional biventricular stimulation for 12 weeks (CRT OFF), then returning to biventricular pacing (CRT ON).
1782892|NCT00450684|Device|Implantation and testing of CRT|Automatic rhythmicity or original conventional biventricular stimulation for 12 weeks (CRT OFF) followed by biventricular pacing (CRT ON).
1782893|NCT00450710|Procedure|ileal interposition with a sleeve gastrectomy|
1782894|NCT00450723|Drug|Isosulfan blue|Administered pre-surgery; injection of 2 cc of Isosulfan Blue in four equal aliquots of 0.5 cc as routinely done for the axillary sentinel node procedure.
1782895|NCT00450723|Procedure|Axillary Lymph Node Dissection|Axillary Lymph Node Dissection
1782896|NCT00450723|Procedure|Surgery|The surgery will be performed under general anesthesia with a single lumen endo-tracheal tube. The patient will be laid in a semi decubitus position on the opposite side with the ipsilateral arm bent over the head and attached to an arm rest.
1782897|NCT00450723|Procedure|Sentinel Lymph Node Biopsy|Sentinel Lymph Node Biopsy
1782898|NCT00450723|Procedure|Thoracoscopic Surgery|Performed only if internal mammary sentinel node cannot be retrieved via same incision of lumpectomy/mastectomy.
1782899|NCT00450723|Radiation|Technetium Tc 99m Sulfur Colloid|Two to three hours prior to surgery, a peritumoral injection of filtered Technetium Sulfur Colloid will be performed in four 0.25 mci/2cc aliquots
1782900|NCT00450736|Drug|celecoxib|
1782901|NCT00450736|Procedure|adjuvant therapy|
1782902|NCT00450736|Radiation|radiation therapy|
1782903|NCT00450749|Other|placebo|Given PO
1782904|NCT00450749|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
1782905|NCT00450749|Other|laboratory biomarker analysis|Correlative studies
1782906|NCT00450749|Drug|lycopene|Given PO
1782907|NCT00450762|Drug|gemcitabine|
1782908|NCT00450762|Drug|carboplatin|
1782909|NCT00450775|Drug|Dermatix Q|Dermatix Q applied twice daily
1782910|NCT00450801|Drug|Rituximab|Rituximab 375 mg/m2 IV, Days 1 of all cycles
1782911|NCT00450801|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m2 IV, Day 1, Cyclophosphamide 200 mg/m2 IV Days 2 - 5, Cycles 1 and 3. Cyclophosphamide will be given in 100 cc NS IV over 30 minutes.
1782912|NCT00450801|Drug|Cytarabine|Cytarabine 2 grams/m2 IV every 12 hours x 4 doses, Days 1 and 2, Cycles 2 and 4.
1782913|NCT00450801|Drug|Doxorubicin|Doxorubicin 45 mg/m2 IV bolus, Day 1, Cycles 1 and 3
1782914|NCT00450801|Drug|Etoposide|Etoposide 60 mg/m2 IV daily x 5 days, Cycles 2 and 4
1782915|NCT00450801|Drug|Ifosfamide|Ifosfamide 1.5 grams/m2 IV once a day (QD) x 5 days, Cycles 2 and 4
1782916|NCT00450801|Drug|Leucovorin|Leucovorin 180 mg/m2 IV beginning 36 hours after start of methotrexate infusion and then 12 mg/m2 IV every 6 hours until methotrexate level is below 0.01 nM. Day 10, Cycles 1 and 3.
1782917|NCT00450801|Drug|Methotrexate|Methotrexate 1,200 mg/m2 in 250 cc 5 percent dextrose in water (D5W) IV over 1 hour followed by Methotrexate 5,520 mg/m2 in 1,000 cc D5W by continuous infusion over 23 hours (240 mg/m2 every hour for 23 hours). Day 10, Cycles 1 and 3.
1782918|NCT00450801|Drug|Thalidomide|Maintenance therapy.
1782919|NCT00450801|Drug|Vincristine|Vincristine 1.5 mg/m2 IVP (maximum of 2 mg), Day 1 and 8 , Cycles 1 and 3.
1782920|NCT00450801|Drug|Mesna|Mesna 360 mg/m2 IV every 3 hours x 5 days, Cycles 2 and 4
1782921|NCT00450801|Drug|Filgrastim (G-CSF)|G-CSF 480 mcg subcutaneous (SQ) starting Day 13 (Cycles 1 and 3), Day 7 (Cycles 2 and 4)
1782922|NCT00450801|Drug|Granisetron|Granisetron 1 mg IV on Day 1, Cycle 1 and 3
1782923|NCT00450801|Drug|Decadron|Decadron 10 mg IV on Day 1, Cycles 1 and 3
1782924|NCT00450814|Drug|Cyclophosphamide|Given IV
1782925|NCT00450814|Other|Laboratory Biomarker Analysis|Correlative studies
1782926|NCT00450814|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IV
1782927|NCT00450814|Other|Pharmacological Study|Correlative studies
1782928|NCT00450827|Biological|bevacizumab|
1782929|NCT00450827|Biological|filgrastim|
1782930|NCT00450827|Procedure|autologous hematopoietic stem cell transplantation|
1782931|NCT00450827|Radiation|iodine I 131 monoclonal antibody 3F8|
1782932|NCT00450840|Drug|Simvastatin|
1782933|NCT00450853|Drug|granisetron|Granisetron SC followed by granisetron IV
1783061|NCT00451945|Device|3d-ultrasound and fusion of UL and PET/CT|
1782934|NCT00450866|Biological|epothilone B|Patupilone will be administered as a single intravenous infusion over 20 minutes, once every 3 weeks. Patupilone will be administered at a dose of 10 mg/m2 (q3weeks) with actual body weight.
1782935|NCT00450879|Drug|Pazopanib Hydrochloride|Given PO
1782936|NCT00450879|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
1782937|NCT00450879|Other|Pharmacological Study|Correlative studies
1782938|NCT00450879|Other|Laboratory Biomarker Analysis|Correlative studies
1782939|NCT00450892|Drug|docetaxel+lapatinib|3 cycles of docetaxel (100 mg/m²) + lapatinib (1000 mg/d) followed by 3 cycles of FEC
1782940|NCT00450892|Drug|docetaxel + trastuzumab|3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule followed by 3 cycles of FEC 100
1782941|NCT00450892|Drug|docetaxel + trastuzumab + lapatinib|"3 cycles of docetaxel (100 mg/m²) + trastuzumab weekly schedule
+lapatinib (1000 mg/d) followed by 3 cycles of FEC 100"
1782942|NCT00450905|Device|PRIMA Device|
1782943|NCT00450931|Other|counseling intervention|
1782944|NCT00450931|Other|educational intervention|
1782945|NCT00450944|Biological|deglycosylated ricin A chain-conjugated anti-CD19/anti-CD22 immunotoxins|
1782946|NCT00450957|Dietary Supplement|lycopene|Given orally
1782947|NCT00450957|Other|pharmacological study|Correlative studies
1782948|NCT00450970|Drug|Oral Satraplatin|The SPERA protocol states that satraplatin may be continued until evidence of disease progression (at the discretion of the investigator), intolerable toxicity, withdrawal of informed consent, or non compliance. The treatment consists of satraplatin 80 mg/m2 administered by mouth once daily for five consecutive days (days 1-5) plus prednison 5 mg po twice daily. The treatment cycle is repeated every 35 days.
1782949|NCT00450983|Biological|muromonab-CD3|
1782950|NCT00450983|Biological|natural killer cell therapy|
1782951|NCT00450983|Drug|fludarabine phosphate|
1782952|NCT00450983|Drug|methotrexate|
1782953|NCT00450983|Drug|thiotepa|
1782954|NCT00450983|Genetic|gene expression analysis|
1782955|NCT00450983|Other|flow cytometry|
1782956|NCT00450983|Other|immunologic technique|
1782957|NCT00450983|Procedure|allogeneic hematopoietic stem cell transplantation|
1782958|NCT00450983|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1782959|NCT00450983|Radiation|total-body irradiation|
1782960|NCT00450996|Drug|Topical Steroids|
1782961|NCT00451009|Device|Viacell's product Media Kits|
1782962|NCT00451035|Drug|LBH589|
1782963|NCT00451048|Drug|sunitinib malate|Given orally
1782964|NCT00451061|Drug|Alfuzosin|
1782965|NCT00451061|Drug|Tamsulosin|
1782966|NCT00451074|Drug|Gentamicin infusions twice a week for six months|Gentamicin infusions twice a week
1782967|NCT00451087|Procedure|leg press training|quadriceps muscle strengthening. 30min/ 3times/ week
1782968|NCT00451087|Procedure|isokinetic training|quadriceps muscle training. 30 min/ 3 times/ week
1782969|NCT00451100|Drug|Sugammadex|Subjects received a bolus dose of 0.6 mg/kg rocuronium. After the last dose of rocuronium, at reappearance of T2, a dose of 2.0 mg/kg Org 25969 was to be administered
1782970|NCT00451100|Drug|neostigmine|Subjects received a bolus dose of 0.15 mg/kg cisatracurium. After the last dose of cisatracurium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered. In accordance to the labeling of neostigmine, a maximum of 5 mg neostigmine was to be administered
1782971|NCT00451113|Drug|Sitagliptin 100 mg|All subjects will receive a single 100 mg dose of sitagliptin and a placebo. Which they are given first is determined randomly.
1782972|NCT00451139|Drug|artemether/lumefantrine|
1782973|NCT00451139|Drug|quinine|
1782974|NCT00451139|Drug|atovaquone/proguanil|
1782975|NCT00451152|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.
1782976|NCT00451152|Other|Anecortave Acetate Vehicle|Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.
1782977|NCT00451165|Procedure|laparoscopic colorectal surgery|laparoscopic colorectal surgery
1782978|NCT00451178|Drug|enzastaurin|1125 mg then 500 mg, oral, daily, six 21 day cycles or up to 3 years
1782979|NCT00451178|Drug|rituximab|375 mg/m2, IV, day 1 every 21 days, six 21 day cycles
1782980|NCT00451178|Drug|cyclophosphamide|750 mg/m2, IV, day 1 every 21 days, six 21 day cycles
1782981|NCT00451178|Drug|doxorubicin|50 mg/m2, IV, day 1 every 21 days, six 21 day cycles
1782982|NCT00451178|Drug|vincristine|1.4 mg/m2, IV, day 1 every 21 days, six 21 day cycles
1782983|NCT00451178|Drug|prednisone|100 mg, oral, days 1-5, six 21 day cycles
1782984|NCT00451191|Drug|botulinum toxin type A (BoNT/A)|100 unit and 300 unit dosages: Dilute each 100 U vial with 1.3 ml of normal saline. Each reconstituted vial is then drawn up into a single syringe with a total of 4 ml = 300 U. The instrument used to inject the botulinum toxin is an ultrasound device with a transrectal ultrasound probe specially designed for prostate biopsies which has a special canal to introduce and direct a needle in to the selected prostatic area.
1782985|NCT00451204|Drug|Estriol|Estriol 8 mg capsule, once per day, duration of treatment is 2 years
1782986|NCT00451204|Drug|Placebo|Placebo capsule, once a day, treatment duration is 2 years
1782987|NCT00451204|Drug|Copaxone|Injection, once a day, all subjects
1782988|NCT00451217|Drug|Sugammadex|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 2.0 mg/kg Org25969 was to be administered
1782989|NCT00451217|Drug|neostigmine|After the last dose of rocuronium or vecuronium, at reappearance of T2, a dose of 50 ug/kg neostigmine was to be administered
1782990|NCT00451230|Drug|cocaine|
1782991|NCT00451230|Drug|hydrocortisone|
1782992|NCT00451256|Drug|AVI-5126|
1782993|NCT00451269|Device|Rapid diagnosis test for malaria|Rapid diagnosis test for malaria
1783056|NCT00451893|Procedure|Lichtenstein operation with a light-weight mesh|Johnson&Johnson Ultrapro, polypropylene/poliglecaprone, 10 x 15 cm, 28 g/m2
1783057|NCT00451906|Drug|Platinum-based chemotherapy|As prescribed
1783058|NCT00451906|Drug|Bevacizumab [Avastin]|15 mg/kg IV on Day 1 of each 3 week cycle
1782994|NCT00451282|Behavioral|stepped preventive care|2 targeted assessments (T1: in hospital within a few days of injury; T2: two weeks post-discharge) are administered by nurse or social worker, and determine need for additional assistance modules. Additional modules include case management, care coordination, assistance with child and family coping with injury/distress, and trauma-focused Cognitive Behavior Therapy (CBT) beginning at 4-6 weeks post-injury if needed.
1782995|NCT00451295|Drug|MCI-196(colestilan(INN), Colestimide(JAN), CHOLEBINE®)|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
1782996|NCT00451295|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose
1782997|NCT00451308|Procedure|Induction of labor with foley balloon - 60cc of saline|60 cc of fluid
1782998|NCT00451308|Procedure|Induction of labor with foley balloon with 30cc|30cc of saline in foley
1783000|NCT00451347|Device|Quadriceps strength training|
1783001|NCT00451347|Device|Taping|
1783002|NCT00451347|Device|Home exercise|
1783003|NCT00451360|Drug|diacerein|
1783004|NCT00451373|Device|CVVH and SLED|
1783005|NCT00451373|Drug|Vancomycin|
1783006|NCT00451373|Drug|Daptomycin|
1783007|NCT00451373|Device|FX60, AV600 (dialyzer)|
1783008|NCT00451386|Drug|MK0826, ertapenem sodium /Duration of Treatment: 14 Days|
1783009|NCT00451386|Drug|Comparator: ceftriaxone sodium /Duration of Treatment: 14 Days|
1783010|NCT00451399|Drug|metformin|
1783011|NCT00451399|Behavioral|lifestyle intervention|
1783012|NCT00451412|Drug|Certoparin|3000 U anti XA of certoparin in 0.3 ml solution, once daily
1783013|NCT00451412|Drug|Unfractionated Heparin|solution, 5000 IU of unfractionated heparin in 0.3 ml, 3 times daily
1783014|NCT00451425|Behavioral|motivational intervention in pregnancy|Motivational program including individualized counseling on diet and physical activity
1783015|NCT00451451|Drug|BG00012|
1783016|NCT00451451|Drug|Placebo|
1783017|NCT00451451|Drug|Glatiramer Acetate|
1783018|NCT00451490|Drug|Agomelatine|
1783019|NCT00451490|Drug|Fluoxentine|
1783020|NCT00451503|Device|Middle Ear Implant|surgery
1783021|NCT00451516|Drug|Herbal medicine (St. John's wort and Kava)|
1783022|NCT00451555|Drug|enzastaurin|1125 mg loading dose then 250 mg, oral, twice daily (for a total of 500 mg), until disease progression
1783023|NCT00451555|Drug|placebo|oral, daily
1783024|NCT00451555|Drug|fulvestrant|500 mg, IM, day 1, 1250 mg, IM, day 15 cycle 1 then 250 mg, IM, q 28 days, until disease progression
1783025|NCT00451568|Drug|Metformin|500 mg 2 tablets 2 times a day
1783026|NCT00451568|Drug|Desorelle|1 tablet/day in 21 days
1783027|NCT00451581|Procedure|Endoscopic papillary balloon dilation-5 minutes|
1783028|NCT00451581|Procedure|Endoscopic papillary balloon dilation-1 minute|
1783029|NCT00451594|Drug|Dexamethasone|"Pulse high dose dexamethasone (Arm 1)
Patients will receive 40 mg of oral dexamethasone daily for four consecutive days.
Other treatments should be considered if there was a platelet count of 30X109/L or less by day 14
If the patient had a platelet count of more than 30X109/L after four days of dexamethasone treatment, no further treatment will be given.
If the platelet count drops below 30X109/L within the first 6 months, another four-day course of dexamethasone will be given, followed by 15 mg of prednisone daily, with gradual tapering.
Patients whose platelet counts can not be maintained at 30X109/L will be offered other treatments."
1783030|NCT00451594|Drug|Prednisolone|"Conventional dose prednisone (Arm 2)
Prednisone, 1 mg/kg is started at diagnosis. If the platelet count is more than 100X109/L, the dose should be used for 4 weeks minimally and then tapered by 10 mg/1 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/1 wk thereafter. (Ann Intern Med 1997, 126, 307-14). If the platelet count is between 30X109/L and 100X109/L, prednisone 1 mg/kg should be used for 8 weeks maximally and then tapered by 10 mg/2 wk until the dose reaches 0.5 mg/kg of body weight and by 5 mg/2 wk thereafter.
Guideline of prednisone tapering Duration of prednisone treatment: 3-6 months"
1783031|NCT00451620|Drug|glyburide|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
1783032|NCT00451620|Drug|GlucoNorm|Subjects will undergo 2 Standard Meal Tests with Ensure 325 ml separated by 15 - 30 days. Group 1 will receive GlucoNorm 1 mg during the 1st Standard Meal Test and Glyburide 2.5 mg during the 2nd Standard Meal Test. Group 2 will receive Glyburide 2.5 mg during the 1st Standard Meal Test and GlucoNorm 1mg during the 2nd Standard Meal Test.
1783033|NCT00451633|Drug|E2007|
1783034|NCT00451646|Drug|SMOF lipid and Intralipid|1-2 g, 5-7 days, 28 days
1783035|NCT00451672|Drug|bromocriptine|
1783036|NCT00451698|Drug|acyanotic erythropoietin|Single dose IV push
1783037|NCT00451698|Drug|acyanotic placebo|Single dose IV push
1783038|NCT00451711|Drug|Liposomal amphotericin B|
1783039|NCT00451724|Drug|Intranasal ketamine|
1783040|NCT00451737|Device|Isokinetic test|
1783041|NCT00451750|Drug|Cortisol|20 mg for 3 times
1783042|NCT00451763|Drug|Intravitreal Injection of Bevacizumab (1.25 mg/0.05ml)|
1783043|NCT00451776|Drug|etomidate|patients who received etomidate
1783044|NCT00451776|Drug|propofol|patients who received propofol
1783045|NCT00451815|Drug|active drug (BIIB014) at 10, 30, 100, or 300 mg once daily.|
1783046|NCT00451815|Drug|placebo|
1783047|NCT00451828|Drug|Simvastatin|40mg/day
1783048|NCT00451841|Device|RTube Exhaled Breath Condensate Collection System|Subjects breath through the device to collect exhaled breath condensate
1783049|NCT00451854|Procedure|Random, no advanced notice drug and alcohol testing|
1783050|NCT00451867|Drug|Mycophenolate Mofetil|
1783051|NCT00451867|Drug|Mycofenolate Mofetil (MMF)|2000 mg per day divided into 2 equal doses.
1783052|NCT00451867|Drug|Placebo|Placebo
1783053|NCT00451880|Drug|XL281|Gelatin capsules supplied as 5-, 25-, and 100-mg strengths
1783054|NCT00451880|Drug|famotidine|single dose, supplied as 20-mg or 40-mg tablets
1783059|NCT00451932|Drug|FK778|
1783062|NCT00451958|Drug|Degarelix 80 mg / Degarelix 80 mg|
1783063|NCT00451958|Drug|Degarelix 160 mg / Degarelix 160 mg|
1783064|NCT00451958|Drug|Leuprolide 7.5 mg / Degarelix 80 mg|
1783065|NCT00451958|Drug|Leuprolide 7.5 mg / Degarelix 160 mg|
1783066|NCT00451971|Drug|LEFLUNOMIDE|
1783067|NCT00451984|Biological|Twinrix|
1783068|NCT00451984|Biological|interleukin-2|
1783069|NCT00451997|Drug|Gleevec|600 mg (capsules) by mouth once daily
1783070|NCT00451997|Drug|Ara-C|10 mg as an injection under the skin daily for 21 days of every 28 day cycle
1783071|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (active)|Active TENS. 4 sessions per day during 3 months.
1783072|NCT00452010|Device|CEFAR PRIMO TENS Class IIA (no active)|Placebo TENS. 4 sessions per day during 3 months.
1783073|NCT00452023|Drug|IFN-alpha2a|Starting dose 90 microgram (mcg) injection under the skin once a week
1783074|NCT00452049|Procedure|parathyroidectomy|parathyroidectomy
1783075|NCT00452062|Drug|Dexamethasone|
1783076|NCT00452075|Drug|erlotinib|150mg daily
1783077|NCT00452088|Biological|MSP 3 Long Synthetic Peptide|Lyophilized vaccine given at 15 or 30 microgrammes
1783078|NCT00452088|Biological|Hepatitis B vaccine|Hepatitis vaccine adjuvanted in Aluminium hydroxide
1783079|NCT00452088|Biological|Hepatitis B control vaccince|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
1783080|NCT00452101|Drug|Aquamin F|
1783081|NCT00452114|Device|In-Exsufflator Cough Assist Device|
1783082|NCT00452127|Drug|PRO131921|Escalating doses by IV infusion
1783083|NCT00452140|Biological|ertumaxomab|10 µg, IV on day 0 followed by 100 µg every 7 days up to a maximum of 12 infusions.
1783084|NCT00452153|Procedure|Characterization Legionnella|"Characterisation Legionnella by polymerase chain reaction (PCR)
Characterization strain of Legionnella by sequencing the 23S-5S ribosomal intergenic spacer region"
1783085|NCT00452166|Drug|rosiglitazone|
1783086|NCT00452179|Drug|APD125|
1783087|NCT00452192|Drug|Telmisartan|telmisartan 80 mg daily over 2 weeks
1783088|NCT00452218|Drug|Sorafenib|200 mg daily and dose escalated to a maximum of 400 mg twice daily
1783089|NCT00452231|Drug|D-cycloserine|
1783090|NCT00452231|Behavioral|Cognitive-Behavioral Therapy|
1783091|NCT00452244|Drug|simvastatin|Simvastatin 40mg/QD po daily every 3 weeks
1783092|NCT00452244|Drug|gefitinib only|gefitinib 250mg/QD po daily every 3 weeks
1783093|NCT00452257|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, up to 3 years or until progressive disease
1783094|NCT00452270|Drug|Xylometazoline|
1783095|NCT00452296|Drug|tight insulin treatment in patients hospitalized with COPD exacerbation|treatment with basal plus bolus insulin
1783096|NCT00452296|Procedure|tight glycemic control|treatment with basal and bolus insulin
1783097|NCT00452322|Drug|Testosterone Substitution by Testosterone Undecanoate i.m.|
1783101|NCT00452348|Drug|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID
1783102|NCT00452348|Drug|Fluticasone propionate 250 mcg BID|Fluticasone propionate 250 mcg BID
1783103|NCT00452361|Drug|Sirolimus+MMF or MPS or AZA+Steroid|Corticosteroids will be administered according to local practice, within a daily maintenance dosage range of 2.5 to15 mg for prednisone or prednisolone (2 to 12 mg/day for methylprednisolone) or the alternate day equivalent.
1783104|NCT00452361|Drug|Calcineurin Inhibitors (either cyclosporine or tacrolimus)+MMF or MPS or AZA+Steroid|"The maintenance dose of:
MMF will not exceed 1500 mg/day or PMS will not exceed 1080 mg/day
AZA will not exceed 75 mg/day
Thereafter, at the discretion of the investigator, MMF/MPS or AZA may be:
continued for the entire 104-week period of randomized therapy
subsequently discontinued
restarted after discontinuation"
1783105|NCT00452374|Drug|Cytarabine|1 g/m^2 given IV for two days (Days 2 and 3).
1783106|NCT00452374|Drug|Fludarabine|30 mg/m^2 given IV for two days (Days 2 and 3).
1783107|NCT00452374|Drug|Oxaliplatin|Starting dose of 17.5 mg/m^2 IV for 4 days (Days 1 through 4).
1783108|NCT00452374|Drug|Rituximab|375 mg/m^2 IV on Day 3 of the first cycle over 4-6 hours and on Day 1 on every cycle following.
1783109|NCT00452387|Drug|Mitoxantrone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.
Dose Level -2, Mitoxantrone 9mg/m2
Dose Level -1 Mitoxantrone 12mg/m2
Dose Level 1 Mitoxantrone 12mg/m2"
1783110|NCT00452387|Drug|Prednisone|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.
Dose Level -2, Prednisone 5mg bid
Dose Level -1 Prednisone 5mg bid
Dose Level 1 Prednisone 5mg bid"
1783111|NCT00452387|Drug|Sorafenib|"Once six patients are accrued at dose level 1, the maximum tolerated dose (MTD) will be assessed by following them through one cycle of treatment. If 2/6 patients experience dose limiting toxicity (DLT) at the 400 mg twice a day (bid) level then the MTD will be defined as 400 mg daily (QD). Additional patients will be enrolled at the MTD for the phase II portion.
Dose Level -2, Sorafenib 400 mg QD
Dose Level -1 Sorafenib 400 mg QD
Dose Level 1 Sorafenib 400 mg bid"
1783112|NCT00452400|Drug|BI 1744CL|
1783113|NCT00452413|Drug|enzastaurin|Administered orally
1783114|NCT00452413|Drug|erlotinib|Administered orally
1783115|NCT00452426|Device|Computer-Assisted Personalized Sedation (CAPS) Device (SEDASYS® System)|propofol sedation per device instructions for use
1783116|NCT00452426|Other|benzodiazepines and opioid sedation|per site's current standard of care
1783117|NCT00452439|Drug|Actonel (Risedronate)|35 mg (pill) by mouth weekly
1783118|NCT00452439|Dietary Supplement|Calcium|500 mg by mouth twice a day for a total of 24 months.
1783222|NCT00463671|Drug|N-acetylcysteine|
1783119|NCT00452439|Dietary Supplement|Vitamin D|400 IU by mouth twice a day for a total of 24 months.
1783120|NCT00452452|Biological|13-valent Pneumococcal Conjugate Vaccine|
1783121|NCT00452465|Behavioral|ElderCare Plan|Nursing assessment and development of an appropriate care plan.
1783122|NCT00452478|Drug|Lanthanum carbonate|2250mg/day starting dose of lanthanum carbonate administered orally, in divided doses, with meals (500mg 750mg and 1000mg strengths)for 2 weeks; dose titration will occur based on serum phosphorus results not to exceed 3000mg/day.
1783123|NCT00452491|Drug|somatropin|0.2 IU/kg/day 7 days per week given sequentially (alternating periods of 6 months of treatment and 6 months of no treatment) for 3 years
1783124|NCT00452491|Drug|somatropin|0.2 IU/kg/day 7 days per week given continuously for 3 years
1783125|NCT00452504|Drug|SRA-444|
1783126|NCT00452517|Procedure|Percutaneous Coronary Intervention|
1783127|NCT00452530|Drug|Enoxaparin|40 mg, administered once daily by subcutaneous injection, for 12 days
1783128|NCT00452530|Drug|Apixaban|2.5 mg, administered twice daily as tablets, for 12 days
1783129|NCT00452530|Drug|Enoxaparin-matching placebo|Administered once daily by subcutaneous injection
1783130|NCT00452530|Drug|Apixaban-matching placebo|Oral tablet administered twice daily
1783131|NCT00452543|Drug|acamprosate|Acamprosate 333mg, 2 capsules by mouth (i.e., PO), three times per day (i.e., TID), for 12 weeks.
1783132|NCT00452543|Drug|escitalopram|Escitalopram is given for 12 weeks. Dosing is flexible, starting at 10mg PO once per day (i.e., QD) with the possibility of increasing to 30mg PO QD.
1783133|NCT00452543|Behavioral|Medical management|Based on the COMBINE study. 1 hour of medical management / behavioral intervention at every study visit (7 times over 12 weeks).
1783134|NCT00452543|Drug|Placebo|Placebo, 2 capsules PO TID, for 12 weeks
1783135|NCT00452556|Drug|Docetaxel|Weekly
1783136|NCT00452556|Drug|Leuprolide Acetate (Eligard®)|2.5 years
1783137|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Standard sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate, followed by irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)
1783138|NCT00452556|Radiation|Intensity-Modulated Radiotherapy|Experimental sequence = irradiation of pelvic lymphatics, seminal vesicles, and prostate last, irradiation of gross tumor (prostate+extraprostatic extension, as determined by MRI)first
1783139|NCT00452569|Drug|Thalidomide|Oral thalidomide (100mg or 200mg or 400 mg/day) administered to the patient once daily until progression of the disease and for a maximum of 336 + 36 days (12 cycles of 28 +/- 3 days).
1783140|NCT00452569|Drug|Dexamethasone|High dose oral dexamethasone will be administered at a dose of 40mg/day on days 1-4, 9-12 and 17-20 of each 28-day cycle for cycles 1-4. Beginning with cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg/day on days 1-4 of each 28-day cycle. Dexamethasone will be administered until progression of the disease and for a maximum of 336 +/- 36 days (12 cycles of 28 +/- 3 days).
1783141|NCT00452582|Drug|Sildenafil (Viagra)|Dose escalation (one of the following): 25 mg daily for 2 weeks, 50 mg daily for 2 weeks, 75 mg daily for 2 weeks, 50 mg twice daily for two weeks, 50 mg AM and 75 mg PM for 2 weeks, 75 mg twice daily for 2 weeks, 75 mg in AM and 100 mg in PM for 2 weeks, 100 mg twice daily for 2 weeks.
1783142|NCT00452582|Other|Usual care|Physical therapy, occupational therapy, speech therapy
1783143|NCT00452595|Drug|DVS-233 SR (desvenlafaxine sustained release )|
1783144|NCT00458107|Drug|SCA-136|
1783145|NCT00458120|Biological|rDEN1delta30|Live attenuated 10^3 dose of rDEN1delta30 vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN2/4delta30(ME) vaccines.
1783146|NCT00458120|Biological|rDEN2/4delta30(ME)|Live attenuated 10^3 dose of rDEN2/4delta30(ME) vaccine. Participants must have been previously vaccinated with rDEN4delta30 or rDEN1delta30 vaccines.
1783147|NCT00458120|Biological|Placebo to rDEN1delta30 or rDEN2/4delta30(ME)|Placebo vaccines for rDEN1delta30 and rDEN2/4delta30(ME)
1783148|NCT00458133|Behavioral|exercise|compared effects on HbA1C on aerobic only, resistance only, combination of aerobic and resistance, and a stretching & relaxing groups.
1783149|NCT00458146|Drug|MM-093|60mg MM-093/week as a subcutaneous injection for 3 months
1783150|NCT00458159|Drug|CC-11006|Doses: 10mg, 15mg, 25mg, 35mg, & 50mg, taken once daily, orally.
1783151|NCT00458172|Behavioral|Assessment of beliefs and attitudes|
1783152|NCT00458185|Drug|etanercept|
1783153|NCT00458198|Behavioral|Integrated behavioral therapy (BT)|Participants in the BT condition will receive twenty 60-minute sessions over 24 weeks. Sessions will focus on graduated exposure to new speaking situations as the primary agent of anxiety reduction. Behavioral procedures will include systematic desensitization, shaping, and self-modeling procedures. Although a variety of exposure exercises will be routinely conducted in-session, any behavioral assignments will take place outside of session. Behavioral exercises will be implemented, as needed, in a modular fashion. For example, exercises may focus on speaking in-session to therapist, either at school or at home with others present. The therapist will be primarily responsible for developing the exposure parameters, but collaboration of parent, teacher, child will be emphasized increasingly over time. Reinforcement for attempts to complete assignments (contingency management program) will occur throughout treatment.
1783154|NCT00458211|Drug|ziprasidone|Ziprasidone by mouth 40mg twice a day (bid) for one day, then 80mg bid; may be increased to 120mg bid after three weeks
1783155|NCT00458224|Behavioral|parental counseling|Group-based family oriented program involving pediatricians, physiotherapists, dieticians, psychologists and nurses with special training
1783156|NCT00458237|Drug|Everolimus|Everolimus is being administered orally 7 days per week.
1783157|NCT00458237|Drug|Trastuzumab|Trastuzumab is being administered at a dose of 6 mg/kg intravenously once every 21 days.
1783158|NCT00458250|Procedure|Haploidentical hematopoietic stem cell transplantation|
1783159|NCT00458250|Drug|Busulfan|
1783160|NCT00458250|Drug|Cyclophosphamide|
1783161|NCT00458250|Drug|CAMPATH-1H|
1783162|NCT00458250|Drug|Cyclosporin A|
1783163|NCT00458250|Drug|Methotrexate|
1783164|NCT00458263|Drug|Somatotropin growth hormone recombinant human|daily Sub Cutaneous injections
1783165|NCT00458276|Drug|tezosentan|Tezosentan (ACT-050089, Ro 61-0612) as a 1% solution in 0.9% NaCl (i.e., normal saline) for i.v. use.
1783166|NCT00458276|Drug|placebo|Placebo (i.e., normal saline) for i.v. use.
1783167|NCT00458289|Drug|Lanthanum carbonate (chewed vs. crushed)|single 1 g oral dose of lanthanum carbonate either chewed or crushed into a fine powder
1783168|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) + 2 NRTI for 144 weeks
1783169|NCT00458302|Drug|darunavir (DRV, TMC114)|800 mg qd (2 x 400 mg tablet) monotherapy for 144 weeks
1783170|NCT00458315|Drug|Cisplatin|
1783171|NCT00458315|Drug|Paclitaxel|
1783172|NCT00458315|Drug|Gemcitabine|
1783173|NCT00458315|Drug|Avastin (Bevacizumab)|
1783174|NCT00458328|Drug|Z-338|
1783175|NCT00458341|Drug|PTC124|
1783176|NCT00458354|Device|Spinal Sealant|Spinal Sealant System which will be sprayed over the stitches to close the opening in the dura.
1783177|NCT00458354|Procedure|Standard Methods of Closing of the Dura|Standard methods such as the closing of the dura with stitches.
1783178|NCT00458367|Drug|Open label risperidone long acting injectable|intramuscular injections every 2 weeks for 26 weeks, flexible dose 25 to 50 mg
1783179|NCT00458380|Procedure|Controlled ovarian stimulation, perifollicular vascularity assessment, IVF, embryo transfer.|
1783182|NCT00458406|Device|Bi-Flex|"Bi-Flex: Subjects in this arm undergo bilevel positive airway pressure with pressure release technology (Bi-Flex) therapy.
Positive pressure used during sleep for 3 months"
1783183|NCT00458406|Device|CPAP|"CPAP: Subjects in this arm undergo standard continuous positive airway pressure (CPAP) therapy.
Positive pressure used during sleep for 3 months."
1783184|NCT00458419|Drug|naloxone versus placebo|10 mg of naloxone administered IV or normal saline administered IV in randomized order at different visits
1783185|NCT00458419|Drug|intravenous injection of normal saline or naloxone|Arm A: 10 mg of naloxone given IV in 25 ml of normal saline Arm B: 25 ml of normal saline
1783186|NCT00463424|Device|NeuFlex metacarpophalangeal implant|
1783187|NCT00463424|Device|Swanson metacarpophalangeal implant|
1783188|NCT00463437|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose.
1783189|NCT00463437|Biological|Prevenar|Intramuscular injection, 1 dose.
1783190|NCT00463437|Biological|Infanrix hexa|Intramuscular injection, 1 dose. In Germany and Poland.
1783191|NCT00463437|Biological|Infanrix IPV Hib|Intramuscular injection, 1 dose. In Spain.
1783192|NCT00463437|Biological|Infanrix penta|Intramuscular injection, 1 dose. In Germany and Poland.
1783193|NCT00463437|Biological|Infanrix IPV|Intramuscular injection, 1 dose. In Spain.
1783194|NCT00463437|Biological|Meningitec|Intramuscular injection, 1 dose.
1783195|NCT00463437|Biological|NeisVac-C|Intramuscular injection, 1 dose.
1783196|NCT00463437|Biological|Menitorix|Intramuscular injection, 1 dose.
1783197|NCT00463450|Drug|Gynodian® Depot (BAY86-5032)|Injection monthly
1783198|NCT00463450|Drug|BAY86-4980|orally
1783199|NCT00463463|Drug|90Yttrium Ibritumomab Tiuxetan (Zevalin)|
1783200|NCT00463476|Biological|Japanese encephalitis live attenuated SA 14-14-2 vaccine|
1783201|NCT00463489|Behavioral|Lifestyle intervention|Women randomized to the lifestyle intervention arm will receive an intervention program that consists of individual weight loss, diet and physical activity goals, incorporated into a 2 year standardized, structured telephone and mail-based intervention. In addition to diet and physical activity, the intervention will address behavioural and motivational issues relating to weight management including maintaining motivation, overcoming obstacles to success, relapse prevention, emotional distress, stress and time management.
1783202|NCT00463489|Behavioral|Mail-based|Participants will receive a standardized mail-based intervention focussing on healthy living. This will include mailings at study entry as well as a two year subscription to health magazine.
1783203|NCT00463502|Drug|Metformin|
1783204|NCT00463515|Drug|carboplatin/gemcitabine|
1783205|NCT00463515|Procedure|cisplatin/radiation therapy|
1783206|NCT00463541|Drug|solifenacin succinate|oral
1783207|NCT00463554|Device|GYNECARE TVT-SECUR* System|A sub-urethral sling for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency
1783208|NCT00463567|Drug|Indacaterol|In the morning, Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
1783209|NCT00463567|Drug|Formoterol (12 µg b.i.d.)|Formoterol 12 µg twice daily (b.i.d.) in the morning and in the evening via an aerolizer.
1783210|NCT00463567|Drug|Tiotropium (18 µg o.d.)|Tiotropium 18 µg once daily (o.d.) dry powder capsules delivered via a SDDPI.
1783211|NCT00463567|Drug|Placebo to Indacaterol|In the morning, Placebo to Indacaterol once daily (o.d.) orally inhaled via a single dose dry powder inhaler (SDDPI).
1783212|NCT00463567|Drug|Placebo to Formoterol|In the morning and in the evening, placebo to formoterol delivered via Aerolizer.
1783213|NCT00463580|Drug|infliximab (remicade)|Three infusions across a 12 week period. (Baseline, week 2 and week 6)
1783214|NCT00463580|Drug|Placebo|Placebo 3 infusions across a 12 week period (Baseline, Week#2 and Week#6)
1783215|NCT00463606|Drug|ABT-335 and rosuvastatin calcium|ABT-335 135 mg in combination with rosuvastatin calcium 5 mg administered orally, once daily for 12 weeks
1783216|NCT00463606|Drug|ABT-335|ABT-335 135 mg monotherapy administered orally, once daily for 12 weeks
1783217|NCT00463606|Drug|rosuvastatin calcium|Rosuvastatin calcium 5 mg monotherapy administered orally, once daily for 12 weeks
1783218|NCT00463619|Drug|Retarded release phosphatidylcholine|2g phosphatidylcholine, given QTD
1783219|NCT00463645|Procedure|microdialysis|
1783220|NCT00463645|Procedure|microperfusion|
1783221|NCT00463658|Other|Falls Prevention|Subjects in the interdisciplinary group will receive home care services from a team of professional service providers (CCAC Case Manager, Public Health Nurse (Registered Nurse), Occupational Therapist, Physiotherapist, Nutritionist) with experience and training in falls prevention. The team will provide a comprehensive, coordinated and evidence based approach to falls prevention through weekly case conferencing, a written interdisciplinary care plan, and joint client visits.
1783223|NCT00463684|Biological|Japanese encephalitis live attenuated SA 14-14-2 vaccine|
1783224|NCT00463697|Drug|GW642444H (100mcg)|H salt
1783225|NCT00463697|Drug|placebo|placebo
1783226|NCT00463697|Drug|GW642444M (25, 100 & 400 mcg)|M salt
1783227|NCT00463710|Drug|Avonex® monotherapy (6.0 MIU administered i.m. each week)|
1783228|NCT00463723|Drug|FK506 0.06% (eye drops)|
1783229|NCT00463736|Drug|Magnesium sulfate|
1783230|NCT00463749|Drug|Acetylcystein|high-dose N-Acetylcystein during PCI and for 2/day for 2 days
1783231|NCT00463749|Drug|Placebo|NaCl as placebo
1783232|NCT00463762|Drug|CP-75385-02 Cefoperazone/sulbactam|
1783233|NCT00463775|Drug|Topiramate|SSRI plus topiramate SSRI plus placebo
1783234|NCT00463788|Drug|cetuximab, cisplatin|"Subjects will receive an initial dose of cetuximab 400 milligram per square meter (mg/m^2) followed by weekly doses of 250 mg/m^2. All doses will be given by intravenous (IV) infusion.
Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.
Administration of the Investigational Medicinal Product (IMP) will be stopped upon the first occurrence of disease progression, unacceptable toxicity or withdrawal of consent."
1783235|NCT00463788|Drug|cisplatin|"Subjects will receive cisplatin (75 mg/m^2 IV on Day 1) every 3 weeks, with a maximum of 6 cycles.
Subjects have the option of receiving cetuximab plus cisplatin at progression within the first 6 cycles, or cetuximab alone at progression after the 6 cycles.
Administration of the IMP will be stopped upon the first occurrence of disease progression (except in cisplatin arm where switch to cetuximab plus cisplatin, or cetuximab alone is possible), unacceptable toxicity or withdrawal of consent."
1783236|NCT00463801|Drug|Daptomycin|
1783237|NCT00463814|Drug|AZD6244|oral capsule
1783238|NCT00463827|Drug|Atorvastatin|
1783239|NCT00463827|Drug|atorvastatin|atorvastatin 40mg
1783240|NCT00463827|Drug|matched placebo|Matched placebo
1783241|NCT00463840|Drug|Oxaliplatin|
1783242|NCT00463840|Drug|5FU|
1783243|NCT00463840|Radiation|Radiation|
1783244|NCT00463840|Procedure|Surgery|
1783245|NCT00463840|Drug|FOLFOX 6|this is an established regimen of Oxaliplatin+infusional 5FU/Leucovorin
1783246|NCT00463853|Procedure|Autologous stem cell therapy|
1783247|NCT00463853|Procedure|CABG|
1783248|NCT00463853|Radiation|CMRI|
1783249|NCT00463866|Drug|Budesonide/formoterol|
1783250|NCT00463879|Drug|Galantamine|
1783251|NCT00463892|Procedure|High-resolution contrast-enhanced MRI scan|High-resolution contrast-enhanced MRI scan of regional lymph nodes every 6 months on study
1783252|NCT00463905|Procedure|Clinical assessment +/- radiography|Clinical assessment: height loss, history of fracture, Margolis pain score, rib/pelvis distance
1783253|NCT00463918|Drug|varenicline|
1783254|NCT00463944|Behavioral|Effect of an electronic voting system|
1783255|NCT00463957|Drug|sildenafil|
1783256|NCT00463957|Drug|tadalafil|
1783257|NCT00463957|Drug|placebo|
1783258|NCT00463970|Behavioral|Brief Intervention|Physical examination, education and follow up by a physiotherapist
1783259|NCT00463970|Behavioral|Cognitive Behavioural Therapy|7 sessions of CBT over a period of 2 months, included a booster session after 3 months
1783260|NCT00463970|Dietary Supplement|Seal oil|20 capsules per day for 3 months
1783261|NCT00463970|Dietary Supplement|Soy oil|20 capsules per day for 3 months
1783262|NCT00463983|Drug|octreotide|
1783263|NCT00464009|Behavioral|Continuing medical education|"Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using learning collaborative methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist."
1783264|NCT00464022|Device|Carbon dioxide|
1783265|NCT00464035|Behavioral|high calcium intake|
1783266|NCT00464048|Procedure|controlled physical exercise|
1783267|NCT00464061|Drug|Volinanserin|oral administration
1783268|NCT00464061|Drug|Placebo|oral administration
1783269|NCT00464087|Drug|Switching from Fondaparinux to Bivalirudin or Unfractionated Heparin|
1783270|NCT00464113|Drug|XL228|1-hour IV infusion
1783271|NCT00464126|Other|5% albumin|5% albumin in 10cc/kg aliquots for postoperative volume resuscitation
1783272|NCT00464126|Other|crystalloid|saline in 10cc/kg aliquots for postoperative volume resuscitation
1783273|NCT00464139|Procedure|Laparoscopy|Laparoscopy
1783274|NCT00464165|Drug|rimonabant|
1783276|NCT00464191|Drug|escitalopram|
1783277|NCT00464204|Drug|"6 % Hydroxyethylstarch 130/0.4 = Voluven®"|Voluven® was administered intravenously. Voluven® rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day on the second to fourth days, according to patient needs.
1783278|NCT00464204|Drug|0.9 % NaCl|NaCl 0.9 % was administered intravenously. NaCl 0.9% rates were not to exceed 50 mL/kg/day on the first day and 25 mL/kg/day from the second to the fourth day, according to patient needs.
1783279|NCT00464217|Drug|ARA-C|
1783280|NCT00464217|Drug|Idarubicin|
1783281|NCT00464217|Drug|Leucomax|
1783282|NCT00464230|Procedure|Bipolar hemiarthroplasty (Charnley/Hastings)|
1783283|NCT00464230|Procedure|Internal fixation with two parallel screws (Olmed)|
1783284|NCT00464243|Drug|volinanserin|oral administration
1783285|NCT00464243|Drug|placebo|oral administration
1783286|NCT00464256|Drug|rimonabant|
1783287|NCT00464269|Other|Placebo|"Active Substance: Placebo
Pharmaceutical Form: Film-coated tablet
Concentration: 2.5 mg, 10 mg and 25 mg
Route of Administration: Oral use"
1783288|NCT00464269|Drug|Brivaracetam 2.5 mg|"Active Substance: Brivaracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 2.5 mg
Route of Administration: Oral use"
1783289|NCT00464269|Drug|Brivaracetam 10 mg|"Active Substance: Brivaracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 10 mg
Route of Administration: Oral use"
1783290|NCT00464269|Drug|Brivaracetam 25 mg|"Active Substance: Brivaracetam
Pharmaceutical Form: Film-coated tablet
Concentration: 25 mg
Route of Administration: Oral use"
1783291|NCT00464295|Drug|Capecitabine in HCC|
1783292|NCT00464308|Drug|Esomeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
1783293|NCT00464308|Drug|Rabeprazole|20mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
1783294|NCT00464308|Drug|Esomeprazole|40mg once daily for 28days - 1 placebo tab/cap & 1 active tab/cap daily
1783295|NCT00464321|Biological|GC1008|1 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
1783296|NCT00464321|Biological|GC1008|2 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
1783297|NCT00464321|Biological|GC1008|4 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
1783298|NCT00464321|Biological|GC1008|0.3 mg/kg, IV infusion on Day 0 and monitored over 24 hours. Post infusion for safety up to 112 days.
1783299|NCT00464334|Biological|V950|V950 will be given in doses of 0.5, 5 or 50 mcg depending on arm assignment.
1783300|NCT00464334|Biological|ISCOMATRIX™|ISCOMATRIX will be given in doses of 0, 16, 47 or 94 mcg depending on arm assignment.
1783301|NCT00464334|Biological|Placebo to V950|
1783302|NCT00464347|Drug|Avastin|
1783303|NCT00464347|Procedure|Photodynamic Therapy (PDT)|
1783304|NCT00464347|Drug|Preservative-Free Triamcinolone Acetonide (TAC-PF)|
1783305|NCT00464373|Drug|Botulinum Toxin Type A|Single intrasphincteric injection at the 3,6,9, and 12 o'clock positions of the external urethral sphincter (1 ml of drug solution each)
1783306|NCT00464373|Drug|Placebo|4ml NaCl 0.9%
1991667|NCT00710684|Drug|SB-742457 15mg|SB-742457 - 15mg added to existing donepezil treatment
1783308|NCT00464399|Drug|everolimus|
1783309|NCT00464412|Behavioral|Education|
1783310|NCT00464425|Procedure|Electroacupuncture|EA using sharp needles placed at various acupoints; electrical stimulation at 50 Hz applied to the needles
1783311|NCT00464425|Procedure|Sham Acupuncture|Acupuncture using blunt-tip needles placed 15 mm away from acupoints; no electrical stimulation used
1783312|NCT00464425|Other|No Acupuncture|Control
1783313|NCT00464438|Drug|gatifloxacin|Day 1-6 = 1 drop of study medication three times a day
1783314|NCT00464438|Drug|moxifloxacin 0.5% eye drops|Day 1-6 = 1 drop of study medication three times a day
1783315|NCT00464451|Drug|Dexmedetomidine|Dexmedetomidine 3 micrograms per kilogram per os; subsequent dose of 1 microgram per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
1783316|NCT00464451|Drug|Chloral hydrate|Chloral hydrate 75 milligrams per kilogram per os; subsequent dose of 25 milligrams per kilogram per os if necessary to treat inadequate sedation 30 minutes following initial dosing.
1783317|NCT00464464|Behavioral|cognitive-behavioral therapy|The therapy will consist of 10 weekly individual cognitive-behavioral treatment sessions, lasting 1 hour each and modified to meet the unique needs of each individual with PD.
1783318|NCT00464490|Drug|Dexmedetomidine|Dexmedetomidine .5mcg/kg/hr-.7mcg/kg/hr 1hour prior to extubation. Dexmedetomidine will be titrated according to blood pressure, RASS and heart rate response and the dose will be lowered only after sedation is discontinued or markedly reduced.
1783319|NCT00464503|Drug|Rosuvastatin-Crestor|
1783320|NCT00464503|Drug|Pravastatin-Pravasine|
1783321|NCT00464516|Drug|placebo|once daily for 14 days orally
1783322|NCT00464516|Drug|Estetrol|once daily for 14 days orally
1783323|NCT00464529|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
1783324|NCT00464542|Drug|Metronidazole|500 mg, taken by mouth, two times a day, 7 days
1783325|NCT00464555|Procedure|Islet transplant|Transplantation of pancreatic islet cells
1783326|NCT00464555|Drug|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
1783327|NCT00464555|Drug|Basiliximab|Will replace antithymocyte globulin in all islet transplantations after the first one
1783328|NCT00464555|Drug|Lisofylline|An anti-inflammatory that may reduce the rate at which islet cells die.
1783329|NCT00464555|Drug|Sirolimus|Maintenance immunosuppressive therapy
1783330|NCT00464555|Drug|Tacrolimus|Maintenance immunosuppressive therapy
1783332|NCT00464594|Behavioral|Standard lifestyle guidance|
1783333|NCT00464594|Drug|Lifestyle guidance and monotherapy with acarbose|
1783334|NCT00464594|Drug|Lifestyle guidance and monotherapy with metformin|
1783335|NCT00464594|Drug|Lifestyle guidance and monotherapy with gliclazide|
1783336|NCT00464607|Drug|hMG-IBSA|
1783337|NCT00464607|Procedure|Ovarian stimulation|
1783338|NCT00464620|Drug|Dasatinib|oral agent, continuous dosing, Cycles = 28 days
1783339|NCT00464633|Drug|alvocidib|"1st dose: 30 mg/m2 as a 30-minute intravenous (IV) infusion followed by 30 mg/m2 as a 4-hour continuous infusion
Then, every treatment week, depending upon the patient's objective response to initial therapy:
30 mg/m2 over 30 minutes followed by 50 mg/m2 over 4 hours or
30 mg/m2 over 30 minutes followed by 30 mg/m2 over 4 hours."
1783340|NCT00464646|Drug|Epirubicin|Both Cohorts: Epirubicin 90 mg/m2 IV every 21 days x 4 cycles
1783341|NCT00464646|Drug|Cyclophosphamide|Both Cohorts: Cyclophosphamide 600 mg/m2 IV every 21 days x 4 cycles
1783342|NCT00464646|Drug|Docetaxel|Both Cohorts: Docetaxel 100 mg/m2 IV on Day 1 every 21 days x 4 cycles
1783391|NCT00465075|Drug|Bazedoxifene/conjugated estrogens combination|
1783392|NCT00465088|Drug|Niacin ER/Simvastatin Tablets|Up to 2000 mg/40 mg at bedtime
1783393|NCT00465088|Drug|atorvastatin|40 mg at bedtime
1783394|NCT00465101|Device|GreenLight HPS|Greenlight HPS laser system for treatment of BPH
1783343|NCT00464646|Drug|Trastuzumab|"Cohort A: Pre-op therapy - 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly (16+ weeks) until 1-7 days prior to surgery. Post-operative therapy (beginning no sooner than 28 days after surgery and continuing every 3 weeks x 13 doses) - 8 mg/kg IV first post-op dose, then subsequent doses at 6 mg/kg IV
Cohort B: 4 mg/kg IV first dose, then subsequent doses at 2 mg/kg IV weekly on days 1, 8, and 15. Three (3) weeks after last dose of docetaxel, 6 mg/kg IV and continuing every 3 weeks x 13 doses"
1783344|NCT00464646|Drug|Bevacizumab|"Cohort A: Cycles 1-4, 15 mg/kg IV on day 1 of cycle 4 only; Cycles 5-7, 15 mg/kg IV on day 1 every 21 days x 3 cycles; post-operative therapy (beginning no sooner than 28 days after surgery), 15 mg/kg IV every 3 weeks x 13 doses
Cohort B: Cycles 5-8, 15 mg/kg IV on day 1 every 21 days x 4 cycles; beginning 3 weeks after last dose of docetaxel, 15 mg/kg IV every 3 weeks x 13 doses"
1783345|NCT00464659|Device|Effective CPAP|Auto-titrating CPAP machines (Remstar Auto; Philips Respironics, Murrysville, PA) provided by a home care company (Bastide Medical, France). Pressure was set between 6 and 14 cm of water
1783346|NCT00464659|Device|Sham CPAP|Similar CPAP machine delivering a 4 cm of water pressure that was too low to suppress sleep respiratory events.
1783347|NCT00464672|Biological|Influenza virus vaccine|Two intramuscular injections of the investigational influenza virus vaccine administered 4 weeks part to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
1783348|NCT00464672|Biological|Comparator influenza vaccine|Two intramuscular injections were administered 4 weeks apart to group 3 to 8 years of age while one injection was administered to groups 9 to 17 years of age and 18 to 64 years of age.
1783349|NCT00464685|Drug|Dexamethasone|Initial intravitreal injection of 700 µg dexamethasone with up to 1 additional treatment based on re-treatment criteria.
1783350|NCT00464685|Drug|Sham injection|Initial sham injection with up to 1 additional treatment based on re-treatment criteria.
1783351|NCT00464685|Procedure|Laser Photocoagulation|Initial laser photocoagulation with up to 3 additional treatments based on re-treatment criteria.
1783352|NCT00464698|Drug|Duloxetine|Participants received increasing amounts of Duloxetine for 7 weeks.
1783353|NCT00464711|Drug|Escitalopram|Dose determined per clinical discretion. All participants begin on 10mg po qd of escitalopram, and can increase the dose to 30mg po qd over the 12 weeks of the study.
1783354|NCT00464724|Procedure|3T Magnetic Resonance Spectroscopic Imaging|Part 1 of Study = One MRSI exam with an air-filled endorectal coil (AIR-MRSI) and one with a PFC-filled endorectal coil (PFC-MRSI); Part 2 of Study = MRSI exam with PFC using an endorectal coil only.
1783355|NCT00464737|Drug|Rotigotine|Titration by Week 4 to two 20 cm2 patches (one placebo patch and one 4 mg/24 hrs patch)
1783356|NCT00464737|Drug|Rotigotine|Titration by Week 4 to two 20 cm2 patches (both are 4 mg/24 hrs patches)
1783357|NCT00464737|Other|Placebo|Titration by Week 4 to two 20 cm2 placebo patches. At all weeks, placebo patches are matched in size and appearance to active patches.
1783358|NCT00464750|Device|Pulmonary artery catheter|Four series of cardiac output measurements, each series consists of eight measurements using cold and eight measurements using tepid injectate. Randomized order of temperature at first series and crossover design.
1783359|NCT00464763|Drug|Dexmedetomidine|
1783360|NCT00464763|Drug|Placebo|
1783361|NCT00464776|Drug|Aliskiren|
1783362|NCT00464776|Drug|Aliskiren|
1783363|NCT00464776|Drug|Aliskiren|
1783364|NCT00464776|Drug|Aliskiren|
1783365|NCT00464789|Drug|Bazedoxifene/Conjugated Estrogens 20 mg/0.625 mg tablet|
1783366|NCT00464802|Drug|MOA-728|
1783369|NCT00464828|Procedure|Internal jugular vein cannulation|
1783370|NCT00464828|Device|ultrasound|
1783371|NCT00464841|Procedure|Combined spinal epidural|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
1783372|NCT00464841|Procedure|Tsui Test for intrathecal catheter|0.7 mL of 0.25% isobaric bupivacaine and 15mcg of fentanyl
1783373|NCT00464854|Drug|Glargine and insulin aspart or lispro|
1783375|NCT00464880|Drug|Aliskiren|
1783376|NCT00464893|Drug|Catumaxomab|10 µg intraoperative and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
1783377|NCT00464893|Drug|catumaxomab|10 µg intraoperatively and 4 ascending doses: 10, 20, 50 and 150 µg
1783378|NCT00464919|Drug|Sorafenib|
1783379|NCT00464919|Drug|tegafur/uracil (UFUR®)|
1783380|NCT00464932|Drug|Vasoactive Intestinal Peptide (VIP)|
1783381|NCT00464945|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2,3,4 and 12 months of age
1783382|NCT00464958|Drug|sublingual tizanidine 12 mg|Single sublingual tizanidine 12 mg tablet, to be administered once nightly, via sublingual administration for 12 months
1783383|NCT00464971|Drug|estradiol, 25 mcg|
1783384|NCT00464984|Behavioral|Lifestyle intervention|Intensive lifestyle intervention at a rehabilitation centre 3 times a week the first 3 months of study
1783385|NCT00465010|Behavioral|Talking Parents, Healthy Teens|Talking Parents, Healthy Teens is a worksite-based parenting program to help parents of 6th-10th graders learn to promote their adolescents' healthy sexual development. The program is administered in 8 weekly one-hour sessions during the lunch hour to groups of about 15 parents and focuses on parent-adolescent relationships and communication, with an emphasis on promoting sexual health and reducing sexual risk. It is led by a trained facilitator and assistant facilitator.
1783386|NCT00465023|Procedure|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday) for 3 weeks.
1783387|NCT00465036|Dietary Supplement|Whole flaxseeds, flaxseed mucilage, glucomannan|
1783388|NCT00465049|Other|PRIMARY CLOSRE|SUTURE
1783389|NCT00465049|Other|SECONDARY CLOSURE|ALLOW TO HEAL SPONTANEOUSLY
1783390|NCT00465049|Other|SPONTANEOUS HALING|SECONDARY HEALING AFTER I&D
1783618|NCT00467402|Drug|placebo|
1783395|NCT00465114|Procedure|Hemodynamic Monitoring|
1783396|NCT00465140|Drug|creatine supplementation|
1783397|NCT00465140|Behavioral|aerobic exercise training|
1783398|NCT00465153|Dietary Supplement|flax oil containing alpha linolenic acid|14g alpha linolenic acid per day
1783399|NCT00465153|Behavioral|Resistance exercise training|Resistance training
1783400|NCT00465166|Procedure|Ultrasound|Lumbar ultrasound from L1-S1, carried out using a portable ultrasound system equipped with a 2-5 MHz curved array probe.
1783401|NCT00465179|Drug|Sunitinib Malate|50 mg by mouth daily for 4 weeks, then 2 weeks off.
1783402|NCT00465192|Drug|estradiol, 10 mcg|
1783403|NCT00465192|Drug|estradiol, 25 mcg|
1783404|NCT00465192|Drug|placebo|
1783405|NCT00465205|Drug|Valacyclovir|500mg oral twice daily
1783406|NCT00465205|Drug|Matching Placebo|500 mg oral twice daily
1783407|NCT00465218|Procedure|Prophylaxis of Thrombosis after aortic valve replacement|Two standard prophylactic treatments of thrombosis within the first 3 months postsurgery currently used in our institution: a) daily dose of aspirin (325 mgs; b) daily dose of aspirin (81 mg) plus Warfarin for target INR 2.0-2.5
1783408|NCT00465231|Drug|bupivacaine, fentanyl|10mL of 0.0625% of bupivacaine plus fentanyl 2 mcg/ml
1783409|NCT00465231|Drug|preservative free saline|10mL saline solution
1783410|NCT00465244|Drug|Levetiracetam 1 g IV + Lorazepam 2 mg IV|Levetiracetam 1 g IV + Lorazepam 2 mg IV
1783411|NCT00465244|Drug|Placebo + Lorazepam 3 mg IV|Placebo + Lorazepam 3 mg IV
1783412|NCT00465257|Drug|artesunate + amodiaquine|
1783413|NCT00465270|Device|AMPLATZER PFO Occluder|patent foramen ovale closure device
1783414|NCT00465270|Other|Standard of Care - Medical Management|Medical management - aspirin alone, Coumadin alone, Clopidogrel alone, aspirin combined with dipyridamole
1783415|NCT00465283|Drug|Donepezil|Tab.Donepezil 5 mg once daily during ECT treatment and the month after the last ECT treatment
1783416|NCT00465296|Drug|rosiglitazone|
1783417|NCT00465309|Procedure|protective ventilation with CO2 removal technique|In ARDS patients, presenting a Pplat ≥ 26 cmH2O, Vt was lowered (reaching a Pplat < 26) with CO2-removal veno-venous pump-driven bypass support for 48 consecutive hours with a pH > 7,30 or at least 72 hours from the beginning of the extracorporeal treatment.
1783418|NCT00465322|Drug|fluvastatin|
1783419|NCT00465361|Procedure|performance feedback with an educational module|individual performance feedback with an educational module
1783420|NCT00465374|Procedure|Change ventilatory parameters with stress index monitoring|
1783421|NCT00465387|Behavioral|Falls, Fractures & Osteoporosis Risk Assessment & Management|
1783422|NCT00465413|Device|Small volume spacer and/or Rinsing the mouth with water|
1783423|NCT00465439|Drug|Subcutaneous Lidocaine 2% (Xylocaine) without epinephrine|10 ml subcutaneously
1783424|NCT00465452|Drug|Continuous Release Dopamine Agonists|Continuous Release Dopamine Agonists
1783425|NCT00465465|Biological|MVA 85A|i.d. injection
1783426|NCT00465478|Procedure|Autologous bone marrow mononuclear cell transplantation|
1783427|NCT00465491|Drug|picoplatin|IV picoplatin 150mg/m2 q3wk
1783428|NCT00465491|Other|best supportive care|best supportive care
1783429|NCT00465504|Procedure|iontophoresis|See Detailed Description.
1783430|NCT00465517|Drug|Ganaxolone|Oral suspension 200-500 mg 3x/day
1783431|NCT00465530|Drug|Saline|Intranasal Saline
1783432|NCT00465530|Drug|Gentamycin|Intranasal irrigation
1783435|NCT00465556|Behavioral|Public Health Nurse Home Visit|The perinatal public health nurse home visit intervention also includes a trifold brochure, printed on 8X10 inch paper, with 6 panels, that can be read with the woman in an interactive manner so that the woman is encouraged to describe her experiences and choose her options as they proceed. Participants will receive three prenatal and three postpartum sessions. The first prenatal sessions will be given during the first (enrollment), second, and third trimesters, with at least three weeks between sessions. Women entering the study after the first trimester will receive the initial session at enrollment, with two subsequent sessions spread out over the remainder of the scheduled prenatal home visitation program sessions.
1783436|NCT00465556|Behavioral|Intimate Partner Violence (IPV) Protocol|The current protocol in use by the participating health departments when a women screens positive for intimate partner violence (IPV), current or history within the last year.
1783437|NCT00465569|Drug|cow's milk powder|Milk powder given orally in escalating doses to a goal of 500 mg for approximately 23 weeks
1783438|NCT00465569|Other|Placebo|
1783440|NCT00465608|Drug|propranolol|propranolol by mouth (per os)
1783441|NCT00465621|Drug|Xalatan|
1783443|NCT00465660|Behavioral|Progressive resistance training|
1783444|NCT00465673|Drug|Liposomal Doxorubicin|40mg/m2 over 1 hour infusion for 21 days
1783445|NCT00465686|Device|ergonomic chair and desk (Q-Learn Classic Chair and Q-Learn Desk)|ergonomic school chair and desk adjusted to fit the child user as per the manufacturer's instructions
1783446|NCT00465686|Device|ergonomic desk and chair (Q-Learn Desk)|child sits on chair and desk for 5 minutes, then provides handwriting sample at one desk, then repeats this for the other desk
1991668|NCT00710684|Drug|SB-742457 35mg|SB-742457 - 35mg added to existing donepezil
1783448|NCT00465712|Procedure|transabdominal amnioinfusion|transabdominal amnioinfusion performed 4 to 24 hours before the second trial of external cephalic version
1783449|NCT00465725|Drug|Picoplatin|The IV dose will be 120 mg/m2. Three oral dose levels will be studied sequentially (6 subjects per dose level) in the absence of dose limiting toxicity 200 mg, 300 mg, or 400 mg total dose.
1991669|NCT00710684|Drug|Placebo|Placebo added to existing donepezil
1991670|NCT00710684|Drug|donepezil 5-10mg|existing donepezil treatment
1783450|NCT00465738|Drug|"incobotulinumtoxinA (Xeomin, also known as NT 201 or Botulinum toxin type A (150 kD), free from complexing proteins)"|active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins; powder for solution for injection; Mode of administration: intramuscular injection; The content of the vial was dissolved in 2.0 or 5.0 mL of sterile sodium chloride [NaCl] 0.9% solution without preservatives. Dilution with 2.0 or 5.0 mL resulted in a dose of 50 or 20 units per 1.0 mL.
1783451|NCT00465751|Drug|chenodeoxycholic acid|chenodeoxycholic acid 500 mg capsules tid po
1783452|NCT00465751|Drug|placebo capsules|placebo capsules containing mannitol tid po
1783453|NCT00465764|Other|Alternate protein infant formula|Feed as per HCP directions
1783454|NCT00465764|Other|Standard infant formula|Feed as per HCP directions
1783455|NCT00465777|Behavioral|Guideline adherence and financial incentive|
1783456|NCT00465803|Drug|Travoprost 0.004%/timolol 0.5% ophthalmic solution|One drop in the study eye(s) once daily at either 8 AM or 8 PM for twelve months using the Dosing Aid
1783457|NCT00465803|Drug|Travoprost ophthalmic solution, 0.004%|One drop in the study eye(s) once daily at 8 PM for twelve months using the Dosing Aid
1783458|NCT00465803|Drug|Timolol maleate ophthalmic solution, 0.5%|One drop in the study eye(s) once daily at 8 AM or twelve months using the Dosing Aid
1783459|NCT00465816|Biological|Nimenrix (Meningococcal vaccine 134612)|Single dose intramuscular injection
1783460|NCT00465816|Biological|Twinrix|3-dose intramuscular injection. Twinrix Adult will be administered to subjects aged 16 years and above and Twinrix Junior will be administered to subjects aged from 11 years up to and including 15 years of age.
1783462|NCT00465868|Procedure|PCI (percutaneous coronary intervention)|Outcome of PCI following AMI
1783463|NCT00465881|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
1783464|NCT00465894|Drug|Tolterodine LA|Tolterodine LA 4 mg once daily for 52 weeks
1783465|NCT00465894|Drug|Estrace Vaginal Cream|17-B estradiol cream 0.5 grams nightly for 6 weeks then two times weekly for 46 weeks
1783466|NCT00465907|Drug|Paclitaxel, Carboplatin, Irinotecan|Paclitaxel-60mg/m2 weekly for 3 weeks Carboplatin - AUC 1.5, weekly for 3 weeks Irinotecan - 60mg/m2, weekly for 3 weeks
1783467|NCT00449982|Drug|Polyphenon E Ointment 10%, Polyphenon E Ointment 15%|
1783468|NCT00449995|Procedure|confocal laser microscopy|
1783469|NCT00450008|Drug|GM-CSF|fixed dose of 250 mcg/m2, 3 days per week by subcutaneous injection
1783470|NCT00450008|Drug|thalidomide|Thalidomide by oral administration at a fixed dose of 200 mg. Prophylactic Coumadin® by oral administration at a fixed dose of 2.5 mg to prevent thromboembolic events (DVT and TIA/stroke) during Thalidomide administration. Thalidomide and Coumadin will be given daily at bedtime without interruption.
1783471|NCT00450008|Drug|docetaxel|Docetaxel will be administered by intravenous piggyback over 1 hour at 75mg/m² every 3 weeks. Pre-medication for the docetaxel infusion will consist of dexamethasone 8 mg administered orally 12 hours, 3 hours and 1 hour before docetaxel.
1783472|NCT00450021|Drug|[(11)C] MePPEP|
1783473|NCT00450034|Procedure|drug - oriented multifaceted intervention|oriented multifaceted intervention
1783474|NCT00450047|Device|Speed-feedback therapy system with a bicycle ergometer|
1783475|NCT00450047|Device|Ergometer at conventional settings|
1783476|NCT00450060|Device|lumbar puncture with Quincke-design needles|
1783477|NCT00450060|Device|lumbar puncture with Sprotte-design needles|
1783478|NCT00450073|Drug|ergocalciferol (vitamin D2)|50,000 IU weekly
1783479|NCT00450073|Device|Sperti Del Sol Lamp|5 times a week for 12 weeks
1783480|NCT00450073|Drug|Vitamin D3|50,000 IU weekly
1783481|NCT00450086|Drug|Budesonide|9 mg per day
1783482|NCT00450086|Drug|Mesalazine|3 g per day
1783483|NCT00450086|Drug|Placebo|0 g per day
1783484|NCT00455507|Drug|Istradefylline|Two 10 mg KW-6002 tablets orally once daily for 12 weeks
1783485|NCT00455507|Drug|Istradefylline|Two 20 mg tablets orally once a day for 12 weeks
1783486|NCT00455507|Drug|Placebo|Two placebo tablets orally once daily for 12 weeks
1783487|NCT00455520|Drug|CG5503|100, 150, 200, 250 mg twice daily given for up to 15 weeks
1783488|NCT00455520|Drug|placebo|matching placebo twice daily for 12 weeks
1783489|NCT00455533|Drug|Ixabepilone|Intravenous Solution, intravenous (IV), 40mg/m², Day 1 every 21 days, 12 Weeks
1783490|NCT00455533|Drug|Paclitaxel|Intravenous Solution, IV, 80mg/m², Weekly, 12 Weeks
1783491|NCT00455533|Drug|Cyclophosphamide|Intravenous Solution, IV, 600mg/m², Day 1 every 21 days, 12 Weeks
1783492|NCT00455533|Drug|Doxorubicin|Intravenous Solution, IV, 60mg/m², Day 1 every 21 days, 12 Weeks
1783493|NCT00455546|Drug|A-002|
1783494|NCT00455559|Drug|Perifosine|All patients: Imatinib mesylate
1783495|NCT00455559|Drug|Imatinib Mesylate|All patients: Imatinib mesylate
1783496|NCT00455572|Biological|Immunotherapeutic GSK1572932A|Intramuscular injection, 8 doses
1783497|NCT00455572|Drug|Cisplatin (CDDP)|Four cycles with doses based on patient's body surface area, intravenous administration
1783498|NCT00455572|Drug|Vinorelbine|Four cycles with doses based on patient's body surface area , intravenous administration
1783499|NCT00455572|Procedure|Radiotherapy|Regimen will be based upon the site's own standard procedures
1783500|NCT00455585|Drug|nevirapine, stavudine, lamivudine|
1783501|NCT00455598|Drug|ISIS 113715|doses of 100 and 200 mg per week
1783502|NCT00455611|Device|CPAP (Continuous Positive Airway Pressure)|
1783503|NCT00465920|Behavioral|modified cognitive behavioural therapy (mCBT)|
1783504|NCT00465933|Drug|AIDA|
1783505|NCT00465946|Behavioral|Salt Supplementation|
1783506|NCT00465959|Drug|trospium chloride inhalation powder (TrIP)|
1783507|NCT00465959|Drug|Placebo|
1783508|NCT00465972|Drug|Doxepin|Doxepin 10 mg po nightly x duration of study length OR Temazepam 15 mg po nightly x duration of study length OR Placebo nightly x duration of study length
1783509|NCT00465972|Drug|Temazepam|Temazepam capsule 15 mg po nightly x duration of study
1783510|NCT00465972|Drug|Placebo|Placebo capsule nightly for duration of study
1783511|NCT00465985|Drug|ACZ885|
1783512|NCT00465985|Drug|Placebo|
1783513|NCT00466024|Behavioral|Health Coach and HEPA Air cleaners|Health Coach for ETS reduction in home and 2 HEPA air cleaners
1783514|NCT00466024|Behavioral|Health Coach and HEPA air cleaners|Behavioral training and 2 HEPA air cleaners
1783515|NCT00466037|Biological|Influenza vaccine|
1783516|NCT00466063|Drug|Deferasirox|
1783517|NCT00466076|Drug|Copaxone (Glatiramer acetate)|
1783518|NCT00466089|Drug|Erlotinib (Tarceva®)|Erlotinib (Tarceva®), 150mg/day p.o during 6 months.
1783521|NCT00466115|Drug|MS-275|
1783522|NCT00466115|Drug|GM-CSF|
1783523|NCT00466128|Drug|indomethacin|Indomethacin 50mg PO followed by 25mg PO q6hrs
1783524|NCT00466141|Behavioral|Increased Exercise for weight loss maintenance|
1783525|NCT00466141|Behavioral|Daily Self-weighing for weight loss maintenance|
1783526|NCT00466141|Behavioral|Education for weight loss maintenance|
1783527|NCT00466154|Drug|Aspirin|
1783528|NCT00466167|Drug|Pramipexol Extended Release|
1783529|NCT00466167|Drug|Pramipexol Immediate Release|
1783530|NCT00466167|Drug|Placebo|
1783531|NCT00466180|Behavioral|Nevirapine from twice-a-day to once-a-day|
1783532|NCT00466193|Drug|zolpidem tartrate sublingual tablet|3.5 milligram zolpidem tartrate sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
1783533|NCT00466193|Drug|Placebo|Placebo sublingual tablet taken as needed following a middle-of-the-night awakening over the 28-night study period. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
1783534|NCT00466206|Device|Magnetic Mini-Mover Procedure (3MP)|"A rare earth magnet encased in FDA-approved titanium will be implanted securely on the outer surface of the lower end of the sternum in patients with pectus excavatum. This is accomplished as an outpatient procedure, under brief general anesthesia.
A 2-inch transverse skinline incision is made at the junction of the sternum and xyphoid and the space in front and behind the sternum is dissected bluntly. The titanium can containing the magnet is securely fixed to the sternum by screwing it into a titanium fixation disk in front of the sternum. The procedure takes 1/2-hour, and the patient can go home the same day.
In another outpatient procedure, the Magnimplant is explanted 18 months after implantation."
1783535|NCT00466206|Device|Magnatract (external magnet in a removable external brace)|"An external orthotic device Magnatract which includes an external magnet in a removable brace is fitted specifically to the patient's chest wall deformity. A calibrated meter in the external device measures the force applied between the two magnets. When the patient and family are comfortable with the device and comfort and skin condition have been assessed, the patient will be allowed to take the Magnatract home and begin the process of gradually advancing the sternum forward as the abnormal costal cartilage is reformed."
1783536|NCT00466206|Procedure|3MP (Magnetic Mini-Mover Procedure)|"Subject has EKG performed to measure baseline cardiac activity.
Magnimplant is implanted.
After one week, Magnatract is fitted.
Chest x-ray and 2nd EKG performed 30 days post-implantation.
Patient and parents complete QoL questionnaire 30d post-implantation.
Patient seen weekly for first month post-implantation to assess comfort and skin condition. Thereafter, will be seen monthly.
At each monthly visit, patient will have lateral and anterior-posterior chest X-rays to monitor sternal correction.
At each visit data logger is downloaded to measure strength of pull since last visit and amount of wear-time.
Magnimplant explanted 18 months later as 1/2-hr outpatient procedure.
CT scan and third EKG performed after explanation.
Patient and parents complete QOL questionnaires after explantation and 1 yr post-explantation."
1783537|NCT00466219|Drug|Ribavirin|
1783538|NCT00466219|Drug|Pegylated interferon alpha2a|
1783539|NCT00466232|Drug|Topotecan|4 mg/m2 IV on day 1, 8, 15. Repeat every 28 days.
1783540|NCT00466232|Drug|Sorafenib|Dose escalation study at 3 dose levels: 200 mg po daily, 200 mg po bid, 400 mg po bid.
1783541|NCT00466245|Drug|MVA Smallpox vaccine|Two 0.5mL subcutaneous injections, separated by 28 days
1783542|NCT00466245|Drug|Placebo|Two 0.5mL subcutaneous injections, separated by 28 days
1783543|NCT00466947|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 4 doses
1783544|NCT00466947|Biological|Havrix|Intramuscular injection, 2 doses in Synflorix group and 3 doses in Control group
1783545|NCT00466947|Biological|Engerix-B|Intramuscular injection, 3 doses
1783546|NCT00466947|Biological|Infanrix hexa|Intramuscular injection,3 doses
1783547|NCT00466947|Biological|GSK Biologicals' DTPa-IPV/Hib vaccine|Intramuscular injection, 1 dose in Synflorix group and 4 doses in Control group
1783548|NCT00466960|Biological|sargramostim|Given SC
1783549|NCT00466960|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1783550|NCT00466960|Other|laboratory biomarker analysis|Correlative studies
1783551|NCT00466960|Other|immunologic technique|Correlative studies
1783552|NCT00466973|Device|AtriCure dry bipolar radiofrequency (RF) clamp|
1783553|NCT00466973|Device|Boston Scientific FLEX 10 unipolar microwave antenna|
1783554|NCT00466973|Device|Cryocath SurgiFrost unipolar cryothermic probe|
1783555|NCT00466973|Device|ESTECH Cobra Adhere irrigated unipolar RF antenna|
1783556|NCT00466973|Device|Medtronic Cardioblate BP irrigated bipolar RF clamp|
1783557|NCT00466973|Device|St. Jude Epicor hi-intensity focused ultrasound wand|
1783558|NCT00466986|Drug|Abraxane|Carboplatin day1 every 28days. Abraxane day1,8,15 every 28days
1783559|NCT00466999|Drug|misoprostol|single dose of 400 mcg misoprostol administered sublingually
1783560|NCT00466999|Procedure|surgery|standard surgical treatment (dilation and curettage or manual vacuum aspiration)
1783561|NCT00467012|Drug|bevacizumab|10mg/kg，Day1, 15 of 1 cycle(4 weeks)
1783562|NCT00467012|Drug|Paclitaxel|90mg/ m2，Day1, 8, 15 of 1 cycle(4 weeks)
1783563|NCT00467025|Drug|AMG 386|3 mg/kg or 10mg/kg IV weekly until unacceptable toxicity or disease progression
1783564|NCT00467025|Drug|Sorafenib|400 mg PO BID
1783565|NCT00467025|Drug|AMG 386 placebo IV|AMG 386 placebo IV
1783566|NCT00467038|Behavioral|Dialectical Behavior|Dialectical Behavior Therapy is an empirically validated treatment approach emphasizing the role of emotion regulation in the treatment of suicidal and self-destructive behaviors in BPD
1783567|NCT00467051|Drug|paclitaxel|Given IV dosage 135 mg/m2/dose
1783568|NCT00467051|Drug|carboplatin|"Given IV dosage in mg/m2 = Target AUC (mg•min/mL) x [(0.93 x GFR mL/min/m2) + 15]= 6.5 x [(0.93 x GFR mL/min/m2) + 15]. (BSA = body surface area in square meters). GFR is reported in institutions as uncorrected or raw (not normalized to BSA) or corrected. This number needs to be converted to GFR in mL/min/m2."
1783569|NCT00467051|Drug|ifosfamide|Given IV dosage 1800 mg/m2/dose
1783570|NCT00467051|Biological|filgrastim|Given IV or subcutaneously dosage 1,080mg/m2/day divided to three equal doses of 360mg/m2
1783571|NCT00467051|Other|laboratory biomarker analysis|Optional correlative studies
1783572|NCT00467064|Behavioral|Arthritis Quick Start|Two week, lay led, workshop focusing on goal setting, problem solving, and content specific to disease management.
1783573|NCT00467064|Other|Delayed treatment intervention|After four months delay, participants in Control Group receive Experimental workshop.
1783574|NCT00467077|Biological|PEG-interferon alfa-2b|PEG-Interferon will be administered subcutaneously (sq) once weekly for 6 weeks
1783575|NCT00467077|Drug|gefitinib|ZD1839 will be administered at a dose of 250 mg orally once daily,
1783576|NCT00467116|Biological|cetuximab|400mg/m2 initial dose week 1; followed by 250mg/m2/weekly starting week 2 with gemcitabine at fixed dose rate (10 mg/m2/min) + XRT. Cetuximab will start 1 week prior to all other treatment.
1783577|NCT00467116|Drug|gemcitabine hydrochloride|"Dose Level Gemcitabine dose Gemcitabine infusion
-1 150mg/m2 15 Minutes 0 200mg/m2 20 minutes
300mg/m2 30 minutes
400mg/m2 40 minutes"
1783578|NCT00467116|Radiation|radiation therapy|"50.4 Gy, 28 fractions, 5.5 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to encompass gross disease with a margin of 1-1.5 cm.
The prescription point will be designated at the intersection of the multiple beams.
There are no planned interruptions > 3 days."
1783579|NCT00467129|Genetic|microarray analysis|
1783580|NCT00467129|Genetic|mutation analysis|
1783581|NCT00467129|Genetic|polymerase chain reaction|
1783582|NCT00467129|Genetic|polymorphism analysis|
1783583|NCT00467129|Other|laboratory biomarker analysis|
1783584|NCT00467129|Other|questionnaire administration|
1783585|NCT00467142|Biological|bevacizumab|
1783586|NCT00467142|Drug|fluorouracil|
1783587|NCT00467142|Drug|irinotecan hydrochloride|
1783588|NCT00467142|Drug|leucovorin calcium|
1783589|NCT00467142|Genetic|polymorphism analysis|
1783590|NCT00467168|Behavioral|Diet|
1783591|NCT00467181|Drug|Fenoldopam|
1783592|NCT00467194|Drug|Rapamycin|
1783593|NCT00467194|Drug|Bevacizumab|
1783594|NCT00467207|Drug|Botulinum Toxin A|
1783595|NCT00467207|Behavioral|Resistance training|
1783596|NCT00467220|Behavioral|calorie restriction|"Subjects in the calorie restriction arm and the alternate day fasting arm will be asked to follow a menu plan, for three months, that includes some level of calorie restriction."
1783597|NCT00467233|Procedure|Laser Treatment|Laser treatment to half of the face at each study visit
1783598|NCT00467233|Procedure|Acid Peel|Acid peel to half of the face at each study visit
1783599|NCT00467246|Drug|Levemir|
1783600|NCT00467259|Drug|Testosterone Transdermal System|Testosterone patch, 300 mcg/day, change patch twice a week for 52 weeks
1783601|NCT00467259|Drug|Placebo patch|placebo patch, changed twice a week for 52 weeks
1783602|NCT00467272|Drug|Daptomycin|6 mg/kg IV every 24 hours for at least 7-14 days, depending on the type of bacteria.
1783607|NCT00467337|Procedure|Medial-Wedge Insole intervention|
1783608|NCT00467350|Drug|PEG 3350|PEG 3350 1.5 gram/kg for disimpaction then 0.8 gram/kg for maintenance
1783609|NCT00467350|Drug|milk and molasses enema|enema 10 cc/kg per rectum (max 500 cc)then PEG 3350 0.8 gram/kg for maintenance
1783610|NCT00467363|Drug|acetylsalicylic-acid (aspirin)|81mg of low-dose aspirin plus 400micrograms of folic acid.
1783611|NCT00467363|Dietary Supplement|Folic acid|400micrograms of folic acid.
1783612|NCT00467376|Drug|Insulin Glulisine|3 times a day before each meal
1783613|NCT00467376|Drug|Lispro|3 times a day before each meal
1783614|NCT00467376|Drug|Insulin Glargine|once daily
1783615|NCT00467389|Drug|Donepezil, 5 mg daily|This is a commercially available cholinesterase inhibitor that is approved for use in Alzheimer's disease.
1783616|NCT00467389|Other|Oral Placebo|Inactive Comparator with Similar Appearance to Active Medication
1783617|NCT00467402|Drug|agomelatine|
1783619|NCT00467415|Behavioral|Partial body weight support treadmill training|Treadmill ambulation for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
1783620|NCT00467415|Behavioral|Exercise|Functional Strengthening exercise program for 12 weeks. First 2 weeks for 10 total dose hours within clinical setting, final 10 weeks with 30 min/5 times week.
1783621|NCT00467428|Drug|NS2359|
1783622|NCT00467428|Drug|Placebo|
1783623|NCT00467441|Drug|VSF-173|
1783624|NCT00467454|Drug|Naltrexone|daily
1783625|NCT00467454|Drug|Placebo|daily
1783626|NCT00467467|Drug|Alfuzosin Hydrochloride|
1783627|NCT00467493|Drug|Anastrozole|
1783628|NCT00467506|Drug|bispecific antibody and di-DTPA-131I|
1783629|NCT00467519|Biological|Tdap (Tetanus Toxoid Reduced Diphtheria Toxoid/Acellular Pertussis)|0.5 mL, IM
1783630|NCT00467519|Biological|DTaP (Diphtheria & Tetanus Toxoids & Acellular Pertussis Adsorbed)|0.5 mL, IM
1783631|NCT00467545|Drug|telbivudine|
1783632|NCT00467558|Drug|Naltrexone|daily
1783633|NCT00467558|Drug|Sugar pill|daily
1783634|NCT00467571|Drug|lansoprazole, clarithromycin, amoxycillin|lansoprazole (15, 30 mg) 1 tab twice daily, clarithromycin 7.5 mg/kg twice daily, amoxycillin 25 mg/kg twice daily; rout: orally; duration 14 days
1783635|NCT00467584|Drug|High Dose Aspirin (1300 mg/day)|1300 milligrams per day (the equivalent of 4 regular aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
1783636|NCT00467584|Drug|Low Dose Aspirin (162 mg/day)|162 milligrams per day (the equivalent of 2 baby aspirin tablets) taken by mouth as two tablets, twice a day in the morning and at noon for 8 weeks
1783637|NCT00467584|Drug|Placebo|Placebo tablets matching the active aspirin tablets in appearance, taken as two tablets, twice per day for 8 weeks
1783638|NCT00467597|Drug|Levodopa (delivered intravenously)|"IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit."
1783639|NCT00467610|Drug|Panhematin|
1783640|NCT00467636|Procedure|Blood glucose monitoring|Regular pre and post meal blood glucose monitoring.
1783641|NCT00467636|Drug|Insulin Glulisine|Sub cutaneous injection given twice daily for 3 days. Dosage titrated to body mass index and body weight (BMI < 30 = 0.1 unit/kg. BMI > 30 = 0.2 unit/kg)
1783642|NCT00467649|Drug|pramlintide acetate (Symlin)|subcutaneous injection (60 mcg or 120 mcg), immediately prior to major meals
1783643|NCT00467649|Drug|rapid acting insulin (Humalog® [insulin lispro], Novolog® [insulin aspart], or Apidra® [insulin glulisine])|subcutaneous injection, dosing based on titration guidelines
1783644|NCT00467649|Drug|basal insulin (Lantus® [insulin glargine], or Levemir® [insulin detemir])|subcutaneous injection, dosing based on titration guidelines
1783645|NCT00467662|Drug|Acyclovir 5%|
1783646|NCT00467662|Drug|Docosanol 10%|
1783647|NCT00467662|Device|Superlysine gel|
1783648|NCT00467675|Device|CGM System for Type 1 and Type 2 Diabetes Mellitus|
1783649|NCT00467688|Device|Real time access to current glucose values during CGMS|One arm gets real time access to current measured glucose values and hypoglycemic or hyperglycemic alerts are elicited, The second arm get´s a retrospective analysis of glucose values
1783650|NCT00467714|Procedure|rhinoplasty|COLUMELLA STRUT PLACEMENT
1783651|NCT00467727|Other|Phase Contrast Mammography|Standard and magnification views
1783652|NCT00467740|Drug|BI 1744 CL|
1783653|NCT00467753|Drug|Oxcarbazepine|Oxcarbazepine is available in a 300mg/5ml solution. Dosage will start at 150 mg (2.5ml) at night for 3 days and will be increased to 150 mg in the am and pm. For children who are able to tolerate the 150 mg BID dose, the oxcarbazepine will be increased to 300 mg at night and 150 mg in the morning for 3 days and 300 mg BID for the next week. The children will remain on this dose until week 3, at which time if they are tolerating the medication and do not have a Clinical Global Improvement Scale (CGI) of 1 (very much improved) they will be increased to 600 mg twice a day in a method similar to the above increases. After week 4, the child will remain on the same stable dose.
1783654|NCT00467753|Other|Placebo/sugar pill|Dosage similar to active drug
1783655|NCT00467766|Behavioral|Psychosocial information, counseling, and support|
1783656|NCT00467766|Drug|Donepezil (Aricept)|
1783657|NCT00467779|Drug|cobimetinib|Repeating oral dose
1783658|NCT00467779|Drug|dextromethorphan|In Stage III only: single dose of dextromethorphan
1783659|NCT00467779|Drug|midazolam|In Stage III only: single dose of midazolam
1783660|NCT00467805|Procedure|Light therapy|
1783663|NCT00467831|Drug|Losartan|Losartan potassium tablet, 25 mg by mouth every night at bedtime.
1783664|NCT00467831|Drug|Zileuton|Zileuton tablet, 1200 mg by mouth twice daily.
1783665|NCT00467831|Drug|N-Acetylcysteine|N-acetylcysteine solution, 600 mg by mouth three times daily.
1783666|NCT00467831|Drug|Pravastatin|Pravastatin sodium tablet, 20 mg by mouth every night at bedtime.
1783667|NCT00467831|Drug|Erythromycin|Erythromycin tablet, 333 mg by mouth three times daily.
1783668|NCT00467844|Drug|GTx-024|1 mg GTx 024
1783669|NCT00467844|Drug|GTx-024|3 mg GTx-024
1783670|NCT00467844|Drug|Placebo|Matching Placebo
1783671|NCT00467857|Procedure|InteguSeal* skin sealant and standard surgical preparation|Surgical skin preparation prior to incision using InteguSeal* skin sealant following standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
1783672|NCT00467857|Other|Standard preoperative skin preparation|Surgical skin preparation prior to incision using standard surgical preparation with povidone iodine or 0.7% available iodine in isopropyl alcohol 74% w/w.
1783673|NCT00467870|Drug|Testosterone Undecanoate 750 mg|
1783674|NCT00467870|Drug|Testosterone Undecanoate 1000 mg|
1783675|NCT00467883|Drug|Liposomal Amphotericin B|high dosage
1783772|NCT00468624|Procedure|GH sampling - every 20 min over 24 hours after each limb (pegvisomant/placebo)|
1783676|NCT00467896|Drug|Iloprost PD-6|Period I: Patients received iloprost administered using PD-6 for the 37 days prior to the first dosing of iloprost using PD-15. Iloprost inhalation solution was delivered using the I-neb® AAD System. Patients were required to use their own I-neb®.
1783677|NCT00467896|Drug|Iloprost PD-15|Period II: Iloprost inhalation solution was delivered using the investigational product PD-15 with I-neb® AAD System for 37 days. Patients were required to use their own I-neb®.
1783678|NCT00467909|Behavioral|micronutrients|
1783679|NCT00467922|Drug|Hextend|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
1783680|NCT00467922|Drug|Lactated Ringers|Assessment of Goal-Directed Intraoperative Fluid Management in Hand Assisted Laparoscopic Colectomy: Standard Care versus Either Colloid and Crystalloid
1783681|NCT00467935|Drug|intravitreal injection Lucentis (ranibizumab)|intravitreal injection Lucentis (ranibizumab)
1783682|NCT00467948|Drug|cefazolin|
1783683|NCT00467961|Device|Miltenyi system|Subjects will receive a myeloablative conditioning regimen of cyclophosphamide, fludarabine and total body irradiation, followed by an infusion of a stem cell product prepared using the Miltenyi CliniMacs system for CD34 selection and a lymphocyte product that has been selectively depleted using the photodepletion approach.
1783684|NCT00467974|Procedure|TEA with LEM|Transarterial ethanol ablation (TEA) with Lipiodol-ethanol mixture (LEM)
1783685|NCT00467974|Procedure|TACE|Transarterial chemoembolisation (TACE)
1783686|NCT00467987|Drug|androgel|androgel 1%
1783687|NCT00467987|Drug|placebo|placebo
1783688|NCT00468000|Biological|Ixmyelocel-T|IM injection
1783689|NCT00468000|Biological|Placebo|IM Injection
1783690|NCT00468013|Behavioral|Resilience Building Exercises|Weekly exercises for 6 weeks
1783691|NCT00468013|Behavioral|Journaling|Weekly exercises for 6 weeks
1783692|NCT00468026|Device|ProstaPlant Stent|
1783693|NCT00468039|Drug|vildagliptin + metformin|
1783694|NCT00468052|Drug|dexmedetomidine|2 micrograms/kilogram as a bolus then 0.7 micrograms/kilogram infusion
1783695|NCT00468052|Drug|fentanyl|1 microgram/kilogram as a bolus
1783696|NCT00468065|Device|VeinViewer|Veinveiwer is used to view veins subQ
1783697|NCT00468065|Device|Veinviewer|near infrared light reveals veins subcutaneously
1783698|NCT00468078|Procedure|PET/CT|10min acquisition, 90min after injection of F-18 FPCIT
1783699|NCT00468078|Drug|F-18 FPCIT|5mCi, intravenous injection
1783700|NCT00468091|Drug|exendin(9-39)amide|
1783701|NCT00468091|Drug|atropine|
1783702|NCT00468104|Drug|Alteplase|25 Mg of Alteplase in 100 cc of normal saline was instilled intrapeurally for daily for three days
1783703|NCT00468104|Drug|Placebo|Placebo in 100 cc of normal saline was instilled intrapleurally daily for three days
1783710|NCT00468143|Drug|Adderall ® Immediate Release|Adderall Immediate release (IR) was provided as treatment for three weeks (at 15, 30 or 45 mg TID). The medication was optimized for titration.
1783711|NCT00468143|Drug|Adderall XR ®|Adderall Extended Release (XR) was provided as treatment for three weeks at (15, 30, or 45 mg QD). The medication was optimized for titration.
1783712|NCT00468156|Behavioral|written materials only|related to fruit/vegetable servings/day
1783713|NCT00468156|Behavioral|written materials|related to fruit/vegetable servings/day
1783714|NCT00468156|Behavioral|telephone support|related to fruit/vegetable servings/day
1783715|NCT00468169|Drug|Cetuximab|Cetuximab - Arm A:250mg/m2(day 1, weekly x 10); Cetuximab - Arm B:250mg/m2(day 1, weekly x 7)
1783716|NCT00468182|Drug|Interferon-beta 1b (Betaseron)|Treatment of patients with FDA-approved Rx
1783717|NCT00468208|Drug|Abatacept|"A participant's abatacept dose depended on body weight and will remain the same throughout the study:
500 mg of abatacept for body weight less than 60 kg
750 mg of abatacept for body weight between 60 and 100 kg
1000 mg of abatacept for body weight greater than 100 kg
Abatacept is administered in a 30-minute intravenous infusion."
1783718|NCT00468221|Drug|Ozone Exposure|Low dose ozone exposure in chamber
1783719|NCT00468234|Drug|nicotine polacrilex|
1783720|NCT00468234|Drug|nicotine transdermal system|
1783721|NCT00468234|Drug|nicotine inhaler|
1783722|NCT00468247|Device|Navigator|Navigator circulatory mgt system
1783723|NCT00468247|Other|Conventional care|Conventional haemodynamic care
1783724|NCT00468260|Drug|Patupilone|
1783725|NCT00468273|Drug|Immune Globulin Intravenous (Human) Omr-IgG-am IGIV|IGIV infusions of 300-900 mg/kg every 3 or 4 weeks
1783726|NCT00468286|Drug|Degarelix|"Experimental
Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 360 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months."
1783727|NCT00468286|Drug|Degarelix|"Experimental
Initial dose of 240 mg SC (by injection under the skin) on day 0. Maintenance dose of 480 mg SC (by injection under the skin) given after 1, 4, 7, & 10 months."
1783728|NCT00468299|Drug|Misoprostol and placebo|Women in this group receive 800 mcg misoprostol plus a placebo
1783729|NCT00468299|Drug|Mifepristone and misoprostol|This group receives mifepristone 200 mg orally; followed by 800 mcg misoprostol bucally
1783730|NCT00468312|Drug|Mometasone furoate nasal spray|Two sprays (50 mcg/spray) in each nostril (200 mcg daily) in the morning
1783731|NCT00468312|Drug|Placebo|Two sprays in each nostril in the morning
1783732|NCT00468325|Procedure|Multi-slice computed tomography|Patient receives a CT scan (multi-slice computed tomography) of the heart.
1783733|NCT00468325|Procedure|Rest-stress Nuclear Myocardial Perfusion Imaging|Patient receives the standard of care for emergency room admitting diagnosis of low to intermediate chest pain. A rest-stress nuclear myocardial perfusion imaging test is performed per the standard of care at each institution.
1783734|NCT00468325|Procedure|Multi-slice Computed Tomography|Patients admitted to the emergency department with low to intermediate chest pain receive a multi-slice computed tomographic test of the heart.
1783735|NCT00468338|Device|BIS monitor|BIS monitor measures the depth of anesthesia and was used in the entire group
1783736|NCT00468351|Procedure|Intravitreal Injection of 1,5 mg of bevacizumab|
1783737|NCT00468351|Procedure|Intravitreal injection of 4 mg of Triamcinolone acetonide|
1783738|NCT00468364|Drug|insulin glargine|
1783739|NCT00468364|Drug|NPH insulin|
1783740|NCT00468403|Biological|Allogeneic Pancreatic Islet Cells|Transplant of islet cells from a healthy pancreas. A dose of at least 5,000 Islet Equivalents (IEQ)/kg recipient body weight (BW) infused intraportally for the first transplant, and at least 4,000 IEQ/kg recipient BW infused intraportally for subsequent transplants.
1783741|NCT00468403|Biological|Belatacept|Belatacept is an inhibitor of the 2 signals that stimulate T-cells. Subjects will receive NULOJIX® (belatacept)10mg/kg through a peripheral vein on Day 0 and post-operative days 4, 14, 28, 56, 84. After Day 84 subjects will receive belatacept at a maintenance dose of 5 mg/kg every 4 weeks for the duration of study follow-up (2 years after the final islet transplant). Infusion doses will be based upon the subject's actual body weight at study Day 0 and will not be modified during the course of the study unless there is a change in body weight plus or minus 10% of Day 0 body weight.
1783742|NCT00468403|Biological|Basiliximab|Immunosuppressive medication for prophylaxis of acute transplant rejection. Two Intravenous (IV) doses of basiliximab, a monoclonal antibody Interleukin 2 (IL-2) receptor blocker, will be given with the first and second (if necessary) transplants. The first dose will be 20 mg and will be given within two hours prior to islet transplant on the day of islet transplantation. The second 20 mg dose will be given on Day 4 after the transplant.If a third islet transplant is deemed necessary and performed more than 70 days after the second transplant, both doses of basiliximab will be repeated. No additional doses of basiliximab will be given with a third transplant that is performed between 30 and 70 days after the second transplant.
1783743|NCT00468403|Drug|Mycophenolate Mofetil|Maintenance immunosuppressive therapy. Subjects will receive mycophenolate mofetil starting immediately pre-transplant on Day 0 at a dose of 1g orally twice a day for the duration of study follow-up (2 years after the final islet transplant).
1783744|NCT00468403|Drug|Tacrolimus|Tacrolimus may be used only as a supplement to maintenance mycophenolate mofetil (MMF) in those cases where the trough level is below the therapeutic range. Tacrolimus will be administered orally twice a day to maintain trough levels of 3-5 ng/mL. Generic equivalents of Prograf® will not be permitted.
1783745|NCT00468403|Procedure|Intraportal infusion of islet cells|The infusion of allogeneic pancreatic islet cells (islet transplant[s]) will occur intraportally.
1783746|NCT00468416|Device|Compression Anastomosis Ring (CAR)|
1783747|NCT00468429|Drug|Subconjunctival Bevacizumab|
1783748|NCT00468442|Biological|Allogeneic Pancreatic Islet Cells|transplant of islet cells injected into the portal vein of the liver
1783749|NCT00468442|Biological|Antithymocyte globulin|Immunosuppressive that selectively depletes activated T-cells and depletes resting T-cells in a dose-dependent manner.
1783750|NCT00468442|Biological|Daclizumab|Will replace antithymocyte globulin in all islet transplantations after the first one
1783751|NCT00468442|Biological|Rituximab|Depletes transient B-cells
1783752|NCT00468442|Drug|Sirolimus|Maintenance immunosuppressive therapy
1783753|NCT00468455|Procedure|Laparoscopic or open colorectal surgery|Application of a post-operative diary to be completed by subjects. The intervention is standard of care laparoscopic or open surgery.
1783754|NCT00468468|Behavioral|CHESS (Comprehensive Health Enhancement Support System) and Human Cancer Mentor|computer based education and support
1783755|NCT00468481|Drug|Drospirenone/Ethinylestradiol/Methyltetrahydrofolate|0.020 mg ethinylestradiol with 3.0 mg drospirenone and 0.451 mg L-5-methyltetrahydrofolate (L-5-MTHF)
1783756|NCT00468481|Drug|Drospirenone/Ethinylestradiol (Yaz)|0.020 mg ethinylestradiol with 3.0 mg drospirenone
1783757|NCT00468507|Dietary Supplement|nutritional intervention with Respifor and Diasip|Four nutritional interventions on four separate days per test person
1783758|NCT00468520|Drug|low dose oxytocin|
1783759|NCT00468533|Drug|Aripiprazole|
1783760|NCT00468546|Drug|MabThera/Rituxan|1
1783761|NCT00468546|Drug|Methotrexate|2
1783762|NCT00468546|Other|Placebo|3
1783763|NCT00468559|Drug|Open Label Run In Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
1783764|NCT00468559|Drug|Double Blind Esomeprazole|Esomeprazole magnesium in capsules dosing weight-dependent (2.5 mg - 10 mg)
1783765|NCT00468559|Drug|Double Blind Placebo|Double Blind Placebo
1783766|NCT00468572|Behavioral|Affectionate Writing|Participants assigned to the experimental group will spend 20 minutes writing an affectionate letter to a loved one. Levels of cortisol will be measured using saliva samples from each participant during the writing session. Levels of oxytocin, a hormone known to transmit signals within the brain and often associated with bonding and building trusting relationships, will be measured from blood samples taken during the writing session as well.
1783767|NCT00468572|Behavioral|Meaningless Writing|Participants assigned to the control group will spend 20 minutes writing about meaningless topics. Participants will undergo the same testing during the writing session as the experimental group.
1783768|NCT00468585|Drug|Capecitabine|
1783769|NCT00468585|Drug|Bevacizumab|
1783770|NCT00468611|Drug|MBP8298|500mg MBP8298 IV every six months for a period of two years
1783771|NCT00468624|Drug|pegvisomant/placebo loading dose 80mg sc, thereafter 20mg daily for 2 weeks|
1783773|NCT00468624|Procedure|blood sampling before and after pegvisomant/placebo|
1783774|NCT00468624|Procedure|arginine stimulation test after each limb|
1783775|NCT00468650|Drug|sildenafil citrate|Tablets, 50mg and 100mg , Medication will be taken orally with a glass of water approximately one hour (30 min to 4 hours) before sexual activity. Subjects are to take one dose in any calendar day.Eligible patients fulfilling all inclusion/exclusion criteria will be assigned at Visit 2/Week 0 (Baseline) to receive sildenafil 50 mg as needed (PRN) during the first two weeks, and,thereafter, at Visit 3/Week 2, all enrolled subjects will be up titrated to sildenafil 100 mg PRN for the following four weeks.
1783776|NCT00468676|Behavioral|Nurse-led case management|The case management intervention will entail approximately 10 visits with a trained nurse at the clinic or by telephone. Participants in this group will receive educational materials about how to manage diabetes and/or heart disease and stress or depression. Nurses will also provide guidance and support in managing medications, phone calls to check participants' progress, and assistance in setting personal goals and in managing physical health problems and symptoms of depression or stress.
1783777|NCT00468676|Behavioral|Treatment as usual|Participants will attend 10 study visits and receive 4 follow-up phone calls over 24 months. During this time, participants will receive usual care.
1783778|NCT00468689|Drug|SB-751689 oral tablets (100 and 400 ng)|
1783779|NCT00468689|Drug|Ketoconazole (NIZORAL) oral tablets (200 mg)|
1783780|NCT00468702|Device|CoaguChek S|
1783781|NCT00468715|Drug|bicalutamide|
1783782|NCT00468715|Other|diagnostic laboratory biomarker analysis|
1783783|NCT00468715|Other|immunohistochemistry staining method|
1783784|NCT00468728|Drug|PAR-101/OPT-80|capsules
1783785|NCT00468728|Drug|Vancomycin|Capsules
1783786|NCT00468741|Behavioral|CHESS (Comprehensive Health Enhancement Support System)|Full CHESS for subject use
1783787|NCT00468741|Behavioral|CHESS|informational services of CHESS available to subject
1783788|NCT00468741|Behavioral|CHESS|CHESS informational services and social support available to subject
1783789|NCT00468754|Device|Insulin pumps|
1783790|NCT00468767|Drug|Vernakalant Injection 20 mg/mL|
1783791|NCT00468793|Procedure|Intravenous fluid|The same intravenous fluids will be used in both arms but the volume will be different
1783792|NCT00468806|Drug|GSK598809, using [11C]-(+)-PHNO|
1783793|NCT00468819|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|In an open-label design, all patients will receive a total dose of 0.1 mmol/kg BW Gadovist 1.01 Days Injection
1783794|NCT00468845|Drug|pregabalin (Lyrica)|150 mg/day double blind (divided doses)
1783795|NCT00468845|Drug|pregabalin (Lyrica)|300 mg/day double blind (divided doses)
1783796|NCT00468845|Drug|matched placebo|matched placebo
1783797|NCT00468858|Other|Placebo|"Lyophilized, single dose vials and sterile water for
> injection; 0.5 mL dose; Vaccination schedule: 0, 6 months"
1783798|NCT00468858|Biological|T-DEN-Post-Transfection F17|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
1783799|NCT00468858|Biological|T-DEN-Post-Transfection F19|Lyophilized, single dose vials and sterile water for injection; 0.5 mL dose at 0 and 6 months
1783800|NCT00468871|Drug|fluocinolone acetonide intravitreal implant|surgical intravitreal implant of fluocinolone acetonide
1783801|NCT00468871|Drug|corticosteroids and immunosuppressants|Systemic corticosteroids alone or combined with immunosuppressants
1783802|NCT00468884|Drug|Increasing doses of GLP-1|
1783803|NCT00468884|Drug|PYY3-36|
1783804|NCT00468897|Drug|RSG XR|RSG XR tablets 8 mg enteric-coated tablet formulation consisting of 3mg fast release plus 5mg slow release. Subject will receive one 8mg of RSG XR on each dosing day. The subject will receive a single oral dose of regiment A or B with 240 milliliter (mL) of water.
1783805|NCT00468910|Drug|acetylsalicylic acid|Given orally
1783806|NCT00468910|Drug|placebo|Given orally
1783807|NCT00468910|Other|laboratory biomarker analysis|Correlative study
1783810|NCT00468936|Drug|Myfortic|enteric coated Cellcept pills in applicable dose for patient
1783811|NCT00468962|Drug|FACOS (functional food)|
1783812|NCT00468975|Drug|PF-610,355|
1783813|NCT00468975|Drug|Salmeterol|
1783814|NCT00468988|Drug|Travatan® Z|
1783815|NCT00468988|Drug|Xalatan®|
1783817|NCT00469014|Drug|Clofarabine|Arm 1 = 10 mg/m^2 intavenous (IV) Daily; Arm 2 = 20 mg/m^2 IV Daily; Arm 3 = 30 mg/m^2 IV Daily; Arm 4 = 40 mg/m^2 IV Daily
1783818|NCT00469014|Drug|Busulfan|Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily; Arm 4: 40 mg/m^2 IV Daily
1783819|NCT00469014|Drug|Fludarabine|Arm 1: 30 mg/m^2 IV Daily; Arm 2: 20 mg/m^2 IV Daily; Arm 3: 10 mg/m^2 IV Daily
1783820|NCT00469027|Biological|eNOS transfected EPCs will be delivered via a PA line|incremental dosing over 3 days
1783821|NCT00469040|Drug|GW642444M for 14 days|M salt
1783822|NCT00469053|Drug|Buprenorphine|
1783823|NCT00469079|Drug|Nicotine gum and lozenge|Nicotine replacement
1783824|NCT00469079|Other|Taboka|smokeless tobacco product
1783825|NCT00469079|Other|Camel Snus|smokeless tobacco product
1783826|NCT00469092|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
1783827|NCT00469092|Drug|insulin glargine|Treat-to-target dose titration scheme. The titration scheme is based on the previous 3 days fasting plasma glucose (FPG) measurements.
1783828|NCT00469092|Drug|metformin|Tablets, 2550 mcg. Administered once daily.
1783829|NCT00469092|Drug|glimepiride|Tablets 2 mg. 4, 6 or 8 mg administered once daily.
1783830|NCT00469105|Behavioral|Literacy/Numeracy oriented educational intervention|Receives comprehensive literacy/num sensitive diabetes care
1783831|NCT00469105|Behavioral|Control Group|Receives standard diabetes disease management
1783832|NCT00469118|Device|DRX9000™|Nonsurgical spinal decompression
1783833|NCT00469131|Drug|tacrolimus + steroid|
1783834|NCT00469131|Drug|tacrolimus + mycophenolate mofetil|
1783835|NCT00469144|Drug|Busulfan|"Fixed Dose = 130 mg/m^2 IV Daily Over Three Hours x 4 Days.
Adjusted Dose = 32 mg/m^2 IV Over 2 Hours Test Dose x 1 Day.
Proceeding dosage level determined by pharmacokinetic studies to achieve a daily area under curve (AUC) of 6,000 microMol-min ± 10%."
1783836|NCT00469144|Drug|Fludarabine|40 mg/m^2 IV Daily Over 1 Hour x 4 Days
1783837|NCT00469157|Drug|Optive|Optive 30ml- (in the eye) Instill one in each eye twice daily starting one week after surgery
1783838|NCT00469170|Device|intravaginal ring|silicone elastomer intravaginal ring containing no drug product
1783839|NCT00469183|Drug|Fluocinolone acetonide .1%, hydroquinone 4%, tretinoin .05%|Apply topically daily for 12 weeks and continue until condition is clear or almost clear for up to 24 weeks; Maintenance phase: Apply topically twice weekly until the end of study (24 weeks) or condition relapses
1783840|NCT00469196|Procedure|Tomotherapy|40 Gy in 15 fractions, at one fraction per day. Dose will be prescribed to the 95% isodose line.
1783841|NCT00469209|Drug|Trisenox (Arsenic Trioxide)|0.25 mg/kg by vein over 2 hours, once a day for 7 days (Days -9 to -3).
1783842|NCT00469209|Drug|Velcade (Bortezomib)|"Arm 1 (Level 1):
1.0 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute).
Arm 2 (Level 2):
1.5 mg/m^2 intravenous (IV) push on Days -9, -6, and -3. An IV push takes a short period of time (less than 1 minute)."
1783843|NCT00469209|Drug|Melphalan|100 mg/m2 by vein days -4,-3, over 30 minutes
1783844|NCT00469209|Drug|Vitamin C (Ascorbic Acid)|1000 mg once a day through the vein for 7 days.
1783845|NCT00469222|Procedure|hypofractionated external beam|
1783846|NCT00469235|Drug|Avotermin|"10 patients:- 50ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure.
10 Patients:- 200ng/100μL Juvista administered by intradermal injection to each linear centimetre of one ear lobe wound margin immediately after and then 24h after wound closure versus 100 μL of placebo administered by intradermal injection to each linear centimetre of the other ear lobe wound margin immediately after and then 24h after wound closure."
1783847|NCT00469248|Device|Intra-aortic balloon pump counterpulsation|
1783848|NCT00469261|Drug|Doxycycline|Doxycycline 100 mg bid for seven days after enrollment
1783849|NCT00469261|Drug|Current medical therapy for AMI|Current medical therapy for AMI
1783850|NCT00469274|Drug|Antibiotic PEP|Azithromycin 1000mg po x 1, then 500mg po Q day for 4 days; TMP-SMX DS one BID for 14 days
1783851|NCT00469274|Drug|Antibiotic PEP|TMP-SMX DS po BID for 14 days
1783852|NCT00469300|Drug|Iontophoretic delivery of acyclovir|
1783853|NCT00469326|Drug|Atorvastatin|two days 80mg atorvastatin pre-treatment before PCI
1783854|NCT00469339|Behavioral|Family Health History|
1783855|NCT00469352|Drug|Ranibizumab|Ranibizumab as needed
1783856|NCT00469365|Behavioral|pharmacist contact with the patient via telephone|
1783857|NCT00469365|Behavioral|Pharmacist contact with the patient's physician via fax|
1783858|NCT00469365|Behavioral|Usual care|
1783860|NCT00469391|Device|GI Sleeve Implantable weight loss device (EndoBarrier)|device for weight loss
1783861|NCT00469391|Procedure|Sham Procedure|Weight loss
1783862|NCT00469404|Drug|Buprenorphine|
1783863|NCT00469417|Procedure|Cryotherapy or Photodynamic therapy with methyl aminolevulinate cream|
1783864|NCT00458445|Drug|SPD465|
1783865|NCT00458458|Drug|Norethindrone Acetate (NA)|52 weeks of treatment with Norethindrone Acetate
1783866|NCT00458458|Drug|GnRH Agonist (Lupron Depot)|24 weeks of treatment with Lupron Depot then 28 weeks of treatment with Norethindrone Acetate
1783867|NCT00458471|Device|Insertion of a urinary catheter coated with benign E. coli|
1783868|NCT00458484|Radiation|stereotactic radiosurgery|"Series I: Radiation will be delivered in 4 fractions. The initial dose level will be 6 Gy per fraction to a total dose of 24 Gy in 4 fractions. Doses will be escalated at 2 Gy per fraction increments to 12 Gy per fraction to a total dose of 48 Gy. The radiation treatment planning and evaluation details are appended.
Series II: The initial dose level will be 48 Gy to the target volume (tumor) in 3 fractions of 16 Gy per fraction. If acute toxicity is acceptable, then the next four patients will be escalated to 54 Gy in 3 fractions of 18 Gy. Finally if a dose limit has not been reached, the last group of four patients will be treated to 60 Gy in 3 fractions of 20 Gy each."
1783869|NCT00458484|Procedure|Renal Biopsy|At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.
1783870|NCT00458484|Procedure|Serum Blood Markers|ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
1783871|NCT00458497|Device|Holofiber fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET) fabric to which Holofiber particles have been added during fiber manufacture.
1783872|NCT00458497|Device|PET fabric|Subjects will be given 3 pairs of socks (subjects with foot pain only) and bedding (mattress pad)fabricated from 1.8 dernier polyethylene terephthalate (PET)fabric.
1783873|NCT00458510|Drug|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|treatment of up to 4 episodes of pain per day
1783874|NCT00458523|Biological|alemtuzumab|
1783875|NCT00458523|Genetic|fluorescence in situ hybridization|
1783876|NCT00458523|Genetic|mutation analysis|
1783877|NCT00458523|Other|flow cytometry|
1783878|NCT00458536|Biological|Dendritic Cell Tumor Fusion Vaccine|3 vaccinations at three week intervals
1783879|NCT00458536|Drug|Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|Combined with the vaccine in the remaining subjects after the first 6 are enrolled.
1783880|NCT00458549|Dietary Supplement|omega-3 fatty acids|
1783881|NCT00458549|Other|immunohistochemistry staining method|
1783882|NCT00458549|Other|laboratory biomarker analysis|
1783883|NCT00458549|Other|liquid chromatography|
1783884|NCT00458549|Procedure|biopsy|
1783885|NCT00458549|Procedure|complementary or alternative medicine procedure|
1783886|NCT00458575|Drug|CNTO 2476|Participant 1 will receive 5.6x100000; Participants 2, 3, 5, 6, and 7 will receive 6.0x10000; Participant 4 will receive 3.0x100000; and Participants 8 and 9 will receive 1.2x100000 of CNTO 2476 as a single dose of viable cells in phosphate buffered saline (PBS) in a total volume of 100 μL injected subretinally.
1783887|NCT00458588|Other|physiologic testing|
1783888|NCT00458588|Other|questionnaire administration|
1783889|NCT00458588|Procedure|breast imaging study|
1783890|NCT00458588|Procedure|dual x-ray absorptometry|
1783891|NCT00458588|Procedure|evaluation of cancer risk factors|
1783892|NCT00458588|Procedure|magnetic resonance imaging|
1783893|NCT00458601|Drug|CDX-110 with GM-CSF|Three biweekly intradermal injections over four weeks followed by monthly injections until tumor progression. Each dose will be 0.8 mL containing approximately 500 mcg CDX-110 and 150 mcg GM CSF.
1783894|NCT00458601|Drug|Temozolomide|Maintenance temozolomide will begin after completion of the three initial injections of CDX-110 plus GM-CSF. 150 to 200 mg/m2 for 5 days during each 28-day cycle for a minimum of six cycles or a maximum of 12 cycles, intolerance or progression.
1783895|NCT00458614|Drug|Lansoprazole|
1783896|NCT00458653|Biological|Dendritic Cell Tumor Fusion|"Post-Transplant (Groups A and B): Given under the skin every four weeks for three doses.
Pre-Transplant (Group B): Injected under the skin in upper part of leg or arm prior to stem cell collection for ASCT"
1783897|NCT00458679|Biological|CD40 LIGAND AND IL-2-EXPRESSING TUMOR CELLS VACCINE|Patients will receive a fixed dose (2 x 10^7) of IL-2 secreting B-cells together with (2 x 10^7)hCD40L expressing B-cells. They will receive 18 deltoid injections over 52 weeks.
1783898|NCT00458705|Drug|bortezomib|
1783899|NCT00458705|Drug|dexamethasone|
1783900|NCT00458705|Drug|pegylated liposomal doxorubicin hydrochloride|
1783901|NCT00458705|Drug|thalidomide|
1783902|NCT00458718|Drug|rimonabant (SR141716)|
1783903|NCT00458731|Biological|bevacizumab|Given IV
1783904|NCT00458731|Drug|cediranib maleate|Given orally
1783905|NCT00458744|Drug|talotrexin|
1783906|NCT00458744|Procedure|chemotherapy|
1783907|NCT00458770|Procedure|position emission transaxial tomography|cerebral position emission transaxial tomography using 18Fluorodeoxyglucose
1783908|NCT00458783|Biological|Prolonged RBC storage|Transfusion with oldest available matching RBCs
1783909|NCT00458783|Biological|Short RBC storage|Transfusion with youngest available matching RBCs
1783910|NCT00458796|Drug|zoledronic acid|
1783911|NCT00458796|Procedure|quality-of-life assessment|
1783912|NCT00458809|Drug|oxaliplatin|Intraperitoneal Hyperthermic Chemoperfusion with Oxaliplatin
1783913|NCT00458822|Drug|bortezomib|Given IV
1783914|NCT00458822|Drug|dexamethasone|Given orally
1783915|NCT00458835|Drug|Ciclesonide|
1783916|NCT00458848|Drug|asparaginase|
1783917|NCT00458848|Drug|daunorubicin hydrochloride|
1783918|NCT00458848|Drug|etoposide|
1783919|NCT00458848|Drug|idarubicin|
1783920|NCT00458848|Drug|imatinib mesylate|
1783921|NCT00458848|Drug|mercaptopurine|
1783922|NCT00458848|Drug|methotrexate|
1783923|NCT00458848|Drug|methylprednisolone|
1783924|NCT00458848|Drug|mitoxantrone hydrochloride|
1783925|NCT00458848|Drug|prednisone|
1783926|NCT00458848|Drug|vincristine sulfate|
1783927|NCT00458848|Procedure|allogeneic hematopoietic stem cell transplantation|
1783928|NCT00458848|Procedure|autologous hematopoietic stem cell transplantation|
1783929|NCT00458848|Procedure|peripheral blood stem cell transplantation|
1783930|NCT00458848|Radiation|radiation therapy|
1783931|NCT00458861|Biological|BG9924|Subcutaneous administration of BG9924 given every other week for 12 weeks
1783932|NCT00458861|Other|Placebo Comparator|Subcutaneous administration of placebo given every other week for 12 weeks
1783933|NCT00458874|Behavioral|CIMT results|"Both groups will receive a weekly confidential packet of scripted materials (e.g. educational materials, class schedules, feedback from diet/exercise logs). The R-CIMT group will also receive an CIMT report which contains a copy of one of their own ultrasound scans, with a comparison normal scan. This report will also include the CIMT thickness, an interpretation that states their measurements are in the highest quartile for persons of their age and gender, and associated CVD risk. Interpreting Your CIMT Results tutorial will be included in the first weekly packet to educate subjects on the detection of atherosclerosis with carotid ultrasound. The CIMT results are withheld from the W-CIMT group until the end of their study participation along with the CIMT tutorial."
1783934|NCT00458887|Procedure|management of therapy complications|Undergo hearing tests
1783935|NCT00458900|Drug|IV and enteral administration of moxifloxacin|IV and enteral administration of moxifloxacin
1783936|NCT00458913|Drug|bortezomib|
1783937|NCT00458913|Drug|cisplatin|
1783938|NCT00458952|Drug|Ultratrace Iobenguane (MIBG) I 131|Phase I: Dose escalation protocol Phase II: Treatment schedule at therapeutic dose
1783939|NCT00458978|Drug|Cediranib Maleate|Given orally
1783940|NCT00458978|Other|Laboratory Biomarker Analysis|Correlative studies
1783941|NCT00458991|Drug|Dextromethorphan and Caffeine|"All subjects received standard medical therapy with rhGH and at specified times low doses of the pharmacologic probes (e.g., caffeine and dextromethorphan) as surrogate markers to determine CYP450 activity. The only direct treatment effect measured was the biological response to rhGH."
1783942|NCT00459004|Drug|rimonabant (SR141716)|
1783943|NCT00459017|Device|Portable blood pressure wrist manometer|
1783944|NCT00459030|Other|educational intervention via internet|additional cancer screening information via password protected internet site
1783945|NCT00459030|Other|educational intervention mailed|
1783946|NCT00459030|Other|No additional educational intervention|
1783947|NCT00459043|Drug|ZD6474|Taken orally once every morning
1783948|NCT00459043|Drug|Docetaxel|Given on the first day of every treatment cycle (every 3 weeks)
1783993|NCT00459420|Drug|Caffeine 100-200 mg BID|Caffeine 100 mg BID for three weeks, then 200 mg BID for three weeks, then 100 mg BID for 1 week, then placebo
1783949|NCT00459056|Drug|Carvedilol CR + Lisinopril|Participants were given Carvedilol CR + Lisinopril for three months. Oral medication. Carvedilol CR and Lisinopril combination therapy was initiated at 20 mg and 10 mg, respectively. Patients returned one week later and doses of carvedilol CR and lisinopril were increased to 40 mg and 20 mg, respectively, depending on blood pressure.
1783950|NCT00459056|Drug|Lisinopril + HCTZ|Participants were given Lisinopril + HCTZ for three months. Oral medication. Lisinopril + HCTZ combination therapy was initiated at 12.5 mg and 10 mg, respectively. Patients returned 1 week later and doses of hydrochlorothiazide and lisinopril were increased to 25 mg and 20 mg, respectively, depending on blood pressure levels.
1783951|NCT00459069|Biological|Dendritic Cell Tumor Fusion Vaccine|Vaccine administered on weeks 0, 3 and 6
1783952|NCT00459082|Drug|Dexmedetomine|
1783953|NCT00459108|Drug|dasatinib|Given orally
1783954|NCT00459121|Drug|carboplatin|Carboplatin AUC6 IV, every 3 weeks starting on day 1 of cycle 1
1783955|NCT00459121|Drug|paclitaxel|Paclitaxel- 200mg/m2 IV, every 3 weeks starting on day 1 of cycle 1.
1783956|NCT00459121|Drug|Zactima|Zactima- 100 mg orally daily, starting on day 1 of cycle 1.
1783957|NCT00459121|Procedure|neoadjuvant therapy|Neoadjuvant surgery: Surgical resection of the tumor will be performed after the resolution of all the adverse effects from the last cycle of treatment but no earlier than 3 weeks after the last cycle of treatment.
1783958|NCT00459134|Dietary Supplement|ArginMax|Given orally
1783959|NCT00459134|Dietary Supplement|Placebo|Given orally
1783960|NCT00459160|Procedure|Intraoperative Hypotensive Resuscitation|Patients will have a target minimum MAP of 50 for the case
1783961|NCT00459173|Drug|rimonabant (SR141716)|
1783962|NCT00459186|Drug|RAD001|Daily for two weeks
1783963|NCT00459186|Drug|Docetaxel|Infusion once per cycle
1783964|NCT00459186|Drug|Prednisone|Prednisone 5 mg by mouth twice daily
1783965|NCT00459212|Drug|GTI-2040|Given IV
1783966|NCT00459212|Procedure|pharmacological study|Correlative study
1783967|NCT00459212|Procedure|laboratory biomarker analysis|Correlative study
1783968|NCT00459225|Drug|Iron (ferrous sulfate)|The subjects in the iron treatment arm of the study will receive 3 mg/kg of oral/enteral iron solution once a day beginning at the time of discharge until the pre-Glenn screening which is the endpoint of the study. The iron will be dispensed for the subjects upon discharge from the hospital. The subjects randomized to the no iron treatment arm and the patients in Group II of the study will not receive iron upon discharge. However, they may be started on iron therapy in an intent-to-treat anemia by their primary physician in which case this will serve as the endpoint of the study for these participants.
1783969|NCT00459238|Other|counseling intervention|subjects will receive telephone based counseling
1783970|NCT00459238|Other|educational intervention|subjects will received telephone based education
1783971|NCT00459264|Drug|Folic Acid|Folic acid oral solution 2.5mg/5ml daily for up to 3 years
1783972|NCT00459264|Drug|Placebo|Matching placebo for folic acid oral solution (2.5mg/5ml)
1783973|NCT00459277|Drug|Fentanyl (Nasalfent, Fentanyl Citrate Nasal Spray)|
1783974|NCT00459290|Drug|mifepristone|
1783975|NCT00459303|Device|aspherical intraocular lens|implantation of aspherical intraocular lenses(AMO Tecnis Z9000)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
1783976|NCT00459303|Device|spherical intraocular lens|implantation of spherical intraocular lenses(Alcon SA60AT Acrysof)during cataract suregry (small cornea incision phacoemulsification, deliver with Monarch II device, in the bag implantation)
1783977|NCT00459316|Biological|Quadrivalent meningococcal conjugate vaccine|MCV4 vaccine (4 µg each of meningococcal A, C, Y, and W-135 polysaccharides conjugated to approximately 48 µg of diphtheria toxoid protein carrier ) was given by injection intramuscularly at least once and no more than three times for each participant, depending on adverse reactions.
1783978|NCT00459329|Behavioral|Program to Encourage Active, Rewarding Lives (PEARL)|"Eight 50-minute in-home sessions over 19 weeks with a masters-level social work counselor using Problem Solving Therapy (PST).
PST is a skills-enhancing behavioral depression treatment based on the assumption that an accumulation of problems in living cause and maintain depressive symptoms, and through systematically identifying and addressing these problems, patients achieve decreased depressive symptoms. Counselors also help participants to increase social and physical activities and to incorporate pleasant activities into patients' lives.
Counselors provide education and monitoring for antidepressant use, and work with the participant's physician and PEARL psychiatrist to recommend initiating or adjusting antidepressant medications. The PHQ-9 is administered at each session to track depression change.
After 19 weeks, counselors will maintain monthly telephone calls with participants, administering the PHQ-9 and assessing PST success."
1783979|NCT00459342|Drug|dasatinib|Given orally
1783980|NCT00459355|Behavioral|Home Safety Toolkit|Health literacy-verified booklet and home safety items to promote competence to make home safety modifications.
1783981|NCT00459368|Behavioral|Feedback of patient adherence information|Patient inhaled corticosteroid adherence information is being provided to physicians at clinic sites randomized to the intervention arm. Adherence information is available via electronic prescribing software, and so is available to physicians when writing, renewing, or viewing medications. Physicians at intervention sites also receive standard training in how to interpret adherence metrics and how to intervene on poor adherence.
1783982|NCT00459368|Behavioral|Active control group|Physician practicing at control sites are given standard training in how to intervene on poor adherence, but no patient adherence information is provided to these clinicians via electronic prescribing software.
1783983|NCT00459381|Drug|pazopanib hydrochloride|Given orally
1783984|NCT00459381|Other|laboratory biomarker analysis|Correlative studies
1783985|NCT00459407|Dietary Supplement|defined green tea catechin extract|Given orally
1783986|NCT00459407|Drug|placebo|Given orally
1783987|NCT00459407|Other|immunohistochemistry staining method|Correlative studies
1783988|NCT00459407|Other|immunoenzyme technique|Correlative studies
1783989|NCT00459407|Other|laboratory biomarker analysis|Correlative studies
1783990|NCT00459407|Procedure|biopsy|Undergo biopsy
1783991|NCT00459407|Other|mass spectrometry|Correlative studies
1783992|NCT00459407|Other|high performance liquid chromatography|Correlative studies
1783995|NCT00459433|Procedure|Biopsychosocial intervention|Psychosocial versus usual care
1783996|NCT00459446|Drug|MS-325 Injection (Gadofosveset Trisodium)|
1783997|NCT00459459|Procedure|Fine needle aspiration of the thyroid|
1783998|NCT00459472|Behavioral|laparoscopic training curriculum|All general surgery interns and PGY-2-5's already participate in a surgery training curriculum that includes lectures, surgery, laparoscopic training, attending surgeons evaluating performance of residents at the end of surgical procedures, written tests, and skills tests.
1783999|NCT00459485|Dietary Supplement|zinc sulfate|20 or 10 mg zinc per day for 3 weeks
1784000|NCT00459485|Dietary Supplement|Placebo|Daily placebo for 3 weeks
1784001|NCT00459511|Procedure|Blood AM, IL-6, ACTH, Cortisol, Glucose and Insulin|
1784002|NCT00459524|Behavioral|Questionnaire|Questionnaires taking about 30 minutes to complete.
1784003|NCT00459524|Behavioral|Neurocognitive Testing|Neurocognitive testing lasting 30 minutes. Patients will be asked to complete certain tasks that require the use of their hands, eyes, and ears.
1784004|NCT00459537|Drug|terbinafine hydrogen chloride|10 % terbinafine hydrogen chloride (HCL)
1784005|NCT00459537|Drug|amorolfine nail lacquer|5 % amorolfine nail lacquer
1784006|NCT00459550|Drug|GSK933776|"Part A planned doses cohort 1 to cohort 3 0.001 mg/kg, 0.01 mg/kg and 0.1 mg/kg.
Part B planned doses cohort 4 to cohort 7 0.1 mg/kg, 1mg/kg, 3mg/kg and 10 mg/kg"
1784007|NCT00459550|Drug|Placebo to match GSK933776|Part A first 2 cohorts 5 patients per cohort 2 placebo and 3 active third cohort part A 2 placebo 6 active. Part B 8 patients per cohort 2 placebo 6 active.
1784008|NCT00459563|Drug|Vitamin D|200,000 IU once weekly for 3 weeks (600,000 IU total dose)
1784009|NCT00459563|Drug|calcitriol|calcitriol 0.5 mcg twice a day for 1 week
1784010|NCT00459563|Drug|Placebo|Placebo once a week for 3 weeks
1784011|NCT00459589|Behavioral|nutritional intervention with dietician plus usual nutritional care|nutritional intervention with dietician at each cycle of chemotherapy in 6 first cycles to maintain 30 kcal/kg/d and 1.2 protein/kg/d
1784012|NCT00459589|Behavioral|usual nutritional care|usual nutritional care
1784014|NCT00459628|Radiation|Conventional radiotherapy|Radiation treatment delivered by conventional linear accelerator using matching fields
1784015|NCT00459628|Radiation|Tomotherapy|CT image guided intensity modulated radiation therapy delivered by the Tomotherapy HiArt system
1784016|NCT00459641|Drug|I-040302|doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
1784017|NCT00459641|Other|Standard of Care|Bone marrow aspirate or steroids
1784018|NCT00459654|Drug|Radium-223 dichloride (BAY88-8223)|Four Radium-223 injections were given at 4-weekly intervals starting after the first fraction of EBR.
1784019|NCT00459654|Drug|Saline|Four Saline injections were given at 4-weekly intervals starting after the first fraction of EBR.
1784020|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 250ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
1784021|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Phase A: 500ug administrated s.c. every other day (double blind). For patients previously randomized in Bayer study 91162 to the same treatment. Phase B: All patients will receive 500µg s.c.every other day (open-label).
1784022|NCT00459667|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|"Phase A: 250ug administrated s.c. every other day (open-label). For patients previously randomized in Bayer study 91162 to 20mg Copaxone® administrated s.c. once daily and patients with premature discontinuation of study medication during the study 91162.
Phase B: All patients will receive 500µg s.c.every other day (open-label)."
1784023|NCT00459680|Device|Laser acupoint treatment|Laser
1784024|NCT00459680|Procedure|Acupuncture|Needle acupuncture on ST36 and LI11.
1784025|NCT00459693|Drug|[11C]PBR28|
1784026|NCT00459706|Device|Enbrel 50 mg Prefilled Syringe|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Prefilled Syringe
1784027|NCT00459706|Device|Enbrel 50 mg Autoinjector|Enbrel 50 mg subcutaneously once weekly for 12 Weeks using Autoinjector
1784028|NCT00459719|Drug|Tacrolimus modified-release|oral
1784029|NCT00459719|Drug|Prograf|oral
1784030|NCT00459732|Dietary Supplement|Zinc|25 mg of elemental zinc as zinc sulphate take once daily for 18 months
1784031|NCT00459732|Dietary Supplement|Placebo|Placebo capsule, identical to the zn capsule in size, shape and color, taken once daily for 18 months
1784032|NCT00459745|Drug|Pravafen (combination of Pravastatin and Fenofibrate)|
1784033|NCT00459758|Device|Hans unit|
1784034|NCT00459771|Drug|AT1 blocker candesartan|AT1 blocker candesartan, 32 mg oral QD
1784035|NCT00459771|Drug|Placebo|Placebo, 32 mg, oral QD
1784036|NCT00459784|Procedure|Dementia Training Program|
1784037|NCT00459797|Device|Conventional (reusable) Glidescope|
1784038|NCT00459797|Device|Single-use Glidescope videolaryngoscope|
1784039|NCT00459810|Drug|transdermal estradiol|Transdermal estradiol given 0.2mg/day for duration of study.
1784040|NCT00459810|Drug|paclitaxel poliglumex|Paclitaxel poliglumex (PPX) is a macromolecular polymer-drug conjugate of paclitaxel. PPX was given every 28 days, at a dose of 150 mg/m2
1784041|NCT00459823|Drug|E7107|E7107 administered by intravenous infusion (as a 2-5 minutes bolus) on days 1, 8 and 15 every 28 days.
1784042|NCT00459836|Drug|PR-104|
1784043|NCT00459836|Drug|docetaxel|
1784044|NCT00459836|Drug|gemcitabine hydrochloride|
1784045|NCT00459836|Other|laboratory biomarker analysis|
1784046|NCT00459836|Other|pharmacological study|
1784047|NCT00459849|Procedure|Intraoperative ultrasonography|Intraoperative ultrasonography will be used to determine plaque placement.
1784048|NCT00459862|Other|laboratory biomarker analysis|Correlative study
1784049|NCT00459862|Drug|pazopanib hydrochloride|Given orally
1784050|NCT00459875|Drug|sunitinib malate|
1784051|NCT00459888|Device|PolarCath Peripheral Dilatation System (Boston Scientific)|
1784052|NCT00459901|Drug|Erlotinib and capecitabine|
1784053|NCT00459914|Device|cpap treatment during sleep|CPAP
1784054|NCT00459927|Device|Floseal tonsillectomy|
1784055|NCT00459927|Device|Coblation tonsillectomy|
1784056|NCT00459940|Drug|Pioglitazone|
1784057|NCT00459953|Drug|Extended treatment|All participants receive an open label phase treatment that includes nicotine patch and cognitive behavior therapy for a period of 10 weeks. The extended treatment group received an additional 9 sessions of cognitive and behavioral skills training.
1784058|NCT00459966|Procedure|Preoperative rehabilitation|
1784059|NCT00459979|Drug|sunitinib malate|Sunitinib will be dosed at 50 mg p.o. daily
1784060|NCT00459979|Procedure|conventional surgery|nephrectomy
1784061|NCT00459992|Drug|Betahistine Hydrochloride|
1784062|NCT00460018|Behavioral|Diet, Exercise, and Breastfeeding Intervention|"Phase I (Pregnancy Program from GDM diagnosis to delivery): One in-person session with the lifestyle coach, two phone calls with the lifestyle coach, and one in-person session with the lactation consultant
Phase II (Early Post-partum Period from delivery to 6 weeks post-partum): Two to four routine phone calls with the lactation consultant
Phase III (Late Post-partum Period 6 weeks to 7 months postpartum): Two in-person sessions with the lifestyle coach, up to 11 phone calls with the lifestyle coach, and two to three routine calls with the lactation consultant
Phase IV (Maintenance Phase 8 months to 1 year postpartum): One newsletter from the lifestyle coaches, two recipe letters and continue calls with the lifestyle coach (optional)"
1784063|NCT00460031|Drug|ketoconazole|400 tid
1784064|NCT00460031|Drug|lenalidomide|Lenalidomide will be administered daily at a dose of 25mg po qd on days 1-21 of the cycle.
1784065|NCT00460031|Drug|therapeutic hydrocortisone|20mg qam 10mg qhs
1784066|NCT00460057|Drug|Alendronate|Take two tablets (alendronate 10 mg) once weekly with a full glass of plain water in the morning after an overnight fast and to refrain from lying down or taking any other beverage or food for at least 1 h thereafter
1784067|NCT00460083|Drug|Elidel(R) (pimecrolimus 1%)|
1784068|NCT00460083|Device|EpiCeram(R) -ceramide based barrier repair cream|
1784069|NCT00460096|Drug|Kamada-API|
1784070|NCT00460837|Drug|bowel preparation: senna & gastrofin versus picolax (standard)|The intervention is a bowel cleansing procedure
1784071|NCT00460850|Drug|peginterferon alfa-2a (40KD) [PEGASYS]|180 micrograms sc weekly for 48 weeks
1784072|NCT00460863|Procedure|using cool versus warm dialysate during hemodialysis|
1784073|NCT00460876|Drug|Topotecan|
1784074|NCT00460889|Procedure|donor nephrectomy|The objective of this protocol is to look at the outcomes of laparoscopic donor nephrectomy performed by using hand assisted (HA)or entirely laparoscopic (LDN) surgical techniques. To define the advantages of each technique, we will use records of patients who underwent laparoscopic live kidney donation with HALDN.
1784075|NCT00460902|Device|Transcranial Magnetic Stimulation (TMS)|
1784076|NCT00460915|Drug|Lacidipine & Amlodipine|
1784077|NCT00460928|Drug|intravenous immune globulin (IVIG)|
1784078|NCT00460941|Drug|Placebo|sc weekly
1784079|NCT00460941|Drug|Taspoglutide 20mg|sc weekly
1784080|NCT00460941|Drug|Taspoglutide 20mg-30mg|sc weekly
1784081|NCT00460941|Drug|Taspoglutide 20mg-40mg|sc weekly
1784082|NCT00460954|Drug|Sinemet® controlled release (Carbidopa/levodopa)|
1784083|NCT00460967|Device|Rheopheresis|8 rheopheresis treatments over 10 wks.
1784084|NCT00460967|Device|Rheopheresis|Sham treatment
1784085|NCT00460980|Behavioral|Virtual reality laparoscopic simulator training|The aim of this project is to determine whether a structured approach to teaching laparoscopic skills to beginning surgeons with a virtual reality trainer will improve skills prior to actual operative experience. We aim to show that with the virtual reality trainer, operative skills will be improved and that overall operative time will be decreased.
1784086|NCT00460993|Drug|Lunesta|"Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.
Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4."
1784087|NCT00461006|Drug|Actos|45mg po daily
1784088|NCT00461006|Drug|aleglitazar|0.6mg po daily
1784089|NCT00461019|Procedure|Implantation and activation of the vagus nerve stimulator|Implantation of the nerve stimulator, cuff nerve electrode and RV sensing lead
1784090|NCT00461032|Drug|montelukast|montelukast 5 mg tablet Once a day (QD) for 8 weeks
1784091|NCT00461032|Drug|Comparator: Placebo|Placebo to montelukast QD for 8 weeks
1784092|NCT00461045|Drug|MRZ 0.5 mg/m^2|NPI-0052 0.5 mg/m2 administered IV over 2 hours on Days 1, 4, 8, and 11 in each 21-day cycle
1784093|NCT00461058|Drug|Actos|Titrated to an individual maximum tolerated dose up to 45mg p.o. daily
1784094|NCT00461058|Drug|aleglitazar|Titrated to an individual maximum tolerated dose up to 0.3mg p.o. daily
1784095|NCT00461071|Behavioral|Guided Self-help for Bulimia nervosa|bibliotherapy
1784096|NCT00461084|Drug|BIAXIN (CLARITHROMYCIN)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
1784097|NCT00461084|Drug|Biaxin (clarithromycin)|Biaxin (clarithromycin) 500 mg will be administered by mouth twice daily for 12 weeks in all patients. In H. pylori positive patients, Prevpak standard therapy (lansoprazole, amoxicillin, clarithromycin) will be administered for the first 2 weeks.Following Biaxin (clarithromycin) antibiotic therapy, the patient will be reassessed for eradication of H. pylori if previously present.
1784098|NCT00461097|Drug|Egg oral immunotherapy|Egg white solid powder
1784099|NCT00461097|Drug|Control Group|Placebo for egg white solid
1784100|NCT00461110|Drug|BMS-663513|mg/kg, IV, 0.3, 1,3,6,10 mg/kg, q 3 wks, 12 weeks
1784101|NCT00461123|Drug|Vardenafil (Levitra, BAY38-9456)|One tablet vardenafil 10 mg with a glass of water the evening before ablation of prostate; the second dose (vardenafil 20 mg) with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
1784102|NCT00461123|Drug|Placebo|One placebo tablet with a glass of water the evening before ablation of prostate; the second placebo dose with a glass of water approximately one hour before Greenlight(TM) laser ablation of prostate commenced.
1784103|NCT00461136|Drug|Aliskiren|
1784104|NCT00461149|Drug|Octreotide-LAR|
1784105|NCT00461162|Behavioral|Internet DSMP|Internet Dyspnea Self-management Program (i-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. I-DSMP participants will receive their accessing the modules through the website and participating in weekly online group chat sessions with the research nurse and other participants.
1784106|NCT00461162|Behavioral|Face-to-Face Dyspnea Self-management|Face-to-Face Dyspnea Self-management Program (f-DSMP): Education and skills training for dyspnea management; an individualized tailored exercise plan; self-monitoring of exacerbation symptoms and exercise; and reinforcement/personalized feedback for self management. F-DMSP participants will attend face-to-face group education sessions. The f-DSMP participants will be provide with a hard copy of the education modules and will participate in six 1-hour group sessions for a period of 6 weeks.
1784107|NCT00461162|Behavioral|Attention Control|6 Monthly general health education classes and biweekly telephone calls from a health educator.
1784108|NCT00461201|Procedure|Nurse practitioner care of patients|
1784109|NCT00461214|Other|Participation in laparoscopic training curriculum|General Surgery Training Outcome
1784110|NCT00461253|Device|Levonorgestrel-releasing IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
1784111|NCT00461253|Device|Copper IUD|"This is a case-control-study; strictly speaking the category intervention type does not apply to this study."
1784112|NCT00461266|Drug|enfuvirtide [Fuzeon]|90mg sc bid
1784113|NCT00461266|Drug|Antiretroviral therapy|As prescribed
1784114|NCT00461279|Behavioral|Cognitive Behavior Therapy|Reframing and understanding cognitions of depression
1784115|NCT00461279|Behavioral|Interpersonal Psychotherapy|Established psychotherapy for depression
1784116|NCT00461292|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U injection at Day 1 followed by botulinum toxin Type A 200 U injection > Week 12; injections into detrusor
1784117|NCT00461292|Biological|botulinum toxin Type A (300U)|botulinum toxin Type A 300 U injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
1784118|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 followed by botulinum toxin Type A 200 U injection > 12 weeks; injections into detrusor
1784119|NCT00461292|Other|Normal saline (Placebo); botulinum toxin Type A (300U)|Placebo injection on Day 1 followed by botulinum toxin Type A 300 U injection > Week 12; injections into detrusor
1784120|NCT00461305|Drug|DRSP 3 mg/EE 20 µg (13 cycles)|1 tablet per day Drospirenone (DRSP) 3 mg/Ethinylestradiol (EE) 20 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 52 weeks (13 cycles)
1784121|NCT00461305|Drug|DRSP 3 mg/EE 30 µg (6 cycles)|1 tablet per day Drospirenone 3 mg/Ethinylestradiol 30 µg for 24 days and 1 tablet per day placebo for 4 days in each 28-day cycle; treatment duration 24 weeks (6 cycles)
1784122|NCT00461318|Procedure|Individual placement and support (vocational rehabilitation)|
1784123|NCT00461331|Drug|Insulin Aspart|Either one of these insulins were given to the patient as the second insulin (depending on which was given as the first one, the other insulin was insulin 2). Patients used this insulin in the same dose as they did prior to entering the study.
1784124|NCT00461331|Drug|Insulin Lispro|Patients were given either insulin Aspart or Lispro in test period 1. Then they were switched to the other insulin in test period 2.
1784125|NCT00461344|Drug|Docetaxel|
1784126|NCT00461344|Drug|Doxorubicin|
1784127|NCT00461370|Drug|SRX251|
1784128|NCT00461396|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Male and females, 18 to 50 years of age, after a first clinical demyelinating event suggestive of multiple sclerosis or with onset of RRMS within the past 12 months
1784129|NCT00461409|Drug|Intravenous levetiracetam|IV levetiracetam escalating to 40mg/kg load and daily 10mg/kg maintenance
1784130|NCT00461422|Drug|Ganirelix|sc injection of Ganirelix 0.25 mg per day
1784131|NCT00461435|Procedure|hyperbaric oxygen therapy|
1784132|NCT00461448|Dietary Supplement|Potassium supplement|Patients were randomly allocated to receive either an EGJ containing 234.5 mmol microcrystalline KCl a total of 6000 mg of K in 2 EGJ, but split into 2 intakes daily) or PGJ for 28 days.
1784133|NCT00461461|Procedure|meeting nurses / physicians, quality improvement sessions|"For each iatrogenic indicator, the interventions are:
Meeting with the ICU staff to discuss the epidemiology of patients on each theme.
Pocket card with guidelines on the theme and ICU protocol in each study ICU.
Feedback meeting twice a month on errors in the unit, preventability, and appropriate changes in procedures on the subject."
1784134|NCT00461474|Behavioral|Shoulder strengthening exercises|
1784135|NCT00461474|Behavioral|Movement Optimization|
1784136|NCT00461487|Behavioral|Active control on hygiene and nutrition|The active control group will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
1784137|NCT00461487|Behavioral|Families Talking Together|The intervention will take place in a primary healthcare clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with a social work interventionist for approximately 25 minutes while her child is being examined by the physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
1784138|NCT00461500|Drug|Salmeterol xinafoate/fluticasone propionate combination|SFC 100
1784139|NCT00461500|Drug|Fluticasone propionate|FP 100
1784185|NCT00461864|Procedure|ultrasound examination of the hip|
1784186|NCT00461890|Drug|Injectable Naltrexone|
1784187|NCT00461903|Drug|Perindopril|Perindopril 4 mg or matching placebo , 1 tablet administrated once daily for the first 2 weeks. If tolarable, dosage increased to 8mg/day until the end of the study (
1784140|NCT00461513|Behavioral|Intervention|Disease management has emerged as a promising strategy to improve the outcomes of patients with CHF. Disease management in this study will use a multidisciplinary collaborative care, leveraging health information technology, and focusing on patient self-care.Collaborative care is the use of multidisciplinary teams to deliver evidence-based treatment to a defined population of patients with chronic illness.
1784141|NCT00461526|Drug|crofelemer|125 mg crofelemer vs. placebo
1784142|NCT00461539|Other|Treatment as usual|Those participants receiving standard care will be referred to special programs as needed to reduce their involvement in risky health behaviors.
1784143|NCT00461539|Behavioral|Behavioral health intervention|Participants assigned to the health education intervention will attend 10 weekly education sessions that will be led by trained health educators. Parents or guardians may be asked to attend sessions depending on their interest in the intervention and the age of the youth participant. Topics covered will include teenage smoking, alcohol and drug abuse, risky sexual behaviors, and obesity. Cognitive-behavioral strategies, role playing, and media clips will be used to stimulate discussion and involvement in the intervention.
1784144|NCT00461552|Drug|Metreleptin (Leptin)|weight based, sub-cutaneous injection, twice daily
1784145|NCT00461565|Drug|Sildenafil|A1) Two dosis of 200 mg Sildenafil orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
1784146|NCT00461565|Drug|Placebo|A2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
1784147|NCT00461565|Drug|Vardenafil (Levitra, BAY38-9456)|B1) At least 15 dosis of 20 mg Levitra orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
1784148|NCT00461565|Drug|Placebo|B2) Matching Placebo orally. Patients receive either A1) or A2) in cross over design with either B1) or B2).
1784149|NCT00461578|Drug|Chlorproguanil-dapsone + artesunate|
1784153|NCT00461617|Drug|Mitiglinide|10mg tablet, 10mg TID
1784154|NCT00461630|Drug|ER niacin/laropiprant|
1784155|NCT00461630|Drug|simvastatin|40 mg simvastatin tablet orally per day as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
1784156|NCT00461630|Drug|ezetimibe/simvastatin|10 mg ezetimibe plus 40 mg simvastatin in single tablet taken once daily as background LDL-lowering treatment allocated at entry based on previous statin treatment and total cholesterol level
1784157|NCT00461643|Drug|Clomiphene citrate, metformin, metformin plus clomiphene citrate, gonadotropins|
1784158|NCT00461656|Drug|Preoperative conjunctival irrigation with 5% or 1.25% PI|Before initiation of surgery, children will have their conjunctival fornices irrigated with 5 ml PI 5% or with 5 ml PI 1.25%
1784159|NCT00461669|Procedure|ultrasound examination of the hip|
1784160|NCT00461682|Drug|SB-705498|
1784161|NCT00461695|Biological|Vaccination against TBEV (FSME Immun CC)|Intramuscular injection into the left (or right) deltoid muscle of 0.5 ml FSME Immun CC for adults (2.4 ug of formalin inactivated TBEV antigen) at time point 0, after 4 weeks and after 24 weeks.
1784162|NCT00461708|Drug|Erlotinib|100 mg, PO, once per day
1784163|NCT00461708|Drug|Gemcitabine|1000 mg/m2, IV, on Days 1, 8 and 15 in 4-week cycles
1784164|NCT00461734|Other|RV lead placement site|Patients randomised to RV apical or high septal lead placement site
1784165|NCT00461747|Drug|VBMCP/VBAD/Velcade|"VBMCP: Vincristine, 0,03 mg/Kg (iv) day 1, BCNU, 0,5 mg/Kg iv day 1, Cyclophosphamide, 10 mg/Kg iv day 1, Melfalan, 0,25 mg/Kg oral days 1 to 4 Prednisone, 1 mg/Kg oral days 1 to 4; 0,5 mg/Kg oral days 5 to 8 and 0,25 mg/Kg oral days 9 to 12.
VBAD : Vincristine, 1mg via iv day 1, BCNU, 30 mg/m2 iv day 1, Adriamycine, 40mg/m2 iv day 1 Dexamethasone, 40 mg oral days 1 to 4, 9 to 12 and 17 to 20."
1784166|NCT00461747|Drug|Thalidomide/Dexamethasone|"Thalidomide day 1, cycle 1 (50 mg/day v.o). If toxicity < grade 2, dose will be 100 mg/day on day 15, cycle 1 and 200 mg/day on day 1, cycle 2.
Dexamethasone:40 mg/day v.o.days 1 to 4 and 9 to 12, with a period without treatment of 16 days"
1784167|NCT00461747|Drug|Velcade/Thalidomide/Dexamethasone|"Thalidomide: day 1 cycle 1 (50 mg/day).If toxicity is < grade 2, the dose increased (100 mg/day) at day 15 cycle 1 and (200 mg de Thalidomide) at day 1 cycle 2.
Dexamethasone: 40 mg/day v.o days 1 to 4 and 8 to 11, with a period without treatment of 17 days.
Velcade: 1,3 mg/m2 iv twice a week (days 1, 4, 8 and 11) with a period without treatment of 17 days"
1784168|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See Detailed Description.
1784169|NCT00461760|Procedure|Cervical cancer screening undertaken by HPV testing as a single primary screening test with cytology triage of women who are HPV positive|See detailed description.
1784170|NCT00461773|Drug|Letrozole|Letrozole 2.5 mg po qd
1784171|NCT00461773|Drug|Bevacizumab|bevacizumab 10 mg/kg IV
1784172|NCT00461786|Drug|pemetrexed|900 mg/m2, intravenous (IV), every 21 days, until disease progression
1784173|NCT00461799|Drug|orlistat|
1784174|NCT00461812|Drug|Mometasone|
1784175|NCT00461812|Drug|Advair|
1784176|NCT00461825|Drug|Cyclosporin A: C0: 75–125ng/ml-dose adapted in the 3 groups|
1784177|NCT00461825|Drug|Group A: CsA + Azathioprine(1 to 2 mg/kg/day)|
1784178|NCT00461825|Drug|Group B: CsA + CellCept(500 mg x 2/day)|
1784179|NCT00461825|Drug|Group C: CsAm|
1784180|NCT00461838|Procedure|multidisciplinary laparoscopy|Multidisciplinary (with active involvement of the colorectal surgeon/urologist) fertility-sparing CO2 laser laparoscopic radical excision of deep infiltrating endometriosis.
1784181|NCT00461838|Other|Questionnaires|Patients (n=56) were asked to complete questionnaires regarding quality of life (QOL), pain, fertility and sexuality to compare their status before and after surgery, and their medical files were analyzed.
1784182|NCT00461851|Drug|Gemcitabine|Gemcitabine will be given at a standard dose schedule of 1000 mg/m² on day 1 and 8.
1784183|NCT00461851|Drug|Carboplatin|Carboplatin will be given on day 1 to an AUC of 5.
1784184|NCT00461851|Drug|Sorafenib|Sorafenib will be administered orally daily on days 2-19 at 400 mg bid
1784188|NCT00461916|Drug|Half-Dose Depot Triptorelin|
1784189|NCT00461916|Drug|Reduced-Dose Daily Buserelin|
1784190|NCT00461929|Procedure|bone marrow aspiration|
1784191|NCT00461942|Drug|Green Tea Polyphenols (EGCG/ECG)|
1784192|NCT00461955|Procedure|autologous peripheral blood stem cell transplantation, ex vivo amplified|autologous peripheral blood stem cell transplantation, ex vivo amplified
1784193|NCT00461968|Drug|Ezetimibe and Simvastatin|
1784194|NCT00461981|Biological|TIV, Trivalent Inactivated Influenza Virus Vaccine|0.25 mL will be administered intramuscularly for each of two doses
1784195|NCT00461981|Biological|FluMist, Influenza Virus Vaccine Live|0.5 mL will be administered intranasally (approximately 0.25 mL into each nostril) for each of two doses
1784196|NCT00461994|Behavioral|diet|
1784197|NCT00461994|Behavioral|exercise|
1784198|NCT00461994|Behavioral|diet and exercise|
1784199|NCT00462007|Drug|Stalevo|Oral 3-4 daily doses for 6 weeks
1784200|NCT00462020|Drug|5 days of IV antibiotics (ceftriaxone and metronidazole)|5 days of IV antibiotics (ceftriaxone and metronidazole once a day dosing)
1784201|NCT00462020|Drug|Home with oral antibiotics when eating (ampicillin/clavulanic acid)|Augmentin 40mg/kg BID when tolerating POs to complete 7 days total
1784202|NCT00462046|Drug|Berberine|
1784203|NCT00462059|Behavioral|Treatment|
1784204|NCT00462072|Drug|Infliximab|Subjects will be on a stable dose of methotrexate 12.5 to 20 mg per week and will be started on infliximab 5 mg/kg.
1784205|NCT00462098|Device|hyperbaric oxygen|40 sessions of 100% oxygen at 2 atmospheres of pressure for 2 hours each
1784206|NCT00462098|Device|non-treated control group|no change from routine care, no HBO
1784207|NCT00462111|Drug|Indometacin|
1957136|NCT02525094|Biological|MEDI9929|Subcutaneous (under the skin) injections administered on Day 1, weeks 2, 4, 6, 8, 10.
1784210|NCT00462137|Procedure|Sleep Studies|
1784211|NCT00462150|Behavioral|home-based emotional disclosure|
1784212|NCT00462150|Behavioral|time management control condition|
1784213|NCT00462176|Procedure|multidisciplinary laparoscopy|Laparoscopic segmental bowel resection for deep infiltrating colorectal endometriosis performed by an experienced colorectal surgeon.
1784214|NCT00462176|Other|Questionnaires|All 45 patients were asked to complete the Oxford Endometriosis Quality of Life questionnaire, a sexual activity questionnaire, visual analogue scales (VAS) for dysmenorroe, chronic pelvic pain and deep dyspareunia, and to answer questions about medication and fertility, to compare their status before surgery and at the moment of the evaluation (December 2008).
1784215|NCT00462189|Drug|Immunotoxin therapy|
1784216|NCT00462189|Drug|CAT-8015 Immunotoxin|
1784217|NCT00462189|Procedure|Biological therapy|
1784218|NCT00462202|Drug|sulodexide|
1784219|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Vietnam/1203/2004
1784220|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Vietnam/1203/2004
1784221|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen strain A/Indonesia/05/2005
1784222|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 6-month booster vaccination with the H5N1 vaccine containing 7.5 mg HA antigen strain A/Indonesia/05/2005
1784223|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 12-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
1784224|NCT00462215|Biological|Whole virion, Vero cell-derived influenza vaccine containing H5N1 HA antigen|Vaccination on Day 0 and Day 21 with the whole virion, Vero cell-derived influenza vaccine containing 7.5 µg H5N1 hemagglutinin (HA) antigen (without adjuvant) of the A/Vietnam/1203/2004 strain + 24-month booster vaccination with the H5N1 vaccine containing 3.75 mg HA antigen of the A/Indonesia/05/2005 strain
1784225|NCT00462228|Drug|Memantine|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
1784226|NCT00462228|Drug|Placebo|After randomization of the subject, subjects will be titrated up to 20 mg of memantine or placebo per day. Memantine and placebo are provided as 5 mg tablets. Subjects will be started at 5 mg per day. The dose will be increased by 5 mg increments to 10 mg per day (5 mg twice per day), 15 mg per day (5 mg and 10 mg as separate doses) and 20 mg per day (10 mg twice per day). The minimum interval between dose increases will be one week. Subjects will take memantine or placebo for 12 weeks during each part of the crossover study. Subjects are randomized to begin either memantine or placebo in each arm of the study.
1784290|NCT00462644|Drug|RSI sedation with etomidate/succinylcholine|etomidate 0.3 mg/kg IV plus succinylcholine 1 mg/kg IV
1784349|NCT00462995|Drug|Erlotinib|150mg once a day for 28 days
1784227|NCT00462241|Procedure|chiropractic treatment|Participants in the therapy group undergo a physical examination by an experienced, primary sector chiropractor, lasting up to one hour. The chiropractors choose an individual treatment strategy based on a combination of their findings, the patient history, and a standardized protocol reflecting routine practice. The standardized treatment protocol includes high velocity, low amplitude manipulation directed towards the thoracic and/or cervical spine in combination with any of the following: Joint mobilisation, soft tissue techniques, stretching, stabilising or strengthening exercises, heat or cold treatment, and advice. The protocol specifies up to ten treatment sessions of approximately 20 minutes, 1-3 times per week, or treatment until the patient is pain free. The chiropractors record the types of treatment rendered at sessions.
1784228|NCT00462241|Other|Self-management|Advice group: Advice is directed towards promoting self-management. The participants are told that their chest pain generally has a benign, self limiting course. The participants receive individual instructions regarding posture and two or three exercises aiming to increase spinal or muscle stretch based on clinical evaluation. They are advised to seek medical attention for re-evaluation (general physician, chest pain clinic or emergency department) in case of severe or unfamiliar chest pain. The session lasts on average 15 minutes. Further, the advice group is also asked not to seek any manual treatment for the next four weeks.
1957137|NCT02525094|Biological|Placebo|Subcutaneous (under the skin) injections administered on Day 1, weeks 2, 4, 6, 8, 10.
1784231|NCT00462267|Behavioral|Enriched lifestyle intervention|Multi-component lifestyle intervention
1784232|NCT00462280|Drug|lovastatin|Given PO
1784233|NCT00462280|Other|placebo|Given PO
1784234|NCT00462280|Procedure|biopsy|Correlative studies
1784235|NCT00462280|Procedure|laboratory biomarker analysis|Correlative studies
1784236|NCT00462306|Procedure|Survey: Berlin questionnaire|Completion of questionnaire
1784237|NCT00462319|Behavioral|Education, weight reduction and physical exercise|
1784238|NCT00462332|Drug|Fludarabine|Induction therapy
1784239|NCT00462332|Drug|Campath|Induction therapy
1784240|NCT00462332|Procedure|Transplant|Post-induction therapy
1784241|NCT00462332|Drug|Campath|Post-induction therapy
1784242|NCT00462332|Drug|Fludarabine|Induction therapy
1784243|NCT00462332|Drug|Campath|Induction therapy
1784244|NCT00462332|Drug|Campath|Post-induction therapy
1784245|NCT00462345|Drug|rituximab|1000 mg i.v. on Days 1 and 15
1784246|NCT00462345|Drug|Methotrexate|10 to 25 mg/week p.o. or parenteral from Day 1 through Week 24
1784247|NCT00462345|Drug|Corticosteroid or NSAID|≤10 mg/day prednisone p.o., or equivalent corticosteroid, or NSAIDs p.o. from Day 1 through Week 24
1784248|NCT00462345|Dietary Supplement|Folate|≥5 mg/week, once daily or b.i.d. from Day 1 through Week 24
1784249|NCT00462358|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
1784250|NCT00462358|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
1784251|NCT00462371|Device|Insulin pump (CSII)|
1784252|NCT00462384|Drug|Methoxy Polyethylene Glycol-epoetin Beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously every 4 weeks (at Weeks 4, 8, 12, 16, 20, 24, 28 and 32). The starting dose will be 1.2 mcg/kg body weight. Thereafter, throughout the duration of study the dose adjustments will be performed depending on the hemoglobin value.
1784253|NCT00462397|Drug|carboplatin|
1784254|NCT00462397|Drug|cisplatin|
1784255|NCT00462397|Drug|paclitaxel|
1784256|NCT00462397|Procedure|neoadjuvant therapy|
1784257|NCT00462397|Radiation|brachytherapy|
1784258|NCT00462397|Radiation|radiation therapy|
1784259|NCT00462410|Other|counseling intervention|
1784260|NCT00462410|Procedure|psychosocial assessment and care|
1784261|NCT00462423|Drug|Avastin|Avastin 10 mg/kg IV every 2 weeks (without rest period).
1784262|NCT00462423|Drug|Abraxane|Abraxane 150 mg/m2 IV weekly for 3 weeks of a 28-day cycle.
1784263|NCT00462436|Behavioral|Consumption of Dietary Portfolio|The study involves following an aggressive low fat diet that is high in viscous fiber, nuts and soy protein. The diet is individually tailored to meet individual participants needs.
1784264|NCT00462449|Device|Functional Electrical Stimulation (FES) through the Ness H200|Specialized exercises will be presented to the participants in this group. They will be instructed on how to attach and complete this exercise program utilizing the FES device.
1784265|NCT00462462|Drug|Ethanol 96% Gel|
1784266|NCT00462462|Drug|Ethanol 98% Solution|
1784267|NCT00462475|Drug|Recombinant Growth Hormone, Genotropin (Pfizer)|
1784268|NCT00462488|Drug|Vicinium|Intravesical administration of Vicinium
1784269|NCT00462501|Biological|bevacizumab|
1784270|NCT00462501|Drug|fluorouracil|
1784271|NCT00462501|Drug|leucovorin calcium|
1784272|NCT00462501|Drug|oxaliplatin|
1784273|NCT00462501|Procedure|conventional surgery|
1784274|NCT00462501|Radiation|radiation therapy|
1784275|NCT00462540|Drug|Formoterol Fumurate inhalation solution 20 mcg|
1784276|NCT00462540|Drug|Ipratropium bromide 18 mcg and albuterol sulfate 103 mcg|
1784277|NCT00462553|Drug|sunitinib malate|Given orally
1784278|NCT00462553|Drug|gemcitabine hydrochloride|Given IV
1784279|NCT00462566|Device|motor cortex stimulation|
1784280|NCT00462592|Drug|budesonide|inhaled budesonide turbuhaler 200ug taken 1 puff morning & 1 puff evening.
1784281|NCT00462592|Drug|montelukast|montelukast 5 mg ( < 15 years) or 10 mg (and matching placebo)will be taken 1 tab in the evening
1784282|NCT00462592|Other|placebo|placebo
1784283|NCT00462605|Drug|entinostat|Given PO
1784284|NCT00462605|Drug|sargramostim|Given SC
1784287|NCT00462631|Device|Paclitaxel Eluting Balloon|Paclitaxel eluting balloon
1784288|NCT00462631|Device|paclitaxel eluting stent|paclitaxel eluting stent
1784289|NCT00462631|Device|bare metal stent|bare metal stent
1784291|NCT00462644|Drug|RSI sedation with fentanyl/midazolam/succinylcholine|100 micrograms fentanyl IV, plus 5 mg midazolam IV, plus 1 mg/kg succinylcholine IV
1784292|NCT00462657|Genetic|polymerase chain reaction|
1784293|NCT00462657|Other|bronchoalveolar lavage|
1784294|NCT00462657|Other|immunoenzyme technique|
1784295|NCT00462657|Other|laboratory biomarker analysis|
1784296|NCT00462657|Procedure|bronchoscopy|
1784297|NCT00462657|Procedure|management of therapy complications|
1784298|NCT00462670|Drug|OPC-41061(Tolvaptan)|0, 15mg of OPC-41061 per day for 7days p.o. administration
1784299|NCT00462696|Drug|docetaxel|
1784300|NCT00462696|Drug|epirubicin hydrochloride|
1784301|NCT00462696|Procedure|conventional surgery|
1784302|NCT00462696|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1784303|NCT00462696|Procedure|neoadjuvant therapy|
1784304|NCT00462696|Procedure|radiomammography|
1784305|NCT00462709|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
1784306|NCT00462722|Drug|Ibuprofen|400 mg with each exercise session (up to 5 days per week) for 9 months
1784307|NCT00462722|Drug|Placebo|with each exercise session (up to 5 days per week) for 9 months
1784308|NCT00462722|Behavioral|musculoskeletal-loading exercise|Exercise training program designed to increase bone and muscle mass, including weight lifting and weight-bearing exercises such as jumping in place and treadmill walking up to 5 days per week for 9 months
1784314|NCT00462748|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40mg. once daily tablet formulation, all tablet form, taken orally, cholesterol lowering medication.
1784315|NCT00462748|Drug|Comparator: atorvastatin|atorvastatin 40mg. once daily tablet formulation, all tablet form, taken orally
1784316|NCT00462748|Drug|Comparator: rosuvastatin|rosuvastatin 10 mg. once daily tablet formulation, all tablet form, taken orally.
1784317|NCT00462761|Drug|AC220|Powder in bottle formulation supplied as 50mg or 350 mg in glass, crimped serum vials. Requires reconstitution by a pharmacist, and must be stored securely and protected from light.
1784318|NCT00462774|Procedure|Intramyocardial injection of autologous CD133+ marrow cells|
1784319|NCT00462787|Biological|filgrastim|
1784320|NCT00462787|Drug|clofarabine|
1784321|NCT00462787|Drug|dexamethasone|
1784322|NCT00462787|Drug|thiotepa|
1784323|NCT00462787|Drug|topotecan hydrochloride|
1784324|NCT00462787|Drug|vinorelbine tartrate|
1784325|NCT00462813|Drug|oral microencapsulated diindolylmethane|
1784326|NCT00462813|Genetic|polymerase chain reaction|
1784327|NCT00462813|Other|cervical Papanicolaou test|
1784328|NCT00462813|Other|cytology specimen collection procedure|
1784329|NCT00462813|Procedure|colposcopic biopsy|
1784330|NCT00462826|Biological|ziv-aflibercept|
1784331|NCT00462839|Procedure|blood loss estimation|Participants were randomized in blocks, by provider type to view either the four calibrated stations or the four non-calibrated stations. The order of the volumes within each set of stations was randomized. Participants received a data card for each station on which they wrote the volume estimated. After each station, the data card was collected. Alterations to the estimations were not allowed once the answers were recorded. Subjects were then crossed over to the other group and asked to estimate the blood volumes in the non-calibrated drapes if they had first viewed the calibrated drape or the calibrated drape if they had viewed the non-calibrated drape. The order of viewing the four volumes was again randomized. The volumes were the same at the corresponding station for the calibrated and non-calibrated stations so the impact of the calibration markings on accuracy could be determined.
1784332|NCT00462852|Drug|dalteparin|
1784333|NCT00462852|Drug|gemcitabine hydrochloride|
1784334|NCT00462852|Other|diagnostic laboratory biomarker analysis|
1784335|NCT00462865|Drug|Gemcitabine and Capecitabine and Avastin|avastin administered concurrently with chemotherapy (gemcitabine + capecitabine) for six cycles followed by single agent avastin to complete one year of treatment. Radiation therapy (if planned) will take place after adjuvant chemotherapy completes.
1784336|NCT00462878|Drug|Meropenem|antibiotic
1784337|NCT00462878|Drug|Vancomycin|Antibiotic
1784338|NCT00462878|Drug|Teicoplanin|Antibiotic
1784339|NCT00462891|Other|IT System|
1784341|NCT00462917|Behavioral|Pleiotropic info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.
Genetic counselors communicate results to participants during an in-person disclosure session."
1784342|NCT00462917|Behavioral|AD-only info, in-person disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.
Genetic counselors communicate results to participants during an in-person disclosure session."
1784343|NCT00462917|Behavioral|Pleiotropic info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping as well as additional pleiotropic information.
Genetic counselors communicate results to participants during a telephone disclosure session."
1784344|NCT00462917|Behavioral|AD-only info, phone disclosure|"Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease based on APOE genotyping.
Genetic counselors communicate results to participants during an in-person disclosure session."
1784346|NCT00462956|Drug|Tykerb|lapatinib 1500mg daily
1784347|NCT00462969|Procedure|Sonohysterography|Sonohysterography
1784350|NCT00462995|Drug|Erlotinib|28 days of Erlotinib before surgery in patients with stage I-IIb NSCLC
1784351|NCT00463008|Drug|methotrexate|
1784352|NCT00463008|Other|pharmacological study|
1784353|NCT00463021|Drug|Hectorol (doxercalciferol capsules)|
1784354|NCT00463021|Drug|Zemplar (paricalcitol injection)|
1784355|NCT00463034|Genetic|microarray analysis|
1784356|NCT00463034|Genetic|polymerase chain reaction|
1784357|NCT00463034|Genetic|polymorphism analysis|
1784358|NCT00463034|Other|high performance liquid chromatography|
1784359|NCT00463034|Other|immunohistochemistry staining method|
1784360|NCT00463034|Other|laboratory biomarker analysis|
1784361|NCT00463034|Other|questionnaire administration|
1784362|NCT00463047|Drug|Fentanyl Buccal Tablets Compared With Immediate-Release Oxycodone|Patients will be randomly assigned in a 1:1 ratio either to titrate immediate-release oxycodone first and to titrate FBT second, or to titrate FBT first and immediate-release oxycodone second, followed by 2 double-blind crossover treatment periods (in randomized order). For the double-blind treatment period of the study involving FBT administration, a patient is randomly assigned to receive FBT at the 200, 400, 600, or 800 mcg strength found to be successful during open-label titration. For the double-blind treatment period of the study to which a patient is randomly assigned to receive immediate-release oxycodone, the patient will receive immediate-release oxycodone at the strength (15, 30, 45, or 60 mg) found to be successful during open-label titration.
1784365|NCT00463073|Drug|Cetuximab|
1784366|NCT00463073|Drug|Bevacizumab|
1784367|NCT00463073|Drug|Irinotecan|
1784368|NCT00463086|Drug|isoniazid|A self-administered daily dose of 5mg/kg of Isoniazid or placebo for 12months(300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
1784369|NCT00463086|Drug|Placebo|A self-administered dose of 5mg/kg of placebo (300mg if weight is more than or equal to 50kg and 200mg if weight is less than 50kg)
1784370|NCT00463112|Drug|Sibutramine|
1784371|NCT00463125|Drug|Platelet Gel|
1784372|NCT00463138|Behavioral|Crisis intervention|
1784373|NCT00463151|Drug|rebamipide|0, 60, 150, 300mg of rebamipide per day for 6 weeks into colon
1784374|NCT00463190|Drug|Biothree|
1784375|NCT00463203|Drug|Bevacizumab|10 mg/kg every 2 weeks
1784376|NCT00463203|Drug|Irinotecan|125 mg/m2 non-EIAED or 340 mg/m2 EIAED every 2 weeks
1784377|NCT00463216|Behavioral|A multidisciplinary diagnostic evaluation|
1784378|NCT00463229|Other|Interprofessional Team Approach|Subject in the second group will receive home care services from a team of professional service providers (CCAC Care Coordinator, Registered Nurse, Occupational therapist, Physiotherapist, Speech language pathologist, Nutritionist) and non-professional service providers (personal support workers) with experience and training in stroke care. The team will provide a comprehensive, coordinated and evidence-based approach to stroke rehabilitation through weekly case conferencing, a written interdisciplinary care plan, and joint visits.
1784379|NCT00463242|Drug|Agomelatine|Either 25 mg or 50 mg agomelatine orally once daily
1784380|NCT00463242|Drug|paroxetine|
1784381|NCT00463242|Drug|placebo|
1784382|NCT00463255|Behavioral|diet|
1784383|NCT00463268|Drug|alendronate|alendronate 70 mg every 2 weeks
1784384|NCT00463268|Dietary Supplement|Calcium/Vitamin D|Calcium 500 mg and vitamin D supplementation according to serum level
1784385|NCT00463268|Drug|placebo|identical placebo every 2 weeks
1784386|NCT00463294|Procedure|Coronary Artery Bypass Graft with the use of CPB|Coronary Artery Bypass Graft (CABG) using median sternotomy, CPB, cardioplegia and complete cross-clamp and no associated or concomitant surgical procedures
1784387|NCT00463294|Procedure|Coronary Artery Bypass Graft without the use of CPB|Coronary Artery Bypass Graft (CABG) with no associated or concomitant surgical procedures, using median sternotomy and without CPB and cardioplegia
1784388|NCT00463320|Drug|Pazopanib eye drops and Allergen Refresh Plus eye drops|
1784389|NCT00463346|Drug|Acamprosate|Acamprosate 1998 mg tid
1784390|NCT00463346|Drug|Placebo|Placebo
1784391|NCT00463359|Drug|Imiquimod cream|
1784392|NCT00463359|Procedure|curettage and cautery|
1784393|NCT00463372|Drug|PF-02545920|
1784394|NCT00463385|Drug|Pomalidomide|
1784395|NCT00463385|Drug|Prednisone|Participants will take oral prednisone in the evening for 3 cycles of 28 days each (up to 84 days). The dose will be as follows: 1st cycle = 30 mg daily, 2nd cycle = 15 mg daily, 3rd cycle = 15 mg every other day.
1784396|NCT00463385|Drug|Placebo to pomalidomide|Matching pomalidomide placebo tablets
1784397|NCT00463385|Drug|Placebo to prednisone|Matching prednisone placebo tablets
1784398|NCT00469430|Drug|cefotaxim and metronidazol|iv administration for at least 24 h
1784399|NCT00469443|Drug|Irinotecan|Irinotecan 150mg/m2 IV on day 1 every 2 weeks for 10 cycles
1784400|NCT00469443|Drug|5-Fluorouracil|5-Fluorouracil 400 mg/m2 infused over 10 min IV and 5-FU 600 mg/m2 infused over 22 hours IV, on Day 1 and 2 (De Grammont regimen), every 2 weeks for 10 cycles
1784401|NCT00469443|Drug|Leucovorin|Leucovorin 200 mg/m2 infused over 2 hours IV, on day 1 and 2 every 2 weeks for 10 cycles
1784402|NCT00469443|Drug|Capecitabine|Capecitabine 2000mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
1784403|NCT00469443|Drug|Bevacizumab|Bevacizumab 5mg/kg IV on day 1 every 2 weeks for 10 cycles
1784404|NCT00469443|Drug|Bevacizumab|Bevacizumab 7,5mg/kg IV on day 1 every 3 weeks for 6 cycles
1784405|NCT00469443|Drug|Irinotecan|Irinotecan 250mg/m2 IV on day 1 every 3 weeks for 6 cycles
1784406|NCT00469456|Drug|Memantine|Memantine 20mg (10mg twice daily) oral administration for 12 weeks
1784407|NCT00469456|Drug|placebo|Placebo oral administration twice daily for 12 weeks
1784408|NCT00469469|Drug|Bevacizumab|
1784409|NCT00469482|Device|RASS Targeting plus BIS Monitoring|Providing patient sedation utilizing standard of care methods (RASS) plus BIS monitoring
1784410|NCT00469482|Other|RASS Targeted|Patient sedation utilizing standard of care methods (RASS targeted)
1784411|NCT00469495|Drug|Anti-helminthic|
1784412|NCT00469495|Drug|meglumine antimony|
1784413|NCT00469508|Drug|Modafinil|400mg pills taken orally daily for 12 wks.
1784414|NCT00469508|Drug|Placebo|400mg pills taken orally daily for 12 wks
1784415|NCT00469521|Drug|Refresh Tears, 9582X|
1784416|NCT00469534|Procedure|IMRT|
1784417|NCT00469547|Other|62% ethanol in emollient gel|62% ethanol in emollient gel used as a topical male microbicide
1784418|NCT00469547|Drug|Placebo|15% ethanol in emollient gel used as a topical male microbicide
1784419|NCT00469547|Other|15% ethanol in emollient gel|15% ethanol in emollient gel used as a topical male microbicide
1784420|NCT00469560|Drug|Deferasirox|
1784421|NCT00469573|Drug|1. Optive|Optive 15ml- (in the eye) Instill one drop twice daily in each eye
1784422|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
1784423|NCT00469586|Drug|metformin|Tablets, 2000 mg/day.
1784424|NCT00469586|Drug|glimepiride|Tablets, 4 mg/day.
1784425|NCT00469586|Drug|inhaled human insulin|Treat-to-target dose titration scheme, post-prandial, inhalation.
1784426|NCT00469599|Drug|paricalcitol|3 microg 3 times a week. dosage is increased/decreased 50 % every second week according to iPTH, ionised s-calcium and phosphate
1784427|NCT00469599|Drug|alfacalcidol|1 microg 3 times a week, dosage is titrated every second week according to iPTH, phosphate and ionised s-calcium.
1784428|NCT00469612|Device|NeuroVision's NVC treatment for Low Myopia|"NeuroVision's NVC vision correction technology is a method in the treatment of low myopia as the technology is directed at specific neuronal interactions at the level of the visual cortex (area responsible for vision in the brain).
The subject will be exposed to a set of visual stimulations (pattern with black and white lines) and visual threshold level will be obtained. The subject will look at these patterns on a computer. The treatment will be applied in successive 30-40 minute sessions, administered 2-3 times a week, for a total of 40 sessions. Every 5 sessions, subject's visual performance (visual acuity and CSF) will be tested in order to continuously monitor a subject's progress."
1784429|NCT00469612|Other|Control - No intervention|In this group, subjects will not be given any intervention. However, similar to the intervention group, every 5th session subject's visual performance (visual acuity and CSF) will be tested in order to compare the performance with the treatment group.
1784430|NCT00469625|Drug|paricalcitol (initial dose 1 mcg orally per day)|
1784431|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Agilis sheeth|Left atrial catheter ablation guided by introducer using Agilis sheeth
1784432|NCT00469638|Procedure|Left atrial catheter ablation guided by introducer using Non-steerable sheeth|Left atrial catheter ablation guided by introducer using Non-steerable sheeth
1784433|NCT00469651|Biological|MSP 3 Long Synthetic Peptide|Lyophilized MSP3 vaccine adjuvanted in Aluminium hydroxide
1784434|NCT00469651|Biological|MSP3 vaccine|Lyophilized vaccine adjuvanted in Aluminium hydroxide
1784435|NCT00469651|Biological|Hepatitis B vaccine|Hepatitis B vaccine adjuvanted in Aluminium hydroxide
1784436|NCT00469651|Biological|MSP3 candidate vaccine|Lyophilized MSP3 adjuvanted in Aluminium hydroxide
1784437|NCT00469651|Biological|Hepatitis B control vaccine|Hepatitis B vaccine adjuvanted in Aluminium Hydroxide
1784438|NCT00469664|Drug|Guanfacine/Tenex|
1784439|NCT00469690|Drug|Acular, Xibrom|"Acular 5ml (in the eye)Instill one drop into the eye to be operated on four times a day at (6am, 12pm, 6pm, 12am)
Xibrom 5ml (in the eye) Instill one drop into the eye to be operated on two times a day (8am and 8pm)"
1784440|NCT00469703|Drug|Thalidomide|
1784441|NCT00469716|Drug|Hypertonic saline (7.2%) hetastarch (6 %)(200/0.5)|
1784442|NCT00469729|Drug|StemEx®|The stem/progenitor cell based product composed of ex vivo expanded allogeneic umbilical cord blood cells, which is infused to subject at a rate of 1-3 ml/min in combination with non-manipulated cells derived from the same cord blood unit.
1784443|NCT00469755|Drug|Adapalene Gel, 0.1%|Apply once daily in the evening for 12 weeks
1784444|NCT00469755|Drug|Tazarotene Cream, 0.1%|Apply once daily in the evening for 12 weeks
1784445|NCT00469755|Drug|Adapalene Gel, 0.1% + Tazarotene Cream, 0.1%|Apply adapalene Gel, 0.1% once daily in the evening for 6 weeks and Tazarotene Cream, 0.1% once daily in the evening for 6 weeks
1784446|NCT00469768|Drug|dapivirine reservoir intravaginal ring|a silicone elastomer reservoir ring containing 25mg of dapivirine
1784447|NCT00469768|Drug|dapivirine matrix intravaginal ring|a silicone elastomer matrix intravaginal ring containing 25mg of dapivirine
1784448|NCT00469768|Other|placebo intravaginal ring|a silicone elastomer intravaginal ring containing no dapivirine
1784449|NCT00470028|Device|Transcranial Magnetic Stimulation|
1784450|NCT00470041|Drug|administration of two anti-viral drugs (lamivudine and zidovudine) from a new oral formulation|
1784451|NCT00470054|Drug|dasatinib|Given PO
1784452|NCT00470067|Drug|carboplatin|IV
1784453|NCT00470067|Drug|pegylated liposomal doxorubicin hydrochloride|IV
1784454|NCT00470080|Procedure|venepuncture|venepuncture
1784455|NCT00470093|Biological|recombinant interferon alfa|
1784456|NCT00470093|Biological|recombinant interleukin-6|
1784457|NCT00470106|Behavioral|Cognitive remediation|Computer exercises in attention, memory, and speed of processing.
1784458|NCT00470106|Behavioral|Social Cognitive skills training|Group training on emotion perception, social perception, and understanding others' mental states.
1784459|NCT00470106|Behavioral|hybrid intervention|A combination of the two groups listed above.
1784460|NCT00470106|Behavioral|skills training|Skills training in how to identify symptoms of illness and medication side effects.
1784461|NCT00470119|Behavioral|behavioral dietary intervention|A group based modification of the DPP and LookAHEAD lifestyle programs with a goal of 10% weight loss
1784462|NCT00470119|Behavioral|Exercise intervention|Facility based and home-based exercise designed to increase moderate-to-vigorous aerobic activity in participants to 45 mins/day 5 days/week
1784463|NCT00470145|Drug|SB-568859|
1784578|NCT00470847|Drug|Lapatinib|Orally twice daily
1784579|NCT00470847|Procedure|Whole Brain Radiation|15 treatments over a period of 3 weeks
1784580|NCT00470847|Drug|Herceptin|Herceptin 4mg/kg loading dose then 2 mg/kg IV once weekly, then once every three weeks after cycle 3.
1784581|NCT00470860|Behavioral|Participation in LOFTS online tutorial|
1784464|NCT00470158|Dietary Supplement|iron and zinc combined|Children >= 12 months received an average of 5mg zinc/day, 6.25 Iron/day, and 25IU folic acid/day. children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
1784465|NCT00470158|Dietary Supplement|iron and zinc on separate days|Children >= 12 months received an average of 5mg zinc/day, alternating daily with 6.25 Iron/day, and 25IU folic acid/day. Children<12 received half that dose. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
1784466|NCT00470158|Dietary Supplement|iron|Children >= 12 months received an average 6.25 Iron/day, and 25IU folic acid/day. Children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
1784467|NCT00470158|Dietary Supplement|Zinc|Children >= 12 months received an average of 5mg zinc/day. Children<12 received half that dose. This dose was alternated daily with placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
1784468|NCT00470158|Dietary Supplement|placebo|Children received daily placebo. Dissolvable doses were distributed in blister packs and reconstituted with a teaspoon of water. Doses were administered in the morning. For missed doses, the mother gave the child the next morning dose, and a second dose in the evening.
1784470|NCT00470184|Drug|capecitabine|Oral
1784471|NCT00470184|Drug|oxaliplatin|IV
1784472|NCT00470184|Genetic|gene expression analysis|Correlative Study
1784473|NCT00470184|Genetic|microarray analysis|Correlative Study
1784474|NCT00470184|Genetic|reverse transcriptase-polymerase chain reaction|Correlative Study
1784475|NCT00470184|Procedure|adjuvant therapy|Metastatic growth control
1784476|NCT00470184|Procedure|biopsy|Examination of tissue type
1784477|NCT00470184|Procedure|conventional surgery|Tissue removal
1784478|NCT00470184|Procedure|neoadjuvant therapy|Tumor shrinkage
1784479|NCT00470184|Procedure|quality-of-life assessment|Correlative Study
1784480|NCT00470184|Radiation|radiation therapy|Undergoing radiation therapy
1784481|NCT00470197|Drug|alvocidib|Given IV
1784482|NCT00470197|Drug|cytarabine|Given IV
1784483|NCT00470197|Drug|mitoxantrone hydrochloride|Given IV
1784484|NCT00470197|Other|pharmacological study|Correlative study
1784485|NCT00470210|Drug|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week|Peginterferón alfa-2a (40 KD) (Pegasys®) 180 ug/week
1784486|NCT00470210|Drug|Ribavirin (Copegus®) 1600 mg/day|Ribavirin (Copegus®) 1600 mg/day
1784487|NCT00470210|Drug|Epoetin β (450 UI/kg/week)|Epoetin β (450 UI/kg/week)
1784488|NCT00470223|Drug|cisplatin|
1784489|NCT00470223|Drug|doxorubicin hydrochloride|
1784490|NCT00470223|Drug|etoposide|
1784491|NCT00470223|Drug|ifosfamide|
1784492|NCT00470223|Drug|methotrexate|
1784493|NCT00470223|Drug|zoledronic acid|
1784494|NCT00470223|Procedure|conventional surgery|
1784495|NCT00470236|Radiation|Standard WB fractionation|A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
1784496|NCT00470236|Radiation|Shorter WB fractionation|A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
1784497|NCT00470236|Radiation|Standard WB fractionation+Boost|"Whole Breast: A total dose of 50 Gy in 25 fractions in 2-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
Tumour bed: A total dose of 10 Gy in 5 fractions in 2-Gy daily fractions, 5 fractions per week."
1784498|NCT00470236|Radiation|Shorter WB fractionation + Boost|"Whole breast: A total dose of 42.5 Gy in 16 fractions in 2.656-Gy daily fractions, 5 fractions per week (at least 9 fractions per fortnight).
Tumour bed: A total dose of 10 Gy in 4 fractions in 2.5-Gy daily fractions, 4 fractions per week."
1784499|NCT00470249|Drug|carboplatin|
1784500|NCT00470249|Drug|gemcitabine hydrochloride|
1784501|NCT00470262|Drug|Fenofibrate 145mg PO QD|Subjects will be randomized to either fenofibrates or combination of both fenofibrate and pioglitazone
1784502|NCT00470262|Drug|Pioglitazone 45 mg PO QD|Subjects will be randomized to either fenofibrate 145 mg PO QD or a combination of both fenofibrate 145 mg PO QD and pioglitazone 45 mg PO QD
1784503|NCT00470275|Drug|cytarabine|Given IV
1784504|NCT00470288|Procedure|bladder flap during cesarean section|
1784505|NCT00470301|Drug|tipifarnib|Given orally
1784506|NCT00470301|Drug|paclitaxel|Given IV
1784507|NCT00470301|Drug|doxorubicin|Given IV
1784508|NCT00470301|Drug|cyclophosphamide|Given IV
1784509|NCT00470314|Drug|L-Ornithine L-Aspartate|
1784510|NCT00470340|Drug|Oxaliplatin, gemcitabine, cisplatin, lipiodol|Oxaliplatin, gemcitabine, cisplatin, lipiodol
1784511|NCT00470353|Dietary Supplement|calcium carbonate|
1784512|NCT00470353|Dietary Supplement|cholecalciferol|
1784513|NCT00470353|Other|immunohistochemistry staining method|
1784514|NCT00470353|Other|laboratory biomarker analysis|
1784515|NCT00470353|Other|pharmacological study|
1784516|NCT00470353|Procedure|biopsy|
1784521|NCT00470379|Drug|resiquimod|Escalating the dose of resiquimod applied to a fixed area of skin followed by application of topical NY-ESO-1b.
1784582|NCT00470873|Drug|Levitra (Vardenafil, BAY38-9456)|Primary care erectile dysfunction patients for whom physician decided to start the treatment with vardenafil
1785089|NCT00475085|Drug|prochlorperazine|Given orally or IV
1784522|NCT00470392|Drug|Imiquimod|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Imiquimod (5% topical cream) was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
1784523|NCT00470392|Drug|Clobetasol|Each study subject served as his/her own control. For this arm of the study, topical vehicle was applied to one plaque for 5 days. Clobetasol propionate 0.05% was applied to two psoriasis plaques for 5 days. Skin biopsies were taken from half of each of the 3 plaques at specific time points after completion of topical pre-treatment. The other half of the plaques were exposed to UVB light (via Excimer laser). Biopsies were subsequently taken at a specified time point.
1784524|NCT00470405|Drug|oxaliplatin|75-100 mg/m2 iv infusion Approximately 2 hours beginning approximately 30 minutes after the end of ALIMTA infusion on Day 1 of a 14-days cycle
1784525|NCT00470405|Drug|pemetrexed disodium|a novel antifolate with multiple targets.
1784526|NCT00470418|Drug|NIC5-15|a natural product, found in many foods and plants with mild insulin sensitizing effects
1784527|NCT00470418|Drug|Placebo|placebo comparator
1784528|NCT00470444|Procedure|Transfusion with Red Blood Cells|Units of donated Red blood cells
1784529|NCT00470444|Biological|1 unit of donated red blood cells|Units of red blood cells
1784530|NCT00470444|Biological|1 unit of donated red blood cells|Units of donated red blood cells
1784531|NCT00470457|Biological|Allergen specific immunotherapy|
1784532|NCT00470470|Drug|imatinib mesylate|Given orally
1784533|NCT00470470|Other|laboratory biomarker analysis|Correlative studies
1784534|NCT00470483|Drug|Placebo treatment during 8 weeks|comparator
1784535|NCT00470483|Drug|Paroxetine treatment during 8 weeks|treatment drug
1784536|NCT00470496|Drug|HPPH|Given IV
1784537|NCT00470496|Drug|photodynamic therapy|Undergo laser light exposure
1784538|NCT00470496|Procedure|conventional surgery|Undergo surgery
1784539|NCT00470509|Drug|adalimumab (2 subcutaneous 40 mg injections on day 0 and 7)|
1784540|NCT00470522|Drug|Methotrexate and folic acid|
1784541|NCT00470535|Drug|erlotinib hydrochloride|Oral
1784542|NCT00470535|Other|immunohistochemistry staining method|Correlative Study
1784543|NCT00470535|Other|laboratory biomarker analysis|Correlative Study
1784544|NCT00470548|Drug|Abraxane|ABI-007 IV administration following pemetrexed on Day 1 of each cycle (infused over 30 minutes)
1784545|NCT00470548|Drug|Alimta|Pemetrexed IV administration on Day 1 of each cycle (infused over 10 minutes)
1784546|NCT00470561|Drug|Aspirin|Two 325 mg doses of aspirin per day for 6 months
1784547|NCT00470561|Drug|Placebo|Two placebo pills per day for 6 months
1784548|NCT00470574|Biological|QS21|
1784549|NCT00470574|Biological|sialyl Lewisª-keyhole limpet hemocyanin conjugate vaccine|
1784550|NCT00470574|Other|immunoenzyme technique|
1784551|NCT00470574|Other|immunologic technique|
1784552|NCT00470574|Other|laboratory biomarker analysis|
1784553|NCT00470600|Drug|Caldolor|800 milligrams intravenous
1784554|NCT00470600|Other|Normal Saline|Placebo comparator
1784555|NCT00470613|Genetic|SGT-53|For Phase Ib: SGT-53 (2.4 mg DNA per infusion) will be administered in combination with docetaxel at 40 mg/m2 starting dose, cohort 1, cycle 1. SGT-53 will be administered weekly, on day 1 in weeks 2, 3, 5, and 6, and biweekly on days 1 and 4 in weeks 1, 4, and 7. Docetaxel will be administered every 3 weeks (weeks 1, 4, and 7)on day 3. Patients completing cohort 1, cycle 1 without DLT at 40 mg/m2 docetaxel will be allowed to dose escalate to 60 mg/m2 docetaxel in cycles 2 and 3.Cohort 2 (2.4mg DNA/infusion;75mg/m2 Docetaxel) will open 3 weeks after demonstration of 0/3 or ≤1/6 DLTs at docetaxel 60 mg/m2. Cohort 3 (3.6 mg DNA/infusion; 75 mg/m2 Docetaxel) will open after demonstration of 0/3 or ≤1/6 DLTs at SGT-53 2.4 mg DNA/infusion and docetaxel 75 mg/m2.
1784556|NCT00470626|Device|Celect Vena Cava Filter|Effective filtration of inferior vena cava blood to prevent thromboembolism.
1784557|NCT00470639|Device|Transcranial Magnetic Stimulation|
1784558|NCT00470652|Device|computer-assisted decision support|at the end of the pre-intervention period, the patient flow software was modified to open popup windows automatically when pain intensity was not documented or pain was not reevaluated within the recommended interval. The popup window also detailed appropriate pain treatment guidelines based on the documented pain intensity. In addition, the patient's icon in the flow software changed from black to red when pain intensity was >4/10. After a 10-day test period, the post-intervention data collection started.
1784559|NCT00470665|Drug|Rapamune|
1784560|NCT00470678|Drug|ranibizumab|
1784561|NCT00470691|Procedure|plaster cast|complete circular plaster cast
1784562|NCT00470691|Procedure|dorsal splint|dorsal plaster splint
1784563|NCT00470704|Drug|Lapatinib|Oral dose taken daily
1784564|NCT00470704|Drug|Herceptin|Given intravenously once a week or once every 3 weeks
1784565|NCT00470717|Procedure|Weekly telephone call|Details of feeding and health/sickness will be obtained
1784566|NCT00470743|Drug|Ibuprofen|
1784567|NCT00470743|Drug|Indomethacin|
1784568|NCT00470756|Other|mechanical triggering of peroneal activity|mechanical triggering of peroneal activity
1784569|NCT00470769|Procedure|Color-Doppler Ultrasound, 99mTc-DTPA scintigraphy|
1784570|NCT00470795|Other|Acupuncture|acupuncture treatment (or placebo), 20 minute treatment each; twice weekly for four weeks (total of eight treatments). repeat treatment schedule following crossover (placebo-treatment)
1784571|NCT00470795|Procedure|placebo/sham acupuncture|acupuncture at sham points without skin penetration
1784572|NCT00470808|Drug|POMx|
1784573|NCT00470821|Drug|Oral melatonin 3mg BID|Identical tablets containing melatonin 3 mg. Nurses are requested to give two tablets daily, at 8 PM and 12 PM
1784574|NCT00470821|Drug|Placebo|Identical tablets without the active principles. Each evening nurses are requested to give 2 tablets at 8 PM and 12 PM
1784575|NCT00470834|Drug|dutasteride|0.5mg dutasteride (Investigation Product)
1784576|NCT00470834|Drug|placebo|making placebo
1784577|NCT00470834|Drug|bicalutamide|50 mg Casodex or generic equivalent
1784583|NCT00470886|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Primary care clinic hypertensive patients for whom physician decided to start the treatment with telmisartan
1784584|NCT00470899|Procedure|drainage of placenta of fetal blood|
1784585|NCT00470912|Drug|sunscreen RV 2547C|
1784586|NCT00470925|Procedure|123-I MZINT injection and SPECT imaging|SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI
1784587|NCT00470938|Device|SpineForce Reactive Neuromuscular Trainer|
1784588|NCT00470951|Procedure|open rectal resection|open rectal resection
1784589|NCT00470951|Procedure|laparoscopic rectal resection|laparoscopic assisted rectal resection
1784590|NCT00470964|Procedure|Titanium Sapphire laser trabeculoplasty|
1784591|NCT00470977|Drug|ranibizumab injection (0.5 mg)|ranibizumab 10mg mg/ml. , 0.3ml/vial, 0.05 ml./injection intravitreally for 3months then prn for the next 21 months.
1784592|NCT00470990|Drug|GnRH antagonist (Acyline)|3 Subcutaneous injections (300 mcg/kg) over 36 days
1784593|NCT00471003|Drug|Pritor (Telmisartan , BAY68-9291)|Primary care hypertensive patients starting the therapy with Telmisartan
1784594|NCT00471016|Behavioral|Guided intervention|
1784595|NCT00471029|Drug|esomeprazole|
1784596|NCT00471042|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
1784597|NCT00471055|Drug|"0.0125% Capsaicin gel CAPSIKA gel"|
1784598|NCT00471055|Drug|Placebo|Placebo
1784599|NCT00471068|Drug|Travatan|Travatan: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
1784600|NCT00471068|Drug|Cosopt|treatment period of 6 weeks with Cosopt (dorzolamide 20 mg/ml and timolol maleate 5 mg/ml eye drops, solution) twice daily at 08:00 and 20:00 in the affected eye(s)
1784601|NCT00471068|Drug|Placebo (Timolol Vehicle)|Travatan group: 6 weeks treatment with Travatan (travoprost 40 mg/ml eye drops, solution) once daily at 08:00 and placebo (timolol vehicle) once daily at 20:00 in the affected eye(s)
1784603|NCT00471094|Drug|Ilaprazole|Ilaprazole 5 mg, capsules, orally, once daily for up to 8 weeks.
1784604|NCT00471094|Drug|Ilaprazole|Ilaprazole 20 mg, capsules, orally, once daily for up to 8 weeks.
1784605|NCT00471094|Drug|Ilaprazole|Ilaprazole 40 mg, capsules, orally, once daily for up to 8 weeks.
1784606|NCT00471094|Drug|Lansoprazole|Lansoprazole 30 mg, capsules, orally, once daily for up to 8 weeks.
1784607|NCT00471107|Device|DC brain polarization|0.08 mA/cm2
1784608|NCT00471120|Other|P2x7 assay|compare P2X7 assay to biopsy
1784609|NCT00471133|Biological|Xenogeneic Tyrosinase DNA Vaccine|
1784610|NCT00471133|Device|TriGrid Delivery System for Intramuscular Electroporation|
1784611|NCT00471146|Drug|AG-013736|oral administration, starting dose 5 mg twice daily [BID] every day until unacceptable toxicity or tumor progression.
1784612|NCT00471146|Drug|Gemcitabine|intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
1784613|NCT00471146|Drug|Gemcitabine|intravenous administration at 1,000 mg/m^2 day 1, day 8 and day 15 every 4 weeks (conventional dose) until unacceptable toxicity or tumor progression.
1784614|NCT00471146|Drug|placebo|placebo
1784615|NCT00471159|Drug|docetaxel|
1784616|NCT00471159|Drug|PF-3512676|
1784617|NCT00471172|Behavioral|Face-to-face counseling by a dietitian (months 1-3: weekly, months 4-6: every other week)|
1784618|NCT00471172|Behavioral|Face-to-face counseling by a dietitian (monthly)|
1784619|NCT00471172|Behavioral|Counseling by a dietitian via telephone (months 1-3: weekly, months 4-6: every other week)|
1784620|NCT00471172|Behavioral|Counseling by a dietitian via e-mail (months 1-3: weekly, months 4-6: every other week)|
1784621|NCT00471172|Behavioral|Self help|
1784622|NCT00471185|Drug|Acyline|10, 20 and 40 mg of Oral acyline, given on 3 occasions, separated by 1 week.
1784623|NCT00471211|Drug|PBT2|
1784624|NCT00471224|Other|Observational Trial|No intervention is being used in this study.
1784625|NCT00471237|Drug|Ronacaleret|100mg, 200mg, 300mg, 400mg
1784626|NCT00471237|Drug|Teriparatide|PTH (1-34)
1784627|NCT00471237|Drug|Alendronate|Bisphosphonate
1784628|NCT00471263|Drug|Casigold|
1784629|NCT00471263|Drug|Casimax|
1784630|NCT00471263|Drug|Placebo|
1784631|NCT00471276|Drug|sunitinib|sunitinib (Sutent), 37.5 mg, daily dosing
1784632|NCT00471289|Device|PTA with placement of paclitaxel-eluting stent|PTA with placement of paclitaxel-eluting stent
1784633|NCT00471289|Device|PTA|PTA
1784634|NCT00471315|Drug|Duloxetine|A preliminary, open-label single center study of duloxetine in patients with SOD
1784635|NCT00471328|Drug|Nilotinib|Nilotinib 400 mg twice daily (bid)
1784636|NCT00471328|Other|Best Supportive Care (BSC) +/- imatinib or sunitinib|Can include pain medication, localized radiotherapy, nutritional support, and/or oxygen therapy and blood transfusions. Imatinib or sunitinib can be administered at the last tolerated dose and regimen or at the Investigator's choice.
1784637|NCT00471341|Drug|Celecoxib|
1784638|NCT00471341|Drug|placebo|
1784639|NCT00471354|Drug|Atomoxetine|atomoxetine 0.5 mg/kg/day once a day (QD), by mouth (PO) starting dose titrated over 1 week to target dose 1.2 mg/kg/day QD, PO for 23 weeks.
1784640|NCT00471367|Drug|AZD4877|intravenous infusion administered twice a week for 2 weeks
1784747|NCT00472238|Behavioral|exercise training|Treadmill exercise training to optimize physical endurance
1784748|NCT00472264|Procedure|PET imaging|Medical imaging assessment
1784641|NCT00471380|Drug|travoprost 0.004% and brinzolamide 1%|Group A = concomitant administration of travoprost 0.004% (ophthalmic drops, 1 drop/eye at approximately 19:45 p.m.) and brinzolamide 1% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.)
1784642|NCT00471380|Drug|fixed combination of timolol 0.5% and dorzolamide 2% plus travoprost vehicle|group B = fixed combination of timolol 0.5% and dorzolamide 2% (ophthalmic drops, 1 drop/eye, at 08:00 a.m. and at 20:00 p.m.), and travoprost vehicle (ophthalmic drops, 1 drop/eye, at approximately 19:45 p.m.).
1784643|NCT00471393|Drug|1.5% diclofenac in 45.5% DMSO (topical treatment)|
1784644|NCT00471393|Drug|45.5% DMSO (topical placebo)|
1784645|NCT00471406|Procedure|Photodynamic Therapy with Verteporfin|
1784646|NCT00471419|Drug|Rimexolone|
1784647|NCT00471432|Drug|custirsen sodium|
1784648|NCT00471432|Drug|docetaxel|
1784649|NCT00471432|Other|pharmacological study|
1784650|NCT00471445|Drug|ketamine/amitriptyline NP-H cream|Subjects were instructed to apply up to, but not exceeding, 4 g of ketamine/amitriptyline NP-H cream two times per day to each area with pain, numbness, and/or tingling. A measuring device was provided to assist in dispensing the proper amount of the cream.
1784651|NCT00471445|Other|placebo|Applied topically
1784652|NCT00471471|Biological|Peptide vaccine|Multi-epitope peptide vaccine containing MART-1 (26-35, 27L), gp100 (209-217, 210M) and tyrosinase (368-376, 370D) peptides
1784653|NCT00471471|Biological|GM-CSF|80 mcg/0.16 mL using lyophilized 500 mcg/vial reconstituted with 1 mL of sterile water given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
1784654|NCT00471471|Biological|PF3512676|0.6 mg/0.04 mL given subcutaneously rotating truncal sites in the vicinity of the four nodal drainage groups of the four extremities, on days 1 and 15 of each cycle (1 cycle = 28 days) for a maximum of 13 cycles (1 year).
1784655|NCT00471484|Biological|recombinant interferon alfa-2b|
1784656|NCT00471484|Drug|doxorubicin hydrochloride|
1784657|NCT00471484|Drug|fluorouracil|
1784658|NCT00471484|Drug|oxaliplatin|
1784659|NCT00471484|Other|diagnostic laboratory biomarker analysis|
1784660|NCT00471484|Other|immunoenzyme technique|
1784661|NCT00471484|Other|immunohistochemistry staining method|
1784662|NCT00471484|Procedure|adjuvant therapy|
1784663|NCT00471484|Procedure|biopsy|
1784664|NCT00471484|Procedure|neoadjuvant therapy|
1784665|NCT00471484|Procedure|therapeutic conventional surgery|
1784666|NCT00471497|Drug|nilotinib|Nilotinib was supplied as 50 mg, 150 mg and 200 mg hard gelatin capsules and administered orally at 300 mg BID (twice a day) or 400 mg BID (twice a day)depending on the randomized dose.
1784667|NCT00471497|Drug|imatinib|Imatinib was supplied as 100 mg and 400 mg tablets and administered orally at 400 mg QD (once a day).
1784668|NCT00471510|Drug|tetrapeptide aldehyde proteasome inhibitor (NEOSH101)|Study preparation (experimental, placebo comparator) will be applied to the scalp once daily for 16 weeks
1784669|NCT00471523|Drug|Clomiphene citrate|
1784670|NCT00471523|Drug|Metformin|
1784671|NCT00471536|Drug|pazopanib hydrochloride|800 mg Given orally
1784672|NCT00471549|Drug|Statin (simvastatin)|
1784673|NCT00471562|Biological|therapeutic angiotensin-(1-7)|sequentially increasing doses 50-1000 mcg/kg
1784674|NCT00471575|Procedure|ultra sound examination|
1784675|NCT00471588|Drug|Pramipexole, Amisulpride|Study Drug
1784676|NCT00471601|Behavioral|counseling intervention|
1784677|NCT00471601|Behavioral|questionnaire administration|
1784678|NCT00471601|Behavioral|psychosocial assessment and care|
1784679|NCT00471601|Behavioral|quality-of-life assessment|
1784681|NCT00471627|Procedure|Pancreaticojejunostomy without stiches through the pancreas|The pancreas is cut with knife, without electric cautery and without stay sutures. Bleeding is controlled with 2-3 exactly placed stiches. The pancreatic stump is sunk inside the jejunum, which is tightened around the pancreas with a purse string. A biodegradable stent is left into the pancreatic duct to prevent its occlusion when tightning the purse string.
1784682|NCT00471640|Drug|dexamethasone|4 days 5 mg
1784683|NCT00471653|Drug|temozolomide|
1784684|NCT00471653|Genetic|comparative genomic hybridization|
1784685|NCT00471653|Genetic|polymorphism analysis|
1784686|NCT00471653|Other|laboratory biomarker analysis|
1784687|NCT00471653|Other|pharmacological study|
1784688|NCT00471653|Radiation|radiation therapy|
1784689|NCT00471679|Drug|ethanol|
1784690|NCT00471692|Drug|Ropivicaine|
1784691|NCT00471705|Drug|Miltefosine|Miltefosine 2.5 mg/Kg/day with a maximum dose of 150 mg PO day.
1784692|NCT00471705|Device|Thermotherapy|One session of local heat using a thermotherapy device at 50 celsius degrees during 30 seconds.
1784693|NCT00471705|Drug|Glucantime®|Glucantime® 20 mg /Kg /day for 20 days (intramuscular)
1784694|NCT00471718|Drug|ABT-751|"Phase I:
Cohort | Number of Patients |Dose (mg) ABT-751 (BID)
-1 | 3-6 |100 mg BID
1 | 3-6 |125 mg BID
2 | 3-6 |150 mg BID
3 | 3-6 |175 mg BID
4 | 3-6 |200 mg BID
Phase II:
Patients receive ABT-751 at 125mg po BID for 7 days on, 7 days off (X2) for a 28 day cycle"
1784695|NCT00471744|Drug|Treatment with levetiracetam or sulthiame over a six-month period.|
1784696|NCT00471783|Procedure|Chlorhexidine is the generic name of the mouthwash, Peridex is the brand name.|
1784697|NCT00471796|Behavioral|Biofeedback|
1784698|NCT00471809|Drug|Budesonide + Salmeterol + Azithromycin|
1784699|NCT00471809|Drug|Budesonide + Salmeterol + Montelukast|
1784700|NCT00471809|Drug|Budesonide + Salmeterol + Placebo|
1784701|NCT00471835|Procedure|computed tomography|
1784702|NCT00471835|Procedure|positron emission tomography|
1784703|NCT00471835|Radiation|stereotactic body radiation therapy|
1784704|NCT00471848|Drug|rabbit antithymocyte globulin|1.5 vials/10kg daily for 5 days
1784970|NCT00472654|Behavioral|Weight Maintenance|Diet for weight maintenance for 6 weeks
1784971|NCT00472667|Procedure|Procalcitonin guided strategy|Procalcitonin guided strategy
1784706|NCT00471900|Drug|dehydroepiandrosterone (DHEA)|
1784707|NCT00471913|Device|Femoral Nailing with Different Entry Points|See Detailed Description.
1784708|NCT00471939|Drug|I-020502|1 mcg/mL TG-PDGF.AB
1784709|NCT00471952|Drug|Maxalt 10mg MLT plus Caffeine 75mg|One migraine attack will be treated
1784710|NCT00471952|Drug|Maxalt 10mg MLT plus Placebo|One migraine attack will be treated with Maxalt 10mg plus placebo
1784711|NCT00471952|Drug|Placebo + Placebo|One migraine attack will be treated with double placebo
1784712|NCT00471965|Drug|Oxaliplatin + 5-Fluorouracil/Leucovorin|"Day 1: Oxaliplatin 85mg/m² 2h IV infusion, leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m2 22h IV infusion.
Day 2: Leucovorin 200mg/m² 2h IV infusion, 5-fluorouracil 400mg/m² IV bolus, 5-fluorouracil 600mg/m² 22h IV infusion.
Repeated every 2 weeks"
1784713|NCT00471965|Drug|Doxorubicin|Day 1: Doxorubicin 50mg/m² iv infusion. Repeated every 3 weeks.
1784714|NCT00471991|Drug|SH T04769G|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.
1784715|NCT00471991|Drug|Ethinyl estradiol / dienogest (SH D00659 AF)|The study consists of 4 cycles resulting in approx. 16 weeks of study participation. The investigational product is an oral contraceptive. 21 tablets are taken each cycle followed by a 7-day tablet-free interval. (One cycle lasts for 28 days.)Volunteers will have to come for a visit every 2 to 4 days over the whole study period.The function of the ovaries is studied by transvaginal ultrasonography and determination of hormonal parameters from blood samples. The mouth of the uterus is inspected during each visit and the cervical smear will be investigated. Adverse events will be recorded and diary entries will be controlled by the investigator.Volunteers have to undergo a series of blood sampling during the 2nd treatment cycle to evaluate the pharmacokinetic (liberation, absorption, distribution, metabolization and excretion) of the new oral contraceptive.
1784716|NCT00472004|Drug|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined (Totelle)|17B Estradiol (1mg) / (0.125 mg) TMG Continuous combined, 1 Daily, 1 year duration
1784717|NCT00472004|Drug|Tibolone (Livial)|Tibolone 2.5 mg 1 daily, 1 year duration
1784718|NCT00472017|Drug|vandetanib|Oral vandetanib administration will start on the same day as RT. Treatment with vandetanib will extend for the entire duration of RT, and then will be continued after completion of RT for a maximum duration of 2 years.
1784719|NCT00472030|Drug|Omalizumab|Patients will be treated with 150-375 milligrams of Omalizumab (Xolair), based on their baseline weight and serum Immunoglobulin E levels. Omalizumab will be administered subcutaneously on Day 1, and on Week 2, 4, 6, 8, 10, 12 and 14 treatment.
1784720|NCT00472030|Drug|prednisone|Prednisone, to a maximum dose of 0.5 mg/kg/day.
1784721|NCT00472043|Procedure|PDT with Metvix 160 mg/g cream and Placebo cream|
1784722|NCT00472056|Drug|Carmustine|300 mg/m^2 IV for 1 Day
1784723|NCT00472056|Drug|Etoposide|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
1784724|NCT00472056|Drug|Cytarabine|Arm 1 = 200 mg/m^2 IV Every 12 Hours x 4 Days; Arm 2 = 100 mg/m^2 IV Every 12 Hours x 4 Days
1784725|NCT00472056|Drug|Melphalan|140 mg/m^2 IV x 1 Day
1784726|NCT00472056|Drug|Rituximab|Cohort 1, High-Dose Rituximab = 1000 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion; Cohort 2, Standard Dose Rituximab = 375 mg/m^2 IV On Days +1 and +8 After Stem Cell Infusion.
1784727|NCT00472069|Procedure|transplantation of the squeletic muscular cells|transplantation of the squeletic muscular cells
1784728|NCT00472082|Drug|efalizumab|Administration of a test dose of efalizumab 0.7mg/kg will be administered at enrollment. Weekly subcutaneous injections of efalizumab 1mg/kg will begin with study visit 2 and continue for 1 year for this pilot study.
1784729|NCT00472095|Procedure|fotonovela|
1784730|NCT00472108|Procedure|PDT with Metvix 160 mg/g cream|
1784731|NCT00472108|Procedure|PDT with placebo cream|
1784732|NCT00472121|Device|TOF-Watch SX (neuromuscular monitor)|The variation between arms (dominant or non-dominant) when monitored with the same method on both arms
1784733|NCT00472134|Drug|bupivacaine|administered locally, 0.5% Bupivacaine (Marcaine Abbott Laboratories) or saline administered continuously for 48 hours at 2 mL/h.
1784734|NCT00472134|Device|On-Q PainBuster pump|local anesthetic (bupivacaine) administered via a pain relief system consisting of a 20 gauge soaker catheter attached to an elastomeric balloon pump that is capable of infusing a set volume of local anesthetic over a wide area of surgical site for 2 to 5 days
1784735|NCT00472147|Procedure|shock efficacy|
1784736|NCT00472160|Procedure|Non Invasive Ventilation|Non Invasive Ventilation
1784737|NCT00472173|Drug|Mineral Trioxide Aggregate|Apexification treatment of the tooth with Mineral Trioxide Aggregate
1784738|NCT00472173|Drug|Calcium hydroxide|Apexification treatment of the tooth with Calcium hydroxide
1784739|NCT00472186|Drug|Lansoprazole|If weight is less than 30 kg, 15 mg of Lansoprazole twice daily will be administered. If weight is greater than or equal to 30 kg, 30 mg of Lansoprazole twice daily will be administered.
1784740|NCT00472186|Drug|Placebo|Placebo will also be administered based on weight.
1784741|NCT00472199|Drug|Pramipexole|
1784742|NCT00472199|Drug|Placebo|
1784743|NCT00472212|Device|Glasses for the correction of low to moderate farsightedness|
1784744|NCT00472212|Device|Glasses with placebo lens|
1784745|NCT00472225|Drug|Rituximab|"Rituximab Induction: Rituximab 375 mg/m2 weekly IV for 4 consecutive weeks
Rituximab Maintenance: Rituximab 375 mg/m2 monthly IV for 4 consecutive months"
1784746|NCT00472238|Behavioral|endurance training|control group.
1785084|NCT00475072|Drug|ribavirin|1000/1200mg po daily for 48 weeks
1784749|NCT00472290|Drug|Romiplostim (formerly AMG 531)|"Subjects will begin the study at an initial dose of 750 µg.
Except for:
Subject whose doses were escalated to doses higher than 750 µg AMG 531 weekly, and maintained a response per IWG guidelines for platelet response.
Subjects who were stable at a lower dose of AMG 531 on the previous study. Doses will be adjusted throughout the study based on individual subject's platelet count."
1784750|NCT00472303|Drug|Tapentadol Extended Release|Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 100 mg, increasing at a minimum of 3 day intervals by 50 mg, with a maximum dose of 250 mg.
1784751|NCT00472303|Drug|Matching Placebo after Tapentadol in the Titration Phase.|Tablet taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. In the maintenance phase only to participants that were randomized to tapentadol in the titration phase.
1784752|NCT00472303|Drug|Morphine Sulphate Controlled Release|Capsule taken orally, twice daily, morning & evening with preferably 12 hours (not less than 6 hours) between doses. Titration phase: Starting at 40 mg, increasing at a minimum of 3 days intervals by 20 mg, with a maximum dose of 100 mg. Maintenance phase: continuing on dose level established in titration phase.
1784753|NCT00472316|Behavioral|Active Case Finding for Tuberculosis|Active case finding of TB in the community using community health workers
1784754|NCT00472329|Procedure|Allogeneic hematopoietic stem cell graft using an allogeneic SCT HLA-Identical or non-identical family donor or unrelated donors|
1784755|NCT00472329|Drug|fludarabine|
1784756|NCT00472329|Procedure|TBI|
1784757|NCT00472342|Behavioral|exercise prescription|
1784758|NCT00472355|Drug|apomorphine|
1784759|NCT00472368|Drug|LBH589|
1784760|NCT00472381|Drug|Insulin|Insulin
1784761|NCT00472407|Device|NPC targets|
1784762|NCT00472420|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv every 3 weeks
1784763|NCT00472420|Drug|First line chemotherapy|As prescribed
1784764|NCT00472433|Drug|Alemtuzumab|
1784765|NCT00472446|Drug|bilateral superficial cervical block|10 ml of 5% bupivacaine (Carbostesin®) was used for each side. Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side.
1784766|NCT00472446|Drug|placebo bilateral superficial cervical block|"10 ml of saline (the carrier of bupivacaine in the experimental treatment) was used for each side.
Along the cranial dorsal edge of the sternocleidomastoid muscle, three deposits of approximately 2.5 ml were injected to anaesthetize the cervical plexus with its nervus transversus colli. To anaesthetize the region of the planned skin incision, the remaining 2·5 ml was injected subcutaneously on each side."
1784767|NCT00472459|Procedure|Photodynamic therapy with Metvix 160 mg/g cream|
1784768|NCT00472472|Device|paclitaxel coated balloon catheter (device with drug)|PTA vs Paccocath
1784769|NCT00472485|Procedure|eye movement therapy|
1784770|NCT00472524|Procedure|Mydriasis/cycloplegia via different modes of administration|
1784771|NCT00472537|Procedure|Retromuscular Mesh repair of midline incisional hernia|
1784772|NCT00472537|Procedure|Laparoscopic repair of midline incisional hernia|
1784773|NCT00460109|Biological|denileukin diftitox|
1784774|NCT00460109|Biological|rituximab|
1784775|NCT00460135|Behavioral|resistance training|2 times a week resistance training
1784776|NCT00460148|Drug|Ropinirole|
1784777|NCT00460161|Procedure|acupuncture|2 treatments/week for 4 weeks
1784778|NCT00460161|Other|placebo/sham acupuncture|2 treatments/week for 4 weeks
1784779|NCT00460174|Biological|bevacizumab|10 mg/kg every 2 weeks as an intravenous infusion after gemcitabine and before radiation
1784780|NCT00460174|Drug|gemcitabine|1000 mg/m2, 30 minute intravenous infusion, cycle 1 (weeks 1, 2), cycle 2 (weeks 4, 5, 6) and cycle 3 (weeks 8 and 9). During cycle 2, gemcitabine will be delivered prior to radiation therapy
1784781|NCT00460174|Procedure|conventional surgery|If resectable, patients will undergo surgery no less than 6 weeks following last dose of bevacizumab. Unresectable patients will not undergo surgery.
1784782|NCT00460174|Radiation|radiation therapy|2.4 Gy fractions, 5 fractions/week during cycle 2 only (weeks 4, 5, 6). Total dose 36 Gy.
1784784|NCT00460200|Genetic|polymorphism analysis|
1784785|NCT00460200|Other|laboratory biomarker analysis|
1784786|NCT00460200|Other|physiologic testing|
1784787|NCT00460200|Other|questionnaire administration|
1784788|NCT00460200|Procedure|conventional surgery|
1784789|NCT00460200|Procedure|fatigue assessment and management|
1784790|NCT00460200|Procedure|psychosocial assessment and care|
1784791|NCT00460213|Drug|Valsartan 80mg daily|
1784792|NCT00460213|Drug|Valsartan 160mg daily|
1784793|NCT00460226|Drug|lamotrigine|lamotrigine treatment for 12weeks
1784794|NCT00460239|Drug|Buprenorphine|Intramuscular, doses (8, 16, 32, 48, 60 mg) are blind; administered up to 1-2 times per week.
1784795|NCT00460239|Drug|Morphine|Intramuscular; up to 1-2 times per week; doses (15, 30 mg) double blind
1784796|NCT00460239|Drug|Placebo|Intramuscular; double blind; once per week
1784797|NCT00460252|Procedure|insulin titration applying a computer algorithm|
1784798|NCT00460265|Drug|ARM 2|Subjects will receive Cisplatin plus 5FU
1784799|NCT00460265|Drug|ARM 1|Subjects will receive Panitumumab plus cisplatin and 5FU
1784800|NCT00460278|Drug|XL418|
1784801|NCT00460291|Device|Implantation of the ProVena vein graft during bypass surgery|
1784804|NCT00460317|Drug|AMG 706|125 mg QD orally every day
1784805|NCT00460317|Drug|placebo|125 mg QD orally every day
1784806|NCT00460317|Drug|paclitaxel|200mg/m2 on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
1784807|NCT00460317|Drug|carboplatin|AUC of 600mg/mL x min by Calvert formula on day 1 of each 3 week cycle +/- 3 days for a max of 6 cycles
1785085|NCT00475085|Drug|aprepitant|Given orally or IV
1784808|NCT00460343|Other|extensive implementation programme|experimental pharmacists follow an extensive implementation programme. They attend two interactive half a day educational meetings tailored to individual needs: one at start of the intervention, and one in May or September 2007. Special attention is given to multiprofessional cooperation with general practitioners and nurse practitioners. Additionally, guided by their own project planning pharmacists receive three or more telephone calls, both as a reminder, feedback, and in order to investigate whether they need any more help.
1784809|NCT00460343|Other|control|pharmacists only receive a written manual with instructions to implement the patient compliance intervention.
1784810|NCT00460356|Other|Laboratory Biomarker Analysis|Correlative studies
1784811|NCT00460356|Procedure|Lymphadenectomy|Undergo lymphadenectomy
1784812|NCT00460369|Drug|sulfadoxine-pyrimethamine|"tablets 1,25/25 mg
1 tablet per 20 kg of body weight Single drug intake"
1784813|NCT00460369|Drug|artemether-lumefantrine|"tablets 20/120 mg
1 tablet twice daily for 3 days below 15 kg of bodyweight
2 tablets twice daily for 3 days below 24 kg of bodyweight
3 tablets twice daily for 3 days below 35 kg of bodyweight"
1784814|NCT00460369|Drug|amodiaquine-artesunate coformulation|"one 25mg/67,5mg tablet, once daily for 3 days below 9 kg
one 50/135mg tablet, once daily for 3 days below 18 kg"
1784819|NCT00460395|Procedure|Surgery|
1784820|NCT00460395|Procedure|Stereotactic radiosurgery|
1784821|NCT00460408|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks.
1784822|NCT00460421|Drug|Palifermin|Palifermin will be administered as an IV bolus injection (40, 60 or 80 µg/kg/day)once daily for 3 consecutive days before the start of conditioning regimen and after HCST (Day -10, -9, -8 and Day 0, +1, +2 respectively).
1784823|NCT00460421|Radiation|Total Body irradiation|
1784824|NCT00460421|Drug|Chemotherapy|High dose etoposide, Cyclophosphamide
1784825|NCT00460434|Device|TVT|Prophylactic TVT
1784826|NCT00460434|Other|Sham|Sham TVT
1784828|NCT00460460|Drug|AZD4877|
1784829|NCT00460473|Drug|Dexmedetomidine|
1784830|NCT00460473|Drug|Placebo|
1784831|NCT00460486|Biological|Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl|
1784832|NCT00460499|Drug|A IV Insulin drip|These patients will receive 100units of insulin in 100ml of saline intravenously to keep blood glucose between 120-180mg/dl.
1784833|NCT00460499|Drug|B Low Dose GIK|These patients will receive D5W+80unitsInsulin+40mEqKCL IV to keep blood glucose between 120-180mg/dl
1784834|NCT00460499|Drug|C High Dose GIK|This group will receive D20W+160units IV insulin to keep blood sugar between 120-180mg/dl
1784836|NCT00460525|Biological|FMP2.1/AS02A|3 doses administered a month apart: 50 µg recombinant subunit protein FMP2.1 (Plasmodium falciparum Apical Membrane Antigen-1 from strain 3D7 expressed in and purified from Escherichia coli), adjuvanted with 0.5 mL of AS02A (proprietary oil-in-water emulsion and phosphate buffered saline with the immunostimulants monophosphoral lipid A and QS21).
1784837|NCT00460525|Biological|Rabies Vaccine|White, freeze-dried vaccine for reconstitution with the diluent prior to use; dosage 1.0 mL of rabies vaccine.
1784838|NCT00460538|Dietary Supplement|Lectranal|"Dosage form: capsule
1: Dosage: 2 capsule Frequency and duration: 2 times daily over the 6 weeks"
1784839|NCT00460538|Dietary Supplement|placebo|Dosage form: capsule 2: Dosage: 2 capsules Frequency and duration: 2 times daily over the 6 weeks
1784840|NCT00460551|Biological|Zalutumumab|8 mg/kg
1784841|NCT00460551|Drug|Induction chemotherapy|Combination of cisplatin and docetaxel administered as two cycles given every three weeks
1784842|NCT00460551|Radiation|Radiotherapy|64 Gy in 32 fractions over 6.5 weeks
1784843|NCT00460564|Drug|GSK1358820|botulinum toxin type A
1784844|NCT00460564|Drug|Placebo|Placebo
1784845|NCT00460577|Drug|Formoterol fumerate|12 micrograms stat (twice if necessary). Inhaled via aerolizer
1784846|NCT00460577|Drug|fenoterol/ipratropium bromide|0.5 micrograms/0.25 milligrams (20 drops) inhaled via nebulization diluted in 3cc of 0.9% saline.
1784847|NCT00460590|Biological|MVA 85A|ID vaccine
1784848|NCT00460603|Drug|bevacizumab|bevacizumab 5 mg/kg every 2 weeks
1784849|NCT00460603|Drug|AG-013726|AG-013726 5 mg bid every 2 weeks
1784850|NCT00460603|Drug|AG-013736 (axitinib)|AG-013736 5 mg bid starting dose
1784851|NCT00460616|Drug|Cabergoline|According with our previous studies, in the patients with microprolactinoma and in those with non-tumoral hyperprolactinemia, cabergoline treatment was administered orally at a starting dose of 0.25 mg twice weekly for the first two weeks and then 0.5 mg twice weekly. After 2 months of treatment, dose adjustment was carried out every 2 months on the basis of serum PRL suppression.
1784852|NCT00460629|Procedure|Application of activated donor T cells|Ex-vivo generated donor T cells stimulated by antigen presenting cells loaded with peptides derived from leukemia-associated antigens
1784853|NCT00460642|Drug|GnRH Antagonist (Cetrotide)|
1784854|NCT00460655|Drug|GSK1358820|botulinum toxin type A
1784855|NCT00460655|Drug|Placebo|Placebo
1784856|NCT00460668|Behavioral|pulmonary rehabilitation|2 or 3 times a week during 8 weeks
1784857|NCT00460681|Drug|Thymopentin|subcutaneously or intramuscular inject at the dosage of 10 mg every second day (twice a week) for consecutive 3 months.
1784858|NCT00460694|Biological|infusion of allogeneic CIK cells|infusion of allogeneic CIK cells at graded doses
1784859|NCT00460707|Drug|Casopitant 150 mg|Casopitant 150 mg will be available as white, film-coated tablets. Casopitant tablets will be taken with 240 milliliters (mL) of water at room temperature on an empty stomach.
1785086|NCT00475085|Drug|dexamethasone|Given orally or IV
1785399|NCT00477269|Drug|Imatinib mesylate|
1784860|NCT00460707|Drug|Ketoconazole|Ketoconazole will be available as 200 mg tablets which will be taken with 240 mL of water on an empty stomach (after a 2 hour fast on Day 4 of Treatment Period 2 and after a 1 hour fast on all other dosing days).
1784861|NCT00460707|Drug|Casopitant 150 mg matching placebo|Casopitant 150 mg matching placebo will be available as white, film-coated tablets.
1784862|NCT00460707|Drug|Casopitant 50 mg|Casopitant 50 mg will be available as pale orange, film-coated tablets. Casopitant tablets will be taken with 240 mL of water at room temperature on an empty stomach.
1784863|NCT00460707|Drug|Casopitant 50 mg matching placebo|Casopitant 50 mg matching placebo will be available as pale orange, film-coated tablets.
1784864|NCT00460720|Other|Observational treatment compliance survey|Observational treatment compliance survey
1784865|NCT00460733|Drug|Risedronate sodium|Actonel® 35 mg (risedronate sodium) and 1000 mg of calcium and 400 UI of Vitamine D3
1784866|NCT00460733|Drug|Calcium & Vitamine D3|1000 mg of calcium and 400 UI of Vitamine D3
1784867|NCT00460746|Drug|TMC125, Darunavir; Ritonavir|TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
1784868|NCT00460759|Drug|Moxifloxacin|
1784869|NCT00460759|Drug|Rifapentine|
1784870|NCT00460785|Drug|Opioid|
1784871|NCT00460798|Other|Sutent: observational study|SUNIKA - A Non-Interventional Study With SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
1784872|NCT00460811|Drug|Linaclotide Acetate|Oral, once daily
1784873|NCT00460811|Drug|Matching placebo|Oral, once daily
1784874|NCT00466258|Drug|R-CHOP|"Cyclophosphamide 750 mg/m2 i.v. day 1
Adriamycin 50 mg/m2 i.v. day 1
Vincristine 1,4 mg/m2 i.v. day 1
Prednisone 100 mg i.v or oral. days 1-5."
1784875|NCT00466258|Drug|Highly active antiretroviral therapy|Combined antiretroviral treatment (TARGA) wich include at lest 3 drugs. The combination should be accepted as an initial or rescue treatment.
1784876|NCT00466258|Drug|Central nervous system (CNS) prophylaxis|methotrexate (12 mg) cytarabine (30 mg) hydrocortisone (20 mg)
1784877|NCT00466258|Drug|Prophylaxis of opportunistic infections and support treatment|Pegfilgrastim
1784878|NCT00466284|Drug|Tarceva (erlotinib)|
1784879|NCT00466297|Behavioral|Face-to-face communication interactions|
1784880|NCT00466310|Drug|Aripiprazole|Aripiprazole for 4 weeks
1784881|NCT00466310|Drug|Risperidone|Subjects will be randomized to risperidone for 4 weeks
1784882|NCT00466310|Other|Healthy volunteers|Healthy volunteers
1784883|NCT00466323|Behavioral|Family Member Provider Outreach|Family Member Provider Outreach is a brief recovery oriented model. THe FMPO meets with the consumer for 2-3 sessions and with the family for 2-3 sessions with the consumer's permission.
1784884|NCT00466323|Behavioral|Enhanced treatment as usual (e-TAU)|Enhanced treatment as usual. In this condition, the consumer is given a list of family services available including the family intervention team.
1784885|NCT00466362|Behavioral|The Evje Model|
1784886|NCT00466375|Genetic|Cheek cell samples or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples from parents and child having hemangioma.
1784887|NCT00466375|Genetic|Cheek cell sample or blood sample (4mL)|DNA will be extracted from cheek cell or blood samples of parents and child with a vascular anomaly.
1784888|NCT00466388|Drug|Cevimeline|
1784889|NCT00466401|Drug|Simvastatin|
1784890|NCT00466401|Drug|Ezetimibe|
1784891|NCT00466414|Device|Polycaprolactone Scaffold|
1784892|NCT00466440|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression, toxicity, or maximum 3 years
1784893|NCT00466440|Drug|placebo|oral, daily
1784894|NCT00466440|Drug|docetaxel|75 mg/m2, IV, q 21 days, six 21 day cycles, maximum 10 cycles
1784895|NCT00466440|Drug|prednisone|5 mg, oral, BID, six 21 day cycles
1784896|NCT00466453|Behavioral|knowledge-adaptive Web-based instruction|
1784897|NCT00466466|Drug|Everolimus|RAD001 will be supplied by Novartis as tablets in 3 different dosage strengths, 2.5, 5 and 10 mg. The drug will be packaged in blisters containing 10 tablets per blister. Blisters and packaging will be compliant with local regulations and be printed in local language.
1784898|NCT00466479|Drug|brimonidine|
1784899|NCT00466479|Procedure|laser trabeculoplasty|
1784900|NCT00466492|Procedure|Sedation or no sedation during mechanical ventilation|No sedation to critically ill patients
1784901|NCT00466505|Biological|cetuximab|400 mg/m2 iv week 1, then 250 mg/m2 weekly thereafter, starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
1784902|NCT00466505|Drug|celecoxib|200 mg po BID starting on day 1 and continuing until progressive disease, excessive toxicity or removal from study for other reasons listed in the protocol.
1784903|NCT00466505|Genetic|proteomic profiling|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction. We will use LC-MS-MS or MALDITOF mass spectrometry.
1784904|NCT00466505|Other|immunohistochemistry staining method|phospho-EGFR levels using western blots of tissue extracts and immunohistochemistry on frozen and (if no other option available, paraffinembedded tissue sections).
1784905|NCT00466505|Other|laboratory biomarker analysis|Serum samples obtained as above will be analyzed by proteomic analysis in order to determine biomarkers of treatment response and toxicity prediction.
1784906|NCT00466505|Other|mass spectrometry|We will use LC-MS-MS or MALDITOF mass spectrometry. Before any tissues are received, the drug of interest is evaluated via MALDI mass spectrometry on a MDS/Sciex QStar QqTOF mass spectrometer.
1784907|NCT00466518|Drug|Administration of sitagliptin|Sitagliptin 100 mg daily for 3 months
1784908|NCT00466531|Biological|therapeutic autologous lymphocytes|
1784909|NCT00466531|Drug|cyclophosphamide|
1784910|NCT00466544|Device|Plasmaknife|
1784911|NCT00466544|Device|Monopolar|
1784912|NCT00466570|Drug|gatifloxacin, moxifloxacin|
1784913|NCT00466583|Drug|Intravenous EZN-2968 (anti-HIF-1α LNA AS-ODN)|IV infusion of EZN 2968 given in 6 week cycles for (3 weeks on 3 weeks off) until recommended phase 2 dose identified. Up to 3 intensification cohorts will receive the recommended Phase 2 dose of EZN-2968.
1785087|NCT00475085|Drug|granisetron hydrochloride|Given orally or IV
1784914|NCT00466596|Drug|Gamma Tocopherol|14 days of daily high dose (1200mg) Gamma Tocopherol. Subjects will receive a 14 day supply (28 softgel capsules, approximately 600 grams of gT each) dispensed by the University of North Carolina Hospitals Investigational Drug Service and provided by YASOO Medical.
1784918|NCT00466622|Drug|Metformin|1000 mg x 2 daily. Orally. First tablet taken after the first Doppler examination and 3 hours before the next Doppler examination.
1784919|NCT00466622|Drug|Placebo|Placebo 2 tablets x 2 daily. Orally from Weifa
1784920|NCT00466635|Drug|GT267-004 (tolevamer potassium sodium)|
1784921|NCT00466648|Procedure|Tissue adhesive|
1784922|NCT00466661|Drug|Acamprosate|666 mg po TID
1784923|NCT00466661|Drug|Placebo|2 tabs po TID
1784924|NCT00466674|Drug|reduced intensity conditioning|reduced intensity conditioning for allogenic transplant
1784925|NCT00466687|Biological|bevacizumab|10mg/kg, slow IV infusion, Days 1 and 14
1784926|NCT00466687|Drug|erlotinib hydrochloride|150mg PO qd
1784927|NCT00466687|Genetic|fluorescence in situ hybridization|Targeting multiple genetic aberrations in isolated tumor cells.
1784928|NCT00466687|Genetic|gene expression analysis|gene expression analysis
1784929|NCT00466687|Other|immunologic technique|immunologic technique
1784930|NCT00466687|Other|laboratory biomarker analysis|laboratory biomarker analysis
1784931|NCT00466687|Procedure|biopsy|biopsy
1784932|NCT00466713|Drug|Rosiglitazone therapy|
1784933|NCT00466726|Biological|bcr-abl p210-b3a2 breakpoint-derived multipeptide vaccine|
1784934|NCT00466726|Biological|sargramostim|
1784944|NCT00466765|Device|Brava Autologous Fat Transfer System|Number of procedures is based on patient need
1784945|NCT00466791|Drug|Methylphenidate Transdermal System|Placebo
1784946|NCT00466804|Procedure|Heart transplant|People in this study will have a heart transplant and be monitored for signs of rejection
1784949|NCT00466830|Other|questionnaire administration|
1784950|NCT00466830|Procedure|management of therapy complications|
1784951|NCT00466830|Procedure|psychosocial assessment and care|
1784952|NCT00466830|Procedure|quality-of-life assessment|
1784953|NCT00466843|Drug|Antithymocyte globulin (ATG)|ATG 2.5 mg/kg/day via IV will be given for 4 doses. Each participant will receive only one cycle of therapy. The daily infusion will be administered over at least 6 hours and slowed as necessary to minimize infusion-related symptoms.
1784954|NCT00466843|Drug|Prednisone|All participants will be pre-treated with prednisone (1 mg/kg/day by mouth) 2 days prior to the first ATG does and continuing for 14 days after the final dose to prevent serum sickness
1784955|NCT00466856|Drug|octreotide acetate|"Lung/liver Ratio Dose of SIR-Spheres
<10% Administer full dose of SIR-Spheres
10% to 15% Reduce dose of SIR-Spheres by 20%
16% to 20% Reduce dose of SIR-Spheres by 40%
>20% Do not give SIR-Spheres"
1784956|NCT00466856|Radiation|yttrium Y 90 resin microspheres|radiation
1784957|NCT00466869|Drug|Betahistine|
1784958|NCT00466882|Device|Inamed Lap-Band System|Patient's will be seen in the physician's office one week post surgery and once a month thereafter. The device can be gradually adjusted by the insertion of a needle into the port and saline is added or removed to inflate or deflate the LAPBAND. This can be conducted in the physician's office setting to enable the patient to lose 1-2 pounds per week over two.
1784959|NCT00466895|Drug|lenalidomide|Dose level -1: 2.5 mg daily for days 1-7, 2.5 mg daily for days 8-21. Dose level 1: 2.5 mg daily for days 1-7, 5 mg daily for days 8-21. Dose level 2: 2.5 mg daily for days 1-7, 7.5 mg daily for days 8-21. Dose level 3: 2.5 mg daily for days 1-7, 10 mg daily for days 8-21. Dose level 4: 2.5 mg daily for days 1-7, 15 mg daily for days 8-21
1784960|NCT00466908|Device|Pentacam and IOL Master|Pentacam and IOL Master
1784961|NCT00466921|Drug|lenalidomide|10 mg daily orally administered on days 1 - 21 followed by 7 days rest of a 28-day cycle, increasing dose by 5 mg every cycle, up to a maximum of 25 mg.
1784962|NCT00472550|Drug|esomeprazole 20 mg|
1784963|NCT00472563|Drug|Bicarbinate 150 mEq/L|75 cc of sodium bicarbonate (8.4%) mixed in 425 cc of D5W
1784964|NCT00472576|Drug|MK-0657|Daily double-blind administration of the NR2B antagonist MK-0657 (4-8 mg/day)
1784965|NCT00472576|Drug|Placebo|Daily double-blind administration of placebo
1784966|NCT00472628|Procedure|Blood samples collected|
1784967|NCT00472641|Drug|Ziprasidone/Geodon|Ziprasidone/Geodon
1784968|NCT00472654|Behavioral|Weight Loss|Diet for weight loss for 6 weeks; all weight loss participants will attend 6 weekly counseling sessions (about 50 minutes per session)
1784969|NCT00472654|Dietary Supplement|Vitamin D 2500 IU|Daily Vitamin D 2500 IU supplement for 6 weeks
1785400|NCT00477269|Drug|Placebo|
1784972|NCT00472680|Behavioral|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
1784973|NCT00472680|Behavioral|Caloric restriction; normal protein|Weight loss with normal level of protein (18%) intake
1784974|NCT00472680|Behavioral|Nutrition Education|Participants will have the opportunity to speak with the dietitian about their diet by phone, or on-site twice per month
1784975|NCT00472693|Drug|Bevacizumab, Abraxane|Bevacizumab, 10 mg/m2 IV days 1 and 15; ABI-007, 100 mg/m2 IV days 1, 8, 15 of each 28 day cycle. Continue treatment until disease progression, patient withdrawal or unacceptable toxicities.
1784976|NCT00472706|Procedure|excision|excision 3 mm margin
1784977|NCT00472706|Procedure|Photodynamic therapy|Photodynamic therapy
1784978|NCT00472719|Biological|VRC-HIVADV027-00-VP|Adenoviral vector booster vaccine
1784979|NCT00472719|Biological|VRC-HIVADV038-00-VP|Adenovirus vector booster vaccine
1784980|NCT00472719|Biological|VRC-HIVDNA044-00-VP|Experimental, multiclade, multigene HIV DNA vaccine
1784981|NCT00472745|Behavioral|Weight Loss|Weight loss participants will consume a reduced calorie diet based on their individual caloric needs to lose 1.5-2 lbs/week, and will attend regular counseling sessions (for about 45 minutes each) with a dietitian for 6 months
1784982|NCT00472745|Behavioral|Weight Maintenance|Diet for weight maintenance for 6 months
1784983|NCT00472758|Biological|MEDI 545|IV dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
1784984|NCT00472758|Other|Placebo|IV Placebo dosed at 1.0 mg/kg, 3.0,g/kg, 10.0mg/kg and 30.0mg/kg
1784985|NCT00472771|Drug|INNO-206|
1784986|NCT00472797|Drug|Rebif New Formulation Non Titrated|human interferon beta 1a - Rebif New Formulation
1784987|NCT00472797|Drug|Rebif New Formulation Titrated|Human interferon beta 1a Rebif New Formulation
1784988|NCT00472810|Device|ologen collagen matrix in glaucoma filtering surgery|If ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
1784989|NCT00472810|Drug|MMC in glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with MMC (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
1784990|NCT00472823|Dietary Supplement|Vitamin D3|Orally for one year
1784991|NCT00472823|Dietary Supplement|Calcium Citrate (Citracal)|Orally for one year; dosage adjusted so that calcium intake is 1200-1400mg daily
1784992|NCT00472836|Drug|CP-945,598|Administration of CP-945,598 in subjects with normal renal function.
1784993|NCT00472836|Drug|CP-945,598|Administration of CP-945,598 in subjects with severe renal impairment.
1784994|NCT00472849|Drug|Oxaliplatin|Oxaliplatin 30 mg/m^2/day, over approximately 2 hours, before fludarabine is started, on days 1-4.
1784995|NCT00472849|Drug|Fludarabine|Fludarabine 30 mg/m^2 daily IV, over approximately 30 minutes, on days 2-3, 2-4, or 2-5 until maximum tolerated dose is reached.
1784996|NCT00472849|Drug|Cytarabine|Cytarabine 500 mg/m^2 daily IV, 2-hour infusion starting 4 hours after first fludarabine dose is started, on days 2-3, 2-4, or 2-5, until maximum tolerated dose is reached.
1784997|NCT00472849|Drug|Rituximab|Rituximab 375 mg/m^2 IV on day 3, course 1 (on day 1, subsequent courses).
1784998|NCT00472849|Drug|Pegfilgrastim|6 mg subcutaneously once per chemotherapy cycle, approximately 24 hours after last dose of chemotherapy
1784999|NCT00472862|Behavioral|Cognitive training|Cognitive training for 16 weeks integrated in OPUS psychosocial treatment
1785000|NCT00472875|Drug|Glibenclamide|
1785001|NCT00474461|Biological|Treatment group|Intracoronary injection of cardiac stem cells
1785002|NCT00474474|Procedure|Virtual patient is NOT introduced|
1785003|NCT00474487|Biological|Meningococcal ACWY Polysaccharide Vaccine|One dose of the licensed meningococcal ACWY polysaccharide vaccine was administered by subcutaneous injection.
1785004|NCT00474487|Biological|MenACWY CRM (19 to 55 years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection to subjects 19 years to 55 years of age.
1785005|NCT00474487|Biological|Meningococcal ACWY Conjugate Vaccine|One dose of the licensed meningococcal ACWY polysaccharide-protein conjugate vaccine was administered by intramuscular injection.
1785006|NCT00474487|Biological|Novartis MenACWY Vaccine (56 to 65 Years)|One dose of the Novartis meningococcal ACWY conjugate vaccine was administered by intramuscular injection administered to subjects 56 years to 65 years of age.
1785007|NCT00474500|Drug|Coca, Cola, Diet Coke|
1785008|NCT00474513|Drug|GSK239512|
1785017|NCT00474539|Biological|13-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
1785018|NCT00474539|Biological|7-valent pneumococcal conjugate vaccine|1 dose at 2,4,6 and 15 months of age
1785019|NCT00474552|Drug|SAM-315|Multiple Ascending Doses of SAM-315 (treatment duration: 14 days): 0.2 mg; 0.5 mg; 1 mg; 2 mg;
1785020|NCT00474565|Procedure|Placement of an aortic root pigtail catheter.|Seldinger technique for placement of catheter.
1785021|NCT00474591|Drug|Fondaparinux|
1785022|NCT00474604|Procedure|diffusion-weighted magnetic resonance imaging|A scan will be performed.
1785023|NCT00474604|Procedure|dynamic contrast-enhanced magnetic resonance imaging|A scan will be performed.
1785024|NCT00474604|Procedure|magnetic resonance spectroscopic imaging|A scan will be performed.
1785025|NCT00474617|Drug|Sugammadex|After the intubation dose or last maintenance dose of rocuronium, at reappearance of T2, subjects were to receive a dose of 2.0 mg/kg Org 25969.
1785026|NCT00474630|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/ day|
1785027|NCT00474630|Drug|Placebo|
1785088|NCT00475085|Drug|palonosetron hydrochloride|Given orally or IV
1785028|NCT00474630|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
1785029|NCT00474656|Device|High-frequency oscillation|
1785030|NCT00474656|Device|Conventional lung-open mechanical ventilation|
1785031|NCT00474669|Drug|docetaxel|Docetaxel will be administered in normal-saline delivered at an inflow temperature of 42 degreesC for 90 minutes by the technique described in Appendix D of the protocol
1785032|NCT00474682|Drug|Micronized dispersible ferric pyrophosphate|
1785033|NCT00474695|Drug|Lucentis|0.05 mg intravitreal injection
1785034|NCT00474708|Drug|Effexor|
1785035|NCT00474708|Drug|SSRI|
1785036|NCT00474721|Drug|ibuprofen|
1785037|NCT00474721|Drug|acetaminophen with codeine|
1785038|NCT00474734|Device|Intravascular ultrasound of the liver|
1785039|NCT00474747|Drug|Antithymocyte Globulin|3 mg/kg IV over no less than four (and preferably six) hours daily x 3 days
1785040|NCT00474747|Drug|Cyclophosphamide|Starting maximum dose 50 mg/kg IV x 3 days (de-escalating doses follow).
1785041|NCT00474747|Drug|Fludarabine|30 mg/m^2 IV over no less than 30 minutes daily x 4 days
1785042|NCT00474747|Radiation|Total Body Irradiation (TBI)|TBI: 200 cGy from a linear accelerator at 20 cGy/min on Day -1 (single dose)
1785043|NCT00474747|Procedure|Bone Marrow Transplant|Infusion of matched unrelated donor marrow on Day 0.
1785044|NCT00474760|Drug|CP-751,871|Currently dosing at 20 mg/kg, IV on day 1 of each 28 day cycle until progression or unacceptable toxicity
1785045|NCT00474773|Drug|Celecoxib|
1785046|NCT00474786|Drug|Sorafenib|Subjects randomized to arm B will take sorafenib 400 mg (2 x 200 mg tablets) PO, BID (total daily dose of 800 mg).
1785047|NCT00474786|Drug|temsirolimus (Torisel)|Subjects randomized to arm A will receive temsirolimus (Torisel) 25 mg via IV infusion once weekly. This infusion is to be administered over a 30-60 minute period. Subjects are to be pre-treated with 25-50 mg IV diphenhydramine (or comparable IV antihistamine) approximately 30 minutes before temsirolimus infusion.
1785048|NCT00474799|Drug|MNS075|MNS075 7.5mg q1h MNS075 15mg q3h
1785049|NCT00474812|Drug|dasatinib|
1785050|NCT00474812|Procedure|laboratory biomarker analysis|Correlative study
1785051|NCT00474812|Procedure|physiologic testing|Correlative study
1785052|NCT00474825|Drug|Hyperbaric Oxygen Therapy|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
1785053|NCT00474825|Drug|Hyperbaric Oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
1785054|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
1785055|NCT00474825|Drug|Hyperbaric oxygen|Compression rate (breathing oxygen): per patient tolerance; 1 - 3 psi per minute Treatment dose: 2.4 ATA oxygen Treatment period: 30 minutes at 2.4 ATA Decompression rate (breathing oxygen): 2 - 3 psi per minute
1785056|NCT00474838|Drug|intensive insulin group|Once daily long acting insulin and preprandial rapid acting insulin injection
1785057|NCT00474838|Drug|Oral AntiDiabetic Drug (glimepiride and metformin)|glimepiride and metformin combined therapy
1785058|NCT00474851|Drug|Norethindrone acetate + estrogens|Norethindrone acetate 5 mg by mouth daily + Conjugated equine estrogens 0.625 mg by mouth daily
1785059|NCT00474851|Drug|norethindrone acetate + placebo|norethindrone acetate 5 mg by mouth daily + Placebo capsule 1 pill by mouth daily
1785061|NCT00474877|Device|Static resting splints|
1785062|NCT00474890|Drug|cetericine and pseudoephedrine|
1785063|NCT00474903|Drug|acetylsalicylic acid|Given orally
1785064|NCT00474903|Drug|esomeprazole magnesium|Given orally
1785065|NCT00474903|Other|placebo|Given orally
1958325|NCT01772823|Behavioral|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
1785068|NCT00474929|Drug|RAD001|Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
1785069|NCT00474929|Drug|Sorafenib|Phase I: Dose level 0: Sorafenib 200 mg twice daily; Dose level 1: Sorafenib 200 mg twice daily; Dose level 2: Sorafenib 400 mg twice daily; Dose level 3: Sorafenib 400 mg twice daily; Phase II: Sorafenib 200 mg twice daily;
1785070|NCT00474955|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms or 135 micrograms sc weekly for 48 weeks
1785071|NCT00474968|Device|e2 Cell Collector [SoftPAP(R)]|Cervical cells collected using the e2 Cell Collector [SoftPAP(R)]
1785072|NCT00474968|Device|Spatula/Brush|Cervical cells collected using a combination of a cervical spatula and an endocervical brush
1785073|NCT00474981|Behavioral|IMNCI|Implementation of IMNCI in the intervention sites
1785074|NCT00474994|Drug|sunitinib malate|
1785079|NCT00475033|Biological|13-valent Pneumococcal Conjugate Vaccine|13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
1785080|NCT00475033|Biological|7-valent pneumococcal conjugate vaccine|7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.
1785081|NCT00475046|Behavioral|Motivational Interviewing|
1785082|NCT00475059|Drug|cimetidine arrow|patients who received cimétidine
1785083|NCT00475072|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
1785090|NCT00475085|Drug|placebo|Given orally
1785091|NCT00475098|Drug|Tinzaparin sodium 100 UI/Kg/OD for 12 weeks|treatment in lung tumours
1785092|NCT00475111|Behavioral|Cognitive Behavior Therapy for Pain (CBT-P)|
1785093|NCT00475111|Behavioral|Mindfulness Meditation for Emotion Regulation (MM-ER)|
1785094|NCT00475111|Behavioral|Rheumatoid arthritis education|
1785095|NCT00475124|Device|Home Monitoring of pacemaker|Daily Home Monitoring data transmission from the implanted pacemaker to Home Monitoring service center.
1785096|NCT00475124|Device|Home Monitoring of pacemaker deactivated|No Home Monitoring data transmission.
1785097|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. For subjects in this combination therapy arm, antidepressant dose will remain constant throughout the study.
1785098|NCT00475137|Drug|Lamotrigine|Lamotrigine will be initiated at 25mg daily for two weeks, then increased to 50mg daily for one week, and then increased to 100 mg daily. The dose may then be adjusted upward or downward by 50-100mg weekly, at the investigator's discretion, provided that it remains within the protocol defined range of 100mg - 400mg daily. Subjects in this group will discontinue their antidepressants prescribed to them before the study.
1785099|NCT00475150|Drug|cediranib maleate|Given orally
1785100|NCT00475150|Other|laboratory biomarker analysis|Correlative studies
1785101|NCT00475163|Behavioral|Behavior modification|
1785102|NCT00475176|Drug|Peginterferon alfa-2a|
1785103|NCT00475176|Drug|Ribavirin|
1785104|NCT00475176|Drug|S-adenosyl methionine for Chronic Liver Disease|
1785105|NCT00475189|Drug|loestrin 24/4 vs loestrin 1/20|One month of loestrin 1/20 then randomized to Loestrin 24/4 or Loestrin 1/20 x 3 months. After 3 months if randomized to 1/20 will be switched to 24/4 if already on 24/4 will be given a choice which OC they want to continue for 3 more months.
1785106|NCT00475189|Drug|loestrin 1/20|loestrin 1/20 1 tab 21/7 x 3mo and then changed to Loestrin 24 FE
1785107|NCT00475215|Drug|Sugammadex 2.0 mg/kg|After the intubation dose or last maintenance dose of rocuronium, at reappearance of T2, subjects were to receive a dose of 2.0 mg/kg Org 25969 in randomized order
1785108|NCT00475215|Drug|Sugammadex 4.0 mg/kg|After the intubation dose or last maintenance dose of rocuronium, at reappearance of T2, subjects were to receive a dose of 4.0 mg/kg Org 25969 in randomized order
1785109|NCT00475228|Drug|Levonorgestrel IUD|intrauterine insertion for arm 1 immediately after D&E procedure and for arm 2 at 3-6 weeks post-procedurem
1785110|NCT00475241|Behavioral|Prolonged Exposure therapy for PTSD|exposure-based treatment for PTSD
1785111|NCT00475241|Behavioral|Present centered therapy for PTSD|present focused coping and problem solving for PTSD
1785112|NCT00475267|Device|Trifecta aortic heart valve|Intended as a replacement for a diseased, damaged, or malfunctioning aortic heart valve.
1785115|NCT00475293|Drug|Panitumumab and CPT-11|"Panitumumab will be administered by IV infusion on day 1 of each cycle just prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg
Irinotecan: 350 or 300 mg/m2. day 1
One treatment cycle is defined as the 21 day period following the commencement of treatment with panitumumab + irinotecan plus additional time, as needed, for the resolution of irinotecan-related toxicities"
1785116|NCT00475306|Drug|metoclopramide 10 mg|an anti-emetic medication
1785117|NCT00475306|Drug|Diphenhydramine 25 mg|used for prophylaxis against akathisia
1785118|NCT00475306|Drug|Placebo|placebo
1785119|NCT00475306|Drug|Metoclopramide 20 mg|Metoclopramide 20 mg
1785120|NCT00475319|Drug|placebo|comparison of different dosages of drug
1785121|NCT00475319|Drug|1% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
1785122|NCT00475319|Drug|2% OPC-12759 ophthalmic suspension|comparison of different dosages of drug
1785123|NCT00475332|Drug|Iodine I -01 Tositumomab (Bexxar)|"Patients will be treated in two dosing phases, each phase includes two infusions. The first phase, termed dosimetric dose, involves an intravenous administration of 450 mg unlabeled tositumomab followed by an intravenous administration of 5 mCi (0.18 GBq) of I-131 tositumomab for the purpose of determining the rate of whole body clearance of radioactivity (residence time) so that the administered activity (mCi or GBq) to deliver a 75 cGy (or 65 cGy for patients with baseline platelet count from 100,000 to 149,999/mm^3) total body radiation dose can be calculated."
1785124|NCT00475332|Procedure|External Beam Radiation Therapy|All patients are to receive 20 Gy in 10 fractions of 200 cGy to the PTV
1785125|NCT00475345|Behavioral|Bedtime snacks|
1785126|NCT00475358|Drug|Duloxetine|
1785127|NCT00475358|Drug|Placebo|
1785128|NCT00475371|Drug|MKC253 Inhalation Powder|Inhalation powder
1785129|NCT00475384|Drug|Fludarabine|40 mg/m^2 By Vein Over 30 Minutes x 5 Days
1785130|NCT00475384|Drug|Thiotepa|5 mg/kg By Vein Daily x 2 Days
1785131|NCT00475384|Radiation|Total Body Irradiation|200 centigray (cGy) (BID) Twice Daily Over 20-40 Minutes x 3 Days
1785132|NCT00475384|Drug|Melphalan|140 mg/m^2 by vein x 1 Day
1785133|NCT00475384|Biological|Stem Cell Transplant (SCT)|Infusion of normal donor stem cells on Day 0
1785134|NCT00475384|Procedure|Anergized Cell Infusion|Infusion of stem cells treated with the anti-B7 antibodies on Day 35+ or 42+.
1785135|NCT00475397|Drug|Duloxetine|
1785136|NCT00475397|Drug|Placebo|
1785137|NCT00475410|Drug|ASCs (Cx401, company code)|"Experimental: ASCs: Subjects will be treated with a dose of 20 million ASCs and evaluated after 12 weeks. If needed a second dose of 40 million ASCs will be applied then.
Experimental: ASCs+fibrin glue: Subjects will be treated with a dose of 20 million ASCs plus fibrin glue and evaluated after 12 weeks. If needed a second dose of 40 million ASCs plus fibrin glue will be applied then."
1785138|NCT00475410|Drug|Fibrin adhesive|Experimental: Fibrin glue: Subjects will be treated with a dose fibrin glue and evaluated after 12 weeks. If needed a second dose of fibrin glue will be applied then.
1785139|NCT00475423|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
1785140|NCT00475436|Drug|GSK573719|
1785141|NCT00475449|Procedure|percutaneous coronary intervention|
1785142|NCT00475449|Procedure|coronary artery bypass grafting|
1785143|NCT00475462|Drug|metoprolol|
1785144|NCT00475462|Drug|conventional treatment|
1785145|NCT00475475|Behavioral|Fructose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
1785146|NCT00475475|Behavioral|glucose|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
1785147|NCT00475475|Behavioral|non-caloric sweetener|25% of energy intake in the form of a fructose-sweetened beverage (arm 1), a glucose-sweetened beverage (arm 2), or an isovolumetric amount of a beverage sweetened with a non-caloric sweetener
1785148|NCT00475488|Procedure|Coronary artery bypass grafting|Surgery performed due to coronary artery disease.
1785149|NCT00475501|Drug|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
1785150|NCT00475501|Drug|Finasteride|5 mg, oral, once/day, for 52 weeks
1785151|NCT00475501|Drug|Testosterone Enanthate|125 mg, i.m. injection, once/week, for 52 weeks
1785152|NCT00475501|Drug|Finasteride|5 mg, oral, once/day, for 52 weeks
1785153|NCT00475514|Drug|Frovatriptan 2.5mg QD|
1785154|NCT00475514|Drug|Frovatriptan 2.5 mg BID|
1785155|NCT00475514|Drug|placebo|
1785156|NCT00475527|Drug|omeprazole,clarithromycin,amoxicillin (or metronidazole)|
1785157|NCT00475540|Device|synthetic monofilament polypropylene mesh|Vaginal prolapse repair with mesh
1785158|NCT00475553|Other|remove ring if bleeding or spotting occurs more than 5 days|Both groups of women will be using the nuvaring continuously, ie if the ring is placed on 3rd of January, on the 3rd of February the ring would be removed and a new one inserted. On the 3rd of March the same thing would happen and so forth. Group 2 if bleeding or spotting occurs for more than 5 days then on the 6th day the ring is removed and will keep it out for three more days and reinsert the same ring on the 4th day.
1785159|NCT00475553|Other|If bleeding does not remove ring|Subject is using the nuvaring continuously. For example she puts the ring in on 3rd of January then the 3rd of February is when that ring is removed and another one is inserted. The 3rd of March the same thing occurs.
1785160|NCT00475566|Device|Dynalink®-E everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
1785161|NCT00475566|Device|Dynalink®-E, everolimus-eluting peripheral stent|Stenting of atherosclerotic de novo or restenotic lesions (> 50% stenosis) in the native superficial femoral or proximal popliteal artery
1785162|NCT00475579|Procedure|tube with subglottic drainage and polyurethane cuff|
1785163|NCT00475592|Device|Esophageal Capsule Endoscopy|
1785164|NCT00475592|Device|Upper Gastrointestinal Endoscopy|
1785165|NCT00475618|Procedure|topical fluoride varnish application.|Vanish application every 6 months in all accesible tooth surfaces
1785166|NCT00475618|Procedure|professional cleaning|Daily use fluoride toothpaste 500 ppm.
1785167|NCT00475618|Procedure|No fluoride toothpaste|Daily use no fluoride toothpaste.
1785168|NCT00475644|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral daily, up to 3 years
1785169|NCT00475657|Drug|pemetrexed|500 mg/m2, intravenous (IV), every 21 days x 6 cycles
1785170|NCT00475657|Drug|cisplatin|75 mg/m2, intravenous (IV), every 21 days x 6 cycles
1785171|NCT00475670|Drug|Trastuzumab|4 mg/kg i.v. loading dose on Day 1, followed by 2 mg/kg i.v. weekly; or 8 mg/kg i.v. loading dose, followed by 6 mg/kg i.v. every 3 weeks until disease progression, unacceptable toxicity, withdrawal or death.
1785172|NCT00475670|Drug|Taxane (docetaxel or paclitaxel)|Docetaxel 100 mg/m2 i.v. every 3 weeks, or paclitaxel administered in a dose of 75 mg/m2 i.v. weekly or 175 mg/m2 i.v. every 3 weeks for at least 18 weeks, or more at the discretion of the investigator. Choice of taxane at the discretion of the investigator. Taxane may be administered at the same time, or 24 hours after, administration of trastuzumab.
1785173|NCT00475683|Other|Mouth wash|Mouth wash with chlorehexidin, three times a day
1785174|NCT00475683|Dietary Supplement|Curcumol|5 ml in 50 ml water, mouthwash for 30 seconds, three times a day
1785175|NCT00475696|Drug|Duloxetine|
1785176|NCT00475709|Device|Trifecta Aortic Heart Valve|Surgical replacement of the aortic valve with the Trifecta Aortic Heart Valve.
1785177|NCT00475722|Behavioral|1 Healthy Eating|6 months telephone counseling
1785178|NCT00475722|Behavioral|2 Mediterranean|6 months telephone counseling
1785179|NCT00475735|Drug|MK0249|MK-0249, 10 mg per day was taken orally daily. If patients were unable to tolerate 10 mg per day, they were allowed to titrate down to 5 mg per day.
1785180|NCT00475735|Drug|Concerta (methylphenidate)|Titration of Concerta began with two 18-mg capsules (36 mg) for 3 consecutive days, followed by three 18-mg capsules (54 mg) for another 3 consecutive days, ending with four 18-mg capsules (72 mg) for the remainder of the treatment period. If patients were unable to tolerate 72 mg per day, they were allowed to titrate down to 54 mg per day. Concerta was taken orally once daily.
1785181|NCT00475735|Drug|Placebo|For 4 of the 6 treatment sequences, patients had one 4-week treatment period with placebo of MK-0249 (tablets) and placebo of Concerta (capsules). For patients assigned to active treatments of MK-0249 or Concerta, in order to preserve the blind, placebo of the non-active component was provided, ie, if MK was assigned (tablets), then placebo of Concerta (capsules) was also provided. Each patient was to dose with tablets and capsules, either active or placebo. Placebo was taken orally once daily.
1785182|NCT00475748|Procedure|Early and late surgery for traumatic central cord syndrome|Surgical decompression of the spinal cord, either front, back or combined
1785183|NCT00475774|Behavioral|Long-chain (C18:2) and medium chain fatty acid (C8 and C10).|
1785184|NCT00475787|Procedure|Spinal Manipulation|Spinal manipulation involves high velocity low amplitude manipulation and flexion distraction and mobilization.
1785185|NCT00475787|Procedure|Detuned Ultrasound|"US machine is turned on and set at 0 w/cm2"
1785186|NCT00475800|Drug|Lumiracoxib|
1785187|NCT00475813|Drug|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
1785188|NCT00475826|Drug|Statins and Ezetimibe|
1785189|NCT00475839|Device|Tension-free Vaginal Tape|
1785190|NCT00475839|Device|Monarc sub-fascial hammock|
1785191|NCT00475852|Drug|Nesiritide|0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
1785192|NCT00475852|Drug|Placebo|matching placebo infusion:0.01 mcg/kg/min IV infusion (with or without 2 mcg/kg bolus) for 24 to 168 hrs
1785193|NCT00475865|Drug|Teriflunomide|"Film-coated tablet
Oral administration"
1785194|NCT00475865|Drug|Placebo (for teriflunomide)|"Film-coated tablet
Oral administration"
1785195|NCT00475865|Drug|Glatiramer Acetate (GA)|Solution in prefilled syringe for subcutaneous injection
1785196|NCT00475878|Drug|escitalopram|10mg escitalopram/day for 3 months
1785197|NCT00475878|Drug|placebo|placebo capsule/day for 3 months
1785198|NCT00475904|Drug|EpiCept-NP-1 Cream|ketamine 4% amitriptyline 2% cream, twice daily for 4 weeks
1785199|NCT00475904|Drug|Gabapentin Capsules|1800mg/day capsules for 4 weeks
1785200|NCT00475904|Drug|placebo|placebo cream and caps
1785201|NCT00475917|Drug|XL844|Gelatin capsules supplied as 5-mg, 25-mg, and 100-mg strengths; twice-weekly dosing.
1785202|NCT00475917|Drug|Gemcitabine|once-weekly 30-minute IV infusion
1785203|NCT00475930|Drug|2% chlorhexidine gluconate (CHG) impregnated cloths|self applied three times per week
1785204|NCT00475930|Drug|Comfort Bath cloths (placebo cloths)|self applied three times weekly
1785205|NCT00475956|Drug|AZD2171|oral tablet multiple ascending doses 20, 30 or 45 mg
1785206|NCT00475956|Drug|AZD0530|oral tablet multiple ascending doses 125 mg or 175 mg
1785207|NCT00475969|Drug|duloxetine|
1785208|NCT00475969|Drug|placebo|
1785209|NCT00475982|Behavioral|Weight Loss|Subjects undergo a weight loss intervention prior to radical prostatectomy. The intervention includes weekly visits with the dietician, DEXA scanning, blood draws, and anthropometrics.
1785210|NCT00475982|Other|No Weight Loss Group|These subjects do not undergo a weight loss intervention prior to radical prostatectomy. This group does undergo DEXA scanning, blood draws, and anthropometrics prior to radical prostatectomy.
1785211|NCT00476008|Drug|Memantine|One tablet memantine (Namenda)10mg morning and evening (BID) for 12 months
1785212|NCT00476008|Drug|Placebo|One tablet placebo morning and evening (BID) for 12 months
1785213|NCT00476021|Device|Levonorgestrel-releasing IUD (Mirena)|levonorgestrel-releasing IUD containing 52 mg levonorgestrel, indicated for use for up to 5 years
1785214|NCT00476034|Drug|lumiracoxib|
1957153|NCT02514889|Behavioral|Calorie-counting|"The Calorie Counting (CC) condition asks obese patients to achieve a daily calorie deficit. For average women consuming 2,000 calories at baseline, the target daily calorie total might be 1,600 calories. Participants are also asked to do at least 150 minutes of moderate to vigorous physical activity per week.
Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the CC condition. The intervention protocol is adapted from the Diabetes Prevention Program. Behavior change strategies include: self-monitoring (e.g., calorie-counting, self-weighing), stimulus control, and relapse prevention strategies. The health coaching will occur during two home visits, two group health education sessions, and 7 telephone coaching calls."
1957154|NCT02514889|Behavioral|MyPlate|"The MyPlate approach asks Americans to limit daily calories but emphasizes eating MORE high-satiation foods by making ½ of daily food choices fruits and vegetables,¼ of daily food choices whole grains. All participants are asked to do at least 150 minutes of moderate to vigorous physical activity per week.
Two community health workers will provide behavior change coaching to 150 TCC obese patients randomly assigned to the MyPlate condition. MyPlate is adapted from the DASH protocol. Behavior change strategies include: progressive goal-setting, stimulus control, and self-monitoring (e.g., % of food choices that are fruits & vegetables). The health coaching will occur during two home visits, two group health education sessions, and 7 telephone behavior change coaching calls."
1785217|NCT00476060|Procedure|Autologous mesenchymal stem cell transplantation|Arm A: 300 million cells will be infused one time through a peripheral vein/// Arm B: Infusion of placebo one time through a peripheral vein
1785218|NCT00476073|Drug|FLUTIFORM® (Formoterol fumarate / Fluticasone propionate)|
1785219|NCT00476086|Drug|Gemcitabine|
1785220|NCT00476086|Drug|Oxaliplatin|
1785221|NCT00476086|Radiation|Radiation|
1785222|NCT00476099|Drug|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI|Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) two puffs via oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
1785223|NCT00476099|Drug|Budesonide 200 µg plus formoterol 6 µg DPI|two oral inhalations twice a day at 8.00 a.m. and 8.00 p.m.
1785224|NCT00476099|Drug|Formoterol 12 µg DPI|one oral inhalation twice a day at 8.00 a.m. and 8.00 p.m.
1785225|NCT00476112|Drug|Vernakalant Injection 20 mg/mL|
1785226|NCT00476125|Behavioral|Dietary manipulation ketogenic diet|Subjects will consume a ketogenic diet for 3 days.
1785227|NCT00476125|Behavioral|Dietary Manipulation - 12 day ketogenic diet|Subjects will consume a ketogenic diet for 12 days.
1785228|NCT00476125|Behavioral|16 Hour Fast|Subjects will fast for 16 hours.
1785230|NCT00476151|Drug|EpiCept NP-1 (4% Amitriptyline/ 2% Ketamine) Topical Cream|topical cream applied daily for 4 weeks
1785231|NCT00476151|Drug|placebo cream|inactive placebo cream applied two times daily
1785232|NCT00476164|Drug|Rituximab|2 doses of 1g 14 days apart
1785233|NCT00476164|Other|Control arm|Continue of optimised oral immunosuppression
1785234|NCT00476177|Biological|Infusion of donor dendritic cells|Given in the outpatient setting
1785235|NCT00476177|Biological|Infusion of donor lymphocytes|Given in outpatient setting
1957160|NCT02510794|Drug|Ranibizumab|Ranibizumab will be administered at dose of 0.5 mg monthly ITV injections of 10-mg/mL formulation or delivered through the implant with three different formulations (Dose 1, 2 and 3).
1785513|NCT00478348|Procedure|Prosthetic repair of abdominal incisional hernia|Rives-Stoppa repair of incisional hernia
1957162|NCT02508649|Drug|selepressin|
1957163|NCT02508649|Drug|placebo|
1957164|NCT02508571|Other|Direct swallowing training (DST)|The DST consists of placing a bolus of 0.05-0.2 mL of formula milk via a 1-mL syringe directly on the medial-posterior part of the tongue approximately at the level of the hard and soft palate junction. The volume is started with 0.05 mL, and increased in increments of 0.05 mL to a maximum of 0.2 mL until the swallowing reflex is observed. Once the minimal volume necessary to initiate the swallow reflex is identified, it is used for the duration of the training. The bolus is provided every 30 sec over the 15-minute program or as tolerated. This training is provided once a day, 5 days a week. And it is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve.
1785250|NCT00476203|Behavioral|Yoga|Instructor-led yoga classes 1/time per week + 4 days of home practice
1785251|NCT00476203|Other|Delayed yoga classes|Delayed yoga classes (after 6 months) offered [wait list control group]
1785252|NCT00476216|Drug|Combination of Arixtra with chemotherapy|"Single arm, 2 cohort feasibility study:
Carboplatin will be administered intravenously over approximately 30 minutes after paclitaxel infusion is completed and the dose will be calculated on basis of an area under the curve (AUC) of 6, according to the formula administered every 21 days. Paclitaxel will be administered 200 mg/m2 over 3 hours every 21 days.
Patients in both cohorts 1 & 2 will receive standard chemotherapy alone during cycle 1.
Cohort 1:During subsequent cycles (2-4) patients will receive a daily prophylactic dose (day 1 through 21) of Arixtra and continue 21 days after the last course of chemotherapy.
Cohort 2: Patients in cohort 2 will receive standard chemotherapy alone during cycle 1. During subsequent cycles, the patient will receive a therapeutic weight based dose of Arixtra for the first 2 days of each chemotherapy cycle followed by a daily prophylactic dose of Arixtra (day 3 through 21) until the next course of chemotherapy."
1785253|NCT00476229|Drug|Thymoglobulin|1.5 mg/kg by vein on Days -11 to -7.
1785254|NCT00476229|Radiation|Total Lymphoid Irradiation|80 cGy daily on days -11 to -7 and -4 to 0.
1785255|NCT00476229|Procedure|Peripheral Blood Stem Cell Infusion|PBSC infusion administered on day 0.
1785256|NCT00476229|Drug|Rituximab|375 mg/m^2 by vein on days -13, -6, 1, & 8. Only those patients whose tumors express CD20 will receive Rituximab.
1785257|NCT00476242|Drug|Vivitrol|intramuscular injection of Vivitrol 380 mg for up to 6 months (six injections)
1785258|NCT00476242|Drug|memantine|Memantine will be given in two divided doses, starting with the second day of the naltrexone induction, with the target doses of 40 mg/day (or the maximum tolerated dose), for a total of twelve weeks of medication treatment.
1785259|NCT00476255|Behavioral|Enhanced Standard Care (ESC)|Reading material
1785260|NCT00476255|Behavioral|Brief Motivational Intervention (BMI)|Motivational interview with trained therapist
1785261|NCT00476268|Drug|beclomethasone/formoterol (100/6µg) pMDI|Two puffs b.i.d
1785262|NCT00476268|Drug|Beclometasone dipropionate 250 µg/unit dose pMDI|2 inhalations bid
1785263|NCT00476268|Drug|Formoterol powder 12 µg/unit dose|2 inhalations bid
1785264|NCT00476281|Procedure|Urinary collect|
1785265|NCT00476281|Procedure|Continuous Glucose Monitoring System (CGMS)|
1785266|NCT00476294|Other|Telephone Questionnaire|Follow-Up Telephone Calls Every 6 Months for 5 Years.
1785267|NCT00476307|Biological|Fluarix™/Influsplit SSW® 2007/2008|
1785268|NCT00476320|Procedure|Magnetic Resonance Imaging|
1785269|NCT00476320|Procedure|Revascularization|
1785270|NCT00476320|Procedure|Echocardiography with myocardial deformation imaging|
1785271|NCT00476333|Device|APOS biomechanical gait system|
1785272|NCT00476346|Dietary Supplement|Calcium & Vitamin D|Calcium 2000mg / daily Vitamin D 800IU / daily
1785273|NCT00476359|Drug|Lopinavir/r plus saquinavir|lopinavir/ritonavir 230/57.5 mg/m2 orally twice daily and saquinavir 50 mg/kg orally twice daily
1785274|NCT00476385|Drug|somatropine|subcutaneous injections, 20 % less than the dosage of Maxomat 1.3 mg
1785275|NCT00476398|Procedure|Capsule endoscopy|Patient will undergo a capsule endoscopy for the evaluation of their chest pain.
1785276|NCT00476411|Biological|HBV vaccine|HBV vaccine 3 doses at month 0, 1, and 6
1785277|NCT00476424|Drug|efavirenz|EFV 400 mg OD for 14 days EFV 600 mg OD for 14 days
1785278|NCT00476437|Drug|biphasic insulin aspart|
1785279|NCT00476437|Drug|biphasic human insulin|
1785280|NCT00476463|Drug|Emtricitabine|Emtricitabine 200 mg OD + Zidovudine 300 mg BID + EFV OD compared to TDF + FTC + EFV
1785281|NCT00476476|Drug|Erlotinib|Orally every day for about 4-6 weeks
1785282|NCT00476502|Genetic|identify genetic polymorphism in Thai HIV infected|Gene sequencing of Cyp450 metabolic pathway
1785283|NCT00476515|Drug|Rituximab|the recommended dosage of Rituximab is 375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22).
1785284|NCT00476528|Behavioral|Reality Orientation|Two matched groups of patients diagnosed with TBI are selected from two university hospitals. In addition to conventional treatment, patients in one group are introduced to a reality- orientation programme consisting of systematic orientation, information, and systematic cooperation with the patient´s relatives.Patients in the other group receive conventional treatment only. All patients are tested on a daily basis in accordance with the RLAS and the GOAT test.
1785285|NCT00476528|Behavioral|Reality Orientation|A quasiexperimental study
1785286|NCT00476541|Drug|Gemtuzumab ozogamicin|Two courses of Gemtuzumab vs. no further therapy
1785287|NCT00476554|Drug|Sapacitabine|Sapacitabine
1785288|NCT00476567|Other|standard|standard antenatal care
1785289|NCT00476567|Behavioral|specific training program|a specific training program 12 weeks between pregnancy week 20 and 36. regular exercise 45-60 minutes minimum three times per week.
1785290|NCT00476580|Behavioral|Questionnaire|Questions to collect health information specific to Sri Lankans.
1785291|NCT00476593|Drug|Diclofenac|"Preservative- free Diclofenac Na 0.1% eye drops (Voltaren Ophta SDU;Novartis Pharms). One drop four times daily in one eys for three days.
The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
1785292|NCT00476593|Drug|Dexamethasone|"Dexamethasone sodium phosphate 0.1% eye drops (Spersadex OmniVision, Novartis Pharma), one drop six times daily for three days in one eye.
Pharms). One drop four times daily in one eys for three days.
The evaluation of macular thickness/function after 3 days use of anti-inflammatory eye drops in healthy subjects is the only sub-study involving an intervention design."
1785293|NCT00476606|Drug|Zidovudine, Stavudine, Didanosine, Lamivudine|Refer to the Thai guideline for HIV management 2007
1785294|NCT00476606|Drug|Nevirapine, Efavirenz|Refer to the Thai guideline for HIV management 2007
1785295|NCT00476606|Drug|LPV/r, Saquinavir, Indinavir, Ritonavir, Nelfinavir|Refer to the Thai guideline for HIV management 2007
1785296|NCT00476619|Drug|erythropoeitin|Subjects will receive a one-time dose of either placebo, or EPO 40,000 U intravenously 30 to 240 minutes prior to intravenous contrast administration.
1785297|NCT00476632|Behavioral|Questionnaire|50 Minute Interview
1785298|NCT00476645|Drug|Fulvestrant|Fulvestrant 250 mg IM on Days 1 and 14 in the first month, thereafter 250 mg monthly
1785299|NCT00476671|Procedure|lumbar puncture, MRI, MRS|lumbar puncture, MRI, MRS are only performed in patients with HIV associated dementia
1785300|NCT00476684|Procedure|radiofrequency treatment|Radiofrequency-neurotomy of the medial branch at 80 degr. C needle temperature for 70 seconds, after diagnostic blocks
1785301|NCT00476684|Procedure|sham neurotomy|Radiofrequency-neurotomy of the medial branch at 37 degr. C needle temperature for 70 seconds, after diagnostic blocks
1785302|NCT00476697|Device|German manufactured UVA1 emitting light system|The dose and scheduling of irradiation is as follows: Up to 130J/cm2 from a UVA1 Sellamed irradiation device with irradiations up to 5 times per week.
1785303|NCT00476710|Drug|Colesevelam HCl|
1785304|NCT00476736|Drug|Effect on small airways (N-Acetylcystein)|
1785305|NCT00476775|Behavioral|after school ethnic dance program - ballet folklorica|
1785306|NCT00476775|Behavioral|culturally-tailored, home-based screen time reduction|
1785307|NCT00476775|Behavioral|culturally-tailored health and nutrition education|
1785308|NCT00476788|Device|Omnipod Insulin Management System|Initiation of insulin pump therapy within three months of the diagnosis of type 1 diabetes mellitus
1785309|NCT00476801|Device|German manufactured UVA1 light emitting device|The UVA1 dose will be up to 130 J/cm2.
1785310|NCT00476827|Drug|Bevacizumab|Bevacizumab(Avastin) 15 mg/kg every 3 weeks in combination with Capecitabine (Xeloda), 2 weeks on and 1 week off on a every 3 week cycle. until progression or unacceptable toxicity develops
1785311|NCT00476827|Drug|Docetaxel|Docetaxel 35mg/m² IV over 60 min days 1, 8, and 15 in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
1785312|NCT00476827|Drug|CPT-11|CPT-11 (Irinotecan, Camptosar) - Patients being treated with an enzyme inducing antiepileptic drug (EIAED) will receive 340 mg/m² IV; others will receive 125 mg/m² IV 90 min on days 1 and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
1785313|NCT00476827|Drug|Paclitaxel|Paclitaxel (Taxol)90 mg/m2 IV over 60-90 min days 1, 8, and 15, in combination with avastin 10 mg/kg on days 1 and 15 of a 28-day cycle.until progression or unacceptable toxicity develops
1785314|NCT00476827|Drug|Vinorelbine Tartrate|Vinorelbine Tartrate (Navelbine®) 25 mg/m² IV over 10 min days 1, 8 and 15 in combination with avastin 10 mg/kg IV on days 1 and 15 of a 28-day cycle. until progression or unacceptable toxicity develops
1785315|NCT00476827|Drug|Gemcitabine|Gemcitabine (difluorodeoxycytidine, dFdC) 1000 mg/m2 IV on days 1 and 8 in combination with avastin 15 mg/kg IV on day 1 of a 21-day treatment cycle.until progression or unacceptable toxicity develops
1785316|NCT00476853|Drug|HAART containing nevirapine|Initially NVP 200 mg BID (400 mg per day) was compared to 400 mg BID and 200 mg OD NVP (600 mg per day). 400 mg/day versus 600 mg/day.
1785317|NCT00476866|Device|intermittent positive-pressure breathing (IPPB)|
1785318|NCT00476879|Drug|Somatropin and pegvisomant|Somatropin are given intravenous, 0.5mg pegvisomant are given subcutaneous, 15 mg NaCl are given subcutaneous, 2 ml
1785319|NCT00476892|Procedure|Pelvic Floor Muscle Training|Women in the intervention group attend 5 physiotherapy sessions. At each appointment a clinical history is taken, pelvic floor muscle assessment carried out, exercises taught and prescribed, and appropriate lifestyle advice given. At the first of these appointments a detailed explanation of the pelvic anatomy and different types of prolapse is given.
1785320|NCT00476905|Device|Spectral Diagnosis Probe|The device collects two types of tissue spectra: i) laser-induced fluorescence spectra and ii) white light reflectance spectra. This portable reflectance spectrofluorimeter collects spectra in a fraction of a second. Light collection and delivery are achieved via an optical fiber probe. The optical fiber probe is approximately 1 mm in diameter and 3 m long. The same probe collects light emitted from the tissue and delivers it back to the instrument for spectral analysis.
1785321|NCT00476918|Drug|Intravitreal injection (triamcinolone acetonide)|
1785322|NCT00476931|Biological|SB-509|60 mg dose
1785323|NCT00476931|Other|Placebo|Saline
1785324|NCT00476944|Procedure|Percutaneous Coronary Intervention (PCI)|
1785325|NCT00476957|Device|Stent|Stent implantation
1785326|NCT00476957|Device|Stent|Stent implantation
1785327|NCT00476970|Behavioral|Patient Navigation|Patient navigators will perform an initial interview with participants to identify and explore barriers, work with patients to overcome barriers, educate patients about CRC screening, motivate and coach patients, and schedule and accompany patients to colonoscopy testing
1785328|NCT00476983|Drug|saquinavir/ritonavir plus truvada|SQV/r 1500/100 mg OD + Truvada OD for 2 years
1785329|NCT00469781|Drug|2. Xibrom (Bromfenac)|Group 1 and 2: 1 drop(Instill one drop in the eye that was operated on twice daily)3 days prior to surgery and 4 doses during dilation immediately before the procedure. Use for 4 weeks after surgery.
1785330|NCT00469781|Drug|1. Pred Forte|"Group 1 Instill one drop in the eye that was operated on four times a day starting on day of surgery and use for four weeks.
Group 2 Instill one drop in the eye that was operated on twice a day starting on day of surgery and use for four weeks."
1785331|NCT00469794|Procedure|stress test|
1785332|NCT00469820|Biological|autologous tumor cell vaccine|
1785333|NCT00469820|Biological|peripheral blood lymphocyte therapy|
1785334|NCT00469833|Drug|insulin glargine|Diabetic subjects will be treated with insulin glargine once daily for 2 months. Subjects will monitor their blood glucose and have their insulin dose adjusted in steps of 4-6 units to achieve a goal of less than or equal to 120 mg/dl for fasting blood glucose.
1785335|NCT00469846|Procedure|L-arginine supplementation in a medical food|
1785336|NCT00469846|Procedure|Vitamin C and E supplementation in a medical food|
1785337|NCT00469859|Drug|cytarabine|given IV
1785338|NCT00469859|Drug|idarubicin|Given IV
1785339|NCT00469859|Drug|lestaurtinib|Given orally
1785340|NCT00469872|Procedure|Context-focused compared to child-focused interventions|
1785341|NCT00469885|Drug|Nicotine replacement|For reduction
1785342|NCT00469885|Behavioral|Motivational counseling|No drugs
1785343|NCT00469898|Drug|Carboplatin|"Carboplatin dosage calculation to be given on day 1, every 21 days:
Carboplatin (mg) = (AUC of 5) x (GFR + 25)
*up to 6 cycles at physician's discretion"
1785344|NCT00469898|Drug|irinotecan hydrochloride|"50 mg/m2 IV on days 1 and 8 every 21 days
Should be infused IV over 30- 90 minutes."
1785345|NCT00469911|Procedure|Magnetic Resonance Spectroscopy|It is basically the same as an MRI. It is a noninvasive procedure that provides detailed body images on any plane.
1785346|NCT00469911|Procedure|Endocardial Biopsy|This is a standard of care procedure that is already performed on heart transplant patients. This is a procedure that takes a biopsy (tissue sample) of the heart muscle.
1785347|NCT00469924|Procedure|Real Time Clinical Alerting|
1785348|NCT00469937|Drug|lithium carbonate|Dose levels Neoadjuvant lithium Concurrent lithium Dose level -1 300mg po QD 300mg po QD Dose level (starting dose) 300mg po BID 300mg po BID Dose level 2 300mg po TID 300mg po TID Dose level 3 300mg po QID 300mg po QID
1785349|NCT00469937|Procedure|cognitive assessment|cognitive assessment
1785350|NCT00469937|Procedure|quality-of-life assessment|quality-of-life assessment
1785351|NCT00469937|Radiation|radiation therapy|Protocol radiotherapy must begin within seven days following initiation of Lithium therapy if day seven falls on a holiday or weekend; it is acceptable to begin treatment the next business day. One treatment of 3Gy will be given daily with the exception of weekends and holidays for a total of (10 fractions) for a total of 30 Gy over 2 to 3 weeks.
1785352|NCT00469950|Behavioral|exercise training|Exercise training in groups
1785353|NCT00469963|Procedure|quality-of-life assessment|quality-of-life assessment
1785354|NCT00469963|Radiation|yttrium Y 90 resin microspheres|radiation therapy
1785355|NCT00469976|Drug|bevacizumab|
1785356|NCT00469976|Drug|carboplatin|
1785357|NCT00469976|Drug|enzastaurin hydrochloride|
1785358|NCT00469976|Drug|gemcitabine hydrochloride|
1785359|NCT00469989|Procedure|Infection with hookworm larvae|
1785360|NCT00470002|Drug|Somatropin|
1785361|NCT00470015|Biological|MART-1 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
1785362|NCT00470015|Biological|IL-2|0.5x10^6/m^2
1785363|NCT00470015|Biological|gp100 antigen|1000 mcg; Day 1 of a 21 day cycle x 4
1785364|NCT00470015|Biological|GM-CSF|300mcg
1785365|NCT00470015|Biological|MART-1a peptide|1000 mcg; Day 1 of a 21 day cycle x 4
1785366|NCT00476996|Drug|leflunomide|Oral repeating dose
1785367|NCT00476996|Drug|methotrexate|Oral or parenteral repeating dose
1785368|NCT00476996|Drug|ocrelizumab|Intravenous repeating dose (200mg)
1785369|NCT00476996|Drug|ocrelizumab|Intravenous repeating dose (500mg)
1785370|NCT00476996|Drug|placebo|Intravenous repeating dose
1785371|NCT00477009|Device|Mandibular repositioning appliance, adjustable|Comparison between mandibular repositioning appliance for nightly use and a placebo device regarding effects on sleep apneas and daytime symptoms as well as blood pressure and markers of oxidative stress and sleepiness.
1785372|NCT00477022|Device|Vasotrain-447|
1785373|NCT00477035|Drug|CIK cells|2x10e8 cells/kg
1785374|NCT00477035|Drug|etoposide|60 mg/kg
1785375|NCT00477035|Drug|bcnu|15 mg/kg
1785376|NCT00477035|Drug|cyclophosphamide|100 mg/kg
1785377|NCT00477035|Drug|gemcitabine|1250 mg/m2
1785378|NCT00477035|Drug|vinorelbine|30 mg/m2
1785379|NCT00477035|Drug|melphalan|200 mg/m2
1785380|NCT00477048|Drug|Saquinavir|SQV/r 1000/100 BID + NNRTI or SQV/r 1600/100 OD + 2 NRTI
1785381|NCT00477061|Drug|Morphine|
1785382|NCT00477074|Procedure|bronchoalveolar lavage, blood analysis|
1785385|NCT00477100|Other|Interview|Personal Interview
1785386|NCT00477100|Procedure|Blood and Tissue Collection|Blood (about 4 tablespoons) collected during routine blood draw, breast tissue collected at the time of standard diagnostic procedure, and a core and a skin biopsy collected at the time of standard diagnostic procedure.
1785387|NCT00477126|Drug|GPO ritonavir versus Norvir|RTV generic compared to reference drugs (Norvir, Abbott)
1785388|NCT00477152|Drug|hyaluronidase (human recombinant)/rehydration fluid|Single 150 U subcutaneous (SC) HYLENEX dose administered immediately prior to start of SC infusion of rehydration fluid. Additional 150 U HYLENEX dose to be administered prior to any additional fluid infusion beyond 24 hours.
1785389|NCT00477165|Drug|Citalopram|20mg/day for 4 weeks, then 40 mg/day for 4 weeks
1785390|NCT00477165|Drug|Placebo|Identical to citalopram 20mg capsules; 1 capsule/day for 4 weeks, then 2 capsules/day for 4 weeks
1785391|NCT00477191|Drug|Etanercept|TNF-alpha antagonist 50 mg twice a week x 3 mos and the 50 mg once a week for 3 months.
1785392|NCT00477204|Drug|Simvastatin|simvastatin 20 mg daily
1785393|NCT00477204|Drug|Ezetimibe/Simvastatin|Ezetimibe (10mg)/Simvastatin (20mg)
1785394|NCT00477217|Drug|Zoledronic acid|
1785395|NCT00477230|Device|Endoscopic Ablation System|Single ablation procedure with Endoscopic Ablation System
1785396|NCT00477230|Drug|Standard Anti-arrhythmic Drug (AAD) Therapy|Medication as prescribed by physician.
1785397|NCT00477243|Behavioral|Questionnaire|8 questionnaires will take about 40 minutes to complete.
1785398|NCT00477256|Behavioral|Questionnaires|5 Paper-and-Pencil Questionnaires: All participants will engage in a one-time completion of all measures.
1785401|NCT00477282|Drug|Karenitecin|Karenitecin 1.0mg/m2/day administered as a single daily IV infusion over 60 minutes for 5 consecutive days every 3 weeks (21 days)
1785402|NCT00477282|Drug|Topotecan|Topotecan 1.5 mg/m2/day administered as a single daily IV infusion over 30 minutes for 5 consecutive days every 3 weeks (21 days)
1785403|NCT00477295|Drug|Zonisamide|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
1785404|NCT00477295|Drug|Carbamazepine|Week 1 and 2 either 100mg zonisamide or 200 mg carbamazepine Week 3 and 4 either 200mg zonisamide or 4800 mg carbamazepine Week 5 and 6 either 300mg zonisamide or 600 mg carbamazepine; this dose then to be maintained unless a subject has a seizure more than two weeks post a dose increase.
1785405|NCT00477308|Procedure|salvage therapy|
1785406|NCT00477321|Drug|CYT 107|3 dose levels: 3, 10 and 20µg/kg/week.3administrations
1785407|NCT00477594|Drug|mipomersen sodium|200 mg/ml, in 1 ml solution for subcutaneous injection.
1785408|NCT00477607|Drug|alpha-lipoic acid|Supplements (1200mg once a day) or placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
1785409|NCT00477607|Behavioral|Audiology|otoscopy, immittance screening, noise exposure questionnaire and individualized behavioral pure-tone in the convention and high-frequency ranges.
1785410|NCT00477607|Biological|laboratory biomarker analysis|Plasma concentrations of Malondialdehyde (MDA) will be measures as an indicator of oxidative stress.
1785411|NCT00477607|Drug|Placebo|Placebo will be administered to each patient prior to first cisplatin treatment and continue until 3 months after last treatment.
1785412|NCT00477620|Behavioral|Wearing of reading glasses during prolonged near work|
1785413|NCT00477633|Drug|Norethindrone/ethinyl estradiol|1 tablet per day
1785414|NCT00477646|Behavioral|Prevention Care Management|Telephone support over 18 months to help women become screened for breast, cervical and colon cancer. Includes barriers assessment, patient education and motivation, provider recommendation letter, appointment reminder, and some scheduling of appointments.
1957165|NCT02508571|Other|Oral sensorimotor stimulation (OSMS)|"The OSMS consists of a 15-minute stimulation program, whereby the first 12 minutes involve stroking the cheeks, lips, gums, and tongue, and the final 3 minutes consist of sucking on a pacifier.
In combined DST and OSMS group, each intervention is provided once a day, 5 days a week. And it is continued until infants are able to complete independent oral feeding, 2 days in a row with no adverse events that do not self-resolve."
1785416|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, 6 weeks
1785417|NCT00477672|Drug|Pimavanserin tartrate (ACP-103)|40 mg, tablet, once daily by mouth, 6 weeks
1785418|NCT00477672|Drug|Placebo|tablet, once daily by mouth, 6 weeks
1785419|NCT00477685|Device|OculusGen Biodegradable Collagen Matrix Implant|OculusGen Biodegradable Collagen Matrix Implant in Trabeculectomy.
1785420|NCT00477711|Drug|cetuximab, cisplatin, capecitabine|Product 1: Cetuximab(Erbitux®) Dosing schedule: 400mg/m2 initial dose and then 250mg/m2 ,weekly dose Mode of administration: intravenously Product 2: capecitabine Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks Mode of administration: orally Product 3: cisplatin Dosing schedule: 80mg/m2, day 1 of every 3 weeks Mode of administration: intravenously
1785421|NCT00477724|Behavioral|exercise and respiratory therapy|exercise and respiratory therapy for three weeks in-hospital and 15 weeks at home
1785422|NCT00477724|Other|sedentary control group|control group with no specific training
1785423|NCT00477737|Drug|Sevoflurane|
1785424|NCT00477737|Drug|propofol|
1785425|NCT00477750|Drug|lenalidomide|"Phase I - dose escalating: 5mg level -1, 10mg level 0, 10mg level 1, 15mg level 2, 20mg level 3, 25mg level 4, orally days 1-21 every 28 days until progression
Phase II - 10 mg orally days 1-21 every 28 days until progression"
1785426|NCT00477750|Drug|melphalan|"Phase I - dose escalating: 5mg/m^2 dose level -1, 5 mg/m^2 dose level 0, 8 mg/m^2 dose level 1 - 4, daily x 4 orally days every 28 days until progression
Phase II - 5mg/m^2 orally days 1-4 every 28 days until progression"
1785427|NCT00477750|Drug|prednisone|60mg/m^2, orally days 1-4 every 28 days until progression
1785428|NCT00477763|Drug|Restasis, Refresh Endura|"Restasis 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening
Refresh Endura 0.4ml- (in the eye) instill twice daily in the randomized eye morning and evening"
1785429|NCT00477776|Drug|Metoclopramide (Maxolon)|Metoclopramide 10 mg 3 times a day for 7 days, 2 times a day from day 8 to day 10, once a day for day 11 and 12
1785430|NCT00477776|Drug|Placebo|Placebo 10 mg 3 times a day for 7 days, 2 times a day from day 8 to 10, once a day from day 11 to 12
1785431|NCT00477789|Drug|allopurinol|
1785434|NCT00477815|Biological|rituximab|375 mg/m2 given as an IV infusion once weekly for four doses (days 1, 8, 15, and 22)
1785435|NCT00477815|Drug|melphalan|100/m2 in 1000 ml 0.9% NaCI IV infusion over 1 hour daily x 2 days.
1785436|NCT00477815|Biological|Stem Cell|greater than or equal to 2 x 106 CD34+/kg by IV
1785437|NCT00477815|Biological|Sargramostim (GM-CSF)|500 mcg by Subcutaneous QD
1785438|NCT00477815|Radiation|90Y-Zevalin|Dose escalation scheme. The dose of Zevalin will be based on the calculated radiation to the liver.
1785439|NCT00477815|Biological|111In Zevalin|5.0 mCi by IV
1785440|NCT00477828|Device|Continuous positive airway pressure|
1785441|NCT00477841|Procedure|Esophageal stent placement|
1785442|NCT00477841|Procedure|dysphagia scores|
1785443|NCT00477841|Procedure|complications of therapy|
1785444|NCT00477841|Procedure|survival time of therapy|
1785445|NCT00477854|Drug|Chromium Picolinate|Test whether Chromium Picolinate supplementation affects food intake at both a test lunch meal and at a test dinner meal presented 4.5 hours later among healthy, overweight and/or obese, adult women who are determined to be carbohydrate creavers.
1785446|NCT00477867|Procedure|quality-of-life assessment|
1785447|NCT00477880|Biological|Cetuximab|
1785448|NCT00477893|Drug|Adalimumab|sc. injection Humira 40 mg every other week, from week 0 or 12 to the end of study
1785449|NCT00477893|Drug|Placebo|sc. inj. placebo every other week, week 0, 2, 4, 6, 8, and 10.
1785450|NCT00477906|Biological|M-Vax- autologous, hapten-modified melanoma vaccine|Autologous, DNP-modified melanoma cells in suspension Dose: 12+-8 million cells Route: intradermal Frequency: weekly X7 + 6 month booster
1785451|NCT00477945|Drug|clofarabine|"Cohort N Clofarabine (mg/m2/day)
3-6 30
3-6 40
3-6 50
3-6 60
6-10 70"
1785452|NCT00477958|Other|questionnaire administration|Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.
1785453|NCT00477958|Procedure|cognitive assessment|Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
1785454|NCT00477958|Procedure|psychosocial assessment and care|Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.
1785455|NCT00477971|Biological|filgrastim|No administration information given
1785456|NCT00477971|Drug|dexamethasone|Given orally
1785457|NCT00477971|Drug|melphalan|Given IV or orally
1785458|NCT00477971|Procedure|autologous hematopoietic stem cell transplantation|Given on day 0
1785459|NCT00477984|Drug|alcohol|alcohol(0.02%, 0.05%, 0.08% and 0.10%) and placebo
1785460|NCT00477997|Device|Physiological Bolus of Growth Hormone|0,5 mg Norditropin
1785461|NCT00478010|Other|counseling intervention|
1785462|NCT00478010|Other|study of socioeconomic and demographic variables|
1785463|NCT00478010|Procedure|psychosocial assessment and care|
1785464|NCT00478010|Procedure|quality-of-life assessment|
1785465|NCT00478023|Drug|Morphine|20 mg IR; 4 - 6 hourly; Total 72 hours
1785466|NCT00478023|Drug|CG5503 IR|50mg; 4 - 6 hourly; Total 72 hours
1785467|NCT00478023|Drug|CG5503 IR|75mg; 4 -6 hourly; Total 72 hours
1785468|NCT00478023|Drug|CG5503 IR|100mg, 4 - 6 hourly; Total 72 hours
1785469|NCT00478023|Drug|Placebo|4 - 6 hourly; Total 72 hours
1785470|NCT00478036|Drug|Acular LS|Details covered in arm description
1785471|NCT00478036|Drug|Pred Forte|Details covered in arm description
1785472|NCT00478036|Other|Refresh Tears|Placebo
1785473|NCT00478049|Drug|Gefitinib|250 mg oral tablet
1785474|NCT00478049|Drug|Docetaxel|intravenous infusion
1785475|NCT00478062|Biological|Hodgkin's antigens-GM-CSF-expressing cell vaccine|
1785476|NCT00478062|Procedure|adjuvant therapy|
1785477|NCT00478075|Drug|bortezomib|
1785478|NCT00478075|Other|immunologic technique|
1785479|NCT00478075|Radiation|samarium Sm 153 lexidronam pentasodium|
1785480|NCT00478088|Device|NeoDisc|The NeoDisc is an artificial cervical intervertebral disc replacement intended for clinical use following a discectomy.
1785481|NCT00478088|Device|Instrumented Anterior Cervical Discectomy and Fusion (ACDF)|Surgical removal of the cervical disc, decompression, and anterior implantation of allograft bone with a cervical plate.
1785482|NCT00478101|Drug|oxycodone fentanyl|
1785483|NCT00478114|Drug|sorafenib|sorafenib in the patients with advanced Renal Cell Carcinoma
1785484|NCT00478140|Biological|trastuzumab|For HER-2/neu positive biopsies, trastuzumab was administered intravenously, once every 3 weeks, at a loading first dose at 8 mg/kg over 90 minutes, and subsequent maintenance doses of 6 mg/kg over 90 minutes then every 30 minutes starting at the third dose.
1785485|NCT00478140|Other|laboratory biomarker analysis|Correlative studies
1785486|NCT00478179|Drug|Transdermal/Patch (Bupivacaine TTS [Eladur™])|
1785487|NCT00478192|Drug|Conivaptan|premix bag
1785488|NCT00478192|Drug|Placebo|premix bag
1785489|NCT00478205|Drug|Aricept (donepezil SR 23 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:
23 mg donepezil SR concurrently with placebo identical in appearance to the 10 mg donepezil IR formulation."
1785490|NCT00478205|Drug|Aricept (donepezil IR 10 mg)|"Patients will receive study medication orally, once daily, for 24 weeks according to a double-dummy design:
10 mg donepezil IR concurrently with placebo identical in appearance to the 23 mg donepezil SR formulation."
1785491|NCT00478218|Drug|cyclophosphamide|300 mg/m2 administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles) OR 300 mg administrated by PO (with food)on Days 1, 8, 15 (up to 12 cycles)
1785492|NCT00478218|Drug|dexamethasone|40 mg administrated by PO (with food)on Days 1, 8, 15 & 22
1785493|NCT00478218|Drug|lenalidomide|25 mg administrated by PO (with food)on Days 1-21
1785494|NCT00478231|Drug|Maraviroc|Maraviroc should be dosed BID with total dose adjusted according to the other drugs the patient is taking. Maraviroc may be taken with or without food. The subject should only take missed doses if it is not within 6 hours prior to the planned next dose. No dose adjustment of OBT is required due to the presence of maraviroc.
1785495|NCT00478244|Drug|busulfan|Day -9 through Day -6: 1.1 mg/kg if < 12 kg IV every 6 hours; 0.8 mg/kg if > 12 kg.
1785496|NCT00478244|Drug|cyclophosphamide|Day -5 through Day -2: 50 mg/kg IV over 120 min.
1785497|NCT00478244|Drug|fludarabine phosphate|Day -5 through Day -3: 25 mg/m2 IV over 60 min.
1785498|NCT00478244|Procedure|hematopoietic bone marrow transplantation|allogeneic bone marrow, peripheral stem cell or umbilical cord blood transplantation
1785499|NCT00478257|Device|bright white light administered via a light box made by Litebook, Inc|Bright white light
1785500|NCT00478257|Device|light box ( Litebook)|dim red light
1785501|NCT00478270|Drug|ibandronate [Bondronat]|6mg iv on days 1-3
1785502|NCT00478283|Other|survey administration|
1785503|NCT00478309|Other|counseling intervention|
1785504|NCT00478309|Other|educational intervention|
1785505|NCT00478322|Drug|Placebo|Matching placebo of 100 mg BID
1785506|NCT00478322|Drug|INCB013739|INCB013739 100 mg BID
1957166|NCT02508571|Other|Routine NICU care|routine NICU care other than OSMS and DST
1957168|NCT02508311|Drug|Oral Albuterol Extended Release|Subjects will receive extended release Albuterol, 4mg twice daily for the first week. The remaining 15 weeks subjects will receive extended release Albuterol, 8mg twice daily.
1957169|NCT02508311|Drug|Placebo|Subjects will receive placebo tablets twice daily for 16 weeks.
1785518|NCT00478374|Drug|Sorafenib|Sorafenib 400mg bid
1785519|NCT00478374|Procedure|Transarterial chemoembolisation with doxorubicin|Transarterial chemoembolisation (TACE)
1785520|NCT00478387|Biological|The current season's trivalent killed influenza vaccine|
1785522|NCT00478439|Dietary Supplement|ZeaVision EyePromise Restore|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, Zeaxanthin 8mg,mixed tocopherols 6mg, lutein 4mg,
1785523|NCT00478439|Dietary Supplement|Multivitamin|Vitamin C 120mg, Vitamin E 60IU, Zinc 15mg, Fish Oil 250mg, Omega 3 125mg, Alphaliploic acid 10mg, mixed tocopherols 6mg, lutein 4mg,
1785524|NCT00478452|Biological|DC-Ova|
1785525|NCT00478452|Biological|DC Ova with Cyclophosphamide|
1785526|NCT00478465|Drug|valganciclovir|
1785527|NCT00478478|Procedure|Mechanical Thrombectomy|Thrombectomy performed with the Merci Retriever in the setting of acute ischemic stroke.
1785528|NCT00478504|Drug|Letrozole|Starting daily dose 2.5 mg on menstrual cycles days 2 to 6, to be increased to 5 mg daily if there is no response to 2.5 mg
1785529|NCT00478504|Drug|Clomifene citrate|Starting daily dose 50 mg on menstrual cycles days 2 to 6, to be increased to 100 mg daily if there is no response to 50 mg
1785530|NCT00478517|Drug|Erythropoetin (rHuEPO, EPREX®)|
1785531|NCT00478530|Procedure|ELECTRORETINOGRAM|Bevacizumab 1.25 mg/0.05 ml unilaterally into the vitreous cavity as part of the standard management for choroidal neovascular AMD. ERG responses form both eyes will be measured at baseline and 1 month after intravitreal injection
1785532|NCT00478543|Drug|Furosemide|
1785533|NCT00478556|Drug|Omnipaque|Oral CT contrast
1785534|NCT00478556|Drug|Gastroview|Oral CT contrast
1785535|NCT00478569|Drug|Parathyroid Hormone (PTH) (1-84)|Adherence to PTH(1-84) treatment in Usual Clinical Settings
1785536|NCT00478582|Procedure|Estimation of Hb concentrations with the HemoHue card|
1785537|NCT00478595|Drug|Rimonabant|Tablet, oral administration
1785538|NCT00478595|Drug|Placebo (for Rimonabant)|Tablet, oral administration
1785539|NCT00478595|Drug|Anti-diabetic monotherapy|Previous treatment with Sulfonylurea or α-glucosidase inhibitor continued at stable dose during the study period
1785540|NCT00478608|Drug|Sirolimus (Rapamune®)|(1mg tablets): Initial loading dose of 6mg/day, followed by maintenance dose of 2mg/day, which was adjusted to specified trough level.
1785541|NCT00478621|Biological|GSK Biologicals' HPV vaccine (GSK1674330A)|Intramuscular administration, 5 different formulations
1785542|NCT00478621|Biological|Cervarix TM|Intramuscular administration
1785543|NCT00478634|Drug|RAD001, Cetuximab, Irinotecan|
1785544|NCT00478647|Biological|GA-GCB (velaglucerase alfa)|15-60 U/kg, every other week via intravenous infusion
1785545|NCT00478660|Drug|adalimumab (Humira)|
1785546|NCT00478673|Device|NexStent Carotid Stent System (Monorail Delivery System)|Self-expanding carotid stent for treating patients at high risk for adverse events from carotid endarterectomy who require carotid revascularization.
1785547|NCT00478673|Device|FilterWire EZ™ Embolic Protection System|Used as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
1785548|NCT00478686|Procedure|Phlebotomy|5 to 7.5 milliliter (mL) Blood Sample
1785549|NCT00478699|Drug|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
1785550|NCT00478699|Drug|Docetaxel|Docetaxel 75 mg/m2 day 1, 4 cycles
1785551|NCT00478699|Drug|Gemcitabine/Cisplatin|Gemcitabine 1250 mg/m2, day 1 and 8 and cisplatin 75 mg/m2 day 1, 4 cycles
1785552|NCT00478699|Drug|Docetaxel/Cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 day 1, 4 cycles
1785553|NCT00478712|Other|Identification of genetic causes of Hirschsprung Disease|Blood, saliva, or DNA samples are requested from all study participants. The blood or saliva samples are used to isolate DNA in all participants. Blood samples are also used to establish cell lines in some participants.
1785554|NCT00478725|Drug|GW786034, oral|oral, 800 mg
1785555|NCT00478725|Drug|GW786034, IV|IV, 5 mg
1785556|NCT00478725|Drug|GW786034, radiolabeled oral|oral, 400 mg radiolabeled
1785558|NCT00478764|Drug|intraocular triamcinolone and gatifloxicin|
1785559|NCT00478777|Drug|Lenalidomide|Oral lenalidomide at a dose of 25 mg daily for 21 days every 28 days. Treatment as tolerated until disease progression.
1785560|NCT00478777|Drug|dexamethasone|Oral pulse dexamethasone at a dose of 40 mg daily on days 1-4, 9-12, and 17-20 for each 28-day-cycle for cycles 1 through 4 (approximately months 1-4). Beginning cycle 5 (approximately month 5) dexamethasone is reduced to 40 mg daily for days 1-4 every 28 days.
1785561|NCT00478790|Device|ologen™ Collagen matrix implantation in glaucoma filtering surgery|ologen™ treatment is used, the collagen matrix will be placed on top of the scleral flap under the conjunctiva after the trabeculectomy.
1785562|NCT00478803|Procedure|Remodeling procedure associated with a subvalvular aortic ring or double sub and supra-valvular aortic annuloplasty|"Remodeling procedure associated with a subvalvular aortic ring: a) Five U stitches are placed inside out in the subvalvular plane (3 stitches 2 mm below the nadir of insertion of each cusp, 2 stitches below 2 of the 3 commissures at the base of the interleaflet triangles (no suture is placed at the base of the interleaflet triangle situated between the right and noncoronary sinuses to avoid injury of the bundle of His)); b) remodeling of the aortic root by scalloping a bulged graft (Gelweave ValsalvaTM); c) The 5 anchoring U stitches are passed through the inner aspect of the prosthetic aortic ring and tied down externally in the subvalvular position; d) anastomosis of the coronary ostia and to distal ascending aorta."
1785563|NCT00478803|Device|Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots|Expansible Prosthetic Aortic Ring: Mechanical valve replacement (isolated or composite valve and graft replacement); actual surgical standard for dystrophic aortic roots
1785615|NCT00479284|Procedure|Average volume assured pressure support (AVAPS)|
1785616|NCT00479297|Drug|SAM-531|
1785617|NCT00479310|Drug|Summers 5% L.A.|
1786082|NCT00481845|Drug|Anastrozole|1 mg daily
1785564|NCT00478816|Biological|Fluad H5N1 Pandemic Influenza Vaccine|Two 0.5 mL doses of MF59-adjuvanted A/Vietnam/1194/2004 (H5N1 Clade 1) hemagglutinin (HA) subvirion influenza vaccine, containing 7.5 μg of H5N1 antigen,administered 3 weeks apart, IM in the deltoid muscle, preferably of the non-dominant arm.
1785565|NCT00478842|Device|Deep brain stimulation|Deep brain stimulation
1785566|NCT00478855|Drug|Tazocin (Piperacillin/Tazobactem)|
1785567|NCT00478881|Drug|Vardenafil HCl (Levitra, BAY38-9456)|vardenafil hydrochloride 10 mg film-coated tablets twice daily (BID) for oral (by mouth) intake for 6 weeks
1785568|NCT00478881|Drug|Placebo|vardenafil hydrochloride-matching film-coated tablets BID for oral intake for 6 weeks
1785569|NCT00478907|Drug|KETAMINE, PROPOFOL, THIOPENTAL|
1785572|NCT00478946|Drug|(FOLPI) Picoplatin with 5-FU and Leucovorin|Picoplatin, 150 mg/m2, 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W and leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
1785573|NCT00478946|Drug|FOLPI|Picoplatin, 150 mg/m2 to be administered with every alternate cycle of 5-FU and leucovorin (q 4 weeks, Schedule B). Leucovorin, 400 mg/m2 in D5W, will be administered as a 2-hour infusion, either alone or, if the patient is to receive picoplatin that cycle, at the same time as picoplatin, in separate bags using a Y-line. The leucovorin (± picoplatin) will be followed by a 5-FU bolus of 400 mg/m2 and then by 5-FU, 2,400 mg/m2 in D5W administered as a 46-hour continuous infusion.
1785574|NCT00478946|Drug|FOLFOX|Oxaliplatin 85 mg/m. Leucovorin (400 mg/m2 in D5W). Oxaliplatin and leucovorin Leucovorin + oxaliplatin 5-FU bolus of 400 mg/m2 and then by 5-FU, 2400 mg/m2 in D5W administered as a 46-hour continuous infusion.
1785575|NCT00478959|Drug|Lenalidomide (Revlimid®)|25mg PO daily for 21 out of 28days per cycle
1785576|NCT00478972|Drug|Rimonabant|Tablet, oral administration
1785577|NCT00478972|Drug|placebo (for Rimonabant)|Tablet, oral administration
1785578|NCT00478972|Other|Diet and exercise|Target daily caloric intake: Ideal body weight × 25 kcal
1785579|NCT00478985|Behavioral|Imatinib ending|Interruption of the treatment by Imatinib
1785580|NCT00478998|Drug|Tamsulosin|
1785581|NCT00479011|Procedure|fluid management based on arterial pulse pressure variation|
1785582|NCT00479024|Drug|iodinated contrast agent|iodinated contrast agent either 370 stength of iopamidol or 320 strength of visipaque
1785583|NCT00479037|Drug|Full Length Parathyroid Hormone, PTH(1-84)|Once daily subcutaneous injection in the abdomen by self administration
1785584|NCT00479037|Drug|Strontium Ranelate|The daily dose of 2 g (one sachet) strontium ranelate was to be mixed in a glass of water and taken immediately after mixing at bedtime at least 2 hours before or after intake of calcium, any food or drinks, other than water
1785585|NCT00479050|Procedure|chemoembolization ,Radiofrequency ablation|
1785586|NCT00479076|Drug|aflibercept (AVE0005)|intravenous infusion
1785587|NCT00479076|Drug|S-1|oral administration
1785588|NCT00479089|Drug|Docetaxel|25 mg/m2 IV over 30 minutes for 4 weeks, followed by 2 weeks off therapy.
1785589|NCT00479089|Drug|ZD1839|250 mg by mouth daily, without break.
1785590|NCT00479089|Drug|Dexamethasone|"Course #1: 3 doses of prophylactic Dexamethasone 4mg orally every 12 hours, starting the night before the Docetaxel infusion.
Course #2: If no hypersensitivity reactions and no significant fluid retention during course 1, the Dexamethasone is reduced to 4mg orally twice daily on the day of therapy.
Course #3 and subsequent courses: If no hypersensitivity reactions and no significant fluid retention during course 2, the Dexamethasone is reduced to 4mg orally one hour before treatment."
1785591|NCT00479102|Drug|Ferripel-3 - iron polysaccharide complex for prevention|
1785592|NCT00479115|Drug|AMD3100|240 mcg/kg subcutaneously, minimum of two days; maximum of eight days
1785593|NCT00479115|Device|AmCell CliniMACs|CD34+ cell selection from peripheral collection
1785594|NCT00479128|Drug|Bortezomib|Starting dose: 0.8 mg/m^2 IV Over 3-5 Seconds
1785595|NCT00479128|Drug|Gemcitabine|Starting dose: 225 mg/m^2 IV Up to 90 Minutes
1785596|NCT00479128|Drug|Doxorubicin|Starting dose: 12.5 mg/m^2 IV Over 15-30 minutes
1785597|NCT00479141|Behavioral|HIV skills training|Eight 2-hour group skills training sessions will occur during Weeks 1 through 8 and booster sessions will occur every two months during Months 3 through 15
1785598|NCT00479141|Behavioral|Popular Opinion Leaders training|Two-hour training sessions about anti-stigma and anti-discrimination will occur for 4 weeks, followed by support meetings every 2 months during Months 2 through 13.
1785599|NCT00479154|Drug|Botulinum Toxin A|Maximum dose of 90 units/leg was injected.
1785600|NCT00479167|Drug|Bortezomib and Tositumomab I-131|
1785601|NCT00479180|Biological|Vascugel|One time implant on the day of surgery
1785602|NCT00479180|Biological|Placebo Comparator|One time implant on the day of surgery
1785603|NCT00479193|Drug|bacitracin/xeroform|single layer, change every 3 days
1785604|NCT00479193|Drug|Polymem|single layer of Polymen, change every 3 days
1785605|NCT00479206|Drug|Artesunate|
1785606|NCT00479219|Drug|GSI-953|
1785607|NCT00479219|Other|Placebo|
1785608|NCT00479232|Drug|vorinostat|
1785609|NCT00479232|Drug|decitabine|
1785610|NCT00479245|Other|Set of questionnaires (respondent)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
1785611|NCT00479258|Drug|Inhaled insulin (Exubera)|Inhaled insulin with dose adjusted according to premeal blood glucose
1785612|NCT00479258|Drug|Subcutaneous Insulin (subject's prescribed)|Subcutaneous insulin with dose adjusted according to premeal blood glucose
1785613|NCT00479271|Behavioral|Home based, flexible, stepped care intervention|Home based, flexible, stepped care intervention
1785614|NCT00479271|Behavioral|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.|Home based, flexible, stepped care intervention after 6 months. Families will be free to choose any health care they desire during the waiting period.
1785618|NCT00479323|Biological|Pneumovax 23|Licensed pneumococcal vaccine (Pneumovax 23).
1785619|NCT00479336|Drug|OPC-41061 7.5mg|7.5mg, 1 tablet a day
1785620|NCT00479336|Drug|OPC-41061 placebo|placebo, 1 tablet a day
1785621|NCT00479336|Drug|OPC-41061 15mg|15mg, 1 tablet a day
1785622|NCT00479336|Drug|OPC-41601 30mg|30mg, 1 tablet a day
1785623|NCT00479349|Drug|SAM-531|Multiple ascending doses of SAM 531: 1,5; 3 and 5 mg.
1785624|NCT00479362|Drug|Warfarin|Warfarin is either interrupted or uninterrupted prior to device implantation
1785625|NCT00479362|Drug|Aspirin|Aspirin is continued without interruption prior to device implantation
1785626|NCT00479362|Device|Permanent pacemaker|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
1785627|NCT00479362|Device|Implantable Cardioverter-defibrillator|Devices are implanted tailored each patient's clinical condition and need following local practices, national and international guidelines.
1785628|NCT00479375|Procedure|Adding Human Papillomavirus testing to organised cervical screening|
1785629|NCT00479388|Drug|Comparator: simvastatin|simvastatin (20mg to 40mg) for 12 weeks.
1785630|NCT00479388|Drug|niacin (+) laropiprant|One tablet of ER niacin/ laropiprant (1g); titrating up to ER niacin/laropiprant (2g) at Week 4 for an additional 8 weeks, with no adjustments to the run-in statin dose.
1785631|NCT00479388|Drug|Comparator: atorvastatin calcium|atorvastatin calcium (20mg to 40mg) for 12 weeks.
1785632|NCT00479401|Drug|Pramipexol Extended Release|
1785633|NCT00479401|Drug|Pramipexol Immediate Release|
1785634|NCT00479401|Drug|Placebo|
1785637|NCT00479440|Drug|SAM-315|
1785638|NCT00479466|Drug|MK0893|MK0893 taken orally once daily; 20 mg and 40 mg tablets used in combination according to dose.
1785639|NCT00479466|Drug|Metformin|Metformin HCL 500 mg tablet twice daily titrating up to 1000 mg twice daily over 3 weeks.
1785640|NCT00479466|Drug|Placebo to MK0893|Dose-matched placebo tablets to MK0893; taken orally once daily.
1785641|NCT00479466|Drug|Placebo to Metformin|Dose-matched placebo tablets to metformin (500 mg); taken orally twice daily.
1785642|NCT00479479|Drug|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|an intramuscular injection of 400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma, Norway)
1785643|NCT00479492|Drug|CP-866,087|1 mg of CP-866,087, administered QD for 84 days
1785644|NCT00479492|Drug|CP-866,087|5 mg of CP-866,087, administered QD for 84 days
1785645|NCT00479492|Drug|CP-866,087|10 mg of CP-866,087, administered QD for 84 days
1785646|NCT00479492|Drug|placebo|placebo administered QD for 84 days
1785647|NCT00479505|Drug|UK-369,003|UK-369,003 100mg, 50mg, 25mg and 10mg doses in addition to placebo.
1785648|NCT00479505|Drug|Placebo|Placebo
1785649|NCT00479531|Device|AirCast Sequential Compression Device|
1785650|NCT00479557|Biological|ACC-001 + QS-21|Vanutide Cridificar (3, 10, 30µg) + QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
1785651|NCT00479557|Biological|ACC-001|Vanutide Cridificar (10, 30µg), IM on day 1, month 1, month 3, month 6 and month 12
1785652|NCT00479557|Biological|QS-21|QS-21 (50µg), IM on day 1, month 1, month 3, month 6 and month 12
1785653|NCT00479557|Drug|Placebo: Phosphate buffered saline|Phosphate buffered Saline (pH : 7.4), IM on day 1, month 1, month 3, month 6 and month 12
1785654|NCT00479570|Drug|PF-00446687|Single 200mg dose
1785655|NCT00479570|Drug|Placebo|
1785656|NCT00479583|Drug|BMS-690514 / FOLFIRI|Tablets / IV, Oral / IV, up to 200 mg / irinotecan 180mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
1785657|NCT00479583|Drug|BMS-690514 / FOLFOX|Tablets / IV, Oral / IV, up to 200 mg / oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, 5FU 400mg/m2 bolus, 2400 mg/m2 inf, once daily / q 2 weeks, up to 24 mos
1785658|NCT00479596|Drug|Botox|
1785659|NCT00479609|Drug|Transdermal testosterone therapy|testosterone 1% hydroalcohol gel
1785660|NCT00479609|Drug|Placebo|Placebo gel
1785661|NCT00479622|Drug|TRU-015|Arm 1 = 800 mg Arm 2 = 2000 mg
1785662|NCT00479635|Drug|TPI 287|160 mg/m2 every three weeks for six cycles
1785663|NCT00479635|Drug|TPI 287|160 mg/m2 intravenously over 60 minutes every three weeks until toxicity or progression of disease.
1785664|NCT00479648|Biological|CSL412|
1785665|NCT00479648|Biological|Inactivated trivalent influenza vaccine|
1785666|NCT00479661|Drug|Dexmedetomidine|Continuous infusion
1785667|NCT00479661|Drug|Propofol|Continuous infusion
1785668|NCT00479674|Drug|Abraxane|100 mg/m2 IV over 30 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death..
1785669|NCT00479674|Drug|Bevacizumab|10 mg/kg IV days 1,15 Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria,intolerable toxicity, or death.
1785670|NCT00479674|Drug|Carboplatin|area under curve (AUC)=2 IV over 15 min days 1,8,15. Cycles Repeated Every 28 days until documented evidence of disease progression by RECIST criteria, intolerable toxicity, or death.
1785673|NCT00479700|Drug|SAM-531|
1785674|NCT00479713|Drug|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20mg. The treatment duration will be 6 weeks.
1785675|NCT00479713|Drug|Comparator : rosuvastatin calcium|rosuvastatin 10mg. The treatment duration will be 6 weeks.
1785676|NCT00479713|Drug|Comparator: Placebo (unspecified)|rosuvastatin 10mg Placebo. The treatment duration will be 6 weeks.
1785677|NCT00479713|Drug|Comparator: Placebo (unspecified)|ezetimibe/simvastatin 10/20mg Placebo. The treatment duration will be 6 weeks.
1785678|NCT00479726|Drug|duloxetine hydrochloride|
1785679|NCT00479739|Drug|Salmeterol/fluticasone propionate or formoterol/budesonide|
1785743|NCT00473005|Drug|RAD001|2.5mg QOD, 2.5mg QD, 5.0mg QD, Oral
1785744|NCT00473018|Behavioral|standard versus enhanced risk reduction counseling|
1785680|NCT00479752|Drug|FOLFOX4 (Oxaliplatin), Cetuximab|"Arm A FOLFOX4:
Oxaliplatin 85 mg/m² d1
Leucovorin 200 mg/m² d1+d2, followed by
Bolus 5FU 400 mg/m², followed by
Infusional 5FU 600 mg/m²,over 22 hours, every 2 weeks
Cetuximab is administered to arm A of the study as an infusion with initial dose 400 mg/m² in week 1 followed by weekly doses of 250 mg/m².
Arm B FOLFOX4:
Oxaliplatin 85 mg/m² d1
Leucovorin 200 mg/m² d1+d2, followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 600 mg/m², over 22 hours, every 2 weeks
Cetuximab is administered to arm B of the study as infusions of 500 mg/m² every two weeks."
1785681|NCT00479765|Drug|OncoGel (ReGel/Paclitaxel)|OncoGel administered into cavity after surgical resection of recurrent glioma. Each subject will receive one dose of OncoGel on the day of surgical resection.
1785682|NCT00479778|Drug|Bazedoxifene/conjugated estrogens|
1785683|NCT00479791|Behavioral|Test meals rich in different fatty acids|
1785684|NCT00479804|Device|inertgas rebreathing|determination of cardiac output by inertgas rebreathing
1785685|NCT00479804|Device|spirometry|spirometry for testing the ventilatory function
1785686|NCT00479804|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
1785687|NCT00479817|Drug|AMG 386|10mg/kg
1785688|NCT00479817|Drug|AMG 386|3 mg/kg
1785689|NCT00479817|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV QW (3 on/1 off)
1785690|NCT00479817|Drug|AMG 386 Placebo|AMG 386 Placebo
1785691|NCT00479830|Behavioral|Focus Groups|Eight Focus Groups Consisting of 8-10 Members Each
1785692|NCT00479830|Behavioral|Questionnaire|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
1785693|NCT00479830|Behavioral|Interview|To collect data to assess the unmet health and cancer needs of the South Asian population in the Greater Houston area and to determine barriers and other factors that affect health in this population.
1785694|NCT00479843|Behavioral|Nutritional programme|
1785695|NCT00479856|Drug|Lapatinib|Small molecule tyrosine kinase inhibitor
1785696|NCT00479856|Drug|Capecitabine|Chemotherapy
1785697|NCT00479856|Drug|Docetaxel|Chemotherapy
1785698|NCT00479856|Drug|nab-Paclitaxel|Chemotherapy
1785699|NCT00479882|Drug|Comparator: simvastatin|
1785700|NCT00479882|Drug|MK-0524A|Extended-release(ER) niacin/Laropiprant (MK-0524) Combination tablet
1785701|NCT00479882|Drug|Placebo|
1785702|NCT00479882|Drug|MK-0524B|
1785703|NCT00479895|Drug|Hemoglobin Based Oxygen Carrier-201 (HBOC-201, Hemopure)|Pre-oxygenated HBOC-201
1785704|NCT00479908|Drug|Sildenafil citrate|
1785705|NCT00479908|Drug|Glyceryl trinitrate|
1785706|NCT00479921|Biological|Trivalent influenza subunit vaccine|
1785707|NCT00479934|Drug|imatinib mesylate|6 month treatment with 400mg/day (per os)
1785708|NCT00479947|Drug|Probiotics (Natural product)|
1785709|NCT00479947|Drug|Probiotics (L. rhamnosus GR-1 and L. reuteri RC-14)|
1785710|NCT00479960|Behavioral|commercially available omega-3 fatty acids supplementation|
1785711|NCT00479973|Dietary Supplement|Cinnamonforce|"Cinnamonforce™ is a proprietary blend of Cinnamomum aromaticum and Cinnamomum verum bark containing 47 mg of hydroethanolic extract (min. 8% total phenolics) and 23 mg supercritical extract (min. 35% cinnamaldehyde) per capsule.
2 capsules after the two largest meals of the day"
1785712|NCT00479973|Dietary Supplement|Placebo|Placebo. 2 capsules after the two largest meals of the day
1785713|NCT00479986|Drug|pioglitazone|
1785714|NCT00479986|Drug|placebo|
1785715|NCT00479999|Drug|VRC-HIVADV027-00-VP|
1785716|NCT00479999|Drug|VRC-HIVADV038-00-VP|
1785717|NCT00480012|Device|rTMS|repetitive transcranial meagnetic stimulation of the brain
1785720|NCT00480038|Other|WHODAS II|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule)
1785721|NCT00480051|Device|Cardiac Resynchronization Pacing|
1785722|NCT00480064|Drug|Lomustine, intermediate dose cytarabine|
1785723|NCT00480077|Device|Programming (CRT-D, ICD OptiVol® and Cardiac Compass® )|OptiVol® Fluid status Monitoring with Cardiac Compass
1785724|NCT00480090|Drug|Ara-C (Cytarabine)|Initially given at 1g/m2 bid for 2 days every 3 weeks over 2 hours. The dose will be escalated: level 1 - 1.25g/m2, level 2, 1.5g/m2.
1785725|NCT00480103|Device|in vivo (ANECOVA D-1) or in vitro culture in 25-µl droplets of cleavage medium (Medicult®) under paraffin oil|
1785726|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 1|20 µg, IM, month 0 and 1
1785727|NCT00480116|Biological|Adjuvanted Hepatitis B vaccine Lot 2|20µg, IM, month 0 and 1
1785728|NCT00480116|Biological|Adjuvanted Hep B vaccine Lot 3|20µg, IM, month 0 and 1
1785729|NCT00480129|Behavioral|Probiotic or placebo yogurt consumed daily|
1785730|NCT00480129|Device|Mini Rhinoconjunctivitis Quality of Life Questionnaire|
1785731|NCT00480129|Procedure|Blood sample|
1785732|NCT00480129|Procedure|Nasal lavage|
1785733|NCT00480142|Drug|Oxycodone 10 mg|
1785734|NCT00480155|Biological|Frozen FluMist®|Monovalent vaccine is supplied in intranasal sprayers containing 0.5 mL.
1785735|NCT00480155|Other|Placebo|
1785736|NCT00472901|Drug|Afamelanotide (CUV1647)|16mg implant
1785737|NCT00472914|Device|portable surface electromyography|
1785738|NCT00472927|Drug|Premarin/MPA 0.45 mg/1.5 mg|
1785739|NCT00472953|Drug|inhaled human insulin|Treat-to-target dose titration scheme, pre-prandial, inhalation.
1785740|NCT00472953|Drug|insulin aspart|Treat-to-target dose titration scheme, pre-prandial, injection s.c.
1785741|NCT00472966|Drug|Fluocinolone acetonide 0.1%/hydroquinone 4%/tretinoin 0.05% Cream in sequence with glycolic acid peels|Apply cream once daily at night. Subjects will be asked to discontinue use of Fluocinolone acetonide/hydroquinone/tretinoin Cream 2 days prior to the peel and restart 2 days after the peel; Glycolic Acid Peels - In office treatment at weeks 2, 4, 6, 8 and 10
1785742|NCT00473005|Drug|Capecitabine|825 mg/m2 bid, Oral
1785745|NCT00473031|Behavioral|Caloric restriction, high protein|Weight loss with higher protein (35%) intake
1785746|NCT00473031|Behavioral|Caloric restriction; normal protein|Weight loss with recommended level of protein (18%)intake
1785747|NCT00473031|Behavioral|Counseling|Participants will be asked to attend eight 50-minute diet counseling sessions, with the opportunity to attend a total of approximately 28 diet counseling sessions, during the year.
1785748|NCT00473044|Behavioral|Sisters in Motion|
1785749|NCT00473057|Other|Autologous cell transplantation|Intra-arterial or intravenous delivery of autologous bone marrow cells
1785750|NCT00473070|Drug|Tobradex AF|
1785751|NCT00473083|Drug|Minocycline|Patients will receive prophylactic treatment with minocycline 100 mg orally twice-daily for at least 4 weeks on the initiation of erlotinib therapy. If rash occurs during the 4 week period of minocycline prophylaxis, the minocycline prophylaxis will continue and additional treatment by grade of rash will be according to the Treatment Arm 2 schedule. If rash occurs after the completion of the 4 week prophylaxis period, treatment by grade of rash will be according to the Treatment Arm 2 schedule.
1785752|NCT00473083|Drug|Clindamycin 2% in hydrocortisone 1% lotion|"Appropriate amounts of clindamycin and hydrocortisone powder are mixed with corresponding amount of Nutraderm® lotion for this mixture.
If preferred, the appropriate amount of clindamycin powder can be mixed with Emo-Cort® lotion (already contains hydrocortisone 1%), available in 60 mL bottles."
1785753|NCT00473083|Drug|Erlotinib|Erlotinib will be given on an outpatient basis at a fixed dose of either 150 or 100 mg as a single daily oral dose.
1785754|NCT00473083|Drug|Topical clindamycin 2%, triamcinolone acetonide 0.1% soln|Clindamycin 2% in Triamcinolone acetonide 0.1% solution in equal parts propylene glycol and water
1785755|NCT00473096|Behavioral|Informed breast cancer surgical treatment|
1785756|NCT00473109|Procedure|Dialysis without systemic heparinization|Dialysis without systemic heparinization
1785757|NCT00473122|Procedure|Delayed-Immediate Breast Reconstruction|Immediate reconstruction surgery if no XRT required; or reconstruction surgery delayed until XRT complete.
1785758|NCT00473135|Biological|rDEN1delta30|Live attenuated rDEN1delta30 vaccine at a dose of 10^3 PFU
1785759|NCT00473135|Biological|Placebo|Placebo for rDEN1delta30
1785760|NCT00473148|Procedure|BNP-guided weaning|BNP-guided weaning
1785761|NCT00473148|Procedure|Standard physician-directed weaning|Standard physician-directed weaning
1785762|NCT00473161|Device|surface EMG biofeedback|
1785763|NCT00473174|Drug|Ramipril|Dosing on awakening versus bedtime
1785764|NCT00473174|Device|ambulatory blood pressure monitoring|Blood pressure measured at 20-min intervals from 07:00 to 23:00 hours and at 30-min intervals at night for 48 consecutive hours
1785765|NCT00473187|Drug|somatropin|
1785766|NCT00473200|Dietary Supplement|S-adenosylmethionine|1200 mg daily
1785767|NCT00473213|Drug|Interferon Beta 1|
1785768|NCT00473239|Drug|cholecalciferol.|100,000 IU of Vitamin D
1785769|NCT00473265|Drug|PTH|
1785770|NCT00473304|Device|Johnson&Johnson Acuevue daily disposable lenses|
1785771|NCT00473317|Behavioral|Sun Exposure|Each subject will wear a swimming suit and be exposed to sunlight for 30 minutes total (15 minutes lying on back, 15 minutes lying on stomach).
1785772|NCT00473330|Drug|Ranibizumab|Sterile solution for intravitreal injection.
1785773|NCT00473330|Drug|Sham injection|
1785774|NCT00473343|Procedure|Photodynamic therapy with Metvix 160 mg/g cream|
1785775|NCT00473356|Dietary Supplement|receive amino acid supplement|Receive amino acid supplement
1785776|NCT00473382|Drug|Ranibizumab|Sterile solution for intravitreal injection.
1785777|NCT00473382|Drug|Sham injection|
1785778|NCT00473408|Device|Functional MRI (DCE-MRI)|MRI examination with i.v. gadolinium contrast to assess blood perfusion in remaining tumor tissue.
1785779|NCT00473408|Procedure|Blood sample|See protocol.
1785780|NCT00473408|Procedure|Tumor sample|See protocol.
1785781|NCT00473421|Procedure|Barium Sulphate and Zirconium Oxide|
1785782|NCT00473434|Drug|Paliperidone|3mg or 6mg or 9mg or 12mg once daily for 52 weeks
1785783|NCT00473447|Behavioral|Modified Constraint-induced movement therapy|
1785784|NCT00473460|Drug|Avelox (Moxifloxacin, BAY12-8039)|Avelox (Moxifloxacin, BAY12-8039), 400 mg capsules orally once daily for 5 days every 8 weeks
1785785|NCT00473460|Drug|Placebo|Matching placebo capsules orally once daily for 5 days every 8 weeks.
1785786|NCT00473473|Drug|Potassium Dichromate (Homeopathy)|twice daily with an interval of 12 hours, for a period of up to 14 days
1785787|NCT00473473|Drug|Placebo homeopathic remedy|identical to treatment without active component
1785788|NCT00473486|Drug|pemetrexed, carboplatin, sorafenib|"Ph. 1: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; Sorafenib 200mg po bid days 2-19; 400mg po bid days 2-19
Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1;sorafenib depending on results of Ph 1"
1785789|NCT00473486|Drug|pemetrexed, carboplatin, placebo|Ph 2: pemetrexed 500mg/m² iv day 1; carboplatin AUC 6 iv day 1; placebo day 2-19
1785790|NCT00473499|Device|DEBlue vs Cypher vs BMS|BMS vs DES vs DEB+BMS
1785791|NCT00473512|Drug|Abiraterone acetate|Abiraterone 250 mg (1 capsule) up to 2000 mg (8 capsules) once daily, each dose will be tested in sequential order for 28 days to determine the MTD.
1785792|NCT00473512|Drug|Abiraterone acetate MTD|Abiraterone acetate MTD orally for 12 cycles (28 day each).
1785793|NCT00473512|Drug|Dexamethasone|Dexamethasone 0.5 mg orally will be given (If participants have disease progression) daily up to 12 cycles.
1785794|NCT00473525|Drug|Placebo|Placebo QD
1785795|NCT00473525|Drug|PF-00734200 10 mg QD|10 mg QD
1785796|NCT00473525|Drug|PF-00734200 20 mg QD|20 mg QD
1785797|NCT00473525|Drug|PF-00734200 5 mg QD|5 mg QD
1785798|NCT00473525|Drug|PF-00734200 2 mg QD|2 mg QD
1785799|NCT00473538|Behavioral|Structured exercise training|
1785800|NCT00473538|Behavioral|Hypocaloric hyperproteic diet|
1785801|NCT00473551|Drug|Rituximab|375 mg/m^2 intravenously over several hours on Day -13, followed by 1000 mg/m^2 intravenously on Days -6, 1, and 8.
1785802|NCT00473551|Drug|Cyclophosphamide|50 mg/kg intravenously over two hours on Day -6, immediately following Fludarabine.
1785803|NCT00473551|Drug|Fludarabine|40 mg/m^2 intravenously over 30 minutes once per day for 4 days, starting Day -6.
1785804|NCT00473551|Drug|Mesna|10 mg/kg continuous intravenous infusion for 4 hours for total of 6 doses (24 hours) following Cyclophosphamide.
1785805|NCT00473551|Radiation|Radiation Treatment|2Gy Total body radiation day before transplantation
1785806|NCT00473551|Procedure|Stem Cell Transplantation (SCT)|Allo CD34+ Selected SCT/Infusion of stem cells.
1785807|NCT00473551|Drug|Sirolimus|6 mg by mouth on day -2 followed by 2 mg daily from day -1 through day +7.
1785808|NCT00473551|Procedure|Anti-third Party Cytolytic T-lymphocytes (CTL)|Intravenous infusion of anti-third party CTL.
1785809|NCT00473564|Procedure|da Vinci® Robotic System|Head and Neck Surgery using the da Vinci® Robotic System
1785810|NCT00473577|Drug|CRA-24781|
1785811|NCT00473590|Drug|Bevacizumab|15 mg/kg administered by intravenous infusion
1785812|NCT00473590|Drug|Bortezomib|1.3 mg/m^2 administered by intravenous bolus injection
1785813|NCT00473590|Drug|placebo|Intravenous repeating dose
1785814|NCT00473603|Drug|lipid/heparin or saline/heparin infusion|
1785815|NCT00473616|Drug|AZD7762|intravenous infusion
1785816|NCT00473616|Drug|Irinotecan|intravenous injection
1785817|NCT00473642|Drug|Ranibizumab|intravitreal administered ranibizumab 0.5 mg in 0.05 mL
1785818|NCT00473642|Drug|Verteporfin|Verteporfin with 50% fluence photodynamic therapy (25 J/cm2)
1785819|NCT00473642|Drug|Verteporfin|Verteporfin with standard fluence photodynamic therapy (50 J/cm2)
1785820|NCT00473655|Drug|rosuvastatin|10mg or 20mg
1785821|NCT00473668|Biological|Zilbrix-Hib|Intramuscular injection, 1 dose
1785822|NCT00473668|Biological|Tritanrix™-HepB/ Hiberix™|Intramuscular injection, 1 dose
1785823|NCT00473681|Behavioral|Self-Help Intervention Program-High Blood Pressure|
1785824|NCT00473694|Drug|sugammadex|Subjects received rocuronium or vecuronium in randomized order with single and maintenance (if applicable) dosing according to local treatment practice. After the last dose of rocuronium or vecuronium, a dose of 4.0 mg/kg Sugammadex (Org 25969) was to be administered.
1785825|NCT00473694|Drug|neostigmine|Subjects received rocuronium or vecuronium in randomized order with single and maintenance (if applicable) dosing according to local treatment practice. After the last dose of rocuronium or vecuronium, a dose of 70 μg/kg neostigmine was to be administered. A maximum of 5 mg neostigmine was to be administered.
1785826|NCT00473707|Procedure|Active management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
1785827|NCT00473707|Procedure|Expectant management of the third stage of labor|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
1785828|NCT00473707|Drug|Oxytocin and gentle cord traction with fundal massage|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) immediately following delivery of the fetus with gentle cord traction and fundal massage
1785829|NCT00473707|Drug|Oxytocin|standardized oxytocin infusion (10 units of oxytocin in 500 mL of Ringers lactate over 20 minutes) in combination with maternal expulsion efforts once spontaneous separation of the placenta had begun
1785830|NCT00473720|Drug|Satraplatin|Dose escalation of 40, 60 and 80 mg/m²/day on days 1-5
1785831|NCT00473720|Drug|Abraxane|Dose escalation of 80 and 100 mg/mm²/day on days 1,8,15,22 every 28 days
1785832|NCT00473733|Procedure|GLP receptors expression|
1785833|NCT00473733|Procedure|ESOPHAGOGASTRODUODENOSCOPY|
1785834|NCT00473746|Drug|Abiraterone acetate|The first cohort was a abiraterone acetate 250 mg/day orally (by mouth), once daily for 28-day treatment periods , if no dose limiting toxicity (DLT) was documented at this dose, the dose will be escalated to next dose levels 500, 750, and 1000 mg/day. The dose escalation will continue to a maximum of 1000mg/day until Maximum Tolerated Dose (MTD) and a recommended Phase II dose was established.
1785835|NCT00473746|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg daily under fasted conditions upto 10 cycles of therapy.
1785836|NCT00473746|Drug|prednisone/prednisolone or dexamethasone|prednisone/prednisolone (5 mg twice daily) or dexamethasone (0.5 mg once daily) concurrent with abiraterone acetate
1785837|NCT00473772|Device|DEBlue stent vs. Cypher stent|DES vs. DEB with BMS
1785838|NCT00473785|Behavioral|Group-based motivational interviewing|
1785839|NCT00473785|Behavioral|Individual CVD-risk factor feedback|
1785840|NCT00473785|Behavioral|Education for protective health behavior change|
1785841|NCT00473798|Behavioral|Questionnaire|Questionnaire
1785842|NCT00473811|Behavioral|Low GI|low-GI education
1785843|NCT00473811|Behavioral|ADA diet|ADA dietary education
1785844|NCT00473824|Biological|Hepatitis C Immune Globulin Intravenous (Human) 5%|Hepatitis C Immune Globulin Intravenous (Human) 5%, [Civacir]: 18 infusions total, per schedule, of 300 or 400 mg/kg of body weight given with standard post-transplant therapy inclusive of immunosuppressive agents.
1785845|NCT00473837|Drug|Chloroquine|This is an orange syrup in a 60ml amber coloured glass bottle containing 50mg of chloroquine base per 5mls as the chloroquine phosphate. The syrup was manufactured by Medreich Sterilab Ltd, Avalahalli, Bangalore, India. Chloroquine: weekly treatment of 7.5mg/kg for 90 days
1785846|NCT00473837|Drug|Placebo|The placebo is an orange syrup in a 60ml amber coloured glass bottle containing sucrose syrup base. The syrup was prepared by the Pharmacy department of the Royal Victorial Teaching Hospital and Atlantic Pharmaceuticals Limited, Banjul
1785847|NCT00473863|Procedure|Coronary Computed Tomographic Angiography|CCTA will be performed
1785848|NCT00473876|Drug|Metformin|Started at 500mg bd for 2 weeks. If well tolerated, increase to 1000mg bd for 14 weeks
1785849|NCT00473876|Drug|Matched Placebo (Capsules)|Similar dosing regime as active comparator
1785850|NCT00473889|Drug|vorinostat|vorinostat 400 mg capsules once daily. Up to 6 months of treatment
1785851|NCT00473889|Drug|Comparator: paclitaxel|intravenous (IV) paclitaxel 200 mg/m2. Up to 6 months of treatment
1785852|NCT00473889|Drug|Comparator: carboplatin|intravenous (IV) carboplatin AUC 6mg/min/ml. Up to 6 months of treatment.
1785853|NCT00473889|Drug|Comparator: placebo|vorinostat 400 mg placebo capsules once daily. Up to 6 months of treatment
1785854|NCT00473902|Behavioral|Training|
1785855|NCT00473902|Drug|Creatine Monohydrate, Conjugated Linoleic Acid|
1785856|NCT00473915|Drug|fluticasone furoate|corticosteroid nasal spray
1785857|NCT00473928|Drug|POT-4|Single intravitreal injection.
1785858|NCT00473941|Behavioral|Expressive writing|Quality of life measures through writing
1785859|NCT00473954|Genetic|EGEN-001 (phIL-12-005/PPC)|"In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.
Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals."
1785860|NCT00473967|Biological|Na-ASP-2 Hookworm Vaccine|Injections of one of three different dose concentrations of the Na-ASP-2 vaccine (10, 50, or 100 mcg) vs. the hepatitis B vaccine, delivered at 0, 2, and 4 months by intramuscular injection.
1785861|NCT00473980|Drug|Indomethacin, celecoxib, esomeprazole|
1785862|NCT00474006|Drug|arm II|Cytarabine 200 mg/m2/d civ x 7 days Daunorubicin 90 mg/m2/d civ x 3 days
1785863|NCT00474019|Drug|esomeprazole|IV qd for 4 days
1785864|NCT00474032|Drug|Botulinum Toxin (Type A) injection (10 U/Kg)|See Detailed Description.
1785865|NCT00474045|Drug|insulin detemir|Treat-to-target, dose titration, s.c. (under the skin) injection
1785866|NCT00474045|Drug|NPH insulin|Treat-to-target, dose titration, s.c. (under the skin) injection
1785867|NCT00474045|Drug|insulin aspart|Treat-to-target, dose titration, s.c. (under the skin) injection
1785868|NCT00474058|Drug|Rotigotine|"Rotigotine transdermal patches:
10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)
Optimal dosing: The maximum Rotigotine dose allowed is 16mg/24h"
1785869|NCT00474058|Other|Placebo|Placebo transdermal patches
1785870|NCT00474071|Drug|Remifentanil|See Detailed Description.
1785871|NCT00474084|Device|Intravascular Coronary Stent|
1785872|NCT00474110|Drug|Ketamine & hydromorphone|See Detailed Description
1785873|NCT00474123|Drug|Simvastatin 80 mg/day for 6 weeks|Simvastatin 80 mg/day, single dose, for 6 weeks.
1785874|NCT00474123|Drug|Ezetimibe 10 mg / Simvastatin 20 mg|"Ezetimibe 10 mg / Simvastatin 20 mg
Patients were treated with daily Ezetimibe 10 mg / Simvastatin 20 mg for 6 weeks"
1785875|NCT00474136|Drug|Intravenous diclofenac sodium (DIC075V) 18.75 mg|DIC075V 18.75 mg
1785876|NCT00474136|Drug|Intravenous diclofenac sodium (DIC075V) 37.5 mg|DIC075V 37.5 mg
1785877|NCT00474136|Drug|Oral diclofenac potassium 50 mg|Oral diclofenac potassium 50 mg
1785878|NCT00474162|Drug|Pentaspan®|15 ml/kg of starch solution, approximately 1 litre
1785879|NCT00474162|Drug|Normal Saline|15 ml/kg of either saline solution, approximately 1 litre
1785880|NCT00474175|Drug|Placebo gel|single dose (less than 1g) of a matching placebo gel
1785881|NCT00474175|Drug|benzocaine|single dose (less than 1g) of 10% benzocaine gel formulation
1785882|NCT00474175|Drug|benzocaine|single dose (less than 1g) of 20% benzocaine gel formulation
1785883|NCT00474188|Drug|CC-5013 (lenalidomide)|Lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle administerd in combination with dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle
1785884|NCT00474188|Drug|dexamethasone|Dexamethasone 40 mg, orally, once daily, on Days 1, 8, 15, and 22 of every 28-day cycle administered in combination with lenalidomide 25 mg, orally, once daily, on Days 1 to 21 of every 28-day cycle.
1785885|NCT00474201|Drug|Lopinavir/Ritonavir|lopinavir 400 mg + ritonavir 100 mg twice daily for 2 weeks
1785886|NCT00474201|Drug|Gemfibrozil|Control arm (no intervention used in this arm)
1785887|NCT00474214|Behavioral|Early hospital discharge facilitated by close nurse practitioner follow-up|
1785888|NCT00474227|Behavioral|group therapy, physical exercise, nutrition lectures|weekly group therapy, physical exercize, nutrition guidance
1785889|NCT00474240|Drug|Atorvastatin 20 mg|
1785890|NCT00474240|Drug|AEGR-733 5 mg|
1785891|NCT00474240|Drug|AEGR-733 10 mg|
1785892|NCT00474240|Drug|Placebo|
1785893|NCT00474240|Drug|AEGR-733 5 mg + atorvastatin 20 mg|
1785894|NCT00474240|Drug|AEGR-733 10 mg + atorvastatin 20 mg|
1785895|NCT00474253|Drug|Sugammadex|Subjects were to receive an intubating dose of 1.2 mg/kg rocuronium followed by 16.0 mg/kg Org 25969 three minutes after the start of rocuronium administration.
1785896|NCT00474253|Drug|succinylcholine|Subjects were to receive an intubation dose of 1.0 mg/kg succinylcholine and allowed to recovery spontaneously from neuromuscular blockade.
1785900|NCT00474279|Drug|Orally active growth hormone secretagogue (MK-677)|
1785901|NCT00474305|Behavioral|Virtual Reality Treatment for PTSD|12 session protocol for Prolonged Exposure with Virtual Reality. All sessions 90 minutes.
1785902|NCT00474357|Behavioral|Brief Structured Psychoeducation Group Therapy|weekly brief structured psychoeducation group therapy for seven weeks for bipolar patients
1785903|NCT00474370|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
1785904|NCT00474370|Drug|Placebo|One tablet of placebo once daily.
1785905|NCT00474383|Drug|Abiraterone acetate|Abiraterone acetate 1000 milligram (mg) capsule or tablet will be administered orally, once daily continuously in 28-day cycle up to disease progression, death, or end of study.
1785906|NCT00474383|Drug|Glucocorticoid|Prednisone/prednisolone 5 mg tablet orally twice daily/dexamethasone 0.5 mg tablet orally once daily continuously in 28-day cycle up to disease progression, death, or end of study.
1785907|NCT00474396|Behavioral|Low fat dairy diet|
1785908|NCT00474409|Drug|Merislon|
1785909|NCT00474422|Behavioral|Proactive assignment to attend a breastfeeding clinic|
1785910|NCT00474435|Drug|Emtricitabine/tenofovir/efavirenz|"Co-formulated in one tablet (taken once daily by oral administration):
emtricitabine 200 mg
tenofovir DF 300 mg
efavirenz 600 mg"
1785911|NCT00480181|Drug|nabilone|Cesamet (nabilone) capsules given at titrating dosages as per protocol.
1785912|NCT00480181|Other|placebo|placebo capsules (identical appearance to Cesamet) given at titrating dosages as per protocol.
1785913|NCT00480194|Drug|xylometazoline hydrochloride and ipratropium bromide (ZyComb)|Common cold in a real-life OTC setting
1785914|NCT00480207|Dietary Supplement|folic acid|
1785915|NCT00480207|Dietary Supplement|omega-3|
1785916|NCT00480207|Dietary Supplement|vit B12|
1785917|NCT00480207|Other|folic acid placebo|
1785918|NCT00480207|Other|omega-3 placebo|
1785919|NCT00480220|Procedure|Global care and support program|
1785920|NCT00480246|Drug|BL 1020|
1785921|NCT00480246|Drug|Perphenazine|
1785922|NCT00480259|Behavioral|hyperproteic nutrition|
1785923|NCT00480272|Drug|adalimumab, plus prednisone|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo or prednisone 50 mg/po day then reduced to 6.25/po day
1785924|NCT00480272|Drug|adalimumab plus placebo|adalimumab 40 mg/sc every 2 weeks plus methotrexate 20 mg/po every week plus placebo daily for 6 months
1785925|NCT00480285|Procedure|Laparoscopic Nissen Fundoplication|
1785926|NCT00480285|Procedure|Laparoscopic anterior partial fundoplication|
1785927|NCT00480298|Drug|Administration of oral methylprednisolone|
1785928|NCT00480311|Other|WHODAS II (World Health Organization Disability Assessment Schedule II)|To determine the measurement characteristics of WHODAS II (World Health Organization Disability Assessment Schedule).
1785929|NCT00480324|Biological|Rotarix|Two-dose oral vaccination.
1785930|NCT00480324|Biological|Placebo|Two-dose oral administration.
1785931|NCT00480337|Procedure|In Vitro Maturation of immature oocytes|
1785932|NCT00480350|Behavioral|rice based food supplement|
1785933|NCT00480363|Procedure|Maintenance with lower doses of lenalidomide and dexamethasone|After 9 cycles of lenalidomide and dexamethasone, it follows with lower doses for maintenance
1785934|NCT00480376|Drug|ofloxacin|
1785935|NCT00480376|Drug|gentamicin|
1785936|NCT00480389|Drug|Sorafenib|Starting dose: 400 mg (2x200mg tablets) BID (total= 800mg/day) taken orally. The dose can be adjusted as per investigator if required due to toxicity (ex. 200mg BID, 200mg QD). Study drug is taken for 12 weeks preoperatively. Patients restart on study drug 6 weeks postoperatively and continue until progression or unacceptable toxicity occurs.
1785937|NCT00480402|Drug|200 mg of Progesterone|Administration of 200 mg of Progesterone
1785938|NCT00480402|Drug|400 mg Progesterone|Administration of 400 mg Progesterone
1785939|NCT00480402|Drug|Placebo|Administration of a Placebo
1785943|NCT00480454|Biological|MVA 85A|intradermal vaccine
1785944|NCT00480467|Drug|SAM-315|
1785945|NCT00480480|Behavioral|Trauma and Grief Component Therapy for Adolescents (Group Version)|
1785946|NCT00480493|Behavioral|STEP|Experimental: Minutes of parent mentor-parent participant interactions Control: Minutes of parent contact-parent participant interactions
1785947|NCT00480818|Drug|SAM-531|
1785948|NCT00480831|Drug|bevacizumab|Intravenous repeating dose
1785949|NCT00480831|Drug|carboplatin|Intravenous repeating dose
1785950|NCT00480831|Drug|paclitaxel|Intravenous repeating dose
1785951|NCT00480831|Drug|placebo|Intravenous repeating dose
1785952|NCT00480831|Drug|PRO95780|Intravenous repeating dose
1785953|NCT00480844|Drug|Sertindole|Oral (tablets), 16-24 mg QD (once a day) for 12 weeks.
1785954|NCT00480844|Drug|Risperidone|Oral (tablets), 4-8 mg QD (once a day) for 12 weeks.
1785955|NCT00480857|Drug|Docetaxel (Taxotere)|Concurrent weekly docetaxel at 20mg/m2 with radiation therapy. Chemo dose may be held or reduced based on specific lab parameters.
1785956|NCT00480870|Drug|donepezil|donepezil 5 mg 1 p / day for 1 month and 2p / day for 5 months on.
1785957|NCT00480870|Drug|Placebo|Placebo 1p / day for 1 month and 2 / day for 5 months on
1785958|NCT00480883|Drug|meglumine antimoniate, allopurinol|first drug in injectable, second is in tablet form.
1785959|NCT00480883|Drug|meglumine antimoniate|injectable 20 mg/kg/day/intramuscular for 21 days.
1785960|NCT00480883|Drug|meglumine antimoniate, allopurinol|injectable meglumine antimoniate 10 mg/kg/day/intramuscular for 21 days plus tablet allopurinol 300mg/4times a day for 21 days.
1785961|NCT00480896|Drug|tacrolimus ointment|Topical application
1785962|NCT00480896|Drug|Placebo ointment|Topical application
1785963|NCT00480922|Behavioral|Low glycemic load diet|Outpatient behavioral counseling
1785964|NCT00480922|Behavioral|Low fat diet|Outpatient behavioral counseling
1785965|NCT00480935|Drug|Sunitinib Malate (Sutent)|Sutent will be given at 50 mg once daily for 4 consecutive weeks followed by a 1 week washout period. The dosage may change during the cycle due to possible drug toxicities. The nephrectomy will then take place following a one-week washout period.
1785966|NCT00480948|Behavioral|Infant formula feeding (InFat™)|Infant formula with InFat™ oil (containing ~49% of C16:0 at sn-2 position), 24 wk
1785967|NCT00480948|Dietary Supplement|Control|Standard vegetable oil based infant formula
1785968|NCT00480961|Procedure|intramiocardiac autograft of autologous stem cells|
1785969|NCT00480974|Other|Clinical follow up and laboratory analysis|Clinical follow up and laboratory analysis
1785970|NCT00480987|Drug|Oxaliplatin|30 mg/m^2 IV days 1-4
1785971|NCT00480987|Drug|Fludarabine|30 mg/m^2 IV days 2-6
1785972|NCT00480987|Drug|Cytarabine|500 mg/m^2 by IV continuous infusion days 2-6
1785973|NCT00481000|Behavioral|Dialectical Cognitive Therapy|Dialectical Behavior Therapy in Combination with Traumafocused CBT
1785974|NCT00481013|Drug|Valproic Acid (VPA)|Drug: Valproic Acid and Levocarnitine; capsules
1785975|NCT00481013|Drug|Placebo|For six months, pts are randomized into placebo or treatment. After 6 months, all pts are on treatment
1785976|NCT00481026|Device|transcranial direct current stimulation (tDCS)|tDCS
1785977|NCT00481026|Device|active tDCS|Active tDCS
1785978|NCT00481039|Procedure|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
1785979|NCT00481052|Drug|Nilotinib|
1785980|NCT00481065|Biological|MF59-eH5N1|
1785981|NCT00481065|Biological|eTIV_a|
1785982|NCT00481065|Biological|MF59-eH5N1 + eTIV_a|
1785983|NCT00481078|Drug|vorinostat|Given PO
1785984|NCT00481078|Drug|paclitaxel|Given IV
1785985|NCT00481078|Drug|carboplatin|Given IV
1785986|NCT00481078|Other|placebo|Given PO
1785987|NCT00481078|Other|laboratory biomarker analysis|Correlative studies
1785989|NCT00481104|Drug|Tesofensine|
1785990|NCT00481117|Drug|LY2405319|
1785991|NCT00481117|Drug|Placebo|
1785992|NCT00481143|Drug|ICL670/Deferasirox|
1785993|NCT00481156|Behavioral|Cognitive Remediation|
1785994|NCT00481156|Behavioral|Cognitive Behavioral Social Skills Training|
1785995|NCT00481169|Drug|Bazedoxifene Acetate (TSE-424)|
1785996|NCT00481182|Drug|fosamprenavir + ritonavir + methadone|
1785997|NCT00481195|Drug|Armodafinil|Patients were randomly assigned to begin oral treatment with armodafinil, which was titrated to 150 mg/day (3 tablets). Armodafinil was titrated up to the target dosage of 150 mg/day (daily dose was administered each morning). Patients began taking blinded armodafinil at a dose of 50 mg/day (1 tablet) on the day following the baseline visit. Doses were increased by 50 mg/day (1 tablet) to a dose of 100 mg/day on Day 2 and 3, and then again by 50 mg /day on day 4 for a target dose of 150 mg/day. Following titration, patients continued taking 150 mg/day of armodafinil for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 100 mg/day [2 tablets]) was allowed. The dosage could not be increased after it was decreased.
1785998|NCT00481195|Drug|Placebo|Patients were randomly assigned to begin oral treatment with placebo, which was titrated to 3 tablets. Placebo tablets matching the 50 mg armodafinil tablet were used in a manner identical to that of the armodafinil tablets. Study drug was titrated up to the target dosage of 3 tablets / day (daily dose was administered each morning). Patients began taking blinded study drug at a dose of 1 tablet daily on the day following the baseline visit. Doses were increased by 1 tablet to a dose of 2 tablets/day on Day 2 and 3, and then again by 1 tablet /day on day 4 for a target dose of 3 tablets/day. Following titration, patients continued taking 3 tablets/day of study drug for the duration of the study. If a patient was unable to tolerate (recurrent or persistent adverse events) the study drug, 1 reduction in dosage (ie, minimum dosage 2 tablets/day) was allowed. The dosage could not be increased after it was decreased.
1785999|NCT00481221|Procedure|Observation of results from laboratory tests|Laboratory data summary only
1786000|NCT00481234|Device|Heart Rate Variability analysis|
1786001|NCT00481247|Drug|Dasatinib|Tablets, oral, dasatinib 50-140 mg once daily (QD)
1786002|NCT00481247|Drug|Imatinib|Tablets, oral, imatinib 200-800 mg, QD
1786003|NCT00481260|Procedure|Medical history and basic laboratory analysis|Medical history and basic laboratory analysis
1786004|NCT00481273|Drug|Azacitidine|Physician's discretion
1786005|NCT00481286|Behavioral|Improving outcomes using group clinics for older patients|Collaborative group clinics to empower older patients to adopt goal-setting behaviors with their health care providers and improve their diabetes-related outcomes.
1786006|NCT00481286|Behavioral|Standard of Care|Standard of care for diabetes patients
1786007|NCT00481312|Drug|Dexmedetomidine|Continuous Infusion
1786008|NCT00481312|Drug|Midazolam|Continuous Infusion
1786009|NCT00481325|Drug|pexacerfont|Tablets & Capsules, Oral, 300mg loading dose then 100 mg, once daily, 1 week loading dose then 8 weeks
1786010|NCT00481325|Drug|escitalopram|Tablets & Capsules, Oral, 10-20mg, once daily, 1 week loading dose then 8 weeks
1786011|NCT00481325|Drug|placebo|Tablets & Capsules, Oral, 0 mg, once daily, 1 week loading dose then 8 weeks
1786012|NCT00481338|Procedure|X-rays|X-rays (hip and knee) every 2 years
1786013|NCT00481338|Biological|biological samples|biological sample (blood and urine) every 2 years
1786014|NCT00481338|Other|medical information about osteoarthritis|several questionnaires about pain and function (WOMAC), physical activity (MAQ), quality of life (generic SF-36 and OA specific OAKHQOL/AMIQUAL), comorbidities (FCI), mental status (MMS), heath status (GHQ 28) and health resource consumption
1786015|NCT00481351|Drug|Simvastatin 20mg plus ezetimibe 10mg|simvastatin 20mg plus ezetimibe 10mg once a day for 6 week.
1786016|NCT00481351|Drug|ezetimibe|ezetimiba 10mg once a day
1786017|NCT00481351|Drug|simvastatin 20mg|simvastatin 20mg once a day
1786018|NCT00481351|Drug|Simvastatin 80mg|simvastatin 20mg for 6week and then simvastatin 80mg for the next 6week.
1786019|NCT00481364|Drug|atorvastatin|atorvastatin 40 mg/day
1786020|NCT00481364|Drug|placebo|1 tb/day
1786021|NCT00481377|Procedure|ablation|
1786022|NCT00481390|Procedure|Cheek cells sample|Cheek cells sample
1786023|NCT00481390|Procedure|Blood sample|Blood sample
1786024|NCT00481403|Behavioral|Microarray analysis|Microarray analysis
1786025|NCT00481403|Behavioral|Microarray|Microarray
1786026|NCT00481416|Device|PillCam Eso|
1786027|NCT00481429|Drug|Rosiglitazone|Rosiglitazone 4mg od, increased to 4mg bg at 4 weeks if HbA1C above 7%.
1786028|NCT00481442|Drug|Phenylephrine|
1786029|NCT00481455|Drug|Panzem NCD|2000 mg q8h, continuous dosing in 28 day cycles
1786030|NCT00481455|Drug|Temozolomide|Fixed dose
1786031|NCT00481481|Drug|tacrolimus|immunosuppression
1786081|NCT00481845|Drug|Vandetanib|300 mg daily
1991710|NCT00657917|Drug|Paromomycin +Gentamicin topical cream|Apply topically twice daily for 20 days
1786032|NCT00481507|Drug|Kefir|The intervention was Kefir,a drink that is commercially available in the United States. The following probiotics are present in the Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150mL) everyday.
1786033|NCT00481507|Drug|Placebo|The intervention was Kefir, a drink that is commercially available in the United States. The following probiotics are present in active Kefir: Lactococcus lactis, Lactococcus plantarum, Lactococcus rhamnosus, Lactococcus casei, Lactococcus lactis subspecies diacetylactis, Leuconostoc cremoris, Bifidobacterium longum, Bifidobacterium breve, Lactobacillus acidophilus, and 1 yeast, Saccharomyces florentinus. The placebo group was heat-treated to kill all cultures. Parents were asked to ensure that their enrolled child consumed at least half of the bottle (150 mL)everyday.
1786034|NCT00481520|Drug|SAM-531|
1786035|NCT00481520|Other|placebo|
1786036|NCT00481533|Drug|Methyl-Ergonovine-Oxytocin|
1786037|NCT00481533|Drug|Oxytocin|
1786038|NCT00481546|Genetic|rAAV2-CBSB-hRPE65|One or two, uniocular, subretinal injections; relative doses: 0.3X (Cohort 1), 0.6X (Cohort 2), 0.45X (Cohort 3), 0.9X (Cohorts 4 and 5)
1786039|NCT00481559|Drug|Voraxaze (glucarpidase)|50 Units/kg in a bolus intravenous injection over 5 minutes
1786040|NCT00481572|Drug|Terlipressin|continuous terlipressin infusion 1.3 µg•kg-1 over a period of 48 hrs
1786041|NCT00481572|Drug|Vasopressin|continuous intravenous infusion of vasopressin 0.03 U•min-1 over a period of 48 hrs
1786042|NCT00481572|Drug|Norepinephrine|titrated norepinephrine over a period of 48 hrs
1786043|NCT00481598|Procedure|magnet resonance spectroscopy|magnet resonance spectroscopy
1786044|NCT00481624|Drug|Epoetin Alfa plus Iron|"One (1) injection of Procrit®, by needle, inserted just under the skin;
125 mg of ferric gluconate (an iron injection product), through an IV injection into a vein.
These injections will take approximately 10-15 minutes to complete. Both will be administered every 3 weeks for a total of 4 cycles, unless the study doctor decides that a change in the amount of Procrit® and iron is necessary once the hemoglobin level rises or is above a certain amount.
In addition to Procrit® and the intravenous iron, the subject will also receive platinum-containing chemotherapy every 3 weeks for 4 cycles as per standard of care for their lung cancer treatment. Radiation therapy will be allowed during this regimen if it is part of the subject's treatment plan."
1786045|NCT00481650|Drug|Leios/Alesse|
1786046|NCT00481663|Drug|Sitagliptin|
1786047|NCT00481663|Drug|Placebo to sitagliptin|
1786048|NCT00481663|Drug|Metformin|
1786049|NCT00481663|Drug|Rescue|Patients whose FPG >240 mg/dL from Week 16 or HbA1C >8.5% from Week 25 up to (not including) Week 52 could receive rescue antihyperglycemic therapy with pioglitazone, and remain in the extension study (Extension 1). Participants were eligible for rescue with pioglitazone 30 mg (or rosiglitazone in countries where pioglitazone was not licensed) if they met the following criteria: from Week 16 and during the second extension: FPG consistently >240 mg/dL (repeated and confirmed within 3 to 7 days); from Week 52 up to (not including) Week 70: HbA1C >8%; from Week 70 up to (not including) Visit 21/Week 106: HbA1C >7.5% (Extension 2). Participants placed on rescue therapy with pioglitazone (rosiglitazone where pioglitazone is not available) in the first or second extensions were not eligible for enrollment in the third extension. Rescue therapy was not available in the third extension.
1786050|NCT00481676|Drug|Omalizumab 75-375 mg|Omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg of omalizumab upon reconstitution with 1.4 ml sterile water for injection.
1786051|NCT00481676|Drug|Placebo to omalizumab|Placebo to omalizumab was supplied as lyophilized, sterile powder in a single-use, 5 ml vial designed to deliver 150 mg placebo to omalizumab upon reconstitution with 1.4 ml sterile water for injection.
1786052|NCT00481676|Drug|Loratadine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
1786053|NCT00481676|Drug|Clemastine|All participants received antihistamines on demand (loratadine and clemastine), as the trial was designed to investigate the effect of omalizumab as an add-on to antihistamines in people with chronic urticaria (CU). Administration of antihistamines is the current gold standard treatment of CU. A significant proportion of people with CU is not well controlled by this standard or by using high doses of antihistamines.
1786054|NCT00481689|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Active Ciprofloxacin XR ( 1000mg) given for 7 to 14 days
1786055|NCT00481702|Drug|Comparator: ceftriaxone sodium / Duration of Treatment: 8 Weeks|
1786056|NCT00481702|Drug|MK0826, /Duration of Treatment : 8 Weeks|
1786057|NCT00481702|Drug|Comparator: metronidazole / Duration of Treatment: 8 Weeks|
1786058|NCT00481715|Behavioral|Web-Based Weight Loss Program|Participants will take part in a Web-based weight loss program.
1786059|NCT00481715|Behavioral|Cash Incentive Weight Loss Program|Participants will take part in a cash incentive weight loss program.
1786060|NCT00481728|Drug|Tolterodine|Single dose per patient as determined by protocol.
1786061|NCT00481728|Procedure|Filling cystometry|This is a procedure.
1786062|NCT00481728|Procedure|Intravesical neurostimulation|This is a procedure.
1786063|NCT00481741|Device|SafeSeal(TM) Hemostasis Patch|
1786064|NCT00481767|Biological|CervarixTM|Three doses of vaccine/control will be administered according to a 0, 1, 6 month schedule
1786065|NCT00481767|Biological|Placebo vaccine (Al(OH)3)|Three doses of vaccine/control will be administered according to a 0, 1, 6 month schedule
1786066|NCT00481780|Device|plain balloon angioplasty|
1786067|NCT00481780|Device|cutting balloon angioplasty|
1786068|NCT00481819|Drug|FK506MR|oral
1786069|NCT00481819|Drug|Prograf|oral
1786070|NCT00481819|Drug|Mycophenolate Mofetil|oral
1786071|NCT00481819|Drug|Methylprednisolone|oral
1786072|NCT00481819|Drug|Prednisolone|oral
1786083|NCT00481871|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
Sequential Dosing: 10 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Same Day Dosing: 15 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
1786084|NCT00481871|Drug|Gemcitabine Hydrochloride|"Gemcitabine will be prepared and administered as an IV infusion as per manufacturer instructions.
Sequential Dosing: 400 mg/m2 every 2 weeks (days 2 and 16) of a 4-week cycle until criteria for discontinuation per the protocol are met.
Same Day Dosing: 600 mg/m2 every 2 weeks (days 1 and 15) of a 4-week cycle until criteria for discontinuation per the protocol are met."
1786085|NCT00481871|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection
Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
1786086|NCT00481871|Dietary Supplement|Folic Acid|"1 mg orally
Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate."
1786087|NCT00481884|Other|RadiaPlexRx Gel|RadiaPlexRx Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply RadiaPlexRx gel topically 3 Times Daily to one half of the irradiated breast skin and the control, Aquaphor gel, to the other half of irradiated breast skin. This is determined through randomization process.
1786088|NCT00481884|Other|Aquaphor Gel|Aquaphor Gel: The treated breast is divided into two vertical halves during the simulation using skin marker (medial and lateral halves). Patients are given detailed instructions to apply Aquaphor gel topically 3 Times Daily to one half of the irradiated breast skin and the experimental, RadiaPlexRx gel, to the other half of irradiated breast skin. This is determined through randomization process.
1786089|NCT00481897|Behavioral|low-fat, vegan diet|Diet that excludes animal products (i.e. meat, dairy, eggs) and keeps oils to a minimum.
1786090|NCT00481923|Drug|rimonabant (SR141716)|
1786091|NCT00481936|Drug|VB6-845|Intravenous infusion once weekly for 4 weeks
1786092|NCT00481962|Drug|Tygacil|Initial dose of 100mg followed by 50mg every 12 hours for 5 to 14 days
1786093|NCT00481975|Drug|rimonabant (SR141716)|
1786094|NCT00481988|Device|transcranial direct current stimulation|Two damp sponges, one placed on the left side of the forehead, the other on the left arm. 0.1mA of current is passed for 20 minutes.
1786095|NCT00481988|Device|transcranial direct current stimulation|transcranial direct current stimulation delivers one milliamp of direct current, supplied by a constant current generator, the the left dorsolateral prefrontal cortex through a scalp electrode. The treatment is given for 20 minutes a day.
1786096|NCT00481988|Device|transcranial direct current stimulation|one milliamp of direct current applied to the left dorsolateral prefrontal cortex through a scalp electrode
1786097|NCT00481988|Device|iomed phoresor transcranial direct current stimulation|for the sham group the current is turned off after 10 seconds
1786100|NCT00482014|Drug|pemetrexed|"Phase 1 - 500 milligram/meter squared (mg/m²), administered intravenously, every 21 days for 3 cycles
Phase 2 - 500 mg/m², administered intravenously, every 21 days for 3 cycles
Consolidation Therapy - 500 mg/m² pemetrexed, administered intravenously, every 21 days for 3 cycles beginning 3 weeks after completion of chemoradiation therapy for each phase"
1786101|NCT00482014|Drug|cisplatin|"Phase 1 - 30 mg/m² and 75 mg/m², administered intravenously, Days 1, 8, 22, 29 and 43
Phase 2 - 75 mg/m², administered intravenously, every 21 days for 3 cycles"
1786102|NCT00482014|Drug|carboplatin|"Phase 1 - dosed at area under the curve (AUC) 2 milligram/milliliter*minute (mg/mL*min), administered intravenously, Days 1, 8, 22, 29 and 43
Phase 2 - dosed at AUC 5 mg/mL*min, administered intravenously, every 21 days for 3 cycles"
1786103|NCT00482014|Radiation|radiation therapy|"Phase 1 - 2 Gray, daily, 5 days a week for Days 1-51
Phase 2 - 2 Gray, daily, 5 days a week for Days 1-45"
1786104|NCT00482027|Biological|tgAAC09|one or 2 doses of AAV-2 HIV vaccine (tgAAC09) at 3 dosage levels, dose escalation and dose optimization
1786105|NCT00482040|Device|Stephanie (TM), Infant Flow (TM), Infant Flow advance (TM), Bubble CPAP|
1786110|NCT00482066|Drug|Abatacept (Orencia)|"500mg for patients under 60kg 750mg for patients 60-100kg
1g for patients>100kg given as i.v. infusion over 30 minutes at day 0, 14, 28 and then monthly for a further 11 months 914 infusions in total) placebo groups receive saline only I.v."
1786111|NCT00482079|Drug|MK0431, sitagliptin phosphate / Duration of Treatment: 21 Weeks|
1786112|NCT00482079|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 21 Weeks|
1786113|NCT00482092|Drug|adult human mesenchymal stem cells|Intravenous infusion of suspension of adult human mesenchymal stem cells, total of 1200 million (high dose) or 600 million (low dose) cells infused in four visits over two weeks.
1786114|NCT00482092|Drug|Placebo|Placebo
1786115|NCT00482105|Other|EGIR Tape|Tape stripping is a non-invasive method that allows the recovery of cells
1786116|NCT00482144|Procedure|PDL 450 microseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 450 microseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
1786117|NCT00482144|Procedure|PDL 1.5 milliseconds|The scar will be randomly divided into three equal fields. One third of the scar will receive PDL 585 nm using a 7 mm spot size at 4.0 J (Joules) for 1.5 milliseconds. First treatment will be immediately after suture removal, and then monthly for 3 months.
1786118|NCT00482157|Drug|Vitamin D (Calcitriol)|
1786119|NCT00482170|Device|Enbrel (etanercept)|Arm 1 = Enbrel 50 mg Prefilled Syringe twice weekly
1786120|NCT00482170|Device|Etanercept|Arm 2 = Enbrel 50 mg Autoinjector twice weekly
1786121|NCT00482183|Drug|Pioglitazone|
1786122|NCT00482196|Drug|MK0493|
1786187|NCT00482625|Genetic|protein expression analysis|Correlative studies
1786123|NCT00482209|Drug|Mifepristone, misoprostol|200mg mifepristone followed by 400mcg misoprostol 36-48 hours later
1786124|NCT00482209|Drug|mifepristone, misoprostol|200mg mifepristone followed by 800mcg misoprostol 36-48 hours later
1786125|NCT00482222|Biological|cetuximab|
1786126|NCT00482222|Drug|capecitabine|
1786127|NCT00482222|Drug|fluorouracil|
1786128|NCT00482222|Drug|leucovorin calcium|
1786129|NCT00482222|Drug|oxaliplatin|
1786130|NCT00482222|Other|study of socioeconomic and demographic variables|
1786131|NCT00482222|Procedure|adjuvant therapy|
1786132|NCT00482222|Procedure|neoadjuvant therapy|
1786133|NCT00482222|Procedure|quality-of-life assessment|
1786134|NCT00482235|Drug|MK0359|
1786135|NCT00482248|Drug|Omalizumab|
1786136|NCT00482261|Drug|Lenalidomide|15mg daily, days 1-21 of a 28 day cycle for 4 cycles. Patients who get stable disease or better will then receive 15mg on days 1-21 from cycle 5 onwards
1786137|NCT00482261|Drug|dexamethasone|20mg day 1-4, 9-12, 17-20 for 4 cycles. Patients who get stable disease or better will then get dexamethasone 20mg on days 1-4 of a 28 day cycle, from cycle 5 onwards
1786138|NCT00482261|Drug|aspirin|100mg/day
1786139|NCT00482274|Drug|docetaxel|Docetaxel 75 mg/m2 intravenously (IV) over 60 minutes will be given on day 1 of each 21 day cycle.
1786140|NCT00482287|Drug|MTR105|Intravenous administration, dose escalating (4 arms), single dose
1786141|NCT00482300|Procedure|Systematic pelvic lymphadenectomy|
1786142|NCT00482313|Drug|PR OROS Methylphenidate|PR OROS Methylphenidate given orally once daily for 5 weeks. The dosage was as follows: 36 mg per day from day 1-3, 54 mg per day from day 4-7 and 72 mg per day from day 8 until end of 5th week.
1786143|NCT00482313|Drug|Placebo|Sugar pill
1786144|NCT00482352|Other|laboratory biomarker analysis|Correlative studies
1786145|NCT00482365|Other|biologic sample preservation procedure|biologic sample preservation procedure
1786146|NCT00482365|Other|medical chart review|review of patients' medical records at study entry and every 6 months
1786147|NCT00482365|Other|Patient interview|Elicit demographic data as well as information about personal habits such as drinking and smoking.
1786148|NCT00482378|Drug|Pamidronate|90 mg by IV monthly.
1786149|NCT00482378|Drug|Zoledronic acid|4 mg by IV monthly.
1786150|NCT00482378|Radiation|Sm 153 lexidronam|0.5 mCi/kg or 1 mCi/kg by IV.
1786151|NCT00482391|Biological|trastuzumab|
1786152|NCT00482391|Drug|cyclophosphamide|
1786153|NCT00482391|Drug|doxorubicin hydrochloride|
1786154|NCT00482391|Drug|lapatinib ditosylate|
1786155|NCT00482391|Drug|paclitaxel|
1786156|NCT00482391|Other|laboratory biomarker analysis|
1786157|NCT00482404|Behavioral|Romantic kissing|
1786158|NCT00482417|Drug|MK0359|
1786159|NCT00482430|Drug|MK0557|MK0557 10mg tablet qd for a 15-wk treatment period
1786160|NCT00482430|Drug|Comparator: Placebo (unspecified)|MK0557 Pbo tablet qd for a 15-wk treatment period
1786161|NCT00482443|Other|A software programme in mobile telephone|Use of Mobile phone technology in maintaining Diabetes Interactive Diary.
1786162|NCT00482443|Other|Standard Education Programme.|Control Arm patients will receive a standard education programme designed to help the Type 1 Diabetic manage their condition.
1786163|NCT00482456|Drug|Nitrous oxide|
1786164|NCT00482482|Behavioral|psychoeducation|on weekly basis for 8 weeks
1786165|NCT00482482|Behavioral|Yoga|on weekly basis for 8 weeks
1786166|NCT00482495|Biological|bevacizumab|
1786167|NCT00482495|Genetic|gene expression analysis|
1786168|NCT00482495|Genetic|protein expression analysis|
1786169|NCT00482495|Other|laboratory biomarker analysis|
1786170|NCT00482508|Drug|Omalizumab|
1786171|NCT00482521|Drug|CC-4047|Oral CC-4047 once daily on days 1-21 followed by a 7-day recovery period. Cohorts of 3-6 patients receive escalating doses of CC-4047 until the maximum tolerated dose (MTD) is determined.
1786172|NCT00482547|Device|Hydrogel Silver Salts Coated Latex Urinary Catheter System|Silver-coated catheter
1786173|NCT00482547|Device|Bard silicone elastomer coated latex catheter system|Silicone-coated catheter
1786174|NCT00482560|Drug|Sucrose solution 30%1 ml|
1786175|NCT00482560|Behavioral|Breastfeeding|
1786176|NCT00482573|Procedure|Dental local anesthesia|"2% lidocaine solution with epinephrine 1:100,000
infusion of 1,8 mL (one cartridge)
Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
1786177|NCT00482573|Procedure|Dental local anesthesia|"2% lidocaine solution without vasoconstrictor
infusion of 1,8 mL (one cartridge)
Technic: modified anesthesia of the periodontal ligament (PDLm injection) was performed applying The Wand II Computerized System (Milestone International)"
1786178|NCT00482586|Other|medical chart review|Review the medical charts of patients with hepatic neoplasms who undergo Image-guided Therapy.
1786179|NCT00482586|Other|questionnaire administration|Patients with hepatic neoplasms who undergo Image-guided Therapy
1786180|NCT00482586|Procedure|quality-of-life assessment|Patients with hepatic neoplasms who undergo Image-guided Therapy
1786181|NCT00482599|Drug|Sugammadex|2 mg/kg sugammadex administered intravenously at reappearance of T2 after 0.6 mg/kg rocuronium in patients with renal impairment and control patients
1786182|NCT00482612|Drug|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing either 1.5, 3.0, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
1786183|NCT00482612|Drug|Placebo|Placebo tablets containing the following excipients: hydroxypropyl cellulose, maize starch (USP name: corn starch), magnesium stearate, and lactose monohydrate. Tablets were administered orally once daily about 30 minutes prior to bedtime.
1786184|NCT00482625|Drug|erlotinib hydrochloride|Given PO
1786185|NCT00482625|Procedure|conventional surgery|Undergo pancreatectomy
1786186|NCT00482625|Other|immunohistochemistry staining method|Correlative studies
1786188|NCT00482625|Procedure|biopsy|Correlative studies
1786189|NCT00482625|Other|pharmacological study|Correlative studies
1786190|NCT00482625|Other|laboratory biomarker analysis|Correlative studies
1786191|NCT00482638|Drug|MK0493|
1786192|NCT00482651|Radiation|Multidetector computed tomography scanning|contrast Multidetector CT-scanning
1786193|NCT00482651|Procedure|Coronary angiography (CAG)|CAG and if necessary PCI. Included patients are already assigned for CAG
1786194|NCT00482651|Procedure|Intravascular ultrasound|During CAG Intravascular Ultrasound will be performed in the three coronary arteries
1786195|NCT00482651|Procedure|Blood sample|a blood sample at baseline after 3 months and at the end of the follow up (after 12 months)
1786196|NCT00482664|Drug|CP-866,087|Tablets for oral administration
1786197|NCT00482664|Drug|CP-866,087|Tablets for oral administration
1786198|NCT00482664|Drug|CP-866,087|Tablets for oral administration
1786199|NCT00482664|Drug|Placebo|Tablets for oral administration
1957194|NCT02498652|Drug|RDEA3170 2.5 mg|"Cohort 1: RDEA3170 2.5 mg, 7.5 mg (2.5 mg × 3 tablets), and 15 mg (2.5 mg × 6 tablets).
Cohort 2: RDEA3170 5 mg (2.5 mg × 2 tablets), 10 mg (2.5 mg × 4 tablets), and 20 mg (2.5 mg × 8 tablets)."
1957195|NCT02498652|Drug|allopurinol 300 mg|allopurinol 300 mg, allopurinol 600 mg (300 mg x 2 tablets)
1786204|NCT00482690|Drug|nicotine polacrilex|
1786205|NCT00482690|Drug|nicotine transdermal system|
1786206|NCT00482690|Drug|nicotine inhaler|
1786207|NCT00482703|Drug|Dasatinib|tablets, Oral, 100 mg, once daily
1786208|NCT00482703|Drug|dasatinib|tablets, Oral, 50 mg, twice daily
1786209|NCT00482716|Biological|epoetin alfa|
1786210|NCT00482716|Biological|epoetin beta|
1786211|NCT00482716|Dietary Supplement|iron dextran complex|
1786212|NCT00482716|Dietary Supplement|iron sucrose injection|
1786213|NCT00482729|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/Metformin HCl 50/500 mg tablet bid, titrating up to sitagliptin/Metformin HCl 50/1000 mg tablet over 4 weeks; for a 44-wk treatment period.
1786214|NCT00482729|Drug|metformin|metformin 500 mg tablet bid, titrating up to 1000 mg tablets bid for a 44-wk treatment period
1786215|NCT00482742|Device|CiTop(TM) Guidewire|
1786216|NCT00482755|Drug|sunitinib malate|
1786217|NCT00482755|Other|immunohistochemistry staining method|
1786218|NCT00482755|Other|laboratory biomarker analysis|
1786219|NCT00482755|Other|pharmacological study|
1786220|NCT00482755|Procedure|needle biopsy|
1786221|NCT00482755|Procedure|neoadjuvant therapy|
1786222|NCT00482768|Behavioral|Practice Facilitation|Clinics in the experimental arm will meet with a trained facilitator to work on change strategies that will improve risk factors for diabetes complications.
1786223|NCT00482781|Biological|Infanrix|
1786224|NCT00482781|Biological|Pediatrix|
1786225|NCT00482807|Drug|bicalutamide|
1786226|NCT00482807|Drug|docetaxel|
1786227|NCT00482807|Drug|goserelin|
1786228|NCT00482807|Radiation|intensity-modulated radiation therapy|
1786229|NCT00482820|Behavioral|attention-bias training|one group recive an attention training away from threat. The second group, the controll group, recive a placebo training
1786230|NCT00482833|Drug|arsenic trioxide|"Induction Arsenic Trioxide (As2O3=ATO), 0.15 mg/Kg IV over 2 hours daily starting on day 1. ATO will be continued until hematological CR or for a maximum of 60 days.
Consolidation ATO, 0.15 mg/Kg IV over 2 hours daily for 5 days every week. Treatment will be continued for 4 weeks on and 4 weeks off, for a total of 4 cycles (last cycle administered on weeks 25 - 28)."
1786231|NCT00482833|Drug|idarubicin|"Induction
Idarubicin, 12 mg/m² on days 2, 4, 6 and 8 by short (20') intravenous infusion .
If no hematological CR is achieved by 60 days after start of induction, patient will go off-study.
Consolidation
1st cycle Idarubicin, 5 mg/m2/day by short (20') intravenous infusion on days 1, 2, 3, 4.
3rd cycle Idarubicin, 12 mg/m2/day as short (20') intravenous infusion only on day 1."
1786232|NCT00482833|Drug|mercaptopurine|Maintenance therapy 6-Mercaptopurine (6-MP), 50 mg/m2/day orally. The dose will be adjusted according to hematopoietic toxicity during the follow-up period
1786233|NCT00482833|Drug|methotrexate|Maintenance therapy Methotrexate (MTX), 15 mg/m2/weekly intramuscularly. The dose will be adjusted according to toxicity during the follow-up period.
1786234|NCT00482833|Drug|all-trans retinoic acid|"Induction ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological CR and for a maximum of 60 days.
Consolidation
st cycle ATRA, 45 mg/m2/day, will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.
nd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.
rd cycle ATRA, 45 mg/m2/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting from day 1 to day 15.
Maintenance therapy
ATRA, 45 mg/m2/day orally, for 15 days every three months until a two year period is completed."
1786235|NCT00482833|Drug|all-trans retinoic acid (ATRA)|"Induction All-trans retinoic acid (ATRA), 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment, starting on day 1. ATRA treatment will be continued until hematological complete remission (CR, see below for definition) or for a maximum of 60 days.
Consolidation ATRA, 45 mg/m²/day will be administered orally in two equally divided doses and rounded to the nearest 10 mg increment. Treatment will be administered for 2 weeks on 2 weeks off and for a total of 7 cycles (last cycle administered on weeks 25 - 26)."
1786236|NCT00482846|Biological|Palifermin|Palifermin 60 mcg/kg/d of the actual body weight unless actual body weight is >40% of the Ideal body weight (IBW), then adjusted body weight (AdBW) will be used for dose calculations - administered on Day - 5,-4, - 3 and then repeated on Day +1, +2 and +3
1786402|NCT00483678|Other|counseling intervention|
1786237|NCT00482846|Drug|melphalan|"Dose of Melphalan + Palifermin (Normal Renal Function): All given on Day -2:
Dose Level 1- 200 mg/m2 I.V; Dose Level 2- 220 mg/m2 I.V; Dose Level 3- 240 mg/m2 I.V; Dose Level 4- 260 mg/m2 I.V; Dose Level 5- 280 mg/m2 I.V;
Dose of Melphalan + Palifermin (Renal Dysfunction CrCl. <60)adm. via I.V.:
Dose Level 1- 140 mg/m2; Dose Level 2- 160 mg/m2; Dose Level 3- 180 mg/m2; Dose Level 4- 200 mg/m2; Dose Level 5- 220 mg/m2;"
1786238|NCT00482846|Other|questionnaire administration|Day -5 to Day +28
1786239|NCT00482846|Procedure|autologous peripheral blood stem cell transplantation|Day 0
1786240|NCT00482846|Other|quality-of-life assessment|Day -5 to Day +28
1786241|NCT00482872|Genetic|gene expression analysis|
1786242|NCT00482872|Genetic|mutation analysis|
1786243|NCT00482872|Genetic|polymerase chain reaction|
1786244|NCT00482872|Genetic|polymorphism analysis|
1786245|NCT00482872|Other|flow cytometry|
1786246|NCT00482872|Other|laboratory biomarker analysis|
1786247|NCT00482898|Drug|MK0359|
1786248|NCT00482911|Drug|cyclophosphamide|25-50 mg by mouth once daily on days 1-28.
1786249|NCT00482911|Drug|lenalidomide|10 mg by mouth once daily on days 1-28.
1786250|NCT00482911|Drug|sunitinib malate|12.5 - 25 mg by mouth once daily on days 1-28.
1786251|NCT00482924|Other|Lifestyle intervention|Regular sports and dietary advices. Controlled by analysis of laboratory parameters, BMI change and performance diagnostics. No drugs included so far.
1786252|NCT00482937|Drug|CD-NP|
1786253|NCT00482950|Drug|PHX1149T|
1786254|NCT00482963|Drug|levonorgestrel, efavirenz|
1786255|NCT00482976|Drug|Ruboxistaurin|
1786256|NCT00482976|Drug|Placebo|
1786257|NCT00482989|Biological|MEDI 545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.
Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
1786258|NCT00482989|Other|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.
Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
1786259|NCT00483002|Drug|varenicline|As prescribed by physician in usual clinical practice.
1786260|NCT00483015|Behavioral|smoking|
1786261|NCT00483028|Drug|donezepil (Aricept)|
1786262|NCT00483041|Other|PLACEBO|Placebo administered as a single intravenous infusion
1786263|NCT00483041|Biological|MEDI528 9 mg/kg|MEDI-528 at a dose of 9 mg/kg administered as a single intravenous infusion
1786264|NCT00483054|Drug|efavirenz|efavirenz 600 mg/day + stavudine + lamivudine
1786265|NCT00483054|Drug|nevirapine|nevirapine 400 mg/day + stavudine +lamivudine
1786266|NCT00483067|Drug|2-CdA|12 mg/m^2/day by vein (IV) Continuous Infusion x 5 Days
1786267|NCT00483067|Drug|Ara-C|1 gm/m^2/day IV Over 2 Hours x 5 Days
1786268|NCT00483067|Drug|G-CSF (Granulocyte colony-stimulating factor)|5 mcg/kg/day given under the skin (subcutaneously) starting Day 9
1786269|NCT00483080|Drug|NGR-hTNF|iv q3W or q1W NGR-hTNF 0.8 μg/m²
1786270|NCT00483093|Drug|NGR-hTNF|iv q3W escalating dose NGR-hTNF up to 1.6 mcg/sqm
1786271|NCT00483093|Drug|Cisplatin|iv q3W 80 mg/sqm 30 minutes after NGR-hTNF infusion for a maximum of six cycles
1786272|NCT00483106|Drug|Ritalin|0.25 mg/kg bid, orally for 7 consecutive days
1786273|NCT00483106|Drug|Placebo|taken orally twice a day for 7 consecutive days
1786274|NCT00483119|Drug|intravenous immunoglobulin|Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
1786275|NCT00483119|Drug|cyclophosphamide|cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
1786276|NCT00483132|Drug|interferon alpha 2a|
1786277|NCT00483145|Device|Long-pulsed dye laser (Candela) and PDT (methylaminolevulinate)|
1786278|NCT00483145|Device|Long-pulsed dye laser|
1786279|NCT00483145|Device|Long-pulsed dye laser assisted fotodynamic therapy (methylaminolevulinate)|
1786280|NCT00483158|Drug|Finafloxacin hydrochloride|Tablets, oral single dose and multiple dose once daily for 7d
1786281|NCT00483171|Drug|CP-945,598|CP-945,598
1786282|NCT00483171|Behavioral|Non-pharmacological weight loss program (NPP)|Nutrition counseling, exercise monitoring and behavioral management will occur for all arms during the NPP.
1786283|NCT00483171|Behavioral|Low Calorie Diet|Low calorie diet
1786284|NCT00483184|Biological|Veldona,|Very low dose oral natural human interferon alpha lozenges
1786285|NCT00483197|Device|VentrAssistTM Left Ventricular Assist Device|
1786286|NCT00483210|Drug|Fenofibrate|
1786287|NCT00483223|Drug|Cisplatin|Given intravenously on the first day of each 3-week treatment cycle at 75mg/m2. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
1786288|NCT00483223|Drug|carboplatin|Given intravenously on the first day of each 3-week treatment cycle at AUC 6. Participants may continue to receive study treatment as long as their disease does not worsen and they do not experience serious side effects.
1786289|NCT00483249|Device|Endovascular Branched Stent-Graft|Industry manufactured branched stent-graft for treatment of TAAA/PVAAA.
1786290|NCT00483262|Drug|CCI-779|Given by injection once a week for 5 weeks (5 weeks equals one cycle) for up to 8 cycles
1786291|NCT00483262|Drug|Bortezomib|Given by injection once a week for 4 weeks (a cycle equals 5 weeks) for up to 8 cycles
1786292|NCT00483275|Drug|Alfacalcidol|
1786293|NCT00483275|Behavioral|Balance, gait and strength training|
1786294|NCT00483275|Behavioral|Patient education|
1786295|NCT00483288|Other|educational intervention|
1786296|NCT00483288|Other|questionnaire administration|
1786297|NCT00483288|Other|study of socioeconomic and demographic variables|
1786298|NCT00483288|Other|survey administration|
1786301|NCT00483314|Drug|N-acetylcysteine|2 g p.o. BID x 60 days
1786302|NCT00483327|Drug|Megestrol Acetate|
1786303|NCT00483353|Procedure|Intra-nasal allergen challenge with Phleum pratense.|
1786304|NCT00483353|Procedure|Collection of nasal effluent using filter paper.|
1786305|NCT00483353|Procedure|Measurement of nasal congestion using acoustic rhinometry.|
1786306|NCT00477334|Drug|Famciclovir|oral; two 500 mg tablets twice a day; single day treatment
1786307|NCT00477334|Drug|Placebo|oral; two tablets twice a day; single day treatment
1786308|NCT00477347|Device|Closed loop administration|intraoperative closed loop administration of propofol and remifentanil
1786309|NCT00477347|Device|Manual administration|intraoperative manual administration of propofol and remifentanil
1786310|NCT00477360|Device|Humeral surface replacement hemiarthroplasty (CAP)|C.A.P hemiarthroplasty
1786311|NCT00477373|Drug|depakine chrono|Depakine Chrono 500 mg
1786312|NCT00477386|Drug|decitabine|"Decitabine dose will be escalated as follows.
Dose level 1: 10mg/m2 IV QD X 5 days Dose level 2: 20mg/m2 IV QD X 5 days Dose level -1: Carboplatin AUC 4."
1786313|NCT00477399|Behavioral|The Evje Model|
1786314|NCT00477412|Drug|Bortezomib|1st Combination = 1.3 mg/m^2 IV Push Over 3-5 Seconds Days 2 & 5; 2nd Combination = 0.7 mg/m^2 IV Push Days 1 & 6.
1786315|NCT00477412|Drug|Rituximab|375 mg/m^2 IV Over 6-8 Hours On Day 1 each cycle.
1786316|NCT00477412|Drug|Cyclophosphamide|1st Combination = 300 mg/m^2 IV Over 3 Hours Twice Daily Days 2,3,& 4.
1786317|NCT00477412|Drug|Vincristine|1st Combination = 1.4 mg/m^2 (maximum 2 mg) IV Push Days 5 & 12.
1786318|NCT00477412|Drug|Methotrexate|2nd Combination = 200 mg/m^2 IV over 2 hours on Day 1, then 800 mg/m^2 IV over 22 hours on Day 2.
1786319|NCT00477412|Drug|Cytarabine|2nd Combination = 3g/m2 grams/m^2 IV over 2 Hours Twice a Day,On Days 3 & 4.
1786320|NCT00477412|Drug|Doxorubicin|Arm 1: 50 mg/m^2 IV Push Over 15-30 min on Day 5
1786321|NCT00477451|Drug|Inhaled placebo|Inhaled Staccato Alprazolam Placebo
1786322|NCT00477451|Drug|Inhaled alprazolam 1 mg|Inhaled Staccato Alprazolam 1 mg
1786323|NCT00477451|Drug|Inhaled alprazolam 2 mg|Inhaled Staccato Alprazolam 2 mg
1786324|NCT00477451|Drug|IV doxapram|0.5 mg/kg doxapram IV approximately 10s after receiving inhaled alprazolam or placebo
1786325|NCT00477464|Drug|Lapatinib|1250mg once daily
1786326|NCT00477464|Drug|capecitabine|2000mg/m^2 twice daily (14 days out of 21 days)
1786327|NCT00477477|Other|Diet|Low glycemic load diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
1786328|NCT00477477|Other|Diet|Low saturated fat diet prepared/delivered for 8 weeks, and counseled for 4 more months. Daily multivitamin.
1786329|NCT00477490|Drug|desmopressin acetate|Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25, 50 or 100 μg
1786330|NCT00477490|Drug|Placebo|Oral placebo placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime.
1786331|NCT00477503|Drug|Gallium-67 Citrate (Ga-67)|"Group A: Ga-67 citrate injection alone, in the baseline study.
Group B: Ga-67 and In 111 DTPA injection in the baseline study.
Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
1786332|NCT00477503|Drug|In-111 DTPA (In-111 pentetate)|"Group B: Ga-67 and In 111 DTPA injection in the baseline study.
Group C: Standard of care with Ga-67 and In 111 DTPA injection in baseline study."
1786333|NCT00477516|Procedure|exposure to a high-calcium dialysate bath|Subjects are exposed to a high calcium (3.5 mEq/L) dialysate bath for 150 minutes (part 1). At defined timepoints (0, 45, 90, and 150 min) blood is sampled for calcium, PTH, phosphorous, and FGF-23. At another (later) dialysis session (part 2), the process is repeated except that the subjects are exposed to a normal calcium bath (2.5 mEq/L). For each subject, results from part 1 are compared to the results from part 2.
1786334|NCT00477529|Drug|ABI-008|nab-docetaxel
1786335|NCT00477542|Drug|clofarabine|"Cohort- n- Clofarabine (mg/m2/day)
-1 3-10 20
3-6 30
3-6 40
3-6 50
3-6 60
6-10 70"
1786336|NCT00477555|Device|Aortic implantation of Mosaic Ultra porcine bioprosthesis|All patients get implanted with a Mosaic Ultra tissue valve to evaluate hemodynamic performance at 6 months post implant.
1786337|NCT00477581|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
1786338|NCT00477581|Drug|sitagliptin|oral administration (100mg), once a day in the morning
1786339|NCT00483366|Drug|capecitabine|"Dose level Capecitabine
-1 400 mg/m2 bid
0 500 mg/m2 bid
500 mg/m2 bid
600 mg/m2 bid
600 mg/m2 bid
725 mg/m2 bid
725 mg/m2 bid
850 mg/m2 bid
850 mg/m2 bid"
1786340|NCT00483366|Drug|gemcitabine hydrochloride|"Dose level Gemcitabine
-1 400 mg/m2 0 450 mg/m2
550 mg/m2
550 mg/m2
675 mg/m2
675 mg/m2
825 mg/m2
825 mg/m2
1000 mg/m2"
1786341|NCT00483366|Drug|imatinib mesylate|"Dose level Imatinib
-1 400 mg/d 0 400 mg/d
400 mg/d
400 mg/d
400 mg/d
400 mg/d
400 mg/d
400 mg/d
400 mg/d"
1786342|NCT00483366|Genetic|mutation analysis|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
1786343|NCT00483366|Genetic|nucleic acid sequencing|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
1786344|NCT00483366|Genetic|polymerase chain reaction|C-kit mutations will be assessed on existing paraffin-embedded blocks by Polymerase Chain Reaction and direct sequencing of both juxtamembrane domains (exons 9 and 11) and the tyrosine kinase domain (exons 13 and 17). Every ABI sequence will be compared to a NCBI Human KIT gene nucleotide sequence and will be blast using a NCBI Standard Nucleotide Blast Search to determine the presence of mutation within a particular exon.
1786345|NCT00483379|Biological|alglucosidase alfa|intravenous infusion
1786346|NCT00483392|Drug|metformin, rosiglitazone|
1786347|NCT00483405|Biological|cetuximab|250 mg/m2, intravenously, once per week
1786401|NCT00483665|Procedure|Magnetic resonance imaging|Magnetic resonance imaging after injection of Vasovist
1786348|NCT00483405|Drug|capecitabine|850 mg/m2, orally, twice daily (dose rounded to accommodate 150 mg and 500 mg tablet sizes. Capecitabine given on days 1-14 of 21 day cycle.
1786349|NCT00483405|Drug|oxaliplatin|130 mg/m2, intravenously on Day 1 of each 21 day cycle
1786350|NCT00483431|Dietary Supplement|no vitamin K|no vitamin K
1786351|NCT00483431|Dietary Supplement|10 mcg Vitamin K for 3 months daily|10 mcg Vitamin K for 3 months daily
1786352|NCT00483431|Dietary Supplement|20 mcg Vitamin K for 3 months daily|20 mcg Vitamin K for 3 months daily
1786353|NCT00483431|Dietary Supplement|45 mcg Vitamin K for 3 months daily|45 mcg Vitamin K for 3 months daily
1786354|NCT00483431|Dietary Supplement|90 mcg Vitamin K for 3 months daily|90 mcg Vitamin K for 3 months daily
1786355|NCT00483431|Dietary Supplement|180 mcg Vitamin K for 3 months daily|180 mcg Vitamin K for 3 months daily
1786356|NCT00483431|Genetic|360 mcg Vitamin K for 3 months daily|360 mcg Vitamin K for 3 months daily
1786357|NCT00483444|Behavioral|Scheduled telephone follow-up|Persons in the experimental group (group 1) received scheduled telephone counseling calls focused on symptom management and self-management skills.
1786358|NCT00483457|Drug|enzyme inhibitor therapy|enzyme inhibitor therapy
1786359|NCT00483457|Genetic|protein expression analysis|protein expression analysis
1786360|NCT00483457|Other|immunohistochemistry staining method|immunohistochemistry staining method
1786361|NCT00483457|Other|laboratory biomarker analysis|laboratory biomarker analysis
1786362|NCT00483457|Procedure|biopsy|biopsy
1786363|NCT00483470|Biological|Hepatitis A vaccine AVAXIM 80U|0.5 mL, Intramuscular
1786364|NCT00483470|Biological|Hepatitis A vaccine (HAVRIX 720)|0.5 mL, Intramuscular
1786365|NCT00483483|Behavioral|Individual and group HIV risk behavior counseling sessions|Healthy Relationships Intervention (HRI) culturally adapted and modified to address substance use and associated risk behaviors; subjects will attend three 2-hour structured group sessions in addition to two 1-hour individualized sessions over the course of 10 days.
1786366|NCT00483483|Behavioral|health education and support group|general health information (nutrition, stress reduction) in 2 individual sessions and 3 group sessions.
1786375|NCT00483509|Drug|NGR-hTNF|iv q3W 0.8 mcg/sqm NGR-hTNF
1786376|NCT00483509|Drug|Doxorubicin|iv q3W 75 mg/sqm doxorubicin 60 minutes after NGR-hTNF infusion
1786377|NCT00483522|Behavioral|Self-management telephone counseling|Subjects are contacted 7 times in year 1 after discharge from hospital rehabilitation unit and 4 times in year 2. Telephone counseling based on a self-management/problem-solving model is conducted by a research care manager.
1786378|NCT00483535|Drug|GW273225|GW273225 will be available as 25 milligram tablets.
1786379|NCT00483535|Drug|COC|COC will consist of Microgynon 30 which is available as ethinylestradiol 30 micrograms/levonorgestrel 150 micrograms beige color, sugar-coated tablets.
1786380|NCT00483548|Drug|Ziprasidone|Oral capsule formulation to be administered every day for duration of patient's participation in the trial - 40 mg on Day 1; 40 mg twice a day (BID) on Day 2; Flexible BID dosing of 40 mg, 60 mg, 80 mg, 100 mg, 120 mg, 140 mg or 160 mg total daily dose from Day 3 through Week 6. Dose increases of up to 40 mg/day can occur after subject has received previous lower dose for at least 1 day.
1786381|NCT00483548|Drug|Placebo|Matching placebo oral capsules to be administered as per the instructions for the ziprasidone arm
1786382|NCT00483561|Drug|etoposide|250 mg p.o. daily, starting on Day 1and taken on a continuous basis throughout the trial.
1786383|NCT00483561|Drug|etoposide|50 mg/m2/day for Days 1-14 out of a 28-day cycle. (Etoposide capsules come in a 50-mg dose formulation, and the patient's dose will be rounded to the nearest 50-mg multiple).
1786384|NCT00483561|Other|laboratory biomarker analysis|The blood samples will be obtained in EDTA tubes, spun down, and the serum removed and stored at 80 degrees C in small aliquots for later use. When we have sufficient samples to use a kit, they will be thawed and sampled for the various biomarkers using ELISA kits from R&D Technology (Seattle). The antiEGFR antibodies will also be determined by using ELISA, but with kits prepared within our institution.
1786385|NCT00483574|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, IM at age 9 and 12 months
1786386|NCT00483574|Biological|Measles-mumps-rubella-varicella vaccine|0.5 mL, intramuscular at 12 months of age
1786387|NCT00483574|Biological|Routine paediatric vaccine - Pneumococcal conjugate (PCV)|0.5 mL, Intramuscular at age 12 months
1786388|NCT00483574|Biological|Routine paediatric vaccine - Hepatitis A|0.5 mL, Intramuscular at age 12 months
1786389|NCT00483587|Drug|Heme arginate|1-3 x heme arginate infusion, in 30 minutes iv. Heme arginate is dissolved in 250 ml NACl.
1786390|NCT00483600|Drug|fondaparinux|injections of 2.5mg every other day for 4 weeks
1786391|NCT00483613|Behavioral|Cognitive-behavioral therapy of Meichenbaum|
1786392|NCT00483626|Drug|oral sildenafil|
1786393|NCT00483639|Other|Medical chart review|medical chart review
1786394|NCT00483639|Other|Liebowitz Social Anxiety Scale and the Social Phobia and Anxiety Inventory|survey administration
1786395|NCT00483639|Procedure|management of therapy complications|management of therapy complications
1786396|NCT00483639|Procedure|Structured Clinical Interview for the Diagnostic and Statistical Manual-IV SCID|psychosocial assessment
1786397|NCT00483639|Other|Functional Assessment of Cancer Therapy-General (FACT-G)|survey administration
1786398|NCT00483652|Drug|Fampridine-SR|Tablets, 10 mg, twice daily, 9 weeks
1786399|NCT00483652|Drug|Placebo|placebo (sugar pill)
1786400|NCT00483665|Procedure|Computed tomography angiography|Computed tomography angiography
1786403|NCT00483678|Other|questionnaire administration|
1786404|NCT00483678|Procedure|psychosocial assessment and care|
1786405|NCT00483691|Behavioral|Home Visit|Homw visits scheduled weekly for one year.
1786406|NCT00489437|Device|ID-PaGIA Heparin/PF4 antibody test|All patients have a 4T's Score completed, a same-day PaGIA performed and a Serotonin Release Assay performed.
1786407|NCT00489437|Procedure|Clinical Prediction Score-HIT Score Card|"clinical prediction rule
rapid immunoassay"
1786408|NCT00489450|Drug|SK3530|
1786409|NCT00489463|Device|intra-uterine device (TCu 380A)|
1786410|NCT00489476|Drug|Staccato Loxapine|
1786411|NCT00489476|Drug|Staccato Placebo|Placebo aerosol inhalation (0mg)
1786412|NCT00489489|Drug|Teriflunomide|"Film-coated tablet
Oral administration"
1786413|NCT00489489|Drug|Placebo (for Teriflunomide)|"Film-coated tablet
Oral administration"
1786414|NCT00489489|Drug|Interferon-β|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
1786415|NCT00489502|Behavioral|Brief Counseling|
1786416|NCT00489502|Device|REE Assessment|
1786417|NCT00489528|Drug|Somatropin; Recombinant human growth hormone (r hGH)|
1786418|NCT00489541|Device|Percutaneous Coronary Intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent implantation
1786419|NCT00489554|Biological|Synflorix|Intramuscular injection, 3 doses.
1786420|NCT00489554|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
1786421|NCT00489554|Biological|Rotarix|Oral, 2 doses.
1786422|NCT00489567|Procedure|Blood sample collection|
1786423|NCT00489580|Device|SaeboFlex Dynamic Hand Orthosis|
1786424|NCT00489580|Procedure|Saebo F.T.M. Arm Training Program|
1786425|NCT00489593|Drug|Olanzapine|2.5 mg by mouth (PO) Daily x 28 days, increasing about every 3-14 days in increments of 2.5-5 mg until the designated dose for that cohort is reached.
1786426|NCT00489606|Drug|SK3530|
1786427|NCT00489632|Behavioral|Questionnaire|Questionnaires administered to pediatric patients and their parent(s) or caregiver(s).
1786428|NCT00489645|Drug|placebo|placebo SC during euglycemia
1786429|NCT00489645|Drug|pramlintide|pramlintide SC during eglycemia
1786430|NCT00489645|Drug|placebo|placebo during hyperglycemia
1786431|NCT00489645|Drug|pramlintide|pramlintide SC during hyperglycemia
1786432|NCT00489658|Drug|Eflornithine plus Nifurtimox combination therapy|
1786433|NCT00489697|Device|real-time contrast-enhanced ultrasound imaging (CEUS)|Real time contrast enhanced sonography was performed using an ultrasound dedicated system after bolus injection of 1.2 and 2x2.4 ml Sonovue ® (Bracco, Milan, Italy)
1786434|NCT00489710|Drug|talabostat mesylate|
1786435|NCT00489710|Procedure|diagnostic procedure|
1786436|NCT00489710|Procedure|enzyme inhibitor therapy|
1786437|NCT00489710|Procedure|flow cytometry|
1786438|NCT00489710|Procedure|laboratory biomarker analysis|
1786439|NCT00489710|Procedure|non-specific immune-modulator therapy|
1786440|NCT00489723|Drug|tamsulosin 0.4mg|
1786441|NCT00489736|Drug|dronedarone (SR33589)|oral administration
1786442|NCT00489736|Drug|amiodarone|oral administration
1786443|NCT00489749|Procedure|Protected early weightbearing/Achilles tendon surgery|
1786444|NCT00489762|Procedure|Installation of an energy efficient heater|
1786445|NCT00489775|Drug|Duloxetine|
1786446|NCT00489775|Drug|Paroxetine|
1786447|NCT00489801|Other|Exercise|Exercise intervention and lifestyle counseling at centre or exercise intervention at home
1786448|NCT00489814|Behavioral|Questionnaire|Questionnaires administered within 3 weeks before the beginning of the radiation treatment course, twice during radiation therapy, and upon completion of radiation therapy.
1786451|NCT00489840|Drug|Anecortave Acetate Sterile suspension 15 mg|anecortave acetate sterile suspension 15 mg., juxtascleral injection, every 6 months. for 24 months
1786452|NCT00489840|Drug|Anecortave Acetate|anecortave acetate suspension 15 mg. juxtascleral injection every 6 months for 24 months.
1786453|NCT00489853|Drug|budesonide/formoterol Turbuhaler 320/9µg|Symbicort (budesonide/formoterol) Turbuhaler 320/9 micrograms
1786454|NCT00489853|Drug|formoterol Turbuhaler 9µg|Formoterol Turbuhaler 9 micrograms, 1 inhalation twice daily
1786455|NCT00489853|Other|Placebo|Placebo, 1 inhalation twice daily
1786456|NCT00489866|Drug|Aripiprazole|Aripiprazole: 5 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-10 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-15 mg taken once a day orally for 2 weeks, then Aripiprazole: 5-20 mg taken once a day orally for 2 weeks
1786457|NCT00489866|Drug|Placebo|Same as active drug.
1786458|NCT00489879|Device|Mobile Health Care System (DrUB)|
1786459|NCT00489892|Drug|Modafinil|
1786460|NCT00489905|Drug|Zolderonic acid (Zometa)|
1786463|NCT00489931|Drug|VRC-AVIDNA036-00-VP|
1786464|NCT00489944|Drug|cisplatin|
1786465|NCT00489944|Drug|sunitinib malate|
1786466|NCT00489944|Drug|tamoxifen citrate|
1786467|NCT00489944|Procedure|adjuvant therapy|
1786468|NCT00489970|Procedure|Taking of blood samples|No treatment is planned to be given in this study. Blood samples will be collected at the following time points: 1 year, 3 years, 5 years and 9 years after the dose of vaccination.
1786469|NCT00489970|Biological|Boostrix|A single dose of Boostrix was administered in the primary study (NCT00346073). No treatment was given in this study.
1786470|NCT00489970|Biological|Adacel|A single dose of Adacel was administered in the primary study (NCT00346073). No treatment was given in this study.
1786471|NCT00489983|Drug|pemetrexed|
1786472|NCT00489983|Drug|gemcitabine|
1786473|NCT00489996|Drug|gemcitabine|
1786474|NCT00489996|Drug|cisplatin|
1786475|NCT00490009|Drug|Bexxar|"Bexxar is a radioimmunotherapeutic drug, an antibody that specifically attaches to the CD20 antigen, which is present on the surfaces of B cells and B cell lymphoma cells. The radioactive isotope then gives off radiation, which kills the cells.
Bexxar will be administered to provide the following patient-specific radiotherapy:
Platelet count of 150,000/mm³ = 75 cGy
Platelet count ≥ 100,000/mm³ but < 150,000/mm³ = 65 cGy"
1786476|NCT00490009|Drug|Acetaminophen|As premedication 30 to 60 minutes before antibody infusion; 650 mg, oral. Used to as to relieve pain
1786477|NCT00490009|Drug|Diphenhydramine|As premedication 30 to 60 minutes before antibody infusion; 50 mg, oral. Used to prevent inflammation or allergic reactions
1786478|NCT00490009|Drug|Potassium Iodide (KI)|Administered to prevent thyroid blockage 130 mg orally 3 times a day,
1786479|NCT00490022|Drug|Dihydrotestosterone (DHT) gel (0.7%)|DHT gel, 70 mg/day for one month
1786480|NCT00490022|Drug|Placebo gel|Placebo gel for one month
1786481|NCT00490035|Other|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 12-week Treatment Period
1786482|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 20 mg /day in a double-blinded way for the 12-week Treatment Period
1786483|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 50 mg /day in a double-blinded way for the 12-week Treatment Period.
1786484|NCT00490035|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, of Brivaracetam 100 mg /day in a double-blinded way for the 12-week Treatment Period.
1786485|NCT00490048|Procedure|Induced sputum (inhalation of 3.5% saline)|
1786486|NCT00490061|Drug|Lapatinib|1500 mg po daily orally
1786487|NCT00490061|Procedure|Radiotherapy (radiation)|Standard of Care
1786488|NCT00490061|Device|G.E. Healthcare 1.5T MR, systems revision 12.0 M5|Standard of Care, used to deliver IMRT
1786489|NCT00490061|Device|DCE-MRI|A subset of patients received imaging before and after Lapatinib loading, prior to starting radiotherapy.
1786490|NCT00490074|Biological|DNA-C|1.0mg per ml of DNA HIV-C vaccine 2x2 ml IM
1786491|NCT00490074|Biological|NYVAC-C|NYVAC-C 1 ml IM
1786492|NCT00490087|Device|Levonorgestrel intrauterine device (IUD)|
1786493|NCT00490100|Drug|Increlex|
1786494|NCT00490113|Drug|Pyridoxamine|Two 250 mg capsules, or placebo, given twice a day for four, 4 week periods. Subjects with primary hyperoxaluria will aslo receive escalated doses up to 3500 mg/day for up to 6 1/2 days.
1786495|NCT00490126|Other|Laparoscopic Surgery Data Collection|Prospectively and retrospectively collect data on patients who had laparoscopic surgery since January 1, 1990 forward. Data from the initial patient visit note, consultation notes, operative report, discharge summary, and follow-up progress notes will be entered into the database.
1786496|NCT00490139|Drug|Lapatinib|Small molecule inhibitor
1786497|NCT00490139|Biological|Trastuzumab|Antibody
1786498|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
1786499|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
1786500|NCT00490152|Behavioral|Automated diary system|"Participants will use a computerized phone diary to describe their experiences with the study product during the 14 days of the trial. They will have three teleconferences with Juliana to discuss the product and the technology used in the study. They will also have the opportunity to send emails to Juliana during the course of the study."
1786501|NCT00490178|Drug|Fenofibrate 80 mg and metformin 1000 mg (fixed combination)|
1786502|NCT00490191|Drug|Somatropin|
1786504|NCT00490230|Drug|WR 279396|
1786505|NCT00490243|Drug|budesonide and montelukast|
1786506|NCT00490243|Drug|budesonide and formoterol|
1786507|NCT00490243|Drug|montelukast|
1786508|NCT00490243|Drug|budesonide|
1786509|NCT00490243|Drug|placebo|
1786510|NCT00490256|Procedure|Modified Selective Cerebral Perfusion|Modified Selective perfusion is a cardiopulmonary bypass circuit that has been modified to allow blood flow to the lower body as well as the upper body while the surgery is being performed.
1786511|NCT00490269|Drug|Placebo|
1786512|NCT00490269|Drug|Dronabinol|
1786515|NCT00490308|Drug|Treatment with estradiol valerate|
1786516|NCT00490321|Device|VentrAssistTM Left Ventricular Assist Device|
1786517|NCT00490347|Device|VentrAssist Left Ventricular Assist Device|
1786518|NCT00490360|Drug|Gemcitabine / Cisplatin|
1786519|NCT00490373|Drug|pemetrexed|
1786520|NCT00490399|Drug|gemcitabine|
1786521|NCT00490399|Drug|cisplatin|
1786522|NCT00490412|Dietary Supplement|Vitamin D supplement|Vitamin D3 (cholecalciferol), 50,000 IU as a single capsule, will be administered orally to subjects in Groups A and C once every four weeks during study visits.
1786523|NCT00490412|Other|Placebo|A placebo will be administered orally to subjects in Groups B and D once every four weeks during study visits.
1786524|NCT00490425|Drug|Lactobacillus rhamnosus strain GG ATCC 53103 (LGG, 1010 cfu)|
1786525|NCT00490451|Drug|LY573636|LY573636 dose is dependent on patient's height, weight, and gender to target a specific Cmax. LY573636 is administered every 21 or 28 days until disease progression or other criteria for patient discontinuation are met.
1786526|NCT00490464|Drug|Nicardipine and Nipride|
1786527|NCT00490477|Device|Polymyxin -B fiber hemoperfusion system|two hours treatment for two days
1786528|NCT00490490|Drug|Bexxar (tositumomab)|Tositumomab is a CD20-directed radiotherapeutic (131-iodine) monoclonal antibody indicated for the treatment of patients with CD20-positive, relapsed or refractory, low-grade, follicular, or transformed non-Hodgkin's lymphoma who have progressed during or after rituximab therapy, including patients with rituximab-refractory non-Hodgkin's lymphoma. Tositumomab (standard regimen) will be administered at whole body exposure of 75 cGy.
1786529|NCT00490490|Procedure|External beam radiotherapy (XRT)|Patient-specific XRT will begin within 24 hours of administration of the therapeutic dose of tositumomab. Subjects will receive local XRT to bulky sites of disease measuring at least 5 cm in at least one dimension. The size and number of fields to be treated will determined by the investigators, but will encompass the patient's most symptomatic/threatening site(s) of disease and not cumulatively include more than 25% of the active bone marrow. Subjects will be treated with the 2 x 2 Gy regimen (2 daily fractions of 2 Gy). Sites of disease previously-irradiated with 30 to 40 Gy will not be treated on this study.
1786530|NCT00490490|Drug|Potassium Iodide (KI)|"Potassium iodide (KI) will be administered as:
Saturated solution potassium iodide (SSKI) 4 drops orally 3-times-a-day,
Lugol's solution 20 drops orally 3-times-a-day, OR
KI tablets 130 mg orally once per day KI treatment will start at least 24 hours prior to tositumomab, and continue daily for 14 days following the last dose of tositumomab"
1786533|NCT00490516|Drug|ACP-104|200 mg, tablet, BID, 6 weeks
1786534|NCT00490516|Drug|ACP-104|100 mg, tablet, BID, 6 weeks
1786535|NCT00490516|Drug|Placebo|placebo, tablet BID, 6 weeks
1786536|NCT00490529|Biological|CpG-MCL vaccine, primed T-cells|
1786537|NCT00490529|Procedure|Autologous peripheral blood stem cell transplantation|Standard of Care
1786538|NCT00490529|Procedure|CT scan|Standard of Care
1786539|NCT00490529|Procedure|PET-CT scan|Standard of Care
1786540|NCT00490529|Drug|PF-3512676|18 mg subcutaneous injection
1786541|NCT00490529|Drug|Rituximab|375 mg/m2 iv Standard of care.
1786542|NCT00490542|Drug|ziprasidone (Geodon)|ziprasidone, geodon. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
1786543|NCT00490542|Drug|placebo|Placebo, sugar pill arm. Dosing instructions began at 40 mg/day and were increased by increments of 20-40 mg weekly weekly based on target symptoms and tolerability with a target range of 80-160 mg/d of ziprasidone for 6 weeks.
1786544|NCT00490555|Drug|Testosterone gel|Testosterone gel 10 g
1786545|NCT00490555|Drug|Dutasteride|dutasteride 0.5 mg orally
1786546|NCT00490555|Drug|Depo-Medroxyprogesterone (DMPA)|300 mg DMPA injection on Day 0 IM (into the muscle)
1786547|NCT00490555|Other|Placebo Testosterone gel|Place gel applied daily for 12 weeks
1786548|NCT00490555|Other|Placebo dutasteride|placebo pill for 12 weeks
1786549|NCT00490555|Other|Placebo DMPA|placebo DMPA injection Once
1786551|NCT00490581|Other|case management and supportive housing|patients randomized to the study group are offerred respite care/interim housing and case management upon discharge from enrolling hospitalization. They are also offerred stable housing within 90 days of enrolling hospital discharge, with case management at all 3 stages - hospital, respite care/interim housing, and stable housing.
1786552|NCT00490594|Device|ACL Reconstruction (SeriACL™ Device)|Bioresorbable ACL
1786553|NCT00490620|Drug|Combination antiviral therapy|Zidovudine 300mg and lamivudine 150mg BID for 6 months
1786554|NCT00490620|Drug|Placebo|placebo BID for 6 months
1786555|NCT00490633|Behavioral|Ear Loop Procedure Mask|Facemasks were requested to be worn while participants were in the residence hall for year one, and while they were in residence halls for a minimum of six hours per day in year two.
1786556|NCT00490633|Behavioral|62% Ethyl Alcohol Hand Sanitizer|Hand sanitizer was provided to participants in the facemask and hand hygiene arm for year one and year two of the study.
1786557|NCT00490646|Drug|ixabepilone|"Ixabepilone 40 mg/m^2 was administered as a 3-hour I.V. continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity.
For the first cycle, ixabepilone was administered the day following the first dose of trastuzumab (in the first cycle trastuzumab was given on Day 0); in all the following cycles, ixabepilone was administered immediately after the subsequent doses of trastuzumab if the preceding dose of trastuzumab was well tolerated."
1786558|NCT00490646|Drug|docetaxel|Docetaxel 100 mg/m^2 was administered as a 1-hour IV continuous infusion on Day 1 in a 21-day cycle until disease progression or unacceptable toxicity. For the first cycle, docetaxel was administered the day following the first dose of trastuzumab (i.e. in the first cycle trastuzumab was given on Day 0); in all following cycles, docetaxel was administered immediately after trastuzumab if the preceding dose of trastuzumab was well tolerated.
1786559|NCT00490646|Drug|trastuzumab|Trastuzumab was administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle at a dose of 2 mg/kg until disease progression or unacceptable toxicity. In cycle 1, a loading dose of 4 mg/kg was administered as a 90-minute IV infusion on a day before initial administration of chemotherapy (i.e. on Day 0). Trastuzumab was given immediately prior to ixabepilone (Arm A) or docetaxel (Arm B) in all subsequent cycles as a 30-minute IV infusion if the initial dose was well tolerated.
1786560|NCT00490659|Drug|gemcitabine|
1786561|NCT00490659|Drug|cisplatin|
1786562|NCT00490659|Procedure|radical surgery|
1786563|NCT00490659|Procedure|chemoradiotherapy|
1786564|NCT00490672|Behavioral|No Active Intervention.|Conventional Chronic Disease Management in Malaysia Primary Care
1786624|NCT00491179|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 48 weeks
1786565|NCT00490672|Behavioral|Community Based Multiple Risk Factor Intervention Strategies|Multi-faceted Intervention in Chronic Diseases Management i.e. Hypertension, Diabetes Mellitus, Hyperlipidaemia involving Primary Health Care Physicians, Nurse Educators, Dieticians and Pharmacists.
1786566|NCT00490685|Drug|Sorafenib (BAY-43-9006)|
1786567|NCT00490698|Drug|Zoledronate|4 mg IV Once Every 4 Weeks
1786568|NCT00490698|Drug|Atorvastatin|20 mg PO Daily
1786569|NCT00490711|Drug|gemcitabine|
1786570|NCT00490711|Drug|carboplatin|
1786571|NCT00490711|Drug|paclitaxel|
1786572|NCT00490724|Drug|Nesiritide (1+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 1 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 15.4 to 35.2 mcg/kg.
1786573|NCT00490724|Drug|Nesiritide (2+0.005)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (fixed-dose) with dose of 0.005 mcg/kg/min and Period 2 (flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 9.2 to 31.7 mcg/kg.
1786574|NCT00490724|Drug|Nesritide (2+0.01)|Intravenous bolus treatment will be administered over 1 minute (min) at a dose of 2 microgram per kilogram (mcg/kg) followed by 24 hour intravenous infusion which is comprised of Period 1 (Fixed-dose) with dose of 0.01 mcg/kg/min and Period 2 (Flexible-dose) where dosage will be increased by 0.005 mcg/kg/min every 3 hours. Total dosage to be administered will be 16.4 to 36.2 mcg/kg.
1786575|NCT00490737|Drug|daptomycin|6mg/kg, i.v. infusion over 30 minutes; every 48 hours for a total of 3 doses
1786576|NCT00490750|Procedure|Dor fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Dor fundoplication
1786577|NCT00490750|Procedure|Toupet fundoplication|Subjects are randomized to undergo Heller myotomy followed by Laparoscopic Toupet fundoplication
1786578|NCT00490763|Behavioral|Survey|7 surveys at the beginning of the study and again every 6 months about diet, coping with the disease, and quality of life.
1786579|NCT00490776|Drug|LBH589|
1786581|NCT00490802|Drug|Oxytocin|Intranasal Oxytocin
1786582|NCT00490802|Drug|Placebo|Placebo Comparator
1786583|NCT00490815|Drug|Fluocinolone Acetonide|0.5 mg fluocinolone acetonide intravitreal insert
1786584|NCT00490815|Drug|Fluocinolone Acetonide|0.2 mg fluocinolone acetonide intravitreal insert
1786585|NCT00490828|Drug|Hydrocortisone|Hydrocortisone
1786586|NCT00490841|Device|Herculink Elite Renal Stent System|This is a prospective, non-randomized, single arm, multi-center study to evaluate the safety and effectiveness of the RX Herculink Elite Renal Stent System in patients with sub-optimal renal PTA results in de novo or restenotic renal artery lesions. Patients who satisfy the inclusion/exclusion criteria will be enrolled at sites in the United States. Patients will have follow up visits for evaluation.
1786587|NCT00490854|Drug|Human Insulin Inhalation Powder|patient specific, inhaled, at meals, 76 weeks
1786588|NCT00490854|Drug|Neutral protamine hagedorn insulin|patient specific dose, injected, daily, 76 weeks
1786589|NCT00490867|Drug|Alpha lipoic acid|
1786590|NCT00490880|Drug|gemcitabine|
1786591|NCT00490880|Drug|cisplatin|
1786592|NCT00490880|Procedure|radical cystectomy|
1786593|NCT00490880|Procedure|radiotherapy|
1786594|NCT00490893|Drug|Detemir|
1786595|NCT00490906|Drug|Copaxone|20 mg, subcutaneous injections, taken daily
1786596|NCT00490906|Drug|Interferon-beta 1a|30 mcg injected intramuscularly, once weekly
1786597|NCT00490906|Drug|Interferon-beta 1b|.25 mg/day, taken every other day, subcutaneous injections
1786598|NCT00490919|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 10 or 20 mcg/h worn for 7 days
1786599|NCT00490919|Drug|Placebo|transdermal system (placebo) worn for 7 days
1786600|NCT00490932|Drug|Hypo-osmolar ORS|
1786601|NCT00490945|Drug|VEC-162|
1786602|NCT00490958|Drug|telmisartan|
1786603|NCT00490971|Drug|Olanzapine|Once daily in dose range of 5 to 20 mg/day for 15 weeks, then until recurrence
1786604|NCT00490971|Drug|Paliperidone ER|Once daily in dose range of 3 to 12 mg/day for 15 weeks, then until recurrence
1786605|NCT00490971|Drug|Placebo|Once daily until recurrence (only after initial 15 weeks on paliperidone ER)
1786606|NCT00490984|Device|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
1786607|NCT00490997|Drug|Ketamine only|"Ketamine 1.0 mg/kg IV and placebo intralipid as initial sedation agents (double blinded).
Ketamine .25 mg/kg IV and placebo intralipid q2 minutes prn for additional sedation"
1786608|NCT00490997|Drug|Ketamine - Propofol|"Ketamine .5 mg/kg and Propofol 1 mg/kg as initial sedation agents (double-blinded).
Saline Placebo and Propofol .5 mg/kg q 2minutes for additional sedation"
1786609|NCT00491010|Procedure|radiofrequency catheter ablation|
1786610|NCT00491036|Device|Intraaortic balloon pump|intraaortic balloon pump from Datascope/Maquet or Arrow/Teleflex will be used
1786611|NCT00491049|Drug|0.5% levofloxacin eye drops|
1786612|NCT00491062|Procedure|Biopsies|
1786613|NCT00491075|Drug|Pemetrexed|500 mg/m^2 IV Over 10 Minutes on Day 1.
1786614|NCT00491075|Drug|Gemcitabine|1500 mg/m^2 IV Over 30 Minutes on Day 1, Immediately After Infusion of Pemetrexed.
1786615|NCT00491088|Device|CPAP|CPAP for 12 weeks
1786616|NCT00491101|Other|Polish Version of PAQLQ(S) by Juniper|Polish Version of PAQLQ(S) by Juniper
1786617|NCT00491101|Other|spirometry|spirometry
1786618|NCT00491114|Drug|Gemcitabine|
1786619|NCT00491127|Drug|gemcitabine|
1786620|NCT00491127|Drug|cisplatin|
1786621|NCT00491127|Drug|dexamethasone|
1786622|NCT00491140|Genetic|Gene mutations analysis and FISH|FISH and mutation analysis of multiple genes
1786623|NCT00491166|Drug|Bromfenac ophthalmic solution|
1786625|NCT00491179|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 weeks
1786626|NCT00491192|Drug|Diclofenac|
1786627|NCT00491244|Drug|Peginterferon alfa-2a and ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week plus ribavirin (Copegus, F. Hoffman-LaRoche) 200 mg/day for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
1786628|NCT00491244|Drug|Peginterferon alfa-2a|Pegylated interferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 135 ug/week for 24 to 48 weeks (genotype 1: 48 weeks, genotype 2: 24 weeks)
1786629|NCT00491257|Biological|Inactivated influenza vaccine (split virion) NH 2007-2008 formulation|0.5 mL, Intramuscular
1786630|NCT00491270|Device|VS Sense|An applicator to diagnose pH increase above 5.2
1786631|NCT00491283|Device|Swab Specimen Collection (QuickVue)|
1786632|NCT00491296|Device|SYNERGO|
1786633|NCT00491296|Device|SYNERGO-intravesical chemotherapy instillation combined with hyperthermia|
1786634|NCT00491309|Behavioral|exercise training|exercise training with specific program (respiratory therapy, dumbbell training, ergometer training, mental training)
1786636|NCT00491348|Drug|duloxetine hydrochloride|duloxetine 30 mg QD, may titrate to 30 mg BID, and maintain the dosage for 6 weeks
1786637|NCT00491374|Drug|Mometasone Furoate Nasal Spray|Nasonex Nasal Spray 50 mcg/spray, 200 mcg (4 sprays) once daily every morning for 28 days.
1786638|NCT00491374|Drug|Placebo|Placebo Nasal Spray 4 sprays once daily every morning for 28 days.
1786639|NCT00491387|Drug|Sustained release metoprolol|Once daily, oral, 12.5 mg to 200 mg, dose titrated to reduce heart rate by 20% or to less than 65 beats per minute.
1786640|NCT00491400|Drug|Fenofibrate|140 mg/day for 8 weeks
1786641|NCT00491400|Drug|Atorvastatin|20 mg/day for 8 weeks
1786642|NCT00491413|Drug|epoetin|
1786643|NCT00491426|Drug|Ampicillin|Drug prescribed per routine medical care.
1786644|NCT00491426|Drug|Metronidazole|Drug prescribed per routine medical care.
1786645|NCT00491426|Drug|Piperacillin/Tazobactam|Drug prescribed per routine medical care.
1786646|NCT00491426|Drug|Acyclovir|Drug prescribed per routine medical care.
1786647|NCT00491426|Drug|Amphotericin B|Drug prescribed per routine medical care.
1786648|NCT00491426|Drug|Ambisome|Drug prescribed per routine medical care.
1786649|NCT00491426|Drug|Anidulafungin|Drug prescribed per routine medical care.
1786650|NCT00491426|Drug|Caspofungin|Drug prescribed per routine medical care.
1786651|NCT00491465|Behavioral|Intensive Physical activity|
1786652|NCT00491465|Behavioral|Control- regular physical activity|
1786653|NCT00491478|Drug|sertraline|
1786654|NCT00491491|Drug|ibritumomab tiuxetan|0.4 mCi/kg
1786655|NCT00491491|Procedure|BEAM chemotherapy and autologous stem-cell transplantation|
1786656|NCT00491504|Drug|Mometasone Furoate Nasal Spray|Mometasone Furoate Nasal Spray: 2 sprays (50 mcg) each nostril (total 200 mcg)
1786657|NCT00491504|Other|Placebo|Placebo: 2 sprays in each nostril
1786658|NCT00491517|Drug|Sirolimus|Patients will be given Sirolimus starting at the oral daily dose of 3 mg with periodically whole blood level measurements. The daily dose will be adjusted to keep sirolimus concentration within 10-15 ng/ml.
1786659|NCT00491517|Drug|conventional therapy|Antihypertensive drugs for patients with high blood pressure.
1786660|NCT00491530|Drug|ABT-335|Oral coadministration of ABT-335 (135 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
1786661|NCT00491530|Drug|rosuvastatin calcium|Oral coadministration of rosuvastatin calcium (20 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
1786662|NCT00491530|Drug|simvastatin|Oral coadministration of simvastatin (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
1786663|NCT00491530|Drug|atorvastatin calcium|Oral coadministration of atorvastatin calcium (40 mg) once daily, beginning in either the 12-week double-blind study or the previous 52-week open-label year 1 study and continuing in 52-week year 2 study
1786664|NCT00491543|Drug|ALT-2074|
1786665|NCT00491556|Procedure|Early Initiation of Highly Active Anti-Retroviral Therapy|Treatment: TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r or other recommended NRTI backbone with ATV/r. Duration: Subjects in the experimental group who achieve virologic control by week 24 and maintain good control through 48 weeks will then de-intensify to ATV/r alone and will be followed for an additional two years.
1786666|NCT00491556|Procedure|Standard Care|Progression: Subjects on the standard care arm will begin therapy when the CD4+ T cell count drops below 350 cells/mm3 or other clinical criteria necessitating treatment as determined by the site clinician occur. Treatment: HAART with TDF/FTC/ATV/r (preferred), AZT/3TC/ATV/r, or other recommended ATV/r based HAART regimen according to current DHHS standard of care. Duration: three years.
1786667|NCT00491569|Drug|Sarcosine and D-serine|
1786668|NCT00491582|Drug|Growth hormone replacement therapy in growth hormone deficient patients only.|Genotropin once/daily sc., titration scheme according to the consensus guidelines of the GH and IGF-research society Duration: 6 months
1786669|NCT00491595|Drug|High Dose Soy isoflavones|
1786670|NCT00491608|Biological|rThrombin|1000 U/mL applied directly or in combination with absorbable gelatin sponge or powder
1786671|NCT00491621|Procedure|surgery or biopsy of the kidney tumor|surgery or biopsy of the kidney tumor
1786672|NCT00491634|Drug|treosulfan|12 g/m2 x 3 days
1786673|NCT00491634|Drug|Treosulfan|12 g/m2 x 3
1786674|NCT00491660|Behavioral|supine positioning|
1786675|NCT00491660|Behavioral|lateral positioning|
1786676|NCT00491673|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
1786677|NCT00491673|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
1786678|NCT00491686|Drug|AZD6765|intravenous infusion
1786744|NCT00480714|Biological|BCG (SSI Strain)|
1786679|NCT00491699|Drug|XL999|XL999 will be administered as a once-weekly 4 hour IV infusion as a single agent. The first cohort will be dosed at 0.4 mg/kg IV once weekly. The maximum dose cohort will not exceed 1.6 mg/kg IV once weekly. Ten subjects are planned for each dosing cohort, with dose escalation dependent on safety and available PK data from prior cohorts
1786680|NCT00491712|Procedure|Glaucoma drainage implant with/without triamcinolone|
1786681|NCT00491725|Drug|repaglinide|
1786682|NCT00491725|Drug|metformin|
1786683|NCT00491738|Drug|bevacizumab|Intravenous repeating dose
1786684|NCT00491738|Drug|sunitinib|Oral repeating dose
1786685|NCT00491738|Drug|placebo|Intravenous repeating dose
1786689|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 100 mg QD for 24 weeks.
1786690|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 200 mg QD for 24 weeks.
1786691|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 24 weeks.
1786692|NCT00491764|Drug|SCH 56592|Posaconazole oral suspension (40 mg/mL) 400 mg QD for 12 weeks.
1786693|NCT00491764|Drug|Terbinafine|Terbinafine 250 mg QD for 12 weeks.
1786694|NCT00491764|Drug|Placebo|Placebo for 24 weeks.
1786695|NCT00491777|Device|Noninvasive Hemodynamic Patient Monitor|
1786696|NCT00491790|Drug|Montelukast|Montelukast 4 mg rapid dissolving granules in sterile water given orally once
1786697|NCT00491790|Other|Sterile water|Sterile water
1786698|NCT00491803|Drug|Sildenafil|sildenafil 20 mg orally
1786699|NCT00491803|Drug|Sildenafil|sildenafil 40 mg orally
1786700|NCT00491816|Drug|Erlotinib with neoadjuvant chemotherapy|150 mg orally (PO) once daily on days 3 to 14, given with cycle 1 to 6 or 3 to 6 of neoadjuvant chemotherapy
1786701|NCT00491829|Drug|50 mg qhs|flibanserin 50 mg
1786702|NCT00491829|Drug|100 mg|flibanserin 100mg
1786703|NCT00491829|Drug|placebo|placebo
1786704|NCT00491855|Drug|Bevacizumab|Starting dose level 2.5 mg/kg given intravenously on day 1.
1786705|NCT00491855|Drug|Oxaliplatin|Starting dose level 25 mg/m^2 given intraperitoneally on day 2.
1786706|NCT00491855|Drug|Paclitaxel|Starting dose level 110 mg/m^2 given continuous infusion on day 1 and 30 mg/m^2 given intraperitoneally on day 8.
1786707|NCT00491868|Drug|R744|100μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
1786708|NCT00491868|Drug|R744|150μg/4week for 8 weeks, then 50~250μg/4week for 16 weeks
1786709|NCT00491868|Drug|rHuEPO|2250IU or 3000IU(i.v.) 2 or 3 times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
1786710|NCT00491868|Drug|rHuEPO|4500IU or 6000IU(i.v.) 2 or 3times/week for 8 weeks, then 750~9000IU(i.v.)/1~3week for 16 weeks
1786711|NCT00491868|Drug|R744 placebo|0 μg/4week for 24 weeks
1786712|NCT00491868|Drug|rHuEPO placebo|0 IU 2 or 3 times/week for 8 weeks, then 1~3 times/week for 16 weeks
1786713|NCT00491881|Behavioral|no added salt diet|
1786714|NCT00491894|Drug|Oral Glycopyrrolate Liquid|Study medication is administered three times a day at 7-8 AM, 1-2 PM, and 7-8 PM by the parent/caregiver
1786715|NCT00491907|Drug|folic acid 5mg/day|
1786716|NCT00480519|Procedure|Meatotomy|
1786717|NCT00480532|Drug|Lybrel|All women enrolled in the study will take the same daily low dose oral contraceptive (20-mcg EE/90 mcg LNG) dosed in a continuous fashion.
1786718|NCT00480532|Drug|Doxycycline|100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline.
1786719|NCT00480532|Drug|Oracea|40-mg tablet daily for 84 days
1786720|NCT00480532|Drug|Placebo|Placebo pill orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of placebo
1786721|NCT00480532|Drug|Doxycycline 100bid x5 days at the time of bleeding|Doxycycline 100 mg orally twice a day for five days starting on the first day of breakthrough bleeding. This regimen will be repeated if bleeding persists or recurs seven days after completing five-day course of doxycycline
1786722|NCT00480532|Drug|Subantimicrobial doxycycline daily|Subantimicrobial dose doxycycline 40mg daily for the first 84 days of the study
1786723|NCT00480532|Drug|placebo daily|Placebo daily for the first 84 days of the study
1786724|NCT00480558|Biological|MVA 85A|Modified vaccinia Ankara virus expressing antigen 85A from M. tuberculosis. Dose is 5x10^7
1786725|NCT00480571|Drug|BL-1020|BL-1020 Low Dose
1786726|NCT00480571|Drug|BL 1020 High Dose|BL 1020 High Dose
1786727|NCT00480584|Drug|gemcitabine|Levels 1 through 4: 1000 mg/m^2
1786728|NCT00480584|Drug|capecitabine|Level 1: 500 mg/m^2; Level 2: 825 mg/m^2; Level 3: 1000 mg/m^2; Level 4: 1250 mg/m^2
1786729|NCT00480584|Drug|erlotinib|Levels 1 through 4: 100 mg
1786730|NCT00480597|Drug|gemcitabine|
1786731|NCT00480597|Drug|cisplatin|
1786732|NCT00480597|Drug|vinorelbine|
1786733|NCT00480597|Drug|capecitabine|
1786734|NCT00480610|Drug|tacrolimus ointment|Topical application
1786735|NCT00480610|Drug|Placebo ointment|Topical application
1786736|NCT00480623|Drug|Satraplatin plus radiation therapy|
1786737|NCT00480636|Drug|Fragmin (dalteparin sodium )|Month 1: dalteparin 200 IU/kg SC once daily. Months 2-6: dalteparin 150 IU/kg SC, once daily.
1786738|NCT00480649|Drug|Salmeterol/ fluticasone propionate|2 active arms (parellel group)
1786739|NCT00480662|Drug|alendronate|Duration of Treatment : 6 Months
1786740|NCT00480675|Procedure|trochanteric bursa injection done under fluoroscopy with depomedrol and bupivacaine|Depomedrol 60 mg + bupivacaine 2.5 ml
1786741|NCT00480675|Procedure|Trochanteric bursa injection with depomedrol and bupivacaine|Trochanteric bursa injection done with sham x-ray and 60 mg of depomedroal and 2.5 ml bupivacaine using landmarks for guidance.
1786742|NCT00480688|Biological|BCG|
1786743|NCT00480701|Drug|[123I]-IBVM|Subjects will be asked to undergo an injection of 123-I IBVM followed by up to three approximately thirty minute SPECT scans during the next 24 hours.
1786745|NCT00480727|Procedure|Halo pin re-tensioning|Re-tensiong every 2 weeks with torque driver. Pins are re-tensioned to 8lb/inch
1786746|NCT00480727|Procedure|Placebo Re-tensioning|Pts undergo re-tensioning procedure with torque driver set at zero to elicit the same clicking sensation with no tightening of the pin.
1786747|NCT00480740|Drug|Dexmedetomidine|Dexmedetomidine load of 1 microgram/kilogram over 10 minutes, followed by a 1 microgram/kilogram/hour infusion during the time of catheterization
1786748|NCT00480753|Drug|Nitroglycerin|
1786749|NCT00480766|Drug|MK0217/Duration of Treatment : 12 Months|
1786750|NCT00480779|Behavioral|GLB Group|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered in face-to-face groups by a trained lifestyle coach.
1786751|NCT00480779|Behavioral|GLB DVD|The Group Lifestyle Balance (GLB) program is a lifestyle change program adapted from the successful lifestyle intervention utilized in the Diabetes Prevention Program. For this arm, the intervention is delivered via DVD and weekly telephone contact with a trained lifestyle coach.
1786752|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 20 microgramme Intramuscular use at M0, M1, M6
1786753|NCT00480792|Biological|GenHevac B Pasteur|Intra-muscular injection 40 microgramme intramuscular use at M0, M1,M2, M6
1786754|NCT00480792|Biological|GenHevac B Pasteur|GenHevac-B 4 microgramme Intradermal use at M0, M1, M2, M6
1786755|NCT00480805|Drug|MK0954A, losartan potassium (+) hydrochlorothiazide (HYZAAR) / Duration of Treatment : 8 Weeks|
1786756|NCT00480805|Drug|Comparator : ramipril /Duration of Treatment : 8 Weeks|
1786757|NCT00491920|Drug|cholecalciferol (Vitamin D3)|"20 000 Iu x2/week
+ calcium 500 mg/cholecalciferol 400 IU x2/d"
1786758|NCT00491920|Drug|placebo|Calcium 500 mg/Cholecalciferol 400 IU x2/d and placebo 2/w
1786759|NCT00491933|Procedure|Quantiferon-TB Gold assay|
1786760|NCT00491933|Procedure|Tuberculin skin test|
1786761|NCT00491946|Drug|Actinomycin-D|
1786762|NCT00491946|Drug|Vincristine|
1786763|NCT00491959|Procedure|Cultured oral mucosa cell sheet transplantation|Cultivated oral mucosal cell sheets will be transplanted on the denuded corneal surface or the scleral surface of the symblepharon area. Therapeutic contact lenses will be applied after surgery.
1786764|NCT00491985|Biological|A/H5N1 Inactivated, split-virion pandemic influenza vaccine|0.5 mL, Intramuscular
1786765|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.5 mL, Intramuscular
1786766|NCT00491985|Biological|A/H5N1 Inactivated, split virion pandemic influenza vaccine|0.25 mL, Intramuscular
1786767|NCT00491998|Drug|V1512|6 doses of IMP at 2-hourly intervals
1786768|NCT00491998|Drug|V1512|3-hourly dosing
1786769|NCT00491998|Drug|V1512 and Entacapone|4 doses of IMP and Entacapone at 3-hourly intervals
1786770|NCT00492011|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally, once nightly for 4 nights.
1786771|NCT00492011|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once nightly for 4 nights.
1786772|NCT00492011|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for 4 nights.
1786773|NCT00492011|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
1786774|NCT00492024|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin - 400 mg once a day for 5 days
1786775|NCT00492024|Drug|Placebo|Placebo - 380 mg Microcrystalline Cellulose
1786776|NCT00492037|Drug|YM087 oral|
1786777|NCT00492050|Drug|Bortezomib|1.6 mg/m^2 IV Weekly on Days 1, 8, 15 and 22.
1786778|NCT00492050|Drug|Rituximab|375 mg/m^2 IV on Day 8 and 22.
1786779|NCT00492050|Drug|Valacyclovir|500 mg orally daily (or acyclovir 200 mg orally twice daily)
1786780|NCT00492063|Biological|Cell culture-derived trivalent subunit influenza vaccine (cTIV)|One vaccination (0.5 mL) of cell culture-derived influenza vaccine (cTIV) was administered in the deltoid muscle
1786781|NCT00492063|Biological|Egg-derived trivalent subunit influenza vaccine (TIV)|One vaccination (0.5 mL) of egg-derived influenza virus vaccine (TIV) was administered in the deltoid muscle
1786782|NCT00492076|Biological|Pangramin Plus D. pteronyssinus 100%|"Active. Pangramin Plus D. pteronyssinus 100%
Placebo. Pangramin Plus placebo"
1786783|NCT00492089|Drug|bevacizumab|Given IV
1786784|NCT00492089|Drug|placebo|Given IV
1786785|NCT00492089|Procedure|magnetic resonance imaging|
1786786|NCT00492089|Procedure|quality-of-life assessment|
1786787|NCT00492102|Drug|Montelukast|One oral dose of Montelukast 0.15mg (infants weighing 500-1000gm) or 0.2mg (infants weighing >1000gm). Two blood samples will be obtained from each infant within 24 hours of the drug administration and plasma Montelukast levels will be determined.
1786790|NCT00492128|Drug|Losartan/amlodipine or losartan/hydrochlorothiazide|Losartan 50mg/amlodipine 5mg and the fixed dose combination drug of losartan 50mg/hydrochlorothiazide 12.5mg once a day during 12 months.
1786791|NCT00492141|Drug|Temozolomide|Cycle 2, Dose Level 1 = 100 mg/m^2 by mouth (PO) Daily, Days 1-5 Prior to L9-NC; Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, advance to 100 mg/m^2 PO Every 12 Hours, Days 1-5 Prior to L9-NC. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2; Cycle 4 and beyond = Patients will continue on dose level 1 or 2 as given in cycle 3.
1786792|NCT00492141|Drug|L9-NC|"Cycle 1 = Administered by aerosol 5 consecutive days per week for 2 weeks. A total of 10 ml of 0.4 mg/ml in an aerosol reservoir delivered over approximately 30 minutes per day given once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.
Cycle 2, Dose Level 1 = Week 1, doses 1-5 preceded by temozolomide. Continue L9-NC once a day, 5 days a week, for 2 weeks, followed by 2 weeks off.
Cycle 3, Dose Level 2 = If the patient has no toxicity greater than grade 2, due to drug, during cycle 2, L9-NC may be increased to twice daily, approximately 12 hours apart. Week 1, the morning dose on days 1-5 preceded by temozolomide. L9-NC will be given twice a day, 5 days a week, for 2 weeks, followed by 2 weeks off. If the patient is not able to advance to dose level 2, the patient may continue at dose level 1 as in cycle 2.
Cycle 4 and beyond, patients will continue on dose level 1 or 2 as given in cycle 3."
1786793|NCT00492167|Biological|beta-glucan|
1786794|NCT00492167|Biological|monoclonal antibody 3F8|
1786795|NCT00492167|Other|immunohistochemistry staining method|
1786796|NCT00492167|Other|laboratory biomarker analysis|
1786797|NCT00492206|Drug|Cetuximab|The initial dose of cetuximab is 400 mg/m2 intravenously administered over 120 minutes, followed by weekly infusions at 250 mg/m2 IV over 60 minutes. Subjects will receive cetuximab from week 0 through week 26.
1786798|NCT00492219|Device|Vanguard M fixed-bearing or Oxford mobile-bearing prostheses|Patients that are appropriate for partial knee replacement will be randomized to receive one of these two FDA-approved implant systems.
1786799|NCT00492219|Device|Total Knee Replacement|Patients undergoing total knee replacement with the Vanguard Complete Knee implant system
1786800|NCT00492232|Drug|Ramelteon and zolpidem|Ramelteon 8 mg, tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
1786801|NCT00492232|Drug|Placebo and zolpidem|Ramelteon placebo-matching tablets, orally, once daily and current zolpidem therapy incrementally reduced by dose, frequency, or both for up to 10 weeks.
1786802|NCT00492245|Procedure|PTK with mitomycin in Adenoviral Opacities|
1786803|NCT00492258|Drug|sorafenib tosylate|
1786804|NCT00492258|Procedure|adjuvant therapy|
1786805|NCT00492271|Drug|Friulimicin B|Intravenous, once daily, single dose
1786806|NCT00492934|Drug|human menopausal gonadotrophins|Daily subcutaneous injections, dose 37.5 IU or 75 IU, start on day 2 of the menstrual cycle until ovulation
1786807|NCT00492947|Biological|dendritic cell vaccine|3 vaccinations total: Day 10, Day 20, Day 30
1786808|NCT00492960|Drug|larazotide acetate|gelatin capsules
1786809|NCT00492960|Drug|placebo|gelatin capsules
1786810|NCT00492960|Dietary Supplement|900 mg gluten|gelatin capsules
1786811|NCT00492973|Drug|methylprednisolone acetate|Same medications and doses as the active comparator, but with the addition of 40 mg of methylprednisolone acetate
1786812|NCT00492973|Drug|active comparator|bupivacaine HCl 80 mg, morphine 4 mg, epinephrine 300 micrograms, clonidine 100 micrograms, cefuroxime 750 mg, and normal saline
1786813|NCT00492986|Drug|Nexavar (Sorafenib, BAY43-9006)|Multikinase inhibitor: Sorafenib mono therapy 400 mg bid
1786814|NCT00492999|Drug|dexamethasone|Given by hepatic arterial infusion
1786815|NCT00492999|Drug|floxuridine|Given by hepatic arterial infusion
1786816|NCT00492999|Drug|fluorouracil|Given IV
1786817|NCT00492999|Drug|irinotecan hydrochloride|Given IV
1786818|NCT00492999|Drug|leucovorin calcium|Given IV
1786819|NCT00492999|Drug|oxaliplatin|Given IV
1786820|NCT00493012|Dietary Supplement|vitamin D|6 drops of a vitamin D containing oil
1957201|NCT02497378|Drug|JNJ-54767414 (Daratumumab)|JNJ-54767414 (Daratumumab) will be administered as an Intravenous (IV) infusion at a dose of 16 milligram per kilogram (mg/kg) weekly for the first 3 cycles, on Day 1 of Cycles 4-8 (every 3 weeks), and then on Day 1 of subsequent cycles (every 4 weeks). First 8 Cycles are 21-day cycles; Cycles 9 and onwards are 28-day cycles.
1957202|NCT02497378|Drug|Bortezomib|Bortezomib will be administered at a dose of 1.3 mg/m^2 subcutaneously (SC) on Day 1, 4, 8 and 11 of each 21-day cycle. Eight Bortezomib treatment cycles are to be administered.
1957203|NCT02497378|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Day 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 bortezomib treatment cycles (except for Cycles 1-3). In Cycles 1-3, participants receive dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11, 12 and 15. During weeks when the participants receives an infusion of daratumumab, dexamethasone will be administered at a dose of 20 mg IV or orally (PO) (only if IV is not available) before the daratumumab infusion as preinfusion medication.
1786833|NCT00493038|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days
1786834|NCT00493038|Drug|Amoxicillin/Clavulanate|Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days
1786835|NCT00493051|Biological|GAM501|Ad5PDGF-B formulated in a collagen gel
1786836|NCT00493051|Biological|Placebo|Collagen gel
1786837|NCT00493051|Other|Standard of care|moist dressing changes daily
1786838|NCT00493064|Drug|Nicotinic acid|topical eye drops
1786839|NCT00493064|Drug|Prednisolone acetate|topical eye drops
1786840|NCT00493077|Drug|low immunogenic interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
1786841|NCT00493090|Behavioral|modification of an interactive seminar|
1786842|NCT00493116|Drug|Interferon-beta-1a|dosage and frequency as per Biogen Idec protocol
1786843|NCT00493116|Drug|methylprednisolone|dosage and frequency as per Biogen Idec protocol
1786844|NCT00493129|Drug|Ontak (Denileukin Diftitox)|9 µg/kg by vein Days 1-5 of a 21 day cycle.
1786845|NCT00493142|Behavioral|Exercise|physical therapy home exercise
1786846|NCT00493155|Drug|RG1530|Administered po at escalating doses (10 cohorts)
1786847|NCT00493181|Drug|Interleukin-11 (IL-11 or Neumega)|10 mcg/kg under the skin (usually of the arms, legs or abdomen) three times weekly. If the treatment is well tolerated but there is not enough of a platelet improvement, the dose and frequency of injections may be increased.
1786848|NCT00493194|Drug|sirolimus|
1786849|NCT00493194|Drug|cyclosporine|
1786850|NCT00493194|Drug|daclizumab|
1786851|NCT00493220|Drug|SC HYLENEX and Ceftriaxone|single, subcutaneous, 150 U dose of HYLENEX; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
1786895|NCT00493519|Procedure|chocolate cake|
1786896|NCT00493532|Drug|ibandronate [Bonviva/Boniva]|3mg iv every 3 months
1786852|NCT00493220|Drug|SC Placebo and Ceftriaxone|single, subcutaneous injection of 1 mL 0.9% sodium chloride solution; followed by single, subcutaneous, 1 gm dose of ceftriaxone (350 mg/mL solution administered at 2.5 mL/min over 1.14 minutes)
1786853|NCT00493220|Drug|IV Ceftriaxone|single, intravenous infusion of 1 gm ceftriaxone (40 mg/mL solution administered at 0.83 mL/min over 30 minutes)
1786854|NCT00493233|Drug|2 antipsychotic medications (combinations of olanzapine, risperidone, clozapine, seroquel, haldol, perphenazine)|"Primary antipsychotic medication (olanzapine, oral risperidone, seroquel, clozapine, haldol, perphenazine) will be determined by the treating physician and participants will continue taking the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician. The dose of the second antipsychotic drug will remain fixed throughout the study period."
1786855|NCT00493233|Drug|main antipsychotic medication and placebo|"The main antipsychotic drug will be determined by the treating physician. Participants will be allocated to placebo in place of the concomitant antipsychotic drug. The dose of the main antipsychotic drug will remain open and flexible at the discretion of the attending physician."
1786856|NCT00493246|Drug|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)
Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
1786857|NCT00493246|Drug|IV Acetaminophen|"This study will investigate two doses (12.5 milligrams/kilogram (mg/kg) and 15 milligrams/kilogram) based on weight administered every four hours (q4h), every six hours (q6h), or every eight hours (q8h) (depending on age)
Neonates: 12.5 mg/kg q6h IV acetaminophen Neonates: 15 mg/kg q8h IV acetaminophen Infants: 12.5 mg/kg q4h IV acetaminophen Infants: 15 mg/kg q6h IV acetaminophen Children: 12.5 mg/kg q4h IV acetaminophen Children: 15 mg/kg q6h IV acetaminophen Adolescents: 12.5 mg/kg q4h IV acetaminophen Adolescents: 15 mg/kg q6h IV acetaminophen"
1786858|NCT00493259|Behavioral|Health-Related Quality of Life instrument|Adolescents will fill out questionnaires regarding quality of life and dealing with diagnosis of Insulin Resistance Syndrome
1786859|NCT00493259|Behavioral|Depression Scale for Children (CES-DC)|questionnaire
1786860|NCT00493272|Drug|Fibrinogen|Fibrinogen behandling
1786861|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10^4 TCID50
1786862|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10 ^5 TCID50.
1786863|NCT00493285|Biological|MEDI-534|Multiple doses of MEDI-534 or Placebo at 10^6 TCID50.
1957210|NCT02491281|Drug|LNA043|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
1786865|NCT00493311|Drug|IV Placebo|IV Placebo
1786866|NCT00493311|Drug|IV Acetaminophen|Intravenous acetaminophen solution 1 g / 100 ml
1786867|NCT00493311|Biological|Reference Standard Endotoxin (RSE)|Administration of Reference Standard Endotoxin (RSE) to induce fever. Applicable to both study arms: Administration of a 1 ng/kg body weight test dose of RSE to test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
1786868|NCT00493324|Drug|alefacept|Intramuscular
1786869|NCT00493324|Drug|polyvalent pneumococcal vaccine|Injection
1786870|NCT00493337|Behavioral|advanced adherence counseling+reminder|
1786871|NCT00493337|Device|Compliance Card|
1786872|NCT00493350|Procedure|Blood Sample|1x4 ml (Serum Tube); 2x10 ml (CellSave Tube); 1x10 ml EDTA (Selected Centers)
1786873|NCT00493363|Drug|artesunate 2 mg/kg/day versus 4 mg/kg/day icm mefloquine|
1786874|NCT00493376|Procedure|Cervical tissue biopsy analysis: Comet assay|Cervical tissue biopsy analysis: Comet assay
1786875|NCT00493376|Procedure|Biopsy: Measurement of histone gamma H2AX phosphorylation|Biopsy: Measurement of histone gamma H2AX phosphorylation
1786876|NCT00493376|Procedure|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha|Biopsy: Immunohistochemistry: Ca9, Glut1, HIF-1 alpha
1786877|NCT00493376|Procedure|Measurement of vascular perfusion: contrast enhanced MRI|contrast enhanced MRI
1786878|NCT00493389|Drug|Adrenocorticotrophic hormone|
1786879|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg, plus particle embolization.
1786880|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|drugs and dosage: chemotherapy with lipiodol mixed with EADM 50mg, lobaplatin 50mg, and MMC 6mg.
1786881|NCT00493402|Procedure|Transarterial chemoembolization (TACE)|Drugs and dosage:chemotherapy with lipiodol mixed with EADM 50mg, plus particle embolization.
1786882|NCT00493415|Drug|nitroglycerin iv|loading dose of 4mg/h iv in the first 30 minutes, 2 mg/h iv in the next 23 hours and 30 minutes
1786883|NCT00493415|Drug|placebo = nacl 0.9%|4 ml/h iv in the first 30 minutes, 2 ml /h iv in the next 23 hours and 30 minutes
1786884|NCT00493428|Drug|Baclofen|Patients will receive an initial dose of: 5 mg tid to be increased as tolerated to a maximum dose of 20 mg qid. This dose range and schedule reflects that suggested for the drug's muscle relaxant properties in human.
1786885|NCT00493441|Drug|AVN944|150, 200, 250, 300, or 400 mg q12h
1786886|NCT00493454|Drug|Zevalin|.3 mCi IV Over 10 Minutes x 1 Day
1786887|NCT00493454|Drug|Rituximab|250 mg/m^2 IV Over 6 to 8 Hours
1786888|NCT00493454|Drug|^111 In Ibritumomab Tiuxetan|1.6 mg IV Over 10 Minutes x 1 Day
1957211|NCT02491281|Drug|Placebo|ascending single dose on Day 1; 1 to 4 week(s) prior total knee replacement surgery
1786891|NCT00493480|Drug|carvedilol|6.25 mg of carvedilol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubled weekly up to a maximum of 25 mg carvedilol daily.
1786892|NCT00493480|Drug|propranolol|80 mg of propranolol for 12 weeks, to achieve a satisfactory pulse reduction the doses are doubles weekly up to a maximum of 360 mg propranolol daily
1786893|NCT00493493|Procedure|surgery (Pore Excision, Curettage, and Injection of Cymetra)|
1786894|NCT00493506|Drug|ProAlgaZyme|
1786897|NCT00493545|Biological|HspE7 and Poly-ICLC|3 injections of HspE7 and Poly ICLC given every 28 days for 3 injections
1786898|NCT00493558|Device|Trabecular Metal Intervertebral Cage with RSA beads|Roentgen Stereophotogrammetric Analysis beads will be inserted at time of implant of the Trabecular Metal Intervertebral Cage.
1786899|NCT00493571|Drug|Gimatecan|Starting dose: 0.6 mg capsules administered orally once daily.
1786900|NCT00493584|Procedure|Primary Percutaneous Coronary Intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
1786901|NCT00493584|Procedure|Coronary angiography / Percutaneous coronary intervention|Coronary Angiography and PCI using standard protocols and guidelines. Contrast either Iomeron or Visipaque at the operators discretion. Equipment used for the PCI is determined at the operators discretion. All patients undergoing primary PCI receive 10.000 units of Heparin, 600 mg of Clopidogrel and a Glycoprotein IIb/IIIa inhibitor. Patients randomized to standard treatment receive 300 mg of Clopidogrel and 120IU/kg of Dalteparin b.i.d until revascularization. Glycoprotein IIb/IIIa inhibitors or thrombin inhibitors can be given as a supplement at the local hospital at the physicians discretion. All patients receive 300 mg of aspirin upon admission or diagnosis in the ambulance.
1786903|NCT00493623|Drug|Placebo|Placebo i.v. single dose
1786904|NCT00493623|Drug|ibandronate [Bonviva/Boniva]|3mg i.v. single dose
1786905|NCT00493636|Drug|Gemcitabine|Gemcitabine will be administered 1000 mg/m2 pm Days 1 and 8 of a 21 day cycle
1786906|NCT00493636|Drug|Sorafenib|Sorafenib will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
1786907|NCT00493636|Drug|Placebo|Placebo will be administered (400 mg; 2 tablets x 200 mg) orally twice daily (approximately every 12 hours)
1786908|NCT00493636|Drug|Capecitabine|Capecitabine will be administered orally at a dose of 1,000 mg/m2 twice daily, within 30 minutes after a meal, for 14 days followed by a 7 day rest period (without capecitabine).
1786909|NCT00493649|Drug|Taxotere|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
1786910|NCT00493649|Drug|Cytoxan|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
1786911|NCT00493649|Drug|Herceptin|On Day 1 of each 21-day cycle for a total of 4 cycles, patients will receive, in this order: docetaxel 75 mg/m2 IV (over 1 hour), plus cyclophosphamide 600 mg/m2 IV (over 15-30 minutes), plus weekly trastuzumab 4 mg/kg IV (loading dose, over 90 minutes Day 1, Cycle 1 only) and 2 mg/kg IV (over 30-60 minutes on Days 1, 8, and 15) thereafter. Once 4 cycles of TC+H have been received, patients will continue with trastuzumab 6 mg/kg every 3 weeks to complete 1 year of anti-HER2 therapy as per the current standard of care. The anticipated time to study completion is 5 years.
1786912|NCT00493662|Drug|Polyethylene Glycol 400 0.4%|
1786913|NCT00493662|Drug|Propylene Glycol 0.3%|
1786914|NCT00493662|Drug|0.15% sodium Hyaluronate|
1786915|NCT00493662|Drug|sodium chloride|
1786916|NCT00493662|Drug|sodium phosphate monobasic|
1786917|NCT00493675|Procedure|endoscopic bile duct stenting|
1786918|NCT00493688|Other|Cardiopulmonary Exercise Testing (CPET)|Pedaling on a Stationary Bicycle at 60 Revolutions Per Minute as the Resistance to Pedaling Gradually Increases.
1786919|NCT00493701|Behavioral|High Fat Diet|Daily eating
1786920|NCT00493701|Behavioral|Low Fat Diet|Life style eating habits
1786921|NCT00493714|Behavioral|Questionnaire|Surveys lasting 30 minutes or more.
1786922|NCT00493727|Drug|N-acetylcysteine(Mucomyst)|
1786923|NCT00493740|Procedure|chocolate cake|
1786924|NCT00493753|Procedure|Acupuncture|
1786925|NCT00493766|Drug|LBH589|
1786926|NCT00493779|Procedure|Blood Collection|4 weeks
1786927|NCT00493792|Device|Stryker X3 crosslink|Radiographs, questionnaires and an exam will be obtained at key post-surgical follow up dates. 3months, 2years, 5 years, 7 years and 10 years.
1786928|NCT00493805|Drug|Combination of pegylated interferon alfa-2b and ribavirin|"Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks(Group A) or 60 weeks (Group B) postrandomization.
200 mg capsules, oral, weight based dose of 800-1400 mg, daily for up to 12 weeks, then up to 4 weeks until HCV PCR results are available, and then for another 36 weeks (Group A) or 60 weeks (Group B) postrandomization"
1786929|NCT00493805|Drug|Combination of pegylated interferon alfa-2b and ribavirin|"Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for 48 weeks
200 mg capsules, oral, weight based dose of 800-1400 mg, daily for 48 weeks"
1786930|NCT00493818|Drug|GSK690693|
1786931|NCT00493831|Drug|nicotine polacrilex, transdermal system or inhaler|
1786932|NCT00493844|Other|Exercise testing|Exercise testing
1786933|NCT00493844|Other|Clinical evaluation + NTproBNP|Clinical evaluation + NTproBNP levels
1786934|NCT00493857|Drug|Nimotuzumab Humanized Monoclonal Antibody|Nimotuzumab 400mg every week
1786935|NCT00493857|Drug|Nimotuzumab|Nimotuzumab 400mg every 2 weeks
1786936|NCT00493870|Drug|Docetaxel|Docetaxel 75 mg/m2 IV over 1 hour on Day 1 followed by cyclophosphamide
1786937|NCT00493870|Drug|Doxorubicin|• Doxorubicin 50 mg/m2 IV push over 5-15 minutes via sidearm through a running IV line on Day 1, followed by cyclophosphamide 500 mg/m2 IV over 15-30 minutes on Day 1, followed by docetaxel 75 mg/m2 IV over 1 hour on Day 1. Administer pegfilgrastim 6 mg SC on Day 2 (or filgrastim 5 mcg/kg SC per standard of care).
1786938|NCT00493870|Drug|Cyclophosphamide|600 mg/m2 IV over 15-30 minutes on Day 1.
1786939|NCT00493883|Device|yttrium Y 90 microspheres (TheraSphere®)|Y-90 is incorporated into very tiny glass beads, it can be injected into the liver through the blood vessels supplying the liver
1786940|NCT00493896|Drug|Fondaparinux|The dose for Arixtra is 2.5 mg once daily, subcutaneously.
1786941|NCT00493896|Drug|Enoxaparin|The dose for Lovenox is 40 mg once daily, subcutaneously.
1786942|NCT00493909|Procedure|intrathecal opioids and thoracic paravertebral analgesia|
1786943|NCT00493909|Procedure|thoracic epidural analgesia|
1786944|NCT00493922|Procedure|Rapid diagnostic test|Introduction of rapid diagnostic test for malaria
1786945|NCT00493922|Procedure|Microscopy|Microscopy for diagnosis of malaria
1786946|NCT00493922|Procedure|Clinical diagnosis for malaria|The use of Clinical diagnosis for the diagnosis of malaria
1786947|NCT00493948|Device|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
1786948|NCT00493961|Drug|gonadotropin releasing hormone (GnRH)|Pulsatile GnRH (25 ng/kg per bolus every two hours via microinfusion pump)
1786949|NCT00493974|Drug|Zileuton|Zyflo tablets, 600 mg, 4 times a day
1786950|NCT00493974|Drug|Placebo|Placebo 4 x daily
1786951|NCT00493987|Drug|Testosterone Enanthate|testosterone ester
1786952|NCT00493987|Drug|Dutasteride|5 alpha-reductase inhibitor
1786953|NCT00494013|Drug|Insulin Lispro Protamine Suspension|Patient specific dose administered subcutaneously once daily or twice daily x 24 weeks.
1786954|NCT00494013|Drug|Detemir|Patient specific dose administered subcutaneously once or twice daily x 24 weeks.
1786955|NCT00494026|Drug|pemetrexed|500 milligrams per square meter (mg/m2), intravenous (IV), every 21 days x 2 cycles then 500 mg/m2, IV, every 21 days x 2 cycles
1786956|NCT00494026|Drug|carboplatin|Area under the curve (AUC) 5, intravenous (IV), every 21 days x 2 cycles then AUC 5, IV, every 21 days x 2 cycles
1786957|NCT00494026|Procedure|radiotherapy|2 Gray (Gy) per fraction, 5 fractions per week, begin day 1, cycle 3 x 5 weeks (Monday-Friday)
1786958|NCT00494039|Procedure|Radioactive seed implant to prostate|
1786959|NCT00494052|Behavioral|Heart to Heart (Web-Based Decision Aid)|Participants in the intervention group will access Heart to Heart, a Web site designed to educate them about their overall CHD risk, specific risk factors, and strategies and preferences for risk reduction.
1786960|NCT00494052|Behavioral|Physician Education Session|A physician education session will be included in the program.
1786961|NCT00494065|Other|Home exercise|Patient education will be provided by trained therapists under the supervision of licensed chiropractic clinicians. Patients will attend four, 1 hour, one-on-one sessions.
1786962|NCT00494065|Other|Chiropractic Spinal Manipulative Therapy + Home exercise|The number and frequency of treatments will be determined by the individual chiropractor, based on patient-rated symptoms, disability, palpation, and pain provocation tests. Up to 20 treatments will be provided over the 12 week treatment period, each treatment visit lasting from 10-20 minutes. Treatment will include manual spinal manipulation and mobilization.
1786963|NCT00494078|Device|Real-time glucose monitoring system (Guardian, Medtronic)|Patients randomised to the intervention arm are treated with intensive insulin therapy guided by the real time glucose monitoring system.
1786964|NCT00494078|Drug|intensive insulin therapy|intensive insulin therapy according to an algorithm
1786965|NCT00494091|Drug|Temsirolimus (CCI-779)|20 mg/m2 IV TEMSR weekly (Japan, n=6)
1786966|NCT00494091|Drug|Temsirolimus (CCI-779)|25 mg IV TEMSR weekly (all other pts)
1786967|NCT00494104|Dietary Supplement|Vitamin D drops, 200 or 400 or 600 IU/day or 800 IU/day|Infants receive daily 0.5 ml of code labeled supplement
1786968|NCT00494117|Device|ApneaLink|A two channel sleep screening device for the assessment of Sleep Disordered Breathing.
1786969|NCT00494143|Device|CESR Prosthetic Foot|a novel prosthetic foot that is designed to store energy and release it at a predetermined time in the gait cycle
1786970|NCT00494143|Device|typical prosthetic foot|patients will wear the prosthetic foot that they were prescribed by the care providers in the clinical team
1786971|NCT00494143|Device|standardized prosthetic foot|a standard foot that has had weights applied to match the mass of the CESR foot
1786972|NCT00494156|Drug|heparin|
1786973|NCT00494156|Drug|aspirin and clopidogrel|
1786974|NCT00494182|Drug|Sorafenib|400 mg by mouth twice daily on Day 2-19
1786975|NCT00494182|Drug|Carboplatin|6 area under the plasma drug concentration-time curve (AUC) by vein over 30 Minutes On Day 1
1786976|NCT00494182|Drug|Paclitaxel|200 mg/m^2 by vein over 3 hours on Day 1
1786977|NCT00494195|Genetic|rAAV1.tMCK.human-alpha-sarcoglycan- First cohort|"The first cohort of subjects with LGMD2D (alpha-sarcoglycan deficiency) and proven mutations will undergo gene transfer with a minimum of three subjects enrolled into this cohort and will receive a total of 1.5 ml volume of study agent in two to six separate injections into the selected muscle (extensor digitorum brevis) or other muscle if more appropriate upon considering the individual patient. The dose will be 3.25 X 10 to the 11 vg in 1.5 ml.
In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo."
1786978|NCT00494195|Genetic|Genetic: rAAV1.tMCK.human-alpha-sarcoglycan- Second cohort|The second cohort will receive the same dosis of 3.25 X 10 to the 11 vg in 1.5 ml delivered to muscle according to the same paradigm. In each cohort, only one extremity will receive vector with transgene while the opposite extremity will be injected with placebo.
1786980|NCT00494221|Drug|AZD2171|oral tablet
1786981|NCT00494221|Drug|FOLFOX (5-fluorouracil, Leucovorin, Oxaliplatin)|intravenous infusion
1786982|NCT00494221|Drug|Placebo Cediranib|oral tablet
1786983|NCT00494234|Drug|KU-0059436 (AZD2281) (PARP inhibitor)|oral
1786984|NCT00494234|Drug|KU-0059436 (AZD2281) (PARP inhibitor)|
1786985|NCT00494247|Device|coronary stent (Genous, OrbusNeich) with immobilised anti-CD34 antibody to capture circulating endothelial progenitor cells|coronary stent covered with anti-CD34 antobody, (Genous, R-stent, produced by OrbusNeich). 30 patients will undergo PCI with implantation of Genous stent and 30 patients will receive bare metal stent (BMS)
1786986|NCT00494260|Behavioral|Social Learning and Cognitive Behavioral Therapy (SLCBT)|The SLCBT condition consists of 3 main components: 1.) relaxation training, 2.) working with parent and child to modify family responses to illness and wellness behaviors, and 3.) cognitive restructuring to address and alter dysfunctional cognitions regarding symptoms and their implications for functioning through cognitive therapy techniques
1786987|NCT00494260|Behavioral|Education Support (ES)|The ES condition focuses on education about GI system anatomy and function, information about the United States Department of Agriculture nutrition guidelines, and additional food-related information such as how to read food product labels. The ES condition was developed to provide a credible alternative condition that would control for therapist and patient time and attention.
1786988|NCT00494273|Behavioral|Cognitive Behavioral and Standard Care with Healthy Living|
1786989|NCT00494286|Behavioral|Abused-focused cognitive behavioral therapy (AF-CBT)|Practitioners will be randomly assigned to provide the AF-CBT treatment for 3 to 6 months. Patient participants will continue to see their regular practitioner, but will receive AF-CBT at treatment visits. Practitioners who are assigned to AF-CBT will first receive training in the treatment method. The training curriculum will include a published treatment book, intensive training sessions, which will occur weekly for 8 hours over 4 weeks, handouts that illustrate key therapeutic information and exercises, and ongoing case consultation reviews for 5 months.
1786990|NCT00494286|Behavioral|Treatment as usual (TAU)|This condition consists of those practitioners in each agency who will not receive study training in AF-CBT. These practitioners will simply provide services as available within their agencies.
1786991|NCT00494299|Drug|Sorafenib (Nexavar, BAY43-9006)|Multikinase Inhibitor; Sorafenib: 400mg bid of sorafenib
1786992|NCT00494299|Drug|Placebo|Placebo: matching placebo
1786993|NCT00494312|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg titrated to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 156 weeks.
1786994|NCT00494312|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 5 mg or 10 mg titrated to 15 mg, capsules, orally, once daily for up to 156 weeks.
1786995|NCT00494338|Drug|Docetaxel|
1786996|NCT00494351|Procedure|Long-pulsed Nd:YAG laser 1064 nm|Laser once monthly
1786997|NCT00494377|Drug|duloxetine|
1786998|NCT00494416|Other|delivery approaches of malaria intermittent preventive treatment in pregnancy|"Health centre based delivery approach (PHC). IPT/SP will be delivered to pregnant women presenting to the health centre for ANC visit.
Joint with advanced strategies delivery approach (JAS). In addition to passive delivery at health centres, the pregnant women will be reached during preventive activities the health staff carry out regularly in villages Community based distribution delivery approach (CBD). In addition to passive delivery at health centres, the pregnant women will be reached by traditional birth attendants (TBAs) or representatives of village women's associations (RWAs)."
1787003|NCT00494455|Device|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
1787004|NCT00494455|Device|continuous subcutaneous glucose monitoring|continuous subcutaneous glucose monitoring for 72h
1787005|NCT00494468|Drug|Zolpidem|
1787006|NCT00494481|Drug|Vandetanib (ZD6474)|once daily oral dose
1787007|NCT00494481|Drug|Docetaxel|intravenous infusion
1787008|NCT00494494|Drug|Standard Care|topical antibiotic for 10 days plus topical corticosteroids for 1 month
1787009|NCT00494494|Drug|nepafenac|liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
1787010|NCT00494507|Drug|Dichlorphenamide (double-blind)|50mg tablet; maximum dosage 400mg/day
1787011|NCT00494507|Drug|Placebo (double-blind)|Inactive substance manufactured to look like Dichlorphenamide 50mg tablet
1787012|NCT00494507|Drug|Dichlorphenamide (open-label)|50mg tablet; maximum dosage 400mg/day
1787013|NCT00494520|Procedure|Errorful training condition|"Errorful training condition: Participant saw a picture and named it without any cues. If an error was produced, the cue with the least amount of information was provided (e.g. for pumpkin, pu). Cues with increasing information were provided until the picture was correctly named (e.g. for pumpkin: pump, pumpki, then pumpkin). Once the correct name was provided, the trial ended."
1787014|NCT00494520|Procedure|Errorless training condition|"Errorless learning (EL) condition: Participant saw a picture with its name, and repeated the word. The participant continued to name the picture as the auditory cues provided less and less of the word (e.g. for banana she would hear banan, bana then ba and finally no cue). If an error was produced at any stage, the whole word was presented, the participant repeated it, and the trial ended."
1787015|NCT00494533|Drug|Remodulin (treprostinil sodium)|
1787016|NCT00494546|Procedure|Pd-103 with 20 vs 44 Gy supplemental beam XRT|
1787017|NCT00494559|Drug|Pioglitazone|Actos 15mg once a day before breakfast
1787018|NCT00494559|Drug|Placebo|Placebo drug with the same appearance as actos
1787019|NCT00494572|Drug|Montelukast|10 mg rapid dissolving granule in sterile water orally once
1787020|NCT00494572|Other|sterile water|sterile water
1787021|NCT00494585|Drug|CEP-701|80 mg orally twice a day for 30 days
1787022|NCT00494598|Drug|Sufentanil|200 mcg intra-arterial one time bolus
1787023|NCT00494611|Drug|Peri operative Cetuximab.|Cetuximab will be given immediately preoperative and early post surgery period.
1787024|NCT00494624|Drug|prednisolone|
1787025|NCT00494637|Drug|sodium bicarbonate|isotonic sodium bicarbonate at 3 cc/kg for one hour followed by 2 cc kg/hr for 4 hours
1787169|NCT00483821|Other|medical chart review|medical chart review
1787026|NCT00494650|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 12 to 16 counseling sessions, occurring weekly or every other week. Participants will learn about PTSD and ways to decrease anxiety associated with PTSD by completing homework assignments and practicing skills learned in counseling sessions.
1787027|NCT00494650|Behavioral|Brief PTSD treatment|Brief PTSD treatment will include three weekly meetings with a therapist. Participants will learn about PTSD, how symptoms may be affecting their lives, and a technique for reducing anxiety associated with PTSD.
1787028|NCT00494663|Drug|DIO-902|150mg tablet once per day for 16 weeks
1787029|NCT00494663|Drug|DIO-902|300mg tablet once per day for 16 weeks
1787030|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet once daily for 16 weeks
1787031|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
1787032|NCT00494663|Drug|DIO-902|150mg tablet of DIO-902 once daily for 16 weeks
1787033|NCT00494663|Drug|DIO-902|300mg DIO-902 tablet daily for 16 weeks
1787034|NCT00494663|Drug|DIO-902|450mg DIO-902 tablet for 16 weeks
1787035|NCT00494663|Drug|DIO-902 placebo|DIO-902 placebo tablet once daily for 16 weeks
1787036|NCT00494676|Device|High power (57 prism diopter) peripheral prism glasses|All patients will wear two pairs of prism glasses in a crossover design: the high power peripheral prism glasses and sham peripheral prism glasses. Each pair of prism glasses will be worn for four weeks
1787037|NCT00494676|Device|Low power sham peripheral prism glasses|Low power (5 prism dioptre) prism glasses that provide only about 2 degrees of visual field expansion.
1787038|NCT00494702|Procedure|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-88%
1787039|NCT00494702|Procedure|Resuscitation|Oxygen inspiratory fraction needed to keep oxygen saturation in the preset limits of 90-93%
1787040|NCT00494715|Drug|Benazepril|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
1787041|NCT00494715|Drug|Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
1787042|NCT00494715|Drug|Benazepril/Valsartan|Patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day).If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
1787043|NCT00494728|Behavioral|Smoking Cessation Treatment|12 60-minute individual sessions of standard smoking cessation treatment.
1787044|NCT00494728|Drug|Nicotine Replacement Therapy|21 mg patch for 4 weeks; 14 mg patch for 2 weeks; 7 mg patch for 2 weeks.
1787045|NCT00494728|Behavioral|CBASP|Individual counseling sessions where taught/develop interpersonal and behavioral coping skills to help decrease depression and negative moods, and to increase ability to quit smoking.
1787046|NCT00494741|Drug|mycophenolate mofetil|Patients randomized in this group will receive 750 mg of MMF per os twice a day starting on the day of transplant. MMF dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
1787047|NCT00494741|Drug|azathioprine|Patients randomized in this group will receive 75 mg of AZA per os (or 125 mg if body weight > 75 kg) once a day starting on the day of transplant. AZA dose will be reduced in case of white blood cell count lower than 2,000/mm3 and whenever deemed clinically appropriate.
1787048|NCT00494767|Drug|GW869682|GW869682 tablet with a dose strength of 250 mg will be available for subjects
1787049|NCT00494767|Drug|GSK189075|GSK189075 tablet with a dose strength of 250 mg will be available for subjects
1787050|NCT00494767|Drug|GSK189075-Placebo|Placebo tablets to match GSK189075 250 mg will be available for subjects
1787051|NCT00494767|Drug|GW869682-Placebo|Placebo tablets to match GW869682 250 mg will be available for subjects
1787052|NCT00494780|Drug|Ofatumumab|ofatumumab 300mg, 500mg or 1000mg should be diluted into 1000mL pyrogen free saline and administered as an IV infusion.Duration of infusion will be approximately 4 hours.Infusions should be given every 3 weeks until a total of 6 infusions has been given
1787053|NCT00494780|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
1787054|NCT00494780|Drug|Doxorubicin|Doxorubicin : 50mg/m2 iv for 1 day, 24-48h post-ofatumumumab infusion start
1787055|NCT00494780|Drug|Vincristine|Vincristine : 1.4mg/m2 iv for 1 day, 24-48h post-ofatumumab infusion start
1787056|NCT00494780|Drug|Prednisolone, Prednisone or equivalent|100mg p.o daily for 5 days, 24-48h post-ofatumumab infusion start
1787057|NCT00494793|Procedure|VAWC and mesh mediated fascial traction|"The first period of 2-5 days only the abdominal VAWC dressing is applied. On day 3-10 a polypropylene mesh is sutured to the fascial edges, between the two layers of the VAWC system, and tightened.
The VAWC dressing is changed and the mesh tightened every 2-3 days, resulting in gradual approximation of the fascial edges.
Finally the mesh is removed and the fascia is closed"
1787058|NCT00494806|Other|Rocking Chair Intervention|Patient out of bed rocking in a rocking chair at a constant rate of one rock cycle per second (back and forth), in ten to twenty minute increments, for at least sixty minutes per day or 3600 rock cycles and ambulate at least twice per day beginning the first postoperative day.
1787059|NCT00494832|Drug|Dexmedetomidine|"10 minutes loading dose of 0.9 mcg/kg
Maintenance dose of 0.6 mcg/kg/hour"
1787060|NCT00494832|Drug|Normal Saline|"10 minutes loading dose of 0.9 mcg/kg
Maintenance dose of 0.6 mcg/kg/hour"
1787170|NCT00483834|Drug|Bevacizumab|7.5mg/kg, IV, day 1 of each cycle
1787061|NCT00494845|Behavioral|Mindfulness|8-week mindfulness program will be compared to an education control group.
1787062|NCT00494845|Behavioral|Control: Health Education Class|8-week education program
1787063|NCT00494858|Behavioral|Cognitive behavioral therapy - focused (CBT-EF)|Focused CBT concentrates only on BN symptoms. There will be 20 sessions over the course of 5 months.
1787064|NCT00494858|Behavioral|Cognitive behavioral therapy - broad (EB)|Broad CBT addresses symptoms of BN, as well as those of the personality disorder. CBT-EB incorporates ED interventions from CBT-EF but also has modules focused on addressing mood intolerance and interpersonal difficulties. There will be 20 sessions over 5 months.
1787065|NCT00494871|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants orally administered rivaroxaban 15 mg OD (CrCL [creatinine clearance] >= 50 mL/min) or 10 mg OD (CrCL 30-49 mL/min)
1787066|NCT00494871|Drug|Warfarin|Participants orally administered a warfarin potassium tablet (INR [international normalized ratio] target was 1.6-2.6 for patients >70 years and 2.0-3.0 for patients <70 years)
1787067|NCT00494871|Drug|Rivaroxaban placebo|Participants orally administered a rivaroxaban placebo tablet
1787068|NCT00494871|Drug|Warfarin placebo|Participants orally administered a warfarin placebo tablet (adjusted based upon sham INR values)
1787069|NCT00494884|Drug|vildagliptin|
1787070|NCT00494897|Drug|Asparaginase|
1787071|NCT00494897|Drug|Cyclophosphamide|
1787072|NCT00494897|Drug|Cytarabine|
1787073|NCT00494897|Drug|Daunorubicin|
1787074|NCT00494897|Drug|Mercaptopurine|
1787075|NCT00494897|Drug|Prednisone|
1787076|NCT00494897|Drug|Vincristine|
1787077|NCT00494897|Drug|Methotrexate|
1787078|NCT00494897|Procedure|Intrathecally treatment|
1787079|NCT00494910|Behavioral|Meaning Centered Group Psychotherapy|this eight-week (1 ½ hour weekly sessions) Session 1 - Concepts of Meaning and Sources of Meaning Session 2 - Cancer and Meaning Session 3 - Meaning and Historical Context of Life Session 4 - Storytelling, Legacy Project (optional) Session 5 - Limitations and Finiteness of Life Session 6 - Responsibility, Creativity, Deeds Session 7 - Experience, Nature, Art, Humor Session 8 - Transitions, Goodbyes, Hopes for the Future
1787080|NCT00494910|Behavioral|Supportive Group Psychotherapy|The eight weekly 1 ½ hour sessions will focus on group discussion on a set of specific themes that emerge for patients coping with cancer. The session themes or topics will include such issues as: the discussion of strategies for coping with medical issues and procedures, communication with health care providers and issues related to family, friends, and occupational life.
1787081|NCT00494949|Drug|Hemospan (MP4OX)|200, 400, 600, 750, or 1000 mL of Hemospan (MP4OX)
1787082|NCT00494949|Drug|Ringer's lactate|200, 400, 600, 750, or 1000 mL of Ringer's lactate solution
1787083|NCT00494962|Drug|lecozotan SR|
1787084|NCT00494975|Device|Narrow band UVB phototherapy , long wave UVA phototherapy|A UV irradiation cubicle (HOUVA II, National Biological Corporation, OH, U.S.A.) equipped with 24 UVA lamps (F72T12/BL9/HO UVA, National Biological Corporation, OH, U.S.A. ) and 24 UVB lamps (TL100W/01 311NB UVB, Philips Company, Eindhoven, The Netherlands).
1787085|NCT00494988|Drug|insulin aspart|
1787086|NCT00494988|Drug|insulin NPH|
1787087|NCT00495014|Drug|GSK376501|
1787088|NCT00495014|Drug|Placebo|
1787089|NCT00495027|Behavioral|Internet-delivered Stress Innoculation Training|
1787090|NCT00495040|Radiation|Proton Radiotherapy|87.5 CGE with 2.5 Gy/fraction for 35 treatments
1787094|NCT00495066|Drug|Ipilimumab|Intravenous Solution, Intravenous, Ipilimumab 3 mg/kg, Ipilimumab - one dose every 3 wks for a total of 4 doses. Subjects who are eligible may receive another 4 doses given every 3 wks; Until disease progression, unacceptable toxicity or withdrawal of consent
1787095|NCT00495079|Drug|Marqibo® (vincristine sulfate liposomes injection)|Dosing was done every 7 days (± 3 days) on Days 1, 8, 15, and 22 with no less than 4 days between dosing days. Dose calculations were based on body surface area using the subject's height (from Screening) and actual weight for each course.
1787096|NCT00495092|Drug|Caffeine|Caffeine from 300 mg/d to 1200 mg/d or 15 mg/kg/d
1787097|NCT00495092|Drug|Biperiden|Biperiden 2-4 mg/d p.o.
1787098|NCT00495092|Drug|Placebo|Placebo + Placebo
1787099|NCT00495105|Behavioral|Two Servings of Dairy Snacks|2 servings of dairy products as snacks at school to third, fourth, and fifth grade students each day for 24 weeks. The serving size of each dairy snack is based on its calcium content with the goal of adding an extra 300 mg of calcium to the intervention group's daily intake.
1787100|NCT00495118|Drug|risperidone|
1787101|NCT00495131|Drug|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 24 weeks
1787102|NCT00495131|Drug|Pegylated interferon alfa-2a plus ribavirin|Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (<75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) for 48 weeks
1787104|NCT00495157|Behavioral|Symptom-based adjustment|Symptom-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
1787105|NCT00495157|Behavioral|Biomarker-based adjustment|Biomarker-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
1787106|NCT00495157|Behavioral|Guideline-based adjustment|Guideline-based adjustment of beclomethasone dipropionate administered via a hydrofluoroalkane (HFA) inhaler (QVAR® 40 mcg or QVAR® 80 mcg)
1787107|NCT00495170|Drug|Carboplatin|2 area under curve (AUC) by vein Weekly
1787108|NCT00495170|Radiation|Proton Radiotherapy|2 GY/fraction for 37 fractions (daily treatment, Monday to Friday, for 7.5 weeks).
1787109|NCT00495170|Drug|Paclitaxel|50 mg/m^2 by vein Weekly
1787110|NCT00495183|Drug|caffeine|caffeine from 300 to 1200 mg/d or 15 mg/kg/d, divided in 3 doses per day.
1787171|NCT00483834|Drug|Irinotecan|200mg/m^2, IV, day 1 each cycle
1787111|NCT00495183|Drug|Biperiden|Biperiden 2-4 mg/d, divided in 2 doses per day.
1787112|NCT00495183|Drug|Placebo|Placebo
1787113|NCT00495196|Procedure|Experimental lung function test|Administration of several CO2 gas mixtures
1787114|NCT00495209|Other|Qigong|EQT daily for 5 consecutive days prior to surgery.
1787115|NCT00495222|Procedure|Tissue plication|Tissue apposition and plication of a dilated GJ anastomosis with the Endoscopic Suturing System
1787116|NCT00495222|Device|Endoscopic Suturing System|Tissue plication of dilated GJ stoma
1787117|NCT00495222|Device|Tissue Plication|Tissue plication for GJ stoma reduction
1787118|NCT00495235|Behavioral|Questionnaire|Questionnaire taking about 20 minutes to complete.
1787119|NCT00495248|Behavioral|Group intervention inspired by Lifestyle Redesign|Group intervention inspired by Lifestyle Redesign
1787120|NCT00495248|Behavioral|Group intervention inspired by Lifestyle redesign|Lifestyle programme once a week for two hours over an intervention period of 9 months
1787121|NCT00495261|Behavioral|Mindfulness-enhanced cognitive behavioural therapy (MCBT)|a variation of cognitive behavioural therapy (CBT)
1787122|NCT00495261|Behavioral|relaxation-enhanced cognitive behavioural therapy (RCBT)|a variation of cognitive behavioural therapy (CBT)
1787123|NCT00495274|Drug|Formulation A|Formulation A represents the original formulation. SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing micronized drug substance. Formulation A will be administered in Part A.
1787124|NCT00495274|Drug|Formulation B|Formulation B will represent SB-649868 10 mg film coated tablet containing micronized drug substance (3 tablets to reach 30 mg), but contains additional surfactant. Formulation B will be administered in Part A.
1787125|NCT00495274|Drug|Formulation C|Formulation C will represent SB-649868 10 mg lipophilic capsule (3 capsules to reach 30 mg). Formulation C will be administered in Part A.
1787126|NCT00495274|Drug|Formulation D|Formulation D will represent SB-649868 10 mg film coated tablet (3 tablets to reach 30 mg), containing nanomilled and spray dried powder. Formulation D will be administered in Part A.
1787127|NCT00495274|Drug|Formulation E|Formulation E will represent SB-649868 10 mg capsule (3 capsules to reach 30 mg), containing nanomilled and spray dried powder. Formulation E will be administered in Part A.
1787128|NCT00495274|Drug|Formulation F|Formulation F will represent SB-649868 15 mg liquid filled capsule (2 capsules to reach 30 mg). Formulation F will be administered in Part A.
1787129|NCT00495274|Drug|Formulation G|Formulation G will be the selected formulation of SB-649868 30 mg to be assessed in Part B. The formulation will be administered after a standard FDA High-Fat breakfast
1787130|NCT00495287|Drug|cytosine arabinoside|"Arm A: use of standard-dose cytosine arabinoside (100 mg/m2/bd iv. on days 1-7) in association with idarubicin and etoposide.
Arm B: use of high-dose cytosine arabinoside (1000-2000 mg/m2/bd according to age +/-65 years iv. on days 1-2 and 8-9) in association with idarubicin."
1787131|NCT00495313|Drug|doxycycline|COL-101, QD plus metronidazole
1787132|NCT00495313|Drug|doxycycline|40 mg with metronidazole QD
1787133|NCT00495326|Drug|Nevirapine based therapy|"Patients below 60 kg: 1 tablet twice a day of Triomune30®, including NVP 200 mg, 3TC 150 mg and D4T 30mg
Patients above 60kg: 1 tablet twice a day of Triomune40®, including NVP 200 mg, 3TC 150 mg and D4T 40 mg)"
1787134|NCT00495326|Drug|Efavirenz based therapy|Efavirenz EFV 200 mg (3 tablets/d) Lamivudine 3TC 300mg (2 tablets of 150mg/d) D4T generic 30mg or 40mg (2 tablets/d)
1787135|NCT00495326|Drug|Rifampicin (RMP) Ethambutol (E) Isoniazid (H) Pyrazinamid (Z)|"Intensive phase: 2 months daily E(RMP)HZ. PTB smear positive patients at month 2 will receive 1 more month intensive phase.
Continuation phase: 4 months daily H(RMP).
Patients with meningitis will receive Streptomycin instead of E during intensive phase."
1787136|NCT00495339|Drug|Levofloxacin|500-1000 mg once a day daily per os with combination of drugs.
1787137|NCT00495352|Drug|Hihg-doseNRT, Low-dose NRT, bupropion|
1787138|NCT00495365|Drug|Epoetin alfa|
1787139|NCT00495378|Drug|epoetin alfa|
1787140|NCT00495391|Drug|Nitazoxanide|One oral 500 mg nitazoxanide tablet twice daily for 52 weeks.
1787141|NCT00495391|Drug|Placebo|One oral placebo tablet twice daily for 52 weeks.
1787142|NCT00495391|Biological|Peginterferon alfa-2a|Weekly injections of 180µg peginterferon alfa-2a for 48 weeks.
1787143|NCT00495391|Drug|Ribavirin|1000 mg (if <75 kg body weight) or 1200 mg (if ≥75 kg body weight) ribavirin in divided daily doses for 48 weeks.
1787144|NCT00495404|Behavioral|Physician Treatment Guidelines|
1787145|NCT00495417|Biological|AFFITOPE AD01|s.c. injection
1787146|NCT00495417|Biological|AFFITOPE AD01 adjuvanted|s.c. injection
1787147|NCT00495443|Device|Peterio|
1787148|NCT00483704|Drug|Telcagepant 140 mg|Telcagepant 140 mg tablets
1787149|NCT00483704|Drug|Talcagepant 280 mg|Telcagepant 280 mg tablets
1787150|NCT00483704|Drug|Placebo|Placebo tablets
1787151|NCT00483717|Drug|Ketorolac tromethamine|31.5 mg of ketorolac 2 x 100uL IN sprays (15% ketorolac tromethamine with 6% lidocaine hydrochloride)
1787152|NCT00483717|Drug|Placebo|Intranasal (IN) placebo
1787153|NCT00483730|Drug|Deproteinised hemoderivative of calf blood (Actovegin)|Symptomatic diabetic peripheral polyneuropathy
1787154|NCT00483743|Drug|TPI 1020|250 mcg/caps 2 caps BID x 42 days
1787155|NCT00483743|Drug|Budesonide|400mcg mcg capsules- 2 capsules BID
1787156|NCT00483743|Drug|Placebo|2 caps BID x42 days
1787157|NCT00483756|Drug|Cyclosporine|Standard of care
1787158|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-6, then 10 mg BID for Months 7-12
1787159|NCT00483756|Drug|CP-690,550|CP-690,550 15 mg BID for Months 1-3, then 10 mg BID for Months 4-12
1787160|NCT00483769|Drug|Glargine|
1787161|NCT00483782|Biological|bevacizumab|
1787162|NCT00483782|Drug|carboplatin|
1787163|NCT00483782|Drug|paclitaxel|
1787164|NCT00483782|Other|questionnaire administration|
1787165|NCT00483782|Other|study of socioeconomic and demographic variables|
1787166|NCT00483782|Procedure|quality-of-life assessment|
1787167|NCT00483795|Drug|sodium citrate, sodium chloride, sodium borate, propylene glycol. citrate, tetronic 1304, AMP 95|
1787168|NCT00483808|Device|Ardian Symplicity™ Catheter|Renal denervation using the Symplicity Catheter
1787172|NCT00483834|Drug|Capecitabine|1000mg/m^2 or 750mg/m^2 for patients over 65yrs old PO BID, day 1-14 each cycle
1787173|NCT00483860|Drug|Topotecan|once a day
1787174|NCT00483886|Drug|Prucalopride|2 mg o.d.
1787175|NCT00483886|Other|Placebo|Placebo o.d.
1787176|NCT00483886|Drug|Prucalopride|4 mg o.d.
1787177|NCT00483899|Drug|GW870086X|Subjects will inhale 0.25 or 1.5 mg/inhalation GW870086X for four times
1787178|NCT00483899|Drug|Placebo|Placebo matching GW870086X will be administered by subjects
1787179|NCT00483912|Device|Molecular adsorbent recirculating system|
1787180|NCT00483938|Drug|Pegylated-interferon Alfa-2a|Participants will receive pegylated-interferon alfa-2a 180 mcg subcutaneously once in a week for the specified duration.
1787181|NCT00483938|Drug|Ribavirin|Participants will receive ribavirin 1000 to 1400 mg orally daily for the specified duration.
1787182|NCT00483964|Drug|Bacopa monnieri|
1787183|NCT00483964|Drug|Nardostachys jatamansi|
1787184|NCT00483964|Drug|Olanzapine|
1787185|NCT00483977|Drug|Oxycodone|Oxycodone: oral controlled release, 20 mg, twice a day for 2 weeks
1787186|NCT00483977|Drug|Placebo|Placebo: oral for 2 weeks.
1787187|NCT00483977|Drug|PF-000592379|PF-00592379: oral, 30 mg, once a day for 2 weeks
1787188|NCT00483990|Drug|PSD502|
1787189|NCT00484003|Drug|Pimecrolimus cream 1%|
1787190|NCT00484029|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
1787191|NCT00484029|Other|Air|Air (Medical Grade)
1787192|NCT00484055|Drug|Local application of collagen-gentamicin|Application of 2 sponges (5 x 20 cm) of collagen-gentamicin between the sternal halves immediately before sternal closure
1787193|NCT00484055|Procedure|Fixation of the sternotomy with more than six wires|At least 7 (or more) sternal fixation wires (preferaby put as separate single wires) used for fixation of the sternum at wound closure
1787194|NCT00484068|Drug|enalapril|
1787195|NCT00484068|Procedure|chicken diet|
1787196|NCT00484081|Procedure|Microdissection Testicular Sperm Extraction|
1787197|NCT00484081|Procedure|ICSI|
1787198|NCT00484094|Drug|sirolimus|Dosage and treatment duration will be decided by physician's discretion considering patient's clinical situations
1787199|NCT00484107|Drug|Conjugated Estrogen Cream (Premarin®)|
1787200|NCT00484120|Drug|3%-Diclofenac-Nano-Emulsion Cream|3%-Diclofenac-Nano-Emulsion Cream
1787201|NCT00484120|Drug|Placebo cream|Placebo cream
1787202|NCT00484133|Drug|Dopamine|
1787203|NCT00484133|Drug|dobutamine|
1787204|NCT00484133|Drug|enoximone|
1787205|NCT00484133|Drug|nitroglycerine|
1787206|NCT00484133|Drug|noradrenaline|
1787207|NCT00484159|Procedure|Radiofrequency denervation of medial branches|Radiofrequency of medial branches that innervate the lumbar facet joints
1787208|NCT00484159|Drug|0.5% bupivacaine|Diagnostic medial branch block with 0.5% bupivacaine. Blocking the nerves that innervate the facet joints with a long-acting local anesthetic.
1787209|NCT00484159|Drug|2% lidocaine|Diagnostic medial branch block with 2% lidocaine. Blocking the nerves that innervate the facet joints with a short-acting local anesthetic.
1787210|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic block
1787211|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation only if positive response to 2 diagnostic blocks.
1787212|NCT00484159|Procedure|Radiofrequency denervation|Lumbar facet radiofrequency denervation if positive response to a single diagnostic facet block
1787213|NCT00484159|Procedure|Radiofrequency denervation|Radiofrequency lumbar facet denervation without a diagnostic facet block.
1787214|NCT00484172|Procedure|blood draws|
1787215|NCT00484185|Drug|BeneFIX (coagulation factor IX (recombinant))|BeneFIX will be administered according to physician's discretion.
1787216|NCT00484198|Drug|pioglitazone|Tablets
1787217|NCT00484198|Drug|placebo|Tablets
1787218|NCT00484198|Drug|rivoglitazone HCl|Tablets
1787219|NCT00484198|Drug|rivoglitazone HCl|Tablets
1787220|NCT00484211|Drug|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
1787221|NCT00484237|Drug|etanercept|
1787222|NCT00484250|Drug|metronidazole,doxycycline|
1787223|NCT00484263|Drug|Hypertonic saline 6% -|Hypertonic saline (6%) - 5mls twice a day via a nebuliser for 12 months
1787224|NCT00484276|Drug|NGR-hTNF|iv q3W or q1W 0.8 mcg/sqm NGR-hTNF
1787225|NCT00484289|Drug|Abatacept|Vials (250 mg/vial), Intravenous, Weight-tiered dose of abatacept (equivalent to 10 mg/kg) based on their body weight at the enrollment visit; 500 mg for participants < 60 kg, 750 mg for participants 60 to 100 kg and 1,000 mg for participants > 100 kg, administered over a period of approximately 30 minutes at week 0, 2, 4 and every 4 weeks thereafter, until approved in Japan and was continued as a post-marketing study until the completion of the shift to a commercially available product.
1787226|NCT00484302|Behavioral|Cognitive behavioral therapy with motivational interviewing|Individual and group therapy, education of family and case-manager.
1787227|NCT00484302|Behavioral|Non-manualized standard treatment|Treatment by case-manager
1787228|NCT00484315|Device|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Element) implantation|TAXUS Element stent placement
1787229|NCT00484315|Device|Percutaneous coronary intervention (PCI) with paclitaxel-eluting stent (TAXUS Express) placement|TAXUS Express Stent Implant
1787230|NCT00484328|Drug|Ribavirin|different dosing regimes of Ribavirin
1787231|NCT00484341|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
1787232|NCT00484341|Drug|NGR-hTNF|NGR-hTNF: 45 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
1787233|NCT00484341|Drug|Doxorubicin|Doxorubicin: 60 mg/m² intravenous infusion over 15 minutes (starting 1 hour after the end of NGR-hTNF infusion) on day 1 every 3 weeks for a maximum of 6 cycles or until cumulative dose of 550 mg/m²
1787234|NCT00484354|Other|Sodium bicarbonate|IV bicarbonate given with amount based on patient weight
1787235|NCT00484354|Other|Normal saline|IV Normal saline with volume given determined by patient weight
1787236|NCT00484354|Other|Bicarbonate|IV bicarbonate, dosed by weight
1787237|NCT00484354|Other|Placebo|Normal saline, with volume given based on patient weight
1787238|NCT00484367|Behavioral|Adolescent group therapy|Adolescent group therapy
1787239|NCT00484367|Behavioral|Transitional family therapy|Transitional family therapy
1787240|NCT00484380|Procedure|Coronary scanner|multislice spiral computed tomography coronary angiography
1787241|NCT00484393|Drug|tetracaine 4% gel|tetracaine applied prior to 1 injection
1787242|NCT00484393|Drug|Placebo|placebo applied prior to 1 injection
1787243|NCT00484419|Drug|Colesevelam HCl|coleveselam tablets 625 mg; 6 tablets/day
1787244|NCT00484419|Drug|rosiglitazone maleate|rosiglitazone tablets 4mg
1787245|NCT00484419|Drug|sitagliptin phosphate|sitagliptin phosphate tablets 100mg/day
1787246|NCT00484432|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs
1787247|NCT00484432|Drug|doxorubicin|Doxorubicin: 60mg/m2 every 3 weeks, until cumulative dose of 550 mg/m²
1787248|NCT00484458|Device|Interspinous process and dynamic stabilization (Wallis System)|Interspinous stabilization
1787249|NCT00484458|Device|Total Disc Replacement|Total disc
1787250|NCT00484471|Drug|aripiprazole|15-30 mg/day aripiprazole, 22 weeks
1787251|NCT00484471|Drug|valproate|sufficient dose as determined by investigator to maintain the therapeutic level.
1787252|NCT00484471|Drug|placebo|placebo to aripiprazole, 22 weeks
1787253|NCT00484484|Drug|Ketamine|Ketamine
1787254|NCT00484497|Drug|cyclamax|
1787255|NCT00484510|Drug|Ascorbic acid (Vitamin C)|Eight 500 mg capsules/day of ascorbic acid. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months. (Total 4 gr/day).
1787256|NCT00484510|Drug|placebo|Eight 500 mg capsules/day of placebo. Subjects will take four (4)capsules each morning and four (4) capsules each evening for 24 months.
1787257|NCT00484523|Procedure|SPET, PET and MRI|60 healthy subjects after a a consultation with a neurologist for wich 4 examinations will be programmed in two days ( 1 cerebral MRI, 1pet scan, 1 spet, 1 datascan
1787258|NCT00484536|Drug|CDP323|250 mg capsules, 500 mg bid (1000 mg/day)
1787259|NCT00484536|Drug|placebo|capsules, once daily
1787260|NCT00484536|Drug|CDP323|250 mg Capsules, 500 mg, once daily
1787261|NCT00484549|Procedure|Blood sample|Ischemic stroke hospitalized
1787262|NCT00484562|Device|Standard oxygen delivery system|Standard oxygen tank with pulse dose regulator
1787263|NCT00484562|Device|Homefill oxygen delivery system|Homefill oxygen delivery system, pre-filled from a larger oxygen concentrator base unit.
1787264|NCT00484562|Device|Helios oxygen delivery system|Liquid oxygen portable system pre-filled from a larger liquid oxygen tank
1787265|NCT00484562|Device|FreeStyle oxygen system|portable battery-powered oxygen concentrator delivery system
1787266|NCT00484575|Drug|Sevoflurane|given by infusion via AnaConDa for sedation with target MAAS 2-3
1787267|NCT00484575|Drug|propofol|propofol given intravenously for sedation in control group
1787268|NCT00484601|Drug|Ifosfamide; Doxorubicin|
1787269|NCT00484614|Procedure|Positron Emission Mammography|Molecular Imaging Device
1787270|NCT00484614|Procedure|Magnetic Resonance Imaging|Imaging Device
1787271|NCT00484627|Procedure|Use of creatine monohydrate (a dietary supplement)|
1787272|NCT00484627|Behavioral|Progressive resistance exercise training|
1787274|NCT00484653|Procedure|cervical smear|biological analysis
1787275|NCT00484666|Drug|Docetaxel|
1787276|NCT00484666|Drug|Topotecan|
1787277|NCT00484679|Drug|Triamcinolone Acetonide 10 mg/mL (Kenalog-10)|Triamcinolone Acetonide 10 mg/ml (Kenalog-10) intralesional injection
1787278|NCT00484692|Drug|sustained-release bupropion (Zyban(R))|
1787279|NCT00484692|Behavioral|Psychodynamic Model Training (R) = PDM(R)|
1787280|NCT00484705|Procedure|Electroacupuncture|
1787281|NCT00484705|Procedure|Physical exercise|
1787282|NCT00484705|Procedure|Untreated control|
1787283|NCT00484718|Drug|celecoxib|oral, 100 mg bid
1787284|NCT00484718|Drug|Oxycodone|oral, 20 mg bid
1787285|NCT00484718|Drug|placebo|oral bid
1787286|NCT00484731|Procedure|Infiltration with Saline|Infiltration with Bupivacaine according to protocol
1787287|NCT00484731|Procedure|Infiltration with Bupivacaine|
1787288|NCT00484744|Drug|Acetaminophen|
1787289|NCT00484744|Drug|Avicel (placebo)|
1787290|NCT00484744|Drug|Ibuprofen|
1787291|NCT00484757|Drug|Orexine A|
1787292|NCT00484770|Device|Brain Natriuretic Peptide Levels -- Diagnostic testing|
1787293|NCT00484770|Other|clinical assessment|
1787294|NCT00484783|Procedure|Natural Orifice Transluminal Endoscopic Surgery (NOTES)|Patients will have the standard laparoscopic procedure and the NOTES procedure will be added. The surgical procedure will require two operating teams: one led by a laparoscopic surgeon, the other by an endoscopic surgeon. During the usual course of the surgery, the flexible endoscope will be passed through the mouth urethra top gain access to the peritoneal cavity.
1787295|NCT00484783|Procedure|Natural Orifice Translumenal Endoscopic Surgery (NOTES)|chart review of historical data from control group
1787296|NCT00484796|Procedure|MED-SEP|intraoperative neurophysiological monitoring
1787297|NCT00484796|Procedure|TRI-SEP|intraoperative neurophysiologic monitoring
1787298|NCT00484796|Procedure|neuropsychological tests|neurological short- and longterm outcome
1787299|NCT00484809|Drug|Enbrel (Etanercept)|
1787300|NCT00484822|Drug|Bemiparina Sodica|3.500 UI/día.
1787301|NCT00484822|Drug|Heparina Cálcica|10.000 UI/día.
1787302|NCT00484835|Procedure|Performing abdominal hysterectomy using gyrus electrocoagulation forceps|
1787303|NCT00484848|Device|Vortex port and Celsite port|
1787305|NCT00484900|Drug|Co-Arinate FDC|
1787306|NCT00484900|Drug|Coartem|
1787307|NCT00484913|Procedure|abdominal hot compress|
1787308|NCT00484926|Drug|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
1787309|NCT00484926|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
1787310|NCT00484939|Drug|Bevacizumab|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Bevacizumab was supplied in single-use vials.
1787311|NCT00484939|Drug|Capecitabine|Treatment continued until unacceptable toxicity, withdrawal of consent, disease progression, or a decision to terminate at the discretion of the Investigator if medically indicated. Capecitabine was supplied as tablets.
1787312|NCT00484965|Procedure|Coronary stenting|
1787313|NCT00484978|Procedure|Stereotactic Radiosurgery|
1787314|NCT00484991|Drug|Sapropterin dihydrochloride|20mg/kg/day orally, physicians may adjust the dose within a range of 5-20mg/kg/day as warranted by their clinical judgment.
1787315|NCT00485004|Device|Cutting balloon|Cutting balloon
1787316|NCT00485004|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
1787317|NCT00485017|Drug|THR-4109|THR-4109 maximum dose in study is 115 mg via oral capsule daily in a.m. and 115 mg via oral capsule daily in p.m. for 24 weeks
1787318|NCT00485017|Drug|Placebo|Oral capsules daily in a.m. and in p.m. for 24 weeks
1787319|NCT00485030|Device|Cypher|sirolimus-eluting stent
1787320|NCT00485030|Device|Xience-V|everolimus-eluting stent
1787321|NCT00485043|Behavioral|Modified T'ai Chi: T'ai Chi for Arthritis|
1787322|NCT00485056|Drug|Pioglitazone|45mgs daily
1787323|NCT00485069|Drug|ROP|Ropinirole Hydrochloride monotherapy group (ROP): Patients will receive ROP tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 mg/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. Concomitant use of L-dopa is prohibited during the study.
1787324|NCT00485069|Drug|ROP+L-Dopa|Ropinirole Hydrochloride with L-Dopa adjunct therapy group (ROP+L-Dopa): Patients will receive ropinirole hydrochloride (ROP) tablets 3 times daily. In the 4-week Fixed Titration Phase (from Week 0 as Baseline), the dose will start at 0.75 milligrams (mg)/day and will be increased weekly by 0.75 mg/day up to 3.0 mg/day. In the 48-week Flexible Titration and Maintenance Phase, the dose will be increased by 1.5 mg/day at intervals of at least 1 week up to a maximum of 15.0 mg/day. The dose will be maintained at a level without further symptomatic improvement is expected. The dosing regimen of L-dopa remain unchanged from 4 weeks prior to the start of the Screening Phase throughout the study.
1787325|NCT00485095|Behavioral|Intake of plant sterols|
1787326|NCT00485108|Drug|prednisolone 1%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
1787327|NCT00485108|Drug|ketorolac 0.5%|eye drop once in each eye treated, 4 times / day for 5 days post-laser
1787328|NCT00485108|Drug|Artificial Tears (Methyl cellulose drops)|eye drop once in each eye treated, 4 times / day for 5 days post-laser
1787329|NCT00485121|Drug|Ezetimibe|
1787330|NCT00485134|Biological|240 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
1787331|NCT00485134|Biological|480 µg Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
1787332|NCT00485134|Biological|690 Shigella flexneri 2a Invaplex 50 vaccine|Vaccines were administered intranasally on Days 0, 14, and 28. The investigational vaccine was supplied as 1 mL of a sterile, clear liquid in a 3 ml glass vial. Each vial contained 3.5 mg of protein and 567 μg of LPS. The pH was 8.9 and the buffer was 250 mM NaCl in 20 mM Tris.
1787333|NCT00485134|Other|Shigella challenge strain|300 colony forming units (CFU) of Shigella challenge strain, Shigella flexneri 2a strain 2457T
1787334|NCT00485147|Procedure|Recording of GPS during a free walking in a public park|Analyse the clinical change after surgery from GPS measurements and compare it with laboratory measurement.
1787335|NCT00485160|Drug|Continuous indomethacin|
1787336|NCT00485160|Drug|ibuprofen|
1787337|NCT00485173|Device|INFUSE® Bone Graft/PEEK Spacer/Anterior Cervical Plate|All patients enrolled in this study will receive the investigational device.
1787338|NCT00485199|Procedure|Pneumatic Retinopexy|
1787339|NCT00485199|Procedure|Vitrectomy with Gas|
1787340|NCT00485212|Device|compression bandage|
1787341|NCT00485225|Drug|EN3270|Transdermal Therapeutic System
1787342|NCT00485238|Procedure|Argon laser Iridoplasty|
1787343|NCT00485238|Drug|Intravenous acetazolamide|
1787344|NCT00485251|Procedure|hand-assisted laparoscopic right hemicolectomy|using the lap disc that allows the insertion of single and into the abdomen for operation
1787345|NCT00485251|Procedure|total laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
1787346|NCT00485251|Procedure|hand-assisted right hemicolectomy|hand-assisted right hemicolectomy
1787347|NCT00485251|Procedure|laparoscopic right hemicolectomy|using laparoscopic instruments for mobilization and dissection inside the abdomen
1787348|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily.
1787349|NCT00485264|Drug|Raltegravir chewable tablet|Final Selected Dose: Weight based dose of ~6 mg/kg according to the dosing table, to a maximum dose of 300 mg, taken orally twice daily.
1787350|NCT00485264|Drug|Raltegravir oral granules for suspension (20 mg/mL)|Weight based dose of ~6 mg/kg orally every 12 hours according to dosing table in protocol or the dose determined by review of all available data.
1787351|NCT00485264|Drug|Raltegravir poloxamer film coated tablet|Final Selected Dose: 400-mg tablet taken orally twice daily for participants weighing at least 25 kg. Participants < 25 kg were switched to a weight-based dose of the chewable tablet.
1787516|NCT00488059|Drug|enfuvirtide [Fuzeon]|90 mg SC twice daily
1787352|NCT00485277|Biological|MVA-BN-HER2|Experimental vaccine, subcutaneous injection q3weeks x 3
1787353|NCT00485290|Behavioral|meal (food intake)|600 kcal. (16% protein, 49%carbohydrate, 35% fatt)
1787354|NCT00485303|Drug|Abiraterone acetate|Abiraterone acetate oral tablets 250 milligram (mg) each will be administered at a total dose of 1000 mg until documented disease progression or unacceptable toxicity.
1787355|NCT00485303|Drug|Prednisone|Prednisone/Prednisolone 5 mg tablet will be taken orally twice daily.
1787356|NCT00485316|Procedure|Laparoscopic assisted resection of colorectal carcinoma|
1787357|NCT00485329|Other|Papain|15,000 USP U/ml
1787358|NCT00485329|Other|Papain|30,000 USP U/ml
1787359|NCT00485329|Other|Papain|60,000 USP U/ml
1787360|NCT00485342|Drug|Peg-interferon alpha 2a and ribavin|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (1000 mg/day if weight < 75 kg and 1200 mg/day if weight ≥ 75 kg).
Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
1787361|NCT00485342|Drug|ribavirin with adaptation dose|"Date of ribavirin AUC : Day 0 (beginning of treatment) Bitherapy : Peg-interferon alpha 2a (180 µg/week) with ribavirin (dose adaptation) Dose adaptation : Day 7, dependant of result of AUC Ribavirin dose increments : 200 mg, 400 mg or 600 mg with a maximum of 50% of the initial dose (600 mg) applied every 4 days up to the adjusted dose proposed in order to reach the targeted AUC.
The maximum daily dose will not exceed 3600 mg Duration of treatment : 48 weeks Duration of study for patients : 72 weeks"
1787362|NCT00485355|Procedure|conventional laparoscopic hysterectomy|Total laparoscopic hysterectomy
1787363|NCT00485355|Procedure|robotic assisted laparoscopic hysterectomy|Robotic assisted laparoscopic hysterectomy with DaVinci robot
1787364|NCT00485368|Drug|Coversyl (perindopril)|
1787365|NCT00485394|Drug|OT-551|OT-551 0.3% ophthalmic solution, 2 drops 4 times daily
1787366|NCT00485394|Drug|OT-551|OT-551 0.45% ophthalmic solution, 2 drops 4 times daily
1787367|NCT00485394|Drug|vehicle placebo|OT-551 0% ophthalmic solution, 2 drops 4 times daily
1787368|NCT00485407|Drug|Atomoxetine Hydrochloride|
1787369|NCT00485420|Other|Internet based disease management program|Usual Care is augmented with internet-based education, self-monitoring and clinician monitoring
1787370|NCT00485433|Drug|Bupivacaine HCl|Bupivacaine HCl given during hernia repair
1787371|NCT00485433|Drug|SKY0402|SKY0402 given during hernia repair
1787372|NCT00485446|Procedure|blood analysis|
1787373|NCT00485459|Drug|Atomoxetine Hydrochloride|
1787374|NCT00485459|Drug|Placebo|
1787375|NCT00485472|Drug|lacosamide|50 or 100mg tablet, 400mg daily, for 12 weeks
1787376|NCT00485472|Other|Placebo|50 or 100mg tablet, 400mg daily, for 12 weeks, matched to Lacosamide
1787377|NCT00485485|Drug|Imatinib Mesylate|400 mg by mouth daily
1787378|NCT00485485|Drug|Docetaxel|60 mg/m^2 by vein (IV) over 1 hour every 3 weeks
1787379|NCT00485498|Drug|Olanzapine Hydrochloride|
1787380|NCT00485498|Drug|Risperidone|
1787381|NCT00485511|Drug|Hydroxyurea|
1787382|NCT00485537|Procedure|oocyte retrieval and ICSI procedure|
1787383|NCT00486941|Behavioral|Exercise and diet - based on DPS and DPP|
1787384|NCT00486954|Drug|Lapatinib|6 pills at 250 mg each once daily
1787385|NCT00486954|Drug|Paclitaxel|Infusion at 80 mg/m2 weekly
1787386|NCT00486980|Drug|Peramivir 150mg|
1787387|NCT00486980|Drug|Peramivir 300mg|
1787388|NCT00486993|Behavioral|Dietary and nutritional modification|
1787389|NCT00486993|Behavioral|Stop smoking|
1787390|NCT00486993|Behavioral|Regular physical activities|
1787391|NCT00486993|Behavioral|Weight reduction to normal ranges|
1787392|NCT00486993|Behavioral|Regular intake of polyphenols, esp. from Ilex paraguayensis|
1787393|NCT00487006|Other|Serum Lab testing|Serum Lab testing
1787394|NCT00487032|Drug|Oxymetazoline 0.05% w/v|2 squirts in each nostril thrice daily
1787395|NCT00487032|Drug|Fluticasone propionate 50 micrograms per actuation|2 Squirts in each nostril twice daily
1787396|NCT00487032|Drug|Prazosin hydrochloride|Prazosin 1mg one dose only
1787397|NCT00487032|Drug|Placebo to Prazosin|Placebo 1 tablet one dose only
1787398|NCT00487045|Device|Hem-Avert Perianal Stabilizer|Hem-Avert Perianal Stabilizer, TNP-01L, single-use, disposable, sterile, individually packaged instrument
1787399|NCT00487058|Drug|Gimatecan|
1787400|NCT00487071|Device|Anal fistula plug|
1787401|NCT00487084|Drug|Morphine-CP-saline (MCS)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
1787402|NCT00487084|Drug|saline-2CP-morphine (SCM)|6ml of saline will be administered epidurally 30 min prior to epidural anesthesia. Epidural 3% 2CP will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 3mg of preservative free morphine will be administered at skin incision
1787403|NCT00487084|Drug|saline-lidocaine-morphine (SLM)|3mg of preservative free morphine will be administered epidurally 30 min prior to epidural anesthesia. Epidural 2% lidocaine with epinephrine 1:200,000 will be used to achieve a T4 dermatomal level for surgical anesthesia for PPTL. 6ml of epidural saline will be administered at skin incision
1787404|NCT00487097|Dietary Supplement|Eicosapentanoic acid, docosahexaenoic acid|Enteral nutrition formula enriched with Eicosapentanoic acid, docosahexaenoic acid
1787405|NCT00487110|Drug|Tropisetron|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
1787406|NCT00487110|Drug|paracetamol|a comparison of the analgesic action of paracetamol versus tropisetron+paracetamol
1787407|NCT00487123|Drug|Valsartan+/- Hydrochlorothiazide|
1787408|NCT00487136|Drug|Warfarin|Warfarin fixed dose plus one capsule containing placebo for ABT-335, one placebo tablet to match rosuvastatin 5 mg and one placebo tablet to match rosuvastatin 20 mg, administered for 10 consecutive days.
1787409|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 5 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one 5 mg tablet of rosuvastatin and one tablet of placebo to match rosuvastatin 20 mg, administered for 10 consecutive days.
1787517|NCT00488059|Drug|Optimized background ARV|As prescribed
1787410|NCT00487136|Drug|warfarin plus ABT-335 plus rosuvastatin 20 mg|Warfarin fixed dose plus one capsule containing ABT-335 mini-tablets equivalent to 135 mg fenofibric acid, one tablet of placebo to match rosuvastatin 5 mg and one 20 mg tablet of rosuvastatin, administered for 10 consecutive days.
1787411|NCT00487162|Procedure|intensive glycemic control|intravenous insulin titrated every 30 minutes to serum glycemic level of 80-100mg/dl
1787412|NCT00487162|Drug|conventional glycemic control|Novo regular insulin administered when glucose level exceeded 200 mg/dl and titrated to maintain level between 180-200 mg/dl
1787413|NCT00487175|Drug|Tramadol|to compare of the analgesic of tramadol versus placebo in a pain model using evoked potentials
1787414|NCT00487188|Drug|Enfuvirtide|90 mg subcutaneous injection twice a day
1787415|NCT00487188|Drug|Highly active antiretroviral treatment (HAART)|An oral HAART regimen of 3-5 antiretrovirals was chosen by the physician and patient, based on the patient's prior treatment history and genotypic antiretroviral resistance testing.
1787416|NCT00487201|Procedure|endoscopic balloon dilatation|
1787417|NCT00487201|Procedure|plastic stent placement|
1787418|NCT00487227|Drug|caffeine|
1787419|NCT00487227|Drug|Placebo|
1787420|NCT00487240|Drug|Insulin Lispro Protamine Suspension|Patient specific dose, twice daily (BID), within 15 minutes before meals, subcutaneous (SC) injection x 32 weeks.
1787421|NCT00487240|Drug|Insulin Levemir|Patient specific dose insulin Levemir (detemir) twice daily (BID) subcutaneous (SC) injection x 32 weeks
1787424|NCT00487266|Other|Acupuncture|Acupuncture of low back and legs.
1787425|NCT00487279|Device|Defibrillator|ICD(Implantable Cardioverter Defibrillator)
1787426|NCT00487279|Other|Control|No Intervention
1787427|NCT00487292|Behavioral|naps and pulses of bright light|
1787428|NCT00487305|Biological|Lethally Irradiated Lymphoma cells with GM-CSF K562 Cells|Dose will vary depending upon number of cells collected and when the participant is enrolled on the study: the vaccine is given as an injection under the skin once weekly for 3 weeks then every other week for 3 vaccines.
1787429|NCT00487318|Drug|standard of care|peginterferon/RBV
1787430|NCT00487318|Drug|fluvastatin|Add fluvastatin at 20-40 mg/day to standard of care
1787431|NCT00487331|Other|Acupuncture|Acupuncture sessions 1-3 times per week.
1787432|NCT00487331|Behavioral|Survey|2 pain questionnaires + satisfaction survey completed at beginning and end of treatment
1787433|NCT00487344|Procedure|Non-Personalized Meal Planning|
1787434|NCT00487344|Procedure|Personalized Meal Planning and Dietetic Consultation|
1787435|NCT00487357|Behavioral|Supplemental Survey|Questionnaire give during home visit to collect behavioral, risk factors and other smoking status data on MATCh parents/guardians.
1787436|NCT00487370|Procedure|Implantation of gold beads around a knee through needles|
1787437|NCT00487370|Procedure|Sham implantation: Insertion of needles around a knee|
1787438|NCT00487396|Device|Capsule Endoscopy|Pillcam Platform with RAPID5 software and supporting SB2 capsules
1787439|NCT00487409|Procedure|Bipolar electrosurgical generator and instruments|laparoscopic colectomy using the Ligasure device
1787440|NCT00487409|Procedure|Disposable stapling instruments|laparoscopic colectomy using clips, cautery and stapler
1787441|NCT00487422|Drug|prucalopride|2 mg o.d.
1787442|NCT00487422|Drug|Prucalopride|4 mg o.d.
1787443|NCT00487422|Other|Placebo|o.d.
1787444|NCT00487435|Drug|Tapentadol (CG5503) Extended Release (ER)|100, 150, 200, 250 mg oral tablet twice daily for 52 weeks
1787445|NCT00487448|Drug|Fludarabine|
1787446|NCT00487448|Drug|Cytarabine|
1787447|NCT00487448|Drug|G-CSF|
1787448|NCT00487448|Drug|Idarubicin|
1787449|NCT00487448|Procedure|Peripheral blood stem cell transplantation|
1787450|NCT00487448|Procedure|Bone marrow transplantation|
1787451|NCT00487461|Drug|Simvastatin 40 mg|Comparing two doses of Simvastatin to placebo
1787452|NCT00487461|Drug|Placebo|Placebo tablet
1787453|NCT00487461|Drug|Simvastatin 80 mg|Comparing two doses of Simvastatin to placebo
1787454|NCT00487474|Device|DL6049 (injectable poly-L-lactic acid)|Subjects will be treated with SCULPTRA® every 4-6 weeks in accordance with SCULPTRA® package insert
1787455|NCT00487500|Device|Electroconvulsive Therapy (ECT)|Electroconvulsive therapy involves applying a small electrical charge to the scalp while the patient is anesthetized and provoking a short-lasting generalized seizure
1787456|NCT00487513|Procedure|Procurement of Follicular B Cell Lymphoma Cells|Participants will undergo the following procedure(s) that are appropriate for collecting their tissue: Blood collection, lymph node biopsy, drainage of an effusion, or bone marrow biopsy
1787457|NCT00487526|Procedure|duodenal jejunal bypass|
1787463|NCT00487552|Device|Cook Magnetic Anastomosis Device (MAD) with Stent|Gastro-jejunal anastomosis
1787464|NCT00487565|Device|Total knee arthroplasty|Total knee arthroplasty using a posterior stabilized implant
1787465|NCT00487578|Drug|naratriptan HCl|naratriptan 2.5mg tablet bid x 30 days OR matching placebo
1787466|NCT00487591|Drug|Omacor (omega-3-acid ethyl esters)plus simvastatin|Omacor(omega-3-acid ethyl esters) - 4/g day (4 one gram capsules) simvastatin - 20 mg/day (1 tablet/20 mg)
1787467|NCT00487591|Drug|simvastatin plus placebo|simvastatin 20mg/day (1 tablet 20 mg)plus 4 capsules matching placebo
1787468|NCT00487617|Procedure|Fruit juice or placebo absorption|absorption of 300 ml of fruit juice ; 24 hours later, absorption of 300 ml of placebo.
1787469|NCT00487630|Drug|recombinant alpha-galactosidase A|
1787470|NCT00487643|Procedure|Tear Collection|The tear sample will be collected from the left eye of each subject. Subjects wearing contact lenses will be instructed to remove their lenses and wait at least 5 minutes before proceeding with the tear collection procedure. The patient will then be instructed to sit with eyes gently closed for two minutes after instilling one (1) drop of 0.5% proparacaine on the cornea and conjunctiva. Tear collection was accomplished by using a polyester fiber rod wick. This wick will be placed in contact with the tear fluid at the lower cul-de-sac for a minimum time to obtain fluid without irritating the subject's eye approx. for 3 to 5 minutes.
1787471|NCT00487656|Drug|ART-123|6mg/ml ampule solution for injection @ .01mg/kg
1787472|NCT00487656|Drug|placebo|6 mg/ml ampule solution for injection at .01mg/kg
1787473|NCT00487669|Drug|paclitaxel poliglumex, pemetrexed|The first 6 eligible patients will be enrolled at a dose of 135 mg/m2 paclitaxel poliglumex in combination with 500 mg/m2 of pemetrexed. Patients who experience disease progression without dose-limiting adverse events after the initial cycle will be replaced. Dose escalation to the next dose level can occur provided that no more than 1 of 6 patients experience in initial dose limiting toxicity (IDLT) following 2 cycles of therapy. If ≥ 2 of 6 patients experience IDLTs at the 135 mg/m2 dose, the maximally tolerated dose (MTD) was surpassed and the study will be discontinued
1787474|NCT00487682|Drug|ASP2151|oral
1787475|NCT00487682|Drug|Valacyclovir hydrochloride|oral
1787476|NCT00487695|Device|confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy is done by performing standard endoscopy, then using a microscope on the tip of the endoscope to obtain microscopic images of the mucosa. This is done by gently placing the tip of the endoscope on the lining of the esophagus.
1787477|NCT00487695|Device|standard endoscopy (EGD)|Standard upper endoscopy (EGD) is performed using a regular upper endoscope, which is used to look at the lining of the esophagus.
1787478|NCT00487708|Drug|canakinumab|
1787479|NCT00487721|Drug|Silibin-Phytosome|Subjects will take Silibin-Phytosome for 2-10 weeks. The dose of Silibin-Phytosome is 13 grams daily, in three divided doses. Patients will be asked to mix 1 level teaspoon and 1 heaping ¼ teaspoon of Silybin-Phytosome powder into 6 tablespoons of applesauce for each dose.
1787480|NCT00487734|Radiation|Testosterone gel|testosterone gel, applied daily. Dosed to achieve testosterone level <500 ng/dL. Possible doses include 2.5g, 5g, 7.5g or 10g gel packets.
1787481|NCT00487734|Drug|Placebo for testosterone gel|Placebo gel, 2.5g for each gel packet
1787482|NCT00487747|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly for 48 weeks
1787483|NCT00487773|Drug|budesonide|budesonide
1787484|NCT00487773|Drug|D3 vitamin|D3 vitamin
1787485|NCT00487773|Drug|montelukast sodium|montelukast sodium
1787486|NCT00487773|Drug|salbutamol|salbutamol
1787487|NCT00487786|Drug|OGX-427|OGX-427 injection at 200mg, 400mg, 600mg, 800mg or 1000mg once a week until withdrawn
1787488|NCT00487786|Drug|Docetaxel|injection - 75 mg/M2 IV on Day 1 every 21 days for cohorts 6 & 7 only, together with appropriate dose of OGX-427 until withdrawn from study
1787489|NCT00487799|Drug|Ularitide|
1787490|NCT00487812|Procedure|Low-dose dobutamine Tc-99-m-mibi gated SPECT imaging|All patients will be evaluated by ce-MRI during the initial hospital stay (5th - 6th day)
1787491|NCT00487825|Drug|Canakinumab (investigational)|Canakinumab was supplied in 6 mL colorless glass vials each containing nominally 150 mg canakinumab (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
1787492|NCT00487825|Drug|Placebo|Matching placebo was supplied in form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
1787493|NCT00487825|Drug|Methotrexate (MTX)|Methotrexate (MTX) was supplied in tablet form, each of 2.5 mg strength.
1787494|NCT00487851|Procedure|surgery|hepaticojejunostomy and gastroenterostomy
1787495|NCT00487851|Procedure|endoscopic strategy|Stent insertion
1787496|NCT00487877|Device|SenseWear Pro3 Armband|
1787497|NCT00487877|Device|i-button DS2191 H|
1787498|NCT00487903|Drug|PB127 for Injectable Suspension|0.062 mg/kg continuous IV (100-250 mL/hr) during echocardiogram, single dose, infusion not to exceed 60 minutes.
1787499|NCT00487916|Drug|AMA1-C1/ISA 720|
1787500|NCT00487929|Device|nasal CPAP|Nocturnal
1787501|NCT00487929|Device|Sham CPAP|Nocturnal
1787502|NCT00487942|Drug|armodafinil|50 mg/day armodafinil
1787503|NCT00487942|Drug|armodafinil|100 mg/day armodafinil
1787504|NCT00487942|Drug|armodafinil|200 mg/day armodafinil
1787505|NCT00487942|Drug|placebo|placebo
1787506|NCT00487955|Procedure|Resting Energy Expenditure examination|
1787507|NCT00487968|Drug|eltrombopag|
1787508|NCT00487981|Device|Precision Spinal Cord Stimulation|Stimulation on throughout the study once device is implanted
1787509|NCT00487994|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin placebo-matching capsules, orally, once daily for up to 96 weeks.
1787510|NCT00487994|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
1787511|NCT00487994|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and Atorvastatin 10 mg, capsules, orally, once daily for up to 96 weeks.
1787512|NCT00488007|Device|Hearing aids used : PHONAK Savia and Valeo|5 hours per day during the first 6 months (active or inactive upon randomization) 5 hours per day during the last 6 months (active)
1787514|NCT00488033|Procedure|CT Angiography|If results indicate blockage, patients will receive interventional assessment (i.e., angiography) and treatment if indicated. All patients will receive aggressive treatment for type II diabetes (hemoglobin A1C) and lipids.
1787515|NCT00488046|Biological|H5N1 (6-2) AA ca Recombinant (A/Hong Kong/213/2003 x A/AnnArbor/6/60 ca)|Intranasal vaccine
1787518|NCT00488059|Drug|Integrase inhibitor|As prescribed
1787519|NCT00488059|Drug|enfuvirtide [Fuzeon]|180 mg SC once daily
1787520|NCT00488072|Drug|Mirtazapine|15 mg by mouth (PO) daily x 15 days; Day 22-29, increased to 30 mg PO daily.
1787521|NCT00488072|Drug|Placebo|One placebo tablet by mouth daily.
1787522|NCT00488098|Drug|GSK372475|
1787523|NCT00488111|Other|Ringer's Lactate|Ringer's Lactate was used 15min before operation
1787524|NCT00488111|Other|6% Starch|6% Starch was used 15min before operation
1787525|NCT00488124|Drug|somatropin (Genotropin® treatment)|0,035 mg /kg bodyweight of Somatropin per day given by subcutaneous injections through an injection device (GenotropinPEN)
1787526|NCT00488137|Drug|Prucalopride|2 mg o.d.
1787527|NCT00488137|Other|Placebo|o.d.
1787528|NCT00488137|Drug|Prucalopride|4 mg o.d.
1787529|NCT00488163|Drug|Atomoxetine|Dose escalation from 40 mg to 50 mg of Atomoxetine active treatment.
1787530|NCT00488176|Drug|montelukast|montelukast sodium
1787531|NCT00488176|Drug|cetirizine|cetirizine
1787532|NCT00488176|Drug|montelukast and cetirizine|montelukast and cetirizine
1787533|NCT00488176|Drug|placebo|placebo
1787534|NCT00488189|Drug|Tazocin (pipercillin/tazobactam)|over 50% third generation cephalosporin should be replaced by Pip/Taz
1787535|NCT00488215|Drug|prucalopride|The dose will be consecutively escalated in 2 mg steps per day, starting from 2 mg up to 20 mg once daily or until severe drug-related adverse events occur (= individual maximum tolerable dose, on decision of the subject and/or investigator).
1787536|NCT00488215|Other|Placebo|During the placebo session, the number of placebo tablets will be consecutively escalated in an identical way as described for prucalopride. This means 1 tablet more every day, up to 10 tablets.
1787537|NCT00488228|Behavioral|self-regulation|The current study involves a behavioral weight loss intervention tailored specifically to young adults. All participants receive calorie and activity prescriptions as well as training in behavior modification. In addition, one group receives training in self-regulation techniques using daily weighing.
1787538|NCT00488241|Device|Zarzenda|Topically applied daily for 2 weeks
1787539|NCT00488267|Drug|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Transdermal patch applied to the knee for 12 hours daily.
1787540|NCT00488267|Drug|Placebo Matrix/CHADD Patch|Transdermal patch applied to the knee for 12 hours daily.
1787541|NCT00488267|Drug|Ketoprofen matrix/placebo CHADD Patch|Transdermal knee applied to the knee for 12 hours daily.
1787542|NCT00488280|Behavioral|Locomotor Training|Task-specific practice of walking with assistance from trainers using body weight support and treadmill followed by training over ground, 5x/week, approximately 1.5 hours/day
1787543|NCT00488293|Procedure|Store and forward teledermatology|Standard electronic consult, standardized history, and image set
1787544|NCT00488306|Drug|tigecycline|
1787545|NCT00488319|Drug|Paliperidone ER|1.5 to 12 mg tablet once daily for 6 months
1787546|NCT00488332|Procedure|Optical Coherence Tomography|Before radiation treatment and once a week thereafter.
1787547|NCT00488332|Procedure|Fluorescence Spectroscopy|Before radiation treatment and once a week thereafter.
1787548|NCT00488332|Behavioral|Pain Scale Questionnaire|Administered before the examination, OCT, and FS and immediately afterward.
1787549|NCT00488345|Drug|Tygacil|
1787550|NCT00488371|Biological|Pneumococcal Conjugated Vaccine (Prevnar®)|
1787551|NCT00488384|Drug|Chemopreventive application (Acitretin)|Chemopreventive application (Acitretin)
1787552|NCT00488397|Other|In-vitro testing|This is an in-vitro study thus only one group in the study and there is no intervention treatment nor procedure involved in this study.
1787553|NCT00488410|Device|Doppler echocardiography|
1787554|NCT00488423|Procedure|Mixed Meal Tolerance test, Hyperglycemic clamp|Subjects undergo a standard mixed meal tolerance test & hyperglycemic clamp to assess insulin secretion & sensitivity (whole body glucose disposal) pre-op. Following surgery, at 1week, 1 month, 6 months and 12 months subjects will undergo hyperglycemic clamp & mixed meal tolerance test. During these tests, measurements will include plasma levels of glucose, insulin, C-peptide, free fatty acid levels and adipocyte hormone profile (adiponectin, leptin, resistin). A gut hormone profile (ghrelin, glucagons-like-peptide 1 GLP-1, glucose-dependent insulinotropic polypeptide GIP, PYY) will be performed at fasting & specific postprandial times. Results will be compared between two groups: patients undergoing laparoscopic Roux-en-Y gastric bypass & gastric banding.
1787555|NCT00488436|Drug|Antithymocyte globulin|
1787556|NCT00488436|Drug|Cyclosporine|
1787557|NCT00488449|Drug|GSK256073A tablets|
1787558|NCT00488462|Device|non-pneumatic anti-shock garment|In the intervention arm, half of the study clinics will use the NASG when a patient meets the study criteria.
1787559|NCT00488475|Drug|etanercept|The patients will be treated in accordance with the requirements of the labelling of Enbrel® in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
1787560|NCT00488488|Drug|tigecycline|The patients will be treated in accordance with the requirements of the labeling of tigecycline in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
1787561|NCT00488514|Drug|Combination Tablet of Treximet (sumatriptan/naproxen sodium)|Combination Tablet of Treximet(sumatriptan/naproxen sodium)
1787562|NCT00488527|Drug|Insulin glargine|Patients will begin with a fixed, subcutaneous dose of insulin glargine, (10 U), in its commercial presentation, which will be adjusted week by week, according to the values of the glycemia when fasting (FBG), adding 2, 4, 6 or 8 units of insulin glargine over the following twelve weeks, during which the therapeutic objective should be attained, namely the glucose goal during fasting of 100 mg/dl (<6.0 mmol/L), and the active treatment is to be continued for three more months.
1787563|NCT00488540|Drug|Paracetamol|Suppository
1787564|NCT00488540|Drug|Placebos|Suppository
1787565|NCT00488553|Behavioral|Questionnaire|Questions about cancer risk factors, medical history, and family history of cancer.
1787643|NCT00489086|Drug|tazarotene|Tazarotene is a member of the acetylenic class of retinoids.
1787569|NCT00488579|Drug|Two policies of iron prophylaxis|Routine: 60mg ferrous sulphate daily (+folic acid); Screening and therapy: Hb measurement on each visit, Hb>9g/dl only folic acid, Hb<9g/dl 60-120 of ferrous sulphate daily (+folic acid).
1787570|NCT00488592|Biological|WT1:126-134|"Subjects were given 6 doses of PR1:169-177 in Montanide adjuvant and 6 doses of WT1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals."
1787571|NCT00488592|Biological|PR1:169-177 Peptide|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
1787572|NCT00488592|Drug|GM-CSF (Sargramostim)|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
1787573|NCT00488592|Biological|Montanide adjuvant|Subjects were given 6 doses of PR1:169-177 in montanide adjuvant and 6 doses of WT-1:126-134 in Montanide adjuvant at 2 weekly intervals. The peptides were injected in the deep subcutaneous tissue of the anterior abdominal wall, the thighs or the upper arms near the deltoid region. The sites of injection were rotated every 2 weeks. GM-CSF (Sargramostim) was co administered with each vaccine dose. Subjects with immunological response to one or both peptide vaccines had the option of receiving a maximum of 6 additional boosters of the WT-1:126-134 and PR1:169-177 peptide vaccines at 3 monthly intervals.
1787574|NCT00488605|Drug|Prednisone, Vinblastin, 6-mercaptopuroine|Initial Therapy:Prednisone- by mouth 3 times/day daily as a 4-week course, then gradually decreased over 2 more weeks. Vinblastine-IV (into a vein)1 day/week for 6 weeks. Patients w/o evidence of active disease at this time will proceed to continuation therapy. If disease is improved or unchanged, pts. will receive additional therapy with: Prednisone- 3 divided doses by mouth for 3 days every week, from week 7-12. Vinblastine- IV 1day/week for 6 more weeks. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP:by mouth daily until the end of month 12. Prednisone in 3 doses daily day 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12.
1787575|NCT00488605|Drug|Leucovorin, Methotrexate, Vinblastine, Prednisone|Initial Therapy:Prednisone-by mouth 3x/day daily as a 4-week course then gradually decreased over 2 more weeks. Vinblastine- IV 1 day/week for 6 weeks. Methotrexate-a 24 hour IV infusion day 1 of weeks 1, 3, and 5, followed by leucovorin.The drug will be given by mouth. Pts w/o evidence of active disease at this time will proceed to continuation therapy. Pts whose disease is improved or unchanged will receive additional therapy w/:Prednisone- 3 divided doses, days 1-3 weekly from week 7-12. Vinblastine IV 1day/week for 6 more weeks. Methotrexate-a 24 hour IV infusion day 1 of week 7, 9, and 11, followed by leucovorin. If the disease is gone or better after this additional therapy continuation will begin. Continuation Therapy: 6-MP by mouth daily until the end of month 12. Prednisone- 3 doses daily days 1-5 every 3 weeks until the end of month 12. Vinblastine IV day 1 every 3 weeks until the end of month 12. Methotrexate by mouth once weekly until the end of month 12.
1787576|NCT00488618|Drug|Cariprazine (RGH-188)|Cariprazine 3 mg - 12 mg oral administration, once per day.
1787577|NCT00488618|Drug|Placebo|Dose-matched placebo oral administration, once per day.
1787578|NCT00488631|Biological|Placebo|Participants receive placebo subcutaneous injection matching to golimumab administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
1787579|NCT00488631|Biological|Golimumab 50 mg|Participants receive golimumab 50 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631).
1787580|NCT00488631|Biological|Golimumab 100 mg|Participants receive golimumab 100 mg subcutaneous injection administered every 4 weeks through Week 52 in the maintenance study C0524T18 (NCT00488631) initially or after dose adjustment following loss of clinical response.
1787581|NCT00488631|Biological|Golimumab 200 mg|Participants receiving golimumab 100 mg initially who on loss of clinical response receive golimumab 200 mg administered every 4 weeks through Week 52.
1787582|NCT00488644|Drug|Levothyroxine|75 mcg by mouth (PO) Daily for 8 Weeks
1787583|NCT00488644|Drug|Liothyronine|15 mcg PO Daily for 8 Weeks
1787584|NCT00488657|Device|SpeechEasy Model ITC|The delayed auditory feedback ranging from 50 to 220 ms, and the altered frequency feedback ranging from 500 to 2,000 Hz.
1787585|NCT00488670|Drug|Escitalopram|See Detailed Description.
1787591|NCT00488696|Device|Endovascular Bifurcated Stent-Graft|Treatment of Aneurysm involving the proximal aortic arch with endovascular bifurcated stent-graft.
1787592|NCT00488709|Drug|Topotecan|
1787593|NCT00488709|Drug|Fludarabine|
1787594|NCT00488709|Drug|Cytarabine|
1787595|NCT00488722|Drug|Zoladex|
1787596|NCT00488735|Behavioral|Cognitive-behavioral rehabilitation|
1787597|NCT00488735|Behavioral|Traditional primary care|
1787598|NCT00488748|Device|Thymatron|Right unilateral placement, 6x seizure threshold, 3 times per week until clinically appropriate to stop (approximately 2-6 weeks)
1787599|NCT00488748|Device|Magstim Theta|100% power, vertex placement, 3 times per week, until clinically appropriate to stop (approximately 2-6 weeks)
1787600|NCT00488761|Drug|Tigecycline|
1957229|NCT02483247|Drug|BBI503|Patients in this trial will receive BBI503 orally, daily, and continuously. The dose-level of BBI503 will be assigned according to the dose-cohort open at the time the patient enrolls into a given arm. The study-arm and combination anti-cancer agent for a given patient will be determined by the investigator. BBI503 Dose Level 1: 200 mg once daily, Dose Level 2: 300 mg once daily.
1787605|NCT00488787|Drug|intranasal ketamine|low dose
1787606|NCT00488787|Drug|intranasal ketamine|medium dose
1787607|NCT00488787|Drug|intranasal ketamine|high dose
1787608|NCT00488787|Drug|placebo|placebo
1787609|NCT00488800|Biological|pneumococcal conjugate vaccine|
1787610|NCT00488813|Drug|Third generation cephalosporins|
1787611|NCT00488826|Biological|7-valent pneumococcal conjugate vaccine|
1787612|NCT00488826|Biological|Diptheria and tetanus toxoids and accelular pertussis vaccine (DTaP)|
1787613|NCT00488839|Drug|IPX056 20 mg|IPX056 Extended Release capsule containing 20 mg baclofen
1787614|NCT00488839|Drug|IPX056 40 mg|IPX056 Extended Release capsule containing 40 mg baclofen
1787615|NCT00488839|Drug|Encapsulated Baclofen 20 mg|Baclofen 20mg tablet was encapsulated for blinding.
1787616|NCT00488839|Drug|Placebo Baclofen Tablet|Placebo capsule encapsulated placebo Baclofen tablet
1787617|NCT00488839|Drug|IPX056 10 mg|IPX056 Extended Release capsule containing 10 mg baclofen
1787618|NCT00488839|Drug|IPX056 30 mg|IPX056 Extended Release capsule containing 30 mg baclofen
1787619|NCT00488839|Drug|IPX056 35 mg|IPX056 Extended Release capsule containing 35 mg baclofen
1787620|NCT00488839|Drug|Placebo IPX056 20 mg|Placebo capsule for IPX056 20 mg
1787621|NCT00488839|Drug|Placebo IPX056 40 mg|Placebo capsule for IPX056 40 mg
1787622|NCT00488865|Device|Intravascular Filter Device|Vena cava filter which is implanted into the inferior vena cava of patients to prevent recurrent pulmonary embolism. The filter can be utilized as a permanent or retrievable device.
1787623|NCT00488878|Behavioral|Data Collection|Data collection from ovarian cancer patients seen at M.D. Anderson since January, 1950.
1787624|NCT00488891|Drug|Paliperidone ER|Route = oral. Paliperidone ER will be prescribed to the patients at the investigator's discretion. Patient receive their medication according to usual care in their treatment setting ie, no study drug is provided
1787625|NCT00488891|Drug|Atypical antipsychotics (AAP)|Route = oral. AAP including quetiapine, risperidone, olanzapine, ziprasidone or aripiprazole. Dosage and administration of antipsychotics will be prescribed at the investigator's discretion
1787626|NCT00488904|Dietary Supplement|supportan|2 sip feed pr. day
1787627|NCT00488904|Dietary Supplement|supportan placebo|2 sip feed pr. day
1787628|NCT00488930|Other|Observational|data collection ONLY
1787629|NCT00488943|Device|AAA Endovascular Bifurcated Stent-Graft|Treatment of Abdominal Aortic Aneurysm with a Zenith Endovascular Bifurcated Stent-Graft.
1787630|NCT00488969|Drug|Modified-release morphine|During the first three weeks of each treatment (drug or placebo), the dose will be escalated toward a maximally tolerated dose or a dose sufficient to eliminate pain (up to a ceiling dose of 120 mg), whichever is reached first. During the entire fourth and fifth week of each period, subjects will receive their maximally tolerated dose of study medication. During the sixth and seventh weeks, they will undergo a seven-day dose tapering and a seven-day complete washout of the study drug.
1787631|NCT00488969|Drug|Placebo|
1787632|NCT00488982|Drug|Docetaxel|Docetaxel 75mg/m2 every 21 days
1787633|NCT00488982|Drug|Docetaxel and GM-CSF|Docetaxel 75mg/m2 every 21 days and GM-CSF 250mcg/m2 SQ days 15-28
1787634|NCT00488995|Drug|CP-675,206|
1787635|NCT00489008|Procedure|Stereotactic Body Radiation Therapy (SBRT)|"Cohorts 1 & 2: 50 gray (GY) with 12.5 GY per Fraction for 4 treatments
Cohort 3: 40 GY with 10 GY per Fraction for 4 treatments"
1787636|NCT00489021|Procedure|sub-acute hospitalization|
1787637|NCT00489034|Behavioral|Quantitative Interview|Index participants will be interviewed every six months (with phone interviews focused on service utilization at each six month interval midpoint) for 18 months while network members will be interviewed at baseline and one year. Interviews will consist of in-depth face-to-face and audio computer-assisted interviews (ACASIs) and a structured diagnostic interview to assess engagement in care (number of clinical visits attended), substance use, attitudes about substance use, friend's substance use, sexual risk behaviors, PTSD (for index participants only), support of index participants care use (network participants only), attitudes about healthcare (network participants only), index participant's adherence (network participants only), own functioning (network participants only), and family functioning (network participants only). At Baseline only, a urine sample will be collected from index participants for drug testing to assess the agreement between urine and ACASI.
1787638|NCT00489034|Behavioral|Ethnographic Interview|Qualitative interviews will be conducted with a small sub-sample of index and identified network participants from each site at least monthly for a period of 18 months. Interviews will be ethnographic in nature and will rely on participants' life stories and narratives of social experience to supply their content and guide their progression.
1787639|NCT00489034|Behavioral|Gender Interview|Qualitative interviews will be conducted with a sub-sample of index participants. These interviews will focus on issues of gender related vulnerabilities and will be used to develop a survey.
1787640|NCT00489060|Procedure|Cryoablation and External Beam Radiation|
1787641|NCT00489073|Drug|duloxetine|
1787642|NCT00489073|Drug|placebo|
1787644|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot A|
1787645|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot B|
1787646|NCT00489099|Biological|V232 Modified Process Hepatitis B Vaccine: Lot C|
1787647|NCT00489099|Biological|V232 Current Process Hepatitis B Vaccine|
1787648|NCT00489112|Drug|Alfuzocine XL 10 mg once a day|
1787650|NCT00489138|Drug|Ertapenem|1g a day by drip of 30 min
1787651|NCT00489151|Drug|adefovir dipivoxil|
1787652|NCT00489151|Drug|lamivudine|
1787653|NCT00489164|Device|Sirolimus-Eluting BX Velocity Balloon-Expandable Stent|
1787654|NCT00489177|Device|A|QuickOpt intra-cardiac electrogram optimization
1787655|NCT00489177|Device|B|Single optimization in initial month post-implant
1787656|NCT00489190|Drug|Insulin Glulisine|
1787657|NCT00489203|Drug|beclomethasone dipropionate|Given orally
1787658|NCT00489203|Drug|placebo|Given orally
1787659|NCT00489203|Drug|tacrolimus|Given after transplant
1787660|NCT00489203|Drug|methotrexate|Given after transplant
1787661|NCT00489203|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo stem cell transplant
1787662|NCT00489216|Biological|efalizumab|"Efalizumab will be administered as a subcutaneous injection once a week for 8 weeks (total of 8 doses). First efalizumab injection will be dosed at 0.7mg/kg. Subsequent weekly injections given on days 8-50 will be dosed at
1mg/kg"
1787663|NCT00489229|Drug|Rosiglitazone|
1787664|NCT00489229|Drug|Ramipril|
1787665|NCT00489242|Procedure|Procedure / Percutaneous angioplasty|
1787666|NCT00489255|Drug|Tigan®|Oral capsule, 300mg three times daily
1787667|NCT00489255|Drug|Placebo|Oral capsule, three times daily
1787668|NCT00489268|Device|HALO Ablation System|"Phase I: 1-2 ablation visits; Phase II 1 to 12 months: 1-2 ablation visits; Phase II 12 to 30 months: 1-3 ablation visits Phase II 55-60 months: 0-1 ablation visit
******Phase I was a dosimetry study and Phase II used the preferred dose. The same intervention was used for each dose."
1787669|NCT00489281|Drug|cyclophosphamide|Cyclophosphamide (CTX) 14.5 mg/kg intravenously for 2 days before and after transplant.
1787670|NCT00489281|Drug|fludarabine phosphate|Fludarabine 30 mg/M2 intravenously for 5 days before bone marrow transplant
1787671|NCT00489281|Drug|mycophenolate mofetil|Mycophenolate mofetil 15 mg/kg by mouth three times a day daily for 30 days beginning 5 days after bone marrow transplant.
1787672|NCT00489281|Drug|Sirolimus|The first dose of Sirolimus is 6 mg and is taken by mouth 5 days after bone marrow transplant. On the 6th day after bone marrow transplant, the dose of Sirolimus is 2 mg by mouth daily for 1 year.
1787673|NCT00489281|Procedure|Allogeneic bone marrow transplantation|An allogeneic bone marrow transplant is a procedure that involves taking bone marrow from a donor and giving it to a recipient.
1787674|NCT00489281|Radiation|total-body irradiation|Radiation of the total body will be administered the day before bone marrow transplant.
1787675|NCT00489281|Drug|Levetiracetam|Levetiracetam 500 mg orally twice a day 6 days before transplant and for 1 year after transplant. Levetiracetam prevents seizures.
1787676|NCT00489294|Drug|Syntropin|
1787677|NCT00489307|Drug|Dexamethasone|4 mg PO (by mouth) twice daily x 14 days
1787678|NCT00489307|Drug|Placebo|Placebo PO twice daily x 14 days
1787679|NCT00489320|Device|Cypher Stent|
1787680|NCT00489333|Drug|ProAlgaZyme|
1787681|NCT00489346|Drug|MK0476, montelukast sodium / Duration of Treatment: 1 Year|
1787682|NCT00489346|Drug|Comparator : fluticasone propionate / Duration of Treatment: 1 Year|
1787683|NCT00489359|Drug|Pemetrexed - Phase 1|500, 600, 700, 800, or 900 milligrams per square meter (mg/m^2), administered intravenously (IV), every 21 days x 6 cycles, dose escalate to Maximum Tolerated Dose (MTD)
1787684|NCT00489359|Drug|Carboplatin - Phase 1|area under the concentration time curve (AUC) 5 or 6 mg/mL*min, administered intravenously (IV), every 21 days x 6 cycles, dose escalation to Maximum Tolerated Dose (MTD)
1787685|NCT00489359|Drug|Pemetrexed - Phase 2|Dose determined from Phase 1: 500 mg/m^2, administered IV, every 21 days x 6 cycles
1787686|NCT00489359|Drug|Carboplatin - Phase 2|Dose determined from Phase 1: AUC 6 mg/mL*min, administered IV, every 21 days x 6 cycles
1787687|NCT00489372|Drug|Se-methyl-seleno-L-cysteine|Given orally
1787688|NCT00489372|Other|placebo|Given orally
1787689|NCT00489372|Other|pharmacological study|Correlative studies
1787690|NCT00489372|Other|laboratory biomarker analysis|Correlative studies
1787691|NCT00489385|Drug|Albinterferon|
1787692|NCT00489385|Drug|Ribavirin|
1787693|NCT00489385|Drug|Albuferon|
1787694|NCT00489398|Drug|epinastine HCL and olopatadine HCL|
1787695|NCT00489411|Drug|duloxetine hydrochloride|Given orally
1787696|NCT00489411|Other|placebo|Given orally
1787697|NCT00489424|Drug|Placebo|
1787698|NCT00489424|Drug|Acetaminophen|
1787699|NCT00489424|Drug|Fluvastatin|
1957230|NCT02483247|Drug|Capecitabine|Capecitabine 1000 mg/m^2 body surface area is administered orally, twice daily, on days 1-14 of each 21 day cycle.
1787702|NCT00495495|Device|Ozone treatment|Ozone treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three, Six and Nine-Month visits.
1787703|NCT00495495|Device|Placebo treatment|Placebo treatment applied to randomly selected tooth for a period of 60 seconds at Baseline, Three-, Six- and Nine-Month visits.
1787704|NCT00495508|Drug|Quinine|
1787705|NCT00495508|Drug|artemether / lumefantrine|
1787706|NCT00495521|Drug|4-Aminosalicylic acid extended release granules|Granules for oral administration will be administered as a volume equivalent to 50 mg/kg of 4-aminosalicylic acid three times daily for 2 weeks followed by 2 times daily for 2 weeks in the active arm or a comparable volume in the placebo arm
1787707|NCT00495547|Drug|Azacitidine|Azacitidine
1787708|NCT00495547|Drug|Beta Erythropoietin|Beta Erythropoietin
1787709|NCT00495560|Drug|Addition of misoprostol 25 mcg 12 hours before induction|Misoprostol given buccally the night before induction
1787710|NCT00495573|Drug|acyclovir|400 mg acyclovir, orally three times a day for 5 days
1787711|NCT00495586|Drug|Placebo|One pill to be taken every eight hours for 8 days
1787712|NCT00495586|Drug|Amoxicillin and clavulanic acid|500-125 mg to be taken every eight hours for 8 days
1787713|NCT00495599|Procedure|Cytokines assessed from fat tissue|Cytokines assessed from fat tissue
1787714|NCT00495612|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
1787715|NCT00495612|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
1787716|NCT00495625|Drug|Sunitinib Malate|Once daily oral doses on days 1-28 of each 42-day cycle. The dose for the first 2 cycles will be 37.5 mg daily for 28 days, every 42 days. Dose may be escalated to 50 mg daily for 28 days at the treating investigator's discretion.
1787717|NCT00495651|Drug|Antiretroviral medications|Antiretroviral medications initiation at any time during the trial if at least one WHO-recommended criterion for starting ART is observed.
1787718|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|"Antiretroviral initiation at any time during the trial if at least one 2009 WHO-recommended criterion for starting ART is observed.
Isoniazid prophylaxis:300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
1787719|NCT00495651|Drug|Antiretroviral medications|Early ART initiation on the day of inclusion, before reaching the current WHO criteria
1787720|NCT00495651|Drug|Antiretroviral medications+Isoniazid prophylaxis|"Early Antiretroviral medications initiation on the day of inclusion, before reaching the current WHO criteria
Isoniazid prophylaxis: 300 mg of INH once a day before breakfast for six months, starting one month after study inclusion"
1787721|NCT00495664|Device|Titan stent and Taxus-Liberte stent|
1787722|NCT00495677|Drug|PF-00232798|Solution, 20 mg. once daily, 10 days
1787723|NCT00495677|Drug|PF-00232798|Solution, 150 mg. once daily, 10 days
1787724|NCT00495677|Drug|PF-00232798|Solution, 5 mg. once daily, 10 days
1787725|NCT00495677|Drug|PF-00232798|Solution, 40 mg. once daily, 10 days
1787726|NCT00495677|Drug|PF-00232798|Solution, 300 mg. once daily, 10 days
1787727|NCT00495677|Drug|PF-00232798|Solution, 400 mg. once daily, 10 days
1787728|NCT00495690|Drug|Oral zinc gluconate (5 mg elemental)|Each infant in the study received placebo or 5 mg of elemental zinc (1 RDA) as zinc acetate syrup once daily from 4 weeks of age till 6 months of age.
1787729|NCT00495703|Behavioral|Exercise|6-months of regular aerobic exercise
1787730|NCT00495703|Behavioral|Usual Care|6-months of behavioral strategies to aid memory/cognition
1787731|NCT00495716|Drug|acyclovir|800 mg acyclovir orally 3 times daily for 2 days at the start of a genital herpes recurrence
1787732|NCT00495716|Drug|acyclovir|400 mg acyclovir orally twice daily for 1 year
1787733|NCT00495729|Drug|SB-649868|Subjects will receive SB-649868 5 mg, 25 mg tablets orally 1 hour prior to simvastatin administration.
1787734|NCT00495729|Drug|Placebo|Subjects will receive matching placebo tablets to SB-649868 orally 1 hour prior to simvastatin administration.
1787735|NCT00495729|Drug|Simvastatin|Subjects will receive Simvastatin 10 mg tablets orally.
1787736|NCT00495755|Drug|Alemtuzumab (Campath)|An escalating dose given over 4 weeks
1787737|NCT00495768|Behavioral|Group Training|Participants will be trained in techniques that are useful to cope with possible side effects of treatment, such as: keeping a journal (expressive writing), breathing exercises, cognitive behavioral therapy, mindfulness meditation, and exercise.
1787738|NCT00495781|Procedure|%-hypo (laboratory parameter, functional iron deficiency)|
1787739|NCT00495781|Procedure|CHr (laboratory parameter, functional iron deficiency)|
1787740|NCT00495781|Procedure|RET-HE (laboratory parameter, functional iron deficiency)|
1787741|NCT00495794|Behavioral|Clinical pharmacist-based intervention|Pharmacist proactive outreach to patients systematically identified as having adherence or intensification problems; their use of tailored adherence counseling strategies; and their authorization to titrate medications according to prespecified algorithms
1787742|NCT00495807|Behavioral|No Words|Without any words was given during pain management
1787743|NCT00495807|Behavioral|Positive words|Positive words was given to PCA pain management patients at different time point,i.e. 3h, 6h, 12h and 18h.
1787744|NCT00495807|Behavioral|Partially Negative Words|Partially negative words was given during PCA pain management at different time point,i.e. 3h, 6h, 12h and 18h.
1787745|NCT00495807|Behavioral|Totally Negative Words|Totally negative words was given during PCA pain management at different time points, i.e. 3h, 6h, 12h and 18h
1787746|NCT00496002|Drug|Clevudine|
1787747|NCT00496002|Drug|Adefovir|
1957231|NCT02483247|Drug|Doxorubicin|Doxorubicin 60 mg/m^2 body surface area is administered intravenously once every three weeks (21-days).
1957232|NCT02483247|Drug|Nivolumab|Nivolumab 3 mg/kg is administered as an intravenous infusion over 60 minutes on day 1 and day 15 of each 28 day cycle.
1957233|NCT02483247|Drug|Pembrolizumab|Pembrolizumab 2 mg/kg is administered as an intravenous infusion over 30 minutes once every three weeks (21-days).
1957234|NCT02483247|Drug|Paclitaxel|Paclitaxel 80 mg/m^2 body surface area is administered intravenously once weekly on day 1, day 8, and day 15 of each 28 day cycle.
1787752|NCT00496028|Drug|AZD0530|oral tablet
1787753|NCT00496028|Drug|Carboplatin|intravenous infusion
1787754|NCT00496028|Drug|Paclitaxel|intravenous infusion
1787755|NCT00496041|Procedure|Registry|A Registry will be used.
1787756|NCT00496054|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|Pentavalent vaccine 9G1, G2, G3, G4 & P1) given 3 times. Dose 1 will be administered at study entry; Dose 2 will be administered 4 to 10 weeks (28 to 70 days) after Dose 1; and Dose 3 will be administered 4 to 10 weeks (28 to 70 days) after Dose 2.
1787757|NCT00496067|Device|Doppler-Guided Uterine Artery Occlusion Device|For bilateral occlusion of the uterine arteries
1787758|NCT00496080|Device|Doppler-Guided Uterine Artery Occlusion Device (DUAO)|Investigational transvaginal clamp inserted one time for 6 hours.
1787759|NCT00496093|Biological|Pneumococcal Vaccine, Polyvalent (23-valent)|
1787760|NCT00496106|Behavioral|Telephone counseling|6 telephone counseling sessions
1787761|NCT00496106|Behavioral|Telephone interview|telephone interview
1787764|NCT00496132|Drug|PRO131921|Escalating doses by IV infusion
1787765|NCT00496145|Behavioral|Spanish Diabetes Self-Management Program|small-group self management education program
1787766|NCT00496158|Drug|Clevudine|
1787767|NCT00496158|Drug|Adefovir|
1787768|NCT00496184|Drug|Nifedipine cream topical application|
1787769|NCT00496197|Drug|Eraxis (anidulafungin)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
1787770|NCT00496197|Drug|Diflucan (fluconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis.
1787771|NCT00496197|Drug|Vfend (voriconazole)|Subjects will receive IV anidulafungin (200 mg loading dose followed by 100 mg maintenance doses QD) for 5-28 days. This will be followed by oral therapy with fluconazole at 400 mg once daily or voriconazole at 200 mg twice daily until 14 days after the last positive culture. Fluconazole will be used if the baseline cultures are positive for C. albicans or C. parapsilosis while voriconazole will be used if cultures are positive for C. glabrata or other non-albicans species.
1787772|NCT00496223|Drug|Sunitinib|Sunitinib will be given PO once daily on days 1-14 of each 21 day cycle. The exact dose of sunitinib will be determined during the Phase I part of the trial.
1787773|NCT00496223|Drug|Dacarbazine|Dacarbazine will be given at 1000 mg/m2 on day 1 of every 21 day cycle.
1787774|NCT00496236|Drug|TNFerade biologic|
1787775|NCT00496262|Biological|Human Fibrinogen Concentrate|Single intravenous infusion of 70 mg/kg body weight
1787776|NCT00496275|Drug|Zactima (ZD6474)|
1787777|NCT00496275|Drug|Vinorelbine plus cisplatin|
1787778|NCT00496275|Drug|Gemcitabine plus cisplatin|
1787779|NCT00496288|Radiation|Prophylactic radiation to the contralateral breast|The contralateral breast will be treated with 2 tangent fields, using 1.8-2 Gy/fx to a total dose of 50-50.4 Gy. The whole breast will be treated according to traditional guidelines and as described in the RTOG/NSABP B39 study. The heart should be maximally blocked for left sided breasts, included lung tissue should be reduced to minimum. No overlapping field is allowed on the skin between the two breast fields in the midline. Maximal dose should not exceed 110%
1787780|NCT00496301|Drug|Gemcitabine, Capecitabine and Sorafenib (6 cycles)|Gemcitabine: 1000 mg/m2 i.v. days 1 and 8. Capecitabine: 650 mg/m2 i.v. day 1 to 14. (change to 500mg/m2 after amendment nº2 (dated on 10/10/2007) Sorafenib:400 mg/12h v.o. day 1 to 21
1787781|NCT00496314|Device|e2TM Cervical Cell Collector|
1787782|NCT00496327|Biological|Varicella Virus Vaccine Live (Oka-Merck)|VARIVAX(TM) (Refrigerated) [Varicella Virus Vaccine Live (Oka/Merck), Refrigerator-Stable Formulation.] Subjects enrolled in the study received one 0.5 mL subcutaneous dose of VARIVAX(TM). Frequency is single dose.
1787783|NCT00496340|Drug|Pentostatin|"Pre-conditioning therapy:
All participants will receive pentostatin 4 mg/m^2 on day -28. Patients may receive additional doses on days -21 & -14 depending on cell counts.
Participant will receive pentostatin at a dose of 4 mg/m^2 by intravenous infusion over 1-2 hours on days -4, -3."
1787784|NCT00496340|Drug|Busulfan|"Pre-conditioning therapy:
Intravenous Busulfan (1st dose) at a dose of 200mg/m^2 on day -4.
Intravenous Busulfan (2nd dose) will be administered on day (-2) to target a total AUC of 16,000 +/- 1600."
1787785|NCT00496340|Drug|Rituximab|"Pre-conditioning therapy:
Patients with CD20+ expressing malignancies will be treated with rituximab at a dose of 375 mg/m^2 according to prescribing and institutional guidelines."
1787786|NCT00496340|Procedure|Allogeneic Hematopoietic Cell Transplant|Hematopoietic progenitor cells to be infused at least 36 hours after last dose of Busulfan.
1787787|NCT00496353|Drug|MK2461|MK2461 treatment, bid, 28-day
1787788|NCT00496366|Drug|Capecitabine|The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
1787789|NCT00496366|Drug|Lapatinib|The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.
1787790|NCT00496379|Drug|ZK219477|Given intravenously over approximately 30 minutes once every 3 weeks
1787791|NCT00496392|Drug|Nasal fentanyl|Breakthrough pain in patients with breast or prostate cancer
1787792|NCT00496405|Drug|bevacizumab|
1787793|NCT00496418|Device|Mesh in permanent colostomy|
1787794|NCT00496431|Drug|histone deacetylase inhibitor (ITF2357)|50 mg b.i.d. (or every 8 hours or every 6 hours), every day
1787795|NCT00496444|Drug|Azacitidine|Starting Dose 20 mg/m^2 administered subcutaneously (under the skin), daily, for ten days (Days 1 -10) of every 4 Week Cycle.
1787796|NCT00496444|Drug|Valproic Acid|Starting Dose 10 mg/Kg once daily by mouth, every day of 4 Week Cycle.
1787797|NCT00496457|Drug|Experimental|Capsules of TRO19622 (125 mg)- Once a day before noon meal during 6 weeks
1787798|NCT00496457|Drug|Placebo comparator|4 Capsules of PBO per day before noon meal
1787799|NCT00496470|Drug|Symbicort (budesonide/formoterol turbuhaler 320/9ug)|Symbicort (budesonide/formoterol turbuhaler 320/9ug)
1787800|NCT00496470|Drug|Spiriva (tiotropium bromide 18ug)|Spiriva (tiotropium bromide 18ug)
1787839|NCT00496730|Drug|Comparator: atorvastatin|atorvastatin 10 mg; tablet, once daily, 8 Weeks
1787840|NCT00496743|Device|Low-dose total skin electron beam therapy (4 Gy)|
1787841|NCT00496756|Drug|sorafenib tosylate|initial dose of Sorafenib will be administered orally with a dose of 400 mg twice a day, daily.Intrapatient dose escalation will occur providing no dose limiting toxicity (Grade 3 or 4) is observed. Dose level 2 600mg. Dose level 2 800mg
1787801|NCT00496483|Drug|LCP Tacro (tacrolimus)|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.
Other Names:
Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
1787802|NCT00496483|Drug|Prograf|"Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day0 through Day 7 to maintain target trough levels of 7-12 ng/mL. On the morning of Day 8, following the final blood draw for the PK assessment, patient will be converted to LCP-Tacro using the conversion Ratio 0.66-0.8. LCP-Tacro tablets will be administered orally once daily in the morning, with an interval of 24 ± 1 hours between doses.
Other Names:
Tacrolimus modified-release LCP-Tacro tablets were provided in 3 strengths: 1 mg, 2 mg, and 5 mg oral tablets."
1787803|NCT00496509|Drug|ZD6474 (Zactima) 100mg|
1787804|NCT00496509|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MR)|
1787805|NCT00496509|Procedure|Biomarker Draws|
1787806|NCT00496509|Drug|ZD6474 (Zactima) 300mg|
1787807|NCT00496522|Procedure|Proton Beam Therapy|A total dose of up to 70 CGE given at 2.0 CGE per daily fraction for 35 fractions.
1787808|NCT00496535|Drug|TNFerade biologic|
1787809|NCT00496548|Procedure|Fecal calprotectin|Fecal calprotectin levels obtained and compared to urinary PGE-M and serum C-reactive protein (CRP) levels.
1787810|NCT00496548|Procedure|Urinary PGE-M Level|Urinary PGE-M level obtained and compared to fecal calprotectin and serum CRP levels.
1787811|NCT00496561|Biological|subcutaneous immunotherapy (House Dust Mites)|subcutaneous immunotherapy (House Dust Mites)
1787812|NCT00496561|Other|placebo of subcutaneous immunotherapy (House Dust Mites)|placebo of subcutaneous immunotherapy (House Dust Mites)
1787813|NCT00496574|Biological|Novo Helisen Depot, Phostal|subcutaneous immunotherapy
1787814|NCT00496587|Drug|Capecitabine|800 mg/m^2 By Mouth Twice Daily On Days 1-21.
1787815|NCT00496587|Drug|Gemcitabine|900 mg/m^2 By Vein Over 30 Minutes on Days 1 and 15.
1787816|NCT00496587|Drug|Bevacizumab|10 mg/kg By Vein On Days 1 and 15.
1787817|NCT00496600|Drug|Patupilone|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
1787818|NCT00496600|Drug|RAD001|RAD001 will be taken orally starting at a dose of 30 mg every week for the first cohort of patients, one hour prior to administration of patupilone. Patupilone will then be administered as an infusion, starting at 5 mg/m2 for the first cohort of patients. The dosage and scheduling of RAD001 and patupilone during each 21-day cycle will vary according to cohort assignment
1787819|NCT00496613|Behavioral|Mini-Mental State Exam and Blood draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
1787820|NCT00496613|Behavioral|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
1787821|NCT00496613|Behavioral|Mini-Mental State Exam and Blood Draw|The neuropsychological testing will be conducted by a psychometrician who will be trained and supervised by Dr. Correa. It should take approximately 2 hours to complete.Two blood samples will be collected in green top tubes for analysis of DNA damage
1787822|NCT00496626|Biological|Quadrivalent Human Papillomavirus (HPV, Types 6, 11, 16, 18) Recombinant Vaccine (Gardasil®)|Human Papillomavirus (Type 6, 11, 16, 18) Recombinant Vaccine (Gardasil®), 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
1787823|NCT00496626|Biological|Comparator: Placebo|aluminum-contained, 0.5mL, 3 Dose of intramuscular injection at Day 1, Month 2 and Month 6
1787824|NCT00496639|Procedure|angioplasty|Balloonplasty of the stenotic lesion at the venous anastomosis of the thrombosed AV graft.
1787825|NCT00496639|Procedure|stent placement|Balloonplasty plus stent deployment at the stenotic lesion at the venous anastomosis of the thrombosed AV graft
1787826|NCT00496652|Radiation|Radiotherapy|Radiotherapy 66-68 Gy, 2Gy/fx, 6 fx/week (+ weekly cisplatin 40 mg/m2 during radiotherapy to stage 3+4)
1787827|NCT00496652|Drug|Zalutumumab|Zalutumumab 8 mg/kg every week during radiotherapy + the week before start of radiotherapy (as loading dose)
1787828|NCT00496665|Drug|Vandetanib|Taken orally once a day in 28-day cycles (the dose will vary)
1787829|NCT00496665|Drug|Cyclophosphamide|Metronic Chemotherapy: Low dose pills taken every day of each 28-day cycle
1787830|NCT00496665|Drug|Methotrexate|Metronic Chemotherapy: low dose pills taken on days 1 and 2 of each week
1787831|NCT00496678|Behavioral|Navigation|Cancer patients are randomly assigned to receive standard of care or the help of a trained person to navigated them through the cancer care system
1787832|NCT00496678|Behavioral|Standard of Care|Cancer patients receive standard of care for their cancer treatment
1787833|NCT00496691|Behavioral|Family-based HIV prevention program|comparison between parent-child intervention targeting parent-teen sexual communication, condom use skills, and assertiveness training to an adolescent-only intervention that targets similar constructs minus parent-teen sexual communication and a general health promotion intervention
1787834|NCT00496704|Drug|capecitabine|
1787835|NCT00496704|Drug|gemcitabine hydrochloride|
1787836|NCT00496704|Drug|oxaliplatin|
1787837|NCT00496717|Device|Helicoidal fast scann|Each patient will have an computed aortic tomodensitometric scan without contrast injection. This procedure lasts few minutes and irradiation is low. The aortic calcium scoring is calculated using a specific program included in the scan machine
1787838|NCT00496730|Drug|simvastatin (+) ezetimibe|simvastatin (+) ezetimibe 10/20 mg ; tablet, once daily, 8 Weeks
1788065|NCT00485693|Drug|Bupivacaine HCl|150 mg Bupivacaine HCl
1787842|NCT00496756|Other|flow cytometry|15 ml of blood drawn for flow cytometry of T4/T8, NK, CD25+, and Fox p3 testing obtained at baseline and on days 28, 56, 84, and 112
1787843|NCT00496756|Other|laboratory biomarker analysis|15 ml of plasma and urine for storage and future determination of VEGF concentration will be obtained at baseline.10 ml of plasma and urine for storage and future determination of VEGF concentration will be obtained on days 28, 56, 84 and 112
1957235|NCT02483247|Drug|Sunitinib|Sunitinib 37.5 mg is administered once daily.
1957236|NCT02482805|Behavioral|Cognitive Behavioral Therapy|Exposure therapy for social anxiety disorder
1787846|NCT00496782|Drug|maraviroc|Treatment-experienced subjects on failed therapy, with HIV RNA ≥ 1000 copies/mL, are eligible who will receive a tropism assay at screening (Day -14 to 0). Subjects who are eligible will receive maraviroc added to a failing regimen from Day 1 to 14. On day 15, subjects will discontinue the current treatment regimen and begin a new OBT. Subjects with only R5 HIV will continue receiving maraviroc plus OBT. Subjects with non-R5 virus will discontinue receiving maraviroc but continue to receive the new OBT. Investigator selects OBT based on results of phenotype/genotype testing at baseline. The nominal dose for maraviroc is 300 mg BID. The maraviroc dose should be adjusted based on OBT patient is taking. If OBT includes CYP3A4 inhibitor (with or without inducers) maraviroc dose should be 150 mg BID and if OBT includes CYP3A4 inducer (without inhibitors) maraviroc dose should be 600mg BID. If OBT does not include any CYP3A4 inducers or inhibitors maraviroc dose should be 300 mg BID.
1787847|NCT00496782|Procedure|Trofile Assay and HIV RNA quantification assay|Trofile Assay and HIV RNA quantification assay
1787849|NCT00496808|Drug|Herceptin (Trastuzumab)|8 mg/kg IV Over 90 Minutes
1787850|NCT00496821|Drug|ALN-RSV01|
1787851|NCT00496834|Drug|losartan potassium|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
1787852|NCT00496834|Drug|Comparator: carvedilol|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
1787853|NCT00496834|Drug|Comparator: losartan (+) hydrochlorothiazide (HCTZ)|Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
1787854|NCT00496834|Drug|Comparator: carvedilol (+) hydrochlorothiazide|Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
1787855|NCT00496847|Drug|PERIOGEN|Implantation of rhPDGF-BB (0.3 mg/ml) + β-TCP (0.5 g)
1787856|NCT00496847|Drug|Beta TCP alone|Implantation of β-TCP (0.5 g) alone
1787857|NCT00496860|Biological|ALT-801|Dose escalation (0.015 mg/kg, 0.04 mg/kg, 0.08 mg/kg, 0.12 mg/kg, 0.14 mg/kg, 0.16 mg/kg), intravenous infusions, two treatment cycle, each cycle with 4 daily on-dose infusion, 10 days rest between cycles.
1787858|NCT00496873|Drug|Cytoxan|600 mg/m^2 on Day 1 of 21-day cycle.
1787859|NCT00496873|Drug|Nipent|4 mg/m^2 on Day 1 of 21 Day Cycle.
1787860|NCT00496873|Drug|Rituxan|375 mg/m^2 on Day 1 of 21 Day Cycle.
1787861|NCT00496938|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
1787862|NCT00496951|Device|Vagal tone assessment|An EKG will be obtained using a Physio-control EKG monitor (R wave Electronics of Florida) in standard application, with three chest leads. The EKG data is inputted into a vagal tone monitor (Delta Biometrix, Bethesda MD) which computes vagal tone from the EKG signal. This data is then transferred to a disk which is analyzed off-line.
1787865|NCT00496977|Procedure|annual CT screening|
1787866|NCT00496990|Behavioral|Enhanced care|this group received counseling, contingency management and methadone or detoxification
1787867|NCT00496990|Behavioral|control|this group receives the opportunity to participate in a support group
1787868|NCT00497003|Drug|Treatment with either metoprolol or carvedilol|
1787869|NCT00497016|Drug|atorvastatin 80 mg|
1787870|NCT00497029|Drug|fluoride varnish|
1787871|NCT00497029|Behavioral|patient education|
1787872|NCT00497042|Device|Self Adjusting File|
1787873|NCT00497055|Drug|Aripiprazole|
1787874|NCT00497055|Drug|Placebo|Sugar pill manufactured to mimic Aripiprazole gel caps.
1787875|NCT00497068|Behavioral|tobacco abstinent contingent|Participants receive vouchers wiht monetary rewards for providing breath samples that show tobacco smoking abstinence
1787876|NCT00497068|Behavioral|non-contingent|Participants receive vouchers regardless of tobacco use status
1787877|NCT00497068|Behavioral|control|this group receives no vouchers
1787878|NCT00497081|Drug|mirtazapine|mirtazapine 30 mg daily for 3 months
1787879|NCT00497081|Drug|placebo|placebo 30 mg daily for 3 months
1787936|NCT00497536|Drug|Insulin Aspart (IAsp)|"IAsp 100 U.
≈ bolus protocol: From 6 pm until 6 am
• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)
From 8 am until 6 pm
1 dose/h + 50 % s.c. (≈ bolus)."
1787880|NCT00497094|Device|carotid artery stenting|Using retrograde transfemoral access an overview aortic angiogram is established. A stiff wire is then placed in the external carotid or distal common carotid artery to introduce a long hydrophilic sheath into the common carotid artery. The stenosis is then crossed with a Filter wire. For stent implantation Monorail Carotid Wallstents or the Monorail Nitinol Stent of Boston Scientific are used. Road map or overlay technique with a magnification of 20 to 28 inch is used to localize the stenosis during the procedure. Finally a control angiogram is performed to ensure correct placement of the stent. After successful completion of the procedure, the arterial access site is closed using a standard closure device.
1787881|NCT00497107|Drug|UFT, Calcium Folinate, PSK|
1787882|NCT00497107|Drug|UFT, Calcium Folinate|
1787883|NCT00497120|Drug|acetazolamide|
1787884|NCT00497120|Drug|placebo|
1787885|NCT00497120|Procedure|uvulopalatopharygoplasty|
1787886|NCT00497146|Drug|paricalcitol|2 µg capsule
1787887|NCT00497146|Drug|placebo|placebo capsule
1787888|NCT00497159|Other|Placebo|Placebo TID x 90 days
1787889|NCT00497159|Drug|Dimebon|Dimebon 20 mg TID x 90 days
1787890|NCT00497172|Device|CYPHER Sirolimus-eluting stent|drug-eluting stent
1787891|NCT00497172|Device|Bx SONIC bare metal stent|bare-metal stent
1787892|NCT00497185|Behavioral|Mindfulness-Based Cognitive Therapy for Functional Disorders|"Mindfulness-based cognitive therapy: A manualized program will be delivered by two instructors who are experienced cognitive therapists in eight weekly 3½-hour group training sessions and one follow-up session after a month involving up to 12 patients with somatoform disorders. The patients must be willing and able to attend and devote up to 1 hour per day for homework.
The therapy is compared with a group of controls receiving shared care defined as: Treatment as usual augmented by psychiatric consultation intervention: The patients are offered a psychiatric consultation after the assessment interview. It is the aim to optimise treatment in the present health care system."
1787893|NCT00497198|Drug|MCI-196|Three tablets of MCI-196 500mg tablet at a time, three times daily, 12 weeks administration (dose in a day: 4500mg)
1787894|NCT00497198|Drug|Placebo of MCI-196 Tablet|Three tablets of Placebo tablet at a time, three times daily, 12 weeks administration
1787895|NCT00497211|Procedure|Intracoronary mononuclear cell infusion|
1787896|NCT00497224|Drug|Erlotinib|Erlotinib starting at 150 mg PO (by mouth) daily. Dose may increase or decrease by the study doctor as per protocol (study plan).
1787897|NCT00497237|Drug|Beclomethasone plus formoterol fixed combination|100+6 pMDI
1787898|NCT00497237|Drug|Fluticasone plus salmeterol fixed combination|diskus 250/50
1787899|NCT00497250|Drug|Gefitinib|gefitinib 250 mg/day,PO concurrent with RT and 250 mg/day,PO for 60 days after the completion of RT.
1787900|NCT00497250|Device|Radiation Therapy|group 1.54Gy/27Fx concurrent with gefitinib group 2.56Gy/28Fx concurrent with gefitinib group 3.58Gy/29Fx concurrent with gefitinib group 4.60Gy/30Fx concurrent with gefitinib
1787901|NCT00497263|Device|Niti CAR|
1787902|NCT00497276|Procedure|placement of popliteal catheter|Bolus naropin 7,5 mg/ml 30 ml; infusion bupivacaine 2,5 mg/ml 5-10 ml/h
1787903|NCT00497289|Drug|Lipofundin MCT/LCT 20 %|daily i.v. infusion for up to 5 days
1787904|NCT00497289|Drug|Lipidem 20%|daily i.v. infusion for up to 5 days
1787905|NCT00497302|Behavioral|RBT|Contingency management and behavioral counseling including motivational interviewing
1787906|NCT00497302|Behavioral|usual care|receives usual comprehensive care at Center for Addiction and Pregnancy
1787907|NCT00497315|Drug|combination chemotherapy (pemetrexed + cisplatin)|pemetrexed 500 mg/m2 + cisplatin 75 mg/m2 (q 3 weeks for 3 cycles)
1787908|NCT00497315|Radiation|thoracic irradiation + pemetrexed|pemetrexed 500 mg/m2 (q 3weeks for 2 cycles), 60 GY (30 fractions of 2 GY)
1787909|NCT00497328|Drug|N-acetylcysteine|
1787910|NCT00497328|Drug|Sodium Bicarbonate|
1787911|NCT00497341|Drug|cefuroxime|cefuroxime is administered at a dosage of 1.5 g before tourniquet inflation and release in experimental arm and only before tourniquet inflation in control arm
1787912|NCT00497341|Drug|placebo|cefuroxime 1.5 g IV before tourniquet inflation + placebo before tourniquet release + cefuroxime 1.5 g IV 6 h after surgery
1787913|NCT00497354|Drug|Variation in volume of local anesthetic|
1787914|NCT00497354|Procedure|Ultrasound-guided interscalene brachial plexus block|
1787915|NCT00497367|Device|Percutaneous Coronary Intervention (PCI) TAXUS Petal|TAXUS Petal, paclitaxel eluting stent
1787916|NCT00497380|Dietary Supplement|Arginine|Oral nutritional supplement
1787917|NCT00497393|Behavioral|Clinical Decision Unit|a dedicated 2-bed area to see patients and then rotate them back into the waiting room area for labs and diagnostic imaging.
1787918|NCT00497406|Procedure|Salivary gland transfer|Retrograde flow method
1787919|NCT00497406|Procedure|Helical Tomotherapy treatment|total of 30 fractions
1787920|NCT00497419|Procedure|fast track|
1787921|NCT00497445|Procedure|angioplasty / surgery|Percutaneous vascular intervention or surgery for peripheral arterial disease
1787922|NCT00497445|Procedure|Angioplasty / surgery and exercise therapy|Percutaneous vascular intervention or surgery for peripheral arterial disease followed by supervised exercise therapy
1787924|NCT00497471|Drug|Deltaprim (3.125 mg pyrimethamine plus 25 mg dapsone)|
1787925|NCT00497471|Drug|iron (2 mg/kg/daily)|
1787926|NCT00497484|Drug|recombinant human somatotropin|
1787927|NCT00497497|Drug|bevacizumab|(Only for patients not previously treated with bevacizumab) Intravenous repeating dose
1787928|NCT00497497|Drug|cetuximab|Intravenous repeating dose
1787929|NCT00497497|Drug|FOLFIRI regimen|Intravenous repeating dose
1787930|NCT00497497|Drug|irinotecan|Intravenous repeating dose
1787931|NCT00497497|Drug|PRO95780|Intravenous repeating dose
1787932|NCT00497510|Procedure|Chiropractic manipulation|
1787933|NCT00497523|Drug|Beclomethasone dipropionate|
1787934|NCT00497523|Drug|Beclomethasone dipropionate/Salbutamol combination|
1787935|NCT00497523|Drug|Salbutamol|
1787983|NCT00498056|Biological|VRC-HIVDNA016-00-VP|DNA vaccine administered intramuscularly
1788066|NCT00485693|Drug|SKY0402|600 mg SKY0402 (study drug)
1787937|NCT00497536|Drug|Insulin Aspart (IAsp).|"IAsp 100 U From 6 pm until 8 am
• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)
From 8 am until 6 pm 50 % increase of basal rate"
1787938|NCT00497536|Drug|Insulin Aspart (IAsp)|"IAsp 100 U From 6 pm until 8 am
• 50 % of habitual 24 hour insulin need/24 hours = basal rate (per hour)
From 8 am until 6 pm 50 % increase of basal rate"
1787939|NCT00497549|Procedure|side-to-side stapled|5 cm of the mobilized stomach will be placed in the neck. Three interrupted sutures will be taken between the posterior wall of esophagus and anterior wall of stomach. A 1.5 cm gastrotomy will be made. Two stay sutures will then be taken, one at the anterior corner of esophagus and another between posterior corner of esophagus and the middle of the gastrotomy. The stapler device (Endopath, EZ45) will be introduced.The staple cartridge will then be rotated so that the posterior wall of the esophagus and the anterior wall of the stomach will align in a parallel manner and fire the stapler. A 16F nasogastric tube will be placed across the anastomosis and the anterior edges of the gastrotomy and open esophagus will be approximated with interrupted 3-0 silk.
1787940|NCT00497549|Procedure|hand sewn|A proper site on the anterior wall of stomach away from the stapled line approximately 2 cm below the highest point of the gastric conduit will be anastamosed to esophagus Posterior interrupted seromuscular sutures will be taken with 3-0 silk. The stomach will then be opened transversely (2.5 to 3 cm long). Interrupted stitches with full thickness of the stomach and esophagus will be placed to achieve mucosa to mucosa approximation. A 16F nasogastric tube will then be placed across the anastomosis into the intrathoracic stomach. The anterior wall of the anastomosis will be completed in a manner similar to posterior wall.
1787941|NCT00497562|Drug|sc recombinant growth hormone + amitriptyline, fluoxetine and tramadol (treated group)|
1787942|NCT00497562|Drug|amitriptyline, fluoxetine and tramadol alone (control group)|
1787943|NCT00497588|Procedure|surgery|
1787944|NCT00497588|Radiation|radiotherapy|
1787945|NCT00497601|Drug|Amphotericin B fat emulsion in visceral leishmaniasis|Amphotericin B in fat emulsion (Amphomul) 7.5 mg/kg on day 1 & 3 in group A Amphotericin B in fat emulsion (Amphomul) 10 & 5 mg/kg on day 1 & 3 in group B Amphotericin B in fat emulsion (Amphomul) 12.5 & 2.5 mg/kg on day 1 & 3 in group C Amphotericin B in fat emulsion (Amphomul) 15 mg/kg on day 1 in group D
1787946|NCT00497601|Drug|Amphotericin B fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
1787947|NCT00497601|Drug|Amphotericin B in fat emulsion|Starting with 7.5 mg/kg on day 1 and 3, 10 and 5 mg/kg on day 1 and 3, 12.5 and 2.5 mg/kg on day 1 and 3 and finally 15 mg/kg on day 1
1787948|NCT00497614|Drug|adalimumab|
1787949|NCT00497640|Procedure|Artificial Neural Network|Use of a predicted optimal CPAP
1787950|NCT00497653|Drug|DCI|D-chiro-inositol 1200mg twicely daily for 6 weeks
1787951|NCT00497653|Drug|Placebo|Placebo, twice daily for 6 weeks
1787952|NCT00497666|Drug|Rosiglitasone (retrospective observation)|
1787953|NCT00497679|Drug|AZD1152|7-day continuous intravenous infusion
1787954|NCT00497692|Drug|Lactoserum|
1787955|NCT00497718|Procedure|Chiropractic Manipulation|
1787956|NCT00497731|Drug|AZD1152|2-hour continuous intravenous infusion
1787957|NCT00497744|Drug|Intraperitoneal Cefepime|
1787958|NCT00497757|Biological|enriched hematopoetic stem cell infusion|Enriched Hematopoetic Stem Cell Infusion
1787959|NCT00497770|Drug|Pemetrexed|Treatment pattern and treatment initiation or changes are solely at the discretion of the physician and the patient
1787960|NCT00497783|Drug|Lactoserum|
1787961|NCT00497796|Drug|maribavir|100mg twice a day for 14 weeks.
1787962|NCT00497796|Drug|ganciclovir|1000mg three times per day for 14 weeks.
1787963|NCT00497809|Drug|AVI-014 versus Filgrastim|3 different dose arms of AVI-014 versus Filgrastim for up to 14 days daily
1787964|NCT00497822|Procedure|Aerobic exercise training|
1787965|NCT00497848|Behavioral|motivational interviewing|"An individual intervention building on the Motivational Interviewing by Miller and Rollnick. Several studies has proved effectiveness of this therapy form in improving drug compliance. Patients will be offered individual motivational therapy"
1787966|NCT00497848|Other|The System-Orientated Intervention|"Principles in this intervention come from Clinical Risk Managing and quality assurance. It focuses on daily problems in drug handling, including dropping out of drug therapy, by looking at the system as a whole.Some cases, where patients dropped out of drug therapy will be carefully analysed in order to identify week points in the system, and subsequently alter the instructions for drug therapy, information, reminders and so on."
1787967|NCT00497861|Procedure|Activator Methods Chiropractic Technique|
1787968|NCT00497874|Behavioral|Computer-tailored intervention|Stage-based manual and three computer-tailored reports
1787969|NCT00497900|Drug|Vitamin D|Daily vitamin D (cholecalciferol) tablets and rocaltrol
1787970|NCT00497913|Drug|NaCl 0.9%|
1787971|NCT00497913|Drug|Botulinum Toxin A|
1787973|NCT00497939|Drug|Saw palmetto and sanmiaoshan capsule|
1787974|NCT00497952|Biological|hematopoetic stem cell infusion|Enriched hematopoietic stem cell infusion
1787975|NCT00497965|Procedure|Chiropractic Manipulation|
1787976|NCT00497965|Behavioral|Balance Exercises|
1787977|NCT00497978|Dietary Supplement|taurine|6 grams of taurine will be given each day in capsules, starting the day of admission till the sixth postoperative day
1787978|NCT00497978|Dietary Supplement|placebo|a similar amount of placebo will be given each day in capsules, starting the day of admission till the sixth postoperative day
1787979|NCT00497991|Drug|AZD1152|
1787980|NCT00498004|Drug|Quetiapine, Risperidone|The dose of quetiapine will be titrated over 4 days to 300mg/day (50mg at day 1, 100mg at day 2, 200mg at day 3 and 300mg at day 4) and thereafter flexible dose will be administered depending on the clinical state. The dose of risperidone will be titrated as following 2mg at day 1 and 4mg at day 4 and thereafter flexible dose will be administered depending on the clinical state. The dosage of drugs should be 400-800mg/day of quetiapine and 4-6mg/day of risperidone between 6 and 8 weeks of trial.
1787981|NCT00498043|Drug|R-CHOP14 induction regimen|R-CHOP14 induction regimen
1787982|NCT00498043|Drug|R-ACVBP14 induction regimen|R-ACVBP14 induction regimen
1787984|NCT00498056|Biological|VRC-HIVADV014-00-VP|Adenovirus vaccine administered intramuscularly
1787985|NCT00498056|Biological|VRC-HIVDNA016-00-VP placebo|DNA vaccine placebo administered intramuscularly
1787986|NCT00498056|Biological|VRC-HIVADV014-00-VP placebo|Adenovirus vaccine placebo administered intramuscularly
1787987|NCT00498069|Device|Harvest Smartprep2 BMAC System|injection of 40cc bmac
1787988|NCT00498069|Device|SmartPReP2 BMAC System|Injection of autologous bone marrow concentrate prepared with the SmartPReP2 BMAC System
1787989|NCT00498069|Biological|placebo|injection of placebo into ischemic tissue of the lower extremity
1787990|NCT00498095|Procedure|Renal biopsy|
1787991|NCT00498108|Drug|Rotigotine|
1787992|NCT00498121|Device|PROCALCITONIN LEVEL|measuring PROCALCITONIN LEVEL
1787993|NCT00498134|Drug|Triple therapy for H. pylori infection|
1787994|NCT00498134|Drug|Cox-2 inhibitor|
1787995|NCT00498147|Other|ADEC Program|Interventions (managed diabetes care) employed by the ADEC Program include: diabetes education, nutrition care, individual and group counseling sessions, foot care, and insulin and oral diabetes medication adjustments with a signed medical directive. ADEC Diabetes Educators (Registered Dietitians and Registered Nurses) will use adult education principles throughout the education process and promote self-care by encouraging responsibility and promoting a positive attitude towards acceptance of diabetes. All patients will be encouraged to self-monitor their blood glucose at home. Team member collaboration and with other agencies to promote a total client care approach to diabetes management will be employed.
1787997|NCT00498173|Drug|Atomoxetine|Available tablet strengths of atomoxetine: 5 mg, 10 mg, 25 mg, 40 mg. Week 1 participant takes 0.5 mg/kg/day, Week 2: 0.8 mg/kg/day, Week 3: 1.2 mg/kg/day. Potential exists for dose increase at Week 4 to 1.8 mg/kg/day based on clinical global impression-improvement rating at Week 4.
1787998|NCT00498173|Drug|Placebo|Placebo tablets dosages: 5 mg, 10 mg, 25 mg, 40 mg.
1787999|NCT00498186|Drug|Rotigotine|"Rotigotine transdermal patches once daily:
2.5cm2 (0.5mg/24 hours) 5cm2 (1mg/24 hours) 10cm2 (2mg/24 hours) 15cm2 (3mg/24 hours) 20cm2 (4mg/24 hours)"
1788000|NCT00498199|Procedure|visual tests|
1788001|NCT00498212|Biological|1018 ISS-HBsAg-Single|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
1788002|NCT00498212|Biological|1018 ISS-HBsAg-Double|Intramuscular (IM) injection at Day 0, Week 4 and Week 24
1788003|NCT00498225|Drug|Gemcitabine plus TS-1|Gemcitabine plus TS-1:Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8 followed by 2 week rest as 1 course. TS-1 was co-administered orally at 40 mg/m2 twice daily for 14 days with a rest period of 1 week as one course.
1788004|NCT00498225|Drug|TS-1|TS-1 was administered orally at 40 mg/m2 twice daily for 28 days with a rest period of 2week as one course.
1788005|NCT00498225|Drug|Gemcitabine|Gemcitabine was administered i.v. by 1000 mg/m2 at day 1, 8, 15 followed by 2 week rest as 1 course.
1788006|NCT00498238|Drug|Levothyroxine|
1788007|NCT00498251|Drug|inhalation of salbutamol (5 mg)|
1788008|NCT00498251|Drug|ipratropium|
1788009|NCT00498264|Behavioral|walking program, resistance muscular exercise|
1788010|NCT00498277|Procedure|Magnetic Resonance Imaging|One MRI sequence done to look for relative fat, and a second extra MRI sequence done to look for the diffusion.
1788011|NCT00498290|Procedure|enhanced recovery after surgery (ERAS) protocol|An integrated protocol aims to allow patients to recover more quickly from major surgery, avoid medium-term sequelae of conventional postoperative care (e.g. decline in nutritional status and fatigue) and reduce health care costs by reducing hospital stay
1788012|NCT00498290|Procedure|control|normal recovery protocol as usually
1788013|NCT00498303|Biological|trivalent split influenza vaccine|
1788014|NCT00498316|Procedure|Cord Blood Infusion|Cord blood transplantation performed on day 0.
1788015|NCT00498316|Drug|Busulfan|32 mg/m2 by vein as an outpatient before Day -14 or as an inpatient on Day -9, and AUC of 4,000 microMol.min-1 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
1788016|NCT00498316|Drug|Fludarabine|"10 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
40 mg/m2 by vein on Days -6 to -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
40 mg/m2 by vein on Days -5 to -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
1788017|NCT00498316|Drug|Rituximab|375 mg/m2 by vein on Day -9 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
1788018|NCT00498316|Other|ATG|"1.25 mg/Kg by vein on Day -4 and 1.75 mg/Kg by vein on Day -3 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
1.25 mg/kg by vein on Day -3 and 1.75 mg/kg by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3."
1788019|NCT00498316|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6 for patients with AML, ALL, NHL, CLL,CML, HD and MM who are > 55 and < 80 years old or of any age with co-morbid condition that in the opinion of the investigators would preclude myeloablative therapy.
1788020|NCT00498316|Drug|Clofarabine|30 mg/m2 by vein on Days -7 to -4 for patients with ALL, AML, NHL, CLL, CML, HD, and MM who are >1 and < 55 years old. Patients >55 but < 65 years who have a Performance Status of 0 or 1 and no comorbidities may receive the myeloablative regimen 4 at the discretion of the investigator(s).
1788021|NCT00498316|Radiation|Total Body Irradiation (TBI)|200 cGy at 25 cGy/minute delivered on Day -3.
1788022|NCT00498316|Drug|Melphalan|140 mg/m2 by vein on Day -2 for patients with AML, ALL, NHL, CLL, CML, and HD who are >1 and < 80 years old that in the opinion of the investigator(s) would preclude myeloablative therapy and who cannot receive Total Body Irradiation (TBI) may receive the reduced intensity treatment regimen 3.
1788023|NCT00498316|Drug|Tacrolimus|0.03 mg/kg by vein daily starting on D-2, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered around Day +180, if no GVHD is present.
1788024|NCT00498316|Drug|Mycophenolate Mofetil|1 gram by vein twice a day Days -3 through Day 100.
1788025|NCT00498316|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on day 0, and continuing until the absolute neutrophil count (ANC) is > 2.5 x 109/L.
1788026|NCT00498342|Drug|N-acetylcysteine|
1788027|NCT00498355|Drug|Lucentis (ranibizumab)|0.5 mg of ranibizumab by intravitreal injection at baseline and at monthly intervals for the following two months for a total of 3 injections. Afterwards, PRN injections for 9 months.
1788028|NCT00498368|Drug|Intravenous Rituximab|"Rituximab Therapy [27 Patients]
Rituximab 1 gm IV on Treatment Day 1
Rituximab 1 gm IV on Treatment Day 15
Rituximab 1 gm IV on Treatment Day 168
Rituximab 1 gm IV on Treatment Day 182"
1788029|NCT00498368|Drug|ACE/ARB|ACE inhibitors and /or ARBs will be used to achieve a blood pressure goal of <130/80 millimeters of mercury (mmHg). Patients not attaining the target blood pressure with an ACE inhibitor or ARB alone should be treated with the combination of ACE inhibitor (ACEi) + ARB
1788030|NCT00498368|Dietary Supplement|Omega-3 Fatty Acid Fish Oil Supplement|Omega-3 Fatty Acid Fish Oil Supplement 3.6 gm eicosapentaenoic acid (EPA)/day
1788031|NCT00498381|Device|CPAP|
1788032|NCT00498394|Behavioral|Clinical diet trial|
1788033|NCT00498407|Drug|CP-4055|CP-4055 5 mg/mL for infusion, dose: 200 mg/m2/day, schedule: d1-5 q4, 30 minutes IV infusion
1788034|NCT00498433|Drug|Aliskiren|300 mg tablet once daily
1788035|NCT00498433|Drug|Amlodipine|5 mg capsule once daily
1788036|NCT00498433|Drug|Placebo of Aliskiren|Matching placebo of aliskiren 300 mg tablet
1788037|NCT00498433|Drug|Placebo of amlodipine|Matching placebo of amlodipine 5 mg capsule
1788038|NCT00498459|Behavioral|Physical activity|Physical promotion according to socio-ecological model Limitation of sedentary behaviour
1788039|NCT00498472|Procedure|Pre-discharge NT-ProBNP based treatment|"Discharge date, treatment and follow-up based also on the knowledge of NT-ProBNP levels measured at 2-3 days before discharge.
Discharge may be postponed and medical treatment may be changed when NT-ProBNP is >3000 pg/ml. Changes in medical treatment will include the following: increase in the diuretic dose, association of a different diuretic; combination of digoxin therapy; increase in the dose of the renin-angiotensin inhibitor; association of an ARB; association of a nitrate; short course of i.v. diuretic, vasodilator and/or inotropic therapy."
1788040|NCT00498485|Drug|Placebo|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
1788041|NCT00498485|Drug|Sodium Oxybate|Subjects will be randomly assigned to either placebo or drug. The medication and the placebo come as a liquid and patients will start taking an initial dose about 30 min before they expect to sleep. If subjects awaken after less than 5 hrs of sleep, they will take a second dose. If they sleep more than 5 hrs, they will skip the second dose. We will call patients weekly to see how they are doing . If they have tolerable side effects or report significant improvement, we will maintain the dose. But if patients report no effect, the dosage will be incremented by 1 ml per week until good sleep is achieved or a predetermined maximum is reached.
1788042|NCT00485550|Drug|Atomoxetine Hydrochloride|
1788043|NCT00485550|Drug|Methylphenidate Hydrochloride|
1788044|NCT00485550|Drug|Placebo|
1788045|NCT00485563|Biological|EC90 (KLH-FITC)|1.2mg in combination with adjuvant GPI-0100 administered subcutaneously (beneath the skin) weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
1788046|NCT00485563|Biological|GPI-0100|3.0 mg in combination with EC90 administered subcutaneously weekly for 4 consecutive weeks during the first cycle of treatment, weekly for 2 consecutive weeks during the second cycle and once for each additional cycle.
1788047|NCT00485563|Drug|EC17 (Folate-FITC)|0.3mg/kg administered subcutaneously 5 days per week (Monday through Friday) for 4 consecutive weeks for the first two treatment cycles and then 3 days per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
1788048|NCT00485563|Drug|Interleukin-2|7.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 2.5 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
1788049|NCT00485563|Drug|Interferon-alpha|3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 4 consecutive weeks during the first 2 cycles of treatment, then 3.0 MIU administered subcutaneously 3 times per week (Monday, Wednesday, Friday) for 3 consecutive weeks for each additional cycle.
1788050|NCT00485576|Drug|eculizumab|eculizumab 600 mg or matching placebo iv infusion.
1788051|NCT00485589|Drug|methotrexate|Oral repeating dose
1788052|NCT00485589|Drug|ocrelizumab|Intravenous repeating dose
1788053|NCT00485589|Drug|placebo|Intravenous repeating dose
1788054|NCT00485602|Procedure|"orthodontic treatment with Rafenalign appliance"|
1788055|NCT00485615|Drug|Omega 3 Joy enteric coated concentrated fish oil|1500-3000mg; one per day
1788056|NCT00485628|Drug|Atomoxetine Hydrochloride|
1788057|NCT00485641|Device|SaeboFlex Dynamic Hand Orthosis|
1788058|NCT00485641|Procedure|Saebo F.T.M. Arm Training Program|
1788059|NCT00485667|Drug|SKY0402|Subects received either 300mg or 450mg
1788060|NCT00485667|Drug|Moxifloxacin 400mg|
1788061|NCT00485667|Drug|Placebo injection|
1788062|NCT00485667|Drug|Placebo tablet|
1788063|NCT00485680|Drug|Olanzapine Hydrochloride|
1788064|NCT00485680|Drug|Lithium Carbonate|
1788067|NCT00485706|Procedure|high calcium dialysate|
1788068|NCT00485719|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths administered orally
1788069|NCT00485732|Biological|HPV-16/18 VLP/AS04 vaccine (Cervarix TM)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
1788070|NCT00485732|Biological|Placebo|Three doses of placebo administered intramuscularly according to a 0, 1, 6-month schedule.
1788071|NCT00485758|Drug|ER niacin/laropiprant|One tablet of ER niacin/laropiprant (1g); advancing to ER niacin/laropiprant (2g) at Week 4 for the remainder of the study 36 Weeks.
1788072|NCT00485758|Drug|Comparator : placebo (unspecified)|ER niacin/laropiprant Placebo
1788073|NCT00485771|Drug|Olanzapine|
1788074|NCT00485771|Drug|Fluoxetine|
1788075|NCT00485771|Drug|Lamotrigine|
1788076|NCT00485784|Other|Blood test|Blood test
1788077|NCT00485797|Drug|Ritalin|The effect of ritalin on postural stability of ADHD childrens will be measured using RCT study design
1788078|NCT00485810|Drug|Olanzapine Hydrochloride|
1788079|NCT00485823|Drug|Olanzapine Hydrochloride|
1788080|NCT00485823|Procedure|Weight Management Program|
1788081|NCT00485836|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
1788082|NCT00485836|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
1788083|NCT00485836|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
1788084|NCT00485849|Drug|Atomoxetine Hydrochloride|
1788085|NCT00485862|Drug|Atomoxetine Hydrochloride|
1788086|NCT00485862|Drug|Sertraline|
1788087|NCT00485862|Drug|Placebo|
1788088|NCT00485875|Drug|Atomoxetine Hydrochloride|
1788089|NCT00485888|Drug|Cipralex|10-20mg; one per day
1788090|NCT00485888|Drug|Placebo|Matched to Cipralex
1788091|NCT00485901|Drug|Olanzapine Hydrochloride|
1788092|NCT00485901|Drug|Haloperidol|
1788093|NCT00485914|Behavioral|On-site work evaluation|Researchers will measure the effects of worksite assessment through an on-site work evaluation by an occupational therapist on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through one-to-one contact and an individualized work plan. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
1788094|NCT00485914|Behavioral|Educational material|Researchers will measure the effects of worksite assessment through educational materials on a person's job satisfaction, capacity to perform work duties, income, health status, and psychological well-being. The scope of the information will be through educational materials to develop strategies to compensate. The strategies will include recommendations for work behaviors, ergonomic and body mechanics considerations, and modifications for job tasks, equipment, and space.
1788095|NCT00485927|Behavioral|stress|
1788096|NCT00485940|Drug|Prucalopride|2 mg o.d.
1788097|NCT00485940|Other|Placebo|Placebo o.d.
1788098|NCT00485940|Drug|Prucalopride|4 mg o.d.
1788100|NCT00485966|Drug|CX-3543|360 mg/m2 daily x 5 q 21 days
1788101|NCT00485979|Drug|larotaxel (XRP9881)|intravenous administration
1788102|NCT00485979|Drug|docetaxel|intravenous administration
1788103|NCT00485979|Drug|trastuzumab|intravenous administration
1788104|NCT00486005|Drug|Olanzapine Hydrochloride|
1788105|NCT00486005|Drug|Nizatidine|
1788106|NCT00486005|Drug|Placebo|
1788107|NCT00486018|Drug|Ranibizumab injection 0.3 mg|Ranibizumab injection 0.3 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
1788108|NCT00486018|Drug|Ranibizumab injection 0.5 mg|Ranibizumab injection 0.5 mg in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six injections.
1788109|NCT00486018|Drug|Sham injection|Sham injection in a single-dose regimen given every month (Day 0 through the Month 5 visit), for a total of six sham injections.
1788110|NCT00486031|Drug|Balsalazide Disodium|
1788111|NCT00486044|Drug|Simvastatin|40 mg tablet each night for one month, then 80 mg for 8 months
1788112|NCT00486044|Drug|Placebo|Matching tablet each night for 9 months
1788113|NCT00486083|Drug|Atomoxetine Hydrochloride|
1788114|NCT00486083|Drug|Methylphenidate Hydrochloride|
1788115|NCT00486109|Device|I-Port(TM) Injection Port|
1788116|NCT00486122|Drug|Atomoxetine Hydrochloride|
1788117|NCT00486122|Drug|Placebo|
1788118|NCT00486135|Drug|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg dosage strengths
1788119|NCT00486135|Drug|XL147 (SAR245408)|Tablets supplied as 100-mg, 150-mg, and 200-mg dosage strengths
1788120|NCT00486148|Other|Infant formula (with GOS)|Infant formula supplemented with 0.4 g/100 ml of galacto-oligosaccharides
1788121|NCT00486174|Drug|methylene blue|2.0 mg/kg of Methylene Blue administered every 6 hours (as required) for up to 48 hours.
1788122|NCT00486187|Drug|rosiglitazone|
1788123|NCT00486187|Drug|metformin or sulfonylurea|
1788124|NCT00486200|Drug|ASP2151|Oral administration.
1788125|NCT00486200|Drug|valacyclovir|Oral administration of active comparator.
1788126|NCT00486200|Drug|Placebo|Oral administration of placebo.
1788127|NCT00486213|Dietary Supplement|pyridoxine hydrochloride|Pyridoxine (200mg) or placebo once daily orally for 21 days out of each treatment cycle
1788128|NCT00486213|Other|Placebo|
1788129|NCT00486226|Device|Vascular Reconstruction Device|CORDIS ENTERPRISE™ VRD
1788130|NCT00486239|Behavioral|neuropsychological evaluation|
1788131|NCT00486252|Other|Observational|This is a non-interventional study. Subgroups of naïve patients and patients with previous failure to beta-blockers therapy were analyzed.
1788132|NCT00486265|Drug|AZD4877|intravenous infusion administered on days 1, 2 and 3
1788133|NCT00486278|Drug|eptacog alfa (activated)|90 mcg/kg, injected i.v.
1788134|NCT00486278|Drug|vatreptacog alfa (activated)|5 mcg/kg, injected i.v.
1788135|NCT00486278|Drug|vatreptacog alfa (activated)|10 mcg/kg, injected i.v.
1788136|NCT00486278|Drug|vatreptacog alfa (activated)|20 mcg/kg, injected i.v.
1788137|NCT00486278|Drug|vatreptacog alfa (activated)|40 mcg/kg, injected i.v.
1788138|NCT00486278|Drug|vatreptacog alfa (activated)|80 mcg/kg, injected i.v.
1788139|NCT00486291|Drug|VI-0521|phentermine 15mg/topiramate 100mg
1788140|NCT00486291|Drug|Placebo|matched placebo
1788141|NCT00486304|Other|ADD|The ADD has a composition of 65% carbohydrate, 20% fat, and 15% protein. The diet will be completely depleted of vitamins A, E and beta-carotene; it will have 10 mg of vitamin C (6.5% of RDA) added per person per day
1788142|NCT00486304|Other|Placebo|Jevity 1.5 (1.5 cal/mL) will be used for the placebo patients in this study. This will simulate the standard of care for patients not on the ADD. Jevity 1.5 is an isotonic, fiber-fortified, high-nitrogen liquid formula providing complete, balanced nutrition for patients requiring short- or long-term tube feeding, given once per day
1788143|NCT00486317|Drug|Oral salmon calcitonin, salmon calcitonin nasal spray|
1788144|NCT00486330|Drug|Buprenorphine, Tipranavir and ritonavir|After determining buprenorphine/naloxone pharmacokinetics over a 24-hour period, tipranavir/ritonavir and buprenorphine/naloxone will be coadministered for 7 days.
1788145|NCT00486343|Drug|Zileuton CR|Zileuton CR tablets 2x600mg BID for 24 weeks
1788146|NCT00486343|Drug|Placebo|Placebo tablets 2x600mg BID for 24 weeks
1788147|NCT00486356|Drug|capecitabine|
1788148|NCT00486356|Drug|carboplatin|
1788149|NCT00486356|Drug|epirubicin hydrochloride|
1788150|NCT00486356|Genetic|microarray analysis|
1788151|NCT00486356|Genetic|polymorphism analysis|
1788152|NCT00486356|Other|pharmacological study|
1788153|NCT00486369|Drug|Oral salmon calcitonin|
1788154|NCT00486382|Biological|Leish-111f + MPL-SE Adjuvant|
1788155|NCT00486395|Device|CPAP|"CPAP administered via Bubble method or Infant Flow Driver"
1788156|NCT00486395|Device|Mechanical ventilation|Volume guarantee strategy
1788157|NCT00486408|Biological|MRKAd5 HIV-1 gag/pol/nef|1.5x10^10 Ad vg
1788158|NCT00486421|Biological|Rituximab|375mg/m2 IV weekly times 4 (days 1, 8, 15, 22)
1788159|NCT00486421|Drug|Prednisone|1mg/kg/d PO, taper to off by 8 weeks
1788160|NCT00486434|Drug|SMC021 Oral Calcitonin|0.8mg SMC021 twice daily
1788161|NCT00486434|Drug|SMC021 Placebo|Placebo twice daily
1788162|NCT00486447|Device|64 Channel VCT|cardiac CT angiography exam
1788163|NCT00486460|Drug|Gemcitabine|
1788164|NCT00486460|Drug|Curcumin|
1788165|NCT00486460|Drug|Celebrex|
1788166|NCT00486473|Drug|Multihance|0.5 Molar at a single dose injection
1788167|NCT00486473|Drug|Magnevist|0.5M at a single dose injection
1788168|NCT00486486|Drug|Drug: bimatoprost/timolol fixed combination AM|3-month chronic dosing in the morning
1788169|NCT00486486|Drug|Bimatoprost/timolol fixed combination dosed PM|Evening dosing of bimatoprost/timolol fixed combination for a period of 3 months
1788170|NCT00486499|Procedure|I-125 versus Pd-103 radioactive seed insertion|
1957238|NCT02479620|Drug|Dexamethasone Sodium Phosphate Injection, USP, 4 mg/mL|Following atherecomy-based revascularization, Investigators will be unblinded to assignment and will treat only patients assigned to the treatment arm with the Bullfrog delivery of dexamethasone.
1957239|NCT02478723|Device|Sonendo GentleWave™ System|The Sonendo GentleWave System is intended to prepare, clean, and irrigate 1st and 2nd molar teeth indicated for root canal therapy.
1788173|NCT00486525|Procedure|Yoga Therapy|Patients will undergo yoga therapy
1788174|NCT00486538|Drug|ABT-869|One oral dose daily.
1788175|NCT00486551|Behavioral|Anger control training|
1788176|NCT00486564|Drug|Nifurtimox|Escalating dose by cohort starting at 20mg/kg/day. PO drug taken TID.
1788177|NCT00486577|Procedure|significant chronic primary auditory cortex stimulation during the first two weeks|significant chronic primary auditory cortex stimulation during the first two weeks of the follow up than wash out period followed by two weeks of non significant stimulation
1788178|NCT00486577|Procedure|non significant chronic primary auditory cortex stimulation during the first two weeks|non significant stimulation during the first two weeks of the follow up than wash out period followed by two weeks of significant chronic primary auditory cortex stimulation
1788179|NCT00486590|Procedure|Prolact-Plus Human Milk Fortifier|
1788180|NCT00486603|Drug|hydroxychloroquine|
1788181|NCT00486603|Drug|temozolomide|
1788182|NCT00486603|Genetic|mutation analysis|
1788183|NCT00486603|Genetic|polymerase chain reaction|
1788184|NCT00486603|Other|immunologic technique|
1788185|NCT00486603|Other|laboratory biomarker analysis|
1788186|NCT00486603|Other|pharmacological study|
1788187|NCT00486603|Procedure|adjuvant therapy|
1788188|NCT00486603|Radiation|3-dimensional conformal radiation therapy|
1788189|NCT00486603|Radiation|intensity-modulated radiation therapy|
1788190|NCT00486616|Device|electrical impedance tomography|
1788191|NCT00486616|Procedure|double-lumen tube placement|
1788192|NCT00486629|Behavioral|Exercise and dietary education|Aerobic exercise or walk for 3-5 times/day for 30-45 min/time from 20 weeks to 36 weeks of pregnancy. Dietary education on nutrition for healthy pregnancy through weekly class during pregnancy.
1788193|NCT00486642|Drug|Bicalutamide|Given PO
1788194|NCT00486642|Other|Laboratory Biomarker Analysis|Correlative studies
1788195|NCT00486642|Drug|Pazopanib Hydrochloride|Given PO
1788196|NCT00486642|Other|Pharmacological Study|Correlative studies
1788197|NCT00486655|Procedure|NOTES-Assisted Cholecystectomy|
1788198|NCT00486668|Drug|doxorubicin|60 mg/m2 IV every 21 days for cycles 1-4
1788199|NCT00486668|Drug|cyclophosphamide|600 mg/m2 IV every 21 days for cycles 1-4
1788200|NCT00486668|Drug|paclitaxel|80 mg/m2 IV on days 1, 8, and 15 every 28 days for cycles 5-8
1788201|NCT00486668|Drug|trastuzumab|First dose: 4 mg/kg IV, subsequent doses: 2 mg/kg IV weekly beginning on day 1 of the first paclitaxel cycle until 1-7 days before surgery
1788202|NCT00486668|Drug|lapatinib|Group 2: 1250 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery. Group 3: 750 mg PO daily beginning on day 1 of the first paclitaxel cycle until 1 day before surgery.
1788203|NCT00486681|Device|Accu Chek Inform and Cobas IT 1000|period II (warning activated)
1788204|NCT00486694|Drug|Sulfadoxine-pyrimethamine + artesunate|
1788205|NCT00486694|Drug|Chloroquine|
1788206|NCT00486707|Behavioral|Questionnaire|A questionnaire will be completed.
1788207|NCT00486720|Drug|vorinostat|vorinostat 400 mg by mouth (P.O.) capsules once daily (q.d.). Treatment in 21 day cycles for up to 8 cycles.
1788208|NCT00486720|Drug|vorinostat|vorinostat 200 mg by mouth (P.O.) capsules three times daily (t.i.d.). Treatment in 21 day cycles for up to 8 cycles.
1788209|NCT00486733|Device|DermaGold|The first four follow-up study assessment and data collection points will coincide with scheduled operative interventions on the wound guided by clinical situation and the treating physician's judgment (approximately every 3-4 days). Subsequent follow-up study assessment and data collection points will occur on study days 28 ± 3, 42 ± 3, 60 ± 3, and 90 ± 3.
1788210|NCT00486746|Behavioral|Lifestyle intervention (physical activity and dietary counseling)|One-year intervention
1788211|NCT00486746|Behavioral|General information on healthy lifestyle habits|A single session
1788212|NCT00486759|Drug|Bevacizumab|Bevacizumab was administered at a dose of 15 mg/kg IV on Day 1 of each 21-day cycle for 8 cycles or at a dose 10 mg/kg IV on Day 1 of each 14-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
1788213|NCT00486759|Drug|Rituximab|Rituximab was administered at a dose of 375 mg/m^2 IV on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
1788214|NCT00486759|Drug|CHOP|Cyclophosphamide was administered at a dose of 750 mg/m^2 IV on Day 1 of each cycle. Doxorubicin was administered at a dose of 50 mg/m^2 IV on Day 1 of each cycle. Vincristine was administered at a dose of 1.4 mg/m^2 IV (maximum of 2 mg) on Day 1 of each cycle. Prednisone was administered at a dose of 100 mg orally on Days 1-5 of each cycle. All 4 drugs were administered either every 21 days for 8 cycles or every 14 days for 6 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
1788215|NCT00486759|Drug|Placebo|Placebo to bevacizumab was administered on Day 1 of each 14- or 21-day cycle for 8 cycles. The cycle duration (14- or 21-day) was chosen by each center prior to initiation of the study and was the same for all patients enrolled at that center.
1788216|NCT00486772|Drug|Sevelamer (Renagel), calcium acetate (Phos-ex)|
1788217|NCT00486785|Drug|Alfuzosin|Alfuzosin 10mg Once Daily for 24 weeks
1788218|NCT00486798|Drug|Quetiapine|
1788219|NCT00486798|Procedure|Rating Scales|
1788220|NCT00486798|Procedure|Self Assessment Form|
1788221|NCT00486798|Procedure|Blood and urine samples|
1788222|NCT00486798|Procedure|Sleeping pattern|
1788223|NCT00486811|Drug|Tapentadol ER (100 to 250 mg twice daily)|50, 100, 150, 200, 250 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
1788224|NCT00486811|Drug|Matching Placebo (twice daily)|Matching Placebo during 15 weeks (3 weeks titration and 12 weeks maintenance)
1788225|NCT00486811|Drug|Oxycodone CR (20 to 50 mg twice daily)|10, 20, 30, 40, 50 mg twice a day (BID) during 15 weeks (3 weeks titration and 12 weeks maintenance)
1788226|NCT00486824|Drug|Indomethacin|One 50 mg tablet of Indomethacin plus 2 pills of placebo followed by one 25 mg tablet of oral indomethacin every 6 hrs for 48 hrs.
1788227|NCT00486824|Drug|Nifedipine|Three 10 mg tablets of Nifedipine followed by one 20 mg tablet every 6 hrs for 48 hrs.
1788228|NCT00486837|Drug|Alpha1-Proteinase Inhibitor (Human)|25 mg of Alpha1-Proteinase Inhibitor (Human) in the lungs, one inhalation per day over 4 weeks.
1788229|NCT00486850|Other|Extubation to Nasal IPPV|Comparison of extubation to NIPPV versus NCPAP
1788230|NCT00486863|Drug|Praziquantel|60 mg/kg administered orally given in split dose (30/mg/kg each) separated by 3 hours; over-encapsulated in gelatin capsules. Two capsule sizes will be made which will be differentiated by color; these will contain 300 mg or 150 mg to allow for best dosing by weight.
1788231|NCT00486863|Other|Placebo|Made with the same color coded gelatin capsules with the inert compound dextrose.
1788232|NCT00486876|Drug|Dextofisopam|capsules, 0 (placebo), 100, 200, and 300 mg BID for 12 weeks
1788233|NCT00486889|Biological|alglucosidase alfa|Intravenous (IV) infusion: 20mg/kg every 2 weeks
1788234|NCT00486902|Drug|Ketamine|Ketamine 10 mg diluted to 20 mL delivered over 10 minutes via an infusion pump set at 2ml/minute
1788235|NCT00486902|Drug|Placebo|Saline 20 mL IV infusion delivered over 10 minutes via an infusion pump set at 2ml/minute
1788236|NCT00486915|Procedure|Left Atrial Appendage Ligation|
1788237|NCT00492284|Drug|verteporfin|Reduced-fluence Visudyne (25 J/cm2, 300 mW/cm2, 83 seconds)
1788238|NCT00492284|Drug|verteporfin|Very-low fluence Visudyne (15 J/cm2, 180 mW/cm2, 83 seconds)
1788239|NCT00492284|Drug|ranibizumab|0.5 mg intravitreal injection
1788240|NCT00492284|Drug|dexamethasone|0.5 mg intravitreal injection
1788241|NCT00492297|Drug|Sorafenib (Nexavar, BAY43-9006) + Dacarbazine (DTIC)|Dacarbazine 1000 mg/m^2 on day one of repeated 21 day cycles, in combination with daily continuous oral sorafenib (Nexavar, BAY 43-9006), 400 mg twice a day (bid)
1788246|NCT00492323|Drug|placebo|twice daily for 4 weeks
1788247|NCT00492323|Drug|carisbamate|200 mg tablet twice daily for 4 weeks
1788248|NCT00492336|Drug|rasagiline (Pharmacodynamics)|Rasagiline 1 mg/day for 12 weeks
1788249|NCT00492336|Drug|Placebo|Placebo 1 tablet each day
1788313|NCT00492687|Procedure|adjuvant therapy|
1788252|NCT00492362|Behavioral|ergometer exercise during hemodialysis|
1788253|NCT00492362|Behavioral|pedometer activity outside of hemodialysis|
1788254|NCT00492388|Drug|PMI-150 (intranasal ketamine)|intranasal dosing
1788255|NCT00492388|Drug|placebo|placebo
1788256|NCT00492401|Drug|decitabine|Given IV
1788257|NCT00492401|Other|laboratory biomarker analysis|Correlative studies
1788258|NCT00492401|Other|pharmacological study|Correlative studies
1788259|NCT00492401|Other|high performance liquid chromatography|Correlative studies
1788260|NCT00492401|Genetic|microarray analysis|Correlative studies
1788261|NCT00492401|Genetic|RNA analysis|Correlative studies
1788262|NCT00492401|Other|mass spectrometry|Correlative studies
1788263|NCT00492401|Genetic|DNA methylation analysis|Correlative studies
1788264|NCT00492401|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
1788265|NCT00492414|Drug|Paroxetine CR|
1788266|NCT00492427|Drug|R744|25μg(s.c.)/2weeks until Hb concentration reaches to 10g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above, then 25~250μg(s.c.)/4week for 24~26weeks in total.
1788267|NCT00492427|Drug|Epoetin beta|6000IU(s.c.)/week until Hb concentration reaches to 10.0g/dL or above and the increasing amount of Hb concentration reaches to 1.0g/dL or above,then 3000k~12000IU(s.c.)/2week for 24~26weeks in total.
1788268|NCT00492440|Biological|recombinant interleukin-7|
1788269|NCT00492440|Genetic|gene expression analysis|
1788270|NCT00492440|Genetic|polymerase chain reaction|
1788271|NCT00492440|Genetic|protein expression analysis|
1788272|NCT00492440|Other|flow cytometry|
1788273|NCT00492440|Other|immunoenzyme technique|
1788274|NCT00492440|Other|immunologic technique|
1788275|NCT00492440|Other|laboratory biomarker analysis|
1788276|NCT00492440|Other|pharmacological study|
1788277|NCT00492453|Procedure|laparoscopic cholecystectomy|elective laparoscopic cholecystectomy using CO2 pneumoperitoneum under different methods of anesthesia
1788278|NCT00492466|Drug|Interferon-beta-1a|dosage and frequency as per label
1788279|NCT00492466|Drug|methylprednisolone|dosage and frequency as per Biogen Idec protocol
1788280|NCT00492479|Drug|Kinerase Pro+Therapy Line day repair, serum, night repair|
1788281|NCT00492479|Drug|Kinerase Pro+Therapy Line Ultra rich day repair|
1788282|NCT00492479|Drug|LubriDerm|
1788283|NCT00492492|Procedure|trans-styloid and intrafocal pinning on the one side|
1788284|NCT00492492|Procedure|volar fixed-angle plating on the other side|
1788285|NCT00492505|Drug|cisplatin|
1788286|NCT00492505|Drug|sorafenib tosylate|
1788287|NCT00492505|Drug|tamoxifen citrate|
1788288|NCT00492505|Procedure|adjuvant therapy|
1788289|NCT00492518|Drug|Acetylcysteine|
1788290|NCT00492518|Drug|Theophylline|
1788291|NCT00492518|Drug|Placebo|
1788292|NCT00492531|Drug|Sildenafil|Oral Sildenafil 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
1788293|NCT00492531|Drug|Placebo|Placebo 20mg three times daily for 6 weeks,followed by 40mg three times daily for 4 weeks followed by 80mg three times daily for 6 weeks.
1788294|NCT00492544|Biological|Cervarix™ (HPV-16/18 L1 VLP AS04)|Three doses of vaccine administered intramuscularly according to a 0, 1, 6-month schedule.
1788295|NCT00492557|Biological|13-valent pneumococcal conjugate vaccine|Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly (IM), followed by a single 0.5 mL vaccine 13vPnC placebo, 1 month later.
1788296|NCT00492557|Biological|13vPnC + TIV|Single 0.5 mL 13vPnC placebo vaccine and a single 0.5 mL TIV, administered IM, followed by a single 0.5 mL 13vPnC vaccine, 1 month later.
1788297|NCT00492583|Drug|Bifidobacterium lactis (BB-12)|The active drink is currently available commercially on campus at The Berkey Creamery at Penn State in State College, Pennsylvania. The active drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus. The active drink was also supplemented with the probiotic BB-12, acquired from Chr. Hansen (Milwaukee, Wisconsin).
1788298|NCT00492583|Drug|Placebo|The placebo drink combined a commercial blend (YFL-702, Chr.) of the following active cultures, Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus.
1788299|NCT00492596|Device|AttenueX IntraVesical System|Insertion of the Solace AttenueX Intravesical System on Day 0
1788300|NCT00492596|Procedure|Sham Procedure|Cystoscopy with Simulated Insertion of AttenuEX Intravescial System
1788301|NCT00492622|Drug|Immediate-release omeprazole|Immediate-release omeprazole 40 mg qam for 7 days
1788302|NCT00492622|Drug|Delayed-release omeprazole|Delayed-release omeprazole 40 mg qam for 7 days
1788303|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months DAILY dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
1788304|NCT00492635|Drug|Levitra (Vardenafil, BAY38-9456)|9 months PRN dosage (double blind) 2 months single-blind placebo wash-out period (subject only is blinded) 2 months open-label PRN treatment with active medication
1788305|NCT00492635|Drug|Placebo|9 months placebo (double blind)2 months single-blind placebo wash-out period (subject only is blinded)2 months open-label PRN treatment with active medication
1788307|NCT00492661|Drug|Tacrolimus With Diet and Exercise Intervention|Participants on tacrolimus for immunosuppression will be provided with intensive dietary advice and supervised for a period of 6 months. Dosage and administration of tacrolimus will be as per Investigator's discretion.
1788308|NCT00492674|Device|APOS biomechanical gait system|
1788309|NCT00492674|Procedure|Physical Therapy|
1788310|NCT00492687|Drug|carboplatin|
1788311|NCT00492687|Drug|tamoxifen citrate|
1788312|NCT00492687|Drug|temozolomide|
1788314|NCT00492687|Radiation|radiation therapy|
1788315|NCT00492700|Drug|rosiglitazone|
1788316|NCT00492713|Other|dark chocolate|dark chocolate
1788317|NCT00492713|Other|Milk chocolate 1|Milk chocolate 1
1788318|NCT00492713|Other|Milk chocolate 2|Milk chocolate 2
1788319|NCT00492726|Drug|Moxifloxacin (Avelox, BAY12-8039)|Moxifloxacin, 400mg, administered intravenously once daily
1788320|NCT00492726|Drug|Ertapenem intravenous|Active treatment: Ertapenem 1.0g, administered intravenously once daily
1788321|NCT00492739|Biological|Vaccination with VZV vaccine|Varicella vaccination 2 doses 2 months apart.
1788322|NCT00492752|Drug|Sorafenib (Nexavar, BAY43-9006)|multikinase inhibitor; Sorafenib 400 mg (orally) twice daily
1788323|NCT00492752|Drug|Placebo|Matching placebo (orally) twice daily
1788324|NCT00492765|Drug|Interferon-beta-1a|dosage and frequency as per label
1788325|NCT00492765|Drug|Simvastatin|dosage and frequency as per Biogen Idec protocol
1788326|NCT00492765|Drug|Placebo|dosage and frequency the same as simvastatin as per Biogen Idec Protocol
1788327|NCT00492778|Radiation|3-Dimensional Conformal Radiation Therapy|Given to the pelvis
1788328|NCT00492778|Drug|Cisplatin|Given IV
1788329|NCT00492778|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1788330|NCT00492778|Radiation|Internal Radiation Therapy|Given intracavitarily or interstitially
1788331|NCT00492791|Device|wireless endoscopy capsule|Firslty patency ingestion then wireless endoscopy capsule exam done
1788332|NCT00492804|Procedure|Lichtenstein hernia repair|Lichtenstein hernia repair with tension free mesh
1788333|NCT00492804|Procedure|Neurectomy|Neurectomy
1788334|NCT00492817|Procedure|Stereotactic Body Radiotherapy|On day 1 of radiation treatment, a CT scan using CT-on-Rails in the same treatment room, immediately before the radiation treatment will be performed.
1788335|NCT00492830|Drug|TRC093 recombinant humanized IgG1k monoclonal antibody|TRC093 is a humanized monoclonal antibody to cleaved collagen administered i.v. on days 1 and 15 of each 28 day cycle until pregression or unacceptable toxicity develops.
1788336|NCT00492843|Drug|Ibandronate (Bondronat)|Intravenous infusion of either 6mg Bondronat on three consecutive days or 6mg Bondronat on one day.
1788337|NCT00492856|Drug|mercaptopurine|Given orally
1788338|NCT00492856|Drug|methotrexate|Given orally
1788339|NCT00492856|Drug|tretinoin|Given orally
1788340|NCT00492869|Drug|AEB071|
1788341|NCT00492882|Drug|usual administration of exogenous recombinant FSH|
1788342|NCT00492895|Drug|Discontinuation of Azathioprin|Discontinuation of Azathioprin
1788343|NCT00492908|Device|Helistent Titan2 (Titanium coated stent)|Titan2
1788344|NCT00492908|Device|EndeavorTM (Zotarolimus-Eluting Stent)|Endeavor
1788345|NCT00492921|Biological|filgrastim|
1788346|NCT00492921|Drug|cyclophosphamide|
1788347|NCT00498511|Procedure|upper gastrointestinal endoscopy, colonoscopy|
1788348|NCT00498524|Device|ICD|Received an ICD
1788349|NCT00498524|Device|ICD|Have not received an ICD
1788350|NCT00498537|Drug|spironolactone|
1788351|NCT00498550|Drug|Clozapine|Clozapine up to 550mg per day
1788352|NCT00498550|Drug|Treatment as usual|Remain on pre-study antipsychotic treatment
1788353|NCT00498563|Procedure|altitude exposure in hypobaric chamber|
1788354|NCT00498589|Drug|methotrexate|25 mg per week IM or SC during 24 weeks
1788355|NCT00498589|Drug|placebo|one intramuscular injection per week
1788356|NCT00498602|Biological|ACC-001 + QS-21|IM injection, ACC-001 (3ug, or 10ug, or 30ug) + QS-21 50ug at Day 1 and weeks 4, 12, 26, and 52
1788357|NCT00498602|Biological|QS-21|IM injection, QS-21 (50 ug) at Day 1 and weeks 4, 12, 26, and 52
1788358|NCT00498602|Other|Diluent: Phosphate Buffered Saline|IM injection, PBS Diluent at Day 1 and weeks 4, 12, 26, and 52
1788359|NCT00498602|Biological|ACC-001|IM injection, ACC 001 (10 ug, 30ug) at Day 1 and weeks 4, 12, 26, and 52
1788360|NCT00498615|Drug|Fasudil|Each subject will be randomly assigned to 1 of 6 possible treatment sequences (ABC, ACB, BAC, BCA, CAB, and CBA) in a double-blind manner: A- a single oral dose of 2 placebo tablets; B- a single, oral 40 mg Fasudil dose as one 40 mg tablet and 1 placebo tablet; C- a single oral 80 mg dose as two 40 mg Fasudil tablets. Subjects will be randomized at the screening/baseline visit to a specific treatment sequence based upon a computer generated code on a 1:1:1:1:1:1 ratio for the 6 possible sequences. A single dose consisting of the two tablets will be taken after fasting for 10 hours once during each treatment period. A washout interval of at least 24 hours and no more than 7 days will be maintained between treatment periods. Concomitant medications will not be taken during the study session.
1788363|NCT00498641|Procedure|computer program and patching|
1788364|NCT00498654|Biological|Ty800 (Salmonella typhi) Oral Vaccine|
1788365|NCT00498680|Drug|Sildenafil, Vardenafil|Sildenafil 100mg, vardenafil 20mg, combination of both half dosage.
1788366|NCT00498680|Drug|Sildenafil|100mg
1788367|NCT00498680|Drug|Vardenafil|20mg
1788368|NCT00498680|Drug|Sildenafil & Vardenafil|50mg & 10 mg
1788369|NCT00498706|Behavioral|Telephone-administered cognitive behavioral therapy (T-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of T-CBT administered by a therapist. Participants will undergo telephone-administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
1788370|NCT00498706|Behavioral|Face-to-face administered CBT (FtF-CBT)|Over 18 weeks, participants will receive eighteen 45-minute sessions of FtF-CBT administered by a therapist. Participants will undergo face-to-face administered sessions twice a week for 2 weeks, once a week for 12 weeks, and once every 2 weeks for the last 4 weeks. Participants will be taught ways to modify thoughts and behaviors that contribute to their depression and ways to maintain the lifestyle changes that they have made.
1788371|NCT00498719|Behavioral|Cognitive Training Program|Cognitive training sessions over a 4 to 6 month training period, each lasting about 2 hours.
1788372|NCT00498719|Other|Control Group|Standard educational support.
1788373|NCT00498732|Device|CPAP|CPAP treatment for 4 weeks
1788374|NCT00498745|Drug|neratinib|HKI-272
1788375|NCT00498758|Device|APOS System - biomechanical wedge shoe|
1788376|NCT00498771|Behavioral|Aquatic Exercise arm|Participants will attend 12 classes of aquatic exercise program (2-3 classes/weekly). Each one hour class is held in warm water pool which is 89 degrees and 3.5'-4'deep.Classes include low impact, dynamic movements for warm up, stretching and breathing exercises, upper and lower body resistance training, and cool down activities. Participants will be evaluated for Circumference & volumetric measurement of the affected limb, BMI, weight and height at the baseline, at 3rd week and at 6th week. Participant will complete a quality of life survey (QOL)at baseline, 6 week, 6 and 12 month.
1788377|NCT00498784|Drug|Mirena|Mirena 52mg during 1 year
1788378|NCT00498797|Drug|Zactima (vandetanib)|
1788379|NCT00498797|Drug|Docetaxel|
1788380|NCT00498797|Drug|Prednisolone|
1788381|NCT00498810|Procedure|complete repair|
1788382|NCT00498810|Procedure|partial repair of the abdominal wall|
1788383|NCT00498836|Drug|CP-4055|CP-4055 5mg/mL for infusion, dose: 200 mg/m2/day, schedule d1-5 q4w, 30 minutes IV infusion
1788384|NCT00498836|Drug|Sorafenib (Nexavar)|Sorafenib 200 mg tablets, dose: 400 mg/day, daily dosing
1788389|NCT00499187|Procedure|Blood Draws|A single whole blood sample was collected for genomic analysis.
1788390|NCT00499200|Drug|SRA-444|
1788391|NCT00499213|Procedure|Home Care Assisted Peritoneal Dialysis|
1788392|NCT00499239|Drug|GS-9219|"GS-9219 Injection is a clear, and colorless to slightly yellow aqueous solution containing 4 mg/mL of GS 9219.
GS 9219 will be administered via IV infusion over 30 minutes in 100 mL of normal saline solution, every 21 days."
1788393|NCT00499252|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|
1788394|NCT00499265|Drug|gemcitabine hydrochloride|1000 mg/m2 as 30 min i.v. infusion once weekly for 7/8 weeks and then every 3/4 weeks
1788395|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
1788396|NCT00499265|Drug|Serine Proteinase Inhibitor WX-671|oral, daily
1788397|NCT00499278|Behavioral|Rehabilitation after joint replacement surgery|
1788398|NCT00499291|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1788399|NCT00499291|Procedure|gene expression analysis|
1788400|NCT00499291|Procedure|laboratory biomarker analysis|
1788401|NCT00499291|Procedure|pharmacological study|
1788402|NCT00499291|Procedure|polymerase chain reaction|
1788403|NCT00499330|Procedure|lobectomy|
1788404|NCT00499330|Procedure|segmentectomy or wedge resection|
1788405|NCT00499343|Drug|Etoposide|150 mg/m^2 given intravenously over 2 hours every 12 hours x 6 doses.
1788406|NCT00499343|Drug|G-CSF|Starting dose on day +6 at 6 mcg/kg injection every 12 hours until completion of apheresis.
1788407|NCT00499343|Drug|GM-CSF|250 mcg/m^2 injection given every evening till the completion of apheresis.
1788408|NCT00499343|Drug|Isophosphamide|10 g/m^2 given intravenously continuous infusion over 72 hours.
1788409|NCT00499343|Drug|Rituximab|Days +1 (375 mg/m^2) and +8 (1000 mg/m^2) given intravenously.
1788410|NCT00499343|Procedure|Apheresis|Peripheral blood stem cell collection.
1788411|NCT00499356|Device|pressure reducing insole|
1788412|NCT00499356|Device|GlideSoft®|
1788413|NCT00499369|Drug|irinotecan hydrochloride|Given IV
1788414|NCT00499369|Drug|leucovorin calcium|Given IV
1788415|NCT00499369|Drug|fluorouracil|Given IV
1788416|NCT00499369|Biological|cetuximab|Given IV
1788417|NCT00499369|Biological|bevacizumab|Given IV
1788418|NCT00499382|Procedure|Nuclear Medicine Cardiac Scan|Scan lasting 30 minutes while being hooked up to a heart monitor that takes pictures every time your heart beats.
1788419|NCT00499382|Procedure|PET/CT Cardiac Scan|Scan lasting 10-15 minutes and performed after the normally scheduled PET/CT scan.
1788420|NCT00499395|Procedure|positron emission tomography|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. When evaluating patients with liver metastases, we routinely obtain a dedicated liver PET study (Liver View) after the whole body PET. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
1788421|NCT00499395|Procedure|radiofrequency ablation|All patients will undergo pre RFA PET prior to ablation for intra and extrahepatic staging and to assess FDG avidity of the lesions. Patients will undergo two post RFA PET scans as part of this project: PET # 1) within 32 hours after RFA. The patients having percutaneous RFA will undergo PET on the same day after the clinical studies at the PET facility are completed; this will be within 8 hours after RFA. In case of laparoscopic and intra-operative RFA, PET will be performed on the following day after the clinical studies are completed; this will be within 32 hours after RFA. PET # 2) on day seven after RFA
1788422|NCT00499408|Dietary Supplement|cholecalciferol|
1788423|NCT00499408|Dietary Supplement|genistein|
1788424|NCT00499408|Dietary Supplement|soy isoflavones|
1788425|NCT00499408|Genetic|polymerase chain reaction|
1788426|NCT00499408|Genetic|protein expression analysis|
1788427|NCT00499408|Other|immunologic technique|
1788428|NCT00499408|Other|laboratory biomarker analysis|
1788429|NCT00499421|Procedure|Computed Tomography (CT) Scan|CT scan of the prostate three times a week, just before the delivery of radiation.
1788430|NCT00499447|Procedure|radiofrequency ablation|
1788431|NCT00499447|Radiation|radiation therapy|
1788585|NCT00500474|Procedure|endolymphatic sac drainage with steroids|
1788432|NCT00499460|Dietary Supplement|garlic powder tablets|Each Garlicin tablet has a claimed allicin content of 3,200 microgram per tablet
1788433|NCT00499460|Drug|oxycodone|Single administration of three 5-mg oxycodone tablets or a 15-mg dose
1788434|NCT00499473|Drug|sunitinib malate|Given orally
1788435|NCT00499473|Other|pharmacological study|Correlative studies
1788436|NCT00499486|Drug|sirolimus|Treatment with rapamycin will begin on Day 1 at a single flat dose level of 5 mg/day. Rapamycin will be administered continuously without interruption through all cycles in an outpatient setting. Each cycle will last 28 days.
1788437|NCT00499499|Drug|E7107|E7107 will be administered as an intravenous infusion over 30 minutes at a starting dose of 0.6 mg/m^2 to the first cohort of patients. The same dose will be given on Days 1 and 8 of a 21-day cycle. Dose escalation will not occur until the maximum tolerated dose is reached. The selection of subsequent dose levels will be performed according to an accelerated design.
1788438|NCT00499512|Behavioral|Questionnaire|Questionnaires that ask questions about religion, spirituality, and decisions about treatment at three points (at time of diagnosis, end of primary chemotherapy, and one year later).
1788439|NCT00499525|Drug|paclitaxel|given IV
1788440|NCT00499525|Drug|sorafenib tosylate|given orallly
1788441|NCT00499525|Other|placebo|given orally
1788442|NCT00499538|Drug|SKI-606|
1788443|NCT00499551|Device|Iontophoresis second generation Eyegate II device|
1788444|NCT00499577|Biological|CMV pp65 peptide|Given intramuscularly
1788445|NCT00499577|Biological|hTERT I540/R572Y/D988Y multipeptide vaccine|Given subcutaneously
1788446|NCT00499577|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
1788447|NCT00499577|Biological|survivin Sur1M2 peptide vaccine|Given subcutaneously
1788448|NCT00499590|Drug|bevasiranib|Bevasiranib (2.5mg) administered intravitreally every 8 or 12 weeks
1788449|NCT00499590|Drug|ranibizumab|Lucentis® (0.5 mg)administered intravitreally every 4 weeks.
1788450|NCT00499603|Drug|Paclitaxel|80 mg/m^2 by vein once weekly over 1 hour on day 1(+/- 2 days) each week for 3 weeks and for 12 cycles.
1788451|NCT00499603|Drug|5-Fluorouracil|500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
1788452|NCT00499603|Drug|Epirubicin|100 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
1788453|NCT00499603|Drug|Cyclophosphamide|500 mg/m^2 by vein on day 1 every 3 weeks (+/- 7 days) for 4 cycles.
1788454|NCT00499603|Drug|RAD001|30 mg by mouth weekly on Days 1, 8, & 15 for 12 cycles.
1788455|NCT00499616|Drug|carboplatin|Given IV
1788456|NCT00499616|Drug|cyclophosphamide|Given IV
1788457|NCT00499616|Drug|doxorubicin hydrochloride|Given IV
1788458|NCT00499616|Drug|etoposide|Given orally
1788459|NCT00499616|Drug|topotecan hydrochloride|Given IV
1788460|NCT00499616|Drug|Isotretinoin|Given orally
1788461|NCT00499616|Procedure|Surgery|With the exception of patients with INSS 4S disease, patients undergo surgery to remove as much of the primary tumor and involved lymph nodes as can safely be accomplished.
1788462|NCT00499616|Drug|Filgrastim|Administered subcutaneously or by IV beginning 24-48 hrs after the last dose of chemotherapy & continuing daily until the ANC is greater than or equal to 1500 following the myelosuppressive nadir . Supportive care given to stimulate neutrophil recovery following chemotherapy and to shorten the duration of chemotherapy-induced neutropenia. On ANBL0531 the use of filgrastim was required for patients less than 60 days of age and was optional for other patients.
1788463|NCT00499629|Drug|FXR 450|capsule, single oral doses from 10 mg to 450 mg
1788464|NCT00499629|Drug|placebo|capsule similar to active drug
1788465|NCT00499642|Drug|Lecozotan SR|
1788466|NCT00499642|Drug|Moxifloxacin|
1788467|NCT00499655|Drug|erlotinib hydrochloride|Given orally
1788468|NCT00499655|Drug|celecoxib|Given orally
1788469|NCT00499655|Other|placebo|Given orally
1788470|NCT00499655|Other|laboratory biomarker analysis|Correlative studies
1788471|NCT00499655|Other|immunohistochemistry staining method|Correlative studies
1788472|NCT00499655|Genetic|fluorescence in situ hybridization|Correlative studies
1788473|NCT00499655|Genetic|mutation analysis|Correlative studies
1788474|NCT00499655|Genetic|protein expression analysis|Correlative studies
1788475|NCT00499655|Genetic|gene expression analysis|Correlative studies
1788476|NCT00499668|Drug|aprepitant|125 mg orally for 7 days
1788477|NCT00499668|Drug|ondansetron hydrochloride|24 mg orally for 7 days
1788478|NCT00499681|Drug|lapatinib ditosylate|Given once daily, 1500mg, for 2 weeks; Given once daily, 1500mg, for 14 weeks in Arm II
1788479|NCT00499681|Drug|letrozole|Given once daily, 2.5mg, for 2 weeks; Given once daily, 2.5mg, for 14 weeks
1788480|NCT00499681|Other|placebo|Given once daily for 2 weeks
1788481|NCT00499694|Biological|bevacizumab|10mg/kg,Intravenous, Day 1 of each Cycle (every 35 days) 15mg/kg,Intravenous, Day 15 of each Cycle (every 35 days)
1788482|NCT00499694|Drug|satraplatin|80 mg/m(2), Orally, Days 1-5, every 35 days
1788483|NCT00499707|Drug|rosiglitazone maleate/metformin hydrochloride|rosiglitazone maleate/metformin hydrochloride
1788484|NCT00499720|Drug|Aztreonam Lysine for Inhalation|75 mg three times a day via inhalation for 28 days followed by 28 days off drug.
1788485|NCT00499733|Drug|cyclophosphamide|
1788486|NCT00499733|Other|laboratory biomarker analysis|
1788487|NCT00499733|Procedure|biopsy|
1788488|NCT00499733|Procedure|cryosurgery|
1957242|NCT02474901|Biological|Quadrivalent Live Attenuated Influenza Vaccine|
1788493|NCT00499759|Behavioral|Resting vitals|The fitness assessments will include the assessment of resting vitals including, blood pressure, heart rate, and hemoglobin saturation (pulse oximeter).
1788586|NCT00500487|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
1788587|NCT00500487|Behavioral|HIV Prevention Skills|12-session group intervention including sexual health skills training.
1788494|NCT00499759|Behavioral|Body Composition|Body composition and body circumference measurements (anthropometry) will be the only assessments performed multiple times during the study to monitor possible changes in the body composition and swelling of the patients. Body composition analyses will be performed via skinfold measurements following generalized three-site skinfold equations for male and females as recommended by the ACSM, 2005 and via the utilization of a bioelectrical impedance body fat analyzer device.
1788495|NCT00499759|Behavioral|Timed Get-up and Go test (TGUG).|"The functional mobility of the subjects that will participate in the study will be assessed through the Timed Get-up and Go test (TGUG). The administration of the TGUG includes measuring a distance of 3 meters from the legs of a straight-backed armchair with a seat height of approximately 46 centimeters. The subject will be asked to sit with the back against the chair with the arms on the arm rests. When instructed to begin the test (on the command Go), the subject will have to stand upright then walk at a normal walking pace toward the 3 meters mark placed on the ground, turn around, return to the chair, and sit down. The stopwatch was started on the word Go and stopped when the subject gets back to starting position."
1788496|NCT00499759|Behavioral|Cardiorespiratory assessment|The cardiorespiratory assessment will be performed on a recumbent cycle ergometer. Subjects will be asked to cycle at a target submaximal intensity of 60 % of their percentage of heart rate range until a RPE (Rate of Perceived Exertion) of 7 is reached on the modified Borg Scale or when the subject requests termination. The Borg modified RPE scale is a scale ranging from 0 to 11 where 0 means no exertion at all and 11 equals to an exertion of absolute maximum. The total time cycling and heart rate (HR) at the end of the test will be recorded immediately after the test is completed.
1788497|NCT00499759|Behavioral|Handgrip evaluation|Handgrip strength will be tested using a handgrip dynamometer. Subjects will be asked to stand and hold the handgrip dynamometer in one hand lined with the forearm that will be placed beside the body. Maximum grip strength is then determined without swinging the arm and by squeezing the handgrip dynamometer as hard as possible using one brief maximal contraction with no extraneous body movement. The test will be administered three times for each hand with a one-minute rest in between trials. The best score within the three trials for each arm will be the one that will be used for analysis.
1788498|NCT00499759|Behavioral|Dynamic muscular endurance|Subjects will be asked to squat to a 75 degree knee angle with moderate speed, pressing back against the ball at all times. This is repeated as many repetitions as it takes for the subject to report an RPE of 7 or wishes to stop. The second test is the biceps curl exercise. The biceps curls exercise test will follow a protocol developed at the Rocky Mountain Cancer Rehabilitation Institute (RMCRI), Greeley, Colorado. The protocol involves the administration of the exercise biceps curls, done with dumbbells. Subjects will be asked to perform as many repetitions as possible during an alternated biceps curl exercise using a percentage of their body weight as resistance.
1788499|NCT00499811|Drug|vorinostat|Given orally
1788500|NCT00499811|Other|pharmacological study|Correlative studies
1788501|NCT00499824|Behavioral|Education of general practitioners on the IDF-WPR guidelines|"The intervention will comprise an educational program on the guidelines for GPs, and will be carried out by the national coordinating centre in each country, based on a template provided by the international coordinating centre (International Diabetes Institute, Australia). This will involve:
an initial educational symposium and a follow-up continuing medical education symposium at 3 months; paper or electronic reminders of the guidelines sent to GPs every 3 months; desktop reminder cards with guideline algorithms; insertion of a flowsheet (diabetes action plan) into the patient's medical notes by the study nurse; provision of each patient with a diabetes passport to be held by the patient."
1788502|NCT00499837|Drug|Aerosolized, human, plasma-derived Alpha-1 Antitrypsin|
1788503|NCT00499850|Drug|ZD6474 (vandetanib)|once daily oral dose
1788504|NCT00499850|Drug|5-Fluorouracil|intravenous infusion
1788505|NCT00499850|Drug|Leucovorin|intravenous infusion
1788506|NCT00499850|Drug|Oxaliplatin|intravenous infusion
1788507|NCT00499863|Drug|methylphenidate transdermal system|dose optimization of 4 doses of the MTS transdermal patch over the same duration of wear
1788508|NCT00499863|Drug|Placebo|Placebo patch
1788509|NCT00499876|Drug|mefloquine|250mg weekly PO for 6 months
1788510|NCT00499876|Other|placebo|1 tablet weekly PO for 6 months
1788511|NCT00499889|Drug|Imatinib Mesylate|400 mg by mouth twice daily for 9 Days
1788512|NCT00499889|Drug|Fludarabine (Fludara)|40 mg/m^2 by vein daily for 4 Days
1788513|NCT00499889|Drug|Busulfan|130 mg/m^2 by vein daily for 2 Days
1788514|NCT00499889|Drug|Antithymocyte Globulin (ATG)|2.5 mg/kg by vein daily for 3 Days
1788515|NCT00499889|Drug|Tacrolimus|Tacrolimus levels maintained between 5-15 ng/dl, first as continuous IV infusion, and converted to oral every 12 hour dosing as tolerated. Starting day -2 until day 180.
1788516|NCT00499889|Drug|Methotrexate|5 mg/m2 on days 1, 3, 6 and 11.
1788517|NCT00499889|Procedure|Donor lymphocyte infusion (DLI)|Infusion of lymphocytes from the original bone marrow donor by vein if relapse after >4 weeks of imatinib.
1788518|NCT00499889|Procedure|Stem Cell Transplant|Infusion of donor bone marrow or blood stem cells by vein over approximately one hour on day 0.
1788519|NCT00499902|Drug|alfimeprase|Alfimeprase will be given as a single bolus of 1mg/2mL, or a split bolus of 5mg/2mL or 10mg/2mL in a three-tier dose escalation format. The 5mg and 10mg doses will be administered as split doses with 1/2 of the total dose given initially and 1/2 of the total dose given 30 minutes after the initial dose.
1788520|NCT00499915|Behavioral|Secondhand Smoke Reduction and Smoking Cessation Counseling|A secondhand smoke reduction program, including smoking cessation counseling (if appropriate), and feedback about the children's cotinine levels will be implemented using principles of Motivational Interviewing.
1788521|NCT00499915|Behavioral|Asthma Education|Asthma education will be provided at NICU discharge.
1788522|NCT00499928|Drug|SB-751689|
1788523|NCT00499954|Procedure|Microdialysis|
1788524|NCT00499954|Device|Guardian RT|
1788525|NCT00499954|Device|Glucoday S|
1788526|NCT00499967|Drug|GS-9191 ointment|GS-9191 ointment (0.01%, 0.03%, or 0.1%) or placebo applied topically to anogenital warts for one or three cycles, each cycle lasting 5 consecutive nights of ointment application followed by 9 nights off-ointment. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
1788527|NCT00499967|Drug|GS-9191|GS-9191 ointment (0.3% or 1.0%) or placebo applied topically to anogenital warts for one or three cycles; each cycle consists of dosing occuring over a 5-night period with ointment application on nights 1, 3 and 5 followed by a 9-day off-ointment period. The strength of GS-9191 ointment is cohort-dependent, with escalation to higher dose cohorts dependent upon safety and tolerability in the previous cohort.
1788528|NCT00499967|Drug|Placebo|Placebo matching GS-9191 ointment
1788529|NCT00499993|Drug|lanreotide (Autogel formulation), duration of treatment 46-48 weeks|
1788530|NCT00500006|Drug|MK0457|"Schedule A: 5-day continuous IV infusion every 28 days MK0457 (dose determined by height and weight). Starting dose = 20 mg/m2/hour titrating up to 33 mg/m2/hour.
Schedule B: 6-hr IV infusion every 14 days MK0457 (dose determined by height and weight). Starting dose = 64 mg/m2/hour titrating up to 216 mg/m2/hour."
1788531|NCT00500006|Drug|dasatinib|Oral dasatinib 70 mg b.i.d. tablets twice daily.
1788532|NCT00500032|Procedure|blood draw|Blood draw from subjects previously vaccinated in 6108A1-500 trial
1788533|NCT00500045|Drug|nicotinic acid|niacin 1500 mg po qd
1788534|NCT00500058|Drug|SB-485232|SB-485232 for injection, 7 mg/vial, will be available as a lyophilized cake. It will be reconstituted with 1.4 mL of water for injection. Each vial of this drug product is a clear, colorless solution containing 5 mg/mL of SB-485232.
1788535|NCT00500058|Drug|Rituximab|Rituximab 375 mg/m^2 will be administered by IV infusion.
1788536|NCT00500071|Drug|Vyvanse (lisdexamfetamine dimesylate)|Vyvanse™ 20mg once daily at 7 a.m.; dose increased weekly by 10mg until an acceptable response is achieved. Titration may proceed to a maximum daily dose 70mg/day.
1788537|NCT00500084|Drug|Liprotamase|Administered orally
1788538|NCT00500097|Device|Digital retina image|
1788539|NCT00500097|Device|direct ophthalmoscopy|
1788540|NCT00500097|Procedure|comprehensive eye exam|
1788541|NCT00500110|Drug|Docetaxel|30 mg/m^2 by vein (IV) Weekly Over 60 Minutes on Days 1, 8, 15, and 22. This will be followed by 2 weeks with no docetaxel.
1788542|NCT00500110|Drug|Imatinib Mesylate|600 mg by mouth (PO) Daily x 42 Days.
1788543|NCT00500110|Drug|Leuprolide|Hormone injections given every other month or every 3 months, as determined by the doctor.
1788544|NCT00500110|Drug|Goserelin Acetate|Hormone injections given every other month or every 3 months, as determined by the doctor.
1788545|NCT00500123|Procedure|Alpha-1 Antitrypsin Genotype|Home fingerstick testing for alpha-1 antitrypsin genotype
1788546|NCT00500136|Procedure|mortality salience|
1788547|NCT00500149|Drug|Vyvanse (lisdexamfetamine dimesylate)|Following completion of the open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day).
1788548|NCT00500149|Drug|Placebo|Placebo
1788549|NCT00500162|Behavioral|Tri-Luma Maintenance regimen|
1788550|NCT00500175|Device|TempTouchRM|
1788551|NCT00500175|Device|Offloading|
1788553|NCT00500201|Drug|SB- 773812 60 mg|SB- 773812 will be available dose strength of 60 mg and administered orally by subjects.
1788554|NCT00500201|Drug|SB- 773812 120 mg|SB- 773812 will be available dose strength of 120 mg and administered orally by subjects.
1788555|NCT00500201|Drug|Placebo|Placebo tablets will be administered orally by subjects.
1788556|NCT00500214|Procedure|elective ilioinguinal nerve excision|
1788557|NCT00500240|Drug|Insulin Glargine|Use of human insulin glargine for slow decrease of blood sugar level over 24 hours.
1788558|NCT00500240|Drug|Insulin Aspart|Use of human insulin aspart for rapid lowering of the blood glucose level over 24 hours.
1788559|NCT00500253|Device|exhaled nitric oxide measurement|exhaled nitric oxide measurement
1788560|NCT00500253|Procedure|bronchial hyperresponsiveness with methacholine (PC20M)|bronchial hyperresponsiveness with methacholine (PC20M)
1788561|NCT00500253|Procedure|symptom score diary (according to 2007 GINA guidelines)|symptom score diary (according to 2007 GINA guidelines)
1788562|NCT00500266|Biological|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|
1788563|NCT00500279|Drug|Celecoxib|
1788564|NCT00500292|Drug|Vandetanib|once daily oral tablet two dose strengths
1788565|NCT00500292|Drug|FOLFOX regimen=oxaliplatin, fluorouracil, & folinic acid|intravenous infusion
1788566|NCT00500305|Procedure|Withhold standard INDO dose if BNP < 100 pg/ml|
1788567|NCT00500318|Drug|Aclidinium Bromide|Aclidinium Bromide, 200μg. Once daily oral inhalation.
1788568|NCT00500318|Drug|Placebo|Dose matched placebo, once daily oral inhalation.
1788572|NCT00500344|Drug|Lucentis (ranibizumab)|intravitreal injection
1788573|NCT00500357|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose 13vPnC
1788574|NCT00500370|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
1788575|NCT00500370|Drug|placebo|subcutaneous injection (equivalent volume to active dose), twice a day
1788576|NCT00500396|Procedure|Open-Sky Vitrectomy|Open-Sky vitrectomy with removal of the Tunica vasculosa lentis and retinal reattachment
1788577|NCT00500409|Drug|Osteoform|Administer Osteoform 20 µg daily subcutaneously and 1000 mg calcium and 500 IU vitamin D orally for 180 days
1788578|NCT00500409|Drug|SHELCAL|Administer calcium and vitamin D (1000 mg calcium and 500 IU vitamin D) orally for 180 days
1788579|NCT00500422|Drug|Doxil|Starting dose of 20 mg/m^2 IV over 2 hours on Day 1, 21 day cycle
1788580|NCT00500422|Drug|Gemcitabine|500 mg/m^2 IV over 30 minutes on Days 1 and 8, 21 day cycle
1788581|NCT00500422|Drug|Velcade|Starting dose of 0.7 mg/m^2 IV on Days 1 and 8 of first 21 day cycle; increased dose of 1.0 to 1.3 on Days 1, 4, 8, and 11 of subsequent 21 day cycles
1788582|NCT00500435|Procedure|Extraperitoneal Laparoscopic Lymphadenectomy|Laparoscope used to find and remove para aortic lymph nodes in abdomen.
1788583|NCT00500448|Device|Electrical Stimulation|Electrical Stimulation (NMES) will be delivered 3 times per week for 4 weeks
1788584|NCT00500461|Drug|GSK233705|GSK233705 will be available as IV infusion and oral solution containing Cellobiose octaacetate.
1788588|NCT00500487|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of health topics.
1788589|NCT00500500|Drug|EGb 761® (Tanakan®)|
1788590|NCT00500513|Procedure|CT Scans|CT scan performed weekly to measure how much the tumor moves + additional pulmonary function measurements.
1788591|NCT00500513|Procedure|Implanted markers|Implanted radio-opaque fiducial markers, diameter of 1.0 - 2.0 mm, inserted through a catheter at several chest locations using a flexible bronchoscope
1788592|NCT00500513|Radiation|Radiation Treatment (RT)|Radiotherapy incorporating respiratory treatment delivery
1788593|NCT00500526|Other|Singing practice|
1788594|NCT00500526|Other|Singing classes|
1788595|NCT00500526|Other|Hand craft classes|
1788596|NCT00500539|Drug|omalizumab|The liquid formulation of omalizumab was packaged in a pre-filled safety syringe containing either 75 mg (0.5ml) or 150 mg (1.0 ml) of drug. The syringes were clearly marked so that the health care provider could differentiate between the 75 mg or 150 mg syringe.
1788597|NCT00500552|Drug|Perhexiline/Placebo|
1788598|NCT00500565|Drug|Saline|On-Q Pain Pump filled with Saline. The On-Q pump will be connected to the catheter to deliver a constant flow of saline for up to 5 days.
1788599|NCT00500565|Drug|Bupivicaine|On-Q Pain Pump filled with 0.375% Bupivicaine through two catheters at a total rate of 4 cc/hr over 111 hours. The On-Q pump will be connected to the catheter to deliver a constant flow of Bupivicaine for up to 5 days.
1788600|NCT00500578|Drug|Ribavirin|Arm 1 = 6 Grams Over 18 hours Every 24 Hours
1788601|NCT00500578|Drug|Ribavirin|Arm 2 = 2 Grams Over 3 Hours Every 8 Hours.
1788602|NCT00500591|Behavioral|Questionnaire|Questionnaire regarding weight history, gynecologic, and medical history, lasting about 30 minutes.
1788603|NCT00500604|Drug|Irbesartan/hydrochlorothiazide|150/12.5mg tablet and 300/12.5mg tablet
1788604|NCT00500604|Drug|Valsartan/hydrochlorothiazide|80/12.5mg tablet and 160/12.5mg tablet
1788605|NCT00500604|Drug|Hydrochlorothiazide|12.5 mg administered orally, once daily in the morning
1788607|NCT00500630|Device|Body fixed 3D sensors|
1788608|NCT00500656|Drug|Icatibant|Icatibant: a stable, synthetic decapeptide and specific BK B2 receptor antagonist.
1788609|NCT00500656|Drug|Tranexamic Acid|over encapsulated film tablet an anti-fibrinolytic agent,is used in some European countries for the treatment of acute oedema episodes and the continuous prophylaxis of HAE.
1788610|NCT00500656|Drug|Oral Placebo|hard capsule matched to tranexamic acid
1788611|NCT00500656|Drug|S.C. Placebo|solution for injection, matched to icatibant for injection
1788612|NCT00500669|Drug|Betadine|Topically
1788615|NCT00500695|Behavioral|Motivational Interviewing|Motivational Interviewing
1788616|NCT00500695|Behavioral|Psychoeducation|Psychoeducation
1788617|NCT00500721|Drug|HCV-796|HCV-796 500mg BID x 14 days
1788618|NCT00500721|Drug|Desipramine|"Period 1: Single oral dose of desipramine (50 mg) on day 1. No test article administration on days 2 to 6.
Period 2: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 1 to 9.
Period 3: Multiple oral doses of HCV-796 (500 mg) every 12 hours on days 10 to 14 and a single oral dose of desipramine (50 mg) on day 10."
1788619|NCT00500734|Procedure|Blood Sample|One time blood draw of 2 teaspoons.
1788620|NCT00500747|Biological|HCV E1E2/MF59|The investigational vaccine contains envelope glycoproteins gpE1 and gpE2 and the adjuvant, MF59. MF59 is a sterile oil-in-water emulsion in a citrate buffer, which comprises 50 percent of the vaccine. The antigen and adjuvant are combined prior to the injection. The volume to be administered is 0.5 mL for all vaccine dose levels. The vaccine has a milky white opacity. Vaccine dosages: 4 mcg, 20 mcg and 100 mcg.
1788621|NCT00500747|Drug|Placebo|Four doses sterile saline (0.5 mL total volume) at 0, 4, 24, and 28 weeks.
1788622|NCT00500760|Drug|Cisplatin|Administered intravenously (IV; in a vein)
1788623|NCT00500760|Radiation|Standard Fractionation Radiotherapy|70 Gy administered in 2 Gy fractions daily for 5 days a week for 7 weeks (35 fractions)
1788624|NCT00500760|Drug|Panitumumab|Administered intravenously
1788625|NCT00500786|Biological|CYT006-AngQb|
1788626|NCT00500812|Drug|Cethrin|
1788627|NCT00500825|Procedure|Measurement of Resting Energy Expenditure|Non-invasive measurement of Resting Energy Expenditure
1788628|NCT00500838|Device|Transthoracic Impedance|Impedance measures will be automatically collected via the device
1788629|NCT00500851|Device|Electromagnetic imaging for jejunal tube placement (CORTRAK)|Jejunal feeding tubes are placed using electromagnetic imaging (CORTRAK)
1788630|NCT00500851|Device|Endoscopy|Endoscopic placement of jejunal feeding tubes
1788631|NCT00500864|Drug|Magnesium Sulfate 2 grams|
1788632|NCT00500877|Behavioral|Mood Management Phone Counseling for Smoking Cessation|Phone counseling addressed mood management and smoking cessation
1788638|NCT00500903|Drug|MLN8237|MLN8237 will be supplied in capsules of 5 or 25 mg and will be given on an empty stomach, with patients remaining nothing by mouth except for water and prescribed medications for 2 hours before and 1 hour after each dose. Each dose will be given by mouth with 8 ounces of water for 7 to 21 consecutive days. A 14-day recovery period will follow each dosing period regardless of its duration.
1788639|NCT00500916|Device|ProSeal LMA|GEB vs digital vs introducer tool
1788640|NCT00500929|Drug|CMI X-11S|
1788641|NCT00500942|Behavioral|Questionnaire|Questionnaires about the pain level experienced during and after standard procedures are performed in the IR.
1788642|NCT00500955|Drug|Rosiglitazone|
1788643|NCT00500968|Procedure|stent|ERCP guided stent insertion before transection of the gland
1788771|NCT00501852|Drug|Tiotropium|Handihaler inhaler
1788644|NCT00500968|Procedure|Distal pancreatectomy|conventional distal pancreatectomy
1788645|NCT00500981|Procedure|Volume challenge|
1788646|NCT00500981|Procedure|Ultrasound evaluation of internal jugular vein|
1788648|NCT00501033|Device|Mechanical induction of labor|
1788649|NCT00501033|Device|Double Balloon|
1788650|NCT00501033|Device|Foley Catheter|
1788653|NCT00501059|Drug|Aspirin (Acetylsalicylic acid, BAYE4465)|100mg enteric coated Aspirin, taken daily
1788654|NCT00501059|Drug|Placebo|Placebo, taken daily
1788655|NCT00501072|Device|Real-Time Continuous Glucose monitoring System (RT-CGMS)|
1788656|NCT00501085|Device|LAP-BAND AP Adjustable Gastric Banding System|Reduction of food intake due to creation of smaller stomach pouch.
1788657|NCT00501098|Drug|Caspofungin|"Patients will receive caspofungin, starting from the first day of induction chemotherapy for leukemia, as a single daily dose intravenously at the dosage of 70 mg q.d. and followed by 50 mg q.d. thereafter until documentation of complete hematologic remission after the first induction cycle or of leukemia persistence after one cycle of induction and one cycle of salvage chemotherapy.
No stratification is planned."
1788660|NCT00501124|Drug|Clevudine|
1788661|NCT00501124|Biological|Purified hepatitis B surface antigen|
1788662|NCT00501137|Biological|HPV (Human Papillomavirus) Vaccine|HPV (Human Papillomavirus) Vaccine received by all participants in groups 1, 2 and 3 according to the arm
1788663|NCT00501150|Drug|linezolid|
1788664|NCT00501176|Procedure|Plastic and metalic stent inserion|Patient randomizes to metal or plastic insertion prior to Whipple procedure
1788665|NCT00501189|Biological|human papillomavirus vaccine L1, type 6,11,16,18|Subjects are those getting gradasil vaccination already. This is really not an intervention
1788666|NCT00501202|Drug|placebo|twice daily for 4 weeks
1788667|NCT00501202|Drug|RWJ-333369 (carisbamate)|200 mg tablet twice daily for 4 weeks
1788668|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery 1-3 weeks after the first PSG.
1788669|NCT00501215|Behavioral|Telephone Interview|Interview about sleep quality lasting 15-20 minutes.
1788670|NCT00501215|Procedure|Parathyroid Surgery|Parathyroid surgery after completing the second PSG and after the study participation ends.
1788671|NCT00501215|Behavioral|Polysomnography (PSG)|"2 overnight sleep tests
Group 1: First PSG 1-3 weeks before surgery + Second PSG 6-8 weeks after surgery
Group 2: First PSG 1-3 weeks before phone interview + Second PSG 6-8 weeks after phone interview"
1788672|NCT00501228|Drug|Filgrastim|5 mg/kg ID Once Daily x 1 Week
1788673|NCT00501241|Drug|ATI-7505|Tablet,placebo, BID
1788674|NCT00501241|Drug|ATI-7505|ATI-7505 20 mg BID for 4 weeks
1788675|NCT00501241|Drug|ATI-7505|tablet, 40 mg, BID, $ weeks
1788676|NCT00501241|Drug|ATI-7505|80 mg ATI-7505, BID for 4 weeks
1788677|NCT00501241|Drug|ATI-7505|120 mg ATI-7505, BID, for 4 weeks
1788678|NCT00501254|Drug|Slow release acetyl salicylic acid|
1788679|NCT00501254|Behavioral|Antithrombotic effect|
1788680|NCT00501267|Drug|solabegron and oxybutynin|
1788681|NCT00501280|Behavioral|Interview|Interview by telephone or on-site in language of choice (English or Spanish), 60 to 70 minutes to complete the mother's and the child participants' questionnaires
1788682|NCT00501293|Drug|Methylphenidate Transdermal System|One of 4 doses of the MTS transdermal patch over the same duration of wear for approximately 6 months
1788683|NCT00501319|Behavioral|Interactive Voice Response (IVR)|Phone calls once weekly for the first 3 months after surgery, then every two weeks for an additional 3 months.
1788684|NCT00501319|Behavioral|Questionnaire|Questionnaires taking 20 minutes to complete.
1788685|NCT00501332|Biological|Maxy-G34|Maxy-G34 will be administered by subcutaneous injection during each of 6 TAC chemotherapy cycles.
1788686|NCT00501345|Drug|Aspirin|325 mg by mouth on Day 1 only, followed by 160 mg by mouth daily
1788687|NCT00501371|Drug|MCS|soft-gel capsule, 15 mg/cap., Qd, 12 weeks
1788688|NCT00501371|Drug|Placebo|soft-gel capsule, Qd, 12 weeks
1788689|NCT00501384|Drug|satavaptan (SR121463B)|
1788690|NCT00501397|Drug|ketoconazole|
1788691|NCT00501397|Drug|GSK189075|
1788692|NCT00501410|Drug|5-FU|2400 mg/m^2 by vein over 46 Hours On Days 1 & 2.
1788693|NCT00501410|Drug|Cetuximab|Initial Dose = 400 mg/m^2 by vein, then 250 mg/m^2 Weekly On Days 1 & 8
1788694|NCT00501410|Drug|Dasatinib|Starting dose level: 100 mg by mouth daily on days 1-14.
1788695|NCT00501410|Drug|Leucovorin|400 mg/m^2 by vein on day 1.
1788696|NCT00501410|Drug|Oxaliplatin|85 mg/m^2 by vein on day 1.
1788697|NCT00501449|Behavioral|Questionnaire|Mailed packets including cover letter describing purpose of study, study questionnaire, and return envelope.
1788698|NCT00501462|Drug|GSK189075|single 250 mg dose of drug
1788699|NCT00501475|Drug|NAC Bicarbonate|
1788700|NCT00501488|Drug|rosiglitazone|
1788701|NCT00501501|Procedure|Cesarean section|
1788702|NCT00501501|Procedure|Vaginal delivery|
1788703|NCT00501514|Drug|Growth hormone|
1788704|NCT00501527|Biological|Immunotherapy with modified extract of P. pratense pollen|Sublingual (2 drops daily)
1788705|NCT00501527|Other|Placebo|Placebo 2 drops daily
1788706|NCT00501540|Drug|Lithium Carbonate|Lithium 300mg PO TID escalating to a lithium level of 0.8-1.2. Lithium carbonate will be administered the first week at 300 mg flat dose three times each day. A serum lithium level will be checked after 4-5 days of treatment by drawing a blood sample prior to the morning dose of lithium. Evaluate every 8 weeks.
1788707|NCT00501566|Drug|satavaptan (SR121463B)|
1788708|NCT00501579|Drug|Difluprednate|
1788709|NCT00501579|Drug|Prednisolone Acetate|
1788710|NCT00501592|Drug|INT-747|25 mg by mouth once daily, 50 mg by mouth once daily
1788711|NCT00501592|Drug|Placebo|Placebo
1788712|NCT00501605|Drug|AZD2171|
1788713|NCT00501618|Drug|Fazaclo|single-arm
1788714|NCT00501631|Drug|VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
1788715|NCT00501631|Drug|Placebo for VIVITROL 380 mg|Administered via IM injection once every 4 weeks.
1788716|NCT00501644|Drug|Carboplatin|AUC of 5 by 1 hour IV infusion every 28 days.
1788717|NCT00501644|Drug|GM-CSF (Sargramostim)|Starting dose of 400 mg injected under the skin once a day for 7 days prior to and following each course of chemotherapy.
1788718|NCT00501644|Drug|Interferon Gamma|0.1 mg injected under the skin for 2 days before and after chemotherapy (Day 5 and Day 7 of each 7-day GM-CSF cycle).
1788719|NCT00501657|Drug|Sitagliptin|100mg mane for 2 days
1788720|NCT00501657|Drug|Placebo|100mg mane for 2 days
1788721|NCT00501670|Procedure|Herpes zoster sampling procedure for VZV PCR|Four types of HZ lesions will be collected (Swabs of vesicles, Swabs of papules, Swabs of crusts and Crusts), 3 replicates of each.
1788722|NCT00501670|Procedure|Blood sampling|Two blood samples taken, the first at the time of HZ diagnosis and the second one month later.
1788723|NCT00501683|Drug|Radiolabelled GSK189075|
1788724|NCT00501696|Drug|4.5 mg Naltrexone|low dose naltrexone 4,5mg on the multiple sclerosis quality of life inventory (MSQLI54)
1788725|NCT00501696|Drug|Naltrexone|4,5mg low dose naltrexone on the multiple sclerosis quality of life inventory (MSQLI54)
1788726|NCT00495820|Drug|Methylphenidate|Subject will receive 5mg twice a day for two weeks then 10mg twice a day until week 12 of the study.
1788727|NCT00495820|Other|Placebo|Standard inactive pill.
1788728|NCT00495833|Behavioral|Personalized brochure|either photo personalization, blood pressure personalization, both, or no personalization
1788729|NCT00495833|Behavioral|Promotional gift|half of participants who go to a fire station will receive a gift card.
1788730|NCT00495846|Drug|Octreotide-LAR, Lanreotide Autogel|Octreotide-LAR intramuscular, dose of 30 mg every 28 days to increase up to 60 mg; lanreotide autogel 120 mg deep subcutaneous every 28 days for 3 months then uptitrated according with the protocol.
1788731|NCT00495846|Other|Locoregional treatments|
1788732|NCT00495859|Dietary Supplement|Immunonutrition|food for special medical purpose (FSMP)
1788733|NCT00495859|Dietary Supplement|food for special medical purposes (FSMP)|an isocaloric isonitrogenous non-specific nutritional support
1788734|NCT00495872|Drug|Dasatinib|50 mg by mouth (PO) Twice Daily for 28 Days Every 28 Days
1788735|NCT00495872|Drug|Erlotinib|100 mg PO Daily for 28 Days Every 28 Days
1788736|NCT00495872|Drug|Lapatinib|1000 mg PO Daily for 28 Days Every 28 Days
1788737|NCT00495872|Drug|Lenalidomide|15 mg PO Daily for 28 Days Every 28 Days
1788738|NCT00495872|Drug|Sorafenib|400 mg PO Daily for 21 Days Every 28 Days
1788739|NCT00495872|Drug|Sunitinib|25 mg PO Daily for 21 Days Every 28 Days
1788740|NCT00495872|Drug|Valproic Acid|40 mg/kg PO Daily for 7 Days, then 7 Days Off
1788741|NCT00495885|Drug|volinanserin (M100907)|oral, one tablet taken around bedtime
1788742|NCT00495885|Drug|Placebo|oral, one tablet taken around bedtime
1788743|NCT00495898|Device|CYPHER sirolimus-eluting stent|drug-eluting stent
1788744|NCT00495898|Device|uncoated Bx VELOCITY balloon-expandable stent|bare metal stent
1788745|NCT00495924|Procedure|Pancreatic resection (PD)|PD is a standard therapeutic surgical procedure. No additional interventions are performed.
1788746|NCT00495950|Behavioral|Questionnaire|Questionnaires relating to symptoms experienced during and following standard cancer treatment.
1788747|NCT00495963|Procedure|bronchoaleolar lavage|
1788748|NCT00495963|Procedure|Bronchoscopy|
1788749|NCT00495976|Other|A commercially produced cordial drink|
1788750|NCT00495989|Procedure|saliva sampling + dental calculus collection|
1788751|NCT00501709|Drug|Belatacept|IV infusion - 10mg per kilo at day 0,4,14,28,56,84 and then 5mg per kilo monthly through month 12 and then 5mg per kilo every 4-6 weeks for the remainder of the study.
1788752|NCT00501722|Drug|satavaptan (SR121463B)|
1788753|NCT00501735|Drug|Forodesine 200 mg|2 x 100mg tablets once daily
1788754|NCT00501748|Drug|Rituximab|Rituximab is a highly purified, 1328-amino acid antibody with an approximate molecular mass of 145 kD. Rituximab is a sterile, clear, colorless, preservative-free liquid concentrate for intravenous (IV) administration. Rituximab is supplied at a concentration of 10 mg/mL in either 100 mg (10 mL) or 500 mg (50 mL) single-use vials. In this single arm study all subjects are treated with two cycles of rituximab. Each cycle consists of two 1000 mg infusions administered two weeks apart. The cycles of rituximab treatment are administered at baseline and at 9 months.
1788755|NCT00501761|Behavioral|Personalized Exercise Program|Walking up to thirty minutes on most days of the week.
1788756|NCT00501761|Behavioral|Questionnaire|Questionnaires regarding physical activity, exercise, and quality of life.
1788757|NCT00501761|Behavioral|Suggested Exercise Program|Exercise program performed over 7 days.
1788758|NCT00501787|Drug|Metformin|
1788759|NCT00501813|Procedure|Hepatectomy|irregular Hepatectomy
1788760|NCT00501813|Procedure|TACE combined with local regional therapies without hepatectomy|TACE combined with RFA, MCT, PEI, and so on.
1788761|NCT00501826|Drug|Doxorubicin|"Hyper-CVAD (odd courses 1, 3, 5, 7):
50 mg/m^2 IV over 24 hours on day 4 after last dose of Cyclophosphamide (CTX)"
1788762|NCT00501826|Drug|Cyclophosphamide|"Hyper-CVAD (odd courses 1, 3, 5, 7):
300 mg/m^2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2)."
1788763|NCT00501826|Drug|Cytarabine|"High-dose Methotrexate plus cytarabine (even courses 2, 4, 6, 8):
Cytarabine 3 gm/m^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3"
1788764|NCT00501826|Drug|Dexamethasone|"Hyper-CVAD (odd courses 1, 3, 5, 7):
40 mg IV or by mouth (PO) daily days 1-4 and 11-14."
1788765|NCT00501826|Drug|Methotrexate|"High-dose Methotrexate plus cytarabine (even courses 2, 4, 6, 8):
200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 over 22 hours on day 1."
1788766|NCT00501826|Drug|Vincristine|"Hyper-CVAD (odd courses 1, 3, 5, 7):
2 mg IV days 4 and 11 (+/- 2 days)"
1788767|NCT00501826|Drug|Nelarabine|650 mg/m^2 IV over 2 hours daily x 5 days every 21 to 35 days x 2 courses.
1788768|NCT00501839|Drug|clomiphene citrate|
1788769|NCT00501852|Drug|NVA237|single-dose dry-powder inhaler (SDDPI)
1788770|NCT00501852|Drug|Placebo|single-dose dry-powder inhaler (SDDPI)
1788772|NCT00501865|Drug|GW273225|GW273225 will be available as white tablets containing 25 mg GW273225.The study drug will be taken with 240 milliliters of water at room temperature.
1788773|NCT00501878|Drug|2.5% or 10% phenylephrine|
1788774|NCT00501891|Drug|Bevacizumab|Bevacizumab administered intravenously 10mg/kg every other week.
1788775|NCT00501891|Drug|Metronomic Temozolomide|Temozolomide 50mg/m2 given orally on a daily basis.
1788776|NCT00501904|Drug|Metformin|
1788777|NCT00501917|Drug|G-CSF with/without darbepoetin, peripheral blood stem cell infusion|
1788778|NCT00501930|Drug|GSK189075|
1788779|NCT00501943|Drug|Avonex (Interferon beta 1a)|
1788780|NCT00501943|Drug|Riluzole|
1788781|NCT00501943|Drug|Placebo|
1788782|NCT00501956|Drug|Intradialytic Parenteral Nutrition (IDPN)|compounded IDPN, 3 x/week, 16 weeks intervention
1788783|NCT00501969|Drug|Rotigotine|"Rotigotine trans-dermal patches once daily:
20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours) 50 cm2 (10 mg/24 hours) 60 cm2 (12 mg/24 hours) 70 cm2 (14 mg/24 hours) 80 cm2 (16 mg/24 hours)"
1788784|NCT00501982|Drug|Poractant alfa (Curosurf®)|
1788785|NCT00501995|Drug|IV Cyclophosphamide|Cyclophosphamide (50 mg/kg) intravenously daily for 4 consecutive days (total 200 mg/kg) followed by granulocyte colony-stimulating factor (5 µg/kg/day)
1788786|NCT00502008|Drug|Coccinia Cordifolia (herbal extract)|
1788787|NCT00502021|Dietary Supplement|Placebo|Manioc powder (placebo) 60 g/day
1788788|NCT00502021|Dietary Supplement|Alpha-linolenic acid/ALA|Flaxseed powder 60 g/day (10 g ALA)
1788789|NCT00502021|Dietary Supplement|Alpha linolenic acid/ALA|Flaxseed oil 30 ml/day (10 g ALA)
1788790|NCT00502021|Dietary Supplement|Placebo|Safflower oil 30 ml/day
1788791|NCT00502034|Drug|Interferon Alfa-2a|Interferon Alfa-2a in combination with Interleukin
1788792|NCT00502034|Drug|Interleukin-2|Interferon Alfa-2a in combination with Interleukin
1788793|NCT00504231|Biological|Fluzone Influenza Vaccine (2007-2008)|Manufactured by Sanofi Pasteur
1788794|NCT00504244|Drug|switch to Myfortic|Myfortic 2 dd 720 mg
1788795|NCT00504244|Drug|continuation of azathioprine|Azathioprine 2 mg/kg
1788796|NCT00504257|Drug|Avastin|Day 1, every 21 day cycle
1788797|NCT00504257|Drug|Docetaxel|Day 1, 8, every 21 day cycle
1788798|NCT00504270|Drug|Placebo|po daily
1788799|NCT00504270|Drug|RG3421 120mg|120mg po daily
1788800|NCT00504270|Drug|RG3421 20mg|20mg po daily
1788801|NCT00504283|Drug|Toradol|
1788802|NCT00504283|Drug|Morphine|
1788803|NCT00504296|Drug|HDAC inhibitor SB939|SB939 will be administered initially for 3 consecutive days every other week at the first dose level and then for 5 consecutive days every other week at escalating doses.
1788804|NCT00504296|Other|immunoenzyme technique|
1788805|NCT00504296|Other|immunohistochemistry staining method|
1788806|NCT00504296|Other|immunologic technique|
1788807|NCT00504296|Other|laboratory biomarker analysis|
1788808|NCT00504296|Other|liquid chromatography|
1788809|NCT00504296|Other|mass spectrometry|
1788810|NCT00504296|Other|pharmacological study|
1788813|NCT00504322|Genetic|AdcuCD40L|Using Weill-IRB protocol #0011004683 dose escalation study to determine the highest non-toxic dose of the AdcuCD40L vector, this dose (likely 10^11 particle units) will be used for all individuals enrolled in this efficacy study. Since there is no evidence that delay of surgery for solid tumors for 15 days following diagnosis alters the prognosis, surgery for removal of the primary tumor will be carried out at either 5 or 15 days after administration of the vector (n= 12/group, including n=6 receiving the AdcuCD40L vector, and n=6 receiving placebo). This will permit assessment of the resulting data (in a randomized, blinded fashion) and the biologic responses to the AdCUCD40L vector over time.
1788814|NCT00504322|Genetic|Placebo|The placebo will be the salt water-sugar solution used as a vehicle for the vector.
1788815|NCT00504335|Drug|BIO 300 Capsules|
1788816|NCT00504348|Drug|Tacrolimus|Start at the standard starting dose of 0.075mg/kg/day divided into two doses, then adjust doses based on clinical response and tolerability, but maintain whole blood trough levels between 5 to 10 ng/mL and total daily doses equal to or below 0.3mg/kg.
1788817|NCT00504374|Behavioral|Questionnaire|Symptoms questionnaire lasting about 5 to 10 minutes.
1788818|NCT00504400|Drug|Intravitreal injection ranibizumab|Monthly intravitreal injection of of 0.5mg ranibizumab in one eye over one year
1788819|NCT00504413|Drug|midazolam(drug), digoxin (drug)|Midazolam (2mg po) and digoxin (0.5mg po) will be administered one time, an hour apart. Blood concentration will be collected at various points in an 8 hour period.
1788820|NCT00504413|Drug|Bupropion (drug)|Bupropion (150mg po) will be administered one time on a separate visit. Blood concentrations will be collected at various points in a 72 hour period.
1788821|NCT00504413|Drug|Methadone (drug)|Methadone (10mg po) will be administered at a separate visit 2 weeks after the bupropion visit. The dose is given once. Blood concentrations will be measured at various points in a 72 hour period. Pupil constriction will be measured and urine will be collected during this period as well.
1788822|NCT00504426|Drug|OPC-249|1 pugh/day for 4 weeks (30 IU, 60IU, or 90IU)
1788823|NCT00504439|Drug|SB-656933-AAA|The doses of SB-656933 (20 mg, 50 mg or 100 mg) will be provided as a combination of 10 mg and 50 mg tablets of SB-656933-AAA. The tablets will be administered orally.
1788824|NCT00504439|Drug|Matching placebo|SB-656933-AAA matching placebo tablets will be administered orally.
1788825|NCT00504439|Drug|Simvastatin|Simvastatin will be provided as a 40 mg tablet.
1788826|NCT00504452|Drug|KP-1461|Oral dosage, 1600 mg bid for 124 days
1788827|NCT00504465|Drug|dinoprostone|
1788828|NCT00504478|Dietary Supplement|omega-3 fatty acids|omega-3 supplement will be given in addition to high complex carbohydrate diet.
1788829|NCT00504478|Other|high complex carbohydrate diet|
1788830|NCT00504491|Drug|Rituximab-CHOP-Alemtuzumab|Four Rituximab - CHOP courses will be given The courses will be given every 21 days
1788831|NCT00504504|Drug|Rituximab|375 mg/m^2 by vein over 3 to 8 hours weekly for 6 weeks in a row.
1788832|NCT00504504|Drug|Adriamycin|25 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
1788833|NCT00504504|Drug|Bleomycin|10 U/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
1788834|NCT00504504|Drug|Vinblastine|6 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
1788835|NCT00504504|Drug|Dacarbazine (DTIC)|375 mg/m^2 injected by vein over 3 hours every other week for a total of 12 treatments.
1788836|NCT00504517|Other|Evaluating Educational Models|Evaluating various forms of educational models for physicians.
1788837|NCT00504530|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
1788838|NCT00504543|Drug|AEB071|oral, twice daily
1788839|NCT00504543|Drug|Certican|twice daily
1788840|NCT00504543|Drug|Neoral|twice daily
1788841|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet once daily
1788842|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet once daily
1788843|NCT00504556|Drug|Edoxaban (DU-176b)|30mg tablet two times a day
1788844|NCT00504556|Drug|Edoxaban (DU-176b)|60mg tablet two times a day
1788845|NCT00504556|Drug|warfarin|warfarin tablets
1788846|NCT00504582|Drug|Fibrin Sealant|Tisseel applied externally to the dissected axillary area.
1788847|NCT00504595|Drug|ACZ885 (investigational)|The ACZ885 was supplied in 6 mL colorless glass vials each containing nominally 150 mg ACZ885 (with 20% overfill). The vials were kept at 2-8°C. At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
1788848|NCT00504595|Drug|Placebo|Matching placebo of ACZ885 was supplied in the form of a lyophilized cake (Powder for Solution for Infusion). At the investigator's site, solutions for infusion were prepared depending on the volume and dose administered.
1788849|NCT00504608|Drug|Emfilermin, recombinant human leukemia inhibitory factor (r-hLIF)|
1788850|NCT00504634|Drug|Bortezomib|1 mg/m^2 IV On Days 1, 4, 8, and 11.
1788851|NCT00504647|Device|Biventricular Pacemaker|
1788852|NCT00504660|Drug|Capecitabine|Arms 1,3 = 825 mg/m^2 By Mouth (PO) Every 12 Hours on Day 14-27; Arms 2,3 = 825 mg/m^2 PO Every 12 Hours on Day 11-24.
1788853|NCT00504660|Drug|Celecoxib (Celebrex)|Arms 1,3 = 400 mg PO Every 12 Hours On Day 14-27; Arms 2,3 = 400 mg PO Every 12 Hours On Day 11-24.
1788854|NCT00504660|Drug|Temozolomide|Arms 1,3 = 150 mg/m^2 PO Daily On Day 4-8.
1788855|NCT00504660|Drug|Lomustine|Arms 2,3 = 100 mg/m^2 PO on Day 4.
1788856|NCT00504660|Drug|6-Thioguanine|Arms 1,2,3 = 80 mg/m^2 PO Every 6 Hours on Day 1-3.
1788857|NCT00504673|Drug|insulin detemir|
1788858|NCT00504673|Drug|insulin NPH|
1788859|NCT00504673|Drug|insulin aspart|
1788860|NCT00504686|Other|manual therapy|manual therapy - thoracic spine thrust manipulation
1788861|NCT00504686|Other|exercise|therapeutic exercise
1788862|NCT00504699|Procedure|Ovarian stimulation in vitro fertilization cryopreservation|Letrozole 5 mg/day during ovarian stimulation
1788863|NCT00504712|Drug|Testosterone|Sustanon- 200mg- Intramuscular testosterone every 2 weeks
1788864|NCT00504712|Drug|0.9% saline|Saline injection every two weeks
1788865|NCT00504725|Drug|Ketamine|Interventional
1788866|NCT00504725|Drug|0.9% saline|placebo
1788867|NCT00504751|Drug|bortezomib, dexamethasone, ifosfamide|"VIPER chemotherapy will be administered every 28 days at the following doses:
Dexamethasone 40 mg IV days 1-4
Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4
Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)
Cisplatin 25 mg IV days 1-4
Etoposide 100 mg/m2 CIVI over 24 hours days 1-4
Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)
VELCADE 1.5 mg/m2 on days 2 and 5"
1788868|NCT00504751|Drug|mesna, cisplatin, etoposide, rituximab|"VIPER chemotherapy will be administered every 28 days at the following doses:
Dexamethasone 40 mg IV days 1-4
Ifosfamide 1.0 gram/m2 CIVI over 24 hours days 1-4
Mesna 1.0 gram/m2 CIVI over 24 hours days 1-4 (mix solution with ifosfamide)
Cisplatin 25 mg IV days 1-4
Etoposide 100 mg/m2 CIVI over 24 hours days 1-4
Rituximab 500 mg/m2 IV day 1 prior to start of DICE (375 mg/m2 for subsequent cycles)
VELCADE 1.5 mg/m2 on days 2 and 5"
1788869|NCT00504764|Drug|Arsenic Trioxide|"Induction ATO 0.15 mg/kg/day IV until CR or a maximum of 60 days In isolated molecular relapse ATO will be administered at same dose, 5 days a week, during 6 weeks.
Consolidation ATO 0.15 mg/kg/day IV 5 days week, during 5 weeks"
1788870|NCT00504764|Procedure|Autologous Transplantation|Autologous Transplantation
1788871|NCT00504764|Procedure|Allogenic Transplantation|Allogenic Transplantation
1788872|NCT00504764|Drug|ATRA|Consolidation: ATRA 45 mg/m²/day oral during 5 weeks
1788873|NCT00504777|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
1788874|NCT00504777|Drug|Methotrexate|10-25mg/week po or parenteral
1788875|NCT00504790|Drug|GSK923295|anti-mitotic compound
1788876|NCT00504803|Procedure|Mesenchymal stem cell infusion|Infusion of mesenchymal stem cells on the same day as hematopoietic stem cell infusion.
1788877|NCT00504816|Drug|GSK189075|Given with Brevicon to determine any effects of GSK189075 on Brevicon PK.
1788878|NCT00504816|Drug|Brevicon|Given with GSK189075 to determine if GSK189075 exerts an effect on GSK189075 PK.
1788882|NCT00504842|Drug|MRX-801|
1788883|NCT00504842|Drug|Placebo|
1788884|NCT00504855|Other|Casting using Gortex (waterproof) cast padding materials|
1788885|NCT00504855|Other|Casting using cotton/cotton-poly cast padding materials|
1788886|NCT00504881|Drug|Placebo|Daily oral dose of two equal intakes, morning and evening, of Placebo in a double-blinded way for the 16-week Treatment Period
1788887|NCT00504881|Drug|Brivaracetam|Daily oral dose of two equal intakes, morning and evening, Brivaracetam 20 mg/day or Brivaracetam 50 mg/day or Brivaracetam 100 mg/day or Brivaracetam 150 mg/day, in a double-blinded way for the 16-week Treatment Period
1788888|NCT00504894|Drug|Placebo|A low dose given intravenously one time for just under an hour while the subject is shown visually stimulating images in an MRI machine.
1788889|NCT00504894|Drug|Propofol|A low dose of propofol 0.90 μgml−1, given intravenously while the subject is shown visually stimulating images in an MRI machine.
1788890|NCT00504907|Drug|BTA9881|Single oral escalating doses
1788891|NCT00504907|Drug|Placebo|
1788892|NCT00504920|Behavioral|Questionnaire|Questionnaires (30 minutes each) + instruction on telephone survey system for measuring symptoms. Questionnaires 2 times a week while in the hospital or until able to use the telephone survey system.
1788893|NCT00504933|Drug|bilastine|20 mg (encapsulated) tablets QD/14days
1788894|NCT00504933|Drug|Cetirizine|10 mg (encapsulated) tablets. QD/14 days
1788895|NCT00504933|Drug|Placebo|(encapsulated) Tablets QD/14 days
1788896|NCT00504946|Drug|prednisone, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:
20mg prednisone+ 0.3mg lactose"
1788897|NCT00504946|Drug|prednisone, colecalciferol, lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:
20mg prednisone + 1000j colecalciferol + 0.3mg lactose"
1788898|NCT00504946|Drug|lactose|"Allergen immunotherapy (build-up phase)premedication with orally administrated in the day of immunotherapy:
0.3mg lactose"
1788899|NCT00504946|Drug|montelukast sodium|Allergen immunotherapy (build-up phase)premedication with montelukast sodium. Children 6-14 years received 5 mg of montelukast and children > 14 years old received 10mg oral tablet once daily at bedtime
1788900|NCT00504946|Drug|lactose|Allergen immunotherapy (build-up phase)premedication with 0,3mg lactose once daily at bedtime
1788901|NCT00504959|Drug|ranibizumab|
1788902|NCT00504972|Drug|hLL1|hLL1 administered intravenously once daily Monday through Friday for 2 consecutive weeks (10 total doses) at one of 4 planned dose levels: 1.5, 4, 6 or 8 mg/kg.
1788903|NCT00504985|Behavioral|Surveys|2 surveys, taking about 10-15 minutes each, during Emergency Center visit
1788904|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu 2 times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
1788905|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
1788906|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
1788907|NCT00504998|Genetic|Rexin-G|Dose Schedule: 3 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has less than Grade 1 or less toxicity.
1788908|NCT00504998|Genetic|Rexin-G|Dosing Schedule: 4 x 10e11 cfu i.v. three times a week for 4 weeks, followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
1788909|NCT00505024|Behavioral|Interactive Voice Response System|Calls twice weekly, where the system will ask you to rate types of symptoms on a scale from 0 to 10.
1788910|NCT00505024|Other|Symptoms Report|A report of severe symptoms will be sent to your doctor or nurse.
1788911|NCT00505037|Drug|ASP1585|Oral
1788912|NCT00505037|Drug|Placebo|Oral
1788913|NCT00505037|Drug|Sevelamer hydrochloride|Oral
1788914|NCT00505050|Other|Disease Program Management|"This DMP inclused intervention content with education for out patients and caregivers; medication management with optimized therapy based on guidelines, and remote monitoring; delivery personnel with nurses, cardiologists, pharmacists, social workers, dietitians, physical therapists, psychologists; face-to-face individual/group communication, and telephone in-person; the intensity/complexity was long-term follow-up with 6 months interval repetitive education; the environment was hospital out-patient; and the outcomes measured were clinical, quality of life, and adherence.
After randomization patients undergone our multidisciplinary education sessions 60-minute long that covered the basic principles related to heart failure. Telephone calls were used to reinforce the contents of the sessions of the ambulatory education activity, and monitoring of the compliance/adherence, symptoms/signs of worsening heart failure, and self-control mechanisms."
1788915|NCT00505063|Biological|Immunization Schedule patients <7 years.|"Time 0 months: Prevnar 13 #1, Hib #1
Time 1 months: Pediarix #1
Time 2 months: Prevnar 13 #2, Hib #2
Time 3-4 months: Pediarix #2
Time 4-6 months: Draw post vaccine titers
Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
1788916|NCT00505063|Biological|Immunization Schedule patients > or = to 7 years and <11 years of age|"Time 0 months: Hib #1, Prevnar 13 #1, Hepatitis B #1
Time 1 month: Td#1, IPV #1(inactivated polio virus vaccine), Hepatitis B #2
Time 2-3 months: Prevnar 13 #2, Hib #2
Time 3-6 months: Td #2, Draw post vaccine titers Time 6-12 months: Administer Hepatitis #3 to patients not immunized prior to treatment for cancer, or with negative Hepatitis B titers after two immunizations."
1788917|NCT00505063|Biological|Immunization Schedule patients > or = to 11 years of age|"Time 0 month: Hib#1, Prevnar 13#1, Hepatitis B #1
Time 1 month: Tdap(BOOSTRIX), Hepatitis B #2
Time 2-3 months: Hib #2, Prevnar 13#2, Menactra
Time 3-6 months: IPV, Draw post vaccine titers
Time 6-12 months: Gardasil (dose #2 given 2 months after first dose, and dose #3 given 6 months after first dose)"
1788918|NCT00505076|Drug|MK-0777|MK-0777 GEM, 8 mg BID
1788919|NCT00505076|Drug|MK-0777|MK-0777 GEM, 3 mg BID
1788920|NCT00505076|Drug|placebo|2 tablets placebo BID
1788921|NCT00505089|Drug|ACZ885|
1788922|NCT00505089|Drug|ACZ885|
1788923|NCT00505089|Drug|ACZ885|
1788924|NCT00505089|Drug|ACZ885|
1788925|NCT00505102|Drug|Everolimus|cyclosporine dose reduced of 50% after introduction of everolimus
1788926|NCT00505128|Procedure|Endoscopic sphincterotomy|procedure
1788927|NCT00505154|Drug|Rosuvastatin|Rosuvastatin 10 mg tablets od for 6 months
1788928|NCT00505154|Drug|placebo|placebo
1788929|NCT00505167|Drug|Memantine|Patients randomized to receive either memantine or donepezil
1788930|NCT00505167|Drug|Donepezil|Patients randomized to receive either memantine or donepezil
1788931|NCT00505219|Biological|Ixmyelocel-T|Core decompression of the femoral head to remove necrotic tissue with Ixmyelocel-T given to treatment arm only.
1788932|NCT00505219|Other|Standard of Care Only|Core decompression of the femoral head to remove necrotic tissue
1788964|NCT00505492|Drug|Cisplatin|40 mg/m^2 by vein (IV) Weekly Over 4 Hours
1788965|NCT00505492|Drug|Paclitaxel|135 mg/m^2 by vein (IV) Once Every 28 Days
1788933|NCT00505232|Drug|Y-90 Ibritumomab tiuxetan|"Study Design
The present study will be split into two cohorts:
Patients younger than 60 years who will receive 8 chemotherapy cycles
Patients older than 60 years who will receive 6 chemotherapy cycles
The induction schema summarises as follows :
Anti-CD20/Hyper -CVAD chemotherapy will be alternated with anti-CD20 +MTX/Ara-C chemotherapy twice. Afterward, response will be evaluated, followed by, either, four cycles further patients younger than 60 years who will obtain a CR or PR, or 2 cycles patients older than 60 y. (see figure 1 and flow chart).
Consolidation treatment will consist in a single dose of Y90-Ibritumomab -Tiuxetan (Zevalin) [0.4 mCi/Kg b.w or 0.3 mCi/kg if platelets < 100,000/µl] will be administered 8 to 12 weeks after last chemotherapy."
1788934|NCT00505245|Behavioral|Survey|Surveys taking about 20 minutes to complete; collected at multiple time points for some patient populations.
1788935|NCT00505258|Drug|ceftobiprole medocaril|
1788936|NCT00505271|Genetic|Rexin-G|"Three patients will receive Rexin-G at Dose Level I. If 1 of 3 patients at Dose Level I develops a grade 3 or 4 adverse event (CTCAE Version 3.0) which appears to be related or possibly related to Rexin-G, then 3 additional patients will be enrolled at the same dose level. If at least 2 of the first 3, or 3 of 6 patients at Dose Level I develop a grade 3 to 4 adverse event which appears to be related or possibly related to Rexin-G, accrual into the study will be held.
At any dose level, up to six patients may be enrolled if there is evidence of biological activity in the first three patients. Dose escalation may stop if there is impressive evidence of biological activity. An amendment would be submitted to allow further expansion of dose level based on impressive biological activity."
1788937|NCT00505284|Drug|Placebo|Placebo tablets, once daily, for 15 weeks (taken orally).
1788938|NCT00505284|Drug|E2007 (2 mg)|Perampanel, 2 mg once daily, for 15 weeks (taken orally).
1788939|NCT00505284|Drug|E2007 (4 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg, once daily, for 12 weeks (taken orally).
1788940|NCT00505284|Drug|E2007 (6 mg)|Perampanel, 2 mg once daily for three weeks, followed by 4 mg once daily, for three weeks and 6 mg, once daily, for nine weeks (taken orally).
1788941|NCT00505284|Drug|E2007 (8 mg)|Perampanel, 2 mg once daily, for three weeks, followed by 4 mg, once daily for three weeks, 6 mg once daily for three weeks and 8 mg, once daily, for six weeks (taken orally).
1788942|NCT00505310|Behavioral|Writing|20 minutes of writing on different topics at four different times.
1788943|NCT00505310|Behavioral|Questionnaire|Questionnaires about mood and quality of life completed 1 month, 4 months, and 10 months after the last writing assignment.
1788944|NCT00505323|Device|Implantation of neurostimulators and their auxiliary components|"Implantation neurostimulators and their auxiliary components :
Stimulateur KINETRA TM modèle 7428, Electrode Resume II modèle 3587A, Extension kit DBS 7482"
1788945|NCT00505336|Drug|Eplerenone|oral Eplerenone titrated to 50mg for duration of 12 months
1788946|NCT00505336|Other|No additional treatment|normal disease modifying therapy for heart failure i.e. ACE-I, beta blockers
1788947|NCT00505336|Drug|Atorvastatin|oral Atorvastatin 40mg
1788948|NCT00505349|Behavioral|Computer-based cognitive training|The experimental cognitive training program consists of interactive training exercises in which the participant responds to visual patterns and stimuli. The program is designed upon the principles of brain-plasticity, and, for the purposes of this study, is intended to be used for an 8-10 week period (40 total hours of training.)
1788949|NCT00505362|Procedure|Rectus closure|Reapproximation of the rectus muscles with three-interrupted sutures
1788950|NCT00505375|Drug|CTLA-4 Ig|Intravenous infusion of 10 mg/kg of CTLA-4 Ig every other week for the first two doses and then every 28 days for a total of 27 doses
1788951|NCT00505375|Other|Placebo|Intravenous infusions of placebo every other week for the first two doses and then every 28 days for a total of 27 doses
1788952|NCT00505401|Biological|recombinant HIV-1 Tat protein|
1788953|NCT00505414|Drug|Tapentadol in the Titration Phase|
1788954|NCT00505414|Drug|Morphine in the Maintenance Phase|"Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted. In the maintenance phase participants continued on the dose level established in titration phase.
Participants randomized to the morphine arm remained on morphine if they qualified for the maintenance phase of the study. The participants were maintained on the dose established at the end of the titration phase. The adverse events listed were documented in the maintenance phase."
1788955|NCT00505414|Drug|Matching Placebo in the Maintenance Phase after Tapentadol in the Titration Phase|Participant randomized to placebo in the maintenance phase received 100 mg tapentadol prolonged release twice daily for 3 days to taper them off of the tapentadol dose they had received in the titration period. From the fourth day of the maintenance period onwards they received placebo twice daily.
1788956|NCT00505414|Drug|Tapentadol in the Maintenance Phase|The participants re-randomized to receive tapentadol prolonged release in the maintenance phase were maintained on the dose established in the titration phase.
1788957|NCT00505414|Drug|Morphine in the Titration Phase|After signing informed consent eligible subjects were randomized to receive morphine controlled release. The oral medication was taken twice daily, morning and evening every 12 hours (with a minimum of 6 hours between doses). Participant started the trials with 45 mg morphine controlled release twice daily. Upward titration could then occur at a minimum of 3-day intervals in increments of 15 mg morphine twice daily. The maximum dose of morphine controlled release was 90 mg twice daily. Downward titration (but not below 45 mg twice daily) was permitted.
1788958|NCT00505427|Dietary Supplement|Alpha Lipoic Acid|
1788959|NCT00505440|Behavioral|Telephone case management and motivational interviewing|'Telephone case management and motivational interviewing': Immediate screening results are given to the physician during the patient's visit. Telephone case management and motivational interviewing (MI) at 1, 6, and 9 weeks to enhance engagement and commitment to change
1788960|NCT00505440|Behavioral|Usual care|Usual care with mailed screening results
1788961|NCT00505453|Biological|Fluviral®|
1788962|NCT00505466|Behavioral|Genetic Counseling|Genetic counseling conducted in person, by telephone with an M. D. Anderson Genetic Counselor, or with a local Genetic Counselor in conference with the M. D. Anderson Genetic Counselor.
1788963|NCT00505492|Drug|Carboplatin|AUC 5 by vein once every 28 Days
1788966|NCT00505505|Drug|Insulin (Actrapid)|50 UI Actrapid diluted in 50 ml of saline
1788967|NCT00505518|Drug|Psychotropic medication (at discretion of psychiatrist)|Antidepressant medication, prescribed at discretion of psychiatrist
1788968|NCT00505518|Behavioral|Collaborative psychiatric and primary medical care|Regular care visits from health workers
1788969|NCT00505544|Behavioral|Questionnaire|Questionnaires that ask about your sleep, symptoms, and mood.
1788970|NCT00505544|Device|Actigraph|Wear actigraph to collect information on activity levels and sleep patterns for one week.
1788971|NCT00505557|Procedure|Transaxillary dual plane technique|
1788972|NCT00505570|Device|AMPLATZER® PFO Occluder Device|PFO device closure
1788973|NCT00505583|Drug|MOA-728|
1788974|NCT00505596|Behavioral|Informed free choice|Women will be instructed to view an updated prenatal testing decision aid and will be told that they can have whatever tests they would like (including no tests) and that tests that are not covered by their insurance will be paid for by the study
1788975|NCT00505609|Behavioral|Standard Days Method|The Standard Days Method is a fertility awareness-based method of family planning. Users avoid unprotected intercourse during cycle days 8 to 19. Study participants were for up to 13 cycles of method use.
1788976|NCT00505622|Drug|Perampanel|
1788977|NCT00505635|Drug|Temozolomide|250 mg/m^2 By Mouth Every 4 Hours x 3 Doses On Day 1
1788978|NCT00505635|Drug|Velban|1.5 mg/m^2 By Vein Over 15-30 Minutes On Days 1-4
1788979|NCT00505635|Drug|Cisplatin|20 mg/m^2 By Vein Over 45-120 Minutes On Days 1-4
1788980|NCT00505635|Drug|Interleukin-2|9 MIU/m^2 By Vein Over 24 Hours x 4 Doses On Days 1-4
1788981|NCT00505635|Drug|Intron-A|5 mu/m^2 Subcutaneously (Under the skin) Daily On Days 1-5
1788982|NCT00505635|Drug|Thalidomide|400 mg By Mouth Daily
1788983|NCT00505648|Drug|Tegeline®|2g/kg in IV on 2days 2g/kg in IV on 4days for patients with renal insufficiency or 65 years old.
1788984|NCT00505661|Drug|Letrozole|2.5 mg PO Once Daily
1788985|NCT00505687|Drug|Rotigotine|"Rotigotine transdermal patches:
10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)
Optimal dosing:
The maximum rotigotine dose allowed is 16 mg/24 hours."
1788986|NCT00505700|Drug|velcade|
1788987|NCT00505700|Drug|Idarubicin|
1788988|NCT00505700|Drug|Cytarabine|
1788989|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu two times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity
1788990|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 1 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
1788991|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 3 x 10e11 cfu i.w. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
1788992|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 4 x 10e 11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
1788993|NCT00505713|Genetic|Rexin-G|Dosing Schedule: 2 x 10e11 cfu i.v. three times a week for 4 weeks followed by a 2-week rest period. Treatment cycle may be repeated if patient has Grade 1 or less toxicity.
1788994|NCT00505726|Procedure|Reflectance Confocal Imaging|Microscopic images taken during routine colposcopy where disinfected probe inserted into vagina and placed against cervix, 1-3 regions imaged (2 abnormal and one normal), and each taking about 1-2 minutes.
1788995|NCT00505739|Drug|Mifepristone|200 mg by mouth (PO) Daily x 4 Weeks
1788996|NCT00505752|Drug|AS900672-Enriched 50 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone [r-hFSH]), 50 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
1788997|NCT00505752|Drug|AS900672-Enriched 100 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 100 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
1788998|NCT00505752|Drug|AS900672-Enriched 150 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 150 mcg will be administered subcutaneously on S1. Duration of treatment cycle will up to adequate follicular response or maximum of 21 days.
1788999|NCT00505752|Drug|Follitropin alfa 150 international unit (IU)|Follitropin alfa (Gonal-f®) 150 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 21 (S21) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 50, 100 and 150 mcg will also receive daily dose of follitropin alfa 150 IU subcutaneously from Stimulation Day 6 (S6) up to S21. Duration of treatment cycle will be up to adequate follicular response or maximum of 21 days.
1789000|NCT00505752|Drug|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, at least 1 follicle with a diameter of greater than or equal to [>=] 18 millimeter [mm], two or more additional follicles with a diameter of >= 16 mm, and Estradiol [E2] levels will approximately 150 picogram per milliliter [pg/mL] per mature follicle).
1789001|NCT00505765|Drug|AL-108|AL-108, 5 mg/day- one spray in each nostril once per day
1789002|NCT00505765|Drug|AL-108|AL-108, 30 mg/day- 3 sprays in each nostril, twice per day
1789003|NCT00505765|Drug|Placebo|Placebo- 3 sprays in each nostril, twice per day
1789004|NCT00505765|Drug|Placebo|Placebo- one spray in each nostril, once per day
1789005|NCT00505778|Drug|Mesalamine Once-Daily|Mesalamine tablets, 1.6-2.4 g/day taken orally once a day for 52 weeks
1789006|NCT00505778|Drug|Mesalamine Twice-Daily|Mesalamine tablets, 1.6-2.4 g/day, taken twice daily for 52 weeks
1789007|NCT00505791|Drug|Nesiritide|Study drug will be administered for 24 hours. Study drug will be initiated with a 2-µg/kg loading bolus followed by .01-µg/kg/min infusion. This may be increased at a rate of .005-µg/kg/min. every 3 hours until maximum dose of .03-µg/kg/min. Any increase in the infusion rate will be preceded by a 1-µg/kg bolus and increases in infusion rates will be permitted only in patients who have a systolic blood pressure > 100 mmHg.
1789008|NCT00505804|Drug|dexmedetomidine|Dexmedetomidine IV infusion of 0.0 to 0.7 mg/kg/min for as long a deemed necessary by the treating clinician.
1789009|NCT00505804|Drug|haloperidol|Haloperidol IV loading dose of 2.5mg, followed by a continuous infusion of 0.0 to 2mg/hr for as long as deemed necessary by the treating clinician
1789010|NCT00505817|Drug|Cetrorelix and Leuprolide|
1789011|NCT00505830|Other|questionnaires|"Primary outcome:
Autism Spectrum Quotient (AQ)
Secondary outcome measure:
Empathy quotient (EQ) Systemizing quotient (SQ) WISC III or WISC IV ADOS score ADI score"
1789012|NCT00505843|Drug|MK0657|7mg MK0657 capsules
1789013|NCT00505843|Drug|Comparator: Placebo (unspecified)|7mg MK0657 Pbo capsules
1789014|NCT00505843|Drug|Comparator: levodopa|levodopa >/=1.0 mg/kg/hr dose of levodopa. levodopa infusions will occur over a 2 hour period
1789015|NCT00505843|Drug|Comparator: carbidopa|carbidopa 25mg administered 3 times: at 1 hour before levodopa infusion and at 1 and 3 hours after the start of levodopa infusion.
1789016|NCT00505869|Behavioral|Health & Wellness Intervention|Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
1789017|NCT00505869|Behavioral|Questionnaire|Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
1789018|NCT00505869|Behavioral|Mood Management Intervention|Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
1789019|NCT00505882|Drug|Pramlintide|Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.
1789020|NCT00505882|Drug|Glargine|
1789021|NCT00505882|Drug|Lispro|
1789022|NCT00505882|Drug|Aspart|
1789023|NCT00505895|Drug|Melphalan|Arm 1 = 140 mg/m^2 intravenous over 20 Minutes on Day -1; Arm 2 = 100 mg/m^2 intravenous over 20 Minutes on Day -1.
1789024|NCT00505895|Drug|Fludarabine|30 mg/m^2 intravenous daily over 30 Minutes for 4 Days (Beginning Day -4).
1789025|NCT00505895|Procedure|Stem Cell Infusion|Stem Cell Infusion on Day 0.
1789026|NCT00505895|Drug|Rituximab|375 mg/m^2 intravenous on Day -5, +2 +9 and +16.
1789027|NCT00505921|Drug|Campath-1H|3 mg through the catheter Day 1 then 10 mg on Day 2, and 30 mg on Days 3 and 10 of chemotherapy treatment.
1789028|NCT00505921|Drug|G-CSF|10 mg/kg subcutaneously (sc) on day +5 (in a.m.) for Stem Cell Mobilization.
1789029|NCT00505921|Drug|GM-CSF|250 m/m2 subcutaneously (sc) on Day +5 (in p.m.) for Stem Cell Mobilization.
1789030|NCT00505921|Drug|BCNU|300 mg/m2 IV over 1 hour on day -6
1789031|NCT00505921|Drug|Stem Cell Transplant|Stem cell infusion on Day 0.
1789032|NCT00505921|Drug|Preparative Regimen for Allogenic Stem Cell Transplantation|Campath 15mg/day (days -6 to -4), fludarabine 30 mg/m2 IV/day (days -6 to -4) and cyclophosphamide 750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4). Low dose total body irradiation of 2 Gy on day 0.
1789033|NCT00505921|Drug|Cytarabine|200 mg/m2 IV twice a day on day -5 through -2 (total 8 doses),
1789034|NCT00505921|Drug|Etoposide|200 mg/m2 IV twice on day -5 to -2 (total 8 doses)
1789035|NCT00505921|Drug|Melphalan|140 mg/m2 IV on day -1.
1789036|NCT00505921|Drug|Campath|15 mg/day (days -6 to -4) for preparative regimen Allogenic Stem Cell Transplantation
1789037|NCT00505921|Drug|Fludarabine|30 mg/m2 IV/day (days -6 to -4)
1789038|NCT00505921|Drug|Cyclophosphamide|750 mg/m2 IV/day (1000 mg/m2 IV/day if unrelated) (days -6 to -4).
1789039|NCT00505921|Radiation|Low dose total body irradiation|Low dose total body irradiation of 2 Gy day 0.
1789040|NCT00505934|Drug|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days
Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose within the following dose range, calculated on the basis of their age and weight:.
Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily) to 42 mg/kg/day (21 mg/kg/day twice daily);
Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily) to 60 mg/kg/day (30 mg/kg/day twice daily).
For subjects not taking levetiracetam oral solution prior to entering the study, the intravenous (IV) dosage corresponded to their age and weight as follows:
Ages ≥ 1 month to < 6 months: 14 mg/kg/day (7 mg/kg twice daily).
Ages ≥ 6 months to < 4 years: 20 mg/kg/day (10 mg/kg twice daily)."
1789041|NCT00505947|Drug|infliximab|infliximab 5 mg/Kg body weight by intravenous infusion
1789042|NCT00505947|Drug|placebo|placebo 5 mg/Kg body weight by intravenous infusion
1789043|NCT00505960|Behavioral|Diabetes Care for Korean Americans|Intervention group participants receive a 6-week in-class education offered by trained nurses, followed by home glucose monitoring with monthly nurse telephone counseling.
1789044|NCT00505973|Drug|SCA-136|
1789045|NCT00505986|Procedure|endometrial biopsy|
1789046|NCT00505999|Behavioral|Questionnaire|Questionnaire taking 30-40 minutes to complete.
1789047|NCT00506012|Drug|T2000|T2000 at doses of 200 mg a day to 1000 mg a day
1789048|NCT00506025|Dietary Supplement|Cranberries|Low-calorie, Low-carbohydrate content 8 oz dose of Cranberry juice
1789049|NCT00506025|Other|De-Activated Cranberry juice|
1789050|NCT00506038|Procedure|fine needle technique|
1789051|NCT00506051|Drug|ZD6474 (vandetanib) 100mg|once daily oral tablet
1789052|NCT00506051|Drug|pemetrexed|intravenous infusion
1789053|NCT00506051|Drug|ZD6474 (vandetanib) 300mg|
1789054|NCT00506064|Drug|Melatonin|0.15 mg/kg by mouth (PO) Daily
1789055|NCT00506064|Drug|Placebo|Two, three, or four starch tablet or capsules before bed
1789056|NCT00506064|Behavioral|Questionnaire|Sleep study surveys, two per day completed each evening, lasting 10 minutes
1789057|NCT00506077|Drug|MK0249|MK0249 10mg (2 x 5 mg) tablet daily (qd) for 28 days.
1789058|NCT00506077|Drug|Comparator: Placebo (unspecified)|MK0249 10mg (2 x 5 mg) Pbo tablet qd for a 28 day treatment period.
1789059|NCT00506090|Procedure|pulsed dye laser therapy|Treatment will begin on the day of suture removal. Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device at 3 weeks intervals for 6 sessions. Another part will be treated with pulsed dye laser and dynamic cooling device at 6 weeks intervals for 6 sessions. Only dynamic cooling device will be used for remaining part serving as control.
1789060|NCT00506116|Behavioral|Videotape, routine care, PME instruction|A 40 minute videotape about non-directed, spontaneous pushing and/or a videotape of antenatal perineal massage and pelvic muscle exerise (PME) at intake visit. The control women received routine care and PME instruction at intake visit.
1789061|NCT00506116|Behavioral|PME practice and record keeping (in diaries)|
1789062|NCT00506116|Behavioral|Non-directed or directed,spontaneous or sustained pushing|Non-directed, spontaneous pushing (experimental group) with perineal massage vs. directed, sustained pushing during delivery.
1789063|NCT00506116|Procedure|Data collection|Baseline at 20 weeks gestation; longitudinal at 35 weeks gestation, 6 weeks postpartum, 6 months postpartum, and 12 months postpartum
1789068|NCT00506142|Drug|Marqibo® (vincristine sulfate liposomes injection)|"Cohort 1 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every 2 weeks.
Cohort 2 subjects will receive MARQIBO at a dose of 2.25 mg/m2 IV over 1 hour every week."
1789069|NCT00506155|Drug|Avastin|10 mg/kg by vein over 90 minutes
1789070|NCT00506155|Drug|Cisplatin|70 mg/m^2 by vein over 4 hours
1789071|NCT00506155|Drug|Doxorubicin|30 mg/m^2 by vein over 15 minutes
1789072|NCT00506155|Drug|Methotrexate|30 mg/m^2 by vein over 30 minutes
1789073|NCT00506155|Drug|Vinblastine Sulfate|3 mg/m^2 by vein over 30 minutes
1789074|NCT00506168|Drug|Irinotecan, Capecitabine|
1789075|NCT00506181|Drug|probiotic mixture|"Jarro-Dophilus probiotic mixture (4,400,000,000 bacteria in each capsule). One capsule X2/day."
1789076|NCT00506181|Drug|Placebo|
1789077|NCT00506194|Drug|Insulin|
1789078|NCT00506194|Drug|OAD|Gliclazide-MR, Metformin, Glimepiride
1789079|NCT00506207|Drug|S-1, Irinotecan, Oxaliplatin|
1789080|NCT00506233|Behavioral|Questionnaire|Completion of questionnaires at 3 different times (when joining this study, 3 months later, and 6 months later). Each should take about 20-30 minutes to complete.
1789081|NCT00506246|Drug|Propofol|"intravenous (total intravenous anaesthesia)
induction and maintenance"
1789082|NCT00506259|Drug|dTR Melatonin (NIH CC PDS)|
1789083|NCT00506259|Device|Phototherapy (Bright Light)|
1789084|NCT00506259|Drug|Melatonin CR|
1789085|NCT00506272|Procedure|Self blood glucose monitoring and insulin administration|Patients will monitor blood glucose using a hand-held blood glucose monitor, and self-administer insulin
1789086|NCT00506272|Procedure|Standard care|finger-stick blood glucose values to be obtained and all insulin administration to be delivered by nursing staff
1789087|NCT00506285|Drug|Methylphenidate Transdermal System (MTS)|MTS is an advanced patch product that provides methylphenidate evenly mixed with the adhesive. This formulation allows good adhesion and a wide range of dose sizes. MTS patch sizes of 12.5, 18.75, 25 and 37.5cm2 are equivalent to nominal doses over a 9-hour wear time of 10, 15, 20 and 30mg of MPH.
1789088|NCT00506285|Other|placebo patch|This patch is designed to appear identical to the actual intervention patch
1789089|NCT00506298|Drug|bezafibrate + diflunisal|bezafibrate + diflunisal
1789090|NCT00506298|Drug|bezafibrate + placebo|bezafibrate + placebo
1789091|NCT00506311|Drug|Fibrin Sealant|Tisseel applied externally to the dissected groin area.
1789092|NCT00506337|Drug|Qingyi granules|"Control group: The therapeutic methods accord to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis introduced by the Pancreatic Surgery Group of Surgical Chapter of Chinese Medical Association.
Treatment group: In addition to the concert schemes cited in the Guides to diagnosis and treatment of severe acute pancreatitis, during the first stage of the disease herbal Qingyi granules 1-B 4 bags dissolved in water 200ml were administered through the gastric tube q6h. Then the gastric tube was closed for 1h, and Qingyi granules 1-B another 4 bags dissolved in water 400ml were given through enema q6h. During the second stage (from the 2nd week to the 4th week after onset) Qingyi granules 2-B 2bags dissolved in water 200ml were added QD."
1789093|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A) - 1 dose|A single dose of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0.
1789094|NCT00506350|Biological|Pandemic influenza candidate vaccine (GSK1562902A) - 2 doses|Two doses of Pandemic influenza candidate vaccine (GSK1562902A) administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and Day 21.
1789095|NCT00506363|Procedure|pulsed dye laser therapy|Each scar will be divided into 3 equal parts. One part will be randomly allocated to be treated with pulsed dye laser and dynamic cooling device on the day of suture removal. Another part will be treated with pulsed dye laser and dynamic cooling device 2 months after suture removal. Only dynamic cooling device will be used for remaining part serving as control. Treatment will repeat for 6 sessions at 3 weeks intervals.
1789096|NCT00506376|Behavioral|Interview|Interview that will take about 20 minutes to complete.
1789097|NCT00506389|Drug|Esmirtazapine|Esmirtazapine maleate was provided as tablets for oral use containing 3.0 mg, or 4.5 mg of active compound. In addition, tablets contain the following excipients: hydroxypropyl cellulose, maize starch (United States Pharmacopeia [USP] name corn starch), magnesium stearate, and lactose monohydrate.
1789098|NCT00506389|Drug|Placebo|The placebo tablets contained the following excipients: hydroxypropyl cellulose, maize starch (USP name corn starch), magnesium stearate, and lactose monohydrate.
1789099|NCT00506402|Drug|MKC-1|Capsule, 30 mg and 100 mg, BID, continuous dosing
1789100|NCT00506415|Drug|Rivastigmine 5 cm^2|5 cm^2 transdermal patch
1789101|NCT00506415|Drug|Rivastigmine 10 cm^2|10 cm^2 transdermal patch.
1789102|NCT00506415|Drug|Rivastigmine 15 cm^2|15 cm^2 transdermal patch.
1789103|NCT00506415|Drug|Placebo to 15 cm^2 patch|Placebo of rivastigmine transdermal patch 15 cm^2.
1789104|NCT00506415|Drug|Placebo to 10 cm^2 patch|Placebo of rivastigmine transdermal patch 10 cm^2.
1789105|NCT00506428|Behavioral|chronic sleep restriction|5.6 hours of sleep per 24 hours for 3 weeks
1789106|NCT00506441|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of flexible dose (Open-label) and 4 weeks of double blind
1789107|NCT00506441|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 4 weeks of double blind
1789108|NCT00506454|Drug|Lipidose|Over the course of 2 weeks, immediately following subject's three (Monday/Wednesday/Friday (M/W/F)) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of Lipidose over a 2-hour period.
1789109|NCT00506454|Drug|Placebo|Over the course of 2 weeks, immediately following subject's three (M/W/F) normal dialysis treatments, based on subject's current weight, subject will receive 1.5 mL/kg of placebo over a 2-hour period.
1789110|NCT00506467|Procedure|Vibration Response Imaging|Lung function test performed using the VRI system immediately before or after the standard lung function test.
1789111|NCT00506480|Procedure|endometrial sampling|Endometrial biopsy is a procedure in which a tissue sample is obtained from the endometrium. This procedure is performed without anesthesia during pelvic examination. The cervix is cleaned with an antiseptic solution and then grasped with an instrument (tenaculum) to steady the uterus. A small, hollow plastic tube is gently passed into the uterine cavity. Gentle suction removes a sample of the lining. The tissue sample and instruments are removed, and the sample is examined by pathology, immunohistochemistry, PCR and western blotting.
1789112|NCT00506493|Device|Cardioblate Surgical Ablation System|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
1789113|NCT00506493|Procedure|Surgical RF Ablation|This investigation is a prospective, nonrandomized multicenter clinical trial evaluating the outcome of patients with AF requiring concomitant open heart surgery plus the Cardioblate Surgical Ablation System using the modified Maze III procedure. The trial population includes patients requiring valve replacements or repairs, atrial septal defect (ASD) repairs, patent foramen ovale (PFO) closure or coronary artery bypass grafts (CABG) procedures.
1789114|NCT00506506|Drug|N-acetylcysteine|N-acetylcysteine 1200 mg twice daily x 48 hours
1789115|NCT00506506|Drug|Placebo|
1789116|NCT00506519|Drug|antithrombin alfa (INN name)|
1789117|NCT00506532|Drug|Surfactant (calfactant)|
1789118|NCT00506545|Drug|SCH 619734|SCH 619734 50-mg capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
1789119|NCT00506545|Drug|Placebo Dose 1|Matching placebo capsule each day orally. One week of treatment with 7 days' follow-up; 1 week of crossover treatment with 7 days' follow-up. A 6 week washout period separates treatments.
1789120|NCT00506558|Procedure|Ventral Surgical Decompression with Instrumented Fusion|Multi-level discectomy or Corpectomy are performed at surgeon's discretion. After decompression an instrumented fusion is performed.
1789121|NCT00506558|Procedure|Dorsal Decompression With or Without Fusion|Dorsal decompressive laminectomy, laminoplasty, or laminectomy with lateral mass instrumented fusion
1789122|NCT00506571|Drug|S-1, irinotecan, oxaliplatin|
1789123|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
1789124|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier is initiated when nutrition volume reaches 40 mL/kg/day
1789125|NCT00506584|Dietary Supplement|Human milk fortifier (bovine-based), pre-term formula|Bovine-based human milk fortifier is initiated when nutrition volume reaches 100 mL/kg/day
1789126|NCT00506584|Dietary Supplement|Pasteurized human milk and pasteurized human milk fortifier|Human milk fortifier initiated when nutrition volume reaches 100 mL/kg/day
1789127|NCT00506584|Dietary Supplement|Pre-term/term formula|Bovine milk-derived nutrition formulated for very low birth weight infants
1789128|NCT00506597|Drug|Erwinase|If allergic to E.Coli Asparaginase = 1 Dose (20,000 Units/m^2) Daily; If allergic to Pegylated Asparaginase = 6 Doses (25,000 Units/m^2) Daily Every Other Day. Received as an injection through a needle in vein, under the skin, or in muscle.
1789129|NCT00506610|Drug|T-62|
1789130|NCT00506623|Drug|Capecitabine, Irinotecan|
1789131|NCT00506636|Behavioral|Tissue engineering for hair follicle regeneration|
1789132|NCT00506649|Other|protocol|management protocols of non-pharmacological strategies and individualized titration of analgesics, sedatives, and anti-psychotics based on observed scores to manage sedation, analgesia and delirium.
1789133|NCT00506662|Drug|insulin detemir|Treat-to-target, s.c. (under the skin) injection, once daily
1789134|NCT00506662|Drug|insulin NPH|Treat-to-target, s.c. (under the skin) injection, once daily
1789135|NCT00506675|Device|Patching|42 hours per week of patching
1789136|NCT00506675|Drug|Atropine|daily atropine (1%)
1789137|NCT00506675|Device|Patching|two hours of daily patching for 4 weeks, then no treatment
1789138|NCT00506675|Drug|Atropine|once weekly atropine for 4 weeks, then no treatment
1789139|NCT00506688|Drug|reduced glutathione sodium salt|646 mg GSH-Na powder per vial to prepare a 4ml solution, twice daily for 24 weeks.
1789140|NCT00506688|Drug|0.9% normal saline (control)|4 ml of a 0.9% normal saline solution (9mg/ml NaCl), twice daily for 24 weeks.
1789141|NCT00506701|Drug|Tadalafil|40 mg tablet
1789142|NCT00506714|Device|single point cane|Adjustable single point cane with SureGrip handle
1789143|NCT00506727|Drug|Mixed amphetamine salts (ADDERALL XR)|
1789144|NCT00506727|Drug|Atomoxetine hydrochloride|
1789145|NCT00506740|Device|Ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
1789146|NCT00506740|Device|monopolar electrosurgery generator and tip|
1789147|NCT00498849|Device|CPAP|
1789148|NCT00498875|Behavioral|Questionnaire|Questionnaire regarding mood, coping with cancer, how closely you follow your treatment schedule, your thoughts, your demographic information (such as age and race), and your medical history. If the answers to your questionnaire indicate that you may be depressed, you will be offered the intervention portion of the study.
1789149|NCT00498875|Behavioral|Depression Intervention|"Sessions given over 7 weeks and each lasting 30-45 minutes, that use cognitive-behavioral techniques."
1789150|NCT00498888|Procedure|tolterodine|Detrusitol SR 4 mg, 1 capsule for a day, 3 months.
1789151|NCT00498888|Procedure|bladder training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for educate and schedule voiding regimen.
1789152|NCT00498888|Procedure|pelvic floor muscle training|Four visits in 3 months with pelvic floor physical therapist, who is trained in the procedure, for reinforced pelvic floor muscles.
1789153|NCT00498888|Procedure|pelvic floor rehabilitation|The Pelvic floor rehabilitation protocol based on bladder training protocol and PFMT and lifestyle advice and information about good bladder and bowel habits. Four visits in 3 months was made with pelvic floor physical therapist, who is trained in the procedure.
1789154|NCT00498901|Drug|goserelin|
1789155|NCT00498901|Drug|letrozole|
1789156|NCT00498901|Drug|leuprolide acetate|
1789157|NCT00498901|Procedure|conventional surgery|
1789158|NCT00498914|Drug|YM155|Continuous IV infusion
1789159|NCT00498927|Drug|temozolomide|
1789160|NCT00498927|Genetic|protein expression analysis|
1789161|NCT00498927|Genetic|reverse transcriptase-polymerase chain reaction|
1789162|NCT00498927|Other|diagnostic laboratory biomarker analysis|
1789163|NCT00498927|Other|immunoenzyme technique|
1789164|NCT00498940|Device|Optimization Testing|Atrioventricular (AVD) and interventricular (VVD) delays and left ventricle lead site location were optimized after weaning off bypass (Phase I), after sternal closure (Phase II), and 12 to 24 hours (Phase III) after bypass. Intrinsic heart rate was also optimized in Phase III.
1789165|NCT00498940|Device|Temporary Biventricular Pacing|Continuous temporary biventricular pacing for 24 hours at a heart rate of 90 bpm or 10 bpm above intrinsic heart rate.
1789166|NCT00498953|Drug|carboplatin|
1789167|NCT00498953|Drug|cisplatin|
1789168|NCT00498953|Drug|docetaxel|
1789169|NCT00498953|Drug|fluorouracil|
1789170|NCT00498953|Drug|lapatinib ditosylate|
1789171|NCT00498953|Genetic|cytogenetic analysis|
1789172|NCT00498953|Genetic|fluorescence in situ hybridization|
1789173|NCT00498953|Genetic|in situ hybridization|
1789174|NCT00498953|Genetic|polymerase chain reaction|
1789175|NCT00498953|Genetic|reverse transcriptase-polymerase chain reaction|
1789176|NCT00498953|Other|immunohistochemistry staining method|
1789177|NCT00498953|Other|laboratory biomarker analysis|
1789178|NCT00498953|Procedure|conventional surgery|
1789179|NCT00498953|Procedure|neoadjuvant therapy|
1789180|NCT00498953|Radiation|fludeoxyglucose F 18|
1789181|NCT00498953|Radiation|radiation therapy|
1789182|NCT00498966|Drug|Perifosine|Perifosine 100 mg PO
1789183|NCT00498979|Biological|recombinant interferon alfa-2b|recombinant interferon alfa-2b
1789184|NCT00498979|Drug|cisplatin|recombinant interferon alfa-2b
1789185|NCT00498979|Drug|sodium stibogluconate|sodium stibogluconate
1789186|NCT00498979|Drug|dacarbazine|dacarbazine
1789187|NCT00498979|Drug|vinblastine|vinblastine
1789188|NCT00498992|Dietary Supplement|collagen/aloe vera/vitamin E/lidocaine topical hydrogel|
1789189|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100microgram
1789190|NCT00499005|Drug|Syntommetrine and Carbetocin|Syntommetrine 1ml and Carbetocin 100micgrams
1789191|NCT00499018|Drug|Rituximab|375 mg/m2 day 1
1789192|NCT00499018|Drug|Ciclofosfamide|1200 mg/m2 day 1
1789193|NCT00499018|Drug|Doxorubicina|70 mg/m2 day 1
1789194|NCT00499018|Drug|Vincristina|1,4 mg/m2 (max 2 mg) day 1
1789195|NCT00499018|Drug|Prednisone|100 mg day g 1-5
1789196|NCT00499018|Drug|Pegfilgrastim|6 mg day +1
1789197|NCT00499018|Drug|Mitoxantrone|8 mg/m2/days 1-3
1789198|NCT00499018|Drug|ARA-C|2000 mg/m2/12h day 1 - 3
1789199|NCT00499018|Drug|Lenograstim|5 μg/Kg/days +2
1789200|NCT00499018|Drug|BCNU|300 mg/m2 day -7
1789201|NCT00499018|Drug|ARA-C|200 mg/m2/12 days -6,-5,-4,-3
1789202|NCT00499018|Drug|VP-16|100 mg/m2/12h days -6,-5,-4,-3
1789203|NCT00499018|Procedure|ASCT|PBSC Reinfusion
1789204|NCT00499018|Drug|Ciclofosfamide|750 mg/m2 day 1
1789205|NCT00499018|Drug|Doxorubicina|50 mg/m2 day 1
1789206|NCT00499018|Drug|Vincristina|1,4 mg/m2 (max 2 mg) day 1
1789207|NCT00499031|Biological|Cetuximab|Given IV
1789208|NCT00499044|Other|CDR Computerized Cognitive Assessment System|Cognitive Drug Research Computerized Cognitive Assessment System consists of performance tasks that measure reaction time, numeric and spatial working memory, word and picture recall and recognition, and episodic secondary memory. CDR is a single, unified battery that can be stored and administered using a laptop computer.
1789209|NCT00499044|Other|MATRICS Consensus Cognitive Battery|The MATRICS Consensus Cognitive Battery measures functioning across various cognitive domains, such as attention, working memory (verbal and nonverbal), learning (verbal and visual), reasoning and problem solving, and social cognition. Its measurements are based on timed paper-and-pencil, computerized, and orally-administered tests, as well as spatial tests using geometric cubes.
1789210|NCT00499057|Radiation|interstitial high dose-rate brachytherapy, PBI|Single arm study Treatment schedule is 4 Gy twice a day, with a time relapse of at least 6 hours between each fraction, for four days, for a total dose 32 Gy.
1789211|NCT00499070|Genetic|polymerase chain reaction|
1789278|NCT00506948|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg by vein or by mouth every 12 hours.
1789279|NCT00506948|Drug|Thymoglobulin|1.5 mg/kg by vein daily for 4 days
1789634|NCT00509665|Drug|doxorubicin hydrochloride|
1789212|NCT00499070|Other|flow cytometry|For analyzing GPI deficient clones full blood will be analyzed by phenotyping using flowcytometry. For that purpose CD14, CD16 and CD24 expression will be evaluated in CD45 positive cells. Erythroid cells will be evaluated for CD55 and CD59 expression searching for clear populations with a lack of GPI-linked molecules. In addition, immunophenotyping using flowcytometry will be performed to evaluate which differentiation stages of the major hematopoietic lineages in BM and PB are associated with TCRVβ repertoire skewing. Comparison between BM and PB will identify which is the optimal compartment to analyze the responsible hematopoietic clones.
1789213|NCT00499070|Other|immunologic technique|
1789214|NCT00499070|Procedure|biopsy|
1789232|NCT00499096|Behavioral|Chronic care model for Bipolar Disorder|The behavioral intervention is based on the Chronic Care Model (CCM) where patients receive information on managing bipolar symptoms and health habits in a group self-management session (up to 6 weekly sessions). The Care Manager then follows up with patients via phone contacts for 12 months following the intervention. The providers receive information on guidelines for care.
1789233|NCT00499109|Drug|Docetaxel|"GD Group: 40 mg/m^2 on days 1 and 8, every 21 days
DCb Group: 75 mg/m^2 on day 1
DV Group: 50 mg/m^2 on days 1 and 15, every 28 days"
1789234|NCT00499109|Drug|Vinorelbine|DV Group: 35 mg/m^2 on days 1 and 15
1789235|NCT00499109|Drug|Carboplatin|"GCb Group: Area under the curve (AUC) 5 on day 1, every 21 days
DCb Group: AUC 6 on day 1, every 21 days
Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
1789236|NCT00499109|Drug|Gemcitabine|"GCb Group: 1,250 mg/m^2 on days 1 and 8
GD Group: 1,250 mg/m^2 on days 1 and 8
Control Arm: Patients received up to 6 cycles, and no maintenance therapy was allowed."
1789237|NCT00499122|Drug|Cyclophosphamide|
1789238|NCT00499122|Drug|Docetaxel|
1789239|NCT00499122|Drug|Doxorubicin|
1789240|NCT00499122|Drug|NOV 002|
1957256|NCT02473783|Drug|Sertraline HCl|The regimen of Sertraline HCl will be administered with starting dose from minimum 25 mg/day for 1 week and maintenance dose of at least 50 mg/day up to 200 mg/day for the rest of 5 weeks.
1957257|NCT02473783|Other|I-123-ADAM SPECT|The subjects underwent the SPECT scan after I-123-ADAM (185 MBq, 5mCi) IV injection.
1789247|NCT00499148|Other|herbal extract; root of woody shrub grown in India/Sri-Lanka|
1789248|NCT00499161|Behavioral|New model of nursing care|
1789249|NCT00506753|Behavioral|MI/CBT|Motivational Interviewing followed by Cognitive Behavior Therapy
1789250|NCT00506753|Behavioral|RT/SU|Relaxation Training followed by Treatment as Usual
1789251|NCT00506766|Behavioral|Bladder Health Class consisting of 6 weekly group sessions|1 time
1789252|NCT00506766|Behavioral|Practice PFMT and BT|As needed for 4 years
1789253|NCT00506766|Behavioral|Clinic examination for pelvic muscle function|1/year for 4 years
1789254|NCT00506766|Behavioral|Record keeping in 3-day voiding diary|Every 6 months for 4 years
1789257|NCT00506792|Drug|QAU145|
1789258|NCT00506792|Drug|Placebo|
1789259|NCT00506805|Drug|SNX-5422|dose escalated, tablets every other day; undetermined duration until disease progression
1789260|NCT00506818|Other|Multifactorial vascular-risk-factor-intervention|
1789261|NCT00506831|Drug|Imatinib mesylate|100 mg orally daily increased by 100 mg/day every 2 weeks to maximum of 400 mg daily as tolerated. Treatment for 6 months total.
1789262|NCT00506844|Drug|Cetuximab, Irinotecan, Capecitabine|
1789263|NCT00506857|Drug|Busulfan|Starting Dose 0.8 mg/kg by vein every 6 hours x 12 doses.
1789264|NCT00506857|Drug|Fludarabine|30 mg/m^2 by vein daily x 4 days.
1789265|NCT00506870|Device|INRatio / Coaguchek XS|INR measured by patient himself using INRation or Coaguchek device. And one follow-up of INR per month, measured in laboratory.
1789266|NCT00506870|Device|Conventional follow-up of anti-coagulation|At least, one follow-up of INR per month. Measured in laboratory.
1789267|NCT00506883|Drug|High Dose Colchicine (4.8 mg total dose)|At randomization, patients were given an identical looking blister pack containing (8) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules. Patients were instructed to take 2 capsules initially (1.2 mg) followed by an additional capsule (0.6 mg) every hour for a total of six additional doses (total colchicine dose 4.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
1789268|NCT00506883|Drug|Low Dose Colchicine (1.8mg total dose)|At randomization, patients were given an identical looking blister pack containing (3) over encapsulated colchicine 0.6 mg tablets identical in appearance to placebo capsules and five placebo capsules. Patients were instructed to take 2 capsules initially (0.6 mg x 2) followed by an additional capsule every hour for a total of six additional doses (one active (0.6 mg) and 5 placebo capsules), a total colchicine dose = 1.8 mg) beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center
1789269|NCT00506883|Other|Placebo Control|At randomization, patients were given an identical looking blister pack containing (8) placebo capsules identical in appearance to the study drug. Patients were instructed to take 2 capsules initially followed by an additional capsule every hour for a total of six additional doses beginning within 12 hours of onset of a qualifying gout flare as confirmed by calling the gout flare call center.
1789270|NCT00506896|Drug|intraarticular injection|Triamcinolone hexacetonide 60mg(3ml)by intraarticular injection Triamcinolone acetonide 60mg (3ml)by intramuscular administration
1789271|NCT00506909|Drug|Oxytocin|20 IU BID or 40 IU BID
1789272|NCT00506909|Drug|Placebo|20 IU BID or 40 IU BID
1789273|NCT00506922|Drug|Pentostatin|"Given intravenously on days +8, +15, +22 and +30 post transplant:
Group 2 - Pentostatin 0.5 mg/m^2
Group 3 - Pentostatin 1 mg/m^2
Group 4 - Pentostatin 1.5 mg/m^2
Group 5 - Pentostatin 2 mg/m^2"
1789274|NCT00506922|Drug|Tacrolimus|Given intravenously from day -2, and will be switched to oral dosing when tolerated.
1789275|NCT00506922|Drug|Methotrexate|Given intravenously on days +1, +3, and +6 at the dose of 5 mg/m2.
1789276|NCT00506935|Drug|GVG|5 grams GVG
1789277|NCT00506935|Drug|placebo|placebo
1789280|NCT00506948|Drug|Sirolimus|6 mg daily by mouth for 1 day, followed by 2 mg daily for 1 day.
1789281|NCT00506948|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
1789282|NCT00506961|Drug|Rosuvastatin|10 mg rosuvastatin for 4 weeks followed by rosuvastatin or another 12 weeks
1789283|NCT00506961|Drug|Simvastatin|20 mg simvastatin for 4 weeks followed by 40 mg simvastatin for another 8 weeks
1789285|NCT00506987|Drug|SCH 486757|SCH 486757 2 x 50-mg capsule twice daily orally for 2 weeks followed by a 2-week washout period and 2 weeks of crossover treatment
1789286|NCT00506987|Drug|Placebo Dose 1|Matching placebo capsules twice daily orally for 2 weeks followed by a 2 week washout period and 2 weeks of crossover treatment
1789287|NCT00507000|Drug|Cholecalciferol|Drug: Cholecalciferol Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months Arms: A, Cholecalciferol
1789288|NCT00507000|Drug|Lactose granules|Drug: Lactose placebo Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
1789289|NCT00507013|Device|QuickClose device|
1789290|NCT00507026|Drug|IV Diclofenac|IV Diclofenac q6h
1789291|NCT00507026|Drug|IV ketorolac|IV ketorolac q6h
1789292|NCT00507026|Drug|Placebo|Placebo q6h
1789293|NCT00507039|Procedure|inhalative grass-pollen provocation|Subjects undergo allergen challenges with incremental doses of grass pollen allergen. In subjects, who develop a fall in FEV1 of more than 20%, this will be followed by two single-step challenges.
1789294|NCT00507052|Drug|N-acetylcysteine|
1789295|NCT00507065|Drug|Mixed salts of a single-entity amphetamine (ADDERALL XR)|
1789296|NCT00507065|Drug|Placebo|
1789297|NCT00507078|Procedure|Surgical treatment for OSA|
1789298|NCT00507351|Behavioral|Questionnaire|3 questionnaires that will take 20 minutes total to complete.
1789299|NCT00507364|Drug|Local injection of activated macrophages to anal fissure|
1789300|NCT00507390|Dietary Supplement|n-3 polyunsaturated fatty acids (PUFAs)|2g n-3 PUFAs once daily for 8 weeks
1789301|NCT00507390|Dietary Supplement|olive oil|1 capsule day
1789302|NCT00507403|Drug|infliximab|
1789303|NCT00507416|Drug|Bortezomib|Bortezomib bolus intravenous (IV) injection
1789304|NCT00507416|Drug|Dexamethasone|Dexamethasone for oral administration
1789305|NCT00507416|Drug|Melphalan|Melphalan for oral administration
1789306|NCT00507416|Drug|Prednisone|Prednisone for oral administration
1789307|NCT00507416|Drug|Thalidomide|Thalidomide for oral administration
1789308|NCT00507429|Drug|CA4P|CA4P 60mg/m squared for Days 1, 8, 15 for 6 cycles
1789309|NCT00507429|Drug|paclitaxel|200mg/m squared on Day 1
1789310|NCT00507429|Drug|carboplatin|6 AUC on Day 1 following paclitaxel
1789311|NCT00507442|Drug|VELCADE (bortezomib)|bortezomib 1.3 mg/m^2 given via IV on days 1, 4, 8, and 11 of a 3-week cycle for 8 cycles, then on days 1, 8, 15 and 22 of a 6-week cycle for 4 cycles (maintenance).
1789312|NCT00507442|Drug|dexamethasone|dexamethasone 40 mg orally on days 1, 8, and 15 of a 3-week cycle for 8 cycles, then stop
1789313|NCT00507442|Drug|cyclophosphamide|cyclophosphamide 500 mg/m^2 orally on days 1 and 8 of a 3-week cycle for 8 cycles, then stop
1789314|NCT00507442|Drug|Revlimid (lenalidomide)|"lenalidomide 25 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDR arm)
lenalidomide 15 mg orally on days 1 to 14 of a 3-week cycle for 8 cycles then stop (VDCR arm)"
1789315|NCT00507455|Drug|solifenacin succinate|Solifenacin succinate tablets
1789316|NCT00507455|Drug|tamsulosin hydrochloride|Tamsulosin hydrochloride Oral Control Absorption System (TOCAS) tablets
1789317|NCT00507455|Drug|Placebo to solifenacin|
1789318|NCT00507455|Drug|Placebo to tamsulosin|
1789319|NCT00507468|Procedure|Transendocaridal Transplantation of Autologous Bone Marrow|Single treatment, harvest and transplant of patients own bone marrow. Cells are delivered to the myocardium via transendocardial delivery catheter.
1789320|NCT00507494|Drug|pioglitazone|Pioglitazone 30 mg o.d. tablet for 12 weeks or placebo o.d. tablet for 12 weeks in random order. After 12 wk treatment there is a 4 wk washout out which is followed by switch of study medication in a cross over fashion and a further 12 wk treatment.
1789321|NCT00507507|Drug|Tenofovir DF|Tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablet taken orally once daily
1789322|NCT00507507|Drug|FTC|Emtricitabine (FTC) 200 mg capsule taken orally once daily
1789323|NCT00507507|Drug|Placebo|Placebo to match FTC taken once daily
1789324|NCT00507520|Procedure|Full dose almonds|
1789325|NCT00507520|Procedure|Half dose almonds+half dose muffin|
1789326|NCT00507520|Procedure|Full dose whole wheat muffin|
1789327|NCT00507533|Procedure|Continuous positive airway pressure|
1789328|NCT00507546|Drug|Ramelteon|8 mg nightly
1789329|NCT00507546|Drug|Placebo|Nightly 8mg of placebo (same appearance as ramelteon)
1789330|NCT00507559|Device|Aptus Endovascular AAA Repair System|EVAR (endovascular aneurysm repair)
1789331|NCT00507572|Other|Data Collection|Information about the type of cancer, type of treatment, and details about pregnancy will be collected.
1789332|NCT00507585|Drug|Fluorouracil|300 mg/m^2 IV over 10 Minutes, then 600 mg/m^2 IV over 22 Hours repeated every 3 weeks (1 Cycle).
1789333|NCT00507585|Drug|Avastin|10 mg/m^2 IV Over 90 Minutes repeated every 3 weeks (1 Cycle).
1789334|NCT00507585|Drug|Leucovorin|200 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
1789335|NCT00507585|Drug|Oxaliplatin|60 mg/m^2 IV Over 2 Hours repeated every 3 weeks (1 Cycle).
1789336|NCT00507598|Other|No intervention|Correlative study collecting serum and tissue samples
1789385|NCT00507988|Behavioral|Complex Problem Solving Training|10 sessions of 45 minutes complex problem solving training over 3 weeks (including 30 minutes of computerized planning and problem-solving training with Plan-A-Day and 15 minutes group session for transfer to everyday situations)
1789337|NCT00507611|Procedure|Sentinel node mapping|Patients will undergo preoperative lymphoscintigraphy in the nuclear medicine department to access axillary and extra-axillary sites of localization. Intraoperatively, patients will also be injected with approximately 4 to 5 mL of 1% isosulfan blue dye (by intradermal, intraparenchymal, or subareolar route). Patients will undergo intraoperative identification and biopsy of all SLN candidates. A confirmatory axillary lymph node dissection will then be performed on all patients.
1789338|NCT00507637|Drug|NT 201|Injection of up to 50 Units NT 201 (incobotulinumtoxinA/Xeomin®) per eye and injection visit (8 injections visits in total).
1789339|NCT00507650|Dietary Supplement|Fluid intervention|Volume of fluid prescribed by physician or provider/day X 5 days.
1789340|NCT00507650|Dietary Supplement|Fluid intervention plus 10 ml/kg/day|Fluid volume and type prescribed by physician or provider plus 10 ml/kg/day X 5 days.
1789341|NCT00507663|Drug|Atenolol|Patients with a standing prescription for β-blockers will be continued on that medication. Pts not currently receiving a beta blocker will be given 50mg of atenolol on the morning of surgery, 50-100mg, twice per day, on the first postoperative day until postoperative day 7.
1789342|NCT00507689|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg was administered as a fixed-dose combination tablet orally once daily.
1789343|NCT00507689|Drug|Hepatitis B Immunoglobulin (HBIg)|HBIg was administered either intravenously or by intramuscular injection at a dose and frequency as prescribed by the investigative site protocol.
1789344|NCT00507702|Procedure|phlebotomy|Standard of care
1789345|NCT00507715|Drug|Plantago ovata husk|5 g of effervescent powder (3.5 g pf plantago ovata husk) t.i.d. during 14 days
1789346|NCT00507715|Other|hemicellulose crystalline|5g effervescent powder t.id. during 14 days
1789347|NCT00507728|Drug|Bupropion|Starting dose 150 mg by mouth daily (150 mg every morning for three days; 150 mg twice a day thereafter)
1789348|NCT00507728|Drug|Varenicline|Starting dose 0.5 mg by mouth daily (0.5 mg every morning for days 1 - 3, then 0.5 mg twice a day for days 4 - 7, then 1 mg twice a day thereafter)
1789349|NCT00507728|Drug|Placebo|Placebo by mouth for 12 weeks.
1789350|NCT00507728|Behavioral|Smoking Cessation Counseling|Counseling over 8 months and telephone support calls.
1789351|NCT00507741|Drug|Vintafolide|Part A: Induction Phase: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance Phase: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting. Part B: vintafolide 2.5 mg intravenous injection, Monday, Wednesday and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
1789352|NCT00507741|Drug|Ertafolide|
1789353|NCT00507754|Other|T-SPOT TB test|Extra blood draw, followed by ten minutes rest and the injection of Tuberculin subcutaneously on forearm.
1789354|NCT00507767|Drug|dasatinib|Given PO or via PEG tube
1789355|NCT00507767|Procedure|pharmacological study|Correlative studies
1789356|NCT00507767|Procedure|laboratory biomarker analysis|Correlative studies
1789357|NCT00507780|Drug|GnRH antagonist|
1789358|NCT00507793|Drug|Sirolimus|
1789359|NCT00507793|Drug|Cyclosporine|
1789360|NCT00507806|Drug|perflutren lipid microsphere|
1789361|NCT00507819|Drug|Sildenafil|One 20 mg capsule of sildenafil will be taken by mouth three times-a-day.
1789362|NCT00507819|Drug|Placebo|One placebo capsule will be taken by mouth three times-a-day.
1789363|NCT00507832|Drug|Pimecrolimus|twice daily topical
1789364|NCT00507832|Drug|Hydrocortisone|twice daily topical
1789365|NCT00507832|Drug|Pimecrolimus|topical application as a cream twice daily
1789366|NCT00507845|Drug|Ramipril-Felodipine|Ramipril + felodipine 2.5/2.5mg per tablet. One tablet to be taken Od for 8 weeks (this dose could be increased at week 2 to 4 to 5 mg daily because of uncontrolled hypertension).
1789367|NCT00507858|Drug|Pemetrexed|Starting dose of 500 mg/m^2 IV Once Over 10 Minutes Every 3 Weeks
1789368|NCT00507858|Drug|Dexamethasone|Arm 2 = 20 mg IV On Day 1; Arm 3 = 4 mg oral (PO) Twice Daily for 3 Days
1789369|NCT00507884|Procedure|3 Tesla MRI Scan|MRI of the kidneys and abdomen to be done within 15 days following the routine CT and lasting 1 - 2 hours.
1789370|NCT00507923|Behavioral|Tibetan Yoga|4 sessions of yoga over 12 weeks.
1789371|NCT00507923|Behavioral|Stretching Program|4 sessions of simple stretching exercises for 12 weeks. Each session lasting 90 minutes.
1789372|NCT00507923|Other|No Intervention|Option of participating in the Tibetan yoga program after completion of the study.
1789373|NCT00507923|Behavioral|Questionnaire|Questionnaires to be completed before and after the end of the yoga or stretching sessions (or similar time for the usual care group).
1789374|NCT00507923|Behavioral|Booster Program|"3 booster sessions consisting of a review and practice of the entire program."
1789375|NCT00507936|Drug|ABT-894|ABT-894 1 mg capsule BID throughout treatment period
1789376|NCT00507936|Drug|ABT-894|ABT-894 2 mg capsule BID throughout treatment period
1789377|NCT00507936|Drug|ABT-894|ABT-894 4 mg capsule BID throughout treatment period
1789378|NCT00507936|Drug|placebo|placebo capsule BID throughout the treatment period
1789379|NCT00507936|Drug|Duloxetine|Duloxetine 60 mg QD throughout treatment period
1789380|NCT00507949|Drug|Megestrol acetate|Sachets of 160 mg of granulated. Dosage 160 mg /b.i.d. Duration 8 weeks.
1789381|NCT00507949|Drug|placebo|sachets of granulate of 160 mg. Dosage 160 mg b.i.d. Duration 8 weeks.
1789382|NCT00507962|Drug|Cisplatin|100 mg/m^2 Intraarterial On Day 1 Every 4 Weeks
1789383|NCT00507962|Drug|Liposomal Doxorubicin|Starting dose 20 mg/m^2 IV On Day 1 Every 4 Weeks
1789384|NCT00507975|Drug|nicotine versus placebo|The main aim of this study is to assess the effectiveness of nicotine patch comparatively to a placebo patch in pregnant women on birth weight and maternal smoking abstinence. The main secondary objective is the assessment of safety of these treatments for the fetus/newborn and for the mother.
1789440|NCT00508430|Drug|Placebo|oral
1789633|NCT00509652|Procedure|Arm 2: Whole blood phlebotomy|Traditional whole blood phlebotomy
1789386|NCT00507988|Behavioral|Basic Cognitive Training|10 sessions over 3 weeks of 45 min basic cognitive training (including 45 min computerized training of attention, processing speed, memory)
1789387|NCT00508001|Drug|Vandetanib|ZD6474 300mg
1789388|NCT00508001|Drug|Vandetanib|ZD6474 100 mg
1789389|NCT00508001|Drug|Best Supportive Care|Placebo + Best Supportive Care
1789390|NCT00508014|Other|Usual Care|Usual Care with primary care provider during time period
1789391|NCT00508014|Behavioral|Concurrent Peer Review visit|Participants are offered an office visit with a peer of their clinician primary clinician. This office visit is structured and focused on blood pressure, diabetic, and/or lipid control with decision support available at point of care
1789392|NCT00508027|Drug|Simvastatin|Comparison of 3 dosages of simvastatin given in a dose-escalating fashion. 20 mg, 40 mg, or 80 mg PO QD x 21 days followed by a drug taper x 4 days.
1789393|NCT00508040|Drug|interferon alpha 2a|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
1789394|NCT00508040|Drug|prednisone|We propose to analyse the potential therapeutic effect of Interferon alpha2 a versus Steroid therapy with a control group for a 4 months period. This short period could not expose to a worsening of the disease because of the slow pathologic processus.
1789395|NCT00508053|Procedure|Small stitches|
1789396|NCT00508053|Procedure|Mass closure|
1789399|NCT00508092|Procedure|local anesthetic administration|"Pre incision skin infiltration with local anesthetic 0.5% bupivacaine by weight
OR
Pre incision skin infiltration and deeper field infiltration (deep to external oblique) with local anesthetic 0.5% bupivavcaine by weight"
1789402|NCT00508118|Drug|Nicardipine|on bypass
1789403|NCT00508118|Drug|0.9% saline|on bypass
1789404|NCT00508131|Other|Whole Cows Milk|400 mL, administered as two 200 mL drinking episodes per day of either fortified or not fortified milk for 12 months.
1789405|NCT00508144|Drug|Alimta|500 mg/m^2 by vein Once Over 10 Minutes Every 3 Weeks
1789406|NCT00508157|Drug|Aripiprazole|Tablets, Oral, 5 to 30 mg, once daily, 16 weeks
1789407|NCT00508157|Drug|Continued Antipsychotic (Risperidone or Quetiapine or Olanzapine)|Tablets, Oral, According to summary of product characteristics (SmPC)
1789408|NCT00508170|Behavioral|Questionnaire|The questionnaire contains 23 questions and is estimated to take approximately 10 minutes to complete.
1789413|NCT00508209|Drug|bortezomib|1.3 mg/sqm days -5 and -2 in connection with high-dose melphalan (200mg/sqm day -2) and autologous stem cell support
1789414|NCT00508222|Drug|Kaletra Tablets|Kaletra 800/200 OD
1789415|NCT00508235|Behavioral|Questionnaire|Questionnaire about the patient's relationship with their best friend.
1789416|NCT00508248|Dietary Supplement|omega 3 fatty acids|1g daily
1789417|NCT00508248|Dietary Supplement|placebo|olive oil capsule
1789421|NCT00508274|Drug|lapatinib in combination with capecitabine|daily oral lapatinib (1250 mg/day) in combination with capecitabine (2000mg/m2/day on days1-14 every 21 days)
1789422|NCT00508287|Drug|BMS-686117|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
1789423|NCT00508287|Drug|Byetta|Injection solution, Subcutaneous, 5 mcg, Once daily, Single dose.
1789424|NCT00508287|Drug|Placebo|Injection solution, Subcutaneous, 1 mg, Once daily, Single dose.
1789425|NCT00508300|Procedure|Epidural analgesia|Thoracic epidural analgesia until day 2
1789426|NCT00508300|Procedure|Patient controlled analgesia|Patient controlled analgesia (morphine-based)
1789427|NCT00508313|Procedure|Thermal Imaging|Thermal imaging sessions, each taking approximately 10 minutes.
1789428|NCT00508326|Drug|Paclitaxel|Starting dose 150 mg/m^2 HAI once every 4 weeks
1789429|NCT00508339|Behavioral|Questionnaire|Toronto Extremity Salvage Score (TESS) questionnaire.
1789430|NCT00508352|Procedure|Helical tomotherapy IMRT|Helical tomotherapy IMRT 50 Gy in 25 fractions, daily treatment
1789431|NCT00508365|Drug|Carvedilol CR capsules|The carvedilol micropump (COREG) CR cpsules will be available with doses of 20 milligrams and 40 milligrams administered orally once daily.
1789432|NCT00508365|Drug|Placebo|Placebo capsules to match each dose level will be provided.
1789433|NCT00508365|Drug|Lisinopril|Lisinopril will be available as 10 milligrams tablets administered orally once daily.
1789436|NCT00508391|Device|Optimized interventricular delay biventricular pacing|Lumax HF-T with optimized interventricular delay biventricular pacing
1789437|NCT00508404|Drug|Panitumumab|Administered by intravenous infusion
1789438|NCT00508404|Drug|FOLFIRI|FOLFIRI chemotherapy was initiated on Day 1 of each treatment cycle at the following starting doses: irinotecan 180 mg/m², leucovorin 400 mg/m², 5-fluorouracil bolus 400 mg/m², 5-fluorouracil infusion 2400 mg/m².
1789439|NCT00508430|Drug|ASP8825|oral
1789441|NCT00508443|Radiation|Radiation Therapy|Three radiation treatments guided by the CT-on-Rails or Trilogy procedure over a period of 2 weeks. Participants prescribed to receive 9 Gy x 3 so that a peripheral dose of 27 Gy is given to the tumor.
1789442|NCT00508456|Drug|Temodar (Temozolomide)|150 mg/m^2 orally once a day for 7 consecutive days (days 8 through 15).
1789443|NCT00508456|Dietary Supplement|Hominex-2|"Methionine free diet during Days 1 - 7 and Days 15 - 21 by consuming only shakes containing Hominex-2®."
1789444|NCT00508469|Drug|Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
1789445|NCT00508469|Drug|Travoprost 0.004% eye drops|One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.
1789446|NCT00508469|Drug|Timolol 0.05% eye drops|One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.
1789447|NCT00508469|Device|Travalert Dosing Aid|Approved device used with study medication to record time of instillation and quantify dosing
1789448|NCT00508482|Other|deep needling|"Huatuo brand needle (0.35×75mm), LH202H electric stimulator, parameter is constant wave, 2/15Hz, and current intensity is the abdominal muscles shiver slightly and the patient feels trivial pain.
Once a day, five times a week, four weeks."
1789449|NCT00508482|Drug|Lactulose|20-30ml, once a day before breakfast, for the whole study except the run-in period
1789450|NCT00508482|Other|shallow needling|Huatuo brand needle (0.30×25mm). The usage of EA apparatus and treatment course were the same as deep needling group.
1789451|NCT00508495|Drug|Paracetamol (acetaminophen)|Four 100 mL, 15 min IV infusions at six hour intervals
1789452|NCT00508495|Drug|Paracetamol 1% solution|Four 100 mL, 15 min IV infusions at six hour intervals
1789453|NCT00508495|Drug|0.9% sodium chloride solution|Four 100 mL, 15 min IV infusions at six hour intervals
1789454|NCT00508508|Behavioral|Interactive Voice Response System|Participants using IVR will receive training in peer communication techniques and participate in an initial nurse-led interactive group visit. They will then be asked to communicate at least weekly with their partner using the IVR system. The IVR system will also automatically send reminder calls to participants and allow them to leave voice mail messages for their partner and their care manager.
1789455|NCT00508508|Behavioral|Nurse-Led Group Clinic Visits|At Months 1, 3, and 6, participants will take part in group visits led by nurses to discuss HF self-management strategies.
1789456|NCT00508521|Device|Functional Electrical Stimulation|commercially available surface electrical stimulator
1789457|NCT00508521|Other|Standard Care|Standard care as ordered by their physician and covered by their insurance company.
1789458|NCT00508534|Drug|SB-751689|
1789459|NCT00508547|Biological|ustekinumab|as prescribed
1789460|NCT00508547|Biological|Biological therapies other than infliximab and ustekinumab|as prescribed
1789461|NCT00508547|Drug|conventional systemic agents|as prescribed
1789462|NCT00508547|Biological|infliximab|as prescribed
1789463|NCT00508560|Behavioral|Contingency Management|"Participants draw from a fishbowl to obtain tokens when they attend a smoking cessation treatment session. The number of draws will be based upon attendance at consecutive sessions. Tokens include messages of encouragement (Good job!) or VA canteen vouchers of varying monetary value."
1789464|NCT00508560|Behavioral|Reward|Participants receive set reward (VA canteen voucher) for each week of smoking cessation treatment they attend. The value of the reward will not change regardless of attendance at consecutive sessions.
1789465|NCT00508573|Behavioral|Questionnaire|Follow-up questionnaire done once a year for five years.
1789466|NCT00508586|Drug|PTC299|PTC299 orally administered twice per day given in combination with anastrozole (Arimidex®), letrazole (Femara®), or exemestane (Aromasin®)
1789467|NCT00508599|Other|Study 2 (48 hours of complete bed rest)|Effects of 48 hours of bed rest on insulin resistance in type 2 diabetic subjects.
1789468|NCT00508612|Behavioral|Williams LifeSkills Stress and Anger Management Workshop|Williams LifeSkills Stress and Anger Management Workshop
1789469|NCT00508612|Behavioral|High school classes|The control group will attend regular high school classes.
1789470|NCT00508625|Drug|AMG 951 (rhApo2L/TRAIL)|AMG 951 is recombinant human Apo2Ligand/Tumor necrosis factor related apoptosis inducing ligand (rhApo2L/TRAIL) that triggers apoptosis through activation of death receptor 4 (DR4) and death receptor 5 (DR5).
1789471|NCT00508625|Drug|Bevacizumab|Bevacizumab is a recombinant humanized version of a murine antibody to vascular endothelial growth factor (VEGF).
1789472|NCT00508625|Drug|Carboplatin|Standard platinum based chemotherapy
1789473|NCT00508625|Drug|Paclitaxel|Standard taxane chemotherapy
1789474|NCT00508651|Biological|MEDI-560|MEDI-560 vaccine was a frozen preparation of live, attenuated rHPIV3cp45 virus filled into Becton Dickinson^TM luer slip tip syringes. Each 0.2 mL dose contained 10^5 TCID50 of MEDI-560 in a sucrose phosphate glutamate buffer.
1789475|NCT00508651|Biological|Placebo|Placebo was a frozen preparation filled into Becton Dickinson^TM luer slip-tip syringes. Each 0.2 mL dose contained sucrose phosphate buffer.
1789476|NCT00508664|Radiation|Radiation|Radiation start in week 11
1789477|NCT00508664|Drug|Cetuximab|Day 1 400mg/m2 i.v. than weekly 250 mg/m2 i.v. for 16 weeks
1789478|NCT00508664|Drug|Docetaxel|75 mg/m2 i.v. day 1 3 times
1789479|NCT00508664|Drug|Cisplatin (TP)|75 mg/m2 i.v. day 1 3 times
1789480|NCT00508664|Drug|5-Fluorouracil (TPF) (only until Feb 2009)|Only patients recruited until Feb 2009: 750 mg/m2 i.v. day 1-5, 3 times
1789481|NCT00508690|Drug|cefmetazole|Intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
1789482|NCT00508690|Drug|kanamycin/metronidazole|2 doses of oral kanamycin(1g)/ metronidazole(750mg) administration on the day before surgery with intravenous dose of 1g cefmetazole just before surgery and additional doses every 3hs during surgery
1789483|NCT00508703|Radiation|Intensity Modulated Radiotherapy (IMRT)|Dose of 45Gy
1789484|NCT00508703|Procedure|CT Scan|CT Scans: Twice a week during the 5 weeks of radiation treatment.
1789485|NCT00508716|Behavioral|Health Literacy-Tailored Education|Intervention group receives a visit from a nurse educator who, using the teach back method of educating patients, provides counseling on their disease methods of controlling their disease. A video is also viewed to reinforce the materials.
1789486|NCT00508729|Drug|Qingyi granules|
1789487|NCT00508742|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose at 2, 4, 6 and 12 months of age
1789488|NCT00508742|Biological|7 valent pneumococcal conjugate vaccine|1 dose at 2, 4, 6 and 12 months of age
1789489|NCT00508755|Device|Gait Robot|gait training with the use of a gait robot
1789490|NCT00508755|Device|Functional Neuromuscular stimulation with intramuscular electrodes|gait training with use of functional electrical stimulation
1789491|NCT00508768|Drug|Oral SCIO-469 capsule|
1789492|NCT00508781|Behavioral|Multiphoton laser image in cutaneous pathology|
1789493|NCT00508794|Behavioral|Yoga Group|3 sessions of yoga each week for 6 weeks.
1789494|NCT00508794|Behavioral|Stretching Control Group|3 sessions of stretching each week for 6 weeks
1789495|NCT00508794|Behavioral|Waitlist Control Group|Option of participating in the yoga or stretching program after the study has ended.
1789496|NCT00508794|Other|Questionnaire|Questionnaire evaluating treatment-related symptoms during the middle of radiotherapy.
1789497|NCT00508807|Drug|RTA 402|5 mg by mouth (PO) daily for 21 days
1789498|NCT00508820|Biological|Romiplostim|Romiplostim will be administered subcutaneously QW. Romiplostim will be manufactured and packaged and distributed using Amgen's clinical study investigational product distribution procedures. Romiplostim is presented as a lyophilized, white powder in 5.0 mL glass vials.
1789499|NCT00508833|Biological|287615 containing HBsAg with adjuvants|
1789500|NCT00508846|Behavioral|Questionnaire|Two-part telephone questionnaire lasting about 60 minutes total.
1789501|NCT00508859|Drug|Sertraline|maintenance treatment with sertraline
1789502|NCT00508859|Drug|placebo|placebo
1789503|NCT00508872|Drug|5-Fluorouracil|400 mg/m^2 IV over 15 minutes, followed by 2400 mg/m^2 IV Over 46 Hours
1789504|NCT00508872|Drug|Bevacizumab|5 mg/kg IV Over 30-90 Minutes On Day 1 Every 14 Days
1789505|NCT00508872|Drug|Leucovorin|400 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
1789506|NCT00508872|Drug|Oxaliplatin|85 mg/m^2 IV Over 2 Hours On Day 1 Every 14 Days
1789507|NCT00508885|Drug|Niacinamide|Niacinamide 250 mg twice daily titrated up to 750 mg twice daily
1789508|NCT00508885|Drug|Placebo|Placebo
1789509|NCT00508898|Drug|Calcitriol|Patients will receive calcitriol (oral capsule) at a fixed dose of 1 mcg twice weekly.
1789510|NCT00508898|Drug|Multivitamin|Patients will receive multivitamin 1 tab daily (with vitamin D2 300 IU).
1789511|NCT00508911|Drug|GW876008|GW876008 tablets will be available as white to off-white coated tablets. Each subject will receive a single oral dose of GW876008, daily for up to 35 days in Session 2. GW876008 will be administered in the morning with a light breakfast.
1789512|NCT00508911|Drug|COC|COC containing ethinylestradiol 30 microgram and levonorgestrel 150 microgram will be administered in the morning with a light breakfast.
1789513|NCT00508924|Drug|Argatroban|
1789514|NCT00508924|Drug|Argatroban|
1789515|NCT00508924|Drug|Argatroban|
1789516|NCT00508924|Drug|Heparin|
1789517|NCT00508937|Other|Diet|15% protein, 55% carbohydrate, 30% fat (7% saturated, 7% polyunsaturated)
1789518|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (7% saturated, 7% polyunsaturated)
1789519|NCT00508937|Other|Diet|20% protein, 35% carbohydrate, 45% fat (15% saturated, 7% polyunsaturated)
1789520|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (7% saturated, 7% polyunsaturated)
1789521|NCT00508937|Other|Diet|30% protein, 35% carbohydrate, 35% fat (15% saturated, 7% polyunsaturated)
1789522|NCT00508950|Procedure|Large volume blood draw|Large volume blood draw
1789523|NCT00508963|Drug|sodium stibogluconate (Pentostam)|20 mg/kg IV every day for 20 or 28 days
1789524|NCT00508976|Drug|Injected bupivacaine post-operatively|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation, and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
1789525|NCT00508976|Drug|Streamed bupivacaine versus streamed normal saline|Patients will receive 30ml of 0.9% normal saline divided equally and injected prior to port site incisions, then 10ml of 0.5% bupivacaine streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
1789526|NCT00508976|Drug|Aerosolized bupivacaine versus aerosolized saline|Patients will receive 30 ml of 0.9% normal saline divided equally and injected prior to port site incision, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.5% bupivacaine aerosolized into coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
1789527|NCT00508976|Drug|Injected lidocaine pre-incision vs saline pre-incision|Patients will receive 30ml of 1% lidocaine divided equally and injected prior to port site incisions, then 10ml of 0.9% normal saline streamed via port directed at operative field, then 10ml of 0.9% normal saline aerosolized into the coelomic cavity prior to deflation and our current standard of care, which is 30ml of 0.5% bupivacaine, divided equally between the five port-sites, injected at the end of the operation.
1789528|NCT00508989|Drug|Niacin-ER|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
1789529|NCT00508989|Drug|Placebo|500 mg daily for 4 weeks, 1000 mg daily for 4 weeks, and 1500 mg daily for 4 weeks
1789530|NCT00508989|Drug|L-NMMA|
1789531|NCT00508989|Drug|Acetylcholine|
1789533|NCT00509015|Drug|Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg)|500mg S&25mg P/20 kg, 1 day, single dose
1789534|NCT00509015|Drug|Artesunate (day 1,2,3: 4 mg/kg)|4 mg/kg, daily single dose over three days
1789535|NCT00509015|Drug|Primaquine-base (day 3: 0.75 mg/kg)|single dose at 0.75 mg/kg on day 3
1789536|NCT00509015|Drug|placebo tablets|3 days of lactose tablets (160mg) albochin
1789537|NCT00509028|Drug|Budesonide|Budesonide Turbuhaler 100 mcg (Pulmicort® Turbuhaler®), 100 - 400 mcg daily
1789538|NCT00509028|Drug|Conventional Asthma Therapy|According to the Japanese Paediatric Guideline for the Treatment and Management of Asthma and at daily dose as judged by the investigator.
1789539|NCT00509041|Drug|dasatinib|50 mg PO bid
1789540|NCT00509054|Procedure|Prophylactic mesh|A low weigth partly absorbable mesh in a subaly posistion
1789541|NCT00509067|Drug|Galantamine|Galantamine will be titrated to 24 mg/day over 2 weeks. Participants will receive 8 mg/day in two divided doses for 1 week, 16 mg/day in two divided doses for 1 week, and 24 mg/day in two divided doses beginning in Week 3. They will be maintained on 24 mg/day for the remainder of the study.
1789542|NCT00509067|Drug|CDP-choline|CDP-choline will serve as the dietary source of choline. CDP-choline will be titrated to 2000 mg/day over 1 week. Subjects will receive 500 mg/day for 3 days; Thereafter, the dose of CDP-choline will be increased to 1,000 mg/day in two divided doses for 4 days. At the beginning of Week 2, participants will receive the maximum fixed dose of 2000 mg/day in two divided doses, which will be held constant through the end of Week 16.
1789543|NCT00509067|Drug|Placebo|The schedule of dose titration of placebo galantamine and placebo CDP-choline will follow the schedule of active medication condition using matching placebos for each agent.
1789544|NCT00509067|Drug|risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole|All participants will continue to take their regular regimen of risperidone, olanzapine, quetiapine, ziprasidone, and/or aripiprazole throughout the trial in addition to their assigned treatment.
1789545|NCT00509093|Drug|imatinib mesylate|Patients will receive treatment with imatinib mesylate at a dose of 600 mg by mouth once a day for 12 months. The study dose can be split but the dose of 600 mg must be given within a 12 hour period.
1789546|NCT00509093|Genetic|gene expression analysis|Multidrug resistance genes: These studies will include: MDR1, MRP1, LRP, and BCRP. Bone marrow blocks or cut slides will be sent to Duke on the diagnostic AML samples. DNA will be eluted from the samples so that the above genes can be analyzed.
1789547|NCT00509093|Genetic|mutation analysis|FLT3 mutation analysis (on bone marrow aspirate or peripheral blood): These analyses will be performed by pathology at the time of diagnosis, at the participating institution. Samples will be analyzed for the FLT3 ITD and/or D835 mutation by PCR.
1789548|NCT00509093|Genetic|polymerase chain reaction|AF1q gene analysis (on bone marrow aspirate)
1789549|NCT00509093|Other|flow cytometry|C-kit MFI on AML samples will be calculated by using a CD45/ orthogonal light scatter gate to isolate blasts. The MFI will be calculated as the c-kit mean channel number (MCN) of the blasts/ MCN auto fluorescence.
1789550|NCT00509093|Procedure|biopsy|Diagnostic bone marrow biopsy/aspirate must be done within 3 weeks of registration documenting complete remission
1789551|NCT00509106|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours for 5 to 7 days
1789552|NCT00509106|Drug|Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours for 5 to 7 days
1789553|NCT00509106|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
1789554|NCT00509132|Drug|trodusquemine|
1789555|NCT00509145|Drug|Laquinimod|Laquinimod 0.6 mg capsule, oral, once daily
1789556|NCT00509145|Other|Placebo|oral, once daily, capsule
1789557|NCT00509158|Biological|arm I: PfLSA-3-rec with aluminium hydroxide as adjuvant|
1789558|NCT00509158|Biological|arm 2: PfLSA-3-rec with Montanide Isa 720 as adjuvant|
1789559|NCT00509171|Device|Reamer Irrigator Aspirator|Use of standard reamer vs reamer irrigator-aspirator during IM nailing of tibial shaft fractures
1789560|NCT00509184|Drug|Rituximab|375 mg/m^2, weekly (4 weeks), repeated after 4 weeks gap
1789561|NCT00509197|Drug|Placebo (sham inhaler)|
1789562|NCT00509197|Drug|Fluticasone|Fluticasone 250mcg bid for one month
1789563|NCT00509210|Drug|telaprevir (VX-950)|
1789564|NCT00509223|Device|Positive Airway Pressure therapy|Positive Airway Pressure (PAP) therapy initiated at Randomization and continued through the entire study duration (6 months), with instructions for use on a daily basis, during periods of sleep.
1789565|NCT00509223|Behavioral|Lifestyle counseling|Lifestyle counseling: All subjects were counseled regarding adopting a healthy lifestyle and advised on the Heart Foundation, National Health and Medical Research Council, and American Diabetes Association nutrition and exercise recommendations.
1789566|NCT00509236|Drug|Sitagliptin|25 mg (one 25-mg tablet) once daily
1789567|NCT00509236|Drug|Glipizide|2.5 mg (1/2 of a 5-mg tablet) once daily, up to 10 mg twice daily (four 5-mg tablets), for a maximum of 20 mg
1789568|NCT00509249|Biological|ziv-aflibercept|Given IV
1789569|NCT00509249|Other|laboratory biomarker analysis|Correlative studies
1789570|NCT00509249|Other|pharmacological study|Correlative studies
1789571|NCT00509262|Drug|Sitagliptin|Participants with moderate renal insufficiency will receive two sitagliptin 25 mg tablets orally daily; participants with severe renal insufficiency will receive one sitagliptin 25 mg tablet orally daily
1789572|NCT00509262|Drug|Glipizide|Participants will receive glipizide 2.5 mg (1/2 tablet) orally once daily up to 20 mg orally daily (10 mg twice daily)
1789573|NCT00509262|Drug|Placebo for Sitagliptin|Participants with moderate renal insufficiency will receive 2 placebo for sitagliptin tablets orally daily; participants with severe renal insufficiency will receive 1 placebo for sitagliptin tablet orally daily
1789574|NCT00509262|Drug|Placebo for Glipizide|Participants will receive 1/2 tablet of placebo for glipizide orally once daily up to 2 tablets orally twice daily
1789575|NCT00509275|Drug|W0027|capsule
1789576|NCT00509275|Drug|Placebo|Placebo
1789577|NCT00509288|Biological|autologous anti-MART-1 F5 T-cell receptor|"Autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes.
A minimum of approximately 5 X 10^8 cells will be given up to 3x10^11 anti-MART-1 F5 TCR engineered TIL or PBL."
1789578|NCT00509288|Drug|Cyclophosphamide|Day -7 to -5: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml D5W with mesna 15 mg/kg/day X 2 days over 1 hr
1789579|NCT00509288|Drug|Fludarabine|Day -5 to 1: Fludarabine 25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days
1789580|NCT00509288|Biological|Aldesleukin|Day 0: Cells will be infused intravenously (i.v.). Patients will receive up to 3x10e^11 (with a minimum of 5x10e^8 cells) anti-MART-1 F5 TCR engineered TIL or PBL Aldesleukin (based on total body weight) 720,000 IU/kg intravenous (IV) over 15 minute every eight hours beginning within 24 hours of cell infusion
1789581|NCT00509288|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered tumor infiltrating lymphocytes|
1789582|NCT00509301|Drug|131-I-chTNT-1/B MAB|The study drug is given interstitially for approximately 25 hours at a dose of 1.5, 2.0, or 2.5 mCi/cc.
1789583|NCT00509314|Behavioral|melanocyte self-assembly and functional analysis|
1789584|NCT00509327|Drug|bisacodyl|10mg capsule twice daily from one day preoperatively to day three postoperatively
1789585|NCT00509327|Drug|glucosemonohydricum|10mg of glucosemonohydricum twice daily from one day preoperative to day three postoperative
1789586|NCT00509340|Behavioral|Cognitive behavioral therapy (CBT)|Participants in this group will receive individual sessions of cognitive-behavioral training for improvement of medication adherence and reduction of depression.
1789587|NCT00509353|Drug|irinotecan hydrochloride|
1789588|NCT00509353|Drug|vincristine sulfate|
1789589|NCT00509353|Radiation|iobenguane I 131|
1789590|NCT00509366|Drug|Cisplatin & Gemcitabine|"Squamous Cell NSCLC:
Gemcitabine 1250 mg/m2 IV over 30 minutes day 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
1789591|NCT00509366|Drug|Cisplatin & Pemetrexed|"Non-Squamous Cell NSCLC:
Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Cisplatin 75 mg/m2 IV over 60 minutes day 1; repeat every 21 days for up to 6 cycles"
1789592|NCT00509366|Drug|Docetaxel & Gemcitabine|"Squamous Cell NSCLC:
Docetaxel 75 mg/m2 IV over 60 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
1789593|NCT00509366|Drug|Pemetrexed & Gemcitabine|"Non-Squamous Cell NSCLC:
Pemetrexed 500 mg/m2 IV over approximately 10 minutes day 1, followed by Gemcitabine 1250 mg/m2 IV over 30-60 minutes day 1 and alone day 8; repeat every 21 days for up to 6 cycles"
1789594|NCT00509379|Drug|Rituximab|Rituximab 375 mg/m2 as slow iv infusion day 1-8-15-22.Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
1789595|NCT00509379|Drug|VELCADE|VELCADE 1,6 mg/m2 iv bolus days 1-8-15-22 (Velcade will be administrated prior of Rituximab infusion).Patients will be treated with six courses of therapy with a thirteen day rest period between them. Courses will be restarted at day 36.
1789596|NCT00509392|Device|Seg. RF Ablation & ClosureFAST catheter|Seg. RF Ablation & ClosureFAST catheter
1789597|NCT00509392|Device|Endovenous Laser|laser catheter
1789598|NCT00509405|Drug|potassium citrate|6 times 10 mEq per day, oral for 24 months
1789599|NCT00509418|Dietary Supplement|Viusid|Viusid, a nutritional supplement. Three oral sachets Daily 24 weeks
1789600|NCT00509418|Other|Hypocaloric Diet with controlled exercise|Modified ADA diet in combination with controlled exercise daily 24 weeks
1789601|NCT00509431|Drug|Erlotinib + Sirolimus|In arm I of dose escalation phase,starting dose of erlotinib is 150 mg daily. Starting dose of sirolimus includes a 15 mg loading dose, followed by continuous dosing at 5 mg daily.Dose escalation will proceed according to protocol Phase II of the study was not conducted only Phase I
1789602|NCT00509444|Behavioral|Educational materials|
1789603|NCT00509444|Behavioral|educational materials, plus patient navigation|
1789604|NCT00509457|Biological|GV 1001 Telomerase peptide|
1789605|NCT00509470|Drug|telmisartan plus hydrochlorothiazide|Combination therapy with telmisartan (40 mg/day) plus hydrochlorothiazide (12.5 mg/day): If blood pressure is not reach to lower than 140/90 mmHg, dose of telmisartan can be increased to 80 mg/day
1789606|NCT00509470|Device|Amlodipine|
1789607|NCT00509483|Radiation|Radioactive iodine|Radioactive iodine preceded by rhTSH
1789608|NCT00509496|Drug|fludarabine phosphate|25 mg/m^2/day intravenous piggy back over 30 minutes for 5 days.
1789609|NCT00509496|Drug|cyclophosphamide|60 mg/kg/day x 2 days intravenous
1789610|NCT00509496|Biological|aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
1789611|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered tumor infiltrating lymphocytes|"Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered TIL .
The cells are infused intravenously over 20-30 minutes."
1789612|NCT00509496|Biological|autologous anti-gp 100:154-162 T-cell receptor gene-engineered peripheral blood lymphocytes|"Patients will receive a minimum of approximately 5 X 10^8 cells and up to 3 x10^11 anti-gp100:154-162 TCR engineered PBL.
The cells are infused intravenously over 20-30 minutes."
1789613|NCT00509535|Drug|vitreoscilla filiformis cream|
1789614|NCT00509548|Drug|TG100801|Eye drop, twice a day, 30 days.
1789615|NCT00509561|Biological|cetuximab|
1789616|NCT00509561|Drug|capecitabine|
1789617|NCT00509561|Drug|cisplatin|
1789618|NCT00509561|Radiation|radiation therapy|
1789619|NCT00509587|Drug|pazopanib hydrochloride|Given orally
1789620|NCT00509587|Procedure|pharmacological study|Correlative studies
1789621|NCT00509587|Procedure|laboratory biomarker analysis|Correlative studies
1789622|NCT00509600|Drug|Etanercept|0.8 mg/kg Subcutaneously Once A Week for 90 Days
1789623|NCT00509613|Drug|Sorafenib|
1789624|NCT00509613|Drug|Sirolimus|
1789625|NCT00509626|Behavioral|exercise intervention|
1789626|NCT00509626|Other|questionnaire administration|
1789627|NCT00509626|Procedure|CAM exercise therapy|
1789628|NCT00509626|Procedure|management of therapy complications|
1789629|NCT00509626|Procedure|psychosocial assessment and care|
1789630|NCT00509626|Procedure|quality-of-life assessment|
1789632|NCT00509652|Procedure|Arm 1: Erythrocyte apheresis|Erythrocyte apheresis
1789635|NCT00509665|Drug|gemcitabine hydrochloride|
1789636|NCT00509665|Other|laboratory biomarker analysis|
1789637|NCT00509665|Other|liquid chromatography|
1789638|NCT00509665|Other|mass spectrometry|
1789639|NCT00509678|Drug|Rituximab|1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15). The first infusion of rituximab should be administered IV at an initial rate of 50 mg/hr. If a hypersensitivity or infusion related reaction does not occur, escalate the infusion rate by 50 mg/hr increments every 30 minutes, to a maximum of 400 mg/hr.
1789640|NCT00509691|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
1789641|NCT00509691|Genetic|polymerase chain reaction|
1789642|NCT00509691|Other|diagnostic laboratory biomarker analysis|
1789643|NCT00509691|Other|flow cytometry|
1789644|NCT00509691|Other|immunologic technique|
1789645|NCT00509717|Other|intensive implementation programme|educational manual; interactive educational meeting tailored to individual needs; reminders and feedback by 3 newsletters and at least 3 telephone calls.
1789646|NCT00509717|Other|control|educational manual
1789647|NCT00509730|Procedure|Urodynamics|
1789648|NCT00509743|Drug|Intravenous diclofenac sodium (DIC075V)|High dose Diclofenac
1789649|NCT00509743|Drug|Intravenous diclofenac sodium (DIC075V)|Low Dose Diclofenac
1789650|NCT00509756|Drug|FXR-450|capsule, single oral doses from 10 mg to 450 mg
1789651|NCT00509756|Drug|Placebo|capsule similar to active drug
1789652|NCT00509769|Drug|Trastuzumab emtansine [Kadcyla]|Trastuzumab emtansine was provided in either a liquid or a lyophilized formulation.
1789653|NCT00509782|Drug|ZIO-101|Starting Dose 78 mg/m^2 intravenously daily for 5 consecutive days repeated every 4 weeks.
1789654|NCT00509795|Biological|ranibizumab|Participants received a 0.5mg dose of ranibizumab via intravitreal (IVT) injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
1789655|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
1789656|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5mg dose of aflibercept injection every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
1789657|NCT00509795|Biological|aflibercept injection (VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0mg dose of aflibercept injection every 8 weeks (including one additional 2.0 mg dose at Week 4) for the first year and were to receive sham injections at interim monthly visits. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
1789658|NCT00509808|Device|Electrostimulation|"1st month GN wearing (activated or sham mode)
2nd month wearing (opposite mode)
3rd - 5th month: activated GN wearing for 1, 5 or 10 minutes
6th - 8th month: activated GN wearing for 1, 5 or 10 minutes
9th - 11th month: activated GN wearing for 1, 5 or 10 minutes"
1789659|NCT00509821|Drug|enzastaurin|"Safety Run in Regimen 1: 1125 mg loading dose D(-)7 then 500 mg QD, oral, daily until disease progression
Regimen 2: 1125 mg loading dose D(-)7 then 250 mg BID, oral, daily until disease progression"
1789660|NCT00509821|Radiation|radiation|Involved-field radiotherapy will be administered D1 after 7 day lead in enzastaurin treatment at a dose of 54 to 60 Gy, given in individual doses of 1.8 to 2 Gy 5 days a week for 6 weeks
1789661|NCT00509834|Drug|hLF1-11|"The study treatment consists of IV administration of:
(A) hLF1-11 (0.5mg IV bolus daily for 14 days) + fluconazole (up to 1g IV four times daily; 14 days): Group #1, n=10; OR (B) Fluconazole (up to 1g IV four times daily; 14 days) + matching placebo for hLF1-11: Group #2, n=10"
1789662|NCT00509834|Drug|hLF1-11|0.5mg hLF1-11 iv per day for 14 consecutive days
1789663|NCT00509834|Drug|Placebo|Placebo
1789664|NCT00502047|Drug|Plantago ovata husk|
1789665|NCT00502060|Drug|AZD2171|
1789666|NCT00502060|Drug|ZD1839|
1789667|NCT00502073|Drug|cyclosporine|
1789668|NCT00502086|Dietary Supplement|Viusid (nutritional supplement)|Viusid three sachets daily during 96 weeks
1789669|NCT00502086|Other|Placebo|Placebo three sachets daily during 96 weeks
1789670|NCT00502099|Drug|Pegylated interferon alpha 2a|Injections: 180 ug once per week
1789671|NCT00502099|Drug|Ribavirin|Tablets, 1000-1200 daily
1789672|NCT00502099|Drug|Pegylated interferon alpha 2 b plus ribavirin|Pegylated interferon alpha 2 b injections
1789673|NCT00502112|Drug|lintuzumab|4 or 8 mg/kg IV (in the vein) on Days 1, 8 and 15 for the first 21-day cycle; 4 or 8 mg/kg IV (in the vein) on Days 1 and 8 for the second through the eighth 21-day cycle
1789674|NCT00502112|Drug|lenalidomide|10 or 15 mg per day, taken orally on Days 1-14 of each 21-day cycle
1789675|NCT00502125|Procedure|Reflectance Confocal Imaging|A photograph will be taken of any abnormal areas inside the mouth. A small probe will expose the oral lining to a small amount of light. Some of this light will be reflected back into the probe, and be picked up by a computer. Pictures will be made of the tissue.
1789676|NCT00502138|Drug|Continuous Pramlintide infusion|pramlintide injection, 9 mcg/hr plus 60 mcg premeal boluses
1789677|NCT00502164|Drug|AZD2171|
1789678|NCT00502177|Behavioral|Questionnaire|QOL Questionnaires taking a total of 10 minutes to complete.
1789679|NCT00502190|Device|Silicon ring positioned in the vagina, around the cervix|Silicon ring positioned in the vagina, around the cervix
1789680|NCT00502203|Drug|Carboplatin|AUC 5 By Vein Over 1 Hour Every 21 Days for 6 Courses
1789681|NCT00502203|Drug|Paclitaxel|175 mg/m^2 By Vein Over 3 Hours Every 21 Days for 6 Courses
1789682|NCT00502216|Drug|Naltrexone|Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day
1789683|NCT00502216|Drug|Varenicline|Arm 1 (Experimental) = Varenicline (Chantix) 1 mg oral tablet twice per day + naltrexone 25 mg oral capsule once per day; Arm 2 (Placebo Comparator) = Varenicline (Chantix) 1 mg oral tablet twice per day + placebo naltrexone 25 mg oral capsule once per day
1789684|NCT00502229|Drug|Clomiphene citrate, metformin, highly purified urinary FSH|
1789685|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (active)- oral - once per day
1789686|NCT00502242|Drug|ramipril|Capsule - initial treatment is 5 mg (placebo) - oral - once per day
1789687|NCT00502255|Device|Health Buddy system|Patients are followed on distance by the Health Buddy system.
1789688|NCT00502255|Device|Telemonitoring in patients with heart failure|Health Buddy in patients home situation.
1789689|NCT00502268|Drug|Doxercalciferol administration|Doxercalciferol administration
1789690|NCT00502268|Drug|Doxercalciferol administered by 1-84-7-84|Doxercalciferol administered by 1-84-7-84
1789691|NCT00502281|Drug|highly purified urinary FSH|
1789692|NCT00502281|Behavioral|timed intercourses, intrauterine insemination|
1789693|NCT00502294|Drug|Visilizumab (HuM291; Nuvion®)|
1789694|NCT00502307|Drug|Tivozanib (AV-951)|solid oral dosage form taken daily for three weeks per one month cycle
1789695|NCT00502307|Drug|Placebo comparator|solid oral capsule containing excipients dosed daily for three weeks per month
1789696|NCT00502320|Drug|Ramelteon|one 8 mg tablet at bed for up to 4 months
1789697|NCT00502320|Drug|Placebo|one tablet at bedtime for up to 4 months
1789698|NCT00502346|Drug|PM10|
1789699|NCT00502359|Device|capillary blood glucose measurement|
1789700|NCT00502372|Dietary Supplement|Nutritional Supplement/Amino acids and HMB|Subjects will be randomized to receive enriched dietary supplement (Juven) v arginine only (Argenaid) dietary supplement
1789701|NCT00502372|Dietary Supplement|Juven|comparison of Juven with arginine only product in wound healing
1789702|NCT00502385|Drug|AZD2171|
1789703|NCT00502398|Procedure|Blood test|
1789704|NCT00502411|Drug|Doxorubicin|17.5 mg/m^2 IV bolus infusion, followed by continuous IV infusion on days 1-4.
1789705|NCT00502411|Radiation|Radiation Therapy|Radiation treatments 5 days a week for 6 - 6 1/2 weeks. 60 Gy in 6 weeks (negative resection margin) to 66 Gy in 6.5 weeks (positive resection margin).
1789706|NCT00502424|Device|Splint|
1789707|NCT00502437|Drug|GRANISETRON|
1789708|NCT00502463|Procedure|radio-immunotherapy|
1789709|NCT00502476|Procedure|Bathing with Chlorhexidine Impregnated Washcloths|
1789710|NCT00502489|Procedure|Closed-loop sytem for5 weaning from mechanical ventilation|
1789711|NCT00502502|Behavioral|Questionnaire|Weekly questionnaires lasting about 30 minutes.
1789712|NCT00502515|Drug|SSR180575|Oral, once daily dosing
1789713|NCT00502515|Drug|Placebo|Oral, once daily dosing
1789714|NCT00502528|Drug|Placebo|Peri-interventional
1789715|NCT00502528|Drug|BQ-123|Peri-interventional
1789716|NCT00502541|Drug|fluocinolone acetonide|fluocinolone acetonide 0.59 mg intravitreal implant
1789717|NCT00502541|Procedure|Standard of Care|Repeat macular grid laser or observation
1789718|NCT00502554|Procedure|photopheresis|2-day cycles of photopheresis every 3 weeks for 3 months
1789719|NCT00502567|Drug|AZD2171|oral tablet once daily
1789720|NCT00502567|Drug|FOLFOX|intravenous infusion
1789721|NCT00502567|Drug|Pemetrexed|intravenous infusion
1789722|NCT00502567|Drug|Irinotecan (administered with & without Cetuximab)|intravenous injection
1789723|NCT00502567|Drug|Docetaxel|intravenous infusion
1789724|NCT00502580|Behavioral|Interview|Interview taking about 10 minutes to complete.
1789725|NCT00502593|Biological|Pandemic Influenza Vaccine (GSK1562902A)|2 doses, intramuscular injection on Days 0 and 21, 3 different formulations are tested.
1789726|NCT00502593|Biological|Fluarix™|2 doses, intramuscular injection on Days 0 and 21.
1789727|NCT00502619|Procedure|Acupuncture|A specific regimen of acupuncture sites will be needled twice weekly for eight weeks and once weekly for a subsequent eight weeks.
1789728|NCT00502619|Other|Treadmill Exercise|After the first four weeks of acupuncture treatments, subjects will initiate a three times per week treadmill program, which will continue for a total of 12 weeks in conjunction with the acupuncture treatments.
1789729|NCT00502632|Drug|Urokinase and Dornase alfa|"Intrapleural administration of:
Urokinase 40,000 in 40ml normal saline, twice daily for 4 days
Dornase alfa 2,500 IU in 25ml normal saline, twice daily for 4 days"
1789730|NCT00502632|Drug|Urokinase|"Intrapleural administration of:
Urokinase 40,000 in 40ml normal saline, twice daily for 4 days
25ml normal saline, twice daily for 4 days"
1789731|NCT00502645|Device|CS-1 DECISION SUPPORT SYSTEM|
1789732|NCT00502658|Behavioral|Dietary supplement containing vitamins, minerals, and herbs|
1789733|NCT00502658|Behavioral|Shakes with nutrients and herbs|
1789734|NCT00502658|Behavioral|Control dietary supplement|
1789735|NCT00502658|Behavioral|Isocaloric, isonitrogenous control shakes without herbs|
1789736|NCT00502658|Behavioral|Personal energy tracking tool|
1789737|NCT00502671|Drug|capecitabine [Xeloda]|1250mg/m2 po bid on days 1-14 of each 3 week cycle
1789738|NCT00502684|Drug|Propranolol, etodolac|propranolol 10 mg X 4 /day, starting on day -3 pre-op, for 6 days, till POD 2 Etodolac 400 mg X2/day, starting on day -3 pre-op, for 6 days, till POD 2
1789739|NCT00502697|Behavioral|Targeted Nurse Home Visits|Advanced practice nurses provide targeted behavioral interventions during home visits. These visits were in addition to regularly scheduled conventional prenatal and postpartum clinic care. Specific protocols guided nurse interventions related to tobacco use, substance use and misuse, stress management, dental health, maternal infections, perinatal depressive symptoms, family violence, reproductive life plans and continuity of care. Home visits were continued in the postpartum period (through 18 months post-delivery) with a continued focus on risk factors identified during the prenatal period and internatal health care.
1789740|NCT00502697|Other|Conventional prenatal/postpartum care|Women in this group received conventional prenatal care and postpartum clinic care.
1789741|NCT00502710|Drug|Placebo|Placebo po daily.
1789742|NCT00502710|Drug|RO4876904|Escalating doses, at a starting dose of 12.5mg po daily.
1789743|NCT00502723|Procedure|Radical retropubic prostatectomy|Radical retropubic prostatectomy
1789744|NCT00502723|Procedure|Radical laparoscopy prostatectomy|Radical laparoscopy prostatectomy
1789745|NCT00502736|Drug|ibandronate [Bondronat]|6mg iv on days 1-3
1789746|NCT00502749|Behavioral|Exercise program|Daily group or personal exercise programs designed to promote flexibility, endurance, and strength.
1789999|NCT00510393|Device|MULTILINK VISION coronary stent system|
1789747|NCT00502749|Behavioral|Questionnaires|Questionnaires taking 15 minutes to complete.
1789748|NCT00502762|Drug|topotecan|
1789749|NCT00502775|Drug|fluticasone furoate, fexofenadine|
1789750|NCT00502788|Drug|Peginterferon Alfa-2a and Ribavirin|"Patients will be treated with alfa-2a and ribavirin as follows:
Peginterferon alfa-2a will be started as a dose of 180 ug subcutaneously once weekly."
1789751|NCT00502788|Drug|Ribavirin|Ribavirin will be started at a dose of 800mg daily for those weighing less than or equal to 50 kg, 1000 mg daily for those with body weight 51 to 75 kg and 1200 mg daily for those with body weight > 75 kg. Ribavirin will be given orally in two divided doses. The lower dose has been included because potentially-eligible patients in the TCRN registry have a mean weight of 57 kg.
1789752|NCT00502801|Drug|doripenem|1g i.v. infused over 4 hours every 8 hours for 8 to 14 days
1789753|NCT00502814|Procedure|3-D Optical Surface Scan|3-D digitized images of the breasts and chest will be taken over a period of five minutes.
1789754|NCT00502814|Procedure|Mechanical Testing|A small device with a mild suction will be used to measure how the skin tends to stretch.
1789755|NCT00502814|Procedure|Cutaneous Ultrasound|Cutaneous ultrasound using a 20 MHz machine and the skin thickness will be recorded.
1789756|NCT00502814|Procedure|Breast MRI and/or CT|Imaging of the breasts and chest using an MRI and/or CT scan over about one hour.
1789757|NCT00502827|Behavioral|Cell Phone Intervention|Study participants called on a cell phone 11 times over course of a 12 - 13 week period, during 10 minute calls questions asked about smoking and quitting smoking.
1789758|NCT00502827|Other|Recommended Standard of Care|Advice from your physician to stop smoking and written materials designed to help you quit smoking.
1789759|NCT00502840|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
1789760|NCT00502853|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
1789761|NCT00502853|Drug|Methotrexate|10-25mg/week
1789762|NCT00502879|Drug|Enbrel (etanercept)|
1789763|NCT00502892|Drug|Topotecan|0.5 mg/m^2 IV Daily x 3 Days
1789764|NCT00502892|Drug|Ifosfamide|1.8 grams/m^2 IV Over 1 Hour x 5 Days
1789765|NCT00502892|Drug|Carboplatin|AUC = 3 mg/ml/min IV Over 1 Hour x 3 Days [for patients > 22 yrs of age, 3 mg/mL/min IV Over 1 Hour x 2 Days]
1789766|NCT00502905|Drug|Busulfan|130 mg/m^2 injected through the intravenous catheter over three hours, once a day, for four days, starting immediately after Fludarabine.
1789767|NCT00502905|Drug|Fludarabine|40 mg/m^2 through a central venous catheter over one hour, once a day, for four days.
1789768|NCT00502918|Device|CLM - HA Continuous Monitoring System Heart Application|
1789769|NCT00502944|Behavioral|Counselor-based HIV screening|Participants will undergo oral HIV screening by HIV counselor and, if positive, further study visits for up to 6 months
1789770|NCT00502944|Behavioral|Emergency staff member-based HIV screening|Participants will undergo oral HIV screening by emergency staff member and, if positive, further study visits for up to 6 months
1789771|NCT00502957|Behavioral|Biofeedback|
1789772|NCT00502970|Drug|16 weeks Interferon Tiw with Ribavirin|16 weeks Interferon Tiw
1789773|NCT00502970|Drug|24 weeks Interferon|24 weeks Interferon Tiw with Ribavirin
1789774|NCT00502983|Behavioral|Interview|Interview lasting approximately 50 minutes.
1789775|NCT00502996|Drug|Methotrexate|>=15 mg po/week
1789776|NCT00502996|Drug|rituximab [MabThera/Rituxan]|1g iv on days 1 and 15
1789777|NCT00503009|Drug|fluticasone propionate/salmeterol|comparator
1789778|NCT00503009|Drug|fluticasone propionate|Comparator
1789779|NCT00503009|Drug|placebo|Placebo
1789780|NCT00503022|Drug|ACZ885|
1789781|NCT00503035|Drug|Celecoxib|400 mg by mouth twice daily x 6 months
1789782|NCT00503035|Procedure|Colonoscopy Biopsy|Up to 23 additional colon tissue biopsies (the size of a pencil tip), additional 20 minutes on colonoscopy procedure
1789783|NCT00503074|Behavioral|TV modification|Parents receive a health behavior-change intervention consisting of 1 in-person visit from a case manager, followed by phone and e-mail contact at least monthly. The intervention is designed to promote healthy TV viewing, including viewing fewer commercials, by the target child aged 2-5 years old, and uses health behavior change theory and social cognitive theory.
1789784|NCT00503074|Behavioral|safety and injury prevention|Parents receive behavior-change counseling around toddler and preschooler safety and injury prevention.
1789785|NCT00503087|Procedure|Saline Injection|
1789786|NCT00503087|Device|Pneumatic Skin Flattening (PSF)|
1789787|NCT00503100|Device|Thermal stimulation|Cerebral SEP response (P300, Medoc Ltd., Israel) to thermal stimulation (550C). Warm-sensation threshold (WST), heat-pain threshold (HPT), Cold sensation threshold (CST) and cold pain threshold (CPT) by using Thermal sensory analyzer (TSA-2001,Medoc Ltd., Israel). Pain threshold to tactile stimulation will be measured by using Von-Frey hairs.
1789788|NCT00503113|Drug|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) injection every 3 months
1789789|NCT00503113|Drug|ibandronate [Bonviva/Boniva]|3mg intravenous (iv) infusion every 3 months
1789790|NCT00503113|Drug|Alendronate|70mg per oral (po) weekly
1789791|NCT00503126|Drug|bivalirudin|anticoagulation
1789792|NCT00503139|Drug|Enbrel (etanercept)|Enbrel 10 to 25 mg twice a week subcutaneous injection
1789793|NCT00503152|Drug|Benazepril|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
1789850|NCT00503659|Procedure|Bronchial methacholine provocation|A short five-breath dosimeter protocol using a five-step dilution schedule according to ATS guidelines (0.0625, 0.25, 1, 4, 16 mg/ml methacholine)
1789851|NCT00503659|Procedure|Bronchial methacholine provocation|A five-step protocol using a single dilution of 16 mg/ml methacholine (0.01, 0.1, 0.4, 0.8, 1.6 mg)
1789852|NCT00503685|Biological|IMC-A12|10 mg/kg intravenous (I.V.) infusion every 2 weeks.
1790000|NCT00510406|Drug|tamsulosin hydrochloride|Alphablocker
1789794|NCT00503152|Drug|Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
1789795|NCT00503152|Drug|Benazepril/Valsartan|After one month wash-out from previous RAS (ARB or ACE) inhibitor therapy, patients satisfying the inclusion/exclusion criteria will be randomly given equivalent doses (half the standard doses recommended by the manufacturer for blood pressure control) of benazepril (10 mg/day) or valsartan (160 mg/day) or one fourth of the standard doses of both agents in combination (benazepril 5 mg/day and valsartan 80 mg/day). If well tolerated, treatment will be up-titrated to full dose of benazepril (20 mg/day) or valsartan (320 mg/day) or one half of the standard doses of both agents in combination (benazepril 10 mg/day and valsartan 160 mg/day).
1789796|NCT00503165|Biological|Menitorix (MenC and Hib conjugate)|
1789797|NCT00503178|Procedure|Biological imaging guided antalgic radiotherapy|Biological imaging guided antalgic radiotherapy is followed.
1789798|NCT00503191|Behavioral|NeuroModulation Technique|NeuroModulation Technique is an informational technique that works by identifying and bringing awareness of the mind-body to incorrect informational states of the nervous system which has led to illness or maladaptive behavior. NeuroModulation Technique then directs the body to correct these information states, thereby helping the nervous system resume more adaptive functioning.
1789799|NCT00503204|Drug|Cediranib|oral tablet
1789800|NCT00503204|Drug|Lomustine|oral capsule
1789801|NCT00503217|Drug|Tryptorelin|
1789802|NCT00503230|Behavioral|Standard Care Intervention (SCI)|Standard Care Intervention (SCI)
1789803|NCT00503230|Behavioral|Culturally Tailored Intervention (CTI)|Culturally Tailored Intervention (CTI)
1789804|NCT00503243|Drug|Delayed and extended release mesalazine|
1789805|NCT00503256|Behavioral|Questionnaire|Questionnaires each taking 60 minutes to complete.
1789806|NCT00503269|Procedure|Hemorrhoidectomy|Hemorrhoidectomy under local anaesthesia
1789807|NCT00503269|Procedure|Hemorrhoidectomy|General anaesthetic haemorrhoidectomy
1789808|NCT00503295|Biological|REOLYSIN®|REOLYSIN® is given intravenously at a dose of 3x10E10 TCID50 over 60 minutes on Days 1-5 of a 28 day cycle.
1789809|NCT00503308|Procedure|Abbreviated HIV test counseling|abbreviated HIV pre-test counseling
1789810|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1), Krestin (PSK)|S-1 80mg/m2 4weeks on 2 weeks off, PSK 3g/day
1789811|NCT00503321|Drug|Tegafur/gimeracil/oteracil potassium (S-1)|S-1 80mg/m2, 4weeks on followed by 2 weks off
1789812|NCT00503334|Dietary Supplement|preOP booster (oral nutritional supplement, food for special medical purposes)|3x1 dosage pre-operatively
1789813|NCT00503347|Drug|bavituximab|The study drug is a sterile solution administered intravenously weekly for 8 weeks. Each cohort is given 0.3, 1, 3, or 6 mg/kg of bavituximab.
1789814|NCT00503360|Drug|SAD448|
1789815|NCT00503386|Drug|Palonosetron|
1789816|NCT00503386|Drug|Granisetron|
1789817|NCT00503399|Drug|Teriparatide|20 µg/day sc for 18 months
1789818|NCT00503399|Drug|Risedronate|35 mg/week po for 18 months
1789819|NCT00503412|Drug|AZD2171|oral 14C
1789820|NCT00503425|Drug|Rituximab [MabThera/Rituxan]|1000 mg IV on days 1 and 15
1789821|NCT00503438|Device|Salto Talaris Ankle|Salto Talaris Anatomic Ankle total joint prosthesis
1789822|NCT00503451|Drug|LBH589|
1789823|NCT00503477|Drug|AZD2171|oral tablet
1789824|NCT00503490|Drug|MP-376 (Levofloxacin solution for Inhalation)|40, 80, 120mg RDD
1789825|NCT00503490|Drug|placebo|BID
1789826|NCT00503503|Drug|Enbrel (etanercept)|
1789827|NCT00503516|Drug|Megestrol acetate|1 sachet of powder containing 160 mg of megestrol acetate b.i.d. during 24 weeks
1789828|NCT00503516|Drug|Placebo|1 sachet of 160 mg of placebo b.i.d.
1789829|NCT00503529|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Vaccination by intramuscular injection into the right or left upper arm (musculus deltoideus)
1789830|NCT00503542|Drug|Terazol or oral fluconazole for candidal vaginitis|Intravaginal terazol qhs x 5 nights; oral fluconazole 150 mg po x 1
1789831|NCT00503542|Drug|Metronidazole or Clindamycin for Bacterial Vaginosis|Metronidazole 500 mg bid x 5 days; Intravaginal metronidazole bid x 5 days; intravaginal clindamycin
1789832|NCT00503542|Drug|Flagyl for definitively diagnosed vaginal trichomoniasis|Metronidazole 2 gms po x 1
1789833|NCT00503542|Other|Empiric Management|In this arm of the study women are treated for vaginal complaints purely on the basis of their symptoms.
1789834|NCT00503568|Biological|Ad100-gp96Ig-HLA A1|Dose Schedule 1 (DS-1): 4x10^7 cells bi-weekly, maximum 9 vaccines/patient; Dose Schedule 2 (DS-2): 2X10^7 cells weekly, maximum 18 vaccines/patient; Dose Schedule 3 (DS-3): 1x10^7 cells twice weekly, maximum 36 vaccines/patient
1789835|NCT00503581|Procedure|Biopsy|Undergo biopsy
1789836|NCT00503581|Other|Laboratory Biomarker Analysis|Correlative studies
1789837|NCT00503581|Drug|Megestrol Acetate|given orally
1789838|NCT00503581|Other|Pharmacological Study|Correlative studies
1789839|NCT00503581|Other|Quality-of-Life Assessment|Ancillary studies
1789840|NCT00503581|Procedure|Therapeutic Conventional Surgery|undergo hysterectomy
1789841|NCT00503594|Drug|Methotrexate and temozolomide|Methotrexate and temozolomide
1789842|NCT00503594|Drug|Methotrexate , procarbazine ,vincristine ,cytarabine|Methotrexate , procarbazine ,vincristine ,cytarabine
1789843|NCT00503607|Drug|BLI-800|
1789844|NCT00503607|Drug|Polyethylene glycol 3350 based bowel preparation|
1789845|NCT00503620|Drug|Botulinum Toxin A|Injection into the gastrocnemius/soleus muscles for spasticity
1789846|NCT00503646|Other|communication intervention|
1789847|NCT00503646|Other|counseling intervention|
1789848|NCT00503646|Other|questionnaire administration|
1789849|NCT00503646|Procedure|psychosocial assessment and care|
1789853|NCT00503685|Biological|cetuximab|Patients will receive cetuximab 500 mg/m2 I.V. over 2 hours every 2 weeks.
1789854|NCT00503698|Drug|somatropin|20 mcg/kg/day, injected s.c. (under the skin)
1789855|NCT00503698|Drug|placebo|Placebo injected s.c (under the skin)
1789856|NCT00503711|Drug|Vandetanib|100 mg every other day, 100mg once daily
1789857|NCT00503711|Drug|Vandetanib 300 mg|300mg once daily
1789858|NCT00503724|Drug|enzastaurin hydrochloride|Participants receive 200, 260, 340, or 440 mg/m2/day of enzastaurin orally once daily for 28 days (one course) during the dose escalation phase of the study. To study the toxicity profile of the MTD or phase II recommended dose established during the dose escalation phase, participants receive twice daily doses of enzastaurin orally at the phase II recommended dose for 28 days (one course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 13 courses (approximately one year).
1789859|NCT00503737|Behavioral|National Colorectal Cancer Roundtable Toolbox|
1789860|NCT00503750|Drug|Pre operativeTrastuzumab|"Trastuzumab one-time loading dose of 4 mg/kg as 90 minute infusion, followed by 20 weekly treatments at 2 mg/kg as 30 minute infusion.
As per standard treatment of HER2-positive breast cancers, patients will continue to receive trastuzumab every 3 weeks at 6 mg/kg beginning week 21 through week 52."
1789861|NCT00503750|Drug|ABI-007 (Abraxane)|ABI-007 will be administered every 2 weeks at a dose of 260mg/m2 as 30 minute infusion on the same days as trastuzumab for a total of 4 cycles (weeks 1 -8).
1789862|NCT00503750|Drug|Vinorelbine|Beginning week 9, patients will then receive weekly vinorelbine at a dose of 25mg/m2 for 12 weeks on the same day as trastuzumab for a total of 4 cycles (weeks 9-20).
1789863|NCT00503763|Drug|Simvastatin|
1789864|NCT00503776|Behavioral|exercise intervention|Patients undergo low weight resistance training.
1789865|NCT00503776|Drug|amifostine trihydrate|Given subcutaneously
1789866|NCT00503776|Procedure|therapeutic dietary intervention|Patients undergo specialized nutrition therapy (SNT) including dietitian counseling and calorie goal instruction.
1789867|NCT00503789|Procedure|fecal bacteria analysis|ad lib feeding
1789868|NCT00503802|Procedure|Radiofrequency Turbinate Reduction|Radiofrequency Turbinate Reduction
1789869|NCT00503802|Procedure|Sham RF|The steps of the procedure are as follows: 1) application of topical anesthetic to the turbinate mucosa bilaterally; 2) injection of 1.0 ml of lidocaine 1% with epinephrine 1:100,000 with a 30-gauge needle into each inferior turbinate anteriorly; 3) delay five minutes for local anesthetic to take full effect; 4) re-insertion of the anesthetic needle to check for complete anesthesia on one side, and injection of another 1.0 ml of lidocaine 1% with epinephrine 1:100,000 5) placement of the radiofrequency electrode (23-gauge, 1 cm long) into the inferior turbinate; 6) delivery of 300 Joules of radiofrequency energy to the turbinate over 29 seconds (no energy will be delivered in sham procedure)7) placement of a cotton pledget (soaked in oxymetazoline solution 0.05%) against the treatment site 8) repeat steps 3 - 8 for the contra-lateral inferior turbinate; 9) removal of the cotton pledgets after several minutes; and 11) observation of hemostasis.
1789870|NCT00503815|Drug|BLI-800|
1789871|NCT00503815|Drug|Polyethylene glycol 3350 based bowel preparation|
1789872|NCT00503828|Drug|Derris scandens Benth extracts|Derris scandens Benth extracts (oral) 400 mg twice per day for 4 weeks
1789873|NCT00503828|Drug|naproxen|Naproxen 500 mg/day for 4 weeks
1789874|NCT00503841|Drug|erlotinib hydrochloride|Patients receive erlotinib hydrochloride PO (orally) QD (every day) on days -14-0 immediately prior to scheduled surgery. Treatment continues in the absence of disease progression or unacceptable toxicity.
1789875|NCT00503841|Other|immunohistochemistry staining method|Assessed at the time of the initial biopsy and at the time of surgery.
1789876|NCT00503841|Other|laboratory biomarker analysis|Correlative studies
1789877|NCT00503841|Procedure|biopsy|14 days prior to surgery
1789878|NCT00503841|Procedure|conventional surgery|14 days after taking study drug erlotinib hydrochloride.
1789879|NCT00503841|Procedure|neoadjuvant therapy|14 days after taking study drug erlotinib hydrochloride.
1789880|NCT00503854|Behavioral|Questionnaire|Questionnaires taking about 15 to 30 minutes total.
1789882|NCT00503880|Biological|filgrastim|subcutaneously one day prior to treatment
1789883|NCT00503880|Drug|clofarabine|single IV dose over 1 hour daily for 5 days
1789884|NCT00503880|Drug|cytarabine|subcutaneously daily for 5 days 2-4 hours following the end of the Clofarabine infusion
1789885|NCT00503880|Genetic|microarray analysis|Both standard cytogenetic testing and FISH (fluorescent in situ hybridization) are adequate to assess responses.
1789886|NCT00503880|Procedure|biopsy|bone marrow biopsy
1789887|NCT00503893|Behavioral|Questionnaire|Questionnaire regarding medical history and family medical history that will take about 1 hour to complete.
1789888|NCT00503893|Other|Blood specimen|Blood (about 10 teaspoons) will be drawn from a vein for genetic testing. The blood may be drawn more than one time.
1789889|NCT00503906|Drug|Avastin|
1789890|NCT00503906|Drug|Gemcitabine|
1789891|NCT00503906|Drug|Abraxane|
1789892|NCT00503919|Procedure|Multi-spectral Digital Colposcopy (MDC)|Use of a digital camera and a special light to take pictures of the cervix and vagina.
1789893|NCT00503932|Procedure|Proton Therapy|Radiation therapy 1 time a day, for 5 days in a row (Monday-Friday) for 6 -7 weeks (30-35 treatments in all).
1789894|NCT00503932|Drug|Capecitabine|825 mg/m^2 by mouth (PO) twice daily on days receive radiation.
1789895|NCT00503945|Device|Nasal continuous positive airway pressure (nCPAP)|
1789896|NCT00503958|Genetic|DNA methylation analysis|
1789897|NCT00503958|Genetic|DNA stability analysis|
1789898|NCT00503958|Genetic|gene expression analysis|
1789899|NCT00503958|Other|epidemiologic study|
1789900|NCT00503958|Other|study of socioeconomic and demographic variables|
1789901|NCT00503958|Procedure|biopsy|
1789902|NCT00503958|Procedure|evaluation of cancer risk factors|
1789903|NCT00503958|Procedure|study of high risk factors|
1789954|NCT00509925|Drug|insulin detemir|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
1790001|NCT00510406|Drug|solifenacin succinate|antimuscarinic
1789904|NCT00503971|Drug|Vorinostat plus Erlotinib|"Phase I:
Dose level 1: 300 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2: 400 mg V d1-7 every 21 days plus 100 mg E daily Dose level 2b: 300 mg V d1-7 and 15-21 every 28 days plus 100 mg E daily Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily
Phase II:
Dose level 3: 400 mg V d1-7 and 15-21 every 28 days plus 150 mg E daily"
1789905|NCT00503984|Drug|Azacitidine|Intravenous infusion over 30 minutes Days 1 - 5 of each 3 weekly cycle.
1789906|NCT00503984|Drug|Docetaxel|Intravenous infusion over 1 hour on day 6 of each 3 weekly cycle.
1789907|NCT00503984|Drug|Prednisone|Patient will receive prednisone 5mg twice a day from Day 1 to 21 of each cycle.
1789908|NCT00503984|Genetic|GADD45α methylation and expression analysis|"Peripheral blood samples from patients will be collected as described in section 8.1 (total of 4 blood samples). DNA will be isolated from serum, bisulfite treated and evaluated for methylation by bisulfite genomic sequencing.
Patients with accessible prostate tissue or metastases will undergo biopsy prior to treatment if they consent to do so."
1789909|NCT00503984|Drug|Pegfilgrastim|Growth factor support.Granulocyte-colony stimulating factor (G-CSF)
1789910|NCT00503984|Drug|Filgrastim|Growth factor support. Granulocyte-colony stimulating factor (G-CSF)
1789911|NCT00503997|Drug|oxaliplatin|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.
Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
1789912|NCT00503997|Drug|pemetrexed disodium|"Group I: Patients receive pemetrexed disodium IV and oxaliplatin IV over 2 hours on day 1. Treatment repeats every 14 days for up to 4 courses. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to surgery.
Group II: Patients receive treatment as in group I. If patient progresses before receiving 4 courses of treatment, treatment will be discontinued and patient will proceed to concurrent chemoradiotherapy."
1789913|NCT00504010|Drug|Arnica Montana|Applied to lower extremity once a day for 3 days
1789914|NCT00504010|Drug|placebo cream|placebo cream applied to leg daily for 3 days
1789915|NCT00504023|Drug|imiquimod|The patient will be seen in clinic every six weeks during treatment for examination. Imiquimod cream is to be applied 3 times per week for 12 weeks.
1789916|NCT00504023|Procedure|biopsy|Punch biopsy and photography will be performed at the baseline and 12 week time points.
1789917|NCT00504023|Procedure|therapeutic conventional surgery|If the lesion is still present after 12 weeks of therapy, the treating physician will recommend excision of the lesion four weeks after completion of therapy (week 16).
1789918|NCT00504036|Device|inflatable intra-gastric balloon|inflatable intra-gastric balloon
1789919|NCT00504062|Drug|budesonide|
1789920|NCT00504062|Drug|fluticasone|
1789921|NCT00504075|Biological|Gammaplex, intravenous immunoglobulin|"Dosage form: Gammaplex® is a sterile liquid of 5 % w/v normal immunoglobulin. Gammaplex® contains 5 g/100 mL of human normal immunoglobulin (i.e. 50 g/L, of which virtually 100% is IgG).
The first course of GAMMAPLEX will be administered as an intravenous infusion of 1 g/kg on each of 2 consecutive days. If required, a further 1 or 2 courses on the same dosage regimen may be administered in the period Day 32 to Day 90 following the first course of GAMMAPLEX."
1789922|NCT00504088|Procedure|Bypass|
1789923|NCT00504088|Procedure|Silverhawk Plaque Excision|
1789924|NCT00504101|Drug|Arsenic trioxide|Arsenic Trioxide will be given on day -6, -5, -4,-3,-2 (total of 5 doses). The dose of Arsenic trioxide (ATO) is 0.25 mg/m2.
1789925|NCT00504101|Drug|Bortezomib|Bortezomib will be given on day -6, -4, -2 (total 3 doses) beginning at a dose of 0.8 mg/m2 each day of therapy.
1789926|NCT00504101|Drug|Melphalan|Melphalan will be given at 200 mg/m2 on day -2 (1 dose only)
1789927|NCT00504101|Biological|Autologous hematopoietic stem cell transplantation|On day 0 a minimal of 2 x 106 CD 34 cells/kg will be infused by central catheter according to institutional standards.
1789928|NCT00504114|Procedure|ACL Reconstruction Surgery|
1789929|NCT00504114|Procedure|Cartilage Resurfacing Surgery|
1789930|NCT00504114|Procedure|Total Knee Replacement|
1789931|NCT00504127|Drug|Naproxcinod 375 mg bid|Naproxcinod 375 mg bid
1789932|NCT00504127|Drug|Naproxcinod 750 mg bid|Naproxcinod 750 mg bid
1789933|NCT00504127|Drug|Naproxen 500 mg bid|Naproxen 500 mg bid
1789934|NCT00504127|Drug|placebo|placebo
1789935|NCT00504140|Drug|Etoposide|100 mg/m^2 Intravenous Daily for 5 days, beginning one hour after IFN-alpha treatment.
1789936|NCT00504140|Drug|Interferon Alpha|5x10^6 mu/m^2 Subcutaneously Daily for 5 Days
1789937|NCT00504153|Drug|dasatinib|
1789938|NCT00504153|Other|laboratory biomarker analysis|Correlative studies
1789939|NCT00504166|Drug|alendronate sodium|alendronate sodium 70 mg tablet once week for 24 months
1789940|NCT00504166|Other|placebo comparator|placebo to match alendronate sodium one tablet once a week for 24 months
1789941|NCT00504179|Procedure|Osteopathic Manipulative Treatment|
1789942|NCT00504192|Drug|Gemcitabine and Oxaliplatin|gemcitabine 1000mg/m2 IV on day 1 and oxaliplatin 85mg/m2 on day 2 every 2weeks
1789943|NCT00504205|Drug|multitargeted receptor tyrosine kinase inhibitor MP470|
1789944|NCT00504205|Other|laboratory biomarker analysis|
1789945|NCT00504205|Other|pharmacological study|
1789946|NCT00504205|Procedure|positron emission tomography|
1789947|NCT00509847|Drug|human lactoferrin peptide 1-11|(A) hLF1-11 (once-daily 0.5mg IV for 10 days): Group #1, n=10; OR (B) Placebo (to match hLF1-11): Group #2, n=10
1789948|NCT00509860|Drug|Irinotecan|16 mg/m2 by vein Daily Over 1 Hour x 5 Days
1789949|NCT00509873|Drug|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
1789950|NCT00509873|Drug|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
1789951|NCT00509886|Drug|Drysol|20% aluminum chloride hexahydrate
1789952|NCT00509886|Drug|Drioff|1% aluminum acetate
1789953|NCT00509899|Drug|Ruxolitinib|5 and 25 mg tablets with a daily dosing range from 10 to 200 mg qd or bid.
1789955|NCT00509925|Drug|insulin NPH|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
1789956|NCT00509925|Drug|insulin aspart|Treat-to-target dose tritation (dose adjusted individually), s.c. (under the skin) injection
1789957|NCT00509938|Drug|human lactoferrin peptide 1-11|Each subject will receive a single intravenous dose of hLF1-11 given in a volume of 20mL given over 20 minutes i.e. 1mL/per minute.
1789958|NCT00509951|Behavioral|One-session exposure treatment|Participants receiving OST will attend one extended treatment session, lasting up to 3 hours in duration. During this session, the child will be taught a number of cognitive and behavioral skills to deal effectively with the feared situation or object. The child will also be exposed to the feared situation or object in a highly structured, safe, and controlled manner.
1789959|NCT00509951|Behavioral|Augmented one-session exposure treatment|Family-enhanced OST (augmented OST) involves the parents of affected children and provides the parents with strategies to assist their children in overcoming phobias. Participants receiving augmented OST will attend the same type of extended treatment session, but, in addition, their parent or guardian will attend a 3-hour session.
1789960|NCT00509964|Drug|irinotecan|Patients will receive irinotecan 150 mg/m2 intravenously on day 1 every 2 weeks.
1789961|NCT00509964|Drug|ILF|Patients will receive irinotecan 150 mg/m2 intravenously, in combination with leucovorin and 5-fluorouracil, on day 1 every 2 weeks.
1789962|NCT00509977|Procedure|Light Treatment|Light treatment applied to half of the face at each study visit
1789963|NCT00509977|Procedure|Laser Treatment|Laser treatment applied to half of the face at each study visit
1789964|NCT00509990|Drug|Pimecrolimus|Pimecrolimus cream 1 %
1789965|NCT00510003|Drug|Pimecrolimus|Pimecrolimus cream 1 %
1789966|NCT00510016|Drug|Clonidine HCL|Duraclon 1 microgram/kg every 4 hours given p.o. as per algorithm
1789967|NCT00510029|Drug|GAP-134|atrial fibrillation 24-hr IV infusion; 1-minute IV bolus; PO
1789968|NCT00510055|Procedure|subdermal manipulation ONLY|scars receive subdermal manipulation ONLY
1789969|NCT00510055|Procedure|subdermal manipulation AND injection of a filler|scars receive subdermal manipulation AND injection of a filler
1789970|NCT00510068|Drug|Everolimus|A 10-mg dose of everolimus was given by continuous oral daily dosing of two 5-mg tablets.
1789971|NCT00510068|Drug|Everolimus Placebo|a 10-mg dose of matching placebo to Everolimus was given by continuous oral daily dosing of two 5-mg tablets.
1789972|NCT00510081|Device|Calcium Hydroxylapatite injection|filler injection
1789973|NCT00510094|Behavioral|Friend to Friend program|Friend to Friend arm is a social information processing group treatment to help aggressive girls learn better social problem solving and decision making choices. Participants will learn how to identify signs of physiological arousal, evaluate others' intentions, react to a potential conflict situation, and generate and evaluate alternatives. Treatment sessions are twice per week (30 to 40 minutes per session) for ten weeks.
1789974|NCT00510094|Behavioral|Psychoeducational attention control intervention|Psychoeducational attention control group also meets two times per week for 10 weeks to control for nonspecific factors of treatment. Participants learn homework, study skills, and organizational skills.
1789975|NCT00510107|Drug|oxaliplatin|oxaliplatin 120 mg/m2 will be given on day 1.
1789976|NCT00510107|Drug|Cisplatin|Cisplatin 60 mg/m2 will be given on day 1.
1789977|NCT00510120|Behavioral|Parent management training (PMT)|PMT primarily involves teaching parents strategies to respond consistently and correctly to their child's behavior. Parents assigned to the PMT group will be taught how to respond consistently and appropriately to their child's positive and negative behaviors. Participants will attend a 1-hour treatment session each week for 10 weeks.
1789978|NCT00510120|Behavioral|Collaborative problem solving (CPS)|CPS is a treatment approach that involves both the parent and child by teaching parents to help their child control their emotions and to problem solve as a family. Parents assigned to the CPS group will be taught strategies to help their child identify and regulate emotions and to solve behavior problems together as a family. Participants will attend a 1-hour treatment session each week for 10 weeks.
1789979|NCT00510120|Behavioral|Waitlist control|Participants assigned to the waitlist control condition group will wait 10 weeks before beginning treatment one of the two treatment options.
1789980|NCT00510133|Biological|GRNVAC1|Autologous dendritic cell vaccine
1789981|NCT00510146|Drug|Olanzapine|5-20 mg, oral, once daily, for 24 weeks (participants randomized to olanzapine in double-blind treatment period) or 18 weeks (participants randomized to placebo in double-blind treatment period).
1789982|NCT00510146|Drug|Placebo|placebo tablets, oral, once daily at bedtime, 6 weeks
1789983|NCT00510159|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamin|
1789984|NCT00510159|Drug|Praziquantel|
1789985|NCT00510172|Drug|Prostacyclin, PGI2|10 ng/kg/min of epoprostenol (stable PGI2)
1789986|NCT00510172|Drug|Placebo|NaCL 0,9%
1789987|NCT00510185|Other|systematic coronary intervention|Coronary angiography within 72 hrs
1789988|NCT00510185|Other|coronary intervention only for cases refractory to medical therapy|Initially conservative treatment with coronary angiography only for recurrent ischemia
1789989|NCT00510302|Behavioral|Questionnaire|Questionnaire regarding melanoma risk-reduction.
1789990|NCT00510302|Behavioral|Interview|Interview via telephone about topics related to melanoma risk-reduction.
1789991|NCT00510315|Other|Questionnaires, Laboratory tests, Abdominal MRI|Height, weight, waist and hip circumference; systolic and diastolic blood pressure; questionnaires; fasting blood tests: insulin, glucose, lipids (low density lipoprotein (LDL), high density lipoprotein (HDL), triglycerides, LDL pattern, HDL and LDL subspecies), cardiac inflammatory markers (hsCRP, IL-1B, IL-6, IL-10, TNFa), leptin, adiponectin, IGF-1, and IGFBP3; abdominal MRI for visceral and subcutaneous fat measurement
1789992|NCT00510328|Device|Whole Body Vibration|
1789993|NCT00510341|Behavioral|Collaborative Management in Pediatrics (CMP) Program|Pediatric residents will receive two 4.5 hour training sessions on the CMP Program.
1789994|NCT00510354|Drug|Imatinib mesylate|
1789998|NCT00510393|Device|XIENCE V everolimus eluting coronary stent system|
1790003|NCT00510419|Drug|"InvestigationalAuto-injector (sumatriptan succinate)"|
1790004|NCT00510445|Drug|Imetelstat Sodium (GRN163L)|"The starting dose of GRN163L for this study will be 3.2 mg/kg. Subsequent dose levels will be 4.8, 6, 7.5, 9, 11, and 13.5 mg/kg. The maximum dose to be administered will not exceed 13.5 mg/kg.
Paclitaxel and carboplatin will be administered on Day 2 of each 21-day cycle."
1790005|NCT00510458|Device|LFIT™ Femoral Heads With X3® Insert|LFIT™ Anatomic CoCr Femoral Heads With X3® Polyethylene Insert in total hip replacement
1790006|NCT00510471|Drug|autologous immunoglobulin idiotype-KLH conjugate vaccine|
1790007|NCT00510484|Drug|Pancrelipase Delayed Release|24000 unit Capsule
1790008|NCT00510484|Drug|Placebo Comparator|Placebo
1790009|NCT00510497|Biological|Autologous HIV-1 ApB DC Vaccine|Autologous dendritic cells pulsed with autologous, inactivated HIV-1 infected, apoptotic cells given subcutaneously 3 times every other week plus a booster dose 2 weeks after start of treatment interruption
1790010|NCT00510510|Drug|NVA237 100 µg|Dry powder inhalation once a day for up to 28 days
1790011|NCT00510510|Drug|Placebo|Placebo to NVA237 dry powder inhalation once a day for up to 28 days
1790012|NCT00510510|Drug|NVA237 200 µg|Dry powder inhalation once a day for up to 28 days
1790013|NCT00510523|Device|Whole Body Vibration machine|
1790014|NCT00510536|Drug|Acetaminophen|dose to be determined by investigator
1790015|NCT00510536|Drug|NSAID|dose to be determined by investigator
1790016|NCT00510549|Procedure|Modality: Peritoneal Dialysis|Peritoneal Dialysis: CAPD; Hemodialysis: 3 times/week
1790017|NCT00510562|Procedure|Cranial osteopathic manipulation|This treatment is performed by exaggerating the motion asymmetry with a minimum of pressure (a few ounces) and holding the position until the motion becomes symmetrical.
1790018|NCT00510562|Procedure|Sham/Placebo|A laying on of hands with no treatment being performed.
1790019|NCT00510575|Device|Spinal rod|Posterior spinal fusion using a 5.5 or 6.35 size rod
1790020|NCT00510588|Other|training|regular physical exercise training for 6 months
1790021|NCT00510588|Other|training + metformin|regular physical exercise training in combination with metformin for 6 months
1790022|NCT00510588|Other|training + glitazon|regular physical exercise training in combination with a glitazon for 6 months
1790023|NCT00510601|Device|Kaneka Liposorber|LDL-apheresis on a bi-weekly basis
1790024|NCT00510614|Drug|tinidazole|1 gram twice weekly for 12 weeks
1790025|NCT00510614|Drug|Placebo|one pill twice weekly for 12 weeks
1790026|NCT00510627|Device|Radiofrequency Ablation (RFA)|The RF3000 radiofrequency generator has the capacity to deliver 200 watts of alternating current to the needle electrode for the coagulation necrosis of soft tissue.
1790027|NCT00510627|Drug|Chemotherapy|Standard of care chemotherapy regimen
1790028|NCT00510640|Drug|Sunitinib|Capsule, 12.5 or 50 mg, starting dose level 50 mg daily
1790029|NCT00510653|Drug|Imatinib Mesylate|600 mg by mouth daily for 6 Weeks
1790030|NCT00510666|Drug|Saline|Saline infusion adjunct to morphine PCA pump
1790031|NCT00510666|Drug|Butorphanol tartrate|Butorphanol was delivered at a continuous infusion manner adjunct to morphine PCA pump
1790032|NCT00510666|Drug|Tramadol Hydrochloride|100mg tramadol was used preemptively to morphine PCA pump
1790033|NCT00510666|Drug|Saline|Preemptive saline as a control group to tramadol one
1790034|NCT00510679|Behavioral|Health worker supports (supervision, job aids, incentives)|
1790035|NCT00510692|Drug|Eicosapentanoic Acid (EPA)|2 x 500mg EPA capsules twice daily for 6 months
1790036|NCT00510692|Procedure|Endoscopy|Endoscopy with video and photographs at baseline and month 6.
1790037|NCT00510692|Procedure|Biopsies taken|9 biopsies taken at baseline and month 6 from the rectum of normal mucosa for analysis of apoptosis (3 biopsies), cell proliferation (3 biopsies) and mucosal fatty acid levels (3 biopsies). Two biopsies taken at baseline and month 6 from polyps for cell proliferation (1 biopsy) and apoptosis (1 biopsy).
1790038|NCT00510692|Drug|Placebo|2 x 500mg placebo capsules twice daily for 6 months
1790039|NCT00510705|Other|exercise training|physical exercise training on a bicycle ergometer daily for 4 weeks
1790040|NCT00510705|Other|exercise training + metformin|physical exercise training on a bicycle ergometer + metformin (2 x 850 mg) daily for 4 weeks
1790041|NCT00510705|Other|exercise training + glitazone|physical exercise training on a bicycle ergometer + glitazone daily for 4 weeks
1790042|NCT00510718|Drug|MDV3100|MDV3100 daily until progression or dose-limiting toxicity
1790043|NCT00510744|Drug|pancreatic enzyme supplement|4 caps with meals, 2 with snacks
1790044|NCT00510770|Device|CPAP application|
1790045|NCT00510783|Drug|Keppra|The patient will receive 1 gram of Keppra added to 100ml diluent and will be infused over 15 minutes.
1790046|NCT00510783|Drug|Fosphenytoin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV Fosphenytoin infused at 15 mg/min or slower depending on vitals.
1790047|NCT00510783|Drug|Dilantin|IV load will be dependant on dilantin level. If no dilantin is detected in the patient, the patient will receive 1 gram of IV phenytoin infused at 25 mg/min or slower depending on vitals.
1790048|NCT00510796|Behavioral|Interview|Interview regarding perception of pain and the benefits and barriers to the combined screening.
1790049|NCT00510809|Drug|Policosanol|Policosanol 20 mg daily
1790050|NCT00510809|Other|Placebo|Placebo daily
1790051|NCT00510809|Drug|Policosanol Plus Already In Use Statin Therapy|Policosanol 20 mg daily Statin Therapy
1790052|NCT00510822|Drug|Cimicoxib|50 mg per tablet, bid (total daily dose 100 mg)
1790053|NCT00510822|Drug|Placebo|tablet
1790054|NCT00510835|Procedure|Early Goal Directed Therapy (EGDT)|Subjects will have a CVC inserted for continuous monitoring of their CVP and Scv02. Early structured treatment will be provided based on subjects' CVP, mean arterial pressure (MAP) and Scv02 measurements.
1790055|NCT00510835|Procedure|Protocolized Standard Care (PSC)|Routine equipment will be used to monitor subjects' blood pressure and oxygen levels. Early structured treatment is based on the subjects' systolic blood pressure and the study doctors' judgment of fluid status and perfusion status.
1790107|NCT00511316|Drug|Placebo|Placebo 20 mg daily for 6 months
1790635|NCT00516503|Other|placebo|Applied topically
1790056|NCT00510835|Procedure|Usual Care (UC)|Attending physicians will provide routine care to subjects. Study measurements and treatments will be based on the physicians'/sites' standard practices.
1790057|NCT00510848|Procedure|autograft tendon|Reconstruction with an autograft tendon (hamstrings)
1790058|NCT00510848|Procedure|allograft tendon|Reconstruction with an allograft tendon (tibialis posterior)
1790059|NCT00510874|Biological|Pumarix™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
1790060|NCT00510874|Biological|Pandemrix ™|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
1790061|NCT00510887|Drug|Bortezomib|Bortezomib 1.6 mg/m2 on days 1 and 8 of each 28-day cycle
1790062|NCT00510887|Drug|Rituximab|Rituximab 375 mg/m2 IV on day 1
1790063|NCT00510887|Drug|Fludarabine|Fludarabine 25 mg/m2 IV on days 1,2,3
1790064|NCT00510887|Drug|Mitoxantrone|Mitoxantrone 10 mg/m2 IV on day 2
1790065|NCT00510887|Drug|Dexamethasone|Dexamethasone 20 mg orally on days 1,2,3,4,5
1790066|NCT00510913|Drug|tacrolimus|
1790067|NCT00510926|Drug|Imatinib Mesilate (Glivec)|
1790068|NCT00510939|Drug|Tipifarnib plus Bortezomib|
1790069|NCT00510952|Drug|Insulin Lispro Protamine Suspension|Patient adjusted dose, once daily (QD) or twice daily (BID), injected subcutaneous (SC) x 24 weeks
1790070|NCT00510952|Drug|Insulin Glargine|Patient adjusted dose, once daily (QD), injected subcutaneous (SC) x 24 weeks
1790071|NCT00510965|Drug|Intravitreal injection ranibizumab|Monthly intravitreal injection of 0.5mg ranibizumab in one eye over one year
1790072|NCT00510978|Biological|Bifidobacterium infantis 35624|1 sachet/day for one year
1790073|NCT00510978|Biological|Lactobacillus salivarius UCC118|1 sachet per day for 1 year
1790074|NCT00510978|Biological|Placebo|1 sachet per day for 1 year
1790076|NCT00511004|Drug|Albendazole|Comparing 400 mg to 800 mg dose
1790077|NCT00511004|Drug|Diethylcarbamazine|Providing diethylcarbamazine more frequently in combination with albendazole
1790078|NCT00511017|Drug|Doxercalciferol|.05 mcg/kg by mouth daily x 28 Days
1790079|NCT00511043|Drug|PTK787|PTK787 - 1250mg p.o. daily. Initial dose of 750mg p.o daily starting on day 1 and increased weekly to an intermediate dose of 1000 mg and then a target dose of 1250mg unless a grade ≥ 2 toxicity. Patients who tolerate the study target dose of 1250mg will remain on that dose until study completion at 12 months or until disease progression, unacceptable toxicity, withdrawal of consent or patient non-compliance with the protocol requirement.
1790080|NCT00511069|Drug|Bortezomib|
1790082|NCT00511095|Biological|HEPLISAV|Intramuscular (IM) injections 0.5mL on Day 0 and Week 4
1790083|NCT00511108|Drug|Comparator: sitagliptin phosphate|sitagliptin phosphate 100 mg as oral tablets. Each patient will be administered 1 tablet once daily.
1790084|NCT00511108|Drug|Comparator: pioglitazone|pioglitazone 30 mg will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
1790085|NCT00511108|Drug|Comparator: placebo to pioglitazone|pioglitazone 30 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
1790086|NCT00511108|Drug|Comparator: placebo to sitagliptin|sitagliptin phosphate 100 mg placebos will be supplied as oral tablets. Each patient will be administered 1 tablet once daily.
1790087|NCT00511121|Drug|STI571 and PEG INTRON|
1790088|NCT00511134|Drug|Eszopiclone|eszopiclone (lunesta) - 3 mg qd x 6 weeks, oral capsule
1790089|NCT00511134|Drug|Bupropion|bupropion SR in oral capsule will be begun at the beginning of week 1 (150 mg qd x 7 days) with an increase to the full dose (150 mg bid x 6 weeks) at the beginning of week 2.
1790090|NCT00511147|Biological|IGIV3I Grifols 10%|IGIV3I Grifols 10% 1 g/kg/day given on two consecutive days, Day 1 and Day 2, for a total dose of 2 g/kg over two days.
1790091|NCT00511160|Procedure|Myocardial biopsies with TRU CUT 14 Gauge needle|Myocardial needle biopsy and right atrial appendectomy
1790092|NCT00511160|Procedure|Endomyocardial biopsies|The control arm C consists of routine-workup of patients with suspected myocarditis, independent of the study arm C, but with analogous screening methods and comparable biopsy sampling
1790093|NCT00511173|Genetic|Warfarin Dose based on pharmacogenetics|Warfarin dose adjustment will be based on the standard clinician dosing compared to the use of the pharmacogenetic base algorithm
1790094|NCT00511186|Drug|Placebo|placebo is administered intravenously over 48 hours. An initial loading dose of over 10-minutes is followed by continuous infusion over 48h.
1790095|NCT00511186|Drug|BIAP|AP is administered intravenously over 48 hours. An initial loading dose of 67.5U/Kg body weight over 10-minutes is followed by continuous infusion of 132.5U/Kg/24H administered over 48H
1790096|NCT00511199|Drug|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg
NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year)."
1790097|NCT00511199|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 13 consecutive 28-day menstrual cycles (1 year).
1790098|NCT00511212|Drug|intravenous immunoglobulin|
1790099|NCT00511225|Dietary Supplement|cholecalciferol|10,000 IU weekly
1790100|NCT00511225|Dietary Supplement|placebo|placebo capsule
1790101|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib 20 mg/m2 as an intravenous bolus over 2 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. A maximum of 12 cycles will be administered.
1790102|NCT00511238|Drug|carfilzomib|Subjects will receive carfilzomib intravenously over up to 10 minutes on Days 1, 2, 8, 9, 15, and 16 of 28 day cycles. In cycle 1, the dose is 20 mg/m2. If all doses are administered and well-tolerated over Cycle 1, beginning with Cycle 2 the dose will escalate to 27 mg/m2 cycle. A maximum of 12 cycles will be administered.
1790103|NCT00511277|Drug|Seroquel®|dosage form: oral, dosage: 300-800mg/d, frequency: twice daily
1790104|NCT00511290|Other|no generic names|
1790105|NCT00511303|Drug|STI571|
1790106|NCT00511316|Drug|Montelukast/ Singulair|20 mg daily for six months
1790109|NCT00511342|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
1790110|NCT00511342|Drug|LNG-EE|Levonorgestrel and Ethinyl Estradiol Tablets, 0.150 mg Levonorgestrel and 0.030 mg Ethinyl Estradiol taken once daily from Day 1 of menstrual period up to and including Day 28 for 26 consecutive 28-day menstrual cycles (2 years).
1790111|NCT00511355|Drug|NOMAC-E2|Nomegestrol Acetate and Estradiol (NOMAC-E2) Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
1790112|NCT00511355|Drug|Levonorgestrel and Ethinyl Estradiol|Levonorgestrel and Ethinyl Estradiol (LNG-EE) Tablets, 150 mcg LNG and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day cycles.
1790113|NCT00511368|Drug|matching placebo|
1790114|NCT00511368|Drug|Bevirimat|
1790115|NCT00511381|Genetic|No intervention|No intervention
1790116|NCT00511394|Drug|20% Human Albumin|Infusion of 100 mL of 20% Albumin over 3 hours
1790117|NCT00511394|Drug|Normal Saline|Infusion of 100 mL of Normal Saline
1790118|NCT00511407|Device|Renal tubule assist device|Standard hemofiltration cartridge containing nonautologous human renal tubule cells, connected to conventional continuous venovenous hemodialysis circuit.
1790119|NCT00511420|Dietary Supplement|Cocoa product type 1|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks.
1790120|NCT00511420|Dietary Supplement|Cocoa product type 2|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
1790121|NCT00511420|Dietary Supplement|Cocoa product type 3|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
1790122|NCT00511420|Dietary Supplement|Cocoa product type 4|6 doses of 13 grams per day during 4 weeks with a prior stabilization period of 2 weeks with cocoa product type 1
1790123|NCT00511433|Drug|NOMAC-E2|"Nomegestrol Acetate and Estradiol Tablets, 2.5 mg NOMAC and 1.5 mg E2 taken once daily from Day 1 of menstrual period up to and including Day 28
for 6 consecutive 28-day menstrual cycles."
1790124|NCT00511433|Drug|DRSP-EE|Drospirenone and Ethinyl Estradiol Tablets, 3 mg DRSP and 30 mcg EE taken once daily from Day 1 of menstrual period up to and including Day 28 for 6 consecutive 28-day menstrual cycles.
1790125|NCT00511446|Drug|docetaxel, oxaliplatin, capecitabine|"Docetaxel: 35 mg/m2, IV day 1, 8 of each 21 day cycle; Oxaliplatin: 70 mg/m2, IV day 1, 8 of each 21 day cycle; Capecitabine: 2x800 mg/m2 PO IV day 1 evening till morning of day 15 of each 21 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops."
1790126|NCT00511459|Drug|AMG 386 Placebo|AMG 386 Placebo [blinded]
1790127|NCT00511459|Drug|AMG 386|AMG 386 3mg/kg IV QW [blinded]
1790128|NCT00511459|Drug|Bevacizumab|Bevacizumab 10mg/kg IV Q2W
1790129|NCT00511459|Drug|AMG 386|AMG 386 10mg/kg IV QW [Open-Label]
1790130|NCT00511459|Drug|AMG 386|AMG 386 10mg/kg IV QW [blinded]
1790131|NCT00511459|Drug|Paclitaxel|Paclitaxel 90mg/m2 IV QW (3 on/1 0ff)
1790132|NCT00511472|Drug|MK-0941|"In Titration Scheme #1, MK-0941/matching placebo was initiated at 10-mg q.a.c. dose and increased on a daily basis (Titration Dose [TD] Days 1 to 4 of the Titration Phase 1) in 10-mg q.a.c. increments.
Titration Scheme #2 was a flexible-dose titration scheme in which MK-0941/matching placebo was given at a dose determined by a pre-prandial plasma glucose concentration for the subsequent meal on the previous day of administration on Days 1 to 4 of the Titration Phase 2."
1790133|NCT00511472|Drug|Placebo|10 mg Placebo (Pbo), 20 mg Pbo, 30 mg Pbo or 40 mg Pbo q.a.c.
1790134|NCT00511472|Drug|LANTUS insulin|LANTUS insulin dose will be similar to participant's previous dose of immediate or long-acting insulin
1790135|NCT00511485|Drug|Vintafolide|Induction: vintafolide 1.0 mg intravenous injection, Monday through Friday, for the first 3 weeks of each 4 week cycle. Maintenance: vintafolide 2.5 mg intravenous injection, Monday, Wednesday, and Friday, weeks 1 and 3 of each 4 week cycle. At the investigator's discretion, participants may receive vintafolide via an ambulatory pump after the first week of therapy has been administered in the clinic setting.
1790136|NCT00511485|Drug|Etarfolatide|
1790137|NCT00511498|Drug|Sildenafil|50 mg daily at bedtime
1790138|NCT00511524|Drug|GW842166X|GW842166X will available with dose strength of 100 mg capsules. Four 100mg GW842166X capsules will be used for the 400 mg oral dose of GW842166X.
1790139|NCT00511524|Drug|[carbonyl-^11C]GW842166|[carbonyl-^11C]GW842166 will b available as Intravenous solution.
1790140|NCT00511563|Drug|GW876008 and GSK561679|GW876008 and GSK561679
1790141|NCT00511576|Drug|MGCD0103 & Docetaxel|"In both Parts 1 and 2, subsequent doses of MGCD0103 will be escalated in 25 mg increments until the MTD of MGCD0103 in combination with each fixed dose (60 mg/m2 or 75 mg/m2) ofIV docetaxel is determined.
In both parts 1 and 2, MGCD0103 will be administered orally TIW for 3 weeks beginning on Day 1 at 1 hour prior to the start of the IV docetaxel infusion.
There will be no scheduled break between cycles and no limit to the number of cycles a subject can receive provided they do not have disease progression as defined by RECIST, or a clinically significant drug-related adverse event (AE) that does not resolve or respond to treatment intervention with 3 weeks."
1790142|NCT00511589|Other|chagas disease diagnostic|
1790143|NCT00511602|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder
1790144|NCT00511602|Drug|Technosphere Placebo|Technosphere Inhalation Powder
1790145|NCT00511615|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|Tissue sample removed from cervix using LEEP and contrast agent.
1790146|NCT00511628|Drug|Risperidone|As prescribed
1790147|NCT00511641|Behavioral|Questionnaire|Questionnaires lasting up to 30 minutes.
1790148|NCT00511654|Drug|GW823296 tablet|GW823296 immediate release tablets will be available as white film-coated tablets containing 5 milligrams (mg) and 20 mg of GW823296 for oral administration.
1790149|NCT00511654|Drug|GW823296 matching placebo|Matching placebo tablets will be identical in appearance to the GW823296 tablets.
1790150|NCT00511654|Drug|Midazolam|Midazolam will be administered as 5 milliliter (mL) of an intravenous solution for oral application (5 mg/5 mL, Dormicum).
1790151|NCT00511667|Drug|MK0941|MK0941 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
1790152|NCT00511667|Drug|Comparator: Placebo|Placebo 10 mg, 20 mg, 30 mg, or 40 mg before each meal or before 2 meals each day, or 60 mg before 2 meals each day
1790153|NCT00511680|Behavioral|Behavioral Based In-Home Intervention|The 10 session intervention delivered by a social worker in the home includes five treatment components (education, referral, care management, stress reduction, behavioral activation). Each component has been shown to be effective in treating depression in previous research.
1790156|NCT00511706|Drug|dexamethasone|Intravitreal injection of dexamethasone 700 µg at Day 1.
1790157|NCT00511706|Biological|ranibizumab|Ranibizumab 500 µg at day -30 and Day 7-14.
1790158|NCT00511706|Other|sham|Sham needle-less injection administered in the study eye at Day 1.
1790159|NCT00511719|Drug|Technosphere Insulin|48U
1790160|NCT00511719|Drug|Actrapid|24IU
1790161|NCT00511732|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder
1790162|NCT00511732|Drug|Technosphere Placebo|Technosphere Inhalation Powder
1790163|NCT00511745|Drug|Rabeprazol|As prescribed
1790164|NCT00511758|Procedure|Digital Imaging|Images of the cervix will be taken using different types of light and compared with the colposcopy procedure.
1790165|NCT00511771|Drug|Tegaserod|Tegaserod maleate
1790166|NCT00511797|Drug|SH T04740B|Drospirenone 1mg/EE 20µg (ß-CDC)
1790167|NCT00511797|Drug|SH T00186DF|Drospirenone 3 mg/EE 20µg (ß-CDC)
1790168|NCT00511797|Drug|SH T04740F|Drospirenone 2 mg/EE 20µg (ß-CDC)
1790169|NCT00511797|Drug|Placebo|Placebo
1790170|NCT00511810|Drug|Low Dose Fish Oil|Omega-3 Fatty Acids 2.4g/day in capsule form (4 capsules per day)
1790171|NCT00511810|Drug|High Dose Fish Oil|Liquid omega-3 fatty acid 15 g/day (2 tablespoons/day)
1790172|NCT00511823|Drug|casopitant|The doses of casopitant will be comprised of 150 mg (one 150 mg tablet) and 50 mg (one 50 mg tablet). Casopitant will be taken with 240 milliliters (mL) of water on an empty stomach following at least 2 hour fast.
1790173|NCT00511823|Drug|dolasetron|The dose of oral dolasetron will be comprised of 100 mg (one 100 mg tablet or two 50 mg tablets). Dolasetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
1790174|NCT00511823|Drug|granisetron|The dose of oral granisetron will be comprised of 2 mg (two 1 mg tablets). Granisetron will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
1790175|NCT00511823|Drug|rosiglitazone|The dose of oral rosiglitazone will be comprised of 4 mg (two 2 mg tablets or one 4 mg tablet). Rosiglitazone will be taken with 240 mL of water on an empty stomach following at least 2 hour fast.
1790176|NCT00511836|Drug|VIVITROL 380 mg|Administered via intramuscular (IM) injection once during the double-blind phase and for 2 additional injections, 4 weeks apart, during the optional open-label extension.
1790177|NCT00511836|Drug|Placebo|Placebo matching VIVITROL 380 mg was administered by IM injection once during the double-blind phase, only.
1790178|NCT00511849|Drug|carboplatin + SU011248 (sunitinib) + paclitaxel|AUC of 6 mg*min/mL administered as a 30-minute infusion, every 21 days for 4 cycles or until progression/unacceptable toxicity. 25 mg, 37.5 mg, or 50 mg (depending on the dose level assigned) orally taken every day or for 2 weeks and 1 week off without for 4 cycles or until progression/unacceptable toxicity. 175 mg/m2, 200 mg/m2, or 225 mg/m2 (depending on the dose level assigned), administered as a 3-hour infusion every 21 days for 4 cycles or until progression/unacceptable toxicity.
1790179|NCT00511862|Device|Yttrium 90 glass microspheres|120 Gy unilobar or bilobar infusion with the second infusion occurring 3-7 weeks following treatment of the first lobe
1790180|NCT00511875|Drug|doxycycline monohydrate|50mg once daily for 24 months
1790181|NCT00511875|Drug|placebo|placebo taken once daily for 24 months
1790182|NCT00511901|Drug|placebo|
1790183|NCT00511901|Drug|epoetin alpha|
1790184|NCT00511901|Drug|Niferex|
1790185|NCT00511914|Biological|cTIV|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle
1790186|NCT00511940|Drug|acamprosate|999 mg/day - 2997 mg/day, oral
1790187|NCT00511940|Other|placebo|oral, placebo
1790188|NCT00511953|Drug|Gabapentin Extended Release tablets|1800mg
1790189|NCT00511953|Drug|Gabapentin|1800mg
1790190|NCT00511966|Other|Non-Pharmacologic Treatment|Non-Pharmacologic Treatment
1790191|NCT00511966|Drug|Rabeprazole|As prescribed
1790192|NCT00511979|Drug|Technosphere Insulin|
1790193|NCT00511979|Drug|Technosphere insulin|
1790194|NCT00511979|Drug|Technosphere insulin|
1790195|NCT00511979|Drug|Regular human insulin|
1790196|NCT00511992|Drug|Avastin|"Initial Treatment Bevacizumab 15mg/kg Day 1 IV every 21 days x 5 cycles (beginning with cycle 2)
Consolidation Treatment:
Avastin 15mg/kg IV every 21 days x 12 cycles"
1790197|NCT00511992|Drug|Paclitaxel|Paclitaxel 135mg/m2 IV Day 1 every 21 days x 6 cycles
1790198|NCT00511992|Drug|Cisplatin|75mg/m2 IP day 2 every 21 days x 6 cycles
1790199|NCT00512005|Device|Percutaneous mitral valve repair|Ventricular reshaping to treat functional mitral insufficiency
1790200|NCT00512018|Device|NMES|"In the contralateral limb, the same protocol was repeated; however, each contraction was associated with overlapped NMES (Ex+NMES limbs).For the NMES, a symmetric double-phase sine-wave was used. Bearing wave frequency was of 2500 Hz, modulated in 50 bursts/s, with pulse duration of 200 µs, interburst interval of 10 ms. This configuration is known as Russian current."
1790201|NCT00512018|Other|Isokinetic exercise|Subjects realized training sessions twice a week with a 2-day minimum interval between the sessions, for 4 weeks. Each session included 5 min period of warm-up in a stationary bicycle, followed by 3 series of quadriceps stretching, as previously described. After being positioned at the isokinetic dynamometer, just as in the evaluation sessions, subjects firstly performed 3 sets of 10 maximum isokinetic concentric repetitions at the speed of 30º/s with one limb (EX limb), respecting the rest interval of 3 minutes between the sets.
1790202|NCT00512044|Procedure|Local anesthesia (pudendal block)|local anesthesia as indicated
1790203|NCT00512044|Procedure|general anesthesia (spinal and general)|general according to guidelines
1790204|NCT00512057|Drug|allopurinol|allopurinol 300mg twice a day
1790205|NCT00512057|Drug|placebo|placebo
1790206|NCT00512070|Drug|olanzapine and melatonin|In treatment phase I, all subjects will receive olanzapine, 10-25 mg/day. In treatment phase II, all subjects will receive olanzapine (10-25 mg/day) plus melatonin. Subjects will be randomized at a ratio of 1:1 to receive melatonin, 0.3 mg/day or 3.0 mg/day. Group IIA will receive 0.3mg day melatonin. Group IIB will receive 3.0 mg/day melatonin.
1790207|NCT00512083|Drug|AS1411|AS1411 IV administration continuously over 7 days. Dose either 10mg/kg/day or 40 mg/kg/day.
1790208|NCT00512096|Drug|Ifosfamide|1200 mg/m^2 By Vein Over 2 Hours on Days 1-3
1790209|NCT00512096|Drug|Paclitaxel (Taxol)|175 mg/m^2 By Vein Over 3 Hours on Day 1
1790210|NCT00512096|Drug|Cisplatin|25 mg/m^2 By Vein Over 2 Hours on Days 1-3
1790211|NCT00512122|Other|Withholding PN during the first week of ICU stay|Patients in this arm will receive exclusively enteral nutrition. If enteral nutrition is insufficient after the seventh day of ICU stay, parenteral nutrition will be started.
1790212|NCT00512122|Drug|Oliclinomel N71000 OR N71000E // Clinimix N17G35 OR N17G35E|PN will be started the morning of the third ICU hospitalisation day. The amount of PN to be given will be calculated to cover the caloric needs of the patient, based on the enteral energy intake the previous 24 hours.
1790213|NCT00512135|Drug|IncobotulinumtoxinA (Xeomin) (20 units)|Injection of a total of 20 Units incobotulinumtoxinA (Xeomin) on day one of each of up to eight cycles, reconstituted in a total injection volume of 0.5 mL administered in five equal parts of 0.1 mL to five predefined points of the glabellar area.
1790214|NCT00512148|Device|Autologous neobladder construct|augmentation cystoplasty with autologous neo-bladder construct
1790215|NCT00512174|Other|BladderScan BVI 3000|
1790216|NCT00512187|Other|low calorie diet|Low calorie diet was designed to achieve a loss of 5-10% of initial weight. All enrolled patients received a balanced diet scheme, based on a caloric intake reduction related to BMI and sex (range 1200-1500 Kcal/day for women, 1300-1600 Kcal/day for men). Calorie intake consisted approximately of 60% carbohydrates, 25% fat, 15% protein
1790217|NCT00512213|Dietary Supplement|Immunonutrition for 5 days preoperative|Impact vs Meritene
1790218|NCT00512213|Dietary Supplement|Standard enteral nutrition for 5 days preoperative|Impact vs Meritene
1790219|NCT00512226|Other|Cardiac and Liver T2* MRI|Laboratory examinations that are routinely used in follow up of those patients and T2* MRI analysis.
1790220|NCT00512252|Drug|AMD3100|
1790221|NCT00512252|Drug|Mitoxantrone|
1790222|NCT00512252|Drug|Etoposide|
1790223|NCT00512252|Drug|Cytarabine|
1790224|NCT00512265|Drug|n-acetylcysteine|150mg/kg N-Acetylcysteine in 250mL Glucose 5% at time of induction of anaesthesia 50mg/kg N-Acetylcysteine in 250mL Glucose 5% on post-op days 1-3
1790225|NCT00512265|Drug|250mL glucose 5%|placebo (250mL glucose 5%) at time of induction of anaesthesia placebo (250mL glucose 5%) on post-op days 1-3
1790226|NCT00512278|Drug|Infliximab|Infliximab weight based injection at baseline, weeks 2,6,14,22,30,38,46
1790227|NCT00512278|Drug|Placebo|Placebo
1790228|NCT00512291|Drug|Olanzapine|5 mg subcutaneous injection every 8 hours for 9 doses. Each injection should take about 1 to 2 minutes.
1790229|NCT00512304|Procedure|association chemotherapy and radiochemotherapy|
1790230|NCT00512317|Drug|ganaxolone|liquid suspension dosed tid
1790231|NCT00512356|Biological|Anti-Adhesion Product|Anti-Adhesion Product (AAP) is a biological two-component product of human origin. The components of AAP are lyophilized Anti-Adhesion Protein Concentrate (AAPC), containing fibrinogen, lyophilized Thrombin Concentrate (TC) and the respective diluents for the reconstitution of the components.
1790232|NCT00512382|Device|WEEM - Wheezy Monitoring|loudspeaker recording (WEEM) is attached externally to the chest simultaneously with PH-Impedance.
1790233|NCT00512395|Drug|epidural analgesia (Duracain/Fentanyl/Naropin)|naropin 0.3% or duracain 0.125% + Fentanyl via epidural catheter 4-12 ml/h
1790234|NCT00512408|Drug|testosterone|
1790235|NCT00512421|Procedure|computer-assisted surgery|
1790236|NCT00512434|Procedure|Osteosynthesis|Nail or external fixator Intervention 'Osteosynthesis'
1790237|NCT00512460|Drug|RTA 744|4.8 mg/m^2 by vein Over 2 Hours On Days 1-3.
1790238|NCT00512473|Drug|Saline infusion|0.9 % NaCl
1790239|NCT00512473|Drug|Human Growth Hormone|0.5 mg genotropin administered as a bolus at t = 0
1790240|NCT00512473|Drug|Pegvisomant|30 mg Somavert administered at t = - 36 hours
1790241|NCT00512486|Biological|MEDI-563|"BIW-8405/MEDI-563 administered at one of five dose levels:
0.03 mg/kg intravenous injection
0.1 mg/kg intravenous injection
0.3 mg/kg intravenous injection
1.0 mg/kg intravenous injection
3.0 mg/kg intravenous injection
Following the -3.0 mg/kg dose level,
BIW-8405/MEDI-563 administered at one of two lower dose levels:
0.003 mg/kg intravenous injection 0.0003 mg/kg intravenous injection"
1790242|NCT00512499|Behavioral|Control group|Informing patient that fracture probably of fragility origin and suggesting to consult primary care practitioner. After 8 months, if not treated, Intensive intervention will be offered
1790282|NCT00507130|Other|PLACEBO|Placebo administered twice weekly as a subcutaneous (SC) dose for 4 weeks
1790283|NCT00507143|Drug|irinotecan|
1790243|NCT00512499|Behavioral|Minimal Intervention|Multiple layers of intervention will be added: results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
1790244|NCT00512499|Behavioral|Intensive Intervention|"INTENSIVE INTERVENTION GROUP: 1/2 of patients, randomly selected results of the basic blood investigation for osteoporosis will be transmitted to the family physician with a personal letter explaining the importance of seeing the patient rapidly and indicating the urgency of initiating a treatment and indicating detailed instructions of treatment. The patient will be called at 4, 8, 12,16 and 24 months to monitor drug adherence, correct inadequate intake, and try to improve adherence. If the patient is not taking an adequate treatment at 4, 8 or 12 months, a letter will be sent again to the family physician asking to treat the patient according to recommendations.
Sequential serum will be stored frozen in order to measure levels of blood markers of bone metabolism (at a later date)"
1790245|NCT00512512|Procedure|Transoral Endoscopic Liver Biopsy|Liver will be biopsied with transoral endoscope instead of the laparoscopic instruments during laparoscopic gastric bypass
1790246|NCT00512525|Drug|Ghrelin and saline (as placebo)|Intravenous infusion
1790247|NCT00512538|Device|Bi-layered cell therapy (Apligraf)|
1790249|NCT00512564|Other|Laboratory analyses of iron overload|Summary of clinical status related to iron overload and laboratory analysis of Iron overload including Total serum Iron, Transferrin, Ferritin and Non transferrin Binding Iron and Labile Plasma Iron
1790250|NCT00512577|Other|Red cell blood transfusion|
1790251|NCT00512590|Behavioral|Relaxation and Guided Imagery|"The intervention consisted of 3 relaxation and guided imagery audiotapes used in a proscribed order for 6 weeks and used in any order for weeks 7 through 10.
Protocol: Tape 1: Basic Relaxation used for weeks 1 and 2. Tape 2: Pleasant Scene Imagery to elicit sensory involvement for enhanced sense of overall well-being; used for weeks 3 and 4. Tape 3: End-State Imagery designed to facilitate improved symptom management; used for weeks 5 and 6. Any of the tapes used as often as desired but at least once daily for weeks 7 to 10."
1790252|NCT00512616|Drug|Ceftriaxone|
1790253|NCT00512629|Drug|Omegaven|Omegaven is a fish based intravenous fat emulsion
1790254|NCT00512629|Drug|Intralipid|Intralipid is a plant based intravenous fat emulsion
1790255|NCT00512655|Behavioral|Fall prevention course|Duration: 5 weeks, 2 sessions of 2 hours per week: 10 sessions in total.
1790256|NCT00512668|Drug|leuprolide acetate|Given intramuscularly
1790257|NCT00512668|Drug|goserelin acetate|Given subcutaneously
1790258|NCT00512668|Drug|bicalutamide|Given PO
1790259|NCT00512668|Drug|nilutamide|Given PO
1790260|NCT00512668|Drug|flutamide|Given PO
1790261|NCT00512668|Drug|temsirolimus|Given IV
1790262|NCT00512668|Other|laboratory biomarker analysis|Optional correlative studies
1790263|NCT00512681|Drug|Irinotecan, Oxaliplatin, TS-1|"S-1 40 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)
Irinotecan 150 mg/m2 mixed in d5w 500 ml iv over 90-min on days 1
Oxaliplatin 85 mg/m2 mixed in d5w 250 ml iv over 2-h on days 1"
1790264|NCT00512707|Drug|Sildenafil citrate (open label)|On demand use of sildenafil citrate (3 tablets per week). Starting dose of 50 mg. Titrated to 100 mg or 25 mg depending on efficacy and tolerability. Begins as open label run in period for 3 - 6 weeks, and continues during the placebo-controlled testosterone gel intervention for 16 weeks.
1790265|NCT00512707|Drug|Testosterone gel|Testosterone Gel 1%: Starting active dose 10 g/day. Increased to 15 g/day or decreased to 5 g/day in order to attain morning total testosterone level between 500 - 1000 ng/dL. Blinding achieved by combining a total of 3 tubes of active or placebo gel, applied to upper arms and shoulders each day.
1790266|NCT00512707|Other|Placebo gel|3 tubes of placebo gel equivalent to the amount of the testosterone gel will be applied during the placebo-controlled testosterone gel intervention for 16 weeks..
1790267|NCT00512746|Other|cytology and cytometry specimen collection procedure|Samples tested and further interventions added if positive
1790268|NCT00512746|Other|Chest x ray|Patients not diagnosed with lung cancer during the course of the study, will be offered an exit chest x-ray after 5 years or sooner if they withdraw from the trial before 5 years. This could help identify a lung cancer that may not have been associated with symptoms earlier.
1790269|NCT00512746|Procedure|Autofluorescence bronchoscopy|The bronchial tree will be inspected first under white light and then under blue light. All areas that appear abnormal will initially be documented and only sampled when the bronchoscopic examination has been completed.
1790270|NCT00512746|Procedure|CT scan|All patients with abnormal sputum cytology and/or cytometry will undergo low dose spiral CT without contrast.
1790271|NCT00512759|Drug|Goal-directed preload and afterload decrement|Early goal-directed preload and afterload decrement with a target systolic blood pressure (RR) of 90-110 mmHg for the entire hospitalization using sublingual nitrates (Nitroglycerin Streuli®) or nitrospray (Corangin Nitrospray®) transdermal nitrates (Nitroderm TTS 10®), ACE-inhibitors (Triatec®) and/or ARB (Atacand®).
1790272|NCT00507091|Drug|ZD6474 (vandetanib) 100mg|once daily oral tablet
1790273|NCT00507091|Drug|Irinotecan|intravenous infusion
1790274|NCT00507091|Drug|5-Fluorouracil|intravenous infusion
1790275|NCT00507091|Drug|Leucovorin|intravenous infusion
1790276|NCT00507091|Drug|ZD6474 (vandetanib) 300mg|once daily oral tablet
1790277|NCT00507117|Drug|Lunesta|Lunesta 3mg prior to PSG
1790278|NCT00507117|Drug|Placebo control|matching placebo
1790279|NCT00507130|Biological|MEDI528 0.3 mg/kg|MEDI-528 at a dose of 0.3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
1790280|NCT00507130|Biological|MEDI528 1 mg/kg|MEDI-528 at a dose of 1 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
1790281|NCT00507130|Biological|MEDI528 3 mg/kg|MEDI-528 at a dose of 3 mg/kg administered twice weekly as a subcutaneous (SC) dose for 4 weeks
1790284|NCT00507156|Procedure|Standard primary PCI|Acute re-opening of the occluded coronary artery
1790285|NCT00507156|Procedure|Mechanical postconditioning|Mechanical postconditioning with 4 cycles 30/30 sek balloon inflations
1790286|NCT00507169|Drug|SVT-40776|
1790287|NCT00507182|Procedure|Fluorescence Spectroscopy|1-5 lesions + several normal-looking areas inside the mouth exposed to a beam of light; exposed tissues will emit very small amounts of fluorescence (light) then will be removed.
1790288|NCT00507195|Drug|Hypnotics: propofol, sevoflurane, desflurane,desflurane,midazolam|
1790289|NCT00507208|Device|Dynasplint Trismus System|The Dynasplint System will be used for 6 months.
1790290|NCT00507208|Other|Tongue Depressors|Tongue depressors to be used for 3 months at which time mouth opening will be measured. If there is no change then the patient will crossover to the Dynasplint Trismus System for another 3 months.
1790291|NCT00507221|Drug|Albendazole|"Every 3 months for 24 months (enrollment 3, 6, 9, 12, 15, 18, 21, and 24 months):
400mg/day X 3 days"
1790292|NCT00507221|Drug|Praziquantel|At enrollment and 12 months: 25mg/kg X 1
1790293|NCT00507221|Drug|Current standard of care in Kenya|Current standard of care for HIV patients in Kenya based on WHO guidelines.
1790294|NCT00507234|Drug|formoterol fumarate inhalation solution|
1790295|NCT00507247|Drug|Daptomycin|6mg/kg/day IV for at least 10 days.
1790296|NCT00507260|Behavioral|Food Record|A record of the amount and kind of food and drink you intake will be completed.
1790297|NCT00507260|Other|Nutritional Consults|Meeting with a dietician consultant regarding issues related to food intake. Participants will also receive the results from the food records.
1790298|NCT00507273|Other|GIST Registry|Internet based data registry about how different physicians treat and manage patients with gastrointestinal stromal tumors.
1790299|NCT00507286|Drug|combination of various doses of sildenefil and alprostadil|
1790300|NCT00507299|Behavioral|Enhanced pediatric primary care|Residents received special training to address targeted psychosocial problems. Parents bringing in children (0 - 5 years) completed a screening questionnaire and gave this to their doctor. The resident briefly assessed the identified problems and helped address them. A social worker was present to assist.
1790301|NCT00507299|Behavioral|Standard pediatric primary care|Residents did not receive special training on the targeted psychosocial problems. They did not use the parent screening questionnaire, and they did not have a dedicated social worker.
1790302|NCT00507312|Device|HD medical device (ViScope)|Device
1790303|NCT00507312|Device|CSIRO device|device
1790304|NCT00507325|Procedure|Blood Sample|Blood samples will be collected.
1790305|NCT00507325|Procedure|Tumor Sample|Tumor samples will be collected using a small needle, a punch knife, or a small surgery.
1790306|NCT00507338|Procedure|PCI|early PCI for NSTEMI; primary PCI for STEMI
1790307|NCT00512785|Drug|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 52 weeks
1790308|NCT00512785|Drug|imidafenacin, KRP-197/ONO-8025|0.1 mg BID for 12 weeks and 0.2 mg BID for 52 weeks
1790309|NCT00512798|Drug|PS-341 (VELCADE)|"Dose Levels PS-341 (day 1)
Level -1 0.7 mg/m2
Level 1 1.0 mg/m2
Level 2 1.0 mg/m2
Level 3 1.3 mg/m2
Level 4 1.5 mg/m2"
1790310|NCT00512798|Drug|temozolomide|"Temozolomide (day 8)
Level - 1 50 mg/m2
Level 1 50 mg/m2
Level 2 75/mg/m2
Level 3 75 mg/m2
Level 4 75 mg/m2"
1790311|NCT00512798|Other|immunoenzyme technique|Not noted
1790312|NCT00512798|Drug|PS-341 (VELCADE)|1.3 mg/m2 by IV on days 1, 4, 8, and 11 of every 21 days
1790313|NCT00512798|Drug|Temozolomide|75 mg/m2 by mouth, daily, during weeks 2-8 (42 days) of every 9-week course.
1790314|NCT00512811|Drug|furosemide|
1790315|NCT00512824|Dietary Supplement|low calcium milk of 180 ml|twice daily for 24 weeks
1790316|NCT00512824|Dietary Supplement|regular milk of 180 ml|twice daily for 24 weeks
1790317|NCT00512824|Dietary Supplement|regular milk of 180 ml + probiotics|twice daily for 24 weeks
1790318|NCT00512824|Dietary Supplement|regular milk of 180 ml + probiotics|twice daily for 24 weeks
1790319|NCT00512837|Behavioral|Mobile phone technology|
1790320|NCT00512850|Dietary Supplement|Folic acid|Intervention group 1g folic acid per day
1790321|NCT00512850|Other|Placebo|One placebo pill per day
1790322|NCT00512863|Drug|Humira (adalimumab)|
1790323|NCT00512876|Drug|Bevacizumab (Avastin)|Bevacizumab 10mg/mL 1 drop BID x 3 weeks
1790324|NCT00512889|Biological|therapeutic autologous lymphocytes|Autologous CTL generated from peripheral blood following culture with MART1/Melan-A peptide pulsed aAPC.
1790325|NCT00512889|Genetic|Use of an artificial antigen presenting cell (aAPC) to generate CTL|A genetically modified artificial antigen presenting cell (aAPC) is used in the generation of anti-tumor CTL.
1790326|NCT00512889|Drug|GM-CSF|GM-CSF will be used as an immune activator and combined with the infusion of MART1/Melan-A specific CTL.
1790327|NCT00512889|Radiation|Irradiation of cutaneous tumor lesion|Irradiation of cutaneous melanoma lesion will be combined with the infusion of MART1/Melan-A specific CTL.
1790328|NCT00512902|Drug|Imatinib|All subjects will receive gleevec. Subjects will have a clinic visit every 2 weeks for the first 20 weeks and then they will have one every 4 weeks for the remainder of the study. Gleevec will be taken by mouth everyday. It will be increased to a maximum of 600 mg every day. It will be increased 100 mg at each visit for the first 12 weeks. Your participation may last up to 1 year and participants will have approximately 18 clinic visits.
1790329|NCT00512902|Drug|Imatinib|Up to 600 mg QD PO for up to 1 year.
1790330|NCT00512915|Device|pacemaker implantation|St. Jude Medical Dual Chamber Pacemaker model Identity (ADx) DR, Victory DR, or newer
1790331|NCT00512928|Drug|acenocoumarol|max 5 mg per day during 10 weeks
1790332|NCT00512928|Dietary Supplement|menaquinone-7|In successive weeks (6 weeks) the dosage is increased over the range 10 µg to 20 µg increasing to 45 µg MK-7 for the final week.
1790333|NCT00512980|Drug|prednisone|
1790334|NCT00512980|Drug|vinblastine|
1790335|NCT00512980|Drug|doxorubicin|
1790336|NCT00512980|Drug|gemcitabine|
1790337|NCT00512993|Drug|Zoledronic acid|Infusion of zoledronic acid (4 mg) every 4 weeks for six doses, followed by every 3 months for 8 doses, followed by every 6 months for 5 doses
1790338|NCT00513019|Drug|Lamictal (lamotrigine)|once daily from beginning to end of study. Dosage varies.
1790339|NCT00513019|Drug|Placebo|daily
1790340|NCT00513032|Drug|methylene blue|5mg.kg-1 methylene blue in 250 ml 5% glucose-saline, administered intravenously approximately 60 min before anaesthesia induction
1790341|NCT00513045|Behavioral|IRT|Cognitive behavior intervention
1790342|NCT00513045|Behavioral|Exposure|Exposure intervention
1790343|NCT00513058|Drug|Lapatinib|Dose level (DL) 1 : 750 mg/d DL2, DL3, DL4: 1000 mg/d DL5, DL7, DL8: 1250 mg/d DL6: 1500 mg/d
1790344|NCT00513058|Drug|vinorelbine|DL1, DL2: 20 mg/m2 DL3: 22.5 mg/m2 DL4, DL5, DL6: 25 mg/m2 DL7: 27.5 mg/m2 DL8: 30 mg/m2
1790345|NCT00513071|Drug|saracatinib|Given orally
1790346|NCT00513071|Other|laboratory biomarker analysis|Correlative studies
1790347|NCT00513084|Behavioral|SDT and Motivational Interviewing in Obesity Treatment|Thirty group sessions, designed to follow SDT, covering PA, eating/nutrition, body image, and other cognitive-behavioral contents. Central to the intervention are improving autonomy, intrinsic motivation, and self-regulation of behavior change. Accepting ambivalence for change, rolling with resistance, and developing discrepancy were used throughout the program, with an emphasis on promoting intrinsic, self-regulated motivation for exercise and weight control.
1790348|NCT00513097|Behavioral|Smoking Prevention Program|Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.
1790349|NCT00513097|Behavioral|Focus Group|A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.
1790350|NCT00513097|Behavioral|Survey|On-line evaluations and questionnaires
1790351|NCT00513110|Genetic|AMPD1 polymorphism|Endotoxin 2ng/kg to subjects with a AMPD1 polymorphism
1790352|NCT00513110|Drug|Caffeine infusion|Endotoxin 2ng/kg combined with caffeine. Caffeine (4mg/kg) is used as an adenosine receptor antagonist.
1790353|NCT00513110|Drug|placebo|Endotoxin 2ng/kg combined with saline infusion (0.9%)
1790354|NCT00514332|Procedure|stent|stent placement for colorectal cancer obstruction
1790355|NCT00514345|Genetic|gene expression analysis|
1790356|NCT00514345|Genetic|polymorphism analysis|
1790357|NCT00514345|Procedure|management of therapy complications|
1790358|NCT00514371|Drug|tanespimycin|High dose
1790359|NCT00514371|Drug|Bortezomib|Mid dose, and low dose
1790360|NCT00514397|Drug|motexafin gadolinium|
1790361|NCT00514397|Drug|temozolomide|
1790362|NCT00514397|Procedure|adjuvant therapy|
1790363|NCT00514397|Procedure|quality-of-life assessment|
1790364|NCT00514397|Radiation|radiation therapy|
1790365|NCT00514410|Drug|Folic Acid|Folic acid 5 mg once a day for three months as a supplement to their antidepressant treatment
1790366|NCT00514410|Drug|Placebo|Matching placebo taken once a day for three months
1790367|NCT00514423|Other|Psychoeducation by professonals|
1790368|NCT00514423|Other|Psychoeducation by peer-moderators|
1790369|NCT00514423|Other|Video-education|
1790370|NCT00514423|Other|Noneducational video group (control group)|
1790371|NCT00514436|Behavioral|Asthma coaching|Inperson contact followed by telephone with approach by issues raised by family
1790374|NCT00514462|Device|diode laser|wavelength at 830nm, 9.7J/cm2 for 10 min
1790375|NCT00514475|Drug|90Y-ibritumomab tiuxetan (Zevalin)|90Y-ibritumomab tiuxetan (Zevalin) at 0.4 mCi/kg is administered one week prior to start high-dose chemotherapy (BEAM/BEAC) in patients who have not achieved CR after induction therapy. Predosing with rituximab 250 mg/m2 one weeks prior to radioimmunotherapy and the same day.
1790376|NCT00514488|Drug|STI571 (400 mg/day; or 800 mg/day)|
1790377|NCT00514501|Drug|Iodofiltic acid I 123|
1790378|NCT00514514|Drug|Everolimus|Tablet containing 0.5 mg or 0.75 mg. Dosing schedule: Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen
1790379|NCT00514514|Drug|Myfortic|"1 tablet containing 180 mg or 360 mg
Dosing schedule:
Initially 1.5 mg/day, then based on blood level (5-10 ng/mL in CNI free, 3-8 ng/mL in CNI low regimen) According to blood level 1440 mg/day (2 x 720 mg), if tolerated. Dose reduction possible in case of side effects (min. dose at BL2 (Month 3): 720 mg/day)"
1790380|NCT00514514|Drug|Sandimmun Optoral|1 capsule containing 10, 25, 50, or 100mg. Dosing: According to blood level
1790381|NCT00514514|Drug|Simulect®|Lyophilisate in vials with ampoules of sterile water for injection (5 ml). Dosing: 1 vial containing 20 mg lyophilisate. Dosing schedule: 2 x 20 mg to be applied as 10 sec. bolus injection, i.v. on Day 0 (2 h before transplant) and on Day 4
1790382|NCT00514527|Drug|oritavancin|Oritavancin as a single, infrequent or daily dose.
1790385|NCT00514566|Device|Suture for midline abdominal closure|closure with Polyamide or Polydioxanone
1790386|NCT00514579|Procedure|Cord blood transplantation|Myeloablative preparative regimen of chemotherapy and radiation followed by double unit umbilical cord blood transplantation
1790387|NCT00514592|Other|New Guidelines|New practical guidelines after half of the study aimed at reducing the delay and increasing the patient safety.
1790388|NCT00514605|Other|Behavioral counseling|Standard-of-Care counseling at the Point-of-Care.
1790389|NCT00514605|Device|HIV-1 Antibody Test Kit|Assay to detect HIV antibodies
1790390|NCT00514618|Drug|Misoprostol|patients will be treated with misoprostol 50 mcg PO q day for two days (days 1 and 4)
1790391|NCT00514618|Dietary Supplement|Placebo|patients will receive placebo (vitamin C) q day for two days (days 1 and 4)
1790392|NCT00514644|Other|Carotid ultrasound examination|Ultrasonographic examination of the carotid arteries to determine the grade of carotid stenosis.
1790393|NCT00514644|Other|Panorama examination|"Examination with the odontological radiological method Panorama, including a frontal verification image"
1790394|NCT00514657|Drug|Trafermin (genetical recombinant of human basic Fibroblast Growth Factor)|
1790395|NCT00514670|Other|Alcohol-based hand sanitizer & quaternary ammonium wipes|
1790396|NCT00514683|Drug|low dose BIBF1120 once daily|low dose BIBF1120 once daily
1790397|NCT00514683|Drug|low dose BIBF 1120 twice daily|low dose BIBF 1120 twice daily
1790398|NCT00514683|Drug|intermediate dose BIBF 1120 twice daily|intermediate dose BIBF 1120 twice daily
1790399|NCT00514683|Drug|high dose BIBF 1120 twice daily|high dose BIBF 1120 twice daily
1790400|NCT00514683|Drug|placebo|placebo
1790401|NCT00514696|Drug|GCS-100|GCS-100: 160 mg/m2 IV (in the vein) Study Days 1-5 of each 21-day cycle
1790402|NCT00514709|Biological|DTaP-HB PRP~T Combined Vaccine|0.5 mL, Intramuscular (IM)
1790403|NCT00514709|Biological|DTaP-HB-PRP~T vaccine|0.5 mL, IM
1790404|NCT00514709|Biological|Oral Polio Vaccine|Oral co-administered with study vaccine.
1790405|NCT00514722|Other|umbilical cord stem cells|umbilical cord stem cell allogeneic transplantation
1790406|NCT00514735|Procedure|Medtronic Cardiac Ablation System|Arm 1 (Ablation Management): Ablation procedures using investigational catheters in left atrium. Cardioversion could be used to restore sinus rhythm if needed.
1790407|NCT00514735|Drug|Class I or III Antiarrhythmic Medications|Arm 2 (Medical Management): Class I or III antiarrhythmic drugs. Changes in dosing, antiarrhythmic drugs or combinations of antiarrhythmic drugs were allowed. Direct current cardioversions were also allowed at the discretion of the investigator.
1790408|NCT00514748|Procedure|DIEP|flap survival, operation time, flap complications, donor site morbidity.
1790409|NCT00514748|Procedure|Interconnected DIEP|flap survival, operation time, flap complications, donor site morbidity.
1790410|NCT00514761|Drug|AZD6244|oral vial
1790411|NCT00514761|Drug|Capecitabine|oral tablet
1790412|NCT00514774|Drug|ursodiol|"ursodiol 300 mg twice daily for study days 0 through 28
ursodiol 600mg twice daily on study days 0 through 28"
1790413|NCT00514774|Drug|placebo|placebo 600mg twice daily for study days 0 through 28
1790414|NCT00514800|Behavioral|Intervention - a validated home BP monitor and support from the specialist nurse|
1790415|NCT00514800|Behavioral|Control - usual care (BP monitoring by their practice)|"Patients will not receive a blood pressure monitor and will continue with usual GP care for hypertension management.
GPs will be sent information about the study design, current guidelines and interpretation of home blood pressure readings."
1790416|NCT00514813|Drug|Dynepo|Subcutaneous injection either BIW, QW, Q2W or Q4W based on what is appropriate for the subject
1790417|NCT00514826|Other|altitude exposure|sojourn at moderate altitude (1860m and 2590m) during 2 days/nights each
1790418|NCT00514839|Behavioral|Motivational Interviewing|Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
1790419|NCT00514852|Drug|Carboxymethylcellulose and Glycerin based artificial tear|1 to 2 drops into each eye as needed but at least twice daily
1790420|NCT00514852|Drug|Carboxymethylcellulose|1 to 2 drops into each eye as needed but at least twice daily
1790421|NCT00514865|Drug|ONO-2333Ms|5-10 mg QD for 8 weeks
1790422|NCT00514865|Drug|ONO-2333Ms|0 mg QD for 8 weeks
1790423|NCT00514865|Drug|ONO-2333Ms|1-2 mg QD for 8 weeks
1790424|NCT00514891|Biological|Vitamin A|The effect of vitamin A given with different vaccines will be studied
1790425|NCT00514904|Biological|Meningococcal vaccine GSK134612|Single dose, intramuscular injection
1790426|NCT00514904|Biological|Mencevax™|Single dose, subcutaneous injection
1790427|NCT00514917|Drug|Docetaxel|75 mg/m^2 intravenous infusion over 1 hour every 3 weeks up to 10 cycles.
1790428|NCT00514917|Drug|Leuprolide|22.5 mg injection subcutaneously every 12 weeks up to 18 months.
1790429|NCT00514917|Drug|Bicalutamide|50 mg tablet orally once daily for first 4 weeks of treatment.
1790430|NCT00514930|Device|Hexablate|
1790431|NCT00514943|Drug|BIBW 2992|experimental drug taken once daily orally
1790432|NCT00514943|Drug|Cetuximab|active comparator administered weekly intravenously
1790433|NCT00514956|Behavioral|Emotional Freedom Techniques (EFT)|
1790434|NCT00514969|Drug|Imatinib (STI571)|
1790435|NCT00514982|Drug|Mesalamine|5-Aminosalicylic Acid Derivative used to treat mild to moderate Ulcerative Colitis
1790436|NCT00514982|Drug|Infliximab|Antirheumatic, Disease Modifying Gastrointestinal Agent, Miscellaneous, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat gastrointestinal disorders.
1790437|NCT00514982|Drug|Corticosteroids|Systemic Corticosteroid used to treat inflammatory conditions.
1790438|NCT00514982|Drug|6-Mercaptopurine|Antineoplastic Agent, Antimetabolite, Immunosuppressant Agent used traditionally to treat Acute lymphoblastic leukemia. Unlabeled use as steroid-sparing agent for corticosteroid-dependent Crohn's disease (CD) and ulcerative colitis (UC); maintenance of remission in CD; fistulizing Crohn's disease.
1790439|NCT00514982|Drug|Tacrolimus|Immunosuppressant Agent used to treat Liver, Heart, Kidney transplant, prevent host vs graft disease, severe atopic dermatitis.
1790440|NCT00514982|Drug|Adalimumab|Antirheumatic, Monoclonal Antibody, Tumor Necrosis Factor (TNF) Blocking Agent used to treat Rheumatoid arthritis and Crohn's disease.
1790441|NCT00514995|Drug|Sodium Oxybate|4.5 g/night - 9 g/night, liquid taken twice per night
1790442|NCT00515008|Behavioral|Tai Chi Intervention|The tai chi intervention took place twice a week for 12 weeks, and each session lasted for 60 minutes. Classes were taught by a tai chi master with more than 20 years of teaching experience. In the first session, he explained the theory behind tai chi and its procedures and provided participants with printed materials on its principles and techniques. In subsequent sessions, participants practiced 10 forms from the classic Yang style of tai chi18 under his instruction. Each session included a warm-up and self-massage, followed by a review of principles, movements, breathing techniques, and relaxation in tai chi. Throughout the intervention period, participants were instructed to practice tai chi at home for at least 20 minutes each day. At the end of the 12-week intervention, participants were encouraged to maintain their tai chi practice, using an instructional DVD, up until the follow-up visit at 24 weeks.
1790482|NCT00515281|Drug|inhaled nitric oxide|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of subject's lungs. The subject will remain on inhaled nitric oxide until he/she reaches 33 weeks of gestation if assigned to the treatment arm, or until the 8th day of the study if he/she is assigned to the control arm.
1790687|NCT00516880|Drug|rosiglitazone|
1790443|NCT00515008|Behavioral|Control Intervention|Our wellness education and stretching program similarly included 60-minute sessions held twice a week for 12 weeks.19 At each session, a variety of health professionals provided a 40-minute didactic lesson on a topic relating to fibromyalgia, including the diagnostic criteria; coping strategies and problem-solving techniques; diet and nutrition; sleep disorders and fibromyalgia; pain management, therapies, and medications; physical and mental health; exercise; and wellness and lifestyle management.20 For the final 20 minutes of each class, participants practiced stretching exercises supervised by the research staff. Stretches involved the upper body, trunk, and lower body and were held for 15 to 20 seconds. Participants were instructed to practice stretching at home for 20 minutes a day.
1790445|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
1790446|NCT00515034|Drug|Imipenem/cilastatin|Vancomycin and/or amikacin may be added as adjunctive therapy as per investigator discretion
1790447|NCT00515034|Drug|Doripenem|1 gram infused over 4 hours at 8-hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
1790448|NCT00515034|Drug|Doripenem|1 gram infused over 1 hour at 8 hour intervals for patients with Ventilator-Associated Pneumonia (VAP) for 7 to 14 days
1790449|NCT00515060|Other|Sensory Tests|Tests to find the threshold at which perceive stimuli.
1790450|NCT00515073|Drug|Paclitaxel|50 mg/m^2 IV over one hour on Day 1, 8, 15, 22, and 29 during radiation therapy followed by 4 additional courses at 135 mg/m^2 IV over 3 hours every 21 days, 4-6 weeks after pelvic radiation is completed.
1790451|NCT00515073|Radiation|Pelvic Radiation|Radiation therapy to the pelvis daily for 25 treatments. Beginning Day 1 or 2 and given for 5 days for 5 weeks, giving a total dose of 45 Gy with external beam radiation to the pelvis. The vaginal apex boost given either with last 3 external beam treatments or after external beam radiation completed for an additional 3 days depending on patient preference. No chemotherapy given with vaginal apex boost.
1790452|NCT00515073|Drug|Dexamethasone|20 mg IV given 30 minutes prior to chemotherapy
1790453|NCT00515073|Drug|Cimetidine|300 mg IV given 30 minutes prior to chemotherapy
1790454|NCT00515073|Drug|Diphenhydramine|50 mg IV given 30 minutes prior to chemotherapy
1790455|NCT00515086|Drug|Everolimus|Tablets taken once a day with a full glass of water.
1790456|NCT00515086|Procedure|Surgery|Salvage surgical resection
1790457|NCT00515099|Drug|Antithymocyte globulin|Daily 4-day escalating dose
1790458|NCT00515099|Drug|Placebo|Daily 4-day saline solution
1790459|NCT00515112|Drug|AndroGel|Androgel 1%, 10g daily
1790460|NCT00515112|Drug|placebo|placebo
1790461|NCT00515125|Behavioral|Dietary Advice|Dietary Advice sheet
1790462|NCT00515125|Dietary Supplement|Oral Nutritional Supplements (Fortisip)|"These products are classified as non-medicinal, borderline substances, foods for special medical purposes.
A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 12 week period."
1790463|NCT00515138|Drug|Rituximab, Ifosfamide, Carboplatin, Etoposide, Bortezomib|Bortezomib starting at 1 mg/m(2), and escalating to 1.3, 1.5, 1.7. Bortezomib will be given on Days 1 (prior to rituximab) and 4, rituximab at 375 mg/m(2) on day 1, carboplatin AUC 5 and ifosfamide with mesna, each 5 mg/m(2), on day 3 and etoposide 100 mg/m(2)/day on days 2, 3, and 4 of a 21-day cycle. They will also receive filgrastim on days 6-13 or pegfilgrastim on day 6
1790464|NCT00515151|Drug|0.1% Octenidine with 30% 1-propanol and 45% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
1790465|NCT00515151|Drug|74% Ethanol with 10% 2-propanol|Before insertion of the catheter, the entry site was disinfected with the assigned solution over an area of >200 cm² for at least one minute. The assigned solution was then applied for care of the entry site during the change of dressings, usually every 2 to 3 days.
1790466|NCT00515164|Drug|Biologic Lung Volume Reduction (BLVR) - 20 mL Hydrogel|20 mL Hydrogel
1790467|NCT00515177|Behavioral|Mindfulness-Based Stress Reduction|The intervention is a standardized program of mindfulness training led by an instructor. 8 weekly 2.5 hours sessions provide information on stress, cognition and health and training in a variety of mindfulness techniques including gentle yoga, body scan and sitting meditations. The program includes homework and home practice of mindfulness.
1790468|NCT00515177|Drug|eszopiclone|"One 3 mg tablet of eszopiclone nightly for 8-weeks followed by 3-months of as needed use"
1790469|NCT00515190|Drug|S-1,oxaliplatin|"Arm A (continuous arm): S-1 80mg/m2/d p.o. twice daily(q 12-h)on D1(evening)-D15(morning)plus oxaliplatin 130mg/m2 IV(in the vein)on D1 every 3 weeks, until disease progression, unacceptable toxicity, or consent withdrawal.
Arm B (intermittent arm):Treatment will be stopped after the initial 6 cycles of S-1 plus oxaliplatin, and then S-1 plus oxaliplatin will be resumed at the disease progression during follow-up, as the same dose as the last chemotherapy of initial 6 cycles."
1790470|NCT00515203|Drug|Placebo|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
1790471|NCT00515203|Drug|AMG 531|Starting dose of 1.0 ug/kg. Dose adjustments are made throughout the study based on individual platelet counts.
1790472|NCT00515216|Drug|5-fluorouracil|
1790473|NCT00515216|Drug|Oxaliplatin|
1790474|NCT00515216|Drug|Leucovorin|
1790475|NCT00515229|Drug|amitriptyline|"Each individual capsule has a filling volume of 25 mg, 50 mg und 75 mg Amitriptyline.
Placebo: 25 mg corn starch"
1957266|NCT02469532|Device|Balloon Angioplasty|Device: Balloon Angioplasty Selection is driven by preference of the operator
1790479|NCT00515255|Drug|Minocycline|Capsules
1790480|NCT00515268|Drug|GSK256066|GSK256066 will be available as dry powder inhaler with dosing strengths of 12.5, 37.5, 50 micrograms per inhalation.
1790481|NCT00515268|Drug|Placebo|Subjects will receive placebo inhaler.
1790580|NCT00516139|Drug|Lamotrigine|Open-label
1790688|NCT00516893|Biological|BG00002-E (natalizumab high titer)|
1790483|NCT00515281|Drug|oxygen|The amount of gas will be carefully controlled and adjusted to the level that best improves the function of the subject's lungs. Subjects in the control arm of the study will receive oxygen beginning on the 8th day of the study until he/she reaches 33 weeks of gestation.
1790484|NCT00515294|Drug|Caffeinated Alcoholic Beer|Alcoholic Beer plus Caffeine Citrate powder.
1790485|NCT00515294|Other|Non-Caffeinated Alcoholic Beer|Alcoholic Non-Caffeinated Beer
1790486|NCT00515294|Drug|Caffeinated Non-Alcoholic Beer|Non-Alcoholic Beer plus Caffeine Citrate powder.
1790487|NCT00515294|Other|Non-Caffeinated, Non-Alcoholic Beer|Non-Alcoholic Beer
1790488|NCT00515307|Procedure|Cellular transplantation|600 million to 1 billion cells will be infused through the portal vein over 30 minutes. Infusion will be done one time.
1957267|NCT02469532|Device|Atherectomy System|Device: Orbital or Directional or Laser Atherectomy Systems Atherectomy selection is driven by preference of the operator
1790491|NCT00515333|Drug|TRx0014|Hard capsule; 60 milligrams; t.i.d.
1790492|NCT00515333|Drug|TRx0014|Hard capsule; 30 milligrams; t.i.d.
1790493|NCT00515333|Drug|Placebo|Hard capsule; 0 milligrams; t.i.d.
1790494|NCT00515333|Drug|TRx0014|Hard capsule, 100 milligrams, t.i.d.
1790495|NCT00515346|Device|Xpert(TM) Self-expanding Transhepatic Biliary Stent System feasibility in treating chronic critical limb ischemia|
1790496|NCT00515359|Procedure|Intermittent Propofol Sedation|Intermittent versus continuous dosage
1790497|NCT00515359|Procedure|Continuous Propofol Sedation|intermittent vs continuous dosage
1790498|NCT00515372|Other|Telephone Counseling|Weekly phone calls lasting about 30 minutes.
1790499|NCT00515372|Other|Usual Care|Lists of professional resources and referral recommendations will be provided.
1790500|NCT00515385|Drug|MGAWN1|"Eight subjects per cohort, each receives a single IV infusion of MGAWN1 of saline control on study day 0 (6 MGAWN1, 2 saline control.
Cohort 1 - 0.3 mg/kg Cohort 2 - 1 mg/kg Cohort 3 - 3 mg/kg Cohort 4 - 10 mg/kg Cohort 5 - 30 mg/kg"
1790501|NCT00515385|Drug|MGAWN1|Single IV dose
1790502|NCT00515385|Other|Placebo|Single IV dose
1790503|NCT00515398|Other|Observation|Ex vivo administration of AT2220
1790504|NCT00515411|Drug|Docetaxel, Leucovorin, Fluorouracil, Cisplatin|Drug Dose (mg/m2) Schedule Docetaxel 40 Day 1 IVPB (60 min) Leucovorin 400 Day 1 IVPB (30 min) Fluorouracil 400 IVP day 1 Fluorouracil 1000 IVCI x 48 hours Cisplatin 40 Day 2 OR 3 IVPB (30 min)
1790505|NCT00515411|Drug|Docetaxel, Cisplatin, Fluorouracil, Neulasta, or Neupogen|"Drug Dose (mg/m2) Schedule Docetaxel 75 Day 1 IVPB (60 min) Cisplatin 75 Day 1 IVPB (60 min) Fluorouracil 750 IVCI daily x 5 days Neulasta 6 mg subcut on d 8, 9, or 10 or Neupogen 300 or 480 mcg* subcut x 7 d 10-17
* 300 mcg for weight < 60 kg, 480 mcg for weight > 60 kg
Arm B is repeated every 3 weeks, and a cycle will be considered every 6 weeks (eg 2 treatments). Tumor assessments will be performed following the completion of every cycle for the first 6 cycles, and then every 2 cycles thereafter."
1790506|NCT00515424|Drug|RKI983|
1790507|NCT00515437|Biological|Botulinum Toxin Type B (Myobloc)|
1790508|NCT00515437|Biological|Matched placebo to Myobloc|
1790509|NCT00515450|Biological|GB-0998 (Intravenous immunoglobulin)|
1790510|NCT00515450|Procedure|Plasmapheresis|
1790511|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
1790512|NCT00515463|Biological|denosumab|60 mg denosumab in 1mL
1790513|NCT00515476|Behavioral|physical exercise|8 weeks of regular exercise training
1790514|NCT00515489|Drug|Risperidone|as prescribed
1790515|NCT00515502|Drug|GSK573719|250 micrograms (μg) per blister, administered via dry powder inhaler, dose-ascending study doses began at 250 ug, then 500 ug, and 1000 μg
1790516|NCT00515502|Drug|Tiotropium|strips of five capsules, each containing 18 μg administered via dry powder inhaler
1790517|NCT00515528|Drug|4-peptide melanoma vaccine|draft
1790518|NCT00515528|Drug|4-peptide melanoma vaccine plus Ontak|draft
1790519|NCT00515528|Drug|ontak|draft
1790520|NCT00515541|Drug|Lovaza|First 6 weeks period take 1 gram Lovaza capsule daily 2nd 6 weeks period take 2 grams of Lovaza (2 1 gram capsules) daily 3rd 6 weeks period take 4 grams of Lovaza (4 1 gram capsules) daily 4th 6 weeks period take 8 grams of Lovaza (8 1 gram capsules) daily
1790521|NCT00515554|Drug|Rituximab|addition of Rituximab to BEACOPP escalated
1790522|NCT00515554|Drug|BEACOPP escalated|chemotherapy with BEACOPP escalated
1790523|NCT00515580|Procedure|Tongue Sutures for Obstructive Sleep Apnea|Mandibular osteotomy with placement of Silhouette sutures for genioglossus advancement and hyoid suspension.
1790524|NCT00515593|Drug|Parathyroid hormone (PTH) (Preotact)|Patients with severe postmenopausal osteoporosis
1790525|NCT00515606|Drug|helium:oxygen|
1790526|NCT00515619|Drug|Lacosamide|50 mg and 100 mg tablets up to 800 mg/day as twice day (BID) dosing throughout the trial
1790527|NCT00515632|Drug|Balaglitazone|One arm balaglitazone 10mg, one arm balaglitazone 20mg, one arm placebo, one arm pioglitazone (Actos®) 45mg, orally taken once daily.
1790528|NCT00515645|Other|Head-down tilt and immersion|Head-down tilt -6° at inclusion, head-down tilt -15° at week one and Water Immersion at week two
1790529|NCT00515658|Device|theta-burst rTMS|
1790530|NCT00515671|Behavioral|Illness Management and Recovery|a structured curriculum to help mental health consumers manage their illnesses and pursue goals related to recovery from mental illness
1790531|NCT00515671|Behavioral|Problem Solving|Weekly problem-solving support group
1790532|NCT00515684|Drug|bevacizumab (Avastin)|
1790533|NCT00515697|Biological|Ramucirumab|Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
1790534|NCT00515723|Drug|risperidone|randomized switch from current antipsychotic treatment to risperidone
1790535|NCT00515723|Drug|olanzapine|randomized switch from current antipsychotic treatment to olanzapine
1790536|NCT00515723|Drug|quetiapine|randomized switch from current antipsychotic treatment to quetiapine
1790537|NCT00515723|Drug|ziprasidone|randomized switch from current antipsychotic treatment to ziprasidone
1790538|NCT00515736|Drug|Selenium (Se), Zinc (Zn), Vitamin C, Vitamin B1, Vitamin E|Se 270mcg, Zn 30mg, C 1.1g, B1 100mg, E 300mg
1790539|NCT00515736|Drug|Placebo|vehicle
1790540|NCT00515762|Device|elasto-gel cap|scalp cooling cap
1790541|NCT00515788|Drug|DepoCyt|Starting dose of 50 mg Intrathecal on Day 1 every 14 days for a total of 12 weeks (6 treatments). After the first 12 weeks, 50 mg Intrathecal on Day 1 every 28 days for 40 weeks (10 treatments).
1790542|NCT00515788|Drug|Temozolomide|100 mg/m^2 (capsules) by mouth daily for 7 consecutive days every 14 days.
1790543|NCT00515801|Drug|glibenclamide|glibenclamide 15 mg single dose
1790544|NCT00515801|Drug|placebo|placebo capsules, single dose
1790545|NCT00515814|Device|Retina implant is surgically placed into subretinal position|Subretinal implant is either in ON or in OFF condition during test periods, such as FrACT, BaLM, grating, orientation & mobility.
1790546|NCT00515827|Drug|Raltegravir (MK-0518)|400 mg tablet taken orally twice daily
1790547|NCT00515827|Drug|Placebo|400 mg placebo tablet taken orally twice daily
1790548|NCT00515840|Other|Physiotherapist|Physiotherapist administered breathing retraining programme
1790549|NCT00515853|Behavioral|Biofeedback|Biofeedback sessions or biofeedback exercises
1790550|NCT00515866|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
1790551|NCT00515866|Drug|Gemcitabine|intravenous injection
1790552|NCT00515879|Drug|D-cycloserine|50 mg
1790553|NCT00515879|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions aim to help participants become more comfortable with social situations.
1790554|NCT00515879|Drug|Placebo|Same dosage as active pill
1790555|NCT00515892|Drug|Immunotoxin therapy|
1790556|NCT00515892|Drug|CAT-8015 Immunotoxin|
1790557|NCT00515892|Procedure|Biological therapy|
1790558|NCT00515892|Procedure|Antibody Therapy|
1790559|NCT00515892|Procedure|Monoclonal Antibody Therapy|
1790560|NCT00515905|Drug|Sevoflurane/propofol|Sevoflurane/propofol
1790561|NCT00515918|Dietary Supplement|iron|
1790562|NCT00515931|Radiation|Radiation therapy (external beam photons)|A cumulative radiation dose of 30 to 40 Gy is administered in 1.8 to 2.0 Gy fractions, 5 fractions per week, to the target lesion(s).
1790563|NCT00515944|Drug|Botulinum neurotoxin type A, free of complexing proteins|
1790564|NCT00515957|Genetic|genetically modified CTLs in combo with CD45 antibodies|"LMP1- and LMP2- specific cytotoxic T-lymphocytes (CTL) in combination with CD45 monoclonal antibody (MAb).
--Infusions of CD45 MAbs: A fixed dose of CD45 MAbs will be used determined from our previous and ongoing studies in stem cell transplant recipients will be used43, 400ug/kg over 6 to 8 hrs daily x 4 given as 4 daily intravenous infusions that will be completed 48-72 hours prior to CTL infusion.
Day 1 YTH 24/54 400ug/kg over 6 to 8 hr 2 YTH 24/54 400ug/kg over 6 to 8 hr 3 YTH 24/54 400ug/kg over 6 to 8 hr 4 YTH 24/54 400ug/kg over 6 to 8 hr 5 Rest 6-8 CTL Infusion (provided CD45 MAb level <100 ng/ml)
--LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.
2x 10^7 cells/m2
1x 10^8 cells/m2 3 x 10^8 cells/m2
1 x 10^9 cells/m2"
1790565|NCT00515970|Procedure|Curettage|"Curettage without subcutaneous tissue using a 7 mm ring curette and the fountain-pen technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The curette is held between the thumb, index and middle finger. This method of holding enables precise guiding of the instrument, so that the piece of tissue can be removed in one well-targeted incision. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining. Measurement of tumor thickness in mm."
1790566|NCT00515970|Procedure|Deep excision|12 o'clock mark. Excision with a scalpel down to the subcutaneous level. Plastic reconstruction. Three vertical, parallel bread loaf sections for histology. Preparation with paraffin. Staining with hematoxylin-eosin. Histologic diagnosis including report of tumor thickness in mm. Comment on complete removal (R0 versus R1). In case of R1 excision directed reoperations are performed until R0 is achieved.
1790567|NCT00515970|Procedure|Shave excision|Shave excision with a safety margin, using a scalpel. Wound healing by secondary intention. Preparation with paraffin. Parallel vertical bread loaf sections for histology. Staining with hematoxylin-eosin. Histologic diagnosis. Comment on complete removal (R0 versus R1). In case of R1 excision a reoperation is performed until R0 is achieved.
1790568|NCT00515970|Procedure|Curettage|"Curettage with a 7 mm ring curette with the potato-peeler technique (http://www.biopsypunch.com/kuerettagetechnik.htm; accessed on March 13, 2008). The handle of the curette is held in the distal inter-digital fold of the index finger, and supported by the other fingers of the curetting hand. The thumbs serve to provide a stable base. This technique makes it possible to guide the instrument, applying greater pressure, but accuracy is reduced. After macroscopically complete removal, a safety margin is removed with the curette. It is used for histology to distinguish between R0 (excision margin without tumor cells) and R1 resection (excision margin containing tumor cells). Preparation with paraffin. Parallel, vertical sections for histologic diagnosis. Hematoxylin-eosin staining."
1790569|NCT00515983|Biological|DC/Apo-Nec|
1790570|NCT00516009|Drug|DEXAMETHASONE|
1790571|NCT00516009|Other|PLACEBO|
1790572|NCT00516022|Drug|Mistletoe extract|The drug will be administered 3 times a week at home.
1790573|NCT00516035|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine given by nasal spray
1790574|NCT00516048|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
1790575|NCT00516074|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
1790576|NCT00516074|Drug|placebo|subcutaneous injection, volume equivalent to active, twice a day
1790577|NCT00516087|Biological|Genetically modified CTLs|"LMP1- and LMP2-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line.
Three different dosing schedules will be evaluated. Each patient will receive two injections, 14 days apart, according to the following dosing schedules:
Group One Day 0 2x10^7 cells/m2 Day 14 2x10^7 cells/m2
Group Two Day 0 2x10^7 cells/m2 Day 14 1x10^8 cells/m2
Group Three Day 0 1x10^8 cells/m2 Day 14 2x10^8 cells/m2"
1790578|NCT00516100|Drug|bortezomib|MTD of bortezomib administered Days 1 and 8 plus 500 mg/m2 pemetrexed on day 1, every three weeks.
1790579|NCT00516113|Drug|paroxetine|Capsules containing either placebo or paroxetine 20 mg. The treatment start after ovulation and when the subject has experienced premenstrual irritability for 2 days. The dosage is one capsule daily at 8 AM
1790581|NCT00516152|Drug|Busulfan/Fludarabine phosphate/Tacrolimus/Methotrexate/G-CSF|"Day Preparative Regimen for GVHD Prophylaxis
7 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV
6 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV
5 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV
4 Busulfan 0.8 mg/kg IV Q6 hurs, Fludarabine 30 mg/m(2)IV
3 Fludarabine 30 mg/m(2)IV
2 REST Tacrolimus 0.01 mg/kg CIVI
1 REST 0 Unrelated Stem Cell/Bone Marrow Infusion
1 Methotrexate 5mg/m(2)IV
3 Methotrexate 5mg/m(2)IV
6 Methotrexate 5mg/m(2)IV
7 G-CSF 5mcg/kg SQ daily
11 Methotrexate 5mg/m(2)IV
90 Evaluate Response"
1790582|NCT00516165|Drug|RAD001|Oral pills taken daily in a 42-day cycle (6 weeks). Cycles will be repeated every 42 days
1790583|NCT00516178|Drug|Fish oil emulsion|0.2 g/kg FO, 3 times in 24 hours, infused over 3 hours each in cardiac surgery, or continuous infusion of 0.6 g/kg post PTCA
1790584|NCT00516178|Drug|Saline|3 infusions, perioperative or post-PTCA
1790585|NCT00516191|Drug|Liposomal Doxorubicin/Melphalan/Bortezomib|"Day 1 Bortezomib 0.7 mg/m(2)IV + Doxil 10-20 mg/m(2)IV+Melphalan 5-10mg/m(2)IV Day 4 Bortezomib 0.7 mg/m(2)IV Day 8 Bortezomib 0.7 mg/m(2)IV Day 11 Bortezomib 0.7 mg/m(2)IV
The treatment cycles will be repeated every 28 days. Dose Level 1: Doxil 10mg/m(2), Melphalan 5 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 2: Doxil 10mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 3: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 0.7mg/m(2) Dose Level 4: Doxil 20mg/m(2), Melphalan 10 mg/m(2), Bortezomib 1.0mg/m(2)"
1790586|NCT00516217|Biological|galiximab|
1790587|NCT00516243|Other|placebo|Given PO
1790588|NCT00516243|Other|quality-of-life assessment|Ancillary studies
1790589|NCT00516243|Procedure|questionnaire administration|Ancillary studies
1790590|NCT00516243|Procedure|laboratory biomarker analysis|Correlative studies
1790591|NCT00516243|Drug|defined green tea catechin extract|Given PO
1790592|NCT00516256|Behavioral|CHESS System|Internet-based computer program for 6 months.
1790593|NCT00516256|Behavioral|Cancer Information Mentor|Phone calls to the patient for 6 months.
1790594|NCT00516269|Drug|Methylphenidate|18 mg by mouth daily for 2 weeks
1790595|NCT00516269|Drug|Placebo|Capsule by mouth daily for 2 weeks
1790596|NCT00516282|Drug|CLORETAZINE|CLORETAZINE will be administered intravenously on day 7. The starting dose of CLORETAZINE will be 100 mg/m2 given within 3 hours after the last dose of Temodar on day 7. CLORETAZINE will be given as an IV infusion over 15-30 minutes via a freely flowing peripheral or central intravenous line. CLORETAZINE will be escalated by 50 mg/m2 for the second cohort then by 25 mg/m2 increments in the following cohorts of 3-6 patients using a standard phase I trial design until a MTD is determined. If dose level 2 has two DLTs then patients will be accrued to a new dose level of 125 mg/m2. Prior to receiving Cloretazine, blood will be drawn for gene methylation studies.
1790597|NCT00516282|Drug|temozolomide|Temozolomide will be given orally at a dose of 75mg/m2 daily on day 1 through 7. There will be no dose modification for this agent. Prior to receiving Temozolomide, blood will be drawn for gene methylation studies.
1790598|NCT00516295|Drug|topotecan hydrochloride|Given IV
1790599|NCT00516295|Drug|vincristine sulfate|Given IV
1790600|NCT00516295|Drug|cyclophosphamide|Given IV
1790601|NCT00516295|Biological|bevacizumab|Given IV
1790602|NCT00516308|Device|NightHawk|
1790603|NCT00516321|Drug|eltrombopag|25, 50, 75, 100 mg tablets taken once daily orally
1790604|NCT00516321|Drug|placebo|matched placebo taken once daily orally
1790605|NCT00516347|Genetic|comparative genomic hybridization|
1790606|NCT00516347|Genetic|genetic linkage analysis|
1790607|NCT00516347|Other|laboratory biomarker analysis|
1790608|NCT00516347|Other|questionnaire administration|
1790609|NCT00516347|Procedure|study of high risk factors|
1790610|NCT00516360|Device|3.15% chlorhexidine as daily antiseptic on needleless access port|3.15% chlorhexidine as daily antiseptic on needleless access port. 1 wipe used to cleanse port each time the port is accessed
1790611|NCT00516373|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
1790612|NCT00516386|Drug|RhIGF-1|35-40 mcg/k/dose twice daily SC
1790615|NCT00516412|Drug|everolimus|Patients receive oral everolimus once daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
1790616|NCT00516412|Genetic|molecular response by PCR|Bone marrow and peripheral blood samples are collected periodically and analyzed for molecular response by PCR. Molecular studies are also performed on DNA level formalin-fixed paraffin-embedded tissue
1790617|NCT00516425|Biological|pegfilgrastim|
1790618|NCT00516425|Drug|cyclophosphamide|
1790619|NCT00516425|Drug|doxorubicin hydrochloride|
1790620|NCT00516425|Drug|epirubicin hydrochloride|
1790621|NCT00516425|Genetic|proteomic profiling|
1790622|NCT00516425|Other|diagnostic laboratory biomarker analysis|
1790623|NCT00516425|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
1790624|NCT00516425|Other|pharmacological study|
1790625|NCT00516425|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
1790626|NCT00516425|Procedure|adjuvant therapy|
1790627|NCT00516438|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
1790628|NCT00516438|Drug|Topotecan|intravenous infusion
1790629|NCT00516451|Drug|BMS-690514|Tablets, Oral, 100, 200, 250 or 300 mg once daily, 29 days or more
1790630|NCT00516464|Drug|Lucentis (ranibizumab)|
1790631|NCT00516477|Biological|AAV2-hRPE65v2|Subjects will be dosed unilaterally (one eye) beginning with the lowest dose. Subjects will be injected with AAV2-hRPE65v2 by means of a subretinal injection. Dose escalation to the next cohort will be dependent on assessment of the safety data by the DSMB out to at least 4 weeks following the injection. Because there is a delay between time of delivery of AAV2 and the peak transgene expression there will be a delay of six weeks between all subjects.
1790632|NCT00516490|Drug|triptorelin acetate|Single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
1790633|NCT00516490|Drug|Na Cl %0.9|0.1 ml sterile saline subcutaneous injection on the 3rd day after embryo transfer
1790634|NCT00516503|Drug|baclofen/amitriptyline/ketamine gel|Applied topically
1790636|NCT00516516|Dietary Supplement|L-Carnitine|L-Carnitine, 1g orally, twice daily
1790637|NCT00516516|Dietary Supplement|Placebo|Placebo, similar in appearance to study tablets, given orally, twice daily.
1790638|NCT00516542|Drug|letrozole|A daily dose of 2.5 mg will be used throughout the study.
1790639|NCT00516542|Drug|DHEA|Will be dispensed in either 500mg or 1000mg tablets. Subjects will start at a dose of 500 mg and may increase up to 5000mg depending on the cohort.
1790640|NCT00516542|Other|pharmacological study|PK draws will happen on day 1 and day 14, then every 2 weeks.
1790641|NCT00516594|Procedure|Diet with polyfructans and viscous fibers or soy protein|
1790642|NCT00516607|Drug|enzastaurin hydrochloride|
1790643|NCT00516607|Drug|temozolomide|
1790644|NCT00516607|Other|pharmacological study|
1790645|NCT00516620|Behavioral|No further instruction|Participants receive Health Canada's Food Guide and Physical Activity Guide and no other intervention for the 6 months of the intervention period.
1790646|NCT00516620|Behavioral|Food Delivery|Participants receive Canada's Food Guide and Physical Activity guide, in addition to a a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products.
1790647|NCT00516620|Behavioral|Fruits (F), vegetables (V), and whole grain (WG) counseling|Participants receive Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
1790648|NCT00516620|Behavioral|Counseling to reduce soft drink intake.|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
1790649|NCT00516620|Behavioral|Food Delivery & F, V & WG counseling.|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling to increase intake of fruits, vegetables, whole grains, and vegetable protein products. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
1790650|NCT00516620|Behavioral|Food delivery & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
1790651|NCT00516620|Behavioral|F, V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counseling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
1790652|NCT00516620|Behavioral|Food delivery and F,V, WG & soft drink counseling|Participants receive Health Canada's Food Guide and Physical Activity guide, receive a weekly sample food basket for 6 months consisting of fruits, vegetables, whole grains, and vegetable protein products, and intensive dietary counseling for 6 months to increase intake of fruits, vegetables, whole grains, and vegetable protein products, and also to decrease intake of sweetened soft drink. The counselling frequency will be weekly intervals for the first month, and then monthly sessions for the second to sixth months.
1790653|NCT00516633|Behavioral|Extra information and support|Four group discussions with parents in close connection to diagnosing the children
1790654|NCT00516646|Drug|ALT-711|200 mg bid
1790655|NCT00516646|Drug|Placebo|bid
1790656|NCT00516659|Biological|Heat-Labile Enterotoxin of Escherichia coli (LT)|Subjects in Group 1 will receive two vaccinations of a patch containing 37.5µg LT 2 to 3 weeks apart.
1790657|NCT00516659|Biological|Placebo|The placebo patch contains all of the components of the active patch, but with no LT included in the formulation.
1790658|NCT00516672|Drug|pazopanib|Pazopanib oral tablet
1790659|NCT00516672|Drug|Lapatinib|Lapatinib oral tablet
1790660|NCT00516685|Biological|Recombinant Human rEGF-P64K/Montanide Vaccine|
1790661|NCT00516698|Genetic|polymorphism analysis|
1790662|NCT00516698|Other|high performance liquid chromatography|
1790663|NCT00516698|Other|laboratory biomarker analysis|
1790664|NCT00516698|Procedure|radiomammography|
1790665|NCT00516711|Drug|Sevoflurane|
1790666|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
1790667|NCT00516724|Drug|Carboplatin|intravenous injection
1790668|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
1790669|NCT00516724|Drug|Paclitaxel|Intravenous injection
1790670|NCT00516724|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|Oral
1790671|NCT00516724|Drug|Paclitaxel + Carboplatin|Intravenous injection
1790672|NCT00516737|Drug|Comparator: rizatriptan benzoate|Rizatriptan 10 mg Orally Disintegrating Tablet (ODT); one dose, treatment of a single migraine attack
1790673|NCT00516737|Drug|Comparator: Placebo|Matching placebo; one dose, treatment of a single migraine attack
1790674|NCT00516750|Drug|cisplatin|
1790675|NCT00516750|Drug|doxorubicin hydrochloride|
1790676|NCT00516750|Drug|methotrexate|
1790677|NCT00516750|Drug|vinblastine|
1790678|NCT00516750|Genetic|gene expression profiling|
1790679|NCT00516750|Procedure|neoadjuvant therapy|
1790680|NCT00516802|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
1790681|NCT00516802|Drug|dacarbazine|intravenous injection over at least 20 minutes
1790682|NCT00516828|Drug|cytarabine|subcutaneously twice daily from Day 1 to 10
1790683|NCT00516841|Drug|Volociximab|15 mg/kg weekly, IV infusions, for 8 weeks or until disease progression or unacceptable toxicity develops
1790684|NCT00516854|Drug|chlordiazepoxide 5 mg, clidinium 2.5 mg, twice daily|
1790685|NCT00516867|Radiation|UV radiation|UV radiation with 99.5% UVA and 0.5%UVB
1790686|NCT00516867|Radiation|UV radiation|UVB 1.4 % and UVA 98.6
1790690|NCT00510211|Drug|olanzapine|
1790691|NCT00510224|Drug|Sandostatin|Sandostatin 30mg intramuscular every 28 days
1790692|NCT00510237|Behavioral|"Adolescents Coping, Connecting, Empowering, and Protecting Together (Project ACCEPT)"|The intervention will consist of a combination of individual and group-based sessions in which the youth will participate. This combination allows for more intensive individualized attention as well as supportive group sessions. Youth will first participate in two individual sessions, followed by nine group sessions, and end with one additional individual session.
1790693|NCT00510250|Drug|Sorafenib|200mg PO BID x 7 days prior to Radiation and Cisplatin for Low-Risk Patients or 200mg PO BID x 7 days prior to, and 35 days during Radiation and Cisplatin for High-Risk Patients
1790694|NCT00510250|Drug|Cisplatin|40mg/m2 administered weekly via IV, with Radiation
1790695|NCT00510250|Procedure|Radiation|Administered for 30-40 days.Combination of external beam radiotherapy followed by intra-cavitary brachytherapy.
1790696|NCT00510263|Drug|Prednisolone + placebo|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
1790697|NCT00510263|Drug|Valaciclovir + placebo|Valaciclovir 500 mg 2 tablets 3 times daily for 7 days. Placebo tablets 12 per day for 5 days, tapering 2 tablets per day until day 10.
1790698|NCT00510263|Drug|Prednisolone + valaciclovir|Prednisolone 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Valaciclovir 500 mg 2 tablets 3 times daily for 7 days.
1790699|NCT00510263|Drug|Placebo + placebo|Placebo 5 mg 12 tablets per day for 5 days, tapering 2 tablets per day until day 10. Placebo 2 tablets 3 times daily for 7 days.
1790700|NCT00510276|Drug|Atomoxetine hydrochloride|20-50 mg, twice a day per by mouth for 12 weeks, followed by up to an additional 12 weeks
1790701|NCT00510276|Drug|Placebo|twice a day, by mouth for 12 weeks
1790702|NCT00510289|Drug|Sorafenib|400 mg twice a day until progression or unacceptable toxicity develops.
1790703|NCT00516906|Drug|Chlorhexidine gluconate|2% Chlorhexidine Transparent Dressing applied as needed up to 7 days of wear
1790704|NCT00516906|Drug|Transparent Adhesive Dressing|Standard of Care Non-antimicrobial Transparent Adhesive Dressing applied as needed for up to 7 days of wear
1790705|NCT00516919|Drug|Xenical + behavioral intervention|120 mg TID; Behavioral weight loss in Spanish
1790706|NCT00516919|Behavioral|Behavioral intervention + placebo|Behavioral weight loss treatment in Spanish Placebo TID
1790707|NCT00516945|Drug|Lamivudine|
1790708|NCT00516958|Drug|Topical Dermacyn|Topical Dermacyn once a day for 10 Days
1790709|NCT00516958|Drug|Topical Dermacyn and Levofloxacin|Topical Dermacyn once a day and levofloxacin 750 mg PO per day; both for 10 days
1790710|NCT00516958|Drug|Topical Saline and Levofloxacin|Topical saline once a day and levofloxacin 750 mg PO daily, both for 10 days
1790711|NCT00516971|Drug|Esomeprazole 20mg once daily|
1790712|NCT00516984|Procedure|Placebo|No-touch control condition applied while subject was at a 50-degree head-up tilt.
1790713|NCT00516984|Procedure|Sham|Touch-only sham treatment applied while subject was at a 50-degree head-up tilt.
1790714|NCT00516984|Procedure|OMT|Cervical myofascial OMT applied while subject was at a 50-degree head-up tilt.
1790715|NCT00517010|Drug|Proton beam irradiation and ranibizumab|ranibizumab 0.5mg intravitreal monthly x 4, then prn combined with low dose proton beam irradiation 24Gy (2 fractions, 24 hours apart) during the first month of study.
1790716|NCT00517023|Device|Sleuth Implantable Loop Recorder|ILR insertion under aseptic conditions in left pectoral region (local anaesthetic procedure only)
1790717|NCT00517023|Other|Other|Routine care and tests usually offered for syncope patients.
1790718|NCT00517036|Dietary Supplement|EPA omega-3 fatty acid|1 gram per day of an EPA-enriched mixture for 8 weeks
1790719|NCT00517036|Dietary Supplement|DHA omega-3 fatty acid|1 gram per day of pure DHA for 8 weeks
1790720|NCT00517036|Dietary Supplement|Placebo comparator|1 gram per day of an inactive substance for 8 weeks
1790721|NCT00517049|Drug|PRO95780|Intravenous repeating dose
1790722|NCT00517049|Drug|rituximab|Intravenous repeating dose
1790723|NCT00517062|Drug|Growth hormone (Genotropin)|Growth hormone 0.1 mg self-injected once a day subcutaneously at bedtime.
1790724|NCT00517062|Drug|Placebo|Placebo self-injected once a day subcutaneously at bedtime.
1790725|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
1790726|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
1790727|NCT00517075|Device|Transcranial Magnetic Stimulation (TMS)|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
1790787|NCT00518531|Drug|denosumab|Subjects will receive 60 mg of denosumab Q6M SC for 1 year. If a subject is randomized to Treatment Sequence A they will receive denosumab for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive denosumab for 1 year in Treatment Period 1.
1790728|NCT00517075|Device|repetitive transcranial magnetic stimulation|For rTMS, the coil is held flat on the scalp. 40 trains of 10 Hz rTMS will be delivered in trains lasting 4 seconds, with an intertrain interval of 26 seconds, for a total of 20 minutes (1600 pulses per day) at 100% motor threshold. Subjects will receive rTMS once a day, 5 days a week, for 4 weeks. During the first week of rTMS sessions only, in the event that the patient cannot tolerate these stimulation parameters, intensity relative to motor threshold may be titrated downward, in a masked fashion, to 80%, with all other dose parameters remaining the same.
1790729|NCT00517088|Drug|IPAQ|
1790730|NCT00517114|Drug|Rabeprazole 20mg twice daily|
1790731|NCT00517127|Drug|Lactated Ringer's Solution|Arm Nr 1: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Lactated Ringer's Solution will be administered.
1790732|NCT00517127|Drug|Hydroxyethylstarch 6% 130/0.4|Arm Nr 2: If corrected flow time (fTc), measured by esophageal doppler, falls below 350 msec, 250 ml of Hydroxyethylstarch 6% 130/0.4 will be administered.
1790733|NCT00517140|Procedure|Repeat Caesaen section|
1790734|NCT00517140|Procedure|vaginal delivery|
1790735|NCT00517153|Drug|miglustat|Patients aged 12 years or more randomised to the treatment group will receive 200 mg OGT 918 three times daily initially for twelve months. An additional sub-study of up to 12 patients aged under 12 years will receive a lower dose of OGT 918 according to their BSA
1790736|NCT00517166|Device|CAT (Combat Arms Tourniquet)|device
1790737|NCT00517179|Drug|Vardenafil 10mg|
1790738|NCT00517192|Drug|Tipranavir|
1790739|NCT00517192|Drug|Darunavir|
1790740|NCT00517192|Drug|Ritonavir|
1790741|NCT00517205|Procedure|Non-contrast helical computerized tomogram (NCHCT)|
1790742|NCT00517218|Drug|Genasense® (, oblimersen sodium G3139)|
1790743|NCT00518219|Drug|TW|TW,120mg/d
1790744|NCT00518232|Drug|OROS-methylphenidate|
1790745|NCT00518245|Drug|enoxaparin|Enoxaparin will be given subcutanteously at a dose of 1mg/kg every 12 hours for a minimum of 48 hours (4 doses) and a maximum of 8 days until a diagnostic / therapeutic procedure is performed, or at the discretion of the investigator.
1790746|NCT00518271|Drug|Rapamune® (Sirolimus)|
1790747|NCT00518271|Drug|Tacrolimus|
1790748|NCT00518271|Drug|Corticosteroids|Perioperative
1790749|NCT00518284|Drug|Nanoparticle Paclitaxel|Nanoparticle albumin-bound paclitaxel, 45 mg/m^2.
1790750|NCT00518297|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily for 5 Days
1790751|NCT00518297|Drug|Atazanavir|Capsule, Oral, 300 mg, twice daily for 7 Days
1790752|NCT00518297|Drug|Atazanavir + Raltegravir|Capsule/Tablet, Oral, 300/400, twice daily for 14 Days
1790753|NCT00518310|Drug|Placebo|
1790754|NCT00518310|Drug|AZAPRED|The initial dose of prednisone will be 0.5 mg/kg/day for 4 weeks, then 0.25 mg/kg/day for 8 weeks. The dose will continue to decrease at a rate of 5 to 10 mg per week, to a dose of 0.25 or 0.125 mg/kg/day. Azathioprine will be given at a dose of 2-3 mg/kg/day (max 100 mg).
1790755|NCT00518323|Drug|Paliperidone ER|3 mg or 6 mg tablet once daily for 6 weeks
1790756|NCT00518323|Drug|Placebo|Once daily for 6 weeks
1790757|NCT00518323|Drug|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
1790758|NCT00518323|Drug|Paliperidone ER|6 mg or 12 mg tablet once daily for 6 weeks
1790759|NCT00518336|Procedure|Blood sampling|Blood sampling at Visit 3, 5 and 7.
1790760|NCT00518336|Procedure|Collection of cervical specimen|Collection of cervical specimen at Visit2, 3, 4, 5, 6 and 7.
1790761|NCT00518336|Biological|Cervarix|Three doses administered intramuscularly at 0, 1 and 6 months.
1957272|NCT02468661|Drug|INC280 single agent|
1957273|NCT02468661|Drug|INC280 in combination with erlotinib|
1790764|NCT00518362|Drug|TW|TW,120 mg/d
1790765|NCT00518375|Drug|Rapamune® (Sirolimus)|
1790766|NCT00518375|Drug|Neoral® (Cyclosporine)|
1790767|NCT00518375|Drug|Corticosteroids|Left up to local practice but steroids are typically used perioperatively
1790768|NCT00518388|Behavioral|Focus Group|Focus groups each lasting about 2 hours.
1790769|NCT00518388|Behavioral|Questionnaire|Questionnaire relating to your health practices and knowledge about cervical cancer and HPV.
1790770|NCT00518401|Biological|Mesendo|Intramuscular injection of 0.5 cc per site of the combination stem cell mixture in approximately 40 different ischemic sites of the gastrocnemius area of the calf.
1790771|NCT00518414|Other|Marketed infant formula with DHA and ARA|
1790772|NCT00518414|Other|Milk-based infant formula with DHA and ARA|
1790773|NCT00518414|Other|Milk-based formula with DHA, ARA, prebiotics|
1790774|NCT00518427|Drug|Insulin Glargine|"Lantus (insulin glargine [rDNA origin] injection), individual dosing , subcutaneous injection, 100 IU/ml.
Duration of treatment will be judge by the investigator. Last QoL assessed in the study will be 9 months after start of glargine treatment."
1790775|NCT00518453|Biological|Surface antigen inactivated influenza vaccine|1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
1790776|NCT00518466|Drug|topiramate|25 mg modified-release capsules
1790777|NCT00518466|Drug|phentermine|7.5 mg immediate-release capsules
1790778|NCT00518466|Drug|topiramate|100 and 25 mg immediate-release tablets
1790779|NCT00518466|Drug|phentermine|37.5 and 7.5 mg immediate-release tablets
1790780|NCT00518479|Drug|Bendroflumethiazide 2.5mg OD; Amlodipine 10mg OD|
1790781|NCT00518479|Drug|Valsartan 160mg OD; Moxonidine 400mcg OD|
1790782|NCT00518492|Procedure|Blood Sampling|Blood draws at 6 and 12 months following end of 6108A1-500 trial.
1790783|NCT00518505|Other|Symptom questionnaire|This questionnaire will assess patient outcomes before and after surgery for gastroesophageal reflux disorder.
1790784|NCT00518518|Drug|Staloral 300|Staloral 300
1790785|NCT00518518|Drug|placebo|placebo
1790786|NCT00518531|Drug|alendronate|Subjects will take 70 mg QW of oral alendronate for 1 year. If a subject is randomized to Treatment Sequence A they will receive alendronate for 1 year in Treatment Period 2. If a subject is randomized to Treatment Sequence B they will receive alendronate for 1 year in Treatment Period 1.
1790831|NCT00518921|Drug|Capadenoson (BAY 68-4986)|2mg Capadenoson, double dummy
1957274|NCT02468661|Drug|Platinum/pemetrexed|
1790788|NCT00518544|Drug|administration of hydroxyehtyl starch|colloid is administered during operation according to blood loss.
1790789|NCT00518557|Procedure|Transcatheter Arterial Chemoembolization|The interventional procedure is performed as following steps: 1)transcatheter hepatic arterial angiography(including any feeding arteries to the tumor) is performed under a DSA unit; 2) super selectively catheterizaton of feeding arteries to the tumor is reached; 3)30 mg of Andostatin (Simcere Co. China) mixtured with 5 ml Lipiodol is injected into the tumor via the feeding arteries; 4) followed by 10 mg of Epifubicin mixtured with 5 ml of Lipiodol; 5) All feeding arteries to the tumor are occluded which is confirmed by re-angiography.
1790790|NCT00518570|Drug|Levetiracetam|Levetiracetam was started at 250 mg qhs at the end of the first week of the follicular phase. Dose was gradually increased up to 1500 mg bid as tolerated or clinically effective. The treatment phase lasted 4 months.
1790791|NCT00518583|Drug|Pegylated Liposomal Doxorubicin (Doxil)|Doxorubicin administered once every three weeks Taxol administered weekly Herceptin administered weekly
1790792|NCT00518596|Dietary Supplement|Probiotic supplementation (Lactobacillus plantarum)|GastroPlan capsules from a single lot will be used. The intervention consists of L. plantarum reconstituted in sterile 2.0 cc of 5% dextrose-saline, administered orally using an opaque-amber syringe.
1790793|NCT00518622|Drug|Comparator: MK7009|Depending on group assignment, patients will receive once daily (q.d.) dosing for 8 days or twice daily (b.i.d.) dosing for 7 days plus one additional dose on Day 8.
1790794|NCT00518622|Drug|Comparator: Placebo|MK7009 Placebo
1790795|NCT00518635|Drug|Nutropin|Nutropin 0.1 mg/day self-administered once a day
1790796|NCT00518648|Other|Multifactorial fall prevention program|Individualised multifactorial fall prevention program containing PD-specific elements as well as generic elements
1790797|NCT00518648|Other|Usual care|Usual care
1790798|NCT00518674|Procedure|local infiltration analgesia|local wound infiltration with 30 ml ropivacaine 0.2 % (60 mg)
1790799|NCT00518687|Biological|V710|0.5-mL single injection of V710 (60 µg)
1790800|NCT00518687|Biological|Placebo|0.5-mL single injection of matching placebo
1790801|NCT00518700|Other|new MPS|
1790802|NCT00518700|Other|RepleniSH|
1790803|NCT00518713|Drug|Clobazam Low Dose|0.25 mg/kg/day; tablets; orally; for 15-18 weeks
1790804|NCT00518713|Drug|Clobazam Medium Dose|0.5 mg/kg/day; tablets; orally; for 15-18 weeks
1790805|NCT00518713|Drug|Clobazam High Dose|1.0 mg/kg/day; tablets; orally; for 15-18 weeks
1790806|NCT00518713|Drug|Placebo|tablets; orally; daily for 15-18 weeks
1790807|NCT00518726|Biological|Surface Antigen, Inactivated, Adjuvanted, Influenza Vaccine, Formulation 2007-2008|seasonal influenza vaccine 15ug
1790808|NCT00518739|Drug|MK2461|Patients will be administered oral MK2461 twice daily and will be treated for 28 day cycles. Patients will be enrolled in cohorts and will be treated at sequentially rising dose levels of MK2461. 60 mg dry filled capsules, escalating to 240 mg ( for dosing in Cohort 4 & beyond).
1790809|NCT00518752|Procedure|Standard Oral Care|Patients in this arm will receive standard oral care with manual brushes and routine oral hygiene products twice a day
1790810|NCT00518752|Procedure|Comprehensive Oral Care|Patients will receive a comprehensive oral care protocol using mechanical brushes and oral care products formulated for patients with a dry mouth twice a day
1790811|NCT00518765|Drug|Aliskiren|
1790812|NCT00518765|Drug|Aliskiren plus placebo|
1790813|NCT00518765|Drug|Aliskiren|
1790814|NCT00518765|Drug|Aliskiren plus placebo|
1790815|NCT00518791|Other|Multidisciplinary Care|A comprehensive individualised assessment by a dedicated multidisciplinary team (Multidisciplinary Assessment Center) and subsequent treatment by specifically trained health professionals (ParkinsonNet).
1790816|NCT00518791|Other|Usual Care|No altered organisation of care
1790817|NCT00518804|Behavioral|Functional Behavioural Skills Group and Parent Training|
1790818|NCT00518830|Other|multi-component intervention|The PND-MCI included psycho-educational groups, structured pharmacotherapy if needed, and systematic monitoring of clinical progress and treatment compliance
1790819|NCT00518830|Other|Usual care|included all services normally available in the clinics, including antidepressant medication, brief psychotherapeutic interventions or referral for specialty treatment
1790820|NCT00518843|Behavioral|FBT-BN|Mobilizing parents to curtail binge eating and purging
1790821|NCT00518843|Behavioral|SPT|Supportive the individual patient to explore factors that might underlie the eating disorder
1790822|NCT00518856|Other|Neonatal resuscitation protocol|training in neonatal resuscitation and sepsis identification early treatment
1790823|NCT00518856|Other|Standard of care|continued with current standard of care for birth attendants
1790824|NCT00518869|Drug|PG2|500 mg PG2 / 500 ml normal saline IV infusion for 3 hours once daily for 4 doses in the 1st week, 3 doses in the 2nd week and 3 doses in the 3rd week of each chemo-cycle for three cycles. Total 10 doses will be given in each cycle even with skip days.
1790825|NCT00518882|Drug|liraglutide|1.8 mg once daily for s.c. (under the skin) injection.
1790826|NCT00518882|Drug|exenatide|10 mcg twice daily for s.c. (under the skin) injection.
1790827|NCT00518895|Drug|dacarbazine plus Genasense|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus Genasense group will receive Genasense 7 mg/kg/day by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the Genasense infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
1790828|NCT00518895|Drug|dacarbazine plus placebo|Protocol therapy will be administered in 21-day cycles for up to 8 cycles. Subjects in the dacarbazine plus placebo group will receive placebo (that is, locally available commercial 0.9% Sodium Chloride Injection) by continuous intravenous infusion beginning on Day 1 and continuing for 5 days (120 hours) plus dacarbazine 1000 mg/m2 as a 60-minute intravenous infusion immediately following the conclusion of the placebo infusion. Subjects who are responding or have stable disease after 8 cycles of therapy may, at the Investigator's discretion, continue that same therapy for up to 8 additional cycles.
1790829|NCT00518908|Drug|Sevoflurane|3.2 Vol % for postconditioning
1790830|NCT00518921|Drug|Capadenoson (BAY 68-4986)|1mg Capadenoson, double dummy
1790832|NCT00518921|Drug|Capadenoson (BAY 68-4986)|4mg Capadenoson, double dummy
1790833|NCT00518921|Drug|Placebo|Placebo, double dummy
1790834|NCT00518934|Other|Study for safety and efficiency of therapeutic angiogenesis for patients with limb ischemia by transplantation of human cord blood mononuclear cell|
1790835|NCT00518947|Drug|Lithium|Treatment with lithium carbonate was initiated at a dose of 900-1200 mg/day. Serum lithium levels were monitored twice weekly, and the dose was adjusted to attain target levels between 0.8 and 1.0 mmol/L by the end of week one, with subsequent levels as high as 1.4 mmol/L permitted if needed.
1790836|NCT00518947|Drug|verapamil|The initial dose of verapamil was 80 mg b.i.d., and this was raised by 80 mg/day every three days to a maximum of 480 mg/day, unless intolerable side effects were produced at a lower level, in which case the dose was maintained at the highest tolerated amount.
1790837|NCT00518947|Drug|verapamil plus lithium|
1790838|NCT00518960|Drug|ProAlgaZyme|
1790839|NCT00518973|Drug|Quetiapine|Subjects will start with 25mg hs on day 1, 25mg bid on day 2, 25mg am and 50mg hs on day 3, 50mg bid on day 4, 50mg am and 75mg hs on day five, and 75mg bid on day six. Dosage will be increased further on an individual basis as determined by the study physician and as tolerated by the subject with a maximum dosage of 400 mg. Dose can be reduced as determined by clinical judgment. In order to determine the most effective dose, the dose of Quetiapine (or placebo) will be titrated at intervals by staff according to the previously stated guidelines, the Pittsburgh Quetiapine Medication Management Assessment and Interview. Subjects will be interviewed about the factors described above and medication dose will be adjusted upward or downward depending upon symptom persistence or side effects.
1790840|NCT00518986|Drug|armodafinil|200 mg/day
1790841|NCT00518986|Drug|placebo|placebo
1790842|NCT00519012|Drug|Sertraline to Paroxetine|For subjects enrolled in this arm, sertraline will be initiated at 25mg, increased to 50mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, sertraline will be continued and titrated at 50 - 100mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, sertraline will be continued and titrated at 50 - 100mg, whereas in the other group sertraline will be switched to paroxetine. In this switching group, paroxetine will be started at 10mg on days 15 and 16, increased to 20mg on day 17, and further increased to 40mg by a weekly 10mg increase, while sertraline will be dosed at 25mg on day 15 and terminated on day 16.
1790843|NCT00519012|Drug|Paroxetine to Sertraline|Paroxetine will be initiated at 10mg, increased to 20mg on day 3, and maintained until day 14. If subjects show an early response (i.e. a 20% improvement in the MADRS total score from baseline) at week 2, paroxetine will be continued and titrated at 20 - 40mg based on clinical judgment. On the other hand, if subjects fail to show an early response at week 2, they will be randomly divided into two groups. In one group, paroxetine will be continued and titrated at 20 - 40mg, whereas in the other group paroxetine will be switched to sertraline. In this switching group, sertraline will be started at 25mg on days 15 and 16, increased to 50mg on day 17, and further increased to 100mg by a weekly 25mg increase, while paroxetine will be dosed at 10mg on day 15 and terminated on day 16.
1790844|NCT00519038|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period with the aim to enhance the quality of care by improving patient outcomes, promoting patient safety, increasing patient satisfaction, and optimizing the use of resources. They are also developed by multi-professional teams
1790845|NCT00519038|Other|Usual Care|Usual care is the current practice actually performed in the hospital
1790846|NCT00519051|Other|monitorized pharmacotherapy with antidepressants drugs (Fluoxetine)|Fluoxetine oral,20-60 mg/day for 6 months with telephone monitorization
1790847|NCT00519064|Biological|Adjuvanted influenza vaccine|
1790848|NCT00519077|Drug|Gefitinib|Patients were started on gefitinib 250 mg orally daily for 2 weeks. At 2 weeks, patients were reevaluated and given skin toxicity grade according to the National Cancer Institute Common Toxicity Criteria version 3.0 (CTC 3.0). Patients with grade 2 or greater skin toxicity remained on 250 mg daily; in patients with grade 0-1 skin toxicity the dose 250-mg oral dose-escalating dose; each patient received treatment at the dose that produced grade 2 skin toxicity until disease progression or withdrawal.
1790849|NCT00519090|Drug|Imatinib|Administered orally as a single agent on a continuous daily schedule given 400 mg bid (twice daily) with food. One cycle comprised of 28 days.
1790850|NCT00519090|Drug|Nilotinib (AMN107)|Administered orally as a single agent on a continuous daily schedule of 400 mg bid (2 x 200 mg twice daily) without food. Once cycle comprised of 28 days.
1790851|NCT00519103|Other|exercise|
1790852|NCT00519116|Drug|Rapamune® (Sirolimus)|
1790853|NCT00519116|Drug|Tacrolimus|
1790854|NCT00519116|Drug|Perioperative Corticosteroids|The corticosteroids use was left up to the investigators decision.
1790855|NCT00519129|Device|3D-imager|3D-imager vs fluoroscopy during coloscopy
1790856|NCT00519142|Drug|placebo for mitiglinide|three times a day with meals
1790857|NCT00519142|Drug|mitiglinide|three times a day with meals
1790858|NCT00519142|Drug|mitiglinide|two times a day with meals
1790859|NCT00519155|Drug|MD05 and open flap debridement|recombinant human GDF-5 coated onto ß-tricalcium phosphate
1790860|NCT00519155|Procedure|Open flap debridement|Open flap debridement alone
1790861|NCT00519168|Procedure|Urine sample|Standard of care
1790862|NCT00519168|Device|Electrode sleep recorder|Standard of care
1790863|NCT00519168|Procedure|phlebotomy|Standard of care
1790864|NCT00519181|Drug|Valproic Acid|Valproic acid by oral route (20mg/Kg/day) during one year.
1790865|NCT00519194|Device|Epicor LP Cardiac Ablation System|Surgical ablation of permanent AF during concomitant open chest and/or open heart surgery
1790866|NCT00519194|Procedure|Surgical ablation of permanent AF|Concomitant AF ablation during mitral valve surgery
1790867|NCT00519207|Drug|Lidocaine|1g of liposomal lidocaine will be administered 30-40 minutes prior to venipuncture and occluded by a dressing.
1790868|NCT00519207|Drug|24% Sucrose Solution|2ml of 24% sucrose will be administered 2 minutes prior to venipuncture
1790869|NCT00519220|Other|Symptom questionnaire|Patients will answer questionnaires evaluating their symptoms of achalasia.
1790870|NCT00519233|Drug|AGS-1C4D4|IV
1790871|NCT00519246|Drug|Saline|Saline 5 ml administrated intravenously
1790872|NCT00519246|Drug|Opioid|Butorphanol tartrate 1 mg i.v.
1790873|NCT00519246|Drug|Opioid|Butorphanol Tartrate 2 mg i.v.
1790874|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 50 mg i.v.
1790875|NCT00519246|Drug|NSAID|Flurbiprofen Axetil 100 mg i.v.
1790876|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 10 mg i.v.
1790877|NCT00519246|Drug|Opioid|Tramadol Hydrochloride 20 mg i.v.
1790878|NCT00519259|Drug|Lobeline|
1790879|NCT00519272|Behavioral|Questionnaire|Series of surveys to be completed at the time of diagnosis and within one month after completion of treatment, taking approximately 45 minutes each time.
1790880|NCT00519285|Drug|Aflibercept|"25 mg/ml solution
6 mg/kg, 1-hour IV on Day 1 of each 3-Week cycle"
1790881|NCT00519285|Drug|Placebo (for aflibercept)|"Sterile aqueous buffered solution identical to aflibercept
1-hour IV on Day 1 of each 3-Week cycle"
1790882|NCT00519285|Drug|Docetaxel|"Marketed formulation
75 mg/m², 1 hour IV on Day 1 of each 3-week cycle (immediately after Aflibercept or placebo)"
1790883|NCT00519285|Drug|Prednisone or Prednisolone|"Marketed formulation
5 mg twice daily PO from day 1 continuously"
1790884|NCT00519298|Drug|SAM-531|dosage form : 0.5 mg and 5 mg capsules 3 different single doses : 1 mg, 3mg and 10 mg of SAM-531
1790885|NCT00519298|Other|placebo|placebo
1790886|NCT00519298|Drug|Donepezil|dosage form: 5 mg encapsulated tablets one single dose of 5 mg.
1790887|NCT00519311|Behavioral|Health Intervention Package|CHAP and Ask Diary
1790888|NCT00519324|Drug|Everolimus|10 mg/day (2 tablets of 5 mg each)
1790889|NCT00519337|Drug|Ascorbic acid|Ascorbic acid, 2 g p.o. the night before surgery followed by 500mg B.I.D. for 4 post-operative days
1790890|NCT00519337|Drug|Placebo|Placebo capsule, 4 capsules the night before surgery followed by 1 capsule B.I.D. for 4 postoperative days
1790891|NCT00519350|Procedure|Blood collection|In arterial or venous lines already present, small amounts of blood will be collected at certain timepoints following operation
1790892|NCT00519363|Drug|atorvastatin|atorvastatin 40mg, given orally daily for 3 months.
1790893|NCT00519376|Drug|GW642444M|drug
1790894|NCT00519376|Drug|GW642444H|drug
1790895|NCT00519376|Drug|placebo|
1790896|NCT00519389|Biological|H5N1 VLP Vaccine|Two doses - Day 0 & Day 28
1790897|NCT00519389|Biological|Placebo|Two doses - Day 0 & Day 28
1790898|NCT00519402|Other|tonsillar examination and questionnaire completion|
1790899|NCT00519415|Other|Tongue plate|A functional appliance use for maxillary protraction.It has two adams clasp and two C clasp to retained the appliance and long palatal plate in the canine area which cages the tongue and transfer the force of the tongue during physiological activity to the upper arch. It has posterior bite plate and middle screw for maxillary expansion.It should be used all the time except meal time and brushing the teeth,the acrylic appliance makes specifically for the patient.
1790900|NCT00519415|Other|Facemask|An extraoral appliance use for treatment of maxillary deficiency in growing patients.It takes anchorage from chin and forehead, it has removable intraoral appliance with hooks for elastics that exerted a force of 300 gr.It should be used 14 hours a day.
1790901|NCT00519428|Drug|escitalopram|10mg/d increasing by 10 mg/week to a maximum of 40 mg/d if tolerated and not remitted
1790902|NCT00519428|Drug|bupropion extra long (XL)|150mg/d increasing to 300 mg/d after 1 week and 450 mg/d after 3 weeks, all increases if tolerated and not remitted
1790903|NCT00519428|Drug|escitalopram + bupropion|same dosing schedule as for monotherapy
1790904|NCT00519441|Other|pH study|All patients will have 48 hour pH study
1790905|NCT00519454|Other|Peripheral lab draws|100ml blood for analysis, taken no more than 4 times in one year.
1790906|NCT00519467|Drug|Chlorproguanil-dapsone-artesunate (CDA)|
1790907|NCT00519480|Drug|GSK189075|GSK189075 will be available as an oral tablet with dosing strengths of 500 milligrams and 250 milligrams.
1790908|NCT00519480|Drug|Metformin|Metformin will be available as an immediate release oral tablet with dosing strengths of 500 milligrams and 850 milligrams.
1790909|NCT00519480|Drug|Placebo|Placebo will be available as an oral tablets.
1790910|NCT00519493|Procedure|Suture|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with sutures.
1790911|NCT00519493|Device|Clozex|One keloid will be surgically excised and the surgical wound generated will be randomized to be closed with Clozex.
1790913|NCT00519519|Drug|Omeprazole|intravenous 80mg bolus followed by 8mg / hr for 3 days
1790914|NCT00519532|Drug|Rotigotine|"Rotigotine transdermal patches:
10cm2 (2mg/24h); 20cm2 (4mg/24h); 30cm2 (6mg/24h); 40cm2 (8mg/24h)
Optimal dosing: The maximum rotigotine dose allowed is 16mg/24h"
1790915|NCT00519545|Behavioral|Prayer|Data collection on physiological biomarkers
1790916|NCT00519558|Drug|somatropin|
1790917|NCT00519571|Device|ImplantLock device|dental implant
1790918|NCT00519584|Drug|Ropivacaine|30 ml 0.5%
1790919|NCT00519584|Drug|dex|8 mg (2 ml)
1790920|NCT00519584|Drug|Bupivacaine|30 ml 0.5%
1790921|NCT00519584|Drug|Saline|0.9% saline; systemic and local
1790922|NCT00519597|Device|ResMed S8 (Auto-CPAP)|AutoCPAP during sleep
1790923|NCT00519610|Other|Chart Review|Patients' charts will be reviewed for relevant medical information.
1790924|NCT00519623|Other|PassPort(R) Transdermal Insulin Delivery System|The PassPort(R) Transdermal Insulin Delivery System is a drug-device combination product used to create micropores in the skin to enable transdermal delivery of insulin.
1790925|NCT00519636|Drug|FPNS|fluticasone propionate nasal spray
1790926|NCT00519636|Drug|FFNS|fluticasone furoate nasal spray
1790927|NCT00519636|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
1790928|NCT00519636|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
1790929|NCT00519649|Biological|Engerix™-B Kinder|Intramuscular injection, 1 dose
1790930|NCT00519662|Drug|SNS-314|"Stage 1 - Escalating doses of SNS-314 Injection on days 1, 8 and 15
Stage 2 - Same as stage 1 except SNS-314 Injection is administered at the maximum tolerated dose established in stage 1"
1790932|NCT00519688|Drug|Thalidomide|100 mg, BID
1790933|NCT00519688|Drug|Tegafur/Uracil|125 mg/m2, based on tegafur, BID
1790934|NCT00519701|Drug|hydroxyurea|
1790935|NCT00519714|Dietary Supplement|1-Methylnicotinamide (1-MNA)|Following a 6-8-week placebo and dietary-controlled baseline period, 195 men and women will be randomized to receive placebo, 30 mg MNA or 90 mg MNA three times daily for twelve weeks.
1790936|NCT00519714|Dietary Supplement|Placebo|Placebo
1790937|NCT00519727|Drug|ISIS 325568|"4 arms of single dose s.c. injections: A 50 mg B 100 mg C 200 mg D 400 mg 4 arms of multi-dose: 3 i.v. infusions over 1 week followed by 5 weekly s.c. injections AA 50 mg BB 100 mg CC 200 mg DD 400 mg or EE 50 mg
Placebo: 0.9% Sodium Chloride"
1790938|NCT00519740|Other|inhalative specific bronchial provocation with grass-pollen|
1790939|NCT00519753|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination ophthalmic solution (DuoTrav)|One drop in study eye(s) once daily in the evening (at 8:00 PM) for 12 weeks
1790940|NCT00519779|Dietary Supplement|omega-3 supplementation|2.5 g/day omega-3
1790941|NCT00519779|Dietary Supplement|Oral omega-3 fish oil placebo|to match experimental dosage
1790942|NCT00519792|Drug|Omega DUROS device|Omega DUROS device 25mcg inserted SC for 48 weeks Omega DUROS device 50mcg inserted SC for 48 weeks
1790943|NCT00519805|Drug|dalteparin|
1790944|NCT00519805|Procedure|quality-of-life assessment|
1790945|NCT00519818|Drug|Chronocort|Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration
1790946|NCT00519818|Drug|Cortef|Cortef 3 times daily(total dose 30 mg)for minimum of 7 days
1790947|NCT00519831|Biological|cetuximab|400 mg/m² week 1,then 250 mg/m² weekly
1790948|NCT00519831|Drug|vinflunine|Vinflunine 320 mg/m² every 21 days
1790949|NCT00519844|Drug|somatropin|
1790950|NCT00519857|Drug|Tibolone|1.25 mg p.o, once daily for 3 years
1790951|NCT00519857|Drug|Placebo|Tablet p.o, once daily for 3 years
1790952|NCT00519870|Drug|nifedipine, losartan|I: nifedipine 30 mg/d II: losartan 50 mg/d
1790953|NCT00519870|Drug|losartan|II: losartan
1790954|NCT00519870|Drug|Nifedipine, losartan|I: nifedipine II: losartan
1790955|NCT00519883|Other|Exercise|
1790956|NCT00519883|Other|Supportive Care|
1790957|NCT00519896|Drug|sunitinib malate|Given PO
1790958|NCT00519909|Other|Dairy calcium|Diets with different content of calcium and fat
1790959|NCT00519922|Other|Kinesthesia, Balance, and Agility (KBA) Exercise|"Participants will exercise three times per week 20 to 30 minutes per session. Agility/Active Range of Motion exercises provide warm-up, improve joint range-of-motion & agility, dynamic proprioception,functional strength & endurance.
Kinesthesia & Balance Training will challenge the subject's proprioceptive and neuromuscular control mechanisms to adapt and stabilize the knee joints during dynamic ADL activities (walking, climbing, etc); improve static and dynamic balance and sense of stability & confidence in ADL activities.
Soft pads will be used to progress some of the kinesthesia & balance challenge training. Thera-Band® balance pads at 3 levels of softness will be used. These balance pads allow both appropriate starting difficulty and progression of difficulty level (i.e., the softer the pad, the greater the difficulty). Subjects will demonstrate safe balance on a stable surface (i.e. one-footed standing on floor) prior to progressing to the first level of the soft pads."
1790960|NCT00519922|Other|Standard LE Strength Training|Standard therapeutic exercises for knee OA which are widely used. Body weight and Thera-Band® color coded elastic bands will be used as appropriate to provide resistance. Exercises will be progressed according to the individual participant's improvement. All training for the ST condition will be conducted on stable surfaces (e.g. standing on floor, sitting in chair, lying on floor). Exercises may include 4-direction straight leg lifts, heel slides, quad sets, internal & external hip rotation, heel raises, toe raises, knee extension, knee flexion, partial squats/wall slides, etc.
1790961|NCT00519935|Behavioral|Multisystemic Therapy|MST is an individualized approach that begins with a comprehensive, multi-informant assessment that allows for the development of treatment goals and interventions that are individually tailored for each family. Therapists draw upon a menu of evidenced-based interventions that include cognitive-behavioral therapy, parent training and behavioral family systems therapy.
1790962|NCT00519948|Drug|new MPS, opti-free express no rub MPS|
1790963|NCT00519961|Device|Elecsys®proBNP|
1790964|NCT00519974|Other|counseling intervention|
1790965|NCT00519974|Other|study of socioeconomic and demographic variables|
1790966|NCT00519974|Procedure|management of therapy complications|
1790967|NCT00519974|Procedure|psychosocial assessment and care|
1790968|NCT00519987|Drug|intranasal ketamine|intranasal ketamine
1790969|NCT00520000|Drug|Carboplatin|standard dose of area under the curve (AUC) AUC of 6 in all arms
1790970|NCT00520000|Drug|Abraxane|75mg/m2 - 150 mg/m2 given on days 1, 8, 15 of every 28 day cycle
1790971|NCT00520000|Drug|Abraxane|180mg/m2 - 340mg/m2, repeated every 21 days
1790972|NCT00520000|Drug|Abraxane|100mg/m2 - 175/mg/m2 given on days 1, 8 of every 21 day cycle
1790973|NCT00520013|Drug|bevacizumab|
1790974|NCT00520013|Drug|erlotinib|
1790975|NCT00520013|Drug|paclitaxel|
1790976|NCT00520013|Drug|carboplatin|
1790977|NCT00520026|Drug|lithium|
1790978|NCT00520026|Drug|placebo|
1790980|NCT00520052|Drug|zoledronic acid|5 doses of 4mg iv given 3 monthly over one year (as infusion over 15 mins in 100 mls normal saline)
1790981|NCT00520065|Other|enteral nutritional formula|Meal glucose tolerance test
1790982|NCT00520065|Other|Diabetes specific enteral product|Meal Glucose tolerance test
1790983|NCT00520091|Drug|CPT- 11|65mg/m2 given on days 1, 8 ,22 and 29 prior to surgery
1790984|NCT00520091|Drug|Cisplatin|Cisplatin 30mg/m2 will be administered on days 1, 8, 22 and 29 prior to surgery
1790985|NCT00520091|Drug|Celecoxib|400 mg, orally, twice per day beginning on day minus 3 and continue until the end of chemoradiation with CPT-11 and Cisplatin
1790986|NCT00520091|Radiation|Radiation|4,500 cGy in 180 cGy fractions 5 days per week, over a period of 5 weeks
1790987|NCT00520091|Procedure|Surgery|Surgery will occur prior to chemoradiation therapy for those patients with resectable disease
1790988|NCT00520104|Drug|intranasal ketamine|drug interaction
1790989|NCT00520130|Biological|Rituximab|Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.
1790990|NCT00520130|Drug|Cyclosporine|Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.
1790991|NCT00520130|Drug|Allogenic stem cell transplant (ASCT)|Allogenic stem cell transplant
1790992|NCT00520130|Drug|Conditioning Chemotherapy|"Fludarabine:30 mg/m(2) per day IV infusion over 30 minutes, daily. On days -6, -5, -4, and -3.
Cyclophosphamide:1200 mg/m(2) per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m(2) per day IV infusion, Daily on days 6, -5,-4, and -3"
1790993|NCT00520130|Drug|TMS|Tacrolimus: starting day -3 before transplant, given initially at 0.02 mg/kg/day CIV. Continue IV and then switch to an equivalent oral dose (when patient taking po) titrated for a goal level of 5 to 10 ng/ml; Sirolimus: given as an initial loading dose of 12 mg p.o. on day -3 pre-transplant, 4 mg starting day -2 pre-transplant and titrated for levels 3-12 ng/ml; Methotrexate 5 mg/m2 IV on days +1, +3, +6, and +11 post-transplant. Tacrolimus and sirolimus will be tapered at day +63, day +119 and day +180 post-transplant as tolerated.
1790994|NCT00520130|Drug|FLAG|Fludarabine:25 mg/m(2) per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m(2) IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day subcutaneous (SC) beginning 24 hours PRIOR to initiation of chemotherapy
1790995|NCT00520130|Drug|EPOCH-F|Fludarabine:25 mg/m(2) per day IV infusion over 30 minutes, daily on days 1-4 Etoposide :50 mg/m(2) per day continuous IV infusion over 24 hours on days 1-4 Doxorubicin:10 mg/m(2)/day CIV, days 1-4 Vincristine:0.4 mg/m(2) per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide:750 mg/m(2) IV infusion over 30 minutes on day 5
1790996|NCT00520130|Biological|Alemtuzumab|Alemtuzumab:20 mg/day IV over 8 h on days 8 to 4 pre-transplant.
1790997|NCT00520143|Biological|alglucosidase alfa (recombinant human acid alpha-glucosidase [rhGAA])|IV infusion: 20mg/kg qow
1790998|NCT00520156|Device|Continuous positive airway pressure (CPAP)|Patients diagnosed with obstructive sleep apnea (OSA) will be offered standard of care treatment of CPAP (patients given oral appliances for OSA are excluded from our study). Note: our study is a survey-based and observational study following patients who are being evaluated for sleep disorders. Those patients diagnosed with OSA would be offered CPAP or possibly an oral appliance regardless of whether they are entered into our study or not.
1790999|NCT00520169|Drug|intranasal ketamine|A randomized, open label, single center, single-dose study to determine the absolute bioavailability and nasopharyngeal absorption of PMI-150 (intranasal ketamine) 30mg in healthy adult volunteers. The Pilot Phase will be conducted as a parallel study, while the Test Phase will be conducted as a crossover study.
1791000|NCT00520182|Behavioral|MUFA diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). MUFA diet included only low glycemic index carbohydrates. The diet consisted of 35% carbohydrates and 45% fat (50% of them were mono-unsaturated fatty acids [MUFA]). Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
1791001|NCT00520182|Behavioral|ADA 2003|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). The carbohydrates are with mixed glycemic index. The diet contains 50-55% carbohydrates, 30% fat and 15-20% protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
1791002|NCT00520182|Behavioral|Low Glycemic index (LGI) diet|Patients were advised to consume 23 cal/kg/day. The diet contained sodium (up to 3000mg/day), potassium (more than 3000 mg/day), calcium (around 1300 mg/day) and magnesium (more than 800 mg/day). LGI diet included only low glycemic index carbohydrates. The diet consisted of 50-55% carbohydrates, 30% fat and 20%. protein. Participants were advised to eat 4-6 meals per day according to their lifestyle and to participate in 30-45 min of aerobic activity at least 3 days a week.
1791003|NCT00520195|Behavioral|Physical activity|Climbing stairs instead of taking elevators at worksite during 12 weeks.
1791004|NCT00520208|Drug|Tamibarotene|For induction therapy, tamibarotene will be self-administered via tablets on an outpatient basis at a dose of 6 mg/m2 per day, taken orally, in two divided doses approximately one hour after breakfast and dinner. Induction therapy will continue for a maximum of 56 days until either a morphologic leukemia-free state or complete response (CR) has been achieved. For patients who achieve a CR with induction therapy, consolidation therapy will commence 4 to 8 weeks after the end of induction therapy. For patients who have a morphologic leukemia-free state after induction therapy but who fail to achieve a CR, consolidation therapy will commence 8 weeks after the end of induction therapy.
1791005|NCT00520234|Drug|Caspofungin|50 mg IV daily
1791006|NCT00520234|Drug|Normal Saline|100 cc IV daily
1791007|NCT00520247|Drug|enalapril plus folic acid|enalapril 10.0 mg daily for 8 weeks (the control group); enalapril 10.0 mg plus folic acid 0.4 mg daily for 8 weeks (Low-dose group); enalapril 10.0 mg plus folic acid 0.8 mg daily for 8 weeks (High-dose group)
1791010|NCT00520273|Device|cobas s 201 TaqScreen MPX Test|Donors testing reactive for one or more of the viral markers will be advised to seek further advice/treatment from their physician.
1791011|NCT00520286|Drug|Modafinil|200 mg or 400 mg /daily
1791012|NCT00520286|Drug|Placebo|Placebo / daily
1791013|NCT00520299|Drug|ADI PEG 20|Intramuscular injections were administered into the deltoid, gluteal, or quadricep muscles once weekly (± 2 days) for 9 weeks during cycle 1 and 8 weeks during subsequent cycles
1791014|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
1791015|NCT00520325|Drug|Intravenous recombinant human mannose binding lectin|Intravenous(i.v.) administration for one dose. Patients will be randomized to one of three cohorts: 0 mg/kg; 0.5 mg/kg, or 1.0 mg.kg
1791016|NCT00520338|Drug|celecoxib|"placebo
celecoxib 400 mg oral single dose"
1791017|NCT00520351|Drug|ClearCare|contact lens care system
1791018|NCT00520351|Drug|Optifree Replenish|contact lens care system
1791019|NCT00520364|Other|Observation of IVF outcomes in relation to chemo history and AMH|Women undergoing IVF with or without history of chemotherapy, AMH levels compared
1791020|NCT00520377|Drug|MD05|recombinant human GDF-5 coated onto beta-tricalcium phosphate
1791021|NCT00520377|Device|Beta-TCP and autologous bone|beta-tricalcium phosphate and autologous bone
1791022|NCT00520390|Drug|EZN-2208|
1791023|NCT00520403|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
1791024|NCT00520403|Drug|Interferon alfa-2a|3 MioIU sc escalating to 18 MioIU sc, 3 times weekly
1791025|NCT00520403|Drug|Vinblastine|0.1mg/kg iv every 3 weeks
1791026|NCT00520416|Procedure|Carbon dioxide angiogram|see description of procedure
1791027|NCT00520429|Behavioral|ACCES - Adjusting to Chronic Conditions with Education and Support|The primary objective of this research is to pilot test a brief mental heath treatment specifically tailored to meet the needs of chronically ill patients with anxiety and/or depression. Using an open-trial format, the proposed study will examine the feasibility of a brief psychosocial intervention. Primary outcomes will assess intervention effects on patient and clinician rated symptoms of anxiety and depression. If proven feasible and effective among this group of participants, the intervention (due to its brief format and focus on medically ill patient needs) will possess unique characteristics that will increase the ability of medical care settings to implement mental health treatments, and will provide valuable pilot data for the development of a larger research project to determine the efficacy of this intervention among a larger group of chronically ill patients relative to usual care.
1791028|NCT00520442|Drug|ibuprofen|
1791029|NCT00520442|Drug|acetamin w codeine|
1791030|NCT00520455|Drug|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B) and condoms|levonorgestrel 0.75mg taken twice 12 hours apart (Plan B). Study subjects to take medication after unprotected vaginal intercourse
1791031|NCT00520468|Drug|Erythropoietin|40,000 units injected under the skin (SQ) weekly
1791032|NCT00520468|Drug|Cyclosporin A|300 mg (tablets) by mouth daily for 6 months
1791033|NCT00520468|Drug|G-CSF|300 mcg injected under the skin (SQ) two times per week
1791034|NCT00520468|Drug|Prednisone|60 mg per day for 7 days, taper over 1 month
1791035|NCT00520481|Drug|IMC-A12 (Cixutumumab)|10 mg/kg intravenous (i.v.)infusion over 1 hour every 2 weeks or 20 mg/kg I.V. infusion over 1 hour every 3 weeks.
1791036|NCT00520494|Drug|Vivaglobin|Human normal immunoglobulin G (IgG) for subcutaneous (SC) use.
1791037|NCT00520507|Drug|Olanzapine|Olanzapine will be taken once daily at 6pm for 1 month. Dosing will be titrated up to 5mg and then changed as clinically indicated.
1791038|NCT00520507|Drug|Placebo|An inactive form of the treatment will be taken once daily at 6pm for 1 month.
1791039|NCT00520533|Biological|Chimeric monoclonal antibody cG250|"First Cycle: cG250 10 mg/m² intravenous infusion, weekly for five weeks, followed by a two-week break. 1st & 5th dose will be trace-labeled with a radioactive substance detectable on a PET scanner (¹²⁴I-cG250)
Second cycle (investigator discretion): cG250 10 mg/m² intravenous infusion, weekly for four weeks followed by a two-week break. No ¹²⁴I-cG250 will be used in the 2nd cycle.
Up to 2 cycles available."
1791040|NCT00520533|Drug|Sunitinib malate|"First Cycle: Sunitinib 50 mg orally daily for 4 weeks (starts 8th day of 1st treatment cycle), followed by a two-week period off sunitinib.
Second cycle (investigator discretion): Sunitinib 50 mg orally daily for 4 weeks (starts on 1st day of 2nd treatment cycle), followed by a two-week period off sunitinib.
Up to 2 cycles available on-study."
1791041|NCT00520546|Other|18F-Ethylcholine Positron Emission Tomography (FEC-PET)|"PET scans were performed on a LSO scanner (ECAT ACCEL, Siemens, Erlangen, Germany) by using a multiphase protocol starting with a cold transmission scan of the lower pelvis. This was followed by a list mode emission scan with 10 frames à 1 minute starting immediately after the administration of 3.3MBq [18F]Fluoroethylcholine chloride (FEC; Eckert & Ziegler EURO-PET Berlin GmbH) as a bolus through the cubital vein. After a short gap due to computer processing time the whole body scan was performed starting at the upper thoracic aperture down to the proximal femur. Acquisition parameters were 3 minutes emission scan and 2 minutes transmission scan for each bed position. Therefore the prostate region was scanned again at 45 minutes p.i. (post injection) A delayed local acquisition at 65 minutes over the lower pelvis with 6 minutes emission and 2 minutes transmission finished the diagnostic acquisition procedure."
1791042|NCT00520546|Other|Endorectal Magnetic Resonance Imaging (1.5Tesla) (eMRI)|The MRI examination was performed on a 1.5Tesla MRI system (Gyroscan ACS-NT, Philips, Hamburg, Germany) with combined QBody and endorectal coil. Pelvic assessment and lymph node staging was effected with 5mm T2 weighted (T2w) turbo spin echo (TSE) transversal and a coronal short-tau inversion recovery (STIR) sequence. For prostate assessment, 3mm endorectal T2w spin echo (SE) sagittal, transversal and coronal sequences were acquired.
1791043|NCT00520572|Drug|AZD9056|
1791044|NCT00520572|Drug|Etanercept|
1791045|NCT00520572|Drug|Placebo|
1791046|NCT00520585|Drug|atorvastatin|atorvastatin 20 mg once vs. atorvastatin 80 mg once vs. placebo
1791047|NCT00520598|Biological|Comparator: V505 formulation 1|0.5 ml injection of V505 formulation 1 as 3 dose regimen at Day 1, Month 2 and Month 6.
1791048|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 3 dose regimen at Day 1, Month 2 and Month 6.
1791049|NCT00520598|Drug|Comparator: V505 formulation 2|0.5 ml injection of V505 formulation 2 as 2 dose regimen at Day 1 and Month 6.
1791050|NCT00520598|Biological|Comparator: V505 formulation 3|0.5 ml injection of V505 formulation 3 as 2 dose regimen at Day 1 and Month 6.
1791051|NCT00520598|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant|0.5 ml injection of Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine as 3 dose regimen at Day 1, Month 2 and Month 6.
1791052|NCT00520598|Biological|Comparator: Placebo (unspecified)|0.5 ml injection of placebo to V505 as a 1 dose regimen at Month 2.
1791053|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify for entry into lottery. Call-in weights are verified at monthly weigh-ins.
1791054|NCT00520611|Behavioral|Financial Incentives|Participants call in their weight on daily basis. Participants must report under their daily targets to qualify to receive daily incentive. Call-in weights are verified at monthly weigh-ins.
1791055|NCT00520624|Device|inspiratory muscle strength training|
1791056|NCT00520624|Procedure|Surgery|
1791057|NCT00520637|Drug|EZN-2208|
1791058|NCT00520650|Drug|Aripiprazole|
1791059|NCT00520663|Drug|14C-SB649868|SB-649868 will be provided as powder in a bottle which will be reconstituted into a solution prior to dosing via a hard gelatin capsule. Each subject will receive one unit dose of SB-649868 30 milligram reconstituted powder presented in a size 00 capsule once. The capsule will be swallowed with 160 milliliters of water.
1791060|NCT00520676|Drug|pemetrexed|500 mg/m^2, IV, q 21 days x 6 cycles maximum
1791061|NCT00520676|Drug|docetaxel|75 mg/m^2, IV, q 21 days x 6 cycles maximum
1791062|NCT00520676|Drug|carboplatin|AUC 5 mg*min/mL, IV, q 21 days x 6 cycles maximum
1791063|NCT00513123|Procedure|Colposcopy|As part of routine colposcopic evaluation, patients will undergo routine colposcopy with the digital colposcope (DC) will then be used to take an image of the vagina and cervix.
1791064|NCT00513136|Behavioral|Group based mind body medicine intervention|Small groups of women (5-15) will participate in 10 weekly sessions that will include learning relaxation and yoga techniques, principles of exercise and nutrition, cognitive behavioral therapy and exploration of common issues and concerns
1791065|NCT00513136|Behavioral|Group-based mind body medicine intervention + family focus|In addition to the 10 weekly group-based sessions, women and their key family members will meet twice with a cognitive therapist and family members will participate in selected aspects of the 10 week program.
1791066|NCT00513149|Drug|Clopidogrel|Clopidogrel 600 mg loading
1791067|NCT00513162|Drug|Valproate|Starting Dose of 10 mg/kg By Mouth Daily
1791068|NCT00513162|Drug|Etoposide|25 - 50 mg/m^2 By Mouth Daily
1791069|NCT00513188|Biological|denileukin diftitox|
1791070|NCT00513188|Drug|cyclophosphamide|
1791071|NCT00513188|Drug|cytarabine|
1791072|NCT00513188|Drug|doxorubicin hydrochloride|
1791073|NCT00513188|Drug|leucovorin calcium|
1791074|NCT00513188|Drug|methotrexate|
1791075|NCT00513188|Drug|prednisone|
1791076|NCT00513188|Drug|vincristine sulfate|
1791077|NCT00513188|Genetic|protein expression analysis|
1791078|NCT00513188|Other|flow cytometry|
1791079|NCT00513188|Other|laboratory biomarker analysis|
1791080|NCT00513201|Drug|lyspro|
1791081|NCT00513201|Drug|regular insulin|
1791082|NCT00513214|Drug|XOMA 052|"Part 1, Single IV infusion at one of six dose levels (mg/kg).
Part 2, Single SC injection at one of three dose levels (mg/kg).
Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
1791083|NCT00513214|Drug|Placebo|"Part 1, Single IV infusion at one of six dose levels (mg/kg).
Part 2, Single SC injection at one of three dose levels (mg/kg).
Part 3, Three biweekly SC injections at one of two dose levels (mg/kg)."
1791084|NCT00513240|Drug|Erythropoetin|Erythropoetin 500 units/kg IV x 3 : dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2
1791085|NCT00513240|Drug|Normal saline|Normal saline placebo in 3 doses:dose 1. 12-72 hours preoperatively, dose 2. Postoperative day #1, 48 hours after separating from cardiopulmonary bypass, and dose 3. postoperative day #3, 48 hours after dose #2.
1791086|NCT00513253|Drug|lapatinib|
1791087|NCT00513266|Biological|bevacizumab|
1791088|NCT00513266|Biological|cetuximab|
1791089|NCT00513266|Drug|fluorouracil|
1791090|NCT00513266|Drug|irinotecan hydrochloride|
1791091|NCT00513266|Drug|leucovorin calcium|
1791092|NCT00513266|Drug|oxaliplatin|
1791093|NCT00513266|Other|laboratory biomarker analysis|
1791094|NCT00513266|Procedure|adjuvant therapy|
1791095|NCT00513266|Procedure|biopsy|
1791096|NCT00513266|Procedure|conventional surgery|
1791097|NCT00513266|Procedure|neoadjuvant therapy|
1791098|NCT00513279|Drug|GSK618334|GSK618334 will be available as white to off-white coated tablets. GSK618334 will be swallowed with 250 milliliters (mL) of water.
1791099|NCT00513279|Drug|GSK618334 matching placebo tablets|GSK618334 placebo tablets visually match the active GSK618334 tablets and contain the same excipients except for the omission of the active ingredient. GSK618334 matching placebo will be swallowed with 250 mL of water.
1791100|NCT00513292|Drug|Cyclophosphamide|Given IV
1791101|NCT00513292|Drug|Epirubicin Hydrochloride|Given IV
1791102|NCT00513292|Other|Laboratory Biomarker Analysis|Correlative studies
1791103|NCT00513292|Drug|Paclitaxel|Given IV
1791104|NCT00513292|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1791105|NCT00513292|Biological|Trastuzumab|Given IV
1791106|NCT00513305|Drug|Arsenic trioxide|Arsenic trioxide will be administered intravenously (iv) at a dose of 0.25 mg/kg.
1791107|NCT00513305|Drug|Low-dose cytarabine alone|Cytarabine will be administered at a dose of 10 mg/m^2 subcutaneously (sc) twice a day (bid).
1791108|NCT00513331|Procedure|Endoscopy|Initial Assessment for lesions can be based on information obtained from previous upper endoscopies and or pathology reports. Repeat Endoscopic assessments are based on initial and follow-up assessments.
1791109|NCT00513331|Procedure|Radiofrequency ablation protocol|Ablation using the HALO 360 system according to protocol established by BARRX, Inc.
1791110|NCT00513331|Procedure|Endoscopic mucosal resection protocol|Excision of lesion using DUETTE, marketed by Wilson-Cook
1791111|NCT00513344|Dietary Supplement|Dark Chocolate|1 portion
1791112|NCT00513344|Dietary Supplement|Milk Chocolate|1 portion
1791113|NCT00513344|Dietary Supplement|"Control (polyphenol-free) Chocolate"|one portion
1791114|NCT00513357|Drug|Melatonin|20 mg by mouth daily for 4 Weeks
1791115|NCT00513357|Drug|Placebo|Capsule by mouth daily for 4 Weeks
1791116|NCT00513370|Biological|Humira (adalimumab)|Study drug will be provided as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). Loading dose of 80 mg of adalimumab subcutaneously (sc) at Baseline, and 40 mg of adalimumab sc at Week 1, followed by 40 mg of adalimumab sc every other week (eow) for 24 weeks.
1791170|NCT00513604|Drug|Fludarabine phosphate|Given intravenously 25 mg/m^2/day over 15-30 minutes, day -5 to -1
1791117|NCT00513383|Drug|Panitumumab|Part A: Intravenously once a week for 7 weeks Part B (Induction Chemotherapy): Intravenously on Day 1 of a 21-day cycle for 3 cycles Part B (After Induction chemotherapy): Intravenously once a week for 7 weeks at the dosing level established during Part A
1791118|NCT00513383|Drug|Carboplatin|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
1791119|NCT00513383|Drug|Paclitaxel|Part A: Intravenously once weekly for 7 weeks Part B (Following induction therapy): Intravenously once a week for 7 weeks
1791120|NCT00513383|Radiation|Intensity Modulated Radiation Therapy|Part A: Daily five days a week for 7 weeks Part B (After Induction therapy): Daily five days a week for 7 weeks
1791121|NCT00513383|Drug|5-Fluorouracil|Intravenously at one of two dose levels on days 1-4 of a 21-day cycle for three cycles
1791122|NCT00513383|Drug|Docetaxel|Intravenously on day 1 of a 21-day cycle for 3 cycles
1791123|NCT00513383|Drug|Cisplatin|Intravenously on day 1 of a 21-day cycle for 3 cycles
1791124|NCT00513396|Drug|Isoniazid|"High-dose isoniazid (16-18 mg/kg/day) in addition to standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
Regular dose isoniazid (5 mg/kg/day) in addition to standard regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)"
1791125|NCT00513396|Drug|Placebo|Similar appearing and similarly packaged placebo tablets in addition to the standardized regimen that included the following: kanamycin (15 mg/kg/day), levofloxacin (7.5-15 mg/kg/day), protionamide (10-20 mg/kg/day), cycloserine (10-20 mg/kg/day) and p-aminosalicylic acid (150 mg/kg/day)
1791126|NCT00513409|Biological|Synflorix|Intramuscular injection, 1 or 2 doses
1791127|NCT00513409|Biological|Infanrix Hexa|1 Intramuscular injection
1791128|NCT00513409|Biological|Havrix|1 Intramuscular injection
1791129|NCT00513422|Dietary Supplement|Glucosamine sulphate and chondroitin|"Glucosamine: Two 750mg capsules once daily for two years;
Chondroitin: Two 400mg capsules once daily for two years."
1791130|NCT00513422|Dietary Supplement|Glucosamine sulphate|"Glucosamine: Two 750mg capsules once daily for two years;
Placebo Chondroitin: Two capsules once daily for two years."
1791131|NCT00513422|Dietary Supplement|Chondroitin sulphate|"Chondroitin sulphate: Two 400mg capsules once daily for two years;
Placebo glucosamine: Two capsules once daily for two years."
1791132|NCT00513422|Dietary Supplement|Placebo capsules for glucosamine and chondroitin|"Two placebo glucosamine capsules once daily for two years;
Two placebo chondroitin capsules once daily for two years."
1791133|NCT00513435|Drug|saracatinib|Given PO
1791134|NCT00513435|Other|laboratory biomarker analysis|Correlative studies
1791135|NCT00513448|Other|Group wellness intervention|
1791136|NCT00513448|Other|Individualized physical rehabilitation|
1791142|NCT00513474|Drug|busulfan|Busulfan 3.2 mg/kg/day from day -7 to day -4 as standard of care for myeloablative (bone marrow depletion) conditioning at the investigator's discretion
1791143|NCT00513474|Drug|cyclophosphamide|Cyclophosphamide as standard of care for myeloablative conditioning at the investigator's discretion
1791144|NCT00513474|Drug|cyclosporin-A|Cyclosporin-A as standard of care for GVHD prophylaxis at the investigator's discretion
1791145|NCT00513474|Drug|etoposide|Etoposide as standard of care for myeloablative conditioning at the investigator's discretion
1791146|NCT00513474|Drug|methotrexate|Methotrexate 1.5 mg/kg/day on days -3, -2, and -1 as standard of care for GVHD prophylaxis at the investigator's discretion
1791147|NCT00513474|Drug|rasburicase|Rasburicase 0.20 mg/kg intravenous infusion over 30 minutes for 5 to 7 days
1791148|NCT00513474|Drug|sirolimus|Sirolimus as standard of care for GVHD prophylaxis at the investigator's discretion
1791149|NCT00513474|Drug|tacrolimus|Tacrolimus as standard of care for GVHD prophylaxis at the investigator's discretion
1791150|NCT00513474|Procedure|allogeneic hematopoietic stem cell transplantation|
1791151|NCT00513474|Procedure|peripheral blood stem cell transplantation|
1791152|NCT00513474|Radiation|total-body irradiation|Total body irradiation 13.2 Gy over 8 fractions from day -7 to day - 4 for myeloablative conditioning at the investigator's discretion
1791153|NCT00513474|Drug|fludarabine|Fludarabine 40 mg/m^2/day from day -6 to day -3 as myeloablative conditioning at the investigator's discretion
1791154|NCT00513474|Drug|allopurinol|Allopurinol per institutional guidelines
1791155|NCT00513487|Drug|Dust mite extract, Fluticasone, Methacholine|Dust mite extract, Fluticasone, Methacholine
1791156|NCT00513500|Drug|Coartem and amoxicillin|Perform RDT and give Coartem for malaria and give amoxicillin for fast breathing
1791157|NCT00513500|Drug|Coartem|Give Coartem without RDT and refer fast breathing
1791158|NCT00513513|Drug|TMC114 (darunavir) / ritonavir|
1791159|NCT00513526|Biological|Gardasil|week 0, 8, 24, 128
1791160|NCT00513539|Drug|porfimer sodium|
1791161|NCT00513539|Procedure|biliary stenting|
1791162|NCT00513552|Drug|Rifabutin, Clarithromycin, and Clofazimine|Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
1791163|NCT00513565|Drug|single dose|Subjects will receive single doses of GSK561679, lorazepam, or placebo at each treatment session.
1791164|NCT00513578|Biological|PR1 leukemia peptide vaccine|
1791165|NCT00513578|Biological|incomplete Freund's adjuvant|
1791166|NCT00513578|Biological|sargramostim|
1791167|NCT00513604|Biological|aldesleukin|Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
1791168|NCT00513604|Biological|therapeutic autologous lymphocytes|Given as infusion, up to 3 x 10^11 lymphocytes (minimum of 1 x 10^9), day 0
1791169|NCT00513604|Drug|Cyclophosphamide|Given intravenously 60 mg/kg/day, day -7 to -6
1791171|NCT00513604|Radiation|Total body irradiation|600 cGy
1791172|NCT00513617|Drug|Arginine|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
1791173|NCT00513617|Drug|Placebo|Depending on the weight of the child or adult, the patients took any where between 4-10 capsules 2 times a day. Patients weighing less than 45 kilograms were on the low dose active (or placebo) so the capsules were smaller. Patients greater than or equal to 45 kgs were on the high dose active or placebo, so these capsules were larger.
1791174|NCT00513630|Drug|Glipizide|
1791175|NCT00513630|Drug|Metformin|
1791176|NCT00513643|Drug|insulin aspart|6, 12, 24 U s.c.
1791177|NCT00513643|Drug|human regular insulin|6, 12 and 24 IU sc
1791178|NCT00513656|Drug|Oxycodone|
1791179|NCT00513656|Drug|Oxycodone/Naloxone|
1791180|NCT00513669|Biological|PEV 301& 302 in virosomes|PEV 301 50 µg plus PEV 302 10 µg formulated in virosomes and injected at day 0 and 90
1791181|NCT00513669|Biological|Inflexal V (active comparator)|Inflexal V is a marketed influenza vaccine that will be given at day 0 and 90
1791182|NCT00513682|Drug|Ultrase® MT20|Ultrase® MT20 capsules will be administered orally with each meal during Day 1 to 15 in screening phase at a dose based on investigator's discretion. During Day 12 to 15, participants will receive high-fat diet and Ultrase® MT20 dose will be adjusted depending on symptoms of steatorrhea. This will be followed by a washout phase of 6 to 7 days, in which participants will receive only high-fat diet; then stabilized dose of Ultrase® MT20 capsule (as identified during screening phase) will be administered orally for 7 to 11 days during treatment phase. The stabilized dose should not to exceed 2500 lipase units per kilogram body weight per meal (lipase units/kg/meal).
1791183|NCT00513695|Drug|sunitinib malate|Given PO
1791184|NCT00513695|Drug|paclitaxel|Given IV
1791185|NCT00513695|Drug|doxorubicin hydrochloride|Given IV
1791186|NCT00513695|Drug|cyclophosphamide|Given PO
1791187|NCT00513695|Biological|filgrastim|Given SC
1791188|NCT00513695|Procedure|therapeutic conventional surgery|Undergo surgery
1791189|NCT00513695|Other|laboratory biomarker analysis|Correlative studies
1791190|NCT00513695|Other|flow cytometry|Correlative studies
1791191|NCT00513708|Behavioral|Motivation Enhancement Therapy (MET)|"Participants assigned to this arm will receive a 60-minute MET intervention in addition to usual care while hospitalized for detoxification."
1791192|NCT00513708|Behavioral|Peer-Twelve Step Facilitation (P-TSF)|"In addition to usual care while hospitalized for detoxification, participants assigned to this arm will receive a 60-minute visit by peers who are recovering from alcoholism and who are active in 12-step oriented self-help programs."
1791193|NCT00513734|Other|Hydrogel dressing|3x3cm hydrogel dressing over closed eye
1791194|NCT00513734|Other|Lacrilube ointment|lubricant put into eye (inferior formix)
1791195|NCT00513747|Biological|rituximab|Given IV over 4 hours
1791196|NCT00513747|Drug|fludarabine phosphate|Given IV over 30 minutes
1791197|NCT00513760|Dietary Supplement|Grapefruit juice|Coingestion of 240 ml of grapefruit juice with 10 mg of montelukast.
1791198|NCT00513760|Dietary Supplement|Orange Juice|Coingestion of 240 ml of orange juice with 10 mg of montelukast.
1791199|NCT00513760|Dietary Supplement|Gatorade|Coingestion of 240 ml of Gatorade with 10 mg of montelukast.
1791200|NCT00513786|Drug|Carboplatin|AUC (area under curve) 5 Intervenous (IV) over 30 minutes given every 21 days for a maximum of 6 cycles.
1791201|NCT00513786|Drug|Paclitaxel|175 mg/m2 over 3 hours given every 21 days for a maximum of 6 cycles.
1791202|NCT00513786|Drug|bevacizumab|15 mg/kg intervenous (IV) given every 21 days for a maximum of 6 cycles.
1791203|NCT00513799|Drug|Mupirocin ointment|Add a small amount of Mupirocin to the cotton end of a swab. Swab in inner nostril, then repeat in other nostril using new cotton swab with ointment. Twice daily treatment for 5 days.
1791204|NCT00513799|Genetic|Chlorhexidine showers|Apply Clorhexidine wash to entire body once daily for 5 days.
1791205|NCT00513799|Procedure|Bleach baths (dilute)|Pour 2 ounces of bleach into water-filled bath tub. Soak in bath for 15 minutes. Apply once daily for 5 days.
1791206|NCT00513799|Behavioral|Intensive education on personal hygiene|Repeat hygiene methods for 5 days.
1791207|NCT00513825|Drug|Sodium Bicarbonate|IV solution of NaCl 0.45% (Arm 1) or IV 75 cc of sodium bicarbonate 8.4% solved in 1 liter of NaCl 0.45% (Arm 2) . Each fluid is infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
1791208|NCT00513851|Drug|OSI-930|Oral OSI-930 administered once daily at increasing doses until disease progression or unacceptable toxicity
1791209|NCT00513851|Drug|OSI-930|Oral OSI-930 administered twice daily at increasing doses until disease progression or unacceptable toxicity
1791210|NCT00513864|Drug|Dextromethorphan|one time dose - 0.3mg/kg PO
1791211|NCT00513864|Drug|Codeine|one time dose - 2mg/kg PO
1791212|NCT00513864|Drug|Morphine|one time dose - 0.15mg/kg IV
1791213|NCT00513877|Drug|bortezomib|
1791214|NCT00513877|Procedure|quality-of-life assessment|
1791215|NCT00513890|Device|Infantflow [EME, Brighton, England]|
1791216|NCT00513903|Behavioral|Minimal intervention|Minimal intervention patients will be seen by a clinical pharmacist during the hospitalization period to improve continuity of pharmacy care following hospital discharge.
1791217|NCT00513903|Behavioral|Enhanced Intervention|Enhanced intervention patients will be visited in the hospital and will also be called by the clinical pharmacist following discharge to follow-up on any problems that might have developed after discharge.
1791218|NCT00513916|Dietary Supplement|soy isoflavones|High or low dose of soy isoflavones in the diet.
1791219|NCT00513929|Dietary Supplement|Zinc sulphate|Arm X : Zinc sulphate 10 mg will be given orally twice a day since admission to resolution of pneumonia episode in addition to standard antibiotic treatment.
1791284|NCT00520702|Procedure|3-Dimensional Conformal Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
1792604|NCT00524459|Procedure|neoadjuvant therapy|
1791220|NCT00513942|Other|Fetal Movement Counting|Women in the intervention group will receive an information pamphlet. The main items will be basic information and interpretation of fetal activity and instructions when to contact health professionals if experiencing DFM.
1791221|NCT00513955|Drug|bortezomib|
1791222|NCT00513955|Drug|cyclophosphamide|
1791223|NCT00513955|Drug|doxorubicin hydrochloride|
1791224|NCT00513955|Drug|prednisolone|
1791225|NCT00513955|Drug|vincristine sulfate|
1791226|NCT00513955|Other|questionnaire administration|
1791227|NCT00513955|Procedure|quality-of-life assessment|
1791228|NCT00513968|Genetic|a mixed plasmid DNA (HB-110)|HB-110 2mg (or 4mg or 8mg), im, every other week, from week 0 to week 22 (total 12 injections) and Adefovir(Adefovir dipivoxil 10mg), od, from week -10 to from week 48.
1791229|NCT00513968|Drug|Adefovir|Adefovir(Adefovir dipivoxil)10mg, od, from week -10 to week 48.
1791230|NCT00513981|Drug|leucovorin calcium|
1791231|NCT00513981|Drug|methotrexate|
1791232|NCT00513981|Other|mass spectrometry|
1791233|NCT00513981|Other|pharmacological study|
1791234|NCT00513994|Drug|Nitroglycerin|MQX-503 1%, a topical microemulsion of nitroglycerin 1% and Nitroglycerin Ointment 2%, USP
1791235|NCT00514007|Drug|OSI-906|OSI-906 administered orally
1791236|NCT00514020|Drug|fluorouracil|Given through a vein over 5 minutes and then continuously over 46 hours on days 1 and 15.
1791237|NCT00514020|Drug|leucovorin calcium|through a vein over 2 hours on days 1 and 15.
1791238|NCT00514020|Drug|oxaliplatin|500 ml D5W through a vein over 2 hours on days 1 and 15.
1791239|NCT00514020|Genetic|gene expression analysis|Blood collection
1791240|NCT00514020|Genetic|polymorphism analysis|Blood collection
1791241|NCT00514020|Genetic|protein expression analysis|Blood collection
1791242|NCT00514020|Other|pharmacological study|Blood collection
1791243|NCT00514033|Biological|Poliomyelitis vaccine (inactivated) -PoliorixTM|Deep intramuscular injections for the primary vaccination and booster vaccination.
1791245|NCT00514059|Drug|Boostrix polio|1 dose (0.5 ml) i.m.
1791246|NCT00514072|Biological|BCG vaccine|given intradermally
1791247|NCT00514072|Biological|prostate cancer vaccine ONY-P1|given intradermally
1791248|NCT00514072|Other|placebo|given intradermally
1791249|NCT00514085|Biological|recombinant human interleukin-21|"Patients enrolled in Part A will receive treatment daily x 5 on weeks 1, 3, and 5 of an 8 week cycle.
Patients enrolled in Part B will receive treatment daily x 5 on weeks 1, and 3 of a 6 week cycle"
1791250|NCT00514085|Other|immunohistochemistry staining method|﻿Cycle 1 Day 1 and Cycle 1 Day 29
1791251|NCT00514085|Other|laboratory biomarker analysis|slides will be blocked for 15 minutes in 20% normal goat serum and then incubated in primary antibody
1791252|NCT00514085|Other|pharmacological study|Starting dose of 50μg/kg/day as an IV push
1791253|NCT00514111|Drug|pegylated-interferon, conventional-interferon, ribavirin|Genotype 1: pegylated-interferon 2a or 2b plus ribavirin for 48 weeks. Genotype 3: conventional-interferon 2a or 2b plus ribavirin for 24 weeks.
1791254|NCT00514137|Drug|sunitinib malate|Oral 37.5 mg each day of the 6-week cycle (continuous dosing).
1791255|NCT00514150|Drug|Sodium Bicarbonate plus normal saline 0.9%|IV sodium bicarbonate 8.4% solved in 154 mEq/ L NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.
1791256|NCT00514150|Drug|normal saline 0.9%|IV 154 mEq/L solution of NaCl 0.9% (infused at the rate of 3 ml/kg/ hour one hour before the angiographic procedure, continuing at the rate of 1 ml/kg/ hour for 6 hours after the procedure. Maximum rate of fluid permitted is that for a body weight of 110 Kg.)
1791257|NCT00514163|Drug|gemcitabine + S-1|gemcitabine on day one and 8th S-1 po days 1 to14 every 3 weeks
1791258|NCT00514163|Drug|gemcitabine|gemcitabine DIV on day one , 8th and 15th
1791259|NCT00514189|Biological|Autologous Dendritic Cells|The first vaccination will be given once your blood counts have recovered from the final dose of chemotherapy. The remaining 3 vaccinations will be given every 28 days (+/- 7 days).
1791260|NCT00514202|Drug|Placebo|matched placebo
1791261|NCT00514202|Drug|Dextroamphetamine SR|60 mg/day
1791262|NCT00514215|Biological|sargramostim|250 μg, inhaled, two times a day, on days 4-10 and days 36-42
1791263|NCT00514215|Other|flow cytometry|Days 1 & 32
1791264|NCT00514215|Other|immunoenzyme technique|Days 1 & 32
1791265|NCT00514215|Procedure|biopsy|CT guided biopsy on days 1 & 32
1791266|NCT00514215|Procedure|cryosurgery|Days 1 and 32
1791267|NCT00514228|Drug|sunitinib malate|"Starting dose: 37.5 mg 3 x 12.5 mg capsule
Reduced dose: 25 mg 2 x 12.5 mg capsule"
1791268|NCT00514241|Device|The GPS™ II Platelet Concentrate Separation Kit|The GPS™ II Platelet Concentrate Separation Kit system is designed to be used for the safe and rapid preparation of autologous platelet-rich-plasma (PRP) from a small sample of blood at the patient's point of care. The PRP can be mixed with autograft and allograft bone prior to application to an orthopedic surgical site as deemed necessary by the clinical use requirements.
1791269|NCT00514254|Other|questionnaire administration|
1791270|NCT00514254|Other|study of socioeconomic and demographic variables|
1791271|NCT00514254|Procedure|evaluation of cancer risk factors|
1791272|NCT00514267|Drug|YM 155|IV
1791273|NCT00514267|Drug|Docetaxel|IV
1791274|NCT00514267|Drug|Prednisone|Oral
1791275|NCT00514293|Drug|bexarotene|
1791276|NCT00514293|Drug|capecitabine|
1791277|NCT00514293|Drug|carboplatin|
1791278|NCT00514293|Drug|cisplatin|
1791279|NCT00514293|Drug|docetaxel|
1791280|NCT00514293|Drug|tretinoin|
1791281|NCT00514306|Drug|OSI-906|Oral OSI-906 administered on an intermittent schedule at increasing doses until disease progression or unacceptable toxicity
1791282|NCT00520689|Device|Silicone Hydrogel Contact Lens|use of lens over 2 days
1791283|NCT00520702|Procedure|Intensity Modulated Radiation Therapy|66 Gy in 33 Daily Fractions at 2 Gy per fraction.
1791285|NCT00520728|Behavioral|Occupational Time Use Intervention|12 week behavioral intervention administered by Occupational Therapists.
1791286|NCT00520741|Drug|Lacosamide|50 mg and 100 mg tablets provided for 200 mg twice daily dosing for up to 20 weeks.
1791287|NCT00520741|Drug|Lacosamide|50 mg and 100 mg tablets provided for 150 mg twice daily dosing for up to 20 weeks.
1791288|NCT00520754|Drug|levocetirizine dihydrochloride|
1791289|NCT00520767|Drug|bortezomib|Bortezomib 1.3 mg/m2 days 1, 8, 15, 22
1791290|NCT00520767|Drug|dexamethasone|Dexamethasone 40 mg/d days 1, 2, 8, 9, 15, 16, 22, 23
1791291|NCT00520767|Drug|melphalan|Melphalan 9 mg/m2/day days 1-4
1791292|NCT00520767|Genetic|microarray analysis|≤28 days prior to enrollment
1791293|NCT00520767|Other|flow cytometry|Day 1 of cycles 6, 12, 18 and at end of study.
1791294|NCT00520767|Other|laboratory biomarker analysis|≤28 days prior to enrollment
1791295|NCT00520767|Procedure|quality-of-life assessment|Start of each cycle
1791296|NCT00520780|Drug|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.
After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
1791297|NCT00520780|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
1791298|NCT00520806|Drug|Relaxin|Intravenous infusion for 48 h at 30 ug/kg/day
1791299|NCT00520806|Drug|Placebo|Intravenous infusion for 48 h
1791300|NCT00520819|Drug|Antioxidant-rich food items|
1791301|NCT00520832|Device|Microcurrent|20 minutes of sub-threshold microcurrent 2 hours before bedtime per day for 21 days.
1791302|NCT00520832|Device|Microcurrent|Participants will receive a device identical to the active device used in the experimental condition, but which produces no current.
1791303|NCT00520845|Drug|celecoxib|600 mg will be taken by mouth twice a day for 6 weeks then 400 mg twice a day for up to a year after chemotherapy is discontinued in the absence of progression.
1791304|NCT00520845|Drug|Docetaxel|75mg/m2 given through a vein over 90 minutes on day 1 of a 3-week cycle
1791305|NCT00520845|Drug|pemetrexed disodium|500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
1791306|NCT00520845|Other|laboratory biomarker analysis|Blood collection
1791307|NCT00520858|Other|Resistance Exercise (RE)|
1791308|NCT00520858|Other|Aerobic Exercise (AE)|
1791309|NCT00520858|Other|Resistance and Aerobic Exercise (RAE)|
1791310|NCT00520871|Drug|Blueberry juice|
1791312|NCT00520897|Drug|Raltegravir (MK0518)|400mg BID; 48 weeks
1791313|NCT00520897|Drug|Placebo|400mg QD
1791314|NCT00520897|Procedure|Leukopheresis|pack of cells as per protocol
1791315|NCT00520897|Procedure|Sigmoid Biopsy|gut samples as per protocol
1791316|NCT00520910|Drug|Polypodium leucotomos|Subject is given a 7.5 mg/kg oral dose of Polypodium leucotomos during Baseline visit, and again at 8 hours and 2 hours before the Follow-up visit #2.
1791317|NCT00520910|Other|No Treatment|Patient is not given any treatment.
1791318|NCT00520923|Drug|LY2140023|80mg, PO (by mouth) BID (twice a day) for up to 4 weeks.
1791319|NCT00520923|Drug|LY2140023|40mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
1791320|NCT00520923|Drug|LY2140023|20mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
1791321|NCT00520923|Drug|LY2140023|5mg, PO (by mouth) BID (twice daily) for up to 4 weeks.
1791322|NCT00520923|Drug|Olanzapine|10mg, PO (by mouth) QPM (every evening) for the first 3 days, then 15mg PO QPM, for up to 4 weeks.
1791323|NCT00520923|Drug|Placebo|Taken PO (by mouth) QAM (every morning) for up to 4 weeks.
1791324|NCT00520923|Drug|Placebo|Taken PO (by mouth) BID (twice daily) for up to 4 weeks.
1791325|NCT00520936|Drug|pemetrexed|1910 milligrams per meter squared (mg/m^2) (or 60 milligrams per kilogram [mg/kg] if patient <12 months old), intravenous (IV), for 21 days x 17 cycles
1791330|NCT00520975|Biological|Bevacizumab|Given IV
1791331|NCT00520975|Drug|Carboplatin|Given IV
1791332|NCT00520975|Drug|Paclitaxel|Given IV
1791333|NCT00520975|Other|Placebo|Given IV
1791334|NCT00520975|Biological|Trastuzumab|Given IV
1791335|NCT00520988|Behavioral|Use of telephone-based Interactive Voice Recognition system|Use of telephone-based Interactive Voice Recognition system, for reporting of health information and blood pressure measurements
1791336|NCT00521001|Drug|everolimus|
1791337|NCT00521001|Drug|temozolomide|
1791338|NCT00521014|Biological|filgrastim|
1791339|NCT00521014|Biological|rituximab|
1791340|NCT00521014|Biological|sargramostim|
1791341|NCT00521014|Drug|carmustine|
1791342|NCT00521014|Drug|cytarabine|
1791343|NCT00521014|Drug|etoposide|
1791344|NCT00521014|Drug|melphalan|
1791345|NCT00521014|Procedure|autologous hematopoietic stem cell transplantation|
1791346|NCT00521027|Device|Versajet Hydrosurgery System|Debridement with Versajet Hydrosurgery System
1791347|NCT00521027|Procedure|Conventional surgical debridement techniques|Conventional surgical debridement with scalpel and pulse lavage
1791348|NCT00521274|Biological|MVA 5T4|Docetaxel will be administered at the completion of the first three TroVax® injections. Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients will receive up to 10 total Docetaxel infusions over the course of the study. Subsequent TroVax® injections will be delivered on Day 1 of each Docetaxel cycle, 2 hours prior to the chemotherapy administration.
1791349|NCT00521274|Drug|Docetaxel|Patients will receive Docetaxel 75 mg/m2 on Day 1 of each cycle (1 cycle = 3 weeks). Patients who demonstrate disease progression will continue with their chemo as scheduled in Arm 2 but will also begin to receive TroVax® (cross-over). Patients will receive up to 10 total Docetaxel infusions over the course of the study. If patients cross-over, TroVax® will be administered 2 hours prior to the chemotherapy administration.
1791350|NCT00521287|Other|Immune profiling and DC vaccine|"For observational study (immune profiling): blood sampling 3-5 mL
For DC vaccine: one dose of DC vaccine(~10 million cells)/2 week for at least 6 month or until progression."
1791351|NCT00521300|Drug|Octreotide|First week: Octreotide 50 micrograms subcutaneously three times daily. Second week: Octreotide 100 micrograms subcutaneously three times daily. From the third week on: Octreotide LAR 20 mg intramuscularly every 28th day for 6 months
1791352|NCT00521300|Procedure|Direct surgery for acromegaly|Direct transsphenoidal surgery
1791353|NCT00521339|Drug|Apremilast|20 mg PO (by mouth) twice per day (BID) for 84 days and then an additional 84 days during the optional treatment extension period. For subjects meeting the dose escalation criteria, dosage during the optional treatment extension period can be increased to 30 mg BID.
1791354|NCT00521352|Device|Active Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic field (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) for 30min, five sessions a week for up to eight weeks.
1791355|NCT00521352|Device|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|Generates a field with the same parameters as active rTMS (see active arm for parameters), however, the actual magnetic fields are blocked by an electromagnetic shield built into a sham coil. The field is impeded from stimulating the brain.
1791356|NCT00521365|Drug|Quetiapine 600mg|"300 mg quetiapine fumarate tablets for oral use.
Day 1: One 300 mg tablet in the evening Day 2: Two 300 mg tablet in the evening Day 3 and onwards: Two 300 mg tablets in the evening, efforts must be done to maintain a daily dose of 600 mg/day."
1791357|NCT00521391|Other|Allez Hop|a tailored physical activity intervention involving moderate-intensity exercise
1791358|NCT00521404|Drug|CS-1008 (humanized anti-DR5 antibody)|CS-1008: 8mg/kg loading dose followed by 3mg/kg weekly.
1791359|NCT00521404|Drug|gemcitabine|Gemcitabine - 1000mg/meter sq
1791360|NCT00521417|Behavioral|short-term dynamic therapy|
1791361|NCT00521417|Behavioral|long-term dynamic therapy|
1791362|NCT00521430|Biological|anti-thymocyte globulin|
1791363|NCT00521430|Drug|busulfan|
1791364|NCT00521430|Drug|cyclosporine|
1791365|NCT00521430|Drug|fludarabine phosphate|
1791366|NCT00521430|Drug|methotrexate|
1791367|NCT00521430|Drug|methylprednisolone|
1791368|NCT00521430|Procedure|allogeneic hematopoietic stem cell transplantation|
1791369|NCT00521430|Procedure|peripheral blood stem cell transplantation|
1791370|NCT00521443|Procedure|Cryopreservation, thawing and blastocyst culture|Good quality human embryos were frozen - thawed and cultured to the blastocyst stage.
1791371|NCT00521456|Drug|ketorolac eye drops|"1 drop twice daily day preop and Days 1-14, and 6 doses on surgery day
Placebo"
1791372|NCT00521469|Device|Pro Adjuster|
1791373|NCT00521482|Drug|Temozolomide|
1791374|NCT00521482|Drug|Temozolomide plus Thalidomide|
1791375|NCT00521495|Device|neodymium permanent magnet|"3/4 diameter by 1/8 thick permanent magnet"
1791376|NCT00521495|Device|neodymium magnet|A. 450 Gauss static magnetic field at target B. 150 Gauss static magnetic field at target C. 0 Gauss static magnetic field at target
1791377|NCT00521495|Device|magnet|0 Gauss magnets are worn every night during hours of sleep for 6 weeks.
1791378|NCT00521508|Procedure|gene transcription and cytometry|samply of 30 ml of blood
1791379|NCT00521521|Drug|docetaxel and cisplatin|
1791380|NCT00521521|Drug|docetaxel|
1791381|NCT00521534|Device|CRT with atrial overdrive pacing|Both groups receive CRT, one group receives atrial overdrive pacing
1791382|NCT00521547|Procedure|Electroacupuncture|
1791383|NCT00521560|Drug|Zevalin|"All applications of 90Y-Ibritumomab-Tiuxetan will be preceded by rituximab infusions at a dose of 250 mg/m2 at days -21 and day -14 (DL1) or day -12 (DL2) or day -10 (DL3-5), respectively.
High dose therapy will be given as BEAM"
1791384|NCT00521573|Other|Dark chocolate|
1791385|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV +13vPnC at dose 1 placebo at dose 2, one month after dose 1 13vPnC at year 5
1791386|NCT00521586|Biological|13 valent pneumococcal conjugate vaccine|TIV + placebo at dose 1 13vPnC at dose 2, one month after dose 1 and 13vPnC at year 5
1791387|NCT00521599|Drug|Mometasone furoate dry powder inhaler|
1791388|NCT00521599|Drug|Placebo|
1791389|NCT00521612|Drug|sevoflurane|Volatile anaesthetic sevoflurane 1 MAC (2,0 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic sevoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic sevoflurane. Change will be +10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of sevoflurane MAC (0,2 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
1791390|NCT00521612|Drug|isoflurane|Volatile anaesthetic isoflurane 1 MAC (1,2 vol%) will be administer to the patients in the form of gas (via respiration). First 20 minutes of anaesthesia will be period of saturation of the body with anaesthetic isoflurane. After 20 minutes the depth of anaesthesia will be titrated with level of anaesthetic isoflurane. Change will be +10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate shallow anaesthesia. Change will be -10 % of isoflurane MAC (0,12 vol%) for every change of signs that indicate too deep anaesthesia. Measuring points will be every 5 minutes during surgery.
1791391|NCT00521638|Biological|TRU-015|Intravenous administration; 400 mg, 700 mg, or 1000 mg; 1x/week dosing for 4 weeks
1791531|NCT00522808|Drug|A-831|
1791788|NCT00524017|Procedure|standard follow-up care|Patients receive regular follow-up care
1791392|NCT00521664|Biological|Prophylactic platelet transfusion|In the PP arm platelet transfusion has to be performed when platelet count is below 10.000/µL in any case and when bleeding (more than petechial) occurs.
1791393|NCT00521664|Biological|Therapeutic platelet transfusion|In the TP arm platelet transfusion is only required if bleeding occurs (more than petechial)or in case of pulmonary infections with or without sepsis.
1791394|NCT00521677|Procedure|Sage oral care|Oral care include teeth brush and oral cavity cleaning with a non alcoholic solution, TID
1791395|NCT00521677|Procedure|Traditional oral care|Cleaning of oral cavity with menthol solution, TID
1791396|NCT00521690|Drug|insulin detemir|
1791397|NCT00521703|Drug|Lidocaine|oral cavity and throat were sprayed with lidocaine 10% two to three puffs before propofol infusing
1791398|NCT00521703|Drug|Tannic acid|oral cavity and throat were sprayed with placebo (tannic acid 0.5%) two to three puffs before propofol infusing
1791399|NCT00521716|Device|Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
1791400|NCT00521716|Device|WaisFix100i for Intracapsular Femoral Fracture Fixation|The WaisFix100i combines a new and unique Internal Triangular Cage nail fixator and three lag screws.
1791401|NCT00521729|Procedure|Exposure to Cold Temperature|
1791402|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg to 45 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally, once daily for up to 52 weeks.
1791403|NCT00521742|Drug|Glyburide|Glyburide 2.5 mg to 15 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
1791404|NCT00521742|Drug|Pioglitazone|Pioglitazone 15 mg or 30 mg, tablets, orally, once daily and glyburide placebo-matching capsules, orally once daily for up to 52 weeks.
1791405|NCT00521742|Drug|Glyburide|Glyburide 5 mg or 10 mg, capsules, orally, once daily and pioglitazone placebo-matching tablets, orally once daily for up to 52 weeks.
1791406|NCT00521755|Device|Seraffix LTB|laser soldering for soft tissue wounds
1791407|NCT00521768|Behavioral|Prolonged exposure|
1791408|NCT00521781|Drug|Abraxane|100 mg/m2 IVPB Day 1, 8, 15, 22, 29,36,43,50 of each cycle for 4 nine-week cycles (Each cycle of Abraxane/hormonal therapy will consist of 8 weeks of Abraxane therapy and 1 week of rest.)
1791409|NCT00521781|Drug|Leuprolide|7.5 mg monthly or 22.5 mg quarterly, can begin within 3 months of initiating Abraxane for 2 years
1791410|NCT00521781|Drug|Bicalutamide|50 mg p.o. daily starts week 36 of initiating Abraxane.
1791411|NCT00521807|Procedure|Hypnosis|a standardized hypnosis treatment with ten consecutive therapeutic sessions once a week,
1791412|NCT00521820|Drug|Pioglitazone|Pioglitazone 30 mg (titrated to 45mg with tolerance), tablets, orally once daily and glyburide placebo-matching tablets, orally, once daily for up to 24 weeks.
1791413|NCT00521820|Drug|Glyburide|Pioglitazone placebo-matching tablets, orally, once daily and glyburide 10 mg (titrated to 15mg with tolerance), capsules, orally, once daily for up to 24 weeks.
1791414|NCT00521833|Procedure|phacoemulsification and intraocular lens implantation|clear cornea phacoemulsification and intraocular lens implantation using temporal or nasal incisions respectively
1791415|NCT00521846|Device|Biomet Explor Modular Radial Head Replacement|As part of the patient's routine care, they will undergo a radial head replacement using the Biomet Explor Modular Radial Head system.
1791416|NCT00521859|Drug|Cloretazine|800 mg/m^2 by vein daily
1791417|NCT00521859|Drug|Fludarabine|25 mg/m^2 by vein daily x 5 Days
1791418|NCT00521872|Procedure|STARR Operation|
1791420|NCT00521898|Procedure|Descemet Membrane Endothelial Keratoplasty (DMEK)|
1791421|NCT00521911|Behavioral|Cognitive Behavioural Therapy|
1791422|NCT00521924|Biological|infliximab|infliximab 3 mg/kg and basic treatment
1791423|NCT00521924|Drug|DMARDs (methotrexate; chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89.|Methotrexate (15 - 25 mg/week); chloroquine; leflunomidum; cyclosporin A; sulfasalazine; OM 89
1791424|NCT00521937|Other|Dermagen®|Weekly topical applications
1791425|NCT00521950|Genetic|TPMT genotyping; Drug: azathioprine or 6-mercaptopurine|"Assessment of the polymorphisms G238C, G460A, and A719G in a venous blood sample to identify functional genetic variants (TPMT*2, *3A, *3C) of the TPMT gene (chromosome 6) associated with reduced or negligible TPMT enzyme activity.
Patients are advised an initial treatment dose based on the enzyme activity:
Normal: AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);
Reduced: AZA 1-1.25 mg/kg/day or 6-MP 0.5-0.75 mg/kg/day;
Negligible: AZA 0-0.2 mg/kg/day or 6-MP 0-0.1 mg/kg/day;"
1791426|NCT00521950|Drug|azathioprine (AZA) or 6-mercaptopurine (6-MP)|"Patients will be advised a standard initial treatment dose:
AZA 2-2.5 mg/kg/day or 6-MP 1-1.5 mg/kg/day (standard care);"
1791427|NCT00521963|Biological|Intraarticular injection of infliximab|A single injection of 100 mg of infliximab
1791428|NCT00521989|Drug|CRx-102 (2.7/90)|CRx-102 dose 1
1791429|NCT00521989|Drug|Prednisolone|Prednisolone
1791430|NCT00521989|Drug|Placebo|Placebo
1791431|NCT00521989|Drug|CRx-102 (2.7/180)|CRx-102 dose 2
1791432|NCT00521989|Drug|CRx-102 (2.7/360)|CRx-102 dose 3
1791433|NCT00522015|Drug|rivastigmine|rivastigmine 6 mg up to 12 mg daily; Taken in two doses from 3 mg to 6 mg Rivastigmine twice a day
1791434|NCT00522041|Drug|Cellegesic|Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.
1791435|NCT00522041|Drug|Placebo|Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.
1791436|NCT00522054|Other|Physical exercise|Tai Chi exercise, twice a week during 12 weeks
1791437|NCT00522067|Biological|Adjuvanted influenza vaccine|Vaccination with MF 59 adjuvanted trivalent seasonal influenza vaccine
1791438|NCT00522093|Drug|TJ-100|TJ-100 2.5g three times per day for 6 weeks
1791439|NCT00522106|Behavioral|Behavioral graded activity|The intervention is directed at increasing the level of activities in a time-contingent way, with the goal to integrate these activities in the daily living of the patients. The intervention is performed by physical therapists in primary care, on individual basis. Treatment period of maximal 12 weeks (with maximal 18 sessions), followed by 5 pre-set boostermoments with a maximum of 7 sessions (respectively in week 18, 25, 34, 42, and 55).
1792784|NCT00532233|Drug|QAX576|
1791440|NCT00522106|Other|Exercise therapy|Treatment according to the Dutch physiotherapy guideline for patients with osteoarthritis of hip and/or knee. This guideline consists of general recommendations, emphasizing provision of information and advice, exercise therapy, and encouragement of a positive coping with the complaints. The treatment consisted of a maximum of 18 sessions within a period of 12 weeks. The treatment could be discontinued within the 12 week period if, according to the physiotherapists, all treatment goals were achieved.
1791441|NCT00522132|Drug|Artesunate|intravenous application
1791442|NCT00522145|Drug|XL647|Daily dosing as a single oral agent at a dose of 300 mg supplied as 50-mg tablets
1791443|NCT00522158|Drug|simvastatin|
1791444|NCT00522158|Drug|atorvastatin|
1791445|NCT00522171|Device|The Harmonic™ ultrasonic scalpel|A surgical instrument that uses ultrasonic energy that allows both cutting and coagulating at the precise point of application.
1791446|NCT00522184|Procedure|intra-articular injection of etanercept|
1791447|NCT00522184|Procedure|intra-articular injection of steroid|
1791448|NCT00522197|Dietary Supplement|multi-herbal agent ACAPHA|
1791449|NCT00522197|Dietary Supplement|Sugar Pill|
1791450|NCT00522210|Drug|Detemir|Patients will discontinue their usual bedtime dose of intermediate acting insulin and replace this with the same unit dose of detemir at supper time. The detemir will not be mixed with the rapid acting insulin and will be given as a separate injection. The patient's morning dose of intermediate acting insulin will be decreased by 20% to adjust for the longer duration of action of detemir. Doses of rapid acting insulin will remain the same at breakfast and at supper.
1791451|NCT00522210|Other|Novolin NPH or Humulin N|Patients will continue on their usual insulin regimen of insulin three times per day. Intermediate and rapid acting insulin at breakfast, rapid acting insulin at supper, and intermediate acting insulin at bedtime.
1791453|NCT00522236|Biological|Surface Antigen, Inactivated, Adjuvanted Influenza Vaccine, Formulation 2007-2008|"A single 0.5mL dose of Novartis adjuvanted subunit influenza vaccine, Fluad contained 45μg of viral hemagglutinin, composed of 15μg of the three influenza antigens:
A(H1N1) strain: IVR-145 (Solomon Island/3/2006 - like strain)
A(H3N2) strain: NYMC X-161B (A/Wisconsin/67/2005-like strain)
B strain: (B/Malaysia/2506/2004-like strain) in accordance with the recommendations of the World Health Organization, the EU and the national Regulatory Agencies for the 2007/2008 season.
The vaccine is a milky liquid, and was packaged in ready to use, single dose syringes.
A single dose of FLUAD vaccine was administered intramuscularly, preferably in the deltoid muscle of the non dominant arm."
1791454|NCT00522249|Drug|Pegylated Alfa Interferon|Each patient will receive PEG-Intron administered subcutaneously one day per week of each 6 week cycle. The dose of PEG-Intron is determined based on the patient's weight and the dose level.
1791455|NCT00522249|Drug|sunitinib|Patients will receive sunitinib orally as a single daily dose on Days 1-28 of each 42-day cycle. The dose will depend on the dose level.
1791456|NCT00522249|Drug|erlotinib|Tarceva will be administered orally, 1-42 of each 42 day cycle. Dose will depend on dose level. Supplied as 150-mg, 100-mg and 25-mg strengths, white film-coated tablets for administration.
1791457|NCT00522262|Behavioral|Aerobic exercise intervention|Women in the exercise arm underwent a year-long exercise intervention of five days per week of 45 minutes/session of moderate-vigorous intensity aerobic exercise.
1791458|NCT00522275|Drug|lacosamide|50mg or 100 mg tablets, up to 800 mg/day given twice daily (BID) throughout the trial
1791459|NCT00522288|Device|Soft contact lenses|Daily wear soft contact lenses disposed of daily or biweekly
1791460|NCT00522288|Device|Spectacle|Spectacles for the treatment of myopia
1791461|NCT00522301|Drug|sorafenib tosylate|
1791462|NCT00522301|Other|immunoenzyme technique|
1791463|NCT00522301|Other|immunohistochemistry staining method|
1791464|NCT00522301|Other|laboratory biomarker analysis|
1791465|NCT00522301|Other|pharmacological study|
1791466|NCT00522314|Device|NIV and ACBT|
1791467|NCT00522314|Other|Active Cycle of Breathing Techniques|
1791468|NCT00522327|Other|remote simultaneous medical interpreting|remote simultaneous medical interpretation
1791469|NCT00522327|Other|usual and customary|usual and customary interpreting
1791470|NCT00522327|Other|ENglish speaking|English speakers
1791471|NCT00522340|Behavioral|Aerobic Exercise Program|Home walking 1 hour a day for 5 days/week for 8 weeks. Then 30 minutes a day on all or most days of the week.
1791472|NCT00522353|Dietary Supplement|Oligofructose|21 grams per day in distributed over 3 doses per day for 3 months
1791473|NCT00522353|Dietary Supplement|Placebo|7.89 grams of placebo maltodextrin divided into 3 equal doses per day for 3 months
1791474|NCT00522379|Drug|Rotigotine|2 mg/24 hr (one 10 cm^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
1791475|NCT00522379|Drug|Rotigotine|4 mg/24 hr (one 20 cm^2) transdermal patch applied daily for titration and maintenance period - 16 weeks
1791476|NCT00522379|Other|Placebo|Placebo transdermal patch applied daily
1791477|NCT00522379|Drug|Rotigotine|6 mg/24 hr (one 10 cm^2 & one 20 cm^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
1791478|NCT00522379|Drug|Rotigotine|8 mg/24 hr (two 10 cm^2 & one 20 cm^2) transdermal patches applied daily for titration and maintenance period - 16 weeks
1791479|NCT00522392|Drug|bortezomib|Given IV
1791480|NCT00522392|Drug|lenalidomide|Given PO
1791481|NCT00522392|Drug|dexamethasone|Given PO
1791532|NCT00522821|Drug|intravenous immunoglobulins|"Adults: 600 mg/kg bodyweight every 3 weeks
Children: 800 mg/kg bodyweight every 3 week"
1791533|NCT00522821|Drug|antibiotics|"Children ≥5-12: If well tolerated, 4 mg trimethoprim and 20 mg sulfamethoxazole per kg bodyweight once daily, every day of the week (max160/800mg/day), combined with 5 mg folic acid.
Adults and children ≥12 years or ≥40 kg: If well tolerated, 160 mg trimethoprim and 800 mg sulfamethoxazole once daily, every day of the week combined with 5 mg folic acid."
1791534|NCT00522834|Drug|Elesclomol (STA-4783)|213 mg/m2 Elesclomol (STA-4783) plus 80 mg/m2 paclitaxel administered intravenously once a week for the first 3 weeks of a 4 week cycle. Number of cycles: Until progression or unacceptable toxicity develops
1791482|NCT00522405|Procedure|TACE|"Under local anesthesia, the Femoral artery would be punctured
A catheter would be introduced and a flush aortogram, superior mesenteric arterioportography and the celiac artery run would be undertaken to define the size and location of the tumors, feeding vessels and to assess the portal vein patency
Superselective catheterization of the hepatic artery feeding the tumor would be done
By placing the catheter tip beyond the gastroduodenal artery, the chemotherapeutic drugs would be administered.
Stable drug mixture would be prepared by using Doxorubicin 50mg, Cisplatin 100mg in combination with 10-15ml of ionic contrast media and 10-20ml of lipiodol by continuously agitating the mixture.
The drug mixture would then be injected through the indwelling arterial catheter by continuously flushing alternately, repeatedly and rapidly between two-luer locks syringes connected across a three way.
Gelfoam particles would be injected following this for embolization"
1791483|NCT00522418|Device|Vagal Nerve Simulation (VNS) Therapy|VNS Therapy + Best Medical Practice including anti-epileptic drugs
1791484|NCT00522418|Drug|Best Medical Practive|Best Medical Practice including anti-Epileptic Drugs
1791485|NCT00522431|Drug|Testosterone|2% gel
1791486|NCT00522444|Drug|Nebulized Magnesium Sulfate|
1791487|NCT00522457|Drug|ertumaxomab|Ertumaxomab will be intravenously administered to see if it can increase the patient's objective response rate.
1791488|NCT00522470|Drug|rosiglitazone|
1791489|NCT00522509|Drug|Floxuridine FUDR|
1791490|NCT00522535|Procedure|Open surgical repair|Open surgical repair of abdominal aortic aneurysm
1791491|NCT00522535|Device|Stent Graft|Endovascular repair of abdominal aortic aneurysm (EVAR)
1791494|NCT00522561|Other|energetic and non invasive limb mechanical measurements|Force velocity stiffness running
1791495|NCT00522574|Drug|XL019|gelatin capsules supplied in 5-mg, 25-mg, and 100-mg strengths
1791496|NCT00522587|Drug|Fixed sevoflurane dose 1|Dose 1 of sevoflurane
1791497|NCT00522587|Drug|Fixed sevoflurane dose 2|Dose 2 of sevoflurane
1791498|NCT00522587|Drug|Fixed sevoflurane dose 3|Dose 3 of sevoflurane
1791499|NCT00522587|Drug|Fixed sevoflurane dose 4|Dose 4 of sevoflurane
1791500|NCT00522587|Drug|Fixed sevoflurane dose 5|Dose 5 of sevoflurane
1791501|NCT00522587|Drug|Fixed sevoflurane dose 6|Dose 6 of sevoflurane
1791502|NCT00522587|Drug|Fixed remifentanil dose 1|Dose 1 of remifentanil
1791503|NCT00522587|Drug|Fixed remifentanil dose 2|Dose 2 of remifentanil
1791504|NCT00522587|Drug|Fixed remifentanil dose 3|Dose 3 of remifentanil
1791505|NCT00522587|Drug|Fixed remifentanil dose 4|Dose 4 of remifentanil
1791506|NCT00522587|Drug|Fixed remifentanil dose 5|Dose 5 of remifentanil
1791507|NCT00522587|Drug|Fixed remifentanil dose 6|Dose 6 of remifentanil
1791508|NCT00522613|Behavioral|Recovery Group Project|Recovery Group Workbook & Group Sessions
1791509|NCT00522626|Device|Maternal fetal monitoring|Simultaneous monitoring of maternal and fetal physiology
1791510|NCT00522639|Other|18F-deoxyglucose (FDG)|contrast medium
1791511|NCT00522652|Drug|PX-478|Oral formulation, dose escalation, taken on days 1 to 5 of a 21 day cycle until progression or development of unacceptable toxicity
1791515|NCT00522678|Drug|GW685698X|Subject will receive GW685698X containing magnesium stearate with unit dose strength of 400, 600 and 800 mcg inhaled via DISKUS
1791516|NCT00522678|Drug|Placebo|Subject will receive Placebo matching GW685698X via DISKUS.
1791517|NCT00522691|Procedure|sacral nerve stimulation|sacral nerve stimulation for fecal incontinence
1791518|NCT00522704|Other|Dynamic Arterial line Pressure (DALP)|eEBF will be record with dynamic arterial line pressure of -60 mmHg (eEBF-60 mmHg), -100 mmHg (eEBF-100 mmHg), -160 mmHg (eEBF-160 mmHg), -200 mmHg (eEBF-200 mmHg) and -260 mmHg (eEBF-260 mmHg) during the first one half hour of the dialysis session. Access Blood flow will be performed with blood thermal monitor.
1791519|NCT00522717|Behavioral|Cognitive Behavioral Therapy (CBT)|Subjects receive CBT in the home for 8 weeks with blood draws every other week during therapy.
1791520|NCT00522717|Behavioral|Usual Care|Subjects receive Usual Care for 8 weeks followed by CBT
1791521|NCT00522730|Other|Parenteral nutrition|Duration : 5 days
1791522|NCT00522730|Other|Enteral nutrition|Duration : 5 days
1791523|NCT00522743|Drug|growth hormone and gonadotropin-releasing hormone agonist|GH & GNRHa treatment
1791524|NCT00522743|Drug|growth hormone|GH treatment
1791525|NCT00522756|Drug|Sodium bicarbonate|Three ampoules of 7.5% sodium bicarbonate (89.3 mOsm/ampoule; total 150 ml for three ampoules) added to 750 ml of 5% dextrose in water, given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
1791526|NCT00522756|Drug|Sodium chloride|0.9% sodium chloride given at 1 ml/kg/hour through a dedicated intravenous line for 6 hours, and completed prior to the initiation of cardiopulmonary bypass.
1791527|NCT00522769|Behavioral|Cognitive Behavioral Therapy|Girls enrolled in the study will either receive the 6-20 session CBT intervention at the time of enrollment or 6 months after they enroll. Assessments including questions about eating behaviors, mood, and general functioning are given on enrollment in the study, and 3- and 6-months following enrollment (also at 9- and 12-months for those in the delayed treatment condition
1791530|NCT00522795|Drug|PPX with cisplatin and radiation|weekly IV treatment of Paclitaxel Poliglumex and Cisplatin for 6 weeks
1791535|NCT00522834|Drug|Paclitaxel|80 mg/m2 paclitaxel alone administered intravenously once a week for the first 3 weeks of a 4 weeks cycle. Number of cycles: Until progression or unacceptable toxicity develops
1791536|NCT00522860|Procedure|Trichiasis surgery with absorbable sutures|Posterior lamellar tarsal rotation. Vicryl sutures, 5/0, 3/8 curved needle, cutting. Three everting sutures.
1791537|NCT00522860|Procedure|Trichiasis surgery with non-absorbable sutures|Posterior lamellar tarsal rotation. Silk sutures. 4/0. 3/8 curved cutting needle. Three sets of everting sutures.
1791538|NCT00522873|Drug|0.25mg DRSP / 0.5mg E2 (BAY86-4891)|One capsule [0.25mg drospirenone/0.5mg 17β-estradiol (DRSP/E2)] per day taken orally for 13 cycles (28 days per cycle).
1791539|NCT00522873|Drug|0.5mg NETA / 1.0mg E2 (Activella)|One capsule [0.5mg norethisterone acetate/1.0mg 17β-estradiol (NETA/E2)] per day taken orally for 13 cycles (28 days per cycle).
1791540|NCT00522886|Drug|Cetuximab|"Eligible patients will be given 2 cycles(of 21 days) of carboplatin (AUC 5) day 1 and gemcitabine (1250 mg/m2) days 1,8. Patients without progressive disease will be entered in the phase I dose-escalation part of the study. Chest radiation will be given concurrently with cetuximab, cisplatin and vinorelbine, which will be escalated in 3 steps until dose-limiting toxicity occurs.
14 days after the last gemcitabine (=day 43), radiotherapy is started : First 3 weeks: 1.5 Gy BID to a dose of 45 Gy in 30 fractions, then 2 Gy QD to a mean lung dose of 19 Gy. Cetuximab: 400 mg/m2 7 days before radiotherapy (= day 36) and during the course of radiotherapy a weekly dose 250 mg/m2. Cetuximab will be delivered at the same days as chemotherapy.
Cisplatin(all steps): 50 mg/m2 days 43, 50; 40 mg/m2 day 64.
Vinorelbine:
Step 1: 10 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 2: 20 mg/ m2 days 43, 50; 8 mg/m2 days 66 and 73. Step 3: 20 mg/ m2 days 43, 50; 15 mg/m2 days 66 and 73."
1791541|NCT00522899|Behavioral|Group 1|Aerobic exercise plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
1791542|NCT00522899|Behavioral|Group 2|Aerobic exercise plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
1791543|NCT00522899|Behavioral|Group 3|Stretching/toning exercise group plus computer-based mental activity training: both 3 days/week, 60 minutes/session for 12 weeks.
1791544|NCT00522899|Behavioral|Group 4|Stretching/toning exercise group plus educational DVDs: both 3 days/week, 60 minutes/session for 12 weeks.
1791545|NCT00522912|Procedure|Trichiasis surgery|Posterior lamella tarsal rotation
1791546|NCT00522912|Procedure|Epilation|Epilation of lashes by another well sighted person using quality epilating forceps
1791547|NCT00522925|Drug|PS433540|200mg capsule, once daily for 28 days
1791548|NCT00522925|Drug|placebo|placebo capsule, once daily for 28 days
1791549|NCT00522925|Drug|PS433540|500mg capsule, once daily for 28 days
1791550|NCT00522938|Drug|CHR-2797 (tosedostat)|Once daily, oral ingestion of CHR-2797 capsules(PhaseI: 120mg, 160mg or 200mg depending on cohort or Phase II: recommended dose) capsules until progressive disease or withdrawal from the study
1791551|NCT00522938|Drug|erlotinib|Once daily, oral ingestion of erlotinib tablets 150mg tablets until progressive disease or withdrawal from the study. Per protocol, the Investigator may reduce the dose of erlotinib or cease treatment with erlotinib(per label) with Sponsor approval.
1791552|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (first injection of gadobutrol 0.1 mmol/kg bw, corresponding to a dose of 0.1 mmol/kg bw)
1791553|NCT00522951|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol enhanced MRI (second injection of gadobutrol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
1791554|NCT00522951|Drug|ProHance|ProHance enhanced MRI (two injections of gadoteridol 0.1 mmol/kg bw, corresponding to a total dose of 0.2 mmol/kg bw)
1791555|NCT00522964|Behavioral|behavioral intervention|The intervention is based on Social Cognitive Theory and principles of Chinese culture and practices. The intervention program includes a one-hour small-group session for eight weeks for children and two 2-hour small-group sessions for parents.
1791556|NCT00522990|Drug|AT9283|Three weekly intravenous administration of AT9283
1791557|NCT00523003|Dietary Supplement|high protein|2.2 g protein/kg of LBM per day
1791558|NCT00523003|Dietary Supplement|standard protein|1.1 g protein/kg LBM/day standard protein diet
1791559|NCT00523016|Procedure|Lyndhurst Central Neuropathic Pain Acupuncture Protocol (LCCNPAP)|LCCNPAP: acupuncture needle insertion at acupuncture points on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks.
1791560|NCT00523016|Procedure|Sham acupuncture|Sham acupuncture: Simulated acupuncture that includes insertion of acupuncture needles on the head that will be stimulated with electricity from a battery-operated Chinese acupuncture stimulation device for 20 minutes. A total of 13 treatments will be administered over 3-4 weeks. This group will be offered the LCCNPAP treatment at the completion of study participation.
1791561|NCT00523029|Behavioral|Chronic Disease Self-Management Program|Chronic disease self-management is a 6-week group program that teaches participants how to manage their chronic medical illness. Group leaders, also suffering from a chronic medical condition, will lead discussions based on the following topics: nutrition; exercise; appropriate use of medications; ways to communicate effectively with family, friends, and health care professionals; and how to make informed treatment decisions.
1791562|NCT00523042|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c.
1791563|NCT00523042|Drug|inhaled human insulin|Treat-to-target dose titration scheme, inhalation.
1791564|NCT00523055|Drug|Lidocaine|Lidocaine, 5 mg/kg, via needle placed adjacent to brachial plexus with ultrasound, dosing separated by 1 week, 2 doses in total, one block will contain 5 mcg/kg of adrenaline
1791565|NCT00523068|Drug|Tolterodine|
1791566|NCT00523068|Procedure|tension free vaginal tape|
1791567|NCT00523081|Behavioral|Cognitive Behavioral Therapy (CBT)|Half the teens in the study will also meet with a research counselor for five to nine individual, weekly sessions that last about 50 minutes each. Whether a teen attends the weekly counseling sessions is decided by chance, like flipping a coin. If teens are assigned to these sessions, they will learn ways to deal with stress and feel better. If teens take part in the counseling sessions, the study counselor will also talk to the teen's doctor from time to time to help plan for the best possible care.
1791612|NCT00523432|Drug|CCI-779 (temsirolimus)|Weekly 25mg dose via IV infusion.
1791789|NCT00524030|Drug|pregabalin 600 mg/day|pregabalin 600 mg/day (300mg BID), duration is 20 weeks.
1791568|NCT00523081|Behavioral|Active control|Teens in the active control arm will keep seeing their doctor as usual. Teens and a parent are interviewed briefly over the phone to see if they are appropriate for the study. If they qualify for the study, there is an hour-long interview with teen over the telephone and a 30 minute interview with the parent. They will be interviewed six more times in the next two years.
1791569|NCT00523107|Drug|PG2|PG2 500 mg / 500 ml normal saline t.i.w. per week
1791570|NCT00523107|Drug|Placebo|500 ml normal saline t.i.w. per week
1791571|NCT00523120|Drug|diclofenac sodium|topical solution used in ear 5 drops 8 3/day
1791572|NCT00523120|Drug|dexotc|aural drops
1791573|NCT00523133|Drug|naltrexone|50 mg naltrexone daily for 3 months
1791574|NCT00523133|Drug|naltrexone|50 mg of naltrexone daily for 6 months
1791575|NCT00523133|Behavioral|Broad Spectrum Treatment|8-14, one hour sessions over 6 months
1791576|NCT00523133|Behavioral|Motivational Enhancement Treatment|4, 20 minute sessions over 3 months
1791577|NCT00523146|Drug|Kanion Capsule|
1791578|NCT00523159|Drug|Endoxana, IMA901, Leukine|a single i.v. infusion of Cyclophosphamid and then patients received vaccination therapy with intradermal (i.d.) injections of GM-CSF followed by i.d. injections of IMA901
1791579|NCT00523159|Drug|IMA901 and Leukine|Intradermal injection of GM-CSF followed by intradermal injection of IMA901
1791580|NCT00523172|Procedure|manual or manipulative therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the hip (HVLA hip manipulations per protocol 1) with pre-manipulative static and post manipulative active-assisted stretch of hip muscles after each manipulation.
1791581|NCT00523172|Procedure|Manual / Manipulative Therapy|Active comparator will receive 9 treatments of manual or manipulative therapy to the lumbosacral, sacroiliac, hip and knee, ankle and foot joints (HVLA and Grades I-IV mobilization per protocol 2) stretching and exercise.)
1791582|NCT00523172|Procedure|Supportive Care|"Supportive Care 3) Groups A and B will receive supportive care after the 9th visit consisting of (up to a maximum of) 6 visits, PRN or as needed, until the 9 month follow up. This is to see if peak gains may be maintained (as noted in the previous trial) throughout the follow up period.
Enrolled subjects will commonly receive 2 treatments per week (occasionally, less or more than 1 to 2 treatments per week due to (College or University) semester breaks, exams, clinic closures and so forth) until 9 treatments are completed."
1791583|NCT00523185|Drug|Lorazepam|Lorazepam 1 to 2 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
1791584|NCT00523185|Drug|Diazepam|Diazepam 20 mg by mouth every two hours x 3 doses, or for parenteral treatment, diazepam 10 mg intravenously every one hour x 6 doses. Give additional diazepam 10 mg by mouth or intravenously every two hours as needed for alcohol withdrawal symptoms.
1791585|NCT00523211|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily.
1791586|NCT00523211|Drug|Placebo|One tablet of placebo once daily.
1791587|NCT00523224|Procedure|Angiogenic Cell Precursors(ACPs) or Vescell TM|at least 1.5 million of ACPs per one time of treatment
1791588|NCT00523224|Biological|Angiogenic Cell Precusors|Stem cells type Angiogenic Cell Precusors(ACPs) at least 1.5 million ACPs per each treatment
1791589|NCT00523237|Drug|Raltegravir|400 mg Twice daily for 24 weeks
1791590|NCT00523250|Drug|AR-102 0.003% Ophthalmic Solution|
1791591|NCT00523250|Drug|AR-102 0.005% Ophthalmic Solution|
1791592|NCT00523250|Drug|AR-102 0.01% Ophthalmic Solution|
1791593|NCT00523250|Drug|AR-102 0.03% Ophthalmic Solution|
1791594|NCT00523250|Drug|AR-102 Vehicle Ophthalmic Solution|
1791595|NCT00523263|Device|heparin-bonded and collagen coated polyster|femoro-popliteal bypass
1791596|NCT00523263|Device|Human umbilical vein femoro-popliteal bypass|
1791597|NCT00523289|Drug|Bupivacaine|Dosage: 150mg at once for anesthesia induction
1791598|NCT00523289|Drug|Ropivacaine|Single dose of ropivacaine, 150mg
1791599|NCT00523302|Device|Neotonus model 2100 xxx|TMS stimulates cortical neurons by creating a time varying magnetic field generated by brief but powerful electrical currents. 59 high intensity current is rapidly turned on and off in the electromagnetic coil through the discharge of capacitors. The end result of TMS is thus electrical stimulation of the brain, and some refer to TMS as electrodeless electrical stimulation. Electrical energy stored in a capacitor discharges and creates about 3,000 Amps. Through Maxwell's equations and Faraday's law, this creates a powerful magnetic field, on the order of 2 Tesla. This rapidly changing magnetic field (~30KT/s) then travels across the scalp and skull and induces an electric field within the brain (~30V/m). This induces current to flow in the brain by creating a transmembrane potential (for a thorough discussion see 60). This localized pulsed magnetic field over the surface of the head depolarizes underlying superficial neurons 61, 62 which then induces electrical currents in the brain.
1791600|NCT00523302|Device|Neotonus model 2100 xxx|A specially designed sham TMS coil will be used for all sham conditions. This sham TMS coil produces auditory signals identical to active coils but is shielded so that actual stimulation does not occur. This approach is currently the state-of-the-art approach to sham TMS procedures and is employed in high-quality clinical TMS trials.
1791601|NCT00523328|Drug|BG9924|dosage administered as per Biogen-idec protocol
1791602|NCT00523341|Biological|Denosumab|Administered by subcutaneous injection once every 6 months.
1791603|NCT00523354|Drug|Infliximab|Induction therapy with 2 infusions, each 5 mg/kg body weight within 2 wks
1791604|NCT00523367|Procedure|24 hour pH testing|24 hour pH testing will be used to screen patients
1791605|NCT00523380|Drug|recombinant interleukin-21|Administered i.v. in treatment cycles of 28 days.
1791606|NCT00523380|Drug|caelyx (pegylated liposomal doxorubicin)|Administered i.v. in treatment cycles of 28 days.
1791607|NCT00523393|Drug|Insulin Glargin|Titration of bedtime insulin glargin aiming at normal morning fasting glucose
1791608|NCT00523393|Drug|Human Insulin|Titration of bedtime human insulin aiming at normal morning fasting glucose
1791609|NCT00523406|Procedure|Photodynamic therapy and intravitreal triamcinolone|combination of photodynamic therapy and intravitreal triamcinolone combination to treat neovascular AMD
1791610|NCT00523419|Drug|Pemetrexed|500 mg/m^2, IV every 21 days until disease progression, unacceptable toxicity, participant or physician's decision.
1791611|NCT00523432|Drug|Topotecan|Weekly doses via IV infusion. Dose will be assigned based on time of study entry.
1791613|NCT00523445|Drug|Varenicline(Chantix)|The dose of antipsychotic drug will remain fixed throughout the study and the titration of varenicline will be as follows: varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice per day for days 4 to 7, then 1 mg twice per day through week 8.
1791614|NCT00523445|Drug|Placebo|The dose of antipsychotic and concomitant medications remained fixed throughout the study and the titration of varenicline was as follows: Placebo will be supplied twice daily through week 8.
1791615|NCT00523458|Drug|efavirenz or nevirapine|"Patients co-infected with HIV and TB will receive either standard doses of nevirapine (200 mg 2x daily) or efavirenz (600 mg daily) or high doses of nevirapine (400 mg and 200 mg daily) or efavirenz (800 mg daily) that are chosen to compensate for the change in pharmacokinetics shown to occur when co-infected patients are treated with the antituberculous drug, rifampin."
1791616|NCT00523471|Procedure|Blood test|
1791617|NCT00523497|Device|Non invasive mechanical ventilation|
1791618|NCT00523510|Procedure|Infant feeding counseling that includes Flash-heat|Intensive infant feeding counseling which includes description and demonstration of the WHO recommended option for HIV-infected mothers to pasteurize their breastmilk. Flash-heat pasteurization will be described and demonstrated to interested mothers. More intensive counseling and support will be provided home visits.
1791619|NCT00523523|Behavioral|Constraint-Induced Movement Therapy + auditory rhythm cues|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. Participants in the experimental group will perform this practice to the beat of a metronome. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
1791620|NCT00523523|Behavioral|Constraint-Induced Movement Therapy|The intervention is functional task practice with the paretic arm and hand for 4 hours/day for 10 sessions over 2 weeks plus a home program for the intervening weekend. All participants will also wear a mitt on the less affected hand for up to 90% of waking hours.
1791621|NCT00523536|Behavioral|Patient Navigator - Nurse Team Intervention|The patient navigator-nurse disease management intervention for treating hypertension and its associated cardiovascular risk factors will use information obtained in earlier phases of the LUCHAR grant: i.e., algorithms, risk factor profiles, and qualitative data from focus groups and interviews. The study will test the effect of this intervention on blood pressure control and utilization of hospital services in adult patients with hypertension.
1791622|NCT00523549|Drug|valsartan|160 mg or 320 mg tablets once a day
1791623|NCT00523549|Drug|amlodipine|5 mg or 10 mg tablets once a day
1791624|NCT00523562|Other|diet intervention|controled hypercalori high fructose, high fat, or high fat/high protein diet
1791625|NCT00523575|Dietary Supplement|Cubitan|400 ml/d
1791626|NCT00523588|Procedure|laser treatment (Candela Vbeam Perfecta™)|This laser has an adjustable pulse duration (0.45-40 ms), fixed wavelength 595 nm, spot size (3 mm, 5 mm, 7 mm, and 10 mm), and incident fluence range of 10-40 J/cm2. The laser is also equipped with a dynamic cooling device (DCD) (FDA cleared under K001589) that delivers cryogen (R-134a) from a small nozzle positioned 4 cm above the skin at an angle of approximately 70 degrees with respect to the skin surface. All patients will be treated with the laser device on which the varying cooling device parameters will be selected based on the clinical judgment of the treating physician. Factors used in this decision include patient age, skin type and epidermal pigmentation, size and depth of vessels, color of lesions, anatomic location, etc. In all instances, a test-dose in an inconspicuous location on the skin will be conducted prior to the first treatment.
1791627|NCT00523640|Drug|combination of gemcitabine, capecitabine, and bevacizumab|gemcitabine 1000 mg/m^2 d1, 8, capecitabine 1000 mg (flat dose) po bid d1-14, and bevacizumab 15 mg/kg d 1, on a 21 day cycle
1791628|NCT00523653|Other|blood test|looking at DNA
1791631|NCT00523692|Drug|Etanercept, methotrexate and depomedrone|Etanercept (50mg weekly; subcutaneous) Methotrexate (7.5-25mg weekly; oral) Depomedrone (up to 120mg; intraarticular / intramuscular)
1791632|NCT00523692|Drug|depemedrone|depomedrone (up to 120mg im/ia) methotrexate (added after symptoms have been present for 12 weeks)
1791633|NCT00523705|Drug|escitalopram|10 mg tablets taken once daily. Dosing in the luteal phase of the menstrual cycle (estimated day 14 to day 2). Start at 10 mg/day (1 tablet) in the first treatment cycle. If unimproved, increase to 20 mg/day (2 tablets) in cycle 2 if not precluded by side effects.
1791634|NCT00523705|Other|placebo|Placebo tablets matched to drug
1791635|NCT00523718|Drug|riluzole|50 mg PO bid, 12 weeks
1791636|NCT00523718|Drug|placebo|placebo, 1 capsule PO bid, 12 weeks
1791637|NCT00523731|Procedure|Angiogenic Cell Precursors (ACPs) or Vescell TM|
1791638|NCT00523744|Drug|Amlodipine|Amlodipine supplied as 5 mg tablets, taken orally once a day during Treatment Phase 1 only.
1791639|NCT00523744|Drug|Olmesartan medoxomil|Olmesartan medoxomil supplied as 10 mg tablets taken once a day during Treatment Phase 1 only.
1791640|NCT00523744|Drug|Amlodipine+valsartan|Fixed-dose combination of amlodipine 10 mg plus valsartan 160 mg tablet taken orally once a day during Treatment Phase 2 and Extension Phase.
1791641|NCT00523744|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg tablets taken once a day during the Extension Phase.
1791642|NCT00523757|Drug|Spironolactone|
1791643|NCT00523757|Drug|Placebo|
1791644|NCT00523770|Procedure|Urine sample collection|Urine samples will be collected and tested for the presence of S. pneumoniae
1791645|NCT00517257|Drug|Atorvastatin|80 mg orally once daily for 24 weeks
1791646|NCT00517257|Drug|Placebo|Placebo tablet orally once daily for 24 weeks
1791647|NCT00517270|Drug|Rabeprazole 20mg twice daily|
1791648|NCT00517283|Drug|exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 3 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
1792785|NCT00532246|Drug|raloxifene|
1791649|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. Period 2 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
1791650|NCT00517283|Drug|Exenatide and placebo|Period 1 = Subcutaneous injections of placebo in an amount equivalent to exenatide twice daily for 4 days and once in the morning of the 5th day. Period 2 = Subcutaneous injections of exenatide 5mcg twice daily for 4 days and once in the morning of the 5th day. Period 3 = Subcutaneous injections of exenatide 5mcg twice daily for 2 days, followed by 2 days of twice daily 10 mcg doses, 10mcg once in the morning of the 5th day. A washout of at least 2.5 days will occur between each treatment period.
1791651|NCT00517296|Procedure|EUA with seton placement if necessary|Patients randomized to the combination therapy group, the surgeon will have access to EUS findings.
1791652|NCT00517296|Drug|adalimumab|Patients began therapy with adalimumab using clinic standards for dosing.
1791653|NCT00517296|Procedure|EUS|Patients in combination therapy group had an EUS done every 12 weeks to help guide therapy.
1791654|NCT00517309|Biological|V501, Gardasil, Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine / Duration of Treatment : 4 Years|
1791655|NCT00517309|Biological|Comparator: placebo (concomitant-vaccine matched) / Duration of Treatment : 4 Years|
1791656|NCT00517322|Drug|ramipril|ramipril 2.5- 5 mg once daily
1791657|NCT00517322|Drug|irbesartan|irbesartan 150-300 mg once daily
1791658|NCT00517335|Procedure|Functional magnetic resonance imaging (fMRI) scan|Healthy control women, recovered bulimia women, and also recovered anorexia women will complete specific tasks in an fMRI scanner that will take up to 60 minutes.
1791659|NCT00517348|Biological|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
1791660|NCT00517361|Drug|carboplatin|AUC 6 in 250mL saline IV over 30 minutes
1791661|NCT00517361|Drug|bevacizumab|15mg/kg in 100mL saline IV over 60 - 90 minutes
1791662|NCT00517387|Drug|Quetiapine XR|All patients will receive Quetiapine XR at an initial dose of 50mg/day to be increased incrementally (dose of 50mg/day 2 and 150mg/day 3) to achieve a target dose of 300 mg/day by day 4. Tablets will be self-administered early each night.
1791663|NCT00517400|Device|Deep repetitive Transcranial Magnetic Stimulation (rTMS) real or sham|
1791664|NCT00517413|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc or iv monthly, starting dose
1791665|NCT00517426|Drug|acetazolamide|i.v. 500 mg of acetazolamide for the acute study and 500 mg of acetazolamide p.o. t.i.d. for two days
1791666|NCT00517439|Drug|Copegus|1000/1200mg po daily for 24 weeks
1791667|NCT00517439|Drug|Pegasys|180 micrograms sc weekly for 24 weeks
1791668|NCT00517439|Drug|Pegasys|90 micrograms sc weekly for 24 weeks
1791669|NCT00517439|Drug|RO4588161|1000mg po bid for 24 weeks
1791670|NCT00517439|Drug|RO4588161|500mg po bid for 24 weeks
1791671|NCT00517439|Drug|RO4588161|1500mg po bid for 24 weeks
1791672|NCT00517465|Drug|Placebo|po bid
1791673|NCT00517465|Drug|RG1511|Starting multiple doses of 100mg po bid escalated in subsequent groups of patients to potential maximum multiple dose of 1200mg po bid.
1791674|NCT00517478|Procedure|Blood Sample|
1791675|NCT00517491|Drug|lanreotide (Autogel formulation)|120 mg administered every 28 days via deep subcutaneous injection. A total of 4 injections will be administered during the study.
1791676|NCT00517504|Drug|Methylphenidate|"1-week single blind placebo lead-in phase.
step-wise single blind titration of MPH at 1.25 mg bid for the first week, 2.5 mg bid for the second week , 5 mg bid for the third week, 7.5 mg bid for the fourth week and 10 mg bid for the 5th week.
Dose increased if room for improvement in child's symptoms and no clinically important side effects. Dose not increased if no room for improvement in child's symptoms or if clinically important side effects.
After single blind titration, child enters a 4-week double-blind randomized crossover study with placebo and child's best dose that produced maximal effect with minimal side effects, with each child serving as his/her own control."
1791677|NCT00517517|Biological|Whole virion, Vero cell-derived influenza vaccine containing either 3.75 µg or 7.5 µg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation|Subjects will be randomized 1:1 to receive two intramuscular injections of the whole virion, Vero cell-derived influenza vaccine containing either 3.75 mg or 7.5 mg H5N1 hemagglutinin (HA) antigen in a non-adjuvanted formulation on Day 0 and Day 21.
1791678|NCT00517530|Drug|Obinutuzumab|Obinutuzumab was provided in single-dose glass vials as a freeze-dried powder.
1791679|NCT00517543|Drug|GW856553|
1791680|NCT00517556|Drug|CCOCP|(CCOCP) continuous treatment with Monophasic oral gestodene/ethinyl estradiol
1791681|NCT00517556|Drug|Traditional OCP|(traditional OCP) (21 active days/7 inactive days) treatment regimen
1791682|NCT00517569|Genetic|GX-12|a mixed plasma DNA (HIV-1 antigen genes and human IL-12 mutant) 4, 8, 16mg, i.m., once every other weeks for 22 weeks (total 12 times)
1791683|NCT00517569|Drug|HAART|Highly active antiretroviral therapy; Discontinuation at 24 weeks; NB: The patients should be treated with 2 NRTIs+1 NNRTI or 2 NRTIs + 1 PI, according to the guidelines published by DHHS in the USA.
1791684|NCT00517582|Drug|HOE-140|Subcutaneous at time 0 and 6 hours
1791685|NCT00517582|Other|Placebo|Subcutaneous at time 0 and 6 hours
1791686|NCT00517595|Drug|Pemetrexed and Gemcitabine plus Bevacizumab|Bevacizumab 10 mg/kg will be given intravenously according to weight. Pemetrexed 500 mg/m^2 and gemcitabine 1500 mg/m^2 will be given intravenously according to weight and height. All agents are administered every 2 weeks.
1791687|NCT00517608|Device|Laparoscopic colectomy|
1791688|NCT00517621|Drug|Paclitaxel|
1791689|NCT00517621|Drug|EPO|
1791690|NCT00517634|Drug|FP|Fluticasone Propionate 100 mcg BD
1791691|NCT00517634|Drug|SFC|Salmeterol/Fluticasone Propionate Combination 50/100 mcg BD
1791692|NCT00517634|Drug|Placebo|Matching Placebo
1791780|NCT00523978|Device|Arctic Front® Cryoablation Catheter|Experimental Subjects received cryoablation intended to isolate the pulmonary veins and ablate arrhythmia foci with the cryoablation catheter system.
1791693|NCT00517647|Drug|ATMX|Medication phase: After screening assessments are completed, the child will enter the medication phase of the study. The child will be started on atomoxetine at 0.5 mg/kg/day, with the dosage increased to a maximum dose of 1.8 mg/kg/day. The dose will be determined by how well the child responds to and tolerates the drug. The dose will be given twice a day to minimize side effects. After the optimum dose is determined, the child will be kept at this stable dose for 4 weeks.
1791694|NCT00517673|Drug|GSK945237|
1791695|NCT00517673|Drug|Sugar Pill|Placebo
1791696|NCT00517686|Other|Information feedback intervention|This study will evaluate an information feedback intervention: measuring, reporting and feeding back information to primary care teams on the need for treatment intensification in patients at high risk for cardiovascular disease (CVD).
1791697|NCT00517699|Drug|rituximab [MabThera/Rituxan]|750mg/m2 iv
1791698|NCT00517699|Drug|Methotrexate|8g/m2 iv
1791699|NCT00517699|Drug|Cytarabine|2g/m2 iv
1791700|NCT00517712|Drug|Single agent arsenic trioxide|duration of maintenance therapy, 6 months versus 12 months
1791701|NCT00517725|Drug|carvedilol|
1791702|NCT00517725|Drug|bisoprolol|
1791703|NCT00517725|Drug|Nebivolol|
1791704|NCT00517738|Other|Physical training|A program of exercising under strict surveillance, with endurance and coordination maneuvers
1791705|NCT00517738|Other|Diet intervention|Energy intake tailored to basal metabolism and level of physical activity. Protein and sodium intake will be adjusted to 1.2-1.5 g/kg/d, and 1.5-2 g/d of salt, respectively. The latter will be adjusted only in those patients presenting ascites and/or edema
1791706|NCT00517751|Device|X-STOP PEEK|Placement of X-STOP PEEK in up to two levels in the lumbar spine for patients diagnosed with moderately symptomatic lumbar spinal stenosis in accordance with current labeling instructions for use.
1791707|NCT00517764|Drug|escitalopram|Patients started on 20mg of escitalopram and this dose was increased based on tolerability and therapeutic response to a maximum dose of 40mg by week 12. The trial was 16 weeks. The treatment trial has completed and is no longer accepting patients.
1791708|NCT00517777|Device|continuous positive airway pressure ventilation|nighttime
1791709|NCT00517777|Behavioral|dietary and life style recommendations|
1791710|NCT00517777|Behavioral|dietary and life style recommendations|
1791711|NCT00517790|Drug|ABT-869 .25 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
1791712|NCT00517790|Drug|ABT-869 0.10 mg/kg|Subjects will take linifanib (ABT-869) based on body weight. Dosing will be determined at baseline and will be based on randomization to either 0.10 mg or 0.25 mg of ABT-869 per kilogram of body weight.
1791713|NCT00517803|Dietary Supplement|Probiotic Yogurt B: with various micronutrients|175g probiotic yogurt / day 25% RDA for each nutrient
1791714|NCT00517803|Dietary Supplement|Probiotic Yogurt A: Kaiser micronutrients|175g probiotic yogurt/ day 25% RDA for each nutrient
1791715|NCT00517803|Dietary Supplement|Probiotic yogurt C: with basic micronutrients|175g yogurt/ day 25% RDA for each nutrient
1791716|NCT00517803|Dietary Supplement|Probiotic Yogurt D: Placebo -- no added micronutrients|175g/day probiotic yogurt
1791717|NCT00517816|Drug|RG1671|Administered iv at escalating doses (with a starting dose of 0.0015mg)
1791718|NCT00517829|Drug|Docetaxel|Taxotere 60 mg/m2 as an intravenous (IV) infusion over 1 hour
1791719|NCT00517829|Drug|cetuximab|ERBITUX 400 mg/m2 IV over 120 minutes (first dose only), all other doses are 250 mg/m2 over 60 minutes.
1791720|NCT00517829|Drug|oxaliplatin|Eloxatin 130 mg/m2 IV over 2 hours
1791721|NCT00517842|Drug|ViNeuro|
1791722|NCT00517855|Biological|PRTX-100 (Staphylococcal protein A)|
1791723|NCT00517868|Drug|URG101|Bladder instillation of URG101 or Placebo in random order on treatment 1 and treatment 2 followed by an open-label URG101 on treatment 3 within the same week.
1791724|NCT00517868|Drug|Placebo|Liquid formulation without active URG101 drug components
1791725|NCT00517881|Drug|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Subcutaneous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 mcg every 4 weeks for 20 weeks. Further dose adjustments will be performed during the study depending on the participant's blood hemoglobin levels.
1791726|NCT00517894|Drug|CEOP/IMVP-Dexa chemotherapy|Cyclophosphamide 750 mg/m2 i.v. d 1, epirubicin 70 mg/m2 i.v d 1, vincristine 1.4 mg/m2 i.v. d 1+8, prednisolone 100 mg p.o. d 1-5, ifosfamide 2000 mg/m2 i.v. d 15-17, etoposide 100 mg/m2 i.v. d 15-17, dexamethasone 40 mg p.o. or i.v. d 15-19, methotrexate 800 mg/m2 i.v. d 22. Mesna was given with ifosfamide, calcium-folinate rescue after methotrexate. Filgrastim was given on days 2-7, 9-12, 18-21, 23-28
1791727|NCT00517907|Drug|Preimplantation factor (PIF-1)|"The study will include 6 patients and will last for at least six months. The first three patients will receive PIF-1 (0.5 mg/kg/day for 14 days) by subcutaneous injection. The dosage in the next three patients may be increased to 1 mg/kg/day for 14 days.
Patients will be treated serially: each patient will be followed for 2 weeks after cessation of PIF-1 administration before the next patient begins PIF-1 administration."
1791728|NCT00517920|Drug|ABT-869|0.25 mg/kg QD
1791729|NCT00517933|Drug|Sildenafil Citrate|Sildenafil citrate (20mg 3 times a day [TID] orally for 12 weeks followed by 20mg TID open-label sildenafil for an additional 12 weeks)
1791730|NCT00517933|Other|Placebo|Placebo (20mg TID orally for 12 weeks followed by 20mg open-label sildenafil for 12 weeks)
1791731|NCT00517946|Drug|pseudoephedrine hydrochloride|
1791732|NCT00517946|Drug|cetirizine hydrochloride|
1791733|NCT00517959|Radiation|Stereotactic Conformal radiotherapy|SCRT
1791734|NCT00517959|Radiation|Conventional radiotherapy|
1791735|NCT00517972|Drug|Omacor (omega-3-acid ethyl esters)|
1791781|NCT00523978|Drug|Flecainide or Sotalol or Propafenone|Flecainide 200 mg / day Propafenone 450 mg / day Propafenone-SR 650 mg / day Sotalol 240 mg / day
1791782|NCT00523991|Drug|tiotropium|Oral inhalation once daily of 18mcg tiotropium via handihaler
1791783|NCT00523991|Drug|Placebo|Oral inhalation once daily of placebo matching tiotropium via handihaler
1791784|NCT00524004|Biological|Anti-CsbD Bovine IgG|Three times a day for seven days
1791785|NCT00524004|Other|Placebo|Three times a day for seven days
1791786|NCT00524004|Biological|Anti-CS17 Bovin IgG|Three times a day for seven days
1791736|NCT00517985|Drug|Duloxetine|During the current study, for a short period of time participants will receive a placebo (a pill that looks like the study drug but which does not contain any medication), although during the majority of the study, participants will be receiving the actual study medication (Duloxetine). The initial dose of Duloxetine to be given will be a 30 mg dose with the dosage increased over time to 60 mg per day. This study will be blinded, meaning that participants will not know whether they are taking placebo or the study drug. However, all subjects will receive duloxetine for the majority of the time they are enrolled in the trial. Investigators will know when subjects are receiving the placebo but in order to maintain the blinding of this study, the study staff will not be able to tell participants when they are taking placebo and when they are taking Duloxetine.
1791737|NCT00517998|Drug|Biologic Lung Volume Reduction (BLVR) - 10 mL Hydrogel|10 mL Hydrogel
1791738|NCT00518011|Drug|Erlotinib|150 mg po daily
1791739|NCT00518011|Drug|Gemcitabine|As prescribed
1791740|NCT00518024|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|Bilateral Theta Burst Stimulation
1791741|NCT00518037|Behavioral|surveys|anxiety surveys
1791742|NCT00518050|Behavioral|Focus group|"Conduct focus groups in melanoma survivors to enhance the understanding of the behavioral aspects of:
Screening, skin self-examination, sun protection, and other cancer preventive practices;
Cognitive factors (knowledge, awareness, melanoma worry, and perceived risk) related to screening and sun protection practices; and,
Impact of melanoma on quality of life, family relationships, and economic issues arising from treatment"
1791743|NCT00518050|Behavioral|Survey|History of sun exposure Medical factors Affect, cognition, and quality of life Behavioral adoption Demographics Phenotypic factors Economic/healthcare factors
1791744|NCT00518089|Drug|Gatifloxacin 0.5% eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
1791745|NCT00518089|Drug|placebo eye drops|Day 1 = 1 drop of study medication every 2hrs up to 8 times total; day 2-5 = 1 drop twice daily
1791746|NCT00518102|Drug|REGRANEX (becaplermin)|A cohort of REGRANEX (becaplermin) users (ie, patients treated with REGRANEX (becaplermin), a topical medication used to treat non-healing neuropathic foot ulcers in patients with diabetes).
1791747|NCT00518102|Other|REGRANEX (becaplermin) comparators|A cohort of REGRANEX (becaplermin) nonusers (ie, patients who are not treated with REGRANEX [becaplermin]) but are similar in characteristics to patients in the REGRANEX [becaplermin] user cohort)
1791748|NCT00518115|Drug|Albiglutide (GSK716155) or exenatide|Albiglutide weekly subcutaneous injection or exenatide twice daily injection
1791749|NCT00518128|Procedure|Surgical OSA treatment|uvulopalatopharyngoplasty +/-tonsillectomy, genioglossus advancement, and hyoid suspension
1791750|NCT00518128|Procedure|Positive Airway Pressure Therapy|Continuous positive airway pressure for treatment of obstructive sleep apnea
1791751|NCT00518141|Drug|Acetyl Salicylic Acid and Terbutalin|ASA 75 mg, Terbutalin 5mg
1791753|NCT00518167|Behavioral|Intensive lifestyle counselling|"Individualized dietary and physical activity counselling aiming at
weight reduction
dietary fibre 15 g /1000 kcal or more
energy proportion of dietary fat less than 30%
energy proportion of saturated fat less than 10%
moderate physical activity >30 minutes per day or 4 hours per week"
1791754|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
1791755|NCT00518180|Biological|Tdap Vaccine|One dose of vaccine administered intramuscularly
1791756|NCT00518180|Biological|Novartis Meningococcal ACWY Conjugate Vaccine|One dose of vaccine administered intramuscularly
1791757|NCT00518193|Drug|ERBITUX|400 mg/m² 2h injection at week 1, then 250 mg/m² in one hour injection the following weeks
1791758|NCT00518206|Biological|NY-ESO-1 ISCOMATRIX® vaccine|NY-ESO-1 ISCOM vaccine (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant) administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
1791759|NCT00518206|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m^2) administered as an intravenous injection 1 day prior to each vaccination with NY-ESO-1 ISCOM (100 μg of the NY-ESO-1 protein formulated with 120 μg of ISCOM adjuvant), which was administered as an intramuscular injection every 4 weeks for 3 doses in every cycle.
1791760|NCT00523809|Drug|Bevacizumab|10 mg/kg IV Daily Over 30 Minutes for 1 Day
1791761|NCT00523809|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Stem Cell Transplantation on Day 8.
1791762|NCT00523809|Drug|Fludarabine|25 mg/m^2 IV Daily Over 30 Minutes for 5 Days
1791763|NCT00523809|Drug|Melphalan|70 mg/m^2 IV Daily Over 30 Minutes for 2 Days
1791764|NCT00523809|Drug|Thymoglobulin|0.5 mg/kg IV on Day - 3, 1.5 mg/kg IV on Day - 2, and 2 mg/kg IV on Day -1.
1791765|NCT00523822|Other|Spinal Manipulative Therapy|
1791766|NCT00523848|Drug|bortezomib|IV
1791767|NCT00523848|Drug|pegylated liposomal doxorubicin hydrochloride|IV
1791768|NCT00523848|Drug|thalidomide|Oral
1791769|NCT00523861|Dietary Supplement|Moderate alcohol consumption|
1791770|NCT00523887|Drug|Fentanyl transdermal therapeutic system|
1791771|NCT00523900|Dietary Supplement|Quaker Complete Nutrition Supplements|3-6 250ml cans of Quaker Complete Nutrition Supplements per day
1791773|NCT00523926|Drug|TMC207|
1791774|NCT00523939|Drug|cytarabine liposome injection|50 mg intrathecal every 14 days for 8 doses, then every 28 days for six doses
1791775|NCT00523952|Drug|tacrolimus ointment|tacrolimus, single arm, 0.1 ointment
1791776|NCT00523965|Drug|amphotericin B deoxycholate|Amphotericin B deoxycholate 1 mg/kg on alternate days for 15 infusions
1791777|NCT00523965|Drug|Liposomal Amphotericin B with Miltefosine|Liposomal Amphotericin B 5 mg Miltefosine 50 mg twice daily if patient weighs equal to or > 25 kg Miltefosine 50 mg once daily if patient weighs <25 mg
1791778|NCT00523965|Drug|Liposomal Amphotericin B and Paromomycin Sulfate|AmBisome 5mg/kg iv infusion over 2 h x 1 day (single dose) + paromomycin sulfate 15 mg/kg/day i.m for 10 days, on day 2-11
1791779|NCT00523965|Drug|miltefosine + Paromomycin sulfate|oral miltefosine 50mg once daily (< 25 kg body weight) or twice daily ( > 25 kg body weight) or 2.5 mg/kg for children under 12 years, for 10 days + Paromomycin sulfate 15 mg/kg/day im. for 10 days
1791787|NCT00524017|Biological|cetuximab|given IV
1792786|NCT00532246|Drug|Placebo|
1791790|NCT00524030|Drug|pregabalin 150 mg/day|pregabalin 150 mg/day (75mg BID), duration is 20 weeks.
1791791|NCT00524043|Drug|Paliperidone ER|1.5 mg tablet once daily for 6 weeks
1791792|NCT00524043|Drug|Placebo|Once daily for 6 weeks
1791793|NCT00524043|Drug|Paliperidone ER|6 mg tablet once daily for 6 weeks
1791794|NCT00524056|Drug|Carisbamate|two 100 mg tablets twice per day
1791795|NCT00524056|Drug|Placebo|two placebo tablets twice per day
1791796|NCT00524069|Biological|bevacizumab|
1791797|NCT00524069|Drug|capecitabine|
1791798|NCT00524069|Drug|gemcitabine hydrochloride|
1791799|NCT00524069|Other|flow cytometry|
1791800|NCT00524069|Other|laboratory biomarker analysis|
1791801|NCT00524069|Procedure|adjuvant therapy|
1791802|NCT00524069|Procedure|computed tomography|
1791803|NCT00524069|Procedure|neoadjuvant therapy|
1791804|NCT00524095|Drug|azithromycin and fluticasone|azithromycin 500 mg once a day three times a week for 6 months and then inhaled steroids (fluticasone 500 ug bid) for 6 months
1791805|NCT00524095|Drug|fluticasone and azithromycin|inhaled steroids (fluticasone 500 ug bid) for 6 months and then azithromycin 500 mg once a day three times a week for 6 months
1791806|NCT00524121|Drug|erlotinib hydrochloride|Oral
1791807|NCT00524121|Other|immunohistochemistry staining method|Correlative Study
1791808|NCT00524121|Radiation|radiation therapy|Radiation Treatment
1791809|NCT00525525|Drug|Bevacizumab|Patients are given 10 mg/kg IV Q2 weeks.
1791810|NCT00525525|Drug|Tarceva|Patients receive 150 mg PO daily. If patients are not experiencing intolerable toxicity, they may escalate their dose to 200 mg PO daily. If patients are experiencing intolerable toxicity, their dose will be held until the toxicity improves or resolves, then re-treated at a lower dose level, i.e. 100 mg PO daily.
1791811|NCT00525525|Drug|Temozolomide|Patients receive 200 mg/m2 for Days 1-5 of every 28 day cycle. Although the calendar days may be slightly altered, the patient should always receive this dose for 5 days within a treatment cycle. If the patient experiences certain toxicities specified in the protocol, Temodar will be held then given at a reduced dose, i.e. 150 mg/m2 Days 1-5.
1791812|NCT00525538|Radiation|conformal radiotherapy|
1791813|NCT00525551|Drug|Acetylcysteine|150 mg / kg body weight. Drug is dissolved in NaCl to a final volume of 300 mL. This volume is infused starting one hour prior to surgery, and continued 1 hour after the end of surgery.
1791814|NCT00525551|Drug|Placebo (NaCl)|300 mL 0.9% NaCl
1791815|NCT00525564|Drug|Placebo|Placebo diskus inhalation powder
1791816|NCT00525564|Drug|Salmeterol diskus inhalation powder|50 micrograms twice a day
1791817|NCT00525577|Drug|Placebo|Placebo tablet, once daily
1791818|NCT00525577|Drug|AGI-1067|75 mg AGI-1067 tablet, once daily
1791819|NCT00525577|Drug|AGI-1067|150 mg AGI-1067 Tablet, once daily
1791820|NCT00525590|Drug|GLIADEL|Resect the tumor as completely as possible. After repeated irrigation of the decompressed area demonstrates no bleeding, and care is taken not to have any foreign material enter the ventricle, up to 8 GLIADEL wafers should be placed to cover the entire surface area of the resection cavity (if possible). Slight overlapping of wafer edges is permitted. The number of wafers will be determined by the size of the tumor resection cavity. Each GLIADEL wafer contains 7.7 mg of carmustine, resulting in a dose of 61.6 mg when 8 wafers are implanted. The GLIADEL wafer is a round white to yellow disk with flat surfaces.
1791821|NCT00525603|Drug|Cyclophosphamide|200 mg/m^2/day 3-5 IV 5-30 minutes
1791822|NCT00525603|Drug|Fludarabine|20 mg/m^2/day 3-5 IV 5-30 minutes
1791823|NCT00525603|Drug|Alemtuzumab|30 mg Days 1, 3, 5 IV 2-4 hours
1791824|NCT00525603|Drug|Rituximab|375 mg/m^2/day 2 IV 4-6 hours
1791825|NCT00525616|Drug|Mabthera|Two IV perfusions of 1000mg at 15 days intervals
1791826|NCT00525629|Dietary Supplement|Walnuts|48 Grams of Walnuts Daily
1791827|NCT00525629|Dietary Supplement|Control|Control Diet with No Walnuts
1791828|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles
1791829|NCT00525642|Drug|Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide|Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
1791830|NCT00525655|Behavioral|Web-Based Multimedia Intervention|Website designed to offer information and support for adolescents and young adults with FAP, viewed for 30-60 minutes.
1791831|NCT00525655|Behavioral|Questionnaire|Questionnaires taking 10-15 minutes to complete.
1791832|NCT00525668|Drug|epigallocatechin-gallate (Sunphenon)|200 mg twice daily, after 3 months 400 mg twice daily
1791833|NCT00525668|Drug|placebo|2 placebo capsules twice daily, after 3 months 4 placebo capsules twice daily
1791834|NCT00525681|Drug|cyclosporine A|Cyclosporine is dosed twice daily and is individualized as per center practice and kept stable during the study.
1791835|NCT00525681|Drug|tacrolimus|Dosing of tacrolimus is given twice daily and individualized as per center practice.
1791836|NCT00525694|Other|Glucose tolerance test|10 ounces glucose tolerance test solution
1791837|NCT00525694|Other|glucose tolerance test solution|75 grams glucose load
1791838|NCT00525694|Other|Diet Coke|10 ounces of Diet Coke
1791839|NCT00525694|Other|Coke Zero|10 ounces of Coke Zero
1791840|NCT00525707|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4ML/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
1791841|NCT00525720|Procedure|Brachytherapy|Brachytherapy implant procedure lasting 1-2 hours.
1791842|NCT00525720|Behavioral|Questionnaire|Questionnaires taking 30 total minutes.
1791843|NCT00525733|Drug|darunavir 800 mg|darunavir 800mg tablet will be administered with 100 mg capsule of ritonavir once daily (may be taken with or without food)
1791844|NCT00525733|Drug|FTC 200 mg/TDF 300mg|Emtricitabine/tenofovir DF fixed-dose tablet containing 200 mg of emtricitabine and 300 mg of tenofovir DF will be administered orally as one tablet once daily (may be taken with or without food)
1791845|NCT00525733|Drug|Maraviroc|Maraviroc will be administered twice daily in 150 mg tablets (may be taken with or without food)
1791846|NCT00525733|Drug|Raltegravir|Raltegravir will be administered twice daily as 1-400 mg tablets (to be taken with food)
1792970|NCT00533663|Drug|guided relaxation|
1791847|NCT00525733|Drug|Ritonavir 100 mg|one tablet of ritonavir is taken with darunavir daily
1791848|NCT00525746|Behavioral|Interview|Interview lasting about 50 minutes.
1791849|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days
1791850|NCT00525759|Drug|5-FU, Epirubicin, Cyclophosphamide, Docetaxel, Zoledronic acid|3 cycles of FEC q3w, followed by 3 cycles of docetaxel q3w FEC: 5FU 500mg/m2 intravenous bolus D1, Epirubicin 100mg/m2 intravenous bolus D1, Cyclophosphamide 500mg/m2 intravenous bolus D1) every 21 days Docetaxel: (100mg/ m2 intravenous infusion) every 21 days Zoledronic acid: 4mg intravenous infusion Day 2, AFTER FIRST CYCLE CHEMOTHERAPY ONLY
1791851|NCT00525772|Drug|ciclesonide|low dose- 50ug and 200ug
1791852|NCT00525772|Drug|ciclesonide|high dose- 100ug and 400ug
1791853|NCT00525785|Drug|5-Fluorouracil|"2.2 Gm/m^2 By Vein Over 48 Hours On Days 1, 15, 29, and 43.
Chemoradiotherapy: 300 mg/m2 a day Monday through Friday, by continuous infusion during radiation through an outpatient portable pump."
1791854|NCT00525785|Drug|Folinic Acid|200 mg/m^2 by vein Over 30 Minutes On Days 1, 15, 29, and 43.
1791855|NCT00525785|Drug|Oxaliplatin|"100 mg/m^2 By Vein Over 2 Hours On Days 1, 15, 29, and 43.
Chemoradiotherapy: 45 mg/m2 over 2 hours weekly for 5 weeks during radiation. (oxaliplatin should be administered on the first day of the radiation week)."
1791856|NCT00525785|Radiation|Radiotherapy|45 Gy (1.8 Gy fx/day) Monday through Friday, 12 days after the last dose of 5FU plus oxaliplatin and no later than 28 days.
1791857|NCT00525798|Drug|SMC021 Oral calcitonin|0.8mg SMC021 - oral calcitonin, once daily
1791858|NCT00525798|Drug|SMC021 Placebo|SMC021 - Placebo, once daily
1791859|NCT00525811|Other|patient dialogue|Information on shared decision making, how to participate in medical decision making, information on acute low back pain, information on depression
1791860|NCT00525811|Other|patient information|Information on acute low back pain, information on depression
1791861|NCT00525824|Drug|Rosuvastatin (Crestor)|10mg and 20 mg
1791862|NCT00525824|Drug|Ezetimibe|10 mg
1791863|NCT00525824|Drug|Simvastatin|40mg and 80 mg
1791864|NCT00525837|Drug|fixed dose varenicline|varenicline 0.5 mg po daily for days 1-3, 0.5 twice daily for days 4-7, 1 mg twice daily thereafter for study duration.
1791865|NCT00525837|Drug|varenicline|up to 1 mg twice daily
1791866|NCT00525850|Other|high fat diet|high saturated fat no starch diet
1791867|NCT00525850|Other|low saturated fat diet|low calorie low saturated fat low trans fat high fiber diet
1791868|NCT00525863|Drug|oxygen|Patients will be treated with oxygen for 1 month and then for 1 month with regular air with the same flow rate and procedure or randomly in the opposite order. We propose to enrich the inspired oxygen partial pressure from 21 kPA to ~40 kPa in a double blind cross-over design. Ninety percent oxygen or regular air will be supplied from oxygen concentrators, through standard plastic nasal prongs, at a flow rate of 5 liters/minute, for 7 hours/day, throughout the night.
1791869|NCT00525876|Drug|Cyclophosphamide|"Matched Donors:
750 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.
Unrelated or Mismatched Donors:
1000 mg/m^2 given intravenously on Day -3, 4 hours after completion of Fludarabine.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
1791870|NCT00525876|Drug|Fludarabine|"30 mg/m^2 given intravenously on Days -5 and -3 before transplantation.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
1791871|NCT00525876|Drug|Rituximab|"Matched Donors:
375 mg/m^2 given intravenously on Days -13, -6 before transplantation and Days 16, 8 after transplantation.
Unrelated/Mismatched Donors:
375 mg/m^2 given intravenously on Days -8, -1 before transplantation and Days 6, 13 after transplantation.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)
For development of disease progression or no response, immunomanipulation with Rituximab 375 mg/m^2 given intravenously, then 1000 mg/m^2 given intravenously weekly for 3 weeks, and taper off Tacrolimus dose over 2 weeks.
DLI = Donor Lymphocyte Infusion/Immunomodulation Post Transplantation Immunomodulation for patients with lymphoid Malignancies:
375 mg/m^2 then 1000 mg/m^2 weekly x 3 if immunomanipulation is undertaken for persistent disease."
1791872|NCT00525876|Drug|Alemtuzumab|"Unrelated/Mismatched Donors:
15 mg per day given intravenously days 1 through 3 after transplantation.
(Stem Cell Transplantation and Low Dose Total Body Irradiation = Day 0)"
1791873|NCT00525876|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells.
1791874|NCT00525889|Drug|IL-2|Administered by subcutaneous injection at a dose of 4.5x10^6 IU/day, three times weekly for 28 days starting on day 0.
1791875|NCT00525889|Drug|Rapamycin|Administered orally, initial daily dose of 2mg. At day 7, dose adjusted to achieve and maintain whole blood trough levels of 5-10 ng/ml.
1791876|NCT00525902|Drug|Adalimumab|40 mg delivered every 2 weeks by subcutaneous injection
1791877|NCT00525915|Drug|5-Fluorouracil|"Arm A = 250 mg/m^2 IV over 24 hours for 5 days weekly for 5 weeks.
Arm B = 2.2 mg/m^2 IV over 48 hours on days 1 and 15."
1791878|NCT00525915|Drug|Oxaliplatin|"Arm A: 40 mg/m^2 IV daily over 2 hours for 5 weeks
Arm B: 100 mg/m^2 IV on Day 1 and 15"
1791879|NCT00525915|Radiation|Radiation Therapy|Radiation treatment every weekday for 5 weeks.
1791880|NCT00525915|Procedure|Surgery|Surgical removal of the primary tumor and lymph nodes following completion of disease status evaluation post chemotherapy and radiation treatments.
1791881|NCT00525928|Drug|varenicline|varenicline 0.5mg daily for days 1-3, 0.5mg twice daily for days 3-7, then 1mg twice daily for length of hospitalization
1791882|NCT00525941|Drug|NBI-34060|10 mg capsules; dosed as needed for falling back asleep after a bothersome awakening provided there are at least 4 hours remaining in bed; no more than one dose per night.
1791883|NCT00525954|Drug|A-002|
1791885|NCT00525980|Behavioral|Computer Program|"Participants will be given a program to learn about breast cancer risk and genetic testing.
Arm 3 Only = Participants will use the program with the assistance of a promotora (female promoter, community health worker, sometimes known as a lay health advisor)."
1791886|NCT00525980|Behavioral|Focus Group|Focus group discussion lasting about 60 to 90 minutes.
1791887|NCT00525980|Other|Written Materials|Printed materials will be given. The CD-ROM will be offered at the end of the study.
1791888|NCT00525980|Behavioral|Questionnaires|Occasional questionnaire, written or verbal phone survey, about knowledge and attitudes toward cancer and genetic testing.
1791891|NCT00526006|Drug|esomeprazole|40 mg od for 8 wks
1791892|NCT00526032|Procedure|OIR Imaging|Images from 4 different positions will be taken per lesion. The entire imaging procedure will take about 5 minutes per lesion.
1791893|NCT00526045|Drug|AUY922|
1791894|NCT00526058|Device|Secura Device: Futura|Randomized to 6 bi-monthly H.E.L.P. therapy treatments with the Plasmat® Secura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Futura apheresis system.
1791895|NCT00526058|Device|Futura Device: Secura|Randomized to 6 bi-monthly H.E L.P. therapy treatments with the Plasmat® Futura apheresis system and then cross over to receive 6 bi-monthly treatments with the Plasmat® Secura apheresis system.
1791896|NCT00526071|Drug|AT1001|AT1001
1791897|NCT00526097|Drug|Bisacodyl 10 mg|2 x 5 mg bisacodyl once daily
1791898|NCT00526097|Drug|Placebo|Placebo-to-match bisacodyl 10 mg (2 x 5 mg) once daily
1791899|NCT00526110|Drug|5-Fluorouracil|2.2 Gm/m^2 IV over 48 hours on Day 1.
1791900|NCT00526110|Drug|Docetaxel|20 mg/m^2 IV over 60 minutes
1791901|NCT00526110|Drug|Oxaliplatin|85 mg/m^2 IV over 120 minutes on Day 1.
1791902|NCT00526123|Device|Symmetric Tip Catheter|Dialysis catheter
1791903|NCT00526123|Device|Conventional Split-tip Catheter|Dialysis Catheter
1791904|NCT00526136|Drug|Placebo|
1791905|NCT00526136|Drug|Vernakalant (oral)|Vernakalant (oral), 150 mg (b.i.d.) Vernakalant (oral), 300 mg (b.i.d.) Vernakalant (oral), 500 mg (b.i.d.)
1791906|NCT00526149|Drug|BI 2536|
1791907|NCT00526149|Other|high performance liquid chromatography|
1791908|NCT00526149|Other|mass spectrometry|
1791909|NCT00526149|Other|pharmacological study|
1791910|NCT00526162|Device|Bi-ventricular Implantable Cardioverter Defibrillator|Implantation of a Bi-ventricular Implantable Cardioverter Defibrillator
1791911|NCT00526175|Drug|Prednisone|60 mg/m2 day, i.v. or oral, dyas 1 to 27 30 mg/m2 day, i.v. or oral, days 28 to 35
1791912|NCT00526175|Drug|Vincristine|1,5 mg/m2 i.v., days 8, 15, 22 and 28
1791913|NCT00526175|Drug|Daunorubicin|30 mg/m2, i.v., days 8 and 15
1791914|NCT00526175|Drug|L-Asparaginase|10.000 UI/m2, i.m. or i.v., days 9 to 11, 16 to 18 and 23 to 25. Total: 9 doses.
1791915|NCT00526175|Drug|Cyclophosphamide|1000 mg/m2, i.v., day 22.
1791916|NCT00526175|Drug|Methotrexate|Age <1 year 1-2 years 2-3 years > 3 years MTX 5 mg 8 mg 10 mg 12 mg
1791917|NCT00526175|Drug|Cytosine Arabinoside|Edad <1 year 1-2 years 2-3 years > 3 years ARA-C 16 mg 16 mg 20 mg 30 mg
1791918|NCT00526175|Drug|Mercaptopurine|50 mg/m2,oral, days 1 to 7, 28-35 and 56-63
1791919|NCT00526175|Drug|VP-16|150 mg/m2 i.v., days 14-15 and 42-43
1791920|NCT00526188|Drug|Gadoxetic Acid Disodium (Primovist, BAY86-4873)|Bolus injection of 0.025 mmol/kg body weight (0.1 ml/kg BW) of Gadoxetic Acid Disodium (Primovist, BAY86-4873). Single i.v. injection during MRI procedure, with one contrast-enhanced MRI procedure per patient
1791921|NCT00526201|Behavioral|12-weeks EnhanceFitness|EnhanceFitness class for 12 weeks, 3 times per week for 1 hour sessions.
1791922|NCT00526201|Behavioral|Control|Participants randomized to the wait-list control group will continue their regular activities for 12 weeks and then be offered the exercise intervention (EnhanceFitness).
1791923|NCT00526214|Drug|celecoxib medication|In the celecoxib group, patients will take celecoxib 400mg twice (per day), orally for 14 days.
1791924|NCT00526227|Device|Implantable Cardioverter Defibrillator|Implantable Cardioverter Defibrillator will be implanted
1791925|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 400 million cells.
1791926|NCT00526253|Biological|MyoCell|Patient will receive injections of cultured, expanded skeletal myoblasts into the myocardium at a dose of 800 million cells.
1791927|NCT00526253|Procedure|Hypothermosol|After the cell culture period of time has passed, patient's myocardium will be injected with the transport media alone. Patient will not receive any cultured myoblasts during these injections.
1791928|NCT00526266|Behavioral|Emotional Freedom Techniques (EFT)|A half hour treatment with EFT following a standardized protocol. Both Range of Motion (ROM) physical issues are treated with EFT, as well as any possible emotional issues underlying limited ROM.
1791929|NCT00526266|Behavioral|Diaphragmatic Breathing (DB)|"Diaphragmatic Breathing (DB) instead of EFT tapping, but with all the Setup Statements and components of the Experimental Group, with the exception of tapping. DB is substituted for tapping."
1791930|NCT00526292|Biological|natural killer cell therapy|The patient must be admitted by Day -8 to the Bone Marrow Transplant Service. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor and will be monitored for hematopoietic recovery.
1791931|NCT00526292|Drug|cyclophosphamide|Day -6 cyclophosphamide 60mg/kg infused over 1 hour (dose adjusted for body weight) for 2 days
1791932|NCT00526292|Drug|fludarabine|Day -5 fludarabine 25mg/m2 CIV for 5 days
1791933|NCT00526305|Drug|Vincristine|1,5 mg/m2 i.v., days 1 and 8
1791934|NCT00526305|Drug|Daunorubicin|60 mg/m2, i.v., days 1 and 8
1791935|NCT00526305|Drug|Prednisone|60 mg/m2 day, i.v. or oral, days 1 to 14
1791936|NCT00526305|Drug|L-Asparaginase|10.000 UI/m2, i.v., days 5-7 and 11-13. Total: 6 doses.
1791937|NCT00526305|Drug|Mitoxantrone|12 mg/m2 i.v days 15, 16 and 17
1791938|NCT00526305|Drug|Cytosine Arabinoside|1.500 mg/m2 /12 hours, days 16, 17 and 18 (total: 6 doses) If slow response to treatment: 3.000 mg/m2/12 hours, days 18, 19, 20 and 21 (8 doses)
1791939|NCT00526305|Drug|Hydrocortisone|10 mg ,15 mg or 20 mg depending of age
1791940|NCT00526305|Drug|Mercaptopurine|50 mg/m2, oral, days 1 to 7, 28-35 and 56-63 in consolidation
1791941|NCT00526305|Drug|Cyclophosphamide|600 mg/m2 day, i.v., days 1 to 15 in consolidation
1791942|NCT00526305|Drug|Dexamethasone|10 mg/m2 day, oral or i.v. days 1-14 5 mg/m2 day, oral. or i.v., days 15-21
1791943|NCT00526318|Biological|filgrastim|
1791944|NCT00526318|Drug|carboplatin|
1791945|NCT00526318|Drug|cisplatin|
1791946|NCT00526318|Drug|cyclophosphamide|
1791947|NCT00526318|Drug|dacarbazine|
1791948|NCT00526318|Drug|doxorubicin hydrochloride|
1791949|NCT00526318|Drug|etoposide phosphate|
1791950|NCT00526318|Drug|ifosfamide|
1791951|NCT00526318|Drug|isotretinoin|
1791952|NCT00526318|Drug|melphalan|
1791953|NCT00526318|Drug|topotecan hydrochloride|
1791954|NCT00526318|Drug|vincristine sulfate|
1791955|NCT00526318|Drug|vindesine|
1791956|NCT00526318|Procedure|autologous hematopoietic stem cell transplantation|
1791957|NCT00526318|Radiation|iobenguane I 131|
1791958|NCT00526318|Radiation|radiation therapy|
1791959|NCT00526331|Device|Vigileo Monitor|Study Group = The monitor and routine vital sign measurements will be used to decide how much fluid to give during surgery; Control Group = Information from the monitor will be collected and compared to the information collected from participants in Study Group.
1791960|NCT00526331|Device|FloTrac Sensor|Device connected to the patient's arterial line and Vigileo monitor that measures fluid requirements during surgery.
1791961|NCT00526357|Drug|omega-3 fatty acid|Pharmaceutical grade fish oil administered daily in the form of 10 capsules (5 capsules b.i.d.) each containing 400mg of eicosapentaenoic acid (EPA) and 200mg docosahexanoic acid (DHA) which will equate to a daily dose of 4000 mg of EPA and 2000 mg or DHA. The matched placebo containing a 50/50 mix of soybean and corn oil will be supplied by the same manufacturer (Ocean Nutrition, Canada)
1791962|NCT00526383|Drug|Tricyclic antidepressants|antidepressant version medical dispositive
1791963|NCT00526396|Drug|cisplatin|80 mg/m2 on day 1 for 6 cycles
1791964|NCT00526396|Drug|etoposide|100 mg/m2 on days 1,2,3 for 6 cycles
1791965|NCT00526396|Drug|cisplatin|cisplatin on day 1 for 6 cycles, starting dose 80 mg/m2, toxicity adjusted after first cycle
1791966|NCT00526396|Drug|etoposide|etoposide on days 1,2,3 for 6 cycles, starting dose 100 mg/m2, toxicity adjusted dosing after first cycle
1791967|NCT00526409|Drug|Prednisolone|Induction: 60 mg/m2/day, oral or i.v x 21 days and 30 mg/m2/day oral or iv x 7 days Reinduction-Intensification Treatment: 60 mg/m2/d x 14 days and 30 mg/m2/day oral x 7 days
1791968|NCT00526409|Drug|Daunorubicin|Induction: 30 mg/m2, i.v, days 1, 8, 15, 22 Consolidation (Bloc II)30 mg/m2, i.v, day 1
1791969|NCT00526409|Drug|Vincristine|Induction: 1,5 mg/m2 iv, days 1, 8, 15, 22 Consolidation (Bloc I):1,5 mg/m2 iv, days 1, 8 Consolidation (Bloc II):1,5 mg/m2 iv, days 1, 8 Reinduction: 1,5 mg/m2 iv, days 1, 8 Maintenance:1,5 mg/m2 iv, day 22
1791970|NCT00526409|Drug|L-Asparaginase|Induction: 10.000 U/m2 im or iv, days 9,11,13,16,18,20,23,25,27 Consolidation (Bloc II): 20.000 U/m2 im or iv, day 7 Maintenance: 20.000 U/m2 im or iv, day 22
1791971|NCT00526409|Drug|Cyclophosphamide|Induction: 500 mg/m2 iv, days 1, 2, 29 Consolidation (Bloc I): 500 mg/m2 iv, day 8 Reinduction:500 mg/m2 iv, day 15
1791972|NCT00526409|Drug|Methotrexate|Consolidation (Bloc I): 5 g/m2 24 hours infusion Consolidation (Bloc II): 5 g/m2 24 hours infusion Reinduction: 3 g/m2 24 hours infusion Maintenance: 20 mg/m2/d, IM/week x 3 (1, 7, 14)
1791973|NCT00526409|Drug|Cytosine Arabinoside|Consolidation (Bloc I): 1 g/m2/12 h iv, days 5, 6 Consolidation (Bloc II): 1 g/m2/12 h iv, days 5, 6 Reinduction: 1 g/m2/12 h iv, days 43, 44
1791974|NCT00526422|Procedure|Dental Preventive|
1791975|NCT00526435|Behavioral|Walk with Ease - Group|Participate in 6-week, 1 hour per week group assisted classes (with instructor).
1791976|NCT00526435|Behavioral|Walk with Ease - Self|SUbject will receive the WWE workbook and follow it without group/instructor assistance.
1791977|NCT00526448|Drug|ribavirin|2000 mg/day
1791978|NCT00526448|Drug|ribavirin|1000-1200 mg/day
1791979|NCT00526448|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a 180 mcg/week
1791980|NCT00526448|Drug|epoetin beta|epoetin beta 450 UI/week
1791981|NCT00526461|Drug|HPPH|IV
1791982|NCT00526474|Drug|Vorapaxar|2.5-mg tablet daily for at least 1 year
1791983|NCT00526474|Drug|Placebo|matching tablet daily for at least 1 year
1791984|NCT00526487|Device|Zenith® Dissection Endovascular System|The Zenith® Thoracic Dissection Study is a clinical trial to study the safety and effectiveness of the Zenith® Dissection Endovascular System in the treatment of dissections (length-wise tear) of the descending thoracic aorta. The Zenith® Dissection Endovascular System is comprised of the Zenith TX2® TAA Endovascular Graft and the Zenith® Dissection Endovascular Stent. Instead of making a large incision in the chest, the physician makes a small incision near each hip to insert, and guides the graft and the dissection stent into place in the aorta.
1791985|NCT00526487|Device|Endovascular Repair|Endovascular Repair
1791986|NCT00526500|Behavioral|Tilt Table With Integrated Stepping System|Passive Gait Training: one session, 20 minutes, table tilted to 70-80 degrees, speed 60 steps per minute.
1791987|NCT00526513|Drug|Insulin Glulisine|subcutaneous injection of insulin glulisine at meal, 1 to 3 injections a day based on the condition of the patient in addition to a basal SC insulin injection at bedtime
1791988|NCT00526539|Other|Total hip replacement, Spectron and Taperloc|
1791989|NCT00526565|Behavioral|Tapas Acupressure Technique|Practice of the TAT technique involves application of pressure to select acupoints combined with specific mental focus. The TAT pose involves lightly touching the tips of the left thumb and 4th finger to the area 1/8 inch above the inner corner of each eye and the 3rd finger to the point midway between the eyes, about ½ inch above eyebrow level. The right hand is on the back of the head, with the palm cradling the occiput and the thumb just above the hairline. Once in this position, the process is to 1) focus attention on the identified problem or behavior to be changed (e.g., over-eating); 2) focus on a positive thought related to the problem; 3) focus on the thought of healing or clearing the origins of the problem; and 4) focus on an awareness of healing or clearing any storage of the problem, at a cellular, mental, emotional, or energetic level.
1792038|NCT00527020|Drug|Placebo|Placebo tablets will be given to the subjects.
1792039|NCT00527033|Drug|YM178|Oral
1792040|NCT00527033|Drug|Placebo|Oral
1792041|NCT00527046|Drug|CP-424,391|
1792971|NCT00533676|Drug|MK0524A, /Duration of Treatment : 8 Weeks|
1791990|NCT00526565|Behavioral|Social support|The LIFE SS maintenance intervention will consist of a series of professionally facilitated social support groups where the session content is directed by the participants. The contact hours for SS will match those of the TAT intervention. The initial SS group session will orient participants to the basics of weight maintenance, and subsequent sessions will provide opportunities for participants to share experiences and ask questions. Participants may choose to use behavioral tools as desired. In addition to the basic materials about weight loss maintenance used in both maintenance interventions, will we use the materials already used in the weight loss program for the SS group as needed. We will measure adherence by taking attendance at the SS group sessions.
1791991|NCT00526578|Behavioral|Questionnaire|Questionnaire taking about 30-40 minutes to complete.
1791992|NCT00526591|Drug|everolimus|Low-dose Cohort: Patients will receive 5.0mg P.O. daily continuously for 8 weeks; High-dose Cohort: Patients will receive 10mg P.O. daily continuously for 8 weeks
1791993|NCT00526591|Procedure|conventional surgery|Radical prostatectomy with bilateral pelvic lymphadenectomy will be performed within 10 days of the completion of week 8 on RAD-001 (Everolimus).
1791994|NCT00526604|Behavioral|work related rehabilitation|"The workplace intervention includes two steps:
Evaluations of the work site: The occupational ergonomists task is to identify conditions at the work site, as for instance ergonomic, work demand and relations to the employer and colleagues.
Therapeutic Return to work: The occupational ergonomists will organize contacts and meetings between the employer and the patients and make a schedule for return to work. The therapeutic return-to-work-process will take place at the work place, with progressively more days at work and progressively increasing tasks."
1791995|NCT00526617|Drug|ABT-888|Oral capsules
1791996|NCT00526617|Drug|Temozolomide|Oral capsules
1791997|NCT00526630|Drug|Methylphenidate (MPD)|Participants will be given 1 mg/kg of MPD divided in three doses (at 8 am, 12 noon, and 4 pm). A four-week titration period will be used, using 0.25-mg/kg increments per week until achieving the weight-adjusted target dosage, which may range from five to eight 10-mg tablets per day. The maximum daily dose will be 80 mg/day.
1791998|NCT00526630|Drug|Placebo|Participants will be given placebo instead of active MPD.
1791999|NCT00526643|Drug|gemcitabine|1200 mg/m2 intravenous infusion on days 1 and 8, every 3 weeks for a maximum of 4 cycles
1792000|NCT00526643|Drug|cisplatin|cisplatin 60 mg/m2 on day 1 for 4 cycles
1792001|NCT00526656|Drug|sunitinib malate|50mg PO daily 4 weeks on -2 weeks off
1792002|NCT00526669|Drug|Lapatinib and Capecitabine|oral lapatinib (1250mg) administered as a monotherapy run-in followed by its combination with capecitabine
1792003|NCT00526682|Dietary Supplement|Irvingia/cissus combo|
1792004|NCT00526695|Drug|Sevoflurane (Preconditioning)|Inhalation of sub-anesthetic doses of sevoflurane
1792005|NCT00526734|Biological|filgrastim|
1792006|NCT00526734|Biological|pegfilgrastim|
1792007|NCT00526734|Drug|melphalan|
1792008|NCT00526734|Procedure|autologous hematopoietic stem cell transplantation|
1792009|NCT00526760|Drug|Dexmedetomidine|
1792010|NCT00526773|Other|telephone management plus a motivational intervention|heart failure intervention
1792011|NCT00526773|Other|telephone management with standard patient education|heart failure intervention
1792013|NCT00526799|Drug|Sorafenib|"Phase I: Dose Escalation, Phase II: MTD
Dose level -1: 200mg po daily Dose level 1: 400mg po daily (MTD) Dose level 2: 400mg po bid"
1792014|NCT00526799|Drug|Topotecan|3.5mg/m2 weekly, 3 weeks on and one week off.
1792015|NCT00526812|Drug|RTA 744|Aqueous solution added to 10%D/W and infused over 2 hours on three consecutive days. 5 mg vials contain 1 mg/ml.
1792016|NCT00526812|Drug|RTA 744 injection|Aqueous solution in 1mg/ml. Doses are escalated. Drug is infused intravenously over 2 hours one day a week for four consecutive weeks.
1792017|NCT00526838|Drug|XL228|1-hour IV infusion
1792018|NCT00526851|Other|survey administration|Nursing home dentists practicing in Ohio are contacted through a recruitment letter and are asked to respond to questions regarding oral cancer screening practices, knowledge of oral cancer detection, and opinions about oral cancer screening using a newly developed survey, which is based on parts of an existing, pre-tested instrument (Oral Cancer Prevention and Early Detection Survey).
1792019|NCT00526877|Drug|Risperidone|Risperidone long-acting injectable 25 milligram (mg) or 37.5 mg or 50 mg will be administered intramuscularly (into a muscle) depending on Investigator's discretion every 2 weeks for 24 weeks.
1792025|NCT00526903|Behavioral|Elimination Diet|Daily diet change for 8 days.
1792026|NCT00526916|Drug|[C-11]PBR28|
1792027|NCT00526929|Drug|darbepoetin alfa|10 mcg NESP administered SC every other week 15 mcg NESP administered SC every other week 20 mcg NESP administered SC every other week 30 mcg NESP administered SC every other week 40 mcg NESP administered SC every other week 50 mcg NESP administered SC every other week 60 mcg NESP administered SC every other week 80 mcg NESP administered SC every other week 100 mcg NESP administered SC every other week
1792029|NCT00526968|Drug|EVT 101|8 mg capsule, single oral dose
1792030|NCT00526968|Drug|EVT 101|15 mg capsule, single oral dose
1792031|NCT00526968|Drug|placebo|Placebo capsule, single oral dose
1792032|NCT00526981|Other|Prone position|Prone position during spontaneous breathing.
1792033|NCT00526994|Other|screened|Asked 4 questions on current exposure to intimate partner violence; if positive, receives referral information
1792034|NCT00526994|Behavioral|universal education|receives referral information
1792035|NCT00527007|Other|External cooling|External cooling
1792036|NCT00527020|Drug|GSK1018921|GSK1018921 will be supplied as 0.5, 5, 10 and 40 milligrams coated tablets.
1792037|NCT00527020|Drug|Nicotine Lozenges|Nicotine Lozenges will be supplied as 4 milligrams lozenges.
1792042|NCT00527059|Drug|Levosimendan in addition to standard therapy|intravenous infusion of levosimendan (10 minutes bolus with 6 mcg/Kg according to physician judgement, followed by 0.1 mcg/Kg/min for 24 hours) in addition to standard therapy
1792043|NCT00527059|Drug|spironolactone, beta-blockers,ecc|
1792044|NCT00527072|Biological|infliximab|Open-label 5 mg/kg infliximab infusions at Weeks 0, 2, 6, 14, and 22.
1792045|NCT00527085|Drug|AMG 073|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
1792046|NCT00527085|Drug|Placebo|30 mg QD orally 50 mg QD orally 70 mg QD orally 90 mg QD orally 120 mg QD orally 180 mg QD orally
1792047|NCT00527111|Drug|Cetuximab|
1792048|NCT00527111|Drug|5-fluorouracil|
1792049|NCT00527111|Radiation|Pelvic irradiation|
1792050|NCT00527124|Drug|cediranib maleate|Given orally
1792051|NCT00527124|Drug|docetaxel|Given IV
1792052|NCT00527124|Drug|prednisone|Given orally
1792053|NCT00527124|Other|laboratory biomarker analysis|Correlative studies
1792054|NCT00527137|Drug|darbepoetin alfa|Dose 100U rHuEPO = 0.42 mcg NESP; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
1792055|NCT00527137|Drug|rHuEPO|same as previous rHuEPO dose at randomization; adjust as necessary (+/- 25% of the starting dose) to maintain Hb withing 10.0 - 12.5 g/dL
1792056|NCT00527150|Drug|Varenicline Tartrate|Varenicline 1.8 mg AMT-8 controlled release tablets administered twice a day for 14 days.
1792057|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 2.4 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
1792058|NCT00527150|Drug|Varenicline Tartrate|Planned dose is Varenicline 3 mg AMT-8 controlled release tablets administered twice a day for 14 days. Actual dose may be adjusted based on emerging data from prior dose cohorts.
1792059|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
1792060|NCT00527150|Drug|Varenicline Tartrate|The dose to be administered is not yet determined and will be based on emerging data from prior dose cohorts. The dose will be administered as Varenicline AMT-8 controlled release tablets twice a day for 14 days. The doses to be tested may be lower, higher or repeat a previously tested dose and may include a titration.
1792061|NCT00527189|Behavioral|Balance Exercises|Home based balance exercises based on Otago Exercise programme
1792062|NCT00527202|Drug|botulinum toxin A and saline|
1792063|NCT00527215|Drug|darbepoetin alfa|starting dose determined by calculating a subject's total dose in the month preceding enrollment. Administered QM for 25 weeks. Change made as necessary to maintain a hemoglobin concentration within the target range os 10.0 - 12.0 g.dL
1792064|NCT00527228|Drug|deflazacort|In the first 12 months, patients will receive no treatment to assess the natural history of the disease. Afterwards, patients will be treated with deflazacort 1mg/kg/day or placebo for the first month on treatment, from the second month on deflazacort or placebo will be administered on an alternate day regimen). Patients will be randomized to six months verum or placebo each, after a 3-months wash-out patients cross over to the alternate treatment for six months. In a 2-years follow-up phase after the double-blind treatment phase, long-term development of the disorder will be documented.
1792065|NCT00527228|Drug|placebo|
1792066|NCT00527241|Behavioral|Raices nuevas|8 90-minute sessions (once a week) of problem-posing and facilitated discussion on respect, anger, support, trust, negotiating, partnership with your intimate partner.
1792067|NCT00527254|Device|Telemedicine system|Possibility of sending the SMBG values of the patients to a web page via phone mobile sms messages. The HCP had a password access to this web page to check the blood glucose values of the patients and if necessary send to them sms messages with recommendations.
1792068|NCT00527267|Drug|Placebo|30 mg placebo once daily orally 60 mg placebo once daily orally 90 mg placebo once daily orally 120 mg placebo once daily orally 180 mg placebo once daily orally
1792069|NCT00527267|Drug|AMG 073|30 mg AMG 073 once daily 60 mg AMG 073 once daily 90 mg AMG 073 once daily 120 mg AMG 073 once daily 180 mg AMG 073 once daily
1792070|NCT00527280|Procedure|Feasibility ot face transplantation|Feasibility ot face transplantation
1792071|NCT00527293|Procedure|adjuvant therapy|If chemotherapy is planned, it must begin no earlier than two weeks following completion of radiation. If chemotherapy is given first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation.
1792072|NCT00527293|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiotherapy twice daily for 5-10 days.
1792073|NCT00527293|Radiation|brachytherapy|Patients undergo partial breast irradiation comprising either MammoSite® brachytherapy twice daily for 5-10 days
1792074|NCT00527306|Dietary Supplement|multivitamin|Subject will be asked to take a multivitamin capsule or a placebo (inactive pill) once a day for one year. There will be an equal chance of getting the multivitamin or the placebo.
1792075|NCT00527319|Drug|VT-122 low dose|VT-122 low dose, dose escalated
1792076|NCT00527319|Drug|VT-122 high dose|VT-122 high dose, dose escalated
1792077|NCT00527332|Drug|Bupivacain|5 mg/mL, 4 mL intrathecally as a single dos
1792078|NCT00527332|Drug|Morphine|0.4 mg/mL; 0.5 mL intrathecally as a single dosage
1792079|NCT00527332|Drug|Propofol|2-5 mg/kg body weight/hours IV (intravenously) for sedation during the surgery
1792080|NCT00527332|Drug|Propofol|Induction of anesthesia with 1-2 mg/kg body weight IV (intravenously). After intubation maintenance dosage of 6-10 mg/kg/hour IV during the surgery
1792081|NCT00527332|Drug|Fentanyl|100-200 microgram IV (intravenously) at start of anesthesia. 50-100 microgram IV on demand during surgery.
1792082|NCT00527332|Drug|Rocuronbromid|0.6 mg/kg body weight IV (intravenously) at induction of anesthesia. If additional muscle relaxation is needed during surgery 5-10 mg is injected IV. The drug is given only at induction of anesthesia and during surgery
1792083|NCT00527332|Drug|Morphine|5 mg is given IV (intravenously) before end of surgery
1792130|NCT00527683|Behavioral|Group therapy|Participants attend group sessions once a week
1792131|NCT00527696|Procedure|transvaginal obturator tape|
1792084|NCT00527358|Behavioral|SAFER (Seguridad, Apoyo, Familia, Educacion, y Recursos)|"community lay workers will do family outreach and assist families in networking with other families and accessing community services, facilitating parent-youth and family-school communication and homework help for children, and help with translation of school or government/official notices;
youth leaders will provide a supportive presence, help youth navigate the system at school so that they can get help if needed, disseminate information about job training and possibilities, provide education about avoiding violence;
school support services will offer academic support, acculturation orientation, language, conflict resolution skills training, advocacy and referrals;
Youth drop-in center will provide youth with an adult supervised place to hang out, do homework, or participate in sports and job training."
1792085|NCT00527371|Device|GreenLight HPS (TM)laser system [Photoselective Vaporization of the prostate (PVP)]|Photoselective vaporization of the prostate will be performed using the GreenLight HPS (TM)laser system (American Medical Systems), which is a high-power (120W) potassium titanyl phosphate (KTP) laser which was licensed by Health Canada in April 2007.
1792086|NCT00527371|Procedure|Transurethral resection of the prostate|Transurethral resection of the prostate will be performed with a continuous flow resectoscope and unipolar cautery using a standard technique.
1792087|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
1792088|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose: adjusted based on the results of self-monitoring of blood glucose before each meal.
1792089|NCT00527397|Drug|CP-464,005|Taken for 1 year (52 weeks) immediately before each meal (breakfast, lunch, and supper). Dose:adjusted based on the results of self-monitoring of blood glucose before each meal.
1792090|NCT00527410|Drug|RTA 744|Aqueous solution of RTA 744 is packaged in 5 ml vials - 1 mg/ ml. The drug is mixed in D10W and infused over 2 hours on three consecutive days.
1792091|NCT00527423|Drug|VEGF Trap Eye|Intravitreal injection
1792092|NCT00527436|Dietary Supplement|fish oil|
1792093|NCT00527449|Drug|Epirubicin, Carboplatin, Docetaxel|75 mg/m² Docetaxel (60 minutes i.v.) and 90 mg/m² Epirubicin (10-15 min i.v.) on day 1, 22, 42. After these 3 cycles 75 mg/m² Docetaxel (60 minutes i.v.) and Carboplatin AUC 5 (30 min i. v.) on day 63, 84, 105.
1792094|NCT00527462|Procedure|Bronchoscopy|bronchoscopy with segmental allergen challenge
1792095|NCT00527462|Other|Exposure to ultrafine carbon black particles|Exposure to ultrafine carbon black particles for 2 hours
1792096|NCT00527475|Drug|ranibizumab|0.5 mg. given as an intraocular injection
1792097|NCT00527475|Drug|verteporfin|Standard dosage of 6 mgs. / meter2 of body surface area given intravenously.
1792102|NCT00527501|Drug|Travoprost/brinzolamide|
1792103|NCT00527514|Drug|Amlodipine|Tablets
1792104|NCT00527514|Drug|Olmesartan medoxomil plus amlodipine|Tablets
1792105|NCT00527527|Procedure|flexion distraction|Chiropractic treatment using the flexion distraction apparatus
1792106|NCT00527527|Other|placebo control|Placebo for comparison with flexion distraction treatment
1792108|NCT00527553|Dietary Supplement|not enriched egg|daily egg, not enriched
1792109|NCT00527553|Dietary Supplement|lutein|daily enriched egg
1792110|NCT00527553|Dietary Supplement|zeaxanthin|daily zeaxanthin enriched egg
1792111|NCT00527553|Dietary Supplement|egg product from enriched eggs|daily egg product from enriched eggs
1792112|NCT00527553|Dietary Supplement|normal diet|control, normal diet, no additional eggs
1792113|NCT00527566|Biological|Mepolizumab|IV mepolizumab, 750 mg
1792114|NCT00527579|Drug|[F-18]FBR|
1792115|NCT00527592|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as travoprost.
1792116|NCT00527592|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop, single dose. Referred to as latanoprost.
1792117|NCT00527605|Drug|Dutasteride 0.5mg capsule|Dutasteride 0.5mg once daily orally
1792118|NCT00527605|Drug|Dutasteride matched placebo|Dutasteride matched placebo once daily orally
1792119|NCT00527618|Drug|valacyclovir|valacyclovir 1000 mg orally twice daily for 12 weeks.
1792120|NCT00527618|Drug|acyclovir|acyclovir 400 mg orally twice daily for 12 weeks.
1792121|NCT00527631|Radiation|whole abdomen irradiation using IMRT|Whole abdomen irradiation as consolidation therapy using intensity modulated radiation therapy (IMRT) to a total dose of 30 Gy in 1.5 Gy fractions
1792123|NCT00527657|Drug|Lomustine|Starting dose 30 mg/m^2 by mouth daily on Day 1 and 29.
1792124|NCT00527657|Drug|Temozolomide|75 mg/m^2 by mouth daily on Days 1 to 42.
1792125|NCT00527657|Drug|Thalidomide|200 mg/m^2 by mouth daily.
1792126|NCT00527670|Procedure|Normal Controls|The control group will have small slivers of tissue removed from the skin and abdomen during surgery to compare genomic information.
1792127|NCT00527670|Procedure|Recurrent Hernia|This group will have small slivers of tissue removed from the skin and abdomen during hernia repair surgery to find genetic proof of hernias being inherited.
1792128|NCT00527683|Drug|Vigabatrin|crystalline drug dissolved in orange juice, dosage escalates from 500 mg twice daily to 1.5 g twice daily over a 3 week period. This dose is maintained for 4 weeks and then tapered to zero over the next two weeks
1792129|NCT00527683|Drug|Placebo|orange juice is administered twice daily in containers indistinguishable from the treatment arm.
1792132|NCT00527722|Device|Bio-Seal Track Plug|The lung plug will be inserted into the left track when the biopsy needle is removed. The smaller sampling needle is removed, and the lung plug is inserted through the larger needle using a delivery tool that has a plunger to push the plug in place. The lung plug remains in the track left when the larger needle is removed.
1792133|NCT00527722|Other|No lung plug|Standard lung biopsy without placement of the plug.
1792138|NCT00527748|Device|Non-Measuring Ankle Exerciser|Stretching exercise performed 10 times per day, for six (6) weeks.
1792139|NCT00527761|Drug|Cisplatin|20 mg in 500 ml of normal saline by vein over 60 minutes daily for 4 days starting on day 1 of chemotherapy.
1792140|NCT00527761|Drug|Docetaxel|Starting dose 20 mg by vein over 1 hour, once a week, for three weeks (on Days 1, 8, and 15).
1792141|NCT00527761|Drug|Temodar|150 mg by mouth (PO) on Days 1 - 5.
1792142|NCT00527787|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
1792143|NCT00527787|Drug|Naproxen|Naproxen (500 mg) dosed twice daily (bid) orally
1792144|NCT00527800|Drug|Dihydroartemisinin-piperaquine|Once daily for 3 days, given in fixed dose tablets (40 mg dihydroartemisinin + 320 mg piperaquine) according to weight-based guidelines
1792145|NCT00527800|Drug|Artemether-lumefantrine|Dosed twice daily for 3 days, given in fixed dose tablets (20 mg artemether + 120 mg lumefantrine) according to weight-based guidelines
1792146|NCT00527800|Drug|Trimethoprim-sulfamethoxazole|Once daily dosing according to weight based guidelines
1792147|NCT00527813|Procedure|prone position|prone position for at least 16 hours per day
1792148|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID fixed combination|comparator
1792149|NCT00527826|Drug|Salmeterol / Fluticasone (50/500 µg) BID separate Inhalers|comparator
1792150|NCT00527852|Device|Flocked swab|
1792151|NCT00527865|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
1792152|NCT00527865|Drug|Placebo|Capsules containing 10.5 mg of lactose will be supplied as placebo.
1792153|NCT00527878|Drug|Ranitidine|Double blinded, randomized placebo controlled crossover study. Patients received 12 months of placebo and 12 months of treatment medication (ranitidine).
1792154|NCT00527878|Drug|Placebo|
1792155|NCT00527891|Procedure|Signa Excite 3.0 T MRI Scan|Signa Excite 3.0 T MRI scan within a two week period from the date of receiving standard 1.5 T MR of the liver area.
1792156|NCT00527904|Drug|PN400 (VIMOVO)|Subjects are instructed to take 2 tablets a day, one in the morning and one in the afternoon/evening. The morning tablet should be taken with water, on an empty stomach 30 to 60 minutes before breakfast, or the first meal. The afternoon/evening tablet should be taken with water, on an empty stomach 30 to 60 minutes before dinner. Tablets should be swallowed whole and not broken, crushed or chewed.
1792157|NCT00527904|Drug|PN 400 (VIMOVO)|500 mg delayed-release naproxen/20 mg immediate release esomperazole dosed twice daily for 12 months
1792158|NCT00527917|Device|placebo|bladder instillation
1792159|NCT00527917|Device|Uracyst|20 ml sterile solution for weekly intravesical instillation
1792160|NCT00527930|Drug|TS-1 and Eloxatin|"S-1 80 mg/m2/day on day 1-14 Oxaliplatin 130 mg/m2 IV for 2 hour on day 1 Every 3 week
Number of Cycles: until progression or unacceptable toxicity"
1792161|NCT00527943|Drug|Vorapaxar|oral tablets; 40-mg loading dose on first day, followed by 2.5 mg once daily for at least 1 year
1792162|NCT00527943|Drug|Placebo|oral tablets; matching placebo for vorapaxar; loading and maintenance dosing; once daily for at least 1 year
1792163|NCT00527969|Drug|HT1001 extract of Panax quinquefolius L|
1792164|NCT00527982|Drug|Celecoxib|600 mg by mouth daily for a total of 12 months.
1792165|NCT00527995|Drug|Sildenafil|Orally administered, Sildenafil 100mg, unique administration
1792166|NCT00528008|Other|povidone-iodine solution|Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.
1792167|NCT00528008|Other|chlorhexidine gluconate|Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
1792168|NCT00528021|Drug|Placebo|Vehicle Only
1792169|NCT00528021|Drug|BGC20-0582|BGC20-0582 is a topical gel formulation of a naturally derived product. Subjects are treated either once (day 1) or twice (day 1 and 7) with either placebo or BGC20-0582 at one of the three concentrations. Following application of the BGC20-0582 lice treatment gel of placebo the product is rinsed from the subjects hair.
1792170|NCT00521040|Drug|Levocetirizine dihydrochloride|
1792171|NCT00521053|Drug|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation
1792172|NCT00521066|Device|GYNECARE PROSIMA* Pelvic Floor Repair System|procedure for pelvic organ prolapse
1792173|NCT00521079|Device|Therapy ON|Intermittent, programmable, intra-abdominal vagal blocking device that delivers therapy (Therapy ON)
1792174|NCT00521079|Device|Therapy OFF|Active intra-abdominal placebo device that delivers no therapy (Therapy OFF)
1792175|NCT00521092|Drug|sunitinib malate|Given orally
1792176|NCT00521092|Procedure|laboratory biomarker analysis|Correlative study
1792177|NCT00521092|Procedure|pharmacological study|Correlative study
1792489|NCT00530842|Drug|Fluticasone/Salmeterol|
1792178|NCT00521105|Other|Virtual visit|Participants will alternate between a multidisciplinary visit (MD, RN and RD) and a phone contact with the diabetes nurse educator (the phone contact will replace the physician-only visit). Prior to the phone contact, transmission of information from the participant will be sent through either fax or a web browser.
1792179|NCT00521118|Other|Laboratory Biomarker Analysis|Correlative studies
1792180|NCT00521118|Procedure|Therapeutic Conventional Surgery|Undergo second curettage
1792181|NCT00521131|Drug|Levocetirizine dihydrochloride|
1792182|NCT00521144|Drug|obatoclax mesylate|Given IV
1792183|NCT00521144|Drug|topotecan hydrochloride|Given IV
1792184|NCT00521144|Other|laboratory biomarker analysis|Correlative studies
1792185|NCT00521157|Drug|Go Medical Naltrexone implants|Naltrexone implants 3.2 g (double of 1,6 g)
1792186|NCT00521170|Drug|Levocetirizine|
1792187|NCT00521183|Drug|Cytochlor|The study's starting dose of CldC is 50 mg/m2/day. The dose of CldC will be escalated / de-escalated for patients. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
1792188|NCT00521183|Drug|Tetrahydrouridine|A fixed dose of H4U at 720 mg/m2/day will be used, regardless of the dose of CldC administered. H4U will be delivered by an IV bolus infusion over a period of 5 minutes, followed 5 minutes later by an IV bolus infusion of CldC. Patients will receive CldC+H4U on 3 days (Wed, Thr, Fri) in week 1, which precedes the initiation of radiation therapy. Patients will receive H4U and CldC IV by bolus infusion. Treatment with CldC+H4U will then continue for 5 days (Mon-Fri) during each of weeks 2 and 3, and will be accompanied by radiation therapy at 3 Gy/fraction initiated 3-4 h after bolus infusion of CldC+H4U. Treatment with CldC+H4U and radiation will then stop at the end of week 3.
1792189|NCT00521183|Radiation|Radiation Therapy|One treatment of 3 Gy will be given daily 5 days per week (10 fractions) for a total of 30 Gy over two weeks.
1792190|NCT00521196|Device|DC Stimulator (Transcranial Direct Current Stimulator)|Subjects will receive a total of 10 sessions of either active tDCS or sham tDCS over a four-week period (administered every other day during weekdays over the course of one month). During each tDCS session, two electrodes are placed over selected areas of the brain. The anode is placed on the motor cortex contralateral to the side where migraines predominant; the cathode is placed near the supraorbital area, opposite the anode. A small battery powered device drives 2 mA of direct current through the two electrodes. The direct current will flow through the electrodes, penetrate the scalp, and create a flow of electrical current in the brain. The procedure will last 20 minutes. For sham tDCS, an alternate method of stimulation will be used.
1792191|NCT00521209|Behavioral|Self-Care Stimulating Disease Prevention Program (SCSDPP)|"The SCSDPP development is guided by the following premises: a) patient-directed lifestyle change or self-prescription of behavior change is potentially a more empowering, sustainable, and proactive approach to addressing personal health habits than the more conventional physician-directed approach; b) patient-directed lifestyle change or self-prescription of behavior change is potentially an important predictor of self-efficacy and long-term adherence to healthy habits; c) behavior change in isolation is less sustainable than change that is reinforced by other distinct but related changes (e.g., the potential synergy of improving diet and physical activity concurrently to prevent chronic disease); d) a multi-level change directed at the service delivery system and physician support, however small, has the added benefit of potentially reducing provider and staff burden while maximizing available clinic and community resources; and f) brief physician counseling"
1792192|NCT00521209|Other|Stand procedures, no intervention|
1792193|NCT00521222|Drug|Fluticasone with salmeterol|Fluticasone 45mcg, 115mcg, or 230mcg with salmeterol 21mcg, via HFA device, 2 puffs every 12 hrs, over 16 week study period.
1792194|NCT00521222|Drug|Fluticasone HFA|Fluticasone HFA alone at 44mcg, 110mcg or 220 mcg 2 puffs every 12 hrs, over 16 week study period.
1792195|NCT00521248|Drug|buprenorphine|sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms
1792196|NCT00521248|Drug|Oral morphine solution|0.4 mg/kg/day morphine every 4 hours
1792197|NCT00521261|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|
1792198|NCT00528034|Procedure|Lymphoscintigraphy|Procedure where a very small amount (less than one tenth of a teaspoon) of a radioactive material is injected around the edge of the tumor in the vagina, followed immediately by the scan. The scan is done before the patient has surgery or begins radiation therapy.
1792199|NCT00528047|Drug|PRLX 93936|PRLX 93936 will be administered intravenously over one hour daily for 5 days.
1792200|NCT00528060|Drug|Atazanavir|2pills/day
1792201|NCT00528060|Drug|Ritonavir|1 pill/day
1792202|NCT00528060|Drug|Tenofovir/emtricitabine|1 pill/day
1792203|NCT00528073|Drug|Rifaximin-EIR|Comparison of 800 mg, 1600 mg and 2400 mg Rifaximin-EIR versus placebo in the treatment of active moderate Crohn's disease
1792204|NCT00528099|Drug|IMA-026|SC and IV ascending single doses from lyophilized dosage form 0.3, 1, 2, 4 mg/kg SC and 3 mg/kg IV
1792205|NCT00528112|Drug|LCS12|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 12 microg/24 h
1792206|NCT00528112|Drug|LCS16|Intrauterine system (IUS) with Levonorgestrel, in vitro releasing rate 16 microg/24 h
1792207|NCT00528125|Procedure|active laser acupuncture|low level laser acupuncture, 830 nm, 30 mW, 0,3 J per acupoint, 2 points per neonate (Hegu and Shen Men). Overall 30 seconds of treatment
1792208|NCT00528125|Procedure|placebo laser acupuncture|placebo laser acupuncture at two acupoints (Hegu, Shen Men). Overall treatment time 30 seconds.
1792209|NCT00528138|Other|Laboratory Test|CRP, white blood cell count, hepatic function tests
1792210|NCT00528151|Drug|curcumin|curcumin 250 mg twice a day in the first group. placebo 1 capsule twice a day in the second group.
1792211|NCT00528164|Behavioral|Team PLAY|Parents will receive intense counseling regarding developmentally appropriate physical activity, strategies for reducing sedentary behaviors, nutritional counseling, and behavioral counseling, including a self-management program to use with their children at home. The group will meet once a week for the initial 8 weeks, bi-weekly for 8 weeks, and monthly for 2 months.
1793502|NCT00537966|Drug|tenofovir|standard dosage
1792212|NCT00528177|Drug|Morphine and oxycodone|"At the end of surgery, group 1 will receive intravenous morphine 0.07 mg/kg and intravenous PCA morphine 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours. Group 2 will receive intravenous oxycodone 0.07 mg/kg and intravenous PCA oxycodone 0.015 mg/kg every time they push the botton with 5 minutes lock-out interval. Maximum 16 mg/2 hours.
The patients will use the PCA until the next morning."
1792213|NCT00528190|Drug|Itraconazole|Oral Itraconazole 5mg/kg/day or identical placebo for 24 weeks
1792214|NCT00528216|Drug|Capsaicin Dermal Liquid|
1792215|NCT00528229|Radiation|Computer Tomography|
1792216|NCT00528242|Drug|SLx-2101|
1792217|NCT00528242|Drug|Placebo|
1792218|NCT00528255|Drug|Misoprostol Vaginal Insert (MVI 100)|The MVI 100 is misoprostol 100 mcg, formulated in a sustained release, nonbiodegradeable hydrogel polymer, with a polyester knit retrieval tape; IV oxytocin is permitted ad lib 30 minutes following removal of the MVI assuming no contraindications.
1792219|NCT00528268|Drug|Sodium phenylbutyrate (NaPB)|The powder form of the drug will be dispensed. The target NaPB dosing is 450-600 mg/kg/day, divided into four doses. For cohort 1, we propose to continue treatment for 18 months. For cohort 2, we propose to continue treatment for 24 months.
1792220|NCT00528281|Drug|Lapatinib|Lapatinib was administered once daily orally. Patients will begin treatment at Dose Level 0, using a lower dose of pemetrexed, 400mg (approved dose is 500mg). Absent a DLT or need for treatment delay in cycle 1, Dose level 0 or 1, patients may be dose escalated to dose level 1 or 2, respectively in cycle 2.
1792221|NCT00528281|Drug|Pemetrexed|Pemetrexed is administered intravenously on a 21 day schedule. Two dose levels are used in the dose escalation: 400 and 500 mg.
1792222|NCT00528294|Radiation|GRID radiotherapy|GRID-radiotherapy followed by biological imaging guided IMRT
1792223|NCT00528307|Device|HIS buldle ablation|HIS bundle ablation, followed by implant of a biventricular pacemaker
1792224|NCT00528320|Device|Ovatio CRT|
1792225|NCT00528333|Drug|Lintuzumab (SGN-33)|600 mg IV on days 1, 8, 15 and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles.
1792226|NCT00528333|Drug|Low dose cytarabine|20 mg SC twice a day on days 1-10 of each 28 day cycle up to a maximum of 12 cycles.
1792227|NCT00528333|Drug|Placebo|IV administration on days 1, 8, 15, and 22 of cycle 1 and days 1 and 15 of each subsequent 28-day cycle up to a maximum of 12 cycles
1792228|NCT00528346|Behavioral|cognitive training using fMRI|Participants will be scanned using fMRI while they employ the cognitive training strategies—allowing them to view their brain activity.
1792229|NCT00528346|Behavioral|placebo|Some participants will see simulated data that does not come from their own brains.
1792230|NCT00528359|Drug|quetiapine or olanzapine or risperidone or aripiprazole|
1792231|NCT00528931|Biological|collagenase clostridium histolyticum|Single dose of AA4500 0.58 mg into the cord
1792232|NCT00528957|Drug|Tenofovir DF|Tenofovir DF (oral powder or tablet): 300-mg tablets for participants > 37 kg; 8-mg/kg oral powder (up to 300 mg) for participants <= 37 kg. During the extension phase, participants whose weight increases to > 37 kg may be switched from the oral powder to the tenofovir DF tablet.
1792233|NCT00528957|Drug|Zidovudine|Zidovudine as prescribed by the investigator prior to study entry.
1792234|NCT00528957|Drug|Stavudine|Stavudine as prescribed by the investigator prior to study entry.
1792235|NCT00528970|Drug|MOA-728|
1792236|NCT00528970|Other|placebo|
1792237|NCT00528983|Drug|Subcutaneous (SC) Azacitidine|75 mg/day for first 7 days of 28 day cycle for 1 cycle only.
1792238|NCT00528983|Drug|Oral Azacitidine|Cycle 2 and beyond starting dose of 120 mg/day for first 7 days of 28 day cycle. Dose will escalate in increments of 60 mg. Following evaluation dose escalation will occur in 120 mg increments until maximum tolerated dose (MTD) is reached.
1792239|NCT00528983|Drug|Oral Azacitidine|Starting dose for 14 day-QD treatment schedule will be 300 mg/day. Starting dose for 14 day-BID, 21 day-QD, 21 day-BID treatment schedules will be 100 mg, 200mg, 300mg. Dose will escalate in increments of 100 mg until MTD is reached.
1792240|NCT00528996|Drug|BEA 2180 BR|
1792241|NCT00528996|Drug|tiotropium|
1792242|NCT00529009|Drug|UDCA|
1792243|NCT00529022|Drug|Azacitidine|75 mg/m^2 Subcutaneous Injection or by vein Daily for 5 Days.
1792244|NCT00529022|Drug|Valproic Acid|40 mg/kg by mouth Daily for 7 days.
1792245|NCT00529022|Drug|Carboplatin|AUC 2 by vein on Days 3 and 10 over 60 Minutes.
1792246|NCT00529035|Drug|Interleukin-2|Dose will vary depending upon when participant enters the trial: Given as a daily injection under the skin for 8 weeks.
1792250|NCT00529074|Device|Epidural Catheter for Analgesia|Patients enrolled will be placed into one of two groups of 30 patients. The decision to place the patients in either one of the two groups will be randomized as above. The Epidural group will have a thoracic epidural catheter placed pre-operatively at the T6-T7 level before general anesthesia is given. (using a .1% Marcaine and .1% Meperidine solution) A dose of Ketorolac will be given 15 minutes before the patient will be awakened from anesthesia (provided that there is good renal function and the patient is not hypovolemic) The catheter will be used preoperatively as an adjunct for general anesthesia as well as used postoperatively for continuous epidural analgesia(CEA). The control group will be given general anesthesia alone and post-operative PCA along with NSAIDS before leaving for the recovery room (as above).
1792251|NCT00529087|Drug|N-methylnaltrexone bromide (MOA-728)|Subcutaneous
1792252|NCT00529087|Other|placebo|placebo
1792253|NCT00529100|Drug|Pemetrexed Phase 1|300 mg/m^2 IV, Days 1 and 22; intermediate dose escalation level of 400 mg/m^2 IV; then 500 mg/m^2 IV, repeated every 21 days (q 21 days) x 2 cycles
1792254|NCT00529100|Drug|Cisplatin Phase 1|"Cohorts 1-3: 25 mg/m^2 IV, Days 1-3 and 22-24 then 75 mg/m^2 IV, q21 days x 2 cycles
Cohort 4 carried into Phase 2: 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles."
1792255|NCT00529100|Procedure|Radiation Therapy|Phases 1 and 2: 61-65 Gy in 33-35 fractions
1792256|NCT00529100|Drug|Pemetrexed Phase 2|Concurrent phase pemetrexed IV bolus as determined by Phase 1 trial to be 500 mg/m^2 IV on Days 1 and 22.
1792257|NCT00529100|Drug|Cisplatin Phase 2|Phase 2 (Cohort 4 carried over from Phase 1): 20 mg/m^2 IV, Days 1-5 and 22-26 then 75 mg/m^2 IV, q21 days x 2 cycles.
1792258|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 21 days
1792259|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (300 mg/day) for 21 days
1792260|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (150 mg/day) for 28 days
1792261|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (200 mg/day) for 28 days
1792262|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (250 mg/day) for 28 days
1792263|NCT00529113|Drug|Bardoxolone methyl|Bardoxlone methyl capsules (300 mg/day) x 28 days
1792264|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl capsules (350 mg/day) x 28 days
1792265|NCT00529113|Drug|Gemcitabine|1,000 mg/m2 administered as an intravenous infusion on days 1, 8, and 15
1792266|NCT00529113|Drug|Placebo|Placebo capsules x 28 days
1792267|NCT00529113|Drug|Bardoxolone methyl|Bardoxolone methyl maximum tolerated dose (as determined in the Phase 1 portion of the study)/day x 28 days
1792268|NCT00529126|Drug|SKY0402|SKY0402
1792269|NCT00529126|Drug|Bupivacaine HCl|Bupivacaine HCl
1792270|NCT00529139|Device|Standard extended dialysis|Standard extended dialysis dosed to maintain plasma urea levels between 120-150 mg/dL (20 -25 mmol/L)
1792271|NCT00529139|Device|Intensified extended dialysis|Intensified extended dialysis dosed to maintain near-normal plasma urea levels, i.e. <90 mg/dL (<15 mmol/L)
1792272|NCT00529152|Drug|Deferiprone|Ferriprox (deferiprone) oral solution will be given orally at a total daily dose of 75 mg/kg body weight or 100 mg/kg body weight, divided into 3 doses, for 24 weeks.
1792273|NCT00529165|Procedure|injection-meal-interval|"The patient injects human insulin (as Actrapid from NovoNordisc) as usual in their insulin routine. The injection is subcutaneous and the dosage is dependent on the blood glucose monitoring. Patients will inject insulin previous every meal, with the following differences:
Group A: with injection-meal-interval: 50 patients educated to inject the insulin with an injection-meal-interval of 15 minutes
Group B: without injection-meal-interval: 50 patients educated to inject the insulin without injection-meal-interval
Cross-over will occur to the other group after 12 weeks. The follow up is 28 weeks."
1792274|NCT00529178|Drug|Pravastatin|
1792275|NCT00529191|Drug|Atorvastatin|Pill, initially at 10 mg, then after 4 weeks, 20 mg Once daily for a total of 12 months
1792276|NCT00529191|Other|Placebo|One out of three subjects will receive a placebo.
1792277|NCT00529204|Drug|exenatide|Subjects meeting the inclusion criteria will be treated with exenatide 5 µg BID s.c. for 3-7 days, followed by 10 µg BID s.c. daily to week 24
1792278|NCT00529217|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Strong electromagnetic fields (~2Tesla) generated briefly (~1ms) but repetitively (1Hz) applied for 30mins, in five sessions per week for up to twelve weeks.
1792279|NCT00529230|Behavioral|Questionnaire|A set of questionnaires regarding sexual function, physical and psychological symptoms.
1792280|NCT00529230|Other|Blood draws to assess gonadal function|Testosterone, FSH, and LH levels at study onset.
1792281|NCT00529243|Drug|raltegravir|This is a single-arm, open-label, non-randomized pilot study in human immunodeficiency virus type 1 (HIV-1) positive patients who have an undetectable viral load on their current enfuvirtide containing medication regimen. The treatment regimen will consist of replacing enfuvirtide with MK-0518 400 mg twice a day given as part of the patient's HIV medication regimen. The study regimen will be administered for 24 weeks, with patients given the option of continuing on the study medication past that time if they wish to. Patients serve as their own control as they have viral control (HIV ribonucleic acid (RNA) below limits of quantification) for at least 6 months with enfuvirtide prior to switch to raltegravir.
1792282|NCT00529256|Behavioral|Feeback group|The intervention practices received a quarterly comparative feedback performance report based on the Achievable Benchmarks of Care (ABC) research conducted by Kieffe (YEAR).
1792283|NCT00529269|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1792284|NCT00529282|Drug|Ceftobiprole Medocaril|500 mg every 8 hours
1792285|NCT00529282|Drug|Cefepime with or without vancomycin|120-minute infusion [250 mL]
1792286|NCT00529295|Drug|misoprostol|Titrated oral misoprostol: one tablet of 200 microgram was dissolved in water 200 ml, and 20 ml P.O. per one hour for 4 doses, then titrated against uterine response; Vaginal misoprostol: 25 microgram per vagina
1792287|NCT00529308|Device|Transcranial Magnetic Stimulation (active)|Magstim Rapid2 stimulator with Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
1792288|NCT00529308|Device|Transcranial Magnetic Stimulation (sham)|Magstim Rapid2 stimulator with Sham Air Film Coil at 110% motor threshold at 1Hz for 30 minutes.
1792289|NCT00529321|Biological|MVA-HCV (Immunotherapy)|MVA-HCV
1792290|NCT00529334|Radiation|CyberKnife Partial Breast Irradiation|Body radiosurgery will be delivered to the lumpectomy cavity with specified margin. Radiation dose will be 600 cGy x 5 stages = 3000 cGy over five to ten total days.
1792291|NCT00529347|Device|neurally adjusted ventilatory assist (NAVA)|assessment of breathing pattern at various ventilator settings
1792292|NCT00529360|Drug|Clofarabine|Dose escalation of clofarabine on Days -9, -8, -7, -6, -5: 1 - 30 mg/m2; 2 - 40 mg/m2; 2 - 46 mg/m2; 3 - 52 mg/m2
1792293|NCT00529360|Drug|Clofarabine|Use dose of clofarabine established in Part A to further define event free, disease free and overall survival.
1792294|NCT00529373|Drug|Odanacatib|50 mg tablet orally once weekly
1792295|NCT00529373|Drug|Placebo for Odanacatib|50 mg tablet orally once weekly
1792296|NCT00529373|Dietary Supplement|Vitamin D3|5600 IU orally once weekly
1792297|NCT00529386|Drug|Botox|300 units
1792298|NCT00529386|Drug|Lidocaine|1%
1792299|NCT00529399|Drug|GAD-Alum|Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
1792300|NCT00529399|Drug|GAD-Alum and Aluminum hydroxide|Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
1792301|NCT00529399|Drug|Aluminum hydroxide|Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
1792302|NCT00529412|Other|Seprafilm|two sheets per body
1792303|NCT00529425|Drug|Ropivacaine|
1792304|NCT00529438|Drug|Bardoxolone methyl|
1792305|NCT00529451|Drug|Aliskiren|Aliskiren
1792306|NCT00529451|Drug|Ramipril|comparator
1792307|NCT00529464|Procedure|Fluorescence Spectroscopy|Pictures of the cervix will be taken before and after the application of acetic acid. A clean probe will be placed against the cervix that sends out light and reads how much light is absorbed by the tissue.
1792308|NCT00529464|Procedure|Colposcopy|A standard colposcopy will be performed.
1792309|NCT00529464|Procedure|LEEP Procedure|A small heated wire loop is used to remove a cone-shaped piece of abnormal tissue. Procedure is performed on the same day as the colposcopy exam.
1792310|NCT00529477|Other|1. Wright Nebulizer|The Wright nebulizer will be used to perform the methacholine challenge.
1792311|NCT00529477|Other|Pari LC Nebulizer|The Pari LC nebulizer will be used to perform the methacholine challenge.
1792312|NCT00529477|Other|The Pari Sinustar Nebulizer|The Pari Sinustar nebulizer will be used to perform the methacholine challenge.
1792313|NCT00529490|Drug|Hypertonic lactate|Parenteral solution administered to a maximal volume of 10 ml/kg BW over the first 12 hours post-CABG
1792314|NCT00529490|Drug|Ringer's lactate|Parenteral solution administered to a maximal dose of 30 ml/kg BW over the first 12 hours post-CABG
1792315|NCT00529503|Drug|SGN-40|2-8 mg/kg IV. Cycle 1: Days -1, 3, 8, 15; Cycles 2, 3: Days 1, 8, 15.
1792316|NCT00529503|Drug|placebo|Volume as equivalent to corresponding SGN 40 dose IV. Cycle 1: Days -1, 3, 8, 15. Cycles 2, 3: Days 1, 8, 15.
1792317|NCT00529503|Drug|rituximab|375 mg/m2 IV. Cycle 1: Day -2; Cycles 2, 3: Day 1
1792318|NCT00529503|Drug|etoposide|100 mg/m2 IV. Cycles 1-3: Days 1, 2 and 3.
1792319|NCT00529503|Drug|carboplatin|AUC=5 mg/mL min IV. Cycles 1-3: Day 2.
1792320|NCT00529503|Drug|ifosfamide|5 g/m2 24 hr. IV infusion. Cycles 1-3: Day2.
1792321|NCT00529516|Biological|Fluarix|Single dose, Intramuscular injection
1792322|NCT00529516|Biological|GSK Biologicals Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
1792323|NCT00529529|Drug|Indacaterol 300 μg|Indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
1792324|NCT00529529|Drug|Salmeterol 50 μg|Salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
1792325|NCT00529529|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied as powder filled capsules together with a single dose dry powder inhaler (SDDPI).
1792326|NCT00529529|Drug|Placebo to salmeterol|Placebo to salmeterol was supplied as powder filled capsules together with the manufacturer's proprietary dry powder inhalation device.
1792327|NCT00529542|Drug|Lipitor|40mg caplets per day for six weeks
1792328|NCT00529542|Drug|Placebo|1 placebo caplet per day for six weeks.
1792329|NCT00529555|Drug|minocycline HCl 2.1%|Minocycline HCl 2.1% gel as an adjunct to scaling and root planing. Dosing is by topical delivery into gingival pockets at baseline, 2 weeks, 4 weeks, 3 months and 6 months.
1792330|NCT00529555|Procedure|Scaling and root planing|scaling and root planing
1792331|NCT00529568|Drug|eltrombopag|double-blind active treatment daily oral administation at dose of 25, 50, 75, or 100 mg
1792332|NCT00529568|Drug|placebo|double-blind matched placebo control daily oral administration
1792333|NCT00529581|Drug|C105|
1792334|NCT00529594|Drug|placebo (Control Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
1792335|NCT00529594|Drug|Etoricoxib (Treatment Group)|Both medication have been given to the patients in both groups 1 hour prior the laser photocoagulation
1792336|NCT00529607|Drug|contrast echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
1792337|NCT00529607|Procedure|2D and 3D echocardiography|directly after PCI, at 24 h after PCI, before discharge and at 6 months
1792338|NCT00529607|Procedure|cardiac MRI|before discharge and after 6 months
1792339|NCT00529607|Procedure|blood sampling|"routine lab work plus infarction and inflammation biomarkers
1: before PCI, after PCI, at 34 hours, at discharge, at 6 months 2 and 3: one blood sample in total before PCI in 2 and at any time in 3"
1792340|NCT00529620|Drug|sulfalene-pyrimethamine plus amodiaquine|Monthly treatments during the malaria transmission season
1792341|NCT00529620|Drug|dihydroartemisinin plus piperaquine|Monthly treatments during the transmission season
1792342|NCT00529620|Drug|sulfadoxine pyrimethamine plus piperaquine|Monthly treatments during the malaria transmission season
1792343|NCT00529633|Drug|Thalidomide|Thalidomide by mouth at night for a total of 24 weeks
1792344|NCT00529633|Other|Sugar pill|Placebo by mouth at night for a total of 24 weeks
1792345|NCT00529646|Drug|APD791|
1792346|NCT00529659|Drug|Comparator: MK-0773|MK-0773 50 mg tablets twice daily, 6 month treatment period
1792347|NCT00529659|Drug|Comparator: Placebo|Placebo tablets twice daily, 6 month treatment period
1792348|NCT00529672|Procedure|crossectomy and short stripping|under spinal or complete anaesthesia
1792349|NCT00529672|Procedure|ultrasound guided sclerotherapy with foam|1 part 3% polidocanol mixed with 3 parts of air. Between 3cc - 12 cc per varicose vein>
1792350|NCT00529672|Procedure|endovenous laser therapy|940 nm Diode laser. About 70 J/cm will be administered. Disposables from Angiocare (registered) will be used.
1792351|NCT00529698|Biological|Biologically active recombinant Tat protein|
1792352|NCT00529711|Drug|Hypertonic lactate|"Solution given parenterally as follows:
Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
1792353|NCT00529711|Drug|Ringer's lactate|"Solution given parenterally as follows:
Intraoperative 3 ml./kg BW for 15 minutes at beginning of surgery; During surgery 1.5 ml/kg BW/hour; Second loading 1.5 ml/kg BW for 15 minutes after protamin administration; Post-operative 1 ml/kg BW/hour for 12 hours."
1792501|NCT00530933|Procedure|Percutaneous posterior tibial nerve stimulation|Once weekly for 30 minutes
1792354|NCT00529724|Behavioral|Energy metabolism by chronic bilateral subthalamic stimulation|Patients will be studied before and after STN-DBS surgery
1792355|NCT00529737|Procedure|Breast Biopsy|Stereotactic-guided breast biopsy via standard practice of care
1792356|NCT00529737|Procedure|Post Procedure Mammogram|View of post-procedure mammogram same projection as used in the biopsy procedure (View A), and mammographic view orthogonal projection to the first view (View B).
1792357|NCT00529750|Drug|IRBESARTAN|Tablets
1792358|NCT00529750|Drug|Atenolol|Tablets
1792359|NCT00529763|Drug|Dasatinib|Tablets, Oral, 70 mg BID (AD CML) or 100 mg QD (Chronic CML), once or twice daily dependent on disease stage, until subjects meet discontinuation (DC) criteria for study
1792360|NCT00529776|Procedure|Continuous lateral rotation therapy|
1792361|NCT00529789|Drug|duloxetine|20 - 120 milligrams (mg) every day, once-daily (QD), by mouth (PO) for 30 weeks; If patient is ≤40 kilograms (kg), initial dose is 20 mg, then titrated up. If patient is >40 kg, initial dose is 30 mg, then titrated up.
1792363|NCT00529815|Device|Continuous Glucose Monitor|The intervention group will alternate the use of the CGM with episodic self blood glucose monitoring for four cycles of two weeks using the CGM and episodic SBGM and one week only using episodic SBGM during the 12 week study.
1792364|NCT00529815|Device|Glucometer|The control group (SBGM) will be instructed in the use of the Accuchek Aviva glucometer.
1792365|NCT00529828|Procedure|Consumption of CLA enriched food|
1792366|NCT00529841|Drug|Hydrocortisone sodium acetate|Subcutaneous administration of medication via insulin pump
1792367|NCT00529854|Other|SIC-IR Billing Module|Medical informatic application designed to help with billing and documentation within the surgical and trauma intensive care unit
1792368|NCT00529867|Drug|Artemether/lumefantrine tablets|"Artemether/lumefantrine tablets containing 20mg artemether and 120mg lumefantrine
Dosage: 5 - 14.9 kg: 1 tablet and 15 - 24.9 kg: 2 tablets
Administered at 0, 8, 24, 36, 48, and 60 hours on days 0, 1, and 2"
1792369|NCT00529867|Drug|Artemether/Lumefantrine suspension|"Artemether/lumefantrine suspension containing 15mg artemether and 90mg lumefantrine per 5ml suspension
Dosage: 5.0 - 7.4 kg = 7 ml, 7.5 - 9.9 kg = 10 ml, 10 - 12.4 kg = 14 ml, 12.5 - 14.9 kg = 17 ml, 15 - 17.4 kg = 20 ml, 17.5 - 19.9 kg = 24 ml, 20 - 22.4 kg = 27 ml and 22.5 - 24.9 kg = 30 ml
Administered once daily at 0, 24, and 48 hours on days 0, 1 and 2"
1792370|NCT00529880|Drug|Fludarabine , cytarabine|
1792371|NCT00529919|Dietary Supplement|Weight loss|Weight loss study including consumption of either 22-25 g of medium chain triglyceride oil or olive oil
1792372|NCT00529932|Other|CD133+ infusion|Subjects will be infused with all available autologous CD133+ cells after processing during one infusion session (during angiography).
1792373|NCT00529932|Other|placebo infusion|Buffered normal saline will be infused in the coronary artery during an angiography.
1792374|NCT00529945|Device|PFx Closure System|
1792375|NCT00529958|Procedure|Patellar Tendon|Patellar Tendon autograft
1792376|NCT00529958|Procedure|Hamstring Tendon|Quadruple Semitendinosus/Gracilis (Hamstring) Tendon Autograft
1792377|NCT00529958|Procedure|Double-Bundle|Double-Bundle Semitendinosus/Gracilis (Hamstring) Tendon Autograft
1792378|NCT00529971|Behavioral|MBSR group|8-week MBSR group, 3 hours per week plus one all day retreat
1792379|NCT00529971|Other|Control|Treatment as usual, which could include medications or psychotherapy
1792380|NCT00529984|Biological|AVX701|4 doses of AVX701 at 4e7 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
1792381|NCT00529984|Biological|AVX701|4 doses of AVX701 at 1e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
1792382|NCT00529984|Biological|AVX701|4 doses of AVX701 at 4e8 IU given at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
1792383|NCT00529984|Biological|AVX701|4 doses of AVX701 given at the maximally tolerated dose at T=0, 3, 6, 9 weeks. Option for subjects to receive additional immunizations every 3 months after the 4th immunization if no dose-limiting toxicities or is without progressive disease
1792384|NCT00529984|Biological|AVX701|4 Doses of AVX701 given to Stage III colon cancer subjects at the maximally tolerated dose at T=0, 3, 6, 9 weeks. There will be no option for subjects to receive additional immunizations.
1792385|NCT00529997|Device|Stabilimax NZ® Dynamic Spine Stabilization System|Surgical Implantation
1792386|NCT00530010|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150 Gy (8,000-15,000 rad). Patients may receive a single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart.
1792387|NCT00530023|Device|MiniMed Paradigm REAL-Time System|MiniMed Paradigm 722 insulin pump The transmitter The sensor Paradigm Link Glucose Meter The ComLink
1792388|NCT00530049|Other|questionnaire administration|
1792389|NCT00530049|Procedure|assessment of therapy complications|
1792390|NCT00530049|Procedure|psychosocial assessment and care|
1792391|NCT00530049|Procedure|quality-of-life assessment|
1792392|NCT00530062|Drug|Albuterol-HFA-MDI|Inhalation Aerosols, 90 mcg, 1 dose per treatment period
1792393|NCT00530062|Drug|Albuterol-HFA-BAI|Inhalation Aerosol (Breath-Actuated), 90 mcg, 1 dose per treatment period.
1792394|NCT00530075|Drug|Gusperimus|SC, 0.5mg/kg/day, consecutive 21 days administration, 1 to 2 weeks rest, 6 cycles
1792395|NCT00530088|Drug|porfimer sodium|IV
1792396|NCT00530088|Drug|Photdynamic Therapy (PDT)|
1792490|NCT00530855|Drug|Lacosamide|50 mg and 100 mg Lacosamide tablets taken for 50 -400 mg twice daily dosing for up to 2 years
1792493|NCT00530881|Drug|PHX1149|
1792494|NCT00530894|Device|Edwards SAPIEN Transcatheter Heart Valve|
1792495|NCT00530894|Device|Surgical Valve Replacement|
1792602|NCT00524459|Drug|pegylated liposomal doxorubicin hydrochloride|
1792397|NCT00530101|Drug|Doxorubicin|"This pilot study will select patients who are at increased likelihood to develop cardiotoxicity, due to borderline cardiac function at baseline, advanced age, or the anticipation of a high cumulative dose of administered doxorubicin. Patients who will receive radiation therapy to the left chest during chemotherapy (i.e., left breast cancer) will be excluded so as to eliminate possible cardiotoxic effects from radiation. CMR studies will be performed at no charge to the patient, supported by the sponsor of this study. CMR imaging will be subject to IRB approval, informed consent, and HIPAA regulations. Contrast-enhanced CMR will be obtained at three time points:
Patients will not undergo contrast-enhanced MR unless calculated GFR is equal to or greater than 60 mL/min/1.73 m2"
1792398|NCT00530114|Drug|AMG 223|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
1792399|NCT00530114|Drug|Placebo|1.0 g TID orally 3.0 g TID orally 4.0 g TID orally 5.0 g TID orally
1792405|NCT00530140|Biological|Follicular lymphoma, patient-specific, soluble protein idiotype vaccine|0.5 mg of idiotype conjugated to 0.5 mg of KLH + 125 mcg of GM-CSF 5 monthly vaccinations followed by 3 bi-monthly vaccinations, followed by one boost every three months until either relapse or death from cause unrelated to lymphoma
1792406|NCT00530153|Behavioral|dietary counseling|Various activities and materials for teachers, students, parents and school catering personnel aiming at increasing their awareness and knowledge of good nutrition.
1792407|NCT00530153|Dietary Supplement|xylitol|Delivery of xylitol lozenges (about 1 g xylitol/student/school day) and guidance on tooth brushing.
1792408|NCT00530166|Drug|JNJ-18054478|3(100 mg) tablets once daily for 12 weeks
1792409|NCT00530166|Drug|sham comparator|3(100 mg) tablets once daily for 12 weeks
1792410|NCT00530179|Procedure|Autologous Blood Stem Transplantation|2 CYCLES OF R-CHOP + R-DICEP/R-BEAM FOLLOWED BY AUTOLOGOUS BLOOD STEM CELL TRANSPLANTATION
1792411|NCT00530179|Drug|R-CHOP (Rituximab, Cyclphosphamide, Etoposide, Cisplatin, Mesna, G-CSF|6 - 21 DAY Cycles of R-CHOP
1792412|NCT00530192|Other|Treatment based on Molecular Profiling|Treatment with commercially available treatments (per package insert instructions)
1792413|NCT00530205|Other|physiologic testing|
1792414|NCT00530205|Other|questionnaire administration|
1792415|NCT00530205|Procedure|management of therapy complications|
1792416|NCT00530205|Radiation|radiation therapy|
1792420|NCT00530244|Dietary Supplement|Docosahexaenoic acid (DHA)|Infant formula with 0.96% of fatty acids as DHA
1792421|NCT00530244|Dietary Supplement|Standard formula (Enfamil)|This is a standard, commercially available infant formula.
1792422|NCT00530257|Drug|Placebo|Placebo (sugar pill)
1792423|NCT00530257|Drug|OROS-methylphenidate|18 mg to 54 mg once a day for 1 week
1792424|NCT00530270|Drug|Dexamethasone|Individuals meeting entry criteria will be randomized to receive dexamethasone 0.3 mg/kg (12 mg maximum single dose). The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
1792425|NCT00530270|Drug|Placebo|Individuals meeting entry criteria will be randomized to receive 0.3 mg/kg (12 mg maximum single dose) of placebo. The study drug will be given by mouth every 12 hours until discharge from the hospital or for a maximum of 4 doses (2 days), whichever occurs first. Thereafter, study drug will be tapered over 6 days for a total duration of therapy not to exceed 8 days.
1792426|NCT00530283|Other|PET-CT|
1792427|NCT00530296|Behavioral|Cognitive Behavioral Therapy|"Group therapy, 12 sessions (90 minutes each, one session per week) manual Coping with depression course"
1792428|NCT00530309|Drug|GSK716155 for injection|GSK716155 will be available with doses of 15 milligrams once a week, 30 milligrams once a week, 50 milligrams biweekly or 100 milligrams once every four weeks.
1792429|NCT00530309|Drug|Placebo|Subjects will also receive placebo.
1792430|NCT00530322|Procedure|Laparoscopy|"A second-look laparoscopy, in patients who require further surgery (for example a liver resection or closure of ileostomy)."
1792431|NCT00530335|Drug|Atomoxetine|40 mg/day every day (QD), by mouth (PO), for 1 week; 80 mg/day every day, by mouth, for 1 week; 105 mg/day every day, by mouth, for 2 weeks; 120 mg/day every day, by mouth, for 4 weeks
1792432|NCT00530348|Biological|Alemtuzumab|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
1792433|NCT00530348|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
1792434|NCT00530361|Drug|Nesiritide|
1792435|NCT00530374|Dietary Supplement|Oral Iron Supplement|Iron Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
1792436|NCT00530374|Dietary Supplement|Placebo|Placebo Sprinkles are provided as a powder in a single-dose sachet to be taken once daily for 60 days
1792437|NCT00530387|Drug|19 organic sunscreen filters and 5 topical NSAIDs|
1792438|NCT00530400|Drug|cefuroxime|preoperative intravenous 1.5g cefuroxime
1792439|NCT00530400|Drug|placebo|preoperative intravenous placebo
1792440|NCT00530413|Drug|Phenobarbital|Phenobarbital will be given based on weight range
1792441|NCT00530413|Other|Placebo|Placebo group
1792442|NCT00530439|Other|Lifestyle intervention|Dietician counselling and physical training
1792443|NCT00530439|Other|Control|Repeated measuring of maternal weight gain, blood samples and ultrasound
1792496|NCT00530894|Other|medical management and/or balloon aortic valvuloplasty|
1792497|NCT00530907|Drug|Valproic Acid|5.3 mg/kg by mouth daily x 28 days
1792498|NCT00530907|Drug|Bevacizumab|2.5 mg/kg by vein over 90 minutes every 2 weeks
1792499|NCT00530920|Drug|tipranavir|
1792500|NCT00530920|Drug|ritonavir|
1792444|NCT00530439|Behavioral|Physical activity, dietetic counselling|"The active intervention consisted of two major components: dietary counseling and physical activity. Dietary counseling was performed by trained dieticians on four separate occasions at 15, 20, 28 and 35 weeks gestation.
Energy requirements for each participant were individually estimated according to weight and level of activity during pregnancy. Women in the active intervention group were encouraged to be moderately physically active 30-60 minutes a day.Women in this group also had free full time membership in a fitness center for six months. In the fitness centers they had closed training classes with trained physiotherapists for one hour each week."
1792447|NCT00530478|Drug|Donepezil|
1792448|NCT00530491|Procedure|Fast track lung surgery|fast track lung surgery: carbohydrate drink preoperatively, PCEA, early removal of chest tube conventional: no carbohydrate drink preoperatively, ICB+PCA, removal of chest tube depending upon chest x-ray
1792449|NCT00530504|Device|PROTÉGÉ™ GPS™ and PROTÉGÉ™ RX Carotid Stent Systems and SpiderFX™ Embolic Protection Device|Carotid artery stenting with distal embolic protection.
1792450|NCT00530517|Device|Intraject Sumatriptan|needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan
1792451|NCT00530530|Drug|ASP8825|oral
1792452|NCT00530530|Drug|Placebo|oral
1792453|NCT00530543|Procedure|Robot-assisted gait training|
1792454|NCT00530556|Drug|zolpidem|
1792455|NCT00530569|Procedure|Blood Test|CBC and HER2 level at baseline, prior to each chemo and/or herceptin cycle, one month after chemo and/or herceptin completion, quarterly up to 12 months or a maximum of 20 blood draws.
1792456|NCT00530582|Drug|progesterone|300mg progesterone /placebo each for 21 days
1792457|NCT00530595|Drug|candesartan or valsartan or losartan|
1792458|NCT00530621|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily Cycle 1 (28 days), subsequent cycles 21 days, until disease progression
1792459|NCT00530621|Drug|placebo|oral, daily
1792460|NCT00530621|Drug|pemetrexed|500 mg/m2, IV, day 8 Cycle 1 (28 days), day 1 subsequent cycles (21 days), until disease progression
1792461|NCT00530634|Drug|cisplatin|
1792462|NCT00530634|Drug|gemcitabine hydrochloride|
1792463|NCT00530634|Genetic|gene expression analysis|
1792464|NCT00530634|Genetic|reverse transcriptase-polymerase chain reaction|
1792465|NCT00530634|Other|immunohistochemistry staining method|
1792466|NCT00530634|Procedure|adjuvant therapy|
1792467|NCT00530634|Procedure|conventional surgery|
1792468|NCT00530634|Radiation|radiation therapy|
1792469|NCT00530660|Biological|H5N1 influenza vaccine (whole virion, Vero cell-derived), 7.5 µg HA antigen, non-adjuvanted|All subjects who have completed the Day 42 visit at the Austrian study site in Study 810501 will be invited to receive a booster vaccination, 12 to 17 months after the first vaccination with the A/Vietnam/1203/2004 influenza vaccine administered in Study 810501, with a heterologous whole virion, Vero cell-derived influenza vaccine containing 7.5 mg A/H5N1/Indonesia/05/2005 hemagglutinin (HA) antigen in a non-adjuvanted formulation.
1792470|NCT00530686|Drug|Islet cell transplantation|The process is based on the enzymatic isolation of the pancreatic islets of Langerhans from an organ procured from a cadaveric donor; the islets obtained are injected into the liver of the recipient via percutaneous catheterization of the portal venous system . This procedure allows the selective transplantation of the insulin-producing cell population avoiding open surgery as well as the transplantation of the duodenum and the exocrine pancreas and their related morbidity.
1792471|NCT00530699|Drug|AZD1152|intravenous
1792472|NCT00530712|Device|PROTÉGÉ® EverFlex™ Self-Expanding Stent System|Implantation of a single study device in the native superficial femoral artery or superficial femoral artery and proximal popliteal artery.
1792475|NCT00530738|Drug|Lipoplus|i.v. fat emulsion for parenteral nutrition
1792476|NCT00530738|Drug|Lipofundin MCT|i.V. fat emulsion for parenteral nutrition
1792477|NCT00530751|Other|counseling intervention|Participants undergo a 45-60 minute interview to assess their attitudes and concerns about providing family medical history online for genetic risk assessment or research. Participants' feelings about whether or not to use an online genetic assessment tool (i.e., Genetic Risk Easy Assessment Tool [GREAT]) are explored.
1792478|NCT00530764|Drug|Sativex Low Dose|Range of 1 to 4 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 10.8mg THC and 10mg CBD.
1792479|NCT00530764|Drug|Sativex Medium Dose|Range of 6 to 10 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 27mg THC and 25mg CBD.
1792480|NCT00530764|Drug|Sativex High Dose|Range of 11 to 16 sprays per day. Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). Thus maximum daily dose is 43.2mg THC and 40mg CBD.
1792481|NCT00530777|Drug|valacyclovir|500 mg oral valacyclovir twice daily from 34 weeks gestation to 1 year postpartum
1792482|NCT00530777|Drug|placebo|oral placebo twice daily from 34 weeks gestation to 1 year postpartum
1792483|NCT00530790|Drug|ropinirole controlled release (CR)-RLS|White film-coated round-shaped tablet
1792484|NCT00530803|Drug|EMLA Cream|60 minutes x1
1792485|NCT00530803|Drug|Synera Patch|20 minutes x1
1792486|NCT00530816|Drug|carfilzomib|Intravenous (IV) injection over 2 to 10 minutes twice weekly for three weeks followed by 12 days of rest.
1792487|NCT00530829|Drug|zinc|10 day blister pack of 20 mg zinc disperable tablets, 1 tablet qd for children 6 months to 4 years, 1/2 tablet qd for children 2-5 months
1792488|NCT00530842|Drug|Tiotropium plus Salmeterol|
1792502|NCT00530933|Procedure|Transcutaneous tibial nerve stimulation|30 minutes once weekly
1792503|NCT00530933|Procedure|Sham transcutaneous tibial nerve stimulation|Once weekly for 30 minutes
1792504|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
1792505|NCT00530946|Drug|Amlodipine 2.5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
1792506|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 5mg|Single pill combination, dosed once daily for 8 weeks
1792507|NCT00530946|Drug|Amlodipine 5mg/Atorvastatin 10mg|Single pill combination, dosed once daily for 8 weeks
1792508|NCT00530972|Drug|Peginterferon alfa-2a plus ribavirin adjusted to body weight|PegInterferon 180 mcg/week, Adjusted body weight Ribavirin (1000 mg <75 kg, 1200 mg >75 kg)
1792509|NCT00530985|Behavioral|Benefits Counseling|Help deciding whether to work
1792510|NCT00530985|Behavioral|VA Orientation|Orientation to services available at VA
1792511|NCT00530998|Procedure|Transvaginal Appendectomy|The appendix will be removed via an incision in the vagina.
1792512|NCT00530998|Procedure|Transvaginal Cholecystectomy|The gallbladder will be removed via an incision in the vagina.
1792513|NCT00531011|Device|XIENCE V® Everolimus Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
1792514|NCT00531011|Device|TAXUS® Liberté™ Paclitaxel Eluting Coronary Stent System|Coronary artery placement of a drug-eluting stent
1792515|NCT00531024|Drug|Bevacizumab|3 intravenous infusions of 5mg/kg bevacizumab at 2 weeks intervals
1792516|NCT00531024|Drug|Sodium Chloride|3 intravenous infusions of 100ml sodium chloride 0,9% at 2 weeks intervals
1792517|NCT00531050|Drug|Indacaterol|Single dose of indacaterol 300μg capsule via Concept 1 inhaler device at approximately the same time in the morning (i.e. between 8am and 9am).
1792518|NCT00531050|Drug|Placebo|Single dose indacaterol matching placebo via Concept 1 device
1792519|NCT00531050|Drug|Salmeterol|Single dose salmeterol 50μg via the Diskus dry powder inhaler (DPI) in part 1 of the study. Morning single inhalational dose and an evening single inhalation dose of salmeterol 50μg via the Diskus DPI in part 2 of the study.
1792520|NCT00531063|Drug|Everolimus (RAD001)|
1792521|NCT00531076|Biological|bevacizumab|"Intravenous bevacizumab at 7.5mg/kg and 15mg/kg concurrently with thoracic radiotherapy in sequential cohorts.
In the final dose level, bevacizumab 15mg/kg concurrent with radiation will be followed by maintenance bevacizumab 15mg/kg up to a maximum of 6 cycles"
1792522|NCT00531089|Drug|Rituximab|Rituximab will be administered on weeks 1, 2, 3, and 4 at a dose of 375 mg/m2 per infusion. Premedications (prednisone 50 mg, diphenhydramine 50 mg, acetaminophen) will be administered prior to study infusion. Patients will also be treated with plasma exchange as per institution/apheresis centre.
1792523|NCT00531102|Other|continuous positive airway pressure|Infants will receive CPAP of 6 cm H2O with 21% oxygen continuously for at least 5 minutes
1792524|NCT00531102|Other|Free flow oxygen|Infants will receive 50% oxygen delivered by a modified neonatal T-piece resuscitator circuit that does not generate pressure for at least 5 minutes.
1792525|NCT00531115|Drug|cetuximab 5mg/ml|"Weekly administration of Cetuximab (initial infusion of 400 mg/m2 for 120 minutes followed by subsequent maintenance doses of 250 mg/m2 for 60 minutes) Oxaliplatin. 130 mg/m2 every three weeks. on day 1 for 4 cycles Capecitabine. 1000 mg/m2 twice daily (2.000 mg/m2 total daily dose) or 750 mg/m2 if Cl Cr=30-50 ml/min (1500 mg/m2 total daily dose) for two weeks (on days 1 to 14) followed by one week of rest (on days 15 to 21).
The patients will receive 4 cycles of cetuximab plus combination chemotherapy administered every 3 weeks in order to achieve a noticeable response. Then, oxaliplatin treatment will be stopped after a maximum of 4 infusions to prevent appearance of neuropathy and then followed by capecitabine 2 weeks out of 3, and cetuximab weekly as maintenance treatment."
1792527|NCT00531141|Other|examination only|OCT performed twice
1792529|NCT00531180|Procedure|4D CT scans|Three 4D CT scans will be performed. After you are out of the CT scanner, ventilation images will be calculated from the 4D CT images and will be compared with the standard ventilation imaging method.
1792530|NCT00531180|Procedure|Lung Function Imaging|Lung function imaging performed to provide information on how well the lungs work, how air moves into the lungs with breathing, and blood circulation into the lungs.
1792531|NCT00531193|Drug|BIIB014|oral administration of BIIB014, given once daily for 8 to 12 consecutive days, at various doses as specified in protocol
1792532|NCT00531193|Other|[11C]SCH442416|11C]SCH442416 is a radiolabelled tracer molecule that specifically binds to adenosine A2A sites and will be used to evaluate receptor occupancy. The target activity will be 370 MBq. [11C]SCH442416 will be administered IV as a bolus injection over 30 seconds following the start of each PET scan.
1792533|NCT00531206|Drug|Tipranavir|
1792534|NCT00531206|Drug|Ritonavir|low dose
1792535|NCT00531219|Procedure|Transgastric Appendectomy|The appendix will be removed through an incision in the stomach and pulled out through the mouth
1792536|NCT00531219|Procedure|Transgastric Cholecystectomy|The gallbladder will be removed through an incision in the stomach and pulled out through the mouth.
1792537|NCT00531232|Drug|clofarabine|Oral daily x 5 every 28 days. 25 mg/day. Up to 8 cycles
1792538|NCT00531245|Drug|TS-1, oxaliplatin|Oxaliplatin(130 mg/m2) day 1, intravenously TS-1 at a dose of 60, 70, 80, 90, 100, 110, 120 mg/m2 given orally starting day 1 until day 14(2 weeks ON, 1 weeks OFF), every 3 weeks
1792539|NCT00531258|Device|rTMS|Bilateral rTMS
1792540|NCT00531258|Device|Sham rTMS|sham rTMS
1792541|NCT00531271|Drug|ABI-008 (nab-docetaxel)|ABI-008; 60-200 mg/m²; Intravenous infusion every 3 weeks.
1792542|NCT00531284|Drug|Carfilzomib|Administered by intravenous (IV) bolus (2-10 minute) infusion or 30 minute infusion
1792543|NCT00531284|Drug|Dexamethasone|Administered orally or by IV infusion prior to carfilzomib
1792544|NCT00531297|Procedure|endoscopic posterior mesorectal resection|6 weeks after local excision of a T1 rectal cancer a rectum sparing endoscopic removal of the dorsal part of the mesorectum by EPMR is performed.
1792545|NCT00531310|Drug|Reduced Intensity Conditioning, Busulfan and Fludarabine|Busulfan and Fludarabine
1792603|NCT00524459|Procedure|conventional surgery|
1957337|NCT02450903|Drug|LDK378|Oral LDK378 750mg once daily
1792548|NCT00531336|Drug|intravitreal injection of Bevacizumab (Avastin)|1.25 mg Avastin intravitreally applied once in arm 1 every 6 weeks in arm 2
1792549|NCT00531336|Drug|Pegaptanib (Macugen)|0.3 mg intravitreally applied every 6 weeks as long as required
1792550|NCT00531349|Procedure|propofol general anesthesia|Regional analgesia combined with sedation or a propofol general anesthesia
1792551|NCT00531349|Drug|Sevoflurane|General anesthesia
1792553|NCT00531375|Device|Silicone hydrogel contact lens|
1792554|NCT00531401|Drug|Salirasib|600mg BID until disease progression or unacceptable toxicity occurs.
1792555|NCT00531427|Drug|Buprenorphine|transdermal system 10 and 20 applied for 7-day wear
1792556|NCT00531427|Drug|Placebo|transdermal system (placebo) applied for 7-day wear
1792557|NCT00531440|Drug|Everolimus (RAD001)|
1792558|NCT00524134|Drug|Carvedilol-CR|Week 1: 20mg capsule once daily Week 2-3: 40mg capsule once daily Week 4-15: 80mg once daily Week 16: tapering (40mg/day x 4d, then 20mg/day x 3d), unless the patient wishes to continue receiving the medication.
1792559|NCT00524147|Procedure|Pigtail drainage|
1792560|NCT00524160|Drug|Fentanyl transdermal patch|
1792561|NCT00524173|Drug|Tenofovir/ &amp; Emtricitabine|
1792562|NCT00524173|Drug|Tenofovir|
1792563|NCT00524186|Drug|fluorouracil|Given IV
1792564|NCT00524186|Drug|irinotecan hydrochloride|Given IV
1792565|NCT00524186|Drug|leucovorin calcium|Given IV
1792566|NCT00524186|Drug|sunitinib malate|Taken Orally
1792567|NCT00524186|Other|flow cytometry|Correlative Study
1792568|NCT00524186|Other|pharmacological study|Correlative Study
1792569|NCT00524199|Drug|Mesna|12 mg/kg IV infusion over five minutes at the beginning of dialysis thrice weekly.
1792570|NCT00524199|Other|Saline|Saline IV infusion over five minutes at the beginning of dialysis thrice weekly.
1792571|NCT00524225|Drug|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 micrograms/kg by subcutaneous injection once daily for four days, followed by once daily on days 1-3 before and after elective surgery or dental procedure
1792572|NCT00524238|Drug|L-thyroxine|The hypothyroid patients receive usual treatment with L-thyroxine in our out patient clinic. The doctors there subscribe the medication, this study has no protocol regarding this, we observe the patients again after having been biochemically euthyroid for at least two months.
1792573|NCT00524251|Drug|esomeprazole|
1792574|NCT00524264|Drug|ketorolac|"Ophthalmic drops, BID pre- and post-operation, and 6 doses on surgery day.
Placebo"
1792575|NCT00524277|Biological|GP2 peptide + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
1792576|NCT00524277|Biological|GM-CSF (sargramostim)|GM-CSF given intradermally very 3-4 weeks for a total of up to 6 inoculations
1792577|NCT00524277|Biological|AE37 + GM-CSF vaccine|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
1792578|NCT00524277|Biological|GM-CSF (sargramostim)|Given intradermally every 3-4 weeks for a total of up to 6 inoculations
1792579|NCT00524303|Drug|Trastuzumab|4mg/kg IV loading dose followed by 2mg/kg IV weekly
1792580|NCT00524303|Drug|Paclitaxel|80mg/m2 IV weekly for 4 (21 day) cycles
1792581|NCT00524303|Drug|FEC75|5FU 500mg/m2 + Epirubicin 75 mg/m2 + cyclophosphamide 500 mg/m2 IV on day 1 of 4 (21 day) cycles
1792582|NCT00524303|Drug|Lapatinib|1250 mg oral daily dose in arm 2, 750 mg oral daily dose for FEC cycles and then 1000 mg oral daily dose during the Paclitaxel cycles in arm 3
1792583|NCT00524316|Drug|doxorubicin hydrochloride|Transarterial chemoembolization
1792584|NCT00524316|Drug|sunitinib malate|Given Orally
1792585|NCT00524316|Other|laboratory biomarker analysis|Correlative Study
1792586|NCT00524316|Procedure|hepatic artery embolization|Surgical procedure
1792587|NCT00524316|Procedure|quality-of-life assessment|Correlative Study
1792588|NCT00524342|Drug|Oprelvekin, Interleukin 11, IL-11|25 micrograms/kg by subcutaneous injection once daily for four days, then once daily on day 1-7 during each of six consecutive menstrual cycles
1792589|NCT00524368|Drug|Darunavir (DRV)|DRV/rtv 800/100 mg once daily group: 2 tablets of 400 mg of DRV administered orally once daily. DRV/rtv 600/100 mg twice daily group: 1 tablet of 600 mg DRV administered orally twice daily.
1792590|NCT00524368|Drug|Ritonavir (rtv)|DRV/rtv 800/100 mg once daily group: One capsule of 100 mg of ritonavir administered orally once daily. DRV/rtv 600/100 mg twice daily group: One capsule of 100 mg of ritonavir administered orally twice daily.
1792591|NCT00524381|Drug|Etanercept (Enbrel)|TNF-alpha antagonist, subcutaneous injection, 25 mg twice/week, 14 days.
1792592|NCT00524381|Drug|Sodium chloride (placebo)|NaCl, isotonic saline, subcutaneous injection, 1 ml twice/week, 14 days.
1792593|NCT00524407|Drug|Epoetin alfa|
1792594|NCT00524420|Device|rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions at 120% motor threshold rTMS to left dorsolateral prefrontal cortex
1792595|NCT00524420|Device|Sham rTMS|10 Hz, 4-second trains, 26-second intertrain interval, 75 trains/session, 15 sessions of sham rTMS
1792596|NCT00524433|Drug|tezosentan|tezosentan delivered i.v. at 20 mL/h (5 mg/h) for 30 min followed by 4 mL/h (1 mg/h) for 23.5 to 71.5 h (24 to 72 h in total)
1792597|NCT00524433|Drug|placebo|
1792598|NCT00524446|Dietary Supplement|Milk-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of fortified spread (FSm) 2-weekly (54 g / day) between 6 and 18 months of age.
1792599|NCT00524446|Dietary Supplement|Soy-containing fortified spread|Counseling + Vitamin A as for ST-DI + 750 g of modified fortified spread (FSs) 2-weekly (54 g / day) between 6 and 18 months of age.
1792600|NCT00524446|Dietary Supplement|Maize-soy flour|Counseling + Vitamin A as for ST_DI + 1 kg fortified maize / soy flour 2-weekly (71 g / day) between 6 and 18 months of age.
1792601|NCT00524459|Drug|docetaxel|
1957340|NCT02449018|Drug|QBW251|QBW251 capsule(s) taken orally twice per day
1957341|NCT02449018|Drug|Placebo|Matching placebo capsule(s) taken orally twice per day
1792607|NCT00524485|Drug|aminolevulinic acid|
1792608|NCT00524485|Procedure|laser therapy|
1792609|NCT00524498|Drug|OPC-18|OPC-18: 500IU * 3 times a week, sc 5-FU : 500mg infusion for 5days into hepatic artery
1792610|NCT00524498|Drug|cisplatin|infusion into hepatic artery with cisplatin 10mg and 5-FU 250mg a day
1792611|NCT00524511|Device|Surgical skin staples|Standard method to close abdominal surgical wounds
1792612|NCT00524511|Device|Dermabond|Alternative method (superglue) to close abdominal surgical wounds
1792613|NCT00524524|Drug|ARQ 501|Weekly IV Infusion; 450 mg/m2
1792614|NCT00524550|Dietary Supplement|moderate alcohol consumption|drinking commercially available alcohol-free beer or beer (26 grams of alcohol per day), for three weeks
1792615|NCT00524576|Biological|Engerix™-B|One dose (10µg Hepatitis B surface antigen (HBsAg))
1792620|NCT00524602|Procedure|Catheter ablation using the Stereotaxis equipment|Energy delivery through ablation catheter during an interventional catheterisation of the heart.
1792622|NCT00524654|Procedure|HVLA chiropractic manipulation|
1792623|NCT00524667|Drug|Valproic acid & fludarabine|valproic acid (VPA) starting dose of 15 mg/day p.o. in divided doses, increased weekly by 5 mg/kg/day until >1mM Fludarabine 40 mg/m2/day orally will be added after completing 28 days of VPA if participant has been identified as having stable or progressive disease.
1792624|NCT00524680|Dietary Supplement|cholecalciferol|Given orally
1792625|NCT00524693|Drug|Montelukast|4mg sachets
1792626|NCT00524693|Drug|Placebo granules|
1792627|NCT00524706|Drug|S-1, oral Leucovorin, Oxaliplatin|
1792628|NCT00524719|Procedure|Open Reduction and Internal Fixation|Fixation with volar locked plate
1792629|NCT00524719|Procedure|Non-Spanning External Fixation|Radio-radial external fixation
1792630|NCT00524719|Procedure|Closed Reduction with Percutaneous Fixation|Percutaneous intrafocal pinning (Kapandji technique)
1792631|NCT00524732|Biological|Tetanus and diphtheria toxoids and acellular pertussis|0.5 mL, Intramuscular
1792632|NCT00524745|Biological|Biological: quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Three doses of quadrivalent HPV recombinant vaccine administered at different dosing intervals in each of four study arms.
1792633|NCT00524758|Device|ologen (oculusgen) collagen matrix|Implant ologen collagen matrix on the top of sclera flap after loose stiched the sclera flap. The traditional trabeculectomy is performed.
1792634|NCT00524758|Drug|MMC in Trabeculectomy|MMC in Trabeculectomy
1792635|NCT00524784|Biological|ApoCell|Three subjects per cohort will be treated with ApoCell according to an escalating schedule of doses starting at a single dose of 35 million apoptotic cells/kg in the first cohort of three subjects. Unless a DLT is experienced by subjects in a given cohort, the dose in the subsequent cohort will be increased by two-fold. The second cohort will receive 70 millions cells/kg, and the third cohort 140 millions cells/kg. The final fourth cohort will receive 210 millions cells/kg.
1792636|NCT00524797|Dietary Supplement|Profonycia|
1792637|NCT00524810|Drug|Pegylated liposomal doxorubicin|Caelyx 30 mg/m² day 1 every 3 weeks
1792638|NCT00524810|Drug|Docetaxel|Taxotere 75 mg/m² day 2 every 3 weeks
1792639|NCT00524836|Drug|levocetirizine dihydrochloride|
1792640|NCT00524849|Biological|Zoledronic acid|Zometa 1 mg weekly (intravenous)
1792641|NCT00524849|Drug|Zoledronic acid|Zometa 4 mg every four weeks (intravenous)
1792642|NCT00524862|Drug|Optimized medical therapy|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
1792643|NCT00524862|Device|Implantable Cardioverter Defibrillator|an implanted device, called a defibrillator, which monitors heart rhythm and treats life-threatening rhythms accordingly
1792644|NCT00524875|Drug|Bevacizumab|One dose of bevacizumab (1.25 mg/0.05 cc) one to two weeks before pars plana vitrectomy for diabetic retinopathy
1792645|NCT00524888|Procedure|suturing laceration|suturing simple lacerations of the hand
1792646|NCT00524888|Procedure|bioadhesive|using bioadhesive on simple lacerations of the hand
1792647|NCT00524901|Drug|Epoetin alpha|A single dose of epoetin alpha during CABG for three vessel disease, 60.000 IU intravenously.
1792648|NCT00524901|Drug|NaCl 0.9%|A single dose of NaCl 0.9% during CABG for three vessel disease, 1 ml intravenously.
1792649|NCT00524914|Drug|apomorphine|Acute apomorphine subcutaneous 3 mg
1792650|NCT00524914|Drug|placebo|placebo subcutaneous
1792651|NCT00524927|Drug|Methoxyflurane|
1792652|NCT00524927|Drug|Normal Saline|
1792653|NCT00524940|Biological|Inactivated, Split-Virion Influenza Virus|0.5 mL, Intramuscular
1792654|NCT00524953|Device|EUMATRON - EN 600 NT|frequency - once a week, starting 4 days after transplantation for four weeks (total of 4 treatments) each treatment will last ~20 minutes. In addition - standard GVHD preventive protocol will be given to patients (including cyclosporine and steroids - if necessary)
1792655|NCT00524966|Procedure|Bipolar Versus Ultrasonic Hemostasis Techniques|OUTLINE: Patients undergoing thyroidectomy for thyroid cancer, thyroid nodules, hyperthyroidism and goiter will be randomized to either bipolar energy sealing system or ultrasonic coagulation.
1792656|NCT00525005|Drug|DOS (Docetaxel, Oxaliplatin and S-1)|Docetaxel 52.5mg/m2 IV on D1 (diluted in 250 ml of normal saline over a 1 hour of each cycle before oxaliplatin) Oxaliplatin 105mg/m2 IV on D1 (diluted in 250 ml of 5% DW for 2 hours) S-1 80mg/m2/day on D1-14 (2 weeks of treatment followed by a 1-week rest period)
1792657|NCT00525018|Device|contact heat evoked potential stimulator|
1792658|NCT00525031|Drug|Temozolomide (TMZ)|150 mg/m^2 by mouth once daily for 7 days, followed by 7 days off (alternating weekly) for a total of 8 weeks.
1792659|NCT00525031|Drug|Pegylated Interferon Alpha-2b (PGI)|0.5 mcg/kg subcutaneous injection once weekly for a total of 8 weeks.
1792660|NCT00525044|Drug|Ambroxol|
1792661|NCT00525044|Drug|Placebo|
1792662|NCT00525057|Drug|Dalteparin|5000 units subcutaneous injection once daily, for 7 - 10 days.
1792663|NCT00525096|Drug|placebo|2 tablets twice a day per os
1792664|NCT00525096|Drug|Celecoxib|2*200 mg tablets twice a day per os
1792665|NCT00525096|Drug|Exemestane|Exemestane 25 mg per day per os
1792666|NCT00525109|Other|No Intervention|No intervention
1792667|NCT00525135|Drug|Valproic Acid|"OUTLINE: This is a pilot study.
Patients receive valproic acid daily for 16 weeks. Dose increases on Days 4 and 8; dose remains the same for weeks 2-10. All patients will undergo a Thyrogen® (thyrotropin alfa for injection) RAI scan at entry to the study and after completion of 10 weeks of valproic acid treatment.
Quality of life is assessed at the end of every week through a study diary.
Patients are followed at 1, 2, 4, 6, 8, 10, 12, 14, 16, and 17 (Schedule 1) weeks. Patients return for follow-up at 3, 6, and 12 months."
1792668|NCT00525148|Drug|BIBW 2992|This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs
1792669|NCT00525161|Drug|sorafenib|400 mg PO (orally) twice daily for 12 months from study enrollment or until disease progression, whichever occurs first.
1792670|NCT00525174|Device|Bangerter filters|Bangerter filter worn on sound eye spectacle lens full time
1792671|NCT00525174|Device|Patching|2 hours daily patching of the sound eye
1792672|NCT00525174|Procedure|Near activities|one hour near visual activities
1792673|NCT00525200|Drug|5-Fluoruracil, Cisplatinum|"5 FU 1000mg/m2; days 1-5; 3 cycles: q21
Cisplatin 80mg/m2; day 1; 3 cycles: q21"
1792674|NCT00525200|Drug|Docetaxel|Docetaxel 75mg/m2, day 1; 3 cycles; q21
1792675|NCT00525213|Drug|Rob 803|two capsules per day during 12 weeks
1792676|NCT00525213|Drug|Placebo|two capsules per day during 12 weeks
1792677|NCT00525239|Drug|ritonavir, lopinavir/ritonavir, atazanavir/ritonavir, efavirenz|100 mg, twice daily, for four weeks
1792678|NCT00525252|Drug|Baclofen|Baclofen orally administered for 12 consecutive weeks. For the first 3 days, baclofen administered at a dose of 5 milligrams 3 times per day; subsequently, the daily dose of baclofen will be increased to 10 milligrams 3 times per day.
1792679|NCT00525252|Drug|placebo|Placebo will be orally administered for 12 consecutive weeks
1792680|NCT00525265|Drug|OPC-41061(Tolvaptan)|Subjects will be orally administered OPC-41061 7.5 mg or 15 mg once daily after breakfast for seven days.
1792681|NCT00525265|Drug|Placebo|Subjects will be orally administered placebo once daily after breakfast for seven days.
1792682|NCT00525278|Drug|Levocetirizine dihydrochloride|
1792683|NCT00525291|Device|Combination of EMG-biofeedback plus EMG-triggered AM-MF-stimulation|In the 3T arm, patients were stimulated with a carrier wave of 25 KHz and biphasic modulations of the pulse train of 40 Hz. Anxious patients trained at first only in the biofeedback mode. The stimulation was introduced after four weeks for these patients. Patients were instructed to carry out the training at home, with an alternating combination in the morning and with EMG-triggered stimulation in the evening, each for 20-minute periods. Apart from this, the protocol of the active treatment group was identical to that of the control group.
1792684|NCT00525291|Device|EMG-biofeedback alone|In the biofeedback arm, patients were instructed to carry out EMG-biofeedback training at home, standing, mornings and evenings, for 20-minute periods. The core of the task was to pull the plug-electrode upward inside the anal channel, like a lift, and to hold it there during varying periods of tension. This can only be done successfully if the perineum rises and at the same time the puborectal muscle is activated. Just squeezing the sphincter muscles does not produce this lifting effect.
1792685|NCT00525304|Behavioral|Self-management program for chronic illness|Self-management program for chronic illness will include between 10 and 16 psychoeducational and supportive group sessions.
1792686|NCT00525317|Drug|"Nycoplus Magnesium (120 mg x 3 daily for 2 weeks)"|120 mg x 3 or placebo
1792687|NCT00525330|Drug|KRP-104 QD Drug: Placebo Drug: Metformin|KRP-104 120 mg: KRP-104 two 50 mg tablets and two 10 mg tablets 15 to 30 minutes before morning meal and 2 placebo tablets 15 to 30 minutes before evening meal
1792688|NCT00525330|Drug|Placebo Drug: Metformin|Two tablets 15 to 30 minutes before each meal, morning and evening.
1792689|NCT00525330|Drug|KRP-104 BID Drug: Placebo Drug: Metformin|KRP-104 60 mg: KRP-104 one 50 mg tablet plus one 10 mg tablet 15 to 30 minutes before each meal, morning and evening.
1792690|NCT00525356|Device|Medtronic Talent Stent-Graft-System|
1792691|NCT00525382|Drug|levocetirizine dihydrochloride|
1792692|NCT00525395|Genetic|Sequential phototherapy|Group A: 2 months treatment-1 month no treatment-2 months treatment-1 month no treatment
1792693|NCT00525395|Procedure|Continuous phototherapy|Group B: 6 months non-stop treatment.
1792694|NCT00525408|Biological|Mycobacterium w.|Immunomodulator
1792695|NCT00525408|Drug|Docetaxel|Chemotherapeutic agent
1792696|NCT00525421|Drug|Curcuminoids|Curcuminoids tablets 2000mg three times per day for 12 days
1792697|NCT00525421|Drug|Placebo|
1792698|NCT00525434|Device|Seraffix LTB|wounds closure by using laser and albumin
1792699|NCT00525447|Drug|SGN-40|2-12 mg/kg IV (in the vein) on Days 1, 4, 8, 15, and 22 of Cycle 1; 4-12 mg/kg IV (in the vein) on Days 1, 8, 15, and 22 of Cycles 2-4; 4-12 mg/kg IV (in the vein) on Days 1, 8, and 15 of Cycles 5-8.
1792700|NCT00525447|Drug|lenalidomide|Up to 25 mg daily of a 21-day cycle.
1792701|NCT00525447|Drug|dexamethasone|40 mg administered weekly.
1792702|NCT00525460|Behavioral|Fertility-Sparing Survey|A questionnaire completed either in the clinic or at home
1792703|NCT00525473|Drug|Azathioprine|azathioprine usual dosage 100mg per day
1792704|NCT00525486|Drug|Nifedipine extended release|Nifedipine extended release PO 30 mg X2/d until 34 weeks' gestation
1792705|NCT00525499|Drug|ASC-J9 cream|Topical application to the face twice daily for 12 weeks.
1792706|NCT00525499|Drug|placebo|vehicle control applied topically twice daily for 12 weeks
1792707|NCT00525512|Drug|tiotropium 18 mcg|Oral inhalation once daily of 18mcg tiotropium via handihaler
1792708|NCT00525512|Drug|Placebo|Oral inhalation of once-daily placebo matching tiotropium via handihaler
1792972|NCT00533676|Drug|Comparator : placebo (unspecified) /Duration of Treatment : 8 Weeks|
1792709|NCT00531453|Drug|bortezomib, dexamethasone, and thalidomide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy (HDT) and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21)
Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.
Thalidomide will be given by mouth (p.o.)every day, starting on Day 1 of Cycle 1 (e.g. the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime)."
1792710|NCT00531453|Drug|bortezomib, dexamethasone, thalidomide, and cyclophosphamide|"VELCADE (bortezomib) twice weekly for 4 cycles (4 doses per cycle), prior to high-dose chemotherapy(HDT)and stem cell transplantation(SCT). Subjects will receive VELCADE 1.3 mg/m2 as an intravenous (i.v.) bolus injection on Days 1,4,8, and 11, followed by a 10 day rest period (Days 12 to 21).
Dexamethasone 40 mg/day will be given by mouth (p.o.) on Days 1-4 and Days 9-12 in each of 4 cycles.
Thalidomide will be given by mouth (p.o.) every day, starting on Day 1 of Cycle 1 (e.g., the same day of the first dose of VELCADE) and continuing until Day 21 of Cycle 4 at a dose of 100 mg/day (bedtime).
Cyclophosphamide will be given as an intravenous (i.v.) dose of 400 mg/m2 on Day 1 and Day 8 of each 3-week cycle, for a total of 4 cycles."
1792711|NCT00531466|Drug|tolperisone HCl (AV650)|One tablet orally three times a day for 28 days
1792712|NCT00531466|Drug|Placebo|One tablet orally three times a day for 28 days
1792713|NCT00531479|Drug|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV BID plus anidulafungin placebo IV qd.
Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin placebo IV qd.
Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin placebo IV qd,
OR
Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
1792714|NCT00531479|Drug|anidulafungin|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.
Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.
Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,
OR
Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
1792715|NCT00531479|Drug|voriconazole|"First week: Voriconazole 6 mg/kg IV bid for the first 24 hours, followed by 4 mg/kg IV bid plus anidulafungin 200 mg IV on day 1, followed by 100 mg IV qd thereafter.
Second week: Voriconazole 4 mg/kg IV bid or 300 mg PO bid plus anidulafungin 100 mg IV qd.
Third and fourth weeks: Voriconazole 4 mg/kg IV bid OR 300 mg PO bid plus anidulafungin 100 mg IV qd,
OR
Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy.
Fifth and sixth weeks: Voriconazole 4 mg/kg IV bid or 300 mg PO bid monotherapy."
1792716|NCT00531492|Behavioral|TK as soon as possible within 24 hours after birth|Start TK as soon as possible within 24 hours after birth
1792717|NCT00531492|Other|Conventional care|Start conventional care (At first use incubator, and start TK when the infants and mother are completely settled and ready)
1792718|NCT00531518|Drug|aripiprazole; fluoxetine; bupropion; sertraline; lamotrigine|Oral, daily, generally at lower than manufacturer's recommendations
1792719|NCT00531518|Behavioral|Psychoeducational multifamily group treatment|Families and patients are educated on psychobiology of psychosis and trained in coping skills to avoid psychosis by reducing stress and optimizing social environment at home, school, work
1792720|NCT00531518|Behavioral|Supported employment and education|Participants are provided direct assistance, guidance and ongoing support to gain employment and succeed in their educational goals.
1792721|NCT00531544|Drug|SU011248|SU011248 Expanded Access Protocol for Systemic Therapy
1792722|NCT00531557|Drug|Darunavir ritonavir|
1792723|NCT00531583|Drug|Autologous peripheral Bld Stem Cell Transplantation with In Vivo Purging as an alternate stem cell transplantation|Autologous PBSCT
1792724|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 6mg/24Hr|EMSAM 6mg/24HR
1792725|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 9mg/24Hr|EMSAM 9mg/24Hr
1792726|NCT00531596|Drug|EMSAM (Selegiline Transdermal System) 12mg/24hr|EMSAM 12mg/24Hr
1792727|NCT00531622|Drug|saredutant (SR48968)|oral administration, capsules
1792728|NCT00531622|Drug|escitalopram|oral administration, capsules
1792729|NCT00531622|Drug|placebo|oral administration, capsules
1792730|NCT00531635|Drug|Mycophenolate Mofetil|Induction of Mixed Hemopoietic Chimerism in Patients Using Mycophenolate Mofetil
1792731|NCT00531661|Device|HF Pressure Measurement System|A pressure sensor is intended to be implanted into the pulmonary artery at the time of Swan-Ganz catheterization.
1792732|NCT00531674|Dietary Supplement|fortified milk-based beverage|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
1792733|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
1792734|NCT00531674|Dietary Supplement|tablets|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
1792735|NCT00531674|Dietary Supplement|Fortified milk-based pap|Fortified with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for children.
1792736|NCT00531674|Dietary Supplement|Sprinkles|Powder with multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
1792737|NCT00531674|Dietary Supplement|Syrup|Multiple vitamins and minerals (1 RDA). Identifical dose and formulation as other supplements for women.
1792738|NCT00531687|Drug|Paclitaxel|"Paclitaxel 175 mg/m2 day 1 (3 hour infusion)
Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
1792739|NCT00531687|Drug|Cisplatin|"cisplatin 50 mg/m2 day 1 and 2
Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered."
1792740|NCT00531687|Drug|Gemcitabine|"gemcitabine 1000mg/m2 days 1 and 8 (in a 30 minute infusion)
Repeat at 21-day intervals for 4 cycles if toxicity is acceptable. If necessary more than 4 cycles can be administered"
1792741|NCT00531700|Other|Health messaging|Combinations of personalized health messages (tailored/targeted) and contextualized health messages (reports about localized epidemiologic risk) will be delivered to subjects
1792973|NCT00533689|Procedure|Electroretinography (ERG), Visual Evoked Potentials (VEP)|
1792742|NCT00531700|Other|Health messages|community level health messages unrelated to the study originating exposures
1792743|NCT00531713|Drug|Triiodothyronine|50 microgram of the usual T4 is withdrawn and the patients is given 20 microgram of T3
1792744|NCT00531726|Device|DBS of Cg25|
1792745|NCT00531739|Other|Polylactic Acid Sheet|SurgiWrapTM film will be secured in two study areas: directly below the abdominal incision and on the posterior pelvic rim. The film will not be wrapped directly around an anastomosis.
1792746|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 0.5 mg QD for Days 1-7, then 1.0 mg QD Days 8-14, then 2.0 mg QD Days 15-21
1792747|NCT00531752|Drug|Placebo capsules|Dosage Form: matching placebo capsules Dosage: Subjects will take two placebo capsules each morning throughout the 3 week double-blind treatment placebo treatment period.
1792748|NCT00531752|Drug|PF-03654746|Dosage Form: 0.5 mg capsules of PF-03654746 Dosage: 1 mg (2 x 0.5 mg capsules) of PF-03654746 given daily for three weeks
1792749|NCT00531765|Other|sodium bicarbonate infusion|short infusion of sodium bicarbonate
1792750|NCT00531791|Drug|prednisone group|Patients in the prednisone group will receive prednisone 40 mg per day with concomitant placebo diskus 2 inhalations twice a day for 10 days. All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
1792751|NCT00531791|Drug|Advair group|Patients in the second group will receive Advair® 50/500 ug 2 inhalations twice daily with placebo pills once a day for 10 days (twice the regular dosage). All patients will receive oral antibiotics for 10 days, which will include moxifloxacin (Avelox®) 400 mg die or amoxicillin/clavulanate (Clavulin®) 875mg bid and short-acting bronchodilators (Ventolin®, Bricanyl®, Atrovent®) as needed.
1792752|NCT00531999|Drug|Raltegravir then lopinavir/ritonavir|raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study
1792753|NCT00531999|Drug|Lopinavir/ritonavir then raltegravir|lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study
1792754|NCT00532012|Drug|RhuDex®|
1792755|NCT00532025|Drug|Sorafenib|Sorafenib will be administered as oral formulation (200 mg tablets) at a dose of 400 mg twice daily starting 28 to 42 days after surgery or surgery plus adjuvant radiotherapy. The dose may be adjusted based on individual toxicities following a predetermined dose reduction schedule. Sorafenib therapy will be continued for 48 months, or until disease progression, patient refusal or intolerable toxicity, whichever comes first. Patients in remission after 48 months will be offered continued Sorafenib treatment in a roll-over study.
1792756|NCT00532038|Drug|ThermoProfen™ (Matrix Transdermal Ketoprofen/CHADD™ System)|Patients will apply ThermoProfen daily for approximately 12 hours for up to 12 months for treatment of the pain associated with osteoarthritis of the knee.
1792757|NCT00532051|Device|OCT measurements|This study is about a new imaging method to study the front part of the eye. This imaging method is called Optical Coherence Tomography (OCT) which provides detailed cross-sectional (layered) views of structures in the eye. The OCT system scans a beam of light across the eye to take a picture. OCT provides a more detailed image than other imaging methods of the eye such as ultrasound, CT scan (computed tomography), and MRI (magnetic resonance imaging). In addition, OCT imaging does not touch the eye. OCT is routinely used in imaging structures in the back of the eye (retina) and cornea. This study uses high-speed FDA approved OCT systemsThe measurements from the OCT systems are used in selecting IOL power.
1792758|NCT00532064|Behavioral|Questionnaire|Symptom questionnaire taking about 10-15 minutes.
1792759|NCT00532077|Drug|rhPTH(1-34)|
1792760|NCT00532077|Drug|SB-751689 100 mg|
1792761|NCT00532077|Drug|SB-751689 400 mg|
1792762|NCT00532090|Drug|RG4733|Administered orally daily at ascending doses to successive cohorts of patients
1792763|NCT00532090|Drug|RG4733|Administered orally at ascending doses to successive cohorts of patients, on a 3 days on/ 4 days off schedule
1792764|NCT00532090|Drug|RG4733|Administered orally at ascending doses to successive cohorts of patients, on days 1-7 of each 21 day cycle
1792765|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 6mg|STS 6mg/24hr
1792766|NCT00532116|Drug|EMSAM (Selegiline Transdermal System) 12mg|EMSAm 12mg/24Hr
1792767|NCT00532129|Drug|Rituximab|375mg/m^2 IV on Day 1 of Cycle 1; 500mg/m^2 on Day 1 of Cycles 2-6.
1792768|NCT00532129|Drug|Chlorambucil|10 mg/m^2/day PO on Days 1 to 7 of each cycle for a maximum of 12 cycles.
1792769|NCT00532142|Drug|Intravitreal Triamcinolone|
1792770|NCT00532142|Procedure|Radial Optic Neurotomy|
1792771|NCT00532142|Other|Placebo - Sham Intravitreal Injection|
1792772|NCT00532155|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|6 mg/kg Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
1792773|NCT00532155|Drug|Placebo|Matching placebo to Aflibercept administered intravenously (IV) over 1 hour once on Day 1, every 3 weeks.
1792774|NCT00532155|Drug|Docetaxel (Taxotere®)|75 mg/m² docetaxel in 250 mL dextrose 5% or NaCl 0.9% administered intravenously (IV) over 1 hour, on Day 1 every 3 weeks.
1792775|NCT00532155|Drug|Dexamethasone (pre- and post-medication for docetaxel)|As a pre- and post-medication for docetaxel, 8 mg dexamethasone was administered orally, the evening before Day 1, on Day 1 (early morning, 1 hour before docetaxel treatment, and evening) and on Day 2 (morning and evening).
1792776|NCT00532168|Drug|tenofovir + emtricitabine + efavirenz|tenofovir + emtricitabine + efavirenz, approved dose, oral route, QD
1792777|NCT00532168|Drug|tenofovir + emtricitabine + lopinavir-ritonavir|tenofovir + emtricitabine (QD) + lopinavir-ritonavir (BID), oral route, approved dose
1792778|NCT00532168|Drug|tenofovir + emtricitabine + atazanavir-ritonavir|tenofovir + emtricitabine + atazanavir + ritonavir (100 mg), oral route, approved dose, QD
1792779|NCT00532181|Behavioral|Savings Behavior and Consumer's Approach to Risk|
1792781|NCT00532207|Drug|teriparatide|subcutaneous 20 micrograms
1792782|NCT00532220|Drug|Ibandronate IV|Ibandronate IV (Bonviva® IV), 10.5 mg divided in 4 single infusions within 2 weeks(1x1.5 mg, 3x3 mg), followed by a fifth infusion after 3 months (V4)
1792783|NCT00532220|Drug|Placebo|Placebo IV, divided in 4 single infusions within 2 weeks, followed by a fifth infusion after 3 months (V4)
1792787|NCT00532259|Drug|CT-011|IV infusion of 1.5 mg/kg of CT-011 on Day 1(60 to 90 days post autologous PBSCT). Treatment was repeated every 42 days for a total of three courses with treatment visits on Days 1, 43, and 85.
1792788|NCT00532272|Drug|Letrozole ,Goserelin|Letrozole 2.5mg qd. Goserlin 3.6mg monthly(premenopausal)
1792789|NCT00532285|Drug|Paclitaxel/Gemcitabine|Treatment will be delivered in the outpatient setting. Each three-week cycle consists of paclitaxel 80 mg/m2 (day 1, 8) and gemcitabine 1200 mg/m2 (day1, 8).Patients will receive four cycles of therapy unless there is any evidence of no response (SD or PD) or unacceptable toxicity defined as unpredictable, irreversible, or Grade 4, or noncompliance by patient with protocol requirements.
1792790|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2006/07 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
1792791|NCT00532298|Biological|GSK Bio's influenza vaccine GSK576389A [NH 2007/08 season]|Single dose, intramuscular injection, GSK Bio's influenza vaccine GSK576389A formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
1792792|NCT00532298|Biological|Fluarix [NH 2006/07 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2006-2007 influenza season.
1792793|NCT00532298|Biological|Fluarix [NH 2007/08 season]|Single dose, intramuscular injection, Fluarix vaccine formulation recommended for the Northern Hemisphere 2007-2008 influenza season.
1792794|NCT00532311|Drug|Lapaquistat acetate and stable statin therapy|Lapaquistat acetate 50 mg, tablets, orally, once daily and stable statin therapy for up to 12 weeks.
1792795|NCT00532311|Drug|Stable statin therapy|Lapaquistat acetate placebo-matching tablets, orally, once daily and stable statin therapy for up to 12 weeks.
1792796|NCT00532324|Other|CA-MRSA Decolonization|In later stages of this study, women found to be nasally and/or vaginally colonized with CA-MRSA will be randomized to receive postpartum, either: 1) attempted decolonization with intranasal mupirocin twice a day for one to two weeks with or without diluted chlorhexidine or Clorox baths two to three times a week for one to two weeks or, 2) no intervention. The primary study is observational only.
1792797|NCT00532337|Drug|ONO-5334|Placebo - 24/mos.
1792798|NCT00532337|Drug|ONO-5334|100mg QD /24 months
1792799|NCT00532337|Drug|ONO-5334|50mg BID /24 mos.
1792800|NCT00532337|Drug|ONO-5334|300mg QD /24 mos.
1792801|NCT00532337|Drug|ONO-5334|Alendronate 70mg once weekly / 24 mos
1792802|NCT00532350|Drug|QAT370|
1792803|NCT00532350|Drug|Placebo|
1792804|NCT00532350|Drug|Tiotropium|
1792805|NCT00532389|Drug|LBH589|
1792806|NCT00532415|Drug|Triamcinolone Acetonide Injectable Suspension|Approximately 1-4 mg (0.025-0.1 cc) as needed for visualization during pars plana vitrectomy with or without membrane removal.
1792807|NCT00532428|Drug|Raloxifene|60 mg QD
1792808|NCT00532428|Drug|Raloxifene|120 mg QD
1792809|NCT00532428|Drug|Placebo|Placebo
1792810|NCT00532441|Drug|Erlotinib|Erlotinib 150 mg p.o. daily, days 2-7, 9-14, 16-28
1792811|NCT00532441|Drug|Docetaxel|Docetaxel 30 mg/m2 IV over 30 min weekly x 3 weeks on days 1, 8 and 15
1792812|NCT00532454|Drug|Tamoxifen|tamoxifen 20mg, PO, QD until disease progression
1792813|NCT00532467|Drug|SRX251|
1792814|NCT00532480|Drug|Duloxetine|60 mg capsules
1792815|NCT00532493|Drug|prazosin|"Subjects will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. As a further precaution, male subjects will be advised to sit on the toilet for urination at night during the first week of dose titration. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) and then titrating the dose upward gradually."
1792816|NCT00532493|Other|placebo|"sugar pill"
1792817|NCT00532506|Drug|SK-0403|
1792818|NCT00532519|Drug|citalopram (cipralex)|10-20 mg/day, for 12 weeks.
1792819|NCT00532532|Drug|tolperisone HCl|Low dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
1792820|NCT00532532|Drug|tolperisone HCl|High dose AV650 three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
1792821|NCT00532532|Drug|tolperisone HCl|Placebo three times a day orally for 5 weeks; followed by optional continuation on either low dose or high dose AV650, as tolerated, for 24 weeks
1792822|NCT00532545|Drug|Teriparatide|Teriparatide 20 micrograms/daily subcutaneously
1792823|NCT00532558|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily for up to 12 weeks.
1792824|NCT00532558|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily for up to 12 weeks.
1792825|NCT00532571|Drug|CoQ10|
1792826|NCT00532584|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
1792829|NCT00532610|Drug|GSK189075|
1792830|NCT00532623|Drug|Gemcitabine plus Vinorelbine|Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles
1792831|NCT00532623|Drug|Sequential|"Gemcitabine monotherapy followed by Vinorelbine monotherapy:
-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles."
1792832|NCT00532636|Procedure|Ventilation|Mask ventilation in neutral and head extension position
1792833|NCT00532636|Procedure|Ventilation|Mask ventilation in neutral and head extension position
1792834|NCT00532662|Drug|S(+)-ketamine|epidural or intravenous 1 mg kg-1 once concurrent with caudal anesthesia
1793026|NCT00534131|Procedure|Standard abdominal approach for rectal excision|Standard abdominal approach for rectal excision
1792836|NCT00532688|Drug|N-acetylcysteine|28 days of oral n-acetylcysteine (500mg bd)(in addition to standard therapy) and then repeat serum creatinine and vascular study then crossover to placebo for 28 days after one week washout period with tests repeated again at 4 weeks and 9 weeks.
1792837|NCT00532701|Drug|Peg-IFN + WB RBV for 16 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4
Rapid virologic response (RVR) at week 4 of therapy: achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 5-16"
1792838|NCT00532701|Drug|Peg-IFN + LD RBV for 16 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-6
Rapid virologic response (RVR) at week 4 of therapy: achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 6-16"
1792839|NCT00532701|Drug|Peg-IFN + WB RBV for 24 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4
Rapid virologic response (RVR) at week 4 of therapy: not achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-24"
1792840|NCT00532701|Drug|Peg-IFN + WB RBV for 48 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day (< 75 kg, 1000 mg/day; >= 75 kg, 1200 mg/day) from weeks 1-4
Rapid virologic response (RVR) at week 4 of therapy: not achieved
Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 1000-1200 mg/day from weeks 5-48"
1792841|NCT00532701|Drug|Peg-IFN + LD RBV for 24 weeks|"Peginterferon alfa-2a (Pegasys, F. Hoffman-LaRoche) 180 ug/week plus ribavirin (Copegus, Hoffman-LaRoche) 800 mg/day from weeks 1-24
Rapid virologic response (RVR) at week 4 of therapy: both achieved and not achieved"
1792842|NCT00532714|Drug|Irinotecan plus capecitabine|"Irinotecan 80 mg/m2 intravenously for 90 minutes once a week for 2 weeks (Days 1 and 8) followed by 1-week rest period.
Capecitabine is administered orally at a dose of 1,000 mg/m2 twice daily (total daily dose 2,000 mg/m2) as an intermittent regimen in 3-week cycles (2 weeks of treatment followed by a 1-week rest period)."
1792843|NCT00532727|Drug|Carboplatin|AUC 6 every 3 weeks for six cycles (18 weeks)
1792844|NCT00532727|Drug|Docetaxel|100mg/m2 every 3 weeks for six cycles (18 weeks)
1792845|NCT00532740|Radiation|Yttrium Y 90 glass microspheres|Between 0.2 to 0.5 Curies (200-500-mCi), either single dose to the whole liver, or lobar treatment delivered as a sequence of treatments approximately 30 -90 days apart per treating physician's discretion.
1792846|NCT00532753|Behavioral|Community Empowerment|
1792847|NCT00532766|Drug|Jusline|
1792848|NCT00532779|Drug|Naltrexone SR 16 mg/Bupropion SR 360 mg /day|
1792849|NCT00532779|Drug|Naltrexone SR 32 mg/Bupropion SR 360 mg /day|
1792850|NCT00532779|Drug|Placebo|
1792851|NCT00532779|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
1792852|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; No LT Patch Day 0 or Day 21
1792853|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
1792854|NCT00532792|Biological|A/H5N1|Low dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
1792855|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
1792856|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
1792857|NCT00532792|Biological|A/H5N1|Medium dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
1792858|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
1792859|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; no LT patch on Day 0; LT Patch on Day 21
1792860|NCT00532792|Biological|A/H5N1|High dose A/H5N1 (0.5mL); Route IM - Day 0 and Day 21; LT patch on Day 0 and Day 21
1792861|NCT00532792|Biological|Placebo|Placebo (0.5ml); Route IM - Day 0 and Day 21; no LT patch on Day 0 or Day 21
1792862|NCT00532818|Drug|Hydralazine and magnesium valproate|Cisplatin + Topotecan plus hydralazine valproate
1792863|NCT00532818|Drug|Placebo|Cisplatin + Topotecan plus placebo
1792864|NCT00532844|Drug|6R-BH4 (sapropterin dihydrochloride)|5 mg/kg BID of 6R-BH4 tablets to be administered orally for 13.5 days
1792865|NCT00532844|Drug|6R-BH4 (sapropterin dihydrochloride)|5 mg/kg BID of 6R-BH4 tablets, plus 500 mg BID of Vitamin C caplets to be administered orally for 13.5 days
1792866|NCT00532857|Drug|Paclitaxel/Gemcitabine/Trastuzumab|80 mg/m2 of paclitaxel 1,200 mg/m2 of gemcitabine, day 1, day 8 every 3-week. trastuzumab at a dose of 4 mg/kg IV on D1 of first treatment cycle subsequently given weekly at a dose of 2 mg/kg
1792867|NCT00532870|Other|laparoscopic|
1792868|NCT00532883|Drug|Hydroxyurea|HU capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
1792869|NCT00532883|Drug|Magnesium Pidolate|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg liquid (0.6 mEq/kg/day for 11 months)
1792870|NCT00532883|Other|Placebo Pills and Placebo Liquid|HU/Placebo capsules (20 mg/kg/day for 11 months) Mg/Placebo liquid (0.6 mEq/kg/day for 11 months)
1792871|NCT00532909|Drug|Vandetanib|100mg or 300mg By mouth every day continuous
1792872|NCT00532909|Drug|Capecitabine|Dosage: 1000mg/m2 By mouth twice a day for 14 days or reduced dose of 800mg/m2 PO BID days1-14.
1792873|NCT00532909|Drug|Oxaliplatin|dosage: 130mg/m2. IV Day 1 of a 21 day cycle or reduced dose of 100mg/m2 IV Day 1.
1792874|NCT00532909|Drug|Bevacizumab|Dosage: 7.5mg/kg or 10mg/kg. IV Day 1 (21 day cycle)
1792875|NCT00532935|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin phosphate (+) metformin hydrochloride 50/500 mg tablet bid, titrating up to sitagliptin phosphate (+) metformin hydrochloride 50/1000 mg tablet for an ~32 wk treatment period
1792876|NCT00532935|Drug|Comparator: pioglitazone|pioglitazone 30 mg tablet qd, titrating up to 45 mg qd for an ~32-wk treatment period.
1792877|NCT00532948|Drug|capecitabine [Xeloda]|500mg/m2 po bid (starting dose)
1792878|NCT00532961|Drug|Loteprednol etabonate 0.5% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals(1-2 drops per eye)for a total of 28 days
1792879|NCT00532961|Drug|Dexamethasone 0.1% and tobramycin 0.3%|ophthalmic suspension, four times daily during the day at roughly 4 hour intervals (1-2 drops/eye) for a total of 28 days.
1792880|NCT00532974|Biological|EP1090|Low dose
1792881|NCT00532974|Biological|EP1090|High dose
1792882|NCT00532987|Behavioral|Questionnaire|Questionnaire form to be completed by patient
1792883|NCT00533000|Procedure|Smoking cessation|Weekly smoking cessation by professional counseling and nicotine substitute on request
1792884|NCT00533013|Other|Usual Care|Management of heart failure is provided by primary practitioners and consultant cardiologists
1792885|NCT00533013|Other|Disease Management and Tele-Monitoring|Management of heart failure is provided by cardiologists at regional heart failure clinics and by nurse practitioners at regional heart failure clinics and a designated call center. Decisions on treatment are guided by designated protocols and information derived for tele-monitoring of blood pressure, body weight and pulse rate.
1792886|NCT00533026|Drug|Duloxetine|
1792887|NCT00533026|Drug|Warfarin|
1792888|NCT00533039|Drug|Varespladib (A-002)|250mg tablets BID for 3-5 days pre-angioplasty and 5 days post-angioplasty.
1792889|NCT00533039|Drug|placebo|250mg tablets BID 3-5 days pre-angioplasty and 5 days post-angioplasty.
1792890|NCT00533052|Behavioral|Standard Behavioral Weight Loss Treatment Plus Affective and Cognitive Skills Training|24-week, weekly, group behavioral weight loss treatment with affective and cognitive skills training
1792892|NCT00533078|Dietary Supplement|omegaven|Trial participants are prescribed TPN by the attending physician as soon as indicated, which will be administered via a central venous line over a time period of approximately 20 hours per day. The formulation given to all patients is Nutriflex lipid spezial®, an emulsion containing the full supply of carbohydrates, amino acids and lipids (SO:MCT = 1:1) with a total energy content of 2215 kcal in a 1875 ml volume, see Investigator's Brochure. In addition, they receive daily infusional Omegaven® 100 ml over 4 hours, which equal FO 10 g/d or omega-3 PUFA 3-6 g/d.
1792893|NCT00533091|Biological|MEDI-545|"MEDI-545 is supplied as a sterile liquid containing 0.75 mL of MEDI-545 solution at a concentration of 100 mg/mL in a 3 mL single-use glass vial.
Dosage, frequency and duration: MEDI-545 (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 26 weeks."
1792894|NCT00533091|Other|Placebo|"Dosage form: Placebo is supplied as a sterile liquid containing a 0.75 mL solution in a 3 mL single-use vial.
Dosage, frequency and duration: Placebo (0.3, 1.0, 3.0, or 10.0 mg/kg) will be administered via infusion over at least 60 minutes every 2 weeks for 12 weeks.
Thereafter, subjects will receive MEDI-545, at the dose specified in the dose cohort they are assigned, every 2 weeks for an additional 12 weeks."
1792895|NCT00533104|Procedure|BM-MNC preparation|"For autologous bone marrow - mononuclear cells preparation, 500ml of bone marrow are collected under general anaesthesia; mononuclear cells are separated using a blood-cells separator (COBE SPECTRA, GAMBRO BCT) and concentrated to produce a final volume of 40ml.
Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
1792896|NCT00533104|Procedure|PB-MNC preparation|"Peripheral blood - mononuclear cells are collected through cytapheresis with the same blood-cells separator which is adjusted to obtain a 40 mL cell product. No previous mobilization with hematopoïetic growth-factor is administered.
Cells are implanted 1 to 3 hours after preparation by multiple intramuscular injections into the gastrocnemius of the ischemic leg.(30 injection sites, 1 to 1.5 cm deep, spaced 1 cm apart,1 ml per injection)."
1792897|NCT00533117|Drug|Fluoxetine|Fluoxetine is administered in standard dosing 20, 40, 60, 80 mg increased monthly if tolerated
1792898|NCT00533117|Behavioral|Dialectical Behavior Therapy|Dialectical Behavior Therapy is a form of CBT originally developed to treat suicidal and self injuring individuals with borderline personality disorder. Treatment consists of 2 sessions/week: individual psychotherapy and skills training group.
1792899|NCT00533117|Behavioral|Supportive psychotherapy|Supportive therapy is a manualized form of psychotherapy designed to enhance individual's strengths and coping mechanisms while reducing distress.
1792900|NCT00533130|Procedure|clinical evaluation|analyze the x ray from each patient and evaluate the treatment y development of bone healing.
1792901|NCT00533130|Procedure|observational study|evaluate the walk patron, bone healing and range of motion at 1,3,6,12 months
1792902|NCT00533143|Other|non invasive ventilation (NIV)|NIV is a form of mechanical ventilation delivered through a face or nasal mask and therefore not requiring endotracheal intubation. It will be delivered according to the compliance and tolerance of the patients.
1792903|NCT00533156|Device|Vascular access site closure (7F Ensure)|
1792904|NCT00533169|Drug|ZD6474|Part A = Starting dose 50 mg/m^2 by mouth daily for 28 days; Part B, C = Starting dose 50 mg/m^2 by mouth daily on days 2-28.
1792905|NCT00533169|Drug|Retinoic Acid|Part B, C = 80 mg/m^2 by mouth twice daily for 2 consecutive weeks out of every four weeks (28 days).
1792906|NCT00533195|Drug|5-Methoxypsoralen|1,2 mg/kg 2 hours before UVA irradiation p.o. 3 times weekly for 5 weeks
1792907|NCT00533195|Device|UVA1 phototherapy|"Treatment 5 x week for 3 weeks (=15 irradiations). Determination of the UVA 1 MED prior to treatment. Start with 1 MED. Increments of the UVA 1 dose in 20 % steps until a maximal dose of 70 J/cm2 in the absence of an erythemal reaction and by good tolerability.
No maintenance therapy except emollients."
1792908|NCT00533208|Drug|MK0524|
1792909|NCT00533221|Drug|somatotropin|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
1792910|NCT00533221|Drug|Placebo|0,015 mg/kg/d as one dose s.c. in the evening over one week followed by a 11 week period with 0,03 mg/kg/d s.c. as one dose in the evening
1792911|NCT00533234|Device|ExploR® Modular Radial Head|The ExploR® Modular Radial Head is a modular head and stem radial head/neck replacement.
1792912|NCT00533247|Drug|Celecoxib|
1792974|NCT00533702|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
1792913|NCT00533273|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 0.58 mg/placebo into the cord of the affected hand in the double-blind phase. In the open-label extension phase, subjects could have received up to five additional injections of AA4500, with each injection separated by at least 30 days. Individual joints could have received up to a maximum of three AA4500 injections.
1792914|NCT00533286|Drug|benzodiacepine|diazepam (2 x 5 mg/ die)
1792915|NCT00533299|Drug|Hydralazine and magnesium valproate|Hydralazine and valproate will start from seven days before day 1 of chemotherapy until the end of the sixth course. Hydralazine will be administered at 182mg (rapid) or 83mg (slow) according to the acetylator phenotype in a single daily dose and magnesium valproate at an oral dose of 40mg/Kg t.i.d.
1792916|NCT00533299|Drug|Placebo|Placebos will start from seven days before day 1 of chemotherapy until the end of the sixth course. Placebo tablets will be administered in an identical form that experimental drugs.
1792917|NCT00533312|Drug|Comparator : placebo (unspecified) / Duraton of Treatment: 4 Weeks|
1792918|NCT00533312|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment : 4 Weeks|
1792919|NCT00533312|Drug|Comparator : niacin / Duraton of Treatment: 4 Weeks|
1792920|NCT00533338|Behavioral|Weight Gain Prevention Program|Intervention program including in-person instruction and counseling about exercise and diet, exercise practice sessions, and telephone counseling.
1792921|NCT00533338|Behavioral|Questionnaire|Packet of questionnaires will be completed.
1792922|NCT00533351|Drug|AGN201781|AGN201781 50 mg capsules three-times daily for 2 weeks
1792923|NCT00533351|Drug|placebo|placebo 50 mg capsules three-times daily for 2 weeks
1792924|NCT00533364|Drug|SBG (Soluble beta-glucan)|Oral administration, three dose levels, administered day 1-8 in each 3-weeks treatment cycle, 4 treatments cycles.
1792925|NCT00533377|Drug|CP-533, 536|Active study drug
1792926|NCT00533377|Drug|Placebo|Placebo vehicle
1792927|NCT00533377|Procedure|Standard of Care|Standard surgical procedure
1792928|NCT00533377|Drug|CP-533,536|Active study drug
1792929|NCT00533377|Drug|CP-533,536|Active study drug
1792930|NCT00533377|Drug|CP-533,536|Active study drug
1792931|NCT00533390|Drug|efavirenz|600mg X 800mg QID during TB therapy with rifampicin associated with other antituberculosis drugs in patients concomitant treated for tuberculosis and AIDS
1792932|NCT00533403|Drug|MK0686|
1792933|NCT00533416|Drug|ON 01910 Na|
1792934|NCT00533429|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until disease progression
1792935|NCT00533429|Drug|pemetrexed|500 mg/m2, IV, day 8 of cycle 1 - 28 days, day 1 of subsequent cycles q 21 days x 3 cycles
1792936|NCT00533429|Drug|carboplatin|AUC 6, IV day 8 cycle 1 - 28 days, day 1 of subsequent cycles q 21 days x 3 cycles
1792937|NCT00533429|Drug|bevacizumab|15 mg/kg, IV, Day 8 of cycle 1 - 28 days, day 1 of subsequent cycles q 21 days x 3 cycles
1792938|NCT00533429|Drug|Placebo|oral, daily
1792939|NCT00533442|Drug|Rapamycin|Rapamycin was initiated on day 1 postoperatively, 4mg/day;levels were maintained 5-8ng/ml. Those patients randomized to receive mycophenolate mofetil were given 1gm twice/day starting on the first post-operative day.
1792940|NCT00533442|Drug|Mycophenolate Mofetil|MMF 1 gm BID beginning 1st day postoperative day
1792941|NCT00533442|Drug|Tacrolimus|Part of standard maintenance.
1792942|NCT00533442|Drug|Steroids|Part of standard maintenance
1792943|NCT00533455|Drug|Gabapentin|
1792944|NCT00533468|Drug|Lidocaine Cream 4%|Topical cream, 2g applied under occlusive dressing for 20 minutes prior to the procedure
1792945|NCT00533481|Drug|MK0557|
1792946|NCT00533494|Behavioral|physician feedback (A)|Feedback information to physicians
1792947|NCT00533507|Biological|Synflorix|Intramuscular injection, 3 doses.
1792948|NCT00533507|Biological|Infanrix hexa|Intramuscular injection, 3 doses.
1792949|NCT00533507|Biological|Rotarix|Oral, 2 doses.
1792950|NCT00533520|Drug|ranibizumab|Arm A: 0.5 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Arm B: 1.0 mg ranibizumab on day 0 with retreatment based on defined criteria not to occur sooner than every 28 days Third Arm 2.0mg Arm with retreatment based on defined criteria not to occur sooner than every 28 days
1792951|NCT00533533|Drug|docetaxel, oxaliplatin|"Oxaliplatin will be administered in combination with docetaxel as a first-line chemotherapy in advanced gastric cancer patients. Each cycle is repeated every 3 weeks.
Docetaxel Oxaliplatin Level 1 60 mg/m2/day 1 100 mg/m2/day 1 Level 2 75 mg/m2/day 1 100 mg/m2/day 1 Level 3 75 mg/m2/day 1 130 mg/m2/day 1"
1792952|NCT00533546|Drug|Activated Protein C|Intravenous APC (10, 15, 22, 33, 50, and 75 mcg/kg) administered to patients with acute ischemic stroke within 0 - 9 hours of symptom onset
1792953|NCT00533559|Drug|sodium phenylbutyrate|buphenyl, 7.5 gm/day for two weeks for two studies, one with saline and one admission with intralipid and heparin
1792954|NCT00533559|Drug|Placebo|Placebo comparator
1792955|NCT00533585|Drug|BAY 43-9006|Starting Dose of 200 mg orally twice a day on Day 3 through Day 19 of Cycle 1 and Days 2 through 19 of Cycle 2 and remaining cycles. Cycle is 21 days.
1792956|NCT00533585|Drug|Paclitaxel|200 mg/m^2 By Vein Over 3 Hours on Day 1.
1792957|NCT00533585|Drug|Carboplatin|Area under curve (AUC) 6 By Vein Over 30 Minutes on Day 1.
1792958|NCT00533585|Drug|Bevacizumab|Starting Dose of 5 mg/kg By Vein Over 90 minutes on Day 1.
1792959|NCT00533598|Drug|MK0557|
1792960|NCT00533611|Drug|MK0524A, /Duration of Treatment : 4 Weeks|
1792961|NCT00533611|Drug|Comparator : niacin /Duration of Treatment : 1 Weeks|
1792962|NCT00533624|Drug|Mycophenolate Sodium Delayed Release Tablets|Myfortic® 1,440 mg/day
1792963|NCT00533624|Drug|Mycophenolate Mofetil|Cellcept® 2,000 mg/day
1792964|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) liposomal formulation|2x110μL in each nostril twice daily for 7 days
1792965|NCT00533637|Drug|Cetirizine dihydrochloride (10 mg/ml) buffer solution|2x110μL in each nostril, as a single dose
1792966|NCT00533637|Drug|Placebo|Citrate buffer with preservatives
1792967|NCT00533650|Drug|MK0429|
1792968|NCT00533663|Procedure|Healing Touch|every other week (during their infusion)
1792969|NCT00533663|Drug|Standard care|
1792975|NCT00533702|Drug|Dacarbazine|1000 milligrams/square meter (mg/m2) intravenously every 3 weeks in the absence of disease progression, unacceptable toxicity, or other withdrawal criteria.
1792976|NCT00533728|Drug|Soluble beta-glucan (SBG)|
1792977|NCT00533741|Drug|Aluminum hydroxide|Adjuvant; administered with SARS-CoV vaccine.
1792978|NCT00533741|Drug|Placebo|Saline for injection.
1792979|NCT00533741|Biological|SARS-CoV|Whole-virus vaccine, grown in certified Vero cells and doubly inactivated by treatment with formalin and ultraviolet light (UV). Supplied in liquid formulation in single dose vials with and without aluminum hydroxide as an adjuvant. Doses supplied without aluminum hydroxide will be 2.5, 5.0 and 10.0 mcg. Doses supplied with aluminum hydroxide adjuvant will be 2.5 and 5.0 mcg.
1792980|NCT00533754|Procedure|drawing blood|
1792983|NCT00533806|Behavioral|Cognitive Behavior Therapy|CBT includes 12 treatment sessions over 14 weeks. The sessions deliver family-based exposure with response prevention. Participants assigned to receive CBT will learn skills to help control OCD. CBT sessions will also include education about OCD, family therapy, parent training to manage child behavior problems, and anxiety management.
1792984|NCT00533806|Behavioral|Relaxation Therapy|Relaxation therapy includes 12 sessions delivered over 14 weeks. Participants assigned to receive relaxation therapy will discuss general family functioning, issues related to OCD, and other behavioral problems the child may be experiencing.
1792985|NCT00533819|Other|6 months of healthy physical activity|half an hour of healthy physical activity including 20 minutes aerobic, 5 minutes warm up and cool down, 4 days a week
1792986|NCT00533832|Device|vagus nerve stimulation (VNS)|"intermittent vagus nerve stimulation
Placebo group were implanted, but did not receive vagus nerve stimulation during the acute phase."
1792988|NCT00533858|Drug|lacidipine (4 mg) or losartan (50 mg)|lacidipine (4 mg) or losartan (50 mg), both given once daily at the same hour in the morning (approximately at 8 AM) for 12 weeks
1792989|NCT00533884|Other|Assessment of therapy complications|Assessment of neurocognitive function, functional status, symptom prevalence and distress, and mood alterations
1792990|NCT00533884|Other|Neurocognitive assessment|Assessment of neurocognitive domains: attention/concentration, executive function, verbal learning, verbal memory, verbal fluency
1792991|NCT00533884|Other|Quality-of-life assessment|Assessment of quality of life using Cantrill's Ladder at baseline and 3 months post-treatment
1792992|NCT00533897|Drug|Abatacept|Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly, (Short Term (3 periods - 12 weeks each; Long Term)
1792993|NCT00533897|Drug|Placebo|Solution in pre-filled syringes, Subcutaneously, 0 mg, Weekly, Period II 12 weeks (Short Term)
1792994|NCT00533910|Drug|Rifaximin|550mg BID rifaximin for 8 weeks
1792995|NCT00533910|Drug|placebo|same as the experimental arm
1792996|NCT00533923|Drug|Cyclophosphamide; Fludarabine; Cyclosporin; CAMPATH-1H (Alemtuzumab); GM-CSF|intravenous
1792997|NCT00533936|Biological|trastuzumab|
1792998|NCT00533936|Drug|cyclophosphamide|
1792999|NCT00533936|Drug|doxorubicin hydrochloride|
1793000|NCT00533936|Drug|fluorouracil|
1793001|NCT00533936|Drug|paclitaxel|
1793002|NCT00533936|Procedure|adjuvant therapy|
1793003|NCT00533936|Procedure|conventional surgery|
1793004|NCT00533936|Procedure|neoadjuvant therapy|
1793005|NCT00533949|Biological|Cetuximab|Loading dose: 400 mg/m2, IV, one week prior to start of radiation therapy (RT). Then, beginning day 1 of RT, 250 mg/m2, IV, weekly; for 60 Gy arm for 15 weeks, for 74 Gy arm for 16 weeks.
1793006|NCT00533949|Drug|Carboplatin|"Concurrent: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy; for 74 Gy arms, on day 43 as well.
Consolidation, 3 weeks after completion of RT, AUC=6, IV, days 1 and 22."
1793007|NCT00533949|Drug|Paclitaxel|"Concurrent: 45 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy (RT); for 74 Gy arms, on day 43 as well.
Consolidation, 3 weeks after completion of RT, 200 mg/m2, IV, days 1 and 22."
1793008|NCT00533949|Radiation|60 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 30 fractions over the course of 6 weeks.
1793009|NCT00533949|Radiation|74 Gy RT|Radiation therapy (RT) in once-daily, 2 Gy fractions, given in 37 fractions over the course of 7.5 weeks.
1793010|NCT00533962|Drug|Anterior Juxtascleral Depot of Anecortave Acetate|
1793011|NCT00533988|Device|Antimicrobial impregnated catheter (5593)|Comparison of 14-day placement of a standard triple lumen (ARROW Standard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US) versus an antimicrobial impregnated catheter (Chlorhexidine-silver sulfadiazine)(ARROWgard Triple Lumen Catheter, Arrow International Inc., Reading, PA, US)
1793012|NCT00534001|Drug|bupropion hydrochloride|Given orally
1793013|NCT00534001|Other|placebo|Given orally
1793014|NCT00534014|Dietary Supplement|Vitamin C|Arm A = 0 mg Vitamin C, Arm B = 250 mg Vitamin C, Arm C = 500 mg Vitamin C, Arm D = 1000 mg Vitamin C
1793015|NCT00534027|Drug|AMG 655|AMG 655 is a monoclonal antibody directed against TR-2.
1793016|NCT00534027|Other|AMG 655 placebo|Inactive dummy AMG 655 (to maintain blind)
1793017|NCT00534053|Other|Mailed Educational Reminder|1 page educational reminder that reminds the patient to return their FOBT cards back to the VA laboratory. In addition, it also contains reasons why colon cancer screening is important.
1793018|NCT00534079|Drug|Dornase alfa (Pulmozyme)|1 x 2,5 ml per day, inhalation use, for 28 days
1793019|NCT00534079|Drug|isotonic saline|1 x 2,5 ml per day, inhalation use, for 28 days
1793020|NCT00534092|Device|X STOP® Interspinous Process Decompression System|The X STOP is a titanium implant that fits between the spinous processes of the lumbar spine. It is made from Ti-6AI-4V Eli titanium alloy (ISO 5832/3) and consists of two components: a spacer assembly and a wing assembly.
1793021|NCT00534105|Other|Total Cholesterol|
1793022|NCT00534105|Other|Triglyceride|
1793023|NCT00534105|Other|HDL|
1793024|NCT00534105|Other|LDL|
1793025|NCT00534118|Biological|donor lymphocytes|Given IV
1793027|NCT00534131|Procedure|APPEAR Procedure|Perineal incision to reach the distal rectum
1793028|NCT00534131|Procedure|Proctectomy|standard rectal excision which does not preserve the anal canal
1793029|NCT00534144|Drug|iron sucrose injection, USP|iron sucrose injection, USP, 100 mg intravenously (IV) per week, for 5 weeks
1793030|NCT00534144|Drug|sodium ferric gluconate complex in sucrose injection|sodium ferric gluconate complex in sucrose injection, 100 mg intravenously (IV) per week, for 5 weeks
1793031|NCT00534170|Dietary Supplement|Probiotic (Yakult)|It is a dietary supplement ,65 ml containing 15 billion lactobacillus
1793032|NCT00534183|Drug|Olanzapine|Olanzapine in dose range of 10-20mg
1793033|NCT00534183|Drug|Risperidone|Risperidone 1-6mg
1793034|NCT00534183|Drug|Haloperidol|Haloperidol 10-20mg
1793035|NCT00534196|Radiation|Permanent iodine-125 (Brachytherapy)|Observational research was conducted by grouping Brachytherapy with/without PI (permanent iodine) seed implantation.
1793038|NCT00534235|Procedure|Decompression|Either microsurgical decompression or laminotomy to remove bone impinging on nerves causes the patient pain
1793039|NCT00534235|Device|Posterolateral Fusion and Implantation of Pedicle Screws|
1793040|NCT00534235|Device|Implantation of coflex Interlaminar Technology|
1793041|NCT00534248|Biological|Zoster Vaccine, Live (Zostavax™)|A single dose 0.65 ml Zostavax™ (Live, attenuated Zoster Vaccine) was administered by subcutaneous injection on Day 1.
1793042|NCT00534248|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo (A vaccine stabilizer of Zostavax™ with no live virus) was administered by subcutaneous injection on Day 1.
1793043|NCT00534261|Drug|Interferon beta-1a|IM injection
1793044|NCT00534274|Other|3'-deoxy-3'-[18F]fluorothymidine|
1793045|NCT00534287|Drug|meropenem|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem. Dosage is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
1793046|NCT00534287|Drug|meropenem, moxifloxacin|Empirical antibiotic therapy with 3 x 1 g intravenous meropenem plus 1 x 400 mg intravenous moxifloxacin. Dosage of meropenem is adjusted in case of renal dysfunction. Recommended duration of therapy is 7 days but can be extended up to 14 days.
1793047|NCT00534300|Drug|Omegaven|Lipid emulsion (omegaven) for intravenous use, 100 ml (25 mL/h)
1793048|NCT00534300|Drug|Isotonic saline|Intravenous infusion, 100 mL, 25mL/h
1793049|NCT00534313|Drug|Abatacept|Solution, intravenous, monthly, short-term = 24 weeks (6 months)
1793050|NCT00534313|Drug|Placebo|Solution, intravenous, placebo (double dummy), monthly, short-term = 24 weeks (6 months)
1793051|NCT00534326|Procedure|Standard Reaming|Femoral reaming using standard reaming techniques of multiple reamers
1793052|NCT00534326|Procedure|Reaming/Irrigating/Aspirating|Reaming using the Reamer/Irrigator/Aspirating
1793053|NCT00534339|Device|Easyband (Telemetrically adjustable gastric banding device)|EasyBand
1793054|NCT00534352|Drug|TMC125; darunavir; ritonavir|TMC125 400mg once daily for 4 weeks; Darunavir-800mg once daily for 48 weeks; Ritonavir-100mg once daily for 48 weeks
1793055|NCT00534365|Device|tension-free vaginal tape|Retropubic mid-urethral sling
1793056|NCT00534365|Device|TVT-SECUR device|Mid-urethral mini-sling
1793057|NCT00534378|Drug|Midazolam|The study drug was administered IM into the anterior thigh using the preloaded autoinjector. The autoinjectors were preloaded with midazolam 5 mg or 10 mg with a total volume of 1 or 2 mL. Healthy subjects were assigned to one of six target dosage groups (0.10, 0.18, 0.25, 0.33, 0.40, 0.49 mg/kg) and, based on their weight, received the necessary combination of fixed 5 or 10 mg doses to provide the assigned target dose.
1793058|NCT00534391|Drug|neomycin sulfate, polymyxin B sulfate and gramicidin|to the effected eye 4 times a day
1793059|NCT00534391|Drug|Artificial tear|4 times daily
1793060|NCT00534404|Drug|Nicotine patches|Participants will wear nicotine patches.
1793061|NCT00534404|Behavioral|Telephone counseling|Participants receiving telephone counseling will receive five phone calls over a 2-month period to discuss their personal smoking cessation plan.
1793062|NCT00534404|Behavioral|iQuit Smoking website|Participants will access the Project Quit (iQuit Smoking) website.
1793063|NCT00534417|Drug|capecitabine|Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po in the morning (AM) and 500 mg po in the evening (PM) in patients of body weight < 80 Kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of ≥80 Kg.
1793064|NCT00534417|Drug|fulvestrant|Fulvestrant will be given at 500mg on Day 1 followed by 250 mg on Days 15 and 29, then 250mg every 28 days(Q28d).
1793065|NCT00534430|Drug|busulfan|
1793066|NCT00534430|Drug|cyclosporine|
1793067|NCT00534430|Drug|etoposide|
1793068|NCT00534430|Drug|mycophenolate mofetil|
1793069|NCT00534430|Procedure|allogeneic bone marrow transplantation|
1793070|NCT00534430|Procedure|allogeneic hematopoietic stem cell transplantation|
1793071|NCT00534430|Procedure|peripheral blood stem cell transplantation|
1793072|NCT00534430|Radiation|total-body irradiation|
1793073|NCT00534443|Procedure|Endoscopy of upper GI tract|"Upper GI endoscopy, one time on diagnosis and a second time 15 days after the end of the treatment. Gastric juice will be aspirated immediately after the entrance of the endoscope into the gastric lumen. Four biopsy specimens will be obtained from adjacent areas of the gastric antrum. Each biopsy will be used for in vitro culture. Blood will be sampled from one antecubital vein under aseptic conditions.
Each patient will be given antisecretory treatment and - if necessary- eradication treatment of H. pylori according to international guidelines."
1793074|NCT00534456|Drug|Placebo|Placebo group to receive volume and dose frequency changes resembling titration dosing in the treatment group.
1793075|NCT00534456|Drug|Darbepoetin alfa|Starting dose: 0.75 mcg/kg subcutaneously Q2W. Subsequent doses: Darbepoetin alfa group to receive darbepoetin alfa titrated to achieve Hb target of 13.0 g/dL, not to exceed 14.5 g/dL.
1793076|NCT00534469|Biological|aldesleukin|
1793077|NCT00534469|Biological|filgrastim|
1793078|NCT00534469|Drug|busulfan|
1793079|NCT00534469|Drug|cytarabine|
1793080|NCT00534469|Drug|etoposide|
1793081|NCT00534469|Drug|idarubicin|
1793082|NCT00534469|Procedure|autologous hematopoietic stem cell transplantation|
1793083|NCT00534469|Procedure|bone marrow transplantation|
1793084|NCT00534469|Procedure|peripheral blood stem cell transplantation|
1793085|NCT00534469|Radiation|total-body irradiation|
1793086|NCT00534482|Behavioral|Enhanced Office|Clinicians and office staff personally engage in AIM-HI fitness program, and promote program to patients
1793087|NCT00534482|Behavioral|Conventional Office|Conventional office: Clinicians and office staff are not personally engaged in the AIM-HI fitness program, but promote program to patients.
1793088|NCT00534482|Behavioral|AIM-HI program with enhanced feedback|Patient receives feedback on two novel indicators of their individual cardiovascular risk that: 1)appear to relate to obesity and lack of physical activity, and 2) may show relatively rapid change with improvements in these areas. These are the Homeostatic Assay - Insulin Resistance or HOMA-IR and Nuclear Molecular Resonance (NMR) lipoprotein profiles (NMRLP). These patients and their physicians also will receive periodic feedback on other outcome measures, including BMI, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
1793089|NCT00534482|Behavioral|AIM-HI program and regular feedback|Patients will not receive feedback on two specific cardiovascular risk indicators (ie, Homeostatic Assay - Insulin Resistance, Nuclear Molecular Resonance lipoprotein profiles). However, patients will receive feedback on Body Mass Index, blood pressure, a 3-minute step test, eating assessment, physical activity assessment, and emotional well-being assessment.
1793090|NCT00534495|Biological|Rilonacept|2.2 mg/kg subcutaneously
1793091|NCT00528372|Drug|Dapagliflozin|Tablets; oral; 2.5, 5.0, or 10 mg; once daily in the morning or evening for up to 102 weeks
1793092|NCT00528372|Drug|Dapagliflozin placebo|Tablets, oral, 0 mg, once daily in the morning or evening for up to 102 weeks
1793093|NCT00528372|Drug|Metformin|
1793094|NCT00528385|Drug|Spironolactone (Spironol) 25 mg|In the 8-weeks run-in period ACEI, cilazapril (5 mg), telmisartan (80 mg) and hydrochlorotiazyd (12.5 mg) were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 25 mg of spironolactone in two active treatment periods lasting 8 weeks each.
1793095|NCT00528398|Drug|cytarabine|
1793096|NCT00528398|Drug|idarubicin|
1793097|NCT00528411|Drug|Ticagrelor Tablets|Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily (BD)
1793098|NCT00528411|Drug|Clopidogrel (over encapsulated) capsule|Oral 75 mg; 600 mg loading dose followed by 75 mg once daily (ODD)
1793099|NCT00528411|Drug|Aspirin Tablets|Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study.
1793100|NCT00528424|Biological|AA4500|Subjects may have received up to five injections of AA4500 0.58 mg into the cords of the affected hand, with each injection separated by at least 30 days. Individual cords may have received up to a maximum of three AA4500 injections.
1793102|NCT00528450|Drug|arsenic trioxide|
1793103|NCT00528450|Drug|idarubicin|
1793104|NCT00528450|Drug|tretinoin|
1793105|NCT00528463|Procedure|sciatic nerve block|Sciatic nerve block, Labatt approach, with a stimuplex needle and catheter. Once localized, a bolus of 20 mL ropivacaine 1,0% is given through the catheter and is followed by a perfusion of ropivacaine 0,2% 6-10 mL/hre for at least 24 hours pre-op and 48 hours post-op
1793106|NCT00528489|Biological|PennVax B|DNA vaccine containing the HIV genes Gag, Pol, and Env
1793107|NCT00528489|Biological|IL-12|Cytokine injection
1793108|NCT00528489|Biological|IL-15|Cytokine injection
1793109|NCT00528502|Drug|Lidocaine|Lidocaine is misted into the air that you breathe during the surgery.
1793110|NCT00528502|Drug|Saline|Saline is misted into the air that you breathe during the surgery.
1793111|NCT00528515|Drug|Diprivan (propofol), Astra-Zeneca|continuous intravenous infusion with a dose of 3-5 mg/kg/h
1793112|NCT00528515|Drug|Suprane (desflurane), Baxter|a vapor concentration of 3-7 vol% is maintained with use of vaporizer and under control of arterial blood pressure, heart rate, and BIS index.
1793113|NCT00528528|Drug|Telaprevir|Oval tablets containing 375 mg of telaprevir for oral administration.
1793114|NCT00528528|Drug|Peg-IFN-alfa-2a|Solution containing Peg-IFN alfa2a for subcutaneous injection in a pre-filled syringe.
1793115|NCT00528528|Drug|Peg-IFN-alfa-2b|Powder containing Peg-IFN-alfa-2b and solvent for solution for subcutaneous injection in a pre-filled pen.
1793116|NCT00528528|Drug|Ribavirin (RBV) tablet|Tablets containing 200 mg RBV for oral administration.
1793117|NCT00528528|Drug|Ribavirin (RBV) capsule|Capsules containing 200 mg RBV for oral administration.
1793118|NCT00528541|Biological|botulinum toxin type A|200 Units at Visit 1 (Day 1)
1793119|NCT00528541|Biological|botulinum toxin type A|750 Units at Visit 1 (Day 1)
1793120|NCT00528554|Procedure|laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, energy dosage 1J/point, average of 8 points to be treated, once daily during chemotherapy course
1793121|NCT00528554|Procedure|placebo laser acupuncture|laser acupuncture according to traditional chinese medicine criteria, average of 8 points to be treated, once daily during chemotherapy course
1793122|NCT00528567|Drug|Bevacizumab|Bevacizumab was administered at a dose equivalent of 5 mg/kg/week using 1 of 3 different scheduling options depending on the schedule of the adjuvant chemotherapy regimen selected for an individual patient.
1793123|NCT00528567|Drug|Standard adjuvant chemotherapy|All chemotherapy schedules and doses for each patient were prescribed according to the labeled indication of the country in which the patient was receiving therapy.
1793124|NCT00528580|Drug|Simvastatin|80 mg once daily PO/NG x 4 days
1793125|NCT00528580|Drug|Identical-appearing placebo|once daily x 4 days
1793126|NCT00528593|Drug|epoetin alfa|Group 1 will receive Procrit once every three weeks, and group 2 will receive Procrit every week.
1793127|NCT00528606|Biological|collagenase clostridium histolyticum|Subjects could have received up to three injections of AA4500 into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
1793128|NCT00528606|Biological|Placebo|Subjects could have received up to three injections of placebo into the cord of the affected hand. Each injection was separated by at least 30 days. Individual cords may have received up to a maximum of three injections.
1793129|NCT00528619|Drug|Sunitinib, Pemetrexed, Cisplatin, Carboplatin|Dose finding study using Sunitinib daily by oral capsule in a continuous regimen or administered for 2 weeks out of every 3 weeks, with pemetrexed every 3 weeks or also with cisplatin 75 mg/m2 or carboplatin AUC=5 mg*min/mL until progression or unacceptable toxicity.
1793130|NCT00528632|Other|Specimen biopsy and serum laboratory tests|"Biopsy of the surgical specimens (gallbladder) submitted after cholecystectomy
Laboratory tests measuring levels of plasma total cholesterol and triglycerides"
1793131|NCT00528645|Drug|saracatinib|Given orally
1793132|NCT00528658|Drug|Paracetamol|1g qid
1793133|NCT00528658|Drug|Ibuprofen|400mg tid
1793134|NCT00528658|Drug|Paracetamol Placebo|equivalent to 1g qid
1793135|NCT00528658|Drug|Ibuprofen placebo|Equivalent to 400mg tid
1793136|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.8 - 2.8 for aortic valve recipients and 2.5 - 3.5 for mitral or double valve recipients, INR-self management once a week
1793137|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management once a week
1793138|NCT00528671|Drug|phenprocoumon|The daily phenprocoumon dose administered should achieve an international normalized ratio (INR) of 1.6-2.1 for aortic valve recipients and 2.0 - 2.5 for mitral or double valve recipients, INR self management twice a week
1793139|NCT00528684|Biological|REOLYSIN®|REOLYSIN® is administered as a single intratumoral infusion over 72 hours. Dose levels in Phase 1 will be 1x10E8, 3x10E8, 1x10E9, 3x10E9, 1x10E10 TCID50. The dose level for Phase 2 will be the top dose reached in Phase 1.
1793140|NCT00528697|Drug|ABT-089|Subjects will take 0.5 and 1 and/or 5 and/or 10 mg ABT-089 tablets (actual dose based on weight) once daily for 8 weeks.
1793141|NCT00528697|Drug|atomoxetine|Subjects will take 10, and/or 18 and/or 25 mg atomoxetine tablets once daily for 8 weeks.
1793142|NCT00528697|Drug|placebo|Subject will take a tablet once daily for 8 weeks
1793143|NCT00528710|Dietary Supplement|SAM-e (S-Adenosyl-L-Methionine)|One 400 mg tablet daily in the morning.
1793144|NCT00528723|Drug|salbutamol 100 mcg|To be used as needed for symptom relief
1793145|NCT00528723|Drug|BDP/salbutamol HFA pMDI|Patients assigned to BDP/salbutamol HFA pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative CFC placebo
1793146|NCT00528723|Drug|BDP/salbutamol CFC pMDI|Patients assigned to BDP/salbutamol CFC pMDI will receive 2 puffs twice daily (morning and evening), for a total daily dose of BDP 1000 mcg/salbutamol 400 mcg, plus 2 puffs twice daily of alternative HFA placebo
1793147|NCT00528749|Other|Patient will wear ARES device while undergoing sleep study|Device is worn on forehead
1793148|NCT00528762|Behavioral|Focus Group|Focus group discussion about puberty and body image lasting 1 1/2 hours.
1793149|NCT00528775|Drug|HPPH|4 mg/m2 IV
1793150|NCT00528775|Procedure|endoscopic procedure|Treatment with 150 joules from laser
1793151|NCT00528788|Drug|doxercalciferol|
1793152|NCT00528801|Behavioral|NP Battery|Neuropsych Battery with 7 different tests that evaluate the patients neurological functioning.
1793153|NCT00528801|Procedure|MRI|The MRI is a standard procedure involving 30 minutes under the machine in order to obtain various images of the patients brain.
1793154|NCT00528814|Other|Active Hand Sanitizer|Active Hand Sanitizer
1793155|NCT00528827|Drug|Cardene® I.V.|"5 mcg/kg/min Cardene I.V.
2.5 mcg/kg/min Cardene I.V.
0.5 mcg/kg/min Cardene I.V."
1793156|NCT00528840|Biological|collagenase clostridium histolyticum|Up to five injections of AA4500 into cord(s) of the affected hand(s). Each injection was separated by at least 30 days.
1793157|NCT00528866|Drug|bicalutamide|50 mg (one tablet) daily orally for 6 months, starting within 6 months after registration
1793158|NCT00528866|Drug|docetaxel|75 mg/m2 IV over 1 hour on day 1 of each cycle q21 days for 6 cycles, starting 3-6 weeks after completion of radiation therapy
1793159|NCT00528866|Drug|flutamide|250 mg (two 125-mg capsules) three times daily (total 750 mg) orally for 6 months, starting within 6 months after registration
1793160|NCT00528866|Drug|LHRH agonist|LHRH agonist (such as leuprolide, goserelin, buserelin, or triptorelin) for 6 months, starting within 6 weeks after registration
1793161|NCT00528866|Radiation|3-dimensional conformal radiation therapy|
1793162|NCT00528866|Radiation|radiation therapy|66.6 Gy (1.8 Gy per fraction, 5 days per week) to the prostate bed (IMRT or 3DCRT), starting 8 weeks after start of hormones
1793163|NCT00528879|Drug|Dapagliflozin|Tablets administered orally as a 2.5-, 5-, or 10-mg dose once daily for up to 102 weeks
1793164|NCT00528879|Drug|Placebo|Dapagliflozin-matching placebo administered as tablets orally once daily for up to 102 weeks
1793165|NCT00528879|Drug|Metformin|Open-label metformin administered as ≥1500 mg per day for up to 102 weeks
1793169|NCT00528918|Drug|Glulisine (Apidra)|An algorithm to determine the initial doses of insulin and dose adjustments is as follows: Lean subjects (BMI less than 25 kg/m2) will initially receive a total of 0.4 units/kg/day, overweight subjects (BMI 25-30 kg/m2) 0.5 units/kg/day and obese subjects (BMI greater than 30 kg/m2) 0.6 units/kg/day. Fifty percent of the total amount of insulin will be given as Glargine and 50% as regular insulin or Apidra. Supplemental short-acting insulin will be given for hyperglycemia before meals. Automated order sets shall be generated to minimize errors in order entries. Glucose concentrations will be measured before each meal and at bedtime, and if symptomatic. In addition, eight-point blood glucose profiles will be obtained every three days starting on day 2. Dose adjustments will be made to keep blood glucose concentrations between 80 and 120 mg/dl pre-prandially and less than180 mg/dl after meals.
1793170|NCT00534508|Drug|Tacrolimus Ointment 0.1%|Twice daily, 14 days treatment
1793268|NCT00536601|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|Undergo tandem ASCT
1793171|NCT00534521|Device|Posterior Tibial Nerve Device|The PTNS device (Urgent® PC) is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve (PTNS). It is a combination of a stimulator and a lead set. The stimulator is a battery powered, external pulse generator and is designed, constructed, and manufactured for multiple use in conjunction with the lead set. The lead set (comprised of the lead wires, needle electrode, and alcohol pad) transfers the electrical current from the stimulator to the tibial nerve via the needle electrode. The tibial nerve travels up the leg to the sacral nerve plexus which regulates the bladder and pelvic floor function.
1793172|NCT00534521|Device|Sham|This 2- piece needle, comprised of a needle handle and blunt-tip shaft feels like a slight prick when touched to the skin. However the shaft retracts as it appears to enter the skin but the skin is not punctured. The Streitberger needle specifically activates the dorsolateral prefrontal cortex, which is associated with the placebo effect.
1793174|NCT00534547|Procedure|Duodenal Exclusion|duodenal-jejunal bypass
1793175|NCT00534560|Drug|Tonabersat|Tablets, 4 week dose titration and 16 weeks treatment at target dose of 40 mg per day
1793176|NCT00534560|Drug|Tonabersat|Tablets: 4 week titration and 16 weeks at target dose of 80 mg per day
1793177|NCT00534560|Drug|Placebo|Tablets; 4 week dose titration with 16 weeks at target dose
1793178|NCT00534573|Drug|Amisulpride, Moclobemide|Amisulpride 400 mg/d; Moclobemide 300 mg/d every medication for 2 week aith 2 week washout
1793179|NCT00534586|Drug|Propofol|TCI 0.5 mcg/ml 1.0 mcg/ml
1793180|NCT00534586|Drug|Remifentanil|continuous infusion 0.05 mcg/kg/min 0.15 mcg/kg/min
1793181|NCT00534586|Drug|S-Ketamine|continuous infusion 0.25 mg/kg/h 0.50 mg/kg/h
1793182|NCT00534586|Drug|Sevoflurane|via face mask 0.40 Vol% 0.80 Vol%
1793183|NCT00534599|Drug|Placebo|oral
1793184|NCT00534599|Drug|quetiapine fumarate XR|oral
1793185|NCT00534612|Procedure|aspiration biopsy|fine needle aspiration biopsy of the parotid gland masses
1793186|NCT00534625|Drug|zileuton|Single injection of zileuton 150 mg
1793187|NCT00534625|Drug|placebo|Single injection of placebo
1793188|NCT00534625|Drug|zileuton|Single injection of zileuton 300 mg
1793189|NCT00534638|Biological|GSK Biologicals' HPV Vaccine GSK580299|Intramuscular injection, 3 doses
1793190|NCT00534638|Biological|Engerix-B™|Intramuscular injection, 3 doses
1793191|NCT00534651|Drug|Paracetamol|Paracetamol 3x1000mg daily or Placebo for two weeks in a crossover design with a two-week washout-phase in between.
1793192|NCT00534664|Device|TheraBionic device|Daily outpatient treatment with theraBionic device
1793193|NCT00534677|Drug|Terlipressin|2 mg stat & then 1 mg q6h iv and Placebo of Octreotide
1793194|NCT00534677|Drug|Octreotide|Octreotide 50mcg/hr infusion & a placebo of Terlipressin
1793195|NCT00534690|Procedure|One-Lung ventilation|Low Vt, High PEP
1793196|NCT00534690|Procedure|One-Llung ventilation|High Vt, low PEP
1793197|NCT00534703|Genetic|AAV1/SERCA2a|AAV1/SERCA2a will be delivered by a percutaneous method in the catheter laboratory. Dose: 1x 10^13 DRP (DNase resistant particles)
1793198|NCT00534703|Drug|Placebo|Placebo aliquots will be of the same composition as the investigational medicinal product with the absence of the active ingredient and will be visually indistinguishable from the medicinal product. Placebo is prepared and handled exactly as above in a blinded fashion.
1793199|NCT00534729|Drug|Weekly Carboplatin & Taxol w/concurrent RT|Chemotherapy
1793200|NCT00534755|Other|Breast Cancer database|prospective breast cancer database
1793201|NCT00534768|Procedure|active debridement|debridement on 1st, 3-5th and 7th postoperative days
1793202|NCT00534768|Procedure|control group|Postoperative debridement on 7th postoperative day
1793203|NCT00534781|Device|plasma microdebrider|Coblation of the Achilles
1793204|NCT00534781|Procedure|Mechanical Surgical Debridement|Surgical Debridement of the Achilles
1793205|NCT00534794|Drug|Elestat|Elestat BID for 2 days
1793206|NCT00534794|Drug|Pataday|Pataday QD for 2 days
1793207|NCT00534807|Drug|Vinflunine|
1793208|NCT00534807|Drug|Rifampin|
1793209|NCT00534820|Procedure|Cytogenetic Analysis of Bone Marrow Specimen|Cytogenetic Analysis of BM Specimen
1793210|NCT00534833|Biological|DTaP-HB-PRP~T vaccine|0.5 mL, Intramuscular
1793211|NCT00534833|Biological|Tritanrix-HepB/Hib™|0.5 mL, Intramuscular
1793212|NCT00534833|Biological|Oral Polio Vaccine|0.5 mL, Oral
1793213|NCT00536211|Behavioral|Exercise|Exercise training will consist of walking and/or jogging on a treadmill 5 out of 7 d each week at ~60% of each subject's predetermined VO2max (75% maximal heart rate as monitored by heart rate monitors), 45 min/session, for 12 weeks. The exercise training will follow a three-stage progression: 1. wk 1 = 30 min, 3 d/wk, 60% VO2max; 2. wk 2 = 30 min, 5 d/wk, 60% VO2max; and 3. wk 3-12 = 45 min, 5 d/wk, 60% VO2max.
1793214|NCT00536211|Drug|Metformin|oral tablet, 1000 mg daily for 17 days
1793215|NCT00536224|Behavioral|Full counseling|"The health educator generated a computerized report for the patient that outlined his/her Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal. Based on the Ask-Advise-Assess-Assist-Arrange follow-up (5A's) framework for behavior change, counseling for specific risk-related behaviors (diet, physical activity, and smoking) was provided by a cardiovascular rehabilitation health educator in the emergency department and during telephone follow-up (2 sessions over 6 weeks). Patients also received a general informational handout on self-management of cardiovascular risk factors (AHA Brochure Controlling your risk factors). A full report was also be sent to the patient's primary care physician (if any) at the conclusion of counseling."
1793269|NCT00536614|Genetic|cetuximab|Cetuximab is an EGFR antibody inhibitor; it has been shown to increase the activity of gemcitabine (GEM) in advanced pancreatic cancer.
1793503|NCT00537966|Drug|Emtricitabine|standard dosage
1793216|NCT00536224|Behavioral|Minimal counseling|"Patients assigned to the minimal counseling intervention received brief counseling (<5 minutes) on the benefits of changing lifestyle and a handout with general information on self-management of cardiovascular risk factors.
Patients assigned to minimal intervention also received an AHA brochure (Controlling your risk factors) with general information on management of cardiovascular risk factors. At the end of 6-month follow-up, patients received a computerized report that outlined their Framingham risk score, the goal for each cardiovascular risk factor based on national guidelines, and recommended actions for achieving each goal."
1793217|NCT00536237|Drug|Comparator: niacin / Duration of Treatment: 17 Weeks|
1793218|NCT00536237|Drug|MK0524A, niacin (+) laropiprant / Duration of Treatment: 17 Weeks|
1793219|NCT00536237|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 17 Weeks|
1793220|NCT00536263|Drug|pegylated interferon alpha-2b|1.0 mcg/kg subcutaneously (S.C.) QW for 24 weeks
1793221|NCT00536263|Drug|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 24 weeks
1793222|NCT00536263|Drug|pegylated interferon alpha-2b|1.5 mcg/kg S.C. QW for 48 weeks
1793223|NCT00536276|Dietary Supplement|Vitamin D2|Daily enteral dose of 100IU/kg
1793224|NCT00536276|Dietary Supplement|Vitamin D3|Daily enteral dose of 100IU/kg
1793225|NCT00536289|Device|Blunt needle|Blunt tipped suture needle
1793226|NCT00536302|Dietary Supplement|Collagen Hydrolysate|Collagen Hydrolysate solution 10 grams per day by mouth for 48 weeks
1793227|NCT00536302|Dietary Supplement|Placebo|Matching placebo solution per day by mouth for 48 weeks.
1793228|NCT00536341|Drug|lenalidomide|2.5 mg orally (PO) daily, Days 8-28, Cycle 1; 5.0 mg PO daily, Days 8-28 Cycles 2-6
1793229|NCT00536341|Drug|Rituximab|375 mg/m2 Cycle 1 (split over Day 1 & Day 2); 500 mg/m2 Day 1 of Cycles 2-6
1793230|NCT00536341|Drug|Fludarabine|25 mg/m2 on Days 1, 2, and 3
1793231|NCT00536354|Other|Postural Orientation|
1793232|NCT00536367|Other|No intervention - observational study only|
1793233|NCT00536380|Drug|5-mg Desloratadine|5-mg desloratadine tablets, once daily for four weeks.
1793234|NCT00536380|Drug|10-mg Desloratadine|10-mg desloratadine tablets, once daily for four weeks.
1793235|NCT00536380|Drug|20-mg Desloratadine|20-mg desloratadine tablets, once daily for four weeks.
1793236|NCT00536393|Drug|Doxorubicin|
1793237|NCT00536393|Drug|Doxorubicin pegylated|
1793238|NCT00536406|Behavioral|BE-ACTIV|BE-ACTIV is 10-week behavioral treatment involving increasing pleasant events.
1793239|NCT00536406|Behavioral|Treatment as usual (TAU)|TAU includes usual treatment in nursing care facility.
1793240|NCT00536419|Drug|Methylphenidate|Methylphenidate SODAS 0.3 mg/kg/day (day 1); 0.7 mg/kg/day (day 2); 1.0 mg/kg/day (days 3 and 4)
1793241|NCT00536419|Other|Placebo|Placebo, daily dose, 4 days, oral administration
1793242|NCT00536445|Device|NAVA|Neurally Adjusted Ventilatory Assist (mechanical ventilation controlled by the diaphragm electrical activity)
1793243|NCT00536458|Procedure|radiotherapy|mini chep+ radiotherapy
1793244|NCT00536458|Drug|MINI CHEP|chemotherapy minichep 6 courses
1793245|NCT00536471|Drug|Duloxetine hydrochloride|
1793246|NCT00536471|Drug|Placebo|
1793247|NCT00536484|Drug|Fesoterodine|4mg tablets once daily for 2 weeks, then either 4mg or 8mg tablets once daily for 10 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
1793248|NCT00536484|Drug|Placebo|Matched placebo tablets once daily for 12 weeks. Subjects were instructed to take 1 tablet every evening within 4 hours prior to bedtime with water, swallowed whole without chewing.
1793249|NCT00536497|Drug|GW842166X|
1793250|NCT00536510|Drug|laropiprant/niacin (MK0524A)|"Treatment Period 1: one 20mg/1g tablet laropiprant/niacin once daily for 4 weeks
Treatment Period 2: two 20mg/1g tablets laropiprant/niacin once daily for 8 weeks.
All patients will receive placebo for a 4 week run-in period before randomization"
1793251|NCT00536510|Drug|Comparator: placebo|"Treatment Period 1: one 20mg/1g tablet placebo to laropiprant/niacin once daily for 4 weeks
Treatment Period 2: two 20mg/1g tablets of placebo to laropiprant/niacin once daily for 8 weeks.
All patients will receive placebo for a 4 week run-in period before randomization."
1793252|NCT00536536|Behavioral|Obesity management framework|Treatment in primary care will be compared to treatment in a secondary hospital setting. Treatment in both cases will be provided by a multi-disciplinary team of: obesity or practice nurse, dietitian, exercise specialist with some input from medical team.
1793253|NCT00536549|Device|Guardian RT|
1793254|NCT00536549|Behavioral|Education about the self monitoring blood glucose|
1793255|NCT00536562|Behavioral|Comprehensive Cardiac Rehabilitation (CR)|6-month Comprehensive Cardiac Rehabilitation program consisting of: 1) initial medical assessment by case manager and physician to determine CR strategies; 2) entry exercise stress test; 3) multi-disciplinary assessment and intervention to achieve risk factor targets in nutrition & psychological services as needed; 4) twice per week supervised exercise training and twice per week home-based exercise following an individualized, progressive prescription; 5) Exit assessment at 6 months.
1793256|NCT00536575|Drug|Bortezomib|"Dose Level 1: Bortezomib 1.3mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.
Dose Level 2: Bortezomib 1.6 mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle.
Dose Level 3: Bortezomib 1.6mg/m2 IV bolus on days 1, 8, 15, and 22 of each 5-week cycle."
1793257|NCT00536575|Drug|Sorafenib|"Dose Levels 1 and 2: 200 mg by mouth twice daily
Dose Level 3: 400 mg by mouth twice daily"
1793258|NCT00536588|Genetic|SCH 721015 with SCH 209702|Each subject receives a single intravesical administration of SCH 721015 with SCH 209702 at dose levels of 1 x 10^9 to 3 x 10^11 particles/mL (based on assessment of tolerability, intermediate dose levels may be used).
1793259|NCT00536601|Drug|etoposide|Given IV
1793260|NCT00536601|Drug|cyclophosphamide|Given IV
1793261|NCT00536601|Drug|carmustine|Given IV
1793262|NCT00536601|Drug|melphalan|Given IV
1793263|NCT00536601|Drug|busulfan|Given IV
1793264|NCT00536601|Drug|carboplatin|Given IV
1793265|NCT00536601|Drug|thiotepa|Given IV
1793266|NCT00536601|Radiation|total-body irradiation|Undergo TBI
1793267|NCT00536601|Procedure|autologous hematopoietic stem cell transplantation|Undergo ASCT
1793435|NCT00537511|Drug|Etoposide|
1793270|NCT00536627|Biological|DNA vaccine pCMVS2.S|Patients will receive injections of 1 ml of vaccine (1 mg/ml) at weeks 0, 8, 16, 40 and 44
1793271|NCT00536640|Drug|Erlotinib|150 mg per os, given daily until tumor progression
1793272|NCT00536640|Drug|Bevacizumab|15mg/kg i.v. on day 1 (three-week cycle) until tumor progression
1793273|NCT00536640|Drug|Gemcitabine|1250 mg/2 i.v. on day 1 and day 8 (three-week cycle) until tumor progression for a maximum of 6 cycles
1793274|NCT00536640|Drug|Cisplatin|80 mg/m2 i.v. on day 1 (three-week cycle) until tumor progression for a maximum of 6 cycles. (The administration of 40 mg/2 Cisplatin on day 1 and day 8 is also possible)
1793275|NCT00536653|Drug|Bicalutamide and Calcium/ Vitamin D supplementation|Bicalutamide 150mg once daily, Calcium and Vitamin D supplementation once daily
1793276|NCT00536653|Drug|LHRH agonists (Goserelin acetate) and Calcium/ Vitamin D supplementation|3 monthly depot injection of LHRH agonist (Goserelin acetate 10.8mg) and Calcium/ Vitamin D supplementation daily
1793277|NCT00536653|Drug|LHRH agonists (Goserelin acetate)|3 monthly depot injection of LHRH agonists (Goserelin acetate 10.8mg)
1793278|NCT00536666|Drug|Iron oligosaccharide|
1793279|NCT00536679|Drug|GSK163090 capsule, fasted|GSK163090 will be available as 1 mg hard gelatine white/white opaque capsules. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 milliliters (mL) of water.
1793280|NCT00536679|Drug|GSK163090 Tablet, fasted|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with approximately 240 mL of water.
1793281|NCT00536679|Drug|GSK163090 Tablet, fed|GSK163090 will be available as 1 mg white coated round tablet. Each subject will receive a single, oral dose of the study medication on the morning of Day 1. The study drug will be administered with Food and Drug Administration (FDA) high fat breakfast.
1793283|NCT00536705|Drug|montelukast|montelukast 5-mg chewable tablet with matching placebo once daily in the evening at bedtime.The study consisted of a 2-week, single-blind placebo baseline period and a 12-week double-blind, active treatment period
1793284|NCT00536718|Genetic|gene expression analysis|
1793285|NCT00536718|Genetic|molecular diagnostic method|
1793286|NCT00536718|Genetic|polymorphism analysis|
1793287|NCT00536718|Genetic|protein expression analysis|
1793288|NCT00536718|Other|medical chart review|
1793289|NCT00536718|Other|questionnaire administration|
1793290|NCT00536731|Drug|Symbicort Turbuhaler|Symbicort Turbuhaler® 80/4.5 μg 1 Inhalation Twice Daily
1793291|NCT00536731|Drug|Symbicort pMDI|Symbicort®pMDI® 40/2.25 μg 2 Actuations Twice Daily
1793292|NCT00536731|Drug|Pulmicort Turbuhaler|Pulmicort®Turbuhaler® 100 μg 1 Inhalation Twice Daily
1793293|NCT00536744|Device|acoustical pulse energy (extracorporeal shockwave)|Acoustical pulse energy (extracorporeal shockwave) + Standard of care wound dressing.
1793294|NCT00536744|Other|Sham|Non-energized (inactive - Sham) application + standard of care
1793295|NCT00536770|Drug|placebo + gemcitabine + erlotinib|
1793296|NCT00536770|Drug|Placebo + gemcitabine|
1793297|NCT00536770|Drug|calcitriol + gemcitabine|
1793298|NCT00536770|Drug|calcitriol + gemcitabine + erlotinib|
1793299|NCT00536783|Drug|Quetiapine|
1793300|NCT00536809|Drug|lapatinib|onced daily Days 1-21
1793301|NCT00536809|Drug|oxaliplatin|Day one of each cycle
1793302|NCT00536809|Drug|capecitabine|given BID days 1-14
1793303|NCT00536835|Drug|GSK461364|GSK461364 will be given intravenously as a 4 hour infusion in either a final volume of 500 or 1000 mLs. The starting dose for Stage A - Schedule 1 was 50 mg and doses were to be escalated as described in protocol until maximum tolerated dose established.
1793304|NCT00536848|Dietary Supplement|Lactobacillus rhamnosus GR-1 + Lactobacillus reuteri RC-14|
1793305|NCT00536848|Dietary Supplement|Placebo|
1793306|NCT00536848|Drug|Metronidazole|
1793307|NCT00536861|Drug|erlotinib|"Level 1 : erlotinib 100 mg/day from day -7 to the time of completion of 10 fractions of cranial irradiation, followed by 150 mg/day until disease progression or toxicity
Level 2 : erlotinib 150 mg/day from day -7 before cranial irradiation, followed by 150 mg/day until disease progression or toxicity"
1793308|NCT00536874|Drug|gemcitabine hydrochloride|1,000 mg/m2 IV over 100 minutes on day 1 every 14 days for 4 cycles
1793309|NCT00536874|Drug|oxaliplatin|80 mg/m2 IV over 2 hours on day 1 every 14 days for 4 cycles.
1793310|NCT00536874|Genetic|protein expression analysis|
1793311|NCT00536874|Genetic|proteomic profiling|
1793312|NCT00536874|Other|diagnostic laboratory biomarker analysis|
1793313|NCT00536874|Procedure|adjuvant therapy|
1793314|NCT00536874|Procedure|neoadjuvant therapy|
1793315|NCT00536874|Procedure|therapeutic conventional surgery|
1793316|NCT00536887|Drug|atorvastatin|atorvastatin 10 mg versus 40 mg during the 8 months of follow-up
1793317|NCT00536900|Behavioral|Advisor-Teller Money Manager|The acronym for the functions of ATM are TTT-- Teller (storing patient funds), Training patients by making and reviewing monthly budgets, and Treatment-Linked Spending in which weekly behavioral contracts link disbursement to completion of abstinence-related activities
1793318|NCT00536900|Behavioral|FIT|FIT (finance instruction therapy) involves review of a financial workbook and budgeting sheets
1793319|NCT00536913|Drug|Budesonide/formoterol pMDI 40/2.25ug + spacer|
1793320|NCT00536913|Drug|Budesonide/formoterol pMDI 40/2.25 ug|
1793321|NCT00536926|Device|Home spirometry with data transfer via cell phone|home spirometry recording
1793322|NCT00536926|Device|Home spirometer with BT-cellphone|Data transfer of home spirometry recordings via bluetooth to clinical database.
1793323|NCT00536926|Device|Home spirometer w/o BT|Standard home spirometry
1793324|NCT00536939|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral daily, until progressive disease
1793325|NCT00536939|Drug|bevacizumab|10 mg/kg, IV, Day 1 and 15 every 28 days, until disease progression
1793326|NCT00536939|Drug|paclitaxel|90 mg/m2, IV, Days 1 ,8, and 15 every 28 days until disease progression
1793327|NCT00536939|Drug|placebo|oral, daily, until disease progression
1793328|NCT00536952|Drug|Pulmozyme|Pulmozyme 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
1793329|NCT00536952|Drug|Placebo|Placebo 2.5 mL ampules (2.5 mg) will be nebulized and inhaled once daily using a recommended nebulizer
1793330|NCT00536952|Radiation|Radiation Therapy|5 days per week for 4 weeks
1793331|NCT00536978|Drug|ARA-C|100 mg/m^2 IV Daily Over 1 Hour for 4 Days
1793332|NCT00536978|Drug|BCNU|300 mg/m^2 IV Over 1 Hour for 1 Day
1793333|NCT00536978|Drug|Campath-1H|15 mg IV Daily Over 30 Minutes for 3 Days
1793334|NCT00536978|Drug|Cyclophosphamide|1000 mg/m^2 IV Daily Over 1 Hour for 3 Days
1793335|NCT00536978|Drug|Etoposide|100 mg/m^2 IV Daily Over 3 Hours for 4 Days
1793336|NCT00536978|Drug|Fludarabine|30 mg/m^2 IV Daily Over 1 Hour for 3 Days
1793337|NCT00536978|Drug|Melphalan|100 mg/m^2 IV Over 30 Minutes for 1 Day.
1793338|NCT00536978|Drug|Rituximab|375 mg/m^2 IV Over 5-7 Hours for 1 Day, followed by 1000 mg/m^2 IV Over 5-7 Hours Weekly for 3 Weeks.
1793339|NCT00536978|Other|Allogeneic Stem Cell Transplantation|Stem Cell Infusion on Day 0.
1793340|NCT00536978|Radiation|Total body radiation (TBI)|TBI on Day 5 following chemotherapy, before stem cell infusion.
1793341|NCT00536978|Drug|Methotrexate|5 mg/m2 IV on Days +1, +3, and +6.
1793342|NCT00536978|Drug|Tacrolimus|0.03 mg/kg/day IV starting on Day -2, to be given through day 60, tapered by 20% every week, then discontinue by day 90.
1793343|NCT00536978|Procedure|Adback NK or T Cell|Adback natural killer (NK) cells or T cells after transplantation to enhance full engraftment of donor cells. Cell adback after transplantation applies only if there is no active GVHD, and no previous episode of grade II-IV GVHD.
1793344|NCT00536991|Dietary Supplement|Calcitriol|Given PO
1793345|NCT00536991|Drug|Ketoconazole|Given PO
1793346|NCT00536991|Other|Laboratory Biomarker Analysis|Correlative studies
1793347|NCT00536991|Other|Pharmacological Study|Correlative studies
1793348|NCT00536991|Drug|Therapeutic Hydrocortisone|Given PO
1793349|NCT00537017|Drug|Preladenant|5 mg BID capsules
1793350|NCT00537017|Drug|L-dopa|Participants must receive L-dopa as part of their usual ongoing treatment for Parkinson's Disease. L-dopa is often administered concomitantly with a dopa decarboxylase inhibitor (e.g., carbidopa).
1793351|NCT00537017|Drug|Other Parkinson's Disease treatments|Participants may also receive other drugs as part of their usual ongoing treatment for Parkinson's Disease, such as dopamine agonists (e.g., pramipexole) and/or the catechol-O methyl transferase (COMT) inhibitor entacapone.
1793352|NCT00537030|Other|laboratory biomarker analysis|Correlative studies
1793353|NCT00537030|Other|pharmacological study|Correlative studies
1793354|NCT00537030|Drug|asparaginase|Given IM
1793355|NCT00537043|Drug|SK&F-105517 (COREG CR FDC)|
1793356|NCT00537056|Procedure|FDG PET CT|nuclear medicine imaging technique which produces a three-dimensional image or picture of functional processes in the body
1793357|NCT00537056|Procedure|DCE MRI|DCE MRI will be acquired using rapid intravenous bolus of gadolinium-DTPA (0.1 mmol/kg).
1793358|NCT00537056|Drug|F-18 Fluoro-deoxi-glucose|15 mCi iv
1793359|NCT00537056|Drug|Gadolinium-DTPA|0.1 mmol/kg iv
1793360|NCT00537056|Drug|Sunitinib|50 mg/day po
1793361|NCT00537082|Drug|FTY720|Administered orally once daily for 6 months
1793362|NCT00537082|Drug|Placebo|Administered orally once daily for 6 months
1793363|NCT00537095|Drug|Vandetanib|300 mg oral once daily oral dose
1793364|NCT00537095|Other|Placebo|
1793365|NCT00537108|Behavioral|Home visiting and care management|Third trimester teens are assigned a Care Manager (CM) who establishes a continuity relationship and provides monthly visits until the index child is 2 years old. Core services for intervention group include: 1)Baseline and ongoing assessment of health, mental health, housing, daycare, and school needs; 2)Administration of a culturally sensitive, developmentally relevant parenting curriculum; 3)Computer Assisted Motivational Interviewing to promote healthy relationships, improve contraceptive practices, focus on goals, and promote school continuation; 4)Efforts to engage the young father; 5)Linkage and coordination with primary care for teen, child, young father; 6)Support & skills-building for school continuation, higher education, and job readiness.
1793366|NCT00537121|Drug|fluorouracil|Given IV
1793367|NCT00537121|Drug|irinotecan hydrochloride|Given IV
1793368|NCT00537121|Drug|leucovorin calcium|Given IV
1793369|NCT00537121|Drug|vorinostat|Taken Orally
1793370|NCT00537121|Other|pharmacological study|Correlative Study
1793371|NCT00537134|Device|Embolization, coiling|Endovascular embolization with platinum coils
1793372|NCT00537147|Biological|WN/DEN4delta30 vaccine|Live attenuated WN/DEN4delta30 vaccine (one of two doses)
1793373|NCT00537147|Biological|Placebo|Placebo for WN/DEN4delta30 vaccine
1793374|NCT00537160|Behavioral|Behavior modification, Nutrition Education, Exercise|
1793375|NCT00537173|Procedure|Core Biopsy|biopsy
1793376|NCT00537173|Procedure|Blood Collection|Blood/serum sample
1793377|NCT00537173|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV, day 1, 8 and 15
1793378|NCT00537173|Drug|Avastin|Avastin 10 mg/kg IV, day 1 and 15
1793379|NCT00537186|Drug|Iron oligosaccharide|
1793380|NCT00537199|Other|Visual Examination|Two (2) scheduled visits for visual examination of mouth for abnormal lesions and glands in the neck.
1793381|NCT00537199|Drug|OraTest|Two (2) scheduled visits for rinse staining: 2 teaspoons of OraTest for 20 seconds, then spit.
1793382|NCT00537212|Other|The South Beach Diet|"Subjects will receive dietary counselling aimed at reducing simple carbohydrates and increasing weight loss. Subjects also receive a copy of The South Beach Diet."
1793383|NCT00537212|Other|The Ornish Diet|"Subjects will receive dietary counselling aimed to reduce fat consumption and increase weight loss. Subjects also receive a copy of The Ornish Diet book."
1793384|NCT00537212|Other|Control Group|This group will receive phototherapy alone. They will not be counselled or give literature on a particular diet.
1793385|NCT00537225|Behavioral|exercise|tailored multifactor CVD risk reduction
1793386|NCT00537238|Drug|pregabalin|300, 450, 600 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
1793501|NCT00537966|Drug|Lamivudine|standard dosage
1793387|NCT00537238|Drug|levetiracetam|1000, 2000, 3000 mg/day administered orally, BID until seizure control/improvement or intolerable side effects
1793388|NCT00537251|Drug|Insulin glargine|
1793389|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
1793390|NCT00537264|Other|Health-related quality of life assessment|Study participants will be asked to complete the following health-related quality of life questionnaires: EQ-5D, Health Utilities Index 3, SF-8 and SF-6D. The Singapore (Chinese) versions of these questionnaires have been previously tested and validated in a pilot cohort of the same study population.
1793391|NCT00537277|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme (dose individually adjusted), injected s.c. (under the skin)
1793393|NCT00537303|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted dose) for a once daily injection s.c. (under the skin)
1793394|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest prandial increment, injection s.c. (under the skin)
1793395|NCT00537303|Drug|insulin aspart|Administered 1 - 3 times daily, at largest meals, injection s.c. (under the skin)
1793400|NCT00537329|Drug|Anidulafungin|Eligible subjects will be initiated on a single loading dose of 200 mg IV anidulafungin, followed by 100 mg IV anidulafungin once daily for a minimum of 5 days but not more than 42 days.
1793401|NCT00537342|Biological|Immunotherapy with modified extract of O. europaea pollen|Sublingual (2 drops daily during 2 months)
1793402|NCT00537355|Biological|Amb a 1 Immunostimulatory Oligoribonucleotide Conjugate|6 weekly subcutaneous injections (escalating doses of 3 mcg to 30 mcg)
1793403|NCT00537355|Drug|Histamine|6 weekly subcutaneous injections (escalating doses of 0.22 mcg to 1.1 mcg)
1793404|NCT00537368|Drug|CNTO 888|
1793405|NCT00537381|Drug|Docetaxel|Docetaxel 75 mg/m^2 as intravenous infusion every 3 weeks.
1793406|NCT00537381|Drug|Prednisone|Prednisone 5 mg orally twice daily.
1793407|NCT00537381|Biological|Intetumumab|Intetumumab 10 mg/kg as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
1793408|NCT00537381|Drug|Placebo|Placebo matching to intetumumab, as intravenous infusion every week for initial 6 weeks, then every 3 weeks.
1793409|NCT00537394|Drug|Enfuvirtide|90mg subcutaneously twice daily
1793410|NCT00537394|Drug|Raltegravir|400 mg twice daily
1793411|NCT00537394|Drug|Darunavir|Two 300-mg tablets twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
1793412|NCT00537394|Drug|Tipranavir|Two 250-mg capsules twice daily, given with ritonavir 100mg twice daily (ritonavir not provided by the study)
1793413|NCT00537394|Drug|Etravirine|Two 100-mg tablets twice daily
1793414|NCT00537394|Drug|Maraviroc|Dosage dependent on regimen in which maraviroc is included
1793415|NCT00537407|Drug|Debio 025|Debio 025 supplied as a 100 mg/mL oral solution
1793416|NCT00537407|Drug|Peg-IFNα2a|Peg-IFNa2a supplied in 180 μg/0.5 mL prefilled syringes
1793417|NCT00537407|Drug|Ribavirin|Ribavirin supplied as 200 mg tablets
1793418|NCT00537420|Drug|Nasal Placebo|Nasal placebo, three times a day, 30 minutes before a meal for 24 weeks.
1793419|NCT00537420|Drug|Placebo Capsule|Placebo capsules will be taken once daily with or without food.
1793420|NCT00537420|Drug|PYY3-36|Nasal PYY3-36, three times a day, 30 minutes before a meal for 24 weeks.
1793421|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
1793422|NCT00537420|Drug|PYY3-36|Nasal PYY3-36 three times a day, 30 minutes before a meal for 24 weeks.
1793423|NCT00537420|Drug|Sibutramine|Sibutramine will be taken once daily with or without food
1793424|NCT00537433|Other|Pictogram|"The plain language, pictogram-based medication instruction sheets (available in English and Spanish) utilize pictograms to convey information about the medication name, indication, dose, dose frequency, and length of treatment, along with information about preparation and storage. The sheets also include a medication log for parents to keep track of when they administer the medication.
Research staff reference the sheets as they demonstrate dosing with a standardized dosing instrument; teachback is performed to reinforce concepts. For medications in which a standardized dosing instrument was not included at dispensing, a standardized oral dosing syringe is provided for the caregiver to use at home. After counseling, the caregiver is given the instruction sheet to take home."
1793425|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of high-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 12 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
1793426|NCT00537446|Device|noninvasive positive pressure ventilation|Each subject will undergo 2 hours of low-level noninvasive positive pressure ventilation, with an inspiratory positive airway pressure of 6 cm H2O and an expiratory positive airway pressure of 3 cm H2O.
1793427|NCT00537459|Drug|16448|
1793428|NCT00537472|Drug|Low dose bupivicaine in spinal anesthetic|Bupivacaine 9 mg intrathecal single shot injection at start of surgery
1793429|NCT00537472|Drug|Standard dose bupivacaine in spinal anesthetic|Bupivacaine 13 mg intrathecal single shot injection at start of surgery
1793430|NCT00537485|Drug|SPM 962|transdermal application, 1 time per day
1793431|NCT00537485|Drug|placebo|transdermal application, 1 time per day
1793432|NCT00537498|Drug|Urokinase|"Daily intravenous application of urokinase over 30 minutes
Dosage:
If plasma fibrinogen is > 2,5g/l application of 1 000 000 IU Urokinase If plasma fibrinogen is < 2,5g/l application of 500 000 IU Urokinase If plasma fibrinogen is < 1,6g/l treatment must be stopped and continued after rising up to >2g/l"
1793433|NCT00537511|Drug|Pomalidomide|
1793434|NCT00537511|Drug|Cisplatin|
1793436|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.5mL injections of H5N1 influenza vaccine containing 7.5μg of H5N1 antigen (A/Vietnam/1194/2004), administered 3 weeks apart, and one 0.5mL injection of H5N1 vaccine 12 months after the second dose, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
1793437|NCT00537524|Biological|H5N1 Influenza Vaccine|Two 0.25mL or 0.5mL injections of H5N1 influenza vaccine, administered 3 weeks apart, IM into the deltoid muscle (preferably of the non-dominant arm) or anterolateral thigh (depending on the muscle mass).
1793438|NCT00537537|Drug|Telbivudine|
1793439|NCT00537550|Drug|Vincristine|Steroids pre-treatment
1793440|NCT00537550|Drug|Vincristin, Daunorubicine, Asparaginase, Methotrexate|Induction therapy
1793441|NCT00537563|Drug|Telithromycin|
1793443|NCT00537589|Procedure|Ultrasound guided arthrocentesis|Guidance of joint aspiration by ultrasound guidance
1793444|NCT00537602|Drug|miglustat|
1793445|NCT00537602|Drug|placebo|
1793446|NCT00537615|Drug|PD 0332334|
1793447|NCT00537654|Drug|Treatment sequence A|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fed state
1793448|NCT00537654|Drug|Treatment sequence B|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fed state
1793449|NCT00537654|Drug|Treatment sequence C|Commercially available tamsulosin hydrochloride 0.4 mg and dutasteride 0.5 mg in a fasted state
1793450|NCT00537654|Drug|Treatment sequence D|Fixed dose combination formulation of dutasteride and tamsulosin hydrochloride (0.5 mg dutasteride, 0.4 mg tamsulosin hydrochloride) in a fasted state
1793451|NCT00537667|Drug|anakinra|anakinra
1793452|NCT00537667|Drug|anakinra and PEG sTNF-R1|anakinra and PEG sTNF-R1
1793453|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 450 mg/day; Patients > 45 kg/99 lbs: idebenone 900 mg/day
1793454|NCT00537680|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
1793455|NCT00537680|Drug|Placebo|Placebo was provided as film-coated tablets that were the same size, weight and appearance as the idebenone tablets.
1793456|NCT00537693|Procedure|Continuous Renal Replacement Therapy|Patients will be randomized to either arm for the first 24 hours of the study and then crossover to the second arm for the second 24 hours of the study.
1793457|NCT00537719|Drug|GSK716155|albiglutide subcutaneous injection
1793458|NCT00537719|Drug|Placebo|placebo injection
1793459|NCT00537732|Drug|omeprazole|20 mg daily
1793460|NCT00537732|Drug|omeprazole|20 vs. 60 mg daily, genotype dependent
1793461|NCT00537745|Drug|Vivitrol (Medication Therapy)|Vivitrol 380 mg/monthly
1793462|NCT00537745|Other|Medication Management Therapy|Medication Management Therapy once a month.
1793463|NCT00537758|Behavioral|Cognitive Behavior Therapy|
1793464|NCT00537758|Behavioral|CBT and BWL|
1793465|NCT00537758|Behavioral|Behavioral Weight Loss Treatment|
1793466|NCT00537771|Drug|Anastrozole|1 mg once daily oral dose
1793467|NCT00537771|Drug|Tamoxifen|20 mg once daily oral dose
1793468|NCT00537784|Biological|Autologous platelets|Local injection 10mL, about 2.5 x 10E10 platelets.
1793469|NCT00537784|Biological|no injection|
1793470|NCT00537797|Other|FDG-PET Scan|Positron emission tomography with 18F-fluorodeoxyglucose
1793471|NCT00537810|Drug|Sibutramine|15 mg daily
1793472|NCT00537810|Drug|Placebo|Daily
1793473|NCT00537810|Behavioral|Self-help CBT + Sibutramine|Cognitive behavioral treatment manual for binge eating Sibutramine 15 mg daily
1793474|NCT00537810|Behavioral|Self-help CBT + Placebo|Cognitive behavioral treatment manual for binge eating Placebo daily
1793475|NCT00537823|Drug|Cetuximab|
1793476|NCT00537823|Drug|Bevacizumab|
1793477|NCT00537823|Drug|Leucovorin|
1793478|NCT00537823|Drug|Oxaliplatin|
1793479|NCT00537823|Drug|Fluorouracil|
1793480|NCT00537836|Drug|BAY 86-5310 (ZK 283197)|3 mg (3 x 1 mg tablet) or 2 mg (2 x 1 mg tablet) ZK 283197 in respective treatment group, once daily p.o. over 8 weeks
1793481|NCT00537836|Drug|Placebo|Placebo, once daily p.o. over 8 weeks
1793482|NCT00537836|Drug|17ß-estradiol|1 mg (2 x 0.5 mg tablet) 17ß-estradiol, once daily p.o. over 8 weeks
1793483|NCT00537849|Device|Sonablate 500(SB-500)|
1793484|NCT00537862|Drug|Enteric-Coated Mycophenolate Sodium (EC-MPS)|
1793485|NCT00537875|Dietary Supplement|Ginger|Capsule, 1000 mg, BID, 3 days
1793486|NCT00537875|Dietary Supplement|Placebo|Capsule, 1000 mg, BID, 3 days
1793487|NCT00537888|Drug|fluconazole|Intravenous or oral 400 md/d
1793488|NCT00537901|Radiation|First-Line Bevacizumab and Chemotherapy|Chemotherapy
1793489|NCT00537901|Drug|Bevacizumab|Chemotherapy
1793490|NCT00537914|Drug|Somatropin|Infant, Small for Gestational Age, Omnitrope®/Somatropin, rhGH,
1793491|NCT00537927|Procedure|laparoscopic correction of hernia with mesh|Correction of hernia with mesh and fixation of mesh using one of the arms.
1793492|NCT00537940|Drug|Pregabalin|150, 300, 450 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
1793493|NCT00537940|Drug|Gabapentin|300, 600, 1200, 2000 mg/day administered orally TID, until seizure control/improvement or intolerable side effects
1793494|NCT00537953|Drug|Miltefosine , meglumine antimoniate|
1793495|NCT00537966|Drug|Dolutegravir|In this arm patients with primary HIV-1 infection are treated with standard antiretroviral combination therapy (only drugs that have been approved by Swiss Medic)
1793496|NCT00537966|Drug|Elvitegravir, Cobicistat, Emtricitabine, and Tenofovir Alafenamid Fumarate|standard dosage
1793497|NCT00537966|Drug|Raltegravir|standard dosage
1793498|NCT00537966|Drug|Darunavir|standard dosage
1793499|NCT00537966|Drug|Ritonavir|used only as booster for the protease inhibitors that are prescribed in this study according to standard boosting
1793500|NCT00537966|Drug|Rilpivirine|standard dosage
1793504|NCT00537966|Drug|Abacavir|standard dosage
1793505|NCT00537979|Drug|Paricalcitol injection|Most recent iPTH level in pg/mL divided by 100 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
1793506|NCT00537979|Drug|Paricalcitol capsules|Most recent iPTH level in pg/mL divided by 80 = dose in mcg; dose is rounded down to nearest mcg and administered 3x weekly
1793507|NCT00537992|Procedure|combined surgery|UV-filter IOL (transparent IOL group) or a blue light-filter IOL (yellow IOL group) combined with a vitreoretinal procedure
1793508|NCT00538005|Biological|bevacizumab|
1793509|NCT00538005|Drug|oxaliplatin|
1793510|NCT00538005|Drug|sorafenib tosylate|
1793511|NCT00538018|Drug|Telithromycin|
1793512|NCT00538031|Drug|cyclophosphamide|Given orally
1793513|NCT00538031|Drug|celecoxib|Given orally
1793514|NCT00538044|Drug|simvastatin|medication with simvastation on the dosage of 40mg per day before the operation and all the time after the operation
1793515|NCT00538057|Drug|GW685698X & GW642444M|study drug
1793516|NCT00538070|Dietary Supplement|Sarcosine|You will receive two grams of sarcosine or placebo per day. Each capsule will contain 500 mg of sarcosine or placebo. You will take two capsules twice per day, once in the morning and once in the evening, every day for six weeks. You can take the pills with or without food. You should continue to take all your other medications throughout the study.
1793517|NCT00538083|Other|Chocolate|74 grams of single dose solid dark chocolate versus placebo
1793518|NCT00538083|Other|Chocolate|22 grams of single dose sugared cocoa, sugar-free cocoa, and placebo
1793519|NCT00538083|Other|Chocolate|22 grams of sugared cocoa, sugar-free cocoa, & placebo given for six weeks
1793520|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (5,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
1793521|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (10,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
1793522|NCT00538096|Drug|MEDI-538|1 of 3 target doses of MEDI-538 (15,μg/m2/24h) as a continuous IV infusion through a central line catheter. The initial treatment period will be 4 weeks in duration (Study Days 0-27), unless the patient discontinues treatment.
1793523|NCT00538109|Drug|Glivec®/Gleevec®|Chemotherapy
1793524|NCT00538122|Device|24 Holter Monitor Recording|"All subjects will be fitted with a device to obtain 24-hour Holter EKG continuous recordings of bipolar leads C5C5R. They will also receive a standard 12-lead EKG recording prior to the placement of the Holter device. The subjects will be asked to keep a diary during the course of the 24 hours to record information such as wake and sleep times and symptoms such as shortness of breath, heart palpitations, lightheadedness, etc.
From each recording, 12 sets of 10 consecutive QRS epochs, plus QRS samplings obtained during sleep will be analyzed by a cardiologist blind to the medication status of subjects."
1793525|NCT00538135|Behavioral|Cognitive Behavioural Therapy|
1793526|NCT00538135|Other|Treatment as usual|Standard National Health Service treatment as usual for borderline personality disorder
1793527|NCT00538148|Drug|Telithromycin|
1793528|NCT00538161|Other|Ventilation strategy|
1793529|NCT00538174|Drug|Dapagliflozin|Tablets, Oral, once daily up, to 14 days
1793530|NCT00538174|Drug|placebo|Tablets, Oral, 0 mg, once daily, up to 14 days
1793531|NCT00538187|Drug|obatoclax mesylate|Given IV
1793532|NCT00538187|Drug|bortezomib|Given IV
1793533|NCT00538187|Other|laboratory biomarker analysis|correlative study
1793534|NCT00538187|Other|pharmacological study|correlative study
1793535|NCT00538200|Dietary Supplement|Oral Nutritional Supplements (Fortisip)|These products are classified as non-medicinal, borderline substances, foods for special medical purposes. A range of commercially available liquid oral nutritional supplements (Fortisip) will be offered daily for a 3 month period.
1793536|NCT00538200|Other|Dietary Advice|Standard dietary advice
1793537|NCT00538213|Biological|Fluarix™|Single dose, Intramuscular injection
1793538|NCT00538213|Biological|GSK Bio's Influenza Vaccine GSK576389A|Single dose, Intramuscular injection
1793539|NCT00538226|Device|External Electric Muscle Stimulation|
1793540|NCT00538239|Drug|ridaforolimus|Four 10 mg tablets taken by mouth for 5 days per week continuously
1793541|NCT00538239|Drug|Placebo|Four 10 mg tablets taken by mouth for 5 days per week continuously
1793542|NCT00538265|Drug|tacrolimus|Tacrolimus started at 0.50 mg/kg b.i.d. starting at D0, by nasogastric tube and then 1 to 2 hours before meals. The dose of tacrolimus will be adjusted as soon as possible to obtain trough concentrations of the product between 10 and 20 µg/L between D0 and 6 months and then between 8 and 15 µg/L after 6 months
1793543|NCT00538265|Drug|tacrolimus, ATG|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combining induction therapy with 3 injections of antithymocyte globulins (ATG) (1.5 mg/kg/d at D0, D2 and D4) and tacrolimus at usual dosage.
In this group of patients, the first injection of ATG will be infused over a period of at least 6 hours and will be started as soon as vascular anastomosis has been completed. It will be preceded by an injection of 3 mg/kg/d methylprednisolone. The second injection of ATG at D2, post transplantation will also be infused over 6 hours and will be preceded by an injection of 1 mg/kg methylprednisolone, and then subsequently steroids will be excluded from the treatment. The third and last injection at D4 post transplantation will be administered over a 6-hour period but will not be preceded by steroids.
In this study arm, tacrolimus will be administered as in arm (A)"
1793544|NCT00538265|Drug|ATG+mycophénolate mofétil+tacrolimus|"immunoprophylaxis allowing sparing of steroids in maintenance therapy combined with mycophenolate mofetil, at an initial dosage of 2 grams a day, and then adjusted to safety and tolerability in such a way so as to maintain PMN ≥ 750/mm3, and platelet counts ≥ 30000/mm3.
In this study arm, the patients will receive the same doses of ATG and steroids (and according to the same methods) as in arm B. Tacrolimus started at 0.05 mg/kg b.i.d. starting at D0 by nasogastric tube and then 1 to 2 hours before meals. In this study arm, the tacrolimus dose will be reduced: targeted trough concentrations will be between 7 and 12 µg/L between D0 and 6 months and then between 3 et 7 µg/L after 6 months."
1793545|NCT00538278|Other|Database|database
1793546|NCT00538291|Biological|cetuximab|
1793548|NCT00538291|Genetic|gene expression analysis|
1793549|NCT00538291|Genetic|microarray analysis|
1793550|NCT00538291|Genetic|polymorphism analysis|
1793551|NCT00538291|Genetic|reverse transcriptase-polymerase chain reaction|
1793552|NCT00538291|Other|immunohistochemistry staining method|
1793553|NCT00538304|Drug|bimatoprost eye drops|1 drop in each eye daily for 1 month
1793554|NCT00538304|Drug|placebo|1 drop in each eye daily for 1 month
1793555|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
1793556|NCT00538317|Drug|tirofiban|bolus of 25 µg/kg lasting 3 minutes then 18h to 24h perfusion of 0.15 µg/kg/min
1793557|NCT00538330|Drug|Tamoxifen|Tamoxifen
1793558|NCT00538343|Drug|berubicin hydrochloride (RTA 744)|
1793559|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature deactivated|Standard care
1793560|NCT00538356|Device|ICD or CRT-D with Home Monitoring feature activated|Standard care + patient management by Home Monitoring
1793561|NCT00538369|Other|Ramsay Scale|While receiving sedation, subjects will be monitored with the Ramsay scale
1793562|NCT00538369|Device|Bispectral index monitor|While receiving sedation, subjects will receive BIS monitoring
1793563|NCT00538382|Drug|Artesunate|A 200 mg dose of orally administered artesunate at the beginning of a 48-hour clinical sampling period.
1793564|NCT00538395|Drug|Adriamycin, Taxol and Cytoxan|Chemotherapy
1793565|NCT00538408|Procedure|Whole body magnetic resonance angiography (dotarem)|
1793566|NCT00538408|Device|Whole body magnetic resonance angiography (vasovist)|
1793567|NCT00538421|Drug|Propofol|Infusion intravenously (IV) 0-10 mg/kg/h
1793568|NCT00538421|Drug|Sevoflurane|0,7-1,5 MAC
1793569|NCT00538434|Biological|Reslizumab|
1793570|NCT00538434|Other|Saline|
1793571|NCT00538447|Other|Database|data base for CML
1793572|NCT00538473|Biological|GSK Biologicals' influenza vaccine GSK576389A|Single dose, intramuscular injection
1793573|NCT00538473|Biological|Fluarix™|Single dose, intramuscular injection
1793574|NCT00538486|Drug|Telmisartan plus Metformin|Telmisartan 80mg 1/d, Metformin 250mg 2/d
1793575|NCT00538486|Drug|Telmisartan|Telmisartan 80mg 1/d
1793576|NCT00538486|Drug|Candesartan|Candesartan 8mg daily
1793577|NCT00538486|Drug|Candesartan plus Metformin|Candesartan 8mg 1/d Metformin 250mg 2/d
1793578|NCT00538486|Drug|Amlodipine|Amlodipine 5mg 1/d
1793579|NCT00538486|Drug|Amlodipine plus Metformin|Amlodipine 5mg 1/d, Metformin 250mg 2/d
1793580|NCT00538499|Drug|Fentanyl citrate|
1793581|NCT00538499|Drug|Bupivacaine hydrocloride|
1793582|NCT00538499|Procedure|videothoracoscopy|
1793583|NCT00538512|Biological|Fluzone|single dose licensed trivalent inactivated influenza vaccine (2007-08)
1793584|NCT00538512|Biological|Flumist|single dose licensed live-attenuated influenza vaccine Flumist (2007-08)
1793585|NCT00538512|Other|Physiologic saline|single dose placebo administered as an intranasal spray or intramuscular injection
1793586|NCT00538525|Drug|Doxorubicin, Docetaxel, Cisplatin|Doxorubicin, Docetaxel, Cisplatin
1793587|NCT00538538|Drug|vitrectomy with subretinal lucentis|A gas bubble will be placed in the eye after the gel has been removed.
1793588|NCT00538538|Drug|vitrectomy with subretinal lucentis|These patients will have a vitrectomy where the gel is removed but will not receive the gas bubble.
1793589|NCT00538551|Other|Database|Database
1793590|NCT00538564|Drug|tadalafil|10mg oral tablets taken 3 times a week for 2 months
1793591|NCT00538564|Drug|placebo|Placebo tablets taken orally 3 times a week for 2 months
1793592|NCT00538590|Device|Collagen Matrix in Glaucoma Filtering Surgery|Collagen Matrix implantation in Glaucoma Filtering Surgery
1793593|NCT00538590|Drug|Mitomycin-C(MMC) and glaucoma filtering surgery|If mitomycin -C is applied, a single cellulose sponge soaked with Mitomycin-C(MMC) (0.2mg/ml - 0.4mg/ml) is fashioned into an approximate 2.0 × 4.0 mm rectangular shape and applied to the scleral bed and subconjunctival space taking care to avoid exposure to the conjunctival wound edge. Application time is 2 minutes for MMC. Then, the area treated is copiously irrigated with balanced salt solution. After operation, appropriate anti-inflammatory and antibiotic eye-drops will be prescribed.
1793594|NCT00538603|Drug|pegylated liposomal Doxorubicin (CAELYX) & Carboplatin|Chemotherapy
1793595|NCT00538603|Drug|Paclitaxel & Carboplatin|Chemotherapy
1793596|NCT00538616|Drug|Dexmedetomidine|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
1793597|NCT00538616|Drug|Propofol|in this crossover study, subjects will receive 6 hours of propofol and 6 hours of precedex (randomized crossover)
1793598|NCT00538629|Other|no intervention|No intervention
1793599|NCT00538642|Drug|ziprasidone|Patients assigned to ziprasidone arm are cross-titrated from current antipsychotic
1793600|NCT00538655|Drug|modafinil|400mg vs. 200mg (PO) daily
1793601|NCT00538668|Drug|117Lu-J591|There will be 9 groups of patients. The first group will receive 20 units of test drug and the 9th group will receive 55 units of the test drug. The exact dose of the test drug will depend upon how many patients have been included in this protocol at the time of patient enrollment. Patients will receive 20-55 units (or millicuries) of radioactivity depending upon patient specific height and weight. The assignment of each patient for a specific dose level is purely based on the sequence of recruitment basis and does not depend on the clinical status of the patient.
1793602|NCT00538681|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
1793603|NCT00538681|Drug|pemetrexed|500 mg/m2, IV, q 21 days, six 21 day cycles
1793604|NCT00538681|Drug|cisplatin|75 mg/m2, IV, q 21 days, six 21 day cycles
1793605|NCT00538681|Drug|placebo|oral, daily
1793606|NCT00538694|Drug|daptomycin|
1793607|NCT00531804|Drug|gantenerumab|Administered iv at escalating doses (7 cohorts)
1793608|NCT00531817|Drug|Tocilizumab|Tocilizumab intravenously at a dose of 8 mg/kg over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
1793609|NCT00531817|Drug|Placebo|Placebo IV over a 1-hour infusion, every 4 weeks, for a total of 6 infusions.
1793690|NCT00539838|Drug|Prednisone|Oral repeating dose
1793610|NCT00531817|Drug|Permitted DMARDs|As prescribed. The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These DMARDs could be used alone or in combination, except for the combination of MTX and leflunomide, which was not allowed.
1793611|NCT00531843|Drug|fondaparinux sodium|fondaparinux 2.5mg SubQ daily for DVT prophylaxis to be started by treating physicians once deemed safe and to be discontinued once patient in discharged from the hospital or at discretion of treating physicians.
1793612|NCT00531843|Device|sequential compression devices|Sequential compression devices at all times during the patient's hospital admission will be used in patients who have a contraindication to pharmacologic DVT prophylaxis. This is already the current standard of care.
1793613|NCT00531856|Drug|Inhaled carbon monoxide|0.7 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
1793614|NCT00531856|Drug|Inhaled carbon monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours post transplant
1793615|NCT00531856|Drug|Inhaled carbon monoxide|3.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
1793616|NCT00531856|Drug|Inhaled Carbon Monoxide|3.5 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant
1793617|NCT00531856|Drug|Inhaled Carbon Monoxide|2.0 mg/kg carbon monoxide/placebo over one hour administered 12-48 hours during transplant.
1793618|NCT00531869|Behavioral|biases towards products|
1793619|NCT00531882|Drug|Pioglitazone|30 mg once a day
1793620|NCT00531882|Drug|Simvastatin|40 mg once a day
1793621|NCT00531882|Drug|Ibuprofen|Ibuprofen 15-23 mg/kg twice daily, maximum 3200 mg/day
1793622|NCT00531895|Drug|duloxetine|duloxetine 60 mg/d
1793623|NCT00531908|Drug|furosemide|furosemide
1793624|NCT00531934|Drug|Doxycline|100mg po daily
1793625|NCT00531934|Drug|erlotinib [Tarceva]|150mg po daily
1793626|NCT00531947|Drug|Selegiline Transdermal System|EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
1793627|NCT00531947|Drug|Placebo|Matching Placebo for EMSAM 6mg, 9mg, or 12mg Flexible Dose- 1 patch/24 hours- 12 Week Study
1793628|NCT00531960|Drug|Erlotinib|150 mg, PO, daily
1793629|NCT00531960|Drug|Bevacizumab|15 mg/kg, IV, Day 1 of Cycles 1 through 7
1793630|NCT00531960|Drug|Standard platinum-based chemotherapy|At the discretion of the investigator
1793631|NCT00531973|Drug|liposomal doxorubicin|5-fluorouracil (500 mg/m²) + pegylated liposomal doxorubicin (50 mg/m²) + cyclophosphamide (500 mg/m²) + adjuvant radiation therapy ± endocrinological therapy (FalipoC)
1793632|NCT00531973|Drug|epirubicin|5-fluorouracil (500 mg/m²) + epirubicin (90 mg/ m²) + cyclophosphamide (500 mg/ m²) + adjuvant radiation therapy ± endocrinological therapy (FEC90)
1793633|NCT00531986|Drug|Lopinavir-Monotherapy|Patients on triple HAART will be switched to LPV/r-monotherapy
1793634|NCT00531986|Drug|HAART|Patients will continued their current HAART
1793635|NCT00538707|Behavioral|2-minute Bondet test|2-minute Bondet test
1793636|NCT00538720|Drug|Vitamin D|Starting dose 50,000 IU by mouth 3 times weekly for three weeks (+/- one week), then 50,000 IU twice weekly for 6 weeks (+/- one week).
1793637|NCT00538720|Device|Four-dimensional computed tomography (4DCT)|Four-dimensional computed tomography (4DCT) scan of the neck.
1793638|NCT00538733|Drug|thalomid|"Cycles 1-4
• Thalidomide (50mg daily for days 1-7, thereafter 100mg daily for days 8-28 of the first 28 day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 for each subsequent cycle)"
1793639|NCT00538733|Drug|lenalidomide|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)
• Lenalidomide (25 mg daily days 1-21 of every 28 day cycle)
During BiRD phase • 25mg daily days 1-21 of every 28 day cycle)
During Maintenance Phase
• 25 mg daily for days 1-21 out of a 28 day cycle"
1793640|NCT00538733|Drug|clarithromycin|"During T-BiRD Phase • Clarithromycin (500mg twice daily for each 28 day cycle)
During BiRD Phase:
• Clarithromycin (500mg twice daily for each 28 day cycle)"
1793641|NCT00538733|Drug|dexamethasone|"During T-BIRD Phase (Cycles 1-4, 5-6, and in the case of T-BIRD re-initiation)
• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)
During BiRD Phase:
• Dexamethasone (40 mg daily on day 1, 8, 15 and 22 of each 28 day cycle)
During Maintenance Phase
• Dexamethasone 20 mg weekly (days 1,8, 15, 22 out of a 28 day cycle)"
1793642|NCT00538746|Device|BIPAP|
1793643|NCT00538746|Device|PSV|
1793644|NCT00538746|Device|PSV + CPAP|
1793645|NCT00538759|Device|External beam radiation therapy|Experimental beam radiation therapy to the aortic valve after successful balloon aortic valvuloplasty
1793646|NCT00538772|Other|Not applicable - blood tests/tissue specimen tests will be undertaken|Not applicable - blood tests/tissue specimen tests will be undertaken
1793647|NCT00538785|Biological|Motavizumab|15 mg/kg IM administered at monthly intervals
1793648|NCT00538785|Biological|Palivizumab|15 mg/kg IM administered at monthly intervals
1793649|NCT00538798|Drug|[18F]SP203|
1793650|NCT00538811|Drug|interferon alpha-2b, ribavirin, interferon-gamma,|
1793651|NCT00538811|Drug|interferon alpha-2b, ribavirin, amantadine|
1793652|NCT00538824|Drug|dexamethasone|"Cycles 1-4 • Dexamethasone (40mg ) will be given on days 1-4, 9-12, 17-20 of a 28-day cycle.
After completing 4 cycles:
Patients who demonstrate disease progression at any time will be taken off study.
Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.
Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.
Maintenance therapy will consist of:
• Dexamethasone 20mg weekly days 1, 8, 15, 22 out of a 28 day cycle)"
1793691|NCT00539838|Drug|immunosuppressive regime (azathioprine, mycophenolate mofetil or methotrexate)|Oral repeating dose
1793692|NCT00539838|Drug|methylprednisolone|Intravenous repeating dose
1793693|NCT00539838|Drug|ocrelizumab|Intravenous repeating dose
1793694|NCT00539838|Drug|placebo|Intravenous repeating dose
1793695|NCT00539864|Biological|FluBlok Influenza Vaccination|0.5mL dose for intramuscular injection
1794152|NCT00535808|Drug|nitroprusside|Administration of nitroprusside
1793653|NCT00538824|Drug|thalidomide|"Cycles 1-4
• Thalidomide will be given 50mg daily on days 1-7, thereafter 100mg daily on days 8-28 of the first 28-day cycle. Thalidomide will then be given at 100mg/daily for days 1-28 of each subsequent cycle.
After completing 4 cycles:
Patients who demonstrate disease progression at any time will be taken off study.
Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.
Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy."
1793654|NCT00538824|Drug|lenalidomide|"Cycles 1-4 • Lenalidomide will be given 25mg daily for days 1-21 of each 28 day cycle.
After completing 4 cycles:
Patients who demonstrate disease progression at any time will be taken off study.
Patients who achieve a resolution of monoclonal gammopathy as detected on serum immunofixation or achieve a plateau of disease (no change in M-spike as detected on serum protein electrophoresis) for > 2 cycles will be transitioned to maintenance therapy.
Patients who continue to respond without achieving either a plateau or a CR will continue on induction therapy until plateau for >2 cycles or CR in the absence of untoward toxicity. These patients will be then transitioned to maintenance therapy.
Maintenance therapy will consist of:
• Lenalidomide 25 mg/daily days 1 - 21 out of a 28 day cycle. 15mg/daily on days 1-21 of a 28 day cycle of lenalidomide will be given to patients with a creatinine clearance of < 40cc/min*"
1793655|NCT00538850|Drug|Fentanyl sublingual spray|In the open-label titration period of the study, participants started at a dose of 100, 200, or 400 µg and titrated upward to a maximum dose of 1600 µg. Titration was stopped when the dose administered provided adequate analgesia for breakthrough pain without unacceptable side effects or the maximum titration period of 21±5 days was reached. In the double-blind period of the study, participants received fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, or 1600 µg determined in the open-label titration period of the study.
1793656|NCT00538850|Drug|Placebo|Matching placebo to fentanyl sublingual spray.
1793657|NCT00538863|Drug|Fentanyl sublingual spray|Fentanyl sublingual spray in doses of 100, 200, 400, 600, 800, 1200, and 1600 µg
1793658|NCT00538876|Drug|decitabine|"Decitabine will be administered by intravenous injection at a dose of 20 mg/m2/day as a daily 1hr infusion (Arm A) or by continuous infusion (Arm B) for 3, 5 or 7 days. On the day following the final dose of decitabine, standard 7+3 induction chemotherapy will begin."
1793659|NCT00538889|Drug|Lecozotan SR|
1793660|NCT00538889|Drug|Citalopram|
1793661|NCT00538902|Biological|Placebo|Placebo administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
1793662|NCT00538902|Biological|Adalimumab 80 mg|Adalimumab 80 mg administered subcutaneously (SC) every other week (eow) for 12 weeks, followed by adalimumab 40 mg SC eow for 92 weeks.
1793663|NCT00538902|Biological|Adalimumab 40 mg|Adalimumab 40 mg administered subcutaneously every other week for 104 weeks
1793664|NCT00538915|Biological|Nabi-IGIV 10% [Immune Globulin Intravenous (Human). 10%]|Nabi-IGIV 10% [Immune Globulin Intravenous (Human), 10%] is a clear or slightly opalescent, colorless to pale yellow sterile solution of 10% protein concentration of immunoglobulin G (100mg/mL). It is packaged as 5g in 50mL solution and 10g in 100mL solution. Dosing will be 300-800 mg/kg based on subject's prior dosing history. Infusions will be every 3 or 4 weeks.
1793665|NCT00538928|Other|lung protective ventilation|tidal volume 6 ml/kg ideal body weight
1793666|NCT00538941|Dietary Supplement|Nestlé Noir intense 40 grx2|daily intake of 40gr chocolate (Nestlé Noir intense or Nestlé Placebo Chocolate) in the morning and 40gr chocolate in the evening.
1793667|NCT00538941|Dietary Supplement|Nestlé Placebo Chocolate 40 grx2|Nestlé Placebo Chocolate 40 gr in the morning and 40gr chocolate in the evening.
1793668|NCT00538954|Drug|Post operative laxation (Magnesium Oxide)|20 ml of Magnesium Oxide twice daily from the day after surgery until discharge
1793669|NCT00538954|Dietary Supplement|Preoperative metabolic conditioning postoperative nutritional supplementation|Nutricia PreOP drinks 800 ml between 8-10 pm the evening before surgery Nutricia PreOP drinks 400 ml completed 2 hours before anaesthesia on the morning of surgery Nutricia Fortisip drinks 2 x 200 ml drinks from the day after surgery until day 30
1793670|NCT00538954|Other|Standard ERAS group|
1793671|NCT00538967|Drug|doxycycline|2 weeks once daily
1793672|NCT00538980|Drug|Dasatinib|Patients will receive a once-daily oral administration of dasatinib at a dose of 100 mg QD (two 50 mg tablets taken together each day) for the duration of the study with the modifications as indicated. If the platelet count remains above 600,000/microL or the spleen remains enlarged in the absence of leukopenia or other side effects, the dose of dasatinib may be escalated to 120 mg QD (two 50 mg tablets plus one 20 mg tablet taken together each day).
1793673|NCT00538993|Behavioral|Stage based counseling|
1793674|NCT00539006|Drug|FPNS|fluticasone propionate nasal spray
1793675|NCT00539006|Drug|FFNS|fluticasone furoate nasal spray
1793676|NCT00539006|Drug|placebo FPNS|placebo nasal spray matching fluticasone propionate nasal spray
1793677|NCT00539006|Drug|placebo FFNS|placebo nasal spray matching fluticasone furoate nasal spray
1793678|NCT00539019|Other|calories measured 5x following wound healing|measure REE at various time points postburn
1793679|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1793680|NCT00539032|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1793681|NCT00539760|Drug|GSK1827771|GSK1827771 will be administered using injection via subcutaneous (SC) route.
1793682|NCT00539760|Drug|Placebo|Placebo to GSK1827771 for Injection will be administered via SC route
1793683|NCT00539773|Drug|BCG, Interferon|Chemotherapy
1793684|NCT00539786|Drug|Proton pump inhibitor (rabeprazole)|Patients receives rabeprazole 20mg AM and 20mg PM for 14 days
1793685|NCT00539799|Drug|prednisolone|5 - 7.5 mg/day
1793686|NCT00539799|Drug|Placebo|Matched placebo to prednisolone
1793687|NCT00539812|Behavioral|Standard Care|Standard 40 hour state mandated batterer intervention program
1793688|NCT00539812|Behavioral|Brief Alcohol Intervention combined with standard care|Brief alcohol intervention combined with standard 40 hour state mandated batterer intervention program
1793689|NCT00539825|Drug|GSK704838|
1793696|NCT00539864|Biological|TIV (Fluzone) Influenza Vaccination|0.5mL dose for intramuscular injection
1793697|NCT00539877|Drug|irinotecan|"Postoperative day 1, IP CPT-11 chemotherapy will be given by CAPD catheter. CPT-11 in 1L of normal saline, prewarmed to 37°C will be given intraperitoneally.
If there is no DLT and patients agree with the treatment, patients can receive 3 more times of IP chemotherapy with same dose of CPT-11 at 3 weeks interval. After total 4 cycles of IP chemotherapy, peritoneal disease will be reassessed with abdominal-pelvis CT. Pharmacokinetic study is not planned with this treatment."
1793698|NCT00539890|Drug|Technosphere Insulin|
1793699|NCT00539903|Behavioral|Physical activity (PA) and immigrants|
1793700|NCT00539916|Behavioral|Regular orange juice consumption|600 mL /day.
1793701|NCT00539929|Drug|E6201 0.005%|
1793702|NCT00539929|Drug|E6201 0.01%|
1793703|NCT00539929|Drug|E6201 0.03%|
1793704|NCT00539929|Drug|Placebo|
1793705|NCT00539942|Drug|Arixtra (fondaparinux sodium)|Treatment will consist of daily injections of pharmacy prepared syringes of Arixtra (fondaparinux sodium) 2.5mg. Treatment will continue for 21 consecutive days to end on post-operative day 22.
1793706|NCT00539942|Device|Intermittent compression devices (ICD)|All patients will receive intermittent compression devices (ICD's) during the patient's entire hospitalization after the operative procedure. Patients randomized to the standard of care management will receive ICD's only. This represents the current standard of care at our institution at the time of initiation of the trial.
1793707|NCT00539955|Behavioral|Standard Batterer Intervention|Standard state-mandated batterer intervention program (40 hours)
1793708|NCT00539955|Behavioral|Brief Alcohol Intervention|Brief alcohol intervention combined with state mandated batterer intervention program
1793709|NCT00539968|Drug|Docetaxel plus lonafarnib|"Docetaxel: 60-75 mg/m2
Lonafarnib: 150-375 mg PO BID"
1793710|NCT00539981|Biological|Influenza Vaccine, recombinant hemagglutinin, FluBlok|0.5mL dose for IM injection
1793711|NCT00539994|Drug|retapamulin|200mg BID retapamulin 3 days
1793712|NCT00539994|Drug|Retapamulin|200mg BID retapamulin 5 days
1793713|NCT00539994|Drug|Placebo|200mg BID placebo 5 days
1793715|NCT00540020|Other|Rehabilitation|
1793716|NCT00540033|Dietary Supplement|infloran|Study group was fed with probiotics as infloran 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
1793717|NCT00540033|Dietary Supplement|infloran|Study group was fed with infloran [Lactobacilli acidophilus (CFU 109 NCDO 1748, obtained from the National Collection of Dairy Organisms)] and Bifidobacteria bifidum [(CFU 109, NCDO 1453 obtained from the National Collection of Dairy Organisms)]; Laboratorio Farmaceutico S.I.T S.r.I ITALY] 125mg/kg/dose twice daily by adding it to breast milk or mixed feeding (breast and formula) for 6 weeks;
1793718|NCT00540046|Device|Copper T 380A IUD|Copper T 380A IUD will be placed at the 2-4 week post-operative visit.
1793719|NCT00540072|Drug|daptomycin|
1793720|NCT00540085|Drug|Rocuronium|0.6 mg/kg given intravenously before intubation
1793721|NCT00540098|Drug|paroxetine + aerobic exercise|paroxetine, 40 mg once daily + regular aerobic exercise
1793722|NCT00540098|Drug|Paroxetine + relaxation|paroxetine, 40 mg once daily + regular relaxation training
1793723|NCT00540098|Drug|Placebo + aerobic exercise|placebo pill once daily + regular aerobic exercise
1793724|NCT00540098|Drug|Placebo + relaxation|placebo pill once daily + regular relaxation training
1793725|NCT00540111|Dietary Supplement|soluble fiber® (partially hydrolyzed guar gum)|HIV-positive individuals with hypertriglyceridemia and who had been on the same HAART regimen for at least 6 months, had no change in therapy during the study,received 20g/day of soluble fiber for 4 months at pre-established times.
1793726|NCT00540124|Drug|Tadalafil|5 mg once a day
1793727|NCT00540124|Drug|Placebo|once a day
1793728|NCT00540124|Drug|Tamsulosin|0.2 mg once a day
1793729|NCT00540137|Drug|nevirapine|400mg once daily
1793730|NCT00540137|Drug|atazanavir/ritonavir|atazanavir 300 mg once daily ritonavir 100 mg once daily
1793731|NCT00540150|Biological|specific subcutaneous immunotherapy house dust mite allergoid (Novo-Helisen Depot)|We treat each patient with mite-allergen following the two different protocols.
1793732|NCT00540176|Drug|Dichloroacetate (DCA)|Oral DCA given twice daily for the 24 week period of the study. Continuation of therapy will be indefinite if efficacious.
1793733|NCT00540189|Procedure|Initial appendectomy|
1793734|NCT00540189|Procedure|Interval appendectomy|
1793735|NCT00540202|Drug|artemether-lumefantrine|Tablets taken twice daily for 3 days according to weight based guidelines.
1793736|NCT00540202|Drug|Oral quinine|Quinine tablets given at 10mg/kg 8 hourly for 7 days
1793737|NCT00540215|Other|Glucagonlike peptide|450 nmol native form, synthetic
1793738|NCT00540228|Biological|Influenza Vaccine GSK1247446A - 4 different formulations|Single dose, Intramuscular injection
1793739|NCT00540228|Biological|Fluarix™|Single dose, Intramuscular injection
1793740|NCT00540241|Drug|Pemetrexed|in-label use
1793741|NCT00540254|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) + Insomnia plus Usual Care for Chronic Fatigue Syndrome -continues standard care for Chronic Fatigue Syndrome plus 4 sessions of CBT targeted for insomnia/sleep problems
1793742|NCT00540254|Other|Usual Care for Chronic Fatigue Syndrome (Active Control Group)|Usual Care for Chronic Fatigue Syndrome (Active Control Group) - continues standard care for Chronic Fatigue Syndrome and comes to the sleep lab for bi-weekly sessions to discuss sleep problems and to review weekly sleep logs
1793743|NCT00540267|Other|No Intervention|No Intervention
1793744|NCT00540280|Radiation|Surgery alone or surgery plus preoperative Gemcitabine-Cisplatin|Surgery + Chemo + RT
1793745|NCT00540293|Drug|Atorvastatin|Prescription of 10/20/40mg dose atorvastatin based on the personal risk factor that is defined in the NCEP ATP III guideline in a single patient group
1793746|NCT00540306|Device|Diffuse Optical Spectroscopy|Changes in physiological and optical properties in healthy pre-menopausal breast tissue during the menstrual cycle using Diffuse Optical Spectroscopy
1793747|NCT00540319|Behavioral|HIP|"The Health in Pregnancy (HIP) computer program provides tailored, interactive Video Doctor counseling about behavioral risks, educational worksheets for the patients, and a cueing sheet for providers."
1793748|NCT00540332|Drug|Placebo|Single IV dose of placebo, 3 days before the start of RT, then once weekly placebo doses at the same dose during a planned 6 week RT course.
1793749|NCT00540332|Drug|palifermin|120μg/kg, single IV, 3 days before the start of Radiotherapy (RT), then once weekly at the same dose during a planned 6-week RT course
1793750|NCT00540345|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 4 weeks followed by pegylated interferon alpha 2a 180 mcg/week and Ribavirin 800 mg/day for 12 weeks, follow up for 24 weeks
1793751|NCT00540345|Drug|Pegylated interferon alfa-2a and ribavirin|pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 16 weeks, follow up for 24 weeks
1793752|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
1793753|NCT00540345|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 48 weeks, follow up for 24 weeks
1793754|NCT00540358|Drug|gemcitabine/carboplatin|Gemcitabine and carboplatin administered according to instructions in the package inserts.
1793755|NCT00540358|Drug|iniparib|"Body weight adjusted dose
1 hour intravenous infusion"
1793756|NCT00540371|Other|Port wine stain Birthmark|Port wine stain Birthmark
1793757|NCT00540384|Drug|Placebo|Placebo
1793758|NCT00540384|Drug|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)|Novel Erythropoiesis Stimulating Protein (NESP) (darbepoetin alfa)
1793759|NCT00540397|Drug|Fuzhenghuayu Tablet, Huangqi Decoction Granule|
1793760|NCT00540410|Drug|Coarsucam® (artésunate (AS) + amodiaquine (AQ) as fixed dose combination)|Infants tablets: AS 25/AQ 67,5 mg Toddlers tablets: AS 50/AQ 135 mg Once daily, dose according to bodyweight range Duration of treatment: 3days Children tablets: AS 100/AQ 270 mg
1793761|NCT00540410|Drug|Coartem® (arthemether+ lumefantrine)|"Tablets, 20/120 mg, oral route, twice daily, dose according to bodyweight range.
Duration of treatment: 3 days"
1793762|NCT00540423|Drug|SB-497115-GR 12.5mg|SB-497115-GR 12.5mg tablet once a day
1793763|NCT00540423|Drug|SB-497115-GR 25mg|SB-497115-GR 25mg tablet once a day
1793764|NCT00540423|Drug|SB-497115-GR 12.5mg matching placebo|SB-497115-GR 12.5mg matching placebo x1 or 2 tablet once a day
1793765|NCT00540423|Drug|SB-497115-GR 50 mg|SB-497115-GR 25mg tablet x2 once a day
1793766|NCT00540436|Drug|GSK1325760A|Primary evaluation period: 5 mg/day, po, 12 weeks. Dose adjustment period: 2.5 mg, 5 mg or 10 mg/day, po, 12 weeks.
1793767|NCT00540449|Drug|TMC278|25 mg tablet once daily for 96 weeks
1793768|NCT00540449|Drug|Efavirenz|600mg once daily for 96 weeks
1793769|NCT00540462|Procedure|gastric bypass|
1793770|NCT00540462|Procedure|sleeve gastrectomy|
1793771|NCT00540488|Other|Adult enteral formula|
1793772|NCT00540501|Drug|Oseltamivir and Intravenous Zanamivir|"Oseltamivir will be administered PO q12h for 3 days (for a total of 5 doses ending the morning of day 3.
Both drugs will be administered simultaneously starting on Day 1 of Period 3. Zanamivir will be administered IV q12h for 3 days (for a total of 5 doses ending on the morning of day 3.
Zanamivir to be given four (4) hours after the oral dose of oseltamivir and infused over 30 minutes."
1793773|NCT00540514|Drug|Albumin-bound paclitaxel|Administered by intravenous infusion.
1793774|NCT00540514|Drug|Paclitaxel|Administered by intravenous infusion.
1793775|NCT00540514|Drug|Carboplatin|Administered by intravenous infusion. Dosing was based on the Calvert formula: carboplatin dose (mg) = (Target AUC) x (glomerular filtration rate [GFR] + 25). For the purposes of this protocol, the GFR is considered to be equivalent to creatinine clearance (calculated by the method of Cockcroft and Gault, 1976).
1793776|NCT00540527|Drug|local interarterial recombinant tissue plasminogen activator|Endovascular treatment must be performed asap after random.and definitely within 6h from symp. onset.It includes intrarterial thrombolysis with rt-PA,if necessary,associated to or substituted by mechanical clot disruption and/or retrieval.Fibrinolytic therapy should be performed within 1h,the full dose of rt-PA infusion should not exceed 0.9 mg/kg (max 90 mg in the case of body weight ≥100 kg).If a complete recanalization is achieved,rt-PA infusion can be interrupted before reaching the maximum dosage.The option of performing a thrombolysis by mechanical means to obtain a mechanical disintegration/shift/detach/fissure of the thrombus and/or a retraction/aspiration can be considered on the basis of the type,location and characteristics of the occlusion.These choices may involve the use of the microguidewire as a mechanical instrument to favour the disintegration of the thrombus,using systems to capture the thrombus by extraction or more complex systems to crush and aspirate the thrombus
1793777|NCT00540527|Drug|intravenous (IV) rt-PA|IV thrombolytic treatment is started immediately after randomization, within 4.5 h of symptoms onset. IV rt-PA is administered at a dose of 0.9 mg/kg (max 90 mg), 10% of which is given as a bolus, followed by the delivery of the remaining 90% as a constant infusion over 60 mins
1793778|NCT00540540|Device|Diffuse Optical Spectroscopy|Breast properties scanning
1793779|NCT00540553|Drug|placebo|
1793780|NCT00540553|Drug|GSK971086|
1793781|NCT00540566|Device|Optical Biopsy imaging|Optical Biopsy imaging
1793782|NCT00540579|Drug|Pomalidomide|Phase 1: Subjects will be enrolled in dose-escalating cohorts to be treated with CC-4047 on days 1-21 Phase II: Subjects will be enrolled to receive oral CC-4047 at the MTD days 1 - 21
1793783|NCT00540579|Drug|Gemcitabine|1000 mg/m2 IV on days 1, 8, and 15 of 28 day cycle
1793784|NCT00540592|Biological|GlaxoSmithKline Biologicals' influenza vaccine GSK576389A|Single dose, Intramuscular injection, 8 different formulations were tested (one per group)
1793785|NCT00540592|Biological|Fluarix|Single dose, Intramuscular injection
1793786|NCT00540605|Drug|Tenofovir 1% vaginal gel|topical gel containing 1% tenofovir
1793787|NCT00540618|Drug|MEDI-507|Compare in a placebo controlled manner, the disease activity of three dosing regimens of MEDI-507 (Monoclonal Antibody)
1793788|NCT00540618|Other|Placebo|
1793789|NCT00540618|Drug|MEDI-507|Monoclonal Antibody (5 mg for 12 weeks and 5 mg for 6 weeks)
1793790|NCT00540618|Drug|MEDI-507|Administered 7 mg for 4 weeks by injection (Monoclonal Antibody)
1793839|NCT00540982|Drug|vinorelbine ditartrate|Varying doses ranging from 30 mg/m2 to 7.5 mg/m2 will be administered based upon liver function
1793840|NCT00540982|Other|high performance liquid chromatography|Used to determine plasma concentrations of vinorelbine
1793791|NCT00540631|Biological|specific immunotherapy with Acaroid, subcutaneously, Up-titration till strength B 0.6 mL (6000 TU)|"Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection
to be det. A 0.1 100 TU
7 (+7) days later A 0.2 200 TU
7 (+7) days later A 0.4 400 TU
7 (+7) days later A 0.6 600 TU
7 (+7) days later B 0.1 1000 TU
7 (+7) days later B 0.2 2000 TU
7 (+7) days later B 0.4 4000 TU
7 (+7) days later B 0.6 6000 TU
Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued Injection Number Date Proposed Dose Individual Dose Strength A=1000 TU/ml B=10000TU/ml ml Dose per Injection
to be det. A 0.1 100 TU
7 (+7) days later A 0.2 200 TU
7 (+7) days later A 0.4 400 TU
7 (+7) days later A 0.6 600 TU
7 (+7) days later B 0.1 1000 TU
7 (+7) days later B 0.2 2000 TU
7 (+7) days later B 0.4 4000 TU
7 (+7) days later B 0.6 6000 TU
Maintenance (Init 2,4) 4-6 weekly B 0.6 6000 TU To be continued"
1793792|NCT00540644|Drug|lenalidomide (Revlimid®)|25 mg p.o. daily on days 1-21 of each 28 day cycle
1793793|NCT00540644|Drug|Cyclophosphamide|50 mg p.o. BID daily on days 1-21 of each 28 day cycle
1793794|NCT00540644|Drug|Prednisone|50 mg p.o. Q.O.D.
1793795|NCT00540657|Drug|CCX282-B|250mg capsule, twice daily, 13 weeks
1793796|NCT00540657|Drug|Placebo|Placebo capsule, twice daily, 13 weeks
1793797|NCT00540670|Drug|E5555 50 mg|E5555 50 mg (tablet) taken orally, once a day.
1793798|NCT00540670|Drug|E5555 100 mg|E5555 100 mg (tablet) taken orally, once a day.
1793799|NCT00540670|Drug|E5555 200 mg|E5555 200 mg (tablet) taken orally, once a day.
1793800|NCT00540670|Drug|Placebo|Placebo (tablet) taken orally, once a day.
1793801|NCT00540683|Device|Diffuse Optical Spectroscopy|Muscle properties
1793802|NCT00540696|Drug|darbepoetin alfa|"Darbepoetin alfa 3.0mcg/kg every 2 weeks for 3 doses. At week 7, if the subject has not experienced an increase of at least 1.0g/dL in hgb from week 1, increase dose of darbepoetin alfa to 5.0mcg/kg every 2 weeks for 5 doses.
Otherwise, maintain darbepoetin alfa 3.0mcg/kg every 2 weeks for 5 doses."
1793803|NCT00540709|Drug|Insulin Glargine|
1793804|NCT00540722|Drug|R-(-)-gossypol acetic acid|Given PO
1793805|NCT00540722|Other|laboratory biomarker analysis|Correlative studies
1793806|NCT00540735|Procedure|photodynamic therapy|
1793807|NCT00540748|Drug|oxytocin|5 U i.v. during surgical abortion
1793808|NCT00540761|Device|OFDI imaging|Intervention of OFDI system and Imaging of the culprit lesion using the OFDI system.
1793809|NCT00540774|Device|detection of oral pathology|detection of oral pathology
1793810|NCT00540787|Device|Radiofrequency ablation, antiarrhythmic drugs|Patients receive either treatment.
1793811|NCT00540787|Drug|Amiodarone, flecainide, propafenone, quinidine, dofetilide, sotalol, cibenzoline, beta blocking and calcium channel blocking agents and antiarrhythmic drugs|Amiodarone will be taken at 600 mg per day for 21 days (as a loading dose) followed by 1.4g per week or 200mg per day. The daily dose may be increased to 300mg or 2.1g per week.
1793812|NCT00540787|Device|ThermoCool Radiofrequency Catheter|Patient is ablated once, repeat ablation if paroxysmal atrial fibrillation reoccurs.
1793813|NCT00540800|Drug|docetaxel|given in combination with epirubicin or capecitabine
1793814|NCT00540800|Drug|epirubicin|for patients with locally advanced breast cancer, or metastatic breast cancer not previously treated with anthracyclines
1793815|NCT00540800|Drug|capecitabine|for metastatic breast cancer patients previously treated with anthracyclines
1793816|NCT00540813|Device|drug eluting balloon|drug eluting balloon bifurcated coronary lesions single arm study
1793817|NCT00540826|Drug|Atomoxetine|in-label use
1793818|NCT00540826|Drug|stimulants (any approved ADHD medication)|in-label use
1793819|NCT00540839|Drug|Montelukast sodium|Montelukast 4 mg OG or montelukast 4 mg CT
1793820|NCT00540839|Drug|Placebo to montelukast|Placebo OG or CT
1793821|NCT00540839|Drug|Fluticasone propionate|Fluticasone 50 mcg inhalation aerosol metered dose inhaler
1793822|NCT00540839|Drug|Placebo to fluticasone|Placebo inhalation aerosol metered dose inhaler
1793823|NCT00540852|Device|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging
1793824|NCT00540865|Behavioral|Problem-solving therapy (PST)|The premise of PST is that psychotherapies implicitly help people to become better managers of their lives, in effect, to become better at solving problems. Unlike Case Management (CM) that seeks to increase its clients' availability and utilization of resources, PST focuses on the patients themselves and helps them develop skills in identifying, prioritizing, and solving problems, and thereby creates a sense of empowerment. Although CM and PST have different theoretical premises, they both focus on the resolution of concrete problems promoting depression.
1793825|NCT00540865|Behavioral|Case management (CM)|Different types of CM exist, but all share the theme of helping individuals cope with their illnesses through linkage to social services, advocacy, rehabilitation, and ongoing support during recovery from illnesses. CM will consist of the following components: 1) socialization to treatment; 2) needs assessment; 3) psychoeducation about depression; 4) service planning; 5) linkage to social services; 6) help with access to health care; 7) advocacy; and 8) exploration of barriers that perpetuate unmet needs.
1793826|NCT00540878|Drug|SB-751689 oral tablets (400 mg)|
1793827|NCT00540891|Drug|ALFUZOSIN|
1793828|NCT00540904|Drug|sodium bicarbonate|IV 154 mEq/L sodium bicarbonate. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
1793829|NCT00540904|Drug|NaCl|IV 154 mEq/L solution of NaCl 0.9%. Infusion of 3 cc/Kg/h 1 hour before the injection of contrast and 1 cc/Kg/h after the injection.
1793830|NCT00540917|Procedure|cooling spray during laser treatment|skin temperature measurement
1793831|NCT00540930|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5mg at the time of radioactive plaque insertion
1793832|NCT00540943|Drug|pazopanib|Pazopanib is a potent, multi-targeted tyrosine kinase inhibitor of VEGFR-1, -2, -3, PDGFR-alpha and -beta and c-kit.
1793833|NCT00540956|Drug|cytarabine|
1793834|NCT00540956|Other|laboratory biomarker analysis|
1793835|NCT00540969|Procedure|cryosurgery|Patients undergo cryosurgery using guidance from CT scan or ultrasound
1793836|NCT00540969|Radiation|radiation therapy|Patients undergo radiotherapy for 1 week
1793837|NCT00540982|Drug|indocyanine green|0.5 mg/kg will be administered by IV push to determine clearance
1793838|NCT00540982|Drug|lidocaine|1 mg/kg will be administered to determine metabolic capacity
1793841|NCT00540982|Other|intracellular fluorescence polarization analysis|Used to determine concentration of lidocaine metabolic capacity
1793842|NCT00540982|Other|liquid chromatography|Used to determine concentrations of vinorelbine and its metabolites
1793843|NCT00540982|Other|mass spectrometry|Used to determine concentrations of vinorelbine and its metabolites
1793844|NCT00540982|Other|pharmacological study|Determination of concentrations of vinorelbine and its metabolites
1793845|NCT00540995|Drug|busulfan|Given IV
1793846|NCT00540995|Drug|etoposide|Given IV
1793847|NCT00540995|Radiation|intensity-modulated radiation therapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
1793848|NCT00540995|Procedure|allogeneic hematopoietic stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
1793849|NCT00540995|Procedure|allogeneic bone marrow transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
1793850|NCT00540995|Procedure|peripheral blood stem cell transplantation|Stem cell transplantation occurs on Day 0 after High Dose Therapy
1793851|NCT00540995|Radiation|tomotherapy|Initially 150 cGy X 8 doses with gradual dose escalation to 200 cGy X 10 doses
1793852|NCT00541008|Drug|sunitinib malate|
1793853|NCT00541021|Drug|gemcitabine hydrochloride|
1793854|NCT00541021|Drug|sorafenib tosylate|
1793855|NCT00541034|Biological|rituximab|
1793856|NCT00541034|Drug|cyclophosphamide|
1793857|NCT00541034|Drug|pentostatin|
1793864|NCT00541060|Genetic|mutation|a mutation of a gene coding
1793865|NCT00541073|Dietary Supplement|vitamin B12|
1793866|NCT00541073|Drug|cisplatin|
1793867|NCT00541073|Drug|pemetrexed disodium|
1793868|NCT00541073|Genetic|gene expression analysis|
1793869|NCT00541073|Other|laboratory biomarker analysis|
1793870|NCT00541073|Other|pharmacological study|
1793871|NCT00541086|Drug|anastrozole|1 mg per day, orally
1793872|NCT00541086|Drug|exemestane|25 mg per day, orally
1793873|NCT00541086|Drug|letrozole|2.5 mg per day, orally
1793874|NCT00541086|Drug|tamoxifen citrate|20 mg per day, orally
1793875|NCT00541099|Biological|bevacizumab|Avastin 10.0 mg/kg on days 1 and 15
1793876|NCT00541099|Drug|docetaxel|Dexamethasone 4 mg evening before, morning of and evening of each dose of docetaxel.Docetaxel 35 mg/m2 on day 1, 8, 15
1793877|NCT00541112|Biological|cetuximab|
1793878|NCT00541112|Drug|capecitabine|
1793879|NCT00541112|Drug|fluorouracil|
1793880|NCT00541112|Drug|leucovorin calcium|
1793881|NCT00541112|Drug|oxaliplatin|
1793882|NCT00541112|Procedure|adjuvant therapy|
1793883|NCT00541112|Procedure|conventional surgery|
1793884|NCT00541112|Procedure|neoadjuvant therapy|
1793885|NCT00541112|Radiation|radiation therapy|
1793886|NCT00541125|Biological|bevacizumab|
1793887|NCT00541125|Biological|filgrastim|
1793888|NCT00541125|Drug|fluorouracil|
1793889|NCT00541125|Drug|irinotecan hydrochloride|
1793890|NCT00541125|Drug|leucovorin calcium|
1793891|NCT00541138|Drug|carboplatin|CBDCA AUC=3
1793892|NCT00541138|Drug|tamoxifen citrate|Tamoxifen 100mg bid
1793893|NCT00541138|Drug|topotecan hydrochloride|Topotecan 0.75 g/m2/d
1793894|NCT00541138|Other|pharmacological study|Start of tx, hours 24,28 and 72 during Topotecan infusion, and hours 1,2,4 and 6 after end of Topotecan infusion.
1793898|NCT00541177|Drug|atropine|0.25% atropine
1793899|NCT00541177|Drug|tropicamide|0.5% tropicamide
1793900|NCT00541190|Other|Technetium [Tc-99m] sulfur colloid and Indium [In-111] DTPA|Subjects perform a single nuclear medicine scan after inhaling an aerosol containing Technetium 99m sulfur colloid and Indium 111 DTPA.
1793901|NCT00541216|Drug|Ephedrine|
1793902|NCT00541229|Drug|sitagliptin phosphate|sitagliptin 100 mg tablets q.d. (once daily) for 7 days.
1793903|NCT00541229|Drug|sitagliptin phosphate|sitagliptin 200 mg tablets q.d. (once daily) for 7 days.
1793904|NCT00541229|Drug|Comparator: Placebo|sitagliptin 100 mg & 200 mg matching Placebo tablets q.d. (once daily) for 7 days.
1793905|NCT00541242|Drug|bimatoprost 0.03% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of bimatoprost 0.03% 1 drop every evening for 12 weeks
1793906|NCT00541242|Drug|latanoprost 0.005% eye drops|Open-labeled latanoprost 0.005% 1 drop into each eye every evening for 6 weeks followed by a masked randomized treatment of latanoprost 0.005% 1 drop every evening for 12 weeks
1793907|NCT00541268|Device|ICD|Intracardioverter defibrillators from 2 different manufacturers
1793908|NCT00541268|Other|Optimal medical treatment|ACEi or angiotensin receptor blockers Betablockers Aldosterone blockers
1793909|NCT00541281|Drug|docetaxel|35mg/m² on day 2 and 9 (21days in a cycle)
1793910|NCT00541281|Drug|estramustine|140mg caps x3 bid from day 1to 5 and day 8 to 12 of each cycle
1793911|NCT00541281|Drug|prednisone|2x5 mg a day
1793912|NCT00541307|Device|Treatment with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface|Endovascular treatment of the study lesion with the GORE VIABAHN Endoprosthesis with Heparin Bioactive Surface
1793913|NCT00541320|Drug|GW813893|
1793914|NCT00541333|Drug|Copaxone Injection|
1793915|NCT00541346|Drug|Methylphenidate Transdermal System|10mg for one week, with weekly stepwise increases to 15mg, 20mg, and 30mg for additional 7 weeks, if symptom reports remained elevated. Titration decreased one stepwise dosage
1793916|NCT00541359|Drug|bortezomib|Given IV
1793917|NCT00541359|Drug|topotecan hydrochloride|Given IV
1793918|NCT00541359|Other|immunohistochemistry staining method|Correlative studies
1793919|NCT00541359|Other|pharmacological study|Correlative studies
1793920|NCT00541372|Device|insulin injection needle size|The intervention in this study is a specific needle with a length of 5 mm and 8 mm to be used with an insulin pen.
1793921|NCT00541385|Drug|pyronaridine artesunate|The strength of the granule formulation is 60:20 mg pyronaridine artesunate per sachet. Depending on their body weight, patients will receive between 1 to 3 pyronaridine artesunate sachets per day, for 3 consecutive days The actual dose-range covered by this regimen is 7.0:2.3 mg/kg to 13.3:4.4 mg/kg pyronaridine artesunate, which has shown to be effective and safe in the phase II studies conducted in children and adults.
1793922|NCT00541385|Drug|arthemeter lumefantrine|"Artemether 20 mg and lumefantrine 120 mg fixed dose combination, 6 dose regimen 120 mg artemether and 720 mg lumefantrine total (Novartis).
The posology is twice daily for 3 consecutive days 1 tablet for patients weighing ≥5 kg to <15 kg, 2 tablets for patients weighing ≥15 to <25 kg."
1793923|NCT00541398|Behavioral|Implementation of guideline|Outreach visits with interactive education for health staff
1793924|NCT00541411|Drug|Vincristine, Actinomycin-D, Ifosfamide|Chemotherapy
1793925|NCT00541424|Procedure|PET/CT Scanning|Full-body PET/CT procedure will be performed. Gas will be pumped into the colon before the scan so the colon will be opened up (inflated) and the study doctor will be able to more easily look for any lesions. This procedure is called gas insufflation.
1793926|NCT00541450|Drug|Comparator: sitagliptin phosphate (sitagliptin)|sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period
1793927|NCT00541450|Drug|sitagliptin phosphate (+) metformin hydrochloride|sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period
1793928|NCT00541450|Drug|Comparator: pioglitazone|pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.
1793929|NCT00541450|Drug|Matching placebo to pioglitazone|"matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.
Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks."
1793930|NCT00541450|Drug|Matching placebo to sitagliptin|matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.
1793931|NCT00541450|Drug|Matching Placebo to Sita/Met FDC|matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
1793932|NCT00541463|Drug|MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks|
1793933|NCT00541463|Drug|Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks|
1793937|NCT00541515|Device|continuous glucose sensors and insulin pump|continuous glucose sensors and insulin pump
1793938|NCT00541541|Procedure|Phrenic nerve stimulation|Patients receive a phrenic nerve stimulation
1793939|NCT00541554|Drug|Abilify (aripiprazole)|
1793940|NCT00541567|Drug|ibipinabant|oral, tablet, once daily
1793941|NCT00541593|Procedure|Pancreatic Pseudocystgastrostomy|An operation to connect the pancreatic pseudocyst to the stomach so it can drain into the stomach and intestines
1793942|NCT00541606|Other|Pharmacist collaboration in diabetes care|Patients attended a minimum of 3 clinic visits (month 0, 6, 12) with one of the clinical pharmacists, where targeted physical assessment, education, and medication changes and follow up were recommended. Additional visits were arranged as clinically appropriate for drug monitoring. Referrals were facilitated to other clinicians where indicated, including ophthalmology, podiatry, CDEs, nutrition, and primary care. The pharmacists' recommendations for medication adjustment, laboratory monitoring and referrals were based upon the most recent guidelines and clinical trial evidence. Any therapy adjustment, lab testing or referrals required approval by the referring physician. A1c, lipid and BP values were collected prospectively at months 0, 6 and 12.
1793943|NCT00541606|Other|Usual care|Control patients received usual care directed by their physician, and the same data were gathered from chart review during the 12-month study period.
1793944|NCT00541658|Drug|risedronate|5 mg Immediate-release Risedronate Administered At Least 30 Minutes Before Breakfast Daily
1793945|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered Immediately Following Breakfast Weekly
1793946|NCT00541658|Drug|risedronate|35 mg Delayed-release Risedronate Administered At Least 30 Minutes Before Breakfast Weekly
1793947|NCT00541671|Drug|Saline|10 c of saline
1793948|NCT00541671|Drug|Phenergan|Physician ordered dose
1793949|NCT00541684|Drug|MK0954, /Duration of Treatment : 16 Weeks|
1793950|NCT00541684|Drug|Comparator : atenolol /Duration of Treatment : 16 Weeks|
1793951|NCT00541697|Drug|MK0653A, ezetimibe (+) simvastatin / Duration of Treatment: 6 Weeks|
1793952|NCT00541697|Drug|Comparator: atorvastatin / Duration of Treatment: 6 Weeks|
1793953|NCT00541710|Dietary Supplement|genistein|pills of 27 mg, twice per day for 12 months
1793954|NCT00541710|Dietary Supplement|placebo|sugar pills twice per day for 12 months
1793955|NCT00541723|Drug|IncobotulinumtoxinA (Xeomin)|Intramuscular injection at day 0, at 3 and 4 injection sites per eye (4 x 3 or 3 x 4 units = 12 units per eye)
1793956|NCT00541723|Drug|Placebo|Intramuscular injection at day 0, at 3 and 4 injection sites per eye.
1793957|NCT00541736|Drug|Nitroglycerine|Nitroglycerine infusion over 20 minutes: 0.5 ug/kg/min
1793958|NCT00541749|Drug|rhuMAb IFNalpha|Intravenous repeating dose
1793959|NCT00541762|Dietary Supplement|Fat perfusion to the small intestine|"Triglycerides, long chain fatty acids, medium chain fatty acids perfused to the small intestine
Orlistat perfused to the small intestine
DEXLOX as CCK-1 receptor antagonist"
1793960|NCT00541775|Drug|Sitagliptin|Sitagliptin 100 mg administered as one oral tablet once daily in the morning for up to 18 weeks.
1793961|NCT00541775|Drug|Comparator: Rosiglitazone|Rosiglitazone 8 mg administered as two 4 mg capsules once daily in the morning for up to 18 weeks.
1794008|NCT00542126|Drug|Decapeptyl 0.1 mg after embryo transfer|Decapeptyl 0.1 mg (Ferring, Kiel, Germany) 3 days following embryo transfer
1793962|NCT00541775|Drug|Comparator: Placebo|placebo - administered as one placebo tablet to match Sitagliptin 100 mg and two placebo capsules to match rosiglitazone 4 mg once daily in the morning for up to 18 weeks.
1793963|NCT00541775|Drug|Comparator: Metformin|Open-label metformin was supplied by the Sponsor as 500, 850, or 1000 mg oral tablets administered at a daily dose of >= 1500 mg.
1793964|NCT00541788|Other|Administration of Common Sage|Administration of Common Sage
1793965|NCT00541801|Device|Doppler-echocardiography and acoustic cardiography|Patients receive a Doppler-echocardiography and an acoustic cardiography
1793966|NCT00541814|Drug|Cyclosporine|Target drug level 50-100 ng/ml or cyclosporine withdrawal
1793967|NCT00541840|Drug|Sorafenib|"Phase I:
Level 1: Sorafenib 200 mg bid, orally Ifosfamide 2,0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration
Level 2: Sorafenib 400 mg bid, orally Ifosfamide 2.00 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 400 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration
Level 3 : Sorafenib 400mg bid, orally Ifosfamide 2.5 g/m2 , intravenously , over 4 hours , on 3 consecutive days . Mesna 500mg/m2,iv,at 0,4 and 8 hours after ifosfamide administration .
Level 4 : Sorafenib 400 mg bid, orally Ifosfamide 3.0 g/m2, intravenously, over 4 hours, on 3 consecutive days Mesna 600 mg/m2 iv, at 0, 4 and 8 hours after the Ifosfamide administration
Phase II:
Sorafenib and Ifosfamide administered at the doses recommended in phase I until progression or unacceptable toxicity."
1793972|NCT00541879|Behavioral|Program ENERGY|Weekly or biweekly classroom and gym based science enrichment focused on how the body works including blood glucose regulation, healthy eating and physical activity, diabetes abd how it can be prevented
1793973|NCT00541879|Other|comparison|
1793974|NCT00541892|Other|Medium with no human serum albumine added|See above
1793975|NCT00541892|Other|Conventional medium|See above
1793976|NCT00541905|Drug|NT 201|Subjects to receive up to 5 injection sessions, with a total dose of up to 300 Units each. No more than 50 units should have be given at any one injection site during one session.
1793977|NCT00541918|Drug|Diprivan (propofol, Astra Zeneca)|Total intravenous anesthesia with propofol
1793978|NCT00541918|Drug|Sevorane (sevoflurane, Abbott)|inhaled anesthesia with sevoflurane
1793980|NCT00541957|Behavioral|behavior therapy|10 sessions over 4 months
1793981|NCT00541957|Drug|Medication prescribed by PCP|Can include any antidepressant medication
1793982|NCT00541970|Biological|Cervarix|Intramuscular injection, different dosing /schedule
1793983|NCT00541970|Drug|Placebo|Intramuscular injection, different dosing /schedule
1793984|NCT00541983|Drug|XOMA 052|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
1793985|NCT00541983|Drug|Placebo|Subjects in six successive dose groups will receive a single IV infusion (mg/kg) of study drug on Day 0. The total time of the infusion will be 1 hour ± 15 minutes.
1793986|NCT00541996|Drug|vabicaserin|
1793987|NCT00542009|Drug|CE-326,597 100 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
1793988|NCT00542009|Drug|CE-326,597 50 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
1793989|NCT00542009|Drug|CE-326,597 25 mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
1793990|NCT00542009|Drug|Placebo|Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).
1793991|NCT00542009|Drug|CE-326,597 5mg QD|Administered orally, once daily with morning meal for duration of trial (84 days).
1793992|NCT00542022|Drug|MK0812 / Duration of Treatment: 12 Weeks|
1793993|NCT00542022|Drug|Comparator: placebo (unspecified) / Duration of Treatment: 12 Weeks|
1793994|NCT00542035|Drug|ARRY-371797, p38 inhibitor; oral|dose 1, dose 2
1793995|NCT00542035|Drug|Placebo; oral|dose 1, dose 2
1793996|NCT00542035|Drug|Placebo; oral|dose 1
1793997|NCT00542035|Drug|ARRY-371797, p38 inhibitor; oral|dose 2
1793998|NCT00542048|Drug|EndoTAG®-1|EndoTAG®-1 22 mg/m² twice weekly
1793999|NCT00542061|Device|half-yearly monitoring routine|A written expert advice for GPs on additional diagnostic, treatment, and referral of patients with asthma and COPD based on half-yearly monitoring routines (lung function assessments including extensive anamnese) supported by half-yearly visits of an AC nurse consultant to the general practices.
1794000|NCT00542074|Other|hygienic information plus 62% ethyl alcohol in emollient gel|The male partner in each couple was asked to apply Purell® to his penis at least daily, and immediately prior to and following intercourse. Couples received a brochure with information on control of STI and good hygienic practices. Brochures for intervention and control arms were similar except the intervention arm brochure provided information on how to use the study product (Purell®).
1794001|NCT00542074|Other|hygienic information|Couples received a brochure with information on control of STI and good hygienic practices.
1794002|NCT00542087|Drug|MK0663, etoricoxib / Duration of Treatment: 6 Weeks|
1794003|NCT00542087|Drug|Comparator: diclofenac sodium / Duration of Treatment: 6 Weeks|
1794004|NCT00542100|Device|PCMRI|
1794005|NCT00542113|Behavioral|DvtProgram ENERGY|11 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
1794006|NCT00542113|Behavioral|DvtProgram ENERGY|6 - weekly or biweekly newsletters about diabetes and its prevention and family challenges sent home with children
1794007|NCT00542113|Behavioral|DvtProgramENERGY|Children participating in Program ENERGY but no newsletters or family challenges sent home to parents
1957361|NCT02443662|Other|Catheterization|Routine catheterization during follow up.
1957362|NCT02442284|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
1957363|NCT02442284|Drug|Ribavirin|Tablet
1794009|NCT00542139|Drug|Betamethasone|Intraarticular injection of 2ml Diprospan (wich contains 4mg Betamethasone sodium phosphate and 10mg Betamethasone dipropionate)
1794010|NCT00542139|Drug|Bupivocaine|Intraarticular injection of 10ml of Bupivocaine
1794011|NCT00542152|Drug|CYCLOSPORINE VS INFLIXIMAB|"Cyclosporine 2mg/kg/day intravenous for 7 days then Neoral 4mg/kg/day orally for 3 months.
Infliximab 5mg/kg at weeks 0, 2 and 6"
1794012|NCT00542165|Drug|Alfuzosin|
1794013|NCT00542178|Drug|Hypoglycemic Agents|Multiple drugs including insulins and oral hypoglycemia agents for HbA1c less than 6%
1794014|NCT00542178|Drug|Standard glycemia control|A strategy of glycemia drugs for HbA1c 7% - 7.9%
1794015|NCT00542178|Drug|Intensive BP treatment|A strategy of multiple BP agents to reduce SBP less than 120 mm Hg
1794016|NCT00542178|Drug|Standard BP control|A strategy of BP drugs for SBP less than 140 mm Hg
1794017|NCT00542178|Drug|Fenofibrate|Blinded fenofibrate
1794018|NCT00542178|Drug|Simvastatin|Simvastatin 20-40 mg/d
1794019|NCT00542178|Drug|Placebo|Placebo
1794020|NCT00542191|Drug|Doxorubicin / Cyclophosphamide / Paclitaxel / Carboplatin|DOXORUBICIN 24mg/m2 IV plus CYCLOPHOSPHAMIDE 60mg/m2 PO weekly x 12 successive weeks followed by PACLITAXEL 80mg/m2 IV over 1 hour plus CARBOPLATIN AUC 2 IV weekly x 12 successive weeks
1794021|NCT00542191|Procedure|Definitive Surgery|Standard of care definitive surgery as determined by medical provider
1794022|NCT00542191|Radiation|Radiotherapy|Standard of care RADIATION THERAPY as indicated
1794023|NCT00542204|Behavioral|Online disease management|The Personalized Health Care Program couples a multidisciplinary care management team with an EHR-integrated Online Disease Management (ODM) system.
1794024|NCT00542217|Biological|Imprime PGG|
1794025|NCT00534846|Drug|toremifene|The medication is given in tablet form, and the participants are instructed to take one tablet daily from cycle day 15 until the next menstruation. The active (toremifene 20 mg) and control (placebo) tablets were identical in appearance.
1794026|NCT00534846|Drug|placebo|tablet equal to toremifene, one tablet daily from cycle day 15 to menstruation during three cycles
1794027|NCT00534859|Device|High Risk PCI|High Risk Percutaneous Coronary Intervention
1794028|NCT00534872|Drug|SB-649868|10 mg
1794029|NCT00534885|Biological|Healive® Lot 1|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
1794030|NCT00534885|Biological|Healive® Lot 2|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
1794031|NCT00534885|Biological|Healive® Lot 3|Inactivated hepatitis A vaccine manufactured by Sinovac Biotech Co., Ltd.; two-dose regimen with 6 months apart
1794032|NCT00534885|Biological|Havrix|Inactivated hepatitis A vaccine manufactured by GlaxoSmithKline Biologicals; two-dose regimen with 6 months apart
1794033|NCT00534898|Drug|Bexarotene|
1794034|NCT00534898|Drug|Fenretinide|
1794035|NCT00534898|Drug|Placebo|
1794036|NCT00534911|Behavioral|Cognitive Behavioral Therapy|"Participants will receive 12 weeks of CBT designed for youth with IBD. During sessions, participants will learn new ways of thinking (e.g., reconstruction of personal physical illness narratives, coping strategies, social skills) and behaving (e.g., positive activities, family communication, sleep hygiene, relaxation) to improve emotional and physical outcomes. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
Other Name: Primary and secondary coping enhancement training (PASCET)"
1794037|NCT00534911|Behavioral|Supportive Non-directive Therapy (SNDT)|SNDT is a 12-week non-directive therapeutic intervention. Participants will receive social support and quality information about the warning signs and risk factors for depression. Parent sessions will be provided at the beginning, middle, and end of the treatment to improve family understanding and communication about the physical illness and about risks of developing depression. There will also be 6-month booster sessions during follow-up.
1794038|NCT00534924|Drug|Vit C|
1794039|NCT00534924|Procedure|Postconditioning|
1794040|NCT00534924|Other|no intervention|
1794041|NCT00534937|Procedure|Compression wrapping|Short-stretch compression wrap will be applied at least once a week.
1794042|NCT00534937|Procedure|Flexitouch compression pump|In addition to short-stretch wrapping, this group will received once-daily Flexitouch compression pump, both at home and during the once-a-week clinic visits.
1794043|NCT00534950|Radiation|5 vs 6 weekly fraction of RT|Chemotherapy
1794045|NCT00534976|Drug|Comparator: montelukast sodium|"Patients 4-5 years: 4 mg Montelukast chewable tablet daily
Patients 6-14 years: 5 mg chewable tablet daily"
1794046|NCT00534976|Drug|Comparator: Comparator: placebo (unspecified)|"Patients 4-5 years: 4 mg Pbo chewable tablet daily
Patients 6-14 years: 5 mg Pbo chewable tablet daily"
1794047|NCT00534989|Procedure|FDG PET|FDG PET
1794048|NCT00535002|Drug|Yohimbine|Participants were pre-treated with either yohimbine or placebo.
1794049|NCT00535002|Drug|Placebo|
1794050|NCT00535015|Drug|Betamarc|2 tabs BID
1794051|NCT00535028|Drug|AER 001|AER 001 25 mgs s.c. once daily for 28 days
1794052|NCT00535028|Drug|placebo|sterile saline
1794053|NCT00535041|Drug|Chemotherapy, radiation therapy & surgery|radiation and chemotherapy
1794054|NCT00535054|Drug|Tears Again|Liposome Eye Spray
1794055|NCT00535067|Behavioral|Questionnaire|Questionnaires taking 60 minutes total to complete.
1794056|NCT00535080|Drug|Metvix (methyl aminolevulinate)|Metvix (methyl aminolevulinate) (MAL), Photodynamic Therapy (PDT), cream, 160 mg/g. MAL cream will be applied for 3 hours then will be removed. The target area will then be exposed to red light (using a large-field LED light source: Aktilite 128) for 7 to 10 minutes at a dosage of 37 J/cm².
1794057|NCT00535093|Device|rapid streptococcal testing|Each patient will have both RST and standard throat culture performed. Final diagnosis and treatment will be determined by throat culture
1794058|NCT00535106|Device|Automated external defibrillator (Philips FR2+ AED)|Patients in this arm will be provided with immediate defibrillatory shock coupled with otherwise standard resuscitative efforts.
1794153|NCT00535808|Drug|nitroglycerine|Administration of nitroglycerine
1794059|NCT00535106|Device|SmartCPR|Patient in this arm will be treated with standard resuscitation efforts except that the first AED analysis will utilize an waveform-based algorithm to recommend either immediate defibrillation or delayed defibrillation for each patient.
1794060|NCT00535106|Other|Delayed defibrillation|In New York City only, all patients not initially treated by study personnel will receive other regional standard for resuscitation - delayed defibrillation.
1794061|NCT00535119|Drug|Carboplatin|Given IV
1794062|NCT00535119|Other|Laboratory Biomarker Analysis|Correlative studies
1794063|NCT00535119|Drug|Paclitaxel|Given IV
1794064|NCT00535119|Other|Pharmacological Study|Correlative studies
1794065|NCT00535119|Drug|Veliparib|Given PO
1794066|NCT00535132|Drug|Oral Risperidone|4 or 6 mg MG once daily for 0-2 weeks
1794067|NCT00535132|Drug|Paliperidone ER|6, 9 or 12 MG once daily for 4-6 weeks
1794068|NCT00535145|Drug|Treatment as usual (TAU), Paliperidone ER|Treatment as usual is the subject's current antipsychotic and doses for 4 weeks; TAU AND Paliperidone ER - per site investigator for 1 week; Paliperidone ER 6mg once daily for 1 week; Paliperidone ER-3 to 12mg tablets once daily for 4 weeks
1794069|NCT00535158|Drug|Ergocalciferol (Vitamin D 2)|50,000units once weekly for 8 weeks then every other week for 4 weeks
1794070|NCT00535197|Procedure|Infusion of autologous CD34+ stem cells into middle cerebral artery|intra-arterial infusion into ipsilateral MCA, via trans-femoral approach
1794071|NCT00535210|Behavioral|Cardiovascular training|The cardiovascular training group will receive their usual therapy plus 3 days of 30 minutes of exercise per week. This program will last for 6 weeks while the participant is in the hospital. The cardiovascular training program will include pushing and pulling on pulleys, wheeling over mats, punching a boxing bag, and using an arm ergometer. The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital.
1794072|NCT00535210|Behavioral|Balance training|The balance training group will receive their usual therapy plus 3 days of 30 minutes of sitting balance activities. This program will last for 6 weeks while the participant is in the hospital. The balance training program will include sitting on mats - moving arm support from in front of the body to behind body, moving from sitting to lying and back up, and catching soft foam ball thrown directly to centre of chest and throwing it back.
1794073|NCT00535223|Behavioral|Group Based Exposure Therapy|GBET is a 16-week program during which patients attend group therapy twice a week for three hours of group per day and are required to make two war trauma presentations to their group. These are recorded and the patients are required to listen to these recordings a minimum of 10 times. There are generally 10 patients per group and through the combination of making their own presentations, listening to recordings of these presentations, and hearing the presentations of the other nine group members, there are over 60 hours of exposure. Patients also learn about PTSD symptoms, sleep hygiene, specific stress/anger management techniques, and ways to cognitively restructure trauma-related thinking.
1794074|NCT00535223|Behavioral|Present Centered Group Therapy|"Present Centered Group Therapy includes psych-education about PTSD and a problem solving here and now focus."
1794075|NCT00535236|Biological|Comparator: V212|0.65 ml V212 in 4 dose regimen. Treatment period of 125 days
1794076|NCT00535236|Biological|Comparator: Placebo|0.65 ml V212 Pbo in 4 dose regimen. Treatment period of 125 days
1794077|NCT00535262|Drug|EmSam|Selegiline Transdermal System (STS); monoamine oxidase inhibitor patch
1794078|NCT00535275|Drug|Chemotherapy with platine|Docetaxel 75 mg/m² D1 + Cisplatine 75 mg/m² or Carboplatin AUC5 D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
1794079|NCT00535275|Drug|Chemotherapy without Cisplatine|Docetaxel 75 mg/m² D1 (D1=D22, 4 cycles) Docetaxel 75 mg/m² D1 (D1=D22, 2 cycles if disease control)
1794080|NCT00535288|Drug|Esmirtazapine|Four different doses (2.25, 4.5, 9.0, and 18 mg) encapsulated esmirtazapine tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
1794081|NCT00535288|Drug|Placebo|Encapsulated placebo tablets in Swedish Orange hard gelatin DB-B capsules for blinding purposes. Encapsulated tablets were administered orally once daily in the evening prior to sleep for 12 weeks.
1794082|NCT00535301|Device|grafted anterior prolapse repair|anterior vaginal prolapse repair with graft
1794083|NCT00535301|Procedure|sutured anterior vaginal prolapse repair|anterior vaginal prolapse repair with suture
1794084|NCT00535314|Drug|RTA 402 Dose1|
1794085|NCT00535314|Drug|RTA 402 Dose2|
1794086|NCT00535340|Drug|SR58611A|
1794087|NCT00535353|Drug|irinotecan hydrochloride|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
1794088|NCT00535353|Drug|olaparib|In Part A, a continuous oral AZD2281 dose will be given in combination with irinotecan given as a 90 minute infusion on day 1 every 21 days. In Part B, AZD2281 will be given on days 1-5 and irinotecan as a 90 minute infusion on day 3 each cycle. Cycles are repeated every 14 days.
1794089|NCT00535366|Drug|Tiotropium|Oral inhalation by HandiHaler® device
1794090|NCT00535366|Drug|Salmeterol|Oral inhalation from Diskus®
1794091|NCT00535366|Drug|Fluticasone|Oral inhalation from metered dose inhaler (MDI)
1794092|NCT00535366|Drug|Ciclesonide low|Oral inhalation from MDI
1794093|NCT00535366|Drug|Ciclesonide high|Oral inhalation from MDI
1794094|NCT00535366|Drug|Placebo|Oral inhalation from MDI
1794095|NCT00535379|Drug|Sunitinib|Patients will receive SUTENT 37.5mg (3 x 12.5mg capsules) PO daily in the morning after breakfast. After 2 weeks without treatment-related adverse events grade ≥ 2 (ECOG common toxicity criteria: refer to Protocol Attachment A.4) a SUTENT dose escalation to 50mg (4 x 12.5mg capsules) PO daily has to be performed. Treatment will continue until patients develop progression of disease or until unacceptable adverse events occur.
1794148|NCT00535782|Drug|Tocilizumab|Administered by intravenous infusion, 8 mg/kg every 4 weeks.
1794149|NCT00535782|Drug|Placebo|Placebo to tocilizumab administered by intravenous infusion every 4 weeks.
1794150|NCT00535782|Drug|Methotrexate|Administered orally or parenterally, 7.5-25 mg weekly.
1794151|NCT00535795|Radiation|Radiation Therapy|Radiation Therapy
1794096|NCT00535392|Drug|Levetiracetam|"Intravenous 100 mg/mL, twice a day, maximum of 4 days
Subjects on oral levetiracetam at study entry receive the same intravenous (IV) dosage (mg-for-mg) to their oral dose.
Dosage for subjects not on levetiracetam at study entry was based on weight: if <50 kg, the dose was 20 mg/kg/day (10 mg/kg/day twice daily); if weight ≥ 50 kg, the dose of levetiracetam intravenous (LEV IV) was 1000 mg/day (500 mg twice daily)."
1794097|NCT00535405|Drug|Atorvastatin 10 mg|Atorvastatin 10 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
1794098|NCT00535405|Drug|Ezetimibe 10 mg/simvastatin 20 mg|Ezetimibe 10 mg/simvastatin 20 mg and Placebo for atorvastatin once daily for 12 weeks
1794099|NCT00535405|Drug|Atorvastatin 20 mg|Atorvastatin 20 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
1794100|NCT00535405|Drug|Ezetimibe 10 mg/simvastatin 40 mg|Ezetimibe 10 mg/simvastatin 40 mg and Placebo for atorvastatin once daily for 12 weeks
1794101|NCT00535405|Drug|Atorvastatin 40 mg|Atorvastatin 40 mg and Placebo for ezetimibe and placebo for simvastatin once daily for 12 weeks
1794102|NCT00535418|Drug|Letrozole|
1794103|NCT00535431|Drug|AER 001|60 mg (in nebuliser), twice daily for 28 days
1794104|NCT00535431|Drug|placebo|Sterile saline nebulised, twice daily for 28 days
1794105|NCT00535444|Other|Parish nurse visit|One visit with the parish nurse in 2 weeks
1794106|NCT00535457|Other|Preoperative Magic Tricks|"Watching magic; Study patients will watch the anesthesiologist performing tricks (magic) before anesthesia induction."
1794108|NCT00535496|Drug|sugammadex|Participants will receive an intubating dose of 0.6 mg/kg rocuronium, followed by one or more maintenance doses of 0.15 mg/kg rocuronium, if necessary. Fifteen minutes after the last dose of rocuronium, 1.0 or 4.0 mg/kg sugammadex will be randomly administered by intravenous (IV) bolus dose based on actual body weight.
1794109|NCT00535509|Radiation|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
1794110|NCT00535509|Other|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
1794111|NCT00535509|Drug|Cisplatin-Docetaxel ± Trastuzumab|Chemo & RT
1794112|NCT00535522|Drug|TAK-285 Dose Escalation Cohorts|TAK-285 50 mg tablet, orally, once or twice daily for three weeks, followed by seven days off. Dose escalation to maximum tolerated dose, with possibility of continuous dosing per cycle (daily dosing for four weeks without a break between cycles).
1794113|NCT00535522|Drug|TAK-285 Recommended Phase 2 Dosing Cohort|Expanded cohort with dose and regimen dependent upon the safety profile of the maximally tolerated dose and schedule determined in the dose escalation phase of the study.
1794114|NCT00535535|Dietary Supplement|Fructose|Fructose, 0.5 g/kg
1794115|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 1 g/kg
1794116|NCT00535535|Dietary Supplement|Fructose and Glucose|Fructose:Glucose 1:1, 2g/kg
1794117|NCT00535548|Biological|Stem cell therapy|Injection of a hematopoietic stem cell suspension (50'000 CD 34+ cells per microliter) into the wound (1 microliter per cm2 of wound surface)
1794118|NCT00535561|Drug|Ferrous sulfate tablets 325 mg, po, TID|
1794119|NCT00535561|Drug|Ferrous sulfate plus levothyroxine|Combination of ferrous sulfate tablet 325mg plus levothyroxine tablet 25 micrograms, po, TID
1794120|NCT00535574|Drug|Bexarotene (Targretin LGD1069)|75 mg per day for 6 weeks
1794121|NCT00535574|Drug|bexarotene|75 mg/day 6 weeks
1794122|NCT00535587|Behavioral|Exercise|
1794123|NCT00535587|Drug|pyridostigmine|
1794124|NCT00535587|Drug|Placibo|
1794125|NCT00535587|Behavioral|Attention Control|
1794126|NCT00535613|Drug|Propofol|IV, single bolus at completion of anesthetic, 0.1 ml/kg
1794128|NCT00535639|Drug|Betula Verrucosa allergen extract|
1794129|NCT00535652|Drug|Ertapenem|powder for infusion, 1 gram I.V., single dose over 30 min.
1794130|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 14 days apart: 5 microgram per dose
1794131|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 5 microgram per dose
1794132|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 10 microgram per dose
1794133|NCT00535665|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|two-dose regimen with 28 days apart: 15 microgram per dose
1794134|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Twice daily, 14 days treatment.
1794135|NCT00535691|Drug|Tacrolimus Ointment 0.03%|Once daily, 14 days treatment.
1794136|NCT00535704|Behavioral|Strong African American Families-Teen Program|5 week educational program for teens and their caregivers.Each meeting lasts approximately 2 hours.
1794137|NCT00535704|Behavioral|FUEL|5 week educational program for teens and caregivers. Each weekly session lasts approximately 2 hours
1794138|NCT00535717|Procedure|uttarbasti (per urethral administration of medicated oil )|
1794139|NCT00535730|Biological|Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™|0.65 mL injection Zoster Vaccine, Live, (Oka-Merck) over 4 week vaccination period
1794140|NCT00535730|Biological|Comparator: placebo (concomitant-vaccine matched)|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL Placebo injection over 4 week vaccination period.
1794141|NCT00535730|Biological|Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23|Pneumococcal Vaccine, Polyvalent (23-valent) 0.5 mL injection over 4 week vaccination period.
1794142|NCT00535743|Drug|sugammadex (Org 25969)|Sugammadex (2, 4, 8, 12 and 16 mg/kg) was given as a reversal agent at 3 and 15 minutes following administration of 1.0 and 1.2 mg/kg of Esmeron®, respectively
1794143|NCT00535743|Drug|Placebo|5 mL NaCl 0.9%
1794144|NCT00535756|Drug|Creon|3 capsules Creon with 25000 lipase units per main meal (3 main meals) plus 2 capsules per snack (2-3 snacks)
1794145|NCT00535756|Drug|Placebo|Placebo
1794146|NCT00535769|Device|Electronic + no text message|Electronic monitor is attached but no text-messages are sent through cellular phones
1794147|NCT00535769|Device|Electronic monitor + text messages|Electronic monitor is attached and text messages are sent through cellphone to remind sunscreen use
1794154|NCT00535808|Drug|sevoflurane|Administration of Sevoflurane
1794155|NCT00535821|Device|Esophageal Doppler monitoring - CardioQ, Deltex Inc|6-hour hemodynamic optimization of severe sepsis or septic shock guided by EDM
1794156|NCT00535821|Device|Central line with CVP and continuous ScvO2 monitoring|6-hour hemodynamic optimization of severe sepsis or septic shock guided by CVP and ScvO2 monitoring
1794157|NCT00535834|Procedure|diagnostic procedure|
1794158|NCT00535834|Procedure|molecular diagnostic method|
1794159|NCT00535834|Procedure|protein expression analysis|
1794160|NCT00535847|Drug|Telaprevir|Tablet
1794161|NCT00535847|Drug|Ribavirin|Tablet
1794162|NCT00535847|Drug|Pegylated interferon alfa 2a|Solution for Injection
1794163|NCT00535860|Drug|Teriparatide|Daily for 96 days
1794164|NCT00535873|Drug|Lenalidomide|Starting dose of 5 mg (capsules) by mouth daily for 28 days, one cycle.
1794165|NCT00535886|Dietary Supplement|Man-made Trans FA|EA as 6% of total energy
1794166|NCT00535886|Dietary Supplement|Natural Trans FA|VA as 6% of total energy
1794167|NCT00535886|Dietary Supplement|Oleic Acid|OA as 6% of total energy
1794168|NCT00535912|Procedure|Stem cells autograft|Treatment by Intensive Chemotherapy and autograft
1794169|NCT00535925|Drug|current therapy|the patients have to be treated according the standard good medical practice by any center
1794170|NCT00535925|Drug|irbesartan|"Therapy for hypertension:
- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
1794171|NCT00535925|Drug|ramipril|"Therapy for hypertension:
- Step 1: irbesartan 300 mg/die and ramipril 10 mg/die"
1794172|NCT00535925|Drug|hydrochlorothiazide|"Therapy for hypertension
- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine <2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
1794173|NCT00535925|Drug|furosemide|"Therapy for hypertension
- Step 2: Diuretic (hydrochlorothiazide 12.5-25 mg/die if serum creatinine <2 mg/dl, furosemide 25-75 mg/die if serum creatinin ≥2 mg/dl)"
1794174|NCT00535925|Drug|amlodipine|"Therapy for hypertension
- Step 3: amlodipine up to 10 mg/die"
1794175|NCT00535925|Drug|atenolol|"Therapy for hypertension
- Step 4: atenolol up to 100 mg/die"
1794176|NCT00535925|Drug|doxazosin|"Therapy for hypertension
- Step 5: doxazosin up to 4 mg/die"
1794177|NCT00535925|Drug|clonidine|"Therapy for hypertension
- Step 6: clonidine"
1794178|NCT00535925|Drug|insulin|"Therapy for Hyperglycaemia (to achieve HbA1c <7):
- insulin"
1794179|NCT00535925|Drug|simvastatin|"Therapy for hypercholesterolemia:
- for reducing LDL cholesterol < 100 mg/dl: simvastatin up to 80 mg/die"
1794180|NCT00535925|Drug|fibrate|"Therapy for hypertriglyceridemia
- for reducing triglycerides < 150 mg/dl and/or increasing HDL cholesterol > 40-50 mg/dl: a fibrate"
1794181|NCT00535925|Drug|erythropoietin|"Treatment of anaemia:
- erythropoietin"
1794182|NCT00535925|Drug|aspirin|"Antiplatelet therapy (in all patients without contraindications):
- aspirin up to 160 mg/die"
1794183|NCT00535938|Other|botulinum toxin type A|There will be no protocol-mandated intervention with regard to physician treatment choice or management of patient condition once the patient is enrolled in the project.
1794184|NCT00535951|Drug|LBH589|
1794185|NCT00535977|Dietary Supplement|Broccoli|400g ITC-enriched broccoli per week for 12 months
1794186|NCT00535977|Dietary Supplement|Peas|400g frozen garden peas per week for 12 months
1794187|NCT00536003|Drug|progesterone|vaginal capsules containing 200 mg of natural progesterone, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
1794188|NCT00536003|Drug|placebo|vaginal capsules containing placebo, once a day, until 36 6/7 weeks of gestation or until preterm delivery (whichever occurs first).
1794189|NCT00536016|Drug|JSM6427|Weekly intravitreal injections for up to 4 weeks, first dose strength is one dose below the MTD. Dose strength concentrations: 1.5 mg/ml, 3 mg/ml, 7.5 mg/ml 04 15 mg/ml.
1794190|NCT00536042|Drug|Minocycline|addition of 150 mg to 250 mg po bid to standard asthma care regiment
1794191|NCT00536068|Drug|Acetylsalicylic acid, acetaminophen, diclofenac, naproxen, placebo|"Acetylsalicylic acid 100mg/po and acetaminophen 3x1g/po for 4 days
Acetylsalicylic acid 100mg/po and diclofenac 3x50mg/po for 4 days
Acetylsalicylic acid 100mg/po and naproxen 3x250mg/po for 4 days
Acetylsalicylic acid 100mg/po and placebo 3x1/po for 4 days"
1794192|NCT00536081|Drug|pegfilgrastim|6 mg s.c. 24-36 h post-chemotherapy
1794193|NCT00536094|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 45-minute psychotherapy sessions once a week for a period of approximately 12 weeks.
1794194|NCT00536094|Behavioral|Treatment as usual (TAU)|TAU includes 45-minute psychosocial treatment sessions once a week for a period of approximately 12 weeks.
1794195|NCT00536107|Drug|Gefitinib|250 mg oral
1794196|NCT00536107|Procedure|CT or MRI|performed at screening and every 6 weeks
1794197|NCT00536107|Drug|Docetaxel|60mg/m2 intravenous infusion
1794198|NCT00536120|Biological|BG00002 (natalizumab)|
1794199|NCT00536120|Biological|keyhole limpet hemocyanin (KLH)|KLH 1 mg administered subcutaneously (SC) in accordance with the Immucothel investigator's brochure.
1794200|NCT00536120|Biological|tetanus diphtheria toxoid vaccine (Td)|Td administered in accordance with the manufacturer's prescribing information.
1794201|NCT00536133|Drug|Zinc|5 ml of syrup containing zinc gluconate equivalent to 10 mg of elemental zinc per day for 60 days
1794202|NCT00536133|Other|placebo|5 ml of syrup, identical in taste, color and consistency to the syrup given to zinc group, but containing no zinc
1794203|NCT00536159|Other|Medicaid Maternal and Infant Support Services|Enhanced services include home visiting, transportation, psychosocial counseling, multidisciplinary planning, case management, nutritional guidance, and pregnancy and parenting education during pregnancy and infancy. The services are delivered primarily by nurses with occasional visits by social workers or nutritionists. In the county of the study (Kent), women who were assessed were provided intervention services.
1794241|NCT00542451|Drug|Paclitaxel|Every week for 12 weeks
1794294|NCT00543153|Behavioral|Interview|Interview lasting approximately 30-45 minutes.
1794204|NCT00536159|Other|Nurse-CHW team|A nurse and two CHWs functioned as a team, using visit and clinical guidelines that detailed expected care. Each team provided services for approximately 50-60 families. While occasional visits were made by both providers, most visits were made by either provider alone. Nurses guided the CHW care, led a multidisciplinary team assessment (with social workers, nutritionists, and others), provided crisis intervention and case management, assessed and managed health problems (including screening for depression and mental health care), and had periodic office visits with prenatal providers. CHWs provided relationship-based support by attempting weekly prenatal contact that alternated phone and face-to-face visits and used peer role modeling and personal empowerment approaches.
1794205|NCT00536172|Drug|Escitalopram|Participants take 10 mg for 1 week and then 20 mg for 15 weeks.
1794206|NCT00536172|Drug|Placebo|Placebo distribution matches the active medication.
1794207|NCT00536185|Dietary Supplement|Fish Oil|capsules, 5.0 g/d fish oil concentrate (3.0 g/d EPA + DHA), 6 weeks
1794208|NCT00536185|Dietary Supplement|Placebo|capsule, 5.0 g/d corn/soybean oil (50/50 mixture), 6 weeks
1794209|NCT00536198|Drug|Sertraline|50 mg of sertraline will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg. Women who report moderate to severe side effects will be allowed to reduce their dose to 25 mg of sertraline and to increase the dose at the next cycle unless rate-limiting side effects continue.
1794210|NCT00536198|Drug|Placebo|50 mg of placebo will be taken at the onset of premenstrual symptoms through the first few days of menses. If a participant shows an insufficient response to this dose, the dose may be increased to 100 mg.
1794211|NCT00542243|Drug|Finasteride|Finasteride (5mg) will be given once per day for 6 months.
1794212|NCT00542243|Drug|Placebo|Placebo will be given once a day for 6 months.
1794213|NCT00542256|Device|Active transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 weekdays of up to 6 hours of training of the affected arm combined with application of tDCS over the primary motor cortex for 40 minutes.
1794214|NCT00542256|Device|Sham transcranial Direct Current Stimulation / Constraint Induced Movement Therapy|14 days of constraint induced movement therapy with 10 days of up to 6 hours of training in the affected arm and sham tDCS applied over the primary motor cortex for 40 minutes with active current applied for 30 seconds.
1794215|NCT00542269|Drug|Amlodipine|amlodipine 5-10 mg tablets. Patients received amlodipine 5 mg (or 10 mg if they were receiving 10 mg prior to study start). Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
1794216|NCT00542269|Drug|Aliskiren|aliskiren 150-300 mg tablets. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
1794217|NCT00542269|Drug|Ramipril|ramipril 5-10 mg capsules. Each dose was to be taken orally with water once daily at approximately 8:00 A.M. with or without food, except on the morning of an office/clinic visit, when the study drug was to be taken at the site after the visit procedures had been completed.
1794218|NCT00542295|Drug|alverine citrate and simeticone|
1794219|NCT00542295|Drug|placebo|
1794220|NCT00542308|Drug|Zalutumumab|Individual dose titration weekly i.v. doses
1794221|NCT00542321|Other|Manual turn|Manual turn from side to back to side every 2 hours by nurses while patient receiving mechanical ventilation
1794222|NCT00542321|Device|kinetic therapy bed|Continuous, automated turning to a maximum of 45 degrees in the lateral positions while the patient is receiving mechanical ventilation
1794223|NCT00542347|Drug|Esomeprazole first|"esomeprazole 20mg po once per day for 7 days
24hr pH study on day 7
followed by washout for 7 days
generic omeprazole 20mg po once per day for 7 days
24hr pH study on day 7"
1794224|NCT00542347|Drug|Generic omeprazole first|"generic omeprazole 20mg po once per day for 7 days
24hr pH study on day 7
followed by washout for 7 days
esomeprazole 20mg po once per day for 7 days
24hr pH study on day 7"
1794225|NCT00542360|Behavioral|Marketing program to motivate exercise class participation|Using qualitative research methods, a targeted social marketing program, including a 'marketing toolkit,' was developed to motivate participation in exercise classes by older adult members of churches. The Health Belief and Transtheoretical Models formed the theoretical basis for the social marketing planning process and guided program design. The marketing program aimed to increase exercise class attractiveness, usability, and uptake by reducing barriers and costs, and using messaging about benefits and enhanced convenience to motivate participation. The intervention was implemented through churches.
1794226|NCT00542373|Procedure|Portable Spectroscopy System|Imaging system that shines different wavelengths (colors) of light in the mouth and can collect and analyze fluorescence and reflected light.
1794227|NCT00542373|Procedure|Multispectral Digital Microscope|Imaging system that takes fluorescence and reflectance pictures through a dental microscope. Different colors of light are used to shine in the mouth and pictures are taken using a digital camera.
1794228|NCT00542373|Procedure|Fast Excitation-Emission Matrix System|Different colors of light are directed through fibers to the lining of the mouth and then light is collected and sent to a special camera and a computer to be analyzed.
1794229|NCT00542386|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
1794230|NCT00542386|Drug|Placebo|3g to 15g/day (3 times a day), Tablet, 12 weeks of fixed dose of study
1794231|NCT00542399|Drug|Levemir (insulin detemir)|Levemir once a day
1794232|NCT00542399|Drug|Levemir twice a day|Levemir twice a day
1794233|NCT00542412|Drug|Riluzole|
1794394|NCT00543920|Drug|MK0777|
1794242|NCT00542451|Drug|Trastuzumab|Once a week for twelve weeks Then once a week or once every three weeks for 40 weeks
1794243|NCT00542464|Biological|Imprime PGG TM for Injection|Doses of 1.0 mg/kg-4.0 mg/kg of Imprime PGG administered over 1-2 hr for 7 consecutive days
1794244|NCT00542490|Radiation|Vaginal Cuff Brachytherapy|Clinical stage I-II endometrial cancer surgically staged. Stage I-II with any high-intermediate risk (H-IR) features OR Stage IIb any histology OR Stage I-II Papillary Serous or Clear Cell Histology Vaginal cuff brachytherapy Followed by Paclitaxel (175 mg/m2 over 3 hours) and carboplatin (AUC 6) Chemotherapy X 3 (high risk)
1794245|NCT00542516|Drug|Hydroxyethyl Starch|Dosage: 30ml/kg; frequency: one time; duration: 60min
1794246|NCT00542516|Drug|Ringer's lactate|Dosage: 30ml/kg; frequency: one time; duration: 60min.After 10ml-kg-h both groups
1794247|NCT00542529|Biological|Imprime PGG TM for Injection|Doses of 2.0 and 4.0 mg/kg intravenous Imprime PGG administered over 1-2 hr for up to 4 consecutive days
1794248|NCT00542542|Procedure|Paravertebral Block|Paravertebral block given as a bolus injection into the paravertebral space.
1794249|NCT00542542|Drug|Propofol|2-2.5 mg/kg IV over 1-4 hours during surgery.
1794250|NCT00542542|Drug|Fentanyl|50-250 mcg IV over 1-4 hours during surgery.
1794251|NCT00542542|Drug|Ropivacaine|Ropivacaine given by injection into the paravertebral space along the spinal canal.
1794252|NCT00542542|Drug|Midazolam|0.08 mg/kg IV over 1-4 hours during the surgery.
1794253|NCT00542555|Drug|Placebo|At 13 weeks, the patients receiving placebo were re-randomized to receive either naproxcinod 375 mg bid or naproxcinod 750 mg bid in a 1:1 ratio in the 301E study.
1794254|NCT00542555|Drug|Naproxcinod 375 mg|
1794255|NCT00542555|Drug|Naproxen|
1794256|NCT00542555|Drug|Naproxcinod 750 mg|
1794257|NCT00542854|Device|MP3|4 different brands of MP3 players will be tested at 3 distances from ICD/pacemaker site in children and adults with congenital heart disease.
1794258|NCT00542880|Drug|Symbicort Turbuhaler (budesonide/formoterol) 320/9 μg|
1794259|NCT00542880|Drug|Seretide Diskus (salmeterol/fluticasone) 50/500 μg|
1794260|NCT00542893|Drug|Genasense® (G3139, oblimersen sodium)|
1794261|NCT00542893|Drug|Genasense followed by DTIC; then DTIC alone|Cycle 1: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2 Cycle 2: DTIC 1000 mg/m2
1794262|NCT00542893|Drug|DTIC alone; then Genasense followed by DTIC|Cycle 1: DTIC 1000 mg/m2 Cycle 2: Genasense 7 mg/kg/day for 5 days followed by DTIC 1000 mg/m2
1794263|NCT00542906|Other|localization|localization of the several types of somatosensory stimuli
1794264|NCT00542919|Drug|enzastaurin|1125 mg loading dose then 500 mg, oral, daily until progressive disease
1794265|NCT00542932|Other|Exercise|"Watched Film A (promotional film)
Film B (30 min exercise video) asked to to perform 4 times a week for 6 weeks at home"
1794266|NCT00542945|Device|ICD|Implantation of an ICD
1794267|NCT00542945|Other|Optimal medical treatment|ACE-inhibitors or ARB Beta-blocker Optional aldosterone antagonist
1794268|NCT00542958|Drug|NK012|Dose escalation starting at 9 mg/m2 in UGT1A1*28 (wt/wt and wt/*28) genotype patients, IV (in the vein) over 30 minutes on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity or disease progression develops: patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient, as long as toxicity remains acceptable.
1794269|NCT00542971|Drug|Idarubicin|12 mg/m2 IV over 1 hour daily (days 1-3)
1794270|NCT00542971|Drug|Sorafenib|Starting dose 400 mg by mouth for 7 days
1794271|NCT00542971|Drug|Ara-C|1.5 g/m2 IV over 24 hours daily (days 1-4)
1794272|NCT00542984|Drug|teriparatide 20 micrograms/day subcutaneous|
1794273|NCT00542984|Drug|salmon calcitonin 100 IU/day subcutaneous|
1794274|NCT00542997|Biological|Human Normal Immunoglobulin for Subcutaneous Administration (IGSC)|IgPro20 is a liquid formulation of normal human IgG at a concentration of 20% administered as a SC infusion at weekly intervals. The initial weekly dose was determined based on subjects' previous treatment. Dose adjustments could be performed during the wash-in/wash-out period at the discretion of the investigator.
1794275|NCT00543010|Drug|MK0767|
1794276|NCT00543023|Drug|teriparatide 20 micrograms/day subcutaneous|
1794277|NCT00543023|Drug|salmon calcitonin 100 IU/day subcutaneous|
1794278|NCT00543036|Device|H-Coil deep TMS|
1794279|NCT00543049|Drug|Sunitinib|Sunitinib, oral, 50mg once daily, 28 days then paused for 14 days, for up to one year
1794280|NCT00543049|Drug|SUNITINIB|Sunitinib, oral, 37,5 mg once daily continuously, up to one year
1794285|NCT00543075|Drug|Genasense (oblimersen, G3139)|3 mg/kg/day by intravenous infusion for up to 48 hours
1794286|NCT00543101|Drug|Darunavir (DRV/r)|Switch to DRV/r at a dose of 600/100 BID for 48 weeks
1794287|NCT00543101|Drug|continue on current dual boosted PI|Continue on current dual boosted PI until week 24. At week 24, participants will be allowed to cross over to the DRV/r arm provided that they have maintained virologic suppression (< 400 copies/ml) for the first 24-weeks of the study and be followed for an additional 24 weeks
1794288|NCT00543114|Drug|Lenalidomide|Dose level will depend upon time the participant enrolls on the study: Given orally once a day for 3 weeks followed by a one week rest period
1794289|NCT00543114|Drug|Fludarabine|Dose level will vary depending upon when participant enters the trial: Given intravenously for 3-5 days
1794290|NCT00543114|Drug|Rituximab|Given intravenously on Day 1 of each 28 day cycle
1794291|NCT00543127|Drug|fulvestrant + anastrozol|500 mg Im Fulvestrant day 0, 250 mg days 14 and 28(charge dose); later 250 mg each 28 days during 3 years plus 1 mg oral anastrozol per day during 5 years.
1794292|NCT00543127|Drug|Anastrozol|1 mg oral Anastrozol per day during 5 years.
1794293|NCT00543140|Device|REALIZE™ Swedish Adjustable Gastric Band|Laparoscopic placement of the Swedish Adjustable Gastric Band
1794295|NCT00543166|Drug|dehydroepiandrosterone|50 mg of dehydroepiandrosterone in the morning for 4 months in the treatment group.
1794296|NCT00543179|Drug|Somatuline (Lanreotide Autogel®)|
1794297|NCT00543205|Drug|Genasense® (G3139, oblimersen sodium)|Genasense 7 mg/kg/day for 5 days
1794298|NCT00543218|Drug|teriparatide 20 micrograms/day subcutaneous|
1794299|NCT00543218|Drug|calcitonin 100 IU/day subcutaneous|
1794300|NCT00543231|Drug|G3139, Oblimersen sodium, Bcl-2 antisense oligonucleotide|
1794301|NCT00543244|Drug|Pegylated interferon alfa and ribavirin|"Pegylated interferon alfa-2a 180 ug/week or pegylated interferon alfa-2b 1.5 ug/kg/week Ribavrin 800-1200 mg/day (genotype 1: < 75 kg 1000 mg/day, >=75 kg 1200 mg/day; genotype 2: 800 mg/day)
HCV genotype: baseline (Day 0) HCV RNA (real time PCR test): baseline (Day 0), Day 1 (4,8,12 hours after pegylated interferon + ribavirin), Day 2 (24,36 hours), Day 3(48 hours), Day 4 (72 hours), Day 5 (96 hours), Week 2,4,6,8,12,16,20,24, and 28,32,36,40,44,48,72 (for genotype 1 with 48 weeks of treatment), and 48 (for genotype 1 or 2 with 24 weeks of treatment)"
1794302|NCT00543257|Other|Use of paper forms to write down information|Parents will be asked to write down information specific to their child's ADHD using paper forms.
1794303|NCT00543257|Other|Computer|Parents will use a computer to complete data entry on information specific to their child's ADHD care
1794304|NCT00543270|Device|Powerlink infrarenal bifurcated stent graft delivery system|Endovascular abdominal aortic aneurysm repair
1794305|NCT00543270|Procedure|Open Surgery|Open surgical abdominal aortic aneurysm repair
1794306|NCT00543296|Drug|0.59 mg Fluocinolone Acetonide implant|0.59 mg Fluocinolone Acetonide implant
1957377|NCT02438358|Drug|LUM015|
1794310|NCT00543335|Drug|Sorafenib|Starting dose 200 mg PO (by mouth) Daily
1794311|NCT00543335|Procedure|Radiation Therapy|45 Gy total in 15 radiation treatments: 3 Gy per day, 5 days a week for 3 weeks
1794312|NCT00543348|Procedure|CUTTING BALLOON ANGIOPLASTY|CUTTING BALLOON
1794313|NCT00543348|Procedure|HIGH PRESSURE BALLOON|
1794314|NCT00543361|Drug|MK0767|Duration of Treatment: 52 Weeks
1794315|NCT00543361|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 52 Weeks
1794316|NCT00543361|Drug|Comparator: metformin|Duration of Treatment: 52 Weeks
1794317|NCT00543374|Drug|Placebo|Placebo
1794318|NCT00543374|Drug|PROCHYMAL adult human mesenchymal stem cells|intravenous infusion four times over two weeks; possibly repeated once
1794319|NCT00543387|Drug|MK-5108|MK-5108 will be administered orally, every 12 hours (Q12H) during the first 2 days of each cycle. Cycle length will be 14-21 days in Panel 1 and 21 days in Panel 2.
1794320|NCT00543387|Drug|docetaxel|intravenous (I.V.) dose of docetaxel (60 mg/m^2)
1957378|NCT02438358|Device|LUM 2.6 Imaging Device|
1794323|NCT00543413|Drug|MK8141|MK8141 250 mg tablet once daily; 500 mg tablet once daily 4 week treatment period
1794324|NCT00543413|Drug|Comparator: placebo (unspecified)|MK8141 Pbo tablet once daily. 4 week treatment period.
1794325|NCT00543413|Drug|Enalapril|Enalapril 20 mg tablet once daily. 4 week treatment period.
1794326|NCT00543426|Drug|Fuzheng Huayu Tablets|Tablet,three times a day,four tablets one time
1794327|NCT00543426|Drug|sham Fuzheng Huayu Tablets (placebo)|Tablet, three times a day, four tablets one time
1794330|NCT00543452|Other|Oxygen|4 liters of oxygen a minute
1794331|NCT00543452|Other|Air from a placebo oxygen delivery|4 liters a minute of air from a placebo device
1794332|NCT00543465|Drug|MK0782|
1794333|NCT00543478|Drug|Saccharomyces boulardii|250mg, twice a day in sachets, for 8 weeks
1794334|NCT00543478|Drug|Methyl cellulose powder (low viscosity)|twice a day sachets for 10 weeks
1794335|NCT00543491|Drug|MK0767|
1794336|NCT00543504|Drug|Bevacizumab|2.5 mg/kg By Vein Over 90 Minutes.
1794337|NCT00543504|Drug|Sorafenib|200 mg By Mouth Daily for 28 Days
1794338|NCT00543504|Drug|Erlotinib|50 mg By Mouth Daily for 28 Days.
1794339|NCT00543504|Drug|Trastuzumab|Loading 2 mg/kg by vein then Maintenance 1 mg/kg by vein on Day 1
1794340|NCT00543504|Drug|Lapatinib|250 mg By Mouth Daily for 21 Days.
1794341|NCT00543504|Drug|Sunitinib|12.5 mg orally daily for 4 weeks, then 2 weeks off.
1794342|NCT00543504|Drug|Cetuximab|Loading 100 mg/m² by vein and Maintenance 75 mg/m² by vein on Days 1, 8, 15, 22
1794343|NCT00543517|Drug|MK0767|
1794344|NCT00543530|Drug|MK0831|
1794345|NCT00543543|Biological|Comparator: GARDASIL|GARDASIL (quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen
1794346|NCT00543543|Biological|Experimental: V503|V503 (9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine), 0.5 mL injection in 3 dose regimen (and a fourth injection for Cohort 1 only).
1794347|NCT00543556|Drug|MK0767|
1794348|NCT00543569|Drug|Alefacept|Administered as a 7.5 mg intravenous bolus on day 0 (intraoperatively, prior to kidney revascularization) and Day 3; subsequently administered subcutaneously either weekly or every 2 weeks.
1794349|NCT00543569|Drug|tacrolimus|The initial dose of tacrolimus was administered orally within 48 hours post-transplant. Subsequent doses were to be adjusted to achieve target whole blood trough concentrations.
1794395|NCT00543933|Drug|iNO administered|iNO at 40 ppm through a non-rebreather mask for 5 minutes
1957380|NCT02437318|Drug|Fulvestrant|
1957381|NCT02437318|Drug|Alpelisib|
1957382|NCT02437318|Drug|Alpelisib placebo|
1794350|NCT00543569|Drug|basiliximab|Administered as a 20 mg bolus injection within 2 hours prior to transplantation and a 20 mg bolus injection on Day 3.
1794351|NCT00543569|Drug|mycophenolate mofetil|Administered at 750 mg twice per day orally or intravenously for patients enrolled under Amendment 6 or earlier and at 1000 mg twice per day orally or intravenously for patients enrolled under Amendment 7. The dose of MMF could be adjusted based on clinical symptoms.
1794352|NCT00543569|Drug|Corticosteroids|Corticosteroids were administered as a 500 to 1000 mg intravenous bolus on Day 0 and a 125 to 250 mg methylprednisone (or equivalent oral/intravenous corticosteroid dose) on Day 1. Oral prednisone was to be tapered per protocol.
1794353|NCT00543582|Drug|MGCD0103 and Azacitidine|"In Part 1 of the study, up to 22 people to enroll will receive a single, oral dose (75 mg gelcap) of MGCD0103 and FB-MGCD0103 during their first 2 weeks in the study. Up to 22 additional people will receive a single dose of both MGCD0103 and TA-FB-MGCE0103. The next group of people to enroll will receive 2 different single doses (25, 50, 100 mg) of FB-MGCD0103 or TA-FB-MGCD0103 during their first 2 weeks in the study.
In Part 2 of the study, from Day 1-5 of each 28-day cycle, all subjects will receive a dose of azacitidine (75 mg/m2) either subcutaneously or through an intravenous device, and on days 5, 8, 10, 12, 15, 17, 19, 22, 24, 26, a single, oral dose (85 mg) of MGCD0103 until progression or unacceptable toxicity develops."
1794354|NCT00543595|Drug|MK0916|
1794355|NCT00543608|Drug|iclaprim|
1794356|NCT00543608|Drug|vancomycin|
1794357|NCT00543621|Other|daily enteral nutritional product and/or behavioral changes|
1794358|NCT00543634|Drug|Premarin/MPA|0.625 mg/2.5 mg X4
1794359|NCT00543634|Drug|Premarin/MPA|0.625 mg/5 mg X 2
1794360|NCT00543634|Drug|Provera 10 mg|2.5 mg of MPA, 4 tablets dissoved in water
1794361|NCT00543647|Drug|Fenofibrate 160 mg tablet|
1794362|NCT00543647|Drug|Placebo|
1794363|NCT00543660|Procedure|Descemet Stripping Automated Endothelial Keratoplasty (DSAEK)|
1794364|NCT00543673|Other|Milk based formula A|feed as per HCP directions
1794365|NCT00543673|Other|#2 Standard formula|Feed as per HCP directions
1794366|NCT00543673|Other|#3 Human Milk|Feed as per HCP directions
1794367|NCT00543673|Other|Milk based formula C|Feed as per HCP direction
1794368|NCT00543686|Drug|Montelukast|Intake of Montelukast
1794369|NCT00543686|Drug|Fluticasone|Intake of Fluticasone
1794370|NCT00543712|Drug|PRO95780|Intravenous repeating dose
1794371|NCT00543725|Drug|TMC278|25 mg tablet once daily for 96 weeks
1794372|NCT00543725|Drug|efavirenz|600 mg tablet once daily for 96 weeks
1794373|NCT00543738|Drug|MK0767|
1794374|NCT00543751|Drug|MK0767|
1794375|NCT00543764|Other|Use of an intraoperative pathway|Utilization of an intraoperative pathway
1794376|NCT00543777|Diagnostic Test|Magnetic Resonance Elastogram|Pneumatic driver will be placed over the upper abdomen. Patient will feel a vibration (like a cell phone or beeper vibrating). This vibration will create very small waves in the body. The scanner will then receive the vibrations from the liver and use them to create images of the liver tissue.
1794377|NCT00543777|Diagnostic Test|2-Point Dixon Magnetic Resonance Imaging|Imaging performed after the MRE procedure and lasting 20-60 seconds. This procedure is useful in identifying fat tissue.
1794378|NCT00543790|Drug|PRA-027|PRA-027 capsules; cohort-specific doses or 40, 120, 240 or 500 mg; 1 dose daily for 28 days
1794379|NCT00543816|Drug|MK0767|
1794380|NCT00543829|Drug|doxorubicin, docetaxel, tamoxifen|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion) with tamoxifen (30 mg tablet p.o. for 5 years post surgery)
1794381|NCT00543829|Drug|doxorubicin, docetaxel|Every 14 days to a total of 4 cycles of doxorubicin (50 mg/m², 15 minutes i.v. infusion) and docetaxel (75 mg/m², 1 hour i.v. infusion)
1794382|NCT00543842|Drug|Bevacizumab|5 mg/kg By Vein Every 2 Weeks x 3 Doses (Weeks 1, 3, 5)
1794383|NCT00543842|Drug|Capecitabine|Starting Dose 650 mg/m^2 By Mouth Twice Daily Monday-Friday x 6 Weeks
1794384|NCT00543842|Drug|Erlotinib|Starting Dose 50 mg By Mouth Daily Weeks 1-3
1794385|NCT00543842|Radiation|Radiation Therapy|30 minute radiation treatments, dose of 50.4 Gy once daily on 5 consecutive days, for up to 5 weeks and 3 days, totaling 28 treatments
1794386|NCT00543842|Procedure|Surgery|At least 8 weeks after radiation therapy, surgical removal of rectal tumor
1794387|NCT00543855|Drug|3 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.
Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
1794388|NCT00543855|Drug|5 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.
Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).
Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 84 (10 weeks)."
1794389|NCT00543855|Drug|10 mg Donepezil hydrochloride|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.
Treatment Period: One 3 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 1- Day 14 (2 weeks).
Followed by one 5 mg Donepezil hydrochloride tablet by mouth plus one Donepezil hydrochloride placebo tablet by mouth, once daily after breakfast for Day 15- Day 42 (4 weeks).
Followed by two 5 mg Donepezil hydrochloride tablets (10 mg) by mouth, once daily after breakfast for Day 43 - Day 84 (6 weeks)."
1794390|NCT00543855|Drug|Placebo|"Observation Period: Two Donepezil hydrochloride placebo tablets once daily by mouth after breakfast for 2 weeks.
Treatment Period: Two Donepezil hydrochloride Placebo tablets by mouth, once daily for 12 weeks (Day 1- Day 84) after breakfast."
1794391|NCT00543868|Drug|MK0782|
1794392|NCT00543881|Device|Remote patient monitoring (Partnership for the Heart)|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits plus daily monitoring of ECG, weight, blood pressure, self-report of health status, weekly monitoring of physical fitness
1794393|NCT00543881|Device|Usual care group|Guideline-based care in heart failure (NYHA II-III) including at least 5 scheduled doctor's visits
1794396|NCT00543946|Drug|GAP-134|24-Hour IV infusion, SAD
1794397|NCT00543959|Drug|MK0533|Initially a 12-wk study of MK0533 30mg, switching at week 12 to a study of daily administration MK0533 5mg, MK0533 15mg, MK0533 30mg. Study period is a total of 24-wks.
1794398|NCT00543959|Drug|Comparator: Placebo (unspecified)|MK0533 Placebo; MK0533 5mg; MK0533 15mg; MK0533 30mg. Study period is a total of 24 wks.
1794399|NCT00543959|Drug|Comparator: pioglitazone|pioglitazone 45mg. Study period is a total of 24 wks.
1794400|NCT00543972|Drug|AVE9633|Intravenous Infusion
1794401|NCT00543985|Procedure|Stress Echocardiography|Echocardiography was performs prior to and within 60 seconds of completing the standard Bruce treadmill protocol.
1794402|NCT00543998|Device|Optical Measurement transillumination|Optical Measurement of sinus
1794403|NCT00544011|Biological|bevacizumab|
1794404|NCT00544011|Drug|capecitabine|
1794405|NCT00544011|Drug|fluorouracil|
1794406|NCT00544011|Drug|irinotecan hydrochloride|
1794407|NCT00544011|Other|diagnostic laboratory biomarker analysis|
1794408|NCT00544037|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Standard Therapy for Multiple Sclerosis
1794409|NCT00544050|Drug|Levetiracetam|
1794410|NCT00544063|Drug|irinotecan hydrochloride|
1794411|NCT00544063|Drug|oxaliplatin|
1794412|NCT00544076|Drug|sildenafil citrate|Given orally
1794413|NCT00544076|Drug|alprostadil|Given intraurethrally
1794414|NCT00544076|Procedure|robotic-assisted laparoscopic surgery|Undergo prostatectomy
1794415|NCT00544076|Procedure|quality-of-life assessment|Ancillary studies
1794416|NCT00544076|Other|questionnaire administration|Ancillary studies
1794417|NCT00544115|Drug|busulfan|
1794418|NCT00544115|Drug|cyclophosphamide|
1794419|NCT00544115|Drug|cyclosporine|
1794420|NCT00544115|Drug|etoposide|
1794421|NCT00544115|Drug|fludarabine phosphate|
1794422|NCT00544115|Drug|melphalan|
1794423|NCT00544115|Drug|methotrexate|
1794424|NCT00544115|Drug|mycophenolate mofetil|
1794425|NCT00544115|Drug|sirolimus|
1794426|NCT00544115|Drug|tacrolimus|
1794427|NCT00544115|Procedure|allogeneic hematopoietic stem cell transplantation|
1794428|NCT00544115|Procedure|peripheral blood stem cell transplantation|
1794429|NCT00544115|Radiation|total-body irradiation|
1794430|NCT00544128|Drug|lamivudine, abacavir , ritonavir, atazanavir|Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg
1794431|NCT00544128|Drug|emtricitabine, tenofovir, ritonavir, atazanavir|Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
1794432|NCT00544154|Drug|CDP870|
1794433|NCT00544167|Drug|Doxorubicin|
1794434|NCT00544167|Drug|Cyclophosphamide|
1794435|NCT00544167|Drug|Paclitaxel|
1794436|NCT00544167|Drug|Sorafenib|
1794437|NCT00544180|Drug|Risedronate|
1794438|NCT00544193|Drug|gemcitabine hydrochloride|
1794439|NCT00544193|Genetic|polymerase chain reaction|
1794440|NCT00544193|Other|immunohistochemistry staining method|
1794441|NCT00544193|Procedure|conventional surgery|
1794442|NCT00544193|Radiation|intraoperative radiation therapy|
1794443|NCT00544193|Radiation|radiation therapy|
1794444|NCT00544206|Other|standard enteral feeding product|16 hrs daily x 5 days
1794445|NCT00544206|Other|Diabetes specific feeding product|16 hrs daily for 5 days
1794446|NCT00544219|Biological|rituximab|375 mg/m2 i.v. per cycle
1794447|NCT00544219|Drug|cyclophosphamide|750 mg/m2 i.v. per cycle
1794448|NCT00544219|Drug|doxorubicin hydrochloride|50 mg/m2 i.v. per cycle
1794449|NCT00544219|Drug|prednisone|100 mg/day p.o. per cycle
1794450|NCT00544219|Drug|vincristine sulfate|1.4 mg/m2 (max. 2.0 mg) i.v. per cycle
1794451|NCT00544219|Procedure|positron emission tomography|PET Scan during treatment
1794452|NCT00544232|Drug|Epirubicin, paclitaxel, cyclophosphamide, Methotrexate, 5 FU, darbepoetin alfa|"Epirubicin (90 mg/m2) d1, q21d - 4× / cyclophosphamide (600 mg/m2) d1, q21d - 4× followed by paclitaxel (175 mg/m2) d1, q21d - 4×
+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first epirubicin dose (day 1) to 14 days after the last dose of paclitaxel"
1794453|NCT00544232|Drug|Epirubicin, Cyclophosphamide, Paclitaxel, dabepoetin alfa|"Epirubicin (150 mg/m2) d1, q14d - 3× followed by paclitaxel (225 mg/m2) d1, q14d - 3×, followed by CMF d1/d8, q28d - 3× Obligatory pegfilgratim 6 mg, subcutaneous injection on day 2 after epirubicin and/or paclitaxel and secondary prophylactic dose after CMF
+/- Darbepoetin alfa 1 × 4.5 μg/kg of body weight every two weeks with the start of the first dose of epirubicin (day 1) until 14 days after the last dose of CMF"
1794454|NCT00544245|Behavioral|Self monitoring of estimated energy balance|Participant estimation of energy intake and energy expenditure
1794455|NCT00544258|Drug|PEP005|
1794456|NCT00544271|Biological|INFANRIX|
1794457|NCT00544271|Biological|BOOSTRIX|
1794458|NCT00544271|Biological|HAVRIX|
1794459|NCT00544284|Drug|bortezomib|
1794460|NCT00544284|Drug|temozolomide|
1794461|NCT00544284|Other|pharmacological study|
1794462|NCT00544297|Drug|PEP005 gel|Two day application, 0.05%
1794463|NCT00544310|Biological|Anti adhesion agent|Adhesions prevention
1794464|NCT00544323|Device|oral implant|
1794465|NCT00544336|Other|questionnaire administration|no intervention
1794466|NCT00544336|Other|survey administration|no intervention
1794467|NCT00544336|Procedure|quality-of-life assessment|no intervention
1794468|NCT00544349|Biological|cetuximab|
1794469|NCT00544349|Drug|fluorouracil|
1794470|NCT00544349|Drug|leucovorin calcium|
1794471|NCT00544349|Drug|oxaliplatin|
1794472|NCT00544362|Biological|cetuximab|
1794473|NCT00544362|Drug|cisplatin|
1794474|NCT00544362|Drug|fluorouracil|
1794475|NCT00544362|Procedure|conventional surgery|
1794476|NCT00544375|Device|Optical measurement|Optical measurement neonatal tissues
1794477|NCT00544388|Drug|levocetirizine dihydrochloride|
1794478|NCT00544401|Other|Hypnopuncture (Hypnosis+Acupuncture)|hypnosis and acupuncture
1794479|NCT00544414|Drug|cisplatin|
1794480|NCT00544414|Drug|docetaxel|
1794481|NCT00544414|Drug|fluorouracil|
1794482|NCT00544414|Drug|gemcitabine hydrochloride|
1794483|NCT00544414|Drug|leucovorin calcium|
1794484|NCT00544414|Genetic|gene expression analysis|
1794485|NCT00544414|Genetic|protein expression analysis|
1794486|NCT00544414|Other|laboratory biomarker analysis|
1794487|NCT00544414|Procedure|adjuvant therapy|
1794488|NCT00544414|Procedure|biopsy|
1794489|NCT00544414|Procedure|conventional surgery|
1794490|NCT00544414|Procedure|neoadjuvant therapy|
1794491|NCT00544414|Procedure|quality-of-life assessment|
1794492|NCT00544414|Radiation|radiation therapy|
1794493|NCT00544427|Device|Optical coherence tomography|Optical coherence tomography imaging
1794494|NCT00544440|Drug|Abiraterone acetate|Abiraterone 1000 mg (4 x 250 mg tablets) taken orally once daily
1794495|NCT00544440|Drug|Prednisone|Prednisone 5 mg tablet taken orally twice daily
1794496|NCT00544453|Drug|[123I] MNI-308|Injection of [123I] MNI-308 and SPECT scanning
1794497|NCT00544466|Drug|fludarabine phosphate|25 mg/m2 day -7 through day -3 prior to transplant
1794498|NCT00544466|Drug|melphalan|140 mg/m2 day -2 prior to transplant
1794499|NCT00544466|Procedure|allogeneic hematopoietic stem cell transplantation|Cells infused on Day 0 of transplant regimen
1794500|NCT00544466|Radiation|intensity-modulated radiation therapy|Each fraction is 150 cGy, 2 fractions each day on day -7 through day -4 prior to transplant
1794501|NCT00544492|Device|catheter for AV fistula cannulation|catheters for buttonhole technique (blunt, bevel point), catheters for rope ladder technique (sharp, bevel point or sharp, cylindrical point)
1794502|NCT00544505|Drug|Fluorouracil/Epirubicin/Cyclophosphamide|Phase III Comparison of Preoperative vs Postoperative FEC (Fluorouracil/Epirubicin/Cyclophosphamide) in Women with Operable Breast Cancer
1794503|NCT00544518|Drug|metformin|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time
1794504|NCT00544518|Drug|benfluorex|2 tablets with breakfast and dinner for the first four weeks, if necessary, increase 2 tablets with noon for the next time, one of 2 tablets is dummy tablet.
1794505|NCT00544544|Drug|Riluzole|50 mg twice daily for 2 weeks 50 mg in the morning and 100 mg in the evening for 1 week 100 mg twice daily for 3 weeks
1794506|NCT00544557|Drug|Etanercept|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
1794507|NCT00544570|Biological|filgrastim|
1794508|NCT00544570|Drug|carmustine|
1794509|NCT00544570|Drug|cyclophosphamide|
1794510|NCT00544570|Drug|etoposide|
1794511|NCT00544570|Drug|melphalan|
1794512|NCT00544570|Procedure|autologous hematopoietic stem cell transplantation|
1794513|NCT00544570|Procedure|peripheral blood stem cell transplantation|
1794514|NCT00544570|Radiation|radiation therapy|
1794515|NCT00544570|Radiation|total-body irradiation|
1794516|NCT00544583|Procedure|Interrupted sutures|Interrupted sutures for abdominal fascia closure with Vicryl equivalent sutures (USP 2, 45 cm)
1794517|NCT00544583|Procedure|Continuous sutures|Continuous sutures for abdominal fascia closure with PDS II equivalent USP 1, 150 cm loops
1794518|NCT00544596|Drug|R-(-)-gossypol acetic acid|Given orally
1794519|NCT00544596|Drug|cisplatin|Given IV
1794520|NCT00544596|Drug|etoposide|Given IV
1794521|NCT00544609|Drug|Sorafenib|Level 1: 200 mg/day Level 2: 400mg/day Level 3: 800mg/day
1794522|NCT00544609|Procedure|Radiotherapy|3th-8th week: sorafenib daily with radiotherapy day 1, 2, 3, 4 and 5, 9th week: sorafenib daily with radiotherapy day 1 and 2
1794523|NCT00544622|Procedure|structured therapeutic chain of stroke treatment|
1794524|NCT00544635|Device|no intervention|no intervention
1794525|NCT00544635|Device|light|scars will be treated with light
1794526|NCT00544648|Drug|carboplatin|(AUC 2) through a vein over 30 minutes following nab-paclitaxel, once per week x 7 weeks
1794527|NCT00544648|Drug|nab-paclitaxel|Phase I: beginning at 40 mg/m2 through a vein over 30 minutes once per week x 7 weeks Phase II: Maximum tolerated dose through a vein over 30 minutes once per week x 7 weeks
1794528|NCT00544648|Radiation|Radiation therapy|3D conformal radiotherapy or Intensity-Modulated Radiation Therapy (IMRT), 2.0 Gy per day x 5 days per week for 33 days during Weeks 1-7 ; Total Dose = 66 Gy
1794529|NCT00544674|Drug|PR104|administered at a dose of 1100 mg/m^2 by intravenous infusion over 1 hour and repeated every three weeks
1794530|NCT00544674|Other|F-18-fluoromisonidazole|administered intravenously prior to PET scan
1794531|NCT00544687|Drug|CRx-191|topical (mometasone furoate + nortriptyline HCl)
1794532|NCT00544687|Drug|mometasone furoate|topical mometasone furoate
1794533|NCT00544687|Drug|nortriptyline HCl|topical nortriptyline HCl
1794534|NCT00544687|Drug|Karison® Creme|topical Karison® Creme (clobetasol-17-propinate 0.05%)
1794535|NCT00544687|Drug|Vehicle|topical (placebo)
1794536|NCT00544700|Biological|bevacizumab|7.5 mg/kg i.v. bevacizumab every 21 days until progression or unacceptable toxicity
1794537|NCT00544700|Other|no maintenance|No treatment until progression
1794538|NCT00544713|Drug|Carboxymethylcellulose and Glycerin based artificial tear|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
1794539|NCT00544713|Drug|Carboxymethylcellulose|As directed by Investigator at the end of each study visit: 1 to 2 drops in each eye, 1 to 2 times a day up to every hour while awake
1794540|NCT00544726|Behavioral|Physical training|
1794541|NCT00544726|Behavioral|No training|
1794542|NCT00544752|Other|16|indoor temperature of 16 degrees celcius
1794543|NCT00544752|Other|indoor temperature of 20 degrees celcius|indoor temperature of 20 degrees celcius
1795019|NCT00548314|Procedure|Split skin graft|
1794544|NCT00544752|Other|indoor temperature of 24 degrees celcius|indoor temperature of 24 degrees celcius
1794545|NCT00544765|Drug|TAC|Docetaxel 75 mg/m² as a 1 hour i.v. infusion on day 1 every 3 weeks in combination with Doxorubicin 50 mg/m² as an i.v. bolus and Cyclophosphamide 500 mg/m2 as an i.v. bolus on day 1 every 3 weeks
1794546|NCT00544765|Drug|NX|Vinorelbine 25 mg/m² as a < 10 min i.v. infusion on days 1 and 8 repeated every 3 weeks and Capecitabine 2000 mg/m² orally in 2 daily doses on days 1-14 repeated every 3 weeks
1794547|NCT00544778|Biological|filgrastim|
1794548|NCT00544778|Drug|dexrazoxane hydrochloride|
1794549|NCT00544778|Drug|doxorubicin hydrochloride|
1794550|NCT00544778|Drug|ifosfamide|
1794551|NCT00544778|Drug|irinotecan hydrochloride|
1794552|NCT00544778|Genetic|protein expression analysis|
1794553|NCT00544778|Other|immunoenzyme technique|
1794554|NCT00544778|Procedure|adjuvant therapy|
1794555|NCT00544778|Procedure|conventional surgery|
1794556|NCT00544778|Procedure|neoadjuvant therapy|
1794557|NCT00544778|Radiation|radiation therapy|
1794558|NCT00544791|Drug|melatonin|5 mg, oral, daily dose for 6 months
1794559|NCT00544791|Drug|placebo like melatonin tablets|
1794560|NCT00544804|Drug|lapatinib ditosylate|
1794561|NCT00544804|Genetic|gene expression analysis|
1794562|NCT00544804|Other|diagnostic laboratory biomarker analysis|
1794563|NCT00544817|Radiation|Radiation Therapy|2 Gy/fraction, single daily fractions M-F, to 60 Gy total
1794564|NCT00544817|Drug|Temozolomide|"In Combined Modality Therapy, administered as 75 mg/m2 by mouth once daily
In follow-up systemic therapy, administered as 150 mg/m2 by mouth on days 1-5 every 28 days for 6 cycles"
1794565|NCT00544817|Drug|Sorafenib|In follow-up systemic therapy, administered as 400 mg by mouth twice daily for 6 months
1794566|NCT00544830|Drug|bicalutamide|50 mg orally every day for a total of 36 weeks (+/- 2 weeks)
1794567|NCT00544830|Drug|goserelin|3.6 mg subcutaneously every 4 weeks or 10.8 mg subcutaneously every 12 weeks for a total of 36 weeks (+/- 2 weeks)
1794568|NCT00544830|Drug|leuprolide acetate|22.5 mg intramuscularly every 12 weeks for a total of 36 weeks (+/- 2 weeks)
1794569|NCT00544830|Radiation|intensity-modulated radiation therapy|All sites will be treated using one of the following fractionation schemes: 1) 300 cGy/day to 3000 cGy; 2) 250 cGy/day to 3750 cGy; 3) 200 cGy/day to 4000 cGy.
1794570|NCT00544830|Radiation|tomotherapy|All sites will be treated using one of the following fractionation schemes: 1) 300 cGy/day to 3000 cGy; 2) 250 cGy/day to 3750 cGy; 3) 200 cGy/day to 4000 cGy.
1794571|NCT00544856|Behavioral|complex cognitive training|
1794572|NCT00544869|Drug|OPC-41061 （Tolvaptan)|15-30mg/day,daily for 14days
1794573|NCT00544882|Drug|DR-1021|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus seven 10 μg EE tablets.
1794574|NCT00544882|Drug|Mircette®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
1794575|NCT00544882|Drug|Kariva®|Twenty-one 150 μg desogestrel/20 μg ethinyl estradiol (EE) combination tablets plus two placebo tablets plus five 10 μg EE tablets.
1794576|NCT00544908|Drug|dasatinib|
1794577|NCT00544908|Other|immunoenzyme technique|
1794578|NCT00544908|Other|immunohistochemistry staining method|
1794579|NCT00544908|Other|laboratory biomarker analysis|
1794580|NCT00544908|Procedure|quality-of-life assessment|
1794581|NCT00544921|Drug|GLY-230|
1794582|NCT00544921|Other|Placebo|No drug administered
1794583|NCT00544934|Drug|GLY-230|125, 250 0r 375 mg bid for 14 days
1794584|NCT00544934|Other|Placebo|No drug administered
1794585|NCT00544960|Drug|AT-101 and docetaxel|AT-101 30 mg bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
1794586|NCT00544960|Drug|placebo and docetaxel|placebo 3 tabs bid on days 1, 2, and 3 of each 21 day cycle, docetaxel, 75 mg/m2 on day 1 of each 21 day cycle; until progression or unacceptable toxicity develops
1794587|NCT00544986|Drug|Anastrozole|
1794588|NCT00544999|Drug|cytarabine|
1794589|NCT00544999|Drug|daunorubicin hydrochloride|
1794590|NCT00544999|Drug|everolimus|
1794591|NCT00544999|Other|laboratory biomarker analysis|
1794592|NCT00544999|Other|pharmacological study|
1794593|NCT00545012|Drug|Levetiracetam|
1794594|NCT00545025|Biological|Influenza Vaccine GSK1247446A|Single dose, Intramuscular injection
1794595|NCT00545025|Biological|Fluarix™|Single dose, Intramuscular injection
1794596|NCT00545051|Drug|Placebo|po monthly for 12 months
1794597|NCT00545051|Drug|ibandronate|150mg po monthly for 12 months
1794598|NCT00545064|Drug|dorzolamide hydrochloride (+) timolol maleate|dorzolamide hydrochloride (2%)/ timolol maleate (0.5%) Preservative free twice a day (BID), for 8 weeks of treatment
1794599|NCT00545077|Drug|Endocrine treatment consisting of either letrozole or fulvestrant.|The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent.
1794600|NCT00545077|Drug|Bevacizumab + Endocrine treatment consisting of either letrozole or fulvestrant.|Bevacizumab will be administered every 21 days (day 1 of cycle 2 will be day 22 of the treatment.The patients will receive the assigned treatment until the progression of the disease, unacceptable toxicity or withdrawal of the consent. Those patients in treatment with bevacizumab who end the study without having progressed will continue to receive the drug out of the study.
1794601|NCT00545090|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months
1794602|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 1.2g administered Once Daily (QD)
1794603|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 2.4g administered Once Daily (QD)
1794604|NCT00545103|Drug|SPD476, MMX™ mesalazine, 1.2g extended release tablet|SPD476 4.8g administered Once Daily (QD)
1794605|NCT00545103|Drug|Placebo|Placebo administered Once Daily (QD)
1794606|NCT00545116|Other|Hesperidin|250 mg of hesperidin twice a day taken oraly in a biscuit or in milk for 6 months
1794794|NCT00546741|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily single dose
1794607|NCT00545129|Drug|Tanezumab 10 mg IV|Single IV infusion of 10 mg tanezumab on Day 1. Maintained on baseline opioid regimen.
1794608|NCT00545129|Drug|IV Placebo for tanezumab|Single IV infusion of placebo for tanezumab on Day 1. Maintained on baseline opioid regimen.
1794609|NCT00545142|Drug|Abilify(Aripiprazole)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
1794610|NCT00545142|Drug|Depakote(Divalproate)|co-administration of Abilify with Depakote in the 6-week treatment of acute mania in patients with bipolar disorder
1794611|NCT00545168|Drug|Spinosad|10 minute topical application of product, followed by a complete rinse off.
1794612|NCT00545168|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen.
1794613|NCT00545168|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
1794614|NCT00545181|Drug|Vaginal acidifying gel (RepHresh)|"placement of vaginal acidifying gel into vagina to restore normal vaginal pH."
1794615|NCT00545181|Drug|Metronidazole control|oral metronidazole therapy alone
1794616|NCT00545194|Drug|Prostaglandin E2|
1794617|NCT00545207|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 2 years
1794618|NCT00545207|Drug|Placebo|po monthly for 2 years
1794619|NCT00545220|Behavioral|problem-solving training|
1794620|NCT00545220|Behavioral|sham intervention|
1794621|NCT00545233|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms subcutaneous weekly for 48 weeks
1794622|NCT00545233|Drug|ribavirin [Copegus]|1000-1600 mg day orally for 48 weeks.
1794623|NCT00545233|Drug|Pioglitazone|30 mg daily for 8 weeks increasing to 45 mg daily for 64 weeks.
1794624|NCT00545246|Drug|aflibercept (AVE0005)|intravenous infusion
1794625|NCT00545246|Drug|docetaxel|intravenous infusion
1794626|NCT00545259|Drug|AEB071|
1794627|NCT00545272|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
1794628|NCT00545272|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
1794629|NCT00545272|Drug|placebo to indacaterol|Placebo TWISTHALER® device
1794630|NCT00545272|Drug|placebo to formoterol|Placebo AEROLIZER® device
1794631|NCT00545272|Drug|short acting β2-agonist|100 μg/ 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
1794632|NCT00545285|Procedure|Total Hip Arthroplasty|Surgical implantation of specific hip replacement components for treatment of osteoarthritis
1794633|NCT00545298|Drug|Nitric Oxide - same dose 6 wks|200ppm, 8hrs / day for 6 weeks NO gas in nitrogen delivered to a patch over the wound
1794634|NCT00545298|Drug|Nitric Oxide modified treatment|200ppm, 8hrs/day for 1 week, followed by 25ppm 8hrs/day for 5 weeks Gas is delivered to a patch over the wound
1794635|NCT00545311|Drug|NVA237|
1794636|NCT00545311|Drug|NVA237|
1794637|NCT00545311|Drug|NVA237|
1794638|NCT00545311|Drug|NVA237|
1794639|NCT00545311|Drug|Placebo|
1794640|NCT00545324|Drug|MK0476 (singulair), montelukast sodium / Duration of Treatment: 6 Weeks|
1794641|NCT00545324|Drug|Comparator: Fluticasone / Duration of Treatment: 6 Weeks|
1794642|NCT00545337|Drug|Insuline glulisine|
1794643|NCT00545350|Other|Fall prevention exercise program|"Weekly physical exercise sessions in small groups, led by a qualified and specially trained instructor, and supplemented by simple exercises to do at home.
The exercise program will focus on progressive balance retraining but will also include strength/resistance, coordination and flexibility training exercises."
1794644|NCT00545363|Drug|Ibandronate|Participants will receive ibandronate 150 mg QM orally for 6 months.
1794645|NCT00545376|Procedure|Osteopathic Manipulative Treatment - in clinic|I will do a thoracic/rib screening and treatment with muscle energy or facilitated positional release, a diaphragm soft tissue release, suboccipital release, and a thoracic compression. This treatment takes 10 minutes and is only done at the first visit.
1794646|NCT00545376|Procedure|Osteopathic Manipulative Treatment - at home|One group will learn how to do three home OMT techniques: suboccipital release, pectoral traction, and rib raising. They will be asked to do this at least 4 times a week for two weeks.
1794647|NCT00545376|Other|Education to physicians|I will educate physicians using demonstration and reading material as to the possible benefits of incorporating it into the treatment of asthma.
1794648|NCT00545389|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
1794649|NCT00539071|Drug|long-acting injectable risperidone|Subjects will be randomized to conventional dose Consta or high dose Consta. All of those who are randomized to the conventional Consta dose will receive it in the form of Consta at a starting dose of 50 mg q 2 weeks. Those who are randomized to high dose Consta will receive a Consta 50 mg injection plus 25 mg injection (total dose 75 mg) q 2 weeks as the starting dose.Oral risperidone will be given up to Week 4 along with the injections for both groups to provide a transition phase.At Week 6, psychopathology will be assessed with a PANSS. If no improvement from baseline is shown, the randomized dose of Consta will be increased to 100 mg q 2 weeks (given as two 50 mg injections ) for those in the high dose Consta group. The dose for those randomized to the conventional dose group will remain the same (50 mg plus placebo).
1794650|NCT00539071|Drug|long acting injectable risperidone|Study dose remains 50 mg for the length of the study.
1794651|NCT00539071|Drug|long acting injectable risperidone|Beginning dose 75 mg. Can be increased to 100 mg at Week 6.
1794652|NCT00539084|Device|MicronJet|The MicronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the layers of the skin). In this study the MicronJet will be used to inject Lidocaine or Saline.
1794653|NCT00539097|Dietary Supplement|Juven (Ross Products) protein supplement|Juven supplement oral x 3 weeks postop
1794654|NCT00539110|Drug|zolipidem|zolpidem dosed at 2200 and 0200 per feeding tube depending on randomization
1794655|NCT00539110|Drug|ramelteon|ramelteon dosed at 2200 and 0200 per feeding tube depending on randomization
1794656|NCT00539123|Behavioral|behavioral drug and HIV risk reduction counseling (BDRC)|BDRC utilizes short-term behavioral contracts to promote abstinence and reduce drug- and sex-related HIV risk behaviors and can be provided by nurses and medical assistants available in medical settings in Malaysia.
1794657|NCT00539123|Behavioral|abstinence-contingent take-home buprenorphine (ACB)|Patients achieving heroin abstinence receive take-home doses of buprenorphine
1794658|NCT00539123|Behavioral|Physician Management (PM)|medically focused advice and brief counseling
1794659|NCT00539136|Drug|GSK561679 tablet or solution|
1794660|NCT00539149|Drug|Amoxycillin|50 mg/kg/day twice daily
1794661|NCT00539149|Drug|Placebo equivalent to amoxycillin|50 mg/kg/d twice daily
1794662|NCT00539162|Behavioral|Questionnaire|Completed during follow up visits.
1794663|NCT00539175|Device|infrared light|pulsed infrared light will be applied to feet, ankles and popliteal fossae of patients with diabetic neuropathy
1794664|NCT00539175|Device|infrared light; placebo|patients will be exposed to the same machine used to provide pulsed infrared light, but the light emitting diodes will not be activated. All other aspects of the treatment will be the same. The patient and investigator will be blind to treatment assignment.
1794665|NCT00539188|Drug|N-Acetylcysteine|3000 mg PO (1200 mg AM, 1800 mg PM), 6 weeks
1794666|NCT00539188|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 6 weeks
1794667|NCT00539201|Drug|GSK706769|
1794668|NCT00539227|Procedure|NAC Sparing Mastectomy|A skin-sparing mastectomy performed with preservation of the nipple-areolar complex (NAC).
1794669|NCT00539227|Behavioral|Questionnaire|Questionnaires taking about 20-30 minutes to complete.
1794670|NCT00539240|Drug|Rabeprazole 20mg, placebo dinner and bedtime|Breakfast study medication - Rabeprazole 20mg, matching placebo at dinner , Placebo for tricyclic antidepressant at bedtime
1794671|NCT00539240|Drug|Rabeprazole 20 mg two times, Placebo at bedtime|Breakfast & Dinner study medication - Rabeprazole, placebo for tricyclic antidepressant at bedtime
1794672|NCT00539240|Drug|Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant|Rabeprazole (Breakfast) study medication, dinner placebo medication, tricyclic antidepressant at bedtime
1794673|NCT00539253|Drug|gadobenate dimeglumine (MultiHance)|The contrast agent, gadobenate dimeglumine, will be used during MR imaging for both the baseline and 1 month f/u studies.
1794674|NCT00539266|Biological|bone marrow derived mononuclear cells|40 IM injections (calf muscle) of 1-8 10E9 mono nuclear cells
1794675|NCT00539266|Biological|placebo|40 IM injections (calf muscle) of placebo suspension
1794676|NCT00539279|Behavioral|Prolonged Exposure Therapy (PE)|PE is a therapy that aims to reduce PTSD symptoms via a systematic exposure to feared memories (by imaginal exposure - repeated narration about the traumatic memory) and situations (by in vivo exposure - engaging in feared but safe activities or facing feared situations).
1794677|NCT00539279|Behavioral|Relaxation Training (RT)|RT aims to teach relaxation methods in an effort to reduce anxiety. RT includes Progressive Muscle Relaxation, Imagery Rehearsal, and breathing training.
1794678|NCT00539292|Procedure|Primary placement of a spring-loaded silo|
1794679|NCT00539292|Procedure|Primary Closure|primary closure of abdomen
1794680|NCT00539305|Drug|testosterone gel|50-100mg applied topically daily for six months
1794681|NCT00539305|Drug|placebo gel|applied topically daily for six months
1794682|NCT00539318|Procedure|Blood drawing|Once when enroll in study
1794683|NCT00539331|Drug|AZD2171|oral tablet
1794684|NCT00539331|Drug|Paclitaxel|intravenous infusion
1794685|NCT00539331|Drug|Carboplatin|intravenous injection
1794686|NCT00539344|Drug|ANG1005|IV infusion once every 21 days
1794687|NCT00539357|Device|Cranial electrotherapy stimulation (CES)|Cranial electrotherapy stimulation (CES) is a noninvasive procedure that involves applying a pulsed, low-amplitude electrical current to the head using electrodes placed on the earlobes. Cranial electrotherapy stimulation CES received U.S. Food and Drug Administration (FDA) approval for the treatment of insomnia, depression, and anxiety in 1979.
1794688|NCT00539383|Drug|ANG1005|IV infusion once every 21 days
1794689|NCT00539396|Drug|Technosphere Insulin|
1794690|NCT00539409|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
1794691|NCT00539422|Genetic|pcr and serum markers for breast cancer|DNA extraction and genotyping of cytochrome P450-2D6*4 gene using conventional PCR followed by restriction enzyme (Mva1) digestion. Separated plasma was used for measurement of plasma malondialdehyde(MDA)concentration, total plasma antioxidant capacity and plasma ferretin level.
1794692|NCT00539435|Procedure|Intravenous Insulin on cardiac disease in diabetic pts|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
1794693|NCT00539448|Drug|insulin glargine|in combination with insulin Glulisine as bolus regimen
1794694|NCT00539448|Drug|insulin glulisine|in combination with insulin Glargine as bolus regimen
1794695|NCT00539474|Procedure|Radio guided occult lesion localisation|ROLL procedure using the Europrobe (Europrobe, Strassbourg, France) WGL using a hook wire
1794701|NCT00539513|Drug|N-Acetylcysteine|3000 mg by mouth PO (1200 mg AM, 1800 mg PM), 12 weeks
1794702|NCT00539513|Drug|placebo|placebo, 2 capsules PO AM, 3 capsules PO PM, 12 weeks
1794703|NCT00539526|Drug|Bimatoprost 0.03%|bimatoprost 0.03%, 1 drop nightly for 3 months
1794704|NCT00539526|Drug|travoprost 0.004%|travoprost 0.004% eye drops, 1 drop nightly for 3 months
1794705|NCT00539526|Drug|latanoprost 0.005% eye drops|latanoprost 0.005%, 1 drop nightly for 3 months
1794742|NCT00545415|Dietary Supplement|Order 5|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
1794706|NCT00539539|Other|Laerdal Q-CPR /technology|For the first three to six months, participating EMS agencies will have defibrillators with automated, real-time feedback inactivated. During this period, the baseline rate of ROSC (and secondary outcomes) will be collected. At the end of this baseline period, EMS agencies will be randomized to one of two interventions, with randomization stratified within site by agency, station, or device. All clusters will cross-over to the opposite feedback strategy at least once during the intervention phase.
1794707|NCT00539565|Drug|prednisolone|"2 mg/kg /day from post-op day 7 - day 21
1 mg/kg /day from post-op day 22 - day 30"
1794708|NCT00539565|Drug|placebo|
1794709|NCT00539578|Drug|MK0777|Duration of Treatment: 4 weeks
1794710|NCT00539578|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 4 weeks
1794711|NCT00539591|Drug|Peginterferon alfa-2b|Given either IV or SQ. Therapeutic drug class: interferon.
1794712|NCT00539591|Drug|Temozolomide|Given PO. Therapeutic drug class: antineoplastic agent.
1794713|NCT00539591|Drug|Recombinant interferon alfa-2b|Given IV. Therapeutic drug classes: antineoplastic agent, immunomodulatory agent, interferon
1794714|NCT00539604|Procedure|MDCT and Coronary Angiography|
1794715|NCT00539617|Drug|erlotinib|Tarceva single agent therapy: 150 mg/day PO
1794716|NCT00539617|Drug|5-fluorouracil|5-FU bolus: 400 mg/m2 IV once every 2 weeks for 16 weeks 5-FU infusion: 2400 mg/m2 IV over 46-48 hours, once every 2 weeks for 16 weeks
1794717|NCT00539617|Drug|leucovorin|400 mg/m2 IV once every 2 weeks for 16 weeks
1794718|NCT00539617|Drug|oxaliplatin|85 mg/m2 IV once every 2 weeks for 16 weeks
1794719|NCT00539630|Drug|Docetaxel|
1794720|NCT00539643|Device|Bead Block microspheres|Bead Block (Beads) microsphere, 100-300 micron with additional larger size beads as necessary to achieve stasis
1794721|NCT00539643|Other|Bead + Dox Arm|Bead + Dox Arm: Hepatic arterial embolization with 100-300 micron drug eluting microspheres (LC Bead) loaded with 150 mg Doxorubicin, followed by embolization with Bead Block microspheres (100-300 micron and larger size beads as necessary) until stasis is evident.
1794722|NCT00539656|Device|Ex vivo expansion of cord blood|One cord blood unit will be thawed on day -14 before transplantation and selected using the CliniMACS for primitive cells that express CD133. These cells will be expanded ex vivo for a total of 14 days, using a two-stage procedure. On Day 0 the expanded cells will be harvested, washed three times with CliniMACS buffer (Miltenyi) plus 1% HSA per standard laboratory and clinical practice and the expanded cell product will be infused to a patient who has been prepared with a standard, myeloablative preparative regimen. A second, unexpanded, cord blood product will be infused on Day +1 for safety.
1794723|NCT00539669|Drug|Docetaxel|
1794724|NCT00539695|Biological|IL-2|"IL2 Administration:
Patients will be given a fixed dose (1x10e5 units/m2/dose) of IL-2 given as a subcutaneous injection three times weekly (separated by at least one day) for 6 weeks beginning no earlier than day +7 after HSCT but beginning no later than 30 days after HSCT. If the patient has not developed >grade I side effects to IL-2 and has not developed >grade I GVHD then the patient may continue the IL-2 for 6 additional weeks. Time will be measured as 'week beginning with first IL-2 injection."
1794725|NCT00539708|Procedure|Non-invasive ventilation|Non-invasive ventilation after extubation for 24 hours
1794726|NCT00539721|Drug|Rolapitant Dose 1|Rolapitant 5 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
1794727|NCT00539721|Drug|Rolapitant Dose 2|Rolapitant 20 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
1794728|NCT00539721|Drug|Rolapitant Dose 3|Rolapitant 70 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
1794729|NCT00539721|Drug|Rolapitant Dose 4|200 mg (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
1794730|NCT00539721|Drug|Ondansetron|Ondansetron 4 mg x 1 intravenous and rolapitant placebo (4 capsules) x 1 oral on Day 1
1794731|NCT00539721|Drug|Placebo|Rolapitant placebo (4 capsules) x 1 oral and ondansetron placebo x 1 intravenous on Day 1
1794732|NCT00539734|Drug|ranibizumab|A single dose of 0.5 mg ranibizumab injected intravitreally.
1794733|NCT00545402|Drug|Mycophenolate mofetil, adjusted dose|3 g/d PO BID during meals from Day 0 to Day 4, followed by dose adjustment based on AUC using the Bayesian method with limited sampling strategy on Days 5 and 14, Months 1, 13, 6, 9, and 12.
1794734|NCT00545402|Drug|Tacrolimus|Target trough level of 8-2 ng/mL from Day 0 to Month 1, adjusted to a target trough level of 3-8 ng/mL from the end of Month 1 through Month 12
1794735|NCT00545402|Drug|Corticosteroids, IV|10-15 mg/kg IV pre-operation on Day 0
1794736|NCT00545402|Drug|Mycophenolate mofetil, Standard dose|2 g/d PO BID during meals from Day 0 to Month 12
1794737|NCT00545402|Drug|Corticosteroids, PO|20 mg/d QDS from Day 0 through Month 1; 15 mg/day, TID from the end of Month 1 through Month 2; 10 mg/d BID from the end of Month 2 through Month 3; and 5 mg/d once per day from the end of Month 3 through Month 6.
1794738|NCT00545415|Dietary Supplement|Order 1|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
1794739|NCT00545415|Dietary Supplement|Order 2|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
1794740|NCT00545415|Dietary Supplement|Order 3|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
1794741|NCT00545415|Dietary Supplement|Order 4|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
1794793|NCT00546728|Drug|Metformin|metformin 500 twice daily
1795017|NCT00548301|Drug|cyclosporine|
1794743|NCT00545415|Dietary Supplement|Order 6|"Supplement is fruit, fruit salad and fruit drink in different order. Fruit (two apples) Fruit salad, 400g (consist of apple, banana, orange, mandarin, pear, strawberry, grape, kiwi and melon) in amount relative to the popularity of the fruits consumed in the Netherlands.
Fruit drink (fruit2day, strawberry/orange, 200ml) Each supplement is taken once, with one week wash out."
1794744|NCT00545428|Procedure|Rhinoplasty|Mastoid bone autograft for dorsal nasal augmentation
1794745|NCT00545441|Device|Surgisis Biodesign Anal Fistula Plug (Surgisis® AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia.
1794746|NCT00545441|Device|Flap|Advancement flap surgery is performed; no anal fistula plug is placed
1794747|NCT00545454|Drug|SSR150106|
1794748|NCT00545454|Drug|Placebos|
1794749|NCT00545467|Drug|Aripiprazole|Aripiprazole will be given as a fixed does, 15 mg/day, orally throughout 8 weeks in the 2 arms.
1794750|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (with feedback)
1794751|NCT00545480|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 12 months (without feedback)
1794754|NCT00545506|Device|conventional bandage|
1794755|NCT00545506|Device|warming bandage|
1794756|NCT00545519|Drug|thymoglobulin|
1794757|NCT00545532|Drug|oseltamivir|Dose ranging between 30 to 150 mg orally administered as syrup or capsules (depending on participants age and weight) po bid for 10 days
1794758|NCT00545532|Other|placebo|Placebo matched to oseltamivir po bid for 10 days
1794759|NCT00545545|Biological|Safety and efficacy of escalating doses|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle) and irinotecan on Day 1 of each week for 4 weeks with a 2-week rest. Number of Cycles: until progression or unacceptable toxicity develops.
1794760|NCT00545545|Biological|Safety and efficacy of escalating doses.|Imprime PGG and Cetuximab on Day 1 of each week for 6 weeks (one cycle). Number of Cycles: until progression or unacceptable toxicity develops.
1794761|NCT00545558|Drug|Efavirenz|600 mg tablet taken orally daily
1794762|NCT00545558|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200 mg emtricitabine/ 300 mg tenofovir disoproxil fumarate tablet taken orally daily
1794763|NCT00545571|Drug|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered intravenously every 4 weeks for a total of 52 weeks. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.
1794767|NCT00545597|Drug|Lorenzo's oil|4:1 glyceryl trioleate-glyceryl trierucate (Lorenzo's oil)given orally, daily as approximately 10% of nutritional calories with supplementation.
1794768|NCT00545623|Procedure|Acupuncture|acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
1794769|NCT00545623|Behavioral|Relaxation Response|listening to CDs with verbal instructions of techniques to elicit relaxation response
1794770|NCT00545623|Other|sham acupuncture|sham acupuncture twice/week for the first 4 weeks and once/week for another 4 weeks
1794771|NCT00545636|Other|education|The intervention is an education of the medical teams that instruct children to fast before the administration of general anesthesia
1794772|NCT00545649|Behavioral|Exercise and education|
1794773|NCT00545649|Behavioral|Education|
1794774|NCT00545662|Drug|Placebo|Drug Placebo Inactive twice a day given orally or enterally. The first dose is given within 24 hours of injury and treatment continues until 90 days or until the 90-day outcome assessment.
1794775|NCT00545662|Drug|citicoline|1000 mg twice a day orally or enterally. The first dose is within 24 hours of injury and treatment continues for 90-days or until the 90-day outcome assessment.
1794776|NCT00545675|Drug|Abilify(aripiprazole)|Abilify and Depakote in 24-week treatment of mania in patients with bipolar disorder
1794777|NCT00545675|Drug|Depakote (divalproate)|Placebo and Depakote in 24-week treatment of mania in patients with bipolar disorder
1794778|NCT00545688|Drug|Herceptin|8mg/kg iv loading dose, followed by 6mg/kg iv 3-weekly
1794779|NCT00545688|Drug|Docetaxel|75mg/m2 iv escalating to 100mg/m2 iv 3-weekly
1794780|NCT00545688|Drug|Pertuzumab|840mg iv loading dose, followed by 420mg iv 3-weekly
1794781|NCT00545701|Biological|A/H5N1 inactivated, split-virion influenza virus|0.5 mL, Intramuscular
1794785|NCT00545727|Behavioral|Diet|Whole-foods, low glycemic index diet
1794786|NCT00545727|Other|Standard diet|Standard diet meeting American Diabetes Association guidelines
1794788|NCT00546676|Drug|Telithromycin|
1794789|NCT00546702|Drug|Insuline Glulisine|
1794790|NCT00546715|Drug|Daclatasvir|Oral Solution, Oral, Single Dose
1794791|NCT00546715|Drug|Placebo|Oral Solution, Oral, Single Dose
1794792|NCT00546728|Drug|Exenatide|exenatide 10 mcg twice daily
1794795|NCT00546741|Drug|Metformin|Tablets, Oral, 1000 mg, once daily, single dose
1794796|NCT00546741|Drug|Dapagliflozin + Metformin|"Tablets, Oral, once daily, single dose
Dapagliflozin: 20 mg
Metformin: 1000 mg"
1794797|NCT00546754|Drug|losartan potassium (+) hydrochlorothiazide|losartan potassium 50 mg/12.5 Hydrochlorothiazide (HCTZ) titrated as needed to losartan potassium 100 mg/25 mg Hydrochlorothiazide
1794798|NCT00546754|Drug|Comparator: Valsartan (+) Hydrochlorothiazide|Valsartan 80 mg/ Hydrochlorothiazide 12.5 mg/day titrated as needed to valsartan 160 mg/25 mg Hydrochlorothiazide
1794799|NCT00546767|Behavioral|Mail and Live Phone|This group will receive assessments of all domains by mail, except for the cognitive performance assessment which will be administered via phone by a live, trained evaluator. Medication compliance will be monitored by a written medication log which will be returned by mail with the other mail-in assessments.
1794800|NCT00546767|Behavioral|Interactive Voice Response (IVR)|In this group, participants will be asked to answer questions via an automated phone system using interactive voice recognition (IVR) and key-pad response entry. Medication compliance will be monitored by the same method. A standard large-key telephone and training in the use of the interactive phone system will be provided to all participants.
1794801|NCT00546767|Behavioral|Home-based Computer Kiosk|Participants at entry will receive a special Kiosk-like device for collecting assessment information and will be taught to use this device. The user interface will consist of a monitor with a touch screen and a telephone handset, similar to what is often used in museum displays. Pre-recorded instructions will be delivered through the handset as well as displayed visually on the screen. Data will be collected using the handset's high-quality microphone. Daily activity assessments of timed medication use will be obtained via an automated medication tracking device.
1794802|NCT00546767|Behavioral|Traditional Evaluation Instruments|Evaluation methods typically used in clinical trials
1794803|NCT00546780|Drug|Tanespimycin|Solution, IV, 340mg/m2, twice weekly for 2 weeks (3 week cycle), 60 minutes infusion
1794804|NCT00546780|Drug|Bortezomib|Solution, IV, 1.3 mg/m2, twice weekly for 2 weeks (3 weeks cycle), 3-5 minute bolus
1794805|NCT00546793|Biological|veltuzumab|veltuzumab (hA20) will be studied at different dose levels, administered subcutaneously once a week for 4 weeks.
1794806|NCT00546806|Other|Programs of Care|Two physiotherapy programs of care for the experimental groups; Physician-based education and activation for the active comparator group.
1794807|NCT00546819|Biological|Zoster Vaccine, Live|A single dose of 0.65 ml Zoster Vaccine, Live, injected subcutaneously on Day 1
1794808|NCT00546819|Biological|Comparator: Placebo|A single dose of 0.65 ml Placebo to ZOSTAVAX™ injected subcutaneously on Day 1.
1794809|NCT00546832|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
1794810|NCT00546832|Drug|celecoxib|
1794811|NCT00546832|Other|placebo|
1794812|NCT00546845|Device|Balloon angioplasty|Balloon angioplasty. Only stent if PTA fails
1794813|NCT00546845|Device|Use of self-expanding Expert stent|Nitinol stent
1794814|NCT00546858|Other|Physical Examination|Patients will be invited to be evaluated in the Urology Research office at a future date.
1794815|NCT00546871|Drug|Immune Globulin Intravenous (Human), 10%|Intravenous administration in Study Part 1, subcutaneous administration in Study Parts 2 and 3
1794816|NCT00546884|Behavioral|MI condition|Individuals randomized to this condition will be provided with written end of life educational materials an advance directive form, along with instructions to complete it.
1794817|NCT00546884|Behavioral|GI|The GI condition will expose participants to education, guidance and counseling, and an advance directive tool.
1794818|NCT00546897|Drug|Lenalidomide|
1794819|NCT00546910|Drug|Atomoxetine|A one-week atomoxetine treatment period with the 0.5 mg/kg per day lead-in dose will be succeeded by a 7 week period at the target dose of 1.2 mg/kg per day. 3 capsules of study medication have to be taken once daily in the morning, with or without food.
1794820|NCT00546910|Drug|Placebo|3 capsules of placebo have to be taken once daily in the morning, with or without food.
1794821|NCT00546923|Drug|Venlafaxine XR|
1794822|NCT00546936|Drug|ranibizumab|0.5mg ranibizumab
1794823|NCT00546936|Drug|verteporfin|Photodynamic therapy with verteporfin every 3 months for 1 year
1794824|NCT00546949|Procedure|Minimal invasive decompression|foraminotomy, laminotomy, microscopic decompression
1794825|NCT00546949|Procedure|Interspinous Process Decompression (IPD)|Interspinous device
1794826|NCT00546975|Dietary Supplement|Resource Support®|
1794827|NCT00546975|Dietary Supplement|Resource Protein®|
1794828|NCT00546975|Dietary Supplement|Placebo|
1794829|NCT00546988|Biological|allogeneic stem cell transplant|
1794830|NCT00547001|Drug|Estradiol|1mg during stabilization & then a taper to 0.75mg, 0.5mg, 0.25mg, 0.125mg.
1794831|NCT00547014|Drug|Placebo Comparator: Cohort 1 Placebo|Drug: placebo for cohort 1 as single dose
1794832|NCT00547014|Drug|52364 3 mg|3 mg capsule single dose administered orally as a single dose
1794833|NCT00547014|Drug|Placebo Comparator: Cohorts 2, 3, 4 & 5 Two subjects each arm will be assigned to receive placebo|Drug: Placebo for cohorts 2, 3, 4 and 5 administered as a single dose
1794834|NCT00547014|Drug|52364 10 mg|Drug: 52364 30 mg capsule as a single dose
1794835|NCT00547014|Drug|52364 30 mg|Drug: 52364 30 mg capsule administered as a single dose
1794836|NCT00547014|Drug|52364 100 mg|Drug 52364 100 mg capsule administered as a single dose
1794837|NCT00547014|Drug|52364 1 mg|1 mg powder diluted in liquid or placebo (liquid alone) administered orally as a single dose
1794838|NCT00547027|Behavioral|print-based physical activity intervention|individually-based, print-based physical activity intervention
1794839|NCT00547027|Behavioral|usual care|print-based materials of nutritional information
1794840|NCT00547040|Other|no intervention|no intervention
1794841|NCT00547053|Drug|Amiloride Solution for Inhalation|4.5 mL, Amiloride Solution for Inhalation, Inhaled via Omron Ultrasonic Nebulizer, TID, 6 months
1794842|NCT00547066|Biological|veltuzumab|hA20 will be administered intravenously in two doses over two weeks
1794843|NCT00547092|Drug|tadalafil|10 mg or 20 mg tadalafil tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
1795018|NCT00548314|Other|dermal matrix|1mm thickness matrix composed of collagen-elastin hydrolosate
1794844|NCT00547092|Drug|sildenafil|25 mg, 50 mg, or 100 mg sildenafil citrate tablets, as needed, no more than once a day, by mouth for 12 weeks (8 week treatment experience phase and a 4 week treatment assessment phase)
1794845|NCT00547105|Drug|erlotinib hydrochloride|
1794846|NCT00547105|Radiation|stereotactic body radiation therapy|
1794847|NCT00547118|Drug|Rimonabant|Rimonabant, 1 20 mg tablet given 1 time per day for 112 days.
1794848|NCT00547118|Drug|Placebo|Placebo
1794849|NCT00547131|Drug|temozolomide|
1794850|NCT00547131|Other|laboratory biomarker analysis|
1794851|NCT00547131|Other|liquid chromatography|
1794852|NCT00547131|Other|mass spectrometry|
1794853|NCT00547131|Other|pharmacological study|
1794854|NCT00547131|Procedure|conventional surgery|
1794855|NCT00547131|Radiation|stereotactic radiosurgery|
1794856|NCT00547144|Drug|Gemcitabine|1000 mg/m2 intravenoulsy once a week according to protocol schedule
1794857|NCT00547144|Procedure|Dendritic Cell Immunotherapy|The cells will be administered by intratumoral injection on 2 different days(at least 21 days apart)
1794858|NCT00547157|Drug|Panitumumab|Arm 2 consists of panitmumab plus RT
1794859|NCT00547157|Drug|Cisplatin|Cisplatin
1794860|NCT00547170|Drug|Doxycycline pre-operatively|"Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
1794861|NCT00547170|Drug|Doxycycline post-operatively|"Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)"
1794862|NCT00547183|Drug|tadalafil|2.5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
1794863|NCT00547183|Drug|tadalafil|5 mg tadalafil tablet taken by mouth once a day, no more than 1 dose a day, for 12 weeks
1794864|NCT00547183|Drug|placebo|Placebo tablet taken by mouth once a day, no more than 1 dose per day, for 12 weeks
1794865|NCT00547196|Biological|filgrastim|
1794866|NCT00547196|Drug|busulfan|
1794867|NCT00547196|Drug|cyclophosphamide|
1794868|NCT00547196|Drug|cyclosporine|
1794869|NCT00547196|Drug|fludarabine phosphate|
1794870|NCT00547196|Drug|melphalan|
1794871|NCT00547196|Drug|mycophenolate mofetil|
1794872|NCT00547196|Procedure|allogeneic hematopoietic stem cell transplantation|
1794873|NCT00547196|Procedure|umbilical cord blood transplantation|
1794874|NCT00547196|Radiation|total-body irradiation|
1794875|NCT00547209|Drug|air|60% air combined with 40% oxygen for ventilation
1794876|NCT00547209|Drug|Nitrous oxide|60% nitrous oxide combined with 40% oxygen for ventilation
1794877|NCT00547235|Biological|therapeutic allogeneic lymphocytes|
1794878|NCT00547235|Procedure|allogeneic bone marrow transplantation|
1794879|NCT00547235|Radiation|total-body irradiation|
1957399|NCT02422615|Drug|Ribociclib|Riblociclib 600mg daily oral (days 1 to 21 in a 28-day Cycle)
1957400|NCT02422615|Drug|fulvestrant|Fulvestrant 500mg i.m. injections every 28 days (Cycle n Day 1) with 1 additional dose on Day 15 of Cycle 1
1957401|NCT02422615|Drug|Ribociclib placebo|Riblociclib placebo 600mg daily oral (days 1 to 21 in a 28-day Cycle)
1794886|NCT00547261|Drug|SSR97225|every 3 weeks
1794887|NCT00547274|Drug|MK0767|
1794888|NCT00547287|Drug|tadalafil|20 mg tadalafil as needed by mouth no more than once a day for a 4 week initiation period and a 4 weeks treatment period.
1794889|NCT00547287|Drug|sildenafil|Current dosage of sildenafil is continued for 4 weeks (no more than once a day) of treatment assessment then the wash-out period will begin.
1794891|NCT00547326|Procedure|treated with osteopatic cranial techniques|treated with osteopatic cranial techniques
1794892|NCT00547326|Procedure|Treatment with placebo|Treatment with placebo
1794893|NCT00547339|Radiation|stereotactic body radiation therapy|
1794894|NCT00547352|Drug|tadalafil|20 mg tadalafil tablets taken by mouth, as needed, no more than once a day for 8 weeks.
1794895|NCT00547352|Drug|sildenafil|Current users of sildenafil citrate for a minimum of 6 weeks prior to visit 1 will continue with an individual dosage to be taken no more than once a day for an additional 4 weeks.
1794896|NCT00547365|Biological|Human immune globulin intravenous (IGIV)|Analyze the therapeutic potential of human immune globulin intravenous (IGIV) when given to patients with cardiac-associated AL amyloidosis
1794899|NCT00547391|Procedure|Tonsillectomy|Tonsillectomy under general anesthesia as a day surgery using diathermy or blunt dissection. Follow up started from the day of surgery.
1794900|NCT00547391|Other|no intervention|No intervention (controls). Follow up started from the day of randomization.
1794901|NCT00547404|Drug|P276-00|IV drug infusion over a period of 30 min on day 1,4,8 and 11 in21 day cycle for 6 cycles
1794902|NCT00547417|Drug|tadalafil|20 mg tadalafil tablet taken by mouth, as needed, no more than once a day, for 12 weeks.
1794903|NCT00547443|Drug|carboplatin|Given IV
1794904|NCT00547443|Drug|paclitaxel|Given IV
1794905|NCT00547443|Drug|sorafenib tosylate|Given orally
1794906|NCT00547443|Radiation|radiation therapy|Given 5 days a week for 7.5 weeks
1794907|NCT00547456|Drug|Oxygen|Oxygen 2-3L Nasal cannula
1794908|NCT00547469|Drug|DDP733|
1794909|NCT00547482|Device|TANTALUS(TM) System|"All subjects will be implanted with the TANTALUS System (IPG with Charge Coil and UltraFlex leads) and randomized into either the Treatment Group or Control Group after surgery at Week 1, Visit 5 (device activation)."
1794910|NCT00547495|Drug|tadalafil|5 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
1794911|NCT00547495|Drug|placebo|placebo tablet taken by mouth, as needed, no more than 1 dose per day, for 12 weeks
1794912|NCT00547495|Drug|tadalafil|10 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
1794913|NCT00547495|Drug|tadalafil|20 mg tadalafil tablet, by mouth, as needed, no more than 1 dose per day, for 12 weeks
1794914|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
1794915|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
1794916|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 24 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
1794917|NCT00547508|Drug|tadalafil|20 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
1794918|NCT00547508|Drug|tadalafil|10 mg tablet taken orally, no more than once a day, at anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
1794919|NCT00547508|Drug|placebo|Placebo tablet taken by mouth, no more than once a day, anytime during the 2-4 week equilibration phase and then 36 hours prior to sexual intercourse for 4-6 weeks in the assessment phase
1794920|NCT00547521|Drug|abatacept|solution, subcutaneous injection, 125 mg/kg, weekly, 106 days in short term; long term is open
1794921|NCT00547521|Drug|Methotrexate (MTX)|Participants who were currently receiving methotrexate at a stable dose ≥ 10 mg for at least 4 weeks
1794922|NCT00547534|Drug|bortezomib|1.3 mg/m^2 on days 1, 4, 8, 11
1794923|NCT00547534|Drug|bendamustine|90 mg/m^2 days 1 and 4
1794924|NCT00547534|Drug|rituximab|375 mg/m^2 day 1
1794925|NCT00547547|Dietary Supplement|high-selenium Brassica juncea|Dose Level A: 3200 mcg orally day -7 through duration of treatment. Dose Level B: 4800 mcg orally day -7 through duration of treatment. Dose Level C: 6400 mcg orally day -7 through duration of treatment. Dose Level D: 7200 mcg orally day -7 through duration of treatment. Dose Level E: 8000 mcg orally day -7 through duration of treatment.
1794926|NCT00547547|Drug|capecitabine|Dose Level 1: 750 mg/m2, 2x daily x 14 days every 21 days. Dose Level 1.5: 850 mg/m2, 2x daily x 14 days every 21 days. Dose Level 2: 1000 mg/m2, 2x daily x 14 days every 21 days.
1794927|NCT00547547|Drug|irinotecan hydrochloride|Dose Level 1: 100 mg/m2 on day 1 and day 8 every 21 days. Dose Level -1: 75 mg/m2 on day 1 and day 8 every 21 days.
1794928|NCT00547560|Drug|GSI-953|Oral capsule, 10- and 50-mg, either once a day for 14 days or twice a day for 14 days, depending on cohort assignment.
1794929|NCT00547573|Drug|tadalafil|10 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
1794930|NCT00547573|Drug|tadalafil|20 mg tadalafil tablet taken by mouth as needed for 12 weeks not more than once a day
1794931|NCT00547573|Drug|placebo|placebo tablet taken by mouth as needed for 12 weeks not more than once a day
1794932|NCT00547586|Drug|N-methylnaltrexone bromide (MOA-728)|Oral
1794933|NCT00547586|Other|placebo|placebo
1794934|NCT00547599|Drug|tadalafil|20 mg tadalafil tablet by mouth as needed, no more than once a day for 8 weeks.
1794935|NCT00547612|Other|high performance liquid chromatography|
1794936|NCT00547612|Other|pharmacological study|
1794937|NCT00547612|Radiation|[18F]-labeled substance P antagonist receptor quantifier|
1794938|NCT00547625|Drug|tadalafil|Treatment phase 1 includes 5 mg tadalafil tablet taken by mouth once a day for 6 weeks then treatment phase 2 which includes 20 mg tadalafil tablet taken by mouth once a day for 6 weeks.
1794939|NCT00547625|Drug|placebo|Placebo tablet run in followed by placebo treatment period with one tablet taken by mouth once a day for twelve weeks.
1794940|NCT00547638|Device|cyanoacrylate with pressure sensitive mesh|Topical Skin Adhesive
1794941|NCT00547638|Device|cyanoacrylate|Topical Skin Adhesive
1794942|NCT00547651|Drug|Amrubicin|Amrubicin for injection is supplied as 50-mg vials. Patients will receive 40 mg/m2 amrubicin as a 5-minute infusion once daily for 3 consecutive days starting on Day 1 of a 21-day course
1794943|NCT00547651|Drug|Topotecan|Topotecan for injection is supplied as 4-mg vials. Patients will receive 1.5 mg/m2 as a 30-minute infusion once daily for 5 consecutive days starting on Day 1 of a 21-day course
1794944|NCT00547664|Drug|Hylenex recombinant , morphine, saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with or without the preceded co-injection of Hylenex. Hospice patients include both home-bound patients as well as those under intensive care in hospice houses.
1794945|NCT00547664|Other|Saline|Subcutaneous infusion of morphine and hydromorphone (Dilaudid) with the preceded co-injection of saline.
1794946|NCT00547677|Radiation|stereotactic radiosurgery|
1794947|NCT00547690|Other|Acupuncture and Strengthening|Acupuncture and strengthening
1794948|NCT00547690|Other|Strengthening Alone|Strengthening training program
1794949|NCT00547703|Drug|Nortriptyline|Nortriptyline 25mg capsule, orally administered, every night for 8 weeks
1794950|NCT00547703|Drug|Placebo|An identical placebo capsule containing lactose, administered orally, every night for 8 weeks
1794951|NCT00547716|Dietary Supplement|Omega-3 Fatty Acids|Omega-3 Fatty Acids - 4 grams per day
1794952|NCT00547716|Drug|Placebo comparator|
1794953|NCT00547729|Device|HeartPOD™ System|HeartPOD™ device automatically measures left heart pressures throughout the day.
1794954|NCT00547742|Procedure|PET/CT Scan|
1794955|NCT00547742|Procedure|phlebotomy|
1794956|NCT00547768|Drug|Fexofenadine HCI|
1794957|NCT00547781|Procedure|PGD|
1794960|NCT00547820|Other|placebo|
1794961|NCT00547820|Device|Urinary sensor|
1794962|NCT00547846|Drug|PDC-748|
1794963|NCT00547872|Procedure|exercise testing - coronary angiography - revascularization|Those patients with a positive exercise ECG test will be studied by coronary angiography and treated according to the severity of coronary lesions by percutaneous stenting or surgery
1794964|NCT00547885|Drug|Dihydrocodeine|"Group 1: 2* 60 mg dihydrocodeine long acting + up to four placebo short action
Group 2: 3* 60 mg dihydrocodeine long acting + up to six placebo short action
Group 3: 4* 60 mg dihydrocodeine long acting + up to eight placebo short action
Group 4: 2 placebo for long acting + up to 4*30 mg dihydrocodeine short acting
Group 5: 3 placebo for long acting + up to 6*30 mg dihydrocodeine short acting
Group 6: 3 placebo for long acting + up to 8*30 mg dihydrocodeine short acting"
1794965|NCT00547898|Drug|Crofelemer 125 mg|Crofelemer 125 mg
1794966|NCT00547898|Drug|Crofelemer 250 mg|Crofelemer 250 mg
1794967|NCT00547898|Drug|Crofelemer 500 mg|Crofelemer 500 mg
1794968|NCT00547898|Drug|Placebo|Placebo
1794969|NCT00547911|Drug|Droxidopa|
1794970|NCT00547911|Drug|Carbidopa|
1794971|NCT00547911|Drug|Entacapone|
1794972|NCT00547924|Behavioral|Transoesophageal echocardiography|Transoesophageal echocardiography in liver transplantation: left ventricular function during reperfusion
1794973|NCT00547937|Device|nasal continuous positive airway pressure (CPAP) therapy|Nocturnal ventilation through a nasal mask to avoid sleep apneas
1794974|NCT00547950|Drug|:Deng Zhan Sheng Mai Capsule|capsule，0.18g，2＃，po，Bid*1year.
1794975|NCT00547963|Behavioral|brief counseling|baseline assessment + two 40 minute sessions of brief counseling
1794976|NCT00547976|Drug|[C-11]PBR28|
1794977|NCT00547989|Drug|standard anaesthesia (bupivacaine)|Local infiltration with bupivacaine and Piritramide and Paracetamol as postoperative analgesic, and ondansetron as required
1794978|NCT00547989|Drug|additional pvb (ropivacaine) and elastomeric disposable infusion pump|Patients in group 2 will receive PVB with ropivacaine and postoperative pump 5ml/h.
1794979|NCT00547989|Drug|additional pvb (ropivacaine)|Patients in group 1 will receive PVB with ropivacaine
1794980|NCT00548002|Drug|trovafloxacin and levofloxacin|Trovafloxacin: <60 kg 200 mg iv/orally once daily and >60 kg 300 mg iv/orally once daily Levofloxacin: < 60 kg 500 mg iv/orally once daily and >60 kg 500 mg iv/orally bid
1794981|NCT00548015|Behavioral|state-of-the art strategy and extented strategy|state-of-the art: education, reminders, performance feedback, extented:state-of-the art and coaching ward manager,modeling of informal leaders, norm and target setting
1794982|NCT00548041|Other|HIV test by oral swab|Eligible subjects underwent rapid HIV testing by oral swab.
1794983|NCT00548054|Biological|Bivalent killed oral cholera vaccine|Oral, 1.5 ml, given 2 times at least 14 days apart
1794984|NCT00548054|Biological|Killed Escherichia coli K12 placebo|oral, 1.5 ml per dose
1794985|NCT00548067|Drug|Valsartan/hydrochlorothiazide (HCTZ)|
1794986|NCT00548067|Drug|Valsartan/amlodipine|
1794987|NCT00548067|Drug|Amlodipine/hydrochlorothiazide(HCTZ)|
1794988|NCT00548067|Drug|Valsartan/amlodipine/hydrochlorothiazide(HCTZ)|
1794989|NCT00548080|Drug|MK0991, caspofungin acetate / Duration of Treatment:|
1794990|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
1794991|NCT00548093|Drug|PF-00299804|PF-00299804 orally at 45 mg daily, on continuous schedule
1794992|NCT00548106|Dietary Supplement|partially hydrolyzed whey|Total infant feeding by study formula.
1794993|NCT00548106|Dietary Supplement|Nan HA|Total infant diet by study formula.
1794994|NCT00548119|Biological|NeoCart|autologous tissue implant
1794995|NCT00548119|Procedure|microfracture|microfracture
1794996|NCT00548132|Device|Chlorhexidine-impregnated foam dressing|Patients in the treatment arm will have the Biopatch incorporated into their catheter care protocol. ICU nurses were instructed on the proper use of this novel dressing/sponge. Catheter dressing changes will only be done every 7 days unless there is visible blood, soiling underneath the dressing, or if the dressing comes off.
1794997|NCT00548145|Drug|Pitavastatin|2 mg by orally/day Duration: 12 months
1794998|NCT00548145|Drug|cholesterol-lowering medicine other than statin(e.g.,Ezetimibe,Colestimide)|duration: 12 months
1795000|NCT00548184|Drug|Lapatinib|Monoclonal Antibody
1795001|NCT00548184|Drug|Trastuzumab|Monoclonal Antibody
1795002|NCT00548184|Drug|Endocrine|Hormonal Therapy
1795003|NCT00548197|Drug|Bevacizumab|one intravitreal injection of 2.5 mg Bevacizumab 3-5 days before performing pars plana vitrectomy
1795004|NCT00548223|Drug|Dengzhan Shengmai capsule|Capsule, 0.18g, 2#, Bid*1year
1795005|NCT00548223|Drug|placebo|Capsule, 0.18g, 2#, Bid*1year
1795006|NCT00548236|Behavioral|Telephone-Based exercise intervention|Exercise counselling offered via telephone calls
1795007|NCT00548249|Device|Standard Bicarbonate Solution|Patients received 0 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
1795008|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 5 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
1795009|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 10 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
1795010|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 12 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
1795011|NCT00548249|Drug|Soluble Ferric Pyrophosphate|Patients received 15 micrograms (µg) of iron/ decilited (dL) of dialysate during dialysis 3 times/week for up to 26 weeks.
1795012|NCT00548262|Drug|Anidulafungin|All patients will receive anidulafungin 200 mg IV dose on Day 1. On Day 2 and daily thereafter the patients will receive one daily IV dose of 100 mg of anidulafungin.
1795013|NCT00548262|Drug|Voriconazole|Patients who complete a minimum of 5 days of IV treatment with anidulafungin may be switched to oral voriconazole 200 mg BID (or 100 mg BID if <40 kg body weight) therapy on Day 5 and thereafter, starting with a loading dose of 400 mg BID (or 200 mg BID if <40 kg body weight).
1795014|NCT00548275|Behavioral|Enhanced Sexual Risk Management|management of sexual risk
1795015|NCT00548275|Behavioral|Standard Sexual Risk Management|management of sexual risk
1795016|NCT00548288|Drug|pamidronate|
1795020|NCT00548314|Device|VAC therapy (KCI)|VAC therapy for 3-5 days 125mmHg
1795021|NCT00548327|Drug|Atomoxetine|Comparison between Atomoxetine and Placebo
1795022|NCT00548327|Procedure|Functional magnetic resonance imaging|Comparison between Atomoxetine and Placebo arms
1795023|NCT00548327|Procedure|Neuropsychological Testing|Comparison between Atomoxetine and Placebo arms
1795024|NCT00548327|Drug|Placebo|25 mg, 40 mg, 60 mg and 80 mg Atomoxetine Placebo
1795025|NCT00548340|Drug|VEC-162 20 mg|20 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
1795026|NCT00548340|Drug|Placebo|Placebo capsules, PO daily for five weeks
1795027|NCT00548340|Drug|VEC-162 50 mg|50 mg VEC-162 (tasimelteon) capsules, PO daily for five weeks
1795028|NCT00548353|Drug|MK3207|M3207 (20 mg); patients will be administered a single dose of 100 mg of MK3207 (i.e., 5 x20-mg tablets).
1795029|NCT00548353|Drug|Comparator: Placebo (unspecified)|M3207 (20 mg) Pbo; patients will be administered a single dose of 100 mg of MK3207 Pbo (i.e., 5 x20-mg tablets).
1795030|NCT00548366|Other|Sodium restriction|4 gram sodium diet
1795031|NCT00548366|Other|Sodium restriction|2 gram sodium diet
1795032|NCT00548379|Drug|vitamin D|vitamin D 100,000 units once in 3 months
1795033|NCT00548379|Drug|placebo|olive oil 1ml
1795034|NCT00548405|Biological|Alemtuzumab 12 mg|Alemtuzumab 12 milligram (mg) per day intravenous (IV) infusion on 5 consecutive days at Month 0, followed by alemtuzumab 12 mg per day IV infusion on 3 consecutive days at Month 12.
1795035|NCT00548405|Biological|Alemtuzumab 24 mg|Alemtuzumab 24 mg per day IV infusion on 5 consecutive days at Month 0, followed by alemtuzumab 24 mg per day IV infusion on 3 consecutive days at Month 12.
1795036|NCT00548405|Biological|Interferon beta-1a|Interferon beta-1a 44 microgram (mcg) subcutaneously 3-times weekly for 24 months. Dose adjustment was done as per Investigator's discretion.
1795037|NCT00548418|Drug|Topotecan|
1795038|NCT00548418|Drug|Cisplatin|
1795039|NCT00548418|Drug|Bevacizumab|
1795040|NCT00548431|Drug|6-mercaptopurine|Standard dose 25 mg/m^2/day. Can be increased up to 75 mg/m^2/day if the myelosuppression is acceptable (ANC>0.5 T-count >50)
1795041|NCT00548444|Biological|MVA85A|Vaccine. Dose: 1 x 10^8 plaque-forming units (pfu) given by intradermal injection into the deltoid region of the upper arm.
1795042|NCT00548444|Other|Deuterated glucose infusion|6,6D2-glucose given as a timed intravenous infusion. The total dose of deuterated glucose will be 1g/kg volunteer body weight (up to a maximum of 60g).
1795043|NCT00548470|Drug|Varenicline|Varenicline 1-2 mg/day
1795044|NCT00548483|Drug|dexamethasone (Oradexon, Nederland)|dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
1795047|NCT00548509|Drug|Menatetrenone (Vitamin K2)|
1795048|NCT00548535|Procedure|Reliability of complication assessment|
1795049|NCT00548548|Drug|Bevacizumab|Intravenous bevacizumab 7.5 mg/kg once every 3 weeks, given until disease progression or unmanageable toxicity.
1795050|NCT00548548|Drug|Capecitabine|Oral capecitabine 1,000 mg/m˄2 twice daily for 14 days every 3 weeks, given until disease progression or unmanageable toxicity.
1795051|NCT00548548|Drug|Cisplatin|Cisplatin 80 mg/m˄2 as a 2 hr intravenous infusion with hyper-hydration and pre-medication (steroids and anti-emetics), given every 3 weeks for a maximum of 6 cycles or until disease progression or unmanageable toxicity.
1795052|NCT00548548|Drug|Placebo|Intravenous placebo every 3 weeks, given until disease progression or unmanageable toxicity.
1795053|NCT00548548|Drug|5-fluorouracil|For participants with difficulty swallowing, malabsorption, or other conditions that could affect intake of oral capecitabine medication, 5-fluorouracil was administered instead, at a dose of 800 mg/m˄2/day as a continuous intravenous infusion over 5 days (days 1 to 5 of each cycle), every 3 weeks.
1795054|NCT00548561|Drug|Dexrazoxane|
1795055|NCT00548574|Drug|SPD476 is a polymeric matrix formulation that displays both delayed- and extended-release of mesalazine|
1795056|NCT00548574|Drug|Mesalazine|
1795057|NCT00548587|Drug|E5555|
1795058|NCT00548587|Drug|Placebo|
1795059|NCT00548600|Procedure|Iridium Implant|Temporary iridium implant of the prostate will be done and a dose of 3000 cGy will be delivered in the next 48-72 hours. Two weeks later 20 fractions of external beam radiation at a dose of 4000 cGy will be administered over a period of 4 weeks.
1795060|NCT00548600|Radiation|Standard external beam irradiation|Standard external beam irradiation at a dose of 6400 cGy in 32 fractions over 6 and a half weeks will be administered.
1795061|NCT00548613|Biological|MESENDO|Intracoronary transplantation of autologous stem cells via balloon catheter
1795062|NCT00548613|Biological|MESENDO|Intracardiac transplantation of autologous stem cells via direct injection
1795063|NCT00548626|Procedure|Single needle|Patients will be sampled for a total of 6 consecutive FNA passes with a single EUS-FNA needle (only replaced if the needle has a reduced performance). After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
1795064|NCT00548626|Procedure|Multiple needle|Patients will be sampled for a total of 6 consecutive FNA passes, replacing the needle after every 2 passes. After completing the 6th pass the endoscopist will be informed by the onsite cytopathologist about the preliminary cytological diagnosis.
1795065|NCT00548639|Other|Statin Choice Decision Aid|Paper based instrument with pictures indicating level of risk.
1795066|NCT00548639|Other|Control Pamphlet|ADA Diabetes Sheet
1795067|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
1795068|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
1795069|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
1795070|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
1795071|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
1795072|NCT00548652|Drug|methyphenidate|methyphenidate will be used to treat apathy dose 10mg bid
1795073|NCT00548652|Behavioral|medical crisis councelling|group counselling sessions
1795119|NCT00548964|Drug|Lithium|600-900mg of Li carbonate
1795074|NCT00548652|Behavioral|MOVE|is a VA based multidesciplinary weight loss intervention
1795075|NCT00548665|Device|Carotid ultrasound for plaque screening|Carotid ultrasound for plaque screening
1795076|NCT00548665|Behavioral|Brief advice for smoking cessation|We will use the 5A's heuristic (Ask about smoking, Advise on cessation, Assess willingness to change, and for those willing to make quit attempt: Assist with attempt to quit, and Arrange for follow-up) and the gold standard for brief smoking cessation advice. At each visit, smokers will receive smoking cessation counseling and nicotine replacement therapy, similar to the experimental group.
1795077|NCT00548678|Drug|intravenous diclofenac sodium (DIC075V)|intravenous diclofenac sodium
1795078|NCT00548678|Drug|ketorolac|intravenous ketorolac
1795079|NCT00548678|Drug|oral diclofenac (Cataflam)|oral diclofenac (Cataflam)
1795080|NCT00548678|Drug|aspirin|oral aspirin
1795081|NCT00548691|Drug|Ferric Carboxymaltose|
1795082|NCT00548691|Drug|Standard Medical Care (SMC)|
1795083|NCT00548704|Drug|Dexrazoxane|
1795084|NCT00548717|Drug|Sirolimus|
1795085|NCT00548717|Drug|Mycophenolate mofetil|
1795086|NCT00548717|Drug|Bortezomib|
1795090|NCT00548756|Procedure|Whole Brain Radiation Therapy|Whole Brain Radiation Therapy. Total dose = 30 Gy over 12 fractions at 2.5Gy per fraction.
1795091|NCT00548756|Other|Observation|Patients who did not receive whole brain radiation and develop recurrent disease shall receive treatment based on the number of lesions.
1795092|NCT00548756|Behavioral|Questionnaire|Questionnaire taking 40 minutes to complete.
1795093|NCT00548769|Drug|Formulation A|Formulation A will contain firategrast drug substance from native drug batch Irvine. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.1 square meter per gram. The tablets will be administered with 240 milliliters of water.
1795094|NCT00548769|Drug|Formulation B|Formulation B will contain firategrast drug substance from native drug batch Tonbridge. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
1795095|NCT00548769|Drug|Formulation C|Formulation C will contain firategrast drug substance from Tonbridge single pass micronized drug. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 3-4 square meter per gram. The tablets will be administered with 240 milliliters of water.
1795096|NCT00548769|Drug|Formulation D|Formulation D will contain firategrast drug substance from Tonbridge with reduced tablet size. Subjects will be administered three tablets of 300 milligrams with drug substance surface area of 2.6 square meter per gram. The tablets will be administered with 240 milliliters of water.
1795097|NCT00548782|Other|Paleolithic diet|diet
1795098|NCT00548782|Other|ADA ( American Diabetes Association) recommended diet|diet
1795099|NCT00548808|Drug|Insulin lispro low mixture|Dose depending on patient's need; subcutaneous injection before meal; start with once-daily injection before evening meal for 48 weeks, may add second injection before breakfast at any time during the treatment period if required, and may further add third injection before lunch at any time in the remainder of the treatment period if required.
1795100|NCT00548808|Drug|Insulin glargine|Dose depending on patient's need; one daily subcutaneous injection before bedtime for 48 weeks
1795101|NCT00548808|Drug|Insulin lispro|Dose depending on patient's need; subcutaneous injection before meal; may start once-daily injection before meal (e.g. lunch if the highest blood glucose value is measured before dinner) on top of insulin glargine at any time of the treatment period if required, and may further add second or even third injection in the remainder of the treatment period if required.
1795102|NCT00548821|Drug|Cisplatin|
1795103|NCT00548834|Drug|CDP870|
1795104|NCT00548847|Biological|GM-CSF|Dosing schedule: 250 mcg/m² subcutaneously Mon-Wed-Fri. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
1795105|NCT00548847|Biological|Interferon-α-2b|Dosing schedule: 1.5 mcg/kg subcutaneously Monday weekly. Response assessed between 2 and 4 weeks. Duration on study is 3 months.
1795106|NCT00548860|Drug|Ferric Carboxymaltose|
1795107|NCT00548860|Drug|Standard Medical Care (SMC)|
1795108|NCT00548886|Drug|Epinephrine|We will follow the protocol outlined by Ackerman et al. known as the Mayo protocol4 which is currently used routinely in our electrophysiology laboratory. Epinephrine infusion will begin at 0.025 ug/kg/minute, for ten minutes and a twelve-lead electrocardiogram is obtained at time=0 minutes, 5 minutes, and 10 minutes. The epinephrine infusion will then be increased to 0.05 ug/kg/minute for five minutes and the electrocardiogram repeated. The epinephrine infusion will then be increased to a maximal dose of 0.1 ug/kg/minute for five minutes and electrocardiogram obtained. The epinephrine infusion is then discontinued and measurements are obtained at five minutes and ten minutes after stopping the epinephrine infusion. The total time of procedure will be 35 minutes.
1795109|NCT00548899|Drug|Nexavar (Sorafenib)|Tablet, Sorafenib follows a patient specific escalation scheme starting with 200 mg daily up to a maximum dose of 800 mg daily during EC chemotherapy on day 2-19. The achieved dose will be continued during paclitaxel chemotherapy during week 1-11 all day
1795110|NCT00548912|Drug|Spironolactone|
1795111|NCT00548925|Drug|ABT-894|6 mg BID tablets, 8 weeks of treatment
1795112|NCT00548925|Drug|placebo|BID tablets, 8 weeks of treatment
1795113|NCT00548938|Drug|Gliadel wafer|Implanted at surgery
1795114|NCT00548938|Drug|Temozolomide|During External Beam Radiation
1795115|NCT00548938|Radiation|External Beam Radiation Therapy|60 Gy
1795116|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room once per week for 12 weeks
1795117|NCT00548951|Other|Snoezelen Room|Session in a Snoezelen room three times per week for 12 weeks
1795118|NCT00548951|Other|Control|Receive no sessions in a Snoezelen Room.
1795120|NCT00548964|Drug|Ketamine|0.5mg/kg of ketamine
1795121|NCT00548977|Other|Drawing blood to study genetic polymorphism|
1795122|NCT00548990|Behavioral|cardiovascular exercise training|
1795123|NCT00548990|Behavioral|flexibility/balance control|
1795124|NCT00549003|Device|Rapid Diagnostic Test for P. falciparum malaria|
1795125|NCT00549016|Device|PTPE Encapsulation of Nitinol Stents|Both common femoral arteries (CFAs) are surgically exposed to allow bilateral access of diagnostic and therapeutic devices. The endoluminal stent graft is then deployed in accordance with the Instructions for Use.
1795126|NCT00549029|Genetic|DNA|withdraw 5~10mL blood from vein only once during the whole design
1795129|NCT00549055|Drug|Macugen|Dosage form: solution for injection (intravitreal) Dosage: 0.3mg Frequency: every 6 weeks (9 injections/year)
1795130|NCT00549068|Drug|Risedronate Sodium (Actonel)|
1795131|NCT00549081|Dietary Supplement|DHEA|oral DHEA tablets 75 mg daily
1795134|NCT00549120|Drug|Propranolol|40 mg tablets
1795135|NCT00549120|Drug|Salbutamol|Metered dose inhaler (600 μg)
1795136|NCT00549120|Drug|Ipratropium|Metered dose inhaler (40 μg)
1795137|NCT00549120|Drug|Placebo|Placebo for propranolol tablets
1795138|NCT00549133|Drug|Irbesartan|
1795139|NCT00549146|Drug|fluticasone propionate/salmeterol 250/50 DISKUS combination product|
1795140|NCT00549146|Drug|fluticasone propionate DISKUS 500mcg|
1795141|NCT00549159|Device|Thermal Balloon Endometrial Ablation|Thermal balloon endometrial ablation
1795142|NCT00549159|Device|Transcervical Resection of the Endometrium|Transcervical resection of the endometrium
1795143|NCT00549172|Procedure|Operative (partial arthroscopy)|Partial arthroscopic resection of degenerative rupture of the medial meniscus
1795144|NCT00549172|Procedure|Conservative (diagnostic arthroscopy)|Diagnostic arthroscopy
1795145|NCT00549185|Drug|SAR3419|Intravenous infusion
1795146|NCT00549198|Drug|Abacavir/lamivudine and efavirenz|
1795147|NCT00549198|Drug|Tenofovir/Emtricitabine and efavirenz|
1795148|NCT00549211|Drug|GSK557296|
1795149|NCT00549237|Dietary Supplement|Glucose load (Nutricia)|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
1795150|NCT00549237|Other|Post operative early enteral feeding|Enteral feeding starting 6 hours post surgery
1795151|NCT00542568|Biological|EPODURE (dermal Biopump for erythropoietin)|Subjects will undergo similar study procedures and evaluations; however each dosage group will receive a different targeted dose of EPO delivered via EPODURE Biopump
1795152|NCT00542581|Device|The Acrysof toric SN60T3 IOL|Intraocular Lens
1795153|NCT00542607|Drug|levocetirizine dihydrochloride|
1795154|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin aspart
1795155|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, mixed with insulin detemir
1795156|NCT00542620|Drug|insulin detemir|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin aspart
1795157|NCT00542620|Drug|insulin aspart|Treat-to-target (individually adjusted) dose titration, s.c. (under the skin) injection, twice a day, injected separately with insulin detemir
1795158|NCT00542633|Drug|VIAject™|Dosage as individually required
1795159|NCT00542633|Drug|Regular Human Insulin|Dosage as individually required
1795160|NCT00542646|Procedure|Endovascular Intervention|Peritoneal Lined Stent Endovascular Intervention
1795161|NCT00542685|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper.
1795162|NCT00542685|Drug|Placebo|Capsules, oral, placebo BID, 8 weeks with 2 week taper.
1795163|NCT00542685|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper.
1795164|NCT00542685|Drug|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper.
1795165|NCT00542698|Behavioral|Effect of Physical Activity on Type II Diabetes Mellitus|Reviewing participants and a role model's continuous glucose monitor graphs, discussing benefits of physical activity and setting physical activity goals.
1795166|NCT00542711|Drug|liquid tumeric/curcumin extract|30 drops (4 participants), 50 drops (4 participants) and 70 drops (4 participants). one dose.
1795167|NCT00542724|Drug|VIAject™|Dosage as individually required
1795168|NCT00542724|Drug|Regular Human Insulin|Dosage as individually required
1795169|NCT00542737|Behavioral|Web-Based Educational Program|Participating clinicians at each hospital will access the Web site as often as necessary for a 6-month period. The Web site will contain background and educational information on ALI/ARDS and LPV, including how to recognize ALI/ARDS and how to implement LPV in patients. Scholarly articles and other materials, including a chart to help clinicians determine appropriate ventilator settings for each patient, will be available to download. Clinicians will also be able to email questions to critical care experts.
1795171|NCT00542763|Drug|Mycophenolate sodium|Medical treatment is initiated with one tablet of 360 mg mycophenolate sodium orally per day for eligible patient. The dosage will be increased weekly by 360 mg up to a maximum stable dose of 1440mg daily. In patients not well tolerating the drug the dosage can be reduced to 720 mg per day.
1795172|NCT00542776|Other|blood draw|drawing blood for seroprotection and antibody titers to the 3 strains of influenza on Day 1 and Month 1 (3-8 weeks)
1795173|NCT00542789|Drug|Esomeprazole|20mg once daily oral
1795174|NCT00542789|Drug|Placebo|once daily oral
1795175|NCT00542802|Drug|Levetiracetam|Levetiracetam tablets 250-500 mg. The drug dosage will be up-titrated from 250 mg bid in the first 2 weeks to 500 mg bid during the rest of the treatment period. The dosage can be incremented until 1500 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
1795280|NCT00551122|Biological|lenograstim|
1795176|NCT00542802|Drug|Carbamazepine|Carbamazepina tablets 200 mg. The drug dosage will be up-titrated from 100 mg die in the first 3 days to 100 mg bid during days 4 to 7, to 200 mg bid in the 2nd week, to 300 mg bid during the rest of the treatment period. The dosage can be incremented until 800 mg bid, at Investigator judgement if crisis continue, or it can be reduced in case of adverse events
1795177|NCT00542815|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 40 weeks of flexible dose
1795178|NCT00542815|Drug|Another Phosphate binder (Sevelamer)|Current approved dosing recommendations for 12 weeks
1795179|NCT00542828|Biological|Thymoglobulin®, Rabbit Anti-thymocyte Globulin (rATG)|All patients were to be treated with rATG 3.75 mg/kg/day administered by intravenous (IV) infusion over ≥6 hours for 5 consecutive days (cumulative dose: 18.75 mg/kg)
1795180|NCT00542841|Procedure|Hydrocortisone withdrawal|This is considered a non-standard treatment. On Day 1, participants will receive one 10-mg pill of hydrocortisone. On Day 3, participants will receive intravenously a medicine called cosyntropin, a synthetic form of a hormone that the body makes. Participants will receive one last pill of hydrocortisone prior to the end of the study.
1795181|NCT00549263|Drug|SB797620|
1795182|NCT00549289|Drug|cyclosporine A|
1795183|NCT00549302|Drug|tadalafil|20 milligram (mg) tablet, taken by mouth once a day for 52 weeks for the phase 1 portion. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of Pulmonary Arterial Hypertension (PAH).
1795184|NCT00549302|Drug|tadalafil|40 mg tablet taken by mouth once a day for 52 weeks in phase 1. Open label phase includes 40 mg tablet taken by mouth once a day until the sponsor concludes the study or tadalafil becomes commercially available for the treatment of PAH.
1795185|NCT00549315|Device|Valiant Endoluminal Stent-Graft Stent-Graft Balloon Catheter|VALIANT stent-graft endoprosthesis is inserted by the Xcelerant Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
1795186|NCT00549328|Drug|Pazopanib (GW786034)|Pazopanib monotherapy
1795187|NCT00549341|Drug|Mentor Purified Toxin, Botulinum Toxn Type A, Purified Neurotoxin|100U vials, doses ranged from 50U-200U, single injection.
1795188|NCT00549341|Other|Physiologic saline|Single injection.
1795189|NCT00549354|Device|Endoluminal Graft|
1795190|NCT00549367|Behavioral|Nutrition Counselling|Clients will receive ongoing nutrition assessment and dietary counselling. The intervention arm will receive all baseline assessments and individual nutritional assessment, counselling and nutrition management plans using standards of practice
1795191|NCT00549380|Device|Endologix, Inc. Endoluminal Technology|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
1795192|NCT00549393|Drug|2% Chlorhexidine gluconate cloth|Daily bathing
1795193|NCT00549406|Procedure|computerized visual training|two one-hour training sessions per week, for five consecutive weeks
1795194|NCT00549406|Procedure|computerized word puzzles|two one-hour sessions per week, for five consecutive weeks
1795195|NCT00549406|Procedure|video-game based visual training|two one-hour training sessions per week, for five consecutive weeks
1795196|NCT00549419|Drug|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine|The Control group will be assessed using the standard care of traditional vital signs
1795197|NCT00549419|Drug|Goal-directed hemodynamic therapy|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
1795198|NCT00549419|Drug|Standard of care|Ringers lactate, hydroxyethyl starch; norepinephrine, dobutamine
1795199|NCT00549432|Device|TALENT Enhanced LPS Endoluminal Stent-Graft System|roadmapping, and angiography for proper implant positioning. The TALENT endoluminal stent-graft endoprosthesis is inserted by delivery catheter and introducer sheath via a surgical cutdown (e.g., external iliac artery, femoral artery) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
1795200|NCT00549445|Drug|Azithromycin|250 mg daily
1795201|NCT00549445|Drug|Placebo|Daily
1795202|NCT00549458|Behavioral|Pilates|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
1795203|NCT00549458|Procedure|Pelvic muscle rehabilitation therapy|The currently popular exercise program, known as Pilates (named after founder, Joseph Pilates) consists of a series of low impact, flexibility and muscle toning exercises. The philosophy centers around developing core strength which includes strengthening the pelvic floor. Its use has been described in the US since the 1920s.4 Five million Americans currently participate, as opposed to five thousand ten years ago.5 Given its mainstream popularity, Pilates would be an appealing as a therapeutic modality for women experiencing pelvic muscle weakness. Currently, there are no studies that assess the efficacy of Pilates in increasing pelvic muscle strength.
1795204|NCT00549471|Other|physiotherapy|CG children will undergo a program of intensive physiotherapy
1795205|NCT00549471|Other|Botulinum Toxin A and physiotherapy|BG children will be given Botox, as clinically required, in addition to an equivalent program of intensive therapy. Botox injection will be tailored according to the specific child. Generally injection site will include biceps and brachioradialis, while flexors of the wrist and digits will be injected according to abnormal postures during function. Maximal total dose will be 23 IU per kg.
1795206|NCT00549497|Drug|GW870086X|
1795207|NCT00549510|Drug|COREG CR and lisinopril (FDC)|
1795208|NCT00549523|Drug|Placebo|Capsules containing 0 mg bid (placebo)
1795209|NCT00549523|Drug|Low Dose|Capsules containing 400 mg bid of L. frutescens.
1795210|NCT00549523|Drug|Mid Dose|Capsules containing 800 mg bid of L. frutescens.
1795211|NCT00549523|Drug|High Dose|Capsules containing 1200 mg bid of L. frutescens.
1795212|NCT00549536|Dietary Supplement|tablets each containing of 1000mg elemental calcium (Mega-Calcium Sandoz)|1500 mg of elemental calcium per day.
1795213|NCT00549549|Drug|Indomethacin|indomethacin 50 mg three times a day (TID) for 8 days.
1795214|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 800 mg followed by a second dose of 400 mg 12 hours later on Day 1 (celecoxib 800/400 mg regimen) and continuing 400 mg two times a day (BID) for 7 days.
1795215|NCT00549549|Drug|Celecoxib|An initial dose of celecoxib 400 mg followed by a second dose of 200 mg 12 hours later (celecoxib 400/200 mg regimen) and continuing 200 mg two times a day (BID) for 7 days.
1795216|NCT00549549|Drug|Celecoxib|Celecoxib 50 mg two times a day (BID) for 8 days
1795217|NCT00549562|Drug|Paliperidone ER|Starting dose is 3 mg per day. Can be titrated up to a maximum dose of 9 mg per day.
1795218|NCT00549575|Drug|L ARG|Patients received 14 g/day of L-arginine (90 mL syrup, Veyron France Laboratories).
1795219|NCT00549575|Drug|Placebo|After double blind randomization, patients received a placebo.
1795220|NCT00550901|Drug|cisplatin|
1795221|NCT00550901|Drug|dexrazoxane hydrochloride|
1795222|NCT00550901|Other|high performance liquid chromatography|
1795223|NCT00550901|Other|laboratory biomarker analysis|
1795224|NCT00550901|Other|mass spectrometry|
1795225|NCT00550901|Other|pharmacological study|
1795226|NCT00550927|Biological|bevacizumab|
1795227|NCT00550927|Drug|enzastaurin hydrochloride|
1795228|NCT00550927|Other|diagnostic laboratory biomarker analysis|
1795229|NCT00550927|Other|pharmacological study|
1795230|NCT00550953|Drug|telmisartan+amlodipine|
1795231|NCT00550953|Drug|telmisartan|
1795232|NCT00550966|Behavioral|Psychoeducative program in fibromyalgic patients|Multi-component program including information about the illness, counselling about physical exercise and training in autogenic relaxation. The intervention consists on nine 2 hour sessions delivered during a two month period. The pharmacological treatment prescribed by the physician is maintained in both groups.
1795233|NCT00550992|Biological|anti-thymocyte globulin|
1795234|NCT00550992|Drug|asparaginase|
1795235|NCT00550992|Drug|busulfan|
1795236|NCT00550992|Drug|cyclophosphamide|
1795237|NCT00550992|Drug|cyclosporine|
1795238|NCT00550992|Drug|cytarabine|
1795239|NCT00550992|Drug|daunorubicin hydrochloride|
1795240|NCT00550992|Drug|etoposide|
1795241|NCT00550992|Drug|leucovorin calcium|
1795242|NCT00550992|Drug|melphalan|
1795243|NCT00550992|Drug|mercaptopurine|
1795244|NCT00550992|Drug|methotrexate|
1795245|NCT00550992|Drug|mitoxantrone hydrochloride|
1795246|NCT00550992|Drug|pegaspargase|
1795247|NCT00550992|Drug|prednisolone|
1795248|NCT00550992|Drug|prednisone|
1795249|NCT00550992|Drug|therapeutic hydrocortisone|
1795250|NCT00550992|Drug|thioguanine|
1795251|NCT00550992|Drug|vincristine sulfate|
1795252|NCT00550992|Procedure|allogeneic bone marrow transplantation|
1795253|NCT00550992|Procedure|allogeneic hematopoietic stem cell transplantation|
1795254|NCT00550992|Procedure|umbilical cord blood transplantation|
1795255|NCT00551005|Drug|celecoxib|
1795256|NCT00551005|Drug|etoposide|
1795257|NCT00551005|Other|immunoenzyme technique|
1795258|NCT00551005|Other|laboratory biomarker analysis|
1795259|NCT00551018|Drug|Vicriviroc|one 30 mg tablet QD
1795260|NCT00551018|Drug|emtricitabine and tenofovir disoproxil fumarate|one 200/300 combination tablet QD
1795261|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1)|0.1 mL, Intradermal (ID)
1795262|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2)|0.1 mL, Intradermal (ID)
1795263|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
1795264|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (High-dose)|0.5 mL, Intramuscular (IM)
1795265|NCT00551031|Biological|Split, Inactivated, Trivalent Influenza Vaccine (Standard dose)|0.5 mL, Intramuscular (IM)
1795266|NCT00551044|Drug|Bicalutamide|Bicalutamide 150mg once daily, oral administration, for 12 months
1795267|NCT00551057|Behavioral|Expression type|to investigate the expression of different inflammatory proteins in cancer and normal pancreatic tissue
1795268|NCT00551070|Drug|selumetinib|Given PO
1795269|NCT00551070|Other|pharmacological study|Correlative studies
1795270|NCT00551070|Other|laboratory biomarker analysis|Correlative studies
1795271|NCT00551083|Other|Computerized Decision Support System for Depression (CDSS-D)|The CDSS for depression was based on an up-to-date model of the Texas Medication Algorithm Project that employs the principles of Measurement Based Care (MBC), while at the same time having a user interface for providers that is easy-to-use. MBC is the systematic use of measuring clinical outcomes at routine visits to guide treatment management. These outcomes may include symptoms, side effects, and medication adherence. Recent efforts from the large, multi-site effectiveness study, Sequenced Treatment Alternatives to Relieve Depression (STAR*D), show that a treatment plan guided by MBC is integral in implementing algorithm based care.
1795272|NCT00551083|Other|Usual Care (UC)|"Usual Care was up to the discretion of the study physician and the patient treated. These physicians were provided with up-to-date treatment protocols for depression, but were not instructed to strictly adhere to a treatment algorithm. Therefore, they treated depressed patients as they usually would."
1795273|NCT00551096|Drug|Gemcitabine|Gemcitabine administered intravenously over 30 minutes on days 1, 8 and 15 of each cycle at a fixed dose of 1000mg/m2.
1795274|NCT00551096|Drug|Capecitabine|Capecitabine administered orally at 1660 mg/m2/day divided into two doses for 21 days followed by a week-off.
1795275|NCT00551096|Drug|ZD6474|Administered orally at 300 mg/day once daily. One cycle will consist of 28 days
1795276|NCT00551109|Drug|placebo|placebo, oral administration, once daily for 8 weeks
1795277|NCT00551109|Drug|SA4503 Low|Low dose, oral administration, once daily for 8 weeks
1795278|NCT00551109|Drug|SA4503 High|High dose, oral administration, once daily for 8 weeks
1795279|NCT00551122|Biological|filgrastim|
1795281|NCT00551122|Biological|pegfilgrastim|
1795282|NCT00551122|Drug|cisplatin|
1795283|NCT00551122|Drug|gemcitabine hydrochloride|
1795284|NCT00551122|Drug|ifosfamide|
1795285|NCT00551122|Drug|paclitaxel|
1795286|NCT00551135|Drug|Pregabalin|150 mg BID
1795287|NCT00551135|Drug|placebo|Placebo
1795288|NCT00551135|Drug|Pregabalin|75 mg BID
1795289|NCT00551135|Drug|Pregabalin|25 mg BID
1795290|NCT00551148|Drug|PD 0200390|oral 15 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
1795291|NCT00551148|Drug|PD 0200390|oral 30 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
1795292|NCT00551148|Drug|PD 0200390|oral 5 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
1795293|NCT00551148|Drug|PD 0200390|oral 60 mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
1795294|NCT00551148|Other|Placebo|oral placebo mg dose on 2 consecutive nights. This is one of 5 treatment doses administered one week apart for 5 consecutive weeks.
1795295|NCT00551161|Drug|memantine|24-week observational lead-in period, wherein patients already on a stable dose of donepezil, rivastigmine, or galantamine continue on that dose, followed by a 24-week open-label memantine period, wherein patients receive open-label memantine treatment titrated to a dose of 10 mg orally b.i.d., in addition to their ongoing stable cholinesterase inhibitor treatment
1795296|NCT00551174|Drug|ibandronate [Bonviva/Boniva]|3 mg IV every 3 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
1795297|NCT00551174|Drug|ibandronate [Bonviva/Boniva]|2 mg IV every 2 months for 3 years. All patients received a minimum of calcium 500 milligrams/day (upper limit 1500 mg/day) and Vitamin D 400 Internation Units/day (IU/day).
1795298|NCT00551187|Biological|V504|V504 0.5 ml injection in 3 dose regimen for 6 month treatment period.
1795299|NCT00551187|Biological|Comparator: Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 ml injection in 3 dose regimen for 6 month treatment period.
1795300|NCT00551187|Biological|Comparator: Placebo (unspecified)|V504 Placebo in 3 dose regimen for 6 month treatment period.
1795301|NCT00551200|Drug|HPN-100|Subjects will be taking prescribed dose of Buphenyl® TID (not to exceed 20g/day) at least two weeks prior to enrollment. Subjects will take prescribed dose of Buphenyl® TID for first week of study, and then switch over to HPN-100 TID during a dose-escalation phase. The dose of HPN-100 will be increased and the dose of Buphenyl® will be decreased each week by 50 mg/kg until entire daily dose of phenylbutyrate is HPN-100. Target HPN-100 dose will contain the same amount of phenylbutyrate as the subject's prescribed daily dose of Buphenyl®. Subject will take HPN-100 alone for one week and then switch back to previous dose of Buphenyl for the last week of the study.
1795302|NCT00551200|Drug|BUPHENYL®|BUPHENYL® (sodium phenylbutyrate) tablets and powder have been approved for marketing in the United States since 1996 as an adjunctive therapy in the long-term management of patients with UCDs involving deficiencies of CPS, OTC, or ASS.
1795303|NCT00551213|Biological|Robatumumab|
1795304|NCT00551213|Drug|Irinotecan|
1795305|NCT00551213|Biological|Cetuximab|
1795306|NCT00551213|Drug|Capecitabine|
1795307|NCT00551213|Drug|FOLFOX|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ oxaliplatin (OX)
1795308|NCT00551213|Drug|CAPEOX/XELOX|Capecitabine (CAPE) or Xeloda® (XEL) + oxaliplatin (OX)
1795309|NCT00551213|Drug|FOLFIRI|Leucovorin calcium (folinic acid)(FOL) + 5-fluorouracil (F)+ irinotecan (IRI)
1795310|NCT00551239|Biological|rituximab|Given IV
1795311|NCT00551239|Drug|fludarabine phosphate|Given IV
1795312|NCT00551239|Drug|pixantrone dimaleate|Given IV
1795313|NCT00551252|Drug|Imatinib mesylate plus Gemcitabine|Imatinib (400 mg daily) + Gemcitabine (500 mg/sqm, days 1 and 8 every 21 days) for a maximum of 6 cycles
1795314|NCT00551265|Drug|Cyclophosphamide|Given IV
1795315|NCT00551265|Procedure|Laboratory Biomarker Analysis|Correlative studies
1795316|NCT00551265|Biological|Oregovomab|Given IV
1795317|NCT00551278|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|"For in vitro diagnostic use only.
The GeneSearch™ Breast Lymph Node (BLN) Assay is a qualitative, in vitro diagnostic test for the rapid detection of greater than 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra‑operative or post-operative decision to remove additional lymph nodes.
Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Veridex lymph node cutting scheme, is required."
1795318|NCT00551291|Drug|Mycophenolate mofetil|1 gm twice daily orally until end of study.
1795319|NCT00551291|Drug|Prednisone|10 mg/day orally until end of study.
1795320|NCT00551291|Drug|Erythropoietin Beta|Recombinant human erythropoietin beta at doses of 30,000 IU/week by the subcutaneous route for 6 weeks.
1795321|NCT00551304|Device|Ardian Catheter|
1795322|NCT00551317|Drug|Darapladib (SB480848)|
1795323|NCT00551330|Drug|Vicriviroc|One tablet of vicriviroc 30 mg once daily
1795324|NCT00551330|Drug|Placebo|One tablet of placebo once daily
1795325|NCT00551343|Drug|Exenatide|10ug Exenatide single s.c. injection
1795326|NCT00551356|Drug|Insulin lispro mix 25|Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.
1795327|NCT00551356|Drug|Glargine|Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
1795328|NCT00551369|Radiation|SBRT|SBRT delivered in 3 fractions of 20 Gy/fraction over 1.5 to 2 weeks for a total of 60 Gy
1795329|NCT00551382|Drug|Muntelukast|Tablets or granules; 4 mg once a day for 12 weeks
1795330|NCT00551382|Drug|Placebo|Look alike tablets or granules 1 per day for 12 weeks
1795331|NCT00551395|Procedure|selective laser trabeculoplasty - early completion|180 degrees of laser on day 1 and other 180 degrees on day 2.
1795332|NCT00551395|Procedure|Selective laser trabeculoplasty - late completion|180 degrees of laser on day 1 and other 180 degrees at 1 month follow up point.
1795333|NCT00551421|Biological|pertuzumab|Given IV
1795334|NCT00551421|Biological|cetuximab|Given IV
1795335|NCT00551421|Drug|irinotecan hydrochloride|Given IV
1795336|NCT00551421|Other|immunohistochemistry staining method|Correlative study
1795337|NCT00551421|Other|fluorescence in situ hybridization|Correlative study
1795338|NCT00551421|Other|gene expression analysis|Correlative study
1795339|NCT00551421|Other|mutation analysis|Correlative study
1795340|NCT00551421|Other|polymerase chain reaction|Correlative study
1795341|NCT00551421|Other|laboratory biomarker analysis|Correlative study
1795342|NCT00551434|Dietary Supplement|Creatine|Creatine 21 g daily
1795343|NCT00551434|Dietary Supplement|L-arginine and creatine|L-arginine
1795344|NCT00551434|Dietary Supplement|l-arginine|l-arginine 9 g daily
1795345|NCT00551434|Dietary Supplement|placebo, double|placebo
1795346|NCT00551447|Drug|MK0653, ezetimibe / Duration of Treatment: 27 Weeks|
1795347|NCT00551447|Drug|MK0733, simvastatin / Duration of Treatment: 27 Weeks|
1795348|NCT00551447|Drug|Comparator: simvastatin / Duration of Treatment: 27 Weeks|
1795349|NCT00551460|Drug|arsenic trioxide|
1795350|NCT00551460|Drug|gemtuzumab ozogamicin|
1795351|NCT00551460|Drug|mercaptopurine|
1795352|NCT00551460|Drug|methotrexate|
1795353|NCT00551460|Drug|tretinoin|
1795354|NCT00551473|Drug|Lavoltidine|
1795355|NCT00551486|Procedure|ultrasound-guided fine needle aspiration biopsy|Fine needle aspiration (FNA)with cytologic analysis has become a mainstay of thyroid nodule evaluation was used. Nonpalpable nodules were aspirated under ultrasound guidance to facilitate precise targeting of the nodule and to sample the part most likely to improve diagnostic yield.
1795356|NCT00551499|Device|CRT in combination with Atrial Overdrive Pacing|The CSA group will undergo 2 sleep evaluation on two consecutive nights, during which the device will be programmed according to the randomization scheme (one night CRT, DDD/45 and the other CRT, DDD/15 bpm over mean nocturnal heart rate). The mean nocturnal heart rate over the last week is derived from the device memory.
1795357|NCT00551512|Drug|CBP501 and Cisplatin|CBP501 is given IV on Day 1 of each cycle (every 21 days). Dose escalation of CBP501 and cisplatin will be starting doses of 3.6 mg/m² CBP501 and 50 mg/m² cisplatin (Dose Level 1). Step 1, if during the first 2 cycles, at least 2 out of 3 to 6 patients experience Dose Limiting Toxicity (DLT) at 50 mg/m² cisplatin, then the cisplatin dose will be de-escalated to 30 mg/m². If no more than 1 out of 6 patients experiences DLT, cisplatin dose will be escalated to 75 mg/m². Step 2, dose escalation will be performed using the cisplatin MTD, with escalating CBP501 doses. CBP501 dose escalation will take place until the MTD has been defined or 74 mg/m² is reached.
1795358|NCT00551525|Radiation|Radiotherapy|3D-CRT or IMRT 64.8-70.2 Gy to the prostatic fossa begins 12 weeks (+/- 1 week) after Samarium 153 administration. Daily tumor doses of 1.8 - 2.0 Gy per day, 5 days per week x 7-8 weeks.
1795359|NCT00551525|Drug|Samarium 153|Samarium 153 lexidronam dose 2.0 mCi/kg by IV injection one time within 2 weeks (+/- 3days) after registration.
1795360|NCT00551538|Drug|Lispro mix 75/25|Lispro mix 75/25 twice-daily, SC injection, given in conjunction with oral antidiabetic medications.
1795361|NCT00551538|Drug|Glargine|SC injection, once-daily, given in conjunction with oral antidiabetic medications.
1795362|NCT00551551|Other|Pelvic floor muscle training with physiotherapist|8 sessions of 20-30 minutes each between 24 and 36 weeks of gestation with a physiotherapist or midwife
1795363|NCT00551551|Other|Written information about kegel exercises|Information about pelvic floor disorders prevention with personal pelvic floor exercises
1795364|NCT00551564|Drug|rosiglitazone maleate|Rosiglitazone tablets 4 mg dose will be administered orally by subjects
1795365|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|3 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 3 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
1795366|NCT00551577|Procedure|neoadjuvant chemotherapy (Carboplatin/Docetaxel)|2 cycles of Carboplatin/Docetaxel (3-weekly) preoperative and 4 cycles of Carboplatin/Docetaxel (3-weekly) postoperative
1795367|NCT00551590|Drug|Placebo tablet|placebo PO (placebo control for sitagliptin) for three days
1795368|NCT00551590|Drug|Sitagliptin tablet|Sitagliptin 100 mg PO for three days.
1795369|NCT00551590|Drug|Saline infusion|Saline IV (placebo control for exendin(9-39)) on two consecutive study days
1795370|NCT00551590|Drug|Exendin(9-39) infusion|Exendin(9-39) IV on two consecutive study days.
1795371|NCT00551603|Drug|switch (epoetinum beta, darbepoetinum)|switching from epoetinum beta once weekly to once-fortnightly darbepoetinum
1795372|NCT00551603|Drug|continuation (darbepoetinum)|continuation of the previous darbepoetinum administration schedule
1795373|NCT00551616|Drug|CDB-2914|Single dose
1795374|NCT00551616|Drug|Levonorgestrel|Single dose
1795375|NCT00551629|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
1795376|NCT00551629|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
1795377|NCT00551629|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
1795378|NCT00551629|Biological|PR51 (6, 15)|vaccine formulation containing 6 mcg of PRP-OMPC and 15 mcg of HBsAg
1795379|NCT00551642|Drug|Nitric Oxide for inhalation|inhaled nitric oxide given at 5 parts per million (ppm) for 7-21 days
1795380|NCT00551642|Drug|Nitrogen|nitrogen gas given at 5ppm for 7-21 days
1795381|NCT00551668|Procedure|proximal patellar surgery|Initial proximal patellar surgery
1795382|NCT00551668|Procedure|Nonoperative|Nonoperative without surgery
1795383|NCT00551681|Device|biventricular pacemaker with epicardial left ventricular lead|epicardial left ventricular lead placement
1795384|NCT00551681|Device|transvenous left ventricular lead placement|implantation of biventricular pacemaker with transvenous left ventricular lead placement
1795385|NCT00551694|Drug|GSK256073A tablets|
1795386|NCT00551707|Drug|CRx-102 (2.7/180)|prednisolone 2.7 mg plus dipyridamole 180 mg
1795387|NCT00551707|Drug|prednisolone|prednisolone (2.7 mg)
1795388|NCT00551707|Drug|dipyridamole|dipyridamole 360 mg
1795389|NCT00551707|Drug|placebo|placebo
1795390|NCT00551707|Drug|CRx-102 (2.7/360)|Prednisolone 2.7 mg plus Dipyridamole 360 mg
1795391|NCT00551720|Behavioral|Standard Care|Brief advice and follow-up provided a smoking-cessation trained Health Educator PLUS nicotine patch
1795392|NCT00551720|Behavioral|Motivational Enhancement|Brief advice and follow-up, nicotine patch, and the addition of a tailored motivational intervention and behavioral skills counseling for smoking cessation.
1795393|NCT00551733|Drug|carboplatin|Given IV
1795394|NCT00551733|Drug|paclitaxel|Given IV
1795395|NCT00551733|Drug|paclitaxel poliglumex|Given IV
1795396|NCT00551746|Dietary Supplement|Purple Grape Juice|Grape Juice
1795397|NCT00551759|Drug|5-Fluorouracil|given IV
1795398|NCT00551759|Drug|Oxaliplatin|given IV
1795399|NCT00551759|Drug|Cetuximab|given IV
1795400|NCT00551759|Drug|Docetaxel|given IV
1795401|NCT00551759|Procedure|Surgery|Patients underwent surgical resection within 4-8 weeks after completion of neoadjuvant chemoradiotherapy and cetuximab.
1795402|NCT00551759|Radiation|Radiotherapy|Patients underwent radiotherapy once daily on days 1-5, 8-12, 15-19, 22-26, and 29-33.
1795403|NCT00551772|Drug|SB-742457|
1795404|NCT00551798|Procedure|TEP au MIBI|Intravenous injection of MIBI.The review lasted 30 min, during which the patient should not move.
1795405|NCT00551811|Drug|SB-656933-AAA|SB-656933-AAA tablets will be available with a dose strength of 50 milligrams, administered orally.
1795406|NCT00551811|Drug|Placebo|Placebo tablets will be intended to be administered orally.
1795407|NCT00551824|Drug|Mitomycin C|Esophageal dilation session with topical mitomycin applied over esophageal mucosa after dilation.
1795408|NCT00551850|Drug|AV-412|oral solid dosage form administered three times weekly for 4 weeks (1 cycle)
1795409|NCT00551863|Behavioral|IVPT|Violence prevention intervention based on Motivational Interviewing and CBT
1795410|NCT00551876|Drug|MK0653, ezetimibe / Duration of Treatment: 30 Weeks|
1795411|NCT00551876|Drug|Comparator : ezetimibe (+) simvastatin / Duration of Treatment: 30 Weeks|
1795412|NCT00551889|Drug|celecoxib|
1795413|NCT00551889|Drug|cyclophosphamide|
1795414|NCT00551889|Other|laboratory biomarker analysis|
1795415|NCT00551902|Procedure|Trabeculectomy with anterior chamber infusion system|Trabeculectomy with anterior chamber infusion system
1795416|NCT00551902|Procedure|Trabeculectomy without anterior chamber infusion system|Standard trabeculectomy surgery
1795417|NCT00551915|Biological|AR51 (12, 10)|vaccine formulation containing 12 mcg of PRP-T and 10 mcg of HBsAg
1795418|NCT00551915|Biological|PR51 (3, 10)|vaccine formulation containing 3 mcg of PRP-OMPC and 10 mcg of HBsAg
1795419|NCT00551915|Biological|PR51 (6, 10)|vaccine formulation containing 6 mcg of PRP-OMPC and 10 mcg of HBsAg
1795420|NCT00551915|Biological|PENTACEL™|licensed vaccine for diphtheria, tetanus, pertussis, poliomyelitis, and invasive disease due to Haemophilus influenzae type b, administered open-label
1795421|NCT00551915|Biological|RECOMBIVAX HB™|licensed vaccine for hepatitis, administered open-label
1795422|NCT00551928|Drug|Melphalan|High dose Melphalan 200mg/sm with autologous stem cell support
1795423|NCT00551928|Drug|Lenalidomide|Six months of oral therapy with Lenalidomide 10mg/day given 21 days in every 28 days cycle with the combination ofMelphalan and steroids (day 22 to 28), for 6 cycles every 28 days.
1795424|NCT00551928|Drug|Prednisone|Given orally at the dose of 2 mg/Kg for 4 days followed by a 24 day rest period (days 5 to 28), for 6 cycles every 28 days
1795425|NCT00551928|Drug|Melphalan|Melphalan will be given orally at the dose of 0.18 mg/Kg for 4 days, followed by a 24 days rest period (day 5 to 28)for 6 cycles every 28 days
1795426|NCT00551941|Procedure|BMP-7 in adjunct to fresh frozen allograft|non-union of diaphysary tibial fractures treated with BMP-7 in adjunct to fresh frozen allograft
1795427|NCT00551941|Procedure|allograft together with DBM|non-union of diaphysary tibial fractures treated with allograft together with DBM
1795428|NCT00551954|Drug|acarbose|100 mg (tablets) t.i.d.
1795429|NCT00551954|Drug|placebo|one tablet t.i.d.
1795430|NCT00551967|Procedure|Hip replacement|Surgical implantation of hip replacement components for the treatment of osteoarthritis
1795431|NCT00551980|Behavioral|Cognitive, Relaxation, Exercise Therapy|The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
1795432|NCT00551993|Procedure|robotic laparoscopic sacrocolpopexy|Da Vinci Robot
1795433|NCT00551993|Procedure|Laparoscopic Sacral Colpopexy|Standard laparoscopy
1795434|NCT00552006|Behavioral|Narrative Exposure Therapy|"Narrative Exposure Therapy (NET) is based on Testimony Therapy in combination with cognitive behavioural exposure techniques and elements of client-centered counselling. In cooperation with the therapist the clients can restore their autobiographic memories about their traumatic experiences. In this way fragmentary memories are transformed into a coherent narrative structure. This practice enables the processing of painful emotions and the construction of clear contingencies of dangerous and safe conditions, generally leading to significant emotional recovery. Therapeutic aims are the reduction of PTSD-Symptomload via activation of fear-network and habituation of fear and the placement of traumatic experiences in a reconstructed, detailed and consistent autobiography.
NET will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
1795435|NCT00552006|Behavioral|Academic Counseling|"Missing time in educational life is one major issue for formerly abducted people. The Academic Counseling (AC) intervention is an active Control condition and improves English skills and works at the same time on concentration, learning and memory abilities. The clients will gain some of the abilities and skills they might have lost or developed weaknesses in due to their abduction.
AC will be applied in eight sessions (90-120min/session) in a standardized, manualized manner."
1795438|NCT00552058|Biological|certolizumab pegol (CDP870, CZP)|Certolizumab Pegol 400 mg CZP sc injection 2 x 1 mL CZP (200 mg/mL) at Week 0, 2, and 4
1795439|NCT00552058|Other|Placebo|Saline 0.9% sc injection 2 x 1 mL Placebo at Week 0, 2 and 4
1795440|NCT00552071|Drug|Sandostatin LAR|use of consistent monthly dose of medication for duration of 6 months.
1795441|NCT00552071|Drug|Sandostatin LAR|All patients receive Sandostatin LAR throughout trial at a fixed dose established at entry into the study.
1795442|NCT00552084|Drug|Fish oil|Fish oil supplements 4 gms will be taken daily for 24 weeks.
1795443|NCT00552084|Drug|Placebo|Placebo supplements will be taken daily for 24 weeks.
1795444|NCT00552097|Drug|ezetimibe (plus simvastatin)|oral tablets; ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
1795445|NCT00552097|Drug|placebo (plus simvastatin)|tablets; placebo to match ezetimibe 10 mg (plus simvastatin 80 mg) once daily for 24 months
1795446|NCT00552110|Drug|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 1 spray per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening (PM).
1795447|NCT00552110|Drug|OXY combination: mometasone furoate nasal spray (MFNS) and oxymetazoline nasal spray (OXY)|MFNS 2 sprays per nostril with OXY 3 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every evening.
1795448|NCT00552110|Drug|mometasone furoate nasal spray (MFNS) once daily|MFNS 2 sprays per nostril once daily x 2 weeks. Matching placebo to MFNS given every morning (AM) and every evening.
1795449|NCT00552110|Drug|oxymetazoline nasal spray (OXY) twice daily|OXY 2 sprays per nostril twice daily x 2 weeks. Matching placebo to MFNS given every morning.
1795450|NCT00552110|Drug|Placebo|Matching placebo to MFNS given every morning and every evening x 2 weeks.
1795451|NCT00552136|Procedure|Ankle Arthroplasty|
1795452|NCT00552136|Procedure|Ankle Arthrodesis|
1795453|NCT00552149|Drug|Gemox, Cetuximab|"GEMOX (Arms 1 and 2), every two weeks:
Day 1: gemcitabine 1000 mg/m² intravenous (IV) infusion over 100 minutes (10 mg/m²/min) Day 2: oxaliplatin 100 mg/m² IV infusion over 2 h
Cetuximab (ErbituxÒ) (Arm B only) every two weeks:
(chemotherapy will be started one hour after the end of the cetuximab infusion).
Day 1 or Day 2: 500 mg/m² IV infusion over 150 minutes"
1795454|NCT00552162|Procedure|NOTES Transvaginal Cholecystectomy|The gallbladder will be dissected free and will be removed through an incision in the vagina.
1795455|NCT00552162|Procedure|NOTES Transvaginal Appendectomy|The appendix will be dissected free and will be removed through an incision in the vagina.
1795456|NCT00552175|Drug|Duloxetine hydrochloride - 40 mg|duloxetine 40 mg taken orally every day
1795457|NCT00552175|Drug|placebo|placebo taken orally every day
1795458|NCT00552175|Drug|Duloxetine hydrochloride - 60 mg|duloxetine 60 mg taken orally every day
1795459|NCT00552188|Drug|VIA-2291|100 mg, oral dosing, 1 time daily for 24 weeks
1795460|NCT00552188|Drug|Placebo|oral dosing, 1 time daily for 24 weeks
1795461|NCT00552201|Drug|Tacrolimus|Administration Twice a day after adjustment to blood level
1795462|NCT00552214|Device|Blood test|Screening of HIV-1 RNA, HCV RNA and HBV DNA in Human Blood Donor Plasma Specimens
1795463|NCT00552227|Drug|ruboxistaurin|oral 32 mg daily
1795464|NCT00552227|Other|placebo|placebo
1795465|NCT00552240|Drug|tenofovir DF 300 mg QD|300 mg QD
1795466|NCT00552240|Drug|tenofovir DF 300 mg QD|300 mg QD
1795467|NCT00552240|Drug|emtricitabine 200 mg QD|200 mg QD
1795468|NCT00552240|Drug|emtricitabine 200 mg QD|200 mg QD
1795469|NCT00552240|Drug|Nevirapine 200 mg BID|200 mg BID
1795470|NCT00552240|Drug|Atazanavir 300 mg|300 mg QD
1795471|NCT00552240|Drug|Ritonavir 100 mg|100 mg QD
1795472|NCT00552253|Drug|Levothyroxin treatment|Levothyroxin 100 micogram will be administered once daily 1 hour before meal of just after meal for 3 months, and the dose will be titrate to keep serum TSH level between 0.1~0.3 mU/L. It will be discontinued for 3 months. Then
1795473|NCT00552266|Drug|Methylphenidate|tablets 10-60 mg/day administered once or twice daily 6 weeks
1795474|NCT00552279|Biological|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 12-month schedule.
1795475|NCT00552279|Biological|Cervarix TM|Intramuscular administration into the deltoid region of the non-dominant arm according to a 0, 1, 6-month schedule.
1795476|NCT00552305|Drug|lacosamide|50mg and 100mg tablets up to 800 mg/day as twice a day (BID) dosing throughout the trial
1795477|NCT00552331|Device|Plates to treat fractures of the distal femur|use of dynamic condylar screws or locking condylar plates in the treatment of distal femur fractures
1795478|NCT00552331|Device|LISS|treatment of distal femur fractures with less invasive stabilization systems
1795479|NCT00552344|Biological|Cimzia|"Active substance: Certolizumab Pegol
Pharmaceutical form:first reconstituted, lyophilized powder formulation of CZP and after implementation of Amendment 2 (after 401 subjects were enrolled) prefilled syringe
Concentration: 200 mg/ml
Route of Administration: Subcutaneous use"
1795480|NCT00552370|Drug|Lantus®|
1795481|NCT00552383|Procedure|NIDCAP based developmental care|"Infants in the intervention arm will receive care in the NICU by nursing staff who have received basic education in NIDCAP - based developmental care. They will also have NIDCAP behavioural observations performed by NIDCAP - Certified staff [this includes 3 of the investigators], at intervals during their stay at the study site NICU. These behavioural observations form the basis for behaviourally guided baby -friendly care, so that the timing and pace of caregiving is synchronised to the infant's readiness. Parents are actively encouraged to become the infant's primary caregiver in the NICU."
1795482|NCT00552396|Drug|Anti-KIR (1-7F9)|human monoclonal antibody
1795483|NCT00552409|Dietary Supplement|Cholecalciferol|2000 IU by mouth daily for one year
1795484|NCT00552409|Dietary Supplement|Placebo|One softgel daily for one year
1795485|NCT00552422|Drug|domperidone|10mg orally four times per day
1795486|NCT00552435|Device|Laser photocoagulation|Laser therapy is applied using a slit lamp and specific laser contact lens.
1795487|NCT00552448|Device|High Frequency Chest Compression VEST|every 6 hours for 20 minutes
1795488|NCT00552461|Drug|rituximab|IV, 1000 mg, two weeks, 2 times
1795489|NCT00552474|Device|Libra Deep Brain Stimulation System|Active DBS Therapy
1795490|NCT00552474|Device|Libra Deep Brain Stimulation System|Implanted system but no stimulation
1795491|NCT00552487|Drug|synacthen|1 µg synacthen in the vein
1795492|NCT00552500|Drug|Depakote (valproate)|500 mg -2000 mg QD based on individual tolerance and VPA levels
1795493|NCT00552513|Procedure|Early Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) as soon as possible (and within 24 hours of randomisation).
1795494|NCT00552513|Procedure|Delayed Coronary Intervention|Perform coronary angiography and intervention (either percutaneous coronary intervention [PCI] or coronary artery bypass graft [CABG] surgery) any time after 36 hours after randomisation.
1795495|NCT00552526|Dietary Supplement|Ketogenic diet|Ketogenic diet is a very strict high fat diet
1795496|NCT00552526|Drug|Antiepileptic drug (AED)|An AED,not used by the patient before, which we consider to be the most appropriate will be given orally or by gastrostomy. Serum concentration, the body weight, side effects and effects on the epilepsy will be considered when deciding the dose of the AED. Traditions for amount of medicine/kg body weight or optimal serum concentration at our center will be followed. This tradition will be the same as in other major European epilepsy centers but might propose lower, but not higher amounts than recommended by the drug company. Drugs from ACT groups N03A, N05BA, N05CD, H02A or S01EC will be used including prednisolon,levetiracetam, valproate, carbamazepine, oxcarbazepine, topiramate, felbamate, zonisamide, vigabatrin, tiagabil, lamotrigine, pregabalin, rufinamide, clobazam, clonazepam, tiagabine, gabapentin, phenytoin, phenobarbital, ethosuximide, acetazolamide, nitrazepam and other new antiepileptic drugs that might be released during the study period.
1795497|NCT00552539|Other|'educational video'|'educational video'
1795498|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|6 weekly sessions, 90 min each
1795499|NCT00552552|Behavioral|Fatigue Patient Education Program (FIBS)|Participation in the program after the second follow-up
1795500|NCT00552565|Drug|Rezular 15mg|Oral Tablets
1795501|NCT00552565|Drug|Placebo|placebo
1795502|NCT00552565|Drug|Rezular|Rezular 37.5mg 3xday up to 12 weeks
1795503|NCT00552565|Drug|Rezular|Rezular 75mg 3xday up to 12 weeks
1795504|NCT00552578|Drug|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, three times a day for one month, twice a day for one month, once a day for one month, then every other day for one month. (dose may be adjusted based on an individual's response)
1795505|NCT00552578|Drug|buprenorphine/naloxone|sublingual tablets, 2/0.5 mg, one tablet three times a day for six months (doses may be adjusted based on an individual's response
1795506|NCT00552591|Behavioral|12-week risk reduction program, managed by a Heart Health Educator|The educator and participant will negotiate a personal plan for achieving the goals through lifestyle change (i.e. smoking cessation, increased exercise, improved nutrition) and, if necessary, pharmacotherapy coordinated by the participant's personal physician. Educational modules have been developed to address specific lifestyle issues including smoking cessation, healthy eating, exercise, and weight management, and will be provided to participants as required. A summary of the risk factor profile and personal plan will be incorporated into a report for the participant's personal physician as well. Participants will also receive telephone-based motivational counseling sessions for 12 weeks to address specific lifestyle issues.
1795507|NCT00552604|Drug|standardized cannabis extract|Cannabis extract (delta-9-THC 2.5mg, CBD 1.25 mg per capsule), flexible dosing between 5 mg and 25 mg THC/d, administered twice daily
1795508|NCT00552604|Drug|Placebo|Matching placebo capsules, twice daily
1795509|NCT00552617|Drug|sugammadex (Org 25969)|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arms 2-5) or 0.1 mg/kg vecuronium (arms 7-10).
Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered"
1795510|NCT00552617|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).
Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.
At reappearance of T2 the randomized single dose of Placebo IV was administered"
1795511|NCT00552630|Device|d-penicillamine|d-penicillamine twice daily, 15 mg/kg/day, for 6 weeks
1795512|NCT00552630|Drug|placebo|placebo with same characteristics as drug
1795513|NCT00552643|Device|Suspension of polystyrene beads (POLYHEAL 1)|Topical application of Polyheal 1 (15 mL/200cm2 of wound area, TID, 28 days, one cycle
1795514|NCT00552643|Device|Saline (0.9% NaCl)|Saline topical application 15 mL/200cm2 of wound area, TID, 28 days, one cycle
1795515|NCT00552656|Device|Firebird(TM) Sirolimus-Eluting Stent|balloon expandable stent that made of stainless steel.The length is from 13mm-33mm,and the diameter from 2.5mm-4.0mm
1795516|NCT00552669|Drug|Oral sirolimus|Oral sirolimus given orally during 14 days plus bare metal stent implantation was compared with DES.Oral sirolimus was given as bolus of 10 mg started day before intervention followed by 3mg per day during 13 days after PCI. 180 mg of Diltiazem was added during oral administration of sirolimus .
1795517|NCT00552669|Device|Drug Eluting stent|Any Drug eluting stent
1795518|NCT00552682|Drug|Duloxetine 60 mg, QD|Duloxetine 60 mg, 1 table/day, 1 year
1795519|NCT00552695|Device|Lidocaine tetracaine|Lidocaine 70 mg/tetracaine 70 mg
1795520|NCT00552695|Device|Placebo|Placebo patch identical in appearance to Synera
1795521|NCT00552708|Drug|COREG CR|
1795522|NCT00552708|Drug|Lisinopril|
1795523|NCT00552721|Other|Physical therapy with strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) with an emphasis on strength training.
1795524|NCT00552721|Other|Physical therapy without strength training|12 weeks of physical therapy after Botulinum-toxin treatment (two 45-min sessions/week) without strength training.
1795525|NCT00552734|Device|Insulin Guidance Software|At baseline a healthcare provider reviewed the features of the software on the PDA and loaded a subject specific insulin dosing algorithm into the software based on the physician's recommendations. The program advised basal, bolus and correction insulin dosages based on individual patients' prescriptions in addition to being alerted for SMBG testing. Subjects in the experimental group were also asked to input their blood glucose values into the PDA via the touch screen. Subjects then received a recommended insulin dose based on their prescription which was programmed by the healthcare provider. The patients were asked to either agree with the recommended insulin dose or disagree, and manually enter the insulin dose they took for a given event.
1795526|NCT00552747|Drug|fenofibrate|fenofibrate 160 mg capsules qd
1795527|NCT00552747|Drug|placebo|capsules placebo
1795528|NCT00552760|Drug|Ramelteon|one 8 mg tablet at bedtime for up to 6 months
1795529|NCT00552760|Drug|Placebo|one tablet at bedtime for up to 6 months
1795530|NCT00552773|Drug|Cyclamen Europaeum|Nasal spray 10% (V/V),one spray per nostril daily for 7 days.
1795531|NCT00552786|Drug|N-acetylcysteine (NAC)|600mg twice daily for 2 weeks
1795532|NCT00552786|Drug|glucose|1 gm glucose capsule
1795535|NCT00552812|Device|Stent therapy of aortic coarctation|Transcatheter delivery of a metallic stent to enlarge region of aortic narrowing caused by the coarctation.
1795536|NCT00552838|Behavioral|Academic Detailing by the Antimicrobial Utilization Team (AUT)|Physicians caring for patients who were prescribed one of three antimicrobials were randomly assigned to academic detailing by the AUT. The AUT would review the antimicrobial prescription and provide consultation to the ordering physician if the prescription is appropriate and provide feedback on a better alternative if inappropriate.
1795537|NCT00552851|Drug|pegvisomant|booster dosage 80 mg once sc., than 10 mg once per day, uptitration in steps of 5 mg up to an IGF-1 level in the normal range (every 4 weeks), max. 30 mg once per day. Duration of treatment: one year
1795538|NCT00552864|Drug|Ropivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
1795539|NCT00552864|Drug|Levobupivacaine|0.5% epidural bolus injection (0.1 mL kg-1) with sufentanil 2.5 µg mL-1 before general anesthesia induction, followed by 0.2% infusion (0.1 mL kg-1 h-1) with sufentanil 1 µg mL-1 throughout surgery; in ICU, 0.1% epidural infusion with sufentanil 1µg mL-1 at 0.1 mL kg-1 h-1 and the rate is modified following this protocol: on awakening (Ramsay 2) VAS on coughing is evaluated: if it is 4 the infusion rate is not changed, if the VAS is ≥ 4 the rate is increased by 2 mL h-1 after giving a 2 mL bolus and VAS is checked again 30 minutes later, if it is ≤ 4 the infusion rate is decreased by 2 mL h-1.
1795540|NCT00552877|Device|Percutaneous coronary intervention (Xience V stent)|Cypher Select plus coronary stent Xience V coronary stent
1795541|NCT00552890|Other|modified Atkins diet|subjects assigned to follow modified Atkins diet for 1 year
1795542|NCT00552890|Other|ADA recommended diet|subjects assigned to follow ADA recommended diet for period of 1 year
1795543|NCT00552903|Behavioral|Health coaching|Personal health coach providing advice and counselling by telephone, weekly contacts
1795544|NCT00552916|Device|Compex Motion Stimulator|'True' Functional Electrical Stimulation Assisted Walking
1795545|NCT00552916|Device|Compex Motion Stimulator|'False' FES
1795546|NCT00552929|Drug|Sugammadex|4 Doses of Sugammadex Administered at 1-2 PTC After 0.9 mg/kg Rocuronium or 0.1 mg/kg Vecuronium
1795547|NCT00552929|Drug|Placebo|4 Doses of placebo Administered at 1-2 PTC After Rocuronium or Vecuronium
1795548|NCT00552942|Procedure|laparoscopic gastric bypass plus omentectomy|
1795549|NCT00552981|Procedure|inhalation of warm air in a Finnish sauna|three times on three following days, each 2-3 minutes
1795550|NCT00552981|Procedure|inhalation of ambient air in a Finnish sauna|three times on three following days, each 2-3 minutes
1795551|NCT00552994|Device|Cypher Select plus|Drug eluting stent
1795552|NCT00552994|Device|Xience V stent|Drug eluting stent
1795553|NCT00553007|Procedure|Periodontal therapy|Normal periodontal therapy is performed.
1795554|NCT00553020|Drug|Insulin glargine|"Lantus (commercial formulation, Reference):
10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)
NPH-insulin (Protaphan) (Test):
10 mL vials (100 IU/mL) solution Dose: 0.3 IU per kg BW injected subcutaneously in the patients usual injection site (either abdomen or thigh)"
1795555|NCT00553033|Procedure|Laparoscopic liver surgery|Ultrasonic dissector, harmonic scalpel
1795556|NCT00553046|Other|survey administration|application of a family survey on last 3 months of life for their relatives under HMV
1795557|NCT00553059|Drug|dexamethasone|10 mg IV 30 minutes prior to administration of chemotherapy
1795558|NCT00553059|Drug|dronabinol|5 mg tablet by mouth three times a day beginning 30 minutes before chemotherapy
1795559|NCT00553059|Drug|palonosetron hydrochloride|0.25 mg IV 30 minutes prior to administration of chemotherapy
1795560|NCT00553059|Other|placebo|1 tablet by mouth three times a day beginning 30 minutes before chemotherapy
1795561|NCT00553072|Drug|Magnesium sulphate|250 mg/kg/dose in 1 ml normal saline
1795562|NCT00553072|Drug|Normal saline|1 ml/kg/dose
1795563|NCT00553098|Biological|Alemtuzumab|Given IV
1795564|NCT00553098|Procedure|Allogeneic Bone Marrow Transplantation|Undergo HCT
1795565|NCT00553098|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
1795566|NCT00553098|Drug|Cyclosporine|Given PO or IV
1795567|NCT00553098|Drug|Fludarabine Phosphate|Given IV
1795568|NCT00553098|Other|Laboratory Biomarker Analysis|Correlative study
1795569|NCT00553098|Drug|Mycophenolate Mofetil|Given PO or IV
1795570|NCT00553098|Radiation|Total-Body Irradiation|Undergo low dose TBI
1795571|NCT00553111|Other|educational video|educational video
1795572|NCT00553124|Drug|selenium|
1795573|NCT00553124|Drug|vitamin E|
1795574|NCT00553124|Procedure|biopsy|
1795575|NCT00553124|Procedure|chemoprevention|
1795576|NCT00553124|Procedure|cryopreservation|
1795577|NCT00553124|Procedure|cytology specimen collection procedure|
1795578|NCT00553124|Procedure|diagnostic procedure|
1795579|NCT00553124|Procedure|gene expression analysis|
1795580|NCT00553124|Procedure|immunohistochemistry staining method|
1795581|NCT00553124|Procedure|laboratory biomarker analysis|
1795582|NCT00553124|Procedure|medical chart review|
1795583|NCT00553124|Procedure|mutation analysis|
1795584|NCT00553124|Procedure|polymerase chain reaction|
1795585|NCT00553124|Procedure|quality-of-life assessment|
1795586|NCT00553124|Procedure|questionnaire administration|
1795587|NCT00553124|Procedure|study of socioeconomic and demographic variables|
1795588|NCT00553137|Drug|fluconazole|750 mg (5 tablets of 150 mg tablets)taken once
1795589|NCT00553137|Drug|fluconazole|150 mg fluconazole tablets once daily for 14 days
1795590|NCT00553150|Drug|everolimus|
1795591|NCT00553150|Drug|temozolomide|
1795592|NCT00553150|Radiation|radiation|
1795595|NCT00553176|Other|No intervention|At six-month intervals (January and July), physicians will document disease characteristics, changes in Crohn's therapy, disease progression, key events, the use of ancillary services, and hospitalizations
1795596|NCT00553189|Drug|ABT-888|
1795597|NCT00553189|Drug|Topotecan|
1795598|NCT00553202|Biological|anti-thymocyte globulin|Given IV
1795599|NCT00553202|Drug|busulfan|Given IV
1795600|NCT00553202|Drug|cyclophosphamide|Given IV
1795601|NCT00553202|Drug|cyclosporine|Given IV or orally
1795602|NCT00553202|Drug|methotrexate|Given IV
1795603|NCT00553202|Drug|methylprednisolone|Given IV
1795604|NCT00553202|Drug|tacrolimus|Given IV
1795605|NCT00553202|Other|laboratory biomarker analysis|Correlative studies
1795606|NCT00553202|Other|pharmacological study|Correlative studies
1795607|NCT00553202|Procedure|allogeneic bone marrow transplantation|allogeneic bone marrow transplantation
1795608|NCT00553202|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic hematopoietic SCT
1795609|NCT00553215|Procedure|quality-of-life assessment|
1795610|NCT00553215|Procedure|questionnaire administration|
1795611|NCT00553228|Biological|Tdap|0.5 mL IM once at visit #2
1795612|NCT00553228|Biological|Td|0.5 mL IM once at visit #2
1795613|NCT00553254|Drug|PF-00299804|Single arm (no comparator) study, oral once daily dosing, dose escalation (it is a phase 1/2 study) until disease progression, unacceptable toxicity or withdrawal of consent
1795614|NCT00553267|Drug|fixed dose combination of telmisartan+amlodipine|
1795615|NCT00553267|Drug|amlodipine|
1795616|NCT00553280|Drug|pregabalin|Dosage: 150-600 mg/day (75-300 mg bid), oral administration, Treatment duration: 52 weeks
1795617|NCT00553293|Drug|recombinant luteinizing hormone (Luveris)|75 iu/day form cycle day 6
1795618|NCT00553293|Drug|recombinant follicle stimulating hormone (Gonal-f)|rFSH 150 iu/day
1795619|NCT00553306|Biological|therapeutic autologous lymphocytes|Given IV
1795620|NCT00553306|Biological|aldesleukin|Given subcutaneously
1795621|NCT00553306|Drug|cyclophosphamide|Given IV
1795622|NCT00553306|Procedure|biopsy|Optional correlative studies
1795623|NCT00553306|Other|immunohistochemistry staining method|Optional correlative studies
1795624|NCT00553306|Other|flow cytometry|Correlative studies
1795625|NCT00553306|Genetic|polymerase chain reaction|Correlative studies
1795626|NCT00553319|Drug|Placebo|Placebo group
1795627|NCT00553319|Drug|Adderall-XR|Adderall-XR 60mg/day
1795628|NCT00553319|Drug|Adderall-XR|Adderall-XR 80mg/day
1795629|NCT00553332|Drug|selumetinib|Given orally
1795630|NCT00553332|Other|laboratory biomarker analysis|Correlative studies
1795631|NCT00553345|Drug|selenium|
1795632|NCT00553345|Drug|vitamin E|
1795633|NCT00553345|Procedure|chemoprevention|
1795634|NCT00553358|Drug|Lapatinib|Small molecule receptor tyrosine kinase inhibitor
1795635|NCT00553358|Biological|Trastuzumab|Therapeutic Monoclonal Antibody
1795636|NCT00553358|Drug|Paclitaxel|antimicrotubule agent
1795637|NCT00553371|Other|biomarker analysis|
1795638|NCT00553371|Procedure|computed tomography|
1795639|NCT00545740|Drug|SPD476 (1.2g)|1.2g SPD476 once daily (QD) orally
1795640|NCT00545740|Drug|SPD476 (2.4 g)|2.4g SPD476 QD orally
1795641|NCT00545740|Drug|SPD476 (4.8 g)|4.8g SPD476 QD orally
1795642|NCT00545740|Drug|Placebo|QD orally
1795643|NCT00545753|Drug|Spinosad|10 minute topical application product, following by a complete rinse off.
1795644|NCT00545753|Drug|Spinosad|10 minute topical application followed by a complete rinse off, followed by a nit combing regimen
1795645|NCT00545753|Drug|Permethrin 1%|Topical application for 10 minutes, followed by a complete rinse off, followed by a nit combing regimen
1795646|NCT00545766|Drug|Vinflunine|Vinflunine 320 mg/m2 will be administered as a 20 minute IV infusion q3w. Patients will be evaluated for toxicity after each cycle of therapy. Response to vinflunine will be assessed every 6 weeks (every 2 cycles) of treatment. A maximum of 6 cycles of therapy are planned.
1795647|NCT00545779|Drug|Ibandronate|150 mg orally once monthly for 6 months
1795648|NCT00545792|Drug|Avastin|Avastin will be administered intravenously (vein) at 10mg/kg every two weeks starting day 1 for a total of 3 doses.
1795649|NCT00545805|Procedure|Roux-en-Y Gastric Bypass plus total omentectomy|Roux-en-Y Gastric Bypass plus total omentectomy
1795650|NCT00545805|Procedure|Roux-en-Y Gastric Bypass|Roux-en-Y Gastric Bypass without omentectomy
1795651|NCT00545818|Device|OsseoSpeed™|OsseoSpeed™ implant, length: 6 mm
1795652|NCT00545818|Device|OsseoSpeed™|OsseoSpeed™ implant, length: 11 mm
1795653|NCT00545831|Device|Taurolidine|2 mL of taurolidine instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
1795654|NCT00545831|Device|Physiologic Serum|2 mL of physiologic serum instillate on the intravascular catheter after each parenteral nutrition session for a duration of 6 months
1795656|NCT00545857|Drug|pioglitazone|Pioglitazone daily; dose varies with size
1795657|NCT00545857|Drug|Placebo control|Comparison of pioglitazone vs. placebo on the outcome of type 1 diabetes mellitus
1795658|NCT00545870|Drug|bevacizumab|intravitreal application
1795659|NCT00545870|Drug|Ranibizumab|intravitreal application
1795660|NCT00545896|Procedure|Extracorporeal shockwave therapy|Extracorporeal application of shockwaves on the surface of chronic wounds.
1795661|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (+ feedback)
1795662|NCT00545909|Drug|ibandronate [Bonviva/Boniva]|150mg po monthly for 6 months (- feedback)
1795663|NCT00545922|Behavioral|Cognitive behavioral therapy|Seven weekly sessions (2 hrs) in groups
1795664|NCT00545922|Behavioral|Minimal Telephone Contact|Telephone contact (max. 10 minutes) every other week during the 7-week intervention
1795665|NCT00545935|Drug|Methylenblue-Amodiaquine (MB-AQ)|For 3 days twice daily 10 mg/kg MB accompanied by once daily 10 mg/kg AQ
1795666|NCT00545935|Drug|Methylenblue-Artesunate (MB-AS)|3 days once daily 4 mg/kg AS accompanied by twice daily 10 mg/kg MB given over 7 days
1795667|NCT00545935|Drug|Artesunate-Amodiaquine (AS-AQ)|For 3 days once daily 10 mg/kg AQ accompanied by 4mg/kg AS.
1795668|NCT00545948|Drug|Vinorelbine followed by Cisplatin|Vinorelbine 25 mg/m2 IV over 6-10 minutes on days 1 and 8, followed by Cisplatin 75 mg/m2 IV over 60 minutes on day 1 (every 21 days x 4 cycles).
1795669|NCT00545948|Drug|Pemetrexed followed by Cisplatin|Pemetrexed 500 mg/m2 IV infusion over approximately 10 minutes on day 1, followed by Cisplatin 75 mg/m2 IV over 60 min on day 1 (every 21 days x 4 cycles)
1795670|NCT00545961|Drug|placebo|mixture, 0.28125 ml/kg twice a day for 7 days
1795671|NCT00545961|Drug|amoxicillin clavulanate acid|mixture 0.28125 ml / kg twice a day for 7 days
1795672|NCT00545974|Drug|memantine|memantine 10mg BID
1795673|NCT00545974|Drug|Placebo pill|Placebo pill BID
1795674|NCT00545987|Device|TriGrid™ Delivery System|Subjects will be administered the study drug using Ichor Medical Systems' intramuscular TriGrid™ delivery device.
1795675|NCT00545987|Device|conventional intramuscular injection|administration of an HIV-1 vaccine encoding the gag, env, pol, nef, and tat antigens (ADVAX)by conventional intramuscular injection
1795676|NCT00546000|Drug|Fluticasone propionate 0.05% lotion|Daily applications
1795677|NCT00546026|Other|placental function assessment|Formal assessment of placental function in mid-gestation by placental morphology and uterine artery Doppler at 20-22 weeks and re-interpretation of prior biochemical tests for Down's syndrome and spina bifida.
1795680|NCT00546052|Drug|losartan potassium (+) hydrochlorothiazide|All patients received Losartan 50mg at Visit 2 titrated to Losartan 100mg (if target BP not achieved) titrated to Losartan 100mg + HCTZ 12.5mg (if necessary) up to Losartan 100mg + HCTZ 25mg. Duration of treatment was one year.
1795681|NCT00546065|Drug|esomeprazole treatment|concomitant esomeprazole treatment
1795682|NCT00546078|Biological|Cervarix™|Intramuscular injection, one or three doses
1795683|NCT00546104|Drug|Dasatinib|An initial dose of 50 mg PO BID; following 4 weeks of treatment, dose adjustment will be based on inhibition of phosphorylation of FAK and paxillin per biopsy assessment, as well as toxicity assessment.
1795684|NCT00546117|Drug|lansoprazole|Prevacid SoluTab 15 mg daily by mouth for 2 months (patients weighing 10-30 kg),or Prevacid SoluTab 30 mg daily by mouth for 2 months (patients weighing >30 kg) is the experimental arm. Placebo Solutabs will be given in the same dosage, frequency, and duration for the placebo arm.
1795685|NCT00546117|Drug|placebo|Placebo Solutab in 15 and 30 mg dosages.
1795686|NCT00546130|Drug|Irinotecan hydrochloride|"Irinotecan hydrochloride 60 mg/m2, IV (in the vein) on days 1, 8, 15 of each 28 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops."
1795687|NCT00546130|Drug|Cisplatin|Cisplatin 60 mg/m2, IV (in the vein) on day 1 of each 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1795688|NCT00546130|Drug|Krestin|Krestin 3,000 mg, PO everyday until progression or unacceptable toxicity develops.
1795689|NCT00546143|Drug|Omalizumab|
1795690|NCT00546143|Drug|Omalizumab|
1795691|NCT00546143|Drug|Omalizumab|
1795692|NCT00546156|Drug|Doxorubicin|Standard chemotherapy regimen
1795693|NCT00546156|Drug|Cyclophosphamide|Standard chemotherapy regimen
1795694|NCT00546156|Drug|Paclitaxel|Standard chemotherapy regimen
1795695|NCT00546156|Drug|Bevacizumab|One intravenous dose given followed 2 weeks later with standard chemotherapy drugs and bevacizumab given intravenously in 8 two-week cycles.
1795696|NCT00546169|Drug|Fibrinogen (human) + thrombin (human) (TachoSil)|haemorrhages in cholecystectomy
1795697|NCT00546221|Behavioral|Psychosocial support exercise programme|The experimental arm will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will comprise: fifteen minutes of psychosocial and motivational support, run by a qualified rehabilitation psychologist and overseen by a qualified health psychologist; a half hour preferred intensity exercise session run by a qualified sports physiotherapist. Participants preferred intensity (chosen exertion level) will be established using the Borg RPE scale (Borg G 1998).
1795698|NCT00546221|Behavioral|Prescribed exercise|This group will experience 12 sessions of intervention, at a rate of three sessions a week for four weeks, exercising in groups of ten women. Each session will be an half hour exercise session, at a typically (GP) prescribed level, designed in accordance with national guidelines and run by a qualified sports physiotherapist.
1795699|NCT00546234|Drug|tiotropium|18 mcg daily via Handihaler
1795700|NCT00546234|Drug|long acting beta agonist|Turbohaler, 6 & 12 mcg
1795701|NCT00546247|Drug|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1, 4, 8 and 11 of a 21-day cycle, until the disease progresses
1795702|NCT00546260|Drug|placebo|administration of iv bolus prior to angiography
1795703|NCT00546260|Drug|PRT060128 Potassium|administration of iv bolus prior to angiography
1795704|NCT00546273|Biological|RUTI|dose: 5 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
1795705|NCT00546273|Biological|RUTI|dose: 25 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
1795706|NCT00546273|Biological|RUTI|dose: 100 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
1795707|NCT00546273|Biological|RUTI|dose: 200 micrograms of FCMtb; given subcutaneously twice, on days 0 and 28
1795708|NCT00546273|Biological|placebo of the vaccine RUTI|placebo of the vaccine RUTI given subcutaneously twice, on days 0 and 28
1795709|NCT00546286|Drug|dorzolamide hydrochloride (+) timolol maleate|"Combination treatment of dorzolamide HCl (2%)/ timolol maleate (0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.
For patients who achieve target IOP at 6 weeks, dorzolamide/timolol is continued for another 6 weeks."
1795710|NCT00546286|Drug|Comparator: dorzolamide HCl/timolol maleate + prostaglandin|"Combination treatment of dorzolamide HCl (2%)/timolol maleate(0.5%) BID for six weeks in patients with open-angle glaucoma or ocular hypertension.
For patients not achieving target IOP at 6 weeks, a prostaglandin is added for another 6 weeks."
1795711|NCT00546299|Drug|oxygen|cylinder and concentrator, dosage to maintain SpO2 above 92%, used during exertion
1795712|NCT00546312|Device|Thoracic EXCLUDER Endoprosthesis|Stent-graft endoprosthesis is inserted by Delivery System via a surgical cutdown (e.g., external iliac artery, femoral artery, common iliac artery conduit, etc.) approach. The insertion method depends on each patient's anatomy and is determined by the Clinical Investigator.
1795713|NCT00546325|Drug|Rimonabant|White opaque film-coated, for oral administration containing 20 mg of active rimonabant. Once daily before breakfast
1795714|NCT00546325|Drug|Placebo|Matching placebo tablets. Once daily before breakfast
1795715|NCT00546351|Drug|Lacosamide|50 to 100 mg Lacosamide film-coated tablets; two times per day up to 600 mg/day; 6.5 years
1795716|NCT00546364|Drug|Ixabepilone, 40 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 40 mg/m^2, administered as a 3-hour intravenous (IV) infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
1795717|NCT00546364|Drug|Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2|Ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
1795718|NCT00546364|Drug|Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2|Docetaxel 75 mg/m^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
1795719|NCT00546377|Biological|filgrastim|
1795720|NCT00546377|Biological|pegfilgrastim|
1795721|NCT00546377|Biological|rituximab|
1795722|NCT00546377|Biological|sargramostim|
1795723|NCT00546377|Drug|cyclophosphamide|
1795724|NCT00546377|Drug|mitoxantrone hydrochloride|
1795725|NCT00546377|Drug|pentostatin|
1795726|NCT00546377|Genetic|fluorescence in situ hybridization|
1795727|NCT00546377|Genetic|gene rearrangement analysis|
1795728|NCT00546377|Genetic|polymerase chain reaction|
1795729|NCT00546377|Genetic|protein expression analysis|
1795730|NCT00546377|Other|flow cytometry|
1795731|NCT00546377|Procedure|biopsy|
1795733|NCT00546403|Drug|Modafinil|Adjunctive treatment with titrated dose of modafinil
1795734|NCT00546403|Drug|Placebo|Adjunctive treatment with placebo
1795735|NCT00546429|Device|Intramedullary nailing|Trochanteric nailing for proximal femoral fractures.
1795736|NCT00546442|Drug|Metformine|850-2550 mg/daily for 48 weeks
1795737|NCT00546442|Other|Placebo of metformine|850-2550 mg/daily for 48 weeks
1795738|NCT00546455|Drug|Fenretinide|200 mg/day
1795739|NCT00546455|Drug|Placebo|2 capsules/day
1795740|NCT00546468|Procedure|laparoscopy assisted distal gastrectomy|under general endotracheal anesthesia, Five laparoscopic ports are made. Lymph node dissection and ligations of vessels are done in laparoscopic field. A 5-6cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, stomach is taken out and resected. A Billroth I gastroduodenostomy using EEA stapler and GIA is performed. Abdomen is closed after hemostasis.
1795741|NCT00546468|Procedure|Open distal gastrectomy|Open distal gastrectomy is performed under general endotracheal anesthesia. A long midline incision is made. omentectomy is skipped and D2 lymph node dissection is performed. Anastomosis is done in same manner as LADG. Abdomen is closed after hemostasis
1795742|NCT00546481|Drug|methoxy polyethylene glycol-epoetin beta [RO0503821, Mircera]|0.6 micrograms/kg every 2 weeks
1795743|NCT00546481|Drug|Epoetin|As prescribed, iv, 3 times weekly
1795744|NCT00546494|Drug|Effexor® (Venlafaxine)|
1795745|NCT00546507|Drug|TDS-943 (topical diclofenac sodium 4% spray)|
1795746|NCT00546507|Drug|celecoxib|
1795747|NCT00546507|Other|placebo|
1795748|NCT00546520|Drug|Ciclesonide|
1795749|NCT00546533|Drug|Etanercept|
1795750|NCT00546546|Drug|early immunosuppressants (azathioprine, methotrexate)|azathioprine 2.5 mg/kg/day SC methotrexate 25 mg/week if aza not tolerated
1795751|NCT00546559|Drug|statins (simvastatin, pravastatin)|
1795752|NCT00546572|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
1795753|NCT00546572|Biological|23vPS|0.5-mL dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5-mL dose 13vPnC will be administered into the deltoid muscle at year 1
1795754|NCT00546585|Biological|Influenza A/H7N7 Vaccine|Monovalent subvirion H7N7 vaccine, 4 dose levels of vaccine, each subject will receive 2 doses (7.5, 15, 45, or 90 micrograms); the same dose will be given at Day 0 and Day 28.
1795755|NCT00546585|Drug|Placebo|Sterile normal saline for injection (0.9%); 0.5 ml volume sodium chloride injection. Subjects will receive 2 doses on Day 0 and Day 28.
1795756|NCT00546598|Device|Total hip replacement/arthroplasty|Hip replacement
1795757|NCT00546598|Device|Hip replacement/arthroplasty|Hip replacement
1795758|NCT00546611|Drug|PEP005|
1795759|NCT00546624|Drug|MK0777|
1795760|NCT00546637|Drug|Fesoterodine|Fesoterodine 4mg or 8mg
1795761|NCT00546637|Drug|Placebo|Placebo
1795762|NCT00546650|Drug|Sumatriptan succinate|NP101 iontophoretic transdermal system
1795763|NCT00546650|Drug|Sumatriptan succinate|oral, subcutaneous, and intranasal formulations
1795764|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg Letrozole daily for 5 years continuously
1795765|NCT00553410|Drug|Letrozole|Film-coated tablet, oral use, 2.5 mg daily, 48 months over 5 yrs: 4 x 9 months (9 mo followed by 3 mo treatment-free interval in yrs 1-4, -> 36 mo) plus 1 x 12 mo in yr 5 -> 48 months
1795766|NCT00553423|Drug|Lactulose|Lactulose 30 ml q6h for 48 hrs
1795767|NCT00553423|Drug|Placebo|Placebo 30 ml q6hrly for 48 hrs
1795768|NCT00553436|Device|Tissue Apposition System (TAS) Device|Closure of defect following polypectomy using the Tissue Apposition System (TAS) Device.
1795769|NCT00553449|Drug|rabeprazole|
1795770|NCT00553462|Drug|carboplatin|
1795771|NCT00553462|Drug|erlotinib hydrochloride|
1795772|NCT00553462|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1795773|NCT00553462|Radiation|radiation therapy|
1795774|NCT00553475|Drug|placebo|Dosage: placebo, oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
1795775|NCT00553475|Drug|pregabalin|Dosage: 300 mg/day (150 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
1795776|NCT00553475|Drug|pregabalin|Dosage: 600 mg/day (300 mg bid), oral administration, Treatment duration: 13 weeks (1-week titration and 12-week fixed dose)
1795777|NCT00553488|Drug|Regular insulin (Humulin)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
1795778|NCT00553488|Drug|Insulin lispro (Humalog)|Insulin will be given either subcutaneously or intra-dermally, and at two different times prior to the liquid meal (T zero). At -17 mins, regular insulin will be given either SC or ID. At -2 mins, regular insulin will be given ID; also insulin lispro will be given either SC or ID. Each patient will receive 1 injection on 5 different study days.
1795779|NCT00553501|Biological|epratuzumab|Days 1, 8, 15, 22 and weeks 12, 20, 28, & 36: 360mg/sq m IV
1795780|NCT00553501|Biological|rituximab|Day 3, 8, 15, 22 and weeks 12, 20, 28, & 36: 375mg/sq m IV
1795781|NCT00553514|Drug|AS900672-Enriched 10 microgram (mcg)|Single injection of AS900672-Enriched (hyperglycosylated recombinant human follicle stimulating hormone [r-hFSH]), 10 mcg will be administered subcutaneously on Stimulation Day 1 (S1). Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
1795782|NCT00553514|Drug|AS900672-Enriched 20 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 20 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
1795783|NCT00553514|Drug|AS900672-Enriched 30 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 30 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
1795784|NCT00553514|Drug|AS900672-Enriched 40 mcg|Single injection of AS900672-Enriched (hyperglycosylated r-hFSH), 40 mcg will be administered subcutaneously on S1. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
1795785|NCT00553514|Drug|Follitropin alfa 75 international unit (IU)|Follitropin alfa (Gonal-f®) 75 IU will be administered subcutaneously once daily from S1 up to Stimulation Day 14 (S14) based upon ovarian response, until recombinant human chorionic gonadotropin (r-hCG) administration day. Subjects who will be receiving AS900672-Enriched 10, 20, 30 and 40 mcg will also receive daily dose of follitropin alfa 75 IU subcutaneously from Stimulation Day 7 (S7) up to S14. Duration of treatment cycle will be up to adequate follicular response received or maximum of 14 days.
1795786|NCT00553514|Drug|Recombinant human chorionic gonadotropin (r-hCG)|Recombinant human chorionic gonadotropin (r-hCG) will be administered as a single dose of 250 mcg subcutaneously, when follicular response is adequate (that is, less than or equal to [=<] 3 follicles with a mean diameter of greater than or equal to [>=] 14 millimeter [mm], and one or two of these follicles with a diameter of >= 17 mm).
1795787|NCT00553527|Procedure|Humeral Stem replacement surgery|Patient will receive humeral stem replacement.
1795789|NCT00553553|Drug|Morphine sulphate|Intravenous morphine titrated up to 0.25 milligrams/kilogram prior to end of resection phase or within first 2 hours of surgery
1795790|NCT00553553|Drug|Morphine hydrochloride, remifentanil hydrochloride|"Pre-induction intrathecal morphine HCl (< 3 attempts), single shot via 25 G pencil point spinal needle at 10 micrograms/kilogram
Intra-operative intravenous remifentanil HCl at titratable dose range 0.1-0.25 micrograms/kilogram/minute until start of wound closure"
1795791|NCT00553566|Procedure|medical chart review|
1795792|NCT00553566|Procedure|questionnaire administration|
1795793|NCT00553566|Procedure|study of socioeconomic and demographic variables|
1795794|NCT00553592|Drug|Bicifadine|600mg/day
1795795|NCT00553592|Drug|Bicifadine|placebo tablet
1795796|NCT00553592|Drug|Bicifadine|1200 mg
1795797|NCT00553605|Drug|Ketoprofen 100mg|Ketoprofen 100 mg diluted in 100 ml of normal sodium chloride solution into the established patient's IV line by slow injection in a 20-minute period; and IV dose of 2 ml of normal sodium chloride solution as placebo for Parecoxib by bolus injection
1795798|NCT00553605|Drug|Parecoxib 40mg|Parecoxib 40 mg diluted in 2 ml of normal sodium chloride solution administered by bolus injection; and an IV dose of 100 ml of normal sodium chloride solution as placebo for ketoprofen administered in a in a 20-minute period
1795799|NCT00553618|Drug|Proleukin and Dacarbazine|"IL-2 (Proleukin), injected just under the skin, at a dose of 12 million units on days 1-4 for each of the six months of therapy.
Dacarbazine, administered as an IV infusion through a freely flowing IV, at a dose of 750 mg, repeated every four weeks."
1795800|NCT00553631|Biological|velaglucerase alfa|IV infusion, 60 U/kg every other week for 9 months
1795801|NCT00553631|Biological|imiglucerase|IV infusion, 60 U/kg every other week for 9 months
1795802|NCT00553644|Drug|Bortezomib|Given IV
1795803|NCT00553644|Other|Laboratory Biomarker Analysis|Correlative studies
1795804|NCT00553644|Drug|Lenalidomide|Given PO
1795805|NCT00553657|Drug|DETROL LA (drug)|
1795806|NCT00553683|Drug|cyclophosphamide|
1795807|NCT00553683|Drug|poly ICLC|
1795808|NCT00553683|Procedure|hepatic artery embolization|
1795809|NCT00553683|Radiation|3-dimensional conformal radiation therapy|
1795810|NCT00553696|Drug|Cisplatin|Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
1795811|NCT00553696|Drug|S-1|S-1 80 mg/m2 on days 1-21 of each 28 day cycle
1795812|NCT00553696|Drug|Sunitinib|Sunitinib 25 mg, 37.5 mg and 50 mg daily S-1 80 mg/m2 on days 1-21 of each 28 day cycle Cisplatin 60 mg/m2 on day 1 of each 28 day cycle
1795813|NCT00553709|Drug|Nicotine|Nicotinell® Patch 10 cm2, containing 17.5 mg of nicotine, with an average delivery rate of 7 mg of nicotine per 24 hours (= TTS 10)
1795814|NCT00553722|Drug|Eplerenone|Administer Eplerenone, 25 mg,orally twice daily for 4 weeks.
1795815|NCT00553722|Drug|Placebo|Administer a placebo tablet orally twice daily for 4 weeks.
1795816|NCT00553930|Drug|Pegylated interferon alfa-2a and Ribavirin|All patients will be treated with the combination of pegIFN-α 2a (135 μg per week)plus oral Ribavirin at a dose of 800 mg per day. The treatment will be continued up to 20 weeks after reaching an undetectable plasma RNA-HCV. Treatment will be discontinued for patients who did not achieve a reduction of al least 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 and will be considered as viral failures.
1795817|NCT00553930|Drug|Pegylated interferon alfa 2a and Ribavirin|Pegylated interferon alfa 2a (135 ug/week)and Ribavirin (800 mg/day). Duration: 20 weeks after reaching an undetectable plasma RNA_HCV. Treatment will be discontinued for patients who did not achieve a decrease of >= 2 log10 IU/ml in plasma HCV RNA levels with respect to baseline at week 12 of treatment or earlier and will be considered as viral failures.
1795818|NCT00553943|Drug|Rituximab, Cytarabine|Intravenous chemotherapy associated with IV rituximab and intrathecal cytarabine
1795819|NCT00553956|Behavioral|Narrative Exposure Therapy/Interpersonal Psychotherapy|The experimental group will receive 5 weekly individual sessions of NET in addition to 3 weekly individual sessions of IPT.
1795820|NCT00553969|Drug|carvedilol phosphate|Extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months
1795821|NCT00553969|Drug|lisinopril|tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
1795822|NCT00553969|Drug|carvedilol phosphate and lisinopril|carvedilol phosphate = extended release capsules, 20mg once daily for 1 month, 40mg once daily for 8 months; lisinopril= tablets, 10mg once daily for 1 month, 20mg once daily for 8 months
1795823|NCT00553969|Drug|placebo and placebo|capsule once daily for 9 months; dosage unknown
1795824|NCT00553982|Procedure|Patellar component|Resurfacing with onlay technique
1795825|NCT00553982|Procedure|No patellar component|Trimming of osteophytes when appropriate
1795826|NCT00553995|Drug|salsalate|Salsalate 3-4 grams per day as tolerated for nine days
1795827|NCT00553995|Drug|Placebo|
1795828|NCT00554008|Procedure|laparoscopic appendectomy|appendix removal via scope
1795829|NCT00554008|Procedure|open appendectomy|open operation for removal of appendix
1795830|NCT00554034|Drug|periopatch|Patients enrolled in the study will be given 1, 2, 3 or 4 patches in a cycle by the order they enter the study.
1795831|NCT00554047|Other|Multidisciplinary Memory Clinic|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by Multidisciplinary Memory Clinics (MMCs)
1795832|NCT00554047|Other|General Practitioners|Post-diagnosis treatment and coordination of care for patients with dementia and their informal caregivers delivered by general practitioners
1795833|NCT00554086|Drug|Escalating dose of Casodex from 50mg daily to 150 mg daily|Casodex dosage increase from 50mg to 150mg daily until baseline serum PSA is reduced by 50%
1795834|NCT00554099|Drug|Mesalamine|6 - 400 mg tablets once daily
1795835|NCT00554099|Drug|Probiotic|Once capsule daily Bifidobacterium infantis 35624 added at Visit 2 (Day 10 + 4 days)
1795836|NCT00554099|Drug|Placebo|6 placebo tablets for first 10 (+4) days followed by once daily placebo tablets.
1795837|NCT00554099|Other|Dietary Advice|Dietary advice
1795838|NCT00554099|Drug|Antibiotic for Diverticulitis|Physician recommended antibiotic for Diverticulitis taken for 10-14 days. Antibiotic not specified for study.
1795839|NCT00554112|Behavioral|Exercise|Exercise
1795840|NCT00554125|Drug|sirolimus|given at an initial dose of 3 mg/m2, and adjusted over time to achieve steady-state whole-blood trough levels of approximately 5-8 ng/mL
1795841|NCT00554138|Drug|placebo|1 dd for 7-10 days
1795842|NCT00554138|Drug|rosuvastatin|1 dd 20 mg for 7-10 days
1795843|NCT00554151|Device|Adjustable Annuloplasty Ring|The investigational device is intended for use in the treatment of mitral valve regurgitation.
1795844|NCT00554164|Drug|(R-)CHOP protocol|Patients with a persistently positive interim-PET scan assigned to arm B1 will receive another six cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone).
1795845|NCT00554164|Drug|B-ALL protocol|Patients with a persistently positive interim-PET scan assigned to arm B2 will receive six blocks of the B-ALL protocol (rituximab, methotrexate, ifosfamide, etoposide, cytarabine, vincristine, cyclophosphamide, doxorubicine, vindesine, dexamethasone).
1795846|NCT00554164|Drug|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A1 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone). Arm A1 was closed when the number of patients required for the randomisation between arms A1 and A2 was reached.
1795847|NCT00554164|Drug|(R-)CHOP protocol|Patients with a negative interim-PET scan assigned to arm A2 will receive another four cycles of the (R-)CHOP regimen (rituximab, cyclophosphamide, doxorubicine, vincristine, prednisone) plus two additional doses rituximab. Since the number of patients required for the randomisation between arms A1 and A2 has been reached, all patients with a negative interim-PET scan are treated according to arm A2.
1795848|NCT00554177|Drug|Medicane (mifepristone)|2 doses of 1200mg, Administered 2-3 days apart
1795849|NCT00554177|Drug|Placebo|2 doses of 1200mg, administered 2-3 days apart
1795889|NCT00554528|Procedure|arthrodesis - cervical disk surgery|discectomy and arthrodesis
1795850|NCT00554190|Device|AdvaCoat sinus gel|A sterile,viscoelastic, bioresorbable gel composed of highly purified hyaluronan, a naturally occurring constituent of tissues in the body
1795851|NCT00554190|Device|Merogel Injectable|Bioresorbable hyaluronic acid product
1795852|NCT00554203|Drug|Sulfasalazine|sulfasalazine 2 grams daily for 6 weeks
1795853|NCT00554216|Drug|VI-0521|3.75 mg phentermine/23 mg topiramate
1795854|NCT00554216|Drug|VI-0521|15 mg phentermine/92 mg topiramate
1795855|NCT00554216|Drug|Placebo matched phentermine/topiramate|Placebo matched phentermine/topiramate
1795856|NCT00554229|Drug|ZD4054|ZD4054 10 mg oral tablet once daily
1795857|NCT00554229|Drug|Placebo|Matching placebo oral tablet once daily
1795858|NCT00554242|Dietary Supplement|Grape seed extract and ascorbic acid|Grape seed extract 450 mg and ascorbic acid 1500 mg daily
1795859|NCT00554255|Drug|SB751689|
1795860|NCT00554268|Drug|PBI-05204|Starting dose = 0.0083 mg/kg/day by mouth (PO) x 3 weeks per cycle
1795861|NCT00554281|Device|Use of glucose sensor (Paradigm Guardian)|Use glucose sensor to prevent episodes of severe hypoglycemia
1795862|NCT00554294|Behavioral|environmental and behavioral change|In intervention schools a water dispenser was installed and children received water bottles as environmental intervention. Children also received a 6-hour-curriculum about the importance of water for the body that were held by the teachers.
1795863|NCT00554307|Device|INVOS Cerebral/Somatic oximeter|Placement of sensors on back, abdomen and forehead for measurement of perfusion beginning 1 hour prior to initiation of drug, during medical treatment for PDA and for 24 hours after the last dose. For control infants, monitoring will continue for 48 hours.
1795864|NCT00554320|Procedure|tDCS|During each session, the anode electrode will be placed on the motor cortex (contralateral to the most [or predominant] painful side [or the side where the symptoms begin or the left as a default]) and the cathode will be placed over the contralateral supraorbital area. In active tDCS subjects, 1 mA of transcranial direct current stimulation will be applied for 30 minutes.
1795865|NCT00554320|Procedure|tDCS|For sham-controlled tDCS subjects, the same montage will be used; however current will be applied only for 30 seconds.
1795866|NCT00554333|Biological|Flu-ID 15μg|Inactivated Split-Virion Influenza Vaccine for Intradermal Route
1795867|NCT00554333|Biological|Inactivated adjuvanted Influenza Vaccine|Inactivated adjuvanted Influenza Vaccine for Intramuscular Route
1795869|NCT00554359|Drug|I5NP (a small interfering RNA)|Single IV injection of experimental drug
1795870|NCT00554359|Drug|placebo|Single IV injection of saline
1795871|NCT00554372|Genetic|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|Patients will be randomized 1:1 to one of two total doses (1e8 or 1e9 pfu)and injected intratumorally in 1-5 intrahepatic tumors on Days 1, 15, and 29.
1795872|NCT00554385|Drug|ABT-089|Up to 4 capsules will be taken once daily for 12 months. Dosage forms include 1 mg, 5 mg, 10 mg capsules and 40 mg tablets. Highest dose allowed is 80 mg per day.
1795873|NCT00554398|Drug|MK-0518 400mg twice a day|Raltegravir, MK-0518
1795874|NCT00554424|Drug|lignocaine|20 mls of 1% lignocaine solution for injection, 10mls into each side of upper vagina, under ultrasound guidance immediately prior to transvaginal oocyte retrieval under ultrasound guidance from each ovary
1795875|NCT00554424|Drug|normal saline|20mls of normal saline solution, 10mls injected each side into upper vagina under ultrasound guidance, immediately prior to ultrasound guided transvaginal oocyte retrieval from each ovary
1795876|NCT00554437|Behavioral|UW Falls Prevention Program|The intervention model is of a community-based multifactorial intervention that links participants to existing medical care and service networks. The intervention used an algorithm based on the University of Wisconsin Falls Prevention Clinic, designed to identify predisposing factors for falls; induce risk reduction changes in medical conditions, medications, behavior, physical status, and home environment through recommendations to participants and their physicians; and make sure these changes are long-lasting through follow-up and linkages to other care networks.
1795877|NCT00554450|Drug|Dapagliflozin|Tablets, Oral, once daily
1795878|NCT00554463|Biological|Filgrastim|5mcg/kg/day subcutaneously on days 4-13 and 25-34 after each concurrent chemotherapy cycle for a total of 20 doses.
1795879|NCT00554463|Biological|Pegfilgrastim|6 mg subcutaneously on day 4 of each adjuvant chemotherapy cycle.
1795880|NCT00554463|Drug|Concurrent chemotherapy|"Beginning day 1 of radiation threapy (+/- 24 hours), repeat cycle every 3 weeks for two cycles:
Day 1: Cisplatin, 60 mg/m^2 i.v.; Days 1-3: Etoposide, 120 mg/m^2 i.v."
1795881|NCT00554463|Drug|Adjuvant chemotherapy|"Cycle 1: Day 43: Cisplatin, 60 mg/m^2 i.v. and Etoposide, 120 mg/m^2 i.v.; Days 44 & 45: Etoposide, 120 mg/m^2 i.v.
Cycle 2: Day 64: Cisplatin, 60 mg/m^2 i.v. and Etoposide, 120 mg/m^2; Days 65 & 66: Etoposide, 120 mg/m^2 i.v."
1795882|NCT00554463|Radiation|radiation therapy|A total of 61.2 Gy in 5 weeks: 1.8 Gy daily x 5 week, for 3 weeks (days 1-16); 1.8 Gy, BID, in 4th week (days 17-20) with off cord boost in p.m.; Off-cord boost, 1.8 Gy BID, in 5th week (days 21-25).
1795883|NCT00554476|Drug|Triamcinolone Acetonide- Indomethacin-Cryotherapy-Casting|
1795884|NCT00554489|Behavioral|exercise intervention|participation in physical activity intervention program weeks 2 through 5
1795885|NCT00554502|Drug|supportive therapy with: ACE-inhibitor / ARB / Statin|"Antihypertensive therapy with a target blood pressure below 125/75 mmHg (following current clinical guidelines).
ACE-inhibitors (ARB when an ACE-inhibitor is not tolerated)
Other antihypertensive medications depending on the clinical decision and following current guidelines.
Statin therapy
Dietary counseling for a low-sodium diet and, if GFR is below 60 ml/min, for a protein intake of 0.8 g/kg/day."
1795886|NCT00554502|Drug|supportive and immunosuppressive therapy|"supportive therapy as outlined above
depending on GFR:
methylprednisolone and prednisolone
cyclophosphamide and prednisolone; after 3 months azathioprine with prednisolone
Concomitant medication with the immunosuppressive treatment following current clinical practice"
1795888|NCT00554528|Device|cervical disc prosthesis with a mobile insert named Mobi-C|"Stage 1: partial discectomy
stage 2: location of the medial axis
stage 3: centering pin
stage 4: installation of the caspar spacer
stage 5: total discectomy
stage 6: parallel distraction
stage 7: depth measurement
stage 8: trial implant
stage 9: assembly
stage 10: implant insertion
stage 11: anchorage optimization"
1795890|NCT00554541|Other|Ankle Brachial Index Venous physiologic study|Assessment of lower extremity venous disease
1795891|NCT00554567|Behavioral|HIV Testing and Care Services|Fully-decentralized HIV Voluntary Counseling and Testing and referral for care
1795892|NCT00554580|Procedure|Continuous Positive Airway Pressure (CPAP)|"Usual treatment of acute pulmonary oedema (see arm A) + CPAP will be administered without interruption for at least one hour and will be stopped for efficacy:
stade I or II KILLIP classification and FR less or equal to 25 /min and SpO2 larger than 90 % ambient air and patient willing the stop of CPAP because of improvement of his clinical status."
1795893|NCT00554580|Procedure|usual care of acute pulmonary oedema|"Usual treatment of acute pulmonary oedema including :
Oxygen, diuretic minimum one bolus IV of 40 mg FUROSEMIDE (LASILIX) possibility to repeat the dose every 15 minutes with a maximum 120 mg.
Bolus of ISOSORBIDE DINITRATE (RISORDAN) of 1 mg maybe repeated every 3 minutes.
As soon as possible perfusion of ISDN with flow adapted to the clinical status If necessary administration of DOBUTAMINE continuous perfusion of to 5 to 20 µg/kg/min."
1795894|NCT00554606|Drug|ACZ885|ACZ885
1795895|NCT00554619|Drug|GSK1325760A|2.5mg, 5mg or 10mg/day, po, GSK1325760A treatment will be continued until its approval by the MHLW.
1795896|NCT00554632|Drug|Ethinyl estradiol and norgestimate|Oral contraceptive
1795897|NCT00554632|Drug|Ethinyl estradiol and norelgestromin|Transdermal hormonal contraceptive changed weekly
1795898|NCT00554645|Behavioral|multi-disciplinary group intervention|children:weekley session in 6 months, monthly sessions for 6 months parents: bi-monthly sessions for 6 months, monthly sessions for 6 months
1795899|NCT00554645|Other|traditional information|1 session of nutritional advise for parents and child and 1 follow-up after one month
1795900|NCT00554658|Drug|Quetiapine|Quetiapine will be administered open label as clinically required according to current guidelines. Target dose range: 400 - 800 mg quetiapine per day.
1795901|NCT00554671|Other|Algorithm driven medication titration|Clinical pharmacists will change medications to achieve goals in hypertension, dyslipidemia and diabetes
1795902|NCT00554671|Behavioral|Monitoring|Clinical pharmacists will monitor the progress of patients in lifestyle modification and cardiac risk factor control goals
1795903|NCT00554671|Behavioral|Group support|Peer support are provided in the group setting
1795904|NCT00554671|Behavioral|Self efficacy|Patients are taught with self-monitoring skills for diabetes and blood pressure, as well as healthy cooking and practiced under supervision
1795905|NCT00554710|Drug|infliximab+azathioprine|infliximab 5 mg/kg at week 0,2 and 6 + azathioprine 2-2.5 mg/kg
1795906|NCT00554710|Drug|methylprednisolone or budesonide|methylprednisolone 32 mg followed by taper or budesonide 9 mg/day followed by taper
1795907|NCT00554723|Drug|NeuroAid|4 capsules 3 times daily, for three months
1795908|NCT00554723|Drug|NeuroAid matched Placebo|NeuroAid matched Placebo, 4 capsules 3 times daily, for three months
1795909|NCT00554736|Biological|Lactobacillus acidophilus L-92|Nasal challenge and acoustic rhinometry will be performed at the first study visit and again at the end of the 4-month supplement period. Standardized perennial ryegrass pollen extract (Lolium perenne) (Hollister-Stier, Inc., Spokane, WA) will be used. Dilutions of the standard product will be made in sterile saline prior to use. The standard product strength is 100,000 BAU/mL. Provocation will start with 100 BAU/mL, delivered as a 100 microliter puff into each nostril nose during breath holding, followed by expiration. Acoustic rhinometry, performed in each nostril, will be recorded at 15 minutes. A change of 30% from baseline in the composite score is considered significant. The dose will be increased every 20 minutes if there is no response. The concentrations used will be 100 BAU, 330 BAU, 1000 BAU, 3300 BAU, 10,000 BAU or 33,000 BAU/mL.
1795910|NCT00554749|Behavioral|Interventions at home, in the kindergarten/school|Weekly interventions including behavior techniques (stimulus fading)
1795911|NCT00554762|Drug|GW842166X|Administer
1795912|NCT00554775|Drug|erlotinib hydrochloride|PO 100 mg daily during WBRT, increasing to 150mg daily after WBRT for up to 24 months
1795913|NCT00554775|Drug|placebo|WBRT plus matched placebo for the same schedule and duration as erlotinib hydrochloride
1795914|NCT00554788|Procedure|autologous bone marrow transplantation|Undergo peripheral blood stem cell or bone marrow transplant
1795915|NCT00554788|Procedure|autologous hematopoietic stem cell transplantation|Undergo peripheral blood stem cell or bone marrow transplant
1795916|NCT00554788|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo peripheral blood stem cell or bone marrow transplant
1795917|NCT00554788|Drug|cisplatin|Given IV
1795918|NCT00554788|Drug|cyclophosphamide|Given IV
1795919|NCT00554788|Drug|etoposide|Given IV
1795920|NCT00554788|Biological|filgrastim|Given SC
1795921|NCT00554788|Drug|carboplatin|Given IV
1795922|NCT00554788|Drug|vincristine sulfate|Given IV
1795923|NCT00554788|Drug|thiotepa|Given IV
1795924|NCT00554788|Radiation|radiation therapy|Undergo radiotherapy
1795925|NCT00554801|Procedure|Audiological testing|Subjects will take part in a battery of audiological tests meant to evaluate the function and status of the auditory system. These tests are similar to the kinds of testing carried out routinely in audiology clinics, and include behavioral tests of pure tone hearing, speech perception, and central auditory function, and electrophysiological testing of the middle ear and of the central auditory system.
1795926|NCT00554814|Drug|Bledilait Biofer®|Bledilait Biofer® 2 mg/100 kcal
1795927|NCT00554814|Drug|Milk supplemented with ferrous sulphate|Milk supplemented with ferrous sulphate (2mg/100kcal)
1795928|NCT00554814|Drug|Blédilait Biofer®|Blédilait Biofer® milk (1,1mg/100kcal)
1795929|NCT00554827|Drug|Pralatrexate Injection|"Intravenous (IV) push over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
Pralatrexate will be administered via intravenous (IV) push over 3-5 minutes. The frequency of pralatrexate will be administered weekly for 3 or 4 weeks (depending on cohort), with 1 week of rest."
1795930|NCT00554827|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection
Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.
Administered every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
1795979|NCT00555139|Drug|alprazolam|Alprazolam capsules 0.25 mg are hard gelatine capsules containing 1 tablet of commercial alprazolam (Xanax 0.25).
1795931|NCT00554827|Dietary Supplement|Folic Acid|"1 mg orally
Administered at least 10 days prior to start of pralatrexate if patient has elevated methylmalonic acid (MMA) and/or homocysteine(Hcy) levels.
Administered daily throughout the study and for at least 30 days after last dose of pralatrexate."
1795932|NCT00554840|Drug|varenicline|Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
1795933|NCT00554840|Drug|placebo|At the end of Pre-med week 1, subjects will receive study medication with the target quit date being the following week. Subjects will be randomized to receive either active drug or matching placebo capsules using the following titration schedule: 0.5mg for three days, 0.5mg twice daily for the next four days, then 1mg twice daily for the rest of the treatment phase. Subjects will be evaluated weekly for abstinence through self report, end expired CO and urine dipstick for cotinine.
1795934|NCT00554853|Drug|pioglitazone|daily dose, 30 mg daily for 2 weeks followed by 45 mg daily until completing 3 months unless higher dose not tolerated in which case patient remained at 30 mg daily
1795935|NCT00554853|Drug|Sublingual nitroglycerine|Used during nitroglycerin-mediated dilatation vascular function measures in both arms of the study if patient's blood pressure permitted. One single tablet was used per vascular test performed.
1795936|NCT00554866|Other|blood sample and buccal swab sample|"one blood sample (500 mL) will be obtained from each VLBW infant between 6 and12 hours after birth from an umbilical-artery or peripheral artery catheter.
Additional DNA collection buccal cell samples were obtained with a sterile OmniSwab."
1795937|NCT00554879|Procedure|Acupuncture|Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.
1795938|NCT00554879|Procedure|Sham acupuncture|Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
1795939|NCT00554892|Procedure|bowel preparation|oral laxatives, retrograde enemas
1795940|NCT00554892|Procedure|no preparation bowel|no preparation bowel
1795941|NCT00554905|Procedure|Radiofrequency ablation|For RFA, we used a commercially available system (RF 2000; Radio Therapeutics, Mountain View, California, USA) and a needle electrode with a 15-gauge insulated cannula with 10 hook-shape expandable electrode tines with a diameter of 3.5cm at expansion (LeVeen; RadioTherapeutics, Mountain View, California, USA).
1795942|NCT00554905|Procedure|TACE|TACE first, then RFA within 2 weeks
1795943|NCT00554918|Drug|docetaxel|
1795944|NCT00554918|Drug|prednisolone|
1795945|NCT00554918|Drug|zoledronic acid|
1795946|NCT00554918|Procedure|quality-of-life assessment|
1795947|NCT00554918|Radiation|strontium chloride Sr 89|
1795948|NCT00554944|Procedure|Esophageal probe|Near-infrared spectroscopy (NIRS) sensor, polarographic-type tissue oxygen sensor (Licox®, esophageal probe
1795949|NCT00554970|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 7 days as per protocol
1795950|NCT00554970|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 7 days as per protocol
1795951|NCT00554970|Drug|Budesonide inhalation suspension 0.25mg|a single dose of Pulmicort Respules® 0.25mg delivered by nebulization twice daily for 7 days as per protocol
1795952|NCT00554970|Drug|Budesonide inhalation suspension 0.5mg|a single dose of Pulmicort Respules® 0.5mg dose delivered by nebulization twice daily for 7 days as per protocol
1795953|NCT00554983|Biological|recombinant birch pollen allergen|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
1795954|NCT00554983|Biological|placebo|subcutaneous injections (s.c.). Dosage escalation phase from 0.75 to 80 microgram maintenance dose s.c. injections of 80 microgram
1795955|NCT00554996|Device|E. coli 83972 coated urinary catheter|E. coli 83972 coated urinary catheter
1795956|NCT00555009|Drug|Genotropin|Subcutaneous injection, starting dose 0.2mg/day for males and 0.3mg/day for female with dose titration at 0.1mg to 0.2 mg increments in accordance to IGF-1 results for a total duration of 36 weeks.
1795957|NCT00555009|Drug|Placebo|Subcutaneous injection, with dummy dose titration for a total duration of 36 weeks.
1795958|NCT00555022|Drug|GSK1160724|GSK1160724 will be available with dosing strengths of 10, 50 and 125 micrograms/blister for inhalation using the DISKUS inhaler.
1795959|NCT00555022|Drug|Tiotropium bromide|Tiotropium bromide capsules will be supplied with a dose of 18 micrograms administered via a HandiHaler device.
1795960|NCT00555022|Drug|Placebo|Subjects will receive placebo.
1795961|NCT00555035|Drug|GSK1349572|
1795962|NCT00555048|Biological|alemtuzumab|
1795963|NCT00555048|Drug|busulfan|
1795964|NCT00555048|Drug|cyclophosphamide|
1795965|NCT00555048|Drug|methotrexate|
1795966|NCT00555048|Drug|tacrolimus|
1795967|NCT00555048|Procedure|allogeneic hematopoietic stem cell transplantation|
1795968|NCT00555048|Procedure|peripheral blood stem cell transplantation|
1795969|NCT00555061|Drug|Retapamulin Ointment, 1%|1% Ointment
1795970|NCT00555074|Drug|Sodium Tungstate|Sodium Tungstate, 200 mg BID, oral route during 6 weeks
1795971|NCT00555074|Drug|Placebo|Placebo, BID, oral route during 6 weeks
1795972|NCT00555087|Drug|Testosterone Undecanoate and/or PDE-5|Testosterone Undecanoate 1000 mg IM injection; PDF5 tab, 20 mg
1795973|NCT00555100|Drug|lenalidomide|10mg-25mg PO/day,day1-day21 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
1795974|NCT00555100|Drug|dexamethasone|40mg PO/day, day1-4,9-12,17-20 of each 28day cycle. Number of Cycles:until progression or unacceptable toxicity develops.
1795975|NCT00555126|Device|Forced Air Warming|Warming after Randomization
1795976|NCT00555126|Device|Warming with endovascular catheter + forced air warming|Warming after Randomization
1795977|NCT00555139|Drug|GSK561679 tablet|GSK561679 tablets are white film-coated tablets, containing 200 (milligrams) mg of the free base, GSK561679A.
1795978|NCT00555139|Drug|GW876008 tablet|GW876008 tablets are white to off-white round film-coated tablets, containing 100 mg of GW876008X (free base).
1795980|NCT00555139|Drug|Placebo|GW876008 placebo tablets will visually match the active GW876008 tablets. GSK561679 placebo tablets will visually match the active GSK561679 tablets. Placebo to match Alprazolam is a hard gelatine capsule that will visually match the active but containing only a filler.
1795981|NCT00555152|Drug|lapatinib ditosylate|Given PO
1795982|NCT00555152|Other|placebo|Given PO
1795983|NCT00555152|Other|laboratory biomarker analysis|Correlative studies
1795984|NCT00555165|Device|Telescope prosthesis|Monocular implantation of the telescope prosthesis after cataract extraction
1795985|NCT00555191|Behavioral|diet restriction|each meal should contain less than 2 gm fructose
1795986|NCT00555204|Drug|ABT-089|10 mg - capsules once daily for 12 weeks
1795987|NCT00555204|Drug|ABT-089|5 mg - capsules once daily for 12 weeks
1795988|NCT00555204|Drug|ABT-089|15 mg - capsules once daily for 12 weeks
1795989|NCT00555204|Drug|ABT-089|20 mg - capsules once daily for 12 weeks
1795990|NCT00555204|Drug|ABT-089|30 mg - capsules once daily for 12 weeks
1795991|NCT00555204|Drug|ABT-089|35 mg - capsules once daily for 12 weeks
1795992|NCT00555204|Drug|placebo|placebo - capsules once daily for 12 weeks
1795993|NCT00555217|Drug|losartan|50 or 100mg/day
1795994|NCT00555217|Drug|lisinopril|10, 20 or 40 mg/day
1795995|NCT00555230|Drug|Rosuvastatin|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
1795996|NCT00555230|Drug|Placebo|5mg daily for 4 weeks then step up to 10mg or matching placebo for 52 weeks
1795997|NCT00555243|Procedure|Laparoscopic Simulation training|five 30-minute faculty-directed sessions at the Laparoscopic Simulator Lab
1795998|NCT00555243|Procedure|Traditional Surgical Education|Traditional surgical teaching (no simulator)
1795999|NCT00555256|Drug|sunitinib and rapamycin (Drug will be held)|Any toxicity causing a total of 14 days delay of therapy will be considered dose limiting.
1796000|NCT00555282|Device|central venous catheter|coated central venous catheter
1796001|NCT00555282|Device|central venous catheter|standard central venous catheter
1796002|NCT00555308|Other|emergency department targeted ultrasound imaging|bedside ultrasound performed by emergency physician to identify hydronephrosis
1957407|NCT02415530|Behavioral|Combined home visiting and group intervention|home visit includes pre-discharge meeting with parents; education of appropriate feeding, breastfeeding, sleeping, position of baby, defecation, environment for baby care and resuscitation on emergency situation first visit (5 days after discharge); understanding baby's sign check feeding, sleeping, sanitation, defecation, environment second visit (14 days after discharge); understanding baby's sign and baby's development support parents check feeding, sleeping, sanitation, defecation, environment special situation third visit (4 weeks after discharge) understanding baby's sign and baby's development support parents special situation fourth visit (8 weeks after discharge) same as third visit Group intervention for parental support with baby 12 times during corrected age 3~6 months
1957408|NCT02415530|Other|No intervention|No intervention
1796008|NCT00555334|Procedure|RFA|radiofrequency ablation
1796009|NCT00555334|Drug|lamivudine or entecavir|lamivudine (100mg qd) or entecavir (0.5mg qd) after RFA
1796012|NCT00555360|Behavioral|HITCM+CP|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6-month and 12-month follow-up.
1796013|NCT00555360|Behavioral|HITCM only|Weekly automated assessment calls with follow-up by a care manager for 12 months. Baseline, 6-month and 12-month follow-up.
1796014|NCT00555373|Drug|Sirolimus|"Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.
Sirolimus (Rapamune®):
At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
1796015|NCT00555386|Dietary Supplement|Soy and Selenium|6g of chocolate per day Control group with no supplementation Active group 50mg of soy protein isolate + 200µg selenium in the form of MSC
1796016|NCT00555399|Drug|Vorinostat|"Phase I/Arm 1: Level 0 = 300 mg PO x 14 days; Level I = 400 mg PO x 14 days; Level II = 500 mg PO x 14 days.
Phase I/Arm 3: Level -II = 300 mg PO x 14 days; Level -I = 400 mg PO x 14 days; Level 0 = 400 mg PO x 14 days; Level I = 500 mg PO x 14 days."
1796017|NCT00555399|Drug|Isotretinoin|"Phase I/Arm 1: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.
Phase I/Arm 2: Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days.
Phase I/Arm 3: Level -II = 100 mg/m^2/day PO x 21 days; Level -I = 100 mg/m^2/day PO x 21 days; Level 0 = 100 mg/m^2/day PO x 21 days; Level I = 100 mg/m^2/day PO x 21 days; Level II = 100 mg/m^2/day PO x 21 days."
1796018|NCT00555399|Procedure|Surgical Resection|Surgical Resection for recurrent Glioblastoma Multiforme
1796019|NCT00555399|Drug|Temozolomide|"Phase I/Arm 2: All Levels = 150 mg/m2/day PO X 14 days.
Phase I/Arm 3: Level 0 = 150 mg/m2/day PO X 14 days; Level I = 150 mg/m2/day PO X 14 days; Level -I = 125 mg/m2/day PO X 14 days; Level -II = 125 mg/m2/day PO X 14 days; Level -III = 100 mg/m2/day PO X 14 days."
1796020|NCT00555412|Drug|A - 10 mg loxapine q 4 h x 3 (30 mg total)|loxapine aerosol inhalation high dose regimen (30 mg total)
1796021|NCT00555412|Drug|B - 10 mg x 1, 5 mg x 2 loxapine q 4 h (20 mg total)|loxapine aerosol inhalation middle dose regimen (20 mg total)
1796022|NCT00555412|Drug|C - 5 mg loxapine q 4 h x 3 (15 mg total)|loxapine aerosol inhalation low dose regimen (15 mg total)
1796023|NCT00555412|Drug|D - inhaled placebo q 4 h x 3|placebo aerosol inhalation (0 mg total)
1796024|NCT00555425|Behavioral|Behavioral: Buprenorphine/naloxone maintenance (Mtn)|Mtn is designed to reflect usual care by primary care physicians and includes weekly drug counseling (DC) and referral to ancillary services. Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Mtn, Bup will continue unchanged for the remainder of the study.
1796064|NCT00555789|Drug|mycophenolic plus tacrolimus|720mg b.i.d. 2yrs
1796065|NCT00555802|Other|exercise|exercise
1796102|NCT00556075|Drug|Proellex 25 mg|1 capsule daily for 4 months
1796025|NCT00555425|Behavioral|Behavioral: Buprenorphine/naloxone detoxification (Dtx)|Dtx and Mtn will be identical for the first 4 weeks (stabilization) following randomization. In Dtx, the dosage of Bup will be tapered to zero over the next 3 weeks, and patients will not receive additional Bup for the remainder of the study. Dtx patients will be offered thrice-weekly DC beginning during the taper and naltrexone will be offered 7 days following the last dose of Bup.
1796026|NCT00555438|Drug|fondaparinux 1.5 mg/day|Subcutaneous injection of fondaparinux 1.5 mg/l after major orthopaedic surgery
1796027|NCT00555451|Drug|HE3286|"Dose escalating cohort driven study. 6 planned cohorts.
HE3286 5 mg or placebo QD for 28 days;
HE3286 10 mg (5 mg BID) or placebo BID for 28 days
HE3286 20 mg (10 mg BID) or placebo BID for 28 days
HE3286 40 mg (20 mg BID) or placebo BID for 28 days
HE3286 4 mg (2 mg BID), 20 mg (10 mg BID) or placebo BID for 28 days
HE3286 10mg (5 mg BID) for 28 days (open-label cohort in patients with T2DM)"
1796028|NCT00555464|Drug|Vincristine|Vincristine (0.05 mg/kg/dose) will be administered into a vein (PICC line) every week for 12 weeks. If assigned to receive Vincristine, a PICC line will be placed by a doctor who is a specialist in this procedure, an interventional radiologist. This will require sedation and when possible, will be coordinated with sedation for the MRI.
1796029|NCT00555464|Drug|Prednisone|Prednisolone given at 3 mg/kg/day by mouth for 12 week
1796030|NCT00555477|Drug|anastrozole|1 mg tablet by mouth once a day
1796031|NCT00555490|Dietary Supplement|Soy protein|35 % of protein from soy protein for 4-years
1796032|NCT00555516|Other|EW02|"Name: EW02
Dosage form: capsule.
Dose(s): 350mg per capsule, 2 capsule tid.
Dosing schedule: 2 capsule tid; 15 days (D3 to D17) of EW02 or placebo in Cycles 2 and 3."
1796033|NCT00555529|Procedure|radial artery applanation tonometry (RAAP)|non-invasive tonometry
1796034|NCT00555542|Drug|rituximab|Patients are taking stable dose of methotrexate and at least 10mg folic acid per week for at least 4 weeks. Rituximab is administrated as 1000mg intravenous infusion on day 1 and day 15. Premedication as standard prescription consists of methylprednisolone 100mg IV, Chlorpheniramine maleate(piriton 10mg IV and oral paracetamol 500mg to be given 30 minutes before each infusion of rituximab. Oral prednisolone 60mg is tob e given from day 1-6 after rituximab infusion and 30mg from day 7-13.
1796035|NCT00555555|Biological|Alphanate SD/HT|A general guideline based on the product Full Prescribing Information is recommended with a maximum dose of 80 VWF:RCof IU/kg. The number of administrations before, during, and after the surgery procedure depends on the subject's clinical condition and the type of surgery itself. Single administrations or multiple doses may be appropriate. The dose of Alphanate® administered to each subject will be recorded as IU of VWF:RCof and also as IU of FVIII:C. The lot number for each vial of concentrate administered will also be recorded.
1796036|NCT00555568|Behavioral|recovery oriented mental health peer support group|This is a recovery-focused mental health education and support group led by peer facilitators
1796037|NCT00555568|Behavioral|recovery-oriented mental health clinician-led group|This is a recovery-focused mental health education and support group led by a mental health clinician
1796039|NCT00555594|Drug|Bevacizumab (Avastin)|One dose of 0.1cc of subconjunctival Bevacizumab was applied
1796040|NCT00555607|Drug|prednisolone|Prednisolone oral tablets (10 mg active ingredient per tablet) once a day at a dose of 0.5mg/kg bodyweight, during 14 days.
1796041|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
1796042|NCT00555620|Drug|oxaliplatin|Oxaliplatin is given 110mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
1796043|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
1796044|NCT00555620|Drug|capecitabine|Capecitabine is given orally at 1000mg/m^2 twice a day for 14 days followed by 7 days of drug free period.
1796045|NCT00555620|Drug|cisplatin|Cisplatin is given 80mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
1796046|NCT00555620|Drug|sunitinib malate|sunitinib is given orally 25mg/day for 14 days followed by 7 days of drug free period.
1796047|NCT00555646|Drug|PH-10 (rose bengal disodium 0.001%)|"PH-10 with 544 nm LED light illumination
OR
PH-10 with ambient light exposure"
1796048|NCT00555646|Drug|Control|No treatment control.
1796049|NCT00555672|Drug|5-fluorouracil|5- fluorouracil is given as 4000 mg/m^2 total dose over 96 hr continuous infusion of a 21 day chemotherapy cycle. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
1796050|NCT00555672|Drug|cisplatin|Cisplatin is given 80 mg/m^2 through a vein on day 1 every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
1796051|NCT00555672|Drug|sunitinib malate|sunitinib is given orally 37.5mg /day for 14 days followed by 7 days of drug free period. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
1796052|NCT00555685|Drug|NaCl 7,5% (Hypertonic Saline Solution)|Patients in the intervention arm will receive 100ml of NaCl 7,5, twice daily during 3 days
1796053|NCT00555685|Drug|NaCl 0,9%|Patients in the placebo arm will receive 100ml of NaCl 0,9% twice daily during 3 days
1796054|NCT00555698|Device|Deep Brain Stimulations for Depression|Deep Brain Stimulations for Depression
1796055|NCT00555711|Device|Modulated Imaging|Modulated Imaging
1796056|NCT00555724|Drug|BIIB022|IV infusion once every three weeks until disease progression or unacceptable toxicity
1796057|NCT00555737|Device|Capsule Endoscopy|Given® Diagnostic system with Pillcam SB
1796058|NCT00555750|Drug|eszopiclone|3mg tablet, by mouth nightly 30 min before bed, for two months
1796059|NCT00555750|Drug|placebo|inactive placebo tablet, by mouth nightly 30 minutes before bed, for two months
1796060|NCT00555763|Device|Tonometry|Tonometry : measurement of intraocular pressure with an applanation tonometer
1796063|NCT00555789|Drug|AEB071|200mg oral b.i.d.
1796066|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection
1796067|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
1796068|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection
1796069|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
1796070|NCT00555828|Genetic|Allogeneic Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
1796071|NCT00555828|Procedure|Standard-of-care treatment with NOGA® mapping and staged injections.|Standard-of-care treatment with NOGA® mapping and staged injections.
1796073|NCT00555854|Behavioral|An individual motivational intervention program to promote and maintain self-care behaviour|5 individual interviews in an one year period
1796074|NCT00555867|Drug|Anastrozole|oral
1796075|NCT00555880|Drug|Midodrine hydrochloride|one dose, 10-30mg, given orally
1796076|NCT00555880|Drug|Placebo|Placebo
1957418|NCT02406859|Behavioral|Bowel Biofeedback|Subjects will complete 2 sessions twice a week for 6 weeks of bowel biofeedback training. Subjects will be asked to squeeze and bear down for a period of 5 seconds followed by rest for 10seconds. Following the training, each subject will complete similar training at home for 6 weeks.
1796079|NCT00555906|Drug|Bortezomib|Escalating doses of bortezomib will be administered intravenously on Days 8, 11, 15 and 18 of a 28-day cycle (Schedule A) or of a 21-day cycle (Schedule B). The planned doses to be evaluated are 0.7, 1 and 1.3 mg/m2 in combination with PD 0332991 and dexamethasone.
1796080|NCT00555906|Drug|Dexamethasone|20 mg, orally on Days 8, 11, 15 and 18 of a 28 day cycle (Schedule A) or of a 21-day cycle (Schedule B) in combination with PD 0332991 and bortezomib.
1796081|NCT00555906|Drug|PD 0332991|Escalating doses of PD 0332991 will be administered orally on Days 1-21 of a 28-day cycle for Schedule A and on Days 1-12 of a 21-day cycle for Schedule B. The planned doses to be evaluated are 50, 75, 100 mg and 125 mg once daily in combination with bortezomib and dexamethasone.
1796082|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|25 mg daily oral treatment
1796083|NCT00555919|Drug|Lonaprisan (ZK 230211, BAY86-5044)|100 mg daily oral treatment
1796084|NCT00555932|Procedure|Ultrasound|All the studies will be performed with the portable ultrasound machine used on a regular basis in the neonatal care unit.
1796085|NCT00555945|Procedure|Gamma3 intramedullary nail (Stryker)|The Gamma3 nail is cannulated for Guide-Wire-controlled insertion, and features a conical tip for optimal alignment with the inner part of the cortical bone. A single distal Locking Screw is provided to stabilize the nail in the medullary canal and to help to prevent rotation in complex fractures.
1796086|NCT00555945|Procedure|Sliding Hip Screw|The sliding hip screw is a single larger diameter partially threaded screw, which is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixation.
1796087|NCT00555958|Device|Active, implantable, intra-abdominal vagal blocking medical device|Intermittent, programmable, intra-abdominal vagal blocking
1957419|NCT02406859|Behavioral|Anorectal Manometry|Subjects will undergo an anorectal manometry to establish baseline pressure characteristics. If subjects qualify for biofeedback training, they will complete two additional manometries to track the changes occuring during training.
1796090|NCT00555984|Drug|Propofol + Remifentanil|Administered intravenously during surgery for maintenance of General Anesthesia
1796091|NCT00555984|Drug|Sevoflurane + Remifentanil|the (Sevoflurane + Remifentanil) arm: Sevoflurane as inhalational agent and Remifentanil as intravenous agent for maintenance of General Anesthesia
1796092|NCT00555997|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
1796093|NCT00555997|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
1796094|NCT00555997|Drug|Placebo|"0mg Placebo per day. Dose increases and dose decreases may occur, but patient will remain at 0mg placebo"
1796095|NCT00556023|Drug|CP-675,206 and gemcitabine|Escalating doses of CP-675,206 will be administered by IV infusion on day 1 of each 84-day treatment cycles (doses of 6, 10 and 15 mg/kg are planned). Gemcitabine will be administered by IV infusion, at a fixed dose of 1000 mg/m2 on days 1 (prior to CP-675,206) and again on days 8, 15, 29, 36, 43, 57, 64, and 71. Repeated cycles of gemcitabine and CP-675,206 will be administered until patients develop progressive disease or unacceptable toxicity, or for a maximum of 4 cycles, whichever occurs first.
1796096|NCT00556049|Drug|Gemcitabine|Intravenously on days 1 and 8 of each 21-day treatment cycle.
1796097|NCT00556049|Drug|Sunitinib|Orally on days 1-14 of each 21-day treatment cycle
1796098|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
1796099|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
1796100|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
1796101|NCT00556062|Biological|seasonal split influenza vaccine|0.5 ml/dose, containing 45 μg influenza HA antigens, 15 μg each subtype; one dose regime
1796103|NCT00556075|Drug|Placebo|1 capsule daily for 4 months
1796104|NCT00556075|Drug|Proellex 50 mg|2 capsules daily for 4 months
1796105|NCT00556088|Drug|LBH589, Paclitaxel, Carboplatin, Bevacizumab|"LBH589 will be administered orally twice weekly. Paclitaxel and carboplatin will be administered intravenously every 21 days.
Once the MTD is established, drug dosages will be adjusted downward by one dose level and bevacizumab 15mg/kg intravenously every 3 weeks will be administered to a subset of patients with non-small cell lung cancer."
1796106|NCT00556101|Procedure|Whole body magnetic resonance angiography|
1796107|NCT00556114|Device|Optical Coherence Tomography|Optical Coherence Tomography
1796108|NCT00556127|Drug|Rituximab|375 mg/m2 on day 1
1796109|NCT00556127|Drug|Epirubicin|110 mg/m2 on day 3
1796110|NCT00556127|Drug|Cyclophosphamide|1200 mg/m2 on day 3
1796111|NCT00556127|Drug|Vincristine|1.4 mg/m2 (maximum 2 mg) on day 3
1796112|NCT00556127|Drug|Prednisone|40 mg/m2 from day 1 to 5
1796113|NCT00556127|Drug|Granulocyte-colony-stimulating factor|(G-CSF 5 μg/Kg/day) from day 5 to day 11
1796114|NCT00556127|Drug|Mitoxantrone|8 mg/m2 for 3-day
1796115|NCT00556127|Drug|Cytarabine ARA-C|2 g/m2/12 hours for six doses in 3-hour infusion
1796116|NCT00556127|Drug|Dexamethasone|4 mg/m2/12 hours before ARA-C administration
1796117|NCT00556127|Drug|Carmustine BCNU|300 mg/m2 on day -7
1796118|NCT00556127|Drug|Etoposide|100 mg/m2/12 hours
1796119|NCT00556127|Drug|Melphalan|140 mg/m2 on day -2
1796120|NCT00556127|Radiation|Radiotherapy|Involved Field Radiotherapy (IF-RT)
1796121|NCT00556127|Procedure|PBSC reinfusion|ASCT
1796122|NCT00556140|Drug|Aripiprazole|"Everyone in this study will receive aripiprazole and an antidepressant called a selective serotonin reuptake inhibitor (SSRI). There is only one arm for this study.
Aripiprazole is an antipsychotic medication that has been approved by the Food and Drug Administration (FDA) for the treatment of schizophrenia.
You will receive aripiprazole (Abilify) and one of the following SSRI antidepressant medications that will be determined by the study doctor and you: sertraline (Zoloft), citalapram (Celexa), or escitalopram (Lexapro). The dose of aripiprazole (Abilify) will be 10 milligrams a day, and the starting doses for the SSRI anti-depressants will be: sertraline (Zoloft) 50 milligrams a day, citalopram (Celexa) 20 milligrams a day, and escitalopram (Lexapro) 10 milligrams a day."
1796123|NCT00556153|Drug|[F-18]Fluoro-DOPA PET, a diagnostic radiopharmaceutical|A single dosage of the diagnostic drug will be administered to individuals who meet inclusion criteria after informed consent.
1796124|NCT00556166|Device|Enterra Therapy Gastric Stimulator|"The intramuscular stomach leads, implanted in a minimally invasive surgical procedure lasting 1-3 hours, are placed on the greater curvature of the stomach. The implanted pulse generator (IPG) is about 2 1/2 x 2 x 1/2 and is implanted in a subcutaneous pocket, generally created in the abdominal area, and is then connected to the leads. The IPG provides the energy source that delivers the electrical pulse to the stomach muscle through the stomach leads to improve the symptoms of gastroparesis.
The doctor will use an external programmer to change the settings of the neurostimulator and control the neurostimulator after implantation. Part of the programmer is held outside the body over the implant site and can adjust or change the settings of the neurostimulator using radio remote control."
1796125|NCT00556179|Drug|Lactoserum (Dermacyd Femina®)|Once a day during three months
1796126|NCT00556192|Drug|rituximab|"Rituximab of 1000 mg given 2 weeks apart. On day the of rituximab, and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5.
A treatment dose rituximab of 1000mg given 2 weeks apart and 'pulse' methylprednisolone 250mg IV be given followed by prednisolone 30mg/day from Day 2 to Day 5, and 'pulse' cyclophosphamide 500mg/m2 at baseline and day 14.
Sequential therapy with oral cyclophosphamide (50 to 100 mg/day) for 6 months followed by azathioprine (up to 2.5mg/kg/day) for maintenance up to 12 months. Oral prednisolone will be given at 0.5 mg/kg/day (up to 30 mg daily) for 4 weeks, tapered by 5 mg every 2 weeks thereafter until 5mg /day for the rest of the study period."
1796127|NCT00556205|Drug|Sunitinib|Sunitinib orally once daily
1796128|NCT00556205|Drug|Bevacizumab|Intravenously every 14 days
1796129|NCT00556218|Behavioral|Tibetan Meditation Program|12 sessions of Tibetan meditation (2 times a week), over a 6-week period. Each class will last about 60 minutes.
1796130|NCT00556218|Behavioral|No Meditation|No meditation; usual care.
1796131|NCT00556244|Procedure|ILM peeling|ILM maculorhexis is initiated using scraper and completed using a 25-gauge Synergetics (St. Louis, MO) forceps.
1796132|NCT00556257|Drug|Cyclosporine|Standard of care
1796133|NCT00556257|Drug|CP-690-,550|CP-690550 20 mg BID in Months 1-6 then 15 mg BID in Months 7-12
1796134|NCT00556270|Drug|Matrifen|as defined in the Summary of Product Characteristics (Fachinformation Chapter 4.2)
1796135|NCT00556283|Device|STARR|Stapled Trans-Anal Rectal Resection for the treatment of ODS
1796136|NCT00556283|Behavioral|Biofeedback|electromyographic-based treatment sessions
1796137|NCT00556296|Drug|NRP104|NRP104 30mg capsule once daily in a.m.
1796138|NCT00556296|Drug|NRP104|NRP104 50mg capsule once daily in a.m.
1796139|NCT00556296|Drug|NRp104|NRP104 70mg capsule once daily in a.m.
1796140|NCT00556296|Drug|Placebo|Placebo
1796141|NCT00556309|Device|Optical Coherence Tomography|Optical Coherence Tomography Imaging of Post Coil Aneurysm Healing.
1796142|NCT00556322|Drug|Alimta or Taxotere|500mg/m2 / 3 weeks (Alimta) or 75mg/m2 / 3 weeks (Taxotere)
1796143|NCT00556322|Drug|erlotinib [Tarceva]|150mg po daily
1796144|NCT00556335|Procedure|manual aspiration|air aspiration
1796145|NCT00556335|Procedure|conventional drainage|drainage, pneumocath
1796146|NCT00556348|Drug|bevacizumab|1.25mg
1796147|NCT00556361|Drug|saline|2 mg/Kg IV saline within 5 minutes of initiation of Cardiopulmonary bypass
1796148|NCT00556361|Drug|ketamine|2 mg/Kg IV within 5 minutes of cardiopulmonary bypass
1796152|NCT00556387|Drug|saline|1 mg/kg IV bolus slowly over 1-2 minutes followed by 0.5 mg/kg IV continuous infusion over 48 hours or until discontinuation of ICP monitor (whichever occurs first)
1796153|NCT00556387|Drug|Ketamine|1 mg/kg IV bolus slowly over 1-2 minutes, followed by 0.5 mg/kg IV continuous infusion for 48 hours or until discontinuation of ICP monitor (whichever occurs first)
1796154|NCT00556400|Drug|Lo-Ovral Oral Contraceptive Pills|
1796155|NCT00556400|Drug|Placebo - sugar pill|
1796156|NCT00556413|Biological|cetuximab|
1796157|NCT00556413|Drug|fluorouracil|
1796158|NCT00556413|Drug|irinotecan hydrochloride|
1796159|NCT00556413|Drug|leucovorin calcium|
1796160|NCT00556413|Drug|oxaliplatin|
1796161|NCT00556426|Device|Bard Recovery G2 Filter System|Retrieval of previously placed RECOVERY G2 IVC filter
1796162|NCT00549588|Other|After-sun-lotion with DNA repair enzymes|2 mg/cm2 immediately after UV exposure
1796163|NCT00549588|Other|SPF30 sunscreen|2 mg/cm2 2o min before UV exposure
1796164|NCT00549588|Other|Placebo after-sun-lotion|2mg/cm2 immediately after UV exposure
1796165|NCT00549588|Other|Intervention: none (only UV)|n.a.
1796166|NCT00549601|Drug|Rivastigmine patch (4.6 mg/day switch to 9.5 mg/day)|Rivastigmine administered transdermally via patches at increasing doses (1 patch/day of 4.6 mg for the first month, changing to 1 patch/day of 9.5 mg for the remaining two months).
1796167|NCT00549601|Drug|Rivastigmine patch (9.5 mg/day)|Rivastigmine administered transdermally via patches at a constant dose (9.5 mg/day for the 3 months of treatment).
1796168|NCT00549601|Drug|Rivastigmine capsules (6 mg to 12 mg/day)|Rivastigmine administered orally, following the same regime as prior to randomization (doses between 6 mg and 12 mg/day), which remained unchanged throughout the 3 months of treatment.
1796169|NCT00549614|Drug|acipimox|capsule, 250 mg, 4 times daily for 28 days
1796170|NCT00549614|Drug|placebo|capsule, 250 mg, 4 times daily for 28 days
1796171|NCT00549627|Device|Pediguard|PediGuard™ is a hand-held drilling tool that allows real-time detection of vertebral pedicle and body breaches in all directions.
1796172|NCT00549640|Drug|Methylphenidate|54 mg Methylphenidate per day for 8 weeks. Allowing for a ramp up in the first two weeks (starting dose is 18 mg/day).
1796173|NCT00549640|Drug|Placebo|non-active (sugar pill)designed to be a look-alike to the methylphenidate. Given at the same frequency and dosage look-alike to the active comparator (methylphenidate 54 mg)
1796174|NCT00549653|Drug|GW856553|
1796175|NCT00549666|Drug|Lurasidone 40 mg|Lurasidone 40 mg days 12-21 once daily
1796176|NCT00549666|Drug|Placebo 40 mg|Placebo 40 mg once daily during treatment period
1796177|NCT00549666|Drug|Ortho Tri-Cyclen|Ortho Tri-Cyclen during 28-day lead in period
1796180|NCT00549692|Drug|Omega-3 fatty acid ethylester90|Dosage form :1g soft capsule Dosage : two capsules, twice a day.
1796181|NCT00549718|Drug|Lurasidone HCl|Once daily
1796183|NCT00549757|Drug|Aliskiren|Aliskiren 150 mg film-coated tablets
1796184|NCT00549757|Drug|Placebo|Placebo to match aliskiren 150 mg film-coated tablets
1796185|NCT00549770|Drug|LCZ696|
1796186|NCT00549770|Drug|Valsartan|
1796187|NCT00549770|Drug|AHU377|
1796188|NCT00549770|Drug|Placebo|
1796189|NCT00549783|Biological|Botulinum Toxin Type A 900kD|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.
First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
1796190|NCT00549783|Biological|Placebo|"The exact dosage and number of injection sites is based on the size, number, and location of muscles involved; the severity of spasticity; and the presence of local muscle weakness.
First intra-muscular injection at the Baseline visit, and optional second injection of the randomised treatment after a minimum of 12 weeks to a maximum of 24 weeks following the Baseline visit."
1796191|NCT00549796|Other|Percutaneous coronary intervention (PCI)|Patients undergo routine, clinically indicated PCI
1796192|NCT00549809|Procedure|Intermittent mandatory ventilation (IMV) and synchronous IMV|Patients divided to receive two different modes of mechanical ventilation.
1796193|NCT00549822|Drug|Letrozole|Treatment is intermittent with possible breaks between each 28 day treatment cycle if CA 15-3 or CA 27.29 level that has decreased by at least 50% of that individual patient's baseline or peak level on firstline letrozole or anastrozole therapy or has decreased into the normal reference range per institutional parameters. Letrozole or anastrozole therapy will be interrupted until CA 15-3 or CA 27.29 levels rise by at least 25% above trough CA 15-3 or CA 27.29 level. If the trough level is in the normal reference range then the CA 15-3 or CA 27.29 must rise into the normal reference range.
1796194|NCT00549835|Procedure|Real Acupuncture|
1796195|NCT00549835|Procedure|Sham Acupuncture|"Sham needles are developed to exclude sham effect and to prove real acupuncture efficacy. We will use specifically retractable Park Sham Device (AcuPrime, Exeter, UK) for control group. Because this sham device gives the impression of insertion with telescopic needle body and some pricking sensation with a bunt needle tip. It is a valid control for many acupuncture trials as it doesn't penetrate skin and doesn't create active stimulation as much as real needles or acupressure. To avoid unnecessary stimulation of penetrating skin in this population, we plan to use non-penetrating sham device rather than penetrating non-acupuncture point with real needles as control intervention.
All other procedures will be same as Real Acupuncture group except using non-penetrating sham needles on non-acupuncture points. After final session, we will ask all subjects in both groups which form of treatment each subject believe to have during study and will analyze blinding credibility."
1796196|NCT00549848|Drug|Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine|See Detailed Description section for details of treatment interventions.
1796197|NCT00549848|Drug|Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib|See Detailed Description section for details of treatment interventions.
1796198|NCT00549861|Procedure|Cardiac Magnetic Resonance study|Cardiac MRI study
1796199|NCT00549874|Drug|Rosiglitazone|oral 8 mg/once daily for 6 months
1796200|NCT00549874|Drug|Glyburide|20 mg/ once daily for 6 months
1796430|NCT00558324|Procedure|LASIK|Femtoseconds laser 100 microns
1796201|NCT00549887|Drug|Analog or Human Insulin|prescribed in accordance with usual clinical practice
1796202|NCT00549900|Biological|GSK580299 (Cervarix™ , HPV -16/18 L1 VLP AS04 vaccine)|Intramuscular injection, 3 doses
1796203|NCT00549913|Genetic|NeoFuse|immunoselected, culture-expanded, nucleated, allogeneic MPCs (NeoFuse) combined with MasterGraft Resorbable Ceramic Granules in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
1796204|NCT00549913|Procedure|posterolateral spinal fusion with instrumentation|autograft in subjects requiring posterior lumbar interbody fusion with NuVasive's radiolucent PEEK OPTIMA cage
1796205|NCT00549926|Drug|Fluvastatin|
1796206|NCT00549926|Drug|Pravastatin|
1796207|NCT00549926|Drug|Pitavastatin|
1796208|NCT00549926|Drug|Atorvastatin|
1796209|NCT00549939|Drug|Alfuzosin|"Form: solution or tablet according to age
Route: oral
Dose: daily dose adjusted to body weight"
1796210|NCT00549939|Drug|Placebo|"Form: matching solution or matching tablet according to age
Route: oral
Dose: daily dose adjusted to body weight"
1796211|NCT00549952|Other|no intervention study|
1796212|NCT00549965|Drug|Risedronate Sodium|
1796213|NCT00549978|Drug|Cilostazol|cilostazol, then cilostazol/probucol
1796214|NCT00549978|Drug|Probucol|Probucol probucol/ cilostazol
1796215|NCT00550004|Drug|RP101|190 mg oral tablet
1796216|NCT00550004|Drug|Gemcitabine (1000 mg/m2)|30 minute intravenous infusion
1796217|NCT00550017|Drug|Epofolate|Intravenous solution, intravenous, initially 3 patients will be treated and if there is a DLT then additional 3 patients will be treated in that dose level. 3-5 minute IV bolus on Days 1 through 4 of a 21-day cycle, until the disease progresses
1796218|NCT00550030|Radiation|UVB-311nm radiation|UVB-311nm radiation randomized to one body half given 3 times a week for 6 weeks; the other body half remains UV-non-irradiated.
1796219|NCT00550030|Other|No treatment|no UV exposure
1796220|NCT00550043|Drug|INCB018424|
1796221|NCT00550043|Drug|Placebo|
1796222|NCT00550056|Behavioral|Narrative Exposure Therapy|Six session of Narrative Exposure Therapy
1796223|NCT00550056|Behavioral|Trauma Counselling|Six sessions of Trauma Counselling, using a variety of skills incl. exposure methods following the skills of the therapist
1796224|NCT00550095|Drug|valsartan|
1796225|NCT00550108|Other|Ethanol lavage|Ethanol lavage of pancreatic cysts.
1796226|NCT00550121|Drug|vitamin C|
1796227|NCT00550121|Drug|placebo|
1796228|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
1796229|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing MRI, Comet assay and Cell senescence
1796230|NCT00550134|Behavioral|Questionnaires, MRI, Comet assay and Cell senescence|Neuropsychological and psychological testing, MRI, Comet assay and Cell senescence
1796231|NCT00550147|Drug|Oros Methylphenidate|"Oros methylphenidate will be titrated over 3 visits according to the following schedule:
Visit 2 dose of 18 mg QAM
Visit 3 dose of 36mg QAM
Visit 4 dose of 54mg QAM."
1796232|NCT00550147|Drug|quetiapine|"Quetiapine will be titrated according to the following schedule as determined by efficacy and safety assessments (See Table 1).
Table 1: Quetiapine Dosing Schedule (subject's required weight = 30-80 kg)
Visit 5 dose of 25mg BID
Visit 6 dose of 50mg BID
Visit 7 dose of 100mg BID
Visit 8 dose of 200mg BID
Visit 9 dose of 300mg BID
Efficacy: For any visit following Visit 5, dosage will remain stable if clinically significant improvement criteria are met.If subjects subsequently fail to meet clinically significant improvement criteria, dose increases will resume at the next level of the dosing schedule."
1796233|NCT00550160|Drug|Amodiaquine plus Artesunate co-administration|"Under the Home Management of Malaria (HMM) strategy the Community Drug Distributors (CDD) will treat all children under 5 years presented to them with measured fever or a history of fever with AQ plus AS co-administered. Children under 12 months receive 75mg of AQ co-administered with 25mg of AS daily for three days. Children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days.
Asymptomatic children under 5 years in the Intermittent Preventive Treatment (IPTc) clusters will receive additional AQ plus AS co-administered during high malaria transmission season. Those under 12 months will receive 75mg of AQ co-administered with 25mg of AS daily for three days; and children who are 12 to 59 months old receive 150mg of AQ and 50mg of AS co-administered daily for three days."
1796234|NCT00550173|Drug|pemetrexed|500 milligrams per meter squared (mg/m^2), intravenous (IV), every (q) 21 days until progression or unacceptable toxicity develops
1796235|NCT00550173|Drug|erlotinib|150 mg, orally, once daily until progression or unacceptable toxicity develops
1796236|NCT00550186|Other|placebo|
1796237|NCT00550186|Drug|Ringers Lactate|
1796238|NCT00550186|Drug|HaemoHES 6%|
1796239|NCT00550199|Drug|LBH589, Gemcitabine|Phase I dose escalation: LBH589 will be administered orally twice weekly. Gemcitabine will be administered intravenously over 30 minutes on days 1, 8, and 15 every 28 days.
1796240|NCT00550212|Drug|neratinib|HKI-272, Single-dose capsule and solution
1796241|NCT00550225|Drug|GSK961081|GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.
1796242|NCT00550225|Drug|GSK961081 matching placebo|GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.
1796243|NCT00550238|Drug|Pimavanserin tartrate (ACP-103)|Tablets taken once daily by mouth for as long as ACP-103 is considered to be tolerated and beneficial to subjects
1796244|NCT00550251|Device|Acupressure Wrist Bands (Sea-Bands)|Elasticated wrist bands with active bead pressing on Pericardium 6 acupressure points bilaterally.
1796245|NCT00550251|Device|Placebo wristbands|Elasticated wrist bands without active bead.
1796246|NCT00550264|Other|Automatic notification of readmissions|The experimental group physicians will receive automatic e-mail notification when a patient is readmitted, including contact information for the readmitting team.
1796431|NCT00558337|Drug|levodopa-carbidopa|novel levodopa/carbidopa formulation or a reference levodopa/carbidopa formulation
1796247|NCT00550277|Drug|LBH589|LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly). To enable patients to undergo cardiac monitoring (Section 3.5.2), all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
1796248|NCT00550290|Drug|Cefazolin (or Clindamycin in patients with allergy to cephalosporins or PCN)|Cefazolin 1 gram IV every 8 hours for a total of 3 doses. Patients in both arms will receive an initial pre-operative 2 gram dose of Cefazolin within 30 minutes prior to incision. In penicillin/cephalosporin allergic patients, the substitute of Clindamycin 900 mg IV q 8 hrs will be used.
1796249|NCT00550303|Drug|bazedoxifene/conjugated estrogens combination|
1796250|NCT00550329|Drug|Glipizide GITS|
1796251|NCT00550342|Drug|rituximab|375 mg/m2 intravenously for 4 doses
1796252|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 1) administered over 12 weeks
1796253|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 2) administered over 12 weeks
1796254|NCT00550355|Drug|PD 0360324|3 doses of PD 0360324 (Dose level 3) administered over 12 weeks
1796255|NCT00550355|Drug|Placebo|3 doses of Placebo administered over 12 weeks
1796256|NCT00550368|Biological|Biological intervention: Enteropathogenic E. coli|5x10^8 or 1x10^9 organisms of EPEC were administered to all participants.
1796257|NCT00550381|Drug|HKI-357|Single-dose capsule
1796258|NCT00550394|Drug|quetiapine and placebo|"Dosing Schedule and Titration of Quetiapine: open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1
Dosing Schedule and Titration of Topiramate:
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
1796259|NCT00550394|Drug|Quetiapine and Topiramate|"Dosing Schedule and Titration of Quetiapine:
open-label quetiapine beginning day 1 at 100 mg/day titrated to 400 mg/day by the end of week 1
Dosing Schedule and Titration of Topiramate:
All subjects will be randomized to topiramate or matching placebo which will be administered in a double-blind manner.
Topiramate/Placebo titrated from 25 mg twice daily to 150 mg bid by week 4."
1796260|NCT00550407|Drug|lamotrigine|lamotrigine 100mg/day or 200mg/day
1796261|NCT00550407|Drug|Placebo|placebo once daily
1796263|NCT00550433|Device|Bazedoxifene/Conjugated Estrogens|
1796264|NCT00550446|Drug|Adalimumab|40mg subcutaneous injections every other week for 6 injections during week 0-10 with oral placebo BID. Subjects switched to CP-690,550 at week 12.
1796265|NCT00550446|Drug|CP-690-550|15 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
1796266|NCT00550446|Drug|CP-690-550|10 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
1796267|NCT00550446|Drug|CP-690-550|5 mg BID oral plus 6 placebo subcutaneous injections (week 0-10)
1796268|NCT00550446|Drug|CP-690,550|3 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
1796269|NCT00550446|Drug|CP-690,550|1 mg BID PO plus 6 placebo subcutaneous injections (week 0-10)
1796270|NCT00550446|Drug|Placebo|Placebo by mouth plus 6 placebo subcutaneous injections (week 0-10)
1796273|NCT00550472|Dietary Supplement|probiotics|Lactobacillus paracasei Lpc-37, Lactobacillus acidophilus 74-2 Bifidobacterium animalis subsp. lactis DGCC 420
1796274|NCT00550485|Drug|escitalopram|escitalopram 10 mg
1796275|NCT00550498|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 3-5 million cells, in a maximum volume of 0.3 ml. Cells will be injected in vitreal at 3.5 millimeter of limbus with a 26 gauge insulin needle.
1796276|NCT00550511|Radiation|Surgeon-performed ultrasound|After clinical investigation including standardized laboratory tests the patient in the intervention arm is examined with abdominal ultrasound performed by the study surgeon.
1796277|NCT00550524|Biological|Autologous Stem Cell Transplantation|Autologous bone marrow aspiration (20 ml) from iliac crest. Separation of mononuclear cells using ficoll hypaque and culture in 10% fetal bovine serum and Dulbecco modified eagles medium. After confluent stage, detachment of cells with trypsin/EDTA, and subculture. Repeated passages until obtainment of required cell number. Confluent cells of last passage are washed with tyrode solution and incubate with M199 for 60 minutes. Cells are separated using trypsin/EDTA and washed 3 times with M199 and 1% HSA. Precipitate will be diluted with heparinized M199 to make solution with 6×106 cells /ml. Sample will be tested for viability and detection of CD45, CD34, CD90, CD44, CD13, CD105, and CD166 before injection. The number of cells for injection will be between 20-25 million cells; in a maximum volume of 4-6 ml. Cells will be injected in the knee joint with a 21 gauge needle.
1796278|NCT00550537|Drug|bevacizumab|15 mg/m2 given through a vein for every 3 weeks
1796279|NCT00550537|Drug|carboplatin|AUC = 6 given through a vein on day 1 of each cycle.
1796280|NCT00550537|Drug|erlotinib hydrochloride|150 mg taken by mouth daily
1796281|NCT00550537|Drug|paclitaxel|200 mg/m2 given through a vein on day 1 of each cycle.
1796282|NCT00550537|Genetic|gene expression analysis|Blood and tissue collection.
1796283|NCT00550537|Genetic|protein expression analysis|Blood and tissue collection.
1796284|NCT00550537|Genetic|proteomic profiling|Blood and tissue collection.
1796285|NCT00550537|Other|laboratory biomarker analysis|Blood and tissue collection.
1796286|NCT00550550|Drug|Placebo|Placebo sublingual tablet, once daily
1796287|NCT00550550|Biological|SCH 697243|Grass sublingual tablet, once daily
1796432|NCT00558363|Drug|Avodart|0.5 mg administered orally once daily
1796493|NCT00558818|Drug|Clevudine|clevudine 30 mg qd
1796288|NCT00550550|Drug|Loratadine Syrup 1 mg/mL Rescue Treatment|Loratadine Syrup 1 mg/mL was dosed orally once daily at a dose of 5 mg for children aged 5 to <6 years of age and at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
1796289|NCT00550550|Drug|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily at a dose of 10 mg for children aged 6 to <18 years of age as rescue medication for symptoms of rhinoconjunctivitis among participants with a total symptom score ≥4.
1796290|NCT00550550|Drug|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was dosed intraocularly at a dose of 1 drop in each affected eye twice daily, in addition to loratadine, as rescue medication for participants with persistent eye symptoms due to rhinoconjunctivitis.
1796291|NCT00550550|Drug|Mometasone furoate 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was dosed intranasally at a dose of one spray in each nostril once daily for participants aged 5 to <12 years and a dose of 2 sprays in each nostril once daily for participants aged 12 to <18 years as rescue medication for nasal symptoms of rhinoconjunctivitis among participants with a total symptom score of ≥4 despite loratadine and mometasone furoate nasal spray.
1796292|NCT00550550|Drug|Albuterol 108 mcg Rescue Treatment|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administered via inhalation at a dose of 2 inhalations every 4 to 6 hours as rescue medication among participants aged 5 to <18 years with asthma symptoms .
1796293|NCT00550550|Drug|Fluticasone 44 mcg Rescue Treatment|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of 2 inhalations twice daily among participants aged 12 to <18 years up to a maximum dose of 10 inhalations twice daily, in combination with albuterol, among participants with ≥4 albuterol sulfate inhalations/day for 2 days as rescue medication for nocturnal asthma or shortness of breath.
1796294|NCT00550550|Drug|Prednisone 5 mg Rescue Treatment|Prednisone tablet 5 mg was administered orally at a dose of 1 mg/kg/day once daily up to a maximum of 50 mg/day on Day 1, and at a dose of 0.5 mg/kg/day once daily up to a maximum of 25 mg/day on Days 2, 3, 5, and 7 as rescue medication for asthma exacerbation at the discretion of the investigator.
1796295|NCT00550563|Dietary Supplement|cholecalciferol|Oral
1796296|NCT00550563|Genetic|polymerase chain reaction|companion study
1796297|NCT00550563|Genetic|polymorphism analysis|companion study
1796298|NCT00550563|Genetic|protein expression analysis|companion study
1796299|NCT00550563|Genetic|reverse transcriptase-polymerase chain reaction|companion study
1796300|NCT00550563|Genetic|western blotting|companion study
1796301|NCT00550563|Other|high performance liquid chromatography|companion study
1796302|NCT00550563|Other|laboratory biomarker analysis|companion study
1796303|NCT00550563|Other|pharmacological study|companion study
1796304|NCT00550563|Procedure|adjuvant therapy|Additional therapy
1796305|NCT00550563|Procedure|immunoscintigraphy|additional testing
1796306|NCT00550576|Drug|Digibind (Fab)|Intravenous Digibind (Digoxin Antibodies-Fab) is delivered only once in 30-45 minutes to patients after receiving the informed concent.
1796313|NCT00550615|Drug|Dasatinib|"Dasatinib will be orally administered once daily for 28 day cycles.
There will be three dose cohorts for the Dasatinib in the Phase I portion of this trial. A minimum of three patients will be enrolled into each of the following dose cohorts:
Dose cohort # 1 will be 100 mg per day
The MTD will be determined in the Phase I portion of this trial. An additional 29 patients using the Two-Stage Simon design will be enrolled into Phase II using the MTD determined in Phase I."
1796314|NCT00550615|Drug|Dasatinib|Dose cohort # 2 will be 150 mg per day
1796315|NCT00550615|Drug|Dasatinib|Dose cohort # 3 will be 200 mg per day
1796316|NCT00550628|Genetic|DNA methylation analysis|
1796317|NCT00550628|Genetic|fluorescence in situ hybridization|
1796318|NCT00550628|Genetic|gene expression analysis|
1796319|NCT00550628|Genetic|polymerase chain reaction|
1796320|NCT00550628|Genetic|protein expression analysis|
1796321|NCT00550628|Genetic|reverse transcriptase-polymerase chain reaction|
1796322|NCT00550628|Other|diagnostic laboratory biomarker analysis|
1796323|NCT00550628|Other|immunoenzyme technique|
1796324|NCT00550628|Other|immunohistochemistry staining method|
1796325|NCT00550628|Procedure|biopsy|
1796326|NCT00550628|Procedure|therapeutic conventional surgery|
1796327|NCT00550628|Radiation|fludeoxyglucose F 18|
1796328|NCT00550641|Other|physical therapy|physical therapy in warm pool performing stretching
1796329|NCT00550641|Other|physical therapy|physical therapy in warm pool performing Ai Chi
1796330|NCT00550654|Other|questionnaire administration|Patients complete a pain assessment questionnaire, Brief Pain Inventory at baseline and at 1 and 3 months after treatment.
1796331|NCT00550654|Radiation|3-dimensional conformal radiation therapy|Conformal radiation therapy improves the ability to spare normal tissues.
1796332|NCT00550654|Radiation|hypofractionated radiation therapy|Hypofractionated radiation therapy is delivered to maximize pain relief while minimizing patient impact if life expectancy is short.
1796333|NCT00550654|Radiation|image-guided radiation therapy|Image guided radiation therapy targets the specific site of disease.
1796433|NCT00558363|Other|placebo|Patients will be randomized at Visit 2 in 1:1 ratio to receive either 0.5 mg dutasteride or placebo
1796494|NCT00558831|Drug|Benzoyl Peroxide|Benzoyl Peroxide 2.5%
1796334|NCT00550654|Radiation|tomotherapy|Tomotherapy is a delivery method which provides megavoltage computed tomography (CT) localization and may provide superior conformality and localization compared to other dynamic intensity modulated radiation therapy techniques.
1796335|NCT00550680|Drug|Methoxy polyethylene glycol-epoetin beta|Participants will receive a starting dose of 120, 200, or 360 mcg via IV injection. Thereafter, the once-monthly dose will be titrated to achieve target Hb concentrations.
1796336|NCT00550693|Device|Chlorhexidine-impregnated foam dressing|Patients during the intervention period had this foam dressing applied around their central venous catheter. This was replaced once a week as recommended by the package insert unless the dressing was soiled, bloody, or fell off.
1796337|NCT00550732|Drug|Posaconazole|Posaconazole oral suspension was administered as 400 mg twice daily (bis in die, BID) with food or 200 mg four times daily (quater in die, QID) without food for a minimum of 1 month.
1796338|NCT00550745|Biological|Zoster Vaccine, Live|single 0.65 mL Zoster Vaccine, Live injection. 6 month treatment period.
1796339|NCT00550745|Biological|Comparator: placebo|single 0.65 mL Placebo injection. 6 month treatment period.
1796340|NCT00550758|Drug|Methachoine|inhalation of triple-concentration increments (0.06 to13.9mg/ml/methacholine)
1796341|NCT00550758|Device|spirometry|spirometry
1796342|NCT00550771|Drug|doxorubicin, cyclophosphamide, paclitaxel, trastuzumab|doxorubicin 60 mg/m^2 IV push + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes (first administration 4 mg/kg IV over 90 minutes) given weekly for 12 weeks (4 courses)
1796343|NCT00550771|Drug|PLD, cyclophosphamide, trastuzumab, paclitaxel|PLD 35 mg/m^2 IV over 60 minutes + cyclophosphamide 600 mg/m^2 IV over 30-90 minutes given every 21 days + trastuzumab 2 mg/kg IV over 30 minutes (first dose 4 mg/kg IV over 90 minutes) given once weekly for 4 courses (12 weeks) followed by Paclitaxel 80 mg/m^2 IV over 60 minutes with trastuzumab 2 mg/kg IV over 30 minutes given weekly for 12 weeks (4 courses)
1796344|NCT00550784|Biological|filgrastim|
1796345|NCT00550784|Drug|cisplatin|
1796346|NCT00550784|Drug|cyclophosphamide|
1796347|NCT00550784|Drug|melphalan|
1796348|NCT00550784|Drug|paclitaxel|
1796349|NCT00550784|Drug|topotecan hydrochloride|
1796350|NCT00550784|Genetic|TdT-mediated dUTP nick end labeling assay|
1796351|NCT00550784|Genetic|gene expression analysis|
1796352|NCT00550784|Other|immunohistochemistry staining method|
1796353|NCT00550784|Other|pharmacological study|
1796354|NCT00550784|Procedure|peripheral blood stem cell transplantation|
1796355|NCT00550797|Biological|TPI ASM8|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
1796356|NCT00550797|Biological|placebo|Administered with the I-Neb device from Respironics once daily by inhalation over 2 treatment periods of 14 days each
1796357|NCT00550810|Drug|Sunitinib (SU011248)|SU011248 (study medication) will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2 week rest period to form a complete cycle of 6 weeks. Study medication will be orally self administered once daily without regard to meals beginning on Day 1 of the study. Cycles will be repeated in the absence of unacceptable toxicity or disease progression
1796358|NCT00550823|Device|Cardiac CT 0BRILLIANT 64|Cardiac CT
1796359|NCT00550836|Biological|panitumumab|Given IV
1796360|NCT00550836|Drug|erlotinib hydrochloride|Given orally
1796361|NCT00550836|Drug|gemcitabine hydrochloride|Given IV
1796362|NCT00550849|Drug|RTA 402|5 mg oral capsules
1796363|NCT00550849|Drug|RTA 402|25 mg oral capsules
1796364|NCT00550849|Drug|RTA 402|50 mg oral capsules
1796365|NCT00550862|Drug|INT-747|Once a day (QD) by mouth (PO)
1796366|NCT00550862|Drug|Ursodeoxycholic Acid (URSO)|Stable dose for at least 6 months prior to screening. Dose as prescribed by physician.
1796367|NCT00550862|Drug|Placebo|Placebo
1796368|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 1000 DPP/ml 2 years
1796369|NCT00550875|Biological|Grass pollen allergenic extract (L. perenne-C. dactylon )|Sublingual. 2 drops/daily 10000 DPP/ml 2 years
1796370|NCT00550875|Biological|placebo|Sublingual. 2 drops/daily 2 years
1796371|NCT00550888|Procedure|suture techniques|
1957433|NCT02395224|Other|cancer treatment and follow-up according to current regional and national guidelines|
1796374|NCT00556452|Drug|Clofarabine/Busulfan x 4|"Clofarabine IV (dose levels)
1st dose level: 20 mg/m2/day x 5 days
2nd dose level: 30 mg/m2/day x 5 days
3rd dose level: 40 mg/m2/day x 5 days
Busulfan IV 3.2 mg/kg daily x 4 days"
1796375|NCT00556452|Procedure|Peripheral blood stem cell transplant|Peripheral blood stem cell transplant, after pre-conditioning drug treatment
1796376|NCT00556452|Radiation|Total Lymphoid Irradiation|Total Lymphoid Irradiation (TLI) of 4 Gy, if cord blood transplant
1796377|NCT00556465|Drug|N-acetylcysteine|600 mg of effervescent N-acetylcysteine tablet twice per day for three months
1796378|NCT00556478|Drug|PSD502, contains a mixture of lidocaine and prilocaine|"PSD502 spray contains a mixture of lidocaine and prilocaine with Norflurane (HFA-134a) is used as both propellant and solvent. A single dose consists of 3 sprays applied to the glans penis.
Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.
During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing
During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
1796492|NCT00558805|Behavioral|Usual Care|
1957437|NCT02393625|Drug|Ceritinib (LDK378)|
1957438|NCT02393625|Drug|Nivolumab|
1796379|NCT00556478|Drug|Placebo|"The placebo is a metered dose aerosol spray that is identical in appearance to the active treatment and contains the same propellant (norflurane) but has no lidocaine or prilocaine.
Approximately 5 minutes before intercourse the study spray can be applied and any excess should be wiped off with a damp cloth or tissue.
During the initial 3 months double-blind phase of the study subjects should leave at least 24 hours between each dosing.
During the subsequent 5 months open label Phase of the study subjects may use the spray for up to a maximum of 3 sexual encounters (intercourse) in a 24 hour period. Each sexual encounter (intercourse) when the spray is used must be separated by at least 4 hour period."
1796380|NCT00556491|Drug|minocycline|given at least for 4 doses (200mg initially then 100mg every 12 hours until surgery)with maximum of 14 doses
1796381|NCT00556491|Drug|placebo|placebo will be given for at least 4 doses pre-op to a maximum of 14 doses
1796382|NCT00556504|Drug|TCM-700C|An add-on drug to conventional treatment of Hepatitis C
1796383|NCT00556504|Drug|Peginterferon alfa-2a|conventional treatment of Hepatitis C
1796384|NCT00556504|Drug|Ribavirin|conventional treatment of Hepatitis C
1796385|NCT00556504|Drug|Placebo|Placebo, without acting ingredient.
1796386|NCT00556543|Device|U-plate fracture repair system|All subjects meeting inclusion criteria will undergo surgery for the repair of their fractured rib/s using the U-plate device. Subjects will be monitored daily during the entire course of their hospitalization for adverse experiences. Subjects will be contacted by phone to complete the MPQ and SF-36 Health Survey. Subjects will be asked if and when they have returned to work or to their previous level of functioning. Subjects will be asked if they had any complications or problems associated with their surgery.
1796387|NCT00556569|Other|CHAM JAM|"CHAM JAM (previously known as Moving Smart (MS) program) is a daily, 10-minute classroom-based physical activity program led by teachers that integrates academic objectives with physical activity"
1796388|NCT00556595|Procedure|primary electrophysiological approach|primary ablation of atrio-venous breakthrough sites followed by circumferential ablation around pulmonary vein orifice
1796389|NCT00556595|Procedure|primary anatomical approach|primary circumferential ablation around the pulmonary vein orifice followed by ablation of possible conduction gaps
1796390|NCT00556608|Device|Sinovial® (syringe containing sodium hyaluronate solution)|2 mL 0.8% sodium hyaluronate (16 mg) solution. 3 intra-articular injections once-a-week.
1796391|NCT00556608|Device|Synvisc® ( syringe containing Hylan G-F 20 solution)|2 mL 0.8% Hylan G-F 20 (16 mg) solution. 3 intra-articular injections once-a-week.
1796392|NCT00556621|Drug|cisplatin|
1796393|NCT00556621|Drug|gemcitabine hydrochloride|
1796394|NCT00556621|Procedure|biopsy|
1796395|NCT00556621|Procedure|cystoscopy|
1796396|NCT00556621|Procedure|therapeutic conventional surgery|
1796397|NCT00556621|Radiation|radiation therapy|
1796398|NCT00556634|Drug|Efavirenz|"Efavirenz given in a stepped dosage over 2 weeks (200 mg qd for 6 days plus placebo, 400 mg qd for 7 days plus placebo and 600 mg qd from day 14 forward)
OR
Efavirenz usual dosage (600 mg/day from the first day)"
1796399|NCT00556647|Procedure|fast track diagnosis|fast-track diagnosis, PET-CT, bronchoscopy
1796400|NCT00556647|Procedure|conventional diagnosis|out-patient diagnosis
1796401|NCT00556660|Procedure|SPECT scan|To assess the dynamic uptake and washout of 123-I AV151, a potential imaging biomarker for β-amyloid burden in brain, using single photon emission computed tomography (SPECT) in similarly aged healthy controls and Alzheimer's (AD) subjects
1796402|NCT00556673|Drug|indacaterol maleate/mometasone furoate|Indacaterol maleate 250 μg / mometasone furoate 200 μg delivered via the Twisthaler device.
1796403|NCT00556673|Drug|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
1796404|NCT00556673|Drug|fluticasone proprionate / salmeterol xinafoate|Fluticasone proprionate 250 μg / salmeterol xinafoate 50 μg delivered via the Accuhaler® device.
1796405|NCT00556699|Drug|rituximab|Escalating intravenous repeating dose
1796406|NCT00556699|Drug|SGN-40|Escalating intravenous repeating dose
1796407|NCT00556712|Drug|erlotinib [Tarceva]|150mg po daily
1796408|NCT00556712|Drug|Placebo|po daily
1796409|NCT00556738|Procedure|Nasal Continuous Positive Airway Pressure ventilation|Nasal Continuous Positive Airway Pressure ventilation
1796410|NCT00556738|Procedure|Intrapulmonary Percussive Ventilation|Intrapulmonary Percussive Ventilation
1796411|NCT00556764|Drug|[123I] IBVM and SPECT imaging|Subjects will be injected with up to 4 mCi of 123-I IBVM followed by SPECT imaging.
1796412|NCT00556764|Drug|Subjects will undergo the 123-I IBVM imaging visit|Subjects will be injected with a bolus of up to 4 mCi of 123-I IBVM followed by serial SPECT imaging.
1796413|NCT00556777|Procedure|axillary lymph node dissection|
1796414|NCT00556777|Procedure|conventional surgery|
1796415|NCT00556777|Procedure|sentinel lymph node biopsy|
1796416|NCT00556777|Radiation|intraoperative radiation therapy|
1796417|NCT00556790|Procedure|Standard Care|standard fluid regime, delayed feeding
1796418|NCT00556790|Procedure|Fast Track care|restrictive fluid regime, early oral feeding, enforced mobilisation
1796419|NCT00556803|Procedure|radiofrequency ablation|radiofrequency ablation
1796420|NCT00556803|Procedure|TACE after RFA|TACE after RFA within one month
1796421|NCT00558285|Drug|indacaterol/glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
1796422|NCT00558285|Drug|indacaterol|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
1796423|NCT00558285|Drug|glycopyrrolate|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
1796424|NCT00558285|Drug|placebo|Inhalation capsule delivered via a single dose dry powder inhaler in the morning for 14 days.
1796425|NCT00558298|Drug|risperidone|
1796426|NCT00558311|Drug|clazosentan|Intravenous clazosentan administered by continuous infusion at 5 mg/h for the duration of the treatment
1796427|NCT00558311|Drug|placebo|Placebo administered by continuous infusion at 5 mg/h for the duration of the treatment.
1796428|NCT00558324|Procedure|LASIK|Mechanical microkeratome Hansatome 160 microns
1796429|NCT00558324|Procedure|LASIK|Mechanical microkeratome K 3000 130 microns
1796817|NCT00560924|Drug|estradiol, 25 mcg|
1796434|NCT00558376|Drug|polyethylene glycol|Single time 3 liters PEG, 250 cc every 15 minutes the day before colonoscopy
1796435|NCT00558376|Drug|Sodium phosphate|Sodium phosphate 45cc, 2 doses 4 hours apart the day before colonoscopy
1796436|NCT00558402|Behavioral|Meditation|meditation class 1/week for 8 weeks
1796437|NCT00558402|Behavioral|Education|Education class, 90 min per week for 8 weeks along with home assignments based on Powerful Tools for Caregivers
1796438|NCT00558402|Behavioral|Respite only|Respite care 90 mins per week for 8 weeks
1796439|NCT00558428|Drug|fixed dose combination of telmisartan+amlodipine|
1796440|NCT00558428|Drug|amlodipine|
1796441|NCT00558441|Device|IVMRI|Intra Vascular Magnetic Resonance Imaging
1796442|NCT00558454|Drug|Iron|Ferrous succinate mixture
1796443|NCT00558467|Drug|pramipexole immediate release (IR)|
1796444|NCT00558467|Drug|Placebo|
1796445|NCT00558480|Drug|Vitamin A|Vitamin A capsules, as retinol palmitate 200,000 IU at enrollment, 3 and 6 months
1796446|NCT00558480|Drug|Vitamin A placebo|Vitamin A placebo at enrollment, 3 and 6 months
1796447|NCT00558493|Drug|Clevudine|clevudine 30 mg qd for 24 seeks
1796448|NCT00558506|Drug|abatacept|intravenously 750mg (in patients with weight of 60- 100kg)
1796449|NCT00558519|Drug|cyclophosphamide|
1796450|NCT00558519|Drug|cytarabine|
1796451|NCT00558519|Drug|daunorubicin hydrochloride|
1796452|NCT00558519|Drug|dexamethasone|
1796453|NCT00558519|Drug|doxorubicin hydrochloride|
1796454|NCT00558519|Drug|mercaptopurine|
1796455|NCT00558519|Drug|methotrexate|
1796456|NCT00558519|Drug|pegaspargase|
1796457|NCT00558519|Drug|thioguanine|
1796458|NCT00558519|Drug|vincristine sulfate|
1796459|NCT00558519|Radiation|radiation therapy|
1796460|NCT00558532|Procedure|Bariatric Surgery|Open roux-en-Y gastric bypass, open banded sleeve gastrectomy, abdominoplasty, other abdominal surgery
1796461|NCT00558545|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly only on weeks when paclitaxel is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
1796462|NCT00558558|Drug|Haelan|4 oz orally twice daily for 8 Weeks
1796463|NCT00558571|Drug|BI 10773 low dose|
1796464|NCT00558571|Drug|placebo to BI 10773|
1796465|NCT00558571|Drug|BI 10773 medium dose|
1796466|NCT00558571|Drug|BI 10773 high dose|
1796467|NCT00558584|Device|protein A immunoadsorption|protein-A immunoadsorption and i.v. IgG substitution
1796468|NCT00558584|Device|pseudo-immunoadsorption|pseudo-immunoadsorption followed by an intravenous infusion without IgG
1796469|NCT00558623|Dietary Supplement|calcium carbonate|daily supplement of 1,200 milligrams calcium (two-600 mg tablets calcium carbonate at bedtime)
1796470|NCT00558636|Drug|Sorafenib + Paclitaxel + Carboplatin|Chemotherapy plus Multi Kinase Inhibitor: Sorafenib Group - Sorafenib (Nexavar, BAY43-9006), [400 mg, (2 tablets x 200 mg each) orally, twice daily] on Study Days 2-19 and paclitaxel (175 mg/m^2, intravenous (IV), over 2.5 to 4 hours) and carboplatin (area under the curve (AUC) =5, IV for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days.
1796471|NCT00558636|Drug|Placebo + Paclitaxel + Carboplatin|Chemotherapy + Placebo: Placebo Group - Placebo (2 tablets twice daily, orally) on Study Days 2-19 and paclitaxel (175 mg/m^2 IV, over 2.5 to 4 hours) and carboplatin (AUC=5 IV, for 15 to 60 minutes) on Study Day 1. The cycle duration will be 21 days
1796472|NCT00558649|Biological|Flu Vaccine (FLUARIX®)|Influenza Virus Vaccine, FLUARIX®, 2006-2007 Formula
1796473|NCT00558662|Device|Coban 2|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
1796474|NCT00558662|Device|SSB|Bandages will be changed after a wear time of seven days, or in case of product or non-product related reason, which would require a dressing or bandage change.
1796475|NCT00558675|Biological|AlloStim|single intravenous infusion of 1 x 10^9 AlloStim cells
1796476|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7
1796477|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7 and day 14
1796478|NCT00558675|Biological|AlloStim|Intravenous infusion of 1 x 10^9 AlloStim on day 1 and a second intravenous infusion of 1 x 10^8 AlloStim on day 7, day 14 and day 21
1796479|NCT00558688|Procedure|Photodynamic therapy|Photodynamic therapy applied to actinic keratoses
1796480|NCT00558701|Device|Microcurrent stimulator|Microcurrent stimulation from 15-50 microamps
1796481|NCT00558701|Device|Silverlon Wound Contact Dressing|Silver coated nylon dressing FDA approved for use on donor sites in burn patients
1796482|NCT00558727|Drug|RH-1|1.5 mg/m2 to 12 mg/m2, depending on protocol cohort, administered via intravenous (IV) infusion over 3 hours once every 21 days.
1796483|NCT00558740|Other|high protein intake|acute high protein intake chronic (6-day) high protein intake acute+chronic high protein intake control
1796484|NCT00558753|Drug|pregabalin|PO pregabalin 300 mg 2 hours prior to surgery, and 150 mg twice a day for 10 postoperative days. Pregabalin will be tapered to 75 mg twice daily between days 11 to 12 and then to 50 mg twice daily between days 13 to 14 post operatively and then stopped.
1796485|NCT00558753|Drug|Placebo|Placebo for Given 2 hours prior to surgery, and twice a day for 14 postoperative days.
1796486|NCT00558779|Procedure|OBCAB (Off Pump Coronary Artery Bypass Grafting)|OPCAB with sparing of aortic manipulation (eg, no aortic cannulation for cardiopulmonary bypass, no aortic cross-clamp, no side-clamping of the aorta). Graft anastomosis to the central circulation with y-grafts on the arteria thoracica interna or on the aorta with help of the Heart-string-system (Guidant)
1796487|NCT00558779|Procedure|CABG (coronary artery bypass grafting)|conventional CABG with cardiopulmonary bypass
1796488|NCT00558792|Drug|Isovue 370, 70 mL|70 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
1796489|NCT00558792|Drug|Isovue 370, 80 mL|80 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
1796490|NCT00558792|Drug|Isovue 370, 90 mL|90 mL of iopamidol injection 370 injected at a rate of >=4 mL/second
1796491|NCT00558805|Behavioral|FISP + Usual Care|
1796495|NCT00558831|Drug|Moisturizing Lotion|
1796496|NCT00558844|Drug|Arikace™|Subjects will be randomly assigned to study drug dose of of Arikace™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikace™ and placebo. They will be blinded whether they receive Arikace™ or Placebo Study subjects will receive Arikace™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
1796497|NCT00558844|Drug|Placebo|Subjects will be randomly assigned to study drug dose of of Arikace™ or placebo in accordance with a code provided by the Sponsor/CRO. Randomization will be made in a 2:1 allocation between Arikace™ and placebo. They will be blinded whether they receive Arikace™ or Placebo Study subjects will receive Arikace™ or placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
1796498|NCT00558857|Device|Dynamic Substrate Mapping-guided ablation|Radiofrequency ablation
1796499|NCT00558870|Drug|Morphine|"Arm 1: 2 Doses of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).Immediate-release morphine may be used, if needed, for pain."
1796500|NCT00558870|Drug|Methadone|"1 Dose of Methadone PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days)
Arm 2: 1 Dose of Slow-Release Morphine PO Every 12 Hours, Every Day for 15 Days (plus or minus 3 days).).Immediate-release morphine may be used, if needed, for pain."
1796501|NCT00558883|Drug|acarbose|oral application
1796502|NCT00558896|Drug|dexamethasone|40 mg/day administered through PO (with food) at Days 1, 8, 15, 22 per cycle.
1796503|NCT00558896|Drug|pomalidomide|2 or 4 mg/day administered through PO at days 1 - 28 or days 1-21 (see Arm description for specific dosing).
1796504|NCT00558909|Drug|BI 44847|
1796505|NCT00558909|Drug|placebo for BI 44847|
1796506|NCT00558922|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1.
1796507|NCT00558935|Dietary Supplement|Red Wine|20g alcohol daily/red wine for 4 weeks
1796508|NCT00558961|Drug|Gleevec and Chlorambucil|The first cohort will receive Gleevec at 300 mg daily on days 1-10 and chlorambucil 8mg/m2/d from day 3-7. This will be repeated every 28 days. Cohort 2 will receive 400 mg Gleevec and Cohort 3 will receive 600 mg Gleevec. Each dose level may be expanded up to 6 patients if 1 of 3 patients experiences any dose limiting toxicities.
1796509|NCT00558987|Behavioral|Discipline Video|"The discipline video will be shown to the caregiver before the visit while they are waiting to see the doctor. The video gives specific guidance on avoiding physical discipline, setting consistent, safe and age appropriate limits.
A copy of the discipline video and the handout reinforcing the messages presented in the video will be given to the caregiver by the research staff to share with other caregivers."
1796510|NCT00558987|Behavioral|Nutrition Video|A brief educational video on nutrition information, a topic not related to discipline.
1796511|NCT00559000|Behavioral|KIDNET|Narrative Exposure Therapy for Children
1796512|NCT00559013|Device|Staple line reinforcement|Placement of reinforcement material on circular anastomotic staple line for prevention of leak during and post surgery.
1796513|NCT00559026|Biological|Melan-A|i.d. injections of Melan-A: 26-35 (A27L) and gp100: 209-217 (210M) peptides (250 µg each) formulated in Montanide ISA-51 plus s.c. injection of 3MU IFN-α, as an adjuvant on day 1 and 8 every 21 days for a total of 5 courses
1796514|NCT00559026|Other|Melan-A plus Dacarbazine|Dacarbazine plus vaccine: the vaccination schedule as in arm 1 was combined with DTIC (800 mg/mq i.v.) administered one day before each vaccine administration according to the standard treatment.
1796515|NCT00559039|Other|questionnaire administration|
1796516|NCT00559039|Procedure|evaluation of cancer risk factors|
1796517|NCT00559052|Drug|VIOKASE 16|The VIOKASE 16 is to be taken as 3 tablets with the perfusion procedure.
1796518|NCT00559078|Other|Interview|Hour-long, qualitative, phone interview
1796519|NCT00559091|Drug|ribavirin|Ribavirin will be administered orally, twice daily, in the morning and evening with food. The dose selected is 400 mg AM and 600 mg PM. Intrapatient dose escalations can also be performed in defined circumstances. The maximal dose administered will be 1000 mg AM and 1000 mg PM.
1796520|NCT00559104|Drug|carmustine|Unique to the Carmustine in Conditioning arm
1796521|NCT00559104|Drug|cyclophosphamide|Used in Both Arms
1796522|NCT00559104|Drug|etoposide|Used in Both Arms
1796523|NCT00559104|Procedure|autologous hematopoietic stem cell transplantation|Both arms are given autologous stem cell transplantation
1796524|NCT00559104|Procedure|peripheral blood stem cell transplantation|Both arms are given peripheral blood stem cell transplantation (Peripheral blood stem cells are the material, autologous transplant is the modality).
1796525|NCT00559104|Radiation|total-body irradiation|Unique to the Radiation in Conditioning Arm
1796526|NCT00559104|Drug|G-CSF|G-CSF is given in both treatment arms, both to mobilize stem cells before apheresis, and to promote recovery of granulocytes after stem-cell re-infusion.
1796527|NCT00559117|Drug|VB-111|A single intravenously infusion of diluted VB-111 should be administered 1 ml/minute
1796528|NCT00559130|Device|CytoSorb Hemoperfusion|Daily hemoperfusion for 6 hours with CytoSorb device
1796529|NCT00559143|Other|Biventricular Pacing (DDD(R)- BiV)|Subjects indicated for DDD(R) pacing due to AV conduction disturbances and preserved LV function will receive biventricular pacing DDD(R)- BiV
1796530|NCT00559156|Dietary Supplement|arginine/omega-3 fatty acids/nucleotides oral supplement|
1796531|NCT00559156|Drug|cisplatin|
1796532|NCT00559156|Procedure|adjuvant therapy|
1796533|NCT00559156|Radiation|radiation therapy|
1796534|NCT00559169|Drug|verapamil hyrochloride|80 mg daily by mouth, 5 days prior to menses for 3 months
1796535|NCT00559182|Drug|Comparator: MK-8033|"MK-8033 will be administered as an oral formulation in sequentially rising dose levels starting at 50 mg and continuing at 100% dose increments until dose level 4 (800 mg total daily dose). Dose levels 5 to 11 will be escalated at ~40% dose increments until 3000mg (total daily dose). The daily dose of MK-8033 will be divided into two equal doses. MK-8033 will be administered in a first cycle of 14 days (continuous drug administration from Day 1 through Day 14), followed by a 1 week drug holiday (Cycle 1, Day 15 through Day 21). Subsequent cycles of MK-8033 will be administered for 14 days (Cycles 2 to 4) and 28 days (Cycle 5 and beyond).
Enrollment in Parts A and B has been completed."
1796536|NCT00559182|Drug|Comparator: MK-8033 +/- omeprazole|"Part C will occur at only one of the investigational sites.
In Cycle 1, patients will be randomized to one of two treatment sequences, A/B or B/A, over two treatment periods. Treatment A: 770 mg MK-8033 twice daily with co-administration of 20 mg omeprazole once daily. Treatment B: 770 mg MK-8033 twice daily. After Cycle 1 is complete, patients may continue to receive MK-8033 until disease progression or unacceptable toxicity.
Enrollment for Part C has been suspended."
1796537|NCT00559195|Biological|epoetin beta|
1796538|NCT00559195|Procedure|quality-of-life assessment|
1796539|NCT00559221|Drug|FLAG+IDA|Fludarabine, cytarabine, G-CSF
1796540|NCT00559247|Drug|BMS-650032 or Placebo|Oral, Once daily, Single Dose
1796541|NCT00559260|Device|Passive monitoring with pulse-oximetry, NIBP and ECG|
1796542|NCT00559273|Drug|Methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg SC monthly, starting dose
1796543|NCT00559273|Drug|Darbepoetin alfa|0.45 mcg/kg SC weekly or 0.75 mcg/kg every 2 weeks, starting dose
1796544|NCT00559286|Drug|Telmisartan|application of 80mg or 20mg Telmisartan per day for 30 days
1796545|NCT00559299|Drug|GSK163090|
1796546|NCT00559312|Drug|fluticasone/salmeterol combination|Diskus inhaler, fluticasone 250μg/salmeterol 50μg, twice daily, 6-week duration
1796547|NCT00559312|Drug|placebo|Placebo Diskus inhaler, twice daily, 6-week duration
1796548|NCT00559338|Drug|recombinant B-type, natriuretic peptide|The intravenous infusion of nesiritide consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The nesiritide was mixed in 250 ml of 0.9% normal saline solution.
1796549|NCT00559338|Drug|placebo|The intravenous infusion of placebo consisted of a bolus dose of 2mcg/kg followed by the infusion rate of 0.01 mcg/kg/min for up to eight hours. The placebo was mixed in 250 ml of 0.9% normal saline solution.
1796550|NCT00559351|Procedure|transthoracic esophagectomy 2-field extended lymphadenectomy|right thoracotomy, mobilization of the esophagus, mediastinal lymph node dissection, laparotomy, gastric tube formation, abdominal lymph node dissection, anastomosis in the neck
1796551|NCT00559351|Drug|neoadjuvant chemotherapy (cisplatin, 5-fluorouracil)|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
1796552|NCT00559351|Radiation|neoadjuvant chemoradiotherapy|21-day combination systemic chemotherapy regimen consisted of a continuous infusion of cisplatin (20mg/m2/day) on days 1-5, 17-21 and 5-fluorouracil at 300mg/m2/day on days 1-21 with concurrent external beam fractionated irradiation to a total dose of 30Gy (2Gy fractions on days 1-5, 8-12, 15-19) followed by 3-phase transthoracic esophagectomy with 2-field extended lymphadenectomy after 3 week interval
1796553|NCT00559364|Drug|Viokase® 16|Patients assigned to Viokase® 16 will be given 22 tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
1796554|NCT00559364|Drug|Placebo|Patients assigned to placebo will be given 22 matching placebo tablets orally daily (that is, 6 tablets per meal and 2 tablets with 2 of 3 snacks) for 6 to 7 days in treatment phase.
1796555|NCT00559364|Drug|Proton pump inhibitor (PPI)|Patients on PPI during Screening will continue their usual PPI therapy throughout the study.
1796556|NCT00559364|Drug|Omeprazole|Patients not using PPI therapy at Screening will be given omeprazole 20 milligram orally once daily throughout the study.
1796557|NCT00559377|Other|18F-fluoromisonidazole|Undergo ^18F FMISO PET scan
1796558|NCT00559377|Radiation|fluorodeoxyglucose F 18|Undergo ^18F FDG PET scan
1796559|NCT00559377|Procedure|positron emission tomography|Undergo ^18F-FMISO and ^18F FDG PET scan
1796560|NCT00559377|Other|tissue oxygen measurement|Undergo ^18 F FMISO PET and ^18F FDG PET
1796561|NCT00559403|Behavioral|HIV/STD Risk-Reduction|Let Us Protect Our Future consists of twelve 1-hour sessions to increase knowledge, motivation, and skills in practicing abstinence and condom use. It is highly structured, and Xhosa-speaking male and female co-facilitators implement the program using standardized manuals. Treatment sessions include mixed-gender and single-gender activities, games, brainstorming, and role-playing. Comic workbooks are used to address abstinence, condom use, and how risky behavior affects goals and dreams. The Xhosa culture is taken into account, including cultural transformations in urban township settings. Take-home assignments enlist parents' help to empower their children to reduce their STD risk and ensure that parents are aware of the nature of the treatment program.
1796562|NCT00559403|Behavioral|Health Promotion|The health promotion treatment is structurally similar to the HIV/STD treatment: each has the same number of sessions and sessions led by Xhosa-speaking male and female co-facilitators. It focuses on behaviors linked with risk of heart disease, diabetes, high blood pressure, certain cancers, and alcohol and drug abuse, which are all leading causes of morbidity and mortality among South Africans. Participants are taught that healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance use, can prevent these health problems. Comic workbook story lines are used to increase risk perception and awareness of health risks. Take-home assignments are used to foster communication with parents about healthful lifestyle.
1796563|NCT00559416|Drug|Cell Transfer|
1796564|NCT00559429|Drug|Docetaxel|Docetaxel 50mg/m2 IV on day 1 and day 22
1796565|NCT00559429|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
1796566|NCT00559429|Drug|Docetaxel|Docetaxel 75mg/m2 IV on day 1 and day 22
1796567|NCT00559429|Drug|Docetaxel|Docetaxel 75 mg/m2 IV on day 1, 22 and day 43
1796568|NCT00559442|Other|Altitude Exposure:|rapid ascent to Margherita Hut (4559 m) within 24 h
1796569|NCT00559455|Drug|Oxaliplatin|85mg/m², 2 hours IV infusion, Day 1; Every 2 weeks
1796570|NCT00559455|Drug|Fluorouracil|400mg/m², 2 hours IV bolus, Day 1; 22 hours continuous IV infusion 600mg/m², Day 1 and Day 2; Every 2 weeks
1796571|NCT00559455|Drug|Leucovorin|200mg/m², Day 1 and Day 2; Every 2 weeks
1796572|NCT00559468|Drug|Sugammadex|single dose 4.0 mg/kg-1 Org 25969, administered at T1 3-10% after continuous infusion of rocuronium
1796573|NCT00559481|Drug|dexamethasone|
1796574|NCT00559481|Drug|ketoconazole|
1796575|NCT00559481|Drug|therapeutic hydrocortisone|
1796576|NCT00559481|Procedure|pharmacological study|
1796577|NCT00559494|Drug|Minocycline|Minocycline IV BID x 7 days (first 10 patients 200 mg/dose, subsequent patients adjusted based on pharmacodynamic profiling to 800 mg loading dose, tapered 100 mg each dose to 400 mg then maintain at 400mg until day 7)
1796578|NCT00559494|Drug|placebo|Normal saline 250cc via central line similar to minocycline arm administration protocol
1796579|NCT00559494|Procedure|SCPP augmentation|maintenance of spinal cord perfusion pressure at 75 mmHg with fluids and inotrope protocol
1796580|NCT00559494|Procedure|SCPP control|maintenance of Mean arterial pressure of >65 mmHg with fluids and inotropes protocol without spinal cord perfusion pressure as target or guiding therapy
1796581|NCT00559507|Drug|saracatinib|
1796582|NCT00559507|Other|laboratory biomarker analysis|Correlative studies
1796583|NCT00559520|Dietary Supplement|Impact|"Patient receiving 3 drinks Impact a day during 5 days before surgery"
1796584|NCT00559520|Dietary Supplement|Oral Impact|"Patient receiving 3 drinks Oral Impact a day during 5 days before surgery"
1796585|NCT00559533|Drug|RO5045337|Administered po at escalating doses (with a starting dose of 20mg/m2/day) (5-10 cohorts)
1796586|NCT00559546|Drug|montelukast|10 mg montelukast tablet each evening for 3 weeks or placebo for 3 weeks in cross-over manner
1796587|NCT00559559|Device|ICD implant + Patient Notifier turned OFF|ICD implant, plus standard care, i.e. Patient Notifier turned off
1796588|NCT00559559|Procedure|ICD Implant + Patient Notifier turned ON|ICD implant. The Patient Notifier™ feature will be turned ON.
1796589|NCT00559572|Behavioral|Motivational group sessions|Motivational group sessions include 4 weeks of weekly 1-hour exercise information sessions.
1796590|NCT00559572|Other|Time and attention control group sessions|Time and attention control group sessions include 4 weeks of weekly 1-hour general health information sessions.
1796591|NCT00559585|Drug|Subcutaneous (SC) Abatacept|Participants received 125 mg weekly SC abatacept injections (with an intravenous [IV] abatacept loading dose on Day 1, based on weight). A double-dummy design was used to protect the blind, thus, participants also received IV injections of placebo (IV Placebo) with the exception that on Day 1 a loading dose of IV abatacept replaced the IV Placebo treatment.
1796592|NCT00559585|Drug|Intravenous (IV) Abatacept|"Participants received IV abatacept infusions on Days 1, 15, 29, and every 28 days, thereafter. A double-dummy design was used to protect the blind, thus, participants also received SC injections of placebo (SC Placebo).
500mg (for body weight up to 60 kg)
750 mg (body weight between 61 and 100 kg)
1g (body weight above 100 kg)infusions"
1796593|NCT00559598|Genetic|proteomic profiling|
1796594|NCT00559598|Other|medical chart review|
1796595|NCT00559611|Procedure|Endobronchial Ultrasound|A small flexible scope is passed down the windpipe. Samples of lymph gland tissue will be collected through a tiny needle that is passed through the scope.
1796596|NCT00559611|Procedure|Mediastinoscopy|Performed if a tumor is not found on the opposite side of your chest from another tumor by the EBUS.
1796597|NCT00559624|Drug|Acadesine|For part I of the study one 4 hour intravenous infusion will be given. In part II upto five 4 hour intravenous infusions will be given over 20 days.
1796598|NCT00559637|Drug|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta will be administered subcutaneously once a month. The starting dose will be 1.2 mcg/kg of body weight. Further dose adjustments will be performed during the study depending on the hemoglobin value. Total duration of treatment will be 9 months for all participants in the study and up to 11 months for participants who will be shifted to the dialysis.
1796599|NCT00559650|Drug|Placebo|Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
1796600|NCT00559650|Drug|Cinaciguat (BAY58-2667)|Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
1796601|NCT00559663|Dietary Supplement|Green tea|"The green tea group consumed first daily one liter of green tea infusate made of 4 bags left in boiling water during 3 minutes.
After a four week washout-time they were switched over to the dark chocolate treatment, which included consumption of 3.5 ounces 70% dark chocolate.
Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels"
1796602|NCT00559663|Dietary Supplement|70% dark chocolate|"The dark chocolate group consumed 3.5 ounces 70% dark chocolate per day during a one week period.
After a four week washout-time they were given the green tea treatment, which included ingestion of one liter green tea infusate (containing 4 green tea bags).
Blood was drawn before and after each intervention, to check platelet activity with flow cytometry, HDL, LDL and hsCRP Levels."
1796603|NCT00559676|Drug|capecitabine|
1796604|NCT00559676|Drug|fluorouracil|
1796605|NCT00559676|Drug|irinotecan hydrochloride|
1796606|NCT00559676|Drug|leucovorin calcium|
1796607|NCT00559676|Drug|oxaliplatin|
1796608|NCT00559676|Other|laboratory biomarker analysis|
1796609|NCT00559676|Other|pharmacological study|
1796610|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone dipropionate|receive twice-daily administration
1796611|NCT00559689|Drug|Budesonide,hydrofluoroalkane-beclomethasone|once-daily administration at bedtime
1796612|NCT00559702|Drug|natalizumab|natalizumab
1796613|NCT00559702|Other|standard of care|standard of care as determined by the Investigator and Treating Neurologist
1796614|NCT00559715|Drug|bevacizumab|1.25 mg intravitreally monthly/on demand
1796615|NCT00559715|Drug|ranibizumab|0.5 mg intravitreally monthly/on demand
1796616|NCT00559741|Biological|cetuximab|
1796617|NCT00559741|Drug|fluorouracil|
1796618|NCT00559741|Drug|irinotecan hydrochloride|
1796619|NCT00559741|Drug|leucovorin calcium|
1796620|NCT00559741|Other|pharmacological study|
1796621|NCT00559754|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
1796622|NCT00559754|Drug|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
1796623|NCT00559754|Drug|Standard chemotherapy|As prescribed
1796624|NCT00559780|Behavioral|Resistance training|12 weeks of resistance training (3/week)
1796625|NCT00559780|Behavioral|Neuromuscular electrical stimulation of the quadriceps muscle|12 weeks of neuromuscular electrical stimulation of the quadriceps muscle (1h/day)
1796626|NCT00559780|Behavioral|Standard rehabilitation|12 weeks of standard physiotherapy exercises (1h/day)
1796627|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
1796628|NCT00559806|Other|2 weeks of unilateral immobilisation and 4 weeks of resistance training|2 weeks of unilateral whole leg casting (side randomized)followed by 4 weeks of unilateral resistance training. The non-imm side served as a within-subject control
1796629|NCT00559819|Drug|placebo|Placebo (orange juice), same volume as alcohol
1796630|NCT00559819|Drug|Alcohol|Dose with Alcohol (Vodka) to make blood alcohol concentration 0.08%
1796631|NCT00559832|Other|Hypoxic Exposure|Sleeping in normobaric hypoxia for 14 nights at altitudes from 2500 - 3300 m prior to one night at 4500 m
1796635|NCT00559858|Dietary Supplement|pyridoxine hydrochloride|
1796636|NCT00559858|Other|placebo|
1796637|NCT00559858|Procedure|quality-of-life assessment|
1796638|NCT00559871|Drug|fipamezole|Fipamezole in Zydis formulation three times per day for up to 28 days
1796639|NCT00559884|Drug|GSK189075 (Modified and immediate release formulations)|
1796640|NCT00559897|Other|3'-deoxy-3'-[18F]FLT|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
1796641|NCT00559897|Procedure|Single photon emission computed tomography|Patient should receive the dose of zoledronic acid within 48 hours of the first FLT PET scan. The second FLT PET scan will be done 6-8 days after the dose of zoledronic acid.
1796642|NCT00559910|Drug|PH-797804|PH-797804 at four dose levels
1796643|NCT00559910|Drug|Placebo|Placebo
1796644|NCT00559936|Drug|Topical Avastin 1%|Avastin (bevacizumab) 1%
1796645|NCT00559949|Other|Laboratory Biomarker Analysis|Correlative studies
1796646|NCT00559949|Drug|Selumetinib|Selumetinib was administered orally as a free base suspension at a dose of 100 mg twice daily for 28-day cycles. Those participants experiencing Common Terminology Criteria for Adverse Events (CTCAE) v3.0 grade 3 toxicity or worse had their dose reduced to 50 mg twice daily and then to 50 mg once daily, if necessary.
1796647|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
1796648|NCT00559962|Drug|placebo|3 capsules each evening for each 4-week period
1796649|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
1796650|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
1796651|NCT00559962|Drug|AEGR-733|3 capsules each evening for each 4-week period
1796652|NCT00559962|Drug|AEGR-733 and atorvastatin|3 capsules each evening for each 4-week period
1796653|NCT00559962|Drug|AEGR-733 and fenofibrate|3 capsules each evening for each 4-week period
1796654|NCT00559962|Drug|AEGR-733 and ezetimibe|3 capsules each evening for each 4-week period
1796655|NCT00559975|Biological|Subunit influenza vaccine|0.5 mL single dose vaccine
1796656|NCT00559975|Biological|Adjuvanted influenza vaccine|0.5 mL single dose vaccine
1796657|NCT00559975|Biological|Adjuvanted influenza vaccine combined with CpG7909|0.5 ml influenza vaccine combined with 10 mcg of CpG7909
1796658|NCT00559975|Biological|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 30 mcg of CpG7909
1796659|NCT00559975|Biological|Adjuvanted influenza vaccine combine with CpG7909|0.5 mL single dose vaccine combined with 100 mcg of CpG7909
1796660|NCT00559988|Drug|Home Monitoring Guided OAC|"Active monitoring for atrial episodes through the automatic HM notifications (email, fax, short message service) is required. If the total duration over 48 consecutive hours reaches the predefined anticoagulation condition, and AF/AFL diagnosis is confirmed using the IEGM online, the site instructs the patient by telephone to start OAC. Clinicians continue to monitor patients using HM, and if freedom from AF/AFL reaches the predefined interval, stop of OAC therapy is requested over the telephone. Following stop of anticoagulation, any recurrence of AF/AFL requires restart of OAC therapy.
OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
1796661|NCT00559988|Drug|Physician-Directed OAC|"Patients will receive physician-directed anticoagulation therapy based on conventional criteria.
OAC drugs used: Dabigatran etexilate, Rivaroxaban, Warfarin, other approved VKA"
1796662|NCT00560001|Behavioral|MD.2 Medication Dispenser|For those subjects receiving an MD.2 Medication Dispenser, the machine organizes medications and provides verbal and auditory explicit reminders for individuals to take their medications. At the scheduled time, the patient gets a series of reminders. The patient is then expected to push a single button to dispense a pre-filled medication cup. An automatic record is kept of the subject's medication adherence. Interviewer-administered surveys of the Geriatric Depression Scale, SF-12 Health Status Inventory, self-reported medication compliance and recent hospitalizations and emergency room visits will be given. Caregivers will complete the Caregiver Burden Interview.
1796663|NCT00560014|Dietary Supplement|Arginine and canola oil|Canola oil 1 tablespoon BID Arginine 9.0grams BID
1796664|NCT00560014|Dietary Supplement|Coromega and Arginine|Arginine 9.0 grams BID Coromega dose based on weight
1796665|NCT00560027|Other|Case Management by Family Support Counselor (not RCT)|N/A. Had planned to study RCT of case management intervention but unable to carry out RCT. Instead studied screening practice and healthcare utilization in mothers with PPD, IPV or both.
1796666|NCT00560053|Drug|Alternating chemotherapy|"4 cycles of alternating chemotherapy VBMCP/VBAD (every 5 weeks). VBMCP: Vcr 2 mg ev day 1, BCNU 0.5 mg/kg ev day 1, Cyclophosphamide 10 mg/kg day 1, Melphalan 0.25 mg/kg v.o. days 1-4, Prednisone 1 mg/kg v.o. days 1-4, 0.5 mg/kg days 5-8 and 0.25 mg/kg days 9-12.
VBAD: Vcr 1 mg e.v. day 1, BCNU 30 mg/m 2 e.v. day 1, Adriamycine 40 mg/m 2 day 1, Dexamethasone 40 mg/m 2 days 1-4, 9-12 and 17-20."
1796667|NCT00560053|Procedure|Autologous Transplantation|"Autologous Transplantation :
BUMEL:Busulfan, total dose 12 mg/kg (days -6 a -3; prophylaxis with difenilhidantoine) Melphalan 140 mg/m 2 , ev day -2 TASPE: To investigator criteria"
1796668|NCT00560053|Drug|Maintenance|"At 3 months of transplantation or with >1.500 neutrophiles/ > 75.000 platelets mm 3 .
Prednisone: 50 mg alternating days during 2 years Interferon alfa 2-b: 3 M UI s.c. Three times a week until relapse."
1796669|NCT00560053|Procedure|Second transplantation|In cases that no reach CR with BUMEL is programmed second transplantation, after 4-8 months .
1796670|NCT00560053|Procedure|ALOGENIC MINI TRASPLANTATION|ALOGENIC MINI TRASPLANTATION Fludarabine 30 mg / m 2 / day, days -7, -6, -5, -4, -3 Melphalan 70 mg / m 2 / day, day -2 Prophylaxis EICH: CsA + MTX or CsA + MOFETIL
1796671|NCT00560066|Biological|Cell-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
1796672|NCT00560066|Biological|Egg-derived influenza vaccine|1 dose of 0.5 mL in the deltoid region of the non-dominant arm
1796673|NCT00560079|Drug|Allopurinol|Allopurinol 600mg/day bid for 28 days
1796674|NCT00560079|Drug|Dipyridamole|Dipyridamole 200mg/day bid for 28 days
1796675|NCT00560079|Drug|Placebo|Placebo
1796676|NCT00560092|Drug|intrathecal magnesium sulfate|intrathecal magnesium sulfate
1796677|NCT00560105|Device|Lung Flute|8 weeks home use, twice daily
1796678|NCT00560105|Device|Acapella|8 weeks home use, twice daily
1796679|NCT00560118|Drug|fotemustine|
1796680|NCT00560118|Genetic|gene expression analysis|
1796681|NCT00560118|Genetic|polymerase chain reaction|
1796682|NCT00560144|Drug|RG1507|3mg/kg iv weekly
1796683|NCT00560144|Drug|RG1507|9mg/kg iv weekly
1796684|NCT00560144|Drug|RG1507|Pharmacokinetic-derived dose, <=16mg/kg iv weekly
1796685|NCT00560157|Dietary Supplement|Crucial (enteral tube feeding)|Evaluation of new enteral product, Crucial, in ICU patients
1796686|NCT00560170|Drug|Simvastatin (Zocor)|40mg of Simvastatin (n=20) orally per-day for 28 days
1796687|NCT00560170|Drug|10mg/10mg of Ezetimibe/Simvastatin (Vytorin)|10mg/10mg of Ezetimibe/Simvastatin (n=20) orally per-day for 28 days
1796688|NCT00560183|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|Capsules, four different mg dosage strengths
1796689|NCT00560183|Drug|Placebo|Capsules
1796690|NCT00560196|Other|Observation|N.A.
1796691|NCT00560209|Drug|ONO-1101|placebo for 1 minute IV
1796692|NCT00560209|Drug|ONO-1101|0.06 mg/kg for 1 minute IV
1796693|NCT00560209|Drug|ONO-1101|0.125 mg/kg for 1 minute IV
1796694|NCT00560222|Dietary Supplement|bovine lactoferrin|1gm of lactoferrin will be given each day
1796695|NCT00560222|Dietary Supplement|placebo [maltodextrin]|placebo that appears identical to lactoferrin will be given daily
1796696|NCT00560235|Drug|CP-751,871|Final dose 30 mg/kg IV on Day 1 of each 28 day cycle until either progression or toxicity
1796697|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
1796698|NCT00560261|Other|NO-CO inhalation and expiration|NO-CO inhalation and expiration
1796699|NCT00560274|Drug|Pegasys|As prescribed
1796700|NCT00560274|Drug|Ribavirin|As prescribed
1796701|NCT00560274|Drug|epoetin beta [NeoRecormon]|30,000 IU sc/week (starting dose)
1796702|NCT00560287|Device|Non invasive ventilation delivered with one of the ventilator specifically designed for NIV and given to the patient by the home care providers|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
1796703|NCT00560287|Device|Non invasive ventilation|A very recent randomized controlled trial show that in ALS without severe bulbar dysfunction, NIV improves survival with maintenance of, and improvement in, quality of life, including sleep quality. The survival benefit from NIV in this group is much greater than that from currently available neuroprotective therapy, like riluzole.
1796704|NCT00560300|Drug|1 alpha D2|Vitamin D sterol
1796705|NCT00560300|Drug|1,25 dihydroxy vitamin D3|Active vitamin D sterol
1796706|NCT00560300|Drug|Sevelamer HCl|Phosphate binder
1796707|NCT00560300|Drug|Calcium Carbonate|Phosphate binder
1796708|NCT00560313|Biological|Men ACWY CRM|A single dose of a 0.5 mL injectable solution
1796709|NCT00560313|Biological|4CMenB|All subjects received the study vaccine following a 0,2,6 vaccination schedule. Pre-filled syringe, administered by intramuscular injection into the deltoid area of the non dominant arm.
1796710|NCT00560326|Drug|Tacrolimus Ointment 0.03%|Once or twice daily topical application
1796711|NCT00560352|Drug|Dasatinib|Tablets; oral; approximately 2 years on study, depending on response; 50 mg once daily (QD), 100 mg QD, 140 mg QD
1796712|NCT00560352|Drug|Bortezomib|Powder; intravenous; approximately 2 years on study, depending on response; 1.0 mg/m^2 QD, 1.3 mg/m^2 QD
1796713|NCT00560352|Drug|Dexamethasone|Tablets; oral; approximately 2 years on study, depending on response; 20 mg QD
1796714|NCT00560365|Other|laboratory biomarker analysis|
1796715|NCT00560365|Procedure|computed tomography|
1796716|NCT00560365|Procedure|magnetic resonance imaging|
1796717|NCT00560365|Procedure|quality-of-life assessment|
1796718|NCT00560378|Drug|Tacrolimus ointment 0.1%|Topical
1796719|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg once daily (QD), for 28 days plus lenalidomide, 15 mg QD, for 21 days plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
1796720|NCT00560391|Drug|Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 70 mg QD, for 28 days plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
1796721|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 20 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
1796722|NCT00560391|Drug|Dasatinib, 100 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 100 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22.
1796723|NCT00560391|Drug|Dasatinib, 140 mg + Lenalidomide, 25 mg + Dexamethasone, 40 mg|Participants received dasatinib, 140 mg QD, for 28 days, plus lenalidomide, 25 mg QD, for 21 days, plus dexamethasone, 40 mg QD, weekly on Days 1, 8, 15, and 22. Cohort includes 4 participants who received treatment during the dose-finding phase and 13 participants who received treatment in the dose-expansion phase.
1796986|NCT00562692|Drug|Nesiritide|Nesiritide 4 hour infusion
1796724|NCT00560404|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc monthly (starting dose)
1796725|NCT00560404|Drug|Epoetin alfa|As prescribed
1796726|NCT00560417|Drug|Insulin Lispro Protamine Suspension|Administered subcutaneously once a day at bedtime
1796727|NCT00560417|Drug|Insulin Glargine|Administered subcutaneously once a day at bedtime
1796728|NCT00560430|Drug|telmisartan|80 mg per day, orally, weeks 1-14
1796729|NCT00560430|Drug|telmisartan|80 mg per day; orally, weeks 1 and 2; 160 mg per day; orally, weeks 3-14
1796730|NCT00560430|Drug|placebo|placebo; orally weeks 1-14
1796731|NCT00560443|Drug|ketorolac|0,5 mg/kg per os one time
1796732|NCT00560443|Drug|tramadol|2,5 mg/ kg per os in one dose
1796733|NCT00560456|Other|Chronic sleep restriction and driving simulator|"One night of normal sleep
Driving simulator
Night 1: night of total sleep deprivation
Night 2: night of sleep recovery
Night 1 to 5: nights of sleep restriction
Driving simulator after night 1 to 5
Night 6: night of sleep recovery
Driving simulator"
1796734|NCT00560469|Other|Administration of 70% deuterated water|Subjects will drink 70% deuterated water daily for 8 weeks.
1796735|NCT00560482|Drug|ABR-215050, tasquinimod|Gelatin capsules containing 0.25mg, 0.50mg, 1.0mg ABR-215050; 0.25mg/day taken orally once daily for 2 weeks, 0.50mg/day taken orally once daily for 2 weeks (dose-titration), and 1.0 mg/day taken once daily for 5 months (+6 months continuation)
1796736|NCT00560482|Drug|Placebo|Identical appearing gelatin capsules containing placebo
1796737|NCT00560495|Drug|ammonium tetrathiomolybdate|4 times daily for up to 3 weeks
1796738|NCT00560495|Other|immunoenzyme technique|
1796739|NCT00560495|Other|laboratory biomarker analysis|
1796740|NCT00560495|Radiation|Tc 99m sestamibi|
1796741|NCT00560495|Radiation|radiation therapy|once daily, 5 days a week, for 6-7 weeks
1796742|NCT00560508|Drug|Pramipexole Immediate Release|titrated as individually needed (0.25 mg - 4.5 mg daily)
1796743|NCT00560508|Drug|Pramipexole Extended Release|titration as individually needed (0.375 mg -4.5 mg daily)
1796744|NCT00560521|Behavioral|CPAP|Frequency of three times a week, using a positive end expiratory pressure (PEEP) of 10 mmH2O for 30 minutes for four weeks.
1796745|NCT00560534|Procedure|Whole body magnetic resonance angiography|Magnetic resonance angiography using a paramagnetic contrast agent.Venous compression performed with a blood-pressure cuff around both thighs.
1796746|NCT00560547|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms / 4 weeks iv (starting dose)
1796747|NCT00560560|Biological|CP-751, 871|Human IgG2 Monoclonal Antibody. 20mg/kg or 30 mg/kg every 3 weeks for 17 cycles, until progression or unacceptable toxicity develops.
1796748|NCT00560573|Drug|CP-751,871|CP-751,871 at doses ranging from 6 to 20 mg/Kg on Day 1 of each 21-day cycle. CP-751,871 may be administered even after active comparators discontinuation, for a total number of 17 cycles (1 year).
1796749|NCT00560573|Drug|Cisplatin|"Cisplatin 75* mg/m2 or 80* mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycles.
* 75 mg/m2 when in combination with pemetrexed, 80 mg/m2 when in combination with gemcitabine"
1796750|NCT00560573|Drug|Gemcitabine|Gemcitabine 1250 mg/m2, IV on Days 1 and 8 of each 21-day cycle up to 6 cycles
1796751|NCT00560573|Drug|Pemetrexed|Pemetrexed 500 mg/m2, IV on Day 1 of each 21-day cycle up to 6 cycle
1796752|NCT00560586|Drug|Budesonide|1 puff each nostril (32 micrograms) at bedtime
1796753|NCT00560586|Drug|placebo|1 puff each nostril at bedtime
1796754|NCT00560599|Drug|mupirocin and chlorhexidine|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.
Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine."
1796755|NCT00560599|Behavioral|household cleaning and disinfection|Environmental cleaning with topical ethanol and laundering of clothes and linen.
1796756|NCT00560599|Drug|mupirocin, chlorhexidine, & household cleaning/disinfection|"Mupirocin (Bactroban Nasal): twice a day for 7 days, apply one pea-sized amount of Bactroban Nasal ointment directly into one nostril and another pea-sized amount for the other nostril.
Chlorhexidine (Hibiclens): once a day for 14 days, rinse body with chlorhexidine.
Environmental cleaning with topical ethanol and laundering of clothes and linen."
1796757|NCT00560612|Drug|Paroxetine|Paroxetine 10 mg-40 mg or placebo; flexible dosing; 12-week duration.
1796758|NCT00560612|Drug|Placebo|Placebo: same as paroxetine (active comparator)
1796759|NCT00560638|Drug|loteprednol etabonate ophthalmic suspension, 0.5%|TID
1796760|NCT00560638|Drug|loteprednol etabonate ophthalmic suspension, 0.5%|QID
1796761|NCT00560638|Drug|vehicle of loteprednol etabonate|TID or BID according to the randomization
1796762|NCT00560651|Procedure|CCL (Corneal Cross Linking)|Apply Riboflavin 0.1% in Dextran 500 20% in NaCl solution Illuminate with UV-light of 365 nm wave-length and 3.0 mW/cm² intensity at 5 cm distance
1796763|NCT00560664|Procedure|Autologous chondrocytes transplantation|Cartilage was harvested, then transferred for cell isolation and culture. Cells are suspended in agarose and transferred to cylindrical molds and surgically implanted 4 weeks later.
1796764|NCT00560664|Procedure|Mosaicoplasty|Osteochondral patch are sampled and then implanted during the same surgical procedure
1796765|NCT00560690|Drug|Metformin|500 mg oral three times a day for 6 months
1796766|NCT00560690|Drug|pegylated interferon|180 micrograms, or 1.5 micrograms/kg body weight weekly SQ injection for 6 or 12 months depending on genotype
1796767|NCT00560690|Drug|Ribavirin|800-1200 mg PO given in 2 divided doses for 6 to 12 months depending on weight and genotype
1796768|NCT00560703|Drug|COL-101 (doxycycline, USP) capsules|40mg, once per day for 84 days
1796769|NCT00560703|Drug|placebo|sugar capsule
1796770|NCT00560716|Drug|CYC116|Dose escalation of CYC116
1796771|NCT00560729|Dietary Supplement|Renutryl 500|
1796772|NCT00560729|Dietary Supplement|Generique|
1796773|NCT00560729|Dietary Supplement|Generique + Renutryl 500|
1796774|NCT00560742|Procedure|Control|Coronary artery bypass grafting without bone marrow cells injection
1796775|NCT00560742|Procedure|Intramuscular administration of bone marrow cells|Coronary artery bypass grafting, and intramuscular administration of bone marrow cells into myocardial scar
1796987|NCT00562692|Drug|Placebo|Placebo infusion
1796776|NCT00560742|Procedure|Intracoronary administration of bone marrow cells|Coronary artery bypass grafting, and intracoronary administration of bone marrow cells into myocardial scar
1796778|NCT00560768|Device|Ovatio VR 6250 or DR6550|"The study requires the implantation of locally approved material:
A right ventricular defibrillation lead
In case of use of a dual chamber ICD a right atrial pacing lead
A single chamber or dual chamber ICD manufactured by SORIN Group. At begin of the study this will be OVATIO VR model 6250 and OVATIO DR model 6550. Any new devices of same type manufactured by SORIN Group which will become locally approved during the conduction of the trial can be used in the study.
Holter recording will be performed with a market approved recording system allowing high resolution ECG recording compatible with the analysis software for TVar."
1796779|NCT00560781|Drug|Pregnenolone or Placebo|Pregnenolone 50 mg BID, Pregnenolone 150 mg BID, Pregnenolone 250 mg BID
1796780|NCT00560794|Biological|Blinatumomab (MT103)|Administered by continuous intravenous (CIV) over 4 weeks per cycle
1796781|NCT00560807|Procedure|Mobilization|Mobilizations are passive movements performed in such a manner that the patient can volitionally prevent the movement. Types of mobilization include: a) passive oscillatory movements (2-3 Hz) of small or large amplitude, applied anywhere in a range of movement, typically for anything between 30 seconds and several minutes depending on the response and desired effects, and b) sustained stretching (glides) with or without tiny amplitude oscillations at the limit of the range.
1796782|NCT00560820|Drug|Deferasirox|30 mg/kg/day
1796783|NCT00560833|Drug|esmirtazapine|
1796784|NCT00560833|Drug|Placebo|
1796785|NCT00560846|Dietary Supplement|Impact|Preoperative 5 day oral Impact and early post-operative enteral Impact
1796786|NCT00560846|Dietary Supplement|Glucose load|Pre-operative glucose load: 800 ml of PreOp (Nutricia) 12 h before surgery; 400 ml of PreOp (Nutricia) 2 hours before surgery
1796787|NCT00553735|Drug|Cyclosporine A 0.05%|Topical cyclosporine A 0.05% (Restasis) three times a day for 18 months.
1796788|NCT00553735|Drug|Arificial Tear|Artificial Tear - three times a day for 18 months.
1796789|NCT00553748|Drug|F-18 FLT|One - 10 mci dose of F-18 FLT is administered IV over about 5 seconds prior to PET imaging. Each imaging dose contains no more than 6.1 micrograms of FLT.
1796790|NCT00553761|Device|Pattern electroretinogram|Full field and hemifield (nasal and temporal) stimulation transient pattern electroretinogram (PERG) were recorded both in patients and controls.
1796791|NCT00553774|Dietary Supplement|Cocoa Flavanols|Cocoa Flavanols (BD for 21 - 28 days)
1796792|NCT00553774|Other|Placebo|Placebo (BD 21 - 28 Days)
1796793|NCT00553787|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
1796794|NCT00553787|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
1796795|NCT00553787|Drug|VI-0521|placebo
1796796|NCT00553800|Drug|bevacizumab|
1796797|NCT00553800|Drug|Erlotinib|
1796798|NCT00553813|Drug|TPI 287|Intravenous dose of 125 mg/m2 TPI 287 on Day 1, Day 8, and Day 15 in a repeating 28 day cycle.
1796799|NCT00553839|Drug|ketamine hydrochloride|Open label pharmacokinetic study to be conducted in infants and children presenting for medical procedures (eg., surgery or cardiac catheterization). After the start of the procedure, a 0.5 cc preload blood sample (T0) will be drawn from an IV line. Then a 2 mg/kg IV bolus of Ketamine will be administered over 5 minutes. Timed 0.5 ml blood samples will be drawn at the following intervals: 5, 10, 15, 20, 30, 45, 60, 120, 180, 240, 300, 360 and 720 minutes after bolus.
1796800|NCT00553852|Drug|Recombinant GH Saizen (Merck-Serono)|Treatment will start at the initial dose 0.15-0.30 mg/day; dose adjustment will be performed according to IGF-I levels. The duration of medical treatment is 6 months.
1796801|NCT00553865|Drug|OJP-2028|Experimental: 1mg/day, 2mg/day, 4mg/day for 8 weeks. Placebo Comparator: Placebo.day for 8 weeks. Reference group(Group 5): Reference Drug/day for 8 weeks.
1796802|NCT00553878|Drug|Dutasteride|dutasteride 0.5mg capsule daily until serum PSA rises to 5ng/ml in the off treatment interval
1796803|NCT00553891|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months.
1796804|NCT00553891|Drug|placebo nasal spray|One spray in each nostril once daily for 3 months.
1796805|NCT00553904|Dietary Supplement|Cranberry juice|480 ml of double strength cranberry juice daily for four weeks
1796806|NCT00560859|Procedure|Adenotonsillectomy (AT) - removal of adenoids and tonsils|Standard surgical intervention for treatment of Obstructive Sleep Apnea Syndrome which includes removal of adenoids and tonsils
1796807|NCT00560859|Other|Watchful Waiting|Children will reevaluated for adenotonsillectomy (AT) after a 7 month primary monitoring period.
1796808|NCT00560872|Device|remote magnetic catheter navigation|use of the Stereotaxis system
1796809|NCT00560872|Procedure|cavotricuspid isthmus ablation|conventional (manual) approach
1796810|NCT00560885|Device|AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
1796811|NCT00560898|Drug|ProClear Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
1796812|NCT00560898|Drug|Acuvue Advance Lens Material soaked in ReNu Multiplus Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
1796813|NCT00560898|Drug|Acuvue Advance Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
1796814|NCT00560898|Drug|ProClear Lens Material soaked in Optifree RepleniSH Multipurpose Solution|Contact lens soaked in multipuprpose solution for 8 hours, then worn for two hours
1796815|NCT00560911|Behavioral|educational program for the self-management of OAC|"Patients in the self-management group participated in 4 consecutive weekly instruction sessions of 90 to 120 minutes each, in groups of 3 to 6 patients.
After participation in the structured programme, the patients were encouraged to control their INR values by self-monitoring once a week and to adjust their anticoagulant dosage accordingly."
1796816|NCT00560911|Behavioral|1 hour education - afterwards physician leaded OAC control|"Patients in the routine control group participated a single 90-minute session
During the whole study period, they were advised with regard to changes in the anticoagulant dosage by their usual attending physicians, either in general practice or at a hospital-based specialised anticoagulation clinic."
1796818|NCT00560937|Drug|Pregnenolone|Pregnenolone 50 mg twice a day (BID) x 2 weeks, Pregnenolone 150 mg BID x 2 weeks, Pregnenolone 250 mg BID x 4 weeks
1796819|NCT00560937|Drug|Placebo|Placebo (similar to active comparator) 50 mg BID x 2 weeks, Placebo (similar to active comparator) 150 mg BID x 2 weeks, Placebo (similar to active comparator) 250 mg BID x 4 weeks
1796820|NCT00560950|Biological|pneumococcal 23v polysaccharide vaccine|Duration of Treatment: Single vaccination on Day 1
1796821|NCT00560963|Drug|everolimus|
1796822|NCT00560976|Drug|Iron Saccharate (Venofer)|Hemodialysis with IV iron administration of 100 mg Iron Saccharate (Venofer) in 150 ml 0.9 % saline to the arterial dialysis line during first hour of mid-week dialysis session. An alternative IV iron brand in some centers participating in the study could bebe 62.5 mg ferric gluconate (Ferrlecit).
1796823|NCT00561002|Biological|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
1796824|NCT00561002|Biological|2007-2008 Influenza Virus Vaccine|0.25 mL, Intramuscular
1796825|NCT00561015|Drug|Telaprevir|Telaprevir 750 mg tablet will be administered three times a day orally for 2 weeks.
1796826|NCT00561015|Drug|Peg-IFN-alfa-2a + Ribavirin (Standard Treatment)|Standard treatment of Peg-IFN-alfa-2a (180 mcg subcutaneous injection, once weekly) and ribavirin (400 mg as oral tablet twice daily) will be administered from Day 15 to Week 24 or 26 in the T2 & PR24 - genotype 2 and 3 group and from Day 1 to Week 24 or 26 in the T2/PR24 - genotype 2 and 3 group.
1796827|NCT00561015|Drug|Placebo|Matching placebo tablet to telaprevir will be administered three times a day orally for 2 weeks.
1796828|NCT00561028|Other|blood sample analysis - mycoplasma and chlamydia antibodies|Anti-Chlamydia and anti-Mycoplasma IgG antibodies were measured by indirect immunofluorescence at baseline (24 hours of hospitalization) and after 6 months (follow-up).
1796829|NCT00561041|Behavioral|Brief phone aftercare intervention|Interventions is composed of 5 integrated cognitive-behavioral and motivational enhancement therapies administered during a period of 3 months according to a similar schedule
1796830|NCT00561041|Behavioral|individual aftercare therapy|composed of 5 integrated cognitive-behavioral and motivational enhancement Therapies administered during a period of 3 months according to a similar schedule
1796831|NCT00561054|Drug|CETUXIMAB|400 mg/m2 starting dose, 250 mg/m2 weekly dose
1796832|NCT00561067|Drug|Erythropoietin|EPO 500 IU/kg diluted in 50 ml saline and infused in 30 minutes; treatment is started within eight hours after the spinal injury; the same drug dosage will be infused at 24 and 48 hours
1796833|NCT00561067|Drug|Methylprednisolone|MP 30 mg/kg intravenous (iv) in the first hour, followed by 5.4 mg/kg/h for 23 hours if treatment is started within three hours after the spinal injury,or for 48 hours if treatment is started between three and eight hours (protocol NASCIS III, National Acute Spinal Cord Injury Study)
1796837|NCT00561093|Drug|pentoxiphylline|pentoxiphylline 400 mg daily, anti-inflammatory and appetite-stimulating while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
1796838|NCT00561093|Dietary Supplement|Nepro|Nepro (8 ounces) one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
1796839|NCT00561093|Dietary Supplement|anti-inflammatory module (similar to Oxepa)|Oxepa-similar anti-inflammatory module (2 ounces) while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
1796840|NCT00561093|Drug|Placebo pill imitating pentoxiphylline|Placebo pill imitating pentoxiphylline 400 mg daily, to imitate the anti-inflammatory and appetite-stimulating pill while subjects undergo thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
1796841|NCT00561093|Dietary Supplement|Placebo to imitate Nepro|Placebo to imitate Nepro (8 ounces), with less protein and calorie, one can while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
1796842|NCT00561093|Dietary Supplement|Placebo to imitate anti-inflammatory module (similar to Oxepa)|Placebo to imitate Oxepa-similar anti-inflammatory module (2 ounces), without anti-inflammatory or anti-oxidative ingredients, while undergoing thrice weekly hemodialysis and during the following non-dialysis day (6 days per week)
1796843|NCT00561106|Drug|prednisone- valacyclovir|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days. The treatment was tapered over the next 14 days. Those taking valacyclovir received 1000 mg in two daily doses for 7 days.
1796844|NCT00561106|Drug|prednisone-placebo|prednisone, a dose of 1 mg/kg body weight was given daily for 7 days
1796845|NCT00561119|Drug|gemcitabine , paclitaxel|"Gemcitabine 1250 mg/m2 i.v. Day 1 & 8
Paclitaxel 175 mg/m2 i.v. day 1
repeat every 3 weeks"
1796846|NCT00561132|Dietary Supplement|Vanadyl sulfate|50 mg twice daily orally for a period of 4 weeks
1796847|NCT00561132|Other|Magnesium oxide|Validation of similar appearance and weight to the intervention component orally 1 unit (<50 mg) twice daily for a period of 4 weeks
1796848|NCT00561145|Other|Energy restriction period|The experiment can be divided in 3 phases, namely (1) run-in phase, (2) energy restriction phase and (3) ad libitum food intake phase. Thus, for all participants the experiment consists of three subsequent phases.
1796849|NCT00561158|Behavioral|Eat Well Live Well Nutrition Program|"12 sessions (6 group and 6 individual)over a period of 3 months with a 3 month follow-up period. The group sessions involve active learning exercises crucial to learning and utilizing nutrition information.
The group sessions included are:
Rate Your Plate: determining high fat foods
Label Reading: reading food labels
Comparison Shopping: using unit pricing labels maximize nutritional value on a limited income
Recipe Modification: preparing old recipes in new ways to reduce fat
Eating Out: order healthier fast foods
Coping with High Risk Situations: coping with situations in which these new habits may be threatened
Six individual sessions will introduce participants to low fat eating patterns or ways to lower fat in their diet, including:
Substituting fat-modified foods for high fat foods
Avoiding fat as a seasoning or flavoring
Avoiding fried foods
Modifying meat
Replacing high fat foods with fruits, vegetables, grains and breads"
1796850|NCT00561171|Drug|SPP635|oral once daily
1796851|NCT00561184|Biological|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 7.5 micrograms of H5N1 influenza antigen
1797094|NCT00563459|Drug|topiramate|200-400mg/day for 12 months
1796852|NCT00561184|Biological|H5N1 influenza vaccine|One 0.5 ml booster injection 12 months after the second injection, of influenza vaccine containing 15.0 micrograms of H5N1 influenza antigen
1796853|NCT00561834|Drug|ranibizumab|All patients (n=15) will be treated with open label 0.5mg ranibizumab given intravitreally monthly as needed for 6 months.
1796854|NCT00561860|Device|Telemedicine Arm|Telemedicine involves the provision or support of direct clinical care via the application of electronic and communicating technology, including the remote monitoring of health status. By providing patient data early in the course of CPAP prescription, we believe that this technology would be immensely useful in improving compliance and acceptance of the device in patients with sleep apnea.
1796855|NCT00561886|Drug|Formoterol|One inhalation of 24µg Formoterol
1796856|NCT00561899|Drug|SP, amodiaquine, piperaquine, dihdroartemisinin|once every month during september, October and November
1796857|NCT00561899|Drug|intermittent preventive treatment|SP(500mg sulfadoxine/25mg pyrimethamine)1.25mg SP per kg stat Amodiaquine (200mg base) 25mg/kg over 3 days Piperaquine (320 mg per tablet) 16.8 g/kg daily for 3 days Du-Cotecxin ( 40mg dihydroartemisinin(DHA)/320mg piperaquine(PQP))PQP/DHA 1.6/12.8mg/kg once daily for 3 days
1796858|NCT00561899|Drug|Du-Cotecxin|Du-Cotecxin (40mg dihydroartemisinin (DHA/320mg Piperaquine (PQP) PQP/DHA 1.6/12.8mg/kg once daily for 3 days
1796859|NCT00561912|Drug|Decitabine|15 mg/m^2 IV Daily over one hour for 5 days
1796860|NCT00561912|Drug|Interferon Alfa-2b|0.5 million Units Subcutaneously Twice Daily Continuously. Interferon Alfa-2b will be added on cycle three, day one.
1796861|NCT00561925|Drug|nevirapine IR|200 mg BID
1796862|NCT00561925|Drug|nevirapine XR|400 mg QD
1796863|NCT00561938|Procedure|Colonoscopy|microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist. General tolerance and potential late adverse events will be assessed by the careful inquiry performed 1 month after the procedure by consultant gastroenterologist.
1796864|NCT00561938|Procedure|Endoscopy|After obtaining a written informed consent from all the patients, standard upper GI endoscopy or colonoscopy will be performed under general anaesthesia using a videoendoscope EC-3870 (Pentax), which includes a miniaturized microscope with a confocal window in its distal part. During ongoing endoscopy, 5 mL of 10% fluorescein (Novartis) will be injected intravenously to perform CLE imaging. In brief, CLE images are obtained few seconds after fluorescein injection by gentle positioning of the confocal window in contact with the digestive mucosa. To stabilize images, some suction can be applied using the operating channel of the endoscope. CLE images ('optical biopsies') will be stored and 1-2 standard biopsies will be performed in the examined area in order to further compare optical and standard biopsies. The overall duration of the procedure will be limited to 1 hour. During and after the procedure, patients will be monitored and surveyed continuously by anaesthesiologist.
1796865|NCT00561951|Drug|fesoterodine fumarate|8mg tablets OD for 12 weeks
1796866|NCT00561951|Drug|Placebo|Corresponding placebo tablets OD for 12 weeks
1796867|NCT00561951|Drug|fesoterodine fumarate|4mg tablets OD for 12 weeks
1796868|NCT00561964|Drug|Irbesartan|Irbesartan capsules strength 150 mg. Irbesartan group will be initiated at one irbesartan and one placebo for 2 weeks and titrated at two capsules if well tolerated after 2 weeks , this dose will be maintained throughout the study without further dose-adjustment (2 capsules daily in the morning will be taken from randomization to study end)
1796869|NCT00561964|Drug|placebo|Placebo group: 2 placebo capsules daily as a single morning intake
1796870|NCT00561977|Behavioral|High Fiber Diet|high fiber diet (≥30 grams of total fiber per day); reduction of calories to -500 from resting metabolic rate (RMR), not less than 1200 kcal per day.
1796871|NCT00561977|Behavioral|low saturated fat diet|low saturated fat diet (≤7% of total calories); -500 calories from RMR, not less than 1200 kcal/day.
1796872|NCT00561977|Behavioral|Combination diet|combination low saturated fat high fiber diet, with calorie restriction as specified.
1796873|NCT00561990|Drug|Nimotuzumab|
1796874|NCT00562003|Procedure|Tenckhoff Catheter placement|'Tenckhoff catheter' will be placed into the abdominal cavity by a minor surgical procedure performed in the Radiology Department.
1796875|NCT00562003|Drug|Ad5-delta24RGD|"Within two weeks before the start of the study, a physical exam, blood tests, removal of fluid from abdominal cavity through the catheter and a CT scan of abdomen and pelvis will be performed.
The procedure will involve receiving the Ad5-delta24RGD virus once a day for 3 days. The virus will be put into the abdominal cavity through a 'Tenckhoff catheter'."
1796876|NCT00562016|Device|IMPLELLA LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5 L/min.
1796877|NCT00562016|Device|IABP Intra-aortic balloon pump|IABP uses counterpulsation to provide 0.2L/min coronary flow
1796878|NCT00562029|Procedure|Duodenal-jejunal Bypass|Patient has undergone a duodenal bypass and bypass of 60cm of proximal jejunum
1796879|NCT00562055|Drug|Atomoxetine|
1796880|NCT00562055|Drug|PNU-165442G; [S,S]-reboxetine|
1796881|NCT00562068|Biological|alemtuzumab|
1796882|NCT00562068|Drug|cyclophosphamide|
1796883|NCT00562068|Drug|doxorubicin hydrochloride|
1796884|NCT00562068|Drug|prednisolone|
1796885|NCT00562068|Drug|vincristine sulfate|
1796886|NCT00562068|Genetic|polymerase chain reaction|
1796887|NCT00562068|Other|flow cytometry|
1796888|NCT00562068|Other|laboratory biomarker analysis|
1796889|NCT00562068|Other|pharmacological study|
1796890|NCT00562081|Behavioral|Education|24/7 access to a Certified Asthma Educator
1796891|NCT00562081|Behavioral|Education|Patient does not have 24/7 access to a Certified Asthma Educator.
1796892|NCT00562094|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
1796895|NCT00562120|Drug|Placebo|A single oral dose of Placebo is dosed during the study in order to ascertain the effect of placebo on measures and in order to maintain the blind of the other drugs.
1796896|NCT00562120|Drug|Allegra|A single oral dose of Allegra is dosed to subjects in combination with PF-03654746.
1796897|NCT00562120|Drug|Allegra-D|A single oral dose of Allegra-D is dosed to subjects as an active comparator.
1796898|NCT00562120|Drug|PF-03654746|A single oral dose of PF-03654746 is the investigational drug being studied.
1796899|NCT00562133|Drug|Insulin Glulisine|100 IU/ml, 0.10 U/kg immediately before ingestion of a standardised liquid meal
1796900|NCT00562133|Drug|Insulin|100 IU/ml, 0.10 U/kg 15 Minutes before ingestion of a standardised liquid meal
1796901|NCT00562146|Procedure|placement of spiral nasojejunal tube|spiral nasojejunal tube will be placed after enrollment of the patients
1796902|NCT00562159|Drug|Placebo|Placebo sublingual tablet
1796903|NCT00562159|Biological|SCH 697243|SCH 697243 (2800 Bioequivalent Allergen Units [BAU] of Phleum pratense extract, containing approximately 15 mcg Phl p 5), administered sublingually once daily.
1796904|NCT00562159|Drug|Loratadine 10 mg Rescue Treatment|Loratadine 10 mg RediTabs tablets were dosed orally once daily as rescue medication among participants with a total symptom score ≥ 4 during the GPS.
1796905|NCT00562159|Drug|Olopatadine 0.1% Rescue Treatment|Olopatadine hydrochloride 0.1% ophthalmic solution was administered intraocularly at a dose of 1 drop in each affected eye twice daily as rescue medication for rhinoconjunctivitis, as needed.
1796906|NCT00562159|Drug|Mometasone 50 mcg Rescue Treatment|Mometasone furoate monohydrate nasal spray 50 mcg was admininstered intranasally at a dose of 2 sprays in each nostril once daily as rescue medication for rhinoconjunctivitis, as needed.
1796907|NCT00562159|Drug|Prednisone 5 mg Rescue Treatment|"Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day
(maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for rhinoconjunctivitis among participants with a total symptom score of ≥ 4 despite treatment with loratadine and mometasone furoate nasal spray."
1796908|NCT00562159|Drug|Albuterol sulfate 108 mcg|Albuterol sulfate inhalation aerosol 108 mcg/inhalation was administed via inhalation at a dose of 2 inhalations every 4 to 6 hours, as needed, as rescue medication for asthma.
1796909|NCT00562159|Drug|Fluticasone propionate 44 mcg|Fluticasone propionate inhalation aerosol 44 mcg/inhalation was administered via inhalation at a dose of two inhalations twice daily, to a maximum dose of 10 inhalations twice daily, as rescue medication for asthma among participants utilizing four or more albuterol sulfate inhalations/day for 2 days for nocturnal asthma or shortness of breath.
1796910|NCT00562159|Drug|Prednisone 5 mg|Prednisone 5 mg tablets were administered orally at a dose of 1 mg/kg/day (maximum 50 mg/day) on Day 1 and 0.5 mg/kg/day (maximum 25 mg/day) on Days 2, 3, 5 and 7 as rescue medication for asthma at the discretion of the investigator for the treatment of asthma exacerbation.
1796911|NCT00562172|Drug|Insulin glargine|Once daily in the morning
1796912|NCT00562172|Drug|Glimepiride|Once daily in the morning
1796913|NCT00562172|Drug|Metformin|At least 1000 mg/day
1796914|NCT00562185|Drug|carboplatin|
1796915|NCT00562185|Drug|doxorubicin hydrochloride|
1796916|NCT00562198|Drug|entacapone and carbidopa|Entacapone 200mg carbidopa 50mg
1796917|NCT00562198|Drug|Sinemet 200mg/50mg|Sinemet 200mg/50mg once
1796918|NCT00562211|Drug|LidoDyn|Application of 2 gram of LidoDyn to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
1796919|NCT00562211|Drug|EMLA creme|Application of 2 gram of EMLA creme to the skin surface the patient's antecubital fossa 60 min prior to venipuncture
1796920|NCT00562224|Drug|PCI-24781|"Up to 7 cohorts will receive PCI-24781 orally at doses starting at 30 mg/m2 three times a day approximately 4 hours apart (TID), up to 90 mg/m2, administered 5 days/week during the first 21 days of each 28 day cycle until MTD is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 twice a day approximately 4 hours apart (BID). If a DLT occurs on the BID schedule, the subsequent cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle). If a DLT occurs on this dosing schedule, then the next cohort will receive PCI-24781 BID for 5 days/week every other week (2 times in a 28 day cycle) until the maximum tolerated dose is reached."
1796921|NCT00562237|Biological|S205 placebo|2 i.m. injections per subject (0.5 mL each)
1796922|NCT00562237|Biological|S205 10ugHA|2 i.m. injections per subject (0.5 mL each)
1796923|NCT00562237|Biological|S205 30ugHA|2 i.m. injections per subject (0.5 mL each)
1796924|NCT00562237|Biological|S205 10ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
1796925|NCT00562237|Biological|S205 30ugHA+500ugAlOH|2 i.m. injections per subject (0.5 mL each)
1796926|NCT00562237|Biological|S205 10ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
1796927|NCT00562237|Biological|S205 30ugHA+1250ugAlOH|2 i.m. injections per subject (0.5 mL each)
1796928|NCT00562250|Drug|Dapagliflozin|Tablets, Oral, 20 mg, once daily, single dose
1796929|NCT00562250|Drug|Glimepiride|Tablets, Oral, 4 mg, once daily, single dose
1796930|NCT00562250|Drug|Dapagliflozin + Glimepiride|Tablets, Oral, Dapagliflozin 20 mg + Glimepiride 4 mg, once daily, single dose
1796931|NCT00562263|Behavioral|Lifestyle modification|Dietary modification and regular physical activity
1796932|NCT00562276|Procedure|Immediate IUD insertion|Insertion of either Paraguard or Mirena IUD within minutes of completing suction aspiration procedure between 5 and 12 weeks gestation
1796936|NCT00562302|Device|Bio-Seal Plug|Deployment of the Bio-Seal plug in needle track
1796937|NCT00562315|Drug|FACBC|Anti-3-[18F]FACBC is an investigational positron emission tomography (PET) radiotracer being studies given intravenously prior to PET scan
1796938|NCT00562315|Other|ProstaScinct|ProstaScint (In-Capromab Pendetide) is used to image the extent of prostate cancer in standard practice. Capromab is a mouse monoclonal antibody which recognizes prostate specific membrane antigen from prostate cancer cells and normal prostate tissue. It is given intravenously prior to undergoing CT imaging.
1796939|NCT00562328|Biological|Alemtuzumab|"Week 1 (dose escalation):
Day 3: 3mg subcutaneously; Day 4: 10mg subcutaneously; Day 5 30mg subcutaneously
Weeks 2-5:
30mg subcutaneously three times a week."
1796940|NCT00562328|Biological|Rituximab|"Weeks 2-5:
375 mg/m^2 by IV once weekly"
1796941|NCT00562328|Biological|Sargramostim|"Week 1-6:
250 mcg subcutaneously three time as week"
1796942|NCT00562341|Procedure|Bariatric Surgery|one time lapb-band gastric bypass surgery
1796943|NCT00562354|Biological|13vPnC|13vPnC for both stratum
1796944|NCT00562367|Drug|Cytomel (liothyronine)|Cytomel (liothyronine) 25-50 mcg/day for 4 weeks
1796945|NCT00562380|Biological|ganitumab|
1796946|NCT00562380|Other|laboratory biomarker analysis|
1796947|NCT00562380|Other|pharmacological study|
1796948|NCT00562380|Procedure|biopsy|
1796949|NCT00562393|Other|Nutritional|Overfeeding high fat diet for 28 days
1796950|NCT00562406|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab after randomisation, at week 4 and 8
1796951|NCT00562406|Procedure|Laser photocoagulation|laser photocoagulation to the retina at the area of edema
1796952|NCT00562419|Drug|CT-322|IV solution, weekly
1796953|NCT00562419|Drug|irinotecan hydrochloride|IV solution, biweekly
1796954|NCT00562432|Device|Plexisyl-AF|Plexisyl-AF implants
1796955|NCT00562432|Other|No Treatment|CABG without the experimental treatment
1796956|NCT00562458|Drug|anastrozole|
1796957|NCT00562471|Other|Adhibit Adhesion Prevention Gel|A resorbable hydrogel, which adheres to itself and the tissues it contacts, is approved for use in sealing vascular reconstructions. The hydrogel is formed when two synthetic derivatized polyethylene glycol (PEG) polymers are mixed together and applied to tissue. Using a gas-assisted delivery device, the hydrogel is sprayed over all myomectomy suture lines and all surgically treated areas during the myomectomy surgery. The hydrogel is totally resorbed within 30 days post-application.
1796958|NCT00562471|Other|Standard of Care Comparator|standard of care for post-operative adhesion prevention included irrigation of tissues and lavage of all fluids with Ringers Lactate solution following surgery and 300 to 500mL of solultion left in the pelvic cavity immediately prior to wound closure
1796959|NCT00562484|Biological|CSL Limited Influenza Vaccine|A single 0.5 mL, intramuscular Injection in the deltoid region of the arm on day 0.
1796960|NCT00562484|Biological|Placebo|Placebo
1796961|NCT00562497|Drug|Prochymal|Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the active treatment group will receive Prochymal™ at 2 x 106 hMSC/kg per infusion.
1796962|NCT00562497|Other|Placebo|Subjects will be treated with a total of 6 infusions of investigational agent during the first 4 weeks of the study. Four infusions will be administered during the first two weeks (twice weekly), then two infusions administered during the next two weeks (once weekly). Subjects assigned to the non active treatment group will receive placebo (excipient, less cells). It is recommended that all subjects receive all six infusions. The discontinuation of investigational agent is allowed for GVHD worsening with subsequent need for salvage therapy. All infusions must be given at least 3 days apart.
1796963|NCT00562510|Drug|Raltegravir|Raltegravir 400 mg BID added to stable HAART
1796964|NCT00562510|Drug|Placebo|Placebo BID added to stable HAART
1796965|NCT00562523|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400mg by mouth daily in combination with docetaxel 60mg/m2 IV once every 3 weeks
1796966|NCT00562536|Procedure|Umbilical cord clamping|Delay of umbilical cord clamping 30 to 45 seconds
1796967|NCT00562549|Drug|SLx-2101|
1796968|NCT00562562|Other|osteopathic manipulative treatment|Treatment will focus on the thoracolumbar junction, L5, the sacrum, and the pubes. Treatment will primarily utilize two techniques, muscle energy and ligamentous-articular release, but will be tailored to the findings of the individual patient.
1796969|NCT00562575|Drug|SLx-4090|
1796970|NCT00562575|Drug|Placebo|
1796971|NCT00562588|Drug|Aggrenox bid (ASA 25mg/Dipyridamole ER 200mg)|
1796972|NCT00562588|Drug|ASA 100 mg qd|
1796973|NCT00562614|Drug|SLx-2101|
1796974|NCT00562627|Drug|ropivacaine|intraoperative and 1. postoperative day
1796975|NCT00562627|Drug|adrenaline|intraoperative LIA (IV and IA) and continuous EDA
1796976|NCT00562627|Drug|ketorolac|intraoperative and 1. postoperative day
1796977|NCT00562627|Drug|morphine|intraoperative
1796978|NCT00562627|Drug|fentanyl|continuous postoperatively
1796979|NCT00562627|Drug|bupivacaine|continuous postoperatively
1796980|NCT00562640|Biological|filgrastim|Stem cell mobilization and harvest: Patients receive filgrastim (G-CSF) subcutaneously daily for five days. PBMC are collected by leukapheresis on the fifth day and then cryopreserved for subsequent reinfusion into the patient, in the event of prolonged cytopenia.
1796981|NCT00562640|Biological|therapeutic autologous lymphocytes|Autologous T-cell infusion with or without conditioning chemotherapy ( fludarabine treatment closed as of 12/01/2009): Approximately 4-6 weeks after T-cell sensitization, patients receive an infusion of autologous WT1-specific T cells over 5-10 minutes on day 0. Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2 and fludarabine phosphate IV over approximately 30 minutes on days -6 to -2. After a 48-hour rest period, patients receive autologous WT1-specific T cells. Treatment repeats every 14 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with responsive or stable disease after completion of therapy, may receive additional courses of autologous WT1-specific T cells every 14 days.
1796982|NCT00562640|Drug|cyclophosphamide|Patients enrolled in dose levels II and III also undergo pre-infusion lymphodepletive conditioning comprising cyclophosphamide IV on day -2
1796983|NCT00562640|Other|laboratory biomarker analysis|Obtained prior to adoptive therapy to quantitate baseline levels of WT1 reactive T cells, by quantitation of WT1 specific CTLp by LDA, T cells secreting IFNγ in response to peptide and, in HLA A0201+ patients, T cell binding WT1 peptide HLA A2 tetramers.
1796984|NCT00562666|Other|T gamma delta lymphocytes|Single hepatic intra arterial administration of increasing doses of T gamma delta lymphocytes
1796985|NCT00562679|Other|There is no intervention|
1796988|NCT00562705|Behavioral|growth hormone- Genotropin or NorditropinSimplex and nutritional intervention|"A combined treatment of growth hormone (Genotropin or NorditropinSimplex or Biotropin) and nutritional intervention"
1796989|NCT00562705|Behavioral|"growth hormone-Genotropin or NorditropinSimplex or Biotropin"|"Growth hormone treatment (Genotropin, or NorditropinSimplex or Biotropin)."
1796990|NCT00562718|Drug|capecitabine|
1796991|NCT00562718|Procedure|adjuvant therapy|
1796992|NCT00562718|Radiation|radiation therapy|
1796993|NCT00562731|Drug|ARD-0403|Daily transdermal ARD-0403
1796994|NCT00562744|Other|Simulation|Use of high-fidelity patient simulator for training and assessment of PALS scenario performance
1796995|NCT00562770|Drug|Valganciclovir|900 mg (two 450 mg capsules) po QD during therapy and for 2 months post alemtuzumab initiation.
1796996|NCT00562770|Drug|Valacyclovir|500 mg po QD during therapy and for 2 months post alemtuzumab initiation.
1796997|NCT00562783|Drug|Vitaliver|
1796998|NCT00562783|Drug|Placebo|
1796999|NCT00562809|Drug|IRBESARTAN|150/12.5 mg tablets one or two tablets orally per day
1797000|NCT00562822|Procedure|Arthroscopic surgery|Arthroscopic surgery to treat unresolved symptoms of osteoarthritis of the knee
1797001|NCT00562822|Other|Physical and medical therapy|Treatment with physical and medical therapy alone
1797002|NCT00562835|Drug|Methylprednisolone|"Drug: Methylprednisolone Day 0 Loading dose 1 mg/kg IV bolus (30 min) followed by continuous infusion; Days 0 to 14*† ‡ 1 mg/kg/day mixed in 240cc Normal saline (NS) and infused at 10 cc/hr; Days 15 to 21*‡ 0.5 mg/kg/day mixed in 240cc NS and infused at 10 cc/hr; Days 22 to 25*‡ 0.25 mg/kg/day; Days 26 to 28*‡ 0.125 mg/kg/day
*Five days after the patient is able to ingest medications, methylprednisolone is given per os in one single daily equivalent dose.
†If between days 1 to 14 the patient is extubated, he is advanced to day 15 of drug therapy and tapered according to schedule.
‡ When leaving ICU, if the patient is still not tolerating p.o. intake for at least five days, he should receive the specified dosage as IV push every 6 hours until tolerating oral ingestion"
1797003|NCT00562835|Other|Normal saline intravenously and vitamin B1 per os|Patients in this group will receive sterile normal saline in an amount that would equal the total diluted dose of study drug (ie. if initial loading dose equals a total of 25 cc [prednisolone + diluting fluid], then the patient will receive 25 cc of sterile normal saline). Tapering doses will be equivalent to that of the study arm. Five days after the patient is able to ingest medications, placebo is administered per os in one single daily equivalent dose. The placebo will be a Vitamin B1 (thiamine) 50-mg tablet. We will now designate each placebo tab as a 16-mg equivalent to each tablet of active drug. These tablets are scored and half tabs can be given if needed. Therefore if a patient is receiving 40 mg of study drug: 40/16 = 2.5 tabs x 50 mg = 125 mg actual dose of thiamine.
1797004|NCT00562848|Drug|GSK962040|GSK962040 will be supplied in the following tablet strengths: 1 milligram, 5m milligrams, 25 milligrams, 125 milligrams.
1797005|NCT00562848|Drug|Placebo|Subjects will receive placebo.
1797006|NCT00562861|Drug|citalopram + mood stabilizer|Citalopram dose will be flexibly designed, beginning at 10 mg/d for at least one week, and the increased by 10 mg per week to a maximum of 50 mg/d. No target dose will be provided but rather clinicians will dose to clinical efficacy. Thus the study will provide clinicians data on the effective dose if it is positive. The dose will not be predetermined at static amounts.
1797007|NCT00562861|Drug|placebo + mood stabilizer|This arm will only receive mood stabilizing medication. All subjects will be required to receive treatment with lithium, lamotrigine, valproate, or carbamazepine for at least one month at therapeutic blood levels or doses before randomization, or they must initiate one of these agents at study entry.
1797008|NCT00562874|Dietary Supplement|Meat Biscuit|75 women and one of their children will receive a biscuit containing dried meat as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
1797009|NCT00562874|Dietary Supplement|Soy Biscuit|75 women and one of their children will receive a biscuit containing soy four as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 21 grams of protein per day and children will receive 350 calories and 14 grams of protein per day.
1797010|NCT00562874|Dietary Supplement|Wheat Biscuit|75 women and one of their children will receive a biscuit containing only wheat lour as a source of protein as an ingredient for 5 days each week for 12 months. Women will receive 525 calories and 8 grams of protein per day and children will receive 350 calories and 5 grams of protein per day.
1797011|NCT00562887|Biological|Placebo|every 4 weeks, IV
1797012|NCT00562887|Biological|ABT-874|400 mg IV every 4 weeks
1797013|NCT00562887|Biological|ABT-874|700 mg IV every 4 weeks
1797014|NCT00562900|Procedure|robotic assisted cholecystectomy|robotic assisted cholecystectomy
1797015|NCT00562900|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
1797016|NCT00562913|Drug|Nexavar (Sorafenib, BAY43-9006)|Cyclophosphamide plus 400 mg BID sorafenib and doxorubicin
1797017|NCT00562926|Procedure|Extraction of 10ml blood sample for extraction of genomic DNA using DNA purification kits|
1797018|NCT00562939|Biological|Pneumococcal vaccines + CPG 7909|Day 0: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 90: 1 ml Prevenar (double dose) + 1 mg CpG 7909, IM Day 270: 0.5 ml Pneumo Novum + 1 mg CpG 7909, IM
1797019|NCT00562939|Biological|Pneumococcal vaccines|Day 0: 1 ml Prevenar (double dose) + placebo, IM Day 90: 1 ml Prevenar (double dose) + placebo, IM Day 270: 0.5 ml Pneumo Novum + placebo, IM
1797020|NCT00562952|Drug|Telmisartan, Bisoprolol|Dosage will be given dependent on the NT-pro-BNP levels. Up-titration will be performed until values are decreased to 50% or below normal cut-point
1797021|NCT00562952|Drug|placebo|no intervention
1957449|NCT02391116|Drug|Copanlisib (BAY80-6946)|Starting dose: 60 mg (Dose reduction due to toxicities to 45 mg is allowed.), will be administered as a slow bolus IV injection on Days 1, 8 and 15 of each 28-day treatment cycle till patient disease progression is observed or patient withdraw treatment for any reason
1957453|NCT02384096|Device|Conventional single source programming|Precision Spectra SCS System using conventional single source programming.
1957454|NCT02384096|Device|Precision Spectra SCS System advanced programming|Precision Spectra SCS System using advanced programming
1957455|NCT02384941|Drug|Sotagliflozin|High dose Sotagliflozin, once daily, before the first meal of the day
1797031|NCT00562978|Biological|filgrastim|
1797032|NCT00562978|Drug|cyclophosphamide|
1797033|NCT00562978|Drug|etoposide|
1797034|NCT00562978|Procedure|autologous hematopoietic stem cell transplantation|
1797035|NCT00562978|Procedure|peripheral blood stem cell transplantation|
1797036|NCT00562978|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1797037|NCT00562991|Device|measurement of exhaled NO is used to guide treatment|exhaled NO
1797038|NCT00563004|Dietary Supplement|DBCARE|Patients receive dbcare 2 tablets TID for 3 months
1797039|NCT00563004|Dietary Supplement|DBCARE|PLACEBO PILLS 2 TABLETS TID FOR 3 MONTHS
1797040|NCT00563017|Drug|Long-acting Risperidone microspheres injection|
1797041|NCT00563043|Procedure|PASCAL laser treatment|Patterns Scan Laser treatment in patients with PDR.
1797042|NCT00563056|Drug|Flutiform|
1797043|NCT00563056|Drug|Flixotide plus Foradil|
1797044|NCT00563069|Drug|Midazolam|
1797045|NCT00563095|Procedure|Transcatheter Arterial Chemoembolization (TACE)|
1797046|NCT00563095|Procedure|Transcatheter Arterial Pegylated Interferon Embolization (TAIE)|
1797047|NCT00563108|Drug|Basiliximab|
1797048|NCT00563108|Drug|Placebo|
1797049|NCT00563121|Procedure|Vitrectomy|Open-Sky vitrectomy, with resection of the tunica vasculosa lentis, and retinal reattachment
1797050|NCT00563134|Drug|GR270774|
1797051|NCT00563147|Drug|tivozanib (AV-951) plus temsirolimus|ascending doses of tivozanib (AV-951) capsules administered orally for 21 days with discontinuation for 7 days; ascending doses of temsirolimus administered intravenously every 7 days
1797052|NCT00563160|Drug|gemcitabine, carboplatin|
1797053|NCT00563160|Procedure|surgery|
1797054|NCT00563173|Drug|CHRONVAC-C®|DNA vaccine, solution for injection, i.m. administration in combination with electroporation
1957456|NCT02384941|Drug|Sotagliflozin|Low dose Sotagliflozin,once daily, before the first meal of the day
1797056|NCT00563199|Behavioral|nurse-delivered stage-matched smoking cessation counseling|
1797057|NCT00563212|Drug|aerosol interferon-gamma|aerosol interferon-gamma-1b 100mcg given via nebulizer three times weekly for one year
1797058|NCT00563225|Drug|Insulin Glargine|Insulin glargine at the discretion of the investigator Subcutaneous, once daily injection (at bedtime)
1797059|NCT00563238|Drug|Metoprolol|Metoprolol administered intravenously in 2.5mg boluses until the resting heart rate falls by 10% from baseline to a maximum dose of 10mg, or until there is any apparent adverse reaction.
1797060|NCT00563251|Drug|Azithromycin|
1797061|NCT00563251|Drug|Placebo tablet|
1797062|NCT00563264|Behavioral|KAN-DO|"The 10 month KAN-DO intervention includes eight mailed interactive activity modules involving both the preschooler and mother that include relevant printed materials emphasizing parenting skills, healthy eating habits and increased physical activity. Mailed kits will each be followed by a supportive telephone counseling session based on motivational interviewing techniques. Mailed modules and telephone calls will be supplemented with two in-person motivational and informational sessions (at the beginning and in the middle of the intervention period).
The Active Comparator group will receive monthly newsletters over the 10 month period related to boosting reading skills in their preschool children."
1797063|NCT00563277|Procedure|combined pterygium and cataract operation|
1797064|NCT00563277|Procedure|pterygium excision followed by cataract operation|
1797065|NCT00563290|Drug|dasatinib|Given PO
1797066|NCT00563290|Other|laboratory biomarker analysis|Correlative studies
1797067|NCT00563303|Drug|hydrocortisone|200mg/jour (solution of 48mL), Day 1 to Day 4 100mg/jour (solution of 48mL), Day 5 50mg/jour (solution of 48mL), Day 6
1797068|NCT00563303|Drug|NaCl|48mL from Day 1 to Day 6
1797069|NCT00563316|Drug|Panitumumab|The first infusion of panitumumab will occur on Cycle 1 Day 4. On Cycle 2 Day 1, panitumumab will be administered on the same day as irinotecan and every 2 weeks thereafter.
1797070|NCT00563316|Drug|Irinotecan|The first infusion of irinotecan will occur on Cycle 1 Day 1. Irinotecan will be administered on the same day as panitumumab on Cycle 2 Day 1 and every 2 weeks thereafter.
1797071|NCT00563329|Procedure|Reduction Intervention + Adherence Intervention|
1797072|NCT00563329|Behavioral|Reduction Intervention|
1797073|NCT00563329|Procedure|control|
1797074|NCT00563342|Drug|Ethanol|Examine the risk of catheter dysfunction during the dialysis session that follows the instillation of ethanol 60% as lock solution in tunneled silicone catheters of end stage renal failure patients treated by hemodialysis
1797075|NCT00563355|Drug|erythropoietin|
1797076|NCT00563368|Drug|VI-0521|phentermine 15 mg and topiramate 92 mg, po once daily
1797077|NCT00563368|Drug|VI-0521|phentermine 7.5 mg and topiramate 46 mg, po once daily
1797078|NCT00563368|Drug|topiramate|topiramate 46 mg, po once daily
1797079|NCT00563368|Drug|topiramate|topiramate 92 mg, po once daily
1797080|NCT00563368|Drug|phentermine|phentermine 7.5 mg, po once daily
1797081|NCT00563368|Drug|phentermine|phentermine 15 mg, po once daily
1797082|NCT00563368|Drug|VI-0521|placebo, po once daily
1797083|NCT00563381|Drug|Tiotropium bromide|18 mcg/daily
1797084|NCT00563381|Drug|Salmeterol|100 mcg/daily
1797085|NCT00563381|Drug|Placebo Salmeterol|Placebo identical to Salmeterol device
1797086|NCT00563381|Drug|Placebo Tiotropium|Placebo identical to Tiotropium device
1797087|NCT00563394|Drug|ofloxacin|400 mg twice a day for 14 days
1797088|NCT00563394|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
1797089|NCT00563420|Procedure|Bronchoscopy|
1797090|NCT00563433|Drug|ofloxacin|400 mg twice a day for 14 days
1797091|NCT00563433|Drug|MSI-78|1%/2% topical cream twice a day for 14 days
1797092|NCT00563446|Drug|Darbepoetin alfa|
1797093|NCT00563459|Drug|carisbamate|400-1200 mg/day for 12 months
1797095|NCT00563459|Drug|levetiracetam|1000-3000mg/day for 12 months
1797096|NCT00563472|Drug|estetrol|10 mg orally per day for 28 days
1797097|NCT00563472|Drug|estetrol|20 mg orally per day for 28 days
1797098|NCT00563472|Drug|estetrol and desogestrel|20 mg estetrol and 150 microg desogestrel orally per day for 28 days
1797099|NCT00563472|Drug|estetrol and progesterone|20 mg estetrol and 200 mg progesterone orally per day for 28 days
1797100|NCT00563485|Drug|Doxazosin GITS (Cardura XL)|
1797101|NCT00563485|Drug|Terazosin (Hytrin)|
1797102|NCT00563498|Drug|Glutamine|
1797103|NCT00563511|Procedure|adherence intervention|
1797104|NCT00563511|Procedure|intervention without adherence advice|
1797105|NCT00563511|Procedure|control|
1797106|NCT00563524|Drug|ILV-094|SC and IV administration on days 1, 14, 28, and 42
1797107|NCT00563537|Radiation|18F-X PET SCAN|18F-X PET Scan : Injection of 7.8 mSv for 370 MBq of dose (0.021 mSv / MBq)
1797108|NCT00563563|Drug|NB32|All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
1797109|NCT00563563|Behavioral|Ancillary therapy|During the study, subjects will receive ancillary therapy including counseling on smoking cessation, diet and exercise.
1797110|NCT00563576|Drug|Femring®|"Estrogen vaginal ring (100 mcg) placed for the first 90 days of Depo-Provera use.
Femring® (estradiol acetate vaginal ring) is a flexible off-white ring designed for vaginal insertion with measurements that include an outer diameter of 56 mm, cross-sectional diameter of 7.6 mm, and core diameter of 2 mm. Femring® 0.1 mg/day has a central core containing 24.8 mg of estradiol acetate which releases at a rate equivalent to 0.1 mg of estradiol per day for 3 months."
1797111|NCT00563576|Drug|DepoProvera ®|Medroxyprogesterone intramuscular injection comes as a suspension (liquid) to be injected into the buttocks or upper arm. It is usually given once every 3 months (13 weeks), and the recommended dose is 150 mg.
1797112|NCT00563589|Drug|mycophenolate mofetil, methotrexate, cyclosporin|
1797113|NCT00563589|Drug|Methotrexate and cyclosporin|
1797114|NCT00563602|Other|Hemodynamic guided therapy|"To switch two or more different treatments for the prevention of variceal rebleeding according to the hemodynamic response. All patients in the experimental group will begin by:
1) LEV + Nadolol. HVPG measurement: if response, no changes, if not, switch to 2) LEV + Nadolol + MNI. HVPG measurement: if response, no changes, if not, switch to: 3) LEV + Nadolol + Prazosin. (drugs carefully titrated until achieve maximum tolerated dose)"
1797115|NCT00563615|Drug|Tegaserod|
1797116|NCT00563628|Device|Panretinal photocoagulation with PASCAL system|Use the PASCAL laser system to deliver a retina photocoagulation
1797117|NCT00563641|Other|Very early surfactant and bubble NCPAP|For patients randomized to early NCPAP plus surfactant, 4ml/kg of surfactant were administered through an endotracheal tube in two aliquots, 2 minutes apart followed by positive pressure ventilation administered for one minute with a Neopuff Infant Resuscitator pre-set to give a peak pressure of 20 cm H2O and 5 cm H2O of positive end expiratory pressure. Infant was then extubated and placed on NCPAP of 6 cmH2O
1797118|NCT00563641|Other|bubble NCPAP|"Premature infants randomized to bubble NCPAP alone will continue on NCPAP until they reach yes or no treatment failure criteria."
1797119|NCT00563654|Drug|Alfuzosin GITS (Xatral XL)|
1797120|NCT00563667|Procedure|pterygium excision|
1797121|NCT00563680|Drug|AMG 479|AMG 479 is a fully human monoclonal antibody (IgG1) against the insulin-like growth factor receptor-1 (IGF-1R). IGF-1R signaling has been shown to play a critical role in the survival of cancer cells. AMG 479 inhibits the binding of both IGF-1 and IGF-2 to IGF-1R, thus inhibiting ligand‑dependent receptor activation. Inhibition of IGF-1R signaling with AMG 479 provides a potential mechanism for inhibiting tumor growth and survival.
1797122|NCT00563693|Device|ASV|Adaptive servo ventilator
1797123|NCT00563693|Other|without Autoset CS2|without Autoset CS2
1797124|NCT00563706|Drug|vabicaserin|This study will utilize a randomized, double-blind, placebo-controlled, comparator-referenced, multicenter, parallel-group adaptive design with placebo, risperidone (4 mg/day), and up to 7 treatment arms of vabicaserin (50, 100, 150, 200, 300, 400 and 600 mg/day) over the course of the study
1797125|NCT00563706|Drug|risperidone|
1797126|NCT00563706|Other|placebo|
1797127|NCT00563732|Drug|Lecozotan|
1797128|NCT00563745|Device|telemedicine program|One year TM with continuous (h 24) on call accessibility to a nurse and/or a pulmonologist, a web-based call centre and a pulse oxymetry tracing will be provided.
1797129|NCT00563758|Drug|tegaserod|
1797130|NCT00563771|Drug|Rasburicase|
1797131|NCT00563784|Drug|Erlotinib|150 mg by mouth daily for 7 Weeks
1797132|NCT00563784|Drug|Carboplatin|2 AUC by vein weekly for 7 Weeks
1797133|NCT00563784|Drug|Paclitaxel|45 mg/m^2 by vein weekly for 7 Weeks
1797134|NCT00563784|Radiation|Radiation Therapy|63 GY/35 fractions for 7 weeks (+/- 5 days)
1797135|NCT00563797|Drug|Mecamylamine|mecamylamine 10mg/day for 12 weeks
1797136|NCT00563797|Drug|Placebo|Placebo pill
1797137|NCT00563810|Drug|MYO-029|
1797138|NCT00563823|Drug|vatalanib|
1797139|NCT00563836|Drug|Catumaxomab|10 µg Catumaxomab intraoperatively and 4 ascending doses (10, 20, 50 and 150 µg) on day 7, 10, 13 and 16
1797140|NCT00563849|Drug|Leflunomide|concomitantly leflunomide (no loading dose, 10 mg/day) and methotrexate (starting at 7.5 mg/week and titrating up to 15 mg/week) for 20 weeks.
1797141|NCT00563862|Procedure|Conventional RT|
1797142|NCT00563862|Procedure|Accelerated RT|
1797143|NCT00563862|Drug|Cisplatin|
1797144|NCT00563862|Drug|5-fluorouracil|
1797145|NCT00563875|Drug|acetylsalicylic acid|75 mg/d for 7 days (healthy volunteers) and continued treatment with 75 mg/d in patients taking daily aspirin.
1797146|NCT00563888|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
1797147|NCT00563914|Drug|ferroquine (SSR97193)|associated with artesunate
1797148|NCT00563914|Drug|amodiaquine|associated with artesunate
1797149|NCT00563927|Procedure|Conventional RT|
1797150|NCT00563927|Drug|Cisplatin|
1797151|NCT00563927|Drug|5-fluorouracil|
1957457|NCT02384941|Drug|Placebo|Placebo, once daily, before the first meal of the day
1797153|NCT00563979|Dietary Supplement|VitaluxPlus®|1 tablet daily
1797154|NCT00563979|Dietary Supplement|Omega 3|1 tablet daily
1797155|NCT00563992|Drug|Lithium|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
1797156|NCT00563992|Drug|Valproic acid|Participants may also be required to take the antidepressant paroxetine and/or the medication olanzapine for a portion of the study.
1797157|NCT00564005|Other|Constraint-induced therapy (CIT)|restraint of the unaffected arm and practice of the affected arm
1797158|NCT00564005|Other|Bilateral arm training (BAT)|bilateral symmetric, repetitive arm training
1797159|NCT00564005|Other|Combined therapy (CT)|combined different treatment approaches
1797160|NCT00564005|Behavioral|Control intervention|Conventional treatment program
1797161|NCT00564018|Drug|Insulin detemir|Dosage adjusted to meet age-specific glycemic goals throughout course of study.
1797162|NCT00564018|Drug|Glargine|Dosage to be adjusted to meet age-specific glycemic goals throughout course of study.
1797163|NCT00564018|Drug|NPH|Dosage to be adjusted to meet age specific glycemic goals throughout course of study.
1797164|NCT00564031|Drug|Femanest|2mg/day
1797165|NCT00564031|Drug|gestapuran|5mg/day
1797166|NCT00564031|Drug|placebo|daily
1797167|NCT00564031|Drug|Femanest plus Gestapuran|combined daily
1797168|NCT00564044|Procedure|excision of the protruding mesh and its surrounding vaginal tissue|A piece of vaginal tissue 12mm*5mm*3mm in sized (for control group) and another piece of vaginal tissue combined with protruding mesh of the same size (for study group) will be obtained respectively for each of the two arms during intervention.
1797169|NCT00564057|Drug|candesartan|tablet 8-16 mg once daily, one year
1797170|NCT00564057|Drug|lercanidipine|tablets 10-20 mg once daily, one year
1797173|NCT00564083|Procedure|sacral colpopexy|This surgery involves supporting the prolapsed vaginal wall with a piece of material (known as a graft) attached to a ligament along your backbone (or sacrum)
1797174|NCT00564096|Device|DEEP TMS H1 coil|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
1797175|NCT00564096|Device|Deep H1 coil TMS|"A new coil (H-coil invented in Weizmann Institute of Science, Neurobiology Department, Rehovot, Israel) capable of stimulating more than twice this depth (Up to 5 cm) was recently developed and hence will be called deep TMS."
1797176|NCT00564109|Procedure|retrospective Observation|retrospective Observation
1797177|NCT00564122|Device|Artificially-Intelligent Stethoscope|After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
1797178|NCT00564122|Other|Physical Examination|A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
1797179|NCT00564135|Procedure|on Foley time|A-no Foley B-remove Foley at 7AM in the morning of postoperative day 1 C-remove Foley at 7AM in the morning of postoperative day 2
1797180|NCT00564148|Drug|Avastin|2,5 mg Avastin intravitreal injections every 4 weeks, 6 months consecutively
1797181|NCT00564174|Drug|Low molecular weight heparin and low dose aspirin|Fragmin 5000 IU/day by subcutaneous injection started at time of randomization and continued until 35 weeks gestation or delivery and low dose aspirin 81 mg/day started pre-conception and continued until 35 weeks gestation or delivery
1797182|NCT00564174|Drug|Low dose aspirin|81 mg enteric coated started pre-pregnancy and discontinued at 35 weeks or delivery
1797183|NCT00564187|Drug|Irbesartan|"Irbesartan: 150mg tablets
Dosage: Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:
• 150mg/day for normalized patients and patients responding non normalized randomized in the group A"
1797184|NCT00564187|Drug|Irbesartan|"Irbesartan: 150mg tablets
Until 6 weeks: 150mg/day, then a dosage adjustment according to the blood pressure(normalized: DBP<90mmHg, responding non normalized:DBP≥90mmHg and a decrease of DBP≥10mmHg, non responding: decrease of DBP<10mmHg and DBP≥90mmHg) for the period between 6 and 12 weeks:
• Or 300 mg/day for non responding patients and responding patients non normalized randomized in the group B"
1797185|NCT00564200|Drug|Bortezomib|"PREACONDICIONAMIENTO:
2 cycles of 21 days : Velcade days: 1, 4, 8 and 11
1 cycle of 13 days : Velcade days 1, 4, 8 and 11
ACONDICIONAMIENTO:
- Day -2: Velcade
POSTRANSPLANTATION:
2 cycles of 21 days : Velcade days 1, 8 and 15
5 cycles of 56 days : Velcade days 1, 8 and 15"
1797186|NCT00564200|Drug|dexamethasone|"PREACONDICIONAMIENTO:
- 2 cycles of 21 days : Dexamethasone: days 1-4 and 8-11"
1797187|NCT00564200|Drug|Fludarabine|"ACONDICIONAMIENTO:
- Days -9 al -5: Fludarabine"
1797188|NCT00564200|Drug|Melphalan|"ACONDICIONAMIENTO:
- Days -4 and -3: Melphalan."
1797189|NCT00564213|Drug|PRK and a single intraoperative topical application of mitomycin C 0.02% for 15 seconds|Mitomycin 0.02%
1797190|NCT00564226|Drug|SSR240600C|oral administration
1797191|NCT00564226|Drug|tolterodine|oral administration
1797192|NCT00564226|Drug|placebo|oral administration
1797193|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions, 8 parent group sessions
1797194|NCT00564239|Behavioral|Cognitive Behavioral Group Therapy|12 children group sessions
1797397|NCT00558246|Device|Suture|Topical Suturing
1957463|NCT02383368|Drug|ASP4132|oral
1797195|NCT00564252|Drug|topical finasteride|0.2%topical(cream)finasteride twice a day for six months
1797196|NCT00564265|Other|Observation|Not applied
1797197|NCT00564278|Drug|Standard antidepressant therapy (SADT)|Treatment with medication will follow the Texas Medication Algorithm (TMA) for Depression. Antidepressant medications may include the following: citalopram (Celexa), escitalopram (Lexapro), paroxetine (Paxil CR), sertraline (Zoloft), venlafaxine XR (Effexor XR), bupropion SR (Wellbutrin SR), duloxetine (Cymbalta), nortriptyline (Pamelor), and mirtazapine (Remeron).
1797198|NCT00564278|Behavioral|Motivational antidepressant therapy (MADT)|The same medication treatment for depression will be offered and supplemented with techniques from motivational interviewing.
1797199|NCT00564291|Other|Examination with an OCT device|
1797200|NCT00564317|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
1797201|NCT00564317|Behavioral|Meditation/Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
1797202|NCT00556816|Behavioral|on demand clinic|Outpatient on demand clinic
1797203|NCT00556816|Behavioral|Control|conventional outpatient clinic
1797204|NCT00556842|Device|Total hip arthroplasty|Proscribed approaches will include minimally invasive total hip arthroplasty (i.e., two incision approaches) and hinged prostheses or capture cups. Other surgical approach aspects, the use of cemented components, the implant manufacturer, and femoral head size will not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
1797205|NCT00556842|Device|Hemi-arthroplasty|Surgeons will use modern implants for hemi-arthroplasty, excluding non-modular, non-canal filling unipolar implants such as Moore's and Thompson's prostheses. The choice of modular unipolar versus bipolar hemi-arthroplasty will not be standardized. Whether implants are inserted with cement or a press-fit design will also not be standardized. Surgeons will use the manufacturers' specific implant guidelines for insertion.
1797206|NCT00556855|Other|E-DO|topical lotion, once daily (evening), total duration: 4 weeks
1797207|NCT00556855|Other|Placebo|topical lotion, once daily (evening), total duration: 4 weeks
1797208|NCT00556868|Other|Breakfast/no breakfast|"A: Breakfast on the first day of intervention. Fasting (no breakfast) on the second day of intervention.
B: Breakfast on the second day of intervention. Fasting (no breakfast) on the first day of intervention"
1797209|NCT00556894|Drug|CF101|orally q12h
1797210|NCT00556907|Radiation|Intraoperative radiotherapy|20Gy to surface of tumor bed and 5Gy at depth of 1cm from surface of tumor bed
1797211|NCT00556907|Device|Intraoperative radiotherapy|20gy to tumor bed, 5gy at depth of 1cm from surface of tumor bed
1797212|NCT00556920|Drug|COREG CR|
1797213|NCT00556933|Drug|rabbit anti-thymocyte globulin|A single 6 mg/kg dose of rATG administered intravenously over 24 hours, beginning before kidney transplantation. Administration of the drug is begun as early as practical, usually after general anesthesia has been established but before surgery has started. The rATG is therefore administered for about two hours before blood flow is restored to the kidney undergoing transplantation.
1797214|NCT00556933|Drug|mycophenolate mofetil|Patients are switched approximately 6 months after kidney transplantation from maintenance immunosuppression with tacrolimus and sirolimus to maintenance with mycophenolate mofetil and sirolimus. The drug is administered orally, taken daily, with dose adjusted in proportion to measured blood levels, and is required indefinitely to prevent rejection of the transplanted kidney.
1797215|NCT00556933|Drug|rabbit anti-thymocyte globulin|6 mg/kg rabbit anti-thymocyte globulin delivered in 4 doses of 1.5 mg/kg each, the first administered at the time of kidney transplantation. Subsequent doses are administered on days 2, 4, and 6.
1797216|NCT00556933|Drug|sirolimus|Oral maintenance immunosuppressant administered daily, dose adjusted according to measured serum trough levels, continued indefinitely to prevent kidney rejection
1797217|NCT00556933|Drug|tacrolimus|Oral maintenance immunosuppressant, taken daily, dose adjusted to maintain target blood trough levels, required indefinitely to prevent kidney rejection.
1797218|NCT00556946|Drug|Combined Photodynamic & Pulsed Dye Laser Treatment|Treatment of Port Wine Stains using Combined Photodynamic and Pulsed Dye Laser
1797219|NCT00556959|Drug|high dose clonidine HCl sustained release|high dose clonidine HCl sustained release tablets for 8 weeks
1797220|NCT00556959|Drug|low dose clonidine HCl sustained release|low dose clonidine HCl sustained release tablets for 8 weeks
1797221|NCT00556959|Drug|placebo|placebo tablets for 8 weeks
1797222|NCT00556972|Device|Fecal Incontinence Management System|The device is intended to remedy fecal incontinence.
1797223|NCT00556998|Drug|Voriconazole|Voriconazole will be used for prophylaxis purpose. 6 mg/kg IV q12h on the first day (Day 1) and 4 mg/kg IV q12h for at least 5.5 days. The IV treatment is no more than 20 days. Then switch to 300 mg oral tablets q12h for at least 6.5 days. The total treatment duration is no more than 30 days.
1797224|NCT00557011|Drug|NRP104|30 mg, 50 mg or 70 mg capsules taken orally once daily in the morning
1797225|NCT00557011|Drug|Adderall XR|10 mg capsules taken once daily in the morning at dosages of either 1x10mg, 2x10mg or 3x10mg
1797226|NCT00557011|Drug|Placebo|Placebo capsule taken once daily in the morning
1797227|NCT00557024|Procedure|RFA|radiofrequency ablation
1797228|NCT00557024|Procedure|radiotherapy after RFA|radiotherapy after RFA
1797229|NCT00557037|Drug|Phenoxodiol|Oral capsule, 400 mg every 8 hours daily, for 12 weeks - assement to a maximum of 12 months
1797230|NCT00557050|Other|Training|10-week eccentric hamstring muscle training
1797231|NCT00557076|Behavioral|Familiar Voice Stimulation High Dose|The High Dose intervention is 1,680 minutes of Familiar Vocal Stimulation (FVs) provided in 40 minute daily segments at least 2 hours apart and for 6 weeks. Four CDs with 10 minutes of FVs preceded by the familiar voice calling out the subject's name, will be played (1 at a time) each day for 6 weeks providing 1,680 minutes of FVs.
1797232|NCT00557076|Behavioral|Sham Auditory Stimulation|The sham intervention is zero minutes of Familiar Voice Stimulation. Each day for 6 weeks 0 minutes of Familiar voice stimulation will be provided in 10 minute daily segments for 6 weeks. Each 10 minute recording is a digital recording of silence.
1797233|NCT00557089|Drug|rhDNAse|2.5 mg rhDNase will be dispensed in 2.5 ml vials and administered once a day for 28 days. Treatment will be administered by inhalation.
1797234|NCT00557089|Other|Placebo|2.5 mg of the placebo will be dispensed in 2.5 ml vials and administered once a day over 28 days. Treatment will be administered by inhalation.
1797235|NCT00557102|Biological|cetuximab|
1797236|NCT00557102|Biological|filgrastim|
1797237|NCT00557102|Drug|fluorouracil|
1797238|NCT00557102|Drug|irinotecan hydrochloride|
1797239|NCT00557102|Drug|leucovorin calcium|
1797240|NCT00557115|Other|Early pulmonary rehabilitation (EPR)|Multidisciplinary exercise programme in the format of standard pulmonary rehabilitation. Consists of 2 supervised exercise and educations sessions per week for up to 16 sessions within 3-months. Participants are encouraged to keep an exercise diary at perform at least one exercise session at home unsupervised.
1797241|NCT00557128|Drug|COREG CR and lisinopril (FDC)|
1797242|NCT00557154|Device|ultrasound|ultrasound used to identify target vein
1797243|NCT00557154|Device|standard technique for venipuncture|routine equipment
1797244|NCT00557180|Drug|Beclomethasone dipropionate HFA|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
1797245|NCT00557180|Drug|Tiotropium bromide|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
1797246|NCT00557180|Drug|Salmeterol xinafoate|Participants will receive the BASALT and TALC study drugs as determined in those protocols NCT00495157, NCT00565266. This study is ancillary to those trials and observational only and does not have any control over study drug allocation
1797247|NCT00557193|Drug|vincristine sulfate|Given IV
1797248|NCT00557193|Drug|daunorubicin hydrochloride|Given IV
1797249|NCT00557193|Drug|cyclophosphamide|Given IV
1797250|NCT00557193|Drug|pegaspargase|Given IM
1797251|NCT00557193|Drug|asparaginase|Given IV, IM, or PO
1797252|NCT00557193|Drug|prednisone|Given PO
1797253|NCT00557193|Drug|methylprednisolone|Given IV
1797254|NCT00557193|Drug|dexamethasone|Given IV or PO
1797255|NCT00557193|Drug|cytarabine|Given IV or IT
1797256|NCT00557193|Drug|methotrexate|Given IV, IT, or PO
1797257|NCT00557193|Drug|therapeutic hydrocortisone|Given IT
1797258|NCT00557193|Biological|filgrastim|Given IV or SC
1797259|NCT00557193|Drug|leucovorin calcium|Given IV
1797260|NCT00557193|Drug|etoposide|Given IV
1797261|NCT00557193|Drug|mercaptopurine|Given PO
1797262|NCT00557193|Drug|lestaurtinib|Given PO
1797263|NCT00557193|Other|laboratory biomarker analysis|Correlative studies
1797264|NCT00557193|Other|pharmacological study|Correlative studies
1797265|NCT00557206|Drug|Oxaliplatin and Docetaxel|"Chemotherapy
Oxaliplatin 130mg/m2 on day 1; and Docetaxel 75mg/m2 on day 1; every 21 days."
1797266|NCT00557219|Drug|fenoldopam (Corlopam)|continuous intravenous infusion of 0.3 μg/kg/min fenoldopam for 24 hours
1797267|NCT00557219|Drug|placebo|continuous intravenous infusion of 2 mL/hour of 0.9% natrium chloride solution for 24 hours
1797268|NCT00557219|Drug|ketanserin (Sufrexal)|continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours
1797269|NCT00557232|Drug|bevacizumab|1.25mg/month
1797270|NCT00557245|Drug|Tenofovir Disoproxil Fumarate (TDF)|TDF 300 mg tablet, once daily + Placebo FTC/TDF orally, once daily.
1797271|NCT00557245|Drug|Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF)|FTC/TDF - 200 mg tablet, once daily + Placebo TDF orally, once daily
1797272|NCT00557245|Drug|Placebo|Placebo TDF & Placebo FTC/TDF, 1 tablet each daily.
1797273|NCT00557284|Drug|Montelukast|4 mg oral granules for ages 12 - 23 months; 4 mg chewable tablet for 2 - 5 years of age; or 5 mg chewable tablet for 6 - 8 years of of age
1797274|NCT00557284|Drug|Placebo|Oral granules or chewable tablet, PO QD (given oral daily)
1797275|NCT00557310|Drug|teriparatide|20 mcg teriparatide subcutaneous injection per day for 18 months, with possibility to continue for 24 months
1797276|NCT00557323|Drug|Lanthanum carbonate|
1797277|NCT00557336|Drug|somatropin|
1797278|NCT00557349|Drug|Omeprazole|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
1797279|NCT00557349|Drug|Famotidine|40mg dose administered as a suspension or capsule as physician directs daily at bedtime for 14 weeks beginning day of hospital discharge following gastric bypass surgery.
1797280|NCT00557362|Drug|Natamycin 5%|One drop of medication will be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake
1797281|NCT00557362|Drug|Voriconazole|"Voriconazole (VFEND® I.V., Pfizer, New York, NY) will be prepared as a 1% solution.
One drop of medication should be given every one hour while awake for one week. For another 2 weeks, one drop of medication should be given every 2 hours while awake"
1797282|NCT00557362|Procedure|Corneal de-epithelialization|Corneal de-epithelialization at 1 week and 2 weeks from enrollment to increase epithelial penetration of antifungal medications.
1797283|NCT00557388|Dietary Supplement|Protein/Amino Acids|Casein Whey Leucine
1797284|NCT00557388|Other|Physical exercise|The physical exercise protocol will consist of low intensity cycling and light resistance-type exercise; after 5 minutes of self-paced cycling, subjects will perform 6 sets of 10 repetitions on the horizontal leg press machine (Technogym BV, Rotterdam, The Netherlands) and 6 sets of 10 repetitions on the leg extension machine (Technogym BV, Rotterdam, The Netherlands). The first 2 sets of both resistance exercises will be performed at 40% of the subjects' 1RM. Sets 3-4, and 5-6 will be performed at 55% and 75% of 1RM, respectively, with 2 minutes rest intervals between sets.
1797285|NCT00557401|Drug|XP19986 SR3, 20 mg QD|XP19986 Sustained Release (SR) 20 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
1797286|NCT00557401|Drug|XP19986 SR3, 40 mg QD|XP19986 Sustained Release (SR) 40 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
1797287|NCT00557401|Drug|XP19986 SR3, 60 mg QD|XP19986 Sustained Release (SR) 60 mg tablet taken orally, once daily (QD) for approximately 32 days with titration and taper periods.
1797288|NCT00557401|Drug|XP19986 SR3, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet taken orally, twice daily (BID) for approximately 32 days with titration and taper periods.
1797289|NCT00557401|Drug|Placebo|Placebo tablet taken orally for approximately 32 days with titration and taper periods.
1797290|NCT00557427|Drug|hypericum|250mg tablets twice daily for 8 weeks
1797291|NCT00557427|Drug|fluoxetine|20mg - 40mg daily for 8 weeks
1797292|NCT00557440|Drug|fluticasone propionate/salmeterol|Fluticasone propionate/salmeterol 250/50 μg twice daily delivered via MDDPI.
1797293|NCT00557440|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 500/400 μg once daily delivered via the TWISTHALER device.
1797294|NCT00557440|Drug|placebo to indacaterol/mometasone|Placebo to indacaterol maleate/mometasone furoate delivered via the TWISTHALER device.
1797295|NCT00557440|Drug|placebo to fluticasone propionate/salmeterol|Placebo to fluticasone propionate / salmeterol delivered via MDDPI.
1797296|NCT00557453|Drug|Antibiotic treatment|Cefuroxime 750mg X3/d, Ampicillin 2G X4/d, Flagyl 500mg X3/d, Augmentin 1G X3/d, Gentamycin 240mg X1/d, Clindamycin 600mg X3/d, Ciprofloxacin 400mg X2/d All drugs will be administered IV until clinical improvement.
1797297|NCT00557453|Drug|No antibiotics|Allowed medications for both groups will include PPI / H2 blockers, home medication, SC insulin for diabetes, and SC clexane if indicated.
1797298|NCT00557466|Drug|indacaterol|Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).
1797299|NCT00557466|Drug|formoterol|Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.
1797300|NCT00557466|Drug|placebo to indacaterol|Placebo TWISTHALER® device
1797301|NCT00557466|Drug|placebo to formoterol|Placebo AEROLIZER® device
1797302|NCT00557466|Drug|short acting β2- agonist|100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
1797303|NCT00557492|Drug|Avastin (bevacizumab)|10 mg/kg, days 1, 15, 29 and 43
1797304|NCT00557492|Drug|Gemzar (Gemcitabine)|On days 1, 15, and 29, subjects will receive gemcitabine 1500 mg/m2 IV over 150 minutes at the fixed-dose rate (10 mg/m2/min).
1797305|NCT00557492|Radiation|external beam radiotherapy|3 Gy/fraction utilizing a 95% isodose field over 10 consecutive weekdays, Monday to Friday, for a total of 30 Gy
1797306|NCT00557505|Drug|PF-03732010|IV infusion. Escalating dose levels, starting at 0.5 mg/kg to Maximum Tolerated Dose. Cycle length of 4 weeks for first cycle, and 2 weekly for subsequently cycles was originally explored, yet based on emerging PK data the Cycle 1 duration is 2 weeks and then weekly. Number of Cycles: Until Progression or unacceptable toxicity develops.
1797307|NCT00557518|Drug|Alagebrium|200 mg bid
1797308|NCT00557518|Drug|Placebo|bid
1797310|NCT00557544|Drug|metoclopramide|metoclopramide 0,15 mg/kg
1797311|NCT00557544|Drug|placebo|placebo per os
1797312|NCT00557544|Drug|ketoprofen|ketoprofen 1 mg/Kg
1797313|NCT00557557|Drug|Drug: 5-FU|Dose escalation (200 to 900 mg/m²) scheme, one hour isolated hepatic perfusion prior to standard treatment.
1797314|NCT00557557|Drug|Drug: Oxaliplatin|40 mg/m², one hour isolated hepatic perfusion prior to standard treatment.
1797315|NCT00557583|Drug|VBY 376|Doses of 50mg and higher or placebo will be evaluated.
1797316|NCT00557596|Drug|AEG35156|AEG35156 will be given as a 2-hour intravenous infusion once weekly, only on weeks when gemcitabine is administered, with a 2-hour loading dose given daily in the 2 days immediately prior to Day 1 (on Days -2 and -1) only in Cycle 1
1797317|NCT00557609|Drug|ARQ 197|360 mg administered twice daily until disease progression or other discontinuation criterion is met
1797318|NCT00557622|Drug|paroxetine|BRL29060A (paroxetine hydrochloride hydrate, hereafter paroxetine) administered orally over the dose range of 20 mg to 50 mg once daily after supper for 12 weeks in Japanese patients with posttraumatic stress disorder (PTSD)
1797319|NCT00557622|Other|placebo|placebo
1797320|NCT00557635|Procedure|Chirurgical procedure|Chirurgical procedure to treat pseudo-arthrosis, with of osseous matrix implantation and autologous bone marrow injection.
1797321|NCT00557648|Behavioral|Group CBT for children|CBT for children consists of 9 weekly group CBT sessions. All sessions occur in the school building during after-school hours.
1797322|NCT00557648|Behavioral|Group CBT for children plus parent training|CBT involving children and parents consists of 9 weekly group CBT sessions for the children and 9 weekly concurrent group parent training sessions.
1797323|NCT00557661|Drug|CD-NP|24 hr intravenous infusion
1797324|NCT00557700|Drug|Administration of inhaled tiotropium bromide|Administration of inhaled tiotropium bromide
1797325|NCT00557700|Drug|Administration of placebo|Administration of placebo
1797326|NCT00557713|Drug|bevacizumab|"-Induction treatment. 4 cycles (every 3 weeks) of bevacizumab (7,5mg/kg day 1) + oxaliplatin (130mg/m2 day 1) + capecitabine (1000mg/m2/12h days 1-14)
-Concomitant (CT+RT) treatment (3 weeks later): bevacizumab (5mg/kg day 1 of 1st, 3th and 5th weeks) + capecitabine (825mg/m2/12h daily during radiotherapy treatment) + radiotherapy (45Gy (25fractions of 1,8Gy/day over 5weeks) followed by boost 5.4Gy (1,8Gy/day over 3days))
-Surgery (6-8 weeks after last bevacizumab dose)
-Adjuvant treatment: It will be individual decision of each investigator, but it's recommended 4 cycles of XELOX (equal dose at induction treatment)"
1797327|NCT00557739|Drug|mometasone furoate|Topical 0.1% mometasone furoate
1797328|NCT00557739|Drug|nortriptyline HCl|Topical 0.05% or 0.1% nortriptyline HCl
1797329|NCT00557739|Drug|Vehicle (placebo)|Topical placebo
1797330|NCT00557752|Device|Non-invasive ventilation|Applied continuously for the first 24 hours, then every 24 hours, trial of discontinuation. Interface specific for the associated injuries.
1797331|NCT00557791|Drug|Bevasiranib|Three doses (1.0mg, 2.0mg, 2.5mg) of bevasiranib administered intravitreally every 8 weeks
1797332|NCT00557791|Drug|ranibizumab|Lucentis® (0.5 mg) administered intravitreally every 4 weeks.
1797333|NCT00557804|Device|MUSE clinical system|non-invasive external monitoring device
1797398|NCT00558259|Drug|dabigatran etexilate 150 mg twice daily (BID)|dabigatran etexilate capsules 150 mg BID
1797399|NCT00558259|Drug|matching placebo twice daily (BID)|Matching placebo BID
1797400|NCT00558272|Drug|AZD0530|Daily oral dose
1797401|NCT00558272|Drug|Zoledronic Acid|
1797402|NCT00564330|Drug|Esomeprazole|20mg bid
1797334|NCT00557817|Drug|Darbepoetin alpha (Aranesp)|Darbepoetin alpha (Aranesp) will be administered subcutaneously (s.c.) at the dose of 300 µg. The first dose will be given on day 28 and the following doses at 2-week intervals around days 42, 56, 70, 84, 98 and 112 post-transplant. Once the target Hb (13 g/dL) has been attained, the dose of Aranesp will be reduced by half to 150 µg. If the Hb increases to > 14 g/dL, Aranesp will be withheld and resumed at the dose of 150 µg when the Hb decreases < 13 g/dL. If the Hb decreases to < 12 g/dL, the dose of Aranesp will be increased to 300 µg again.
1797335|NCT00557817|Drug|Iron saccharate (Venofer)|Iron saccharate (Venofer) will be administered intravenously (i.v.) at the dose of 200 mg (2 vials of Venofer) on days 28, 42 and 56 after the transplant. Venofer will be diluted in 250 ml saline and infused over 60 minutes. Iron will be omitted in patients with severe iron overload (serum ferritin > 2500 µg/L in the absence of inflammation or liver necrosis) or elevated transferrin saturation (TS > 60%) between days 21 and 56. No iron supplementation will be allowed in arm 1. No iron supplementation will be allowed in arm 2 before day 70 after the transplant. In arms 2 and 3, if patients have evidence of functional iron deficiency (transferrin saturation < 20%) on day 70 or later, they will receive 300 mg of Venofer over 90 min, for a minimum of 2 doses.
1797336|NCT00557830|Drug|Sorafenib Escalated Dose|Patients randomized to Group A will receive sorafenib 600 mg bid for Weeks 5 through 8 (Dose Level 2). Patients who tolerate this dose through Week 8 will be further escalated to Dose Level 3 (800 mg po bid) for Weeks 9 through 12.
1797337|NCT00557830|Drug|Sorafenib Standard Dose|Patients randomized to Group B will receive Dose Level 1 (sorafenib 400 mg po bid) until progression of disease, intolerable toxicity, patient refusal to continue with the study, or investigator decision to remove the patient from the study.
1797340|NCT00557856|Drug|PF-03446962|To determine the maximum tolerated dose (MTD), and recommended Phase 2 dose (RP2D) of PF-03446962 administered in patients with advanced solid tumors.
1797341|NCT00557882|Device|synthetic polypropylene mesh|Mesh used will be synthetic monofilament polypropylene. In this trial, patients in the experimental group will undergo interpositional multi-armed mesh placement using trocars for transobturator +/- ischioanal fossa placement at the level of the ischial spine.
1797342|NCT00557908|Drug|VWF/FVIII products|"Participants in the prospective phase of the study undergo an escalation of treatment from receipt of one to three levels of VWD product. All subjects enrolled will begin treatment on the level one and remain on this regimen for the duration of follow-up, or until they meet the criteria for escalation to level two or three (if indeed they do meet the criteria.)
Dosing for joint bleeding, epistaxis, and GI bleeding indications: 50 U RCo/kg once per week, 50 U RCo/kg twice per week, or 50 U RCo/kg three times per week.
Dosing for menorrhagia: 50 U RCo/kg on day 1 of menses for 2 cycles, 50 U RCo/kg on days 1 and 2 of menses for 2 cycles, or 50 U RCo/kg on days 1, 2, and 3 of menses"
1797343|NCT00557921|Drug|CGT-2168 (clopidogrel 75 mg/omeprazole 20 mg) and aspirin|(CGT-2168 active and Comparator placebo, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
1797344|NCT00557921|Drug|Plavix (clopidogrel 75 mg) and aspirin|(CGT-2168 placebo and Comparator active, one capsule each daily; and enteric coated aspirin at daily dose level assigned by study physician)
1797345|NCT00557934|Other|dobutamine|dobutamine stress (10 µg/kg/min) for 10 minutes during heart catheterization
1797346|NCT00557947|Device|Suture|intradermal and topical suturing
1797347|NCT00557947|Device|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
1797348|NCT00557960|Drug|Mixed salts of a single-entity amphetamine|
1797349|NCT00557960|Drug|Atomoxetine hydrochloride|
1797350|NCT00557973|Drug|XP19986 SR1, 10 mg BID|XP19986 Sustained Release (SR) 10 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
1797351|NCT00557973|Drug|XP19986 SR1, 20 mg BID|XP19986 Sustained Release (SR) 20 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
1797352|NCT00557973|Drug|XP19986 SR1, 30 mg BID|XP19986 Sustained Release (SR) 30 mg tablet dosed orally, twice a day (BID), for approximately 26 days with titration and taper periods
1797353|NCT00557973|Drug|Placebo|Placebo tablets to match active intervention, taken twice a day (BID) for approximately 26 days with titration and taper periods. Also taken during placebo washout periods.
1797354|NCT00557986|Procedure|Primary surgery|Primary breast surgery before systemic therapy
1797355|NCT00557999|Other|Application of mechanical ventilation weaning protocol|Application protocol for 8 months in experimental group
1797356|NCT00558012|Drug|Intravenous zoledronic acid|Intravenous zoledronic acid 5.0 mg once
1797357|NCT00558012|Dietary Supplement|Vitamin D 800 IU/daily|Daily divided dose
1797358|NCT00558012|Dietary Supplement|Calcium 1200 mg/daily|supplement plus diet
1797359|NCT00558025|Drug|Pramipexole Extended Release|
1797360|NCT00558025|Drug|Pramipexole Immediate Release|
1797361|NCT00558038|Drug|AST-120|AST-120
1797362|NCT00558038|Drug|lactulose|lactulose
1797363|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 4 intradermal injections once a day for 4 days.
1797364|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of 1 intranodal injection.
1797365|NCT00558051|Biological|DC-based vaccine|Each patient will receive four courses of vaccination with 2 million tumor-loaded DCs at week 0, 4, 8, and 12. A course consists of a 4-day intralymphatic infusion.
1797366|NCT00558064|Drug|telmisartan+amlodipine|
1797367|NCT00558064|Drug|amlodipine|
1797368|NCT00558077|Drug|Metformin plus clomiphene citrate|Metformin administration will start from 3rd day of a P-induced withdrawal bleeding with a dose of 850 mg (1 tablet daily) and increasing the dosage after one week up to 1700 mg/day (two tablets daily). Clomiphene citrate CC will be administered for five days beginning on cycle day 3rd of a P-induced withdrawal bleeding using a starting dose of 50 mg daily. If ovulation will not occur, the dose will be increased by 50 mg in successive cycles until the ovulation will be achieved or up to a maximal dose of 150 mg daily.
1797369|NCT00558077|Procedure|Laparoscopic ovarian drilling|Laparoscopic ovarian drilling will be performed as follows: according to ovary size three to six punctures will be performed at each ovary inserting an insulated needle cautery of 36 mm perpendicularly as possible to the ovarian surface with a cutting current of 100 watt power. Then, the needle will be activated for 2-3 seconds at each point using a coagulating current of 40 watt power. At completion of the procedure, the ovarian surface will be washed with a crystalloid solution and all injured areas will be completely covered with hyaluronic acid gel.
1797370|NCT00558090|Drug|morphine|patients receive 7,5 mg morphine iv 30 minutes before intervention (turning of the patient), the day after admission in the ICU. before, during and after, the patient will be asked to rate the pain using the NRS
1797371|NCT00558103|Drug|lapatinib|Oral administration
1797372|NCT00558103|Drug|Pazopanib|Oral administration
1797373|NCT00558116|Device|Dynamic splinting|The Dynasplint carpal tunnel device will be worn for 30 minutes, twice daily, for 60 consecutive days.
1797374|NCT00558129|Device|X-STOP®|Surgical implantation of X-STOP IPD device
1797375|NCT00558129|Procedure|Laminectomy|Standard laminectomy techniques will be used and may include laminotomy, foraminotomy and/or laminectomy as appropriate. In some cases at the discretion of the treating physician, fusion may indicated to stabilize the segment.
1797376|NCT00558142|Drug|Acetylcysteine|Participants will receive packs of either 8 placebo capsules or 8 acetylcysteine (600mg) capsules. They will be asked to take 2 tablets at 08.00 and 22.00 on the day before the study and the day of the study. On the day of the study participants will receive an IV infusion of either normal saline or acetylcysteine (200mg/kg)
1797377|NCT00558142|Drug|Visipaque 320|100mls IV dose as single dose
1797378|NCT00558142|Drug|Visipaque 320|The dose of Visipaque will be administered by the consultant cardiologist performing the coronary angiography
1797379|NCT00558155|Drug|peptisorb|standard isocaloric eteral diet (1 ml = 1 kcal)
1797380|NCT00558155|Drug|Stresson|Oligopeptic, enteral diet (1 ml=1.25 kcal)
1797381|NCT00558155|Drug|Parenteral nutrition|Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
1797382|NCT00558155|Drug|Omegaven, Dipeptiven|Immunostimulating components: Omegaven (omega-3-fatty acids) and Dipeptiven (Glutamine Arginine) Protein requirements were covered by 10 and 15% amino acid solutions (Aminoplasmal, B Braun, Poland). Energy requirements were covered by glucose (10, 20 and 40% solutions, B Braun, Poland) and lipid emulsions (10 and 20% Lipofundin MCT/ LCT, B Braun, Poland). Addtional: Tracutil, Addamel
1797383|NCT00558181|Drug|rituximab, methylprednisolone|Subjects will receive up-to 6 courses of IV infusion of Methylprednisolone and Rituximab every 21 day.
1797384|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment with Affective and Cognitive Skills Training|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
1797385|NCT00558194|Behavioral|Standard Behavioral Weight Loss Treatment|12-month (6-month weekly, 3-month biweekly, 3-month monthly) group treatment
1797386|NCT00558207|Drug|ARQ 197|120 mg capsule administered twice daily for 240 mg total daily dose
1797387|NCT00558207|Drug|gemcitabine|1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 4 weeks for the first 28 days (cycle). Each subsequent cycle will consist of 1000 mg/m2 administered as an intravenous infusion over 30 minutes once weekly for 3 weeks with no drug administered in the 4th week.
1797388|NCT00558220|Procedure|immunotherapy|"Given together with induction chemotherapy:
Rituximab - 375 mg/m2 iv every 3 weeks, 4-6 doses"
1797389|NCT00558220|Procedure|Induction treatment part 1|"cyclophosphamide 3000 mg/m2 iv every 3 weeks, 3 cycles vincristin 2 mg iv every 3 weeks, 3 cycles doxorubicin 75 mg/m2 iv every 3 weeks, 3 cycles Prednisolone 300 mg/m2 divided into five days po every 3 weeks, 3 cycles pegfilgrastim 6 mg sc every 3 weeks.
3 cycles consisting of combination treatment of above mentioned drugs are given."
1797390|NCT00558220|Procedure|Induction treatment part 2 with PBPC collection|"Starts three weeks after last cycle of Induction part 1.
Etoposide 240 mg/m2 divided into equal doses for four days, together with methylprednisolone 2000 mg divided into equal doses for four days, together with cisplatin 100 mg/m2 divided into equal doses for four days, and together with cytarabine 2000 mg/m2 iv one dose on 4th day of treatment. Filgrastim 10-12 ug/kg from day five after start of chemotherapy untill stem cell collection.
Peripheral blood progenitor cell collection (PBPC) is started when CD34 positive cells are >20/cubic milimeter of blood and continued untill 5 million of CD34 positive cells are collected from peripheral blood."
1797391|NCT00558220|Procedure|Induction treatment part 3|"Part 3 of induction treatment is given approximately one week after the end of Part 2.
Etoposide 240 mg/m2 divided into equal doses for four days, methylprednisolone 2000 mg divided into equal doses for four days, cisplatin 100 mg/m2 divided into equal doses for four days, cytarabine 2000 mg/m2 iv one dose on day 4 of chemotherapy and pegfilgrastim 6 mg on day five of chemotherapy are given twice three weeks apart."
1797392|NCT00558220|Procedure|Consolidation treatment part 1: HD-chemotherapy with ASCT|"Consolidation treatment Part 1 starts 4-8 weeks after the second cycle of Induction treatment Part 3.
High dose chemotherapy (HD-chemotherapy) consists of:
BCNU 300 mg/m2 is given on day 1, etoposide 800 mg/m2 divided into four equal doses is given on day 2-5, cytarabine 1600 mg/m2 divided into eight equal doses is given on day 2-5, melphalan 140 mg/m2 is given on day 6.
On day 7, collected stem cells from peripheral blood (see Induction treatment part 1) are infused back to the patient. This is called autologous transplantation (ASCT). Filgrastim 5 ug/kg is given from day 14 (start of the chemotherapy being day 1) until neutrophil recovery."
1797393|NCT00558220|Radiation|Consolidation treatment part 2: Radiotherapy|Radiotherapy is started given 4-8 weeks after the autologous transplantation. It is given to patients with initially bulky disease (>10 cm at diagnosis) or to patients with residual disease after Induction treatment part 1-3 and Consolidation treatment part 1. 30-40 Gy are given in 2 Gy fractions over 3-4 weeks.
1797394|NCT00558233|Behavioral|CHOICE decision aid|computer-based patient decision aid about colorectal cancer screening delivered immediately before a healthcare provider visit
1797395|NCT00558233|Behavioral|YourMeds patient education program|computer-based patient education program about prescription drug safety seen immediately before a healthcare provider visit
1797396|NCT00558246|Device|Dermabond Protape (Prineo)|cyanoacrylate and pressure sensitive adhesive mesh - topical skin adhesive
1797403|NCT00564330|Drug|Placebo|Placebo bid
1797404|NCT00564343|Other|water based training program to improve balance|The exercise group will meet on 24 occasions over a period of 12 weeks (2 times/week), 45 minute training session.
1797405|NCT00564356|Procedure|cataract surgery with phacoemulsification|removal of cataract with phacoemulsification technique
1797406|NCT00564369|Other|CDC HIV testing recommendations|Current vs. prior CDC recommendations
1797407|NCT00564382|Procedure|Cardiac magnetic Resonance study|Routine cardiac MR study including contrast application
1797408|NCT00564395|Drug|Insulin detemir mixed with RAI injection|Insulin detemir injection and RAI injection
1797409|NCT00564408|Drug|Carbachol|3 microgram per kg bodyweight infused intravenously
1797410|NCT00564421|Drug|epinastine nasal spray, low concentration, low dose volume|2 sprays in each nostril, dosed twice a day
1797411|NCT00564421|Other|placebo nasal spray|2 sprays in each nostril, dosed twice a day
1797412|NCT00564421|Drug|epinastine nasal spray, low concentration, high dose volume|2 sprays in each nostril, dosed twice a day
1797413|NCT00564421|Drug|epinastine nasal spray, high concentration, low dose volume|2 sprays in each nostril, dosed twice a day
1797414|NCT00564421|Drug|epinastine nasal spray, high concentration, high dose volume|2 sprays in each nostril, dosed twice a day
1797415|NCT00564447|Drug|Azithromycin|azithromycin topical solution 1% given as a single drop in a single eye
1797416|NCT00564447|Drug|Moxifloxacin|Moxifloxacin topical solution given as a single drop in a single eye
1797419|NCT00564473|Behavioral|questionnaire|"questionnaire of demographic and medical data, use of and attituded toward herbal medicine.
Beck Depression Inventory-Second Edition (BDI-II)- Hebrew Translation"
1797420|NCT00564486|Drug|IV Placebo|IV, every 6 hours for 24 hours (4 doses total)
1797421|NCT00564486|Drug|IV Placebo|IV, every 4 hours for 24 hours (6 doses total)
1797422|NCT00564486|Drug|IV Acetaminophen|IV, every 6 hours for 24 hours (4 doses total)
1797423|NCT00564486|Drug|IV Acetaminophen|IV, every 4 hours for 24 hours (6 doses total)
1797424|NCT00564512|Biological|Campath|Fludarabine-Cyclophosphamide-Campath (FCCam)
1797425|NCT00564512|Biological|rituximab|Fludarabine-Cyclophosphamide-Rituximab (FCR)
1797426|NCT00564512|Drug|cyclophosphamide|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
1797427|NCT00564512|Drug|fludarabine|Fludarabine-Cyclophosphamide-Campath (FCCAM) Fludarabine-Cyclophosphamide-Rituximab (FCR)
1797428|NCT00564525|Drug|Amitriptyline|Medication taken for 4 weeks
1797429|NCT00564525|Drug|Placebo|Medication taken for 4 weeks
1797430|NCT00564538|Drug|anti-thymocyte globulin (rabbit)|1.5mg/kg per dose with the first dose initiated in the operating room prior to reperfusion of the transplanted liver. It will then be administered again on post operative day #1, 3 and 5 for a total cumulative dose of 6mg/kg.
1797431|NCT00564538|Drug|tacrolimus|Tacrolimus will be administered orally on post op day #1 as per standard of care.
1797432|NCT00564551|Behavioral|High dairy and calcium intake|High intake of low-fat milk product intake (3-4 servings per day) plus one 350 mg calcium supplement per day during 500 kcal/day deficit diet.
1797433|NCT00564551|Behavioral|Usual intake|Usual intake of low milk product intake (1 serving/day) and low calcium intake with a placebo during a 500 kcal/day deficit diet
1797436|NCT00564577|Biological|CFA/I and CS17 challenge strain|Wild type ETEC strain expressing the colonization factor CS17, and heat labile (LT) enterotoxin
1797437|NCT00564590|Drug|Melatonin|4 mg of Melatonin once a day for 3 months
1797438|NCT00564590|Other|omeprazole|omeprazole 20 mg once a day
1797439|NCT00564590|Drug|Placebo|Placebo once a day
1797440|NCT00564603|Drug|Dexamethasone Sodium Phosphate Injection|Dexamethasone, 10mg, continuously infused up to 48h after surgeries.
1797441|NCT00564603|Other|0.9% Saline|Saline, in same volume of 2mL
1797442|NCT00564616|Device|video cell phone|"the voice group received voice CPR instruction via a voice-only cell phone, and the video group received interactive voice and video instruction via a video cell phone"
1797443|NCT00564629|Drug|Intravenous acetaminophen plus oral placebo|Single dose of 1 gm IV acetaminophen
1797444|NCT00564629|Drug|Oral acetaminophen plus IV placebo|Single dose of 1 g PO APAP
1797445|NCT00564629|Biological|Reference standard endotoxin (RSE)|To subjects in both study arms: Administration of a 1 ng/kg body weight test dose of RSE to induce fever and test for fever response. Observation period of at least 60 minutes to ensure no exaggerated systemic responses, followed by administration of a 4 ng/kg of RSE to induce fever.
1797446|NCT00564642|Drug|N Acetylcysteine|1200 mg, BD, 2weeks
1797447|NCT00564655|Procedure|bupivacaine with epinephrine (mid and upper abdomen)|Patients will receive localized infiltration of local anesthesia (0.25% bupivacaine with epinephrine 1:200,000) at the beginning of the procedure as is current standard practice. Localized anaesthetic of the mid and upper abdomen.
1797448|NCT00564655|Procedure|bupivacaine with epinephrine (transversus abdominis plane)|0.6 cc/kg (to a maximum of 20 ccs) of 0.25% bupivacaine with epinephrine 1:200,000 will be injected into the neuro-vascular plane between the internal oblique and transversus abdominis muscles. Regional anaesthetic block of the transversus abdominis plane.
1797449|NCT00567606|Other|risedronate, calcium/vit D, strength weight training|G1 group receives 1200 mg of calcium and 400 IU of vitamin D supplements per day, 35 mg of risedronate per week and strength/weight training exercises for upper and lower extremities and the spine. G2 group receives the calcium, vitamin D, and risedronate, but do not participate in strength/weight training exercises.
1797450|NCT00567658|Drug|Esomeprazole|Esomeprazole or Nexium 40 mg BID is given for four months.
1957464|NCT02383225|Behavioral|Lakota Language enhancement|This intervention component includes more extensive adaptation for Lakota families, focusing on use of Lakota language specifically around relationship/kinship terms. Study arms without this component will include the same adapted intervention but with use of English language rather than Lakota.
1797453|NCT00567684|Other|Computed Tomography Urography (CTU)|CTU performed at least a day before or after the IVU procedure.
1797454|NCT00567684|Other|Intravenous Urography (IVU)|A routine IVU procedure performed prior to or after CTU.
1797455|NCT00567697|Drug|ranibizumab|0.5 ml 10mg/ml (0.5 mg) ranibizumab for intravitreal injection. Monthly injection for 3 months, followed by reinjection if edema for a total of 6 months.
1797456|NCT00567697|Drug|ranibizumab|Sham injection with an empty, sterile 3-ml stopped glass vial. # monthly sham-injections, followed by reinjection for 3 months if present edema.
1797461|NCT00567736|Drug|Disci/Rhus toxicodendron comp.®|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites verum group 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
1797462|NCT00567736|Drug|placebo solution|s.c. application 10 ml (1 ampul) in 5 to 10 parts on different back pain sites 12 treatments: 8 in the first 4 weeks and 4 in the next 4 weeks
1797463|NCT00567762|Drug|FK506|Opthalmic suspension
1797464|NCT00567762|Drug|placebo|placebo eye drops
1797465|NCT00567775|Drug|human insulin|
1797466|NCT00567775|Drug|inhaled human insulin|
1797467|NCT00567788|Drug|Latanoprost-Bimatoprost|latanoprost 0.005% once daily followed by bimatoprost 0.03%
1797468|NCT00567788|Drug|Bimatoporost-Latanoprost|bimatoprost 0.03% once daily followed by latanoprost 0.005%
1797469|NCT00567801|Procedure|conventional embolectomy/thrombectomy|
1797470|NCT00567801|Procedure|embolectomy/thrombectomy with controlled reperfusion|
1797471|NCT00567814|Drug|Metyrapone|Twice daily
1797472|NCT00567814|Drug|Oxazepam|Twice Daily
1797473|NCT00567814|Drug|Placebo|Twice daily
1797474|NCT00567840|Drug|PA-824|200 mg, 600 mg, 100 mg, 1200 mg qd
1797475|NCT00567853|Device|Implantation of the MEMO 3D Annuloplasty Ring|Implantation of the MEMO 3D Annulopalsty Ring for mitral valve repair.
1797476|NCT00567866|Drug|Quetiapine|50 or 100 mg of quetiapine orally
1797477|NCT00567879|Drug|Panobinostat|Participants received escalating doses of panobinostat until the maximum tolerated dose (MTD) was reached. The starting dose of panobinostat i.v. was 10mg/m^2 at days 1 and 8 during a 21-day treatment cycle. The oral panobinostat starting dose was 20 mg twice weekly.
1797478|NCT00567879|Drug|Trastuzumab|Fixed doses of trastuzumab were given in parallel with panobinostat. Trastuzumab i.v. was given weekly according to the instruction in the package insert.
1797479|NCT00567892|Device|rTMS|"Stimulation Settings:
Frequency -- 1Hz on 330 sec (5 min 30 sec.) per train for the first 5 trains with the last train 350 sec. (5 min. 50 sec.) in duration Off -- 90 sec (1 min. 30 sec.) Intensity -- 110% of motor threshold Duration -- 42½ minutes (total 2000 pulses in 6 trains)"
1797481|NCT00567918|Drug|FK506|Ophthalmic suspension
1797482|NCT00567931|Drug|1-methyl-d-tryptophan|Given orally
1797483|NCT00567931|Other|pharmacological study|Correlative studies
1797484|NCT00567931|Other|laboratory biomarker analysis|Correlative studies
1797485|NCT00567944|Device|BrainPort Balance Device|The BrainPort balance device, is a non-invasive medical device that provides head and body position information to a person via their tongue.
1797486|NCT00567957|Drug|Remifentanil|1 microg/kg iv bolus before induction followed by 0.5 microg/kg/min infusion
1797487|NCT00567957|Drug|Saline|same volume iv bolus before induction followed by same volume infusion
1797488|NCT00567970|Procedure|quality-of-life assessment|
1797489|NCT00567970|Radiation|stereotactic body radiation therapy|
1797490|NCT00567983|Drug|Restasis|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
1797491|NCT00567983|Drug|Endura|Restasis- (in the eye) Instill one drop twice daily Endura- (in the eye) Instill one drop twice daily
1797492|NCT00567996|Drug|Indacaterol 150 μg|Indacaterol 150 μg once daily (o.d) inhaled
1797493|NCT00567996|Drug|Salmeterol 50 μg|Salmeterol 50 μg twice daily (b.i.d) delivered via a proprietary dry powder inhaler
1797494|NCT00567996|Drug|Placebo to Indacaterol|Placebo to Indacaterol inhaled via SDDPI.
1797495|NCT00567996|Drug|Placebo to Salmeterol|Placebo to salmeterol delivered via a proprietary dry powder inhaler
1797496|NCT00568009|Drug|SLV320|1, 2.5, 5, 10 and 20 mg twice daily and placebo group. Duration of treatment 84 days
1797497|NCT00568022|Drug|Ixabepilone|Ixabepilone: Intravenous (IV) Solution, IV, 32(40)mg/m^2, once every 3 weeks, up to 6 cycles
1797498|NCT00568022|Drug|Capecitabine|Capecitabine: Tablets, Oral, 1650(2000)mg/m^2, twice daily for 2 weeks, one week off, up to 6 cycles
1797499|NCT00568035|Drug|QR-333|QR-333 or placebo will be applied three times a day for 12 weeks
1797500|NCT00568048|Biological|bevacizumab|10 mg/kg i.v., on day 1 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
1797501|NCT00568048|Drug|temozolomide|150 mg/m2 p.o., on days 1-7 of every cycle (14 days) until PD or any other event qualifying for stopping treatment
1797502|NCT00568061|Drug|nitric oxide for inhalation|MI size at 48-72 hours
1797503|NCT00568074|Drug|repaglinide|
1797504|NCT00568074|Drug|Glurenorm®|
1797505|NCT00568074|Drug|Glucobay®|
1797506|NCT00568087|Drug|N-acetylcysteine|Patients will take oral N-acetylcysteine 900 mg/day for 1 week, 1800 mg/day for 1 week, 2700 mg/day for 1 week, and then 3600 mg/day.
1797507|NCT00568087|Drug|Placebo|Patients will take oral placebo (identical matching placebo) during the study period.
1797508|NCT00568100|Procedure|PSV and NAVA|evaluated the effect of PSV and NAVA on breathing pattern, respiratory effort, gas exchange and level of breathing comfort in COPD patients
1797551|NCT00568451|Drug|carboplatin|AUC=2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
1797552|NCT00568451|Drug|paclitaxel|100mg/m^2 intravenously on days 1, 8 and 15. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal
1797509|NCT00568113|Drug|acetylcysteine in arm 1|"Arm 2, control group: given hydroxyl progesterone caproate (150mgm) every 3 days starting from the 28th week of pregnancy till completed 36 weeks of gestation.
Arm 1 patients were given hydroxyl progesterone caproate (150mgm) weekly injections plus NAC 0.6 gm (Sedico, Egypt) orally daily starting from the 28th week of pregnancy till delivery or completed 36th week of pregnancy."
1797510|NCT00568126|Drug|Maca Root|3g/day of Maca Root for 12 weeks.
1797511|NCT00568126|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks
1797512|NCT00568152|Dietary Supplement|Low PA apple puree|Golden Delicious apple puree 230grams consumed daily for 14 days
1797513|NCT00568152|Dietary Supplement|High PA apple puree|High PA apple puree (Mitchalin) consumed daily for 14 days
1797514|NCT00568152|Drug|Aspirin|75mg dispersable aspirin taken daily for 14 days
1797515|NCT00568165|Procedure|Mobile team|a mobile team including a cardiologist with mobile echocardiography, systematic follow up à 3 days, a dietician advice in patients hospitalized for acute heart failure in a non cardiology ward
1797516|NCT00568165|Procedure|Standard care|Standard care
1797523|NCT00568204|Device|Mexyn-A|Atomised topical self-chilled pressurised spray
1797524|NCT00568217|Drug|Diclofenac, Paracetamol, Ibuprofen|Immediately if temperature > 38 degree Celsius, diclofenac suppository 1,5 mg/kg once or placebo suppository After eight hours, if temperature still < 38 degree Celsius, acetaminophen mixture 15 mg/kg up to four times a day, or ibuprofen mixture 10 mg/kg up to four times a day, or placebo mixture up to four times a day as long as temperature < 38 degree Celsius
1797525|NCT00568230|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
1797526|NCT00568256|Behavioral|Mind/Body Courses|8-week Mind/Body course held once a week for 2 hours at a time.
1797527|NCT00568269|Procedure|Open repair|Open repair is according to the Lichtenstein technique
1797528|NCT00568269|Procedure|Laparoscopic repair|The TEP (Totally ExtraPeritoneal patch) repair is used as the laparoscopic repair
1797529|NCT00568282|Procedure|phlebotomy|Standard of care
1797530|NCT00568295|Drug|acetaminophen|Acetaminophen Extended Release: Caplets 650 mg x 2, oral, C-112-10AP - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
1797531|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg, oral, C-904-1A - - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
1797532|NCT00568295|Drug|Rofecoxib|Rofecoxib: Capsules 12.5 mg x 2, oral, C-904-1A - Subjects were instructed to dose every eight hours according to the specified dosing schedule and to record the designated parameters in the subject diary on a daily basis throughout the course of the study until the final visit at the end of Week 4 or until discontinuation of study medication.
1797533|NCT00568308|Drug|PI-88|160mg subcutaneous injection
1797534|NCT00568308|Drug|placebo|matched placebo
1797535|NCT00568321|Drug|RN624|50 mcg/kg
1797536|NCT00568321|Drug|RN624|200 mcg/kg
1797537|NCT00568321|Drug|Placebo|placebo
1797538|NCT00568334|Biological|Varilrix (inactivated varicella vaccine)|subcutaneously injection
1797539|NCT00568347|Drug|fluticasone 100mcg/ salmeterol 50mcg|inhaled fluticasone 100mcg/salmeterol 50mcg bid X 3 months
1797540|NCT00568347|Drug|fluticasone 250/salmeterol 50|inhaled fluticasone 250/salmeterol 50 X 3 months to evaluate effect on lung function and exhaled nitric oxide
1797541|NCT00568347|Drug|salmeterol|salmeterol 50 mcg by dry powder inhaler disk bid to evaluated effect on lung function and exhaled nitric oxide
1797542|NCT00568347|Drug|Salmeterol|salmeterol 50mcg bid X 3months
1797543|NCT00568347|Drug|salmeterol and fluticasone propionate|salmeterol 50mcg/fluticasone 250mcg by DPI bid
1797544|NCT00568360|Device|Oximeter|
1797545|NCT00568373|Device|Enterra Gastric Pacemaker|Gastric Pacemaker
1797546|NCT00568386|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye once time
1797547|NCT00568386|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
1797548|NCT00568399|Drug|sodium thiosulfate|sodium thiosulfate 12.5-25 gm/M2 after each thrice weekly hemodialysis treatments for 5 months.
1797549|NCT00568412|Device|Zarzenda|Topical cream, applied twice daily for three weeks
1797550|NCT00568412|Drug|Elidel|1% cream, applied topically twice daily for three weeks
1797609|NCT00568880|Drug|bortezomib|
1797553|NCT00568451|Drug|temozolomide|150mg/m^2 at cycle 1, 200mg/m^2 at cycle 2 and beyond, orally on days 1-5. Re-treat every 4 weeks until progression, unacceptable toxicity, or refusal. One treatment cycle=four weeks
1797554|NCT00568464|Drug|VCR, CTX, ADM; IFO, VP-16|VCD: VCR 2 mg d1, CTX 1200 mg/m2 d1, Mesna 240 mg/m2 tid d1, ADM 75mg/m2 d1, G-CSF 300 ug/d d5-11; IE: IFO 1800mg/m2 d1-5,Mesna 360 mg/m2 tid d1-5,VP-16 100 mg/m2 d1-5,G-CSF 300 ug/d d6-12; q3w. Surgery or radiation will be done to the patients with local diseases after four cycles of VCD/IE.
1797555|NCT00568477|Drug|MabThera|"Rituximab (MabThera):
375 mg/m² as IV infusions over >=6h each at time point 0 and 2 weeks. Initial infusion rate of 50 mg/h, stepwise rise is possible after 30 minutes"
1797556|NCT00568490|Procedure|Tumor biopsy|For patients who undergo tumor biopsy or resection at Stanford, approximately 500 mg of the tumor will be removed from the resection specimen
1797557|NCT00568490|Procedure|Phlebotomy|Blood draw (approximately 20 cc) prior to any anticancer therapy Weekly blood draw (approximately 20cc) only for patients who are undergoing radiation treatment at Stanford University
1797558|NCT00568503|Drug|QAX028|
1797559|NCT00568503|Drug|Placebo|
1797560|NCT00568503|Drug|Tiotropium bromide|
1797561|NCT00568503|Drug|QAX028|
1797562|NCT00568503|Drug|QAX028|
1797563|NCT00568516|Drug|ASP3550|subcutaneous administration
1797564|NCT00568529|Drug|Capecitabine and Oxaliplatin|Capecitabine 1000mg/m2 Bid d1-14 Oxaliplatin 130mg/m2 d1 q3w
1797565|NCT00568542|Drug|erythropoetin beta|35 I.E. kg body weight subcutaneous once per week for 6 months
1797566|NCT00568542|Drug|placebo|35 I.E. kg body weight placebo to erythropoetin beta
1797567|NCT00568555|Drug|Low Dose Naltrexone|3-4.5mg Naltrexone once daily
1797568|NCT00568555|Drug|Placebo - sugar pill|Placebo pill once daily
1797569|NCT00568568|Drug|Growth hormone|GH infusion from 8.00 pm to 03.00 am (dose 10,2 ng/kg/min) c) GH infusion from 02.00 am to 09.00 am (dose 10,2 ng/kg/min).
1797570|NCT00568594|Drug|APL180|
1797571|NCT00568594|Drug|Placebo|
1797572|NCT00568607|Drug|IFO, VP-16, DDP, DXM|DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 75 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
1797573|NCT00568620|Procedure|Placement of nasogastric feeding tube|"Glucose tolerance test via nasogastric feeding tube
50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
1797574|NCT00568620|Procedure|Nasojejunal feeding tube|"Glucose tolerance test via nasojejunal feeding tube
50 g glucose tolerance test on day 1; 50 g glucose tolerance test with 30 mL oil on day 2; Intravenous glucose tolerance test on day 3"
1797575|NCT00568633|Procedure|Hematopoietic Cell Transplantation|Standard of care
1797576|NCT00568633|Drug|Anti-Thymocyte Globulin|1.5 mg/kg x 5 days, iv
1797577|NCT00568633|Drug|Cyclosporine|6.25mg/kgBID, po
1797578|NCT00568633|Drug|Cellcept|15mg/kgBID, po
1797579|NCT00568646|Drug|MKC-1|Oral MKC-1 capsules, administered twice daily, for 14 consecutive days, in a 28-day cycles
1797580|NCT00568659|Procedure|specific elastance|The investigators study the specific lung elastance in ALI/ARDS patients in supine and prone position.
1797581|NCT00568672|Drug|Olanzapine|Olanzapine 5 mg / day for 6 months
1797582|NCT00568685|Drug|Atomoxetine Hydrochloride|Patients receive 0.2 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
1797583|NCT00568685|Drug|Atomoxetine hydrochloride|Patients receive 0.5 mg/kg/day atomoxetine administered orally in two divided doses for the duration of the 6-week acute treatment period
1797584|NCT00568685|Drug|Atomoxetine hydrochloride|"Patients initially receive atomoxetine 0.5 mg/kg/day administered orally in two divided doses for approximately 7 days. Patients will then receive atomoxetine 0.8 mg/kg/day administered orally in two divided doses for approximately 7 days.
Patients will receive atomoxetine 1.2 mg/kg/day administered orally in two divided doses for the remainder of the study, lasting approximately 28 days"
1797585|NCT00568698|Drug|Hydroxyurea|
1797586|NCT00568711|Drug|doxycycline|a 5-day course of 100 mg bid doses of doxycycline
1797587|NCT00568711|Drug|rifampin|a 5-day course of daily 600-mg doses of rifampin
1797588|NCT00568737|Drug|Drotrecogin alfa (activated)|Drotrecogin Alfa (activated)
1797589|NCT00568737|Drug|Placebo|0.9% sodium chloride
1797590|NCT00568750|Drug|dasatinib|Dasatinib is given orally 70 mg BID. Dasatinib will be continued until progression, unacceptable toxicity and up to 2 years (26 cycles, each cycle lasting 4 weeks).
1797591|NCT00568763|Biological|sargramostim|
1797592|NCT00568763|Other|immunoenzyme technique|
1797593|NCT00568763|Other|immunohistochemistry staining method|
1797594|NCT00568763|Other|immunologic technique|
1797595|NCT00568763|Other|laboratory biomarker analysis|
1797596|NCT00568763|Procedure|biopsy|
1797597|NCT00568763|Procedure|cryosurgery|
1797598|NCT00568763|Procedure|radiofrequency ablation|
1797599|NCT00568776|Drug|Placebo Control|ELND005 matched placebo capsules for oral administration, bid for 78 weeks
1797600|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 2000 mg bid for 78 weeks
1797601|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 250 mg bid for 78 weeks
1797602|NCT00568776|Drug|ELND005|ELND005 capsules for oral administration at a dose of 1000 mg bid for 78 weeks
1797603|NCT00568789|Drug|Ramelteon, zolpidem and placebo|"Ramelteon 8 mg, tablets, orally, one night only during Period 1, 2 or 3
Zolpidem 10 mg, tablets, orally, one night only during Period 1, 2 or 3
Ramelteon/Zolpidem placebo-matching tablets, orally one night only during Period 1, 2 or 3"
1797604|NCT00568802|Drug|Hydroxyurea|
1797605|NCT00568815|Drug|Rituximab combined with ESHAP|Rituximab 375mg/m2 d1, VP-16 40mg/m2 d1-4, Ara-C 2g/m2 d5, DDP 25mg/m2 d1-4, Met 500mg/m2 d1-5
1797606|NCT00568841|Drug|erlotinib|erlotinib p.o. (by mouth), 150 mg once daily for week 1-6 (day 1-42)
1797607|NCT00568841|Procedure|FDG-/FLT-PET|
1797608|NCT00568854|Biological|BCG|Both arms: diabetics and nondiabetics will receive vaccination in the upper arm with a 0.1-mg intradermal dose of a single strain of BCG (Mycobax, Sanofi-Aventis), which is FDA approved for this indication.
1797611|NCT00568880|Other|immunologic technique|
1797612|NCT00568880|Other|laboratory biomarker analysis|
1797613|NCT00568880|Other|mass spectrometry|
1797614|NCT00568880|Other|pharmacological study|
1797615|NCT00568880|Procedure|biopsy|
1797616|NCT00568893|Drug|drotrecogin alfa (activated)|
1797617|NCT00568945|Drug|Capadenoson (BAY68-4986)|4 mg BAY68-4986 for five days
1797618|NCT00568958|Behavioral|BASICS counseling|Brief Alcohol Screening and Intervention for College Students (BASICS) is a form of counseling that was developed originally for use with undergraduates. It combines three main elements: motivational enhancement strategies, skills for moderating consumption, and provision of individualized feedback.
1797619|NCT00568958|Drug|naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) naltrexone, 25mg each for a total possible dose of 50mg (the FDA-approved dose for alcohol dependence) in a given day for a period of 8 weeks.
1797620|NCT00568958|Drug|placebo naltrexone|Daily + targeted (i.e., taken as needed in anticipation of a high-risk situation) placebo for a period of 8 weeks.
1797621|NCT00568971|Drug|Docetaxel, Cisplatin, 5-Fu|Docetaxel 33.3 mg/m2, Cisplatin 30 mg/m2 and 5-FU 1500 mg/m2 of 24-hour continuous intravenous infusion;d1,8,15 q4w.The treatment will not stopped until disease progression or unaccepted toxicities.
1797622|NCT00568984|Drug|repaglinide|
1797623|NCT00568984|Drug|metformin|
1797624|NCT00568984|Drug|glicazide|
1797625|NCT00568997|Drug|Pimecrolimus|Pimecrolimus 1% cream
1797626|NCT00569010|Drug|Azacitidine|Group 1 and 3 at Level 0 = 37.5 mg/m^2 IV Over 20-30 minutes Daily for 7 Days Group 2 and 4 at Level 1 = 75.0 mg/m^2 IV Over 20-30 minutes Daily for 7 days
1797627|NCT00569010|Drug|Ara-C|"Group 1 and 2 at Low-Dose = 100 mg/m^2 Daily continuous intravenous infusion (CIV) for 7 days
Arms 3 and 4 at High-dose = 1 g/m^2 Daily CIV for 4 days (age<65 years) or 3 days (age>=65 years)"
1797628|NCT00569023|Dietary Supplement|alga Dunaliella bardawil|"Each patients will be treated with four capsules daily of Dunaliella bardawil for 90 days.
Alga Dunaliella bardawil containing 15 mg approximately 50% all-trans beta-carotene and 50% 9-cis beta-carotene isomers"
1797629|NCT00569036|Drug|BMS-754807|Tablets, Oral, Dose Cohorts: 4mg, 10mg, 20mg, 30mg, 50mg, 70mg, 100mg, 130mg, 160mg, 200mg, Once Daily, Until disease progression, unacceptable toxicity or at the subject's request
1797630|NCT00569049|Procedure|breast tissue, lymph node tissue or blood|Molecular Analyses of samples
1797633|NCT00569075|Other|collection of gingival crevicular fluid|GCF samples will be collected at 3 month intervals
1797634|NCT00569088|Drug|Chinese herbs formula|"The chinese herbs formula includes eight herbs,and they are Radix et Rhizoma Rhei Palmati(Rhubarb,10 grams),Cornu Bubali(Buffalo Horn,30 grams),Radix Paeoniae Bubra(Red Peony Root,15 grams),Cortex Moutan Radicis(Tree Peony Root-bark,10 grams),Radix Rehmanniae(Adhesive Rehmannia Root Tuber,20 grams),Pheretima Aspergillum(Earth-worm,10 grams),Radix Notoginseng(Sanchi,5 grams)and Rhizoma Acori Tarainowii(Tararinow Sweetflag Rhizome,10 grams).
Boiled together. 150ml of the juice,p.o.,twice a day,for 28 days"
1797635|NCT00569088|Drug|Mannitol|250 ml Mannitol Injection or Glycerin and Fructose Injection ,once a day, for 3-5 days
1797636|NCT00569101|Drug|tacrolimus|during the first 2 months : tacrolimus 0.1 mg/kg + prednisolone 0.8 mg/kg p.o. ,then after : tacrolimus 0.1 mg ~0.02 mg/kg + prednisolone tapering
1797637|NCT00569114|Drug|TG01|Drug:TG01tablets given orally QD Drug: erlotinib tablets 150mg QD
1797638|NCT00569127|Biological|Recombinant Interferon Alfa-2b|Given SC
1797639|NCT00569127|Drug|Octreotide Acetate|Given IM
1797640|NCT00569127|Biological|Bevacizumab|Given IV
1797641|NCT00569140|Drug|E10030|Intravitreal injection
1797642|NCT00569153|Drug|TAK-700|"Phase 1 portion of study:
TAK-700 dose escalation. Tablets administered orally, twice daily until disease progression or occurrence of an unacceptable adverse event.
Phase 2 portion of study:
Patients will receive one of 4 treatments:
TAK-700 at 300 mg twice/day
TAK-700 at 400 mg and 5 mg prednisone twice/day
TAK-700 at 600 mg and 5 mg prednisone twice/day
TAK-700 at 600 mg once/day in the morning"
1797643|NCT00569166|Behavioral|Paced breathing (15 min once daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes once daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
1797644|NCT00569166|Behavioral|Paced breathing (15 min twice daily, 6 breaths/min)|Patients practice paced breathing for 15 minutes twice daily, 6 breaths/min, 5-7 days weekly, following an instructional CD, for 8 weeks.
1797645|NCT00569166|Behavioral|Paced breathing (10 min once daily, 14 breaths/min)|Patients practice paced breathing for 10 minutes once daily, 14 breaths /min, 5-7 days weekly, following an instructional CD, for 8 weeks.
1797646|NCT00569179|Device|CliniMACS CD34 Reagent System|Alloreactive NK cells will be purified by a two-step immunomagnetic selection (CD3 depletion followed by CD56 selection) using the CliniMACS device.
1797647|NCT00569192|Drug|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
1797648|NCT00569192|Drug|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 12 weeks
1797649|NCT00569192|Drug|Placebo|Placebo delivered by nebulization twice daily for 12 weeks
1797650|NCT00569231|Drug|Candida Antigen|Intralesional injection of 0.3ml candida antigen into largest wart at baseline visit and then every 3 weeks +/- 3 days for a maximum of 10 treatments.
1797651|NCT00569244|Drug|Drug: YAZ flex (SH T00186D)|Extended flexible regimen of YAZ (SH T00186D); triggered by bleeding events(Tablet p.o. (oral))
1797652|NCT00569244|Drug|YAZ (SH T00186D)|YAZ (SH T 00186D) administered in the conventional regimen (24 days active + 4 days placebo) (Tablet p.o. (oral))
1797653|NCT00569257|Drug|AEZS-108|intravenous infusion at a dose of 267 mg/sqm every 3 weeks, up to 6 treatment cycles
1797654|NCT00569270|Drug|tiotropium|Procedure/Surgery - tiotropium 18ug capsule daily for 1 month vs placebo to study the effect of trough and peak effect on bronchodilation and effect of metronome paced hyperventilation induced dynamic hyperinflation
1797655|NCT00569270|Drug|placebo|18ug tiotropium placebo capsule daily for 1 month
1797656|NCT00569270|Drug|tiotropium|daily tiotropium 18ug versus daily placebo for 30 days
1797657|NCT00569283|Biological|therapeutic allogeneic lymphocytes|
1797658|NCT00569296|Biological|EGFRBi-armed autologous activated T cells|Dose escalation, dosage depends on when entered in study. 8 infusions (twice a week over 4 weeks. Each infusion will be over at least 1 hour.
1797659|NCT00569296|Biological|aldesleukin|300,00IU/m2/day beginning 3 days before the first Activated T-cell infusion and ending 1 week after the last infusion
1797660|NCT00569296|Biological|sargramostim|250 micrograms/m2/twice weekly beginning 3 days before the first activated T-cell infusion and ending 1 week after the last Activated T-cell infusion
1957465|NCT02383225|Behavioral|Facebook Supplement|This intervention component includes a social media supplement to engage families outside of weekly intervention sessions and will include postings and polls for participating parents/other caregivers to complete between sessions.
1957466|NCT02383225|Behavioral|Substance Use Resistance Skills|This intervention component consists of the original substance use resistance skills training from the Iowa Strengthening Families Program for Parents and Youth 10-14; arms without this component will include a session on healthy eating and exercise (attention control).
1957467|NCT02381548|Drug|Belinostat|Given IV
1797664|NCT00569322|Procedure|BG Test|
1797665|NCT00569335|Drug|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 21-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).
Irinotecan 150 mg/m2 is administered by intravenous infusion on day 1. Bevacizumab 7.5 mg/kg (body weight) is administered by intravenous infusion on day 1."
1797666|NCT00569361|Procedure|Collection of nasal epithelial cells|Collection of nasal epithelial cells by brushing
1797667|NCT00569374|Drug|Modafinil|subjects attend clinic for the first week in order to receive meds; oral, 200mg/day doses for three days for initiation doses; increased to oral 400mg/day for the remainder of the trial (weeks 2-6); washout period during week 7
1797668|NCT00569387|Biological|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
1797669|NCT00569400|Drug|human insulin|
1797670|NCT00569426|Device|NovoFine® needle 6 mm|
1797671|NCT00569426|Device|NovoFine® needle 8 mm|
1797672|NCT00569439|Drug|D5NS|5% Dextrose in Normal Saline (6.25 gr/hr) at 125 cc/hr
1797673|NCT00569439|Drug|D10NS|10% Dextrose Solution (12.5 gr/h) in Normal Saline at 125 cc/hr
1797674|NCT00569439|Drug|NS|Normal Saline solution at 125 cc/hr
1797675|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|One basal rate
1797676|NCT00569452|Device|Accu-Chek Spirit Insulin Pump|Multiple basal rates
1797677|NCT00569465|Drug|Arginine|1200 mg, once a day
1797678|NCT00569465|Drug|Acetylcysteine|600 mg twice a day
1797679|NCT00569465|Drug|Placebo|3 vials a day
1797680|NCT00569478|Other|rehabilitation|Nursing consultations and physical training
1797681|NCT00569491|Device|TAXUS Express 2™|TAXUS Express™ Paclitaxel-Eluting Coronary Stent System
1797682|NCT00569517|Behavioral|CBT|6-CBT based sesions
1797683|NCT00569517|Other|educational|subjects receive one hour of nutrition education and 5 weekly phone calls
1797684|NCT00569530|Drug|Infasurf (ONY Inc.)|Infasurf 3ml/kg will be given to infants on study days 0, 3, 7, 10, and 14, if remains intubated.
1797685|NCT00569530|Drug|Sham|Sham instillation (no treatment) will be given to study infants on days 0, 3, 7, 10, and 14, if remains intubated.
1797686|NCT00569543|Other|high performance liquid chromatography|urine analysis
1797687|NCT00569543|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
1797688|NCT00569543|Other|mass spectrometry|The urine samples will be analyzed for 40 estrogen metabolites, conjugates and depurinating DNA adducts by UPLC with tandem mass spectrometric detection.
1797689|NCT00569543|Other|medical chart review|Collection of information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease.
1797690|NCT00569556|Other|Case Management|Phone contact by specially trained nurse case managers; lifestyle recommendations and medication changes as needed
1797691|NCT00569569|Drug|juxtascleral depot injection of Retaane|juxtascleral depot injection of Retaane
1797692|NCT00569582|Drug|mifepristone|Patients take mifepristone by mouth once a day. The dose is increased during scheduled timepoints during the study or until symptoms improve or the highest dosage allowed is reached. Dose escalation will be based upon weight. During clinic visits, blood pressure, glucose tolerance and blood chemistries are measured and EKG and urinalysis will be performed.
1797693|NCT00569595|Behavioral|Self-Care Stimulating Disease Prevention Program|The intervention is aimed at improving diet, increasing physical activity, and reducing sedentary behaviors among low-income patients, assuming that this will increase motivation and self-confidence to adhere to self-care regimens based on personal prioritizing and progressive goal setting.
1797694|NCT00569595|Behavioral|Fighting Cancer with Advice|"Patient health counseling program by lay health educators entitled Fighting Cancer with Advice."
1797695|NCT00569608|Other|Early Discharge|Application of an early discharge protocol from the neonatal intensive care unit.
1797696|NCT00569621|Drug|Moxaverine|intravenous administration
1797697|NCT00569621|Drug|physiological saline|intravenous administration
1797698|NCT00569634|Procedure|Venous blood gas analysis|When an ABG is deemed to be necessary as part of ICU management, a central venous sample will also be obtained with minimum delay (always < 2 minutes) between the samples. The samples will be analyzed by a blood gas analyzer as quickly as possible.
1797699|NCT00569647|Device|Virtual Reality Hypnosis|Use of virtual reality headset to induce hypnotic state
1797700|NCT00569647|Device|Placebo|no use of device
1797701|NCT00569660|Drug|Azacitidine|75 mg/m^2 subcutaneous daily for 7 days (every 4 week cycle)
1797702|NCT00569673|Biological|filgrastim|
1797703|NCT00569673|Biological|pegfilgrastim|
1797704|NCT00569673|Drug|docetaxel|
1797705|NCT00569673|Drug|trabectedin|
1797706|NCT00569686|Drug|lovaza|lovaza 4 gm po daily
1797707|NCT00569686|Drug|placebo|placebo
1797844|NCT00561795|Drug|pazopanib (GW786034)|800 mg orally once a day for 6 cycles
1797708|NCT00569699|Drug|S-1, Bevacizumab|"S-1 is administered orally on days 1 to 28 of a 42-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25 m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).
Bevacizumab 5 mg/kg (body weight) is administered by intravenous infusion on days 1, and 15."
1797709|NCT00569712|Drug|budesonide/formoterol fumarate dihydrate inhalation aerosol|
1797710|NCT00569712|Genetic|DNA methylation analysis|
1797711|NCT00569712|Genetic|comparative genomic hybridization|
1797712|NCT00569712|Genetic|microarray analysis|
1797713|NCT00569712|Other|bronchoalveolar lavage|
1797714|NCT00569712|Other|immunoenzyme technique|
1797715|NCT00569712|Other|laboratory biomarker analysis|
1797716|NCT00569712|Procedure|bronchoscopy|
1797717|NCT00569738|Procedure|PET scan with Ga68-DOTANOC|Imaging: PET scan with Ga68-DOTANOC
1797718|NCT00569751|Device|TAXUS™ Express2™ Paclitaxel-Eluting Coronary Stent System|Drug Eluting Stent used to treat de novo coronary artery lesions.
1797719|NCT00569777|Device|K-Lens (generic name not established) and Ketotifen|combination drug-device product: contact lens (device) and anti-allergy drug
1797720|NCT00569777|Device|Placebo Lens|contact lens without drug
1797721|NCT00569790|Drug|S-1, Irinotecan, Bevacizumab|"S-1 is administered orally on days 1 to 14 of a 28-day cycle. Patients are assigned on the basis of body surface area (BSA) to receive one of the following oral doses twice daily: 40 mg (BSA <1.25m2), 50 mg (BSA >1.25 to <1.50 m2), or 60 mg (BSA >1.50 m2).
Irinotecan 100 mg/m2 is administered by intravenous infusion on days 1 and 15. Bevacizumab 5 mg/kg (body weight)is administered by intravenous infusion on days 1 and 15."
1797722|NCT00569803|Drug|belatacept|single dose, 116 days
1797723|NCT00569803|Drug|Placebo|Subcutaneous injection of placebo solution (product ID: 224818-N000- 029)
1797724|NCT00569816|Drug|Sevoflurane|1 MAC Sevoflurane will be given either continuously after induction of anesthesia until initiation of cardiopulmonary bypass or will be repetitively washed in and out twice before initiation of cardiopulmonary bypass.
1797725|NCT00569829|Behavioral|cognitive behavioral therapy|1 to 16 weekly sessions of modular cognitive behavioral therapy, each lasting 60-80 minutes
1797726|NCT00569855|Drug|Phenoxybenzamine|0.125 to 1 mg/kg given i.v. over 15 to 45 minutes in preparation for cardiopulmonary bypass; may be continued at 0.125 mg/kg/day in ICU
1797727|NCT00569868|Drug|Velcade|"Except for the two PCR-based genotyping assays, which will be conducted only on baseline samples, tests will be assessed at baseline, 1-3 hours after the first dose of Velcade day 1 and on day 11 of the first cycle of Velcade.
The platelet Aggregation Test will be done only if Platelet count is 100 000."
1797728|NCT00569881|Drug|gatifloxacin and moxifloxacin|Comparison of wound healing between drugs
1797729|NCT00569894|Biological|FLuMist|One or two vaccinations with FluMist depending on prior vaccination status.
1797730|NCT00569894|Biological|TIV (Injection)|One or two injections of TIV depending on previous status.
1797731|NCT00569894|Other|Unvaccinated Control|no vaccine
1797732|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,15 mg/kg bodyweight. Single-dose bolus injection after start of anesthesia. Medication is opened and administrated to the patient from a coded ampoule by the physician. The medication is diluted in such a way that 1 mL is equivalent to 10 kg body weight (1,5 mg/mL).
1797733|NCT00569920|Drug|natriumchloride 0,9%|iv natriumchloride 0,9% (placebo). 1 mL is equivalent to 10 kg body weight.
1797734|NCT00569920|Drug|dexamethasone|IV dexamethasone 0,30 mg/kg body weight. Drug diluted to 3,0 mg/mL and administrated in same way as arm 2.
1797735|NCT00569933|Behavioral|Audio recording|Using audio recording to investigate if possitive affirmations help with pain management and other post of compllication.
1797736|NCT00569946|Drug|AG-013736|"AG-013736 5 mg BID will be administered orally on continuous schedule. Cycle length is 28 days. If the drug is well tolerated at 5 mg BID, the dose of AG-013736 may be titrated to 7 mg BID and then to a maximum of 10 mg BID.
Number of cycles: until progression or unacceptable toxicity develops."
1797737|NCT00569959|Other|fasting 12+ hours|fasting 12+ hours
1797738|NCT00569959|Other|Non-fasting|Non-fasting
1797739|NCT00569972|Drug|PD 0200390|Capsules, 15 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
1797740|NCT00569972|Drug|PD 0200390|Capsules, 30 mg, 3 capsules each night before bedtime; Duration - Visit 3-7 for 28 days
1797741|NCT00569972|Drug|PD 0200390|Capsules, 45 mg, 3 capsules each night before bedtime, Duration- Visit 3-7 for 28 days
1797742|NCT00569972|Drug|PD 0200390|Capsules, 60 mg, 3 capsules each night before bedtime, Duration - Visit 3-7 for 28 days
1797743|NCT00569972|Drug|Placebo|Matched oral placebo for weeks 2-7.
1797744|NCT00569985|Biological|lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
1797745|NCT00569985|Drug|carmustine|Given IV
1797746|NCT00569985|Drug|cyclophosphamide|Given IV
1797747|NCT00569985|Drug|etoposide|Given IV
1797748|NCT00569985|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplantation comprising lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cells and non-bound CD34+ cells
1797749|NCT00569998|Device|NovoPen™ 4|
1797750|NCT00569998|Device|NovoPen® 3|
1797751|NCT00570011|Drug|Somatropin|3 microg/kg/day for the first three months.The dose was then doubled (6 microg/kg/day) for the next three-months.
1797752|NCT00570011|Drug|Somatropin|6 microg/kg/day for the first three months. The dose was then doubled (12 microg/kg/day) for the next three-months.
1797753|NCT00570024|Procedure|Traditional Acupuncture|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
1797838|NCT00561730|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
1797839|NCT00561743|Drug|Bortezomib + pegylated liposomal doxorubicin HCl + dexamethasone|
1797754|NCT00570024|Procedure|AA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
1797755|NCT00570037|Biological|Trivalent inactivated influenza vaccine|Intramuscular injection, 0.5 mL or 0.25 mL depending on age of vaccine recipient, one or two doses administered a month apart depending on age and prior influenza vaccination history of recipient
1797756|NCT00570050|Drug|Diluent / Insulin|Diluent (4 Weeks ) / Intranasal insulin (4 weeks)
1797757|NCT00570050|Drug|Insulin / Diluent|Intranasal Insulin (4 Weeks ) / Diluent (4 Weeks)
1797758|NCT00570063|Drug|PF-02545920|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days
1797759|NCT00570063|Drug|Placebo|Participants are assigned to 15 mg oral tablets twice a day of PF-02545920 or placebo in parallel for the duration of the study which is 21 days.
1797762|NCT00570102|Dietary Supplement|A highly hydrolyzed formula|Weaning to a highly hydrolyzed formula, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin up to the age of 6-8 months
1797763|NCT00570102|Dietary Supplement|A regular cow's milk based formula|Weaning to a regular cow's milk based formula supplemented with 20% of the highly hydrolyzed formula used in arm 1 to make the study formulas similar in smell and taste, avoidance of all supplemental food containing cow's milk proteins and/or bovine serum albumin
1957468|NCT02381548|Other|Laboratory Biomarker Analysis|Correlative studies
1797766|NCT00570141|Device|OASIS Wound Matrix|OASIS (an acellular biomaterial that supports tissue repair with a scaffold-like matrix having a natural structure and composition).
1797767|NCT00570167|Procedure|Hip resurfacacing|Hip resurfacing with cementless acetabular cup and cemented femoral head
1797768|NCT00570167|Procedure|Cementless total hip arthroplasty with m-o-m bearings|Cementless monoblock acetabular cup and cementless femoral stem with modular large head and metal-on-metal bearings..
1797769|NCT00561197|Drug|AT-101|Patients will receive AT-101 starting at 10 mg once daily for 5 of 7 days in conjunction with RT (50.4 Gy for 28 fractions) for approximately 5.5 weeks. Concurrently, patients will receive docetaxel (20 mg/m2) IV weekly (Monday) and 5-fluorouracil (300 mg/m2) as a 24 hour continuous infusion for 5 of 7 days (Monday-Friday) of each RT week for approximately 5 weeks. Patients will continue for full 5.5 weeks unless unacceptable toxicity occurs.
1797770|NCT00561210|Dietary Supplement|Crucial|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
1797771|NCT00561210|Dietary Supplement|Sondalis HP|Treatment between minimum 14 days and maximum 6 months. Apports depend on method of CURRERI.
1797772|NCT00561223|Drug|iloprost Inhalation|inhale 2.5 mg, repeat times one
1797773|NCT00561223|Drug|iloprost|inhaled 2.5 mg, repeat times one
1797774|NCT00561249|Procedure|laser assisted hatching|Embryos for transfer are subjected to laser assisted hatching(LAH) following the standard procedure.The LAH procedure lasts two minutes per embryo
1797775|NCT00561262|Other|questionnaire administration|
1797776|NCT00561262|Procedure|high-intensity focused ultrasound ablation|
1797777|NCT00561262|Procedure|quality-of-life assessment|
1797778|NCT00561275|Biological|LY6K, VEGFR1, VEGFR2|1 mg/body every two week with GM-CSF, 4 cycles
1797779|NCT00561288|Drug|acetaminophen|2 x 1000 mg doses per day
1797780|NCT00561288|Other|cornstarch|2 x 1000 mg cornstarch per day
1797781|NCT00561301|Drug|GemDOx|gemcitabine oxliplatin
1797782|NCT00561314|Other|questionnaire administration|
1797783|NCT00561314|Procedure|biopsy|
1797784|NCT00561314|Procedure|high-intensity focused ultrasound ablation|
1797785|NCT00561314|Procedure|magnetic resonance imaging|
1797786|NCT00561314|Procedure|quality-of-life assessment|
1797787|NCT00561327|Drug|losartan|Daily treated with losartan 100mg for at least the past 2 months (retrospective, no new drug treatment/ intervention)
1797788|NCT00561340|Dietary Supplement|Pediasure|50% will be randomized to pediasure with nutritional counseling
1797789|NCT00561340|Behavioral|Nutritional counseling|50% randomized to nutritional counseling only
1797790|NCT00561353|Drug|TMC435|TMC435 25 mg, 75 mg, 150 mg, or 200 mg capsules taken orally (by mouth) once daily for 21 or 28 days.
1797791|NCT00561353|Drug|Placebo|Placebo capsules identical in appearance to TMC435 capsules taken orally (by mouth) once daily for 28 days.
1797792|NCT00561353|Drug|Peginterferon (PegIFNα-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFNα-2a on Days 1, 8, 15, and 22
1797793|NCT00561353|Drug|Ribavirin|200-mg tablets of ribavirin (body-weight adjusted dose) taken orally (by mouth) twice daily for 21 or 28 days in Cohorts 1 and 2 and for 28 days in Cohorts 4 and 5.
1797794|NCT00561366|Drug|Placebo|Placebo t.i.d.
1797795|NCT00561366|Drug|Arimoclomol|capsule, 400 mg t.i.d.
1797796|NCT00561379|Drug|CHOP+RITUXIMAB|CHOP-14- Rituximab x 8 courses
1797797|NCT00561379|Drug|CEEP-RITUXIMAB|High dose chemotherapy with rituximab including autologous stem cell support.
1797798|NCT00561392|Drug|Rivastigmine 5 and 10 cm^2 patch|
1797799|NCT00561405|Behavioral|Motor Learning Walking Program|Motor Learning principles based Walking Program (MLWP) Participants practice variety of real life over ground walking related activities. Order of practice, instructions, guidance and feedback are provided in a manner that facilitates cognitive engagement of learner. Sessions 45 minutes, 3x per week over 5 weeks for a total of 15 sessions
1797840|NCT00561756|Biological|plasmid DNA vaccine therapy|
1797841|NCT00561756|Other|flow cytometry|
1797842|NCT00561756|Other|immunoenzyme technique|
1797800|NCT00561405|Behavioral|Body Weight Supported Treadmill Training|Participants practice walking on a treadmill while supported with an overhead harness system. Up to 40% body weight support. Target Treadmill speed 2.0 mph. 1 or 2 Trainers (at least one Physical Therapist plus another Physical Therapist or Physiotherapy Assistant) will help guide participants leg, foot and trunk during treatment. Aim is to practice high numbers of repetition of the normal gait cycle on treadmill. Duration of sessions - 20 minutes of treadmill training within a 45 minute session ( 4 sets of 5 minutes of training with 5 minute rests). 3 sessions per week for 5 weeks. Total of 15 sessions.
1797801|NCT00561418|Drug|vorinostat|Vorinostat (SAHA) will be administered orally starting approximately day +60 post HSCT for 21 consecutive days of a 28-day cycle for up to a maximum of 11 cycles.
1797802|NCT00561418|Other|Correlative studies|Laboratory as well as quality of life correlative studies will be obtained at days +26 to +38 (at approximately 1 month post HSCT),days +56 to +66 (≈2 mos), and at Cycle 2 Day 1 (≈3 mos.), Cycle 3 Day 1 (≈4 mos.), Cycle 5 Day 1 (≈6 mos.),Cycle 7 Day 1 (≈8 mos.), and off study (ideally at ≈12 mos.)
1797803|NCT00561431|Device|Standard dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent dose of 20 ml/kg/hr
1797804|NCT00561431|Device|High dose of dialysis|Continuous Venovenous Hemodiafiltration (CVVHDF) effluent rate 35 ml/kg/hr
1797805|NCT00561444|Behavioral|Questionnaire|Questionnaires taking 20 minutes to complete.
1797806|NCT00561457|Device|Bard Luminexx Iliac Stent and Delivery System|Iliac Stenting
1797807|NCT00561470|Drug|Placebo|4 mg/kg of sterile aqueous buffered vehicle (pH 6.0) was administered intra venously (IV) over 1 hour on Day 1, every 2 weeks
1797808|NCT00561470|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg of Aflibercept was administered IV over 1 hour on Day 1, every 2 weeks.
1797809|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Placebo administration on Day 1
The FOLFIRI regimen included:
180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:
5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:
5-FU 2400 mg/m² continuous IV infusion over 46-hours"
1797810|NCT00561470|Drug|FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin)|"The FOLFIRI regimen was initiated immediately after Aflibercept administration on Day 1
The FOLFIRI regimen included:
180 mg/m² Irinotecan (Campto®, Camptosar®) IV infusion over 90 minutes and dl leucovorin 400 mg/m² (200 mg/m² for the l-isomer form) IV infusion over 2 hours, followed by:
5-FU 400 mg/m² IV bolus given over 2-4 minutes, followed by:
5-FU 2400 mg/m² continuous IV infusion over 46-hours"
1797811|NCT00561496|Drug|Tenofovir gel|Intravaginal (4grams)single dose followed by fourteen days
1797812|NCT00561509|Drug|SSRIs|Use within normal clinical practice
1797813|NCT00561509|Drug|Dual antidepressants|Use within clinical practice
1797814|NCT00561522|Drug|Capecitabine|Capecitabine 1,250 mg/m2 twice daily on days 1-14, followed by a 7-day drug-free interval. Treatment repeats every 21 days. The above cycle is repeated for 4-6 times.If disease recurrence or unacceptable toxicity or other criteria for withdrawal are met, treatment will be stopped.
1797815|NCT00561522|Other|No other preventive treatment|No other preventive treatment
1797816|NCT00561535|Dietary Supplement|Lactobacillus FARCIMINIS|10.10 UFC of lactobacillus FARCIMINIS
1797817|NCT00561535|Dietary Supplement|placebo (starch)|Once daily
1797818|NCT00561548|Procedure|rectosigmoïdal biopsies|rectosigmoïdal biopsies
1797819|NCT00561561|Procedure|acoustic startle testing|recording of eyeblink component of acoustic startle reflex with small surface electrodes during presentation of acoustic stimuli through headphones
1797820|NCT00561574|Drug|Esmirtazapine|One tablet daily
1797821|NCT00561587|Drug|Seroquel®|dosage form: oral, adjusted in the range of 25 to max. 300 mg /day
1797822|NCT00561600|Device|ASR™-XL Modular Acetabular Cup System|The ASR™-XL Modular Acetabular Cup System treatment device is comprised of a metal acetabular cup, a unipolar femoral head and a taper sleeve adapter.
1797823|NCT00561600|Device|Pinnacle™ acetabular shell|The Pinnacle™ shells are cementless, titanium alloy cups with Porocoat® porous coating and HA DuoFix™ coating. There are various different liners available for use with the Pinnacle™ Acetabular Cup System. For the purpose of this investigation, the CoCrMo ULTAMET® 28mm or 36 mm metal liners will be used.
1797824|NCT00561613|Other|SILCS and lubricant|
1797825|NCT00561613|Other|SILCS and spermicide|
1797826|NCT00561626|Dietary Supplement|high fat diet followed by low fat diet|High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
1797827|NCT00561626|Dietary Supplement|low fat diet followed by high fat diet|Low fat diet : 20 Energy (En)% fat, 65 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily High fat diet : 40 Energy (En)% fat, 45 En% carbohydrates, 15 En% proteins, 250 mg cholesterol,4 weeks, daily
1797828|NCT00561652|Behavioral|Education & Exercise|Education & Exercise
1797829|NCT00561652|Procedure|Chiropractic treatment (plus Education & Exercise)|Chiropractic treatment (plus Education & Exercise)
1797830|NCT00561678|Drug|Precedex (Dexmedetomidine)|0.5/ug/kg/hr Dexmedetomidine infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
1797831|NCT00561678|Drug|Placebo|0.5/ug/kg/hr Placebo infusions will begin prior to the surgery (no loading dose), and will be maintained at 0.5 mcg/kg/hour throughout surgery and titrated postoperatively for 2 hours postoperatively.
1797832|NCT00561691|Drug|nimotuzumab|monoclonal antibody
1797833|NCT00561704|Drug|losartan|losartan, 100mg daily,
1797834|NCT00561717|Drug|Azelastine and placebo|One Astelin spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
1797835|NCT00561717|Drug|Loratadine and Placebo|One placebo spray per nostril plus one Loratadine 10 mg tablet. In Cross-Over-Design with other arms.
1797836|NCT00561717|Drug|Cetirizine and Placebo|One placebo spray per nostril plus one 10 mg Cetirizine tablet. In Cross-Over-Design with other arms.
1797837|NCT00561717|Drug|Placebo and Placebo (spray and Tablet)|One placebo spray per nostril plus one placebo tablet. In Cross-Over-Design with other arms.
1797843|NCT00561769|Drug|Norditropin pen|12 IU per day
1797845|NCT00561795|Drug|carboplatin|IV over one hour every 3 weeks of 6 cycles
1797846|NCT00561795|Drug|paclitaxel|IV 175 mg/m^2 given over 3 hours on day one of a 21 day cycle for six cycles
1797847|NCT00561808|Other|In-vitro maturation oocytes|Immature oocytes (development stage GV or M1) will be matured in-vitro in IVM culture medium for approximately 28-32 hours. The oocytes will be routinely observed and when they reach maturation (M2) they will be fertilized. The developed embryo will be transferred to the patient 24 hours post-fertilization.
1797848|NCT00561821|Drug|Esmirtazapine|one tablet daily
1797849|NCT00561821|Drug|Placebo|one tablet daily
1797850|NCT00570180|Drug|Bortezomib|21 day-cycle Induction therapy:bortezomib 1.3 mg/m2 (I.V. Days 1, 4, 8, and 11), then 10-day rest period. DOXIL 30 mg/m2 given after bortezomib (I.V. infusion Day 4 of each cycle). Dexamethasone 40 mg PO on days 1-4,8-11 and 15-18 during the first cycle. Subsequent 3 cycles, dexamethasone 40 mg PO given on days 1-4 and 11-14. Patients who don't progress may undergo elective stem cell mobilization, stem cell collection and cryopreservation. Patients will then receive post-induction therapy 1.5 mg/m2 bortezomib days 1, 8, and 15 I.V. + cyclophosphamide 300 mg/m2 PO weekly + prednisone 100 mg PO on alternate days for 8 monthly 28 day cycles.Maintenance therapy with weekly 40 mg dexamethasone (days 1, 8, 15 and 22) every month until disease progression occurs.
1957469|NCT02381548|Other|Pharmacological Study|Correlative studies
1957470|NCT02381548|Drug|WEE1 Inhibitor AZD1775|Given PO
1797853|NCT00570206|Behavioral|Motivational Interviewing|Probation officers trained to use Motivational Interviewing while conducting meetings with probationers.
1797854|NCT00570219|Drug|valproate|Valproate 20 mg/kg per day for 2 weeks, reduction during week 3. Conversion of benzodiazepines to an equivalent dose of diazepam (maximum 80 mg per day). Dosage reduced 10 mg daily until 40 mg per day. Reduction then continued 5 mg daily.
1797855|NCT00570232|Drug|Erlotinib|150 mg per day by mouth for 12 months
1797856|NCT00570245|Drug|Nitric oxide|inhalation, 10 ppm, for up to 48 hours
1797857|NCT00570245|Drug|Nitric oxide|inhalation; 10ppm; 3 hours (donor) up to 48 hours (recipient)
1797858|NCT00570258|Drug|Fulvestrant|Fulvestrant: 250 mg IM Q 4 weeks
1797859|NCT00570258|Drug|erlotinib|150 mg PO QD
1797860|NCT00570258|Drug|Fulvestrant|250 mg IM Q 4 weeks
1797861|NCT00570258|Drug|Placebo|Placebo 150 mg PO QD
1797862|NCT00570271|Other|Placebo with BP dec (written form)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects in written form.
1797863|NCT00570271|Other|Placebo with BP dec (doctor)|Placebo administration with a blood pressure decrease suggestion. Information provided to subjects by doctor.
1797864|NCT00570271|Other|Placebo with BP inc (written)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects in written form.
1797865|NCT00570271|Other|Placebo with BP inc (doctor)|Placebo administration with a blood pressure increase suggestion. Information provided to subjects by doctor.
1797866|NCT00570271|Other|Placebo info given (written)|Subject informed about receiving placebo. Information provided to subjects in written form.
1797867|NCT00570271|Other|Placebo info given (doc)|Subject informed about receiving placebo. Information provided to subjects by doctor.
1797868|NCT00570284|Drug|LBH589|orally administered panobinostat at 20 mg twice weekly (core phase); orally administered panobinostat 45 mg twice weekly if 20 mg twice weekly was tolerated in Cycle 1 (extension phase)
1797869|NCT00570310|Drug|Comparator: pregabalin|pregabalin (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
1797870|NCT00570310|Drug|Comparator: Placebo (unspecified)|pregabalin Pbo (up to 600 mg/day by mouth (po)). Duration of Treatment: 6 Weeks
1957471|NCT02375971|Drug|Ranibizumab|0.2 mg Intravitreal administration Administration in both eyes on day 1 Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections
1797873|NCT00570336|Drug|CTS-1027|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd (quaque die, once daily).
1797874|NCT00570336|Other|Placebo|Eligible patients were randomized to one of four doses of CTS-1027 (2.5 mg, 5 mg, 10 mg, or 30 mg) or placebo qd.
1797875|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 20 ppm via nasal cannula over a 44 hour period.
1797876|NCT00570349|Drug|Nitric Oxide for Inhalation|Nitric oxide will be administered at 40 ppm via nasal cannula over a 44 hours period.
1797877|NCT00570349|Drug|Nitrogen|100% nitrogen (placebo) will be administered at 20 ppm or 40 ppm via nasal cannula over a 44 hour period.
1797878|NCT00570375|Drug|Erlotinib|150 mg, PO, QD beginning day 1 week 1. Patients will receive treatment for 16 weeks as long as there is no evidence of disease progression. In no response is noted after 16 weeks of treatment, patients will be taken off the study. Patients achieving response (HI, CR, or PR) will continue on treatment until evidence of disease progression or relapse.
1797879|NCT00570388|Drug|Prometa Treatment Program|"Day 1-3•Hydroxyzine HCL 50 mg and multivitamins with minerals po one hour before flumazenil infusion. Flumazenil infusion.
Day 1•Gabapentin 300 mg po 9PM w/ hydroxyzine HCL 50 mg PRN for sleep.
Day 2•Gabapentin 600 mg po 9PM w/ hydroxyzine HCL 50 mg PRN
Day 3•Gabapentin 900 mg po 9PM w/ hydroxyzine HCL 50 mg PRN
Days 4 through 28•Gabapentin 1200 mg po 9 PM
Days 29 through 31•Gabapentin 900 mg po 9 PM
Days 32 through 34•Gabapentin 600 mg po 9 PM
Days 35 through 38•Gabapentin 300 mg po 9 PM
Flumazenil Dosing Schedule
2 mg flumazenil is given as a slow IV push. Subjects in the placebo group will receive placebo flumazenil, gabapentin, and hydroxyzine; subjects in the active group will receive flumazenil, gabapentin, and hydroxyzine per protocol."
1797880|NCT00570401|Drug|dasatinib|
1797881|NCT00570414|Device|Laryngeal mask airway|Airway management by the use of the flexible, reinforced laryngeal mask airway
1797882|NCT00570414|Device|Endotracheal tube|Airway management by the use of endotracheal tube
1797883|NCT00570427|Behavioral|Problem Solving Therapy (PST)|Counseling
1797884|NCT00570427|Behavioral|Medication Management|If a participant chooses to receive antidepressant medication while in the study, a depression care specialist works with the participant's usual primary care provider to initiate an appropriate prescription and to follow-up with side effects, adherence, efficacy, etc. on a monthly or biweekly basis.
1798040|NCT00572143|Other|ca coli follow-up by GP|patients randomized to follow up by GP
1797885|NCT00570440|Drug|Oral contraceptives--ethinyl estradiol, levonorgestrel|3 visits - screening/enrollment, 6-months and 12 months
1797886|NCT00570466|Behavioral|Video Games|Two interactive, computer-based video games (9 sessions each) played in sequence to increase fruit,vegetable,water intake + physical activity + decrease TV viewing.
1797887|NCT00570466|Behavioral|Web and DVD knowledge|Web and DVD based knowledge games
1797888|NCT00570479|Drug|anecortave acetate|Patients will receive the specified dose of anecortave acetate every 4 months in an anterior juxtascleral depot injection
1797889|NCT00570492|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray 110mg QD
1797890|NCT00570492|Drug|Placebo nasal spray|Placebo nasal spray
1797891|NCT00570505|Device|LAP-BAND System|Reduction of food intake due to creation of smaller stomach pouch
1797892|NCT00571090|Procedure|Thyroid ultrasonography|Ultrasound-guided thyroid fine-needle aspiration biopsy
1797893|NCT00571103|Drug|acamprosate|Two 333mg tablets taken three times daily.
1797894|NCT00571116|Drug|Disulfiram|Given PO
1797895|NCT00571116|Drug|Arsenic trioxide|Given IV
1797896|NCT00571129|Procedure|DCR|"The patients were randomized into the two study groups, either with or without the insertion of a bicanalicular silicone tube after primary DCR.
In revision group patients were randomized into the two groups,ether with or without application of mitomycin C after DCR"
1797897|NCT00571142|Procedure|Bevacizumab + Pars plana vitrectomy|2.5 mg / 0.1 ml bevacizumab after pars plana vitrectomy. Limitorexis would be optional.
1797898|NCT00571142|Procedure|Bevacizumab + pars plana vitrectomy|2.5 mg /0.1 ml of bevacizumab after pars plana vitrectomy
1797899|NCT00571155|Drug|levetiracetam|oral and intravenous dosing 2000-3000 mg per day
1797900|NCT00571168|Drug|Emend|125 mg/d on day 1; 80 mg/d on day 2-4
1797901|NCT00571168|Drug|Placebo|Placebo capsules on day 1-4
1797902|NCT00571181|Device|Closed-loop system|Automatic delivery of propofol and remifentanil
1797903|NCT00571181|Device|TCI (Infusion Toolbox)|TCI administration of propofol and remifentanil
1797904|NCT00571194|Drug|pravastatin|"A single 10 mg dose of pravastatin will be administered 3 mL blood samples for pravastatin Pharmacokinetic evaluations will be collected at 0.5, 1, 2, 3, 4, 6, and 8 hours. 5 mL blood samples for pravastatin PK and laboratory evaluations will be drawn at pre-dose and 24 hours.
Vital Signs and Physical Exams will also be done throughout the study"
1797905|NCT00571207|Device|On-site oral fluid screening devices|Comparison of screening device results to oral and/or blood sample results
1797906|NCT00571207|Behavioral|Checklist: drug recognition expert|Correlation of drug recognition expert observations to findings for drugs in non-suspected/suspected cases
1797907|NCT00571220|Procedure|gastric bypass surgery|weight loss bariatric surgery
1797908|NCT00571220|Other|Diet induced weight loss|low calorie diet with meal replacements. weekly outpatient visits with nutritionist.
1797909|NCT00571246|Drug|lamotrigine and topiramate|lamotrigine (250 mg/day) 2 times a day, topiramate (250mg/day) 2 times a day, placebo
1797910|NCT00571259|Drug|Heparin 1000U/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
1797911|NCT00571259|Drug|4% Sodium Citrate with Gentamicin 320 mcg/mL|A volume sufficient to fill the catheter length will be instilled in both catheter ports post dialysis
1797912|NCT00571285|Dietary Supplement|Vitamin D3|600 IU Vitamin D3 capsule daily
1797913|NCT00571285|Dietary Supplement|Vitamin D3 - high dose|50,000 IU Vitamin D3 capsule once a week
1797914|NCT00571285|Dietary Supplement|Placebo|Placebo capsule given once a week
1797915|NCT00571298|Procedure|Extrapleural pneumonectomy (EPP)|Resection of the lung, the lining of the lung (pleura), the covering of the heart (pericardium), and the muscle that separates the chest and abdomen (diaphragm)
1797916|NCT00571298|Drug|Cisplatin|Given after the tumor is removed as a bath (perfusion) for one-hour
1797917|NCT00571298|Drug|gemcitabine|Given after the tumor is removed as a bath (perfusion) for one-hour
1797918|NCT00571298|Drug|amifostine|Given intravenously before perfusion chemotherapy and then 2 hours after the first dose
1797919|NCT00571298|Drug|sodium thiosulfate|Given intravenously immediately at the end of perfusion chemotherapy
1797920|NCT00571298|Procedure|Pleurectomy/Decortication|Resection of the lining of the lung (pleura), while the lung remains intact.
1797923|NCT00571337|Drug|Infliximab|Stopping infliximab in patients having been treated with this drug for at least one year and in stable remission for at least 6 month.
1797924|NCT00571350|Procedure|tvt-o operation|transvaginal tention free obturator tape
1797925|NCT00571350|Procedure|tvt o operation|transobturator vaginal tape insertion
1797926|NCT00571363|Procedure|standard surgery|excision with 4 mm margins
1797927|NCT00571363|Procedure|Mohs micrographic surgery|excision of basal cell carcinoma with 2 mm margins and immediate examination of margins for residual tumour. residual tumour was excised until complete tumour removal was achieved.
1797928|NCT00571376|Other|Health information technology and exchange|Health information technology includes electronic health records, electronic prescribing, and electronic results notification and/or viewers. Health information exchange includes use of central repositories of data and peer-to-peer models.
1797929|NCT00571402|Behavioral|Family-focused therapy for adolescents|FFT includes 25 sessions of psychoeducation, communication enhancement training, and problem-solving skills training plus ongoing pharmacological maintenance.
1797930|NCT00571402|Behavioral|Enhanced care|Enhanced care includes 3 sessions of family psychoeducation plus ongoing pharmacological maintenance.
1797931|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 15 microgram twice a day (BID)
1797932|NCT00571428|Drug|Arformoterol Tartrate Inhalation Solution|Nebulized arformoterol tartrate inhalation solution 30 microgram once a day (QD)
1797933|NCT00571428|Drug|Placebo|Placebo inhalation solution (citrate buffered 0.9% saline solution) once a day
1797934|NCT00571454|Behavioral|telephone depression care management|"1 call per week for first 4 weeks
1 call every other week for next 8 weeks"
1797935|NCT00571467|Drug|PRTX-100 (Staphylococcal protein A)|"4 weekly IV (in the vein) doses of 1 of the 3 following PRTX-100 dose levels:
Cohort 1: 0.075 mcg/kg
Cohort 2: 0.15 mcg/kg
Cohort 3: 0.30 mcg/kg"
1797936|NCT00571480|Other|acupuncture|ear acupuncture needles will be inserted into three preselected acupuncture points which are thought to be specific for low back pain
1797937|NCT00571480|Other|Sham acupuncture|ear acupuncture needles are inserted into three preselected acupuncture points which are thought not specific to low back pain
1797938|NCT00571480|Other|standard of care|participants can take acetaminophen 650 mg no more than every 6 hours and frequent rest and topical warm/cold compress
1797939|NCT00571493|Drug|Bortezomib|Velcade will be administered in four dose cohorts, 0.8 mg/m², 1.0mg/m², 1.3mg/m² and 1.5mg/m². Three patients will be accrued in each dose cohort with enrollment starting at dose cohort 1, 0.8mg/m². Subjects participating in this study will receive Velcade on Days -11, -8, -5, and -2.
1797940|NCT00571493|Drug|BEAM|carmustine 300mg/m2, etoposide 100mg/m2 BID, cytarabine 100mg/m2 BID, melphalan 140mg/m2 BID
1797941|NCT00571493|Procedure|autologous peripheral blood stem cell transplantation|Peripheral blood stem cells will be collected as per the discretion of the treating physician. Once an adequate number of CD34+ cells/kg have been collected (as per existing institutional guidelines) the patient will begin the preparative regimen with for transplant. On day 0 of treatment, the previously stored hematopoietic stem cells will be re-infused. The cells will be removed from the storage freezer, brought to the patient area, thawed in a 370C water bath, and administered intravenously through a central line to the patient. Patients will then be cared for as standard transplant patients.
1797942|NCT00571506|Drug|Rosiglitazone|Rosiglitazone 4 mg tablets by mouth daily for 3 months
1797943|NCT00571506|Drug|Pioglitazone|Pioglitazone 30 mg tablet by mouth once daily
1797944|NCT00571519|Drug|Rivoglitazone HCl|0.5 mg tablets
1797945|NCT00571519|Drug|rivoglitazone HCl|1.0 mg tablets
1797946|NCT00571519|Drug|rivoglitazone HCl|1.5 mg tablets
1797947|NCT00571519|Drug|placebo|placebo tablets matching rivoglitazone tablets
1797948|NCT00571519|Drug|pioglitazone HCl|15 mg tablets
1797949|NCT00571519|Drug|pioglitazone HCl|30 mg tablets
1797950|NCT00571519|Drug|pioglitazone HCl 45 mg|45 mg tablets
1797951|NCT00571519|Drug|placebo|placebo capsules for pioglitazone
1797952|NCT00571519|Drug|metformin|Oral tablets. Rescue medication.
1797953|NCT00571545|Behavioral|Aerobic exercise|A supervised aerobic exercise program occurred weekly for 30 minutes with a 15 minute warm-up and a 15 minute cool down. A half hour educational session on aspects of exercise and overcoming barriers to exercise was also instituted.
1797954|NCT00571545|Behavioral|No exercise|Controls were wait-listed for the exercise program during the 10 week study period.
1797955|NCT00571558|Drug|aminolevulinic acid hydrochloride|Given PO
1797956|NCT00571558|Drug|photodynamic therapy|Undergo photodynamic therapy
1797957|NCT00571558|Other|laboratory biomarker analysis|Correlative studies
1797958|NCT00571571|Behavioral|Psychotherapy|Individual psychotherapy with parent collateral/psychoeducation as necessary.
1797959|NCT00571571|Behavioral|Individual Psychotherapy|Individual psychotherapy and family interventions (as needed)
1797960|NCT00571584|Drug|activated recombinant human factor VII|
1797961|NCT00571610|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous access from right or left subclavian vein, diagnostic assessment, then placement of the PTMA implant in the coronary sinus, great cardiac vein.
1797962|NCT00571623|Other|Chest Physiotherapy|10-minutes of chest physiotherapy using programmed parameters that are components of the specialty beds used in ICU
1797963|NCT00571636|Drug|Fentanyl|"The experimental drug will be diluted according to each NICU scheme and administered as an attach dose of 1 mcg/kg in 30' followed by continuous i.v. infusion of 1 mcg/kg/h. Infusion of the experimental drug has to begin within 24 hrs from the beginning of MV and has to be continued until the end of MV and not after 7 days of life. If the newborn is still on MV after the 7th day of life he/she will be treated for pain according to local protocols.
Open label boluses of Fentanyl during the study phase will be administered, in both groups when the EDIN pain score is > 6 and before performing the following invasive procedures:Peripherally inserted central venous catheter positioning;Re-intubation;Lumbar puncture;Pneumothorax or hydrothorax drainage."
1797964|NCT00571636|Drug|5% glucose solution|ev continuous infusion
1797965|NCT00571649|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Oral rivaroxaban 10 mg once daily administered for 35 +/- 4 days
1797966|NCT00571649|Drug|Enoxaparin|Subcutaneous enoxaparin 40 mg once daily (OD) administered for 10 +/- 4 days
1797967|NCT00571649|Drug|Rivaroxaban placebo|Oral rivaroxaban-matched placebo tablet OD for 35 +/- 4 days
1797968|NCT00571649|Drug|Enoxaparin placebo|Subcutaneous enoxaparin-matched placebo solution OD for 10 +/- 4 days
1797969|NCT00571662|Drug|Pentostatin|4 mg/m^2 intravenous(IV)once a day(QD)x3days (days -10, -9, -8)
1797970|NCT00571662|Radiation|Total-body irradiation (TBI)|TBI will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. TBI will be given on day -1.
1797971|NCT00571662|Drug|Cyclosporine A (CsA)|CsA will be given at 2.0 mg/kg intravenous (IV) Q 12hrs on days -1,0,and+1 (total 6 doses) then converted to oral at 2 mg/kg by mouth (PO) twice a day (BID) until day+80, then tapered 10% per week over approximately 3 months if no GVHD for related donor transplants. For unrelated CsA will be given at same dose and schedule until day+100 then tapered by 10% per week if no GVHD
1797972|NCT00571662|Drug|Mycophenolate Mofetil (MMF)|MMF 15 mg/kg by mouth twice a day (PO BID) will be given from day 0-27 then stopped without tapering for related donor transplants. For unrelated donor transplants MMF will be given at same dose until day+40 then tapered over 2months. in absence of GVHD. Doses will be rounded to nearest 250 mg.
1797973|NCT00571662|Drug|G-CSF|10 mcg/kg/day subcutaneously for at least 4 consecutive days.
1797974|NCT00571675|Drug|AT-101, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour on day 1, every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral AT-101 on cycle days 1-3
1797975|NCT00571675|Drug|placebo, prednisone and docetaxel|docetaxel (75mg/m2 intravenously over 1 hour every 21 days [one cycle]), oral prednisone (5mg BID on days 1-21), and oral placebo on cycle days 1-3
1797976|NCT00571688|Drug|Risperdal (risperidone) Consta|Risperdal Consta (TM) will be administered every 2 weeks by deep intramuscular (IM) gluteal injection, by a trained health care professional. Injections will alternate between the two buttocks. The initial dose will be 25 mg IM every 2 weeks. A minimum dose of 25 mg. every 2 weeks will be maintained. At the clinician's discretion, the dose may be advanced to 37.5 mg. or 50 mg. In addition, the dose will be raised to 37.5 mg. or 50 mg. if the following conditions remain: (1) Young Mania Rating Scale (YMRS) score > 12; or (2) Evidence of impending relapse; and no dose limiting side effect. If the 25 mg. dose is not tolerated, the dose can be held temporarily; however, attempts will be made to achieve and maintain the dose at 25 mg. (or higher) until the end of the study period.
1797977|NCT00571688|Drug|Treatment as usual|Treatment was provided in this arm based solely on the choice of the treatment provider and participant. Treatment providers were not part of the study staff and were completely free to make treatment choices except that they were not allowed to select a long-acting injectible.
1797978|NCT00571701|Drug|celebrex (celecoxib)|Adults: 400 mg celebrex (celecoxib) daily Pediatrics: 100 mg celebrex (celecoxib) daily for weight between 12-25 kg or 200 mg Celebrex (celecoxib) daily for weight >25 kg
1797979|NCT00571701|Drug|placebo|similar appearing capsules containing inert ingredients
1797980|NCT00571714|Drug|Peginterferon alpha-2a and ribavirin|Peginterferon alpha-2a 180mcg by subcutaneous injection every week and weight based ribavirin, 800 to 1400mg/day by mouth in two divided doses every day for 48 weeks
1797981|NCT00571714|Drug|Peginterferon alpha-2a , ribavirin and betaine|Peginterferon alpha-2a 180mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400 mg/day by mouth in divided doses twice a day plus betaine 10 gm dissolved in juice twice a day for twelve weeks followed by peginterferon alpha-2a 180 mcg given by subcutaneous injection every week plus weight based ribavirin 800 to 1400mg/day by mouth in divided doses twice a day for 36 weeks.
1797982|NCT00571727|Drug|mecasermin|injections BID of rhIGF-1, mecasermin
1797983|NCT00571740|Biological|bevacizumab|Given IV
1797984|NCT00571740|Biological|cetuximab|Given IV
1797985|NCT00571740|Drug|fluorouracil|Given IV
1797986|NCT00571740|Drug|leucovorin calcium|Given IV
1797987|NCT00571740|Drug|oxaliplatin|Given IV
1797988|NCT00571753|Drug|isoniazid|modified daily isoniazid dose according to NAT2 genotype (appr. 2.5 mg/kg, 5 mg/kg and 7.5 mg/kg for slow, intermediate and rapid acetylators, respectively).
1797989|NCT00571753|Drug|isoniazid|Treatment with a standard isoniazid dose of isoniazid (appr. 5 mg/kg b.w.)
1797990|NCT00571766|Drug|L-Arginine|Oral L-Arginine 2g, twice a day for 14 weeks
1797991|NCT00571766|Drug|Placebo|Placebo 2 g twice a day for 14 weeks
1797992|NCT00571779|Device|AtriCure Bipolar System|
1797993|NCT00571805|Drug|varencline|2.0 mg/day varencline (1.0 mg BID)
1797994|NCT00571805|Drug|placebo|matching placebo
1797995|NCT00571818|Procedure|Oral glucose tolerance test|test done over 2 hours
1797996|NCT00571818|Procedure|IV Glucose Tolerance Test|Done over 4 hours
1797997|NCT00571831|Procedure|intraocular lens implantation|Intraocular lens implantation
1797998|NCT00571844|Behavioral|DASH diet|Participants in the DASH diet condition receive instruction in modifying the content of their diet to meet DASH guidelines. Participants are explicitly asked not to exercise or to attempt weight loss at this time, and to focus their attention on what they eat. Following the 2-week feeding period, participants will receive instruction on the DASH diet and feedback on their adherence to the diet in a series of half-hour, weekly small group sessions (3 to 5 participants).
1797999|NCT00571844|Behavioral|DASH diet plus Weight loss|Participants in the DASH diet plus weight loss condition will receive the DASH dietary intervention as described in the DASH diet intervention and will participate in a program to promote weight loss consisting of 2 components: Supervised Aerobic Exercise and CBWL (Cognitive Behavioral Weight loss). During supervised exercise participants will exercise 3x/week under medical supervision at the Duke Center for Living. A trained exercise physiologist will supervise all exercise sessions, and will obtain exercise BP measurements to make sure that BP is not abnormally elevated. For the CBWL participants will meet in small groups of 3-5 patients for instruction in weight management techniques. CBWL will include Appetite Awareness Training (AAT), a self-monitoring strategy developed to provide more specific guidelines regarding how much to eat. Individuals learn to identify moderate hunger and fullness and use these internal cues to guide their eating.
1798000|NCT00571870|Drug|cetrorelix acetate|The GnRH antagonist, cetrorelix acetate (Cetrotide; Serono) 0.25 mg was added daily, starting when the leading follicle reached 14 mm in diameter during ovarian stimulation for IVF. When the leading follicle reached a mean diameter of 18 mm or two follicles or more reached a diameter of 17 mm, 250 μg of recombinant hCG (Ovidrel; Serono) SQ was injected. In Group A, the GnRH antagonist continued to be used until the day of hCG administration. In Group B, the GnRH antagonist was not administrated on the hCG day
1798001|NCT00571883|Other|questionnaire administration|
1798002|NCT00571883|Procedure|psychosocial assessment and care|
1798003|NCT00571883|Procedure|quality-of-life assessment|
1798004|NCT00571883|Procedure|regional lymph node dissection|
1798005|NCT00571883|Procedure|therapeutic conventional surgery|
1798006|NCT00571896|Drug|Senna+ docusate|Senna+Docusate: dose will be 8.6 mg senna concentrate with 50 mg docusate. The participants will take the medication as follows: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
1798041|NCT00572156|Drug|NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg once daily injection
1798042|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 150µg/kg once daily injection
1798043|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH (Somatropin) 45µg/kg and rhIGF-1 (Mecasermin) 50µg/kg once daily injections
1798007|NCT00571896|Drug|placebo|Placebo pill: The participants will use the placebo pills in the following manner: 1. Drink 4-6 glasses of fluid a day for the first two weeks after surgery 2. Take 2 SennaS tabs at bedtime the first night home from the hospital 3. If no bowel movement that next morning, take 2 tabs after breakfast. 4. If no bowel movement by evening, take 3 tabs at bedtime 5. If no bowel movement that next morning, take 3 tabs after breakfast 6. Once you do have a bowel movement, use the regimen described in the step two steps prior to the last one you used as your daily regimen. So, if you had a BM the morning after 3 tabs at bedtime, use steps 2 & 3 (2 tabs at night and in the morning) until the first-postoperative visit.
1798009|NCT00571922|Drug|Acamprosate|2 gr/day (333 mg, TID)
1798010|NCT00571922|Drug|placebo|matching placebo
1798011|NCT00571935|Drug|insulin aspart|
1798012|NCT00571935|Drug|soluble human insulin|
1798013|NCT00571948|Other|more meat and a vegetable oil rich in omega-3 fatty acids|"The vegetable-potato-meat-meal was given 5 to 7 times a week for at least during the seventh to tenth month.
The intervention meals had more meat (about 13 % of weight) and rapeseed oil (rich in omega-3 fatty acids)."
1798014|NCT00571948|Other|Babyfood with usual meat content and corn oil|The active comparator (which is the control group) got babyfood with usual meat content (8%) and with corn oil, which is rich in omega 6 linoleic acid
1798015|NCT00571961|Drug|Kaletra (lopinavir/ritonavir)|4 tablets, once a day (800 mg/dose) on Days 2 through 14 of this study
1798016|NCT00571961|Drug|buprenorphine|Buprenorphine will be obtained through prescription at the subject's drug treatment program.
1798017|NCT00571961|Other|Clinical evaluations/Blood draws|Physical examinations, vital sign measurements, 12-lead electrocardiogram (ECG), clinical laboratory evaluations (blood chemistry and blood counts), PK blood draws.
1798018|NCT00571974|Device|PDL-585, ScleroPLUS laser|PDT Treatment; emits light with 585 nm wavelength in pulses of 1.5 milliseconds in sections of 5 mm diameter to target the lesion and surrounding tissue
1798019|NCT00571974|Drug|5-Aminolevulinic Acid (Levulan KerastickTM)|Topically administered; incubation time 60-180 minutes; single dose (345 mg of active 5-ALA in 1.5 ml solution); soaked onto white gauze and applied to lesion, covered with sterile Xeroform gauze
1798020|NCT00571974|Procedure|Fluorescence Diagnosis Imaging|FD Image taken prior to PDL-585 usage
1798021|NCT00571987|Device|AngioDynamics (previously RITA Med,Inc) radiofrequency delivery system (consisting of a generator and Starburst XL probe)|Generator is connected to a single use probe. Probe is inserted into the lumpectomy cavity and heated to 100 degrees Celsius and held there for 15 minutes, after which probe is removed.
1798022|NCT00572000|Biological|HPV-16/18 L1 VLP AS04 vaccine|Representation: 0.5ml monodose vials Administration: intramuscular Schedule: 0, 1, 6 month
1798023|NCT00572013|Drug|Rituxan|375mg/m2 IV on days -20 to -8. Infusion to begin at rate of 50mg/hour for 1st hour.If no toxicity rate may be increased. A second infusion 375mg/m2 given 30days post transplant and again at 60 days post transplant
1798024|NCT00572013|Drug|BEAM|BCNU(carmustine)on day -6 300mg/M2 IV, etoposide 100mg/M2 BID on days -5 through -2, cytarabine 100mg/m2 BID on days -5 through -2, melphalan 140mg/m2 IV on day -1
1798025|NCT00572013|Procedure|Autologous stem cell transplant|following chemotherapy, on day 0 of treatment, the previously stored hematopoietic stem cells will be reinfused via the central venous line
1798026|NCT00572026|Drug|Methylphenidate Transdermal System|Daytrana wear time up to 15 hours
1798027|NCT00572039|Behavioral|PST|PST will be delivered in subjects' homes over the course of 6 weeks.
1798028|NCT00572039|Behavioral|ST|ST will be delivered in subjects' homes over the course of 6 weeks.
1798029|NCT00572052|Device|NovoFine® needle 6 mm|
1798030|NCT00572052|Device|Ultra-Fine needle 12.7 mm|
1798031|NCT00572065|Drug|arsenic trioxide|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Triseonx will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.
Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
1798032|NCT00572065|Drug|cytarabine|"Cytarabine will be administered at a dose of 10 mg/m2 subcutaneously (sc) twice daily (bid) from days 1-14. Trisenox will be administered at a dose of 0.25 mg/kg on days 1-5 and days 8-12. Trisenox will be restarted only when the QT interval returns to less than 500 msec. One treatment cycle consists of 2 weeks, with 14 days of cytarabine and 10 days of ATO.
Subsequent cycles will be administered at the investigator's discretion, depending on response and tolerability. Patients may continue to receive treatment with Trisenox /LDAC for a period of up to 2 years as long as stable disease or clinical benefit and absence of unacceptable toxicity can be demonstrated."
1798033|NCT00572078|Drug|Sorafenib|Cohort 1 200 mg po BID D1-5; Cohort 2 200 mg po BID; Cohort 3 400 mg po BID D1-5 Cohort 4 400 mg po BID
1798034|NCT00572091|Device|PTMA Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein.
1798035|NCT00572104|Other|resistance exercise|12 month training intervention of weight resistance exercise. All participants receive a daily calcium and vitamin D supplement
1798036|NCT00572104|Other|plyometric exercise|12 month training intervention of plyometric exercise. All participants receive a daily calcium and vitamin D supplement
1798037|NCT00572117|Drug|Topiramate|Medication will be slowly increased over 5 weeks from 25 mg a day to 150 mg twice a day in an effort to minimize side effects that might enable participants and raters to guess whether they are on active drug or placebo. Subjects will continue on 150 mg twice a for Weeks 6-12 of the study.
1798038|NCT00572130|Genetic|Rexin-G Dose 1|Rexin-G i.v., 1 x 10e11 cfu, two times a week x 4 weeks, rest 2 weeks May be repeated if grade 1 or less toxicity
1798039|NCT00572130|Genetic|Rexin-G Dose 2|Rexin-G i.v., 1 x 10e11 cfu, three times a week x 4 weeks; rest 2 weeks May repeated if grade 1 or less toxicity
1798044|NCT00572156|Drug|Increlex® (Mecasermin [rDNA origin] injection) + NutropinAq® (Somatropin [rDNA origin])|rhGH 45µg/kg and rhIGF-1 100µg/kg once daily injections
1798045|NCT00572169|Drug|Velcade|Will be given in central venous catheter
1798046|NCT00572169|Drug|Thalidomide|Capsule taken by mouth
1798047|NCT00572169|Drug|Dexamethasone|A pill taken by mouth
1798048|NCT00572169|Drug|Adriamycin|Given into the vein (IV) by a continuous infusion through a central catheter
1798049|NCT00572169|Drug|Cisplatin|Given into the vein (IV) by a continuous infusion through a central catheter
1798050|NCT00572169|Drug|Cyclophosphamide|Given into the vein (IV) by a continuous infusion through a central catheter
1798051|NCT00572169|Drug|Etoposide|Given into the vein (IV) by a continuous infusion through a central catheter
1798052|NCT00572182|Drug|MK-0752|This is a dose escalation study. Patients may receive 150, 200, 260 or 325 mg/m2 orally for 3 consecutive days of every 7 days for 28 days (dosing regimen 1 - closed to accrual 2/23/2010) or 800, 1000, 1400, or 1800 mg/m2 orally once weekly for 28 days (1 course). In the absence of unacceptable toxicity or disease progression, treatment may continue for 6 courses.
1957472|NCT02375971|Drug|Ranibizumab|0.1 mg Intravitreal administration Administration in both eyes on day 1 Up to 2 re-treatments in each eye 28 days minimum interval between 2 injections
1798054|NCT00572208|Drug|Gabapentin group|"Gabapentin group:
Preoperative (2 h before surgery): Tablet Gabapentin 1200 mg (blinded)
st Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
nd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
rd Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)
th Postoperative day: Tablet Gabapentin 300 mg twice a day (blinded)"
1798055|NCT00572221|Behavioral|Continuing Quality Improvement and Quality Assurance system|The main intervention is a facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation.
1798056|NCT00572221|Behavioral|CQI and QA System with Best-Practice Care Protocols|A facility-wide Continuing Quality Improvement and Quality Assurance system, with problem recognition and ongoing evaluation. Research clinical staff will also provide best-practice care protocols designed by our research team to address targeted problem conditions.
1798057|NCT00572234|Drug|bupropion SR|12 week course of bupropion SR 150 mg, BID
1798058|NCT00572247|Behavioral|Psychiatric Rehabilitation Approach to Weight Loss|The use of psychiatric rehabilitation as a way to lose weight
1798059|NCT00572260|Drug|daptomycin 6 mg/kg IV|daptomycin 6 mg/kg IV given during induction phase as a one-time prophylactic dose for patients undergoing cardiac valve replacement and coronary artery bypass grafting (CABG) who are at increased risk for infection due to methicillin-resistant Staphylococcus aureus (MRSA)
1798060|NCT00572299|Drug|alendronate|70 mg of alendronate orally per week for at least three months in patients receiving at least 10 mg/day or oral prednisone for at least three months
1798061|NCT00572312|Drug|atorvastatin (Sortis) 40 mg|In the 8-weeks run-in period angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor blockers were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 40 mg of atorvastatin in two active treatment periods lasting 8 weeks each
1798062|NCT00572338|Other|No drugs are involved|No treatment or drugs are involved in this research. Participating in this study requires that blood and bone marrow samples be obtained as a part of the diagnostic work-up or follow-up of participant's multiple myeloma. Bone marrow/peripheral blood samples will be collected at the same time for research purposes. Data will be collected including demographic information gathered from your medical record, including gender, date of birth, ethnicity, date of diagnosis, laboratory and pathology results, treatment protocols, dates of relapses, subsequent treatment protocols, and current treatments and medications.
1798063|NCT00572351|Other|Red Wine|8 ounces of assigned beverage (red wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
1798064|NCT00572351|Other|White Wine|8 ounces of assigned beverage (white wine) each evening and abstinence from any other alcoholic beverages, grape juice, grapes, or raisins.
1798065|NCT00572364|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
1798066|NCT00572377|Drug|FemLife Gel|the gel or placebo (240 mcg)applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
1798067|NCT00572377|Drug|Placebo|the gel or placebo (240 mcg) applied to the vagina; 20 doses to be used over the 30 day period and to complete the Female Sexual Encounter Profile (FSEP).
1798068|NCT00572390|Drug|oestrogen|Cyclic oestrogen substitution therapy
1798069|NCT00572416|Behavioral|Individual Sleep Promotion Plan|Four components, including activity-rest, sleep-wake, psychological distress, and symptom management. Sleep-wake component has four strategies: stimulus control, sleep restriction, relaxation, and sleep hygiene
1798070|NCT00572416|Behavioral|Healthy Eating Control|Equal time and attention and information about healthy eating
1798071|NCT00572429|Dietary Supplement|l-carnitine|3 gram daily dose
1798072|NCT00572455|Drug|PF-04217329 - Lowest Dose|1 drop of lowest dose PF-04217329, once a day, per dosed eye for duration of study.
1798073|NCT00572455|Drug|PF-04217329 - Low Dose|1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
1798074|NCT00572455|Drug|PF-04217329 - Middle Dose|1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
1798075|NCT00572455|Drug|PF-04217329 - High Middle Dose|1 drop of high middle dose PF-04217329, once a day, per dosed eye for duration of study.
1798076|NCT00572455|Drug|PF-04217329 - High Dose|1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
1798077|NCT00572455|Drug|PF-4217329 - Highest Dose|1 drop of highest dose PF-04217329, once a day, per dosed eye for duration of study.
1798078|NCT00572455|Drug|PF-04217329 - Vehicle|1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
1798079|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
1798080|NCT00572455|Drug|PF-04217329 - Low Dose|Five minutes after latanoprost vehicle, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
1957473|NCT02375971|Procedure|Laser therapy|Treatment in both eyes on day 1 Supplementary laser treatments are allowed until 11 days after first treatment
1798081|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
1798082|NCT00572455|Drug|PF-04217329 - Middle Dose|Five minutes after latanoprost vehicle, 1 drop of middle dose PF-04217329, once a day, per dosed eye for duration of study.
1798083|NCT00572455|Drug|Latanoprost Vehicle|1 drop of latanoprost vehicle, once a day, per dosed eye for duration of study.
1798084|NCT00572455|Drug|PF-04217329 - High Dose|Five minutes after latanoprost vehicle, 1 drop of high dose PF-04217329, once a day, per dosed eye for duration of study.
1798085|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
1798086|NCT00572455|Drug|PF-04217329 - Low Dose|Five minutes after latanoprost 0.005%, 1 drop of low dose PF-04217329, once a day, per dosed eye for duration of study.
1798087|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
1798088|NCT00572455|Drug|PF-04217329 - Middle Dose|Five minutes after latanoprost 0.005%, 1 drop middle dose PF-04217329, once a day, per dosed eye for duration of study.
1798089|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
1798090|NCT00572455|Drug|PF-04217329 - High Dose|Five minutes after latanoprost 0.005%, 1 drop high dose PF-04217329, once a day, per dosed eye for duration of study.
1798091|NCT00572455|Drug|Latanoprost 0.005%|1 drop of latanoprost 0.005%, once a day, per dosed eye for duration of study.
1798092|NCT00572455|Drug|PF-04217329 - Vehicle|Five minutes after latanoprost 0.005%, 1 drop of PF-04217329 vehicle, once a day, per dosed eye for duration of study.
1798093|NCT00572468|Drug|Simvastatin|40 mg of simvastatin
1798094|NCT00572468|Other|Placebo|placebo
1798095|NCT00572481|Procedure|Axillary Reverse Mapping|During surgery, the technetium-99m sulfur colloid will be injected into the breast and the blue dye injected (if the patient is not allergic and it is not required to locate the SLN) in the patient's ipsilateral upper arm. The lymph node biopsy and/or dissection will be performed by the surgeon, according to standard practice.
1798096|NCT00572494|Device|MAGIC EXPLORER (Biotronik AG)|The lesion is pre-dilated with the PLEON EXPLORER balloon with a length of 10 mm or 15 mm or 20 mm under angiographic control. After dilation, the stenosed area is treated by one AMS implant. If the implanted stent is not fully apposed to the vessel wall or if initial angiography reveals a residual stenosis, the stent may be post-dilated with the delivery system balloon. If necessary, a high-pressure, non-compliant balloon catheter may be used.
1798097|NCT00572494|Device|PLEON EXPLORER (Biotronik AG)|The lesion is dilated with the PLEON EXPLORER balloon with lengths of 10 mm or 15 mm or 20 mm, respectively. In case that the PTA procedure results in a residual stenosis of >50%, the AMS implant should be used to improve the result. A flow-limiting dissection does not qualify for stenting. Best effort must be made to obtain a satisfactory result (e.g. multiple and prolonged inflations) before a patient in the PTA group can be treated with a stent.
1798098|NCT00572507|Device|MonoMax®|Abdominal wall closure with ultra-longterm absorbable monofilament suture after primary median laparotomy
1798099|NCT00572520|Behavioral|Weight loss treatment|Over 2 years, this treatment involves a total of 26 group visits and 10 individual visits with a health education counselor. Group visits, led by a registered dietitian and a licensed exercise physiologist, will target diet and physical activity.
1798100|NCT00572520|Behavioral|Behavior therapy for depression|Behavior therapy for depression will be delivered by a trained behavior therapist. Participants receiving behavioral counseling will learn about depression, links between activity and mood, and will be asked to keep a diary of moods and activities.
1798101|NCT00572520|Behavioral|Health education counseling|Health education counseling will be delivered by a trained health education counselor. Participants receiving health education will learn about women's health topics and receive tips on staying healthy and preventing disease.
1798102|NCT00572533|Other|ESA Dose Adjustment per standard Anemia Management Protocol|Amount of ESA dose adjustment in Units per week guided by standard Anemia Management Protocol in use at the facility
1798103|NCT00572533|Other|"ESA Dose Adjustment per Smart Anemia Manager Algorithm"|"Amount of ESA dose adjustment in Units per week individualized to subject's dose-response profile guided by Smart Anemia Manager algorithm"
1798104|NCT00572559|Drug|Vancomycin|1 gram IV every 12 hours for 7 to 14 days
1798105|NCT00572559|Drug|Linezolid|600 mg every 12 hours (intravenously [IV] for a minimum of the first 4 days followed by a switch to oral if tolerated by patient) for a total duration of 7 to 14 days
1798106|NCT00572572|Drug|Aprepitant|Subjects will be randomized to receive aprepitant 125mg PO day 3 then 80mg on days 4-7 on either cycle 1 or cycle 2.
1798107|NCT00572572|Drug|Placebo|Subjects will be randomized to receive placebo on days 3-7 on either cycle 1 or cycle 2.
1798108|NCT00572585|Drug|AEB071|
1798109|NCT00572585|Drug|Placebo|
1798110|NCT00572598|Drug|4- [F-18] fluoropaclitaxel|4- [F-18] fluoropaclitaxel, <84 micrograms, <10 mCi, IV followed by PET/CT imaging
1798111|NCT00572611|Drug|[14C]-bilastine|Single oral dose of 20 mg [14C]-bilastine. 1 capsule. 1 day dosing only
1798112|NCT00572624|Behavioral|Diet|Participants attended 20 group behavioral modification sessions led by a behaviorist, a registered dietician, and a physical therapist. The meal plans ranged from 1200 to 1500 kilocalories per day, depending on subject sex and BMI, and were designed to achieve ≤1% body weight loss/week. Participants completed daily food records, and were taught a variety of weight management skills. The exercise component included strength, flexibility, balance, and endurance instruction, gradually increasing to 30 minutes of exercise 5 days/week.
1798113|NCT00572624|Procedure|Gastric bypass surgery|The same surgeon performed all bypass procedures using standard techniques. A small (~20 ml) proximal gastric pouch was created by stapling the stomach, and a 75-cm Roux-en-Y limb was constructed by transecting the jejunum distal to the ligament of Treitz, and creating a jejunojejunostomy 75 cm distal to the transection.
1798114|NCT00572637|Drug|CEP-18770|Administered as intravenous infusion on days 1, 4, 8, and 11 of a 21-day cycle up to 6 cycles. Starting dose 0,1 mg/sqm
1798115|NCT00572650|Drug|vildagliptin|16 volunteers in each group of mild renal impairment patients and their matched healthy volunteers will receive once daily doses of 100mg LAF237 for 14 days.
1798160|NCT00573001|Drug|Tenofovir/Emtricitabine/Efavirenz (Atripla)|Tenofovir/Emtricitabine/Efavirenz (Atripla) 300/200/600mg 1cp/day
1798900|NCT00577135|Drug|Furosemide-Continuous Infusion|Continuous infusion
1798116|NCT00572663|Drug|ACC (N-acetylcysteine) 1200 mg|N-acetylcysteine (ACC) 1200 mg In the 8-weeks run-in period angiotensin converting enzyme inhibitors and/or angiotensin II subtype 1 receptor antagonists were administered to achieve the target blood pressure below 130/80 mmHg. Next, they were randomly assigned to add (or not) 1200 mg N-acetylcysteine in two active treatment periods lasting 8 weeks each
1798117|NCT00572689|Drug|Exenatide|10 microgram injected sub-cutaneously once
1798118|NCT00572689|Genetic|Buccal/blood Sample Collection|Buccal/blood Sample collection for TCF7L2 polymorphism genetic testing
1798119|NCT00572702|Procedure|Vaginal fixation Amreich-Richter|Descending vaginal cuff will be treated with fixation of the cuff on sacrospinous ligament
1798120|NCT00572702|Procedure|Prolift total|Descending vaginal cuff will be treated with insertion of site-specific mesh into the vesico-vaginal and recto-vaginal space
1798121|NCT00572728|Procedure|CT|Undergo 18F-FLT PET/CT
1798122|NCT00572728|Drug|18F-FLT|Undergo 18F-FLT PET/CT
1798123|NCT00572728|Procedure|PET|Undergo 18F-FLT PET/CT
1798124|NCT00572741|Dietary Supplement|B12|Methylcobalamin Dose: 75 μg/kg every 3 days
1798125|NCT00572741|Dietary Supplement|Placebo|cellulose
1798126|NCT00572741|Dietary Supplement|folate|Folinic acid: Dose: 400 µg twice a day (BID)
1798127|NCT00572741|Dietary Supplement|B complex|B-Complex: B-1 (3 mg); B-2 (3.4 mg); B-352 (20 mg); B-6 (4 mg;) Pantothenic Acid(10 mg); Biotin (300 mcg); pyridoxal (25mg)
1798128|NCT00572741|Dietary Supplement|vitamin C|Vitamin C 500 mg
1798129|NCT00572741|Dietary Supplement|cod liver oil|Cod liver oil 1/2 teaspoon
1798130|NCT00572741|Dietary Supplement|Mineral complex|Magnesium citrate (200 mg); Selenium (50 mcg); Zinc picolinate (25 mg); Molybdenum (50 mcg); Calcium citrate (400 mg)
1798131|NCT00572741|Dietary Supplement|carnitine|Acetyl L-Carnitine Dose: 250 mg
1798132|NCT00572754|Procedure|Circumcision|Circumcision by tying a ligature around the foreskin.
1798133|NCT00572767|Drug|Dextro-Amphetamin|After a two week baseline phase the patients will receive a dose of 10mg Dexamphetamine on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
1798134|NCT00572767|Other|Glucose|"After a two week baseline phase the patients will receive a dose of 10mg of a placebo (same appearance as the experimental drug) on two days per week for five weeks. Within a time frame of one to three hours they should receive physiotherapy focusing on neurodevelopmental (NDT) for one hour.
The treatment of the control group will be the same as for the experimental group except the content of the drug capsule."
1798135|NCT00572806|Drug|insulin aspart|
1798138|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine on-time administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given six months after dose 1.
1798139|NCT00572832|Biological|Quadrivalent human papillomavirus vaccine delayed administration|The vaccine is given in three doses: Dose 1; dose 2 given 60 days later; dose 3 given 12 months after dose 1.
1798140|NCT00572845|Other|Weaning of Antispasticity Medication|Weaning of antispasticity medication over a three day period and then titration back to previous dose over a three day period.
1798141|NCT00572858|Procedure|Blood test|for cholesterol, glucose and insulin levels and levels of various hormones, including but not limited to estrogen
1798142|NCT00572858|Genetic|Blood test|Blood test for genetic testing
1798143|NCT00572858|Procedure|Ultrasound of neck arteries|Non-invasive test using ultrasound waves to measure the thickness of the arteries
1798144|NCT00572858|Procedure|Saliva test|Saliva test for cotisol levels
1798145|NCT00572871|Other|plyometric exercise|single bout of plyometric exercise
1798146|NCT00572871|Other|resistance exercise|single bout of resistance exercise
1798147|NCT00572871|Other|No exercise|Will not do any exercise
1798148|NCT00572884|Other|permethrin insecticide|25 mg neat carbon-14 labelled permethrin applied dermally in isopropyl alcohol, once for 8 hours containing 1 microcurie of carbon-14
1798149|NCT00572897|Drug|Fludarabine, Melphalan +/- ATG|"Conditioning regimen for Allogenic Stem Cell Transplant:
Related Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily)
Unrelated Donor Fludarabine days -6 to -2 (30mg/m2 IVPB over 30 minutes daily) Melphalan days -3 to -2 (70mg/m2 IVPB over 30 minutes daily) ATG (Thymoglobulin®) days -3 to -1 (0.5 mg/kg IV on day -3 [given over 6 hours], and 2 mg/kg on days -2 and -1 [given over 4 hours])"
1798150|NCT00572910|Biological|Comparator: Placebo (PBO)|Group 6: Placebo (PBO / PBO / PBO)
1798151|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 5A: V710 (90 mcg / 90 mcg / 90 mcg) with MAA
Group 5B: V710 (90 mcg / 90 mcg / PBO) with MAA"
1798152|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 4A: V710 (60 mcg / PBO / 60 mcg) with MAA
Group 4B: V710 (60 mcg / PBO / PBO) with MAA"
1798153|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 3A: V710 (60 mcg / 60 mcg / 60 mcg) with MAA
Group 3B: V710 (60 mcg / 60 mcg / PBO) with MAA"
1798154|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 2A: V710 (60 mcg / PBO / 60 mcg) without MAA
Group 2B: V710 (60 mcg / PBO / PBO) without MAA"
1798155|NCT00572910|Biological|V710 Comparator: Placebo (PBO)|"Group 1A: V710 (60 mcg / 60 mcg / 60 mcg) without MAA
Group 1B: V710 (60 mcg / 60 mcg / PBO) without MAA"
1798157|NCT00572962|Procedure|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair|use of a tissue separating mesh (Proceed®) in Laparoscopic Ventral hernia repair
1798158|NCT00572975|Other|Pentadecanoic acid (PA) and Triheptadecanoin (THA)|"Two fats (Pentadecanoic acid and Triheptadecanoin) are administered in a breakfast shake for the purposes of determining malabsorption.
in breakfast shake x1"
1798159|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Nevirapine|Tenofovir/Emtricitabine(Truvada) 245/200mg 1cp/day ; Nevirapine 200mg 2cp/day after first 14 days
1799071|NCT00570752|Other|Placebo|
1798161|NCT00573001|Drug|Tenofovir (Viread) and Lopinavir/Ritonavir (Aluvia)|Tenofovir (Viread) 300mg 1cp/day ; Lopinavir/Ritonavir (Aluvia) 400/100mg 4cp/day
1798162|NCT00573001|Drug|Tenofovir/Emtricitabine (Truvada) and Zidovudine|Tenofovir/Emtricitabine (Truvada) 245/200mg 1cp/day ; Zidovudine 300mg 2cp/day
1798163|NCT00573014|Other|Cervical Spine Clearance|All OBTPs with gross movement of all four extremities admitted to MetroHealth Medical Center who underwent a CT CS at MHMC between October 2006 and September 2008 will be included. Prospective data will be collected on these patients including age, gender, mechanism of injury, Glasgow Coma Scale (GCS) on admission, results of CT CS, GCS at the time of collar clearance, day of collar clearance, collar complications, date of reexamination, and results of reexamination. We will define an obtunded patient as a patient who was unable to reliably describe the presence or absence of CS symptoms in the opinion of the examining physician. Patients needed to have gross movement of all four extremities to be included in the study. We defined cervical collar complications as skin breakdown identified either by the skin care team during weekly rounds in the intensive care unit or by the treating physician at any time.
1798164|NCT00573027|Procedure|noninvasive tests|clinically indicated coronary angiography with adenosine coronary flow reserve measurement and acetylcholine provocative testing in the cardiac catheterization laboratory; Peripheral Artery Tonometry (PAT) testing; Cardiac Magnetic Resonance (CMR) imaging.
1798165|NCT00573053|Other|Oxygen saturation range|Maintain functional oxygen saturation range between 91 and 95%
1798166|NCT00573053|Other|Oxygen saturation range|Maintain functional arterial oxygen saturations in the range of 85- 89%
1798167|NCT00573066|Drug|Dexmedetomidine|Dosage levels: Dose Level 1: Loading dose 0.35mcg/kg and CIVI 0.25mcg/kg/hr Dose Level 2: Loading Dose of 0.7mcg/kg and CIVI 0.5mcg/kg/hr and Dose Level 3: Loading Dose 1 mcg/kg and CIVI 0.75 mcg/kg/hr.
1798168|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by heavy weight mesh|Laparoscopic Ventral hernia repair by heavy weight mesh
1798169|NCT00573105|Procedure|Laparoscopic Ventral hernia repair by lighter weight mesh|Laparoscopic Ventral hernia repair by lighter weight mesh
1798170|NCT00573131|Drug|OncoGel (Paclitaxel gel)|6.3 mg/mL tumor volume, injected into the esophagus during endoscopy, once, before starting chemoradiotherapy
1798171|NCT00573131|Drug|cisplatin|75 mg/m2 IV (in the vein) once on Day 1 and Day 29
1798172|NCT00573131|Drug|5-FU|1000 mg/m2/day, IV (in the vein) for 4 days (96 hours) for two cycles starting on Day 1 and Day 29
1798173|NCT00573131|Radiation|radiation therapy|50.4 Gy, given in 28 treatments, once per day for 5 1/2 weeks
1798174|NCT00573131|Procedure|esophageal resection|Removal of esophagus after completion of chemotherapy and radiation therapy
1798175|NCT00573144|Drug|Nesiritide|Infusion of 72 hours of IV nesiritide at 0.006 mcg/kg/min.
1798176|NCT00573144|Drug|Placebo|Infusion of 72 hours of saline solution (packaged to match active comparator)
1798177|NCT00573157|Drug|Atacicept|Atacicept will be administered at a dose of 150 milligram (mg) subcutaneously (SC) twice weekly for 4 weeks followed by maintenance dose of 150 mg SC once weekly for 48 weeks.
1798178|NCT00573157|Drug|Mycophenolate mofetil|MMF will be administered orally with a starting dose of 500 mg twice daily for 1 week, will be increased to 1000 mg twice daily for 1 week, then it will be adjusted to 1500 mg or lower twice daily as per investigator's discretion.
1798179|NCT00573157|Drug|Placebo|Placebo will be administered at a dose of 150 mg SC twice weekly for 4 weeks followed by 150 mg SC once weekly for 48 weeks.
1798180|NCT00573157|Drug|Corticosteroids|High dose CS of 0.8 mg per kilogram per day or maximum of 60 mg per day prednisone or prednisone equivalent, whichever is less will be administered for 4 Weeks and will be tapered to 7.5 to 10 mg/day up to Week 12.
1798181|NCT00573170|Drug|TREXIMET®|Sumatriptan + Naproxen Sodium (fixed dose combination tablet of sumatriptan succinate [equivalent to sumatriptan 85mg] and naproxen sodium 500mg)
1798182|NCT00573170|Drug|Butalbital-containing Combination Medications (BCM)|butalbital-containing combination medication (BCM; acetaminophen 325mg, caffeine 40mg, and butalbital 50mg) [currently marketed as Fioricet]
1798183|NCT00573170|Drug|placebo|placebo
1798184|NCT00573183|Behavioral|STAGE-12|The STAGE-12 intervention will consist of a combination of five group and three individual sessions. The five group sessions will be taken from the Project MATCH Twelve Step Facilitation manual as modified for use with drug abusers and adapted for delivery in a group format. The group sessions will be augmented by three individual sessions derived from the introductory and termination sessions from the TSF manual and incorporating elements of the brief intensive 12-step referral procedure.
1798185|NCT00573183|Behavioral|Treatment as Usual|
1798186|NCT00573196|Radiation|Far infrared|Far infrared radiation (5μm to 15μm wavelength)
1798187|NCT00573209|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
1798188|NCT00573222|Drug|Symbicort|
1798189|NCT00573248|Drug|Nicotine|"21 mg nicotine patches for smokers for 2 days
7 mg nicotine patches for nonsmokers for 2 days"
1798190|NCT00573248|Other|Placebo|Placebo Patch
1798191|NCT00573261|Drug|Pregabalin|Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
1798192|NCT00573261|Drug|Placebo|Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.
1798193|NCT00573274|Device|Physioflow Impedance|6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
1798194|NCT00573287|Drug|clozapine|clozapine--tabs, 450mg. max, daily, 24 weeks
1798195|NCT00573287|Drug|risperidone|risperidone--tabs, 6mg max, daily, 24 weeks
1798196|NCT00573300|Procedure|Phlebotomy|Single blood draw
1798197|NCT00573313|Drug|S-adenosylmethionine|Alcoholic liver disease patients received drug at dose of 400 mg three times daily for 24 weeks.
1798198|NCT00573313|Drug|Placebo|Alcoholic liver disease patients received identical size and shape sugar pill placebo three times daily for 24 weeks.
1798199|NCT00573326|Drug|Imatinib|200 mg p.o. once a day for 6 months
1798200|NCT00573339|Other|Cardiac MRI|up to 3 Cardiac MRI scans per participant in 1-4 months
1798201|NCT00573352|Radiation|Far Infrared|Far Infrared Radiation (5μm to 20μm wavelength). Duration is 30 to 40 minutes per session
1799072|NCT00570752|Drug|BMS-582949|
1798202|NCT00573365|Device|Gentlewaves Select™ handheld high energy LED array|LED photomodulation within 5-10 minutes before and within 5-10 minutes after each radiation treatment
1798203|NCT00573365|Radiation|Radiation|Weekly radiation treatment
1798204|NCT00573365|Radiation|Radiation|Weekly radiation treatment
1798205|NCT00573378|Drug|PEG-IFN-a2b|Patients will receive pegylated interferon α-2b (Pegintron®) (PEG-IFN-α2b) 150 µg subcutaneously, once a week. Patients and/or caregivers identified by the patient will be taught how to perform subcutaneous injections of the PEG-IFN-α2b by trained nurses in the chemotherapy infusion center at the University of Michigan Comprehensive Cancer Center. Those patients who do not feel comfortable receiving the injections outside of the cancer center, or are deemed unreliable in administering injections per the training nurse, will return to the cancer center infusion room on a weekly basis to receive subsequent injections.
1798206|NCT00573391|Drug|Velcade, Thalidomide, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11
Yr 1: Every 28-35 days-12 cycles
Yr 2: Every 8-10 weeks- 6 cycles
Thalidomide - By Mouth Days 1-28
Yr 1: Every 28-35 days-12 cycles
Yr 2: Every 8-10 weeks- 6 cycles"
1798207|NCT00573391|Drug|Velcade, Melphalan, and Dexamethasone|"Velcade - Into vein (IV) Days 1, 4, 8, 11
Yr 1: Every 28-35 days-12 cycles
Yr 2: Every 8-10 weeks- 6 cycles"
1798208|NCT00573404|Drug|imatinib mesylate|will start at 200 mg daily and will be escalated up to 400 mg bid.If the 400 mg bid dose is tolerated, no further dose escalation will be performed. In the case of excessive toxicity on the starting dose, the option for de-escalation is provided. Sunitinib will start at 25 mg daily and if tolerated, will be escalated to 37.5 mg daily for subsequent dose levels.
1798209|NCT00573404|Drug|sunitinib malate|Not specified
1798210|NCT00573404|Other|pharmacological study|Not specified
1798211|NCT00573417|Drug|modafinil|modafinil 100mg tablets. dose excalation up to 300mg
1798212|NCT00573417|Drug|Placebo|
1798213|NCT00573430|Drug|Candesartan Cilexetil|8 mg oral once daily dose
1798214|NCT00573430|Drug|Candesartan Cilexetil|16 mg oral once daily dose
1798215|NCT00573430|Drug|Candesartan Cilexetil 32mg|32 mg oral once daily dose
1798216|NCT00573443|Drug|dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 20 mg/ Q 10 mg, taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
1798217|NCT00573443|Drug|dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg|Dextromethorphan hydrobromide (DM) and quinidine sulfate (Q) capsules (AVP-923 capsules), containing DM 30 mg/ Q 10 mg taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
1798218|NCT00573443|Drug|Placebo|Placebo capsules (identical in appearance to AVP-923 capsules being studied in this trial), taken once daily for 1 week and then twice daily for 11 consecutive weeks to complete a 12-week period
1798219|NCT00573456|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
1798220|NCT00573469|Drug|D9421-C, 9mg|D9421-C 9 mg was given once daily for 8 weeks.
1798221|NCT00573469|Drug|D9421-C, 15mg|D9421-C 15 mg was given once daily for 8 weeks.
1798222|NCT00573469|Drug|Placebo|D9421-C matching placebo was given once daily for 8 weeks.
1798223|NCT00573482|Behavioral|REDE|"The intervention group received the education in REDE techniques.
The intervention in this study comprised four components:
Four group education sessions to introduce the REDE principles of eating;
Approximately 10 new lower energy-dense foods were introduced in the employee cafeteria daily at lunchtime;
Food labels for all foods sold in the employee cafeteria at lunch time, which provided the energy density, calories, and macronutrient content of the prepared cafeteria foods. Prior to the intervention almost no foods had food labels.
Price reductions for lower energy density items. Both groups were exposed to the food labels and the new lower ED foods, but only the intervention group received the education sessions about how to take advantage of the new labels and cafeteria foods and only they were eligible for the price reductions."
1798224|NCT00573482|Behavioral|control|The control group received no REDE intervention at all. Both groups were exposed to the food labels and the new lower ED foods, but the control group did not receive the education sessions.
1798225|NCT00573495|Biological|hTERT/Survivin Multi-Peptide Vaccine|100 mcg subcutaneous every 2 weeks four times, then monthly up to 28 vaccinations
1798226|NCT00573508|Drug|Placebo|Oral Administration
1798227|NCT00573508|Drug|Solifenacin Succinate|Oral Administration
1798228|NCT00573534|Drug|Vyvanse|Patients will be titrated from 30 mgs to 50 mgs to 70 mgs over four weeks, as tolerated and as needed to control ADHD symptoms
1798229|NCT00573547|Drug|Fluoxetine|Fluoxetine will be dosed at 90 mg once a week
1798230|NCT00573560|Device|VPD Implant System|Percutaneous introduction using standard catheterization techniques of the VPD Implant.
1798231|NCT00573573|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each session.
1798232|NCT00573586|Device|Sonablate 500 (SB-500)|Sonablate 500 (SB-500)
1798233|NCT00573599|Drug|prochlorperazine and benadryl IV|prochlorperazine and benadryl IV, saline subQ
1798234|NCT00573599|Drug|Imitrex SubQ, saline IV|Imitrex SubQ, saline IV
1798235|NCT00573612|Behavioral|Attention Control Counseling|Subjects will receive educational-based telephone counseling regarding fibromyalgia.
1798236|NCT00573612|Behavioral|Motivational Interviewing|Subjects will receive Motivational Interviewing telephone counseling.
1798237|NCT00565058|Biological|GTI-2040|GTI-2040 will be administered one day after HiDAC in the pilot PD study and one day before HiDAC in the Phase II study for a cycle. Those who achieve a complete remission (CR) will be permitted to receive one cycle of consolidation of GTI-2040 and HiDAC
1798238|NCT00565071|Device|Field microscopy and Paracheck Pf®|Malaria diagnosis based on microscopy and or Paracheck Pf®. Artemether/Lumefantrine (20mg/120mg) is first-line drug in all arms
1798239|NCT00565084|Drug|ibuprofen|Patients will receive 800 mg ibuprofen in one of the three treatment periods.
1798240|NCT00565084|Drug|Placebo|Patients will receive placebo to ibuprofen in two of the three treatment periods.
1798241|NCT00565097|Drug|Placebo|
1798242|NCT00565097|Drug|Lanreotide|
1799073|NCT00570752|Drug|Atorvastatin|
1798243|NCT00565110|Behavioral|ADAPt-C intervention|Experimental Arm patients receive: first-line choice of antidepressant medication management,psychotherapy or both; depression education, and maintenance/relapse prevention counseling based on a stepped care depression treatment algorithm, treatment follow-up and feedback to the oncologist, and systems navigation; a psychiatric consultant who prescribes antidepressant medication for individual patients; and a didactic for oncologists on depression management. Cultural adaptations include: patient choice of first line treatment and degree of family participation in their depression care; PST tailored for literacy and patients with cancer; bilingual, bicultural CDCS; Spanish educational materials.
1798244|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops three times daily to each eye for 5 days
1798245|NCT00565123|Drug|0.5% levofloxacin eye drops|0.5% levofloxacin eye drops 2 hours on days 1 and 2, and then every 4 hours on days 3-5 (up to 4 times per day)
1798246|NCT00565136|Device|TOPAS|A mesh sling permanently implanted to increase pelvic floor support
1798247|NCT00565149|Behavioral|PROOF|dietary overfeeding with high, low or normal protein content
1798248|NCT00565162|Drug|Insulin Glargine|Insulin glargine administered by subcutaneous injection daily at bedtime for 24 weeks.
1798249|NCT00565175|Drug|famotidine|Capsules containing 100 mg of famotidine p.o., twice daily for 4 weeks.
1798250|NCT00565175|Drug|Placebo (Microcrystallized cellulose)|Placebo administered in identical capsules as the experimental drug.
1798251|NCT00565188|Drug|Adenosine 5'-triphosphate|Weekly ATP infusions (in total 8 infusions) during 8 - 12 hours in a maximum dose of 50 mcg/kg.min
1798252|NCT00565201|Drug|Botox and rehab|Patients will BOTOX® (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
1798253|NCT00565201|Drug|Placebo and rehab|Patients will receive placebo saline (100 to 360 U) injected into any of the following muscles: 30-100U in the Flex. Dig. Sublimes (3 sites), 30-100U in the flex. Carpi Rad. (3 sites), 30- 100 U flex Carpi Ulnaris (3 sites), 30-100 U in the flex Dig Superficiali ( 3 sites), 25U Prontator Teres (1 site), 25 U Brachioradialis (1 site) followed by Physical Rehabilitation: One hour session divided into 3 categories of treatment - 1.) Pre-functional/modalities for a general guideline of treatment; 2.)Repetitive task practice and strengthening; 3.)Functional activities - ADL and IADLs.
1798254|NCT00565214|Dietary Supplement|Group 1|The treatment plan involves the administration of a combination of 3 vitamins (vitamin C 1000 mg, vitamin E 400 IU, selenomethionine 400 μg) to study volunteers in a 2:1 randomization, Vitamins are to be taken orally, once a day, for a duration of 30 days.
1798255|NCT00565214|Dietary Supplement|Group 2|The treatment plan involves the administration of a combination of 3 placebos to be taken orally, once daily for a duration of 30 days.
1798256|NCT00565227|Drug|vorinostat (suberoylanilide hydroxamic acid)|Vorinostat will be administered by mouth as a pill for the first 14 days on a continuous basis during of each 21-day cycle (2 weeks of treatment, 1 week break).
1798257|NCT00565227|Drug|docetaxel|Docetaxel will be administered as an intravenous infusion (through the vein) on day 4 of each 21-day cycle.
1798258|NCT00565240|Drug|Marvelon|oral contraceptive
1798259|NCT00565240|Drug|Nuvaring|contraceptive vaginal ring
1798260|NCT00565240|Drug|Letrozole|Aromatase Inhibitors
1798261|NCT00565253|Drug|Inhaled nitric oxide (NO)|20 ppm for 15 minutes
1798262|NCT00565266|Drug|tiotropium bromide|tiotropium bromide inhalation powder 18 mcg once daily
1798263|NCT00565266|Drug|salmeterol xinafoate|salmeterol xinafoate inhalation powder 50 mcg twice daily
1798264|NCT00565266|Drug|beclomethasone dipropionate|beclomethasone dipropionate 80 mcg twice daily (1xICS) or 160 mcg twice daily (2xICS)
1798265|NCT00565279|Drug|ASF1057|Twice daily, topical
1798266|NCT00565279|Drug|ASF1057|Twice daily, Topical
1798267|NCT00565292|Drug|MK0859|
1798268|NCT00565305|Behavioral|Healing Touch|Healing Touch (HT) is a non-invasive therapeutic approach to healing which describes its mode of action as using touch to modulate the patient's energy system. The goal of HT is to restore harmony and balance in the patient's energy system to assist the person to self-heal.88 Healing Touch, as used here, refers to the techniques taught in Mentgen's standardized curriculum of Healing Touch offered through Healing Touch International and endorsed by the American Holistic Nurse's Association
1798269|NCT00565305|Radiation|Standard Treatment|4-6 cycles of cytotoxic chemotherapy followed by 5040 cGy of external beam whole breast radiotherapy in 28 fractions usually followed by a boost of 1000-1600 cGy
1798270|NCT00565318|Drug|Benfotiamine|3x 300 mg film coated tablet daily (900 mg per day). Duration: 12 weeks.
1798271|NCT00565318|Drug|Placebo|3x 1 film coated tablet daily. Duration: 12 weeks.
1798272|NCT00565331|Drug|Rituximab|single dose of rituximab of 375 mg/m2 intravenously at the time of transplantation
1798273|NCT00565331|Drug|Placebo|saline solution
1798274|NCT00565357|Device|Silicone Earplugs|Silicone earplugs worn from within 1 week of birth through 35 weeks post-menstrual age or hospital discharge, whichever came first
1798275|NCT00565357|Other|Control|Standard care in the neonatal intensive care unit
1798276|NCT00565370|Drug|Capecitabine, Cisplatin, Sorafenib|Capecitabine ( ) mg/m2 bid D1-D15 Cisplatin 80 mg/m2 D1 Sorafenib ( ) mg bid PO daily every 3 weeks
1798277|NCT00565383|Procedure|Combined spinal-epidural analgesia|Combined spinal-epidural
1798278|NCT00565383|Procedure|Intravenous fentanyl (50mcg)|Intravenous fentanyl
1798279|NCT00565396|Drug|Fosinopril and Losartan|Fosinopril 10mg/day(oral) Losartan 50mg/day(oral)
1798280|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 50 mg, once weekly for 88 weeks
1798281|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.
If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
1798282|NCT00565409|Drug|Etanercept|Subcutaneous (SC), 25 mg, once weekly from week 36 to week 88.
1798283|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.
If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
1798284|NCT00565409|Drug|Placebo|Subcutaneous (SC), once weekly from week 36 to week 88.
1798285|NCT00565409|Drug|Methotrexate|"Oral, 15 to 25 mg (varying based on dosage the subject is receiving at the time of screening and may be increased at the discretion of the investigator through Week 28 to a maximum of 25 mg/week), once weekly for 88 weeks.
If a subject experiences an adverse event (AE) during the study, Methotrexate may be decreased by 2.5 or 5.0 mg weekly (the minimum dose to stay in the study is 10 mg/week)."
1798286|NCT00565422|Drug|Escitalopram|10 mg/day
1798287|NCT00565448|Drug|docetaxel|"Pharmaceutical form:solution for infusion
Route of administration:intravenous"
1798288|NCT00565448|Drug|cisplatin|"Pharmaceutical form:solution for infusion
Route of administration:intravenous"
1798289|NCT00565448|Drug|5-fluorouracil|"Pharmaceutical form:solution for infusion
Route of administration:intravenous"
1798290|NCT00565461|Biological|heat-labile enterotoxin of E. coli (LT)|37.5ug patch applied on either the deltoid or the thigh
1798291|NCT00565474|Drug|Fluvastatin|Graft vasculopathy
1798292|NCT00565487|Drug|Capecitabine, Tarceva|Capecitabine is a self-administered (oral) medication & will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine & Tarceva is continued daily until the completeness of the radiation or toxicity.
1798293|NCT00565500|Drug|celecoxib|celecoxib capsules 200 mg bid for 1 week
1798294|NCT00565500|Drug|ibuprofen|ibuprofen tablets 600 mg tid for 1 week
1798295|NCT00565500|Drug|placebo|placebo capsules tid for 1 week
1798296|NCT00565513|Procedure|blood test|cord blood and maternal milk test
1798297|NCT00565539|Drug|PEGylated recombinant interleukin 29 (PEG-rIL-29)|subcutaneous administration either weekly or every other week
1798298|NCT00565552|Drug|Silicone gel (Dermatix®)|The half one the scar to treat was randomised among patients. After regular cleaning of the skin around the scar one half was thinly creamed with the silicone gel from medial to lateral and let dry for 5 minutes. It was done twice daily.
1798299|NCT00565565|Drug|BAY60-4552|Single dose escalation planned at dose of 1 mg, 2.5 mg, 5 mg, 7.5 mg, and 10 mg
1798300|NCT00565591|Drug|Albuterol sulfate|Single dose dry powder by inhalation
1798301|NCT00565604|Device|Short Catheter Delivery|For treating incompetent perforator veins of the lower extremities
1798302|NCT00565617|Device|Synergy, Epidural cortical stimulation|Epidural cortical stimulation
1798303|NCT00565630|Device|Vigamox delivered via the device in spray form|Vigamox delivered 4 times, 1 hour prior to cataract surgery
1798304|NCT00565643|Device|modified sodium hyaluronic acid and carboxymethylcellulose|Adhesion barrier applied at the time of initial cesarean delivery
1798305|NCT00565643|Device|Placebo|Routine abdominal closure without placement of adhesion barrier
1798306|NCT00565656|Drug|BEVACIZUMAB|Administration of Bevacizumab
1798307|NCT00565669|Drug|Cyclosporin A Restasis®|systane to be used twice a day for the duration of the study
1798308|NCT00565682|Drug|etoricoxib 120 mg|etoricoxib 120 mg, tablet, orally, OD
1798309|NCT00565695|Device|aspheric ReSTOR multifocal intraocular lens (IOL)|Multifocal intraocular lens
1798310|NCT00565708|Other|placebo|Placebo Comparator
1798311|NCT00565708|Drug|Acetylsalicylic acid|Adjuvant Therapy
1798312|NCT00565721|Drug|Fluciclatide Injection - (AH111585 (F18))|18F labelled Cyclic RGD peptide PET agent for injection.
1798313|NCT00565747|Device|Test culture|A standard culture medium with added GM-CSF (ready-to-use)
1798314|NCT00565747|Device|Control culture|The same standard culture medium, but without any additions (ready-to-use)
1798315|NCT00565760|Drug|Q8003|Capsules
1798316|NCT00565760|Drug|Placebo|Capsules
1798317|NCT00565773|Drug|Belatacept|Belatacept will be given as an IV infusion of 10mg /kg over 30 minutes. This will be repeated on study days 4 and 8 (prior to bone marrow infusion in the first group of subjects) and 15 then every 2 weeks for 5 additional doses. After week 24, belatacept will be given at a dose of 5 mg/kg once every 4 weeks indefinitely.
1798318|NCT00565773|Drug|Belatacept|Belatacept will be given as an IV infusion at 10mg/kg over 30 minutes on the day of transplantation. This dose will be repeated on study days 4, 8, and 15, then every 2 weeks for 5 additional doses. After week 24, belatacept will be given as an infusion of 5 mg/kg once every 4 weeks indefinitely.
1798319|NCT00565773|Drug|Alemtuzumab|All patients will receive a single dose of 30 mgs. on the day of transplantation.
1798320|NCT00565773|Other|donor bone marrow|"The bone marrow was given as an IV infusion over 3 hours on postoperative day 7 (study day 8) in the initial group of 20 randomized subjects. The formulated dose was 1 x 10(8th power) unfractionated nucleated cells/kg recipient ideal body weight.
A proposed total of forty patients will be enrolled in this study. Enrollment was reopened December of 2012 to include 20 additional living or deceased donor kidney recipients.
Half of the first group of 20 recipients were randomized to receive a single donor bone marrow infusion. Half did not receive the infusion. Donor bone marrow infusion in the second group of 20 subjects has been eliminated."
1798321|NCT00565786|Device|ArCom® Polyethylene|Argon packaged compression molded polyethylene
1798322|NCT00565786|Device|ArComXL® Polyethylene|Highly crosslinked Ultra High Molecular Weight Polyethylene
1798323|NCT00565799|Procedure|Omentectomy|Removing the omentum
1798324|NCT00565799|Other|No intervention|Only LAGB without Omentectomy
1798325|NCT00565812|Drug|SD-6010|200 mg tablets once a day for 2 years
1798326|NCT00565812|Drug|SD-6010|50 mg tablets once a day for 2 years
1798327|NCT00565812|Drug|Placebo|Placebo tablets once a day for 2 years
1798328|NCT00565838|Procedure|AFS and TVT|Autologous Fascial Sling and Tension- Free Vaginal Tape
1798336|NCT00565864|Drug|L-thyroxine (L-T4)|L-thyroxine at doses appropriate to attain target TSH levels for the different arms for 24 weeks
1798337|NCT00565877|Other|Ultrasound inspection|post-PICC insertion Ultrasound inspection of the ipsilateral neck for PICC in a malposition (ipsilateral internal jugular vein)
1798338|NCT00565890|Drug|thyroxine|thyroxine at the dose of 5 μg/kg-wt /day
1798339|NCT00565916|Drug|Estrogen|HRT with estrogen involves wearing a topical patch of 0.3 mg estradiol. The patch is to be placed on the lower abdomen and worn for 3 days. All participants will also undergo various heart metabolism tests, including a positron-emission tomographic (PET) scan, an electrocardiogram (ECG), and an echocardiogram (ECHO).
1798340|NCT00565916|Drug|Progesterone|Progesterone therapy involves taking a daily pill of 200 mg Prometrium for the same 3 days that the estradiol is taken.
1798341|NCT00565916|Drug|Placebo Progesterone|Placebo progesterone therapy involves taking a daily placebo pill for the same 3 days that the estradiol is taken.
1798342|NCT00565929|Drug|Placebo|Sterile saline (0.9%).
1798343|NCT00565929|Biological|MVA-BN|The smallpox vaccine is a liquid frozen solution formulated to contain 0.605 mg Tris and 4.090 mg sodium chloride (NaCl) per 0.5 mL dose. The concentration of the virus will be 1 X 10^8 tissue culture infectious dose 50 (TCID 50) per 0.5 mL dose and may be diluted in a solution of 0.9% saline prior to vaccination. Smallpox vaccine administered in 2 doses approximately 28 days apart in one of the following doses: 1X10^7 or 1X10^8 TCID 50.
1798344|NCT00565942|Procedure|Integrative care|In short, integrative care was up to 10 complementary therapy treatments delivered to the patient in addition to the usual care over an intervention period of up to 12 weeks. The integrative care was provided by a multidisciplinary team coordinated by a gate keeping general practitioner with clinical knowledge and experience of CTs and senior licensed/certified CT providers representing Swedish massage therapy, manual therapy/naprapathy, shiatsu, acupuncture and qigong.
1798345|NCT00565942|Procedure|Usual care|The usual care treatment was coordinated by the patient's general practitioner and complied with the clinical practice routines at the participating primary care units. Conventional procedures included but were not exclusive to advice, prescription of drugs, sick leave and physiotherapy/physical therapy. There were no constraints to the provided usual care as the study aimed to pragmatically reflect the general practitioners' standard care and treatment as usual.
1798346|NCT00565955|Drug|montelukast|"Standard case management will be carried out as per guidelines given by British Thoracic Society. All patients will receive montelukast or similar looking placebo tablets. The doses of montelukast will be as follows:
5-12 years: 5 mg chewable tablet of montelukast; > 12 years: 10 mg chewable tablet of montelukast. Study drug will be administered at time of administration of steroid."
1798347|NCT00565955|Drug|Placebo|The patients will receive placebo tablets.
1798348|NCT00565968|Drug|melphalan|
1798349|NCT00565968|Drug|sorafenib tosylate|
1798350|NCT00565968|Genetic|gene expression analysis|
1798351|NCT00565968|Genetic|protein expression analysis|
1798352|NCT00565968|Genetic|western blotting|
1798353|NCT00565968|Other|pharmacological study|
1798354|NCT00565981|Drug|Fludarabine phosphate|orally, 40 mg/m2 d1-3 q4w, x4 cycles
1798355|NCT00565981|Drug|Alemtuzumab|subcutaneous, starting dose 3 mg and escalation to 10 mg, then 30 mg, followed by 30 mg thrice weekly for 16 weeks in escalated dose
1798356|NCT00565994|Procedure|Blood Draw|For patients undergoing routine hemodialysis for chronic renal failure, 5-10 ml of blood will be removed from the dialysis tubing during vascular access. All other subjects will have 5-10 ml of blood drawn by routine venipuncture.
1798357|NCT00566007|Procedure|Discectomy/ micro discectomy|Standard discectomy or micro discectomy
1798358|NCT00566007|Drug|Ozone therapy|Infiltration of intradiscal ozone: O3/O2 in a 27 micrograms/ml concentration + foraminal infiltration of O3/O2 + corticoid + anesthetic
1798359|NCT00566007|Drug|Oxygen therapy|Intradiscal oxygen therapy: O3/O2 at a concentration of 0 micrograms/ml (only oxygen) + foraminal infiltration of O2 + corticoid + anesthetic
1798360|NCT00566020|Drug|BW430C (lamotrigine)|lamotrigine 50mg/day-400mg/day
1798361|NCT00566033|Behavioral|Audit-driven intervention|Patients included in this arm will undergo to the multi-method quality improvement intervention (intensive intervention) that adds practice visits, telephone and e-mail contacts (for quality improvement facilitation) and audits to the approach of periodic guideline dissemination and feedback on demand used in the less intensive intervention.
1798362|NCT00566046|Drug|Levetiracetam|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
1798363|NCT00566046|Drug|Placebo|1500 mg/day orally until the first episode of late epilepsy for a maximum duration of 3 months
1798364|NCT00566072|Behavioral|instructions and coaching|instructions and coaching or no intervention on the use and intake of ganciclovir
1798365|NCT00566085|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 28-32 mCi of 99m Tc-sestamibi.
1798366|NCT00566098|Biological|therapeutic autologous lymphocytes|
1798367|NCT00566098|Biological|therapeutic tumor infiltrating lymphocytes|
1798368|NCT00566098|Drug|melphalan|
1798369|NCT00566098|Procedure|autologous hematopoietic stem cell transplantation|
1798370|NCT00566111|Drug|ceftriaxone|2g per day which will be administered IV via midline, 7 days a week for 4 weeks.
1798371|NCT00566111|Drug|Saline solution|Saline solution will be administered IV via midline, 7 days a week for 4 weeks.
1798372|NCT00566124|Drug|Insulin detemir|0.4 U/kg bw insulin detemir injected s.c. in the thigh.
1798373|NCT00566124|Drug|Insulin glargine|0.4 U/kg bw insulin glargine injected s.c. in the thigh
1798374|NCT00566124|Drug|Insulatard|0.4 U/kg bw NPH insulin injected s.c. in the thigh
1798375|NCT00566150|Drug|Levetiracetam|Flexible dose up to 2500mg per day, for 6 weeks.
1798376|NCT00566150|Drug|Placebo|Flexible dose up to 2500mg per day, for 6 weeks.
1798377|NCT00566176|Device|Surgical Ablation using the AtriCure Bipolar System|Surgical Ablation using the AtriCure Bipolar System
1798456|NCT00566696|Drug|Alemtuzumab|After January 2010, due to the unavailability of muromonab, transplant recipients received a conditioning regimen consisting of systemic chemotherapy and antibodies, including alemtuzumab.
1798378|NCT00566189|Procedure|Roux-en-Y Bypass Gastroplasty|Under open laparotomy, a stomach section separates a 80-ml proximal gastric pouch. A jejunum section below Treitz's Angle creates an excluded gastrobiliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the continuity between the gastric pouch and the jejunum and a silastic ring reduces the pouch outlet.The anastomosis of the excluded limb is done 100cm below the silastic ring.
1798379|NCT00566202|Drug|Placebo|Form= capsule, route= oral use. Administration once daily for 8 weeks.
1798380|NCT00566202|Drug|Escitalopram|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 20 mg daily for 6 weeks, and 10 mg daily for 1 week.
1798381|NCT00566202|Drug|JNJ-18038683|Type= range, unit= mg, number= 10 to 20, form= capsule, route= oral use. Administration of 10 mg daily for 1 week, 10 or 20 mg daily for 6 weeks, and placebo daily for 1 week.
1798382|NCT00566215|Procedure|Duodenal exclusion plus omentectomy|"Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
Additionally, total omentectomy is performed."
1798383|NCT00566215|Procedure|Duodenal exclusion without omentectomy|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create a excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
1798384|NCT00566228|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
1798385|NCT00566228|Procedure|leukapheresis|Stem cells collected
1798386|NCT00566241|Drug|recombinant human IGF-1|rhIGF-1
1798387|NCT00566241|Drug|Placebo|Placebo
1798388|NCT00566254|Drug|Zonisamide|8mg/kg per day for approximately 24 weeks.
1798389|NCT00566254|Drug|Placebo|
1798390|NCT00566267|Drug|simvastatin 20 mg/ezetimibe|see protocol
1798391|NCT00566280|Procedure|Molecular Breast Imaging|A dual-detector cadmium-zinc-telluride gamma camera system mounted on a modified mammography gantry is used to image the breast. The injection dose of the radiopharmaceutical given to the patient is 20 mCi of 99m Tc-sestamibi.
1798392|NCT00566306|Other|Polyhexamethyleneguanidine (PHMG)|6 months in 3 experimental wards
1798393|NCT00566319|Behavioral|PREPARE with pedometer|Structured educational programme with pedometer use
1798394|NCT00566319|Behavioral|PREPARE|Structured educational programme
1798395|NCT00566332|Drug|Chlorambucil|Chlorambucil 8 mg/m² (6 mg/m² if patient aged more than 75 years old) 10 days every 28 days during 12 months By oral route
1798396|NCT00566332|Drug|Fludarabine|Fludarabine 40 mg/m² (30 mg/m² if patient aged more than 75 years old) 5 days every 28 days during 6 cycles By oral route
1798397|NCT00566345|Biological|Inactivated seasonal influenza vaccine (split virus, Vero cell-derived)|Trivalent, non-adjuvanted vaccine; dose: 0.5 ml
1798398|NCT00566345|Biological|Phosphate buffered saline|Packaged in syringes identical to those used for the investigational vaccine; dose: 0.5 ml
1798399|NCT00566358|Procedure|Duodenal exclusion surgery|Under open laparotomy, a duodenum section 2cm below the pylorus and a jejunum section below Treitz's Angle to create an excluded biliopancreatic limb of 150cm. A Roux-in-Y retrocolic anastomosis of the alimentary limb promotes the gastrojejunal continuity and the anastomosis of the excluded biliopancreatic limb is done 100cm below the jejunal-pyloric union.
1798402|NCT00566384|Drug|Dehydroepiandrosterone, BAY86-5314|Treatment with daily oral intake of two capsules containing 50 mg DHEA each. Treatment duration will be 24 weeks
1798403|NCT00566384|Drug|Placebo|Treatment with daily oral intake of two capsules containing Placebo. Treatment duration will be 24 weeks
1798404|NCT00566397|Drug|PF-04494700|15 mg for 6 days followed by daily dosing of 5mg
1798405|NCT00566397|Drug|PF-04494700|60 mg for 6 days followed by daily dosing of 20mg. Dosing in this arm has been discontinued.
1798406|NCT00566397|Drug|Placebo|Placebo
1798407|NCT00566410|Drug|Dichloroacetate|Continuous daily oral dosage (bid).
1798408|NCT00566423|Other|Blood draw|Venous and Arterial Blood draw samples; 6 Minute Walk test
1798409|NCT00566436|Procedure|Remote endarterectomy of the superficial femoral artery|Exposure of the common femoral, superficial femoral and profunda femoral artery through a single groin incision. Arteriotomy in the proximal SFA followed by dissection of the intima core beyond the occluded segment using the Vollmar ringstripper. The ringstripper is exchanged for a Mollring cutter all under fluoroscopic guidance. With the Mollring Cutter transection of intima core is carried out, remote from the site of entry. After removal of the intima core the transection zone is secured with an aSpire stent after balloon angioplasty. A completion arteriography will verify a patent artery, and embolectomy can be performed when necessary. As indicated a common femoral artery and profundaplasty can be performed and the arteriotomy may be closed with or without patch.
1798410|NCT00566436|Procedure|Suprageniculate femoropopliteal bypass|Groin and suprageniculate incision, venous (Saphenous vein) or PTFE graft with end to side anastomoses. If the saphenous vein is truly applicable for grafting will ultimately be an intra-operative decision (despite pre-operative venous mapping)
1798411|NCT00566449|Drug|Placebo|one dose daily for 4 weeks
1798412|NCT00566449|Drug|JNJ-31001074|10 mg daily for 4 weeks
1798413|NCT00566449|Drug|JNJ-31001074|30 mg daily for 4 weeks
1798414|NCT00566462|Drug|perampanel|2 mg/d for 14 days followed by 4 mg/d for 14 days
1798415|NCT00566462|Drug|placebo|Matching placebo for for 14 days followed by 4 mg/d for 14 days
1798457|NCT00566696|Drug|Cyclophosphamide|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
1798417|NCT00566488|Biological|Thymus/Parathyroid Transplantation|Thymus tissue, thymus donor, mother of thymus donor, & parental parathyroid donor screened for transplant safety. Depending on T cell phenotype & function, subjects were given 1 of 2 immunosuppression regimes. All received rabbit anti thymocyte globulin pretransplantation. Others also received cyclosporine pre & post-transplantation. The thymus dose was over 0.2 grams/kg recipient weight. Thymus transplant occurred in operating room; thymic slices were placed in quadriceps. Parathyroid harvest was done under general anesthesia. One parathyroid gland was minced and placed in quadriceps muscle. There was no dose in mg. An open biopsy of thymus allograft was done 2-3 months post-transplant. Biopsy tissue was examined by immunohistochemistry to evaluate for thymopoiesis & graft rejection.
1798418|NCT00566501|Drug|23 mg SR in Study 326|Patients will receive 23 mg donepezil SR orally, once daily for 12 months.
1798419|NCT00566501|Drug|10 mg IR in Study 326|Donepezil SR 23 mg once daily orally for 12 months to patients who either (a) received donepezil 23 mg SR in the preceding double-blind study E2020-G000-326, or (b) received donepezil 10 mg IR in that study.
1798420|NCT00566514|Dietary Supplement|D-ribose|5 grams administered orally TID
1798421|NCT00566514|Other|dextrose|5 grams orally TID
1798423|NCT00566540|Drug|Cisplatin|Patients will receive Cisplatin (30 mg/m2 i.v.) daily x 3 days in week 1.
1798424|NCT00566540|Drug|Paclitaxel|Patients will receive Paclitaxel (45 mg/m2i.v.) infusion over 3 hours during weeks 7,8,9,10
1798425|NCT00566540|Radiation|Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation|Patients will receive Intensity-Modulated Radiation Therapy (IMRT) External Beam Radiation to tumor and involved regional nodes 20Gy over 10 daily (M-F) treatments (2 Gy Fractions with 6 millivolts photons)week 1 and 2.
1798426|NCT00566540|Procedure|Triple endoscopy and biopsy|Resection of the primary tumor: Patients must have surgery performed according to the following surgical guidelines. The extent of the surgical resection will be dictated by the extent of the tumor at the time of initial evaluation. The primary lesion must be widely excised using accepted criteria for adequate excision depending on the region involved. All patients will undergo percutaneous endoscopic gastrostomy tube placement at the time of endoscopy and biopsies.
1798427|NCT00566553|Dietary Supplement|Grape Seed Extract|200 mg dose daily for 12 weeks.
1798428|NCT00566553|Dietary Supplement|Grape Seed Extract|400 mg dose daily for 12 weeks.
1798429|NCT00566553|Dietary Supplement|Grape Seed Extract|600 mg dose daily for 12 weeks.
1798430|NCT00566553|Dietary Supplement|Grape Seed Extract|800 mg dose daily for 12 weeks.
1798431|NCT00566566|Other|sample without DNA|family history, anthropometric measurements and blood sampling
1798432|NCT00566579|Procedure|Cryotherapy|Double freezing technique
1798433|NCT00566592|Other|oral ethanol, overnight|Oral ethanol before bedtime to achieve approximate BAL of 0.08%
1798434|NCT00566592|Other|IV ethanol|IV ethanol before bedtime to achieve approximate BAL of 0.08%
1798435|NCT00566592|Other|soda water|Oral Placebo before bedtime to achieve approximate BAL of 0.00%
1798436|NCT00566592|Other|soda water|Oral Placebo to achieve approximate daytime BAL of 0.00%
1798437|NCT00566605|Procedure|Penetrating keratoplasty with IntraLase|penetrating keratoplasty with femtosecond laser shaped incisions- IntraLase TM (IntraLase Enabled Keratoplasty [IEK])
1798438|NCT00566605|Procedure|Penetrating keratoplasty with vacuum trephine|Group 2 - penetrating keratoplasty with vacuum trephine
1798439|NCT00566618|Drug|Dasatinib|"Phase I: First Cohort = 100 mg PO Daily x 28 days; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.
Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
1798440|NCT00566618|Drug|Zoledronic Acid|"Phase I: First Cohort = 4 mg IV Over 15 min. every 4 Weeks; Next Cohort = Dose Expansion or Reduction Based on Dose Limiting Toxicity (DLT) in Initial Cohort.
Phase II: Recommended Phase II Dose (RP2D) as determined with Phase I."
1798441|NCT00566631|Drug|Paliperidone|Paliperidone ER tablet in flexible daily dose of 3, 6, 9 or 12 milligram (mg) as per Investigators' discretion will be given once daily orally for 6 weeks in the core treatment phase and no longer than 12 months in the extension phase after the completion of core treatment phase.
1798442|NCT00566644|Device|levonorgestrel-releasing intrauterine system|
1798443|NCT00566644|Other|questionnaire administration|
1798444|NCT00566644|Procedure|observation|
1798445|NCT00566657|Biological|riferminogene pecaplasmid|"Formulation: 5 ml glass vials containing 2,5 ml riferminogene pecaplasmid
Route: intramuscular (IM) injection of 2.5 mL in the ischemic leg to be treated"
1798446|NCT00566657|Biological|Placebo (for riferminogene pecaplasmid)|"Formulation: 5 ml glass vials containing 2,5 ml placebo
Route: IM injection of 2.5 mL in the ischemic leg to be treated"
1798447|NCT00566683|Drug|diazemuls, pethidine|5mg Diazemuls and 25mg Pethidine one min. before procedure followed by bolus doses of 2.5mg Diazemuls / 12.5mg Pethidine at the discretion of endoscopists Maximal dose of 0.2mg/kg Diazemuls and 1mg/kg Pethidine
1798448|NCT00566683|Drug|Propofol and Alfentanil|Loading dose of 40-60mg or 0.8mg/kg Propofol one min. before procedure Propofol 200mg + Alfentanil 0.5mg, 1.5ml per bolus (bolus dose of 14.3mg Propofol + 35ug Alfentanil) via PCA pump No maximal dose Zero lockout time
1798449|NCT00566696|Device|CliniMACS|Miltenyi Biotec CliniMACS stem cell selection device
1798450|NCT00566696|Procedure|Stem cell transplantation|An infusion of HLA mismatched family member donor stem cells processed through the use of the investigational Miltenyi Biotec CliniMACS device.
1798451|NCT00566696|Drug|Fludarabine|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
1798452|NCT00566696|Drug|Thioplex®|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
1798453|NCT00566696|Drug|L-phenylalanine mustard|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
1798454|NCT00566696|Drug|Mycophenolate mofetil|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
1798455|NCT00566696|Drug|Rituxan™|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
1798458|NCT00566696|Drug|Anti-thymocyte globulin (Rabbit)|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
1798459|NCT00566696|Drug|G-CSF|Transplant recipients will receive a conditioning regimen consisting of systemic chemotherapy and antibodies.
1798460|NCT00566696|Drug|Muromonab|Prior to January 2010, transplant participants received a conditioning regimen consisting of systemic chemotherapy and antibodies, including muromonab. Muromonab became unavailable from the manufacturer at that time and was replaced by alemtuzumab.
1798461|NCT00566709|Procedure|Red blood cells transfusion|Patients will be transfused (one to one red blood cells unit transfusion)
1798462|NCT00566722|Biological|adalimumab|Participants received an 80 mg adalimumab loading dose by subcutaneous injection at Baseline (Week 0). From Week 1 to Week 15, participants received 40 mg adalimumab by subcutaneous injection every other week.
1798463|NCT00566735|Drug|Razadyne|The starting dose of study medication is 4 mg twice a day
1798464|NCT00566735|Drug|Placebo|4 mg, 2 times a day
1798465|NCT00566761|Drug|bevacizumab and triamcinolone|three applications monthly administrated of bevacizumab 2.5mg for group 1 and bevacizumab 2.5 mg + triamcinolone 4mg first dose followed by two of bevacizumab alone for the group 2
1798466|NCT00566774|Other|Full drug coverage|Patients randomized to first-dollar coverage will have their pharmacy benefits changed so that they have no out-of-pocket costs for any beta-blocker, angiotensin converting enzyme inhibitor (ACEI) or angiotensin II receptor blocker (ARB) antagonist, or statin for every subsequent prescription after randomization. All co-pays and co-insurance will be waived at the point of care (i.e. pharmacy) as will any contribution that the cost of these drugs contributes to a patient's deductible
1798467|NCT00566774|Other|Usual coverage|Patients randomized to usual coverage will have no change in their existing benefits
1798468|NCT00566787|Device|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System|Surgical bipolar radiofrequency ablation using the AtriCure Bipolar System
1798469|NCT00566800|Drug|erlotinib hydrochloride|
1798470|NCT00566800|Other|laboratory biomarker analysis|
1798471|NCT00566800|Procedure|biopsy|
1798474|NCT00566826|Behavioral|Patient support sessions|Patient support sessions aim to enhance patient self-care for independent exercise and physical activity.
1798475|NCT00566826|Behavioral|Treatment as usual|Treatment as usual includes standard care for TKR surgery rehabilitation.
1798476|NCT00566839|Procedure|awake nonresectional LVRS|Thoracoscopic nonresectional lung volume reduction surgery carried out in awake patients under sole epidural anesthesia through plication of most emphysematous target areas of the lung
1798477|NCT00566839|Procedure|Nonawake resectional LVRS|Thoracoscopic lung volume reduction surgery carried out under general anesthesia and one-lung ventilation through nonanatomic resection of the most emphysematous target areas of the lung
1798478|NCT00566852|Drug|Memantine|Patients began taking memantine(by mouth) while receiving radiation therapy. Patients continued taking memantine for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
1798479|NCT00566852|Other|Placebo|Patients began taking placebo(by mouth) while receiving radiation therapy. Patients continued taking placebo for 24 weeks or until doctor thinks it is in their best interest to stop. They started with 5 mg once a day. After a week dose increased to 5 mg twice a day. At week 3, dose increased to 10 mg in the morning and 5 mg in the evening. Weeks 4-24, dose was 10 mg twice a day.
1798480|NCT00566852|Radiation|Whole brain radiation therapy|Whole brain radiation therapy (WBRT) once a day (2.5Gy), five days a week (Monday to Friday) for three weeks, for total fifteen treatments and 37.5 Gy
1798481|NCT00566865|Drug|placebo for gemfibrozil|mitiglinide + placebo for gemfibrozil 600 mg bid
1798482|NCT00566865|Drug|gemfibrozil|Mitiglinide + 600 mg gemfibrozil bid
1798483|NCT00566878|Biological|alglucosidase alfa|At least one infusion of alglucosidase alfa post partum
1798484|NCT00566891|Drug|tirofiban|tirofiban high dose bolus 25µ/Kg
1798485|NCT00566891|Drug|Clopidogrel|
1798486|NCT00566904|Drug|Epikeia coatings with aspirin|Applied to affected skin area using a roll-on ball applicator
1798487|NCT00566904|Drug|Epikeia coatings with lidocaine|Applied to affected skin area using a roll-on ball applicator
1798488|NCT00566904|Other|Epikeia coatings alone|Applied to affected skin area using a roll-on ball applicator
1798489|NCT00566917|Procedure|Anterior colporrhaphy|Standardised colporrhaphy of the anterior vaginal wall
1798490|NCT00566917|Procedure|Anterior PROLIFT|Transvaginal mesh surgery of the anterior vaginal wall
1798491|NCT00566930|Other|spinal manipulation|Monthly cervical spinal manipulation
1798492|NCT00566930|Other|Spinal manipulation + exercises|Monthly cervical spine manipulation and daily home exercises
1798493|NCT00566943|Device|PSD Veritas Collagen Matrix|Roux-en-Y gastric by-pass surgery. Surgeon creates a small pouch from the stomach and then by-passes a large portion of the small intestine. The body cannot absorb as many calories or nutrients thus resulting in weight loss.
1798494|NCT00566943|Procedure|Roux-en-Y gastric by-pass surgery with no buttress|Patients who have laparoscopic Roux-en-Y gastric by-pass surgery without staple line buttress material. No buttress material will be used on staple line including stomach/pouch, anastomostic junctions, (gastrojejunostomy (GJ) gastric to intestine, or jejunojejunostomy (JJ) intestine to intestine intestine to mesentery.
1798495|NCT00566956|Procedure|Hydrosalpinx needle aspiration to arm 1|For those assigned to Group I, the hydrosalpinx will be aspirated after all the eggs have been collected, under GA. Under ultrasound-guidance, the aspiration (egg collection) needle will be inserted into the hydrosalpinx and suction applied until no more fluid is obtained. If there are bilateral hydrosalpinges, the process is repeated on the opposite side. The hydrosalpinx fluid is discarded
1798496|NCT00566969|Drug|sugar pill|Subjects randomized to placebo, carvedilol 25mg or 50mg
1798497|NCT00566969|Drug|Carvedilol 25 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
1798498|NCT00566969|Drug|Carvedilol 50 mg|subjects randomized to placebo, carvedilol 25mg or 50mg
1798499|NCT00566982|Drug|Ospemifene 60 mg|60 mg/day (QD) dose of ospemifene (1 tablet) will be taken for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52). Dosing will be oral and the ospemifene 60 mg tablet will be taken once daily, in the morning, with food.
1798500|NCT00566982|Drug|Placebo|Dosing will be oral and placebo will be taken once daily, in the morning, with food for 52 weeks - from Visit 2 (Randomization, Day 1) to Visit 6 (End of Therapy or Early Discontinuation, Week 52)
1798501|NCT00566995|Drug|ZACTIMA (Vandetanib) (ZD6474)|
1798502|NCT00567008|Drug|varenicline|1.0 mg BID for 8 weeks
1798503|NCT00567008|Drug|placebo|placebo BID for 8 weeks
1798504|NCT00567034|Drug|naltrexone|50mg naltrexone, 1 tablet a day for 12 weeks.
1798505|NCT00567034|Drug|placebo|lactose placebo, 1 capsule every day for 12 weeks
1798506|NCT00567047|Drug|vildagliptin|
1798507|NCT00567060|Drug|Piracetam|
1798508|NCT00567073|Biological|alglucosidase alpha|
1798509|NCT00567073|Other|No Treatment|
1798510|NCT00567086|Drug|TEZAMPANEL|Single Administration of: TEZAMPANEL 40 mg; TEZAMPANEL 70 mg; TEZAMPANEL 100 mg; Placebo (Sterile Water for Injection)
1798511|NCT00567099|Drug|Aripiprzole|"Dosage form, dosage, frequency and duration:
Aripiprazole 5-30 mg tabs po qday x 3 months"
1798512|NCT00567112|Drug|10 mg MK-0941 DFC (fasted)|single dose of 10 mg MK-0941 dry filled capsules (DFC) administered in a fasted state
1798513|NCT00567112|Drug|10 mg MK-0941 OCT (after meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered after consumption of a high-fat meal
1798514|NCT00567112|Drug|10 mg MK-0941 OCT (before meal)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered before consumption of a standard breakfast
1798515|NCT00567112|Drug|10 mg MK-0941 OCT (fasted)|single dose of 10 mg MK-0941 oral compressed tablet (OCT) administered in a fasted state
1798516|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
1798517|NCT00567164|Drug|EE20/DRSP (BAY86-5300)|Combination tablet containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone
1798518|NCT00567164|Drug|EE20/DRSP (YAZ, BAY86-5300)|Fixed package per cycle containing combination tablets containing 0.02 mg ethinyl estradiol as betadex clathrate and 3.0 mg drospirenone (24 per cycle) + tablets without active substance (4 per cycle)
1798519|NCT00567177|Drug|Restasis, Refresh Plus|Restasis 0.4ml- (in the eye) Instill one drop twice daily in morning and evening Refresh Plus 0.4ml- (in the eye) Instill one drop twice daily in morning and evening
1798520|NCT00567190|Drug|Pertuzumab|Pertuzumab will be administered as an IV loading dose of 840 milligrams (mg) Q3W on Day 1 of Cycle 1 (1 Cycle length = 21 days), and 420 mg Q3W on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity.
1798521|NCT00567190|Drug|Placebo|Pertuzumab matching placebo will be administered intravenously.
1798522|NCT00567190|Drug|Trastuzumab|Trastuzumab will be administered as an IV loading dose of 8 milligrams per kilogram (mg/kg) Q3W on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 6 mg/kg Q3W on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity.
1798523|NCT00567190|Drug|Docetaxel|Docetaxel will be administered as an IV dose of 75 milligrams per square meter (mg/m^2) Q3W on Day 2 of Cycle 1 (1 Cycle length = 21 days), and 75 mg/m^2 (up to 100 mg/m^2 as per treating physician discretion) Q3W on Day 1 of subsequent cycles until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity.
1798524|NCT00567203|Drug|PF-3463275|PF-3463275 10mg
1798525|NCT00567203|Drug|PF-3463275|PF-3463275 25mg
1798526|NCT00567203|Drug|Placebo|Placebo
1798527|NCT00567216|Drug|Nadolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
1798528|NCT00567229|Biological|rituximab|
1798529|NCT00567229|Drug|lenalidomide|
1798530|NCT00567229|Genetic|microarray analysis|
1798531|NCT00567229|Other|flow cytometry|
1798532|NCT00567229|Other|laboratory biomarker analysis|
1798533|NCT00567242|Behavioral|Word-finding with intention component|Word-finding trials (picture-naming) with intention manipulation (initiating word-finding trials with a complex left-hand movement). 8 (or more) baseline sessions over 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
1798534|NCT00567242|Behavioral|Word-finding with no intention component|Word-finding trials with no intention manipulation. 8 (or more) baseline sessions in 4 days followed by 30 treatment sessions (2 sessions/day, 5 days/week for 3 weeks).
1798535|NCT00567255|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
1798536|NCT00567255|Drug|Placebo|
1798537|NCT00567255|Behavioral|Ancillary therapy|Ancillary therapy consisting of diet instruction, advice on behavior modification, and exercise counseling
1798538|NCT00567268|Drug|Gabapentin|"GABAPEN Tablets 200mg, GABAPEN Tablets 300mg, GABAPEN Tablets 400mg. GABAPEN is Brand name in Japan.
Dosage, frequency: According to Japanese LPD, Normally, oral gabapentin 600 mg, 3 div., should be given on the first day of administration and an effective dose of 1200mg, 3 div, should be given on day 2. From day 3 on, adults should be maintained on oral gabapentin 1200 mg to 1800 mg, 3 div. Subsequently, the maintenance dose should be suitably adjusted depending on the symptoms (up to a maximum daily dose of 2400 mg).
Duration: According to the protocol of A9451163, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 12 weeks after the first administration."
1798539|NCT00567281|Device|Magstim Rapid 2 system triggering Magstim Super Rapid system|Week 1 treatment includes rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 treatment includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, active rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
1798540|NCT00567281|Device|Magstim Rapid-2 system triggering Magstim Super Rapid system|Week 1 includes repetitive rTMS for 5 sessions to either to left or right Wernicke's area (BA22) synchronous with sham rTMS to opposite hemisphere middle temporal cortex (BA21). Week 2 includes rTMS given for 5 sessions with positions reversed (e.g., if Wernicke's stimulation was on the left during Week 1, position of rTMS will switch to the right side during Week 2 and vice-versa). As in Week 1, sham rTMS will also be given synchronously to the opposite hemisphere middle temporal cortex. Weeks 3 and 4 include 10 stimulation sessions to the configuration of sites producing greater improvement in comparing results of Week 1 and Week 2. rTMS for each stimulation session will be given at 1-Hertz (once per second) for 16 minutes without interruption.
1798541|NCT00567294|Behavioral|Mailed education|Mailed education materials on osteoporosis and medication use over a 1-year period
1798542|NCT00567294|Behavioral|Telephone coaching program for patients|A telephone coaching program that will involve twelve monthly 5- to 10-minute phone calls from a health educator who is specially trained in osteoporosis. The phone calls will involve coaching participants on behavioral reinforcement strategies that will help them to continue taking their medications on schedule; phone calls will also include specially tailored education on osteoporosis and fracture prevention. A close family member or friend of the participant will also be contacted via phone two times during the study by the health educator. During these phone calls, the family member or friend will learn how to support the participant in such a way that medication adherence is more likely.
1798543|NCT00567294|Behavioral|Medication adherence alert program for doctors|Doctors of participants will receive written educational information on the rates of medication adherence, implications of nonadherence, and methods for improving adherence among people with osteoporosis. Doctors will also receive alerts on any patients who are not filling their medication prescriptions.
1798544|NCT00567307|Drug|Red Heart Pill 2b (Polypill)|Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)
1798545|NCT00567307|Other|Standard Practice|Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
1798546|NCT00567320|Drug|Varenicline|Varenicline up to 2 mg a day
1798547|NCT00567320|Drug|Sugar pill or Placebo|Placebo
1798548|NCT00567333|Other|Chiropractic care|A combination of professional therapies with the scope of practice, including spinal manipulation therapy, spinal mobilization, stretching and strengthening exercises, and self-care education.
1798549|NCT00567333|Other|Multidisciplinary, integrative care|A combination of therapies which may include acupuncture/Oriental medicine, chiropractic, cognitive behavioral therapy, exercise therapy, medicine, self-care information, and massage therapy.
1798550|NCT00567346|Drug|Oralgen|Patients will receive drops of grass pollen immunotherapy sublingually
1798551|NCT00567346|Drug|grass pollen extract|Patients will receive matching placebo sublingually
1798552|NCT00567359|Drug|Erlotinib|Oral drug taken daily around the same time.
1798553|NCT00567372|Drug|bevacizumab (Sub-tenon´s injection)|a single posterior sub-tenon's capsule injection of bevacizumab (2.5 mg /0.1ml)
1798554|NCT00567385|Drug|somatropin|
1798555|NCT00567398|Drug|Dianeal|Dianeal 1.5% Dextrose (1.38% Glucose), 2.5% Dextrose (2.27% Glucose), 4.25% Dextrose (3.86% Glucose)
1798556|NCT00567398|Drug|Physioneal|Physioneal 40 or Physioneal 35
1798557|NCT00567398|Drug|Extraneal|Extraneal - 7.5% Icodextrin
1798558|NCT00567398|Drug|Nutrineal|Nutrineal - 1.1% Amino Acids
1798559|NCT00567411|Drug|brimonidine 0.1%|1 drop, 1 hour prior to selective laser trabeculoplasty (SLT)
1798560|NCT00567411|Drug|Apraclonidine 0.5%|1 drop applied 1 hour prior to SLT
1798561|NCT00567424|Drug|GW273225|
1798562|NCT00567437|Other|NT-pro-BNP levels|pre- and post-exercise NT-pro-BNP levels
1798563|NCT00567450|Drug|ropivacaine|30ml of a mixture of ropivacaïne 0.75%
1798564|NCT00567450|Drug|ropivacaine plus mepivacaine|30ml of a mixture of ropivacaïne 0.75% associated with mepivacaïne 1.5%
1798565|NCT00567463|Device|Fluticasone|Fluticasone 250mcg for 3 months followed by 100mcg for 9 months, one puff once a day at supper time
1798566|NCT00567476|Drug|Omalizumab|Omalizumab 150 to 375 mg was administered subcutaneously every 2 or 4 weeks to provide a dose of at least 0.016 mg/kg per UI/ml of IgE.
1798567|NCT00567476|Drug|Inhaled corticosteroids (ICS)|Any ICS with proprietary drug and device > 500 mcg of fluticasone or equivalent
1798568|NCT00567476|Drug|Long-acting beta 2-adrenergic agonist (LABA)|Fixed dose of LABA as prescribed prior to study entry
1798569|NCT00567476|Drug|Short-acting beta 2-adrenergic agonist (SABA)|Home use of nebulized Β2-agonist such as salbutamol 5 mg or terbutaline 10 mg for symptoms of intercurrent bronchospasm.
1798570|NCT00567489|Drug|Physioneal|Physioneal 40 or Physioneal 35
1798571|NCT00567489|Drug|Dianeal|Dianeal 1.5% Dextrose (1.30% glucose), 2.5% Dextrose (2.27% glucose), 4.5% Dextrose (3.86% glucose)
1798572|NCT00567489|Drug|Extraneal|7.5% Icodextrin
1798573|NCT00567489|Drug|Nutrineal|Amino Acids 1.1%
1798574|NCT00567515|Device|AtriCure LAA Exclusion System|Placement of clip of LAA.
1798575|NCT00567528|Drug|Ibuprofen|Apply by rubbing into skin for 30 to 60 seconds placebo ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking active capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
1798576|NCT00567528|Drug|ibuprofen|Apply by rubbing into skin for 30 to 60 seconds active ibuprofen 10% gel, 0.5cc to skin over injured area 3 times a day and taking placebo capsules of ibuprofen 3 times a day 10-40mg/kg per day, not to exceed 1200mg per day for 2 weeks.
1798577|NCT00567541|Device|Battery Powered Microneuromodulator (BBPM)|The Battery Powered Microneuromodulator (BBPM) is programmed to deliver bursts of electrical stimulation to deliver therapeutic stimulation beginning with a frequency of 30Hz, current of 5mA, for 200 microseconds. These settings were applied to deliver greater or lesser intensity based on study arm (active vs placebo).
1798578|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel|
1798579|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + bevacizumab|
1798580|NCT00567554|Drug|paclitaxel|
1798581|NCT00567554|Drug|paclitaxel + everolimus (RAD001)|
1798582|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + trastuzumab|
1798583|NCT00567554|Drug|epirubicin - cyclophosphamide / docetaxel + lapatinib|
1798584|NCT00567567|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
1798585|NCT00567567|Drug|Carboplatin|Given IV
1798586|NCT00567567|Drug|Cisplatin|Given IV
1798587|NCT00567567|Drug|Cyclophosphamide|Given IV
1798588|NCT00567567|Drug|Doxorubicin Hydrochloride|Given IV
1798589|NCT00567567|Drug|Etoposide|Given IV
1798590|NCT00567567|Radiation|External Beam Radiation Therapy|Undergo EBRT
1798591|NCT00567567|Biological|Filgrastim|Given IV or SC
1798592|NCT00567567|Drug|Isotretinoin|Given orally
1798593|NCT00567567|Other|Laboratory Biomarker Analysis|Correlative studies
1798594|NCT00567567|Drug|Melphalan|Given IV
1798595|NCT00567567|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous peripheral blood stem cell transplant
1798596|NCT00567567|Other|Pharmacological Study|Correlative studies
1798597|NCT00567567|Drug|Thiotepa|Given IV
1798598|NCT00567567|Drug|Topotecan Hydrochloride|Given IV
1798599|NCT00567567|Drug|Vincristine Sulfate Liposome|Given IV
1798600|NCT00567580|Drug|bicalutamide|Oral, daily
1798601|NCT00567580|Drug|flutamide|Oral, daily
1798602|NCT00567580|Radiation|radiation therapy|Once daily, 5 days a week
1798603|NCT00567593|Drug|Rosiglitazone|8mg tablet once a day for 14 days
1798605|NCT00573651|Other|Blood Draws for Serum Titers|All study subjects are receiving the Gardasil vaccine as part of their clinical care. The Gardasil vaccine is not given because of study participation. The study observes outcomes related to this clinical care. Study intervention consists of some blood samples taken to measure antibody and RNA titers. Other study specific procedures performed include Questionnaires and observational data.
1798606|NCT00573664|Drug|Gabapentin|single oral dose of 600mg gabapentin
1798607|NCT00573664|Other|lactose|Single dose
1798608|NCT00573690|Drug|carboplatin|Given IV
1798609|NCT00573690|Drug|cisplatin|Given IV
1798610|NCT00573690|Drug|etoposide|Given IV
1798611|NCT00573690|Drug|pemetrexed disodium|Given IV
1798612|NCT00573690|Drug|sorafenib tosylate|Given orally
1798613|NCT00573703|Procedure|Laparoscopic Burch colposuspension|Lapaparoscopic approach. One or two nonadsorbable sutures are placed at the level of the midurethra without penetrating the vaginal mucosa and fixed to Cooper's ligament with a tension free knotting technique.
1798614|NCT00573703|Procedure|Transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of needle. Application of resorbable tensioning suture that maintains the mesh and enables fine adjustments in mesh tension during the procedure and in the immediate postoperative period.
1798615|NCT00573729|Other|Pulsed Dye Laser 577 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
1798616|NCT00573729|Other|Pulsed Dye Laser 595 nm|Comparison of 577 nm Versus 595 nm Wavelengths of Pulsed Dye Laser Treatment of Port Wine Stain Birthmarks
1798617|NCT00573742|Drug|Candesartan Cilexeotil 16mg|
1798618|NCT00573755|Drug|anastrozole|given orally
1798619|NCT00573755|Drug|exemestane|given orally
1798620|NCT00573755|Drug|letrozole|given orally
1798621|NCT00573755|Drug|sorafenib tosylate|given orally
1798622|NCT00573755|Other|placebo|given orally
1798623|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel|Diclofenac diethylamine 2.32% gel twice daily
1798624|NCT00573768|Drug|Placebo|Vehicle 2 times daily
1798625|NCT00573768|Drug|Diclofenac diethylamine 2.32% gel / Placebo|Diclofenac diethylamine 2.32% gel once daily / Vehicle once daily
1798626|NCT00573781|Dietary Supplement|Diet with increased intake of rye bread, berries and fish|Dietary modification with commercial food items
1798627|NCT00573781|Dietary Supplement|Increased intake of whole grain and rye bread|Dietary modification with commercial food items
1798628|NCT00573781|Dietary Supplement|Control diet with decreased intake of rye bread, berries and fish|Dietary modification with commercial food items
1798629|NCT00573794|Biological|adalimumab|Prefilled syringes 40 mg EOW subcutaneous and prefilled syringes 40 mg weekly subcutaneous
1798630|NCT00573807|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength)for 30 to 40 minutes per treatment session.
1798631|NCT00573820|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes each treatment session.
1798635|NCT00573859|Drug|ADHD medication|For the ADHD medication condition, participants received their usual dosage of their usual ADHD medication for two consecutive days.
1798636|NCT00573859|Drug|Placebo|For the placebo condition, participants received placebo pills for two consecutive days.
1798638|NCT00573885|Drug|defined green tea catechin extract|Given orally
1798639|NCT00573885|Other|placebo|Given orally
1798640|NCT00573911|Procedure|Endoscopy and pH study|endoscopy and PH study done one time
1798641|NCT00573924|Drug|Proton pump inhibitor (lansoprazole)|"120 mg PO and then 30 mg PO q 3 h from 3 to 21 hrs
90 mg IV bolus followed 9 mg/hr infusion for 24 hrs"
1798642|NCT00573937|Drug|Methadone|Oral methadone 2.5 mg every 8 hours, and oral methadone 2.5 mg every 4 hours as needed for breakthrough pain.
1798643|NCT00573937|Drug|Morphine|Oral slow-release morphine 15 mg every 8 hours, and oral immediate-release morphine 10 mg every 4 hours as needed for breakthrough pain.
1798646|NCT00573963|Drug|ropivacaine|2 injections of 20mL 0.375% ropivacaine - one given on each side.
1798647|NCT00573963|Drug|saline solution|2 injections of 20mL plain saline solution - one on each side.
1798648|NCT00575328|Drug|Maca Root|3g/day of Maca Root for 12 weeks
1798649|NCT00575328|Drug|Placebo|Placebo provided by research pharmacy daily for 12 weeks
1798650|NCT00575341|Drug|Dehydroepiandrosterone|25 mg DHEA, oral, once daily
1798651|NCT00575341|Drug|placebo|placebo, oral, once daily
1798652|NCT00575354|Drug|Sevoflurane|3-6% sevoflurane inhaled for anesthesia induction, and 2-3% sevoflurane was used to maintain the anesthesia till the end of the operation.
1798653|NCT00575354|Drug|Isoflurane|3-6% isoflurane inhaled for anesthesia induction, and 2-3% isoflurane was used to maintain the anesthesia till the end of the operation.
1798654|NCT00575367|Drug|AzaSite (azithromycin ophthalmic solution)|One drop ophthalmic solution at Visit 2
1798655|NCT00575367|Drug|Vigamox (moxifloxacin hydrochloride ophthalmic solution)|One drop ophthalmic solution at Visit 2
1798656|NCT00575380|Drug|AzaSite Eye Drops|One drop two times a day for two days and once a day for the next five days.
1798657|NCT00575380|Drug|Vigamox Eye Drops|One drop three times a day for seven days
1798658|NCT00575393|Drug|gold sodium thiomalate|
1798659|NCT00575393|Genetic|gene expression analysis|
1798660|NCT00575393|Other|fluorine F 18 fluorothymidine|
1798661|NCT00575393|Other|mass spectrometry|
1798662|NCT00575393|Other|pharmacological study|
1798663|NCT00575406|Drug|Rituximab|i.v., 375 mg/m2, d0 or d1 of each treatment cycle
1798664|NCT00575406|Drug|Cyclophosphamide|i.v., 750 mg/m2, d1 of each treatment cycle
1798665|NCT00575406|Drug|Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
1798666|NCT00575406|Drug|liposomal Doxorubicin|i.v., 50 mg/m2, d1 of each treatment cycle
1798667|NCT00575406|Drug|Vincristin|i.v., 2mg, d1 of each treatment cycle
1798668|NCT00575406|Drug|Prednisolone|p.o., 100mg, d1 - d5 of each treatment cycle
1798669|NCT00575419|Drug|N-acetylcysteine|"Dose Level 1: 150 mg/kg/day
Dose Level 2: 300 mg/kg/day
Dose Level 3: 600 mg/kg/day
Dose Level 4: 900 mg/kg/day
Dose Level 5: 1200 mg/kg/day"
1798670|NCT00575432|Radiation|diffusion MRI|diffusion MRI
1798671|NCT00575432|Radiation|BOLD MRI|BOLD MRI
1798672|NCT00575432|Other|Clinical Outcome|Clinical outcome
1798673|NCT00575471|Drug|Rivoglitazone HCl|0.5 mg tablets once daily for 12 weeks
1798674|NCT00575471|Drug|rivoglitazone HCl|1.0 mg tablets once daily for 12 weeks
1798675|NCT00575471|Drug|rivoglitazone HCl|1.5 mg tablets once daily for 12 weeks
1798676|NCT00575471|Drug|Placebo|Matching placebo tablets once daily for 12 weeks
1798677|NCT00575484|Drug|Hypertonic saline, then oral sodium chloride|2mL/kg hypertonic saline (4.4% NaCl if serum sodium </=135, else 2.8% NaCl) infused over 30min BID and dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) until patient is switched to oral loop diuretic. After switch to oral diuretic, subject will receive oral 0.75gm sodium (NaCL) capsule dosed BID with loop diuretic (latter dose per treating physician) until 60d after discharge.
1798678|NCT00575484|Drug|Normal saline, then oral placebo capsule|20mL normal saline infusion X 30min BID dosed simultaneously with IV bolus furosemide BID (latter dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction. After switch to oral diuretic, begin oral placebo capsule BID, dosed with loop diuretic (dose per treating physician) PLUS 2gm sodium diet PLUS 1.5L fluid restriction.
1798679|NCT00575497|Procedure|More frequent hemodialysis|Six Day per week short daily hemodialysis
1798680|NCT00575497|Procedure|More frequent hemodialysis|Six nights per week nocturnal hemodialysis
1798681|NCT00575497|Procedure|More frequent hemodialysis|Every other day short daily hemodialysis
1798682|NCT00575497|Procedure|More frequent hemodialysis|Every other night hemodialysis
1798683|NCT00575497|Procedure|More frequent hemodialysis|5 days per week short daily hemodialysis
1798684|NCT00575497|Procedure|More frequent hemodialysis|5 nights per week hemodialysis
1798685|NCT00575497|Procedure|Conventional Hemodialysis|3 days per week short daily hemodialysis
1798686|NCT00575510|Behavioral|Intervention|Multiple component intervention based in the unified theory of behavior
1798687|NCT00575510|Behavioral|Active control|Partial intervention (full intervention minus cultural-specific component)
1798688|NCT00575523|Drug|Atropine|Atropine 0,5mg is administered once intravenously immediately before starting percutaneous ethanol instillation.
1798689|NCT00575523|Drug|Placebo|1ml 0,9% Saline solution is administered intravenously immediately before starting percutaneous ethanol instillation.
1798690|NCT00575536|Procedure|Rhizotomy for children with spasticity|Optical Stimulation versus electrical stimulation in children who need Rhizotomy Surgery for spasticity
1798691|NCT00575549|Other|Dobutamine: Perflutren Lipid Microsphere|Dobutamine with starting dose of 10 micrograms/kg/min and increased gradually to a maximum dose of 50 micrograms/kg/min Definity will be infused continuously at a rate of 4mL/min
1798692|NCT00575562|Drug|KRN330|Open-label, dose-escalation study of KRN330 in patients with relapsed or refractory advanced or metastatic colorectal cancer
1798693|NCT00575575|Behavioral|cognitive behavior therapy|cognitive behavior therapy once a week
1798694|NCT00575588|Drug|Metformin|open-label metformin
1798695|NCT00575588|Drug|Sulphonylurea|Glipizide 5-20 mg capsules (titrated to optimal effect or highest tolerable dose during 18 weeks)
1798696|NCT00575588|Drug|Saxagliptin|Saxagliptin 5 mg tablets
1798697|NCT00575601|Drug|SIMVASTATIN|20 mg/day,po,for two months until the day of hCG injection placebo pills as like as simvastatin will be used
1798698|NCT00575614|Drug|prucalopride|1 mg o.d.
1798699|NCT00575614|Drug|placebo|o.d.
1798700|NCT00575627|Drug|Peg-Interferon alpha2a plus Ribavirin|Peg-Interferon alpha2a: 180 micrograms per week Ribavirin:100-1200 mg/daily
1798701|NCT00575640|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
1798702|NCT00575666|Drug|Insulin or Placebo|intranasal, 40IU, 4 times daily
1798703|NCT00575679|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
1798704|NCT00575718|Behavioral|Hospital Counseling + Nicotine Replacement Therapy. questionaires|"brief face-to-face or telephone tobacco cessation counseling provided by a tobacco cessation specialist prior to admission and during hospitalization (15-20 minutes per encounter)provision of multi-media self-help materials (e.g., Smoking Cessation Guide for Cancer Patients and Their Families) tailored to address cancer-specific issues such as the benefits and barriers of quitting for cancer patients; 3) tobacco cessation pharmacotherapy, unless medically contraindicated (for this study we will standardize the pharmacotherapy as transdermal nicotine patch), and; 4) two brief telephone counseling (15 minutes) sessions completed as seen clinically appropriate by the tobacco cessation specialists. The content of these counseling sessions is based on the patient's smoking status."
1798705|NCT00575718|Behavioral|Hospital Counseling + Nicotine Replacement + Presurgical Scheduled Reduced Smoking, questionaires|Same components of HC+NRT as well as the PS/SRS enhancement.The research team will provide education about scheduled reduced smoking either in person or over the phone. Purpose of the training session, will be audio taped, to prepare participants for daily PDA use over the dur of the scheduled-reduced smoking intervention. Training will demonstrate use of PDA and simulate common technical and procedural issues that might arise during the intervention (e.g., forgetting to record a cigarette or wake time; repeating a day's schedule if needed, prior to the quit date). The simulation will reflect anticipated problems and those identified by users of the PDA. A study helpline number and instructional manual will be provided. A member of the research staff will contact the study participants, once the reduced smoking schedule has begun, to check that the patient understands the schedule and that the PDA is working properly. Estimate patient training with the PDA will require 30 minutes.
1798706|NCT00575731|Behavioral|Weight management strategies|
1798707|NCT00575744|Procedure|Sentinel Node Biopsy|Once the patient is asleep under anesthetic, they receive an intraoperative injection of 1.0 mCi of Technetium-99 sulfur colloid into normal breast tissue surrounding the primary cancer or biopsy cavity directed subareolar or around the tumor. This is followed by blue dye injected in the subareolar complex approximately 5 minutes prior to incision. The sentinel node biopsy is performed, followed by lumpectomy/mastectomy, and a completion axillary node dissection if the sentinel node(s) were positive.
1798708|NCT00575796|Drug|Vinblastine Sulphate|Vinblastine dose: 6 mg/m2 (10 mg maximum dose) route intravenous administration once a week.
1798709|NCT00575809|Other|Mucositis and nutritional assessments|Mucositis and nutritional assessments before and during the hematopoietic stem cell transplantation
1798710|NCT00575822|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
1798711|NCT00575822|Device|Sham Control|The sham procedure was identical to the treatment procedure through the positioning of the retroflexed Plicator 1cm below the GE junction. The Plicator instrument remained in this position for 15 minutes, based on average procedure times established in previous studies. During the sham procedure, physician investigators were required to talk through the procedure steps to maintain the patient blind.
1798712|NCT00575835|Dietary Supplement|vitamin D twice daily|Kalsipos-D, vitamin D3 400 ID/tbl, 2 tbl/day for one year
1798713|NCT00575835|Dietary Supplement|Vitamin D3 oil three times in a year|Vigantol oil , D3 20000IU/ml, 4.9 ml every four months for one year
1798714|NCT00575848|Dietary Supplement|Glycine|Subjects will consume glycine twice daily, once with breakfast and once with dinner. The medication is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
1798715|NCT00575848|Dietary Supplement|Placebo|Subjects will consume placebo twice daily, once with breakfast and once with dinner. The placebo is in liquid form. They will be instructed to refrigerate the liquid until the time that they take it. Subjects start by taking 10g per day for the first 2 days. Starting on the 3rd day, subjects take 0.2g/kg (15g for a 75kg adult) per day, and increase dosage by 0.2g/kg every two days, until they reach 0.8g/kg per day, which they take for the remainder of the 6-week period.
1798716|NCT00575861|Drug|zileuton|zileuton (Zyflo) 600mg qid for 2hr and for 30 days
1798717|NCT00575874|Drug|Rivoglitazone HCl|0.5 mg rivoglitazone HCl tablets once daily for 12 weeks
1798718|NCT00575874|Drug|rivoglitazone HCl|1.0 mg rivoglitazone HCl tablets once daily for 12 weeks
1798719|NCT00575874|Drug|rivoglitazone HCl|1.5 mg rivoglitazone HCl tablets once daily for 12 weeks
1798720|NCT00575874|Drug|pioglitazone HCl|30 mg capsules once daily for 12 weeks
1798721|NCT00575874|Drug|placebo|matching tablets or capsule once daily for 12 weeks
1798722|NCT00575887|Drug|Temozolomide|100 mg/m2/day, (PO) orally, on days between 1 and 21 of each 28 day cycles. Number of cycles: Until progression or unacceptable toxicity
1798723|NCT00575900|Behavioral|dietary intervention|12 weeks of dietary intervention
1798724|NCT00575913|Drug|Alfuzosin|Alfuzosin 10 mg One tablet per day after evening meal
1798725|NCT00575926|Drug|LingZhi capsule|LingZhi or Placebo 300 mg x 4 or 300 mg x 6 capsules daily according to age group
1798726|NCT00575952|Drug|Cisplatin|Given IV or IP
1798727|NCT00575952|Drug|Doxorubicin Hydrochloride|Given IV
1798728|NCT00575952|Biological|Filgrastim|Given SC
1798729|NCT00575952|Drug|Paclitaxel|Given IV or IP
1798730|NCT00575952|Biological|Pegfilgrastim|Given SC
1798731|NCT00575965|Drug|Simvastatin|Oral tablets taken daily
1798732|NCT00575978|Drug|Hydralazine|Dose Level 1: 150 mg/d 50 mg PO TID Dose Level 2: 200 mg/d 50 mg PO QID Dose Level 3: 225 mg/d 75 mg PO TID
1798733|NCT00575991|Dietary Supplement|Conjugated linoleic acid|3 grams per day of 80% CLA in safflower oil (2.4 grams active CLA isomers in triglyceride form)
1798816|NCT00576667|Drug|Rimonabant|Tablet, oral administration
1798734|NCT00576004|Procedure|Pelvic organ prolapse repair and Burch colposuspension|Abdominal pelvic organ prolapse repair and retropubic Burch colposuspension
1798735|NCT00576017|Drug|Fentanyl-TTS|
1798736|NCT00576030|Other|hab cof with water|habitual coffee drinker provided with water
1798737|NCT00576030|Other|hab cof with dec espresso|habitual coffee drinkers given decaffeinated espresso
1798738|NCT00576030|Other|hab cof with caf espresso|habitual coffee drinkers given caffeinated espresso
1798739|NCT00576030|Other|non-hab cof with water|non-habitual coffee drinkers given water
1798740|NCT00576030|Other|non-hab cof with dec espresso|non-habitual coffee drinkers given decaffeinated espresso
1798741|NCT00576030|Other|non-hab cof with caf espresso|non-habitual coffee drinkers given caffeinated espresso
1798742|NCT00576043|Procedure|Simulator Training|3 weeks/2 hours per day of structured training for a total of 20 hours on the virtual endoscopy simulator with the GI-Mentor Virtual simulator device
1798743|NCT00576056|Drug|Sorafenib|Oral sorafenib (400 mg BID) will start the next day after the first TACE treatment until unacceptable toxicity occurs, or until study termination.
1798744|NCT00576056|Drug|TACE|TACE will be accomplished with gelatin microspheres (Embospheres) following delivery of 125 mg/m2 of cisplatin.
1798745|NCT00576069|Drug|budesonide/formoterol|2 inhalations 2X/daily in treated arm/group. No placebo group
1798746|NCT00576069|Drug|fluticasone/salmeterol|fluticasone 100ug/salmeterol 50ug, 1 inhalation bid noplacebo fluticasone 250ug/salmeterol 50ug, 1 inhalations bid no placebo Spiriva handihaler daily or respihaler 2 inhalations daily no placebo group
1798747|NCT00576069|Drug|mometasone/formoterol|"200/5 mcg two puffs bid 100/5 mcg two puffs bid Breo Ellipta once daily Spiriva capsule handihaler once daily or Spiriva respihaler 2 in
no placebo group"
1798748|NCT00576069|Drug|Prednisone|0-15 mg daily as needed
1798749|NCT00576082|Other|Cutaneous biopsy|Cutaneous biopsy in order to search Borrelia by means of culture and PCR in this tissue sample
1798750|NCT00576108|Drug|KD7040 Topical Gel|KD7040 topical gel
1798751|NCT00576108|Drug|Placebo gel|Placebo gel
1798752|NCT00576134|Device|Implantation of intralaryngeal prosthesis with a new double valve system, allowing tracheotomy closing|An artificial Larynx composed of a tracheobronxane ® Dumon ST prosthesis and a valves system will be implant under general anesthesia by endoscopy. The 3 first patients will be patients with tracheotomy, in order to allow breathing through this tracheotomy in case of valves dysfunction.
1798753|NCT00576147|Device|Infrascanner|The main Near-Infrared spectroscopy (NIRS) head measurement
1798754|NCT00576160|Behavioral|PST therapy|Problem-Solving Therapy (PST) is a behavioral approach that teaches patients how to systematically solve their own behavioral difficulties. During telephone treatment sessions, the patient will discuss the problems and difficulties they face and that give rise to medication non-adherence.
1798755|NCT00576173|Drug|tramadol hydrochloride; acetaminophen|
1798756|NCT00576199|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
1798757|NCT00576199|Procedure|Transarterial chemoembolisation (TACE)|"TACE was conducted by the transfemoral artery approach with selective cannulation of the artery supplying the tumor. Cisplatin mixed with Lipiodol in a 1 mg:1 mL ratio was infused intra-arterially up to a maximum dose of 30 mg, depending on tumor size, followed by embolization of the artery using Gelfoam particle until the blood flow slowed. Bilobar lesions were treated by separate catheterization of right and left hepatic arteries followed by injection of the cisplatin-Lipiodol mixture and embolization.
Patients with stable disease or a partial response after 4 TACE sessions could be given further TACEs upon the investigator's discretion until there was evidence of progressive disease or contraindication due to severe complication or technical failure to perform the TACE."
1798758|NCT00576212|Behavioral|supportive call|Each subject in the intervention group will receive a 10 minute (or longer) biweekly telephone call from a psychologist intended to provide non-judgemental support to TOPFA women with the aim of reducing depression, guilt, isolation, shame, marital discord, and other common psychological sequelae of termination for fetal anomalies.
1798759|NCT00576225|Drug|CT-2103/carboplatin|CT-2103 (175 mg/m2 10 min IV infusion) and carboplatin (AUC 6, 30 min IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
1798760|NCT00576225|Drug|paclitaxel/carboplatin|Paclitaxel (175 mg/m2, 3 hr IV infusion) and carboplatin (AUC 6) (30 minute IV infusion) on day 1 of each 21-day cycle for up to 6 cycles.
1798761|NCT00576238|Drug|betamethasone valerate|Topical application according to a fixed schedule for three weeks
1798762|NCT00576238|Drug|betamethasone valerate|Topical application according to a fixed schedule for three weeks
1798763|NCT00576238|Drug|urea|Topical application twice daily for up to 6 months
1798764|NCT00576251|Drug|Tobramycin 0.3%/Dexamethasone 0.05%|Tobramycin 0.3%/Dexamethasone 0.05% 1 drop in both eyes 4 times daily for at least 3 days
1798765|NCT00576251|Drug|TOBRADEX|TOBRADEX 1 drop in both eyes 4 times daily for at least 3 days
1798766|NCT00576277|Drug|AV411|
1798767|NCT00576303|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
1798768|NCT00576316|Drug|Symbicort Turbuhaler 160/4.5|
1798769|NCT00576329|Drug|Ketorolac|Topical use before surgery
1798770|NCT00576342|Drug|AL-3862+timolol ophthalmic suspension|
1798771|NCT00576342|Drug|Dorzolamide+timolol ophthalmic solution|
1798772|NCT00576355|Behavioral|Interpersonal and Social Rhythm Therapy for Adolescents (IPSRT-A)|IPSRT-A involves 20 weeks of individual therapy, incorporating informed psychological, behavioral, and practical strategies adapted to the developmental needs of adolescents.
1798773|NCT00576355|Behavioral|Treatment As Usual (TAU)|TAU includes the offering of educational information about bipolar disorder and referral to a mental health provider.
1798774|NCT00576368|Drug|INSULIN GLARGINE|The physician will be guided by the prescribing information outlined in the summary of product characteristics. The administration will be done by once daily subcutaneous injection.
1798775|NCT00576381|Drug|Dexmedetomidine|Dosage Level 1=0.25mcg/kg loading dose, 0.2 mcg/kg/hr infusion Dosage Level 1A= 0.35mcg/kg loading dose, 0.3 mcg/kg/hr infusion Dosage Level 2= 0.5mcg/kg loading dose, 0.4 mcg/kg/hr infusion
1798776|NCT00576394|Drug|IV Insulin drip|IV insulin drip at 100units insulin in 100ml saline designed to keep blood glucose between 120-180mg/dl
1799074|NCT00570752|Drug|Statin|
1798777|NCT00576394|Drug|Insulin|IV insulin drip to keep serum glucose between 80-120mg/dl.
1798778|NCT00576407|Biological|Thymus Tissue for Transplantation|Thymus transplantation is done using allogeneic cultured postnatal tissue from unrelated donors. Thymus tissue, the donor, & donor's mother were screened for safety. Approximately 2-3 weeks post-harvest thymus slices were transplanted into the recipient's quadriceps. Dose is number of grams of transplanted tissue divided by the recipient's weight in kilograms. Minimum dose was 4 g/m2. Maximum dose 18g/m2. At time of transplantation, a skin biopsy was obtained to look for preexisting T cells. 2-3 months post-transplant allograft biopsy to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. Post-transplant, subjects followed by routine research immune evaluations, using blood samples for 2 years.
1798779|NCT00576420|Biological|FS VH S/D 500 s-apr, 60-seconds polymerization time|FS VH S/D 500 s-apr (FS) is applied to the study suture line. The actual dose of FS VH S/D 500 s-apr depends on the length of the suture line and the intensity of bleeding and is to be decided by the surgeon, but the maximum dose per suture line shall not exceed 4 mL FS VH S/D 500 s apr. After application of FS VH S/D 500 s-apr to the study suture line is completed, the surgeon will wait for 1 minute to allow polymerization of FS VH S/D 500 s-apr.
1798780|NCT00576420|Biological|FS VH S/D 500 s-apr, 120-seconds polymerization time|Treatment will be identical to the FS VH S/D 500 s-apr Group, 60 seconds polymerization time, except that the surgeons will wait 2 minutes to allow polymerization and will then open the cross clamps.
1798781|NCT00576420|Procedure|Manual compression with surgical gauze pads|Treatment of the study suture line with manual compression with surgical gauze pads.
1798782|NCT00576433|Drug|Methotrexate|As prescribed
1798783|NCT00576433|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
1798784|NCT00576446|Biological|Dendritic cell Vaccine|Patients will receive three vaccines every two weeks
1798785|NCT00576459|Drug|0.59 mg fluocinolone acetonide intravitreal implant|0.59 mg
1798786|NCT00576459|Drug|2.1 mg fluocinolone acetonide intravitreal implant|2.1 mg
1798787|NCT00576459|Procedure|standard of care laser photocoagulation|standard of care laser photocoagulation
1798788|NCT00576472|Drug|Methylphenidate|Please see detailed description for dosing information and study design.
1798789|NCT00576485|Procedure|Cataract surgery and intraocular lens implantation|Cataract surgery and implantation of an intraocular lens
1798790|NCT00576498|Other|NBI-AFI imaging|"Narrow Band Imaging- Patients will be evaluated with a standard magnification endoscope (Olympus GIF Q240Z, 115x or GIF-H180 or equivalent) using a NBI light source.Target biopsies with standard biopsy forceps will be obtained from the different visualized patterns in separate jars.
Autofluorescence Imaging- Patients will be evaluated using a prototype autofluorescence endoscope (Olympus, Tokyo, Japan; excitation 395-475 nm, fluorescence detection 490-625 nm, red reflectance 600-620 nm and green reflectance 540-560 nm).In this system, normal squamous and non-dysplastic BE appears green while the dysplastic areas appear magenta/purplish. Targeted biopsies will be obtained from the areas with abnormal fluorescence."
1798791|NCT00576498|Other|Standard Endoscopy|Standard Endoscopy- Patients will undergo EGD with biopsies using a standard diagnostic video endoscope (Olympus, GIF 140 or 160) using the Seattle protocol - 4 quadrant biopsies using standard biopsy forceps every 2 cms; stored in separate jars.
1798792|NCT00576511|Drug|prucalopride|4 mg o.d.
1798793|NCT00576511|Drug|placebo|Placebo o.d.
1798794|NCT00576524|Device|ITD|ITD will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
1798795|NCT00576524|Device|Sham|Sham will be applied for 30 minutes at a time with 10 minute breaks for the entire duration of hemodialysis on 2 separate occasions
1798796|NCT00576537|Biological|Dendritic Cell Immunotherapy|Patients will receive four vaccines.
1798797|NCT00576537|Biological|Dendritic Cell Vaccine|Four vaccines
1798798|NCT00576537|Biological|Dendritic Cell Vaccine|Four vaccines will be given to patients
1798799|NCT00576550|Drug|Urea|Urea cream applied twice daily up to six months
1798800|NCT00576550|Drug|betamethasone valerate|Application once daily for two weeks
1798801|NCT00576550|Drug|betamethasone valerate|Application twice daily for two weeks
1798802|NCT00576563|Drug|FDG|contrast medium
1798803|NCT00576576|Drug|Atorvastatin|Atorvastatin 80 mg a day
1798804|NCT00576589|Drug|CE-326,597|CE-326,597 administered orally, once daily for 14-days at 1 to 2 doses (25 mg QD, 100 mg QD) with the morning meal.
1798805|NCT00576589|Drug|Placebo|CE-326,597 matching placebo administered orally, once daily for 14-days with the morning meal.
1798806|NCT00576602|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose of 0.6 micrograms/kg sc every 2 weeks
1798807|NCT00576602|Drug|Supportive treatment|As prescribed
1798808|NCT00576615|Drug|Placebo solution|On the day of the study infusion into the vein of a solution containing no drug, Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion. Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks.
1798809|NCT00576615|Drug|propofol|"On the study day you will receive study drug propofol. Complete about half a dozen memory tasks over the period of the study, each about 5-10 minutes in length, that involve identification of a list of words, or listen to a list of words/tones before, during, and/or after drug infusion.
Allow the recording of your brain waves - the faint electrical activity constantly occurring in your brain- using the electroencephalogram (EEG) while completing memory tasks. Allow the imaging of your brain using functional magnetic resonance imaging (MRI), which measures images of water in your brain in a strong magnetic field, while completing memory tasks."
1798810|NCT00576628|Drug|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Recommended starting dose 1.2 micrograms/kg sc monthly
1798811|NCT00576641|Biological|autologous dendritic cells|
1798817|NCT00576667|Drug|Placebo (for Rimonabant)|Tablet, oral administration
1798818|NCT00576680|Drug|RAD001|Given orally once a day
1798819|NCT00576680|Drug|Temozolomide|Taken orally once a day for one week followed by a one-week break period
1798820|NCT00576693|Device|intracranial angioplasty and stenting|intracranial angioplasty and stenting using the Gateway balloon and Wingspan self-expanding nitinol stent (or any future FDA approved iterations of the balloon, stent, or the delivery systems) plus intensive medical therapy (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl).
1798821|NCT00576693|Other|intensive medical management|intensive medical therapy alone (aspirin 325 mg / day for entire follow-up, clopidogrel 75mg per day for 90 days after enrollment unless cardiologist recommends continuing clopidogrel beyond 90 days for a cardiac indication, and aggressive risk factor management primarily targeting blood pressure < 140 / 90 mm Hg (< 130 / 80 if diabetic) and LDL < 70 mg / dl)
1798822|NCT00576706|Drug|Rebamipide|Rebamipide 100㎎, 12 weeks
1798823|NCT00576706|Drug|Misoprostol|Misoprostol 200㎍ 12 weeks
1798824|NCT00576719|Behavioral|Intensive panic control treatment without parent involvement|Intensive panic control treatment without parent involvement is an 8-day, intensive form of cognitive behavioral therapy (CBT) with exposure, including 15-20 hours of direct therapist contact. The basic treatment components are psychoeducation about anxiety, restructuring anxiety-provoking thoughts, exposure to bodily sensations that trigger panic, and in vivo exposures.
1798825|NCT00576719|Behavioral|Intensive panic control treatment with parent involvement|Intensive panic control treatment with parent involvement involves the same form of intensive CBT, but with direct parent involvement. Parents will attend the last 30 minutes of didactic sessions, complete homework assignments, learn ways to coach their children, and participate in selected exposures.
1798826|NCT00576719|Other|Waitlist control|Waitlist control participants will receive active treatment (treatment with or without family involvement) after 6 weeks of waitlist.
1798827|NCT00576732|Drug|Placebo|Oral solution qd or bid for 6 weeks
1798828|NCT00576732|Drug|Risperidone high dose|Risperidone oral solution 1.25 mg (if <45 kg) or 1.75 mg (if >=45 kg) qd or bid for 6 weeks
1798829|NCT00576732|Drug|Risperidone low dose|Risperidone oral solution 0.125 mg (if <45 kg) or 0.175 mg (if >=45 kg) qd or bid for 6 weeks
1798830|NCT00576745|Procedure|Vicryl Suture|A 4-0 vicryl suture will be used to close the subcuticular layer
1798831|NCT00576745|Device|3M TM S Surgical Skin Closure System|These steri-strips will be applied to close the skin in this cohort of patients
1798832|NCT00576758|Drug|obinutuzumab (RO5072759)|1000 mg obinutuzumab intravenous (IV) infusion once a week for 4 weeks.
1798833|NCT00576758|Drug|rituximab|375 mg/m^2 rituximab IV infusion once a week for 4 weeks.
1798834|NCT00576771|Procedure|PSV|Pressure Support Ventilation
1798835|NCT00576771|Procedure|NAVA|Neurally Adjusted Ventilatory Assist
1798836|NCT00576771|Procedure|patient-controlled|assisted controlled MV through a button
1798837|NCT00576784|Drug|pioglitazone and glimepiride|switch from any insulin treatment to 30 mg pioglitazone and 3 mg glimepiride.
1798838|NCT00576810|Drug|sodium picosulphate|
1798839|NCT00576823|Drug|Alfuzosin|"Dose: 0.2 mg/kg/day
Route: oral"
1798840|NCT00576836|Biological|Thymus Tissue for Transplantation|Thymus tissue (from unrelated donor), donor, and donor's mother screened for safety. Thymus transplantation done under general anesthesia. Thymus transplanted into quadriceps. Thymus dose at least 4grams/m2 body surface area (0.2 grams/kg body weight) and not >18 grams/m2 body surface area (1.0 grams/kg body weight). At time of transplant, skin biopsy obtained to look for preexisting T cells. 2-3 months post-transplant allograft biopsy done to evaluate for thymopoiesis & graft rejection. At time of biopsy, skin biopsy done to look for T cell clonal populations. (Allograft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples.
1798841|NCT00576836|Other|Parathyroid Tissue for Transplantation|Parental parathyroid donors screened for eligibility and transplant safety. If both parents meet eligibility criteria, the parathyroid will be harvested from parent who shares the most HLA alleles with thymus donor. Parathyroid harvest & transplant preferably done at same time as thymus transplant. (If parathyroid transplant cannot be done at same time, then it is done within 3-8 weeks of thymus transplant.) Parathyroid harvest done under general anesthesia. One parathyroid gland is minced & placed in quadriceps muscle; there is no dose in mg. No biopsy done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
1798842|NCT00576849|Drug|Balanced HES 130/0.42|Volume is administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) was <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
1798843|NCT00576849|Drug|Balanced HES 130/0.42|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
1798844|NCT00576849|Drug|6% HES 130/0.4 prepared in saline solution|Volume will be administered perioperatively and during the first 48 hrs after surgery when mean arterial pressure (MAP) is <60mmHg and pulmonary capillary wedge pressure (PCWP) or central venous pressure (CVP) is <10 mmHg
1798845|NCT00576862|Drug|INSULIN GLARGINE|The subjects will continue the treatment with HOE 901 in the same way as they have done in the previous study. Based on the investigator's assessment and the approved SPC in Belgium/Luxembourg, the dosage can be adjusted individually. HOE 901 is to be injected once daily. HOE 901 must not be mixed with any other insulin, including regular human insulin or fast-acting insulin analogues.
1798846|NCT00576888|Other|no intervention|no intervention - observational only
1798847|NCT00576901|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
1798848|NCT00576901|Drug|Docetaxel|75mg/m2 iv on day 1 of each 3 week cycle
1798849|NCT00576901|Drug|Xeloda|2000mg/m2 po on days 1-15 of each 3 week cycle
1798850|NCT00576914|Drug|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
1799075|NCT00570765|Drug|Placebo|Placebo
1798851|NCT00576927|Drug|Ramelteon|Subjects demonstrating low sleep efficiencies and prolonged sleep latencies, will be randomly assigned to continue to receive SHI accompanied by either placebo or Ramelteon (8 mg). Matching placebo will be obtained and the medication pre-packaged and ordered based on the randomization results.
1798852|NCT00576927|Drug|Placebo|
1798853|NCT00576940|Drug|Reconvan|isocaloric, immunomodulating entral diet
1798854|NCT00576940|Drug|Peptisorb|isocaloric, isopeptic standard diet
1798855|NCT00576979|Drug|cyclophosphamide|Given IV
1798856|NCT00576979|Drug|etoposide|Given IV
1798857|NCT00576979|Procedure|allogeneic bone marrow transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
1798858|NCT00576979|Procedure|allogeneic hematopoietic stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
1798859|NCT00576979|Procedure|peripheral blood stem cell transplantation|Occurs approximately 48 hours after completion of cyclophosphamide
1798860|NCT00576979|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1798861|NCT00576979|Radiation|tomotherapy|Undergo IMRT using helical tomotherapy
1798862|NCT00577005|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
1798863|NCT00577005|Drug|Placebo|
1798864|NCT00577018|Drug|Prucalopride|4 mg o.d.
1798865|NCT00577018|Drug|Prucalopride|1 mg o.d. for 2 days, 2 mg o.d. for 2 days and 4 mg o.d. thereafter
1798866|NCT00577018|Other|Placebo|o.d.
1798867|NCT00577031|Drug|bevacizumab [Avastin]|7.5mg iv on day 1 of each 3 week cycle
1798868|NCT00577031|Drug|Oxaliplatin|130mg/m2 iv on day 1 of each 3 week cycle
1798869|NCT00577031|Drug|Xeloda|1000mg/m2 po bid on days 1-14 of each 3 week cycle
1798870|NCT00577057|Procedure|Conventional Radiotherapy|
1798871|NCT00577057|Procedure|Accelerated Radiotherapy|
1798872|NCT00577057|Drug|Cisplatin|
1798873|NCT00577057|Drug|5-fluorouracil|
1798874|NCT00577057|Drug|Capecitabine|
1798875|NCT00577070|Device|TMS|Transcranial Magnetic Stimulation (TMS) is a new tool in neuropsychiatry. This method is based on creating pre determined magnetic fields, which alternate rapidly. The magnetic fields are intended to cause electric induction in the brain cells and, as a consequence, generation of action potentials. The magnetic stimulation is delivered/ generated by a coil, positioned on the patient's scalp, inducing nerve stimulation within the brain. Therefore, when placed over the motor cortex, the magnetic stimulation creates Muscular Evoked potential, which can be measured by EMG.
1798876|NCT00577083|Device|Cap-fitted colonoscopy|Subjects will be randomized to either initial cap-fitted colonoscopy or regular colonoscopy. Patients in the initial regular arm, will undergo cap-fitted colonoscopy for their second, tandem examination. Patients in the initial cap-fitted arm, will under undergo regular colonoscopy (without the cap) for their second, tandem examination.
1798877|NCT00577096|Drug|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg og body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl.
1798878|NCT00577096|Behavioral|Exercise|A home-based individualized exercise program that incorporated aerobic and strength resistance training.
1798879|NCT00577096|Biological|Autologous Peripheral Blood Stem Cell Transplantation|Standard PBSCT for multiple myeloma
1798880|NCT00577096|Biological|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
1798881|NCT00577096|Drug|Thalidomide|Fifty percent of the participants received 400 mg daily
1798882|NCT00577096|Drug|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
1798883|NCT00577096|Biological|Platelet Transfusion|Platelet transfusions were administered as needed
1798884|NCT00577096|Drug|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
1798885|NCT00577096|Drug|Epoetin Alfa|Epoetin alfa was administered per an IRB approved algorithm to study participants when hemoglobin levels dropped during high dose chemotherapy. The usual dose is 150 units/kg of body weight, three times per week, or 40,000 units weekly, with suggested target hemoglobin range of 10-12 g/dl
1798886|NCT00577096|Drug|Total Therapy II|Standard Induction chemotherapy care included: vincristine, doxorubicin, and dexamethasone (VAD) (0.5 mg, 10 mg/m2, and 40 mg, respectively);dexamethasone, cyclophosphamide,etoposide, and cisplatin (DCEP) (40 mg, 400 mg/m2, 40 mg/m2, and 15 mg/m2,respectively); and cyclophosphamide,doxorubicin, and dexamethasone (CAD) (750 mg/m2, 15 mg/m2, and 40 mg, respectively) for mobilization.
1798887|NCT00577096|Biological|Red Blood Cell Transfusion|RBC Transfusion was administered as needed
1798888|NCT00577096|Drug|Thalidomide|Fifty percent of participants received 400 mg daily
1798889|NCT00577096|Drug|Heparin, Low-Molecular-Weight|Patients who received thalidomide also received prophylactic low molecular weight heparin
1798890|NCT00577096|Biological|Platelet Transfusion|Platelet transfusions were administered as needed
1798891|NCT00577096|Drug|Melphalan|Administered with autologous peripheralblood stem cell transplantation (PBSCT) for multiple myeloma
1798892|NCT00577109|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle
1798893|NCT00577109|Drug|Irinotecan|180mg/m2 iv on day 1 of each 2 week cycle
1798894|NCT00577109|Drug|Leucovorin|200mg/m2 iv on day 1 of each 2 week cycle
1798895|NCT00577109|Drug|5 FU|400mg/m2 iv on day 1 of each 2 week cycle
1798896|NCT00577109|Drug|Cetuximab|Loading dose of 400mg/m2 iv followed by 250mg/m2 iv on day 3 of each 2 week cycle
1798897|NCT00577122|Drug|Medroxyprogesterone progesterone acetate (MPA)|1000 mg po daily
1798898|NCT00577122|Drug|Medroxyprogesterone with Cyclophosphamide + Methotrexate|Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
1798899|NCT00577135|Drug|Furosemide-Q12 hour bolus|Q12 hours bolus
1798901|NCT00577135|Drug|Furosemide-Low Intensification|1x oral dose
1798902|NCT00577135|Drug|Furosemide-High Intensification|2.5x oral dose
1798903|NCT00577148|Drug|Rimonabant|Tablet, oral administration
1798904|NCT00577148|Drug|Placebo (for Rimonabant)|Tablet, oral administration
1798905|NCT00577161|Drug|fludarabine and rituximab|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2
1798906|NCT00577161|Drug|fludarabine, rituximab, pixantrone|days 1 to 4 of six 28-day cycles rituximab 375 mg/m2 fludarabine 25 mg/m2 pixantrone 120 mg/m2 day 2 only
1798907|NCT00577187|Device|EnSite NavX-Guided CRT implant|LV lead placement during CRT implant using EnSite NavX
1798908|NCT00577200|Drug|Midazolam|Midazolam
1798909|NCT00577200|Drug|Sufentanil|Sufentanil
1798910|NCT00577200|Drug|Propofol|Propofol bolus of 300 µg/kg + infusion at 75 µg/kg/min.
1798911|NCT00577278|Biological|rituximab|Given IV
1798912|NCT00577278|Drug|fludarabine phosphate|Given IV
1798913|NCT00577278|Drug|melphalan|Given IV
1798914|NCT00577278|Drug|sirolimus|Given PO
1798915|NCT00577278|Drug|tacrolimus|Given PO or IV
1798916|NCT00577278|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo APBSCT
1798917|NCT00577278|Radiation|indium In 111 ibritumomab tiuxetan|Given IV
1798918|NCT00577278|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
1798919|NCT00577278|Other|laboratory biomarker analysis|Correlative Studies
1798920|NCT00577304|Drug|Nitroglycerin|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix with Nitroglycerin. Each dose contains 4.5mg of Nitroglycerin. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
1798921|NCT00577304|Drug|Topical AmphiMatrix|Individual pouch applicators containing 0.5 grams of Topical AmphiMatrix. Each dose is intended for topical usage on both hands up to five minutes before an anticipated Raynaud's attack or up to 5 minutes after the beginning of an actual Raynaud's attack. Limited to four applications per day; minimum of two hours between applications.
1798922|NCT00577317|Procedure|Management of Therapy Complications|Receive standard home maintenance therapy and perform self-manual lymphatic drainage
1798923|NCT00577317|Procedure|Management of Therapy Complications|Receive Flexitouch home maintenance therapy
1798924|NCT00577317|Other|Quality-of-Life Assessment|Ancillary studies
1798925|NCT00577330|Dietary Supplement|Myalgesin™ (celery seed extract, Boswellia serrata extract, Phellodendron extract)|Twice daily
1798926|NCT00577356|Drug|Docetaxel|Docetaxel 75mg/m2 will be given intravenously every 3 weeks for four cycles.
1798927|NCT00577356|Biological|CG1940/CG8711|Immunotherapy allogeneic GM-CSF secreting cellular vaccine
1798928|NCT00577369|Other|Desflurane Levels|The subject's participation will take place over one surgical procedure. It will begin with the first blood collection and end with either the second blood draw or the end of the procedure.
1798929|NCT00577382|Drug|Sunitinib|
1798930|NCT00577395|Drug|placebo|oral tablet once a month for 12 months
1798931|NCT00577395|Drug|risedronate|tablet, 150 mg once a month for 12 months
1798932|NCT00577408|Drug|depot naltrexone|On the afternoon of Day 7, patients assigned to Depot-BNT receive an intramuscular injection of Vivitrol (380 mg) in one buttock. The patient spends the night of Day 7 in the hospital and is discharged on the morning of Day 8. Each injection contains 192 mg of naltrexone. The double dose (384 mg) is what was found to produce optimal blockade and outcome in preliminary work. During the subsequent 6-month course of outpatient treatment, patients are dosed with two injections (384 mg total) of depot naltrexone at monthly intervals (weeks 4, 8, 12, 16, 20).
1798933|NCT00577408|Drug|Oral Naltrexone|For patients assigned to BNT-Oral, administration is clinic-based for at least the first two weeks, and doses are 50mg, 100mg, or 150mg, depending on whether one, two or three days will elapse before the next visit (typically 100 mg on Monday and Wednesday and 150 mg on Friday). The ultimate goal with BNT-Oral is for patients to take naltrexone (50 mg per day) on their own at home under supervision of their significant other/monitor.
1798934|NCT00577421|Drug|risedronate|5 mg tablet of risedronate once a day for 2 years
1798935|NCT00577447|Dietary Supplement|docosahexaenoic acid (DHA)|Capsule containing 200mg of DHA
1798936|NCT00577447|Dietary Supplement|Placebo|Placebo capsule containing corn and soybean oil
1798937|NCT00577460|Drug|Pramipexole|Pramipexole ER 0.375 -4.5 mg
1798938|NCT00577460|Drug|Placebo|Placebo tablets identical to Pramipexole ER tablets
1798939|NCT00577473|Drug|mesalamine|mesalamine 2.4 g/day (400 mg tablet) for 6 weeks
1798940|NCT00577473|Drug|mesalamine|mesalamine 4.8 g/day (800 mg tablet) for 6 weeks
1798944|NCT00577590|Drug|Lovaza|Dosage of 4 g to be taken daily for 2 months
1798945|NCT00577590|Drug|Metformin|Dosage of at least 1000 mg to be taken daily for 4 months
1798946|NCT00577603|Procedure|mesh reinforcement of stoma|Patients randomized to receive mesh will undergo stoma formation and will have a 8 cm x 12 cm piece of AlloDerm graft placed as a tissue reinforcement around the stoma and extending under the midline incision. The mesh will be trimmed to provide a minimum of 3cm of overlap around the stoma in all directions. The mesh will be secured with transabdominal number one Prolene (Ethicon, Inc) sutures every 4cm around the mesh. Additional fixation will be provided with Protack spiral tacks (US Surgical, Inc) every 1cm around the mesh. The midline fascia will be closed with running number one Prolene sutures. Skin will be closed in standard fashion.
1798947|NCT00577603|Other|no intervention|
1798948|NCT00577616|Procedure|Endovascular repair|Endovascular repair of the asymptomatic aneurysms of the abdominal aorta
1799076|NCT00570765|Drug|INT-747|10 mg po qd
1957489|NCT02363153|Other|Diet and Exercise|"Exercise will consist of 2x/week aerobic exercise, 2x/week strength training and 1x/week core-stabilizing exercise.
Diet will be constructed so that 30% of the daily caloric goal will be protein, 35% fat, and 35% carbohydrates."
1798949|NCT00577629|Drug|cyclophosphamide|1.5g/m2 IV over 1 hour on days 1-4 of induction for a total dose of 6.0g/m2
1798950|NCT00577629|Drug|etoposide|300mg/m2 IV over 1 hour every 12 on days 1-3 of induction for a total dose of 1.8 g/m2.
1798951|NCT00577629|Drug|rituximab|375mg/m2 each week x 4 weeks of induction, beginning on day 1
1798952|NCT00577629|Drug|cytarabine|3g/m2 IV over 1 hour every 12 during consolidation for a total of 8 doses
1798953|NCT00577629|Drug|doxorubicin|45mg/m2/day IV over 30 minutes on days 1, 2, 3 during consolidation
1798954|NCT00577629|Drug|tositumomab|450mg unlabeled tositumomab over 1 hour, followed by 5 millicurie (mCi) Iodine I-131 labeled tositumomab over 20 minutes on day 0. Therapeutic dose of labeled tositumomab will be administered on day 15.
1798955|NCT00577642|Drug|Zoledronic acid|4mg IV over at least 15 minutes or corrected for creatinine clearance x 1
1798956|NCT00577655|Drug|Albuterol|Albuterol HFA MDI 180 mcg four times a day (q.i.d) for a total daily albuterol dose of 720 mcg for 21 days.
1798957|NCT00577655|Drug|Placebo|Placebo HFA MDI four times a day (q.i.d) for 21 days.
1798958|NCT00577655|Drug|Proventil® HFA|Proventil® HFA (albuterol sulfate) Inhalation Aerosol (Key Pharmaceuticals) was used as rescue medication in this study. The rescue medication was over-labeled with instructions for emergency use in which subjects were instructed to self-administer up to two puffs every 20 minutes to a maximum of six puffs for any given episode while attempting to seek medical assistance.
1798959|NCT00577668|Drug|Melphalan, Velcade, Thalidomide, Dexamethasone|To assess, in patients with one or two prior auto transplants, the efficacy of a high-dose combination chemotherapy with MEL 300 (in 3 fractions of 100 mg/m2 on days -7, -4, -1) plus VTD (Velcade = bortezomib 1.3 mg/m2 on days -7, -4, -1; Thalidomide 200 mg/d on days -1 through -7; Dexamethasone 40 mg on days -7, -6, -4, -3, -1, 0) followed by autologous peripheral blood stem cell (PBSC) infusion of a minimum dose of 3 million CD34 cells/kg.
1798960|NCT00577681|Drug|Antiretroviral Therapy (ART)|Either episodic ART or continuous ART. All groups will have plasma specimens taken to compare changes in lipoprotein particle sizes and numbers and changes in inflammatory and coagulation markers.
1798961|NCT00577694|Drug|clofarabine|Intravenous, 20mg/m2, Days 1, 2, 3, 4 and 5; 2 cycles
1798962|NCT00577694|Drug|gemtuzumab ozogamicin|Intravenous, 3mg/m2, Day 1, one cycle
1798963|NCT00577707|Drug|pemetrexed, cisplatin and erlotinib before surgery then erlotinib is given to patients after surgery for 2 years|One tablet daily of erlotinib pills (150 mg daily) for the first 21 days on this study and then a CT scan will be performed. After the CT scan you will start treatment with intravenous pemetrexed and cisplatin (pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 every 3 weeks for 4 cycles treatment) on the first day of each cycle of treatment. The duration of each cycle is 21 days. You will receive treatment for 4 cycles. You will be asked to stop taking the erlotinib at least 2 days before surgery. After surgery, you will be asked to take adjuvant erlotinib 150 mg po daily x 2 years.
1798964|NCT00577720|Drug|risedronate|35mg immediate release risedronate tablet before breakfast, once a week for 13 weeks
1798965|NCT00577720|Drug|risedronate|35mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
1798966|NCT00577720|Drug|risedronate|50mg delayed release risedronate tablet following breakfast, once a week for 13 weeks
1798967|NCT00577720|Drug|risedronate|50mg delayed release risedronate tablet before breakfast, once a week for 13 weeks
1798968|NCT00577759|Other|Active Intervention|Quality improvement activities, including monthly teleconferences and chart audit with feedback, to help practices refer to community resources
1798969|NCT00577759|Other|Passive Intervention|Provision of tools to help with referrals to community resources
1798970|NCT00577759|Other|No intervention|No intervention
1798971|NCT00577772|Drug|Xifaxan|Open-Label Treatment at 400 mg by mouth, 3 times a day, for 7 days; only for those symptomatic and positive SBBO patients.
1798972|NCT00577772|Device|SmartPill|The SmartPill is a single-use, ingestible capsule that utilizes sensor technology to measure pressure, pH and temperature throughout the entire GI tract. The ACT-1 (SmartPill) GI Monitoring System includes an ingestible capsule, a receiver and video display software.
1798973|NCT00577772|Procedure|Lactulose hydrogen breath test (H_2BT)|A hydrogen breath test provides information about the digestion of certain sugars or carbohydrates, such as milk sugar (lactose) or fruit sugar (fructose). The test is also used for detecting abnormal growth of bacteria within the small bowel by having the patient ingest lactulose.
1798974|NCT00577785|Other|tissue procurement|No intervention. Tissue procurement study.
1798975|NCT00577798|Drug|doxorubicin hydrochloride|Standard therapy for patients undergoing chemotherapy for their non-Hogdkin's lyphoma and Hogdkin's lymphoma
1798976|NCT00577798|Procedure|contrast-enhanced magnetic resonance imaging|Cardiac magnetic resonance imaging (cMRI) offers the unique advantage of being able to analyze both function and structure (myocardial changes in the form of both a functional decrease in ejection fraction and structural changes within the myocardium defined as delayed contrast uptake).
1798977|NCT00577824|Drug|exenatide|subcutaneous injection, 5mcg, twice a day
1798978|NCT00577824|Drug|exenatide|subcutaneous injection, 10mcg, twice a day
1798979|NCT00577824|Drug|placebo|subcutaneous injection, volume equivalent to 5mcg or 10mcg exenatide, twice a day
1798980|NCT00577837|Drug|risedronate|tablet, 5 mg risedronate daily for 6 months
1798981|NCT00577837|Drug|risedronate|tablet, 100 mg risedronate monthly for 6 months
1798982|NCT00577837|Drug|risedronate|tablet, 150 mg risedronate monthly for 6 months
1798983|NCT00577837|Drug|experimental|tablet, 200 mg risedronate monthly for 6 months
1798984|NCT00577850|Drug|risedronate|0.23 mg 14C-labeled risedronate, followed 7 days later with oral 35 mg risedronate once a week for 52 weeks followed by another 14C-labeled risedronate followed weekly by 35 mg risedronate for 3 weeks
1798985|NCT00577850|Drug|alendronate|0.45 mg 14C-labeled alendronate, followed 7 days later with oral 705 mg alendronate once a week for 52 weeks followed by another 14C-labeled alendronate followed weekly by 70 mg alendronate for 3 weeks
1798986|NCT00577863|Drug|teriparatide|Subcutaneous injection of teriparatide 20 micrograms once daily using the Forteo B Pen. The primary phase of the study is 8 weeks after which time patients may participate in a study extension until the patient completes their maximum duration of teriparatide therapy or the Forteo B Pen becomes commercially available.
1799077|NCT00570765|Drug|INT-747|50 mg po qd
1798987|NCT00577876|Procedure|Trimix Injection with Doppler Ultrasound|"In case a large APA was identified, it will be dissected following the usual technique. Upon completion of the dissection, patients will have intracavernosal injection of 10 units (0.1 ml) of a Trimix administered (PGE1 10 mcg/ml, papaverine hydrochloride 30 mg/mL and phentolamine mesylate 1mg/mL.
Once the patient achieves a pharmacologic erection, the initial Doppler Ultrasound is completed, the accessory pudendal artery will be temporarily clamped to stop blood flow. After the artery is clamped, the Doppler Ultrasound will be repeated. We estimate an extension of the surgery no longer than 5 or 10 minutes in comparison to the usual operating time. Once the Doppler Ultrasound is completed, the clamp will be removed and the surgery continued in its usual fashion."
1798988|NCT00564668|Drug|biphasic insulin aspart|
1798989|NCT00564681|Biological|botulinum toxin type A|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
1798990|NCT00564681|Biological|botulinum toxin type A Formulation 2|Intramuscular injections into the affected muscles. Maximum dose of 360 units. Subjects may receive up to three treatments.
1798991|NCT00564681|Drug|Normal Saline|Intramuscular injections of placebo (normal saline) into the affected muscles for treatment cycle 1.
1798992|NCT00564694|Procedure|psychosocial assessment and care|
1798993|NCT00564694|Procedure|quality-of-life assessment|
1798994|NCT00564707|Behavioral|Biofeedback therapy|EMG guided biofeedback therapy using standard biofeedback computer software
1798995|NCT00564707|Procedure|Botulinum Toxin Type A Injection|Under EMG guidance Botox is injected directly into the painful levator ani muscle.
1798996|NCT00564720|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on days 1, 8, and 15 every 28 days for 6 cycles
1798997|NCT00564720|Drug|Gemcitabine|Gemcitabine 1100 mg/m2 IV on days 1 and 8 every 21 days for 6 cycles
1798998|NCT00564720|Drug|Erlotinib|Erlotinib 100 mg by mouth (p.o.), daily until disease progression
1798999|NCT00564720|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 IV on day 8, every 21 days for 6 cycles
1799000|NCT00564733|Drug|carboplatin|Given IV
1799001|NCT00564733|Drug|docetaxel|Given IV
1799002|NCT00564733|Drug|gemcitabine hydrochloride|Given IV
1799003|NCT00564733|Drug|paclitaxel|Given IV
1799004|NCT00564733|Procedure|computed tomography|Undergo FDG PET/CT
1799005|NCT00564733|Procedure|positron emission tomography|Undergo FDG PET/CT
1799006|NCT00564733|Radiation|fludeoxyglucose F 18|Given IV
1799007|NCT00564733|Other|imaging biomarker analysis|Correlative studies
1799008|NCT00564746|Drug|A single 10 milligram (50 microcurie) oral dose of [14C]SB-681323|"[14C] SB-681323 oral solution, is available as a powder which will be made into a solution of 0.1 milligram/milliliter (0.5 microcurie) [14C] SB-681323 in dextrose and water for injection on the day prior to dosing.
For a 10 milligram/50 microcurie oral dose of [14C]SB-681323, 100 milliliters of 0.1 milligram/milliliter (0.5 microcurie/milliliter [14C] SB-681323 oral solution will be dosed."
1799009|NCT00564759|Drug|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo retroviral transduced (SF71-gp91phox) CD34+ cells
1799010|NCT00564772|Drug|Raltegravir, lopinavir, ritonavir|4 days of raltegravir, then 10 days of Kaletra, then 4 days of both with 12 PK sampling at the end of each period.
1799011|NCT00564785|Drug|Synera(TM)|Synera(TM) patch applied 20 minutes prior to epidural
1799012|NCT00564785|Other|Placebo patch|placebo patch applied 20 minutes prior to epidural
1799013|NCT00564811|Dietary Supplement|Agaricus blazei (Murrill) ss. Heinemann (sun mushroom)|Agaricus blazei powder, 10 grams/day, for 5 months
1799014|NCT00564824|Drug|Caffeine|Caffeine 200 mg tablet
1799015|NCT00564824|Drug|Placebo|Placebo pills
1799016|NCT00564837|Procedure|Home-based rehabilitation program|Home-based rehabilitation program that includes 4 physiotherapy sessions in the first 3 post-op months
1799017|NCT00564837|Procedure|Physiotherapy-supervised rehabilitation program|Physiotherapy-supervised rehabilitation program that includes 17 scheduled physiotherapy sessions in the first 3 post-op months
1799018|NCT00564850|Drug|Triptorelin pamoate 11.25mg (Decapeptyl® SR)|One intra muscular injection at day 1 and month 3.
1799019|NCT00564863|Biological|CS19 expressing ETEC strain|Wild type ETEC strain expressing the colonization faction CS19, and LT and ST enterotoxins.
1799020|NCT00564876|Drug|Dasatinib|Fresh frozen tumor tissue must be available prior to initiating dasatinib. Eligible patients will receive neoadjuvant dasatinib 70 mg PO twice daily for 3 weeks followed by surgery. The surgical specimen will be evaluated for pathologic response. The second tumor sample will be obtained after 3 weeks of dasatinib therapy at the time of definitive surgical resection which will be evaluated for changes in genomic expression profiles. Patients with at least a 15% decrease or better objective response, without evidence of progression (per tumor evaluation pre-surgery) or pathologic response (as defined as ≥30% tumor necrosis or cell death) to neoadjuvant dasatinib therapy will be eligible to receive dasatinib 70 mg twice daily for 90 days after the completion of standard adjuvant therapy.
1799021|NCT00564889|Drug|cyclophosphamide|300 mg/m^2 days 1, 8 & 15 of a 28 day cycle taken orally with food
1799022|NCT00564889|Drug|dexamethasone|40 mg weekly taken orally
1799023|NCT00564889|Drug|lenalidomide|15 mg daily days 1-21 of a 28 day cycle taken orally with food
1799024|NCT00564902|Drug|3R 3'R Zeaxanthin|8 mg per day during 12 months
1799025|NCT00564902|Dietary Supplement|Lutein|9 mg of Lutein during 12 months
1799026|NCT00564902|Dietary Supplement|Lutein and Zeaxanthin|8 mg of lutein and 8 mg of Zeaxanthin administered during 12 months
1799027|NCT00564915|Dietary Supplement|Ketogenic diet|Ketogenic diet
1799028|NCT00564928|Drug|IPI-504|IPI-504 at 400mg/m2, IV, 2 times a week for 2 weeks with 10 days off treatment. Twenty-one (21) day cycle
1799029|NCT00564941|Drug|deferasirox|
1799030|NCT00564954|Drug|Dex-methylphenidate hydrochloride extended-release (Focalin XR)|20 mg capsule orally once a day for 7 days
1799031|NCT00564954|Drug|Placebo|orally once a day for 7 days
1799032|NCT00564967|Behavioral|CBT via the Internet|15 weeks, patients learn about CBT primarily thru a self-help book published on teh Internet, Minimal therapy contact via e-mail(10 minutes/week),
1799033|NCT00564967|Behavioral|CBT group therapy|15 weeks, 1 session/week, (2,5 hours.)
1799125|NCT00577980|Drug|Testosterone|Initial dose of Testosterone 200 mg IM administered followed by 200 mg - 400 mg every 2 weeks.
1799034|NCT00564980|Procedure|Wafer Procedure|A dorsal approach to the distal ulna is used dividing the extensor retinaculum between the 5th and 6th compartments. The ulnar head is exposed through a transverse capsulotomy. Cartilage and bone are resected to result in slight negative ulnar variance based on the preoperative pronated grip view. The ulnar styloid and TFCC attachments are preserved. The dorsal capsule and retinaculum are repaired in separate layers.
1799035|NCT00564980|Procedure|Ulnar shortening osteotomy|A longitudinal incision of approximately 8 cm is made at the distal third of the ulna along the ulnar border of the forearm. The interval between the flexor carpi ulnaris is used. The ulna is exposed at its distal third preserving the periosteum. Care is taken to protect the sensory branches of the lunar nerve. An oblique osteotomy is performed using a reciprocating saw, removing enough bone to result is slight negative ulnar variance. Fixation and compression at the osteotomy site is achieved using a 5 or 6 hole titanium LC-DCP plate.
1799036|NCT00564993|Drug|Dobutamin|10&20 µg/kg/min
1799037|NCT00565006|Drug|MK0859|
1799038|NCT00565019|Drug|Triamcinolone Acetonide|"Triamcinolone acetonide will be administered into the cord following surgery with a tuberculin syringe and a 25-gauge needle.
Doses will range from 60-120 mg depending on extent of the disease.
Patients will receive injections at 6 weeks and 3 months for persisting nodules or cords.
PI will determine the dosages. Estimates will be made based on the following:
Size of nodule/cord: 1-2 cm2, dosage 20-40 mg
Size of nodule/cord: 2-6 cm2, dosage 40-80 mg
Size of nodule/cord: 6-10 cm2, dosage 80-100 mg
Size of nodule/cord: >10 cm2, dosage 100-120 mg"
1799039|NCT00565045|Device|Neuromuscular electrical stimulator|"Intervention Characteristics Common to Both Groups
• 6-week intervention
Home exercise, daily
Exercise (at home) 2 sessions/day
A session consists of 3 (for CCFES) or 4 (for cNMES) 15-min sets separated by 5 min rest
A set entails hand opening, closing, and relaxing in response or synchrony to light and sound cues and according to group-specific instructions
Lab therapy, 2x/week
Two 1.5-hr sessions/week, working on functional hand tasks and tracking task (if possible)."
1799040|NCT00570531|Drug|Bevacizumab|Pre-Operative Treatment: Bevacizumab will be given over 60-90 minutes through an I.V. catheter on days # 2 and 16. Post-Operative Treatment:Bevacizumab given over 60-90 minutes through an I.V. catheter every 21 days for 12 months, starting 6-8 weeks after surgery.
1799041|NCT00570531|Drug|Paclitaxel|Pre-Operative Chemotherapy treatment: Paclitaxel 45 mg/m2 will be administered as a 1-hour intravenous infusion on days #2, 9, 16, 23, and 30. It will be given before cisplatin administration.
1799042|NCT00570531|Drug|Cisplatin|Pre-Operative Chemotherapy Treatment: Cisplatin 30 mg/m2 over 1 hour on days #2, 9, 16, 23, and 30. It will be given after paclitaxel.
1799043|NCT00570531|Drug|5-Fluorouracil|Pre-Operative Chemotherapy Treatment: 5-Fluorouracil at 200 mg/m2/day will be given as a continuous intravenous infusion on days #2-33.
1799044|NCT00570531|Radiation|Radiation Therapy|Pre-Operative Treatment: Radiotherapy will be given Monday through Friday five days a week on days 1-5, 8-12, 15-19, 22-26, and 29-33. Radiotherapy will be administered using MV x-rays. CT scans, the barium swallow, the endoscopy and endoscopic ultrasound reports and PET scans should be used for tumor definition. Post-Operative Radiotherapy: In the event that gross residual disease is left behind at the time of surgery or the patient is found to have a microscopic positive deep or gastric margin following surgery, additional treatment with radiation therapy will be considered.
1799045|NCT00570531|Procedure|Esophagectomy|Transhiatal esophagectomy performed on approximately Day #57 (6 weeks after last dose of bevacizumab.)
1799046|NCT00570544|Drug|tiotropium|18ug capsule daily for 30 days
1799047|NCT00570557|Other|TOR-BSST© Refresher Training|Web-based refresher training in dysphagia screening
1799048|NCT00570570|Procedure|Muscular Strengthening for paretic knee flexor and extensor|thrice a week during 6 weeks
1799049|NCT00570570|Other|conventional physiotherapy|trice a week during 6 weeks
1799050|NCT00570609|Other|CPR Anytime education|After consent, participants will be asked to complete the 22 minute DVD CPR Anytime program with their parent(s)/legal guardian(s) and encouraged to include other friends and family members in the program
1799051|NCT00570622|Drug|Pioglitazone|Patients receive 60mg of pioglitazone once a day orally for 9 days
1799052|NCT00570622|Drug|Placebo|Patients receive placebo once a day orally for 9 days
1799053|NCT00570635|Drug|XL820|XL820 capsules administered orally as a single agent at a dose of 800 mg daily
1799054|NCT00570635|Drug|XL820|XL820 capsules administered orally as a single agent at a dose of 300 mg twice daily
1799055|NCT00570648|Drug|sodium hyaluronate|1% sodium hyaluronate applied at the end of corneal transplant surgery. The amount will be determined on how much is necessary to cover the ocular surface.
1799056|NCT00570661|Drug|ITF2357|ITF2357 will be supplied as hard gelatine capsule for oral administration at the dose strengths of 7.5, 10, 12.5, 15, 20 and 50 mg, identifiable by different colours. The dose of 1.5 mg/kg/day will be achieved by administration, at 12-hour interval, of an appropriate number of capsules of definite strength(s) as specified here below
1799057|NCT00570674|Drug|Abraxane|
1799058|NCT00570674|Drug|Erbitux|
1799059|NCT00570674|Drug|Carboplatin|
1799060|NCT00570674|Radiation|Intensity Modulated Radiation Therapy|
1799061|NCT00570687|Drug|Technosphere Insulin|Inhalation 15U/30U
1799063|NCT00570713|Drug|MORAb-009|Monoclonal antibody administered once weekly by intravenous injection.
1799064|NCT00570713|Drug|Placebo|As per package insert.
1799065|NCT00570713|Drug|Gemcitabine|Gemcitabine was administered by i.v. infusion at an initial dose of 1000 mg/m2 once weekly for up to 7 weeks (or until toxicity necessitated reducing or holding a dose), followed by a week of rest from treatment. Subsequent cycles consisted of infusions once weekly for 3 consecutive weeks, followed by a week of rest from treatment.
1799066|NCT00570726|Drug|Ranibizumab (Lucentis)|
1799067|NCT00570739|Drug|Metformin HCl and Colesevelam Placebo|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg placebo tablets once daily for 16 weeks
1799068|NCT00570739|Drug|Metformin HCl tablets and Colesevelam tablets|One or two Metformin HCl tablets 850 mg (depending on tolerability) and 6 colesevelam 625 mg tablets once daily for 16 weeks
1799069|NCT00570739|Drug|Colesevelam placebo|Six colesevelam 625 mg placebo tablets will be given once a day for 16 weeks
1799070|NCT00570739|Drug|Colesevelam|Six colesevelam 625 mg tablets will be given once a day for 16 weeks.
1799078|NCT00570778|Drug|indacaterol/glycopyrrolate|Inhalation capsule indacaterol/glycopyrrolate 300/50 μg inhaled once daily via a single dose dry powder inhaler for 7 days.
1799079|NCT00570778|Drug|indacaterol|Inhalation capsule indacaterol supplied as 300 μg capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
1799080|NCT00570778|Drug|placebo|Placebo inhalation capsules inhaled once daily via a single dose dry powder inhaler for 7 days.
1799081|NCT00570791|Device|Tonometer|Tonometer devices used to measure IOP: Pascal Dynamic Contour Tonometer, Goldman Applanation Tonometer, Tono Pen, Reichart pneumatonometer, Langham Ocular Blood Flow, Schiotz Tonometer and ICare tonometer
1799082|NCT00570804|Behavioral|Telephone Counseling|7 counseling calls where quit date set on first counseling call; then counseling calls on quit date, 3-5 days after quit date, 7-10 days after quit date, 15-30 days after quit date, 45-60 days after quit date, and 90 days after quit date, each taking about 15 to 30 minutes to complete.
1799083|NCT00570804|Behavioral|Telephone Assessments|4 assessment telephone calls at Weeks 12, 26 and 52 (interview by a research staff member), taking about 30 minutes each to complete.
1799084|NCT00570817|Other|12 hours of prehydration|12 hours of prehydration with an infusion rate of 150 ml/m2/hour with a solution of 5% glucose with 40 mmol sodium bicarbonate/L and 20 mmol potassium chloride/L.
1799085|NCT00570830|Device|Retisert (fluocinolone acetonide implant)|Patients with intermediate, posterior or pan-uveitis underwent simultaneous fluocinolone acetonide implantation (0.59 mg or 2.1 mg) and phacoemulsification and intraocular lens.
1799086|NCT00570843|Drug|New PEG based artificial tear|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
1799087|NCT00570843|Drug|Optive|1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
1799088|NCT00570856|Drug|Folic acid|Folic acid 5 mg/day
1799089|NCT00570856|Drug|Placebo|Placebo similar to the folic acid tablets, 1/day
1799090|NCT00570869|Other|CPR Anytime|These participants will be consented, surveyed, asked to watch a 22-minute instructional Infant CPR DVD with an infant manikin.
1799091|NCT00570882|Drug|Sunitinib 2/1|Sunitinib 50 mg PO 2 weeks followed by 1 week rest
1799092|NCT00570882|Drug|Sunitinib 4/2|Sunitinib 50 mg PO 4 weeks followed by 2 week rest
1799093|NCT00570895|Dietary Supplement|Vitamin C|"Visit 1: Subjects will receive 1mg iron-58 sulfate as an aqueous solution with 50mg ascorbic acid.
Visit 2: Subjects will consume a meal of a bread muffin labelled with 4mg of iron-57 as ferrous fumarate, and a glass of apple juice containing 0 or 25mg ascorbic acid.
Visit 3: During this admission the apple juice will contain either 0 or 25mg ascorbic acid, the opposite of what was given to the subject in visit 2."
1799094|NCT00570908|Drug|sunitinib|Sutent
1799095|NCT00570908|Drug|capecitabine|concurrently
1799096|NCT00570908|Radiation|WBRT|Whole Brain Radiotherapy 30 Gy in 10 fractions
1799097|NCT00570921|Drug|Everolimus|Everolimus tablets, two-5 mg tablets a day
1799098|NCT00570921|Drug|Fulvestrant|intramuscular, 500 mg in two divided doses- one on each side- on day 1, then 250mg on day 14, then 250 mg on day 28 and every 4 weeks +/- 3 days thereafter
1799099|NCT00570934|Dietary Supplement|Cholecalciferol|2000IU Cholecalciferol P.O. Q.D.
1799100|NCT00570934|Dietary Supplement|Calcium|1 gm calcium as calcium carbonate
1799101|NCT00570934|Dietary Supplement|Calcium and cholecalciferol|2000IU cholecalciferol and 1 gm calcium P.O. Q.D. for 6 months
1799102|NCT00570934|Drug|Placebo|Placebo
1799103|NCT00570947|Other|CPR Anytime Kit|The study group will be asked to fill the CPR Anytime ™ prescription and complete the program. They will be encouraged to include other friends and family members in the program
1799104|NCT00570960|Drug|Dextran 70|dextran 70, 1.0 g/kg on days one, two and three
1799105|NCT00570960|Biological|human albumin|human albumin 1.5 g/kg on day one and 1.0 g/kg on day three
1799106|NCT00570973|Procedure|endoscopic band ligation|Endoscopic Band ligation of esophageal varices, performed every 2-4 weeks until resolution of varices
1799107|NCT00570973|Procedure|TIPS-Implantation|Transjugular intrahepatic portosystemic stent shunt with PTFE-covered stent, placed once, under fluoroscopic control,
1799108|NCT00570986|Drug|Placebo|Two injections at weeks 0 and 4. One injection at week 8. At week 12, arm is rerandomized to placebo every 4 weeks.
1799109|NCT00570986|Biological|ABT-874|200mg at week 0 and week 4. 100mg at week 8. On week 12, arm is rerandomized to 100mg every 4 weeks.
1799110|NCT00570986|Biological|ABT-874|100mg every 12 weeks.
1799111|NCT00570999|Drug|Palifermin|60 mg/kg/day
1799112|NCT00570999|Other|Placebo|1,2 mL once daily
1799113|NCT00571025|Behavioral|APOE Disclosure|Individuals are provided with a lifetime percentage risk of developing Alzheimer's disease and told their own APOE genotype.
1799114|NCT00571038|Behavioral|Peer Led|Post provided with blood pressure cuffs, pedometers and scale. Two post members trained as peer leaders who encourage post members to take positive steps to improve BP. Peer leader training involves 20 hours of training over 12 months, telephone/email access to clinical experts and educational materials to share with post members.
1799115|NCT00571038|Behavioral|Seminar|Post provided with blood pressure cuffs, pedometers and scale. Post members, including study participants invited to didactic sessions on cardiovascular health.
1799116|NCT00571051|Behavioral|Mindfulness Based Stress Reduction|8 week course in mindfulness training
1799117|NCT00571064|Drug|Donepezil HCl|One 5 mg tablet per day (for the first 6 weeks) with a full glass of water. For the last 6 weeks, one 10mg tablet per day with a full glass of water.
1799118|NCT00571077|Device|Electrical Impedance Scanning (EIS) of the Thyroid gland|Patients will be examined in the supine position. A cylinder electrode conveying 2.5V electrical current will be held by the patient. The patient will be scanned by a probe (similar to an ultrasound probe. The examination takes 5 minutes and there is no risk or discomfort.
1799119|NCT00577889|Drug|gemcitabine hydrochloride|750 mg/m2 Given IV
1799120|NCT00577889|Drug|tanespimycin|154 mg/m2 Given IV
1799121|NCT00577902|Other|Observation|Head and neck cancer patients receiving chemoradiation
1799122|NCT00577915|Other|Radiology/MRI scan|MRI spectroscopy
1799123|NCT00577954|Procedure|Multimodal MRI|Multimodal MRI
1799124|NCT00577967|Drug|Gabapentin|
1799199|NCT00579020|Drug|Moxifloxacin ophthalmic solution 0.5%|
1799126|NCT00577993|Drug|Fludarabine|Group 1= 25 mg/m^2 IV over 15 min. Days 2 through 4 for 8 Cycles; Group 2 = 25 mg/m^2 IV over 15 min. Days 1 through 3 for 8 Cycles.
1799127|NCT00577993|Drug|Novantrone|Group 1 = 10 mg/m^2 IV over 15 min. Day 2 for 8 Cycles; Group 2 = 10 mg/m^2 IV over 15 min. Day 1 for 8 Cycles; Group 3 = 10 mg/m^2 IV over 15 min. Day 2 of 3rd Sequence.
1799128|NCT00577993|Drug|Decadron|Group 1 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 2 = 20 mg IV over 15 min. Days 1 through 5 for 8 Cycles, then Days 1 through 3 Every Month for 1 Year; Group 3 = 40 mg PO Days 1 through 4 of 1st Sequence; After Completion of 3 Sequences, Days 1 through 3 Every Month for 1 Year.
1799129|NCT00577993|Drug|Rituximab|Group 1 = 375 mg/m^2 IV Days 1 through 8 of Course 1, then Day 1 Only of Cycles 2 through 5; Group 2 = 4 Months after IFN Starts, 375 mg/m^2 IV Once Per Month for 6 Months; Group 3 = 375 mg/m^2 IV Days 1 through 8 of 1st Sequence; 375 mg/m^2 IV Days 1 through 8 of 3rd Sequence.
1799130|NCT00577993|Drug|Interferon|Group 1 = After Completion of Fludarabine, Novantrone, & Rituximab, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 2 = After Completion of Fludarabine & Novantrone, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year; Group 3 = After Completion of 3 Sequences, IFN 3 mcg/ml/m^2 SQ Days 1 through 14 Each Month for 1 year.
1799131|NCT00577993|Drug|Doxorubicin|25 mg/m^2 IV Days 2 & 3 of 1st Sequence.
1799132|NCT00577993|Drug|Vincristine|.7 mg/m^2 IV Days 2 & 3 of 1st Sequence; 1.4 mg/m^2 IV Day 2 of 3rd Sequence.
1799133|NCT00577993|Drug|Bleomycin|5 unit/m^2 IV Days 2 & 3 of 1st Sequence.
1799134|NCT00577993|Drug|Cyclophosphamide|750 mg/m^2 IV Day 2 of 1st Sequence.
1799135|NCT00577993|Drug|Etoposide|40 mg/m^2 IV Days 1 through 4 of 2nd Sequence.
1799136|NCT00577993|Drug|Cisplatin|25 mg/m^2 IV Days 1 through 4 of 2nd Sequence
1799137|NCT00577993|Drug|Ara-C|1.5 gm/m^2 IV Day 5 of 2nd Sequence.
1799138|NCT00577993|Drug|Methyl-Prednisolone|500 mg IV Days 1 through 5 of 2nd Sequence.
1799139|NCT00577993|Drug|Procarbazine|100 mg/m^2 PO Days 2 through 11 of 3rd Sequence.
1799140|NCT00577993|Drug|Prednisone|100 mg PO Days 1 through 5 of 3rd Sequence.
1799141|NCT00578006|Behavioral|Questioners|The investigators will ask you to fill out a brief paper questionnaire periodically to tell us how you are feeling, and how satisfied you are with your care.
1799142|NCT00578006|Behavioral|STAR website|You can report your symptoms every time you come to Sloan-Kettering for an appointment or chemotherapy.
1799143|NCT00578019|Procedure|IM Nailing|Patients randomized to Arm 1, A will be treated with a retrograde intramedullary nailing of the femur fracture utilizing the Smith & Nephew supracondylar nail.
1799144|NCT00578019|Procedure|LISS|Group B patients will have their fracture stabilized with the LISS plates (Synthes [USA], Paoli, PA, USA).
1799146|NCT00578045|Procedure|Transfusion|Approximately 24 hours after the chemotherapy is completed you will receive the transfusion of the human cord blood
1799147|NCT00578058|Other|Counseling and Sound Therapy|Tinnitus counseling and sound therapy
1799148|NCT00578071|Drug|Panitumumab|Dose per cohort level (3.6, 4.8 or 6.0 mg/kg ), given intravenously (IV) days 1, 15 and 29 of radiation.
1799149|NCT00578071|Drug|Capecitabine|Dose per cohort level (500, 625 or 825 mg/m2) taken by mouth twice each day of radiation
1799150|NCT00578071|Drug|Oxaliplatin|Dose per cohort level (30, 40, or 50 mg/m2). Given IV one day each week during radiation
1799151|NCT00578071|Radiation|Radiation Therapy (RT)|Daily for 6 weeks
1799152|NCT00578097|Drug|Botulinum type A (Dysport®)|Single injection cycle, intradetrusor injection at baseline visit 2 of either 125 units (arm A), 250 units (arm B) or 500 units (arm C) in total.
1799153|NCT00578097|Other|Placebo|Single injection cycle, intradetrusor injection at baseline (visit 2).
1799154|NCT00578110|Device|Glaucoma Diagnosis, Name: Neucodia|Sensitivity and Specificity
1799155|NCT00578123|Behavioral|Quality of Life Questionnaires|Three surveys you will need to complete. We will give you the surveys during your regularly scheduled clinic visits at three, six, and twelve months after surgery. You will NOT be asked to make additional appointments just for the study. You will have the option of completing some of the surveys in an easy to use computer format in the clinic waiting area or on paper.
1799156|NCT00578136|Drug|Bupivacaine|Bupivacaine, 0.25%, dose amount is weight based, injection is divided per dise with rectus sheath injection or with local infiltration of the operative area.
1799157|NCT00578149|Drug|Bevacizumab|
1799158|NCT00578149|Drug|Carboplatin|
1799159|NCT00578149|Drug|Paclitaxel|
1799160|NCT00578162|Behavioral|we will screen potential agencies using our CALL SCRIPT and our AGENCY SCREENER|A cancer care facility or 'agency' is the study's unit of analysis. Data about participating agencies will be collected by electronic survey. Agencies will be identified using the NYSDOH's existing mailing list of care facilities located in the five boroughs of New York City, referral databases and resource guides created by the American Cancer Society (ACS), the New York Hospital Directory
1799161|NCT00578175|Biological|Priorix-Tetra™ (MMRV vaccine 208136)|One subcutaneous injection.
1799162|NCT00578175|Biological|ProQuad®|One subcutaneous injection.
1799163|NCT00578175|Biological|Havrix®|Two intramuscular injections.
1799164|NCT00578175|Biological|Prevnar®|One intramuscular injection.
1799165|NCT00578201|Drug|radiochemotherapy,combination Cetuximab-FOLFOX|objective response rate at 12 weeks with radiochemotherapy then combination Cetuximab-FOLFOX
1799166|NCT00578214|Drug|Randomized Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. In the randomized arm, patients received a single-dose administration of 5 ml (10 mg) of the midazolam syrup.
1799167|NCT00578214|Other|Placebo|The placebo was prepared as a color- and texture-matched cherry flavored syrup without midazolam.
1799168|NCT00578214|Drug|Local Anesthesia|Lidocaine 1% with 1:100,000 epinephrine
1799200|NCT00579020|Drug|Dexamethasone phosphate solution, 0.1%|
1799169|NCT00578214|Drug|Prospective Midazolam|Midazolam was prepared in a 2 mg/ml cherry flavored syrup. Dosing in the prospective arm was based on weight (>45 to 77 kg, 10 mg; >77 to 100 kg, 15 mg; greater than or equal to 100 kg, 20 mg). In the prospective arm patients were given additional doses of midazolam as necessary (in 5 mg increments) to achieve and maintain the desired level of anxiolysis.
1799170|NCT00578227|Biological|Cervarix™|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
1799171|NCT00578227|Biological|Twinrix ™ Paediatric|Three doses of vaccine administered intramuscularly with the second and third dose given one month and six months after the first dose
1799172|NCT00578851|Device|C2a - Taper™ Acetabular System|The C2a-Taper™ Acetabular System is a ceramic on ceramic hip articulating system. The bearing surfaces consist of ceramic femoral heads and acetabular liners.
1799173|NCT00578864|Drug|Protracted Oral Etoposide|"IV Cisplatin and Oral Protracted Etoposide for induction
Induction chemotherapy will consist of five cycles 21 days apart. Cycles 1, 2 and 4 will be IV cisplatin and etoposide. Patients on the phase II window will receive the first two cycles of chemo with IV cisplatin and oral protracted etoposide. If their tumor responds with a CR, VGPR or PR, it will be repeated during cycle 4. If their tumor does not respond cycle 4 will include bolus etoposide
Cisplatin with Oral Protracted Etoposide for cycles 1, 2 and 4
Day 1 - 5
Hour 0: Etoposide 50 mg/m2 po daily
Hours 1 to 7: Cisplatin 40 mg/m2
Day 6 - 14
Etoposide 50 mg/m2 po once daily"
1799174|NCT00578864|Drug|Adriamycin and Cyclophosphamide|"Induction chemotherapy will consist of 5 cycles given 21 days apart. Cycle 3 and 5 will be adriamycin and cyclophosphamide.
Day 1 and 2
Hours 0 to 6: Cyclophosphamide 2000 mg/m2 (67 mg/kg if < 12 kg) with Mesna 400 mg/m2 (13 mg/kg if < 12 kg) in D5½NS 600 mL/m2 IV over 6 hours to run at 100 mL/m2/hr
Hours 6 to 6.25: Adriamycin 37.5 mg/m2 (1.25 mg/kg if < 12 kg) IV over 15 minutes"
1799175|NCT00578864|Drug|IV Cisplatin and IV Bolus Etoposide|"Induction chemotherapy will consist of five cycles of chemotherapy given 21 days apart. The 1st, 2nd and 4th cycles will the IV Cisplatin and Etoposide. Patients ineligible to participate on the phase II window will receive IV bolus etoposide during cycles 1, 2 and 4.
Cisplatin with Bolus IV Etoposide
Day 1
Hours 0 to 6: Cisplatin 40 mg/m2
Days 2, 3, 4:
Hours 0 to 1: Etoposide 200 mg/m2 Hours 1 to 7: Cisplatin 40 mg/m2
Day 5:
Hours 0 to 6: Cisplatin 40 mg/m2"
1799176|NCT00578877|Device|SILCS Diaphragm|SILCS Diaphragm used with 5 ml gel
1799177|NCT00578877|Combination Product|Nonoxynol-9 Gel|Gynol II (2% N-9 gel)
1799178|NCT00578877|Combination Product|Buffer Gel|Buffer Gel
1799179|NCT00578890|Procedure|Medical/surgical treatment versus medical treatment|A 12 week course antibiotics versus a limited resection of infected bone associated with a 4 week course antibiotics.
1799180|NCT00578903|Drug|Cytoxan|Cytoxan will be given at 50 mg/kg per dose for 4 successive days.
1799181|NCT00578903|Drug|Campath|Campath will be given at a dose of 3 mg for patients whose weight is between 5 and 15 kg; at a dose of 5 mg for patients whose weight is between 16 and 30 kg; and at a dose of 10 mg for patients whose weight is greater than 30 kg. The last dose of Campath should be 24 hours or more before stem cell infusion.
1799182|NCT00578903|Radiation|Total Body Irradiation (TBI)|TBI will be given at a dose of 200 cGy for 6/6 HLA match and at a dose of 400 cGy in two fractions of 200 cGy each for 5/6 HLA matched donor.
1799183|NCT00578903|Drug|FK-506|FK-506 will be given at a dose of 0.03 mg/kg/day via continuous infusion over 24 hours from 4pm on day -2 until engraftment or when patient is able to take by mouth (PO), then 0.03 mg/kg PO every 12 hours.
1799184|NCT00578903|Drug|Methotrexate|Methotrexate will be administered on day +1, day +3, day +6 and day +11 at a dose of 5 mg/m2. The day +11 dose may be omitted at the discretion of the bone marrow transplant (BMT) in-patient attending physician.
1799185|NCT00578903|Procedure|Stem cell infusion|Where possible patients will receive bone marrow. Marrow will be collected as per National Marrow Donor Program (NMDP) guidelines to provide a volume of 15-20 ml/kg of marrow and/or 2-4 X 10^8 nucleated cells/kg. In case marrow cannot be collected, peripheral blood stem cell (PBSC) will be substituted. A minimum of 5-6 X 10^6 CD 34+ cells/kg should be collected, with a target of 10 X 10^6/kg.
1799186|NCT00578916|Drug|EVRI (BMS-690514)|Oral Solution, Oral, 200 mg, single dose followed by 10-12 day inpatient stay
1799187|NCT00578929|Drug|Olopatadine Hydrochloride Nasal Spray 0.6%|Olopatadine HCl 1 or 2 sprays per nostril twice daily
1799188|NCT00578929|Drug|Vehicle|Vehicle 1 or 2 sprays per nostril twice daily
1799189|NCT00578942|Drug|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.
Subject Evaluation will occur 2-3 times per week by physical exam for toxicity through day 45."
1799190|NCT00578955|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
1799191|NCT00578955|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
1799192|NCT00578955|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
1799193|NCT00578968|Drug|Tiotropium|Participants received once daily Spiriva capsules for oral inhalation: 18 mcg tiotropium powder, for use with HandiHaler device.
1799194|NCT00578968|Drug|Placebo|Participants randomized to this arm received a once daily oral inhalation of placebo powder to match the standard active comparator dose, using the HandiHaler device.
1799195|NCT00578981|Behavioral|Osteoporosis Choice Decision Aid|The provider will introduce the patient to the choice of bisphosphonates using the decision aid.
1799196|NCT00578994|Device|Oxford® Meniscal Unicompartmental Knee System|Oxford® Meniscal Unicompartmental Knee System is a medial, unicompartmental knee prosthesis containing three components: a femoral component, a tibial component, and a tibial meniscal bearing.
1799197|NCT00579007|Behavioral|telephone interviews|Telephone interviews take place before the first counseling appointment (baseline), and 1 week, 6 months and 12 months post-notification of the individual's genetic test results. In the event that a participant chooses not to undergo genetic testing, follow-up interviews will take place 1 month, 6 months and 12 months after the initial counseling visit.
1799198|NCT00579020|Drug|Moxifloxacin/dexamethasone phosphate ophthalmic solution|
1799201|NCT00579033|Other|Tactile training + sham rTMS|tactile training for 2.5/hr/day for 15 days - this plus the sham rTMS
1799202|NCT00579033|Other|Tactile training + rTMS|tactile training 2.5/hr/day for 15 days plus daily 5Hz rTMS
1799203|NCT00579046|Drug|Darbepoetin alfa|"Dosage form: injection (to store between 2 and 8 °C). Dosage: various dosages are available (10, 15, 20, 30, 40, 50, 60, 80, 100, 150 or 300 µg/ml).
Frequency: every week for 2 months: 8 injections"
1799204|NCT00579059|Device|Maxim® Knee System with Removable Molded Polyethylene Tibia|Used for total knee replacements
1799205|NCT00579059|Device|Regular Maxim® Knee System|Used for total knee replacements
1799206|NCT00579072|Behavioral|Questionaires|We will use a 6-month longitudinal design to assess the short-term cognitive effects of androgen ablation therapy. We will collect 6-month longitudinal data on 170 men with prostate cancer. All 170 men will be hormone naïve at the start of this study (Hormone Naïve Group). These 170 men will consist of two subgroups. The first subgroup will comprise 70 men with prostate cancer age 65 and older scheduled to start androgen ablation therapy. Their cognitive functioning will be assessed prior to starting androgen ablation therapy or within 21 days after initiation, (i.e. baseline) and then 6 months later (Androgen Ablation Subgroup).The second subgroup will serve as a control group, and consist of 100 men with prostate cancer age 65 and older who are at least 1-year post definitive localized treatment with no evidence of disease and no plan to start androgen ablation therapy (No Androgen Ablation Subgroup).
1799207|NCT00579072|Behavioral|Questionaires|To supplement the pilot data collected in Aim 1, Aim 2 we will utilize a group comparison design to assess the long-term cognitive effects of androgen ablation therapy. We will collect data on the cognitive functioning of 110 men with prostate cancer age 65 and older who have been on continuous androgen ablation therapy for 1-3 years (2-Year Androgen Ablation Group). These men will complete the study battery once (i.e., the neuropsychological battery, psychosocial questionnaires, and a functional status battery). We will compare the cognitive functioning of these 110 men in the 2-Year Androgen Ablation Group to the 170 men with prostate cancer who are hormone naïve (Hormone Naïve Group).
1799208|NCT00579072|Device|fMRI scan (optional)|Main study participants will be offered to complete an optional fMRI. Fifteen participants from the No Androgen Ablation Subgroup and 15 participants from the Comparison Androgen Ablation Subgroup will be recruited for this portion of the study. The fMRI will be scheduled either the same day as the neurocognitive assessment or within eight weeks of the neurocognitive testing. The fMRI will be performed only once at baseline.
1957490|NCT02360371|Drug|Within-subject assessment of double-blind study drug|Participants will receive a double-blinded study drug as part of their daily sessions and will provide feedback regarding the effects of the drug on various measures. Though the study drug is FDA approved, it is being used here for a non-FDA approved purpose (though the FDA has provided permission to use the drug in this study).
1799212|NCT00579098|Drug|Atorvastatin|80 mg tablet taken by mouth daily for 90 days
1799213|NCT00579098|Drug|Placebo|Placebo tablet taken by mouth once daily for 90 days
1799214|NCT00579111|Drug|Campath|10 mg/day IV daily for 3 days on days -6 to D-4. Campath may be omitted from the conditioning regimen for patients with malignant diseases and matched related donor transplants
1799215|NCT00579111|Drug|Busulfan|3.2 mg/kg/day IV daily for 2 days, infused over 3 hours, on Day -5 and Day -4
1799216|NCT00579111|Drug|Fludarabine|30mg/m2/day IV daily for 4 days on Day -5 to D -2
1799217|NCT00579111|Procedure|Hematopoietic stem cell infusion|Peripheral blood stem cells when possible. Bone marrow cells will be used if peripheral blood cells are insufficient or unavailable.
1799218|NCT00579111|Drug|FK-506|FK-506 at a dose of 0.03 mg/kd/day will be administered via continuous infusion over 24 hours from 4pm on Day -2 until engraftment or when the patient is able to take PO, then 0.03 mg/kg PO every 12 hours.
1799219|NCT00579124|Device|CliniMACs|T and B Cell depletion
1799220|NCT00579137|Biological|Campath -1H|"Given intravenous on Days -8,-7, and -6
Campath dose is weight based: for patients less than 15 kg the dose is 3 mg; for patients >15 kg to 30 kg the dose 5 mg; for patients > 30 kg the dose is 10 mg"
1799221|NCT00579137|Drug|Fludarabine|"Given intravenous on Days -8,-7,-6,-5, and -4
Dose is 30 mg/m2"
1799222|NCT00579137|Biological|Anti-CD45|"Given intravenous over 6 hours on Days -5,-4,-3, and -2
Dose is 400 microgram/kg"
1799223|NCT00579137|Procedure|Stem cell infusion|stem cells are infused on day 0
1799224|NCT00579189|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
1799225|NCT00579189|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
1799226|NCT00579189|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
1799227|NCT00579202|Device|Gambro HD-C4 Small Dialyzer|Involves the use of FDA 510(k) cleared hemodialyzers and will have no impact on the patient's routine dialysis therapy.
1799228|NCT00579215|Behavioral|Enhance Care|EC will receive a decision aid with seven components: social support, anticipatory guidance, adhering to the patient's preference for participation in treatment decision making, a quality decision-making process tutorial, normalization (using a CD program), structured time with oncology professionals to discuss difficult decisions, and values clarification of 3 decisions throughout treatment. Self-report measures will be used for all participants in addition to probes for the taped interviews with EC. The outcome measures are quality decision making and decisional conflict. Two panels (decision making and lung cancer) will review the protocol twice. The plan will include serially screening the appointment roster. The decision aid will be administered during three clinic visits
1799229|NCT00579215|Behavioral|Usual Care|As an intentional control, the usual care group will receive standard care related to lung cancer and treatment; they will not receive any oral, written, or recorded information related to decision making. Usual care includes anticipatory guidance related to the disease and treatment (e.g., what to do about treatment side effects, signs of an infection, why a treatment would be changed or stopped) using patient education materials normally used in the MSKCC, TOS, Outpatient Clinic.
1799259|NCT00579527|Drug|Cyclosporine|Csa may be given every 8 to 12 hours orally or IV before and after thymus transplantation or thymus and parathyroid transplantation. The Csa dose is dependant on T cell numbers and the targert Csa trough levels. Csa is weaned as per protocol.
1799550|NCT00574496|Drug|vinorelbine tartrate|
1799230|NCT00579241|Procedure|Ultrasound on Temporal Bone|All Patients undergoing dobutamine stress echocardiography have an intravenous line placed and a continuous infusion of a commercially available contrast agent administered. Prior to contrast infusion, baseline transcranial ultrasound images at 0.4 mechanical index using low mechanical index pulses and color Doppler will be performed and recorded. After this the contrast infusion will begin, and resting cardiac images will occur.
1799231|NCT00579254|Drug|CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)|Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study
1799232|NCT00579267|Other|MINI-KID|Structured Diagnostic Interview for children and adolescent psychiatric disorders.
1799236|NCT00579332|Dietary Supplement|brassica intervention|diet and phyto-chemical intervention
1799237|NCT00579345|Biological|Cell culture derived seasonal trivalent influenza vaccine (cTIV)|cell cultured trivalent influenza vaccine (cTIV) vaccine administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
1799238|NCT00579345|Biological|Influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a).|egg based trivalent influenza vaccine (eTIV_a) administered as 0.5 mL single dose in the deltoid muscle, preferably of the non-dominant arm.
1799239|NCT00579345|Biological|cTIV or eTIV_a|0.5 mL, Single dose of either cell cultured trivalent influenza vaccine (cTIV) or egg based trivalent influenza vaccine eTIV_a administered.
1799240|NCT00579345|Biological|cTIV+PV OR eTIV_a+PV|0.5 mL, Single dose of either cell culture derived seasonal trivalent influenza vaccine (cTIV) or influenza virus vaccine (egg-derived seasonal trivalent, thiomersal free; eTIV_a) administered concomitantly with 23-valent pneumococcal polysaccharide vaccine (PV).
1799241|NCT00579371|Other|Islets of Langerhans|Subjects will receive islets isolated from one donor pancreas per transplantation event. Subjects will receive a cumulative dose of 8,000IE/kg. Islets will be infused intraportally. If necessary, additional transplantation events will be performed.
1799242|NCT00579384|Drug|JNJ-26489112|Single oral dose of JNJ-26489112 up to 3000 mg on Day 2.
1799243|NCT00579384|Drug|Placebo|Single dose of placebo on Day 1, and a second single dose of placebo on Day 3.
1799244|NCT00579423|Biological|QS21|"Treatment schedule and dose: Thirty patients will be treated with specified doses of each carbohydrate or peptide constituent as has been determined. QS21 will be administered at the standard dose of 100 ug.
Sites: The vaccine conjugate will be administered subcutaneously on a rotating basis to random sites on the upper arms and upper legs.
Dose modifications: If a patient experiences a Grade III or greater local or Grade II or greater systemic toxicity at any time a decrease by 50% in all components of future vaccinations will be administered for that patient. Any evidence of autoimmunity, however, will result in a cessation of immunization in that patient."
1799245|NCT00579436|Drug|omega-3 fatty acid|4g of omega-3 fatty acid daily by mouth for 12 weeks.
1799246|NCT00579436|Drug|placebo|4 inert capsules daily by mouth for 12 weeks.
1799247|NCT00579449|Behavioral|Healthy Families Durham|Implementation of Healthy Families America program plus Parents As Teachers curriculum
1799248|NCT00579449|Behavioral|Yearly Checkup|Mother and child are assessed annually and based on responses and stated needs, referrals to community resources are made.
1799249|NCT00579462|Other|Blood and Tissue studies|Blood will be collected from participating patients at baseline, as close as possible to the date of their baseline radiologic assessment. Three follow-up blood collections will be drawn, each within 7-10 days of each follow-up radiologic evaluation.
1799250|NCT00579475|Drug|Mifegyne|tablets, 50 mg every other day
1799251|NCT00579475|Drug|placebo|
1799252|NCT00579501|Drug|Trabectedin|Trabectedin 1.5 mg/m^2 over a 24-hour iv infusion every 3 weeks for a minimum of 3 and a maximum of 6 cycles of trabectedin.
1799253|NCT00579501|Drug|Dexamethasone|Dexamethasone 20 mg iv will be administered within 30 minutes before start of each trabectedin iv infusion
1799254|NCT00579514|Genetic|PCR/PCR/LDR Strategy|Evaluate the extent to which polymorphisms in BRCA1, BRCA2, PTEN, T β R1, TGF β-1, DNA repair genes (including ATM and CHK2), APC, ER, PR, MCP-1, MPIF, CCR2/5 and CCR3 are correlated with cancer incidence. Candidate genes will also be selected from 1) cytokine signaling and 2) apoptosis regulatory pathways.
1799255|NCT00579527|Biological|Thymus Tissue for Transplantation|Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and donor's biological mother are screened for safety. Thymus transplantation is done under general anesthesia in the operating room. Thymus tissue if transplanted into the subject's quadriceps. Two to three months post thymus transplantation, if medically stable, the subject undergoes allograft biopsy. At the time of transplantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol.
1799256|NCT00579527|Other|Thymus Tissue and Parental Parathyroid Transplantation|If the recipient has hypoparathyroidism, and is eligible, the subject may receive both a thymus and parathyroid transplant. If the subject is not eligible the subject will receive only a thymus transplant. For parathyroid transplant, parental parathyroid donors screened. If both parents met criteria, parathyroid harvested from the parent who shares the most HLA alleles with the thymus donor. Parathyroid harvest is done under general anesthesia. One parathyroid gland is minced and placed in quadriceps muscle of 1 leg; there is no dose. No biopsy is done of the parathyroid. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely.
1799257|NCT00579527|Procedure|Blood Draw|Biological Mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab amy be done.
1799258|NCT00579527|Drug|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV prior to thymus or thymus and parathyroid transplantation. Each dose is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to thymus or thymus and parathyroid transplantation. Medications (diphenenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin.
1799431|NCT00580957|Drug|Intact|Saline IV infusion to simulate trimethaphan infusion in active arm Insulin clamp will be done to determine insulin resistance
1799260|NCT00579527|Drug|Tacrolimus|If unable to tolerate cyclosporine, then FK506 is given. FK506 may be given every 8 to 12 hours orally or IV before and after the thymus transplant or the thymus/parathyroid transplant. FK506 dose is dependent on the T cell numbers and the target FK506 trough levels. FK506 is weaned as per protocol.
1799261|NCT00579527|Drug|Methylprednisolone or Prednisolone|Steroids IV or orally may be given before and after thymus or thymus/parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Steroids are weaned as per protocol.
1799262|NCT00579527|Drug|Daclizumab|A single dose of Daclizumab 1 mg/kg IV may be given. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before thymus transplantation. If Daclizumab is not given before thymus transplantation, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after thymus transplantation.
1799263|NCT00579527|Drug|Mycophenolate mofetil|Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after thymus transplantation. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after thymus transplantation or continued for up to six months after thymus transplantation.
1799264|NCT00579540|Dietary Supplement|Flax Seed Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed oil, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
1799265|NCT00579540|Dietary Supplement|Fish Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
1799266|NCT00579540|Dietary Supplement|Soybean Oil|Subject will follow their usual diet for 4 weeks, at week 6 they will be randomized to receive either flax seed, fish oil, or soybean oil capsules for 6 weeks. They will take six capsules orally six times a day for a total of six weeks.
1799267|NCT00579553|Drug|Intramuscular Progesterone|Intramuscular Progestone: 17 alpha hydroxyprogesterone caproate: weekly 1 cc injections containing 250 mg of 17P
1799268|NCT00579553|Drug|Vaginal Progesterone|Vaginal Progesterone: 100 mg vaginal suppository daily
1799269|NCT00579566|Other|Specimen protocol|The research specimen will be obtained from the residual specimen that would otherwise be discarded per usual hospital procedure.
1799270|NCT00579579|Behavioral|Questionaires|Prior to surgery, patients will be asked to complete baseline surveys. In addition, a random subsample of approximately 30 patients will be asked to participate in a short qualitative interview to explore expectations regarding bowel function and quality of life following surgery. Follow-up surveys will be completed at 6, 12 and 24 months after bowel continuity has been restored (defined by their last surgical procedure). Patients with a permanent stoma will receive the Stoma-specific QOL questions in place of the MSKCC Bowel Function Instrument at 6 and 12 months after initial surgery.
1799271|NCT00579592|Drug|Campath-1H, rituximab, myfortic|Campath-1H 30mg IV x 2 doses, rituximab 375mg/m2 IV x 1 dose, myfortic 720mg bid, cyclosporine po bid (target trough 200ng/ml) x 10-20 days
1799272|NCT00579605|Behavioral|Motivational Interviewing|Client-centered strategy that may decrease ambivalence in behavior performance with attention intervention (infant safety) on: a) breastfeeding self-efficacy, b) intended length of breastfeeding, and c) duration of breastfeeding.
1799273|NCT00579618|Other|Saliva or Blood samples|Extracting sample of saliva or blood only once.
1799274|NCT00579631|Behavioral|Questionnaire or Interview|Complete a self-report survey once over the telephone or by mail. The questions are about your health beliefs and behaviors, your current health, and your mood. It should not take longer than 45 minutes to complete. About 15 of these people will participate in an additional, short audiotaped interview about sun protection.
1799275|NCT00579644|Drug|Combination of Minocycline and MTX or MTX alone|"Methotrexate Dosing:
1)initial dose of methotrexate for all patients will be 10 mg/week. 2)2 month: dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, increased to 15 mg/week.
3)4 month: dose of MTX will remain at its current level if full remission criteria are met; otherwise, be increased to 20 mg/week.
4)6, 8 and 10 month: If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week,dose will be increased to 20 mg/week. If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 5)12 month evaluation: End of the blinded portion of the study. minocycline dosage 200 mg"
1799276|NCT00579644|Drug|methotrexate|"Initial evaluation: The dose of methotrexate for all patients will be 10 mg/week.
2 month evaluation: The dose of MTX will remain at 10 mg/week if full remission criteria are met; otherwise, it will be increased to 15 mg/week.
4 month evaluation: The dose of MTX will remain at its current level if full remission criteria are met; otherwise, it will be increased to 20 mg/week.
6, 8 and 10 month evaluations:
If the patient has fallen below full remission criteria and is not already receiving the maximum dose of 20 mg/week, the dose will be increased to 20 mg/week.
If the patient meets ACR 50 criteria prednisone will be tapered by 1mg/month 12 month evaluation: End of the blinded portion of the study."
1799277|NCT00579657|Other|control diet, supported by dietary supplement twice daily|control diet, see above
1799278|NCT00579657|Other|high cereal fiber diet, supported by dietary supplement twice daily|high cereal fiber diet, see above
1799279|NCT00579657|Other|high protein diet, supported by dietary supplement twice daily|high protein diet, see above
1799280|NCT00579657|Other|diet moderately high both in cereal fiber and protein, supported by dietary supplement twice daily|MIX diet, see above
1799281|NCT00579670|Drug|Ziprasidone|Ziprasidone 20mg, 40mg, 60mg, 80mg capsules, hard; Ziprasidone 10 mg/ml oral suspension Ziprasidone 20mg/ml powder and solvent for the reconstitution of solution for injection
1799282|NCT00579683|Other|Tumor core biopsy for RNA isolation|RNA isolation will be carried out using approximately 25 mg of gross tissue from these tumor specimens.
1799310|NCT00580021|Other|Genotyping|Samples for DNA extraction will be shaved from archival paraffin-embedded tissue blocks (using normal lymph node preferentially)and placed in appropriate receptacles labeled only with the subject unique study number. This material will be transported to the genotyping laboratory, where it will be stored until the clinical record abstraction is complete. Briefly, DNA will be extracted from the archive paraffin-embedded material using standard protocols and the samples will be analyzed for the presence of the Ashkenazi BRCA founder mutations using either PCR-based or gel-electrophoresis-based approaches.
1799283|NCT00579709|Biological|Thymus Tissue for Transplantation|"3 Thymoglobulin doses given prior to thymus tx. Atypical subjects given Cyclosporine (Csa) pre-tx. Desired Csa concentration 180-300ng/ml. If post-tx T cell count remained <4000/cumm Csa weaned over 8 weeks. If T cell >4,000/cumm, Csa held at 180-300ng/ml.
Thymus tissue, donor, & mother of donor were screened for transplant safety. In operating room, thymic slices were transplanted into quadriceps muscle in 1 or both legs.
Subjects had routine blood research immune evaluations. 2-3 months post-tx, open biopsy of allograft. Immune blood studies continued on surviving subjects until January 2010. Biological Mother: Mother provided blood sample used for DNA extraction, to identify/look for maternal T cell presence in recipient pre-tx, and/or for immune testing post-tx."
1799284|NCT00579774|Other|Low AGE Diet|Diet
1799285|NCT00579774|Other|Regular Diet|Diet
1799286|NCT00579800|Procedure|new software sequences, FIESTA and Vibrant-DE and IDEAL|Conventional images will be taken using the standard sequences consisting of T2-weighted imaging and T1-weighted imaging before and after contrast; these will be used for the diagnostic examination. FIESTA will be performed on 50 patients, while Vibrant-DE and IDEAL will be performed on the other 50 patients.
1799287|NCT00579813|Drug|Pioglitazone|Pioglitazone 30mg for 2 weeks, then Pioglitazone 45mg for 8 weeks.
1799288|NCT00579826|Drug|Letrozole|Letrozole 2.5 mg tablet daily. Then optional open label letrozole for another 6 months.
1799289|NCT00579826|Drug|Placebo|Placebo tablet daily for 6 months then optional open label letrozole for 6 months.
1799290|NCT00579839|Procedure|Delayed Cord Clamping|Delayed Cord Clamping: 30-35 seconds after birth
1799291|NCT00579839|Procedure|Immediate Cord Clamping|Immediate Cord Clamping: within 5 seconds of birth
1799292|NCT00579852|Procedure|CT Scan|Patients with NSCLC undergoing non-contrast CT scan of the chest will have a second, high resolution, non-contrast CT scan of the chest performed on the same day. The scans will be performed on the same CT scanner, generally within 30 minutes. Unidimensional, bi-dimensional, and volume measurements for the primary NSCLC lesion will be determined on both scans and the values compared. After completing the second scan, the patient will have completed participation in the protocol.
1799293|NCT00579865|Behavioral|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure.
1799294|NCT00579865|Behavioral|questionnaires|complete the FACT-Hep, the SSQ, and the Visual Analog Scale for Pruritus Assessment at 1 week and 4 weeks post procedure. Patients who have undergone bypass or resection will complete an additional set of questionnaires at 9 and 14 weeks.
1799295|NCT00579878|Drug|Leflunomide|A loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations
1799296|NCT00579878|Drug|Methotrexate-Sulfasalazine-Hydroxychloroquine|"Methotrexate:
dosing starts at 10mg/week (4 tabs/wk). If total remission (according to ACR criteria found in Appendix II) has not been achieved and the labs are acceptable at the 8-week evaluation, the dose increased to 15 mg/week (6 tabs/wk);at the 16-week evaluation, the dose increased to 20 mg/week (8 tabs/wk). This dose will remain stable until the end of the study.
Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable,dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day)."
1799297|NCT00579878|Drug|Leflunomide-Sulfasalazine-Hydroxychloroquine|Leflunomide: dose of 100 mg (or placebo) for three (3) days. Followed by a dose of 20 mg/day will be maintained throughout the remainder of the study. dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur Sulfasalazine: dosing will start at 500 mg bid (1000 mg/day). This dose will remain steady until the 24-week evaluation. If total remission has not been achieved by this time and the labs remain acceptable, dose will be increased to 1000 mg bid (2000 mg/day) Hydroxychloroquine: dosing will be started and maintained throughout the study at 200 mg bid (400 mg/day).
1799298|NCT00579878|Drug|Leflunomide|a loading dose of 100 mg (or placebo) for three (3) days will be given. Following that three-day period, a dose of 20 mg/day will be maintained throughout the remainder of the study. This dose may be decreased to 10 mg/day at the discretion of the treating physician if minor toxicities occur (e.g., diarrhea, liver enzyme elevations).
1799299|NCT00579904|Dietary Supplement|walnuts|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to walnuts. They will eat walnuts once daily for six weeks.
1799300|NCT00579904|Dietary Supplement|almonds|Subjects will follow their usual diet for 4 weeks; after that they will be randomized to almonds. They will eat almonds once daily for six weeks.
1799301|NCT00579917|Behavioral|Cognitive Behavioral Therapy: Questionnaires|CBT, we will interview you again after you have completed the 10 sessions. We call these follow-up interviews, and they include several phone calls and a questionnaire you would be asked to complete and then mail in. Each follow-up interview will take between 60 and 210 minutes. If you wish, these follow-up interviews can be done over different days. We will do the follow-up interviews three times; at approximately 4 months, 7 months, and 10 months after you complete the baseline interview.
1799302|NCT00579917|Behavioral|Usual Care: Questionnaires|If you receive Usual Care, you will not receive CBT while you are in the study. You will complete the questionnaires at the same time as participants who receive CBT. If you receive Usual Care you will be offered 10 sessions of CBT at no charge at the end of the study.
1799303|NCT00579956|Drug|Meropenem|Meropenem 1gm, diluted with 50ml normal saline solution IV every 8 hours for at least 10 days. The dose will be adjusted according to the creatinine clearance.
1799304|NCT00579956|Drug|Ceftazidime|Ceftazidime 120mg/kg/day divided into 3 equal doses (maximum dose 2 gram/dose), diluted with 50ml normal saline solution IV every 8 hours for at least 10 days The dose will be adjusted according to the plasma creatinine level
1799305|NCT00579969|Drug|Latanoprost|dosage form:eye drops, dosage: One drop in each eye twice a day
1799306|NCT00579969|Drug|Timolol|dosage form:eye drops, dosage: One drop in each eye twice a day
1799307|NCT00579982|Drug|Lamotrigine|Experimental formulation
1799311|NCT00580034|Drug|Campath Purged Non-myeloablative ASCT|"Preparative regimen: Begins on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours.
Patient Evaluation: Will occur 2-3 times per week by physical exam for toxicity through day 45."
1799312|NCT00580034|Procedure|Donor Apheresis|Donor will receive Granulocyte colony-stimulating factor (G-CSF) 10-16 mcg/kg/d subcutaneously (dose will be rounded to the nearest whole vial size and may be divided into twice daily dosing). Granulocyte-macrophage colony-stimulating factor (GM-CSF) 15 mcg/kg/d subcutaneous or similar growth factor for donor mobilization. Donors will receive at least 3-6 doses of daily growth factor until adequate cells are mobilized.
1799316|NCT00580060|Biological|GM-CSF DNA, NSC 683472 gp100: 209-217(210M), NSC 699048 Tyrosinase: 368-376(370D)|In the Dose Ranging part of the study, cohorts of 3 patients will be treated at increasing dose levels of GM-CSF DNA delivered subcutaneously (100, 400, or 800 mg), followed by administration of both peptides subcutaneously to the same site on day 5 or day 6. Patients will be treated monthly for three immunizations.
1799317|NCT00580073|Drug|FOLFOX4|oxaliplatin (85mg/m2 on days 1 and 15 of each cycle)+ 5FU Bolus (400mg/m2 on days 1, 2, 15, and 16 of each cycle) + 5FU CI (600mg/m2 on days 1, 2, 15, and 16 of each cycle) + Leucovorin (200mg/m2 on days 1, 2, 15, and 16 of each cycle)
1799318|NCT00580073|Drug|Cetuximab|Cetuximab 400mg/m2 on day 1 only, 250mg/mr on days 8, 15, and 22 of each cycle.
1799319|NCT00580086|Other|MR spectroscopy|(1H MRS) on 1.5 Tesla (1.5T), using a software package from General Electric Medical Systems, Milwaukee, WI
1799320|NCT00580099|Other|assisted exercise|4 weeks of passive range of motion exercise
1799321|NCT00580099|Other|cuddle|cuddle infant for 20 minutes
1799322|NCT00580112|Drug|Dexamethasone|Dexamethasone 4 mg orally 24 hrs and 12 hrs before study drug infusion on Day -1, followed by dexamethasone 20 mg intravenously 30 minutes before study drug infusion on Day 1, followed by dexamethasone 4 mg orally 24, 36, 48, 60 and 72 hrs after the start of study drug infusion on Day 1 to 3.
1799323|NCT00580112|Drug|Trabectedin|Trabectedin 1.3 mg/m^2 intravenous infusion over 3-hrs every 3 weeks, on Day 1 of each cycle. Each cycle length will be 3 weeks.
1799324|NCT00580125|Drug|PF-00217830|PF-00217830 5 mg, oral capsule, once daily for 21 days
1799325|NCT00580125|Other|Placebo|Placebo, oral capsule, once daily for 21 days
1799326|NCT00580125|Drug|Aripiprazole|Aripiprazole 15 mg, oral capsule, once daily for 21 days
1799327|NCT00580125|Drug|PF-00217830|PF-00217830 15 mg, oral capsule, once daily for 21 days
1799328|NCT00580125|Drug|PF-00217830|PF-00217830 2 mg, oral capsule, once daily for 21 days
1799329|NCT00580151|Drug|clonidine|3-5 microgram per kilogram every 6 hours for 10 days
1799330|NCT00580151|Drug|placebo|1 dose every 6 hours
1799331|NCT00580177|Procedure|Lichtenstein mesh|The different techniques are compared and evaluated according to primary and secondary objectives.
1799332|NCT00580177|Procedure|PerFix Plug®|The different techniques are compared and evaluated according to primary and secondary objectives.
1799333|NCT00580177|Procedure|Prolene® Hernia System|The different techniques are compared and evaluated according to primary and secondary objectives.
1799334|NCT00580190|Drug|alprazolam|tablet, 0.5 mg, single dose, only on Day 7 of the study
1799335|NCT00580190|Other|Placebo|solution, matching placebo to 500 mg PF-00572778, single dose, Days 1 and 7 of the study
1799336|NCT00580190|Drug|PF-00572778|solution, 500 mg, single dose, only on Day 7 of the study
1799337|NCT00580216|Drug|Idrabiotaparinux sodium|"Pre-filled syringes containing:
0.5 mL for the 3.0 mg dosage;
0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);
0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).
Subcutaneous injection"
1799338|NCT00580216|Drug|Warfarin|"Capsules with 1 or 5 mg for INR-adjusted dose (INR checked at least once a month)
Oral administration"
1799339|NCT00580216|Drug|Placebo (for idrabiotaparinux)|"Matching pre-filled syringes containing:
0.5 mL for the 3.0 mg dosage;
0.33 mL for the 2.0 mg dosage (maintenance dosage for participants with mild renal impairment and less than 75 years old);
0.25 mL for the 1.5 mg dosage (maintenance dosage for participants with moderate renal impairment or age ≥75 years).
Subcutaneous injection"
1799340|NCT00580216|Drug|Placebo (for warfarin)|"Warfarin matching capsules
Oral administration"
1799341|NCT00580216|Drug|Avidin|"Vial containing 105 mg of lyophilized powder for dilution
Intravenous infusion for 30 minutes"
1799342|NCT00580216|Drug|Placebo (for avidin)|"Vial containing 105 mg of matching lyophilized powder for dissolution
Intravenous infusion for 30 minutes"
1799343|NCT00580229|Drug|prednisone|prednisone 40mg by mouth 30-60 minutes prior to rituximab
1799344|NCT00580242|Drug|Bortezomib|First cohort: Bortezomib 0.7mg/m2 IV on Days on Days 1, 4, 8, and 11. Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
1799345|NCT00580242|Drug|Bortezomib|Second cohort: Bortezomib 1mg/m2 IV on Days 1, 4, 8, and 11 Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
1799346|NCT00580242|Drug|Bortezomib|Third Cohort: Bortezomib 1.3mg/m2 IV on Days 1, 4, 8, and 11 of each cycle Patients may receive up to 9 cycles with each cycle lasting a total of 28 days
1799347|NCT00580242|Drug|Lenalidomide|Lenalidomide 10 mg PO QD on Days 1 -21 followed by a 7 day rest period
1799348|NCT00580281|Other|blood test, urine test, and bone density x-ray.|start of the study (month 0), and at months 3, 6, 9, 12 (1 year), 15, 18, 21, and 24 (2 years)
1799349|NCT00580294|Drug|Oxymorphone|IV PO
1799350|NCT00580307|Procedure|Septoplasty|Surgical straightening of nasal septum
1799351|NCT00580307|Procedure|Septoplasty and endoscopic contact point correction|Septoplasty (as previously described). Contact point correction: structures of the lateral nasal wall that impinge on the nasal septum are mobilized to a more lateral position under endoscopic guidance.
1799430|NCT00580957|Drug|Blocked|Trimethaphan 4 mg/min IV will be infused for the duration of the study. L-NMMA 125-500 mcg/k/min IV will be titrated to restore blood pressure to pre-trimethaphan levels Insulin clamp will be used to determine insulin resistance
1799352|NCT00580320|Drug|Dacarbazine and bortezomib|Level 0: Dacarbazine 190 mg/m2 + Bortezomib 1.0 mg/m2; Level 1: Dacarbazine 250 mg/m2 + Bortezomib 1.0 mg/m2; Level 2: Dacarbazine 250 mg/m2 + Bortezomib 1.3 mg/m2; Level 3: Dacarbazine 250 mg/m2 + Bortezomib 1.6 mg/m2; Level 4: Dacarbazine 330 mg/m2 + Bortezomib 1.6 mg/m2; Level 5: Dacarbazine 440 mg/m2 + Bortezomib 1.6 mg/m2; Level 6: Dacarbazine 580 mg/m2 + Bortezomib 1.6 mg/m2
1799353|NCT00580333|Drug|cisplatin|Preoperatively: Given intravenously on day one of the treatment cycle (once every 3 weeks) for four cycles
1799354|NCT00580333|Drug|bevacizumab|Preoperatively: Given intravenously on day 1 of the treatment cycle (once every three weeks) for three cycles Postoperatively: Intravenously for four 2-week cycles (once every two weeks) and after the 8 weeks (study doctor will determine course of treatment) for an additional four 2-week cycles with or with out paclitaxel
1799355|NCT00580333|Drug|doxorubicin|Postoperative: Given intravenously for four 2-week cycles
1799356|NCT00580333|Drug|cyclophosphamide|Postoperative: Given intravenously for four two-week cycles
1799357|NCT00580333|Drug|paclitaxel|Postoperative: 8 weeks after postoperative chemotherapy regimen (study doctor will determine course of treatment) paclitaxel for four 2-week cycles (once every two weeks)
1799358|NCT00580346|Device|Placement of laryngeal implant|Placement of stimulator over anterior chest wall, and electrodes around recurrent laryngeal nerve, and tunneling leads between both
1799359|NCT00580359|Drug|S-1, capecitabine|S-1 40mg/m2 orally twice daily on days 1(evening) - 15 (morning)every 3 weeks, until disease progression, Capecitabine 1250mg/m2 orally twice daily on days 1 (evening) - 15 (morning)every 3 weeks, until disease progression
1799360|NCT00580372|Drug|VAD|3 Cycles (3rd cycle optional): Vincristine 0.5 mg/d d 1 - 4 CI Adriamycin 10 mg/m2/d d 1 - 4 CI Dexamethasone 40 mg/d d 1-4, 9-12, 17-20
1799361|NCT00580372|Drug|High-Dose cyclophosphamide|"Approximately 5-6 weeks after VAD 2 or 3:
Cytoxan 1.2g/m2/d d 1 - 5 Mesna 3.6 g/m2 d 1"
1799362|NCT00580372|Procedure|Hemopoietic stem cell procurement|Collection target = 10 x 10^6 cells/kg
1799363|NCT00580372|Drug|EDAP|Approximately 5-6 weeks after high-dose cyclophosphamide Etoposide 100 mg/m2/d d 1 - 4 CI Cisplatin 25 mg/m2/d d 1 - 4 CI Ara C l g/m2 d 5 Dexamethasone 40 mg d 1-5
1799364|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 1|4-6 weeks after EDAP: Melphalan 100 mg/m2 days -1 and -2
1799365|NCT00580372|Procedure|Autologous Hemopoietic Stem Cell Transplant 2|4-6 months after Transplant 1: Melphalan 100 mg/m2 days -1 and -2
1799366|NCT00580372|Drug|Maintenance|3 months after Transplant 2: Intron A 3 X 10^6 units /m2 M-W-F subcutaneously until relapse
1799367|NCT00580385|Biological|Tissue Procurement|MTX polyglutamylation, MTX transport, XTT cytotoxicity assays, Quantitative RT-PCR, Southern blotting, Mutation detection, and Western blotting
1799368|NCT00580398|Behavioral|Smoking cessation counseling|Median of 9 tobacco treatment counseling sessions conducted in person or by telephone.
1799369|NCT00580398|Drug|varenicline|varenicline (1mg bid, with initial titration up over week 1) for 12 weeks
1799370|NCT00580424|Drug|Norethindrone|Norethindrone 0.35 mg orally daily
1799371|NCT00580437|Procedure|Dobutamine Stress Echocardiogram|stress echocardiograms involving the use of intravenous Optison or Definity contrast agents to improve endocardial definition
1799372|NCT00580450|Drug|Thymosin alpha 1|1.6 mg sc once a day for 16 weeks
1799374|NCT00580502|Device|LAP-BAND® Adjustable Gastric Band (LAGB®)|Bariatric surgery for patient whose BMI is between 30 and 40 kg/m^2
1799375|NCT00580515|Behavioral|Family Focused Group Therapy|6 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months.
1799376|NCT00580515|Behavioral|Family Focused Group Therapy|10 Sessions of Family Focused Group Therapy (FFGT). The FFGT intervention will have assessment, focused therapy, consolidation, and termination phases. The first two sessions are assessment sessions and occur one week apart. There will be two or six focused intervention sessions depending on the predetermined length of therapy. The first focused intervention session is approximately two weeks after the last assessment session. Subsequent focused intervention sessions are expected to follow once every month. Finally, there will be two consolidation/termination sessions, which will occur one time each, approximately two months apart. The six session program is expected to extend over a period of 6 months and the 10 session program over 10 months
1799377|NCT00580515|Behavioral|Standard of Care|Standard of Care Families assigned to the Usual Care Condition will receive standard psychosocial care which is based on the following patterns: Social work consultations are routinely provided to the cancer patients, but relatives are only seen during admissions or upon request.
1799378|NCT00580528|Behavioral|Tailored Internet Newsletters|Tailored newsletters delivered via the Internet with content for improving eating and activity to reduce blood pressure
1799379|NCT00580528|Behavioral|Tailored print newsletters delivered via mail|Tailored Newsletters with content to improve eating and activity to reduce blood pressure
1799380|NCT00580541|Behavioral|variety|variety and nonvariety
1799381|NCT00580580|Drug|Optison|0.1-0.4 mL through intravenous injection at the beginning of the study.
1799382|NCT00580580|Drug|Definity|intravenous injection at 0.05-0.20 mL
1799383|NCT00580580|Drug|PESDA|intravenous injections dosage 0.05-0.20 mL
1799384|NCT00580593|Device|BiPAP® S/T System|The BiPAP® S/T System is a NIPPV device that provides intermittent ventilatory assistance to people with difficulty breathing secondary to respiratory muscle weakness.
1799385|NCT00580593|Other|sham-NIPPV|a sham-device
1799475|NCT00581321|Dietary Supplement|water|water 500 ml x 1
1799551|NCT00574496|Procedure|allogeneic bone marrow transplantation|
1799388|NCT00580619|Other|Autonomic Function Testing|The autonomic function tests include asking the subject to breathe deeply for two minutes and breathing as fast and as hard as they can for 30 seconds, maintaining a handgrip for 3 minutes, breathing against pressure for 15 seconds, placing one hand in ice water for 1 minute and an orthostatic test. All these tests are meant to stimulate the autonomic nervous system to produce changes in blood pressure and heart rate of short duration that reflect how well the involuntary nervous system is working. In addition, a 24-hour blood pressure monitoring and exercise test may be also performed in some subjects.
1799389|NCT00580619|Other|Saline infusions|The effects of continuous IV infusion or pulse IV administration of saline in increasing total blood volume and fatigue score will be evaluated
1799390|NCT00580619|Drug|L-NMMA trimethaphan|Trimethaphan IV infusion for approximately 60 minutes at a dose of 4-6 mg/min L-NMMA IV infusion for approximately 45 minutes at 125, 250, and 500 mg/kg/min for 15 minutes each
1799391|NCT00580619|Drug|methyldopa|Aldomet oral twice a day for 12 weeks
1799392|NCT00580645|Drug|varenicline|"Studies 1A and 1B: 2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered twice daily during laboratory session (day 8) and for 4 weeks after laboratory session.
Study 1C: 2mg/day (see above) or 1mg/day with 1-week medication lead-in period. The starting dose is 0.5 mg/day for days 1-5, followed by 0.5mg twice daily for days 6-7. 0.5mg twice daily administered during laboratory session (day 8) and for 4 weeks after laboratory session."
1799393|NCT00580645|Drug|bupropion|Study 1A only: 300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8) and for 4 weeks after laboratory session.
1799394|NCT00580645|Drug|placebo|placebo
1799395|NCT00580658|Device|Medtronic Activa Gpi|Activa Therapy, Gpi
1799396|NCT00580671|Behavioral|MET/CBT|Weekly Individual Counseling Sessions
1799397|NCT00580671|Behavioral|CM|Abstinence-based incentives delivered contingent on drug-negative urine test results.
1799398|NCT00580671|Behavioral|BPT|Behavioral parent training involve 14 weekly counseling curriculum to improve parenting skills.
1799399|NCT00580684|Biological|pneumococcus conjugate vaccine 7 valent to reduce carriage|plain polisacaride vaccine 23 valent to reduce carriage
1799400|NCT00580723|Other|PRK 124|Topical PRK 124 (0.125%) moisturizing lotion applied twice daily to the face for 48 weeks
1799401|NCT00580736|Device|Optical Clearing|Optical Clearing
1799402|NCT00580749|Procedure|Naso jejunal feeding tube insertion|Placement of feeding tube through nare and into jejunum for administration of enteral feeding.
1799403|NCT00580749|Procedure|NG feeding tube insertion|Placement of naso gastric feeding tube into stomach for purpose of enteral feedings.
1799404|NCT00580762|Procedure|Roux-en-y gastric bypass (RYGB)|
1799405|NCT00580788|Drug|PTHrP (1-36)|IND # 49,175
1799406|NCT00580801|Drug|Telaprevir|Telaprevir 750 milligram (mg) tablet will be administered three times a day orally for 2 weeks.
1799407|NCT00580801|Drug|Pegylated-interferon-alfa-2a|Pegylated-interferon-alfa-2a (180 microgram [mcg] subcutaneous injection, once weekly) will be administered from Week 1 to Week 48 or 50.
1799408|NCT00580801|Drug|Placebo|Matching placebo tablet to telaprevir was administered three times a day orally for 2 weeks.
1799409|NCT00580801|Drug|Ribavirin|Ribavirin (1000-1200 mg as oral tablet daily) will be administered from Week 1 to Week 48 or 50.
1799411|NCT00580827|Drug|Placebo|Matched placebo.
1799412|NCT00580827|Drug|Disulfiram|disulfiram at 62.5 mg/day for 12 weeks.
1799413|NCT00580827|Drug|Disulfiram|Disulfiram at 125 mg/day for 12 weeks.
1799414|NCT00580827|Drug|Disulfiram|disulfiram at 250 mg/day for 12 weeks.
1799415|NCT00580840|Drug|Certolizumab pegol|400 mg certolizumab pegol given every 4 weeks and placebo given every 4 weeks given as two injections (alternating injections every two weeks)
1799416|NCT00580840|Drug|Certolizumab pegol|200 mg certolizumab pegol and placebo administered every 2 weeks (one injection of each)
1799417|NCT00580840|Other|Placebo|placebo (saline) administered as two injections every 2 weeks
1799418|NCT00580853|Drug|varenicline|2mg/day, with 1-week lead-in medication period The starting dose is 0.5 mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5 and then 1mg twice daily for days 4-7. 1mg administered during laboratory session (day 8).
1799419|NCT00580853|Drug|bupropion|300mg/day, with 1-week lead-in medication period The starting dose is 150mg/day for days 1-3, 300mg/day for days 4-7. 300mg administered during laboratory session (day 8).
1799420|NCT00580853|Drug|Placebo|Placebo
1799421|NCT00580866|Device|JAS Brace|For approximately 6 weeks after surgery, the brace will be utilized for a period of 30 minutes, 3 times per day. Participants will also receive physical therapy 3 times per week.
1799422|NCT00580892|Device|Optical Coherence Tomography imaging|Optical Coherence Tomography imaging
1799423|NCT00580905|Drug|Adenosine|IV infusion of adenosine at a dose of 80 mcg/kg/min for 30 minutes.
1799424|NCT00580905|Drug|Sodium Nitroprusside|To compare the effects of adenosine on increasing cytokines, sodium nitroprusside will be infused at 5 mcg/kg/min (a dose expected to produce similar systemic effects to adenosine)
1799425|NCT00580905|Drug|Adenosine|"The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.
A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion."
1799426|NCT00580918|Other|functional magnetic resonance imaging fMRI|functional magnetic resonance imaging fMRI
1799427|NCT00580931|Drug|Nicotinamide|1500 mg twice a day for 6 months
1799428|NCT00580931|Drug|Enduramide placebo|1 tab twice a day
1799429|NCT00580944|Procedure|laser treatment of port wine stain birthmarks|Combined alexandrite and pulsed dye laser treatment of port wine stain birthmarks
1799432|NCT00580970|Drug|lovastatin|The HMG-coA reductase inhibitor used in this study will be lovastatin. Dosage: 20 mg/d PO with evening meal. Patients on a higher dose of lovastatin at the time of study entry may continue at that dose level; for patients switching to lovastatin, the dose will be at the discretion of the prescribing physician, but must be at least 20 mg/day.Schedule: begin on the first day of external beam radiation therapy (external beam alone or external beam followed by brachytherapy) or on the day of brachytherapy (brachytherapy alone or brachytherapy followed by external beam radiotherapy) and continue for 12 months. Patients or their third party payers will be expected to cover the cost of the drug.
1799433|NCT00580983|Radiation|IMRT|
1799434|NCT00580983|Drug|Paclitaxel|
1799435|NCT00580983|Drug|Carboplatin|
1799436|NCT00580983|Drug|Cisplatin|
1799437|NCT00580983|Drug|5-Fluorouracil|
1799438|NCT00580996|Other|water high dose|water 16 oz PO x 1
1799439|NCT00580996|Other|water tiny dose|water 1 oz PO x 1
1799440|NCT00581009|Other|chronobiological augmentation|Sleep deprivation for one night, Chronobiological augmentation consists of partial sleep phase advance for three nights and Light therapy for two hours for three days
1799441|NCT00581009|Drug|sertraline, lithium|"Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.
Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks."
1799442|NCT00581009|Radiation|one night of sleep deprivation and two FDG PET scans|MDD Mechanism Only depressed subjects will have two FDG PET scans consisting of a baseline FDG PET scan and a sleep deprived FDG PET scan. One night of regular sleep,one night of sleep deprivation and one night of recovery sleep for a total of four nights at a sleep laboratory facility.
1799443|NCT00581022|Procedure|Polysomnography|Overnight Sleep Study
1799444|NCT00581035|Biological|Prevenar and Meningitec|1 dose of Prevenar at 2,3.5,6 and 12 months and 1 dose of Meningitec at 2,6 and 12 months
1799445|NCT00581035|Biological|Prevenar|1 dose at 2,3.5,6 and 12 months
1799446|NCT00581035|Biological|Meningitec|1 dose at 2,6 and 12 months
1799447|NCT00581048|Drug|Natural source d-α-tocopheryl acetate|1500 units daily for 16 weeks
1799448|NCT00581061|Drug|Vesicare|Vesicare will be taken daily for one or three months, depending on symptoms of subject.
1799449|NCT00581074|Behavioral|diet (grapefruit or grapefruit juice)|weight loss diet
1799450|NCT00581087|Drug|DHEA treatment|DHEA : 200 mg/day hard gelatine capsule
1799451|NCT00581087|Drug|Placebo|Treatment : 200 mg/day hard gelatine capsule
1799452|NCT00581100|Drug|etanercept|"Subjects randomized to Arm 1 shall be treated with ETN 50 mg twice weekly for 12 weeks reducing thereafter to ETN 50 mg once weekly to 24 weeks.
Subjects randomized to Arm 2 shall be treated with ETN 50 mg once weekly for the entire 24 week treatment period."
1799453|NCT00581113|Radiation|Radiotherapy|Treatments are delivered through parallel opposed or 5 degree RAO/LAO fields that cover the entire cranial contents. There should be beam fall-f of at least 1 cm. The eyes must be excluded from the beam either by field arrangement or shielding.
1799454|NCT00581126|Drug|Recombinant Factor IX Coagulation|Benefix IV each 12 hours for 2 a 5 days
1799455|NCT00581139|Behavioral|Preoperative Preparation Program (Child Life Specialist)|This group will receive the standard preoperative visit to the hospital with Child Life intervention
1799456|NCT00581139|Drug|Midazolam|0.5 mg/kg oral midazolam
1799457|NCT00581139|Behavioral|Parental Presence during Induction of Anesthesia|One parent will be present during induction of anesthesia of the child. The parent will be accompanied out of the OR by a nurse once the induction is completed. These parents will have completed a parent preparation program.
1799458|NCT00581139|Other|PPIA preparation program PLUS Midazolam premedication|Subjects in this group will receive both interventions 2 and 3.
1799459|NCT00581165|Drug|Etanercept|recommended dose of enbrel is 25mg administered twice weekly.
1799460|NCT00581191|Drug|SLV-351|SLV-351 capsules taken once
1799461|NCT00581204|Device|Near-Infrared Diffuse Optical Spectroscopy|Early predictor of hemorrhagic shock
1799462|NCT00581217|Other|Aquacel Ag|Aquacel Ag will be applied to one donor site.
1799463|NCT00581217|Other|Glucan II|Glucan II to be applied to a donor site on same patient for comparison
1799464|NCT00581230|Device|Laryngoscopy with RAMP|inflatable positioning ramp
1799465|NCT00581230|Device|Laryngoscopy without RAMP|Laryngoscopy without RAMP
1799466|NCT00581243|Drug|SLV-313 SR|sustained relase tablets taken once daily for 14 days
1799469|NCT00581269|Behavioral|low-impact aerobic exercise|subjects will undergo supervised physical activity for a maximum of 30-60 minutes, every other day, 3 days per week for 3 months; to offer variety in the exercise prescription, subjects will alternately use a treadmill, an elliptical trainer, a Nu-Step cross-trainer and a recumbent stationary bicycle
1799470|NCT00581269|Dietary Supplement|low-calorie (low-fat) diet|subjects will undergo a 20% reduction in total daily calories from their usual daily energy consumption every day for 3 months
1799471|NCT00581282|Radiation|PET scan|positron emission tomography PET scan
1799472|NCT00581282|Other|fMRI|functional magnetic resonance imaging fMRI
1799473|NCT00581295|Device|Diffuse optical spectroscopy|Diffuse optical spectroscopy measurment
1799476|NCT00581334|Procedure|Robotic-assisted laparoscopic sacrocolpopexy|4 abdominal incisions will be made: 1 infraumbilical port and 3 lateral ports. The peritoneum overlaying the sacrum is entered and the anterior longitudinal ligament is exposed. 3 permanent sutures are placed through the ligament at the S2-S3. Then a vaginal obturator is placed transvaginally and the apex of vagina is elevated into the operative field. The peritoneum overlying the anterior and posterior vaginal epithelium is reflected and the bladder is dissected off the underlying vagina to expose 4cm of apical vagina. 2 segments of polypropylene mesh are prepared and one segment is anchored along the anterior vagina with a series of interrupted permanent suture and the second segment is anchored along the posterior vagina. These 2 segments are brought together to the previously placed sutures within the anterior longitudinal ligament of the sacrum. The peritoneum is then closed over the graft complex and the pelvis irrigated. The 4 robotic ports are removed and the abdomen closed.
1799477|NCT00573989|Drug|erlotinib hydrochloride|
1799478|NCT00573989|Drug|pemetrexed disodium|
1799479|NCT00573989|Procedure|quality-of-life assessment|
1799480|NCT00573989|Radiation|intensity-modulated radiation therapy|
1799481|NCT00574015|Drug|hydrocodone/acetaminophen|oral hydrocodone 10 mg/acetaminophen 650 mg
1799482|NCT00574015|Drug|bupivacaine (supraperiosteal nerve block)|Administration of Bupivacaine 0.5% 2 ml adjacent to tooth root
1799483|NCT00574041|Drug|Interferon beta-1a|injected, once a week
1799484|NCT00574054|Radiation|Far Infrared|Far infrared radiation (5 μm to 20 μm wavelength) for 30 to 40 minutes per treatment session.
1799485|NCT00574067|Drug|Buprenorphine +OTP|Buprenorphine thrice weekly and counseling for four months while in pre-release prison, with referral for continued treatment at an opioid agonist treatment (OTP) program upon release. Such treatment lasts for 1 year in the community. Buprenorphine dosage, following an induction period,is 32 mg Mondays and Wednesdays and 48 mg Fridays
1799486|NCT00574067|Drug|Buprenorphine +CHC|Buprenorphine thrice weekly and counseling provided in pre-release prison for 4 months, with referral for continued treatment for 1 year in the community at a community health center (CHC). Following an induction period, buprenorphine dosing will be 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
1799487|NCT00574067|Drug|Counseling +OTP|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at an opioid agonist treatment program to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
1799488|NCT00574067|Drug|Counseling +CHC|Counseling only for 4 months in pre-release prison, with referral upon release for buprenorphine treatment and counseling at a community health center to last for 1 year. Following an induction period, buprenorphine dosing will be thrice weekly, with 32 mg on Mondays and Wednesdays and 48 mg on Fridays.
1799491|NCT00574093|Drug|Ranibizumab; Verteporfin|Patients will be administered Lucentis™ 0.5 mg on Day 1, at Months 1 and 2, and then as needed at intervals of at least 30 days through Month 11 based on the retreatment criteria algorithm. These patients will also be administered Visudyne® only on Day 3.
1799492|NCT00574106|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength)
1799493|NCT00574119|Drug|spironolactone|spironolactone 50 mg daily for 6 months
1799494|NCT00574132|Drug|Bapineuzumab 0.5 mg/kg|infusion every 13 weeks for a total of 6 infusions
1799495|NCT00574132|Drug|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
1799496|NCT00574132|Drug|Bapineuzumab 1.0 m/kg|infusion every 13 weeks for a total of 6 infusions
1799497|NCT00574145|Procedure|Bio-field energy therapy|Practitioner's hands to influence the human energy field surrounding the patient's body.
1799498|NCT00574145|Procedure|fatigue assessment and management|duration
1799499|NCT00574145|Procedure|psychosocial assessment and care|duration
1799500|NCT00574145|Procedure|quality-of-life assessment|duration
1799501|NCT00574145|Procedure|therapeutic touch|Practitioner's hands to influence the human energy field surrounding the patient's body
1799502|NCT00574171|Drug|lapatinib|1250mg by mouth daily one hour before or after breakfast on a continuous basis.
1799503|NCT00574171|Drug|Capecitabine|2000mg/m2 of body surface area (BSA), by mouth, divided into twice daily dosing. Capecitabine will be given for days 1 through 14 of a 21 day cycle.
1799504|NCT00574197|Drug|Mycophenolate Sodium|1440mg/day (720mg by mouth, twice a day)
1799505|NCT00574210|Drug|Bilastine|Bilastine Tablets, administered at a dosage strength of 10 mg or 20 mg, once or twice per day.
1799506|NCT00574210|Drug|Placebo|Placebo Tablets administered twice per day
1799507|NCT00574223|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 8 visits
1799508|NCT00574223|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 8 visits
1799509|NCT00574236|Drug|PS-341, doxorubicin|bortezomib:1.3 mg/m2 IVP over 3-5 sec. days 1, 4, 8, 11 of 21 day cycle doxorubicin: 20 mg/m2 IV over 3-5 min. days 1,8 (one hour after bortezomib) of 21 day cycle
1799510|NCT00574249|Biological|adalimumab|subcutaneous injection using prefilled pen/syringe, solution containing 40 mg in 0.8 milliliters; 2 injections given at Baseline (Day 1) then once every other week from Weeks 1 though 15
1799511|NCT00574249|Drug|Calcipotriol/Betamethasone Ointment|Topical ointment (calcipotriol 50 mcg/g and betamethasone 500 mcg/g) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
1799512|NCT00574249|Drug|placebo (vehicle ointment)|Topical vehicle ointment (matching active calcipotriol/betamethasone ointment) to be applied once daily to affected psoriasis skin on trunk and extremities for first 4 weeks and as needed from Week 5 through Week 16
1799513|NCT00574275|Drug|Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®)|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle.
1799514|NCT00574275|Drug|Placebo|4 mg/kg was administered intravenously (IV) over 1 hour once every 2 weeks, on Days 1 and 15 of each 28-day cycle
1799549|NCT00574496|Drug|vincristine sulfate|
1799515|NCT00574275|Drug|Gemcitabine|1000 mg/m^2 administered IV over 30 minutes on Days 1, 8, 15, and 22 of Cycle 1 (28 days), and then Days 1, 8, and 15 of subsequent 28-day cycles.
1799516|NCT00574288|Drug|Part 1: Daratumumab|First participant will receive intravenous (injection of a substance into a vein) 0.005 milligram per kilogram (mg/kg) (planned dose) infusion of daratumumab and other participants will receive different doses. The participants will receive 7 full infusions of daratumumab and 2 predose infusions every 2 weeks. The dose of daratumumab will be escalated sequentially and considering the safety and efficacy of dose in Part 1, dose for Part 2 of the study will be decided. A predose infusion of 10% of the full dose of daratumumab will be administered a day before the first 2 full infusions.
1799517|NCT00574288|Drug|Part 2: Daratumumab|In Part 2, the participants will receive dose of daratumumab as determined in part 1 (16 mg/kg) of the study. Participants will receive 8 full infusions at weekly intervals followed by biweekly (every 2 weeks) infusions for 16 additional weeks and monthly infusions until disease progression or unmanageable toxicity, whichever comes first. Predose was dropped at some point in Part 2. A predose infusion of 10 mg daratumumab will be administered on the day before the first full infusion in select cohorts.
1799518|NCT00574288|Other|Methylprednisolone|"Pre-dose: Participants (part 1) will receive methylprednisolone 80 mg intravenous (IV) injection 30 minutes to 2 hours before treatment. Participants (part 2) will receive 100 mg methylprednisolone IV 60 minutes to 2 hours before treatment; if a patient experiences no significant infusion-related reactions, the dose of methylprednisolone may be decreased to 50 mg after Visit 4.
Post-dose: All participants (part 1) will receive 40 mg methylprednisolone orally on the first and the second day after all full infusions. During Part 2, all participants will receive 20-25 mg methylprednisolone orally or equivalent on the first and second days after all full-dose infusions."
1799519|NCT00574288|Other|Dexamethasone|Participants (Part 2) will receive 20 mg dexamethasone intravenous (IV) injection pre-dose, on the first and second days after every full-dose infusions.
1799520|NCT00574301|Procedure|Percutaneous Removal and Margin Ablation|Patients with a diagnosis of unicentric invasive breast cancer diagnosed by IVEB will then be assigned to the next available surgery date. On that day, the patient's axillary staging will be done, followed by ablation of the biopsy cavity using RFA. The breast surgery may include lumpectomy (which will be directed with US-guidance to assure more accurate removal of the en bloc IVEB site and the margin zone of ablation) or simple mastectomy with or without reconstruction. The tissue specimen will be sent immediately from the operating room to Pathology for routine processing.
1799521|NCT00574314|Other|No Intervention|Participants will be consented.
1799522|NCT00574340|Other|Hyperinsulinemic Hypoglycemic Clamp|all participants received (2) hyperinsulinemic glucose clamp studies separated by 8 weeks
1799524|NCT00574366|Drug|erlotinib|"Levels:
1 Erlotinib 50 mg/d
2 Erlotinib 50 mg/d
1 Erlotinib 100 mg/d
2 Erlotinib 100 mg/d
3 Erlotinib 150 mg/d
4 Erlotinib 150 mg/d"
1799525|NCT00574366|Drug|RAD001|"Levels
minus 1: RAD001 2.5 mg/d
minus 2: RAD001 2.5 every other day
RAD001 2.5 mg per day
RAD001 5 mg per day
RAD001 10 mg per day
RAD001 10 mg per day"
1799526|NCT00574379|Drug|Bilastine|Bilastine 10 or 20mg, once or twice daily for 14 days. Tablets
1799527|NCT00574379|Drug|Placebo|Placebo tablets twice daily for 14 days
1799528|NCT00574392|Device|Multiwavelength and coherence confocal reflectance microscopy (Vivascope 1500m multiwavelength)|Patients will be imaged with the Vivascope 1500m multiwavelength coherence microscope during a single patient visit. The lesion will be photographed with high resolution photography and surface epiluminescence microscopy. The clinically uninvolved site will be imaged in the same manner.
1799529|NCT00574405|Drug|MDI (split-mix NPH insulin + regular insulin or Lantus + Novolog® [or Humalog®])|MDI = 3-4+ insulin injections/day, using NPH + regular insulin or Lantus + insulin lispro; 12 month treatment duration.
1799530|NCT00574405|Device|CSII (Animas Corporation insulin pump, model IR 1200)|CSII (insulin pump), using Animas Corporation insulin pump, model IR 1200.
1799531|NCT00574418|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes during each session.
1799532|NCT00574431|Other|Data Collection|Collection of patient data before implementation of a nutritional management protocol
1799533|NCT00574431|Other|Nutritional management protocol|Collection of patient data after implementation of a nutritional management protocol
1799534|NCT00574444|Procedure|transvaginal diagnostic peritoneoscopy|For patients with pelvic pain, a transvaginal procedure can be done to explore the abdomen. Entering through the vagina, will hopefully decrease the number of ports in the abdomen and decrease pain and healing time.
1799535|NCT00574457|Other|Carotid Ultrasound|All subjects that meet the inclusion criteria at each certified site will be invited to participate and go through the same intervention (questionaire-scan-post scan questionaire and 1 month follow up questionaire)
1799536|NCT00574470|Drug|daclizumab, infliximab|Daclizumab 1 mg/kg IV days 1, 4, 8, 15 and 22. Infliximab 10 mg/kg IV days 1, 8, 15 and 22.
1799537|NCT00574483|Drug|quinacrine|100 mg day
1799538|NCT00574496|Drug|cyclophosphamide|
1799539|NCT00574496|Drug|cyclosporine|
1799540|NCT00574496|Drug|fludarabine phosphate|
1799541|NCT00574496|Drug|gemcitabine hydrochloride|
1799542|NCT00574496|Drug|ifosfamide|
1799543|NCT00574496|Drug|mechlorethamine hydrochloride|
1799544|NCT00574496|Drug|melphalan|
1799545|NCT00574496|Drug|methotrexate|
1799546|NCT00574496|Drug|mycophenolate mofetil|
1799547|NCT00574496|Drug|prednisone|
1799548|NCT00574496|Drug|procarbazine hydrochloride|
1799552|NCT00574496|Procedure|allogeneic hematopoietic stem cell transplantation|
1799553|NCT00574496|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1799554|NCT00574496|Procedure|peripheral blood stem cell transplantation|
1799555|NCT00574496|Procedure|umbilical cord blood transplantation|
1799556|NCT00574496|Radiation|total-body irradiation|
1799557|NCT00574509|Radiation|131Iodine-Anti-B1 Radioimmunotherapy|Dosimetric dose of 450 mg unlabeled Anti-B1 followed by 35 mg Anti-B1 which has been trace labeled with 5mCi of 131I-Anti-B1.
1799558|NCT00574522|Radiation|Far infrared|Far infrared radiation with the wavelength between 5μm and 20μm for 30 to 40 minutes per session.
1799559|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and year 1
1799560|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
1799561|NCT00574548|Biological|13 valent Pneumococcal Conjugate Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
1799562|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 23vPS will be administered into the deltoid muscle at year 0 and 0.5 ml dose 13vPnC at year 1
1799563|NCT00574548|Biological|23-valent Pneumococcal Polysaccharide Vaccine|0.5 ml dose 13vPnC will be administered into the deltoid muscle at year 0 and 0.5 ml dose 23vPS at year 1
1799564|NCT00574574|Dietary Supplement|anthocyanin|500mg/d of anthocyanin each day for 12 weeks (84days). Route of administration: oral capsules, 4 X 250mg capsules (125mg anthocyanin/ capsule). Dosage advice; 2 capsules to be taken with food, twice per day (n=4 in total).
1799565|NCT00574587|Drug|Vorinostat|Vorinostat 200 or 300 mg PO BID on days 1-3 of each weekly paclitaxel dose
1799566|NCT00574587|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 12 weeks
1799567|NCT00574587|Drug|Trastuzumab|Part A: Trastuzumab 4 mg/kg, then 2 mg/kg weekly for 12 weeks including loading dose
1799568|NCT00574587|Drug|Doxorubicin|Doxorubicin 60 mg/m2 every 2 weeks for 8 weeks
1799569|NCT00574587|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2 every 2 weeks for 8 weeks
1799570|NCT00574587|Procedure|Mastectomy or Lumpectomy|Surgical excision of tumor from breast
1799571|NCT00574587|Drug|Post surgery therapy (Trastuzumab)|Part D: After Surgical intervention Post Protocol Therapy- Trastuzumab 8 mg/kg as a loading dose, then 6 mg/kg every 3 weeks for a total of 14 doses
1799572|NCT00574600|Biological|SAAVI DNA-C2 vaccine|DNA vaccine
1799573|NCT00574600|Biological|SAAVI MVA-C vaccine|Boost vaccine
1799574|NCT00574600|Biological|Placebo|Placebo vaccine
1799575|NCT00574613|Drug|P144|Cream 0,3 ml once a day (3 months)
1799576|NCT00574613|Drug|placebo|Cream 0,3 ml once a day (3 months)
1799577|NCT00574626|Procedure|PBSCT|Peripheral Blood Stem Cell Transplant
1799578|NCT00574626|Procedure|Bone Marrow Transplant|Bone Marrow Transplant
1799579|NCT00574639|Drug|Alprazolam|1 mg given orally prior to morning and afternoon clamps on Day 1
1799580|NCT00574639|Drug|Placebo|1 mg given orally prior to glucose clamps on Day 1 (morning and afternoon)
1799581|NCT00574652|Drug|Proleukin|3 millions IU/day from day 1 to 5 every 21 days will be carried out at W1, W3, W6, and W9)
1799582|NCT00574665|Other|Hyperinsulinemic Hyperglycemic Clamp|Glucose Clamp
1799583|NCT00574678|Other|Tear collection|"A tear sample (~75 microliters in a tuberculin syringe with the needle removed) will be taken at time of the initial clinic visit. After collection, the tears will be put directly on ice and taken to the lab. If it is not possible to obtain natural tears, an eye wash method using sterile saline will be employed and the fluid collected using the aforementioned technique. The SELDI-MS process will be conducted on the specimen immediately. The remainder of the tear specimen will be stored in a -80ºC freezer until completely analyzed."
1799584|NCT00574691|Device|7F Ensure Medical Vascular Closure Device|Vascular Closure Device
1799585|NCT00574704|Drug|CYT005-AllQbG10 (combination of house dust mite allergen extract with CYT003-QbG10)|subcutaneous injections at 6 visits
1799586|NCT00574704|Drug|House dust mite allergen extract in combination with CYT003-QbG10-placebo|subcutaneous injections at 6 visits
1799587|NCT00574704|Drug|CYT003-AllQbG10 in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
1799588|NCT00574704|Drug|CYT003-QbG10-placebo in combination with house dust mite allergen extract placebo|subcutaneous injections at 6 visits
1799589|NCT00574717|Procedure|Spectacles|Infants will receive spectacles with 3.00D of under-correction relative to the spherical equivalent in each eye as measured by the cycloplegic retinoscopy performed at baseline. They will also receive the full amount of measured astigmatism in their glasses. Changes in spectacle lens power will be made as needed at follow-up visits to keep the level of under-correction within 0.50D of the target 3.00D. A program of visual engagement is also provided to encourage the normal development and use of accommodation. Treatment will continue for 15 months (until 18 months of age) or until the infant reaches a spherical equivalent refractive error of +3.00D or less hyperopia.
1799590|NCT00574730|Drug|CHOP/Rituximab|"Six cycles of CHOP/Rituximab therapy at 21-day intervals. CHOP chemo will be administered on day 1 after rituximab.
Cyclophosphamide750mg/m2 IV, Doxorubicin 50mg/m2 IV, Vincristine 1.4mg/m2 (max 2mg) IV, Prednisone 100mg PO daily x 5 days Rituximab 375mg/m2"
1799591|NCT00574730|Drug|PEG INTRON|Pegylated Interferon-alpha 2mg/kg/week for 52 weeks
1799592|NCT00574743|Drug|Enteric-coated Mycophenolate Sodium|
1799593|NCT00574756|Drug|ranolazine|extended release 500 mg twice a day for two weeks
1799594|NCT00574769|Drug|RAD001, Docetaxel, Bevacizumab|"RAD001 oral, 2.5 mg daily RAD001 oral, 5mg daily
Bevacizumab infusion (IV), 15 mg/kg every 21 days
Docetaxel infusion (IV), 75 mg/m^2 every 21 days"
1799595|NCT00574795|Biological|13vPnC|"First dose during 2 to 6 months of age Second dose at least 28 days after the first dose Third dose at least 28 days after the second dose Forth dose during 12 to 15 months of age"
1799633|NCT00575094|Drug|tigecycline|Dosage form: Tigecycline 50 mg for injection (Lyophilized powder in 5 mL vial) Dosage frequency: Tigecycline 100 mg loading followed by 50 mg every 12 hrs (bid) Duration of therapy: 7 to 14 days
1799783|NCT00583531|Drug|AST-120|Oral, 2 grams TID in sachets for 4 weeks
1799784|NCT00583544|Drug|TC-2216|Multiple ascending dose groups will be explored.
1799597|NCT00574834|Drug|Ramipril|Ramipril 20 mg once daily for 6 months
1799598|NCT00574834|Drug|HCTZ-hydrochlorothiazide|HCTZ 25 mg once daily for 6 months
1799599|NCT00574834|Drug|Ramipril+HCTZ|Ramipril 20 mg and HCTZ 25 mg, both once daily for 6 months
1799600|NCT00574847|Drug|Escitalopram|Dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
1799601|NCT00574847|Drug|Placebo|Placebo dosage will range from 5 mg to 20 mg once a day for the duration of the study (6 weeks). Tablets are in 5 mg or 10 mg form, depending upon the dosage the patient is prescribed.
1799602|NCT00574860|Drug|EN3285|Oral rinse
1799603|NCT00574860|Drug|Placebo|Oral rinse
1799604|NCT00574860|Other|Standard of care|This will be the therapy most commonly used the the institution treating the patient
1799605|NCT00574873|Drug|Bosutinib|500 mg once daily, by mouth (tablet) with food preferably in the morning. Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
1799606|NCT00574873|Drug|imatinib|400 mg once daily, by mouth (tablet). Drug can be increased up to 600mg daily in case of lack of efficacy, and can be reduced to 300mg daily in case of toxicity. The drug will be given daily for up to 8 years until treatment failure, unacceptable toxicity, death or withdrawal of consent.
1799607|NCT00574886|Biological|Id-KLH|Idiotype vaccine - .5mg recombinant idiotype immunoglobulin protein given subcutaneously for a total of five administrations over 6 months.
1799608|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.
Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
1799609|NCT00574899|Other|Questioners, blood specimens, prostate tissue specimens|"You will be asked to fill out a confidential questionnaire asking for information such as medical history, family history of cancer, and potential exposures.
Each patient will provide 7 unstained paraffin sections from prostate biopsies, one tube of blood for serum, and one tube for plasma and buffy coat."
1799610|NCT00574912|Drug|Placebo|single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
1799611|NCT00574912|Drug|Insulin Glargine 0.5 u/kg body wt SC|8 weeks later, a differing dose (0.5, 1.0, 1.5, 2.0 u/kg body wt.) of Insulin Glargine and monitoring over a 24 hour period each separated by 8 weeks (5 separate study visits)
1799612|NCT00574912|Drug|Insulin Glargine 1.0 u/kg body wt SC|
1799613|NCT00574912|Drug|Insulin Glargine 1.5 u/kg body wt SC|
1799614|NCT00574912|Drug|Insulin Glargine 2.0 u/kg body wt SC|
1799615|NCT00574925|Drug|Esomeprazole|
1799617|NCT00574964|Other|Gliadel Wafer, Temodar and Radiotherapy|Given concurrently starting 10-30 days after surgery.
1799618|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.
Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
1799619|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 treatment of vvDD-CDSR. A dose can be divided between 1-3 lesions. The sum total of the maximal diameters of the lesion(s) to be injected must be < 10cm.
Cohort 1: 3 x 10e7 p.f.u. Cohort 2: 1 x 10e8 p.f.u. Cohort 3: 3 x 10e8 p.f.u. Cohort 4: 1 x 10e9 p.f.u. Cohort 5: 3 x 10e9 p.f.u."
1799620|NCT00574977|Biological|Vaccinia virus (vvDD-CDSR)|"Eligible subjects will receive 1 infusion of vvDD-CDSR.
Cohort 1: 3 x 10e8 p.f.u; Cohort 2: 1 x 10e9 p.f.u.; Cohort 3: 3 x 10e9 p.f.u."
1799621|NCT00575003|Drug|CYT003-QbG10|6 subcutaneous injections
1799622|NCT00575016|Biological|Normal saline (Placebo); botulinum toxin Type A (200U)|Placebo injection on Day 1 and botulinum toxin Type A injection 200 U > Week 12; injection into the detrusor
1799623|NCT00575016|Biological|botulinum toxin Type A (50U); botulinum toxin Type A (200U)|botulinum toxin Type A 50 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
1799624|NCT00575016|Biological|botulinum toxin Type A (100U); botulinum toxin Type A (200U)|botulinum toxin Type A 100 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
1799625|NCT00575016|Biological|botulinum toxin Type A (200U)|botulinum toxin Type A 200 U on Day 1 followed by botulinum toxin Type A 200 U > 12 weeks; injections into the detrusor
1799626|NCT00575029|Drug|megestrol acetate|600 mg by mouth daily
1799628|NCT00575055|Drug|Bapineuzumab 0.5 mg/kg|given by infusion every 13 weeks for a total of 6 infusions.
1799629|NCT00575055|Drug|Placebo Control|given by infusion every 13 weeks for a total of 6 infusions.
1799630|NCT00575055|Drug|Bapineuzumab 1.0 m/kg|given by infusion every 13 weeks for a total of 6 infusions.
1799631|NCT00575068|Drug|IDEC-114|Phase 1-A Group 1 - 125 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 2 - 250 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-A Group 3 - 375 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase 1-B Group 4 - 500 mg/m2 x 4 infusions - Study Days 1, 8, 15, 22 Phase II-A & II-B - Dosage start at the MTD (up to 375 mg/m2)
1799632|NCT00575081|Device|Stereotactic brain procedures|Stereotactic brain procedures
1799634|NCT00575107|Other|Exercise|Velocity-controlled variable resistance protocols enable trainees to load their muscles more optimally along the entire ROM in either or both of the shortening (VSC) and lengthening (VLC) phases of a training repetition
1799635|NCT00575107|Other|Exercise|Standard training of leg extension
1799636|NCT00575120|Other|ischemia reperfusion|reperfusion after a 15 min. lasting cuff induced arm ischemia
1799637|NCT00575146|Dietary Supplement|TAVARLIN|ketogenic diet, dietary supplementary products provided by TAVARLIN
1799640|NCT00575185|Drug|Valomaciclovir|4 grams orally of valomaciclovir (2 grams BID) for 21 days.
1799641|NCT00575185|Drug|placebo|Placebo tablets orally twice daily for 21 days.
1799642|NCT00575198|Other|No drainage threshold|Removal of the thoracostomy tube independently of the amount of fluid that drained from the tube in the prior 24 hours
1799643|NCT00575198|Other|Drainage <2 mL/kg|Removal of the thoracostomy tube only if the drainage from the tube in the prior 24 hours is less than 2 mL/kg of the patient's ideal body weight
1799644|NCT00575224|Drug|Pegylated interferon and ribavirin|180 ug of peg-IFN per week and 1000-1200 mg of ribavirin per day (weight-dependent). Treatment duration is determined by treatment arm.
1799645|NCT00575237|Procedure|Recruitment manouver|In the intervention group, CO2 was removed by means of Trendelenburg position (> 30 degrees) with 5 manual pulmonary recruitment maneuvers.
1799646|NCT00575250|Behavioral|Osteoporosis Prevention and Self-Management Course|Four weekly education sessions of 2 1/2 hours duration, in a group session facilitated by a community nurse and trained lay leader.
1799647|NCT00575250|Behavioral|Introductory education session on osteoporosis|Introductory education session, 1 x 2 1/2 hours in a group session facilitated by a community nurse and trained lay person.
1799648|NCT00575302|Drug|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 300 U
1799649|NCT00575302|Drug|Gonal-f®: follitropin alpha|Gonal-f®: follitropin alpha, administration of 450 U
1799650|NCT00581347|Other|outreach services|Tracking/reminder/recall/home visit strategy.
1799651|NCT00581360|Drug|doxorubicin and bortezomib|Patients will be treated with bortezomib 1.3 mg/m2, intravenously on days 1, 4, 8 and 11, and doxorubicin 20 mg/m2, intravenously on days 1 and 8, every 21 days. Zinecard will be added at the 8th cycle and all subsequent cycles with doxorubicin. After the completion of 14 cycles, if there is no progression, bortezomib once a week at a dose of 1.6 mg/m2 on days 1,8,15, every 28 days, will be administered alone. Treatment will continue unless disease progression or intolerable toxicity emerges.
1799652|NCT00581373|Other|water 16 fl oz|water 16 fl oz in AM and repeat in late afternoon
1799653|NCT00581386|Device|LTS-D|supra-glottic airway device
1799654|NCT00581386|Device|ProSeal Laryngeal Mask Airway|pre-existing double-lumen supra-glottic device
1799655|NCT00581386|Device|Esophageal Tracheal Combitube (ETC)|disposable double-lumen tube
1799656|NCT00581399|Device|NO-NUMO™ High Vacuum Body Cavity Drainage System|(1) disposable NO-NUMO™ body cavity drainage tubes, (2) disposable Vario™ fluid management canisters and (3) Vario™ portable vacuum pump
1799657|NCT00581399|Device|PVC Chest Tube|Standard PVC Chest Tube Sizes 14-36 French
1799659|NCT00581451|Drug|bifeprunox|oral tablet once daily
1799660|NCT00581464|Behavioral|Standard Behavioral Therapy|Standard therapy to help participants with smoking cessation.
1799661|NCT00581464|Behavioral|Mindfulness Based Addiction Therapy|A novel mind body therapy that extends basic behavioral therapy principles to include the practice of mindfulness, which fosters a dispassionate approach to the experience of craving.
1799662|NCT00581477|Drug|droxidopa|up to 300mg four times daily
1799663|NCT00581477|Drug|placebo|same frequency as experimental medication
1799664|NCT00581477|Drug|alpha-methyldopa|up to 250mg two times daily
1799665|NCT00581477|Drug|carbidopa|up to 25mg four times daily
1799666|NCT00581477|Drug|metyrosine|up to 1000mg three times daily
1799667|NCT00581477|Drug|levodopa|up to 250mg three times daily
1799668|NCT00581477|Drug|atomoxetine|up to 40mg twice daily
1799669|NCT00581477|Drug|metoclopramide|up to 10mg four times daily
1799670|NCT00581503|Device|diagnostic|oct imaging
1799672|NCT00581542|Drug|moxifloxacin|1-2 drops three times a day for 8-10 days.
1799673|NCT00581542|Drug|polytrim|1-2 drops four times a day for 8-10 days.
1799674|NCT00581555|Drug|Etanercept|Etanercept 50 mg QW initiated during taper of ciclosporin
1799675|NCT00581555|Other|Placebo|Randomized to placebo during taper of ciclosporin
1799676|NCT00581568|Other|Cutaneous Effects of Cryogen Spray Cooling|Cutaneous Effects of Cryogen Spray Cooling
1799677|NCT00581594|Procedure|Graft-augmented colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years for a pelvic exam for evaluation of posterior wall support and the questionnaires.
1799710|NCT00582842|Behavioral|Interview|The phone interview will consist of the following items from the follow up questionnaire; 14, 16, 20, 32, 33, 46, 47, 60, and 65. An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
1799785|NCT00583557|Drug|belimumab|IV 10mg/kg Q28 days
1799786|NCT00583570|Behavioral|dietary education|dietary education
1799678|NCT00581594|Procedure|Traditional posterior colporrhaphy|Patients will undergo randomized surgical procedure. Patients will be seen at 2 weeks for routine post-op care and evaluation of any post-op complications. Patients will be seen at 6 weeks for a pelvic exam and evaluation of the posterior wall. Points Ap and Bp will be recorded with values at 0.5cm intervals being on the posterior vaginal wall that is 3cm above the hymen. Point Bp is the most dependent portion of the posterior vaginal wall when the patient performs a Valsalva maneuver. Patients will be seen at 6 months, for a pelvic exam evaluation of posterior wall support and completion of SF-36, PISQ and FISI. Patients will be given 60 minute Questionnaires on defecatory dysfunction, pelvic pain and/or symptoms of prolapse. Patients will be seen at 1 year and yearly intervals up to five years to have a pelvic exam for evaluation of posterior wall support and the questionnaires.
1799679|NCT00581607|Drug|Bosentan|62.5 mg bid for 4 weeks, then 125 mg bid
1799680|NCT00581607|Drug|Placebo|Placebo twice a day
1799681|NCT00581607|Drug|Bosentan|drug given for 16 weeks
1799682|NCT00581607|Drug|Placebo|placebo
1799683|NCT00581620|Biological|pneumococcus conjugate vaccine|Infants from 1 to 6 months: 3 doses at 2; 4; 6 m and booster from 12 to 15 months.
1799684|NCT00581633|Other|normal saline (0.9%)|liter normal saline over 30 minutes x 1 dose
1799685|NCT00581646|Behavioral|survey instrument|Participants will be mailed or given a one time survey instrument and data will be collected either in person or by telephone. We expect the study survey to take approximately 35-45 minutes to complete. The domains assessed will include psychological functioning, reproductive knowledge, perception of third party reproduction and concerns, sexual functioning, and quality of life.
1799686|NCT00581672|Behavioral|questionnaires of quality of life|Subjects will be asked to complete the MAX-PC along with additional psychosocial questionnaires which include anxiety, depression coping methods, resilience spirituality, religiosity, and quality of life measures and will take approximately one 30 to 45 minutes to complete by patient.
1799687|NCT00582660|Drug|Celecoxib|400 mg twice a day for 7 days prior to surgery
1799688|NCT00582660|Drug|Placebo|one tablet of placebo will be given for 7 days prior to surgery
1799689|NCT00582673|Drug|AFQ056|
1799690|NCT00582673|Drug|Placebo|
1799691|NCT00582686|Procedure|ORIF of Calcaneus with bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) and Tricortical Iliac Crest bone grafting
1799692|NCT00582686|Procedure|ORIF of Calcaneus without bone grafting|The calcaneus fracture will be surgically repaired with open reduction and internal fixation (ORIF) (no bone grafting)
1799693|NCT00582699|Behavioral|assessment interview and blood draw|All subjects will be administered a battery of clinician rated and self report instruments including measures of depression, fatigue, and cognitive functioning. In addition, measures of pain, sleep, and anxiety will also be utilized to assess these important potential confounding variables. The SCIDIV will be used to ascertain the presence or absence of a current DSMIV diagnosis of Major Depressive Episode for all subjects. The interview should take approximately fortyfive minutes to complete. Patients will have their blood drawn once, in order to determine plasma levels of the cytokines IL1, IL6, TNFalpha, IL10, IL15 and IFNgamma.
1799694|NCT00582712|Drug|Lithium carbonate|Lithium 300mg by mouth, three times daily, escalating to a lithium level of 0.8-1.2; Continue until progressive disease/unacceptable toxicity; Evaluate every 4 weeks.
1799695|NCT00582725|Drug|R-CHOP+GM-CSF|addition of GM-CSF
1799696|NCT00582738|Drug|CsA-TAC (standard Treatment)|Continuation of current immunosuppressive regimen (continuation of CNI with or without MPA, with or without steroids) / no everolimus introduction.
1799697|NCT00582738|Drug|Everolimus|Hepatitis C recurrence after orthotopic liver transplantation (OLT)
1799698|NCT00582764|Other|perform dynamic contrast enhanced (DCE) MRI|With an IV catheter in place, the patient will lie prone on the MRI scanner table with the breasts positioned in the commercial breast coil and then be moved feet first to the center of the MRI scanner. The only difference introduced by the addition of DCE MRI is that before the patient is moved into the scanner for the first time, the IV catheter will be hooked up with a programmable power injector (Medrad, Indianola, PA) which is loaded with Gd contrast and saline. The contrast injection and saline flush will be delivered by the injector while the patient is inside the scanner and the DCE MRI data collection is in process. The Gd contrast dose used for DCE MRI is the same as for clinical MRI: 0.1 mmol/kg. The injection speed of 2 mL/sec is safe and similar to that of manual injection.
1799699|NCT00582777|Behavioral|USUAL - take your BP Meds as you usually do|The patient's antihypertensive regimen at the baseline visit is the comparison (or control) regimen. All once a day medications will be administered in the morning.
1799700|NCT00582777|Behavioral|HS DOSING|Take your usual BP meds at bed time
1799701|NCT00582777|Drug|ADD On Dosing|Take your usual BP meds but add one more med at bed time.
1799704|NCT00582816|Device|Clinimacs Cell Separation System|Depletion of T-cells
1799705|NCT00582816|Drug|conditioning chemotherapy|Methylprednisolone, Equine ATG, Cyclosporine, Fludarabine, Melphalan, Thiotepa and Rituximab.
1799706|NCT00582816|Other|DLI|NK Cell selected DLI
1799707|NCT00582829|Other|Generic Print Intervention|"Generic Print Intervention: The generic print intervention will consist of the pamphlet, Colorectal Cancer Screening Saves Lives published by the Center for Disease Control that will be mailed to the participant."
1799708|NCT00582829|Other|Tailored Print Intervention|Tailored Print Intervention: The tailored print intervention will consist of a cover letter detailing the participant's stage of readiness along with a color pamphlet with information personally tailored for the individual participant.
1799709|NCT00582829|Other|Tailored print plus tailored phone intervention|Tailored print plus tailored phone intervention: The tailored print plus tailored telephone intervention will consist of a phone counseling session and the tailored print information described above. The tailored print material will serve as a guide during the telephone counseling contact and a reinforcement of the information.
1799711|NCT00582842|Behavioral|survey instruments using Web-Based Data Collection System (WBDC) survey content|The content of the WBDC questionnaire will be similar to the paper form, no alteration in the wording, the order, or the formate of the items will be done. In addition, at the time of each outpatient clinic visit to MSKCC, these subjects will be able to login to WBDC using a computer located in the patient waiting-area, and enter their responses to the different items of the questionnaire if their clinic visit corresponds to any of the study time points 3, 6, 9, 12, 15, 18, 24, 36, and 48 following treatment). An additional component of this study would be dispensing the HRQOL tool to long-term survivors 10 years or greater after the completion of therapy. The long term QoL study will be a cross-sectional assessment measuring HRQOL in prostate cancer survivors, free of disease at least ten years post-treatment. Patients will complete a questionnaire by selfreport focusing on assessment of HRQOL.
1799712|NCT00582855|Drug|AQW051|
1799713|NCT00582855|Drug|Placebo|
1799714|NCT00582868|Device|Licox Brain Oxygen Monitor|use of data from brain oxygen monitor for analysis
1799715|NCT00582868|Other|CSF|analysis of CSF for cleaved tau protein
1799716|NCT00582868|Other|Whole blood|Analysis of whole blood for cleaved-tau protein
1799717|NCT00582894|Drug|Busulfex, Fludarabine, ALemtuzumab|Busulfex 3.2 mg/kg/day for 2 days infused over 3 hours, Days -6 and Day-5 Fludarabine 30 mg/m2/day for 5 days on Day -6 to D-2 Alemtuzumab 10 mg/day IV on Days -5 to -1
1799718|NCT00582907|Drug|Rilonacept|2.2 mg/kg/wk by subcutaneous injection, for 3 months
1799719|NCT00582907|Drug|Placebo|placebo by subcutaneous injection weekly for 3 months
1799720|NCT00582920|Radiation|Zometa™|Patients who will be receiving zoledronic acid therapy and are scheduled for an extent of disease evaluation with bone scan would undergo a second bone scan within 1 day of zoledronic acid therapy to assess changes in imaging.
1799721|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25 mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (thymoglobulin®) prior to transplant to promote engraftment.All research participants will also receive G-CSF posttransplant to foster engraftment.
The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
1799722|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.
The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
1799723|NCT00582933|Drug|BUSULFAN, MELPHALAN, FLUDARABINE, G-CSF|"All research participants will be conditioned for transplantation with intravenous busulfan (busulfex®) (0.8- 1.0 mg/Kg/dose Q6H x 10 doses), melphalan (70 mg/m2/dose x 2 doses) and fludarabine (25mg/m2/day x 5 doses). Doses of busulfan will be adjusted according to plasma levels. All research participants will also receive ATG (Thymoglobulin®) prior to transplant to promote engraftment. No drug prophylaxis against GvHD will be administered post transplant. All research participants will also receive G-CSF posttransplant to foster engraftment.
The preferred source of stem cells will be peripheral blood stem cells (PBSC) induced and mobilized by treatment of the donor with G-CSF for 5-6 days. PBSC obtained through 2-3 leukaphereses will be Isolex® 300i separated CD34+ stem cell column selected and E-rosette depleted (E-). The CD34+Eperipheral blood progenitors will be administered to the research participants after they have completed cytoreduction."
1799724|NCT00582946|Device|Hearing Aid|Subjects were treated with a hearing aid which provided amplification intended to treat mild to moderate sensorineural hearing loss.
1799725|NCT00582959|Other|Cone Beam Imaging|Prototype, third generation EPID based portal imaging system utilizing the MV approach.
1799726|NCT00582972|Drug|Omeprazole|40 mg po qAM one-half hour before breakfast for 30 days
1799727|NCT00582985|Drug|TRC105 chimeric anti-CD105 antibody|TRC105 is a human/murine chimeric IgG1 antibody administered i.v. every two weeks (on days 1 and 15) or weekly (on days 1, 8, 15 and 22) of each 28 day cycle; until progression or unacceptable toxicity develops.
1799730|NCT00583011|Drug|Local anesthesia - lidocaine|Local anesthesia: 2 cc of 1% Lidocaine
1799731|NCT00583011|Drug|Placebo Group|Placebo Group: 2cc Normal Saline
1799732|NCT00583024|Biological|ADENOVIRUS/PSA VACCINE|1x10E8 pfu in Gelfoam subcutaneously on days 0, 30, 60
1799733|NCT00583037|Device|Neurally Adjusted Ventilatory Assist (NAVA)|Mechanical ventilation controlled by diaphragm electrical activity
1799734|NCT00583050|Device|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
1799735|NCT00583063|Drug|sunitinib|25 mg daily (oral dosing)
1799736|NCT00583063|Drug|rapamycin|4 mg daily (oral dosing)
1799737|NCT00583076|Drug|AST-120|AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
1799782|NCT00583518|Drug|Parathyroid hormone (PTH)|Postmenopausal women with primary osteoporosis
1957516|NCT02345642|Device|ActiveCare+SFT Supine|
1957517|NCT02345642|Device|VenaFlow Elite Supine|
1957518|NCT02345642|Device|ActiveCare+SFT Standing|
1957519|NCT02345642|Device|VenaFlow Elite Standing|
1799739|NCT00583115|Drug|Gleevec|260 mg/M2/day, given once daily by mouth
1799740|NCT00583128|Drug|AST-120|oral, sachet, 2 grams three times daily for 8 weeks
1799741|NCT00583128|Drug|Celphere® CP-305|oral, placebo, sachet, 2 grams three times daily for 8 weeks
1799742|NCT00583154|Drug|BLI-801|Dose 1
1799743|NCT00583154|Drug|BLI-801|Dose 2
1799744|NCT00583154|Drug|BLI-801|Dose 3
1799745|NCT00583154|Drug|BLI-801|Dose 4
1799746|NCT00583180|Drug|Capsaicin|instillation of sterile water or 1000 micrograms of capsaicin into the wound at the end of open groin hernia surgery in previous study.no new intervention will be performed in the current study.
1799747|NCT00583193|Drug|Duloxetine hydrochloride|Start 30 mg Q.D. for 7 days, then increased to 60 mg Q.D. @ the week 1 visit. Thereafter, dose may be increased or decreased by 30 mg increments based on tolerability and efficacy between a dosage range of 60 to 120 mg.
1799748|NCT00583219|Drug|Botulinum-A toxin|A simple bladder catheterization in the office with a standard urinary catheter and instill the Botulinum-A toxin/DMSO solution.
1799749|NCT00583219|Drug|Dimethyl sulfoxide (DMSO)|Subjects received 50 cc of DMSO in an aqueous solution for intravesical instillation with botulinum-A toxin. Each cc contained 0.54 gm DMSO.
1799750|NCT00583232|Drug|Stable isotope infusions|Stable isotope infusion will be given via an intravenous catheter. Subjects will receive a priming dose and a continuous dose.
1799751|NCT00583245|Other|Gait Training|Gait training with physical therapist 2/week for 3 months
1799752|NCT00583258|Drug|Alfuzosin (Xatral)|10 mg PO once a day
1799753|NCT00583258|Drug|Placebo Alfuzosin|10 mg PO once a day
1799754|NCT00583271|Drug|triamcinolone|80mg of triamcinolone injected into the celiac ganglion during the EUS-CB
1799755|NCT00583271|Drug|98% dehydrated alcohol|10ml of 98% dehydrated alcohol injected into the celiac ganglion during the EUS-CB
1799757|NCT00583310|Behavioral|Telephone-based lifestyle counseling|Four 30-minute telephone sessions including education and behavioral counseling strategies that have been shown to be effective in promoting behavior change and reducing blood pressure.
1799758|NCT00583323|Drug|Lomotil|Orally 10ml of Lomotil
1799759|NCT00583323|Other|Normal saline|10 ml orally
1799760|NCT00583336|Device|ShuntCheck|Thermal dilution test for CSF flow
1799761|NCT00583349|Drug|Paclitaxel, nanoparticle albumin-bound|Intravesically administered, dose escalation, 6 weekly instillations
1799762|NCT00583362|Biological|Belimumab|Belimumab 10mg/kg IV over one hour every 28 days
1799763|NCT00583375|Device|GEM OS1|GEM OS1 with sodium acetate buffer containing rhPDGF-BB
1799764|NCT00583375|Procedure|Standard of Care|Autologous Bone Graft
1799765|NCT00583388|Dietary Supplement|L-arginine|Each subject will be exposed to three treatments, a) 5 g of L-arginine, b) 15 g of L-arginine, and c) placebo, the sequences will be randomly assigned to the 42 volunteers. The washout period between interventions will be from one to two days.L-arginine will be mixed in 60 cc of dextrose-based syrup to blind the taste and color of the L-arginine powder.
1799766|NCT00583388|Device|Ultrasound|Ultrasound from the brachial artery will be done on 3 occasions: at 9 pm after 4hs of fasting, at 6 am and at 11 am. The brachial artery images will be acquired above the antecubital fossa in the longitudinal plane of the artery with an ultrasound machine using a 6-MHz linear transducer. Flow-mediated vasodilatation will be assessed by the reactive hyperemia method (inflation of a blood pressure cuff around the forearm to 200 mmHg for 5 minutes and then released). The diameter of the brachial artery will be assessed 60 to 90 s after deflation of the cuff. After a 10min period a second baseline image of the brachial artery will be obtained. Non-low-mediated vasodilatation will be measured by an administration of a sublingual dose of nitroglycerin (0.4 mg).
1799767|NCT00583401|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
1799768|NCT00583414|Device|Endovascular Aneurysm Repair|Endovascular exclusion of aneurysm
1799769|NCT00583427|Drug|Sulodexide|200 mg per day in an oral gelcap form
1799770|NCT00583440|Behavioral|12-step facilitation|12 weekly individual 12-step facilitation sessions
1799771|NCT00583440|Behavioral|Treatment as usual|Usual clinical treatment in a dual diagnosis treatment program
1799772|NCT00583453|Drug|Celecoxib|"Celecoxib 200 mg capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery"
1799773|NCT00583453|Drug|Placebo|"Placebo capsule
capsule the night before surgery
capsules the morning of surgery
1 capsule the night of surgery
1 capsule twice daily for 10 days immediately after the surgery"
1799774|NCT00583466|Drug|Autologous blood injection|Autologous blood will be drawn from the patient and then reinjected under the lesion to create a safety cushion
1799775|NCT00583466|Drug|Normal saline|Normal saline will be injected under the lesion to create submucosal cushion
1799776|NCT00583466|Drug|HPMC|Hydroxypropyl methylcellulose (HPMC) will be injected under the lesion to create submucosal cushion
1799777|NCT00583479|Other|one injection into the celiac ganglion|one injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
1799778|NCT00583479|Other|two injections into the celiac ganglion|two injection into the celiac ganglion of the standard medication for CB for with chronic pancreatitis or pancreatic cancer
1799779|NCT00583492|Biological|Ad5-yCD/mutTKSR39rep-ADP|Ad5-yCD/mutTKSR39rep-ADP (1 x 10^12 vp) on day 1 Plus Radiation - 40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy Plus 2 week course (weekdays only) of 5-FC and vGCV prodrug therapy
1799780|NCT00583492|Radiation|IMRT|40 x 2 Gy for a total dose of 80 Gy or 44 x 1.8 Gy for a total dose of 79.2 Gy
1799781|NCT00583505|Device|Device closure with the AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
1799787|NCT00583583|Device|Device closure with the AMPLATZER Duct Occluder|Device closure with the AMPLATZER Duct Occluder
1799788|NCT00583596|Device|Device closure with AMPLATZER Duct Occluder|Device closure with AMPLATZER Duct Occluder
1799789|NCT00583596|Other|Objective Performance Criteria|Compare results of device closure to objective performance criteria
1799790|NCT00583609|Drug|PEG3350|PEG3350
1799791|NCT00583622|Drug|Bevacizumab|5 mg/kg by vein daily over 90 minutes for 2 Days
1799792|NCT00583622|Drug|Carboplatin|333 mg/m^2 by vein over 2 hours for 3 Days
1799793|NCT00583622|Drug|Docetaxel|300 mg/m^2 by vein over 2 hours for 1 Day
1799794|NCT00583622|Drug|Gemcitabine|1,800 mg/m2 by vein over 3 hours for 4 Days
1799795|NCT00583622|Drug|Melphalan|50 mg/m^2 by vein over 15 minutes for 3 Days
1799796|NCT00583622|Procedure|Stem Cell Transplant|"Stem Cell Removal via apheresis through a central venous catheter (CVC), usually in chest
Stem Cell Replacement through CVC over about 30-60 minutes, Day 7 of treatment, following study drug regimen"
1799797|NCT00583648|Other|Urinanlysis|sending a Urine sample to the laboratory for processing
1799798|NCT00583661|Device|EXCOR Pediatric|Extracorporeal Ventricular Assist Device
1799799|NCT00583674|Drug|AMG 386 placebo|AMG 386 placebo IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
1799800|NCT00583674|Drug|AMG 386 10mg/kg|AMG 386 10 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
1799801|NCT00583674|Drug|AMG 386 3mg/kg|AMG 386 3 mg/kg IV QW until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
1799802|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
1799803|NCT00583674|Drug|Capecitabine|Capecitabine1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
1799804|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
1799805|NCT00583674|Drug|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
1799806|NCT00583674|Drug|Cisplatin|Cisplatin 80 mg/m2 IV Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
1799807|NCT00583674|Drug|Capecitabine|Capecitabine 1000 mg/m2 PO BID x 14 days Q3W until radiographic disease progression, clinical progression, unacceptable toxicity, subject withdrawal of consent, or death
1799808|NCT00583687|Device|Vigileo TM / Flotrac TM (Minimally invasive cardiac output system consisting of arterial line sensor and cardiac output monitor)|Attachment of the arterial line sensor and pulse contour cardiac output monitor to the arterial line of the patient.
1799809|NCT00583687|Other|Passive leg raising|Passive leg raising for prediction of fluid responsiveness with arterial pulse contour analysis.
1799810|NCT00583687|Other|Volume challenge / Change of vasoactive drugs or inotropics|Either a volume challenge (using colloids or crystalloids) or a change in the dosage of of vasoactive drugs or inotropics, or a combination of them, as proposed by the treating physician.
1799811|NCT00583687|Device|Inspectra TM/O-To-See TM (Tissue oxymetry with near infrared spectroscopy and laser-Doppler)|Tissue oxymetry continuously measured with near infrared spectrometry and laser Doppler during the whole study period.
1799812|NCT00583700|Drug|Pentoxifylline|Pentoxifylline 400 mg, 3 times daily for 7 months, beginning immediately after radiation therapy.
1799813|NCT00583700|Drug|Vitamin E|Vitamin E (Over-the-counter) 400 I.U. once daily
1799814|NCT00583713|Drug|BLI-800|BLI-800 oral solution (two doses)
1799815|NCT00583726|Behavioral|motivational interviewing|telephone counseling
1799816|NCT00583726|Behavioral|written materials only|dietary guidance materials and pedometers
1799817|NCT00583739|Behavioral|Yoga|Gentle Yoga for breast cancer survivors, 1 time weekly, for 8 weeks.
1799818|NCT00583752|Biological|Adenovirus/PSA Vaccine|1x10E8pfu in Gelfoam subcutaneously on day 0, 30, 60
1799819|NCT00583765|Drug|Regional citrate anticoagulation|Continuous venovenous hemodiafiltration with regional anticoagulation using dilute trisodium citrate. This requires the use of a continuous renal replacement therapy (CRRT) machine in venovenous hemodiafiltration mode. Anticoagulation and buffer are provided by the use of a dilute solution of trisodium citrate in the replacement fluid which is infused in a predilution mode. Standard bicarbonate containing dialysate is used.
1799820|NCT00583778|Drug|ipratropium|0.5 mg of ipratropium added to 1.25 mg levalbuterol given every 20 minutes for 3 doses
1799823|NCT00583817|Device|Endovascular stent-graft implantation|Endovascular repair with a research device
1799824|NCT00583830|Biological|Mapatumumab|30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
1799825|NCT00583830|Biological|Mapatumumab|10 mg/kg IV (in the vein), on day 1 of each 21 day cycle
1799826|NCT00583830|Drug|Paclitaxel|200 mg/m^2 IV (in the vein), on day 1 of each 21 day cycle
1799827|NCT00583830|Drug|Carboplatin|AUC 6.0 mg min/ml IV (in the vein), on day 1 of each 21 day cycle
1799828|NCT00583843|Procedure|Ultrasound|Ultrasound weekly during initial fields of radiation, and daily during the boost phase.
1799829|NCT00583869|Drug|Placebo|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive a placebo PO BID beginning on the day of surgery until discharge.
Upon discharge, the patient will be given study medication (placebo PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
1799830|NCT00583869|Drug|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 75mg PO BID beginning on the day of surgery until discharge.
Upon discharge, the patient will be given study medication (pregabalin 75mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
1799831|NCT00583869|Drug|Pregabalin|"Two hours before surgery, patients will receive 75mg of pregabalin. Patients will be placed on a patient-controlled anesthesia pump (PCA) for 24 hours. On post-operative day one, the patients will be switched to oral oxycodone as needed with supplementation with IV Demerol for breakthrough pain. In addition, patients will receive 150mg PO BID beginning on the day of surgery until discharge.
Upon discharge, the patient will be given study medication (pregabalin 150mg PO BID). Rescue medications will be allowed during the study (including post-operative and outpatient periods). Outpatient rescue medications will consist of hydrocodone/APAP 7.5mg PO Q6H PRN. Patients will be followed for three months as an outpatient."
1799832|NCT00583882|Other|Routine change of central venous catheters|Changeing CVCs on a regular basis to decrease infection rate.
1799833|NCT00583895|Drug|10% ImCOOH cream|Twenty patients will receive a hydrophilic cream containing 10% ImCOOH and a placebo cream randomized over both limbs twice daily for 14 days with an additional morning application on Day 15.
1799834|NCT00583895|Drug|Placebo|Five patients will receive placebo cream on both limbs twice daily for 14 days with an additional morning application on Day 15.
1799835|NCT00583908|Device|senofilcon A|toric contact lens
1799836|NCT00583908|Device|balafilcon A toric|toric contact lens
1799837|NCT00583908|Device|lotrafilcon B toric|toric contact lens
1799838|NCT00583908|Device|omafilcon A|toric contact lens
1799839|NCT00583947|Drug|arformoterol|Arformoterol is given at a 7.5 ug per dosing during the cross-over phase and 15 ug per dosing during the open-label phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
1799840|NCT00583947|Drug|levalbuterol|Levalbuterol is given at a 0.63 mg per dosing during the cross-over phase. Each treatment consists of one nebulization every 30 minutes over a 60 minute treatment interval (totaling 3 cumulative dosings at 0,30 and 60 minutes).
1799841|NCT00583986|Drug|Levalbuterol HFA MDI with top mounted actuation indicator|Levalbuterol HFA MDA with top mounted actuation indicator
1799842|NCT00583999|Other|no interventions, only regular blood-draw|No interventions, only regular blood-draw (liver biopsy obtained per routine during the surgery)
1957528|NCT02340962|Drug|TG-2349|TG-2349 (Furaprevir) is available as a Swedish orange capsule (size 0) for oral administration. Each capsule contains an equivalent of 100 mg of TG-2349 spray dried solid (SDD) and the following inactive ingredients: microcrystalline cellulose, croscarmellose sodium, sodium lauryl sulfate, magnesium stearate, and colloidal silicon oxide.
1799844|NCT00584025|Drug|levetiracetam|100 - 500mg IV q 15 min
1799845|NCT00584025|Drug|Placebo|Placebo equivalent of 100 - 500 mg levetiracetam IV q 15 min
1799846|NCT00584038|Behavioral|educational instruction and phone follow-up|Educational instruction and phone follow-up.
1799847|NCT00584038|Behavioral|educational instruction in clinic|Educational instruction in clinic.
1799848|NCT00584064|Device|Device closure with the AMPLATZER PFO Occluder|Device closure with the AMPLATZER PFO Occluder
1799849|NCT00584090|Drug|Solifenacin Succinate (VESIcare)|5 - 10 mg po qd for 1 month
1799850|NCT00584090|Drug|Placebo|Placebo equivalent of 5-10 mg po qd for 1 month
1799851|NCT00584103|Device|Alpha P Control|Subjects will be fitted with a terminal device with their current prosthesis and evaluated using the NYU trans-radial prosthesis checkout form.
1799852|NCT00584103|Device|Beta P Experimental|Subjects will be fitted with the inexpensive prosthesis model from Prestige Healthcare Technologies. Then the terminal device will be fitted and evaluated using the NYU trans-radial prosthesis checkout form.
1799853|NCT00584129|Other|Pre-treatment swallowing exercises|Swallowing exercises will be started pre-treatment with radiation.
1799854|NCT00584129|Other|Post-treatment swallowing exercises.|Patients to start swallowing exercises after completion of radiation therapy.
1799855|NCT00584142|Behavioral|Mindfulness-Based Stress Reduction|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program.
1799856|NCT00584155|Drug|Normal Saline and 0.3% ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear and are only to be used in the designated ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
1799857|NCT00584155|Drug|Lactated Ringer's with 0.03% Ofloxacin|The patient will be instructed to place one dropper full of solution in the external auditory canal. The bottle will be marked right or left ear. The drops will be administered at the start time, 30 minutes after chemotherapy starts and hourly for 4 hours after infusion.
1799858|NCT00584168|Drug|Dexamethasone|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
1799859|NCT00584168|Drug|Placebo|They will take a pill the day before surgery, twice daily for the next four days and then once daily for the next two days for a total of seven days.
1799935|NCT00584935|Drug|Rituximab|The Rituximab dose is 1000mg (1gm) given as an IV infusion every two weeks for 2 doses (days 1 and 15).
1799860|NCT00584194|Biological|TSI-GSD 200 RVF Vaccine|Part A: Inactivated, Dried (TSI-GSD 200) RVF vaccine will be given as three 1.0-ml subcutaneous primary series injections, with doses on day 0, once on days 7-14, once on days 28-42 (the third dose will be given at least 21 days after the second dose).Part B: Subcutaneous 1.0-ml booster doses (maximum of four boosters over 12 months) will be given if the volunteer fails to respond to the primary series with a PRNT80 ≥ 1:40 or annually if titer wanes to < 1:40.
1799861|NCT00584207|Procedure|radiofrequency ablation|Intraoperative RFA of uterine fibroids
1799862|NCT00584220|Device|senofilcon A toric|contact lens
1799863|NCT00584220|Device|alphafilcon A toric|contact lens
1799864|NCT00584233|Device|computed tomography|Computed tomography of both breasts. For all subjects, CT scanning will be performed before and after an I.V. iodinated contrast injection (100 mL).
1799865|NCT00584246|Drug|Pregabalin (Lyrica)|50 - 150 mg po qhs for 2 months
1799866|NCT00584246|Drug|Placebo|50 - 150 mg po qhs for 2 months
1799867|NCT00584259|Other|Coffee|3 cups of coffee over a 24 hour period
1799869|NCT00584298|Drug|SMS995|
1799870|NCT00584298|Drug|Placebo|
1799871|NCT00584311|Other|MRI and Ultrasound|MRI and US of the joint
1799872|NCT00584324|Combination Product|BIS 40|"Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.
Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.
Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.
Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.
Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
1799873|NCT00584324|Combination Product|BIS 60|"Mini-mental state exam: For subjects > 60, this exam will be administered pre-operatively.
Spielberger State-Trait anxiety test: Spielberger test just before being taken to the operating room.
Spoken word-stem completion test: After discharge from recovery but within 24 hrs. post surgery, this test along with the anxiety test will be administered.
Bispectral Index Monitor: The physiologic monitor is used intraoperatively to assess surgical anesthesia.
Audio File: Playing an audio file (a list of spoken words) via headphones under general anesthesia during the surgical procedure."
1799874|NCT00584350|Other|Hydratation according LVEDP + NaHCO3|"Hydration with bolus of NaCl 0.9 to reach a LVEDP of 18 mmHg or more. This procedure is done while the patient is in the laboratory, with a catheter in the left ventricle.
At the same time, an infusion of a sodium bicarbonate solution (150 mEq/L) is started at a rate of 1 ml/kg/h (max 110 ml/h) for 7 hours."
1799875|NCT00584350|Other|normal saline|hydratation with normal saline (1 cc/kg/h; max 110 cc/h) starting at 8PM the day before the test and ending at 8PM the day of the test (24 hours total).
1799876|NCT00584350|Other|Sodium bicarbonate|hydratation with sodium bicarbonate (150 mEq/L) at 3 cc/kg/h (max 330 cc/h) for 1 hour before the test and then, to be continued at 1 cc/kg/h (max 110 cc/h) for 6 hours (total of 7 hours of hydratation).
1799877|NCT00584376|Drug|Pregabalin|Gradually titrated dose ranging from 75mg po bid to 225mg po bid.
1799878|NCT00584376|Drug|Placebo|Placebo capsules which are identical in packaging, appearance and dosing as the active capsules.
1799879|NCT00584389|Drug|rimonabant|20mg/d (oral) once daily for 12 weeks
1799880|NCT00584389|Behavioral|Dietary intervention|Dietary intervention to match weight loss in group 1. The energy prescription will be based on the estimate of the energy deficit estimated from the weight loss in group one. For example a weight loss of 5kg over 12 weeks equates to an approximate energy deficit of 30,000 kcal or a daily energy reduction of approximately 357 kcal. If this is achieved in group 1 the daily energy target for subjects in group 2 will be daily energy expenditure minus 357 kcal.For the subjects randomised to the dietary intervention group there will be a delay until group 1 subjects have completed the study.
1799881|NCT00584402|Drug|perflutren lipid microspheres|perflutren lipid microspheres IV in 0.1 cc doses, as needed, to enhance lesion conspicuity
1799882|NCT00584415|Device|GP ablation + PV isolation|All patients underwent GP ablation and PV isolation using the NaviStar ThermoCool ablation catheter
1799883|NCT00584428|Procedure|High-Dose Chemo with Autologous BMT|Carboplatin/VP-16/Cytoxan for women 18-59 and Carboplatin/Thiotepa/Cytoxan for women 60-70
1799884|NCT00584454|Biological|Q Fever Vaccine (NDBR 105|Each volunteer will receive an intradermal dose of 0.1 ml of the skin test antigen (Q fever Skin Test Antigen, Henzerling Strain, Phase I, MNLBR 110) in the volar aspect of the arm on Day -7 of the study.Volunteers with skin test reactions that are considered negative may be vaccinated with Q Fever Vaccine, Phase I, Inactivated, Freeze-Dried, NDBR 105 (subcutaneously, 0.5 ml) in the upper outer aspect of the arm on Day 0 of the study.
1799885|NCT00584480|Other|Hyperbaric Oxygen Treatment (HBOT)|1.5 ATA at 100% Oxygen of HBOT
1799886|NCT00584493|Drug|CP-675,206|"This is a single arm study. Patients will receive intravenous administration of CP-675,206 at a dose of 15 mg/kg on Day 1 of every 90-day cycle for up to 4 cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 (± 4 day) period. Patients who discontinue treatment after 4 doses of CP-675,206 without disease progression and who subsequently experience disease progression more than 3 months after the last dose may receive 2 additional doses of CP-675,206 provided that they have not received other systemic therapy for their melanoma
Survival in this study will be monitored on all patients for up to 5 years from the date of first dose of CP-675,206."
1799887|NCT00584519|Other|non-interventional|non-interventional
1799888|NCT00584532|Drug|Placebo|10 Placebo Capsules taken orally every day.
1799889|NCT00584532|Drug|GCP - Genistein Combined Polysaccharide|Ten 500 mg capsules given orally per day. Total of 5 grams per day per patient.
1799890|NCT00584558|Procedure|Catheter Ablation|Catheter Ablation of arrhythmias
1799936|NCT00584948|Drug|Memantine|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
1800051|NCT00578695|Drug|Placebo|Oral Capsule
1800052|NCT00578708|Device|AMPLATZER Membranous VSD Occluder|Device closure with the AMPLATZER Membranous VSD Occluder
1799891|NCT00584571|Procedure|Sensory Adaptation Training with Barostat|This study will last for approximately 3 months and will include 4-6 clinic visits with each visit lasting 2 hours every week or every 2 weeks. At the beginning of each visit we will ask you about your health status and level of satisfaction of your bowel habits. We will then place the pencil-thick probe and balloon inside your rectum and attach it to the barostat device and a computer. We will increase and decrease the volumes of the balloon until the most pressure you can tolerate or a certain level of pressure as measured by the machine is reached, whichever occurs first. You will continue to keep stool diaries and pain diaries for 7 days before and after each visit.
1799892|NCT00584571|Drug|Escitalopram Therapy|Escitalopram; 10 mg every day, orally.
1799893|NCT00584584|Drug|QAX576|
1799894|NCT00584584|Drug|Placebo|
1799895|NCT00584597|Drug|Saline|Saline Control
1799896|NCT00584597|Drug|Traumeel S|Traumeel S 1 mL
1799897|NCT00584597|Drug|Traumeel S|Traumeel S 2mL
1799898|NCT00584597|Drug|Traumeel S|Traumeel S 3mL
1799899|NCT00584610|Device|Levonorgestrel-containing IUD (Mirena®)|Levonorgestrel-containing intrauterine device insertion
1799900|NCT00584610|Device|Copper-containing IUD (Paraguard®)|Copper-containing intrauterine device insertion
1799901|NCT00584636|Drug|pulmicort respules|pulmicort respules 0.5 mg twice a day for 28 days versus placebo
1799902|NCT00584649|Procedure|electrophysiology study and radiofrequency ablation|stimulation protocol searching for the neural inputs to the sinus node region and radiofrequency ablation of neural input to the heart
1799904|NCT00584675|Device|Dx-pH Measurement Probe|Dx-pH Measurement Probe measures gaseous pH values in the nasopharynx and oropharynx over a period of 24 hours.
1799905|NCT00584688|Drug|quetiapine|quetiapine dosage will be titrated to subject tolerance beginning at 50 mg every 24 hours upwards to 400 mg every 24 hours.
1799906|NCT00584701|Drug|Risperidone|Dose will start at 0.5 mg and may be increased throughout the course of the study if no adverse events occur
1799907|NCT00584727|Device|senofilcon A toric contact lens|contact lens
1799908|NCT00584727|Device|alphafilcon A toric|contact lens
1799909|NCT00584727|Device|etafilcon A sphere|contact lens
1799910|NCT00584740|Drug|AIN457|10 mg/kg
1799911|NCT00584740|Drug|Placebo|Matching placebo to AIN457
1799912|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
1799913|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
1799914|NCT00584753|Radiation|Positron emission tomography and computed tomography|Positron emission tomography and computed tomography
1799915|NCT00584766|Procedure|High-dose chemotherapy|Cyclophosphamide 500 mg/m2 IV day 1; Doxorubicin 30 mg/m2 IV Day 1; Methotrexate 300 mg/m2 IV Day 8;5-FU 500 mg/m2 IV day 8; leucovorin 20 mg po q 6 h x 6 doses, day 9- cycles repeated q 21 days
1799916|NCT00584779|Drug|Gabapentin|CLcr:14-5 mL/min
1799917|NCT00584779|Drug|Gabapentin|CLcr: 29-15 mL/min
1799918|NCT00584779|Drug|Gabapentin|Hemodialysis
1799919|NCT00584779|Drug|Gabapentin|CLcr: 29-30 mL/min
1799920|NCT00584805|Biological|Inactivated, Dried, TSI-GSD 104, EEE|Subjects will receive 0.5ml SQ, as a two-dose primary series (days 0 and 28) and 0.1ml, as a mandatory booster dose at 6 months. A booster dose may be administered before 6 months if PRNT80 is < 1:40 after day 28. Up to four booster doses may be given in any 1-year period.
1799921|NCT00584818|Drug|PB127 for Injectable Suspension|"Stages 1 & 2 0.009 - 0.204 mg/kg continuous IV during rest and stress conditions. Infusion rate of 50 - 125 mL/hr will be adjusted for image quality and diagnostic quality. Infusion limited to 60 minutes or less.
Stage 3 - will utilize infusion rate and dose established in Stages 1 & 2. 0.062 mg/kg continuous IV infusion at 150 mL/hr during rest and 100 mL/hr during stress conditions."
1799922|NCT00584831|Device|senofilcon A|toric contact lens
1799923|NCT00584831|Device|balafilcon A|toric contact lens
1799924|NCT00584831|Device|omafilcon A|toric contact lens
1799925|NCT00584831|Device|lotrafilcon B|toric contact lens
1799926|NCT00584844|Biological|Live F tularensis Vaccine|Subjects will receive one drop of reconstituted F tularensis vaccine (approximately 0.0025 ml), applied with a bifurcated needle to the volar surface of the forearm, and the skin will be pricked 15 times over the prepared area. A booster dose will be given at the same dose volume and route of administration if the titer (days 56-84) is inadequate (< 1:20).
1799927|NCT00584857|Drug|Paclitaxel ,Carboplatin , Megesterol Acetate|Paclitaxel will be administered at an appropriate dose (175mg/m2) as a 3 hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate. Megesterol Acetate will be given orally four times a day at an anti-tumor dosage of 40 mg. This will be given for a total of 6 cycles over 18 weeks with the Megace continuing for 5 years as long as no evidence of recurrence is present.
1799928|NCT00584870|Drug|Naproxen|Oral naproxen 500 mg twice daily for Weeks 1-12.
1799929|NCT00584870|Drug|Placebo|Single IV infusion of placebo on Day 1 and placebo for naproxen twice daily for Weeks 1-12.
1799930|NCT00584870|Drug|PF-04383119 (RN624)|Single IV infusion of 200 micrograms/kg RN624 on Day 1
1799931|NCT00584883|Drug|ABT 510|ABT 510 (TSP-1 mimetic peptide) is a parenterally available nonapeptide analog of the heptapeptide and is a potent inhibitor of angiogenesis. ABT 510 competes with TSP-1 for binding to endothelial cells, but the exact mechanism of anti-angiogenesis is unknown. ABT 510 is administered by SQ injection. The starting dose of ABT 510 will be 20mg once daily (QD) SQ. Doses will be escalated by approximately 50% increments in consecutive cohorts of 3-6 patients until maximum tolerated dose is achieved.
1799932|NCT00584896|Drug|PB127 for Injectable Suspension|0.062 mg/kg continuous IV infusion (100-250 mL/hr) during echocardiography, not to exceed 60 minutes infusion, single dose.
1799933|NCT00584909|Drug|Paclitaxel and carboplatin combination|Paclitaxel will be administered at an appropriate dose (175 mg/m2) as a 3-hour continuous IV infusion every 21 days. Carboplatin will be administered at an appropriate dose utilizing the Calvert formula for determining the area under the curve (AUC) based on the patient's glomerular filtration rate (GFR).
1800045|NCT00578669|Drug|Dextrose|Once daily for 16 weeks
1799937|NCT00584948|Drug|Placebo|Week 1: Take 5mg tab every morning. Week 2: Take 5mg tab every morning and evening. Week 3: Take 10mg tab in the morning and 5 mg in the evening. Week 4: Take 10 mg tab in the morning and evening, and remain on this dose through the remainder of the study.
1799938|NCT00584961|Other|non-interventional|non-interventional
1799939|NCT00584974|Drug|SEP-225289|0.5 mg SEP-225289
1799940|NCT00584974|Drug|SEP-225289|2.0 mg SEP-225289
1799941|NCT00584974|Drug|Venlafaxine|150 mg Venlafaxine
1799942|NCT00584974|Drug|placebo|Placebo
1799943|NCT00584987|Drug|Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
1799944|NCT00584987|Drug|Placebo Fluticasone furoate|2 puffs of each nasal spray in each nostril in the pm
1799945|NCT00584987|Drug|Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
1799946|NCT00584987|Drug|Placebo Oxymetazoline|2 puffs of each nasal spray in each nostril in the pm
1799947|NCT00585000|Drug|CP-675,206|15 mg/kg. IV (in the vein) over 1 hour on Day 1 of each 90 day cycle. Number of cycles: maximum of 4 cycles unless progression of disease or unacceptable toxicity.
1799948|NCT00585013|Drug|Nitric Oxide|Patients will receive standard care with the addition of NO gas. During cardiopulmonary bypass, NO at 20 ppm will be added to the sweep gas of the extracorporeal circuit. Following termination of cardiopulmonary bypass, inhaled NO will be discontinued.
1799949|NCT00585026|Device|D-28 bifocal lenses and frame|
1799950|NCT00585026|Device|Progressive addition computer lenses and frame|
1799951|NCT00585039|Drug|xopenex|will receive xopenex rather than albuterol to treat acute exacerbation
1799953|NCT00585065|Other|Cardiac Resynchronization Therapy|Cardiac Resynchronization Therapy
1799954|NCT00585078|Drug|Capecitabine|
1799955|NCT00585078|Drug|Oxaliplatin|
1799956|NCT00585091|Drug|phenylephrine|All patients undergo repeated phenylephrine infusions during standard up-titration and maintenance of carvedilol treatment.
1799957|NCT00585104|Drug|levosimendan|10-minute infusion
1799958|NCT00585117|Procedure|PET-imaging with CuATSM|imaging with CuATSM
1799959|NCT00585117|Procedure|PET Imaging|Imaging with CuATSM
1799960|NCT00585117|Procedure|PET CuATSM|Imaging with CuATSM
1799961|NCT00585117|Procedure|PET imaging|imaging with CuATSM
1799962|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
1799963|NCT00585117|Procedure|PET imaging with CuATSM|Imaging with CuATSM
1799964|NCT00585143|Drug|ABT-335|45 mg once daily for 10 consecutive days
1799965|NCT00585143|Drug|Rosuvastatin|10 mg once daily for 10 days
1799966|NCT00578266|Drug|Cyclophosphamide,Campath IH and TBI|"DAY 5 TREATMENT
6 5 CYTOXAN 50 mg/kg WITH MESNA
5 CYTOXAN 50 mg/kg WITH MESNA;
4 CYTOXAN 50 mg/kgWITH MESNA; CAMPATH 3-10 mg
3 CYTOXAN 50 mg/kg WITH MESNA; CAMPATH;
2 TBI; CAMPATH; TACROLIMUS
1 TBI (second fraction); CAMPATH (am) 0 STEM CELL INFUSION (pm)"
1799967|NCT00578279|Drug|dehydrated alcohol|subject randomized to 10ml or 20ml of dehydrated alcohol one time during the EUS-CPN procedure
1799968|NCT00578292|Drug|Busulfan|"4.0 mg/kg/day divided into four doses daily for four days; total dose = 16 mg/kg
Days -9 through -6"
1799969|NCT00578292|Drug|Fludarabine|30mg/m2 Day -5 through Day -2
1799970|NCT00578292|Drug|Campath 1H|Per institutional guidelines Days -5 through -2
1799971|NCT00578292|Drug|Cyclophosphamide|50 mg/kg Days -5 through -2
1799972|NCT00578292|Drug|MESNA|10 mg/kg x 5 Days -5 through -2
1799973|NCT00578305|Biological|Rituximab|Rituximab was supplied as a sterile liquid for iv administration.
1799974|NCT00578305|Drug|Placebo|Placebo was supplied as a sterile liquid in single-use vials for iv administration.
1799975|NCT00578305|Drug|Methylprednisolone|
1799976|NCT00578305|Drug|Methotrexate|
1799977|NCT00578305|Drug|Folic acid or folate|
1799978|NCT00578318|Behavioral|Motivational Interviewing Active|Patients received 2 sessions of an in-person talk based intervention utilizing culturally relevant Motivational Interviewing.
1799981|NCT00578344|Drug|Busulfan|Starting Day -9 / Busulfan 4.0 mg/kg/day IV divided into four doses daily for four days; total dose = 16 mg/kg.
1799982|NCT00578344|Biological|Campath 1H|Day -5 through Day -2; Campath-1H dosed as per institutional guidelines.
1799983|NCT00578344|Drug|Cyclophosphamide and MESNA|Day -5 through Day -2; Cyclophosphamide 50 mg/kg + MESNA.
1799984|NCT00578357|Behavioral|personalized feedback intervention|personalized feedback will be sent to participants after they complete and return self-help materials/questionnaires
1799985|NCT00578370|Drug|Ciclosporin 0.5% (Formulation 01B)|Cutaneous emulsion 200µl once a day (26 days)
1799986|NCT00578370|Drug|Ciclosporin 1.5% (Formulation 02B)|Cutaneous emulsion 200µl once a day (26 days)
1799987|NCT00578370|Drug|0.1% betamethasone|Solution 200µl once a day (26 days)
1799988|NCT00578370|Drug|0.005% calcipotriol|Solution 200µl once a day (26 days)
1799989|NCT00578370|Drug|Formulation 00B|Cutaneous emulsion (Vehicle to Formulation 01B and Formulation 02B) 200µl once a day (26 days)
1799990|NCT00578383|Device|Low Field Magnetic Stimulation Device|The LFMS Device is an electromagnetic coil situated on a cylinder with an inside diameter of 13.2 inches. It produces weak electromagnetic fields at a frequency of about 1 kHz; the magnetic fields are less than 30 Gauss and the electric fields are up to 1.43 V/m. Subjects will receive one 20 minute treatment.
1799991|NCT00578396|Dietary Supplement|grapes|1 pound of seedless red grapes
1799992|NCT00578396|Dietary Supplement|grapes|2/3 lb/day fresh red grapes
1799993|NCT00578396|Dietary Supplement|grapes|1/3 lb/day fresh red grapes
1800046|NCT00578682|Biological|MEDI-557|Single IV dose of 3 mg/kg
1800047|NCT00578682|Biological|MEDI-557|Single IV dose of 15 mg/kg
1800048|NCT00578682|Biological|MEDI-557|Single IV dose of 30 mg/kg
1800049|NCT00578682|Biological|MEDI-557|Single IV dose of 0.3 mg/kg
1800050|NCT00578695|Drug|lixivaptan|Oral Capsule
1799994|NCT00578422|Other|Ivus (Intravascular Ultrasound) of Amputation Specimens|Human lower extremity arterial segments will be obtained at autopsy and from amputation specimens. All imaging studies and vessel fixation will be undertaken immediately upon vessel procurement; in most cases this will occur within 2 hours of dissection and within 24 hours of death. The ex vivo portion of the study will make use of 150 excised vessels obtained over a 48-month period from randomly selected autopsy cases. From these vessels we expect to collect data from a minimum of 560 plaques
1799995|NCT00578422|Procedure|IVUS (Intravascular Ultrasound)|Standard diagnostic arteriographic images will be obtained. Appropriate oblique views will be acquired at the common femoral bifurcation. Next, IVUS will be performed obtaining ultrasound data from a 10 cm lower extremity artery.
1799996|NCT00578435|Procedure|Busulfan, Cyclophosphamide, BMD|Busulfan 0.8 or 1 mg/Kg/day Days 8-6 Cyclophosphamide 50 mg/Kg/day Days 2-5 BMT Day 0
1799998|NCT00578461|Drug|Ara C|3000 mg/m^2 - pts will recieve via IV every 12 hours for 6 doses starting at 20:00 hours on day -8
1799999|NCT00578461|Drug|Mesna|45 mg/kg; divided into 5 doses-will be administered 15 minutes prior to Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide
1800000|NCT00578461|Drug|Cyclophosphamide|45 mg/kg; IV once daily on day -7 and day -6 starting at 1400 hours
1800001|NCT00578461|Radiation|TBI-Total Body Irradiation|Total dose 12 Gy, will be delivered in 8 fractions of 150 cGy, each, two fractions per day beginning day -4
1800002|NCT00578474|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
1800003|NCT00578474|Drug|Ofloxacin otic solution|5 drops into the infected ear(s) twice daily (morning and evening) for 10 days
1800004|NCT00578474|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
1800005|NCT00578500|Procedure|ovarian transplantation|Patients will undergo laparoscopic oophorectomy, aspiration of oocytes and maturation followed by cryopreservation. In case of ovarian failure and approval by treating physicians, restoration of fertility will be attempted by thawing of oocytes or by transplantation of ovarian cortex to induce ovulation and obtain oocytes for fertilization and embryo transfer.
1800006|NCT00578526|Drug|SU011248|50 mg capsule OD PO for 28 days followed by 14 days of rest until tumor progression
1800007|NCT00578526|Drug|Placebo|50 mg capsule OD PO for 28 days then 14 days rest until disease progression
1800008|NCT00578539|Drug|ARA C|Ara C (3000 mg/m2) IV every 12 hours for 6 doses (days -8 to -5)
1800009|NCT00578539|Drug|Cyclophosphamide|Cyclophosphamide (45mg/kg) IV once daily on day -7 and day -6
1800010|NCT00578539|Drug|MESNA|MESNA (45mg/kg; divided into 5 doses) will be administered 15 minutes prior to each dose of Cyclophosphamide and 3, 6, 9, and 12 hours after each dose of Cyclophosphamide.
1800011|NCT00578539|Radiation|Total Body Irradiation (TBI)|TBI: total dose 14.0 Gy, will be delivered in 8 fractions of 1.75 Gy in two fractions on day -4, day -3, day -2, and day -1
1800012|NCT00578539|Biological|Campath-1h|CAMPATH (3 mg IV for patients between 5 and 15 kg; 5 mg for patients between 16 and 30 kg; and 10 mg for patients greater than 30 kg) will be given on day -4, day -3, day -2 and day-1.
1800013|NCT00578539|Procedure|Stem Cell Infusion|Stem cells are infused on day 0
1800014|NCT00578552|Drug|Placebo|Placebo pill - non active sugar pill designed to look alike to the gabapentin medication
1800015|NCT00578552|Drug|Gabapentin - 1800 mg/day|gabapentin - 1800 mg/day for 12 weeks.
1800016|NCT00578552|Drug|Gabapentin - 2700 mg/day|gabapentin - 2700 mg/day for 12 weeks.
1800017|NCT00578565|Drug|Rituximab|Rituximab 1000 mg. I.V.on each days 1 and 15 with repeat dosing at 6 months.
1800018|NCT00578578|Dietary Supplement|eicosapentaenoic acid (EPA),|three capsules daily (1350 mg daily) of EPA for 8 weeks or three capsules daily placebo for 8 weeks
1800019|NCT00578591|Drug|Rituximab|"Rituximab 375 mg/m^2 is given weekly X 4. For patients with a partial response, an additional 4 doses will be permitted as needed (after 4 weeks from the last dose).
Diagnosis of grade II to IV aGVHD will be confirmed, whenever possible, by a biopsy taken from at least one of the following three sites: skin, gut, or liver."
1800020|NCT00578604|Device|diffuse near infrared spectroscopy measurements|Measure blood flow to diabetic wounds
1800021|NCT00578617|Drug|Rate Control|Metoprolol 50-100mg
1800022|NCT00578617|Device|Ablation Therapy|
1800023|NCT00578617|Drug|Rate Control|Atenolol 50-100mg,
1800024|NCT00578617|Drug|Rate control|Propranolol 40-80mg
1800025|NCT00578617|Drug|Rate control|Acebutolol 200mg
1800026|NCT00578617|Drug|Rate control|Carvedilol 6.25mg
1800027|NCT00578617|Drug|Rate Control|Diltiazem 180-240mg
1800028|NCT00578617|Drug|Rate Control|Verapamil 180-240mg
1800029|NCT00578617|Drug|Rate Control|Digoxin 0.125mg
1800030|NCT00578617|Drug|Rhythm Control|Propafenone 450mg
1800031|NCT00578617|Drug|Rhythm control|Flecainide 200mg
1800032|NCT00578617|Drug|Rhythm control|Sotalol 240mg
1800033|NCT00578617|Drug|Rhythm control|Dofetilide 500mcg
1800034|NCT00578617|Drug|Rhythm control|Amiodarone 200mg
1800035|NCT00578617|Drug|Rhythm control|Quinidine 600-900mg
1800036|NCT00578630|Other|buccal swabs and obtaining peripheral blood|will be the collection of normal cells and assessments of toxicity following chemotherapy at routine clinic visits.
1800037|NCT00578643|Drug|Busulfan|"Days -9 through -6
1 mg/kg initially (based on weight)"
1800038|NCT00578643|Biological|Alemtuzumab|"Day -5 through Day -2
Dose is based on weight:
Less than 15 kg: 3 mg
More than 15 kg to 30 kg: 5 mg
More than 30 kg: 15 mg"
1800039|NCT00578643|Drug|Cyclophosphamide|"Days -5 through -2
50 mg/kg"
1800040|NCT00578643|Drug|Fludarabine|"Day -5 through Day -2
30 mg/m^2"
1800041|NCT00578643|Drug|Cyclosporine|Cyclosporine will be administered beginning Day -2. Initial dose will 5 mg/kg infused over 24 hours.
1800042|NCT00578643|Procedure|Stem Cell Infusion|Stem Cell: Either bone marrow, cord blood, or peripheral blood stem cells may be used for stem cell transplantation. It is desired to infuse: for bone marrow, nucleated cells ≥ 4 X 10^8/kg recipient weight; for cord blood ≥ 3 X 10^7/kg nucleated cells; for peripheral blood stem cells ≥ 1 X 10^/kg CD34+ cells.
1800043|NCT00578656|Dietary Supplement|Baked Milk|Extensively heated milk
1800044|NCT00578669|Drug|Fluoxetine|20mg once daily for 16 weeks
1800053|NCT00578721|Drug|Aspirin|325 mg taken daily with an arginine-restricted diet
1800054|NCT00578734|Drug|Lucinactant|Slow intra-tracheal instillation
1800055|NCT00578734|Other|Sham Comparator|Slow intra-tracheal instillation
1800056|NCT00578760|Drug|aspirin|325mg ASA OD for the duration of the cisplatin
1800057|NCT00578760|Drug|placebo|OD for course of cisplatin chemotherapy
1800058|NCT00578773|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
1800059|NCT00578773|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
1800060|NCT00578773|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
1800061|NCT00578786|Drug|ambrisentan|2.5, 5.0 or 10.0 mg ambrisentan po, qd, long-term
1800062|NCT00578799|Dietary Supplement|Kyo-Dophilus|5x109 bacteria/capsule, twice a day, 1 in the morning, 1 in the evening
1800063|NCT00578799|Dietary Supplement|placebo|placebo capsules (potato starch
1800064|NCT00578812|Device|Anterior Cervical Discectomy and Fusion (ACDF)|Anterior cervical discectomy and fusion (ACDF) using a cervical plate and bone graft in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
1800065|NCT00578812|Device|PCM Cervical Disc|PCM Cervical Disc replacement in patients with degenerated cervical discs and neurological symptoms at one level from C3 to T1
1800066|NCT00578825|Drug|Lopinavir / Ritonavir plus Ribavirin|
1800067|NCT00578838|Other|Magnetic Resonance|Patients each will undergo 4 MR examinations as part of this research study.
1800068|NCT00578838|Other|Magnetic Resonance|You will have two MR exams on two different days. There will be no injection of contrast material. An MR exam requires about 1 hour. The second MR exam will take place 2-3 weeks after the first one. This second MR exam will take about 1 hour and will look at whether the results from the MR exams are reliable and repeatable.
1800069|NCT00585156|Drug|Celecoxib|Twelve hours prior to their first total knee surgery, patients will need to take an oral dose of Celebrex, 1 pill of 200mg. Following the patient's first total knee surgery, they will continue taking oral doses of Celebrex, 1 pill of 200 mg every twenty-four hours (200mg/day) for a two-week period.
1800070|NCT00585169|Drug|Memantine Hydrochloride|10 mg/day for two weeks, dose increase to 20 mg at week 3, 30 mg at week 4 unless clinical improvement is achieved with a lower dose. Total treatment is 10 weeks.
1800071|NCT00585182|Drug|Enoxaparin 0.5 mg/kg once daily|Enoxaparin 0.5 mg/kg (kg= actual body weight) subcutaneous once daily for 2 doses.
1800077|NCT00585221|Drug|Peginterferon-alpha 2b (PegIFNa2b);|Treatment include PegIFNa2b high dose (3 mcg/kg/wk) X 4 doses and low dose (1.5 mcg/kg/wk) X 18 doses, followed by surgical evaluation to render pt disease free if possible.
1800078|NCT00585221|Drug|Imatinib|Continue imatinib until progression.
1800079|NCT00585234|Other|Digital Photography|Digital Photography
1800082|NCT00585260|Other|guideline based dose adjustment|standard dose adjustment
1800083|NCT00585260|Drug|mannitol|indirect mannitol challenge
1800084|NCT00585260|Drug|methacholine|methacholine challenge
1800085|NCT00585286|Device|10,600 nm fractional carbon dioxide laser system|1-3 laser treatments using 20-100 millijoules (mJ) with 100-400 microscopic treatment zones (MTZ)/cm2 per pass and total density of 600-1200 MTZ/cm2
1800086|NCT00585299|Other|Low-fat diet|20% calorie from fat diet followed for 8 weeks then maintenance diet for additional 8 weeks
1800087|NCT00585299|Other|Traditional diet|Traditional low-fat diet with dietitian follow-up in 16 weeks
1800088|NCT00585312|Drug|Celecoxib|celecoxib, 16 mg/kg/day, for 5 years
1800089|NCT00585312|Drug|Placebo|Masked, placebo comparator
1800090|NCT00585325|Drug|Instilled 1% Lidocaine|5 mg/kg of 1% lidocaine instilled into their VAC sponge ½ hour prior to VAC dressing change
1800091|NCT00585325|Other|Placebo (0.9% Normal Saline)|.9 normal saline instilled into their VAC sponge ½ hour prior to VAC dressing change
1800092|NCT00585338|Device|Tandem 532/1064 nm Laser|Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser
1800093|NCT00585351|Drug|Ranitidine|50 mg single dose injection of Ranitidine
1800094|NCT00585351|Drug|Placebo|50 mg single dose injection of normal saline (placebo)
1800095|NCT00585351|Other|Advanced notification|Advanced notification of study via faxed consent to local Emergency Room (ER)
1800096|NCT00585351|Other|No advanced notification|No advanced notification of study via faxed consent to local Emergency Room (ER)
1800097|NCT00585377|Drug|Bevacizumab and Erlotinib|Erlotinib 150 mg/day orally plus bevacizumab 15 mg/kg intravenously every 21 days
1800098|NCT00585390|Dietary Supplement|Omega-3 Fatty Acids|"Essential omega-3 fatty acid replacement therapy with Eicosapentaenoic acid at 3.2 grams
Docosahexaenoic acid fish oil concentrate at 1.6 grams"
1800099|NCT00585390|Other|Olive oil placebo|Olive oil capsules, 8 capsules per day
1800100|NCT00585390|Dietary Supplement|EPA fish oil concentrate; DHA fish oil concentrate|3.2 grams for EPA 1.6 grams for DHA
1800101|NCT00585390|Drug|Placebo|Olive oil capsule
1800102|NCT00585416|Drug|CGC-11047|CGC-11047 IV weekly for 3 weeks followed by one rest week (4weeks=1cycle)
1800103|NCT00585442|Drug|calcitriol|1.0 mcg daily
1800104|NCT00585442|Drug|Placebo|Placebo
1800105|NCT00585455|Drug|sertraline|open label 25-50 mg daily as tolerated
1800106|NCT00585468|Drug|Myfortic|Myfortic 720 mg orally twice daily
1800107|NCT00585481|Procedure|Samples collection for viral diagnosis|"At Enrollment and Termination Visits all subjects will have phlebotomy performed for RSV antibody levels (3 mL of blood).
Subjects diagnosed with an LRTI during the study will have a nasopharyngeal lavage (NPL) for viral diagnosis. Phlebotomy for antibody levels will be performed if the current episode represents the first LRTI since study enrollment."
1800108|NCT00585481|Procedure|Lung Function Analysis|Subjects enrolled in one study site (located in Porto Alegre city) will perform Lung Function Analysis. First measurement will be performed up to Visit 6 and repeated at Termination Visit. Measurements collected in the first analysis will include respiratory compliance and resistance by passive deflation pressure - volume curve, lung volumes by gas dilution method (washout with SF6), lung clearance index with SF6, and maximal flows (rapid thoracic compression from raised volumes).
1800109|NCT00585832|Behavioral|DASH-4-Teens|24-week behavioral nutrition intervention emphasizing a diet high in fruits, vegetables and low fat dairy foods and that is low in fat and sodium
1800110|NCT00585832|Other|Routine Care|individual in-person counseling sessions on guidelines consistent with the Fourth Pediatric Report of the National High Blood Pressure Education Program.
1800111|NCT00585845|Biological|CRS-207, Live-attenuated Listeria monocytogenes expressing human Mesothelin|2-hour IV infusion once every 21 days, up to 4 doses. Doses from 1x10^8 cfu to 1x10^10 cfu.
1800114|NCT00585897|Behavioral|discontinuation of sugar sweetened beverages|Individual sessions which utilize motivational interviewing to assist participants to eliminate sugar sweetened beverages from their diet.
1800115|NCT00585910|Drug|Atomoxetine and OROS Methylphenidate|Subjects must have at least attempted to tolerate a dose of 1.2 mg/kg of atomoxetine. If tolerated, they must remain on this dose for at least two weeks. OROS methylphenidate will be target dosed and titrated to a maximum dose of 54 mg.
1800116|NCT00585923|Device|Fixed hole C-Tek™ Plate|Fixed hole C-Tek™ Plate
1800117|NCT00585923|Device|Slotted hole C-Tek™ Plate|Slotted hole C-Tek™ Plate
1800118|NCT00585949|Procedure|Percutaneous Coronary Angioplasty|This is a procedure by which the blood vessels of the heart are imaged with an insertion of a catheter in the groin and blocked arteries are opened.
1800119|NCT00585962|Radiation|Proton Beam Radiation|Once a day, 5 days a week (Monday-Friday), for 8 weeks.
1800120|NCT00585975|Drug|bromfenac ophthalmic solution|sterile opthalmic solution
1800121|NCT00585988|Device|Hip Resurfacing System|This arm will utilize a hip resurfacing system.
1800122|NCT00585988|Device|M2a-Magnum™ Large Metal Articulation|This arm will utilize the M2a-Magnum™ implant system.
1800123|NCT00586001|Behavioral|Unified treatment|Cognitive-behavioral treatment in development for emotional disorders
1800124|NCT00586014|Procedure|High-Dose Sequential Chemotherapy followed by ASCT|Patient will receive Cyclophosphamide(4 g/m2 over 2 hours) and blood progenitor cell collection (day -49). G-CSF (10 mcg/kg/d) will be administered SQ. A six hour leukapheresis will be performed,cells will undergo CD34+ cell selection, patients will receive high dose VP-16 (Etopophos)(day -28)(2 g/m2 over 4 hours)and G-CSF (5 mcg/kg/d) will be administered SQ two days following VP-16. The an IV of sulfamethoxazole-trimethoprim 1 ampule BID for 5 days (Day -5). BCNU 500 mg/m2 IV over 2 hours (Day -4). Melphalan (Day -2) will be administered IV (200 mg/m2 over 20 minutes). The frozen peripheral blood mononuclear cells will be transfused on Day 0. Day +1: G-CSF 5 mcg/kg/d SQ for 3 days.
1800125|NCT00586040|Procedure|tissue bonding|application of rose bengal and treatment with green light
1800126|NCT00586040|Procedure|sutures|interrupted superficial sutures
1800127|NCT00586066|Drug|Memantine|Week 0: 5 mg memantine or placebo once a day (q.d.) Week 1: 5 mg memantine or placebo twice a day (b.i.d.) Week 2-3: 5 mg memantine or placebo once in the morning (q.a.m.)/10 mg once in the evening (q.p.m.) Week 4-12: 10mg Memantine or placebo b.i.d.
1800128|NCT00586066|Drug|Placebo|Inactive comparator. Placebo-matching memantine tablet.
1800129|NCT00586079|Procedure|Deep brain stimulation surgery.|Deep brain stimulation surgery.
1800130|NCT00586092|Drug|bevacizumab, ABT-510|"Stage 1 (Cohorts -1, 2, 2, 3) ABT-510: 25, 50, 50, 100 mg SC BID*, bevacizumab: 5, 5, 10, 10 mg/kg IV every 14 days*
Stage 2 (RPTD) ABT-510: X mg SC BID**, bevacizumab: Y mg/kg IV every 14 days**
Stage I is the dose escalation stage. Stage II will include an additional 20 patients (10 patients in each group) enrolled at the RPTD in two different schedules to better assess safety and biomarker correlates.
*Both agents begin on Day 1 of Cycle 1.
**At the RPTD, ½ the patients will begin ABT-510 (Dose X) on Day 1 and bevacizumab (Dose Y) on Day 15 and the other ½ of the patients will begin bevacizumab on Day 1 and ABT-510 on Day 15. This will allow for a collection of some preliminary data of wound angiogenesis effects of ABT-510 alone versus the combination and bevacizumab alone versus the combination."
1800131|NCT00586105|Drug|Sorafenib (Nexavar, BAY43-9006)|400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID)
1800132|NCT00586118|Drug|Sevoflurane|Sevoflurane sedation, 0.5-1 Vol%, continuously via syringe pump, up to 72 hours in ICU
1800133|NCT00586118|Drug|Propofol|Propofol, 1.5-3 mg/kgBW/h, continuously via syringe pump, up to 72 hours
1800134|NCT00586131|Drug|ammonium chloride or sodium citrate/citric acid|Dose dictated by changes in pH
1800135|NCT00586131|Drug|Sodium citrate/citratic acid|dictated by pH
1800136|NCT00586157|Drug|Methylphenidate Transdermal System|Medication skin patch titrated to 20mg (at 10 mg and 20 mg doses)
1800137|NCT00586157|Drug|Placebo|Placebo skin patch titrated to 20mg (at 10 mg and 20 mg doses)
1800138|NCT00586170|Device|EBI Bone Healing System|10 hours of treatment per day for up to 24 weeks
1800139|NCT00586170|Device|Placebo Device|10 hours of treatment per day for up to 24 weeks
1800140|NCT00586170|Procedure|Surgery|Open Reduction and Internal Fixation of the nonunion site
1800141|NCT00586183|Procedure|PET scan|The subject will then be positioned in the PET scanner . After optimal positioning of the left ventricle within the field of view, a transmission scan will be performed with either a germanium-68 or CT source for subsequent attenuation correction.
1800142|NCT00586196|Drug|donepezil|5 mg each day for 30 days
1800143|NCT00586196|Drug|Placebo|Encapsulated cornstarch One capsule daily for 30 days
1800144|NCT00586209|Drug|L-Glutamine|L-Glutamine at: 5 g 2X daily (17-33.3 Kg) 10 g 2x daily (33.4-66.6 Kg) 15 g 2x daily (>66.7 kg)
1800145|NCT00586209|Drug|Placebo|Placebo (75% Maltodextrin, 24.5 % Starch, 0.5% Tricalcium Phosphate) - given at the same dosage as L-glutamine
1800146|NCT00586222|Dietary Supplement|Omega-3 Fatty Acid|600 mg of eicosapentaenoic acid, 340 g of docosahexanoic acid, and 96 mg gama-linoleic acid for 12 weeks.
1800147|NCT00586222|Other|Placebo|placebo pill of the same size, color, and shape as the dietary supplement.
1800148|NCT00586261|Drug|Pioglitazone|Pioglitazone 30 mg daily for 6 months
1800149|NCT00586261|Drug|Placebo|Placebo 30 mg daily for 6 months
1800150|NCT00586261|Drug|Nitroglycerin|0.4 mg sublingual nitroglycerin tablet was given to all patients without a contraindication to check the brachial reactivity.
1800151|NCT00586274|Procedure|CD34 selected haploidentical PBSCT|Infusion of CD34 selected haploidentical PBSCT
1800152|NCT00586274|Drug|Fludarabine|day -8 through day -4 Fludarabine 30 mg/m^2
1800153|NCT00586274|Biological|T cell infusion|"At least 30 days after the stem cell infusion, patients will be dosed with T cells. This study will begin with a dose of T cells known not to cause GvHD even in haploidentical recipients, even when the T cells administered have not first been allodepleted. Dose escalation will follow a traditional up and down method, but as results become available they will be used to determine subsequent dose levels by the continual reassessment method. Initially, 2 patients will be entered beginning at dose level 1. Each and every patient will receive up to three additional injections of T cells at the same dose, at monthly intervals, provided there is no evidence of grade 2 or higher GVHD, until total T cell numbers are > 1000/ul.
Dose level -1 (1 x 10^3 T cells/Kg); Dose level 1 (1 x 10^4 T cells/Kg); Dose level 2 (1 x 10^5 T cells/Kg); Dose level 3 (1 x 10^6 T cells/Kg); Dose level 4 (5 x 10^6 T cells/Kg)"
1800154|NCT00586274|Biological|Campath 1h|10 mg iv over 4 hours day-8 through day-6
1800155|NCT00586274|Biological|anti-CD45|anti-CD45 400 ug/kg over 6 hours day -5 through day -2
1800156|NCT00586287|Other|Algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm A published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
1800157|NCT00586287|Other|algorithm for phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according algorithm B published in (Good AC, Henz S. A clinical algorithm to predict the loading dose of phenprocoumon. Thromb Res. 2007;120(6):921-5.)
1800158|NCT00586287|Drug|Phenprocoumon|Dosing of phenprocoumon for days 1 to 3, measuring INR and adjust dose according to the discretion of the treating physician
1800159|NCT00586300|Other|Physical training program|The physical training will be completed in two phases. In Phase 1, which will last 9 months, participants will complete the program under the supervision of an experienced trainer. Sessions will occur three times each week in a designated study facility. The program will include the following components: stretching and balance, flexibility and range of motion, muscle strengthening, and aerobics. The program will also emphasize the importance of individualizing exercise regimens according to each person's specific needs (function and fitness). In Phase 2, the primary objective will be to promote long-term exercise (for up to 24 months from the time of study entry) that incorporates the four modalities of exercise instruction introduced in Phase 1, but on an independent basis.
1800160|NCT00586300|Behavioral|Self-management training program|The self-management training program is designed to target primarily coping skills and self-efficacy. This will be accomplished by using a variety of educational and behavioral methods. The program will be delivered in two phases. The initial 9-month phase will consist of 12 weekly 60-minute classroom sessions, followed by 24 weeks of a structured telephone intervention program. Phase 2 will continue to incorporate the telephone intervention program, at less frequent intervals, for up to 24 months from the time of study entry.
1800161|NCT00586300|Other|Physical training and self-management training programs|"This multidimensional intervention will combine both the physical training and self-management training programs described for Groups 1 and 2."
1800162|NCT00586313|Device|Tru-cut biopsy|Tru-cut biopsy may be an alternative to percutaneous and transjugular liver biopsy.
1800163|NCT00586313|Procedure|Tru-cut|Tru-cut may be an alternative to percutaneous and transjugular liver biopsy.
1800164|NCT00586326|Device|MammoSite Radiation Therapy System|The MammoSite is a balloon catheter that is designed to position a radioactive source inside the lumpectomy cavity. The MammoSite applicator is inserted into the cavity created by the tumor removal surgery. The MammoSite applicator is then inflated and expands to fill the cavity.
1800167|NCT00586352|Other|stable isotope infusions|Subjects receive stable isotope infusions through an IV for about 3 hours. The dosage is based on weight.
1800168|NCT00586365|Drug|Naproxen|500 mg Naproxen twice a day for two weeks
1800169|NCT00586378|Device|Ovatio DR and Ovatio VR|implantable cardioverter defibrillator
1800170|NCT00586391|Genetic|CD19CAR-28-zeta T cells|"Intravenous injection
Dose Level 1:
CD19CAR-28zeta - 2x10^7 cells/m^2
Dose Level 2:
CD19CAR-28zeta - 1 x10^8 cells/m^2
Dose Level 3:
CD19CAR-28zeta - 2x10^8 cells/m^2"
1800171|NCT00586391|Drug|Ipilimumab|For patients with intermediate or low grade leukemia/lymphoma, patients may receive ipilimumab once during the week 2 visit after the T cell infusion.
1800172|NCT00586417|Other|punch biopsy|skin biopsies
1800173|NCT00586430|Drug|lorazepam|single 2 mg dose of lorazepam
1800174|NCT00586430|Drug|placebo|single dose of placebo
1800175|NCT00586443|Drug|bevacizumab, everolimus, panitumumab|"Cohort # subjects Bevacizumab Everolimus Panitumumab
3 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 3.6 mg/kg IV Q2 weeks
2 3-6 5 mg/kg IV Q2 weeks 5 mg PO QoD 4.8 mg/kg IV Q2 weeks
1 3-6 10 mg/kg IV Q2 weeks 5 mg PO QD 4.8 mg/kg IV Q2 weeks
3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 4.8 mg/kg IV Q2 weeks
3-6 10 mg/kg IV Q2 weeks 10 mg PO QD 6 mg/kg IV Q2 weeks 3a 10 RPTD* RPTD* RPTD* 3b 10 RPTD** RPTD** RPTD**
Panitumumab and RAD001 started on Day 1, bevacizumab started on Day 15. **Bevacizumab and RAD001 started on Day 1, panitumumab started on Day 15."
1800176|NCT00586469|Biological|Fluviral|One dose, Intramuscular injection
1800177|NCT00586482|Drug|Nicotine Lozenge|Nicotine lozenges, 2 or 4 mg, taken without restriction by mouth from 7 pm the evening before surgery until surgical admission the next day and a 2 minute behavioral intervention. Dosed according to time to first morning cigarette; if within 30 minutes of awakening, 4 mg lozenge used. If first cigarette smoked greater than 30 minutes of awakening, 2 mg lozenge used.
1800178|NCT00586482|Drug|Placebo Lozenge|Placebo lozenges, matching in appearance the 2 and 4 mg active nicotine lozenges, taken by mouth without restriction from 7 pm the night before surgery to the time of surgical admission the next day and a 2 minute behavioral intervention.
1800179|NCT00586482|Behavioral|Abstinence Advisement|A brief (approximately 2 minute) behavioral intervention advising abstinence from smoking after 7 pm the night before surgery, the potential benefits of abstinence and to use a lozenge at usual smoking times.
1800180|NCT00586495|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 200 mg tablets (400 mg [2 x 200 mg tablets] twice daily [bid] or 400 mg once daily [od] or 400 mg every other day [qod]) administered orally
1800181|NCT00586508|Drug|enzastaurin|1125 mg loading dose then 500 or 875 mg, oral, daily, 4 week cycles with patients evaluated after each cycle. The dose difference is for patients who are on enzyme-inducing antiepileptic drugs versus non-enzyme inducing antiepileptic drugs.
1800182|NCT00586508|Drug|bevacizumab|10mg/kg, IV, every 2 weeks, patients are evaluated after each cycle
1800183|NCT00586521|Drug|Kogenate (BAY14-2222)|One group two treatment schedules, first on-demand then switch to prophylaxis
1800184|NCT00586534|Behavioral|I/GDC + VR/CER|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment plus virtual reality (VR) based cue exposure/extinction software and cellular phone-based computerized extinction reminder (CER) technology for use in high-risk situations outside treatment sessions.
1800185|NCT00586534|Behavioral|I/GDC|NIDA approved Individual/Group Drug Counseling (I/GDC) cocaine treatment
1800186|NCT00586547|Drug|Ara-C|"Day -8,-7,-6, and-5:
(3g/m2) IV every 12 hours for 6 doses"
1800187|NCT00586547|Drug|Cyclophosphamide|"Days -7 and -6:
Intravenous 45mg/kg"
1800188|NCT00586547|Drug|Mesna|(45mg/kg, divided into 5 doses) administered 15 minutes prior to each dose of cyclophosphamide and 3, 6, 9 and 12 hours after each dose of cyclophosphamide.
1800189|NCT00586547|Biological|Campath 1H|"Days -3,-2, and -1:
Intravenous, according to age and weight."
1800190|NCT00586547|Radiation|TBI|"Days -4,-3,-2, and-1:
Total dose 14.0 Gy will be delivered in 8 fractions of 1.75 Gy in two fractions. The dose rate will be 10cGy/min."
1800191|NCT00586547|Procedure|Stem Cells Infusion|once
1800192|NCT00586547|Procedure|T-cell Infusion|"30 Days after stem cell infusion
Patients will be entered starting at level 1, according to the following doses:
Dose level -1 (1 x 10^3 T cells/Kg); Dose level 1 (1 x 10^4 T cells/Kg); Dose level 2 (1 x 10^5 T cells/Kg); Dose level 3 (1 x 10^6 T cells/Kg); Dose level 4 (5 x 10^6 T cells/Kg)."
1800193|NCT00586560|Drug|Kareniticin and cyclophosphamide|"An accelerated titration dose escalation design will be used in this study. Dose escalation will function independently for each stratum. Patients in both strata will receive Karenitecin and cyclophosphamide administered as an IV infusion each day for 5 consecutive days. In addition, patients in Stratum 1 will receive prophylactic G-CSF starting 24 hours after completion of the fifth dose of Karenitecin and cyclophosphamide (and continuing daily until the ANC is over 1500/mm3 after nadir). The regimen will be repeated every 21 days (1 treatment cycle).
Treatment may continue for up to 20 cycles, provided there is continued evidence of clinical benefit and absence of unacceptable toxicity."
1800194|NCT00586573|Drug|memantine hydrochloride|tablet, 5-20 mg, twice daily, by mouth, 12 weeks
1800195|NCT00586586|Behavioral|Cognitive behavioural therapy|The FRIENDS program developed by Paula Barrett, 10 weekly sessions of 60-90 minutes, with two additional parent meetings, and booster sessions 4 and 12 weeks after treatment.
1800196|NCT00586599|Other|measurement of inflammatory markers|measuring inflammatory markers and comparing to controls.
1800197|NCT00586612|Biological|Menitorix™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
1800198|NCT00586612|Biological|Infanrix™ penta|Intramuscular injection, 3 doses in the primary study
1800199|NCT00586612|Biological|Prevenar™|Intramuscular injection, 3 doses in the primary study and 1 dose in the Booster study.
1800200|NCT00586612|Biological|Infanrix™ IPV|Intramuscular injection, 1 dose in the Booster study.
1800201|NCT00586625|Drug|Bepreve|One drop, both eyes, twice a day
1800202|NCT00586625|Drug|Placebo|One drop, both eyes, twice a day
1800203|NCT00586638|Behavioral|Video game based training|36 one-hour sessions over 12 weeks
1800204|NCT00586651|Drug|lestaurtinib|60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration
1800205|NCT00586664|Drug|Bepreve (bepotastine besilate ophthalmic solution) 1.5%|sterile ophthalmic solution
1800206|NCT00586664|Drug|placebo comparator|sterile ophthalmic solution
1800207|NCT00586664|Drug|Bepotastine Besilate Ophthalmic Solution 1.0%|sterile ophthalmic solution
1800208|NCT00586677|Behavioral|Parent-Child Interaction Therapy|Sixteen one hour sessions done in-home for children ages 2-7. Proceed through protocol based on mastery of predefined skills.
1800209|NCT00586677|Behavioral|Health and Safety|Sixteen one hour sessions for children age 0-7 conducted in the home. Participants are quizzed on material to determine mastery.
1800210|NCT00586677|Behavioral|Early Relationships|Sixteen one-hour sessions for children age 0-2 provided in-home.
1800211|NCT00586690|Device|NK Cell infusion using CD56 monoclonal antibody|The cells from leukapheresis will be natural killer (NK) cell selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II acute graft versus host disease (aGVHD) at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
1800212|NCT00586690|Procedure|Donor Apheresis|Apheresis repeated daily up to 3 days until target dose of cells reached (preferably without donor receiving growth factors). Cells were transfused immediately after collection and processing. If collections occurred during initial mobilization at the time of stem cell transplant, the donor was off growth factor for >24 hours. These extra cell collections from the donor were sufficient for the natural killer cells used in the trial. The cells were NK selected using a CD56 antibody (CliniMACS CD56 Reagent), CliniMACSplus instrument and CliniMACS tubing set provided by Miltenyi Biotec using the company protocol (Miltenyi Biotec Inc, Auburn, California). Pre and post processing cell count, viability, Hematopoietic Progenitor Cell Assay (HPCA) and flow analysis were done.
1800322|NCT00587730|Device|GE Attenuation Corrected Hawkeye Camera|GE Hawkeye AC system and 360˚ camera orbit
1800213|NCT00586703|Device|NK-CD56|NK Cell infusion using CD56 monoclonal antibody following nonmyeloablative SCT from mismatched donors: The cells from leukapheresis will be NK selected using a CD56 antibody and a cell column system provided by Miltenyi Biotec. The target cell dose for each NK cell infusion will be up to 1 X 10(7) CD56+ cells/kg patient weight with less than 0.5 X 10(6) CD3+ cells/kg patient weight. The first NK cell infusion will be administered 6 weeks post transplant in patients who have ≤ grade II aGVHD at the time of infusion. Patients will be evaluated for toxicity and response until 20 weeks after the last NK Infusion.
1800214|NCT00586716|Drug|intravenous immune globulin|0.5-2 gm/kg monthly (maximum dose of 140 gm/dose) x 4 treatments
1800215|NCT00586729|Device|Vashe|Antimicrobial irrigant
1800216|NCT00586729|Drug|Mafenide acetate|Antimicrobial solution
1800217|NCT00586742|Procedure|labral repair|labral repair with suture anchors
1800218|NCT00586742|Procedure|biceps tenodesis|biceps tenodesis with suture anchor
1800219|NCT00586742|Procedure|diagnostic arthroscopy|diagnostic arthroscopy
1800220|NCT00586755|Procedure|Intensive Induction-BMT|Patients will undergo an induction regimen consisting of 1 cycle of cytarabine (3 gm/m2 intravenously over 1 hour every 12 hours for 8 total doses) and mitoxantrone (10 mg/m2/d intravenously over 30 minutes daily on days 1, 2, and 3). This will be combined with Alemtuzumab (anti-CD52 antibody) for 6-8 weeks. If, after this one cycle, subjects have not had progression of disease as noted on physical exam or radiographic scans, they will proceed to stem cell mobilization with cyclophosphamide. This will be immediately followed by high dose therapy with stem cell support. Following count recovery, rituximab will be used for 8 total doses as consolidation therapy. Involved field irradiation may be given post-transplant to those with localized bulky disease as well.
1800221|NCT00586781|Device|Scandinavian Total Ankle Replacement (STAR)|The device has three parts: two metal bearing surfaces (cobalt-chromium alloy) plates with bars that fit into the bone and one plastic (polyethylene) spacer that moves between the metal plates like a ball bearing. The materials in the S.T.A.R. device are the same materials used in total hip and knee implants.
1800222|NCT00586794|Drug|Sildenafil|3x per day 20 mg TID
1800223|NCT00586794|Drug|Placebo|3x per day, 20 mg TID
1800224|NCT00586807|Other|Stable amino acid isotopes|Stable amino acid isotopes given per IV, dose based on weight and given over the length of the study visit.
1800225|NCT00586820|Drug|BQ-123|BQ-123 is a cyclic peptide consisting of five amino acids. BQ-123 will be infused at 300 nmol/min for 20 minutes prior to percutaneous coronary intervention (PCI).
1800226|NCT00586820|Drug|Placebo|Subjects randomized to the placebo arm will receive a placebo infusion (saline) for 20 minutes prior to PCI.
1800227|NCT00586833|Procedure|O2 consumption max bike test|Single visit exercise study
1800228|NCT00586846|Drug|Cisplatin|Cisplatin 120 mg/m^2
1800229|NCT00586846|Drug|Doxorubicin|75mg/m^2
1800230|NCT00586846|Drug|Methotrexate|Methotrexate 12g/m^2
1800231|NCT00586859|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument. Additional sutures were placed in the same manner described above, with each additional implant placed incrementally closer to the GE junction in a linear configuration along the anterior gastric cardia. All plications were placed de novo, and re-treatment was not permitted.
1800232|NCT00586885|Drug|L-alanine|6g of L-alanine (powder)once per day for the first month, twice per day for the second month, then three times per day from the third month for 10 months.
1800233|NCT00586898|Drug|GnRH|leuprolide and goserelin are gonadotropin-releasing hormone analogues
1800234|NCT00586898|Drug|Ketoconazole|An imidazole antifungal agent. reduces adrenal and testicular androgen production in men
1800235|NCT00586898|Drug|Bicalutamide|A pure nonsteroidal antiandrogen
1800236|NCT00586898|Drug|Testosterone transdermal gel|an androgenic anabolic steroid
1800237|NCT00586898|Drug|Estrogen transdermal patch|Estradiol is the primary and most potent estrogen
1800238|NCT00586911|Drug|Cystadane|Betaine 20 mg a day or identical placebo for 1 year.
1800239|NCT00586911|Drug|Identical Placebo|Placebo
1800241|NCT00586937|Behavioral|questionnaires or telephone interview|In the first phase, a random sample of lung cancer survivors will complete a comprehensive telephone interview or questionnaire by self-report focusing on assessment of quality of life and related covariates. We estimate the total time for completion of the survey by telephone interview or self-report to be 45-60 minutes. second phase of the study, a subset of telephone survey participants will take part in a focus group discussion that will explore their perceptions of barriers for delivery of post-treatment medical and psychosocial follow-up care.
1800242|NCT00586976|Drug|Ropivacaine|0.3% ropivacaine infusion at 4 ml/hr for 64 hours.
1800243|NCT00586976|Drug|Normal saline|Normal saline infusion at 4 ml/hour for 64 hours.
1800244|NCT00586989|Procedure|Upper endoscopy with biopsy|Endoscopy with biopsy 6 weeks after the initial endoscopy
1800245|NCT00587002|Procedure|IVUS|Intravascular ultrasound with virtual histology
1800246|NCT00587015|Drug|CAT-8015|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60…μg/kg until toxicity supervenes.
1800247|NCT00587041|Dietary Supplement|Oxadrop|Oxadrop 1 packet daily plus 1 placebo capsule twice daily. Each gram of Oxadrop® contains 2x1011 bacteria (L. acidophilus, L. brevis, S. thermophilus, and B. infantis).
1800248|NCT00587041|Dietary Supplement|Agri-King Synbiotic (AKSB)|AKSB 1 capsule twice daily plus 1 placebo packet daily. AKSB contains Fructo-oligosaccharide; Enterococcus faecium (SF68); Saccharomyces cerevisiae subspecies Boulardi; and Saccharomyces cerevisiae
1800249|NCT00587041|Other|Placebo|1 placebo packet daily and 1 placebo capsule twice daily
1800472|NCT00588406|Drug|albuterol|2.5mg/dose by nebulizer, 7 doses over 6 hours
1800250|NCT00587054|Drug|cytoreductive regimen followed by a CD34+E- selected allogeneic stem cell transplant|"Myeloablative and will consist of hyperfractionated TBI - 1375 cGy administered in 11 doses of 125 cGy each over a total of four days, with three doses on three days and two doses on the last day, fludarabine 25 mg/m2 IV x 5 days, and thiotepa 5mg/kg IV x 2 days. Recipients of HLA identical related transplants will not receive ATG to promote engraftment. Recipients of HLA mismatched related or unrelated stem cells will receive ATG for two days prior to the transplant. G-CSF mobilized CD34+E- PBSCs obtained from the HLA compatible donor will be infused on day 0. Post transplantation G-CSF will be administered only if clinically indicated and should begin on or after d+7.
Patients will be clinically evaluated at each clinic visit for incidence and severity of acute and chronic GVHD and transplant associated morbidity. Sequential evaluation of functional reconstitution of hematopoiesis and immunity will be made as per the BMT Service guidelines."
1800251|NCT00587067|Drug|FLOXURIDINE|"[0.16* mg/kg/day X 30 ml] / pump flow rate
* If the patient is >25% above ideal body weight, the dose of FUDR will be calculated from an average of the patients actual and ideal body weights. For example, for a patient who is 5ft. 10 inches and weighs 100kg: Ideal Body Weight (kg) = 50 + (2.3 X height in inches over 5 feet) = 50 + (2.3 X 10) = 73 Weight Used for dose calculation = (100 + 73)/2 = 86.5 Therefore, FUDR Dose will be = (0.16 X 86.5 X 30)/Flow Rate If no dose modification due to toxicity is required, the dosages given above (adjusted for changes in weight and pump flow rate) will be repeated on Day 1 of Week 1 of Cycle 2 and all subsequent cycles."
1800252|NCT00587093|Other|CA 125 and CT scan|Within 14 days prior to surgery serum for CA125 will be obtained. The patient will also undergo a CT scan of the abdomen and pelvis with oral and intravenous contrast within 35 days prior to the procedure.
1800253|NCT00587119|Drug|Budesonide|Oral Budesonide, 3 mg three times daily, will be given for 1 year.
1800254|NCT00587132|Drug|Synthetic Human Secretin|0.2mcg/kg one time dose.
1800255|NCT00587145|Drug|S-1,Docetaxel|"S-1 80 mg/m2/day every 12-h p.o. on days 1(evening)-15 (morning)
Docetaxel 35 mg/m2 mixed in d5w 250 ml iv over 60-min on days 1 and 8"
1800256|NCT00587158|Drug|Paricalcitol|Zemplar® - this medicine, which is the medicine being studied, will be given as a capsule containing 1 microgram of Zemplar® once daily beginning the day after the transplant. It will be continued at the same dose for the first two weeks then, depending on the results of blood and urine testing, will be increased to 2 micrograms daily. The dose will remain at 2 micrograms daily until the end of the study unless there is a medical reason to reduce or stop it or unless the study is stopped early.
1800257|NCT00587158|Other|Corticosteroid Avoidance Immune Suppression Protocol|Induction with Alemtuzumab and maintenance with Tacrolimus and Mycophenolate Mofetil. With standard antimicrobial prophylaxis and calcium supplementation.
1800258|NCT00587171|Device|Patching|2 hours daily patching
1800259|NCT00587171|Procedure|Near activities|30 minutes daily near activities at home
1800260|NCT00587171|Procedure|Active vision therapy|30 minutes of daily at-home active vision therapy and a weekly 45 minute in-office active vision therapy session
1800261|NCT00587171|Procedure|Control vision therapy|30 minutes of daily at-home control vision therapy and a weekly 45 minute in-office control vision therapy session
1800262|NCT00587223|Device|Apligraf|Up to 3 applications: Day 0, Month 1, Month 2.
1800263|NCT00587223|Other|Standard dressing regimen|Dressing regimen will be comprised of a primary nonadherent dressing, nonstick gauze and standard dressing retainer
1800264|NCT00587249|Biological|Malaria ICC-1132|ICC-1132, a candidate malaria vaccine, with alhydrogel will be in 2 ml glass vials containing ICC-1132 at either 40 mcg/ml or 100 mcg/ml concentration formulated with alhydrogel at 1mg/ml. Each vial will contain approximately 0.8 ml solution to permit recovery of 0.5 ml for injection. When shaken, the solution is off-white to greyish-white turbid liquid free of foreign particulate matter.
1800265|NCT00587249|Biological|Alhydrogel|Aluminum hydroxide gel.
1800266|NCT00587275|Drug|AST-120|Oral, sachet, 2 grams daily for 4 weeks
1800267|NCT00587275|Drug|Celphere CP-305|Oral, sachet, 2 grams daily for 4 weeks
1800268|NCT00587288|Biological|Reslizumab|
1800269|NCT00587288|Other|Saline|
1800270|NCT00587301|Device|Lap-Band|Obesity and adolescents
1800271|NCT00587314|Other|Biopsy|Biopsies for research purposes will be obtained when returning for clinically indicated surveillance of Barrett's Esophagus
1800272|NCT00587327|Drug|Barusiban|Solution for IV treatment. Bolus and infusion for 4 hours
1800273|NCT00587327|Drug|Atosiban|Solution for IV administration. Bolus and infusion for 4 hours
1800274|NCT00587327|Drug|Placebo|Saline solution for IV administration. Bolus and infusion for 4 hours.
1800275|NCT00587353|Other|Behavioral and pharmacologic tobacco use intervention|A novel approach to providing an intervention for tobacco users who are receiving radiation therapy is to provide an individual tobacco use intervention that utilizes concepts of motivational interviewing strategies to facilitate self-exploration of the reasons for continued smoking and a treatment plan that is comprehensive and builds self-efficacy, provides one-on-one counseling, and includes tobacco treatment pharmacotherapies. The pharmacotherapies will be tailored to the patients needs. One could utilize varenicline, bupropion, and/or nicotine replacement therapies.
1800276|NCT00587379|Drug|Atorvastatin|40 mg atorvastatin pill daily
1800277|NCT00587379|Drug|placebo|40 mg pill per day
1800278|NCT00587392|Device|NDO Full-thickness Plicator|The NDO Full-thickness Plicator intervention was performed as part of the original open-label Plicator study as previously reported. This intervention did not take place as part of this long-term follow-up data collection study.
1800279|NCT00587405|Procedure|cryotherapy|"The Polar Wand device (GI Supply, Wayne, PA) is FDA 510(k) approved for endoscopic tissue ablation in the GI tract. It consists of a portable cryogen-containing unit and a single-use flexible cryogen spray catheter, designed for use with CO2 that is supplied in standard 20-lb cylinders. Controlled delivery of the cryogen is achieved by a foot pedal, and the tip of the catheter is maintained at about 1 cm from the mucosa. A cryogenic spray is applied to all vascular lesions until a whitened appearance of the mucosa is achieved within 3-5 seconds. Affected areas will be 'painted' by the spray catheter starting at the pylorus and sweeping proximally.
A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy."
1800323|NCT00587756|Procedure|One-stage ultrasound guided hepatectomy|Surgical strategy was based on tumor-vessel relationship at intraoperative ultrasonography (IOUS)and on findings at color-Doppler IOUS.
1800280|NCT00587405|Procedure|Argon Plasma Coagulation|As per current clinical standard, the APC 300 device (ERBE Inc., Marietta, GA) will be used in this study. Targeted ablation of all vascular ectasias as best possible will be performed in standard fashion using an end-firing probe at a setting of 60 W and 2 L/min argon flow rate.A proton pump inhibitor, at double dose, will be prescribed for 1 month after each APC or cryotherapy session to promote mucosal healing post therapy
1800281|NCT00587418|Dietary Supplement|L-arginine|Arginaid (Novartis) 1 package (9.2g) bid for 7 days
1800282|NCT00587418|Dietary Supplement|Placebo|Placebo powder 9.2g bid for 7 days
1800283|NCT00587431|Drug|GnRh (Leuprolide)|Leuprolide LUPRON
1800284|NCT00587431|Drug|Testosterone Gel|Starting during week 3 (day 19) of cycle 1, 7.5G applied topically daily for 3 days (applied at approximately 9p)
1800285|NCT00587431|Drug|Docetaxel|70 mg/m2 given on day o1 of each 3 week cycle
1800286|NCT00587444|Drug|Heparin|300u/kg of heparin for CPB ACT performed. If ACT is < 480 seconds a bolus of 5000u heparin will be given. ACT will be repeated and bolus given until ACT is>480 seconds
1800287|NCT00587444|Drug|HH or high heparin|initial dose of 450u/kg for CPB ACT performed additional bolus given if result is <600 seconds anytime during CPB
1800288|NCT00587444|Drug|heparin concentration HC|"will have anticoagulation during CPB assessed with heparin concentration monitoring and heparin dose response (HDR) to determine the optimal dosage of heparin. This group will evaluate the possible benefit of the HDR to determine heparin dosing and monitoring to achieve maximal suppression of thrombin compared to a fixed dose of heparin as the other two groups. Additional heparin doses will be given to maintain a specific heparin concentration according to the HDR. This is a recognized way of managing heparin dosing and anticoagulation for CPB.
All three groups will have heparin neutralized by protamine. Adequacy of heparin neutralization will be based on a difference between the ACT and heparinase-treated ACT values of less than 10%"
1800289|NCT00587457|Drug|CAT-8015 5 mcg/kg|Participants received a single intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
1800290|NCT00587457|Drug|CAT-8015 10 mcg/kg|Participants received a single intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
1800291|NCT00587457|Drug|CAT-8015 20 mcg/kg|Participants received a single intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) on Days 1, 3, and 5 of every 28-day cycle and continued cycles of therapy until progressive disease (PD) or until otherwise they become ineligible.
1800292|NCT00587470|Drug|Candesartan|Maximum vasodilation.
1800293|NCT00587470|Drug|atacand|maximum vasodilation
1800294|NCT00587470|Drug|Placebo|Placebo
1800295|NCT00587483|Drug|Lidocaine|Lidocaine is a class I (sodium channel block) antiarrhythmic drug
1800296|NCT00587483|Drug|Amiodarone|300 mg
1800297|NCT00587483|Drug|Placebo|Saline
1800298|NCT00587496|Drug|valacyclovir hydrochloride|500 mg capsule, one per day for 30 days
1800299|NCT00587496|Drug|placebo|lactose placebo capsule, six per day for 30 days
1800300|NCT00587496|Drug|valacyclovir plus aspirin|500 mg valacyclovir capsule, one per day for 30 days 325 mg acetyl salicylic acid (aspirin) capsule, three per day for 30 days placebo capsule, two per day for 30 days
1800301|NCT00587522|Device|NDO Full-thickness Plicator|The Plicator and gastroscope assembly were passed into the stomach. The stomach was distended with air. The gastroscope was advanced and retroflexed so that the instrument could be visualized and accurately positioned. The Plicator was retroflexed to within 1cm below the GE junction, and the helical tissue retractor was advanced deeply into the gastric wall. The gastric wall was retracted into the Plicator instrument arms. The arms were then closed, and the suture-implant was deployed to secure the full-thickness plication. The tissue retractor is then disengaged and the suture-implant released from the instrument.
1800302|NCT00587548|Other|Localizing the ureters during surgery|One-time injection 4.5mCi of 99mTechnetium labeled diethylene-triamine-penta acetate (DTPA) prior to the time of ureteral localization. The Neoprobe 2000 gamma probe will be utilized for ureter location.
1800303|NCT00587561|Behavioral|Social Cognition Interaction Training|manualized group therapy
1800304|NCT00587561|Behavioral|WLC|wait-list control for 6 months, followed by the experimental group therapy
1800305|NCT00587587|Device|Apligraf|Application at Day 0, potential re-application at Week 4
1800306|NCT00587587|Other|Standard dressing regimen|A primary nonadherent dressing, dry gauze dressing and bolster gauze dressing if necessary
1800307|NCT00587600|Procedure|Photodynamic therapy|Photofrin 2mg/kg Photoradiation The light dose delivered will be a total of 200 joules per centimeter fiber which has previously been shown to ablate Barrett's mucosa.
1800308|NCT00587600|Procedure|radiofrequency ablation of barrett's esophagus|radiofrequency ablation
1800309|NCT00587626|Device|Inactive InterX 5000|Patients will receive will receive InterX placebo treatment 3 times a week for 4 weeks.
1800310|NCT00587626|Device|InterX 5000 Treatment|Patients will receive will receive InterX treatment 3 times a week for 4 weeks.
1800311|NCT00587639|Device|rTMS Treatment|Active rTMS treatment.
1800312|NCT00587665|Drug|ketamine|Single IV dose of 0.1 mg/kg of ketamine
1800313|NCT00587665|Drug|Placebo|Saline given of equal volume to drug
1800314|NCT00587678|Drug|Simvastatin|40mg each night
1800315|NCT00587678|Drug|Ezetimibe|10mg daily
1800316|NCT00587678|Drug|Simvastatin/Ezetimibe|40mg/10mg each night
1800317|NCT00587691|Biological|Tovaxin Autologous T Cell Vaccine|"Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.
Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.
Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods."
1800318|NCT00587704|Procedure|PVB using nerve stimulation|5ml of 1% ropivacaine injected incrementally
1800319|NCT00587704|Procedure|PVB using anatomic landmarks|5ml of 1% ropivacaine injected incrementally
1800320|NCT00587717|Drug|simvastatin|Two 80 mg pills simvastatin taken 24 hours prior to surgery
1800321|NCT00587717|Drug|placebo|take 2 80 mg pills placebo 24 hours prior to surgery
1800473|NCT00588406|Drug|Ipratropium bromide|2.5 mg, one dose
1800324|NCT00587769|Drug|Bupropion SR & Varenicline|"Bupropion SR 150 mg by mouth once day for 3 days then 150 mg by mouth twice per day.
Varenicline 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment."
1800325|NCT00587795|Device|StabilAir Wrist Brace|Patient will be placed in a StabilAir Wrist Brace 10-14 days after initial injury and return for follow up visits at 6 weeks; 3, 6, 12 and 24 months.
1800326|NCT00587795|Other|Placement of sugar tong splint or plaster cast|Patients will receive a sugar tong splint or plaster cast for their wrist fracture. They will return for x-rays and an exam at 6 weeks; 3, 6, 12 and 24 months.
1800327|NCT00587808|Procedure|RHC with VO2 consumption|All pressure-volume data is acquired at 250 Hz and stored on the Leycom system for offline analysis. Volume data will be calibrated using the most recent EF from echocardiogram and stroke volume from the Fick method. Measured O2 consumption will be utilized along with sampling of SVC and arterial blood oximetry to determine cardiac output at rest and during exercise
1800328|NCT00587821|Other|Blood draw|Peptide profiles from blood samples of all subjects will be determined by mass spectrometric analysis.
1800329|NCT00587834|Device|Gintuit|Application of Gintuit at Day 0 to the gingival bed
1800330|NCT00587834|Other|Autologous palatal tissue|Tissue will be harvested from the subject's palate and placed on the gingival bed
1800331|NCT00587847|Drug|Campath|Campath 30 mg administered subcutaneously at varying intervals for up to 1 year
1800332|NCT00587860|Drug|St. John's wort|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
1800333|NCT00587860|Drug|Placebo|Dosage form: Tablet (450 mg) Dose: 450 mg twice a day, placebo twice a day
1800334|NCT00587873|Drug|Methotrexate|MTX 6mg/m2 given IV bolus, followed by 24mg/m2 given in 24hrs continuous infusion
1800335|NCT00587873|Drug|Leucovorin calcium|5 mg orally at 12 hours after the end of MTX infusion then every 12 hrs for a total of 3 doses.
1800336|NCT00587873|Drug|6-Thioguanine|6-TG 300 mg/m2 PO as a single oral dose
1800337|NCT00587886|Behavioral|Questionnaire|The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
1800338|NCT00587886|Behavioral|Questionnaire|"The main questionnaire will cover established risk and protective factors for endometrial and ovarian cancer, as well as other possible risk factors. This includes: menstrual history; pregnancy history; use of hormones for menopausal symptoms or other reasons; smoking history; height and weight; use of oral contraceptives and other methods of birth control; family history of cancer; medical history; demographic characteristics. We will also collect dietary data using the Gladys Block questionnaire, to which we have added a supplement to measure consumption of phytoestrogens. We will also obtain a buccal sample from each respondent as the source of DNA for genetic analysis.
We will conduct interviews mainly by telephone but also in person (at home or another convenient place)if the participant prefers."
1800339|NCT00587899|Procedure|Pulmonary Vein Isolation|The treatment group will undergo operation for mitral valve disease with an additional procedure called Pulmonary Vein Isolation using a device that delivers radiofrequency energy to the heart muscle in order to create scar tissue to block electrical impulses that can trigger episodes of AF.
1800340|NCT00587925|Other|Bone Mineral Density|Clinic visits twice during the first 2 years of the study with medical care directed by your treating doctor.BMD is measured by an X-ray test. The most common type of BMD testing is by energy x-ray absorptiometry (DEXA). Usually BMD is measured every other year, but to closely monitor women on this study, the BMD will be evaluated more often. The BMD will be measured 3 times (baseline, 12 months and 24 months) on this study. Study blood work is obtained three times (baseline, 6 months, and 12 months). Blood (about 3 teaspoons).
1800341|NCT00587964|Radiation|Stereotactic Radiosurgery|"All patients would undergo craniotomy and the goal of surgery in all cases would be total removal of the metastases. The patient will initially receive premedication with 0.5- 1mg of Ativan orally prior to SRS procedure. Subsequently, the patient will have the stereotactic head ring placement under local anesthesia. A peripheral IV will be placed for administration of the intravenous contrast. Thin-section CT images will be obtained with intravenous contrast with head ring in place for the purpose of treatment planning.
A fusion program will be used to combine the recently obtained MRI images along with the CT scans. The target volume as well as the critical structures will be contoured. SRS would be delivered using either the Brain Lab or Radionics Radiosurgery planning and delivery system. Patients would receive a single treatment ranging from 15-22 GY."
1800342|NCT00587990|Genetic|Lower dose mesenchymal stem cell (MSC) injection|Participants will receive between 10 and 20 intramyocardial injections of 2 million MSCs per 0.25-0.5 cubic centimeter (cc) for a total of 2 x 107 cells. The injections will be administered following completion of CABG surgery.
1800343|NCT00587990|Genetic|Placebo|Participants will receive between 10 and 20 placebo injections that consist of phosphate buffered saline (PBS) and 1% human serum albumin (HSA).
1800344|NCT00587990|Genetic|Higher dose MSC injection|Participants will receive between 10 and 20 intramyocardial injections of 20 million MSCs per 0.25-0.5 cc for a total of 2 x 108 cells. The injections will be administered following completion of CABG surgery.
1800345|NCT00588003|Drug|anastrozole|anastrozole 1mg/day 11 days before their surgery and to take the last dose of the oral endocrine agent (anastrozole) on the day before their surgery.
1800346|NCT00588003|Other|Placebo|No medication before surgery
1800347|NCT00588016|Drug|Itraconazole|Topical application of Itraconazole in Sterile Water 100 mg/1000 ml, irrigating each nostril with 20 ml of solution twice daily for 7 days.
1800348|NCT00588042|Device|Blood pressure cuff|Arm ischemia will be induced using a blood pressure cuff that will be placed around the upper part of the arm, and inflated to 200 mm Hg for 3-minutes and then deflated for 3-minutes
1800349|NCT00588042|Device|blood pressure cuff|3-cycles of cuff inflation (10 mmHg)-deflation will also be performed in the control group for similar durations without inducing ischemia
1800350|NCT00588068|Other|Tumor and Marrow Markers|Tumor and Marrow Markers
1800351|NCT00588081|Behavioral|QOL|Those women who chose to have an interview will be scheduled for a 45 to 60 minute open-ended interview with a trained research assistant and sign consent at the time of the interview.
1800352|NCT00588094|Drug|Rituximab, Ifosfamide, Carboplatin, VP-16, Mesna, G-CSF, Stem Cell Transplant|"ANC must be ≥1000/µl and platelet count must be ≥50,000/µl. Rituximab will be administered at a dose of 375 mg/m2 IV on days 1 and 3 of the each cycle. Premedication will be given.ICE will be administered as follows: Day 3: Etoposide 200 mg/m2 IV q12 hrs x 3. Day 4: Ifosfamide 10 g/m2 and MESNA 10 g/m2 mixed and infused together as a continuous infusion over 48 hours. Day 5: Carboplatin IV dosed by the Calvert formula using an AUC of 5.
Carboplatin dose (mg) = 5 x (Clcr + 25) For the first ten patients enrolled, G CSF will be administered beginning on day seven of each cycle and G CSF will continue until stem cell collection is completed. The dose will be 960 ug or 10 ug/kg if weight is greater than 100 kg.
For the remaining patients, G-CSF will be administered for 10 days beginning on day 7 for cycle 1. The dose will be 300-480 ug/d. For cycle 2 the dose will be 960 ug or 10ug/kg if weight is > 100kg. Leukapheresis will continue."
1800353|NCT00588107|Other|Web Intervention|Receives pharmacotherapy and access to an interactive Web site (Web condition). The Web site will offer tailored intervention messages and strategies in an interactive format that is much less labor-intensive and costly than the prior PFH peer telephone counseling intervention.
1800354|NCT00588107|Behavioral|print materials|tailored print materials designed to aid in smoking reduction and cessation
1800355|NCT00588120|Drug|C-13 labeled oxalate|"A single prescribed dose of C-13 labeled oxalate will be given orally in capsule form or in jello. Urine will be collected for 24 hours after the dose.
Take one capsule by mouth for one day."
1800356|NCT00588133|Drug|tranexamic acid|"Loading dose: 6.6 mg/kg Prime dose: 50 mg for 2.5 Liter circuit (assuming 1 L/kg Vd in prime fluids), 40 mg for 2 Liter circuit Rate of infusion: 6 mg/kg/hr
Renal Insufficiency (normal loading dose and prime dose):
Serum Creatinine = 1.6-3.3: reduce infusion to 4.5 mg/kg/hr Serum Creatinine = 3.3-6.6: reduce infusion to 3.0 mg/kg/hr Serum Creatinine = >6.6: reduce infusion to 1.5 mg/kg/hr"
1800357|NCT00588133|Drug|tranexamic acid|10 mg/kg tranexamic acid given over 20 minutes followed by an infusion of 1 mg/kg/hr
1800358|NCT00588146|Drug|Pegylated Interferon Alpha2b|Weekly subcutaneous injection of 1 microgram/kg/week
1800359|NCT00588146|Other|Standard care|Standard care
1800360|NCT00588159|Drug|Gabapentin|gabapentin 600 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
1800361|NCT00588159|Drug|Diphenhydramine|Diphenhydramine 12.5 mg orally within 2 hours preoperatively, epidural infusion of 0.075% bupivacaine with 10 mcg/ml of hydromorphone at 6 ml/hour, fentanyl intravenous patient controlled analgesia at 10 mcg every 10 minutes as needed with a 200 mcg 4 hour lockout, oral acetaminophen 650 mg orally every 6 hours as needed for pain, intravenous ketorolac 15 mg every 6 hours as needed for pain.
1800362|NCT00588172|Drug|Metformin|1000mg bid for 1 week
1800363|NCT00588185|Drug|[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone|Registered patients will undergo PET scanning using either FDHT alone or FDG and FDHT depending on the clinical question being asked. Scans will be performed serially at baseline, week 4, week 12, and every 12 weeks of treatment up to a maximum of 8 FDHT/FDG scan set in a 12 month period (maximum 40 scan sets per lifetime) unless the therapeutic protocol or scientific rationale of the therapeutic drug being applied specifically dictates an alternative schedule. Patients may have blood drawn for the purposes of establishing the pharmacokinetics of FDHT and may also undergo an initial dynamic scan if further pharmacokinetic information is warranted, followed by a standard whole body image. If no further pharmacokinetic information is warranted, then patients will only undergo a standard whole body image.
1800364|NCT00588211|Behavioral|Interviews|45-minute individual interviews after the conclusion of their dental appointment
1800365|NCT00588211|Behavioral|focus group|A focus group of the preliminary cancer-related risk perception item pool.
1800366|NCT00588211|Behavioral|Survey|Quantitative item analysis of the final item pool.
1800367|NCT00588211|Behavioral|Survey|A second confirmatory factor analysis.
1800368|NCT00588224|Other|3D ultrasound|measurement of stomach volume by 3D ultrasound
1800369|NCT00588237|Drug|Paclitaxel,Cisplatin, Bevacizumab|IV paclitaxel, followed by IV Bevacizumab on Day 1. Bevacizumab treatment will begin cycle 2, day 1. IP cisplatin will be given on Day 2, and IP Paclitaxel on Day 8. Subjects will receive up to six cycles of therapy, or until disease progression or unacceptable toxicity.
1800370|NCT00588250|Other|EmbryoGlue|G2 culture media from Vitrolife which contains hyaluronic acid
1800371|NCT00588276|Radiation|124I-Iodo-Azomycin Galacto-Pyranoside|You will receive the radioactive tracer through an injection in your vein. Blood (about 5 tablespoons in all) will be taken after the radioactive tracer has been given. Over the course of study day 1, bloods will be drawn 8 times and then 4 more times on study day 2. You will undergo three *IAZGP PET scans, one shortly after you receive the injection, one later the same day and one the following day. Each scan will take about an hour. This means you would be asked to come back 2 days in a row.
1800372|NCT00588302|Drug|Moexipril|Moexipril was given at a starting dose of 7.5 mg daily for 1 week to all enrolled patients. If tolerated (no clinically significant hypotension or medication associated adverse event), the daily dosage was increased to 15 mg daily at the beginning of the 2nd treatment week. Patients took moexipril orally in the morning and 1 hour prior to food intake. The target dose was maintained for the 1-year period of the study unless the development of toxicities warranted dose reduction or discontinuation.
1800373|NCT00588328|Device|PET/CT scan|PET/CT scans
1800408|NCT00581971|Drug|Paclitaxel|IV 30 mg/m2, weekly for weeks 1 through 7
1800409|NCT00581971|Radiation|Radiation Therapy|70.2Gy, at 1.8Gy qd, Monday through Friday
1800410|NCT00581997|Drug|QAX576|
1800411|NCT00581997|Drug|Placebo|
1800414|NCT00582036|Drug|Regular Insulin|Use of sliding scale insulin as per Appendix 1
1800415|NCT00582036|Device|Deployment of the MiniMed Paradigm monitoring device|Automated insulin delivery system
1800474|NCT00588406|Drug|Prednisone|60mg PO
1800374|NCT00588341|Drug|Temozolomide|"At the start of the trial a core needle biopsy of a palpable tumor will be obtained percutaneously in the office after administration of local anesthesia. Patients will then be treated with TMZ according to the extended dosing schedule of 75mg/m2/day x 6 weeks every 8 weeks. After each cycle, patients will be re-evaluated for response.
Responding patients will be offered another cycle of treatment. Patients will be treated until best response, progression of disease, or 6 cycles, whichever comes first.
After completing temozolomide treatment, patients will be evaluated for surgical resection. It is expected that, unless there is progression of disease, patients will undergo resection (i.e. therapeutic lymph node dissection). In patients who have a complete clinical response to temozolomide, whether or not to do a subsequent lymph node dissection will be left up to the discretion of the surgeon and the patient."
1800375|NCT00588354|Drug|Clonidine|200 or 400 micrograms clonidine
1800376|NCT00588354|Drug|Triamcinolone hexacetonide|40 or 80 milligrams triamcinolone
1800377|NCT00588354|Drug|Lidocaine HCl|1 ml 2% lidocaine (20 mg/mL)
1800378|NCT00588367|Device|Mayo Interactive Breath Hold Monitor|Biofeedback device
1800380|NCT00581711|Other|3-Part Intervention|A combination of training, an otitis media episode grouper, and clinical decision support.
1800381|NCT00581711|Other|4-Part Intervention|A combination of clinician training, an otitis media episode grouper, clinical decision support, and feedback.
1800382|NCT00581711|Other|1-part intervention|Provision of feedback on otitis media quality indicators
1800383|NCT00581724|Behavioral|Telephone interview or self report survey.|We estimate that the completion time for the telephone interview or self-report survey will be 45-60 minutes.
1800384|NCT00581750|Other|Tissue specimen|Human tissues taken after the clinically indicated removal of these tissues from patients as part of their routine care.
1800385|NCT00581776|Drug|Bortezomib|Administered by IV at 1.3 mg/m2 days 1 and 4 of each 21 day cycle.
1800386|NCT00581776|Drug|Rituximab|Administered by IV 375 mg/m2 IV day 1 of each cycle during induction chemotherapy, then weekly for four weeks during consolidation therapy; and then once every 12 weeks for up to 5 years (or until disease progression).
1800387|NCT00581776|Drug|Cyclophosphamide|Administered by IV at 300 mg/m2, 6 doses spaced 12 hours apart on days 1-3 of each cycle, to start after completion of rituximab infusion
1800388|NCT00581776|Drug|Doxorubicin|Given as a continuous infusion, 50 mg/m2 over 48 hours days 1-2 of each cycle, to start after completion of rituximab infusion.
1800389|NCT00581776|Drug|Vincristine|1 mg administered by IV on day 3 of each cycle.
1800390|NCT00581776|Drug|Dexamethasone|40 mg orally on days 1-4 of each cycle.
1800391|NCT00581789|Drug|erlotinib, sunitinib|erlotinib 150mg PO daily + sunitinib 25mg PO daily (level 1) or 37.5mg PO daily (level 2)
1800392|NCT00581815|Device|Proton-decoupled 31P MRS at 1.5T|The study will use a dual 1H-31P surface coil pair obtained from IGG Medical Advances, Milwaukee, WI. The coil pair consists of a fixed, 12 cm square 31P resonator co-mounted with a flexible two-loop proton coil. The P.I. and colleagues have used this device for approximately 10 years with no apparent ill effects
1800393|NCT00581815|Device|1H Spectroscopy at 1.5T and 3T|The study will use surface coils manufactured by commercial vendors. The pulse sequence programs to be used will be monitored automatically by the scanner to insure that SAR limits are not exceeded.
1800394|NCT00581828|Drug|Vitamin D|50,000 IU po qd for 15 days and 50,000 IU po twice month for 10 months (until final study visit at one year)
1800395|NCT00581841|Other|Gait analysis, knee x-ray, and knee MRI|Gait analysis, knee x-rays, and knee MRIs will be done twice for each participant, 1 week apart.
1800396|NCT00581854|Drug|modified Hyper-CVAD|rituximab and modified hyperfractionated cyclophosphamide, vincristine doxorubicin, dexamethasone (hyperCVAD) administered every 28 days for 4-6 cycles followed by rituximab maintenance therapy consisting of four weekly doses every six months for two years
1800397|NCT00581867|Drug|Insulin Aspart|40IU insulin aspart applied intranasally
1800398|NCT00581867|Drug|Placebo|Placebo
1800399|NCT00581880|Behavioral|questionnaires|A battery of questionnaires concerning your thoughts, opinions, and attitudes about your illness and outlook on life. In addition, we will ask to provide some background information about you and your illness. The questions will take approximately 30 to 45 minutes to complete. You fill out the questionnaire once only.
1800401|NCT00581906|Radiation|DCE-MRI, DW-MRI and MRS|Pts undergo DCE-MRI, DW-MRI or 1^H-MRS studies on either the 1.5T scanner or the 3T MRI scanners. Patients will be grouped based on their treatment: group one will include pts who undergo surgery (we will no longer accrue pts in this group) & group two will include pts who undergo chemoradiation therapy.Pts who undergo surgery will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the GE 1.5T or 3T MRI scanner. Pts who participate in chemo-radiation therapy protocols will have pretreatment DCE-MRI, DW-MRI &/or 1H-MRS studies on the 3T Philips MRI scanner in the radiation oncology suite & will undergo additional recommended weekly DW-MRI including IVIM studies at the same MRI scanner during the course of treatment. Pts will undergo two recommended DCE-MRI studies (unless contraindicated) when possible. 1st intra-treatment DCE-MRI is recommended between the 1st & 2nd weeks of treatment & the 2nd intra-treatment DCE-MRI is recommended between the 3rd & 4th weeks of treatment.
1800402|NCT00581919|Drug|Bort, Dex, and Dox with ALCAR|Bortezomib 1.3 mg/m2 IV days 1, 4, 8, and 11 Dexamethasone 20 mg PO days 1, 4, 8, and 11 Doxorubicin 15 mg/m2 IV days 1 and 8 Acetyl-L-Carnitine (ALCAR) 1.5 g PO BID days 1-21 Maximum of 8 cycles. Each cycle is 21 days long
1800403|NCT00581945|Drug|Canakinumab|The dose of canakinumab (ACZ885) administered was individualized, based on the subject's weight pre-dose, and was administered via intravenous infusion.
1800404|NCT00581945|Drug|Placebo|Matching placebo to ACZ885 administered via intravenous infusion.
1800405|NCT00581958|Other|Blood Samples|blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
1800406|NCT00581971|Drug|celecoxib|400mg bid starting 1 week before radiotherapy and taken through radiotherapy.
1800407|NCT00581971|Drug|Carboplatin|IV, AUC 2.0, weekly for weeks 1 through 7
1800416|NCT00582062|Other|washings for experimental marker testing|During the laparoscopy, a small amount of a mild salt solution will be introduced to gently wash the inside of the abdomen. The fluid will be removed and sent to the laboratory for two analyses: 1) washings for cytology (routine), and 2) washings for experimental marker testing (experimental).
1800417|NCT00582075|Drug|temozolomide|TMZ 200mg/m2 days 1-5 repeat q28 days. Patients who have received prior chemotherapy will receive 150 mg/m2 days 1-5
1800419|NCT00582101|Behavioral|Family-Based HIV Prevention for Latinos|7-hour one-day workshop with adolescents and parents in separate and joint sessions
1800420|NCT00582101|Behavioral|General Health Promotion|7 hour one-day workshop on general health promotion topics
1800421|NCT00582114|Drug|Lisinopril|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
1800422|NCT00582114|Drug|Atenolol|Patients will be randomized into two groups, one that is beta blocker based, the other angiotensin converting enzyme (ACE) inhibitor (lisinopril) based. Patients who are on no medications will receive atenolol 25 mg. t.i.w. or lisinopril 10 mg. t.i.w. for one month at the end of which, dose will be titrated to twice the drug doses following monthly interval to another doubling of dose. If BP is still poorly controlled felodipine will be added. Other antihypertensive therapies will be added to control home BP to <140/90 mm Hg.
1800423|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 1: 100 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
1800424|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 2: 500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
1800425|NCT00582140|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (dose 3: 1,500 μg) with rhGM-CSF (200 μg); administered i.d. biweekly for 6 total doses
1800426|NCT00582166|Drug|Zevalin (Ibritumomab Tiuxetan )+ Rituximab|Subjects will receive the Zevalin(Ibritumomab Tiuxetan) therapeutic regimen; then rituximab consolidation and maintenance therapy every 3 months until disease progression
1800427|NCT00582179|Procedure|Standard Pressure Dressing|If hematoma still draining at 5 days post surgery, patients who randomize to Group A will have a standard pressure dressing applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
1800428|NCT00582179|Device|VAC|If hematoma still draining at 5 days post surgery, patients who randomize to Group B will have a VAC negative pressure device applied and checked every 24-48 hours for continued draining. If still draining at 10 days post surgery, patient is at end point of study and must return to OR for Irrigation and Debridement of the wound. If infection occurs, patient is at end point of study and must return to OR for I&D.
1800429|NCT00582192|Other|Consult visit|Your appointment with your doctor will be audio taped. The research team will listen to the tape(s) and type them up. The team will then look for patterns in the discussions between patients and doctors. They will use this information to see if the discussions can be improved.
1800430|NCT00582205|Drug|Paclitaxel, Cisplatin IP|Paclitaxel 135 mg/m2 IV (3-hr infusion) on Day 1, Cisplatin 50 mg/m2 IP on Days 1 and 8, Repeat every 3 weeks for 6 cycles
1800431|NCT00582231|Other|Questionnaires.|Questionnaires.
1800432|NCT00582244|Behavioral|CBT and relaxation|Group A: CBT and relaxation.
1800433|NCT00582244|Behavioral|Physical activity|Group B: Physical exercise program.
1800434|NCT00582244|Behavioral|CBT and physical activity|Group AB: Combined CBT and exercise program. Women assigned to Group AB will undergo the CBT and exercise elements of the program concurrently. To as great an extent as possible, the on-site CBT and in-clinic exercise training sessions will be scheduled on the same day.
1800435|NCT00582244|Other|Control group|Waiting list control group
1800436|NCT00582257|Behavioral|questionnaires|Participation in the registry will consist of adequately completing the family history questionnaire (one per family) the gastric cancer risk factor questionnaire and providing a blood sample for future correlative studies. Registry participants (both Patient/Relative and Control cohorts) will be required to submit tissue (both normal and/or tumor) to create a Tissue and DNA repository. Select participants will be invited to undergo Genetic Counseling, eg. those participants who meet clinical criteria for HDGC.
1800437|NCT00582283|Drug|I124-NM404|I-124-NM404
1800438|NCT00582296|Behavioral|questionnaires, telephone interview, optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family & personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
1800439|NCT00582296|Behavioral|questionnaires, telephone interview and optional blood drawn|Initial CGS Visit (All Prospective Participants)Clinical assessment (screening, family & personal history of CA, surgeries) 6 Month Follow-Up Phone Interview (Prospective) Follow-Up Questionnaire (prospective and retrospective) Retrospective Initial Interview Participants may also donate an additional blood, serum, saliva, urine, or stool sample for research, (in addition to the blood drawn for clinical testing) or for the sole purpose of research testing (in absence of clinical testing or prior external testing).
1800440|NCT00582309|Procedure|Glucommander-Guided Intravenous Insulin Infusion|"Glucommander-Guided Intravenous Insulin Infusion.
Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.
During the infusion, enter glucose levels into the Glucommander and follow recommendations regarding infusion rate and time to measure next blood glucose levels."
1800470|NCT00588393|Drug|FolateScan (Technetium Tc 99mEC20)|0.1 mg. of EC20 labeled with 20-25 mCi of technetium-99m followed by FolateScan
1800471|NCT00588406|Drug|Budesonide|2mg/dose by nebulizer, four doses over 3 hours
1800441|NCT00582309|Procedure|Standard Intravenous Insulin Infusion|"Standard Intravenous Insulin Infusion Standard Intravenous Insulin Infusion in the ICU setting Prepare IV Insulin Drip: 250 units of glulisine (Apidra®) insulin with 250 ml NS (1.0 unit/ml). Piggyback insulin drip into IV fluids.
Algorithm 1: Start here for most patients. Algorithm 2: For patients not controlled with Algorithm 1, or receiving glucocorticoids, or patient with diabetes receiving >80 units/day of insulin as an outpatient.
Algorithm 3: For patients not controlled on Algorithm 2.No Patients Start Here."
1800442|NCT00582309|Procedure|Simple Calculated Intravenous Insulin Infusion|If the patient was on insulin prior to this admission, 1/2 of the total insulin dose divided by 24 will be the initial insulin infusion rate. The amount of insulin given will be dependant upon blood sugar levels ( BG levels 80-120= 0.5 units/hr, 121-160=1.0 units/hr, 161-200= 2.0 units/hr, 201-240= 3.0 units/hr, 241-280= 4.0 units/hr, 281-320= 5.0 units/hr, 321-360=6.0 units, 361-400= 7.0 units, greater than 400= 8.0 units.
1800443|NCT00582361|Procedure|Standard Wound Dressing|Group A patients will have a standard dressing applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
1800444|NCT00582361|Device|VAC|Group B patients will have a Vacuum Assisted Closure (VAC) device applied following initial treatment of their open fracture. They will return to the operating room approximately 48 hours following the initial trauma, and approximately every 48 hours thereafter, for irrigation and debridement and concomitant wound cultures (qualitative and quantitative) until such time as the wound is judged by the surgeon to be ready for either delayed primary closure or flap/skin graft coverage.
1800445|NCT00582387|Genetic|specimen samples|blood, urine and tissue
1800446|NCT00582387|Behavioral|questionnaires|
1800447|NCT00582400|Drug|arsenic trioxide|"Trisenox will be diluted with 100 to 250 mL 0.9% Sodium Chloride injection, USP, using proper aseptic technique, immediately after withdrawal from the ampule. The Trisenox ampule is single-use and does not contain any preservatives. Unused portions of each ampule should be discarded properly. Trisenox is not to be mixed with other medications.
The loading dose of Trisenox will be administered intravenously over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. The drug will be administered IV through a functional peripheral or central venous line. Trisenox is not a vesicant, and may be a mild irritant if administered into the skin without dilution."
1800448|NCT00582413|Behavioral|questionnaires|Patient will fill out questionnaires, initial clinic visit, first post-surgery clinic evaluation and 3, 6, 12, 18 and 24 months following completion of all therapy.
1800449|NCT00582426|Drug|Octreotide Long Acting Release|Patients will receive the first dose of Octreotide LAR (30 mg) at chemotherapy initiation, in addition to a minimum of two more identical monthly doses of Octreotide LAR (with an interval of 28 days between them), until first-line chemotherapy is discontinued or for a maximum of six doses of Octreotide LAR, whichever occurs first.
1800450|NCT00582426|Other|Standard Treatment|Physician treatment of choice for chemotherapy induced diarrhea other than Octreotide LAR.
1800451|NCT00582439|Device|Reamer-Irrigator-Aspirator (RIA)|Patients must already be scheduled for bone grafting of a fracture or nonunion with harvest of autologous graft material from their femur using the RIA system. The reaming procedure will be conducted using the trochanteric entry portal through the tip of the greater trochanter.
1800452|NCT00582452|Other|Telephone survey|Telephone survey
1800453|NCT00582478|Behavioral|questionnaires|Participants will be followed regularly at 3, 6, 12, and 18-month intervals
1800454|NCT00582491|Drug|Modafinil|Modafinil 400mg orally every day for 16 days
1800455|NCT00582491|Drug|Placebo|Placebo orally everyday for 16 days
1800457|NCT00582517|Device|Compass Universal Hinge External Fixator|Application of the Compass Knee Hinge adds approximately 30 minutes to the surgical time. After the apparatus has been in place for the appropriate amount of time (6-8 weeks), it is removed either in the clinical setting, or in the one-day surgery area of UAB Highlands.
1800458|NCT00582517|Procedure|Non-invasive External Knee Brace|For Group A patients, an external knee brace (several brands available and no one brace specified for this study) will be placed on the leg following surgical repair of the knee dislocation.
1800459|NCT00582530|Other|Whole Blood Draw|The plan is to obtain the research blood sample at the time of routine preoperative and postoperative blood testing, typically performed 1-2 weeks prior to surgery and then again 6 weeks to 12 months after surgery
1800460|NCT00582543|Other|eMRI/MRSI|Patients will undergo eMRI/MRSI examination. All subjects will be asked to administer a Fleet enema on the day of the study in order to reduce the potential for fecal residue to interfere with imaging acquisition and quality. Upon arrival at the MRI suite, patients will be asked to complete a standard MRI screening form. Patients will be scanned in the supine position. The entire eMRI/MRSI study will be performed within 55-60 minutes.
1800461|NCT00582556|Drug|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min x 1, given 7 days prior to beginning androgen deprivation therapy
1800462|NCT00582556|Drug|zometa|GnRH analogue 3-mo depot - q3 months for 1 yr andZometa 4 mg IV over 15 min x 1, given at mo 6
1800463|NCT00582556|Drug|Zometa|GnRH analogue 3-mo depot - q3 months for 1 yr and Zometa 4 mg IV over 15 min, given monthly x 6 months, beginning in month 6.
1800464|NCT00582582|Drug|Docetaxel plus doxercalciferol|Docetaxel 35mg/m2 IV weekly x3 every 4 weeks plus Doxercalciferol 10mcg orally every day
1800465|NCT00582582|Drug|Docetaxel plus placebo|Docetaxel 35mg/m2 IV weekly x3 every 4 week cycle plus placebo taken orally every day
1800466|NCT00582608|Drug|131I-8H9|This is an open-label single arm study of 131I-8H9, injected intravenously at 10 mCi/1.73 m^2 dose [intended specific activity of ~20 mCi/mg protein]
1800467|NCT00582608|Drug|8H9|administration of 50mg/1.73m^2 of unlabeled 8H9.
1800468|NCT00582634|Drug|docetaxel and cisplatin|Docetaxel (75mg/m2) followed by cisplatin (75mg/m2) on day 1 of a 21 day cycle. Both drugs will be administered intravenously over 1 hour each for4 cycles.
1800469|NCT00588380|Drug|GLP-1|GLP-1 infused at 0.75 pmol/kg/min from 121-180 minutes, GLP-1 infused at 1.55 pmol/kg/min from 181-240 minutes,
1800475|NCT00588419|Behavioral|breast exam and questionaire|A physical examination of your breast(s), we will ask you to complete a short questionnaire that asks questions regarding sensations in your reconstructed breast(s) and another short questionnaire that asks questions regarding your medical and surgical history. The physical examination and the questionnaires will be completed in the outpatient clinic. This should take about 30 minutes to complete.
1800476|NCT00588445|Drug|Gefitinib|"Patients will receive gefitinib 250 mg po daily for at least 21 days preoperatively (depending on the timing of the surgery). Treatment with gefitinib will be stopped 2 days before the date of surgery.
Patients who have had at least a minor response to gefitinib therapy preoperatively (> 25% reduction in tumor measured bidimensionally) and / or have mutations in the protein-tyrosine kinase domain of the EGF receptor gene identified will continue on the study and will resume gefitinib treatment after at least 7 days from surgery providing adequate wound healing has occurred.
Patients who are determined to be candidates for adjuvant chemotherapy and/or radiation therapy by their treating physician may receive treatment with adjuvant chemotherapy and/or radiation therapy. The post-operative gefitinib will be started after completion of the chemotherapy and/or radiation therapy."
1800477|NCT00588458|Procedure|CT cholangiography|Cholografin 20ml will be diluted in 100 ml of normal saline and infused over 30 minute time interval. Following the infusion of the cholografin, morphine (0.04 mg/kg) will be administered to contract the sphincter of Oddi and improve bile duct distension and visualization. Thirty minutes following the administration of morphine a test scan (CT cholangiography) will be performed through the liver to determine if there is adequate biliary excretion. The test scan will consist of 10 mm thick image obtained through the mid liver. If there is evidence of biliary excretion, high-resolution images will be performed through the liver and bile ducts. The axial images will be reconstructed into maximum intensity projection models and volume rendered models that can be viewed in 3-dimension.
1800478|NCT00588471|Drug|Simvastatin|Subjects randomized to this arm will be pretreated with 80 mg (2 pills) simvastatin approximately one hour prior to percutaneous coronary intervention.
1800479|NCT00588471|Drug|Placebo|Subjects randomized to this arm will be pretreated with 2 placebo pills approximately one hour prior to percutaneous coronary intervention.
1800480|NCT00588497|Procedure|Micro-insert hysteroscopic sterilization|Placement of micro-inserts transcervically with the aid of a hysteroscope
1800481|NCT00588497|Radiation|Plain abdominal Xray|Performed immediately after micro-inserts placement and at 3 months
1800482|NCT00588497|Procedure|Pelvic Ultrasound|Performed immediately after micro-inserts placement and at 3 months.
1800483|NCT00588497|Radiation|Hysterosalpingogram|Performed 3 months after micro-inserts placement
1800484|NCT00588510|Other|Blood draw|Peripheral blood samples (6-9 ml) will be collected in purple top tubes, when routine laboratory tests are being drawn. The blood will be drawn through central venous catheters, whenever possible. Blood will be drawn once from patients with malignant diagnoses other than osteosarcoma, neuroblastoma, Ewing's sarcoma or synovial sarcoma. In patients with osteosarcoma we will obtain blood when baseline laboratory tests are obtained, after every two cycles of treatment (approximately every six weeks), at the end of planned surgery and chemotherapy, every three months for the first year off therapy and yearly thereafter. We will also obtain blood if the patient relapses.
1800485|NCT00588523|Drug|temozolomide followed by high dose busulfan and thiotepa|Temozolomide 200mg/m2 PO Days 1-5 recycled every 28 days Day minus -8 thiotepa 250 mg/m2 intravenously Day minus -7 thiotepa 250 mg/m2 intravenously Day minus -6 thiotepa 250 mg/m2 intravenously Day minus -5 busulfan 3.2 mg/kg intravenously over two hours Day minus -4 busulfan 3.2 mg/kg intravenously over two hours Day minus -3 busulfan 3.2 mg/kg intravenously over two hours Day minus -2 rest Day minus -1 rest Day 0 peripheral blood stem cell or bone marrow reinfusion
1800486|NCT00588536|Drug|Methotrexate|MTX 30mg/m2 (or 1mg/kg for infants) orally, given in three equally divided doses at 0,8, and 16hrs
1800487|NCT00588536|Drug|6-Thioguanine|6-TG 300mg/m2 (or 10mg/kg for infants) orally, given in one dose.
1800488|NCT00588536|Drug|Leucovorin Calcium|5mg orally at 36,48, and 60hrs (or 12 hrs after the dose of 6-TG and then every 12 hrs for a total of 3 doses)
1800489|NCT00588588|Procedure|Bronchoscopy|Bronchoscopy procedure
1800490|NCT00588588|Procedure|Clinical pulmonary infection score (CPIS)|Calculate CPIS
1800491|NCT00588640|Drug|d-Methadone|8 subjects to receive 40 mg d-Methadone twice a day
1800492|NCT00588640|Drug|D-methadone|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
1800493|NCT00588640|Drug|placebo|After randomization, patients will take the study drug or placebo for 12 days and then they will cross-over to the opposite arm for another 12 days. The study will end on day 24.
1800494|NCT00588653|Device|Capsule endoscopy, CT enterography, colonoscopy, small bowel follow-through|Each patient undergoes each of the 4 diagnostic modalities, but the readers are blinded to results of the other 3.
1800495|NCT00588666|Drug|Bevacizumab|
1800496|NCT00588666|Drug|Carboplatin|
1800497|NCT00588666|Drug|Gemcitabine|
1800498|NCT00588679|Other|Magnetic Resonance Imaging; Spectroscopic Imaging, Contrast Enhanced Imaging|All MR examinations will be performed on a 3.0 Tesla whole body GE MR scanner located at the main campus (1275 York Avenue) or the Breast and Imaging Center (BAIC)(located on Second Ave. between 65th and 66th Streets). The MR examination will include MR imaging and spectroscopic imaging employing a combined torso phased array and endorectal coil receiver. The examination will require one hour to one hour and ten minutes.
1800499|NCT00588692|Device|SphygmoCor|The SphygmoCor, a hand-held tonometer will assess central blood pressure noninvasively. This pencil-like device is applied over the radial artery, and uses a validated mathematical transformation to derive central aortic pressure.
1800500|NCT00588705|Behavioral|focus group & questionaire|The focus group will last about 90 minutes. However, your involvement in this study will last from the time you join until you read over the summary of what happened during the focus group and return your comments. This should be approximately 2 months. Patient will complete a questionnaire and we estimate total time for completion to be approximately 7 minutes.
1800501|NCT00591981|Behavioral|TOGA Tools|ADL's, Zubrod, IADL's, BFI, MMS, MNS, GDS
1800502|NCT00591994|Drug|piribedil|50 mg once a day, after lunch 3 month therapy
1800540|NCT00592332|Other|control group|control group is two hyperinsulinemic glucose clamps on day 1 with no drug given.
1800503|NCT00592007|Drug|Fulvestrant and Erlotinib|Upon enrollment, patients will continue to receive erlotinib daily orally at 150 mg/day or at 100 mg/day if 150 mg was associated with adverse events requiring dose reduction before enrollment in this study. Doses less than 100 mg/day will not be allowed. Fulvestrant will be added intramuscularly 500 mg Day 0, 250 mg Days 14 and 28. In cycles 2 and up, fulvestrant will be given 250 mg on day 28. Patients will receive this therapy until they progress.
1800504|NCT00592020|Procedure|Short Transverse Incision|Short Transverse Incision for kidney transplantation
1800505|NCT00592020|Procedure|Hockey Stick Incision|Hockey Stick Incision for kidney transplantation
1800506|NCT00592033|Other|oxygen from a portable concentrator|2 l/minute during exercise
1800507|NCT00592046|Drug|ZIO-101 (Darinaparsin)|ZIO-101 (Darinaparsin) given for five consecutive days to be repeated every 28 days for up to six months. This is a dose escalation study.
1800508|NCT00592072|Dietary Supplement|Medium chain fatty acid (Octanoic and Decanoic acid)|Octanoic acid(67%) and Decanoic acid (27%); MCFA 50g total at 25 minute intervals with front loading of 20g then 10g for three administrations.
1800509|NCT00592072|Other|Splenda (Placebo Control)|Placebo drink will consist of dietary sweetener Splenda mixed in water at a concentration of 1g/100mL. An unsweetened cherry flavor Koolaid mix will be added at a concentration of 0.3g/100mL of the Splenda drink to enhance flavor.
1800510|NCT00592085|Behavioral|Questionnaires|Participants will use a computer to complete a series of questionnaires.
1800511|NCT00592085|Behavioral|Motivational Relapse Prevention Counseling|Total of 6 counseling calls for Smoking Relapse: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
1800512|NCT00592085|Behavioral|Relapse Plus Alcohol Risk Reduction Counseling|Total of 6 counseling calls for both Smoking Relapse and Alcohol Risk: First counseling call will be to set up your quit date; then 5 additional counseling calls within 12 weeks after enrollment, each 20 to 30 minutes to complete.
1800513|NCT00592098|Drug|Strontium chloride hexahydrate|Cutaneous solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
1800514|NCT00592098|Drug|Placebo|Cutaneous saline solution, 1 ml dose per 100 sq cm of affected skin area, To be applied twice daily for 28 days.
1800515|NCT00592111|Drug|COPP/ABV|4 courses of COPP/ABV hybrid
1800516|NCT00592111|Drug|COPP/ABV|6 courses of COPP/ABV hybrid
1800517|NCT00592111|Drug|intensive chemo with concurrent growth factor|6 cycles (2 courses) of intensive chemotherapy with concurrent growth factor
1800518|NCT00592124|Drug|Tenofovir disoproxil fumarate|300 mg tablet daily
1800519|NCT00592124|Drug|Tenofovir gel|1 gm/100 ml of 1% gel vaginally daily
1800520|NCT00592137|Dietary Supplement|C (smoothies based on soy protein containing no additional calcium)|Two smoothies per day based on soy protein containing no additional calcium
1800521|NCT00592137|Dietary Supplement|B (smoothies based on soy protein containing calcium)|Two smoothies daily based on soy protein containing 650 mg calcium as calcium carbonate
1800522|NCT00592137|Dietary Supplement|A (smoothies based on dairy protein containing calcium)|Two smoothies daily based on dairy protein containing 650 mg calcium
1800523|NCT00592150|Drug|fenoldopam|The fenoldopam infusion rate will be 0.05 μg/kg/min for 3 hours
1800524|NCT00592150|Drug|Placebo|Placebo infusion for 3 hours
1800525|NCT00592163|Drug|ZIO-101-C (Darinaparsin)|Dose Escalation study, 200 mg - 900 mg, cumulative daily dose split to be taken BID 7 times a week (>8 hours between doses) for 3 weeks followed by 1 week of rest
1800526|NCT00592176|Drug|local injection of bevacizumab|Upon enrollment into the study: - initial injection of bevacizumab, a 1 week post-injection visit,and monthly visits thereafter for a total of 6 months. At the 1-month and 3-month visit post-injection visit, an additional bevacizumab injection will be offered if pterygium regression has not occurred. All injections of bevacizumab will consist of injecting 0.1mL of a 2.5mg/0.1mL concentration of bevacizumab into the head of the pterygium.
1800527|NCT00592189|Procedure|blood draw|blood collection
1800529|NCT00592215|Drug|Experimental (mifepristone and misoprostol)|Mifepristone 200mg followed by labor induction with misoprostol after 6-8 hours
1800530|NCT00592228|Device|Cypher, Taxus or Endeavor|"percutaneous drug-eluting stent implantation,
FFR group: if FFR<0.75
Routine DES group"
1800531|NCT00592241|Device|"Adi Insulin Pump Usability"|no intervention
1800532|NCT00592280|Device|Two-Layer Method pancreas preservation system|Preserving the pancreas before transplantation in an oxygenated system containing highly oxygenated liquid perfluorocarbon (perfluorodecalin, C10F18. The perfluorocarbon combines low toxicity with a capacity to dissolve 75 times more oxygen than the UW solution used in standard pancreas storage. When preserved under these conditions, the pancreas absorbs oxygen by diffusion and steadily consumes it, supporting sufficient aerobic metabolism to maintain tissue ATP concentrations at near-physiologic levels and prevent, or even reverse, pancreas anoxic injury.
1800533|NCT00592293|Radiation|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
1800534|NCT00592306|Drug|rabbit antithymocyte globulin + placebo|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.
Each arm will also receive a single placebo dose.
Arm I will receive thymoglobulin intraoperatively followed by a postoperative placebo dose and two subsequent thymoglobulin doses."
1800535|NCT00592306|Drug|placebo + rabbit antithymocyte globulin|"All patients (Arm I and Arm II) will receive 3 doses of thymoglobulin at 1.5mg/kg IV over 6 hours; only the timing of the medication is being altered.
Each arm will also receive a single placebo dose.
Arm II will receive placebo intraoperatively followed by 3 postoperative doses of thymoglobulin."
1800536|NCT00592319|Drug|Celebrex|oral taking of Celebrex (100 mg, BID) for 9 months
1800537|NCT00592319|Device|PDL|once time radiation on laryngeal papilloma with PDL , at 6.0-8.0 J
1800538|NCT00592319|Procedure|CO2 laser or microsurgery|once-time surgery to remove laryngeal papilloma
1800539|NCT00592332|Drug|Alprazolam|1 mg alprazolam given orally 60 minutes prior to each 2 hour glucose clamp on day 1 (x2)
1800816|NCT00594568|Drug|Placebo|Administered orally once daily
1800541|NCT00592345|Radiation|Proton Beam Radiation|Administered over a period of 12 weeks.
1800542|NCT00592345|Radiation|Photon Beam Radiation|Administered over a period of 12 weeks.
1800543|NCT00592345|Radiation|Interoperative radiation|Radioactive plaque applied at the time of surgical removal of the tumor.
1800544|NCT00592358|Drug|paliperidone|tablet, 3mgQAM - 6mgQAM, taken daily for 8 weeks
1800545|NCT00592384|Drug|venlafaxine XR|Once daily oral dose of venlafaxine XR ranging from 37.5 mg up to 300 mg
1800546|NCT00592384|Drug|placebo|Once daily oral dose of placebo ranging from 37.5 mg up to 300 mg
1800547|NCT00592397|Other|Balanced macronutrient diet intervention|Isocaloric dietary changes from typically Western diet to balanced macronutrient composition.
1800548|NCT00592410|Drug|human regular insulin|administration of a primed continuous infusion of human regular insulin at a rate of 2.0 mU/kg/min while maintaining the plasma glucose level at 100 mg/dl via adjusting a variable infusion of 50% dextrose (i.e., a hyperinsulinemic euglycemic blood glucose clamp); duration of 3 hours; performed concomitantly with amino acid supplementation
1800549|NCT00592423|Other|Continuous Positive Airway Pressure during MRI|10 cm H20 pressure for CPAP while lateral neck positioning is done for MRI - each side should take 5 minutes.
1957529|NCT02340962|Drug|Ribavirin|RBV (Ribavirin or COPEGUS®) is available as a light pink to pink colored, flat, oval-shaped, film-coated tablet for oral administration. Each tablet contains 200 mg of ribavirin and the following inactive ingredients: pregelatinized starch, microcrystalline cellulose, sodium starch glycolate, cornstarch, and magnesium stearate. The coating of the tablet contains Chromatone-P® or Opadry® Pink (made by using hydroxypropyl methyl cellulose, talc, titanium dioxide, synthetic yellow iron oxide, and synthetic red iron oxide), ethyl cellulose (ECD-30), and triacetin.
1800552|NCT00592462|Procedure|Whole Body MRI|The whole body MRI will include T1-weighted and T2-weighted phase-sensitive MR imaging as well as diffusion weighted imaging of the whole body in multiple patient table stations.
1800553|NCT00592475|Drug|conivaptan|IV
1800554|NCT00592475|Drug|Placebo|IV
1800555|NCT00592488|Drug|Acetyl-L-Carnitine|Acetyl-L-Carnitine - 4 g IV over 30 minutes, then 8 g iv over the next 12 hours
1800556|NCT00592501|Radiation|Proton/Photon Radiotherapy|Given once a day, five days a week, for seven weeks.
1800557|NCT00592501|Drug|Cisplatin|Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
1800558|NCT00592501|Drug|Fluorouracil|Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
1800559|NCT00592527|Drug|insulin detemir|
1800560|NCT00592540|Procedure|Unrelated Donor BMT|Unrelated donor bone marrow transplantation has not been performed with these patients in the past
1800561|NCT00592553|Drug|PTC124 High Dose|PTC124 High Dose - 20-, 20-, 40-mg/kg dose level
1800562|NCT00592553|Drug|PTC124 Low Dose|PTC124 Low Dose - 10-, 10-, 20 mg/kg dose level
1800563|NCT00592553|Drug|Placebo|Placebo
1800564|NCT00592566|Drug|Dexamethasone, desmopressin|200 mg of dexamethasone IV infusion OD for 3 days or 0.3 microgram/ kg of desmopressin in 50 ml of saline, as a 30- minute infusion
1800565|NCT00592579|Drug|2-methoxyestradiol|800 mg of 2ME2 (capsules) administered orally every 12 hours for a total daily dose of 1600 mg.
1800567|NCT00592618|Drug|Oral N-Acetylcysteine 1200 mg x 2/day for 4 weeks|
1800568|NCT00592631|Device|CPAP-Continuous Positive Airway Pressure|Cpap will be worn at night by subjects 6 to 7 days duration.
1800569|NCT00592631|Device|SHAM|SHAM will be worn at night by subjects 6 to 7 days duration.
1800570|NCT00592644|Procedure|Pulse Dye laser (PDL)|one-time PDL, in 10 subjects
1800571|NCT00592644|Procedure|CO2 laser or other traditional surgeries|once-time CO2 laser or other conventional surgeries, in other 10 subjects
1800572|NCT00592670|Drug|Fluoxetine|20 mg fluoxetine orally one per day for 1 week, 40 mg fluoxetine orally once per day for one week, 80 mg Fluoxetine orally for remaining 4 weeks of treatment
1800573|NCT00592670|Drug|Placebo|20 mg placebo pill taken orally once per day for one week, 40 mg placebo pill taken orally one per day for one week, 80 mg placebo pill taken orally once per day for remaining 4 weeks.
1800574|NCT00592683|Drug|Aripiprazole|tablet, start at 2mg and increase/decrease each week, taken daily for 12 weeks
1800575|NCT00592683|Dietary Supplement|fish oil|1600mg (4 capsules) daily for 12 weeks
1800576|NCT00592683|Drug|Placebo|Placebo
1800577|NCT00592735|Procedure|laparoscopic gastric banding|standard surgical procedure
1800578|NCT00592748|Radiation|Charged Particle Radiation Therapy|Radiation doses will be determined by planning CT
1800579|NCT00592761|Behavioral|Mendelsohn Maneuver|Mendelsohn Maneuver with Surface Electromyography
1800580|NCT00592774|Drug|E2007 (perampanel)|2 mg titrated up to 8 mg maximum; taken once daily.
1800581|NCT00592774|Drug|Placebo|2 mg titrated up to 8 mg maximum; taken once daily.
1800582|NCT00592813|Behavioral|Enhanced Strong for Life|"The program contains 5 minutes of warm-up, 25 minutes of strengthening, and 5 minutes of cool-down exercises. The SFL program is contained on a 35 minute videotape. Subjects are instructed to increase resistance when they can perform 10 repetitions of a movement pattern without significant fatigue or loss of proper execution. Subjects are instructed to move within a comfortable range of motion.
Participants will be taught the SFL program during two home visits conducted by a physical therapist. On the first visit, the exercise techniques will be taught, modified as needed based on individual needs and practiced as necessary until proper technique is attained. Each participant will be given written guidelines for how to progress resistance of the program, how to modify the exercises and how to complete bimonthly exercise calendars."
1800583|NCT00592813|Behavioral|cardiovascular nutrition education|administered as an attention control intervention using home visits, phone calls and mail-outs of information
1800584|NCT00592839|Drug|SCE-B|0.3 mg or 0.625 mg SCE-B tablets daily plus matching placebo
1800585|NCT00592839|Drug|Placebo|Matching placebo for 0.3 mg and 0.625 mg tablets
1800586|NCT00592852|Drug|fluoxetine|capsules, dose range of 10mgQD - 60mgQD, given daily for 12 weeks
1800587|NCT00592891|Drug|Hyperbaric oxygen therapy|Total body pressurized oxygen
1800726|NCT00594113|Other|Touch screen intervention|Touch screen intervention
1800588|NCT00592904|Drug|E2007|Perampanel doses will be up-titrated in 2 mg steps at minimum weekly intervals starting at 2 mg daily and up-titrated to 12 mg daily (taken orally).
1800589|NCT00592917|Dietary Supplement|calcium carbonate and cholecalciferol|one tablet (calcium carbonate resembling 500 mg of calcium and 400 IU or 5 micrograms of vitamin-D3, cholecalciferol) twice daily for the whole duration of the study
1800590|NCT00592930|Drug|olanzapine|flexibly dosed oral olanzapine 2.5 to 15 mg/day
1800591|NCT00592930|Drug|placebo|
1800592|NCT00592943|Drug|armodafinil|tablet, taken by mouth, once each study day
1800593|NCT00592969|Drug|metformin|
1800594|NCT00592969|Drug|biphasic insulin aspart|
1800595|NCT00592995|Drug|Creatine monohydrate|10 to 30 grams daily
1800596|NCT00592995|Drug|Placebo|10 to 30 grams daily
1800597|NCT00593008|Drug|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 8, 15 and 22). Participants may continue to receive study treatment as long as their tumor is responding and they don't experience any serious side effects.
1800598|NCT00593008|Drug|Gemcitabine|Given intravenously every other week of each 28-day cycle.
1800599|NCT00593047|Drug|KB2115|tablet formulation given once daily for 12 weeks
1800600|NCT00593060|Drug|Temsirolimus|Given intravenously every week of each 28-day cycle (days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
1800601|NCT00593060|Drug|Cetuximab|One dose is given intravenously 7 days prior to the start of each 28-day cycle, then it is given every week (along with temsirolimus)of each 28-day cycle (on days 1, 7, 15, 22). Participants can continue to receive study treatment as long at their tumor is responding.
1800602|NCT00593073|Behavioral|Electronic tailored messaging|Tailored CRC message based on patient screening barriers, preferences and attitudes and reminder to get screened.
1800603|NCT00593073|Behavioral|General Reminder Message|General CRC health education message and reminder to get screened.
1800604|NCT00593086|Procedure|Pain management|Pain mamagement for burn care procedures.
1800605|NCT00593086|Other|Standard of care/no virtual reality game|no intervention for standard of care
1800606|NCT00593099|Drug|Bupropion|BUP [as the intermediate-release (IR) formulation] was inducted on Day 1 of the trial at 75 mg po qd x 3 days, then increased to 150 mg [as BUP SR formulation] qd x 4 days, and then increased to a final dose of up to 150 mg po bid (300 mg/day) by Day 15 (target quit date; TQD) as tolerated. This dose was continued for an additional eight (8) weeks at up to 150 mg po bid. Flexible dosing was permitted to allow for adjustments needed if a bipolar subject did not tolerate the full dose of BUP at 300 mg/day. BUP was discontinued at the end of Week 10.
1800607|NCT00593099|Drug|Placebo|matching placebo capsules (PLA) containing only a dextrose matrix.
1800608|NCT00593112|Drug|OROS methylphenidate|Concerta is given in capsule form with a minimum dose of 18 mg/day and a max of 126 mg/day. Subjects take Concerta once per day for 6 weeks.
1800609|NCT00593112|Other|No intervention|No intervention
1800610|NCT00593125|Drug|levetiracetam|The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will not be blind to the subject's medication administration. The medication will be discontinued over a two-week period
1800611|NCT00593138|Drug|dex-methylphenidate|The drug is administered as a capsule by mouth. Participants are assigned to receive either 20, 30 or 40 mg doses before each scan visit.
1800612|NCT00593151|Other|Locteron (controlled-release interferon alpha 2b)|biological+device, bi-weekly subcutaneous injections for 4-12 weeks, 160 mcg per injection
1800613|NCT00593151|Biological|pegylated IFNa2b|biological, weekly subcutaneous injections for 4-12 weeks, 1.5 mcg/kg
1800614|NCT00593164|Device|Cooling with ThermoSuit with Magnesium Sulfate Infusion|Cooling with LRS ThermoSuit within 15 minutes of intravenous Magnesium Sulfate infusion (30 mg/kg, added to 100 ml normal NaCl solution, given over 15 min).
1800615|NCT00593164|Device|Cooling with ThermoSuit with Normal Saline Infusion|Cooling with LRS ThermoSuit within 15 minutes of normal saline infusion (100 ml of normal NaCl solution, given over 15 min).
1800616|NCT00593177|Drug|PTH (1-34) Gel / Placebo Gel|Topical dosing of gel twice daily for eight weeks.
1800617|NCT00593190|Drug|Gas SF6 (Sulfur Hexafluoride)|ONCE
1800618|NCT00593216|Device|Functional MRI imaging|The functional MRI imaging of whole brain will be obtained before, during and after the vestibular response which is induced by the designated caloric stimulation. Post-imaging analysis will reveal which region or neural pathways in the central nervous system may attributed to the development of vertigo.
1800619|NCT00593242|Biological|infusion of autologous cord blood|infants who meet study enrollment criteria for history of moderate to severe hypoxic ischemic encephalopathy in the neonatal period will receive up to 4 infusions of their own volume reduced cord blood cells. The number of doses will be determined by the amount of available cord blood cells. The dose for each infusion is 5x10e7 cells/kg
1800620|NCT00593242|Other|Neurodevelopmental outcomes|historical controls, no experimental intervention, standard therapies of hypoxic ischemic encephalopathy in the newborn period with autologous cord blood
1800621|NCT00593255|Drug|soluble human insulin|
1800622|NCT00593255|Drug|insulin aspart|
1800623|NCT00593255|Drug|insulin NPH|
1800624|NCT00593281|Drug|Hylenex|Add Hylenex to SC injection of Morphine
1800625|NCT00593294|Behavioral|Physical exercise|45 minutes each day for three times/week for 6 months
1800626|NCT00593294|Drug|OC - Drospirenone plus Ethynylestradiol|1 cp for 21 days each month for 6 months of OC (Drospirenone 3 mg plus Ethynylestradiol 30 microgram = Yasmin, Schering, Milan, Italy)
1800627|NCT00593294|Dietary Supplement|Vitamin, polyvitamins tablets|Tablet of vitamin 1cp for 21 days each month for 6 months
1800628|NCT00593307|Other|high GI|high GI and high carb breakfast
1800629|NCT00593307|Other|Low GI|low GI, high carb breakfast
1800630|NCT00593307|Other|Low GI Low Carb|low GI low carb breakfast
1800631|NCT00593307|Other|High GI Low carb|high GI low carb breakfast
1800632|NCT00593320|Radiation|Stereotactic Radiosurgery|
1800727|NCT00594126|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
1800633|NCT00593333|Device|Antegrade Intramedullary Nail|Use of an antegrade intramedullary nail implanted through the Piriformis fossa of the femur. The use of these nails has yielded a union rate of 97 - 99%, and has clearly become the most commonly utilized implant for femur fractures.
1800634|NCT00593333|Device|Trigen Trochanteric Femoral Nail|Antegrade intramedullary nails developed with a proximal lateral bend that allows implantation through the greater trochanter rather than the piriformis fossa. This start portal is remarkably easier to locate and may be associated with decreased risk of abductor muscle weakness and pain.
1800635|NCT00593346|Radiation|brachytherapy|brachytherapy (radioactive implants)
1800636|NCT00593372|Behavioral|Spaced Retrieval Training|Increasing time to remember important information.
1800637|NCT00593385|Device|iCAST covered stent|Iliac stent implantation
1800638|NCT00593424|Other|Low Fat/High Carbohydrate|Low Fat/High Carbohydrate for 6 week period
1800639|NCT00593424|Other|High Monounsaturated Fat/Low Carbohydrate|High Monounsaturated Fat/Low Carbohydrate for 6 week period
1800640|NCT00593450|Drug|ranibizumab|• 0.5 mg (0.05 mL)intravitreal injection
1800641|NCT00593450|Drug|bevacizumab|• 1.25 mg (0.05 mL)intravitreal injection
1800642|NCT00593463|Drug|Cycloserine|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given
1800643|NCT00593463|Drug|Diltiazem|Diltiazem: 30, 60, 120 mg oral capsule may possibly be
1800644|NCT00593463|Drug|Gabapentin|Gabapentin: 100, 200, 400 mg oral capsule may possibly be given
1800645|NCT00593463|Drug|Isradipine|Isradipine: 5, 10 mg oral capsule may possibly be given
1800646|NCT00593463|Drug|Naloxone|Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given
1800647|NCT00593463|Drug|Nifedipine|Nifedipine: 5, 10, 20 mg oral capsule may possibly be given
1800648|NCT00593463|Drug|Placebo|Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given
1800649|NCT00593463|Device|Saline|Saline: I.M. injection may possibly be given
1800650|NCT00593463|Drug|Verapamil|Verapamil: 30, 60, 120 mg oral capsule may possibly be given
1800651|NCT00593476|Other|PCD|pre-packaged, portion-controlled (PCD) meal plan for 24 weeks
1800652|NCT00593476|Other|DSE|12 weeks of diabetes support and education (DSE) (weeks 0-12) and then crosses over to 12 weeks of PCD from weeks 13-24
1957530|NCT02340962|Drug|Interferon Alfa-2a|"IFN (Interferon, Peg-interferon alpha-2a or PEGASYS®) is available as a sterile, preservative-free, colorless to light yellow injectable solution administered subcutaneously.
Each prefilled syringe of 180 μg/0.5 mL IFN (expressed as the amount of interferon alfa-2a) also contains acetic acid (0.0231 mg), benzyl alcohol (5 mg), polysorbate 80 (0.025 mg), sodium acetate trihydrate (1.3085 mg), and sodium chloride (4 mg) at pH 6 ± 0.5."
1800654|NCT00593502|Drug|oseltamivir|Body weight: ≤ 15 kg, 30 mg twice daily; 15 - ≤ 23 kg, 45 mg twice daily; 23 - ≤ 40 kg, 60 mg twice daily; > 40 kg, 75 mg twice daily, for 5 days
1800655|NCT00593502|Drug|placebo|The dosage of placebo will be similar to the active drug
1800656|NCT00593515|Behavioral|Family cognitive behavioral therapy|12-16 weekly sessions of family cognitive behavioral therapy, 60-80 minutes each
1800657|NCT00593515|Behavioral|Child-focused cognitive behavioral therapy|12-16 weekly sessions of child-focused cognitive behavioral therapy, 60-80 minutes each
1800658|NCT00593528|Device|Naked Stents: Wallstent® (Boston Scientific), Luminexx® (Bard), Zilver® (Cook), Palmaz Genesis® and Smart Control® (Cordis)|Vascular Stents
1800659|NCT00593528|Device|PTFE Covered Stents: Fluency® (Bard), Advanta V12® (Atrium) and Viatorr® (Gore)|Vascular Stents
1800660|NCT00593528|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt (TIPS)
1800661|NCT00593554|Radiation|Total Body Irradiation|8 Gy on Day -9
1800662|NCT00593554|Drug|Thiotepa|5 mg/kg/d on Day -8 to -7
1800663|NCT00593554|Drug|Fludarabine|40 mg/m2/d on Day -6 to -3
1800664|NCT00593554|Biological|Rabbit ATG|2.5 mg/kg/d on Day -5 to -2
1800665|NCT00593554|Drug|Palifermin|60 ug/kg (actual body weight) on Day -9 to -7 and Day 0 to +2
1800666|NCT00593567|Drug|gentamicin-collagen sponge|Inserted daily into open ulcer
1800667|NCT00593567|Drug|Levofloxacin|750mg oral levofloxacin daily
1800668|NCT00593580|Drug|placebo|placebo
1800669|NCT00593580|Drug|alendronate/cholecalciferol|FOSAVANCE (70 mg/2800 IU of alendronate and cholecalciferol) or placebo will be given weekly for 1 years duration
1800670|NCT00593606|Drug|Rotigotine|Strength: 2,4,6,and 8mg/24h, form: transdermal application, once daily application
1800671|NCT00593619|Drug|Iron dextran|300mg in 250cc normal saline given over 2 hours
1800672|NCT00593619|Drug|Iron sucrose|300mg in 250cc normal saline given over 2 hours
1800673|NCT00593632|Dietary Supplement|Uncle Sam Cereal|two 3/4 cup servings daily of Uncle Sam Cereal dietary instruction on high fiber diet
1800674|NCT00593645|Drug|Clofarabine|
1800675|NCT00593645|Drug|Cytarabine|
1800676|NCT00593645|Drug|Thymoglobulin|
1800677|NCT00593645|Procedure|Stem cell infusion|
1800678|NCT00593658|Drug|pentoxifylline|pentoxifylline extended release 800mg PO TID for 8 weeks
1800679|NCT00593671|Procedure|Preimplantation genetic screening after embryo biopsy|Preimplantation genetic screening after embryo biopsy
1800680|NCT00593684|Device|Silver Alginate|This is a sterile patch of polyurethane foam coated with silver alginate and maltodextrin matrix that is impregnated with 141 mg of ionic silver per 100 cm2.
1800681|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel|"Patients diagnosed with early breast cancer with a high risk of disease recurrence will be randomly allocated to one of the following 2 arms in a 1:1 ratio:
A. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) (HT x3 ->FE75C x3) B. Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)"
1800728|NCT00594139|Biological|Autologous neobladder construct|provision of an autologous neo-bladder construct
1800682|NCT00593697|Drug|trastuzumab (9 weeks) + docetaxel + CEF + trastuzumab (up to 51 weeks)|Weekly or 3-weekly trastuzumab plus 3-weekly docetaxel (3 cycles) (HT) -> 3-weekly FE75C (3 cycles) -> trastuzumab to complete 1 year (14 3-weekly infusions) (HT x3 ->FE75C x3 -> H3wkly x14)
1800683|NCT00593710|Drug|Losartan|Losartan (25mg OD)
1800684|NCT00593710|Drug|Atenolol|Atenolol (25-50mg OD)
1800685|NCT00593723|Radiation|IMRT|
1800686|NCT00593736|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally, once daily for up to two weeks.
1800687|NCT00593736|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to two weeks.
1800688|NCT00593736|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to two weeks.
1800689|NCT00593736|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to two weeks.
1800690|NCT00593749|Behavioral|Healthy Corner Store Initiative|modification of snacks and beverages offered in corner store surrounding 10 schools
1800691|NCT00593749|Behavioral|Control|control group in study
1800692|NCT00593775|Procedure|assisted hatching|assisted hatching with laser
1800693|NCT00593801|Drug|epoetin beta|250 IU/kg/week rhEPO treatment subcutaneously 3 times a week from the first week for 9 weeks, all infants received enteral iron 3-9 mg/kg/day
1800694|NCT00593801|Drug|epoetin beta|250 IU/kg/week subcutaneously 3 times a week, from the fourth week for 6 weeks, all infants received enteral iron 3-9 mg/kg/day
1800695|NCT00593814|Device|GORE EXCLUDER® Bifurcated Endoprosthesis-Low Permeability|Implant
1800696|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 16 mg/m^2 was administered as a 1-hour IV continuous infusion on Days 1, 8, and 15 in a 28-day cycle until progressive disease or intolerable toxicity.
1800697|NCT00593827|Drug|Ixabepilone|Injection, IV, Until progressive disease or intolerable toxicity Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day cycle provided the subject met the retreatment criteria.
1800698|NCT00593840|Radiation|Intensity modulated radiation therapy|
1800699|NCT00593853|Drug|Methylphenidate Hydrochloride|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
1800700|NCT00593853|Drug|Matched Placebo|Run in period of 5mg QD,PO for 2 weeks followed by 5mg BID,PO for 8 weeks (full daily dose of 10mg). Followed by a 2 week taper period of 5mg QD,PO to complete 12 week cycle.
1800701|NCT00593866|Radiation|INTENSITY MODULATED RADIOTHERAPY|Five fractions weekly, fraction size determined by dose level
1800702|NCT00593866|Drug|Gemcitabine|1000mg/m2 will be infused over 100 minutes on days 1, 8, 22 and 29 of the radiation treatment
1800703|NCT00593879|Drug|Mecamylamine|2.5mg mecamylamine Hcl, tablet form taken twice a day (total of 5.0mg). For 7.5 mg dose group, 2 tablets taken morning, one tablet evening. At 10.0mg, 2 tablets taken twice daily.
1800704|NCT00593905|Drug|Sitaxsentan|Sitaxsentan sodium 100 mg tablet every morning
1800705|NCT00593905|Drug|Bosentan, Ambrisentan|Bosentan 125 mg tablet twice daily Ambrisentan 5-10 mg tablet once daily
1800706|NCT00593931|Other|fMRI|Functional Magnetic Resonance Imaging without contrast
1800707|NCT00593944|Biological|MDX-1342|MDX-1342 is given as a 90 minute i.v. infusion. Patients will receive one of the following dose levels, 0.7, 7, 40, 200, 1000, 2000 mg/dose.
1800708|NCT00593957|Drug|Dextromethorphan|Subjects will be randomized to receive one of three dosage groups either 0.25 mg/kg per day; or 2.5 mg/kg/day; or 5mg/kg/day of Dextromethorphan Polistirex (Delsym)oral syrup, which will be given exactly 12 hours apart in two divided doses during the 6 month trial.
1800709|NCT00593957|Drug|Dextromethorphan|Dextromethorphan polistirex. Doses are 0.25 mg/kg/day, 2.5mg/kg/day, and 5 mg/kg/day. The drug is given in two divided doses 12 hours apart for 6 months.
1800710|NCT00593983|Behavioral|Peer-driven intervention|Consists of four structured intervention sessions lasting 6 hours in total, three peer education/recruitment experiences, and brief liaison contacts by an intervention facilitator during AIDS clinical trial screening
1800711|NCT00593983|Behavioral|Time-matched health education|Health education and standard of care treatment
1800712|NCT00593996|Other|Ergocalciferol (vitamin D2)|50,000 IU 3 times weekly for 4 weeks
1800713|NCT00594009|Device|Rotaflow centrifugal pump (Maquet, Inc.)|Patients who meet criteria will be placed on an extracorporeal device for CO2 removal for up to 96 hours for treatment of COPD exacerbation requiring hospitalization and intensive care
1800714|NCT00594022|Device|"Electric stimulation of the Vestibular Nerve - VirtuSom"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. A small electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes.
1800715|NCT00594022|Device|"Electric stim of the Vestibular Nerve - VirtuSom - SHAM"|This device is similar to a Tens or Micro-Current electrical stimulator with respect to current levels deliver; however, because of the location of the stimulation it is similar to a Cranial Electrical Stimulator. For the Sham Group, NO electric stimulation (100 uA - 1000 uA) will be provided at the mastoids (bi-laterally) via small hydrogel electrodes. This is a sham / placebo device only.
1800716|NCT00594035|Device|Spinal Sealant System|
1800717|NCT00594035|Device|Standard of care|Standard of care: devices intended to provide a watertight closure
1800718|NCT00594048|Device|Resperate|Use of the device 15 minutes a day for 9 weeks
1800719|NCT00594048|Device|discman with freely chosen music|Use the discman 15 minutes a day for 9 weeks
1800721|NCT00594074|Other|white wine|3.25 ounces of white wine twice a day with lunch and dinner
1800722|NCT00594087|Drug|eszopiclone|eszopiclone 2mg or 3mg at bedtime
1800723|NCT00594087|Other|placebo|2 mg or 3 mg at bedtime
1800724|NCT00594100|Device|GORE Flow Reversal System (GFRS)|Carotid artery angioplasty and stenting with embolic protection
1800725|NCT00594113|Other|Touch 2 Screen|"Multi-media presentation and survey to increase screening for colorectal cancer. Content of this presentation is based on the concept of implementation intentions, an advanced planning model taken from the Theory of Planned Behavior"
1800729|NCT00594152|Drug|CIIIT|The intravenous infusion group received three one-hour courses of pulsed intravenous insulin infusion on a single day per week in addition to subcutaneous insulin.
1800730|NCT00594165|Drug|Rotigotine|"Rotigotine trans-dermal patches:
10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)
Optimal dosing:
During the first year:
The maximum Rotigotine dose allowed is 6 mg/24 hours.
After the first year: allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
1800731|NCT00594178|Device|Motorized bicycle exercise training|Passive exercise with a bicycle to bilateral legs. 5 days per week for 3 months
1800732|NCT00594191|Drug|Simvastatin|20 mg/day p.o., increased to 40 mg/day at day 15 if no safety end-point was met
1800733|NCT00594191|Drug|Placebo|Placebo with the same characteristics of the drug and at the same dose
1800734|NCT00594204|Drug|varenicline tartrate (CP-526, 555-18)|1 mg twice a day for 12 weeks, starting with a 1-week titration period.
1800735|NCT00594204|Drug|Placebo|matching placebo 1 tablet twice a day for 12 weeks
1800736|NCT00594217|Drug|oral micronized progesterone suspension|oral micronized progesterone suspension, single 100 mg oral dose
1800737|NCT00594217|Other|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
1800738|NCT00594230|Drug|Panobinostat|Panobinostat(20 mg or 30 mg PO) will be administered three times a week on Monday, Wednesday and Friday. Treatment will be given over 21 days followed by a 7 day rest period and repeated every 28 days. Patients will be assessed for toxicity on an ongoing basis and disease assessment will be determined every 2 treatment cycles (8 weeks). Patients will be allowed to continue on treatment for a maximum of eight four week treatment cycles. Treatment will be discontinued if there is evidence of disease progression, unacceptable toxicity and/or at the discretion of the investigator.
1800739|NCT00594243|Behavioral|Mindfulness based stress reduction program|8-week mindfulness based stress reduction program
1800740|NCT00594243|Other|Wait-list control|No treatment given.
1800741|NCT00594256|Drug|Sodium Oxybate|Patients will undergo a one-week evaluation period, which will include a taper and discontinuation of any currently prescribed sedative/hypnotics, as well as baseline diagnostic, psychopathology, neurocognitive and polysomnographic measurements (see below for details). Hypnotic taper may be extended or abbreviated, depending on clinical judgment. Patients will then begin a 4-week trial of adjunctive Xyrem (sodium oxybate). Patients will begin at 4.5 g/night (in divided doses of 2.25 g, with 1st dose at bedtime and then 2nd dose four hours later). Dosage will increase by 1.5 g/day every week, until a dose of 9 g nightly is reached, or a patient cannot tolerate further dose escalations. Medication will be administered in divided dosage for the duration of the study. A three-week taper (by 3 g/day weekly) of sodium oxybate will follow the four-week trial of sodium oxybate.
1800742|NCT00594269|Drug|Risperidone|Discontinuation
1800743|NCT00594269|Drug|Escitalopram|Discontinuation
1800744|NCT00594269|Drug|Citalopram|Discontinuation
1800745|NCT00594269|Drug|Sertraline|Discontinuation
1800746|NCT00594269|Drug|Paroxetine|Discontinuation
1800747|NCT00594282|Device|Radiolucent cushion|MammoPad radiolucent breast plate cushion used during mammogram
1800748|NCT00594308|Drug|Cyclophosphamide|60mg/kg/day for two consecutive days (-7,-6).
1800749|NCT00594308|Drug|Fludarabine|25mg/m2/day for 5 consecutive days
1800750|NCT00594308|Drug|Cyclosporine|3mg/kg/day will be given by continuous intravenous infusion beginning on Day -1.
1800751|NCT00594308|Drug|Mycophenolate mofetil|1000 mg will be administered through day +60 and then discontinued if there is no GVHD.
1800752|NCT00594308|Drug|Basiliximab|20mg , will be given by intravenous infusion (without an in-line filter) over at least 15 minutes beginning 3 days after engraftment.
1800753|NCT00594321|Device|SPACE CpsXL Bone Cement and SPACE 360 Delivery System|SPACE CpsXL Bone Cement and SPACE 360 Delivery System
1800754|NCT00594321|Device|standard vertebroplasty|standard vertebroplasty
1800755|NCT00594334|Drug|Risedronate|Weekly Risedronate
1800756|NCT00594347|Biological|Pneumo 23|Vaccine (Pneumo 23)
1800757|NCT00594347|Biological|Prevnar|Vaccine (Prevnar)
1800758|NCT00594360|Behavioral|Exercise on Prescription|Exercise two times a week for two months at a physiotherapist. Afterwards exercise one time a week at a physiotherapist and self-contained training one time a week for 2 months.
1800759|NCT00594373|Drug|Tenofovir gel|1 gm/100 ml of 1% tenofovir gel vaginally daily
1800760|NCT00594373|Drug|Tenofovir gel placebo|1 gm/100 ml of placebo gel vaginally daily
1800761|NCT00594386|Drug|Rotigotine|"Rotigotine transdermal patches:
10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours)
Optimal dosing:
During the first year: The maximum Rotigotine dose allowed is 6 mg/24 hours.
After the first year: Allowed dose increase of Rotigotine up to a maximum of 16 mg/24 hours."
1800762|NCT00594399|Behavioral|Physical Activity Counseling|Physical activity (PA) counseling program with the following components: a baseline in-person counseling session; telephone calls biweekly for 6 weeks then monthly; one physician endorsement of PA in a primary care clinic visit; monthly automated telephone calls from the primary care provider encouraging PA; and (5) quarterly mailed materials providing personalized feedback.
1800763|NCT00594412|Procedure|Diagnostic Radiology: 1H-MRS of the liver|
1800764|NCT00594425|Drug|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
1800765|NCT00594438|Device|Synthes Reamer-Irrigator-Aspirator (RIA)|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram (TEE) will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using the RIA device.
1800814|NCT00594555|Drug|CLAG|"Cladribine: 5mg/m2 administered through a 2 hour intravenous infusion daily for 5 consecutive days starting on Day 2
Cytarabine: 2gm/m2 administered through a 4 hour intravenous infusion starting 2 hours after the ignition of Cladribine for 5 days starting on Day 2
G-CSF: 300mcg sc for 6 days starting at 24 hours (Day 1) before the first dose of Cladribine; administration starting on Day 1 for 6 days"
1800815|NCT00594568|Drug|LY450139|Administered orally once daily
1800766|NCT00594438|Device|Zimmer Sentinel Reamer|A standard lateral approach to the proximal femur will be utilized. The starting point will be identified using a guide pin and fluoroscopy using standard technique. The attending surgeon will perform the case from the opening of the canal with a drill through the completion of reaming. A transesophageal echocardiogram TEE will be recorded from the time the initial reamer engages the cortex until it is removed from the bone. A guide wire will be passed across the fracture site and its position confirmed by fluoroscopic imaging. The femoral canal will be reamed using either a conventional reaming technique or the RIA device.
1800767|NCT00594464|Drug|Rotigotine|"2 mg/24 h, 4 mg/24 h, 6 mg/24 h and 8 mg/24 h patch;
Single patches and a combination of 2 of these patches for a dosage of up to 16 mg/24 h;
One (1) regimen on day of surgery, but exceptionally extended for up to 2 (two) weeks if the patient requires unexpected ventilation after surgery."
1800768|NCT00594477|Radiation|IMRT|
1800769|NCT00585507|Drug|Fulvestrant|500mg into the muscle on days 1, 15 and 29 and then every 28 days thereafter.
1800770|NCT00585520|Drug|Progesterone|200mg BID for 5 days
1800771|NCT00585520|Drug|Placebo|Placebo
1800772|NCT00585533|Drug|Erlotinib (Tarceva)|Erlotinib
1800774|NCT00585559|Drug|Placebos for acetaminophen and N-acetylcysteine|Placebos for acetaminophen and N-acetylcysteine
1800775|NCT00585559|Drug|APAP 1 gm every 6 hours and N-acetylcysteine placebo|Acetaminophen 1 gm every 6 hours and N-acetylcysteine placebo
1800776|NCT00585559|Drug|NAC IV infusion at 0.5 gm hourly and APAP placebo|N-acetylcysteine IV infusion at 0.5 gm hourly and acetaminophen placebo
1800777|NCT00585559|Drug|APAP 1 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
1800778|NCT00585559|Drug|APAP 1.5 gm q6 hours, plus NAC IV infusion at 0.5 gm hourly|Acetaminophen 1.5 gm every 6 hours, plus N-acetylcysteine IV infusion at 0.5 gm hourly
1800779|NCT00585585|Drug|betahistine dihydrochloride|oral, 50-300 mg, daily
1800780|NCT00585598|Other|replacing supralaryngeal airway with ET tube|changing tube in trauma bay
1800781|NCT00585611|Drug|Atorvastatin|Atorvastatin - 40 mg orally daily for 6 months
1800782|NCT00585611|Other|placebo|placebo
1800783|NCT00585624|Dietary Supplement|Impact Advanced Recovery|Nutritional supplement
1800784|NCT00585624|Dietary Supplement|No supplement|No supplement
1800785|NCT00585637|Drug|Vitamin D|Taken orally every day for three months
1800786|NCT00585637|Dietary Supplement|Placebo|Placebo pill taken once daily for 3 month
1800787|NCT00585650|Biological|Entercept|Subcutaneous injections 50 mg Entercept or placebo will occur twice weekly over the first 12-week treatment period. At the end of the first 12 weeks, all subjects will be treated with etanercept 50 mg twice a week for an additional 12 weeks.
1800788|NCT00585650|Other|Placebo injections|Placebo injections twice weekly for first 12 weeks
1800789|NCT00585689|Drug|ABI-007|ABI-007 will be administered at a dose of 260 mg/m2 over a 30 min IV infusion on day 1 of each 21 day cycle.
1800790|NCT00585689|Drug|Carboplatin|Carboplatin will be administered at a dose of TARGET AUC=5 over a 15 min IV infusion of day 1 of each 21 day cycle.
1800791|NCT00585689|Drug|Gemcitabine|Gemcitabine will be administered at a dose of 800 mg/m2 over a 30 min IV infusion on days 1 and 8 of each 21 day cycle.
1800792|NCT00585689|Procedure|Radical Cystectomy|
1800793|NCT00585715|Device|1064 nm Nd:YAG laser|3 treatments at 3-5 week intervals Spot size: 10 - 18 mm diameter Fluence: 50 J/cm2 Laser pulse duration: 50 ms Rep. rate: Up to 2 Hz DCD cooling 0-50 ms
1800794|NCT00585728|Procedure|CT Virtual Proctoscopy (CTVP)|CTVP done prior to initiation of therapy and a couple of weeks before patient has surgery.
1800795|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
1800796|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
1800797|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
1800798|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
1800799|NCT00585741|Procedure|Imaging with 18F-FLT PET|Imaging with 18F-FLT PET
1800800|NCT00585754|Drug|Guanfacine|1.5mg BID
1800801|NCT00585754|Drug|Placebo|placebo
1800802|NCT00585780|Drug|Prazosin|three week dose titration schedule at the start of study with the full dose schedule of 5.0mg in the morning, 5.0mg at 3pm, and 11.0mg at bedtime for 8 weeks and then a 5-day taper in week 12.
1800803|NCT00585780|Drug|placebo|placebo
1800804|NCT00585793|Drug|NRTI/NNRTI/ Kaletra|Fixed dose and cild formulation Kaletra
1800805|NCT00585819|Procedure|reproduce breathing cycle utilizing spirometry|reproduce breathing cycle utilizing spirometry
1800806|NCT00585819|Procedure|Freebreathing in Body fix mold|Freebreathing in Body fix mold
1800807|NCT00594503|Drug|Hyperbaric oxygen therapy|Total body exposure to increased atmospheric pressure oxygen
1800808|NCT00594516|Drug|tapentadol (CG5503) Immediate Release IR|21 day Open Label: an adjustable dose of Tapentadol IR 50-100mg orally every 4-6 hours to maximum total daily dose (TDD) dose of 500 mg during open label period
1800809|NCT00594516|Drug|tapentadol (CG5503) Extended Release (ER)|During 2 double blind periods: Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in the first intervention period of double-blind phase and Tapentadol IR in the second or Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER in second
1800810|NCT00594516|Drug|tapentadol (CG5503) Immediate Release (IR)|Following open label period is 2 double blind periods: Tapentadol IR in first intervention period of double-blind phase and Tapentadol ER 100, 150, 200 or 250 mg tablets twice daily in second or Tapentadol ER in first intervention period of double-blind phase and Tapentadol IR in second
1800811|NCT00594529|Procedure|Surgery|Liver resection for metastatic liver lesions
1800812|NCT00594542|Drug|lidocaine|Each group is the appropriate concentration of lidocaine with epinephrine for local anesthesia at the beginning of each Mohs stage and the reconstruction.
1800813|NCT00594555|Drug|Imatinib Mesylate|Imatinib Mesylate: 400mg po BID every day. Imatinib Mesylate will be administered Day 2 to Day 15
1800817|NCT00594581|Drug|Juvista (avotermin) plus placebo, standard-care (within-subject controls)|Intradermal Juvista (avotermin) at 50ng or 200ng per 100μl per linear cm of wound margin
1800818|NCT00594594|Other|Probiotic Lactobacillus GR-1 and RC-14|Two capsules of Lactobacillus GR-1 and RC-14 daily for 12 months
1800819|NCT00594607|Device|AN69ST dialysis membrane|AN69ST is the filter that the blood goes through during hemodialysis
1800820|NCT00594607|Device|Fx8 (Fresenius)|Polysulphone dialysis membrane
1800821|NCT00594620|Dietary Supplement|Flav-ein capsules|Soy/isoflavone supplementation
1800822|NCT00594620|Drug|Placebo|Placebo
1800823|NCT00594633|Other|donepezil and questionaires|Patients will undergo a brief cognitive evaluation prior to (baseline/Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 1), Cognitive Re-Evaluation (about 12 weeks after Time 2) ,Cognitive Re-Evaluation (about 6 months after discontinuation of Donepezil). Then pt will be tx with donepezil, an acetylcholinesterase inhibitor. They will undergo a four-week dose titration (i.e., 5mg QD during weeks 1-4) to reach a final dose of 10mg QD of oral donepezil there after for a maximum of 24 weeks.
1800824|NCT00594646|Drug|TRUVADA + raltegravir|TRUVADA (tenofovir disoproxil fumarate (DF) 300mg + emtricitabine 200mg) + RALTEGRAVIR 400mg
1800825|NCT00594659|Behavioral|Psychotherapy|Nine session treatment
1800826|NCT00594659|Behavioral|Computerized Psychotherapy|Nine session computer delivered treatment
1800827|NCT00594659|Behavioral|Motivational enhancement therapy|Two session treatment
1800828|NCT00594698|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL 5% Dextrose for Injection in glass bottles, to be administered as a single continuous infusion during image acquisition. Infusion time not to exceed 60 minutes
1800829|NCT00594724|Procedure|MRI|Adaptation Using Functional Magnetic Resonance Imaging and Diffusion Tensor Imaging
1800830|NCT00594737|Drug|memantine hydrochloride|memantine hydrochloride oral tablets, 10mg po bid
1800831|NCT00594776|Device|Cone Beam CT Scan|The Cone Beam Computerized Tomographic (CBCT) device utilizes computerized tomographic technology, a special digital imaging plate and a computer to create a three-dimensional image. The special imaging plate and software allow for small details to be imaged without tissue overlap.
1800833|NCT00594815|Drug|Cytarabine, Leucovorin, Methotrexate, Procarbazine, Rituximab, Vincristine|Immunochemotherapy
1800834|NCT00597519|Drug|Fludarabine, Cyclophosphamide|"Fludarabine 25 mg/m2/day IV in the morning x 3 days (days -7, -6 and -5) for a total dose of 75 mg/m2 followed by Cyclophosphamide on days -6 and -5. 60mg/kg/day IV over 30-60 minutes x 2 days (days -6 and -5). High volume fluids should commence approximately 12 hours prior to drug and continue until 24 hours after second dose.
Total Body Irradiation: 125 cGy x 11 doses (TID on days -3, -2, -1 and BID on day 0) for a total TBI dose of 1375 cGy. Pediatric patients unable to tolerate a TID dosing schedule can receive 150 cGy x 8 doses (BID on days -3, -2, -1, and 0). All patients will receive GVHD prophylaxis with 2 drugs: Cyclosporine A and Mycophenolate mofetil (MMF).
Units should be given consecutively each over approximately 10-30 minutes.Pre-medication should include acetaminophen and diphenhydramine or hydroxyzine.G-CSF 5 mcg/kg/day IV/SQ (dose rounded to vial size to a maximum of 480 mcg) will be given from day +1 until ANC recovery."
1800835|NCT00597519|Procedure|Transplantation|The UCB ( Umbilical Cord Blood) collection known as a unit is processed to remove excess plasma and red cells, tested for sterility, HLA-typed, cryopreserved and stored. This protocol involves the administration of two UCB units from two different donors. The units will be thawed in the Cytotherapy Laboratory as per the current standard operating procedure.
1800836|NCT00597532|Dietary Supplement|Soy|soy (soy protein supplementation 50 grams/day)
1800837|NCT00597532|Dietary Supplement|Milk|placebo (milk protein supplementation 50 grams/day)
1800838|NCT00597545|Procedure|Carotid endarterectomy|When a shunt is inserted to increase blood flow to the brain
1800839|NCT00597545|Device|Shunt|A tube inserted below and above the surgical area at the time when the carotid artery is clamped to allow the surgeon to work in a bloodless field and to supplement blood flow to the brain.
1800840|NCT00597558|Drug|Egg white protein|Egg white protein powder
1800841|NCT00597584|Drug|peginesatide|"Participants received peginesatide by intravenous (IV) or subcutaneous (SC) injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa or beta dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa or beta dose. Participants who received epoetin alfa or beta IV at the time of screening received peginesatide IV during the study, and participants who received epoetin alfa or beta SC at the time of screening received peginesatide SC during the study.
The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
1800842|NCT00597584|Drug|Epoetin alfa or Epoetin beta|"Participants continued to receive commercially available epoetin alfa or beta by intravenous or subcutaneous injection, at the same starting dose, frequency and route of administration as received during the last week of the Screening Period, with the first study dose of epoetin alfa or beta administered after randomization at Week 0.
The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period."
1800843|NCT00597597|Drug|Erlotinib|During the treatment period, subjects will receive single agent erlotinib, 150mg/day.
1800878|NCT00597896|Drug|pramipexole|po pramipexole versus matching placebo minimum 0.125 mg bid and maximum 0.75 mg bid
1801046|NCT00599430|Dietary Supplement|Lactobacillus acidophilus NCFM|1e10 CFU/day
1800844|NCT00597610|Other|Transrectal ultrasound 3-D (TRUS)|Transrectal ultrasound (TRUS) is widely accepted as an accurate and effective technique for staging of rectal cancer. The decision to administer pre-operative chemotherapy/radiation therapy is often made based on the results of the TRUS. Three-dimensional TRUS (3-D TRUS) is a new modality that provides all of the information of traditional TRUS as well as the ability to provide three dimensional views of the tumor.
1800845|NCT00597623|Other|Adalimumab (Humira®)|syringes for injections under cutaneous dose = 40mg vol = 0.8 ml
1800846|NCT00597623|Other|Placebo|syringes under cutaneous vol = 8 ml
1800847|NCT00597636|Behavioral|Questionaire, blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
1800848|NCT00597636|Behavioral|Questionaire, Blood sample|Provide 30ml blood for laboratory assays Complete Health Questionnaire
1800849|NCT00597649|Drug|Bicifadine|SR dosage form of 400 mg bid or tid for one year
1800850|NCT00597662|Device|polylactide-caprolactone-trimethylenecarbonate copolymer|Polylactide-caprolactone-trimethylenecarbonate copolymer membrane is applied directly over the surgical scar on the visceral peritoneum
1800851|NCT00597662|Device|Icodextrin 4%|1 liter icodextrin 4% is instilled into the peritoneal cavity at the end of the operation
1800852|NCT00597675|Biological|Peanut OIT|Defatted peanut flour ingested daily as oral mucosal immunotherapy
1800853|NCT00597675|Biological|Placebo|Oat flour matched by weight and consistency that is ingested daily as a placebo
1800854|NCT00597688|Drug|Chlorhexidine gel|Oral mucosal application of chlorhexidine gel
1800855|NCT00597688|Drug|Placebo gel|Oral mucosal application of placebo gel
1800856|NCT00597701|Drug|Baclofen|Baclofen 10 mg by mouth every 8 hours for 72 hours or until discharge if before 72 hours.
1800857|NCT00597701|Drug|Placebo|Placebo
1800858|NCT00597701|Drug|Lorazepam|"Lorazepam was provided to all subjects (both arms of the study), as indicated by clinical condition. Standard symptom-triggered dosing of lorazepam for alcohol withdrawal was used. That is, the size and the frequency of the dose of lorazepam was determined by the severity of the alcohol withdrawal symptoms."
1800859|NCT00597714|Drug|Non-myeloablative Stem Cell Transplantation|The preparative regimen is 4 days of daily fludarabine at 40 mg/m2/d infused over 30 minutes; melphalan 140 mg/m2/d for 1 day administered over 15 minutes; 4 days of Alemtuzumab at 20 mg/d in 250 ml of normal saline infused over 3 hours. Group B's prep regimen will begin on day -5 or day -4 and busulfan 130mg/m2/d for 2 days over 3 hours. The peripheral blood stem cells (PBSCs) will be infused over 2-4 days. Patient evaluations will occur 2 times per week by physical exam for toxicity through day 45.
1800860|NCT00597727|Drug|Peanut SLIT|Liquid peanut protein drops diluted in glycerin which are dosed under the tongue.
1800861|NCT00597727|Drug|Placebo SLIT|Liquid glycerin without peanut which are dosed under the tongue.
1800862|NCT00597753|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks. The starting dose was based on the participant's total weekly epoetin alfa dose during the last week of the Screening Period; the first dose was administered one week after the last epoetin alfa dose. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 grams per deciliter (g/dL) and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
1800863|NCT00597753|Drug|Epoetin Alfa|Participants continued to receive commercially available epoetin alfa by intravenous injection, at the same starting dose and frequency as received during the last week of the Screening Period, with the first study dose of epoetin alfa administered after randomization at Week 0. The dose was adjusted to maintain hemoglobin levels in a target range of 10.0-12.0 g/dL and ± 1.5 g/dL from baseline during the Titration and Evaluation Periods, and 10.0-12.0 g/dL during the Long-Term Safety and Efficacy Period.
1800868|NCT00597779|Device|Dynamic Hip Screw (DHS); Trochanteric Fixation Nail (TFN)|Surgical stabilization of unstable intertrochanteric hip fractures using two commonly used implant categories
1800869|NCT00597792|Device|NDO Full-thickness Plicator|A low-profile (≤6mm) gastroscope was advanced and an EGD followed by Savary wire placement was performed. The gastroscope was then removed and the Plicator was advanced directly over the wire and into the stomach. The gastroscope was re-introduced through the Plicator, and the Plicator was retroflexed under direct endoscopic visualization to the anterior gastric cardia, approximately 1cm below the gastroesophageal (GE) junction. The Plicator arms were opened and the endoscopic tissue retractor was advanced deeply into the gastric cardia. The gastric wall was then retracted into the open arms of the Plicator. The arms were closed and a single, transmural pledgeted suture was deployed. The Plicator and gastroscope were then removed and the gastroscope re-inserted to evaluate the post-plication GE junction.
1800871|NCT00597818|Drug|Cobiprostone|6 mcg and 12 mcg capsules
1800872|NCT00597818|Drug|Placebo|0 mcg capsules
1800873|NCT00597844|Other|voice evaluation and fMRI|will undergo voice evaluation and fMRI prior to surgical rehabilitation of UVCP and in approximately one month and six months following treatment.
1800874|NCT00597844|Other|undergo voice evaluation and fMRI prior|in approximately one month and six months
1800875|NCT00597857|Drug|Hydrocortisone|Participants will receive a tapering low-dose of hydrocortisone in pill form for 10 days, twice a day, after the trauma.
1800876|NCT00597857|Drug|placebo|receipt of a placebo pill for 16 days
1800879|NCT00597909|Drug|sodium phenylacetate and sodium benzoate injection 10% / 10%|5.5 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
1800880|NCT00597909|Drug|sodium phenylacetate and sodium benzoate injection 10% / 10%|2.75 g/m² diluted in 10% dextrose, IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
1800881|NCT00597909|Drug|placebo solution (10% dextrose)|Placebo solution (10% dextrose), IV as a 2-hour loading (initial) dose, followed by the same dose over 24 hours (maintenance infusion); maintenance infusion will be continued for 3 days (70 hours)
1800882|NCT00597935|Procedure|SSLF|sacrospinous ligament fixation (SSLF)
1800883|NCT00597935|Procedure|ULS|uterosacral vaginal vault ligament suspension (ULS)
1800884|NCT00597935|Behavioral|PMT|Pelvic muscle training and exercises (PMT)
1800885|NCT00597948|Behavioral|Healthy Lifestyles Curriculum|Three consecutive days of six hours of training comprised of instruction and participant interaction.
1800886|NCT00597974|Procedure|Angioplasty|(non-experimental) Carotid artery angioplasty and/or stent-supported angioplasty
1800887|NCT00597974|Device|Stent|(non-experimental) Precise™ Nitinol Self-Expanding Stent (Cordis Endovascular, Johnson & Johnson), S.M.A.R.T.® Control™ Stent (Cordis Endovascular, Johnson & Johnson), Wallstent® (Boston Scientific Medi-Tech)
1800888|NCT00597974|Other|Neurological and neuropsychological evaluations|Clinical examinations consisting of a neurological and neuropsychological evaluation
1800889|NCT00597974|Procedure|Angiography|(non-experimental) Coronary angiography
1800890|NCT00598000|Behavioral|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.
Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
1800891|NCT00598000|Behavioral|questionnaires|"QOL Measures- The following measures will be administered at Pre-Op, First Post-Op Visit 4, 8, 12 months Post-Op.
Brief Pain Inventory and daily analgesic log- enrollment, patients will fill out the BPI preoperatively, postoperative days 2 to 4, initial, 4-month, 8-month and 12-month postoperative visits."
1800892|NCT00598013|Drug|Pioglitazone|The pioglitazone treatment group received 30mg pioglitazone at 2 weeks after renal transplantation for 12 months.
1800893|NCT00598026|Other|Tele- follow-up|Remote transmission to the implantation centre every 3 months
1800894|NCT00598026|Other|Conventional follow-up|Visits at the implantation centre every 3 months
1800895|NCT00598052|Drug|Escitalopram|10mg/day
1800896|NCT00598065|Other|PET/CT|Synchronized PET/CT Imaging
1800897|NCT00598078|Drug|Sodium Oxybate|Dose 1
1800898|NCT00598078|Drug|Sodium Oxybate|Dose 2
1800899|NCT00598078|Other|Placebo|Dose 3
1800900|NCT00598091|Drug|gemcitabine|1000mg/m2, Days 1, 8, 15
1800901|NCT00598091|Drug|dasatinib|50mg, PO, QD
1800902|NCT00598091|Drug|gemcitabine|1000mg/m2, days 1, 8, 15
1800903|NCT00598091|Drug|dasatinib|50mg, PO, BID
1800904|NCT00598104|Drug|QAX576|
1800905|NCT00598104|Drug|Placebo|
1800906|NCT00598117|Behavioral|Questionnaires|"Newly diagnosed patients will be assessed at four points Time 1 (prior to treatment)
Initial QOL form
FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 2 (initial post-op)
Follow up QOL form
FACT-E, PAR, Symptom Assessment Scale, MDSS Time 3 (6 months post op)
Follow up QOL form
FACT-E, PAR, Symptom Assessment Scale, MDSS, Time 4 (1 year post op)
Follow up QOL form
FACT-E, PAR, Symptom Assessment Scale, MDSS"
1800907|NCT00598130|Biological|Fleece|Fibrin Patch
1800908|NCT00598143|Behavioral|Vignette, questionnaires and Saliva Samples|The short vignette discusses the health implications of potential molecular markers of cancer risk assessment. The questionnaire asks several multiple-choice questions to assess the participant's interest in and understanding of molecular risk assessment. Patients are instructed to swish with 10cc of Scope mouthwash and to expectorate into a sterile 50cc conical tube.
1800909|NCT00598143|Behavioral|Urine Collection, Smoking cessation treatment|Single void urine specimens (approximately 50 ml) will be collected in pre-labeled specimen containers on a 3-monthly (±1 month) basis for 12 months. Standard evidence-based therapy for smoking cessation, including behavioral therapy and pharmacological therapy, is provided.
1800910|NCT00598156|Drug|erlotinib (Tarceva)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
1800911|NCT00598156|Drug|bevacizumab (Avastin)|Chemotherapy for 18 weeks (XELOX, XELIRI, FOLFOX or FOLFIRI)
1800912|NCT00598169|Biological|rituximab|375mg/m2 on Day 1
1800913|NCT00598169|Drug|bortezomib|Part A: Velcade Day 1 and Day 8 of a 28-day cycle, with inter-subject dose escalation over four dose levels: 0.7 mg/m2, 1 mg/m2, 1.3 mg/m2 and 1.5 mg/m2 Part B: Velcade on Days 1 and 8 of a 21-day cycle.
1800914|NCT00598169|Drug|carboplatin|"Carboplatin will be dosed to an AUC=5, calculated using the Calvert formula (5 x [creatinine clearance + 25]; the maximum dose of carboplatin is 750 mg.
Part A: AUC=5 (maximum 750 mg) IV administered on Day 9. Part B: AUC=5 (maximum 750 mg) IV administered on Day 2."
1800915|NCT00598169|Drug|dexamethasone|Part A: 20 mg IV on Days 8-10. Part B: 20 mg IV on Days 1-3 and on Day 8.
1800916|NCT00598169|Drug|etoposide|Part A: 100 mg/m2 IV Days 8-10. Part B: 100 mg/m2 IV daily on Days 1 to 3.
1800917|NCT00598169|Drug|ifosfamide|"Part A: 5000 mg/m2 mixed with an equal amount of Mesna as a 24 hour continuous IV infusion on Day 9.
Part B: 5000 mg/m2 mixed with an equal dose of Mesna administered via continuous infusion for 24 hours beginning on Day 2."
1800918|NCT00598169|Genetic|polymerase chain reaction|Correlate EBV/HHV-8 viral load changes with lymphoma response. HIV and EBV/HHV-8 viral loads will be assessed on baseline, day 2, 4, and 8 of week 1 of Part A.
1800919|NCT00598169|Genetic|western blotting|Peripheral blood mononuclear cells will be collected at Day 1 prior to chemotherapy, Day 2, 4 and 8 (prior to chemotherapy) then weekly during Part A, just prior to each additional cycle of Part B and at treatment completion. Western blot using antibody specific for APOBEC3G and antibody against actin for internal control will be used to quantify APOBEC3G levels. Changes at will be compared with baseline using a paired t-test.
1800921|NCT00598208|Drug|corifollitropin alfa|On Cycle Day 2, a single injection of 60 μg, 120 μg, or 180 μg Org 36286 was administered. One week later (Treatment Day 8), treatment was continued with a fixed daily subcutaneous (SC) dose of 150 IU Puregon® up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and up to and including the Day of hCG. The maximum total treatment duration was 19 days.
1800922|NCT00598208|Drug|Follitropin beta injection|Starting on Cycle Day 2, a fixed daily dose of 150 IU Puregon® SC was administered for the entire stimulation period up to and including the Day of hCG. Orgalutran® (0.25 mg) was administered once daily SC starting on Treatment Day 5 and given up to and including the day of hCG. The maximum total treatment duration was 19 days.
1800923|NCT00598234|Drug|Celecoxib (Celebrex)|The study group received 400mg oral celecoxib about 1 hr prior to surgery, and 200mg every 12 hrs, along with PCA morphine, over the first five post-operative days. The control group received placebo, along with PCA morphine over the same postoperative period. All patients received Acetaminophen 500mg qid for pain control.
1800924|NCT00598247|Drug|Paclitaxel Poliglumex|Paclitaxel Poliglumex 175 mg/m2 will be given over ten minutes every 3 weeks.
1800925|NCT00598260|Procedure|induction of labor|study group - induction of labor at optimal time of delivery between 38 weeks and 41 weeks.
1800926|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
1800927|NCT00598273|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
1800928|NCT00598273|Drug|Darbepoetin alfa|As prescribed, starting dose of 0.75 microgram per kilogram (mcg/kg) administered by subcutaneous injection once every 2 weeks. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
1800930|NCT00598299|Procedure|venous puncture|venous puncture
1800931|NCT00598299|Other|obtain serum from perripheral blood or cord blood|obtain serum from perripheral blood or cord blood
1800932|NCT00598312|Drug|Leuprolide Acetate for Injectable Suspension|Sustained release injectable microspheres, 22.5 mg, one injection every 84 days, 3-month product
1800933|NCT00598325|Biological|3'-aminomethyl-Nic r-EPA Conjugate (NicVAX®)|1.0 ml injection IM given every 4 weeks (weeks 0, 4, 8, 12, 16)
1800934|NCT00598338|Drug|Prucalopride|4 mg o.d.
1800935|NCT00598338|Other|Placebo|o.d.
1800937|NCT00598390|Drug|[11C]MePPEP|
1800938|NCT00598403|Drug|cefditoren pivoxil|400 mg, oral, single dose during 3 days
1800939|NCT00598403|Drug|Ciprofloxacin|250 mg, oral, twice a day for 3 days
1800940|NCT00598416|Behavioral|Family-Responsive Psychoeducation Program (PERF)|Group psychoeducation for HCV patients and their primary caregiver.
1800941|NCT00598429|Drug|Inhaled Prostaglandin E1|Delivery of one dose of either high dose PGE1 (300 ng/kg/min), low dose PGE1 (150 ng/kg/min), or placebo (normal saline, the diluent for the drug) via nebulizer over a 72-hour period
1800942|NCT00598442|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.025 milligram per kilogram (mg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
1800943|NCT00598442|Drug|peginesatide|Participants received peginesatide by subcutaneous injection once every 4 weeks. The starting dose was 0.04 mg/kg and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
1800944|NCT00598442|Drug|Darbepoetin alfa|Participants received darbepoetin alfa by subcutaneous injection once every 2 weeks, as prescribed. The starting dose was 0.75 microgram per kilogram (mcg/kg) and was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
1800945|NCT00598481|Genetic|Gene transduced CD34+ cells|infusion of autologous CD34+ cells transduced with retroviral vector encoding ADA after non-myeloablative conditioning with Busulphan
1800946|NCT00598507|Drug|ZK-EPO|Participants were treated with 16 mg/m^2 of ZK-EPO (EpothiloneZK) (Sagopilone) administered as a single 3 hour intravenous infusion every 21 days. Prior to each treatment, participants were premedicated with either granisetron or ondansetron and additional anti-emetics if needed. Chemotherapy was continued until disease progression, withdrawal of consent, or for unacceptable treatment-associated toxicity.
1800947|NCT00598533|Device|Rapamycin + Probucol-eluting stent (ISAR stent)|due to randomization, Rapamycin- + Probucol-eluting stent will be implanted
1800948|NCT00598533|Device|polymer based Zotarolimus-eluting stent (Endeavor Resolute)|due to randomization, Zotarolimus-eluting stent with polymer will be implanted
1800949|NCT00598546|Behavioral|EORTC QLQ-C30, QLQ-STO22, and MSK-10|QLQ-C30 is the generic QOL tool for patients with cancer undergoing clinical trials.QLQ-STO22, containing 22 questions specific to gastric cancer, is currently the only standardized disease-specific questionnaire to measure the QOL of gastric cancer and must be used in conjunction with the QLQ-C30.MSK-10 consists of ten additional questions that were developed by surgeons on the GMT service to answer specific questions about outcomes related to proximal subtotal, distal subtotal, and total gastrectomies. These questions focus on eating capabilities, work status and major life changing events.
1800950|NCT00598559|Drug|IV Acetaminophen|Arm 1: 1 g IV Acetaminophen every 6 hours administered for five days. Arm 2: 650 mg IV Acetaminophen every 4 hours administered for five days. Arm 3: The standard of care treatments were defined as any medication the investigator deemed appropriate to treat the subject, including products containing acetaminophen but excluding IV acetaminophen.
1800999|NCT00599001|Drug|SD-101|Single subcutaneous escalating dose
1801000|NCT00599001|Drug|placebo|placebo
1800951|NCT00598572|Drug|Deferoxamine Mesylate|Various dose-regimens ranging from 7 mg/kg to 125 mg/kg (with a maximum allowable total daily dose of 6000 mg at any of the tested dose tiers, regardless of patient's weight), administered daily by IV infusion for three consecutive days.
1800952|NCT00598585|Drug|Sildenafil (Viagra)|25 mg tid of either Sildenafil(Viagra) for first week. 50 mg tid of either Sildenafil (Viagra) for second week. 100 mg tid of either Sildenafil (Viagra) 3rd,4th, 5th and 6th week of study participation.
1800953|NCT00598585|Drug|Placebo|Placebo pills 3X/day for 6 weeks
1800954|NCT00598611|Drug|desloratadine|singel dose, oral, 20 mg
1800955|NCT00598611|Drug|desloratadine|single dose, oral, 5 mg
1800957|NCT00598637|Device|Everolimus-eluting stent (Xience)|stent is implanted due to randomization
1800958|NCT00598637|Device|Zotarolimus-eluting stent (Endeavor Resolute)|stent is implanted due to randomization
1800959|NCT00598650|Drug|E2020|Dosage and administration: Patients will receive oral administration of 1 tablet of 3 mg (E2020) from Day 1 to Day 14 of treatment period, 1 tablet of 5 mg (E2020) from Day 15 onwards once daily after breakfast.
1800960|NCT00598663|Device|insulin pump with continuous glucose sensing (Paradigm Real-Time Insulin Pump System)|6 months of pump plus continuous glucose sensing in conjunction to SMBG
1800961|NCT00598663|Device|insulin pump and blinded continuous glucose sensing (Paradigm Real-Time insulin pump)|insulin pump with smbg to be worn for 6 months. 15 days in each 6 week period blinded continuous glucose sensing will be conducted.
1800962|NCT00598676|Device|biodegradable polymer Rapamycin-eluting stent|due to randomization, rapamycin-eluting stent with biodegradable polymer will be implanted
1800963|NCT00598676|Device|permanent polymer rapamycin-eluting stent (Cypher)|due to randomization, rapamycin-eluting stent with permanent polymer will be implanted
1800964|NCT00598676|Device|permanent polymer everolimus-eluting stent (Xience, Promus)|due to randomization, everolimus-eluting stent with permanent polymer will be implanted
1800965|NCT00598689|Drug|0.3% hypromellose|0.3% hypromellose four times a day for 5 days prior to LASIK surgery
1800966|NCT00598702|Drug|IV Acetaminophen|Target is 1 to 7 days of therapy with intravenous (IV) Acetaminophen (IV APAP) at a dose of 40 to 75 mg/kg body weight/day administered as an IV infusion (or by syringe pump) over 15 minutes and given every 4 to 6 hours as a scheduled dose
1800967|NCT00598715|Device|Sirolimus eluting stent|Sirolimus-eluting stent will be implanted
1800968|NCT00598715|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent will be implanted
1800969|NCT00598728|Behavioral|Quality of Life Questionaires|A patient questionnaire, which includes questions on medical morbidities and QOL, will be mailed to participants.
1800970|NCT00598741|Other|DCE-MRI|"Patients will undergo DCE-MRI prior to, and within 18-24 days of starting chemotherapy. These studies are designed to determine if the DCE-MRI data will provide an a priori or early prognostic marker of tumor response. The dynamic MRI is done on a standard clinical scanner using standard techniques described below.
MR imaging studies will be acquired on a 1.5T GE (Milwaukee,WI) Signa LX scanner."
1800971|NCT00598793|Drug|biphasic insulin aspart|
1800972|NCT00598793|Drug|insulin glargine|
1800973|NCT00598793|Drug|metformin|
1800974|NCT00598793|Drug|pioglitazone|
1957544|NCT02335944|Drug|INC280|cMET inhibitor
1957545|NCT02335944|Drug|EGF816|EGFR-TKI
1800978|NCT00598819|Device|CDI 1000 COM|CDI 1000 COM sensors were attached to subject's forehead for a 12 hour period.
1800979|NCT00598832|Drug|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
1800980|NCT00598832|Drug|Adapalene Lotion Vehicle|Adapalene Lotion Vehicle will be applied topically to the face, once a day, for 12 weeks
1800981|NCT00598845|Procedure|Tumor biopsy study|Tumor specimens from endometrial cancer patients, collected preoperatively and during primary hysterectomy, are investigated.
1800982|NCT00598858|Drug|Docetaxel|Given IV
1800983|NCT00598858|Drug|Prednisone|Given PO
1800984|NCT00598871|Drug|Thymosin Beta 4 (Tβ4)|There are 2 groups: active drug and placebo. The patients in the active arm receive an administration of 0.01% Tβ4 (w/w) eyedrops to the affected eye, 2 drops 4 times daily (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
1800985|NCT00598871|Other|Placebo|There are 2 groups: active drug and placebo. The patients in the placebo arm receive an administration of 0.00% Tβ4(w/w) eyedrops to the affected eye, 2 drops four times a day (QID) (breakfast, lunch, dinner, and bedtime) for 14 days. The first of 4 daily doses will be administered following surgery (vitrectomy).
1800986|NCT00598884|Behavioral|Internet-Based Self-Management for Prolonged Grief Symptoms|The treatment consists of empirically derived cognitive behavioral therapy strategies to promote stable and active routines, self-care, accommodation of loss, enhanced self-efficacy, re-engagement in pleasurable activities, and reattachment with significant others. Treatment sessions will be Internet-based and will occur three times per week for 6 weeks.
1800987|NCT00598897|Drug|clarithromycin, rifabutin|Clarithromycin three times per week (variable dosage) in combination with multiple drugs including rifabutin or rifampin three times per week (variable dosage). Dosage dependent on age, weight and other patient-specific health factors.
1800988|NCT00598910|Drug|Omacor|n-3 PUFA
1800989|NCT00598910|Drug|Placebo|Placebo
1800990|NCT00598923|Drug|topiramate|100 mg twice per day for 3 months
1800991|NCT00598923|Drug|topiramate|100 twice per day for 6 days after loading dose of phenytoin
1800992|NCT00598923|Drug|phenytoin|loading dose of 20 mg/kg and then 300 mg/day for total of 7 days
1800993|NCT00598936|Device|CDI 1000 COM and INVOS 5100|CDI 1000 and INVOS 5100 sensors were attached to subject's forehead for a 12 hour period, digital photographs were taken before and after sensor placement.
1800994|NCT00598962|Drug|Azithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
1800995|NCT00598962|Drug|Rifabutin/rifampin|
1800996|NCT00598975|Drug|NKTR-102 + Cetuximab|Drug: NKTR-102 + Cetuximab
1957546|NCT02336048|Drug|Chlorambucil|Chlorambucil at a dose of 0.5 milligrams per kilogram (mg/kg) will be administered orally per local prescribing information, on Days 1 and 15 of Cycles 1 to 6.
1801001|NCT00599027|Drug|Mometasone furoate nasal spray (MFNS)|Mometasone furoate nasal spray (MFNS) 200 mcg once daily (two 50 mcg puffs per nostril) in the morning.
1801002|NCT00599027|Drug|Placebo nasal spray|Placebo nasal spray once daily (two puffs per nostril) in the morning.
1801003|NCT00599040|Behavioral|The DASH diet with weight loss|A reduced calorie diet is provided to participants based on the DASH diet.
1801004|NCT00599040|Behavioral|The DASH diet without weight loss|participants are given a weight maintainenance diet based on the DASH diet
1801005|NCT00599040|Behavioral|Dairy diet|participants are given a high dairy, reduced calorie diet
1801006|NCT00599053|Drug|Azithromycin|10 mg/kg IV per dose given for 10 days
1801007|NCT00599066|Device|study cases|Application of a second M-Entropy probe on the forehead of the patient, which will happen in the OR along with the application of other monitors immediately before induction of general anesthesia.
1801008|NCT00599079|Drug|Azithromycin|Azithromycin Daily Dosage dependent on clinical factos such as age, weight and patient specific health descriptors
1801009|NCT00599105|Procedure|magnetic resonance imaging|MRI contrast agent, 0.1 mmol/kg
1801010|NCT00599131|Drug|Cisplatin|1. Day 1: 100 mg/m2, administered as an i.v. infusion will run over one hour. 2. Day #23: Subjects with a < 50% response (NR) to induction chemotherapy will undergo salvage laryngectomy followed by RT. Cisplatin will be added to radiation for patients whose surgical pathology reveals high-risk features (i.e. extracapsular spread, > 2 positive lymph nodes, perineural invasion, or positive margins). Cisplatin will either be dosed a 100 mg/m2 every 21 days or 40 mg/m2 weekly at the discretion of the prescribing physician.
1801011|NCT00599131|Drug|Cetuximab|1. Cetuximab will be administered at 400 mg/m2 on Day 20 (2 hour administration). 2. Cetuximab will be administered in combination with radiation therapy to those subjects who had a Partial or Complete response after the first cycle of the chemotherapy regimen is administered. The dosage for these administrations is 250 mg/m2 over sixty minutes and it will be administered for six weeks.
1801012|NCT00599131|Drug|5-Fluorouracil|5-FU will be administered 750 mg/m2 in 0.9% normal saline as a 24-hour continuous infusion, days #1-4.
1801013|NCT00599131|Drug|Docetaxel|75 mg/m2 by I.V. over one hour on Day # 1 only
1801014|NCT00599144|Procedure|videolaparocholecystectomy|Group1: a bupivacaine 0,5% (2mg/kg) soaked-tabotamp is placed in gallbladder bed after remove of gallbladder
1801015|NCT00599144|Procedure|videolaparocholecystectomy|Group2: bupivacaine 0,5%(2mg/kg)is infiltrated in trocar incision after their closure.
1801016|NCT00599144|Procedure|videolaparocholecystectomy|Group3: control group without any local anesthetic use.
1801017|NCT00599170|Drug|Rituximab|375 mg/m2 IV
1801018|NCT00599183|Other|MRI-Diffusion Tensor Imaging and Tractrography|MRI scan: Baseline: Conventional MRI (as part of clinical care) with additional diffusion tensor imaging (DTI)sequence (research). 6-week follow up: MRI with DTI and tractography as part of the research
1801019|NCT00599196|Drug|Rotigotine|"Rotigotine trans-dermal patches, once daily:
10 cm2 (2 mg/24 hours); 20 cm2 (4 mg/24 hours); 30 cm2 (6 mg/24 hours); 40 cm2 (8 mg/24 hours); 50 cm2 (10 mg/24 hours); 60 cm2 (12 mg/24 hours); 70 cm2 (14 mg/24 hours); 80 cm2 (16 mg/24 hours);
Optimal dosing:
During the first year: The maximum Rotigotine dose allowed is 8 mg/24 hours.
After the first year: allowed dose increase of rotigotine up to a maximum of 16 mg/24 hours."
1801020|NCT00599209|Other|clinical decision support|CDS is provided to prescribers on intervention units upon ordering medication which offers advice on prescribing and monitoring practices
1801021|NCT00599222|Biological|ranibizumab|0.5 mg intravitreal injection
1801022|NCT00599222|Procedure|TTT|Transpupillary thermotherapy (TTT)
1801023|NCT00599222|Procedure|Sham TTT|Sham Transpupillary thermotherapy (TTT)
1801024|NCT00599235|Drug|sildenafil|50mg 3 times daily for 7 days
1801025|NCT00599235|Drug|hydralazine|25mg 3 times daily for 7 days
1801026|NCT00599235|Drug|placebo|3 times daily for 7 days
1801027|NCT00599248|Biological|TissueGene-C|TissueGene-C at 3x10e6, 1x10e7 or 3x10e7 cells/joint to be administered by intra-articular injection
1801028|NCT00599248|Biological|Placebo|Placebo control (DMEM)
1801029|NCT00599261|Procedure|ICD/pacemaker pocket revision|Pocket revision consists of complete removal of the fibrous capsule surrounding the device and leads
1801030|NCT00599274|Drug|Interferon beta-1a|injection once a week
1801031|NCT00599274|Drug|Interferon beta-1a|injection three times a week
1801032|NCT00599287|Drug|Haloperidol|Haloperidol 2,5 mg. 2 dd 1, oral. (if patient is 69 years or younger) Haloperidol 1 mg. 2 dd 1, oral (if patient is 70 years or older)
1801033|NCT00599287|Drug|Methylphenidate|Methylphenidate 5 mg. 2 dd 1, oral, increased every day with 10 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 30 mg./day
1801034|NCT00599287|Drug|Rivastigmine|Rivastigmine 1,5 mg. 2 dd 1, oral, increased every third day with 3 mg. until negative CAM(-ICU) or side-effects. Maximum dosage 12 mg./day
1801035|NCT00599287|Other|No intervention|No intervention
1801036|NCT00599313|Drug|Sunitinib|50 mg/day orally each of Days 1-28 of each 6 week cycle
1801037|NCT00599326|Drug|Deferasirox|250 mg of deferasirox once daily for 6 months
1801038|NCT00599352|Dietary Supplement|magnesium|Single infusion of elemental magnesium given over 4 hours, 0.2mEq/kg (2.4 mg/kg)
1801039|NCT00599365|Other|Pharmacy care arm|"The pharmacist will take all your medication bottles, and give you medication boxes filled with your medications in the order you should take them in.
You will need to give a complete list of medications to the pharmacist.
You will need to describe how you take these medications.
The pharmacist will teach you about the medications. This includes side effects, drug interactions, and directions.
The pharmacist will give you a medication schedule, and other papers about your medications."
1801040|NCT00599378|Behavioral|Implementation Intentions-based telephone counseling|Implementation Intentions-based telephone counseling
1801041|NCT00599391|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation for 30 to 40 minutes per session.
1801042|NCT00599404|Drug|PN400|500 mg esomeprazole/20 mg naproxen, once daily on Days 1-10 and twice daily on Days 2-9
1801043|NCT00599417|Drug|Bacterial Lysates|Bacterial Lysates ampoules 3 mL, oral route, daily for 10 days, followed by 30 days free of medication and then 10 days of administration of the drug
1801044|NCT00599417|Drug|placebo|placebo controlled
1801045|NCT00599430|Dietary Supplement|Placebo|Inert excipient
1801047|NCT00599430|Dietary Supplement|Combination of Lactobacillus acidophilus and Bifidobacterium lactis|1x10e10 CFU/day
1801048|NCT00599443|Biological|Seasonal cell-derived influenza vaccine|0.5 mL im, single dose
1801049|NCT00599443|Biological|Placebo Comparator|0.5 mL im, single dose
1801050|NCT00599456|Dietary Supplement|Omega 3 fatty acid vitamins|Omega 3 fatty acid vitamins, 2 capsules, by mouth, daily, for 3 months
1801051|NCT00599456|Dietary Supplement|Placebo capsules|Placebo capsules,2 capsules, by mouth, daily for 3 months
1801052|NCT00599469|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared radiation for 30 to 40 minutes per treatment session.
1801053|NCT00599482|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far infrared radiation for 30 to 40 minutes during each session.
1801054|NCT00599495|Procedure|allogeneic HSCT|dose-reduced conditioning regimen
1801055|NCT00599508|Dietary Supplement|Concord grape juice|Several ounces Concord grape juice administered 3 times a day for 12 or 16 weeks. Specific dosage determined by participant's weight.
1801056|NCT00599508|Dietary Supplement|placebo juice|several ounces placebo juice consumed three times a day for 12 or 16 weeks; dosage determined according to participant's weight
1801057|NCT00599508|Dietary Supplement|blueberry juice|wild blueberry juice administered daily for 12 weeks, dosage determined according to participant's weight
1801058|NCT00599508|Dietary Supplement|whole fruit blueberry powder|whole fruit, freeze dried blueberry powder derived from a blend of cultivated blueberries administered daily for 16 weeks
1801059|NCT00599508|Dietary Supplement|berry placebo powder|berry placebo powder administered daily for 16 weeks
1801060|NCT00599521|Drug|Adapalene lotion 0.1%|Adapalene, 0.1% will be applied topically to the face, once a day, for 12 weeks
1801061|NCT00599521|Drug|Adapalene Lotion Vehicle|Vehicle will be applied topically to the face, once a day, for 12 weeks
1801062|NCT00599534|Drug|Montelukast|4 mg oral tablets
1801063|NCT00599534|Drug|Placebo|5mg tablets
1801064|NCT00599547|Procedure|Allogeneic Stem Cell Transplantation|Allogeneic Stem Cell Transplantation after dose-reduced Conditioning for Myelofibrosis Patients
1801065|NCT00599560|Genetic|vasopressin, V2 receptor and cyclic AMP|plasma vasopressin, V2 receptor, cyclic AMP
1801066|NCT00599573|Drug|ondansetron|Ondansetron 4mg BID for six weeks
1801067|NCT00599586|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
1801069|NCT00599612|Drug|GW856553|A dose of 10mg GW856553 containing 50µCi of [14C]GW856553 will be delivered as 100mL of a 0.1mg/mL GW856553/0.5 µCi/mL oral solution.
1801070|NCT00599625|Drug|Pravastatin|80mg administered daily for 6 consecutive weeks
1801071|NCT00599638|Drug|pregabalin|75mg bid titrating to 150mg bid on day 4
1801072|NCT00599638|Drug|pregabalin/PF-00489791|Pregabalin 75mg bid titrating to 150mg bid on day 4; PF-00489791: 4mg od titrating to 10mg od on day 4
1801073|NCT00599638|Drug|Placebo|Placebo
1801074|NCT00599651|Device|Surfactant administered via Laryngeal Mask Airway (LMA)|Standard volume of Infasurf surfactant (3 mL/kg) will be injected in 2-4 aliquots into the proximal end of the LMA.
1801075|NCT00599651|Other|standard of care (nasal CPAP and supplemental oxygen)|Standard of care will be utilized which may mean surfactant is administered
1801076|NCT00599664|Drug|OMS201|OMS201 irrigation solution during surgery
1801077|NCT00599664|Drug|Vehicle|Vehicle irrigation solution during surgery
1801078|NCT00599677|Other|acupuncture|Subjects are treated five days a week continuously, and for four weeks.They are treated 30min every time.
1801079|NCT00599677|Drug|Itopride|Each pill weighs 50mg, once a pill, three times a day. The pills are taken half an hour before meals, and be taken 4 weeks continuously.
1801080|NCT00599690|Procedure|Epi-LASK|10 eyes of 10 patients underwent epi-LASK, epithelial flaps were created with the Amadeus II, epi-LASIK-LASIK microkeratome (Ziemer ophthalmics systems AG, Switzerland). A Visx star 4 system (Visx, Santa Ana, CA, USA) was used to perform the laser ablation in all eyes
1801081|NCT00599703|Other|fMRI Scan, pre- and post language evaluation|All subjects will undergo functional MR imaging, pre- and post-surgical language evaluation, and electrocortical stimulation mapping. The brain tumor patients will undergo these procedures twice.
1801082|NCT00599716|Drug|sodium hyaluronate|a sterile, unpreserved eye drop containing sodium hyaluronate in a proprietary formulation to be administered by ocular instillation
1801083|NCT00599716|Drug|vehicle|identical to proprietary formulation of active eye drop but without active ingredient, sodium hyaluronate
1801084|NCT00599742|Behavioral|Balance training|Physical exercise of balance. The training will last 7 weeks, twice per week, 1 hour per session.
1801085|NCT00599742|Behavioral|Motor training|Motor exercise of power and flexibility. The training will last 7 weeks, twice per week, 1 hour per session.
1801086|NCT00599755|Radiation|Comparator: CT or MRI and FDG-PET|Participants have 4 computed tomography (CT) or magnetic resonance imaging (MRI) scans at screening, baseline, at the end of each treatment cycle (day 21 and day 42.) They also have FDG-PET scans, 2 at Baseline and one at the end of each treatment cycle.
1801087|NCT00599755|Drug|Gemcitabine and Cisplatin or Gemcitabine and Carboplatin|Gemcitabine administered intravenously at a dose of 1000-1250 mg/m^2 on Day 1 and Day 8 of each cycle; Cisplatin administered intravenously at a dose of 60-85 mg/m^2 or Carboplatin at a dose of 4-6 Area Under the Curve (AUC) on Day 1 of each cycle. Two cycles are given 3 weeks apart.
1801088|NCT00599768|Other|ID-Pain DN4 Questionnaire|This is a non-interventional questionnaire validation study
1801089|NCT00599781|Genetic|gene transduced PBL and/or gene transduced HSC|infusions of autologous PBL and/or HSC transduced with retroviral vectors encoding ADA
1801090|NCT00599807|Dietary Supplement|Vitamin D3 (cholecalciferol)|the intervention is a dietary supplement comparing the current standard (800 IU) to the current safe upper limit (2000 IU)
1801091|NCT00599820|Drug|Intravitreal Bevacizumab|
1801092|NCT00599833|Biological|cetuximab|
1801093|NCT00599833|Radiation|3-dimensional conformal radiation therapy|
1801094|NCT00599859|Dietary Supplement|lactose|consumption of 50g lactose/day in 2 divided doses mixed in water.
1801095|NCT00599859|Dietary Supplement|lactose|consumption of lactose 50g/day in 2 divided doses mixed in water
1801096|NCT00599872|Biological|Standardized Ragweed Allergenic Extract|Standardized Ragweed Allergenic Extract, sublingual oral
1801097|NCT00599872|Biological|Placebo|Placebo, sublingual oral
1801098|NCT00599885|Drug|telmisartan|telmisartan 40-80mg once per day for 8 months
1801099|NCT00599885|Drug|valsartan|valsartan 80-160mg once per day for 8 months
1801100|NCT00599898|Drug|Atosiban|Atosiban group will receive an atosiban bolus (6.75 mg) over 1 min then an intravenous infusion of 300mcg/min for 3 h followed by 100mcg/min for another 45h. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, atosiban will be stopped and the women will receive nifedipine as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
1801101|NCT00599898|Drug|Nifedipine|Nifedipine group: the initial dose will be 20 mg (one tab) orally every 20 min for 3 doses. If the contractions is inhibited, a maintenance dose of 20 - 40 mg every 6 h up to 48 h will be followed. If contractions continue or recur within 48 hours or the dilatation of the cervix progresses by 1 cm or more within 48 hours, nifedipine will be stopped and the women will receive atosiban as a 2nd line (see arm 2). If the second line fails and gestational age is less than 28 weeks, indomethacin will be administered as a 3rd line.
1801102|NCT00599911|Drug|Lu AA24530|per oral, once daily for 6 weeks
1801103|NCT00599911|Drug|Duloxetine|per oral, once daily for 6 weeks
1801104|NCT00599911|Drug|Placebo|per oral, once daily for 6 weeks
1801105|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
1801106|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 2/2)
1801107|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 ( CRC, only Schedule 2/2)
1801108|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
1801109|NCT00599924|Drug|sunitinib + FOLFOX|50 mg sunitinib + modified FOLFOX6 (Schedule 4/2)
1801110|NCT00599924|Drug|sunitinib + FOLFOX|37.5 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
1801111|NCT00599924|Drug|sunitinib + FOLFOX|25 mg sunitinib + modified FOLFOX6 (Continuous Dosing)
1801112|NCT00599937|Drug|ATRA|early introduction of ATRA
1801113|NCT00599937|Drug|ATRA and or Chemo as maintenance|patients were randomized both to receive or not receive intermittent ATRA (45 mg/m2/d, 15 days every 3 months) and to receive or not receive continuous CT with 6 mercaptopurine (90 mg/m2/d, orally) and methotrexate (15 mg/m2/wk, orally), according to a 2-by-2 factorial design stratified on the initial induction treatment group
1801114|NCT00599950|Drug|Mitomycin C and Photorefractive keratectomy (PRK)|Topical mitomycin C on the corneal epithelium of patients undergoing photorefractive keratectomy (PRK)
1801115|NCT00599963|Drug|paricalcitol|paricalcitol 1 mg/day
1801116|NCT00599976|Procedure|Pulmonary vein isolation|Pulmonary vein isolation
1801117|NCT00599989|Procedure|adjuvant therapy|
1801118|NCT00599989|Procedure|conventional surgery|
1801119|NCT00599989|Radiation|3-dimensional conformal radiation therapy|
1801120|NCT00599989|Radiation|brachytherapy|
1801121|NCT00599989|Radiation|intracavitary balloon brachytherapy|
1801122|NCT00599989|Radiation|proton beam radiation therapy|
1801123|NCT00600002|Biological|GM-CSF|Cohort 1: 50 ug/m2 given Intravenous. Cohort 2: 150 ug/m2 given Intravenous. Cohort 3: 250 ug/m2 given Intravenous. Cohort 4: 0 ug/m2 and vehicle (normal saline) given Intra-tumoral. Cohort 5: 50 ug/m2 given Intra-tumoral. Cohort 6: 150 ug/m2 given Intra-tumoral. Cohort 7: 250 ug/m2 given Intra-tumoral.
1801124|NCT00600015|Drug|Erlotinib + Sorafenib|Patients who are randomized to Cohort A will take sorafenib 400 mg (2 x 200-mg tablets) orally twice a day, and erlotinib 150 mg orally once a day.
1801125|NCT00600015|Drug|Erlotinib + Placebo|Patients who are randomized to Cohort B will take erlotinib 150 mg orally once a day and placebo orally twice a day.
1801126|NCT00600028|Drug|Thalidomide|Thalidomide 50 - 100 mg by mouth daily
1801127|NCT00600028|Drug|Placebo|Placebo 50-100 mg by mouth per day
1801128|NCT00600041|Drug|Pantoprazole|80 mg IV over 2 minutes, followed by 8 mg/h IV for 60 minutes
1801129|NCT00600041|Drug|Placebo|Identical infusion manner like experimental arm
1801130|NCT00600054|Biological|nimotuzumab (anti EGFR humanized monoclonal antibody)|150 mg/m2 I.V. Induction phase: infusions once a week for 8 weeks. Consolidation phase: infusions once every 2 weeks for 10 weeks. Patients may then continue on the consolidation regimen of nimotuzumab, until disease progression or the occurrence of unacceptable toxicity.
1801131|NCT00588731|Drug|Cannabidiol|Active Cannabidiol daily over 6 weeks
1801132|NCT00588731|Drug|Placebo|Placebo
1801133|NCT00588757|Device|Optease IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
1801134|NCT00588757|Device|Gunter-Tulip IVC filters|IVC filters will be implemented and evaluated for retrieval after 2-3 weeks.
1957547|NCT02336048|Drug|Obinutuzumab|Obinutuzumab at a dose of 100 milligrams (mg) as an intravenous (IV) infusion will be administered on Cycle 1 Day 1; 900 mg as IV infusion on Cycle 1 Day 2; 1000 mg as IV infusion on Cycle 1 Days 8 and 15; and 1000 mg as IV infusion on Day 1 of each subsequent cycle for up to 6 cycles.
1801141|NCT00588783|Device|I-beam design|This group will utilize tibial components with an I-beam design for total knee replacement.
1801142|NCT00588783|Device|Cruciate design|This group will utilize tibial components with cruciate designs for total knee replacement.
1801143|NCT00588809|Drug|selumetinib|Given PO
1801144|NCT00588822|Biological|Rituximab|Rituximab will be given as a 375 mg/m^2 intravenous infusion once weekly for four doses (days 1, 8, 15, and 22).
1801145|NCT00588835|Drug|aprepitant|125mg on Day 1; 80mg on Day 2-3 during CE cycle. Dexamethasone is added as well.
1801146|NCT00588835|Drug|Dexamethasone and Ondansetron during CE-treatment|Standard anti-emetic regimen during CE treatment
1801147|NCT00588848|Device|Autoadjusting CPAP (VPAP Auto)|An autoadjusting CPAP unit is used in place of subject's own CPAP unit during the night of the polysomnography study (the first night after surgery).
1801148|NCT00588848|Device|CPAP|Subject's own CPAP unit is applied to the subject during the polysomnography study night (the first night after surgery)
1801149|NCT00588861|Device|Answer® hip stem|Total hip replacement using Palacos® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
1801150|NCT00588861|Device|Answer® hip stem|Total hip replacement using Simplex® bone cement, the Answer® hip stem and the Ranawat/Burnstein® acetabular shell.
1801151|NCT00588887|Device|Duracon®|This group utilizes the Duracon® prostheses for total knee replacement.
1801152|NCT00588887|Device|Vanguard™|This group will utilize the Vanguard™ prostheses for total knee replacement.
1801153|NCT00588900|Drug|cediranib maleate|
1801154|NCT00588900|Drug|irinotecan hydrochloride|
1801155|NCT00588913|Biological|aldesleukin|
1801156|NCT00588913|Biological|therapeutic autologous lymphocytes|
1801157|NCT00588913|Drug|zoledronic acid|
1801158|NCT00588926|Drug|Remifentanil|After the mapping electrode is in situ, recording of baseline electrical activity is done for two-three minutes and an infusion of Remifentanil, 0.1 microgram per kilogram per minute is started. This procedure continues for a few minutes until the patient is sedated and then the infusion is stopped and the patient allowed to recover. The recordings continue during the whole procedure.
1801159|NCT00588939|Device|Cell~vizio (Laser connfocal microscopy)|completed during endoscopy
1801160|NCT00588952|Drug|Ketamine and Placebo|Two test days will involve administration of placebo and Ketamine (0.23 mg/kg, loading dose and infusion rate 0.58 mg/kg/minute) intravenously for 60 minutes
1801161|NCT00588965|Drug|Placebo|Placebo will be given 1 pill daily for a week, then 2 pills daily, followed by the exercise test.
1801162|NCT00588965|Drug|Propranolol LA|Subjects will receive propranolol LA 80 mg one pill daily for 1 week then 2 pills daily for 1 week followed by exercise test.
1801163|NCT00588978|Behavioral|diet and/or exercise|Three arms are included: Diet Alone, Exercise Alone, and Combined Diet and Exercise
1801168|NCT00589030|Radiation|brachytherapy|The target dose of TheraSphere® is 80-150Gy
1801169|NCT00589030|Radiation|yttrium Y 90 glass microspheres|The target dose of TheraSphere® is 80-150Gy
1801170|NCT00589056|Drug|cisplatin|
1801171|NCT00589056|Drug|etoposide|
1801172|NCT00589056|Drug|nelfinavir mesylate|
1801173|NCT00589056|Genetic|protein expression analysis|
1801174|NCT00589056|Other|immunohistochemistry staining method|
1801175|NCT00589056|Other|laboratory biomarker analysis|
1801176|NCT00589056|Procedure|biopsy|
1801177|NCT00589056|Radiation|radiation therapy|
1801178|NCT00589082|Drug|DaunoXome|
1801179|NCT00589082|Drug|Daunorubicine|
1801180|NCT00589095|Other|dynamic contrast enhanced magnetic resonance imaging|dynamic contrast enhanced MRI using contrast agent gadodiamide
1801181|NCT00589108|Device|Sigma Knee System|Sigma Knee System (mobile-bearing knee with the P.S. polyethylene insert)
1801182|NCT00589108|Device|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System with a metal back tibial tray (fixed-bearing knee with the metal backed tray)
1801183|NCT00589108|Device|Sigma Pressfit Condylar Posterior Cruciate Substituting System all polyethylene tray|Sigma Pressfit Condylar Posterior Cruciate Substituting System (fixed bearing with an all polyethylene tray)
1801184|NCT00589446|Device|Hysteroscope|An 8mm hysteroscope with irrigation channel and 30 degree view will be inserted into the uterus prior to curettage in cases of recurrent missed abortion
1801185|NCT00589472|Drug|Bicalutamide|Given PO
1801186|NCT00589472|Drug|Goserelin Acetate|Given SC
1801187|NCT00589472|Other|Laboratory Biomarker Analysis|Correlative studies
1801188|NCT00589472|Drug|Leuprolide Acetate|Given IM
1801189|NCT00589472|Procedure|Therapeutic Conventional Surgery|Undergo radical prostatectomy
1801190|NCT00589472|Drug|Vorinostat|Given PO
1801191|NCT00589485|Device|Simplex® Bone Cement|This arm will utilize Simplex® Bone Cement in total knee replacement.
1801192|NCT00589485|Device|Cobalt™ Bone Cement|This arm utilizes Cobalt™ Bone Cement in total knee replacement.
1801193|NCT00589498|Dietary Supplement|1000 extra calories|Each subject received 1000 kcal/d in addition to weight maintenance requirements. The diet composition throughout the study was 40% carbohydrate, 40% fat, and 20% protein.
1801194|NCT00589524|Device|Computed tomography (CT)|Computed tomography (CT), as performed by Dual Source Computed Tomography (DSCT)(Siemens Medical Solutions Germany) to be conducted no sooner than 3 days before or after cardiac catheterization, but with 3 months of the cardiac cath.
1801195|NCT00589537|Other|questionnaire administration|
1801196|NCT00589537|Procedure|computed tomography|
1801197|NCT00589537|Procedure|magnetic resonance imaging|
1801198|NCT00589537|Procedure|quality-of-life assessment|
1801199|NCT00589550|Biological|PEG-interferon alfa-2b|administered SC on day 1 of each week of therapy. This will most likely be a Monday or a Tuesday. Sorafenib will be initiated on day 15 (start of week 3) of the first course and continued daily without breaks.
1801200|NCT00589550|Drug|Sorafenib|
1801201|NCT00589550|Genetic|gene expression analysis|
1801202|NCT00589550|Genetic|polymerase chain reaction|
1801203|NCT00589550|Genetic|reverse transcriptase-polymerase chain reaction|
1801204|NCT00589550|Other|flow cytometry|
1801205|NCT00589550|Other|immunoenzyme technique|
1801206|NCT00589550|Other|laboratory biomarker analysis|
1801207|NCT00589563|Biological|anti-thymocyte globulin|0.5 mg/kg on day -3, 1.5 mg/kg on day -2 and 2.5 mg/kg on day -1 or day 0 from stem cell transplant
1801208|NCT00589563|Drug|cyclophosphamide|60mg/kg on days -5 and -4 from stem cell transplant
1801209|NCT00589563|Drug|etoposide|60mg/kg on day -4 from stem cell transplant
1801210|NCT00589563|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant
1801211|NCT00589563|Drug|melphalan|Melphalan 140 mg/m2 on day -4 from stem cell transplant
1801293|NCT00590187|Drug|sapacitabine|300 mg b.i.d. x 3 consecutive days per week for 2 weeks every 4 weeks
1801212|NCT00589563|Drug|methotrexate|For high risk HLA-mismatch transplant only: 5 mg/m2 on days +1, +3 and +6 from stem cell transplant
1801213|NCT00589563|Drug|sirolimus|"Adults: 12 mg loading dose on day -3 from stem cell transplant followed by 4 mg orally single morning daily dose.
Pediatric Patients <40kg: 3 mg/m2 orally on day -3 from stem cell transplant followed by 1 mg/m2 orally single morning daily dose"
1801214|NCT00589563|Drug|tacrolimus|0.02 mg/kd/d CIV beginning on day -3 from stem cell transplant
1801215|NCT00589563|Procedure|allogeneic hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
1801216|NCT00589563|Procedure|hematopoietic stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
1801217|NCT00589563|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Fludarabine 25 mg/m2/d from days -9 to -5 from stem cell transplant, Melphalan 140 mg/m2 on day -4 from stem cell transplant
1801218|NCT00589563|Procedure|peripheral blood stem cell transplantation|The target peripheral blood stem cell dose will be 5-10 x 106/kg actual body weight
1801219|NCT00589563|Radiation|total-body irradiation|1320 cGy in 11 fractions from day -8 to day -5 or day -9 to day -6 prior to stem cell transplant
1801220|NCT00589589|Device|Endo Tool|Computer tool to help achieve glucose control
1801221|NCT00589602|Procedure|peripheral blood lymphocyte therapy|T-cell depletion will be accomplished using CD34 selection with the Baxter Isolex 300i v. 2.5 device. The desirable T-cell dose will be >0.5 x 105 but <1.0 x 105 CD3+ cells per kg. The targeted CD34 cell dose will be >2 x 106 cells/kg.
1801222|NCT00589602|Procedure|allogeneic hematopoietic stem cell transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
1801223|NCT00589602|Procedure|peripheral blood stem cell transplantation|Peripheral blood stem cell transplantation
1801224|NCT00589602|Radiation|total-body irradiation (TBI)|Treatment will be delivered using 6MV photons twice daily for 3 days
1801225|NCT00589615|Behavioral|multidisciplinary osteoporosis prevention educational program|The program includes individualized counseling aimed at improving diet, muscle strength, balance, and informing individuals about home hazards and the use of medicine.
1801226|NCT00589628|Drug|infliximab|5mg/kg/dose IV at 4 week intervals
1801227|NCT00589628|Drug|infliximab|10mg/kg/dose IV at 4 week intervals
1801228|NCT00589641|Behavioral|CBT-RP (relapse prevention) + Enhanced TAU|CBT-RP is an 20-week augmenting intervention. CBT-RP is based primarily on Alan Marlatt's cognitive behavioral relapse prevention model for substance abuse, but also includes motivational interviewing and mindfulness meditation approaches. Sessions are twice a week in first week, then weekly thereafter, with tapering to biweekly in the last 8 weeks depending on improvement. Participants also receive treatment as usual, and monthly check-ins regarding treatment use.
1801229|NCT00589641|Behavioral|Enhanced TAU Alone|Treatment as usual in the community, monthly check-ins regarding treatment use or needs, and monitoring
1801230|NCT00589654|Other|Questionnaire|Data collection instruments will be obtained at baseline and every six months. Follow-up will range between 26-42 months for participants.
1801231|NCT00589667|Drug|Pemetrexed plus Gemcitabine|"Patients will receive pemetrexed (500 mg/m2 IV infusion over approximately 10 minutes) followed immediately by gemcitabine (1250 mg/m2 IV infusion given over approximately 30 minutes) on day 1 and day 15 of a 28-day cycle. Vitamin supplementation will be as follows: Vitamin B12: 1000 µg IM injection no less than 1 week prior to the first dose of pemetrexed, and continuing approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
Folic acid: The preferred oral daily dose of folic acid is 350 to 1000 µg. Daily folate supplementation begins no less than 1 week prior to the first dose of pemetrexed and continues until 3 weeks after the last dose of pemetrexed.
For rash prophylaxis, dexamethasone (4 mg po twice per day) should be taken on the day before, the day of, and the day after each dose of pemetrexed unless clinical contraindications exist."
1801232|NCT00589693|Drug|Doripenem|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 4-hour infusion of doripenem will be administered every 8 hours for 7 days.
1801233|NCT00589693|Drug|Imipenem-Cilastatin|Type=exact number, number=1, unit=g, form=solution for injection, route=intravenously. 1 gram 1-hour infusion of imipenem-cilastatin will be administered every 8 hours for 10 days.
1801234|NCT00589693|Drug|Placebo|Form=solution, route=intravenous. Doripenem pacebo will be administered from Days 1 to 7 in imipenem-cilastatin arm and imipenem-cilastatin placebo will be administered in doripenem arm.
1957548|NCT02336048|Drug|Placebo|Placebo matching to tocilizumab will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
1801236|NCT00589732|Drug|Valsartan|Valsartan 160mg per day
1801237|NCT00589745|Other|Nasal potential difference measurement|Nasal potential difference measurement involves dripping small amounts of 5 test solutions into the anterior nostril. This is designed to test the ability of the cells to regulate the movement of salt and water in people with features of CF in whom the diagnosis is not entirely clear.
1801238|NCT00589758|Diagnostic Test|Echocardiography|2D and 3D echocardiography
1801239|NCT00589758|Other|Biomarker evaluation|Blood and urine collected
1801240|NCT00589771|Drug|Saccharomyces boulardii|"Saccharomyces boulardii one capsule 250mg TDS for 6 weeks
Ispaghula husk 1 Tsf daily after dinner for six weeks"
1801241|NCT00589771|Drug|Placebo|"Cap Placebo TDS for six weeks
Ispaghula husk 1 Tsf daily after dinner for six weeks"
1801242|NCT00589784|Drug|Sunitinib|The study drug will be administered on an outpatient basis. The starting dose will be 50 mg daily for 28 days (4 consecutive weeks) followed by 14 days off for patients not on CYP3A4 inducers or inhibitors. A cycle equals 42 days.
1957549|NCT02336048|Other|Standard Premedication|Standard-of-care premedication consisting of antipyretic, antihistamine, and corticosteroid will be administered as per United States Package Insert/ Summary of Product Characteristics on Cycle 1 Days 1 and 2 (prior to the first and second dose of obinutuzumab, respectively).
1801245|NCT00589823|Drug|Fentanyl citrate|nasal spray, 100, 200, 400 or 800 mcg dosage according to need, to treat up to four episodes of BTCP per day
1801246|NCT00589823|Drug|Immediate release morphine sulphate|drug dose as required by patient taken to treat up to four epsiodes of BTCP per day
1801247|NCT00589849|Procedure|T-wave Alternans|T-wave alternans is an electrocardiographic finding that is defined as the beat-to beat fluctuation in the amplitude or shape of T wave
1801646|NCT00601614|Drug|temozolomide|
1801248|NCT00589862|Drug|Plavix (Clopidogrel)|150 mg tablet of Plavix (Clopidogrel) per day for 12 months if resistance is identified
1801249|NCT00589875|Biological|AdV-tk|Single dose of 3x10e11 vector particles of AdV-tk delivered to the tumor bed after resection on day 0.
1801250|NCT00589875|Drug|Valacyclovir|Single course of valacyclovir at dose of 2 grams orally three times per day for 14 days starting on day 1-3
1801251|NCT00589888|Drug|Intralipid 20%|Intralipid 20% IV continuous infusion at 20cc/hour for 8 hours
1801252|NCT00589888|Drug|Intralipid 20%|Intralipid 20% IV continuous infusion at 40cc/hour for 8 hours
1801253|NCT00589888|Drug|Normal Saline|0.9% Normal Saline continuous IV infusion at 40/cc for 8 hours
1801254|NCT00589888|Dietary Supplement|32-gram oral fat load|oral liquid fat load prepared by the GCRC every 2 hours for 8 hours.
1801255|NCT00589888|Dietary Supplement|64-gram oral fat load|60-gram oral fat load intake every 2 hours for 8 hours
1957550|NCT02336048|Drug|Tocilizumab|Tocilizumab at a dose of 8 mg/kg or adjusted dose (up to a maximum threshold of 20 mg/kg) will be administered as IV infusion on Cycle 1 Day 1 (prior to the first dose of obinutuzumab).
1801257|NCT00589914|Drug|RISPERDAL CONSTA|RISPERDAL CONSTA: Type=exact number, unit=mg, number=25, 37.5, or 50, form=suspension for injection, route=Intramuscular use. One i.m. injection of RISPERDAL CONSTA 25-50 mg eq every 2 weeks at V4, V6, V7, V8, V9, and V10. PALIPERIDONE PALMITATE PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 2 weeks at Baseline and at V4, V7, and V9. RISPERIDONE: Type=up to, unit=mg, number=1 to 6, form=Tablet, route=Oral Use. One tablet for the first 4 weeks (28 days) of the DB treatment period.
1801258|NCT00589914|Drug|Paliperidone palmitate|PALIPERIDONE PALMITATE: Type=exact number, unit=mg, number=50, 100, or 150, form=suspension for injection, route=Intramuscular use. One i.m. injection of Paliperidone palmitate 50-150 mg eq every 4 wks at Baseline, V4, V7, and V9. RISPERDAL CONSTA PLACEBO: Form=suspension for injection, route=Intramuscular use. One i.m. injection every 4 weeks at Baseline, V4, V7, and V9.
1801259|NCT00589927|Drug|cilostazol|cilostazol 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
1801260|NCT00589927|Drug|placebo|placebo 200mg loading dose within 1 hours after successful stenting, followed by 100mg bid for 8 months
1957551|NCT02334722|Drug|Levetiracetam extended release|
1801263|NCT00589966|Behavioral|Coping Skills Training|Coping Skills Training teaches skills for managing physical, emotional, and social challenges of symptoms commonly experienced by men who have undergone treatment for early stage prostate cancer. Coping skills include activity pacing, managing negative mood, communication enhancement, and applied relaxation.
1801264|NCT00589966|Behavioral|Prostate Cancer Education|Prostate Cancer Education provides information on the following topics: common treatment side-effects, medical options for symptom management, nutrition to support recovery, and guidelines for communicating with your healthcare team.
1801265|NCT00589979|Drug|Lidoderm (Lidocaine 5% Patch)|Topical Patch
1801266|NCT00589979|Drug|Placebo Patch|Topical Patch
1801267|NCT00589992|Drug|Ibutilide fumarate|During scheduled radio frequency ablation for atrial fibrillation patients will be infused with 1mg of ibutilide over 10 minutes.
1801268|NCT00590018|Drug|Hydrocortisone|Hydrocortisone taper (100mg/m2/day --> 25mg/m2/day) over 5 days intravenously.
1801269|NCT00590018|Drug|Placebo|Placebo for 5 days intravenously.
1801270|NCT00590031|Drug|Cisplatin|pts will receive weekly cisplatin 30mg/m2 after hydration on weeks 8,9,11 and 12
1801271|NCT00590031|Drug|Irinotecan|Irinotecan will be given 65 mg/m2
1801272|NCT00590031|Radiation|External Beam Radiation Therapy|will be delivered with multiple (>2) field techniques using mega-voltage radiation therapy. pts will receive 50.4 Gy and will be treated over a 6 week period.
1801273|NCT00590044|Drug|insulin glargine+ glulisine|Daily insulin glargine + glulisine before meals
1801274|NCT00590044|Drug|NPH + Regular insulin|Split-mixed NPH + Regular insulin twice daily
1801275|NCT00590070|Drug|adenosine|Adenosine (80 mcg as fast bolus followed by 2 mg given in 33cc of saline in 2 minutes as slow bolus)
1801276|NCT00590070|Drug|nitroprusside|Nitroprusside (60 mcg as fast bolus followed by 100 mcg given in 33cc of 5% glucose in 2 minutes as slow bolus)
1801277|NCT00590070|Drug|placebo|33 cc of heparinized saline given in 2 minutes as slow bolus
1801278|NCT00590083|Biological|CTL administration|"Adenovirus specific T cells will be given by intravenous injection from day 30 post transplant.
One infusion of Adenovirus-specific CTL given to patients at risk for Adenoviral disease after matched or mismatched unrelated or matched or mismatched related donor stem cell transplant. Four dose levels will be explored. The lowest level will be 1x dose of 5x10e6cells/m2 and the highest will be 1x dose of 1.35x10e8/m2."
1801279|NCT00590109|Other|Blood test|subjects will provide one 8ml blood sample drawn into one ACD tube and 16ml of blood drawn into two EDTA (purple top) tubes.
1801280|NCT00590109|Other|Questionnaire|A questionnaire encompassing medical, environmental exposure, and reproductive history.
1801283|NCT00590135|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg by mouth once daily
1801284|NCT00590161|Drug|pentoxifylline (PTX)|400 mg PO tid
1801285|NCT00590161|Drug|placebo|placebo tid
1801286|NCT00590174|Drug|Aspirin|stopping clopidogrel at 1 year after DES implantation
1801287|NCT00590174|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
1801288|NCT00590187|Drug|sapacitabine|200 mg b.i.d. x 7 days every 3-4 weeks
1801289|NCT00590187|Drug|sapacitabine|300 mg b.i.d. x 7 days every 3 - 4 weeks
1801290|NCT00590187|Drug|sapacitabine|400 mg b.i.d. x 3 days/week x 2 weeks every 3 - 4 weeks
1801291|NCT00590187|Drug|sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
1801292|NCT00590187|Drug|sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
1801647|NCT00601614|Drug|vandetanib|
1801294|NCT00590187|Drug|sapacitabine|200 mg b.i.d. x 7 consecutive days every 4 weeks
1801295|NCT00590187|Drug|Sapacitabine|300 mg q.d. x 7 consecutive days every 4 weeks
1801296|NCT00590187|Drug|sapacitabine|100 mg q.d. x 5 consecutive days per week for 2 weeks every 4 weeks
1801297|NCT00590213|Drug|Casodex 150mg|
1801298|NCT00590213|Procedure|Radiotherapy|
1801299|NCT00590213|Procedure|Haematology|
1801300|NCT00590226|Drug|Detemir + aspart insulin before meals|Detemir insulin SQ once daily + aspart insulin SQ before meals
1801301|NCT00590226|Drug|NPH insulin + regular insulin|NPH insulin SQ + regular insulin SQ before breakfast and dinner
1801302|NCT00590265|Device|Northern Light Technology (SADelite lamp) bright light-therapy|10 000 lux for 30 minutes
1801303|NCT00590265|Device|Northern Light Technology (SADelite lamp) Dim light-therapy|<100 lux for 30 minutes
1801304|NCT00590278|Drug|Tomudex|
1801305|NCT00590278|Procedure|Radiotherapy|
1801306|NCT00590278|Procedure|Haematology|
1801307|NCT00590278|Procedure|Biochemistry|
1801308|NCT00590317|Drug|Prochlorperazine|Patients receiving Prochlorperazine
1801309|NCT00590317|Drug|Ondansetron|Patients receiving Ondansetron
1801310|NCT00590343|Drug|vatalanib|Subjects who meet all inclusion and exclusion criteria will receive an initial dose of PTK787/ZK222584 1,250mg once daily, and subjects will remain on the scheduled doses of Sandostatin LAR 30mg every 4 weeks.
1801311|NCT00590356|Device|StarClose®|Closure device for femoral artery suture site occlusion
1801312|NCT00590356|Device|AngioSeal®|Closure device for femoral artery suture site occlusion
1801313|NCT00590369|Device|KCI -VAC|Negative pressure wound therapy device
1801314|NCT00590369|Device|Versatile One (EZCare)|Negative pressure wound therapy device
1801315|NCT00590382|Device|AMPLATZER Muscular VSD Occluder|AMPLATZER Muscular VSD Occluder
1801316|NCT00590395|Drug|18FDG (an FDA-approved radiopharmaceutical)|Route: Intravenous, Dosage: 5-10mCi, frequency: Single Administration
1801317|NCT00590408|Dietary Supplement|coenzyme Q10|60mg capsule twice daily for 12 weeks
1801318|NCT00590408|Dietary Supplement|matching placebo|matching placebo capsule twice daily for 12 weeks
1801319|NCT00590447|Drug|rituximab monotherapy|375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).
1801320|NCT00590447|Drug|sequential R-CHOP|"375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.
In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy."
1801321|NCT00590460|Biological|CAMPATH-1H|Given intravenous on days -8, -7, and -6
1801322|NCT00590460|Biological|Anti-CD45|"Given intravenous on days -5, -4, -3 and -2
dose is 400 micrograms/kg"
1801323|NCT00590460|Drug|Fludarabine|"Given intravenous on days -8, -7, -6, -5 and -4
Dose is 30 mg/m2"
1801324|NCT00590460|Procedure|Stem cell infusion|Stem cells are infused on day 0
1801326|NCT00590512|Dietary Supplement|High sodium|
1801327|NCT00590512|Dietary Supplement|Low sodium|
1801328|NCT00590525|Procedure|Cardioversion|Baseline hsCRP will be drawn the morning of, prior to, cardioversion. An EKG to document the patient's rhythm will be obtained at the one-month mark
1801329|NCT00590538|Drug|Sodium 4-Phenylbutyrate|The standard oral adult dose is 20 g/day (tablets) for 4 days.
1801330|NCT00590538|Drug|Genistein (Unconjugated Isoflavones 100)|Every participant will be administered a perfusion of 50 MicroM of Genistein (Unconjugated Isoflavones 100) during the modified NPD procedure.
1801331|NCT00590538|Drug|Placebo|The placebo is given to match the active comparator for four days.
1801332|NCT00590551|Other|sling or no sling|Groups will be assigned as follows: 1-supine and with sling, 2-30o HOB elevation without leg elevation and with sling, 3-30o HOB elevation with 10o leg elevation and with sling, 4-supine and without sling, 5-30o HOB elevation without leg elevation and without sling, and 6-30o HOB elevation with 10o leg elevation and without sling
1801333|NCT00590564|Drug|Sho-saiko-to|All patients will receive treatment with 2.5grams of SST as granules in packet form by mouth three times a day every day for 52 weeks unless occurrence of unacceptable adverse events or patient withdrawal. Patients will be seen for clinical follow-up at three month intervals: at 3, 6, 9, and 12 months, and assessed for compliance and asked about side effects and pulmonary symptoms. At each clinic visit, a comprehensive metabolic profile will be performed. At the 6-month clinic visit, a CBC will be performed. At the 12-month clinic visit, quantitative HCV-RNA by PCR will be obtained (Viromed Labs, Inc., 6101 Blue Circle Drive, Minneapolis, MN 5534). Within 4 weeks after the 12-month clinic visit (after 52 weeks of SST therapy), the second liver biopsy will be scheduled and performed.
1801334|NCT00590577|Drug|Paliperidone palmitate 25 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 25 mg eq. i.m. Days 8, 36, 64
1801335|NCT00590577|Drug|Paliperidone palmitate 150 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Days 1, 8, 36, 64
1801336|NCT00590577|Drug|Placebo|Placebo i.m. Days 1, 8, 36, 64
1801337|NCT00590577|Drug|Paliperidone palmitate 100 mg eq.|Paliperidone palmitate 150 mg eq. i.m. Day 1 and 100 mg eq. i.m. Days 8, 36, 64
1801338|NCT00590590|Drug|Lidocaine/Diphenhydramine|semi solid, twice weekly, 4 months
1801339|NCT00590590|Drug|lidocaine|semi solid, twice weekly for 4 months
1801340|NCT00590590|Drug|placebo|semi solid, twice weekly for 4 months
1801341|NCT00590603|Drug|Arsenic Trioxide, Ascorbic Acid and Bortezomib|"Phase I/Cohort I
Loading:
Arsenic Trioxide (ATO): 0.25 mg/kg IV over 1-2 hr qd x 5 days (Monday-Friday)
Ascorbic Acid: 1000 mg by IV infusion over 15 minutes after each infusion of arsenic trioxide qd x 5 days
Maintenance cycles (21 days)
ATO: 0.25 mg/kg IV over 1-2 hr once a week x 2 weeks every 3 weeks (one cycle) for a total of 6 cycles.
Ascorbic Acid 1000mg IV will be given within 30 minutes of completion of ATO.
Bortezomib 1 mg/m2 is administered intravenously in a 3-5 second bolus on days 1, 8 of a 21-day cycle. ATO is given at least one hour prior to Bortezomib. The first cycle will start on week 2, after loading dose week.
Phase I/Cohort 1 is followed by Cohort 2. Phase II uses maximum tolerated dose from Phase I."
1801342|NCT00590616|Procedure|transthoracic examination|observational transthoracic examination
1801343|NCT00590629|Drug|Niaspan|1500 mg Niaspan for 16 weeks
1801344|NCT00590655|Behavioral|weight loss programme with maintenance programme|After usual weight loss treatment, there will be a one-year maintenance programme with monthly visits.
1801345|NCT00590655|Behavioral|weight loss programme|
1801346|NCT00590668|Diagnostic Test|Transesophageal Echocardiography|Measurement of peak diastolic flow velocity
1801347|NCT00590681|Drug|Bevacizumab and Temozolomide|This is an open-label, single arm, multi-center, phase II study involving 48 subjects with newly diagnosed supra-tentorial GBM. Following surgery, subjects with radiographically evaluable disease will receive external beam radiotherapy (59.4 - 60 Gy in 30 - 33 fractions) with daily temozolomide (75 mg/m2). Two to three weeks later, subjects will begin treatment with temozolomide (150-200 mg/m2 daily for five of 28 consecutive days) in conjunction with Avastin (10 mg/kg, every 14 days).
1801348|NCT00590694|Drug|ranibizumab|0.5mg injection monthly according to protocol for one year
1801349|NCT00590707|Device|Deeper sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 0.
1801350|NCT00590707|Device|Moderate sedation|The depth of sedation, as measured by the use of the Observer's Assessment of Awareness/Sedation Scale (OAA/S), will be maintained at an OAA/S score of 4-5.
1801351|NCT00590720|Biological|MEDI528 50 mg|MEDI-528 at a dose of 50 mg administered as a subcutaneous injection twice weekly for 4 weeks
1801352|NCT00590720|Other|PLACEBO|Placebo administered as a subcutaneous injection twice weekly for 4 weeks
1801353|NCT00590759|Device|GORE TAG® Thoracic Endoprosthesis|implant
1801354|NCT00590772|Drug|montelukast|10 mg po each day (compared to placebo for 2 weeks)
1801355|NCT00590772|Drug|placebo|placebo for 2 weeks
1801356|NCT00590785|Drug|Doxorubicin|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
1801357|NCT00590785|Drug|Cyclophosphamide|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
1801358|NCT00590785|Drug|G-CSF|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
1801359|NCT00590785|Drug|tamoxifen|High-dose doxorubicin + cyclophosphamide (AC) x 6 cycles with G-CSF on Days 3 - 12 and followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamoxifen 20 mg daily for 5 years.
1801360|NCT00590785|Drug|ciprofloxacin|High-dose sequential doxorubicin x 4 given with G-CSF on Days 3 - 12+ and followed by high-dose cyclophosphamide x 3 (A+C) given with G-CSF and ciprofloxacin on Days 3-12, followed in postmenopausal patients and hormone receptor-positive premenopausal patients by tamxifen 20 mg daily for 5 years.
1801361|NCT00590798|Behavioral|Walking|Patient will walk within 30 minutes of vascular closure system procedure
1801362|NCT00590824|Drug|hu14.18-IL2|6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course followed by surgery and up to 2 additional courses of hu14.18-IL2
1801363|NCT00590824|Drug|hu14.18-IL2|Surgery followed by 3 courses of 6 mg/m2 hu14.18-IL2 administered via IV on days 1, 2, and 3 of a 28-day course
1801364|NCT00590837|Drug|Lomustine|"Induction: chemotherapy + lomustine (CCNU), 200 mg/m2 orally at day 1.
Consolidation: chemotherapy + lomustine (CCNU), 80 mg orally at day 1.
Reinductions: chemotherapy + lomustine (CCNU), 40 mg orally at day 1."
1801365|NCT00590850|Device|ORIF with Plate and Screws|ORIF with plate and screws
1801366|NCT00590850|Device|Pin Fixation|Clavicle fixation with clavicle pin
1801367|NCT00590863|Drug|SSRI + placebo|Participants will take escitalopram (10 - 20 mg/day)+ placebo (1 to 3 pills per day). Medications taken orally. Participants will take escitalopram plus placebo for up to 28 weeks. Dosages were adjusted as need at each clinic visit.
1801368|NCT00590863|Drug|Escitalopram + Bupropion SR|Participant will take Burpopion SR (150 to 450 mg/day) + Escitalopram (10 to 20 mg/day) for up to 28 weeks. Medications taken orally. Bupropion SR was blinded, and escitalopram was given open label. Dosages were adjusted as need at each clinic visit.
1801369|NCT00590863|Drug|Venlafaxine XR + Mirtazapine|Participants will take Venlafaxine XR (75 to 225 mg/day) + Mirtazapine (15 to 45 mg/day) for up to 28 weeks. Medications taken orally. Venlafaxine XR was blinded, and mirtazapine was given open label. Dosages were adjusted as need at each clinic visit.
1801370|NCT00590889|Device|Artificial Mechanical Heart Valve|Both arms used market released mechanical heart valves in accordance with approved labeling
1801371|NCT00590902|Drug|OSI-774: erlotinib, TarcevaTM|150 mg, 100 mg and 25 mg tablets
1801372|NCT00590915|Drug|Erwinia L-asparaginase|"Substitute Erwinia L-asparaginase 25,000 international units per meters squared, IM every other day (including weekends and holidays) x 6 doses for each dose of PEG-asparaginase that is replaced.
NOTE: Erwinia L-asparaginase dosing to replace native E.coli L-asparaginase varies; consult protocol for specifics."
1801373|NCT00590928|Drug|esomeprazole|40mg once daily
1801374|NCT00590928|Drug|ranitidine|50mg every h hours
1801375|NCT00590941|Procedure|Blood draw|Sample Collection for Genotyping prior to cycle 1 treatment of R-CHOP, if patient is enrolled after cycle 1, sample for genotyping should be collected prior to cycle 2.
1801376|NCT00590954|Drug|Perifosine|"Dosing will be continuous, and for the purpose of this trial a cycle will be defined as 28 days. Perifosine will be given as a 600 mg loading dose on day 1. The loading dose will be divided into 4 equal doses of 150 mg each. The first 3 doses should be given with food in the adult day hospital to allow intravenous antiemetic prophylaxis, and 4th dose at bedtime at home. The interval between doses of perifosine should be no less than 4 hours. On day 2, patients will start the maintenance dose of 100 mg daily at bedtime at home.
In addition to baseline serum, all patients will have weekly serum drawn during weeks 2-4."
1801377|NCT00590967|Radiation|IMRT extended field external beam radiation therapy|
1801378|NCT00590967|Radiation|Brachytherapy|
1801379|NCT00590967|Drug|Cisplatin|
1801380|NCT00590993|Other|MRI and MRSI|Compare treatment impact when using MRI and MRSI
1801648|NCT00601614|Other|immunoenzyme technique|
1801381|NCT00591006|Drug|Phenytoin (brand name Dilantin)|Three days prior to imaging, participants will take two capsules containing phenytoin tablets (100 mg) by mouth at 0900 hours and 2100 hours (400 mg/day) for a total of three days with the last dose at 0900 hours on the day of the imaging (7 doses total).
1801382|NCT00591006|Drug|Hydrocortisone|Beginning two days prior to the imaging (the day after initiating the phenytoin or placebo), participants will begin taking 4 tablets containing hydrocortisone (20 mg) or placebo also at 0900 hours and 2100 hours (160 mg/day) with the last dose at 0900 hours on the day of the imaging (5 doses total). The doses were selected to achieve a low therapeutic blood level of phenytoin and stress level of cortisol. Newcomer et al. (1999) used this dose of hydrocortisone in healthy controls. The imaging will be performed at approximately 1300 hours.
1801383|NCT00591006|Drug|Placebo|Participants take two capsules of placebo 100 mg at 0900 hours and 2100 hours for a total of 3 days with the last dose at 0900 hours on the day of imaging (7 doses total). Beginning two days prior to the imaging (the day after initiating placebo), participants will being taking 4 tablets containing placebo (20 mg) also at 0900 hours and 2100 hours with the last dose at 0900 hours on the day of the imaging (5 doses total).
1801384|NCT00591019|Drug|Modafinil|200 mg/day, morning dose
1801385|NCT00591019|Other|Placebo|Sugar pill once per day in the morning.
1801386|NCT00591045|Drug|mFOLFOX|oxaliplatin 100mg/m2, CF 400mg/m2, 5-FU 2400 mg/m2 46hr civ
1801387|NCT00591058|Drug|TM-601|TM-601, administered intravenously (IV), once/week for 3 weeks
1801388|NCT00591071|Other|Strict glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level below 6.1 mmol/L
1801389|NCT00591071|Other|Conventional glycemic control|Continuous intravenous insulin treatment (NOVORAPID) according to an algorithm to maintain glucose level at 11 mmol/L
1801390|NCT00591084|Drug|ginsenoside-Rd 10 mg|infusion ginsenoside-Rd 10 mg (group A)once a day and continued for 14 days
1801391|NCT00591084|Drug|placebo|infusion placebo (group B)once a day and continued for 14 days
1801392|NCT00591084|Drug|ginsenoside-Rd 20mg|infusion of ginsenoside-Rd 20mg (group C) once a day and continued for 14 days
1801393|NCT00591110|Behavioral|Eye care education|Participants will receive an educational intervention communicating practical information about vision, eye conditions and eye care pertinent to the older African American population
1801394|NCT00591110|Behavioral|Social-contact control|Participants receive an engaging informational session on a non-health related topic
1801396|NCT00591136|Drug|indibulin|Dose escalation, daily dosing for 14 days every 3 weeks, for up to 4 months
1801397|NCT00591149|Drug|Oxaliplatin|130 MG/M2 IV over 2 hours on day 1 of 21 day cycle over a period of 4 cycles
1801398|NCT00591149|Drug|Docetaxel|60 MG/M2 IV over 1 hour on day 1 of a 21 day cycle for a period of 4 cycles
1801399|NCT00591149|Drug|Cetuximab|400 MG/M2 on week 1 then 250 MG/M2 weekly for a total of 12 weeks
1957557|NCT02326597|Other|Decision Aid|Use of decision aid tool to aid in understanding treatment option and identifying personal values and beliefs accessible via devices: iPad, Smart phone, Computer, Tablet
1801403|NCT00591175|Behavioral|Standard Care only|Dentist Provided Standard Care, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
1801404|NCT00591175|Behavioral|Dental Hygienist provided counseling + Brief Questionnaire|Dental Hygienist provided + Brief Questionnaire, 3-month follow-up assessment,Clinic visit salivary cotinine test, 12-month follow-up, Clinic visit salivary cotinine test assessment
1801405|NCT00591175|Behavioral|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire|Dental Hygienist provided counseling with personalized risk communication + Brief Questionnaire, 3-month follow-up assessment, Clinic visit salivary cotinine test, 12-month follow-up assessment, Clinic visit salivary cotinine test
1801406|NCT00591188|Drug|capecitabine, interferon-alpha|Patients who meet inclusion/exclusion criteria will receive combination of study drugs.
1801407|NCT00591201|Drug|infliximab|Infliximab 5mg/kg diluted in 250 ml of isotonic solution of sodium chloride will be administered by the intravenous route on weeks 0, 2, 6, 12, 18, 24, 30, 36, 42, and 48.
1801408|NCT00591201|Drug|Placebo|Placebo -powder diluted in 250 ml of isotonic solution of sodium chloride- will be administered on weeks 0, 2 and 6.
1801409|NCT00591214|Drug|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 12 weeks administration (dose in a day: 2250 mg)
1801410|NCT00591227|Drug|insulins aspart and detemir|insulin aspart will be given every 2 hours dosed from 0.05 to 0.15 units per kg weight to patients with a prior history of diabetes if blood glucose is more than 200 mg/dl in the ER. If subjects are admitted to hospital then they will receive insulin detemir 0.3 units/kg daily and insulin aspart 0.1 units/kg per meal if they are eating.
1801411|NCT00591253|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg, tablets, orally, once daily for up to 6 weeks.
1801412|NCT00591253|Drug|Azilsartan medoxomil|Azilsartan medoxomil 80 mg, tablets, orally, once daily for up to 6 weeks.
1801413|NCT00591253|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily for up to 6 weeks.
1801414|NCT00591266|Drug|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 40 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
1801415|NCT00591266|Drug|Azilsartan Medoxomil and amlodipine|Azilsartan Medoxomil 80 mg, tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
1801416|NCT00591266|Drug|Amlodipine|Azilsartan medoxomil placebo-matching tablets, orally, once daily and amlodipine 5 mg, tablets, orally, once daily for up to 6 weeks.
1957558|NCT02326597|Other|Standard Practice|Standard care teaching and discussion in addition to web-based decision aid tool accessible via devices: iPad, Smart phone, Computer, Tablet
1801417|NCT00591292|Drug|indibulin|Dose escalation of indibulin given twice daily for up to 6 months
1801418|NCT00591305|Dietary Supplement|diindolylmethane (DIM)|3-month DIM
1801419|NCT00591305|Device|585 nm pulsed dye laser|once-time PDL
1801420|NCT00591318|Drug|ceftriaxone|2 grams of ceftriaxone given daily, Monday to Friday, excluding major holidays, for a total of 40 doses
1801421|NCT00591318|Drug|Normal Saline|50 cc of normal saline, daily, Monday through Friday, except for major holidays, for a total of 40 normal saline infusions.
1801422|NCT00591331|Drug|Spinosad (the active ingredient in NatrOVA)|This is a patch test in which the test material is applied to the patch and the patch applied to the skin.
1801423|NCT00591331|Drug|placebo|
1801424|NCT00591344|Behavioral|Progressive resistance training|Exercise twice a week for 2 years doing either progressive resistance training. The The PRE program consisted of 11 strengthening exercises: chest press, latissimus pull downs, reverse flys, double leg press, hip extension, shoulder press, biceps curl, rotary calf (ankle plantar flexion), triceps extension, seated quadriceps extension and back extension.
1801425|NCT00591344|Behavioral|Modified Fitness Counts|The modified Fitness Counts program was taken from Chapters 2 and 3 of the Parkinson's disease: Fitness Counts booklet and focused on non-progressive stretching, strengthening and balance exercises.
1801426|NCT00591357|Drug|loperamide|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
1801427|NCT00591357|Drug|placebo|4 mg PO initially and 2 mg after each water stoll not to exceed 10 mg qd
1801428|NCT00591370|Drug|Temozolomide (TMZ)|One group treatment study
1801429|NCT00591383|Drug|indibulin|indibulin, dose escalation, 200 mg - 600 mg. Taken twice every day.
1801430|NCT00591383|Drug|erlotinib|erlotinib taken at 150 mg every morning with food.
1801431|NCT00591396|Drug|ZIO-101 (Darinaparsin)|Dose Escalation of ZIO-101 (Darinaparsin) given daily for five consecutive days to be repeated every 28 days for up to six months
1801432|NCT00591409|Drug|sugammadex|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arms 2-5) or 0.1 mg/kg vecuronium (arms 7-10).
Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.
At reappearance of T2 the randomized single dose of sugammadex (0.5 to 4 mg/kg) IV was administered."
1801433|NCT00591409|Drug|Placebo|"After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).
Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.04 mg/kg vecuronium IV could be administered if necessary.
At reappearance of T2 the randomized single dose of placebo IV was administered"
1801434|NCT00591422|Drug|ZIO-101-C (Darinaparsin)|Capsule, Dose escalation study from 100 mg to 1000 mg (or Maximum Tolerated Dose). 3 times weekly (>36 hours between doses) for 3 weeks with 1 week rest.
1801435|NCT00591435|Other|Comparison of performance of consultants versus residents|Anesthesia as well as surgical workflow will be analysed. Performance of consultants will be compared to residents
1801436|NCT00591448|Other|Virtual Reality (VR)|See above
1801437|NCT00591474|Dietary Supplement|probiotics|100 gms of a yogurt drink containing probiotics will be given to pVRE positive patients for 4 weeks
1801438|NCT00591474|Dietary Supplement|yogurt|100 gms of pasteurized yogurt drinks with no live cultures will be given to VRE positive patients for 4 weeks
1801440|NCT00591500|Behavioral|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs
1801441|NCT00591500|Behavioral|Questionnaire|Exposures of interest will be measured by a self-administered personal residence, occupation and vacation calendar, a telephone interview, and by testing DNA from buccal cells and blood, when available. Standardization of diagnosis will be undertaken by review of tissue slides. Questionnaire data will be completed by interviewers. DNA will be obtained from each individual in the form of 4-6 buccal swabs.
1801442|NCT00591513|Device|Autologous engineered skin substitutes|Autologous skin cells combined with a biopolymer sponge which is transplanted to excised, full-thickness burns, excised or incised burn scars, or excised full-thickness congenital giant melanocytic nevus. Repeated administrations until all skin wounds are closed.
1801443|NCT00591526|Drug|Arac|Ommit ARAC in the chemotherapy
1801444|NCT00591539|Procedure|Carotid Ultrasound|Bilateral carotid ultrasound measurements: A test that uses sound waves to look at the blood vessels in the neck.
1801445|NCT00591552|Device|Harmonic ACE23P Scalpel|Lymph node dissection
1801446|NCT00591552|Device|Electrocautery|
1801447|NCT00591565|Drug|Acamprosate|acamprosate 333mg tab, 3 by mouth 3 times a day
1801448|NCT00591578|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 40 mg, tablets, orally, once daily for up to 22 weeks.
1801449|NCT00591578|Drug|Azilsartan Medoxomil|Azilsartan Medoxomil 20 mg, tablets, orally, once daily for 2 weeks; titrated to 80 mg, tablets, orally, once daily for up to 22 weeks.
1801450|NCT00591578|Drug|Valsartan|Valsartan 80 mg, tablets, orally, once daily for 2 weeks; titrated to 320 mg, tablets, orally, once daily for up to 22 weeks.
1801451|NCT00591591|Device|OxiplexTS|OxiplexTS is a Frequency Domain Near-Infrared Tissue oximeter which provides absolute values of tissue oxygenation in real time. It also provides physiological quantities of oxy, deoxy and total hemoglobin concentration, which form the basis for the functional measurement of brain hemodynamics. Both the control and OSA groups will undergo standard overnight sleep study (PSG). In addition to the standard PSG, with or without Continuous Positive Airway Pressure (CPAP), we will add the OxiplexTS, allowing us to assess brain oxygenation and hemodynamics during sleep. The hemodynamic patterns of the healthy controls will be compared to the OSA sufferers. Participants with OSA who undergo PSG/CPAP will be also tested with the OxiplexTS. Their PSGs and PSG/CPAP data will be compared.
1801649|NCT00601614|Other|laboratory biomarker analysis|
1801452|NCT00591604|Drug|Vitamin D|Vitamin D, 50,000IU,once weekly for 8 weeks, then every other week for 4 weeks
1801453|NCT00591617|Other|Psychosocial treatment plus Suboxone pharmacotherapy|Participants randomly assigned to one of four psychosocial treatment conditions building on pharmacotherapy with Suboxone (buprenorphine + naloxone)
1801454|NCT00591630|Drug|Zevalin|(111In Zevalin) 5 millicurie (mCi) by vein and (90Y Zevalin) 0.4 mCI/kg by vein.
1801455|NCT00591630|Drug|Carmustine|300 mg/m^2 by vein.
1801456|NCT00591630|Drug|Etoposide|200 mg/m^2 by vein every 12 hours.
1801457|NCT00591630|Drug|Cytarabine|200 mg/m^2 by vein every 12 hours.
1801458|NCT00591630|Drug|Melphalan|140 mg/m^2 by vein.
1801459|NCT00591630|Drug|Rituximab|"Arm 1, Arm 2 = 250 mg/m^2 by vein;
Arm 1, Arm 2, Arm 3, Arm 4 = 1000 mg/m^2 by vein following Stem Cell Transplant;
Arm 1, Arm 3 = 375 mg/m² by vein Maintenance Therapy."
1801460|NCT00591630|Procedure|Stem Cell Transplant|Injection of stem cells (Autologous SCT)
1801461|NCT00591643|Procedure|Imaging, Adrenal acans|The patient will be given 5 drops of saturated solution of potassium iodide daily for 2 days prior to the study and will continue for 5 to 7 days later to minimize the radiation dose to the thyroid gland. One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes. Anterior and posterior images of the adrenal area will be obtained 72 and 96 hours later. Additional images will be made if indicated. Each image would require 30 minutes carried out in the nuclear medicine laboratory. To verify the exact location of the adrenal glands, renal scan with 99m Tc DTPA or Mag 3 (routine nuclear medicine radiopharmaceuticals) will also be obtained whenever indicated. In some patients, dexamethasone suppression will be carried out to improve the specificity of NP 59 diagnosis for autonomous hormonal secretions by the adrenal tumors.
1801462|NCT00591643|Radiation|(NP-59)|One to 2 mCi of I 131 1,6-beta-iodomethyl-19-norcholesterol (NP-59) in 10% ethanol, 0.23% polysorbate 80 and 0.9% NaCl will be given intravenously slowly over 1-5 minutes.
1957561|NCT02320487|Drug|Bendamustine|Bendamustine will be administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2‐6.
1801465|NCT00591682|Drug|MSX-122|"Dosage form = capsule
Starting Dose (First Patient Cohort - Dose Level 1) = 50 mg taken orally once daily, 7 days per week for 4 weeks (total of 28 days), followed immediately by a second course of 28 days with identical dosage form and schedule. (Each patient in each cohort treated for a minimum of 56 days, unless obviated by toxicity.)
If there is no evidence of toxicity at the current dose level, then the dose of MSX-122 will be increased by 100% for the next patient cohort.
If a grade 1-2 toxicity is observed, then the dose will be increased by 50% for the next patient cohort.
If a grade 3 toxicity (non-dose limiting toxicity) is observed then the dose will be increased by 25% for the next patient cohort."
1801466|NCT00591695|Procedure|Stent bridge to surgery + elective surgery|positioning in emergency of a metallic self-expanding stent followed, in case of successful colic decompression, by an elective surgical (laparoscopic or open) resection of the tumour
1801467|NCT00591695|Procedure|Emergency Surgery|Emergency surgery performed in these ways: Resection followed by enterostomy (Hartmann procedure), 'On table' washing and primary anastomoses, Subtotal colectomy
1801468|NCT00591708|Dietary Supplement|Beverage containing calcium citrate malate|Beverages containing a lower amount of calcium (0-400 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
1801469|NCT00591708|Dietary Supplement|Beverage fortified with calcium citrate malate|Beverages containing a higher amount of calcium (500-1300 mg/d) will be supplemented to a basal diet containing 600 mg/d Ca. The controlled diet will be consumed for 21 consecutive days.
1801470|NCT00591721|Behavioral|Energy conservation education|The intervention for this study is a group-based educational program delivered by teleconference to 4-6 individuals with MS by a licensed occupational therapist. The program involves 6 weekly sessions. Each session is 1 hour and 15 minutes in duration. Key topics addressed include: importance of rest, positive and effective communication, modification of the environment, using equipment and technology, setting priorities, and activity analysis and modification. Direct instruction, group discussion, and peer support are key elements of the program. Participants receive a manual with application activities that are completed in between sessions.
1801471|NCT00591734|Drug|Bevacizumab|15 mg/kg of bevacizumab intravenously (IV) once every 3 weeks.
1801472|NCT00591734|Drug|Everolimus|10 mg by mouth daily
1801473|NCT00591747|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
1801474|NCT00591747|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
1801475|NCT00591760|Drug|Somatotropin|Subcutaneous Somatotropin (recombinant human Growth Hormone) 0.012 mg/kg every second day for 6 months
1801476|NCT00591773|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily; and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
1801477|NCT00591773|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg, tablets, orally, once daily; azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily and chlorthalidone 25 mg, tablets, orally, once daily for up to 6 weeks.
1801650|NCT00601627|Biological|panitumumab|
1957562|NCT02320487|Drug|Obinutuzumab|Obinutuzumab will be administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2‐6.
1801478|NCT00591773|Drug|Chlorthalidone|Chlorthalidone 25 mg, tablets, orally, once daily; azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily and azilsartan medoxomil 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
1801479|NCT00591786|Drug|Sugammadex|4 Doses of Sugammadex Administered at 1-2 PTC After 0.9 mg/kg Rocuronium or 0.1 mg/kg Vecuronium
1801480|NCT00591786|Drug|Placebo|4 Doses of placebo Administered at 1-2 PTC After 0.9 mg/kg Rocuronium or 0.1 mg/kg Vecuronium
1801481|NCT00591799|Device|The Jarvik 2000 Ventricular Assist System|Jarvik 2000 Heart implantation is intended for patient's with end-stage heart failure who are approved heart transplant candidates - who meet all of the study's inclusion criteria and none of its exclusion criteria.
1801482|NCT00591812|Device|ComPreSs Distal Femoral Replacement System.|ComPreSs system of intramedullary fixation along with the Finn Knee system
1801483|NCT00591825|Drug|D-cycloserine|D-cycloserine
1801484|NCT00591825|Drug|Placebo|Placebo
1801486|NCT00591851|Drug|AC [Adriamycin (A) (also known as doxorubicin) and Cyclophosphamide (C)] Followed By Paclitaxel (P)|No Intervention
1801487|NCT00591864|Device|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
1801488|NCT00591877|Procedure|Acupuncture|"Each patient will undergo a 30 minute session, twice a week, for a total of 12 sessions. The technique will involve electro-stimulation at predefined points followed by needle manipulation.
The acupoints that will be used are:
ST-36: 3 finger breadths inferior to lower edge of patella between tibialis anterior muscle and the tibia, 1 finger breadth lateral to the anterior crest of the tibia.
PC-6: 2 finger breadths proximal to and in the middle of the most distal transverse crease of the wrist, between the tendons of palmaris longus and flexor carpi radialis.
CV-12: 4 finger breadths superior to the umbilicus."
1801489|NCT00591877|Procedure|Sham Acupuncture|"The acupoints for SAC are:
LI-4 : adjacent to and at the middle of the radial side of the 2nd metacarpal bone, at the same level as the end of the crease when the thumb and index fingers approximate.
GB-32: on the lateral aspect of the thigh 5 finger breadths proximal to the popliteal crease, 2 finger breadths inferior to GB31.
UB -15: 1.5 finger breadths lateral to the midline of the spine on a level between the 5 th and the 6 th thoracic vertebrae."
1801490|NCT00591877|Other|Yoga|The participants in this arm will undergo a 60 min session of yoga exercises. These exercises are specifically designed for reflux symptoms by a yoga instructor. This includes a set of specific physical postures (asana) and breathing techniques within the four-element setup. The set of asana are divided into (a) standing, (b) sitting, and (c) lying down positions. The session will begin with asana in standing position, followed by a position called Shavasan (relaxation), then asana in sitting down position followed by Shavasan, finally asana in lying down position followed by Shavasan. At the end of all asana, Pranayam (special breathing exercises) will be practiced.
1801491|NCT00591890|Drug|indibulin|dose escalation of indibulin given twice daily for 21 days, to be repeated every 28 days.
1801492|NCT00591916|Drug|Application of donor site dressing [scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT)]|Application of donor site dressing: scarlet red, Microbial Nanocellulose (NC), or hyaluronan and thrombin (HT).
1801493|NCT00591916|Procedure|Blood sample|Obtain blood specimen at surgery donor site harvest, 14 days post surgery and 6 months post surgery
1801494|NCT00591916|Procedure|Biopsy|Tissue biopsy of donor site treated area at admission, wound healing and 2-6 months post burn.
1801495|NCT00591929|Other|Continuous Passive Motion|at least 48 hours of continuous passive motion following ORIF of fractures around the knee
1801497|NCT00591968|Device|SonoSite Titan portable ultrasound coupled with email telediagnosis|"Sonographic exam will be performed by principal investigator. A first-look diagnosis, correlated with patient symptomology and laboratory analysis, will be made at the point of care. Using a store-and-forward framework, properly formatted non-compressed sonographic images and Request for Interpretation (RFI) forms will be transmitted to participating radiologists. RFI forms will be used to record diagnostic findings and rate the quality of the images and/or diagnostic value using a five-point Likert scale. RFI forms will also include a five-digit patient number, age, sex, and symptomology / reason for sonographic exam. Completed RFI forms will be transmitted back to the clinic at the radiologist's earliest convenience."
1801498|NCT00591968|Other|Control|This group will receive the current standard of care (referral to tertiary medical center for sonographic exam).
1801499|NCT00600067|Drug|Phentermine/Topiramate|phentermine 15mg/ topiramate controlled release (CR) 92mg, oral capsule, once daily, 28 weeks
1801500|NCT00600067|Drug|Placebo|Oral placebo capsules, once daily, 28 weeks
1801501|NCT00600080|Device|etafilcon A|contact lens worn daily for one week (first or second week depending on arm)
1801502|NCT00600080|Device|nelfilcon A|Contact lens worn daily for one week (first or second week depending on arm)
1801503|NCT00600093|Drug|Amantadine|IV Amantadine 200mg *1/d at the beginning of surgery and 24 hours following surgery
1801504|NCT00600119|Drug|placebo|placebo, oral, once daily (QD)
1801505|NCT00600119|Drug|NKTR-118|5 mg, 25 mg, 50 mg or 100 mg, oral,once daily (QD)
1801506|NCT00600145|Drug|Mirtazapine|15 mg Mirtazapine is administered followed 2 hours later by 20 mg of methamphetamine / placebo (administered at each testing visit)
1801507|NCT00600145|Other|Placebo|Placebo
1801508|NCT00600158|Drug|bupivacaine with hydromorphone|bupivacaine 0.125% with hydromorphone 6 mcg/ml epidurally at 10 ml/h
1801509|NCT00600158|Drug|lidocaine|lidocaine 2 mg/min intravenously (or 3 mg/kg in patients > 70 kg)
1801510|NCT00600171|Drug|GW642444M|GW642444M
1801511|NCT00600171|Drug|Placebo|Placebo mulit-dose dry powder inhaler
1801651|NCT00601627|Drug|capecitabine|
1801512|NCT00600184|Device|The AMES device|The AMES device is a investigational device which cyclically rotates the ankle while muscle vibrators stimulate sensory receptors in the muscles opposite to the joint being rotated. Each subject will be tested before and after the 10-week treatment period. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
1801513|NCT00600197|Behavioral|back school|A kind of educational program for low back pain
1801514|NCT00600210|Drug|Bevacizumab|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
1801515|NCT00600210|Drug|Carboplatin|Bevacizumab will be delivered intravenously on day -7 at a dose of 10 mg/kg followed by carboplatin AUC 2.0 intravenously. This will allow therapy to start one week before starting radiotherapy to assess the initial tolerability of the combination without having radiation as a confounding factor, to start treatment while the patient's radiation is being planned, and to possibly optimize the tumor vasculature and allow optimal carboplatin delivery by the time chemoradiotherapy starts. Thereafter, bevacizumab will be given intravenously at 10 mg/kg every two weeks. Carboplatin will be given intravenously weekly at AUC 2.0. On weeks where both drugs are given, bevacizumab will be given first since it could help sensitize the tumor cells to carboplatin.
1801516|NCT00600210|Radiation|Radiation Therapy|"Whole pelvis will be treated to a total dose of 45 Gy in 5 weeks.
Cesium will be used with standard intracavitary systems preferably in two intracavitary applications. An effort should be made to deliver a minimum cumulative external and intracavitary dose to Point A of 85 Gy in 2 insertions."
1801517|NCT00600223|Behavioral|questionnaires and standardized, digital voice recording|Patient will be asked to complete four sets of forms. Upon completion of these forms, the study subject and the investigator will proceed to a quiet room for the standardized, digital voice recording. Recording will be made on digital audiotape using a standardized portable, digital audio recorder.
1801518|NCT00600236|Procedure|blood sample|
1801519|NCT00600249|Drug|Cetuximab|dosage : 5mg/ml one administration per week: 400 mg/m2 then 250 mg/m2 during 18 weeks
1801520|NCT00600249|Drug|Docetaxel|100mg/m2 every 21 days 6 cycles of 21 days
1801521|NCT00600262|Drug|intravitreal bevacizumab|
1801522|NCT00600275|Drug|BGT226|
1801523|NCT00600288|Drug|diquafosol tetrasodium Ophthalmic Solution, 2%|1-2 drops administered in each eye 4 times a day for 6 weeks
1801524|NCT00600288|Drug|Non-preserved saline solution (Placebo)|1-2 drops administered in each eye 4 times a day for 6 weeks
1801525|NCT00600301|Drug|Triamcinolone Acetonide and Bevacizumab|
1801526|NCT00600327|Device|EndoTex™ NexStent™|EndoTex™ NexStent™ is a flexible, fine mesh Nitinol stent used to treat patients that are at high risk of adverse events from carotid endarterectomy and require carotid revascularization of a target vessel that has a reference diameter between 4mm and 9mm and stenosis that is less than 30mm in length.
1801527|NCT00600327|Device|Filter Wire EZ™|EPI Fliter Wire EZ™ Embolic Protection System is indicated for use as a guide wire and embolic protection system to contain and remove embolic material (thrombus/debris) while performing angioplasty and stenting procedures in coronary saphenous vein bypass grafts and carotid arteries.
1801528|NCT00600340|Biological|Bevacizumab and Paclitaxel|A: Bevacizumab 10 mg/kg i.v., days 1 and 15, every 4 weeks Paclitaxel 90 mg/m2, days 1, 8 and 15, every 4 weeks
1801529|NCT00600340|Biological|Bevacizumab and Capecitabine|B:Bevacizumab 15 mg/kg i.v., day 1, every 3 weeks Capecitabine twice-daily 1000 mg/m², day 1 to 14, every 3 weeks
1801530|NCT00600353|Drug|Palonosetron|Palonosetron 0.25 mg IV over 30 seconds
1801531|NCT00600353|Drug|Aprepitant|Aprepitant 125 mg PO and Aprepitant 80 mg PO
1801532|NCT00600353|Drug|Dexamethasone|Dexamethasone 4 mg IV and Dexamethasone 4 mg IV push
1801533|NCT00600366|Drug|biphasic insulin aspart|
1801534|NCT00600379|Device|Virtual reality system (CAREN™ Integrated Reality System; MOTEK BV, Netherlands).|Training 2/w for 9 weeks (total 18 sessions).
1801535|NCT00600405|Drug|tamsulosin|Tamsulosin 0.4 mg orally daily for ten days.
1801536|NCT00600405|Drug|Standard therapy with ibuprofen and oxycodone.|Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
1801537|NCT00600808|Drug|BPLG-003|
1801538|NCT00600821|Drug|Bevacizumab|Bevacizumab is available as 100 and 400 mg preservative-free, single use vials- The starting dose is 15 mg/kg, iv infusion, every 3 weeks.
1801539|NCT00600821|Drug|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
1801540|NCT00600821|Drug|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
1801541|NCT00600821|Drug|AG-013736 (axitinib)|AG-013736 (axitinib) is available as 1mg, and 5 mg film-coated tablets for oral administration- The starting dose is 5 mg BID-
1801542|NCT00600821|Drug|Carboplatin|Carboplatin is available as pre-mixed 10mg /ml aqueous solution- The starting dose is AUC 6 mg*min/ml, iv infusion, every 3 weeks.
1801543|NCT00600821|Drug|Paclitaxel|Paclitaxel is available in multidose vials (30 mg/5ml;100mg/16.7 ml;300 mg/50ml)- The starting dose is 200 mg/m2, every 3 weeks
1801544|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 20mg
1801545|NCT00600847|Drug|desloratadine|single dose for 7 days, oral, 5 mg
1801546|NCT00600847|Drug|placebo|single dose for 7 days, oral
1801547|NCT00600860|Other|No interventions|Only registration of clinical practice
1801548|NCT00600873|Drug|R(+) pramipexole dihydrochloride monohydrate|100 mg tid orally daily
1801549|NCT00600886|Drug|Pasireotide|Pasireotide LAR - intramuscular (i.m.) depot injection given once every 28 days.
1801550|NCT00600886|Drug|Octreotide|Octreotide LAR - i.m. depot injection given once every 28 days.
1801551|NCT00600899|Procedure|elastomeric pump with reservoir of 500 ml, infusion rate of 8 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 500 ml reservoir and infusion rate of 8 ml/h)
1801552|NCT00600899|Procedure|elastomeric pump with reservoir of 275 ml, infusion rate of 5 ml/h|Continuous perisciatic infusion of ropivacaine 2mg/ml (Baxter infusor with 275 ml reservoir and infusion rate of 5ml/h)
1801553|NCT00600912|Drug|SMOFlipid®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
1801554|NCT00600912|Drug|2-ClinOleic 20%®|continuously, for 5 days postoperatively, corresponding to the observation time. Nonprotein calories: to 60% as glucose and to 40% as lipid emulsion. The total energy intake per day was adjusted to 25 kcal kg-1 body weight.
1801555|NCT00600925|Drug|gentamicin-collagen sponge dipped in saline|2 gentamicin-collagen sponges inserted before closure of the laparotomy
1801556|NCT00600938|Drug|Core Study: Deferasirox|20 mg/kg/day once daily (od) for 2 weeks, followed by 30 mg/kg/day od for 1 week and a subsequent continuation of 40 mg/kg/day
1801557|NCT00600938|Drug|Core Study: Deferoxamine|50 mg/kg/day to 60 mg/kg/day infused subcutaneously in 8- to 12-hour intervals administered 5 to 7 days/week
1801558|NCT00600938|Drug|Extension: deferoxamine to deferasirox|40 mg/kg deferasirox once daily administered 30 minutes before taking food.
1801559|NCT00600938|Drug|Extension: deferasirox to deferoxamine|DFO at a target range of 50 mg/kg/day to 60 mg/kg/day via subcutaneous (sc) infusion lasting a period of 8 to 12 hrs administered for 5 to 7 days per week,
1801560|NCT00600938|Drug|Deferasirox|
1801561|NCT00600938|Drug|Deferoxamine|
1801562|NCT00600964|Drug|GX15-070MS|A 60-minute or 3-hour IV infusion every 2-3 weeks.
1801563|NCT00600964|Drug|GX15-070MS|GX15-070MS at various doses and schedules
1801564|NCT00600977|Drug|Doxorubicine|9mg/m² J1 J4 2 COURSES
1801565|NCT00600977|Drug|Doxorubicine pegylated|40 MG/M² J1 2 courses
1801567|NCT00601003|Drug|Nifurtimox|30mg/kg/day PO divided into TID dosing q day
1801568|NCT00601003|Drug|Cyclophosphamide|250 mg/m2/dose in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
1801569|NCT00601003|Drug|Topotecan|0.75mg/m2/dose, in normal saline, IV, infused over 30 minutes on days 1-5 of each cycle.
1801570|NCT00601016|Drug|Imiquimod 5% cream|Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
1801571|NCT00601042|Other|Swedish snus (smokeless tobacco)|Snus in sachets 1.0 g or 0.5 g, 2 flavors. Usage ad libitum.
1801572|NCT00601042|Other|Onico|Tobacco-free, nicotine-free placebo snus, 2 sachet sizes (1.0 g, 0.5 g), 2 flavors (same as in the experimental arm). Usage ad libitum.
1801573|NCT00601055|Behavioral|Problem Solving-Rx Adherence (PSA)|In PSA, a therapist teaches the participant to identify problems related to depression, functioning, and treatment adherence; to generate multiple solutions; and to choose and implement one or more of those solutions.
1801574|NCT00601055|Behavioral|PID-C|In PID-C, a therapist identifies obstacles to treatment adherence and helps the participant overcome those obstacles.
1801575|NCT00601068|Other|Observational|Group of patients with osteochemonecrosis related to oral bisphosphonate use
1957567|NCT02317744|Drug|Naltrexone and bupropion combination|
1801577|NCT00601107|Drug|Doxercalciferol|
1801578|NCT00601107|Drug|Placebo|
1801579|NCT00601120|Procedure|Radiofrequency Ablation|Needles are inserted into the tumor(s) under guidance by a CT scan or ultrasound. The electrodes in the needles will be heated up to 202 degrees Fahrenheit and will remain heated for up to 12 minutes.
1801580|NCT00601133|Other|Walking Test|"Timed Test 1: From sitting position walk 10 feet quickly, return to sitting position Timed Test 2: Walk 25 feet, turn around, and walk back
Tests conducted twice, once on departure from rehabilitation center, and again at a return visit 1 month later"
1801581|NCT00601133|Other|Balance Test|Machine balance test: Stand on a platform with a rail, shift weight and try to maintain balance and center of gravity; Results displayed.
1801582|NCT00601133|Behavioral|Questionnaire|To be completed when leaving the rehabilitation program and again at the study visit 1 month later, lasting about 5 minutes.
1801583|NCT00601133|Behavioral|Diary|Record any physical exercise done from departure of rehabilitation center to return visit 1 month later; includes exercises; approximately 5 minutes per entry
1801584|NCT00601146|Procedure|chest computed tomography scan|Once a year for three years
1801585|NCT00601159|Drug|gemcitabine and cisplatin|Cispaltin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 repeat every 3 weeks
1957568|NCT02317744|Other|Pill Placebo|
1957569|NCT02317393|Other|K5-RGD PET|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
1801589|NCT00601185|Procedure|confocal microscopy in vivo|A dermatologist will perform a shave biopsy according to standard clinical procedures. This study will be carried out after the shave biopsy. The deep surface and the peripheral margins will be imaged on each patient.
1801590|NCT00601198|Drug|Amifostine|Patients should be treated with oxaliplatin-based chemotherapy in combination with amifostine for 12 cycles, or until unacceptable toxicity is observed or disease progression
1801591|NCT00601211|Drug|Pilocarpine|
1801592|NCT00601224|Behavioral|Social cognition and interaction training (SCIT)|SCIT is a group-based treatment that has the goal of improving social cognition and social functioning for individuals with psychotic disorders. SCIT is composed of three phases: emotion training, figuring out situations, and integration. SCIT will be delivered by two therapists in 20 weekly sessions over 5 months.
1801593|NCT00601224|Behavioral|Treatment as usual (TAU)|TAU will involve routine care and meeting with case-managers and healthcare providers on an as-needed basis.
1801594|NCT00601237|Behavioral|HIV-related text messaging|Participants will receive up to 90 text messages related to abstinence, monogamy, and condom use over 3 months.
1801595|NCT00601237|Behavioral|Nutrition-related text messaging|Participants will receive up to 30 text messages about nutrition and healthy eating over 3 months.
1801652|NCT00601627|Drug|fluorouracil|
1801596|NCT00601250|Drug|linagliptin|Patients receive linagliptin 5 mg tablets once daily
1801597|NCT00601250|Drug|linagliptin|Patients receive linagliptin 5 mg tablets once daily
1801598|NCT00601263|Drug|Anti-Asthma Herbal Medical Intervention (ASHMI)|We propose to test 3 daily doses in which 2,4, or 6 ASHMI or placebo capsules will be administered orally twice daily (BID) for 7 days.
1801599|NCT00601276|Drug|leuprorelin|Subcutaneous injection, 3.75 mg every 4 weeks
1801600|NCT00601276|Drug|Cyproterone acetate|2.0 mg/kg/day, tablet, per os
1801601|NCT00601289|Drug|temozolomide|
1801602|NCT00601289|Genetic|DNA methylation analysis|
1801603|NCT00601289|Genetic|microarray analysis|
1801604|NCT00601289|Genetic|protein expression analysis|
1801605|NCT00601289|Genetic|proteomic profiling|
1801606|NCT00601289|Other|laboratory biomarker analysis|
1801607|NCT00601302|Drug|Amlodipine|
1801608|NCT00601315|Drug|Clarithromycin|
1801609|NCT00601328|Drug|Calcitriol|
1801610|NCT00601341|Other|lumbosacral joint manipulation|lumbosacral joint manipulation
1801611|NCT00601341|Other|lumbar passive range of motion|lumbar passive range of motion
1801612|NCT00601341|Other|No active intervention|Lie on exam table for 3 minutes
1801613|NCT00601354|Behavioral|Emotion regulation group therapy|Emotion regulation guided self-help group therapy involves twelve 2-hour sessions of guided self-help group psychotherapy.
1801614|NCT00601354|Drug|Orlistat/alli program|The orlistat/alli program involves taking 60 mg orlistat three times a day and participating in the alli program, a comprehensive behavioral weight loss program with online access.
1801615|NCT00601367|Drug|flibanserin flexible dose|"Initial dosage:
Patients were to take one 50 mg flibanserin tablet in the evening.
Subsequent dosage titrations:
Flibanserin may have been titrated to 25 mg flibanserin b.i.d at Week 1 (Visit 2) for safety/tolerability ONLY, as determined by the clinician and given feedback from the patient.
Flibanserin may have been up-titrated (higher daily dose) at week 4 (Visit 3) if efficacy was unsatisfactory or later in the study at a scheduled face-to-face office visit ONLY.
Flibanserin may have been down-titrated (lower daily dose or b.i.d. regimen) at week 4 (visit 3) for safety/tolerability or later in the study at any time following patient contact with the site."
1801616|NCT00601393|Behavioral|Cognitive behavioral therapy (CBT)|CBT treatment is delivered via the Internet. Adaptations to the CBT program will include the addition of content of particular relevance to mothers of young children and the incorporation of instructional design principles to promote self-learning. The treatment program will take advantage of the unique properties of the Internet, including multimedia presentations and interactive components with professional and moderated peer social support.
1801617|NCT00601393|Other|Treatment as usual (TAU)|Participants receiving TAU will be offered the CBT treatment after a wait-list period. During the wait-list period, participants will be offered facilitated referrals to treatment provided in the community.
1801618|NCT00601406|Genetic|gene expression analysis|
1801619|NCT00601406|Genetic|gene rearrangement analysis|
1801620|NCT00601406|Genetic|polymorphism analysis|
1801621|NCT00601406|Other|laboratory biomarker analysis|
1801622|NCT00601406|Radiation|radiation therapy|
1801623|NCT00601419|Drug|Somatropin|"Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.
Dosage, Frequency: According to Japanese LPD, The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day.
Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration."
1801624|NCT00601432|Drug|levofloxacin oral solution|
1801625|NCT00601445|Behavioral|Amount of sleep and wake|4 groups with different patterns of sleep and wake
1801626|NCT00601458|Drug|pregabalin|Patients will be randomized just prior to surgery to 1 of 3 study treatments: pregabalin (300 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, pregabalin (150 mg) will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
1801627|NCT00601458|Drug|naproxen sodium|Patients will be randomized just prior to surgery to 1 of 3 study treatments: naproxen sodium (550 mg) treatment will be administered approximately 1 hour prior to surgery. Postoperatively, naproxen sodium will be dosed starting 12 hours following T=0 and every 12 hours until 36 hours following T=0.
1801628|NCT00601458|Drug|Comparator: Placebo|Patients will be randomized just prior to surgery to 1 of 3 study treatments: placebo treatment will be administered approximately 1 hour prior to surgery. Postoperatively, placebo will be dosed starting at 8 hours following T=0 and every 8 hours until 40 hours following T=0.
1801629|NCT00601471|Other|proximal tibiofibular manipulation|proximal tibiofibular manipulation
1801630|NCT00601471|Other|distal tibiofibular manipulation|distal tibiofibular manipulation
1801631|NCT00601471|Other|no intervention|no intervention / control
1801632|NCT00601484|Drug|PF-04383119|PF-04383119 200 mcg/kg IV, single dose
1801633|NCT00601484|Drug|Placebo|placebo IV, single dose
1801634|NCT00601497|Device|InterX 5000|20-30 minute device sessions on the following schedule: 3 times per week for 3 weeks, then 2 times per week for 3 weeks, then 1 time per week for 2 weeks.
1801635|NCT00601510|Drug|capecitabine|
1801636|NCT00601510|Drug|cisplatin|
1801637|NCT00601510|Drug|imatinib mesylate|
1801638|NCT00601523|Drug|Placebo|Patient to receive placebo tablets identical to Pramipexole ER tablets. Only during transfer phase.
1801639|NCT00601523|Drug|Pramipexole|ER 0.375-4,5 mg
1801640|NCT00601536|Drug|Lithium|
1801641|NCT00601549|Procedure|Laparoscopic surgery|Laparoscopic surgery
1801642|NCT00601549|Procedure|Traditional open surgery|Open surgery
1801643|NCT00601562|Drug|Zidovudine|
1801644|NCT00601575|Drug|Lithium|
1801645|NCT00601588|Drug|Sertraline|
1801653|NCT00601627|Drug|gemcitabine hydrochloride|
1801654|NCT00601627|Radiation|radiation therapy|
1801655|NCT00601640|Drug|Diclofenac Na gel|Given topically twice daily on days 1-90
1801656|NCT00601640|Drug|Eflornithine HCL ointment|Given topically twice daily on days 1-90
1801657|NCT00601653|Behavioral|Cognitive behavioral therapy plus general nutrition counseling (CBT+GN)|CBT+GN includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling.
1801658|NCT00601653|Behavioral|Cognitive behavioral therapy plus low energy density diet counseling (CBT+LED)|CBT+LED includes 21 sessions over 6 months. Each treatment session includes 40 minutes of CBT and 20 minutes of nutritional counseling that centers upon eating higher volumes of low-calorie foods.
1801659|NCT00601666|Drug|Zolpidem|
1801660|NCT00601679|Other|NT-proBNP guided care|knowledge of NT-proBNP results
1801661|NCT00601692|Drug|cisplatin|Given IV
1801662|NCT00601692|Drug|docetaxel|Given IV
1801663|NCT00601692|Drug|irinotecan hydrochloride|Given IV
1801664|NCT00601692|Radiation|radiation therapy|Given 5 days a week for 3 weeks
1801665|NCT00601705|Drug|cisplatin|20 mg/m2/day IV continuous infusion over 24 hours for 96 total hours.
1801666|NCT00601705|Drug|epirubicin hydrochloride|50 mg/m2 IV bolus
1801667|NCT00601705|Drug|fluorouracil|200 mg/m2/day will be given as a continuous intravenous infusion for all 9 weeks, beginning on day 1.
1801668|NCT00601705|Drug|oxaliplatin|130 mg/m2 IV infusion over 2 hours
1801669|NCT00601705|Procedure|adjuvant therapy|Between 6-10 weeks after surgery patients will begin postoperative chemoradiotherapy. Daily radiation therapy fractions of 180-200 cGy will be given to the esophago-gastric bed and draining lymphatic regions to a total dose of 50-55 Gy (60 Gy in the event of an R1 or R2 resection). Concurrent with this radiation, two cycles of chemotherapy will be given, during the first and fourth weeks of the radiation
1801670|NCT00601705|Procedure|neoadjuvant therapy|"Three weeks after discontinuing the fluorouracil (12 weeks after study entry) patients will be fully restaged to assess for a clinical response, and to ensure that there is no contraindication to surgical resection, which will be scheduled for approximately one week later (13 weeks after study entry).
Surgery will consist of a transthoracic esophagogastrectomy or a total gastrectomy with Roux-en-Y esophagojejunostomy depending on the location and extent of the tumor at surgery. An appropriate lymphadenectomy will be performed. Immediate reconstruction is anticipated if possible."
1801671|NCT00601718|Drug|vorinostat|Given PO
1801672|NCT00601718|Biological|rituximab|Given IV
1801673|NCT00601718|Drug|ifosfamide|Given IV
1801674|NCT00601718|Drug|carboplatin|Given IV
1801675|NCT00601718|Drug|etoposide|Given IV
1801676|NCT00601718|Other|pharmacological study|Correlative studies
1801677|NCT00601718|Other|laboratory biomarker analysis|Correlative studies
1801678|NCT00601718|Genetic|gene expression analysis|Correlative studies
1801679|NCT00601731|Biological|MenACWY-CRM197|Blood test, 40-months and 60-months children
1801680|NCT00601731|Biological|Blood test|Blood test, 40-months and 60-months children
1801681|NCT00601744|Behavioral|Audio-Taped Interview|"Meeting with a research staff member either in person or by phone, lasting 2 to 2 1/2 hours
Arm 1: Questions about emotional well-being, appearance, coping ability with the cancer, and the types of social relations and support available (such as relationships with friends and family)
Arm 2: Questions regarding if and how social relations may have been affected by his/her cancer experiences after the orbital exenteration."
1801682|NCT00601744|Behavioral|Questionnaire|5-10 minute questionnaire to be completed after the interview.
1801683|NCT00601757|Behavioral|The Postpartum Prevention Program (PPP)|PPP includes interpersonal therapy sessions as well as distribution of educational material on postpartum depression. The group sessions will take place during the participant's last trimester of pregnancy. There will be four weekly sessions prior to delivery and one booster session within the first 2 weeks of the postpartum period.
1801684|NCT00601757|Behavioral|Enhanced care as usual (ECU)|ECU includes the usual medical care provided for pregnant women at the Women's Primary Care Center at Women and Infants Hospital as well as the provision of educational material and a list of treatment resources for postpartum depression. Participants will also receive more intensive follow-up in terms of their mental health status than is typically provided in usual practice.
1801685|NCT00601770|Biological|IC41|injection
1801686|NCT00601796|Biological|Vaccine Treatment|We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized the vaccine would induce tumor regression in metastatic lung adenocarcinoma. Intradermal vaccine was given every 14 days x3, followed by monthly x3.
1801687|NCT00601796|Drug|Cyclophosphamide|Cyclophosphamide (300 mg/m^2 IV) was administered before 1st and 4th vaccines to deplete regulatory T-cells.
1801688|NCT00601796|Drug|All-trans retinoic acid (ATRA)|All-trans retinoic acid was given (150/mg/m^2/day) after 1st and 4th vaccines to enhance dendritic differentiation.
1801689|NCT00601809|Other|traditional conservative treatment (TT)|In the control group (TT: Traditional Treatment), the patients have been treated as in our daily surgical practice of traditional conservative treatment for ASIO, consisting in nil per os diet, nasogastric tube (NGT) decompression and intravenous fluid resuscitation therapy with electrolytes imbalances correction.
1801690|NCT00601809|Drug|Gastrografin®: G|The study group (GG: Gastrografin Group) received, beyond the traditional conservative treatment for ASIO above mentioned, a G meal with a follow-through study immediately.
1801691|NCT00601822|Behavioral|Cognitive remediation therapy (CRT)|CRT includes eight sessions over 6 months that aim to improve cognitive flexibility and strengthen thinking skills.
1801692|NCT00601822|Behavioral|Cognitive behavioral therapy (CBT)|CBT includes 20 to 28 weekly psychotherapy sessions over 6 months, depending on treatment group assignment. CBT sessions aim to change participants' beliefs and behaviors toward eating disorders and to teach ways to handle the daily struggles of an eating disorder.
1801693|NCT00601835|Biological|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, single dose
1801694|NCT00601835|Biological|Tetanus and Diphtheria Toxoids Adsorbed (Td) Vaccine|0.5 mL, Intramuscular, Single dose
1801695|NCT00601848|Drug|chemotherapy|
1801696|NCT00601848|Drug|porfimer sodium|
1801697|NCT00601848|Other|immunohistochemistry staining method|
1801698|NCT00601848|Other|laboratory biomarker analysis|
1801699|NCT00601848|Procedure|spectroscopy|
1801700|NCT00601848|Procedure|therapeutic conventional surgery|
1801701|NCT00601861|Drug|recombinant interleukin-21|Fixed and equal dose for s.c. injection, 3 times weekly
1801702|NCT00601874|Drug|Pilocarpine|
1801703|NCT00601887|Drug|Meloxicam|
1801709|NCT00601913|Drug|erlotinib hydrochloride|
1801710|NCT00601913|Genetic|protein analysis|
1801711|NCT00601913|Genetic|western blotting|
1801712|NCT00601913|Other|immunohistochemistry staining method|
1801713|NCT00601913|Other|laboratory biomarker analysis|
1801714|NCT00601913|Other|liquid chromatography|
1801715|NCT00601913|Other|mass spectrometry|
1801716|NCT00601913|Procedure|neoadjuvant therapy|
1801717|NCT00601913|Procedure|therapeutic conventional surgery|
1801718|NCT00601926|Biological|bevacizumab|15 mg/kg over 90 minutes every 3 weeks
1801719|NCT00601939|Behavioral|Psychoeducational intervention (PEI)|PEI consists of 10 culturally competent group empowerment psychoeducational sessions. The sessions are directed by a treatment manual and are co-led by two therapists. The sessions are guided by the theory of triadic influence (TTI) model, which incorporates cultural-environmental influences, social-situational influences, and intrapersonal influences into treatment.
1801720|NCT00601939|Behavioral|Enhanced treatment as usual (ETAU)|ETAU contains an adherence protocol plus access to weekly support group and a resource room.
1801721|NCT00601952|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
1801722|NCT00601952|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
1801723|NCT00601965|Drug|Escitalopram|20 mg daily oral escitalopram
1801724|NCT00601965|Drug|Placebo|Placebo pill of daily oral escitalopram
1801725|NCT00601965|Behavioral|Cognitive behavioral therapy (CBT)|16 weekly 1-hour sessions
1801726|NCT00601978|Drug|carbidopa/levodopa|
1801727|NCT00601978|Drug|Carbidopa/Levodopa/Entacapone|
1801728|NCT00601991|Biological|VEGF Trap|Drug under investigation
1801729|NCT00601991|Procedure|Bone marrow biopsy|To determine response to treatment
1801730|NCT00601991|Procedure|bone marrow aspiration|To determine response to treatment
1801731|NCT00601991|Procedure|Venipuncture|For test of free VEGF Trap compared to bound VEGF Trap and for routine clinical testing during treatment
1801732|NCT00602004|Drug|losartan|losartan 50 mg a day
1801733|NCT00602017|Drug|Amlodipine|
1801734|NCT00602030|Drug|entinostat|"Dose cohort 1: SNDX-275 5mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)
Dose cohort 2: SNDX-275 10mg tablets on days 1 and 15 of 28-day cycle (max. 6 cycles)"
1801735|NCT00602030|Drug|SNDX-275|entinostat 5mg or 10mg (determined by Lead in study findings) on days 1 and 15 of a 28-day cycle until progression or unacceptable toxicity develops; maximum of 6 cycles
1801736|NCT00602030|Drug|erlotinib|erlotinib 150mg PO QD
1801737|NCT00602043|Radiation|F-18 16 alpha-fluoroestradiol|Undergo [^18F] FES PET
1801738|NCT00602043|Radiation|fludeoxyglucose F 18|Undergo standard clinical FDG PET/CT
1801739|NCT00602043|Procedure|positron emission tomography|Undergo [^18F] FES PET
1801740|NCT00602043|Procedure|positron emission tomography|Undergo standard clinical FDG PET/CT
1801741|NCT00602043|Procedure|computed tomography|Undergo standard clinical FDG PET/CT
1801742|NCT00602043|Other|laboratory biomarker analysis|Correlative studies
1801743|NCT00602056|Other|Redesigned immunization card|A low cost nad simplified redesigned immunization card
1801744|NCT00602056|Other|Center based education to mothers/caregivers|A 2-3 minute center based education to mothers/caregivers
1801745|NCT00602056|Other|Redesigned immunization card with center based education to mother/caregivers|Redesigned immunization card with center based education to mother/caregivers
1801746|NCT00602069|Behavioral|Helping to Overcome PTSD through Empowerment (HOPE)|HOPE includes a maximum of 16 sessions of cognitive behavioral therapy. The sessions will emphasize stabilization and empowerment, both of which are identified as important goals by the theoretical and empirical literature on abused women and PTSD.
1801747|NCT00602069|Behavioral|Treatment as usual|Treatment as usual includes standard shelter services for abused women.
1801748|NCT00602082|Drug|capecitabine|
1801749|NCT00602082|Drug|cisplatin|
1801750|NCT00602082|Drug|streptozocin|
1801751|NCT00602082|Genetic|DNA analysis|
1801752|NCT00602082|Genetic|RNA analysis|
1801753|NCT00602082|Genetic|protein analysis|
1801754|NCT00602082|Genetic|proteomic profiling|
1801755|NCT00602082|Other|laboratory biomarker analysis|
1801756|NCT00602095|Drug|misoprostol|0.025mg tablet vaginally every 4 hour until progress
1801757|NCT00602095|Drug|dinoprostone|2mg vaginal gel every 6 hours until progress
1801758|NCT00602095|Device|Bard Catheter (balloon catheter)|Intracervical balloon catheter positioned above internal cervical os and filled with sterile water. Removed when cervix was dilated
1801759|NCT00602108|Procedure|adjuvant therapy|
1801760|NCT00602108|Procedure|conventional surgery|
1801761|NCT00602108|Radiation|hypofractionated radiation therapy|
1801762|NCT00602108|Radiation|intraoperative radiation therapy|
1801763|NCT00602134|Drug|6-Mercaptopurine|
1801764|NCT00602147|Other|laboratory biomarker analysis|Blood or cheek cells wil be collected.
1801765|NCT00602160|Drug|FAHF-2 (TM)|"We propose to test 10 tablets administered orally three times daily (t.i.d.) for 6 months in the Phase II study. The subjects will be randomized to 1 of 2 groups; FAHF-2 or Placebo group.
Both groups will undergo physician supervised Double-blinded placebo controlled food challenges, once during screening before starting treatment and again after 6 months of therapy."
1801766|NCT00602173|Drug|Cilostazol|
1801767|NCT00602186|Drug|tamsolusin|0.4 mg /day
1801768|NCT00602186|Drug|prazosin|1 mg/day
1801769|NCT00602199|Drug|ABT-510|
1801770|NCT00602199|Other|immunoenzyme technique|
1801771|NCT00602199|Other|immunohistochemistry staining method|
1801772|NCT00602199|Other|laboratory biomarker analysis|
1801773|NCT00602199|Other|pharmacological study|
1801774|NCT00602199|Procedure|biopsy|
1801775|NCT00602212|Behavioral|relaxation with virtual reality (VR)|VR relaxing environment and audio-visual mobile narratives will be used to teach patients how to relax themselves
1801776|NCT00602212|Behavioral|relaxation and biofeedback virtual reality|The patients experienced the same protocol described above, but with the biofeedback support. Specifically, in the sessions with the therapist, HR variations were used to modify specific features of the virtual environment:
1801777|NCT00602225|Drug|clofarabine|Given IV
1801778|NCT00602225|Drug|cytarabine|Given IV
1801779|NCT00602225|Biological|filgrastim|Given subcutaneously
1801780|NCT00602251|Drug|Terbinafine|
1801781|NCT00602277|Other|Laboratory Biomarker Analysis|Correlative studies
1801782|NCT00602277|Biological|Wild-type Reovirus|
1801783|NCT00602290|Drug|Citalopram|Citalopram dosage will be 20 to 60 mg a day prior to FDA warning limiting it to 20-40 mg in 2011. Participants will begin taking one 20-mg capsule once per day for 4 weeks, and this dosage may be increased or decreased depending on the participant's response to the medication or side-effect profile. Participants will continue on their assigned dosage of citalopram that will be titrated up after week 4 if clinical global impressions (CGI) scores were > 2 until treatment completion.
1801784|NCT00602290|Drug|Methylphenidate (MPH)|MPH dosage will be 5 to 40 mg a day. Participants will initially take 1 capsule (2.5 mg) twice per day, which will be increased to a maximum up to 8 x 2.5 mg capsules twice per day. After Visit 11, MPH dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
1801785|NCT00602290|Drug|Placebo|Placebo pills will be taken in combination with the active pills. Participants will initially take 1 capsule twice per day, which will be increased to a maximum of 16 capsules twice per day matching methylphenidate, and 1-3 capsules matching citalopram. After Visit 11, placebo dosage will be gradually reduced over 2 weeks until participants are no longer taking any capsules.
1801786|NCT00602303|Drug|Torsemide|
1801787|NCT00602316|Drug|gadolinium-chelate|
1801788|NCT00602316|Procedure|conventional surgery|
1801789|NCT00602316|Procedure|magnetic resonance imaging|
1801790|NCT00602316|Procedure|magnetic resonance spectroscopic imaging|
1801791|NCT00602329|Biological|bevacizumab|Given IV
1801792|NCT00602329|Drug|fluorouracil|Given IV
1801793|NCT00602329|Drug|leucovorin calcium|Given IV
1801794|NCT00602329|Drug|oxaliplatin|Given IV
1801795|NCT00602342|Drug|Terbinafine|
1801796|NCT00602355|Drug|Sertraline|"Participants assigned to sertraline treatment will take 25 to 50 mg daily for Weeks 1 through 3, and dosage will be increased to 100 to 150 mg daily in Weeks 4 through 10. Participants will be titrated up to 200 mg daily at Week 11 for the final 2 weeks of treatment. In addition, at each week participants will receive specific mother-crafting techniques keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information to the mother about infant care."
1801797|NCT00602355|Drug|Placebo|"Participants taking the placebo will follow the same titration schedule as those taking sertraline. In addition, the participates will receive the same specific mother-crafting techniques as those taking sertraline."
1801798|NCT00602355|Behavioral|Interpersonal psychotherapy (IPT)|IPT will be administered in 13 individual 50-minute sessions over 13 weeks. These sessions will focus on improving relationships with others, setting goals, and increasing coping skills.
1801799|NCT00602355|Behavioral|Clinical management|Clinical management includes treatment as usual for those receiving medication for depression.
1801800|NCT00602355|Behavioral|Mothercrafting|Mother-crafting techniques are keyed to the baby's age and development. The mother-crafting component is aimed at providing relevant information about infant care
1801801|NCT00602368|Other|histological technique|
1801802|NCT00602368|Other|laboratory biomarker analysis|
1801803|NCT00602368|Procedure|colposcopic biopsy|
1801804|NCT00602368|Procedure|colposcopy|
1801805|NCT00602368|Procedure|light-scattering spectroscopy|
1801806|NCT00602368|Procedure|loop electrosurgical excision procedure|
1801807|NCT00602381|Drug|Lithium|
1801808|NCT00602394|Drug|Lithium|
1801809|NCT00602407|Drug|Cilostazol|
1801810|NCT00602420|Drug|naproxen|Oral naproxen twice daily for 5-8 days.
1801811|NCT00602420|Other|placebo|Oral placebo twice daily for 5-8 days.
1801812|NCT00602446|Drug|deferasirox|20 mg/kg once daily orally for 6 months
1801813|NCT00602459|Drug|Cyclophosphamide|Given IV
1801814|NCT00602459|Drug|Fludarabine Phosphate|Given IV or PO
1801815|NCT00602459|Other|Laboratory Biomarker Analysis|Correlative studies
1801816|NCT00602459|Drug|Lenalidomide|Given PO
1801817|NCT00602459|Biological|Rituximab|Given IV
1801818|NCT00602472|Drug|linagliptin|active
1801819|NCT00602472|Drug|placebo|placebo to linagliptin 5 mg
1801820|NCT00602485|Other|Action Control Education|30 minute educational intervnetion
1801821|NCT00602498|Drug|Clarithromycin|
1802199|NCT00597103|Other|Sleep Assessment Testing|"Sleep Assessment will be performed using an Actiwatch with subjects wearing the watch for 72 hours continuously"
1801822|NCT00602511|Drug|Bortezomib|"Bortezomib 1,3 mg/m2 intravenously on days 1, 4, 8 och 11 of every 3 weeks cycle until maximal response, toxicity or maximum 8 cycles
Dexamethasone 20 mg days 1-2, 4-5, 8-9 and 11-12 during the first 2 cycles, thereafter individualized dose depending on response and toxicity"
1801823|NCT00602511|Drug|Thalidomide|"Thalidomide 50 mg/day with dose escalation every 3 weeks until response or toxicity, maximal dose 200 mg/day
Dexamethasone 40 mg/day day 1-4 every 3 weeks for at least 2 courses, thereafter individualized dose depending on response and toxicity"
1801824|NCT00602524|Drug|Pilocarpine|
1801825|NCT00602537|Drug|Venlafaxine|75 to 375 mg
1801826|NCT00602537|Drug|Lithium Carbonate|300 to 2400 mg
1801827|NCT00602550|Drug|Zidovudine|
1801828|NCT00602563|Behavioral|AMP|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word.
1801829|NCT00602563|Behavioral|Applied Relaxation (AR)|Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways to reduce the physiological cues associated with anxiety and worry (Öst, 1987; Siev & Chambless, 2007)
1801830|NCT00602563|Behavioral|Clinical Monitoring (CM)|participants assigned to the clinical monitoring (CM) condition will receive the same information about the nature of GAD provided to participants in the active conditions
1801831|NCT00602563|Behavioral|Combining the AMP and AR|The AMP is a computer-delivered attention modification protocol designed to enhance attention disengagement from threatening stimuli. The AMP protocol includes twelve 20-min sessions delivered over a 6-week period. During each session, participants will see 240 trials consisting of the various combinations of probe type (E or F), probe position (top or bottom), and word type (Neutral or Threat). 192 trials include one neutral word and one threat word: 2 (probe type) X 2 (probe position) X 2 (repetitions) X 24 (word pairs). On trials where participants see one neutral word and one threat word (i.e., 80% of the trials), the probe always follows the neutral word. Applied Relaxation (AR) is a behavioral, skills-based intervention where individuals learn ways
1801832|NCT00602576|Drug|sorafenib tosylate|Given orally
1801833|NCT00602576|Drug|temozolomide|Given orally
1801834|NCT00602589|Drug|Levofloxacin oral suspension; Levofloxacin oral solution; and Levofloxacin marketed tablet formulations|
1801835|NCT00602602|Biological|bevacizumab|
1801836|NCT00602602|Drug|fluorouracil|
1801837|NCT00602602|Drug|gemcitabine hydrochloride|
1801838|NCT00602602|Drug|oxaliplatin|
1801839|NCT00602602|Other|immunohistochemistry staining method|
1801840|NCT00602602|Other|laboratory biomarker analysis|
1801841|NCT00602602|Procedure|conventional surgery|
1801842|NCT00602602|Procedure|endoscopic biopsy|
1801843|NCT00602602|Procedure|laparoscopy|
1801844|NCT00602602|Radiation|radiation therapy|
1801845|NCT00602615|Drug|Torsemide|
1801846|NCT00602628|Other|questionnaire administration|
1801847|NCT00602628|Procedure|adjuvant therapy|
1801848|NCT00602628|Procedure|biopsy|
1801849|NCT00602628|Procedure|computed tomography|
1801850|NCT00602628|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1801851|NCT00602628|Procedure|magnetic resonance imaging|
1801852|NCT00602628|Procedure|therapeutic conventional surgery|
1801853|NCT00602628|Procedure|ultrasound imaging|
1801854|NCT00602628|Radiation|radiation therapy|
1801855|NCT00602641|Drug|melphalan|Given PO
1801856|NCT00602641|Drug|prednisone|Given PO
1801857|NCT00602641|Drug|thalidomide|Given PO
1801858|NCT00602641|Drug|lenalidomide|Given PO
1801859|NCT00602667|Drug|Induction Chemotherapy|All patients will receive 4 identical cycles of induction chemotherapy including highdose (5 g/m2 or 2.5g/m2 for patients less than or equal to 31 days of age at enrollment) intravenous methotrexate and standard dose vincristine, cisplatin, and cyclophosphamide.
1801860|NCT00602667|Drug|Low-Risk Therapy|Induction will be followed by further conventional chemotherapy with carboplatin, cyclophosphamide, and etoposide. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
1801861|NCT00602667|Drug|High-Risk Therapy|High risk patients will also receive vinblastine with each course of induction chemotherapy. Induction will be followed by either chemotherapy with targeted intravenous topotecan and cyclophosphamide or optional craniospinal irradiation (CSI). CSI will be offered only to patients who reach 3 years of age by the end of induction only. After consolidation, all patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
1801862|NCT00602667|Drug|Intermediate-Risk Therapy|"Induction will be followed by consolidation focal radiotherapy (RT) to the tumor bed. Patients less than 12 months old upon completion of induction will receive low risk chemotherapy to delay RT until the age of 12 months. After consolidation, patients will receive 6 cycles of oral maintenance chemotherapy with cyclophosphamide, topotecan, and depending on the diagnosis, either erlotinib or etoposide (VP-16).
Note: The option to receive focal proton beam irradiation was suspended 10/29/2015. Focal photon beam irradiation continues as part of the treatment plan."
1801863|NCT00602680|Drug|SSR180711C|duration of treatment: 4 weeks
1801864|NCT00602680|Drug|donepezil|duration of treatment: 4 weeks
1801865|NCT00602680|Drug|placebo|duration of treatment: 4 weeks
1801866|NCT00602693|Biological|umbilical cord blood transplantation|Infusion of umbilical cord blood
1801867|NCT00602693|Drug|Allopurinol|Administration begins Day -7 through Day 0, tablet or powder prescribed on an individual basis.
1801868|NCT00602693|Drug|fludarabine phosphate|40 mg/m^2 intravenously over 1 hour on Days -6, -5, -4, -3, -2
1801869|NCT00602693|Drug|Cyclophosphamide|50 mg/kg intravenous over 2 hours on Day -6
1801870|NCT00602693|Radiation|Total body irradiation|200 cGy on Day -1
1801871|NCT00602693|Biological|Treg infusion|Infusion of T regulatory cells on Day +1 (also Day +15 for Dose level 5 only). Dose escalation ranges include 1, 3, 10, 30, 100, 300 1000, and 300 x 10^5 Treg/kg.
1801872|NCT00602693|Drug|Sirolimus|Beginning on day -3 and continuing until day +100, patients receive sirolimus intravenously (IV) with 8-12 mg oral loading dose followed by a single dose of 4mg/day with a target serum concentration of 3-12 mg/mL with a taper until day +180.
1801873|NCT00602706|Biological|sargramostim|
1801874|NCT00602706|Drug|melphalan|
1801875|NCT00602706|Procedure|autologous hematopoietic stem cell transplantation|
1801876|NCT00602706|Procedure|peripheral blood stem cell transplantation|
1801877|NCT00602706|Radiation|samarium Sm 153 lexidronam pentasodium|
1801878|NCT00602719|Drug|Zolpidem|
1801879|NCT00602732|Behavioral|The Reach Out for a Safe Environment (ROSE) program|Participants in the ROSE program will receive a course on managing stress and negative feelings and will learn how to access resources for help. The ROSE program involves four 90-minute group sessions over a 4-week period prior to delivery. Participants will also attend one 50-minute booster session within 4 weeks prior to delivery of their babies.
1801880|NCT00602732|Behavioral|Enhanced care as usual (ECU)|Participants in ECU will receive the usual medical care provided for pregnant women at their prenatal clinic. Participants will also receive educational material and a list of treatment resources for depression.
1801881|NCT00602745|Drug|S-1|oral administration
1801882|NCT00602745|Drug|5-Fluorouracil|intravenous bolus
1801883|NCT00602758|Behavioral|Motivational interviewing with cognitive behavioral therapy|Counseling sessions are completed face-to-face or by telephone at baseline and Weeks 1, 2, 4, 6, 9, 11, 15, 19, and 23. Counselors are trained in motivational interview technique and focus on ART medication adherence.
1801884|NCT00602758|Behavioral|Modified directly observed therapy|From baseline to Week 16, Monday through Friday, study staff meet the participants daily to observe one dose of their ART and to leave with the participants all other doses needed until the next observed dose. The frequency of observed doses begins to taper at Week 17 through to Week 24.
1801885|NCT00602771|Drug|tipifarnib|Given orally
1801886|NCT00602771|Drug|etoposide|Given orally
1801887|NCT00602784|Biological|IC41|
1801888|NCT00602797|Drug|vinorelbine tartrate|Given IV
1801889|NCT00602797|Drug|paclitaxel|Given IV
1801890|NCT00602797|Procedure|quality-of-life assessment|Ancillary studies
1801891|NCT00602797|Other|questionnaire administration|Ancillary studies
1957570|NCT02317393|Other|FDG|Both PET examinations will be performed within 4-6 weeks after the end of chemotherapy
1801896|NCT00602849|Drug|Sertraline|
1801897|NCT00602862|Drug|Sorafenib|Sorafenib 200 mg 2dd2 po for 4 weeks before surgery
1801898|NCT00602862|Drug|111Indium-bevacizumab|100 MBq / 1 mg 111Indium/bevacizumab iv
1801899|NCT00602862|Drug|111Indium-cG250|100 MBq / 10 mg 111Indium-cG250 iv
1801900|NCT00602901|Other|HVLA-SM|High-velocity low amplitude spinal manipulation (HVLA-SM)
1801901|NCT00602901|Other|LVVA-SM|Low-velocity variable amplitude spinal manipulation (LVVA-SM)
1801902|NCT00602901|Drug|Usual medical care|Celebrex: po, 200mg, qd, six weeks; Aleve: po, 220mg, bid, six weeks; Bextra: po, 10mg, qd, six weeks; Naproxen: po, 500mg, bid, six weeks.
1801903|NCT00602914|Device|MicronJet|The micronJet is a microneedle injection device designed for intradermal delivery of drugs (i.e. delivery into the skin). In this study the MicronJet will be used to inject insulin vs. a convention needle injection.
1801904|NCT00602914|Device|MicronJet|MicronJet, Intradermal Injection
1801905|NCT00602927|Drug|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - Day 13 1.0mg twice daily
1801906|NCT00602927|Drug|Placebo|Participants will take placebo pills for 13 days using the same regimen as the varenicline study period.
1801907|NCT00602940|Procedure|Acupuncture|12 treatments over 8 weeks
1801908|NCT00602940|Procedure|Sham Acupuncture|12 treatments over 8 weeks
1801910|NCT00602979|Device|Macintosh laryngoscope|Used during laryngoscopy to facilitate intubation.
1801911|NCT00602979|Device|Airtraq® Optical Laryngoscope|Used during laryngoscopy to facilitate intubation.
1801912|NCT00602979|Device|Storz DCI Video Laryngoscope®|Used during laryngoscopy to facilitate intubation
1801913|NCT00602979|Device|GlideScope® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
1801914|NCT00602979|Device|McGRATH® Video Laryngoscope|Used during laryngoscopy to facilitate intubation
1801915|NCT00603005|Device|Use of TravAlert dosing aid with or without drop guider|Each patient will use a dosing aid and/or drop guider for 6 months
1801916|NCT00603018|Drug|Fluoxetine|8 weeks of fluoxetine(2.5mg,5mg,10mg,20mg,30mg,40mg,40mg,40mg)each week per day.
1801917|NCT00603031|Other|glucagon like peptide -1|continuous infusion 1,2 pmol pr. kg pr minute at 120 minutes
1801918|NCT00603031|Other|NaCl|infusion with NaCl for 120 minutes as placebo-arm
1801919|NCT00603031|Other|glucose dependent insulinotropic polypeptide|continuous infusion with GIP-1 (3,6pmol/kg/min) at 120 minutes.
1801920|NCT00603044|Drug|fluticasone furoate|treatment with fluticasone furoate (55 mcg/nostril once daily) for 2 weeks prior to adenotonsillectomy
1801921|NCT00603070|Other|E-prescribing system|Transition from home-grown to vendor-based ambulatory e-prescribing systems
1801922|NCT00603070|Other|Electronic transmission of medication discharge lists|Patient discharge medication lists will be transmitted upon discharge from their inpatient medical record to their outpatient medical record and their outpatient provider will be notified of this transmission.
1802200|NCT00597103|Other|Periodic Leg Movement Syndrome Assessment|"Subjects will wear and Actiwatch on both legs for three consecutive nights."
1802201|NCT00597116|Drug|Vinorelbine|
1801923|NCT00603083|Drug|Ropivacaine, Ketorolac and Adrenalin|The local analgesic with Ropivacaine 200 mg, Ketorolac 30 mg and Adrenaline 1 mg is given 10 and 22 hours after the operation. The medicine solution is administrated in a catheter, which is placed in the hip at the end of the operation.
1801924|NCT00603083|Drug|Placebo|This group receive Placebo 10 and 22 hours after the operation. The Placebo is given in a catheter, which is placed in the hip at the end of the operation.
1801925|NCT00603096|Device|GoodKnight 425ST - Mallinckrodt DF, Tyco Healthcare|The aim of this randomized controlled trial is comparing the improvement of diurnal PaCO2 in OHS patients after one month of NIV treatment depending upon the tools used for adjusting settings. In one arm settings will be adjusted using only nocturnal oxygen SaO2 and PaCO2 at awakening whereas in the other arm patients will benefit from a complete polysomnography under NIV.
1801926|NCT00603109|Drug|rimonabant|rimonabant capsule 20 mg per day PO for 6 months
1801927|NCT00603109|Drug|placebo|Subjects take 20 mg placebo capsule one a day PO for 6 months
1801928|NCT00603122|Behavioral|ascent protocol|ascent protocol for the two groups has different acclimatization time
1801929|NCT00603135|Drug|first-line i/v-levetiracetam|No effect after 30 min, standard therapy with f.e. lorazepam for NCSE
1801930|NCT00603174|Device|neurally adjusted ventilatory assist (NAVA)|Following the titration of PEEP and the NAVA level, the infant will be ventilated on NAVA with the titrated levels. The following will be monitored and recorded for 20 min at 1 hour intervals: Phasic EAdi, tonic EAdi, tidal volume, ventilator-delivered pressure, respiratory rate, oxygen saturation, end tidal PCO2, and heart rate.
1801931|NCT00603187|Drug|Acyline|20 mg GIPET enhanced oral dose, daily for 7-days
1801932|NCT00603213|Procedure|Blood Volume Analysis, Echocardiogram|"Blood Volume Analysis: The use of radioactive tracer to determine plasma volume and red cell mass.
Echocardiogram is an ultrasound of the heart."
1801933|NCT00603239|Drug|exenatide|subcutaneous injection, 5 mcg or 10 mcg, twice a day (BID)
1801934|NCT00603239|Drug|placebo|subcutaneous injection, volume equivalent to 5 mcg or 10 mcg of active drug, twice a day
1801935|NCT00603252|Biological|Twinrix|
1801936|NCT00603252|Biological|Engerix-B|
1801937|NCT00603252|Biological|Havrix|
1801938|NCT00603252|Biological|HBVAXPRO|
1801939|NCT00603252|Biological|Vaqta|
1801940|NCT00603265|Drug|ADL5859|
1801941|NCT00603265|Drug|Duloxetine|
1801942|NCT00603265|Drug|Placebo|
1801943|NCT00603278|Drug|GW685698X|GW685698X
1801944|NCT00603278|Drug|placebo|placebo
1957577|NCT02309138|Diagnostic Test|Gestational diabetes screening with fasting 3 hour 100 gm|Participants receive fasting 3 hour 100 gm oral glucose tolerance test
1957578|NCT02309138|Diagnostic Test|Gestational diabetes screening with fasting 2 hour 75g|Participants receive fasting 2 hour 75 gm oral glucose tolerance test
1957579|NCT02308761|Drug|RO6870810|Participants will receive RO6870810 once daily (at escalated doses) via subcutaneous injection in either 28-day cycles (continuous 28 days dosing or 21 days dosing followed by 7 days off drug) or in 21-day cycle (14 days dosing followed by 7 days off drug), until MTD is identified.
1801948|NCT00603304|Drug|Saw Palmetto - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
1801949|NCT00603304|Drug|Placebo - first 24 weeks|Participants will take one 320 mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
1801950|NCT00603304|Drug|Saw Palmetto - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
1801951|NCT00603304|Drug|Placebo - weeks 24 - 48|Participants will take 640 mg (2) chocolate-colored soft gelcaps containing a placebo for 24 weeks.
1801952|NCT00603304|Drug|Saw Palmetto - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a standardized saw palmetto fruit extract for 24 weeks.
1801953|NCT00603304|Drug|Placebo - weeks 48 - 72|Participants will take 960 (3) mg chocolate-colored soft gelcaps containing a placebo for 24 weeks.
1801954|NCT00603317|Drug|Firstly : Amoxicillin-Clavulanic acid and secondly : Placebo|Amoxicillin : 2g twice daily Clavulanic acid : 125 mg twice daily
1801955|NCT00603317|Drug|Firstly : Placebo and secondly : Amoxicillin-Clavulanic acid|Amoxicillin : 2g twice daily Clavulanic acid : 125mg twice daily seven consecutive days
1801956|NCT00603330|Biological|Mesenchymal stem cells|Mesenchymal Stem Cell infusion
1801957|NCT00603343|Drug|Mictonetten 5 mg, coated tablet|propiverine 10 mg b.i.d. (17-27.9 kg BW) or propiverine 15 mg b.i.d. (28-45.0 kg BW)
1801958|NCT00603343|Drug|placebo|placebo corresponding to body weight
1801959|NCT00603356|Drug|OSI-930 and erlotinib|OSI-930 administered daily in combination with Erlotinib at increasing doses until disease progression or unacceptable toxicity
1801960|NCT00603369|Behavioral|group intervention|13-session intervention
1801961|NCT00603369|Behavioral|group intervention|2-session intervention
1801962|NCT00603382|Drug|GW685698X|GW685698X
1801963|NCT00603382|Drug|Placebo|placebo comparator
1801964|NCT00594958|Biological|IC51|6 mcg, intramuscularly [i.m.], 0.5 mL
1801965|NCT00594971|Other|Organisational intervention|A shared care approach in which extra effort is put into improving the communication between the hospital and the primary sector.
1801966|NCT00594971|Other|Referral to a specialist palliative care team.|Discharge with referral to a specialist palliative care team. This is a patient-centred shared care model in which the palliative team helps to organise the patient's treatment and care.
1801967|NCT00594984|Drug|Cetuximab|IV solution, IV, QW, 400 mg/m2 X 1, followed by 250mg/m2, until progression
1801968|NCT00594984|Drug|Irinotecan|IV solution, IV, Q3W, 350 mg/m2, until progression
1801969|NCT00594984|Drug|Brivanib|Oral, Tablet, QD, (200 mg, 400 mg, 600 mg, 800 mg dose escalation) until progression
1801970|NCT00594984|Drug|Brivanib|Oral, Tablet, QD, MTD determined in Arm 1, Phase 1, until progression
1801971|NCT00594984|Drug|Brivanib Placebo|Oral, tablet, QD, until progression
1802202|NCT00597116|Drug|Vandetanib|once daily oral dose
1802501|NCT00605761|Drug|SB656933|50 mg treatment
1801974|NCT00595010|Behavioral|SafeCare|Treatment will be based on an updated version of the SafeCare program, which specifically addresses parenting and discipline associated with child physical abuse. Participants will receive services from Comprehensive Home-Based Services.
1801975|NCT00595023|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
1801976|NCT00595049|Drug|bosentan|Bosentan 62.5 mg bid for 4 weeks, then 125 mg bid
1801977|NCT00595062|Radiation|Intra Operative Radiation Therapy (IORT)|Quadrant High Dose Rate Intra Operative Radiation Therapy (IORT)
1801978|NCT00595075|Drug|Ramelteon|Ramelteon 8 mg tablet by mouth x 1 dose
1801979|NCT00595075|Drug|placebo|placebo identical in appearance to active experimental drug x 1 dose
1801980|NCT00595088|Biological|BC-819/PEI|Papillary tumors will be resected with the exception of one marker tumor that will remain to examine the effects of the treatment on the remaining tumor. Study treatments will consist of an induction course of six weekly instillations of 20 mg of DTA-H19/PEI into the urinary bladder. Intravesical therapy will be delivered through a Foley catheter. Patients will be instructed to hold the dose in the bladder for two hours after administration. If the patient has a complete response, then she/he will be eligible to receive three additional courses of 3 weekly intravesical administrations of the same dose of investigational product every 12 weeks.
1801981|NCT00595101|Drug|PF-03187207|
1801982|NCT00595101|Drug|Latanoprost 0.005%|
1801983|NCT00595101|Drug|PF-03187207 Vehicle|One drop in study eye once daily for the first 28 days to all subjects, followed by 28 days in combination with PF-03187207.
1801984|NCT00595101|Drug|Latanoprost Vehicle|
1801985|NCT00595127|Drug|Cyclophosphamide|Cyclophosphamide (10mg/kg/day x 4days)
1801986|NCT00595127|Drug|Fludarabine|Fludarabine (30mg/m^2/day x 5 days)
1801987|NCT00595127|Radiation|Total body irradiation (TBI)|TBI (450 cGY in a single fraction)
1801988|NCT00595140|Drug|pegvisomant|growth hormone receptor antagonist pegvisomant in patients´ individual dose
1801989|NCT00595140|Drug|combination with somatostatin analogue octreotide|s.c., 100µg, one time
1801990|NCT00595140|Drug|combination with dopamine agonist cabergoline|oral, 0.5mg, one time
1801991|NCT00595153|Drug|Pulmicort|inhaled powder of inhaled corticosteroid, 1 puff (180mcg) twice a day for 8-10 weeks
1801992|NCT00595166|Device|Vaginal Speculum Sheath|Patients received the sheathed speculum exam: The clinician will begin to place the sheath onto the speculum. The sheath is attached to a thin piece of cardboard. The proximal end of the cardboard is placed between the speculum blades and is pushed toward the speculum handle. The blades of the speculum are simultaneously guided to enter the 2 pockets of the sleeve, like fingers going into a glove. The speculum exam will then be completed according to usual procedures. In the event the sheathed speculum exam is unsatisfactory the clinician will do standard of care (the clinician's usual routine at the bedside).
1801993|NCT00595205|Other|Hospital log review.|Reviewing of the hospital log to monitor for the occurrence of intussusception.
1801994|NCT00595218|Behavioral|Physician behavior related to Patient Preference Survey|Access to initial Patient preference survey results
1801995|NCT00595218|Other|Patient Preference Results|Knowledge of Patient Preference Results
1801996|NCT00595231|Drug|SYN111 - Placebo|SYN111 - Placebo
1801997|NCT00595231|Drug|SYN111|500 mg for 1 week followed by 1000 mg for 7 weeks
1801998|NCT00595244|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
1801999|NCT00595257|Device|centrifuge, laboratory, tabletop (SmartPReP2 BMAC System)|autologous bone marrow aspirate will be concentrated using the SmartPRep2 BMAC system and then injected/infused into ischemic limbs
1802000|NCT00595270|Biological|IC51|
1802001|NCT00595283|Behavioral|Parent Child Interaction Therapy-Emotion Development (PCIT-ED)|PCIT-ED includes fourteen 1-hour therapy sessions over 14 weeks. Sessions will focus on positive parent-child interactions skills, ways to manage emotions, and relaxation techniques.
1802002|NCT00595283|Behavioral|Developmental Education Parenting Intervention (DEPI)|DEPI includes 14 weekly, 1-hour education sessions covering a range of child development and parenting topics. Classes are in a small group format and will emphasize emotional and social development.
1802003|NCT00595296|Device|GeneSearch™ Breast Lymph Node (BLN) Assay|The GeneSearch™ BLN Assay is a real time Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) assay that detects the presence of breast tumor cell metastasis in lymph nodes through the detection of gene expression markers present in breast tissue, but not in nodal tissue (cell type specific messenger RNA).
1802004|NCT00595309|Biological|IC51|IC51, 6 mcg, intramuscular (i.m.) booster vaccination 15 months after the primary immunization
1802005|NCT00595322|Other|bevacizumab and radiation (IMRT)|bevacizumab 10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (cycle defined as 28 days). If the tumor volume remains < 40 cc, the patient will undergo stereotactic radiotherapy with IMRT (30Gy) beginning anywhere from day 7-10 of cycle 2 (5 doses of 6 Gy over 2 and a half weeks)
1802006|NCT00595335|Drug|Rituximab|Subjects will receive 2 infusions of rituximab (1000 mg IV), two weeks apart.
1802007|NCT00595335|Drug|Saline|Subjects will receive 2 infusions of saline IV, 2 weeks apart, each preceded by a premedication saline IV.
1802008|NCT00595335|Drug|Methylprednisolone|Subjects will receive methylprednisolone 100 mg IV as premedication to the rituximab infusion.
1802009|NCT00595361|Drug|salmeterol|salmeterol 50 micrograms twice daily for 2 weeks
1802010|NCT00595374|Drug|insulin detemir|
1802011|NCT00595374|Drug|insulin NPH|
1802012|NCT00595374|Drug|insulin aspart|
1802013|NCT00595387|Other|Supportive Psychotherapy|Participants will attend 18 supportive therapy sessions over 5 months. Supportive psychotherapy focuses on reflecting and expressing feelings about current life issues. Participants are supported and comforted when coping with difficult situations, depression, mood swings, or anger.
1802203|NCT00597129|Biological|90Y-hPAM4|Single dose of 90Y-hPAM4 will be given and all patients will be followed for 12 weeks.
1802014|NCT00595387|Other|Cognitive Behavioral Therapy (CBT)|Participants will attend 18 CBT sessions over 5 months. CBT for depression targets depressive symptoms through a range of different treatments. This includes psychoeducation about the disorder and educating patients about the role of thoughts and behaviors in the maintenance of depressed mood. CBT also includes mood and activity monitoring, activity scheduling, and teaching participants to critically investigate and challenge negative thoughts and core beliefs that help to maintain depression.
1802015|NCT00595413|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 21 weeks.
1802016|NCT00595413|Drug|Atacicept: with loading dose|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 21 weeks.
1802017|NCT00595413|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg once a week for 25 weeks.
1802018|NCT00595413|Biological|Adalimumab|Adalimumab (Humira®) will be administered subcutaneously at a dose of 40 mg every other week for 25 weeks.
1802019|NCT00595426|Drug|YM150|Oral
1802020|NCT00595426|Drug|Warfarin|Oral
1802021|NCT00595465|Biological|Japanese Encephalitis purified inactivated vaccine|IC51 6 mcg i.m. injection on Day 0 and Day 28
1802024|NCT00595491|Biological|Bronchoscopy, Segmental Allergen Challenge, and Broncheoalveolar Lavage|Bronchoalveolar lavage is performed in the lingula without instillation of diluent or allergen. A 2ml aliquot of diluent is instilled into the right upper lobe. The procedure is repeated in the right middle lobe with instillation of 2ml of Cat or Mite allergen. A test dose of allergen is administered first. This will consist of 2ml allergen at 1/10th the threshold concentration for Cat or DF Mite Allergen or at 1/30th the threshold concentration for DP Mite Allergen. If on visual inspection through the bronchoscope there is no evidence of reaction to the test dose, a 2nd allergen challenge is done in the right middle lobe using 2ml of full-dose allergen. After a 1,6, or 24hr recovery period, a single 2nd bronchoscopy is performed after delivery of allergen extract and diluent and 1 Tbsp of blood is obtained. Bronchoalveolar lavage will be obtained from the lobes in which the diluent and allergen were instilled. OFDI and endobronchial brushing of the airways will also be performed.
1802025|NCT00595504|Drug|Ramelteon|Two week supply of ramelteon 8mg/day first dispensed at baseline. New two week supply of study medication dispensed at each biweekly visit for 8 consecutive weeks.
1802026|NCT00595504|Drug|Placebo|Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
1802027|NCT00595517|Drug|Esomeprazole 20 mg|Esomeprazole 20 mg once daily
1802028|NCT00595530|Drug|ketamine|"Medication administered via IV. This study will utilize 4 doses of ketamine: 0.05 mg/kg/hr, 0.1 mg/kg/hr, 0.15 mg/kg/hr, and 0.2 mg/kg/hr.
Dosing Regimen:
Patients begin the ketamine infusion at 0.05 mg/kg/hr.
4 or more hrs after infusion is started, the dose may be increased to 0.1 mg/kg/hr if:
patient's pain has not improved to an acceptable level
side effects remain acceptable
4 hrs or more after the previous increase, the dose may be adjusted to 0.15 mg/kg/hr
4 hrs or more after the previous increase, the dose may be adjusted to 0.2 mg/kg/hour
Maximum dose of ketamine is limited to 300 mg per 24 hrs
Patient may receive ketamine up to 72 hrs after initiation."
1802029|NCT00595543|Drug|Bromfenac|1 drop (in the eye) Instill one drop in the affected eye twice daily for three months
1802030|NCT00595543|Drug|Ketorolac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
1802031|NCT00595543|Drug|Diclofenac|1 drop (in the eye) Instill one drop in the affected eye four times daily for three months
1802032|NCT00595556|Drug|zonisamide|flexible dosages of 100-500mg/day
1802033|NCT00595556|Drug|Placebo|Placebo
1802034|NCT00595569|Behavioral|Flexible insulin therapy (FIT)|Flexible insulin therapy (FIT) courses consisting in 7 weekly ambulatory sessions lasting 90 minutes each
1802035|NCT00595582|Dietary Supplement|curcumin + bioperine|Subjects who are currently in the primary Mild Cognitive Impairment study will be asked to be treated with 5.4 grams of curcumin + bioperine per day (900 mg pills, two pills 3x/day with meals) for 24 months concordant with the last two years of the primary longitudinal Mild Cognitive Impairment study.
1802036|NCT00595608|Drug|Sterimar Spray|Post-op nasal spray, three times a day
1802037|NCT00595608|Drug|Generic homemade nasal saline spray (salt and water)|post op nasal saline spray in syringe, three times a day
1802039|NCT00595647|Device|Drug eluting stent|Implantation of stent
1802040|NCT00595647|Device|Bare metal stent|Implantation of stent
1802041|NCT00595660|Procedure|FNA - fine needle aspiration|Fine Needle aspiration
1802042|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
1802043|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
1802044|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
1802045|NCT00595660|Procedure|FNA - fine needle aspiration|Fine needle aspiration
1802046|NCT00595673|Drug|PB127 for injectable suspension|0.175 mg/kg diluted in 150 mL Dextrose in Water 5% in glass bottles to be infused at 250 mL/hour until stead state achieve, 150 mL/hour during rest image acquisition, and 100-150 mL/hr during stress image acquistion. Single IV infusion, not to exceed 60 minutes.
1802047|NCT00595686|Drug|SNX-5422|dose escalated; tablets every other day; undetermined duration until disease progression
1802048|NCT00595699|Drug|escitalopram|10 mg daily for the first week followed by an increase to 20 mg daily for the remainder of the study
1802049|NCT00595699|Drug|placebo|Placebo
1802050|NCT00595712|Procedure|Iliac crest allograft|Opening wedge osteotomy of proximal tibia with allograft from iliac crest
1802051|NCT00595712|Procedure|Iliac crest autograft|open wedge osteotomy of proximal tibia using autogenous iliac bone graft
1802052|NCT00595725|Other|Lymphatic Mapping|Intra-Operative Lymphatic Mapping
1802053|NCT00595738|Other|Standard of care therapy for severe decompensated heart failure|Standard of care therapy for severe decompensated heart failure
1802054|NCT00595764|Behavioral|Manual-guided Physician Management (PM)|Manual-guided Physician Management (PM) PM, consistent with federal regulations, is designed to reflect usual care by primary care physicians and includes referral to ancillary services.
1802055|NCT00595764|Behavioral|Physician Management (PM) combined with on-site manual-guided Cognitive Behavioral Therapy (CBT)|CBT is provided by skilled psychologists in weekly sessions for the first 12 weeks and focuses on reducing illicit drug use and increasing Buprenorphine adherence.
1802056|NCT00595777|Behavioral|EPAT© Educational Package|The EPAT package consists of an education programme, which deals with the known common barriers to effective pain control and the bedside pain tool. The pain tool is uniquely incorporated into the vital signs chart to enable a systematic approach to cancer pain assessment and review. EPAT consists of 2 steps: step 1 is a colour-coded pain assessment on the bedside vital signs chart. Patients with moderate or severe pain on step 1 will progress to to step 2, which helps to identify the aetiology of the pain, screening for opioid side effects and is linked via flags to simple management plans. The intervention will be delivered to the clusters randomised to the intervention, after collection of baseline data (pre-intervention data) on 50 patients.
1802057|NCT00595790|Biological|IC51|
1802058|NCT00595816|Other|physical training and counselling|Neuromuscular training program 3 times per week 30 minutes per session and counselling on back problems and other musculosceletal injuries
1802059|NCT00595829|Drug|XL019|XL019 capsules administered orally
1802060|NCT00595855|Procedure|trabeculectomy|Cairns-like trabeculectomy, limbus based, with 5_FU supplementation and argon laser suturelysis
1802061|NCT00595855|Procedure|deep sclerectomy|deep sclerectomy with no implant and no sutures to the superficial flap, limbus based with suppplementation of FU (if needed)
1802062|NCT00595868|Drug|Varenicline|0.5 milligrams two times per day for 3 days, then 1.0 milligrams two times per day for an addition 11 days - 2 months
1802063|NCT00595868|Drug|Placebo|same as Varenicline arm
1802064|NCT00595881|Device|Bedside emergency ultrasound|Ultrasound will be performed on the lesion in question.
1802065|NCT00595920|Biological|Tovaxin|2 mL subcutaneous injections administered by a healthcare provider at weeks 0, 4, 8, 12, and 24 every year as required.
1802066|NCT00595933|Other|sugar-free chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
1802067|NCT00595933|Other|chewing gum|Chew gum 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
1802068|NCT00595933|Other|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week questionaire
1802069|NCT00595933|Other|mouth rinse|Rinse mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week.
1802070|NCT00595933|Drug|mouth spray|Spray mouth with mouth spray 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
1802071|NCT00595933|Drug|mouth spray|Spray mouth 4 times a day with additional allowances for as needed. Fill out daily questionaire and an end of week
1802072|NCT00595946|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
1802073|NCT00595946|Drug|Placebo|0 mcg capsules twice daily (BID)
1802074|NCT00595959|Device|CLiRpath Photoablation System|Use of CLiRpath Laser Catheter to improve vessel lumen diameter.
1802075|NCT00595972|Drug|ECF-endostar|Epirubicin 50mg/M2 D1, Cisplatin 60mg/M2 D1, FU 500mg/M2 D1-5, endostar 7.5mg/M2 D1-14, treatment cycle repeat every 3 weeks. Treatment should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
1802076|NCT00595985|Drug|sorafenib|sorafenib 400mg bid, and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent
1802079|NCT00596024|Dietary Supplement|lutein/zeaxanthin|daily supplementation of lutein and zeaxanthin at dose of 12 mg/day
1802080|NCT00596024|Dietary Supplement|placebo|placebo capsules with the same size and coating as those of lutein/zeaxanthin supplements without active ingredients
1802081|NCT00596037|Drug|Growth hormone - LB03002|
1802082|NCT00596050|Drug|ketamine and midazolam|ketamine 1 mg/kg/dose, midazolam 0.05 mg/kg/dose max 2 mg
1802083|NCT00596050|Drug|etomidate, fentanyl, and lidocaine|etomidate 0.2 mg/kg/dose, fentanyl 1 microgram/kg/dose, lidocaine 0.5 mg/kg/dose
1802084|NCT00596063|Biological|Wosulin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
1802085|NCT00596063|Biological|Novolin R|Penfill cartridges; Single Dose, 0.2 IU/ kg;
1802086|NCT00596076|Behavioral|Back School|"All the workers undergo a clinical examination for low back pain, by two trained practitioner. Those workers who are diagnosed for mechanical low back pain during the last six months fulfill a self report Quality of Life Questionnaire (SF36). The objective level of low back pain will obtain by a visual analogue scale. Then a back school training course will be held in 6 sessions, in 6 consecutive weeks. Two previously trained physiotherapists are responsible for the training course. Each series will have 10 participants. They will learn vertebral column anatomy and its function at the first session. The proper posture and exercises to reduce or inhibit low back pain are taught in the next 4 sessions. The 6th session is arranged for answering questions and checking how exercises are performed.
A visual analogue scale and quality of life assessment will be held at the end of the last session and the end of the sixth month."
1802087|NCT00596102|Biological|Japanese Encephalitis purified inactivated vaccine|Japanese Encephalitis purified inactivated vaccine
1802088|NCT00596115|Drug|R(+) pramipexole dihydrochloride monohydrate|20 mg tid per day orally
1802089|NCT00596128|Behavioral|Implementation of SOP|SOP for blood sugar monitoring and intervention will be defined and ICU nurses will be educated to use this SOP in clinical routine
1802090|NCT00596141|Device|OroScience Topical Oral Wound Emulsion|TOWE will be applied 3 times daily for a period of 7 days by the patient dispensing TOWE into a disposable dental tray and placing the dental tray over the dental arch and covering the surgical site.
1802198|NCT00597103|Other|Cognitive Function Testing-10 Tests|Trailmaking A, Trailmaking B, Rey Auditory Verbal Learning, Letter Number Sequencing, Digit Symbol Substitution, Grooved Pegboard, Controlled Oral Word Association, Beck Depression Index, Feeling Thermometer, Modified Mini-Mental Status
1802091|NCT00596154|Other|Rituximab, Methotrexate, Vincristine, Procarbazine, PBPCs collection, Busulfan, Thiotepa, and Cyclophosphamide|"The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1.
On day 2 you will be admitted to the hospital and will receive 3 other drugs:
Methotrexate will be given by vein over 2 to 3 hours only on day 2. Vincristine will be given as a single injection over a few minutes only on day 2.
Procarbazine is a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine is only given every other cycle."
1802092|NCT00596167|Drug|Intravenous antibiotics|Each subject will receive a single dose of 15 mg/kg vancomycin; 2 mg/kg gentamicin and 250 mg levofloxacin administered intravenously over a one-hour infusion period through the venous limb of their HD access (or tunneled catheter) via an IV pump.
1802093|NCT00596180|Drug|HBOT|total body exposure to greater than atmospheric pressure oxygen
1802094|NCT00596206|Drug|leflunomide|20 or 100 mg per os, Film coated tablet, for 3 days + matching placebo, then 20 mg once daily for 3 months
1802095|NCT00596219|Drug|celecoxib|celecoxib
1802096|NCT00596245|Drug|MT400|MT 400, naproxen sodium 550mg
1802098|NCT00596271|Biological|IC51|
1802099|NCT00596271|Biological|HAVRIX|
1802100|NCT00596271|Other|Placebo|
1802101|NCT00596284|Behavioral|Cognitive Behavioral Therapy of Anxiety in Dementia (CBT-AD)|Cognitive behavioral therapy (CBT) will consist of 8 to 10 sessions over a period of 10 to 12 weeks. Each CBT session will last about 1 hour and will include meeting with a study staff member to discuss anxiety and how to cope with it. Participants will also complete practice activities at home for about 20 minutes per day.
1802102|NCT00596284|Behavioral|Enhanced Usual Care (EUC)|Following in-person meetings, participants will receive weekly phone calls for 3 months, followed by biweekly phone calls for the next 3 months.
1802103|NCT00596297|Drug|bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 day after baseline; pars plana vitrectomy 4 weeks after baseline
1802104|NCT00596297|Procedure|pars plana vitrectomy|4 weeks after baseline
1802105|NCT00596310|Other|CT|Screening CT
1802106|NCT00596336|Drug|Imiquimod cream|Imiquimod (aldara) 0.5 % cream to site of vaccination on day 2 to 6
1802107|NCT00596336|Drug|influenza vaccine|trispecific influenza vaccine 0.5 ml subcutaneously
1802108|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
1802109|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL-Cancer Survivor FACT-Ovarian SF-36 (general QOL scale) CES-D (depression scale) Impact of Events Scale (anxiety scale) FACT-GOG-NTX (neurotoxicity scale) Female Sexual Functioning Index (FSFI) Cognition Testing Perception of disease chronicity/acuity Concerns about Recurrence Report of surveillance type, frequency, utility Health behaviors Self-report of co-morbidities Self-report of potential unmet needs Background information form List of current medications Patient-defined QoL domains
1802110|NCT00596349|Behavioral|questionnaires|study participants complete one-time survey, questionnaires, and cognition testing, comprising the following: QOL- Cancer Survivor, FACT-Ovarian, SF-36, CES-D, IES, FACT-GOG-NTX, FSFI, Cognition Testing, Perception of disease chronicity/acuity, Report of surveillance type, frequency, utility, Health behaviors, Self-report of co-morbidities, Self-report of potential unmet needs, Background information form, List of current medications,Patient-defined QoL domains
1802111|NCT00596362|Drug|AVASTIN|a single injection of Avastin at the outpatient clinic. This will be done as follows: the pupil in the eye being treated will be enlarged with a liquid solution. Thirty minutes later, a numbing solution and then a cleansing solution will be put in to the eye. Finally, an injection of Avastin will be given into the eye. Right after this injection, your eye will be examined by your doctor. The pressure in your eye will also be tested before and after the injection. Patients will use antibiotic drops for 5 days following the injection. Following the injection, you will have weekly examinations for four weeks in the office.
1802112|NCT00596375|Procedure|Lubricant Instillation|Lubricant jelly instilled in urethra prior to catheterization
1802113|NCT00596375|Drug|Lidocaine Lubricant|2% Lidocaine lubricant instillation prior to urethral catheterization
1802114|NCT00596414|Procedure|transjugular liver biopsy|liver biopsy through the transjugular route with hepatic-venous pressure gradient measurement
1802115|NCT00596414|Drug|placebo|
1802116|NCT00596414|Drug|midazolam|
1802117|NCT00596414|Drug|midazolam + pethidine|
1802118|NCT00596427|Drug|Colesevelam HCL|Colesevelam HCL 625 mg: 3 tablets twice per day
1802119|NCT00596427|Drug|Placebo|Placebo tablets: 3 tablets twice per day
1802120|NCT00596440|Drug|Transdermal nicotine patch|8 weeks; 4 weeks of 21mg, 2 weeks of 14mg, and 2 weeks of 7mg.
1802121|NCT00596453|Drug|Ciprofloxacin hydrochloride|250 mg Ciprofloxacin hydrochloride twice a day for 14 days
1802122|NCT00596453|Drug|Placebo|Placebo twice a day for 14 days
1802123|NCT00596466|Drug|pregabalin|pregabalin
1802124|NCT00596479|Drug|Filgrastim (rG-CSF)|
1802125|NCT00596492|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
1802126|NCT00596492|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
1802127|NCT00596518|Drug|PF-00734200|The drug is administered as a single dose of four 5-mg tablets
1802128|NCT00596531|Drug|Acamprosate|Oral administration, 666 mg, tid, for 4 months
1802129|NCT00596531|Drug|Placebo|Oral administration of 2 pills, tid, for 4 months
1802193|NCT00597038|Drug|Dasatinib and Dacarbazine (DTIC)|"Arm A/ Phase I Potential Dose Levels.
Dose Level -1: Dasatinib 40 mg; DTIC 600 mg/m^2. Dose Level 1: Dasatinib 50 mg; DTIC 800 mg/m^2. Dose Level 2: Dasatinib 70 mg; DTIC 800 mg/m^2. Dose Level 3: Dasatinib 70 mg; DTIC 1000 mg/m^2.
Arm B/Phase II Potential Dose Levels.
MTD1: Dasatinib 70 mg; DTIC 1000 mg/m^2. MTD2: Dasatinib 70 mg; DTIC 800 mg/m^2. MTD3: Dasatinib 100 mg: DTIC 1000 mg/m^2."
1802130|NCT00596544|Behavioral|questionnaires|will be offered referral to the Sexual Health Clinic (SHC) at MSKCC for evaluation and possible treatment. The effectiveness and compliance of the intervention offered at the SHC will be assessed at approximately 3, 6 and 12 months using the FSFI, SAQ, CES-D, MSC and IES. At each evaluation they will complete a Health Surveillance Form (HSF). They will have completed the study at 12 months after entering the study or at the time they have evidence of recurrent disease requiring treatment
1802131|NCT00596544|Behavioral|questionnaires|Those women who have a FSFI score > 26 will be reassessed at approximately 3, 6 and 12 months. They will complete the FSFI, SAQ, CES-D, IES, MSC and HSF at each assessment. They will be followed out until 12 months after entering the study or until they have evidence of recurrent disease.
1802132|NCT00596557|Drug|everolimus|reduced dose CNI (cyclosporine level of 50-100)with everolimus levels of 3-8.
1802133|NCT00596570|Procedure|PCI|Percutaneous coronary interventiom
1802134|NCT00596583|Drug|DYME|2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
1802135|NCT00596583|Drug|DYME|2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution
1802136|NCT00596596|Drug|prucalopride|0,5 mg once daily
1802137|NCT00596596|Drug|prucalopride|1 mg once daily
1802138|NCT00596596|Drug|2 mg prucalopride|2 mg once daily
1802139|NCT00596596|Drug|4 mg prucalopride|4 mg once daily
1802140|NCT00596596|Other|Placebo|placebo once daily
1802141|NCT00596609|Drug|Intrathecal Morphine|"In the IT morphine group, prior to IT morphine injection (within 15 minutes of the injection), the neurophysiologist will be asked to obtain a set of TceMEP recordings. The recordings collected at this time will be labeled Baseline. These will serve as controls for subsequent recording comparisons.
In the IT morphine group, the time of IT morphine injection will be recorded, as well as the dose. A timer will be started. The neurophysiologist will then be asked to collect four additional sets of TceMEP recordings, at 5, 10, 20, and 30 minutes after morphine injection."
1802142|NCT00596622|Drug|Lithium|Dosing will start as one 300-mg capsule per day and will be titrated up to four 300-mg capsules per day for a total of 8 weeks of treatment.
1802143|NCT00596635|Dietary Supplement|Once Daily Cranberry Capsule|650mg capsule pure cranberry powder
1802144|NCT00596635|Dietary Supplement|Twice Daily Cranberry Capsules|One 650mg cranberry capsule administered twice per day
1802145|NCT00596648|Drug|XL184|Capsules administered orally daily
1802146|NCT00596648|Drug|erlotinib|Tablets administered orally daily.
1802147|NCT00596661|Device|TriMaxx Coronary Stent placement|Angioplasty with coronary artery stent placement
1802148|NCT00596674|Behavioral|Lifestyle Counts|8 weeks of classes focused on health behavior change, individualized goal setting and 3 months of follow-up phone support
1802149|NCT00596674|Other|Attention Control|8 weeks of classes on general health information topics followed by 3 months of phone calls to solicit questions
1802150|NCT00596687|Drug|Insulin glargine|Insulin glargine once daily SQ
1802151|NCT00596687|Drug|Regular insulin|Sliding scale regular insulin SQ four-times daily before meals or every 6 hours if patient NPO
1802152|NCT00596687|Drug|Insulin glulisine|scheduled glulisine given SQ at mealtime TID; none given if patient NPO
1802153|NCT00596700|Device|Given® Diagnostic System including PillCamTM SB Capsules|"Device for detection of pathologies as a tool in the diagnosis of gastrointestinal disorders.
An ingestible,disposable video camera that transmits high quality images of the small intestinal mucosa"
1802154|NCT00596726|Device|IMPELLA LP/LD 5.0|IMPELLA LP/LD 5.0 Support System is intended to be used for up to seven (7) days as a left ventricular cardiac assist device for postcardiotomy patients who, despite having been weaned from cardiopulmonary bypass (CPB), require hemodynamic support
1802155|NCT00596752|Drug|Alprostadil|"Active Substance: Prostaglandin E1
Pharmaceutical Form: solution for infusion
Concentration: 40 μg b.d.
Route of Administration: intravenous infusion"
1802156|NCT00596752|Other|Placebo|"Active Substance: Lactose
Pharmaceutical Form: solution for infusion
Concentration: 40 μg b.d.
Route of Administration: intravenous infusion"
1802157|NCT00596765|Behavioral|Neuropsychological Cognitive Behavioral Therapy|Neuropsychological Cognitive Behavioral Therapy encompasses 2 foci: First emphasis is on neuropsychological compensatory strategies for the treatment of deficits in attention, memory, and executive functions. Secondly, cognitive behavioral intervention techniques are employed to support the patient in the process of coping with chronic illness: i.e. improve regulation of negative affect, diversify the impaired self-concept after acquired brain injury, and adjust important life-goals to changed circumstances.
1802158|NCT00596778|Other|chest physiotherapy|The protocol consisted of breathing exercises during 30 minutes and included: passive and localized exercises, deep diaphragmatic breathing and exercises of chest wall expansion.
1802159|NCT00596791|Drug|tafluprost|prostaglandine analoque
1802160|NCT00596804|Drug|veltuzumab|once weekly intravenous dosing for 4 weeks
1802161|NCT00596817|Drug|Placebo|capsules, daily, orally
1802162|NCT00596817|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
1802163|NCT00596830|Drug|CP-751,871 (Figitumumab)|CP 751,871 is a potent and selective fully human monoclonal antibody against the insulin like growth factor 1 receptor (IGF-1R). Patients in Arm A will receive CP-751, 871 intravenously every 21 days for up to six cycles.
1802164|NCT00596830|Drug|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive carboplatin intravenously every 21 days for up to six cycles.
1802165|NCT00596830|Drug|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patients in Arm A will receive paclitaxel intravenously every 21 days for up to six cycles.
1802166|NCT00596830|Drug|Carboplatin|Carboplatin is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive carboplatin intravenously every 21 days for up to six cycles.
1802167|NCT00596830|Drug|Paclitaxel|Paclitaxel is a standard chemotherapeutic agent used in patients with lung cancer. Patient in Arm B will receive paclitaxel intravenously every 21 days for up to six cycles.
1802168|NCT00596843|Behavioral|Motivational interviewing|6 one-on-one individual sessions lasting from 30 minutes to 1-hour each
1802169|NCT00596843|Behavioral|Educational intervention|6 1-hour sessions. 2 sessions are delivered by an interventionist and 4 sessions are delivered as videos
1802194|NCT00597051|Drug|ARD-0403|
1802170|NCT00596856|Behavioral|Development and dissemination of priority oral health risk assessment and referral guidelines - PORRT|The RCT will compare passive distribution of guidelines by mail to an in-office intervention consisting of guideline distribution combined with educational outreach providing training in guideline use and patient mediated information provided by the risk and referral assessment tool (PORRT). The three-arm trial will consist of 25 medical practices that have never participated in IMB and 25 practices that are currently participating, both of which will receive the guidelines through the mail, and 25 practices currently participating in IMB that will receive the more intense in-office training intervention.
1802171|NCT00596882|Other|Message Prime|Participants will be randomized to genetic prime messages or threat only message at the time of the intial telephone screen. Following phone screen, all eligibleparticipants will receive 13 weeks of Chantix with smoking cessation counseling.
1802172|NCT00596882|Other|Message Prime|Particpants will be randomized into 1 of 2 groups. 1 group will recieve a message detailing the negative helaht consequenes of smoking and the other group will receive this information along with information about the genetic incluences on smoking behavior.
1802173|NCT00596895|Dietary Supplement|Isoflavone|Ingested 47 mg of isoflavone in three 8 oz servings per day
1802174|NCT00596934|Drug|metreleptin|0.1 mg/kg/day once a day via subcutaneous injections
1802175|NCT00596947|Drug|prednisone|In this group, participants had prednisone rapidly decreased until completely eliminated by day 6 after transplant. Participants began on 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20mg on day 5, none from day 6-on.
1802176|NCT00596947|Drug|rabbit antithymocyte globulin|Participants in both groups received 3 to 5 doses of an intravenous medication to prevent rejection called Thymoglobulin (rabbit antithymocyte globulin) as per our standard of care. This drug was dosed at 1.5 milligrams/killograms per dose and dosing was then based on body weight. The dose was decreased in half or held if the participant had a low white blood cell count or if the participant a low platelet count. The first dose was given intravenously in the operating room and subsequent intravenous doses were administered either while participants were inpatients or outpatients for a total of 3 to 5 doses for a total of up to 6mg/kg. The number of doses was based on transplant kidney function and risk factors for rejection.
1802177|NCT00596947|Drug|Tacrolimus|Participants in both groups received tacrolimus per our standard of care. This medication helped to prevent rejection and was initially dosed at 0.1-0.2 milligrams/killograms/day in two divided doses, given orally, based on participant's body weight. We then looked at the trough levels of this medication(the lowest level before the next dose), and aimed to keep the trough level between 5-10 nanograms/milliliter throughout the study.
1802178|NCT00596947|Drug|Prednisone|Participants in this group continued on prednisone indefinitely. Participants began with 500mg of intravenous methylprednisolone on the day of transplant, followed by the following doses of oral prednisone: 160mg on day 1, 120mg on day 2, 80mg on day 3, 40mg on day 4, 20 mg days 5-9, 15 mg day 10-19, 10 mg day 20-24, 7.5 mg day 25-29, and 5mg from day 30-on indefinitely.
1802179|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone withdrawal group was 1000mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
1802180|NCT00596947|Drug|Mycophenolate mofetil|Participants in both groups received mycophenolate mofetil by mouth twice daily indefinitely. Dosing for patients in the Prednisone maintenance group was 500 mg orally twice daily. The dose was decreased or held at the discretion of the physician, for side effects such as low white blood cell count, or low platelet count, or if the participant experienced stomach side effects such as heartburn, nausea, vomiting or diarrhea.
1802181|NCT00596960|Behavioral|Motivational Enhancement Therapy (MET)|MET is a 4 session intervention based on motivational approaches that was successful in project MATCH.
1802182|NCT00596960|Behavioral|Health education|Health education intervention will serve as the active control. The intervention will consist of 4 sessions of health education with a focus on sleep hygiene, nutrition, exercise and relaxation training.
1802183|NCT00596973|Procedure|Surgical Treatment|Ileal transposition with sleeve gastrectomy
1802184|NCT00596986|Drug|Duloxetine|Duloxetine 30mg up to 120mg per day.
1802185|NCT00596986|Behavioral|Cognitive Behavioural Analysis System of Psychotherapy|Cognitive Behavioural Analysis System of Psychotherapy (CBASP): 20 sessions of psychotherapy, beginning with twice weekly, then weekly sessions.
1802186|NCT00596999|Procedure|UCB and HPDSC|single dose of UCB followed by one unit of HPDSC
1802187|NCT00597012|Procedure|Arthroscopic partial menisectomy|Arthroscopic partial meniscectomy is a surgical procedure that is performed to remove a piece of torn cartilage in the knee joint. Incisions for arthroscopy are quite small, usually about 1 centimeter each. The torn meniscus can be removed using a number of different instruments, including small shavers and scissors.
1802188|NCT00597012|Other|Standard physical therapy|Participants will undergo standard physical therapy that will include strengthening and stretching sessions one to three times a week for 8 weeks. This physical therapy regimen will have similar elements and goals as the postoperative intervention offered to Group 1 participants.
1802189|NCT00597012|Other|Postoperative rehabilitative physical therapy|This physical therapy is geared specifically toward rehabilitation after APM surgery.
1802190|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given one protein bar at each dialysis treatment, 3 times per week for 3 months
1802191|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given 7 bars per week. In addition to the the three bars given on Hemodialysis each week, the patients will be given on the first treatment of the week four protein bars to be eaten on non-dialysis days
1802192|NCT00597025|Dietary Supplement|Protein Food Bar Intelligent Indulgence|Patients will be given a monthly supply of protein bars to provide for daily intake of one protein bar.
1802196|NCT00597077|Other|Rate vs rhythm control strategies for atrial fibrillation|Rate vs rhythm control strategies for atrial fibrillation
1802197|NCT00597077|Other|Rate vs rhythm control strategies in atrial fibrillation|rate vs rhythm control strategies in atrial fibrillation
1802204|NCT00597142|Device|Express™ Renal Premounted Stent System|"This device is indicated for use as an adjunct to percutaneous transluminal renal angioplasty (PTRA) of a:
Single, de novo or restenotic (from PTRA) atherosclerotic lesion in the ostium of the renal artery
Lesion length ≤15mm
Lesion involving the aortorenal ostium or the leading edge of the stenosis is located within 5 mm of the opacified aortic lumen
RVD 4.0-7.0mm"
1802205|NCT00597181|Procedure|Trabeculectomy with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
1802206|NCT00597181|Procedure|Ex-Press mini shunt with mitomycin c|mitomycin c 0.2 mg/cc for 2 minutes
1802207|NCT00597194|Procedure|Hernia repair|Hernia repair laparoscopically (LH) or by open operation (OH)
1802208|NCT00597207|Device|AutoPulse|Mechanical device that provides chest compression
1802209|NCT00597207|Other|Manual|Manual chest compression
1802210|NCT00597220|Dietary Supplement|Omega 3 (n-3 PUFA)|1 gram of n-3 PUFA containing DHA and EPA
1802211|NCT00597220|Drug|Placebo|Placebo
1802212|NCT00597233|Drug|insulin aspart|
1802213|NCT00597233|Drug|soluble human insulin|
1802214|NCT00597233|Drug|insulin NPH|
1802215|NCT00597246|Drug|FACBC, Methionine|F-18 labeled FACBC is prepared stereo-specifically in a semi-automated, NCA procedure utilizing the General Electric FDG MicroLab, a system employing a quaternary 4-aminopyridinium resin to effect F-18 fluorination. The triflate species is displaced with F-18 fluoride in the MicroLab, and then the 1-t-butyl carbamate-3- trifluoromethane sulfonoxy-1-cyclobutane-1-carboxylic acid methyl ester is hydrolyzed with 1 N HCl. The final product is isotonic and sterile, and has been utilized in animal experiments. The product was obtained in 30% radiochemical yield after 65 minutes from EOB. The radiochemical purity was greater than 95% and no preparative HPLC was required. The procedure could be considered routine, and is performed on the FDG synthetic module without changes either to the programming or to the cassettes.
1802216|NCT00597246|Other|PET Scan|GE Advance PET scanner for sequential body imaging
1802217|NCT00597259|Drug|Pegasys plus Entecavir|Pegasys 180 mcg in 0.5 mL solution administered sc once weekly for 24 weeks plus entecavir (0.5mg mg/capsule) 0.5 mg administered po daily for 24 weeks
1802218|NCT00597259|Drug|Entecavir|ETV 0.5 mg daily monotherapy for 144 weeks
1802219|NCT00597272|Biological|KLH conjugates with GD2L and GD3L|6 vaccinations (on weeks 1, 2, 3, 8, 20 and 32) which will contain the same KLH conjugates with GD2L and GD3L. All vaccines contain KLH conjugates containing 30mcg of GD2L and 30mcg of GD3L and QS-DG or OPT-821. The initial 8 patients will receive the same QS-DG or OPT-821 vaccine dose in all of their vaccines. This dose will be 50 mcg for the first patient, 75 mcg for the second patient and 100 mcg for the third through eighth patients. In all subsequent patients the 1st, 4th and 5th vaccinations will include 150 mcg of OPT-821. The 2nd and 3rd vaccinations will contain 100 mcg of OPT-821 and the 6th vaccination will contain 200 mcg of OPT-821.
1802220|NCT00597298|Device|Threshold|Inspiratory muscle training program using a variable pressure device. An inspiratory muscle training device comprises a chamber having an opening for the passage of air to be inhaled and exhaled, and an inlet permitting air to be inhaled to enter the chamber and to pass to the opening. A one-way exhaust valve permits exhaled air entering through the opening to escape from the chamber, and another valve is provided to resist the entry of air to be inhaled into the chamber, the latter valve serving to vary the degree of resistance in dependence upon the volume of air that has passed through the inlet.
1802221|NCT00597298|Device|sham threshold|non-training physical activity
1802222|NCT00597311|Radiation|radiotherapy|"Short term radiotherapy 5x5 Gy during 5 days
Chemoradiotherapy 50 Gy + 5Fu/Lv"
1802223|NCT00597324|Procedure|coronary catheterisation|Coronary angiography which may be followed by ad hoc percutaneous intervention if indicated clinically
1802224|NCT00597337|Behavioral|FearNot|Behavioral: Three sessions of FearNot!v.2.0 software interaction over a three-week period (each session lasting approximately 30 minutes)
1802225|NCT00597350|Dietary Supplement|Trigonella foenum-graecum (fenugreek)|2 slices of bread containing 5 grams of the natural herb fenugreek 2 times, 1 week apart
1802226|NCT00597363|Device|Neptune P.A.D. (R)|The Neptune Pad ® (Biotronik GmbH & Co. KG, Berlin, Germany) is a soft and hydrophilic wound dressing, which has been developed to accelerate local hemostasis, reduce compression times, enable early ambulation and minimize the risk for bleeding complications. Neptune Pad ® consists of calcium alginate, which is cationically charged and exerts potent procoagulant properties.
1802227|NCT00597363|Other|conventional manual compression|The most common technique for puncture site management is manual compression. This technique requires an extended pressure on the puncture site, and after achievement of hemostasis a pressure bandage is applied for several hours at bed rest.
1802228|NCT00597376|Other|Cerefolin NAC (a medical food)|Cerefolin NAC one tablet each day
1802229|NCT00597376|Other|Cerefolin NAC placebo|Placebo tablet once a day
1802230|NCT00597389|Drug|Inderol (propranolol)|Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
1802231|NCT00597402|Drug|Avastin|Avastin will be administered 10 mg/kg every other week beginning a minimum of 28 days after last major surgical procedure, open biopsy, or significant traumatic injury. Following completion of XRT, patients will receive treatment that includes 6 cycles of Avastin, beginning a minimum of 14 days after last XRT.
1802232|NCT00597402|Drug|Temozolomide|Daily temozolomide 75 mg/m2/day for 6.5 weeks of radiation treatment. Following completion of XRT, patients will receive treatment including temozolomide 200 mg/m2/day on the 1st 5 days of each 28-day cycle.
1802233|NCT00597402|Radiation|Radiation Therapy (XRT)|Treatment with standard XRT (radiation) for 6.5 weeks.
1802234|NCT00597402|Drug|Irinotecan|Following completion of XRT, patients will receive 6 cycles of treatment that includes irinotecan. Beginning a minimum of 14 days after last XRT, the irinotecan dose will depend on whether the patient is on enzyme-inducing antiepileptic drugs (EIAED). (EIAED:340 mg/m2 every other week, non-EIAED: 125 mg/m2.)
1802237|NCT00597428|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
1802238|NCT00597428|Drug|Placebo|0 mcg capsules twice daily (BID)
1802281|NCT00603616|Drug|Rifaximin|Oral rifaximin 550mg to be taken twice daily for a total of 8 weeks
1802282|NCT00603642|Drug|Placebo|Subcutaneously administered, once a week, for 12 weeks
1802239|NCT00597441|Biological|Thymic Transplantation for Recipients of UCB transplant|Subjects with hematologic malignancies or bone marrow failure disorders will undergo umbilical cord blood transplantation and two months post transplant will have thymic tissue from a third party donor transplanted into the thigh muscle.
1802240|NCT00597454|Other|Patient Navigation|"we will conduct a detailed analysis of how the patient navigators' time is actually utilized by having them record a detailed log categorizing their activities as it relates to the elimination of recognized barriers to care. Second, we will measure the time interval from receipt of a suspicious mammogram to appropriate diagnostic evaluation and or treatment.
We will measure the number of women who experience diagnostic and or treatment delay and whether the presence of a Patient Navigator enables delivery of coordinated care that avoids delays. Third, we will measure patients' satisfaction with aspects of their care, focusing particularly on care coordination using validated instruments designed for this purpose."
1802241|NCT00597467|Device|VISA (comfilcon A) Silicone Hydrogel Soft contact lens|Test device
1802242|NCT00597467|Device|Acuvue 2 Soft Contact Lens|Control device
1802243|NCT00597480|Drug|rhGH (Norditropine SimpleXx®)|the recommended dose in the EU of rhGH (Norditropine SimpleXx®
1802244|NCT00597480|Drug|rhGH norditropine simple Xx|"the dose to achieve a treat-to target value of IGF-1 levels within a +1.5 to +2.5 SDS interval (starting dose, 0.067 mg/kg/day)"
1802245|NCT00597493|Drug|Sorafenib and Temozolomide|Temozolomide (50 mg per meter-squared of body surface area)every day by mouth in combination with sorafenib. Sorafenib will be taken by mouth twice every day. The dose of sorafenib will be 400 mg (2 x 200mg tablets).
1802246|NCT00597506|Drug|Bevacizumab|10 mg/kg intravenous bevacizumab given days 1 and 15 of each cycle
1802247|NCT00597506|Drug|Everolimus|10 mg Everolimus(RAD001) daily by mouth, days 1-28
1802248|NCT00603395|Device|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
1802249|NCT00603408|Drug|Cisplatin|
1802250|NCT00603408|Radiation|Radiation Therapy|
1802251|NCT00603408|Procedure|Mastectomy|(RECOMMENDED BUT NOT REQUIRED)
1802252|NCT00603421|Other|24 hour phone line|24 hour phone line is available as soon as the patient himself feels necessary. This phone line is supported by professionals of mental health, all specialised in borderline personality disorder
1802253|NCT00603421|Other|treatment as usual|Treatment as usual
1802254|NCT00603434|Drug|OROS-MPH|18 mg bid on days 1 and 2
1802255|NCT00603434|Drug|OROS-MPH|27mg bid on days 3 and 4
1802256|NCT00603434|Drug|OROS-MPH|35 mg bid on days 5-9
1802257|NCT00603447|Drug|Carfilzomib|Carfilzomib for Injection was administered intravenously over 10 minutes on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for the first 12 cycles. Each dose of Carfilzomib for Injection was normalized to body surface area.
1802258|NCT00603447|Drug|Lenalidomide|Lenalidomide was administered orally on Days 1 to 21 of each 28-day cycle.
1802259|NCT00603447|Drug|Dexamethasone|Dexamethasone 40 mg orally or intravenous equivalent was administered 30 minutes to 4 hours before carfilzomib on Days 1, 8, and 15, as well as on Day 22 of each 28-day cycle.
1802260|NCT00603460|Biological|DCVax-L and T Cells|"Arm A
Optional DCVax-L prior to chemotherapy
Apheresis
Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)
Infusion of activated T cells
DCVax-L vaccine
End of study visit
Arm B
Optional DCVax-L prior to chemotherapy
Apheresis
Chemotherapy for 3 days (IV fludarabine/cyclosphosphamide)
Infusion of activated T cells
DCVax-L vaccine
Oral cyclophosphamide (one week on/one week off) for a total for a total of 6 weeks
End of study visit"
1802261|NCT00603473|Drug|gabapentin|Orally administered gabapentin
1802262|NCT00603486|Device|GE DINAMAP with SuperSTAT algorithm monitor|Apply cuff on a limb, cuff is inflated and deflated, monitor will displays non-invasive blood pressure values (systolic, diastolic, MAP, and pulse rate)
1802263|NCT00603499|Dietary Supplement|Magnesium chloride|Subjects in the intervention group received 2.5 gr of MgCl2 daily during 4 months, from a solution solution containing 50 gr of MgCl2 by 1000 ml.
1802264|NCT00603499|Other|Placebo|Subjects in the control group received inert placebo once per day during 4 months
1802265|NCT00603512|Drug|Placebo|0 mg BID, 3 blinded tablets administered BID for 12 weeks
1802266|NCT00603512|Drug|CP-690,550|10 mg BID, 3 blinded tablets administered BID for 12 weeks
1802267|NCT00603512|Drug|CP-690,550|1 mg BID, 3 blinded tablets administered BID for 12 weeks
1802268|NCT00603512|Drug|CP-690,550|3 mg BID, 3 blinded tablets administered BID for 12 weeks
1802269|NCT00603512|Drug|CP-690,550|5 mg BID, 3 blinded tablets administered BID for 12 weeks
1802270|NCT00603525|Drug|Ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each treatment cycle consisting of two IV infusion taken 14 days apart. A total of 8 infusion cycles given over a 144 week period
1802271|NCT00603525|Drug|Placebo|1000 mL sterile, pyrogen free 0.9% NaCl. A treatment cycle consisting of two IV infusion taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
1802272|NCT00603538|Drug|CP-751,871 + carboplatin + paclitaxel|Chemotherapy (carboplatin and paclitaxel) and CP-751,871 (6, 10 or 20mg/kg) will be administered by intravenous infusion every three weeks.
1802273|NCT00603564|Procedure|Castar Starmed (CPAP) delivered by a helmet|Continuous Positive Airway Pressure delivered by a helmet with PEEP valve of 10 cmH2O and FiO2 0.5
1802274|NCT00603577|Drug|Placebo|Xaliproden matching placebo. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
1802275|NCT00603577|Drug|Xaliproden|1.0 mg capsule. 1 capsule per day for 6 months or until resolution of PSN (whichever comes first).
1802276|NCT00603590|Drug|Polypill|Fixed dose combination therapy - aspirin 81mg, hydrochlorothiazide 12.5mg, enalapril 2.5mg and atorvastatin 20mg Once daily
1802277|NCT00603590|Drug|Placebo drug|Inactive tablet Once a day Identical in appearance to intervention drug
1802278|NCT00603603|Other|80% inhaled oxygen via non-rebreather mask|Patients randomized to treatment group will receive 80% inhaled oxygen via a non-rebreather face mask during their cesarean section and for 2 hours afterwards.
1802279|NCT00603603|Other|30% inhaled oxygen via nasal cannula|Patients randomized to treatment group will receive 30% inhaled oxygen via a nasal cannula (standard of care)during their cesarean section.
1802280|NCT00603616|Drug|Placebo Comparator|Matching oral placebo pills to be taken twice daily for a total of 8 weeks
1802283|NCT00603642|Drug|AMG 531|Subcutaneously administered, once a week, for 12 weeks
1802284|NCT00603655|Other|Low glycemic load diet|Low glycemic load diet
1802285|NCT00603655|Other|High glycemic load diet|High glycemic load diet
1802286|NCT00603668|Biological|milatuzumab|two or three times a week dosing of hLL1 for a total of 4 weeks
1802287|NCT00603681|Drug|Polyethylene glycol 4000|powder for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
1802288|NCT00603681|Drug|Polyethylene glycol 4000 with electrolytes|granules for oral solution 12 g of PEG once a day, twice a day or once every other day for 4 weeks
1802289|NCT00603720|Drug|L-NAME|nitric oxide synthase inhibitor 4mg/kg infusion over 30-60 minutes prior to PET imaging
1802290|NCT00603720|Drug|L-Arginine|aids in nitric oxide production
1802291|NCT00603720|Drug|Phenylephrine|alpha agonist; 10 μg/kg/min infusion during PET study
1802292|NCT00603993|Biological|Adalimumab|40 mg or 80 mg every other week (eow), subcutaneous (sc), self-injection
1802293|NCT00604006|Drug|Spironolactone|25 mg tablets (placed in capsules for blinding) once daily.
1802294|NCT00604006|Drug|Placebo|Placebo (lactose in capsules for blinding) once daily
1802295|NCT00604019|Drug|Dopamine|Dopamine 5-20 mcg/kg/min to pre-determined max of 20
1802296|NCT00604019|Drug|Norepinephrine|Norepinephrine 5-20 mcg/min, to a pre-determined max of 20
1802297|NCT00604032|Drug|Atralin (tretinoin) Gel, 0.05%|Assess potential of tretinoin gel, 0.05% to produce phototoxic reactions, measured 24 and 48 hours after UV radiation of drug on the skin.
1802298|NCT00604045|Behavioral|Attention Bias Modification (ABM)|The ABM comprised a probe detection paradigm described above, modified to facilitate the allocation of attention away from threatening material. In this task, the probe always replaced the neutral word. Stimuli comprised a different set of 12 threat-neutral word pairs different than those used in the attention bias assessment. Participants completed 288 training trials: 2 (probe type) x 2 (probe location) x 2 (threat location) x 12 (threat-neutral word pairs) x 3 (repetition). Thus, although there were no explicit instructions to direct attention away from threat words, on all trials, the position of the neutral word indicated the position of the probe.
1802299|NCT00604045|Behavioral|Attention Control Condition (ACC)|The ACC condition was identical to the ABM procedure with the exception that the probe appeared with equal frequency in the position of the threat and neutral words, such that attention was neither trained towards nor away from threat.
1802300|NCT00604058|Biological|Inactivated Poliomyelitis vaccine (IMOVAX)|Fractional dose (1/5th) 0.1 mL, intradermally
1802301|NCT00604058|Biological|Inactivated Poliomyelitis vaccine (IMOVAX)|A full dose, 0.5 mL, intramuscular
1802302|NCT00604084|Drug|Ivermectin|Ivermectin 200ug/kg, 1 dose Q 6 months x 2, total duration = 12 months
1802303|NCT00604084|Drug|Permethrin 5% lotion|apply lotion to entire body, excluding head, at bedtime, rinse off following morning, wait one week, repeat application for a total of 2 applications, PRN frequency, NMT 6 applications in 12 months, total duration = 12 months.
1802304|NCT00604097|Behavioral|Attachment-Based Family Therapy|12-16 week family-based therapy
1802305|NCT00604097|Behavioral|Enhanced Usual Care|Rapid referral to community outpatient care with weekly monitoring of symptoms by study team
1802306|NCT00604110|Other|Biventricular pacing post cardiac surgery|Determine which biventricular pacing after cardiac surgery, in patients with reduced left ventricular function (EF<45%), is hemodynamically favourable.
1802307|NCT00604123|Drug|JNJ-17166864|JNJ-17166864 0.5 mg per nostril twice daily for 2 weeks.
1802308|NCT00604123|Drug|Placebo|Placebo nasal spray twice daily for 2 weeks.
1802309|NCT00604136|Biological|tumor infiltrating lymphocytes|Patients will have a melanoma metastasis resected and cultured in IL-2 in vitro. Tumor infiltrating lymphocytes from these cultures will be assessed for tumor reactivity and those with such activity will be further expanded and adoptively transferred. Patients will receive a non-myeloablative lymphocyte-depleting preparative regimen consisting of cyclophosphamide (60 mg/kg/day x2 days IV)and fludarabine (25 mg/mE2/day IV x5days). Following this regimen, patients will receive an intravenous adoptive transfer of at least 10E9 tumor-reactive lymphocytes followed by high dose IL-2 (720,000 IU/kg/dose IV every 8 hours for up to 15 doses).
1802310|NCT00604162|Device|PillCam COLON|The PillCam COLON capsule is an ingestible capsule equipped with an endoscope that has two imagers, enabling it to acquire video images from both ends. the device measures 31 by 11 mm and acquires images at a rate of 4 frames per second. Recording and downloading of data are similar those of the data for small-bowel capsule endoscopy.
1802311|NCT00604162|Procedure|Standard colonoscopy|Standard colonoscopy was the standard against which capsule endoscopy was compared,and it was performed after capsule endoscopy (after capsule excretion or at least 10 hours after capsule ingestion, whichever came first), on either the same day as ingestion or the next morning.
1957580|NCT02305732|Biological|INTERCEPT Platelets|INTERCEPT platelet components (PC). Leukocyte reduced apheresis platelet components collected in Platelet Additive Solution (PAS) or 100% plasma without gamma irradiation, bacterial detection, and Cytomegalovirus (CMV) serology testing.
1802313|NCT00604188|Drug|Suboxone (SCH 000484)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride and Naloxone. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
1802314|NCT00604188|Drug|Subutex (SCH 028444)|2 mg and 8 mg sublingual tablets, Contains Buprenorphine Hydrochloride. Daily dosage of 8 mg - 24 mg. Duration: 28 Days
1802318|NCT00604214|Drug|Drotrecogin alfa (activated)|24 microgram/kilogram/hour, intravenous, 96 hours (hr)
1802319|NCT00604214|Drug|Placebo|0.9% sodium chloride, intravenous, 96 hours
1802320|NCT00604227|Other|Hypoxic Exposure|ascent to 4559 m within 24 h without prior acclimatization
1802321|NCT00604253|Drug|insulin detemir|
1802322|NCT00604253|Drug|insulin NPH|
1802323|NCT00604279|Drug|Paliperidone palmitate (R092670)|Paliperidone palmitate suspension for intramuscular injection at a dose of 150 milligram equivalent (mg eq.) at baseline, 100 mg eq. on Day 8, flexible dose, either 50 or 100 mg eq on Day 36 and 50, 100, or 150 mg eq.on Day 64 depending on investigator's discretion.
1802454|NCT00605332|Device|inferior vena cava filter|Crux Biomedical IVC Filter
1802324|NCT00604279|Drug|Risperidone|Risperidone LAI intramuscular at a dose of 25 mg on Day 8 and Day 22; flexible dose of either 25 or 37.5 mg on Day 36 with same dose on Day 50; and either 25, 37.5, or 50 mg on Day 64 with same dose on Day 78; along with oral risperidone 2 mg tablet on Day 1, flexible doses (1-6 mg/day) for first 28 days; and 1-2 mg/day during Day 36-57 and Day 64-85 if the dose of risperidone LAI was increased on Day 36 and Day 64.
1802325|NCT00604305|Device|Acrysof|Monofocal IOL
1802326|NCT00604305|Device|Acuity's AIOL|Accommodating IOL
1802327|NCT00604318|Drug|rhTSH|The patients will be randomised to either T3 (Liothyronine) pause related to the first radioiodine treatment and Thyrogen injection with continuing Liothyronine treatment related to the second treatment/uptake - or Thyrogen related to the first treatment and T3 pause related to the second treatment /uptake.
1802328|NCT00604331|Drug|Pyruvate|sodium pyruvate 300 mmol/L, 360 mL/h i.c. over 30 minutes.
1802329|NCT00604344|Drug|insulin detemir|
1802330|NCT00604344|Drug|insulin NPH|
1802331|NCT00604357|Drug|anti-CD 25 mAb, Sirolimus, MMF|"Prior to reperfusion: 500 mg Prednisolone After OLT: anti-CD25-mAB (basiliximab 20 mg on day 0 and day 4 after the procedure)
MMF 2 g/d, 2 applications per day i.v., later conversion to oral intake)
Earliest, on day 10 after LT Sirolimus: 5 mg/d, thereafter a dosage of 2 mg/d (4 and 8 ng/mL)
Steroids: 1mg/kg BW (tapered every 2 days for 5 mg to a dosage of 20 mg, 2.5 mg every two days to 7.5 mg, reduced to 5 mg and 2.5 mg for 1 week each and eliminated thereafter)."
1802332|NCT00604383|Drug|ruboxistaurin|32-mg tablet, orally, daily, up to 42 months
1802333|NCT00604383|Drug|placebo|1 tablet, orally, daily, up to 42 months
1802334|NCT00604396|Drug|insulin detemir|
1802335|NCT00604396|Drug|insulin NPH|
1802336|NCT00604409|Radiation|SIRT|Undergo SIRT
1802337|NCT00604409|Drug|capecitabine|Given PO
1802338|NCT00604435|Drug|docetaxel and epirubicin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, totally 3 cycles
1802339|NCT00604435|Drug|docetaxel and epirubicin plus endostatin|docetaxel 75mg/m2, IV (in the vein) on day 1 of each 21 day cycle; epirubicin 60 mg/m2, IV (in the vein) on day 1 of each 21 day cycle; endostatin 7.5mg/m2, IV (in the vein) on 1st to 14th days of each 21 day cycle; every 3 weeks, totally 3 cycles
1802340|NCT00604448|Other|Dietary advise|Subjects in energy-restricted group will follow dietician advise to keep a conventional energy restriction diet.
1802341|NCT00604448|Other|Diet enriched with a meal containing pulses|Subjects in pulse group will consume the commercially available pulses for 8 weeks
1802342|NCT00604461|Drug|Carboplatin, Bevacizumab and Pemetrexed|Chemotherapy was given for 2 cycles after maximal response. Patients were taken off study at the time of progression. If the patient had stable disease or better, as a response, then the patient was maintained on pemetrexed plus bevacizumab for a total of one year after initiation of maintenance or until progression which ever occured first. Computed tomography (CT) scans were be done every 12 weeks during the maintenance phase.
1802343|NCT00604474|Device|HiResolution Bionic Ear System (Cochlear Implant)|Subjects are required to have bilateral implantation of the Advanced Bionics HiResolution Bionic Ear System (Cochlear Implant)
1802344|NCT00604487|Device|ARD (Atad Ripener Device)|Atad double balloon ripener device
1802345|NCT00604487|Device|AID (Atad double balloon Instillation Device)|Double balloon instillation device and continuous extra-amniotic instillation of NS 50 Ml/hour
1802346|NCT00604487|Device|folly catheter|folly catheter (40 ml NS in the balloon) and continuous extra-amniotic instillation of NS 50 Ml/hour
1802347|NCT00604500|Drug|SCH No. 418131 (Mometasone Furoate/Formoterol Furoate abbreviated MF/F )|MF/F MDI 100/10 mcg BID with an integrated dose counter (administered as two inhalations of MF/F MDI 50/5 mcg, twice a day) over a 4-week Treatment Period.
1802348|NCT00604513|Other|Ready. Set. ACTION! Protocol|"The intervention included three components: theater sessions; booster sessions; and family outreach. After-school theater sessions were conducted in the fall in the intervention schools. Sessions included: a check-in about changes made over the past week; healthy snacks; a movement component that involved fun and easy activities; and creating/education. Children at intervention schools participated in weekly after-school booster sessions in the winter to further address the behavioral messages addressed during the intervention. Throughout the program, weekly Fun & Fitness packs were sent home to families that included a healthy food with a simple recipe using that food or fitness incentives for the family. There were also two family events: a theater performance, and a reception."
1802349|NCT00604513|Other|Control|The control condition also participated in a theater-based intervention that addressed a health topic unrelated to weight, hand-washing and overall personal hygiene.
1802350|NCT00604526|Radiation|High dose rate (HDR) brachytherapy using Iridium 192 radioactive seeds|"Pre-tx Sexual function questionnaire Quality of Life baseline, Treatment with HDR (Two days) Treatment: Iridium 192 radioactive seeds temporarily inserted into patient. Post treatment (after HDR) Month 1 (+/- 2 weeks), 3 (+/- 1 month), 6 (+/- 1 month), 9 (+/-1 month), 12 (+/- 1 month)* NCI CTC GU and GI assessment,IPSS, IIEF, PSA lab test, Prostate HRQOL
*After 1 year, will follow up with doctor about every 6 months."
1802351|NCT00604539|Drug|Chondroitin sulphate (Condrosan)|800 mg (two capsules of 400 mg each) taken once a day for one year
1802352|NCT00604539|Drug|Placebo|Two placebo capsules taken once a day for six months followed by an additional six month treatment of 800 mg (two capsules of 400 mg of Chondroitin sulphate each) taken once a day
1802353|NCT00604552|Device|AneuRx Stent Graft|Abdominal Aortic Aneurysm Repair
1802354|NCT00604565|Drug|soluble ferric pyrophosphate (SFP)|"Subjects will be randomized to undergo dialysis with either Fe-HD (dialysate containing SFP) The experimental concentrate containing SFP (Fe-HD)has 95mg of SFP per gallon, or 10.9 mg total iron per gallon (96 µg of SFP per dL or 11 µg of total iron per dL).
Control concentrate lacking SFP (C-HD) does not contain SFP (total iron = 0)"
1802355|NCT00604565|Other|placebo|Subjects will be randomized to undergo dialysis with C-HD (conventional dialysate lacking SFP)
1802356|NCT00604578|Drug|Pioglitazone Hydrochloride|
1802357|NCT00604591|Drug|Tolcapone|200 mg by mouth three times a day
1802358|NCT00604591|Drug|Placebo|200 mg by mouth three times a day
1802455|NCT00605345|Drug|Darbepoetin alfa|As prescribed
1802456|NCT00605345|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms sc 4-weekly (starting dose)
1802359|NCT00604604|Behavioral|Peer support|Mothers allocated to the peer support group had access to all of the standard community postpartum services in addition to having received telephone-based support from a peer volunteer (a mother who has previously experienced, and recovered from, postpartum depression and has participated in a 4-hour training session). Telephone contact with a new mother was initiated within 48 to 72 hours of trial enrolment and then as frequently as the dyad deemed necessary; a minimum of four contacts were required.
1802360|NCT00604617|Procedure|Interferon-Gamma Release Assay|IGRAs
1802361|NCT00604617|Drug|RT-23|TST - tuberculin skin test
1802362|NCT00604630|Drug|recombinant human erythropoietin alfa|40,000 IU in 50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
1802363|NCT00604630|Drug|0.9% NaCl|50ml 0.9% NaCl iv on 3 consecutive days, starting within 6 hours after onset of symptoms
1802364|NCT00604643|Device|TALENT Aortic Cuff Abdominal Stent Graft|Endovascular Aneurysm Repair
1802365|NCT00604656|Drug|insulin aspart|
1802366|NCT00604682|Drug|CC10004|2 X 10 mg caps taken once daily for a daily dose of 20 mg. Must be taken upon awakening and fasted
1802367|NCT00604695|Drug|Tenecteplase|Intracoronary injection of IV tenecteplase.
1802368|NCT00604695|Drug|Sterile Saline|Intracoronary injection of IV sterile saline
1802369|NCT00604708|Biological|IC51|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
1802370|NCT00604708|Biological|JE-VAX|JE-VAX, 1mL s.c. injection, 3 vaccinations, days 0, 7 and 28
1802371|NCT00604721|Drug|selumetinib|Given orally
1802372|NCT00604721|Other|pharmacological study|
1802373|NCT00604734|Device|ReCap Total Hip Resurfacing System|This is a hip resurfacing system.
1802374|NCT00604747|Other|Structure practice|there were 2 groups which received random practice and constant practice during acquisition phase
1802375|NCT00604760|Drug|MEM 3454|Capsule 5 mg once a day
1802376|NCT00604760|Drug|MEM 3454|Capsule 15 mg once a day
1802377|NCT00604760|Drug|MEM 3454|Capsule 50 mg once a day
1802378|NCT00604760|Drug|Placebo for MEM 3454|Capsule once a day
1802379|NCT00604786|Drug|omalizumab|Dosing is based on IgE level and weight given every 2 or 4 weeks
1802380|NCT00604786|Drug|placebo|Dosing is based on IgE level and weight given every 2 or 4 weeks
1802381|NCT00604799|Device|Talent Thoracic Stent Graft|TEVAR
1802382|NCT00604812|Drug|rizatriptan benzoate (5 mg)|A single dose of rizatriptan 5 mg administered on Day 1.
1802383|NCT00604812|Drug|rizatriptan benzoate (10 mg)|A single dose of rizatriptan 10 mg administered on Day 1.
1802384|NCT00604812|Drug|Rizatriptan 5 mg Placebo|A single dose of rizatriptan 5 mg placebo administered on Day 1.
1802385|NCT00604812|Drug|Rizatriptan 10 mg Placebo|A single dose of rizatriptan 10 mg placebo administered on Day 1.
1802386|NCT00604825|Drug|Other: Placebo|
1802387|NCT00604825|Drug|GSK232802|
1802388|NCT00604825|Drug|PREMARIN|
1802389|NCT00604838|Device|AL-SENSE Diagnostic Absorbent Panty liner|worn for 12 hours
1802390|NCT00604838|Device|AL-SENSE Diagnostic Absorbent Panty liner|Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours
1802391|NCT00604851|Drug|lansoprazole|participants < 30 kg: 15 mg by mouth once daily; participants >= 30 kg: 30 mg by mouth once daily
1802392|NCT00604851|Drug|placebo|placebo medication taken by mouth once daily
1802393|NCT00604864|Drug|anti TNFa monoclonal antibody - Infliximab|Chimeric A2 (infliximab, RemicadeTM) IgG ; 100 mg infliximab IgG, Infliximab was freshly prepared immediately before each administration. Infliximab or placebo was administered as a slow infusion of 250mL on weeks 0, 2 and 6. Women were closely observed during, and for 1 hour after, the infusion in the event of any serious adverse reactions.
1802394|NCT00604864|Drug|placebo|Placebo
1802395|NCT00604877|Behavioral|Treadmill Exercise|3 times per week for 6 months, with target of 45 minutes at 60-70% heart rate range
1802396|NCT00604877|Behavioral|Stretching/ROM|3 times per week for 6 months, passive and active stretching and range of motion (ROM) exercises for the upper and lower extremities
1802397|NCT00604890|Drug|API 31510 Topical Cream|Topical treatment to lesion twice daily of randomized treatments that include 1.5% active cream, 3% active cream or placebo cream
1802398|NCT00604903|Device|Implant of Pressure sensor.|Implant of an Remon ImPressure implantable pulmonary artery pressure sensor utilizing the corresponding delivering system.
1802399|NCT00604916|Other|standardized oral care protocol - electronic toothbrush|a standardized 20-minute oral care protocol using an electronic toothbrush to clean and moisturize oral cavity twice daily.
1802400|NCT00604916|Other|mimic protocol|a mimic 20-minute protocol involving moisturizing and attention control was performed for the same intervals.
1802401|NCT00604929|Dietary Supplement|carbohydrate and protein|The intake of carbohydrate and protein during endurance type exercise
1802402|NCT00604942|Procedure|Heller's Myotomy|Long vs Short Heller's Myotomy for Achalasia
1802403|NCT00604942|Procedure|Nissen Fundoplication|Partial vs Full Fundoplication for GORD
1802404|NCT00604942|Drug|domperidone or esomeprazole (Conservative management)|Conservative management for dysphagia not referred for surgery. Conservative management: balloon dilatation or drugs such as domperidone 10 mg or esomeprazole 40 mg
1802405|NCT00604942|Drug|Esomeprazole 40 mg|Esomeprazole vs no esomeprazole for GORD not referred for surgery
1802406|NCT00604955|Drug|Paromomycin sulfate|Paromomycin will be administered intramuscularly at 11 mg/kg, once a day, for 21 consecutive days
1802407|NCT00604968|Drug|Caelyx (pegylated liposomal doxorubicin; SCH 200746)|Caelyx will be administered intravenously at a dose of 40 mg/m^2 on day one every 4 weeks until progression, or unacceptable toxicity, or other reason to discontinue the study treatment. The drug is diluted in 250 ml glucose 5% (500 ml for doses >=90 mg).
1802457|NCT00605358|Behavioral|Open Door intervention|"Open Door intervention subjects will:
receive an evaluation
receive a referral to a local mental health provider
identify barriers, set goals and problem-solve to achieve a mental health evaluation using available resources."
1802458|NCT00605371|Drug|Lamotrigine tablet|Lamotrigine extended release single dose tablet will be available with dosing strengths of 200 milligrams and 50 milligrams intended to be administered orally in fasted state. It will be a round standard convex shape tablet.
1802408|NCT00604981|Behavioral|Multisystemic Therapy (MST)|MST is an intensive, family centered, community based treatment originally designed for use with adolescents presenting with serious mental health problems. In this study, MST interventions are aimed at increasing adolescent and family adherence to dietary and exercise recommendations and targeting barriers within the family system, and the broader community systems within which the family is embedded (peers, schools, health care). Decreasing caloric consumption consistent with recommended intake targets, increasing daily exercise and decreasing sedentary activity, are treatment focuses depending on whether the adolescent has difficulty with this aspect of weight management or not.
1802409|NCT00604981|Behavioral|Shapedown|Shapedown, is a clinic-based, adolescent weight loss intervention. Shapedown utilizes psycho educational, behavior, and family therapy techniques in a 10-week group intervention. In order to match MST's length of intervention (6 months), three follow-up sessions are added at monthly intervals.
1802410|NCT00605020|Drug|insulin detemir|
1802411|NCT00605020|Drug|insulin aspart|
1802412|NCT00605020|Device|biphasic insulin aspart|
1802413|NCT00605033|Drug|Suboxone, Buprenorphine Hydrochloride + Naloxone, SCH 484|Suboxone sublingual tablet 4 mg/1 mg - 24 mg/6 mg, daily for 28 days
1802414|NCT00605033|Drug|Subutex, Buprenorphine Hydrochloride, SCH 28444|Subutex sublingual tablet 4-24 mg, daily for 28 days
1802415|NCT00605046|Drug|SPECT scan|AV151-01: Evaluation of [123I] AV151 and SPECT as a marker of beta-amyloid protein deposition in subjects with Alzheimer disease in comparison to healthy subjects
1802416|NCT00605059|Drug|[123I]AV94|Evaluation of [123I] AV94 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects
1802417|NCT00605072|Drug|candesartan|orally 8 mg increased to 16 mg then 32 mg to achieve target blood pressure of 140/90, then daily for 12 months
1802418|NCT00605072|Drug|lisinopril|orally 10 mg increased to 20 mg then 40 mg to achieve target blood pressure of 140/90, then daily for 12 months
1802419|NCT00605072|Drug|hydrochlorothiazide|orally 12.5 mg increased to 25 mg to achieve target blood pressure of 140/90, then daily for 12 months
1802420|NCT00605072|Drug|nifedipine, long acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 30 mg increased to 60 mg and 90 mg in 2 week increments
1802421|NCT00605072|Drug|metoprolol, long-acting|If needed to achieve target blood pressure of 140/90, added to ARB or ACEI at 12.5 mg increased to 25 mg and 50 mg
1802422|NCT00605085|Biological|Japanese Encephalitis purified inactivated vaccine (IC51)|IC51 (JE-PIV), 6 mcg, i.m. injection, 2 vaccinations, days 0 and 28
1802423|NCT00605085|Biological|Placebo|Placebo: Phosphate-buffered saline (PBS) solution containing 0.1% aluminum hydroxide as an adjuvant, 0.5 mL, i.m. injection, 2 injections, days 0 and 28
1802424|NCT00605098|Drug|Lopinavir / ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation and maintained for at least 6 weeks after delivery.
1802425|NCT00605098|Drug|Lopinavir/ritonavir|Lopinavir/r (200/50 mg, 2 tablets every 12 hours) plus two nucleoside analogs, starting at any time between 14 and 30 weeks of gestation, increase the lopinavir/r dosage (200/50 mg, 3 tablets every 12 hours) in the third trimester (from 25 weeks on), and return to standard dose(200/50 mg, 2 tablets every 12 hours)for at least 6 weeks after delivery.
1802426|NCT00605111|Drug|biphasic insulin aspart|
1802427|NCT00605124|Other|Knee muscle exercises|Home exercises three times a week, control every three months
1802428|NCT00605137|Drug|insulin detemir|
1802429|NCT00605137|Drug|insulin NPH|
1802430|NCT00605150|Radiation|TheraSphere-Yttrium 90 microsphere|TheraSphere is delivered to the liver via a catheter placed into the femoral artery and guided by fluoroscopy to the hepatic artery. Once the catheter is properly positioned, the physician infuses TheraSphere, which localizes preferentially in the tumor.
1802431|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
1802432|NCT00605176|Drug|imiquimod cream|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
1802433|NCT00605176|Drug|Placebo|cream, 250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 2 weeks of daily treatment followed by 2 weeks of no treatment, and the second treatment cycle consisted of an additional 2 weeks of daily treatment followed by 8 weeks of no treatment.
1802434|NCT00605189|Device|Powered Suction Pump (VAC Freedom)|continuous suction
1802435|NCT00605189|Device|Powered Suction Pump|continuous suction
1802436|NCT00605202|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg a day for 14 days.
1802437|NCT00605202|Dietary Supplement|Licorice|Licorice candy 32 grams a day for 14 days.
1802438|NCT00605215|Drug|laquinimod|0.6 mg oral once daily for 24 months
1802439|NCT00605215|Drug|placebo|oral placebo once daily for 24 months
1802440|NCT00605215|Drug|Interferon β-1a (Avonex®)|Interferon β-1a (Avonex®) 30 mcg IM once weekly for 24 months
1802441|NCT00605228|Drug|MOVIPREP|2L Drug
1802442|NCT00605228|Drug|COLOPEG|4L Drug
1802443|NCT00605241|Drug|GSK598809|Drug
1802444|NCT00605267|Drug|Tamoxifen|20 mg once daily oral dose
1802445|NCT00605267|Drug|Anastrazole (Arimidex)|1 mg once daily oral dose
1802446|NCT00605267|Drug|Goserelin acetate (Zoladex)|3.6mg/month depot injection
1802447|NCT00605280|Drug|Standard of Care|Clinicians decision to use optional laser therapy.
1802448|NCT00605280|Drug|Macugen|Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
1802449|NCT00605293|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv/month (starting dose)
1802450|NCT00605293|Drug|Epoetin alfa|As prescribed
1802451|NCT00605306|Drug|indacaterol maleate / mometasone furoate|Indacaterol maleate / mometasone furoate 250/400 μg, 2 puffs once daily delivered via the Twisthaler device.
1802452|NCT00605306|Drug|placebo to indacaterol maleate/mometasone furoate|Placebo to indacaterol maleate/mometasone furoate delivered via the Twisthaler device.
1802459|NCT00605371|Drug|Lamotrigine caplet|Lamotrigine extended release single dose caplet will be available with dosing strength of 200 milligrams and 50 milligrams intended to be administered orally in fasted and fed state.
1802460|NCT00605384|Drug|Entecavir + Tenofovir|Tablets, Oral Entecavir 1 mg + Tenofovir 300 mg, once daily, 100 weeks
1802461|NCT00605384|Drug|Adefovir + continuing Lamivudine|Tablets, Oral, Adefovir 10 mg + Lamivudine, 100 mg, once daily, 100 weeks
1802462|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The first 8 patients enrolled will undergo two complete PET studies, up to 3-6 weeks apart, to assess for reproducibility of measures of tracer uptake into individual organs and known sites of metastatic disease.
1802463|NCT00605397|Radiation|PET Imaging With Cu-64 Labeled Trastuzumab|The remaining 20 patients will undergo one PET study.
1802464|NCT00605410|Drug|ipratropium bromide|2 puffs (40 micrograms) 2 puffs (0micrograms)
1802465|NCT00605410|Drug|placebo|Matched placebo
1802466|NCT00605423|Drug|Fluocinolone Acetonide/Medidur|0.2 ug/day implant
1802467|NCT00605423|Drug|Fluocinolone Acetonide/Medidur|0.5 ug/day implant
1802468|NCT00605436|Behavioral|Restorative yoga therapy|3-hour workshop at study initiation. Then twice-weekly group yoga classes for 5 weeks, then once-weekly group yoga classes for 5 weeks. Home yoga practice for 90 minutes/week throughout the 10 week trial.
1802469|NCT00605449|Drug|GSK376501|
1802470|NCT00605475|Drug|Canakinumab|Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
1802471|NCT00605475|Drug|Placebo|Placebo to Canakinumab given as single dose IV injection of 0.03 mg/kg, or single dose IV infusion at doses of 0.1 mg/kg 0.3 mg/kg, 1.5 mg/kg or 10 mg/kg.
1802472|NCT00605475|Drug|Metformin|Participants continued on their stable daily dose of metformin throughout the study
1802473|NCT00605488|Procedure|novel PET tracer FACBC|Two IV catheters (heplock) will be placed in your forearms for injection of the dye-like material (FACBC) and blood sampling. An IV blood sample and a urine sample will be taken for testing. These samples will be used to measure the dye, FACBC, in blood and urine. You will be placed in the PET machine, where FACBC will be injected slowly over 30 seconds. Pictures of one region of your body will be taken for up to 60 minutes. Depending on your condition, your actual picture time may be shorter. You will come out of the scanner to stretch, walk around or sit in a chair. An optional urine sample and an IV blood sample will also be taken at this time. Again, these samples will be used to measure the dye, FACBC, in blood and urine. This will be followed by a picture of your body from the neck to the upper thighs. This picture will take about 30 minutes.
1802474|NCT00605514|Drug|VRC-EBODNA023-00-VP|
1802475|NCT00605514|Drug|VRC-MARDNA025-00-VP|
1802476|NCT00605553|Drug|Placebo|"Placebo oral capsules
Placebo for 7 days"
1802477|NCT00605553|Drug|Tozadenant|20 mg oral capsules with a daily dosage of either 20 mg BID or 60 mg BID
1802479|NCT00605592|Procedure|Pancreatic Islets of Langerhans Cell Transplant|Transplantation of islet cells will be given to eligible patients, up to three times during the study, using cell quantities based on body weight.
1802480|NCT00605605|Drug|Dextromethorphan|120 mg/day, single once daily dose taken after breakfast by oral route
1802481|NCT00605618|Drug|BMS-777607|Suspension/Tablet, Oral, Dose escalation to an MTD from a starting dose of 10 mg, once daily, until disease progression/subject discontinuation
1802482|NCT00605631|Device|Cardiac pacing using any Guidant/Boston Scientific Implantable ICD or CRT-D System and any Guidant/Boston Scientific Intracardiac Lead System|No specific device model is required - any FDA-approved, market-released Guidant/Boston Scientific implantable ICD or CRT-D system and any FDA-approved, market-released Guidant/Boston Scientific intracardiac lead system may be implanted as part of MENDMI.
1802483|NCT00605644|Drug|MOA-728|Oral Capsules
1802484|NCT00605644|Drug|Placebo|Placebo
1802485|NCT00605657|Drug|Valproic Acid|Oral administration of valproic acid
1802486|NCT00605657|Procedure|CT Scan|CT scans were done before and after treating the patient with valproic acid
1802487|NCT00605657|Procedure|Blood Sample|Blood samples were collected before and after the intervention to monitor blood counts and biomarkers of ALPS
1802488|NCT00605670|Behavioral|questionnaires|patients will fill out two questionnaires post surgery
1802489|NCT00605670|Behavioral|questionnaires|Patient will fill out questionnaire before and 3 to 6 months after treatment.
1957581|NCT02306278|Drug|gabapentin|gabapentin capsules 0.3g
1957582|NCT02306278|Drug|vitamin capsules|vitamin B
1802493|NCT00605696|Drug|Insulin|Participants will receive intravenous insulin to target tight glycemic control (80 to 110 mg/dL) for up to 48 hours after ICU admission.
1802494|NCT00605709|Drug|API 31510 Topical Cream|Topical treatments to lesion twice daily of randomized treatments.
1802495|NCT00605722|Drug|bevacizumab (Avastin)|5 mg/kg iv on day 1 of each 2 week cycle.
1802496|NCT00605722|Drug|erlotinib (Tarceva)|150 mg orally (po) daily.
1802497|NCT00605735|Drug|BMS-582949|Tablets, Oral, 300 mg, once daily, 12 weeks
1802498|NCT00605735|Drug|Placebo|Tablets, Oral, placebo, once daily, 12 weeks
1802499|NCT00605748|Procedure|Segmental PV-Isolation of the arrhythmogenic vein(s)|isolation of pulmonary veins for curing atrial fibrillation
1802500|NCT00605748|Procedure|Segmental PV-Isolation of all veins|isolation of pulmonary veins for curing atrial fibrillation
1802502|NCT00605761|Drug|SB656933|150 mg treatment
1802503|NCT00605774|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infused over two hours during experimental period on Day 2
1802504|NCT00605774|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during hyperinsulinemic euglycemic clamp on day 2
1802505|NCT00605787|Drug|Tetradecylthioacetic acid (TTA)|1000mg capsules once daily for 28 days
1802506|NCT00605800|Other|blood drawn|Baseline levels of bone marrow derived liver stem cells from normal healthy volunteers, which will be drawn once Two 5ml blue tubes).
1802507|NCT00605800|Other|blood drawn|At the time of preoperative testing, patients will have two extra test tubes (5cc blue top) of blood drawn for determination of pre-operative base line levels of bone marrow derived liver stem cells in peripheral blood. Intraoperatively, blood will be drawn after liver resection (two tubes of 5cc blue top). Two extra tube of blood will be drawn at the same time of routine postoperative blood drawing to determine levels of bone marrow derived liver stem cells in peripheral blood on post-operative days #1, and #3.
1802508|NCT00605813|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.
Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.
Duration: According to the protocol of A0501091, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 52 weeks after the first administration."
1802509|NCT00605826|Device|NASHA/Dx Injectable Gel|Injection of 4 x 1ml of NASHA/Dx Gel
1802510|NCT00605826|Device|Sham Injection|Sham injection
1802514|NCT00605852|Drug|GSK835726|GSK835726 will be available in single dose and repeat dose formulations.
1802515|NCT00605852|Drug|Placebo|Placebo will be given to subjects.
1802516|NCT00605865|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.
Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.
Duration: According to the protocol of A0501090, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 16 weeks after the first administration."
1802517|NCT00605891|Drug|carmoterol (CHF 4226)|"carmoterol pMDI 2.0 μg once a day, in the morning
(1 puff of carmoterol 1.0 mcg + 1 puff of carmoterol 1.0 mcg)"
1802518|NCT00605891|Drug|carmoterol (CHF 4226)|"carmoterol pMDI 1.0 μg once a day, in the morning
(1 puff of carmoterol 1.0 mcg + 1 puff of placebo pMDI))"
1802519|NCT00605891|Drug|carmoterol (CHF 4226)|"carmoterol pMDI 4.0 μg once a day, in the morning
(1 puff of carmoterol 2.0 mcg + 1 puff of carmoterol 2.0 mcg)"
1802520|NCT00605891|Drug|salmeterol|Salmeterol 50 μg DPI, in the morning and in the evening (1 blister BID)
1802521|NCT00605891|Drug|placebo|Placebo pMDI once a day, in the morning (1 puff of placebo pMDI + 1 puff of placebo pMDI)
1802522|NCT00605904|Drug|Acamprosate|orally administered tablet, 333mg, three times daily for a minimum of 2 weeks (14 days)
1802523|NCT00605904|Drug|Yohimbine|Intravenous infusion of yohimbine (0.4 mg/kg) administered once over 10 minutes
1802524|NCT00605904|Drug|mCPP|Intravenous infusion of mCPP (0.05 mg/kg) over 10 minutes, two times, for a total of 0.1 mg/kg
1802525|NCT00605904|Drug|Saline|"Intravenous infusion of 0.9% sodium chloride solution over 10 minutes, three times during the study (2 times for the Saline Infusion milestone, and one time immediately following the Yohimbine Infusion milestone)"
1802526|NCT00605917|Drug|Sertraline hydrochloride|"J ZOLOFT® Tablets 25 mg and J ZOLOFT® Tablets 50 mg. J ZOLOFT is Brand name in Japan.
Dosage, Frequency: According to Japanese LPD, The usual initial dose of J ZOLOFT in adults is 25 mg daily as sertraline and then gradually increased up to 100 mg, which should be given orally once daily. The dose may be adjusted within the range not exceeding 100mg according to the patient's age and symptoms.
Duration: According to the protocol of A0501092, the duration of the investigation for findings regarding safety and efficacy of a panic disorder patient is from the first drug administration to the 16 weeks after the first administration."
1802527|NCT00605930|Dietary Supplement|Pyruvate, creatine, niacinamide|A bar of 2 gm of pyruvate and 1 gm of creatine, and a pill of 1 gm of niacinamide once a day for 24 weeks.
1802528|NCT00605930|Dietary Supplement|Placebo|25% of subjects will receive a placebo bar and a placebo pill once a day for 24 weeks.
1802529|NCT00605956|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse - 1% spinosad
1802530|NCT00605956|Drug|NatrOVA Creme Rinse Vehicle Only|NatrOVA Creme Rinse Vehicle - no spinosad
1802531|NCT00605956|Drug|Blank Patch|Blank Patch
1802532|NCT00605969|Procedure|Motion analysis|Motion analysis and CT
1802533|NCT00605969|Procedure|Motion analysis|Motion analysis and CT
1802534|NCT00605982|Procedure|MRI|The patient will then undergo a breast MRI as part of their preoperative work-up of DCIS. Biopsy of any suspicious areas by needle biopsy or at the time of surgery. If appropriate, repeat MRI after biopsy or surgery. Follow-up for 10 years (you will be contacted once a year to see how you are doing).
1802535|NCT00605995|Drug|Simvastatin|20 mg taken orally once daily for the first 4 weeks. Dosage will be increased to 40 mg/day at the end of week 4.
1802536|NCT00606008|Drug|Sunitinib Malate|Initially, patients were started on sunitinib at a dose of 50 mg daily. If 50 mg daily resulted in unacceptable toxicity, 2 dose modifications were allowed (to 37.5 and to 25 mg daily, if necessary). Study patients who could not tolerate 25 mg daily of sunitinib were taken off study.
1802537|NCT00606021|Drug|pemetrexed|500 mg/m², IV, Day 1 of each 21-day cycle for 6 cycles
1802538|NCT00606021|Drug|Best Supportive Care|Patients will receive best supportive care (dose, frequency, duration) as judged by their treating physician.
1802616|NCT00589277|Behavioral|"Yale coaching"|Novel messages for quitting smoking
1802617|NCT00589277|Behavioral|Standard care|Standard messages for quitting smoking
1802539|NCT00606034|Drug|U-500 Insulin delivered by Omnipod (disposable insulin pump)|U-500 insulin (concentrated insulin) will be infused continuously subcutaneously using a disposable insulin pump called an Omnipod; the insulin infusion dosage will be individualized to each subject's needs
1802540|NCT00606060|Drug|Kogenate (BAY14-2222)|100 IU/mL (250 IU/vial nominal potency) continuous infusion over 6-11 days in 12 patients. 400 IU/mL (1000 IU/vial nominal potency) continuous infusion over 6-11days in 3 patients.
1802541|NCT00606073|Other|Universal IVF Medium + ISM1 Medium|Sibling oocytes will be equally divided and incubated separately in different 4-well culture dishes containing either IVF medium or ISM1 Medium and while ICSI will be returned to the same culture dish following injection. Fertilization assessment will be performed approximately after 15-20 hours for standard IVF and 12-18 hours post ICSI performance. After assessment, fertilized oocytes from different culture media will be transferred separately into fresh culture dishes containing ISM1 medium only. The zygotes will be incubated until embryo transfer on day 2 or 3. Embryo quality will be assessed according to the morphology of blastomeres as well as it's developmental stage.
1802542|NCT00606086|Drug|GI-5005|40YU, subcutaneous
1802543|NCT00606086|Drug|Pegylated Interferon and Ribavirin|Pegylated interefron is an injection and ribavirin is an oral tablet
1802544|NCT00606099|Drug|telbivudine|To compare the rate and pattern of treatment-emergent Hepatitis B virus (HBV) viral genotypic mutations after 24 weeks of treatment.
1802545|NCT00606099|Drug|adefovir dipivoxil|Active Comparator
1802546|NCT00606112|Drug|Trodusquemine (MSI-1436)|A single dose will be administered on Day 0. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2, 10mg/m2 in cohort 3 and 15mg/m2 in cohort 4/
1802547|NCT00606125|Drug|Nexavar (Sorafenib, BAY43-9006)|The purpose of this study is to: 1)evaluate how your body reacts to sorafenib when taken daily in combination with paclitaxel and carboplatin, 2) measure your blood levels of sorafenib, paclitaxel and carboplatin at specific times after taking the medication, and 3) to determine the safety of sorafenib.
1802548|NCT00606138|Drug|ranibizumab|One 0.5 mg intravitreal injection
1802549|NCT00606138|Procedure|Laser photocoagulation|panretinal photocoagulation (up to 500 300-500 um laser spots)
1802550|NCT00606164|Drug|Bryostatin for Injection|A single one-hour intravenous infusion of 10 or 15 ug/m2 Bryostatin for Injection on Day 1
1802551|NCT00606164|Drug|Placebo|A single one-hour intravenous infusion of placebo on Day 1
1802552|NCT00606177|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
1802553|NCT00606177|Drug|placebo|oral, 0mg(4tablets)/day
1802554|NCT00606190|Procedure|Retrograde brain perfusion|observational
1802555|NCT00606190|Procedure|Antegrade brain perfusion|observational
1802556|NCT00606203|Drug|milnacipran|taking milnacipran(50) 1#bid after stoke to prevent the occurence of depression
1802557|NCT00606203|Drug|placebo|placebo
1802558|NCT00606216|Procedure|MRI and cognitive evaluation|Patients will undergo a brain MRI study and a brief neuropsychological evaluation, at the time of enrollment for controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients. A follow-up MRI and cognitive evaluation will be performed approximately 12 months after the transplant for patients.
1802559|NCT00606216|Procedure|MRI and cognitive evaluation|Pt will undergo a Magnetic Resonance Imaging (MRI) study of the brain and a brief neuropsychological evaluation, at the time of enrollment for healthy controls and prior to undergoing the conditioning treatment required for the stem cell transplant for patients (Baseline/Time 1).
1802560|NCT00606216|Procedure|brain MRI study and a brief neuropsychological evaluation|A brain MRI study and a brief neuropsychological evaluation will be performed at baseline (Time 1). A follow-up MRI and cognitive evaluation will be performed and about 12 months after the baseline for healthy controls
1802561|NCT00606229|Drug|Aripiprazole|oral, 24mg/day
1802562|NCT00606242|Drug|Fluticasone|Inhaled Fluticasone, either 100 or 1000 mcg per day
1802563|NCT00606268|Drug|Micafungin|IV
1802564|NCT00606281|Drug|Aripiprazole|oral, 24mg/day
1802565|NCT00606281|Drug|placebo|oral, 0mg(4tablets)/day
1802566|NCT00606294|Radiation|fluorine-18-labeled fluoro-misonidazole (18F-FMISO)|
1802567|NCT00606294|Device|18F-FMISO PET scan|
1802568|NCT00606294|Device|MRI|
1802569|NCT00606294|Device|FDG PET/CT scan|
1802570|NCT00606307|Drug|ITF2357|50 mg b.i.d. PO every day
1802571|NCT00606320|Drug|Aripiprazole|oral, 24mg(4 tablets)/day
1802572|NCT00606333|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the Conor Cobalt Chromium Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
1802573|NCT00606333|Device|Drug-eluting stent (TAXUS Liberte Paclitaxel-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single coronary lesion using standard coronary intervention techniques. Intervention in this arm will include treatment with the TAXUS Liberte Paclitaxel-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
1802574|NCT00606346|Biological|Anti TNF therapy including infliximab|Treatments will be prescribed according to investigator judgement.
1802575|NCT00606346|Drug|No Biologics|Treatments will be prescribed according to investigator judgement.
1802576|NCT00606359|Biological|Inactivated, split-virion influenza virus|0.1 mL, Intradermal. 2 vaccinations 12 months apart
1802577|NCT00606359|Biological|Inactivated, split-virion influenza virus|0.5 mL, Intramuscular. 2 vaccinations, 12 months apart
1802578|NCT00606372|Procedure|OPCAB - the off-pump coronary artery bypass|surgical myocardial revascularisation without use of cardio-pulmonary bypass, using stabilising devices on beating heart
1802579|NCT00606385|Procedure|Liver resection|Laparoscopic or Open hepatectomy
1802580|NCT00606398|Procedure|surgical resection for patients with both intra- and extra-hepatic metastases|Simultaneous resection with R0 intent of intra-abdominal metastases from CRC. For patients with extra-abdominal disease, sequential resection will be permitted
1802581|NCT00606411|Drug|Topiramate or Placebo|25-300 mg tablets of topiramate and matching placebo, placed in blinded capsules
1802582|NCT00606424|Drug|20 mCi dose for a 50 kg individual of [F-18]HX4|All subjects, normal volunteers and cancer subjects will receive HX4 administered through a previously placed suitably sized angiocatheter or a butterfly needle. Prior to injection, qualified site personnel will assay the dose in the dose calibrator and document the activity of the dose and time of assay. After injection, the line will be flushed with saline (approximately 10 mL).
1802583|NCT00606437|Procedure|Total Body Irradiation with Fludarabine in UCB Transplants|Administration of the preparative regimen, infusion of the stem cell graft, inpatient care during the immediate post-transplant period and outpatient follow-up for the first 3 months after transplant and at 6, 12, 24 and 36 months. Patients will have human leukocyte antigen (HLA) serologic typing and DNA typing. Bags of UCB are thawed, and diluted by 1:1 volume using a 5% albumin/dextran solution. The thawed and diluted umbilical cord blood unit (UCBU) is next weighed and centrifuged. Specimens are obtained for cell count and viability, culture, clonogenic assays, and phenotype. The UCB is infused at a rate of 1-3 ml/min. Furosemide (0.5-1.0 mg/kg/dose) may be given if volume overload or decreased urine output occurs. Each UCB infusion shall be tested for sterility, CFU content, number of CD34+ cells, cell count and viability.
1802584|NCT00606450|Drug|CC-10004|20 mg CC-10004 taken 1 time per day for 12 weeks
1802585|NCT00606450|Drug|CC-10004|20 mg of CC-10004 taken 2 times per day for 12 weeks
1802586|NCT00606450|Drug|Placebo|matching placebo taken either 1 or 2 times per day for 12 weeks
1802587|NCT00606463|Device|Cardiac Ablation (Gen2 Cardiac Ablation System)|Ablation of isthmus-dependent atrial flutter
1802588|NCT00606476|Drug|Bapineuzumab (AAB-001)|IV q13w
1802589|NCT00606489|Drug|Caldolor|800 milligrams of intravenous ibuprofen (patients greater 12 years of age) or 10 milligrams/kilograms (patients greater than 12 years; maximum of 400 milligrams) every 6 hours
1802590|NCT00606489|Drug|Placebo|Placebo
1802591|NCT00589121|Drug|Chemotherapy|Up to 6 courses of investigator's choice of neoadjuvant, adjuvant, concurrent, or interdigitated chemotherapy
1802592|NCT00589121|Radiation|Radiation therapy|Preoperative IGRT (3D-CRT or IMRT): If receiving neoadjuvant or adjuvant chemotherapy or no chemotherapy: 50 Gy (2 Gy once a day, 5 times a week). If receiving concurrent or interdigitated chemotherapy: 44 Gy (2 Gy once a day, 5 times a week). Postoperative radiotherapy boost for patients with positive margins following surgery: 16 Gy (2 Gy once a day, 5 times a week) external beam radiation therapy or 16 Gy at ≤ 80 cGy per hour brachytherapy or 3.4 Gy/fraction in 4 fractions brachytherapy or 10-12.5 Gy in a single fraction intraoperative radiation therapy boost.
1802593|NCT00589121|Procedure|Surgery|Resection of the sarcoma with the goal of having negative pathologic margins. Every effort should be made to have limb preservation surgery unless there is documented evidence of tumor progression that would require amputation for an appropriate negative margin resection. All lesions of the extremities should be treated with wide excision.
1802594|NCT00589134|Dietary Supplement|Gatorade Endurance Formula|carbohydrate electrolyte beverage
1802595|NCT00589134|Other|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days.
1802596|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, modular cemented tibia|modular cemented tibia
1802597|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, non-modular cemented tibia.|non-modular cemented tibia.
1802598|NCT00589147|Device|The Zimmer NexGen Legacy Knee System, non-modular uncemented tibia|non-modular uncemented tibia
1802599|NCT00589173|Behavioral|Interactive Preventive Health Record (IPHR)|Preventive health record designed to a) show patients the status of their preventive care recorded in their electronic record and b) make recommendations on what USPSTF endorsed preventive services that the user needs to receive.
1802600|NCT00589173|Behavioral|"Standard preventive care"|Existing mechanisim for receiving preventive care in primary care (i.e. patients not referred to the IPHR).
1802601|NCT00589186|Biological|Ad5F35-LMP1/LMP2-transduced autologous dendritic cells|
1802602|NCT00589186|Drug|celecoxib|
1802603|NCT00589186|Other|flow cytometry|
1802604|NCT00589186|Other|immunoenzyme technique|
1802605|NCT00589186|Other|laboratory biomarker analysis|
1802606|NCT00589199|Procedure|Placement and use of the device|Surface electrodes currently used for peripheral muscle stimulation by other groups will be applied to the abdominal wall and over the posterior lower thoracic rib cage. Between two and three pairs (anodic and cathodic) of electrodes will be used in combination to activate the expiratory muscles. Electrodes will be positioned at various points over the abdominal wall and the posterior thoracic rib cage to ascertain optimal placement for airway pressure and expiratory airflow generation. The electrical stimulators to be used (EMPI and NeuroMedic) are powered by 9-volt batteries. These stimulators are currently in clinical use to stimulate other skeletal muscles and are known to be quite safe.
1802607|NCT00589212|Device|GliaSite Radiation Therapy System|GliaSite RTS is designed to deliver intracavitary radiation therapy for brain tumors. Following surgical resection, the balloon catheter is inflated to fill the cavity and Iotrex radiotherapy solution infused. It is a single applicator system that provides a uniform and conformal dose to the resection cavity.
1802608|NCT00589225|Genetic|Genetic Analysis|We will draw one tube of blood from your arm to obtain white blood cells. These white blood cells will be used as a source of DNA for genetic testing.
1802609|NCT00589238|Drug|carboplatin|
1802610|NCT00589238|Drug|cyclophosphamide|
1802611|NCT00589238|Drug|doxorubicin hydrochloride|
1802612|NCT00589238|Drug|paclitaxel|
1802613|NCT00589251|Other|penicillin skin test|"Prick skin tests will be performed on the volar surface of the forearm with each penicilloate and control reagents. The skin test sites will be examined at 15 minutes. A positive test result is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. Patients with negative prick test results to penicillin will undergo intradermal testing.
Intradermal skin tests will be performed on the volar surface of the forearm. The test reagents will be injected intradermally to produce an initial wheal of 2x2 mm. The skin test sites will be examined at 15 minutes. A positive intradermal test is defined as a wheal of 3x3 mm or greater with a surrounding zone of erythema. In order to ensure patient safety, we will consider using an end point titration technique."
1802614|NCT00589264|Dietary Supplement|zinc|10 mg elemental zinc + 10 mg elemental iron + 0.5 mg copper syrup taken daily for 1 year, from 6 to 18 months of age
1802615|NCT00589264|Dietary Supplement|iron + copper|10 mg elemental iron + 0.5 mg copper in syrup given daily for one year from 6 months to 18 months of age
1802618|NCT00589290|Drug|Belinostat (PDX101)|1000 mg/m^2/day as a 30 minute intravenous (IV) infusion daily for 5 days every 3 weeks (day 1-5 of the 3 week treatment cycle). After 12 cycles of treatment, cycles will be given for 5 days every 4 weeks.
1802619|NCT00589303|Drug|FDA approved rate and rhythm control drugs|"Any approved rate or rhythm control drugs for treatment of atrial fibrillation may be prescribed under the primary physician's discretion.
Rate Control:
Beta-Blocker:
metoprolol
atenolol
carvedilol
Calcium Channel Blocker:
verapamil
diltiazem
Rhythm Control:
procainamide
quinidine
disopyramide
propafenone
flecainide
sotalol
dofetilide
amiodarone"
1802620|NCT00589303|Device|AV Node ablation and device implant|"Pacing Systems:
Enpusle Premarket Approval Number (PMA#) P980035
EnRhythm PMA# P980035
Adapta PMA# P980035
Cardiac Resynchronization Therapy (CRT) Pacing Systems:
- InSync III/ Insync Maximo/InSyncII Marquis PMA# P010031
Implantable Cardioverter-Defibrillator (ICD) Pacing Systems:
EnTrust PMA# P980016
Virtuoso PMA# P980016
ICD CRT Pacing Systems:
InSync Maximo PMA# P980016
InSync Sentry PMA# P890003
Concerto PMA# P980016"
1802621|NCT00589316|Procedure|Allogeneic Bone Marrow Transplantation|Given via central line
1802622|NCT00589316|Drug|Cyclophosphamide|Given IV
1802623|NCT00589316|Drug|Fludarabine Phosphate|Given IV
1802624|NCT00589316|Radiation|Iodine I 131 Monoclonal Antibody BC8|Given IV (dosimetry dose) or via central line (therapeutic dose)
1802625|NCT00589316|Other|Laboratory Biomarker Analysis|Correlative studies
1802626|NCT00589316|Drug|Mycophenolate Mofetil|Given IV or PO
1802627|NCT00589316|Drug|Tacrolimus|Given IV or PO
1802628|NCT00589316|Radiation|Total-Body Irradiation|Undergo TBI
1802629|NCT00589329|Drug|erythromycin and metronidazole (antibiotics)|"Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.
Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days"
1802630|NCT00589329|Drug|placebo|IV and pill placebo
1802631|NCT00589368|Behavioral|Transfer of grasp control across hands|transfer of planning and execution of grasp across hands in terms of its effect on fingertip forces, and the timing and magnitude of muscle contraction in patients with hemiparesis and healthy controls
1802632|NCT00589381|Drug|fenretinide lipid matrix|
1802633|NCT00589394|Biological|pneumococcal vaccination (Pneumovax)|pneumovax was given
1802634|NCT00589420|Drug|docetaxel|
1802635|NCT00589420|Drug|sorafenib tosylate|
1802636|NCT00594828|Device|CoaguChek (Patient self testing)|Patients will test their INR at home either biweekly, weekly or every 2 weeks using a CoaguChek point of care meter and communicate with the healthcare provider via an internet based expert system
1802637|NCT00594828|Device|Anticoagulation Management Service (AMS)|Patients will attend the AMS for six months and have their INR checked every 4-6 weeks or more frequently, at the discretion of the clinician
1802638|NCT00594841|Procedure|Open Reduction Internal Fixation of AC joint dislocation|"Definitive surgical treatment (i.e., ORIF) will be performed within 28 days of the injury. In all cases the procedure will be performed by an orthopedic staff surgeon with the assistance of a fellow/resident(s). The operating surgeon will determine the positioning of the patient for surgery. ORIF of the AC joint dislocation will be carried out as follows:
Anatomic reduction of the AC joint
Definitive fixation with a hook plate and screws"
1802639|NCT00594841|Other|Non operative treatment of AC joint dislocation (sling)|Standard protocol for conservative treatment will consist of the implementation of a sling, for shoulder support and patient comfort, for four weeks followed by physiotherapy. Pendulum exercises may be implemented at any time as dictated by the attending surgeon.
1802640|NCT00594854|Drug|PN400 (VIMOVO)|PN400 tablet (500 mg delayed-release naproxen/20 mg immediate-release esomeprazole) given by mouth twice daily (bid).
1802641|NCT00594854|Drug|Diclofenac/Misoprostol|Over-encapsulated ARTHROTEC® 75 (75 mg diclofenac sodium/200 mcg misoprostol) capsules given by mouth bid.
1802642|NCT00594867|Drug|Acetaminophen - 4 grams per day + Placebo|Acetaminophen - 4 grams per day + Placebo
1802643|NCT00594867|Drug|Aspirin - 325 mg per day + Placebo|Aspirin - 325 mg per day + Placebo
1802644|NCT00594867|Drug|Acetaminophen 4 gram per day + Aspirin 325 mg per day|Acetaminophen 4 gram per day + Aspirin 325 mg per day
1802645|NCT00594880|Drug|Pegylated Interferon-alpha 2a, 180 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL < 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
1802646|NCT00594880|Drug|Pegylated Interferon-alpha 2a, 90 mcg/week sc|Pegylated Interferon-alpha 2a, 90 mcg/week sc for 24 weeks, 5 weeks in combination with ART, then 7 weeks without ART to primary endpoint (VL < 400 c/ml at 12 weeks) and further 12 weeks without ART (24 weeks) to secondary endpoints
1802647|NCT00594893|Procedure|Mini Incision Approach|Mini Incision Approach
1802648|NCT00594893|Procedure|2 Incision Approach|2 Incision Approach
1802649|NCT00594906|Drug|Teriparatide|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
1802650|NCT00594906|Drug|Placebo|Daily 20-mcg subcutaneous injections for the duration of the study (16 weeks)
1802654|NCT00594945|Drug|Clonazepam|1 Dose
1802655|NCT00600444|Procedure|Venae sectio|surgical preparation of the cephalic vene to insert a totally implantable access port.
1802656|NCT00600444|Procedure|Punction of V. subclavia|radiological punction of the v. subclavia with Seldinger technique to implant a totally implantable access port
1802657|NCT00600457|Device|Polyurethane Film|The modified polyurethane film is combined with a secondary absorbent dressing and remained intact until the 10th postoperative day
1802700|NCT00600730|Procedure|Hyperinsulinemic hypoglycemic clamp study with fMRi|Hyperinsulinemic hypoglycemic clamp on day1 with fMRi in morning
1802701|NCT00600743|Drug|GSKI181771X (CCK-1R agonist)|Drug one trial vs placebo
1802968|NCT00608907|Drug|bortezomib|1.3 mg/m^3 on days 1, 4, 8, 11 over a 21-day treatment cycle
1802658|NCT00600470|Behavioral|Doctor-office collaborative care (DOCC) management|DOCC is an evidence-based psychosocial treatment approach that incorporates (1) adaptation of an evidence-based collaborative care approach using the chronic care model and participatory management theory to enhance training, implementation, and sustainability; (2) revised protocol content that includes medication management for ADHD, brief anxiety management, and attention to parental/partner dysfunction; (3) technological developments to facilitate screening/assessment, monitoring, and communication; and (4) an improved methodology that includes new samples, measures, and settings.
1802659|NCT00600470|Behavioral|Treatment as usual (TAU)|TAU involves routine care: psychoeducation and referral to outside providers.
1802660|NCT00600483|Drug|gentamicin-collagen sponge dipped in saline|100-cm2 sponge
1802661|NCT00600496|Drug|AZD6244|twice daily oral dose
1802662|NCT00600496|Drug|Dacarbazine|intravenous infusion
1802663|NCT00600496|Drug|Erlotinib|daily oral dose
1802664|NCT00600496|Drug|Docetaxel|intravenous infusion
1802665|NCT00600496|Drug|Temsirolimus|intravenous infusion
1802666|NCT00600509|Drug|Levetiracetam|
1802667|NCT00600522|Procedure|Ultrasound-guided hepatectomy|"After laparotomy and staging by intraoperative ultrasound (IOUS), anterior surface of the hepatocaval confluence is exposed. Than, compression by means of the surgeon's finger-tip is applied at the MHV caval confluence verifying at color-Doppler IOUS the disappearance of the blood flow in the MHV or its inversion. Then, MHV clamping itself is carried out, and parenchymal sparing resection would be selected if at least one of these 3 findings is confirmed:
Reversal color-Doppler IOUS flow direction in the peripheral portion of the MHV, which suggests the drainage through collateral circulation in the RHV/LHV depending on the side of the MHV branch with reversal flow.
Detectable shunting collaterals at color-Doppler IOUS with RHV or LHV.
Hepatopetal flow in P5-8 and/or P4inf portal branches. If none of these finding is confirmed and in particular hepatofugal flow direction in the P5-8 and/or P4 inf is detected the hepatectomy has to be extended."
1802668|NCT00600535|Drug|Stage 1 Group 1: abiraterone acetate|1000 mg capsules/day orally on Day 1. On Day 8, patients will crossover and receive tablet formulation at the same dose.
1802669|NCT00600535|Drug|Stage 1 Group 2: abiraterone acetate|1000 mg tablets/day orally on Day 1. On Day 8, patients will crossover and receive capsule formulation at the same dose.
1802670|NCT00600535|Drug|Stage 2: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle) according to assigned group from Stage 1.
1802671|NCT00600535|Drug|Stage 3: abiraterone acetate|1000 mg tablets/day orally for 12 cycles (28 days/cycle).
1802672|NCT00600535|Drug|Stage 3: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for 12 cycles (28 days/cycle).
1802673|NCT00600535|Drug|Stage 4: abiraterone acetate|1000 mg tablets/day orally for up to 24 cycles (28 days/cycle).
1802674|NCT00600535|Drug|Stage 4: glucocorticoid|prednisone/prednisolone 5 mg twice daily orally or dexamethasone 0.5 mg once daily for up to 24 cycles (28 days/cycle).
1802675|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
1802676|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
1802677|NCT00600548|Drug|Miltefosine.|Miltefosine: Capsules containing 10 mg or 50 mg miltefosine; administered orally for 28 days at dosage of 2.5 mg/kg body weight per day.
1802678|NCT00600548|Drug|Meglumine antimoniate.|Meglumine antimoniate administered by intravenous route for 20 days at the dosage of 20mg/kg/day.
1802679|NCT00600561|Behavioral|MBSR|Mindfulness-Based Stress Reduction Intervention
1802680|NCT00600574|Other|physical therapy|weekly pool physiotherapy with muscle stretching
1802681|NCT00600574|Other|physical therapy|weekly pool physiotherapy with Ai Chi movements during a 6 months period
1802682|NCT00600587|Drug|neoadjuvant erlotinib therapy|150mg erlotinib taken once daily and continued uninterrupted for 42 days before evaluation/thoracotomy/radiotherapy.
1802683|NCT00600587|Drug|neoadjuvant gemcitabine/carboplatin therapy|3 cycles of neoadjuvant gemcitabine(1250mg/m2,d1,d8)/carboplatin(AUC=5,day1) chemotherapy before evaluation/thoracotomy/radiotherapy.
1802684|NCT00600600|Drug|Tigecycline|Tigecycline dosage based on age and clinical status of patient.
1802685|NCT00600613|Radiation|cone beam imaging|All study patients will undergo simulation, treatment planning and verification as currently practiced. The contrast injection and cone beam imaging will be added to the standard procedure just prior to treatment delivery on the first and last days of treatment only.
1802686|NCT00600626|Drug|biphasic insulin aspart|
1802687|NCT00600626|Drug|insulin NPH|
1802688|NCT00600626|Drug|insulin aspart|
1802689|NCT00600639|Device|Non-invasive mechanical ventilation using a BiPAP Vision or any other ICU ventilators with NIV option|A mode of ventilation that does not require the insertion of the endotracheal tube, since the support is delivered throgh a full face or nasal mask
1802690|NCT00600639|Drug|standard medical therapy plus oxygen that includes salbutamol, prednisolone and antibiotics as needed|Standard medical therapy includes drugs like beta2-agonists, steroids, anthicolinergic agents- antibuiotics as needed
1802691|NCT00600639|Drug|standard medical therapy that includes salbutamol, prednisolone and antibiotics as needed|oxygen plus medical therapy for ARF
1802692|NCT00600665|Behavioral|PAINReportIt|A pain assessment data collection tool
1802693|NCT00600665|Behavioral|PAINUCope|A multimedia patient education program tailored to the participant's SCD pain management misconceptions
1802694|NCT00600665|Behavioral|PAINConsultN|A decision support tool for doctors that will provide algorithm-based pain medication therapies tailored to each participant's pain level
1802695|NCT00600678|Dietary Supplement|ProvideXtra DRINK (oral nutritional supplement, food for special medical purposes)|Single, oral administration of nutritional supplement under fasting condition within 2 minutes.
1802696|NCT00600691|Drug|Finasteride|one tablet (5mg) of finasteride
1802697|NCT00600704|Procedure|Fluid Restriction Policy|Infusion of Hes 130/0.4 up to 500 ml until the beginning of Cardiopulmonary bypass
1802698|NCT00600704|Procedure|Free fluid infusion|Free fluid infusion unless Hb< 6g/dl(allogenic blood use), until the beginning of Cardiopulmonary bypass
1802699|NCT00600730|Procedure|Hyperinsulinemic euglycemic clamp with fMRi|Hyperinsulinemic euglycemic clamp on day 1 with morning fMRi
1802702|NCT00600743|Behavioral|Instructions to binge eat|Subjects will be instructed to binge eat and will also be given either drug or placebo
1802703|NCT00600743|Behavioral|Instructions to eat normally|Subjects will be instructed to eat normally and will also be given either drug or placebo
1802704|NCT00600743|Drug|Placebo|Drug one trial vs placebo
1802705|NCT00600756|Drug|Quetiapine XR|Oral, once daily, tablets of 400 mg to 800 mg
1802706|NCT00600756|Drug|Risperidone|Oral, once daily, tablets of 2 mg to 6 mg
1802707|NCT00600769|Drug|Clarithromycin|Dosage dependent on clinical factors such as age, weight and patient-specific health status
1802708|NCT00600782|Biological|GSK Biologicals' Candidate Tuberculosis (TB) Vaccine (692342)|Intramuscular injection, 2 doses at 0, 1 month
1802709|NCT00600795|Other|CSF collection|CSF collection at time of VPS insertion
1802710|NCT00606502|Drug|Pralatrexate|"Intravenous (IV) push administration over 3-5 minutes into a patent IV line containing normal saline (0.9% sodium chloride).
Initial dose: 230 mg/m2, increased to 270 mg/m2 if patient does not have specific adverse events (AEs) as per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/m2 decrements to 190 mg/m2 per the protocol defined dose modifications.
Protocol amended dose: 190 mg/m2, then 230 mg/m2 if patient does not have specific AEs per the protocol after receipt of 2 consecutive doses 2 weeks apart. Reductions allowed in 40 mg/2 decrements to 150 mg/m2 per the protocol defined dose modifications.
Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
1802711|NCT00606502|Drug|Erlotinib|"150 mg orally in tablet form
Administered daily 1 hour before or 2 hours after ingestion of food until criteria for discontinuation per the protocol are met."
1802712|NCT00606502|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection
Administered within 10 weeks of randomization, every 8-10 weeks throughout the study and for at least 30 days after last dose of study treatment."
1802713|NCT00606502|Dietary Supplement|Folic Acid|"1-1.25 mg orally
Administered daily for at least 7 days prior to randomization, throughout the study and for at least 30 days after last dose of study treatment."
1802716|NCT00606528|Other|No intervention|None. This is an observational study.
1802717|NCT00606541|Drug|Quetiapine XR|This is an investigator-initiated, single site study, consisting of two phases: 1) 8-week, open label treatment with quetiapine XR (50-400 mg/day) in subjects (n=55 in order to randomize 20 into each of the quetiapine XR and PBO arms in the 2nd phase of the study) with SAD; and 2) in those who demonstrate at least minimal improvement (i.e. CGI≤3), 12-weeks randomized, double-blind treatment with either quetiapine XR or placebo (PBO).
1802718|NCT00606541|Drug|Placebo|Placebo
1802719|NCT00606554|Device|Computer-driven weaning program - Drager Evita Smartcare System|Closed-loop, knowledge-based, computer driven weaning program initiated at the start of ventilator weaning.
1802720|NCT00606554|Behavioral|Standard of Care weaning|Evidence-based standard of care weaning process.
1802721|NCT00606567|Other|Methods for monitoring patients with ICD's|Intervention comparing 2 different methods of monitoring patients with ICDs; at home monitoring vs. quarterly monitoring in the clinic.
1802722|NCT00606580|Drug|WR 279,396 topical cream|WR 279,396 is a topical antibiotic cream containing 15% paromomycin and 0.5% gentamicin that will be applied to each lesion once a day and covered with a sterile gauze and tape dressing.
1802723|NCT00606580|Drug|Paromomycin Alone topical cream|The antibiotic paromomycin 15% in the same topical cream used in arm 1 will be applied to lesions daily and covered with a protective sterile gauze and tape dressing.
1802724|NCT00606580|Drug|Vehicle placebo cream|Applied daily to cutaneous leishmaniasis lesions, primarily ulcerative, and covered with a protective, sterile gauze and tape dressing.
1802725|NCT00606593|Drug|ACT-078573 oral capsules at 25 and 100 mg and matching placebo|5-period, 5-treatment crossover: sequences: ABECD, BCADE, CDBEA, DECAB, EADBC DCEBA, EDACB, AEBDC, BACED, CBDAE Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
1802726|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
1802727|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
1802728|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
1802729|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
1802730|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
1802731|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
1802732|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
1802733|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
1802734|NCT00606593|Drug|ACT-078573 and matching placebo|ACT-078573 oral capsules at 25 and 100 mg and matching placebo 5-period, 5-treatment crossover Where A = 200mg, B = 100 mg, C = 50 mg, D = 25mg, E = Placebo
1802735|NCT00606606|Other|Clinical Decision Support|
1802736|NCT00606619|Other|Conventional feeding|Procedure of Conventional feeding group: Patients are supplied water on day 3 after operation, liquid diet on day 4 and 5 and soft diet on 6 day.
1803053|NCT00609492|Biological|Infanrix™-IPV/Hib|Single dose, intramuscular injection
1802737|NCT00606619|Other|Early oral feeding|Procedure of Early oral feeding group: Patients are supplied water on day 1 after operation, liquid diet on day 2 and soft diet on day 3 day.
1802738|NCT00606632|Drug|124-Iodine-cG250 (124I-cG250)|i.v. and PET/CT scan 4+/-2 days after administration
1802739|NCT00606632|Procedure|CT|contrast enhanced CT scan
1802740|NCT00606645|Biological|XmAb2513|Intravenous infusion of XmAb2513 administered at a dose of 0.3, 1.0, 3.0, 6.0, 9.0, or 12 mg/kg in sequential dose cohorts.
1802741|NCT00606658|Procedure|Shirodhara Oil Treatment|Oil dripping on the forehead in a constant stream for about 40 minutes for five consecutive days.
1802742|NCT00606684|Drug|GW642444 6.25|GW642444 6.25
1802743|NCT00606684|Drug|GW642444 3mcg|once daily
1802744|NCT00606684|Drug|GW642444 12.5mcg|GW642444 12.5mcg
1802745|NCT00606684|Drug|GW642444 25mcg|GW642444 25mcg
1802746|NCT00606684|Drug|GW642444 50mcg|GW642444 50mcg
1802747|NCT00606684|Other|placebo|placebo
1802750|NCT00606710|Device|Cognis 100-D, Teligen DR, VR 100 HE|ICD or CRT - Therapy
1802751|NCT00606723|Biological|Hematopoietic stem cells from bone marrow or peripheral blood|> = 2 x 10*8 nucleated cells (WBC)/kg body weight of the recipient or rather > = 4 x 10*6 nucleated CD34+ cells / kg body weight are required for engraftment. Suspension of stem cells is administered via intravenous infusion.
1802752|NCT00606749|Drug|KC706|300 mg once daily (QD) for 12 weeks.
1802753|NCT00606762|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy is performed at either 8 mm Hg or 12 mm Hg intra-abdominal pressure
1802754|NCT00606775|Drug|Carvedilol|2.5-5mg/day
1802755|NCT00606788|Device|SmartCare/PS (Automated Weaning)|Patients received computer-driven protocolized weaning
1802756|NCT00606788|Procedure|Conventional weaning|Patients received physician-directed non-protocolized weaning
1802757|NCT00606801|Drug|Galantamine|Galantamine 8 mg/day
1802758|NCT00606801|Drug|placebo|sugar pill
1802759|NCT00606814|Drug|IPI-504, docetaxel|"IPI-504 administered IV at a dose of 300mg/m2
Docetaxel at a fixed dose of 75 mg/m2 for every 3 weeks dose administration or 36 mg/m2 for weekly administration"
1802760|NCT00606827|Drug|Sodium Bicarbonate|Patients in the sodium bicarbonate group (154 mEq/L) received 3 ml/kg for 1 hour before contrast medium, followed by an infusion of 1 ml/kg/h for 6 hours after the procedure
1802761|NCT00606827|Drug|Isotonic Saline|Patients assigned to the isotonic saline group received 1 ml/kg/h 0.9% sodium chloride for 12 hours before and after the procedure
1802763|NCT00607308|Biological|PF-04360365|Single dose of 0.1 mg/kg IV on Day 1
1802764|NCT00607308|Biological|PF-04360365|Single dose of 0.5 mg/kg IV on Day 1
1802765|NCT00607308|Biological|PF-04360365|Single dose of 1 mg/kg IV on Day 1
1802766|NCT00607308|Biological|PF-04360365|Single dose of 5 mg/kg IV on Day 1
1802767|NCT00607308|Drug|Placebo|Single dose of placebo IV on Day 1
1802768|NCT00607308|Biological|PF-04360365|Single dose of 10 mg/kg IV on Day 1
1802769|NCT00607321|Device|Medtronic Bifurcation Stent System|Percutaneous Coronary Stenting
1802770|NCT00607334|Behavioral|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
1802771|NCT00607334|Behavioral|Word-learning|Exposure to five nonwords for three sessions of controlled interaction with the experimenter
1802772|NCT00607347|Other|Glucose|Oral Glucose Tolerance Test
1802773|NCT00607360|Behavioral|Therapeutic Workplace Intervention|Therapeutic workplace intervention is intended for individuals with drug addiction and chronic unemployment. Participants are invited to participate in work and receive salary for participation and productivity contingent upon drug abstinence.
1802774|NCT00607373|Drug|mipomersen|200 mg mipomersen administered once a week for 26 weeks as a 1 mL subcutaneous injection. Subjects weighing less than 50 kg received a lower dose of 160 mg (0.8mL) mipomersen.
1802775|NCT00607373|Drug|Placebo|1 mL subcutaneous injection once a week for 26 weeks. Subjects weighing less than 50 kg received 0.8 mL subcutaneous injection.
1802776|NCT00607386|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg weekly
1802777|NCT00607399|Drug|SGX523 Capsules|This is a dose escalation study
1802778|NCT00607412|Behavioral|Integrated psychotherapy for PTSD and substance use|integrated, present focused psychotherapy for PTSD and substance use disorders tailored to women who have experienced intimate partner violence
1802779|NCT00607412|Behavioral|12-step based supportive therapy|supportive psychotherapy based on 12-step model
1802780|NCT00607438|Drug|Paclitaxel Albumin Nanoparticle for Injectable Suspension (Abraxane)|125 mg/m2 Paclitaxel by 30-minute IV infusion weekly for 3 weeks.
1802781|NCT00607438|Drug|Sorafenib (Nexavar)|400 mg orally twice a day continuously (even during rest week) starting on Day 1.
1802782|NCT00607451|Drug|Neu-120|Capsules of 300, 900 and 2700mg; administered as a single dose with a one week washout between each administration.
1802783|NCT00607464|Device|Polyethylene occlusive skin wrap|Polyethylene occlusive skin wrap applied immediately after birth and removed after the infant has been admitted to a stable thermoneutral environment
1802784|NCT00607477|Drug|Minoxidil|2.5 mg taken twice daily for 1 week, followed by 5 mg taken twice daily for the next week, followed by 10 mg twice daily for the next week
1802785|NCT00607477|Drug|Hydralazine|25 mg taken twice daily for 1 week, followed by 50 mg taken twice daily for the next week, followed by 100 mg twice daily for the next week
1802786|NCT00607490|Behavioral|Cognitive-Behavioral Therapy|Behavioral, cognitive, sex therapy and relaxation interventions administered to teach self-management skills for pain control.
1802787|NCT00607490|Behavioral|Supportive Psychotherapy|Patient-centered talk therapy to assist participants in expressing their thoughts and feelings.
1802833|NCT00607906|Drug|SB-756050 immediate release capsule|SB-756050 immediate release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white drug layered pellets. Each capsule will contain 5, 25 or 100 milligrams of SB-756050.
1803052|NCT00609492|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Single dose, intramuscular injection
1802788|NCT00607503|Drug|Terbutaline|"Each subject will be treated with terbutaline for 21-28 days following the initiation of treatment during the CRC admission.
Subjects weighing between 25 and 45 kg will be treated with a nightly oral dose of 2.5 mg and subjects who weigh more than 45 kg will be treated with 3.75 mg.
The standard 2.5 mg terbutaline tablets available in a pharmacy will be used in the study, with subjects taking either 1 or 1.5 tablets nightly."
1802789|NCT00607516|Procedure|Cemented primary bipolar hemiarthroplasty of the hip|Cemented primary bipolar hemiarthroplasty of the hip
1802790|NCT00607516|Procedure|Uncemented primary bipolar hemiarthroplasty of the hip|Uncemented primary bipolar hemiarthroplasty of the hip
1802791|NCT00607529|Other|hand-held POC creatinine analyzer-blood test|"This study will require the collection of a finger-puncture capillary blood specimen in addition to one green stoppered heparin containing collection tube. This is taken pre-therapy. The capillary whole blood specimen will be used to perform a creatinine determination on the investigational hand-held creatinine analyzer using special test strips for the analysis."
1802793|NCT00607555|Device|Insertion of specialized feeding tube for monitoring of EAdi|The specialized feeding tube will be inserted into the esophagus and positioned at the level of the crural diaphragm. EAdi will be measured with miniaturized coated stainless steel electrodes mounted on the feeding tube. The tube is connected to a monitor where EAdi will be recorded continuously throughout the entire study period
1802794|NCT00607568|Drug|Atomoxetine|"atomoxetine 40mg per day or placebo
For Phase I, subjects will be assigned to atomoxetine or placebo for 4 days. Subjects will then have a 4-15 day washout period and will be crossed over to the alternative treatment for Phase II."
1802795|NCT00607581|Drug|cyclophosphamide|cyclophosphamide: 500 mg orally on days 1, 8, 15
1802796|NCT00607581|Drug|lenalidomide|lenalidomide: 15 mg orally on days 1-21
1802797|NCT00607581|Drug|dexamethasone|dexamethasone: 40 mg orally on days on days 1, 8, 15, 22
1802798|NCT00607594|Drug|saracatinib|Patients receive AZD0530 (saracatinib) PO QD in the absence of disease progression or unacceptable toxicity.
1802799|NCT00607607|Drug|MKC-1|capsules, provided 125 mg/m2 BID x 14 days in 28 day cycles
1802801|NCT00607646|Drug|Dehydroepiandrosterone|Placebo tablets or tablets containing DHEA will be given orally before each hyperinsulinemic clamps on day 1 (x 2). Placebo tablets or tablets containing DHEA will be given orally before Day 2 hyperinsulinemic hypoglycemic clamp x 1.
1802802|NCT00607646|Drug|Placebo|Placebo oral administration prior to each clamp period x2 on day 1. Hyperinsulinemic hypoglycemia on day 2.
1802803|NCT00607659|Other|No intervention, only observational|No intervention, only observational
1802804|NCT00607672|Drug|Placebo|Placebo
1802805|NCT00607672|Drug|Ramipril|Ramipril 2.5mg day 1 and 2 and then 5mg/d thereafter
1802806|NCT00607672|Drug|Candesartan|Candesartan 16mg/d
1802807|NCT00607685|Drug|5 Fluorouracil with hyaluronic acid|Participants will receive a subconjunctival injection of 0.1ml of a mixure of 5 Fluorouracil (50mg/ml) with hyaluronic acid (23mg/ml) once at enrollment into the study.
1802808|NCT00607685|Drug|5 Fluorouracil|Pariticpants will receive a subconjunctival injection of 0.1ml of 5 Fluorouracil 50mg/ml once at enrollment
1802809|NCT00607711|Drug|oral palifosfamide tris|Capsule(s) given daily for 15 days followed by a 6 day rest. This is a dose escalation arm.
1802810|NCT00607724|Drug|GDC-0449|
1802811|NCT00607737|Drug|insulin detemir|3 cutaneous injections
1802812|NCT00607737|Drug|saline|3 cutaneous injections
1802813|NCT00607750|Drug|ATG003 (mecamylamine)|1% Ophthalmic solution, eyedrop BID, 48 weeks
1802814|NCT00607750|Drug|Placebo|Placebo eyedrops, BID, 48 weeks
1802815|NCT00607763|Drug|Micafungin (Mycamine)|IV
1802816|NCT00607776|Drug|(9587X) Blink Tears, classified as an OTC Drug with the active ingredient being plyethylene glycol 400|Drops
1802817|NCT00607776|Drug|Systane|Drops
1802818|NCT00607789|Drug|Duloxetine|30 mg/day - 120 mg/day
1802819|NCT00607789|Drug|Placebo|identical to study drug
1802820|NCT00607802|Biological|leukocyte therapy|
1802821|NCT00607802|Genetic|polymerase chain reaction|
1802822|NCT00607815|Behavioral|Cognitive Processing Therapy|CPT is a highly structured protocol in which the client learns the skill of recognizing and challenging dysfunctional cognitions, first about the worst traumatic event and then later with regard to the meaning of the events for current beliefs about self and others.
1802823|NCT00607815|Behavioral|Present Centered Therapy|"Present centered therapy is a supportive counseling model developed by Drs. Foa and Shea. The treatment is called present centered therapy to 1) emphasize the need to focus on the participant's current life and 2) to conceptualize the problems as being caused by PTSD, and in some cases they may have been present for a long period of time. The treatment makes a connection between PTSD and current problems thus making it a more realistic PTSD treatment and still allowing PCT to control for nonspecific therapeutic factors"
1802824|NCT00607828|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
1802827|NCT00607854|Drug|Ibritumomab Tiuxetan (Zevalin)|"Conditioning regimen followed by allogeneic hematopoietic stem cell transplantation.
Ibritumomab Tiuxetan(Zevalin): 0.4 mCi/kg IV at day -14 (Day 0 is the transplantation)"
1802828|NCT00607867|Other|LoBAG30 diet|A LoBAG30 diet consists of 30% of total energy intake as carbohydrate, 30% protein, and 40% fat.
1802829|NCT00607867|Other|Control Diet|A control diet consists of 55% of total energy intake as carbohydrate, 15% protein, 30% fat
1802830|NCT00607880|Procedure|vascular access device placement|
1802831|NCT00607893|Device|Continuous Positive Airway Pressure (CPAP)|Participants will use the higher pressure CPAP, as determined by an in-laboratory attended titration study, every night for 12 weeks.
1802832|NCT00607893|Device|Sham CPAP|Participants will use the lower pressure CPAP every night for 8 weeks.
1802834|NCT00607906|Drug|SB-756050 modified release capsule|SB-756050 modified release capsules will be size 0, white, opaque capsules with no identifying markings, containing white to off-white enteric coated drug layered pellets. Each capsule will contain either 25or 100 milligrams of SB-756050.
1802835|NCT00607906|Drug|Placebo|Subjects will also receive placebo capsules.
1802836|NCT00607919|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 16 to 32 weeks
1802837|NCT00607919|Drug|Placebo|oral, daily, for 16 weeks
1802838|NCT00607932|Behavioral|behavioral dietary intervention|Not specified
1802839|NCT00607932|Dietary Supplement|Brassica vegetable|Not specified
1802840|NCT00607932|Drug|indole-3-carbinol|follow up at 2,4,6 months post baseline.
1802841|NCT00607932|Other|counseling intervention|2, 4, 6 months post baseline
1802842|NCT00607932|Other|medical chart review|2,4,6 months post baseline
1802843|NCT00607932|Other|questionnaire administration|not specified
1802844|NCT00607932|Procedure|adjuvant therapy|not specified
1802845|NCT00607945|Drug|Rosiglitazone (Avandia) OR other diabetes medication currently prescribed to participant|Rosiglitazone 4-8mg/day, pill, from week -4 to week 32 OR other diabetes medication taken as prescribed from week -4 to week 32
1802846|NCT00607945|Dietary Supplement|conjugated linoleic acid (CLA)|3.2 g/day, capsule, week 0 to week 32
1802847|NCT00607945|Dietary Supplement|conjugated linoleic acid (CLA)|6.4 g/day, capsule, week 0 to week 32
1802848|NCT00607958|Drug|tipranavir/ritonavir (dose reduction)|tipranavir/ritonavir 500/100 BID
1802849|NCT00607971|Drug|Renzapride|All subjects take two capsules (2x renzapride 2 mg) daily, from the day of enrolment until the scheduled visit at the end of Week 52
1802850|NCT00607984|Drug|thiotepa melphalan|thiotepa 900 mg per meter squared total, on days -11,-10,-4,-3 melphalan 140 mg per meter squared total on days -11,-10,-4,-3 autologous stem cell transplant in day 0
1802851|NCT00607997|Drug|vosaroxin|Vosaroxin was administered by slow intravenous (IV) infusion or via syringe pump within 10 minutes.Patients could have completed up to 4 treatment cycles consisting of 1 or 2 induction treatment cycles and up to 2 consolidation treatment cycles. For Schedule A, an induction cycle was a minimum of 21 days during which patients received vosaroxin on Days 1, 8, and 15, followed by weekly observations until hematologic recovery for patients with aplastic marrow after the postinduction bone marrow assessment. For Schedules B and C, an induction cycle was a minimum of 15 days, during which patients received vosaroxin on Days 1 and 8 (Schedule B), or Days 1 and 4 (Schedule C), followed by the same weekly observations until hematologic recovery as for Schedule A.
1802852|NCT00608010|Procedure|Vitrification|Embryos were vitrified according to a previously described technique
1802853|NCT00608010|Procedure|Slow freezing|Embryos were frozen with slow freezing technique
1802854|NCT00608023|Drug|Tesamorelin|
1802855|NCT00608023|Drug|Placebo for Tesamorelin|
1802856|NCT00608049|Behavioral|High carbohydrate and low glycemic index (GI) diet|The high carbohydrate and low GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
1802857|NCT00608049|Behavioral|Low carbohydrate and low GI diet|The low carbohydrate and low GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of less than 45 on the glucose scale.
1802858|NCT00608049|Behavioral|High carbohydrate and high GI diet|The high carbohydrate and high GI diet will require 58% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
1802859|NCT00608049|Behavioral|Low carbohydrate and high GI diet|The low carbohydrate and high GI diet will require 40% of daily calories to be from carbohydrates and will be composed of meals with a GI of greater than 65 on the glucose scale.
1802863|NCT00608075|Drug|lithium|600 mg - 1800 mg per day
1802864|NCT00608075|Drug|Lithium|600 - 1800 mg
1802865|NCT00608088|Behavioral|Usual Care|"The usual care group will received standard care from the Johns Hopkins Hospital lactation consultant and nurses, which may have included a visit in the hospital by the lactation consultant if mothers delivered Monday through Friday. The lactation consultant was also available by request. A warm-line was also standard. This was a telephone line that was connected to an answering machine; the lactation consultant checked this line once daily (Monday through Friday) and returned calls."
1802866|NCT00608088|Behavioral|Community Health Nurse/Peer Councelor Team|"Visits by a community health nurse/peer counselor team during the first six postpartum months. Based on prior research and experience, the team was developed to provide culturally relevant support and health-care education to low-income mothers, who were a high percentage of African American women. The goals of this team were to 1) increase the duration of breastfeeding while emphasizing ways to decrease fatigue, and decrease breast discomfort; 2) strengthen maternal competence with breastfeeding and commitment to breastfeeding; 3) provide parent education about the infant regarding breastfeeding; 4) provide/find social support needed for continued breastfeeding; and 5) foster linkages to community services that will facilitate the maintenance of breastfeeding.
The specific activities of the CHN/peer counselor team included hospital visitation after enrollment, home visiting during the first postpartum month, and telephone support throughout the first six postpartum months."
1802867|NCT00608101|Drug|Fludrocortisone|Oral Fludrocortisone 0.2 mg x 2 prior to each experimental period on Day 1
1802868|NCT00608101|Drug|Dexamethasone|Oral Dexamethasone 0.75 mg x 2 administered prior to each experimental period on Day 1
1802966|NCT00608894|Drug|LCP-Tacro (tacrolimus)|LCP-Tacro(tacrolimus)tablets starting at 2 mg once daily, then adjusted to achieve and maintain target whole blood tacrolimus levels of 3 - 6 ng/mL, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
1803054|NCT00609505|Other|Telemedicine|Telemedicine genetic counseling
1802870|NCT00608140|Procedure|Surgical mitral valvuloplasty with placement of annular ring (SMVR)|Participants will undergo open heart surgery to mechanically reduce mitral regurgitation (MR). A complete rigid or semi-rigid annular ring will be placed unless specifically contraindicated by intraoperative findings. The ring size will be between 24 mm and 27 mm in the anteroposterior diameter. Annular ring sutures will be placed circumferentially approximately 1 mm off the hinge point between the leaflet and the atrial tissue. The total number of sutures will vary between 4 and 7 sutures anteriorly, while 8 to 12 sutures will be utilized for the posterior segment of the annulus. Additional repair of the mitral apparatus itself will be based on intraoperative findings. Leaflet repair will be performed for significant prolapse. Submitral apparatus repair will be performed for ruptured or significantly elongated chordae as well as significant chordal tethering.
1802871|NCT00608140|Drug|Optimal medical therapy (OMT)|Optimal medical therapy can include, but is not limited to, any of the following treatment regimens: combination of vasodilator therapy and diuretics, nitrates and nifedipine, and beta-adrenergic blocker therapy.
1802872|NCT00608179|Drug|Glimepiride|Glimepiride (Amaryl) 4 mg oral dose during protocol, given once during each protocol.
1802873|NCT00608179|Drug|glyburide|Glyburide (Dia-Beta) 10 mg oral dose during protocol, given once during each protocol.
1802874|NCT00608179|Other|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure-120 minutes
1802875|NCT00608179|Other|glucose clamp|hypoglycemic glucose clamp procedure -120 minutes
1802876|NCT00608192|Behavioral|Testing, Education, & Counseling (TEC)|Trained research staff will provide a two-session HIV/hepatitis education class. Participants will also be offered serological testing for hepatitis A, B and C, and HIV (optional), and off-site referrals for vaccination and hepatitis care. The content of the TEC intervention is evidence based. The TEC condition is comparable to screening and education methods commonly used in many drug treatment settings. Those in the TEC intervention group who do not adhere to needed off site vaccinations will be offered on site vaccination 30 days after vaccination referral.
1802877|NCT00608192|Behavioral|Hepatitis Care Coordination (HCC)|HCC Participants will be offered serological testing and counseling for hepatitis A, B and C, and HIV (optional). HCC participants will be offered on-site hepatitis A and B combination vaccination at the methadone clinic. They will also receive a two-session HIV/hepatitis education class with Motivational Interviewing. In addition, participants will receive 6 months of weekly case management to facilitate entry into hepatitis care.
1802878|NCT00608205|Drug|cisplatin|Given IV
1802879|NCT00608205|Drug|fluorouracil|Given IV
1802880|NCT00608205|Radiation|radiation therapy|Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks
1802881|NCT00608218|Drug|Ciclesonide|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
1802882|NCT00608231|Drug|Dexmedetomidine Hydrochloride Infusion|Dexmedetomidine Hydrochloride Infusion(0.5-1.0 mg/kg)intravenous over 10 minutes with dose adjustment for goal Richmond Agitation and Sedation Scale of -1 During deep brain stimulator implantation surgery
1802883|NCT00608231|Drug|Normal Saline|Normal Saline intravenous over 10 minutes during deep brain stimulator implantation surgery
1802884|NCT00608244|Drug|LCP Tacro|"In the morning of Day 8 (after completing one week treatment with Prograf), all patients will be converted to LCP Tacro QD with a conversion ratio of 0.66-0.8.
LCP-Tacro will be administered for 14 Days with one fixed dose change allowed at Day 15. LCP-Tacro will be administered orally once daily in the morning, with an interval of 24 ± 1 h between doses.
Trough levels were to be maintained within predefined therapeutic ranges of 5 to 15 ng/mL."
1802885|NCT00608244|Drug|Prograf|Prograf will be administrated twice a day, per product labeling, with an interval of 12 ± 1 hours between the morning and evening doses. Patients will continue on the same dose on Day 0 through Day 7 to maintain target trough levels of 5-12 ng/mL.
1802886|NCT00608322|Drug|Inhaled nitric oxide|Inhaled nitric oxide, 40 parts per million, for six hours.
1802887|NCT00608322|Other|Sham inhaled nitric oxide|Sham inhaled nitric oxide administration, 0 parts per million, for six hours.
1802888|NCT00608335|Drug|Micafungin|IV
1802889|NCT00608348|Procedure|Hyperinsulinemic glucose clamp procedures|2 hours of either euglycemic or hypoglycemic glucose clamping
1802890|NCT00608348|Procedure|moderate exercise|90 minutes of moderate exercise with either hyperinsulinemia or euinsulinemia
1802891|NCT00608361|Drug|Dasatinib|Given PO
1802892|NCT00608361|Other|Pharmacological Study|Correlative studies
1802893|NCT00608374|Drug|chlorambucil|
1802894|NCT00608374|Drug|fludarabine phosphate|
1802895|NCT00608374|Procedure|quality-of-life assessment|
1802896|NCT00608387|Behavioral|Chronic disease management Web-based software|Participants will have access to remotely based medical providers through the use of the Web-based software.
1802897|NCT00608400|Dietary Supplement|Clarinol CLA|0, 1.5 or 3.0 g/d dietary conjugated linoleic acids glycerides for 4 months, capsule form
1802898|NCT00608426|Behavioral|Proactive Outreach with choice of telephone or in-person smoking cessation services|This group of participants is sent a recruitment letter, then receives a phone call to offer them their choice of smoking cessation services (either telephone care or in-person care).
1802899|NCT00608439|Drug|Centella asiatica selected triterpenes (CAST)|Drug provided to subjects in 60 mg capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52.
1802900|NCT00608439|Other|Placebo|"Placebo provided to subjects in 60 mg color-matched capsules. Dose escalation phase: subjects take 2 capsules/day for weeks 1-4, 3 capsules/day for weeks 4-8 and 4 capsules/day weeks 8-12. Subjects remain on highest tolerated dose from week 12 to 52."
1802901|NCT00608452|Other|Symptom Assessment Scale|"Memorial Symptom Assessment Scale
History and neurologic examination"
1802902|NCT00608465|Drug|Eplerenone|5 mg x 1 week followed by 10 mg x 9 weeks.
1802903|NCT00608465|Drug|Ramipril|Ramipril 5mg qd x 1 week f/b Ramipril qd x 9 weeks.
1802904|NCT00608491|Drug|Stepped pharmacologic care|Stepped care will provide treating physicians with guidelines for the intensification of diuretic therapy and the possible use of vasodilators and inotropes.
1802967|NCT00608894|Drug|Azathioprine|Azathioprine tablets 50 - 100 mg (approximately 1 mg/kg) once daily, plus prednisone 30 mg/day for one week, then 20 mg/day for one week, then 15 mg/day for two weeks, then 10 mg/day through Month 6.
1802905|NCT00608491|Device|Ultrafiltration|All loop diuretics will be discontinued. Treatment will involve slow continuous ultrafiltration until an optimal volume status has been achieved. Ultrafiltration therapy will be initiated after the placement of appropriate intravenous access and will continue until the participant's signs and symptoms of congestion have been optimized. Fluid status will be managed exclusively by ultrafiltration using the Aquadex system 100 (CHF Solutions, Inc.) according to the manufacturer's specifications. The use of vasodilators or inotropic agents will be prohibited unless deemed necessary for rescue therapy.
1802906|NCT00608517|Biological|anti-thymocyte globulin|Given IV
1802907|NCT00608517|Drug|cyclophosphamide|Given IV
1802908|NCT00608517|Drug|fludarabine phosphate|Given IV
1802909|NCT00608517|Drug|methylprednisolone|Given IV
1802910|NCT00608517|Radiation|total-body irradiation|Given daily for 1-4 days
1802911|NCT00608530|Behavioral|Cognitive behavioral therapy|Cognitive behavioral self-management skills training actively teaches techniques to evaluate and manage symptoms
1802912|NCT00608530|Behavioral|Rogerian psychotherapy|Rogerian therapy encourages self-identification of goals and solutions using a supportive but not didactic approach
1802913|NCT00608543|Drug|Aripiprazole|varied dose (5, 10, 15 mg qd) for 6 wks
1802914|NCT00608569|Drug|Lopinavir/ritonavir|Two tablets (200-mg lopinavir and 50 mg ritonavir in each tablet), taken orally twice daily
1802915|NCT00608569|Drug|Emtricitabine/Tenofovir disoproxil fumarate|200-mg emtricitabine and 300 mg tenofovir disoproxil fumarate in each tablet, taken orally once daily
1802916|NCT00608569|Drug|Tenofovir disoproxil fumarate|300-mg tablet taken orally once daily
1802917|NCT00608569|Drug|Zidovudine|300-mg tablet taken orally twice daily
1802918|NCT00608569|Drug|Emtricitabine|200-mg tablet taken orally once daily
1802919|NCT00608582|Device|Transcranial Magnetic Stimulation, Repetitive|10 rTMS treatments (90% of motor threshold, 20 minutes, at 1 Hz) to specific right hemisphere area of brain cortex; 5 days per week for 2 weeks at the Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; or at the Neurology Department, Hospital of the University of Pennsylvania, Philadelphia, PA.
1802920|NCT00608595|Drug|celecoxib|Will be administered orally 400 mg po BID starting 5 days prior to planned surgical resection.
1802921|NCT00608595|Genetic|gene expression analysis|not noted
1802922|NCT00608595|Genetic|protein expression analysis|Not noted
1802923|NCT00608595|Other|immunohistochemistry staining method|not noted
1802924|NCT00608595|Other|laboratory biomarker analysis|not noted
1802925|NCT00608595|Other|mass spectrometry|Not specified
1802926|NCT00608595|Procedure|biopsy|At the time of preoperative evaluation by surgeon as well as one week after administration of Celecoxib.
1802927|NCT00608595|Procedure|neoadjuvant therapy|not noted
1802928|NCT00608595|Procedure|therapeutic conventional surgery|not noted
1802929|NCT00608634|Drug|perillyl alcohol|Applied as topical cream
1802930|NCT00608634|Other|placebo|Applied as topical cream
1802931|NCT00608660|Other|acupuncture|staging acupuncture
1802932|NCT00608660|Other|acupuncture and moxibustion|staging acupuncture and moxibustion
1802933|NCT00608660|Other|electroacupuncture|staging electroacupuncture
1802934|NCT00608660|Other|acupuncture along yangming tendons|staging acupuncture along Yangming musculature
1802935|NCT00608660|Other|acupuncture|non-staging acupuncture
1802936|NCT00608673|Drug|Pimecrolimus 1% cream|a very thin coat of pimecrolimus 1% cream, twice daily topically to the facial lesions of discoid lupus erythematosus
1802937|NCT00608673|Drug|betamethasone valerate 0.1% cream|A very thin coat of betamethasone valerate 0.1% cream, twice daily to facial lesions of discoid lupus erythematosus for 8 weeks.
1802938|NCT00608686|Dietary Supplement|Pregnenolone|30mg of pregnenolone administered orally, once, at 2 of 5 study visits.
1802939|NCT00608699|Drug|GSK256073A tablets + IR niacin tablets|single dosing for 4 to 5 sessions
1802940|NCT00608712|Drug|Esomeprazole|Esomeprazole 20mg oral tablet
1802941|NCT00608725|Radiation|DAXOR|131-I-Human Serum Albumin Blood Volume Assessment Kit
1802942|NCT00608725|Procedure|QSweat|Quantitative Sweat Testing
1802943|NCT00608725|Drug|Intrinsic Heart Rate|Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
1802944|NCT00608738|Other|informational intervention|
1802945|NCT00608738|Other|medical chart review|
1802946|NCT00608738|Other|questionnaire administration|
1802947|NCT00608738|Procedure|assessment of therapy complications|
1802948|NCT00608738|Procedure|management of therapy complications|
1802949|NCT00608751|Radiation|IMRT|
1802950|NCT00608777|Drug|Calcipotriene/betamethasone|One application to affected areas, once a day for two weeks. The PI may choose to extend treatment until Week 4 if necessary.
1802951|NCT00608790|Drug|Salbutamol|Prophylactic salbutamol administered at a dose of 200 micrograms by metered dose inhaler (MDI) via a spacer.
1802952|NCT00608790|Drug|Sodium chloride 5%|30 ml sterile hypertonic saline solution (sodium chloride 5%) will be administered by jet nebulisation for 15-20 minutes.
1802953|NCT00608803|Drug|ZIO-201-T and doxorubicin|ZIO-201-T given for 3 consecutive days every 3 weeks. Doxorubicin is given once every 3 weeks. This is a dose escalation arm.
1802954|NCT00608816|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during a two hour experimental period on Day 2
1802955|NCT00608816|Drug|epinephrine|Epinephrine 0.06 µg/kg/min infusion during two hour experimental period on Day 2
1802956|NCT00608829|Device|GORE TAG® Thoracic Endoprosthesis|Implant
1802957|NCT00608842|Drug|Deoxycholic Acid Injection|Administered via intralipomal injection.
1802958|NCT00608842|Drug|Placebo|Matching vehicle placebo administered via intralipomal injection.
1802959|NCT00608855|Other|questionnaire administration|
1802960|NCT00608855|Procedure|cryosurgery|
1802961|NCT00608855|Procedure|pain therapy|
1802962|NCT00608855|Procedure|quality-of-life assessment|
1802963|NCT00608868|Drug|Gefitinib|Gefitinib tablet 250mg once daily orally
1802964|NCT00608881|Drug|coenzyme Q10|4 - 300 mg CoQ chewable wafers taken orally twice a day
1802965|NCT00608881|Other|placebo|an inactive substance
1802969|NCT00608907|Drug|bortezomib, rifampicin|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, rifampicin 600 mg once daily days 4 to 10 in cycle 3
1802970|NCT00608907|Drug|bortezomib, dexamethasone|bortezomib 1.3 mg/m^2 on days 1, 4, 8, 11 over a 21-day treatment cycle, dexamethasone 40 mg once daily days 1 to 4, and 9 to 12 in cycle 3
1802971|NCT00608920|Other|Single Photon Emission Computed Tomography (SPECT)|
1802972|NCT00608933|Other|educational intervention|Health providers receive educational materials comprising a brief video about communicating with and providing guidance to patients regarding complimentary and alternative medicine (CAM) and a list of resources they can access to obtain information about herbs, CAM modalities, and drug/herb interactions. Approximately 2 weeks after the educational intervention, health providers receive a follow-up e-mail reminding them to ask patients about CAM use. The e-mail also includes a brief update regarding current research findings on CAM modalities and drug/herb interactions.
1802973|NCT00608933|Other|questionnaire administration|Patients complete questionnaires
1802974|NCT00608946|Dietary Supplement|copper|intake of copper orotate 8 mg per day per os, once daily for one year, vs. placebo under observation of the cognitive status
1802975|NCT00608946|Dietary Supplement|placebo|placebo
1802976|NCT00608959|Drug|omiganan 1% gel|"Omiganan 1% gel will be applied to 6 sites on the chest and/or abdomen.Swab cultures will be obtained at specified timepoints over a period of 3 days (Part1) or 7 days (Part 2).
In addition, subjects in Part 2 will have omiganan 1% gel applied to one intravenous (IV) catheter site."
1802977|NCT00608959|Drug|chlorhexidine 2% solution|"Part 1- chlorhexidine 2% solution will be applied to 6 sites on the chest and/or abdomen. All application sites will be covered with semi-transparent dressings.Swab cultures will be obtained at specific timepoints over a period of 3 days.
Part 2: Subjects in Part 2 will have chlorhexidine 2% solution applied to one intravenous (IV) catheter site only."
1957602|NCT02300142|Biological|GEN-003 Vaccine (30μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
1957603|NCT02300142|Biological|GEN-003 Vaccine (60μg of each antigen)|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
1957604|NCT02300142|Biological|Matrix-M2 Adjuvant (25μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
1802981|NCT00608985|Drug|almorexant|2 100 mg almorexant tablets and 1 placebo matching over-encapsulated zolpidem
1802982|NCT00608985|Drug|almorexant|1 100 mg almorexant tablet, 1 placebo matching almorexant tablet, and 1 placebo matching over-encapsulated zolpidem
1802983|NCT00608985|Drug|Placebo|2 placebo matching almorexant tablets and 1 placebo matching over-encapsulated zolpidem
1802984|NCT00608985|Drug|zolpidem|2 placebo matching almorexant tablets and 1 zolpidem 10 mg over-encapsulated
1802985|NCT00609011|Drug|MPC-6827 + Temozolomide|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Temozolomide at 85 mg/m2 administered orally daily for 21 days in a 4 week cycle.
1802986|NCT00609050|Behavioral|Self-Regulated Exercise with Telephone Reinforcement|The self-regulated exercise with telephone reinforcement group will engage in a three-times-a-week (or more) at home exercise regimen for 6 months during which they may choose the mode of exercise. They will receive weekly telephone calls about exercise and airway clearance. After 6 months, they will be instructed to maintain their self-regulated exercise activity for the remaining 6 months of the study, but they will not receive telephone calls
1802987|NCT00609050|Behavioral|Standard Treatment|The attention control group will receive standard recommendations for exercise activity, during the first 6 months, as is common in our clinic. Also during the first 6 months, they will receive weekly telephone calls about airway clearance. For the final 6 months of the study, the attention control group will cross over to self-regulated exercise without telephone reinforcement.
1802988|NCT00609050|Behavioral|Qualitative Approach|A qualitative naturalistic approach is nested within the primary experimental framework to explore the experiences of the children and parents, in both groups, with the exercise regimen.
1802991|NCT00609089|Behavioral|CRAFT-T|The Community Reinforcement and Family Training for Treatment Retention and HIV Risk Reduction treatment (CRAFT-T) was be developed in phase 1 and 2 of the current study and consists of twelve manual-guided weekly one-hour individual sessions for the concerned significant other and 2 one hour sessions for the identified patient. The intervention also allows for up to two additional sessions (total of 14 visits) to help arrange re-entry into substance abuse treatment when needed. The identified patient receives this intervention in addition to the usual services at the drug treatment program (Maryhaven).
1802992|NCT00609089|Behavioral|Treatment as usual|Treatment as usual will be the normal course of treatment for concerned significant others (CSOs) in the outpatient department.
1802993|NCT00609102|Drug|Placebo|one capsule BID
1802994|NCT00609102|Drug|n-aceylcysteine|450 mgm BID
1802995|NCT00609115|Device|AMES device|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed within the 6 month anniversary date of the subject's stroke.
1802996|NCT00609115|Device|AMES device (sham)|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session to provide thirty minutes of the placebo form of AMES therapy.
1802997|NCT00609115|Device|AMES device|Eighteen treatment sessions for each qualifying subject limb using the AMES device. Each treatment session being 30 minutes long. Sessions to be scheduled preferable 2 to 3 times per week, with the 18 sessions to be completed as soon as possible after the completion of Arm C-1 Sham Comparator.
1802999|NCT00609141|Biological|cixutumumab|Given IV
1803000|NCT00609141|Other|pharmacological study|Correlative studies
1803001|NCT00609141|Other|laboratory biomarker analysis|Correlative studies
1803002|NCT00609154|Drug|glucagon like peptide-1|GLP-1 1 pmole/kg/min
1803003|NCT00609154|Drug|glucose control|glucose without GLP-1
1803004|NCT00609167|Drug|bortezomib|"First 33 patients: 1.3 mg/m^2 IV Days 1, 4, 8 & 11
Remaining 30 patients: 1.5 mg/m^2 IV Days 1, 8, 15 & 22"
1803005|NCT00609167|Drug|cyclophosphamide|300mg/m^2 PO days 1, 8, 15 & 22
1803006|NCT00609167|Drug|dexamethasone|"First 33 patients: 40 mg PO Days 1-4, 9-12, 17-20
Remaining 30 patients: 40 mg PO Days 1-4, 9-12, 17-20 for cycles 1-2; Days 1, 8, 15, 22 for cycle 3+2 for cycle 3 and beyond"
1803007|NCT00609180|Behavioral|Minimal (Trophic) Feeding|Enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
1803008|NCT00609180|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
1803009|NCT00609180|Dietary Supplement|Omega-3 Fatty Acids and Antioxidant Supplements|Omega-3 fatty acids, GLA, and antioxidants will be administered through a feeding tube every 12 hours as a 120-cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
1803010|NCT00609180|Dietary Supplement|Placebo|The study placebo will be administered through a feeding tube every 12 hours as a 120 cc bolus. Dosing will continue for 21 days or until discontinuation of mechanical ventilation.
1803011|NCT00609193|Drug|lithium|standard clinical care
1803012|NCT00609193|Drug|quetiapine|standard clinical care
1803013|NCT00609219|Biological|autologous EBV specific CTLs|"30-40cc of peripheral blood will be used to generate EBV specific CTLs
Group One:
Day 0 - 2 x 10^7 cells/m2 Day 14 - 2 x 10^7 cells/m2
Group Two:
Day 0 - 2 x 10^7 cells/m2 Day 14 - 1 x 10^8 cells/m2
Group Three:
Day 0 - 1 x 10^8 cells/m2 Day 14 - 2 x 10^8 cells/m2"
1803014|NCT00609245|Drug|Valproic Acid|The investigators will utilize intravenous sodium valproate at visit 3. Dosage will be individualized to each patient's body weight, age, and hepatic-enzyme-inducing status. Intravenous VPA dose predictions will be based upon population VPA pharmacokinetic parameters (Dutta 2003).
1803015|NCT00609245|Drug|Placebo|Each patient will have a placebo-infusion (with 0.9% NS or D5W) of 12-hour duration at visit 2.
1957605|NCT02300142|Biological|Matrix-M2 Adjuvant (50μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
1803021|NCT00609297|Other|medical chart review|The Research Nurse will conduct a chart review after the patient's death.
1803022|NCT00609297|Other|questionnaire administration|The questionnaires will be completed at the end of week 1, week 2 and week 4.
1803023|NCT00609297|Other|survey administration|Given to patient and caregivers throughout the study
1803024|NCT00609310|Dietary Supplement|Flavonoids|Nutritional Supplement: flavonoid mixture with 20 mg apigenin and 20 mg epigallocathechin gallate as tablets per day
1803025|NCT00609323|Drug|lidocaine and tetracaine cream 7%/7%|One treatment of up to 400 cm2 Cream applied for 60 minutes.
1803026|NCT00609323|Drug|Placebo|One treatment of up to 400 cm2 Cream applied for 60 minutes.
1803027|NCT00609336|Drug|gemcitabine hydrochloride|Given IV
1803028|NCT00609336|Drug|docetaxel|Given IV
1803029|NCT00609336|Drug|capecitabine|Given PO
1803030|NCT00609336|Radiation|intensity-modulated radiation therapy|Undergo IMRT
1803031|NCT00609336|Drug|oxaliplatin|Given IV
1803032|NCT00609336|Procedure|pancreatic surgical procedure|Undergo pancreaticoduodenectomy
1803033|NCT00609336|Procedure|therapeutic conventional surgery|Undergo therapeutic conventional surgery
1803034|NCT00609336|Other|laboratory biomarker analysis|Correlative studies
1803035|NCT00609349|Device|ETED, CPET, RHC|"exercise tricuspid echo doppler (ETED): allows the estimation of systolic pulmonary arterial pressure at exercise cardiopulmonary exercise test (CPET) allows to measures exercise capacity (peakVO2)
right heart catheterisation (RHC): is the gold standard for the measurement of pulmonary arterial pressure values"
1803036|NCT00609362|Drug|Rosiglitazone|one tablet of rosiglitazone 8 milligrams per day for 14 weeks
1803037|NCT00609362|Drug|Placebo pill|One encapsulated placebo pill a day for 14 weeks
1803038|NCT00609375|Drug|cefepime|Administration of cefepime in continuous infusion (3 Gr over 24 hours) for 7-14 days at the discretion of the investigator. Administration of saline solution 0.9%, 50-100 mL over 30 minutes every 8 hours.
1803039|NCT00609375|Drug|cefepime|Administration of cefepime in intermittent infusion (1 Gr over 30 minutes every 8 hours) for 7-14 days at the discretion of the investigator.Administration of saline solution 0.9%, 50-250 mL over 24 hours
1803040|NCT00609388|Drug|Tacrolimus|Immunosuppression, intraoperative intraportal infusion of 1ml Tacrolimus with a concentration of 20 ug/mL
1803041|NCT00609388|Other|Saline solution 0.9% (250mL)|intraoperative intraportal infusion of Saline solution 0.9% (250mL)
1803042|NCT00609401|Drug|Nexavar (Sorafenib)|400 mg bid
1803043|NCT00609401|Drug|IL-2|IL-2 3 MU per 5 day/week for 2 weeks every 4
1803044|NCT00609427|Behavioral|MEMO programme (Inst Universitaire de Geriatrie, Montreal)|8 weekly group training sessions in mnemonic strategies, administered by clinical psychologist.
1803045|NCT00609427|Behavioral|External memory aids training|8 weekly group sessions of training in the use of external memory aids, administered by clinical psychologist
1803046|NCT00609440|Other|physiotherapeutic treatment|At first, the patient was submitted to a conventional physiotherapeutic treatment and respiratory exercises; then, we gave emphasis to the motor development marks and to the march training; eventually, the kid was conducted to hydrotherapy.
1803047|NCT00609453|Behavioral|Brief Behavioral Activation Treatment for Depression|Weekly individual therapy sessions
1803048|NCT00609466|Drug|CG5503 IR|75mg IR 4 - 6 hourly Total: 72 hours
1803049|NCT00609466|Drug|Morphine|Morphine 30 mg IR 4 - 6 hourly Total: 72 hours
1803050|NCT00609466|Drug|Placebo|Placebo; 4 - 6 hourly; Total: 72 hours
1803051|NCT00609479|Procedure|Osteosynthesis|"Micronail osteosynthesis. A cast for the first 14 days, thereafter starting physiotherapy. Control at weeks 1,2,5,12.
Hoffmann-II-non-bridging osteosynthesis. Removal of device after 5 weeks. physiotherapy starts at 14 days. Control at weeks 1,2,5,12."
1803055|NCT00609505|Other|Face-to-Face|Face-to-face genetic counseling
1803056|NCT00609518|Drug|pemetrexed|500 mg/m^2 intravenous infusion on day 1 of each 21-day cycle. Number of Cycles: Until progression or to a maximum of 6 cycles.
1803057|NCT00609518|Dietary Supplement|Folic acid|350-1000 micrograms taken orally for at least 5 daily doses during the 7-day period prior to the first dose of pemetrexed then continues daily throughout treatment until 3 weeks after the last dose of pemetrexed.
1803058|NCT00609518|Dietary Supplement|Folic Acid|350-1000 micrograms taken orally for two consecutive daily doses of folic acid the day before and the day of the first dose of pemetrexed the continues throughout treatment and for 3 weeks after the last dose of pemetrexed.
1803059|NCT00609518|Dietary Supplement|Vitamin B12|1000 micrograms intramuscular injection of vitamin B12 during the week prior to the first dose of pemetrexed then further injections given approximately every 9 weeks until 3 weeks after the last dose of pemetrexed.
1803060|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day the day before, the day of, and the day after the first day of pemetrexed. Continue to give dexamethasone twice per day the day before, the day of, and the day after each dose of pemetrexed.
1803061|NCT00609518|Drug|dexamethasone|4 mg taken orally [or equivalent] twice per day on the day of the first dose of pemetrexed. Continue to give dexamethasone twice per day on the day of each dose of pemetrexed.
1803062|NCT00609531|Drug|Citalopram|Pill, 5-20mg once a day for twelve weeks
1803063|NCT00609531|Drug|Placebo|Placebo pill once a day for twelve weeks
1803064|NCT00609544|Drug|Rilonacept|Loading dose of 320 mg Rilonacept or placebo followed by 160 mg Rilonacept or placebo once a week for 11 weeks
1803065|NCT00609557|Drug|duloxetine|Weeks 0-2 placebo Weeks 2-3 30mg duloxetine Weeks 3-4 60mg duloxetine Weeks 4-12 60-90mg duloxetine Week 13 30 mg duloxetine Week 14 stop
1803066|NCT00609570|Dietary Supplement|NanoGreens|fruits and vegetables
1803067|NCT00609570|Dietary Supplement|Whey protein|Whey
1803068|NCT00609570|Dietary Supplement|Calcium pills|CA
1803069|NCT00609596|Drug|GI198745|
1957606|NCT02300142|Biological|Matrix-M2 Adjuvant (75μg)|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
1803072|NCT00609622|Drug|sunitinib|Sunitinib: 37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2).
1803073|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
1803074|NCT00609622|Drug|bevacizumab|Bevacizumab: 5 mg/kg, IV infusion, every 2 weeks.
1803075|NCT00609622|Drug|mFOLFOX6|FOLFOX will be administered every 2 weeks, using the modified FOLFOX6 (mFOLFOX6) regimen, consisting of: - oxaliplatin 85 mg/ m^2 + leucovorin 400 mg/ m^2 (or 200 mg/ m^2 levo-leucovorin) as a 2-hr IV infusion followed by 5-fluorouracil 400 mg/ m^2 IV bolus on day 1 and 5-fluorouracil 2400 mg/ m^2 IV infusion over 46 hours on Days 1 and 2 of each 2 week cycle
1803076|NCT00609648|Behavioral|Computer Assisted Relaxation Learning|A self-paced computer program for reducing dental injection fear.
1803077|NCT00609648|Behavioral|Pamphlet|A pamphlet reassuring patients about dental injections.
1803078|NCT00609674|Drug|Fluticasone furoate nasal spray|Fluticasone furoate nasal spray
1803079|NCT00609674|Drug|Placebo|Placebo
1803080|NCT00609687|Procedure|Diagnostic Vitrectomy|"Three-port, 20-gauge pars plana vitrectomy instrumentation was utilized. An infusion line was inserted into one sclerotomy and secured to the globe. A second sclerotomy was made, and a fiberoptic light pipe was immediately inserted to minimize vitreous egress. A third sclerotomy was created, and the vitreous cutter was inserted. To obtain an undiluted vitreous sample, the vitreous was cut mechanically with the vitreous cutter, while the assistant surgeon simultaneously manually aspirated the vitreous. After sufficient undiluted sample was obtained, infusion fluid was allowed to enter the eye and a diluted vitreous sample was obtained in a similar manner. The samples were personally carried to the clinical laboratories by the operating surgeon.
Vitreous fluid analysis was guided by clinical suspicion based on the pre-operative differential diagnosis and the intraoperative posterior segment appearance."
1803081|NCT00609713|Behavioral|Comprehensive behavioral weight control program|Participants will meet weekly for 12 weeks, then every other week for 12 weeks, and once a month thereafter through week 52. Adolescents and parents will receive manuals that provide lessons and homework assignments for each meeting. The program for the first 22 weeks includes the following topics: 1) the causes of obesity; 2) components of healthy nutrition; 3) self-monitoring of calories, physical activity, and inactivity; 4) stimulus control procedures; 5) coping with high-risk social or psychological situations that trigger excess eating; 6) increasing physical activity; and 7) minimizing inactivity. At each session, participants will submit their self-monitoring diaries and completed homework. Incentives for completion of self-monitoring tasks are an integral part of the behavior modification program and a small gift certificate will be given to subjects for successful completion at each intervention session.
1803082|NCT00609713|Other|Individual 12-month nutrition education program|The other half of the participants (44 subjects) will be randomized to this arm of the intervention (usual care), which will also start in five waves. In contrast to the comprehensive behavioral weight control program, the nutrition education program will take place through individual appointments with a clinical dietician to reflect usual care and mimic the present approach used for the treatment of obese adolescents at the Children's Hospital of Philadelphia (CHOP) Nutrition Consultation. Parents will be required to take part in the consultations. The first consultation will last 60 minutes and the following consultations of 30 minutes will take place once a month for the first six months, then every other month for the second six months, as is the usual practice in our clinical setting.
1803120|NCT00609869|Drug|Lenalidomide|Lenalidomide was administered orally with escalating doses on 28-days cycles. The first cycle was administered with a starting dose of 2.5 mg daily on days 1-7, 5mg on days 8-14 and 10 mg on days 15-21, followed by seven days off. On cycle 2 and beyond lenalidomide was administered at 20 mg daily on days 1-21.
1803083|NCT00609739|Drug|cyclosporine|Patients will receive CSA therapy beginning on day -3, with a taper commencing on day +60 (unless GVHD) and ending on day +90. For patients >40 kg with normal renal function (creatinine <1.3 mg/dL), the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg, the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
1803084|NCT00609739|Drug|cytarabine|3000 mg/m^2 intravenously (IV) over 2 hours x 2 (i.e. total 6000 mg/m^2/day) on days -9 through -4.
1803085|NCT00609739|Drug|filgrastim|Patients with absolute neutrophil count (ANC) <0.2 x 10^8/L on day 21 may receive G-CSF at 5 mcg/kg/day. G-CSF will be continued until ANC ≥2.5 x 10^8/L for two consecutive days. As the malignant cell population of JMML is known to be hypersensitive to GM-CSF, this cytokine will not be given to these patients.
1803086|NCT00609739|Drug|methotrexate|MTX will be administered to recipients of non-genotypically identical BMT. MTX will be administered at a dose of 15 mg/m^2 (based on adjusted ideal body weight) intravenously (IV) on day +1 and at a dose of 10 mg/m^2 IV on days +3, +6, and +11.
1803087|NCT00609739|Drug|methylprednisolone|Recipients of UCB will receive methylprednisolone 2 mg/kg/day from day +5 to +19 at a dose of 1 mg/kg twice a day (bid) with a 10% taper every week thereafter.
1803088|NCT00609739|Drug|mitoxantrone hydrochloride|10 mg/m^2 over 30 minutes intravenously (IV) on days -9 through -7.
1803089|NCT00609739|Procedure|allogeneic bone marrow transplantation|Donor marrow will be collected in the usual sterile manner with a collection goal of 2.0 >10^8/kg recipient weight. Infused on Day 0.
1803090|NCT00609739|Procedure|umbilical cord blood transplantation|Umbilical cord blood (UCB) will be cryopreserved prior to transplantation. Cord blood units will be selected for transplantation according to current University of Minnesota Department of Blood and Marrow Transplantation Guidelines.
1803091|NCT00609739|Drug|Cis-Retinoic acid|Post-Transplant Cis-Retinoic Acid (CRA) Therapy - CRA will be given at a dosage of 100 mg/m^2/day by mouth in a single daily dose starting on day +60 and continuing until 1 year after transplant.
1803092|NCT00609752|Drug|prednisolone|Standard treatment regimens based on body weight will be used (approximately 2 mg per kg), with a stepwise dose reduction over a 10-14 week period.
1803093|NCT00609752|Dietary Supplement|Alicalm (polymeric liquid formula)|"Subjects will receive all of their nutritional requirements in the form of a nutritionally balanced polymeric feed, volume based on EAR for age. Duration of 5 to 8 weeks with subjects returning to a normal unrestricted diet by 10 weeks."
1803094|NCT00609765|Drug|Avastin|Every 28 Days: Avastin 5mg/kg iv days 1 and 15
1803095|NCT00609765|Drug|Fluorouracil|Every 28 Days: Fluorouracil 400mg/m^2 iv bolus daily days 1-5
1803096|NCT00609765|Drug|Doxorubicin|Every 28 Days: Doxorubicin 40mg/m^2 iv bolus day 1
1803097|NCT00609765|Drug|Streptozocin|Every 28 Days: Streptozocin 400mg/m2 iv bolus daily days 1-5
1803098|NCT00609765|Drug|Dexamethasone|Premedication: Dexamethasone 20mg intravenously days 1-5
1803099|NCT00609765|Drug|Ondansetron|Premedication: Ondansetron 16mg intravenously days 1-5
1803100|NCT00609778|Device|LUCAS|Mechanical chest compression
1803101|NCT00609778|Other|Conventional manual resuscitation method|Manual compression
1803102|NCT00609791|Drug|paclitaxel albumin-stabilized nanoparticle formulation|100 mg/m2 3 weeks on 1 week off
1803103|NCT00609791|Other|pharmacological study|Cycle 1, week 1 at 0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 24 and 48 hours
1803104|NCT00609791|Other|physiologic testing|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
1803105|NCT00609791|Other|questionnaire administration|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
1803106|NCT00609791|Other|study of socioeconomic and demographic variables|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
1803107|NCT00609791|Procedure|cognitive assessment|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
1803108|NCT00609791|Procedure|psychosocial assessment and care|Prior to treatment, at the end of 2 cycles of therapy and upon completion of therapy
1803109|NCT00609804|Drug|Sorafenib|Sorafenib 400 mg twice daily by mouth Study treatment will be given in cycles of 28 days. Patients will be re-staged every 2 treatment cycles (every 8 weeks). Patients with an objective response or stable disease will continue study treatment. Patients will continue until disease progression or intolerable toxicity occurs.
1803110|NCT00609804|Drug|Erlotinib|Erlotinib 150 mg once daily by mouth
1803111|NCT00609817|Drug|GCS-100|GCS-100 160mg/m2 IV (in the vein) on Study Days 1, 4, 8 and 11 for up to 12 consecutive 21-day treatment cycles. Three patients will be assigned to each cohort until maximum tolerated dose is reached. The dose levels: 1) 160 mg/m2; 2) 210 mg/m2; 3) 280 mg/m2; 4) 370 mg/m2
1803112|NCT00609817|Drug|Bortezomib/Dexamethasone|Bortezomid 1.3 mg/m2 and dexamethasone 20 mg/day plus an additional 20 mg of dexamethasone on the day following each of the GCS-100/bortezomib and dexamethasone dosing. GCS-100/bortezomib and dexamethasone dosed on Study Days 1, 4, 8 and 11 of each 21-day cycle after disease progression is noted.
1803113|NCT00609830|Behavioral|Tailored Materials|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participants' stage of change with respect to each behavior.
1803114|NCT00609830|Behavioral|Tailored Materials Plus Physician Feedback|Participants received written educational materials concerning each behavior targeted. The materials were tailored to the participant's stage of change with respect to each behavior. In additon, the participant's physician received information concerning the participant's status on each behavior targeted.
1803115|NCT00609830|Behavioral|Generic Materials|Participants received generic written educational materials about osteoporosis prevention.
1803116|NCT00609830|Behavioral|No Information|Participants received no informational materials.
1803117|NCT00609843|Other|Lipiodol demarcation of the bladder tumour|1-3 drops of Lipiodol Ultra Fluid (iodine 38%W/W) will be injected into the submucosa on 4 locations around the bladder tumour. The procedure is done once during a planned cystoscopy approximately a week before the planning CT.
1803118|NCT00609856|Drug|pioglitazone|tablet, 30 mg, once daily, 26 weeks
1803119|NCT00609856|Drug|insulin glargine|subcutaneous injection, start dose 6-10 units, once daily, 26 weeks
1803171|NCT00609960|Drug|midazolam|midazolam
1803172|NCT00609973|Drug|Ciprofloxacin|Ciprofloxacin 500 mg oral bid for 6 months
1803173|NCT00609973|Drug|Placebo|Placebo bid for 6 months
1803121|NCT00609869|Drug|Rituximab|Rituximab was administered at 375 mg/m^2 intravenously on a weekly basis for the first cycle starting on day 15. Subsequent rituximab doses were administered on day one of cycle 2 and beyond, every 4 weeks. Doses were repeated on 28-day cycles until disease progression or unacceptable toxicity, but were planned for 12 cycles.
1803122|NCT00609882|Other|Nasal CPAP|"Infants randomized to the Standard nasal CPAP via bubble or ventilator support at levels of 4-8 cm H2O post extubation"
1803123|NCT00609882|Other|Humidified High Flow Nasal Cannula (HHFNC)|HHFNC
1803124|NCT00609895|Drug|INSULIN GLARGINE|
1803125|NCT00609908|Procedure|Split skin graft|After wound bed preparation the skin defect is covered with a skin transplant (split skin graft)
1803126|NCT00609908|Procedure|skin stretching device|after woundbed preparation the wound is primarily closed by aid of the skin stretching device
1803127|NCT00609908|Procedure|serial excision|as much scar as possible is excised, whereafter the wound is closed
1803128|NCT00609908|Procedure|skin stretching device|after the scar is excised, the wound is primarily closed by aid of the skin stretching device
1803129|NCT00609921|Drug|ARQ197|treatment
1803130|NCT00609934|Drug|Sorafenib|Dose level 1: sorafenib 200mg PO OD on Days 1-84 Dose level 2: sorafenib 400mg PO OD on Days 1-84
1803131|NCT00609934|Radiation|external beam radiotherapy|3000cGy in 10 fractions
1803132|NCT00609947|Device|Endeavor Zotarolimus-Eluting Coronary Stent|
1803133|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet (modified extended release)
1803134|NCT00603733|Drug|5-ASA (5-Aminosalicylate)|500 mg tablet
1803135|NCT00603746|Drug|GW685698X|GW685698X
1803136|NCT00603759|Drug|celecoxib|100 mg qid
1803137|NCT00603759|Drug|placebo|1 cap qid
1803138|NCT00603772|Drug|Atralin (tretinoin) gel, 0.05%|Assess photoallergic reactions for tretinoin 0.05% and vehicle, measured as skin reactions following induction and challenge.
1803139|NCT00603785|Drug|Placebo|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (>30 and <700 IU/ml) will be randomized to receive placebo treatment for 6 months.
1803140|NCT00603785|Drug|Xolair|Subjects with chronic sinusitis and evidence of atopy and an elevated total IgE (>30 and <700 IU/ml) will be randomized to receive Xolair treatment for 6 months.
1803141|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
1803142|NCT00603798|Drug|Placebo cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
1803143|NCT00603798|Drug|Imiquimod cream|250 mg/packet, up to 2 packets applied daily for 2 treatment cycles. The first treatment cycle consisted of 3 weeks of daily treatment followed by 3 weeks of no treatment, and the second treatment cycle consisted of an additional 3 weeks of daily treatment followed by 8 weeks of no treatment.
1803144|NCT00603811|Biological|VAX102 [Flagellin.HuM2e]|dose ranging, 2 i.m. doses given 28 days apart
1803145|NCT00603811|Biological|Placebo|Placebo
1803146|NCT00603824|Drug|fondaparinux|fondaparinux subcutaneous injection once daily until INR stable in therapeutic range, at least five days: 5 mg if less than 50 kg, 7.5 mg if 50-100 kg, 10 mg if >100 kg
1803147|NCT00603824|Drug|argatroban or lepirudin|continuous infusion titrated into therapeutic range and for at least 5 days and until INR stable in therapeutic range
1803148|NCT00603837|Device|NeoWrap|This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.
1803149|NCT00603837|Device|InfaTherm|A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
1803150|NCT00603850|Device|ForeseeHome|human factor
1803151|NCT00603863|Biological|IMMU-107 (hPAM4)|90Y-hPAM4 once weekly for 3 weeks gemcitabine once weekly for 4 weeks
1803152|NCT00603876|Dietary Supplement|Almonds|100-110 grams (about 3/4 cupful)of almonds consumed daily for 28 days
1803153|NCT00603889|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
1803157|NCT00603915|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) day 1 and day 8
1803158|NCT00603915|Drug|Carboplatin/Cisplatin|Area under curve (AUC)=5 (Carboplatin) or 70mg/m^2 (Cisplatin) intravenous (IV) day 1
1803159|NCT00603915|Drug|erlotinib|150mg daily (post GC therapy)
1803160|NCT00603941|Drug|CS7017|At Phase 1, CS-7017 will be tested in combination with paclitaxel at the following dosage levels: 0.15, 0.25, 0.35, and 0.50mg BID. At Phase 2, CS-7017 will be administered at the RP2D. Commercially available paclitaxel will be administrated as IV infusion over 3 hours once every 3 weeks.
1803161|NCT00603941|Drug|Paclitaxel|
1803162|NCT00603954|Drug|Conditioning regimen TBI + Fludarabine|2 Gy TBI, Fludarabine 90 mg/m²
1803163|NCT00603954|Drug|Conditioning regimen II (TLI 8 Gy + ATG [Thymoglobulin])|TLI 8 Gy + ATG (Thymoglobulin) 7.5 mg/kg
1803164|NCT00603967|Procedure|Dual x-ray absorptiometry (DXA)|Baseline, 6 months, and 12 months
1803165|NCT00603967|Procedure|Blood draw|Baseline - genotyping Baseline, 6 months, and 12 months - markers of bone turnover and hormonal assays
1803166|NCT00603967|Behavioral|Questionnaire|"Menopausal symptom questionnaire - baseline, 3 months, 6 months, 12 months
Cognitive tests - baseline, 6 months, 12 months
Depression assessment - baseline, 6 months, 12 months
Dietary calcium intake questionnaire - baseline"
1803170|NCT00609960|Behavioral|clowns present|clowns present during the proccess of induction of anesthesia
1803174|NCT00609986|Drug|insulin|"The intravenous regular insulin infusion will be delivered continuously during the transplant surgery and after surgery for a total of three days. While receiving the insulin infusion, the dose will be calculated to keep the blood sugar levels between 70-110 mg/dL.
After the regular insulin infusion is discontinued, the blood sugar levels will be measured by a finger stick blood glucose up to 5-6 times per day and the blood sugar levels will be corrected by a subcutaneous basal-bolus insulin injection for a blood sugar goal 70-110 mg/dL.
Upon discharge from the hospital, the patient will be placed on a basal-bolus regimen consisting of 3-4 insulin injections to maintain a blood sugar between 70-140."
1803175|NCT00609986|Drug|NPH Insulin or glargine insulin and aspartame insulin|"The NPH or glargine and aspartame insulin will be given subcutaneously using a small-short needle to administer the insulin.
The blood sugar level will be checked every 1 hour while in the operating room and treated with rapid-acting insulin as needed to keep the blood sugar levels 70-180 mg/dL. The blood sugar level will be checked every 4 hours when in the recovery room and on the 6 East transplant unit. Once the patient is able to eat, the blood sugar will be checked five times a day (before meals, at bedtime, and at 3:00 am). Long-acting and rapid-acting insulin will be used to maintain the target blood sugar level.
Upon discharge from the hospital, the patient will be placed on a minimum of one to two insulin injections to maintain a blood sugar between 90-180 mg/dL"
1803176|NCT00609999|Drug|Erlotinib and Dasatinib|You will begin study drug regimen on day 1 of cycle 1 w Dasatinib. If you are undergoing Dasatinib pharmacokinetic blood analysis, Dasatinib will be taken alone until initial PK assessments are collected. Erlotinib will be begin after initial Dasatinib PK assessments are collected & will continue to be administered w Dasatinib on continuous daily dosing schedule. Initial Dasatinib PK assessments will be collected over 24hrs between days 3-7 of cycle 1 & at end of cycle 1. If you are not undergoing Dasatinib PK collections you will begin both Dasatinib & Erlotinib together on day 1 of cycle 1. Both drugs will be given in continuous daily oral manner. Cycle is defined as Dasatinib & Erlotinib given daily for 28 days for purpose of scheduling evaluations.
1803177|NCT00610025|Procedure|Transgastric access to the abdomen|Upper endoscopy, gastrotomy created with a needle knife followed by lower endoscopy.
1803178|NCT00610038|Drug|glibenclamide|Switching the patients from subcutaneous insulin to oral glibenclamide therapy
1803179|NCT00610051|Drug|Alprostadil|central venous access continuous delivery with 2.5ng/kg/min
1803180|NCT00610064|Radiation|Baseline neuroimaging|Baseline neuroimaging using PET and MRI of the brain in patients before sacral neuromodulation
1803181|NCT00610064|Radiation|Neuroimaging during sacral neuromodulation|Neuroimaging during sacral neuromodulation using PET
1803182|NCT00610077|Drug|Letrozole|Tablet Letrozole 2.5 mg once a day for 5 days for 3 cycles
1803183|NCT00610077|Drug|Clomiphene citrate|Clomiphene citrate 100 mg or 150 mg once a day for 5 days in 3 cycles
1803184|NCT00610090|Device|UniFit AAA Stent Graft|Endovascular repair of Abdominal Aortic Aneurysms
1803185|NCT00610103|Drug|apomorphine hydrochloride|Apomorphine hydrochloride (started at 1 mg and titrated to a maximum of 6 mg) is subcutaneously administered.
1803186|NCT00610116|Device|Electronic Repositioning|Change of pacing vectors for CRT pacing
1803187|NCT00610129|Drug|MK-0646|MK-0646 (20 mg/mL) in sterilized solution for IV infusion (12.7 mL to deliver 12.0 mL) will be used for a dose of 10 mg/kg IV weekly administered over 60 minutes.
1803188|NCT00610142|Drug|pimecrolimus 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
1803189|NCT00610142|Drug|hydrocortison 1% cream|twice a day one fingertip at a 2 times 2 cm2 area of uninvolved skin on the lateral forehead for 4 weeks
1803190|NCT00610155|Drug|Placebo|BID
1803191|NCT00610155|Drug|Pregabalin|Dose 75 mg titrated to 150 mg, bid
1803192|NCT00610155|Drug|Tramadol SR|Dose 50mg titrated to 200 mg, bid
1803193|NCT00610168|Biological|Boostrix TM|Single booster dose of vaccine
1803194|NCT00610181|Procedure|MRI|MRI of both breasts, results used for surgery, then MRI repeated in 1 year as part of routine follow-up after surgery.
1803195|NCT00610194|Drug|RDEA119|In the dose escalation phase, subjects will receive a single oral dose of RDEA119 on Day 1, wait 1 week, then begin a 28-day course of daily continuous dosing of RDEA119. In the expanded MTD phase, subjects will receive RDEA119 once or twice a day beginning on Day 1, and begin a 28-day course of continuous dosing at that time.
1803196|NCT00610207|Device|Surgisis Biodesign Anal Fistula Plug (SurgiSIS AFP)|Surgical placement of the Surgisis AFP is performed under general anesthesia
1803199|NCT00610233|Procedure|deep brain stimulation ON|deep brain stimulation in the ON state
1803200|NCT00610233|Procedure|Deep brain stimulation OFF|Urodynamic investigation with deep brain stimulation in the OFF state
1803201|NCT00610246|Drug|Sorafenib|Sorafenib orally for one week prior to radiation, then concomitantly for two weeks with radiation and then for one week following completion of radiation. Each anatomic cohort will dose escalate independently. Dose level 1 is 200mg of sorafenib. If full oral dose (400mg orally, twice a day) is reached in a given cohort then an additional dose level will open where sorafenib treatment is extended following radiation for a total of eight weeks.
1803202|NCT00610259|Behavioral|brief behavioral therapy for insomnia (bBT-I)|4 50-minute individual sessions every week for 4 weeks
1803203|NCT00610259|Other|Treatment as usual (TAU)|The psychiatrist-in-charge sees the patient once every 2 weeks for approximately 10 minutes each to monitor pharmacotherapy.
1803204|NCT00610272|Radiation|Radiotherapy|4 Gy single fraction; mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
1803205|NCT00610272|Radiation|Radiotherapy|8 Gy single fraction, mandate first retreatment if moderate or severe pain persists or recurs (as measured by categorical pain scale or VAS greater than 50 mm), >4 weeks after initial RT) retreat with 8 Gy single fraction; second retreatment is optional if moderate or severe pain recurs (as measured by categorical pain scale or VAS greater than 50 mm), retreat with 8 Gy after > 4 weeks
1803433|NCT00612612|Biological|rituximab|Given IV
1803206|NCT00610272|Radiation|Radiotherapy|8 Gy in a single fraction; retreatments > 4 weeks, using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy) ; second reirradiation with 8 Gy using local RT fields optional (at discretion of PI);
1803207|NCT00610272|Radiation|Radiotherapy|12 Gy in 4 fractions of 3 Gy in 2 consecutive days interfraction interval of a minimum of 6 hrs; retreatments > 4 weeks using local RT fields to sites of residual or recurrent, moderate or severe pain with a single fraction of 8 Gy); second reirradiation with 8 Gy using local RT fields optional (at discretion of PI) ;
1803208|NCT00610285|Other|Fabrication of thermoplastic face (The Orfit thermoplastic face mask system is routinely used for the treatment of brain and head)|Each patient in the protocol will receive their regularly scheduled SRS treatment plus an additional mock treatment using the non-invasive immobilization system.
1803209|NCT00611156|Dietary Supplement|ginger|added to a brunch meal
1803210|NCT00611156|Dietary Supplement|black pepper|Added to a brunch meal
1803211|NCT00611156|Dietary Supplement|horseradish|Added to a brunch meal
1803212|NCT00611156|Dietary Supplement|mustard|Added to a brunch meal
1803213|NCT00611156|Dietary Supplement|placebo|Added to a bruch meal
1803214|NCT00611169|Drug|tirofiban|tirofiban (25 μg/kg bolus and 0.15 μg/kg/min maintenance infusion for 24 hours)
1803215|NCT00611195|Drug|propofol, remifentanil|propofol 3micrgr/ml (TCI plasma concentration Kataria model) versus propofol 3micrgr/ml and remifentanil 0.05microgr/kg/min
1803216|NCT00611208|Biological|A-dmDT390-bisFv(UCHT1)|A-dmDT390-bisFv(UCHT1) will be administered as 60 μg/kg total given as 7.5 μg/kg/injection twice a day 4-6 hours apart for four consecutive days (days 1-4) into a free flowing IV over a period of approximately 15 minutes
1803217|NCT00611221|Procedure|Massage|Massage therapy by an RMT during labour
1803218|NCT00611221|Procedure|Massage|Massage by anyone else, eg. husband, nurse, doula
1803219|NCT00611247|Drug|Temozolomide|"Priming, Group 2 only, 100 mg/m2/day temozolomide.
Induction (both arms) 200 mg/m2/day temozolomide"
1803220|NCT00611260|Behavioral|Vipassana Meditation practice and instruction|2-3 instructed meditation sessions per week in addition to standard medical care.
1803221|NCT00611260|Other|Standard Medical Care|Standard medical care for patients with congestive heart failure plus implanted cardiac defibrillators.
1803222|NCT00611273|Device|GFX|The GFX system employs minimally invasive technique utilizing Bi-polar (radio frequency) RF technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
1803223|NCT00611286|Drug|clopidogrel treatment after bare metal stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of bare metal stent
1803224|NCT00611286|Drug|clopidogrel treatment after bare metal stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 1 month after BMS implantation.
1803225|NCT00611286|Drug|clopidogrel after zotarolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of zotarolimus-eluting stent coronary implantation
1803226|NCT00611286|Drug|clopidogrel after paclitaxel-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of paclitaxel-eluting stent
1803227|NCT00611286|Drug|clopidogrel after everolimus-eluting stent implantation|extending use of clopidogrel on top of aspirin up to 24 months after coronary implantation of Everolimus-eluting stent
1803228|NCT00611286|Drug|clopidogrel after zotarolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
1803229|NCT00611286|Drug|clopidogrel after paclitaxel-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
1803230|NCT00611286|Drug|clopidogrel after everolimus-eluting stent implantation|Adding clopidogrel on top of Aspirin according to the practice suggested by Italian national institute of health, i.e. 6 month after DES implantation.
1803231|NCT00611299|Dietary Supplement|BB-12 and CRL 431|
1803232|NCT00611312|Behavioral|Cognitive Training|Intense cognitive training, two consecutive weeks, each weekday, 6 hours/day
1803233|NCT00611325|Drug|Avastin|Avastin was administered intravenously at the dose 15 mg/kg every 3 weeks.
1803234|NCT00611325|Drug|Bortezomib|Bortezomib was administered on days 1, 4, 8, 11, 22, 25, 29, & 32 of a 42-day cycle. Bortezomib was 1.7 mg/m2 for patients not taking EIAEDs & 2.5 mg/m2 for patients taking EIAEDs.
1803235|NCT00611338|Behavioral|HIV Skills-based Prevention|
1803236|NCT00611351|Biological|anti-thymocyte globulin|
1803237|NCT00611351|Drug|busulfan|
1803238|NCT00611351|Drug|cyclophosphamide|
1803239|NCT00611351|Drug|mycophenolate mofetil|
1803240|NCT00611351|Drug|tacrolimus|
1803241|NCT00611351|Genetic|polymerase chain reaction|
1803242|NCT00611351|Genetic|polymorphism analysis|
1803243|NCT00611351|Other|flow cytometry|
1803244|NCT00611351|Other|laboratory biomarker analysis|
1803245|NCT00611351|Other|pharmacogenomic studies|
1803246|NCT00611351|Other|pharmacological study|
1803247|NCT00611351|Procedure|allogeneic bone marrow transplantation|
1803248|NCT00611351|Procedure|allogeneic hematopoietic stem cell transplantation|
1803249|NCT00611351|Procedure|peripheral blood stem cell transplantation|
1803250|NCT00611364|Other|Physical Therapy and education meetings|Physical therapy was realized three two times per week and education meeting every fifteen days
1803251|NCT00611364|Other|education meetings|This group only participed of education meeting (every fifteen days)
1803252|NCT00611390|Dietary Supplement|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the larynx.
1803253|NCT00611390|Dietary Supplement|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the larynx.
1803254|NCT00611403|Drug|Cyclosporine Ophthalmic Emulsion 0.05% (RESTASIS®)|Cyclosporine Ophthalmic Emulsion 0.05% administered twice daily in each eye for 6 months following LASIK surgery
1803434|NCT00612612|Other|laboratory biomarker analysis|Correlative study
1803255|NCT00611403|Drug|Artificial Tears REFRESH ENDURA®|REFRESH ENDURA® administered twice daily in each eye for 6 months following LASIK surgery
1803256|NCT00611416|Dietary Supplement|green tea|different catechin combinations
1803257|NCT00611416|Dietary Supplement|Mix of catechins and caffeine|3 tablet a day
1803258|NCT00611416|Dietary Supplement|EGCG|3 tablets a day
1803259|NCT00611416|Dietary Supplement|EGC|3 tablets a day
1803260|NCT00611416|Dietary Supplement|Caffeine|3 tablets a day
1803261|NCT00611416|Dietary Supplement|Placebo|3 tablets a day
1803262|NCT00611429|Behavioral|Counseling sessions|The individual counseling sessions will last 60 minutes and will involve discussion about health care options and information on the latest advances in HIV treatment.
1803263|NCT00611429|Behavioral|Group workshop|During the 3-hour group workshop, doctors, nurses, and case managers will talk to participants about HIV treatments and what it is like to undergo treatment. Participants will also hear from other people with HIV and their experiences with treatment.
1803264|NCT00611442|Drug|lubiprostone|lubiprostone 24mcg gelcap, 1 gelcap taken at noon the day prior to the colonoscopy
1803265|NCT00611442|Drug|placebo|placebo gelcap, taken at noon the day prior to the colonoscopy
1803266|NCT00611455|Drug|ofatumumab|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two 700mg IV infusions taken 14 days apart. A total of 8 infusions cycles given over a 144 week period
1803267|NCT00611455|Drug|Placebo|1000 mL dilution of 35ml of ofatumumab in sterile, pyrogen free 0.9% NaCl. Each Treatment Cycle consisting of two IV infusions taken 14 days apart. Only one placebo treatment cycle provided over a 24 week period
1803268|NCT00611468|Drug|Topotecan|All subjects receive treatment with intravenous topotecan and oral erlotinib.
1803269|NCT00611468|Drug|Erlotinib|All subjects receive treatment with intravenous topotecan and oral erlotinib.
1803270|NCT00611481|Behavioral|Tai Chi|a set of pre-designed Tai Chi Movements
1803271|NCT00611481|Behavioral|Strength training|Lower-extremity strength training exercises
1803272|NCT00611481|Behavioral|Low-Impact Exercise Control|a set of chair-based low-impact exercises
1803273|NCT00611494|Drug|MMF|Gradual optimization of drug dosage, as clinically tolerated.
1803274|NCT00611494|Drug|EC-MPS|Conversion from MMF to EC-MPS. Gradual optimization of drug dosage, as clinically tolerated.
1803275|NCT00611507|Drug|Oxaliplatin, 5-Fluorouracil|5FU 500 mg/m² per week in IV bolus infusion during 30 min AF 20mg/m²/week in infusion, during 10-20 minutes prior 5FU infusion; Eloxatin 85 mg/m² as IV infusion 2-6 hours, every 2 weeks. Three weeks of treatment, one week rest.
1803276|NCT00611533|Drug|atomoxetine|Subjects will receive ATX 40mg/d x 1 week, then 80mg/d x 5 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
1803277|NCT00611533|Drug|placebo|Subjects will receive placebo equivalent for 6 weeks followed by a 4-week wash out period that is followed by an additional 6 weeks of treatment in the alternate condition. The 4-week washout period include a 4-day taper in the first week.
1803278|NCT00611546|Other|Photo-protection|Parenteral solutions are protected from day light using aluminum covers
1803279|NCT00611546|Other|Photo-exposure|Perenteral nutrition bottles and tubings are allowed to be exposed to day light.
1803280|NCT00611559|Biological|Infanrix™ penta|Subjects received a booster dose
1803281|NCT00611559|Biological|Infanrix™ hexa|Subjects received a booster dose
1803282|NCT00611572|Drug|iomazenil|Given as IV infusion
1803283|NCT00611572|Drug|iomazenil|saline IV infusion
1803284|NCT00611585|Device|Birmingham Hip Resurfacing|Hip resurfacing system: single use device for hybrid fixation in patients requiring primary hip resurfacing arthroplasty
1803285|NCT00611598|Other|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
1803286|NCT00611598|Other|Blood draw and Questionnaires|Pt will have three green top tubes of blood drawn. The questionnaire will be filled out by the study subject. This may be completed at home and mailed in a provided stamped addressed envelope if the patient prefer, or obtained by phone interview with a research assistant.
1803287|NCT00611611|Biological|fluzone|once
1803288|NCT00611611|Biological|pneumovax|once
1803289|NCT00611624|Radiation|Mammosite brachytherapy radiation|Treatment using MammoSite will begin within five days of placement of the catheter. Only high dose rate (HDR) with Ir-192 treatment is allowed. The balloon will remain inflated throughout the treatment course. A total of 34 Gy will be prescribed to an approximate 1 cm radial distance from the balloon surface. Two fractions per day, each of 3.4 Gy, separated by at least 6 hours, given on 5 treatment days (over a period of 5 to 10 days), will sum to 10 fractions and 34 Gy.
1803290|NCT00611637|Biological|CMV pp65 Specific T Cells|Donor derived CMV pp65 specific T cells (1 x 105 CD3+ cells/kg (maximum 1 x 107 CD3+ cells) will be infused into recipient over 10 minutes.
1803291|NCT00611650|Drug|defined green tea catechin extract|Given orally
1803292|NCT00611650|Other|placebo|Given orally
1803293|NCT00611663|Biological|Prevenar® and Pneumo23®|Vaccination with conjugate vaccine Prevenar® (WYETH-LEDERLE)at week 0 and Poly Saccharidic vaccine Pneumo23® (Sanofi Pasteur MSD) after 6 months (W24)versus2)
1803294|NCT00611663|Biological|Placebo, Pneumo23®|Vaccination with placebo at W0 and Poly Saccharidic vaccine Pneumo23® at W24
1803295|NCT00611676|Drug|Venlafaxine|Weeks 0-2: placebo. Weeks 2-3: 75 mg Venlafaxine. Weeks 3-4: 150 mg Venlafaxine. Weeks 4-12: 150-225 mg Venlafaxine.
1803333|NCT00611910|Device|biodegradable-polymer-based sirolimus-eluting stent|due to randomization a rapamycin-eluting stent with biodegradable polymer will be implanted
1803334|NCT00611910|Device|bare metal stents|Due to randomization one bare-metal stent will be implanted. The decision about the stent type will be up to the interventionalist
1803335|NCT00611923|Drug|Flutamide|Participants will take one 125-mg flutamide capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
1803435|NCT00612625|Drug|glucagon-like peptide-1|continuous infusion of GLP-1 (1½ pmol/kg/min)
1803296|NCT00611689|Drug|Imatinib and PTK/ZK222584|Imatinib and PTK/ZK will each be administered orally daily. Two dose levels of imatinib (400 mg and 600 mg) will be tested with 4 dose levels of PTK/ZK (250 mg, 500 mg, 750 mg, and 1000 mg). 3 patients will be accrued at each individual dose level. If dose-limiting toxicities are reported in ≤ 1/3 patients, the dose level will be expanded to 6 patients. If dose-limiting toxicities are reported in < 2/6 patients, then dose escalation will continue. If ≥ 2/6 patients experience dose-limiting toxicity, the next lower dose will be considered the maximum tolerated dose and will be expanded to a total of 12 patients. There will be no intrapatient dose escalations. Patients may continue to receive treatment until unacceptable toxicity or disease progression is encountered.
1803297|NCT00611702|Procedure|Kidney biopsy|Kidney biopsy (recipients only) will be obtained for RT-PCR, microarray analyses and histology.
1803298|NCT00611715|Drug|erlotinib hydrochloride|OSI-774 150 mg/day
1803299|NCT00611715|Drug|letrozole|Letrozole 2.5 mg/day
1803300|NCT00611715|Genetic|fluorescence in situ hybridization|To determine HER2 gene amplification or excess copies of the HER2 gene
1803301|NCT00611715|Other|immunohistochemistry staining method|to measure the epidermal growth factor receptors (EGFR)
1803302|NCT00611715|Other|laboratory biomarker analysis|To determine if specific biomarkers exhibit a longer time to tumor progression after treatment with the study drugs
1803303|NCT00611728|Drug|SU011248 & Irinotecan|"Sutent given in daily oral manner for 1st 4 wks of each 6wk cycle. You will not take any Sutent during last 14 days of each 6 wk cycle. CPT-11 will be given intravenously over 1 & 1/2 hrs on 1st day of each cycle & then again on days 14 & 28.
Sutent is approved for adult subjects w some forms of kidney cancer. It is considered investigational for brain tumors. Dosing will begin on day 1 of cycle 1 & continue daily for 4 wks by mouth.
Irinotecan is approved for adult subjects with some forms of colorectal cancer. It is also considered investigational for brain tumors. Irinotecan dose will depend on your height & weight. Irinotecan will be given intravenously over 90 min on days 1, 14 & 28 of 6wk cycle.
You will be seen in clinic approximately every 42 days for 1st 3 cycles of study drug, & then every other cycle thereafter. Your brain MRI examination will be done within 1 wk prior to completion of cycles 1-3, & then within 1 week prior to completion of every other cycle."
1803304|NCT00611741|Drug|furosemide, Na supplements|furosemide 20 mg, Na supplements 8g in divided doses/day for 5 days
1803305|NCT00611754|Drug|Oxaliplatin, 5-FU|Oxaliplatin: 130 mg/m² in 500 mL of 5% glucose solution as a 2-hour intravenous (IV) infusion on Day 1 and repeated every 3 weeks; 5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 toDay 4, every 3 weeks.Dose adjustments were made if the patient experienced AEs.
1803306|NCT00611767|Drug|Thiopental|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
1803307|NCT00611767|Drug|Placebo|A 2-day test design involving 2 conditions: saline (Placebo) or Thiopental 1.5mg/kg (loading) with a subsequent infusion rate of 40 mcg/kg/minute (60 minute infusion).
1803308|NCT00611780|Radiation|tube voltage|standard 120 kV
1803309|NCT00611780|Radiation|tube voltage|reduced voltage of 100 kV
1803310|NCT00611793|Drug|PTK787/ZK222584 and Bevacizumab|PTK787/ZK222584 will be administered as a single agent orally on days 1-14 of cycle 1. The day 14 dose of PTK787/ZK222584 will be administered in the outpatient clinic and PK samples will be obtained. On Day 15 the patient will receive the initial dose of IV bevacizumab and PTK787/ZK222584. Bevacizumab will be repeated at 2 week intervals in patients with stable disease or better for four cycles of treatment (16 weeks). After four treatment cycles, only patients with a PR or CR will continue treatment with PTK787/ZK222584 and bevacizumab. Patients with stable disease may continue single agent PTK787/ZK22258 from cycle 5 onward. Protocol treatment will continue until disease progression or intolerable toxicity warrants drug discontinuation.
1803311|NCT00611806|Dietary Supplement|Folic Acid|Folic acid 2mg po daily
1803312|NCT00611806|Dietary Supplement|B12|B12 400 micrograms po daily
1803313|NCT00611806|Other|Placebo|1 capsule po daily
1803314|NCT00611819|Drug|Peg interferon + Ribavirin|Peg interferon 180 mcg/weekly Ribavirin 800 mg/daily during 24 weeks
1803315|NCT00611819|Drug|Peg interferon + Ribavirin|Peg interferon alpha 2a 180 mc/weekly Ribavirin 800 mg/daily during 48 weeks
1803316|NCT00611832|Behavioral|"Triple P Media Series -- Standard Information-Only version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors.
1803317|NCT00611832|Behavioral|"Triple P Media Series -- Enhanced Behavior Activation version"|10 episodes, 12 minutes per episode, 2 episodes viewed per week for a total of 5 weeks. Demonstrates parenting practices for effectively handling a range of difficult child behaviors; includes specific content elements designed to promote parents' adoption of the targeted parenting skills
1803318|NCT00611845|Drug|Aprotinin (Trasylol, BAYA0128)|Trasylol at either 1,000,000 KIU or 2,000,000 KIU
1803319|NCT00611858|Drug|Cetuximab|Given once a week for 9 weeks
1803320|NCT00611858|Drug|5-Fluorouracil|Given by continuous infusion for weeks 4 through 9
1803321|NCT00611858|Radiation|External Beam Pelvis Radiation Therapy|Monday through Friday beginning after the 2nd sigmoidoscopy and biopsy is completed
1803322|NCT00611871|Drug|Propranolol|40mg propranolol, followed 2 hrs after with 60mg propranolol, immediately following memory recollection
1803323|NCT00611871|Drug|Placebo|40mg placebo, followed 2 hrs after with 60mg placebo
1803324|NCT00611884|Drug|insulin glargine|Treat-to-target dose titration scheme, s.c. injection.
1803325|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, once daily
1803326|NCT00611884|Drug|insulin degludec|Formulation E: Treat-to-target dose titration scheme, s.c. injection, once daily
1803327|NCT00611884|Drug|insulin degludec|Formulation D: Treat-to-target dose titration scheme, s.c. injection, 3 times weekly
1803328|NCT00611884|Drug|metformin|Tablets, 1500-2000 mg/day
1803329|NCT00611897|Drug|N-acetylcysteine and ketamine|Active drug (N-acetylcysteine)
1803330|NCT00611897|Drug|placebo and ketamine|placebo N-acetylcysteine
1803331|NCT00611910|Device|sirolimus-eluting stent|due to randomization Cypher stent will be implanted
1803332|NCT00611910|Device|paclitaxel-eluting stent|due to randomization Taxus stent will be implanted
1803336|NCT00611923|Drug|Placebo|Participants will take a lactose capsule twice a day for two menstrual cycles. If a participant is unable to tolerate a twice-daily dose due to side effects, the dose will be reduced to one capsule per day.
1803337|NCT00611936|Drug|Placebo|Placebo
1803338|NCT00611936|Drug|Atomoxetine|20mg maximum of d-amphetamine
1803339|NCT00611949|Other|Geranium oil|2 applications of topical oil per week for 2 weeks
1803340|NCT00611962|Drug|Oxaliplatin, Paclitaxel|"Oxaliplatin was provided in clear glass vials sealed with a rubber stopper and an aluminum seal with a flip-off cover. Each vial contained 50 or 100 mg of active ingredient with 450 or 900 mg, respectively, of lactose monohydrate as excipient
Paclitaxel was supplied as single dose vials of 30 mg/5 mL or 100 mg/17 mL."
1803341|NCT00611975|Drug|Fluoxetine|Participants will begin taking 10 mg of fluoxetine, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 20 mg of fluoxetine once a day after 7 days, to be maintained until the luteal phase (start of ovulation) of menstrual cycle 3. If side effects are intolerable, the dose will be lowered to 10 mg of fluoxetine per day. Participants will undergo a total of 2 months of treatment with fluoxetine.
1803342|NCT00611975|Drug|Bupropion|Participants will begin taking 150 mg of bupropion, once a day by mouth, on the first day of their second menstrual cycle during the study. Dosage will be increased to 300 mg of bupropion once a day after 7 days, to be maintained until the luteal phase of menstrual cycle 3. If side effects are intolerable, the dose will be decreased to 150 mg of bupropion per day. Participants will undergo a total of 2 months of treatment with bupropion.
1803343|NCT00611988|Behavioral|Self-managed walking|The intervention includes individual therapy, group reinforcement, and follow-up phone contact
1803344|NCT00611988|Other|Control group|Attention control group will receive routine follow-up phone calls
1803345|NCT00612001|Biological|glioma-associated antigen peptide-pulsed autologous dendritic cell vaccine|
1803346|NCT00612014|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
1803347|NCT00612014|Drug|TZP-101|"40 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days"
1803348|NCT00612014|Drug|TZP-101|"80 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days"
1803349|NCT00612014|Drug|TZP-101|"160 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days"
1803350|NCT00612014|Drug|TZP-101|"320 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days"
1803351|NCT00612014|Drug|TZP-101|"600 micrograms/kg iv 2ml/minute for 30 minutes
1 infusion/day for 4 consecutive days"
1803352|NCT00612040|Drug|insulin degludec|Formulation 1: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
1803353|NCT00612040|Drug|insulin degludec|Formulation 2: Treat-to-target dose titration scheme, injection s.c. (under the skin), once daily
1803354|NCT00612040|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
1803355|NCT00612040|Drug|insulin aspart|Treat-to-target dose titration scheme, injection s.c. (under the skin), 3 times daily
1803356|NCT00612066|Drug|rosiglitazone maleate|
1803357|NCT00612079|Drug|Sertindole|oral 3 x 4mg
1803358|NCT00612079|Drug|Placebo|3 x 4mg Placebo
1803359|NCT00612092|Radiation|Spiral image acquisition|standard spiral scan protocol
1803360|NCT00612092|Radiation|sequential image acquisition|sequential CT scan protocol
1803361|NCT00612105|Drug|Retigabine|150mg/day up to 900mg/day
1803362|NCT00612105|Drug|Placebo|daily
1803365|NCT00612144|Drug|Glimepiride/metformin fixed combination|"Amaryl M 1/250mg~4/1000mg bid for 12~26 weeks
Maintenance dose for 10 weeks after 2~14 weeks of dose titration
Dose titration according to titration algorithm based on daily mean SMBG"
1803366|NCT00612144|Drug|Metformin HCl|"Metformin HCl 500mg~1250mg bid for 12~26 weeks
Maintenance dose for 10 weeks after 2~14 weeks of dose titration
Dose titration according to titration algorithm based on daily mean SMBG"
1803367|NCT00612157|Drug|Eszopiclone|Eszopiclone 3mg orally at bedtime for 14 nights
1803368|NCT00612157|Drug|Placebo control|Matching placebo
1803369|NCT00612170|Drug|[S,S]-Reboxetine|10 mg oral tablet once a day dosing
1803370|NCT00612170|Drug|Placebo|0 mg oral tablet once a day dosing
1803371|NCT00612170|Drug|[S,S]-Reboxetine|4 mg oral tablet once a day dosing
1803372|NCT00612170|Drug|[S,S]-Reboxetine|8 mg oral tablet once a day dosing
1803373|NCT00612183|Drug|bendamustine hydrochloride|bendamustine hydrochloride is administered by 60-min drip infusion at 120 mg/m2/day for 2 consecutive days, and the course is then observed for 19 days. This is one cycle and administration is repeated for 3 - 6 cycles. From the second cycle, the dose is reduced or administration is discontinued as required based on adverse events observed in the previous cycle or observation of the course.
1803374|NCT00612196|Drug|TB-402|Solution for infusion, 0.015ug/kg-1.8mg/kg, single dose, iv infusion over 30 minutes
1803375|NCT00612196|Drug|Placebo|
1803376|NCT00612209|Drug|ARQ 197|Treatment with ARQ 197
1803377|NCT00612222|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
1803378|NCT00612222|Biological|ALVAC MART-1 Vaccine|ALVAC vaccine-approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the MART-1 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2 mL). This will be repeated on day 14.
1803379|NCT00612222|Biological|aldesleukin|Aldesleukin - 720,000 IU/kg intravenous over 15 minutes every 8 hours beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses)
1803380|NCT00612222|Drug|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
1803381|NCT00612222|Drug|fludarabine phosphate|25 mg/m^2 day intravenous piggy back over 30 minutes for 5 days
1803436|NCT00612625|Drug|Saline|continuous infusion of saline
1803382|NCT00612248|Other|Splint|Patients in the study group received the splint on the day of the first evaluation and took it with them for use during activities of daily living and patients in the control group only used the splint during the evaluations
1803383|NCT00612261|Procedure|Arteriovenous Crossing Sheathotomy|In each sheathotomy patient, a standard pars plana vitrectomy is performed, followed by surgical separation of the posterior cortical vitreous from the optic nerve and posterior retina. After the relevant arteriovenous crossing site is identified based on preoperative FA, a bent microvitreoretinal blade is used to open the internal limiting membrane and the nerve fiber layer over the artery, with the incision commencing 100-200 micrometer proximal to the AV crossing. The incision is continued parallel to and under the retinal arteriole, with a gentle lifting motion, until the common AV crossing sheath is encountered and incised in a side-to-side manner. The completion of AV dissection is confirmed by an elevation of the overlying artery.
1803384|NCT00612261|Procedure|Intravitreal Triamcinolone Acetonide Injection|The IVTA group receive intravitreal injection of 4 mg/0.1 mL triamcinolone acetonide (40 mg/mL; Tamceton®; Hanall Pharmaceutical, Seoul, Korea). The injections are performed using 0.5% proparacaine drops (Alcaine®; Alcon Laboratories, Fort Worth, TX) for topical anesthesia under sterile conditions. The drug is injected through the inferotemporal pars plana using a 30-gauge needle. The correct intravitreal localization of the suspension, and perfusion of the optic nerve head, are then confirmed by indirect ophthalmoscopy.
1803385|NCT00612274|Drug|tacrolimus|Tacrolimus will be administered at a dose of .02mg/kg/d IVCI beginning day -3 until able to take oral medicines reliably. Blood levels will be maintained at 5-10 ng/ml. The oral dose will be 4 times the IV dose. Tacrolimus will be converted to oral dosing prior to hospital discharge. Tacrolimus will be continued until 4 months post transplant (day +120) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
1803386|NCT00612274|Drug|Sirolimus|Sirolimus will be administered as a 12 mg oral loading dose on day -3 followed by 4mg daily. Sirolimus levels will be obtained on day +0 and then at least twice weekly to maintain a trough serum level of 3-12 ng/ml. Sirolimus will be continued until 5 months post transplant (day +150) unless toxicity, refractory GVHD or the development of disease recurrence mandate discontinuation of the drug.
1803387|NCT00612274|Drug|Methotrexate|Methotrexate, dose #1 will be administered on day +1 post transplantation, as an IV bolus, provided at least 24 hours have elapsed following infusion of donor stem cells at a dose of 10mg/m2. Dose #2 of Methotrexate will be administered 48 hours later, as IV bolus on day +3 at a dose of 5mg/m2.
1803388|NCT00612287|Drug|buprenorphine|Sublingual buprenorphine; product name Suboxone® (buprenorphine/naloxone). Dosing is informed by a clinical guideline which permits flexibility dependent up physician's clinical judgment. During the induction period (Day 1, at the physician's office) the first dose is 2 mg and can be brought up to 20 mg depending on patient's response. On Day 2 going forward dose can range from 2 mg q8h to 12 mg q8h. Rescue doses with buprenorphine are also permitted.
1803389|NCT00612300|Behavioral|Lokomat - Physical therapy|A: Lokomat training, 30 minutes per day for 3 weeks, 5 days per week. B: Categorized gait training by physical therapist, 30 minutes per day for 3 weeks, 5 days per week
1803390|NCT00612300|Behavioral|Physical therapy - Lokomat|"B: Daily 30 minutes of gait training with a physical therapist, 5 days per week for 3 weeks.
A: Daily 30 minutes of Lokomat training, 5 days per week for 3 weeks."
1803391|NCT00612313|Drug|Fluoxetine|Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
1803392|NCT00612313|Behavioral|Relapse prevention cognitive behavioral therapy (CBT)|After the first 6 weeks of treatment with fluoxetine, some participants will be assigned to additionally receive relapse prevention CBT for the remaining 24 weeks of treatment. These participants will attend 10 to 12 CBT sessions, during which they will learn specific skills to reduce and prevent the occurrence of residual depressive symptoms.
1803393|NCT00612326|Procedure|MRI and PET scanning procedures|a CT scan, MRI, and C-11 Acetate PET scan. All these scans will be done as an outpatient. After you finish these scans, your doctor will schedule you for surgery to remove your bladder and lymph nodes.
1803394|NCT00612339|Drug|Avastin and Temozolomide|This is Phase II study with the combination of Avastin & Temozolomide for unresectable or multifocal WHO grade IV malignant glioma patients. Patients will receive up to 4 cycles of Avastin & Temozolomide . Avastin administered at 10 mg/kg every 14 days beginning minimum of 7 days after biopsy or 28 days after craniotomy. Temozolomide will be dosed at 200 mg/m2 daily x 5 days in 28-day cycle. Patients will have baseline MRI & repeat MRI every 4 weeks. If there is no evidence of disease progression after each cycle, or unacceptable toxicity, or as determined by investigators, patient non-compliance or patient withdraws consent to continue therapy & requests discontinuation, patients will receive up to 4 cycles of Avastin & Temozolomide, then proceed with standard XRT therapy, & future therapy after 4 cycles will be at discretion of patient & treating physicians.
1803395|NCT00612352|Drug|Ethanol High Dose, Ethanol Low Dose, and Placebo|Three test days will involve administration of placebo, ethanol high dose (BrAc=100mg%) or ethanol low dose (BrAc=40mg%)intravenously for approximately 20 minutes, until the target BrAc is achieved. Once BrAc is achieved (40mg% or 100mg%) it will be maintained using a clamp procedure for 60 minutes.
1803396|NCT00612378|Device|GFX System|The GFX system employs minimally invasive technique utilizing bi-polar radio frequency (RF) technology. GFX ablates nerves activating the muscles that cause glabellar furrowing.
1803397|NCT00612391|Procedure|Lateral minimally invasive approach (plate fixation)|A longitudinally oriented, 4-cm incision will be made laterally starting at the acromion. The deltoid will be split proximally at the most strategic location (vis-à-vis the fracture), and after the deltoid is bluntly elevated from the humerus more distally the axillary nerve will be identified by digital palpation. The nerve is easily identified posteriorly as it emerges from the quadrilateral space. With a finger maintained on the nerve for protection, the plate will be inserted onto the lateral side of the proximal humerus and fixed according to the described technique. A second, 2-cm longitudinal incision will then be made further distally for diaphyseal screw placement. This incision is well distal to the course of the axillary nerve.
1803428|NCT00612586|Drug|5-FU|400 mg/m2 bolus then 2400 mg/m2 IV over 46 hours, day 1 of 14 day cycle (up to 1 yr or until progressive disease)
1803429|NCT00612586|Drug|Bevacizumab|5 mg/kg IV, day 1 of 14 day cycle (up to 1 yr or until progressive disease)
1803430|NCT00612599|Drug|biphasic insulin aspart|
1803431|NCT00612612|Drug|obatoclax mesylate|Given IV
1803432|NCT00612612|Drug|fludarabine phosphate|Given IV
1803398|NCT00612391|Procedure|Deltopectoral approach (plate fixation)|Anterior, Delto-Pectoral Approach - A 10-cm incision will be made over the deltopectoral groove, starting at the coracoid process proximally. As the clavipectoral fascia is incised, the cephalic vein will be identified and retracted laterally with the deltoid muscle. The pectoralis major as well as the conjoint tendon will be retracted medially, and the long head of the biceps tendon will be identified and used as a guide for achieving an anatomic reduction of the different fracture parts. Next, internally rotating the humerus will allow access to the lateral side of the proximal humerus, on which the plate will then be fixed according to the described technique.
1803399|NCT00612417|Drug|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402|Administration of recombinant FVIII/placebo in healthy male subjects treated with TB-402
1803400|NCT00612430|Drug|Bevacizumab and Etoposide|32 pts w recurrent WHO grade III MG & 27 pts w recurrent WHO grade IV MG will be enrolled in this study. Estimated rate of accrual is 10 pts per month. The estimated date of study completion is 6-9 months from study initiation. Bevacizumab administered intravenously at dose 10 mg/kg every two weeks. If pt tolerates 1st bevacizumab dose, subsequent doses may be given by local oncologists under direct supervision of Duke investigators. Etoposide administered orally, once daily for 1st 21 days of each 28-day treatment cycle. Dose of Etoposide will be 50 mg/m2/day. The Duke investigators will review all la data & order treatment. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent.
1803403|NCT00612456|Drug|Pazopanib|Pazopanib eye drops formulation
1803404|NCT00612469|Drug|Sodium Fluoride|Topical application of 1.23% sodium fluoride to the dentition, every 24 hours, during 6 consecutive days
1803405|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 3% vancomycin hydrochloride to the dentition, every 24 hours, during 6 consecutive days
1803406|NCT00612469|Drug|vancomycin hydrochloride|Topical application of 10% vancomycin hydrochloride to the primary dentition, every 24 hours, during 6 consecutive days
1803407|NCT00612469|Drug|chlorhexidine digluconate|Topical application of 1% chlorhexidine digluconate to the dentition, every 24 hours, during 6 consecutive days
1803408|NCT00612482|Other|drug prevention curriculum|"Participants in the experimental arm of the study will receive the 5-lesson, science-based drug prevention curriculum in their science classes."
1803409|NCT00612495|Drug|oxaliplatin, 5 FU|"Oxaliplatin:130 mg/m² as a 2-hour intravenous (IV) infusion in 500 mL of 5% glucose solution on Day 1 and repeated every 3 weeks.
5-FU: following oxaliplatin administration, 1000 mg/m²/day as a continuous IV infusion from Day 1 to Day 4, repeated every 3 weeks."
1803410|NCT00612508|Drug|Desogen (ethinyl estradiol and desogestrel)|1 tablet every day; each tablet contains 0.15mg desogestrel and 0.03mg ethinyl estradiol
1803411|NCT00612508|Drug|NuvaRing (ethinyl estradiol and etonogestrel)|Place the ring in the vagina for 3 weeks, remove for one week. Repeat with new Ring
1803412|NCT00612521|Drug|Adenosine|For lesions in the left coronary system the patient will receive either 120 micrograms of adenosine in 20 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis. For lesions in the right coronary system the patient will receive either 60 micrograms of adenosine in 10 mls of normal saline or placebo prior to the wiring, pre-dilatation, stenting and post-dilatation of the target coronary stenosis.
1803413|NCT00612534|Drug|Sufentanil NanoTab|5 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
1803414|NCT00612534|Drug|Placebo NanoTab|Placebo NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
1803415|NCT00612534|Drug|Sufentanil NanoTab|10 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
1803416|NCT00612534|Drug|Sufentanil NanoTab|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
1803417|NCT00612547|Drug|Artesunate + Amodiaquine Fixed Dose Combination (CoArsucam)|"Tablet:
Children aged between 2 and 11 months: Artesunate 25 mg + Amodiaquine 67.5 mg et Children aged between 12 and 59 months: Artesunate 50 mg + Amodiaquine 135 mg Per os one intake per day/3 day"
1803421|NCT00612573|Drug|Doxycycline 0.6 mg/kg/day|doxycycline 40 mg/day, oral, 12 weeks
1803422|NCT00612573|Drug|Doxycycline 1.2 mg/kg/day|doxycycline 80 mg/day, 12 weeks
1803423|NCT00612573|Drug|Doxycycline 2.4 mg/kg/day|doxycycline 160 mg/day, 12 weeks
1803424|NCT00612573|Drug|Placebo|Placebo, 12 weeks
1803425|NCT00612586|Drug|Enzastaurin|1125 mg loading dose, then 250 mg twice daily, oral(up to 1 yr or until progressive disease)
1803426|NCT00612586|Drug|Placebo|oral, daily (up to 1 yr or until progressive disease)
1803427|NCT00612586|Drug|Leucovorin|400 mg/m2 IV, day 1 of 14 day cycle (up to 1 yr or until progressive disease)
1803437|NCT00612638|Drug|Temodar, O6-BG, and Irinotecan|2 separate strata accrued independently: Stratum 1-pts receiving Dilantin, Tegretol or phenobarbital. Stratum 2-pts on anti-convulsants other than Dilantin, Tegretol/phenobarbital/pts not on any anti-convulsants. O6-BG administered intravenously 120mg/m2, over 1hr, prior to administration of Temozolomide on day 1 of 21day cycle. O6-BG administered intravenously 30mg/m2/day, over 48hrs, immediately after completion of CPT-11 infusion on day 1 of 21-day cycle. Temozolomide administered orally 355mg/m2 within 60 mins of end of 1hr O6-BG infusion. Treatment cycles may be repeated every 3wks following dose of Temozolomide from previous cycle. CPT-11 administered intravenously in fasting state over 90mins. CPT-11 infusion will begin 1hr after Temozolomide administration. Initial doses 60mg/m2 for stratum 1 & 40mg/m2 for stratum2. Treatment cycles repeated every 3 wks following dose of CPT-11 from previous cycle.
1803438|NCT00612651|Drug|Temodar and SCH 66336|2 separate strata accrued independently: Stratum 1-pts receiving CYP3A4-inducing anticonvulsants. Stratum 2-pts on non CYP3A4-inducing anticonvulsants or pts not on any anti-convulsants. Each strata treated & escalated independent of each other. Temozolomide administered orally at dose of 150 mg/m2 daily for 5 days, at bedtime, for 1st cycle & escalated to 200 mg/m2 daily for 5 days, at bedtime during subsequent cycles if tolerated. Treatment cycles repeated every 4wks following doses of Temozolomide from previous cycle. SCH 66336 administered orally twice daily, approximately every 12hrs. Except as specifically noted, pts advised to take capsules wh morning & evening meals, with approximately 240ml of non-carbonated water. Initial doses will be 125mg BID for stratum 1 & 75mg BID for stratum2. Treatment cycles repeated every 4 wks following dose of Temozolomide from previous cycle.
1803439|NCT00612664|Drug|Anti-CD137 (4-1BB) (BMS-663513)|IV solution, IV, until PD or toxicity
1803440|NCT00612677|Drug|Oxaliplatin|Dose Regimen: 120 mg/m^2 on Days 1 every 21 days
1803441|NCT00612677|Drug|Pemetrexed|Dose Regimen: 500 mg/m^2 on Days 1 every 21 days
1803442|NCT00612690|Behavioral|Community mental health consultation model program|The community mental health consultation model program included collaboration among community mental health providers and (1) parent advocates to effectively maintain families in a school-based mental health program, (2) classroom teachers to enhance children's academic performance, and (3) peer-identified influential teachers to influence classroom teachers' use of behavior management strategies. This model further focused on the strongest teacher and parent predictors of student learning.
1803443|NCT00612690|Behavioral|Treatment as usual (TAU)|TAU included referral to community mental health clinic-based services, where participants received standard care for mental health-related problems.
1803444|NCT00612703|Drug|ARQ 197|Treatment with ARQ 197 in combination with erlotinib
1803445|NCT00612716|Drug|busulfan|For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.
1803446|NCT00612716|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.
1803447|NCT00612716|Biological|Stem cell infusion|Infused on Day 0
1803448|NCT00612716|Radiation|Total body irradiation|165 cGy morning and evening on days -4 through -1.
1803449|NCT00612729|Procedure|Polylens Y30 intraocular lens|cataract surgery
1803450|NCT00612729|Procedure|Orange Series Model PC 440 Y intraocular lens|cataract surgery
1803451|NCT00612742|Drug|testosterone gel|once daily transdermal testosterone gel, 300 mcg
1803452|NCT00612742|Drug|placebo gel|once daily transdermal placebo gel
1803453|NCT00612755|Drug|Peginterferon alfa-2a + ribavirin|Peginterferon alfa-2a 180 mcg/week ribavirin 1000-1200 mg/day during 24 weeks
1803455|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UY] YA-60BB)|implantation of a yellow Hoya AF-1 (UY) YA-60BB intraocular lens
1803456|NCT00612781|Procedure|cataract surgery (Hoya AF-1 [UV] VA-60BB lens)|implantation of an uncoloured Hoya AF-1 (UV) VA-60BB
1803457|NCT00612794|Drug|exenatide once weekly|subcutaneous injection, once weekly
1803458|NCT00612794|Drug|placebo|subcutaneous injection, once weekly
1803459|NCT00612807|Behavioral|Weekly marital therapy|Weekly marital therapy for 6 months.
1803460|NCT00612807|Drug|As indicated: Sertraline, bupropion, venlafaxine, mirtazepine, nortriptyline, tranylcypromine, lithium augmentation, etc.|"Study doctor may prescribe antidepressant medication for the treatment of depression. Medications will be prescribed according to empirically supported guidelines outlined in the Duke Somatic Treatment Algorithm for Geriatric Depression (STAGED Approach; Steffens, 2002).
SSRIs (daily dose of at least 20 mg for citalopram, 20 mg for fluoxetine, 100 mg for sertraline, 20 mg for paroxetine)
SNRIs (e.g., venlafaxine)
Bupropion SR (achieve dose of at least 150 mg BID)
Mirtazapine
Tricyclic antidepressants (nortriptyline with drug levels 80-120 ng/dl)
Lithium augmentation
MAOI (daily dose of at least 30 mg tranylcypromine or 45 mg of phenelzine)"
1803463|NCT00612833|Procedure|Vasectomy occlusion techniques|Cautery and excision with fascial interposition Cautery and excision without fascial interposition Ligation and excision with fascial interposition
1803464|NCT00612846|Procedure|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy|Endoscopic sphincterotomy and subsequent laparoscopic cholecystectomy
1803465|NCT00612846|Procedure|Laparoscopic bile duct exploration during cholecystectomy|Laparoscopic bile duct exploration during cholecystectomy
1803466|NCT00612859|Drug|levetiracetam|
1803467|NCT00612872|Drug|[123I]CLINDE|Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
1803468|NCT00612898|Drug|apricitabine|800mg BID apricitabine orally for 48 weeks
1803469|NCT00612898|Drug|lamivudine|150mg BID lamivudine orally for 48 weeks
1803470|NCT00612911|Other|Cell therapy|bone marrow mononuclear cell
1803473|NCT00612950|Drug|glucagon-like peptide-1,|GLP-1:continuous infusion of ½ pmol/kg/min for a total time of 120 minutes.
1803474|NCT00612950|Drug|glucose dependent insulinotropic polypeptide|continuous infusion of GIP (1½ pmol/kg/min) for 120 min.
1803475|NCT00612950|Drug|Saline|continuous infusion of Saline for 120 min
1803476|NCT00612963|Drug|Frio Oral Rinse|Prescription Mouth Rinse
1803477|NCT00612989|Drug|Temodar and O6-Benzylguanine|"O6-BG 120mg/m2 administered intravenously over 1 hr followed by continuous infusion of O6-BG at 30 mg/m2/day for 5 consecutive days. Every 48 hrs repeat dose of 120 mg/m2 over 1 hr administered for total of 3 doses.
Temodar administered orally, in fasting state within 60 minutes of end of 1st 1-hr infusion of O6-BG & then every 24 hrs during continuous infusion of O6-BG. Temodar administered on day 1 of treatment cycle & every 24 hrs thereafter for 5 days with treatment cycles repeated every 28 days.
Pts must fast for minimum of 1 hr prior to administration of each dose of Temodar & continue fasting 2 hrs after administration of each Temodar dose."
1803478|NCT00613002|Drug|testosterone gel|once daily transdermal testosterone gel, 300 mcg
1803479|NCT00613002|Drug|placebo gel|once daily transdermal placebo gel
1803480|NCT00613015|Drug|Guanfacine|
1803481|NCT00613015|Drug|Modafinil|
1803482|NCT00613015|Drug|Placebo|
1803483|NCT00613028|Drug|Temo + Avastin|Patients have progressed/had gr3/> toxicity related to etoposide, with no had progression/gr 3/> toxicity related to temozolomide, will only be considered for bevacizumab and temozolomide. Bevacizumab intravenously at dose 10mg/kg every other wk. For patients on bevacizumab and temozolomide, temozolomide administered on continuous dosing schedule at 50mg/m2/day.
1803484|NCT00613028|Drug|VP-16 + Avastin|Patients have progressed/had gr3/> toxicity related to temozolomide, but have not progressed/gr3/> toxicity related to etoposide,considered only for bevacizumab and etoposide. Bevacizumab intravenously at dose 10mg/kg every other wk. Patients on bevacizumab and etoposide, etoposide once daily at 50mg/m2/day first 21 days of each 28-day cycle.
1803485|NCT00613041|Procedure|CT Scan|All patients will undergo serial CT scans after 3 months, 6 months, 9 months, 12 months, 18 months, and 24 months as is standard care. Nodules are to be scanned at 2.5mm collimation / 1.25 mm reconstruction. This resolution is necessary for volume measurements of nodules less than 1cm in diameter.
1803486|NCT00613054|Drug|Zactima, Gleevec, Hydroxyurea|"Pts will start treatment on day 1 of cycle 1 w Zactima, imatinib mesylate & hydroxyurea. All 3 agents administered in continuous daily, oral manner. Imatinib mesylate dose 400 mg/day for pts not on EIAEDs & 1000 mg/day for pts on EIAEDs based on previous studies demonstrating that pts on EIAEDs require significantly higher doses of imatinib mesylate & that such doses are safe & well tolerated. Dose of hydroxyurea 500 mg twice day. Dose level of Zactima will be increased in successive cohorts of pts as described below.
Cohorts of 3-6 pts will accrue at each dose level until MTD is defined. Each cohort will consist of a mini of 3 newly enrolled pts. Intra-patient dose escalation is not permitted. Cohorts may be expanded at any dose level for further elaboration of safety & pharmacokinetic parameters as required.
Treatment cycle is defined as daily administration of Zactima + imatinib mesylate & hydroxyurea for 28 days for purpose of scheduling evaluations."
1803488|NCT00613080|Drug|capecitabine|1650 mg/m^2/day orally 5 days/week during radiotherapy.
1803489|NCT00613080|Drug|oxaliplatin|
1803490|NCT00613080|Procedure|resection|All patients undergo surgery 4 to 8 weeks following the completion of radiation therapy. The choice of procedure (abdominoperineal resection (APR), low anterior resection (LAR), or LAR/coloanal anastomosis) is at the discretion of the surgeon.
1803491|NCT00613080|Radiation|radiation therapy|Pelvic intensity modulated radiation therapy (IMRT): 45 Gy in 25 fx Three dimensional conformal radiation therapy (3D-CRT) boost: 5.4 Gy in 3 fx to total dose of 50.4 Gy in 28 fx
1803492|NCT00613080|Drug|FOLFOX|"Postoperative chemotherapy is administered to all patients who have a complete resection of rectal cancer with negative surgical margins and begins within 4-8 weeks following surgical resection, consisting of a total of 9 14-day cycles. Oxaliplatin 85 mg/m^2, IV over 2 hours, day 1.
Leucovorin 400 mg/m^2, IV over 2 hours, day 1. 5-fluorouracil bolus 400 mg/m^2, IV push, day 1. 5-fluorouracil infusion 2400 mg/m^2, IV continuous infusion over 46 hours, day 1."
1803493|NCT00613093|Drug|Temodar and O6-Benzylguanine (BG)|"Objectives of study are to define role of BG in restoring Temodar sensitivity in patients with Temodar-resistant malignant glioma and to further define the toxicity of combination therapy using Temodar + BG. 2 separate strata accrued independently of each other: Stratum 1-patients with glioblastoma multiforme (GBM). Stratum 2-patients with anaplastic glioma (AG).
BG at 120mg/m2 administered intravenously over 1 hour followed immediately by 48-hour infusion at 30mg/m2/24 hours. Temodar 472mg/m2 administered orally, in fasting state, within 60 minutes of end of the 1-hour administration of BG infusion. Treatment cycles may be repeated every 28 days following dose of Temodar from previous cycle."
1803494|NCT00613106|Drug|HZT-501|Ibuprofen 800mg/famotidine 26.6 mg administered orally 3 times daily for 2 weeks
1803495|NCT00613106|Drug|Ibuprofen|Ibuprofen 800mg administered orally 3 times daily for at least 28 weeks
1803496|NCT00613132|Drug|Gleevec, RAD001, and Hydroxyurea|Dose of Gleevec will be 400 mg in 1st cohort & will be increased to 600 mg po/day & then to 400 mg bid in successive cohorts. Prescribed dose should be administered orally, w large glass of water. Pts should not eat large or high fat meal within 1 hour before or after gleevec dosing. Doses of 600 mg or less should be administered once daily, whereas doses greater than 600 mg should be administered as equal doses twice day. It is recommended that pts take their prescribed Gleevec at same time that they take their prescribed RAD001 & hydroxyurea, however, 30-60 minute interval between agents is acceptable if required for practical or other compliance issues.
1803497|NCT00613145|Drug|Capecitabine and Sorafenib|"During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:
Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle."
1803498|NCT00613145|Drug|Capecitabine and Sorafenib|During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
1803499|NCT00613171|Drug|STI571|STI571 tablets taken orally once a day
1803502|NCT00613197|Drug|Epanova|4g/day in divided doses
1803503|NCT00613223|Drug|Vandetanib and Etoposide|Vandetanib will be given orally once day. Swallow tablet with 240 ml of non-carbonated water. Initial dose is 100 mg/day for stratum 1 & 200 mg/day for stratum 2. Etoposide will be taken by mouth in capsule form at a flat dose of 50 mg/day for 1st 21 days of 28-day cycle. You will not take etoposide for following 7 days of the cycle.
1803504|NCT00613249|Drug|Dapivirine Gel 4750, 0.05%, 2.5g|intravaginal gel, dosed daily
1803505|NCT00613249|Drug|Dapivirine Gel 4789, 0.05%, 2.5g|intravaginal gel, dosed daily
1803506|NCT00613249|Drug|HEC-based Placebo Gel|intravaginal gel, dosed daily
1803507|NCT00613262|Other|Narrow Band Imaging|Narrow Band Imaging Colonoscope offers an alternative lightsource to view colon polyps in real time
1803508|NCT00613275|Other|patient Navigation|Assigning a patient navigator to patients with abnormal breast and cervical cancer screening results at one of 6 affiliated community health centers
1803509|NCT00613288|Drug|Testosterone (Testogel), GnRH analog (Leuprorelide) and Placebo|"The trial is a double blinded, randomised cross-over study of 4 x 2 days with an interval of 1 month in between. 12 healthy young male participants will receive the GnRH-agonist leuprorelide 7,5 mg s.c. 3 weeks before examination on 3 occasions, and a fourth day without intervention.
The four days will include treatment on the examination day, Day 1 with:
Placebo (hypogonadism after leuprorelide injection)
Testosterone gel 50 mg applicated in the morning at 06.00 am (physiologic substitution - after leuprorelide injection).
Testosterone gel 150 mg applicated in the morning at 06.00 am (supra-physiologic substitution - after leuprorelide injection).
No treatment."
1803510|NCT00613327|Drug|Oxybutynin chloride OROS|Participants will receive oxybutynin chloride OROS tablet at starting dose of 10 milligram (mg) orally once daily. The dose will be adjusted by 10 mg every 2 weeks up to first 6 weeks, based on the criteria for evaluation of optimal dose. The optimal dose obtained in first 6 weeks will be continued up to Week 12. Maximum allowed dose will be 30 mg per day.
1803511|NCT00613340|Procedure|Cervical medial branch blocks|Cervical medial branch blocks done with 0.25 ml of local anesthetic and contrast
1803512|NCT00613340|Procedure|Cervical medial branch blocks|Cervical medial branch blocks with 0.5 ml of local anesthetic and contrast
1803513|NCT00613353|Other|Behavioral|Participants will be asked to wear an accelerometer
1803514|NCT00613366|Drug|Misoprostol|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
1803515|NCT00613366|Dietary Supplement|Magnesium Oxide|Place 2 tablets between the teeth and cheek and allow to dissolve for 30 minutes.
1803516|NCT00613379|Drug|PRO 140|10 mg/kg PRO 140, one IV dose (N=10)
1803517|NCT00613379|Drug|PRO 140|5 mg/kg PRO 140, one IV dose (N=10)
1803518|NCT00613379|Drug|Placebo|PBO, one IV dose (N=10)
1803519|NCT00613392|Dietary Supplement|powdered antioxidant|one vial mixed with water every day orally or through enteral tube
1803520|NCT00613392|Dietary Supplement|powdered cornstarch placebo|one vial mix with water and administer orally or via enteral tube
1803521|NCT00613405|Other|Stress + cue exposure|Trier Social Stress Task(TSST): subject is asked to give a talk and perform a math task in front of an audience, follwed by neutral and marijuana cue exposure.
1803522|NCT00613405|Other|No stress + cue exposure|Neutral and marijuana-associated cue exposure (scripted imagery, in vivo cues).
1803523|NCT00613418|Device|IDev SUPERA® Interwoven Self Expanding Nitinol Stent Peripheral Vascular System|Interwoven, self-expanding nitinol stent system, including delivery system and stent
1803524|NCT00613431|Drug|CS8080|CS-8080 tablets will be administered once daily at doses of 1, 3, 10, 20, 50 and 100 mg.
1803525|NCT00613431|Drug|Placebo|Some subjects will receive matching placebo instead of CS-8080.
1803526|NCT00613444|Device|LumaCare LC-122M non-coherent light source|Subjects will receive a series of up to 6 treatment sessions with a treatment interval of from approximately 1 to 4 weeks. In all cases, light treatment parameters will be within the guidelines normally used clinically for red-light non-coherrent light sources, and thus fluences used will not exceed 75 J/cm2.
1803527|NCT00613457|Drug|dexamethasone|10 mg/sqm/day from for 21 days
1803528|NCT00613457|Drug|asparaginase|native E-coli Asparaginase 5,000 IU/sqm x 8 doses
1803529|NCT00613457|Drug|Asparaginase|native E-Coli Asparaginase 10,000 IU/sqm x 4 doses
1803530|NCT00613457|Drug|cyclophosphamide|1,000 mg/sqm i.v. 2 doses in Induction phase 1000 mg/sqm i.v. 1 dose in Protocoll II 500 mg/sqm i.v. 1 dose in protocol III
1803531|NCT00613457|Drug|cytarabine|75 mg/sqm i.v.or s.c. 4 doses/week for 4 weeks in Induction phase 75 mg/sqm i.v.or s.c. 4 doses/week for 2 weeks in Protocol II and III
1803532|NCT00613457|Drug|daunorubicin|30 mg/sqm i.v. 4 doses in Induction phase
1803533|NCT00613457|Drug|doxorubicin|30 mg/sqm i.v. x 4 doses in Protocol II and III
1803534|NCT00613457|Drug|Etoposide|100 mg/sqm i.v. for 3 doses in HR block 3
1803535|NCT00613457|Drug|Ifosfamide|800 mg/sqm i.v.q12h x 5 in HR block 2
1803536|NCT00613457|Drug|mercaptopurine|60 mg/sqm p.o. c 28 days in Induction phase 60 mg/sqm p.o. x 56 days in Protocol M 50 mg/sqm daily in Maintenance phase
1803537|NCT00613457|Drug|Methotrexate|by age i.t. in Induction/Protocol M/Protocol II/Protocol III/HR Blocks and maintenance
1803538|NCT00613457|Drug|prednisone|60 mg/sqm daily p.o. for 28 days then tapered in Induction phase
1803539|NCT00613457|Drug|thioguanine|60 mg/sqm p.o. x 14 days in Protocol II and Protocol III
1803584|NCT00606905|Other|normal saline|equivalent volume of normal saline
1803540|NCT00613457|Drug|Vincristine|1.5 mg/sqm i.v. x 4 doses in Induction phase and Protocol II 1.5 mg/sqm i.v. x 2 doses in Protocol III and HR block 1
1803541|NCT00613457|Drug|Vindesine|3 mg/sqm i.v. x 2 doses in HR block 2
1803542|NCT00613470|Drug|citalopram and escitalopram|"escitalopram tablets starting at 10 mg, increase to 20 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5.
citalopram tablet or solution starting at 2o mg, increase to 40 mg at 4 weeks if QIDS-C16 > 5, keep at same dose if QIDS-C16 < 5."
1803543|NCT00613496|Drug|irbesartan|Irbesartan-tablet (150 mg) 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8 if no contraindication for up titration (investigator will decide on the basis of creatinin, urea and potassium after taking a blood sample) for 9 weeks.
1803544|NCT00613496|Drug|placebo|Placebo-tablet, 1 in the morning for 7 days, 2 tablets (1 in the morning and 1 in the evening) after day 8.
1803545|NCT00613509|Biological|ALVAC(2) Melanoma multi-antigen therapeutic vaccine|0.5 mL, 2 cycles
1803546|NCT00613509|Biological|Intron A, Interferon alpha -2b|0.5 mL, 5 times per week for 4 weeks
1803547|NCT00613522|Other|polygraphic study|"Berlin scale will be measured. A polygraphic study will be performed to subjects with a Berlin scale > 2.
Patients stroke characteristics will be recorded (initial severity, stroke mechanism) at baseline and stroke outcome will be evaluated at 3 months (stroke recurrence and functional outcome).
Controls will be evaluated at 3 months using a phone interview"
1803548|NCT00613535|Device|Mechanical debridement|Mechanical shaver will be used to remove large chondral flaps and loose fragments
1803549|NCT00613535|Device|Paragon T2|Use Paragon device to debride after removal of larger chondral lesion flaps with mechanical shaver.
1803550|NCT00613535|Procedure|Lavage debridement|Remove loose chondral fragments
1803551|NCT00613535|Device|Mechanical Debridement|Use of a mechanical device such as a shaver, punch, or biter to remove large chondral flaps and loose fragments
1803552|NCT00613535|Device|RF- based Debridement|Use of debridement device to remove large fragments followed by use of RF-based debridement to smooth the base of the shoulder of the tear.
1803553|NCT00613548|Procedure|CABG alone|CABG alone
1803554|NCT00613548|Procedure|CABG + Mitral repair|CABG + Mitral repair
1803555|NCT00613561|Drug|Fludarabine, Busulfan, and Anti-Thymocyte Globulin|Patients on this study will receive 5 days of Fludarabine, 1 day of Busulfan Test Dose, 2 Days of Busulfan Regimen Dose, and 4 days of Anti-Thymocyte Globulin
1803556|NCT00613574|Drug|tiotropium-bromide|Spiriva® inhaled capsule 18 mcg once daily administered via HandiHaler® on the top of usual care
1803557|NCT00613600|Dietary Supplement|Glucomannan|Two 665 mg capsules of glucomannan three times a day for 8 weeks
1803558|NCT00613600|Dietary Supplement|Inert microcrystalline cellulose|Two capsules of inert microcrystalline cellulose three times a day for eight weeks
1803559|NCT00613613|Drug|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
1803560|NCT00613613|Drug|fenofibrate|Fenofibrate 145mg tablets once daily for 4 weeks
1803561|NCT00613626|Drug|Cisplatin|Cisplatin 60 mg/m2 IV day 1 every 21 days for a total of 4 cycles
1803562|NCT00613626|Drug|Etoposide|Etoposide 120 mg/m2 IV days 1, 2, and 3 every 21 days for a total of 4 cycles
1803563|NCT00613626|Drug|Placebo|Matched placebo oral daily
1803564|NCT00613626|Drug|ZD6474|ZD6474 100mg oral daily to be continued for the duration of the study.
1803565|NCT00613652|Drug|AZD4877|10 mg IV (3 weeks treatment 1 week rest)
1803566|NCT00613665|Biological|helicobacter pylori vaccine|Experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
1803567|NCT00613665|Biological|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 month schedule (alum control was administered at 4 months), administered intramuscularly
1803568|NCT00613665|Biological|helicobacter pylori vaccine|Seven subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
1803569|NCT00613665|Biological|helicobacter pylori vaccine|Eight subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,4 month schedule (alum control was administered at 2 months), administered intramuscularly
1803570|NCT00613665|Biological|Placebo|Nine subjects, alum control (placebo comparator), 0,1,2,4 month schedule (served as control for arms 1-4), administered intramuscularly
1803571|NCT00613665|Biological|helicobacter pylori vaccine|Nine subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 10 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
1803572|NCT00613665|Biological|helicobacter pylori vaccine|Ten subjects, experimental H. pylori vaccine including NAP, CagA and VacA antigens (abbreviated HP3), 25 micrograms of each antigen, 0,1,2 week schedule, administered intramuscularly
1803573|NCT00606840|Behavioral|large changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
1803574|NCT00606840|Behavioral|small changes in eating and activity|Behavioral self-regulation interventions to prevent weight gain in young adults.
1803575|NCT00606853|Behavioral|Contingency Management|Rewards valued $1-$100 for abstinence or treatment attendance
1803576|NCT00606866|Drug|placebo|Placebo for four weeks
1803577|NCT00606866|Drug|Sorafenib|Sorafenib 200 mg twice daily
1803578|NCT00606866|Drug|Sorafenib|Sorafenib, 400 mg twice daily
1803579|NCT00606879|Drug|SGX523 Capsules|This is a dose escalation study
1803580|NCT00606892|Drug|Varenicline|Varenicline (1 mg per day) given for 4 days prior to laboratory session
1803581|NCT00606892|Drug|Placebo|Sugar Pill
1803582|NCT00606892|Drug|IV Nic|IV Nicotine given during the laboratory session following 4 days of exposure to the study medication (varenicline or placebo). This nicotine was given during each laboratory session which followed the 4 days of exposure to either placebo then varenicline or varenicline then placebo.
1803583|NCT00606905|Biological|Gamimune N or Gamunex 10%|500 mg/kg administered in the follicular phase of the menstrual cycle. With conception, infusions every four weeks until 18-20 weeks of gestation.
1803585|NCT00606931|Device|Stereo Navigator Accessory to PEM Flex PET Scanner|For patients with suspicious breast abnormalities seen on high resolution PET image, the patients will be biopsied using commercial vacuum biopsy devices (pre-validated to work with Stereo Navigator) using Naviscan's Stereo Navigator (interventional device) for PET image guidance.
1803586|NCT00606944|Behavioral|fast-track rehabilitation|fast-track rehabilitation with early ambulation and diet after elective colorectal resection
1803587|NCT00606957|Dietary Supplement|Vitamin D3 (cholecalciferol)|Vitamin D will be taken orally, 10,000 IU (0.25 mg) three times per week.
1803588|NCT00606970|Dietary Supplement|Seigen Alpha EV|Orally administered Seigen Alpha EV, 1 packet (6 grams)3 times daily, for maximum of 3 months. Each packet is clearly marked for breakfast, lunch, or supper. The contents are to be dissolved in water or liquid and taken orally with meal. Subjects will be required to return any unused packets to study doctor at end of each month.
1803589|NCT00606970|Dietary Supplement|Placebo Comparator|Identically packaged placebo packets (each 6 grams) taken 3x daily with meals for 3 months maximum.
1803590|NCT00606983|Drug|Tamsulosin|oral administration of Tamsulosin
1803591|NCT00606996|Behavioral|Group interpersonal psychotherapy (IPT-G)|
1803592|NCT00606996|Behavioral|Psychoeducation on co-occurring disorders (PSYCHOED)|
1803593|NCT00607009|Behavioral|ALIVE|email-based behavioral program
1957620|NCT02292771|Drug|Retosiban|Solution for infusion, consisting of a clear colorless solution of retosiban at a concentration of 15 milligram/milliliter (mg/mL) in 56% volume/volume ethanol/acetate buffer concentrate supplied in 5 mL vial containing 75mg retosiban.
1803595|NCT00607035|Drug|Olmesartan medoxomil ＋Azelnidipine|The ARB plus CCB combination therapy group is administered olmesartan 20 mg/day and azelnidipine 16 mg/day for 6 months.
1803596|NCT00607035|Drug|Olmesartan medoxomil + Hydrochlorothiazide|The ARB plus Diuretics combination therapy group is administered olmesartan medoxomil 20mg/day and hydrochlorothiazide 12.5mg/day for 6 months.
1803597|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 3 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
1803598|NCT00607048|Drug|Paclitaxel + Carboplatin + CP-870,893|Paclitaxel is administered intravenously on day 1 of a 21-day cycle at a dose of 175 mg/m^2. Carboplatin is administered intravenously on day 1 of a 21-day cycle at AUC 6. CP-870,893 is administered intravenously on DAY 8 of a 21-day cycle in escalating doses (0.1 mg/kg and 0.2 mg/kg)
1803599|NCT00607061|Procedure|Blood sample collection|Blood of the umbilical cord will be collected after delivery. A mother blood sample will be also collected in the few hours preceding delivery to determine glutathione and cysteine concentrations.
1803600|NCT00607074|Drug|Anti-Giardia and antihelmintic treatment (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) or a placebo was administered Every 12 weeks: Albendazole (syrup, 200mg)
1803601|NCT00607074|Drug|Anti-Giardia treatment only (secnidazole or albendazole)|Every 4 weeks: Secnidazole (70mg/ml suspension, 0.5ml per kg of body weight) Every 12 weeks: placebo of Albendazole
1803602|NCT00607074|Drug|Control group (placebo)|Every 4 weeks: Secnidazole placebo Every 12 weeks: Albendazole placebo
1803603|NCT00607087|Drug|Insulin glulisine|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
1803604|NCT00607087|Drug|Insulin lispro|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
1803605|NCT00607087|Drug|Insulin aspart|100 U/ml, administration by Continuous Subcutaneous Insulin Infusion with external pump
1803606|NCT00607113|Drug|Avastin|15 mg/kg By Vein Over 90 Minutes Every 21 Days
1803607|NCT00607113|Drug|RAD001|10 mg By Mouth Daily For 21 Days
1957621|NCT02292771|Drug|Atosiban|Clear, colorless solution for injection in a 0.9-mL vial containing 6.75 mg of atosiban. Clear, colorless concentrate for solution for infusion in a 5-mL vial containing 37.5 mg atosiban.
1803610|NCT00607152|Drug|Rasburicase|0.20mg/kg per day IV
1803611|NCT00607152|Drug|Allopurinol|100mg tablets
1803612|NCT00607178|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
1803613|NCT00607178|Biological|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
1803614|NCT00607217|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
1803615|NCT00607217|Biological|placebo for influenza vaccine|Intramuscular injection of one 0.5-mL dose of placebo for influenza vaccine
1803616|NCT00607217|Biological|influenza vaccine|Intramuscular injection of one 0.5-mL dose of influenza vaccine
1803617|NCT00607230|Biological|BCG|BCG vaccination at 0 and 4 weeks
1803618|NCT00607230|Biological|Saline|Saline vaccination at 0 and 4 weeks
1803619|NCT00607243|Biological|smallpox vaccine CJ-50300|Conventional dose group: 2.5 x 10 5 pfu/dose Diluted dose group:2.5 x 10 4 pfu/dose
1803620|NCT00607256|Drug|[S,S]-reboxetine|S_S reboxetine dosed daily.
1803621|NCT00607269|Behavioral|Voucher-Based Reinforcement Therapy|"Participants were randomized into either the CM or control condition. Both conditions earned points for attendance and participation (max 364 points).
Participants in the CM condition also earned points for targeted health-promoting behaviors and for drug/alcohol abstinence. CM points for targeted health-promoting behaviors were not limited. Points for abstaining from substance use were awarded based on a Level 1 (recent abstinence for amphetamine, methamphetamine, PCP, and cocaine metabolites, as well as blood alcohol <0.05) urine sample."
1803622|NCT00607282|Drug|Udenafil|oral administration of Udenafil, prn(2hours before anticipated intercourse, 8 times/months)
1803623|NCT00613678|Behavioral|Activity Strategy Training|The AST component will involve training in specific behavioral and environmental strategies to facilitate performance in daily activities and routines. The activity strategy training group sessions will use education, group discussion, and demonstration and practice of techniques to facilitate activity performance. Homework assignments will be given after many of the sessions to practice and reinforce concepts learned.
1803624|NCT00613678|Behavioral|Education|The health education program is based on educational materials from the Arthritis Foundation.
1803625|NCT00613691|Drug|SPI-1620|SPI-1620 in escalating doses from 0.5 μg/m2 intravenous over sixty seconds
1803626|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vits A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.
Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
1803627|NCT00613717|Dietary Supplement|folic acid + iron prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid, 30 mg Fe.
Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
1803628|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D + iron postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.
Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1 mg/kg/day Fe, 1500 IU vitamin A, 500 IU vitamin D."
1803629|NCT00613717|Dietary Supplement|folic acid prenatally, vitamins A & D postnatally|"Prenatally: pills by mouth, one per day, from the first prenatal visit until delivery, 400 mcg folic acid.
Postnatally: liquid by mouth, once per day, from 6 weeks old until 9 months old, 1500 IU vitamin A, 500 IU vitamin D."
1803630|NCT00613730|Drug|Gemcitabine|Intravenous administration
1803631|NCT00613730|Drug|panitumumab|Intravenous administration
1803632|NCT00613743|Drug|mouth wash with morphine|morphine solution 0.2% concentration; 15ml per unit mouthwash 6 time à day
1803633|NCT00613743|Drug|placebo|placebo solution Quinine diHCl 0.3% at 50 mg/15 ml mouthwash 6 time/day
1803634|NCT00613769|Drug|trimethoprim-sulfamethoxazole + metronidazole|trimethoprim-sulfamethoxazole (160mg/800mg)p.o.+ metronidazole (1200mg)p.o.
1803635|NCT00613769|Drug|cefuroxime and metronidazole|cefuromime 1500mg i.v. + metronidazole 1500mg i.v.
1803636|NCT00613782|Drug|Reandron 1000|1000mg at 0,6,18,30 weeks
1803637|NCT00613782|Drug|placebo|placebo injection 0,6.18.30 weeks
1803638|NCT00613795|Dietary Supplement|Lactobacillus GG|Every 12 hours, the contents of a single capsule containing Lactobacillus GG will be suspended in 3 ml of water-soluble jelly. The suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second capsule will be suspended in 10 ml of sterile water and pushed through the NG tub followed by 10 mL of air to ensure complete administration.
1803639|NCT00613795|Dietary Supplement|placebo|Every 12 hours, the contents of a single identical placebo capsule containing the inert plant carbohydrate inulin will be suspended in 3 ml of water-soluble jelly. This suspension will be applied to the oropharyngeal mucosa via sterile syringe. The contents of a second placebo capsule will be suspended in 10 ml of sterile water and pushed through eh NG tube followed by 10 mL of air to ensure complete administration
1803640|NCT00613808|Drug|Nitric Oxide 200ppm Group B|200 ppm, 8hrs / day for 6 weeks
1803641|NCT00613821|Drug|Lidocaine|5 milliliter intrauterine infusion of 4% lidocaine, infusion will be placed slowly over 3 minutes.
1803642|NCT00613821|Drug|Lidocaine|Standard paracervical block (8 milliliter 1% lidocaine at 4 and 8 o'clock at the cervical-vaginal reflection) will be placed.
1957622|NCT02292771|Drug|Placebo matching retosiban|A placebo infusion containing 0.9% sodium chloride (NaCl) matched for retosiban loading (bolus) dose and continuous infusion.
1957623|NCT02292771|Drug|Placebo matching atosiban|A placebo infusion containing 0.9% NaCl matched for the atosiban loading (bolus) dose and continuous infusion.
1803645|NCT00613847|Radiation|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
1803646|NCT00613847|Radiation|PET Imaging with Ga-68 Labeled F(ab') 2- Trastuzumab|Once safety and feasibility has been established in this group, then enrollment to the HER2 1+ cohort will commence. Pt will undergo one PET study following the i.v. administration of 10mCi of 68Ga-F(ab')2-trastuzumab fragments (HERScan). The PET study will be performed within 4 weeks of the patient's most recent imaging studies. A subset of 10 patients who have evidence of tumor uptake and localization with the 68Ga-F(ab')2-trastuzumab fragments will be asked to undergo follow-up PET scans (up to a maximum of 3) to examine the time course of HER-2 expression. These follow-up PET scans will be performed concurrently with the patient's standard imaging studies to evaluate response to their current therapy as per their treating physicians.
1803647|NCT00613860|Device|Zephyr endobronchial valve|Endobronchial valve system to redirect the airflow within the bronchial system
1803648|NCT00613873|Procedure|Colonoscopy and Questionnaire|Pt is asked to complete attitude and belief questionnaire then have a Colonoscopy. Then within 6 weeks post colonoscopy a final telephone interview.
1803649|NCT00613886|Device|Programmable Shunt Insertion (Codman, Medtronic)|Medical Device - Shunt insertion surgery of adjustable valve and laparoscopic assistance for placement of peritoneal catheter. Patient will be brought to operating room suite where general anesthesia is induced. Patient will be placed with a small roll on shoulder, supine, on the operating room table. Patient's head will be turned with the parietal area uppermost in the field. Patient will be prepared and draped in the usual sterile fashion. Site prep includes parietooccipital area, side of neck, chest, and entire abdomen. Ventricular catheter placed and then attached to shunt valve. Catheter is then fitted over grooved blue burr hole guide. Excess catheter pulled down to pull valve into pocket on the skull. Sterile dressings applied.
1803650|NCT00613886|Behavioral|Assessments in physical therapy, occupational therapy, and speech therapy|Follow-up testing to be administered by trained Physician Assistant in the outpatient setting on an approximately monthly basis: 10m walk, timed up-and-go, Mini-Mental Status Exam, 9-hole Grooved Pegboard, Motor Visual Perception Test (MVPT), Modified Rankin Score (MRS)
1803651|NCT00613899|Other|telesurveillance|A telesurveillance program for cough assistance will be approched by the use of an in-exoflator device. Measurement of oxygen saturation (SpO2) will be performed by a Nonin 9500 oxymeter (Minneapolis Plymouth USA).
1803736|NCT00616291|Biological|NY-ESO-1/LAGE-1 HLA class I/II peptide vaccine|
1803780|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 1.5 mg
1803652|NCT00613912|Other|Magnetic Resonance Imaging|"Morphological sequences
Arterial Spin Labelling (Perfusion)
Spectroscopy: anterior cingulate cortex Naa, Cho, Cr, Myo-inositol, glutamate TE 30 Reference voxel in Parietal white matter"
1803653|NCT00613925|Device|Pipelle de Cornier|A flexible suction cannula 23.5 cm in length with an inner diameter of 2.6 mm and an outer diameter of 3.1 mm. It has a 2.4mm diameter opening on the distal end, on one side of the cannula. It is a disposable polypropylene sheath with an inner plunger and is used for blind endometrial biopsy.
1803654|NCT00613925|Device|Explora curette|The curette has an outer diameter of 3.0 mm and is slightly more rigid. This cannula has a sharp Randall-type cutting edge on the distal end, on one side of the cannula.
1803655|NCT00613938|Drug|Tapentadol (CG5503)|50mg capsule q4-6 hrs for 3 days
1803656|NCT00613938|Drug|Tapentadol (CG5503)|75mg capsule q4-6 hrs for 3 days
1803657|NCT00613938|Drug|oxycodone|10mg capsule q4-6 hrs for 3 days
1803658|NCT00613938|Drug|placebo|1 capsule q4-6 hrs for 3 days
1803659|NCT00613951|Drug|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
1803660|NCT00613951|Drug|insulin degludec/insulin aspart|Formulation B: Treat-to-target dose titration scheme, injection s.c., twice daily
1803661|NCT00613951|Drug|biphasic insulin aspart|Treat-to-target dose titration scheme, injection s.c., twice daily
1803662|NCT00613951|Drug|metformin|Tablets, 1500-2000 mg/daily
1803663|NCT00613964|Drug|Carperitide heart failure therapy|carperitide(alpha-human atrial natriuretic peptide, 0.025-0.05μg/kg/min)
1803664|NCT00613964|Drug|Standard heart failure therapy|Loop diuretics, Aldosterone blockers, Beta blockers, ACE inhibitors, Angiotensin receptor blockers, Nitrates, digitalis
1803665|NCT00614003|Behavioral|Decision support skills building Intervention|Decision support skills
1803666|NCT00614016|Drug|Sodium ST20|single administration of oral dosage form
1803667|NCT00614029|Device|Sumatriptan (via Intraject System)|0.5 mL of solution with 6 mg of sumatriptan (base) as the succinate salt
1803668|NCT00615654|Other|aquatic physical therapy|The aquatic physiotherapy program for the SG was applied twice a week, in groups of six to seven people, with sessions lasting 40 minutes, over a 12-week period. The Control Group protocol included maintenance of the individuals' medication therapy and absence of any physical activity during the study period.
1803669|NCT00615667|Drug|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
1803670|NCT00615693|Drug|AEB071|
1803671|NCT00615706|Other|No intervention|no intervention
1803672|NCT00615732|Procedure|Qigong|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
1803673|NCT00615732|Procedure|exercise therapy|18 therapy sessions, during the first 3 months once a week, month 4 to 6 once every second week
1803674|NCT00615745|Drug|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg|Atripla (ATR) consisting of EFV 600 mg/FTC 200 mg/TDF 300 mg as one tablet orally once daily taken on an empty stomach at bedtime.
1803675|NCT00615758|Drug|Erlotinib|Erlotinib at the dose of 150 mg orally once a day continually until progression
1803676|NCT00615771|Procedure|Day 3 embryo transfer|Standard of care
1803677|NCT00615771|Procedure|Day 2 embryo transfer|Embryos are transferred 1 day prior to standard of care
1803678|NCT00615784|Drug|Bexarotene|Bexarotene given orally at a dose of 300mg/m2 until disease progression or unacceptable toxicities experienced by patient
1803679|NCT00615797|Biological|Intravenous immunoglobulin|intravenous immunoglobulin 2g/kg total given over 2 days
1803680|NCT00615797|Drug|standard interventions penicillin VK and haloperidol|Penicillin V K 500mg 12hrly po or 250mg 6 hrly for 10 days IM penicillin to be given at discharge, 1.2 million units if over 30 KG and 600,000 units if weight less than 30 KG haloperidol 0,025mg/kg/day orally in divided doses gradually increasing to a maximum of 0,05mg/kg/day
1803681|NCT00615810|Drug|Atripla|Open label once daily for oral administration to be taken on an empty stomach
1803682|NCT00615810|Drug|Kivexa plus Sustiva|Open label once daily for oral administration
1803683|NCT00615823|Drug|Atorvastatin|Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
1803684|NCT00615823|Drug|Placebo|Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.
1803685|NCT00615836|Drug|Desmopressin Melt|An orally disintegrating tablet of desmopressin administered under the tongue (sublingually), without water.
1803686|NCT00615849|Procedure|thoracoscopic surgery|stapled wedge resection of the lung mechanical pleural abrasion
1803687|NCT00615862|Other|Observational study; no interventions|Validated questionnaires will be administered. Blood samples will be analyzed for levels of immune markers as well as cortisol. This is an observational study and patients will not undergo any treatment as part of study participation. Patients will not receive medications or other interventions if they participate in the study. Blood samples analyzed are from samples remaining in the hospital laboratory that were collected as part of routine patient care and destined to be discarded.
1803688|NCT00615875|Drug|naproxen|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice.
1803689|NCT00615875|Drug|placebo|opaque pale orange suspension: 20mL q12h x 4 doses mixed in juice
1803690|NCT00615888|Procedure|Fast track patient management|no bowel washout, patient controlled epidural anesthesia, early enteral feeding
1803691|NCT00615888|Procedure|Traditional management|preoperative bowel washout, patient controlled analgesia, delayed start of enteral feeding
1803779|NCT00616642|Drug|rosiglitazone maleate|Given orally
1803692|NCT00615901|Drug|cyclophosphamide, methotrexate, fluorouracil, PEG-filgrastim|C (cyclophosphamide) 600 mg/m2 M (methotrexate) 40 mg/m2 F (fluorouracil) 600 mg/m2 P (PEG-filgrastim ) 6 mg. Eight doses of CMF q 14 days with PEG-filgrastim administered approximately 24 hours after chemotherapy. Day 14, is also considered day 1 of the next cycle.
1803693|NCT00615927|Drug|Imatinib Mesylate & Hydroxyurea|"Imatinib administered orally on daily. Imatinib is local irritant & must be taken in sitting position; mini of 2hrs should be allowed between last drug intake & going to bed. Imatinib doses 400mg/600mg administered once daily, whereas daily doses of 800mg/> administered as equally divided dose taken twice day. Dose for imatinib: Pts not receiving p450-inducing antiepileptic drugs: 400 mg/day. Pts receiving p450-inducing antiepileptic drugs: 500 mg twice day. It is recommended that pts take their prescribed imatinib mesylate at same time that they take their prescribed hydroxyurea, however, 30-60min interval between agents is acceptable if required for practical/other compliance issues.
Hydroxyurea administered orally twice day. Dosing will begin on day 1 of cycle 1 & continue daily. Drug is approximately 80 percent bioavailable. Dose will be 500mg twice day for all pts."
1803694|NCT00615940|Drug|WX-671|capsules taken per os once daily until progression or toxicity
1803695|NCT00615940|Drug|placebo|capsule taken per os once daily until progression or toxicity
1803696|NCT00615966|Drug|Diannexin|single dose, 200 µg/kg IV
1803697|NCT00615966|Drug|Placebo|Single dose, IV
1803698|NCT00615966|Drug|Diannexin|Single dose, 400 µg/kg IV
1803699|NCT00615979|Device|Miniature echo machine|Images captured and real-time and store-and-forward file transfers performed
1803700|NCT00615992|Drug|Tiotropium|
1803701|NCT00616005|Drug|Temodar and Irinotecan|Temozolomide-orally 200mg/m2 in fasting state 1hr prior to CPT-11 infusion. Temozolomide-day 1 of treatment cycle & every 24hrs thereafter for 5days w treatment cycles repeated every 6wks. Treatment cycles repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. CPT-11-intravenously in fasting state over 90min. CPT-11 1hr after Temozolomide administration on day 1 of treatment cycle. CPT-11-days 1, 8, 22, & 29 of 6wk treatment cycle. Treatment cycles may be repeated up to maxi of 3 cycles until occurrence of either unacceptable toxicity/evidence of disease progression. Dose of CPT-11 will be based on whether pt is receiving EIAEDs due to increased drug clearance produced by agents. For pts receiving EIAEDs, CPT-11 dose of 325mg/m2 administered. For pts not receiving EIAEDs, CPT-11 dose of 125mg/m2 administered.
1803702|NCT00616018|Drug|acetaminophen|4 g/day for 10 consecutive days
1803703|NCT00616031|Drug|carboplatin|
1803704|NCT00616031|Drug|nitroglycerin|
1803705|NCT00616031|Drug|paclitaxel|
1803706|NCT00616044|Procedure|continuous spinal anesthesia|bupivacaina isobaric 0.5%, 5 mg
1803707|NCT00616044|Procedure|Spinocath a catheter for continuous spinal anesthesia|Continuous spinal anesthesia with low dose of bupivacaine isobaric Combined epidural spinal anesthesia with low dose of bupivacaine isobaric
1803708|NCT00616044|Procedure|combined spinal epidural anesthesia|CSE was performed with the needle-through-needle technique using a single interspace (Espocan, B.Braun Melsungen, Germany
1803709|NCT00616057|Dietary Supplement|Synergy 1|8 grams/day during the first week and then 8 grams twice a day during 3 months
1803710|NCT00616057|Dietary Supplement|maltodextrin|8 grams/day during the first week and then 8 grams twice a day during 3 months
1803711|NCT00616070|Drug|Difluprednate|Difluprednate
1803712|NCT00616070|Other|Placebo|Vehicle
1803713|NCT00616096|Procedure|immunoadsorption|"First cycle: week 1, day 1-5
Second cycle: week 5, day 1-5"
1803714|NCT00616109|Drug|sunitinib|Sunitinib will be given at 50 mg/day as a single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks.
1803715|NCT00616122|Drug|cyclophosphamide|
1803716|NCT00616122|Drug|methotrexate|
1803717|NCT00616122|Drug|sunitinib malate|
1803718|NCT00616122|Other|laboratory biomarker analysis|
1803719|NCT00616135|Procedure|ADRC-Enhanced Autologous Fat Transplant|Autologous fat harvested from the patient is enhanced with ADRCs derived from a portion of the harvested fat and transplanted into the breast(s) that have a volume deficit post lumpectomy. This is a single arm study with no control. All patients receive cell therapy.
1803720|NCT00616148|Drug|YKP3089|Oral dosage form
1803721|NCT00616148|Drug|Placebo|
1803722|NCT00616161|Drug|Istaroxime|0.5 microgram/kg/min IV for 6 hours
1803723|NCT00616161|Drug|Istaroxime|1.0 microgram/kg/min IV for 6 hours
1803724|NCT00616161|Drug|Istaroxime|1.5 microgram/kg/min IV for 6 hours
1803725|NCT00616161|Drug|Placebo|Placebo
1803726|NCT00616174|Procedure|Active warming with Bair Hugger blanket|Standard care at BC Women's Hospital plus a Bair Hugger full access underbody blanket model 635 (Health Canada Licence # 12692) warmed by Bair Hugger temperature management unit model 750. Patient will lie on the underbody blanket and it will be turned on once patient is supine on operating table following the insertion of anesthetic. The warming device will be set to the medium temperature setting (380C). Warming will continue until the end of surgery unless otherwise requested by the mother.
1803727|NCT00616187|Drug|interferon beta treatment to add-on atorvastatin treatment|IFN-β-1a 22 µg s.c. 3 times weekly or IFN-β-1b s.c. every other day (3 months baseline) and add on oral daily 80 mg atorvastatin (9 months add on treatment)
1803728|NCT00616187|Drug|untreated to atorvastatin treatment|no treatment(3 months baseline)and oral daily 80 mg atorvastatin (9 months add on treatment)
1803730|NCT00616213|Biological|filgrastim|filgrastim will be administered at a standard dose and schedule
1803731|NCT00616213|Drug|PR104|PR104 is administered intravenously once every 21 days
1803732|NCT00616213|Other|F-18-fluoromisonidazole|F-18-fluoromisonidazole is administered intravenously prior to performance of PET scan
1803733|NCT00616239|Drug|20-30% Salicylic Acid peels to the right side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the right side of the face.
1803734|NCT00616239|Drug|20-30% Salicylic Acid peels to the left side of the face|Two 20% salicylic acid peels two weeks apart followed by 2 30% salicylic acid peels two weeks apart to the left side of the face
1803735|NCT00616265|Device|CPAP|Pressure device on airway to maintain it open
1803737|NCT00616304|Drug|L-arginine hydrochloride|Patients will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo Block 1: Standard RSMM artesunate regimen for severe falciparum malaria plus 12g of L-arginine diluted to a 10% solution and given over 8 hours (n=12); Block 2: Standard RSMM artesunate regimen for severe falciparum malaria plus a 24g dose of L-arginine diluted to a 10% solution given over 8 hours (n=12) Phase 2b: To evaluate any additional benefits of a longer infusion, a further 24 patients will receive L-arginine infusion 1.5g/hour for 24 hours
1803738|NCT00616304|Other|Normal saline|Patients with severe malaria will be randomized in two blocks of 18. The first block of 18 patients will receive either 12 g L-arginine or saline placebo. If safety is demonstrated in the first block, a further 18 patients will be enrolled in the second block and randomized to receive either 24g arginine or saline placebo. Blocks 1 and 2: Standard RSMM antimalarial artesunate regimen for severe falciparum malaria plus saline placebo, 240 ml given over 8 hours (n=12).
1803739|NCT00616330|Drug|clindamycin phosphate/butoconazole nitrate|semi solid, single dose
1803740|NCT00616330|Drug|clindamycin phosphate|semi solid, single dose
1803741|NCT00616330|Drug|butoconazole nitrate|semi solid, single dose
1803742|NCT00616343|Drug|Zonisamide|100mg tablets once a day for two weeks, then increased to 200mg qhs for two weeks.
1803743|NCT00616382|Drug|Indomethacin|IV indomethacin starting at a dose of 0.4 mg/kg given over 30 minutes, increased daily by increments of 0.2 mg/kg/dose and given at intervals of 12 hours until a maximum dose of 1 mg/kg is reached, or until a total indomethacin dose of 6 mg/kg has been given. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later, using the same dose used in the last indomethacin infusion.
1803744|NCT00616382|Drug|Pentoxifylline|IV indomethacin will be re-started at a dose of 0.2 mg/kg to run over 30 minutes at 12 hour intervals to be given concurrently with pentoxifylline (5 mg/kg/hour to run over 6 hour once a day for a maximum of 6 days. Daily echocardiography will be performed to monitor the progress of ductal closure. Once echocardiographic evidence of a closed ductus is achieved, two additional doses indomethacin will be given 24 hours and 48 hours later and another day of pentoxifylline infusion, provided that the 6 day maximum has not yet been
1803745|NCT00616395|Device|No intervention|
1803746|NCT00616408|Drug|Octreotide-LAR|Initial dose is 20 mg every 28 d for three months, then the dose is down-titrated to 10 mg/q28d if GH levels are below 1 ng/ml, up-titrated to 30 mg/q28d if GH levels are above 10 ng/ml and remains to 20 mg/q28 d if GH is between 1-10 ng/ml
1803747|NCT00616421|Biological|MenACWY-CRM|1 injection of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly
1803748|NCT00616421|Biological|MenACWY-CRM|2 injections of the Novartis MenACWY-CRM conjugate vaccine administered intramuscularly to children 2 to 5 years of age
1803749|NCT00616421|Biological|Licensed meningococcal ACWY vaccine|1 injection of the licensed meningococcal ACWY was administered intramuscularly
1803750|NCT00616434|Drug|BG9418 (Interferon beta-1a)|Avonex IM injection, self-administered per protocol
1803751|NCT00616434|Drug|Placebo|Placebo IM injection, self-administered per protocol.
1803752|NCT00616447|Device|Repetitive transcranial magnetic stimulation|6 weeks of repetitive transcranial magnetic stimulation . Treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of MT, 20 trains, 9 sec/train, 51 sec ITI applied over right dorsolateral prefrontal cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
1803753|NCT00616447|Device|placebo sham|Sham treatment will mimic active treatment mentioned above.
1803754|NCT00616460|Drug|Bivalirudin|Bivalirudin: loading dose 0.75mg/kg bolus During procedure: 1.75mg/kg/hour. UFH: loading dose 60 Units /kg During procedure: keeping ACT < 250
1803755|NCT00616486|Device|repetitive transcranial magnetic stimulation|6 weeks of stimulation with RMT frequency 1Hz, intensity 110% of RMT for 20 minutes, 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6.
1803756|NCT00616486|Device|sham (placebo)|Sham treatment will mimic active treatment mentioned above.
1803757|NCT00616499|Drug|gefitinib|
1803758|NCT00616499|Procedure|neoadjuvant therapy|
1803759|NCT00616499|Procedure|therapeutic conventional surgery|
1803760|NCT00616512|Procedure|GF Strong Water Protocol|The Purpose of the GF Strong water protocol is to allow clients who have thin liquid dysphagia to drink water under certain specified conditions according to the rules of the water protocol.
1803761|NCT00616538|Device|Epiceram(r)|Topical barrier repair emulsion cream
1803762|NCT00616538|Drug|Fluticasone Propionate 0.05%|Topical mid-strength steroid
1803763|NCT00616551|Drug|C2L-OCT-01 PR, 30 mg|Administered by deep IM injection (gluteus) on days 1 and 42
1803764|NCT00616551|Drug|Octreotide acetate prolonged release, 30 mg|Administered by deep IM (gluteus) on Days 1, 28 and 56
1803766|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
1803767|NCT00616577|Drug|Ropivacaine|caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
1803768|NCT00616577|Drug|Ropivacaine|local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
1803769|NCT00616590|Other|medical chart review|
1803770|NCT00616590|Other|questionnaire administration|
1803771|NCT00616590|Procedure|fatigue assessment and management|
1803772|NCT00616590|Procedure|quality-of-life assessment|
1803773|NCT00616603|Drug|Ropivacaine|20 ml of 0.2% ropivacaine injected locally as regional anesthesia given once.
1803774|NCT00616603|Drug|Dexamethasone|8mg Dexamethasone injected locally along with ropivacaine for regional anesthesia given once.
1803775|NCT00616603|Drug|Dexamethasone|2ml(8mg)Dexamethasone given once intravenously.
1803776|NCT00616603|Drug|Normal Saline|2ml of normal saline given once intravenously.
1803777|NCT00616616|Procedure|single incision laparoscopic surgery|Surgery will be performed with ine laparoscopic incision
1803778|NCT00616629|Drug|AZD1305|Intravenous infusion
1803781|NCT00616655|Drug|eszopiclone|SEP-225441 (eszopiclone) total daily dose of 0.9 mg
1803782|NCT00616655|Drug|Placebo|Placebo total daily dose 0.9 mg
1803783|NCT00616668|Device|Air- Limb|
1803784|NCT00616681|Drug|Oxcarbazepine|
1803785|NCT00616694|Drug|Actonel|Actonel 5 mg orally once daily (OD), calcium 500 mg + vitamin D 200 units twice daily (BID)
1803786|NCT00616720|Biological|aldesleukin|
1803787|NCT00616720|Biological|idiotype-pulsed autologous dendritic cell vaccine APC8020|
1803788|NCT00616720|Biological|recombinant interferon gamma|
1803789|NCT00616720|Genetic|polymerase chain reaction|
1803790|NCT00616720|Genetic|reverse transcriptase-polymerase chain reaction|
1803791|NCT00616720|Other|flow cytometry|
1803792|NCT00616720|Other|laboratory biomarker analysis|
1803793|NCT00616733|Drug|CS-0777 tablets|0.1 mg, once-weekly, for 12 weeks
1803794|NCT00616733|Drug|CS-0777 tablets|0.3 mg, once-weekly or once every 2 weeks, for 12 weeks
1803795|NCT00616733|Drug|CS-0777 tablets|0.6 mg, once-weekly or once every 2 weeks, for 12 weeks
1803796|NCT00616746|Drug|Nicotine|1.0 microg/kg/min IV x 10 minutes
1803797|NCT00616746|Drug|Ethanol|IV
1803801|NCT00616772|Drug|ABT-335|Capsule
1803802|NCT00616772|Drug|Placebo|Capsule
1803803|NCT00616772|Other|Atorvastatin|Capsule
1803804|NCT00616785|Drug|cisplatin|
1803805|NCT00616785|Drug|etoposide|
1803806|NCT00616785|Drug|irinotecan hydrochloride|
1803807|NCT00616785|Radiation|radiation therapy|
1803808|NCT00616798|Drug|RO4917838|10mg po daily
1803809|NCT00616798|Drug|RO4917838|30mg po daily
1803810|NCT00616798|Drug|RO4917838|60mg po daily
1803811|NCT00616798|Drug|Placebo|po daily
1803812|NCT00616798|Drug|Standard antipsychotic therapy|As prescribed
1803813|NCT00616811|Drug|vildagliptin|
1803814|NCT00616811|Drug|Sitagliptin|
1803815|NCT00616824|Procedure|Dermamatrix to cover lateral aspect of tissue expander|Dermamatrix used to cover lateral aspect of breast tissue expander after mastectomy
1803816|NCT00616824|Procedure|Serratus anterior to cover lateral aspect of tissue expander|Traditional use of serratus anterior for coverage of lateral aspect of tissue expander
1803817|NCT00616837|Other|Telemedicine consultation|Outpatient consultation by help of telemedicine (video conference)
1803818|NCT00616837|Other|Standard care in orthopaedic outpatient clinic|Standard care in orthopedic outpatient clinic (usual care)
1803819|NCT00616850|Procedure|Continuous femoral catheter block|A constant infusion of ropivacaine 0.2% without epinephrine will be given to each subject via continuous femoral catheter in Group A.
1803820|NCT00616850|Drug|Lidocaine|Lidocaine 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
1803821|NCT00616850|Other|Preservative free normal saline|Preservative free normal saline 1.33mg/kg/hr continuous IV infusion following induction of general anesthesia to 24 hours postoperatively.
1803822|NCT00616863|Drug|Oxcarbazepine|
1803823|NCT00616876|Drug|Lactulose|Babies in the study group received lactulose in a dose of 1% in their entire mother's breast milk or preterm formula feeds (1 gram per 100 ml feeds, based on the daily volume of feeds, and evenly distributed between all the feeds for the entire duration of their hospital stay). 67% lactulose in the original preparation (Laevolac, Fresenius Kabi, Austria) was diluted by distilled water to 33.5% preparation in the pharmacy in strict sterile conditions under hood. Just before feeding the nurses added the required volume of this 33.5% lactulose solution to the ordered volume of feed to generate a final concentration of 1% lactulose in each feed.
1803824|NCT00616876|Dietary Supplement|Dextrose|Babies in the control groups were given equal volumes of the comparable placebo in all their preterm formula feeds at final concentration of 1% dextrose. The 33.5% dextrose placebo solution was prepared by dissolving dextrose (Dextrose Pulv. USP.24/BP, Roquette Frores 6280, Lestrem, France) in distilled water under heat to the point of near boiling under the same strict sterile conditions in the pharmacy. This gave a placebo solution that looked similar in color, odor and liquidity to the study solution of 33.5% lactulose. Dark bottles were used to further blind the medical team as to what solution was the baby given.
1803825|NCT00616889|Drug|Seroquel|The dosage is flexible from 50-600 mg based on the investigator's clinical judgement and patient tolerance. It may be raised or lowered at will.
1803826|NCT00616902|Drug|paricalcitol injection 4 mcg/mL|Paricalcitol Injection 4 mcg/mL intravenously three times a week during dialysis
1803827|NCT00616902|Drug|Placebo Injection 4 mcg/mL|Placebo Injection 4 mcg/mL given intravenously three times a week during dialysis
1803828|NCT00616915|Drug|Wellbutrin XL|Wellbutrin XL 300mg daily
1803829|NCT00616928|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|Two intramuscular injections at Days 0 and 21.
1803830|NCT00616928|Biological|Placebo|Two intramuscular injections at Days 0 and 21.
1957626|NCT02290431|Drug|LBH589 (panobinostat)|
1803834|NCT00616954|Drug|ATG-F|ATG-f
1803835|NCT00616967|Drug|carboplatin|Given IV
1803836|NCT00616967|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1803837|NCT00616967|Drug|vorinostat|Given orally
1803838|NCT00616967|Other|placebo|Given orally
1957627|NCT02290431|Drug|bortezomib|
1957628|NCT02290431|Drug|dexamethasone|
1803842|NCT00616993|Drug|Difluprednate|Difluprednate
1803843|NCT00616993|Other|Placebo|Vehicle
1803844|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single Dose 1x10^10 DNase resistant particles (DRP) / mL joint volume
1803845|NCT00617032|Genetic|tgAAC94 gene therapy vector|Single dose 1x10^11 DNase resistant particles (DRP) / mL joint volume
1803846|NCT00617032|Genetic|tgAAC94 placebo|Single dose
1803847|NCT00617045|Drug|duloxetine|"Total treatment period is 12 weeks
30mg po qd times 1 week
60mg po qd times 11 weeks"
1803848|NCT00617058|Drug|metformin|open dosed, randomly assigned flexible dose treatment with 250-2000mg/day divided BID or TID
1803849|NCT00617058|Behavioral|healthy lifestyle intervention|additional component to regular psychiatric visits that includes monitoring of lifestyle and eating behaviors.
1803850|NCT00617071|Other|medical chart review|
1803851|NCT00617071|Other|survey administration|
1803852|NCT00617071|Procedure|fecal occult blood test|
1803853|NCT00617071|Procedure|screening colonoscopy|
1803854|NCT00617084|Device|Medtronic Endeavor Resolute|Medtronic Endeavor Resolute
1803855|NCT00617084|Device|Abbott Xience V|Abbott Xience V
1803856|NCT00617097|Drug|lidocaine|paracervical block with lidocaine
1803857|NCT00617097|Drug|ketorolac and lidocaine|paracervical block with ketorolac and lidocaine
1803858|NCT00617110|Other|live attenuated influenza virus (LAIV) with clean air|Allergic subjects will be exposed to air followed by administration of live attenuated influenza virus
1803859|NCT00617110|Other|LAIV and diesel exhaust particles|subjects with allergic rhinitis will be exposed to diesel exhaust particles followed by LAIV
1803860|NCT00617123|Drug|Vorapaxar 2.5 mg|Vorapaxar 2.5 mg oral tablet
1803861|NCT00617123|Drug|Placebo|matching placebo oral tablet
1803862|NCT00617136|Device|Intraoperative warming (Bair Hugger)|Intraoperative warming
1803863|NCT00617136|Device|Pre- and intraoperative warming (HotDog)|Pre- and intraoperative warming by HotDog
1803864|NCT00617136|Device|Intraoperative warming (HotDog)|Intraoperative warming
1803865|NCT00617149|Behavioral|Supervised exercise for the prevention high weight gain|Each session starts with ca 5 minutes warm up, followed by 30 minutes of aerobic activity, including cool down. This is followed by 15 minutes of strength training of the upper and lower limbs, and special focus on the deep abdominal stabilization muscles. The last 5 minutes contains stretching, relaxation and body awareness exercises. The exercise-program follows the ACOG exercise prescription, and all aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate), measured by ratings of perceived exertion at 11-14 (somewhat hard) on the 6-20 Borg's rating scale. Control-participants are neither encouraged nor discouraged from exercising.
1803866|NCT00617175|Device|Implantable Defibrillator|Number of 30 out of 40 intervals to detect (NID)Fast Ventricular Tachycardia
1803867|NCT00617175|Device|Implantable Defibrillator|number of 18 out of 24 intervals to detect (NID)Fast Ventricular Tachycardia
1803868|NCT00617188|Drug|Fulvestrant|Fulvestrant, 500 milligrams (mg) intramuscularly (IM) on Day 1, 250 mg IM on Day 15, and 250 mg IM on Day 29 and every 28 days thereafter until either intolerance or disease progression.
1803869|NCT00617201|Drug|atomoxetine|Once daily oral dosing
1803870|NCT00617201|Drug|placebo|Once daily oral dosing - matched placebo
1803871|NCT00617240|Drug|metformin|500mg tablets, 250mg to 2000mg/day, po, BID to TID, 26 weeks
1803872|NCT00617240|Drug|placebo|500/0mg tablets, 250-2000mg/day divided BID to TID, po, 26 weeks
1803873|NCT00617253|Drug|recombinant interleukin-21|3 mcg/kg, s.c. injection
1803874|NCT00617253|Drug|sunitinib|Hard gelatine capsules, 12.5 mg
1803875|NCT00617253|Drug|recombinant interleukin-21|10 mcg/kg, s.c. injection
1803876|NCT00617253|Drug|recombinant interleukin-21|30 mcg/kg, s.c. injection
1803877|NCT00617253|Drug|recombinant interleukin-21|100 mcg/kg, s.c. injection
1803882|NCT00617279|Device|GORE PROPATEN Vascular Graft|Arterial Occlusion Bypass
1803883|NCT00617279|Procedure|Disadvantaged Autologous Vein Graft|Arterial Occlusion Bypass
1803884|NCT00617305|Drug|Ambrisentan|Ambrisentan was administered orally once daily; dose level was 5 mg for the first 4 weeks, followed by 10 mg for the remainder of the study; ambrisentan was supplied as 5-mg and 10-mg tablets.
1803885|NCT00617305|Drug|Placebo|Placebo to match ambrisentan was administered orally once daily.
1803886|NCT00617305|Drug|Sildenafil|Sildenafil was administered at the dose previously established for each subject (20-100 mg) orally three times daily. Sildenafil was supplied as 20-mg tablets, or formulated as sildenafil citrate in 25-, 50-, or 100-mg tablets.
1803887|NCT00617305|Drug|Tadalafil|Tadalafil was administered at the dose previously established for each subject (not to exceed 40 mg per day) orally once daily. Tadalafil was supplied as 20-mg tablets.
1803888|NCT00617318|Dietary Supplement|Pomegranate|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
1803928|NCT00617552|Drug|TZP-101|40 micrograms/kg IV 2 ml/minute for 30 minutes
1803929|NCT00617552|Drug|TZP-101|80 micrograms/kg IV 2ml/minute for 30 minutes
1803930|NCT00617552|Drug|TZP-101|160 micrograms/kg IV 2ml/minute over 30 minutes
1803931|NCT00617552|Drug|TZP-101|320 micrograms/kg IV 2ml/minute for 30 minutes
1803932|NCT00617552|Drug|TZP-101|480 micrograms/kg IV 2ml/minute over 30 minutes
1803889|NCT00617318|Dietary Supplement|Placebo|"All subjects were randomized and assigned to a 16-week treatment with either POM concentrate or placebo. The placebo matched the taste, smell, and appearance of the POM concentrate. Supplies were shipped to the investigation site in equal proportions marked as A and B, and site personnel did not know the code. The treatment products (POM concentrate or placebo) were supplied as 2-oz packages, each containing a single day's consumption, and were dispensed as packages of 33 units (a 4-week plus 5-day supply). The subjects were to consume one 2 oz. package daily for a period of 16 weeks."
1803890|NCT00617331|Biological|Subvirion inactivated influenza A/H9N2 (G9 variant) vaccine|Inactivated subvirion influenza A/chicken/Hong Kong/G9/97 (H9N2) vaccine administered via intramuscular (IM) injection, dose 7.5 or 30 micrograms.
1803891|NCT00617344|Biological|ChimeriVax™ Tetravalent Dengue Vaccine|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
1803892|NCT00617344|Biological|ChimeriVax™ Tetravalent Dengue Vaccine|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
1803893|NCT00617344|Biological|ChimeriVax™ Tetravalent Dengue Vaccine|A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
1803894|NCT00617357|Device|LTM (Strattice Reconstructive Tissue Matrix)|Surgical mesh
1803895|NCT00617370|Drug|epirubicin, cyclophosphamide, Paclitaxel,|EC (epirubicin 100 mg/m2, cyclophosphamide 600 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg). Paclitaxel (175 mg/m2) q 14 days x 6 treatments with pegfilgrastim SQ day # 2 (6 mg).
1803896|NCT00617396|Drug|Quetiapine (50 mg/day-100mg/day)|Subject begin with a dose quetiapine of 50mg for 2 weeks, increasing to 100mgs for the remainder of the study. (8 weeks total)
1803897|NCT00617409|Drug|Paclitaxel|All groups wil receive paclitaxel as second line chemotherapy if their cancer spreads. At any point when a patient develops evidence of progressive disease, the patient will be treated with second-line chemotherapy. Paclitaxel will be given at a dose of 200 mg/m² on day 1 of 21 day cycles.
1803898|NCT00617409|Biological|Drug: Ad.p53-DC vaccines|Patients randomized to Arm B will receive vaccinations on 3 occasions, at 2 week intervals. 1-5x106 p53 positive DCs in 1 ml will be injected intradermally into 4 separate sites (0.25 ml injected at each site), in bilateral proximal upper and lower extremities (in the regions of the axillary and inguinal nodal basins). Patients will be restaged approximately 2-3 weeks after vaccine # 3 (first vaccine course). If patients show no sign of disease progression at restaging, then a second leukopheresis will be performed. Patients will then be vaccinated 3 more times (second vaccine course) at 4-week intervals, for a total of 6 possible vaccines. Restaging will occur 2-4 weeks after completing the second vaccine course. Patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
1803899|NCT00617409|Drug|All -trans Retinoic Acid (ATRA)|The patients in Arm C will receive vaccines at the same dose and schedule as described for patients in Arm B. In addition, they will receive 150 mg/m² of ATRA for 3 days prior to each vaccine administration (followed by vaccine administration on the fourth day).
1803900|NCT00617435|Dietary Supplement|vaccenic acid enriched diet|"The experimental milk fat, entitled vaccenic acid enriched milk fat (VAMF), has been obtained by feeding cows with a diet containing sunflower oil."
1803901|NCT00617435|Dietary Supplement|Elaidic acid enriched diet|Mixture of vegetable oils (including partially hydrogenated oils)
1803902|NCT00617435|Dietary Supplement|control diet|Mixed of different oil
1803903|NCT00617448|Procedure|diathermy haemorrhoidectomy under espinal anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan).For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
1803904|NCT00617448|Procedure|diathermy haemorrhoidectomy under local anesthesia|For surgery: conventional haemorrhoidectomy with diathermy (Milligan-Morgan). For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine [20 mL, 7.5 mg/mL] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
1803905|NCT00617448|Procedure|Ligasure haemorrhoidetomy under spinal anestesia|For surgery: ligasure haemorrhoidectomy For anesthesia: lidocaine 2% at doses of 50-70 mg was used for spinal anaesthesia.
1803906|NCT00617448|Procedure|Ligasure haemorrhoidectomy under local anesthesia|For surgery: haemorrhoidectomy with Ligasure For anesthesia: pudendal nerve block, infiltration of the right and left pararectal spaces, anterior and presacral regions with ropivacaine (150 mg of ropivacaine [20 mL, 7.5 mg/mL] diluted in 50 mL of 0.9% physiological saline). Ten minutes before local anaesthesia, patients were sedated with i.v. remifentanil 0.05-0.15 μg·kg-1
1803907|NCT00617461|Drug|GEn 1200mg/day|1200mg/day gabapentin enacarbil
1803908|NCT00617461|Drug|GEn 3600mg/day|3600mg/day gabapentin enacarbil
1803909|NCT00617474|Drug|Erythropoietin|sub cutaneous injection, 2000 unit in per injection, 3 times 1 week.
1803910|NCT00617474|Drug|Placebo|placebo
1958326|NCT01772823|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
1803915|NCT00617513|Drug|Prucalopride|0.5 mg once daily
1803916|NCT00617513|Other|Placebo|o.d.
1803917|NCT00617513|Drug|Prucalopride|1 mg o.d.
1803918|NCT00617513|Drug|Prucalopride|2 mg o.d.
1803919|NCT00617526|Drug|RDEA806 400 mg|
1803920|NCT00617526|Drug|Placebo|Placebo
1803921|NCT00617526|Drug|RDEA806 1000 mg|
1803922|NCT00617526|Drug|RDEA806 600 mg|
1803923|NCT00617526|Drug|RDEA806 800 mg|
1803924|NCT00617539|Drug|irinotecan hydrochloride|
1803925|NCT00617539|Drug|temozolomide|
1803926|NCT00617552|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
1803927|NCT00617552|Drug|TZP-101|20 micrograms/kg IV 2ml/minute for 30 minutes
1803933|NCT00617552|Drug|TZP-101|600 micrograms/kg IV 2ml/minute for 30 minutes
1803934|NCT00617565|Drug|biphasic insulin aspart|
1803935|NCT00617565|Drug|biphasic human insulin|
1803936|NCT00617578|Device|ATP One Shot ON|"The new antitachycardia pacing algorithm ATP One Shot attempts to terminate fast VT by one ATP sequence and thus avoid defibrillation shock delivery"
1803937|NCT00617578|Device|ATP One Shot OFF|Standard defibrillation shock delivery
1803938|NCT00617591|Drug|Lenalidomide|25 mg orally on days 1-21
1803939|NCT00617591|Drug|Pegylated Liposomal Doxorubicin (PLD)|40 mg/m^2 intravenously on day 1 (reduced to 30 mg/m^2 after the initial 29 patients were treated)
1803940|NCT00617591|Drug|Dexamethasone|40 mg orally on days on 1-4
1803941|NCT00617604|Drug|Alefacept|IV and subcutaneous injection
1803942|NCT00617604|Drug|placebo|IV and subcutaneous injection
1803943|NCT00617604|Drug|Tacrolimus|The initial daily dose was 0.2 mg/kg orally given in 2 doses commencing 24 hours after completion of surgery.
1803944|NCT00617604|Drug|Mycophenolate Mofetil|Mycophenolic mofetil was administered as 750 mg twice per day orally
1803945|NCT00617604|Drug|Steroids|"Methylprednisolone or equivalent:
Day 0: 500 - 1000 mg IV bolus Day 1: 125 - 250 mg IV bolus
Prednisone or equivalent:
Days 2 - 14: 20 - 30 mg orally Days 15 - 28: 10 - 20 mg orally Days 29 - 60: 10 - 15 mg orally Days 61 onwards: 5 - 10 mg orally"
1803946|NCT00617617|Dietary Supplement|Prevastein HC®|Experimental Group - Participants in the experimental group will consume an isoflavones supplement in the form of Prevastein HC®, which will deliver 80 mgs (40 mg/dose) biologically active isoflavones.
1803947|NCT00617617|Other|Placebo|Control Group - Control Group participants will receive an identical placebo.
1803948|NCT00617643|Drug|Nevirapine without dose escalation|Fixed dose combination tablets of stavudine 30mg,lamivudine 150mg and nevirapine tablets 200mg twice daily at initiation of antiretroviral therapy in patients receiving rifampicin for tuberculosis therapy
1803949|NCT00617643|Drug|Nevirapine initiation with dose escalation|Triomune® 30 (according to body weight) one tablet once daily (am) plus Zerit® 30 + Epivir 150mg once daily (pm) for two weeks
1803950|NCT00617656|Drug|Cisplatin, Docetaxel|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2, both on day 1, every 21 days. Total number of cycles: 6
1803951|NCT00617656|Drug|Gemcitabine, Cisplatin|Gemcitabine 1250 mg/m2, days 1 and 8, and Cisplatin 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
1803952|NCT00617656|Drug|Docetaxel, Cisplatin|Docetaxel 75 mg/m2 and Cisplatin 75 mg/m2, both administered on day 1, every 21 days. Total number of cycles: 6
1803953|NCT00617656|Drug|Docetaxel|Docetaxel 75 mg/m2, day 1. 21-day cycles. Total number of cycles: 6
1803954|NCT00617669|Drug|Docetaxel|intravenous infusion given every three weeks
1803955|NCT00617669|Drug|ZD4054|10 mg oral once daily dose
1803956|NCT00617669|Drug|Placebo|placebo oral tablet once daily
1803957|NCT00617682|Biological|PNCRM9|0.5 mL IM at 30-35 wks gestation
1803958|NCT00617682|Biological|Placebo comparator|Sucrose cake (NaCl and sucrose) in aluminum phosphate adjuvant diluent at 0.5 mg per 0.5 mL dose IM at 30-35 wks gestation
1803959|NCT00617695|Drug|Zolmitriptan|5mg nasal spray
1803960|NCT00617695|Drug|Placebo|
1803961|NCT00617708|Biological|cixutumumab|Given IV
1803962|NCT00617708|Drug|erlotinib hydrochloride|Given PO
1803963|NCT00617708|Drug|gemcitabine hydrochloride|Given IV
1803964|NCT00617721|Other|Blood withdrawal|Observational study. Limited blood withdrawal. Any other intervention will be determined by the patient's clinical status.
1803965|NCT00617734|Biological|IMC-A12 (cixutumumab)|IMC-A12 10 mg/kg over one hour every two weeks. A cycle is defined as four weeks of therapy. Patients will continue on study until evidence of progressive disease, or unacceptable toxicity develops.
1803966|NCT00617734|Biological|cetuximab (Erbitux ®)|IMC-A12 10 mg/kg over one hour followed by cetuximab 500 mg/m2 over 2 hours. This sequence will be repeated every 2 weeks. Patients will continue on study until evidence of disease progressive disease or unacceptable toxicity develops.
1803967|NCT00617747|Drug|Zolmitriptan|5mg Nasal Spray
1803968|NCT00617747|Drug|Placebo|
1803969|NCT00617760|Biological|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT) vaccine and 7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle, PCV7 (0.5 ml) to be administered in the right thigh muscle
1803970|NCT00617760|Biological|7-valent Pneumococcal CRM197-conjugate vaccine (PCV7)|PCV7 (0.5 ml) to be administered in the right thigh muscle
1803971|NCT00617760|Biological|Group C Meningococcal Polysaccharide-Tetansu Toxoid Conjugate (MenC-TT)|MenC-TT vaccine (0.5 ml) to be administered in the left thigh muscle
1803972|NCT00617773|Biological|hu3S193|20 mg/m2, intravenous, weekly for a maximum of 3 cycles (of 8 weeks each)
1803973|NCT00617786|Procedure|Current Perception Threshold (CPT) Testing|During the CPT testing a catheter will be placed in the bladder. The catheter has sensors to record the body's sensation of pressure. The sensation felt will be similar to a light touch and is painless. A gel pad will be placed in the general area of the vagina to record the feeling of a light touch.
1803974|NCT00617799|Biological|aldesleukin|
1803975|NCT00617799|Genetic|gene expression analysis|
1803976|NCT00617799|Genetic|mutation analysis|
1803977|NCT00617799|Other|flow cytometry|
1803978|NCT00617812|Biological|Shan5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
1803979|NCT00617825|Other|cyrotherapy as a cool gel wrap|A cool gel wrap made of a hydrogel with silicon will be applied to the lower leg of skin affected by venous disorders for 30 minutes each day for 30 days during the study
1803980|NCT00617838|Other|Optimal gluten introduction|Optimization of gluten introduction by nutritional counselling
1803981|NCT00617851|Biological|Lot A of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot A) administered intramuscularly
1803982|NCT00617851|Biological|Lot B of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot B) administered intramuscularly
1803983|NCT00617851|Biological|Lot C of Influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine (lot C) administered intramuscularly
1804072|NCT00610636|Procedure|Hepatic resection|Hepatic resection
1803984|NCT00617851|Biological|Comparator influenza virus vaccine|1 injection of the trivalent subunit influenza virus vaccine administered intramuscularly
1803985|NCT00617851|Biological|All 3 consecutive lots of influenza virus vaccine pooled|1 injection of the pooled trivalent subunit influenza virus vaccine administered intramuscularly
1803986|NCT00617864|Drug|Human Albumin Infusion|Group will receive single infusion of albumin at the time of oocyte retrieval.
1803987|NCT00617864|Drug|Saline Infusion|Group will receive single infusion of saline at the time of oocyte retrieval.
1803988|NCT00617877|Drug|losartan potassium|Losartan 50 mg/day for 4 weeks, then doubled to losartan 100 mg/day (in case of BP more than 140/90 mm Hg.) Continued until the end of the study (visit 9-week 48).
1803989|NCT00617877|Drug|Comparator: Hydrochlorothiazide|Hydrochlorothiazide 25 mg will be added at week 8 if BP is more than 140/90 mm Hg. This last regimen will be continued until the end of the study (visit 9-week 48).
1803990|NCT00617890|Biological|robatumumab|Robatumumab IV every two weeks until disease progression.
1803991|NCT00617903|Drug|Azelaic acid|15% foam to be applied topically twice daily
1803992|NCT00617903|Drug|Vehicle foam|Active-ingredient-free vehicle to be applied topically twice daily
1803993|NCT00617929|Biological|anti-thymocyte globulin|administer 3 mg/kg intravenously (IV) over 4 hours on days -6, -5 and -4.
1803994|NCT00617929|Biological|rituximab|administered 375 mg/m^2 intravenously (IV) in 1 mg/mL normal saline on day -7.
1803995|NCT00617929|Drug|clofarabine|administered 30 mg/m^2 intravenously (IV) over 1 hour on Days -4, -3, and -2.
1803996|NCT00617929|Procedure|stem cell transplantation|administered on Day 0 per institutional guidelines.
1803997|NCT00617942|Drug|Cohort 1 neo-adjuvant|"Cohort 1 : Trastuzumab 6 mg/kg IV over 60 minutes day -14
Trastuzumab 2 mg/kg IV over 60 minutes weekly then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16"
1803998|NCT00617942|Drug|Cohort 2 neo-adjuvant|Cohort 2 :Abraxane 100 mg/m2 IV over 30 minutes days -14 and -7 Trastuzumab 2 mg/kg IV over 60 minutes weekly (4 mg/kg week 1) then Abraxane 100 mg/m2 IV over 30 minutes weekly x 18 weeks followed by Carboplatin at AUC 6 IV over 30 min weeks 1,4,7,10,13 and 16
1803999|NCT00617942|Drug|Cohort 1 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
1804000|NCT00617942|Drug|Cohort 2 adjuvant|Trastuzumab 8 mg/kg x 1 dose, then 6 mg/kg q3wks x 11 doses Adjuvant chemotherapy, post-op radiation and hormonal therapy at discretion of treating physicians
1804001|NCT00617955|Drug|Aprotinin|compare outcomes of Aprotinin versus Amicar
1804002|NCT00617955|Drug|Amicar|compare outcomes of Aprotinin versus Amicar
1804003|NCT00617968|Drug|DOCETAXEL|
1804004|NCT00617981|Drug|ThermoDox|Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion
1804005|NCT00617981|Drug|5% Dextrose Solution|Single 30 minute intravenous infusion
1804006|NCT00617994|Drug|INCB018424|INCB018424 1.5% cream BID for 28 days
1804007|NCT00618007|Drug|PF-00734200 30 mg QD|30 mg QD
1804008|NCT00618007|Drug|PF-00734200 20 mg QD|20 mg QD
1804009|NCT00618007|Drug|Placebo|Placebo
1804010|NCT00618020|Device|CiTop(tm) Guidewire|CiTop(tm)6 Guidewire
1804011|NCT00618033|Procedure|Hemodialysis|varying concentration of glucose in dialysate
1804012|NCT00618046|Drug|Oxcarbazepine|
1804013|NCT00618059|Drug|Pilocarpine|
1804014|NCT00618072|Drug|metformin and rosiglitazone|4 week dosage escalation of metformin, 500 mg/day (or placebo) to a total dose of 2000mg/day; starting dose of rosiglitazone 2mg/day(or placebo) added at weeks 3 and weeks 4 to a a total dose of 4 mg/day
1804015|NCT00618085|Behavioral|Motor imagery practice|During motor imagery practice a person imagines performing a skill or movement with all its sensory consequences without actually moving. In this study the therapists follow a motor imagery guideline designed for rehabilitation of skills and movement performance in subjects with neurological disease or damage. The guideline offers therapists structure and a strategy to deliver subject-specific imagery. The guideline is based on three major frameworks, namely; principles of motor learning, phased process of human movement and a training guide for sports coaches and performers from the National Coaching Foundation.
1804016|NCT00618085|Other|Standard physiotherapy and occupational therapy|Patients with neurological disease or damage will receive standard physiotherapy and occupational therapy.
1804017|NCT00618098|Biological|Octaplex (human prothrombin complex concentrate)|INR is determined 15 minutes after the end of each infusion. Each dose (mL/kg body weight) was calculated as = ln(INR/1.4)/0.52. The maximum dose for initial treatment was not to exceed 5500 IU. If the INR is ≥ 1.5 after the initial infusion, additional infusions will be repeated until the INR was < 1.5. Octaplex (500 units, IU) is supplied in vials and was reconstituted with 20 mL of Water for Injection (Ph.Eur.).
1804018|NCT00618098|Biological|Fresh frozen plasma|INR is determined 15 minutes after the end of each infusion. The initial dose is 10 mL/kg for a participant with an initial INR of < 3 and 15 mL/kg for a participant with an initial INR of ≥ 3. If the INR is ≥ 1.5 after the initial infusion, additional infusions of 5 mL/kg will be repeated until the INR was < 1.5. Fresh frozen plasma is supplied by the blood bank at each study site and will be prepared and handled according to the site's standard practice.
1804019|NCT00618111|Drug|Granisetron|
1804020|NCT00618124|Drug|SU011248; Capecitabine|Dose finding study using SU011248 daily by oral capsule in a continuous regimen or administered for 4 out of every 6 weeks (Schedule 4/2) or 2 out of every 3 weeks (Schedule 2/1), with capecitabine administered 2 out of every 3 weeks until progression or unacceptable toxicity.
1804021|NCT00618150|Behavioral|Patient education|An educational program: Three lessons spaced over 2 weeks.
1804022|NCT00610298|Device|whole body vibration using a Galileo vibrating platform|whole body vibration at 20 hertz for 3 minutes 3 to 5 days per week for up to 12 weeks
1804023|NCT00610311|Drug|cyclophosphamide|60 mg/kg day x 2 days intravenous in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg day x 2 days over 1 hour
1804024|NCT00610311|Drug|fludarabine phosphate|25 mg/m^2 day intravenous piggy back over 30 minutes for 5 days
1804025|NCT00610311|Biological|Aldesleukin|720,000 IU/kg intravenously over 15 minutes every 8 hours (+/- 1 hour) for up to 5 days.
1804073|NCT00610649|Drug|MK-8777|Orally administered capsules containing either 50 mg or 100 mg MK-8777.
1804026|NCT00610311|Biological|ALVAC gp100 Vaccine|0.5 ml containing a target dose of 10^7 CCID50 (with a range of approximately 10^6,4 to 10^7,9/mL) of the gp100 ALVAC virus subcutaneously in each extremity (total of 4 x 10^7 CCID50/2mL)
1804027|NCT00610311|Biological|anti-gp100:154-162 Tcell receptor (TCR) peripheral blood lymphocyte (PBL)|3 x 10^11 anti-gp100:154-162 TCR engineered PBL by intravenous infusion. A minimum of approximately 5 x 10^8 cells will be given.
1804028|NCT00610324|Drug|Chlorhexidine gluconate|Twice-daily oropharyngeal cleansing with 0.2% Chlorhexidine gluconate
1804029|NCT00610324|Drug|Potassium permanganate|Twice-daily oropharyngeal cleansing with 0.01% Potassium permanganate
1804030|NCT00610337|Drug|Cethrin® (BA-210)|Intraoperative epidural administration during spinal decompression surgery
1804031|NCT00610337|Procedure|placebo|Spinal decompression surgery without administration of Cethrin® BA-210
1804032|NCT00610350|Drug|levosimendan|24 μg/kg administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
1804033|NCT00610350|Drug|Placebo|an identical-appearing placebo prepared and labelled by the pharmacy was administered as a slow i.v. 50 ml bolus through the central venous port of a pulmonary artery catheter over the 10 minutes before initiation of CPB
1804034|NCT00610363|Biological|Rilonacept|Rilonacept 320 mg loading dose on Day 1 followed by Rilonacept 160 mg/2 mL injections qw for 17 weeks.
1804035|NCT00610363|Other|Placebo (for Rilonacept)|Placebo loading dose on Day 1 followed by single placebo injections (2 mL) qw for 17 weeks.
1804036|NCT00610376|Behavioral|Preschool handwashing intervention program|This preschool-based intervention program used a multi-pronged approach that included elements aimed at preschool staff, children, and school nurses, as well as hygienic changes to the classroom environment.
1804037|NCT00610376|Behavioral|Home component intervention|The home component was intended to reinforce handwashing practices through education in the home. It consisted of a video, a magnet, and a card.
1804038|NCT00610389|Biological|immunotherapy with dendritic cells|We will administer four daily doses (repeated every 24 hours)o dendritic cells in two cycles one month apart. We will administer systemic treatment with PEG-IFN alfa and GM-CSF to potentiate activity.
1804039|NCT00610402|Other|blood sample tear drop sample|blood sample tear drop sample
1804040|NCT00610415|Procedure|tumor biopsy|
1958327|NCT01772823|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
1804044|NCT00610441|Drug|MK-8777|
1804045|NCT00610441|Drug|Placebo|
1804046|NCT00610454|Drug|Levetiracetam|
1804047|NCT00610467|Device|combined optical and MR imaging|MRI contrast agent (0.1 mmol/kg) optical contrast agent ICG (0.5 mg/kg)
1804048|NCT00610480|Drug|Optive|Instillation of Optive followed by Evaporametry assessment at 30 and 60 minutes
1804049|NCT00610480|Drug|Systane|Instillation of Systane followed by Evaporametry assessment at 30 and 60 minutes
1804050|NCT00610480|Drug|Systane|
1804051|NCT00610493|Drug|Bevacizumab|5 mg/kg By Vein Over 90 Minutes on Day 1 of Each 21 Day Cycle
1804052|NCT00610493|Drug|Temsirolimus|5 mg By Vein Over 30-60 Minutes on Days 1, 8, 15 of Each 21 Day Cycle
1804053|NCT00610493|Procedure|Additional Blood Drawn|2 teaspoons each time: 4xDay Cycle 1 after start of first infusion; at Day 8 of Cycle 1; at Day 15 of Cycle 1; and at end of Cycle 1.
1804054|NCT00610493|Procedure|Biopsy|First tumor biopsy during screening visit and Second at the end of Cycle 1
1804055|NCT00610493|Procedure|DCE-MRI Scan|DCE-MRI (dynamic contrast-enhanced magnetic resonance imaging) scan during screening visit, at 24-48 hours after the start of Cycle 1, and at the end of Cycle 1
1804056|NCT00610506|Drug|Escitalopram|Escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability.
1804057|NCT00610519|Dietary Supplement|mixture of aromatic essential oils.|3% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the throat.
1804058|NCT00610519|Dietary Supplement|placebo|0:1% of Lemon VIP (Florasynth,Israel), spraying to the throat.
1804059|NCT00610532|Drug|phenytoin|intravenous phenytoin (15 mg/kg) single dose
1804060|NCT00610532|Drug|phenytoin and probenecid|intravenous phenytoin (15 mg/kg) single dose and oral probenecid 2000 mg single dose
1804061|NCT00610545|Drug|Atorvastatin|Atorvastatin 80 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
1804062|NCT00610545|Drug|Atorvastatin|Atorvastatin 20 mg; Use Atorvastatin for 60 days , and the vascular surgery will be made between day-7 and day-60
1804064|NCT00610571|Drug|Oral Topotecan and Temodar|"Temozolomide is taken by mouth once day, every day for 5 consecutive days at dose of 200 mg/m2/day.
Oral Topotecan will be taken daily for 5 consecutive days beginning 12-24 hrs after 1st dose of Temozolomide. Dose escalation of Oral Topotecan will be carried out in cohorts of 3 new subjects beginning w dose level 1 @ 0.75 mg/m2/dose."
1804065|NCT00610584|Procedure|acupuncture|arm 1: verum acupuncture group: 12 interventions (semi-standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
1804066|NCT00610584|Procedure|minimal (sham)acupuncture|arm 2: minimal (sham) acupuncture group: 12 interventions (standardised): 8 in the first 4 weeks and 4 in the next 4 weeks + rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily))
1804067|NCT00610584|Drug|cetirizine dihydrochloride (rescue medication)|arm 3: rescue medication (up to 2 doses of second-generation oral antihistamines daily (e.g. 2 x 1 cetirizine dihydrochloride/daily)) alone
1804068|NCT00610610|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in the following manner: week 1: 12.5 mg per day, week 2: 25 mg per day, week 3: 37.5 mg per day, wk 4: 50 mg per day and week 5: 62.5 mg per day.
1804069|NCT00610610|Drug|Placebo|Same shape Placebo
1804070|NCT00610623|Drug|azithromycin|300 mg/day, IV from day 1 to 20
1804071|NCT00610623|Drug|placebo|once per day, IV from day 1 to 20
1804074|NCT00610649|Drug|Placebo|Orally administered matching placebo capsules.
1804075|NCT00610675|Drug|Org 50081|One tablet daily
1804076|NCT00610688|Drug|Prenatal Vitamin|Once daily, prenatal vitamin containing 400IU of Vitamin D, until delivery
1804077|NCT00610688|Drug|Cholecalciferol (Vitamin D3)|Once daily, 1600IU dose of Vitamin D from 12 weeks gestation to delivery
1804078|NCT00610688|Drug|Cholecalciferol (Vitamin D3)|Once daily, 3600IU dose of Vitamin D, from 12 weeks until delivery
1804079|NCT00610701|Device|Anterior pin placement|Anteriorly-placed (front of the leg) femoral external fixator pins
1804080|NCT00610701|Device|Lateral pin placement|Laterally-placed (side of the leg) femoral external fixator pind
1804081|NCT00610714|Drug|AZD0530|oral once daily dose
1804082|NCT00610714|Drug|Carboplatin|intravenous injection
1804083|NCT00610714|Drug|Paclitaxel|intravenous infusion
1804092|NCT00610740|Drug|topical gemcitabine hydrochloride|Gemcitabine 100 mg/m2 will be administered as a single dose, directly to the cervix via the CerviPrep™ device.
1804093|NCT00610740|Procedure|therapeutic conventional surgery|hysterectomy
1804094|NCT00610753|Behavioral|Family Behavior Therapy|This treatment is usually delivered in two phases: In the first phase there is an initial investigation of family behavior around feeding using a family meal followed by family therapy focused on enhancing feeding of the anorexic child in order to promote weight gain. In the second phase, once weight gain is well established the adolescent is given greater autonomy over feeding and in later sessions over other issues.
1804095|NCT00610753|Behavioral|Systems Family Therapy|This therapy is applied in three phases. 1. In the first 2 or 3-sessions the treatment is explained to the family and an initial examination of family issues begins. 2. In the second phase family interactions and psychological processes are explored with clarification for family members. 3. In the third phase knowledge of family patterns is refined aiming for behavior change.
1804096|NCT00610779|Dietary Supplement|mixture of aromatic essential oils.|1% of mixture containing aromatic essential oils of Eucalyptus citriodora, Eucalyptus globulus, Mentha piperita, Origanum syriacum, and Rosmarinus Officinalis, spraying to the nose.
1804097|NCT00610779|Dietary Supplement|placebo|0.1% of Lemon VIP (Florasynth,Israel), spraying to the nose.
1804098|NCT00610792|Drug|bortezomib|1.3 mg/m2 on Days 1, 4, 8 & 11 every 3 weeks (1 cycle = 21 days) for up to six cycles
1804099|NCT00610792|Drug|pegylated liposomal doxorubicin|30 mg/m2 on Day 1 every 3 weeks (1 cycle = 21 days) for up to six cycles
1804100|NCT00610805|Other|Preventive Cardiology|Patients will receive those interventions recommended by the Preventive Cardiologist. This may include: exercise, electrocardiogram, specialized blood testing, blood pressure monitoring, nutrition counseling, smoking cessation counseling, and pharmacotherapy for hypercholesterolemia, hypertension, and blood sugar abnormalities.
1804101|NCT00610805|Other|Usual Care|Participants will receive usual care per their primary care physician.
1804102|NCT00610818|Other|Palifermin|day -14, -13, -12 before transplant and then day 0,1,2 after transplant
1804103|NCT00610831|Device|DIRECTVIEW CR Mammography|4 views screening mammogram
1804104|NCT00610844|Procedure|pulmonary radiofrequency ablation|CT-guided pulmonary radiofrequency ablation
1804105|NCT00610857|Drug|Anti-CTLA4 monoclonal antibody and HDI|"One course of therapy consists of three cycles (1 cycle=28days). Anti-CTLA4 monoclonal antibody (15 mg/kg i.v.) will be given during the first cycle only. HDI will be given all three cycles - cycle 1: 20 MU/m2 i.v. on days 0, 1, 2, 3, 4 a week (MTWRF) for 4 weeks; cycle 2: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks; and cycle 3: 10 MU/m2 s.c. 3 days a week (MWF) for 4 weeks.
Response assessment will be carried out at day 56 and day 84. Every patient will receive 3 cycles regardless of response status after the first 2 cycles. However, a patient may be taken off therapy in the event of clinical progression at the discretion of the treating physician.
Patients without evidence for disease progression after 3 cycles may be offered additional cycles two weeks after completion of the third cycle. Therapy will continue for a maximum of 12 months."
1804106|NCT00610870|Drug|atorvastatin|atorvastatin 80mg/day before primary coronary intervention
1804107|NCT00610883|Drug|LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU|LSA4 intervention includes three phases: induction, consolidation and maintenance
1804108|NCT00610909|Drug|Paroxetine CR|Those in the active treatment group will receive doses of Paxil CR in increments of 12.5 mg daily for the first week and increased at 12.5 mg increments at visit weeks to a maximum of 50 mg daily, as determined by the investigator. The investigator will adjust dosage based on clinical response. Following the completion of the double-blind phase, patients on placebo and non-responders to the study drug will be tapered off the study drug back to 0 over 2 weeks, and they will be referred to their Primary Care Physician, Internist or Gastroenterologist to be prescribed treatment for Irritable Bowel Syndrome.
1804109|NCT00610909|Drug|Placebo|Placebo
1804110|NCT00610922|Dietary Supplement|Docosahexaenoic acid (DHA)|DHA 20 mg per day through 12 months of life
1804111|NCT00610935|Drug|Peramivir|To evaluate the efficacy of peramivir administered intramuscularly compared to placebo on the time to alleviation of clinical symptoms in adult subjects with uncomplicated acute influenza.
1804112|NCT00610935|Drug|Placebo|Single intramuscular injection
1804113|NCT00610948|Biological|panitumumab|Given IV
1804114|NCT00610948|Drug|everolimus|Given orally
1804115|NCT00610948|Drug|fluorouracil|Given IV
1804116|NCT00610948|Drug|leucovorin calcium|Given IV
1804117|NCT00610948|Drug|oxaliplatin|Given IV
1804118|NCT00610974|Behavioral|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
1804119|NCT00610974|Behavioral|Body-weight supported treadmill training|BWSTT for 3 times/week for 12 weeks. Each session, subjects will first complete a 10-minute warm-up period followed by 45 minutes of the assigned therapy. Rest breaks will be provided as needed, but subjects must complete 45 minutes of walking per session.
1804120|NCT00610987|Drug|cefazolin|Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group I will receive 1-g doses of cefazolin every eight hours for the next 24 hours.
1804121|NCT00610987|Drug|Placebo|Patients will be randomly assigned to one of two groups. Both groups will receive 1 gram (g) of IV cefazolin prior to incision, per standard protocol at our institution. A 2-g dose of cefazolin will be administered IV for patients weighing more than 80 kg. A second 1-g dose of cefazolin will be given three hours later if the patient is still in the operating room. Upon completion of the surgical procedure, Group II will receive no additional antibiotic. Instead, they will receive normal saline injection every eight hours as a placebo.
1804122|NCT00611000|Dietary Supplement|folic acid|
1804123|NCT00611000|Genetic|DNA methylation analysis|
1804124|NCT00611000|Genetic|gene expression analysis|
1804125|NCT00611000|Genetic|microarray analysis|
1804126|NCT00611000|Genetic|polymorphism analysis|
1804127|NCT00611000|Other|laboratory biomarker analysis|
1804128|NCT00611013|Device|Magnetic Resonance Imaging|Some participants may receive MRI contrast agent, 0.1 mmol/kg
1804129|NCT00611026|Drug|Tolterodine ER|The tolterodine treatment will be 4 mg once daily(QD) for 12 weeks.
1804130|NCT00611026|Drug|Placebo|Placebo treatment will be once daily(QD) for 12 weeks.
1804131|NCT00611026|Drug|Fesoterodine|The fesoterodine treatment will start with 4 mg once daily(QD) for 1 week followed by a forced dose-escalation to 8mg once daily(QD) for 11 weeks.
1804132|NCT00611039|Drug|Darunavir 900mg + ritonavir 100 mg once a day|Darunavir 900mg + ritonavir 100 mg once a day
1804133|NCT00611039|Drug|Darunavir 600mg + ritonavir 100mg twice day|Darunavir 600mg + ritonavir 100mg twice day
1804134|NCT00611052|Behavioral|the Adolescent Coping with Stress|A group cognitive intervention, manualized and highly structured. Includes 8 sessions (á 1.5 hours) and a booster session 6 months after termination of the actual intervention. Groups leaders are specifically trained for this course.
1804135|NCT00611052|Behavioral|Treatment as usual|The usual treatment received by the adolescent with mild to moderate self-reported depressive symptoms in school health care.
1804136|NCT00611052|Other|usual health education|usual health education given by the school nurses, targeted for healthy controls with no depressive symptoms according to the self-report scale
1804137|NCT00611065|Device|magnetic resonance imaging|MR contrast agent (0.1 mmol/kg)
1804138|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|Follow-up appointment needs/plans
1804139|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|Laboratory follow-up needs
1804140|NCT00611091|Other|Electronic delivery of enhanced discharge information to the ambulatory physician|New medications
1804141|NCT00611104|Dietary Supplement|standardized freeze-dried table grape powder|
1804142|NCT00611104|Other|laboratory biomarker analysis|
1804143|NCT00611104|Other|pharmacological study|
1804144|NCT00611117|Other|Physical Activity Level|High vs. low physical activity during a high fat diet consumption.
1804147|NCT00611143|Drug|atorvastatin|atorvastatin 20 mg/d, started 3 days before surgery
1804148|NCT00618163|Drug|Meloxicam|
1804149|NCT00618176|Drug|Zidovudine (AZT)+ Didanosine (ddI)+ Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Didanosine (ddI) 200mg bid (W>60Kg)125mg bid (W<60Kg) Nevirapine (NVP) 200mg bid
1804150|NCT00618176|Drug|Stavudine (d4T), Lamivudine (3TC), Nevirapine (NVP)|Stavudine (d4T) 30mg bid (W>60Kg)20mg bid (W<60Kg) Lamivudine (3TC)300mg qd Nevirapine (NVP)200mg bid
1804151|NCT00618176|Drug|Zidovudine (AZT), Lamivudine (3TC), Nevirapine (NVP)|Zidovudine (AZT) 300mg bid Lamivudine (3TC) 300mg qd Nevirapine (NVP) 200mg bid
1804152|NCT00618202|Drug|Balsalazide|
1804153|NCT00618215|Behavioral|peer group educational implementation strategy|"Delivery CPG
Education session IQual group
Online training website (individual feed back)
Reminder (flow chart), individual feed back record form
Feed back by email
Registration in practice"
1804154|NCT00618228|Drug|Balsalazide|
1804155|NCT00618241|Drug|lamotrigine|100 mg
1804156|NCT00618241|Drug|Raltegravir|400 mg BD
1804157|NCT00618254|Drug|Granisetron|
1804158|NCT00618280|Drug|nicotine nasal spray|0,5 mg nicotine nasal spray or placebo (pepperspray)
1804159|NCT00618293|Drug|Haemate HS|intravenous infusion of Haemate (dosage dependent on body weight)
1804160|NCT00618293|Other|NaCl-solution|intravenous infusion of 0.9%NaCl-Solution
1804161|NCT00618319|Drug|BIIB021|Dose, schedule, and duration specified in protocol
1804162|NCT00618332|Drug|mometasone furoate nasal spray|2 puffs in each nostril once a day for 2 weeks
1804163|NCT00618332|Drug|placebo|2 puffs in each nostril once a day for 2 weeks
1804164|NCT00618345|Drug|everolimus|
1804165|NCT00618345|Genetic|DNA analysis|
1804166|NCT00618345|Genetic|protein analysis|
1804167|NCT00618345|Genetic|western blotting|
1804168|NCT00618345|Other|flow cytometry|
1804169|NCT00618345|Other|laboratory biomarker analysis|
1804170|NCT00618345|Procedure|biopsy|
1804171|NCT00618358|Device|Vascular Sealant System|The Vascular Sealant System is intended for use in vascular reconstructions to achieve adjunctive hemostasis by mechanically sealing areas of leakage.
1804172|NCT00618358|Other|Gelfoam/Thrombin|
1804173|NCT00618371|Drug|Raltegravir (MK-0518)|Antiretroviral drug intensification with Raltegravir (MK0518) 400mg orally every 12 hours for 28 days in addition to the prescribed antiretroviral therapy
1804217|NCT00618631|Drug|Carfentanil|
1804218|NCT00618644|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection
1804174|NCT00618384|Drug|Sorafenib|patients get transarterial chemoembolization (TACE) will get film-coated tablets of Sorafenib (2 x 400 mg/day) until progressive disease
1804175|NCT00618397|Drug|Ketamine|Ketamine administered in doses of 0.01mg/kg/hr, 0.1mg/kg/hr and 0.5mg/kg/hr to PICU patients.
1804176|NCT00618410|Device|Carbon dioxide, USP|Carbon dioxide (CO2) delivered via a nosepiece at a flow rate of 0.5 (± 0.05) SLPM for 10 seconds /nostril
1804177|NCT00618410|Other|Placebo|Nasal placebo
1804178|NCT00618423|Drug|Placebo|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
1804179|NCT00618423|Drug|Ketamine|50 ml syringes provided by the HUG pharmacy will contain 1% ketamine or 0.9% NaCl. After induction and before start of surgery, patients will receive an intravenous bolus of 0.025 ml/kg of the study solution (corresponding to 0.25 mg/kg ketamine). Maintenance will be with a syringe driver at a rate of 0.025 ml/kg/h (corresponding to 0.25 mg/kg/h ketamine) until one hour before the end of surgery, and will then be decreased to a rate of 0.01 ml/kg/h (corresponding to 0.1 mg/kg/h ketamine) throughout the stay in the recovery room (usually 2 to 3 hours). The infusion will be stopped when the patient leaves the recovery room.
1804180|NCT00618436|Drug|Levetiracetam|Levetiracetam group will receive a loading dose of 20 mg/kg IV(rounded to nearest 250mg) to a maximum of 2000mg, then started on maintenance dose (1000 mg,IV q 12h) as prophylaxis for seven days.
1804181|NCT00618436|Drug|Phenytoin|The group will receive a loading dose of fosphenytoin 20 mg/kg IV to a maximum of 2000 mg, then started on maintenance dose of 5mg/kg/day, rounded to nearest 100mg dose, IV, q 12h for seven days.
1804182|NCT00618449|Drug|Azithromcyin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given 30 days apart; at Day 0 & Day 30 for a total of 2 doses.
1804183|NCT00618449|Drug|Azithromycin|1 gm Azithromycin orally, provided as four 250 mg tablets for adults; pediatric suspension will be provided to children > 1 year old (20 mg/kg body weight) to a maximal dose of 500 mg - Given at Day 30 for a total of 1 dose.
1804184|NCT00618462|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include weekly 50-minute sessions for 8 weeks. The sessions will focus on learning skills to cope with urges to gamble and developing alternatives to gambling.
1804185|NCT00618462|Behavioral|Contingency management (CM)|CM will provide incentive, such as a gift certificate to a store or restaurant, for completing activities not related to gambling. Participants and their therapists will decide upon two potential alternative activities to gambling during each therapy session.
1804186|NCT00618462|Behavioral|Psychoeducation therapy|Psychoeducation therapy will include weekly 50-minute therapy sessions for 8 weeks. The sessions will focus on education about gambling and related problems.
1804187|NCT00618462|Behavioral|Case management|Case management will assist participants in obtaining additional services from the community as needed.
1804188|NCT00618462|Behavioral|Gamblers Anonymous (GA)|All participants will be referred to GA, a support group of people who are recovering from gambling addiction, and will be encouraged to attend meetings.
1804189|NCT00618475|Behavioral|Cognitive behavioral therapy|"10 sessions
1 hour per week"
1804190|NCT00618488|Dietary Supplement|Probiotic BB12 - Bifidobacterium lactis|Bifidobacterium lactis (3.1 oz yogurt) administered once a day for 6 weeks
1804191|NCT00618488|Dietary Supplement|Placebo|Placebo administered once a day for 6 weeks
1804192|NCT00618501|Drug|cytarabine|
1804193|NCT00618501|Drug|daunorubicin hydrochloride|
1804194|NCT00618501|Drug|etoposide|
1804195|NCT00618501|Drug|imatinib mesylate|
1804196|NCT00618501|Drug|leucovorin calcium|
1804197|NCT00618501|Drug|methotrexate|
1804198|NCT00618501|Drug|prednisolone|
1804199|NCT00618501|Drug|therapeutic hydrocortisone|
1804200|NCT00618501|Drug|vincristine sulfate|
1804201|NCT00618501|Procedure|allogeneic hematopoietic stem cell transplantation|
1804202|NCT00618514|Device|Bright Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber with a fitted ceramic tip on the end. Treatment performed on one leg.
1804203|NCT00618514|Device|Bare Tip Laser Fiber|Endovenous laser ablation treatment for varicose veins in a section of the Greater Saphenous Vein (GSV) using a laser fiber readily available on the market with a bare tip on the end. Treatment performed on one leg.
1804204|NCT00618540|Biological|alemtuzumab|Administered intravenously (IV) 0.2 mg/kg on Days -8 through -4.
1804205|NCT00618540|Drug|fludarabine phosphate|Administered 30 mg/m2 intravenously (IV) over 30-60 min on Days -7 through -3. (dose adjust if age <12 months)
1804206|NCT00618540|Drug|melphalan|Administered 140 mg/m2 intravenously (IV) over 30 min on Day -2 (dose adjust if age <12 months)
1804207|NCT00618540|Procedure|stem cell transplantation|Administered as allogeneic hematopoietic, peripheral blood or umbilical cord blood transplantation
1804208|NCT00618553|Other|Questionnaire|Questionnaire regarding quality-of-life that lasts about 30 minutes.
1804209|NCT00618553|Behavioral|Pulmonary Rehabilitation|Rehabilitation treatment given over about 3-4 weeks.
1804210|NCT00618566|Behavioral|WPD and Depression Treatment Group|Intervention selected will depend on Phase I data analysis.
1804211|NCT00618579|Drug|LWMH in TB-402 treated subjects or TB-402 in warfarin treated subjects|Administration of LMWH in healthy male subjects treated with TB-402 and administration of TB-402 in healthy male subjects treated with warfarin
1804212|NCT00618592|Dietary Supplement|PreOp carbohydrate drink|800 mL of PreOp evening before surgery, 400 mL at least two hours before surgery
1804213|NCT00618605|Biological|Ad26.ENVA.01 HIV-1 vaccine|Recombinant adenovirus serotype 26 HIV-1 vaccine
1804214|NCT00618618|Drug|Deoxycholic Acid Injection|Formulated as an injectable solution containing deoxycholic acid at a concentration of 10 mg/mL.
1804215|NCT00618618|Drug|Placebo|
1804216|NCT00618631|Drug|Nicotine|
1804219|NCT00618657|Drug|Carboplatin|Given IV
1804220|NCT00618657|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1804221|NCT00618657|Drug|bevacizumab|Given IV
1804222|NCT00618657|Drug|trastuzumab|Given IV
1804223|NCT00618657|Procedure|magnetic resonance imaging|Optional correlative studies
1804224|NCT00618657|Procedure|therapeutic conventional surgery|Post-chemotherapy surgery for patients with a response or stable disease must take place no sooner than 21 days after last dose of Herceptin; and 40 days after last dose of bevacizumab to allow for normalization of blood counts
1804225|NCT00618670|Behavioral|Walking Exercise|Three times per week for 3 months
1804226|NCT00618670|Behavioral|Control--Resistance Training|Three times per week for 3 months
1804227|NCT00618683|Procedure|Cardiac Invasive Electrophysiological Study|Mapping and localizing of the components of the reentrant circuit as part of the Electrophysiological Study
1804228|NCT00618696|Biological|anti-CD45 monoclonal antibody AHN-12|150 mg/m^2 cold antibody at Day 0
1804229|NCT00618696|Radiation|yttrium Y 90 anti-CD45 monoclonal antibody AHN-12|Dose per scheduled level; 2.5-12.5 mCi/m^2
1804230|NCT00618709|Drug|ATX-101|ATX-101 single dose
1804231|NCT00618722|Drug|Deoxycholic Acid Injection|
1804232|NCT00618722|Drug|Placebo|
1804233|NCT00618735|Drug|BIIB021|Dosage, frequency (once daily), and duration as specified in protocol. This dosing arm is currently on hold.
1804234|NCT00618735|Drug|BIIB021|Twice daily dosing
1804235|NCT00618748|Drug|Olanzapine|5-20 mg/day, oral, daily
1804236|NCT00618761|Other|hyperglycemic clamp test|hyperglycemic clamp test
1804237|NCT00618774|Drug|telmisartan40/amlodipine5|
1804238|NCT00618774|Drug|telmisartan80/amlodipine5|
1804239|NCT00618787|Device|COPA AMD (note: name is not an acronym)|Foam dressing impregnated with Polyhexamethylene Biguanide
1804240|NCT00618787|Device|COPA (note: name is not an acronym)|Regular foam dressing without PHMB
1804241|NCT00618800|Behavioral|Pharmaceutical Care|Participants receive written information about falls prevention and a personal consultation from a community pharmacist concerning their medication regimen. The pharmacist follows up, as required, with participants' physicians to coordinate any recommended medication changes.
1804242|NCT00618800|Other|Written Materials|Participants receive written information about falls prevention.
1804243|NCT00618813|Other|radiation therapy|Undergo radiation therapy
1804244|NCT00618813|Other|therapeutic conventional surgery|Undergo surgery
1804245|NCT00618813|Drug|etoposide|Given IV
1804246|NCT00618813|Drug|ifosfamide|Given IV
1804247|NCT00618813|Drug|doxorubicin hydrochloride|Given IV
1804248|NCT00618813|Drug|cyclophosphamide|Given IV
1804249|NCT00618813|Drug|vincristine sulfate|Given IV
1804250|NCT00618813|Drug|topotecan hydrochloride|Given IV
1804251|NCT00618813|Biological|filgrastim|Given SC
1804252|NCT00618826|Drug|Paclitaxel|Patients will be premedicated with dexamethasone and diphenhydramine hydrochloride. Patients will received 150mg of paclitaxel via IV over 120 mins.
1804253|NCT00618826|Drug|Gemcitabine|Patients will receive 1500mg of Gemcitabine via IV over 30-60 minutes. Gemcitabine will be given after Paclitaxel.
1804254|NCT00618826|Drug|Avastin|10mg/kg will be given via IV over 90 mins (1st dose). Patients must remain under supervision for 1 hr after completion of the initial dose of Avastin. If no side effects occur, shortened, 60-min 2nd infusion, the post-infusion observation period for the subsequent infusions may be shortened to 20 minutes, and eliminated entirely with the fourth and subsequent infusions.
1804255|NCT00618839|Biological|StrataGraft Skin Tissue|StrataGraft™ skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal cells (NIKS™ cells).
1804256|NCT00618839|Procedure|Cadaver allograft|The standard of care for temporary coverage of full thickness skin defects is coverage with cadaver allograft until the wound can be autografted.
1804257|NCT00618852|Drug|Furosemide|The dose of furosemide will be 1 mg/kg by intravenous bolus injection
1804258|NCT00618852|Drug|Saline|1 mg/kg by intravenous bolus injection
1804259|NCT00618865|Dietary Supplement|Omega-3 fatty acids|
1804260|NCT00618878|Procedure|Electroacupuncture|twice a week for 26 treatments in total
1804261|NCT00618878|Procedure|Laser Therapy|twice a week for a total of 26 treatments
1804262|NCT00618904|Dietary Supplement|Probiotics - Lactobacillus and bifidobacterium|Probiotics administered bid for 6 weeks.
1804263|NCT00618904|Dietary Supplement|Placebo|Placebo administered bid for 6 weeks.
1804264|NCT00618917|Genetic|MnSOD|15 ml of a liquid that contains either 0.3 mg, 3.0 mg or 30.0 mg (depending on which cohort is open when the subject is entered) of MnSOD PL. This will be given on Day 1 and 3 of each week of the experimental treatment for a total of 14 doses.
1804265|NCT00618930|Drug|Moviprep®|use of Moviprep®
1804266|NCT00618930|Drug|Fleet|Use of Fleet
1804267|NCT00618943|Behavioral|Tobacco Use Cessation|The proposed intervention will proceed in three steps. Step 1, provided to all intervention participants, includes multimedia, stage-based, expert-system contacts at intake, 3- and 6-months follow-up supported with brief (15-min) motivational counseling sessions. Step 2, reserved for intervention participants interested in quitting, consists of 12-weeks of individual CBT sessions for smoking cessation. Step 3, a 12-week course of nicotine patch, will be offered to adolescents who enter the CBT Cessation Treatment, who do not have any medical contraindications, and who smoke an average of 5 cigarettes or more per day in the past month.
1804268|NCT00618956|Drug|Milnacipran hydrochloride|Milnacipran 100 to 200 mg/day tablet (administered in divided doses, twice daily [BID]), oral administration.
1804269|NCT00618956|Drug|Placebo|Placebo
1804270|NCT00618969|Other|haploidentical allogeneic PBSC transp|"Days -5 and -4: IV busulfan 3.2 mg/kg/dose daily for 2 days
Day -3: IV melphalan 100 mg/m2 as a single dose
Days -2 and -1: IV alemtuzumab 30 mg/dose daily for 2 days
Day 0: Transplantation of haploidentical related allogeneic peripheral blood stem cells (PBSCs)- target cell dose 10 x 106 donor CD34+ cells per kilogram of recipient weight"
1804447|NCT00620126|Other|UC Home Automated Telemanagement|Weekly assessment with UC Home Automated Telemanagement
1805003|NCT00623298|Behavioral|Narrative Exposure Therapy|
1804271|NCT00618982|Drug|Sorafenib (Nexavar, BAY43-9006)|The initial dose of sorafenib will be 400 mg bid administered orally, on a continuous basis. A treatment cycle is considered to be 28 days. Intrapatient dose escalation will occur according to the following schedule, providing no grade 3 or 4 toxicities are observed (except for alopecia, nausea and vomiting); Day 1-28 400 mg bid, Day 29-56 600 mg bid, Day 57 onwards 800 mg bid. Subjects will continue on treatment until progression, unacceptable toxicity, subject withdraws consent or the decision is taken to stop the study following the analysis of response rates.
1804272|NCT00618995|Drug|Comparator: ER niacin (+) laropiprant|ER niacin 2 g/ laropiprant 40 mg daily for 7 days.
1804273|NCT00618995|Drug|Comparator: ER niacin|ER niacin 2 g daily for 7 days.
1804274|NCT00618995|Drug|Comparator: laropiprant|laropiprant 40 mg daily for 7 days.
1804275|NCT00618995|Drug|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
1804276|NCT00619008|Other|Ad libitum low carbohydrate diet|6 week ad libitum low carbohydrate diet
1804277|NCT00619008|Other|Ad libitum High Complex Carbohydrate Diet|6 week ad libitum high complex carbohydrate diet
1804278|NCT00619008|Other|Energy-restricted high complex carbohydrate diet|6 week energy-restricted (68% of estimated energy requirement for weight maintenance) high complex carbohydrate diet.
1804279|NCT00619021|Drug|gemcitabine hydrochloride|4 dose levels designated by cohort; 600 mg/m^2, 800 mg/m^2, 1000 mg/m^2, 1200 mg/m^2
1804283|NCT00619060|Drug|Topical Myristyl Nicotinate Cream|Participants apply topical myristyl nicotinate to one forearm once daily for 4 weeks.
1804284|NCT00619060|Drug|Placebo|Participants apply topical placebo to one forearm once daily for 4 weeks.
1804285|NCT00619073|Drug|clopidogrel + aspirin|Clopidogrel 75mg plus aspirin 81mg, tablet by mouth daily for 14 days.
1804286|NCT00619073|Drug|placebo|Placebo plus aspirin 81 mg, tablet by mouth daily for 14 days.
1804287|NCT00619073|Drug|Aspirin|Aspirin 81mg tablet by mouth continued daily alone for 43 days after day 14.
1804288|NCT00619086|Drug|Dexamethason Helvepharm ®|8 mg Dexamethason i.v. 45 minutes prior to surgery
1804289|NCT00619086|Drug|Placebo|100 ml sodium chloride i.v. 45 minutes prior to surgery
1804290|NCT00619099|Drug|decitabine|Schedule A: decitabine will be administered subcutaneously (SQ) daily for 3 consecutive days (Days 1 to 3) every 28 days. The dose will be 20 mg/m^2/day. One course will be considered 28 days.
1804291|NCT00619099|Drug|decitabine|Schedule B: decitabine will be administered SQ every 7 days for 21 days (Days 1, 8, and 15) followed by 7 days without an administration of decitabine. The dose will be 20 mg/m^2/day. One course will be considered 28 days.
1804293|NCT00619125|Other|palm pilot recording responses to questionnaires|Short interval assessment (provided by data from palm pilot) may provide a more accurate picture of patient symptom experience.
1804294|NCT00619138|Behavioral|individual cognitive-behavioural therapy|1 session per week for 12 weeks
1804295|NCT00619138|Behavioral|stepped care model|three steps: short psycho-education, a 10 weeks Internet-based self-help program, 12 weeks individual cognitive-behavioural therapy
1804296|NCT00619151|Device|Top Hat|Implant of CarboMedics Top Hat mechanical valve.
1804297|NCT00619151|Device|Regent|Implant of the St. Jude Medical Regent mechanical valve
1804298|NCT00619164|Drug|E5555|E5555, 50 mg (tablet), taken orally, once a day.
1804299|NCT00619164|Drug|E5555|E5555, 100 mg (tablet), taken orally, once a day.
1804300|NCT00619164|Drug|E5555|E5555, 200 mg (tablet), taken orally, once a day.
1804301|NCT00619164|Drug|Placebo|Placebo tablet taken orally, once a day.
1804302|NCT00619190|Drug|aripiprazole|aripiprazole, open label, flexibly dosed from 1mg to 30mg, provided for up to 12 months
1804303|NCT00619203|Drug|Glycerol and paracetamol|"glycerol by mouth (po) 1.5ml/kg max 25 ml/dose x 6 hourly x 8 doses
paracetamol PR 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7"
1804304|NCT00619203|Drug|Paracetamol|paracetamol 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses
1804305|NCT00619203|Drug|Paracetamol|paracetamol po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
1804306|NCT00619203|Drug|Paracetamol|po 35 mg/kg first dose, then 20 mg/kg 6 hourly x 7 doses plus placebo suppository
1804307|NCT00619203|Drug|Placebo|2 placebos, one po, one suppository
1804308|NCT00619203|Drug|Paracetamol and glycerol|"35 mg/kg po first dose, then 20 mg/kg 6 hourly x 7 paracetamol
1.5 ml/kg max 25 ml/dose 6 hourly x 8 doses"
1804309|NCT00619203|Drug|Glycerol|glycerol 1.5 ml/kg /dose 6 hourly x 8 max dose = 25ml
1804310|NCT00619216|Drug|Mycophenolic Acid (Myfortic)|Equimolar conversion from mycophenolate mofetil to mycophenolic acid
1804311|NCT00619229|Drug|Alprostadil (prostaglandin E1)|Alprostadil 20 µg ampoules; 60 µg alprostadil/d i.v. for 15 days.
1804312|NCT00619229|Other|Placebo|Placebo/d i.v. for 15 days
1804313|NCT00619242|Drug|sorafenib|2 tablets with water by mouth twice a day for two weeks.
1804315|NCT00619268|Drug|Temsirolimus|25 mg once per week administered intravenously
1804316|NCT00619268|Drug|Bevacizumab|10 mg/kg * 1 time /2 weeks administered intravenously
1804317|NCT00619268|Drug|Sunitinib|50 mg administered orally once daily in 6 weeks cycles :4 weeks of treatment followed by 2 weeks off
1804318|NCT00619268|Drug|Interferon alpha-2a|Administered subcutaneously as 9 MU three times per week
1804358|NCT00619567|Behavioral|Smartbrain|The initial session will be set for 10 minutes, with weekly increases (of 10 minutes) to a maximum of 30 minutes per day, 7 days a week. Each subject will be trained using the same modules of the Smartbrain protocol, with an emphasis on speed of information processing.
1804319|NCT00619307|Drug|Rebif New Formulation + prophylactic Ibuprofen|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected
1804320|NCT00619307|Drug|Rebif New Formulation + ibuprofen PRN|Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
1804321|NCT00619320|Behavioral|Safer Sex Skills Building (SSB)|Test the effectiveness of an intervention for reducing sexual risk factors for HIV infection in two samples of pregnant drug-using women. The intervention, Safer Sex Skills Building (SSB)(El Bassel and Schilling (1991, 1992)), is a manual-driven, gender-specific group intervention delivered by mental health counselors. To date, its effectiveness has not been examined in pregnant, drug using women. The proposed study will examine the effectiveness of the intervention in both drug treatment (RBHA, N = 200) and prenatal care (PCC, N = 200) settings. Using a randomized clinical trial design, the study will compare the five-session SSB group intervention to a one-session standard group HIV Education session (ED). Study hypotheses: that women in the SSB intervention will have better outcomes (e.g., fewer unprotected penetrative sexual behaviors) than women in the control group (ED).
1804322|NCT00619333|Drug|follitropin and lutropin|follitropin and lutropin
1804323|NCT00619346|Drug|Placebo|Placebo tablets, BID X 14 days
1804324|NCT00619346|Drug|pafuramidine maleate|Pafuramidine maleate, 100 mg tablet BID X 14 days
1804325|NCT00619359|Drug|Comparator: fosaprepitant dimeglumine|single IV dose of 150 mg of fosaprepitant dimeglumine on Day 1.
1804326|NCT00619359|Drug|Comparator: Aprepitant|Aprepitant 3-day dosing oral regimen (125 mg on Day 1 followed by 80 mg on Days 2 and 3).
1804327|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, 8 mg on Day 2, and 8 mg twice a day on Days 3-4.
1804328|NCT00619359|Drug|Dexamethasone|Oral dose of 12 mg of dexamethasone on Day 1, and 8 mg on Days 2-4.
1804329|NCT00619359|Drug|Ondansetron|single IV dose of 32 mg of ondansetron on Day 1.
1804330|NCT00619372|Drug|OKT3|0.2 mg OKT3, PO (in the mouth) on day 1 through 5.
1804331|NCT00619372|Drug|OKT3, GC|0.2 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
1804332|NCT00619372|Drug|OKT3|1 mg OKT3, PO (in the mouth) on day 1 through 5
1804333|NCT00619372|Drug|OKT3, GC|1 mg OKT3 and 7.5 mg GC, PO (in the mouth) on day 1 through 5
1804334|NCT00619372|Drug|OKT3|5 mg OKT3, PO (in the mouth) on day 1 through 5
1804335|NCT00619372|Drug|GC|7.5 mg GC, PO (in the mouth) on day 1 through 5
1804336|NCT00619385|Drug|Proellex|Proellex 25 mg capsules 100 mg, 150 mg or 200mg daily for 7 days
1804337|NCT00619398|Drug|Prograf|Oral
1804338|NCT00619398|Drug|FK506MR capsule|Oral
1804339|NCT00619411|Behavioral|Interpersonal Therapy for Depressed Adolescents & Parents|15 weekly psychotherapy sessions
1804340|NCT00619424|Drug|pazopanib|Oral tablet administered daily in dosages of 400 - 800 mg.
1804341|NCT00619424|Drug|erlotinib|oral tablet taken daily in dosages of 100-150 mg.
1804342|NCT00619424|Drug|pemetrexed|IV chemotherapeutic agent administered every 21 days in dosages of 400-500 mg/m2
1804343|NCT00619450|Other|3D C-arm CT scan|The patient will be given an intravenous contrast dye and then hold their breath for 15 seconds while pictures are taken. The equipment used to take the pictures is like an arch that will rotate around the body. As the arch rotates, it will collect the pictures of the heart. These pictures will then be used to compute a three-dimensional image of the heart. The physicians will then continue with the planned procedure. The three-dimensional images will be reconstructed and available for the doctor to view during the case. The images will also be examined after the procedure by the physician.
1804344|NCT00619463|Behavioral|Exercise|Eight weeks in an aerobic exercise program- 50 minutes of aerobic exercise on a treadmill - 3 days a week for 8 -16 weeks.
1804345|NCT00619463|Behavioral|Exercise|Aerobic exercise program - 55 min aerobic exercise on the treadmill 3 days a week for either 8 or 16 weeks
1804346|NCT00619476|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
1804347|NCT00619476|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
1804348|NCT00619476|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
1804349|NCT00619476|Drug|Placebo|placebo
1804350|NCT00619489|Drug|vedolizumab|Vedolizumab for intravenous (IV) infusion
1804351|NCT00619502|Biological|DTaP-IPV-HB-PRP~T vaccine|0.5 mL, intramuscular (IM)
1804352|NCT00619515|Other|questionnaire administration|Patients complete 4 questionnaires at baseline and periodically during study to assess acute and late toxicities and quality of life (e.g., overall health status, patient function, sexual function, and urinary symptoms).
1804353|NCT00619515|Procedure|implanted fiducial-based imaging|Undergo fiducial placement imaging
1804354|NCT00619515|Radiation|stereotactic radiosurgery|Patients undergo fiducial placement using ultrasound. At least 5-10 days later, patients undergo CyberKnife® stereotactic radiosurgery once daily for 5 days.
1804355|NCT00619528|Biological|Infusion of Donor Hematopoietic Stem Cells and Campath-1H|Intervention: a four-dose (peri-operative and 3, 6, and 9-month boost) DHSC infusion protocol using two-dose Campath-1H induction combined with transient (conditioning) Tacrolimus/Sirolimus and MMF therapy will result in a high degree of macro-chimerism (>10%), and a robust prolonged donor-specific (post-thymic) immunoregulatory condition that will allow renal transplant survival in the absence of permanent immunosuppression.
1804356|NCT00619541|Drug|Infusional 5-Fluorouracil|5-FU 3000 mg/sqm 48 hours continuous infusion every 14 days. 5-FU will be administered for a maximum of 12 cycles.
1804357|NCT00619541|Drug|Sorafenib (Bay 43-9006)|Sorafenib 400 mg bid orally continuously. Sorafenib will be administered from the start of treatment in combination with 5-FU until progression of disease.
1804444|NCT00620113|Dietary Supplement|Vitamin D3|Two Vitamin D3 tablets (5600 IU total) taken orally once weekly for 52 weeks.
1804491|NCT00620412|Dietary Supplement|placebo control|2 capsules by mouth twice a day for 28 days
1804359|NCT00619593|Other|Intensified diagnostic and treatment measures following 1st appropriate ICD therapy|"Assessment of general health status (weight, BP, NYHA)
Laboratory tests (hemoglobin, Nt-proBNP, creatinine, GDF-15)
Echocardiography (LVEF, LVEDD, mitral regurgitation)
Non-invasive ischemia evaluation
Coronary angiography (if indicated by ischemia evaluation)
Upgrade to CRT, if indicated
Ventricular ablation (if indicated: VT storm, slow VT, bundle branch reentry)
24 hrs ECG Holter (Heart rate variability)
Further treatment (if applicable)
Changes in ICD settings, or medication"
1804360|NCT00619593|Other|Standard follow-up|Standard follow-up in patients without appropriate ICD therapy
1804361|NCT00619606|Device|TwinGuard|A system consisting of an endoscopic bite block that fits together with a nasal cannula. After gastroscopy, the bite block is discarded leaving the patient receiving oxygen in recovery.An optional carbon dioxide sampling device fits with the TwinGuard in endoscopy to monitor expired air.
1804362|NCT00619606|Device|Standard endoscopic bite block|Placed in the mouth during gastroscopy to protect the endoscope and the patient's teeth
1804363|NCT00619606|Device|Standard nasal cannula|Delivers oxygen to the nose. Tubing runs from the nose around the back of the ears and under the chin which then runs to an oxygen source.
1804364|NCT00619606|Device|CO2 sample line|Samples expired air from a patients nose. Tubing is connected to a capnograph.
1804365|NCT00619619|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|DVS SR Tablets of 10mg, 25mg, 50mg, and 100mg. Assigned DVS SR daily doses of 10mg, 25mg, 50mg, 100mg, or 200mg for up to 8 weeks.
1804366|NCT00619632|Behavioral|Lactation Consultant|Lactation consultant- primary care based, meets with women pre-natally, in the hospital, and at home up to 6 months post-partum.
1804367|NCT00619632|Behavioral|Provider Prompt|Prompt in electronic prenatal record will appear 5 times throughout pregnancy re: up to 10 open-ended discussion points for provider to raise
1804368|NCT00619632|Behavioral|LC+ Provider Prompt|Participants in this group receive both the LC and Provider Prompt interventions.
1804369|NCT00619645|Drug|busulfan|
1804370|NCT00619645|Drug|cyclosporine|
1804371|NCT00619645|Drug|fludarabine phosphate|
1804372|NCT00619645|Drug|mycophenolate mofetil|
1804373|NCT00619645|Procedure|allogeneic hematopoietic stem cell transplantation|
1804374|NCT00619645|Procedure|peripheral blood stem cell transplantation|
1804375|NCT00619658|Other|telephone follow-up|subjects undergoing medical abortion will recieve a telephone call and be asked a series of clinical questions. Expulsion of the pregnancy will be assessed based on the answers to those questions.
1804376|NCT00619671|Drug|Rituximab (Rituxan)|Four weekly IV infusions of Rituxan with dosage individually calculated per subject.
1804377|NCT00619684|Drug|lenalidomide|Given PO
1804378|NCT00619697|Drug|biphasic insulin aspart|
1804379|NCT00619697|Drug|insulin glargine|
1804380|NCT00619697|Drug|metformin|
1804381|NCT00619697|Drug|glimepiride|
1804382|NCT00619710|Drug|Meropenem|Intravenous
1804383|NCT00619710|Drug|Imipenem-cilastatin|Intravenous
1804387|NCT00619736|Drug|NSA-789|
1804388|NCT00619736|Other|Placebo|
1804389|NCT00619749|Dietary Supplement|juice rich in polyphenols|juice during 2 weeks
1804390|NCT00619749|Dietary Supplement|juice poor in polyphenols|juice during 2 weeks
1804391|NCT00619762|Device|LTM - a porcine-based surgical mesh|Use of LTM to support weak and/or absent soft tissue to facilitate immediate breast reconstruction postmastectomy
1804392|NCT00619775|Device|PROTÉGÉ® GPS™ and PROTÉGÉ® RX Carotid Stent Systems and Spider Embolic Protection Device|Carotid artery stenting with distal embolic protection.
1804393|NCT00619788|Device|4.0-5.0mm AngioSculpt Scoring Balloon Catheter|The AngioSculpt Scoring Balloon Catheter is a line of innovative angioplasty catheters comprising an angioplasty balloon surrounded by a unique system of nitinol scoring elements. Creating focal concentrations of dilating force, the scoring elements score arterial lesions as the balloon expands.
1804394|NCT00619801|Drug|Levocetirizine|Levocetirizine dihydrochloride 1.25 mg oral drops formulation (5 drops containing 5mg/mL) dosed twice a day for 2 weeks
1804395|NCT00619801|Drug|Placebo|Placebo oral drops (5 drops) dosed twice a day for 2 weeks.
1804396|NCT00619814|Procedure|Double-contrast Barium enema, colonoscopy|This is a blinded cohort study comparing double contrast barium enema (DCBE) and colonoscopy in detecting polyps and/or cancer in patients with positive FOBT. Initial evaluation consisted of complete clinical history and physical examination. A DCBE and a colonoscopy were performed in all patients. All polyps identified during colonoscopy were removed and classified by histology. Sensitivity and specificity of DCBE for polyp and/or cancer detection was determined. Tolerability and grade of satisfaction with study procedures was assessed.
1804397|NCT00619827|Drug|300 IR grass pollen allergen extract tablet|300 IR grass pollen allergen extract tablet once daily during four months
1804398|NCT00619827|Drug|Placebo tablet|Placebo tablet once daily during four months
1804399|NCT00619840|Drug|methylphenidate hydrochloride|sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
1804400|NCT00619840|Drug|Placebo|10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
1804401|NCT00619853|Behavioral|treatment approach - CIMT|CIMT, 2 months, 2Hr per day
1804402|NCT00619853|Behavioral|treatment approach - HABIT|HABIT-2 months, 2Hr per day
1804403|NCT00619866|Drug|NBI-56418|150 mg tablet
1804404|NCT00619866|Drug|NBI-56418|250 mg tablet
1804405|NCT00619866|Drug|placebo|placebo tablet to match NBI-56418
1804445|NCT00620113|Dietary Supplement|Calcium carbonate|Calcium carbonate 500 mg tablet taken orally every day for 52 weeks.
1804446|NCT00620113|Drug|Placebo|Dose-matched placebo tablets to odanacatib, taken orally once weekly for 52 weeks.
1804406|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Lymphoid Malignancies or Cord Blood Unit Recipients|"Total Body Irradiation (TBI) 1200 cGy will be given on days -8,-7,-6 and -5 in eight sessions, delivering 150cGy in each session.
Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.
Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3, -2."
1804407|NCT00619879|Drug|Myeloablative Chemotherapy Regimen for Non-Cord Blood Unit Recipients with Myeloid Malignancies|"Busulfan administration:
For children >/= 4 years of age, Busulfan 0.8 mg/kg/dose will be given every 6 hours over days -8,-7, -6, and -5 for a total of 16 doses.
For children < 4 years of age, Busulfan 1 mg/kg/dose will be given every 6 hours over days -8, -7, -6, -5 for a total of 16 doses.
Pharmacokinetic analysis will guide dose modifications targeted to receive an average AUC of 800-1200 microMols*min for the 16 doses.
Lorazepam (0.05 mg/kg) IV will be administered one half hour before the initial dose of Busulfan is given and every 6 hours through day -4.
Etoposide 1000 mg/m2 as a 24 hour continuous infusion started on day -4.
Cyclophosphamide 60 mg/kg/day IV given over 1 hour daily on days -3 and -2."
1804408|NCT00619879|Other|Hematopoietic Progenitor Cell Transplantation (HPCT)|Hematopoietic progenitor cells (HPCs) will be infused on day 0. Source of cells may be bone marrow, peripheral blood cells, or cord blood units, from matched related or unrelated donors.
1804409|NCT00619879|Radiation|CNS radiation treatment for ALL with prior CNS disease patients|"Patients with prior CNS disease over the age of 1 year will be treated with 600 cGy of cranial irradiation in addition to 1200 cGy of TBI.
Patients diagnosed with ALL with CNS disease (at the time of diagnosis or relapse) < 1 year of age will receive CNS treatment as Intrathecal Methotrexate as follows:
Infants ≤ 1 year of age at the time of Intrathecal Therapy will receive a dosing of 7.5 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count
Children 1-2 years of age at the time of Intrathecal Therapy will receive 8 mg once a month for 6 months after transplant beginning at day +30 with an adequate white count"
1804410|NCT00619892|Drug|quetiapine XR|Subjects will receive daily dosing at night, with a flexible dosing schedule, 50-400 mg.
1804411|NCT00619892|Drug|placebo|Subjects will receive daily dosing at night with caplets matching the appearance of the active drug. However, caplets will not contain any active medication.
1804412|NCT00619905|Drug|ACZ885|
1804413|NCT00619905|Drug|ACZ885|
1804414|NCT00619918|Drug|Nebulized 3% saline|4 ml inhaled q8h
1804415|NCT00619918|Drug|Placebo|normal saline
1804416|NCT00619931|Drug|APD791|APD791 or matching placebo in escalating doses
1804417|NCT00619944|Drug|Lumefantrine - lopinavir/ritonavir drug interaction|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as single dose to HIV-positive adults receiving lopinavir/ritonavir 400 mg/100 mg twice daily
1804418|NCT00619944|Drug|Lumefantrine only arm|Lumefantrine 480 mg co-formulated with artemether 80 mg administered as a single dose to antiretroviral naive HIV-positive patients
1804419|NCT00619957|Drug|Placebo tablet|one placebo once a week for two years followed by one 35 mg risedronate once a week for two years
1804420|NCT00619957|Drug|Risedronate|one 35 mg risedronate once a week for two years followed by one 35 mg risedronate once a week for two years
1804421|NCT00619970|Procedure|Lactulose Breath Test|Healthy controls will receive one lactulose breath test to assess for SIBO
1804422|NCT00619970|Drug|xifaxan|xifaxan 550mg TID x10days
1804423|NCT00619970|Drug|placebo|placebo TID x 10days
1804424|NCT00619970|Procedure|Lactulose Breath Test|Children with CAP will receive one lactulose breath test to assess for SIBO and one after receiving either Rifaximin or Placebo
1804430|NCT00619996|Drug|Sorafenib (Nexavar)|"Sorafenib 400 mg bid orally continuously
Sorafenib will be administered from the start of treatment in combination with Docetaxel until progression of disease."
1804431|NCT00619996|Drug|Docetaxel|Docetaxel 75 mg/mq ev g1 every 21 days. Docetaxel will be administered for a maximum of 9 cycles.
1804432|NCT00620009|Behavioral|Empathy Feedback|Discussion of empathy ratings between patients and therapists during psychotherapy sessions.
1804433|NCT00620022|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
1804434|NCT00620022|Drug|Placebo|Placebo was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
1804435|NCT00620035|Drug|Radiopaque Etonogestrel Implant|One implant inserted for a 3-year treatment period
1804436|NCT00620048|Biological|Intramyocardial injection of autologous CD34-positive cells (stem cells)|Comparison between a low dose and high dose of autologous (one's own) CD34-positive cells (stem cells) delivered via injections into the heart muscle.
1804438|NCT00620074|Drug|voriconazole|Subjects with creatinine clearance at least 50 ml/min will receive initial treatment with IV (loading dose of 6 mg/kg Q12h followed by maintenance dose of 4 mg/kg Q12h) or oral (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h). Subjects with creatinine clearance <50 ml/min will receive oral voriconazole (loading dose of 400 mg Q12h followed by maintenance dose of 300 mg Q12h).
1804439|NCT00620074|Drug|anidulafungin|Loading dose of 200 mg QD followed by maintenance dose of 100 mg QD for up to a total of 28 days therapy
1804440|NCT00620087|Procedure|Molecular Breast Imaging|Molecular breast Imaging is a new nuclear medicine technique for imaging the breast. It uses small filed of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
1804441|NCT00620087|Procedure|Screening Mammography|A screening mammogram is used to look for signs of breast cancer in women who don't have any breast symptoms or problems. X-ray pictures of each breast are taken from 2 different angles.
1804442|NCT00620100|Drug|Docetaxel|
1804443|NCT00620113|Drug|Odanacatib|Odanacatib tablets 10 mg, 25 mg, or 50 mg (depending upon randomization), taken orally once weekly for 52 weeks.
1804448|NCT00620126|Other|Best Available Care|Routine follow up visits and as needed telephone calls and clinic visits, written action plans, educational fact sheets from the CCFA
1804449|NCT00620139|Biological|the arachidonic acid and EGFR signaling pathways and their interaction in HNSCC tumorigenesis,|patient will undergo transoral pretreatment biopsy of the tumor. A comparable second tumor biopsy will be performed in the office after exactly 5 days of concurrent CRT (5 daily fractions of 180-200 cGy radiotherapy and a single cycle of Cisplatin or Carboplatin/5-FU based chemotherapy).Blood plasma and single-void urine specimens will be collected contemporaneously,before and after 5 days of concurrent CRT.
1804450|NCT00620152|Behavioral|1|Low glycemic load diet by telephone counseling
1804451|NCT00620152|Behavioral|2|Low fat diet by telephone counseling
1804454|NCT00620178|Drug|Candesartan Cilexetil|oral once daily dose
1804455|NCT00620178|Drug|Losartan|once daily oral dose
1804458|NCT00620204|Drug|atorvastatin|atorvastatin 40mg qd for 1 year
1804459|NCT00620217|Genetic|intramyocardial injection of VEGF-A165/bFGF:placebo plasmid|The plasmid will be given at a total dose of 0.5 mg, 10 injections of 0,2 ml each into the region of reversible ischemia. The process of injecting the solution into each of ten points within the ischemic zone will take 20 to 40 seconds to minimize muscle disruption
1804460|NCT00620230|Drug|NVP-VAK694|
1804461|NCT00620230|Drug|NVP-VAK694|
1804462|NCT00620243|Procedure|1: FDG PET|The study will evaluate the potential of PET imaging to identify early responders to chemotherapy. Patients entered into this study will undergo FDG PET within 2 weeks prior to chemotherapy and prior to initiation of the second course of chemotherapy. All images will be carried out in the same manner with respect to equipment, acquisition parameters, and time post injection, to ensure that changes in standard uptake value(SUV) correlate with metabolic changes. This will be correlated with response determined by changes in serum CA 125 levels.
1804463|NCT00620256|Drug|AL-37807 ophthalmic suspension, 0.1%|
1804464|NCT00620256|Drug|Timolol gel forming solution, 0.5%|
1804465|NCT00620256|Other|AL-37807 ophthalmic solution vehicle|
1804466|NCT00620256|Drug|Latanoprost ophthalmic solution|
1804467|NCT00620269|Drug|Erlotinib|Erlotinib 150 mg p.o. daily x21 days every 3 weeks
1804468|NCT00620269|Drug|Induction or consolidation IP chemotherapy|Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
1804469|NCT00620269|Drug|CCRT with IP chemotherapy (Irinotecan + Cisplatin)|Irinotecan (60mg/m2) + cisplatin (30mg/m2) IV on D1 & 8 every 3 weeks X 2 cycles
1804470|NCT00620269|Radiation|CCRT|CCRT :Concurrent Thoracic Radiotherapy (2.4 Gy/fr, Total 60 Gy, 25fr over 5 weeks)
1804471|NCT00620282|Drug|liraglutide|Stepwise dose increase, s.c. (under the skin) injection, once daily
1804472|NCT00620282|Drug|placebo|Liraglutide placebo, stepwise dose increase, s.c. (under the skin) injection, once daily
1804473|NCT00620282|Drug|glimepiride|Tablets, 1 - 4 mg daily
1804474|NCT00620295|Drug|bortezomib|Bortezomib will be given 1 hour after gemcitabine by intravenous pyelogram (IVP) over 3 to 5 seconds followed by a standard saline flush or through a running intravenous (IV) line at the patient's assigned dose (1.0 up to 1.8 mg/m^2) on days 1 and 8 of a 21 day treatment cycle until disease progression or for a maximum of 6 cycles.
1804475|NCT00620295|Drug|gemcitabine hydrochloride|Gemcitabine will be administered as a 30 minute intravenous infusion at the patient's assigned dose (800 up to 1000 mg/m^2) on day 1 and day 8 of a 21 day cycle.
1804476|NCT00620308|Drug|CD-NP|One of two dosage levels (20 ng/kg/min and another level to be finalized) as a continuous intravenous infusion for four hours
1804477|NCT00620308|Drug|Placebo|Dextrose 5% in water (the vehicle)
1804478|NCT00620321|Drug|LY2181308 sodium|750 mg is administered as a 3 hour intravenous (IV) infusion on Days 1, 2, 3, 8, 15, 22 of Cycle 1 and Days 1, 8, 15, 22 of Cycle 2 until disease progression or unacceptable toxicity develops.
1804479|NCT00620321|Drug|cytarabine|1.5g/m2 will be administered as a 4 hour IV infusion on Days 3, 4, 5 of Cycle 1 and Days 1, 2, 3 of Cycle 2 until disease progression or unacceptable toxicity develops.
1804480|NCT00620321|Drug|idarubicin|12mg/m2 will be administered as a 30 minute IV infusion on Days 3, 4, 5 of Cycle 1 and on Days 1, 2, 3 of Cycle 2 until disease progression or unacceptable toxicity develops.
1804481|NCT00620347|Drug|sunitinib|sunitinib (50mg/day, 4weeks on, 2 weeks off) Repeat every 6 weeks. Treatment will continue until disease progression, unacceptable toxicity, or patients' refusal.
1804482|NCT00620360|Dietary Supplement|fructose|acute administration of 4 times 0.3g fructose/kg lean body mass
1804483|NCT00620360|Dietary Supplement|Fructose|acute administration of 4 times 0.3 g/kg fat-free mass oral fructose
1804484|NCT00620373|Device|Molecular Breast Imaging|Molecular breast imaging is a new nuclear medicine technique for imaging the breast. It uses small field of view semiconductor-based gamma cameras that use Cadmium Zinc Telluride detectors. These have superior spatial and energy resolution to conventional sodium iodide detectors.
1804485|NCT00620373|Device|Conventional Mammography|Mammography is the process of using low-energy X-rays (usually around 30 kVp) to examine the human breast and is used as a diagnostic and a screening tool.
1804486|NCT00620373|Drug|Technetium (99mTc) sestamibi|Technetium (99mTc) sestamibi is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six methoxyisobutylisonitrile (MIBI) ligands.
1804487|NCT00620386|Device|Bonfils|Endotracheal intubation using Bonfils Intubating Fiberscope
1804488|NCT00620386|Device|Macintosh|Endotracheal intubation using Macintosh laryngoscopy
1804489|NCT00620399|Other|lumbar corset|
1804490|NCT00620412|Dietary Supplement|Lactobacillus rhamnosus|2 capsules by mouth 2 times a day for 28 days. Each capsule contains 1x10^10 LGG organisms.
1805004|NCT00623298|Behavioral|group IPT|
1804492|NCT00620412|Biological|Influenza Virus Vaccine Live, Intranasal|intranasal spray, 0.1ml per nostril, one time dose
1804493|NCT00620425|Drug|Sumatriptan|injection
1804494|NCT00620438|Drug|Lumefantrine-artemether and nevirapine|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive patients receiving nevirapine 200mg twice daily as part of their antiretroviral treatment
1804495|NCT00620438|Drug|lumefantrine-artemether and efavirenz|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to HIV positive adults receiving efavirenz tablets 600mg once daily
1804496|NCT00620438|Drug|Lumefantrine-artemether and rifampicin|Administration of lumefantrine 480mg co-formulated with artemether 80mg twice daily for three days to patients receiving rifampicin as part of fixed dose combination therapy for tuberculosis
1804497|NCT00620451|Drug|larazotide acetate|gelatin capsule
1804498|NCT00620451|Drug|placebo|gelatin capsule
1804499|NCT00620464|Drug|Radiopaque Implanon|Radiopaque rod for 3 years
1804500|NCT00620464|Drug|Implanon (etonogestrel implant)|Implanon (etonogestrel implant) for 3 years
1804501|NCT00620477|Drug|injection in the knee joint with 20 ml of chirocaine 0.125%|injection in the knee joint with 20 ml of chirocaine 0.125%
1804502|NCT00620477|Drug|injection in the knee joint with 20 ml of physiological fluid|injection in the knee joint with 20 ml of physiological fluid
1804503|NCT00620490|Drug|ropivacaine|Ropivacaine 0.5% 0.1 ml/kg per hour
1804504|NCT00620490|Other|nacl 0,9%|saline 0.9% 0.1 ml/kg per hour
1804507|NCT00620529|Dietary Supplement|Ocean Nutrition 2050|1000mg capsules, 4 capsules/day for 8 weeks
1804508|NCT00620529|Dietary Supplement|Olive oil capsules|Olive oil capsules, 4 per day for 8 weeks
1804509|NCT00620542|Drug|Rosuvastatin|capsule, oral, once daily
1804510|NCT00620542|Drug|Atorvastatin|capsule, oral, one daily
1804511|NCT00620555|Drug|gabapentin|Orally administered gabapentin
1804512|NCT00620568|Drug|SLV-313 SR|sustained release tablets taken once daily for 14 days
1804513|NCT00620581|Drug|Paroxetine|Paroxetine 10mg and 20mg during the luteal phase of the menstrual cycle
1804514|NCT00620594|Drug|BEZ235|
1804515|NCT00620607|Drug|huC242-DM4|dose of 126 mg/m2 or 168 mg/m2 given as IV once every 3 weeks
1804516|NCT00620620|Drug|Inhaled placebo|Inhaled Staccato Placebo
1804517|NCT00620620|Drug|Inhaled Zaleplon 0.5 mg|Inhaled Staccato Zaleplon 0.5 mg
1804518|NCT00620620|Drug|Inhaled Zaleplon 1 mg|Inhaled Staccato Zaleplon 1 mg
1804519|NCT00620620|Drug|Inhaled Zaleplon 2 mg|Inhaled Staccato Zaleplon 2 mg
1804520|NCT00620620|Drug|Inhaled Zaleplon 4 mg|Inhaled Staccato Zaleplon 4 mg
1804521|NCT00620633|Biological|WT1-sensitized T cells|Eligible patients who consent to enter this trial and for whom WT1 sensitized T cells have been generated in vitro, will receive a single dose of allogeneic WT1-sensitized T cells by bolus intravenous infusion. In this phase I trial, 6 dose levels of T cells will be evaluated, in sequential groups of 3 patients. Dose Escalation will be based on the incidence and severity of toxicities.
1804522|NCT00620646|Drug|aspirin, clopidogrel|aspirin 100 mg plus clopidogrel 150mg qd
1804523|NCT00620646|Drug|aspirin, clopidogrel, cilostazol|aspirin 100mg qd,clopidogrel 75mg qd plus cilostazol 100mg bid
1804524|NCT00620659|Drug|Comparator: MK0249|Patients will be assigned to receive MK0249 film coated tablet (FCT). The doses of MK0249 that are included for possible investigation (depending upon an adaptive allocation process) are 3 mg, 5 mg, 8 mg, 10 mg, and 12 mg. Study medication will be taken for 14 days, during each of the 3 treatment periods, by mouth (po) once a day (qd).
1804525|NCT00620659|Drug|Comparator: placebo|Placebo; Patients will be assigned to receive placebo, across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
1804526|NCT00620659|Drug|Comparator: modafinil|Patients will be assigned to receive modafinil 200mg oral compressed tablet (OCT), across 3 treatment periods. Study medication will be taken for 14 days, during each of the 3 treatment periods, po qd.
1804527|NCT00620672|Dietary Supplement|omega 3 fatty acids|The supplements are taken orally with a meal, each day. The amount of the omega 3 fatty acid docosahexaenoic acid is 400 mg/day; taken in two 500 mg capsules each providing 200 mg docosahexaenoic acid. The placebo is two 500 mg capsules soybean/canola oil. Both the supplement and placebo are a total of 1 gm/day (2x500 mg) and about 10 calories per day.
1804528|NCT00620672|Dietary Supplement|vegetable oil|The supplement is a dietary supplement of vegetable oil as a placebo
1804529|NCT00620685|Drug|Placebo|Tablet, once daily for 4 weeks
1804530|NCT00620685|Drug|PH-797804|Tablet, 1 mg PH-797804, once daily for 4 weeks
1804531|NCT00620685|Drug|PH-797804|Tablet, 5 mg PH-797804, once daily for 4 weeks
1804532|NCT00620711|Device|Olympic Cool Cap|Olympic Cool Cap will be applied to infants 32-35 weeks gestation who meet criteria for HIE.
1804533|NCT00620724|Drug|Placebo|Placebo three times daily
1804534|NCT00620724|Drug|Nifedipine|20 mg of slow-release Nifedipine three times daily
1804535|NCT00620737|Biological|Autologous Human Fibroblasts (Isolagen TherapyTM)|"Collection of skin biopsy.
Administration of 2 study injections
Performance of various study assessments during clinic visits"
1804536|NCT00620737|Biological|Placebo|"Collection of skin biopsy.
Administration of 2 study injections
Performance of various study assessments during clinic visits"
1804537|NCT00620750|Drug|Extended release injectable naltrexone (Vivitrol)|Three sequential monthly injections of extended release injectable naltrexone (Vivitrol), with option to extend participation for an additional 12 months.
1804538|NCT00620763|Other|High Meat - High Potential Renal Acid Load (PRAL) diet|Menu high in meat protein
1804539|NCT00620763|Other|Low Protein - Low Potential Renal Acid Load (PRAL) diet|Menu low in meat protein
1804574|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 3 cycles
1804575|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 3 cycles
1804576|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
1805005|NCT00623298|Other|6 months-baseline|
1804540|NCT00620776|Behavioral|Cognitive Behavioral Therapy|This cognitive behavioral therapy for GAD has a cognitive restructuring component and an applied relaxation component. Patients will be educated about the nature of anxiety and be trained in the recognition and monitoring of situational, physiological, cognitive, and behavioral cues associated with anxious responding. They will be guided through copings skill rehearsals in addition to imaginal and in vivo exposure to anxiety cues. This cognitive behavioral treatment will consist of 1 to 1.5 hour sessions of psychotherapy, which will be held once weekly over a period of 12 weeks.
1804541|NCT00620776|Drug|Venlafaxine XR|Venlafaxine XR, 75-225 mg/d, oral administration. 14 days at 75 mg/d, 150 mg/d for the remaining 6 months, 225 mg/3 for patients unimproved at week 6, tapered at 75 mg/week (this intervention is provided by protocol 709012).
1804545|NCT00620802|Drug|CGT-2168|(CGT-2168, one capsule each daily)
1804546|NCT00620802|Drug|Plavix|(clopidogrel, 75 mg)
1804547|NCT00620815|Biological|MF59-eTIV-H5N1+ placebo /pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)and placebo on day 1 followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1+V3.
1804548|NCT00620815|Biological|Pandemic influenza vaccine + placebo /MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo on day 1 followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1+V3.
1804549|NCT00620815|Biological|Pandemic influenza vaccine + seasonal influenza vaccine /pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine, 3-5 weeks later pandemic influenza vaccine , including serology blood draw at V1+V3.
1804550|NCT00620815|Biological|Pandemic influenza vaccine + placebo / MF59-eTIV-H5N1|Pandemic influenza vaccine plus placebo followed 3-5 weeks later by tetravalent influenza vaccine (MF59-eTIV-H5N1), including serology blood draw at V1, V2 and V3.
1804551|NCT00620815|Biological|Pandemic influenza vaccine + seasonal influenza vaccine / pandemic influenza vaccine|Pandemic influenza vaccine plus seasonal influenza vaccine followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
1804552|NCT00620815|Biological|MF59-eTIV-H5N1 + Placebo/pandemic influenza vaccine|Tetravalent influenza vaccine (MF59-eTIV-H5N1)plus placebo followed 3-5 weeks later by pandemic influenza vaccine, including serology blood draw at V1, V2 and V3.
1804553|NCT00620828|Other|Placebo saline injection|20 cc of sterile, injectable saline
1804554|NCT00620828|Drug|Ropivicaine 0.5%|Ropivicaine
1804555|NCT00620841|Other|genotyping|Restriction fragment lenght polymorphisms
1804556|NCT00620854|Drug|Recombinant Salmon Calcitonin (rsCT)|Single dose of a nasal spray or one of two doses of tablets, randomized to visits 2, 3, and 4.
1804557|NCT00620854|Drug|Oral Tablet|0.15 mgs recombinant salmon calcitonin, single oral dose
1804558|NCT00620854|Drug|Oral Tablet|0.2mgs recombinant salmon calcitonin, single oral tablet
1804559|NCT00620854|Drug|Nasal Spray|200 IU recombinant salmon calcitonin, single intranasal spray
1804560|NCT00620867|Drug|Ibuprofen|800 mg oral tablet three time daily with meals for 6 weeks
1804561|NCT00620867|Drug|celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
1804562|NCT00620867|Other|placebo|matched placebo orally for 6 weeks
1804563|NCT00620880|Behavioral|Blood sample|
1804564|NCT00620893|Drug|PEG- 400 based artificial tear|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
1804565|NCT00620893|Drug|Systane|Baseline: Instill one drop in the randomized eye four times daily starting the day after surgery can be used more frequently if needed Month 3: Instill one drop in the randomized eye twice daily
1804566|NCT00620906|Procedure|Manipulation|HVLA manipulation to Sacroiliac Joint
1804567|NCT00620919|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
1804568|NCT00620932|Behavioral|Exercise|Patients will be randomly assigned to groups and will either be given an exercise program individually tailored to them for them to participate in for 6 months or else be wait-listed for 6 months and remain on whatever exercise regimen they were already on.
1804570|NCT00620958|Behavioral|Individual cognitive behavioral therapy (ICBT)|ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
1804571|NCT00620958|Behavioral|Parent relationship training (PRT2) With Individual Cognitive Behavioral Therapy (ICBT)|Parent relationship training will teach the parent ways to communicate with the child and to solve problems to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
1804572|NCT00620958|Behavioral|Parent reinforcement training (PRT1) With Individual Cognitive Behavioral Therapy (ICBT)|Parent reinforcement training will teach the parent strategies for managing the child's behavior through the use of positive rewards and positive parental behaviors to help discourage child avoidant behaviors. ICBT will include 12 to 14 sessions during which child participants will learn how to change anxious and fearful thoughts and to deal with feared objects and events.
1804573|NCT00620971|Drug|Vinorelbine|Vinorelbine (oral) 60 mg/m2, on days 1 and 8 every 3 weeks for 3 cycles
1804577|NCT00620971|Drug|Gemcitabine|Gemcitabine(IV) 1,100 mg/m2 on day 1 and d8 every 3 weeks for 6 cycles
1804578|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
1804579|NCT00620971|Drug|Docetaxel|Docetaxel (IV) 75 mg/m2 on day 1 every 3 weeks for 6 cycles
1804580|NCT00620971|Drug|Cisplatin|Cisplatin (IV) 80 mg/m2 on day 1 every 3 weeks for 6 cycles
1804581|NCT00620971|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
1804582|NCT00620997|Drug|Proparacaine drops 0.05%|topical, 0.05% drops, PRN continuously for up to 7 days
1804583|NCT00620997|Drug|saline drops|saline drops continuously PRN for up to 7 days
1804584|NCT00621010|Drug|CTS21166 (ZPQ-21166)|"Cohort 1: (7.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 2: (22.5 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 3: (45 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 4: (90 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 5: (150 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days; Cohort 6: (225 mg): 6 subjects, plus 2 placebo. If no safety concerns after 7 days,proceed to Part B.
Cohort 7: (225 mg): Up to 10 subjects, open label, 3 hour infusion"
1804585|NCT00614042|Drug|TRU-016 (anti-CD37 protein therapeutic)|TRU-016 administered via IV infusion weekly for 8 weeks and then monthly
1804586|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 1: Treat-to-target dose titration scheme, injection s.c., once daily
1804587|NCT00614055|Drug|insulin degludec/insulin aspart|Formulation 2: Treat-to-target dose titration scheme, injection s.c., once daily
1804588|NCT00614055|Drug|insulin glargine|Treat-to-target dose titration scheme, injection s.c., once daily
1804589|NCT00614055|Drug|metformin|Tablets, 1500-2000 mg/day
1804590|NCT00614068|Behavioral|Trauma-focused cognitive behavioral therapy (TF-CBT)|TF-CBT sessions will include trauma-focused treatment and will teach participants behavioral management and coping skills to overcome their PTSD.
1804591|NCT00614068|Behavioral|Treatment as usual (TAU)|TAU outpatient sessions will include routine community care and nontrauma-focused therapy.
1804592|NCT00614081|Device|Contrast-enhanced dynamic MRI|
1804593|NCT00614120|Drug|liraglutide|0.6 mg/day, s.c. (under the skin) injection
1804594|NCT00614120|Drug|placebo|Glimepiride placebo, capsules
1804595|NCT00614120|Drug|liraglutide|1.2 mg/day, s.c. (under the skin) injection
1804596|NCT00614120|Drug|liraglutide|1.8 mg/day, s.c. (under the skin) injection
1804597|NCT00614120|Drug|glimepiride|Capsules, 4.0 mg/day
1804598|NCT00614120|Drug|metformin|Tablets, 1.5-2.0 g/day
1804599|NCT00614120|Drug|placebo|Liraglutide placebo, s.c. (under the skin) injection
1804600|NCT00614133|Other|Intravenous nutrition with glucose and amino acids|Glucose and amino acids intravenously starting 20 hours before the operation until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient`s measured resting energy expenditure.
1804601|NCT00614133|Other|Intravenous nutrition with glucose and amino acids.|Glucose and amino acids intravenously starting with surgical skin incision until the second postoperative day. Glucose provides 50% and amino acids 20% of each patient`s measured resting energy expenditure.
1804602|NCT00614146|Device|MARS device|10 treatments with the MARS system during the first three weeks after enrollment of 5-8 hours each.
1804603|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
1804604|NCT00614146|Procedure|Standard medical therapy|Standard medical therapy for treatment of the liver disease according to local policy with recommendations as per protocol
1804605|NCT00614159|Drug|Ketamine|Weight based dosage for Peds subjects, used for duration of the endoscopy.
1804606|NCT00614159|Drug|Propofol|Weight based dosage for Peds subjects, used for duration of the endoscopy.
1804607|NCT00614172|Radiation|Proton radiation therapy|Proton radiotherapy will start 2-4 weeks following surgical excision. The treatment area will include the lumpectomy site with an additional margin. Daily proton therapy will be given as an out-patient over a two week coarse.
1804608|NCT00614198|Other|Gluten- and casein-free diet|Removal of foods containing gluten (cereal produce) and casein (dairy produce)
1804609|NCT00614211|Procedure|Total Abdominal Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
1804610|NCT00614211|Procedure|Total Laparoscopic or Robotic Radical Hysterectomy|In a radical hysterectomy the uterus, the upper one to two centimetres of the vagina and the soft tissues around the cervix are excised.
1804611|NCT00614224|Behavioral|treadmill exercise training|3 months (3 times/week) progressive graded aerobic treadmill training with a duration of 10-45 min per training session
1804612|NCT00614250|Drug|AVE0657|capsules once a day at bedtime
1804613|NCT00614250|Drug|placebo|capsules once a day at bedtime
1804614|NCT00614276|Behavioral|Focus Group|To evaluate a multimedia intervention program for women with cancer-related sexual dysfunction.
1804615|NCT00614276|Behavioral|TENDRILS|Tendrils: A Sexual Renewal Program for Women Surviving Cancer - a website designed to give women information about sexual problems related to cancer and its treatment, and the website suggests ways to overcome those problems.
1804616|NCT00614276|Behavioral|Questionnaires|The questionnaires ask about your background (such as age, education, relationships), your cancer diagnosis and treatment, and the quality of your life in terms of your health, your general emotions, and your sexual function. The questionnaires take about 30-45 minutes to complete.
1804617|NCT00614276|Behavioral|Sexual Counseling Sessions|Attend 3 sexual counseling sessions at M. D. Anderson.
1804618|NCT00614289|Device|Epikeia Coatings|Topical skin coating
1804619|NCT00614302|Drug|TPV|
1804620|NCT00614315|Device|FLAIR™ Endovascular Stent Graft|The FLAIR™ Endovascular Stent Graft is designed to treat venous anastomotic stenoses of AV access grafts, providing both structural support of the site following angioplasty (stent), and a barrier to locally recurrent flow-limiting neointimal tissue growth (covering/graft).
1804621|NCT00614328|Drug|Naltrexone, Baclofen, Placebo and Behavior Therapy|Naltrexone 50mg/day for 12 weeks Baclofen 10mg tid = 30mg/day for 12 weeks Behavior Therapy 9 sessions
1804741|NCT00615277|Dietary Supplement|Omega-3 fatty acids|600 mg EPA 120mg DHA daily, 16 weeks
1804622|NCT00614341|Device|MedRelief SE 55|4150 Hz signal continuous or pulse, high intensity, high modulation for 6 hours each night during treatment phase
1804623|NCT00614354|Drug|99mTc-glucarate solution|Patients will receive a single 22 - 27 mCi bolus intravenous dose of 99mTc-glucarate solution, as soon as possible after their arrival in the emergency department or the chest pain center
1804624|NCT00614380|Drug|telmisartan/amlodipine 40/5 mg fixed combination|
1804625|NCT00614380|Drug|telmisartan/amlodipine 80/5 mg fixed combination|
1804626|NCT00614393|Biological|dalotuzumab|IV infusion
1804627|NCT00614393|Drug|irinotecan hydrochloride|IV infusion
1804628|NCT00614393|Biological|cetuximab|IV infusion
1804629|NCT00614393|Drug|placebo|IV infusion
1804630|NCT00614406|Drug|Celebrex|One 400mg tablet daily.
1804631|NCT00614406|Drug|Placebo|One tablet daily.
1804632|NCT00614419|Device|Prolene Polypropylene Mesh|The Lichtenstein tension-free hernioplasty consists of a swatch of polypropylene mesh, partway slit 1 cm from its inferior edge to accommodate the spermatic cord. The mesh is sutured circumferentially to the internal oblique abdominal muscle, the rectus sheath and the shelving edge of the inguinal ligament. The tails of the mesh are drawn around the cord and the inferior edge of each tail is sutured to the inguinal ligament. In case of direct hernias, no effort is made to repair the hernia itself. In indirect hernias the sac is excised, except for sliding hernias. The polypropylene mesh group: in this group of patients the polypropylene mesh will be fixed by the above mentioned sutures in Prolene 3/0.
1804633|NCT00614419|Device|Surgisis Inguinal Hernia Matrix|The Surgisis mesh group: in this group of patients a 7x20cm Surgisis ES Soft Tissue Graft sheet will be used. In sterile manner the sheet will be removed from the peel-open package. The Surgisis sheet will be cut and fashioned as appropriate. Then the pre-shaped sheet will will be placed for at least 10 minutes into a sterile dish with sterile room-temperature normo-saline to be rehydrated. Using aseptic techique, the rehydrated Surgisis sheet will be transferred to the already prepared and dissected inguinal region and will be fixed with PDS II 2/0.
1804634|NCT00614445|Drug|doxylamine succinate 10 mg/pyridoxine hydrochloride 10 mg|up to 4 tablets daily, titrated according to the protocol
1804635|NCT00614445|Drug|Placebo|2 to 4 tablets daily titrated according to the protocol
1804636|NCT00614458|Drug|Raltegravir; valproic acid|raltegravir 400mg po BID; valproic acid 1000mg - 2000mg daily
1804637|NCT00614471|Drug|Entecavir|0.5mg po daily for 24 weeks
1804638|NCT00614471|Drug|Entecavir|0.5mg po daily from week 13 to week 36
1804639|NCT00614471|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
1804640|NCT00614471|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week from week 21 to week 68
1804641|NCT00614484|Radiation|Proton Radiation Therapy|A five week coarse of proton radiotherapy begins on day 28 and is given once daily for the first two weeks and twice daily for the final 3 weeks. The total dose given with proton beam is 76 Gy. Weekly chemotherapy with carboplatin and taxol is given during proton therapy.
1804642|NCT00614484|Drug|Taxol|200 mg/m2, IV, for 2 cycles followed by 50 mg/m2 weekly for 5 weeks during radiotherapy.
1804643|NCT00614484|Drug|Carboplatin|AUC 6, IV, for two cycles followed by AUC 2 weekly for 5 weeks during radiotherapy.
1804644|NCT00614510|Device|CardioWest temporary Total Artificial Heart (TAH-t)|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) system is a pulsatile biventricular device that replaces a patient's native ventricles and valves and pumps blood to both the pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external console connected by drivelines.
1804645|NCT00614523|Drug|Placebo|Placebo is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
1804646|NCT00614523|Biological|Romiplostim|Romiplostim is supplied in a 5 mL single use glass vial as a sterile, white, preservative-free, lyophilized powder.
1804647|NCT00614536|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12weeks
1804648|NCT00614562|Device|Neurally adjusted ventilatory assist (NAVA)|NAVA for 72 hours
1804649|NCT00614588|Device|Body temperature thermometers|Temperature readings every 30 minutes during and post surgery using internal stethoscope, catheter and adhesive patches/electronic thermometer.
1804650|NCT00614601|Biological|HyperAcute(R)-Pancreatic Cancer Vaccine|100 million vaccine cells will be injected intradermally for up to 14 vaccinations over approximately 8 months
1804651|NCT00614614|Biological|GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)|One dose in the booster phase as intramuscular injection
1804652|NCT00614614|Biological|GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)|Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection
1804653|NCT00614614|Biological|Infanrix®|One dose as intramuscular injection
1804654|NCT00614614|Biological|ActHIB®|Three doses in the priming phase as intramuscular injection
1804655|NCT00614614|Biological|Pediarix®|Three doses in the priming phase as intramuscular injection
1804656|NCT00614640|Biological|DermaVir patch|DNA Vaccine
1804657|NCT00614640|Biological|Placebo patch|10% dextrose (D-glucose) solution
1804658|NCT00614653|Drug|Bevacizumab|5 mg/kg IV Over 90 Minutes Every 2 Weeks
1804659|NCT00614653|Drug|Erlotinib|100 mg by mouth Once Daily on days with radiation.
1804660|NCT00614653|Drug|Capecitabine|400 mg/m^2 PO Twice Daily on days with radiation.
1804661|NCT00614653|Radiation|Radiation Therapy|Radiation treatment once daily for 5 1/2 weeks or 28 doses, Dose 50.4 Gy
1804662|NCT00614666|Drug|nikkomycin Z|"Stage I: Multiple rising doses. Doses packaged on a unit dose basis in 50 and 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.
50 mg BID (n=8) vs placebo capsule BID (n=2)
250 mg BID (n=8) vs Placebo capsule BID (n=2)
500 mg BID (n=8) vs Placebo capsule BID (n=2)
750 mg TID (n=8) vs Placebo capsule TID (n=2)
At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos.
Stage II will be a single dose level selected based on pharmacodynamics and safety from Stage I for 20 additional subjects using 4:1 randomization."
1804742|NCT00615290|Drug|tipranavir|
1805092|NCT00623935|Drug|Fludarabine|Fludarabine (40 mg/m2/day x 4 days)
1804663|NCT00614679|Drug|catheter lock solution consisting of N-acetylcystein, tigecycline and heparin|N-acetylcystein 80 mg/ml, tigecycline 1 mg/ml, and heparin 2000 units/ml. This will be a 5 ml catheter lock solution
1804664|NCT00614705|Drug|PH-797804|6 mg dose in oral capsule form, once daily for 28 days
1804665|NCT00614705|Drug|Placebo|oral capsule form, once daily for 28 days
1804666|NCT00614731|Biological|KLH carrier-protein|KLH carrier-protein vaccination containing no other protein or antibodies
1804667|NCT00614744|Procedure|Hypothermia|Induced Whole-body hypothermia (with a target esophageal temperature of 33.5°C) for 96 hours
1804668|NCT00614744|Procedure|Normothermic Control|Normothermic Control group (with esophageal temperature at or near 37.0°C) for 96 hours
1804669|NCT00614757|Drug|N-acetylcysteine 20% 4ml|N-acetylcysteine 20% 4ml
1804670|NCT00614757|Drug|N-acetylcysteine 20% in 4 ml|N-acetylcysteine 20% in 4 ml
1804671|NCT00614770|Procedure|standard of care colonoscopy|"Standard White Light Colonoscopy
one exam per patient"
1804672|NCT00614770|Procedure|colonoscopy|"Narrow Band Imaging Colonoscopy
one exam per patient"
1804673|NCT00614770|Procedure|standard of care colonoscopy|"High Definition White Light Colonoscopy
one exam per patient"
1804674|NCT00614796|Behavioral|Coach, using a stepcounter with exercise counseling|5 counseling meetings of 30 min in the first 3 months. In counseling, patients will be stimulated individually to enhance a physically active lifestyle.
1804675|NCT00614809|Drug|gefitinib|gefitinib 250mg qd until disease progression or unacceptable toxicity.
1804677|NCT00614835|Drug|Docetaxel plus Gemcitabine|Gemcitabine 900 mg/m2 IV over 90 minutes day 1 Gemcitabine 900 mg/m2 IV over 90 minutes day 8 + Docetaxel 75 mg/m2 IVPB day 8 Dexamethasone 8 mg po bid days 7-9 GCSF 150 ug/m2 (round to nearest vial size: 350 ug or 480 ug) SQ days 9-15 Repeat every 21 days for total of 4 cycles
1804678|NCT00614848|Device|Endeavor drug eluting coronary stent|Zotarolimus coated coronary stent (10ug/mm)
1804679|NCT00614861|Other|Non-cancer pain management survey|Non-cancer pain management survey
1804680|NCT00614874|Drug|rosiglitazone|2mg, 4mg, 8mg
1804681|NCT00614913|Radiation|Proton radiation therapy|A total dose of 63 Gy will be delivered in 15 equally divided daily fractions over a 3 week coarse as an out-patient.
1804682|NCT00614926|Drug|Modafinil|Dose schedule: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day as clinically indicated, in the absence of dose-limiting side effects. Dose is daily, in A.M., for 4 weeks.
1804683|NCT00614926|Drug|Placebo|Placebo capsules are administered on the same schedule as active drug: 50 mg/day for 1 week, increasing to 100 mg/day at Week 2. Thereafter, dose may be increased to 300 mg/day in the absence of clinical improvement and dose limiting side effects. Dose is daily, in A.M.
1804684|NCT00614939|Drug|Saxagliptin|2.5 mg once daily oral dose
1804685|NCT00614939|Drug|Placebo|Placebo
1804686|NCT00614952|Device|PSG (polysomnography)|POLYSOMNOGRAPHY
1804687|NCT00614952|Other|PR (respiratory polygraphy)|respiratory polygraphy: level III of AASM
1804688|NCT00614965|Drug|Irinotecan|Irinotecan at the dose of 110 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
1804689|NCT00614965|Drug|Cisplatin|Cisplatin at the dose of 80 mg/m2 IV on day 1 every 3 weeks for 6 consecutive cycles
1804690|NCT00614965|Drug|Pemetrexed|Pemetrexed at the dose of 500mg/m2 IV every 3 weeks for 6 consecutive cycles
1804691|NCT00614978|Drug|lapatinib and temozolomide|Temozolomide will be given orally for 5 days of every 28 days, at doses of either 100mg/m2/day or 150mg/m2/day or 200mg/m2/day AND Lapatinib will be given orally every day at either 1000mg/day or 1250mg/day or 1500mg/day.
1804692|NCT00614991|Drug|Raltegravir|400mg BID
1804693|NCT00614991|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
1804694|NCT00614991|Drug|Ritonavir|100 mg BID or QD
1804695|NCT00615017|Drug|AZD9773 (CytoFab)|intravenous infusions
1804696|NCT00615017|Other|Placebo|Placebo
1804697|NCT00615030|Drug|Indacaterol|300 µg dosed in the morning/evening via single dose dry powder inhaler (SDDPI)
1804698|NCT00615030|Drug|Salmeterol|50 µg twice daily delivered via dry powder inhaler (DPI)
1804699|NCT00615030|Drug|Placebo to Indacaterol|Placebo matching indacaterol was delivered via SDDPI.
1804700|NCT00615030|Drug|Placebo to Salmeterol|Placebo matching salmeterol was delivered via DPI
1804701|NCT00615043|Procedure|Bladder biopsy|provision of bladder tissue via cystoscopic biopsy during planned TURBT
1804702|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous [IV] infusion 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
1804703|NCT00615056|Drug|FOLFIRI (Irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) intravenous [IV] and a subsequent 5-FU infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
1804704|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
1804705|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) intravenous infusion [IV] over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
1804706|NCT00615056|Drug|AG-013736 (axitinib)|Axitinib is given at a starting dose of 5 mg twice daily [BID] continuous dosing until disease progression, intolerance or withdrawal of consent.
1804707|NCT00615056|Drug|FOLFIRI (irinotecan, leucovorin, 5-fluorouracil [5FU])|Irinotecan (180 mg/m²) intravenous infusion [IV] over 90 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed immediately by 5-FU bolus (400 mg/m²) IV and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
1804708|NCT00615056|Drug|Bevacizumab (avastin)|Bevacizumab intravenous infusion [IV] 5 mg/kg every two weeks until disease progression, intolerance or withdrawal of consent.
1804709|NCT00615056|Drug|FOLFOX (oxaliplatin, leucovorin, 5-fluorouracil [5FU])|Oxaliplatin (85 mg/m²) IV infusion over 120 minutes, concurrently with leucovorin (400 mg/m²) intravenous infusion [IV] over 2 hours followed by 5-FU IV bolus (400 mg/m²) and a subsequent 5-FU IV infusion (2400 mg/m² over 46-48 hours), repeated every 2 weeks until disease progression, intolerance or withdrawal of consent.
1804710|NCT00615069|Device|31 mm GORE EXCLUDER® AAA Endoprosthesis|GORE EXCLUDER® AAA Endoprosthesis - 31 mm device implanted for the primary treatment of infrarenal abdominal aortic aneurysms (AAA)
1804711|NCT00615082|Behavioral|Mindfulness-Based Stress Reduction|An 8-week course led by an experienced instructor in a group format of up to 15 people. Participants in the MBSR course learn mindfulness meditation techniques and simple yoga exercises such as stretching.
1804712|NCT00615082|Behavioral|Caregiver Education & Social Support|An 8-week course led by experienced instructors in a group format of up to 15 people. Participants in the CESS course learn about a variety of important issues related to elder care and receive social and emotional support in a group discussion format.
1804713|NCT00615095|Other|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
1804714|NCT00615095|Other|self-administered questionnaire and blood draw|Epidemiologic data will be collected via a self-administered questionnaire which will be distributed to subjects by a member of the study staff. It should take less than fifteen minutes to complete, and subjects will have the options of completing it at the time of their blood-drawing or filling it out at home and mailing it back to the study staff.
1804715|NCT00615095|Other|health questionnaire, blood draw and skin exam|Numbers will be randomly selected from a pool of prefixes. Numbers will be screened by computer for being working, non-business, non-fax, and non-modem numbers. After establishing eligibility for the study, we will send the potential control a letter further explaining the purpose of the study and its requirements. An interviewer will then call to arrange an appointment. During the interview, the subject will sign informed consent, be given the public health questionnaire, have 30 ml of blood drawn, and undergo the skin examination of arms and back.
1804716|NCT00615134|Drug|enfuvirtide [Fuzeon]|90mg sc bid
1804717|NCT00615134|Drug|Optimized background ARV therapy|As prescribed
1804718|NCT00615147|Procedure|CT pulmonary angiogram and d-dimer draw|A CT pulmonary angiogram and a d-dimer drawn within 24 hours.
1804719|NCT00615160|Drug|PTK787/ZK 222584|PTK-ZK capsules taken orally with a daily flat dose of 1250 mg
1804720|NCT00615160|Drug|Dacarbazine|Dacarbazine 850 mg/m² on day 1 q4w
1804721|NCT00615173|Drug|tacrolimus (FK506)|Started: 0.05-0.1mg/kg/d,divided into two daily dose at 12hr; the blood level:5-10ng/ml in induction phase;and 4-6ng/ml in maintenance phase;
1804722|NCT00615173|Drug|cyclophosphamide or azathioprine|Induction phase: CTX 0.75g/m2 monthly Maintenance phase: AZA 2mg/kg/d.
1804723|NCT00615186|Drug|Neuradiab + Radiotherapy + Temozolomide|"Prior Surgery
Rickham Catheter placement 99mTc-DTPA Flow Study
Neuradiab Dosimetry Study
Neuradiab Therapeutic Dose Administration
Radiation Therapy (XRT) + Temozolomide:
XRT 5 days/week + temozolomide (75 mg/m2/day) over 6.5 weeks.
Post-Radiation Temozolomide Therapy:
Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
1804724|NCT00615186|Drug|Radiation Therapy + Temozolomide|"Prior Surgery: Gross total resection (< 1 cm. enhancing rim)
Radiation Therapy (XRT) + Temozolomide:
XRT 5 days/week + 42 days of temozolomide (75 mg/m2/day) over 6.5 weeks
Post-Radiation Temozolomide Therapy:
Temozolomide 150-200 mg/m2/day × 5 days, every 28 days until patient's death, confirmed disease progression, unacceptable toxicity, non-compliance with the protocol, withdrawal of consent, and/or other factor that in the opinion of the consulting oncologist precludes continued study treatment."
1804725|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
1804726|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
1804727|NCT00615199|Drug|CP-690,550|administration via oral route twice daily
1804728|NCT00615199|Drug|Placebo|administration via oral route twice daily
1804729|NCT00615212|Drug|GSK376501|GSK376501 oral tablet will be available with dosing strengths of 75 milligrams administered once daily. Biconvex, It will be a round, white film-coated tablets with both plain sides and no identifying markings.
1804730|NCT00615212|Drug|Midazolam|Midazolam oral syrup will be available with a dose of 5 milligrams administered once daily. It will be a clear, red to purplish-red, cherry-flavored syrup.
1804731|NCT00615212|Drug|Rosiglitazone|Rosiglitazone oral tablet will be available with dosing strengths of 4 milligrams administered once daily. It will be a orange colored tablet debossed with SB on one side and 4 on the other.
1804732|NCT00615212|Drug|Flurbiprofen|Rosiglitazone oral tablet will be available with dosing strengths of 50 milligrams administered once daily. It will be a blue, oval, film coated tablet.
1804733|NCT00615225|Procedure|Muscle biopsy|Muscle biopsies were taken through the operation site from the vastus lateralis thigh muscle at the beginning of surgery
1804734|NCT00615238|Behavioral|Diet plus continuous bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform 4 30-60 minute aerobic workouts per week
1804735|NCT00615238|Behavioral|Diet plus short bouts|Patients consumed a 1200 kcal/d diet and were instructed to perform short 10 minutes bouts of aerobic exercise 4 times per week
1804736|NCT00615238|Behavioral|Diet plus moderate lifestyle activity|Patients consumed a 1200 kcal/d diet and were instructed to accumulate moderate intensity physical activity on most days of the week.
1804737|NCT00615251|Drug|DR-2011|Progesterone vaginal ring for approximately 10 weeks
1804738|NCT00615251|Drug|Crinone 8%|progesterone vaginal gel for approximately 10 weeks
1804739|NCT00615264|Drug|DiaPep277|1.0mg dose, administered as subcutaneous injection, on 0, 1, 3, 6, 9, 12, 15, 18 and 21 months
1804740|NCT00615264|Drug|Placebo|Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
1804743|NCT00615303|Drug|Simethicone|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day. The colonoscopic examination was recorded
1804744|NCT00615303|Drug|Placebo|2 dosages of either 45 ml of sodium phosphate plus 240 mg of simethicone tablets or 45 ml of sodium phosphate plus placebo in the evening before and in the morning of the procedure day
1804745|NCT00615316|Drug|Guaraná|Guaraná extract 75mg/day
1804746|NCT00615316|Drug|Placebo|Placebo 1tab/d
1804747|NCT00615355|Radiation|UVB 311 nm radiation|UVB 311 nm radiation randomized to one half of the transplanted vitiligo lesion given 2 times a week for 3 months; the other half of the transplanted lesion remains UV-non-irradiated
1804748|NCT00615355|Device|UVB 311nm|Repeated UVB 311nm narrowband irradiation (24 exposures)
1804749|NCT00615368|Drug|Epoetin alfa|1 (one) intravenously injection of 40.000 IU epoetin alfa 6 days before induction of experimental hypoglycemia.
1804750|NCT00615368|Drug|Isotonic NaCl (Placebo)|1 ml. of isotonic NaCl is intravenously injected 6 days before induction of experimental hypoglycaemia
1804751|NCT00615381|Drug|Insulin|insulin infusion (0-10 U/hr) vs. 0.3 U/kg/hr and boluses (0-8 U) adjusted every 15 minutes during the intraoperative period to maintain intraoperative euglycemia (blood glucose levels 80-120 mg/dL)
1804752|NCT00615394|Procedure|intramyocardial bone marrow stem cells implantation|Patients with previous diagnosis of non-ischemic dilated cardiomyopathy. were included. Bone-marrow was collected from in the antero-superior iliac crest and mononuclear stem-cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Surgical technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5 ml), in the anterior, lateral, posterior and apical faces of the left ventricle(average 9.6 ± 2.6 x 107 cells). After the procedure, the patients were kept in the post-operative intensive care unit for a minimum period of 24 hours. They were released from the hospital in a period that varied from five to seven days.
1804753|NCT00615420|Dietary Supplement|manuka honey|Irradiated organic manuka honey 5ml 4 times a day held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
1804754|NCT00615420|Dietary Supplement|placebo gel|Sugar-free honey-flavoured gel 5ml 4 times a day swished and held in mouth for 30 secs then swallowed. May be diluted with equal or twice the volume of water to reduce nausea in patients already nauseated from chemotherapy.
1804755|NCT00615433|Drug|Lurasidone|120mg/day
1804756|NCT00615433|Drug|Olanzapine|15mg/day
1804757|NCT00615433|Drug|Placebo comparator|Placebor Comparator
1804758|NCT00615433|Drug|Lurasidone 40 mg tablets|Lurasidone 40 mg tablets
1804759|NCT00615446|Drug|SU011248; Gemcitabine|Dose finding study using SU011248 (sunitinib) daily by oral capsule in 4/2 (administered for 4 out of every 6 weeks) or 2/1 (administered for 2 out of every 3 weeks) schedule with gemcitabine administered on Days 1, 8, 22 and 29 on Schedule 4/2 and Days 1 and 8 on Schedule 2/1 until progression or unacceptable toxicity
1804760|NCT00615459|Drug|Indacaterol|Indacaterol 150 μg or 300 μg, delivered via SDDPI
1804761|NCT00615459|Drug|Tiotropium|Tiotropium 18 μg once daily delivered via inhalation device
1804762|NCT00615459|Drug|Placebo|Placebo to indacaterol (150 or 300 μg) delivered via SDDPI. The placebo for blinding tiotropium was delivered via the tiotropium manufacturer's proprietary inhalation device (HandiHaler®)
1804763|NCT00615472|Drug|Isoflurane|Group 1 Inhaled anesthesia Patients will be maintained on 50% oxygen in air and isoflurane 0 to 4%, titrated as needed to maintain a standard blood pressure (standard practice). If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
1804764|NCT00615472|Drug|Remifentanil|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
1804765|NCT00615472|Drug|Propofol|Group 2 Intravenous anesthesia Patients will be ventilated with 50% oxygen in air. Patients will receive continuous propofol infusion 0.05 mg/kg-min to 0.15 mg/kg-min titrated as needed; and remifentanil (ultra-short acting narcotic) 0.1 ug/kg-min to 0.5 ug/kg-min. These will be titrated as needed to maintain a standard blood pressure. Both infusions will be turned off at the end of the procedure. If needed, muscle relaxation will be provided by additional boluses or an infusion of mivacurium (4-10 ug/kg/min).
1804766|NCT00615511|Dietary Supplement|placebo pregnenolone|Sugar pill, taken twice a day
1804767|NCT00615511|Dietary Supplement|pregnenolone|500mg in tablet form taken orally twice a day
1804768|NCT00615524|Drug|exemestane and pazopanib|
1804769|NCT00615537|Procedure|Laser Ablation of Thyroid Nodule|Laser ablation using a laser generator, disposable fiberoptic laser fiber, cooling catheter and pump, will be performed under conscious sedation. Ultrasound will be used to localize masses. Local anesthesia will be administered both intradermally and subcutaneously. The laser applicator will be placed into the mass and laser energy will be delivered at 15W for 30-120 seconds. Real-time ultrasound monitoring of the ablation front will be used to ensure complete treatment of the target lesion. In larger masses applicators may be placed of the applicator into multiple locations. The number of locations will be determined by the treatment team, and based on lesion morphology, size, location, and accessibility.
1804770|NCT00615550|Drug|progesterone|8% vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
1804771|NCT00615550|Drug|placebo|vaginal gel, 1.125 Grams once daily, beginning at 19 0/7 to 23 6/7 weeks gestation through 36 6/7 weeks gestation
1804772|NCT00615563|Behavioral|NO BI Drug administered|
1804773|NCT00615576|Drug|SB-656933|SB-656933 will be available as white film coated, round tablet and will be available in strengths of 50 milligrams, administered orally once daily.
1804774|NCT00615576|Drug|Placebo|A placebo tablet to visually match the SB-656933 tablet will also be supplied, administered orally once daily.
1804807|NCT00621153|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg
1804808|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 32 mg oral
1804775|NCT00615589|Drug|Fludarabine/Busulfan x 4 days|"Fludarabine: 40 mg/m2/day in NS, administered IV over 30 minutes on days -5, -4, -3, and -2 pre-transplant.
Busulfan: 3.2 mg/kg IV daily in NS over 4 hours on days -5, -4, -3, and -2.
The Fludarabine shall be administered prior to the Busulfan each day."
1804776|NCT00615589|Procedure|stem cell transplant|Allogeneic, peripheral blood stem cell transplant
1804777|NCT00615602|Drug|Docetaxel|Docetaxel 75 mg/m2 as an IV infusion over 1h every two weeks for 4 cycles
1804778|NCT00615602|Drug|Trastuzumab|Trastuzumab 6 mg/Kg IV over 30 min every two weeks for 4 cycles. Subsequently,trastuzumab 6 mg/Kg IV over 30 min for 12 months
1804779|NCT00615602|Drug|Epirubicin|Epirubicin 75 mg/m2 IV push on day 1 every 2 weeks for 4 cycles
1804780|NCT00615602|Drug|Cyclophosphamide|Cyclophosphamide 700 mg/m2 IV push on day 1 every 4 weeks
1804781|NCT00615602|Drug|5-fluoruracil|5-fluoruracil 700 mg/m2 IV push on day 1 every 4 weeks
1804782|NCT00615602|Drug|Granulocyte-colony stimulating growth factor|rhG-CSF 5 μg/kg/d on days 3-10 after each cycle
1804783|NCT00615602|Drug|Trastuzumab|Trastuzumab 6mg/Kg IV over 30 min every 2 weeks for 4 cycles. Subsequently, trastuzumab 6mg/Kg IV over 30 min for 6 months
1804784|NCT00615615|Drug|Levetiracetam|
1804785|NCT00621023|Drug|Decitabine, Arsenic Trioxide and Ascorbic Acid|Subjects receive decitabine 20 mg/m2 IV over one hour for days1-5 of each cycle, and arsenic trioxide 0.25 mg/kg IV for days 1-5 of cycle 1 followed by 0.25 mg/kg twice weekly (Mon-Thursday or Tues-Fri) for all remaining cycles. Patients will have transfusion and supportive care therapy administered per the treating physician's discretion. Patients with a response after 4 cycles of therapy may choose to continue on two more cycles of decitabine with arsenic and ascorbic acid given only during the first week of those two additional cycles.
1804786|NCT00621036|Biological|autologous immunoglobulin idiotype-KLH conjugate vaccine|
1804787|NCT00621036|Biological|sargramostim|
1804788|NCT00621036|Drug|methotrexate|
1804789|NCT00621036|Drug|thiotepa|
1804790|NCT00621036|Radiation|radiation therapy|
1804791|NCT00621049|Drug|Docetaxel/Carboplatin/Bevacizumab/Erlotinib|"Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1 Bevacizumab 15mg/kg IV D1
Docetaxel should be administered before carboplatin.
After completion of four cycles of treatment, patients in Cohort A will then proceed with Maintenance treatment defined as follows:
Maintenance Treatment for patients in Cohort A:
Bevacizumab 15mg/kg IV D1 Erlotinib 150mg PO daily
Treatment cycle = 21 days. Patients will complete 8 cycles (24 weeks) of maintenance therapy unless there is evidence of disease recurrence or unacceptable toxicity."
1804792|NCT00621049|Drug|Docetaxel/Carboplatin|"Adjuvant Treatment Cohort B:
Docetaxel 75mg/m2 IV D1 Carboplatin AUC=6 IV D1
Docetaxel should be administered before carboplatin.
Treatment cycle = 21 days. Patients in Cohort B will complete 4 cycles of treatment."
1804793|NCT00621062|Procedure|High Ligation of the GSV|Performed in local or general anesthesia in accordance to clinical praxis and the patients own preference. After high ligation the GSV is stripped from the groin to the most distant insufficient part or just under the knee joint.All proximal branches are ligated. Including the superficial epigastric vein. The stripping instrument can be inserted in either cranial or caudal direction but all veins are stripped in the cranio-caudal direction.
1804794|NCT00621062|Procedure|Endovenous Laser Ablation|Laser ablation is performed in tumescence anesthesia which is performed with a 150-200 ml (sometimes more is required, up to 400ml in patients with a poorly formed saphenous sheath) solution of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). Laser is performed under duplex guidance and the catheter is inserted percutaneously into the GSV at knee level and parked distant to the saphenofemoral junction (SFJ) just distal to the superficial epigastric vein. Laser ablation is performed down to the most distal insufficient part of GSV or just below the knee joint. We use an effect of 14 Watt administration of 70-80 J / cm at a continuous mode at a speed of 1cm/5sec.
1804795|NCT00621062|Procedure|Radiofrequency ablation|RF ablation is performed in tumescence anesthesia which is performed with a 150-200 ml solution (same as above) of lidocaine with adrenaline supplement. General sedation can be administrated as a supplement (with intravenous Propofol or Dormicum when needed). RF is performed under duplex guidance and the Closure-FAST catheter is inserted percutaneously into the GSV at the knee level and parked distant to the SFJ just distal to the superficial epigastric vein. Probe size and length used for RF is chosen in accordance to the manufacturer's recommendation and with a probe temperature of 120 degrees C. RF closure is performed down to the most distal insufficient part of GSV or just under the knee joint.
1804796|NCT00621062|Procedure|Foam Sclerotherapy|Sclerosant foam consists of 2ml 3% aethoxysclerol mixed with 8ml air (Tessari method). A maximum of 10 ml is injected. Access to the vein for the sclerosant is gained by a duplex guided puncture or a mini incision mid-thigh or just above the knee and the amount of sclerosant foam used is 2,5-10 ml. Duplex is used prior to the operation in order to mark the vein and during the operation in order to control the extent of the sclerofoam. Duplex validates that foam is deposed to the whole length of the GSV. Blood from the veins is drained by means of elevation prior to the deposition of the sclerofoam. The leg is then bandaged with elastic bandage.
1804797|NCT00621075|Other|Pulmonary Arterial Hypertension - Lung Perfusion Scans|Correlation of data from non-invasive tests such as lung perfusion scans with hemodynamic measurements
1804798|NCT00621088|Procedure|Intertan|Operations performed either with a Sliding Hip Screw or a nail (Intertan)
1804799|NCT00621101|Drug|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
1804800|NCT00621101|Drug|1 tablet Rapamune(R) (sirolimus), Wyeth Pharma, Germany|administration of 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling
1804801|NCT00621101|Drug|1 tablet Ezetrol(R) + 1 tablet Rapamune(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 5 ml Rapamune(R) oral solution (1 mg/ml sirolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
1804802|NCT00621114|Device|GamCath® central venous catheter|Choice of central venous catheter type
1804803|NCT00621114|Device|GamCath Dolphin® Protect central venous catheter|Choice of central venous catheter type
1804804|NCT00621140|Drug|linagliptin|active
1804805|NCT00621140|Drug|placebo|placebo
1804806|NCT00621153|Drug|Candesartan Cilexetil|Candesartan Cilexetil 16 mg oral
1804809|NCT00621166|Drug|generic lopinavir/ritonavir|"Patients will start with lopinavir/ritonavir new formulation 400/100 mg bid with a low fat diet plus 2 nucleoside reverse transcriptase inhibitors (NRTIs). The choice of the 2 NRTIs is at the discretion of the investigator, though in general the use of zidovudine+lamivudine (300/150mg Combivir®) is recommended. If patients can be included at or before gestational week 20, a 12h pharmacokinetic curve will be recorded at week 20 (± 2 weeks)(Group 1). There should be a minimum of 2 weeks between start of lopinavir and pharmacokinetic recording. If they are included after week 20, the first 12h pharmacokinetic curve will be recorded at gestational week 33 (± 2 weeks)(Group 2). For the patients in both groups a 12 hr curve will be recorded.
Subjects in Group 1 will be offered to conduct a second 12h pharmacokinetic curve at week 20 (± 2 weeks), but this is only optional. Both groups will be asked to participate in the post partum curve, again this is optional."
1804810|NCT00621179|Drug|Leuprolide acetate in depot suspension|Leuprolide acetate in depot suspension 3.75 mg intramuscularly every 28 days x 3
1804811|NCT00621179|Drug|Leuprolide acetate|leuprolide acetate 20 mcg subcutaneously twice daily for two days or 0.5 mg daily for 7 days prior to initiation of controlled ovarian stimulation
1804812|NCT00621179|Drug|leuprolide acetate|Leuprolide acetate 20 mcg subcutaneously twice daily or 0.5 mg subcutaneously once daily prior to initiation of gonadotropin stimulation
1804813|NCT00621192|Drug|meropenem|"Meropenem was administered concomitantly with compatible medications. Because an in-line filter is not appropriate due to drug binding, the 30 minute infusion was rate controlled by using appropriate infusion (syringe) pumps. Dosing and administration of other antimicrobial therapy (e.g., an aminoglycoside) was administered per local standard of care at the discretion of the infant's neonatologist. If there was a delay in the study drug shipment, sites were to use open-label meropenem to protect the safety of the participant.
20 mg/kg every 12 hours in infants <32 weeks GA and PNA < 2 weeks 20 mg/kg every 8 hours in infants <32 weeks GA and PNA ≥ 2 weeks 20 mg/kg every 8 hours in infants ≥32 weeks GA and PNA < 2 weeks 30 mg/kg every 8 hours in infants ≥32 weeks GA and PNA ≥ 2 weeks"
1804814|NCT00621205|Behavioral|Weight reduction, Resistance training, Aerobic exercise training, Control|Weight reduction: 12 weeks intensive weight loss, 20 weeks maintenance Resistance and aerobic exercise training: individualized and progressive training programs
1804815|NCT00621218|Drug|tretinoin gel 0.05%|Apply tretinoin gel, 0.05% topically once or twice daily to female subjects with rosacea
1804816|NCT00621218|Drug|vehicle|Apply Atralin Gel vehicle topically once or twice daily to female subjects with rosacea.
1804817|NCT00621231|Dietary Supplement|Placebo|Placebo
1804818|NCT00621231|Dietary Supplement|Protein|30 E% from protein
1804819|NCT00621244|Drug|LBH589|
1804820|NCT00621257|Dietary Supplement|ergocalciferol|8000 units/ml
1804821|NCT00621257|Dietary Supplement|Cholecalciferol|400 units per drop
1804822|NCT00621270|Drug|BCI-540|BCI-540 80 mg once (q.d.) or three times (t.i.d.) a day versus placebo
1804823|NCT00621283|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
1804824|NCT00621296|Drug|MP-424 (Telaprevir)|Three tablets of MP-424 250mg tablet at a time, every 8 hours, 24 weeks administration (dose in a day: 2250 mg)
1804828|NCT00621322|Biological|GSK Biologicals' Candidate Tuberculosis Vaccines (692342) - different formulations|Intramuscular injection, 2 doses
1804829|NCT00621322|Biological|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses
1804830|NCT00621322|Biological|Control vaccine with physiological saline|Intramuscular injection, 2 doses
1804831|NCT00621348|Drug|Isotonic fluid|0.9% saline with 5% dextrose at standard maintenance rate
1804832|NCT00621348|Drug|Hypotonic fluid|Reduced volume (two thirds of standard maintenance rate) of N/5 saline in 5% dextrose
1804833|NCT00621348|Drug|Hypotonic fluid|N/5 saline in 5% dextrose at standard maintenance rate
1804834|NCT00621361|Drug|AZD2171|Oral
1804835|NCT00621361|Drug|Etoposide|Intravenous
1804836|NCT00621361|Drug|Cisplatin|Intravenous
1804837|NCT00622193|Drug|anamorelin HCl|50 mg tablet
1804838|NCT00622193|Drug|anamorelin HCl|100 mg tablet
1804839|NCT00622193|Drug|placebo|placebo tablet
1804840|NCT00622206|Drug|ritonavir and saquinavir|saquinavir/ritonavir 1500/100 mg or 1500/50 mg Twenty HIV-infected volunteers on stable doses of SQV/RTV 1500/100 mg OD for at least 3 months with an NRTI backbone and undetectable viral load will participate. After collecting samples for a full PK curve subjects will be switched to SQV/RTV 1500 /50 mg OD + 2NRTIs for 1 week before repeating the PK assessment. Blood samples will be drawn at T 0, 1, 2, 4, 6, 8, 10, 12 and 24 hours post ingestion. Consecutively to the assessment, subjects will return to SQV/RTV 1500/100 mg OD dosage.
1804841|NCT00622219|Other|Randomized Drug Testing Trial|Adolescents in the experimental condition will receive all of the services offered by the Adolescent Substance Abuse Program (including individual meetings, parent and adolescent group meetings, psychopharmacology as indicated)and will be enrolled in a random drug testing program (with an average of 12 requests for testing over a 12 week period).
1804842|NCT00622232|Genetic|VRX496-transduced autologous CD4 T cells|The cell dose will consist of approximately 10 billion VRX496-transduced autologous CD4 T cells provided as a single bolus infusion.
1805006|NCT00623324|Drug|Aplindore|Tablets .05 - 5 mg BID dosing for 14 days
1804843|NCT00622245|Drug|Lu AA34893|per oral doses, divided in twice daily administrations as capsules, during 12 weeks, followed by a one-week tapering period
1804844|NCT00622245|Drug|Quetiapine fumarate|per oral, once daily, during 12 weeks, followed by a one-week tapering period
1804845|NCT00622245|Drug|Placebo|per oral doses, twice daily as capsules during 13 weeks
1804846|NCT00622258|Drug|Everolmus|
1804847|NCT00622271|Behavioral|Group Therapy|Self-management Group Protocol: The parent sessions will be structured by general topic area, but teaching of clinical and behavioral information will be derived from questions and problems posed by the group in order to actively meet the needs and concerns of participants. The parent sessions will be an interactive process of eliciting concerns and questions, presenting information to address those questions, and following up with a discussion to review concerns and strategies to address the behavioral aspects of the issues. The child sessions will be activity focused, with hands-on opportunities to practice the skills being taught.
1804848|NCT00622284|Drug|Placebo identical to BI 1356 5mg|Placebo tablet once daily
1804849|NCT00622284|Drug|Placebo identical to Glimepiride 1mg or 2mg or 3mg or 4 mg|Placebo tablets once daily
1804850|NCT00622284|Drug|BI 1356|5mg, once daily in the morning for 104 weeks
1804851|NCT00622284|Drug|Glimepiride|1mg or 2mg or 3mg or 4mg in the morning for 104 weeks
1804852|NCT00622310|Behavioral|Walking exercise|Subjects will be randomly assigned to either a structured, vigorous-intensity endurance exercise training program or an intermittent, low-intensity exercise program. Individualized exercise prescriptions will be designed to target an increase of 2500 kcal/wk, and the theoretical weight loss will be approximately 15 pounds (~6.8 kg) during the 6 month intervention.
1804853|NCT00622336|Drug|Lenalidomide|Oral Lenalidomide 25mg daily on Days 1-21 every 28 days.
1804854|NCT00622349|Drug|Cisplatin, Ifosfamide, Gemcitabine|Cisplatin 50 mg/m² day 1 Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
1804855|NCT00622349|Drug|Ifosfamide, Gemcitabine|Ifosfamide 3g/m² day 1 (+ uromitexan rescue) Gemcitabine 1 g/m² days 1 and 8 Cycles every 3 weeks
1804856|NCT00622349|Drug|Cisplatin, docetaxel|Cisplatin 50 mg/m² day 1 Docetaxel 75 mg/m² day 1 Cycles every 3 weeks
1804857|NCT00622362|Biological|DEPIGOID Dermatophagoides pteronyssinus|Subcutaneous administration:0.5 ml/month during 1 year
1804858|NCT00622362|Biological|Polymerized TOL of Dermatophagoides pteronyssinus|Sublingual immunotherapy. Two drops daily during 1 year
1804859|NCT00622362|Biological|Placebo Comparator|Sublingual immunotherapy. Two drops daily during 1 year
1804860|NCT00622375|Drug|mesalamine|encapsulated mesalamine granules
1804861|NCT00622388|Drug|Ofatumumab|8 weekly intra-venous (i.v.) infusions, 1 x 300mg and 7 x 1000mg
1804862|NCT00622401|Biological|Dendritic Cell/Tumor Fusion Vaccine|Vaccine is derived from the participants dendritic cells and tumor cells
1804863|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 30ng/kg
1804864|NCT00622401|Drug|Interleukin-12|Given subcutaneously at dose of 100ng/kg
1804865|NCT00622414|Biological|ziv-aflibercept|Given IV
1804866|NCT00622427|Drug|Ramelteon|8 mg tablets every night for 2 weeks
1804867|NCT00622427|Drug|Placebo|placebo tablets for every night for 2 weeks
1804868|NCT00622440|Drug|AIJP (Arnebia Indigo Jade Pearl)|Participants will administer their own treatment using 1/4 teaspoon of the cream twice daily for 48 weeks.
1804869|NCT00622440|Drug|Placebo|Placebo twice daily for 48 weeks.
1804870|NCT00622453|Other|Screening|Electrocardiography Blood Test
1804871|NCT00622466|Drug|paclitaxel|The chemotherapy drug called paclitaxel (Taxol) treats breast cancer, lung cancer, ovarian cancer and Kaposis sarcoma
1804872|NCT00622466|Drug|sorafenib tosylate|Sorafenib is a type of targeted therapy known as a kinase inhibitor used to treat advanced renal cell carcinoma and unresectable hepatocellular carcinoma
1804873|NCT00622479|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib will be administered at 400mg BID for a 28 day cycle.
1804874|NCT00622492|Other|echocardiography Doppler sonography, blood and urine sampling|data registration and collection at standard intervals from directly before cannulation until 24 hours after decannulation from ECMO
1804875|NCT00622505|Drug|zoledronic acid|4 mg either 4 or 12 weeks for 96 weeks
1804876|NCT00622518|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
1804877|NCT00622531|Device|BNP assay (Siemens ADVIA Centaur BNP)|Diagnostic test
1804878|NCT00622531|Other|hidden BNP value|no intervention
1804879|NCT00622570|Drug|Pentobarbital|10 mg/kg in 30 minutes; then 5 mg/kg/h during 3 hours; then 1 mg/kg/h
1804880|NCT00622570|Drug|thiopental|"2 mg/kg in bolus; if ICP is not below 20 mmHg then 3 mg/kg in bolus; if ICP is not below 20 mmHg it can be administrated a third bolus of 5 mg/kg.
Maintenance: 3 mg/kg/h in perfusion"
1804881|NCT00622596|Other|Mobile Access|Subjects would access buprenorphine through mobile access. On day 1: 8 mg of buprenorphine, then on Day 2: 16 mg daily of buprenorphine sublingually.
1804882|NCT00622609|Drug|GSK249320A|GSK249320A intravenous infusion will be formulated as 100 milligrams/milliliters in 2 milliliters vials (filled to 1 milliliter), in phosphate buffer and delivered by a syringe and programmable pump.
1804883|NCT00622609|Drug|Placebo|Sodium chloride intravenous infusion will be given as matching placebo.
1804884|NCT00622622|Biological|VEGFR2-169 and gemcitabine|Escalating doses of VEGFR2-169 will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles(doses of 0.5,1.0,2.0mg/body are planned). Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on days 1,8 and 15. Repeated cycles of VEGFR2-169 and gemcitabine will be administered until patients develop progressive disease or unacceptable toxicity,or for maximum 2 cycles, whichever occurs first.
1804885|NCT00622635|Drug|Indacaterol 300 μg|Indacaterol 300 μg was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
1804886|NCT00622635|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single-dose dry-powder inhaler (SDDPI).
1804887|NCT00622635|Drug|Salmeterol 50 μg|Salmeterol 50 μg was provided in powder filled capsules with a multi-dose dry-powder inhaler (MDDPI).
1804888|NCT00622648|Drug|Enoxaparin|40 mg once daily for 6 to 14 days (10 ± 4 days)
1804889|NCT00622648|Drug|Placebo|Enoxaparin placebo 40mg once daily for 6 to 14 days (10 ± 4 days)
1804890|NCT00622661|Other|Low Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
1804891|NCT00622661|Other|High Glycemic Load Diet|consume both high and low glycemic load diets for 28 days each
1804892|NCT00622674|Biological|cetuximab|A loading dose of cetuximab will be given on day 1 (400 mg/m2) followed by a weekly dose of 250 mg/m2.
1804893|NCT00622674|Drug|bortezomib|The starting dose of bortezomib will be 1.3 mg/m2 with a 0.1 increment increase with each successive dose level to a maximum of 2.0 mg/m2.
1804894|NCT00622687|Drug|iloprost|0.5-2 ng/kg x min for 6hours a day for 21 consecutive days
1804895|NCT00622687|Drug|iloprost low dose|0.5 ng/kg x min over 6 h per day for 21 consecutive days
1804896|NCT00622687|Drug|iloprost therapy up to 2 ng/kg x min|starting therapy at doses of 0.5 ng/kg x min, increase the dose every two days for 0.5 ng/kg x min up to the maximally tolerated dose or to 2 ng/kg x min
1804897|NCT00622700|Drug|Teriflunomide|Film-coated tablet Oral administration
1804898|NCT00622700|Drug|Placebo|Film-coated tablet Oral administration
1804899|NCT00622713|Drug|Rivastigmine transdermal patch|The study treatment was delivered as a patch sizes 5 and 10 cm^2 containing respectively 9 and 18 mg of rivastigmine. During the first 4 weeks of the study, patients applied a new rivastigmine 5 cm^2 patch once daily. At the end of the 4 weeks, if tolerability was satisfactory, the dosage was increased and patients applied rivastigmine 10 cm^2 patch once daily for an additional 4 weeks. Thereafter, and until the end of the study, patients remained at the maximum tolerated dose, either 5 or 10 cm^2.
1804900|NCT00622726|Drug|Bevacizumab|Anti-angiogenic drug: intravitreal injection of 0.625 mg (0.025 ml) once into each eye.
1804901|NCT00622726|Procedure|Conventional Laser for ROP|Conventional Laser is applied to the Avascular Peripheral Retina (Anterior to the Vascularized Posterior Retina)
1804902|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20 mg to a maximum of 160 mg. Arm 1 will have the dose of Ziprasidone titrated at a rate of 20 mg every 2 days, reaching the maximum dose in 14 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
1804903|NCT00622739|Drug|Ziprasidone|Subjects will be treated openly with Ziprasidone for 6 weeks. Dose will be titrated from 20mg to a maximum of 160mg. Arm 2 will have the dose of Ziprasidone titrated at a rate of 20mg every 3-4 days, reaching the maximum dose in 25 days. Final dose of Ziprasidone will be determined by symptoms reduction and the presence or absence of side effects.
1804904|NCT00622752|Drug|EVT 302, 10 mg|2 X EVT 302, 5 mg tablets
1804905|NCT00622752|Drug|placebo|2 X placebo tablets to match EVT 302 5 mg
1804906|NCT00622752|Drug|Nicotine replacement therapy (NRT)|NRT patch containing 21 mg of nicotine
1804907|NCT00622752|Device|NRT placebo|Medically inert plaster cut to match the NRT plaster
1804908|NCT00622765|Drug|placebo|Placebo capsule twice daily
1804909|NCT00622765|Drug|R256918|5 mg capsule twice daily
1804910|NCT00622765|Drug|R256918|10 mg capsule twice daily
1804911|NCT00622765|Drug|R256918|15 mg capsule twice daily
1804912|NCT00622804|Procedure|Billroth-II (B-II)|After conventional distal gastrectomy with lymphadenectomy, jejunum of a distal segment from 10 to 20cm from Treitz is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done.
1804913|NCT00622804|Procedure|Roux en Y gastrojejunostomy (RY-GJ)|After conventional distal gastrectomy with lymphadenectomy, jejunum is transected in the segment from 10 to 20 cm, and then distal end is transposed in a way of retro-colon to perform anastomosis using 60mm linear cutting stapler or hand-sawing technique with absorbable suture. After anastomosis, reinforcement suture is done. The resected proximal jejunum and the portion of jejunum distal 45 cm from gastrojejunostomy are anastomosed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture.
1804914|NCT00622804|Procedure|uncut Roux en Y gastrojejunostomy|After conventional distal gastrectomy with lymphadenectomy, jejunum of distal segment 45 cm from Treitz ligament is used for reconstruction. Jejunal segment is transposed in a way of ante-colon, and then gastrojejunostomy is performed using 60mm linear cutting stapler or hand-sawing technique with absorbable suture followed by reinforcement suture. After anastomosis, afferent loop distal 5cm is obstructed using non-cutting stapler or hand sawing suture. And then, distal jejunum 10 cm from obstructive portion and efferent jejunal loop distal 45 cm from gastrojejunostomy are anastomosed in a manner of side to side followed by reinforcement suture.
1804915|NCT00622817|Drug|xylometazoline HCL 0.05%|Receive four inhalation of 0.9% saline four times a day and one nasal drop of xylometazoline HCL 0.05% to each nostril twice a day.
1804916|NCT00622817|Drug|Epinephrine 1mg|Patients are treated with inhalation of epinephrine 1mg and nasal drops of 0.9% saline for each nostril every twelve hours.
1804917|NCT00622830|Drug|SB-480848 (Darapladib)|
1804918|NCT00622843|Biological|pneumococcal conjugate vaccine|"Prevnar is manufactured as a liquid preparation. Each 0.5 mL dose is formulated to contain:
2 μg of each saccharide for serotypes 4, 9V, 14, 18C, 19F, and 23F, and 4 μg of serotype 6B per dose (16 μg total saccharide); approximately 20 μg of CRM197 carrier protein; and 0.125 mg of aluminum per 0.5 mL dose as aluminum phosphate adjuvant. After shaking, the vaccine is a homogeneous, white suspension."
1804919|NCT00622843|Biological|pneumococcal polysaccharide vaccine|PNEUMOVAX 23 is manufactured according to methods developed by the Merck Research Laboratories. Each 0.5 mL dose of vaccine contains 25 μg of each polysaccharide type in isotonic saline solution containing 0.25% phenol as a preservative.
1804920|NCT00622856|Behavioral|psychological intervention|Psychological intervention
1804921|NCT00622856|Behavioral|Diabetes education|5 sessions with diabetes nurse
1804922|NCT00622869|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
1804966|NCT00623077|Drug|etoposide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 100 mg/m^2/day intravenous (IV) over 1 hour for 5 days.
1804967|NCT00623077|Drug|ifosfamide|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day intravenous (IV) over 1 hour on for 5 days.
1804923|NCT00622869|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
1804924|NCT00622869|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
1804925|NCT00622869|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
1804926|NCT00622869|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
1804927|NCT00622869|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6.
1804928|NCT00622882|Other|infectious disease specialist consultation|Randomised trial to determine the utility of an early Infectious disease Consultation in Staphylococcus aureus bacteremic patients ( in the first 48 hours of a positive blood culture)
1957636|NCT02285010|Drug|placebo|Placebo in capsule is prescribed to the patient 60 min prior to the surgery. Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed.
1957637|NCT02285010|Drug|Pregabalin|"Pregabalin (150 mg) one capsule is prescribed to the patient 60 min prior to the surgery.
Ringer Lactate Solution preload 15 mL/kg prior to surgery. Spinal anesthesia is done with 0.5% Heavy bupivacaine + morphine 0.2 mg total volume 3.0 - 3.6 mL. IV PCA Morphine is applied at PACU (bolus dose only 1 mg, lockout interval 5 min, 4 hr limit 35 mg). As soon as the patient is allowed to sip, paracetamol (500 mg) 1 tab PO every 6 hours is prescribed."
1804940|NCT00622908|Drug|ISV-403|0.6% TID, 5 days
1804941|NCT00622908|Drug|Vehicle|Vehicle of ISV-403 TID, 5 days
1804942|NCT00622921|Behavioral|Couples-based behavioral psychotherapy|12 weeks of Couples-based behavioral psychotherapy
1804943|NCT00622934|Drug|erythropoietin|300mg/kg erythropoietin 3 times on the first week of admission
1804944|NCT00622934|Drug|placebo|placebo
1804945|NCT00622947|Procedure|right temporal low frequency (1 hz) rTMS|A Magstim Rapid stimulator (the Magstim Company Ltd, Whiteland, UK)with a 90 mm circular coil is used. Low frequency rTMS at 1 Hz of right temporal cortex. Each session covering 2 trains of 60 sec. and 180 sec intertrain interval.
1804946|NCT00622947|Procedure|Sham-rTMS|The coil is angled 90 degrees away from the scalp
1804947|NCT00622960|Other|High-MUFA diet|The effects of high monounsaturated fat diet on body weight, body composition, lipid profile, and glycemic control.
1804948|NCT00622960|Other|High-CHO diet|The effects of high carbohydrate diet on body weight, body composition, lipid profile, and glycemic control.
1804949|NCT00622973|Other|Imaging: diffusion-weighted MRI|Diffusion-weighted MRI of the entire pelvis to detect lymph node metastases
1804950|NCT00622973|Other|Sinerem (USPIO) enhanced MRI|USPIO (Sinerem) will be administered intravenously immediately after the first MR examination at a dose of 2.6 mg Fe/kg body weight diluted in 100 ml of saline (optimal dose according to: (9, 10)) during a period of about 30 minutes under medical supervision. Postcontrast MR imaging will be performed 24-36 hours after contrast medium injection.
1804951|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
1804952|NCT00622986|Drug|an extract of Cimicifuga Foetida L.|Each patient will be given the medication of extract of Cimicifuga Foetida L. 2 tablets each day for 3 months.
1804953|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
1804954|NCT00622986|Drug|placebo|Each patient will be given placebo of 2 tablets each day for 3 months.
1804955|NCT00623012|Drug|Rapamycin|Rapamycin will be initiated 24 weeks post SCT, while the patient is on Tacrolimus. The initial dose of rapamycin is 12 mg of loading dose, followed by 4 mg daily. The dose will be adjusted to keep trough level at 3-12 ng/dl. Rapamycin will be continued at the therapeutic dose for 4 additional weeks after Tacrolimus is stopped. Rapamycin will then be tapered off over 2 weeks. The patients will be on 50% of steady state dose for one week and 25% of the steady state dose for the last week.
1804956|NCT00623012|Drug|Tacrolimus|Tacrolimus target level is 5-10 ng/dl. Tacrolimus taper will start at 26 weeks post SCT. Tacrolimus will be tapered off over 4-8 weeks. The rate of taper will be 25% every to weeks for patients on 4 mg or more tacrolimus daily. For the patients on 3 mg or less of tacrolimus, the dose will be reduced 1 mg every two weeks, and the last dose will be 1 mg every other day for two weeks.
1804957|NCT00623025|Drug|Creon 25000|6 to 9 capsules Creon 25000 per day
1804958|NCT00623025|Drug|Placebo|6 to 9 capsules placebo per day
1804959|NCT00623051|Procedure|Male Circumcision|
1804960|NCT00623064|Drug|cisplatin|
1804961|NCT00623064|Drug|gemcitabine hydrochloride|
1804962|NCT00623064|Drug|lapatinib ditosylate|
1804963|NCT00623064|Other|pharmacological study|
1804964|NCT00623077|Biological|filgrastim|"Beginning 24 hours after chemotherapy end: 10 microgram/kg/day subcutaneously (SQ) or intravenously (IV) until absolute neutrophile count (ANC) > 1,000/mm^2.
Starting that day, increase dose to 15 microgram/kg/day SQ or IV given as a single injection for 3 doses."
1804965|NCT00623077|Drug|busulfan|Part of pre-transplant conditioning chemotherapy: Administered as Busulfan 9.6 mg/kg IV (>4 yrs of age) or 13.2 mg/kg IV (< 4 years of age),every 6 hours on Days -8 through -6.
1804968|NCT00623077|Drug|melphalan|Part of pre-transplant conditioning chemotherapy: Administered as 100 mg/m^2 intravenous (IV) over 30 min on Days -5 through -4.
1804969|NCT00623077|Drug|thiotepa|Part of pre-transplant conditioning chemotherapy: Administered as 500 mg/m^2 intravenously (IV) over 2 hrs on Days -3 through -2.
1804970|NCT00623077|Procedure|stem cell transplantation|Regardless of whether the patient will be receiving peripheral cells or bone marrow, infusion will be intravenous on day 0, immediately after thawing.
1804971|NCT00623077|Radiation|tomotherapy|"We plan to deliver the total marrow irradiation (TMI) to the upper half of the body using Tomotherapy TMI as explained in this protocol. However the lower part of the body will be treated with Anterior/Posterior linac based radiation treatment. Tomotherapy will then be delivered at a dose rate so as to keep the total treatment time to no more than 30 minutes. We anticipate that the dose rate will be around 400 cGy
/minute (instantaneous dose rate)."
1804972|NCT00623077|Radiation|total marrow irradiation|"TMI will be delivered to all bony sites as part of the conditioning. Additional spot therapy to PET positive lesions, primary disease (if not previously irradiated to maximum tolerated dose), and lungs will be performed on Day +60. Cohorts of 3 patients will be treated at a total dose of 600 cGy, 900 cGy or 1200 cGy on Days -11 through -9."
1804973|NCT00623077|Drug|Mesna|Part of Mobilization chemotherapy and Peripheral blood progenitor cell collections (day -100 to -30): Given as 1.8 g/m^2/day divided in every 6 hrs dosing for 5 days.
1804974|NCT00623077|Radiation|Whole lung radiation|At Day 60, patients with prior lung metastasis should receive whole lung irradiation (1500cGy in 10 fractions).
1804975|NCT00623090|Behavioral|educational internet site on prostate cancer screening|Healthy men between 45-70 receive the login information to access our educational internet site on prostate cancer screening.
1804976|NCT00623090|Behavioral|Educational print booklet|Healthy men between 45-70 receive a copy of our educational print booklet in the mail.
1804977|NCT00623090|Behavioral|Usual care|Healthy men aged 45-70 receive no intervention and are followed for one year, along with the men in the two intervention arms.
1804978|NCT00623103|Drug|Rivastigmine capsule|Rivastigmine capsules orally twice a day. Target dose 12 mg/day.
1804979|NCT00623103|Drug|Rivastigmine transdermal patch|Rivastigmine patch once a day in the morning, worn for 24 hours. Target dose 10 cm^2/day delivering 9.5 mg over a 24 hour period.
1804980|NCT00623116|Drug|Short withdrawal of testosterone, gonadotropins or estrogenic compounds (see below)|clinical examination, biochemical profile, and genetic characterization. Possibility to stop hormone therapy with drugs containing testosterone (Atmos®, Testim®, Testogel®, Nebido®, Panteston®, Sustanon®), FSH (Gonal-F®, Puregon®), hCG (Pregnyl®), estrogenic compounds (such as Estrofem®, Divigel®, Estrena®, Climara®, Estradot®, Evorel®, Femseven®: Merimono®, Progynova®, Ovestin®, Zumenon®, Estrogel®, Femoston®, Femoston combi®, Divina®, Divitren®, Indivina®, Estalis sekvens®, Evorel sequi®, Novofem®, Trisekvens®, Activelle®, Estalis®, Evorel conti®, Kliogest®, Mericomb®, Mericomb Mite®, Merigest®: Angeliq®) for 3 mo to assess reversibility of GnRH-deficiency will be offered.
1804981|NCT00623129|Other|questionnaire administration|
1804982|NCT00623129|Procedure|electroacupuncture therapy|
1804983|NCT00623129|Procedure|management of therapy complications|
1804984|NCT00623129|Procedure|quality-of-life assessment|
1804985|NCT00623142|Drug|Hyperbaric Oxygen|100% Oxygen at 2.4 ATA for 30 minutes followed by 5 minutes break followed by 100% Oxygen at 2.4 ATA for another 30 minutes. This intervention was given about 4 to 5 hours prior to CABG
1804986|NCT00623155|Drug|Seasonal IPT in children - Sulfadoxine-pyrimethamine|Subjecs randomized to receive two intermittent preventive treatments with standard recommended treatment doses of Sulfadoxine-pyrimethamine at 8 weeks interval during the peak malaria transmission season.
1804988|NCT00623181|Biological|Fluzone: Influenza virus vaccine|0.1 mL, Intradermal Right deltoid, 0.5 mL, Intramuscular Left deltoid
1804989|NCT00623181|Biological|Fluzone: Influenza virus vaccine|0.5 mL, Intramuscular Right deltoid, 0.1 mL, Intradermal Left deltoid
1804990|NCT00623194|Drug|insulin detemir|Treat-to-target dose titration scheme (individually adjusted), injection s.c. (under the skin), once or twice daily.
1804991|NCT00623194|Drug|insulin aspart|Treat-to target dose titration scheme (individually adjusted), injection s.c. (under the skin), at larger meals.
1804992|NCT00623207|Drug|Atropine|I.V Atropine 0.5mg up to 2 mg
1804993|NCT00623220|Other|N2O|EMONO
1804994|NCT00623220|Other|oxygen|oxygen
1804995|NCT00623233|Drug|Gemcitabine|Gemcitabine 2500 mg/m^2 IV over 30 minutes given on Day 1 q 14 days prior to bevacizumab until PD or unacceptable toxicity.
1804996|NCT00623233|Drug|Bevacizumab|"Bevacizumab 10 mg/kg IV over 90 minutes at Cycle 1; infusion time may have been decreased for subsequent cycles. (For example, if the first infusion was tolerated without an infusion-associated adverse event [AE], the second infusion was delivered over 60 minutes. If the 60-minute infusion was well tolerated, all subsequent infusions were delivered over 30 minutes.)
Bevacizumab 10 mg/kg initially over 90 minutes given on Day 1 q 14 days until PD or unacceptable toxicity."
1804997|NCT00623246|Behavioral|MET|MET will involve motivational counseling sessions and phone calls, with a focus on building self-efficacy and providing personalized feedback on health and adherence patterns based on CPAP adherence monitoring.
1804998|NCT00623246|Behavioral|ED|ED will involve sessions and phone calls that include educational information, problem-solving, and adherence feedback from study staff.
1804999|NCT00623259|Biological|MVA-mBN120B|
1805000|NCT00623272|Other|compare measurements of left ventricular volumes and LVEF (by Cardiac Magnetic Resonance and Echocardiography)|To compare measurements of left ventricular volumes and LVEF obtained by 2DE, 3DE, and CMR after a ST elevation myocardial infarction (STEMI) complicated by systolic left ventricular dysfunction.
1805001|NCT00623285|Drug|Pregabalin|Pregabalin 150mg orally 60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive 150mg twice a day through the first 2 post-operative days for a total of six doses.
1805002|NCT00623285|Drug|Placebo/Lactose|Matching Placebo orally,60 minutes pre-operatively. Patients will receive the first dose post-operatively 12 hours after the initial dose was taken (+ 6 hours) given that patient is able to swallow and then they will receive placebo twice a day through the first 2 post-operative days for a total of six doses. If the patient is unable to swallow and NG tube is in place, the medication can be dissolved in water and administered through the NG tube.
1805007|NCT00623324|Drug|Placebo|Placebo tablets to match the number of active tablets
1805008|NCT00623337|Behavioral|Home visits|Home visits by community based surveillance volunteers (2 during pregnancy & 3 during 1st week of life) to promote facility delivery, careseeking during pregnancy and childbirth and essential newborn care practices and to identify & refer sick babies
1805009|NCT00623350|Other|Telephone|Acute Stroke consult by Telephone for the decision of tPA within 3 hours of symptom onset.
1805010|NCT00623350|Other|Two way audio/video telemedicine consult|Acute Stroke consult by two way audio video telemedicine for the decision of tPA within 3 hours of symptom onset.
1805011|NCT00623363|Drug|piclozotan|piclozotan, IV
1805012|NCT00623363|Drug|0.9% sodium chloride (normal saline)|0.9% sodium chloride (normal saline)
1805013|NCT00623376|Drug|nabilone then placebo|The subjects were first on Nabilone, then crossed over to placebo
1805014|NCT00623376|Drug|placebo then nabilone|the subjects were first on placebo then crossed over to nabilone
1805015|NCT00623389|Device|IST-16 (16-channel implanted stimulator-telemeter)|Pre-surgical exercise with surface electrical stimulation, surgery including electrode insertion and IST-16 stimulator/telemeter implantation, exercise and physical therapy with the implanted system, functional training and laboratory assessment of clinical and technical performance.
1805016|NCT00623402|Drug|Sorafenib|2x 400 mg orally per day (4 tablets)
1805017|NCT00623402|Drug|pegylated interferon α-2b|3 µg/kg body weight s.c. once a week
1805018|NCT00623415|Drug|Flupirtine|300 mg daily (divided in two doses)
1805019|NCT00623415|Drug|Placebo|twice daily
1805020|NCT00623428|Drug|peginterferon alfa-2a|
1805021|NCT00623428|Drug|Ribavirin|
1805022|NCT00623441|Device|Endeavor Zotarolimus Eluting Coronary Stent|Drug eluting stent
1805023|NCT00623454|Behavioral|Cognitive behaviour therapy|Three hours with cognitive therapy focusing on the chest pain and palpitations.
1805024|NCT00623467|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Gadobutrol single injection 0.1 mmol/kg BW via IV bolus administration at 2mL/sec.
1805025|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Prophylaxis treatment includes three times per week administration of 25 IU/kg of Kogenate FS. Dose escalation steps by 5 IU/kg (to 30 IU/kg or 35 IU/kg maximum) exhibiting a bleeding frequency of 12 bleeding episodes per year or greater.
1805026|NCT00623480|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Treated according to the Kogenate FS package insert indications and study physician recommendations
1805027|NCT00623506|Drug|Pregnenolone|"Placebo for two weeks (during placebo lead-in), then:
Pregnenolone 100 mg in divided doses (50 mg, PO, BID) Pregnenolone 300 mg in divided doses (150 mg, PO, BID) Pregnenolone 500 mg in divided doses (250 mg, PO, BID)"
1805028|NCT00623506|Drug|Placebo|"Placebo for two weeks (placebo lead in), then:
Placebo equivalent to Pregnenolone arm: 100 mg in divided doses (50 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 300 mg in divided doses (150 mg, PO, BID) Placebo equivalent to Pregnenolone arm: 500 mg in divided doses (250 mg, PO, BID)"
1805029|NCT00623532|Behavioral|Mind-body exercises|
1805030|NCT00623532|Behavioral|Adapted Tai-chi|
1805031|NCT00623545|Drug|Exenatide|Exenatide dose was 5 microgram for 2 weeks that was increased to 10 microgram for 10 weeks of treatment.
1805032|NCT00623558|Drug|Cetuximab|400 mg/m2 first dose, then 250 mg/m2 weekly for 9 weeks
1805033|NCT00623558|Drug|Docetaxel|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
1805034|NCT00623558|Drug|Cisplatin|75 mg/m2, day 1 of every 3 weeks for 9 weeks (3 cycles)
1805035|NCT00623571|Other|Treatment of elderly patients in a GMW|
1805036|NCT00623571|Other|Treatment of elderly patients in GHHS|
1805037|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
1805038|NCT00623584|Procedure|Corneal transplantation|Full thickness penetrating keratoplasty
1805039|NCT00623597|Drug|ritonavir|2.5-3.0mg/kg po bid (starting dose) for 48 weeks
1805040|NCT00623597|Drug|saquinavir [Invirase]|50mg/kg po bid (starting dose) for 48 weeks
1805041|NCT00623610|Procedure|islet cell grafts|Intraportal injection of an islet cell graft into the liver.
1805042|NCT00623623|Procedure|primary PCI|Standard primary PCI
1805043|NCT00623623|Drug|enoxaparin|Adjunctive treatment
1805044|NCT00623623|Procedure|catheterisation|Routine or rescue coronary intervention
1805045|NCT00623623|Drug|tenecteplase|Single, weight-adjusted i.v. bolus of tenecteplase
1805046|NCT00623623|Drug|clopidogrel|Adjunctive treatment
1805047|NCT00623636|Drug|MAP0004|MAP0004 1.0mg inhaled to treat a qualifying migraine up to 8 weeks followed by MAP0004 1.0mg inhaled to treat qualifying migraines for up to an additional 52 weeks. Placebo treated patients will receive MAP0004 1.0mg inhaled to treat qualifying migraines for up to 52 weeks only.
1805048|NCT00623636|Drug|Placebo|Placebo 1.0mg inhaled to treat a qualifying migraine up to 8 weeks.
1805049|NCT00623649|Drug|VCH 916|Dose escalation study with a full review of all safety data following each cohort.
1805050|NCT00623649|Drug|Placebo|Dose escalation study with a full review of all safety data following each cohort.
1805051|NCT00623662|Other|Preoperative glucose infusion|Glucose infusion from 15:00 on the day before the operation until beginning of surgery.
1805052|NCT00623662|Other|Preoperative normal saline infusion|Normal saline infusion from 15:00 on the day before surgery until beginning of the operation.
1805053|NCT00623675|Dietary Supplement|Mineralox C|Mineralox C 2 capsules three times a day.
1805054|NCT00623688|Device|Metered Dose Inhaler & Optichamber Advantage Valve Holding Chamber (VHC)|Albuterol is delivered by metered dose inhaler with valved holding chamber. For children less than 6 years of age, a mask is also used.
1805055|NCT00623688|Device|Airlife Sidestream High Efficiency Nebulizer|Albuterol is delivered as a mist mixed with normal saline using a nebulizer machine and face mask or mouth piece.
1805056|NCT00623701|Biological|Allerslit forte|sublingual placebo preparation, daily
1805057|NCT00623701|Biological|Allerslit forte|Sublingual preparation, 40 micro grams Phl p 5 maintenance dose,daily
1805090|NCT00623909|Device|AvicennaTM class IV laser application|AvicennaTM class IV laser for application over the skin of human subjects in the treatment of post-thoracotomy pain syndrome. Six sessions, twenty minutes applications over a period of six weeks.
1805058|NCT00623714|Drug|Comparator: fluticasone|Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
1805059|NCT00623714|Drug|Placebo|Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
1805060|NCT00623727|Biological|rFVIII-FS/pegylated liposomes (BAY79-4980)|35 IU/kg body weight intravenous 1x/week for 52 weeks This arm will be stopped by 30.04.10 the subjects will be offered to change to the active comparator arm
1805061|NCT00623727|Biological|rFVIII-FS/WFI (BAY14-2222)|25 IU/kg body weight intravenous 3x/week for 52 weeks
1805062|NCT00623740|Drug|hydrocortisone|Intravenous slow of hemisuccinate hydrocortisone 0.5 mg/kg/12 hours during 7 days then 0.5mg/kg/24 hours during 3 days.
1805063|NCT00623740|Drug|placebo|intravenous slow of placebo 0.5mg/kg/12 hours during 7 days then 0.5 mg/kg/24 hours during 3 days
1805064|NCT00623753|Biological|EnvDNA, PolyEnv1, EnvPro|Description: The vaccine regimen is a series of 6 injections given 28 days apart. EnvDNA is administered intramuscularly as 100 mcg of recombinant DNA in 1.5 mL of PBS as injections #1, 2 and 5. PolyEnv1 is recombinant vaccinia virus administered subcutaneously as 107 pfu in 0.8 mL of PBS as injection #3. EnvPro is administered intramuscularly as 100 mcg of recombinant protein and 500 mcg of aluminum hydroxide (alum) adjuvant in 1.0 mL of PBS as injections #4 and 6.
1805075|NCT00623779|Drug|AZD0837|ER formulation
1805076|NCT00623779|Drug|Aspirin|Oral form
1805077|NCT00623792|Behavioral|Preoperative lifestyle Intervention|"6 month individual intervention consisting of weekly face-to-face and telephone sessions addressing diet, activity and preparation for surgery, followed by 3 booster telephone calls after surgery"
1805078|NCT00623805|Drug|Bevacizumab|Bevacizumab was supplied as a solution in single-use vials.
1805079|NCT00623805|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
1805080|NCT00623805|Drug|Oxaliplatin|Oxaliplatin was supplied as a lyophilized powder in vials.
1805081|NCT00623831|Biological|Mixed bacterial vaccine|MBV was administered twice weekly by subcutaneous injection in Cohort 1 and by intralesional (preferred) or subcutaneous (if intralesional not possible) injection in Cohort 2. In Cohort 1, the MBV starting dose was 250 EU (dose level 1) with possible intrasubject escalations up to 547,000 EU (dose level 8). In Cohort 2, all subjects received MBV at a fixed dose of 60,800 EU (dose level 6).
1805082|NCT00623844|Behavioral|physical activity|activity program at kindergarten 5 * 30 min per week plus education of parents (letters, flyers, presentations, counselling) plus activity homework for children involving also the families
1805083|NCT00623857|Dietary Supplement|Zinc|Daily oral supplementation with zinc, 10 mg, for an average of 60 weeks
1805084|NCT00623857|Dietary Supplement|Vitamins and minerals other than zinc|Daily supplementation with vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
1805085|NCT00623857|Dietary Supplement|Vitamins plus zinc and other minerals|Daily oral supplementation with zinc, vitamin A, vitamin B1, vitamin B2, niacin, vitamin B6, folic acid, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K, iron, iodine, copper, selenium, magnesium and calcium; for an average of 60 weeks
1805086|NCT00623857|Dietary Supplement|Placebo|Daily oral supplementation with placebo for vitamins and all minerals; for an average of 60 weeks
1805087|NCT00623870|Drug|RO5045337|Multiple ascending doses
1805088|NCT00623883|Procedure|Surgical removal of ACF|All ACF removed by either cold or hot colonoscopic biopsy forceps
1805089|NCT00623883|Procedure|Colonoscopic evaluation only|Stain-enhanced magnification endoscopy performed, ACF quantified at entry and after one year
1805091|NCT00623922|Behavioral|Patient education with individual nurse consultations|3 group meetings followed by 1-2 individual nurse consultations.
1957654|NCT02279082|Drug|DFN-02|Active Experimental Drug
1957655|NCT02278341|Drug|roxadustat|Oral Tablet
1957656|NCT02278341|Drug|epoetin alfa|Subcutaneous (SC) or Intravenous (IV) Injection
1957657|NCT02278341|Drug|darbepoetin alfa|Subcutaneous or Intravenous Injection
1805093|NCT00623935|Drug|Busulfan|Busulfan (3.2 mg/m2/day x 2 days or x 4 days).
1805094|NCT00623935|Radiation|Total Body Irradiation|Patients who receive Busulfan 3.2 mg/m2/day x 2 days and a mismatched allograft (7/8 HLA match) will also receive 200 cGy of total body irradiation (TBI) pre-transplant.
1805095|NCT00623935|Procedure|Stem Cell Transplant|Allogeneic stem cell transplant from related or unrelated donor
1805096|NCT00623948|Device|A fully implanted gluteal stimulation (GSTIM) system|A fully implanted gluteal stimulation system
1805097|NCT00623974|Drug|Teriparatide (Forteo)|Subcutaneous Injection Every 12 Hours for 7 Days
1805098|NCT00623974|Drug|Calcium|1000 milligrams by mouth (PO) Every 12 Hours
1805099|NCT00623974|Drug|Calcitriol|0.25 micrograms PO Every 12 Hours
1805100|NCT00623987|Drug|warfarin accordingly INR value|warfarin accordingly to INR value between 2.0-3.0
1805101|NCT00624000|Drug|IV tpa (Alteplase) vs IA tpa (Alteplase)|Alteplase was administered Either IA or IV x 1
1957658|NCT02277769|Drug|Dupilumab|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
1805103|NCT00624026|Drug|Memantine-HCl|20 mg per day (once daily)
1805104|NCT00624039|Other|UBM with pilocarpine in presbyopia|ultrasound biomicroscopic examination in both eyes 30 minutes after one drop of 2% pilocarpine hydrochloride (Ocucarpine®, Samil Pharm., Seoul, Korea) instillation before and two months after cataract surgery
1805105|NCT00624052|Drug|fixed-dose combination of telmisartan 40mg+amlodipine 10mg|
1805106|NCT00624052|Drug|fixed-dose combination of telmisartan 80mg+amlodipine10mg|
1805107|NCT00624065|Drug|carvedilol controlled release/lisinopril|carvedilol CR + lisinopril given as separate pills
1805108|NCT00624065|Drug|lisinopril + placebo|lisinopril plus placebo to match carvedilol CR
1957659|NCT02277769|Drug|Placebo (for Dupilumab)|Subcutaneous injection alternated among the different quadrants of the abdomen, upper thighs and upper arms.
1805110|NCT00624091|Procedure|Cardiac surgery|Cardiac surgery within 48 hours of randomization
1805111|NCT00624091|Procedure|State-to-the-art treatment|Antibiotic treatment and surgery if emergency or sequelae of endocarditis as recommended in the guidelines
1805112|NCT00624104|Dietary Supplement|Food (fat free meal)|Fat free meal (40% of REE)
1805113|NCT00624117|Behavioral|Progressive exercise|home-based exercise program, 2 to 3 exercise sessions per week
1805114|NCT00624130|Drug|Yasmin 20|Yasmin 20, 24-d regimen vs Mercilon, Tablet p.o. (oral)
1805115|NCT00624130|Drug|Mercilon|Mercilon, 24-d regimen vs Yasmin 20 , Tablet p.o. (oral)
1805116|NCT00624143|Drug|ORAL VORICONAZOLE and IV Amphotericin B|Oral Voriconazole will be given in dose of 6mg/kg 12 hourly on day1 then 4mg/kg 12 hourly daily or IV Amphotericin B 0.5 mg/kg/day weekly thrice till the completion of induction or recovery of ANC >1000/MM3 or development of fungal infection
1805117|NCT00624156|Behavioral|Writing Intervention|Participants in the emotional disclosure condition will be instructed to write continuously for 20 minutes about their deepest thoughts and feelings regarding their cancer experience.
1805118|NCT00624156|Behavioral|Writing Intervention|Participants assigned to the control condition will be instructed to describe in a detailed, nonemotional manner their daily activities. The 20-minute writing task will be introduced as a time management intervention
1805119|NCT00624169|Procedure|An optimized perioperative course|A number of interventions before, during and after surgery
1805122|NCT00624195|Drug|FDA Approved Antiretroviral Therapy (see list below)|"Combinations of FDA approved antiretroviral agents:
Atripla, Combivir, Emtriva, Epivir, Epzicom, Retrovir, Trizivir, Truvada, Viread, Ziagen, Intelence, Rescriptor, Sustiva, Viramune, Agenerase, Aptivus, Invirase, Kaletra, Lexiva, Norvir, Prezista, Reyataz, Viracept, Fuzeon, Selzentry, Isentress
Generic names: Efavirenz/Emtricitabine/Tenofovir, Lamivudine/Zidovudine, Emtricitabine, Lamivudine, Abacavir/Lamivudine, Zidovudine, Abacavir/Lamivudine/Zidovudine, Emtricitabine/Tenofovir, Tenofovir, Abacavir, Etravirine, Delavirdine, Efavirenz, Nevirapine, Amprenavir, Tipranavir, Saquinavir, Lopinavir/ritonavir, Fosamprenavir, Ritonavir, Darunavir, Atazanavir, Nelfinavir, Enfuvirtide, Maraviroc, Raltegravir"
1805123|NCT00624208|Drug|droperidol and saline|droperidol 20 mcg.kg-1 and saline
1805124|NCT00624208|Drug|ondansetron and saline|ondansetron 0.1 mg.kg-1 and saline
1805125|NCT00624208|Drug|droperidol and ondansetron|droperidol 20 mcg.kg-1 and ondansetron 0.1 mg.kg-1
1805126|NCT00624208|Drug|saline and saline|saline and saline
1805127|NCT00624221|Procedure|Descemet's stripping endothelial keratoplasty|Small incision corneal transplant procedure to treat dysfunctional endothelium.
1805128|NCT00624234|Behavioral|Tutoring Program I|Tutoring Program I is a structured multi-sensory program that is designed to gradually present the range of sounds and letters with focus on accuracy of phonological concepts and application of those concepts in phrases and sentences. The instruction uses a sequenced defined lesson plan with accuracy and automaticity criteria for skill progression. A range of manipulative and kinesthetic activities is outlined to maintain learner engagement in the intensive intervention design.
1805129|NCT00624234|Behavioral|Tutoring Program II|Tutoring Program II is designed to teach visual and speech elements of reading separately at first, and then bring them together for maximum efficiency. The program uses the idea of teaching concepts about the structure of words. For example, students transfer the rules they have learned about one vowel or structure to another without specific instructions on the new one. Tutoring Program II incorporates pictures and activities to help remember strategies for increasing basic reading skills. Speed drills are also used for development of decoding automaticity.
1805181|NCT00624494|Device|Conventional monitoring|In the CM group, therapy was guided by central venous pressure, mean arterial pressure (MAP) and heart rate (HR)
1805279|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
1805130|NCT00624247|Other|routine HIV testing|Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
1805131|NCT00624260|Other|semi-annual systematic PET-TDM|semi-annual systematic PET-TDM
1805132|NCT00624260|Other|PET-TDM for current indication|PET-TDM for current indication (high isolated markers or before a metastasis curative resection)
1805133|NCT00624273|Drug|Sildenafil therapy|oral use
1805134|NCT00624286|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
1805135|NCT00624286|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
1805136|NCT00624299|Drug|Botox|Botox injection (100 ius) per muscle
1805137|NCT00624299|Other|Saline|Saline injection
1805138|NCT00624312|Drug|Procrit|"10 days prior to surgery - injection of 60,000 IU of Procrit
Day of surgery - injection of 60,000 IU of Procrit"
1805139|NCT00624312|Drug|Placebo|"10 days prior to surgery - injection with 60,000 IU of placebo
Day of surgery - injection with 60,000 IU of placebo"
1805140|NCT00624325|Drug|interferon alfa-2b|12 MU daily continuously subcutaneous
1805141|NCT00624325|Drug|interferon alfa-2b|9 MU daily continuously subcutaneous
1805142|NCT00624325|Drug|interferon alfa-2b|6 MU daily continuously subcutaneous
1805143|NCT00624338|Drug|Atacicept 75 mg|75 milligram (mg) atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
1805144|NCT00624338|Drug|Atacicept 150 mg|150 mg atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
1805145|NCT00624338|Other|Placebo Comparator|Placebo matched to atacicept injection will be administered subcutaneously twice weekly during initial loading period for 4 weeks followed by once weekly during maintenance period for subsequent 48 weeks.
1805146|NCT00624351|Biological|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only Phosphate buffered Saline (PBS) as a vehicle/buffer for the infusion procedure.
1805147|NCT00624351|Other|Placebo|Phosphate-buffered Saline (PBS) infusion.
1805148|NCT00624364|Drug|biphasic insulin aspart|
1805149|NCT00624364|Drug|metformin|
1805150|NCT00624377|Drug|Tiotropium|Tiotropium 18 mcg HandiHaler once daily
1805151|NCT00624390|Device|Sepraspray|
1805152|NCT00624403|Device|Laryngeal mask insertion (LMA ProSeal)|Laryngeal mask insertion
1805153|NCT00624403|Device|Laryngeal mask insertion (I-Gel)|Laryngeal mask insertion
1805154|NCT00624416|Drug|Prednisolone synthetic cortisone and Isoproterenol together|Approximately 0.2 to 0.4cc of isoproterenol-prednisolone solution (0.04 - 0.08 mg isoproterenol and 0.07 - 0.14 mg prednisolone) in one or more sites in the lipoma depending on its size, 5 days a week for 4 weeks.
1805156|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.125 mg/kg/hr followed by 1 hour at 0.0625 mg/kg/hr
1805157|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.25 mg/kg/hr followed by 1 hour at 0.125 mg/kg/hr
1805158|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.5 mg/kg/hr followed by 1 hour at 0.25 mg/kg/hr
1805159|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.75 mg/kg/hr followed by 1 hour at 0.375 mg/kg/hr
1805160|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0 mg/kg/hr followed by 1 hour at 0.5 mg/kg/hr
1805161|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.25 mg/kg/hr followed by 1 hour at 0.125 mg/kg/hr followed by 22 hours at 0.025 mg/kg/hr
1805162|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.5 mg/kg/hr followed by 1 hour at 0.25 mg/kg/hr followed by 22 hours at 0.05 mg/kg/hr
1805163|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0 mg/kg/hr followed by 1 hour at 0.5 mg/kg/hr followed by 22 hours at 0.1 mg/kg/hr
1805164|NCT00624442|Drug|Placebo|I.V. infusion for 2 hours
1805165|NCT00624442|Drug|Placebo|I.V. infusion for 24 hours
1805166|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0mg/kg/hr followed 1 hour at 0.5mg/kg/hr followed by 70 hours at 0.1mg/kg/hr
1805167|NCT00624442|Drug|Placebo|I.V. infusion for 72 hours
1805168|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.75 mg/kg/hr followed 1 hour at 0.5mg/kg/hr followed by 70 hours at 0.1 mg/kg/hr
1805169|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.25 mg/kg/hr followed by 23 hours at 0.025 mg/kg/hr
1805170|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 0.5 mg/kg/hr followed by 23 hours at 0.05 mg/kg/hr
1805171|NCT00624442|Drug|CK-1827452|I.V. infusion for 1 hour at 1.0 mg/kg/hr followed by 23 hours at 0.1 mg/kg/hr
1805172|NCT00624455|Drug|Gabapentin|One dose of oral premedication of Gabapentin 10 mg kg-1 given at least 30 but not more than 90 minutes before surgery. Max dose is 600mg.
1805173|NCT00624455|Drug|Placebo|Placebo
1805174|NCT00624468|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
1805175|NCT00624468|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
1805176|NCT00624481|Drug|Teriparatide|20ug subcutaneous injection daily for 24 weeks
1805177|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
1805178|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
1805179|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
1805180|NCT00624481|Drug|Teriparatide Nasal Spray|teriparatide intranasally daily for 24 weeks
1805182|NCT00624494|Device|Advanced monitoring|In the AM group by the intrathoracic blood volume index, MAP, HR, central venous oxygen saturation (ScvO2) and cardiac index (CI). The measurements were performed before and during surgery, and at 2, 4 and 6 hrs post-operatively.
1805183|NCT00624520|Behavioral|Cognitive Behavioral Stress Management (CBSM)|10 week program of weekly CBSM therapy group sessions
1805184|NCT00624520|Other|Patient Education|"10 week program of Patient Education group sessions, involving presentations of educational materials relating to heart disease."
1805185|NCT00624533|Behavioral|GDS Method (muscular chains physical therapy method)|Experimental group received 15 GDS method sessions based on the equilibration of articular and muscular tensions that reduced trunk and lumbopelvic stability. GDS method combine specific technics of manual therapy, spinal stabilisation and stretching exercises (4 sessions),supervised group exercise therapy (10 sessions) and home exercise programme with individualised exercises (1 session) Experimental group received 2 sessions of 50 minutes per week during 8 weeks.
1805186|NCT00624533|Behavioral|Conventional Physical Therapy in Primary Health Care|"Conventional Physical Therapy in Spanish Primary Care Units are based on Electrotherapy (TENS and microwave thermotherapy) and a standard written advices. Patients received 14 sessions of 40 minutes of conventional TENS, 10 minutes of microwave thermotherapy and 1 last session of standard written advices.
Conventional Physical Therapy group received 2 sessions of 50 minutes per week during 8 weeks."
1805187|NCT00624546|Drug|Prevacid Solutabs|BID Prevacid Solutabs
1805188|NCT00624546|Procedure|Antireflux surgery|Lap Nissen
1805189|NCT00624559|Drug|celecoxib (Celebrex)|Celecoxib (Celebrex) was administered at 100 mg, twice per day for each day of sodium diet
1805190|NCT00624559|Other|Placebo|Placebo pill taken twice per day on each day of the diet
1805191|NCT00624572|Drug|chlorexidine|Chlorexidine gel 1% during 7 days inside root canals
1805192|NCT00624585|Drug|Dasatinib|"DOSE ESCALATION OF DASATINIB AFTER 8 WEEKS IF ELIGIBLE
Dose Level and Dose of dasatinib:
Starting dose (1-8 weeks)= 100 mg orally (po) daily
+1 (<8 weeks if no PR and well tolerated) = 150 mg po daily
DOSE MODIFICATION OF DASATINIB
Dose Level and Dose of dasatinib:
Starting dose = 100 mg po daily
-1 = 70 mg po daily
-2 = 50 mg po daily
OR
Dose Level and Dose of dasatinib:
Starting dose = 150 mg po daily
-1 = 120 mg po daily
-2 = 90 mg po daily
-3 = 50 mg po daily"
1805193|NCT00624598|Behavioral|SMART|Use of measured resting metabolic rate from indirect calorimetry for personalized diet program and use of a computer application for journalizing food and exercise.
1805194|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|Residual pump blood will be maximally hemoconcentrated by further ultrafiltation within the CPB machine. Resulting hematocrit will be approximately 0.4. The total residual pump blood volume, approximately 300ml, will be reinfused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Additional protamine sulfate will be given every 30 minutes during the infusion, .03 mg/ml of residual pump blood. Procedures in this group do not deviate from current standard practice.
1805195|NCT00624611|Procedure|Residual pump blood management post aortic cannula removal|All residual pump blood will be processed with a bedside red cell washing device (Cell Saver). The resulting total volume of concentrated red cells will be infused over one hour, beginning 15 minutes after removal of the aortic cross clamp. Administration of additional protamine is not required due to the low concentrations of heparin in the resulting product.
1805197|NCT00624650|Drug|Diuresis (furosemide) part I|"Goal: Overall I/O net negative 50ml/hour
Initiation:
Continuous IV furosemide at 3mg/hour or last known protocol specified dose
Titrate up or down by 3mg/hour increments every hour as needed to establish diuresis goal
Do not exceed 30mg/hour
Furosemide Bolus:
If unable to establish adequate diuresis at maximum dose may attempt furosemide bolusing as follows
By intravenous bolus give 30, then 60, then 80, and 120 mg - one bolus dose every hour until urine output results in 1 ml/kg PBW/hr net negative fluid balance per hour
Bolusing trials may be done at will but total furosemide dose may not exceed 800mg/24hour period"
1805198|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|15 ml/kg PBW crystalloid (round to nearest 250 ml) or 25 grams albumin as rapidly as possible. Used for patients with a measured CVP<8 or measured PaOP <12mmHg in addition to concurrent urine output of <0.5 ml/kg/hr
1805199|NCT00624650|Other|Fluid Bolus (crystalloid or albumin)|"10 ml/kg PBW crystalloid (round to nearest 70ml) or 25 grams albumin as rapidly as possible.
Perform thermodilution immediately before and after and 60 minutes after each bolus. If EVLW increases > 2ml/kg PBW within 60 minutes after a bolus do not give any further boluses until next regularly scheduled measurement. This therapy is available for patients with a map < 60 or who are on vasopressors that also have a measured GEDI less than goal"
1805200|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use any alone or in combination)
Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.
Vasopressin - 0.04 international units/hour
Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.
Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.
Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg."
1805201|NCT00624650|Drug|Vasopressors (Norepinephrine, Vasopressin, Phenylephrine, Epinephrine)|"(may use alone or in combination)
Norepinephrine - 0.05mcg/kg/min - increase for effect not to exceed (NTE) 1mcg/kg/min.
Vasopressin - 0.04 international units/hour
Phenylephrine - 7mcg/min - may increase to for effect not to exceed 500mcg/min.
Epinephrine - 1 mcg/min - may increase for effect not to exceed 20mcg/min.
Weaning: When MAP ≥ 60 mm/Hg on stable dose of vasopressor begin reduction of vasopressor by greater than or equal to 25% stabilizing dose at intervals ≤ 4 hours to maintain MAP ≥ 60 mm/Hg.
In the experimental arm vasopressors are a treatment option in patients with a Mean Arterial Pressure of < 60"
1805202|NCT00624650|Drug|Dobutamine|"Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.
Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.
If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol.
Used in patients with a measured cardiac index < 2.5"
1805276|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0.5 mg and 1500 IU
1805203|NCT00624650|Drug|Dobutamine|"Begin at 5mcg/kg/min and increase by 3 mcg/kg/min increments at 15 minute intervals until C.I. ≥ 2.5 or maximum dose of 20mcg/kg/min has been reached.
Begin weaning 4 hours after low CI is reversed. Wean by ≥ 25% of the stabilizing dose at intervals of ≤ 4 hours to maintain hemodynamic algorithm goals.
If patient is on dobutamine as a result of an earlier cell assignment, dobutamine should be ignored for the purpose of subsequent assignment, but should be continued to be weaned per protocol."
1805204|NCT00624650|Other|Concentrate all drips and nutrition|"Concentrate all drips and nutrition in order to minimize fluid volume as much as possible. Intravenous fluid to be run at keep vein open rate.
EVLW arm: Patients with a MAP > 60 and off vasopressors for >12 hours, as well as patients with a measured cardiac index >2.5 that also have a measured GEDI > goal."
1805205|NCT00624650|Drug|Diuresis (furosemide) part II|"Withhold furosemide if:
Significant hypokalemia (K+ <= 2.5 meq/L), or hypernatremia (Na+ >= 155 meq/L) occurs within last 12 hours may then be restarted if the prevailing condition no longer exists
Dialysis dependence
Oliguria (less than 0.5ml/kg/hour) with either creatinine > 3, or clinical suspicion of rapidly evolving ARF
More than 800mg has been given in less then 24 hours
Creatinine increases > 1.5 mg/dl in any 24 hour period"
1805206|NCT00624650|Procedure|Dialysis|"Need for CVVHD or intermittent hemodialysis to be determined by treating clinicians.
CVC arm: If fluid management to be accomplished with dialysis then fluid balance goals to be determined per clinicians.
EVLW arm: Fluid balance as per algorithm
When using intermittent HD it is recommended that no more than 2 liters net negative fluid is removed per dialysis session. Total fluid removal per run to be estimated by the clinicians to attain CVP or GEDI goals per algorithm."
1805207|NCT00624663|Drug|Rivastigmine|Administration 1 (A): 1 x 1.5 mg Exelon® Capsule (Novartis) + 1 x Placebo Capsule Administration 2 (B): 2 x 1.5 mg Exelon® Capsules (Novartis) Administration 3 (C): 2 x Placebo Capsules
1805208|NCT00624676|Drug|Lipo Hydroxy Acid|Twice a day
1805209|NCT00624676|Drug|5% benzoyl peroxide gel|Once a day
1805210|NCT00624689|Dietary Supplement|Modified formula (MFGM-enriched formula with reduced energy and protein content)|MFGM-enriched formula with reduced energy and protein content
1805211|NCT00618527|Drug|mycophenolate mofetil (Cellcept)|1 gram po, bid
1805212|NCT00618527|Drug|human interferon beta 1a (Rebif)|44mcg sq injection every other day
1805213|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
1805214|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
1805215|NCT00624702|Drug|Indacaterol maleate|Four single dose treatments (each dose is 400 µg-for the active salts-via SDDPI), with at least a 7 day inter-dose interval
1805216|NCT00624702|Drug|Placebo|
1805217|NCT00624715|Drug|THC|"High dose: 0.036 mg/kg (2.5 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking a full joint
Low dose: 0.018 mg/kg (1.25 mg in a 70kg individual) IV (in the vein) dissolved in ethanol.Equivalent to smoking ½ of a joint
Very low dose: 0.0036 mg/kg (0.25 mg in a 70 kg individual)IV (in the vein) dissolved in ethanol. Equivalent to smoking 1/10 of a joint"
1805218|NCT00624715|Drug|Placebo|Placebo: Small amount of ethanol IV (in the vein), (quarter teaspoon).
1805219|NCT00624728|Radiation|18F Fluorothymidine PET CT|"18 FLT will be provided by the Laboratoire des Radiopharmaceutiques- Université Bordeaux2, Hôpital Xavier Arnozan and prepared according to the method described by Grierson and Shields ( Grierson J, Shields A. Nucl Med Biol 27 :143-156 ; 2000).
Specific activity of 18FLT will be more than 37 GBq/µmol (>1Ci/µmol) corrected for decay at the end of bombardment of cyclotron target. Before tracer injection to patients, each dosis will be tested for pH and for radiochemical purity (> 95%) via HPLC technique and thin layer chromatography.
18FLT dosis will be injected intravenously to the patients (10 mL of salted isotonic solution with less than 10 % (v/v) of ethanol (USP). Administrated activity will be calculated estimating total body surface of patient (2,6 MBq/kg ou 0,07 mCi/kg) with maximal activity of 185 MBq.
PET acquisition will be realized as follows : Dynamic acquisition in 3D mode for 35 min, Iterative reconstruction (OSEM) with and without attenuation correction."
1805220|NCT00624741|Drug|Pergolide|Pergolide tablets should be initiated with a daily dosage of 0.05 mg for the first 2 days. The dosage should then be gradually increased by 0.1 or 0.15 mg/day every third day over the next 12 days of therapy. The dosage may then be increased by 0.25 mg/day every third day until an optimal therapeutic dosage is achieved.
1805221|NCT00624754|Drug|Formoterol/Budesonide|Budesonide/Formoterol 400/12: 800 µg b.i.d for 1 month
1805222|NCT00624754|Drug|lactose|Lactose 2 puffs b.i.d for 1 month
1805223|NCT00624767|Drug|Insulin (recombinant human insulin)|Insulin Nasal Spray at doses up to 200 IU.
1805224|NCT00624767|Drug|NovoLog|NovoLog at doses up to 30 IU
1805225|NCT00624780|Drug|Pregabalin|Pregabalin 150-300 mg given twice a day
1805226|NCT00624780|Drug|Lorazepam|Lorazepam 3-4 mg given twice a day
1805227|NCT00624780|Drug|Pregabalin|Pregabalin 450-600 mg given twice a day
1805228|NCT00624780|Drug|Placebo|Placebo
1805229|NCT00624793|Other|Acupuncture|Standard Acup point protocol for treating nausea
1805230|NCT00624793|Other|Individualized Acup based on TCM diagnosis|Acup
1805231|NCT00624793|Other|Sham Acup|Sham Acup - Non-Active
1805232|NCT00624806|Behavioral|Daily telephone calls|Patients randomized to this group receive daily phone calls to remind them what they should do to prevent ulcers.
1805233|NCT00624806|Behavioral|Weekly telephone calls|Patients randomized to this group receive weekly phone calls to remind them what they should do to prevent ulcers.
1805236|NCT00624832|Drug|Xolair|Xolair (Omalizumab) dose: 2 x 450 mg, 2 x 525 mg or 2 x 600 mg; subcutaneous injection;
1805237|NCT00624832|Drug|Placebo|Matching placebo of Xolair (omalizumab), by subcutaneous injection of a solution with a concentration of 125 mg/mL in a supine position.
1805238|NCT00624845|Drug|OMS103HP|Maximum 6 bags of OMS103HP irrigation solution
1805239|NCT00624845|Drug|Vehicle|Maximum of 6 bags of vehicle irrigation solution
1805277|NCT00627406|Drug|Pregnyl|Subcutaneous injection 5000 IU
1805278|NCT00627406|Drug|Buserelin and Pregnyl|Subcutaneous injection 0,5 mg and 1500 IU + 1500 IU after 7 days
1805240|NCT00624858|Drug|naltrexone SR 32 mg/ bupropion SR 360 mg daily|"All subjects are to complete a 4 week titration period at which time subjects will be titrated up to a maintenance level of study drug. Subjects will then take the maintenance dose of study drug for an additional 20 weeks.
During the study, subjects will receive ancillary therapy including advice on diet and exercise"
1805241|NCT00624871|Drug|Ascorbic acid (vitamin C)|IV, 100 mg/kg/day, every day, for 3 days
1805242|NCT00624871|Drug|Ibuprofen|PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life
1805243|NCT00624871|Drug|Placebo|
1805244|NCT00624910|Drug|Bupivacaine Collagen Sponge (CollaRx®)|The bupivacaine sponge contains 70 mg Type I collagen and 50 mg bupivacaine hydrochloride. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
1805245|NCT00624910|Drug|placebo|The placebo sponge contains 70 mg Type I collagen. A total of 3 sponges will be implanted during surgery; one sponge divided between areas in the vault, one sponge divided and placed across the incision in the peritoneum and the final sponge divided and placed between the sheath and skin around the incision.
1805248|NCT00624936|Drug|Vidaza|Vidaza 75mg/m2 IV over 30min daily on days 1-7. This dose is the same for all dose levels.
1805249|NCT00624936|Drug|Velcade|Dose level 1 Velcade 0.7mg/m2 IVP on days 2 and 5 Dose level 2 Velcade 0.7mg/m2 IVP on days 2, 5, 9, 12 Dose level 3 Velcade 1.0 mg/m2 IVP on days 2, 5, 9, 12 Dose level 4 Velcade 1.3 mg/m2 IVP on days 2, 5, 9, 12
1805250|NCT00624962|Dietary Supplement|nutritional intervention|Nutritional status assessment on enrollment in study, beginning of course 1 and end of study period (week 12 or beginning of Course 5 chemotherapy)
1805251|NCT00624962|Dietary Supplement|therapeutic nutritional supplementation|enteral feedings via a nasogastric tube for 50% or more of the total nutritional support days.
1805252|NCT00624975|Biological|Peru-15 Vaccine|up to 1 x 10^9 CFU of Peru-15 given in 5ml single dose vials with 20 ml buffer solution, given once
1805253|NCT00624975|Biological|Placebo|25 mL of buffer solution (2.5 g sodium bicarbonate and 1.65 g ascorbic acid per 100mL potable water)
1805254|NCT00624988|Procedure|Vibration Therapy|Treatment will consist of 10 sessions of 60 seconds each with one minute intervals in between at 50 Hz frequency three times per week for three months.
1805255|NCT00625014|Drug|Haloperidol|Haloperidol 3 mg/day for 8 days
1805256|NCT00625027|Other|Survey and Chart Review|After obtaining consent the survey will be completed. After a staff physician has assessed the patient, the chart will be consulted to retrieve the triage notes, diagnosis, treatment, and discharge recommendations. The physician will be asked to comment on the 'urgency' of the complaint and whether the patient would have been treated equally well at a walk-in clinic.
1805257|NCT00625040|Other|Oral glucose tolerance test (OGTT), isoglycemic iv. clamp, liquid meal test, gastric emptying rate|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml water
Isoglycemic iv. clamp: Iv. glucose infusion mimicking the glucose response curves from the OGTT
Liquid Meal test: The test is performed with 100g of formula milk deluded in 300 ml. water
Gastric Emptying Rate: Paracetamol absorption test."
1805258|NCT00627302|Drug|PEG-400|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
1805259|NCT00627302|Drug|Systane|Day of Surgery: Starting 2 hours after surgery Instill one drop in randomized eye every two hours. Day 1-Week 1: Instill one drop in randomized eye four times daily
1805260|NCT00627315|Procedure|Gastric bypass|NOTE: Surgery will not be paid by the study
1805261|NCT00627315|Procedure|Gastric banding|NOTE: Surgery will not be paid by the study
1805262|NCT00627341|Behavioral|Food Exposure Therapy and Ritual Prevention with Motivational Enhancement for Relapse Prevention in Anorexia Nervosa (AN-EX/RP)|AN-EX/RP will consist of in-session exposures to feared eating situations without using avoidance behaviors as well as formal motivational interviewing techniques.
1805263|NCT00627341|Behavioral|Cognitive behavioral therapy (CBT)|CBT for anorexia nervosa sessions will focus on behaviorally normalizing eating patterns throughout the day and on cognitively addressing dysfunctional thinking that promotes disordered eating.
1805264|NCT00627354|Drug|etoposide|
1805265|NCT00627354|Drug|mitoxantrone hydrochloride|
1805266|NCT00627354|Drug|prednisone|
1805267|NCT00627354|Drug|vinorelbine tartrate|
1805268|NCT00627367|Drug|Hydromorphone|Hydromorphone 1mg IV, followed by an optional dose of 1mg IV hydromorphone 15 minutes
1805269|NCT00627367|Drug|Nonprotocolized|An IV opioid the type and dose of which will be determined by the treating clinician
1805270|NCT00627380|Behavioral|Yoga lifestyle intervention|Sixteen weeks of 2-3 yoga sessions per week, 1.5 hrs per session administered by a certified yoga instructor. Sessions include breathing exercises and yoga postures/positions.
1805271|NCT00627380|Other|Standard of care|Participants are observed/followed for 16 weeks during which lifestyle and medication changes are discouraged, unless medically necessary.
1805272|NCT00627393|Drug|Standard antimicrobial therapy|Antimicrobial therapy is broadly defined as therapy within the standard of care for a particular infection and should be consistent within a given institution. Participants will undergo the recommended therapy for specific infections for 42 days.
1805273|NCT00627393|Biological|Granulocyte transfusions|Participants will receive one granulocyte transfusion per day until one of the following occurs: recovery from neutropenia, life-threatening toxicity, resolution or improvement of infection, or Day 42 after treatment. Granulocyte content of each transfusion is targeted to be at least 4 x 10^10 per collection (or proportionately less for participants less than 30 kg in weight).
1805274|NCT00627393|Drug|G-CSF/dexamethasone|Twelve hours before each donation, participants will be injected with G-CSF and will take one dose of dexamethasone by mouth.
1805275|NCT00627393|Device|Apheresis machine|Participants will undergo a procedure using an apheresis machine for granulocyte collection. The procedure will last 3 to 4 hours and will involve the drawing of blood from each arm, the separation of granulocytes from the red cells and plasma in the machine, and the return of the red cells and plasma to the participants.
1805280|NCT00627419|Drug|IPI-504|Dose as a 30 to 60 minute IV infusion as part of a 21-day treatment cycle until unacceptable toxicity, disease progression, initiation of alternative anticancer therapy, or other reasons for patient withdrawal. IPI-504 will be administered twice weekly on Study Days 1, 4, 8, and 11 of each 21-day cycle.
1805281|NCT00627432|Drug|gemcitabine hydrochloride|
1805282|NCT00627432|Drug|oxaliplatin|
1805283|NCT00627445|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before dinner
1805284|NCT00627445|Drug|metformin|Tablets, 500 - 2000 mg, once, twice or three times daily
1805285|NCT00627445|Drug|biphasic insulin aspart 50|Treat-to-target dose titration scheme (dose adjusted individually), s.c. (under the skin) injection before breakfast and lunch
1805286|NCT00627458|Biological|Infanrix Hexa|Vaccine administered as a booster dose at 16-20 months of age
1805287|NCT00627471|Drug|Insulin Glargine|For the control group (following the physician's standard practice) a minimum of 4 visits to the clinic is required. Insulin titration and concomitant medications will be done at the discretion of the physician. Strips will be distributed among patients in this group, but there will not be a requirement in frequency or type of SMBG.
1805288|NCT00627471|Drug|Insulin Glargine|"In the group following the algorithm, fasting SMBG will be asked 3 times a week until FBG<100 mg/dl is achieved. Afterwards, 1 fasting SMBG will be asked weekly. Pre-prandial SMBG will be performed at the discretion of the physician.
For the group following the algorithm, during the titration period, weekly telephone contacts will be required and a minimum of 4 visits to the clinic."
1805289|NCT00627484|Procedure|Gastric bypass|NOTE: the surgery is not paid for by the study
1805290|NCT00627484|Procedure|Gastric banding|NOTE: the surgery is not paid for by the study
1805291|NCT00627484|Procedure|Sleeve gastrectomy|NOTE: the surgery is not paid for by the study
1805292|NCT00627484|Behavioral|Very low calorie diet|Weight loss with calorie restricted liquid diet. Subject will be asked to stay in our in-patient research unit for 2-3 weeks and consume only those foods supplied by our bionutrition unit. Expected weight loss should be between 7-10% of body weight. Subjects will receive the diet at no cost and will be compensated for their time.
1805293|NCT00627497|Procedure|Single-Level Posterior Decompression|The single level posterior decompression is a posterior surgical procedure.
1805294|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach.
1805295|NCT00627497|Device|DIAM Spinal Stabilization|The DIAM Spinal Stabilization System is a spacer that is implanted between adjoining spinous processes using a posterior surgical approach
1805296|NCT00627497|Device|Fusion|Posterolateral Interbody Fusion
1805297|NCT00627510|Other|Routine psychiatric inpatient treatment|Routine psychiatric inpatient treatment. This is not an interventional study.
1805298|NCT00627523|Drug|Genotropin (PN-180,307) Somatropin|Injectable Genotropin
1805299|NCT00627523|Drug|Control-no treatment|Control-no treatment
1805300|NCT00627536|Drug|Avotermin|A single intradermal injection of avotermin administered at the dose to both margins of a full-thickness incision immediately following closure.
1805301|NCT00627536|Drug|Placebo|Matched to avotermin dosage strength
1805302|NCT00627549|Procedure|Avaulta (surgical procedure using a mesh implant)|The use of Avaulta
1805303|NCT00627549|Procedure|Conventional surgery (anterior repair)|Anterior repair surgery
1805304|NCT00627562|Device|robot assisted endoscopic head and neck surgery using the DaVinci Robotic Surgical System|Planned endoscopic surgery of the head and neck performed with the DaVinci Robotic Surgical System
1805305|NCT00627575|Drug|lamotrigine|Lamotrigine tablets will be available in 25, 50, 100 and 200 mg dose strength.
1805306|NCT00627575|Drug|atorvastatin|Atorvastatin will available as 40 mg tablets.
1805307|NCT00627575|Drug|phenytoin|Phenytoin will available as 100 mg capsules.
1805308|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
1805309|NCT00627588|Biological|ProSavin|ProSavin is a gene therapy designed to delivery three key enzymes involved in the synthesis of dopamine
1805310|NCT00627614|Other|breast imaging study|"1. A set of vibro-acoustography (VA) scans will be taken of the breast by an experimental vibro-acoustography device that uses ultrasound for imaging.
2- An ultrasound scan (sonography) of the breast using a clinical ultrasound machine may be taken during the procedure."
1805311|NCT00627627|Drug|IPI-504|dose of 400 mg/m2 as a 30-60 minute IV infusion as part of a 21-day treatment cycle
1805314|NCT00627653|Drug|fenofibrate|148mg daily for 30 days
1805315|NCT00627666|Biological|anti-thymocyte globulin|
1805316|NCT00627666|Drug|busulfan|
1805317|NCT00627666|Drug|fludarabine phosphate|
1805318|NCT00627666|Drug|leucovorin calcium|
1805319|NCT00627666|Drug|methotrexate|
1805320|NCT00627666|Procedure|allogeneic bone marrow transplantation|
1805321|NCT00627666|Procedure|allogeneic hematopoietic stem cell transplantation|
1805322|NCT00627666|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1805323|NCT00627679|Drug|Budesonide Inhalation Suspension|Treatment A = a single dose of Pulmicort Respules® (budesonide inhalation suspension) delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
1805324|NCT00627679|Drug|MAP0010 low dose|Treatment B = a single dose of MAP0010 (unit dose budesonide) low dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
1805325|NCT00627679|Drug|MAP0010 intermediate dose|Treatment C = a single dose of MAP0010 (unit dose budesonide) intermediate dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
1805326|NCT00627679|Drug|MAP0010 high dose|Treatment D = a single dose of MAP0010 (unit dose budesonide) high dose delivered by nebulization at Visit 2, 3, 4, or 5 as per protocol.
1805327|NCT00627692|Drug|Prucalopride|0.5 mg o.d.
1805328|NCT00627692|Other|Placebo|o.d.
1805329|NCT00627692|Drug|Prucalopride|1 mg o.d.
1805330|NCT00627692|Drug|Prucalopride|2 mg o.d.
1805331|NCT00627692|Drug|Prucalopride|4 mg o.d.
1805332|NCT00627705|Drug|N-Acetyl Cysteine|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks
Entire intervention lasts for 12 weeks (drug administration is continuous)."
1805333|NCT00627705|Other|Placebo - sugar pill|"Phase 1: Oral, 900 mg daily for 4 weeks Phase 2: Oral, 900 mg twice daily 4 weeks Phase 3: Oral, 900 mg three times daily for 4 weeks
Entire intervention lasts for 12 weeks (drug administration is continuous)."
1805334|NCT00627718|Device|HRT screening for macula edema|HRT screening for macula edema at time of initial diagnosis of macular degeneration
1805335|NCT00627731|Drug|methylprednisolone sodium succinate (mPSL)|mPSL IV 240mg per day for 5 days and oral PSL 40mg per day for 5 days
1805336|NCT00627731|Drug|prednisolone (PSL)|PSL 40 mg per day for 10 days
1805337|NCT00627744|Drug|Sitagliptin|BE 1 receives Placebo tablets od during 12 weeks BE 2 receives Sitagliptin tablets 100 mg od during 12 weeks
1805338|NCT00627770|Device|bioimpedance spectroscopy ImpediMed SFB7 Brisbane Australia|edema evaluation using bioimpedance
1805339|NCT00627783|Other|a bicycle exercise test|
1805340|NCT00627796|Drug|Lanreotide-Autogel 120 mg|ATG120 mg is given as deep subcutaneous injection into the buttock. Each patient receives one deep subcutaneous injection of ATG120 mg at Visit 1 (V1) and subsequent injection every 4 weeks for 3 injections. Based on GH levels, the dosing interval has been determined as follows: if GH levels were > 2.5 mcg/l, ATG 120 mg is given every 4 weeks while if they were < 2.5 mcg/l ATG 120 mg is administered every 6 weeks for another 3 injections. Afterwards, the dose is maintained as above except in patients with GH levels <1 mcg/l receiving ATG 120 mg every 8 weeks. The estimated duration of treatment is 48-52 weeks according with dose titration.
1805341|NCT00627809|Drug|Streptokinase|intracoronary infusion, 250.000 Units
1805342|NCT00627809|Procedure|primary percutaneous coronary intervention|balloon catheter, stent
1805343|NCT00627835|Drug|sorafenib|Cohort 1 - sorafenib 200 mg PO bid concurrent with radiation
1805344|NCT00627835|Drug|sorafenib|o Cohort 2 - sorafenib 400 mg PO bid concurrent with radiation
1805345|NCT00627835|Drug|sorafenib and cisplatin|Cohort 3 - sorafenib 200 mg PO bid / cisplatin 75 mg/m2 weeks 1, 4 and 7
1805346|NCT00627835|Drug|sorafenib and cisplatin|o Cohort 4 - sorafenib 400 mg PO bid/ cisplatin 75 mg/m2 weeks 1, 4 and 7
1805347|NCT00627835|Drug|sorafenib and cisplatin|Cohort 5 - sorafenib 400 mg PO bid/ cisplatin 100 mg/m2 weeks 1, 4 and 7
1805348|NCT00627848|Drug|rivastigmine|Acute dose 3 mg or placebo. Thereafter 1.5 mg x 2 ad 30 days and thereafter increasing the dose upto 4.5 mg x 2 according to instructions.
1805349|NCT00627861|Drug|Aliskiren|150mg orally daily for 6 weeks. Dose may increase to 300mg orally daily dependent upon blood pressure parameters set by the protocol.
1805350|NCT00627861|Drug|Extended-release metoprolol|50mg orally daily for 1 week, dose will increase to 100mg orally daily or decrease to 25mg daily for a second week dependent upon blood pressure parameters set by the protocol. Subjects will take metoprolol for a total of 2 weeks, then be tapered off of it over 5-7 days.
1805351|NCT00627874|Device|+3D Lenses|wear +3D glasses for 30 minutes per day and engage in activities which require vision at more than 1m
1805352|NCT00627887|Procedure|Electroconvulsive therapy|unilateral briefpulse ECT weekly for the first 6 weeks thereafter every 2 weeks for a total of one year
1805353|NCT00627887|Drug|venlafaxine|extended release target dose of 300mg/day duration of one year
1805354|NCT00627887|Drug|Lithium|serum concentration 0,5-0,8 mmol/L, one year duration
1805355|NCT00627900|Device|bare metal stent|implantation of a bare metal stent
1805356|NCT00627900|Device|Cypher-Stent (Implantation of a sirolimus-eluting stent)|Implantation of a sirolimus-eluting stent
1805357|NCT00627913|Procedure|Healon 5 injection|Healon 5 (2.3% Sodium hyaluronate) ophthalmic viscoelastic device will be injected into the anterior chamber as needed for pupillary dilation and adequate cataract extraction with intraocular lens placement.
1805358|NCT00627913|Procedure|Retrobulbar anesthetic injection|3-4cc of anesthetic (1% lidocaine/0.75% bupivicaine) will be injected with a 25 gauge needle into the extraocular muscle cone prior to patient and microscope positioning. Cataract extraction with intraocular lens placement will then proceed in standard fashion.
1805359|NCT00627926|Biological|Pegylated Interferon Alfa 2a|subcutaneous injection, 180 micrograms once per week
1805360|NCT00627926|Drug|Telaprevir|375 mg tablets administered orally every 8 hours at a dose of 750 mg
1805361|NCT00627926|Drug|Ribavirin|200 mg tablets administered orally twice daily at a dose of 1000 mg/day for subjects weighing <75 kg and 1200 mg/day for subjects weighing ≥75 kg
1805362|NCT00627926|Other|Placebo|Telaprevir matching placebo
1805363|NCT00627952|Drug|amlodipine 10 mg|amlodipine 10 mg once daily
1805364|NCT00627952|Drug|manidipine 20 mg|manidipine 20 mg once daily
1805365|NCT00627952|Drug|amlodipine 5 mg + delapril 30 mg|amlodipine 5 mg + delapril 30 mg once daily
1805366|NCT00627952|Drug|manidipine 10 mg + delapril 30 mg|manidipine 10 mg + delapril 30 mg once daily
1805367|NCT00627965|Drug|Sildenafil citrate|50mg tds
1805368|NCT00627965|Drug|Placebo|Placebo tds
1805369|NCT00627978|Drug|ixabepilone|ixabepilone 40 mg/m2 Q3w over 3 hours
1805370|NCT00627991|Drug|Valsartan|
1805371|NCT00628004|Device|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
1805372|NCT00628004|Device|Local best practice|"N/A - since intervention is local best practice"
1805373|NCT00628017|Dietary Supplement|omega-3 polyunsaturated fatty acids ( EPA+DHA)|Group 1 received omega-3 PUFAs as 3 capsules twice daily (total daily omega-3 fatty acid dosage of 1080 mg of EPA and 720 mg of DHA). Group 2 received three identical placebo capsules twice daily which contained olive oil esters. Identical gelatin capsules were used. Both treatment and placebo capsules were vacuum deodorized and supplemented with tertiary-butyl hydroquinone, 0.2 mg/g, and tocopherols, 2 mg/g, as antioxidants. The source of the omega-3 fatty acids was menhaden fish body oil concentrate.
1805374|NCT00628030|Behavioral|NOURISH|Participants in the NOURISH intervention will have 6 weekly face-to-face parent group sessions regarding healthy eating and physical activity.
1805375|NCT00628030|Other|Wellness Group|Participants in the Wellness Group will have one face-to-face group meeting and information regarding healthy eating and physical activity will be provided on a regular basis via mail.
1805376|NCT00628043|Drug|epoetin beta|Subcutaneous administration of epoetin beta 36,000 IU once-weekly for 12 weeks
1805377|NCT00628043|Drug|placebo|Subcutaneous administration of placebo once-weekly for 12 weeks
1805378|NCT00628056|Drug|Perhexiline|Intervention with Perhexiline/Placebo at 100mg twice a day for 2 weeks
1805379|NCT00628095|Drug|CE-224,535|500 mg po BID
1805380|NCT00628095|Drug|Placebo|no active ingredient
1805381|NCT00628108|Drug|Levocetirizine 1.25 mg|Levocetirizine dihydrochloride 1.25 mg (5 drops containing 5 mg/mL) dosed once a day for 2 weeks
1805382|NCT00628108|Other|Placebo|Placebo oral liquid once a day for two weeks
1805383|NCT00628121|Drug|Cetrorelix|1, 2 or 3mg, subcutaneouly dosed with single dose
1805384|NCT00628134|Drug|calfactant|single inhaled dose by nebulizer
1805385|NCT00628134|Drug|isotonic saline|single inhaled dose by nebulizer
1805386|NCT00628147|Device|Narrow band imaging colonoscope|Adult colonoscopes with narrow band imaging capabilities (XCF-H160AY2L and XCF-Q160W6L, Olympus Medical Systems Corporation, Hachioji, Japan). There is an automatic switch on the handle of the endoscope that allows the physician to instantly switch between narrow band imaging and standard full spectrum white light modes.
1805387|NCT00628160|Drug|Terlipressin|Terlipressin 2-12 mg/24h intravenously in continuous infusion. Duration: until 24h after shock resolution.
1805388|NCT00628160|Drug|alpha adrenergic drugs|Dopamine (1-20 µg/Kg/min) and/or norepinephrine (0.05-4 µg/Kg/min) until shock resolution
1805389|NCT00628173|Procedure|AGV implantation|
1805390|NCT00628186|Device|external drainage tube [polyethylene pancreatic drainage tube]|External drainage tube was intubated with a 5F polyethylene pancreatic drainage tube with a small knob (Sumitomo Bakelite Co., Japan)(MD41515) across pancreaticojejunostomy in pancreaticoduodenectomy, and exteriorized through the jejunal limb.
1805391|NCT00628186|Device|internal drainage tube [polyethylene pancreatic drainage tube]|Internal drainage tube was intubated 5cm length of stent tube cut a 5F polyethylene pancreatic drainage tube with a small knob across pancreaticojejunostomy in pancreaticoduodenectomy, and pancreatic juice was led to reconstructed jejunum.
1805392|NCT00628199|Procedure|Improving the scientific process of human cell reprogramming|
1805393|NCT00628212|Drug|Teneligliptin 10mg|
1805394|NCT00628212|Drug|Teneligliptin 20 mg|
1805395|NCT00628212|Drug|Teneligliptin 40 mg|
1805396|NCT00628212|Drug|Placebo|
1805397|NCT00628225|Behavioral|Counseling and Nicotine replacement (CN)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. General practitioners were encouraged to advise nicotine replacement.
Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement."
1805398|NCT00628225|Behavioral|Counseling, Nicotine replacement and Bupropion (CNB)|"Professionals in general practice received a central training (4 hours) about smoking, smoking cessation and COPD. They received materials (leaflet, video, smoking cessation protocol and informationfolder). Moreover, professionals received a maximum of 4 practice visits from an outreach visitor. The general practitioner was encouraged to advice the patients to use both nicotine replacements and Bupropion-SR.
Smoking COPD patients received smoking cessation counseling and were advised to use nicotine replacement and Bupropion-SR."
1805399|NCT00628238|Drug|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
1805400|NCT00628238|Drug|Lenalidomide and Rituximab|Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
1805401|NCT00628251|Drug|AZD2281|400mg Oral twice daily
1805402|NCT00628251|Drug|Liposomal Doxorubicin|50mg/m2 Monthly Intravenous
1805403|NCT00628251|Drug|AZD2281|200mg oral twice daily
1805404|NCT00628264|Drug|AP214|Three AP214 bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
1805405|NCT00628264|Drug|Placebo|Three placebo bolus infusions administered over 10 minutes (prior to skin incision, at time of clamp-release and 6 hours after clamp-release).
1805406|NCT00628277|Behavioral|high caloric expenditure exercise|high caloric expenditure exercise plus dietary counseling
1805407|NCT00628277|Behavioral|low caloric expenditure exercise plus dietary counseling|low caloric expenditure exercise plus dietary counseling
1805408|NCT00628290|Drug|Cannabidiol|Capsules, 3 times daily, 200 mg, 4 weeks
1805409|NCT00628290|Drug|Amisulpride|Capsules, 3 times daily, 200 mg, 4 weeks
1805410|NCT00628303|Biological|Motavizumab|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
1805411|NCT00628303|Other|Placebo|15 mg/kg administered by IM injection every 30 days during the RSV season for a total of 5-6 injections
1805412|NCT00628316|Dietary Supplement|caffeine|caffeine daily intake will be reduced form 150 ml per day
1805413|NCT00628342|Drug|Esomeprazole|20mg Oral tablet once daily
1805414|NCT00628342|Drug|Esomeprazole|40mg Oral tablet once daily
1805415|NCT00628342|Drug|Placebo|Oral once daily
1805416|NCT00628355|Drug|lidocaine|Women randomized for this treatment was submitted to 2mL of lidocaine 0,5% without vasoconstrictor, directly and perpendicularly on trigger point. Patients received lidocaine injections once a week for 4 weeks
1805458|NCT00628719|Drug|amphotericin B deoxycholate|amphotericin B as a 1x test dose and then at a dose of 1 mg/kg/every other day for a total of 15 doses over 30 days.
1805459|NCT00628732|Drug|Cyclophosphamide and Topotecan|Two courses of cyclophosphamide at 50 mg/m2/dose and topotecan 0.8 mg/m2/dose by mouth every morning for 14 days each.
1805417|NCT00628355|Procedure|Ischemic compression|Women randomized for treatment with ischemic compression will be first subjected to transcutaneal electrostimulation(TENS) for 30 minutes on trigger point to inhibit the painful stimulation. For this will be used 100 Hertz of frequency and pulse of 250ms. The intensity will be varying according the painful threshold of each patient. After, the ischemic compression will be applied. For this we will use an algometer to get maximum of homogeneity on therapy. The pressure intensity will be placed by the average between the values gotten during three previously measurements of threshold pain in each patient. The therapy will be applied in trigger point three times (60 seconds each) with 30 seconds of rest between the applications.
1805418|NCT00628368|Genetic|gene expression analysis|
1805419|NCT00628368|Genetic|mutation analysis|
1805420|NCT00628368|Genetic|polymorphism analysis|
1805421|NCT00628368|Other|laboratory biomarker analysis|
1805422|NCT00628368|Procedure|biopsy|
1805423|NCT00628368|Procedure|endoscopic biopsy|
1805424|NCT00628381|Dietary Supplement|L-citrulline supplementation|L-citrulline, 1.8micromol/kg/min, during 8 hours continuously supplemented
1805425|NCT00628381|Dietary Supplement|L-alanine|L-alanine enteral infusion, isocaloric dosage (3.6 micromol/kg/min), during 8 hours, continuously supplemented
1805426|NCT00628394|Drug|Atomoxetine|40mg 2po qam
1805427|NCT00628394|Drug|Placebo|40mg 2po qam
1805428|NCT00628420|Drug|ACP-104|25mg, 75mg, 125mg, 175mg, 225mg, or 275mg once a day for 2 weeks
1805429|NCT00628420|Drug|ACP-104|Patient will be given either 50mg, 100mg, 150mg, 200mg, 250mg, or 300mg daily for 2 weeks
1805430|NCT00628420|Drug|Placebo|patients will be given a placebo: 25mg, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg, 200mg, 225mg, 250mg, 275mg, or 300mg (to match the doses given) daily for 2 weeks.
1805433|NCT00628459|Dietary Supplement|micronutrient supplementation|Supplements are given daily, 5days/week, for 6 months, involving 15 mg iron (arm 1), 15 mg iron and 10 mg zinc (arm 2), or multiple micronutrient (arm 3): 15 mg iron, 10 mg zinc, 375 µg vitamin A, 5 µg vitamin D, 6 mg vitamin E, 0.5 mg vitamin B1, 0.5 mg vitamin B2, 6 mg niacin, 150 µg folic acid, 0.5 mg vitamin B6, 0.9 mg vitamin B12, 35 mg vitamin C, 10 µg vitamin K, 50 µg iodine, 0.6 mg copper.
1805434|NCT00628472|Drug|botulinum type a|12 Units total were injected into 6 sites in the glabellar complex to determine if injecting through the follicle versus a traditional approach would decrease patient discomfort
1805435|NCT00628485|Device|BION|"The second group will have a High Stimulation paradigm at a frequency that produces strong, fused contractions (20-30pps) for a total of 1h/d, also in two spaced sessions. Stimulation intensity will be adjusted to produce the strongest contractions that are tolerated."
1805436|NCT00628485|Device|BION|"The first group will have a stimulation paradigm employing low-frequency (1-5 pps), supramaximal twitch stimulation. The period of the stimulation will probably be short for the first sessions as the muscles gain strength and fatigue resistance, but will eventually be 60 minutes per day in two spaced sessions of about 30 minutes each."
1805437|NCT00628485|Device|BION|A third group of experimental subjects will have a standardized program of voluntary swallowing exercises. Their BIONs will not be activated until they have worsening of dysphagia, and thus are considered to have failed conventional therapy.
1805438|NCT00628498|Drug|Defibrotide|"Defibrotide is a single-stranded polydeoxyribonucleotide derived from porcine intestinal mucosa by controlled depolymerisation. Defibrotide has a complex mechanism of action with antithrombotic, anti-ischemic, anti-inflammatory, anti-adhesive and thrombolytic properties but no significant systemic anti-coagulant effects.
Defibrotide is dose intravenously as a 2-hour infusion every 6 hours at a dose of 25 mg/kg/day. Recommended duration of therapy is 21 days."
1805439|NCT00628498|Drug|Defibrotide|
1805440|NCT00628511|Device|ARES (Apnea Risk Evaluation System)|application of portable monitoring device with PSG
1805441|NCT00628537|Device|BION stimulation|"BION™ Experimental Group
The goal for the BION™ patients is to achieve 30 minutes of stimulation twice daily, using a cycled stimulation at frequencies adequate to produce tetanic contraction, (typically 25-35 pps) that raises the joint through full range of motion against gravity (a range graded as 3/5) based on the available range of motion.
Surface Stimulation Group
Patients will be instructed to stimulate twice daily for 30 minutes through surface electrodes placed according to instructions that the subject has been given. Every effort will be made to ensure that the parameters needed in this group are chosen to produce a similar type of contraction to that obtained with BION™ stimulation.
Control Group with conservative therapy (Range of motion exercises)
The research participant is instructed in self-administered, standard range of motion stretching exercises."
1805442|NCT00628550|Drug|Vasopressin|One dose of vasopressin (0.8 units/kg) intravenously rescue as the second vasopressor medication.
1805443|NCT00628550|Drug|Epinephrine|One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
1805444|NCT00628576|Drug|unfractionated heparin|UFH: Continuous i.v. infusion 100 IU/kg/4hrs initially and then adjusted to maintain APTT value 1.5 - 2.5 the pre-treatment value
1805445|NCT00628576|Drug|Tinzaparin (Leo)|FH (Tinzaparin): 175 iu/kg s.c. in the abdomen once daily
1805446|NCT00628589|Drug|Inhaled loxapine 5 mg|Inhaled loxapine 5 mg
1805447|NCT00628589|Drug|Inhaled loxapine 10 mg|Inhaled loxapine 10 mg
1805448|NCT00628589|Drug|Inhaled placebo|Inhaled placebo
1805449|NCT00628602|Device|BION|"30 patients operated will be randomized into 2 equal groups, a BION Therapy Group (Rx group) and a Control Group (Control group)."
1805450|NCT00628628|Drug|As Needed Rasburicase|.15 mg/kg IV Over 30 Minutes On Day 1. Day 2-5, once daily as needed.
1805451|NCT00628628|Drug|Fixed Dose Rasburicase|.15 mg/kg IV Over 30 Minutes Daily
1805452|NCT00628667|Drug|Esomeprazole|40mg orally twice daily
1805453|NCT00628667|Drug|Placebo|
1805454|NCT00628680|Device|AAT-023 solution (Zuragen)|Amount equal to the catheter lumen plus 0.3mL. Three times per week (after each Hemodialysis) for 26 weeks
1805455|NCT00628680|Drug|Heparin|Hepaarin 5000 units diluted with normal saline to the exact catheter lumen volume.
1805456|NCT00628706|Drug|Delta9-tetrahydrocannabinol (THC)|inhalation of 6 mg liquid THC, vaporized by means of a Volcano vaporizer
1805457|NCT00628719|Drug|Liposomal Amphotericin B|a single dose of 10 mg/kg of liposomal amphotericin B
1805461|NCT00628758|Drug|Symbicort TBH - Turbuhaler|Symbicort Single Inhaler Therapy ( Turbuhaler 160/4.5 microgram, 1 inhalation bid + as needed)
1805462|NCT00628758|Drug|beta-II-agonist, inhale steroid|Salbulin inh. 200-400 dosage 100 microgram (mcg)/dosage Salbutamol Sustained Release(SR)capsule 4 mg/8 mg Salbutol tablet (tb) 2 mg Salbutol forte syrup 2 mg/5 ml Ventolin tb, syrup, intravenous(IV),5mgx10 ampule(amp) Ventolin inhaler (inh) 200 dosage, 100 mcg/dosage Ventolin nebul 2.5 mg Volmax tb 4 mg/8 mg Vent-o-sal inh 100 mcg/200 dosage Combivent inh 100 mcg/dosage Combivent neb 2.5 mg/dosage Bricanyl tb 2.5 mg Bricanyl durules ret tb 5 mg Bricanyl syrup 30mg Bricanyl inhaler 0.25 mg/dosage, 400 dosage Bricanyl turbuhaler 0.5 mg/dosage, 200dosage
1805463|NCT00628771|Behavioral|CenteringPregnancy Plus (CP+)|The CenteringPregnancy model of group prenatal care involves skill-building in the areas of efficacy, risk assessment, negotiation, and prevention. CP+ integrates HIV prevention into prenatal care, builds on motivations for healthy pregnancy, and creates a sustainable model via reimbursement mechanisms for prenatal care. There will be ten 2-hour prenatal group sessions.
1805464|NCT00628771|Behavioral|Usual care|Usual care includes standard individual prenatal care and no prenatal group sessions.
1805465|NCT00628784|Procedure|Endoscopic spray cryotherapy|A special orogastric venting tube is passed alongside the endoscope and the cryocatheter then used to perform cryotherapy. Liquid nitrogen is sprayed through the catheter to achieve a uniform white frost in a hemicircumferential sector for 10 seconds. A thaw time of 45-60seconds is observed. This freeze-thaw cycle is repeated x 3 for a total of 40sec cryotherapy per segment. This therapy is repeated every 6 weeks until visible re-epithelialization is seen or a maximum of 6 sessions. Once a squamous lining is seen, biopsies are taken throughout the original area to assess for buried Barretts. If none is seen, followup with 4 quadrant q2cm biopsies are taken at 3,6,9,12, 18, 24, 36, 48 months.
1805466|NCT00628784|Procedure|Endoscopic spray cryotherapy|After passing a special orogastric venting tube, the cryocatheter is used to spray liquid nitrogen onto the tumor to achieve a white frost (frozen state) for 20 seconds. A 45-60 sec thaw is allowed and then retreatment x 2 for a total of 60 seconds therapy per session. Repeat treatments are permitted every 2 weeks for a maximum of 8 treatments.
1805467|NCT00628797|Radiation|UVA1|intraindividual half body irradiation
1805468|NCT00628797|Other|UVA1|60 J/cm2 at least 36 tx
1805469|NCT00628810|Biological|bevacizumab|
1805470|NCT00628810|Drug|fluorouracil|
1805471|NCT00628810|Drug|irinotecan hydrochloride|
1805472|NCT00628810|Drug|leucovorin calcium|
1805473|NCT00628823|Dietary Supplement|Gluten-free diet|Gluten containing foods removed from diet
1805474|NCT00628836|Device|BION stimulation|"The study will have two phases, each with a six week duration. During phase 1, the BION group will be implanted with BIONs in the middle deltoid and supraspinatus muscles. The muscles will be stimulated electrically by way of the BION and an external controller for one to two hours per day at 5pps in an on-off duty cycle train. The SE group will begin surface stimulation similar to that of BE group.
Subjects in either group whose initial therapy in phase 1 successfully reduces the amount of shoulder subluxation to 5mm or less will go off stimulation for six weeks, and be reassessed whether subluxation is redeveloping.
If a subject in either group does not respond sufficiently to phase 1 therapy, the participant will move to phase 2 where the shoulder will be stimulated at up to 25 pps either with surface stimulation (SE group) or BION stimulation (BE group) for another six weeks. At the end of phase 2, participants will go off stimulation for six weeks and then be reevaluated."
1805475|NCT00628862|Drug|Formoterol Turbuhaler® 4.5mg|4.5 mg inhaled twice daily
1805476|NCT00628862|Drug|Formoterol Turbuhaler® 9 mg|9 mg inhaled twice daily
1805477|NCT00628862|Drug|Turbuhaler® placebo|placebo inhaled twice daily
1805478|NCT00628888|Behavioral|Unified Protocol for Adolescents (UP-A)|All participants will be offered the UP-A intervention, inclusive of 8 and 21 weekly sessions of an emotion-focused treatment with cognitive-behavioral elements, either immediately following randomization or after an 8-week delayed treatment waitlist. The UP-A sessions are delivered in a flexible manner. Several of the UP-A's treatment elements are fixed and received by all participants (psychoeducation about emotions and emotional behavior, awareness and mindfulness skills, antecedent cognitive reappraisal/problem-solving skills, emotion exposure strategies, and relapse prevention skills), although applied for varying numbers of sessions depending on clinical need. Other strategies (motivational enhancement, parenting strategies and crisis management strategies) are applied on an as-needed basis based on client needs.
1805479|NCT00628901|Procedure|Uterine Fibroid Embolization (UFE)|Uterine Fibroid Embolization is used in treating Uterine Fibroids. The procedure involves injecting embolization particles into the fibroid via the uterine artery which causes the fibroid to shrink or subside. Patients are usually released from the hospital the day after the procedure.
1805480|NCT00628901|Device|Contour SE™ Microspheres|Polyvinyl alcohol Microsphere embolization devices intended to provide targeted vascular occlusion or reduction of blood flow upon selective placement and are currently marketed for use in hypervascular tumors, including leiomyoma uteri and arteriovenous malformations
1805481|NCT00628901|Device|Embosphere® Microspheres|Biocompatible, hydrophilic, nonresorbable, microspheres used in the embolization of arteriovenous malformations, hypervascular tumors, and symptomatic uterine fibroids.
1957667|NCT02270905|Device|dCELL® Meniscus|decellularised porcine xenograft
1805485|NCT00628940|Radiation|PET images with 18F-fluoromethylcholine|sequential PET images with 18F-fluoromethylcholine
1805486|NCT00628953|Drug|Esomeprazole|40mg twice a day
1805487|NCT00628953|Drug|Placebo|40mg twice a day
1805488|NCT00628979|Behavioral|CBT|cognitive- behavioral treatment for panic disorder.
1805489|NCT00628992|Other|No specific intervention, standard therapy serving as a control group, passive mobilization of the legs|Muscular rehabilitation of the leg
1805490|NCT00628992|Other|Electrical stimulation of the thigh|Muscular rehabilitation of the leg
1805491|NCT00628992|Other|Cycloergometer training|Muscular rehabilitation of the leg
1805492|NCT00628992|Other|Electrical stimulation of the thigh and cycloergometer training|Muscular rehabilitation of the leg
1805493|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + strength training|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of resistance elastic band exercises
1805494|NCT00629005|Behavioral|Constraint-Induced Movement Therapy + range of motion|Participants wears a mitt on non-paretic hand for 90% of waking hours and completes 3 hours of functional task practice (e.g., flipping cards, putting coins in coin slot, putting cans on a shelf) plus 1 hour of unresisted arm movements for
1805495|NCT00629018|Biological|CD34+ autologous stem cell transplantation|Peripheral blood stem cells will be mobilized by daily subcutaneous injections of filgrastim; CD34+ cells will be collected via apheresis and labeled with technetium. Patients will undergo myocardial perfusion scintigraphy for myocardial viability assessment and the collected CD34+ cells will be injected intracoronary in the artery supplying the segments of reduced tracer accumulation
1805496|NCT00629018|Drug|Bone Marrow Stimulation|Patients will undergo filgrastim stimulation and viability assessment using the same protocol as in Arm 1. However, in this group, no intracoronary stem cell delivery will be performed; the patients will receive placebo (saline).
1805497|NCT00629018|Biological|SC therapy|In the SC group, CD34+ cells were mobilized by granulocyte colony-stimulating factor and collected via apheresis. Patients underwent myocardial scintigraphy and cells were injected in the artery supplying segments with the greatest perfusion defect
1805498|NCT00629031|Drug|Paromomycin|11 mg/kg for 14 days
1805499|NCT00629031|Drug|Paromomycin|Paromomycin for 21 days @ 11mg/kg by intramuscular injections
1805500|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S Hydroxylase|Comparison of venous blood level of Cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma and AMD and in healthy subjects.
1805501|NCT00629044|Biological|Assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with Glaucoma, AMD end in healthy subjects
1805502|NCT00629044|Biological|assessing the blood level of cholesterol 24 S hydroxylase|Comparison of venous blood level of cholesterol 24 S hydroxylase and 24 hydroxycholesterol in patients with glaucoma, AMD and in healthy subjects
1805503|NCT00629057|Biological|MVA-BN-PRO|1x10e8 TCID50 q 4 wks x 6
1805504|NCT00629057|Biological|MVA-BN-PRO|2 x 10e8 TCID50 q 4 wks x 6
1805505|NCT00629057|Biological|MVA-BN-PRO|4 x 10e8 TCID50 q 4 wks x 6
1805506|NCT00629070|Other|Traditional strength training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise)at 30 degrees/second; 6 sets of 5 maximum-effort concentric actions
1805507|NCT00629070|Other|Velocity-enhanced training|Performed 3 x week for 8 weeks on an isokinetic dynamometer (knee extension exercise). Subjects will perform 2 sets of 5 concentric exertions at 30°/second. The following 4 sets of 5 repetitions will be performed at a faster speed, starting at 60° /second. The velocity will be increased weekly in 15° /second increments up to a maximum of 120°/second.
1805508|NCT00629083|Device|Bulkamid|Bulking injection with Bulkamid injection device
1805509|NCT00629083|Device|Contigen|Transurethral bulking injection
1805510|NCT00629096|Procedure|Intracoronary infusion of autologous bone marrow cells|Autologous mononuclear bone marrow cells will be administered by intracoronary infusion via a percutaneous catheter
1957668|NCT02268110|Other|Exercise therapy|Supervised exercise therapy with a 12 week progressive abdominal exercise home program for
1957669|NCT02268110|Other|Abdominal binding|Wearing an abdominal binder for 12 weeks
1805513|NCT00629135|Drug|Moxifloxacin/Metronidazole or Piperacillin/Tazobactam|Antibiotic therapy for patients with intra-abdominal abscesses; Intervention consists of antibiotic treatment of the patients with intraabdominal abscess with either the combination of Moxifloxacin and Metronidazole or Piperacillin/Tazobactam.1. Moxifloxacin 400 mg, administered intravenously once daily in combination with Metronidazole 500 mg, administered two times daily intravenously, followed by an oral medication with Moxifloxacin 400 mg once daily and Metronidazole 500 mg twice daily. 2. Piperacillin / Tazobactam 4,5 g administered intravenously three times daily.
1805514|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w Capecitabine 1000mg/m2 D1-D14 q3w
1805515|NCT00629148|Drug|Vinorelbine and Capecitabine|Vinorelbine 25mg/m2 D1, D8 q3w. When disease progression or untolerated toxicity occurs, Capecitabine 1000mg/m2 D1-D14 q3w
1805516|NCT00629161|Drug|Traditional Chinese Medicinal Mixture (composed of Roucongrong and adjuvant)|12 months period of Traditional Chinese Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
1805517|NCT00629161|Drug|placebo|12 months period of placebo plus 1 month period without placebo
1805518|NCT00629174|Behavioral|Exercise|Endurance and resistence training, 90 minutes, 3 times weekly
1805519|NCT00629174|Behavioral|Mental activity|Participation at computer lessons, 3 times weekly, 90 minutes each
1805576|NCT00629564|Drug|Esomeprazole|20mg oral
1805577|NCT00629564|Drug|Esomeprazole|15 minute intravenous infusion
1805578|NCT00629577|Genetic|microarray analysis|
1805579|NCT00629577|Other|flow cytometry|
1805580|NCT00629577|Procedure|biopsy|
1957672|NCT02264327|Behavioral|Motivational Interviewing Simulator (SIM)|The interactive, case-based, multiplayer web-based game allows service providers to deepen their skills in Motivational Interviewing (MI), a widely recognized evidence-based practice that supports people to make positive behavior changes related to health, wellness, mental illness, and addiction.The SIM will have three arenas for play, so that users can practice more advanced MI skills and include: Single Player, Two Player, and Advanced Free play. The SIM is equipped with multiple story-lines and characters to keep learners engaged over time and to provide practice on diverse case scenarios, making the Sim relevant to a wide audience. Lastly the SIM will provide an opportunity for feedback from peers and MI experts.
1805520|NCT00629187|Drug|Temozolomide|Before taking part in this study, subjects will have stem cells collected in a procedure called apheresis. Once on this study, subjects will be admitted to the hospital and receive daily doses of temozolomide by mouth for 5 days. Stem cells will be given back to subjects who will remain in the hospital until blood counts have recovered. Doses of temozolomide will range from 350 mg to 1500 mg/m(squared) daily for 5 days (total dose 1750 to 7500 mg/m(squared).
1805521|NCT00629200|Drug|Sodium Stibogluconate|400 mg/m^2 IV daily on days 1-5.
1805522|NCT00629200|Drug|Interferon Alpha-2b|3x10^6 units subcutaneously three times weekly
1805523|NCT00629213|Drug|acarbose|
1805524|NCT00629213|Drug|placebo|
1805525|NCT00629226|Biological|cetuximab|Given IV
1805526|NCT00629226|Drug|bortezomib|Given IV
1805527|NCT00629226|Drug|cisplatin|Given IV
1805528|NCT00629226|Radiation|intensity-modulated radiation therapy|Once daily, 5 days a week, for up to 8 weeks
1805529|NCT00629239|Drug|AZD4818|Dry Powder, inhalation, b.i.d., 4 weeks
1805530|NCT00629239|Drug|Placebo|
1805531|NCT00629252|Drug|Sertindole|oral 12-20 mg/day
1805532|NCT00629252|Drug|Risperidone|oral 2-6mg / day
1805533|NCT00629265|Device|Neurotech NT2000 Neuromuscular Electrical Stimulation (NMES)|NMES or Sham NMES will be paired with repeated, effortful swallowing behavior, for 60 swallows, 2 times a day, 6 days a week, for 12 weeks.
1805534|NCT00629278|Biological|trastuzumab|
1805535|NCT00629278|Drug|aromatase inhibition therapy|
1805536|NCT00629278|Drug|cyclophosphamide|
1805537|NCT00629278|Drug|docetaxel|
1805538|NCT00629278|Drug|doxorubicin hydrochloride|
1805539|NCT00629278|Drug|epirubicin hydrochloride|
1805540|NCT00629278|Drug|fluorouracil|
1805541|NCT00629278|Drug|paclitaxel|
1805542|NCT00629278|Drug|releasing hormone agonist therapy|
1805543|NCT00629278|Drug|tamoxifen citrate|
1805544|NCT00629278|Procedure|adjuvant therapy|
1805545|NCT00629278|Radiation|radiation therapy|
1805546|NCT00629304|Device|placebo|Patients will have face to face visits at 3 and 6 months and no PDA-FIT system. Patients will record glycemia on paper support.
1805547|NCT00629304|Device|VISITS + PDA-FIT system|patients will have face to face visits at 3 and 6 months + PDA-FIT system
1805548|NCT00629304|Device|PDA-FIT System + telephone follow-up|patients will received PDA-FIT system + a telephone follow up (12 phone calls) and a face to face visit at 6 months
1805549|NCT00629317|Other|Moisturizer|Cetaphil cream(For 3 hours) + Aktilite ( Photodynamic Therapy for 8 minutes)
1805550|NCT00629317|Drug|Methyl Aminolevulinate|Methyl Aminolevulinate cream for 3 hours before Photodynamic therapy ( Aktilite)
1805551|NCT00629330|Behavioral|Academic Detailing|Multi-component academic detailing including an interactive, digitized CD-ROM, focused on the discussion of risks and benefits, screening options or alternatives, values clarification, and mutual decision-making, alongside patient education materials designed for low literacy patients
1805552|NCT00629343|Drug|Azacitidine In Combination With Temozolomide|mg, oral
1805553|NCT00629356|Genetic|dengue fever|
1805554|NCT00629369|Device|Extra 3 mouth guard, Shock doctor mouth guard v3.0|Dental mouthguard, molded for each individual patient when in labor. The device is put in the water then in microwave for one minute to soften the device. The device is then applied to the patient's mouth for over 10 seconds to mold it.
1805555|NCT00629382|Device|Polymyxin B immobilized fiber column|Hemoperfusion with PMX will be performed in ICU. The 1st PMX treatment (day 0) will be carried out for 2 hours and ideally within 24 hours but not later than 48 hours after diagnosis of severe sepsis. The second PMX treatment has to be performed 24 to 48 hours after the end of the first PMX treatment, ideally after 24 hours. Hemoperfusion therapy will be performed in addition to conventional medical therapy in the ICU.
1805556|NCT00629382|Other|Conventional medical therapy in the ICU|Including, but not limited to: antibiotic therapy, nutrition, administration of gamma-globulins, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, corrective measures for metabolic abnormalities, renal replacement therapy when appropriate.
1805557|NCT00629395|Behavioral|Captain's Log Computer Program|12 Computer Program
1805558|NCT00629434|Other|diabetes education via telemedicine|This arm will receive diabetes group education via telemedicine
1805559|NCT00629434|Other|diabetes education in-person|In this arm the group of patients with diabetes will receive diabetes education in-person
1805560|NCT00629447|Drug|Innohep|The patients will receive a single daily subcutaneous injection of Tinzaparin at 4500 IU.
1805561|NCT00629473|Drug|NPI-0052 on Days 1, 8, 15 every 28 days|NPI-0052 dose ranging from 0.1 to 0.9 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 8, and 15 of 4-week cycles
1805562|NCT00629473|Drug|NPI-0052 on Days 1, 4, 8, 11 every 21 days|NPI-0052 dose ranging from 0.075 to 0.6 mg/m2 NPI-0052 IV injection over 1 to 120 minutes on Days 1, 4, 8, and 11 of 3-week cycles
1805563|NCT00629473|Drug|Dexamethasone|20 mg oral or IV day before and day after NPI-0052 dosing.
1805564|NCT00629486|Genetic|Polymorphism of IL-1 beta and TNF-alpha|To analyze the role of polymorphisms of IL-1beta and TNF-alpha gene on risk of hepatitis B-related chronic liver disease and hepatocellular carcinoma
1805565|NCT00629499|Drug|nab paclitaxel|100 mg/m2 of intravenous (IV) nab paclitaxel weekly (i.e., on Days 1, 8, and 15 of each 3 week treatment cycle)
1805566|NCT00629499|Drug|Cyclophosphamide|600 mg/m2 of IV cyclophosphamide
1805567|NCT00629499|Drug|Trastuzumab|8 mg/kg loading dose of IV trastuzumab will be administered on Day 1, followed by doses of 6 mg/kg IV trastuzumab once every 3 weeks.
1805568|NCT00629512|Drug|Esomeprazole|20mg oral daily
1805569|NCT00629512|Drug|Esomeprazole|40mg oral daily
1805570|NCT00629512|Drug|Placebo|
1805571|NCT00629525|Drug|RAD001|RAD001 at a dose of 10 mg PO daily
1805572|NCT00629538|Procedure|Therapeutic thoracentesis|Thoracentesis was performed with drainage of 500 ml of pleural fluid first and every 200 ml thereafter until pleural pressure was lower than -20 cm H2O, chest discomfort developed, or no more pleural fluid could be removed.
1805573|NCT00629551|Drug|saredutant (SR48968)|oral administration,capsules
1805574|NCT00629551|Drug|paroxetine|oral administration, capsules
1805575|NCT00629551|Drug|placebo|oral administration, capsules
1805582|NCT00629590|Drug|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~12 days
1805583|NCT00629603|Genetic|cytokine|polymorphisms of fibrosis-relating cytokine were measured to validate the effectiveness of fibrosis in HCV-related chronic liver disease
1805584|NCT00629603|Genetic|cytokine polymorphisms|Fibrosis-relating cytokine polymorphisms in hepatitis C virus-related chronic liver disease were measured to validate the degree of fibrosis
1805585|NCT00629603|Genetic|cytokine polymorphism|fibrosis-relating cytokine polymorphism
1805586|NCT00629616|Drug|anastrozole|1 mg/day for either 4 months or 6 months depending on the clinical evaluation
1805587|NCT00629616|Drug|fulvestrant|500mg at day 1, day 15 and day 29 500mg every 28 days for either 4 months or 6 months depending on the clinical evaluation
1805588|NCT00629629|Behavioral|Dietary Advice|
1805589|NCT00629642|Drug|Solifenacin Succinate|Oral, 10mg
1805590|NCT00629642|Drug|Solifenacin Succinate|Oral, 5mg
1805591|NCT00629642|Drug|Oxybutynin Hydrochloride|Oral, 15mg
1805592|NCT00629642|Drug|Placebo|Oral
1805593|NCT00629655|Other|motor task, sensory stimulation|"motor task: finger tapping, simple type and complex type
sensory stimulation: electric or tactile stimulation"
1805594|NCT00629668|Genetic|TNF-alpha and HBV genotype|
1805595|NCT00629668|Other|TNF-alpha and HBV genotypes|
1805596|NCT00629681|Drug|Pregabalin|Pregabalin capsules; initial dose of 75 mg twice daily for 4 days. Dose could be increased based on individual patient's response and tolerability to 150 mg twice daily from Day 4 onwards, with a further increase to 300 mg twice daily from Day 14 onwards if needed. Total duration of treatment was 28 days.
1805597|NCT00629694|Procedure|adenoidectomy, myringotomy, tubes insertion|adenoidectomy, myringotomy and tubes insertion (A-T)against adenoidectomy and myringotomy alone (A-M)
1805598|NCT00629694|Procedure|A-M|adenoidectomy and myringotomy alone
1805599|NCT00629707|Other|intravenous fluid treatment|infusion of intravenous fluids (0.9% saline and 0.45% saline)
1805600|NCT00629720|Drug|alfuzosin (SL770499)|
1805601|NCT00629733|Drug|RO-14|
1805602|NCT00629746|Device|Medtronic Xomed Nerve Integrity Monitor (NIM)|"patients receive surgery will be intubated with Medtronic Xomed NIM EMG endotracheal tube and the device will be connected to the monitoring system
The channel leads from the NIM EMG reinforced endotracheal tube were connected to a NIM-response monitor
A Prass monopolar probe was used in direct contact with the vagus nerve and RLN for laryngeal nerve stimulation.
The stimuli were generated from the NIM-Response monitor for vagal and RLN stimulation.
The NIM-response monitor was set to run with a 50 millisecond time window and an amplitude scale at 0.2 mV/division. Event capture was activated with a threshold at 100 μV. Peak to peak amplitudes of evoked EMG activities were directly read on the monitor screen."
1805603|NCT00629759|Genetic|JX-594: Recombinant vaccinia virus (TK-deletion plus GM-CSF)|The total dose is divided between 1-3 tumors located within the liver. Patients are treated with JX-594 once every 3 weeks until progression at the site(s) of injection or until the patient has received a maximum of 4 treatments.
1805604|NCT00629772|Drug|Placebo|Patients receive placebo on weeks 0, 2 and 6. They receive infliximab 5mg/kg at weeks 14, 16 and 20.
1805605|NCT00629772|Drug|Infliximab|Patients in infliximab group receive infliximab 5mg/kg at weeks 0, 2, 6, 14 and 22. Patients in placebo then infliximab group receive placebo at weeks 0, 2, 6, then receive infliximab at weeks 14, 16 and 20.
1805606|NCT00629798|Drug|Busulfan, Melphalan, Fludarabine, Anti-Thymocyte Globulin, Palifermin, Stem cell transplant|Patients will receive Palifermin 60 mcg/kg/day IV on three consecutive days with the last dose administered no less than 24 and no more than 48 hr prior to start of cytoreduction. The preparative regimen to be used for transplants will consist: of busulfan administered in 12 doses over three days of 0.8 mg/kg IV for patients > or = to 4 years of age or 1.0 mg/kg IV for patients < 4 years of age; melphalan 70 mg/m2 IV x 2 days; and, fludarabine 25 mg/m2 IV x 5 days
1805607|NCT00629811|Drug|Avotermin (Juvista)|"Intradermal avotermin administered to four wound sites per subject, one wound site per anatomically matched pair, according to the subject's assigned dose group:
Group 1: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 1)
Group 2: avotermin concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site (pre-wounding, Day 0) and 100μL per linear cm of wound margin (post-wounding, Day 0)
Each subject received four doses of active drug at concentrations of 5, 50, 200 and 500ng per 100μL per linear cm of wound site, one dose to one wound site per anatomically matched pair of wounds."
1805608|NCT00629811|Drug|Placebo|"Reference therapy was Placebo (vehicle). On Day 0, the four sites randomised to receive Placebo were administered with a 100μL intradermal injection of Placebo.
Subjects in Group 2 were dosed again on Day 0 at 10 to 30 minutes after wound closure.
Subjects in Group 1 were dosed again on Day 1 at 24 (+/-4) hours after initial administration of drug."
1805609|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
1805610|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day, 24weeks of treatment for genotype non-1 infected patients and 48 weeks of treatment for genotype 1 infected patients, follow up for 24 weeks
1805611|NCT00629824|Drug|pegylated interferon alpha and plus ribavirin|pegylated interferon alpha 180 ug/week and ribavirin 1000-1200 mg/day for 24 weeks
1805612|NCT00629837|Biological|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|Low dose of BAY 79-4980 [13mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU).
1805613|NCT00629837|Biological|Recomb. Factor VIII (Kogenate FS Liposome, BAY79-4980)|High dose of BAY 79-4980 [22mg of liposomes/kg] then cross over to rFVIII-FS (35 IU/kg reconstituted in 2.5 mL WFI / 1000 IU)
1805614|NCT00629837|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to low dose of BAY 79-4980 [13mg of liposomes/kg]
1805615|NCT00629837|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|rFVIII-FS (35 IU/kg reconstituted in 2.5mL WFI /1000 IU) then cross over to high dose of BAY 79-4980 [22mg of liposomes/kg]
1805649|NCT00621530|Drug|placebo|placebo will be added to the patient's routine spinal anesthetic for surgery
1805616|NCT00621374|Behavioral|Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP)|There is also the possibility that the two treatments together may be even more helpful than either one alone. Because some of the patients in this study will get both CBT and self-hypnosis, we will be able to determine if each one facilitates the efficacy of the other. If the patients treated in this study report benefits, as we expect they will, then this will encourage us to design and complete a larger study to better understand how patients with MS would benefit from these treatments.
1805617|NCT00621374|Behavioral|Cognitive Behavioral Therapy (CBT)|"One treatment module is we will study is called cognitive restructuring or cognitive-behavior therapy (CBT). In this treatment, people learn to identify negative thoughts that make them feel bad or anxious. Such negative thoughts lead to feelings of frustration and anxiety, and can even increase the experience of pain, because they cause a person to focus more on pain. With CBT, people learn to identify and stop these thoughts, and then replace them with more reassuring ones. When they do this, they feel more relaxed and focus less on their pain. As a result, they often say that they feel much better and are less aware of pain."
1805618|NCT00621374|Behavioral|Self-Hypnosis Training (HYP)|Self-hypnosis (HYP) is another strategy that people can learn to manage pain. With this treatment, people learn to enter a state of focused attention, and then change how they experience pain. Although we do not yet know how hypnosis works, research has repeatedly shown that the effects are real; when people report decreases in pain with hypnosis, scans and images of the brain's activity show decreases in the parts of the brain that process pain information. With hypnosis, people are not just pretending to feel less pain, they actually do feel less pain.
1805619|NCT00621374|Behavioral|Education Control (CONT)|The CONT condition for this study will include lectures that are interactive and are compelling and informative enough to be both (1) credible as an attentional control condition and (2) perceived as helpful to subjects. The CONT condition will not, however, include instructions in making specific cognitive or behavioral changes related to pain management. Thus, it could control for non-specific factors related to behavioral treatment, but will not impact the primary outcome measure (pain).
1805620|NCT00621387|Drug|ofloxacin and roxithromycin|150 mg roxithromycin tablet twice daily and 200mg ofloxacin tablet twice daily for 3 months
1805621|NCT00621387|Drug|placebo|placebo tablets identical to ofloxacin and roxithromycin twice daily for 3 months
1805622|NCT00621400|Drug|Lenalidomide|5 mg/day, orally for 21 days with 7 days rest (28 day cycle) for the first cohort; or 10mg/day, orally for 21 days with 7 days rest (28 day cycle) for the second cohort, 15mg/day, orally for 21 days with 7 days rest (28 day cycle) for the third cohort or 20mg/day, orally for 21 days with 7 days rest (28 day cycle) for the last and fourth cohort
1805623|NCT00621400|Drug|Melphalan|0,18mg/Kg/day from day 1- 4
1805624|NCT00621400|Drug|Dexamethasone|40mg/day from day 1- 4.
1805625|NCT00621439|Drug|Pegylated Interfon Alpha 2B|Patients will receive PEG-IFN 6 mcg/kg subcutaneously 4 days prior to surgery. Patients will be premedicated with acetaminophen 700 mb orally prior to the injection. Only one dose of drug will be given. Enucleation will follow in 4 days.
1805626|NCT00621439|Drug|Placebo|Patients will receive placebo.
1805627|NCT00621452|Biological|therapeutic autologous lymphocytes|Given IV
1805628|NCT00621452|Drug|cyclophosphamide|Given IV
1805629|NCT00621452|Biological|aldesleukin|Given subcutaneously
1805630|NCT00621452|Genetic|polymerase chain reaction|Correlative studies
1805631|NCT00621452|Genetic|gene rearrangement analysis|Correlative studies
1805632|NCT00621452|Procedure|lymph node biopsy|Optional correlative studies
1805633|NCT00621452|Biological|genetically engineered lymphocyte therapy|Receive genetically modified T cells
1805634|NCT00621452|Procedure|bone marrow aspiration|Optional correlative studies
1805635|NCT00621452|Other|flow cytometry|Correlative studies
1805636|NCT00621452|Other|laboratory biomarker analysis|Correlative studies
1805637|NCT00621452|Other|enzyme-linked immunosorbent assay|Correlative studies
1805638|NCT00621465|Behavioral|Critical Time Intervention (CTI)|CTI is designed specifically to enhance the continuity and focus of care during the transition from psychiatric hospital to community care. CTI does not replace community treatment and support, but instead is meant to complement available services. CTI will provide training in community living skills and in team-managed transfer of caregiving from hospitals to services and supports in the community. Participants will receive CTI for 9 months after hospital discharge.
1805639|NCT00621465|Behavioral|Usual care|Usual care will include the standard aftercare and community care services.
1805640|NCT00621478|Drug|lorazepam or diazepam|"Administration instructions will ask to deliver 0.04 ml per kilogram of child's weight of the study medication up to a maximum of 1.6 ml. 0.04 ml/kg (maximum dose 1.6 ml) will deliver 0.1 mg/kg of lorazepam (maximum dose 4 mg) and 0.2 mg/kg of diazepam (maximum dose 8 mg). Half of this dose can be repeated in 5 minutes if the patient is still convulsing.
The medication will be administered as a slow IV push."
1805641|NCT00621491|Drug|Warfarin|Single daily dose of Warfarin (5 mg/orally), adjusted to achieve an International Normalized Ratio (INR) between 2 to 3.5 times the normal value during six months
1805642|NCT00621504|Drug|Ceftaroline fosamil for Injection|2 consecutive, 300 mg dose parenteral infused over 30 minutes, every 12 hours, for 5 to 7 days
1805643|NCT00621504|Drug|IV Ceftriaxone|1 g dose parenteral infused over 30 minutes, every 24 hours, for 5 to 7 days
1805644|NCT00621504|Drug|Placebo|Subjects randomized to receive ceftriaxone will receive ceftriaxone at a dose of 1 g infused over 30 minutes followed by IV saline placebo infused over 30 minutes, every 24 hours (q24h). Twelve hours after each dose of ceftriaxone and saline placebo (ie, between ceftriaxone doses), subjects in this group will receive two consecutive saline placebo infusions, each infused over 30 minutes q24h. The ceftriaxone and saline placebo infusions will correspond to the q12h infusions of ceftaroline, thereby maintaining the blind
1805645|NCT00621504|Drug|Clarithromycin|In both treatment groups, two doses of oral clarithromycin (500 mg q12h), defined as adjunctive therapy, were initiated on Study Day 1 with study drug therapy in order to provide an immunomodulatory benefit and initial therapy for possible infection due to an atypical organism.
1805646|NCT00621517|Drug|Bupropion|Partipants will receive 150 mg bupropion per night
1805647|NCT00621517|Drug|Placebo|1 capsule nightly for six weeks
1805648|NCT00621530|Drug|ketorolac tromethamine opthalmic solution|ketorolac 2 mg will be added to the patient's routine spinal anesthetic for surgery
1805650|NCT00621543|Device|IUD insertion [Copper T-380A or Levonorgestrel (intrauterine system) IUS]|When a subject has chosen a method of intra-uterine contraception and has agreed to participate in the study, she will have the intra-uterine device of her choice inserted according to the Food and Druga Administration (FDA) instructions.
1805651|NCT00621556|Drug|RG1068 (Synthetic Human Secretin)|Dose: 0.2 μg/kg of synthetic human or 18.5 µg for patients over 50 kg Route: Intravenous Frequency: Once Duration: Over 1 minute
1805652|NCT00621569|Behavioral|Dietary Approaches to Stop Hypertension-The DASH diet|The purpose of this study is to create a culturally appropriate diet to test the effectiveness of the intervention to lower blood pressure in a grou pof African American individuals at risk for developing hypertension (pre-hypertension) and those with mild hypertension (stage I).
1805653|NCT00621569|Behavioral|Intervention with no dietary component - information regarding useful life skills|Participants receive information regarding useful life skills in a group setting
1805654|NCT00621595|Dietary Supplement|USDA School Breakfast|Breakfast containing 340 calories, 57 g carbohydrate, 14 g protein, 6 g fat.
1805655|NCT00621608|Procedure|Hyperbaric Oxygen Therapy|Hyperbaric Oxygen Therapy (HBOT) will be provided 5 days per week for 6 weeks for a total of 30 treatments on average. Subjects will be placed into the hyperbaric chamber for approximately 90 minutes of HBOT at 2.4 ATA (partial pressure of oxygen = 1,800 mmHg) when inside the chamber. Subjects will receive dressing changes as required per standard of care.
1805656|NCT00621608|Procedure|Placebo Hyperbaric Oxygen Chamber|Patients will receive HBOT placebo 5 days per week for 6 weeks for a total of 30 treatments. Each patient will be placed into the hyperbaric chamber and will receive 90 minutes of room air while inside the chamber and the initial flow of air into the chamber will produce a small increase in pressure (0.3 ATA partial pressure of oxygen = 210 mmHg) which will then be released over a period of 10 minutes. Subjects will receive dressings changes as required per standard of care.
1805657|NCT00621621|Device|Freezor® Cardiac Cryoablation Catheter CryoConsole System|cryoablation
1805658|NCT00621634|Dietary Supplement|Omega-3 fish oil capsules (including DHA)|Fish oil capsules of 1000 mg ea., including DHA 460-540 mg/capsule 2 capsules TID daily at mealtime for 12 consecutive weeks
1805659|NCT00621634|Dietary Supplement|Placebo|Corn/Soybean (1:1) placebo 1000 mg capsules 2 capsules TID daily at mealtime for 12 consecutive weeks
1805660|NCT00621647|Drug|Quetiapine Fumarate|
1805661|NCT00621647|Drug|Quetiapine Fumarate|
1805662|NCT00621647|Drug|Placebo|
1805663|NCT00621660|Procedure|Acupuncture|"Acupuncture was administered bilaterally to the standard antiemetic point2-4 pericardium six (PC6) located between the tendons of palmaris longus and flexor carpii radialis at two body-inches proximal of the wrist crease. Sharp needles, diameter 0.25 x length 40 millimetres, were inserted into a depth of a half body-inch. One body-inch (or a cun in traditional Chinese medicine context) is equivalent to the greatest width of the individual patients´ thumb at the distal phalanx, approximately one and a half centimetres or one American thumb. The needles were manipulated three times (at the start, middle and end of the treatment session) by twirling, thrusting and lifting until deqi occurred."
1805664|NCT00621660|Procedure|Sham|Sham acupuncture was administered bilaterally to a non-acupuncture point two body-inches proximal of PC6 with the telescopic Park sham device16, 0.30 x 40 millimetres (fully extended length). That needle looks identical with a real needle but is blunted and glides upwards into its handle instead of penetrating, which gives an illusion of penetration. The marking tubes hold the needles in place. The therapist gave an illusion of manipulation by turning the needle three times, each time for a couple of seconds until the needle touched the skin, but no deqi occurred. Except when placing and manipulating the sham needle, it was not pressed against the skin at all.
1805665|NCT00621673|Drug|Kogenate (BAY 14-2222)|Antihemophilic factor (recombinant) 20-40 IU/ kg based on body weight of rFVIII, IV, 3 times a week
1805666|NCT00621686|Biological|bevacizumab|
1805667|NCT00621686|Drug|sorafenib tosylate|
1805668|NCT00621699|Drug|1 tablet Ezetrol(R) (ezetimibe), MSD Sharp & Dohme GmbH, Germany|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
1805669|NCT00621699|Drug|1 capsule Prograf(R) (tacrolimus), Astellas Pharma GmbH, Germany|administration of 1 capsule Prograf(R) (5 mg tacrolimus), 0-144 h blood sampling
1805670|NCT00621699|Drug|1 tablet Ezetrol(R) + 1 capsules Prograf(R)|administration of 1 tablet Ezetrol(R) (10 mg ezetimibe) and 1 capsule Prograf(R) (5 mg Tacrolimus), 0-144 h blood sampling, 0-5 d urine sampling (24 h intervals) and 0-10 d feces sampling
1805671|NCT00621712|Device|GamCath® central venous catheter|choice of catheter type
1805672|NCT00621712|Device|GamCath Dolphin® Protect central venous catheter|choice of catheter type
1805673|NCT00621725|Drug|AZD2171|Oral dose
1805674|NCT00621751|Drug|Carbamazepine|800 mg daily
1805675|NCT00621751|Drug|Placebo|Placebo
1805676|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 Plaque forming units (PFU), Subcutaneous (SC; Day 0); 0.5 mL intramuscular (IM; Day 28)
1805677|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
1805678|NCT00621764|Biological|Japanese encephalitis vaccine (Day 0) Hepatitis A vaccine (Day 28)|≥4.0 Log10 PFU SC (Day 0); 0.5 mL IM (Day 28)
1805679|NCT00621764|Biological|Hepatitis A vaccine (Day 0) Japanese encephalitis vaccine (Day 28)|0.5 mL IM (Day 0); ≥4.0 Log10 PFU SC (Day 28)
1805680|NCT00621777|Drug|Varenicline|"At each weekly study visit from the baseline visit to study week 11, ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.
In addition, participants who enter the relapse prevention phase and are randomized to the varenicline condition will receive varenicline at the dose used to attain initial abstinence for 40 weeks."
1805681|NCT00621777|Drug|Placebo|"At each weekly study visit from the baseline visit to study week 11,ALL subjects will receive a one-week supply of varenicline with instructions on how to take the study medication. Titration is as follows: 0.5 mg varenicline per day for 3 days, then 0.5 mg twice per day for 4 days, and then 1 mg twice per day for 11 weeks.
In addition, participants who enter the relapse prevention phase and are randomized to the placebo condition will receive placebo pills for 40 weeks."
1805868|NCT00632983|Radiation|3-dimensional conformal radiation therapy|
1805682|NCT00621790|Drug|fenoldopam|fenoldopam 0.1 ug/kg/min (from 0.025 to 0.3 ug/kg/min)for up to 4 days
1805683|NCT00621790|Drug|placebo|placebo
1805684|NCT00621803|Drug|Probiotic Lactobacillus casei rhamnosus (Lcr35)|
1957673|NCT02264327|Behavioral|Motivational Interviewing eBook (eBook)|"The Phase I research team developed a 69-page eBook as a credible online comparator that presents information comparable to that included in the Sim, but without the interactive, role-playing, peer learning functionalities embodied in the Sim. Developed in Hyperlink Markup Language, the eBook presented MI skills, followed by transcripts of effective and not-effective samples of MI from the Sim itself. The e-Book includes the story-lines along with sample dialogue and expert feedback on MI skills."
1805687|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take the (EPA)-enriched omega-3 polyunsaturated fatty acids (n3-PUFA) supplements as a capsule (3-4 g of EPA/day) for 90 days, followed by an 8 week washout period, and then will take a Placebo capsule for 90 days.
1805688|NCT00621829|Dietary Supplement|EPA enriched fish oils|Subjects will take a Placebo capsule for 90 days, followed by an 8 week washout period, and then will take the (EPA)-enriched omega-3 polyunsaturated fatty acids supplements as a capsule (3-4 g of EPA/day) for 90 days.
1805689|NCT00621842|Drug|Lamotrigine regular tablet formulation|Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds.
1805690|NCT00621842|Drug|Lamotrigine novel formulation|"Participants will have the option of trying a novel formulation of lamotrigine tablets instead of the lamotrigine regular formulation tablets. The dosing will remain the same regardless of which type of lamotrigine tablet is used.
Day 0 lamotrigine regular tablet formulation or lamotrigine novel formulation will be initiated at 25 mg/day and upward titrated as per package insert to targeted maximum dose of 200 mg/day. Dosing will be reduced for individuals who experience adverse effects. Dosing will be modified as per package insert for lamotrigine for individuals on anticonvulsant compounds."
1805691|NCT00621855|Drug|placebo|matched placebo
1805692|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
1805693|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
1805694|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
1805695|NCT00621855|Drug|dabigatran etexilate|capsules, twice daily, 26 weeks treatment
1805696|NCT00621868|Drug|ASP1941|Oral
1805697|NCT00621868|Drug|Placebo|Oral
1805698|NCT00621881|Drug|naproxcinod|750 mg bid
1805699|NCT00621894|Drug|LGD-4665|LGD-4665 Thrombopoietin mimetic
1805700|NCT00621894|Drug|Placebo|Placebo
1805701|NCT00621907|Drug|chirocaine (Levobupivacaine)|levobupivacaine 0,5 % 30 ml infiltration (150 mg)
1805702|NCT00621907|Drug|sodium chloride|sodium chloride : 0,9% 30 ml
1805703|NCT00621920|Drug|FM-601|Dose-escalation, split dosage, liquid
1805704|NCT00621946|Drug|Placebo|Placebo Matching Escitalopram
1805705|NCT00621946|Drug|Escitalopram|Active Escitalopram
1805706|NCT00621959|Drug|levocetirizine dihydrochloride|5mg daily (oral tablet) for 14 days
1805707|NCT00621959|Drug|placebo|0mg (matching oral tablet)for 14 days
1805708|NCT00621985|Drug|dexamethasone|Dexamethasone will be given at a dose that equals 1/50 of the total daily hydrocortisone dose of the patient. It will be given in solution form at 10 PM for 3 days.
1805709|NCT00621985|Drug|Hydrocortisone|Subjects were given their baseline hydrocortisone regimen which was three times daily for 4 of the subjects and twice daily for one subject. Doses were given at 8 AM, 2 PM, and 8 PM. The 2 PM time point was skipped for the subject who received hydrocortisone twice daily. Doses ranged from 6.9 to 18.5 milligrams per meter squared per day and were based on each individual's baseline regimen.
1805710|NCT00621998|Drug|risperidone|0.5-6 mg/day
1805711|NCT00621998|Drug|olanzapine|2.5-20 mg/day
1805712|NCT00622011|Drug|Risperidone and Zolpidem for delirium|try risperidone or zolpidem in the treatment of delirium
1805713|NCT00622037|Drug|PEG-400 based artificial tear|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
1805714|NCT00622037|Drug|Systane|Instill one drop in the randomized eye four times daily. Can be used more frequently if needed
1805715|NCT00622050|Behavioral|No TV viewing reduction|In the control group, no intervention will be acted upon. This group will receive the exact same protocol as the intervention group, but with observation only.
1805716|NCT00622050|Behavioral|TV viewing reduction|In the experimental arm, TV viewing time will be reduced for half of the study protocol time (3-4 weeks of a 6-8 week protocol).
1805717|NCT00622063|Drug|ARQ 501|Treatment with ARQ 501 or ARQ 501 as combination therapy at the dose and regimen previously received
1805719|NCT00622089|Drug|DIO-902|150mg DIO-902 + 10mg atorvastatin
1805720|NCT00622089|Drug|DIO-902|300mg dose once per day for 24 weeks
1805721|NCT00622089|Drug|DIO-902|450mg dose once per day for 24 weeks
1805722|NCT00622102|Behavioral|Lottery arm (Lottery and Med-eMonitor)|Lottery and Med-eMonitor
1805723|NCT00622102|Behavioral|Non-Lottery (Med-eMonitor only)|Med-eMonitor only
1805724|NCT00622115|Drug|Enoxaparin|
1805725|NCT00622128|Behavioral|Preventing Aggressive Behavior in Demented Patients|Preventing Aggressive Behavior in Demented Patients
1805726|NCT00622141|Drug|generic GPO saquinavir and novir vs invirase and norvir|Norvir® 100mg capsules, Invirase® 1,000 mg capsules Generic GPO Saquinavir 1,000 mg capsules For phase 1 and 2 - At day 1 subjects of group A will receive a single dose of Invirase®/Norvir® 1,000 mg / 100mg, while group B will receive generic GPO saquinavir / Norvir® 1,000 mg / 100mg as single dose. The same day the first 24 hr PK curve will be done. After this, a 7-day washout period will follow. At day 8 group A will take generic GPO saquinavir / Norvir® and Group B will take Invirase®/Norvir®. At this day, the second 24 hr PK curve will be done
1805727|NCT00622167|Device|Integrated Backscatter IVUS|All subjects have Integrated Backscatter IVUS and Dual Source CT imaging.
1805728|NCT00622167|Device|Dual Source Computed Tomography|All subjects have DSCT and IBIVUS imaging
1805731|NCT00629850|Device|Powerlung Performer|Inspiratory/Expiratory muscle trainer
1805732|NCT00629863|Drug|cisplatin|
1805733|NCT00629863|Drug|fluorouracil|
1805734|NCT00629863|Other|questionnaire administration|
1805735|NCT00629863|Procedure|diagnostic endoscopic procedure|
1805736|NCT00629863|Procedure|neoadjuvant therapy|
1805737|NCT00629863|Procedure|quality-of-life assessment|
1805738|NCT00629863|Procedure|therapeutic conventional surgery|
1805739|NCT00629863|Procedure|therapeutic endoscopic surgery|
1805740|NCT00629863|Procedure|ultrasound imaging|
1805741|NCT00629863|Radiation|radiation therapy|
1805742|NCT00629863|Radiation|radioisotope therapy|
1805743|NCT00629876|Drug|Peginesatide|"Peginesatide 0.075, 0.1, 0.125, 0.15, 0.175, 0.2, 0.225 or 0.25 mg/kg administered subcutaneously every 3 weeks for a total of at least 2 doses. Subsequent injections given every 3 weeks thereafter regardless of the schedule of subsequent chemotherapy cycles.
Following Study Day 43, subjects may continue on Peginesatide treatment, dosing every 3 weeks until 4 weeks after discontinuation of taxane-containing chemotherapy regimen, the occurrence of a dose limiting toxicity, documented disease progression or change in chemotherapy regimen."
1805744|NCT00629889|Drug|levetiracetam|"After inclusion, patients receive Levetiracetam 2x250mg per day. The medication may be increased, in intervals of 500mg of Levetiracetam of at least 24h up to maximally: Levetiracetam 2x1500mg.
Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
1805745|NCT00629889|Drug|pregabalin|"After inclusion, patients receive Pregabalin 2x75mg per day. The medication may be increased, in intervals of 150mg of Pregabalin of at least 24h up to maximally: Pregabalin 2x300mg.
Patients might be treated up to one year within the study. If well tolerated, treatment might continue after end of study."
1805746|NCT00629928|Drug|Esomeprazole|20mg oral capsule daily
1805747|NCT00629928|Drug|Esomeprazole|40mg oral capsule daily
1805748|NCT00629928|Drug|Placebo|
1805749|NCT00629941|Drug|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
1805750|NCT00629967|Drug|pegylated interferon alpha 2a and ribavirin|pegylated interferon alpha 2a 180 mcg/week and ribavirin 1000-1200 mg/day for 48 weeks
1805751|NCT00629967|Drug|Pegylated interferon alfa-2a and ribavirin|Pegylated interferon alfa-2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
1805752|NCT00629980|Drug|AzaSite®|ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
1805753|NCT00629993|Behavioral|Academic Detailing|It will involve multiple intervention components, some of which are standardized across physicians (i.e., self learning packets, post-tests for CME credit, CD-ROMS, videos, newsletters, culturally sensitive patient education materials, office staff informational sessions, chart and patient reminders, and a general office routine for cervical cancer counseling, including performance feedback, as well as media-ready materials). Academic detailing and the specific office routines will be customized to each physician, although the frequency of the detailing visits will be routinized across all participants, to reduce cost and to maximize its potential for dissemination.
1805754|NCT00630006|Genetic|TNF-alpha and IL-10|
1957674|NCT02264327|Behavioral|Motivational Interviewing Training (MI Training)|The training intervention consists of a free two-day standardized Motivational Interviewing (MI) training provided by experienced MI trainers.
1957675|NCT02263040|Biological|Fluzone High-Dose|Influenza vaccine
1805757|NCT00630032|Drug|cyclophosphamide|500 mg/m2 every 3 weeks
1805758|NCT00630032|Drug|Docetaxel|100 mg/m2 every 3 weeks
1805759|NCT00630032|Drug|epirubicin hydrochloride|100 mg/m2 every 3 weeks
1805760|NCT00630032|Drug|fluorouracil|500 mg/m2 every 3 weeks
1805761|NCT00630032|Drug|ixabepilone|40 mg/m2 every 3 weeks
1805762|NCT00630045|Drug|neoadjuvant chemotherapy with oxaliplatin and capecitabine|oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
1805763|NCT00630045|Procedure|resection of liver metastasis|surgery with the aim of R0 resection
1805764|NCT00630058|Drug|MP-424(H), PEG-IFN-a-2b, RBV|MP-424 (three tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
1805765|NCT00630058|Drug|MP-424 (L), PEG-IFN-a-2b, RBV|MP-424 (two tablets of 250mg tablet at a time, every 8 hours) + PEG-IFN-a-2b + RBV for 12 weeks
1805766|NCT00630084|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
1805767|NCT00630084|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
1805768|NCT00630097|Drug|modafinil|Modafinil, 100mg, 400mg, or 600 mg tablets QD for 4 weeks.
1805769|NCT00630110|Drug|docetaxel|docetaxel (75 mg/m2)
1805770|NCT00630110|Drug|NPI-2358 + docetaxel|NPI-2358 (30 mg/m2) + docetaxel (75 mg/m2)
1805771|NCT00630136|Behavioral|interview|The parent/LAR who has consented to have their child undergo an outpatient endoscopy procedure will be interviewed prior to the procedure being performed.
1805772|NCT00630149|Drug|Pemetrexed (Alimta)|500 mg/m2 in Cycle 1, every 3 weeks, with folic acid and vitamin B12 supplementation.
1805773|NCT00630162|Genetic|amoeba|
1805774|NCT00630175|Drug|zolpidem-MR (modified release)|
1805775|NCT00630175|Drug|zolpidem (SL800750)|
1805776|NCT00630175|Drug|placebo|
1805778|NCT00632372|Device|Cardiac Resynchronization Therapy|Pacing of the left ventricle to resynchronize ventricular contraction.
1805779|NCT00632372|Device|HeartPOD™ System|Left atrial pressure monitoring.
1805780|NCT00632385|Drug|Eletriptan|40 mg oral tablet for migraine attack, followed by 40 mg oral tablet if migraine reoccurred >2 hours from first dose and within 24 hours of first dose
1805781|NCT00632398|Behavioral|Attention control (reading)|Caregivers read to the patient from literature of the patient's choice for recommended 20 minutes at least 3 times per week for 4 weeks
1805869|NCT00632996|Other|Rehabilitation|Exercise, manual therapy, patient education, posture, home exercise program
1805949|NCT00633633|Behavioral|Dietary Counseling|Food log, booklet, and a cookbook to help decrease the salt content in your diet.
1806070|NCT00634387|Dietary Supplement|Anthocyans|
1805782|NCT00632398|Behavioral|Touch, Caring and Cancer DVD program|DVD- and manual-based instruction for caregivers and patients in the use of touch and massage techniques as supportive care in cancer, including: preparation for a session, safety precautions related to cancer and its treatments, communication about touch, centering to calm the mind; manual techniques for the head, neck, shoulders, back, feet and hands to promote relaxation; and acupressure for pain, nausea and anxiety.
1805783|NCT00632411|Drug|Nicotine Patch|"Participants who smoke more than 20 cigarettes per day will use a 21-mg patch for 4 weeks, a 14-mg patch for the next 2 weeks, a 7-mg patch for the next 2 weeks, and then no patch.
Participants who smoke between 10 to 19 cigarettes per day will use a 14-mg patch for 4 weeks, a 7-mg patch for the next 4 weeks, and then no patch.
Participants who smoke between 5 to 9 cigarettes per day will use a 7-mg patch for 8 weeks and then no patch.
The proactive group will be given 8 weeks of patch treatment and the reactive group will be given 2 weeks of patch treatment."
1805784|NCT00632411|Behavioral|Tobacco Quit Line Program|"Phone session 1 will focus on smoking reduction.
Phone session 2 will focus on preparing to quit and surviving the first days as a non-smoker. A quit date will be set in 7 to 10 days. Nicotine patches will be sent to participant with detailed instructions for patch use.
Phone session 3 will focus on the first days after the quit date.
Phone session 4 will focus on a review of progress and challenges of quitting. Plans to manage high-risk situations will be discussed.
Phone session 5 will focus on short-term relapse prevention.
Phone session 6 will focus on long-term relapse prevention."
1805785|NCT00632424|Drug|Ixabepilone (oral formulation)|Capsules, Oral, Dose escalating (Phase 1), 3 doses on 1 day every 3 weeks, until disease progression or unacceptable toxicity
1805786|NCT00632437|Procedure|Speckle-Contrast Imaging|Imaging camera scan that uses reflected red light to take pictures of the amount of blood flowing in brain and the amount of oxygen in blood.
1805787|NCT00632463|Biological|RI-001|Dose 1
1805788|NCT00632463|Biological|RI-001|Dose 2
1805789|NCT00632463|Biological|RI-001|Placebo
1805790|NCT00632476|Other|Placebo|Placebo capsule once a day
1805791|NCT00632476|Dietary Supplement|Vitamin C|A 500-mg vitamin C capsule once a day
1805792|NCT00632489|Drug|LBH589|LBH589 will be evaluated when administered twice weekly at the following possible dose levels: 20 mg, 30 mg, 45 mg, and 60 mg. Capecitabine will be paired with LBH589 and will range in dose from 825 mg/m2 to 1250 mg/m2 orally BID 14 of every 21 days. Treatment cycles will be 21 days in length. Once determined safe, 10 additional patients will be treated at the determined MTD to further assess safety.
1805793|NCT00632489|Drug|Capecitabine|Capecitabine will be administered orally twice daily for 14 days out of every 21 days.
1805794|NCT00632489|Drug|Lapatinib|Lapatinib, 1000 mg PO daily will be added to this combination.
1805795|NCT00632502|Drug|Navarixin|Navarixin 30 mg capsule to be taken by mouth once daily in the morning for 4 weeks.
1805796|NCT00632502|Drug|Placebo|Placebo capsule to match navarixin to be taken by mouth once daily in the morning for 4 weeks.
1805797|NCT00632502|Drug|Rescue medication|Participant choice of short-acting beta-2 agonist (salbutamol/albuterol), anticholinergic, or combination medication as needed for asthma symptoms
1805798|NCT00632515|Behavioral|Questionnaire|Questionnaire regarding awareness of screening tests and attitudes toward colorectal cancer screening, taking 30-45 minutes to complete.
1805799|NCT00632528|Drug|MEOPA|Administration of MEOPA gaz during postoperative physical therapy
1805800|NCT00632528|Drug|Medicinal air|Administration of medical air during postoperative physical therapy
1805801|NCT00632541|Drug|Sorafenib|Sorafenib 200mg po daily
1805802|NCT00632541|Drug|Bevacizumab|"Bevacizumab 5mg/kg every other week
1 Cycle = 4 weeks"
1805803|NCT00632541|Other|Imaging|Imaging every third cycle
1805804|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for three months|period of treatment
1805805|NCT00632554|Drug|prednisolone 0.5 mg/kg/day for six months|period of therapy
1805806|NCT00632567|Procedure|caesarean section|caesarean section for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
1805807|NCT00632567|Procedure|vaginal delivery|vaginal delivery for second delivery if the first had to be traumatic after forceps with anal sphincter rupture diagnosed with anal endosonography.
1805808|NCT00632580|Drug|intraarticular injection with ropivacaine|
1805809|NCT00632580|Drug|extraarticular injection with ropivacaine|
1805810|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
1805811|NCT00632593|Procedure|Laparoscopic Gastric Bypass|
1805812|NCT00632606|Drug|magnesium sulfate|magnesium sulfate 2 grams intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
1805813|NCT00632606|Drug|metoclopramide|metoclopramide 10 mg intravenously; both groups will receive acetaminophen (Tylenol®) 1 gram orally
1805814|NCT00632619|Behavioral|Group-based behavior therapy|Group-based behavior therapy with a parenting class will include 12 weeks of sessions that focus on reducing oppositional and aggressive behaviors. Children will participate in 12 weeks of social skills training integrated with a cognitive behavioral therapy (CBT) component to target mood symptoms. Parents will learn ways to identify and address their child's mood problems, communicate better with their child, and work with school staff to address academic and behavioral problems.
1805815|NCT00632619|Drug|Stimulant medication therapy|All participants will be stabilized on an FDA-approved stimulant medication for 2 to 6 weeks prior to therapy assignment.
1805816|NCT00632619|Behavioral|Community-based psychosocial treatment|Participants will receive referrals to community-based psychosocial treatments that will focus on ADHD symptoms and management of aggression.
1805817|NCT00632632|Drug|D-Cycloserine|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality with D-Cycloserine -100 mg on days when receiving exposure with virtual reality (approximately 10-12 times)
1805818|NCT00632632|Other|Placebo|Cognitive behavioral treatment (CBT) including prolonged exposure enhanced by virtual reality. Placebo given on days when receiving exposure with virtual reality (approximately 10-12 times).
1805819|NCT00632645|Drug|Olanzapine|Olanzapine Mylan oral dispersible form 5 to 10 mg / 2,5 à 20 mg per day
1805820|NCT00632645|Drug|Xenazine|Xenazine (tetrabenazine) tabs of 25mg , from 25 mg to 200 mg
1805821|NCT00632645|Drug|Tiapridal|Tiapridal (Tiapride), tabs 100 mg / from 300 to 800 mg per day
1806071|NCT00634400|Drug|Candesartan|
1805822|NCT00632684|Behavioral|Interviews with a single treatment planning session|Participants in Phase 1 will attend four 90-minute interviews over 4 months. During interviews, participants will be asked about their experiences caring for their relatives, physical and emotional well-being, and ideas on helpful types of assistance. Participants will also receive information about programs and services that may help them carry out caregiving activities.
1805823|NCT00632684|Behavioral|Adaptive treatment model|The adaptive treatment model will include up to ten 60- to 75-minute planning sessions. The sessions will focus on psychosocial issues and will be tailored to participants' specific risk factors.
1805824|NCT00632697|Drug|pentoxifylline|800 mg daily for six months
1805825|NCT00632697|Drug|placebo|
1805826|NCT00632710|Other|phototherapy|The laser used was low-level Aluminum Gallium Arsenide (AlGaAs)diodo laser, at a wavelength of 785 nm (infrared), dose of 3 J/cm2, mean power of 70 mW, 3 sec. per point, laser beam of 0,06cm2, BIOSET brand - Indústria de Tecnologia Eletrônica Ltda -Rio Claro, Brazil.
1805827|NCT00632710|Other|phototherapy placebo|disconnected laser (same device - experimental group)
1805828|NCT00632723|Drug|gefitinib (IRESSA™, ZD1839)|250 mg tablet; daily dose 500 mg daily
1805829|NCT00632736|Drug|Ropinirole XL (formerly CR)|
1805830|NCT00632749|Drug|BI 811283 (d 1 and 15)|BI 811283 (24 hours i.v.c.i.) on day 1 and 15 of a 4-week treatment cycle
1805831|NCT00632749|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
1805832|NCT00632749|Drug|BI 811283 (d1)|BI 811283 (24 hours i.v.c.i.) on day 1 of a 4-week treatment cycle
1805833|NCT00632749|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c. on days 1-10 of a 4-week treatment cycle
1805834|NCT00632762|Drug|mantadix|dose greater or equal to 200 mg/day and progressively increasing doses (100mg every 3 days until the pre-study dose is reached).
1805835|NCT00632775|Drug|Hypotonic (0.45% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:
100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg."
1805836|NCT00632775|Drug|Isotonic (0.9% NaCl/5% dextrose) IV maintenance fluids|"Total daily fluid infusion equal to:
100 mls/kg/day for children weighing <10kg, 1000 mls + 50mls/kg for those weighing 10 to 20 kg, and 1500 mls +20 mls/kg for those >20kg."
1805837|NCT00632788|Other|acute myocardial infarction checklist|For every patient fulfilling the criteria of enrollment, an acute myocardial infarction checklist was incorporated into the patient's medical records at emergency department immediately after a diagnosis of acute ST-elevation myocardial infarction was made. All the time sequences concerning different managements at different locations were recorded by nurses and/or physicians as instructions on the checklist.
1805838|NCT00632801|Other|chewing gum|The patients in the gum chewing group (intervention group) will chew one stick of gum the first post-operative day, after the nasogastric tube is removed or if they patient does not have a nasogastric tube, with the head of bed elevated a minimum of 30 degrees for 30 minutes, three times a day at set intervals
1805839|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 70 IU/kg, dosing once per week|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection once per week (weekly on Day 7 + 1 after previous injection) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 35 IU/kg twice a week or further escalation to 25 IU/kg three times a week)
1805840|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222), 70 IU/kg twice per week (30 IU/kg + 40 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 70 IU/kg, dosing by injection twice per week (30 IU/kg [day 1] + 40 IU/kg [day 4]) for 9 months. Dose escalation was permitted due to joint bleeding (escalation to 25 IU/kg three times a week)
1805841|NCT00632814|Drug|rFVIII-FS (Kogenate FS, BAY14-2222) 75 IU/kg, dosing three times per week (3 x 25 IU/kg)|rFVIII-FS (Octocog-alfa, antihemophilic factor [recombinant]) 75 IU/kg, dosing by injection three times per week (3 x 25 IU/kg [day 1, 3, 5]) for 9 months. No escalation opportunity for patients in this group
1805842|NCT00632827|Drug|REGIMEN|Induction chemotherapy
1805843|NCT00632827|Drug|REGIMEN B|Induction Chemotherapy
1805844|NCT00632840|Drug|Atorvastatin and fenofibrate|atorvastatin (40mg/day) fenofibrate (200mg/day)
1805845|NCT00632853|Radiation|Standard Radiation Dose Therapy|45 Gy
1805846|NCT00632853|Drug|cisplatin|IV
1805847|NCT00632853|Drug|etoposide|IV
1805848|NCT00632853|Radiation|High Radiation Dose Therapy|70 Gy
1805849|NCT00632853|Drug|carboplatin|IV
1805850|NCT00632866|Drug|Hydroxychloroquine|Hydroxychloroquine : 200mg / day since 24 weeks
1805851|NCT00632866|Drug|Placebo|Placebo : 2cp/ day since 24 weeks
1805852|NCT00632931|Drug|vorinostat|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat 800 mg capsules (Period 1) crossing over to Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1) crossing over to Single dose of vorinostat 800 mg capsules (Period 2). Part 2: All patients will receive 400 mg vorinostat capsules once daily. Treatment will continue until disease progression or intolerable toxicity.
1805853|NCT00632931|Drug|Comparator: placebo (unspecified)|A 2-part, crossover study. Part 1: Arm A: Single dose of vorinostat Placebo capsules (Period 2) Arm B: Single dose of vorinostat Placebo capsules (Period 1).
1805854|NCT00632957|Dietary Supplement|Omega-3 Fatty acid (with SRP or OHI)|1000mg capsules three times daily, duration 28 weeks.
1805855|NCT00632957|Dietary Supplement|Placebo|corn/soybean oil capsules 1g/three times daily
1805856|NCT00632970|Drug|Raltegravir|1, 400mg tablet twice a day, with Truvada 1 tablet once a day
1805857|NCT00632970|Drug|Lopinavir/Ritonavir|2 tablets twice a day, with Truvada 1 tablet once a day
1805858|NCT00632970|Drug|Truvada|1 tablet, once a day, with either Raltegravir (Isentress) or Lopinavir/Ritonavir(Kaletra)
1805859|NCT00632983|Drug|cyproterone acetate|
1805860|NCT00632983|Drug|releasing hormone agonist therapy|
1805861|NCT00632983|Other|active surveillance|
1805862|NCT00632983|Other|medical chart review|
1805863|NCT00632983|Other|questionnaire administration|
1805864|NCT00632983|Procedure|assessment of therapy complications|
1805865|NCT00632983|Procedure|quality-of-life assessment|
1805866|NCT00632983|Procedure|therapeutic conventional surgery|
1805867|NCT00632983|Procedure|therapeutic lymphadenectomy|
1806072|NCT00634400|Drug|Placebo|
1805870|NCT00633009|Biological|Leishmania tropica Skin Test Antigen (LtSTA)|Administer 15 ug, 30 ug or 50 ug of LtSTA into DTH positive volunteers. Repeat drug administration 30 days after initial injection and 60 days after initial injection. Read and interpret reaction 48 hours after each injection. Observe subjects for conversion or adverse reaction.
1805871|NCT00633009|Biological|Leishmania tropica Skin Test Antigen Placebo (Placebo)|Administer Placebo concurrently with 15 ug, 30 ug and 50 ug doses of LtSTA. Read and interpret the reaction 48 hours after injection. Observe subjects for reaction to Placebo
1957676|NCT02263040|Biological|Fluzone (standard dose)|Influenza vaccine
1957677|NCT02263495|Drug|Paclitaxel|175mg/m2 + D5W 500mL MIV over 3hrs before gemcitabine administration
1957678|NCT02263495|Drug|Eribulin|1.0 mg/m2, 2-5min iv before gemcitabine (or miv with NS 100ml in max.)
1805875|NCT00633035|Drug|esomeprazole 40 mg|esomeprazole 40 mg po given for 7 days
1805876|NCT00633035|Drug|famotidine 20 mg|famotidine 20 mg intravenous bolus q12h for 7 days
1805877|NCT00633048|Drug|NSA-789|
1805878|NCT00633048|Drug|placebo|
1805879|NCT00633061|Drug|Enoxaparin|Lovenox ® is a sterile aqueous solution containing enoxaparin sodium, a low molecular weight heparin. It is given as a subcutaneous injection twice daily. Dose of enoxaparin (Lovenox ®) will be 1 mg/kg every 12 hours for children >2 months and 1.5 mg/kg every 12 hours for infants <2 months. Duration of treatment is 6 weeks.
1805880|NCT00633074|Biological|Thiomersal-free FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
1805881|NCT00633074|Biological|Thiomersal reduced FluAS25 adjuvanted vaccine (GSK576389A)|Intramuscular administration, 1 dose
1805882|NCT00633087|Drug|2-deoxyglucose|30 mg/kg of 2-deoxyglucose administered orally on a daily schedule for two weeks (Days 1-14) of a three week (21 Day) cycle.
1805883|NCT00633113|Procedure|MPPA|- Medial Parapatellar Arthrotomy
1805884|NCT00633113|Procedure|SV|- Subvastus Technique
1805885|NCT00633126|Drug|ceftaroline|Single parenteral infusion at a dose of 8 mg/kg for subjects weighing less than 75 kg or at a dose of 600 mg for subjects weighing greater than or equal to 75 kg infused over 60 minutes.
1805886|NCT00633139|Biological|Recombinant human Arylsulfatase A (rhASA)|intravenous infusion, every other week for 26 weeks
1805887|NCT00633152|Drug|ceftaroline|600 mg injected every 12 hours for at least 5 but not more than 14 days
1805888|NCT00633152|Drug|linezolid|600 mg parenteral infused over 60 minutes for a minimum of 5 days and a maximum of 14 days
1805889|NCT00633152|Drug|Aztreonam|1000 mg infused over 60 minutes every 24 hours may be started with linezolid or added later (up to 72 hours after the first dose of linezolid) for subjects with a gram-negative infection indicated.
1805890|NCT00633165|Drug|Brostallicin|Patients will receive Brostallicin administered intravenously (IV) over 10 minutes at a dose of 10 mg/m2 on day one of a 21-day cycle. Safety and efficacy will be closely monitored and assessed.
1805891|NCT00633178|Behavioral|Group interpersonal therapy (IPT)|Group IPT will include weekly treatment sessions with a psychiatrist for 12 weeks. The sessions will focus on overcoming relationship problems associated with depression. The first two and last sessions will be alone with the psychiatrist and the remaining sessions will be with a group of five to eight other pregnant women.
1805892|NCT00633178|Behavioral|Treatment as usual (TAU)|TAU will include referrals to outpatient treatment, which may include cognitive behavioral psychotherapy, insight-oriented psychotherapy, and/or antidepressant medication. TAU participants receiving psychotherapy will attend 12 weekly treatment sessions comparable to the IPT group sessions; treatment for TAU participants receiving medication for their depression may last longer than 12 weeks.
1805893|NCT00633191|Drug|Anti-pseudomonas IgY gargle|Gargle (solution), > 5FKU, every night after toothbrushing, life-long
1805894|NCT00633204|Biological|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week after curative surgery 8 times and BCG in bladder simultaneously. Then, DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered once every month. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
1805895|NCT00633217|Drug|Fluticasone Propionate/Salmeterol DISKUS 250/50mcg|treatment drug
1805896|NCT00633217|Drug|Fluticasone Propionate/Salmeterol Hydrofluoroalkane 134a MDI 230/42mcg|treatment drug
1805897|NCT00633230|Drug|standardized herbal formula, Sho-saiko-to (SST)|3 capsules containing 700 mg of the Sho-saiko-to (SST) herbal extract/capsule and 28 mg of the excipients, magnesium stearate, and silicon dioxide/capsule 2 x day
1805898|NCT00633230|Other|placebo capsule identical to the active herbal formula|3 placebo capsules 2 x day
1805899|NCT00633243|Procedure|Modified Directly Observed Therapy (mDOT)|
1805900|NCT00633243|Procedure|Self-Administered Therapy (SAT)|
1805901|NCT00633256|Drug|Cycloserine|50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
1805902|NCT00633256|Drug|Placebo|Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
1805903|NCT00633269|Drug|AZD2281|100mg Oral Dose
1957679|NCT02263495|Drug|Gemcitabine|PG:1250mg/m2 + NS 100ml MIV over 30mins EG:1000mg/m2 + NS 100ml MIV over 30mins
1805907|NCT00633295|Drug|AMN107- NILOTINIB|The dose of nilotinib will be 400 mg bid.
1805908|NCT00633308|Device|NxStage System One (NxStage Medical, Lawrence, MA)|Each patient will be studied on 4 separate occasions. The study sessions are longer than routine daily hemodialysis therapy using the System One.
1805948|NCT00633633|Behavioral|Exercise Training|Exercise training 3 times a week.
1806171|NCT00625183|Radiation|radiation therapy|
1805911|NCT00633334|Other|Specimen bank|Patients will be asked to provide approximately 60-120 cc (4-8 tablespoons) of peripheral blood. Select patients who undergo surgical resection of their tumor will be asked to provide portions of the tumor and tumor draining lymph nodes for further analysis. In addition patients undergoing surgical resection may be asked to provide additional peripheral blood samples at time of routine follow-up (at least 4-6 weeks after initial blood draw and between subsequent draws).
1805912|NCT00633347|Drug|Antagonist GnRH Cetrotide|Cetrotide 0.25 mg. daily/ 7 days
1805913|NCT00633347|Drug|Agonist GnRH Acetate Triptoreline|Acetate Triptorelina (Agonist GnRH), 3.75 mg. single dose
1805914|NCT00633360|Drug|Drospirenone and ethinyl estradiol|Once daily by mouth
1805915|NCT00633360|Drug|Placebo|Once daily by mouth
1805916|NCT00633373|Drug|Cyclosporine Inhalation Solution|Cyclosporine USP Inhalation Solution (CIS) 300mg/4.8 mL delivered via a disposable nebulizer. A titration phase of 10 days is recommended starting with 100 mg and then increasing over the 10 days to a maximum of 300 mg or the highest tolerated dose.
1805917|NCT00633386|Drug|Celecoxib|400 mg oral capsule as a single dose 1 hour prior to surgery and 200 mg oral capsule as a single dose as needed post-surgery
1805918|NCT00633386|Other|Placebo|Matched placebo
1805919|NCT00633399|Drug|Ziprasidone|20mg-80mg a day. Dose increases of 20mg per day may occur at three study visits as directed by clinician. Maximum; 80mg per day per patient.
1805920|NCT00633399|Drug|Placebo|"0mg Placebo per day (1-4 tablets per day). Dose increases and dose decreases may occur, but patient will remain at 0mg placebo."
1805921|NCT00633412|Drug|Esomeprazole|20mg oral daily
1805922|NCT00633412|Drug|Ranitidine|150mg oral twice daily
1805923|NCT00633412|Drug|Esomeprazole|40mg oral tablet daily
1805924|NCT00633425|Drug|GLIMEPIRIDE|
1805925|NCT00633438|Other|Placebo|Matched oral capsule administered 1 hour prior to surgery and matched oral capsule administered post surgery as needed
1805926|NCT00633438|Drug|Celecoxib|400 mg oral capsule as single dose administered 1 hour prior to surgery and 200 mg oral capsule as single dose administered post surgery as needed
1805927|NCT00633451|Other|Manual Therapy and Exercise|Manual therapy to the thoracic spine and shoulder, and therapeutic exercise to the shoulder and spine applied in a prescribed progression of therapeutic exercise aimed at improving shoulder function.
1805928|NCT00633451|Other|Exercise Only|A prescribed progression of therapeutic exercise for the shoulder and spine aimed at improving shoulder function
1805929|NCT00633464|Drug|ixabepilone|"injection, intravenous (IV), until unacceptable toxicity or progression or 15 months after the Last Subject First Visit (LSFV), whichever comes first.
Ixabepilone 40 mg/m^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant met the re-treatment criteria."
1805930|NCT00633464|Drug|ixabepilone + cetuximab|"Ixabepilone: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.
Ixabepilone 40 mg/m^2 was administered as a 3-hour IV continuous infusion on Day 1 in a 21-day cycle provided the participant meets the re-treatment criteria.
Cetuximab: injection, IV, until unacceptable toxicity or progression or 15 months after the LSFV, whichever comes first.
Cetuximab 400 mg/m^2 was administered as a 2-hour IV loading dose via in-line filtration with an infusion pump, gravity drip, or a syringe pump on Day 1 of first cycle then 250 mg/m^2 1-hour IV once a week, i.e. on Days 1, 8, and 15 of each cycle provided the participant meets the re-treatment criteria."
1805931|NCT00633477|Drug|Resatorvid|Resatorvid 1.2 mg/kg emulsion, injection for 30 minutes and resatorvid 2.4 mg/kg per-day emulsion, injection, continuous infusion for 96 hours.
1805932|NCT00633477|Drug|Placebo|Resatorvid placebo-matching emulsion, injection for 30 minutes and resatorvid placebo-matching emulsion, injection, continuous infusion for 96 hours.
1805933|NCT00633490|Drug|apatinib|apatinib is a tablet in the form of 250mg and 100mg and 50mg, orally, daily
1805934|NCT00633516|Device|Optical Spectroscopy|Optical Spectroscopy imaging are Modified Two Layer Diffuse Optical Spectroscopy and multi-spectral imaging and Spatially Modulated Quantitative Spectroscopy
1805935|NCT00633529|Drug|IMO-2055|0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.
1805936|NCT00633542|Drug|thalidomide|100 mg/day orally until progression or severe toxicity
1805937|NCT00633542|Drug|interferon alpha|3 MU 3 times a week until progression or severe toxicity
1805938|NCT00633568|Drug|Concomitant Radiochemotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
1805939|NCT00633568|Drug|Concomitant Chemoradiotherapy - Radiotherapy 66 Gy, Cisplatin, and Docetaxel|Concurrent chemoradiotherapy: Radiotherapy 66 Gy in 2 Gy/fraction, 5 fractions/wk (6.5 weeks)with Cisplatin 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy)and Docetaxel 20 mg/m²/week (6 times, beginning on day 1 of radiotherapy) Chemotherapy : Cisplatin 60 mg/m² and Docetaxel 75 mg/m² on day 1
1805940|NCT00633581|Dietary Supplement|Ascorbic acid (Vitamin C)|Single intravenous injection of vitamin C 10g(20ml) with 100ml of normal saline over 30 minutes
1805941|NCT00633581|Dietary Supplement|Normal saline|Single intravenous injection of 120ml of normal saline over 30 minutes
1805942|NCT00633594|Drug|Rituximab|"DL 1, DL 2, and DL 3: 375 mg/m2 IV Days 1, 8, and 15; Cycles 2-6: 375 mg/m2 IV Day 1
Same for DL-1."
1805943|NCT00633594|Drug|Bortezomib|"DL 1, DL 2, and DL 3: 1.3 mg/m2 IV Days 1, 4, 8, and 11
Same for DL-1."
1805944|NCT00633594|Drug|Lenalidomide|"DL 1: 15 mg PO daily Days 1-14 followed by 7 days of rest
DL 2: 20 mg PO daily Days 1-14 followed by 7 days of rest
DL 3: 25 mg PO daily Days 1-14 followed by 7 days of rest
DL-1: 10 mg PO daily Days 1-14 followed by 7 days of rest"
1805945|NCT00633607|Other|Research Registry|Information regarding medical and family history is stored in the registry to be used for potential future studies
1805946|NCT00633620|Device|Olympus NBI colonoscope 180 HDTV narrow band imaging (diagnostic test)|colonoscopy withdrawal with NBI mode
1805947|NCT00633633|Other|Usual Care|Monthly visits with the cardiology team and a booklet about coping with heart failure.
1805950|NCT00633646|Dietary Supplement|diets contained different levels of protein|diets contain protein in the range of 0.6-0.8 or 1.0-1.2 g/kg/d
1805951|NCT00633659|Drug|Hemospan (MP4OX)|250 mL of Hemospan (MP4OX)
1805952|NCT00633659|Drug|Voluven (HES 130/0.4)|250 mL of Voluven (HES 130/0.4) solution
1805953|NCT00633672|Drug|Esomeprazole|20mg Oral tablet once daily
1805954|NCT00633672|Drug|Ranitidine|150mg oral twice daily
1805955|NCT00633672|Drug|Esomeprazole|40mg oral tablet once daily
1805956|NCT00633685|Drug|Fluoxetine|Fluoxetine will be administered at 20-60 mg daily for 12 weeks in a flexible dosage schedule based upon clinical response
1805957|NCT00633685|Drug|Placebo|Placebo will be empty gelatin capsules that are identical in size and shape to active treatment
1805958|NCT00633698|Drug|Nicotinic acid (niacin)|oral medication Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
1805959|NCT00633698|Drug|Placebo|Placebo Week 1-4: 500 mg per day Week 5-8: 1000 mg per day Week 9-12: 1500 mg per day Week 13-20: 2000 mg per day
1805960|NCT00633711|Device|Automatic (variable, automatically controlled) pressure CPAP|"CPAP at a variable level according to instantaneous patients' needs for treatment of sleep respiratory disorders, as evaluated by machine's software.
Home nocturnal usage. Two-month treatment."
1805961|NCT00633711|Device|fixed continuous positive airway pressure (CPAP)|"CPAP at a constant level, whose efficacy on respiratory disorders has been determined by nocturnal titration.
Home nocturnal usage. Two-month treatment."
1805962|NCT00633724|Biological|HLA-A*2402restricted URLC10, TTK, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 0.5mg, 1.0mg and 3.0mg.
1805963|NCT00633737|Behavioral|Stress reduction intervention|In addition to standard care, patients in the intervention group will receive a one-hour individually delivered programme administered once by a psychologist at least 3 days prior to surgery. This session aims to reduce stress and involves teaching relaxation and guided imagery exercises. Patients are provided a CD (or audiotape)of the relaxation instructions to take home and practice once a day.
1805964|NCT00633750|Drug|erlotinib hydrochloride|Tarceva will be given orally at a dose of 150 mg/day for 5-14 days. Patients are to undergo surgical resection of their tumor within 24 hours of the last dose of Tarceva.
1805965|NCT00633750|Genetic|TUNEL assay|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
1805966|NCT00633750|Genetic|protein expression analysis|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
1805967|NCT00633750|Other|immunohistochemistry staining method|Used to assess drug-induced changes in tumor cell proliferation and cell death in pre-therapy and surgical specimens
1805968|NCT00633750|Other|laboratory biomarker analysis|Used to assess level of expression of genetic markers in pre-therapy and surgical specimens
1805969|NCT00633750|Other|liquid chromatography|Used to determine blood plasma levels of Erlotinib on the day of surgery
1805970|NCT00633750|Other|mass spectrometry|Used to determine blood plasma levels of Erlotinib on the day of surgery
1805971|NCT00633750|Other|matrix-assisted laser desorption ionization mass spectrometry|After treatment and following surgery, intervention will be used to determine Tarceva levels in tissue
1805972|NCT00633750|Procedure|therapeutic conventional surgery|Surgical treatment will occur within 24-hours following completion of therapy.
1805973|NCT00633763|Drug|18F-fallypride|Single bolus i.v. injection 60 minutes before PET-CT scanning. Maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
1805974|NCT00633763|Drug|18F-fallypride|I.v. bolus maximum activity per single administration 5 mCi; maximum amount of drug per administration <10 micrograms.
1805975|NCT00633776|Drug|formoterol fumarate|Nebulized formoterol fumarate 20 mcg one-time treatment; aerosolizer dry powder formoterol fumarate 12 mcg one-time treatment
1805976|NCT00633789|Drug|brivanib|Tablets, Oral, 800 mg, once daily, until progression
1805977|NCT00633789|Drug|Placebo|Tablets, Oral, 0 mg, once daily, until progression
1805978|NCT00633802|Drug|Risperidone|1 mg/d risperidone for 10 weeks or placebo
1805979|NCT00633815|Other|Supine positioning|Subjects underwent exercise testing on a stationary bicycle in the supine position
1805980|NCT00633815|Other|Upright positioning|Subjects underwent exercise testing on a stationary bicycle in the upright position
1805981|NCT00633828|Behavioral|Increased physical education in primary school (daily)|Increased physical education in primary school, 40 minutes per day
1805982|NCT00633841|Biological|AFFITOPE AD02|4 subcutaneous injections of IP in 4-week intervals
1805983|NCT00633854|Procedure|Ultrasound examination|Immersion Ultrasound Exam: In the immersion technique, the patient lies down on the examination table. A steridrape with a central aperture is used to form a water-tight seal around the eye. After installation of 2 drops of 0.5% proparacaine HCl, a wire lid speculum is used to hold the patient's lids open. Warm 0.9% sterile saline solution is then used to create a waterbath about 1/2 inch deep to provide acoustic coupling between the transducer and the eye. The transducer (either the 10- and 20-MHz sector scan probe or the annular array) is placed in the waterbath, but does not touch the eye.
1805984|NCT00633867|Device|McGrath|Tracheal intubation, using Mcgrath video-laryngoscope
1805985|NCT00633867|Device|Tracheal intubation using Macintosh Laryngoscope|Tracheal intubation using Macintosh Laryngoscope
1805986|NCT00633880|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
1805987|NCT00633880|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
1805988|NCT00633893|Drug|Apixaban|Tablets, Oral, twice daily, 12 months
1805989|NCT00633893|Drug|Placebo|Tablets, Oral, twice daily, 12 months
1805990|NCT00633906|Behavioral|HORIZONS HIV Intervention|Two-session, group-based interactive HIV prevention intervention
1805991|NCT00633906|Behavioral|enhanced standard-of-care|1 hour group session consisting of an HIV prevention video, a question and answer session with an African American woman health educator, and participation in a group discussion about how to avoid acquiring HIV.
1805992|NCT00633919|Biological|SLITone(TM) Dermatophagoides mix|Sublingual immunotherapy with SLITone Dermatophagoides mix (200 STU) once daily for 2 years
1805993|NCT00633919|Biological|Placebo|Sublingual immunotherapy once daily for 2 years
1805994|NCT00633919|Drug|Salbutamol inhaler|200 µg per puff; a short acting beta2-agonist (please refer to the 'detailed description' for details on the use)
1805995|NCT00633919|Drug|Budesonide/formoterol inhaler|80/4.5 µg per inhalation; a combination of inhaled corticosteroids and long acting beta2-agonist (please refer to the 'detailed description' for details on the use)
1805996|NCT00633919|Drug|Prednisone tablet|5 mg per tablet; oral corticosteroids (please refer to the 'detailed description' for details on the use)
1805997|NCT00633919|Drug|Desloratadine tablet|5 mg per tablet: anti-histamine (please refer to the 'detailed description' for details on the use)
1805998|NCT00633919|Drug|Budesonide nasal spray|64 µg per puff; inhaled corticosteroid (please refer to the 'detailed description' for details on the use)
1805999|NCT00633932|Drug|Esomeprazole|20mg once daily
1806000|NCT00633932|Drug|Esomeprazole|40 mg once daily
1806001|NCT00633932|Drug|Omeprazole|20mg once daily
1806003|NCT00633958|Other|[18F]-Fluorothymidine|Patients will receive a dose of 18F-FLT through a fresh intravenous catheter as per standard PET procedures. Dosing will be based on age.
1806004|NCT00633971|Other|complex lymphedema therapy|Patients with established post thrombotic syndrome will be randomized to either compression stocking use or complex lymphedema therapy.
1806005|NCT00633984|Behavioral|Cognitive Behavioral Group Therapy (CBGT)|The patient will then receive 12 weekly sessions of Cognitive Behavioral Therapy lasting approximately two and a half hours each. During these sessions, patients will receive information on the nature of social phobia and a model of treatment and will receive weekly training in how to become more comfortable with social situations, with the goal of achieving confidence in social interactions. As part of this training, the therapist will practice social interactions with the patient, who will also be asked to practice what they have learned outside of the therapists' office.
1806006|NCT00633984|Drug|D-Cycloserine|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a 50mg pill of d-cycloserine. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
1806007|NCT00633984|Drug|Placebo|For the third, fourth, fifth, sixth, and seventh sessions of the twelve-session program of Cognitive Behavioral Therapy, the patient will be asked to arrive one hour early to take one of the study pill, a placebo. A physician will be available in the unlikely event that a patient begins to experience side effects. Before the treatment starts, before the eighth session, and one week after the final session patients will have a separate visit in which their levels of symptoms assessed with measures of mood, anxiety, and avoidance.
1806008|NCT00633997|Drug|Vildagliptin|50 mg orally twice daily for 10 days (last dose morning of day 10)
1806009|NCT00633997|Drug|Vildagliptin|
1806010|NCT00634010|Drug|Morphine|15 mg oral every 12 Hours; additional capsules taken every 2 hours as needed.
1806011|NCT00634010|Drug|Methadone|5 mg orally every 12 hours; additional capsules every 2 hours as needed.
1806012|NCT00634036|Drug|pioglitazone|pioglitazone tablets: 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
1806013|NCT00634036|Drug|placebo|matching placebo (inert tablet)
1806014|NCT00634049|Drug|isavuconazole|Administration of 200 mg isavuconazole 3 times a day in the vein (IV) or oral as a capsule for 2 days, followed by daily administration of 200 mg isavuconazole (IV) or oral
1806015|NCT00634062|Drug|Lamotrigine|Subject in active active drug group will receive lamotrigine tablets 12.5 per day for the first week of the study. Dose of lamotrigine can be increased to 25mg per day during the second week of the study and may be increased each week thereafter for the next 9 weeks by 25mg per day. Subjects in active treatment group will receive lamotrigine for total of 12 weeks
1806016|NCT00634062|Drug|Placebo|Subjects will receive 12.5mg of inert placebo per day during the first week of the study. Inert placebo can be increased to 25mg per day during the second week of the study and by 25mg per day each week for the next 9 weeks. Subjects can receive a total of 12 weeks of placebo.
1806017|NCT00634075|Drug|omega-3-fatty acids (Omegaven)|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
1806018|NCT00634075|Drug|placebo|The enrolled patients will be randomized to receive either supplementation of fish oil-based lipid emulsion (10 % Omegaven) as group 1 or placebo (0.9% Normal Saline) as group 2 via a central venous catheter within 24 hours after ICU admission, 100 ml daily for 5 days, respectively.
1806019|NCT00634088|Drug|Ixabepilone, 32 mg/m^2 + Lapatinib, 1000 mg|Lapatinib, 1000 mg, administered orally, once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone (Day 1). Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion. Lapatinib, 1000 mg, administered orally, once a day, every day, for a 21-day cycle.
1806020|NCT00634088|Drug|Ixabepilone, 32 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1000 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 32 mg/m^2, administered as a 3-hour IV infusion. Lapatinib administered, 1250 mg, orally, once a day, every day, for a 21-day cycle.
1806067|NCT00634374|Device|Rx Medibottle|Comparing use of the Rx medibottle to the oral syringe in delivering a one-time dose of prednisolone syrup
1806068|NCT00634387|Dietary Supplement|Anthocyans|Anthocyans
1806021|NCT00634088|Drug|Ixabepilone, 40 mg/m^2 + Lapatinib, 1250 mg|Initiated a minimum of 14 days following Day 1 of previous cohort (ixabepilone, 32 mg/m^2 + lapatinib, 1250 mg). Lapatinib, 1250 mg, administered orally once a day, every day, for 7 to 14 consecutive days as a lead-in period prior to the first administration of ixabepilone. Following the lapatinib lead-in phase of Cycle 1, and on Day 1 of subsequent cycles, ixabepilone, 40 mg/m^2, administered as a 3-hour IV infusion. Lapatinib, 1250 mg, administered orally, once a day, every day, for a 21-day cycle.
1806022|NCT00634088|Drug|Ixabepilone + Lapatinib + Capecitabine|Planned escalating doses of the triplet combination of ixabepilone, lapatinib, and capecitabine. No participants were enrolled in this arm due to premature termination of the study.
1806023|NCT00634101|Device|nelfilcon A|contact lens
1806024|NCT00634101|Device|narafilcon A|contact lens
1806025|NCT00634114|Drug|Esomeprazole|10mg once daily oral administration
1806026|NCT00634114|Drug|Esomeprazole|20mg once daily oral administration
1806027|NCT00634114|Drug|Omeprazole|10mg once daily oral administration
1806028|NCT00634140|Drug|ezetimibe|ezetimibe 10 mg daily for 4 to 6 weeks
1806029|NCT00634140|Drug|Placebo|placebo for 4-6 weeks
1806030|NCT00634153|Other|Research Registry|We are asking for permission to allow us to place subject's past, current and future medical record information into a Surgical Gastrointestinal Disease Registry. By placing the medical record information of many subjects into a research registry, researchers will be able to conduct research studies directed at increasing our knowledge about Gastrointestinal Diseases.
1806031|NCT00634166|Drug|Sulfamylon® For 5 % Topical Solution|Sulfamylon® For 5% Topical Solution is indicated for use as an adjunctive topical antimicrobial agent to control bacterial infection when used under moist dressings over meshed autografts on excised burn wounds.
1806032|NCT00634166|Drug|Topical Antimicrobial/Antifungal Medications|Various topical antimicrobials and antifungals.
1806033|NCT00634179|Drug|Bortezomib|Bortezomib 1.6 mg/m² given on days 1 and 8
1806034|NCT00634179|Biological|Rituximab|Rituximab 375 mg/m²
1806035|NCT00634179|Drug|Doxorubicin|Doxorubicin 50 mg/m²
1806036|NCT00634179|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m²
1806037|NCT00634179|Drug|Vincristine|Vincristine 1.4 mg/m² (capped at 1.5 mg maximum) given on day 1
1806038|NCT00634179|Drug|Prednisone|Prednisone 100 mg/day given orally on days 1-5
1806039|NCT00634192|Drug|tobramycin|1x300mg/d inhaled
1806040|NCT00634192|Drug|tobramycin|2x300mg/d inhaled
1806041|NCT00634205|Drug|Valproate plus doxorubicin|Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
1806042|NCT00634218|Behavioral|Mail-based Self-help plus Internet-based Smoking Treatment|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants.
1806043|NCT00634218|Behavioral|Self-Help Manual plus Telephone counseling|Participants will receive a self-help manual specifically developed for LGBT smokers plus 6 telephone-based counseling sessions. The counseling sessions focus on the development of a personalized plan to quit smoking and occur over a 3 month period.
1806044|NCT00634218|Behavioral|Self-Help Manual|Participants will receive a self-help smoking cessation manual specifically developed for LGBT smokers. The manual provides information on quitting smoking and encourages the development of a personalized quit plan through various activities and exercises.
1806045|NCT00634218|Behavioral|Self-Help Manual plus Internet-based Intervention plus Telephone Counseling|Participants in this condition will received a self-help manual developed specifically for LGBT smokers and access to an Internet-based smoking cessation treatment program. The website provides education and information about smoking cessation alond with development of a personalized quit plan. Participants have access to a message board where they can contact other participants. Smokers will also receive 6 telephone-based counseling sessions which occur over a 3 month period
1806046|NCT00634231|Biological|AdV-tk|
1806047|NCT00634231|Drug|valacyclovir|
1806048|NCT00634231|Radiation|Radiation|
1806049|NCT00634244|Drug|alvocidib|Given IV
1806050|NCT00634244|Drug|mitoxantrone hydrochloride|Given IV
1806051|NCT00634244|Drug|carboplatin|Given IV
1806052|NCT00634244|Drug|cytarabine|Given IV
1806053|NCT00634244|Drug|sirolimus|Given PO
1806054|NCT00634244|Drug|etoposide|Given IV
1806055|NCT00634244|Drug|topotecan hydrochloride|Given IV
1806056|NCT00634257|Behavioral|Questionnaires|Nine questionnaires taking about 40 minutes to complete.
1806057|NCT00634270|Drug|Sirolimus|This phase II study will evaluate children and adults with neurofibromatosis type-1 (NF1) and plexiform neurofibromas treated with sirolimus. It is divided in two strata. The first stratum will evaluate time to progression (TTP) in children and adults with NF1 and progressive plexiform neurofibromas with the potential to cause significant morbidity treated with sirolimus. The second stratum will evaluate objective radiographic response to sirolimus in children and adults with NF1 and inoperable plexiform neurofibromas with the potential to cause significant morbidity that do not have documented progression of the PN at time of trial entry.
1806059|NCT00634296|Other|Inspiratory muscle added by aerobic to aerobic alone|Inspiratory muscle added by aerobic to aerobic alone
1806060|NCT00634309|Drug|Candesartan|
1806061|NCT00634309|Drug|Placebo|
1806062|NCT00634322|Drug|glucarpidase|IV dose based on weight, two doses given for 5 minutes, 24 hours apart
1806063|NCT00634322|Drug|leucovorin|IV or po given every 6 hours
1806064|NCT00634348|Drug|Aripiprazole|Oral aripiprazole capsules 15 mg once daily from Days 1-14; thereafter, doses could be adjusted on Days 14 and 21 to 10, 15, or 30 mg once daily; patients treated for 28 days
1806065|NCT00634348|Drug|Ziprasidone|Oral ziprasidone capsules 40 mg twice daily on Day 1, 60 mg twice daily on Day 2, 80 mg twice daily on Days 3-14; thereafter, doses could be adjusted on Days 14 and 21 to 40, 60, or 80 mg twice daily; patients treated for 28 days
1806066|NCT00634361|Drug|ethyl-eicosapentaenoic acid|2 mg per day
1806069|NCT00634387|Other|placebo|
1806073|NCT00634413|Drug|Theophylline - ADC4022|Inhaled theophylline (ADC4022) administered twice daily for 28 days
1806074|NCT00634413|Drug|Placebo|Inhaled matching placebo administered twice daily for 28 days
1806075|NCT00634413|Drug|Budesonide|Inhaled budesonide twice daily for 28 days
1806076|NCT00634426|Procedure|Surgical excision of the metastatic process|Surgical excision of the metastatic process
1806077|NCT00634426|Radiation|Radiotherapy of the metastatic spine process|Standard of care radiotherapy for patients with metastatic epidural spinal cord compression.
1806078|NCT00634439|Drug|atomoxetine|
1806079|NCT00634439|Drug|Stimulants|Methylphenidate, amphetamines (including Adderall and mixed salts)
1806080|NCT00634439|Other|No intervention (general population)|
1806081|NCT00634452|Biological|MDX-1401|IV weekly for 4 weeks
1806082|NCT00634465|Device|RSA Beads|Radiostereometric Analysis, or RSA, is an accurate in vivo measurement technique using two simultaneous radiographs. It provides researchers with three dimensional motion analyses to look not only at routine flexion/extension, but also other rotational and translational changes
1806083|NCT00634478|Radiation|Pre-lemniscal Radiation Deep Brain Stimulation|
1806084|NCT00634491|Drug|sodium bicarbonate|150 meq/l Sodium bicarbonate 3cc/kg/hr before and 1cc/kg/hr after angiography
1806085|NCT00634491|Drug|Acetazolamide|Acetazolamide 250 mg+ 1 cc/kg/hr normal salin before and after angiography
1806086|NCT00634491|Drug|normal salin|1 cc/kg/hr 6 hour before and after angiography
1806087|NCT00634504|Drug|glucarpidase, high-dose methotrexate, leucovorin|single intravenous dose
1806088|NCT00634504|Drug|high-dose methotrexate, leucovorin|standard of care, leucovorin every 6 hours
1806089|NCT00634517|Drug|Armstrong Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
1806090|NCT00634517|Drug|Albuterol Sulfate Inhalation Aerosol|Albuterol Sulfate Inhalation Aerosol, 216 mcg albuterol sulfate (108 mcg/actuation) is equivalent to 180 mcg albuterol base (90 mcg/actuation).
1806091|NCT00634530|Behavioral|Dietary Advice|The specific dietary advices according to nutritional status. Main advices: reduction of fat and sugar intake, increase of total energy, dairy intake of vegetables and fruits.
1806092|NCT00634543|Drug|Tramadol hydrochloride/ Acetaminophen|Participants will receive 1 tablet containing tramadol HCl 37.5 milligram (mg) and acetaminophen 325 mg once daily, at bed time on Days 1 to 3,. 1 tablet twice daily on Days 4 to 7 and 1 tablet thrice daily on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 8 tablets per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
1806093|NCT00634543|Drug|Gabapentin|Participants will receive Gabapentin 300 mg once daily at bed time on Day 1, 300 mg twice daily on Day 2 and 300 mg thrice daily on Day 3. Gabapentin 300 mg will be administered twice daily (in the morning and midday) and gabapentin 600 mg in the evening on Day 8 to 14. If there is no pain relief, the dosage can be increased up to 3600 mg per day for Days 15 to 28. The increased dose will be maintained for Days 29 to 42.
1806094|NCT00634556|Drug|levodopa solution 2mg/ml for i.v. use|2mg/mL in normal saline
1806095|NCT00634556|Drug|placebo|normal saline
1806096|NCT00634569|Biological|Flebogamma 5% DIF|Intravenous Immune Globulin (Human)
1806097|NCT00634582|Drug|paricalcitol|
1806098|NCT00634582|Other|immunoenzyme technique|
1806099|NCT00634582|Other|laboratory biomarker analysis|
1806100|NCT00634582|Procedure|dual x-ray absorptometry|
1806101|NCT00634582|Procedure|quality-of-life assessment|
1806102|NCT00634595|Drug|E10A|E10A 1*10(12)VP, intratumoral injection, d1 d8, repeat every 3 weeks for 4 cycles
1806103|NCT00634595|Drug|Cisplatin|25 mg/m2/d ivd d3 d4 d5, repeat every 3 weeks for 4 cycles.
1806104|NCT00634595|Drug|Paclitaxel|160 mg/m2 ivd d3, repeat every 3 weeks for 4 cycles.
1806105|NCT00634608|Other|Health Information Prescription|The patient education materials will consist of approximately 21 topics representing some of the most common conditions seen at the Fairview Internal Medicine Clinic. Twenty-one e-mails, one per topic, will be created by Fairview physicians to be distributed to selected clinic patients. There will be a standard e-mail for each condition with a specific link to MedlinePlus. To create the targeted health information topic email, the physician will review the information available at MedlinePlus. The physician will then select several links of appropriate information and, using the template, will write a short annotation on each link.
1806106|NCT00634621|Drug|Hexaminolevulinate (Hexvix)|Each patient enrolled into the study will be infused with 50 mL of a 2 mg/mL Hexvix solution in the bladder using a catheter. Subsequently, after fluid retention by the patient in the bladder for one hour, the bladder will be emptied.
1806107|NCT00634634|Drug|Sorafenib|sorafenib dose will be given at a daily dose to be determined based upon the phase of study that patient is enrolled The phase II dose of sorafenib will be determined from the phase I portion of the study.
1806108|NCT00634634|Drug|Letrozole|Patients will take letrozole orally at a daily dose of 2.5 mg/day on Days 1 through 28
1806109|NCT00634647|Drug|Satraplatin|80 mg/m^2 days 1-5 of every 35 day cycle
1806110|NCT00634647|Drug|prednisone|5 mg twice daily every 35 days
1806111|NCT00634660|Drug|rAvPAL-PEG|rAvPAL-PEG will be administered as a single, SC injection at dose levels of 0.001, 0.003, 0.01, 0.03, 0.1, 0.3, and 1.0 mg/kg. The duration of treatment is a single dose of study drug with 42 days (6 weeks) of follow-up.
1806112|NCT00634673|Other|sandwich|standard meal:sandwich (7.23 kcal/kg-total energy; 43.35% fat, 21.95% protein, and 34.70% carbohydrate)
1806113|NCT00634686|Dietary Supplement|DHA/EPA|1.2 gram capsule daily for 6 months
1806114|NCT00634686|Dietary Supplement|Placebo capsule|daily for 6 months
1806115|NCT00634686|Dietary Supplement|Calcium with vitamin D|1000 mg of calcium with 1000 IU vitamin D daily for 6 months
1806116|NCT00634699|Procedure|Active Comparator, ischemic compressions|Ischemic Compressions,3 times a week,5 weeks.
1806117|NCT00634712|Drug|Candesartan|
1806118|NCT00634712|Drug|Placebo|
1806119|NCT00634725|Drug|capecitabine|
1806120|NCT00634725|Drug|erlotinib hydrochloride|
1806121|NCT00634725|Drug|gemcitabine hydrochloride|
1806122|NCT00634725|Other|laboratory biomarker analysis|
1806123|NCT00634725|Radiation|radiation therapy|
1806124|NCT00634738|Procedure|Ischemic Compression (thumb Pressure)|Pressure, one thumb on the other, applied on the trigger points
1806125|NCT00634751|Drug|Oxaliplatin|On days 1 and 15 of each 28 day treatment cycle, patients receive oxaliplatin 85 mg/m2 as a 2-hour IV infusion. Following the infusion of oxaliplatin, the infusion line should be flushed with Dextrose 5% in Water.
1806126|NCT00634751|Drug|Capecitabine|Each course of oral capecitabine administration will commence following administration of oxaliplatin. Capecitabine 2250 mg/m2 will be given every 8 hours for a total of 6 doses as above, commencing with each cycle of therapy. Because capecitabine is provided in fixed dose forms, rounding will be necessary. Rounding will be to the nearest 150 mg on a per dose basis.
1806127|NCT00634751|Drug|Sorafenib|"Cohort 1 will receive 200 mg of sorafenib orally twice daily, cohort 2 will receive 400 mg orally twice daily, both beginning on the first day of the first cycle (see section 9.1). If needed, cohort -1 will be used, at 200 mg of sorafenib once daily. Sorafenib should be taken without food (at least 1 hour before or 2 hours after eating).
Cohort I (Dose escalation phase) Agent Dose Route Day Cycle length
Sorafenib 200 mg BID Oral Daily Every 28 days
If 1/3 patients develop a DLT, enroll 3 patients at dose level -1 Sorafenib 200 mg po qd.
Cohort II (Phase II studies at MTD) Agent Dose Route Day Cycle length
Sorafenib 400 mg BID Oral Daily Every 28 days"
1806128|NCT00634777|Other|pet scan|pet scan
1806129|NCT00634790|Drug|alprazolam XR|Alprazolam XR oral tablet 1 mg daily for 7 days; thereafter the daily dose will be titrated at a maximum rate of 1 mg every 7 days up to a maximum dose of 6 mg; dose adjustments up or down may be made, at a rate not to exceed 1 mg every 7 days; alprazolam XR will be administered for a total of 6 months followed by a gradual taper at a rate of 1 mg every 7 days.
1806130|NCT00634803|Behavioral|CBT|Cognitive behavioral therapy
1806131|NCT00634803|Drug|Buprenorphine|buprenorphine/naloxone
1806132|NCT00634803|Other|Educational Counseling|Didactic, lecture-discussion format to supplement information and advice provided by physicians
1806133|NCT00634803|Other|Physician Management|Brief physician counseling
1806134|NCT00634816|Radiation|DXA Scan|The patients will undergo total body, spine, proximal femoral, and forearm DEXA testing in a standardized fashion. Patients who have undergone limb surgery or irradiation to an extremity for local disease control will also undergo selected site DEXA or pQCT scanning, depending upon the site, of the affected extremity and the identical site on the contra-lateral extremity.
1806135|NCT00634829|Drug|albuterol (Armstrong Albuterol HFA)|2 inhalations of 108 mcg albuterol sulfate prior to exercise, single dose
1806136|NCT00634829|Drug|Albuterol Sulfate (Provenetil-HFA)|2 inhalations of Proventil-HFA, 108 mcg/inhalation prior to exercise
1806137|NCT00634829|Drug|Placebo-HFA|Placebo containing HFA propellant without active drug substance
1806138|NCT00625053|Procedure|Laparoscopic repair|Complete adhesiolysis between viscera and abdominal wall, complete dissection of round ligament and subumbilical fatty tissue to expose the posterior fascia at least 5 cm further than the cranial and caudal limits of the fascial defect or the original incision. Overlap of minimum 5 cm is calculated and mesh inserted in the abdominal cavity through 12mm optical trocar. Fixation of a antiadhesive composite mesh with helicoidal pins with maximum 15mm interval, double crown technique. No pressure decrease maneuver is done during mesh fixation or at another time during the operation. No transparietal suture fixation. No fascial closure.
1806139|NCT00625053|Procedure|Open midline incisional hernia repair|"Underlay retromuscular repair: Medial border of the anterior fascia opened, posterior aspect of rectus muscle dissected to reach lateral border of rectus sheet, bilaterally. Peritoneum and posterior rectus fascia closed with absorbable running suture. Polyester or light-weight polypropylene mesh is cut to fit the reconstructed area, to have 3cm overlap on caudal and cranial defect limits. Mesh is fixed by absorbable sutures. Anterior fascia is closed with absorbable running suture. Components separation upon need.
Intraperitoneal onlay repair: Mesh is inserted intraperitoneally and fixed by a complete running suture (optional fixation with helicoidal pins or stapler). Fascial defect is closed with interrupted or running absorbable suture. Components separation upon need."
1806148|NCT00625079|Drug|sildenafil|sildenafil 20mg three times per day (orally)
1806149|NCT00625079|Drug|sildenafil|sildenafil (placebo) 20mg three times per day (orally)
1806150|NCT00625092|Drug|fluorouracil|Post-operative day 1 and day 2, 600mg/m^2 intraperitoneal (IP) held for 23 hours
1806151|NCT00625092|Drug|leucovorin calcium|Day 0 200 mg/m^2 intraperitoneal held for 2 hours
1806152|NCT00625092|Drug|oxaliplatin|Day 0 hyperthermic intraperitoneal oxaliplatin held for 30 minutes - assigned dose level: Levels 1 through 7 - 300 to 600 mg/m^2
1806153|NCT00625092|Procedure|cytoreductive surgery|Day 0 Cytoreductive surgery is a systematic attempt to remove all or nearly all peritoneal nodules.
1806154|NCT00625105|Behavioral|Biofeedback|
1806155|NCT00625131|Drug|Nicotine|Delivered through transdermal nicotine patch
1806156|NCT00625131|Behavioral|Cognitive Behavioral Therapy for Smoking Cessation|Manualized protocol for CBT in smoking cessation
1806157|NCT00625131|Drug|Bupropion Sustained Release (SR)|Antidepressant
1806158|NCT00625131|Drug|Placebo patch|Pre-treatment placebo transdermal patch
1806159|NCT00625157|Drug|ASF 1096 0.5 % cream|
1806160|NCT00625157|Drug|ASF 1096 placebo cream|
1806161|NCT00625170|Drug|olanzapine|olanzapine 10 mg/day for 8 days
1806162|NCT00625170|Drug|Haloperidol|haloperidol 3 mg/day for 8 days
1806163|NCT00625183|Dietary Supplement|selenomethionine|
1806164|NCT00625183|Drug|capecitabine|
1806165|NCT00625183|Drug|oxaliplatin|
1806166|NCT00625183|Other|laboratory biomarker analysis|
1806167|NCT00625183|Other|pharmacological study|
1806168|NCT00625183|Procedure|adjuvant therapy|
1806169|NCT00625183|Procedure|neoadjuvant therapy|
1806170|NCT00625183|Procedure|therapeutic conventional surgery|
1806172|NCT00625196|Drug|Fluticasone foroate/ vilanterol|Fluticasone foroate/ vilanterol 800 micrograms/ 50 micrograms will be available as dry powder inhaler.
1806173|NCT00625196|Drug|Fluticasone foroate|Fluticasone foroate 800 micrograms will be available as dry powder inhaler.
1806174|NCT00625196|Drug|Vilanterol|Vilanterol will be available as dry powder inhaler.
1806175|NCT00625196|Drug|Placebo|Placebo will be supplied as dry powder inhaler.
1806176|NCT00625209|Drug|placebos|placebo of hydrocortisone as an iv bolus every 6 hours for seven days plus placebo of fludrocortisone given through the nasogastric tube once a day for seven days plus placebo of activated protein C given as a continuous infusion for 96 hours
1806177|NCT00625209|Drug|hydrocortisone and fludrocortisone and placebo|hydrocortisone will be given as 50mg iv bolus every 6 hours for seven days and a tablet of 50µg of fludrocortisone will be given once a day via the nasogastric tube for seven days and a placebo of activated protein C will be given as a continuous infusion for 96 hours
1806178|NCT00625209|Drug|recombinant human activated protein C and placebos|activated protein C will be given as a continuous infusion at a dose of 24 µg/kg/h four 96 hours and hydrocortisone placebo as an iv bolus every 6 hours and fludrocortisone placebo once a day through the gastric tube will be given for seven days
1806179|NCT00625209|Drug|recombinant human activated protein C and hydrocortisone and fludrocortisone|96 hours continuous infusion of 24µg/kg/h of activated protein C plus seven day treatment with 50mg iv bolus of hydrocortisone every 6 hours and 50µg of fludrocortisone via the nasogastric tube once a day
1806180|NCT00625222|Procedure|transcranial direct current stimulation|1mA, 15 Minutes, constant direct current
1806181|NCT00625235|Dietary Supplement|VLED followed by a high protein or high carbohydrate diet|
1806182|NCT00625248|Drug|Antithrombotics|With or without or discontinuted use of Antithrombotics
1806183|NCT00625261|Other|Heidelberg Parent-based Language Intervention HPLI|The HPLI is a group program for parents of young children with language delay. This 12-14week program includes seven two-our sessions and one three-our session six months later. It is designed for 5 to 10 people and based of an interactive model of language intervention, wich presumes that optimized parental input will provide better language-learning opportunities.
1806184|NCT00625274|Drug|Esomeprazole|40mg Oral
1806185|NCT00625274|Drug|Lansoprazole|30mg Oral
1806186|NCT00625274|Drug|Pantoprazole|40mg Oral
1806187|NCT00625300|Device|repetitive transcranial stimulation (r-TMS)|Each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of 20Hz stimulation trains (active) over the motor cortex and the prefrontal cortex.
1806188|NCT00625300|Device|Repetitive transcranial stimulation|Sham treatment group: each patient will be given 3 treatment sessions per week for 4 weeks (a total of 12 sessions). Each session is 20 minutes long and will be consisted of sham stimulation trains over the motor cortex and the prefrontal cortex.
1806189|NCT00625313|Device|HMY Model YA-60BB IOL|Following phacoemulsification cataract extraction, insertion of a Hoya HMY posterior chamber intraocular lens will be performed.
1806190|NCT00625326|Drug|COL-121|75 µg/g COL-121 Ointment
1806191|NCT00625326|Drug|50 µg/g Calcipotriene Ointment|50 µg/g Calcipotriene Ointment
1806192|NCT00625326|Drug|Placebo|Placebo
1806193|NCT00625326|Drug|COL-121|150 µg/g COL-121 Ointment
1806194|NCT00625326|Drug|COL-121|300 µg/g COL-121 Ointment
1806195|NCT00625339|Drug|Entecavir|entecavir 0.5 mg QD
1806196|NCT00625339|Drug|Lamivudine|lamivudine 100 mg QD
1806198|NCT00625365|Drug|DEFINITY®|DEFINITY may be injected by either an intravenous or bolus injection or infusion. Dosage as per standard clinical practice and Package Insert
1806200|NCT00625391|Drug|Placebo|500 mg medicinal starch pills daily
1806201|NCT00625391|Drug|Green Tea Polyphenols (GTP)|500 mg green tea polyphenols daily
1806202|NCT00625391|Drug|Placebo+Tai Chi (TC)|500 mg medicinal starch daily and Tai Chi (3x/week) for 24 weeks
1806203|NCT00625391|Drug|GTP+TC|500 mg GTP daily plus TC exercise (3x/week) for 24 weeks
1806206|NCT00625417|Procedure|breast biopsy|
1806207|NCT00625417|Procedure|histopathologic examination|
1806208|NCT00625417|Procedure|light-scattering spectroscopy|
1806209|NCT00625417|Procedure|therapeutic conventional surgery|
1806210|NCT00625430|Biological|Gene Directed Enzyme Prodrug Therapy, FP253/Fludarabine|"Subjects within a treatment group will be administered a single transrectal intraprostatic injection of FP253.
Group A: 1 x 10Exp9 virus particles (VP); Group B: 3.2 x 10Exp9 VP; Group C: 1 x 10Exp10 VP; Group D: 3.2 x 10Exp10 VP; Group E: 1 x 10Exp11 VP; Group F: 3.2 x 10Exp 11 VP.
If there are no dose-limiting toxicities, three additional patients may be treated at the highest dose.
Twenty four hours following administration of the FP253, subjects will receive a first dose of fludarabine phosphate (20mg/m2 administered as an intravenous bolus). The first dose of fludarabine phosphate will be followed by 4 further doses at 24 hour intervals on treatment Days 3 to 6."
1806211|NCT00625443|Drug|Blinded (placebo)|"Placebo Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)
Duration - 6 months"
1806212|NCT00625443|Drug|Open Label (AKR-501 tablets)|"Dose 10 mg
Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)
Duration - 6 months"
1806213|NCT00625443|Drug|Blinded (AKR-501 tablets)|"Dose: 2.5, 5, 10, or 20 mg
Orally, once daily administered under fasting conditions (at least 1 hr prior to or at least 2 hours after a meal or snack)
Duration - 6 months"
1806727|NCT00636987|Device|Biocor and Biocor Supra valves|Replacement for a diseased, damaged, malformed aortic or mitral heart valve
1806214|NCT00625456|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intravenous Dosage from 1 x 10^5 pfu/kg to 3 x 10^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
1806215|NCT00625469|Drug|bosentan|62.5mg orally bid for first month, followed by 125mg bid thereafter
1806216|NCT00625469|Other|No specific intervention|No specific intervention
1806217|NCT00625469|Other|No specific intervention|No specific intervention
1806218|NCT00625482|Biological|OPV|
1806219|NCT00625482|Biological|OPV plus BCG|
1806220|NCT00625482|Biological|OPV|
1806221|NCT00625482|Biological|OPV plus BCG|
1806222|NCT00625495|Drug|Esomeprazole|40mg Intravenous infusion over 3 minutes
1806223|NCT00625495|Drug|Esomeprazole|40mg Oral
1806224|NCT00625521|Drug|ASF 1096 0.5 % cream applied twice daily|
1806225|NCT00625521|Drug|Cream vehicle for ASF 1096 cream applied twice daily|
1806226|NCT00625534|Procedure|Laparoscopic totally extraperitoneal inguinal hernia repair|3 trocars procedure. Blunt camera dissection without use of balloon dissector. Anatomical, preformed, polyester mesh passed around spermatic cord structures. No fixation of mesh.
1806227|NCT00625534|Procedure|Open tension free inguinal hernia mesh repair|Classical Lichtenstein repair. Polyester flat 14x8cm mesh
1806228|NCT00625547|Drug|cabergoline|Cabergoline oral tablets: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 3 mg daily if patient experienced insufficient efficacy without impairing adverse events
1806229|NCT00625547|Drug|levodopa|Levodopa oral capsules: 25 mg twice daily on Days 1 to 3, 50 mg twice daily on Days 4 to 7, 100 mg twice daily on Days 8 to 14 and then administered as a stable dose for a further 4 weeks; at Week 6, dose could be increased to 150 mg twice daily if patient experienced insufficient efficacy without impairing adverse events
1806230|NCT00625560|Drug|Entecavir|entecavir 1.0 mg QD
1806231|NCT00625560|Drug|Lamivudine|lamivudine 100 mg QD
1806233|NCT00625586|Biological|RAV12 plus gemcitabine|"Initial dose of gemcitabine plus RAV12 at 0.375 mg/kg qw escalated to 0.75 mg/kg qw.
During the efficacy segment, 63 pts were to be treated with gemcitabine 1000 mg/m2 iv over 30 min., weekly days 1, 8, 15, 22 of the first cycle and 1000 mg/m2 iv over 30 min., weekly days 1, 8, and 15 of each subsequent cycle of 28 days plus RAV12 at Maximum Tolerated Dose (MTD) iv days 1; 4 or 5; 8, 11 or 12; and 15, 18 or 19 of each 28-day cycle until progression."
1806234|NCT00625599|Other|Osteoporosis Prevention Information|Primary investigator designed osteoporosis prevention information.
1806235|NCT00625612|Drug|Denufosol Tetrasodium (INS37217) Inhalation Solution|Drug: Denufosol Tetrasodium (INS37217) Inhalation Solution, Denufosol 60 mg is administered as an inhalation solution, three times daily for twelve months.
1806236|NCT00625612|Drug|Placebo|Placebo - 0.9% w/v sodium chloride solution, three times daily for twelve months.
1806237|NCT00625625|Drug|isosulfan blue|
1806238|NCT00625625|Genetic|polymerase chain reaction|
1806239|NCT00625625|Other|diagnostic laboratory biomarker analysis|
1806240|NCT00625625|Other|immunohistochemistry staining method|
1806241|NCT00625625|Procedure|diagnostic lymphadenectomy|
1806242|NCT00625625|Procedure|therapeutic conventional surgery|
1806243|NCT00625625|Procedure|therapeutic lymphadenectomy|
1806244|NCT00625638|Behavioral|Interactive Voice Response System|Phone calls made once daily, each taking about 3-5 minutes to complete.
1806245|NCT00625638|Other|Standard Care|Participants will return with the caregiver on day 15 to complete a questionnaire lasting 30 minutes.
1806246|NCT00625651|Drug|Placebo|Inactive dummy AMG 655 (to maintain blind)
1806247|NCT00625651|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
1806248|NCT00625651|Drug|Modified FOLFOX6|Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)] administered by intravenous infusion once every 14 days (+3 days)
1806249|NCT00625651|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 5 mg/kg by intravenous infusion on day 1 of each 14 day cycle (+3 days).
1806250|NCT00625664|Drug|larotaxel (XRP9881)|administered on day 1 as a 1-hour infusion
1806251|NCT00625664|Drug|gemcitabine|administered on day 1, 8 and 15 as a 30-minute infusion
1806252|NCT00625664|Drug|cisplatin|1 hour infusion administered on day 1, 30 minutes after the other treatment
1806253|NCT00625677|Biological|NeisVacC (Meningococcal C conjugate vaccine)|Dosage
1806254|NCT00625677|Biological|Menjugate (Meningococcal C conjugate vaccine)|Dosage
1806255|NCT00625690|Other|questionnaire administration|Subjects will be asked to complete an additional detailed questionnaire regarding personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members.
1806256|NCT00625690|Procedure|computed tomography|The baseline and repeat screening CT scans will be performed with a multi-slice helical CT scanner (8 or more rows), at a low-dose setting (120kVp, 40-80mA, slice thickness of 1.25 mm or less). In a single breath-hold, contiguous slices from the thoracic inlet to the adrenal glands will be obtained. Contrast material will not be used. Multi-slice scanners will be used because they provide higher-resolution images. Diagnostic studies, including HRCT will be performed with a multi-slice helical CT at diagnostic settings (120kVp, 140-300mA, slice thickness of 1.25 or less) with the nodule retrospectively reconstructed at a 15cm field of view.
1806257|NCT00625690|Procedure|evaluation of cancer risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
1806358|NCT00626301|Drug|LPV/r|LPV/r 230/57.5 mg/m2 orally q12h or the adjusted dose based on therapeutic drug monitoring of LPV/r prior to enrollment as maintenance monotherapy
1806359|NCT00626314|Biological|myoblast|autologous myoblast
1806258|NCT00625690|Procedure|study of high risk factors|When the CT scan at baseline does not lead to the diagnosis of malignancy, repeat screening will be scheduled 12 months later. If the initial scan led to further evaluation, the repeat scan will be performed 12 months after the most recent scan. The subjects will be allowed to add relevant health information to their record in the web-based database as it develops. Similarly, when in the first repeat screening malignancy is not diagnosed; the second repeat screening will be scheduled 12 months later for a total period of 5 years.
1806259|NCT00625703|Drug|Linezolid|"Pharmacokinetics
daily dose of linezolid at 15 mg/kg/dose Intravenously (IV) based on subject's weight at study entry, over half an hour period, every 8 hours for a minimum of 7 days to a maximum of 28 days total. The primary doctor may change the route of administration of linezolid from IV to oral (by mouth)after 72 hours on IV formulation and demonstrated clinical improvement based on the clinical evaluation by the primary doctor and comparison of cystic fibrosis exacerbation criteria scores before and after initiating treatment with linezolid."
1806260|NCT00625729|Biological|aldesleukin|Day 0-14, 10 million international units, 3 times per week for 6 doses
1806261|NCT00625729|Biological|allogeneic natural killer cells|Day 0 infusion of cells (1.5-8 x 10^7 cells/kg).
1806262|NCT00625729|Biological|rituximab|Administered Day -8, day -1, day +6 and day +13, intravenously (IV) 357 mg/m^2
1806263|NCT00625729|Drug|cyclophosphamide|60 mg/kg intravenous (IV) on Day -5.
1806264|NCT00625729|Drug|fludarabine phosphate|Day -6 through day -2, 25 mg/m^2 intravenous (IV)
1806265|NCT00625742|Behavioral|Graded Resistance Training|Resistance training sessions twice weekly using Thera-bands.
1806266|NCT00625742|Behavioral|Aerobic Exercise|Walking or running for 3-4 minutes at 70-80% of your maximum predicted heart rate.
1806267|NCT00625742|Drug|Melatonin|20 mg by mouth (PO) Daily
1806268|NCT00625742|Dietary Supplement|Juven|90 calories of Juven, twice a day.
1806269|NCT00625742|Drug|Atenolol|Atenolol will only be taken if there's evidence of increased sympathetic activity (resting heart rate >110 beats/min) or resting energy expenditure (REE) > 110% of predicted.
1806270|NCT00625742|Drug|Ibuprofen|Ibuprofen 1200mg/day in three divided doses.
1806271|NCT00625755|Biological|Electrofusion DC vaccine|To assess the safety and efficacy of vaccinations
1806272|NCT00625768|Drug|AS1409|Study drug
1806273|NCT00625781|Drug|Insulin aspart and Insulin human (isophane)|Insulin treatment if fasting p-glucose >5.0 mmol/l or post meal value >6.5 mmol/l according to study protocol.
1806274|NCT00625794|Drug|Nicotine nasal spray|8 weeks or counseling plus 6 weeks of nicotine nasal spray (2 sprays each nostril as needed).
1806275|NCT00625794|Behavioral|Smoking cessation counseling|8 weeks or counseling
1806276|NCT00625807|Behavioral|RR|A well-validated 8 week stress reduction course. Classes meet once a week from 5-8:30 PM. Participants will be asked to perform stress reduction techniques each night for 25 minutes throughout the entire 8-week course
1806277|NCT00625807|Behavioral|MBSR|A well-validated 8 week stress reduction course. Classes meet once a week from 5-8:30 PM. Participants will be asked to perform stress reduction techniques each night for 25 minutes throughout the entire 8-week course
1806278|NCT00625820|Drug|6R BH4|400 mg 6R BH4 oral BID for 6 weeks then 400 mg of 6R BH4 for another 6 weeks in all arms
1806279|NCT00625820|Dietary Supplement|Vitamin C|500 mg Vitamin C oral BID for another 6 weeks
1806280|NCT00625833|Drug|Placebo|Oral tablet once a day dosing for 10 weeks.
1806281|NCT00625833|Drug|[S,S]-Reboxetine|Oral tablet once a day dosing for 10 weeks.
1806284|NCT00625859|Drug|GSK189075|GSK189075 will be available as film-coated tablets with a dose of 250 milligrams.
1806285|NCT00625859|Drug|Bupropion|Bupropion will be available as sustained release film-coated tablets with a dose of 150 milligrams administered orally.
1806286|NCT00625859|Drug|Placebo|Placebo tablets will be given to subjects.
1806287|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
1806288|NCT00625872|Drug|Somatropin|Patients will be randomized at baseline in a 1:1 ratio into treatment group or control group. After six months the control group will undergo GH therapy with a higher dose of 0.067 mg/kg/day, too. All patients are treated with growth hormone for 12 months.
1806289|NCT00625898|Drug|Docetaxel|"75 mg/m2 IV on day 1 every 3 weeks for cycles 1-6, Arms 1A and 1B
100 mg/m2 on day 1 every 3 weeks for cycles 1-3, Arms 2A and 2B"
1806290|NCT00625898|Drug|Trastuzumab|"First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-6. Following completion of chemotherapy cycles: 6 mg/kg IV every 3 weeks until 1 year following first trastuzumab dose. Arms 1A and 1B
First dose: 8 mg/kg IV on day 1 of cycle 1 only. Subsequent doses: 6 mg/kg IV on day 1 every 3 weeks for cycles 2-3. 21 days after last dose of FEC: 8 mg/kg IV first post-FEC dose only; subsequent doses 6 mg/kg IV every 3 weeks for a total of 1 year. Arms 2A and 2B"
1806291|NCT00625898|Drug|Carboplatin|6 mg/ml/min IV on day 1 every 3 weeks for cycles 1-6
1806292|NCT00625898|Drug|Bevacizumab|"15 mg/kg IV on day 1 every 3 weeks for cycles 1-6. Following completion of chemotherapy cycles: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 1B
15 mg/kg IV on day 1 every 3 weeks for cycles 1-3. 21 days after the last dose of FEC: 15 mg/kg IV on day 1 every 3 weeks until 1 year following first bevacizumab dose. Arm 2B"
1806293|NCT00625898|Drug|5-Fluorouracil|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
1806294|NCT00625898|Drug|Epirubicin|90 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
1806295|NCT00625898|Drug|Cyclophosphamide|600 mg/m2 IV on day 1 every 3 weeks for cycles 4-6
1806296|NCT00625911|Drug|morphine|intravenous patient controlled analgesia, standard protocol
1806297|NCT00625911|Drug|morphine ketamine|low dose ketamine added to 2/3 standard dose of morphine
1806298|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States - Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
1806299|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
1806300|NCT00625924|Behavioral|questionnaires|Patients will be evaluated at one time point using the Breast Sensation Assessment Score (BSAS©), the SF-36 Health Survey, the MSKCC BREAST Q, the Brief Pain Inventory, the Hopwood Body Image Scale, the Profile of Mood States -Brief Version (POMS - BRF), and the 'Patient Demographic and Treatment Information Form'
1806301|NCT00625937|Drug|cisplatin|
1806302|NCT00625937|Drug|docetaxel|
1806303|NCT00625937|Drug|tegafur-gimeracil-oteracil potassium|
1806304|NCT00625937|Radiation|radiation therapy|
1806305|NCT00625950|Procedure|ENDOMETRIAL BIOPSY|Two routine laparoscopies in period of three months with endometrial biopsy comparative study performed.
1806306|NCT00625976|Behavioral|Graded exposure in vivo|Graded exposure in vivo according to the protocol of de Jong et al. (2005)
1806307|NCT00625976|Behavioral|Physiotherapy|Physiotherapy according to the protocol of Oerlemans, Oostendorp, de Boo and Goris (1999)
1806308|NCT00625989|Drug|Aeroallergen|
1806309|NCT00626002|Drug|ABT-874|100mg ABT-874 administered SQ every 4 wks for approximately 204 weeks
1806310|NCT00626015|Biological|PEP-3-KLH conjugate vaccine|Given intradermally
1806311|NCT00626015|Biological|daclizumab|Given IV
1806312|NCT00626015|Drug|temozolomide|Given by mouth.
1806313|NCT00626015|Other|placebo|Given IV
1806314|NCT00626015|Biological|PEP-3-KLH|Basiliximab 20 mg IV over 30 minutes with PEP-3-KLH vaccine # 1 only.
1806315|NCT00626028|Drug|Nitric Oxide for inhalation|Nitric Oxide (NO) for inhalation, given at 80ppm over 10 minutes using an INOvent®
1806316|NCT00626028|Drug|Oxygen|100% oxygen (O2) for inhalation, given at 80ppm over 10 minutes using an INOvent®
1806317|NCT00626028|Drug|Nitric Oxide plus Oxygen|Nitric Oxide (NO) for inhalation plus oxygen, given at 80ppm over 10 minutes using an INOvent® delivery system
1806318|NCT00626041|Other|participant referral to primary care network physician|blood pressure, cholesterol and hemoglobin A1c screening and management
1806319|NCT00626054|Drug|PEG solution in a single dose of 3 liters|Group 1 will receive the precolonoscopy PEG solution in a single dose of 3 liters in the evening preceding the test.
1806320|NCT00626054|Drug|PEG solution|PEG solution: half the dose (1.5 liters) of the identical solution in the evening preceding the test and the other half (1.5 liters) on the morning of the test
1806321|NCT00626067|Device|Fully functional monitoring device|Pt received fully functional monitoring dispenser for use with their Travatan eye drops
1806322|NCT00626067|Device|Partially functional monitoring device|Patient received a particually functional Travatan Compliance Monitoring Dispenser
1806323|NCT00626067|Device|Non-functional monitoring device|Patient received a non functioning Travatan Compliance Monitoring Dispenser
1806324|NCT00626080|Drug|Insulin detemir|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
1806325|NCT00626080|Drug|Insulin NPH|100 IU/ml, QD, dose individually adjusted, to be used for a period of 12 weeks; in combination with insulin aspart TID
1806326|NCT00626093|Device|Cardiac Resynchronization Therapy - Defibrillator (CRT-D)|"Patients in the study who receive Cardiac Resynchronization Therapy - Defibrillator (CRT-D) are indicated for Cardiac Resynchronization Therapy (CRT).
Patient undergoes Defibrillation threshold (DFT) testing at implant and at 6 months. Defibrillation threshold (DFT) testing will include 3 ventricular fibrillation (VF) inductions."
1806327|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 2 - placebo with exemestane or fulvestrant
1806328|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 3 - roll over to open-label AMG 479 with exemestane or fulvestrant
1806329|NCT00626106|Drug|AMG 479 or placebo administered with either exemestane or fulvestrant|Arm 1 - AMG 479 administered with exemestane or fulvestrant
1806330|NCT00626132|Dietary Supplement|Eucommia|two capsules three times a day orally for 2 weeks
1806331|NCT00626145|Procedure|saline infusion|Patients receive intracoronary injections of saline 7 days after PCI.
1806332|NCT00626145|Procedure|autologous bone marrow mononuclear cells infusion|Patients receive intracoronary injections of autologous bone marrow mononuclear cells 7 days after PCI.
1806333|NCT00626158|Drug|gemcitabine|1000 mg/m2 IV day 1 of every cycle for 100 minutes (each cycle 14 days)
1806334|NCT00626158|Drug|capecitabine|starting dose 1000 mg/m2 PO twice a day for days 1-7 of each cycle (each cycle 14 days)
1806335|NCT00626171|Procedure|Allergen Challenge|Allergen challenge
1806336|NCT00626184|Drug|4 dose levels of ALV003|4 dose levels of ALV003 vs placebo
1806337|NCT00626197|Drug|corticosteroids|Intravenous and oral repeating dose
1806338|NCT00626197|Drug|cyclophosphamide|Intravenous repeating dose
1806339|NCT00626197|Drug|mycophenolate mofetil|oral repeating dose
1806340|NCT00626197|Drug|ocrelizumab|Intravenous repeating dose
1806341|NCT00626197|Drug|placebo|Intravenous repeating dose
1806342|NCT00626210|Drug|modafinil|100-400 mg daily for 4 weeks
1806343|NCT00626223|Drug|5-MTHF (5-methyltetrahydrofolate)|50 mg intravenous at the end of each hemodialysis session
1806344|NCT00626223|Drug|folic acid|5 mg per day of oral folic acid
1806345|NCT00626236|Drug|SPN-810|capsule taken three times a day
1806346|NCT00626236|Drug|SPN-810|capsule taken TID
1806347|NCT00626236|Drug|SPN-810|capsule taken TID
1806348|NCT00626236|Drug|SPN-810|capsule taken TID
1806349|NCT00626249|Drug|Technosphere Inhalation Powder|Technosphere Inhalation Powder
1806350|NCT00626262|Drug|Esomeprazole|Oral and Intravenous
1806351|NCT00626275|Drug|ADL5859|
1806352|NCT00626275|Drug|Naproxen|
1806353|NCT00626275|Drug|Placebo|
1806354|NCT00626275|Drug|ADL5859|
1806355|NCT00626275|Drug|Placebo|
1806356|NCT00626288|Drug|Mesalazine|Mesalazine 800mg t.i.d. 12 weeks
1806357|NCT00626288|Drug|Placebo|Placebo cpr, t.i.d. 12 weeks
1806360|NCT00626314|Biological|sham|sham injection procedure
1806361|NCT00626327|Biological|MenACWY-CRM + MMRV|One injection of MenACWY-CRM vaccine at 7-9 months of age; the second injection of MenACWY-CRM vaccine concomitantly administered with MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age.
1806362|NCT00626327|Biological|MMRV|one injection of MMRV (Measles, Mumps, Rubella and Varicella) vaccine at 12 months of age
1806363|NCT00626327|Biological|MenACWY-CRM|Two injections of MenACWY-CRM at 7-9 months and 12 months of age; one injection of MMRV (Measles, Mumps, Rubella and Varicella) at 13.5 months of age
1806364|NCT00626340|Drug|MDD diagnosis and Estrogen treatment|Treatment for major depressive disorder occurring in the context of the menopause while participating in brain imaging sessions pre and post treatment. Women receiving treatment for depression will be compared to normal controls receiving estrogen only for physical symptoms of menopause.
1806365|NCT00626340|Drug|MDD diagnosis and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with fluoxetine alone.
1806366|NCT00626340|Drug|MDD diagnosis with both Estrogen and Fluoxetine treatment|Menopausal women between the ages of 40-70 diagnosed with Major Depressive Disorder receiving treatment with estrogen and fluoxetine combined.
1806367|NCT00626340|Drug|No depression and estrogen treatment|Control participants with no MDD diagnosis received estrogen only for the treatment of physical symptoms of menopause.
1806368|NCT00626353|Other|Home-based rehabilitation|Rehabilitation at home during hospital stay and after discharge
1806369|NCT00626353|Other|Standard care|Standard care during hospital stay and in the municipality after discharge
1806370|NCT00626366|Radiation|Sinus CT Scan|Subjects will undergo a Xoran miniCAT scan of their sinuses
1806371|NCT00626366|Drug|Omnipaque 240 Contrast Solution|Subjects will spray 2-4 drops of half-strength Omnipaque 240 mgI/mL into each nare. Each spray is approximately 0.1 ml.
1806372|NCT00626366|Drug|Omnipaque 240 mg I/mL|Subjects will place two drops of half-strength Omnipaque 240 mg I/mL intranasally to each nose. Each drop is approximately 1 ml.
1806373|NCT00626392|Drug|niacin extended-release (NER)|Tablets administered once daily; titrated to 2000 mg maximum dose during coadministration period
1806374|NCT00626392|Drug|aspirin (ASA)|325 mg tablets administered once daily
1806375|NCT00626392|Drug|aspirin placebo (ASA Pbo)|Tablets administered once daily
1806380|NCT00626418|Drug|Aplindore|Tablets 0.05, 0.1, 0.2, 0.3, 0.5 and 0.7 mg QD for up to 6 nights
1806381|NCT00626418|Drug|Placebo|Placebo tablets
1806382|NCT00626431|Drug|Leuprolide acetate - Formulation A|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation A, 45 mg 6 month depot, 24 weeks apart.
1806383|NCT00626431|Drug|Leuprolide acetate - Formulation B|Leuprolide acetate was administered as 2 intramuscular (IM) injections of Formulation B, 45 mg 6 month depot, 24 weeks apart.
1806384|NCT00626444|Drug|Intravenous vitamin C|Up to 100 gms of intravenous vitamin C, three times per week for 10 weeks.
1806385|NCT00626457|Behavioral|Behavioral weight-loss/lifestyle interventions|6-month intervention (28 weekly classes)
1806386|NCT00626470|Procedure|Addition of TSP to DHS|All patients operated with DHS. Of these two groups. One operated with TSP and one without.
1806387|NCT00626483|Biological|RNA-loaded dendritic cell vaccine|Only one dose of DCs (2 x 10^7) is being assessed.
1806388|NCT00626483|Drug|basiliximab|Basiliximab 20 mg and 40 mg is being assessed depending on dose-cohort enrollment.
1806389|NCT00626509|Drug|sunitinib malate|
1806390|NCT00626509|Procedure|adjuvant therapy|
1806391|NCT00626509|Procedure|neoadjuvant therapy|
1806392|NCT00626509|Procedure|therapeutic conventional surgery|
1806393|NCT00626522|Drug|Aclidinium bromide and formoterol|once daily
1806394|NCT00626522|Drug|Aclidinium bromide and formoterol placebo|once daily
1806395|NCT00626535|Drug|Esomeprazole|20mg Oral Once Daily
1806396|NCT00626535|Drug|Matching placebo|Oral Once Daily
1806397|NCT00626548|Drug|ZD4054|10 mg once daily oral dose
1806398|NCT00626548|Drug|Palcebo|Matching Plcebo oral tablet once daily
1806399|NCT00626561|Drug|Bevacizumab|10 mg/kg IV twice weekly on days 1 and 15.
1806400|NCT00626561|Drug|Paclitaxel|60 mg/m^2 IV weekly on days 1, 8, 15, and 22.
1806401|NCT00626574|Drug|Epoetin alfa|Intravenous administration of epoetin alfa (40,000 IU) immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
1806402|NCT00626574|Drug|Saline|3ml of saline will be administered via an IV push immediately before clipping surgery. Successive doses will be given 24 and 48 hours after the first dose.
1806403|NCT00626587|Device|Olympus NA-2C-1 Transbronchial needle aspiration (TBNA)|The TBNA apparatus (Olympus NA-2C-1) is inserted through the working channel, and is advanced until it reaches the target lesion which is localized by EBUS. Negative manual suction is applied with the 20 ml syringe. The specimens are then smeared on glass slides and immersed in 95% alcohol. At least 3 aspirates per lesion are obtained.
1806404|NCT00626600|Drug|Oxycodone Hydrochloride|
1806405|NCT00626613|Drug|Risperdal,reminyl|Risperdal:The dosage of treatment medication will begin with 0.5 ml/ per day (0.5mg), The maximum dose will be 2ml/ per day reminyl:8 mg/ per day
1806457|NCT00626990|Procedure|adjuvant therapy|Patients randomized to adjuvant temozolomide will start adjuvant temozolomide after a 4 week resting period after the end of radiotherapy.
1806458|NCT00626990|Procedure|quality-of-life assessment|Quality of Life analysis will also be used to assess neurological deterioration free progression
1806819|NCT00637650|Procedure|Ureteroscopy, Holmium Laser lithotripsy and active retrieval of fragments|
1806408|NCT00626639|Drug|Placebo|Administered by intravenous (IV) bolus injection
1806409|NCT00626639|Drug|palifermin|Administered by intravenous (IV) bolus injection
1806410|NCT00626639|Radiation|Radiotherapy|Once daily irradiation of 20 centigray (cGy)/day x 33 fractions for a total target dose of 6600 cGy (conventional radiation therapy using standard fractionation [one fraction per day])
1806411|NCT00626639|Drug|Cisplatin|100 mg/m^2 intravenously (IV) on days 1, 22 and 43.
1806412|NCT00626652|Drug|K201 Injection|single intravenous infusion of Dose 1 - 10 or placebo (saline) or single oral capsule Dose A or placebo capsule
1957702|NCT02246205|Procedure|Pancreaticoduodenectomy|Pancreaticoduodenectomy is the classical operative technique to resect cephalic pancreatic cancer. In a first phase of the surgery, the resection may be performed. In the second phase, the digestive tract must be restored. We planify two different reconstruction techniques.
1806417|NCT00626691|Behavioral|Walnut consumption|Subjects will be randomized to receive either 0.75 oz (22.5 g) or 1.5 oz (45 g) of walnuts daily for the first 6 wk period, followed by a 6 wk washout period, and an additional 6 wk period during which they will receive the reverse dose of walnuts daily. Each serving of walnuts will be pre-weighed and pre-packaged.
1806418|NCT00626704|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibody that selectively binds to Death Receptor-5 (DR5).
1806419|NCT00626704|Other|Placebo|Inactive dummy AMG 655 (to maintain blind)
1806420|NCT00626704|Drug|Doxorubicin|Antineoplastic antibiotic obtained from Streptomyces peucetius. It is a hydroxy derivative of Daunorubicin.
1806421|NCT00626717|Procedure|Riboflavin/UVA crosslinking|Removal of epithelium. Riboflavin eye drops. UVA exposure.
1806422|NCT00626717|Procedure|Sham treatment|Fluorescein eye drops. Exposure with blue light
1806423|NCT00626730|Procedure|adjuvant therapy|
1806424|NCT00626730|Radiation|radiation therapy|
1806425|NCT00626743|Drug|SK3530 100mg, Placebo, Amlodipine|
1806426|NCT00626756|Device|LiDCO technology|non invasive monitoring of cardiac output
1806427|NCT00626769|Dietary Supplement|aglycone genistein|2 capsules per day containing 27 mg of aglycone genistein, calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
1806428|NCT00626769|Dietary Supplement|placebo|2 capsules per day containing calcium carbonate (500 mg) and vitamin D (400 IU), for a 3-year period.
1806429|NCT00626782|Drug|Ranibizumab|Ranibizumab 0.5mg (0.05mL)one injection in sub-tenon's at the conclusion of glaucoma surgery
1806430|NCT00626782|Drug|Mitomycin C 0.4 mg/ml|Mitomycin C 0.4 mg/ml applied with soaked pledget inserted in the sub-tenon's space during glaucoma surgery.
1806431|NCT00626795|Drug|TD1414 2% cream|BID 7 days
1806432|NCT00626795|Drug|TD1414 2% cream|TID 7 days
1806433|NCT00626795|Drug|Bactroban® (mupirocin) 2% cream|BID 7 days
1806434|NCT00626808|Drug|No Intervention|There were no interventions. No subjects were enrolled in this retrospective database study.
1806435|NCT00626821|Device|SenSura|Real life assessment of SenSura
1806436|NCT00626834|Drug|Vigabatrin|Dose 1 BID
1806437|NCT00626834|Drug|Vigabatrin|Dose 2 BID
1806438|NCT00626834|Drug|Vigabatrin|Dose 3 BID
1806439|NCT00626834|Drug|Matching placebo|Matching placebo BID
1806440|NCT00626860|Biological|DC/tumor fusion vaccine|SC vaccinations administered to each patient at 3-week intervals for 2-3 doses
1806441|NCT00626873|Drug|Definity|Definity - perflutren lipid microspheres, 1-10 microns in diameter, which is approved for the use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border, to enhance the visualization of the ovarian vascular system.
1806442|NCT00626873|Other|medical chart review|
1806443|NCT00626886|Drug|Bupivacaine Collagen Sponge|collagen; Bupivacaine hydrocholoride
1806444|NCT00626886|Drug|placebo collagen sponge|collagen
1806446|NCT00626925|Drug|topiramate|up to 200mg/day orally (over 12 weeks during which the dosage is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
1806447|NCT00626925|Drug|placebo|placebo (12 weeks during which the dosage of study medication is gradually increased up to 200 mg orally and then maintained, and 1 week of medication taper)
1806448|NCT00626951|Device|LMA Supreme|Extraglottic airway devices
1806449|NCT00626951|Device|LMA ProSeal|
1806450|NCT00626964|Procedure|Bariatric Surgery|Bariatric Surgery Treatment: Duodenal Switch, Gastric Sleeve or Gastric bypass.
1806451|NCT00626964|Behavioral|Conservative Treatment:|Intensive Lifestyle Intervention Program
1806452|NCT00626977|Drug|ropivacaine|15 ml of ropivacaine 0.125% peridural once
1806453|NCT00626977|Drug|ropivacaine and clonidine|15 ml of ropivacaine 0.0625% plus 75 mcg clonidine
1806454|NCT00626990|Drug|temozolomide|Patients randomized to concomitant temozolomide will receive temozolomide continuously at a daily dose of 75 mg/m² during radiotherapy.
1806455|NCT00626990|Genetic|DNA methylation analysis|MGMT methylation status is used for stratification at randomization.
1806456|NCT00626990|Other|laboratory biomarker analysis|Prognostic factor analyses
1806777|NCT00637351|Procedure|Blood sample|One blood sample will be collected at the time of screening for subjects
1806459|NCT00626990|Radiation|radiation therapy|Radiotherapy will consist of a conventionally fractionated regimen for 6.5 weeks in a once daily schedule
1806460|NCT00627003|Drug|Cabergoline|Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks
1806461|NCT00627003|Other|Placebo|Placebo oral tablets administered daily for 5 weeks
1806462|NCT00627016|Drug|Dexlansoprazole|30 mg capsule, orally, once daily for 4 weeks
1806463|NCT00627016|Drug|Placebo|1 capsule, orally, once daily for 4 weeks
1806464|NCT00627029|Behavioral|Care Coordination|Depending on the demonstration site, may consist of nurse telephonic counseling and monitoring, nurse in-person or home visits, home telemonitoring equipment, patient educational materials, patient group educations classes, physician education and feedback.
1806465|NCT00627042|Biological|Ramucirumab (IMC-1121B)|Participants will receive ramucirumab (IMC-1121B) at 8 milligrams per kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
1806466|NCT00627055|Drug|LPV/r|LPV/r dosing = 400mg/100mg orally q12h for 48 weeks
1806467|NCT00627055|Drug|LPV/r + TDF/FTC or TDF/3TC|TDF/FTC (Truvada) 1 pill orally q 24 hr or TDF 300mg orally q 24 hr/3TC 300mg orally q 24 hr (or 3TC 150mg orally q 12 hr) for 48 weeks
1806468|NCT00627081|Drug|remifentanil|dosage
1806469|NCT00627094|Device|Biatain|A standard polyurethane foam dressing Biatain non-adhesive (Coloplast A/S) with an elastic semi-permeable backing film, size 15x15 cm. The product is CE marked.
1806470|NCT00627094|Device|Biatain Ibu|Biatain Ibu non-adhesive (Coloplast A/S), a polyurethane foam dressing with an elastic semi-permeable backing film with an added pain relieving medicinal substance ibuprofen (Albermarle Inc.), size 15x15 cm. The product is CE marked.
1806471|NCT00627107|Device|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device.
1806472|NCT00627120|Drug|VGX-1027|Subject will be given a single dose of VGX-1027 ranging from 1-800mg and monitored for safety and pharmacokinetics for 8 days.
1806473|NCT00627133|Drug|levetiracetam|2 gram iv load, 500mg bid
1806474|NCT00627146|Drug|ChAgly CD3|6 days treatment 8mg/d intravenous
1806475|NCT00627146|Drug|Placebo|6 days
1806476|NCT00627159|Other|High risk assessment|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All participants predicted to be at high risk are referred for assessment to a High Risk clinic in the community via the family doctor.
1806477|NCT00627159|Other|Low to moderate risk|For all participants screened in the program, a cardiovascular risk profile is determined using information from the cardiovascular health history, blood pressure and cholesterol measurements, and The British Joint Societies Risk Prediction chart. All low to -moderate risk participants are directed to self-refer to the Calgary Health Region Multicultural education classes.
1806478|NCT00627185|Behavioral|Internet-delivered continuing professional development|Interactive motivational website for dentists and hygienists with practice improvement resources, discussion forum, and educational cases on cessation counseling with email reminders.
1806479|NCT00627185|Other|No intervention arm|
1806480|NCT00627198|Drug|PTK787/ZK222584 - Experimental|250mg tablets; 500mg (2 tablets) in the am and 750mg (3 tablets) in the pm.
1806481|NCT00627211|Procedure|CO2 insufflation|From the CO2 rack through the endoscopy rack CO2 will be insufflated to visualize the mucosa during oesophagogastroduodenoscopy.
1806482|NCT00627237|Behavioral|Immediate Start|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
1806483|NCT00627237|Behavioral|Waitlist|Participation in an intensive cognitive rehabilitation program 3 days a week (3 hours a day) for 12 weeks. Each day consists of a 50 minutes of problem solving group, 50 minutes of individualized attention training, and a 50 minute emotional regulation group session with 10 minutes breaks between each module.
1806484|NCT00627250|Drug|Amantadine|Amantadine 100 mg every morning and 12 noon
1806485|NCT00627263|Behavioral|Stress reduction treatment (SRT) program|The SRT program is a cognitive behavioral program that consists of 8 group sessions over a period of 10 weeks.
1806486|NCT00627276|Dietary Supplement|omega-3 fatty acid|Oral, 3 times daily
1806487|NCT00627276|Other|placebo|Oral, 3 times daily
1806488|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 70-90 mg/dL
1806489|NCT00634842|Drug|insulin detemir|Treat-to-target dose titration scheme, s.c. injection, once daily. Fasting plasma glucose (FPG) titration target range of 80-110 mg/dL
1806490|NCT00634868|Other|Qray light therapy device|The light is filtered from harmful UV and InfraRed light and only light at wavelight of 405nm until 1000nm is delivered.
1806491|NCT00634868|Device|Qray light therapy device-Sham|non curative light- the device emits the same broad light, but with very low intensity
1806492|NCT00634881|Biological|Alemtuzumab i.v.|"Alemtuzumab will be administered once per week as a 2 h infusion
Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration
Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)
Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
1806493|NCT00634881|Biological|Alemtuzumab s.c.|"Alemtuzumab will be administered once per week subcutaneously
Dose level I: 10mg once weekly (start with dose escalation : 3 mg on day 1, 10mg on day 2) Duration
Dose level II: 20mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 20mg on day 3)
Dose level III: 30mg once weekly (start with dose escalation: 3mg on day 1, 10mg on day 2, 30mg on day 3)"
1806494|NCT00634894|Drug|Femara|2.5 mg by mouth daily x 12 weeks
1806495|NCT00634894|Drug|Placebo|Placebo capsule by mouth daily x 12 weeks
1806531|NCT00635076|Other|placebo|Patients continued taking the matching placebo that they were taking when they completed Study A6131002 (oral tablets taken once daily).
1806496|NCT00634907|Genetic|Pharmacogenetic-based warfarin dosing|"Prior to elective joint replacement surgery a blood sample is collected for genetic information(genotyping)which was used for calculating warfarin doses for patients randomized to the cytochrome arm. Outcomes in terms of efficacy, safety, and management of warfarin were compared between this group and the group in which warfarin doses are determined per usual care.
NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
1806497|NCT00634907|Other|Usual care warfarin dosing|"For patients in arm 2, the control group, warfarin dosing is per usual care. Outcomes in terms of safety, efficacy, and warfarin management was compared to that of patients in the other arm, who receive warfarin dosing based on genotyping.
NOTE: Standard of care for elective knee and hip replacement at our institution is to receive post-operative warfarin thromboprophylaxis. Administration of warfarin was not specific to this study, nor was the duration of prophylaxis, however, warfarin dosing was influenced by the study arm as noted above."
1806498|NCT00634920|Drug|everolimus|Everolimus (Certican®) tablets administered orally in two divided doses (b.i.d.) at a starting dose of 4 mg/day adjusted to target a trough blood concentration between 6 and 10 ng/mL in period 2.
1806499|NCT00634920|Drug|cyclosporine A|CsA (Sandimmun Neoral), based on C0-h levels 75-200 ng/mL or C2-h levels 700 900 ng/mL from randomization to Month 6, or C0-h levels 50-150 ng/mL or C2-h levels 600 800 ng/mL from Month 6 to Month 36, according to local method
1806500|NCT00634920|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|Target dose 1440 mg in the control group, target dose 1080 in the everolimus group (higher dose in the CsA group because of interactions of CsA on gastric reabsorption of mycophenolate)
1806501|NCT00634920|Drug|corticosteroids|For both groups: minimum corticosteroid dose of 10 mg until week 12, 5-10 mg until month 12, month 12-36 corticosteroid treatment on investigator's descretion.
1806502|NCT00634920|Drug|Basiliximab|Induction therapy 20 mg basiliximab on Day 0 prior to reperfusion and 20 mg on Day 4 post-TX.
1806503|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Baseline (both arms) and Week 24 (both arms); corresponding IV Placebo at Week 12 and Week 36 (both arms).
1806504|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 1a) and Week 24 (both arms); corresponding IV Placebo at Week 12 (Arm 1b) and Week 36 (both arms).
1806505|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 1a), and Week 24 (both arms); corresponding Oral Placebo at Week 12 (Arm 1b) and Week 36 (both arms)
1806506|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 24 (both arms).
1806507|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (both arms), and Week 36 (both arms); corresponding IV Placebo at Week 36 (both arms).
1806508|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 2a) and Week 36 (both arms); corresponding Oral Placebo at Week 12 (Arm 2b) and Week 24 (both arms).
1806509|NCT00634933|Drug|TRU-015|IV 800 mg TRU-015 at Week 24 (both arms) and Week 36 (arm 3a); corresponding IV Placebo at Baseline (both arms), Week 12 (both arms) and Week 36 (arm 3b).
1806510|NCT00634933|Drug|Methylprednisolone|IV 100 mg Methylprednisolone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms), and Week 36 (arm 3a); corresponding IV Placebo at Week 12 (arm 3b) and Week 36 (arm 3b).
1806511|NCT00634933|Drug|Prednisone|Oral 20 mg tablets Prednisone at Baseline (both arms), Week 12 (arm 3a), Week 24 (both arms) and Week 36 (arm 3a); corresponding Oral Placebo at Week 12 (Arm 3b) and Week 36 (arm 3b).
1806512|NCT00634946|Drug|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
1806513|NCT00634946|Drug|Placebo|Placebo is administrated into the nucleus pulposus of an intervertebral disc.
1806514|NCT00634959|Drug|Maraviroc (UK-427,857)|150 mg oral tablet twice daily while fasted on Days 1-9 and on Day 10 (morning dose only)
1806515|NCT00634959|Drug|Maraviroc (UK-427,857)|100 mg oral tablet once daily while fasted on Days 1-10
1806516|NCT00634959|Drug|Maraviroc (UK-427,857)|300 mg oral tablet once daily while fasted on Days 1-10
1806517|NCT00634959|Drug|Maraviroc (UK-427,857)|150 mg oral tablet twice daily with food on Days 1-9 and on Day 10 (morning dose only)
1806518|NCT00634959|Other|Placebo|Matching placebo oral tablet on Days 1-10 (fed and fasted)
1806519|NCT00634972|Drug|ACULAR|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
1806520|NCT00634972|Drug|REFRESH TEARS|infants enrolled in the study will receive 1 drop of the ROP Study drug in each eye 3 times a day (every 8 hours.
1806521|NCT00634972|Drug|placebo|
1806522|NCT00634985|Drug|eletriptan|40 mg oral tablet for migraine attack; additional 40 mg oral tablet >2 hours from first dose if migraine reoccurred within 24 hours of achieving response
1806523|NCT00634998|Dietary Supplement|Vitamin C|1000mg Vitamin C capsules orally twice daily
1806524|NCT00634998|Dietary Supplement|Placebo|1000mg Placebo capsules orally twice daily for 90 days
1806525|NCT00635011|Behavioral|psychotherapy|Cognitive Behavioral therapy
1806526|NCT00635024|Biological|anti-thymocyte globulin|2.5 mg/kg
1806527|NCT00635024|Drug|melphalan|16 mg/m^2
1806528|NCT00635037|Drug|bupivacaine and acupuncture|"trigger point injection of 0.25% bupivacaine (1 ml/point) twice a week, 10 mg/day cyclobenzaprine and 500 mg dipyrone every 8 h.
acupuncture twice a week"
1806529|NCT00635050|Drug|Doxil, Paclitaxel, Cyclophosphamide, Avastin|"Regimen A: Doxil 25 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3 . Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin 15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation.
Regimen B: Doxil 30 mg/M2 iv and Avastin 10 mg/kg iv every 2 weeks x 3, then paclitaxel 175 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3, then cyclophosphamide 600 mg/M2 i.v. and Avastin 10 mg/kg iv every 2 weeks x 3. Patients who experience <pCR to primary chemotherapy will receive an additional year of Avastin15 mg/kg iv every 3 weeks, beginning 6-8 weeks after operation."
1806530|NCT00635063|Drug|AD 923|
1806925|NCT00630370|Drug|Placebo|2 Placebo tablets, TID, orally, 58 days
1806532|NCT00635076|Drug|alprazolam XR|Patients continued taking the same dosage of alprazolam that they were taking when they completed Study A6131002 (oral tablets taken once daily (1-6mg)); patients taking less than 6 mg/day who failed to show a satisfactory clinical response since the previous visit, and who were free of dose-limiting adverse events, could have their dosage titrated upward by 1 mg/day; upward daily dosage titration of 1 mg was allowed every 7 days, up to a maximum daily dosage of 6 mg/day; patients who were unable to tolerate the previous dosage level of alprazolam XR could have their daily dosage reduced.
1806533|NCT00635089|Drug|reslizumab|
1806534|NCT00635102|Drug|D-Cycloserine PO and Glycine IV|Test days will involve administration of D-Cycloserine in the morning in pill form then 4 hours later a 30 minute infusion of Glycine.
1806535|NCT00635102|Drug|Placebo D-Cycloserine PO and placebo Glycine IV|Placebo
1806536|NCT00635102|Drug|Placebo D-Cycloserine PO and Glycine IV|
1806537|NCT00635102|Drug|D-Cycloserine PO and placebo Glycine IV|
1806538|NCT00635115|Device|a new generation of corrective lens for presbyopia (i.e., Varilux Panamic Orma Crizal)|
1806539|NCT00635115|Device|an old generation of corrective lens for presbyopia (i.e., Varilux Comfort Orma Crizal)|
1806540|NCT00635128|Biological|Boostrix-Polio|A single booster dose of dTpa-IPV vaccine will be administered to all subjects. IM administration in the deltoid muscle of the non-dominant arm.
1806541|NCT00635141|Drug|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 1 will receive hypertonic saline (7 %) during the first phase of the study and will crossover to placebo (0.9% isotonic saline) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
1806542|NCT00635141|Drug|hypertonic saline (7 %) and isotonic saline (0.9%)|Patients in study arm 2 will receive placebo (0.9% isotonic saline) during the first phase of the study and will crossover to hypertonic saline (7 %) during the second phase. Both drugs will be administered via PARI LC® Star reusable nebulizer.
1806543|NCT00635154|Biological|Anakinra (IL-1Ra)|100mg daily subcutaneously administered
1806544|NCT00635154|Drug|Dexamethasone acetate|"Low dose - 20 mg/week
High dose - 40mg days 1-4, 9-12, 17-20 every 28 days ODD cycles OR 40 mg days 1-4 every 28 days EVEN cycles. (Starting dose was determined by treating physician)"
1806545|NCT00635167|Procedure|Contrast Enhanced-Transrectal Ultrasound|Once a subject is identified TRUS schedule will be set up revolving around the EBRT treatment schedule. A schedule of 6 contrast enhanced TRUS examinations per subject is planned as follows: week 0 (prior to EBRT, baseline [Visit 2]); week 5 (middle of treatment [Visit 3]); week 10 (end of treatment [Visit 4]); week 18 (2 months after end of EBRT [Visit 5]); week 26 (4 months after end of EBRT [Visit 6]); and week 36 (6 months after end of EBRT [Visit 7]).
1806546|NCT00635674|Device|CPAP device - REMstar Plus, Respironics, Murrysville, USA|continuous positive airway pressure device with heated humidification
1806547|NCT00635687|Device|Fibroscan|transient elastography measure - Liver stiffness
1806548|NCT00635700|Drug|ziprasidone|20-160 mg/d
1806549|NCT00635700|Drug|placebo|placebo
1806550|NCT00635713|Drug|Fulvestrant|125mg
1806551|NCT00635713|Drug|Anastrozole|ARIMIDEX
1806552|NCT00635713|Drug|Fulvestrant|250mg
1806553|NCT00635726|Drug|Methotrexate|Methotrexate intravenous (IV) 30 mgr/m2 on day 1 every 2 weeks for 6 courses
1806554|NCT00635726|Drug|Vinblastine|Vinblastine IV 3 mgr/m2 on day 1 every 2 weeks for 6 courses
1806555|NCT00635726|Drug|Doxorubicin|Doxorubicin IV 30 mgr/m2 on day 2 every 2 weeks for 6 courses
1806556|NCT00635726|Drug|Cisplatin|Cisplatin IV 70 mgr/m2 on day 2 every 2 weeks for 6 courses
1806557|NCT00635726|Drug|Cisplatin|Cisplatin IV 70 mgr/m2 on day 1 every 3 weeks for 4 courses
1806558|NCT00635726|Drug|Gemcitabine|Gemcitabine 1000 mgr/m2 on days 1 and 8 every 3 weeks for 4 courses
1957705|NCT02244528|Drug|Sildenafil|
1806561|NCT00635752|Other|TF-CBT|TF-CBT sessions will include trauma-focused treatment, and will teach participants behavioral and coping skills.
1806562|NCT00635752|Other|Treatment as Usual (TAU)|Participants will receive regular therapy as is usually practiced in clinics
1806563|NCT00635765|Drug|C2L-OCT-01 PR 30 mg|Administered by deep IM (gluteus) on Day 1. Beginning on Day 42, drug injection frequency (6, 5 or 4 weeks) and dose modification/adjustment will be allowed for every 3 drug injections based on the mean serum GH and clinical symptoms obtained at the last visit of study C2L-OCT-01 PR-301 and during the course of this study.
1806564|NCT00635778|Drug|MK-0646|Patients receive an intravenous (IV) infusion over one to two hours, at escalating dose levels (2.5, 5 10, 15, and 20 mg/kg).
1806565|NCT00635791|Drug|Sorafenib|Given by mouth
1806566|NCT00635791|Drug|Vorinostat|Given by mouth
1806567|NCT00635804|Drug|MK-3281|MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose. The PM dose of MK-3281 was not administered on Day 7 (for HCV-infected males) or Day 10 (for healthy males)
1806568|NCT00635804|Drug|Placebo to MK-3281|Dose-matched placebo to MK-3281 capsule administered orally BID for 7 or 10 consecutive days depending on randomized dose of MK-3281 in serial panel. The PM dose of matched placebo was not administered on Day 7 or 10 (depending upon allocation).
1806569|NCT00635817|Drug|Leuprolide acetate 11.25 mg|Two intramuscular injections of leuprolide acetate for depot suspension 11.25 mg administered 3 mo apart.
1806570|NCT00635817|Drug|Leuprolide acetate 30 mg|Two intramuscular injections of leuprolide acetate for depot suspension 30 mg administered 3 mo apart.
1806571|NCT00635830|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|HPV 6,11,16,18 VLP, 0.5 mL 1 dose injection.
1806572|NCT00635843|Device|MAVERICK™ Disc|The MAVERICK™ disc is a spinal arthroplasty system and is intended to replace a damaged disc in the lumbar spine. It is a permanent implant used to maintain motion at the treated level and is inserted using an anterior surgical approach.
1806573|NCT00635843|Device|LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft|The control is the treatment with LT-CAGE® Lumbar Tapered Fusion Device and INFUSE® Bone Graft. It is commercially available for anterior lumbar spine interbody fusion procedures.
1806574|NCT00635856|Drug|Gefitinib|Iressa
1806815|NCT00637624|Drug|Placebo|Placebo once every 3 weeks intravenous saline fluid
1806575|NCT00635869|Behavioral|ARCC standard information|EBP didactic education sessions, EBP toolkit, environmental prompts, identification of an EBP champion among unit staff RNs
1806576|NCT00635869|Behavioral|ARCC enhanced|same as ARCC standard plus EBP mentor on-site twice each week plus available by e-mail for consultation
1806577|NCT00635869|Behavioral|Placebo|didactic education sessions on physical assessment
1806578|NCT00635882|Drug|mometasone furoate/formoterol 100/10 mcg|mometasone furoate/formoterol 100/10 mcg twice daily (BID) (two inhalations of MF/F 50/5 from a metered-dose inhaler) for 14 days
1806579|NCT00635882|Drug|mometasone furoate/formoterol 200/10 mcg|mometasone furoate/formoterol 200/10 mcg twice daily (BID) (two inhalations of MF/F 100/5 from a metered-dose inhaler) for 14 days
1806580|NCT00635882|Drug|mometasone furoate/formoterol 400/10 mcg|mometasone furoate/formoterol 400/10 mcg twice daily (BID) (two inhalations of MF/F 200/5 mcg from a metered-dose inhaler) for 14 days
1806581|NCT00635882|Drug|MF DPI 200 mcg|MF DPI 200 mcg twice daily (BID) (one inhalation of MF DPI 200 mcg) for 14 days
1806582|NCT00635882|Drug|MF MDI 200 mcg|MF MDI 200 mcg twice daily (BID) (two inhalations of MF MDI 100 mcg) for 14 days
1806583|NCT00635882|Drug|Placebo|MF/F MDI placebo twice daily (BID) (2 inhalations)
1806584|NCT00635895|Other|Manual Lymph Drainage Therapy and Connective Tissue Massage|The treatment program was carried out five times a week, during a 3-week period for both Manual Lymph Drainage Therapy and Connective Tissue Massage groups
1806587|NCT00635934|Device|A-MAV™ disc|The A-MAV™ device is a spinal arthroplasy system intended to replace a damaged spinal disc. It is inserted using an anterior surgical approach and aims to reduce low back pain and maintain disc height at the affected level.
1806588|NCT00635947|Other|isotonic solution|1.5 L- during 2-4hours
1806589|NCT00635947|Other|water|1.5 L- during 2-4hours
1806590|NCT00635947|Other|water|200mL- during 2-4hours
1806591|NCT00635960|Drug|Growth Hormone (Somatropin)|The initial dose will be 2U s.c. every other day. The dose will be progressively increased to reach 1.5-2x the normal levels of IGF-I.
1806592|NCT00635960|Drug|Placebo|Same as for Growth hormone group
1806593|NCT00635973|Drug|Gefitinib (Iressa)|Iressa
1806594|NCT00635986|Drug|Fentanyl|100 mcg Fentanyl intravenous or epidural route
1806597|NCT00636012|Procedure|verum acupuncture|acupuncture at St36 and Pe6
1806598|NCT00636012|Procedure|sham acupuncture|superficial needling at sham points
1806599|NCT00636038|Dietary Supplement|corn beta-carotene|yellow corn beta-carotene in a 1 mg level to be taken as corn porridge in one meal by volunteers
1806600|NCT00636064|Drug|Parecoxib Sodium/Valdecoxib|Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
1806601|NCT00636064|Drug|Placebo/Valdecoxib|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
1806602|NCT00636064|Other|Placebo/Placebo|Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
1806603|NCT00636077|Device|Polyflux HD-C4 Big|Three consecutive treatments with the HD-C4 Big. During the third treatment, dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
1806604|NCT00636077|Device|HD-C4 Small|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
1806605|NCT00636077|Device|Optiflux 160NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
1806606|NCT00636077|Device|Optiflux 200NR|Three consecutive treatments with the HD-C4 Small. During the third treatment dialyzer clearances of urea, phosphorus and β2-microglobulin will be determined at a blood flow rate of 400 mL/min and dialysate flow rates of 350 mL/min, 500 mL/min and 800 mL/min.
1806607|NCT00636103|Drug|CUF2|"0.619g of dried aqueous extract of equal weights of 5 herbs (Astragalus mongholius Bunge, Cordyceps sinensis Sacc., Radix Stemonae, Bulbus Fritillariae Cirrhosae, Radix scutellariae).
The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.
Duration: 6 months"
1806608|NCT00636103|Other|Placebo|"Dark coloured corn starch
The dosage for children above 12 years old was three capsules twice daily and for children under 12 years old two capsules twice daily.
Duration: 6 months"
1806612|NCT00636129|Behavioral|Relaxation Response + Stress Management Curriculum|Subjects will receive 8 weeks of Stress Management curriculum and guidance through 20 minute Relaxation Response with a research coordinator. They will also practice 20 minutes of Relaxation Response at home daily.
1806613|NCT00636142|Biological|Infliximab|5 mg/kg body weight, maximal dose 500 mg; intravenous administration
1806614|NCT00636155|Drug|cenersen sodium|2.4 mg/kg/day as a continuous infusion over 24 hours starting on day one and ending on day 4
1806615|NCT00636155|Drug|Rituximab|375 mg/m2 on day 2
1806616|NCT00636155|Drug|Cyclophosphamide|250 mg/m2 on days 2, 3, and 4
1806617|NCT00636155|Drug|Fludarabine|25 mg/m2 on days 2, 3, and 4
1806618|NCT00636168|Drug|ipilimumab|IV solution, IV, 10 mg/kg, 4x every 21 days, then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
1806619|NCT00636168|Drug|Placebo|IV solution, IV, 10 mg/kg, 4x every 21 days then starting from Week 24 every 12 weeks until Week 156 (3 years), disease recurrence, unacceptable toxicity or patient withdrawal
1806620|NCT00636181|Device|Auto AFlex|Positive pressure therapy treatment
1806621|NCT00636181|Device|Auto CPAP|Positive pressure therapy treatment
1806622|NCT00636181|Device|CPAP|Positive pressure therapy treatment
1806623|NCT00636194|Device|Bausch & Lomb Multipurpose Solution|daily care of contact lenses
1806624|NCT00636194|Device|Alcon OptiFree Replenish Multipurpose Solution|daily care for contact lenses
1806625|NCT00636207|Drug|Montelukast|Montelukast dry powder inhaler, 0.1 mg, 0.3 mg, 1 mg, 3 mg or 10 mg
1806626|NCT00636207|Drug|Placebo|Placebo dry powder inhaler
1806627|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/4mg [S,S]-reboxetine for 5 and one half weeks.
1806628|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/4mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/6mg [S,S]-reboxetine for 5 and one half weeks.
1806629|NCT00636246|Drug|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks.
1806630|NCT00636246|Drug|sertraline|Tablets, 50 mg/day orally for 3 days, followed by 100 mg/day orally for 4 and one half weeks, followed by 150 mg/day orally for 3 weeks
1806631|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine for 3 days orally, followed by 100mg sertraline/2mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg [S,S]-reboxetine for 5 and one half weeks.
1806632|NCT00636246|Drug|Placebo|Tablets, orally once per day for 8 weeks
1806633|NCT00636246|Drug|sertraline/[S,S]-reboxetine|Tablets, 50mg sertraline/2mg [S,S]-reboxetine orally for 3 days, followed by 100mg sertraline/2mg [S,S]-reboxetine for 4 and one half weeks, followed by 150mg sertraline/2mg [S,S]-reboxetine for 5 and one half weeks
1806634|NCT00636246|Drug|[S,S]-reboxetine monotherapy|Tablets, 2 mg/day orally for 3 days, followed by 4 mg/day orally for 4 and one half weeks, followed by 6mg/day for 3 weeks
1806635|NCT00636259|Drug|Bicalutamide (Casodex)|150mg
1806636|NCT00636285|Drug|Placebo|Placebo
1806637|NCT00636285|Drug|BSYX-A110|BSYX-A110, Dosed intravenously, 3 mg/kg
1806638|NCT00636285|Drug|BSYX-A110|BSYX-A110, Dosed intravenously, 10 mg/kg
1806639|NCT00636298|Drug|Bevacizumab, cetuximab|"Cetuximab - 400 mg/m2 loading, then 250 mg/m2 weekly
Bevacizumab - 10 mg/kg every 2 weeks"
1806640|NCT00636311|Drug|Ifosfamide, Gemcitabine, Vinorelbine|Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
1806641|NCT00636311|Drug|Bortezomib + IGEV|Bortezomib 1,3 mg/sqm, day 1, 4, 8; Ifosfamide 2000 mg/sqm, day 1-4 (plus MESNA); Gemcitabine 800 mg/sqm, day 1 and 4; Vinorelbine 20 mg/sqm, day 1; Prednisone 100 mg, day 1-4; G-CSF 1 vial sc, day 7-12 of each 21-day course.
1806642|NCT00636324|Device|Nasal CPAP, level 7 to 9 cmH2O|Apply nasal CPAP pressure of 7-9 H2O for the first 72 hours of extubation
1806643|NCT00636324|Device|Nasal CPAP, level 4 to 6 cmH2O|Apply nasal CPAP pressure of 4 to 6 cmH2O for the first 72 hours of extubation
1806644|NCT00636337|Behavioral|Attention Training|Computer program training for attention difficulties.
1806645|NCT00636337|Behavioral|Placebo|Comparison computer program
1806647|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - Rub Care|Daily care for contact lenses - rub care regimen
1806648|NCT00636363|Device|Bausch & Lomb Multipurpose Solution - No Rub Care|Daily care for contact lenses - no rub care regimen
1806649|NCT00636363|Device|Ciba Vision Aquify Multipurpose Solution|daily care for contact lenses
1806650|NCT00636376|Procedure|Place HOB in alternate positions from 0-50 degrees.|Patients will receive an US while the HOB(Elevation of the head of bed) is 30 degrees(baseline) then they will increase the angle to 40 degrees, then 50 degrees. Another US will be done then in 20, 10, and o degree angles. Then another US will be done
1806651|NCT00636389|Device|Polyflux 210H dialyzer|Three consecutive treatments with the Polyflux 210H dialyzer. All study treatments will be performed in the standard hemodialysis mode.
1806652|NCT00636389|Device|Polyflux HD-C4|Three consecutive treatments with the Polyflux HD-C4 dialyzer. All study treatments will be performed in the standard hemodialysis mode.
1806653|NCT00636402|Procedure|Cold Knife Tonsillectomy|Cold Knife Tonsillectomy (CKT) will be done on the other side.
1806654|NCT00636402|Procedure|Vessel Sealing System Tonsillectomy|Intervention by Vessel Sealing System Tonsillectomy (VSST) will be randomized and will be performed on one side.
1806816|NCT00637637|Drug|indinavir sulfate|
1806655|NCT00636415|Drug|morphine|1 mg (1 ml) morphine diluted in 9 ml saline by the intra-articular route, and 25 mg (10 ml) 0.25% bupivacaine without epinephrine.
1806656|NCT00636428|Drug|Midazolam|oral midazolam, was prepared into a final solution (2.5 mg/mL) from injectable midazolam hydrochloride and a orange flavored syrup. For preparation, midazolam injection (5 mg/mL) was diluted 1:1 with the flavored syrup.
1806657|NCT00636441|Drug|Doxorubicin/Cyclophosphamide (AC) or Docetaxel/Cyclophosphamide (TC)|Doxorubicin 60 mg/m² and Cyclophosphamide 600 mg/m² (AC) or Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² (TC) every 3 weeks for 4 cycles as neoadjuvant therapy
1806658|NCT00636454|Behavioral|Coping skills training (CST) for chronic pain|Participants will attend 10 sessions lasting between 45 and 60 minutes each. Topics will include relaxation training, managing activity cycles, and changing thought patterns to reduce the negative effects of pain.
1806659|NCT00636454|Other|Usual care|Participants will receive the care usually given to patients with knee or hip OA.
1806660|NCT00636467|Other|No name|Injection of Nanocis® or Nanocoll® on the day before surgery followed by lymphoscintigraphy (long protocol, method n°1) or injection of Nanocis® or Nanocoll® on the morning of the surgery followed by lymphoscintigraphy at least 2h30 later (short protocol, method n° 2)
1806661|NCT00636480|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base, 26 ml applicator. Active drug contains alcohol and the placebo contains no drug. Administered topically.
1806662|NCT00636480|Drug|ChloraPrep One Step|Administer topically
1806663|NCT00636480|Drug|Sterile saline|0.9% NaCl solution
1806664|NCT00636493|Device|fluocinolone acetonide (Retisert Implant)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
1806666|NCT00636519|Biological|Botulism Antitoxin Bivalent (Equine) Types A and B|One vial of Botulism Antitoxin Bivalent(Equine) Types A and B (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage A
1806667|NCT00636519|Biological|Botulism Antitoxin Heptavalent (Equine) Types A-G|One vial of Heptavalent Botulism Antitoxin (1:10 in saline) or an Equivalent Volume of Placebo on Day 0 in Stage B
1806668|NCT00636545|Drug|Oblimersen (Genasense)|Intravenous
1806669|NCT00636545|Drug|Oblimersen (Genasense)|Intravenous
1806670|NCT00636558|Drug|CVA21|IV infusion, dose escalation of one or two infusions of escalating strength
1806671|NCT00636571|Behavioral|Exercise|Upright bike intervention for post-surgical lung cancer survivors.
1806674|NCT00636610|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules in 3 different strengths, 25 mg, 125 mg, and 150 mg.
1806675|NCT00636610|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
1806676|NCT00636610|Drug|Bevacizumab|Bevacizumab 5 mg/kg was administered intravenously (IV) over 90 minutes for the first infusion, shortening to 60 and 30 minutes for subsequent infusions.
1806677|NCT00636610|Drug|Modified FOLFOX|Following administration of bevacizumab, patients received oxaliplatin 85 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) IV administered over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
1806678|NCT00636610|Drug|FOLFIRI|Following administration of bevacizumab, patients received irinotecan 180 mg/m^2 IV administered over 90 minutes concurrently with folinic acid 400 mg/m^2 (d,I-racemic form, or 200 mg/m^2 I-isomer form) administered IV over 120 minutes, then fluorouracil 400 mg/m^2 administered as an IV bolus, then fluorouracil 2400 mg/m^2 administered as a continuous IV infusion over 46 hours.
1806679|NCT00636623|Other|Pilates exercises|15 FM patients participated in the PE programme three times a week during a 4-week period
1806680|NCT00636623|Other|Connective tissue massage|21 patients received CTM, three times a week during a 4-week period
1806681|NCT00636636|Drug|Gabapentin Extended Release tablets|Once-Daily; 300 mg and 600 mg tablets
1806682|NCT00636636|Drug|Placebo|Once daily; 300 mg and 600 mg tablets
1806683|NCT00636649|Drug|Escitalopram|10-20 mg
1806684|NCT00636649|Drug|Placebo|Placebo
1806685|NCT00636662|Other|Non-invasive diagnostic testing|No patient treatment is altered by enrollment in this trial
1806686|NCT00636675|Behavioral|Falls QI|"Falls uses the Falls Management Program (AHRQ); it is familiar to nursing homes, uses minimal researcher time, is adaptable, and simulates real word quality improvement practices. Falls is delivered over 3 months. Components include:
In-House Falls Coordinator training on content and falls processes.
Case-based modules about fall prevention and tailored for various team members.
Academic Detailing in which researcher consults with staff regarding challenging residents with falls.
Audit and Feedback. Discussions about comparison of nursing home's current practice on fall-related process and outcome measures, and how it compares with the median and the 90th percentile of peer NHs.
Toolbox: Handbook of useful measures and worksheets."
1806687|NCT00636675|Behavioral|Connect|"Connect, delivered over 12 weeks, helps nursing home staff learn interactions that increase exchange of new information, number and quality of connections among staff, and improve problem-solving about patient care. Protocols:
In-class learning sessions introduce interaction strategies.
Relationship map protocols assist staff to examine existing interaction patterns and agree on goals for improvement. Individuals develop their own relationship maps and use them to practice new horizontal and vertical connections and self-monitoring their own interactions.
Researcher facilitates authentic learning which occurs when learners directly and independently apply concepts. In-house staff volunteers and are facilitated to assume a mentoring role."
1806688|NCT00636688|Behavioral|Lifestyle - detailed advice|Detailed advice about how to achieve a loss of 10% or more in their total body weight by reducing caloric intake and increasing their level of physical activity
1806689|NCT00636688|Behavioral|Control - general information|General information about healthy food choices and exercise
1806690|NCT00636701|Device|Repetitive Transcranial Magnetic Stimulation|We will position a coil over the motor cortex of the head and give a series of stimulations (called magnetic pulses).
1806817|NCT00637637|Drug|ritonavir|
1806818|NCT00637637|Radiation|radiation therapy|
1806691|NCT00636714|Behavioral|Nursing judgement|Based on the nursing judgement, titrate insulin infusion and determine glucose check frequency to achieve a target glucose of 5-8 mmol/L
1806692|NCT00636714|Behavioral|Nomogram|A preprinted order outlining a nomogram with instructions for how insulin infusion should be changed based on measured glucose values and how frequent the glucose checks should be
1806693|NCT00636727|Procedure|arthrocentesis|Irrigate the TMJ with lactated ringers
1806694|NCT00636727|Procedure|arthroscopy|The TMJ will be inspected with an arthroscope and the joint irrigated with lactated ringers
1806695|NCT00636727|Procedure|arthroplasty|The disc will be surgically repositioned with open surgery
1806696|NCT00636740|Drug|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, weekly, 8 weeks
1806697|NCT00636740|Drug|Zoledronic Acid|Zoledronic Acid infusion, 4mg, every 4 weeks for 8 weeks
1806698|NCT00636740|Drug|Zoledronic Acid 20mg Tablets|Oral enteric coated tablets, 20mg, once a day for 4 consecutive days during week 1, weekly for weeks 5, 6, 7, 8
1806699|NCT00636766|Drug|atorvastatin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
1806700|NCT00636766|Drug|rimonabant|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
1806701|NCT00636766|Drug|rosiglitazone|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
1806702|NCT00636766|Drug|metformin|A:Experimental study of atherosclerosis B1:Effects of exercise on experimental atherosclerosis B2:Effects of exercise on high risk patients C1:Effects of statins on atherosclerotic plaque stability (experimental) C2:Effects of statins on atherosclerotic plaque stability (clinical) D:Effects of rosiglitazone and metformin on cardiovascular risk factors E:Effects of rimonabant on atherosclerotic plaque stability (experimental)
1806703|NCT00636792|Drug|VELCADE|VELCADE administered as a 3- to 5-second intravenous (IV) bolus prior to Bendamustine and Rituximab on Days 1,8,15 and 22 of each cycle.
1806704|NCT00636792|Drug|Bendamustine|Bendamustine administered IV over 30-60 minutes after VELCADE on Days 1 and 2 of each cycle
1806705|NCT00636792|Drug|Rituximab|Rituximab administered by IV infusion after VELCADE and Bendamustine on Days 1, 8, 15 and 22 of Cycle 1, and on Day 1 of Cycles 2, 3, 4 and 5
1806706|NCT00636805|Drug|Palonosetron (Aloxi) and Dexamethasone|single i.v. , dose of palonosetron 0.25 mg, and 10mg dexamethasone infused over 15 min, administered 30 min before the first dose Irinotecan and Bevacizumab chemotherapy.
1806707|NCT00636818|Drug|Atomoxetine|Study drug is administered once daily in the morning. This study is designed with 4-step titration. At Day 1, study drug is started from 40 mg/day, and is increased to 80 mg/day on Day 7, 105 mg/day on Day 14, and 120 mg/day on Day 28. Total administration period is 8 weeks. The dosage is adjusted according to investigator's decision based on safety and tolerability.
1806708|NCT00636831|Drug|Antibiotic: cefazolin Sodium|1g continuous IV at 30 minutes before starting operation
1806709|NCT00636857|Procedure|Fluid administration|Preoperative: bolus of 10 ml/kg body weight. During operation: 5 ml/kg body weight/hr. Postoperative: 3 ml/kg body weight/hr
1806710|NCT00636857|Procedure|Perioperative fluid management based on Lean Body Mass|Preoperative: bolus of 12 ml/kg LBM. During operation: 6 ml/kg LBM/hr. Postoperative: 3.5 ml/kg LBM/hr
1806711|NCT00636870|Drug|Fexofenadine|
1806712|NCT00636883|Drug|Gemcitabine|GEMOX-Erlotinib consists of erlotinib 100 mg orally daily starting day 1, Gemcitabine 1000 mg/m2 in 10 mg/m2/min (100 minutes) infusion on day 1 followed on day 2 by oxaliplatin 100 mg/m2 in a 2-hour infusion. Treatment will be repeated every 2 weeks. Each two weeks is a cycle.If at end of 12 cycles response continues, will administer Gemox and erlotinib till achieve maximum response. Then start Erlotinib maintenance therapy.
1806713|NCT00636896|Drug|Olanzapine plus modafinil|Olanzapine 10 mg/d plus modafinil 200 mg/d
1806714|NCT00636896|Drug|Olanzapine plus placebo|Olanzapine 10 mg/d plus placebo
1806715|NCT00636909|Drug|Cyclophosphamide|preparative cytoreduction
1806716|NCT00636909|Drug|fludarabine|preparative cytoreduction
1806717|NCT00636909|Drug|cyclosporine|immunosuppressive therapy
1806718|NCT00636909|Drug|methotrexate|immunosuppressive therapy
1806719|NCT00636909|Biological|G-CSF|foster engraftment
1806720|NCT00636922|Drug|RAD001(Everolimus)|In this study, 5-azacitidine will be administered sc for 7 doses over 9 days in a 28 day cycle. Everolimus will be administered orally with the first dose starting on day 5 (first Friday) of each cycle and continued until day 21 of each cycle. Patients will be treated with combined azacitidine + Everolimus for a minimum of 6 cycles and until at least 2 cycles after documentation of CR. Upon cessation of azacitidine, the patient will be permitted to take Everolimus maintenance therapy until progression at the investigator's discretion.
1806721|NCT00636935|Drug|Antibiotics only|Antibiotic only for treatment for mild (pO2 > 70mmHg) PCP. Antibiotic Treatment with Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone.
1806722|NCT00636935|Drug|Antibiotics + Corticosteroids|Prednisone 40mg orally twice daily for 11 days, followed by 40mg once daily for 5 days, followed by 20mg once daily for 5 days and antibiotics (Bactrim, Pentamidine, Atovaquone, Primaquine/Clindamycin, or Trimethoprim/Dapsone).
1806723|NCT00636935|Drug|Corticosteroids + antibiotics|Drugs will be prescribed per standard of care for patients with PCP and pO2 < 70mmHg.
1806724|NCT00636961|Drug|Indacaterol 300μg|300μg indacaterol maleate inhalation powder in hard gelatin capsules administered via Concept1 inhalation device
1806725|NCT00636961|Drug|Placebo|Matching placebo devices and hard gelatin capsules
1806726|NCT00636974|Procedure|Combined spinal epidural anaesthesia|
1806728|NCT00637000|Drug|Buprenorphine soluble film|Buprenorphine soluble film strips administered sublingually with doses escalated from 12 mg per day up to 24 mg daily for 5 days of total treatment.
1806729|NCT00637000|Drug|Buprenorphine/naloxone film strip|Buprenorphine/naloxone soluble film strips administered sublingually with doses escalated from 12 mg buprenorphine/3 mg naloxone to 24 mg buprenorphine /6 mg naloxone daily for 5 days of total treatment.
1806730|NCT00637000|Drug|Placebo|Placebo soluble film administered on the same schedule as active treatment to maintain the study blind.
1806731|NCT00637013|Procedure|Acromioplasty|Arthroscopic or open acromioplasty
1806732|NCT00637013|Procedure|Physiotherapy|Physiotherapy according to a standardized protocol
1806733|NCT00637026|Drug|Gefitinib|Iressa
1806734|NCT00637039|Drug|AZD8931|Tolerability and Pharmacokinetics of AZD8931 in Patients with Advanced Solid Malignancies.
1806735|NCT00637052|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
1806736|NCT00637065|Drug|Bosentan|Bosentan tablets - 62.5mg bd for first 4 weeks, then 125mg bd if tolerated until trial completion.
1806737|NCT00637065|Drug|Placebo|Placebo tables - identical to active drug but without the active ingredient -
1806738|NCT00637078|Other|Treatment algorithm:caduet, Amlodipine, ACEI-ARB combo dose, a-blocker, b-blocker or spironolactone, dyslipidemic therapy with ezetamide|initial treatment with a low dose diuretic/ACE-inhibitor or ARB combination followed by a low dose DHP-CCB/statin combination
1806739|NCT00637091|Drug|Cetuximab, irinotecan|cetuximab, irinotecan
1806740|NCT00637104|Device|Mar-Tyn TiN coated Co-Cr Numen stent implant|Implant of the Mar-tyn TiN coated stent
1806741|NCT00637104|Device|Vision Co-Cr stent implant|Implant of the Vision stent
1806742|NCT00637117|Biological|Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS|Day 1 and Day 2: 2 Gy Radiation on Day 1 and Day 2 to tumor site. Day 4, 8, 11, 18: 0.5mL injection of Autologous dendritic cells generated using GM-CSF, interferon alpha and LPS.
1806743|NCT00637130|Drug|Travoprost ophthalmic solution, 0.0008%|
1806744|NCT00637130|Drug|Travoprost ophthalmic solution, 0.001%|
1806745|NCT00637130|Drug|Travoprost ophthalmic solution, 0.0012%|
1806746|NCT00637130|Drug|TRAVATAN|
1806747|NCT00637130|Other|Vehicle|
1806748|NCT00637143|Drug|Tacrolimus|Oral
1806749|NCT00637143|Drug|Cyclosporine|Oral
1806750|NCT00637156|Device|PRESTIGE LP device at two adjacent levels|PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
1806751|NCT00637156|Device|Bi-level fusion with ATLANTIS Cervical Plate System|Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
1806752|NCT00637169|Other|Titration of oxygen therapy|Supplemental oxygen to maintain functional arterial oxygen saturations in one of two saturation target ranges.
1806753|NCT00637182|Drug|Anastrozole|
1806754|NCT00637195|Biological|Subjects received 3 doses of GSK Biologicals' HPV vaccine (580299) (Cervarix™)|Intramuscular administration, 3 doses.
1806755|NCT00637195|Biological|Engerix™|Intramuscular administration, 4 doses.
1806756|NCT00637208|Procedure|venographic occlusion of spermatic veins|Through the femoral vein a catheter is inserted into the spermatic veins in succession and the veins are occluded.
1806757|NCT00637221|Drug|NPL-2009|Single doses of either 50mg, 100 mg or 150 mg NPL-2009
1806758|NCT00637234|Drug|Oxcarbazepine|Oxcarbazepine (OXC), 300 mg tablets, up to 600 mg three times daily
1806759|NCT00637234|Drug|Placebo|Placebo, 300 mg tablets, up to 600 mg three times daily
1806760|NCT00637247|Drug|imexon in combination with gemcitabine|875 mg/m^2 imexon IV + 1000 mg/m^2 gemcitabine IV
1806761|NCT00637247|Drug|imexon placebo + gemcitabine|imexon placebo IV + 1000 mg/m^2 gemcitabine IV
1806762|NCT00637260|Device|Motor cortex stimulation on.|The parameters of stimulation will be: contact 0 cathode, contact 3anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5Volts. The stimulator will be switched on, continuously.
1806763|NCT00637260|Device|motor cortex stimulation off|The parameters of stimulation will be: contact 0 cathode, contact 3 anode, 120microsec, 80 Hz, subthreshold for any movement or sensation, usually 3-5 volts. The stimulator will be switched off.
1806764|NCT00637273|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
1806765|NCT00637273|Drug|sitagliptin|oral tablet, 100mg, once a day
1806766|NCT00637273|Drug|pioglitazone|oral tablet, 45mg, once a day
1806767|NCT00637273|Drug|placebo tablet|oral tablet, once a day
1806768|NCT00637273|Drug|placebo once weekly|subcutaneous injection, once a week
1806769|NCT00637286|Drug|Zolmitriptan|5mg Nasal Spray
1806770|NCT00637299|Other|Active osteopathic treatment (OMT+PR): Active Comparator|The treatment was done once a week for 4 weeks and lasted 30 minutes.The examination was done according to the following scheme: anamnesis; physical examination (evaluation of the posture, palpation, tests for passive and active motion of areas linked to altered respiratory function); cranic-sacral evaluation (by means of a palpation of the cranic-sacral mechanism).
1806771|NCT00637299|Other|sham osteopathic treatment (SOT+PR)|Only soft manipulation was performed
1806772|NCT00637312|Device|Cervical Artificial Disc (Advent™ Cervical Disc)|Advent™ Cervical Disc
1806773|NCT00637312|Device|Hallmark™ Anterior Cervical Plate System|Hallmark™ Anterior Cervical Plate System with AlloQuent Structural Allograft (corticocancellous allograft bone)
1806774|NCT00637325|Drug|trastuzumab|In the maintenance study trastuzumab will be administrated once every 3 weeks at the dose of 6 mg/kg by intravenous infusion over 90 minutes until progression of disease. In the 2nd line study, to accomplish the schedule of concomitant second line chemotherapy, trastuzumab will be given on a weekly (2 mg/kg) or a 3-weekly (6 mg/kg).
1806775|NCT00637338|Biological|PF-04603629|Subjects will be given either PF-04603629 or Placebo in a blinded fashion. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
1806776|NCT00637338|Biological|Placebo|Subjects will be given either PF-04603629 or Placebo in a blinded fashion during the study. Subjects will receive 4 weekly injections of PF-04603629 or Placebo.
1806778|NCT00637351|Procedure|Urine sample|One urine sample will be collected at the time of screening for subjects
1806779|NCT00637364|Procedure|High intensity focused ultrasound, HIFU|"The FEP-BY02 HIFU system uses extracorporeal generated high intensity ultrasound, focused on a tumor region of interest, to ablate tissue. A stand-alone B-mode ultrasound is used to locate and define the tumor region of interest. Once defined, the acoustic energy is delivered using a large aperture; fixed focus; sparse transducer array. The concentration of acoustic energy may result in thermal and/or mechanical bioeffects including tissue necrosis, apoptosis, and/or disruption (temporary or permanent) of normal cellular function within the targeted volume (such as nerve conduction).
The FEP-BY02 High Intensity Focused Ultrasound (HIFU) system is intended to ablate ductal adenocarcinoma of the pancreas with ultrasound-guided targeted delivery of focused ultrasound energy to effect thermal and/or mechanical bioeffects leading to ablation (destruction) of the targeted tumor tissue."
1806780|NCT00637377|Drug|Ranibizumab|Participants received a 0.5 mg dose of Ranibizumab via intravitreal (IVT) injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
1806781|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
1806782|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 0.5 mg dose of Aflibercept Injection administered every 4 weeks for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
1806783|NCT00637377|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Participants received a 2.0 mg dose of Aflibercept Injection administered every 8 weeks (including one additional 2,0 mg dose at Week 4) for the first year. Thereafter a dose may be administered as frequently as every 4 weeks, but no less frequently than every 12 weeks.
1806784|NCT00637390|Drug|Alemtuzumab|will be given Alemtuzumab therapy three times in your first week on the study and then once a week for six additional weeks
1806785|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with normal renal function (CLcr >80 mL/min)
1806786|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with mild renal impairment (CLcr 50 - 80 mL/min)
1806787|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with moderate renal impairment (CLcr 30 - <50 mL/min)
1806788|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally for a total dose of 300 mg (2.4 mL x 125 mg/mL) in subjects with severe renal impairment (CLcr <30 mL/min and not on hemodialysis)
1806789|NCT00637403|Drug|Megestrol acetate concentrated suspension 125 mg/mL|Megestrol acetate concentrated suspension (125 mg/mL) administered orally as 2 single doses of 300 mg (2.4 mL x 125 mg/mL) each in subjects with end stage renal disease undergoing hemodialysis. Washout period of 21 days between each dose
1806790|NCT00637416|Drug|Lansoprazole|Lansoprazole 30 mg taken by mouth daily for 3 months
1806791|NCT00637416|Other|Placebo|placebo taken by mouth daily for 3 months
1806792|NCT00637442|Drug|Reminyl retard|retard tablets once a day WEEK1-4: 8mg; WEEK 5-8: 16mg, WEEK 9-24: 24mg
1806793|NCT00637455|Drug|fexofenadine HCl|
1806794|NCT00637468|Drug|Intravenous injection of heparin|
1806795|NCT00637468|Drug|Intravenous injection of acetazolamide|
1806796|NCT00637468|Procedure|Local intra-arterial fibrinolysis|
1806797|NCT00637468|Procedure|Globe massage|
1806798|NCT00637468|Drug|Topical use of beta-blocker|
1806799|NCT00637468|Drug|Isovolaemic haemodilution|
1806800|NCT00637468|Drug|Acetylsalicylic acid|
1806801|NCT00637481|Drug|atorvastatin calcium|Given orally
1806802|NCT00637481|Other|laboratory biomarker analysis|Correlative studies
1806803|NCT00637494|Drug|mifepristone|1200 mg (administered as four 300 mg tablets) once a day by mouth for the initial 7 days
1806804|NCT00637494|Drug|placebo|Tablets of identical appearance to active drug, once a day by mouth for the initial 7 days
1806805|NCT00637507|Other|High-frequency Oscillation and Tracheal Gas Insufflation|Patients will receive daily sessions of High-frequency Oscillation and Tracheal Gas Insufflation (HFO-TGI), which will last at least 6 hours. These sessions will comprise a recruitment period of at least 90 min, a stabilization period of at least 4 hours, and a weaning period of at least 60 min. The HFO-TGI strategy will be aimed at initially maximizing PaO2/FiO2 without causing hemodynamic compromise (e.g., >10% reduction in cardiac output/index), and subsequently maintaining PaO2/FiO2 >150 mm Hg, while gradually reducing mPaw to 4-6 cm H2O below its initial setting. The weaning from TGI and HFO will be according to the reversal of the oxygenation criterion that mandated their use (see also Detailed Description).
1806806|NCT00637533|Procedure|Lumbar sympathetic block with Botulinum Toxin type A|
1806807|NCT00637546|Other|Physiotherapy|Gait and Balance training based on recommendations of Robertson et al. and Page et al. (different balance control exercises; progression in consecutive stages: Sensimotor training, a static phase, a dynamic phase combined with functional tasks. The treatment takes place twice a week over 12 weeks. Patients were encouraged to perform specific home exercises.
1806808|NCT00637559|Drug|Esomeprazole Magnesium|
1806809|NCT00637572|Drug|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL|Megestrol acetate oral suspension nanocrystal dispersion 115 mg/mL administered as 575 mg once per day (5 mL dose)
1806810|NCT00637572|Drug|Megestrol acetate oral suspension 40 mg/mL|Megestrol acetate oral suspension 40 mg/mL administered as 800 mg once per day (20 mL dose)
1806811|NCT00637585|Drug|Fexofenadine|
1806812|NCT00637598|Radiation|Mammography and tomosynthesis imaging|All subjects receive the same radiation dose associated with mammography and tomosynthesis imaging (which is comparable to mammography).
1806813|NCT00637611|Drug|Fexofenadine HCl|
1806814|NCT00637624|Drug|N-Acetylcysteine|N-Acetylcysteine intravenously once every 3 weeks 40 mg/kg
1806820|NCT00637650|Procedure|Ureteroscopy, Holmium laser lithotripsy, no intent to retrieve any remaining fragment|
1806821|NCT00637663|Drug|Entecavir|entecavir 0.5 mg QD
1806822|NCT00637663|Drug|Lamivudine|lamivudine 100 mg QD
1806823|NCT00637676|Procedure|VATS, Talc-Pleurodesis, tunneled pleural drainage|poudrage of 4 gr talc into the pleural cavity implantation of tunneled pleural catheter
1806824|NCT00637676|Procedure|VATS, Talc-pleurodesis|poudrage of 4 gr. talc into the pleural cavity no tunneled pleural catheter
1806825|NCT00637702|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|single dose and multiple dose, escalating
1806826|NCT00637715|Drug|Alfuzosin|
1806827|NCT00637728|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
1806828|NCT00637728|Drug|Placebo|Placebo oral suspension, 5 mL once daily
1806829|NCT00637741|Device|Everflex 200|
1806830|NCT00637767|Drug|melphalan|
1806831|NCT00637767|Procedure|autologous hematopoietic stem cell transplantation|
1806832|NCT00637767|Radiation|yttrium Y 90 anti-CD66 monoclonal antibody BW 250/183|
1806833|NCT00637780|Drug|Sulfasalazine|Sulfasalazine delayed release tablets 30-60 mg/kg/day (divided into BID doses) for 7 days. Blood sampling for Pharmacokinetic assessment to be performed on Day 7
1806834|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
1806835|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
1806836|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
1806837|NCT00637793|Drug|NGX267|2 capsules in the am of each treatment period
1806838|NCT00637806|Drug|Megestrol acetate concentrated suspension 110 mg/mL|Megestrol acetate concentrated suspension 110 mg/mL given as an oral dose of 550 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
1806839|NCT00637806|Drug|Megestrol acetate concentrated suspension 60 mg/mL|Megestrol acetate concentrated suspension 60 mg/mL given as an oral dose of 300 mg (5 mL) once per day for 56 days, with an optional 28 days extension phase
1806840|NCT00637806|Drug|Placebo|Placebo oral suspension, 5 mL once daily
1806841|NCT00637819|Drug|Leflunomide|A loading dose of LEF 100mg daily for 3 days, followed by LEF 20mg daily for the remainder of the study or matching placebo
1806842|NCT00637832|Biological|rituximab|
1806843|NCT00637832|Drug|cyclophosphamide|
1806844|NCT00637832|Drug|doxorubicin hydrochloride|
1806845|NCT00637832|Drug|prednisolone|
1806846|NCT00637832|Drug|vincristine sulfate|
1806847|NCT00637832|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1806848|NCT00637845|Drug|Esomeprazole Magnesium|40mg once daily
1806849|NCT00637845|Drug|Lansoprazole|30mg twice daily
1806850|NCT00637858|Dietary Supplement|Lyc-O-Mato 5mg|Daily Lyc-O-Mato 5mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
1806851|NCT00637858|Dietary Supplement|Lyc-O-Mato 15mg|Daily Lyc-O-Mato 15mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
1806852|NCT00637858|Dietary Supplement|Lyc-O-Mato 30mg|Daily Lyc-O-Mato 30mg with lunch for 8 weeks (After 4 weeks of placebo run in). Lyc-O-Mato 6%, Natural tomato Complex, is packed into soft gelatin capsule
1806853|NCT00637858|Dietary Supplement|Lycopene capsules (non Lyc-o-mato) 15 mg|Daily Lycopene capsules (non Lyc-o-mato) 15 mg with lunch for 8 weeks (After 4 weeks of placebo run in).
1806854|NCT00637858|Other|Placebo|Placebo capsules, identical looking to previous capsules for double-blind treatment period (8 weeks) and single blind run-in (4 weeks).
1806855|NCT00637871|Drug|Casodex|150mg once daily
1806856|NCT00637871|Drug|Tamoxifen|
1806857|NCT00637884|Drug|Fexofenadine HCl|
1806858|NCT00637897|Drug|docetaxel|
1806859|NCT00637897|Drug|ixabepilone|
1806860|NCT00637897|Drug|paclitaxel|
1806861|NCT00637897|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1806862|NCT00637897|Drug|paricalcitol|
1806863|NCT00637910|Drug|Erlotinib|Erlotinib 150 mg/day per os until disease progression or unacceptable toxicity develops
1806864|NCT00637910|Drug|Docetaxel|Docetaxel 75 mg/mq on day 1, every 21 days (3-weekly schedule) or Docetaxel 35 mg/mq 0n day 1,8 and 15 every 28 days (weekly schedule). _Until disease progression or unacceptable toxicity develops
1806865|NCT00637923|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet orally with food twice daily (b.i.d.) for 4 weeks followed by 500 mg nitazoxanide b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
1806866|NCT00637923|Drug|Placebo|One placebo tablet orally with food twice daily (b.i.d.) for 4 weeks followed by placebo b.i.d. plus one weekly injection of 180µg of peginterferon α-2a plus weight-based ribavirin for 48 weeks.
1806867|NCT00637923|Biological|Peginterferon alfa-2a|One weekly injection of 180µg of peginterferon α-2a for 48 weeks.
1806868|NCT00637923|Drug|Ribavirin|Weight-based ribavirin for 48 weeks.
1806869|NCT00637936|Drug|Oxygen|Inspiratory fraction during anaesthesia
1806870|NCT00637949|Device|lumiracoxib|400 mg once daily, oral over 6 weeks
1806871|NCT00637949|Drug|rofecoxib|25 mg, oral, daily over 6 weeks
1806872|NCT00637962|Biological|HIV glycoprotein CN54gp140 (vaccine)|vaginal immunisation with 100ug CN54gp140 antigen in gel on 9 occasions in one menstrual cycle
1806873|NCT00637962|Biological|Carbopol 974|vaginal immunisation with Carbopol 974 P 0.924%; benzyl alcohol 1.09%; sodium hydroxide 0.176%; and purified water 97.81%. alone on 9 occasions in one menstrual cycle
1806874|NCT00637975|Drug|oxycodone|"Arm A - 20 mg/day
Arm B - increasing dose startnig at 20 mg/day
For 15 days or until unacceptable toxicity develops."
1806875|NCT00637975|Drug|pregabalin|"Arm A - pregabalin at increasing dose starting from 50 mg/day
Arm B - pregabalin 50 mg/day
For 15 days or until unacceptable toxicity develops."
1806876|NCT00637988|Drug|Esomeprazole|40mg twice daily
1806877|NCT00637988|Drug|Aspirin|
1806878|NCT00637988|Drug|Rofecoxib|25mg once daily
1806926|NCT00630370|Drug|20 mg ATI 7505|1 ATI 20mg and 1 placebo tablet, TID, orally, 58 days
1807604|NCT00635245|Other|pharmacological study|
1806879|NCT00638001|Device|custom-molded insoles and custom-molded shoes|"custom-made insoles in PELITE foam (hypoallergenic prosthesis grade foam) or leather top cover cork insoles for patients suffering of mild to moderate ankle arthropathy
custom-molded shoes in leather for patients suffering of end-stage ankle arthropathy"
1806880|NCT00638014|Device|Rapid Sternal Closure System|Sternal talons will be used and supplemented with wires
1806881|NCT00638014|Device|Conventional wire closure|Conventional wire closure of sternum
1806882|NCT00638027|Drug|placebo|matched tablets bid
1806883|NCT00638027|Drug|memantine|10 mg bid
1806884|NCT00638053|Genetic|somatropin|Somatropin will be administered as a daily subcutaneous injection; Fixed doses starting with 0.1 mg/day in patients older than 55 years or patients weighing less than 50 kg; all other patients: 0.1 mg/day or 0.2 mg/day (these doses should all be lower than 0.04 mg/kg/week); all patients starting at 0.1 mg/day will have their dose progressively increased in 0.1 mg/day increments to a maximum clinically- and pharmacologically- tolerated plateau dose; all patients starting at 0.2 mg/day will increase in 0.2 mg/day increments; all incremented dose changes will occur at monthly intervals based on IGF-I levels; treatment will continue for 12 months
1806885|NCT00638066|Drug|botulinum toxin|500 units of botulinum toxin for the second arm
1806886|NCT00638066|Drug|botulinum toxin A|250 units of botulinum toxin A once
1806887|NCT00638079|Drug|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered with a high fat meal
1806888|NCT00638079|Drug|Megestrol acetate oral suspension 625 mg/5 mL|Megestrol acetate oral suspension 625 mg/5 mL. Single dose (5 mL) administered following an overnight fast
1806889|NCT00638092|Drug|sodium iodide|sodium iodide 30 micrograms/kg/day, daily dose, from randomisation (within 42 hours of birth) to 34 corrected weeks gestation
1806890|NCT00638092|Drug|Sodium Chloride|Sodium Chloride 30 micrograms/kg/day, daily dose, from randomisation (from within 42 hours of birth)to 34 corrected weeks gestation
1806891|NCT00638118|Drug|Fexofenadine|
1806892|NCT00638131|Drug|bosentan|62.5mg bid x4 weeks, up-titrate to 125mg bid x12 weeks
1806893|NCT00638157|Drug|daptomycin|Intravenous (i.v.) 6 mg/kg q24h
1806894|NCT00638157|Drug|daptomycin and gentamicin|i.v. daptomycin 6 mg/kg q24h plus initial i.v. gentamicin
1806895|NCT00630188|Other|You Decide|"For Patients: Video-based decision aid on prostate cancer screening, One-on-One values clarification session with research assistant, One-on-One coaching session with research assistant to encourage good interaction with clinician
For Physicians: a one-time educational session on prostate cancer and the value of shared decision making"
1806896|NCT00630188|Other|Reducing Your Risks in the Crash|Publicly available video on highway safety and reducing individual risks in a crash
1806897|NCT00630201|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants, 6-month duration).
1806898|NCT00630214|Dietary Supplement|Oral calcium plus vitamin D|calcium supplementation took 3 g/day oral calcium (1 g every 8 h) plus 1 mcg/day vitamin D (0.5 mcg every 12 h), beginning on the night of surgery and continuing for 14 days.
1806899|NCT00630214|Dietary Supplement|Oral calcium alone|calcium carbonate (3 g/day, 1 g every 8 h)
1806900|NCT00630227|Biological|Biologic Lung Volume Reduction|20 mL Hydrogel
1806901|NCT00630253|Biological|Anti-Thymocyte Globulin|30 mg/kg/day will be administered after MP on days -6, -5, -4, -3 and -2.
1806902|NCT00630253|Drug|Cyclophosphamide|5 mg/kg is to be given as a 2 hour infusion, Days -6 through -3.
1806903|NCT00630253|Drug|Fludarabine|35 mg/m^2 intravenously (IV) on days -6 through -2.
1806904|NCT00630253|Procedure|Hematopoietic Stem Cell Transplantation|Bone marrow or umbilical cord blood infusion on day 0.
1806905|NCT00630253|Drug|Methylprednisolone|Methylprednisolone (MP) 2 mg/kg/day intravenously every 24 hours will be given from day -6 until day -2 as a premedication for ATG.
1806906|NCT00630253|Drug|Filgrastim|5 mcg/kg per day intravenously (IV) continue until Absolute neutrophil count > or = 2.5 x 10^9/L
1806907|NCT00630253|Drug|Cyclosporine|Cyclosporine IV over 2 hours or orally every 8-12 hours beginning on day -3 and continuing until day 100, followed by a taper.
1806908|NCT00630253|Drug|Mycophenolate Mofetil|Day -3 through day +30 or for 7 days after engraftment, whichever day is later, if no acute GVHD. Engraftment is defined as 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9/L. MMF will be given at a dose of 15 mg/kg/dose every 8 hours PO (to a maximum dose of 1 gram).
1806909|NCT00630266|Device|CorCap CSD|The surgical procedure includes implantation of the CorCap CSD with concommitant mitral valve surgery through a sternotomy.
1806910|NCT00630279|Drug|Placebo|Placebo
1806911|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 150 mg/d, 7 days treatment
1806912|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 300 mg/d, 7 days treatment
1806913|NCT00630279|Drug|Recombinant Microbial Lipase SLV339|oral, 600 mg/d, 7 days treatment
1806914|NCT00630292|Other|Magnetic Resonance Angiography (MRA) of the Breast|Magnetic Resonance Angiography (MRA) of the breast will be performed before or after pre-treatment magnetic resonance imaging (MRI) and then once again before or after the post-treatment MRI.
1806915|NCT00630305|Device|alphafilcon A toric|Subjects that were randomized to receive alphafilcon A toric during one of the four sessions (Sessions A, B, C and D).
1806916|NCT00630305|Device|lotrafilcon B toric|Subjects that were randomized to receive lotrafilcon B toric during one of the four sessions (Sessions A, B, C and D).
1806917|NCT00630305|Device|senofilcon A toric|Subjects that were randomized to receive senofilcon A toric during one of the four sessions (Sessions A, B, C and D).
1806918|NCT00630318|Device|MRI|15-20 minutes MR imaging
1806919|NCT00630331|Biological|Cell culture-derived influenza vaccine|One dose (0.5 mL) of cell culture-derived influenza vaccine, administered in the deltoid muscle.
1806920|NCT00630331|Biological|Egg-derived influenza virus vaccine|One dose (0.5 mL) of the trivalent egg-derived influenza virus vaccine, administered in the deltoid muscle.
1806921|NCT00630331|Biological|Placebo|One dose (0.5 mL) of phosphate buffered solution.
1806922|NCT00630344|Drug|RAD001|Taken orally once daily
1806923|NCT00630344|Drug|Bicalutamide|Taken orally once daily
1806924|NCT00630357|Drug|Levetiracetam (Keppra)|
1806927|NCT00630370|Drug|40 mg ATI 7505|1 ATI 40mg and 1 placebo tablet, TID, orally, 58 days
1806928|NCT00630370|Drug|80 mg ATI 7505|2 ATI 40mg tablets, TID, orally, 58 days
1806929|NCT00630383|Biological|Live Hookworm Larvae|25 live hookworm will be applied to the arm and will infect transdermally. They will be eradicated after 48 weeks.
1806930|NCT00630383|Other|Histamine|0.01% histamine solution is pipetted onto a plaster dressing.
1806931|NCT00630396|Drug|Minocycline|"Dose level 1 = 3mg/kg intravenous (IV) initial dose, followed by 1.5mg/kg every 12 hours times 5 more doses.
Dose level 2 = 4.5mg/kg intravenous (IV) initial dose, followed by 2.25mg/kg every 12 hours times 5 more doses.
Dose level 3 = 6 mg/kg intravenous (IV) initial dose, followed by 3 mg/kg every 12 hours times 5 more doses.
Dose level 4 = 10 mg/kg intravenous (IV) initial dose, followed by 5 mg/kg every 12 hours times 5 more doses"
1806932|NCT00630409|Drug|Gemcitabine|800 mg IV day 1 and 8
1806933|NCT00630409|Drug|Doxil|24 mg/m2 every 21 days IV
1806934|NCT00630435|Drug|Premarin®/MPA formulation A|
1806935|NCT00630435|Drug|Premarin®/MPA formulation B|
1806936|NCT00630435|Drug|Premarin®/MPA formulation C|
1806937|NCT00630435|Drug|Premarin®/MPA currently marketed product|
1806938|NCT00630461|Biological|Clinical Center Reference Endotoxin|single inhalation challenge
1806939|NCT00630474|Drug|xylometazoline|xylometazoline (0.1 % solution, 3 drops, 0.15 mg) in each nostril
1806940|NCT00630487|Drug|Placebo|Patients of Placebo Group will be treated with placebo sub-cutaneous in the same way as Somatropin during the double blind treatment phase. To maintain blind subject will be measured in the same way as the treatment group for IGF-I- Levels. Central lab will randomize placebo patients to dose change or maintenance of dose. This will ensure continued blinding of the study to patients and personnel.
1806941|NCT00630487|Drug|Somatropin|Fixed doses for patients: MALE: < 45y 0,4 mg, > 45y 0,2mg FEMALE: < 45y 0,5mg, >45y 0,3mg. for the first 4 weeks half of the dose will be given. After that dose will be increased to the targeted maintenance dose according to IGF-I Levels +/- 2 SD of age adjusted reference range. In case of side effects dosage will remain on half-dose (during the first 4 weeks) or reduced to half dose (after the first 4 weeks). At week 52 patients have the opportunity to switch to open label study restarting with half the given fixed dose which will be adjusted to full dose after 4 weeks.
1806942|NCT00630500|Drug|Memantine|Tablets, 5 or 10 mg, twice daily
1806943|NCT00630500|Drug|Placebo|Tablets corresponding to 5 or 10 mg, twice daily, 6 months
1806944|NCT00630513|Drug|Ertapenem|3 days regimen with Ertapenem (1 g/day i.v.)
1806945|NCT00630513|Drug|Ampicillin-Sulbactam|3 days treatment with Ampicillin-Sulbactam (AS 3g x 3/ day i.v.)
1806946|NCT00630539|Drug|Placebo|1 tablet per day, orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
1806947|NCT00630539|Drug|Ospemifene 5 mg|1 tablet of ospemifene 5 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
1806948|NCT00630539|Drug|Ospemifene 15 mg|1 tablet of ospemifene 15 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
1806949|NCT00630539|Drug|Ospemifene 30 mg|1 tablet of ospemifene 30 mg (QD), orally, in the morning, with food for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (End of therapy, Week 12).
1806950|NCT00630552|Other|Placebo|Inactive dummy of AMG 655.
1806951|NCT00630552|Drug|AMG 479|AMG 479 is fully human monoclonal antagonist antibody targeted against insulin-like growth factor receptor type 1 (IGF-1R).
1806952|NCT00630552|Drug|AMG 655|AMG 655 is a fully human monoclonal agonist antibody directed against TRAIL Receptor 2 (TR-2).
1806953|NCT00630565|Biological|sargramostim|Given subcutaneously (SC) 10 μg/kg/day from day +3 until apheresis is completed
1806954|NCT00630565|Drug|busulfan|4 mg/kg po in 4 divided doses (.8 mg/kg/dose orally every 6 hours) on days -7 through -4.
1806955|NCT00630565|Drug|cyclophosphamide|4 gm/m^2 x 1 (day 0) and 60 mg/kg intravenous (IV) over 2 hours on days -3 and -2.
1806956|NCT00630565|Drug|dexamethasone|20 mg/m^2 x 4 doses every 12 hours given intravenously (IV) push before cytoxan on day 0 and then every 12 hours
1806957|NCT00630565|Drug|etoposide|300 mg/m^2/day x 2 days (day 0-1) over 3 hours intravenously (IV)
1806958|NCT00630565|Procedure|bone marrow transplantation|Day 0 infusion of bone marrow cells
1806959|NCT00630565|Procedure|hematopoietic stem cell transplantation|Stem cell infusion (>48 hours after the last dose of cyclophosphamide)
1806960|NCT00630565|Procedure|peripheral blood stem cell transplantation|Day 0 infusion of peripheral blood stem cells
1806961|NCT00630565|Radiation|total-body irradiation|165 cGy/dose given twice a day on days -7 through -4.
1806962|NCT00630578|Behavioral|Cognitive Processing Therapy|Clients will receive between 4 and 20 sessions of Cognitive Processing Therapy.
1806963|NCT00630591|Behavioral|Standardized Materials Group|7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
1806964|NCT00630591|Behavioral|Independent Tailored Intervention|Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
1806965|NCT00630591|Behavioral|Partner-Assisted Tailored Intervention|Daughters and Mothers, as a team, will each receive personalized notebooks and newsletters of diet and exercise information. A short survey about the information received and how useful it was will be completed.
1806966|NCT00630617|Behavioral|Diet, Physical activity, Physical inactivity|Community based participatory research design
1806967|NCT00630630|Drug|Levetiracetam|
1806968|NCT00630630|Other|Placebo|
1806969|NCT00630643|Biological|NI-0401 (anti-CD3 mAB)|0.05 mg up to 10 mg
1806970|NCT00630643|Drug|Placebo|Placebo
1806971|NCT00630656|Drug|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
1806972|NCT00630656|Drug|Placebo|Placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
1806973|NCT00630669|Procedure|Rubber band ligation|placing rubber bands around the internal hemorrhoids
1806974|NCT00630669|Procedure|Bipolar coagulation|using electricity to cauterize
1806975|NCT00630682|Drug|Dextroamphetamine|1 week placebo and 8 weeks 60mg d-AMP QD.
1806976|NCT00630682|Drug|Placebo|9 weeks of placebo 60mg capsules QD.
1806977|NCT00630695|Drug|Lanreotide LP 90|Lanreotide LP 90
1806978|NCT00630695|Drug|Placebo lanreotide|Placebo
1806979|NCT00630708|Drug|Benazepril|20 mg per day
1806980|NCT00630708|Drug|Losartan|100 mg per day
1806981|NCT00630708|Drug|Benazepril+Losartan|combination treatment of 10 mg benazepril and 50 mg losartan per day
1806982|NCT00630721|Other|IFNbeta-1b|no drug was given under study arm. only blood draw on patients already on IFNbeta-1b.
1806983|NCT00630734|Drug|Pravastatin|Pravastatin 40 mg by mouth daily on days 1-4
1806984|NCT00630734|Drug|Darunavir|Darunavir 600mg by mouth twice daily on days 12-18
1806985|NCT00630734|Drug|Ritonavir|Ritonavir 100mg by mouth twice daily on days 12-18
1806986|NCT00630734|Drug|Pravastatin|Pravastatin 40 mg by mouth daily on days 15-18
1806987|NCT00630734|Other|Washout|Washout (no medication) on days 5-11.
1806988|NCT00630747|Biological|Idursulfase|Solution for intravenous infusion, 0.5 mg/kg once-weekly
1806989|NCT00630760|Drug|NRX 194204|NRX 194204 capsules given 3mg/m2 daily x 28 days. Repeated until PD
1806990|NCT00630786|Drug|Panitumumab|Administered by intravenous infusion
1806991|NCT00630786|Drug|Conatumumab|Administered by intravenous infusion
1806992|NCT00630799|Drug|leuprolide acetate|17 mg i.m.
1806993|NCT00630812|Drug|inhaled mannitol|400 mg BD for 26 + 26 weeks
1806994|NCT00630812|Drug|Placebo comparator|BD for 26 weeks followed by 26 weeks of inhaled mannitol in the open label phase
1806995|NCT00630825|Drug|LY2189265|
1806996|NCT00630825|Drug|Placebo|
1806997|NCT00630838|Drug|VSL#3|"Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (360 billion bacteria or 4 sachets) of VSL#3 will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (180 billion bacteria or 2 sachets) daily in the same amount of formula or breast milk.
E.2.6. Time of start of probiotics: Probiotic vs. placebo will begin once the infant has reached full oral feeding."
1806998|NCT00630838|Drug|Placebo|Dosing will be based on patient weight. For those infants greater or equal to 5 kg, one gram (4 sachets) of placebo will be administered into 3 ounces of either expressed breast milk or formula daily. For patients under 5 kg, 0.5 gm (2 sachets) daily in the same amount of formula or breast milk Initiation: within one week of pullthrough Duration: 3 months
1806999|NCT00630851|Drug|Donepezil (Aricept)|Donepezil (Aricept) 5 mg tablet orally once daily for 30 days, followed by 10 mg tablet orally once daily to complete 6 months of treatment
1807000|NCT00630851|Drug|Placebo|Matching placebo tablets orally once daily for 6 months
1807001|NCT00630864|Drug|Fx-1006A|During Part 1, patients will receive Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for two weeks. During Part 2, patients will receive Fx-1006A 20mg soft gelatin capsules once daily to complete a total of 12 months of dosing
1807002|NCT00630877|Drug|Niacin extended-release (NER)|Tablets administered once daily for 6 weeks; titrated to a maximum dose of 2000 mg
1807003|NCT00630877|Drug|Niacin extended-release (NER) placebo|Tablets administered once daily for 6 weeks
1807004|NCT00630877|Drug|Aspirin (ASA)|Tablets (325 mg) administered once daily for 6 weeks
1807005|NCT00630877|Drug|Aspirin (ASA) placebo|Tablets administered once daily for 6 weeks
1807006|NCT00630890|Radiation|External beam radiation and Cyberknife radiosurgery boost and capecitabine|External Beam Radiation to 45 Gy Stereotactic Body Radiotherapy with Cyberknife to 20 Gy in 5 fractions dose escalation to 25 Gy in 5 fractions, and then 30 Gy in 5 fractions Capecitabine 825 mg/m2 q12 hours taken orally 5 days per week
1807007|NCT00630903|Drug|PUVA (8MOP + UVA) + IFN|Weeks 3-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated) IFN: week1: 3, 6 and 9 MU (Mon, Wed, Fry). Weeks 2-24: 9MU 3 times a week)
1807008|NCT00630903|Drug|PUVA (8-MOP + UVA)|Weeks 1-24: 8.MOP: 0.6 MG/K, 3 times a week, 2 hours pre UVA irradiation (1-2 jul/cm2 according to phototype, increasing until 10 Jul/cm2, if tolerated)
1807009|NCT00630916|Device|Mitroflow Aortic Heart Valve|Replacement of the native aortic valve or a previously implanted prosthetic aortic valve
1807010|NCT00630929|Drug|Ibuprofen|800 mg oral tablet 3 times daily with meals for 6 weeks
1807011|NCT00630929|Drug|Placebo|Matched placebo orally for 6 weeks
1807012|NCT00630929|Drug|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
1807013|NCT00630942|Drug|Minocycline|Minocycline 100 mg capsules twice a day before breakfast and before dinner.
1807014|NCT00630955|Drug|memantine|Memantine 20 mg once per day for 7 days
1807015|NCT00630955|Drug|Memantine|Memantine 40 mg once per day for 7 days
1807016|NCT00630955|Drug|Placebo|Placebo once per day for 7 days
1807017|NCT00630968|Drug|Levetiracetam (Keppra)|
1807020|NCT00630994|Drug|Dacogen|
1807021|NCT00631007|Drug|INT131 besylate|Once-daily, oral
1807022|NCT00631007|Drug|Pioglitazone HCl|Once-daily, oral
1807023|NCT00631007|Drug|Placebo|Once-daily, oral
1807024|NCT00631020|Behavioral|CBME|6 weeks of once a week one-on-one CBME
1807025|NCT00631020|Drug|Optional NRT|NicoDerm CQ nicotine transdermal patch
1807026|NCT00631033|Drug|Placebo|
1807027|NCT00631033|Drug|Diazoxide|
1807028|NCT00631033|Drug|Metformin + Diazoxide|
1807029|NCT00631046|Dietary Supplement|Fish Oil|Daily dosage of 5 ml of fish oils from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
1807030|NCT00631046|Dietary Supplement|Sunflower Oil|Daily dosage of 5 ml of sunflower oil from 9 months +/- 2weeks to 18 months +/- 4 weeks of age
1807031|NCT00631059|Other|Hem(A)+ Technology|The purpose of the study is to test patients blood. A blood draw will be taken and examined with Hem(A)+ technology.
1807032|NCT00631072|Biological|INKT|Administered in 3 equal doses by intravenous infusion on days 1, 15 and 29.
1807200|NCT00638248|Drug|Desmoteplase|Desmoteplase 90µg/kg BW i.v. bolus
1807033|NCT00631072|Drug|GM-CSF|Given subcutaneously once daily for 10 days beginning the second day of the second and third infusion
1807034|NCT00631085|Drug|gamma tocopherol|Maxi Gamma softgels 1200mg QD
1807035|NCT00631098|Procedure|venous cannulation|External jugular and cubital vein cannulation
1807036|NCT00631111|Drug|effervescent ibuprofen tablets|
1807037|NCT00631111|Drug|effervescent Aspirin plus Vitamin C tablets|
1807038|NCT00631111|Drug|ibuprofen tablets|
1807039|NCT00631111|Drug|placebo|
1807040|NCT00631124|Drug|BAY86-4891 (Estradiol / Drospirenone)|Monophasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
1807041|NCT00631124|Drug|BAY86-4891 (Estradiol / Drospirenone)|Triphasic regimen containing estrogen and progestin 1 pre-treatment cycle, 3 treatment cycles
1807044|NCT00631150|Drug|Levetiracetam (Keppra)|
1807045|NCT00631163|Drug|Deferasirox (ICL670)|The recommended initial daily dose of Deferasirox is 20 mg/kg body weight.
1807046|NCT00631176|Behavioral|Just-In-Time Training|On-call pediatric residents from 7 south PICU (24 beds) will receive 20 minutes of just-in-time pediatric airway management training. This training will occur before their shift starts before the morning round. This training will cover direct laryngoscopy technique, orotracheal intubation technique, confirmation of the tube placement and recognition of associated events. This training will be done with or without high fidelity simulation function.
1807047|NCT00631189|Drug|Rosuvastatin|5mg oral
1807048|NCT00631189|Drug|Pravastatin|40mg oral
1807049|NCT00631189|Drug|Atorvastatin|10mg oral
1807050|NCT00631202|Drug|Epoetin alfa|Patients that will satisfy all inclusion/exclusion criteria will be sequentially treated with three single Epoetin alfa administrations. The first time the dose will be 600U/KG BW s.c. in a single administration. The outcome measures will be assessed. A washout period of 1 month will be necessary to eliminate any carry-over effect. A second administration of 1200U/KG BW s.c. will be performed. Outcome measures will be again assessed.
1807051|NCT00631215|Procedure|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy: 1.3 atmospheres of pressure, 100%0xygen by face mask, for 60 minutes
1807052|NCT00631228|Device|XIENCE V® Everolimus Eluting Coronary Stent|Drug eluting stent implantation stent in the treatment of coronary artery disease
1807053|NCT00631241|Procedure|Single Photon Emission Computed Tomography|First 3 Patients = Performed 30-45 minutes, 2-3 hours, and 20-24 hours after injections of the radioactive material or just before surgery; Remaining 17 Patients = Performed only one at a time as was found to be best based on the scans from first 3 patients.
1807054|NCT00631241|Procedure|Intraoperative Lymphatic Mapping|Isosulfan Blue and India ink will be injected into the cervix to help the surgeon identify the sentinel nodes by their blue color and their level of radioactivity.
1807057|NCT00631267|Procedure|Manual Manipulation|The currently used method for reduction: using manual traction to reduce the distal radial fragment by hyperextension followed by hyperflection.
1807058|NCT00631267|Procedure|Finger Trap Traction|Using a finger trap traction device in vertical suspension. After 10min reduction by dorsal pressure.
1807059|NCT00631280|Behavioral|Choice|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a decision aid. Parent treatment preferences will be elicited and parents will receive coaching in deliberation about striking a balance between benefit and tolerable side effects. Parent will then choose the week that was best for their child and plan their next steps. Parents will also receive a consultation report that contains a physician dosage recommendation.
1807060|NCT00631280|Behavioral|Recommendation|Parent and teacher reports of child behavior and side effects observed during a 4-week trail of placebo and methylphenidate at lower, medium, and higher dosages will be summarized in a consultation report that also contains a physician dosage recommendation.
1807061|NCT00631293|Dietary Supplement|lactisole|administration of lactisole followed by placebo
1807062|NCT00631293|Other|placebo|administration of placebo followed by lactisole
1807064|NCT00631345|Behavioral|Group-Based Lifestyle Intervention (Phases 1 and 2)|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for the first 6-months of treatment (Phase 1) for a total weight loss of 5-7%. During Phase 2 (months 7-24) participants will be encouraged to continue weight loss as long as their BMI does not fall below 20 kg/m2, but the primary focus will be on weight maintenance. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
1807065|NCT00631345|Other|Individual Education Program (All Phases)|Comparison participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the RD will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle and will receive the lifestyle intervention manual and video series at the conclusion of their participation. These participants will be approached about the continuation at 24 months. If they agree to participate, these participants will continue to receive a monthly newsletter and will also receive biannual RD contacts.
1807201|NCT00638248|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW i.v. bolus
1807202|NCT00638248|Drug|Placebo|Placebo i.v. bolus
1807066|NCT00631345|Behavioral|Self-Directed Maintenance (Phase 3)|Individuals from the lifestyle intervention group in the original HELP PD project who are randomized to self-directed maintenance will receive biannual nutrition counseling from the study RDs. In these sessions, the RD will cover basic aspects of transition from the group maintenance to individual maintenance, answer questions about healthy eating and activity to support weight loss, and discuss existing community resources that may fit the participants' needs as they attempt to maintain their weight loss, physical activity and dietary goals.
1807067|NCT00631345|Behavioral|Extended Group Maintenance (Phase 3)|The extended group maintenance condition will consist of monthly CHW-led group meetings, monthly individual telephone contacts with the CHW, biannual RD contacts, and other contacts as needed. During Phase 3, the objectives for Phase 2 of the initial program will be continued. That is, participants who were successful at weight loss (≥ 7% of initial body weight) are encouraged to either maintain their weight loss or to advance towards their own personal goals. Participants who were not successful are encouraged to problem solve the reasons for lack of success. The groups will focus on maintaining the healthy behaviors that produced weight loss and/or problem solving to overcome barriers to weight loss.
1807068|NCT00631358|Drug|Maxidex|Maxidex (0.1% Dexamethasone) 1 drop in each eye 2 times daily
1807069|NCT00631358|Other|No treatment|Healthy normal control group receiving no treatment
1807070|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
1807071|NCT00631371|Drug|Temsirolimus|Temsirolimus 25 mg IV weekly
1807072|NCT00631371|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenous (IV) q8wks
1807073|NCT00631371|Drug|Interferon-Alfa 9MU|Interferon-Alfa 9MU SC TIW
1807074|NCT00631384|Behavioral|Couples VCT|Offer women coming to antenatal clinics to have their husbands come with them for couples VCT
1807075|NCT00631384|Behavioral|Individual VCT|Women to receive individual VCT
1807076|NCT00631397|Device|Ultrasound machine|Weekly Bone Density measurements using the Sonometer
1807077|NCT00631410|Drug|sunitinib + mFOLFOX6|37.5 mg/day, oral, administered on an outpatient basis for 4 weeks on, 2 weeks off (Schedule 4/2)
1807078|NCT00631410|Drug|sunitinib + mFOLFOX6|50 mg/day, oral, administered on an outpatient basis for 2 weeks on, 2 weeks off (Schedule 2/2)
1807079|NCT00631449|Drug|Raltegravir|For subjects assigned to the raltegravir group, subjects will receive raltegravir 400 mg to be taken by mouth twice daily, in addition to continuing to take their current anti-HIV medicines.
1807080|NCT00631449|Drug|Placebo|For subjects assigned to the placebo group, subjects will receive a matching placebo pill 400 mg to be taken by mouth twice daily for 24 weeks, in addition to continuing to take their current anti-HIV medicines.
1807081|NCT00631462|Drug|TG101348|Orally administered, once a day, for 28 days, up to 6 cycles.
1807082|NCT00631475|Drug|Bosentan|"For patients who were administered Bosentan during BUILD 3 (NCT00391443):
continue on same dose
For patients who were administered placebo during BUILD 3 (NCT00391443):
Oral Bosentan 62.5 mg for 4 weeks; maintenance dose: 125 mg ( 62.5 if patient weighs < 90 lbs.)"
1807083|NCT00631488|Drug|MK-0893|Initial loading dose of 200 mg MK-0893 at randomization, followed by MK-0893 administered orally as 40 mg tablets daily throughout the double-blind treatment period (4 weeks).
1807084|NCT00631488|Drug|Sitagliptin|Sitagliptin Phosphate administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
1807085|NCT00631488|Drug|Metformin|Metformin taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin then administered throughout the double-blind treatment period (4 weeks).
1807086|NCT00631488|Drug|Placebo for MK-0893|Matching placebo for MK-0893 was orally administered for the loading dose (200 mg) and for the following daily treatment (40 mg) over the 4 week double blind treatment period.
1807087|NCT00631488|Drug|Placebo for Sitagliptin|Matching placebo for Sitagliptin (100 mg) administered orally as 100 mg tablets daily before the morning meal throughout the double-blind treatment period (4 weeks).
1807088|NCT00631488|Drug|Placebo for Metformin|Metformin-matched placebo taken orally (500 mg tablets) over an initial 2-week titration period starting at 500 mg administered twice daily before the morning and evening meals, increasing to 1500 mg daily, and ending with 1000 mg twice daily. Metformin-matched placebo then administered throughout the double-blind treatment period (4 weeks).
1807089|NCT00631501|Drug|Placebo|
1807090|NCT00631501|Drug|Doxycycline|
1807091|NCT00631514|Drug|acetaminophen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
1807092|NCT00631514|Drug|ibuprofen|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
1807093|NCT00631514|Drug|piroxicam|acetaminophen 1000 mg t.i.d. per os ibuprofen 400-600 mg t.i.d. per os piroxicam 10-20 mg o.d. per os
1807094|NCT00631527|Drug|Leuprolide|Injections given through a needle in the muscle every 3 months.
1807095|NCT00631527|Drug|Goserelin|Subcutaneous injections given once every 3 months.
1807096|NCT00631527|Drug|Sunitinib Malate|Starting dose of 12.5 mg by mouth daily for 4 weeks
1807097|NCT00631527|Drug|Casodex|Once a day by mouth for 2 weeks.
1807098|NCT00631527|Radiation|Radiation Therapy (RT)|Radiation treatment once daily over a period of 8 weeks.
1807099|NCT00631540|Device|Formula Balloon-Expandable Stent|renal artery stenting
1807101|NCT00631566|Drug|Mupirocin (Bactroban) 2%; hexachlorophene (pHisoHex) 3%|"BACTROBAN NASAL is a white to off-white ointment that contains 2.15% w/w mupirocin calcium (equivalent to 2.0% pure mupirocin free acid) in a soft white ointment base. The inactive ingredients are paraffin and a mixture of glycerin esters (SOFTISAN 649).
pHisoHex, brand of hexachlorophene detergent cleanser, is an antibacterial sudsing emulsion for topical administration.
Some randomized patients will receive mupirocin (Bactroban) nasal ointment plus hexachlorophene (pHisoHex) body washes for seven days."
1807102|NCT00631566|Drug|Placebo|Some randomized patients will receive a placebo nasal ointment (white petroleum) and a placebo body soap with no antimicrobial activity for seven days.
1807103|NCT00631579|Drug|Rasburicase (SR29142)|
1807104|NCT00631592|Drug|GSK1349572|
1807105|NCT00631618|Drug|Sutent (sunitinib)|The initial dose will be 50mg daily taken for 4 consecutive weeks followed by 2-weeks off to comprise a complete cycle of 6 weeks.
1807106|NCT00631631|Drug|Mifamurtide (L-MTP-PE)|Solution for intravenous infusion
1807107|NCT00631657|Drug|Esmirtazapine|One esmirtazapine 4.5 mg tablet once a day
1807108|NCT00631657|Drug|Placebo|One placebo tablet once a day
1807109|NCT00631670|Radiation|Stereotactic Body Radiation Therapy|15 Gy in one treatment
1807110|NCT00631670|Radiation|Stereotactic Body Radiation Therapy|Dose: 70 Gy at 2.8 Gy/treatment
1807111|NCT00631696|Drug|Pregabalin|pregabalin 600 mg given twice a day
1807112|NCT00631696|Drug|Placebo|Placebo
1807113|NCT00631709|Other|CareLink Remote Monitoring|Substitution of CareLink Remote Monitoring of Pacemakers for in-clinic pacemaker follow-up visits
1807114|NCT00631722|Drug|Quatiapine Fumarate|600-750mg/day
1807115|NCT00631722|Drug|Haloperidol|12-20mg/day
1807116|NCT00631748|Drug|quetiapine fumarate|At baseline, subjects in the experimental group will initially be administered 50 mg/day of Seroquel XR™ (extended release formulation of quetiapine fumarate), to be titrated up to 400 mg/day of Seroquel XR™ by the end of the second week. By the end of week 2, subjects will be stabilized on a dose of 400 mg/day or alternatively 300, 200, 100, or 50 mg/day of study drug, as tolerated. If a subject is unable to tolerate the 50 mg/day dose, he or she will be discontinued from the drug portion of the study.
1807117|NCT00631748|Drug|Matched Placebo|Subjects randomized to the placebo comparator group will follow the same titration and dosing procedures as the experimental group, but will receive matched placebo tablets.
1807118|NCT00631748|Behavioral|Cognitive-behavioral Therapy|During the 12 week treatment phase, all subjects attended weekly group cognitive-behavioral therapy sessions. This therapy platform utilized the cognitive-behavioral therapy manual, Seeking Safety. Seeking Safety has been shown to effectively reduce substance use and to improve psychological functioning in a variety of populations.
1807119|NCT00631761|Other|educational workshop|The intervention group will view a 20 minute video, receive a 30 minute didactic lecture on urethrocystoscopy, and 30 minute coaching/practice performing diagnostic cystoscopy on anatomic replicas.
1807120|NCT00631761|Other|no intervention (usual resident activities)|usual activities
1807121|NCT00631774|Dietary Supplement|Glucerna SR|Each randomized subject in the meal replacement group will receive Glucerna SR to replace one meal (breakfast) and one pre-sleep snack for 24 weeks. The subjects in the group with exchange-diet plan only will receive a meal plan like they have in the lead-in period.
1807122|NCT00631800|Drug|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 60, 90 mg/kg intravenously at Days 0, 7, 14
1807123|NCT00631813|Drug|Prucalopride|0.5 mg bid
1807124|NCT00631813|Drug|Prucalopride|1 mg bid
1807125|NCT00631813|Drug|Prucalopride|2 mg bid
1807126|NCT00631813|Drug|Placebo|bid
1807127|NCT00631839|Radiation|Thoracic 3-D Conformal Radiotherapy|Thoracic RT tailored for each patient, about 60Gy (NSCLC) or 55Gy (SCLC) with photon energies >=6MV.
1807128|NCT00631852|Drug|American Ginseng root|four, 250mg tablets daily 5-14 days prior to surgery
1807129|NCT00631865|Biological|Melanocyte transplantation|Injection of melanocytes directly in Epidermis
1807130|NCT00631878|Drug|Pagibaximab (formerly BSYX-A110)|Pagibaximab at 10, 30, 60, 90 mg/kg intravenously at Days 0 and 14.
1807131|NCT00631917|Drug|Aliskiren|Aliskiren 300 mg once a day
1807132|NCT00631917|Drug|Ramipril|Ramipril 10 mg once a day
1807133|NCT00631917|Other|Placebo to Ramipril|Placebo capsules to match ramipril.
1807134|NCT00631917|Other|Placebo to Aliskiren|Placebo tablets to match aliskiren.
1807135|NCT00631943|Drug|Pregabalin (Lyrica)|Oral pregabalin (Lyrica) capsules, initial dose of 75 mg twice daily, which could be increased to 300 mg twice daily at the discretion of the investigator. Patients were treated for up to 21 days.
1807136|NCT00631969|Drug|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10mg orodispersible tablet (ODT)
1807137|NCT00631969|Drug|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
1807138|NCT00631982|Procedure|in vitro matuartion of oocytes|in vitro maturation of (immature) oocytes
1807139|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
1807140|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
1807141|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
1807142|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
1807143|NCT00631995|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
1807144|NCT00631995|Dietary Supplement|Meningococcal polysaccharide group C conjugated|0.5 mL, Intramuscular
1807145|NCT00632008|Drug|Soluble beta-glucan (SBG)|Topical application of SBG to the wound, at least twice a week until complete healing or for 8 maximum weeks
1807146|NCT00632008|Drug|Placebo comparator|Topical application of placebo to wound, at least twice a week until compleate healing or for maximum 8 weeks.
1807147|NCT00632021|Behavioral|Pharmacist Intervention for Low-Literacy in Cardiovascular Disease|Before hospital discharge, a pharmacist will provide medication reconciliation and counseling on how to take medications. Participants will receive a follow-up phone call 1 to 4 days after hospital discharge to discuss any medication problems, and additionally as needed.
1807148|NCT00632034|Other|CD34+ haemopoietic stem cells|Expanded subset of CD34+ haemopoietic stem cell. Harvested from pelvic marrow aspiration at Day 0 of study. Undergoes refinement and minimum of 1000 fold expansion over 7 days in a dose escalation regime of a maximum dose of 1,000,000,000 cells in 5 millilitres. Injected at Day 7 via contralateral femoral artery under angiographic guidance. First regime up to 10,000,000 cells, second 100,000,000 cells, final regime maximum of 1,000,000,000 cells.
1807149|NCT00632047|Other|active surveillance|
1807150|NCT00632047|Other|educational intervention|
1807151|NCT00632047|Procedure|examination|
1807152|NCT00632047|Procedure|long-term screening|
1807337|NCT00639782|Device|SJM Heart valve replacement|SJM Heart valve replacement
1807154|NCT00632073|Drug|Vicriviroc|One tablet of vicriviroc maleate 30 mg once daily for 24 weeks (added to the subject's failing antiretroviral background regimen for 2 weeks, and then administered with optimized background therapy).
1807155|NCT00632086|Drug|PA32540|
1807156|NCT00632086|Drug|aspirin component of PA32540|The 325 mg aspirin component of PA32540
1807157|NCT00632086|Drug|Ecotrin|325 mg Ecotrin
1807158|NCT00632099|Drug|Oral micronized progesterone|Oral micronized progesterone (up to 400 mg/day), suspended in olive oil
1807159|NCT00632099|Drug|Placebo|matched placebo
1807160|NCT00632125|Drug|HX575 recombinant human erythropoietin alfa|HX575 epoetin alfa i.v. will be administered according to the SmPC
1807161|NCT00632138|Behavioral|exercise intervention|
1807162|NCT00632138|Other|questionnaire administration|
1807163|NCT00632138|Procedure|biofeedback|
1807164|NCT00632138|Procedure|management of therapy complications|
1807165|NCT00632138|Procedure|psychosocial assessment and care|
1807166|NCT00632138|Procedure|quality-of-life assessment|
1807167|NCT00632190|Other|fluorophotometry|
1807168|NCT00632190|Procedure|colposcopic biopsy|
1807169|NCT00632190|Procedure|colposcopy|
1807170|NCT00632190|Procedure|light-scattering spectroscopy|
1807171|NCT00632203|Drug|Temozolomide|5-mg, 20-mg, and 100-mg gel capsules, 75 mg/m^2 PO daily for 21 consecutive days, followed by a 7-day rest period, until progression or up to a maximum of 6 cycles, whichever occurs first.
1807172|NCT00632216|Drug|Risedronate Sodium|
1807173|NCT00632229|Drug|Paliperidone|Paliperidone medication taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
1807174|NCT00632229|Drug|Placebo|Pill placebo taken daily ranging from 3-9mg/day depending on tolerability and efficacy.
1807175|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min.
1807176|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min.
1807177|NCT00632242|Drug|ARC1779|Initial stepwise infusion of 0.46 mg/kg over 30 minutes and subsequent continuous infusion of an additional 2.88 mg/kg given over 24 hours at a rate of 0.002 mg/kg/min.
1807178|NCT00632242|Drug|ARC1779|"Initial stepwise infusion of 0.23 mg/kg given over 30 minutes and subsequent continuous infusion of an additional 1.44 mg/kg given over 24 hours at a rate of 0.001 mg/kg/min to produce a target plasma concentration of 6 mcg/mL.
Continuous infusion of ARC1779 Injection may continue for ≤ 14 days. After initial 24 hours dose may be titrated to achieve a target plasma concentration of 12 mcg/mL as needed, on the basis of clinical and laboratory data, according to the Investigator's judgment."
1807179|NCT00632242|Drug|ARC1779|In one period of the sequence, ARC1779 will be administered to all subjects as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min in combination with a dummy 30-minute infusion of placebo. In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion followed by 4-hour continuous infusion of placebo. In the one other period, subjects will receive the combination of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes and ARC1779 given as a stepwise infusion of 0.23 mg/kg over 30 minutes and subsequent continuous infusion of an additional 0.24 mg/kg given over 4 hours at a rate of 0.001 mg/kg/min
1807180|NCT00632255|Drug|Imatinib|Conventional therapy with imatinib
1807181|NCT00632268|Drug|RAD001; Cisplatin; 5-FU; Leucovorin|RAD001: oral 10mg/day on Day 1,8,15 Cisplatin:infusion 35mg/m2/day on Day 1,8 5-FU:infusion 2000mg/m2/day on Day 1,8,15
1807182|NCT00632281|Radiation|Stereotactic Body Radiation Therapy|Prescription dose: 48 Gy or 60 Gy RT
1807183|NCT00632294|Procedure|Tissue Sample|A leftover sample of the removed allograft bone will be collected.
1807184|NCT00632333|Biological|URLC10, TTK, KOC1, VEGFR1, VEGFR2, cisplatin, fluorouracil|Escalating dose of multiple peptides (URLC10, TTK, KOC1 VEGFR1, and VEGFR2) emulsified with Montanide ISA51 will be administered by subcutaneous injection on days 15, 22, 28 and 35 of treatment cycle. Doses of each peptide are planning 0.5mg, 1mg and 3mg/body. Chemotherapy plus radiation therapy will be done as follows: fluorouracil (400mg/m2) on day1-5 and 8-12, cisplatin (40mg/m2) on days 1 and 8, radiation (2Gy) on days 1-5, 8-12 and 15-19. Two cycles of combination of chemoradiation therapy and epitope peptide vaccine therapy will be done.
1807185|NCT00638170|Biological|Cranberry juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
1807186|NCT00638170|Biological|Placebo juice|5 ml/kg up to 300 ml, 1-2 doses daily for six months
1807187|NCT00638196|Drug|Linoleic Acid/Oleic Acid|Dietary Supplement: Linoleic acid emulsion 30g bid/Oleic acid emulsion 30g bid
1807188|NCT00638209|Drug|Human insulin|
1807189|NCT00638209|Drug|Saline|
1807190|NCT00638222|Other|Carvedilol and Placebo|All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
1807191|NCT00638235|Device|AMS Apogee™ with IntePro|Mesh implant for posterior wall pelvic organ prolapse
1807192|NCT00638235|Device|AMS Apogee™ with Intexen LP|Graft implant for posterior wall pelvic organ prolapse
1807193|NCT00638235|Device|AMS Perigee™ with IntePro|Mesh implant for anterior wall pelvic organ prolapse
1807194|NCT00638235|Device|AMS Perigee™ with IntePro Lite|Mesh implant for anterior wall pelvic organ prolapse
1807195|NCT00638235|Device|AMS Apogee™ with IntePro Lite|Mesh implant for posterior wall pelvic organ prolapse
1807196|NCT00638235|Device|AMS Elevate™ Apical & Posteiror with IntePro Lite|Mesh implant for apical and posterior wall pelvic organ prolapse
1807197|NCT00638235|Device|AMS Elevate™ Apical & Posteiror with IntXen LP|Graft implant for apical and posterior wall pelvic organ prolapse
1807198|NCT00638235|Device|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 1, For Study Use Only)|Mesh implant for anteiror and apical wall pelvic organ prolapse
1807199|NCT00638235|Device|AMS Elevate™ Anterior & Apical with IntePro Lite (Gen 2)|Mesh implant for anteiror and apical wall pelvic organ prolapse
1807203|NCT00638261|Radiation|UVB-311nm|UVB-311nm radiation given 3 times a week to one randomized body-half
1807204|NCT00638274|Procedure|Air|3 mls used for identifying epidural space
1807205|NCT00638274|Procedure|Saline|3 mls of saline used to identify epidural space
1807206|NCT00638300|Device|large pore (FX80) compared to small pore dialyzer (F8HPS)|Effect of pore size
1807207|NCT00638300|Other|Dialysate bicarbonate of 33 mEq/L compared to 40 mEq/L|Effect of dialysate bicarbonate concentration
1807208|NCT00638300|Other|Dialysate calcium of 3 mEq/L compared to 2.5 mEq/L|Effect of dialysate calcium concentration
1807209|NCT00638313|Biological|Placebo|Subjects will be given either Placebo or PF-04603629.
1807210|NCT00638313|Biological|PF-04603629|Subjects will be given either Placebo or PF-04603629. The specific dose of PF-04603629 given depended on the Cohort to which the patient was assigned. Doses administered ranged from 1 mg to 70 mg.
1807211|NCT00638326|Drug|clopidogrel|150 mg maintenance dose (2 capsules of 75 mg clopidogrel) for 28 days followed by standard 75 mg clopidogrel for one year
1807212|NCT00638326|Drug|clopidogrel plus placebo|75 mg maintenance dose (one capsule of 75 mg clopidogrel and one capsule placebo) for 28 days followed by standard 75 mg clopidogrel for one year
1807213|NCT00638365|Biological|KB001|Single-dose, 3mg/kg or 10mg/kg dose administered intravenously
1807214|NCT00638365|Other|Placebo|Placebo single-dose administered intravenously
1807215|NCT00638378|Drug|Ruxolitinib|Ruxolitinib 25 mg tablets taken with water twice a day.
1807216|NCT00638391|Drug|Anastrozole|
1807217|NCT00638417|Procedure|Maximal strength training|Group 1 intervention: maximal strength training Group 2 intervention: conventional rehabilitation programme
1807218|NCT00638443|Drug|Pregabalin|Pregabalin started at 75mg twice daily for 3 days; pregabalin increased to 150mg twice daily for 7 days; pregabalin reduced to 75mg twice daily for 3 days.
1807219|NCT00638443|Drug|Diphenhydramine|diphenhydramine started at 6.25mg twice daily for 3 days; diphenhydramine increased to 12.5mg twice daily for 7 days; diphenhydramine reduced to 6.25mg twice daily for 3 days.
1807220|NCT00638456|Drug|Budesonide plus Prevacid|Budesonide is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
1807221|NCT00638456|Drug|placebo plus Prevacid|Placebo is taken daily for three months. In addition, Prevacid is taken twice daily for three months.
1807224|NCT00638482|Drug|Hydrochlorothiazide|Hydrochlorothiazide
1807225|NCT00638495|Drug|Nalfurafine Hydrochloride (TRK-820)|TRK-820 2.5, 5 and 10 microg is to be administered orally once daily, after supper in principle, for 28 days.
1807226|NCT00638495|Drug|Placebo|Placebo is to be administered orally once daily, after supper in principle, for 28 days.
1807227|NCT00638924|Other|Shuttle walk test|the test requires patients to walk at a gradually increasing speed, up and down a 10 m course identified by two marker cones, until they reach a symptom limited maximum. The walking speed was externally paced and controlled by a series of beeps played on a compact disk.
1807228|NCT00638937|Drug|saracatinib|Given PO
1807229|NCT00638950|Dietary Supplement|n-3 LC-PUFA|Patients received about 40 g fat daily (200 g yoghurt with 3.8% fat, 30 g cheese with about 50% fat in the dry matter, and 20-30 g butter). The milk fat was partially exchanged by special oils. The daily dose of n-3 FA amounted to 2.4 g, consisting of 1.1 g ALA, 0.7 g EPA, 0.1 g DPA, and 0.4 g DHA.
1807230|NCT00638950|Dietary Supplement|Placebo|The placebo products were commercial dairy products with comparable fat contents.
1807231|NCT00638963|Drug|temozolomide|Capsules to equal 75 mg/m^2, orally, daily for 6 weeks, in 3 eight-week cycles
1807232|NCT00638976|Drug|eptifibatide|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES >33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure
1807233|NCT00638976|Drug|placebo|Enrolled patients will be randomized in the catheterization laboratory, after the decision to perform PCI by means of planned implantation of DES >33 mm in length in the same coronary vessel, to IV placebo or IV eptifibatide (double bolus [180 microg/kg] followed by infusion [2 microg/kg per minute] for 18 to 24 hours after the procedure
1807234|NCT00638989|Biological|CAT-354 150 mg (intravenous)|A single dose of CAT-354 150 milligram (mg) intravenous infusion over 30 minutes on Day 0.
1807235|NCT00638989|Biological|CAT-354 150 mg (subcutaneous)|A single dose of CAT-354 150 mg injection subcutaneously on Day 0.
1807236|NCT00638989|Biological|CAT-354 300 mg (subcutaneous)|A single dose of CAT-354 300 mg injection subcutaneously on Day 0.
1807237|NCT00639002|Drug|Ruxolitinib 25 mg|Ruxolitinib was supplied as 5 and 25 mg tablets.
1807238|NCT00639002|Drug|Dexamethasone 40 mg|Dexamethasone was obtained commercially by Investigators in tablet strengths of 20 or 40 mg.
1807241|NCT00639028|Other|Ankle echography|Ankle echography
1807242|NCT00639028|Other|Ankle echography + stress radiography|Ankle echography + stress radiography
1807243|NCT00639028|Other|stress radiography|ankle stress radiography
1807244|NCT00639041|Dietary Supplement|n-3 LC-PUFA|n-3 LC-PUFA supplemented dairy products (yoghurt, cheese, butter): 3.3 g n-3 FA/d
1807245|NCT00639041|Dietary Supplement|Placebo|dairy products without special oils
1807246|NCT00639054|Procedure|Bone marrow examination|7.5 ml of iliac crest bone marrow drawn in addition to diagnostic samples.
1807247|NCT00639054|Procedure|Blood samples|24 ml of cubital vein blood drawn in addition to diagnostic samples.
1807248|NCT00639067|Device|Breath Collection Apparatus|Breath collected and analyzed for markers of lung cancer.
1807249|NCT00639080|Other|Stop lipid lowering therapy (statin)|Subjects will only be included in the study and thus asked to stop the statin if they are taking less than or equal to 10 mg of lipitor or an equivalent of another statin.
1807250|NCT00639093|Behavioral|psychoeducational / motivational combined with crushing|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).
During the immersions in VR, 45 of the participants will use a virtual reality arm to catch and crush virtual cigarettes (on a computer)."
1807251|NCT00639093|Behavioral|psychoeducational / motivational combined with control|"All participants will receive an eight-session psychoeducational and motivational program. During the first four weeks, all participants will be immersed in virtual reality (VR).
During the immersions in VR, the 45 participants in the control condition will use a virtual reality arm to catch and crush virtual fruits (on a computer)."
1807252|NCT00639106|Procedure|Alloderm, Questionnaires|All patients will undergo placement of a temporary tissue expander immediately following mastectomy.Patients will undergo the surgical creation of an expander pocket using implantable Alloderm.
1807253|NCT00639106|Procedure|Without ALLODERM, Questionnaires|A standard, sub-muscular pocket dissection will be performed in the patients assigned to the control group. No Alloderm will be used.
1807254|NCT00639119|Drug|Ropinirole|8 + 8 weeks cross-over placebo controlled
1807255|NCT00639158|Drug|ABT-335|135 mg capsule, daily, 12 weeks
1807256|NCT00639158|Drug|placebo|placebo capsule, daily, 12 weeks
1807257|NCT00639158|Drug|atorvastatin|40 mg, tablet, daily, 12 weeks
1807258|NCT00639158|Drug|ezetimibe|10 mg capsule, daily, 12 weeks
1807259|NCT00639184|Other|Early intervention counseling|Bi-monthly home visits by counselor
1807260|NCT00639184|Other|Health education counseling|World Health Education health education counseling program at home visits,twice per month
1807261|NCT00639197|Procedure|To tunnel|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter will pass through a 3-5cm subcutaneous tunnel before it is eventually secured to reside at the internal jugular vein.
1807262|NCT00639197|Procedure|Standard (not to tunnel)|Using the standard Seldinger technique and under the guidance of ultrasound, the catheter is secured to reside at the internal jugular vein, without a subcutaneous tunnel.
1807263|NCT00639210|Other|supervised training|Design: supervised training is organised for the exercise group once a week in groups of 10 to 15 subjects. The training is guided by an experienced physical therapist.Content: The supervised training of the exercise group consists of two different classes alternating at four week periods; step aerobics class and circuit training class. The 60-minute aerobics and circuit training classes also include warming-up and cooling-down periods both lasting 10-15 minutes.
1807264|NCT00639223|Dietary Supplement|Red Yeast Rice|Four 600mg capsules twice daily for 12 weeks
1807265|NCT00639223|Drug|Pravastatin|One 20mg capsule twice daily for 12 weeks
1807266|NCT00639223|Behavioral|Lifestyle modification program|Weekly sessions each lasting 3 1/2 hours for 12 weeks
1807267|NCT00639236|Other|hypertonic saline|inhaled hypertonic saline (at a dose of 5 ml of a 3% solution) three times a week, combined with a program of physical exercises.
1807268|NCT00639249|Drug|placebo|Oral administration
1807269|NCT00639249|Drug|SA4503 Low|Oral administration
1807270|NCT00639249|Drug|SA4503 High|Oral administration
1807271|NCT00639262|Drug|Sorafenib|Sorafenib 200mg twice daily during XRT and 30 days after. (Sorafenib will be escalated for both cohorts to determine maximum tolerated dose)
1807272|NCT00639262|Drug|Temozolomide|For Cohort 2 - Gliomas only.
1807273|NCT00639262|Radiation|Radiotherapy|Radiation Therapy (XRT)
1807274|NCT00639288|Other|modified CPT-C|modified CPT-C
1807275|NCT00639301|Behavioral|Questionnaires|The survey will be administered by mail or telephone interview, based upon the participant preference. The survey has been adapted from the 2008 questionnaire being administered through the CCSS (11); it has been supplemented with questions addressing areas of interest specific to the retinoblastoma survivor population (eg, validated instruments that assess visual impairment).
1807276|NCT00639314|Procedure|pylorus-preserving pancreaticoduodenectomy|pylorus-preserving resection is division of the duodenum 3-4cm distal to the pylorus
1807277|NCT00639314|Procedure|pylorus-resecting pancreaticoduodenectomy|In PrPD, the stomach is divided just above the pylorus ring. The nearly total stomach more than 95% was preserved.
1807278|NCT00639327|Drug|S-1 + irinotecan|Irinotecan 150mg/m2 iv on day one and S-1 po days 1 to 14 every 3 weeks until PD
1807279|NCT00639327|Drug|irinotecan|Irinotecan 150mg/m2 iv on day one every two weeks until PD
1807280|NCT00639353|Device|senofilcon A toric soft contact lens|contact lens
1807281|NCT00639353|Device|senofilcon A sphere soft contact lens|contact lens
1807282|NCT00639366|Biological|trastuzumab|
1807283|NCT00639366|Drug|chemotherapy|
1807284|NCT00639366|Radiation|radiation therapy|
1807285|NCT00639379|Device|senofilcon A toric|silicone hydrogel toric lens, 2 wk replacement, daily wear
1807286|NCT00639379|Device|alphafilcon A toric|hydrogel toric lens, 2 wk replacement, daily wear
1807287|NCT00639392|Drug|Placebo|Patients will receive a single dose of placebo administered by vein over about 15 minutes. Placebo is mostly water without Zoledronic Acid.
1807288|NCT00639392|Drug|Zoledronic Acid|Patients will receive a single dose of Zolendronic Acid. Zoledronic Acid is administered by vein over about 15 minutes.
1807289|NCT00639418|Biological|Influenza vaccination|This non-interventional study prospectively captured vaccine coverage and practices of participating physician offices through use of surveys during the influenza vaccination season.
1807292|NCT00639444|Dietary Supplement|gluten-free, normocaloric diet from 6 to 12 months|Gluten-containing cereals (wheat, rye and barley) will be replaced by gluten-free starchy food (rice, corn, tapioca-based, etc) in a normocaloric diet
1807293|NCT00639457|Drug|Pioglitazone|Oral 30mg/day for 16 weeks
1807294|NCT00639457|Behavioral|Exercise training|Supervised aerobic and resistance exercise training (1.5hrs/day x 3 days/wk) for 16 weeks
1807295|NCT00639470|Other|easy to read fact sheets|easy to read fact sheets with illustrations and without illustrations
1807296|NCT00639483|Drug|Celecoxib|200 mg oral capsules twice daily as add-on therapy to risperidone twice daily (range 2-8 mg/day) for 11 weeks
1807297|NCT00639483|Drug|Placebo|Matched oral placebo as add-on to risperidone twice daily (range 2-8 mg/day) for 11 weeks
1807298|NCT00639496|Drug|n-acetylcysteine|600 mg x 3, for 12 months
1807299|NCT00639496|Drug|placebo|Placebo
1807300|NCT00639509|Biological|cixutumumab|Given IV
1807301|NCT00639509|Procedure|computed tomography|Undergo contrast-enhanced computed tomography
1807302|NCT00639509|Procedure|contrast-enhanced magnetic resonance imaging|Undergo contrast-enhanced magnetic resonance imaging
1807303|NCT00639522|Drug|Liposomal paclitaxel and capecitabine|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2、185mg/m2、195mg/m2、 200mg/m2、205mg/m2 and so on ,at the first day of chemotherapy. Capecitabine will be given on d1 to d14 with the dose of 185mg/m2、200mg/m2 or d8 to d21 with the dose of 175mg/m2、195mg/m2、205mg/m2 .Cycle duration will be 21 days. Each patient will receive 2 cycles of therapy. Only in the first cycle blood samples will be taken on 16 points in 48 hours after the infusion of liposomal paclitaxel.
1807304|NCT00639561|Dietary Supplement|10 g of fibres per day|10 g of fibres per day
1807305|NCT00639561|Dietary Supplement|40 g of fibres per day|40g of fibres per day
1807306|NCT00639574|Drug|Néfopam|"There are two groups :
a group N : néfopam
a group P : placebo All the patients receive, before randomization, 100 mg of ketoprofen (Profenid) on 20 minutes."
1807307|NCT00639587|Drug|Ketotifen|Ketotifen dry syrup 0.1%; 1 mg b.i.d.; for 2 weeks
1807308|NCT00639587|Drug|Cetirizine|Cetirizine tablet; 10 mg o.d.; for 2 weeks and 5 mg b.i.d.; for 2 weeks
1807309|NCT00639600|Procedure|human pancreatic islet transplantation|human pancreatic islet transplantation
1807310|NCT00639613|Procedure|Double-balloon enteroscopy|Double-balloon enteroscopy allows for the entire gastrointestinal tract to be visualized in real time. The technique involves the use of a balloon at the end of a special enteroscope camera and an overtube, which is also fitted with a balloon. The procedure is usually done with the use of conscious sedation. The enteroscope and overtube are inserted through the mouth and passed in conventional fashion (that is, as with gastroscopy) into the small bowel. Following this, the endoscope is advanced a small distance in front of the overtube and the balloon at the end is inflated. Using the assistance of friction at the interface of the enteroscope and intestinal wall, the small bowel is accordioned back to the overtube. The overtube balloon is then deployed, and the enteroscope balloon is deflated. The process is then continued until the entire small bowel is visualized. Double-balloon enteroscopy allows for the sampling or biopsying of small bowel mucosa.
1807311|NCT00639613|Other|Standard meal test|"Liquid meal consisting of 100 g Ny NAN dissolved in 300 ml water (ca. 5000 kJ) to be ingested over 5 minutes. Blood will be sampled for 4 hours following ingestion. Samples are centrifuges and plasma will be analysed for glucagon, GLP-1, GIP, insulin and C-peptide concentrations."
1807313|NCT00639639|Biological|tetanus toxoid|Given by injection
1807314|NCT00639639|Biological|therapeutic autologous dendritic cells|Given intradermally
1807315|NCT00639639|Biological|therapeutic autologous lymphocytes|Given IV
1807316|NCT00639652|Procedure|3D-histology|The tumor is marked at the 12 o'clock-position. Excision with a safety margin between 2 and 10 mm, depending on tumor size and location. Plastic reconstruction. Removal of the specimen's margins and base as thin layers, using a scalpel. These primarily three-dimensional layers of the specimen's borders are flattened to one level and microscopically screened for tumor cells. 3D-histology is combined with representative vertical sections for histologic diagnosis. Consecutive excisions are performed topographically at the tumor-positive areas and 3D-histology is repeated until tumor-free margins are obtained.
1807317|NCT00639652|Procedure|Shave excision|Tumor removal by shave excision with a safety margin. Healing by secondary intention. Histologic diagnosis of BCC type (nodular, superficial, morpheaform, micronodular, other type, mixed type) or diagnosis of another tumor than BCC. Comment on complete removal (R0 versus R1).
1807318|NCT00639665|Other|Cocoa|Polyphenol rich or poor cocoa was administered to study subjects to measure hemodynamic responses and the role of nitric oxide in the renal vasodilator response.
1807319|NCT00639678|Drug|placebo|40 mg/kg intravenously, double dose (day 0 and 14), Group 3
1807320|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, double dose (day 0 and 14), Group 1
1807321|NCT00639678|Drug|placebo|40 mg/kg placebo, single dose (day 0), Group 4
1807322|NCT00639678|Drug|raxibacumab|40 mg/kg intravenously, single dose, day 0, Group 2
1807323|NCT00639691|Biological|omalizumab|sc
1807324|NCT00639717|Procedure|stem cell transplant|reduced intensity, matched unrelated donor stem cell transplant
1807325|NCT00639717|Drug|tacrolimus (standard GVHD prophylaxis)|"Tacrolimus(or cyclosporine when necessary)
Tacrolimus will begin on day -3, IV or oral.
Target trough level for tacrolimus is 8-12 ng/ml.
In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant"
1807326|NCT00639717|Drug|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
1807327|NCT00639717|Drug|etanercept|Etanercept will be given at a dose 0.4 mg/kg (actual weight) up to a maximum dose of 25 mg, subcutaneously, twice weekly from day 0 to day 56 (16 doses)
1807328|NCT00639717|Drug|methoxsalen|"Methoxsalen (UVADEX) treatments by Extracorporeal photopheresis (ECP) will be started day +28 post transplant and given weekly.
On day +70 post transplant ECP frequency will be given every other week.
On day +100 post transplant ECP will be given monthly until day +180 and stopped."
1807329|NCT00639730|Dietary Supplement|modified Atkins diet|High fat, low carbohydrate diet
1807330|NCT00639743|Drug|placebo ( group B)|placebo ( group B)
1807331|NCT00639743|Drug|tenecteplase (group A)|tenecteplase (group A)
1807332|NCT00639756|Drug|Allopurinol|Allopurinol 300 mg
1807333|NCT00639756|Drug|Placebo|Placebo given for 2 weeks
1807334|NCT00639769|Drug|cisplatin|Starting dose 30 mg/m2 Dose level -1 20 mg/m2
1807335|NCT00639769|Drug|irinotecan hydrochloride|50 mg/m2 IV over 60 minutes, plus Cisplatin 30mig/m2 IV, repeated weekly for two weeks. followed by a one-week rest. This 3-week schedule given two times to equal one 6-week cycle. Maximum of 6 cycles.
1807336|NCT00639782|Device|On-X Heart valve replacement|On-X Heart valve replacement
1807338|NCT00639795|Procedure|Thoracic Paravertebral Nerve Block|One Single-injection, thoracic peripheral nerve blockade performed intraoperatively following patient induction with general endotracheal anesthesia
1807339|NCT00639795|Procedure|Thoracic Paravertebral Nerve Block|Sham single-injection thoracic peripheral nerve blockade following patient induction with general endotracheal anesthesia
1807340|NCT00639808|Drug|5% dextrose in water|60 ml IV infusion over 30 minutes
1807341|NCT00639808|Drug|TZP-101|1 infusion: IV 2ml/min for 30 minutes for 1 day of either 160, 320 or 600 micrograms/kg
1807342|NCT00639834|Biological|MDX-1342|One dose of active MDX-1342 (anti-CD19 fully human monoclonal antibody) will be administered to patients as an i.v. infusion. Patients will receive one dose of MDX-1342 given in combination with Methotrexate treatment.
1807343|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by nurses|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
1807344|NCT00639847|Behavioral|In-home asthma management program (AMP) provided by respiratory therapists|The AMP included asthma education (medications use, monitoring, triggers, steps to manage asthma attacks), demonstration and training (peak flow meter use, MDI and nebulizer use, asthma diary), home environment assessment and suggestions for environmental changes (mattress covers, control of dust, pets, fumes, cleaning materials, cock roach control, etc.)
1807345|NCT00639860|Device|OSSIX-Plus|resorbable collagen membrane
1807346|NCT00639873|Drug|Artesunate|2 or 4 mg/kg/day for 7 days
1807347|NCT00639873|Drug|quinine-doxycycline|quinine-doxycycline for 7 days
1807348|NCT00639899|Procedure|Sclerotherapy|Super-selective retrograde venography and sclerotherapy of internal spermatic veins and associated venous bypasses and retro-peritoneal collateral
1807349|NCT00639912|Drug|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 1 ml/Kg/hour for 12 hours.
1807350|NCT00639912|Drug|sodium chloride|Solution of 154 mEq/L of sodium chloride. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours
1807351|NCT00639912|Drug|sodium bicarbonate|154 mEq/L of sodium bicarbonate in dextrose solution. Rate of infusion: 1 ml/Kg/hour for 12 hours.
1807352|NCT00639912|Drug|sodium bicarbonate|154 mEq/L of sodium chloride in dextrose solution. Rate of infusion: 3 ml/Kg for 1 hour, followed by 1 ml/Kg/hour for 12 hours.
1807353|NCT00639925|Biological|VEGFR1-1084, VEGFR2-169, and gemcitabine|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 of each 28-day treatment cycles. Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8 and 15.
1807354|NCT00639938|Drug|Nevirapine|200 mg Nevirapine tablet
1807355|NCT00639938|Drug|HIV immune globulin solution|5% intravenous HIV immune globulin solution
1807356|NCT00639951|Biological|A|20 vials up front in a Single Dose of Antivipmyn
1807357|NCT00639951|Biological|Antivipmyn ®|20 vials fractionated into 4 doses of 5 vials each of Antivipmyn ®
1807358|NCT00639964|Other|blood tests|3 measures during pregnancy and 1 at post partum, 1 measure at time of delivery from fetal cord
1807359|NCT00639964|Other|diet questionnaire|questions about nutrition before and during pregnancy
1807360|NCT00639964|Other|umbilical cord blood collect|collected at the delivery
1807361|NCT00639964|Other|placenta collect|collected at the delivery
1807362|NCT00639977|Other|Acupuncture|20-minute session of acupuncture with needles inserted in specific points: Tong Zi Liao, Yang Bai and Jing Ming
1807363|NCT00639977|Other|Sham|20- minute session of acupuncture with needles inserted in false points allocated 1 cm from the true points in areas without acupuncture's meridians
1807364|NCT00639990|Other|PEEP|Application of positive end expiratory pressure
1807365|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
1807366|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
1807367|NCT00639990|Other|PEEP|Application of positive end-expiratory pressure
1807368|NCT00640003|Drug|Baclofen|Drug given by orally via capsules. Escalation steps in 4-day intervals. Step 1: 5mg QAM. Step 2: 5mg BID. Step 3: 5mg TID. Step 4: 10mg QAM, 5mg BID. Step 5: 10mg BID, 5mg QMid-day. Step 6: 10mg TID. Step 6 will last up to 2 weeks. De-escalation will start from highest dose step and work backwards in 2-day intervals. Complete drug administration of escalating, staying constant at 10mg TID and de-escalating will be done with both drug and placebo.
1807369|NCT00640003|Drug|Placebo|placebo drug
1807370|NCT00640016|Other|Placebo|Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.
1807371|NCT00640016|Biological|CAT-354 1 mg/kg|CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
1807372|NCT00640016|Biological|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
1807373|NCT00640016|Other|CAT-354 10 mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.
1807374|NCT00640029|Procedure|Arthrodesis|"posterior,
anterior,
circumference approach"
1807375|NCT00640029|Device|Arthroplasty (PRODISC-C® , PRODISC-L®, Mobi-C®, Mobidisc®, PrestigeLP®, A-Mav®, O-Mav®, DISCOCERV®)|"SYNTHES : PRODISC-C® , PRODISC-L®
LDR : Mobi-C®, Mobidisc®
MEDTRONIC : PrestigeLP®, A-Mav®, O-Mav®
SCIENT'X : DISCOCERV®"
1807376|NCT00640042|Drug|morphine sulfate extended release capsules|30 mg, 60 mg, 90 mg, 120 mg morphine will be prescribed by the Investigator in accordance with the AVINZA prescribing information.
1807377|NCT00640055|Other|Coordinator|Coordinator (non-physician) assigned cause of death
1807378|NCT00640055|Other|Physician-assigned cause of death|Physician (gold standard) cause of death
1807379|NCT00640081|Biological|cetuximab|
1807380|NCT00640081|Drug|capecitabine|
1807381|NCT00640081|Drug|fluorouracil|
1807382|NCT00640081|Drug|leucovorin calcium|
1807383|NCT00640081|Drug|oxaliplatin|
1807384|NCT00640081|Other|immunohistochemistry staining method|
1807385|NCT00640081|Other|laboratory biomarker analysis|
1807542|NCT00641108|Drug|ADAM SPECT plus Cognitive Therapy|
1807543|NCT00641108|Drug|ADAM SPECT plus No Therapy|
1807386|NCT00640094|Drug|melatonin|Patients will receive a total intravenous melatonin dose of 12 mg + intracoronary melatonin dose of 2 mg. The intravenous dose will be distributed in a volume of 50 ml of a isotonic and sterile solution and administered by intravenous infusion during 60 minutes. The intracoronary dose will be distributed in a volume of 10 ml of a isotonic and sterile solution and administered as a bolus.
1807387|NCT00640120|Device|WIM-PC™ device|wheeze detection during dynamic bronchial situations in infants
1807388|NCT00640133|Device|Active DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant. After a post-operative rest, participants will receive immediate DBS treatment throughout.
1807389|NCT00640133|Device|Sham DBS|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will mimic adjusting the settings of the electrical stimulation. After a post-operative rest, participants will receive DBS treatment after a delay of several months. Afterwards, all participants will receive open-label long-term DBS.
1807390|NCT00640146|Drug|Methylnaltrexone bromide|Subcutaneous Methylnaltrexone
1807391|NCT00640146|Drug|Placebo|Subcutaneous Placebo
1807393|NCT00640185|Drug|ABT-089|Subjects will take up to two 40 mg tablets once daily for 8 weeks.
1807394|NCT00640185|Drug|Placebo|Subjects will take one or two placebos once daily for the duration of the study.
1807395|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended,from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24)
1807396|NCT00640198|Behavioral|constraint-induced language therapy (CIAT)|CIAT is an intensive form of language-action therapy for aphasia performed in a small group setting. In a therapeutic game context, participants had to request objects or cards from each other and understand requests made by others. Feedback of communicative success was regularly given, along with guidance, help and reinforcement. Gesturing replacing verbal language was discouraged although gestures accompanying speech were allowed. Difficulty levels were adjusted to the patients´ communicative abilities by choosing language materials and actions and reinforcement was administered taking into account each patient´s level of performance. Communication rules were introduced by shaping and modelling. Each patient received 30 hours of therapy.
1807397|NCT00640198|Drug|memantine|Memantine was titrated in 5-mg weekly increments as recommended, from a starting dose of 5 mg/day to 20 mg/day. After the 3-week up-titration phase all patients received a fixed dose of either memantine (10 mg) or placebo twice daily without CIAT during the next 3 months (week 16). During the next 2 weeks (weeks 16-18), the drug treatment was combined with CIAT. This phase of combined treatment was followed by a 2-week period (weeks 18-20) where patients received memantine or placebo treatment alone and, finally, by a 4-week period of drug withdrawal (weeks 20-24).
1807398|NCT00640198|Drug|placebo|Placebo
1957719|NCT02234323|Biological|rFVIIIFc|Administered as specified in the treatment arm
1807401|NCT00640237|Dietary Supplement|Alpha-D3|We will use the vitamin alpha-D3 drops of CTS pharmaceutical firm , that contains 5000 IU in ml. Every patient in the interventional group will receive two dose of 100000 IU (20 ml)vitamin alpha-D3 within a month period.
1807403|NCT00640263|Drug|lopinavir/ritonavir (LPV/r)|Oral liquid formulation lopinavir/ritonavir(80 mg lopinavir + 20 mg ritonavir/mL); Dosing : 40/10mg twice daily if infant weight is between 2 to 4 kg and 80/20mg twice daily if infant weight is above 4kg The lopinavir/ritonavir will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight.
1807404|NCT00640263|Drug|Lamivudine (3TC)|"Oral liquid solution lamivudine(10 mg/mL). Dosing : 7,5 mg twice daily if if infant weight is between 2 to 4 kg ; 25 mg twice daily if infant weight is between 4 to 8 kg ; 50 mg twice daily if infant weight is above 8kg.
The lamivudine will be given to the baby from Day 7 postnatal until 4 weeks after the cessation of breastfeeding. During the treatment period, dosing will be adapted according to the infant weight."
1807405|NCT00640276|Drug|pitavastatin|Pitavastatin 2mg daily once
1807406|NCT00640276|Behavioral|Lifestyle Modification|conducting mainly exercises and diet
1807407|NCT00640289|Drug|Fibrogammin P|Prophylaxis treatment
1807408|NCT00640315|Drug|Riociguat (Adempas, BAY63-2521) 1.0 mg|1.0 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
1807409|NCT00640315|Drug|Riociguat (Adempas, BAY63-2521) 2.5 mg|2.5 mg BAY63-2521 will be given twice per subject, as single dose administration during the hemodynamic investigation (on study day 1) and during the lung function testing (on study day 3).
1807410|NCT00640328|Drug|Ofatumumab 100|100mg
1807411|NCT00640328|Drug|Ofatumumab 300|300mg
1807412|NCT00640328|Drug|Ofatumumab 700|700mg
1807413|NCT00640328|Drug|Placebo|matching placebo
1807414|NCT00640341|Device|PureVision Contact Lens|contact lens for daily wear
1807415|NCT00640341|Device|Acuvue Oasys Contact Lens|contact lens for daily wear
1807416|NCT00640341|Device|O2Optix Contact lens|contact lens for daily wear
1807599|NCT00635232|Drug|PS433540|400 mg (4 x 100 mg capsules) once daily for 12 weeks
1807417|NCT00640354|Device|Automated external defibrillator|Residents randomized to this group had an automated external defibrillator available for the simulated cardiac arrest. The automated external defibrillator did not actually discharge energy into the simulated patient
1807418|NCT00640354|Device|Manual defibrillator|Residents randomized to this group had a manual defibrillator available for the simulated cardiac arrest. The defibrillator did not actually discharge energy into the simulated patient.
1807419|NCT00640367|Other|Alteplase IA and/or mechanical thrombolysis|loca intra-arterial recombinant tissue plasminogen activator and/or mechanical thrombolysis
1807420|NCT00640367|Drug|Alteplase IV|intravenous recombinant tissue plasminogen activator
1807421|NCT00640380|Other|Nerve stimulation|CPVB with NS
1807422|NCT00640380|Other|Loss of resistance to air|CPVB with LOR
1807423|NCT00640393|Drug|Etanercept|Etanercept 50 mg, subcutaneous (SC) injection.
1807424|NCT00640393|Device|nbUVB|
1807425|NCT00640406|Device|Dynamic Renal Stent plus Best Medical Treatment|percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards
1807426|NCT00640406|Drug|Best Medical Treatment|best medical treatment for hypertension secondary to renal artery stenosis according to local standards
1807427|NCT00640419|Drug|ABT-089|Subjects will take 10 mg capsules and/or 40 mg tablets (actual dose based on weight) once daily for 6 weeks.
1807428|NCT00640419|Drug|placebo|Subjects will take placebo capsules and/or tablets (number of capsules or tablets will be based upon weight) once daily for duration of the study.
1807429|NCT00640432|Drug|Diclofenac|75 mg oral capsule twice daily for 7 days
1807430|NCT00640432|Drug|Celecoxib|400 mg oral capsule followed by 200 mg oral capsule with the evening meal (>=4 hours from first dose) on Day 1 then 200 mg oral capsule twice daily for 6 days
1807431|NCT00640445|Behavioral|Expressive Writing|In EW, people are asked to write about their deepest thoughts and feelings surrounding a significant life event for 20 minutes a day for 4 days
1807432|NCT00640445|Behavioral|Control Writing|Those assigned to control writing conditions are asked to describe factual information for 20 minutes a day for 4 days.
1807433|NCT00640458|Drug|Sildenafil 100 mg|
1807434|NCT00640458|Drug|Placebo|
1807435|NCT00640471|Biological|cetuximab|cetuximab (Erbitux®) - Initial dose - Day 1 (Week 1): 400 mg/m2 IV over 120 minutes Maintenance Infusions (subsequent weeks): 250 mg/m2 IV over 60 minutes
1807436|NCT00640471|Drug|brivanib alaninate|brivanib (BMS-582664) 800 mg po, QD
1807437|NCT00640484|Drug|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 2 μg once a day, in the morning
(1 puff of carmoterol 2 μg + 1 puff of placebo pMDI)"
1807438|NCT00640484|Drug|carmoterol (CHF 4226)|"carmoterol (CHF 4226) 4 μg once a day, in the morning
(1 puff of carmoterol 2 µg + 1 puff of carmoterol 2µg)"
1807439|NCT00640484|Drug|placebo|"placebo once a day, in the morning
(1 puff of placebo pMDI + 1 puff of placebo pMDI)"
1807440|NCT00640484|Drug|salmeterol|"Salmeterol 50 μg twice daily, in the morning and in the evening
(1 blister of Serevent Diskus BID)"
1807441|NCT00640497|Biological|IT-Combination|The treatment consists of a standard dose of 4 infusions of IT-combination (4 mg/m2), given 48-hours apart over a 4-hour period. The IT-combination is a combination of two immunotoxins. One immunotoxin is a mAb anti-CD3 conjugated to recombinant ricin A chain and the other immunotoxin is a mAb anti-CD7 conjugated to recombinant ricin A chain.
1807442|NCT00640510|Drug|Rapid Acting Intramuscular Olanzapine|10mg/injection, IM. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
1807443|NCT00640510|Drug|Isotonic sodium chloride solution|0.9% sodium chloride (NaCl) solution. If patients do not respond to the first study medication or if patients do not have enough improvement based on the investigator's judgment, and in addition, if the investigator judges it is reasonable, the patient will receive a second injection at the same dose strength as the first injection after 2 hours following the first injection (no later than 8 hours after the first injection).
1807444|NCT00640523|Drug|forodesine HCl|2 x 100mg capsules daily
1807445|NCT00640549|Drug|Atorvastatin|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the atorvastatin group were treated with atorvastatin 20 mg tablets administered once daily orally for 8 weeks.
1807446|NCT00640549|Drug|Placebo|After a run-in phase of 4 weeks eligible patients were randomized at a ratio of 2 : 1 (atorvastatin : placebo). Patients in the placebo group were treated with placebo 20 mg tablets administered once daily orally for 8 weeks.
1807447|NCT00640562|Drug|Quetiapine Extended Release|Uptitrated starting from 300 mg in the evening on day 0, then increasing to 600 mg and up to 800 mg in the following two evenings. Previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 3 onwards it was possible to adjust the Seroquel XR dose, depending on the clinical response and tolerability of the patient, within the range of 400-800 mg per day
1807448|NCT00640562|Drug|Risperidone|Uptitrated starting from 1 mg bid (morning and evening) on day 0, then increasing to 2 mg bid and up to 3 mg in the following two days. As per the other arm, previous antipsychotic was taken at the full dose on day 0, half dose on day 1 and stopped from day 2. From day 2 onwards, it was allowed to adjust he dose of Risperidone depending on the clinical response and tolerability of the patient.
1807449|NCT00640575|Drug|triamcinolone and lidocaine hydrochloride|Ultrasound-guided lidocaine hydrochloride 5 ml (10 mg/ml) injection in the subacromial bursa and a triamcinolone 2 ml (10 mg/ml) and 2 ml lidocaine hydrochloride (10 mg/ml) intramuscular injection in the gluteal region
1807450|NCT00640575|Drug|triamcinolone and lidocaine hydrochloride|Ultrasound-guided injection of 2 ml triamcinolone (10 mg/ml) and 5 ml lidocaine hydrochloride (10 mg/ml) in the subacromial bursa and 4 ml intramuscular injection of lidocaine hydrochloride in the gluteal region
1807451|NCT00640588|Drug|Telbivudine|Arm 1: 600 mg/day, oral telbivudina for 24 weeks
1807452|NCT00640588|Drug|oral adefovir|Arm 2: 600 mg/day, oral telbivudina plus 10 mg/day oral adefovir for 24 weeks
1807600|NCT00635232|Drug|PS433540|800 mg (8 x 100 mg capsules) once daily for 12 weeks
1807601|NCT00635245|Biological|figitumumab|
1807453|NCT00640601|Drug|Quetiapine Fumarate Extended- Release|Open-label seroquel XR tablets: On Day 1 Patients received 300 mg, on Day 2 600 mg, on Day 3 600-800 mg and between Day 4-168 400-800 mg Seroquel XR, according to clinical judgement of investigator. Dose changes were in 200 mg fixed doses. Investigational product (IP) was supplied in open label wallet blister cards and subjects were instructed to take the IP once daily in the evening.
1807454|NCT00640614|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Polyvinylpyrrolidone (PVP; excipient 1) Hydrocortisone-17-butyrate, 0.020 mg/cm2 in PVP Hydroxypropylcellulose (HPC; excipient 2) MDBGN, 0.0055 mg/cm2 in PVP Bacitracin, 0.60 mg/cm2 in HPC Gold sodium thiosulfate, 0.075 mg/cm2 in HPC Parthenolide, 0.0030 mg/cm2 in PVP Disperse Blue 106, 0.050 mg/cm2 in PVP Bronopol, 0.25 mg/cm2 in PVP
Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
1807455|NCT00640627|Drug|Celecoxib|200 mg oral capsule once daily for 6 weeks
1807456|NCT00640627|Drug|Placebo|Matched oral placebo for 6 weeks
1807457|NCT00640640|Device|Pascal Dynamic Contour Tonometer|Pascal Dynamic Contour Tonometer is an ocular device that is able to safely measure the intraocular pressure and the ocular pulse amplitude
1807458|NCT00640640|Drug|Ranibizumab|measure the effect of intravitreal 0.5mg/0.05ml ranibizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
1807459|NCT00640640|Drug|Bevacizumab|measure the effect of intravitreal 1.25mg/0.05ml bevacizumab on the intraocular pressure and ocular pulse amplitude with the Pascal Dynamic Contour Tonometer
1957720|NCT02234310|Biological|rFIXFc|Adjustments to the dose and interval of rFIXFc can be made in this study based on investigator discretion using available pharmacokinetic (PK) data, subsequent FIX trough and peak levels, level of physical activity, and bleeding pattern, in accordance with local standards of care for a prophylactic regimen. There is an option to start study dosing as episodic treatment (on-demand).
1807465|NCT00640666|Behavioral|Exercise Behavior Change|Multidisciplinary
1807466|NCT00640679|Drug|Abrupt Clopidogrel Interruption|Patients assigned to this group will receive Clopidogrel 75mg per day for an additional period of 4 weeks. Afterwards they will stop the drug abruptly.
1807467|NCT00640679|Drug|Clopidogrel Tapering|Patients assigned to this group will have Clopidogrel gradually decreased according to a fixed tapering schema of Clopidogrel and Placebo over 4 weeks.
1807468|NCT00640705|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
1807469|NCT00640705|Drug|Matching placebo patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
1807470|NCT00640731|Device|OmniWave Endovascular System|Treatment with mechanical thrombolysis/thrombectomy
1807471|NCT00640744|Drug|Atorvastatin|Atorvastatin 80 mg tablet/day for 3 months
1807472|NCT00640757|Dietary Supplement|Methionine deficient diet|Hominex with a low protein diet
1807473|NCT00640757|Dietary Supplement|Methionine sufficient diet|Hominex, low protein diet and methionine capsules
1807474|NCT00640770|Device|balloon angioplasty|balloon angioplasty
1807475|NCT00640770|Device|drug eluting stent|Cypher Select+ Coronary or Infrapopliteal Stent
1807476|NCT00640783|Behavioral|Mediterranean diet|The dietary advice was tailored to each patient on the basis of 3-day food records. The recommended composition of the dietary regimen was as follows: carbohydrates, 50% to 60%; proteins, 15% to 20%; total fat, less than 30%; saturated fat, less than 10%; and cholesterol consumption, less than 300 mg per day. Moreover, patients were advised to consume at least 250 to 300 g of fruits, 125 to 150 g of vegetables, and 25 to 50 g of walnuts per day; in addition, they were also encouraged to consume 400 g of whole grains (legumes, rice, maize, and wheat) daily and to increase their consumption of olive oil.
1807477|NCT00640783|Behavioral|Control|Patients consuming the control diet were given general oral and written information about healthy food choices at baseline and at subsequent visits but were offered no specific individualized program. However, the general recommendation for macronutrient composition of the diet was similar to that for the intervention group (carbohydrates, 50%-60%; proteins, 15%-20%; and total fat, <30%).
1807478|NCT00640796|Procedure|Haploidentical donor derived natural killer cell infusion|Therapeutic cell infusion
1807479|NCT00640796|Drug|Chemotherapy|Cyclophosphamide, Fludarabine, Interleukin-2, Mesna
1807480|NCT00640796|Device|CliniMACS|Cell selection system based on magnetic-activated cell sorting
1807481|NCT00640809|Drug|Celecoxib|200 mg oral capsule twice daily for 2 weeks
1807482|NCT00640809|Other|Placebo|Matched placebo for 2 weeks
1807602|NCT00635245|Other|imaging biomarker analysis|
1957734|NCT02223390|Behavioral|Improving AIDS Care after Trauma (ImpACT)|
1807483|NCT00640809|Drug|Ibuprofen plus Omeprazole|ibuprofen 800 mg oral tablet three times daily plus omeprazole 20 mg oral capsule once daily for 2 weeks
1807484|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment vehicle|Once daily application for up to 8 weeks
1807485|NCT00640822|Drug|Tacalcitol Ointment|Once daily application for up to 8 weeks
1807486|NCT00640822|Drug|Calcipotriol plus hydrocortisone ointment|Once daily application for up to 8 weeks
1807487|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by sublingual route
1807488|NCT00640835|Drug|Buprenorphine/naloxone Film Strip|Buprenorphine/naloxone dosed between 4/1 mg to 32/8 mg once a day for 12 weeks by buccal route
1807489|NCT00640848|Drug|almorexant|1 dose of 400 mg in two treatment sequences
1807490|NCT00640848|Drug|almorexant|1 dose of 200 mg in two treatment sequences
1807491|NCT00640848|Drug|almorexant|1 dose of 100 mg in two treatment sequences
1807492|NCT00640848|Drug|almorexant|1 dose of 50 mg mg in two treatment sequences
1807493|NCT00640848|Drug|almorexant|1 dose of 1000 mg in two treatment sequences
1807494|NCT00640861|Biological|CpG oligodeoxynucleotide|
1807495|NCT00640861|Biological|HER-2/neu peptide vaccine|
1807496|NCT00640861|Biological|MUC-1 peptide vaccine|
1807497|NCT00640861|Biological|incomplete Freund's adjuvant|
1807498|NCT00640861|Biological|sargramostim|
1807499|NCT00640861|Other|immunoenzyme technique|
1807500|NCT00640861|Other|immunologic technique|
1807501|NCT00640887|Drug|rifabutin in combination with efavirenz|"Ia. arm 1a:
D4T/3TC/EFV(600mg)+INH/Rifabutin(450 mg OD 4 wks switch to 600 mg OD 4 wks);
Ib. arm 1b:
D4T/3TC/EFV(600mg)+INH/Rifabutin(600 mg OD 4 wks switch to 450 mg OD 4 wks);"
1807502|NCT00640887|Drug|rifabutin in combination with nevirapine|"IIa. arm 2a:
D4T/3TC/NVP(200mg)+INH/Rifabutin(300 mg OD 4 wks switch to 450 mg OD 4 wks);
IIb. arm 2b :
D4T/3TC/NVP(200mg)+INH/Rifabutin(450 mg OD 4 wks switch to 300 mg OD 4 wks);"
1807503|NCT00640887|Drug|rifabutin in combination with lopinavir/ritonavir|"IIIa. arm 3a :
D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg TPW 4 wks switch to 150 mg OD 4 wks);
IIIb. arm 3b:
D4T/3TC/LPV/r(2 tabs BD)+INH/Rifabutin(150 mg OD 4 wks switch to 150 mg TPW 4 wks)."
1807504|NCT00640900|Behavioral|Usual care|Two individualized weight loss counseling sessions with a dietetics professional, and monthly contacts to maintain communications.
1807505|NCT00640900|Behavioral|Commercial weight loss program|Active weekly participation until weight loss goals are reached, and monthly participation to maintain the weight loss.
1807506|NCT00640913|Procedure|Reversal of defunctioning stoma|Reversal of defunctioning stoma
1807507|NCT00640926|Drug|Radezolid|300 mg/day, orally for 7-10 days
1807508|NCT00640926|Drug|Radezolid|450 mg/day orally for 7-10 days
1807509|NCT00640926|Drug|Radezolid|900 mg/day orally for 7-10 days
1807510|NCT00640939|Drug|diclofenac sodium|15 mg (1%) topical patch; measuring 7 cm by 10 cm; applied once daily
1807511|NCT00640939|Drug|Matching Placebo|Matching placebo patch, containing identical constituents to active patch except for diclofenac sodium; measuring 7 cm by 10 cm; applied once daily
1807512|NCT00640952|Drug|acamprosate|333 mg 2 tabs tid
1807513|NCT00640965|Drug|DP-VPA|DP-VPA dose escalation to 900mg, then continued for 8 weeks
1807514|NCT00640965|Drug|DP-VPA Placebo|Matching Placebo to Active, dose escalation, then continued for 8 weeks
1807515|NCT00640978|Drug|RAD001|30 mg orally weekly for 4 weeks
1807516|NCT00640978|Drug|Erlotinib|150 mg by mouth daily for 28 Days
1807517|NCT00640991|Drug|glulisine insulin, glargine insulin|IV infusion of glulisine, SC injection of glargine
1807518|NCT00641004|Drug|Rebamipide and Esomeprazole|"Rebamipide 100mg TID for 12 weeks
Esomeprazole 40mg OD + Esomeprazole-matching placebo BID for 12 weeks"
1807519|NCT00641017|Biological|rHPIV1 84/del170/942A, Lot PIV1 #104A vaccine|Live attenuated Human Parainfluenza Type 1 Virus Vaccine
1807520|NCT00641017|Biological|Placebo|Placebo for rHPIVI1 84/del170/942A, Lot PIV1 #104A vaccine
1807521|NCT00641030|Drug|clofarabine|Administered at the appropriate dose level(dose level one = 30 mg/m2, dose level two and three = 40 mg/m2)on days -9 to day -5 from transplant
1807522|NCT00641030|Drug|melphalan|Administered at the appropriate dose level (dose level one and two = 100 mg/m2, dose level three = 140 mg/m2) on day -4 from transplant
1807523|NCT00641030|Genetic|gene expression analysis|Peripheral blood draw on day -9 and day -4 prior to transplant
1807524|NCT00641030|Genetic|reverse transcriptase-polymerase chain reaction|Peripheral blood draw on day -9 and day -4 prior to transplant
1807525|NCT00641030|Other|flow cytometry|Bone marrow aspirate and biopsy to confirm diagnosis prior to transplant, day -9 pre-transplant, day 30 post-transplant, day 100 post-transplant, 6 months post-transplant, one year post-transplant, then yearly through year 5 post-transplant
1807526|NCT00641030|Other|laboratory biomarker analysis|Peripheral blood draw day -9 or earlier pre-transplant, day 14 post-transplant, day 30 post-transplant, day 60 post-transplant, day 100 post-transplant, 6 months and one year post-transplant.
1807527|NCT00641030|Procedure|allogeneic hematopoietic stem cell transplantation|Infusion of allogeneic hematopoietic stem cells on day 0 of transplant
1807528|NCT00641043|Drug|placebo + pioglitazone (30 mg)|placebo + overcapsulated 30 mg tablet, once daily
1807529|NCT00641043|Drug|Linagliptin + pioglitazone (30 mg)|5 mg tablet + overcapsulated 30 mg tablet, once daily
1807530|NCT00641056|Drug|Exenatide Once Weekly|subcutaneous injection, 2.0mcg, once weekly
1807531|NCT00641056|Drug|Insulin Glargine|subcutaneous injection, variable dose, QD
1807532|NCT00641069|Device|Automated load-distributing band device|Blood pressure recording before and after starting up the automated band device
1807533|NCT00641082|Drug|Clevudine|30mg for 48 weeks
1807534|NCT00641082|Drug|Adefovir dipivoxil|10mg for 48 weeks
1807535|NCT00641095|Biological|rituximab|
1807536|NCT00641095|Drug|cyclophosphamide|
1807537|NCT00641095|Drug|fludarabine phosphate|
1807538|NCT00641095|Genetic|fluorescence in situ hybridization|
1807539|NCT00641095|Other|immunohistochemistry staining method|
1807540|NCT00641095|Other|immunologic technique|
1807541|NCT00641095|Other|laboratory biomarker analysis|
1957738|NCT02216500|Dietary Supplement|Ketogenic Therapy|Ketogenic Therapy is based on a ratio of fat: protein+carbohydrate in which protein intake is adequate, fat intake is high, and carbohydrate intake is minimal.
1807545|NCT00641147|Drug|Curcumin|Given PO
1807546|NCT00641147|Other|Laboratory Biomarker Analysis|Correlative studies
1807547|NCT00641147|Other|Placebo|Given PO
1807548|NCT00641160|Drug|vinorelbine tartrate|Dose Level #1 PO for at least 7 days
1807549|NCT00641160|Drug|vinorelbine tartrate|Dose Level #2 PO for at least 7 days
1807550|NCT00641160|Drug|vinorelbine tartrate|Dose Level #3 PO for at least 7 days
1807551|NCT00641173|Drug|paroxetine|treatment with SSRI paroxetine
1807552|NCT00641173|Drug|placebo|treatment with placebo
1807554|NCT00641199|Other|Jarro-Dophilus EPS probiotics|Jarro-Dophilus EPS product 2 capsules twice daily. 4.4 billion live bacteria per capsule.
1807555|NCT00641212|Drug|Budesonide|
1807556|NCT00641212|Drug|Placebo|
1807557|NCT00641225|Drug|SBI-087|Single IV doses of SBI-087 from 0.015 mg/kg to 2 mg/kg and Single SC doses of SBI-087 from 50 mg to 300 mg.
1807558|NCT00641238|Device|Radiofrequency ablation|Radiofrequency ablation
1807559|NCT00641251|Other|intensive medical management|IMM will include rigorous lifestyle modification for weight loss and stepped pharmacologic treatment consistent with standard of care for diabetes and other CVD risk factors.
1807560|NCT00641251|Other|RYGB & IMM|Roux-en-Y gastric bypass Surgery combined with intensive medical management
1807561|NCT00641264|Drug|Omeprazole|
1807562|NCT00641264|Behavioral|Quality of Life questionnaire|
1807563|NCT00641290|Device|Vigileo FloTrac Sensor|Comparing the Vigileo FloTrac against the conventional Pulmonary Artery Catheter using the thermodilution method for measurements of cardiac output.
1807564|NCT00641303|Procedure|acupuncture therapy|Given weekly for 8 sessions
1807565|NCT00641303|Procedure|sham intervention|Given weekly for 8 sessions
1807566|NCT00641316|Procedure|AtraumaticTeeth Extraction|Teeth extraction alone, allowed to heal for 2 months followed by implant therapy to the sites
1807567|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with Freeze-Dried Bone Allograft (FDBA) mixed with Tri-Calcium Phosphate(TCP) allowed to heal for 2 months followed by dental implant therapy to the sites
1807568|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Autologous Platelet-Rich Plasma (PRP) allowed to heal for 2 months followed by dental implant therapy to the sites
1807569|NCT00641316|Procedure|Atraumatic Teeth Extraction/Grafted Extraction Sockets|Teeth extraction/post-extraction socket grafting with FDBA/TCP enriched with Platelet-Derived Growth Factors (PDGF) allowed to heal for 2 months followed by dental implant therapy to the sites
1807570|NCT00641329|Drug|CLONICEL (clonidine HCl sustained release)|Flexible Dose (0.1 - 0.4 mg)
1807571|NCT00641329|Drug|Placebo|Matching placebo tablets
1807572|NCT00641342|Device|onlay mesh|StomaMesh (Precut heavyweight polypropylene mesh) Vypro Mesh (lightweight Prolene and vicryl mesh)
1807573|NCT00641355|Procedure|No intervention|No intervention
1807574|NCT00641368|Behavioral|R4Power Program|In the 10-lesson online R4Power Program, adolescents will learn cognitive skills (link between thoughts, feelings, and behaviors; thinking traps; challenging negative beliefs) and problem-solving skills (assertiveness; relaxation and distraction; overcoming procrastination; decision-making) in order to cope with stressful situations.
1807575|NCT00641368|Other|Waitlist Control|Adolescents in the waitlist control group will complete the R4Power program during the second year of the study.
1807576|NCT00641381|Drug|carmustine|150 mg/m2 day -7, -6,and -5 prior to stem cell reinfusion
1807577|NCT00641381|Drug|cyclophosphamide|100 mg/kg on day -2 prior to stem cell reinfusion
1807578|NCT00641381|Drug|etoposide|60 mg/kg on day -4 prior to stem cell reinfusion
1807579|NCT00641381|Other|pharmacological study|Prior to start of etoposide infusion, 2 hours after start of infusion, just prior to the end of infusion, then at 0.5, 1, 2, 4, 24 and 48 hours after the end of infusion
1807580|NCT00641381|Procedure|autologous hematopoietic stem cell transplantation|Reinfusion of autologous stem cells
1807581|NCT00641381|Procedure|peripheral blood stem cell transplantation|Reinfusion of autologous stem cells
1807582|NCT00641394|Behavioral|Psychotherapy: Emotional Freedom Techniques (EFT)|A form of therapy that includes cognitive reframing with somatic reinforcement through touch or tapping of specified points on the body
1807583|NCT00641394|Behavioral|Cognitive Behavioral Therapy (CBT)|A form of therapy that focuses on negative cognitions of problems, and reframing them in positive terms, but without somatic reinforcement.
1807584|NCT00635180|Behavioral|isometric exercise|
1807585|NCT00635193|Drug|M200 (Volociximab)|7.5 mg/kg, IV infusion every week until disease progression
1807586|NCT00635193|Drug|Liposomal Doxorubicin|40 mg/m2, IV infustions every 4 weeks until disease progression, the maxium number of doses a subject can receive is 12.
1807587|NCT00635193|Drug|M200 (Volociximab)|15 mg/kg, IV infusions every week until disease progression
1807588|NCT00635193|Drug|M200 (Volociximab)|15 mg/kg, IV infustions every other week until disease progression
1807589|NCT00635206|Device|BiPap auto with Fi Flex|"MinEPAP = 4 cmH2O for prescribed CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)
MaxIPAP = 25 cm H2O
MinPS = 2 cm H2O (cannot be adjusted)
MaxPS = 8 cm H2O
Bi-Flex setting of 3"
1807590|NCT00635206|Device|Standard CPAP|CPAP ≤ 10 cmH2O (use 6 cmH2O for prescribed CPAP > 10 cmH2O)
1807591|NCT00635219|Drug|Placebo|capsules; daily; orally
1807592|NCT00635219|Drug|Vortioxetine (Lu AA21004)|2.5 mg/day; encapsulated tablets; orally
1807593|NCT00635219|Drug|Vortioxetine (Lu AA21004)|5 mg/day; encapsulated tablets; orally
1807594|NCT00635219|Drug|Vortioxetine (Lu AA21004)|10 mg/day; encapsulated tablets; orally
1807595|NCT00635219|Drug|Duloxetine|60 mg/day; encapsulated capsules; orally
1807596|NCT00635232|Drug|irbesartan|300 mg (2 x 150 mg capsules) once daily for 12 weeks
1807597|NCT00635232|Drug|placebo|placebo capsules once daily for 12 weeks
1807598|NCT00635232|Drug|PS433540|200 mg (2 x 100 mg capsules) once daily for 12 weeks
1807603|NCT00635245|Other|laboratory biomarker analysis|
1807605|NCT00635245|Procedure|conventional surgery|
1807606|NCT00635245|Procedure|magnetic resonance spectroscopic imaging|
1807607|NCT00635245|Procedure|neoadjuvant therapy|
1807608|NCT00635258|Drug|triptorelin (Decapeptyl®, Ipsen Pharma, Barcelona, Spain)|0.1 mg/day triptorelin s.c (Decapeptyl®, Ipsen Pharma, Barcelona, Spain) was started on day 21-24 of the preceding cycle for at least 14 days to produce an agonadal state.
1807609|NCT00635258|Drug|GnRH antagonist (Orgalutran®)|GnRH antagonist (Orgalutran®; 0,25 mg/d, sc.) commencing on day 1 of the menstrual cycle and maintained until the day of donor's hCG administration.
1807610|NCT00635284|Drug|ABI-009|nab-rapamycin
1807611|NCT00635297|Procedure|Percutaneous vertebroplasty|PMMA injection 3-10 milliliter in each treated vertebrae
1807612|NCT00635310|Procedure|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
1807613|NCT00635310|Procedure|Percutaneous liver biopsy|Two passes of PLB from the right hepatic lobe by US guidance (ToshibaTM PLF-308P, Toshiba Co. Ltd., Tokyo, Japan) and 16-gauge automatic cutting needles (Temno EvolutionTM, Allegiance, McGaw Park, IL, USA)
1807614|NCT00635323|Drug|Irinotecan plus capecitabine|Irinotecan 200-250 mg/m2 intravenous infusion over 30 to 90 minutes on day 1 of a 3-week cycle. Capecitabine 1000 mg/m2 oral tablet twice daily for 14 days followed by a 7 day rest throughout the treatment period for
1807615|NCT00635336|Biological|MPHOSPH1 and DEPDC1|DEPDC1-9-294, and/or MPHOSPH1-9-278 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. These peptides are determined to administer in accordance with the protein expression using immunohistochemical staining. These peptides are conjugated with Montanide ISA 51 as an adjuvant.
1807616|NCT00635349|Drug|Meloxicam|Meloxicam 7.5 mg or 15 mg per day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and meloxicam 7.5 mg or 15 mg per day from Day 29 to Day 85.
1807617|NCT00635349|Drug|Aceclofenac|Aceclofenac 100 mg twice a day along with fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day from Day 1 to Day 28, and aceclofenac 100 mg twice a day from Day 29 to Day 85.
1807618|NCT00635349|Drug|Tramadol Hydrochloride Plus Acetaminophen|Fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 to 3 tablets per day along with NSAIDs (meloxicam [7.5 mg or 15 mg once daily] or aceclofenac [100 mg twice daily]) from Day 1 to Day 28, and fixed dose combination of tramadol hydrochloride 37.5 mg plus acetaminophen 325 mg, 1 or 2 tablets 4 times daily from Day 29 to Day 85 (maximum daily dose will be 8 tablets).
1807619|NCT00635362|Device|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Immediate postplacental insertion of the LNG-IUS through the uterine incision during cesarean, within 10 minutes after delivery of the placenta
1807620|NCT00635362|Device|Levonorgestrel-releasing intrauterine system (LNG-IUS)|Insertion of the LNG-IUS 4-8 weeks after cesarean delivery
1807625|NCT00635388|Other|Placebo|oral, placebo, once/day for 12 weeks
1807626|NCT00635388|Other|Lactobacillus (Probiotic 1)|oral, Lactobacillus, once/day for 12 weeks
1807627|NCT00635388|Other|Lactobacillus and Bifidobacterium (Probiotic 2)|oral, Lactobacillus and Bifidobacterium, once/day for 12 weeks
1807628|NCT00635401|Drug|Varenicline|0.5 mg BID for 7 weeks
1807629|NCT00635414|Drug|Esomeprazole|40mg oral
1807630|NCT00635414|Drug|Esomeprazole|15 minute intravenous infusion
1807631|NCT00635427|Biological|VPRIV®|Intravenous infusion, every other week (EOW)
1807632|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day.The amplitude of the electrical stimuli in the stimulated leg was adjusted to ensure maximum tolerable muscle contraction.
1807633|NCT00635440|Device|neuromuscular electrical stimulation: Cefar-Sport (CefarCompex Scandinavia AB)|Electrical stimuli of 50 Hz (pulse width 0.25ms, 8 sec on, 4 sec off) were applied daily for 30 min, for 4 days, starting on the first postoperative day. Current was increased until the patient could feel a tingling sensation but no muscle contraction was visible or palpable.
1807634|NCT00635453|Behavioral|Dietary Advice|The content of the dietary intervention follows the recommendations of the guidelines of the Brazilian Ministry of Health for healthy feeding of children younger then two years.
1807635|NCT00635466|Procedure|laparoscopic surgery for rectal carcinoma|Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (<8 cm).
1807636|NCT00635479|Device|VAC device|Vacuum Assisted Closure (VAC) device for surgical incision
1807637|NCT00635479|Other|Gauze dressing|Gauze dressing for surgical incision
1807638|NCT00635492|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
1807639|NCT00635492|Drug|any human insulin or analog insulin(s) given in any regimen by subcutaneous injection|
1807640|NCT00635505|Drug|albuterol HFA (Armstrong's)|180 mcg QID 12 weeks
1807641|NCT00635505|Drug|albuterol HFA (Proventil HFA)|180 mcg QID 12 weeks
1807642|NCT00635505|Drug|HFA placebo|2 actuations QID 12 weeks or until use of rescue drug
1807643|NCT00635518|Behavioral|Ten Steps for Healthy Feeding children programme|Ten Steps for Healthy Feeding children
1807644|NCT00635531|Other|placebo|Placebo dosing same as alprazolam, except a placebo equivalent was substituted for alprazolam
1807645|NCT00635531|Drug|alprazolam XR|Oral treatment started at a daily dose of 1 mg tablets for the first 7 days; thereafter the daily dosage was titrated at a maximum rate of 1 mg every 7 days up to a maximum dosage of 6 mg for lack of response, and in the absence of dose-limiting adverse events; no further increases in daily dose were permitted after Day 36; dosage reductions were permitted if required for tolerability; subjects who were not eligible for entry into the 18-week continuation study, or who were eligible but elected not to participate, were tapered off study drug at a rate of 1 mg every 7 days for up to a 6-week taper period.
1807646|NCT00635544|Other|dietary treatment|dietary treatment with a high-glycemic index low-fibre diet (HGI-LF)
1807647|NCT00635544|Other|dietary treatment|dietary treatment with a low-glycemic index high-fibre diet (LGI-HF)
1807648|NCT00635557|Drug|MPC-6827 + Carboplatin|MPC-6827 at 2.1mg/m2, 2.7mg/m2 or 3.3mg/m2 administered by intravenous infusion over 2 hours once weekly for three weeks in a 4 week cycle. Carboplatin at AUC4 administered by intravenous infusion over 1 hour on Day 1 of each 4 week cycle.
1807649|NCT00635570|Drug|Ortho Tri-cyclen Lo|Low dose oral contraceptive
1807650|NCT00635570|Device|NuvaRing|Contraceptive vaginal ring
1807651|NCT00635583|Other|Dairy Products|"3 additional servings of dairy (two of which must be milk or yogurt)
8 oz milk
6 oz yogurt
1.5 oz cheese"
1807652|NCT00635596|Biological|MT110|MT110 treatment as continuous intravenous infusion over at least 28 days with increasing doses
1807653|NCT00635609|Drug|Doxycycline hyclate (Doryx)|150mg/day, oral, delayed release tablets
1807654|NCT00635609|Drug|Doxycycline hyclate|100 mg/day, oral, tablets, immediate release
1807657|NCT00635635|Behavioral|Guided Imagery Audio|Guided Imagery Audio listened to 5x per week
1807658|NCT00635635|Behavioral|Music Audio|Music only audio to be listened to 5x per week
1807659|NCT00635648|Drug|caspofungin acetate|Intravenous (IV) caspofungin acetate 50 mg/day. Participants with esophageal candidiasis will be treated for at least 7 days and for at least 72 hours after symptoms resolve for a maximum of 28 days; participants with invasive candidiasis will have a 70 mg loading dose on study day 1 and will be treated for at least 14 days after the last positive culture of Candida from the blood or other normally sterile body site for a maximum of 60 days; these participants should also have improvement in clinical and radiographic signs of disease for at least 48 hours before completion of the study therapy.
1807660|NCT00641407|Drug|NPL insulin|Starting dose 10 IU bedtime and then titration
1807661|NCT00641407|Drug|Insulin glargine|10 IU bedtime and then titration
1807662|NCT00641420|Procedure|Fractionated Laser Resurfacing|
1807663|NCT00641433|Device|oxidized regenerated cellulose collagen-silver|Wound dressed daily with oxidized regenerated cellulose collagen-silver matrix.
1807664|NCT00641433|Drug|topical silver sulfadiazine cream|Cream will be applied to nailbed daily and dressed with a bandage until healing occurs.
1807665|NCT00641446|Drug|budesonide|
1807666|NCT00641446|Drug|varicella zoster virus|
1807667|NCT00641459|Other|Observational BPSD treatment study|Observational BPSD treatment study
1807668|NCT00641472|Drug|Budesonide inhalation suspension|0.5mg
1807669|NCT00641472|Drug|Montelukast Sodium|4mg or 5mg
1807670|NCT00641498|Behavioral|Psychotherapy|Individual supportive
1807671|NCT00641511|Drug|SYN117 (nepicastat)|120 mg per day
1807672|NCT00641511|Drug|Placebo comparator|once per day placebo capsules
1807673|NCT00641524|Procedure|Phlebotomy|Phlebotomy involves the removal of blood (approximately 500mL) each week until body iron levels reach the low-normal level
1807674|NCT00641537|Drug|Cladribine|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
1807675|NCT00641537|Drug|Placebo|Participants who received Cladribine 3.5 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
1807676|NCT00641537|Drug|Cladribine|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
1807677|NCT00641537|Drug|Cladribine|Participants who received placebo in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive cladribine tablet orally as cumulative dose of 0.875 mg/kg over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 resulting in total cladribine dose of 3.5 mg/kg during the treatment period of 96 weeks.
1807678|NCT00641537|Drug|Placebo|Participants who received Cladribine 5.25 mg/kg in the previous study 25643 (NCT00213135) and completed will be re-randomized in this extension study and receive placebo matched to cladribine tablet 0.875 mg/kg orally administered over a course of 4 or 5 consecutive days of 28-day period at Week 1, 5, 48, and 52 during the treatment period of 96 weeks.
1807679|NCT00641550|Other|Physical exercise|Walking 3 times a week during 1 hours (moderate activity)
1807680|NCT00641563|Drug|Dexmedetomidine|Infusion of dexmedetomidine
1807681|NCT00641563|Drug|Midazolam|Midazolam infusion
1807682|NCT00641563|Drug|Remifentanil|Infusion of remifentanil
1807867|NCT00643370|Other|CT scan of the chest under deep inspiration breath hold|computed tomography scan of the chest under dep inspiration breath hold conditions
1957743|NCT02207088|Drug|ombitasvir/paritaprevir/ritonavir|tablet
1957744|NCT02207088|Drug|dasabuvir|tablet
1807683|NCT00641576|Device|ACE CONNECT Endosseous dental implant|"Subjects in this study receive ACE CONNECT Internal-Connection dental implants to: 1)replace a missing tooth in an edentulous area of the maxilla or mandible restored with a single-unit crown (may include up to two non-adjacent areas as study sites) or, 2)subjects with an edentulous mandible will receive two implants placed in the lower canine position and restored with an implant-retained removable over-denture.
Subjects will return for four follow-up evaluations scheduled at 6, 12, 18 and 24 months after delivery of the permanent restoration."
1807684|NCT00641589|Drug|epoetin alfa|
1807685|NCT00641602|Drug|Esomeprazole|40mg once daily
1807686|NCT00641602|Drug|Lansoprazole|30mg once daily
1807687|NCT00641615|Biological|RNF43-721|Doses of 0.5mg, 1.0mg, 3.0mg/body/week
1807688|NCT00641628|Procedure|mastectomy|
1807689|NCT00641641|Drug|Tenofovir + emtricitabine + raltegravir.|TDF 300mg once daily + FTC 200mg once daily + RAL 400mg twice daily.
1807690|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm A: Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
1807691|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm B:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 48 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 48 weeks
1807692|NCT00641654|Drug|Pegylated interferon alfa-2a and ribavirin|Arm C:Pegylated interferon alfa-2a Injection, 180 µg sc x 1/w for 24 weeks Ribavirin Tablet 200 mg weight based 5 or 6 per day for 24 weeks
1807693|NCT00641667|Drug|Fentanyl|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
1807694|NCT00641680|Drug|Budesonide|
1807695|NCT00641680|Drug|Fluticasone propionate|
1807696|NCT00641680|Drug|Placebo|
1807697|NCT00641693|Drug|Budesonide|16mg Nasal Spray
1807698|NCT00641693|Drug|Budesonide|32mg Nasal Spray
1807699|NCT00641693|Drug|Budesonide|64mg Nasal Spray
1807700|NCT00641693|Drug|Placebo|
1807701|NCT00641706|Drug|vorinostat|Given orally
1807702|NCT00641706|Procedure|therapeutic conventional surgery|Patient undergoes surgery
1807703|NCT00641706|Drug|bortezomib|Given IV
1807704|NCT00641719|Drug|Duloxetine hydrochloride|Duloxetine 40 mg QD, PO, 1 year
1807705|NCT00641719|Drug|Duloxetine hydrochloride|Duloxetine 60 mg QD, PO, 1 year
1807706|NCT00641732|Drug|TAK-442|TAK-442 40 mg, tablets, orally, once daily for up to 10 days.
1807707|NCT00641732|Drug|TAK-442|TAK-442 80 mg, tablets, orally, once daily for up to 10 days.
1807708|NCT00641732|Drug|TAK-442|TAK-442 10 mg, tablets, orally, twice daily for up to 10 days.
1807709|NCT00641732|Drug|TAK-442|TAK-442 20 mg, tablets, orally, twice daily for up to 10 days.
1807710|NCT00641732|Drug|TAK-442|TAK-442 40mg, tablets, orally, twice daily for up to 10 days.
1807711|NCT00641732|Drug|TAK-442|TAK-442 80 mg, tablets, orally, twice daily for up to 10 days.
1807712|NCT00641732|Drug|Enoxaparin|Enoxaparin 30 mg, syringe, subcutaneous injection, twice daily for up to 10 days.
1807713|NCT00641745|Drug|Lurasidone HCl|40 - 120mg per day
1807714|NCT00641745|Drug|Risperidone|Risperidone
1807715|NCT00642473|Drug|Erlotinib|Participants will receive erlotinib 150 milligrams (mg) orally daily for 4 weeks.
1807716|NCT00642473|Drug|Metronidazole Actavis|Metronidazole actavis 1% topical cream will be applied on the face and chest twice daily for 4 weeks.
1807717|NCT00642473|Other|Non-active Moisturizing Cream|Left side of the face and chest will be treated according to local standard procedures (ie, with non-active moisturizing cream).
1807718|NCT00642486|Other|Portable (Embla Embletta X30 system and Respironic REMStar Auto M series with CFlex)|portable, home-based using the Embla Embletta X30 system as the diagnostic device and the Respironic REMStar Auto M series with CFlex as the PAP titration device.
1807719|NCT00642486|Other|Standard polysomnography (PSG)|laboratory-based testing
1807720|NCT00642499|Drug|Dronabinol|2.5 mg to 40 mg
1807721|NCT00642499|Drug|Placebo|placebo
1807722|NCT00642512|Drug|dronabinol|10 - 20 mg
1807723|NCT00642512|Drug|ondansetron|8 - 16 mg
1807724|NCT00642512|Drug|dronabinol/ondansetron|10 - 20 mg/8 - 16 mg
1807725|NCT00642512|Drug|placebo|placebo
1807726|NCT00642525|Procedure|Contrast swallow radiography, endoscopy|Contrast swallow radiography is performed using water soluble contrast medium Esophagoscopy is performed according to standard safety guidelines
1807727|NCT00642538|Drug|MKC253 Inhalation Powder|Inhalation Powder, prandial
1807728|NCT00642538|Drug|Technosphere Inhalation Powder|Inhalation Powder, prandial
1807729|NCT00642538|Drug|subcutaneous injection|10µg Exenatide, prandial
1807730|NCT00642551|Dietary Supplement|menaquinone-7|180 µg menaquinone-7 daily for three years
1807731|NCT00642551|Dietary Supplement|placebo|1 placebo capsule daily for three years
1807732|NCT00642564|Other|Observational study in Epileptic Patients|Observation study in Epileptic Patients with Migraine and Headache
1807733|NCT00642577|Drug|bevacizumab [Avastin]|5mg/kg iv every 2 weeks
1807734|NCT00642577|Drug|irinotecan|125mg/m2 iv weekly for 4 weeks of each 6 week cycle
1807735|NCT00642577|Drug|leucovorin|20mg/m2 iv weekly for 4 weeks of each 6 week cycle
1807736|NCT00642577|Drug|fluorouracil|500mg/m2 iv weekly for 4 weeks of each 6 week cycle
1807737|NCT00642603|Drug|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
1807738|NCT00642603|Drug|capecitabine [Xeloda]|1000 mg/m2 twice-daily, taken orally on Days 1-7 of each 2 week cycle
1807739|NCT00642603|Drug|bevacizumab [Avastin]|5 mg/kg taken intravenously on Day 1 of each 2 week cycle
1807740|NCT00642603|Drug|oxaliplatin|85 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
1807741|NCT00642603|Drug|irinotecan|135 mg/m2 taken intravenously on Day 1 of each 2 week cycle, for first 9 cycles
1807868|NCT00643383|Drug|Combination drug (Acetaminophen + Tramadol)|
1807869|NCT00643383|Drug|Placebo|
1807742|NCT00642616|Drug|Technosphere® Insulin|Technosphere® Insulin delivered with Gen 2 inhaler with doses individualized for each participant in combination with an antidiabetic regimen of insulin and/or oral antidiabetic agents
1807743|NCT00642616|Drug|Usual Care|Type 1 diabetics: long-acting (basal) insulin plus rapid-acting insulin, or pre-mix insulin Type 2 diabetics: oral anti-diabetic medications with or without long-acting (basal) insulin
1807744|NCT00642629|Drug|STA 5326 mesylate|STA 5326 mesylate 100mg taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
1807745|NCT00642629|Drug|Placebo|Placebo taken orally twice a day for 8 weeks with the option to continue at the same dose and frequency for an additional 4 weeks.
1807746|NCT00642642|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.
Administration of 3 study treatments administered 14 ± 7 days apart."
1807747|NCT00642642|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.
Administration of 3 study treatments administered 14 ± 7 days apart."
1807748|NCT00642655|Drug|IVIG and Rituximab|IVIG 2gm/kg given intravenously on day#0 and day#30 Rituximab 1gm given intravenously on day#7 and day#22
1807749|NCT00642668|Drug|methoxy polyethylene glycol-epoetin beta|1.2 mcg/kg administered subcutaneously (sc) monthly for 36 weeks (initial recommended dose)
1807750|NCT00642681|Drug|Technosphere Insulin|Technosphere® Insulin (TI) Inhalation Powder, prandial
1807751|NCT00642694|Drug|Escitalopram|Escitalopram 10 or 20mg qd based on symptoms at patient visit
1807752|NCT00642694|Drug|Ramelteon|Ramelteon 8 mg qd
1807753|NCT00642694|Other|Placebo|Matching placebo qd
1807754|NCT00642707|Drug|PRO 140 (humanized monoclonal antibody to CCR5)|
1807755|NCT00642707|Drug|Placebo Comparator|
1807756|NCT00642720|Drug|Pegvisomant|if the addition of 40 mg pegvisomant weekly will improve the quality of life of acromegaly patients compared to placebo weekly
1807757|NCT00642733|Drug|erlotinib [Tarceva]|100mg po daily
1807758|NCT00642733|Drug|gemcitabine|1000mg/m2 iv weekly for 8 weeks, then weekly for 3 weeks of each 4 week cycle
1807759|NCT00642746|Drug|Erlotinib|"Erlotinib oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. In addition to the active ingredient, erlotinib contains lactose (hydrous), microcrystalline cellulose, sodium starch glycolate, sodium lauryl sulfate, and magnesium stearate.
Tablets containing 25 mg, 100 mg, and 150 mg of erlotinib are available. Each bottle will contain 30 tablets, a quantity sufficient for 4 consecutive weeks of dosing, with overage."
1807760|NCT00642746|Drug|Fluorouracil|Antimetabolite used as a chemotherapy. Administered intravenously as a bolus injection at 400mg/m2 on Day 1 followed by 2400 mg/m2 continuously over 46 hours.
1807761|NCT00642746|Drug|Leucovorin|Chemotherapy agent given as a supplement to Fluorouracil. Given intravenously 400mg/m2 in combination with Fluorouracil dosing.
1807762|NCT00642746|Drug|Oxaliplatin|Platinum-based antineoplastic chemotherapy agent given intravenously at 85 mg/m2.
1807763|NCT00642746|Drug|Irinotecan|Chemotherapy agent given intravenously at 180 mg/m2.
1807764|NCT00642759|Drug|carboplatin|Given by infusion on day 1 of each 3 week cycle for a maximum of 6 cycles
1807765|NCT00642759|Drug|Nab-paclitaxel|Given by infusion once weekly (days 1, 8 and 15) of each three week cycle for a maximum of 6 cycles
1807766|NCT00642759|Drug|Bevacizumab|IV infusion
1807767|NCT00642772|Other|Group Physical Therapy|12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
1807768|NCT00642798|Drug|sitagliptin phosphate|Sitagliptin 100mg once daily on Day 1 for single dose, and once daily on Day4-9 for multiple dose.
1807769|NCT00642811|Drug|Ticagrelor|Tablets, Oral, 90 mg; 180 mg loading dose followed by 90 mg twice daily for 2 weeks
1807770|NCT00642811|Drug|Clopidogrel|(over encapsulated) capsule, Oral, 75 mg; 600 mg loading dose followed by 75 mg once daily for 2 weeks
1807771|NCT00642811|Drug|Aspirin|Tablets, Oral, 75 mg to 100 mg once daily. Aspirin obtained locally by the investigator, according to local practice. The dose remained constant throughout the study
1807772|NCT00642824|Drug|Standard chemotherapy|As prescribed--chemotherapy may be a)gemcitabine/cisplatin, b)vinorelbine + cisplatin/docetaxel + cisplatin or c)vinorelbine or docetaxel.
1807773|NCT00642824|Drug|bevacizumab [Avastin]|15mg/kg iv or 7.5mg/kg on day 1, and subsequently once every 3 weeks
1807774|NCT00642837|Drug|Tramadol/acetaminophen|Osteoarthritis, flexible dose depending on patients' pain relief
1807775|NCT00642837|Drug|Tramadol/acetaminophen|Post surgical neurophatic pain, flexible dose depending on patients' pain relief
1807776|NCT00642837|Drug|Tramadol/acetaminophen|Post traumatic neuropathic pain, flexible dose depending on patient pain relief
1807777|NCT00642837|Drug|Tramadol/acetaminophen|Spinal Cord Injury, flexible dose depending on patients' pain relief
1807778|NCT00642837|Drug|Tramadol/acetaminophen|Failed Back Surgery Syndrome,flexible dose depending on patients' pain relief
1807779|NCT00642837|Drug|Tramadol/acetaminophen|Diabetic Neuropathy, flexible dose depending on patients' pain relief
1807780|NCT00642837|Drug|Tramadol/acetaminophen|Post stroke pain, flexible dose depending on patients' pain relief
1807781|NCT00642837|Drug|Tramadol/acetaminophen|Low back pain, flexible dose depending on patients' pain relief
1807782|NCT00642837|Drug|Tramadol/acetaminophen|Post Herpetic Neuralgia, flexible dose depending on patients' pain relief
1807783|NCT00642837|Drug|Tramadol/acetaminophen|Complex Regional Pain Syndrome, flexible dose depending on patients' pain relief
1807784|NCT00642850|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms iv monthly (starting dose)
1807785|NCT00642863|Dietary Supplement|Ferrous Sulfate (liquid) + vitamins A and D|a single daily dose of 1-2 mg/kg of elemental iron (5 mg from 6 wk to 9 mo and 15 mg from 9 to 18 mo.) and 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
1807786|NCT00642863|Dietary Supplement|vitamins A and D|a single daily dose (liquid) of 1500 IU vitamin A and 500 IU vitamin D from 6 wk to 18 mo.
1807787|NCT00642863|Dietary Supplement|Ferrous sulfate (liquid)|Infants who become iron deficient/anemic at 9 or 18 mo will take a single daily dose of 3 mg/kg of elemental iron for 3 months.
1807788|NCT00642876|Device|Allograft Fusion and ATLANTIS™ Cervical Plate System|The patients that received the control treatment underwent a single level anterior cervical fusion procedure involving allograft bone and the ATLANTIS™ Cervical Plate System.
1807789|NCT00642876|Device|PRESTIGE® Cervical Disc|The PRESTIGE® Cervical Disc is a stainless steel device that was inserted into the intervertebral disc space. The device is composed of two metal plates that interface via a ball and socket mechanism permitting segmental spinal motion.
1807790|NCT00642889|Drug|Safinamide|
1807791|NCT00642889|Drug|Safinamide|
1807792|NCT00642889|Drug|Placebo|
1807793|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 25 milligram (mg) twice a week for initial 4 weeks as loading dose, followed by 25 mg once a week for subsequent 32 weeks.
1807794|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 75 mg twice a week for initial 4 weeks as loading dose, followed by 75 mg once a week for subsequent 32 weeks.
1807795|NCT00642902|Drug|Atacicept|Atacicept will be administered subcutaneously at a dose of 150 mg twice a week for initial 4 weeks as loading dose, followed by 150 mg once a week for subsequent 32 weeks.
1807796|NCT00642902|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously twice a week for initial 4 weeks, followed by once a week for subsequent 32 weeks.
1807797|NCT00642915|Drug|Lantus, Amaryl|
1807798|NCT00642928|Drug|Placebo|1 capsule per day during 4 weeks
1807799|NCT00642928|Drug|BF 2.649 5 mg|one BF 2.649 capsule of 5 mg per day during 4 weeks
1807800|NCT00642928|Drug|BF 2.649 10 mg|One BF 2.649 capsule of 10 mg per day during 4 weeks
1807801|NCT00642928|Drug|BF 2.649 20 mg|One BF 2.649 capsule of 20 mg per day during 4 weeks
1807802|NCT00642928|Drug|BF 2.649 40 mg|One BF 2.649 capsule of 40 mg per day during 4 weeks
1807803|NCT00642941|Drug|RG1507|Participants will receive R1507 IV infusion as 9 mg/kg once weekly or 27 mg/kg every 3 weeks, depending upon the cohort in which the participants are enrolled.
1807804|NCT00642954|Drug|Comparator: vorinostat|"Dose escalation study. Level 1: 300 mg q.d. vorinostat p.o. for 14 days. Level 2,3, 4 & 5: 400 mg q.d. vorinostat p.o. for 14 days. Each treatment cycle will be 28 days with a maximum of 8 treatment cycles.
Participants who do not have disease progression and who continue to meet the eligibility criteria after the 8 cycles will be offered continued treatment at the same dose level and schedule."
1807805|NCT00642954|Drug|Comparator: lenalidomide|Dose escalation study. Level 1 & 2: 10 mg q.d. lenalidomide p.o. for 21 days. Level 3: 15 mg q.d. lenalidomide p.o. for 21 days. Level 4: 20 mg q.d. lenalidomide p.o. for 21 days. Level 5: 25 mg q.d. lenalidomide p.o. for 21 days. Each treatment cycle will be 28 days with a maximum of 8 treatment cycles.
1807806|NCT00642954|Drug|Comparator: dexamethasone|Dose escalation study. 40 mg q.d. Dexamethasone p.o. will be given in each level on days 1, 8, 15, and 22 of each treatment cycle. Each treatment cycle will be 28 days with a maximum of 8 treatment cycles.
1807807|NCT00642967|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|s.c. every 4 weeks (starting dose based on previous ESA therapy)
1807808|NCT00642980|Drug|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: three times a month apart
1807809|NCT00642980|Drug|Placebo|Double blinded capsules(per os) Intervention= 2 capsules/d during 4 days: three times a month apart
1807810|NCT00642980|Drug|Clindamycin|300 mg capsules (per os) Intervention= 2 capsules/d during 4 days: one time and then, after one month placebo capsules 2 capsules/d during 4 days: two times a month apart
1807811|NCT00642993|Drug|SCH 497079|100 mg capsule administered orally
1807812|NCT00642993|Drug|Placebo|Placebo capsules matching SCH 497079 administered orally
1807813|NCT00643006|Behavioral|Physical exercise|Supervised walks with poles twice a week at moderate-high intensity
1807814|NCT00643006|Behavioral|Active comparator: low intensive exercise|Supervised walks once a week at low-intensity.
1807815|NCT00643019|Behavioral|SAFE Behavioral Intervention|Group cognitive behavioral intervention sessions
1807816|NCT00643019|Other|Control|Individual Sexually Transmitted Infection Risk Reduction Counseling
1807817|NCT00643032|Procedure|Transcutaneous iliohypogastric|
1807818|NCT00643032|Procedure|Perioperative administration near the nerve|
1807819|NCT00643045|Drug|Safinamide|
1807820|NCT00643045|Drug|Safinamide|
1807821|NCT00643045|Drug|Placebo|
1807822|NCT00643058|Biological|LPS endotoxin|"Low challenge: saline (diluent), 5000EU, 10,000EU and 20,000EU LPS endotoxin as tolerated
High challenge: Saline (diluent), 40,000EU and 80,000EU as tolerated
Diluent Challenge: 3 X Sterile saline inhalation (2 ml)"
1807823|NCT00643071|Drug|Tacrolimus|Oral
1807824|NCT00643084|Procedure|low residue diet/no standard bowel preparation|low residue diet/no standard bowel preparation
1807825|NCT00643084|Procedure|standard bowel preparation|standard bowel preparation
1807826|NCT00643097|Biological|PEP-3 vaccine|Given intradermally
1807827|NCT00643097|Biological|sargramostim|Given intradermally
1807828|NCT00643097|Drug|Temozolomide|Standard of care chemotherapy
1807829|NCT00643110|Drug|D50 glucose|D50 glucose would be administered, if necessary.
1807830|NCT00643123|Drug|Allopurinol|300-600 mg/day over a 4 week period
1807831|NCT00643123|Drug|Placebo|Inactive substance
1807832|NCT00643136|Drug|Pregabalin|Pregabalin capsules 75 mg twice daily on Days 1-4, then 150 mg twice daily on Days 5-28
1807833|NCT00643136|Drug|Placebo|Matching placebo capsules twice daily for 28 days
1807834|NCT00643149|Drug|amoxicillin|10 day regimen, 45 mg/kg/day, given in divided doses every 12 hours
1807835|NCT00643149|Drug|azithromycin SR|60 mg/kg dose of azithromycin SR was as safe and effective as a 10-day regimen of amoxicillin when used to treat children with strep throat
1807836|NCT00643162|Drug|Lexapro|5mg-10mg of lexapro, daily, for 9 weeks for all study participants.
1807837|NCT00643162|Behavioral|Light touch|Light touch twice a week, for 8 weeks
1807838|NCT00643162|Behavioral|Massage|Massage twice a week, for 8 weeks.
1807870|NCT00643396|Radiation|thoracic radiotherapy|
1807871|NCT00643409|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|Azithromycin SR 2.0 g by mouth in the form of a slurry x 1 dose
1807872|NCT00643409|Other|placebo|placebo
1957745|NCT02207088|Drug|Ribavirin|tablet
1807839|NCT00643175|Behavioral|Automated follow up|Treatment of osteoporosis after hip fracture is also being targeted as a future hospital quality assessment measure. Hospitals which have no plan in place to address osteoporosis treatment after hip fracture may be cited, and may have medicare money withheld. The goal of the study is to create an automated in-patient endocrinology consultation for osteoporotic hip fractures. We plan to gather patient data in a prospective manner including the endocrinologist recommendations, adherence to medical therapy after discharge, and future fracture rates. Planned interventions include only appropriate medical therapy for osteoporosis, DEXA bone scanning, and regularly scheduled telephone follow-up.
1807840|NCT00643188|Procedure|Radiofrequency ablation|Radiofrequency ablation of atrial fibrillation
1807841|NCT00643188|Other|Conventional treatment|The best medical treatment according to the ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult and the ACC/AHA/ESC 2006 Guidelines for Management of Patients with Atrial Fibrillation.
1807842|NCT00643201|Drug|Enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until International normalized ratio (INR) ≥2.
1807843|NCT00643201|Drug|warfarin|tablets, oral, dosing to target INR range between 2.0 - 3.0, once daily, 6 months
1807844|NCT00643201|Drug|Placebo for apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by placebo for apixaban 5 mg tablets, twice daily, 6 months
1807845|NCT00643201|Drug|Placebo for enoxaparin|solution, subcutaneous, 1 mg/kg Q12h until sham INR ≥2.
1807846|NCT00643201|Drug|Placebo for warfarin|tablets, oral, dosing to target sham INR range between 2.0 - 3.0, once daily, 6 months
1807847|NCT00643201|Drug|apixaban|tablets, oral, 10 mg tablets, twice daily, for 7 days followed by apixaban 5 mg, twice daily, 6 months
1807848|NCT00643214|Device|Tetrix|Twice daily topical application
1807849|NCT00643214|Device|Tetrix|Twice daily topical application
1807850|NCT00643227|Drug|clarithromycin extended release (ER)|7 days of clarithromycin extended release (ER), 1.0 g by mouth once daily
1807851|NCT00643227|Drug|azithromycin SR|Single, 2.0 g oral dose of azithromycin sustained release (SR) by mouth once daily
1807852|NCT00643240|Radiation|yttrium Y 90 anti-CD19 monoclonal antibody BU12|Patients in whom the biodistribution is as expected (unaltered) AND a HAMA response does not develop will receive a single dose of 90Y-BU-12 in a dose escalated manner to establish the maximum tolerated dose (MTD) of 90Y-BU-12 over 60 minutes on Day 0. A single course of BU-12 includes the imaging dose of 111In-BU-12 followed 7-8 days later by the therapy dose of 90YBU- 12.
1807853|NCT00643240|Radiation|111In-BU-12|Patients receive indium-111 BU-12 IV over 60 minutes on day 0
1807854|NCT00643253|Behavioral|LC and Electronic Prompt|Women will receive: a) International Board of Certified Lactation Consultant (IBCLC) education/counseling during the pre-natal, intra-partum and post-hospital discharge period to promote early and continued exclusive breastfeeding. The protocol specifies 2 prenatal meetings, a hospital visit, and a home visit if indicated and accepted, and; b) Electronic Medical Record Prompts- will appear on the prenatal record 5 times throughout the pregnancy. They are brief discussion points re breastfeeding that the provider is asked to raise with their patients.
1807855|NCT00643266|Behavioral|Recollection Training|"Participants are exposed to long lists of words. Each word is presented either visually or auditorily, and each word is repeated after a variable number of intervening words (the lag), in each the same modality, or the other modality. Participants are instructed to respond yes only to words repeated in the same modality. If a performance criterion is met, the lag is increased for the next session; if the performance criterion is not met, the same lag is repeated in the next session."
1807856|NCT00643266|Behavioral|Control|Participants view PowerPoint presentations on various topics related to memory and aging (e.g., structural brain changes, diet, stress, depression) and how each of these topics affect memory, and after each presentation, play a Jeopardy-like game to test their knowledge gain
1807857|NCT00643279|Device|Chronicle Implantable Hemodynamic Monitor|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead.
1807858|NCT00643292|Drug|amoxicillin/clavulanate postassium (Augmentin ES-600)|amoxicillin/clavulanate postassium 90/6.4 mg/kg/day, given in divided doses q12h, for 10 days
1807859|NCT00643292|Drug|azithromycin SR|azithromycin SR 60 mg/kg x 1 dose
1807860|NCT00643305|Behavioral|Skills Building with Motivational Interviewing|Based on the Stages of Change model, participants are provided with feedback related to their current HIV risk and Motivational Interviewing strategies are used to increase motivation to decrease HIV risk behaviors. Participants are also provided with information and training in skills critical for reducing HIV risk
1807861|NCT00643305|Behavioral|Skills Building|Participants are provided with information and training in skills critical for reducing HIV risk.
1807862|NCT00643318|Radiation|CyberKnife Stereotactic Radiosurgery|"Central tumors defined as < 2 cm from carina and < 2 cm from right and left mainstem bronchus and/or < 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus, and the right and left lower lobe bronchus. For central tumors, 4 fractions of 12 Gy will be delivered (12 Gy x 4 fractions = 48 Gy)
Peripheral tumors are defined as being > 2 cms from the carina and > 2 cms from the right and left mainstem bronchus and/or > 2 cms from the right and left upper lobe bronchus, bronchus intermedius, middle lobe bronchus and the right and left lower lobe bronchus. For peripheral tumors, 3 fractions of 20 Gy will be delivered (20 Gy x 3 fractions = 60 Gy)"
1807863|NCT00643331|Behavioral|Exercise|Exercise performed at gym and at home comprising strength, balance and impact exercise
1807864|NCT00643344|Behavioral|Craving and Lifestyle Management through Mindfulness(CALMM+)|MBSR is a program that provides systematic training in mindfulness meditation and gentle yoga as a self-regulation approach to reduce stress and improve medical and psychological symptoms. In this randomized controlled pilot study, we aim to test a 16-week intervention that further integrates diet and exercise into the CALMM program (CALMM+). This novel program, which includes elements drawn from MBSR, will be actively compared with the conventional diet and exercise group(TLC). Both groups will receive about 7 hours of in-class and out-of-class activities per week. The activities includes exercise, keeping dietary records, and stress reduction practices (if they are assigned to the intervention group).
1807865|NCT00643357|Drug|50% Oxygen/50% Nitrous oxide premix (KALINOX 170 bar)|gaz flow between 4 to 15 L/min inhalation between 15 to 60 minutes
1807866|NCT00643357|Drug|50%Oxygen/50% Nitrogen premix|inhalation between 15 to 60 minutes gaz flow between 4 to 15 l/min
1807922|NCT00643760|Drug|Placebo|placebo
1807873|NCT00643409|Drug|levofloxacin|levofloxacin 500 mg capsule by mouth qd x 10 days
1807874|NCT00643409|Other|placebo|placebo
1807875|NCT00643422|Device|Cirrus™ HD-OCT, Carl Zeiss Meditec AG|the retinal thickness and volume is determined on two different days with the Cirrus™ HD-OCT.
1807876|NCT00643435|Behavioral|Self-efficacy enhancing interviewing techniques training|Teaching by standardized patient instructors regarding use of self-efficacy enhancing interviewing techniques to be applied in patient encounters
1807877|NCT00643435|Behavioral|Control intervention|These residents receive training provided by a standardized patient instructor, regarding the common co-occurrence of chronic medical and mental health problems, without any interviewing technique discussion or training.
1807878|NCT00643448|Drug|AZD1305|AZD1305 loading dose 250 mg + 125 mg evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
1807879|NCT00643448|Drug|AZD1305|AZD1305 loading dose 500 mg + placebo evening dose on Study Day 1, maintenance dose 125 mg twice daily from Study Day 2
1807880|NCT00643448|Drug|Placebo|Placebo corresponding to AZD1305 loading dose + evening dose on Study Day 1, maintenance dose twice daily from Study Day 2
1807881|NCT00643461|Device|Adhesive A|Applied per manufacturer's instructions.
1807882|NCT00643461|Device|Adhesive B|Applied per manufacturer's instructions.
1807883|NCT00643461|Device|Adhesive C|Applied per manufacturer's instructions.
1807884|NCT00643474|Device|Accu-Chek Aviva Meter|4-point daily glucose monitoring profile 3 times per week
1807885|NCT00643474|Device|Accu-Chek Aviva Meter|Frequency and timing of SMBG not specified
1807886|NCT00643487|Procedure|observation of the behavior of the infrapatellar plica|Local anesthesia using bupivicaine will be initiated. The IPP, if present will be injected with contrast material. In order to minimize discomfort, lidocaine 1%, in as small a volume as possible, will be injected into the fat pad under direct vision to avoid any intra-articular damage from the #25 needle. Radiographic visualization will be verified and the knee taken through a full range of passive and active exercises. Active quadriceps contraction in the subject will be performed at 0, 15, 30 60 and 90 degrees of flexion. In so far as is technically possible, the behavior of the IPP will be videotaped and recorded on lateral fluoroscopy.
1807887|NCT00643500|Drug|Levetiracetam|
1807888|NCT00643526|Device|Pre-filled Auto-injector Containing Placebo|Participants will self-inject placebo subcutaneously at thigh and abdomen.
1807889|NCT00643539|Drug|Zithromax|azithromycin (Zithromax) pediatric suspension formulation (200 mg/5 ml) administered as an oral suspension at a dose of 20 mg/kg once a day (maximal dose 500 mg/day) for 3 consecutive days
1807890|NCT00643539|Drug|Clamoxyl|Amoxicillin (Clamoxyl) pediatric formulation (500 mg/5 ml) administered as an oral suspension at a dose of 25 mg/kg twice daily (maximal dose 2 g/day) for 6 consecutive days
1957746|NCT02205112|Drug|Nemonoxacin|
1957747|NCT02205112|Drug|Levofloxacin|
1807893|NCT00643578|Drug|formoterol|a single dose of 24 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
1807894|NCT00643578|Drug|formoterol|a single dose of 12 mcg of formoterol delivered by dry powder inhaler (Twisthaler)
1807895|NCT00643578|Device|Dry Powder Inhaler (Twisthaler)|subjects inhaled deeply and forcefully and held their breath for 10 seconds for each dose
1807896|NCT00643591|Other|imaging (dynamic PET-CT scan)|dynamic PET-CT scan
1807897|NCT00643604|Drug|treprostinil sodium|rapid switch from intravenous epoprostenol on CADD ambulatory pump to intravenous treprostinil sodium
1807898|NCT00643617|Radiation|CyberKnife Stereotactic Radiosurgery|38 Gy delivered in 4 fractions of 9.5 Gy per fraction
1807899|NCT00643630|Device|Tetrix|Twice daily topical application
1807900|NCT00643630|Device|Tetrix|Twice daily topical application
1807901|NCT00643643|Drug|Maraviroc (UK-427,857)|25 mg oral tablet once daily for 10 days
1807902|NCT00643643|Drug|Maraviroc (UK-427,857)|50 mg oral tablet twice daily for 10 days
1807903|NCT00643643|Drug|Maraviroc (UK-427,857)|100 mg oral tablet twice daily for 10 days
1807904|NCT00643643|Drug|Maraviroc (UK-427,857)|300 mg oral tablet twice daily for 10 days
1807905|NCT00643643|Other|Placebo|Matching placebo oral tablet twice daily for 10 days
1807906|NCT00643656|Drug|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
1807907|NCT00643656|Drug|Mix of 50% oxygen and 50% nitrogen|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
1807908|NCT00643669|Drug|AL-3789 Sterile Suspension|Single administration by anterior juxtascleral depot
1807909|NCT00643682|Other|Educational card|"A 4x6 inch educational card containing a photo of an unprepared colon and a clean colon with the caption: Drinking all the bowel cleaning medicine as described in the enclosed instructions lets the doctor see your colon better during your colonoscopy."
1807910|NCT00643695|Behavioral|Home-based walking program|The exercise intervention is a 12 week home-based exercise program. Ideally Individuals will walk for 30 minutes, at a moderate intensity, a minimum of three times per week. However, the duration and relative intensity will be tailored for each individual.
1807911|NCT00643695|Other|Educational intervention|Participants in the control group will receive a packet of information regarding hepatitis C
1807912|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group A, one point per ovary.
1807913|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group B, two points per ovary.
1807914|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group c, three points per ovary.
1807915|NCT00643708|Procedure|ovarian interstitial laser treatment|Different dose of laser: group D, four-five points per ovary.
1807916|NCT00643721|Other|dehydration|dehydration to 3% and 5% loss of total body water
1807917|NCT00643734|Drug|azithromycin sustained release|azithromycin SR 2.0 g by mouth in the form of a slurry for 1 dose
1807918|NCT00643734|Other|placebo|placebo
1807919|NCT00643734|Drug|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
1807920|NCT00643734|Other|placebo|placebo
1807921|NCT00643747|Biological|tgAAG76 (rAAV 2/2.hRPE65p.hRPE65)|Single subretinal injection of vector suspension; up to 3x10e12 vector particles
1807923|NCT00643760|Drug|GEn 1200mg/day|gabapentin enacarbil 1200mg/day
1807924|NCT00643760|Drug|GEn 2400mg/day|gabapentin enacarbil 2400mg/day
1807925|NCT00643760|Drug|GEn 3600mg/day|gabapentin enacarbil 3600mg/day
1807926|NCT00643760|Drug|Pregabalin|pregabalin 300mg/day
1807927|NCT00643773|Dietary Supplement|Leucine|capsules are 0.5g, subjects take 5 capsules with every main meal for 6 months In total this is 15 capsules per day
1807928|NCT00643773|Dietary Supplement|Wheat flour|Wheat flour
1807929|NCT00643786|Drug|Oxygène|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
1807930|NCT00643786|Drug|Air Médical|Flow of gas administrated to the patient between 4 and 15 litre/min during 5 minutes after the end of Kalinox's inhalation
1807931|NCT00643799|Drug|Celecoxib|200 mg oral capsule once daily for 6 months
1807932|NCT00643799|Drug|Naproxen|500 mg oral capsule twice daily for 6 months
1807933|NCT00643799|Drug|Placebo|Matched oral placebo for 6 months
1807934|NCT00643812|Other|Installation of gun locker in household|Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Early arm received gun lockers at baseline.
1807935|NCT00643812|Other|Installation of gun locker in household|"Households were randomized to 'early' and 'late' arms. Each household received a gun locker, which was installed in the household. Late arm received the gun locker 12 months after baseline."
1807936|NCT00643825|Drug|Temozolomide|Capsules 5,10,20,100,250 mg 200mg/m2/day , 5days per 28 till PD
1807937|NCT00643825|Drug|Temozolomide|Observation till Progression then rechallenging with TMZ
1807938|NCT00643838|Drug|Kalinox 170 bar|Flow of gas administrated to the patient between 4 and 15 litre/min and less than 1 hour
1807939|NCT00643851|Drug|Dapagliflozin|Tablets, Oral, Once daily, 24 weeks
1807940|NCT00643851|Drug|Metformin XR|Tablets, Oral, Once daily, 24 weeks
1807941|NCT00643864|Behavioral|motor training|Mirror training and motor imagery
1807942|NCT00643877|Procedure|Preoperative hepatic and regional arterial chemotherapy using oxaliplatin, MMC and FUDR|PHRAC which included of two parts(common hepatic artery chemotherapy and main tumor supplying artery chemotherapy) was performed 7 days before surgery： common hepatic artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg main tumor supplying artery chemotherapy: FUDR 500mg, Oxaliplatin 50mg and MMC 10mg
1807943|NCT00643877|Procedure|surgery|radical surgery only
1807944|NCT00643890|Genetic|Bilateral surgical infusion of AAV-GAD into the subthalamic nucleus|One-time bilateral administration of rAAV-GAD at 1X10^12 vector genomes in 35 uL.
1807945|NCT00643903|Behavioral|Cognitive behavioral coping effectiveness training|Coping effectiveness training will include five individual 90-minute counseling sessions. The sessions will focus on coping with stress, dealing with medication side effects, and staying on track with medications.
1807946|NCT00643903|Behavioral|Standard care|Participants will receive standard of care for HIV infections.
1807947|NCT00643903|Behavioral|Single group workshop on coping effectiveness training|Participants will attend one group workshop covering the same material as in the individual sessions. The workshop will be delivered after completion of the Month 18 final assessment.
1807948|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 12 months)
1807949|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 9 and 15 months)
1807950|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 12 and 15 months)
1807951|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 15 months)
1807952|NCT00643916|Biological|Meningococcal Polysaccharide Diphtheria Protein Conjugate (Menactra®)|0.5 mL, Intramuscular (at age 18 months)
1807953|NCT00643916|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.5 mL, Subcutaneous (at 3 years to <6 years of age)
1807954|NCT00643929|Drug|Eltrombopag|Subjects participated in a prior eltrombopag study, having received either eltrombopag or placebo
1807955|NCT00643942|Other|No intervention required|
1807956|NCT00643955|Other|muscle strength|muscle strength
1807957|NCT00643968|Drug|EFV+TDF|
1807958|NCT00643968|Drug|EFV+3TC+TDF|
1807959|NCT00643981|Biological|MESENDO|"2 ml of the final cell mixture will be injected through the lumen of an intracoronary percutaneous balloon designed for angioplasty into the ishcemic vessel."
1807960|NCT00643994|Radiation|CyberKnife Stereotactic Radiosurgery|36.25 Gy delivered in 5 fractions of 7.25 Gy per fraction
1807961|NCT00644007|Drug|Placebo|Placebo as a substitute of SK3530 100mg
1807962|NCT00644007|Drug|SK3530|SK3530 100 mg
1807963|NCT00644020|Drug|mitomycin, Fluorouracil|All participants will receive 10mg mitomycin and 1g Fluorouracil through the chemoradiative pump which was transplanted during the operation, and this procedure would be executed a day before each research treatment period.
1807964|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered once daily for 6 days starting 2 days before the anticipated onset of a MAM headache
1807965|NCT00644033|Drug|Frovatriptan|2.5 mg tablet administered twice daily for 6 days, starting 2 days before the anticipated onset of a MAM headache.
1807966|NCT00644033|Drug|Placebo|placebo tablet administered for 6 days, starting 2 days before the anticipated onset of a MAM headache.
1807967|NCT00644046|Behavioral|multidisciplinary predialysis education|teaching of renal knowledges, dietary support and recall of period medical visits
1807968|NCT00644059|Biological|Adjuvanted trivalent inactivated subunit influenza vaccine|Either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
1807969|NCT00644059|Biological|Non-adjuvanted trivalent inactivated subunit influenza vaccine or non-adjuvanted trivalent inactivated split influenza vaccine|For both vaccines, either two intramuscular (IM) injections of half dose or one IM injection of full dose, depending on age of subject, were administered in the deltoid muscle preferably of the non-dominant arm.
1808094|NCT00644943|Drug|cefdinir (Omnicef)|oral suspension (7 mg/kg, ql2hr) for 5 days
1807970|NCT00644059|Biological|Meningococcal C conjugate vaccine or tick-borne encephalitis vaccine|"Meningococcal vaccine: two IM injections
Tick-borne encephalitis vaccine: two IM injections"
1807971|NCT00644072|Drug|SNX-5422|
1807972|NCT00644085|Drug|aspirin|oral administration of aspirin 100 mg
1807973|NCT00644085|Drug|placebo|oral administration of placebo
1807974|NCT00644098|Dietary Supplement|soluble fibre complex and medium chain triglycerides|
1807975|NCT00644098|Dietary Supplement|cellulose and soybean oil|
1807976|NCT00644111|Drug|Bupivicaine, Hydromorphone|0.1% Bupivicaine with 0.015mg hydromorphone per mL at 6 mL per hour in Arm 2
1807977|NCT00644111|Drug|Saline Placebo|Saline placebo continuous epidural infusion of 6 mL per hour in Arm 1
1807978|NCT00644124|Drug|aflibercept|in combination with standard treatment R-CHOP
1807979|NCT00644137|Drug|pregabalin|Help stop smoking
1807980|NCT00644137|Other|cigarettes|help stop smoking with study medication
1807981|NCT00644150|Behavioral|Physician Ai Shi Zi training|This training uses a curriculum developed specifically for Project Ai Shi Zi and includes training in stigma; risk-reduction counseling; and quality HIV/STI diagnosis, treatment, and management. Physician training will consist of multiple components: an orientation workshop on fundamental knowledge and skills of HIV/STI treatment and prevention, a 3-month practice period, a 3-month post-practice seminar on preventive counseling, another 3-month practice period, and a 6-month post-practice seminar on clinical HIV and STI management. The practice periods will promote learning-by-doing to further enhance physicians' abilities to deliver high quality, integrated HIV/STI prevention and treatment. Post-practice seminars will allow participants to share experiences gained during the previous 3-month practice period.
1807982|NCT00644150|Drug|Standard care|If an STI is confirmed by a lab test, participants will receive standard of care treatment. Gonorrhea will be treated with a single dose of 250 mg of ceftriaxone sodium administered by intramuscular injection. If patients are allergic to ceftriaxone, they will be treated with azithromycin (2 g single oral dose). Chlamydia will be treated with azithromycin (1 g single oral dose).
1807983|NCT00644150|Behavioral|Patient risk-reduction counseling|On the initial visit, participants will receive HIV/STI risk-behavior counseling from the physician trained in Ai Shi Zi. The process is based on motivational interviewing techniques and will include discussing topics such as partner notification, HIV/STI prevention, and expected difficulties in changing behaviors. This risk-reduction model encourages the HIV/STI-infected or -uninfected person to develop a risk-reduction plan. The objective is to decrease the chance of infection for that individual and for others, too. Patients will develop a list of risk-reduction strategies to follow.
1807984|NCT00644163|Behavioral|Eban HIV/STD Risk Reduction Intervention|The eight-session Eban HIV/STD Risk Reduction Intervention is embedded in a cultural context and is gender tailored in its prevention messages and activities. Sessions will focus on the couple and will teach the couple about communication skills. The approach will draw upon social cognitive theory, an ecological framework, and HIV/STD risk-reduction research with inner-city African-American populations.
1807985|NCT00644163|Behavioral|Eban Health Promotion Intervention|The eight-session Eban Health Promotion Intervention is guided by a social cognitive approach that engages health promotion skills. Sessions will focus on the individual and will provide factual information on health, screening, exercise, diet management, and medication adherence.
1807986|NCT00644176|Drug|azithromycin immediate release (Zithromax)|azithromycin IR 500 mg tablet by mouth for 1 dose
1807987|NCT00644176|Other|placebo|placebo
1807988|NCT00644176|Drug|azithromycin SR|2.0 g by mouth in the form of liquid for 1 dose
1807989|NCT00644176|Other|placebo|placebo
1807990|NCT00644189|Drug|Clofarabine|Taken orally once a day (in the AM) on days 1 through 21 of a 28-day cycle for a maximum of 6 cycles.
1807991|NCT00644202|Behavioral|Counseling Sessions|Counseling Sessions at each study visit around diet and physical activity from a registered dietician
1807992|NCT00644202|Behavioral|Specialized Website|Specialized website that allows participants to track their eating and physical activity patterns, learn new weight management skills, interact with the dietician, and receive support from other participants
1807993|NCT00644202|Behavioral|Telephone Counseling Calls|5 telephone calls with a health counselor, lasting 15-20 minutes each.
1807994|NCT00644215|Drug|5-FU and Mitomycin|"5-FU injection 5mg
Mitomycin drop 0.02%"
1807995|NCT00644228|Drug|Bortezomib|Given IV
1807996|NCT00644228|Drug|Dexamethasone|Given PO
1807997|NCT00644228|Other|Laboratory Biomarker Analysis|Optional correlative studies
1807998|NCT00644228|Drug|Lenalidomide|Given PO
1807999|NCT00644241|Biological|stem cell harvest|stem cells will be harvested from the iliac crest of the patients
1808000|NCT00644241|Procedure|angiographic transplantation of stem cells|autologous bone marrow derived stem cells will be transplanted in the gastroduodenal artery of the patient angiographically
1808001|NCT00644254|Procedure|Pancreatic resection|PPPD, Whipple, Total pancreatectomy or left pancreatectomy.
1808002|NCT00644267|Behavioral|Telemedicine|Telemedicine reporting of blood pressure, weight, physical activity
1808003|NCT00644280|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab 1 week prior to tube insertion and then monthly x 2 more injections
1808004|NCT00644293|Drug|azithromycin (Zithromax)|azithromycin 500 mg tablet by mouth once daily for 3 days
1808005|NCT00644293|Drug|placebo|placebo
1808006|NCT00644293|Drug|azithromycin SR|azithromycin SR 2.0 g by mouth as an oral slurry for 1 dose
1808007|NCT00644293|Drug|placebo|placebo
1808008|NCT00644306|Drug|Thalidomide|100 mg/day continuously for 18 months
1808009|NCT00644306|Drug|melphalan, prednisone|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus placebo 100mg/d continuously for 18 months
1808010|NCT00644306|Drug|melphalan, prednisone, thalidomide|12 cycles every 6 weeks :melphalan 0.2 mg/kg day 1 to 4, prednisone 2 mg/kg/d day 1 to 4 plus thalidomide 100mg/d continuously for 18 months
1808011|NCT00644319|Drug|ibuprofen|
1808012|NCT00644319|Drug|morphine sulfate|
1808013|NCT00644319|Procedure|management of therapy complications|
1808014|NCT00644319|Procedure|pleurodesis|
1808015|NCT00644332|Drug|Ranolazine|Oral dosage form.
1808016|NCT00644358|Drug|vilazodone|titration to 40 milligrams (mg) every day (qd) for 1 year
1808017|NCT00644371|Drug|Ibritumomab Tiuxetan (Zevalin)|"Conditioning Regimen
Rituximab, 250 mg/m2 on days -21 and -14.
Ibritumomab tiuxetan (Zevalin): 0.4 mCi/kg (14.8 MBq/kg). Maximum: 32 mCi on day -14.
Chemotherapy:
Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.
Melphalan 70 mg/m2/day on days -3 and -2 as a 15-min infusion.
Chemotherapy for relapsing patients after autologous transplantation including melphalan over the last 6 months:
Thiotepa 5 mg/kg over 4 hours every 12 hours on day -8.
Fludarabine 30 mg/m2/day on days -7, -6, -5, -4 and -3 as a 30-min infusion.
Melphalan 70 mg/m2/day on day -2 as a 15-min infusion."
1808018|NCT00644384|Drug|acitretin|
1808019|NCT00644384|Genetic|gene expression analysis|
1808020|NCT00644384|Genetic|northern blotting|
1808021|NCT00644384|Genetic|polymerase chain reaction|
1808022|NCT00644384|Genetic|protein expression analysis|
1808023|NCT00644384|Other|laboratory biomarker analysis|
1808024|NCT00644397|Device|95-degree Angled Blade Plate|
1808025|NCT00644397|Device|4.5mm Condylar Locking Plate|
1808026|NCT00644410|Biological|Mesenchymal stromal cell|Mesenchymal stromal cells 20 - 40 mill.
1808027|NCT00644410|Biological|Saline|12 injection with 0.2 ml saline
1808028|NCT00644423|Drug|Omega-3 Fatty Acid|One capsule three times per day x 1 day (325mg EPA/225mg docosahexaenoic acid (DHA) tid) Two capsules three times per day x 1 day (650mg EPA/450mg DHA tid) Three capsules three times per day thereafter (975mg EPA/675mg DHA tid)
1808029|NCT00644423|Drug|Placebo|Matching Placebo
1808030|NCT00644436|Device|Tetrix|single topical application
1808031|NCT00644436|Device|Tetrix|Single topical application
1808032|NCT00644449|Other|placebo|placebo
1808033|NCT00644449|Drug|azithromycin SR (Zithromax; compound: CP-62,993)|azithromycin 2.0 g by mouth in the form of a slurry for 1 dose
1808034|NCT00644449|Other|placebo|placebo
1808035|NCT00644449|Drug|levofloxacin|500 mg (two 250 mg capsules) by mouth once daily for 7 days
1808036|NCT00644462|Device|PulmoTrack® 2010 with WIM-PC™ Technologies|wheeze detection during dynamic bronchial situations in infants
1808037|NCT00644475|Drug|Imidapril|tablets; 5, 10, 15, 20 mg; od; 12 weeks
1808038|NCT00644475|Drug|Candesartan|tablets; 8, 16, 24, and 32 mg; od; 12 weeks
1808039|NCT00644488|Drug|BMS-641988 (AR#2)|Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks
1808040|NCT00644501|Drug|DiaPep277|1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
1808041|NCT00644514|Biological|Endotoxin - lipopolysaccharide (LPS)|Nebulized 5000EU, 10,000EU, 20,000EU endotoxin doses delivered to completion. Nebulized dose inhaled 30 minutes apart if no adverse events occur after the previous dose. Fiberoptic Bronchoscopy with Bronchoalveolar Lavage (BAL) and brush samples performed 24 hours after LPS nebulization.
1808042|NCT00644527|Other|Purpose designed music and sound listening program|Listening to one of two different specific music programs (Group A and B), which is composed for the treatment of depressive symptoms. The music is listened to during a period of 30 minutes in the morning and 30 minutes in the evening over 5 - 15 weeks.
1808043|NCT00644527|Other|Sham music for depression|Listening 30 min in the morning and 30 min in the evening to selection of Mozart compositions over 5 weeks.
1808044|NCT00644540|Biological|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.
Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.
Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
1808045|NCT00644540|Biological|Influenza Trivalent Inactivated Vaccines|"This phase II, observer-blind, parallel groups, single center, extension study will be performed over a period of approximately 6 months in a study population of healthy children up to 48 months of age.
Up to two hundred and forty-four children (244) having previously participated in Novartis Vaccines Study V70P2 will be vaccinated with the same influenza vaccines received in the previous trial.
Each subject will receive a single vaccine dose of 0.25mL, or of 0.5mL, if aged respectively up to 35 months or 36 up to 48 months, administered intramuscularly (IM) in the deltoid muscle, preferably of the non-dominant arm."
1808046|NCT00644553|Drug|Clarithromycin|Clarithromycin Extended-Release 500 mg tablet (2 tablets QD)
1808047|NCT00644553|Drug|Amoxicillin|Amoxicillin-clavulanate 875/125 mg tablet (1 tablet BID)
1808048|NCT00644566|Other|Shared Care|A psychologist co-located in the pediatric primary care clinic shared care with the subject's pediatrician. The psychologist offered regular appointments and psychoeducation. On an individual basis, parent management training, behavioral management training, individual psychotherapy, educational intervention assistance, teacher communication, and medication education were provided as needed.
1808049|NCT00644579|Drug|bLAC|bLAC high and low dose and placebo
1808050|NCT00644579|Drug|Placebo|Placebo
1808051|NCT00644592|Drug|Fenofibrate capsule daily for 4 weeks|Placebo capsule daily for 4 weeks
1808052|NCT00644592|Drug|Fenofibrate|160 mg/day orally for 4 weeks
1808053|NCT00644605|Drug|sildenafil|sildenafil 40 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
1808054|NCT00644605|Drug|sildenafil|sildenafil 80 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks; initially, patients received 40mg TID for one week and were then up-titrated to 80mg TID
1808055|NCT00644605|Drug|placebo|placebo by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
1808056|NCT00644605|Drug|sildenafil|sildenafil 20 mg by mouth three times daily (TID), with doses at least 6 hours apart, for 12 weeks
1808057|NCT00644618|Drug|gemcitabine|a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
1808058|NCT00644618|Other|125I brachytherapy PLUS gemcitabine|125I brachytherapy PLUS a 30-minute intravenous infusions of gemcitabine 1,000 mg/m2 weekly×7, followed by a 1-week pause, and then weekly×3
1808095|NCT00644943|Drug|amoxicillin|oral suspension (45 mg/kg/day, q l2 hours) for 10 days
1808059|NCT00644631|Drug|sildenafil|sildenafil 50 mg (initial dose) tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks; depending upon safety, efficacy and tolerability, the dose could be increased to 100 mg or reduced to 25 mg, if necessary.
1808060|NCT00644631|Drug|placebo|placebo tablet by mouth 30 to 60 minutes prior to sexual activity for 12 weeks
1808061|NCT00644644|Other|Rapid Response Team (NTX wireless monitoring system)|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
1808062|NCT00644657|Drug|Clopidogrel|All subjects will receive a 300 mg loading dose
1808063|NCT00644670|Drug|Atorvastatin|In previously treated patients, starting atorvastatin doses (oral tablets given once daily) of 20 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline) or 40 mg (in patients with LDL-C levels between 165 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
1808064|NCT00644670|Drug|Atorvastatin|In statin-naive patients, starting atorvastatin doses (oral tablets given once daily) of 10 mg (in patients with LDL-C levels between 115 and 164 mg/dL at baseline), 20 mg (in patients with LDL-C levels between 165 and 174 mg/dL at baseline), or 40 mg (in patients with LDL-C levels between 175 and 235 mg/dL at baseline) were given for 6 weeks. If LDL-C target was achieved at Week 6, doses remained the same. If LDL-C target was not achieved at Week 6, doses were doubled.
1808065|NCT00644696|Drug|Irinotecan and Bortezomib|Dose level-1a: IV Irinotecan 30 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-1: IV Irinotecan 35 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-2: IV Irinotecan 40 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-3: IV Irinotecan 45 mg/m2/day, IV bortezomib 1.2mg/m2/day Dose level-4: IV Irinotecan 50 mg/m2/day, IV bortezomib 1.2mg/m2/day
1808066|NCT00644709|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, 40, or 80 mg once daily. Three dose adjustments were allowed at baseline, Week 17, and Week 34. Patients who did not meet the LDL-C target at any of these time points had their doses doubled except for those who were on the 80 mg dose. Treatment was given for 52 weeks.
1808067|NCT00644722|Device|MacIntosh Green Lite (metal single use laryngoscope blades)|metal single use laryngoscope blades
1808068|NCT00644722|Device|MacIntosh Green Spec II (metal reusable laryngoscope blades)|metal reusable laryngoscope blades
1808069|NCT00644735|Drug|Esomeprazole|
1808070|NCT00644735|Drug|Lansoprazole|
1808071|NCT00644748|Drug|gabapentin|"Gabapentin oral capsules:
Week 0: Day 1: 300 mg; Day 2: 600 mg (2 doses of 300 mg); Day 3: 900 mg (3 doses of 300 mg), maintained until the end of the week; After this point, the total daily dose was divided in 3 equal doses. Week 1: Day 1: 1200 mg; Day 2 to 7: 1800 mg Week 2: Day 1: 2100 mg; Day 2 to 7: 2400 mg Week 3: Day 1: 2700 mg; Day 2 to 7: 3600 mg Weeks 4 to 11: 3600 mg"
1808072|NCT00644761|Drug|Adefovir Dipivoxil|Adefovir dipivoxil 10 mg once daily for 14 days co-administered with tacrolimus or cyclosporine
1808073|NCT00644774|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
1808074|NCT00644774|Drug|azithromycin|2.5 ml of cherry flavored oral suspension 100 mg/5 ml
1808075|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Titration Phase)|Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is done as per Investigator's discretion (maximum applied dose is 100 mcg/hr) up to Day 11 and then dose is fixed up to end of treatment period, that is Day 14.
1808076|NCT00644787|Drug|Fentanyl 1-day transdermal patch (Double Blind Phase)|Fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
1808077|NCT00644787|Drug|Fentanyl 3-day transdermal patch (Double Blind Phase)|Fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase with maximum applied dose of 100 mcg/hr for 10 days.
1808078|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 3-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
1808079|NCT00644787|Drug|Placebo|Placebo matching to fentanyl 1-day application transdermal patch applied once daily releasing the drug at the same dose as maintained at the end of Titration Phase for 10 days.
1808080|NCT00644800|Drug|Ziprasidone|Intramuscular ziprasidone 10 or 20 mg at the investigator's discretion for 1 to 3 days followed by oral ziprasidone capsules 40 to 80 mg twice daily at the investigator's discretion to complete 7 days of treatment
1808081|NCT00644826|Behavioral|preventive home visit|A multidimensional geriatric assessment within the dimensions: cognition, health related functioning, risk of falling, nutritional status, social situation, economic situation, mood. Two more home visits: (1) home counseling visit 2-3 weeks after assessment (2) booster session 1 month after home counseling visit
1808082|NCT00644839|Drug|CP-945,598|Administration of CP-945,598 alone in period 1
1808083|NCT00644839|Drug|CP-945,598|Adminstration of CP-945,598 with omeprazole in period 2
1808084|NCT00644852|Other|Retrospective chart review study|Retrospective study chart review long acting risperidone
1808085|NCT00644878|Drug|Nilotinib|Nilotinib 300 mg is taken by mouth twice a day at 12 hour intervals. Nilotinib is to be taken with water on an empty stomach. No food two hours prior to the dose of nilotinib and for one hour following the dose.
1808086|NCT00644891|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 ml
1808087|NCT00644891|Drug|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 ml
1808088|NCT00644904|Dietary Supplement|Vitamin D3|
1808089|NCT00644904|Dietary Supplement|Vitamin D3|
1808090|NCT00644917|Drug|Xenaderm|20mg under Finn chambers
1808091|NCT00644917|Drug|Placebo|20mg under Finn chambers
1808092|NCT00644930|Device|the application of NPPV|ARDS patients in the NPPV group showing no indications for urgent intubation received NPPV in addition to standard medical therapy, and those with indications were intubated. BIPAP Vision machine (Respironics, PA, USA) were used for NPPV.
1808093|NCT00644930|Device|invasive ventilation|Standard therapy group (invasive ventilation). Patients in need of endotracheal intubation were mechanically ventilated with Amadeus (Hamilton, Via Nova, Switzerland) and Esprit (Respironics, PA, USA) ventilators in the assist—control or synchronized intermittent mandatory ventilation (SIMV) mode.
1808098|NCT00638534|Drug|Telithromycin (HMR3647)|
1808099|NCT00638547|Drug|IRT Laronidase|"Laronidase belongs to a class of drugs called enzyme replacement therapies or ERT that provides people with sufficient quantities of an important enzyme that they cannot create on their own. The main ingredient in laronidase is a protein that is identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. Laronidase replaces the missing enzyme alpha-L-iduronidase and restores sufficient enzyme activity to break down GAG buildup.
Subjects will receive an infusion of Laronidase into his/her spinal fluid approximately 12 weeks before, 2 weeks before, 100 days after and 6 months after transplant. This procedure is done by lumbar puncture"
1808100|NCT00638560|Dietary Supplement|Vitamin C, Vitamin E|Vitamin C, 1g po, twice daily Vitamin E, 400 IU po, once daily
1808101|NCT00638560|Dietary Supplement|Antioxidant treatment|no treatment
1808102|NCT00638599|Device|LMA®|LMA® is placed after anesthesia induction and removed after the operation
1808103|NCT00638599|Device|Endotracheal tube|Standard endotracheal tube is inserted after anesthesia induction and extubated after the operation
1808104|NCT00638612|Biological|AdV-tk|Four dose levels of AdV-tk with a fixed dose level of valacyclovir are evaluated independently in the two arms of the study due to differences in the concomitant standard of care treatments. The first AdV-tk course is given prior to surgery or radiation by CT or EUS guided injection into the tumor followed by 14 days of valacyclovir. The second AdV-tk injection is into the tumor bed at the time of surgery in Arm A or same as the first injection in Arm B again followed by 14 days of valacyclovir. The AdV-tk dose levels are: Level 1= 3x10e10 vector particles (vp), Level 2= 1x10e11 vp, Level 3= 3x10e11 vp, Level 4= 1x10e12 vp
1808105|NCT00638612|Drug|Valacyclovir|Valacyclovir caplets at a dose of 2 grams orally three times per day is administered for 14 days starting 1-3 days after each of the two AdV-tk injections in both arms.
1808106|NCT00638638|Drug|Abciximab|"Abciximab: 0.25 mg/Kg bolus
Abciximab placebo bolus
Abciximab infusion 10 µg/Kg/min"
1808107|NCT00638638|Drug|Abciximab placebo|"Abciximab placebo Bolus
Abciximab: 0.25 mg/Kg bolus
Abciximab infusion 10 µg/Kg/min"
1808108|NCT00638651|Device|1064 nm Nd:YAG laser|The laser used will be a 1064 nm Nd:YAG, with a 10ns pulse, 3mm spot size and 4 joules of energy
1808109|NCT00638651|Drug|Imiquimod, 5% cream|2 weeks after the laser procedure the imiquimod will be applied 3 times a week for one month
1808110|NCT00638677|Dietary Supplement|Sorbitol|Sorbitol tablet delivered with a slow-release pacifier starting 1 mo after delivery and lasting max 2 years
1808111|NCT00638677|Dietary Supplement|Xylitol + BB12|Xylitol + BB12 tablet delivered with a slow-release pacifier starting 1 mo after delivery and continuing max 2 years
1808112|NCT00638677|Dietary Supplement|Xylitol|Xylitol+BB 12 delivery with a pacifier max until 2 years
1808113|NCT00638690|Drug|Placebo|Four tablets once daily until disease progression
1808114|NCT00638690|Drug|Abiraterone acetate|Four 250-mg tablets once daily until disease progression
1808115|NCT00638690|Drug|Prednisone/prednisolone|5 mg twice daily until disease progression
1808116|NCT00638703|Biological|Oxalobacter formigenes|NLT (not less than) 10^7 CFU Oxalobacter formigenes twice daily for 24 weeks
1808117|NCT00638703|Drug|Placebo|placebo
1808118|NCT00638716|Drug|CJC-1134-PC|1.5 or 2.0 mg CJC-1134-PC
1808119|NCT00638716|Drug|Placebo|Placebo
1808120|NCT00638729|Drug|midazolam|midazolam, 7.5 mg p.o., 60-90 min prior to estimated induction time
1808121|NCT00638729|Drug|clonidine|pre-anesthetic medication with clonidine, 150 µg p.o., 60-90 min prior to estimated induction time
1808122|NCT00638729|Drug|placebo|inert tablet p.o., 60-90 min prior to estimated induction time
1808123|NCT00638742|Drug|latanoprost|latanoprost 0.005% (1.5 ug) will be administered. A single drop of latanoprost 0.005% will be instilled into both eyes by the investigator.
1808124|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
1808125|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
1808126|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
1808127|NCT00638755|Drug|Nasal Carbon Dioxide|Nasal Carbon Dioxide
1808128|NCT00638768|Other|Physiotherapy|10 weekly individual sessions with the therapist each lasting approximately 45 minutes. Techniques included postural taping, massage, mobilisation, exercises. The patients also performed home exercises
1808129|NCT00638781|Drug|Desmoteplase|Desmoteplase 62.5 µg/kg BW
1808130|NCT00638781|Drug|Desmoteplase|Desmoteplase 90 µg/kg BW
1808131|NCT00638781|Drug|Desmoteplase|Desmoteplase 125 µg/kg BW
1808132|NCT00638781|Drug|Placebo|Placebo
1808133|NCT00638794|Device|Drug -Eluting Stent (Taxus™, Cypher®, Endeavor™, Xience V™)|PCI using any FDA approved drug-eluting stent; Taxus Express2 - Paclitaxel-Eluting Coronary Stent System Cypher Sirolimus-eluting coronary stent Endeavor ABT-578 Eluting Coronary Stent System Xience V Everolimus Eluting Coronary Stent System
1808134|NCT00638807|Drug|Celecoxib|200 mg oral capsule once daily with morning meal for 6 weeks
1808135|NCT00638807|Other|Placebo|Matched oral placebo for 6 weeks
1808136|NCT00638820|Procedure|Stem Cell or Umbilical Cord Blood Transplantation|Stem Cell (unrelated or matched related donor grafts (both peripheral blood and marrow) infusion on Day 0 and 42; Umbilical Cord Blood on Day 0 and 42
1808137|NCT00638820|Drug|Campath, Busulfan, Clofarabine|"12 Campath-1H 0.3 mg/kg intravenously (IV) over 2 hours
11 Campath-1H 0.3 mg/kg intravenously over 2 hours
10 Campath-1H 0.3 mg/kg intravenously over 2 hours
9 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours
8 Busulfan <12 kg: 2.2 mg/kg/dose IV every 12 hours >12 kg: 1.6 mg/kg/dose IV every 12 hours
7 Rest
6 Clofarabine 40 mg/m2 intravenously over 2 hours
5 Clofarabine 40 mg/m2 intravenously over 2 hours
4 Clofarabine 40 mg/m2 intravenously over 2 hours
3 Clofarabine 40 mg/m2 intravenously over 2 hours
2 Clofarabine 40 mg/m2 intravenously over 2 hours"
1808138|NCT00638820|Procedure|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior (PA) fields (250 cGy AP and 250 cGy PA).
1808139|NCT00638833|Drug|Memantine|Memantine 30 mg/day (20-10-0)
1808140|NCT00638833|Drug|Placebo|Placebo pills
1808141|NCT00638846|Device|senofilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
1808142|NCT00638846|Device|balafilcon A toric|silicone hydrogel toric lens, worn daily for 2 wks (2wks replacement)
1808143|NCT00638859|Drug|Telithromycin (HMR3647)|
1808144|NCT00638872|Drug|Polydeoxyribonucleotide|3 times a week perilesional or intramuscular injections
1808145|NCT00638872|Other|0.9% NaCl|same as PDRN
1808146|NCT00638898|Drug|busulfan|Given IV
1808147|NCT00638898|Drug|melphalan|Given IV
1808148|NCT00638898|Drug|topotecan hydrochloride|Given IV
1808149|NCT00638898|Other|laboratory biomarker analysis|Correlative studies
1808150|NCT00638898|Biological|filgrastim|Given IV or subcutaneously
1808151|NCT00638898|Procedure|autologous hematopoietic stem cell transplantation|Undergo transplantation
1808152|NCT00638898|Other|pharmacological study|Correlative studies
1808153|NCT00638898|Procedure|autologous bone marrow transplantation|Undergo transplantation
1808154|NCT00644956|Drug|tadalafil|tadalafil 20 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
1808155|NCT00644956|Drug|sildenafil|sildenafil 100 mg tablet by mouth for 2 doses (at Week 0 and Week 1)
1808156|NCT00644969|Drug|placebo|Randomization 2:1 treatment to placebo
1808157|NCT00644969|Drug|varenicline (CP-526,555)|One week of titration up to 1mg bid and 11 weeks of dosing at 1mg bid
1808158|NCT00644982|Drug|sertraline|Flexibly-titrated 50 mg tablets, 50-150 mg/day and venlafaxine placebo orally for 10 weeks.
1808159|NCT00644982|Drug|venlafaxine XR|Flexibly-titrated 75 mg capsules, 75-225mg/day and sertraline placebo orally for 10 weeks.
1808162|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with mild hepatic function
1808163|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with moderate hepatic function
1808164|NCT00645021|Drug|CP-945,598|Administration of CP-945,598 in subjects with normal hepatic function
1808165|NCT00645034|Drug|placebo|placebo by mouth as a single dose
1808166|NCT00645034|Drug|sildenafil|sildenafil 100 mg by mouth as a single dose
1808167|NCT00645047|Behavioral|Telemedicine CBT|Use of Videoconfrence Technology To Provide Cognitive Therapy
1808168|NCT00645047|Behavioral|In-Person CBT|In-Person Provision Of Cognitive Therapy
1808169|NCT00645060|Other|high performance liquid chromatography|Performed on serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
1808170|NCT00645060|Other|pharmacological study|Serial blood samples from 0 to 168 hours and daily X5 days 24 hour urine samples
1808171|NCT00645060|Procedure|radionuclide imaging|1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post Y-90 anti-CEA antibody infusion
1808172|NCT00645060|Procedure|single photon emission computed tomography|2 days and 3-5 days post antibody infusion
1808173|NCT00645060|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Dose escalation from 12 mCi/m2 through 18 mCi/m2 increasing by 2 mCi/m2 with each escalation
1808174|NCT00645073|Drug|cefdinir (Omnicef)|Two 300 mg cefdinir capsules on Study Days 1-10.
1808175|NCT00645073|Drug|levofloxacin|Two 250 mg levofloxacin capsules on Study Days 1-10
1808176|NCT00645086|Drug|clarithromycin extended-release tablets|5-day course of clarithromycin extended-release tablets (2 x 500 mg QD)
1808177|NCT00645086|Drug|clarithromycin immediate-release tablets|7-day course of clarithromycin immediate-release tablets (1 x 500 mg BID)
1808178|NCT00645099|Drug|olanzapine|10-15 mg (using 5-mg or 10-mg tablets) once daily flexible dosing for 6 months
1808179|NCT00645099|Drug|paliperidone ER|6-mg or 9-mg tablet once daily flexible dosing for 6 months
1808180|NCT00645112|Drug|cefdinir (Omnicef)|oral suspension, 7 mg/kg every 12 hours for 5 days
1808181|NCT00645112|Drug|azithromycin|oral suspension 10 mg/kg QD on Day 1 then 5 mg/kg QD on Days 2-5 for a total of 5 days.
1808182|NCT00645125|Drug|cefdinir (Omnicef)|2.5 ml of strawberry cream flavored oral suspension 125 mg/5 mL
1808183|NCT00645125|Drug|amoxicillin|2.5 ml of bubble-gum flavored amoxicillin oral suspension 125 mg/5 mL
1808184|NCT00645138|Procedure|Paravertebral Block|"Sedation will be provided with midazolam and fentanyl. The transverse processes of T1-T6 will be located using ultrasound guidance. The area will be prepped with betadine. At each level, a 21 Gauge, 4-inch Stimuplex needle will be inserted in order to make contact with the transverse process. Once the transverse process has been located, the needle will be walked off the process and inserted 1 cm deep to its inferior border. After negative aspiration, 3 mL of 1.5% mepivacaine with epinephrine 1:200,000 and bicarbonate and 3 mL of 0.5% bupivacaine with epinephrine 1:200,000 will be injected. Sedation will be provided with 50-100 mcg/kg/min of propofol during the surgical procedure. Approximately 20 minutes before the end of the procedure, 4 mg of zofran will be administered."
1808185|NCT00645138|Procedure|General Anesthesia|Patients in the general anesthesia group will receive midazolam preoperatively for anxiolysis. Anesthesia will be induced with propofol and fentanyl. An LMA will be inserted and anesthesia maintained with sevoflurane in air and oxygen. 4 mg of zofran will be administered approximately 20 minutes before the end of the surgical procedure. The LMA will be removed and the patient will be transported to the PACU at the conclusion of the surgery.
1808186|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
1808187|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
1808295|NCT00646256|Behavioral|COGPACK training, psychoeducation|Bifocal psychoeducation group program (Munich Psychoses Information Program - PIP) with preceding computerbased cognitive training program (COGPACK)
1808328|NCT00646568|Drug|s.c. human chorionic gonadotropin (Pregnyl)|S.C. Pregnyl 10000 IU once
1808188|NCT00645151|Drug|Atorvastatin|Atorvastatin calcium 10, 20, 40, or 80 mg tablets (dose dependent on individual risk factors and baseline LDL-C level) once daily for 4 weeks. After 4 weeks of treatment, subjects who did not achieve the LDL-C target goal were up-titrated to 20, 40, or 80 mg and subjects who achieved their LDL-target goal remained on the same dose for the following 4 weeks.
1808189|NCT00645164|Other|Ointment Vehicle|Subject acts as own control. 20 mg under Finn chambers
1808190|NCT00645164|Drug|Xenaderm|20 mg under Finn chambers
1808191|NCT00645177|Drug|ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
1808192|NCT00645177|Drug|paclitaxel|90 mg/m2 IV infusion over 1 hour, weekly every 3 out of 4 weeks
1808193|NCT00645177|Drug|Placebo for ABT-869|0.20 mg/kg (or dose from Lead-in) QD, tablets taken orally days 1-28 of every 28-day cycle
1808194|NCT00645190|Drug|Galantamine HBr|
1808195|NCT00645203|Drug|cefdinir|cefdinir oral suspension, 25 mg/kg once daily for 10 days
1808196|NCT00645216|Drug|CP-945,598|Subjects take CP-945,598 alone for 21 days
1808197|NCT00645216|Drug|CP-945,598|Subjects take CP-945,598 from Days 1 to 7, then take CP-945,598 and Grapefruit Juice from Days 8 to 21
1808198|NCT00645229|Drug|Ziprasidone|Ziprasidone 20 mg capsules twice daily on Days 1-3; dose could be increased if clinically indicated up to 80 mg twice daily; total treatment duration was to be 24 weeks
1808199|NCT00645242|Drug|fluconazole|Fluconazole oral suspension 6 mg/kg/day for 6 weeks followed by 4 weeks without treatment
1808200|NCT00645255|Drug|placebo|placebo one capsule daily
1808201|NCT00645255|Drug|sibutramine or placebo|one capsule daily
1808202|NCT00645268|Drug|sildenafil|In the double-blind phase, patients received sildenafil 50 mg once daily during Week 1 (7 doses), followed by a daily dose of sildenafil 100 mg during the next 3 weeks.
1808203|NCT00645268|Drug|placebo|In the double-blind phase, patients received placebo once daily during Week 1 (7 doses), followed by a daily dose of placebo during the next 3 weeks.
1808204|NCT00645268|Drug|sildenafil|Eligible subjects then entered an open-label phase during which all subjects received sildenafil 50 mg as needed for sexual activity for the next 2 weeks, which could be titrated to either 25 mg or 100 mg based on the investigator's assessment of efficacy and tolerability, for 10 weeks (12 weeks total).
1808205|NCT00645281|Drug|tolterodine extended release|Tolterodine ER capsule 4 mg daily for 12 weeks
1808206|NCT00645671|Drug|0.5% Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
1808207|NCT00645671|Drug|Vehicle of Loteprednol Etabonate Ophthalmic Ointment|1/2 inch ribbon four times a day for 14 days
1808208|NCT00645684|Procedure|Gastrointestinal Anastomosis|Gastrointestinal Anastomosis with synthetic, absorbable, coated suture material using two different suture-techniques
1808209|NCT00645710|Drug|gemcitabine hydrochloride|Given IV
1808210|NCT00645710|Drug|floxuridine|Given via hepatic arterial infusion
1808211|NCT00645710|Genetic|proteomic profiling|Correlative studies
1808212|NCT00645710|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Correlative studies
1808213|NCT00645710|Other|liquid chromatography|Correlative studies
1808214|NCT00645710|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Given IV
1808215|NCT00645710|Other|laboratory biomarker analysis|Correlative studies
1808216|NCT00645710|Other|mass spectrometry|Correlative studies
1808217|NCT00645710|Other|pharmacological study|Correlative studies
1808218|NCT00645723|Drug|Colistin|intravenous colistin and nebulized colistin
1808219|NCT00645723|Drug|Colistin and saline solution|intravenous colistin and nebulized saline solution
1808220|NCT00645736|Other|No intervention|No intervention
1808221|NCT00645749|Biological|Helminth ova|2500 ova per dose (liquid form)
1808222|NCT00645762|Device|RS-Series Rhinosinusitis Treatment System|Single arm
1808223|NCT00645762|Device|FinESS Balloon|
1808224|NCT00645775|Dietary Supplement|IGOB131|Comparison of 250 mg per day of Irvingia gabonensis to placebo
1808225|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|32.5 mg ciprofloxacin DPI corresponding to 50 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days
1808226|NCT00645788|Drug|Placebo|50 mg matching placebo powder formulation twice a day for 28 days
1808227|NCT00645788|Drug|Ciprofloxacin (Cipro Inhale, BAYQ3939)|48.75 mg ciprofloxacin DPI corresponding to 75 mg Ciprofloxacin PulmoSphere Inhalation powder twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
1808228|NCT00645788|Drug|Placebo|75 mg matching placebo powder formulation twice a day for 28 days (Arm 3 and Arm 4 was introduced after amendment 2)
1808229|NCT00645801|Drug|lubiprostone (Amitiza)|24 mcg administered 4 times over the two days before the colonoscopy. 96 mcg total
1808230|NCT00645801|Drug|Placebo|Amitiza Placebo
1808231|NCT00645814|Drug|placebo for adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
1808232|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg eow through Week 11
1808233|NCT00645814|Drug|adalimumab|80 mg at Week 0 and 40 mg weekly through Week 11
1808234|NCT00645827|Other|IICE Dosing|Subcutaneous insulin was dosed according to an equation (too long for publication here) which gives the patient's 24 hour SC insulin requirement. If patient was eating, 65% of equation result was given as insulin glargine SC qHS and 35% of equation result was divided evenly between three qAC doses of insulin aspart. If patient was not eating, 100% of ISC was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + [3 x scheduled aspart dose]). For BG < 70 mg/dL, ½ ampule D50W IV x1 was given.
1808296|NCT00646269|Behavioral|Standard intervention protocol|The control group involves a standardized medical follow-up of patients with Alzheimer's disease and a psychoeducative group program for caregivers of patients.
1808297|NCT00646269|Behavioral|Standard intervention protocol + Cognitive training therapy|"Cognitive training therapy is provided in small groups of 5 to 8 patients. It consists in classroom type sessions designed to provide general cognitive stimulation. A set of standard cognitive exercises (involving memory, attention, or problem-solving…) related to activities of daily living is realized at each session."
1808235|NCT00645827|Other|Healthcare Provider dosing|Twenty-four hour subcutaneous insulin dosing requirement was determined according to the judgment of the patient's healthcare provider. If patient was eating, insulin glargine SC qHS and three qAC doses of insulin aspart was given according to the judgment of the patients's healthcare provider. If patient was not eating, 100% of insulin was given as insulin glargine. If IV insulin was stopped between 7 AM and 3 PM, 1/2 to 1/3 of scheduled insulin glargine dose was given as a one time insulin NPH SC dose at time of IV insulin cessation. Correctional insulin was given as follows: For BG ≥ 150 mg/dL, (BG-100)/X units insulin aspart SC, X = 1500 / (scheduled glargine dose + [3 x scheduled aspart dose]). For BG < 70 mg/dL, ½ ampule D50W IV x1 was given.
1808236|NCT00645840|Drug|Anakinra|Patients will receive daily anakinra therapy for 28 days
1808237|NCT00645853|Drug|AZD0837|Treatment with AZD0837 starting with 4 different doses, 150 mg od, 300 mg od, 200 mg bid or 450 mg od and then switching to one general common dose, 300 mg od
1808238|NCT00645853|Drug|VKA INR 2-3|Vitamin K antagonists (VKA), titrated to an international normalised ratio (INR) of 2.0 to 3.0 with a target value of 2.5
1808239|NCT00645866|Drug|capecitabine|
1808240|NCT00645866|Drug|docetaxel|
1808241|NCT00645866|Drug|epirubicin hydrochloride|
1808242|NCT00645866|Other|laboratory biomarker analysis|
1808243|NCT00645866|Other|pharmacogenomic studies|
1808244|NCT00645866|Procedure|biopsy|
1808245|NCT00645866|Procedure|neoadjuvant therapy|
1808246|NCT00645866|Procedure|therapeutic surgical procedure|
1808247|NCT00645879|Drug|ornithine alpha ketoglutarate|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effect, drug will be taken for 30 weeks.
1808248|NCT00645879|Drug|glutamine|A dose of 400 mg/kg up to 16 g per day was selected. Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
1808249|NCT00645879|Drug|disodium citrate|Dose: 7.5 mEq/Kg or 658 mg/kg up to 16 g per day Split into 2 doses taken for 4 weeks. If determined the drug with the best effects, drug will be taken for 30 weeks.
1808250|NCT00645892|Drug|adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded 40 mg eow through Week 24
1808251|NCT00645892|Drug|placebo for adalimumab|OL 80 mg at Weeks 0 and 1, 40 mg weekly Week 2 - Week 11, blinded placebo eow through Week 24
1808252|NCT00645905|Drug|adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded 40 mg eow through Week 48, withdrawal and observation for 360 days after last dose
1808253|NCT00645905|Drug|placebo for adalimumab|OL 80 mg at Week 0, 40 mg weekly through Week 12, blinded placebo eow through Week 48, withdrawal and observation for 360 days after last dose
1957754|NCT02197247|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
1808257|NCT00645931|Behavioral|protein and calorie controlled diet and self-hypnotic relaxation|daily
1957755|NCT02197247|Drug|Rifampicin|Rifampicin (CYP inducer) 600mg taken once daily from Day 29 to Day 49 (Part A)
1808260|NCT00645957|Procedure|penrose drain|incision and drainage of the infection with placement of a penrose drain
1808261|NCT00645957|Procedure|red rubber drain|incision and drainage of infection and placement of a red rubber drain
1808262|NCT00645983|Dietary Supplement|Chamomile Extract|220 mg - 1100 mg daily
1808263|NCT00645983|Other|Placebo|1 to 5 capsules daily
1808264|NCT00645996|Dietary Supplement|Probiotics (L.acidophilus and B.lactis)|2.1 X 109 L.acidophilus and B.lactis
1808265|NCT00645996|Dietary Supplement|Cornflor|Cornflour 2 gram daily
1808266|NCT00646009|Drug|budesonide/formoterol|
1808267|NCT00646009|Drug|fluticasone/salmeterol|
1808268|NCT00646009|Drug|albuterol|
1808269|NCT00646035|Drug|paricalcitol capsules|baseline iPTH/60
1808270|NCT00646048|Device|TriVascular Stent-Graft System|TriVascular Stent-Graft System
1808271|NCT00646061|Drug|buscopan|
1808272|NCT00646074|Behavioral|Self-Care Talk|6 conversational sessions
1808273|NCT00646087|Drug|Ketamine|0.5 mg/kg of ketamine every other day for 12 days (days 1, 3, 5, 7, 9, 11)
1808274|NCT00646087|Drug|Ketamine/Saline|0.5 mg/kg of ketamine on days 1 and 7, placebo (saline) on days 3, 5, 9, 11
1808275|NCT00646100|Procedure|transcatheter arterial chemoembolization|chemo-lipiodolization with EADM 50mg, Lobaplatin 50mg, and MMC 6mg,plus particleembolization.
1808276|NCT00646113|Device|OsseoSpeed™|OsseoSpeed™ 3.0 mm diameter
1808277|NCT00646126|Drug|Sulfadoxine / Pyrimethamine (SP) plus artesunate (AS)|Standard three day regimen
1808278|NCT00646126|Drug|placebo tablet similar to active drug in shape and size|Dosage similar to active drug(standard three days regimen)
1808279|NCT00646139|Drug|Src kinase inhibitor KX2-391|
1808280|NCT00646139|Other|immunoenzyme technique|
1808281|NCT00646139|Other|pharmacological study|
1808282|NCT00646152|Drug|Poly-ICLC|
1808283|NCT00646165|Drug|Forodesine|
1808284|NCT00646178|Drug|adalimumab|40 mg adalimumab eow Week 0 - Week 12
1808285|NCT00646178|Drug|placebo for adalimumab|placebo eow Week 0 - Week 12
1808286|NCT00646191|Drug|adalimumab|40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
1808287|NCT00646191|Drug|adalimumab|40 mg weekly through Week 48 (OL Week 12 - 48)
1808288|NCT00646191|Drug|adalimumab|80 mg W0, 40 mg eow through Week 12 followed by OL 40 mg eow through Week 48, permitted to escalate to weekly dosing upon relapse
1808291|NCT00646217|Behavioral|Self Care Talk|6 weekly telephone sessions
1808292|NCT00646230|Drug|fenretinide|
1808293|NCT00646230|Other|high performance liquid chromatography|
1808294|NCT00646230|Other|pharmacological study|
1808298|NCT00646269|Behavioral|Standard intervention protocol + Reminiscence therapy|"Reminiscence therapy is provided in small groups of 5 to 8 patients. This therapy involves the discussion of past activities, events and experiences enhanced by aids such as photographs, familiar items, songs, or personal recordings. A particular topic of life (i.e. a wedding) is discussed at each session."
1808299|NCT00646269|Behavioral|"Standard intervention protocol + Made-to-measure program"|"The made to measure program involves no systematic intervention. The psychologist is asked to choose among the two possible therapies (Cognitive training therapy or Reminiscence therapy) the one more suitable for the patient after considering his clinical characteristics including socio-demographic characteristics, disease severity or cognitive and behavioural disturbance. It is an individualized approach emphasizing the importance of flexibility to allow adjustment to individual needs."
1808300|NCT00646282|Drug|doxercalciferol|The study drug dosage will be initiated according to baseline iPTH levels. For patients with iPTH>300 pg/ml, oral Doxercalciferol will be given at 1 mcg/day; for patients with iPTH <300 pg/ml, oral Doxercalciferol will be initiated at 0.5 mcg/day.
1808301|NCT00646295|Device|To measure the IOP (with Goldmann and Pascal DCT tonometers) and OPA (with Pascal DCT) in primary and upright gazes|Pascal Dynamic Contour Tonometer Goldmann Applanation Tonometer
1808302|NCT00646321|Drug|budesonide/formoterol (Symbicort)|
1808303|NCT00646321|Drug|budesonide|
1808304|NCT00646334|Device|Mesh Implantation|An elective incisional Hernia repair is performed by using Optilene® Mesh Elastic, a lightweight and large pore mesh, knitted from monofilament polypropylene. Due to the multidirectional elasticity the mesh is able to adapt to all movements taking place in the abdominal wall.
1808305|NCT00646334|Device|Mesh Implantation|Ultrapro® Mesh is a knitted, partly absorbable, lightweight mesh, consisting of equal parts of nonabsorbable polypropylene and absorbable polyglecaprone (Monocryl®). Polyglecaprone is fully absorbed in the body by hydrolysis. The addition of polyglecapron filament is only intended to reinforce the mesh to allow a convenient intraoperative handling and mesh placement, without additional function. Ultrapro® is an elastic mesh having enlarged elasticity cross to the blue strips.
1808306|NCT00646347|Other|Conventional upper limb stroke rehabilitation|"Patient will be given a ten weeks conventional upper limb therapy. 3 sessions will be provided weekly in the first 4 weeks and 2 therapy sessions will be provided weekly in the subsequent 6 weeks. Patients will receive half an hour of conventional therapy in each session.
Patient will be taught to carry out two and half hours conventional self practice exercise daily for a period of ten weeks."
1808307|NCT00646347|Device|Neuro Hand Orthosis Program (NHOP)|"The NHO is based on a design of dynamic hand orthosis for orthopaedic patients after hand surgery. We use it to support CVA patient's wrist and finger to perform grasping to transport an object (ball) from place to place to achieve the follows;
NHO can assist stroke patients to experience successful hand grasping with an object and produce voluntary movement from their paralytic arm. This successful experience will positively reinforce the patient to continue to use their paralytic arm and change the patient's behavior and perception in the arm usage.
The NHO Program is able to engage patients to perform their exercises and activities by themselves independently with the effect of intensive therapy.
The intervention (NHOP) group will receive same treatment intensity as the control group but with a Neuro Hand Orthosis."
1808308|NCT00646360|Dietary Supplement|DHA|400 mg/d of docosahexanoic acid (DHA) during pregnancy
1808309|NCT00646360|Dietary Supplement|Placebo|2 tablets daily during pregnancy
1808310|NCT00646373|Other|Low Prime|The CPB circuit will be primed with mannitol (50 g of 20% solution) and crystalloid solution (Ringer's lactate) for a total volume of approximately 1200 ml.
1808311|NCT00646386|Drug|adalimumab|40 mg eow Week 0 - Week 24
1808312|NCT00646386|Drug|placebo for adalimumab|40 mg eow Week 0 - Week 24
1808313|NCT00646399|Drug|Placebo|Phosphate Buffered Saline on Days 0, 1, 2, 9, 16 and 23.
1808314|NCT00646399|Drug|Pagibaximab 50 mg/mL|Pagibaximab 100 mg/kg dosed on Days 0, 1, 2, 9, 16 and 23
1808315|NCT00646412|Device|A-Part® Gel|10 - 20 ml of A-Part® Gel will be administered before abdominal wall closure in a standardised fashion
1808316|NCT00646425|Drug|Basiliximab|40 mg basiliximab administered as short iv infusion once every 2 weeks for 3 doses and at Weeks 8 and 12 for a total of 5 doses
1808317|NCT00646425|Drug|Placebo|Placebo to match basiliximab
1808318|NCT00646438|Drug|Strict Glycemic Control for one year post-op CABG|"The CDE and Study Coordinator will also meet with the patient in the hospital to show how the Lifescan One-Touch Ultra II glucometer works and review the study follow-up schedule. Patients will be sent home with the Lifescan One-Touch Ultra II glucometer and a supply of strips.
Post-Discharge Period Patients will meet alternatively with the CDE and study doctor on a specific schedule including every week for the first month, every 2 weeks in the second month, and every month thereafter till the 12th month. During these sessions the BG records will be downloaded from the Lifescan One-Touch Ultra II glucometer and reviewed to see patterns and any areas that could be improved or changed.
For all patients in the study arm, the medications that are being taken and the results of glucose monitoring charts will be reviewed weekly with endocrinologists so that any additional recommendations may be made to improve glucose control."
1957756|NCT02197247|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken daily from Days 1 to 77. Part B: AZD9291 80mg tablet taken daily for 12 months.
1808321|NCT00646477|Device|titration night|"Each subject undergo 1 night of full polysomnography split into 2 consecutives and randomized sequences, using the Sandman device into two different modes:
in APAP mode - Data analysis of this sequence will be used to evaluate the therapeutic effectiveness of the CPAP/autoCPAP Sandman in APAP mode compared both to the polysomnography registration and the diagnosis night for each enrolled patient. The type of respiratory events and their index/hour of sleep and the total arousal index will be appraised as markers of the efficacy of OSAS treatment, constituting the primary outcomes.
in CPAP mode for manual titration sequence.During the manual titration, 5 constant pressure levels settings were studied for equal periods of 30 minutes gradually increasing the pressure. The aim of this sequence is to determine the sensitivity and the specificity of the CPAP/autoCPAP Sandman in detecting respiratory events."
1808322|NCT00646503|Drug|Telbivudine|600 mg/day, oral telbivudine for 52 weeks
1808323|NCT00646516|Drug|budesonide/formoterol (Symbicort)|
1808324|NCT00646529|Drug|budesonide/formoterol (Symbicort)|
1808325|NCT00646529|Drug|budesonide (Pulmicort)|
1808326|NCT00646542|Drug|Vildagliptin|
1808330|NCT00646581|Drug|Insulin (Humulin)|40 IU Intranasal Insulin will be administered once
1808331|NCT00646594|Drug|budesonide/formoterol (Symbicort)|
1808332|NCT00646594|Drug|fluticasone/salmeterol (Advair)|
1808333|NCT00646607|Drug|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|To assess whether a 3-month FOLFOX-4 treatment is at least equivalent to a 6-month FOLFOX-4 treatment
1808334|NCT00646607|Drug|FOLFOX (Oxaliplatin, 5Fluorouracil, Lederfolin)|standard treatment
1808335|NCT00646620|Drug|budesonide/formoterol (Symbicort)|
1808336|NCT00646620|Drug|fluticasone/salmeterol (Advair Diskus)|
1808337|NCT00646620|Drug|albuterol (Ventolin)|
1808338|NCT00646633|Procedure|Acupuncture and patient education|Acupuncture involves the insertion of extremely thin needles, much thinner than those used for drawing blood, into very specific acupuncture points. Patients will receive a total of 8 acupuncture treatments, each lasting 50 minutes. Patient education will be delivered to individuals over the course of approximately 50 minutes for each of the four sessions; topics will include acupressure, nutrition, exercise, stress management, and lifestyle advice.
1957757|NCT02197247|Procedure|Pharmacokinetic sampling - rifampicin|Blood sampling to measure rifampicin levels
1957758|NCT02197247|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
1808343|NCT00646659|Biological|cetuximab|
1808344|NCT00646659|Drug|carboplatin|
1808345|NCT00646659|Drug|cisplatin|
1808346|NCT00646659|Drug|docetaxel|
1808347|NCT00646659|Drug|fluorouracil|
1808348|NCT00646659|Genetic|fluorescence in situ hybridization|
1808349|NCT00646659|Genetic|molecular genetic technique|
1808350|NCT00646659|Genetic|reverse transcriptase-polymerase chain reaction|
1808351|NCT00646659|Other|immunoenzyme technique|
1808352|NCT00646659|Other|immunohistochemistry staining method|
1808353|NCT00646659|Other|laboratory biomarker analysis|
1808354|NCT00646659|Procedure|biopsy|
1808355|NCT00646659|Radiation|3-dimensional conformal radiation therapy|
1808356|NCT00646659|Radiation|intensity-modulated radiation therapy|
1808357|NCT00646685|Procedure|surgical technique: duct-to-duct biliary reconstruction|surgical reconstruction
1808358|NCT00646685|Procedure|surgical technique: roux-en-y biliary reconstruction|surgical reconstruction
1808359|NCT00646711|Drug|Depakote Delayed-Release/Depakote Sprinkle|Administered according to the subject's usual regimen.
1808360|NCT00646711|Drug|Depakote ER|Dose converted to 8-20% higher than Depakote DR or Depakote Sprinkle.
1808361|NCT00646724|Biological|cotransplantation of islet and mesenchymal stem cell|islet of allograft and MSCs of autograft
1808362|NCT00646737|Drug|Mycophenolate sodium|Mycophenolate sodium
1808363|NCT00646750|Drug|Ybritumomab Tiuxetan (Zevalin); Rituximab; BEAM (BCNU, ARAC, VP16 and Melphalan)|"Day -21: rituximab. 250 mg/m2 iv
Day -14: rituximab. 250 mg/m2 plus Ybritumomab Tiuxetan (Zevalin)(0.4 mCi/kg maximum dose 32 mCi).
Days -6 to -1: BEAM regimen as follows BCNU: 300 mg/m2 over 2 hours, day -6. ARAC: 200 mg/m2/12 hours over 12 hours, days -5 through -2. VP16: 200 mg/m2/day over 2 hours, days -5 through -2. Melphalan: 140 mg/m2/day over 15 minutes, day -1."
1808364|NCT00646763|Drug|G-CSF, GM-CSF administered at extremities|Injection site Extremities: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a twice daily schedule of G-CSF/GM-CSF until stem cell collection is complete.
1808365|NCT00646763|Drug|G-CSF and GMCSF administered at abdomen|Injection site Abdomen: G-CSF injections will commence on the day after completion of mobilization chemotherapy, at least 24 hours after completion of the last chemotherapy dose. On the seventh day of cytokine administration, GMCSF injections will be started, and patients will maintain a BID schedule of G-CSF/GM-CSF until stem cell collection is complete.
1808366|NCT00646776|Drug|Rifabutin|Capsule, Oral, 150 mg, once daily, 11 Days
1808367|NCT00646776|Drug|Rifabutin + Atazanavir + Ritonavir|"Capsules, Oral, 18 Days
Rifabutin (150 mg, 2x/wk)
Atazanavir (300 mg, once daily)
Ritonavir (100 mg, once daily)"
1808368|NCT00646789|Drug|Comparator: MK0633|patients will receive single 50mg oral dose with follow-up observation for 5 weeks.
1808369|NCT00646802|Drug|Progesterone|1 vaginal capsule, 200 mg, once daily since gestation age 36 weeks and 6 days
1808370|NCT00646802|Drug|Placebo|1 vaginal capsule, once daily since gestational age of 36 weeks and 6 days
1808371|NCT00646815|Drug|growth hormone (genotropin)|Dosage regulation will follow the local recommendations of GHD treatment
1808372|NCT00646841|Drug|Doxazosin gastrointestinal therapeutic system (GITS)|4 mg/day, and was titrated, if necessary, to 8 mg/day at Week 3 (Visit 5) or Week 5 (Visit 6).
1808373|NCT00646854|Drug|CHOP14 chemotherapy (cyclophosphamide, hydroxydaunorubicin, vincristin, prednison) plus G-CSF, combined with alemtuzumab|Cyclophosphamide 750 mg/m2 i.v. on day 1 Hydroxydaunorubicin 50 mg/m2 i.v. on day 1 Vincristin 1 mg/m2 i.v. day 1 (max. 2mg) Prednisone 50 mg/m2 p.o. day 1 to 5 Alemtuzumab 30 mg s.c.on day 1 of CHOP-14 cycles 1-4
1808374|NCT00646854|Drug|CHOP14 chemotherapy (see specification under Arm B) plus G-CSF|6 cycles of CHOP every 2 weeks
1808375|NCT00646867|Device|Tetrix|Twice daily topical application
1808376|NCT00646867|Device|Placebo|Twice daily topical application
1808377|NCT00646880|Drug|propiverine|Two week washout period followed by propiverine 20 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to tolterodine PR 4 mg capsule daily for 1 week.
1808378|NCT00646880|Drug|tolterodine PR|Two week washout period followed by tolterodine PR 4 mg capsule daily for 1 week, followed by a second 2-week washout; patients were then crossed over to propiverine 20 mg capsule daily for 1 week.
1808379|NCT00646893|Procedure|Preimplantation Genetic Diagnosis (PGD)|"one-cell embryo biopsy on day 3 of development. The cell will be analyzed by FISH using probes for X,Y,13,15,16,17,18,21,22 chromosomes. Cells with dubious results will be reanalyzed by no result rescue (Colls et al. 2007)"
1808380|NCT00646906|Drug|Aspirin first|Subjects will receive 81 mg aspirin at approximately 8 am followed by 1000 or 2000 mg acetaminophen at approximately 10 am during this intervention phase.
1808492|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h|single application
1808381|NCT00646906|Drug|Aspirin last|Subjects will receive 1000 or 2000 mg acetaminophen at approximately 8am followed by 81 mg aspirin at approximately 10 am during this intervention phase.
1808382|NCT00646906|Drug|Acetaminophen|The data will be handled the same as Part A.
1808383|NCT00646919|Procedure|Nose swab|
1808384|NCT00646932|Drug|paricalcitol|paricalcitol 0.04 mcg/kg three times a week
1808385|NCT00646932|Drug|paricalcitol|paricalcitol 0.08 mcg/kg three times a week
1808386|NCT00646932|Drug|paricalcitol|paricalcitol 0.16 mcg/kg three times a week
1808387|NCT00646932|Drug|paricalcitol|paricalcitol 0.24 mcg/kg three times a week
1808388|NCT00646945|Drug|50% Oxygen/50% Nitrous oxide premix (Kalinox 170 bar)|gas flow between 4 to 15 L/min
1808389|NCT00646945|Drug|50% Oxygen/50% Nitrogen premix|gas flow between 4 to 15 L/min
1808390|NCT00646958|Drug|Radezolid|450mg PO QD
1808391|NCT00646958|Drug|Radezolid|450mg PO BID
1808392|NCT00646958|Drug|Linezolid|600mg PO BID
1808393|NCT00646971|Device|CPAP device|for 4 weeks
1808394|NCT00646971|Device|Placebo device|for 4 weeks
1808395|NCT00646984|Drug|Standard continuous antiretroviral therapy|
1808396|NCT00646984|Drug|CD-4 guided therapy interruption|Stop antiretroviral therapy when CD-4 equal or above 350 and reinitiate when below 350
1808397|NCT00646984|Drug|Viral load driven treatment interruption|Stop antiretroviral therapy when viral load below 30,000 copies/ml and reinitiate when equal or above 30,000 copies/ml
1808398|NCT00647023|Drug|metformin|1000 mg metformin x 2 daily during 8 months
1808399|NCT00647036|Dietary Supplement|Isonitrogenous Vaminolact|Isonitrogenous Vaminolact
1808400|NCT00647036|Drug|Dipeptiven (L-glutamine- Lalanine)|0.6g/kg/day
1808401|NCT00647049|Drug|methotrexate|8000mg/m2 i.v., max. 2 cycles
1808402|NCT00647049|Drug|Rituximab|375mg/m2, max. 8 times
1808403|NCT00647049|Drug|Cytarabine|3000mg/m2 die i.v., 2 days (max. 2 cycles)
1808404|NCT00647049|Drug|Thiotepa|40mg/m2 i.v. (max. 2 cycles) 2 x 5mg/kg/die i.v. for 2 days
1808405|NCT00647049|Drug|Carmustin|400mg/m2 i.v. for 1 day
1808406|NCT00647075|Dietary Supplement|Yunzhi extract|3.5 g/day
1808407|NCT00647075|Dietary Supplement|Placebo|Placebo (starch)
1808408|NCT00647101|Drug|Latanoprost|Latanoprost 0.005% drops: 1 drop in the diseased eye(s) in the evening for 3 months
1808409|NCT00647114|Biological|V930|V930 - Over a 94 week duration, patients will receive a series of 5 injections (2.5 mg/injection), one every other week. Within 2 minutes of each injection of V930, each patient will be given an EP-IM injection consisting of two 60 msec pulses.
1808410|NCT00647114|Biological|V932|V932 - Over a 94 week duration, patients will receive a series of 5 injections, 6 patients will initially received intramuscular V932 vaccinations at a low dose (0.5x109 vg/injection),and following a safety assessment, up to an additional 35 patients will be treated with the high dose V932 (0.5x1011 vg/injection).
1808411|NCT00647127|Drug|Buprenorphine|Buprenorphine: 20microg/h
1808412|NCT00647127|Drug|Fentanyl|Fentanyl: 25microg/h
1808413|NCT00647127|Drug|Placebo|Placebo: '5microg/h' (not active drug, it is just called '5microg/h')
1808414|NCT00647140|Other|18F-L-DOPA PET|PET performed 30 minutes after IV injection of 4 MBq/kg of 18F-DOPA
1808415|NCT00647153|Other|pharmacological study|Pre-infusion and 30 min., 1h,2h, and 3-4h post start of infusion. Day 1 and 2 post infusion.
1808416|NCT00647153|Procedure|single photon emission computed tomography|One day post infusion
1808417|NCT00647153|Radiation|iodine I 123 anti-CEA recombinant diabody T84.66|10mCi/mg
1808418|NCT00647166|Drug|corticosteroid and azathioprine|"Corticosteroid 1 mg/kg/day with a conventional decrease dose
Azathioprine : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
1808419|NCT00647166|Drug|corticosteroid and placebo|"Corticosteroid 1 mg/kg/day with a conventional decrease dose
Placebo : 2 mg/kg/day during one year in 2 to 3 times a day by oral route"
1808420|NCT00647179|Procedure|Transsphenoidal adenomectomy|Surgery
1808421|NCT00647192|Drug|Eplerenone|50 mg per day
1808422|NCT00647192|Drug|Placebo|50 mg per day
1808423|NCT00647205|Device|QuantiFERON TB Gold In-Tube|
1808424|NCT00647205|Device|T-SPOT.TB®|
1808425|NCT00647218|Drug|Post-operative adjuvant therapy|Adriamycin 60 mg/m2 IV over 20 minutes and Cytoxan 600 mg/m2 IV over 1 hour will be given every three weeks for 4 cycles.
1808426|NCT00647218|Drug|neoadjuvant therapy|Paclitaxel 175 mg/m2 IV every 3 weeks x 3 cycles
1808427|NCT00647218|Procedure|therapeutic surgical procedure|Modified radical mastectomy or segmental mastectomy plus axillary dissection 6-8 weeks following completion of chemotherapy/Radiotherapy.
1808428|NCT00647218|Radiation|Radiation therapy with concurrent Paclitaxel|Radiation to breast 4680 cGy/26 fractions with concurrent Paclitaxel 30 mg/m2, twice per week
1808429|NCT00647218|Drug|Hormonal Therapy|After completion of postoperative adjuvant Adriamycin and Cytoxan, hormonal therapy should be given at the discretion of the treating physician for all post-menopausal ER and/or PR positive patients. It is also recommended for pre-menopausal patients who are ER and/or PR positive.
1808430|NCT00647231|Drug|HKT-500 Topical Patch|Treatment with Ketoprofen Topical Patch
1808431|NCT00647231|Other|Placebo Patch|Treatment with placebo patch
1808432|NCT00647244|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil 245 mg oral tablet once daily
1808433|NCT00647244|Drug|Abacavir|Abacavir 300 mg oral tablet twice daily
1808434|NCT00647257|Drug|Losartan|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Losartan 100mg add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
1808435|NCT00647257|Drug|Placebo|Patients, aged 20 to 80 years, with SSS will be enrolled and randomly assigned to the Placebo add on physiological atrial-based pacing or physiological atrial-based pacing alone treatment arm.
1808436|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
1808437|NCT00647270|Drug|Placebo|Pre-filled syringe. See arm for more detail
1808438|NCT00647270|Drug|adalimumab|Pre-filled syringe. See arm for more detail
1808493|NCT00647699|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
1808695|NCT00648388|Drug|Pletal® Tablets 100 mg|100 single dose fasting
1808439|NCT00647283|Procedure|Gradual immunosuppression drug withdrawal|After the obtention of biological samples (peripheral blood, liver tissue), enrolled patients undergo gradual weaning of all immunosuppressive therapy over a 6-9 month period under close medical supervision.
1808440|NCT00647296|Drug|KNS-760704|Oral tablet 2 x 12.5 mg twice daily for 12 weeks
1808441|NCT00647296|Drug|KNS-760704|Oral tablet 2 x 37.5 mg twice daily for 12 weeks
1808442|NCT00647296|Drug|KNS-760704|Oral tablet 2 x 75 mg twice daily for 12 weeks
1808443|NCT00647296|Drug|Placebo|Placebo oral tablet (2 tabs twice daily) for 12 weeks
1808444|NCT00647322|Other|Reduction of anti-epileptic medications|Reduction in anti-epileptic medications
1808445|NCT00647322|Procedure|No drug change|No change in anti-epileptic treatment
1808446|NCT00647348|Drug|Simvastatin|80mg simvastatin oral once daily for 24 months
1808447|NCT00647348|Drug|Placebo|Oral placebo tablet once daily for 24 months
1808448|NCT00647361|Device|Neurally adjusted ventilatory assist (NAVA) provided by a commercially available mechanical ventilator (Servo i, Maquet Critical Care, Solna, Sweden).|Neurally adjusted ventilatory assist (NAVA) and pressure support ventilation (PSV)
1808449|NCT00647374|Other|this is an observational study|
1808450|NCT00647387|Device|Muscular VSD Occluder device implantation (AMPLATZER Muscular VSD Occluder)|Device
1808451|NCT00647400|Biological|adalimumab|Adalimumab 40 mg every other week, subcutaneous
1808452|NCT00647400|Biological|adalimumab|Adalimumab 80 mg every other week, subcutaneous
1808453|NCT00647413|Behavioral|bio-chemical feedback and expert system intervention ETS|"Urinary cotinien will be measured using urine collected from the infants diaper. It will be analysed and the result will be explained to the participant in a written letter approximately 2 weeks after the intervention.
The intervention will also be a counselling session about the consequences of ETS to the infant. The counselling will be guided by the principles of motivational intervieweing and an expert system letter tailored to the data assessed will be send to the participants"
1808454|NCT00647426|Drug|Sorafenib + Docetaxel/Carboplatin|400 mg po BID Sorafenib + 75 mg/m2 IV Docetaxel on day 1 plus AUC 6 on Carboplatin on day 1 of each 21 day cycle
1808455|NCT00647452|Behavioral|Exercise|Moderate Intensity Exercise (50 % af VO2max) for 90 minutes
1808456|NCT00647465|Drug|vaccine|IFNalpha 2b
1808457|NCT00647465|Drug|Placebo|Placebo
1808458|NCT00647491|Biological|adalimumab|20 mg sc eow
1808459|NCT00647491|Biological|adalimumab|40 mg sc eow
1808460|NCT00647491|Biological|adalimumab|80 mg sc eow
1808461|NCT00647491|Biological|placebo|placebo sc eow
1808462|NCT00647517|Drug|Ultracet|"For the treatment arm: Tramadol 37.5 mg/APAP 325 mg combination tablets (Ultracet®) one tablet twice a day plus aceclofenac tablet per oral 100 mg twice a day.
For the control group: Placebo plus aceclofenac tablet per oral 100 mg twice a day."
1808463|NCT00647530|Biological|panitumumab|
1808464|NCT00647530|Drug|capecitabine|
1808465|NCT00647530|Drug|fluorouracil|
1808466|NCT00647530|Drug|oxaliplatin|
1808467|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
1808468|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
1808469|NCT00647543|Drug|Atorvastatin|Atorvastatin tablets at starting doses of 10, 20, or 40 mg once daily for at least 8 weeks. Patients who achieved their LDL-C target by Week 4 continued on their starting dose for the next 4 weeks. Patients who did not achieve their LDL-C target by Week 4 were titrated up 1 dose step for the next 4 weeks.
1808470|NCT00647556|Drug|adapalene gel, 0.3%|applied topically once daily in the evening
1808471|NCT00647556|Drug|tretinoin 0.05% emollient cream|applied topically once daily in the evening
1808472|NCT00647569|Procedure|Mesh repair|A Surgisis Gold Hernia repair graft (Cook Biotech Incorporated, West Lafayette, IN, U.S.A) is placed at the donor site of the rectus abdominis muscles used for the rotation flap before the abdominal fascia is sutured with continuous running suture.
1808473|NCT00647569|Procedure|Conventional facial closure|The abdominal facia is closed with with continuous running suture
1808474|NCT00647582|Procedure|adjuvant therapy|
1808475|NCT00647582|Procedure|therapeutic conventional surgery|
1808476|NCT00647582|Radiation|intraoperative radiation therapy|
1808477|NCT00647582|Radiation|radiation therapy|
1808478|NCT00647595|Behavioral|Experimental group|Intervention group will exercise 3 times per week at moderate-vigorous intensity for 45 minutes per session. Control group women will continue their usual physical activity throughout pregnancy.
1808479|NCT00647608|Drug|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fed
1808480|NCT00647608|Drug|Inderal® LA Capsules 160 mg|160mg, single dose fed
1808481|NCT00647621|Drug|Extended Phenytoin Sodium Capsules 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
1808482|NCT00647621|Drug|Dilantin® Kapseals® 100 mg|3x100mg for 14 days, fasting conditions, continuing 2 days with dosing following high-fat breakfast on Day 16
1808483|NCT00647634|Drug|Alprazolam Extended-Release Tablets 3 mg|3mg, single dose fasting
1808484|NCT00647634|Drug|Xanax XR® Tablets (3 mg|3mg, single dose fasting
1808485|NCT00647647|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fasting
1808486|NCT00647647|Drug|Lamisil® Tablets 250 mg|250mg, single dose fasting
1808487|NCT00647660|Drug|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fasting
1808488|NCT00647660|Drug|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fasting
1808489|NCT00647673|Drug|Verapamil HCL Extended-Release Capsules 300 mg|300mg, single dose fasting
1808490|NCT00647673|Drug|Verelan® PM Extended-Release Capsules 300 mg|300mg, single dose fasting
1808491|NCT00647686|Drug|Fentanyl Transdermal System 25 mcg/h + Askina Derm Overlay|single application
1808494|NCT00647699|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
1808495|NCT00647712|Drug|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fasting
1808496|NCT00647712|Drug|Depakote ER® Tablets 500 mg|500mg, single dose fasting
1808497|NCT00647725|Procedure|Active phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
1808498|NCT00647725|Procedure|Latent phrase epidural analgesia|Continuous epidural analgesia with sufentanil plus ropivacaine
1808499|NCT00647738|Drug|Baclofen|Single-dose 20 mg immediate-release oral tablets
1808500|NCT00647738|Drug|Baclofen|Single-dose 20 mg immediate-release oral tablet
1808501|NCT00647751|Drug|Lamotrigine Tablets 25 mg|2x25mg, single dose fed
1808502|NCT00647751|Drug|Lamictal® Tablets 25 mg|2x25mg, single dose fed
1808503|NCT00647764|Drug|SNX-5422 Mesylate Hsp90 inhibitor|dose escalated, tablets twice a week; undetermined duration until disease progression
1808504|NCT00647777|Drug|Olanzapine Tablets 5 mg|5mg, single dose fed
1808505|NCT00647777|Drug|Zyprexa® Tablets 5 mg|5mg, single dose fed
1808506|NCT00647790|Procedure|PET scan with injection of 5-8 mCi of 18FES|Following injection of the tracer 18FES, dynamic images will be obtained for 30 minutes over the chest area to include cardiac region and breasts. Following the first dynamic imaging for 30 minutes, whole body images (base of skull to pelvis) will be obtained at 5 minute/bed position. An additional, longer scan after 60 minutes will be obtained for the chest (1-2-FOV for 15 minutes each). Total time from injection to completion of imaging will be about 90 minutes.
1808507|NCT00647816|Drug|Propranolol Hydrochloride Extended-Release Capsules 160 mg|160mg, single dose fasting
1808508|NCT00647816|Drug|Inderal® LA Capsules 160 mg|160mg, single dose fasting
1808509|NCT00647829|Drug|valdecoxib|valdecoxib 20 mg tablet by mouth twice daily (BID) for 2 doses over a 24-hour period
1808510|NCT00647829|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth once daily (QD) for 2 doses over a 24-hour period
1808511|NCT00647829|Drug|placebo|placebo tablet by mouth for 2 doses over a 24-hour period
1808512|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h + Bioclusive Overlay|single application
1808513|NCT00647842|Drug|Fentanyl Transdermal System 25 mcg/h|single application
1808514|NCT00647855|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
1808515|NCT00647855|Drug|Synthroid® Tablets 300 μg|2x300mcg, single dose fasting
1808516|NCT00647868|Drug|testosterone|Intranasal testosterone, 7.6 mg (3.8 mg in each nostril) per application
1808517|NCT00647868|Other|No treatment|24-h blood sampling in healthy, eugonadal men
1808518|NCT00647881|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fed
1808519|NCT00647881|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fed
1808520|NCT00647894|Drug|Alprazolam Extended-Release Tablets 1 mg|
1808521|NCT00647894|Drug|Xanax XR Tablets 1 mg|
1808522|NCT00647907|Drug|Voriconazole|Oral or intravenous voriconazole. Oral tablets 400 mg twice daily loading dose on first day, followed by 200 mg twice daily taken at least 1 hour before or after a meal. Oral doses could be increased to a maximum of 300 mg twice daily if there was no clinical improvement after at least 3 days of treatment, no serious adverse events were reported, and clinical chemistry parameters were within the acceptable range for study entry. Intravenous treatment was initiated with a loading dose of 6 mg/kg twice daily for the first day followed by 4 mg/kg twice daily for at least 3 days (maximum infusion rate of 3 mg/kg/hr if administered by peripheral intravenous line). An intravenous loading dose was not required in patients who were restarted after oral treatment. Total duration of therapy (intravenous and oral) was 12 weeks.
1808523|NCT00647920|Biological|adalimumab|40 mg adalimumab sc, every other week
1808524|NCT00647920|Biological|placebo|placebo sc, every other week
1808525|NCT00647933|Drug|Org 36286|Subcutaneous Org 36286
1808526|NCT00647933|Drug|Lyndiol®|Lyndiol® (50 μg ethinylestradiol + 2.5 mg lynestrenol) tablets orally once a day for 6 weeks.
1808527|NCT00647946|Drug|tenofovir DF|tenofovir DF 300mg once daily along with the other antiviral drugs
1808528|NCT00647946|Drug|abacavir 300mg twice daily|abacavir 300mg twice daily along with the other antiviral drugs
1808529|NCT00647959|Drug|Doxycycline Tablets, 150mg|150mg, single dose fasting
1808530|NCT00647959|Drug|Adoxa Tablets 150 mg|150mg, single dose fasting
1808531|NCT00647972|Drug|Olanzapine Tablets 20 mg|20mg, single dose fasting
1808532|NCT00647972|Drug|Zyprexa® Tablets 20 mg|20mg, single dose fasting
1808533|NCT00647985|Drug|Fexofenadine Tablets 180 mg|180mg, single dose fed
1808534|NCT00647985|Drug|Allegra® Tablets 180 mg|180mg, single dose fed
1808535|NCT00647998|Drug|Darbepoetin alfa|Patients will receive one IV injection of Darbepoetin alfa at doses ranging from 1mcg/kg to 6.5 mcg/kg prior to surgery
1808536|NCT00647998|Other|Standard care|
1808537|NCT00648011|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
1808538|NCT00648011|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fed
1808539|NCT00648024|Drug|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fasting
1808540|NCT00648024|Drug|Agrylin® Capsules 1 mg|1mg, single dose fasting
1808541|NCT00648037|Drug|Rituximab|Rituximab 375 mg/m^2 starting approximately 1 month post transplant (no later than day 45), and continuing monthly until the CD4 cell count is > 200 cells/ul or a maximum of 6 doses have been given.
1808542|NCT00648050|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fasting
1808543|NCT00648050|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fasting
1808544|NCT00648063|Drug|Letrozole Tablets 2.5 mg|2.5mg, single dose fasting
1808545|NCT00648063|Drug|Femara® Tablets 2.5 mg|2.5mg, single dose fasting
1808546|NCT00648076|Drug|Divalproex Sodium Extended-Release Tablets 500 mg|500mg, single dose fed
1808547|NCT00648076|Drug|Depakote ER® Tablets 500 mg|500mg, single dose fed
1808548|NCT00648089|Drug|EPO|Single Injection of 1000 U/kg Erythropoietin beta IV immediately after primary PCI
1808549|NCT00648102|Biological|CDX-1307|
1808550|NCT00648115|Other|Basic Vocational Services|Vocational services
1808551|NCT00648115|Other|Self-Study|Veteran receives self-study resources
1808552|NCT00648115|Other|Group Program|Veteran participates in group vocational program
1808553|NCT00648128|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
1808554|NCT00648128|Drug|Clarithromycin|single-dose 500 mg immediate-release oral dose`
1808555|NCT00648141|Drug|Celecoxib|200 mg oral capsule once daily for 12 weeks
1808556|NCT00648141|Drug|Celecoxib|200 mg oral capsule twice daily for 12 weeks
1808557|NCT00648141|Drug|Diclofenac|75 mg oral capsule twice daily for 12 weeks
1808558|NCT00648154|Drug|Letrozole Tablets 2.5 mg|2.5mg, single dose fed
1808559|NCT00648154|Drug|Femara® Tablets 2.5 mg|2.5mg, single dose fed
1808560|NCT00648167|Drug|ferric citrate|ferric citrate will be provided as a 375mg capsule. Dosing and frequency are dependent on patient's serum phosphorus levels. Dosing will occur over the 28-day study.
1808561|NCT00641758|Drug|Pycnogenol|Pycnogenol 100mg twice daily
1808562|NCT00641758|Drug|Placebo|Placebo 100mg twice daily
1808563|NCT00641771|Drug|alendronate sodium (+) cholecalciferol|MK0217A, a tablet containing alendronate 70-mg and vitamin D3 2800 IU, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
1808564|NCT00641771|Drug|Comparator: Placebo (unspecified)|MK0217A, Pbo tablet, once weekly for 4 weeks. All patients will be instructed to take the tablet fasting upon arising for the day with 6 to 8 oz. of plain water (i.e., tap), wait at least one-half hour while continuing to fast and before the first food, beverage (except water), or other medication. All patients must eat before lying down.
1808565|NCT00641784|Drug|Magnesium|Intravenous Magnesium 6 gram load, 3 grams/hr
1808566|NCT00641784|Drug|Nifedlipine|Oral Nifedpine 10 mgs q 20 min to effect (max 40mgs)...then 20 mgs q 4hrs
1957759|NCT02197130|Drug|PF-02545920|20 mg twice a day (BID) for 26 weeks. Each 20 mg dose will be taken as 4 tablets of 5 mg. The 20mg dose will be titrated as follow: 5mg BID for 7 days, 10mg BID for 7 days, 15 mg BID for 7 days and 20 mg BID to week 26. Study drug will be provided in weekly blister cards.
1808572|NCT00641810|Behavioral|Caffeine reduction|Reduction in daily caffeine consumption from usual amounts to none.
1808573|NCT00641836|Procedure|Transplantation of autologous endothelial progenitor cells|
1808574|NCT00641849|Behavioral|Group A|Minimum Intervention Group A will fill out data forms at zero (0), two (2), four (4), and six (6) months.
1808575|NCT00641849|Behavioral|Group B|Maximum Intervention Group B will fill out data forms at zero (0), one (1), two (2), three (3), four (4), five (5), and six (6) months.
1808576|NCT00641862|Dietary Supplement|Vitamin B12|Daily oral administration of 50 µg of Vitamin B12 taken from enrollment (at or before 14 weeks gestational age) until delivery
1808577|NCT00641862|Other|Placebo|Placebo taken daily from enrollment (at or before 14 weeks gestational age) until delivery
1808578|NCT00641875|Procedure|Nocturnal Hemodialysis|
1808579|NCT00641901|Behavioral|counseling|"The 8-week study includes 3 visits to the dental facility at the Center for Women's Reproductive Health at UAB. Study visits are scheduled to coincide with pre-natal visits in the same facility.
Each visit will include individually tailored one-to-one discussion with a dental professional coupled with a demonstration and instructions for using oral hygiene products. Home-care kits will be dispensed, to include a helpful digital video disk (DVD), a high-tech powered toothbrush, dental floss, toothpaste and alcohol-free mouth rinse and subjects will have their teeth professionally cleaned.
First and final visits will include collection of gingival crevicular fluid and blood samples and subjects will complete pre and post study questionnaires."
1808580|NCT00641914|Drug|budesonide|
1808581|NCT00641914|Drug|Placebo|
1808582|NCT00641927|Drug|Venlafaxine|37.5 mg - 375 mg daily, 12 Weeks
1808583|NCT00641927|Drug|Lithium Carbonate|300 mg - 2100 mg daily, 12 weeks
1808584|NCT00641940|Behavioral|Girls in Transition (GT) program|In the 11-session after-school GT program, girls learn cognitive and behavioral skills related to intrapersonal, interpersonal, and social/contextual risk factors for depression.
1808585|NCT00641940|Behavioral|Waitlist Control|Participants in the waitlist control group will complete the GT program during the third year of the study.
1808586|NCT00641953|Drug|IMX-150|(0.3%) 0.5g topically BID to each foot for 4 weeks
1808587|NCT00641953|Drug|IMX-150|(0.6%) 0.5g topically BID to each foot for 4 weeks
1808588|NCT00641953|Drug|Placebo|0.5 g topically BID to each foot for 4 weeks
1808589|NCT00641979|Drug|budesonide|Current product
1808590|NCT00641979|Device|Budesonide|New type device
1808591|NCT00641979|Drug|Placebo|
1808592|NCT00642005|Procedure|Fisher and Paykel Humidifier (MR860)|Humidification to 98% relative humidity, and warming to 37 degrees C of laparoscopic insufflate. This will be done for the duration of the operation.
1808593|NCT00642005|Procedure|Standard insufflation|No humidifier or warmer will be used (device switched off). This will deliver laparoscopic insufflate at 0% humidity and 20 degrees C.
1808594|NCT00642018|Drug|docetaxel|Docetaxel 75 mg/m2 intravenously on day one of every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
1808595|NCT00642018|Drug|LY2181308 sodium|LY2181308 administered weekly plus docetaxel 75 mg/m2 intravenously administered every 21 days. Patients may receive up to 10 cycles of study therapy or until progressive disease. Additional cycles may be approved by sponsor as long as the patient is benefitting from therapy.
1808596|NCT00642018|Drug|Prednisone|Prednisone 5 mg given orally twice daily continuously while receiving docetaxel therapy
1808597|NCT00642031|Drug|Triciribine|15 mg/m^2 IV Weekly Over 1 Hour On Days 1, 8, and 15.
1808598|NCT00642044|Procedure|Corneal Collagen Crosslinking|UV light and Riboflavin eyedrops every 5 minutes for 30 minutes.
1808599|NCT00642057|Drug|tetrabenazine|25 mg titrated to optimal dose per patient
1808646|NCT00642382|Device|Agilus|Hyaluronic acid (Agilus)given by an intra-articular injection into the ankle for a total of 3 injections for 3 consecutive weeks.
1808751|NCT00649558|Drug|Actos® Tablets 45 mg|45mg, single dose fasting
1808600|NCT00642083|Device|Viabahn stent-graft|The viabahn stent-graft is a combined ePTFE-Nitinol self-expanding stent-graft preloaded on a catheter-based delivery system. It was originally designed for improving blood flow in patients with symptomatic peripheral arterial disease in superficial femoral artery lesions with reference vessel diameters ranging from 4.8 to 7.5 mm. This device is also increasingly used for the exclusion of popliteal aneurysms. Its flexibility might make the device ideal for the treatment of recurrent outflow stenosis in AV loop-fistula.
1808601|NCT00642096|Drug|Metoprolol Succinate|
1808602|NCT00642096|Drug|Hydrochlorothiazide|
1808603|NCT00642109|Procedure|midurethral sling procedure|quality of life, voiding dysfunction
1808604|NCT00642122|Drug|Budesonide|0.5mg once daily
1808605|NCT00642122|Drug|Budesonide|1mg once daily
1808606|NCT00642122|Drug|Budesonide|1mg twice daily
1808607|NCT00642122|Drug|Budesonide|2mg once daily
1808608|NCT00642122|Drug|Budesonide|4.00mcg twice daily
1808609|NCT00642135|Drug|Mydriasert®|Premature newborns and neonates treated using ophthalmologic insert Mydriasert®
1808610|NCT00642135|Drug|phenylephrine and tropicamide eyedrops|Premature newborns and neonates treated using reference treatment (association of Phenylephrine and tropicamide eyedrops)
1808614|NCT00642161|Drug|budesonide|
1808615|NCT00642174|Drug|prasugrel|Oral prasugrel 60-mg loading dose, followed by 6-9 days of oral prasugrel 10-mg/day tablet maintenance dose.
1808616|NCT00642174|Drug|Clopidogrel|Oral clopidogrel 600-mg loading dose, followed by 6-9 days of oral clopidogrel 150-mg/day tablet maintenance dose.
1808617|NCT00642187|Drug|budesonide|
1808618|NCT00642187|Drug|Placebo|
1808619|NCT00642200|Procedure|Lichtenstein hernioplasty|
1808620|NCT00642200|Procedure|Laparoscopic TEP|
1808621|NCT00642226|Procedure|Grid Laser|ETDRS Grid Laser
1808622|NCT00642226|Procedure|Vitrectomy and 20 mg triamcinolone|Pars plana vitrectomy is followed by an injection of 20 mg purified triamcinolone acetate
1808623|NCT00642239|Drug|placebo|placebo in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
1808624|NCT00642239|Drug|Sodium Glycididazole|Sodium Glycididazole 700mg/m2 in 100 mL 0.9% NaCl intravenous drip in 30 minutes,then begin radiotherapy in 60 minutes.duration of treatment is 6 weeks.
1808625|NCT00642252|Drug|Fluoride|Over-the-counter level of fluoride (226 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
1808626|NCT00642252|Drug|Fluoride|Over-the-counter level of fluoride (226 ppm) plus calcium (30 ppm) in a fluoride mouthrinse; FDA considers fluoride in a rinse formulation as a 'drug'; dosage is 10 mL per treatment.
1808627|NCT00642265|Procedure|osteosynthesis|operative treatment
1808628|NCT00642265|Other|sling|conservative treatment
1808629|NCT00642278|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, 200 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks or one 300 mg over-encapsulated tablet orally twice daily for 12 weeks.
1808630|NCT00642278|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
1808631|NCT00642278|Drug|Placebo|One matching placebo capsule orally (by mouth) once or twice daily for 12 weeks.
1808632|NCT00642291|Drug|Emtricitabine|emtricitabine (6mg/kg QD; max 200 mg QD) plus stavudine 1 mg/kg BID (if <30kg)plus lopinavir/ritonavir (12/3 mg/kg BID if >=7 to <15kg; 10/2.5 mg/kg BID if >=15 to <=40 kg)
1808633|NCT00642291|Drug|Emtricitabine|emtricitabine (6 mg/kg QD, up to 200 mg QD capsule formulation or up to 240 mg QD using the oral solution) plus didanosine (240 mg/m2 up to 400 mg QD) plus efavirenz (up to 600 mg QD capsule formulation or up to 720 mg QD using the oral solution).
1808634|NCT00642304|Drug|methoxy polyethylene glycol-epoetin beta [C.E.R.A.]|Methoxy polyethylene glycol-epoetin beta is administered SC every four week up to Week 20.The starting dose is 120, 200 or 300 mcg based on the dose of darbepoetin alfa or epoetin beta participants shall be receiving in the week preceding the study start. Further dose adjustment during the study depending on the hemoglobin (Hb) values.
1808635|NCT00642317|Behavioral|Questionnaire|Questionnaire about tobacco and alcohol use, acculturation, and other related topics.
1808636|NCT00642330|Drug|oral ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
1808637|NCT00642330|Drug|intravenous ibuprofen|one (10 mg / kg), two (10 mg / kg followed 24 hours after by 5 mg /kg) or three (10 mg / kg followed at 24-hour intervals by two doses of 5 mg /kg each) doses of oral ibuprofen starting on the third day of life.the number of doses is depending on echocardiographic findings concerning ductal closure.
1808638|NCT00642343|Behavioral|Evaluation of motor proficiency skills.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
1808639|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
1808640|NCT00642343|Behavioral|Evaluation of motor proficiency|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
1808641|NCT00642343|Behavioral|Evaluation of motor proficiency.|The balance subtest of the Bruininks-Oseretsky Test 2nd Ed. will be administered and scored.
1808642|NCT00642356|Drug|Carbidopa/levodopa/entacapone|Carbidopa/levodopa/entacapone 25/100/200 mg tablets plus placebo immediate release carbidopa/levodopa capsules, administered orally for 8 weeks. Total daily dosage and frequency of dosing for each patient was determined by the investigator and stabilized upon entry into the study.
1808643|NCT00642356|Drug|Immediate release carbidopa/levodopa|Immediate release carbidopa/levodopa 25/100 mg capsules plus placebo carbidopa/levodopa/entacapone tablets, administered orally for 8 weeks. The maximum daily dose is 800 mg. Total daily dosage and frequency of dosing for each patient was determined by the investigator.
1808644|NCT00642369|Drug|quetiapine fumarate|600-750mg/day
1808645|NCT00642369|Drug|haloperidol|6-40mg/day
1808694|NCT00648388|Drug|Cilostazol Tablets 100 mg|100mg, single dose fasting
1808647|NCT00642382|Device|Normal saline|Normal Saline given by an intra-operative injection into the ankle for a total of 3 injections for 3 consecutive weeks.
1808648|NCT00642395|Drug|Bortezomib|bortezomib-Melphalan
1808649|NCT00642408|Dietary Supplement|Multiple micronutrient supplements (MMN)|Iron and folic acid: iron 60 mg and folic acid 400µg
1808650|NCT00642408|Dietary Supplement|IFA|Iron and folic acid (IFA)(iron 60 mg and folic acid 400µg).
1808651|NCT00642421|Drug|C2L-OCT-01 PR, 10 or 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (35 days) and V3 (70 days). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
1808652|NCT00642421|Drug|C2L-OCT-01 PR, 20 mg|The first three injections of study medication will be given at V1 (Day 1), V2 (Day 35) and V3 (Day 70). Dose titration and/or injection interval adjustment will be allowed during the Treatment Period should any patients have a mean GH concentration below 1.0 ng/mL or above 2.5 ng/mL. Dose titration (10, 20 or 30 mg) and/or injection interval adjustment (4, 5 or 6 weeks) will be allowed at V3, V6 and V9 based on clinical symptoms and the mean GH concentration determined at V2, V5 and V8.
1808655|NCT00642447|Drug|helium:oxygen mixture|
1808656|NCT00642460|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (patients>=30kg) or 12mg/kg (patients <30kg) iv every 2 weeks. In Part III, administration frequency may be reduced to every 3 and every 4 weeks, respectively, according to an optional alternative dosing schedule.
1808657|NCT00642460|Drug|Placebo|iv every 2 weeks for 12 weeks
1808658|NCT00642460|Drug|Non-steroidal anti-inflammatory drugs (NSAIDs)|as prescribed
1808659|NCT00642460|Drug|methotrexate|as prescribed
1808660|NCT00642460|Drug|corticosteroids|orally, as prescribed
1808661|NCT00648180|Drug|Doxycycline Monohydrate Tablets 100 mg|100mg, single dose fed
1808662|NCT00648180|Drug|Adoxa Tablets 100 mg|100mg, single dose fed
1808663|NCT00648193|Drug|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fasting
1808664|NCT00648193|Drug|Paxil® 40 mg Table|40mg, single dose fasting
1808665|NCT00648219|Drug|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fed
1808666|NCT00648219|Drug|Benicar® Tablets 40 mg|40mg, single dose fed
1808667|NCT00648232|Behavioral|Voluntary brief HIV counseling and testing|Participants will receive 10 to 15 minutes of pretest counseling on the importance of HIV testing and on available services for people infected with HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
1808668|NCT00648232|Behavioral|Voluntary longer, more detailed HIV counseling and testing|Participants will receive 45 to 60 minutes of pretest counseling on general HIV/AIDS information and testing for HIV. After pretest counseling, participants will undergo a blood draw for HIV testing. Participants will receive test results and additional counseling 1 hour after the blood sample is drawn.
1808669|NCT00648232|Behavioral|Enhanced linkage to care|Participants will be provided with more detailed counseling on how to access HIV services, will be introduced to a specific HIV clinic, and will be given a list of other HIV services available in the area. After leaving the hospital, participants will receive reminder telephone calls 1 week before their scheduled visits at the HIV clinics.
1808670|NCT00648232|Behavioral|Routine referral to care|Participants will be provided with information on the importance of receiving HIV care and will be given a list of available HIV area services.
1808671|NCT00648245|Drug|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered once per day for 21 days by nebulizer
1808672|NCT00648245|Drug|BIO-11006 Inhalation Solution|150 mg of BIO-11006 administered once per day for 21 days by nebulizer
1808673|NCT00648245|Drug|BIO-11006 Inhalation Solution|75 mg of BIO-11006 administered twice per day for 21 days by nebulizer
1808674|NCT00648245|Drug|Placebo|Placebo given once daily for 21 days by nebulizer
1808675|NCT00648245|Drug|BIO-11006|125 mg BIO-11006 given twice per day for 21 days by nebulizer
1808676|NCT00648258|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
1808677|NCT00648258|Drug|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
1808678|NCT00648271|Drug|Metoprolol Tartrate Tablets 25 mg|2x50mg, single dose fed
1808679|NCT00648271|Drug|Lopressor® Tablets 50 mg|1x50mg, single dose fed
1808680|NCT00648297|Drug|Nadolol/Bendroflumethiazide Tablets 80 mg/5 mg|80/5mg, single dose fed
1808681|NCT00648297|Drug|Corzide® Tablets 80 mg/5 mg|80/5mg, single dose fed
1808682|NCT00648310|Drug|Tolterodine 4 mg|
1808683|NCT00648310|Drug|arm 2: Tolterodine 4 mg + local oestrogens once daily for 12 weeks|
1808684|NCT00648323|Drug|Doxazosin mysylate GITS|Subjects initiated on 4 mg doxazosin GITS once daily at Visit 1 for four weeks. At Visit 2 (Week 4) increased to 8 mg Doxazosin GITS if efficacy response criteria not met.
1808685|NCT00648336|Drug|Mercaptopurine 50 mg|50mg, single dose fasting
1808686|NCT00648336|Drug|Purinethol® Tablets 50 mg|50mg, single dose fasting
1808687|NCT00648349|Drug|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fasting
1808688|NCT00648349|Drug|Aciphex® Delayed-Release Tablets 20 mg|20mg, single dose fasting
1808689|NCT00648362|Drug|Glimepiride Tablets 1 mg|1mg, single dose fasting
1808690|NCT00648362|Drug|Amaryl® Tablets 1 mg|1mg, single dose fasting
1808691|NCT00648375|Drug|Propanolol|Participants will take a 40-mg dose of propranolol immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
1808692|NCT00648375|Drug|Placebo|Participants will take a single dose of placebo immediately after they experience a traumatic memory associated with strong hyperarousal symptoms. Participants may take up to two doses a day, if the doses are separated by at least 6 hours.
1808693|NCT00648375|Behavioral|Cognitive therapy workbook|Participants will also receive a cognitive behavioral therapy-based workbook in which they will track symptoms and efforts to use cognitive techniques to relieve symptoms each day.
1808696|NCT00648401|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose fed
1808697|NCT00648401|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose fed
1808698|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow, while samples collected
1808699|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
1808700|NCT00648414|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
1808701|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 1|blood pressure cuff inflated directly over the transdermal system to 60-100 mmHg for 1 minute to block venous blood flow
1808702|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 2|tourniquet applied just below patch application site and above blood draw site, while samples collected
1808703|NCT00648414|Drug|Duragesic 25 mcg/h + Clinical Procedure 3|tourniquet applied just above patch application site, while samples collected
1808704|NCT00648427|Drug|Paroxetine Hydrochloride Controlled-Release Tablets 25 mg|25mg, single dose fasting
1808705|NCT00648427|Drug|Paxil CR™ Tablets 25 mg|25mg, single dose fasting
1808706|NCT00648440|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fed
1808707|NCT00648440|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fed
1808708|NCT00648453|Drug|Clopidogrel (Plavix)|
1808709|NCT00648466|Drug|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fasting
1808710|NCT00648466|Drug|Imitrex® Tablets 100 mg|100mg, single dose fasting
1808711|NCT00648479|Device|The Guiding Star|
1808712|NCT00648479|Device|fluoroscopy (OEC 9800 - General Electric)|
1808713|NCT00648492|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
1808714|NCT00648492|Drug|Glucophage® XR 500 mg|500mg, single dose fed
1808715|NCT00648505|Drug|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fed
1808716|NCT00648505|Drug|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fed
1808717|NCT00649337|Procedure|Comparison of Automated Whole Breast Ultrasound Screening with Blinded Screening Mammography|"AWBU is a computer-based system for performing and recording ultrasound scans of the whole breast. The transducer of any suitable high-resolution compound ultrasound equipment is attached to a mechanical arm guided by computer, and images are acquired in longitudinal rows, overlapping to assure complete coverage. The mechanical arm controls transducer speed and position, with a technician maintaining appropriate contact pressure and orientation vertical to the skin. Approximately 150-300 images per row are immediately displayed on the AWBU monitor, then permanently stored.
The AWBU software creates a continuous ciné loop of the images, creating the appearance of real-time scanning. With spatial registration, any point on an image can be identified as a distance from the nipple in a specific radius. Image review is optimized by playback on a high-resolution monitor to allow compressed image size, 3-D reconstruction, and adjustment of contrast, brightness and review speed."
1808718|NCT00649350|Drug|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fed
1808719|NCT00649350|Drug|Glucophage XR 750 mg|750mg, single dose fed
1808720|NCT00649363|Drug|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fasting
1808721|NCT00649363|Drug|Zofran ODT® Tablets 8 mg|8mg, single dose fasting
1808722|NCT00649376|Drug|Fexofenadine Tablets 180 mg|180mg, single dose fasting
1808723|NCT00649376|Drug|Allegra® Tablets 180 mg|180mg, single dose fasting
1808724|NCT00649389|Drug|Olmesartan medoxomil|40mg olmesartan medoxomil
1808725|NCT00649389|Drug|Amlodipine|Amlodipine 10mg
1808726|NCT00649389|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg
1808727|NCT00649402|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/120mg, single dose fed
1808728|NCT00649402|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fed
1808729|NCT00649415|Drug|piroxicam|piroxicam 40 mg capsule QD for up to the first 3 days of the menstrual cycle
1808730|NCT00649415|Drug|valdecoxib|valdecoxib 40 mg capsule twice a day (BID), taken as required, on the first day of treatment in the menstrual cycle followed by oral valdecoxib 40 mg once a day (QD) for up to the first 3 days of the menstural cycle
1808731|NCT00649428|Biological|Autologous Human Fibroblast (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.
Three injection treatments administered 5 ± 1 weeks apart on each side of the face."
1808732|NCT00649428|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.
Three injection visits administered 5 ± 1 weeks apart on each side of the face."
1808733|NCT00649441|Drug|Quinapril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
1808734|NCT00649441|Drug|Accuretic™ Tablets 20 mg/25 mg|20/25mg, single dose fasting
1808735|NCT00649454|Drug|Glipizide and Metformin HCl Tablets 5 mg/500 mg|5/500mg, single dose fasting
1808736|NCT00649454|Drug|Metaglip® Tablets 5 mg/500 mg|5/500mg, single dose fasting
1808737|NCT00649467|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose applesauce
1808738|NCT00649467|Drug|Topamax® Sprinkle Capsules 25 mg|25mg, single dose applesauce
1808739|NCT00649480|Drug|BALSALAZIDE DISODIUM CAPSULES, 750 MG|3x750mg, single dose fed
1808740|NCT00649480|Drug|COLAZAL® Capsules 750 mg|3x750mg, single dose fed
1808741|NCT00649493|Drug|Rabeprazole Sodium Tablets 20 mg|20mg, single dose fed
1808742|NCT00649493|Drug|Aciphex® Tablets 20 mg|20mg, single dose fed
1808743|NCT00649506|Drug|Nitrofurantoin Macrocrystals 100 mg Capsules|100mg, single dose fed
1808744|NCT00649506|Drug|Macrodantin® 100 mg Capsules|100mg, single dose fed
1808745|NCT00649519|Drug|Amlodipine and Benazepril HCl Capsules 10 mg/20 mg|10/20mg, single dose fasting
1808746|NCT00649519|Drug|Lotrel® Capsules 10 mg/20 mg|10/20mg, single dose fasting
1808747|NCT00649532|Drug|Ondansetron Tablets 24 mg|24mg, single dose fasting
1808748|NCT00649532|Drug|Zofran® Tablets 24 mg|24mg, single dose fasting
1808749|NCT00649545|Biological|adalimumab|40 mg every other week
1808750|NCT00649558|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fasting
1808752|NCT00649571|Drug|Doxycycline Monohydrate Tablets (100 mg|100mg, single dose fasting
1808753|NCT00649571|Drug|Adoxa Tablets 100 mg|100mg, single dose fasting
1808754|NCT00649584|Drug|SGN-35|IV; 0.4 up to 1.8 mg/kg weekly 3 out of 4 weeks; minimum of two 28-day cycles
1808755|NCT00649584|Drug|gemcitabine|IV; 1000 mg/m2 weekly 3 out of 4 weeks
1808756|NCT00649597|Drug|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fasting
1808757|NCT00649597|Drug|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fasting
1808758|NCT00649610|Drug|valdecoxib|valdecoxib 40 mg QD for 7 days with a second dose of 40 mg the first day
1808759|NCT00649610|Drug|diclofenac|diclofenac 75 mg twice daily (BID) for 7 days
1808760|NCT00649623|Drug|Olmesartan Medoxomil Tablets 40 mg|40mg, single dose fasting
1808761|NCT00649623|Drug|Benicar® Tablets 40 mg|40mg, single dose fasting
1808762|NCT00649636|Drug|Fluoxetine Capsules 40 mg|40mg, single dose fasting
1808763|NCT00649636|Drug|Prozac Pulvules 40 mg|40mg, single dose fasting
1808764|NCT00649649|Drug|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fed
1808765|NCT00649649|Drug|Accupril® Tablets 40 mg|40mg, single dose fed
1808766|NCT00649662|Drug|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fasting
1808767|NCT00649662|Drug|Cipro® XR Tablets 1000 mg|1000mg, single dose fasting
1808768|NCT00649675|Drug|Meloxicam Tablets 15 mg|15mg, single dose fed
1808769|NCT00649675|Drug|Mobic® Tablets 15 mg|15mg, single dose fed
1808770|NCT00649688|Drug|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fasting
1808771|NCT00649688|Drug|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fasting
1957760|NCT02197130|Drug|PF-02545920|5 mg twice a day (BID) for 26 weeks. Each 5 mg dose will be taken as 4 tablets: one tablet of 5 mg and 3 tablets of matching placebo. The 5mg dose will not be titrated. Study drug will be provided in weekly blister cards.
1957761|NCT02197130|Other|Placebo|Matching Placebo twice a day (BID) for 26 weeks. Each placebo dose will be taken as 4 tablets of matching Placebo. The placebo dose will not be titrated. Matching placebo will be provided in weekly blister cards.
1808776|NCT00649714|Drug|Zonisamide Capsules 100 mg|100mg, single dose fed
1808777|NCT00649714|Drug|Zonegran® Capsules 100 mg|100mg, single dose fed
1808778|NCT00649727|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
1808779|NCT00649727|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
1808780|NCT00649740|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fasting
1808781|NCT00649740|Drug|Topamax® Sprinkle Capsule 25 mg|25mg, single dose fasting
1808782|NCT00649753|Procedure|Category II Pelvic Blocking|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction.
1808783|NCT00649753|Procedure|Category II Pelvic Blocking and Cranial|Supine Orthopedic Blocking consists of placing padded wedges underneath the Ilium and greater trochanter to correct pelvic torsion and associated sacroiliac dysfunction. During pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
1808784|NCT00649753|Procedure|Cranial Only|Without pelvic blocking a cranial procedure is performed using a zygomae release and sphenobasilar release. These cranial procedures are manual therapy procedures using light pressure from hand and/or finger contacts.
1808787|NCT00649779|Drug|albuterol sulfate extended-release 8 mg tablets|8mg, single dose fasting
1808788|NCT00649779|Drug|VoSpire™ ER 8 mg tablets|8mg, single dose fasting
1808789|NCT00649792|Drug|Fampridine-SR|Tablets, 10 mg, BID (twice daily)
1808790|NCT00649805|Drug|Verapamil Hydrochloride Extended-Release Capsules, 300 mg|300mg, single dose applesauce
1808791|NCT00649805|Drug|Verelan® PM Extended-Release Capsules, 300 mg|300mg, single dose applesauce
1808792|NCT00649818|Drug|Lorazepam Tablets 2 mg|2mg, single dose fasting
1808793|NCT00649818|Drug|Ativan Tablets 2 mg|2mg, single dose fasting
1808794|NCT00649831|Drug|Amoxicillin/clavulinic acid|amoxicillin/clavulinic acid 500 mg/62.5 mg tablet; take 2 tablets by mouth twice daily (BID) for 10 days
1808795|NCT00649831|Drug|Azithromycin|Azithromycin 250 mg tablet; take 2 tablets by mouth on the first day, then 1 tablet by mouth from Days 2 to 5
1808796|NCT00649844|Drug|Clozapine|Clozapine 25 or 100 mg tablets. Patients were initially titrated over the first 10 days to 300 mg/day and remained at this dose for 1 week. Thereafter, the dose could be varied between 250 and 600 mg/day based on response and tolerability for a total treatment duration of 18 weeks
1808797|NCT00649844|Drug|Ziprasidone|Ziprasidone 40, 60, or 80 mg capsules. Patients were initially titrated over the first 3 days to 80 mg/day, which could subsequently be increased to between 80 and 160 mg/day based on response and tolerability for a total treatment duration of 18 weeks
1808798|NCT00649857|Drug|Cetirizine HCl Tablets 10 mg|10mg, single dose fed
1808799|NCT00649857|Drug|Zyrtec® 10 mg|10mg, single dose fed
1808800|NCT00649870|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fed
1808801|NCT00649870|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fed
1808802|NCT00649883|Biological|Influenza Trivalent Inactivated vaccines Novartis|Children 6 to <36 months of age will receive two 0.25 mL doses, and children 36 to <60 months of age will receive two 0.5 mL doses of investigational influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
1808803|NCT00649883|Biological|Influenza Trivalent Inactivated vaccines|Children 6 to <36 months of age will receive two 0.25 mL doses, and children 36 to <60 months of age will receive two 0.5 mL doses of active control influenza vaccine, administered four weeks apart intramuscularly (IM) in the deltoid muscle preferably of the non-dominant arm.
1808804|NCT00649896|Drug|Mylan Estradiol Transdermal System 0.025 mg/day|
1808805|NCT00649896|Drug|Climara® Transdermal System 0.025 mg/day|
1808806|NCT00649922|Biological|adalimumab|80 mg adalimumab (2 injections) day 1; 40 mg (1 injection) Day 15 and Day 29
1808807|NCT00649922|Biological|placebo|2 injections Day 1, 1 injection Days 15 and 29
1808808|NCT00649922|Biological|adalimumab|40 mg adalimumab every other week
1808809|NCT00649935|Drug|Azithromycin Tablets 600 mg|600mg, single dose fed
1808810|NCT00649935|Drug|Zithromax® Tablets 600 mg|600mg, single dose fed
1808811|NCT00649948|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fed
1808812|NCT00649948|Drug|Glucophage XR 500 mg|500mg, single dose fed
1808813|NCT00649961|Drug|Melatonin injection|"A single intravenous infusion of melatonin will be given to each infant over 6 hours so that successive groups will receive increasing doses until the correct dose for age is found.
Based on the pharmacokinetics and clearance of melatonin in adults an approximate dose has been calculated. The starting dose of melatonin will be 0.1 microgram/kg/hr to be given over 6 hours intravenously. The range of expected dose is 0.1-0.5 microgram/kg/hr."
1808814|NCT00649974|Drug|Valacyclovir Hydrochloride Tablets 1000 mg|1000mg, single dose fasting
1808815|NCT00649974|Drug|Valtrex® Tablets 1000 mg|1000mg, single dose fasting
1808816|NCT00649987|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
1808817|NCT00649987|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
1808818|NCT00650000|Drug|Modafinil Tablets 200 mg|200mg, single dose fasting
1808819|NCT00650000|Drug|Provigil® Tablets 200 mg|200mg, single dose fasting
1808820|NCT00650013|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fed
1808821|NCT00650013|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fed
1808822|NCT00650026|Biological|adalimumab|40 mg adalimumab every other week
1808823|NCT00650039|Drug|placebo|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, placebo BID by mouth on Days 2 to 5.
1808824|NCT00650039|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg once daily (QD) by mouth on Days 2 to 5.
1808825|NCT00650039|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) by mouth followed by valdecoxib 20 mg 1 to 12 hours after the first dose or 12 hours after the first dose, but no later than midnight on Day 1; then, valdecoxib 20 mg twice daily (BID) by mouth on Days 2 to 5.
1808826|NCT00650052|Drug|Zonisamide Capsules 100 mg|100mg, single dose fasting
1808827|NCT00650052|Drug|Zonegran® Capsules 100 mg|100mg, single dose fasting
1808828|NCT00650065|Drug|Cetirizine HCl Tablets 10 mg|10mg, single dose fasting
1808829|NCT00650065|Drug|Zyrtec® Tablets 10 mg|10mg, single dose fasting
1808830|NCT00650078|Drug|MR prednisone|1 x 5 mg daily
1808831|NCT00650078|Drug|Placebo|1x daily
1808832|NCT00650091|Drug|N-acetylcysteine (NAC)|Participants will receive 600 mg of NAC three times a day.
1808833|NCT00650091|Drug|Placebo|Participants will receive placebo each day.
1808834|NCT00650104|Drug|Ropinirole XL (formerly CR)|Active Ropinirole CR tablets of 2.0mg, 4.0mg, 8.0mg where subjects can tritrate to an stable optimum dose level of either 2.0mg, 4.0mg, 6.0mg, 8.0mg, 12mg, 16mg, 20mg, or 24mg per day.
1808835|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Scotch Duct Tape (3M)|single application
1808836|NCT00650117|Drug|Duragesic 25 mcg/h + Scotch Duct Tape (3M)|single application
1808837|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
1808838|NCT00650117|Drug|Duragesic 25 mcg/h + Blenderm Clear Plastic Surgical Tape (3M)|single application
1808839|NCT00650117|Drug|Mylan Fentanyl Transdermal System 25 mcg/h + Microfoam Tape (3M)|single application
1808840|NCT00650117|Drug|Duragesic 25 mcg/h + Microfoam Tape (3M)|single application
1808841|NCT00650143|Drug|Lenograstim (GRANOCYTE)=GCSF|10 µg/kg/d s.c. for 5 days divided in two dosages per day
1808842|NCT00650143|Drug|Sitagliptin (Januvia)|100 mg p.o. per day for 28 days
1808843|NCT00650143|Drug|Sodium Chloride (NaCl) 0.9 %|applied s.c. twice a day for 5 days
1808844|NCT00650143|Drug|Gelatin|One capsule p.o. per day for 28 days
1808845|NCT00650156|Biological|adalimumab|40 mg single sc dose
1808846|NCT00650156|Biological|adalimumab|80 mg single sc dose
1808847|NCT00650169|Drug|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fed
1808848|NCT00650169|Drug|Plavix® Tablets 75 mg|75mg, single dose fed
1808849|NCT00650182|Drug|fentanyl; naltrexone|
1808850|NCT00650195|Drug|Metolazone Tablets 10 mg|10mg, single dose fasting
1808851|NCT00650195|Drug|Zaroloxyn® Tablets 10 mg|10mg, single dose fasting
1808852|NCT00650208|Drug|Lamotrigine Tablets 25 mg|2x25mg, single dose fasting
1808853|NCT00650208|Drug|Lamictal® Tablets 25 mg|2x25mg, single dose fasting
1808854|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release oral tablet
1808855|NCT00650221|Drug|Pravastatin|Single-dose 80 mg immediate-release tablet
1808856|NCT00650234|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
1808857|NCT00650234|Drug|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
1808858|NCT00650247|Drug|Sumatriptan Succinate Tablets 100 mg|100mg, single dose fed
1808859|NCT00650247|Drug|Imitrex® Tablets 100 mg|100mg, single dose fed
1808860|NCT00650260|Device|Dynatherm Medical vitalHEAT Temperature Management System vH2|The vH2 system consists of a Control Unit containing the heating system and the vacuum generation pump which connects via an umbilical containing the fluid and vacuum tubing to the Warming Sleeve. The Control Unit also contains the user interface and alarm management systems. The disposable Warming Sleeve consists of a manifold attached to the warming pads and a polyurethane pouch (Vacuum Sleeve) that are placed over the patient's hand and forearm and secured with tape. The Warming Sleeve manifold contains connectors for the fluid and vacuum tubing contained in the umbilical.
1808912|NCT00650598|Drug|diclofenac|diclofenac sodium delayed release tablets 75 mg by mouth twice daily (BID) for 6 days
1808861|NCT00650260|Device|Bair Hugger™ (Arizant Healthcare, Eden Prairie, MN)|The Bair Hugger system is the current standard of care at Tampa General Hospital. It consists of a Temperature Management Unit that contains the heating element, the air circulating motor and the temperature control mechanisms. This unit connects via a hose to the operating room blankets. The Bair Hugger technology relies on heated air convection. Warm air is circulated evenly through the air space in the specially designed blanket, warming the skin surface as well as any insulating blankets placed over the Bair Hugger blanket.
1808862|NCT00650273|Drug|Azithromycin Tablets 600 mg|600mg, single dose fasting
1808863|NCT00650273|Drug|Zithromax® Tablets 600 mg|600mg, single dose fasting
1808864|NCT00650286|Drug|Modafinil Tablets 200 mg|200mg, single dose fed
1808865|NCT00650286|Drug|Provigil® Tablets 200 mg|200mg, single dose fed
1808866|NCT00650299|Drug|Alprazolam Extended-release Tablets 3 mg|3mg, single dose fed
1808867|NCT00650299|Drug|Xanax XR® Tablets 3 mg|3mg, single dose fed
1808868|NCT00650312|Drug|Metformin Hydrochloride ER Tablets 500 mg|500mg, single dose fasting
1808869|NCT00650312|Drug|Glucophage® XR Tablets 500 mg|500mg, single dose fasting
1808870|NCT00650325|Drug|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fasting
1808871|NCT00650325|Drug|Zoloft® Tablets 100 mg|100mg, single dose fasting
1808877|NCT00650351|Drug|Ciprofloxacin Extended-Release Tablets 1000 mg|1000mg, single dose fed
1808878|NCT00650351|Drug|Cipro® XR Tablets 1000 mg|1000mg, single dose fed
1808879|NCT00650364|Drug|Midodrine HCl Tablets 5 mg|5mg, single dose fasting
1808880|NCT00650364|Drug|ProAmatine® Tablets 5 mg|5mg, single dose fasting
1808881|NCT00650377|Drug|Finasteride Tablets 5 mg|5mg, single dose fed
1808882|NCT00650377|Drug|Proscar® Tablets 5 mg|5mg, single dose fed
1808883|NCT00650390|Biological|adalimumab|40 mg adalimumab every other week
1808884|NCT00650403|Drug|Paroxetine hydrochloride 40 mg tablet|40mg, single dose fed
1808885|NCT00650403|Drug|Paxil® 40 mg Tablet|40mg, single dose fed
1808886|NCT00650416|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fasting
1808887|NCT00650416|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fasting
1808888|NCT00650429|Drug|Ziprasidone|IM ziprasidone at an initial dose of 10 or 20 mg for the first 3 days; additional doses could be administered according to clinical need, with the maximum total daily IM dose of 40 mg. On Day 4, IM treatment was switched to oral (PO) treatment at an initial dose of 40 mg twice daily for the first 2 days; doses could be subsequently adjusted within the range of 40 to 80 mg twice daily. Total treatment duration was 6 weeks.
1808889|NCT00650442|Drug|Estradiol Transdermal System Placebo - Alternate Adhesive|single application
1808890|NCT00650442|Drug|Estradiol Transdermal System Placebo - Current Adhesive|single application
1808891|NCT00650455|Drug|valdecoxib|valdecoxib 10 mg tablet once daily for 12 weeks
1808892|NCT00650455|Drug|naproxen|naproxen 500 mg capsule twice daily for 12 weeks
1808893|NCT00650455|Drug|placebo|placebo tablet every morning and capsule every evening for 12 weeks
1808894|NCT00650468|Drug|tacrolimus|Oral
1808895|NCT00650468|Drug|CellCept|IV or Oral
1808896|NCT00650468|Drug|steroids (methylprednisone or prednisone)|IV or Oral
1808897|NCT00650481|Drug|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fasting
1808898|NCT00650481|Drug|Ditropan XL® Tablets 5 mg|4x5mg, single dose fasting
1808899|NCT00650494|Drug|Valacyclovir Hydrochloride Tablets 1000mg|1000mg, single dose fed
1808900|NCT00650494|Drug|Valtrex® 1000 mg|1000mg, single dose fed
1808901|NCT00650507|Procedure|Remote ischemic preconditioning (RIPC)|The RIPC stimulus will be delivered in the OR prep room after the induction of anesthesia (while the anesthesiologist and staff are inserting vascular cannulae and preparing the patient for surgery). Whenever possible, the left lower limb will be selected for delivery of the stimulus. An appropriate sized cuff will be selected and connected to a hand aneroid sphygmomanometer. A second cuff and hand aneroid sphygmomanometer will be placed beside the one connected to the study subject. The cuff on the limb will be inflated and deflated to provide a total of four cycles of limb ischemia and reperfusion.
1808902|NCT00650507|Procedure|SHAM|For this group, the procedure will be identical for that described for the RIPC stimulus, with the exception that the blood pressure cuff placed on the subject will not be inflated, but the second cuff, that has been placed beside, will be inflated.
1808903|NCT00650520|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
1808904|NCT00650520|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|4x2.5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
1808905|NCT00650533|Drug|Glimepiride Tablets 1 mg|1mg, single dose fed
1808906|NCT00650533|Drug|Amaryl® Tablets 1 mg|1mg, single dose fed
1808907|NCT00650546|Drug|Exenatide|5 mcg twice a day titrated to 10 mcg twice a day
1808908|NCT00650559|Procedure|Chest wall enlargement|Widening sternotomy
1808909|NCT00650572|Drug|ARRY-380, HER2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
1808910|NCT00650585|Behavioral|Project ALERT|Project ALERT (Adolescent Learning Experiences in Resistance Training) is a drug prevention curriculum designed for middle-school students (11 to 14 years old). The 11 lessons in the first year and 3 booster lessons in the second year focus on alcohol, tobacco, marijuana, and inhalants - the substances that adolescents are most likely to use. Project ALERT uses participatory activities and videos to help motivate youth to avoid drug use, to teach youth skills and strategies to resist peer pressures to use drugs, and to establish social norms against drug-use. More information about Project ALERT may be found at http://www.projectalert.best.org/.
1808911|NCT00650598|Drug|valdecoxib|valdecoxib 40 mg (two 20-mg tablets) loading dose by mouth on Day 1 followed by 20 mg twice daily (BID) on Days 2-6
1808913|NCT00650611|Drug|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 20 mg twice daily, which was titrated up in 20 mg twice daily increments to a maximum dose of 80 mg twice daily by Day 10.
Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
1808914|NCT00650611|Drug|Ziprasidone|"Period 1: Initial dose of oral ziprasidone suspension 10 mg twice daily, which was titrated up in 10 mg twice daily increments to a maximum dose of 40 mg twice daily by Day 10.
Period 2: patients could switch to oral capsules or remain on oral suspension; doses were flexibly titrated to between 10 and 80 mg twice daily based on the individual needs of the patient as determined by the investigator; concomitant antidepressants and/or mood stabilizers were allowed during Period 2 but not Period 1."
1808915|NCT00650624|Drug|valdecoxib|valdecoxib 5 mg tablet by mouth once daily in the morning for 6 weeks
1808916|NCT00650624|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily in the morning for 6 weeks
1808917|NCT00650624|Drug|valdecoxib|valdecoxib 20 mg tablet by mouth once daily in the morning for 6 weeks
1808918|NCT00650624|Drug|placebo|placebo tablet by mouth once daily in the morning for 6 weeks
1808919|NCT00650637|Drug|Calcium Carbonate|Calcium carbonate 500 mg oral tablet twice a day; given in combination with the following antiretroviral combination: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day); If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly; All study drugs continued through to Week 12
1808920|NCT00650637|Drug|nelfinavir|1250 mg twice a day
1808921|NCT00650637|Drug|lamivudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
1808922|NCT00650637|Drug|loperamide|If diarrhea develops, loperamide 2 mg oral caplet 3 times weekly;
1808923|NCT00650637|Other|Calcium carbonate not administered|Prophylaxis with calcium carbonate not administered in this group; The following antiretroviral combination was administered: nelfinavir 1250 mg twice a day, and lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
1808924|NCT00650637|Drug|nelfinavir|nelfinavir 1250 mg twice a day
1808925|NCT00650637|Drug|lamivudine + zidovudine|lamivudine 150 mg/zidovudine 300 mg twice a day (or stavudine 40 mg twice a day plus lamivudine 150 mg twice a day);
1808926|NCT00650663|Drug|Ezetimibe + Simvastatin|oral tablets; ezetimibe 10 mg and simvastatin 20 mg once daily for 12 weeks
1808927|NCT00650663|Drug|Simvastatin|oral tablet; simvastatin 20 mg once daily for 12 weeks
1808928|NCT00650689|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
1808929|NCT00650689|Drug|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
1808930|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the low dose of Latanoprost-PPDS for 4 months or until loss of efficacy
1808931|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the medium dose of Latanoprost-PPDS for 4 months or until loss of efficacy
1808932|NCT00650702|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the high dose of Latanoprost-PPDS for 4 months or until loss of efficacy
1808933|NCT00650715|Device|Vibratory platform, PowerPlate®, Badhoevendorp, Netherlands|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. The Whole-body vibration intensity was kept constant at 30 Hz of frequency and 2 mm of amplitude.
1808934|NCT00650715|Device|Placebo Whole-body vibration exercise|Six exercises (static and dynamic tasks) while standing on a Whole-body vibration platform. The six exercises (30 seconds each) were repeated six times with a recovery of 3 minutes in between. All exercises were performed without the influence of a vibratory stimulus.
1808935|NCT00650728|Procedure|placing gastric tube|
1808936|NCT00650754|Dietary Supplement|Dehydroepiandrosterone|25 mg PO TID
1808937|NCT00650754|Other|Placebo|Placebo
1808938|NCT00650767|Drug|ARRY-438162, MEK inhibitor; oral|multiple dose, single schedule
1808939|NCT00650767|Drug|Placebo; oral|matching placebo
1808940|NCT00650793|Drug|Extended Release OROS® Paliperidone|
1808941|NCT00650806|Drug|Canagliflozin (JNJ-28431754)|One 50 mg, 100 mg, or 300 mg over-encapsulated tablet orally (by mouth) once daily for 12 weeks.
1808942|NCT00650806|Drug|Placebo|One matching placebo capsule orally once daily for 12 weeks.
1808943|NCT00650819|Drug|Ezetimibe + Simvastatin|ezetimibe 10 mg plus simvastatin 20 mg once daily for 8 weeks
1808944|NCT00650819|Drug|Simvastatin|simvastatin 20 mg plus ezetimibe placebo once daily for 8 weeks
1808945|NCT00650819|Drug|Ezetimibe|Ezetimibe 10 mg plus simvastatin placebo once daily for 8 weeks
1808946|NCT00650832|Drug|TMC114; darunavir; Prezista|
1808947|NCT00650845|Drug|Dotarem®-enhanced MRI|Single IV administration before MRI exam
1808948|NCT00650845|Other|non-enhanced MRI|non injected MRI
1808949|NCT00650858|Drug|tissue plasminogen activator, rt-PA (thrombolytic) (Cathflo)|0.3 mg and 1.0 mg of rt-PA (Cathflo) were administered every 12 hours (dose finding) and every 8 hours (dose frequency) via the intraventricular catheter to treat intraventricular hemorrhage.
1808952|NCT00650884|Device|Ankle Dorsiflexion Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn at night while sleeping (6-8 hours) and, this does not affect activities of daily living.
1808953|NCT00650897|Drug|Escitalopram|10-20 mg once daily
1808954|NCT00650910|Drug|lapatinib|1500 mg oral lapatinib starting Day 2 continuing through Day 9. Part 2 subjects received 1500mg daily through week 10.
1808955|NCT00650910|Drug|Digoxin|0.5mg on Days 1 and 9
1808956|NCT00650923|Drug|ziv-aflibercept|Given IV
1808957|NCT00650923|Procedure|radiation therapy|Undergo RT
1808958|NCT00650923|Drug|temozolomide|Given PO
1808959|NCT00650923|Procedure|pharmacological study|Correlative studies
1808960|NCT00650923|Procedure|laboratory biomarker analysis|Correlative studies
1808961|NCT00650936|Device|AMPLATZER Septal Occluder|AMPLATZER Septal Occluder
1808962|NCT00650949|Drug|CYT997|Escalating doses (100mg/m^2 to 150mg/m^2), 24-hour intravenous infusion on Day 2 of a 21-day cycle (Phase Ib component). Dose selected in Phase Ib component to be used for Phase II component.
1808963|NCT00650949|Drug|Carboplatin|Intravenous infusion over 1 hour at area under the concentration-time curve (AUC)=5 on Day 1 of a 21-day cycle
1808964|NCT00650962|Other|cardiopulmonary resuscitation|10 cycles of 30:2 cardiopulmonary resuscitation before rhythm analysis by AED
1808965|NCT00650962|Other|Rhythm analysis|Rhythm analysis as soon as AED is ready
1808966|NCT00650975|Device|Laser Thromboablation|Laser Thromboablation using the Spectranetics CVX-300® excimer laser system
1808967|NCT00650975|Device|PTCA (Direct Stenting)|Balloon predilatation or Direct Stenting using conventional techniques according to local standards and device specific instructions for use
1808968|NCT00650988|Procedure|Cryospray Ablation|Liquid nitrogen spray with a cryospray catheter through an upper endoscope that enables the direct visualization of mucosal freeze (cryoburn) of the mucosa treated which avoids the need for direct tissue contact. Frozen state is defined as mucosa appearing white. Cryofreeze is preformed in cycles of 10 second sprays with a minimal thaw of 60 seconds each spray. This cycle is repeated 4 times in each area of treatment.
1808969|NCT00651014|Drug|Ezetimibe|oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
1808970|NCT00651014|Drug|Placebo|oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
1808971|NCT00651027|Drug|PF-868554|200 mg, Child-Pugh Class A
1808972|NCT00651027|Drug|PF-868554|200 mg, Child-Pugh Class B
1808973|NCT00651027|Drug|PF-868554|200 mg, healthy volunteers
1808974|NCT00651040|Drug|Prednisone|Prednisone will be administered orally, initially at 1.0 mg/kg/day dosage and then tapered gradually equally in the two arms
1808975|NCT00651040|Drug|Methotrexate|MTX will be administered orally (in case of oral intolerance intramusculary (i.m.)), once weekly for 48 weeks. There will be a clinically oriented dose escalation starting from 10 up to 20-25 mg of MTX. Five to ten mg of folic acid will be given 24 hours after each methotrexate dose.
1808976|NCT00651053|Device|EUS|Sensitivity and specificity of EUS will be compared with PFT as reference standard.
1808977|NCT00651066|Drug|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 1|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg TPW 3 wks switch to 150 mg OD 4 wks);
1808978|NCT00651066|Drug|rifabutin in combination with lopinavir boosted by ritonavir - dosing schedule 2|3TC(300mg)/D4t(60mg)/LPV/r(800mg/200mg)+INH/PZA/EMT/Rifabutin(150 mg OD 3 wks switch to 150 mg TPW 4 wks);
1808979|NCT00651079|Drug|GSK1247303|
1808980|NCT00651092|Procedure|bilateral nasal inferior turbinectomy|the operation is performed endonasally under general or local anesthesia, the inferior turbinates are resected and removed
1808981|NCT00651092|Procedure|endoscopic submucosal resection of the inferior turbinates|surgery of the inferior turbinates- endonasally with endoscopic instruments and by performing submucosal resection of the nasal turbinates
1808982|NCT00651105|Drug|Vildagliptin|
1808983|NCT00651105|Drug|Placebo|
1808984|NCT00651118|Drug|Placebo|placebo
1808985|NCT00651118|Drug|azelastine Hcl|azelastine Hcl 548 mcg
1808986|NCT00651118|Drug|azelastineHcl / fluticasone propionate|azelastine Hcl 548 mcg / fluticasone propionate 200 mcg
1808987|NCT00651118|Drug|fluticasone propionate|fluticasone propionate 200 mcg
1808988|NCT00651131|Drug|daptomycin|daptomycin i.v. 4 mg/kg q24h for 7-14 days
1808989|NCT00651144|Drug|Ezetimibe + Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe 10 mg, once daily for 14 days
1808990|NCT00651144|Drug|Rosuvastatin|oral tablets; rosuvastatin 10 mg + ezetimibe placebo once daily for 14 days
1808991|NCT00651144|Drug|Placebo|oral tablets; two ezetimibe placebo once daily for 14 days
1808992|NCT00651144|Drug|Ezetimibe|oral tablets; ezetimibe 10 mg + ezetimibe placebo once daily for 14 days
1808993|NCT00651157|Biological|wild-type reovirus|Given IV: Administered at a dose of 3 x 10^10 TCID50/day in 250 mL 0.9% sodium chloride infused intravenously over 60 minutes daily on days 1-5 of each 28-day cycle.
1808994|NCT00651183|Drug|Pramipexole immediate release|
1808995|NCT00651209|Drug|Tenofovir|All patients receive 600 mg/day, oral telbivudine for 24 weeks. Patients with non-detectable HBV DNA continue 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 1) Patients with detectable HBV DNA receive 300 mg/day, oral tenofovir plus 600 mg/day, oral telbivudine for the remaining treatment period (Sub-group 2)
1808996|NCT00651222|Other|No intervention was required|Death records were reviewed, therefore, there was no intervention
1808997|NCT00651235|Drug|Losartan and Atenolol or Propranolol|"50 mg of Atenolol once daily, 20 mg of Propranolol twice daily for adult and 1 mg/Kg/day for children.
Losartan is 100 mg/day for adult and 50 mg/day for children."
1808998|NCT00651235|Drug|Atenolol or Propranolol|The maximal dose of Atenolol or Propranolol is 150 mg/day for adult and 2 mg/Kg/day for children.
1808999|NCT00651261|Drug|cytarabine|Given IV
1809000|NCT00651261|Drug|daunorubicin|Given IV
1809001|NCT00651261|Drug|midostaurin|Given orally
1809002|NCT00651261|Other|placebo|Given orally
1809003|NCT00651261|Drug|dexamethasone acetate|ocular medication administration
1809004|NCT00651274|Drug|Ezetimibe|oral tablets: ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
1809005|NCT00651274|Drug|Placebo|oral tablets: placebo to match ezetimibe 10 mg once daily for 6 weeks (plus continued simvastatin)
1809006|NCT00651287|Drug|quinapril 20 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks, and if a responder, continued on quinapril 20 mg for an additional 6 weeks
1809007|NCT00651287|Drug|quinapril 20 mg plus hydrochlorothiazide 12.5 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 20 mg plus hydrochlorothiazde 12.5 mg daily (Accuzide tablets) for 6 weeks
1809008|NCT00651287|Drug|quinapril 40 mg|Quinapril 20 mg oral tablet daily for the first 6 weeks; if nonresponder, could be randomized to quinapril 40 mg oral tablet daily for 6 weeks
1809009|NCT00651300|Drug|Parecoxib/Valdecoxib|A single 40mg dose of intravenous (IV) parecoxib sodium administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of valdecoxib 40 mg (2 x 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
1809010|NCT00651300|Drug|Placebo|A single dose of IV saline (placebo) administered on Day 1 immediately before the surgical procedure as part of the Investigator's usual analgesic management practice, followed by oral doses of placebo (2 x matching valdecoxib 20 mg tablets) at 6-8 hours post-surgery on Day 1 and in the morning of Day 2 and Day 3
1809011|NCT00651313|Drug|Lidocaine|Lidocaine vaginal gel 10% (150mg) administered once daily for 4 days
1809012|NCT00651313|Drug|Placebo|Placebo vaginal gel administered once daily for 4 days
1809013|NCT00651326|Drug|bicalutamide|
1809014|NCT00651326|Drug|buserelin|
1809015|NCT00651326|Drug|flutamide|
1809016|NCT00651326|Drug|goserelin|
1809017|NCT00651326|Drug|leuprolide acetate|
1809018|NCT00651326|Procedure|neoadjuvant therapy|
1809019|NCT00651326|Procedure|quality-of-life assessment|
1809020|NCT00651326|Radiation|radiation therapy|"46 Gy in 23 fractions over < 5 weeks.
Boost:
24-28 Gy in 12-14 fractions over < 3 weeks"
1809021|NCT00651326|Drug|Docetaxel|
1809022|NCT00651339|Drug|botox|botox injection
1809023|NCT00651352|Drug|4 mg nicotine lozenge|marketed formulation
1809024|NCT00651352|Drug|2 mg nicotine lozenge|marketed formulation
1809025|NCT00651352|Drug|2 mg nicotine prototype|2 mg
1809026|NCT00651352|Drug|4 mg nicotine prototype|4 mg
1809027|NCT00651365|Drug|JNJ-38877605|
1809028|NCT00651378|Drug|Rosuvastatin|oral tablets: rosuvastatin 10 mg once daily for 6 weeks (switch from previous run-in with atorvastatin 10 mg daily)
1809029|NCT00651378|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg plus atorvastatin 10 mg once daily for 6 weeks (add ezetimibe to previous run-in with atorvastatin 10 mg daily)
1809030|NCT00651378|Drug|Double Atorvastatin|oral tablets: atorvastatin 20 mg once daily for 6 weeks (double dose from previous run-in with atorvastatin 10 mg daily)
1809031|NCT00651391|Drug|Ezetimibe + Simvastatin|oral tablet of ezetimibe 10 mg plus simvastatin 20 mg once daily in the evening for 12 weeks
1809032|NCT00651391|Drug|Simvastatin|oral simvastatin 20 mg once daily in the evening for 12 weeks
1809033|NCT00651391|Drug|Placebo|oral placebo once daily in the evening for 12 weeks
1809034|NCT00651404|Drug|Ezetimibe|oral tablets; ezetimibe 10 mg daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
1809035|NCT00651404|Drug|Placebo|oral tablet; ezetimibe placebo daily for 6 weeks (added to ongoing therapy with atorvastatin 10 mg daily)
1809036|NCT00651417|Dietary Supplement|Organic Germanium|Oral organic Germaium tablets on the tongue 3 to 5 times per day as tolerated
1809037|NCT00651417|Dietary Supplement|Placebo|Placebo tablets orally 3 - 5 times per day as tolerated
1809038|NCT00651443|Drug|Galiximab|Galiximab 500 mg/m2 IV once weekly times 4, followed by Galiximab 500 mg/m2 IV once monthly times 4 as an extended dosing regimen.
1809039|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin)|"Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation Day 1 (D1=D22, 6 cycles)
Cisplatin 75 mg/m² Day 1 (D1=D22, 6 cycles)"
1809040|NCT00651456|Drug|Standard Chemotherapy (Pemetrexed and Cisplatin) + Bevacizumab|"Pemetrexed 500 mg/m² with previous Folic acid and vitamin B12 supplementation D1 (D1=D22, 6 cycles)
Cisplatin 75 mg/m2 D1 (D1=D22, 6 cycles)
Bevacizumab 15 mg/kg D1 (D1=D22, until progression)"
1809041|NCT00651469|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
1809042|NCT00651469|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
1809043|NCT00651482|Drug|Everolimus|
1809044|NCT00651482|Drug|Bevacizumab|
1809045|NCT00651495|Behavioral|Patient decision aids for chronic conditions|Videos providing comprehensive information about chronic disease management
1809046|NCT00651508|Drug|KOS-1584|25 mg/m2, IV (in the vein) on day 1 and 8 of each 21 day cycle until progression or unacceptable toxicity develops.
1809047|NCT00651534|Drug|Ronacaleret|
1809048|NCT00651547|Drug|budesonide/formoterol|
1809049|NCT00651547|Drug|budesonide|
1809050|NCT00651547|Drug|formoterol|
1809051|NCT00651560|Drug|ezetimibe (+) simvastatin|ezetimibe 10mg (+) simvastatin 20 mg once daily for 4 weeks of treatment.
1809052|NCT00651573|Procedure|Blood transfusion at hematocrit value less than 25%|transfusion
1809053|NCT00651573|Procedure|Blood transfusion at hematocrit value less than 28%|transfusion
1809054|NCT00651586|Drug|Gatifloxacin 0.3% ophthalmic solution|Gatifloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
1809055|NCT00651586|Drug|Ciprofloxacin 0.3% ophthalmic solution|Ciprofloxacin 0.3% ophthalmic solution. On Day 0, one drop instilled in affected eye every 5 minutes for the first 30 minutes, every 30 minutes while awake, and every 2 hours after retiring; on Day 1, one drop instilled in affected eye every hour while awake and 4 hours after retiring; on Days 2 to 6, one drop instilled in affected eye every 2 hours while awake; on Days 7 to 21, one drop instilled in affected eye 4 times daily while awake. Treatment continued through Day 21 (or Day 28 if ulcer had not healed but was improving); dosing terminated when re-epithelialization was complete or on Day 28, whichever occurred sooner
1809140|NCT00645606|Biological|Rituximab|rituximab :500 mg/m² every 8 weeks during 2 years
1809141|NCT00645632|Drug|cisplatin|
1809056|NCT00651599|Drug|Angeliq (Drospirenone/17ß-estradiol, BAY86-4891)|Treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
1809057|NCT00651599|Drug|Placebo|Placebo treatments will be administered daily, orally during the whole treatment period of 16 weeks without a treatment-free interval.
1809058|NCT00651612|Drug|Brimonidine 0.2%/Timolol 0.5% Fixed Combination Ophthalmic Solution|Brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution 1 drop instilled in each eye two times daily (morning and evening)
1809059|NCT00651612|Drug|Concurrent brimonidine 0.2% and 0.5% timolol|Brimonidine 0.2%, 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and timolol 0.5% timolol, 1 drop instilled in each eye twice daily (morning and evening) and vehicle of brimonidine combination ophthalmic solution 1 drop instilled in each eye (morning, afternoon and/or evening)
1809060|NCT00651625|Device|Reciprocating Procedure Device (RPD) - AVANCA Re No. 1091001|The RPD is a safety syringe device that is hypothesized to be safer, less painful, and more effective for patients undergoing a syringe and needle procedure (please see arm #1).
1809061|NCT00651625|Device|conventional syringe - BD Ref 309604|the conventional syringe or the RPD will be used for syringe and needle procedures performed by physicians.
1809062|NCT00651638|Drug|Treatment with ARQ 197|Treatment with ARQ 197
1809063|NCT00651651|Drug|budesonide/formoterol|
1809064|NCT00651651|Drug|budesonide|
1809065|NCT00651651|Drug|formoterol|
1809066|NCT00651664|Drug|MLN8237|MLN8237 will be administered orally once a day for 7 to 21 consecutive days followed by a 14-day recovery period.
1809067|NCT00651677|Procedure|HAL proctectomy|Hand-assisted laparoscopic proctectomy
1809068|NCT00651677|Procedure|"straight laparoscopic proctectomy"|"straight laparoscopic proctectomy"
1809069|NCT00651677|Procedure|Hand-assisted laparoscopic proctectomy|hand-assisted laparoscopic proctectomy
1809070|NCT00651677|Procedure|SL Proctectomy|Straight laparoscopic proctectomy
1809071|NCT00651690|Biological|Botulinum Toxin Type A|200 U to 360 U of botulinum toxin Type A on Day 0. Patients who met retreatment criteria received a second treatment (open-label) at Week 12 or Week 18
1809072|NCT00651690|Biological|Placebo|Saline injection on Day 0
1809073|NCT00651703|Biological|CYT004-MelQbG10 + Montanide|
1809074|NCT00651703|Biological|CYT004-MelQbG10 + Montanide + Imiquimod|
1809075|NCT00651703|Biological|CYT004-MelQbG10 + Imiquimod|
1809076|NCT00651703|Biological|CYT004-MelQbG10 intra nodal injection|
1809077|NCT00651716|Other|flow cytometry|Lymphocyte Analysis: Lymphocyte subset studies will be performed on samples obtained from the patient, donor, or graft. Aliquots will be analyzed using standard flow cytometry.
1809078|NCT00651716|Other|laboratory biomarker analysis|Identification of gut-homing and skin-homing Treg subsets
1809079|NCT00651716|Other|Data Collection|Patient samples will receive an alphanumeric code assigned by the principal investigator so that patient and donor identity will be known only to study investigators and research staff. Clinical records on each patient will be reviewed by participating investigators or research staff on a routine basis so that relevant clinical information including survival, malignancy relapse, and GVHD can be included in the patient database. Flow cytometry results will also be included in this database.
1809080|NCT00651729|Biological|Botulinum Toxin Type A|Each patient received from 1 to 5 treatments, with a minimum of 12 weeks between treatments. For each treatment, a total dose of 200 U to 400 U botulinum toxin Type A was injected into the wrist and finger flexor muscles of the affected upper limb, not to exceed 6 U/kg
1809081|NCT00651742|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
1809082|NCT00651755|Drug|Aprepitant|125 mg By Mouth (PO) On Day 1, followed by 80 mg PO Daily On Days 2-3.
1809083|NCT00651755|Drug|Cyclophosphamide|750 mg/m^2 By Vein On Day 1
1809084|NCT00651755|Drug|Doxorubicin|25 mg/m^2 By Vein Over 48 Hours On Days 1-2
1809085|NCT00651755|Drug|Vincristine|2 mg By Vein On Day 1
1809086|NCT00651755|Drug|Prednisone|100 mg PO for 5 Days
1809087|NCT00651755|Drug|Rituximab|375 mg/m^2 By Vein On Day 1.
1809088|NCT00651755|Drug|Ondansetron|8 mg daily for 2 days
1809089|NCT00651768|Drug|budesonide/formoterol|
1809090|NCT00651768|Drug|Symbicort pMDI + budesonide HFA pMDI|Symbicort 2 X 160/4.5mcg & budesonide HFA pMDI 4 X 160mcg
1809091|NCT00651781|Drug|Bortezomib|2 times per week of Velcade administration.
1809093|NCT00645294|Drug|Adefovir dipivoxil|0.14 mg/kg on Day 1, followed by 0.3 mg/kg on Day 8
1809094|NCT00645294|Drug|Adefovir Dipivoxil|0.3 mg/kg on Day 1, followed by 0.14 mg/kg on Day 8
1809095|NCT00645294|Drug|Adefovir Dipivoxil|ADV 10 mg on Day 1
1809096|NCT00645307|Drug|Extended Release OROS® Paliperidone|
1809097|NCT00645320|Drug|Ziprasidone|Oral ziprasidone tablets 40 or 80 mg twice daily with meals for 3 months. Doses were flexible based on investigator's discretion.
1809098|NCT00645333|Drug|MK-0752, Docetaxel, Pegfilgrastim|MK-0752 in escalating doses of 300, 450, 600, and 800 mg given orally on days 1-3, followed by docetaxel 80 mg/m2 day 8 and pegfilgrastim 6 mg SQ on day 9
1809099|NCT00645346|Biological|GBS glycoconjugate vaccine|Study subjects will receive either GBS conjugate vaccine or placebo. Total study size is 65. Study subjects will be followed for a total of 12 months after their last vaccination.
1809100|NCT00645346|Biological|Placebo|Subjects will receive one dose of placebo
1809142|NCT00645632|Drug|doxorubicin hydrochloride|
1809143|NCT00645632|Drug|ifosfamide|
1809101|NCT00645359|Procedure|diffusion MRI|Diffusion MRI involves using MRI scanning to measure water transport at the cellular level. In this study, dMRI is being used to measure the response of tumors to chemotherapy.
1809102|NCT00645372|Drug|Risperidone|Oral risperidone capsules 1 and 2 mg; doses were 1 mg once daily on Days 1-2, 2 mg once daily on Days 3-4, 3 mg once daily on Days 5-7, and 1, 2, or 3 mg twice daily during Weeks 2-6
1809103|NCT00645372|Drug|Ziprasidone|Oral ziprasidone capsules 40, 60, and 80 mg; doses were 40 mg twice daily on Days 1-2, 60 mg twice daily on Days 3-7, and 40, 60, or 80 mg twice daily during Weeks 2-6
1809104|NCT00645385|Other|MRS Spectroscopy|"Magnetic Resonance Spectroscopy uses a continuous band of radio wave frequencies to excite hydrogen atoms in a variety of chemical compounds other than water. These compounds absorb and emit radio energy at characteristic frequencies, or spectra, that can be used to identify them. Generally, a color image is created by assigning a hue to each distinctive spectral emission. This comprises the spectroscopy part of MRS. MRS is still experimental, and is available in only a few research centers.
Physicians mainly use MRS to study the brain and disorders such as epilepsy, Alzheimer's disease, brain tumors, and the effects of drugs on brain growth and metabolism. The technique is also useful in evaluating metabolic disorders of the muscles and nervous system. MRS is a noninvasive scan similar to an MRI that may be done at the same time as an MRI."
1809105|NCT00645398|Drug|Pregabalin|Pregabalin 225 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
1809106|NCT00645398|Drug|Pregabalin|Pregabalin 150 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
1809107|NCT00645398|Drug|Pregabalin|Pregabalin 300 mg BID taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
1809108|NCT00645398|Drug|Placebo|Matching placebo capsules taken orally, 2 capsules BID for 13 weeks (1 week titration phase + 12 weeks fixed-dose phase).
1809109|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|One 0.5 ml injection of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
1809110|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|One 0.5 ml injection of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm.
1809111|NCT00645411|Biological|Cell culture-derived influenza subunit vaccine (cTIV)|Two 0.5 mL injections,of the cell culture-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm, administered four weeks apart.
1809112|NCT00645411|Biological|Egg derived influenza subunit vaccine (eTIV)|Two 0.5 mL injections of the conventional egg-derived influenza vaccine in the deltoid muscle, preferably of the nondominant arm,administered four weeks apart.
1809113|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 10 mg orally once daily in the evening for 12 weeks
1809114|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 20 mg orally once daily in the evening for 12 weeks
1809115|NCT00645424|Drug|atorvastatin|Atorvastatin calcium tablets 40 mg orally once daily in the evening for 12 weeks
1809116|NCT00645437|Drug|Levofloxacin|
1809119|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 + 240 mg MR Diltiazem
1809120|NCT00645463|Drug|CP-945,598|20 mg CP-945,598 alone
1809121|NCT00645476|Drug|Memantine|"Week 0 Memantine 5 mg q.d.
Week 1 if mild side effects -continue previous dose Memantine, 5 mg q.d. if well tolerated - Memantine 5 mg b.i.d
Weeks 2-3 if well tolerated - Memantine 5 mg b.i.d - if mild side effects - continue Memantine , 5 mg b.i.d. if well tolerated - Memantine 5 mg q.a.m and 10 mg q.p.
Week 4-12 if well tolerated - Memantine 5 mg q.a.m and 10 mg q.p.m - if mild side effects - continue Memantine, 5 mg q.a.m and 10 mg q.p.m if well tolerated - Memantine 10 mg b.i.d"
1809122|NCT00645476|Drug|Placebo|"Week 0 placebo 5 mg q.d.
Week 1 if mild side effects -continue previous dose placebo, 5 mg q.d. if well tolerated - placebo 5 mg b.i.d
Weeks 2-3 if well tolerated - placebo 5 mg b.i.d - if mild side effects - continue placebo , 5 mg b.i.d. if well tolerated - placebo 5 mg q.a.m and 10 mg q.p.
Week 4-12 if well tolerated - placebo 5 mg q.a.m and 10 mg q.p.m - if mild side effects - continue placebo, 5 mg q.a.m and 10 mg q.p.m if well tolerated - placebo 10 mg b.i.d"
1809123|NCT00645489|Behavioral|psychoeducational|Psychoeducation intervention includes information about self-care of heart failure, and a communication training intervention for patients and family members
1809124|NCT00645489|Other|wait list|Wait list
1809125|NCT00645502|Drug|risperidone|
1809126|NCT00645515|Drug|Ziprasidone|Initial dose of 40 mg capsules twice daily on Days 1-3; dose could be flexibly changed within the range of 40 to 80 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
1809127|NCT00645515|Drug|Risperidone|Initial dose of 10 mg once daily on Days 1-3; dose could be flexibly changed within the range of 3 to 9 mg twice daily for the remainder of the study; treatment duration was 24 weeks.
1809128|NCT00645528|Other|Insulin Education Class|Participation in an Insulin Education Class at week 0 and week 2
1809129|NCT00645541|Procedure|Axillary Reverse Mapping|Lymphazurin, isosulfan blue dye, injected into arm then a standard axillary lymph node surgery to remove any blue dyed lymph nodes found (lymph nodes that have traveled down the drainage pathways).
1809130|NCT00645554|Drug|Galantamine oral solution|
1809131|NCT00645567|Device|Unassisted Manual Transfer|No device assistance
1809132|NCT00645567|Device|Standard Transfer Board|Flat surface board
1809133|NCT00645567|Device|Glide n' Go|Flip down power lift chair
1809134|NCT00645567|Device|Easy Reach lift|Original chair is converted to a chair that swivels out of the vehicle and lowers to wheelchair height
1809135|NCT00645567|Device|Ryno lift|Lift for the wheelchair
1809136|NCT00645580|Drug|Fluvoxamine|Fluvoxamine 100mg/day PO for 6 weeks.
1809137|NCT00645593|Drug|Gemcitabine,|Gemcitabine will be administered intravenously at a dose of 1000 mg/m2 on Days 1, 8 and 15 of cycle. One treatment cycle is 28 days.
1809138|NCT00645593|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 70 mg/m2 per institutional standards on Day 1 of each cycle.
1809139|NCT00645593|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
1809145|NCT00645632|Procedure|adjuvant therapy|
1809146|NCT00645632|Procedure|neoadjuvant therapy|
1809147|NCT00645632|Procedure|therapeutic conventional surgery|
1809148|NCT00645658|Drug|Testim (1% testosterone gel)|Subjects apply contents of gel packet to skin daily.
1809149|NCT00651807|Drug|etonogestrel|Lowest dose of Org 3236 per two days, lowest dose of Org 3236 per day, highest dose of Org 3236 per day for 8 weeks
1809150|NCT00651807|Drug|Placebo|Every day one tablet up to 8 weeks
1809151|NCT00651820|Drug|Collagenase Santyl|"Dermatome-induced skin wounds treated with drug active.
Each subject serves as his own control receiving both treatments in parallel."
1809152|NCT00651820|Drug|Collagenase Santyl Vehicle|Dermatome-induced skin wounds treated with Vehicle alone. Each subject serves as his own control receiving both treatments in parallel.
1809153|NCT00651833|Drug|S-1|All patients will receive S-1 orally at a dose of 25 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the third stage only if 7/31 (23%) or more patients have achieved a confirmed response (CR or PR) in stages 1 and 2 combined.
1809154|NCT00651846|Drug|Yasmin (DRSP 3mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (3mg DRSP/0.03 mgEE). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
1809155|NCT00651846|Drug|Microgynon (LNG 0.15 mg/EE 0.03 mg)|The study medication was packaged in 21-tablet blister packs. Each subject kit contained 7 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the treatment group received 21 consecutive days of hormonally active tablets (LNG 0.15 mg/EE 0.03 mg). In each treatment cycle 21 tablets (1 tablet daily) have to be taken in sequence, followed by a pill-free interval of 7 days. The treatment period was 7 cycles (28 days per cycle).
1809156|NCT00651859|Drug|Bimatoprost 0.01% Ophthalmic Solution|Bimatoprost 0.01% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
1809157|NCT00651859|Drug|Bimatoprost 0.03% Ophthalmic Solution|Bimatoprost 0.03% ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
1809158|NCT00651859|Drug|Bimatoprost Vehicle Ophthalmic Solution|Bimatoprost vehicle ophthalmic solution 1 drop instilled in each eye once daily in the evening between 19:00 and 21:00
1809159|NCT00651885|Drug|treprostinil dienthanolmine sustained release|UT-15C SR 1mg tablet
1809160|NCT00651885|Drug|Placebo|Placebo
1809161|NCT00651911|Drug|urate oxidase|First injection of Rasburicase will be done the day of initiation of chemotherapy, or the day before, according to hyperuricemia. Additional doses are permitted q12h during the first 72 hours of chemotherapy if hyperuricemia persists or subject is considered to be at significant risk of tumor lysis complications.
1809162|NCT00651924|Behavioral|IVR-based Cognitive-behavior therapy|Standard cognitive-behavior therapy for chronic pain management using Interactive Voice Response (IVR) compatible materials and handouts
1809163|NCT00651937|Drug|Melphalan|100 mg/m^2 via a Central Venous Catheter (CVC) Over 15-20 Minutes on Days -3 and -2 prior to stem cell infusion.
1809164|NCT00651937|Procedure|Stem Cell Infusion|"Stem Cell Infusion is Day 0.
Standard Dose (Arm 1) = Stem cell dose of between 4-6 x 10^6 CD34/kg On Day 0
High Dose (Arm 2) = Stem cell dose of between 10-15 x 10^6 CD34/kg On Day 0."
1809165|NCT00651937|Behavioral|Questionnaires|Beginning Visit 1, twice a week, paper and automated phone interview of symptoms and quality of life questionnaires.
1809166|NCT00651937|Drug|Granulocyte-colony stimulating factor (G-CSF)|5 mcg/kg given subcutaneously (under the skin) on a daily basis for approximately 10 days.
1809167|NCT00651937|Procedure|Apheresis|Collection of stem cells from blood collected either through CVC or from a vein in one arm.
1809168|NCT00651963|Drug|ezetimibe|"Ezetimibe 10 mg daily was added during 4 weeks.
The patients continued taking their usual Statin without titrating the dose."
1809169|NCT00651976|Drug|letrozole|Take by mouth at a dose of 2.5 mg on days 7-21
1809170|NCT00651976|Other|Blood Collection|Blood used for gene expression analysis and reverse transcriptase-polymerase chain reaction
1809171|NCT00651976|Procedure|biopsy/lumpectomy/mastectomy|Tissue collection,Surgery to remove tumor, Tumor tissues used for laboratory biomarker analysis
1809172|NCT00651989|Other|optical coherence tomography foveal thickness measurement|In the same session in one randomly selected eye of each subject three consecutive measurements of foveal thickness were performed using both time-domain OCT and spectral-domain OCT.
1809173|NCT00652002|Drug|budesonide/formoterol|
1809174|NCT00652002|Drug|budesonide|
1809175|NCT00652002|Drug|formoterol|
1809176|NCT00652028|Drug|Dexmedetomidine, midazolam; fentanyl|Dexmedetomidine for sedation; midazolam for rescue sedation according to label; fentanyl for rescue pain according to the label
1809177|NCT00652041|Drug|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4 and Prednisone, 60 mg/m2 oral, days 1 to 4
1809178|NCT00652041|Drug|Thalidomide|Thalidomide, day 1 cycle 1, 100 mg/24 h. oral, in combination with cyclophosphamide and dexamethasone. If toxicity is <Grade 2, dose should be increased to 200 mg/24 h. in day 15
1809179|NCT00652041|Drug|Bortezomib|Bortezomib, 1,3 mg/ m2 iv twice a week in combination with Melfalán 9 mg/m2 oral, days 1 to 4, Prednisone, 60 mg/m2 oral, days 1 to 4 and Adriamicine, 40 mg/m2 IV day 1 or Caelyx 30 mg/m2 IV day 1.
1809180|NCT00652054|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The trial will proceed to the second stage only if sufficient efficacy is demonstrated in Stage 1.
1809181|NCT00652080|Drug|API 31510|Topical Cream; 3% active; AM & PM application
1809182|NCT00652093|Drug|opana then darvocet then placebo|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
1809228|NCT00652457|Drug|Memantine|10 mg BID x 3 months
1809283|NCT00652821|Drug|Ultracet|Tablets, 37.5mg/325mg
1809284|NCT00652834|Procedure|Small bowel capsule endoscopy (SBCE)|SBCE will be performed at Day 2 and Day 30.
1809183|NCT00652093|Drug|opana then placebo then darvocet|Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
1809184|NCT00652093|Drug|placebo then opana then darvocet|Placebo tablet tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) was given one time at the third study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the fourth study visit.
1809185|NCT00652093|Drug|Placebo then darvocet then opana|Placebo tablet tablet was given one time at the second study visit, four days later darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
1809186|NCT00652093|Drug|Darvocet then opana then placebo|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the third study visit, four days later placebo tablet was given one time at the fourth study visit.
1809187|NCT00652093|Drug|Darvocet then placebo then opana|Darvocet (100mg Propoxyphene/650mg Acetaminophen) tablet was given one time at the second study visit, four days later placebo tablet was given one time at the third study visit, four days later Opana IR, 5mg (oxymorphone hydrochloride) tablet was given one time at the fourth study visit.
1809188|NCT00652106|Drug|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution|0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
1809189|NCT00652106|Drug|Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution|Brimonidine 0.2% 1 drop instilled in each eye three times daily (morning, afternoon, and evening) and concurrent timolol 0.5% ophthalmic solution 1 drop instilled in each eye twice daily (morning and evening)
1809190|NCT00652106|Drug|Brimonidine 0.2% ophthalmic solution|Brimonidine 0.2% ophthalmic solution 1 drop instilled in each eye three times daily (morning, afternoon, and evening)
1809191|NCT00652119|Drug|Paclitaxel|Cycle 1 = 60 mg/m^2 IV weekly over 1 hour x 3 weeks; Cycles 2-6 = 60 mg/m^2 IP weekly over 1 hour x 3 weeks of each cycle.
1809192|NCT00652119|Drug|Carboplatin|Cycle 1 = AUC 6 IV over 1 hour on day 1; Cycles 2-6 = AUC 6 IP over 1 hour on day 1 of each cycle.
1809193|NCT00652119|Drug|Avastin|Cycle 2 = 15 mg/kg IV over 90 minutes on day 8; Cycles 3-6 = 15 mg/kg IV on day 1 of each cycle.
1809194|NCT00652132|Drug|cisplatin|
1809195|NCT00652132|Drug|sodium thiosulfate|
1809196|NCT00652132|Genetic|gene rearrangement analysis|
1809197|NCT00652132|Genetic|microarray analysis|
1809198|NCT00652132|Genetic|proteomic profiling|
1809199|NCT00652132|Other|immunohistochemistry staining method|
1809200|NCT00652132|Other|laboratory biomarker analysis|
1809201|NCT00652132|Procedure|adjuvant therapy|
1809202|NCT00652132|Procedure|neoadjuvant therapy|
1809203|NCT00652132|Procedure|therapeutic conventional surgery|
1809204|NCT00652314|Device|Thrombi-Gel|Applicaton of Hemostatic product during surgery
1809205|NCT00652327|Drug|Ezetimibe + Statin (simvastatin, atorvastatin, or pravastatin)|ezetimibe 10 mg plus ongoing statin (simvastatin 20 mg or atorvastatin 10 mg or pravastatin 20 mg) once daily for 8 weeks
1809206|NCT00652327|Drug|Double Statin (simvastatin, atorvastatin, or pravastatin)|simvastatin 40 mg or atorvastatin 20 mg or pravastatin 40 mg once daily for 8 weeks
1809207|NCT00652340|Drug|apricoxib/erlotinib|"apricoxib: 100 mg tablets, 400mg/day
erlotinib: per package insert"
1809208|NCT00652340|Drug|erlotinib/placebo|"erlotinib: per package insert
placebo: 100 mg tablets, 400 mg/day"
1809209|NCT00652353|Other|44-55-66-PM|"The mnemonic 44-55-66-PM helps to remember the components of the Ottawa Ankle and foot Rule.
44: Is to remember that an X-ray is required if the patients is unable to walk 4 steps at the moment of the Accident AND during the physical examination 55: Is to remember that an X-ray of the foot is required if the patient has pain at the basis of the 5Th metatarsal of at the 5caphoid 66-PM: Is to remember that an X-ray of the ankle is required if the patient has pain in the Posterior of the lateral or medial malleolar"
1809210|NCT00652353|Other|control|Participants will be instructed of the components of the Ottawa Ankle Rule on a standardized sheet
1809211|NCT00652366|Drug|Erlotinib, escalating dose|100mg, PO, once daily, escalating to a maximum of 250mg, PO, once daily
1809212|NCT00652366|Drug|Erlotinib, standard dose|100mg, PO, once daily
1809213|NCT00652366|Drug|Gemcitabine|1000 mg/m2, IV, on days 1,8 and 15 of each 4 week cycle
1809214|NCT00652379|Drug|Pegvisomant|Pegvisomant s.c 15-30 mg 2 times a week
1809215|NCT00652379|Drug|Somatostatin analog (lanreotide or octreotide)|Study arm 2: usual dosage of a somatostatin analog Study arm 1: half dosage of somatostatin analog
1809216|NCT00652392|Drug|budesonide/formoterol|
1809217|NCT00652392|Drug|budesonide and placebo|
1809218|NCT00652405|Dietary Supplement|alcohol|250 ml of white wine (13% vol; ~25 gram of alcohol per day)
1809219|NCT00652405|Dietary Supplement|Placebo|250 ml of mineral water (Brand name: Vittel)
1809220|NCT00652418|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
1809221|NCT00652418|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882, SH L 451A)|Magnevist at a dose of 0.2 mmol/kg
1809222|NCT00652431|Drug|Vytorin + Niaspan|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days + Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
1809223|NCT00652431|Drug|Vytorin|Vytorin (1 tablet containing ezetimibe 10 mg and simvastatin 20 mg) once daily in the morning for 7 days
1809224|NCT00652431|Drug|Niaspan|Niaspan 1000 mg (1 x 1000-mg tablet) once daily in the morning on Days 1 and 2, followed by Niaspan 2000 mg (2 x 1000-mg tablets) once daily in the morning on Days 3 to 7
1809225|NCT00652444|Drug|ezetimibe|ezetimibe 10mg. Blood samples were collected again at the end of study treatment, week 6.
1809226|NCT00652444|Drug|simvastatin|simvastatin 20mg . Blood samples were collected again at the end of study treatment, week 6.
1809227|NCT00652444|Drug|Placebo (Unspecified)|Matching ezetimibe placebo
1809229|NCT00652470|Procedure|Endoscopic Third Ventriculostomy|A standard frontal burr hole will be made and an endoscopic camera used to visualize the floor of the third ventricle. A ventriculostomy will be created in the floor of the third using the surgeon's own preferred method of perforation.
1809230|NCT00652470|Procedure|CSF Shunt Insertion|The procedure involves creating a burr hole in the frontal or occipital regions and cannulating the ventricle with a silastic catheter. This is then attached to a valve mechanism and distal silastic tubing which runs subcutaneously in the peritoneal cavity.
1809231|NCT00652483|Drug|Brimonidine ophthalmic solution 0.1%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
1809232|NCT00652483|Drug|Brimonidine ophthalmic solution 0.2%|1 drop instilled in each eye 3 times daily (08:00, 14:00, 20:00)
1809233|NCT00652496|Drug|Bimatoprost 0.01% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
1809234|NCT00652496|Drug|Bimatoprost 0.015% formulation 1 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
1809235|NCT00652496|Drug|Bimatoprost 0.015% formulation 2 ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
1809236|NCT00652496|Drug|Bimatoprost 0.02% ophthalmic solution|One drop in one eye, once daily in the morning for 4 consecutive days, the other eye received the active control eye drop
1809237|NCT00652496|Drug|Bimatoprost 0.03% ophthalmic solution|Bimatoprost 0.03% ophthalmic solution, one drop in one eye, once daily in the morning for 4 consecutive days, the other eye received one drop of any of the 4 study drugs
1809238|NCT00652509|Behavioral|Interactive Dialogue to Educate and Activate (IDEA)|IDEA - patients receive group sessions totaling 8 hours, with an average of 10 patients per group, using conversation maps as a conduit to facilitate dialogue between providers and patients.
1809239|NCT00652509|Behavioral|Individual Education (IE)|IE - patients receive 2 hours with a nurse educator and 1 hour with a dietitian.
1809240|NCT00652522|Device|ICD/CRT implant|Implantation of a ICD/ CRT device if not yet implanted
1809241|NCT00652522|Procedure|AF ablation|Atrial Fibrillation ablation by pulmonary vein isolation
1809242|NCT00652522|Other|Best Medical Treatment|Best medical treatment according to current guidelines for Management of Patients with Atrial Fibrillation and for Management of Chronic Heart Failure.
1809243|NCT00652561|Drug|S-1|All patients will receive S-1 orally at a dose of 30 mg/m2 twice daily (BID) for 14 days followed by a 1-week recovery period, repeated every 3 weeks. The study may go to the second stage only if the stage 2 criteria are met, where 3/30 (10%) or more patients must have achieved a confirmed response (CR or PR) in stage 1.The study may go to the third stage only if at least 8/50 patients (16%) must have achieved a confirmed response in stage 2
1809244|NCT00652574|Drug|Dasatinib|70 mg by mouth twice daily x 28 days, for up to 2 years after surgery.
1809245|NCT00652587|Procedure|hepatectomy and transcatheter arterial chemoembolization|partial hepatectomy with adjuvant transcatheter arterial chemoembolization
1809246|NCT00652587|Procedure|hepatectomy|hepatectomy alone
1809247|NCT00652600|Drug|Propranolol|ER Capsules, 160 mg, single-dose
1809248|NCT00652600|Drug|Inderal-LA|ER Capsules, 160 mg, single-dose
1809249|NCT00652613|Radiation|3 Dimensional Radiation Therapy|Radiation with 6 MV photons to dose of 70Gy/ 35#/ 7 weeks
1809250|NCT00652613|Radiation|Intensity Modulated Radiation Therapy|IMRT with 6 MV photons to a dose of 66Gy/30#/ 6 weeks
1809251|NCT00652626|Drug|azacitidine|
1809252|NCT00652639|Drug|Clonazepam|Tablets, 1 mg, single-dose
1809253|NCT00652639|Drug|Klonopin|tablets, 1 mg, single-dose
1809254|NCT00652652|Drug|nesiritide, furosemide|
1809255|NCT00652665|Drug|Leflunomide|Tablets, 20mg, single-dose
1809256|NCT00652665|Drug|ARAVA|Tablets, 20mg,single-dose
1809257|NCT00652691|Biological|filgrastim|
1809258|NCT00652691|Drug|carboplatin|
1809259|NCT00652691|Drug|cyclophosphamide|
1809260|NCT00652691|Drug|topotecan hydrochloride|
1809261|NCT00652691|Procedure|autologous hematopoietic stem cell transplantation|
1809262|NCT00652691|Procedure|peripheral blood stem cell transplantation|
1809263|NCT00652704|Drug|Doxycycline monohydrate|Capsules, 100 mg, fed
1809264|NCT00652704|Drug|Monodox|Capsules, 100 mg, fed
1809265|NCT00652704|Drug|Doxycycline Monohydrate|Capsules, 100 mg, fasting
1809266|NCT00652717|Drug|Ezetimibe|Ezetimibe 10 mg daily for 42 days.
1809267|NCT00652717|Drug|simvastatin|simvastatin (prescribed clinically suitable dose by the physician), for mean follow up of 42 days.
1809268|NCT00652730|Drug|Buspirone HCl|Tablets, 30 mg, single-dose, fasting conditions
1809269|NCT00652730|Drug|Buspirone HCl|Tablets, 30 mg, single-dose, fed conditions
1809270|NCT00652730|Drug|Buspar|Tablets, 30 mg, single-dose, fed conditions
1809272|NCT00652756|Device|Use of ventilator during patient transport (Versamed iVent)|The goal of the transport ventilator is to provide optimal ventilation.
1809273|NCT00652756|Other|Bag-valve ventilation|Use of bag-valve ventilation during patient transport.
1809276|NCT00652782|Drug|rolofyline|rolofyline 2.5 mg IV QD; 15 mg IV QD; 30 mg IV QD; 60 mg IV QD; 3 days
1809277|NCT00652782|Drug|Comparator Placebo (unspecified)|Matching placebo for rolofyline IV QD; 3 days
1809278|NCT00652795|Drug|Doxycycline Monohydrate|Tablets, 150 mg, single-dose
1809279|NCT00652795|Drug|Monodox|Capsules 50 mg (3 x 50 mg dose), single-dose
1809280|NCT00652808|Drug|valdecoxib|valdecoxib 10 mg tablet by mouth once daily for 6 weeks
1809281|NCT00652808|Drug|naproxen|naproxen 500 mg capsule by mouth twice daily for 6 weeks
1809282|NCT00652821|Drug|Tramadol/ APAP|Tablets 37.5mg /325mg
1809285|NCT00652834|Drug|myfortic|switching from mycophenolate mofetil to mycophenolic acid on equimolar basis
1809286|NCT00652847|Drug|ezetimibe|ezetimibe 10 mg/day for a six week course of treatment.
1809287|NCT00652847|Drug|statins|patients on statins have their dose doubled for 6 weeks followed by another 6 month observational phase
1809288|NCT00652860|Biological|aerosol sargramostim|
1809289|NCT00652860|Biological|sargramostim|
1809290|NCT00652860|Drug|cisplatin|
1809291|NCT00652860|Drug|doxorubicin hydrochloride|
1809292|NCT00652860|Drug|ifosfamide|
1809293|NCT00652860|Drug|mitomycin C|
1809294|NCT00652860|Other|flow cytometry|
1809295|NCT00652860|Other|immunological diagnostic method|
1809296|NCT00652860|Other|laboratory biomarker analysis|
1809297|NCT00652860|Procedure|adjuvant therapy|
1809298|NCT00652860|Procedure|multimodality therapy|
1809299|NCT00652860|Procedure|neoadjuvant therapy|
1809300|NCT00652860|Procedure|therapeutic conventional surgery|
1809301|NCT00652860|Radiation|intraoperative radiation therapy|
1809302|NCT00652860|Radiation|selective external radiation therapy|
1809303|NCT00652873|Drug|Cabergoline|Tablets 0.5 mg (2 x 0.5 mg dose), fed
1809304|NCT00652873|Drug|Dostinex|Tablets, 0.5 mg (2 X 0.5 mg dose), fed
1809305|NCT00652886|Drug|Oxandrolone|Tablets, 10mg, single-dose
1809306|NCT00652886|Drug|Oxandrin|tablets, 10mg, single-dose
1809307|NCT00652899|Biological|Allopurinol|All patients are to receive allopurinol 300 mg PO daily (unless known allergy) before beginning chemotherapy and continuing through day 14 post natural killer cell infusion.
1809308|NCT00652899|Drug|Cyclophosphamide|60 mg/m^2 on Days 4 and 5 preceding natural killer cell infusion.
1809309|NCT00652899|Drug|Fludarabine phosphate|25 mg/m^2 on Days 6 through 2 preceding natural killer cell infusion.
1809310|NCT00652899|Radiation|total-body irradiation|200 cGy Day 1 preceding natural killer cell infusion.
1809311|NCT00652899|Biological|Allogeneic natural killer cells|Given day 0 - dose of 1.5-8.0 * 10^7/kg
1809312|NCT00652899|Biological|Aldesleukin|10 MU 3 times/week for a total of 6 doses beginning Day 0
1809313|NCT00652912|Drug|Clonazepam|ODT, 1 mg
1809314|NCT00652912|Drug|Klonopin Wafers|ODT, 1 mg
1809315|NCT00652925|Drug|Celecoxib|Higher dose, 6 mg/kg/dose BID
1809316|NCT00652925|Drug|Celecoxib|Active drug at lower dose
1809317|NCT00652925|Drug|Naproxen|Control comparator, 15 mg/kg/dy target dose
1809318|NCT00652938|Biological|HPV Vaccine (GSK580299) Cervarix TM|IM administration
1809319|NCT00652938|Biological|Engerix B|IM administration
1809324|NCT00652964|Device|CPAP|CPAP treatment for patients with congenital central hypoventilation syndrome
1809325|NCT00652977|Procedure|Ritgens maneuver|Delivery of the fetal head should be managed by Ritgens maneuver, i.e. lifting the fetal chin anteriorly, using the fingers of one hand placed between the anus and the coccyx, and thereby extending the fetal neck, whereas the other hand should be placed on the fetal occiput to control the pace of the expulsion of the fetal head. The maneuver was used during a uterine contraction
1809326|NCT00652977|Procedure|Standard care (Manual support of the perineum)|The protocol entailed our standard care: using one hand to apply pressure against the perineum, and the other hand on the fetal occiput to control the expulsion of the fetal head, and only to use Ritgen´s maneuver in case of labor arrest or abnormal fetal heart rate pattern when the fetal head was at the pelvic floor.
1809327|NCT00653003|Drug|Leflunomide|tablets, 20mg, single-dose
1809328|NCT00653003|Drug|ARAVA|Tablets, 20mg, single-dose
1809329|NCT00653016|Drug|norelgestromin; ethinyl estradiol|
1809330|NCT00653042|Drug|Nesiritide|
1809331|NCT00653055|Drug|Cabergoline|Tablets, 0.5 mg (2 x 0.5 mg dose),fasting
1809332|NCT00653055|Drug|Dostinex|Tablets, 0.5 mg (2 x 0.5 mg dose), fasting
1809333|NCT00653068|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSC rescue
1809334|NCT00653068|Radiation|3-dimensional conformal radiation therapy|Undergo 3D-CRT
1809335|NCT00653068|Drug|methotrexate|Given IV
1809336|NCT00653068|Drug|leucovorin calcium|Given IV or orally
1809337|NCT00653068|Drug|etoposide|Given IV
1809338|NCT00653068|Drug|cyclophosphamide|Given IV
1809339|NCT00653068|Drug|cisplatin|Given IV
1809340|NCT00653068|Biological|filgrastim|Given IV or SC
1809341|NCT00653068|Drug|carboplatin|Given IV
1809342|NCT00653068|Drug|thiotepa|Given IV
1809343|NCT00653068|Drug|vincristine sulfate|Given IV
1809344|NCT00653068|Other|laboratory biomarker analysis|Correlative studies
1809345|NCT00653081|Procedure|Physical therapy method called Supervised Exercises|Performed at ullevaal Hospital, 45 min each time, 2-3 times pr week in max 12 weeks
1809346|NCT00653081|Procedure|Radial Extracorporeal Shockwave Therapy|Radial Shock Wave therapy performed at ulleval Hospital, once a week, 4-6 times, 3-5 points each time.
1809347|NCT00653094|Device|Halevy kit|the use of Halevy kit in Crohn patients with Fistulas
1809348|NCT00653107|Procedure|Stent insertion|Self-expanding metal stents will be used. These will be of the type which the hospital at any given time uses, at present Ultraflex®.
1809349|NCT00653107|Radiation|Brachytherapy|a flexible applicator (with a diameter adapted to the stent's diameter) will be introduced into the oesophagus, so the applicator will be lying in the middle of the lumen of the stent. Thereafter, the flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
1809575|NCT00654732|Drug|Bleomycin|10 U/m^2 IV Over 1 Hour On Day 1 and 15.
1957779|NCT02188264|Drug|Cyclosporine|Given PO
1957780|NCT02188264|Other|Laboratory Biomarker Analysis|Correlative studies
1957781|NCT02188264|Other|Pharmacological Study|Correlative studies
1809350|NCT00653107|Radiation|Brachytherapy|a flexible applicator will be introduced into the oesophagus. The flexible applicator is connected to a MicroSelectron afterloading device (Iridium-192), and the treatment is given with a high dose rate (> 12 Gy/h).
1809351|NCT00653120|Drug|Propranolol|ER capsules, 160 mg, single-dose
1809352|NCT00653120|Drug|Inderal-LA|ER capsules, 160 mg, single-dose
1809353|NCT00653133|Device|Ultrasound imaging|Ultrasound guided techniques for placement of peripheral nerve block catheters for continuous infusion of local anesthetic
1809354|NCT00653133|Device|Peripheral nerve stimulator|either stimulating needle or stimulating catheter used for placement of catheter for continuous infusion of local anesthetic
1809355|NCT00653146|Behavioral|Mindfulness-Based Stress Reduction|In the intervention program, a variety of mindfulness meditation techniques will be taught, including the body scan, awareness of breathing, mindful yoga, eating meditation and walking meditation.
1809356|NCT00653146|Behavioral|Healthy Lifestyles|In the control condition, information on healthy lifestyles will be presented in a didactic fashion. Session topics include diet and nutrition, physical activity, and healthy behaviors to prevent cardiovascular disease and cancer.
1809357|NCT00653159|Device|Levonorgestrel-releasing intrauterine device (LNG-IUS)|Teens are randomly assigned to receive the LNG-IUS after completing a screening visit.
1809358|NCT00653159|Device|Copper T380A intrauterine device (CuT380A)|Teens are randomly assigned to Copper T380 after the screening visit
1809359|NCT00653172|Drug|NXL103|600mg orally twice daily
1809360|NCT00653172|Drug|comparator|comparator twice daily
1809361|NCT00653172|Drug|NXL103|500mg orally twice daily
1809362|NCT00653185|Drug|SYR-472|SYR-472 25 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
1809363|NCT00653185|Drug|SYR-472|SYR-472 50 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
1809364|NCT00653185|Drug|SYR-472|SYR-472 100 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
1809365|NCT00653185|Drug|SYR-472|SYR-472 200 mg, tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
1809366|NCT00653185|Drug|Placebo|SYR-472 placebo-matching tablets, orally, once daily and lifestyle modification and/or metformin for up to 12 weeks.
1809367|NCT00653198|Other|No intervention|
1809368|NCT00653224|Drug|levocetirizine dihydrochloride|5 mg daily (oral tablet) for 14 days
1809369|NCT00653224|Drug|placebo|0 mg daily (matching oral tablet) for 14 days
1809370|NCT00653237|Device|I-gel and LMA Supreme: supraglottic airway devices|Insertion of a supraglottic airway device
1809371|NCT00653250|Drug|celecoxib|400 mg P.O. BID for five days prior to obtaining second serum/urine collection (starting after initial biopsy, serum and urine collection)
1809372|NCT00653250|Procedure|biopsy|in patients with newly diagnosed NSCLC, a pretreatment excision of a small amount of tumor tissue
1809373|NCT00653250|Procedure|therapeutic conventional surgery|surgery to remove the lung tumor
1809374|NCT00653276|Drug|ezetimibe|ezetimibe 20 mg (2 x 10 mg tablets) on Days 1 through Day 7.
1809375|NCT00653276|Drug|Comparator: cyclosporine|single oral dose of cyclosporine 100 mg capsules on Day 1 or Day 7.
1809376|NCT00653302|Drug|Lantus (insulin glargine) + Glucophage (Metformin)|
1809377|NCT00653315|Drug|Tramadol APAP|Tablets, 37.5mg/325mg, single dose
1809378|NCT00653315|Drug|Ultracet|Tablets, 37.5mg/325mg
1809379|NCT00653328|Drug|atrasentan hydrochloride|Atrasentan 10 mg orally everyday continuously beginning on Day 1.
1809380|NCT00653328|Drug|doxil|50 mg/m2 intravenously every 28 days
1809381|NCT00653341|Drug|insulin glargine|
1809382|NCT00653341|Drug|NPH human insulin|
1809383|NCT00653354|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by valdecoxib 20 mg tablet by mouth 1 to 12 hours after the first dose
1809384|NCT00653354|Drug|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
1809385|NCT00653354|Drug|placebo|placebo within 6 hours of surgery followed by placebo 1 to 12 hours after the first dose
1809386|NCT00653367|Procedure|Nerve section|Intercostal nerve is divided during surgery
1809387|NCT00653380|Drug|Doxycycline Monohydrate|Capsules, 100 mg, single-dose
1809388|NCT00653380|Drug|Monodox|Capsules, 100 mg, single-dose
1809389|NCT00653393|Drug|Tranylcypromine|Tablets, 10 mg, single-dose
1809390|NCT00653393|Drug|Parnate|Tablets, 10 mg, single-dose
1809391|NCT00653406|Drug|Risperidone long acting injectable|
1809392|NCT00653419|Drug|buspirone HCl|Tablets, 30 mg, single-dose
1809393|NCT00653419|Drug|Buspar|Tablets, 30 mg, single-dose
1957782|NCT02188264|Drug|Selumetinib|Given PO
1809395|NCT00653445|Drug|Rosuvastatin|40mg
1809396|NCT00653445|Drug|Ezetimibe|10mg
1809397|NCT00653458|Drug|Ondansetron|ODT, 8 mg, single-dose, fed conditions
1809398|NCT00653458|Drug|Zofran|ODT, 8 mg, single-dose, under fed conditions
1809399|NCT00653471|Device|Microcapmicro-stream device with Smart CapnoLine Plus|nasal oxygen mask tested to determine accuracy of endtidal CO2 monitoring
1809400|NCT00653471|Device|Microcap micro-stream device with CapnoLine|CO2 measured via nasal cannula
1809401|NCT00653471|Device|TG-920 main-stream device (Nihon Kohden, Tokyo, Japan).|CO2 measured via nasal cannula
1809402|NCT00653484|Behavioral|Physical Activity|
1809403|NCT00653484|Behavioral|Energy Restriction|
1809404|NCT00653484|Behavioral|Physical Activity and Energy Restriction|
1809405|NCT00653497|Behavioral|Aquatic exercise|"Arthritis Foundation Aquatics Program
community-based aquatic exercise program
participants asked to attend 2 classes per week for 20 weeks
each class 45-60 minutes in duration"
1809406|NCT00653510|Drug|Actrapid (human insulin)|On day one the patients will receive glucose and insulin in order to reach a blood sugar around 18 and 20 mmol/L and on day two the patients will receive glucose and insulin in order to have a blood sugar around 5 and 7 mmol/L. On both days amino acid, lipid and glucose metabolism will be assessed by means of whole body isotope dilution.
1809407|NCT00653523|Drug|Ezetimibe|Ezetimibe 10 mg once daily
1809408|NCT00653523|Drug|Simvastatin|Simvastatin 20 mg daily
1809409|NCT00653536|Device|NeuroFlo|The device will be inflated for 45 minutes in acute ischemic stroke patients who have failed mechanical recanalization.
1809410|NCT00653549|Drug|Torsemide|Tablets, 20 mg, single-dose
1809411|NCT00653549|Drug|Demadex|tablets, 20 mg, single-dose
1809412|NCT00653562|Drug|zolpidem|Oral
1809413|NCT00653575|Behavioral|Information-Motivation-Behavioral Skills model|The Information-Motivation-Behavioral Skills model is an influential and empirically supported theory of health behavior. The model suggests that HIV-related information, motivation, and behavioral skills are important determinants of sexual behavior; thus, childhood sexual abuse may lead to deficits in these areas. This model will be used to guide research interviews.
1809414|NCT00653575|Behavioral|Traumagenic Dynamics model|The Traumagenic Dynamics model is an influential and empirically supported model of the effects of childhood sexual abuse. The model suggests that childhood sexual abuse leads to traumatic sexualization, stigmatization, betrayal, and powerlessness and that these four traumagenic dynamics lead to adverse outcomes, including increased rates of sexual risk behavior. This model will be used to guide research interviews.
1809415|NCT00653588|Drug|Rosuvastatin|40mg
1809416|NCT00653588|Drug|Atorvastatin|80mg
1809417|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 1 (SH T04984E)|Single dose administration of E2 + DRSP as a tablet
1809418|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 2 (80458739)|Single dose administration of E2 + DRSP as a tablet
1809419|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 3 (80458755)|Single dose administration of E2 + DRSP as a tablet
1809420|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 4 (80458720)|Single dose administration of E2 + DRSP as a tablet
1809421|NCT00653614|Drug|E2/DRSP (BAY 86-4891) dose 5 (80458712)|Single dose administration of E2 + DRSP as a tablet
1809422|NCT00653614|Drug|DRSP (ZK 30595) dose 1 (SH T04984F)|Single dose administration of DRSP as a tablet
1809423|NCT00653614|Drug|DRSP (ZK 30595) dose 2 (80458690)|Single dose administration of DRSP as a tablet
1809424|NCT00653614|Drug|Placebo|Placebo administration in each arm
1809425|NCT00653627|Biological|BCG|Mycobacterium bovis Bacille Calmette-Guerin
1809426|NCT00653640|Procedure|body weight supported treadmill training|BWSTT for 12 weeks, 3 times per week
1809427|NCT00653640|Procedure|traditional physical therapy|traditional PT for 12 weeks, 3 times per week
1809428|NCT00653666|Other|Medically supervised fasting|Metabolic fasting studies will be conducted over an 18-hour period or until blood glucose is < 40 mg/dl. If the YSI reading is 40 mg/dl or less, at any time during the study, then a blood sample will be collected, and the fast terminated by giving D25W IV and then feeding orally.
1809429|NCT00653679|Other|exercise|1 hour of endurance or resistance exercise
1809430|NCT00653705|Other|Yogurt drink with probiotic bacteria BB12|Probiotic yogurt dairy drink with Bifidobacterium Lactis and prebiotics. One bottle a day for 16 weeks.
1809431|NCT00653705|Other|Placebo|Vanilla flavored dairy drink. One bottle a day for 16 weeks.
1809432|NCT00653731|Behavioral|Snoezelen ©|Nursing individual intervention one time a week for 20 minutes
1809433|NCT00653731|Behavioral|structured reminiscence therapy|Individual nursing intervention: one time a week 20 minutes
1809434|NCT00653731|Behavioral|10-minutes activation|Individual nursing intervention: two times a week for 10 minutes
1809435|NCT00653731|Behavioral|Unstructured verbal communication|Individual nursing intervention: one time a week for 20 minutes
1809436|NCT00653744|Drug|Rosuvastatin|
1809437|NCT00653744|Drug|Atorvastatin|
1809438|NCT00653757|Drug|goserelin acetate|
1809439|NCT00653757|Drug|leuprolide acetate|
1809440|NCT00653757|Radiation|image-guided radiation therapy|
1809441|NCT00653757|Radiation|intensity-modulated radiation therapy|
1809442|NCT00653770|Biological|FP85A|Recombinant Fowlpox virus 9 expressing antigen 85A from M. tuberculosis (5 x10^7 pfu)
1809443|NCT00653770|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis (5 x 10^7 pfu)
1809444|NCT00653796|Drug|Ezetimibe + Atorvastatin|oral tablets: ezetimibe 10 mg + atorvastatin 10 mg once daily for 6 weeks
1809445|NCT00653796|Drug|Atorvastatin|oral tablets: atorvastatin 10 mg + ezetimibe placebo once daily for 6 weeks
1809446|NCT00653822|Drug|alefacept|IC and SC
1809447|NCT00653822|Drug|placebo|IV and SC
1809448|NCT00653835|Drug|Ezetimibe + Simvastatin|oral tablets: ezetimibe 10 mg + simvastatin 20 mg once daily for 6 weeks
1809449|NCT00653835|Drug|Simvastatin|oral tablets: simvastatin 20 mg + ezetimibe placebo once daily for 6 weeks
1809450|NCT00653848|Drug|docetaxel|docetaxel 75 mg/square meter i.v. every third week, six cycles
1809451|NCT00653861|Device|JUVÉDERM™ Injectable Gel with Lidocaine|Single treatment, volume determined by investigator
1809452|NCT00653861|Device|JUVÉDERM™ Injectable Gel|Single treatment, volume determined by investigator
1809453|NCT00653874|Device|BiliChek (jaundice assessment)|assessment of jaundice was done by either transcutaneous bilirubinometry (TcB) method or by clinical assessment of bilirubin (CaB)
1809454|NCT00653874|Procedure|Transcutaneous bilirubinometry (TcB)|transcutaneous bilirubinometry was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
1809455|NCT00653874|Other|Clinical asessment of bilirubin (CaB)|Clinical assessment of bilirubin (CaB) was used for jaundice assessment in healthy term and near-term jaundiced neonates between 24 to 168 hours of life
1809456|NCT00653887|Other|Biofeedback|4 sessions of biofeedback one session each week
1809457|NCT00653887|Other|Placebo|4 sessions, one each week, of discussion about anorectal disease
1809458|NCT00653913|Drug|SCH 58235|SCH 58235 10 mg (once daily)
1809459|NCT00653913|Drug|pitavastatin|Pitavastatin 2 mg (once daily)
1809460|NCT00653926|Drug|ropivacaine, ketorelac and epinephrine|In Group A, 200 mg ropivicaine, 30 mg ketorelac and 0.5 mg epinephrine (total volume 106 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue After 21 postoperative hours in Group A, 150 mg ropivicaine, 30 mg ketorelac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
1809461|NCT00653926|Drug|saline|In Group P (placebo) no injections were given intaoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
1809462|NCT00653939|Drug|Fosbretabulin|Arm 2 only: Fosbretabulin (60 mg/m2) on Days 7,14 and 21 for 6 cycles.
1809463|NCT00653939|Drug|Carboplatin|Chemotherapy: Carboplatin (AUC 6) on Day 1 of each 21 day cycle for 6 cycles.
1809464|NCT00653939|Drug|Paclitaxel|Chemotherapy: Paclitaxel (20 mg/m2) on Day 1 of each 21-day cycle for 6 cycles.
1809465|NCT00653939|Drug|Bevacizumab|Bevacizumab (15 mg/kg) on Day 1 of each 21-day cycle for 6 cycles.
1809466|NCT00653952|Drug|CAELYX|Dose of 50 mg/m2 by i.v. infusion over 1 hour every 28 days for up to 1 year
1809467|NCT00653952|Drug|Paclitaxel HCl|Dose of 175 mg/m2 by i.v. infusion over 3 hours starting on Day 1 of a 21-day cy
1809468|NCT00653965|Drug|Rosuvastatin|
1809469|NCT00653965|Drug|Atorvastatin|
1809470|NCT00653978|Procedure|ERCP plus one biliary stent|ERCP ＋ one biliary stent insertion
1809471|NCT00653978|Procedure|ERCP plus two biliary stents|ERCP ＋ two biliary stents insertion
1809473|NCT00654017|Drug|placebo|Placebo comparator to be given per protocol.
1809474|NCT00654017|Drug|sildenafil|oral sildenafil citrate at an initial dose of 25 mg, which could have been up-titrated to 50 mg at Visit 3 based on the patient's efficacy, safety and tolerability responses; at Visits 4 and 5, the dose could remain the same, be increased to 100 mg, or decreased to 25 mg depending on the safety, efficacy, and tolerability
1809475|NCT00654030|Drug|1650-G Vaccine|.6ml injection administered intradermally in the thigh at week 0 and week 4
1809476|NCT00654043|Drug|Torsemide|tablets, 20 Mg, single-dose
1809477|NCT00654043|Drug|Demadex|Tablets, 20 mg, single-dose
1809478|NCT00654056|Drug|Actrapid (human insulin)|On day one: 0,5 IU/kg/min for 3 hours, 1,5 IU/kg/min for 3 hours, on day two: 3,0 IU/kg/min for 3 hours, 5,0 IU/kg/min for 3 hours
1809479|NCT00654069|Drug|Oxycodone HCl/Niacin Tablets 5/30 mg|Tablets 5/30 mg, 2 tablets every 6 hours for 48 hours
1809480|NCT00654069|Drug|Oxycodone HCl/Niacin 7.5/30 mg|Tablets 7.5/30 mg, 2 tablets every 6 hours for 48 hours
1809481|NCT00654069|Drug|Placebo|Tablets, 2 tablets every 6 hours for 48 hours
1809482|NCT00654082|Drug|sildenafil|sildenafil 50 mg tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks; after 2 weeks on treatment, doses could be escalated to 100 mg or reduced to 25 mg
1809483|NCT00654082|Drug|placebo|placebo tablet by mouth 1 hour prior to anticipated sexual activity, but not more than once daily (QD) for 6 weeks
1809484|NCT00654095|Drug|Ezetimibe|Ezetimibe 10 mg once daily
1809485|NCT00654095|Drug|atorvastatin|atorvastatin 20 mg once daily
1809486|NCT00654108|Drug|Ciprofloxacin 500 mg|500 milligrams(mg) will be administered orally twice daily for 5 days.
1809487|NCT00654108|Biological|Peru-15-pCTB|Live attenuated oral combined ETEC-cholera (Peru-15 pCTB) vaccine co-administered with bicarbonate buffer solution; vaccine dose levels 1 X 10^7; 1 X 10^8; 1 X 10^9; and 1 X 10^10.
1809488|NCT00654108|Drug|Placebo|Buffer solution: 2.5 grams (g) Sodium Bicarbonate powder, 1.65 g Ascorbic Acid and 25 mg Aspartame, in 100 milliliters (mL) water for injection.
1809489|NCT00654121|Drug|Actrapid HM|56 subjects will receive metabolically active insulin by subcutaneous injections for 36 months (twice daily)
1809490|NCT00654134|Biological|Clinical Center Reference Endotoxin|20,000 EU inhaled
1809491|NCT00654147|Drug|Raltegravir & Lopinavir/ritonavir|Two drug regimen of an integrase inhibitor and ritonavir boosted protease inhibitor
1809492|NCT00654147|Drug|Raltegravir and emtricitabine/tenofovir|Three drug regimen of an integrase inhibitor and a fixed dose combination of a non-nucleoside/nucleotide inhibitors
1809493|NCT00654160|Drug|fluorouracil|
1809494|NCT00654160|Drug|irinotecan hydrochloride|
1809495|NCT00654160|Drug|leucovorin calcium|
1809496|NCT00654160|Other|pharmacogenomic studies|
1809497|NCT00654160|Other|pharmacological study|
1809498|NCT00654173|Drug|Rosuvastatin|
1809499|NCT00654173|Drug|Simvastatin|
1809500|NCT00654173|Drug|Atorvastatin|
1809501|NCT00654186|Drug|Revlimid|25mg daily on days 1 - 21 followed by 7 days of rest repeated every 28 days
1809502|NCT00654212|Procedure|endo-laparoscopic approach|endoluminal stenting followed by laparoscopic resection
1809503|NCT00654212|Procedure|open approach|emergency open surgery
1809504|NCT00654225|Drug|Rosuvastatin|
1809505|NCT00654225|Drug|Atorvastatin|
1809506|NCT00654238|Drug|sorafenib|400mg PO BID daily
1809507|NCT00654264|Procedure|Water immersion|Subjects will sit in tub for four hours.
1809508|NCT00654277|Drug|Ondansetron|ODT, 8 mg, single-dose
1809509|NCT00654277|Drug|Zofran|ODT, 8 mg, fasting conditions
1809510|NCT00654290|Drug|Amiodarone + Propranolol|Amiodarone and Propranolol 7 days pre-operation to 5 days post CABG
1809511|NCT00654290|Drug|Amiodarone|Amiodarone treated 7 days pre-operation to 5 days post CABG
1809512|NCT00654290|Drug|Propranolol|Propranolol from 7 days pre-operation to 5 days post CABG
1809513|NCT00654303|Drug|Rosuvastatin|
1809514|NCT00654316|Biological|BCG|intradermal injection of 0.1ml BCG over the deltoid muscle
1809515|NCT00654329|Drug|Saline|Normal saline, given intranasally
1809516|NCT00654329|Drug|Fentanyl|Fentanyl, nasal transmucosal, 2 micrograms/kilogram
1809517|NCT00654329|Drug|Dexmedetomidine|Dexmedetomidine, transmucosal, 1 microgram/kilogram
1809518|NCT00654329|Drug|Dexmedetomidine|Dexmedetomidine, 2 microgram/kilogram, transmucosal route
1809519|NCT00654342|Procedure|Intraoperative injection (in vivo)|Intraoperative injection
1809520|NCT00654342|Procedure|Postoperative injection (ex vivo)|postoperative injection
1809576|NCT00654732|Drug|Vinblastine|6 mg/m^2 IV Over 1 Hour On Day 1 and 15.
1809521|NCT00654355|Drug|tacrolimus ointment|tacrolimus ointment to be applied twice daily to affected areas during duration of study
1809522|NCT00654368|Biological|Etanercept|Commercially available etanercept administered subcutaneously at 50 mg/week.
1809523|NCT00654368|Drug|Methotrexate|Commercially available methotrexate administed orally, subcutaneously or intramuscularly 15 mg/week (or 10 mg/week in case of documented intolerance to higher doses)
1809524|NCT00654381|Drug|BI 1356|5 mg/daily
1809525|NCT00654381|Drug|BI 1356|10 mg/daily
1809526|NCT00654381|Drug|voglibose placebo|three times daily
1809527|NCT00654381|Drug|BI 1356 placebo|once daily
1809528|NCT00654381|Drug|voglibose|0.6 mg/daily
1809529|NCT00654394|Drug|Rosuvastatin|
1809530|NCT00654407|Drug|Rosuvastatin|
1809531|NCT00654407|Drug|Atorvastatin|
1809532|NCT00654407|Drug|Simvastatin|
1809533|NCT00654420|Drug|Dalotuzumab|Dalotuzumab 20 mg/mL in sterile solution. Intravenous (IV) infusion over 60 minutes at 5 mg/kg, administered weekly at dosage according to treatment group.
1809534|NCT00654420|Drug|Erlotinib|Open-label erlotinib administrated orally (tablets) by mouth (PO) at 150 mg daily.
1809535|NCT00654433|Biological|ALD-101|A subpopulation of cord blood cells composed of cells that express a high level of the intracellular enzyme aldehyde dehydrogenase (ALDH).
1809536|NCT00654446|Drug|Rosuvastatin|
1809537|NCT00654446|Drug|Simvastatin|
1809539|NCT00654485|Drug|Rosuvastatin|
1809540|NCT00654485|Drug|Atorvastatin|
1809541|NCT00654498|Drug|Pramipexole|
1809542|NCT00654498|Drug|Placebo|
1809543|NCT00654511|Drug|Fentanyl|Fentanyl 1mcg/kg, Intravenous (IV)
1809544|NCT00654511|Drug|Fentanyl|Fentanyl 2mcg/kg, Intravenous (IV)
1809545|NCT00654511|Drug|Dexmedetomidine|Dexmedetomidine, 2mcg/kg, Intravenous (IV)
1809546|NCT00654511|Drug|Dexmedetomidine|Dexmedetomidine, 4mcg/kg Intravenous (IV)
1809548|NCT00654537|Drug|Rosuvastatin|
1809549|NCT00654537|Drug|Atorvastatin|
1809550|NCT00654537|Drug|Pravastatin|
1809551|NCT00654537|Drug|Simvastatin|
1809552|NCT00654550|Drug|Nexagon™ or Nexagon™ vehicle|Dose-escalation design in which cohorts of 6 subjects will be studied sequentially.
1809553|NCT00654576|Drug|Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole|patient will receive one of the seven study drugs (Chlorpromazine, Sulpiride, Clozapine, Olanzapine, Risperidone, Quetiapine, Aripitrazole) as the maintain treatment. the dose is flexible, is based on the study doctor's judgment.
1809554|NCT00654576|Behavioral|psychosocial intervention|the psychosocial interventions include psychoeducaiton, family intervention, skill training, and cognitive-behavioral therapy.
1809555|NCT00654589|Drug|Deferasirox|
1809556|NCT00654602|Drug|Rosuvastatin|
1809557|NCT00654602|Behavioral|Maintenance of specific diet|
1809560|NCT00654628|Drug|ezetimibe (+) simvastatin|Vytorin 10/20 (ezetimibe 10 mg /simvastatin20 mg) tablet once daily consecutively for 6 weeks.
1809561|NCT00654641|Procedure|Negative pressure wound closure|Applying negative pressure to primary wound closure
1809562|NCT00654641|Procedure|Standard wound closure|Standard wound closure
1809563|NCT00654654|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm biopsies
Two injection treatments of facial wrinkles and creases
Conduct of study assessments"
1809564|NCT00654667|Drug|Placebo|Placebo, no active drug, take 5 capsules by mouth daily for one month
1809565|NCT00654667|Drug|Resveratrol|
1809566|NCT00654680|Drug|Vardenafil (Levitra, BAY38-9456)|5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
1809567|NCT00654680|Drug|Placebo|Matching placebo
1809568|NCT00654693|Other|Rapid Response Team|If the subject is experiencing a life threatening change in their vital signs, the Rapid Response Team will be initiated per VUMC protocol.
1809569|NCT00654706|Drug|Sertindole|Once daily oral dose. Day 1-20: 4-16 mg/day (titration period). Day 21-84: 12, 16 or 20 mg/day (flexible treatment period).
1809570|NCT00654706|Drug|Quetiapine|Twice daily oral dose. Day 1-20: 50-500 mg/day (titration period). Day 21-84: 400, 500 or 600 mg/day (flexible treatment period).
1809571|NCT00654719|Dietary Supplement|NutriDrink|Nutritional supplementation that contains 600 kcal/day: protein content 20 g, carbohydrates 72 g, fat 26 g
1809572|NCT00654719|Dietary Supplement|Placebo|Nutritional supplementation containing only 12 kcal/day
1809573|NCT00654732|Drug|Rituximab|375 mg/m^2 IV Weekly Over 7 Hours On Days 1, 8, 15, 22.
1809574|NCT00654732|Drug|Adriamycin|25 mg/m^2 IV Over 1 Hour On Day 1 and 15.
1809577|NCT00654732|Drug|Dacarbazine|375 mg/m^2 IV Over 1 Hour On Day 1 and 15.
1809578|NCT00654745|Drug|Amlodipine|Amlodipine 5 mg tablets , Daily for 3 weeks;
1809579|NCT00654745|Drug|amlodipine / olmesartan medoxomil combination|amlodipine / olmesartan medoxomil combination tablets 5 mg/20 mg or 5 mg/40 mg or 10 mg/40 mg
1809580|NCT00654745|Drug|Hydrochlorothiazide|hydrochlorothiazide tablets, 12.5 mg or 25 mg.
1809581|NCT00654758|Drug|M200 (Volociximab), Carboplatin, Paclitaxel|Volociximab will be administered via IV infusion at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels during the first cycle. Volociximab will be given for at least 6 cycles (3 weeks/cycle) and subjects who have stable disease at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All three drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
1809582|NCT00654771|Other|urine collection|clean catch urine collection and catheterized urine collection
1809583|NCT00654784|Drug|idebenone|idebenone 450 mg/day (150 mg three times a day)
1809584|NCT00654784|Drug|placebo|
1809585|NCT00654797|Procedure|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
1809586|NCT00654810|Behavioral|Walking Exercise|Intermittent treadmill walking to near maximal claudication pain three days per week
1809587|NCT00648518|Drug|Metformin Hydrochloride ER Tablets 750 mg|750mg, single dose fasting
1809588|NCT00648518|Drug|Glucophage® XR Tablets 750 mg|750mg, single dose fasting
1809589|NCT00648531|Drug|Balsalazide Disodium Capsules 750 mg|3x750mg, single dose fasting
1809590|NCT00648531|Drug|Colazal® Capsules 750 mg|3x750mg, single dose fasting
1809591|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablet
1809592|NCT00648544|Drug|Pravastatin|Single-dose 80 mg oral immediate-release tablets
1809593|NCT00648557|Drug|Levothyroxine Sodium Tablets 200 mg|3x200mcg, single dose fasting
1809594|NCT00648557|Drug|Synthroid Tablets 200 mg|3x200mcg, single dose fasting
1809595|NCT00648570|Drug|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fasting
1809596|NCT00648570|Drug|Lexapro® Tablets (20 mg|20mg, single dose fasting
1809597|NCT00648583|Drug|Ondansetron Tablets 24 mg|24mg, single dose fed
1809598|NCT00648583|Drug|Zofran® Tablets 24 mg|24mg, single dose fed
1809599|NCT00648596|Drug|sildenafil|sildenafil 50 mg tablet by mouth 1 hour before sexual activity for 12 weeks; the dose could be increased to 100 mg or decreased to 25 mg.
1809600|NCT00648596|Drug|placebo|placebo tablet by mouth 1 hour before sexual activity for 12 weeks
1809601|NCT00648609|Other|Palliative home care in advanced COPD|Interdisciplinary palliative care team on community based self care management of advanced COPD.
1809602|NCT00648609|Other|Standard of care|Usual care for COPD patients
1809603|NCT00648622|Drug|Carvedilol Tablets 12.5 mg|12.5mg, single dose fed
1809604|NCT00648622|Drug|Coreg® Tablets 12.5 mg|12.5mg, single dose fed
1809605|NCT00648635|Behavioral|Questionnaire|Questionnaires taking 30-60 minutes to complete every 3 months.
1809606|NCT00648648|Drug|MK1775|Dose escalation study. Part 1: MK1775 capsules will be given on Day 1 of a 14-day cycle: starting dose of MK1775 is 325 mg and will escalate up to 1300 mg or until MTD achieved. Dose Levels for MK1775: 325 mg, 650 mg, and 1300 mg.
1809607|NCT00648648|Drug|gemcitabine|gemcitabine - IV infusions dosage ranging from 1000 mg/m^2 to 600 mg/m^2 in a 28-day cycle. Dose Levels for Gemcitabine: 1000 mg/m^2, 800 mg/m^2, 600 mg/m^2
1809608|NCT00648648|Drug|cisplatin|cisplatin - IV infusion dosage ranging from 75 mg/m^2 to 50 mg/m^2 in a 21-day cycle. Dose Levels for cisplatin 75 mg/m^2, 60 mg/m^2, 50 mg/m^2
1809609|NCT00648648|Drug|carboplatin|carboplatin - IV infusion dosage ranging from AUC/time curve of 5 mg/min/mL to AUC 3 in a 21-day cycle. Dose levels for carboplatin: AUC 5, AUC 4, AUC 3
1809610|NCT00648648|Drug|MK1775|Part 2-A: consists of three treatment arms, each combining a single starting dose of MK1775, 100 mg in a 21-28 day cycle. Dose Levels for MK1775: 50 mg, 100 mg, 200 mg, 325 mg, 475 mg, 675 mg, 900 mg, 1200 mg, 1600 mg (undetermined interim doses are allowed)
1809611|NCT00648648|Drug|MK1775|Part 2-B: consists of three treatment arms, each combining a starting dose of MK1775, 50 mg (for gemcitabine) in a 28 day cycle. Dose Levels for MK1775: 25 mg, 50 mg, 100 mg, 125 mg, 150 mg, 200 mg, 250 mg, 325 mg, 425 mg (undetermined interim doses are allowed)
1809612|NCT00648648|Drug|MK1775|Part 3: consists of treatment with MTD of MK1775 from Part 2-B.
1809613|NCT00648648|Drug|gemcitabine|gemcitabine - IV infusions dosage ranging from 1000 mg/m^2 to 600 mg/m^2 in a 28-day cycle.
1809614|NCT00648648|Drug|cisplatin|cisplatin - IV infusion dosage ranging from 75 mg/m^2 to 50 mg/m^2 in a 21-day cycle.
1809615|NCT00648648|Drug|carboplatin|carboplatin - IV infusion dosage ranging from AUC/time curve of 5 mg/min/mL to AUC 3 in a 21-day cycle.
1809616|NCT00648661|Drug|Escitalopram Oxalate Tablets 20 mg|20mg, single dose fed
1809617|NCT00648661|Drug|Lexapro® Tablets 20 mg|20mg, single dose fed
1809618|NCT00648674|Device|Apligraf|Applied at Day 0, possible re-application at Week 6
1809619|NCT00648687|Behavioral|suck 12.5% dextrose in water 5 minutes before the procedure|Newborns will suck 2 ml of D12.5W 5 minutes before eye exam for ROP
1809620|NCT00648700|Drug|Levothyroxine Sodium Tablets 300 μg|2x300mcg, single dose fasting
1809621|NCT00648700|Drug|Levothroid® Tablets 300 μg|2x300mcg, single dose fasting
1809622|NCT00648713|Drug|Terbinafine Hydrochloride Tablets 250 mg|250mg, single dose fed
1809623|NCT00648713|Drug|Lamisil® Tablets 250 mg|250mg, single dose fed
1809624|NCT00648726|Drug|cefuroxime plus erythromycin|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days plus erythromycin ethylsuccinate 0.5 g twice daily, which was given for a total duration of 14 days for subjects with suspected pneumonia due to atypical pathogens
1809685|NCT00649155|Drug|Cipro® XR Tablets (500 mg|500mg, single dose fasting
1809625|NCT00648726|Drug|azithromycin (Zithromax)|intravenous azithromycin 500 mg once daily for 4 +/-1 days, followed by oral azithromycin 500 mg once daily for a total duration of 9 +/-1 days
1809626|NCT00648726|Drug|cefuroxime|intravenous cefuroxime 1.5 g twice daily for 4 +/-1 days, followed by oral cefuroxime 0.5 g twice daily for a total duration of 9 +/-1 days
1809627|NCT00648739|Drug|ALXN6000|Part A is a comparison of different dosages of ALXN6000 by cohort ranging from 50 mg/m2 up to 600 mg/m2 given as a single IV dose. Once the most appropriate dose is determined it will be given over a 28 day cycle for 4 cycles in Part B Cohort 1 = 50 mg/m2 Cohort 2 = 100 mg/m2 Cohort 3 = 200 mg/m2 Cohort 4 = 300 mg/m2 Cohort 5 = 400 mg/m2 Cohort 6 = 500 mg/m2
1809628|NCT00648765|Drug|Anagrelide Hydrochloride Capsules 1 mg|1mg, single dose fed
1809629|NCT00648765|Drug|Agrylin® Capsules 1 mg|1mg, single dose fed
1809630|NCT00648778|Drug|Loxapine Succinate Capsules 25 mg|25mg, single dose fasting
1809631|NCT00648778|Drug|Loxitane® Capsules 25 mg|25mg, single dose fasting
1809632|NCT00648791|Drug|Finasteride Tablets 5 mg|5mg, single dose fasting
1809633|NCT00648791|Drug|Proscar Tablets 5 mg|5mg, single dose fasting
1809634|NCT00648804|Drug|Ondansetron Orally Disintegrating Tablets 8 mg|8mg, single dose fed
1809635|NCT00648804|Drug|Zofran ODT® Tablets 8 mg|8mg, single dose fed
1809636|NCT00648817|Drug|Tenofovir Disoproxil Fumarate|Tenofovir DF 300 mg QD (equivalent to 245 mg of tenofovir disoproxil)
1809637|NCT00648817|Drug|Tenofovir DF placebo|Tenofovir DF placebo tablet QD
1809638|NCT00648830|Procedure|Clarithromycin|Single-dose of Clarithromycin 250 mg oral immediate-release tablets
1809639|NCT00648830|Drug|Clarithromycin|single-dose 250 mg immediate-release oral tablets
1809640|NCT00648843|Drug|Oxybutynin Chloride Extended-release Tablets 5 mg|4x5mg, single dose fed
1809641|NCT00648843|Drug|Ditropan XL® Tablets 5 mg|4x5mg, single dose fed
1809642|NCT00648856|Drug|Sertraline Hydrochloride Tablets 100 mg|100mg, single dose fed
1809643|NCT00648856|Drug|Zoloft® Tablets 100 mg|100mg, single dose fed
1809644|NCT00648869|Drug|metformin tablet, metformin gum|500 mg, 250 mg
1809645|NCT00648882|Drug|LEVOTHYROXINE SODIUM TABLETS,|2x300mcg, single dose fasting
1809646|NCT00648882|Drug|SYNTHROID® 300 mcg Tablets|2x300mcg, single dose fasting
1809647|NCT00648895|Drug|Nebivolol|nebivolol 10mg, 20mg, 40mg daily dosage, oral administration
1809648|NCT00648895|Drug|Metoprolol ER (TM)|Metoprolol ER 100mg, 200mg, 400mg, daily dosage, oral administration
1809649|NCT00648908|Drug|Fampridine-SR|Tablets, 10 mg, BID
1809650|NCT00648921|Drug|Olanzapine Tablets 5 mg|5mg, single dose fasting
1809651|NCT00648921|Drug|Zyprexa® Tablets 5 mg|5mg, single dose fasting
1809652|NCT00648934|Drug|Topiramate Sprinkle Capsules 25 mg|25mg, single dose fed
1809653|NCT00648934|Drug|Topamax® Sprinkle Capsules 25 mg|25mg, single dose fed
1809654|NCT00648947|Drug|Clopidogrel Bisulfate Tablets 75 mg|75mg, single dose fasting
1809655|NCT00648947|Drug|Plavix® Tablets 75 mg|75mg, single dose fasting
1809656|NCT00648960|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral tablet
1809657|NCT00648960|Drug|Clarithromycin|Single-dose 500 mg immediate-release oral dose
1809658|NCT00648973|Drug|Diphenhydramine 50 mg|"Three times daily: two diphenhydramine 25 mg capsules
Twice daily: one pseudoephedrine-matching placebo tablet"
1809659|NCT00648973|Drug|Diphenhydramine 25 mg|"Three times daily: one diphenhydramine 25 mg capsule and one diphenhydramine-matching placebo capsule
Twice daily: one pseudoephedrine-matching placebo tablet"
1809660|NCT00648973|Drug|Pseudoephedrine 120 mg|"Three times daily: two diphenhydramine-matching placebo capsules
Twice daily: one pseudoephedrine 120 mg tablet"
1809661|NCT00648986|Drug|Tazorac|All patients were to apply topical tazarotene (Tazorac) twice daily to all affected fingernails for 24 weeks.
1809662|NCT00648999|Drug|lopinavir/ritonavir|lopinavir/ritonavir 400 mg/100 mg bid 48 weeks of treatment
1809663|NCT00649012|Drug|Pioglitazone HCl Tablets 45 mg|45mg, single dose fed
1809664|NCT00649012|Drug|Actos® Tablets 45 mg|45mg, single dose fed
1809665|NCT00649025|Drug|FlutiForm 250/10|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 12 weeks.
1809666|NCT00649025|Drug|SKP-Fluticasone|SKP Fluticasone 250 ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
1809667|NCT00649025|Drug|Flovent Fluticasone HFA|Flovent 250 ug HFA is a pMDI that delivers after priming 125ug of Fluticasone propionate per actuation. Patients will take 2 actuations BID for 12 weeks.
1809668|NCT00649038|Drug|Benazepril HCl and Hydrochlorothiazide Tablets 20 mg/25 mg|20/25mg, single dose fed
1809669|NCT00649038|Drug|Lotensin HCT® Tablets 20 mg/25 mg|20/25mg, single dose fed
1809670|NCT00649051|Drug|Metolazone Tablets 2.5 mg|4x2.5mg, single dose fasting
1809671|NCT00649051|Drug|Zaroloxyn® Tablets 2.5 mg|4x2.5mg, single dose fasting
1809672|NCT00649064|Drug|Ziprasidone|Ziprasidone 40 mg capsules twice daily for the first 7 days followed by flexible dosing between 40 and 80 mg twice daily for the remaining 5 weeks.
1809673|NCT00649077|Drug|Meloxicam Tablets 15 mg|15mg, single dose fasting
1809674|NCT00649077|Drug|Mobic® Tablets 15 mg|15mg, single dose fasting
1809675|NCT00649090|Drug|exemestane|Exemestane 25 mg oral tablet once daily for a maximum of 3 years
1809676|NCT00649103|Drug|Quinapril Hydrochloride Tablets 40 mg|40mg, single dose fasting
1809677|NCT00649103|Drug|Accupril® Tablets 40 mg|40mg, single dose fasting
1809678|NCT00649116|Drug|Metoprolol Tartrate Tablets 100 mg|100mg, single dose fed
1809679|NCT00649116|Drug|Lopressor® Tablets 100 mg|100mg, single dose fed
1809680|NCT00649129|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fasting
1809681|NCT00649129|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fasting
1809682|NCT00649142|Procedure|Open sutured mesh repair|Open sutured mesh repair
1809683|NCT00649142|Procedure|Laparoscopic mesh glue fixation|Laparoscopic mesh glue fixation
1809684|NCT00649155|Drug|Ciprofloxacin Extended-Release Tablets 500 mg|500mg, single dose fasting
1809686|NCT00649168|Drug|BROMOCRIPTINE MESYLATE CAPSULES, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
1809687|NCT00649168|Drug|Parlodel® (bromocriptine mesylate) capsules, USP 5 mg|2x5mg bromocriptine mesylate, single dose fed; with 10mg metoclopramide HCl prophylactic injection
1809688|NCT00649181|Drug|Metolazone Tablets 5 mg|2x5mg, single dose fasting
1809689|NCT00649181|Drug|Zaroloxyn® Tablets 5 mg|2x5mg, single dose fasting
1809690|NCT00649194|Drug|Rabeprazole Sodium Delayed-Release Tablets 20 mg|20mg, single dose fed
1809691|NCT00649194|Drug|Aciphex® Tablets 20 mg|20mg, single dose fed
1809692|NCT00649207|Drug|ABT-888|Oral Capsules
1809693|NCT00649207|Radiation|Whole Brain Radiation Therapy|15 fractions of 2.5 Gy over 3 weeks to a total dose of 37.5 GY or 10 fractions of 3.0 Gy over 2 weeks to a total dose of 30 Gy
1809694|NCT00649220|Drug|Memantine|memantine tablets, twice a day (bid), for 20 weeks
1809695|NCT00649233|Drug|Metoprolol Tartrate/Hydrochlorothiazide Tablets 100/50 mg|100/50mg, single dose fed
1809696|NCT00649233|Drug|Lopressor HCT® Tablets 100/50 mg|100/50mg, single dose fed
1809697|NCT00649259|Drug|Oxybutynin Chloride ER Tablets 10 mg|2x10mg, single dose fed
1809698|NCT00649259|Drug|Ditropan XL® Tablets 10 mg|2x10mg, single dose fed
1809699|NCT00649272|Drug|Oxybutynin Chloride Extended-Release Tablets, 15 mg|15mg, single dose fasting
1809700|NCT00649272|Drug|Ditropan XL® Extended-release tablets, 15 mg|15mg, single dose fasting
1809701|NCT00649285|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|100mg, single dose fed
1809702|NCT00649285|Drug|Macrobid® Capsules 100 mg|100mg, single dose fed
1809703|NCT00649298|Procedure|haemodialysis|Comparison of different weekly duration of haemodialysis treatment
1809704|NCT00649311|Drug|eplerenone|Eplerenone 50 mg oral film-coated tablet once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to eplerenone 100 mg oral film-coated tablet once daily for 4 weeks.
1809705|NCT00649311|Drug|Losartan|Losartan 50 mg oral capsule once daily for 8 weeks. If blood pressure was uncontrolled (DBP ≥ 90 mmHg) at Week 4, the dose was increased to losartan 100 mg oral capsule once daily for 4 weeks
1809706|NCT00649324|Drug|Hydrochlorothiazide Tablets 50 mg|50mg, single dose fasting
1809707|NCT00649324|Drug|Hydrochlorothiazide Tablets (50 mg|50mg, single dose fasting
1809708|NCT00654836|Biological|bevacizumab|Participants will receive bevacizumab 15 mg/kg on days 1,22, and 43.
1809709|NCT00654836|Drug|Carboplatin|Participants will receive a standard carboplatin dose according to their area under the plasma drug concentration-time curve (AUC-6) on days 1, 22, and 43.
1809710|NCT00654836|Drug|ABI-007|Participants will receive ABI-007 (Abraxane) 100mg/m2 on days 1,8, 15, 22, 29, 36,43,and 50.
1809711|NCT00654849|Procedure|Plasmakinetic bipolar energy forceps|Use of bipolar plasmakinetic vessel sealing during abdominal hysterectomy
1809712|NCT00654849|Procedure|Abdominal Hysterectomy with traditional suture technique|The abdominal hysterectomy was realized using sutures in the haemostasia of pedicles.
1809713|NCT00654862|Dietary Supplement|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
1809714|NCT00654862|Dietary Supplement|cocoa polyphenols|Oral administration of capsules with 1000 mg polyphenols, 250 mg polyphenols or placebo
1809715|NCT00654875|Drug|Aliskiren|Aliskiren supplied in 150 mg and 300 mg tablets.
1809716|NCT00654875|Drug|Placebo to Aliskiren|Placebo to Aliskiren matching 150 and 300 mg tablets
1809717|NCT00654888|Procedure|ALK (automated lamellar keratectomy)|ALK is performed with a microkeratome, to make a free cap.
1809718|NCT00654888|Drug|Mitomycin|mitomycin 0,02%, 30 seconds after ALK
1809719|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 1)|0.5 mL, Intramuscular
1809720|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 2)|0.5 mL, Intramuscular
1809721|NCT00654901|Biological|DTaP-IPV-Hep B-PRP~T vaccine (Batch 3)|0.5 mL, Intramuscular
1809722|NCT00654901|Biological|Infanrix Hexa™|0.5 mL, Intramuscular
1809723|NCT00654914|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg per dose of vardenafil for the first four weeks. A further 8 weeks ( in two treatment periods of four weeks, respectively) where patients will either maintain the previous dosage regimen or will step up to 20 mg per dose of vardenafil or will step down to 5 mg per dose of vardenafil, at interval visits of four weeks .
1809724|NCT00654927|Drug|Fampridine-SR b.i.d. (Twice Daily)|Dosage form - tablets.
1809725|NCT00654940|Drug|Pregabalin (Lyrica)|Oral, 75mg or 150mg capsules, BID
1809726|NCT00654940|Drug|Placebo|Oral, matched capsules, BID
1809727|NCT00654953|Drug|sertraline|Sertraline hydrochloride (200 mg/day) will be administered once daily. While subjects are at RCA-NLR they initially receive 50 mg/day of sertraline. This dose is gradually increased over a 3-week period until subjects receive 200 mg. When subjects are transferred to the outpatient program, they will be administered capsules once weekly, with take-home doses given in blister packs to take once a day for the rest of the week.
1809728|NCT00654953|Drug|Placebo|Placebo (cellulose or lactose) administered twice per day for 12 weeks.
1809729|NCT00654953|Drug|gabapentin|Gabapentin (Neurontin; Parke-Davis; 1200 mg/day) will be administered twice daily. Initially, patients will receive 200 mg twice daily on days 1-5, 400 mg twice daily on days 6-10, then 600 mg twice daily on days 11 on. Subjects are then maintained on this dose for the duration of the trial, unless side-effects are too severe, in which case the dose of gabapentin is decreased to no less 800 mg/day. If symptoms persist, subjects' participation would then be terminated.
1809730|NCT00654966|Drug|Urotensine II|A few drops of the drug will be administered to the skin by iontophoresis.
1809731|NCT00654966|Drug|Soluble epoxide hydrolase|A few drops of the drug will be administered to the skin by iontophoresis.
1809732|NCT00654979|Device|SafeFlo IVC Filter|SafeFlo IVC Filter
1809733|NCT00654992|Drug|Erythropoietin-Beta|300 IU/kg of EPO or saline intravenously before surgery
1809734|NCT00654992|Drug|Normal Saline|300 IU/kg of normal saline intravenously before surgery
1809735|NCT00655005|Other|questionnaire administration|Newly diagnosed HNC patients
1809736|NCT00655005|Procedure|quality-of-life assessment|following treatment
1809779|NCT00657410|Procedure|quality-of-life assessment|
1809737|NCT00655018|Dietary Supplement|Vitamin treatment (alpha tocopherol plus ascorbic acid)|alpha tocopherol 600 IU/d plus ascorbic acid 500 mg/d and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
1809738|NCT00655018|Dietary Supplement|Placebo|placebo and lifestyle intervention [hypocaloric Diet(25-30 cal/kg/d) or isocaloric (40-45 cal/kg/d) and physical activity].
1809739|NCT00655031|Dietary Supplement|Pomegranate Concentrate (POMx)|3.3 oz bottle containing antioxidants equivalent to 8 oz of pomegranate juice taken once daily for 7 days prior to infection and for 4 days after.
1809740|NCT00655031|Dietary Supplement|Placebo|3.3 oz bottle containing fruit flavored juice low in antioxidants taken once daily for 7 days prior to infection and for 4 days after.
1809741|NCT00655044|Drug|insulin detemir|Safety and effectiveness data collection in connection with the use of drug Levemir in daily clinical practice.
1809742|NCT00655057|Drug|S-citalopram|Participants will take 10 to 30 mg of s-citalopram daily for 12 weeks.
1809743|NCT00655057|Behavioral|Cognitive behavioral therapy (CBT)|Participants will attend twice weekly CBT sessions for 2 weeks and then once weekly sessions for 10 weeks. Sessions will focus on modifying thoughts and behaviors that may contribute to depression.
1809744|NCT00655057|Procedure|TRODAT-1 single photon emission computed tomographic (SPECT) imaging|Participants' striatal dopamine transporter (DAT) levels will be measured using [99mTc]TRODAT-1 SPECT with magnetic resonance imaging (MRI) co-localization on two separate occasions. Participants with depression will undergo TRODAT-1 SPECT imaging immediately before and after 12 weeks of their assigned treatment. Healthy participants will undergo TRODAT-1 SPECT imaging at baseline and 12 weeks later.
1809745|NCT00655070|Device|Timi3 Transthoracic ultrasound|Low frequency ultrasound over the chest using Timi3 ultrasound device
1809746|NCT00655083|Drug|Nepadutant|0.1 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
1809747|NCT00655083|Drug|Nepadutant|0.5 mg/Kg as one single oral dose divided in three age strata (from 6 to 24 weeks old)
1809748|NCT00655109|Drug|Olopatadine|Ophthalmic solution
1809749|NCT00655109|Drug|Fluticasone|Nasal spray
1809750|NCT00655109|Drug|Saline|Nasal spray
1809751|NCT00655109|Drug|Artificial tears|Ophthalmic Solution
1809752|NCT00655122|Drug|Dalteparin sodium|Dalteparin sodium was administered at a daily dosage of 5,000 UI anti-Xa by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
1809753|NCT00655122|Drug|Placebo|Placebo was administered with a daily injection of 0.2 mL by subcutaneous route. The treatment duration was 7 days in a single daily injection throughout the bedridden period.
1809754|NCT00655135|Drug|LDP-02|Each patient in arms 2 & 3 received a single IV dose of study drug at 0.5 or 2.0 mg/kg LDP-02 on Days 1 and 29.
1809755|NCT00655135|Drug|Placebo|Each patients in arm 1 received a single IV dose of placebo on Days 1 and 29.
1809756|NCT00655148|Biological|DTaP-IPV vero vaccine|DTaP-IPV vero 0.5 mL solution for intramuscular injection at 2, 3½, 5 and 16 months of age
1809757|NCT00655148|Biological|DTaP-IPV mkc vaccine|DTaP-IPV mkc 0.5 ml solution for intramuscular injection at 2, 3½, 5 and 16 months of age
1809758|NCT00657228|Drug|Intravenous heparin|"Intravenous heparin as an adjunct for the treatment of anaphylactic/anaphylactoid reactions in the Emergency Department.
To determine if a single bolus of intravenous unfractionated heparin (in conjunction with standard therapy) given to patients with anaphylactic/anaphylactoid reactions results in a faster time to recovery when compared to standard therapy alone."
1809759|NCT00657228|Drug|Saline|Standard treatment (epinephrine, corticosteroids, diphenhydramine, and H2 blockers) and saline.
1809760|NCT00657241|Drug|carvedilol|Coreg CR 20 mg (one week) and Coreg CR 40 mg (3 weeks).
1809761|NCT00657241|Drug|valsartan|Valsartan 160 mg (one week); valsartan 320 mg (3 weeks)
1809762|NCT00657254|Drug|Nexavar (Sorafenib, BAY43-9006)|Bay 43-9006 400mg (2 x 200mg tablets) orally twice daily until withdrawal.
1809763|NCT00657267|Drug|Temozolomide|Taken orally daily for the first three weeks of a four-week cycle.
1809764|NCT00657280|Drug|Sitagliptin|No one is blinded to the treatments.
1809765|NCT00657293|Behavioral|Arm training program|Patients will undergo a specific arm training program (ATP) three times a week for the duration of the 6 week program. The ATP will consist predominantly of resistance exercises. Muscle groups targeted during the ATP will include deltoid, biceps and triceps, pectoralis and latissimus. Subjects will train using multi station gym equipment and free weights.
1809766|NCT00657293|Behavioral|Purdue pegboard test (sham)|In an attempt to make the groups comparable in terms of attention, the control group will perform the purdue pegboard test of finger dexterity. The tasks will be performed in a sitting position with the arms supported on a table. This test will consist of 4 timed tasks where as many pins as possible will be placed on a pegboard in a given time. Performance of the pegboard test is likely to improve with practice which may serve to motivate the patients to continue practicing over the 6-week period. Subjects will perform this activity 3 times per week with supervision provided by a physiotherapist.
1809767|NCT00657306|Drug|hydrocortisone|50 mg/6 h per day
1809768|NCT00657306|Drug|dextrose solution 5%|dextrose solution 5% 100 ml/6 h per day
1809769|NCT00657319|Drug|biphasic insulin aspart 30|The observation is performed under normal clinical practice conditions without any additionally required diagnostic/therapeutic features. Physicians are allowed to decide the treatment regimen according to the medical standards.
1809770|NCT00657332|Procedure|blood sample draw|
1809771|NCT00657332|Procedure|urine sample|
1809772|NCT00657358|Drug|Lidocaine|Lidocaine 2% (2mg/ml) was administered via a computer assisted infusion to achieve a target plasma concentration of 2 mcg/ml; infused within 20 minutes.
1809773|NCT00657371|Device|Third Eye Retroscope Auxiliary Imaging System|A thin, flexible probe that is inserted in a standard colonoscope in order to display very detailed images of the colon tissue.
1809774|NCT00657384|Drug|acid tranexamic|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention.
1809775|NCT00657384|Drug|Nacl 0.9%|10 mg/kg Iv after randomization of the patient in the study,follow-up by continuous infusion of 10 mg/kg/h up to the end of the intervention
1809776|NCT00657397|Drug|Methadone|Methadone sirup once daily
1809777|NCT00657410|Drug|dexamethasone|
1809778|NCT00657410|Drug|prednisone|
1809780|NCT00657423|Drug|Treated by endostar combined with docetaxel and cisplatin|recombinant human endostatin given intravenously,7.5mg/㎡,d1-14,2cycles. docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
1809781|NCT00657423|Drug|Treated by docetaxel and cisplatin|docetaxel given intravenously,75mg/㎡,d1,2cycles. cisplatin given intravenously,75mg/㎡,d1,2cycles.
1809782|NCT00657449|Drug|valdecoxib|valdecoxib 80 mg (two 40 mg tablets) by mouth on Day 1 and valdecoxib 40 mg tablet once daily on Days 2-8
1809783|NCT00657449|Drug|rofecoxib|rofecoxib 50 mg (two 25 mg capsules) by mouth once daily for 8 days
1809784|NCT00657462|Other|Reminders|Users of the PAML Builder application will receive reminders about three application features (copy/paste, audit trail, sort medications by class) at the startup of the application
1809785|NCT00657475|Drug|Heparin Low Dose|Loading heparin dose of 150 IU / kg to achieve an ACT (activating clotting time) target more than 240 seconds.
1809786|NCT00657475|Drug|Heparin Full Dose|Loading heparin dose of 300 IU / kg to achieve an ACT (activating clotting time) target more than 400 seconds.
1809787|NCT00657488|Drug|Thalidomide|Thalidomide 100mg/day or 400 mg/day at bed time during one year
1809788|NCT00657501|Drug|testosterone gel|once daily transdermal gel, 300 mcg
1809789|NCT00657501|Drug|placebo gel|once daily transdermal placebo gel
1809790|NCT00657514|Drug|Ranolazine|500mg tablet po bid up to 1000mg (2 500mg tablets) po bid
1809791|NCT00657514|Drug|Placebo|1 tablet po bid up to 2 tablets po bid if tolerated
1809792|NCT00657527|Drug|Rosuvastatin|
1809793|NCT00657527|Behavioral|Cholesterol lowering diet|
1809794|NCT00657540|Drug|Analatro|30 mL of lyophilized antivenom, reconstituted in 50 mL saline infused over 10 minutes, up to 2 doses
1809795|NCT00657540|Drug|Saline|50 mL of saline infused over 10 minutes
1809797|NCT00657566|Other|duration of antibiotics|4 +/- 1 days of antibiotics
1809798|NCT00657566|Other|duration of antibiotics|active comparator antibiotics given until 2 days after resolution of fever, elevated white blood cell count, and gastrointestinal dysfunction.
1809799|NCT00657579|Drug|DE-104 ophthalmic solution, low concentration|
1809800|NCT00657579|Drug|DE-104 ophthalmic solution, medium concentration|
1809801|NCT00657579|Drug|DE-104 ophthalmic solution, high concentration|
1809802|NCT00657579|Drug|DE-104 vehicle|
1809803|NCT00657605|Drug|Recombinant methionyl human leptin|Recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
1809805|NCT00657631|Behavioral|Acceptance and Commitment Therapy|"Considered part of the third wave of CBT along with Dialectical Behavior Therapy (DBT; Linehan, 1993) and Mindfulness-based Cognitive Therapy (MBCT; Segal, Williams, & Teasdale, 2001), ACT is built upon the strong, research-based foundation of CBT. However, while CBT for psychosis focuses on reducing symptoms, ACT focuses on changing the way in which the person experiences his or her symptoms so that the person can still live his or her life in accordance with his or her life values. Specifically, CBT attempts to reduce delusions by disputing the evidence for the delusion and ACT attempts to increase the person's ability to live his or her life while still experiencing delusions (Hayes, Strosahl & Wilson, 1999)."
1809806|NCT00657644|Drug|Levitra (Vardenafil, BAY38-9456)|4 weeks treatment with 10 mg vardenafil followed by a flexible titration phase for 8 weeks
1809807|NCT00657657|Biological|Engerix™-B|A challenge dose of hepatitis B vaccine will be administered to all subjects as a deep intramuscular injection in the deltoid region of the non-dominant arm.
1809808|NCT00657670|Device|Ready-made spectacles|Ready-made spectacles will be dispensed to correct refractive error. Ready-made spectacles are spectacles which are available from an existing inventory. This is different to prescription spectacles which are usually made to order. They have the same spherical power for the right and left eyes and do not include a correction for astigmatism. The limited inventory for this trial includes +1.00 to +4.00 in 0.50 steps, +5.00, +6.00 and +8.00, -1.00 to -6.00 in 0.50 steps, -7.00, -8.00, -9.00 and -10.00. The appropriate spectacles are selected based on the spherical equivalent refractive error. If there is a difference between the two eyes the lower correction is selected.
1809809|NCT00657670|Device|Spectacles|Spectacles will be prescribed to correct refractive error. These spectacles will be custom-prescribed based on the sphero-cylindrical refractive correction. The spectacles used in this arm will be custom made for each participant based on their refraction and can be made in a full range of spherical powers and astigmatic corrections for up to 2.00 dioptres of cylinder.
1809810|NCT00657683|Biological|Monovalent GBS-CRM glycoconjugate vaccine|1 dose of GBS conjugate vaccine
1809811|NCT00657683|Biological|Placebo|1 dose of placebo
1957790|NCT02181062|Behavioral|Walking Intervention|"4-week series of twice-weekly 1-hour group-based case-manager-led interactive sessions.
The intervention will provide the knowledge necessary to improve stroke risk factors. Case manager group leaders will teach that seeing a healthcare provider regularly and monitoring blood pressure prevents strokes; all participants will be provided with the National Institute on Aging booklet, How to Talk to your Doctor and the contact information for their healthcare provider.
Participants will be given a pedometer and be trained to use it to measure steps, with the goal of reaching 10,000 steps each day.
The intervention will utilize attribution retraining to teach seniors that stroke risk factors including sedentary lifestyle should not be attributed to old age."
1809818|NCT00657722|Other|Angiography and Computed Tomography|Preoperative angiography and Computed Tomography
1809819|NCT00657735|Device|H-Coil deep TMS|20 daily deep rTMS treatments
1809820|NCT00657735|Device|sham|inactive treatment
1809821|NCT00657748|Drug|Lithium Gluconate (drug) Glyceryl Triacetate GTA (drug)|Lithium 1.3 mEq/kg/day (three administrations a day)during the study GTA 500 mg/kg/day in four administrations a day during the study
1809822|NCT00657761|Drug|Enfuvirtide|90 mg/12h sc for 7 days
1809823|NCT00657761|Drug|Placebo|0.9% saline solution/12h sc for 7 days
1809824|NCT00657774|Drug|FlutiForm 250/10 ug|SKP FlutiForm 250/10ug is a HFA pMDI that delivers 125ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
1809825|NCT00657774|Drug|FlutiForm 100/10 ug|SKP FlutiForm 100/10ug is a HFA pMDI that delivers 50ug of Fluticasone propionate per actuation and 5ug of Formoterol fumarate per actuation. Patients will take 2 actuations BID for 6 weeks.
1809826|NCT00657774|Drug|Oral Prednisone 10mg|2 x 5 mg oral prednisone tablets, over encapsulated, once a day for one week.
1809827|NCT00657774|Drug|Placebo|2 x 5 mg placebo tablets, over encapsulated, once a day for six weeks. SKP FlutiForm placebo HFA pMDI. Two actuations BID for six weeks.
1809828|NCT00657800|Behavioral|Intensified inpatient diabetes education program (IDEP)|Assessment of educational needs and coordination of inpatient unit based education program by Certified Diabetes Educator (CDE)
1809829|NCT00657813|Drug|MNI-330 as a brain SPECT tracer of Beta-Amyloid|Each subject will receive a bolus injection targeted to be 5 miCi and not to exceed 5.5 mCi of MNI-330. Following injection serial dynamic imaging will be obtained over 8 hrs.
1809830|NCT00657826|Device|ATS 3f® Aortic Bioprosthesis, Model 1000, 19mm|Isolated aortic valve replacement with a size 19mm valve
1809831|NCT00657839|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil bid
1809832|NCT00657839|Drug|Placebo|Matching placebo
1809833|NCT00657852|Drug|Disodium pamidronate|Single dose of 90 mg disodium pamidronate within days 7-12 and at 3 months after liver transplantation, diluted in 500 ml of 5% glucose serum and administered as a 4-hour continuous intravenous infusion
1809834|NCT00657852|Drug|Placebo|500 ml of 5% glucoside serum infusions within days 7-12 and at 3 months after liver transplantation and administered as a 4-hour continuous intravenous infusion
1809835|NCT00657865|Drug|ramipril|oral intake
1809836|NCT00657865|Drug|placebo|placebo
1809837|NCT00657878|Drug|stealth liposomal doxorubicin|stealth liposomal doxorubicin 40 mg/m2 IV day 1 every 28 days
1809838|NCT00657878|Drug|carboplatin|carboplatin AUC 5 IV day 1 every 21 days
1809839|NCT00657878|Drug|paclitaxel|paclitaxel 175 mg/m2 IV day 1 every 21 days
1809840|NCT00657878|Drug|Topotecan|dosing and schedule according to Institutional guidelines
1809841|NCT00657878|Drug|Gemcitabine|1000 mg/m2 on days 1,8,15 every 28 days
1809842|NCT00657891|Drug|Omalizumab|0.016 mg/kg/IgE(iU/ml)/4 wks, Subcutaneously
1809843|NCT00657891|Drug|Placebo|Placebo Injection
1809844|NCT00657904|Drug|Bicalutamide|150mg daily
1809845|NCT00657904|Drug|Placebo|once daily
1809847|NCT00657930|Drug|insulin detemir|observational study - dose and frequency to be prescribed by the physician as a result of standard clinical practice.
1809848|NCT00657943|Drug|metformin|metformin tablets 2 g x 2
1809849|NCT00657943|Drug|insulin detemir|insulin as requested
1809850|NCT00657943|Drug|insulin aspart + insulin aspart protamin|insulin as requested
1809851|NCT00657943|Drug|Insulin aspart|insulin as requested
1809852|NCT00657956|Device|Advance Biofoam porous metal backed tibial component with or without screw augmentation|total knee arthroplasty tibial component that has a backing of porous titanium metal to facilitate bone in-growth
1809853|NCT00657982|Drug|RAD001|10mg BID
1809854|NCT00657995|Device|Artificial Pancreas (STG-22)|safe tool
1809855|NCT00658008|Drug|PD 0332334|Capsules, oral, 175 mg BID, 8 weeks with 2 week taper
1809856|NCT00658008|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
1809857|NCT00658008|Drug|PD 0332334|Capsules, oral, 75 mg BID, 8 weeks with 2 week taper
1809858|NCT00658008|Drug|Paroxetine|Capsules, oral, Paroxetine 20 mg QD, 8 weeks with 2 week taper
1809859|NCT00658008|Drug|Placebo|Capsules, oral, placebo bid, 8 weeks with 2 week taper
1809863|NCT00658034|Procedure|Acupuncture|Subjects will receive acupuncture weekly for six weeks. Subjects will complete a Brief Fatigue Inventory (BFI) questionnaire, a Functional Assessment of Cancer Treatment scale (FACT-G), and a Hospital Anxiety and Depression Scale(HADS) at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why.
1809864|NCT00658034|Procedure|Placebo Acupuncture|"Subjects will receive placebo acupuncture weekly for six weeks. During the placebo phase, placebo acupuncture needles will be applied a few mm away from the required points. The placebo acupuncture needle is a blunt tipped needle that moves up inside its handle. When it is pressed against the skin, the subject feels a slight prick and sees the handle of the needle moving towards the skin as if the needle has been inserted.
Subjects will complete a BFI, a FACT-G, and a HADS at week 7. The BFI and FACT-G will be repeated at week 8. At the end of the study, subjects will be asked to state whether they thought they were on true or placebo acupuncture and why. Subjects in the placebo group will be given the option to receive true acupuncture."
1809865|NCT00658047|Drug|CH-1504|Comparison of different doses of CH-1504
1809866|NCT00658047|Drug|Methotrexate (MTX)|10mg/week for 2 weeks escalated to 15mg/week for 2 weeks escalated to 20mg/week for 8 weeks
1809867|NCT00658073|Procedure|Kidney transplantation with MSCs infusion|Patients in Group A will receive the first MSCs infusion intravenously within 24 hours after kidney transplant operation , and the second infusion of MSCs will be performed two weeks later.
1809868|NCT00658073|Procedure|kidney transplantation without MSC infusion|kidney transplantation with standard immunosuppressive treatment regime
1809869|NCT00658086|Drug|ALN-RSV01|administered by nebulization once daily for 3 days
1809870|NCT00658086|Drug|normal saline|administered by nebulization once daily for 3 days
1809871|NCT00658099|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
1809918|NCT00658476|Dietary Supplement|Fish Oil|Omega-3 fatty acid supplements.
1809872|NCT00658099|Drug|insulin NPH|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
1809873|NCT00658112|Drug|Benzoyl Peroxide|Benzoyl peroxide 5% gel. Applied once daily to face, minimum amount usable to cover area. Every day for six weeks.
1809874|NCT00658125|Procedure|Deep Brain Stimulation (Fornix DBS)|Fornix DBS for Alzheimer Disease
1809875|NCT00658138|Device|3M ESPE Adper Scotchbond SE|To be used per manufacturer's instructions.
1809876|NCT00658138|Device|3M ESPE Adper Scotchbond 1XT|To be used per manufacturer's instructions.
1809877|NCT00658164|Other|Iron depletion treatment|Effect of iron depletion by phlebotomy plus lifestyle changes vs. lifestyle changes alone on liver damage in patients with nonalcoholic fatty liver disease with increased iron stores
1809878|NCT00658177|Drug|Levitra (Vardenafil, BAY38-9456)|20mg to be taken 1 h prior to sexual intercourse
1809879|NCT00658177|Drug|Placebo|Matching placebo
1809880|NCT00658203|Device|New Living CHF|PEA CRT optimization
1809881|NCT00658203|Device|New Living CHF|Standard optimized CRT.
1809882|NCT00658229|Behavioral|Strength training group|After 5-10 months on androgen deprivation therapy the patients in the intervention group go through a four months strength training intervention. The patients will perform three strength-training sessions per week, two under supervision of a sport instructor. Each session will consists of one-three sets of nine strength-training exercises, performed at an intensity of 6 or 10 repetitions of maximum (6-10 RM).
1809883|NCT00658255|Drug|budesonide/formoterol|
1809884|NCT00658255|Drug|formoterol|
1809885|NCT00658268|Drug|Clodronate|60 mg/ml, 10 ml, single dose mixed in bone graft at operation
1809886|NCT00658268|Drug|Placebo|10 ml, single dose mixed in bone graft at operation
1809887|NCT00658281|Procedure|CBCT Scan|Cone Beam Computed Tomography (CBCT) scan performed once a week.
1809888|NCT00658281|Procedure|OBI KV Imaging|On Board Imager kilovoltage (OBI KV) Imaging performed once a week.
1809890|NCT00658307|Device|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz
The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
1809891|NCT00658307|Device|repetitive transcranial magnetic stimulation (rTMS)|"20Hz
The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
1809892|NCT00658307|Device|sham repetitive transcranial magnetic stimulation (rTMS)|"The rTMS device is the MagPro X100 Series (produced by Magventure A/S, Farum, Denmark)"
1809893|NCT00658320|Drug|Everolimus|0.75 mg twice daily, trough level adjusting between 3 and 8 ng/ml.
1809894|NCT00658320|Drug|Mycophenolate mofetil (MMF)|The initial dose of 2 gm/day Mycophenolate mofetil was started within 24-36 hours from reperfusion after transplantation. MMF was administered daily for 12 months in the core study and 12 months in the extension study.
1809895|NCT00658320|Drug|Basiliximab|Patients received first dose of basiliximab (20 mg) 2 hours prior to transplantation and 20 mg at Day 4 or according to local practice
1809896|NCT00658320|Drug|Cyclosporine A|The cyclosporine was initiated either pre-transplant or within 24 hours after transplantation following local regime. Standard dose of cyclosporine was administered with MMF. The Reduced dose of cyclosporine was administered with everolimus.
1809897|NCT00658320|Drug|Corticosteroid|Corticosteroid was administered according to local practice during the trial but at a dose not less than 5mg per day for 12 months of the study
1809898|NCT00658333|Drug|Enteric-coated Mycophenolate Acid (EC-MPA)|
1809899|NCT00658333|Drug|Mycophenolate Mofetil (MMF)|
1809900|NCT00658333|Drug|Placebo MMF|
1809901|NCT00658333|Drug|Placebo EC-MPA|
1809902|NCT00658346|Drug|Treatment initiation for HIV-1 group O infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :
If Hb > 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)
If Hb <= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)
If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
1809903|NCT00658346|Drug|Treatment initiation for HIV-1 group M infected patients|"The first line regimen is adapted according to the hemoglobin level and the AgHBs status :
If Hb > 8 g/ml and negative AgHBs : AZT-3TC (DUOVIR) + LPV/RTV (ALUVIA)
If Hb <= 8 g/ml and negative AgHBs : TDF-3TC (LAMIVIR-S) + LPV/RTV (ALUVIA)
If positive AgHBs : TDF + 3TC + LPV/RTV (ALUVIA)"
1809907|NCT00658372|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks with 2 week taper
1809908|NCT00658372|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks with 2 week taper
1809909|NCT00658372|Drug|Paroxetine|Capsules, oral, Paroxetine, 20 mg QD, 8 weeks with 2 week taper
1809910|NCT00658372|Drug|Placebo|Capsules, oral, placebo, BID, 8 weeks with 2 week taper
1809911|NCT00658385|Genetic|GCSF, Central venous line placement, Stem cell Collection (leukapheresis)|"Daily injections under the skin of a GCSF. This is done for 5 to 6 days. On days 1, 3,5, and if need on day 6. To collect stem cells, we need good access to this blood. If the patient has good veins, we do this by placing an IV on each one of their arms. The peripheral blood stem cell collection is usually an outpatient procedure and takes about 3 to 4 hours. You will have blood work and a physical exam on days one, three, and five while you are getting GCSF.
These will be done again 24 hours after your stem cells are collected."
1809912|NCT00658398|Behavioral|Interactive Computer Program to prevent alcohol misuse.|Interactive Computer Program with questionnaires, video and informations
1809913|NCT00658411|Drug|deferoxamine|Given intravenously or subcutaneously over 8-12 hours daily for at least three weeks prior to transplantation date and continue until the day before the participant receives their donor's stem cells.
1809914|NCT00658437|Drug|CY-503|solution for subcutaneous injection, 350 ng twice weekly
1809915|NCT00658450|Behavioral|Cognitive rehabilitation training|"A computerised cognitive training package where children will be required to complete several cognitive tasks. The aim is to strengthen the different cognitive processes during these tasks which in turn may lead to improve cognitive processes.
Children will complete these tasks in 16 session for 8 weeks."
1809916|NCT00658463|Drug|Rosuvastatin|rosuvastatin 20 mg/day during 6 weeks versus placebo during 6 weeks in a cross-over design
1809917|NCT00658463|Drug|Placebo|Placebo
1809919|NCT00658476|Behavioral|Cognitive Behavior Therapy|Adolescents receive cognitive behavior therapy.
1809920|NCT00658476|Other|Placebo|
1809921|NCT00658489|Behavioral|Education|One group of residents will receive extensive web-based training in the promotion of oral health. The second group of residents will complete a single training module in the prevention of iron deficiency. The third arm consists of parent-child dyads, who will participate in one well-child care visit.
1809922|NCT00658515|Drug|Dalcetrapib (RO4607381)|600mg po daily
1809923|NCT00658515|Drug|Evidence-based medical care for Acute Coronary Syndrome|As prescribed
1809924|NCT00658515|Drug|Placebo|po daily
1809925|NCT00658528|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, taken orally, once daily for 4-8 weeks.
1809926|NCT00658528|Drug|Esomeprazole|Esomeprazole 40 mg capsule, taken orally, once daily for 4-8 weeks.
1809927|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
1809928|NCT00658541|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered following an overnight fast of at least 10 hours and a standardized, high fat breakfast.
1809929|NCT00658554|Drug|ARQ 197|Treatment with ARQ 197
1809930|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|10 mg, tablet, once daily by mouth, for six weeks
1809931|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|20 mg, tablet, once daily by mouth, for six weeks
1809932|NCT00658567|Drug|Pimavanserin tartrate (ACP-103)|Placebo, tablet, once daily by mouth, for six weeks
1809933|NCT00658580|Drug|Cisplatin + etoposide|"Cisplatin 90 mg/m² day 1, every 3 weeks
Etoposide 100 mg/m² days 1-3, every 3 weeks"
1809934|NCT00658580|Drug|Epirubicin + ifosfamide + etoposide|"Epirubicin 60 mg/m² day 1, every 3 weeks
Ifosfamide (+ uromitexan) 1.5 g/m² days 1-3, every 3 weeks
Etoposide 100 mg/m² days 1-3, every 3 weeks"
1809935|NCT00658593|Drug|capecitabine|
1809936|NCT00658593|Drug|gemcitabine hydrochloride|
1809937|NCT00658593|Procedure|quality-of-life assessment|
1809938|NCT00658606|Drug|alefacept|IM
1809939|NCT00658606|Procedure|Narrow Band UVB Phototherapy|UVB Phototherapy
1809940|NCT00658619|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
1809941|NCT00658619|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 and Month 6.
1809942|NCT00658619|Other|Sham (no implant)|Sham in one or both eyes on Day 1 and Month 6.
1809943|NCT00658632|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
1809944|NCT00658632|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
1809945|NCT00658645|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
1809946|NCT00658645|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
1809947|NCT00658645|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
1809948|NCT00658658|Biological|Panitumumab|Panitumumab administered by intravenous infusion
1809949|NCT00658671|Drug|ENMD-2076|Capsules, daily dosing in 28 day cycles
1809950|NCT00658684|Drug|fesoterodine fumarate|4 mg tablets OD for 4 weeks, then either 4 mg or 8 mg tablets OD for 48 weeks
1809951|NCT00658697|Drug|Docetaxel|Intravenously given at 75 mg/m2 on day 1 of every 3 weeks for 4 cycles
1809952|NCT00658697|Drug|Bevacizumab|Intravenously given at (15 mg/kg) on day 1 of every 3 weeks for 8 cycles
1809953|NCT00658697|Drug|ADT|Either subcutaneously or intramuscularly every three months for a total of 6 doses (total of 18 months)
1809954|NCT00658697|Drug|Bicalutamide|Starting on day 84 orally once daily until hormone therapy is completed
1809955|NCT00658710|Behavioral|physical therapy sessions|two physical therapy sessions per week for two months
1809956|NCT00658723|Drug|Fibrin Pad|Fibrin Patch is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
1809957|NCT00658723|Device|SURGICEL™|Absorbable hemostat
1809958|NCT00658736|Drug|Triamcinolone|Injection of bupivacaine and triamcinolone
1809959|NCT00658736|Drug|Bupivicaine alone|Injection of bupivacaine
1809960|NCT00658749|Drug|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
1809961|NCT00658749|Drug|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
1809962|NCT00658762|Drug|PD 0332334|Capsules, oral, 225 mg BID, 8 weeks, with 2 week taper
1809963|NCT00658762|Drug|PD 0332334|Capsules, oral, 300 mg BID, 8 weeks, with 2 week taper
1809964|NCT00658762|Drug|paroxetine|Capsules, oral, 20 mg q am, 8 weeks, with 2 week taper
1809965|NCT00658762|Drug|Placebo|Capsules, oral, BID, 8 weeks, with 2 week taper
1809966|NCT00658775|Drug|Rabeprazole sodium|Rabeprazole ER 50 mg capsule, once daily for 4-8 weeks.
1809967|NCT00658775|Drug|Esomeprazole|Esomeprazole 40 mg capsule, once daily for 4-8 weeks.
1809968|NCT00658788|Drug|clobetasol propionate spray 0.05%|clobetasol propionate spray, 0.05%, applied topically twice daily
1809969|NCT00658788|Drug|calcitriol ointment|calcitriol ointment, 3 µg/g, applied topically, not to exceed 30 g daily
1809970|NCT00658801|Radiation|Respiratory gated proton beam radiotherapy|"Prescription dose to PTV as according to the following dose escalation schema:
Group 1: Tumor size ≤5cm Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
Group 2: 5cm <Tumor size ≤10cm Dose level 1: 54 GyE /18 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week."
1809973|NCT00658827|Other|No intervention|This is an observational study. Patients receiving infliximab or anti-TNF as per the prescribing information will be observed.
1810028|NCT00659217|Biological|mesenchymal stem cell|Autologous MSC transplantation
1809976|NCT00658853|Behavioral|4 times 4 minutes high aerobic intensity one leg cycling|3 times per week for 10 weeks
1809977|NCT00658866|Procedure|Microdialysis|PK measurements with microdialysis
1809979|NCT00658892|Biological|B7-DC cross-linking antibody rHIgM12B7|
1809980|NCT00658892|Other|flow cytometry|
1809981|NCT00658892|Other|immunologic technique|
1809982|NCT00658892|Other|laboratory biomarker analysis|
1809983|NCT00658905|Drug|rhBSSL|0.15 g/L rhBSSL added to infant formula; one week treatment
1809984|NCT00658905|Drug|Placebo|One week treatment
1809985|NCT00658918|Drug|Ciclesonide nasal|safety of Ciclesonide (200µg, 100µg, 25µg)
1809986|NCT00658918|Drug|Placebo|placebo
1809987|NCT00658931|Drug|Drug treatment with Cymbalta|Drug treatment with Cymbalta
1809988|NCT00658957|Drug|gentamicin-collagen sponge|5 × 5 cm sponge
1809989|NCT00658957|Drug|placebo collagen sponge|5 × 5 cm sponge
1809990|NCT00658970|Drug|KX2-391|2 mg (starting dose)rising dose, oral dosing, twice daily, 21 day cycle(s); until progression or unacceptable toxicity develops
1809991|NCT00658983|Other|Autologous Platelet Enriched Gel|Treatment with Autologous Platelet Enriched Gel
1809992|NCT00658983|Other|Metalloproteinase Inhibitor|Treatment with Metalloproteinase Inhibitor (Promogran)
1809993|NCT00658996|Device|SofLens DD Toric|daily disposable wear contact lens for 2 weeks
1809994|NCT00658996|Device|Ciba Vision Focus Dailies Toric Contact Lens|daily disposable wear contact lens for 2 weeks
1809995|NCT00659009|Other|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
1809996|NCT00659009|Other|Sea level equivalent barometric pressure|Sleep in barometric pressure equivalent to sea level.
1809997|NCT00659009|Other|Reduced barometric pressure|Sleep in reduced barometric pressure environment.
1809998|NCT00659022|Procedure|immediate surgery (resection of primary colorectal tumor)|no neo-adjuvant treatment, immediate surgery
1809999|NCT00659022|Drug|neo-adjuvant treatment with bevacizumab|neoadjuvant treatment with bevacizumab during 7 weeks prior to surgery of the colorectal primary
1810000|NCT00659022|Drug|neoadjuvant treatment with capecitabine and oxaliplatin|neoadjuvant treatment with CAPOX during 7 weeks prior to surgery of the colorectal primary
1810001|NCT00659022|Drug|neo-adjuvant treatment with bevacizumab, capecitabine and oxaliplatin|neoadjuvant treatment with bevacizumab and CAPOX during 7 weeks prior to surgery of the colorectal primary
1810002|NCT00659048|Drug|Ciclesonide|Ciclesonide 200µg versus Placebo
1810003|NCT00659048|Drug|Placebo|placebo
1810004|NCT00659061|Dietary Supplement|SPRINKLES|"Sprinkles is a multiple micronutrient fortificant. It is packed as a single serving sachets each containing micro encapsulated iron (12.5 mg), zinc (7.5 mg), vitamin C (30 mg), vitamin A (300 µg), vitamin D (5 µg), folic acid (150 µg) and iodine (90µg).
Two month supply of the Sprinkle sachet along with advice on its benefits as well as its appropriate use will be given by the LHWs. The LHWs will also provide their age-appropriate nutritional advice as per their regular door to door community services."
1810005|NCT00659061|Behavioral|Advice only|No sprinkle sachets will be given by the LHW. However, the LHWs will provide the age-appropriate nutritional advice as per their regular routine monthly door to door community services
1810006|NCT00659074|Drug|Ondansetron|ODT, single-dose, fasting
1810007|NCT00659074|Drug|Zofran|ODT, single-dose, fasting
1810008|NCT00659087|Procedure|Femoral Block|Those receiving femoral block postoperatively
1810009|NCT00659087|Other|Usual Care|Those receiving only usual pain management postoperatively
1810010|NCT00659100|Drug|Gabapentin|Gabapentin 50 mg oral capsule 30 minutes before bedtime
1810011|NCT00659113|Drug|cisplatin|
1810012|NCT00659113|Drug|tegafur-gimeracil-oteracil potassium|
1810013|NCT00659113|Other|cytology specimen collection procedure|
1810014|NCT00659113|Procedure|endoscopic biopsy|
1810015|NCT00659126|Procedure|3 Tesla Magnetic Resonance Imaging|Undergo 3T MRI
1810016|NCT00659126|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
1810017|NCT00659126|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
1810018|NCT00659126|Drug|Ferumoxytol|Given IV
1810019|NCT00659126|Drug|Gadolinium|Given IV
1810020|NCT00659126|Procedure|High Field Strength Magnetic Resonance Imaging|Undergo 7T MRI
1810021|NCT00659126|Procedure|Susceptibility Weighted Imaging|Undergo SWI
1810022|NCT00659165|Drug|Insulin Detemir|Subjects will be given a dose of detemir equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
1810023|NCT00659165|Drug|Insulin Glargine|Subjects will be given a dose of glargine equivalent to their current long acting insulin regimen. Study insulin will be injected subcutaneously at 8 AM and 8 PM for at least 3 weeks.
1810024|NCT00659178|Drug|SB-485232 (interleukin 18), pegylated liposomal doxorubicin|SB-485232 (interleukin 18), pegylated liposomal doxorubicin
1810025|NCT00659191|Drug|GSK1265744|
1957805|NCT02168920|Drug|2 mg/day|Once daily for 10 weeks
1957806|NCT02168920|Drug|3 mg/day|Once daily for 10 weeks
1957807|NCT02168920|Drug|6 mg/day|Once daily for 10 weeks
1957808|NCT02168920|Drug|Placebo (0 mg/day)|Once daily for 10 weeks
1810031|NCT00659243|Drug|rhBSSL|0.15 g/L rhBSSL added to pasteurized breast milk; one week treatment
1810032|NCT00659243|Drug|Placebo|One week treatment
1810033|NCT00659269|Dietary Supplement|Multivitamin (MV)|Multivitamins containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12 will be given to the patients on this arm.
1810034|NCT00659269|Dietary Supplement|Multivitamin + Vitamin B12 + Vitamin B6|Multivitamin (containing no more than 10 mg of pyridoxine and/or 10 micrograms of Vitamin B12), plus Vitamin B6 tablets and Vitamin B12 injections
1810035|NCT00659269|Drug|Chemotherapy|"Patients are treated per standard of care according to the choice of the treating physician with heavy metals (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), or vinca alkaloids (vincristine, vinorelbine)
Ranges of cumulative doses (in mg/m2) are:
paclitaxel, 700-960; docetaxel, 240-400; vincristine, 8-16; vinorelbine, 360-480; cisplatin, 240-400; oxaliplatin, 400-800; abraxane, 1200-1800"
1810036|NCT00659282|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
1810037|NCT00659295|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical practice.
1810038|NCT00659308|Procedure|amniotic membrane transplantation|patients are submitted to amniotic membrane transplantation
1810039|NCT00659308|Procedure|anterior stromal puncture|the other group is submitted to anterior stromal puncture
1810040|NCT00659321|Drug|nicotine acid|16 weeks, randomisation with 500 mg, after 4 weeks elevation of 1000 mg, after week 8 to week 16 1500 mg study medication
1810041|NCT00659321|Drug|placebo|16 weeks treatment with placebo
1810042|NCT00659334|Drug|Ferumoxtran-10 (Combidex)|2.6 mg/kg
1810043|NCT00659334|Procedure|Neurosurgery|neuro-surgical tumor biopsy or resection to assess particle localization. Biopsy (stereotactic, when possible) will take place following the 24 hour post- Combidex MR and within 48 hrs of i.v. Combidex administration. Biopsies will be taken from the tumor, brain around tumor (BAT) and brain distant to tumor and the MR localization and histology will be compared. The tissue will be obtained by either resection or needle frameless stereotactic biopsy.
1810044|NCT00659347|Drug|DOV 21, 947|Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks
1810045|NCT00659347|Drug|Placebo|Capsules,25 mg,BID,6weeks
1810046|NCT00659360|Drug|saracatinib|Given orally
1810047|NCT00659373|Drug|Tamoxifen|
1810048|NCT00659373|Drug|triptorelin|
1810049|NCT00659373|Drug|Exemestane|
1810050|NCT00659386|Drug|Intravenous immunoglobulin therapy|Patients received total dose of 2 g/kg of immune globulin administered as 0.5 g/kg IV over a period of 6 hours on each of 3 consecutive days.
1810051|NCT00659399|Drug|Fondaparinux|Arixtra 2.5 mg by subcutaneous injection once daily for 8 weeks or until disease recurrence or grade 3, 4 adverse events.
1810052|NCT00659412|Drug|Alefacept|Intramuscular
1810053|NCT00659412|Drug|Methotrexate|Oral
1810054|NCT00659412|Drug|Placebo|Intramuscular
1810055|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 5 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
1810056|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 10 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
1810057|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
1810058|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 20 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
1810059|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
1810060|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 30 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
1810061|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 40 mcg/kg moxetumomab pasudotox (CAT-8015) with concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
1810062|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 32 mcg/kg moxetumomab pasudotox (CAT-8015) of process 3 material every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
1810063|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) without concomitant corticosteroid administration every other day (QoD) in a 21-day cycle for a total of 6 doses per cycle.
1810064|NCT00659425|Drug|CAT-8015 (Moxetumomab Pasudotox)|Participants received intravenous infusion of 50 mcg/kg moxetumomab pasudotox (CAT-8015) continuous every other day (QoD) in a 21-day cycle for a total of 10 doses per cycle.
1810065|NCT00659438|Drug|ZD6474 (Vandetanib)|300mg orally, once daily
1810066|NCT00659438|Drug|Bicalutamide|150mg orally, once daily
1810067|NCT00659438|Drug|Placebo|orally, once daily
1810068|NCT00659451|Drug|Losartan|tablets; 50, 100 mg; od; 12 months
1810069|NCT00659451|Drug|Amlodipine|tablets; 5, 10 mg; od; 12 months
1810070|NCT00659477|Drug|insulin glargine|once daily
1810071|NCT00659490|Drug|AZD1940|800ug oral administration
1810072|NCT00659490|Drug|Naproxen|500mg oral administration
1810073|NCT00659490|Drug|Placebo|Placebo given pre-surgery
1810074|NCT00659503|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
1810075|NCT00659503|Drug|Placebo|placebo
1810076|NCT00659529|Drug|sildenafil|Sildenafil will be given 20mg po tid for 1 week, and then will be give 40mg po tid for 5 weeks.
1810077|NCT00659542|Procedure|cyanoacrylate glue|1 ml glue
1810078|NCT00659555|Drug|pazopanib eye drops and ketoconazole tablets|
1810079|NCT00659568|Drug|metformin hydrochloride|
1810080|NCT00659568|Drug|temsirolimus|
1810081|NCT00659581|Drug|Telmisartan|Oral administration
1810082|NCT00659594|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
1810083|NCT00659594|Drug|Placebo|placebo
1810084|NCT00659620|Biological|mesenchymal stem cell|transplantation of mesenchymal stem cell
1810085|NCT00659633|Drug|lidocaine|intravenous, effect site concentration: 2mcg/ml, 15-20 min infusion, once
1810086|NCT00659646|Drug|gentamicin-collagen sponge and levofloxacin|Topical Gentamicin Collagen Sponge: 10 × 10 cm in size And 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours.
1810087|NCT00659646|Drug|Levofloxacin only|levofloxacin, 750 mg tablet po every 24 hours or 750 mg IV administered by slow infusion over 90 minutes every 24 hours
1810088|NCT00659659|Drug|MEDI-563|1.0 mg/kg IV: MEDI-563
1810089|NCT00659659|Drug|MEDI-563|100 mg, 200 mg SC
1810090|NCT00659659|Other|Placebo Comp.|Placebo SC
1810091|NCT00659659|Other|Placebo|Placebo as a single IV infusion (Certain number of subjects)
1810092|NCT00659672|Dietary Supplement|Whey Protein|40 grams per day Whey Protein
1810093|NCT00659672|Dietary Supplement|Soy Protein|40 grams per day soy protein
1810094|NCT00659672|Dietary Supplement|Control (carbohydrate)|40 grams per day maltodextrin
1810095|NCT00659685|Drug|Ondansetron|ODT, single-dose, fasting
1810096|NCT00659685|Drug|Zofran ODT|
1810098|NCT00659711|Drug|Januvia (Sitagliptin) 100 mg|The first group will be started on 100 mg sitagliptin daily for 12 weeks
1810099|NCT00659711|Drug|Placebo|will be placed on a placebo for 12 weeks.
1810100|NCT00652145|Drug|mesalamine|Increase dose by 2.4gm per day over baseline dose
1810101|NCT00652158|Drug|MLN8054|"10 mg doses of MLN8054 were given orally once daily following a schedule of 5 days on/2 days off/5 days on repeated every 28 days"
1810102|NCT00652171|Drug|Lamotrigine|Lamotrigine was added to the ongoing antidepressant. The doses were titrated to 200mg/day.
1810103|NCT00652171|Dietary Supplement|Amide|Capsule of amide were given to this group of patients. They continued the ongoing antidepressants.
1810104|NCT00652184|Drug|ARYS-01 (sorivudine) cream 3% or placebo cream|sorivudine cream 3% or placebo cream twice daily for 10 days
1810105|NCT00652184|Drug|placebo|placebo cream and placebo valaciclovir
1810106|NCT00652184|Drug|valaciclovir|active valaciclovir
1810107|NCT00652210|Other|Multiphoton microscopy|Use of multiphoton microscopy to diagnose cancer
1810108|NCT00652223|Biological|CYT005-AllQbG10|Immunomodulator CYT003-QbG10 in combination with commercial house dust mite extract as used for routine SIT
1810109|NCT00652236|Other|Physiotherapy|The two groups passed an in-patient rehabilitation and a physiotherapy: FCT function-centred vs. PCT pain-centred
1810110|NCT00652262|Drug|Levitra (Vardenafil, BAY38-9456)|Patients received BAY 38-9456 10 mg for the first 4 weeks of the treatment period, and then went on to receive 10 mg or 20 mg for the following 8 weeks.
1810111|NCT00652275|Biological|MSP3 Long Synthetic Peptide 30 micrograms of MSP3 LSP|189 children will receive 3 doses of experimental vaccine
1810112|NCT00652275|Biological|Verorab vaccine|189 volunteers will receive Verorab vaccine, 0.5 Ml at day 0, 28 and 56.
1810113|NCT00652288|Drug|Insulin analogs (Lispro and Aspart)|Insulin bolus given through insulin pump
1810114|NCT00652288|Drug|Insulin analogs (Aspart and Detemir)|Drugs given separately
1810115|NCT00652288|Drug|Insulin analogs (Aspart and Detemir)|Drugs given in the same injection
1810116|NCT00652288|Drug|Insulin analogs (Lispro and Glargine)|Drugs given separately
1810117|NCT00652288|Drug|Insulin analogs (Lispro and Glargine)|Drugs given in single injection
1810118|NCT00652301|Drug|ezetimibe|ezetimibe 10 mg tablet. Duration of Treatment 31 Weeks.
1810119|NCT00652301|Drug|Comparator: Placebo (unspecified)|matching placebo tablet. Duration of Treatment 31 Weeks.
1810120|NCT00652301|Drug|simvastatin|simvastatin 20 mg tablet. Duration of Treatment 31 Weeks.
1810121|NCT00659737|Drug|Aprepitant|40mg tablet
1810122|NCT00659737|Drug|Scopolamine|1.5 mg patch delivering transdermally in vivo approx. 1.0mg over 3 days
1810123|NCT00659750|Drug|Ciclesonide|200µg Ciclesonide versus Placebo
1810124|NCT00659750|Drug|Placebo|placebo
1810125|NCT00659763|Other|Exclusion diagnosis|"Patient fulfill ROME III criteria No Alarmsignals Blood tests: FBC,CRP, ALAT, bilirubins, bas.phosphatases, Albumine, TSH, calcium, celiac screening, lactase gene test.
3 consecutive fecal samples for worm, ovaes and parasites Sigmoidoscopy with biopsy"
1810126|NCT00659763|Other|Clinical diagnosis|Patient fulfill ROME III criteria No Alarm signals Blood tests: FBC, CRP.
1810127|NCT00659776|Drug|Ferumoxytol|Ferumoxytol will be injected as i.v. bolus(es) at 3ml/s followed by a saline flush. The maximum total dose over 30 to 60 minutes will be 510mg Fe. Separate boluses will be used for perfusion MR and MRA. Ferumoxytol may be diluted up to 28 fold in normal saline to reduce T2* effects in the MR angiography. Rate of administration can be varied based on the subject's iv site, but will never exceed 510mg Fe /17s (as was done in phaseIII trials)
1810128|NCT00659789|Drug|Vacc-4x|Vacc-4x is a peptide-based HIV immunotherapy administered intradermally. Vacc-4x peptides are reconstituted in sterile water.
1810129|NCT00659789|Drug|Sterile water|Sterile water is used in place of Vacc-4x and in place of Leukine
1810130|NCT00659802|Drug|HMPL-004|HMPL-004, 400 mg (2 x 200 mg) t.i.d. (total of 1200 mg/day), 600 mg (3 x 200 mg t.i.d. or placebo.
1810131|NCT00659802|Drug|Placebo|Placebo
1810132|NCT00659815|Device|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in the Currently Marketed Resin Bottle.|Daily care for contact lenses.
1810133|NCT00659815|Device|Bausch & Lomb ReNu MultiPlus Multi-Purpose Solution Packaged in a Clear Resin Bottle.|Daily care for contact lenses
1810134|NCT00659828|Drug|Recombinant methionyl human leptin|recombinant methionyl human leptin, subcutaneous, once a day, 0.02 to 0.04 mg/kg (adjusted according to weight loss), indeterminate duration.
1810135|NCT00659841|Drug|Ciclesonide|200µg Ciclesonide versus placebo
1810136|NCT00659841|Drug|Placebo|placebo
1810137|NCT00659854|Dietary Supplement|Non milk or soy based formula|Babies will be given a non milk or soy base formula for 12 weeks
1810138|NCT00659854|Dietary Supplement|milk based formula|Babies will be given a milk based formula for 12 weeks
1810139|NCT00659867|Device|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|chromoscopy-guided endomicroscopy with targeted biopsies
1810140|NCT00659867|Device|PENTAX EC-3870CIFK / EC-3870CILK confocal colonoscopes|Standard endoscopy with random and targeted biopsies
1810141|NCT00659880|Other|BioCleanse Meniscus|Subjects will undergo routine meniscal allograft transplant surgery.
1810142|NCT00659893|Drug|PEP005 Topical gel|0.05%, two day dose
1810143|NCT00659906|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
1810144|NCT00659906|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
1810145|NCT00659919|Drug|Placebo|
1810146|NCT00659919|Drug|Trazodone|
1810147|NCT00659932|Behavioral|Immediate Cognitive behavioural therapy (CBT)|The Dealing with Anxiety CBT Group Program comprises 7 group sessions: an initial five hour session followed by 6 three hour sessions over a three month period
1810148|NCT00659932|Behavioral|Delayed CBT|Commencement of the CBT Group Program is delayed 3 months
1810149|NCT00659945|Drug|Aprepitant plus Ondansetron|Aprepitant plus Ondansetron
1810150|NCT00659945|Drug|Ondansetron plus placebo|Ondansetron plus placebo
1810151|NCT00659958|Drug|Zonisamide|300 mg tablet. Maintenance dosing period of 12 weeks, at the beginning of which, physicians will decide to keep the 300 mg dose from the titration period, lower it to 200 mg, or take it up to 400 mg.
1810152|NCT00659971|Drug|PAC113|PAC113 mouthrinse 0.15%; 0.075%; 0.0375% QID for 14 days
1810153|NCT00659984|Drug|UltratraceTM Iobenguane I 131 Imaging|0.1 mCi/kg [3.7 MBq/kg] (minimum dose 1mCi [37MBq] but not to exceed 5 mCi [185 MBq]) of UltratraceTM Iobenguane I 131 given 7 -28 days before therapeutic dose administration on day 0. Thyroid protection will be administered per institutional protocol for I-131-MIBG however, thyroid blocking must be started prior to the Ultratrace imaging dose. Anterior and posterior whole body images will be taken to assess organ distribution, tumor uptake and dosimetry calculations.
1810154|NCT00659984|Drug|UltratraceTM Iobenguane I 131 Therapy|Therapeutic dose will be given on Day 0 if dosimetry scans showed that the prescribed or adjusted dose will not exceed > 23 Gy to the kidneys, > 30 Gy to the liver, or > 15 Gy to the lungs. and tumor uptake confirmed with UltratraceTM imaging dose. Only one treatment course of therapeutic UltratraceTM will be given in this study.
1810155|NCT00659997|Drug|Albendazole|Single oral dose of 400mg
1810156|NCT00659997|Drug|Levamisole|Single oral dose of 2.5mg/kg
1810157|NCT00660010|Drug|Lupron (leuprolide acetate)|Leuprolide acetate was administered monthly by intramuscular injection starting at 300 mcg/kg with adjustments of 3.75 mg upward, at subsequent clinic visits based on physical and laboratory parameters. Dosing continued until NDA was approved, or until subject no longer required leuprolide acetate to treat CPP.
1810158|NCT00660023|Drug|Methoxy polyethylene glycol-epoetin beta|Participants will receive intravenous CERA/Mircera every month, with starting dose based on previous ESA therapy. Treatment will continue for 52 weeks.
1810159|NCT00660036|Drug|Gemtuzumab ozogamicin|On Day 6 of an inpatient hospital stay: Based on the study design patients will be treated with one of three doses (3 mg/m^2, 6 mg/m^2 or 9 mg/m^2), administered intravenously in 100 ml of 0.9% sodium chloride over 2 hours.
1810160|NCT00660036|Drug|Mitoxantrone|On Days 1-3 of an inpatient hospital stay: 10 mg/m^2 administered via IVPB (intravenous piggy-back) in 50ml normal saline (NS) over 15 minutes
1810161|NCT00660036|Drug|Etoposide|On Days 1-5 of an inpatient hospital stay: 100 mg/m^2 administered intravenously in 500 ml of 0.9% sodium chloride over 2 hours
1810162|NCT00660049|Device|SNaP Advanced Wound Care System|Application of negative pressure device daily per instructions
1810163|NCT00660049|Other|SNaP|Daily use
1810164|NCT00660049|Other|SNaP|Daily application per protocol
1810165|NCT00666796|Drug|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
1810166|NCT00666796|Drug|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
1810167|NCT00666796|Drug|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
1810168|NCT00666796|Drug|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
1810169|NCT00666796|Drug|Ethanol|Ethanol 0.7 g/kg in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
1810170|NCT00666796|Drug|Placebo|Matched placebo oral capsule with 8 oz of water 2 hours prior to assessment timepoint
1810171|NCT00666796|Drug|Gabapentin|Gabapentin 500 mg oral capsule with 8 oz of water 2 hours prior to assessment timepoint
1810172|NCT00666796|Drug|Placebo ethanol|Matched placebo ethanol 0.4% in a total volume of 300 mL as an orange juice cocktail (consumed within 15 minutes) at 1 hour prior to assessment timepoint
1810173|NCT00666809|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg BID p.o. for 12 weeks + 4 weeks follow-up
1810174|NCT00666809|Drug|Placebo|Placebo BID p.o. for 12 weeks + 4 weeks follow-up
1810225|NCT00667095|Drug|DMSO Instillation|DMSO 50% w/w aqueous solution; 50 cubic centimeters instilled into the bladder via ureteral catheter and retained up to 30 minutes then spontaneously voided.
1810226|NCT00667108|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
1810175|NCT00666822|Behavioral|compliance monitoring|To examine the relationship between adherence to endocrine therapy and variables from the Health Belief Model (i.e., perceived risk, barriers to and benefits of adherence, and cues to action such as physician recommendation) as well as measures of patient's perceptions of patient- and family-centered care in women with estrogen receptor-positive stage I-IIIA breast cancer.
1810176|NCT00666822|Other|medical chart review|Patient's medical records are reviewed for information about the time since diagnosis, tumor characteristics, treatment, and comorbidity.
1810177|NCT00666822|Other|questionnaire administration|Patients complete a 15 minute questionnaire on-line or by mail comprising questions of demographic and medical variables (i.e., age, race/ethnicity, marital and educational status, and medication side effects) as well as health beliefs and selected aspects of patient- and family-centered care. Data collected from the questionnaire will be stored in an Excel database.
1810178|NCT00666835|Drug|HX575 epoetin alfa Hexal AG|HX575 Solution for i.v. injection Containing 1000, 2000 and 4000 IU of rh erythropoietin
1810179|NCT00666835|Drug|ERYPO®, Janssen-Cilag|Solution for i.v. injection
1810180|NCT00666848|Drug|Placebo|Enalapril 0mg after 5 days of placebo versus after 5 days sitagliptin 100mg/d
1810181|NCT00666848|Drug|Enalapril 5mg|Enalapril 5 mg after 5 days placebo versus after 5 days sitagliptin 100mg/d
1810182|NCT00666848|Drug|Enalapril 10mg|Enalapril 10mg after 5 days placebo versus after 5 days sitagliptin 100 mg/d
1810183|NCT00666848|Drug|Sitagliptin|Sitagliptin 100mg/day for 5 days crossed over to placebo daily for 5 days prior to arms.
1810184|NCT00666874|Behavioral|lifestyle changes|Detailed advice about how to achieve a reduction of weight of 10% or more through a low-energy Mediterranean-style diet and increased physical activity.
1810185|NCT00666874|Behavioral|Control - general information|General information about healthy food choices and exercise
1810186|NCT00666887|Drug|Minocycline|100 mg twice daily to be taken for up to 2 years
1810187|NCT00666887|Drug|Placebo|placebo twice daily for 2 years
1810188|NCT00666900|Drug|Low Strength IDP-107|Once a day for 12 weeks
1810189|NCT00666900|Drug|High Strength IDP-107|Once a day for 12 weeks
1810190|NCT00666900|Drug|Placebo Comparator|Once a day for 12 weeks
1810191|NCT00666913|Other|informational intervention|Data from an archived database of a closed clinical trial is retrieved.
1810192|NCT00666926|Drug|PF00562271|125 mg twice daily [BID] with food, tablet
1810193|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
1810194|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
1810195|NCT00666926|Drug|PF00562271|125 mg BID with food, tablet
1810196|NCT00666939|Drug|Gabapentin|Gabapentin 100 mg oral capsule 30 minutes prior to bedtime
1810197|NCT00666939|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
1810198|NCT00666939|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
1810201|NCT00666965|Drug|SPM 962|transdermal application, 1 time per day, 0-6.75 mg/body, titration, 6weeks
1810202|NCT00666978|Behavioral|smoking cessation intervention|
1810203|NCT00666978|Drug|bupropion hydrochloride|
1810204|NCT00666978|Genetic|gene expression analysis|
1810205|NCT00666978|Genetic|polymerase chain reaction|
1810206|NCT00666978|Other|counseling intervention|
1810207|NCT00666978|Other|educational intervention|
1810208|NCT00666978|Procedure|psychosocial assessment and care|
1810209|NCT00666991|Drug|nanoparticulate paclitaxel|This is a Phase 1, dose-escalation study with 6 cohorts of 1 - 6 patients. Patients receive Nanotax via intraperitoneal infusion once every 28 days continuing on this treatment schedule until disease progression or unacceptable toxicity is experienced. Dosing cohorts are as follows: 50 mg/m2, 82.5 mg/m2, 125 mg/m2, 175 mg/m2, 225 mg/m2, and 275 mg/m2.
1810210|NCT00667004|Drug|ecabet ophthalmic solution|sterile ophthalmic solution
1810211|NCT00667004|Drug|placebo|sterile ophthalmic solution
1810212|NCT00667017|Biological|RFT5-dgA immunotoxin|
1810213|NCT00667017|Other|fluorescence activated cell sorting|
1810214|NCT00667017|Other|immunohistochemistry staining method|
1810215|NCT00667030|Behavioral|Weight loss and aerobic exercise training|Weight loss and aerobic exercise training
1810216|NCT00667043|Drug|remifentanil and propofol|Patients will receive: propofol, continuous intravenous infusion, concentration 10 mg/ml, 1-4 mg/kg/hour and remifentanil; continuous intravenous infusion 0,050 mg/ml, 0.1-0.3 microgram/kg/min. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
1810217|NCT00667043|Drug|fentanyl and midazolam|Patients will receive: midazolam; continuous intravenous infusion, concentration 5 mg/ml, 2-10 mg/hour and fentanyl; continuous intravenous infusion, concentration 0,050 mg/ml, 0.025-0.5 mg/hour. Drugs are administered to sedate the patients as part of normal treatment for as long as sedation is needed. Doses are titrated to achieve the desired level of sedation.
1810218|NCT00667056|Drug|tacrolimus ointment|topical
1810219|NCT00667056|Drug|placebo ointment|topical
1810220|NCT00667069|Drug|triptorelin|
1810221|NCT00667069|Procedure|adjuvant therapy|
1810222|NCT00667069|Radiation|3-dimensional conformal radiation therapy|
1810223|NCT00667082|Drug|NPI-0052 (marizomib) + vorinostat|"NPI-0052 IV injection over 1 to 10 minutes at doses ranging from 0.15 to 0.7 mg/m2 on Days 1, 8, and 15 of each 28-day Cycle
Oral vorinostat 300 mg was administered with food on Days 1 to 16 of each 28-day Cycle"
1810224|NCT00667095|Drug|Botox Instillation|Botox instilled into the bladder via ureteral catheter and retained for up to 30 minutes then spontaneously voided.
1810227|NCT00667108|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
1810228|NCT00667108|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
1810229|NCT00667121|Drug|citalopram hydrobromide|
1810230|NCT00667121|Drug|escitalopram oxalate|
1810231|NCT00667121|Drug|gabapentin|
1810232|NCT00667121|Drug|sertraline hydrochloride|
1810233|NCT00667121|Drug|tamoxifen citrate|
1810234|NCT00667121|Drug|venlafaxine|
1810235|NCT00667121|Genetic|molecular genetic technique|
1810236|NCT00667121|Other|high performance liquid chromatography|
1810237|NCT00667121|Other|laboratory biomarker analysis|
1810238|NCT00667121|Other|pharmacological study|
1810239|NCT00667121|Procedure|adjuvant therapy|
1810240|NCT00667147|Drug|Weekly Abraxane and Daily Vandetanib|Abraxane once a week for three weeks, followed by one week with no Abraxane. Vandetanib once a day every day for 28 days. This four week period is called a cycle.
1810241|NCT00667147|Drug|Abraxane every three weeks and daily vandetanib|Abraxane on day one of study therapy, followed by 20 days of no Abraxane. Vandetanib once a day every day for 21 days. This three week period is called a cycle.
1810242|NCT00667160|Drug|tacrolimus ointment|topical
1810243|NCT00667160|Drug|pimecrolimus cream|topical
1810244|NCT00667173|Drug|IDP-115|Topical application for 12 weeks
1810245|NCT00667173|Drug|Vehicle|Topical application for 12 weeks
1810246|NCT00667173|Drug|Vehicle|Topical application for 12 weeks
1810247|NCT00667186|Other|Targeted Screening|Selection method for screening is based on risk
1810248|NCT00667186|Other|Routine Screening|Selection method for screening is not based on risk
1810249|NCT00667199|Drug|Radium-223 dichloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight, the dose (5 , 25 , 50 or 100 kBq/kg b.w.)
1810250|NCT00667212|Behavioral|Cognitive Behavioral Therapy|Twelve weekly therapy sessions, approximately one hour each in duration
1810251|NCT00667212|Behavioral|Supportive Psychotherapy|Twelve weekly therapy sessions, approximately one hour each in duration
1810252|NCT00667225|Drug|cantharidin's vehicle|Cantharidin's vehicle is composed of: Hydroxypropylcellulose, Acetone, and Collodion Flexible. The vehicle will be topically applied to molluscum lesions at each visit. Only two lesions will be treated at the first visit, and up to 20 lesions can be treated at subsequent visits.
1810253|NCT00667225|Drug|Cantharidin 0.7%|Subjects in this arm will receive cantharidin at all visits. At the first visit, up to 2 lesions can have application with cantharidin. All other visits will have up to 20 lesions with application of the cantharidin. During every visit, lesions will be counted and subjects will be assessed for any adverse events.
1810254|NCT00667238|Behavioral|Questionnaire|
1810255|NCT00667251|Biological|trastuzumab|IV q weekly (loading dose 4mg/kg; subsequent doses 2mg/kg) or IV q 3 weekly (loading dose 8mg/kg, subsequent doses 6mg/kg).
1810256|NCT00667251|Drug|docetaxel|75mg/m2 IV q 3 weekly, day 1 of a 3 week cycle for 8 cycles plus G-CSF (when given together with lapatinib).
1810257|NCT00667251|Drug|lapatinib ditosylate|1250 mg po daily (while given with taxane). 1500mg PO daily (when given alone after taxane completion).
1810258|NCT00667251|Drug|paclitaxel|80mg/m2 IV q weekly days 1, 8 and 15 of a 4-week cycle for 6 cycles.
1810259|NCT00667264|Procedure|perineural ropivacaine|Subjects will be randomized to one of two groups: ropivacaine 0.4% or normal saline (placebo). The basal rate will be set at 7 mL/h.
1810260|NCT00667277|Drug|bevacizumab (Avastin)|15 mg/kg of bevacizumab by IV infusion once every 3 weeks (1 cycle) for 12 weeks (4 cycles)
1810261|NCT00667290|Behavioral|Treadmill exercise|Graded treadmill walking 3 times per week for 3 months
1810262|NCT00667303|Other|Nasopharyngeal Washes|A total of eight nasopharyngeal washes will be done at the following time points: Prior to conditioning, on the day of admission and thereafter every two weeks until day +100 (Day +14, 28, 42, 56, 70, 84 and 98). To allow for flexibility over the weekends and holidays the specimen may be collected on the scheduled day ± 3 days. The baseline sample obtained prior to conditioning is required for patient to be considered evaluable.
1810263|NCT00667303|Other|Fluorescent antibody detection|For IF (Direct IF for hHRSV and indirect IF for the other viruses), the specimens will be spotted onto glass slides. Samples without respiratory epithelial cells will be considered inconclusive. Labelled antibodies against Flu A, Flu B, HPIV 1 to 3, RSV, hMPV and Adv will be used.
1810264|NCT00667303|Other|Respiratory viral culture|Shell vial culture specimens will be inoculated and incubated for 48 hours. The following RVs: Flu A, Flu B, HPIV 1-3, RSV, Adv and hMPV will be identified on the basis of cytopathic effects in cell cultures and confirmed by staining with fluorescein-conjugated monoclonal antibodies.
1810265|NCT00667316|Behavioral|Set of questionnaires (respondent)|A set of questionnaires to determine risk factors for sick leave due to low back pain.
1810266|NCT00667329|Drug|2CdA|1.5 mg/m^2 subcutaneous injection three times daily x 7 days.
1810267|NCT00667329|Drug|Cyclophosphamide|40 mg/m^2 PO twice daily x 7 days.
1810268|NCT00667329|Drug|Rituximab|375 mg/m^2 IV once weekly x 4 weeks.
1810269|NCT00667342|Biological|Bevacizumab|Monoclonal Antibody against vascular endothelial growth factor (VEGF). Given intravenously (IV).
1810270|NCT00667342|Drug|Cisplatin|Given IV.
1810271|NCT00667342|Drug|Doxorubicin|Given IV.
1810272|NCT00667342|Drug|Methotrexate|Given IV.
1810273|NCT00667342|Drug|Ifosfamide|Given IV.
1810274|NCT00667342|Drug|etoposide|Given IV.
1810275|NCT00667342|Procedure|Surgery|Participants undergo definitive surgery and assessment of histologic response at week 10.
1810276|NCT00667342|Radiation|Radiotherapy|Radiation therapy delivered for positive margins or intralesional resections.
1810277|NCT00667355|Biological|adalimumab|40 mg or 80 mg every other week, subcutaneous
1810278|NCT00667368|Drug|Metronidazole|Bi-monthly testing and treatment for BV with Metronidazole if BV is detected; 500mg twice daily for 7 days.
1810279|NCT00667381|Device|Real-time Ultrasound Guidance (Site-Rite 5 or 6 machine)|Real-time ultrasound guidance will be used to aid in femoral artery cannulation. This will occur with a 7 MHz ultrasound probe covered with a sterile cover.
1810280|NCT00667394|Biological|Bevacizumab|Bevacizumab 10 mg/kg dose intravenous repeated once every 2 weeks.
1810281|NCT00667394|Drug|MLN-518 (Tandutinib)|Tandutinib 500 mg by mouth daily dose twice a day.
1810282|NCT00667394|Procedure|Quality-of-life assessment|Forty-five one-sentence questionnaire to assess health related quality of life in patients with brain cancer.
1810283|NCT00667407|Drug|Levalbuterol 1.25 mg|"levalbuterol 1.25 mg Period I: administered every 20 minutes for the first 3 doses, and then every 40 minutes for the next 3 doses; then as clinically indicated.
Period II: TID for 3 days (same time of day), then PRN to TID for 7 days"
1810284|NCT00667407|Drug|Racemic Albuterol Sulfate|"Racemic Albuterol 2.5 mg Period I: every 20 min for the first 3 doses, then every 40 min for the next 3 doses, then as clinically indicated.
Period II: TID for 3 days then PRN to TID for 7 days"
1810285|NCT00667420|Drug|panitumumab, epirubicin, oxaliplatin, xeloda|pilot study
1810286|NCT00667433|Drug|Raltegravir + Truvada|Raltegravir 400 mg tablet BID PO X 104 weeks; Truvada 200/300 mg tablet once a day PO x 104 weeks
1810287|NCT00667446|Drug|Leuprolide Acetate 3 Month Depot|
1810288|NCT00667459|Device|PRESTIGE® LP Cervical Disc|The PRESTIGE® LP Cervical Disc was inserted into the intervertebral disc space of the cervical spine using the anterior surgical approach.
1810289|NCT00667459|Device|ATLANTIS Anterior Cervical Plate|Anterior cervical discectomy and fusion with ATLANTIS plate for control group
1810290|NCT00667472|Drug|Ranibizumab|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
1810291|NCT00667472|Device|Pulsed Dye Laser|Combined Pulsed Dye Laser and Topical Ranibizumab for Treatment of Port Wine Stain Birthmarks
1810292|NCT00667485|Drug|Rapamycin (liquid)|Weekly Rapamycin (liquid) 90mg (dose will be split 45mg on Day 1 and Day 2 of each week)
1810293|NCT00667485|Drug|Bevacizumab|Multiple doses (dose depends on time of study entry) given by IV once every 3 weeks
1810294|NCT00667485|Drug|Rapamycin (Tablets)|Daily oral rapamycin (tablets) - 2 doses will be tested 4mg and 6mg
1810295|NCT00667498|Drug|Metformin|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.
The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
1810296|NCT00667498|Drug|Placebo|"The subject will receive either metformin or placebo drug, given as 500mg tablets (or corresponding placebos) necessary to increase the dose incrementally over a three week period.
The time it takes to incrementally increase the dose to the desired dose of 500mg in am and 1000mg in pm will count as intervention time. Both the metformin and placebo group will also be given a multivitamin with vitamin B12 to avoid potential anemia."
1810297|NCT00667511|Device|NxStage System One|Comparison of Nocturnal (NHD) and Short Daily Hemodialysis (DHD) with the NxStage System One
1810298|NCT00667537|Drug|Radium-223 chloride (Xofigo®, BAY88-8223) injection|Sterile, clear and colourless aqueous solution of radium-223 chloride free of endotoxins, for intravenous administration
1810299|NCT00667563|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|Vaccination with the Quadrivalent Human Papillomavirus Recombinant vaccine (0.5 mL Gardasil®) by intramuscular (IM) injection at Day 0, Weeks 8 and 24.
1810300|NCT00667563|Genetic|DNA analysis|Weeks 0, 2, 10, 26, and 52.
1810301|NCT00667563|Genetic|polymerase chain reaction|Screening, week 36, and week 52.
1810302|NCT00667563|Other|cytology specimen collection procedure|Screening, week 36, and week 52.
1810303|NCT00667563|Procedure|colposcopic biopsy|Screening, week 36, and week 52.
1810304|NCT00667576|Drug|Maxacalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
1810305|NCT00667576|Drug|Paricalcitol|Study drug was administered 3 times per week (no more frequently than every other day) intravenously immediately before the completion of hemodialysis. The initial dosage was administered for 2 weeks, with subsequent dosage adjustment based on the subject's iPTH, calcium (adjusted), and phosphorus levels every 2 weeks. Total duration of treatment was 12 weeks.
1810306|NCT00667589|Drug|urea 40% cream|urea 40% cream applied twice per day to affected areas
1810307|NCT00667589|Drug|fluocinonide 0.05% cream|fluocinonide 0.05% cream applied twice per day to affected areas
1810308|NCT00667589|Drug|tazarotene 0.1% cream|tazarotene 0.1% cream applied twice per day to affected areas
1810309|NCT00667589|Drug|bland emollient cream (Udderly smooth® Udder Cream)|bland emollient cream applied twice per day to affected areas
1810310|NCT00667602|Biological|MenACWY-CRM197 (two doses)|Two 0.5mL doses of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
1810311|NCT00667602|Biological|MenC|One 0.5mL dose of MenC vaccine was administered by intramuscular injection.
1810312|NCT00667602|Biological|PCV7|One 0.5mL dose of Pneumococcal 7-valent Conjugate Vaccine (PCV7) was administered by intramuscular injection.
1810313|NCT00667602|Biological|DTPa-IPV-HepB-Hib|One 0.5mL dose of Combined Diphtheria-Tetanus-acellular Pertussis, Hepatitis B, Inactivated Poliovirus and Haemophilus influenzae type b (DTPa-IPV-HepB-Hib) vaccine was administered by intramuscular injection.
1810314|NCT00667602|Biological|MenACWY-CRM197 (one dose)|One 0.5mL dose of MenACWY conjugate vaccine (MenACWY-CRM197) was administered by intramuscular injection.
1810316|NCT00667628|Drug|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
1810317|NCT00667628|Drug|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
1810318|NCT00667641|Drug|bortezomib|Starting dose level 0.70mg/m2
1810319|NCT00667641|Drug|paclitaxel|Starting dose level 40mg/m2
1810320|NCT00667654|Drug|CNTX-4975|Testing a range of dosing configurations to optimize patient tolerability
1810321|NCT00667667|Device|vertical vibration device (Vibrafit whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with vertical device
1810322|NCT00667667|Device|side alternating vibration device (Board 3000 whole body vibration platform)|3 sessions/week 15 min each, leg exercises performed on whole body vibration platforms with side alternating device
1810323|NCT00667667|Behavioral|stretching and wellness (control group)|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months
1810324|NCT00667680|Device|Transcranial direct current stimulation (tDCS) - Eldith DC-Stimulator|real or sham tDCS for 20 minutes at 2mA intensity over the left DLPFC (F3 according to the 10-20 system)
1810325|NCT00667693|Device|Macintosh intubation|Macintosh intubation
1810326|NCT00667693|Device|Pentax AWS|Intubation with Pentax AWS
1810327|NCT00667706|Procedure|laparoscopic operation Sleeve Gastrectomy|Laparoscopic Sleeve Gastrectomy will be performed employing a 5-6 trocar technique, and includes gastric resection starting 4-5 cm proximal to the pylorus, using a 38 fr. Bougie and endoscopic stapler with blue and green load.
1810328|NCT00667706|Procedure|laparoscopic operation Roux-en-Y Gastric bypass|Divided LRYGB will employ 5-7 trocars technique, and includes stapled jejunojejunostomy 30-50 cm distal to the Treitz ligament, gastric pouch of 20 cc., and antecolic, antegastric gastrojejunal anastomosis, either two layered hand-sawn, GIA, or EEA-25 -stapled, at surgeons preference. The length of the Roux limb will be 100 centimeters or 150 centimeters in patients with BMI of <50, and >50, respectively.
1810329|NCT00667719|Drug|aliskiren /amlodipine/hydrochlorothiazide|1x aliskiren/amlodipine/hydrochlorothiazide
1810330|NCT00667732|Drug|exenatide|5mcg twice a day, increasing to 10mcg twice a day for 24 weeks
1810331|NCT00667732|Drug|placebo|5mcg twice a day, increased to 10mcg twice a day for 24 weeks
1810332|NCT00667745|Drug|Lithium Carbonate|Lithium was started at 300 mg and then increased to 600 mg after 3 days. Lithium doses were maintained at 600 mg per day for 8 weeks, but may have been adjusted after that time as needed up to a serum level of 1.2 mEq/L.
1810333|NCT00667745|Drug|Optimized Treatment (OPT)|The foundation of OPT was to maintain treatment that will typically include at least one FDA-approved mood stabilizer other than lithium (e.g., divalproex, carbamazepine, risperidone, quetiapine, olanzapine, aripiprazole, ziprasidone) and to follow the recommendations summarized in the evidence-based stages of the Texas Implementation of Medication Algorithm (TIMA) revised guidelines.
1810334|NCT00667758|Drug|Cetrorelix|3-5 mg s.c. on days 1-5
1810335|NCT00667758|Drug|Placebo|3-5 ml NaCl s.c. on days 1-5
1810336|NCT00667771|Drug|Naltrexone|
1810337|NCT00667784|Behavioral|Questionnaire|Questionnaires completed before the bone marrow or stem cells are collected, after the transplant, and 6 months after the transplant.
1810338|NCT00667797|Drug|levalbuterol HCl|Levalbuterol 1.25 mg will be prescribed every 6-8 hours, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of levalbuterol administration at their discretion.
1810339|NCT00667797|Drug|albuterol Sulfate|Racemic albuterol 2.5 mg will be prescribed per the standard of care used in the institution, with standing orders for as needed PRN use. However, the prescribing physician may change the dose, frequency, and/or duration of racemic albuterol administration at their discretion.
1810340|NCT00667810|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
1810341|NCT00667810|Drug|bapineuzumab|Bapineuzumab 1.0 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
1810342|NCT00667810|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
1957829|NCT02162693|Biological|Mesenchymal progenitor cells|Administrated for intra-articular injection
1810344|NCT00667849|Device|Exogen 4000+|Low-intensity pulsed ultrasound (LIPUS)
1810345|NCT00667849|Device|Sham|sham device identical to active device with the exception of administration of ultrasound
1810346|NCT00667862|Drug|Panobinostat|
1810347|NCT00667875|Drug|Placebo|placebo
1810348|NCT00667875|Drug|Naltrexone|Naltrexone (25mg or 50 mg per titration schedule)
1810349|NCT00667875|Drug|Naltrexone + Aripiprazole|Naltrexone + Aripiprazole (5mg - 15mg per titration schedule)
1810350|NCT00667888|Radiation|Conventional Fractionated Intensity Modulated Radiotherapy|A total dose of 75.6 Gy will be delivered in 42 fractions to the planning target volume (PTV).
1810351|NCT00667888|Radiation|Hypofractionated Intensity Modulated Radiotherapy|A total dose of 72 Gy will be delivered in 30 fractions to the PTV.
1810352|NCT00667901|Drug|riluzole|
1810353|NCT00667901|Genetic|protein expression analysis|
1810354|NCT00667901|Genetic|reverse transcriptase-polymerase chain reaction|
1810355|NCT00667901|Genetic|western blotting|
1810356|NCT00667901|Other|immunohistochemistry staining method|
1810357|NCT00667901|Other|laboratory biomarker analysis|
1810358|NCT00667901|Other|pharmacological study|
1810359|NCT00667901|Procedure|neoadjuvant therapy|
1810360|NCT00667901|Procedure|therapeutic conventional surgery|
1810361|NCT00667914|Procedure|geriatric work-up|Pre- and postoperative treatment of hip-fracture patients in an orthogeriatric unit(geriatric evaluation and management)
1810362|NCT00667914|Procedure|Orthopedic care as usual|treatment in ordinary orthopedic unit
1810363|NCT00667927|Drug|Busulfan|See Detailed Description section for description of treatment plan.
1810364|NCT00667927|Drug|Cyclophosphamide|See Detailed Description section for description of treatment plan.
1810365|NCT00667927|Drug|Mesna|See Detailed Description section for description of treatment plan.
1810366|NCT00667940|Behavioral|Rater training workshop|Rater training workshop: rater error training, performance dimension training, behavioral observation training, and frame of reference training using lecture, video, and facilitated discussion
1810367|NCT00667953|Drug|Gleevec + Temozolomide|Temzolomide (1000 mg/m2) over 5 days on a 28 day cycle. Gleevec (600 mg) daily.
1810368|NCT00667966|Drug|Vardenafil (Levitra, BAY 38-9456), 10 mg|10 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
1810369|NCT00667966|Drug|Placebo|10/20 mg placebo in sequence in respective arm
1810370|NCT00667966|Drug|Vardenafil (Levitra, BAY 38-9456), 20 mg|20 mg vardenafil was administered with a glass of water 1 h before starting the test with the stimulator.
1810371|NCT00667979|Drug|Levitra (Vardenafil, BAY38-9456)|10mg and 20mg to be taken 12, 18, 24 hours prior to sexual intercourse
1810372|NCT00667979|Drug|Placebo|Matching placebo
1810373|NCT00667992|Drug|Budesonide HFA|standard daily inhaled dose
1810374|NCT00667992|Drug|Budesonide CFC|standard daily inhaled dose
1810375|NCT00668005|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
1810376|NCT00668005|Drug|Placebo|Matching placebo
1810377|NCT00668018|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg orally on demand prior to intercourse
1810378|NCT00668031|Drug|Trasylol (Aprotinin, BAYA0128)|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of aprotinin using an IV infusion pump
1810379|NCT00668031|Drug|Placebo|A loading dose IV infusion of 2,000,000 KIU (200 mL) followed by 500,000 KIU (50 mL) IV per hour until the end of surgery of of placebo using an IV infusion pump
1810380|NCT00668044|Drug|Ciprofloxacin (BAYO9867)|400 mg iv BID
1810381|NCT00668044|Drug|Ciprofloxacin (BAYO9867)|400 mg iv TID
1810382|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|5 mg Vardenafil orally 1 hour prior to sexual intercourse
1810383|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil orally 1 hour prior to sexual intercourse
1810384|NCT00668057|Drug|Levitra (Vardenafil, BAY38-9456)|20 mg Vardenafil orally 1 hour prior to sexual intercourse
1810385|NCT00668057|Drug|Placebo|5 mg matching placebo
1810386|NCT00668057|Drug|Placebo|10 mg matching placebo
1810387|NCT00668057|Drug|Placebo|20 mg matching placebo
1810388|NCT00668070|Drug|ASP9831|Oral
1810389|NCT00668070|Drug|Placebo|Oral
1810390|NCT00668096|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5 mg or 10 mg or 20 mg, orally1 hour prior to sexual activity
1810391|NCT00668096|Drug|Placebo|Matching Placebo
1810392|NCT00668109|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg one hour prior to sexual intercourse
1810393|NCT00668109|Drug|Tadalafil|10 mg taken approximately 24 hours prior to sexual intercourse
1810394|NCT00668122|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin XR 1000 mg orally once a day
1810395|NCT00668122|Drug|Cipro IR (Ciprofloxacin, BAYQ3939)|Ciprofloxacin IR 500 mg orally twice a day
1810396|NCT00668135|Drug|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg orally on demand prior to intercourse
1810397|NCT00668135|Drug|Placebo|Matching placebo
1810398|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Ewing's Sarcoma/peripheral neuroectodermal tumor (PNET)
10 mg/kg intravenous (I.V.) infusion every two weeks.
A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
1810399|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Rhabdomyosarcoma
10 mg/kg intravenous (I.V.) infusion every two weeks.
A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
1810400|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Leiomyosarcoma
10 mg/kg intravenous (I.V.) infusion every two weeks.
A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
1810401|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Adipocytic sarcoma
10 mg/kg intravenous (I.V.) infusion every two weeks.
A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
1810402|NCT00668148|Biological|IMC-A12 (cixutumumab)|"Synovial sarcoma
10 mg/kg intravenous (I.V.) infusion every two weeks.
A treatment cycle will be defined as 6 weeks, with radiological evaluation at every cycle."
1810403|NCT00668161|Behavioral|Exercise|60 minutes/session of aerobic exercise, 6 d/week at 50-50% HHR. All sessions will begin with 10 minutes of stretching and 5 minutes of warm-up, and will end with 5 minutes of cool down.
1810404|NCT00668174|Behavioral|Exercise|Moderate intensity exercise, 5 days per week, 45 min per session, 50-70% max HR, divided into a 3-month individualized and 9-month maintenance period.
1810405|NCT00668200|Drug|Reclast (ZOL446, zoledronic acid)|"5 mg i.v. annually (real-life, physician prescribed)"
1810406|NCT00668200|Dietary Supplement|Calcium|1500 mg elemental calcium daily in divided doses (the divided doses were 2-3 times per day depending on the formulation)
1810407|NCT00668200|Dietary Supplement|Vitamin D|800 IU vitamin D daily, particularly in the immediate 2 weeks following zoledronic acid administration
1810408|NCT00668226|Drug|Lactic acid (Dermacid)|
1810409|NCT00668239|Drug|intravitreous triamcinolone|Intravenous injection of 0.1 ml (4 mg) of triamcinolone acetate was performed through the pars plana in a surgical environment. The medication used was manipulated by the Ophthalmos chemist. This type of formulation is different from the similar American one (Kenalog ®) since it does not use a conservation agent
1810410|NCT00668239|Procedure|laser therapy|pan fotocoaglulation by laser therapy
1810411|NCT00668265|Drug|Quetiapine|Dosage is 50 - 300 mg, once daily, at bedtime.
1810412|NCT00668278|Device|Insertion of laryngeal mask airway (AuraOnce mask)|Insertion of laryngeal mask airway under anaesthesia: Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg; AuraOnce disposable laryngeal mask
1810413|NCT00668278|Device|Insertion of I-gel airway|Insertion of I-gel airway under anaesthesia; Fentanyl 1-2mcg/kg; Propofol 1-3mg/kg; Atracurium 0.5mg/kg
1810414|NCT00668278|Other|Measurement of airway pressures|Measurement of peak airway pressure under steady state; measurement of device seal pressure
1810415|NCT00668304|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg once orally daily
1810416|NCT00668317|Drug|Omeprazole|20 mg BD tablet 8 weeks duration
1810417|NCT00668317|Drug|Ranitidine|300 mg od nocte tablet 8weeks duration
1810418|NCT00668330|Drug|Ibandronate+alfacalcidol+calcium|Ibandronate 150 mg monthly plus daily alfacalcidol (1ug)500mg plus calcium
1810419|NCT00668330|Drug|placebo ibandronate+alfacalcidol+calcium|placebo ibandronate monthly plus daily alfacalcidol(1ug)500mg calcium
1810420|NCT00668343|Drug|simvastatin|40 mg/ day
1810421|NCT00668343|Drug|placebo|80 mg /day
1810422|NCT00668356|Drug|didanosine|28 days 400 mg/m2/day during the meal 28 days 240 mg/m2/day during fasting
1810423|NCT00668356|Drug|didanosine|28 days 240 mg/m2/day during fasting 28 days 400 mg/m2/day during the meal
1810550|NCT00655330|Drug|Placebo|Placebo
1810424|NCT00668369|Procedure|Gradual immunosuppression drug withdrawal.|Ater obtention of biological samples (peripheral blood, liver tissue) enrolled patients undergo gradual decrease in the doses of immunosuppression drugs (tacrolimus, cyclosporine A and/or mofetil mycophenolate) until complete discontinuation or appearance of rejection.
1810425|NCT00668382|Biological|Alpha-Gal Glycosphingolipid|Intra-tumoral injection of Alpha-Gal Glycosphingolipid to evaluate toxicity
1810426|NCT00668395|Drug|Efavirenz|The metabolism and pharmacokinetics of efavirenz were assessed at a single 600 mg oral dose of efavirenz and after subjects took multiple doses of efavirenz (600 mg/day orally for 17 days).
1810427|NCT00668408|Other|LTOT (oxygen therapy)|Patients on LTOT will receive oxygen for at least 15 hours/day from the liquid oxygen systems at a flow rate adjusted to raise resting SaO2 between 93 and 96% and / or PaO2 between 65 and 80 mmHg every day for 3 years.
1810428|NCT00668408|Other|Pharmacological therapy of COPD and CHF|"Optimal pharmacologic treatment will include :
Long (LABD, salmeterol, formoterol, tiotropium) - as well as short-acting (SABD, Salbutamol, terbutaline, ipratropium)bronchodilators (beta-2 agonists, anticholinergics)
Inhaled steroids (ICS, beclomethasone, fluticasone, budesonide always associated with LABD)
Beta-blockers
Diuretics
Angiotensin-converting enzyme (ACE) inhibitors alone or in associations with diuretics
Statins and any other treatment required for associated co-morbidities (eg insulin and/or anti-diabetic drugs, other antihypertensive, etc).
The treatment of the deseases will follow the international guidelines."
1993889|NCT03111420|Device|Platelet function test|Blood is drawn for testing of platelet aggregation activity
1810430|NCT00668434|Drug|Prednisone|For participants who weigh 50 kg or more, the prednisone dose will be 60 mg daily for 5 days, then 40 mg daily for 5 days, and then 20 mg daily for 5 days. For participants who weigh less than 50 kg, the dose will be 40 mg daily for 10 days, and then 20 mg daily for 5 days.
1810431|NCT00668434|Drug|Placebo|Placebo capsules will look the same as the study medication but will not contain active medicine.
1810432|NCT00668447|Dietary Supplement|Soy Isolate|20 grams of powder mixed in beverages or food daily for one year
1810433|NCT00668447|Dietary Supplement|Control protein|20 grams of powder mixed in beverages or food daily for one year
1810434|NCT00668447|Dietary Supplement|Novasoy isoflavones|3 tablets daily for one year
1810435|NCT00668447|Dietary Supplement|Placebo tablets|3 tablets daily for one year
1810436|NCT00668460|Drug|Lactic acid (Dermacid)|
1810437|NCT00668486|Drug|Lactic acid (Dermacid)|
1810438|NCT00668499|Drug|VEGF-Antisense Oligonucleotide , Pemetrexed, Cisplatin|VEGF-AS either 100 or 200mg/m2 IV days 1-5, Pemetrexed 500mg/m2 and Cisplatin 75mg/m2 IV on day 1. Cycle repeated every 3 weeks until 6 cycles completed, unless PD or toxicities
1810439|NCT00668512|Biological|Antimelanoma injection of GSL alpha-Gal|Single arm, phase 1 trial of escalating doses of GSL alpha-Gal (0.1mg, 1mg, 10mg)injected into a melanoma metastasis at day 0 and then again 4 weeks later.
1810440|NCT00668525|Drug|Escitalopram|Escitalopram low dose, oral administration, once daily dosing for 8 weeks.
1810441|NCT00668525|Drug|Placebo|Placebo, oral administration, once daily dosing for 8 weeks
1810442|NCT00668525|Drug|Escitalopram|Escitalopram high dose, oral administration, once daily dosing for 8 weeks
1810443|NCT00668538|Drug|Brentan (miconazole)|Vaginal suppository 1200 mg at day 6
1810444|NCT00668564|Procedure|Stem Cell Transplantation|The purpose of hematopoietic stem cell transplantation is to introduce blood producing cells from a normal donor. These cells can either provide what is missing in the body to the other cells, or can change the body's immune response to the substances that have accumulated in the body. These normal hematopoietic stem cells can come from bone marrow, peripheral blood (i.e., the blood circulating in our body's blood vessels) or umbilical cord blood (i.e., blood taken from the umbilical cord after a baby is born and umbilical cord is cut). The new donor cells repopulate the blood and bone marrow system and enter the organs of the body, including the brain. Wherever these cells go, they will produce the needed enzyme.
1810445|NCT00668564|Drug|Cyclophosphamide|"Days before Transplant Drug Frequency
4 Cyclophosphamide Once, given over 2 hours
3 Cyclophosphamide Once, given over 2 hours
2 Cyclophosphamide Once, given over 2 hours
1 Cyclophosphamide Once, given over 2 hours"
1810446|NCT00668564|Drug|Campath-1H|"Days before Transplant Drug Frequency
12 Campath-1H Once, given over 2 hours
11 Campath-1H Once, given over 2 hours
10 Campath-1H Once, given over 2 hours"
1810447|NCT00668564|Drug|Busulfan|"Days before Transplant Drug Frequency
9 Busulfan Four times per day
8 Busulfan Four times per day
7 Busulfan Four times per day
6 Busulfan Four times per day"
1810448|NCT00668577|Drug|Lactic acid (Dermacid)|
1810449|NCT00668590|Behavioral|Patient video decision aid & telephone coaching|The decision aid is a 30 minute video program that educates patients about their role in diabetes care. Telephone coaching will assist patients in initiating behavior change.
1810450|NCT00668590|Behavioral|Printed educational brochure|The printed brochure is an educational brochure developed by the NIH.
1810451|NCT00668603|Drug|17-b-estradiol|2mg oral daily for 6 months
1810452|NCT00668603|Drug|17-b-estradiol + medroxyprogeterone acetate|2mg E2 + 5mg MPA daily for 6 months
1810453|NCT00668603|Drug|17-b-estradiol hemihydrate|1 mg skin gel daily for 6 months
1810454|NCT00668603|Drug|placebo pill + gel|placebo daily for 6 months
1810455|NCT00668616|Drug|Cyclophosphamide, Epirubicin, Paclitaxel|4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d
1810456|NCT00668616|Drug|Epirubicin, Paclitaxel, Filgrastim|cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)
1810457|NCT00668629|Drug|Lactic acid (Dermacid)|
1810458|NCT00668642|Drug|Dutasteride|0.5 mg capsule given orally on daily basis
1810459|NCT00668642|Drug|Placebo|Identical placebo
1810460|NCT00668655|Drug|Metronidazole Gel|Topical, Once daily for 2 weeks
1810461|NCT00668668|Drug|Lactic acid (Dermacid)|
1810462|NCT00668681|Device|EndoRefix|
1810463|NCT00668694|Behavioral|Stimulation|Stimulation given to the child by mother
1810464|NCT00668707|Dietary Supplement|melatonin|20 mgs ingested nightly
1810551|NCT00655330|Drug|Probucol|Probucol (750mg/day)
1996758|NCT02386800|Drug|Ruxolitinib|
1810465|NCT00668707|Dietary Supplement|placebo|similar to experimental in all ways except for lack of active ingredient
1810466|NCT00668720|Device|transcranial magnetic stimulation (Magstim rapid2)|Neuronavigated rTMS will be applied bilaterally to the auditory cortices, which will be identified through a structural MRI scan. Stimulation will be performed with 1 Hz frequency and an intensity of 110% motor threshold for 2000 stimuli (32 minutes) on each side, on five subsequent days.
1810467|NCT00668720|Device|sham stimulation|The official sham stimulator for the magstim rapid2 will be used. Sham stimulation will follow the same placement protocol and will also last 2x32 minutes on five subsequent days
1810468|NCT00668746|Drug|Minocycline HCl microspheres|At Baseline and all interim visits, a single unit dose of 1mg minocycline HCl (with approximately 3mg PGLA) will be professionally administered subgingivally into periodontal pockets at each site exhibiting a PD ≥ 5mm.
1810469|NCT00668759|Drug|Vernakalant Injection|10-minute infusion of 3 mg/kg vernakalant injection followed by a 15-minute observation period, followed by an additional 10-minute infusion of 2 mg/kg of vernakalant if required (if the subject is still in AF).
1810470|NCT00668759|Drug|Amiodarone Injection:|60-minute infusion of 5 mg/kg amiodarone followed by a maintenance infusion of 50 mg amiodarone over an additional 60 minutes (equivalent to approximately 15 mg/kg over 24 hrs).
1810471|NCT00668772|Drug|Tiotropium/Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
1810472|NCT00668772|Drug|Tiotropium/Salmeterol QD + Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
1810473|NCT00668772|Drug|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
1810474|NCT00668772|Drug|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
1810475|NCT00668772|Drug|Tiotropium|Tiotropium Inhalation Powder, hard gelatine capsule (Spiriva®)
1810476|NCT00668785|Drug|ranibizumab|Ranibizumab 0.5mg at baseline and then again at 30 days and/or 60 days after PRP as deemed appropriate by the Investigator.
1810477|NCT00668811|Drug|SU011248, Sutent|Sutent 37.5 mg/day will be given orally after radioactive iodine therapy. Total time of Sutent drug administration will be 52 weeks, absent unacceptable toxicity or disease progression. Sutent is supplied as 12.5mg and 25 mg tablets. Patients are to swallow the tablets whole with approximately 250 ml (8 oz.) of water, fasting each morning. Patients will be given monthly calendars (patient diaries) to document the time when the Sutent pills are taken. At monthly visits, patients will bring back this record and the drug bottles.
1810478|NCT00668824|Drug|Vasovist|
1810479|NCT00668837|Drug|Paliperidone|
1810482|NCT00668863|Drug|FOLFIRI (The combination regimen of Irinotecan, l-Leucovorin and 5-Fluorouracil)|FOLFIRI treatment with Sunitinib on Day, Irinotecan 180M/M IV , l-Leucovorin 200M/M, 5FU 400M/M bolus and 2400M/M in 46-hour continuous infusion on Day1 each 42 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1810483|NCT00668863|Drug|Sunitinib|37.5mg daily P.O., 4 weeks On 2weeks Off each 42 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
1810484|NCT00668876|Dietary Supplement|Oral IMPACT|oral supplementation for 5 days(1 L/d )before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
1810485|NCT00668876|Dietary Supplement|Oral IMPACT|postoperative enteral infusion of the formula with arginine, omega-3 fatty acids, and RNA
1810486|NCT00668876|Dietary Supplement|Parenteral nutrition|Parenteral nutrition
1810487|NCT00668889|Drug|Lactic acid (Dermacid)|
1810488|NCT00668902|Drug|[13C]Pantoprazole|[13C]Pantoprazole was administered to EM, IM and PM of CYP2C19 and enzyme activity was measured through breath test and compared among the genotypes
1810489|NCT00668928|Other|Polyphenols (flavon-3-ol monomers and oligomers)|Flavanols
1810490|NCT00668941|Drug|Teriparatide|Teriparatide will be given subcutaneously in 20-mcg doses either continuously or cyclically.
1810491|NCT00668941|Drug|Alendronate|Participants will take 70 mg per week of alendronate for 48 months.
1810492|NCT00668941|Dietary Supplement|Calcium|Calcium supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily calcium intake to 1,200 mg.
1810493|NCT00668941|Dietary Supplement|Vitamin D3|Vitamin D3 supplements will be administered in varied amounts for all participants, but each participant will take enough to bring her total daily intake to 1,200 mg.
1810494|NCT00668954|Dietary Supplement|Pomegranate Juice|Group A drinks 8 oz. pomegranate juice/day for 12 weeks
1810495|NCT00668954|Dietary Supplement|Placebo Juice|Group B drinks 8 oz. placebo juice/day for 12 weeks
1810496|NCT00668967|Drug|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
1810497|NCT00668967|Drug|verapamil|240 mg extended release tablets once daily at bedtime for 28 days
1810498|NCT00668993|Behavioral|EFT - the Emotional Freedom technique|"EFT combines cognitive strategies with somatic procedures adapted from acupuncture and related systems for altering the cognitive, behavioural, and neurochemical foundations of psychological problems. It is often referred to as psychological acupuncture. Few adequately controlled studies have been conducted on EFT however acupuncture has been quite extensively studied, with hundreds of research reports published"
1810499|NCT00669019|Drug|saracatinib|
1810500|NCT00669032|Device|Hyaluronic acid|3 cycles of 5 hyaluronic acid injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
1810501|NCT00669032|Other|Placebo|3 cycles of 5 saline solution injections, with a 6 month interval between each one. A 4th treatment cycle of five injections will be carried out at the end of one year
1810502|NCT00669058|Drug|Lactic acid (Dermacid)|
1810503|NCT00669071|Drug|Fluocinolone acetonide 0.01%, hydroquinone 4%, tretinoin 0.05%|Applied once daily at bedtime on one side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
1810504|NCT00669071|Drug|Cetaphil® Moisturizing Cream as Inactive Control|Applied once daily at bedtime on the opposite side of the face; this was a randomized, split face study where one cream was used on the right side of the face and the other cream on the left side of the face and IPL (Intense Pulsed Light) was used on both sides of the face.
1810505|NCT00669097|Drug|TKI258|
1810506|NCT00669110|Drug|Desvenlafaxine Succinate Sustained-Release Tablets (DVS SR)|"tablet
subjects randomly assigned to 10-200 mg/day by age group
6 month treatment period(~182 days)"
1810507|NCT00669123|Drug|Chondroitin sulphate|Chondroitin sulphate 800 mg/day
1810508|NCT00669123|Drug|Placebo|
1810509|NCT00669136|Drug|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost|AFP + GM-CSF Plasmid Prime and AFP Adenoviral Vector Boost
1810510|NCT00669149|Drug|clopidogrel + aspirin|
1810511|NCT00669149|Drug|heparin + clopidogrel + aspirin|
1810512|NCT00669149|Drug|enoxaparin + clopidogrel + aspirin|
1810513|NCT00669149|Drug|bivalirudin + clopidogrel + aspirin|
1810514|NCT00669162|Drug|Docetaxel|20mg/m2 IV weekly for 7 weeks
1810515|NCT00669162|Radiation|Radiation Therapy|66.0 Gy delivered in 33 daily fractions at 2.0 Gy/fx
1810516|NCT00669162|Drug|Casodex and Zoladex (or Lupron)|Casodex 50 mg po daily for 6 months, and Zoladex 10.8 mg sc q 3 mos x 2 (or Lupron 22.5 mg im q 3 mos x 2)
1810518|NCT00669214|Drug|efalizumab|All patients received a conditioning dose of efalizumab 0.7 mg/kg subcutaneously (SC) on Day 0, followed by 11 weekly doses of 1.0 mg/kg SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label treatment period from Day 84 (Week 12) through Day 168 (Week 24).
1810519|NCT00669214|Drug|placebo|All patients received a conditioning dose of placebo equivalent SC on Day 0, followed by 11 weekly doses of placebo SC beginning on Day 7. After 12 weeks of blinded treatment, all patients continued into the open-label efalizumab treatment period from Day 84 (Week 12) through Day 168 (Week 24).
1810520|NCT00669227|Other|autologous stem cells|intracoronary administration at the same day of cell aspiration using the stop flow technique
1810521|NCT00669227|Other|placebo suspension|intracoronary administration at the same day as cell aspiration
1810522|NCT00669240|Drug|Varenicline|According to the approved Summary of Product Characteristics (SmPC), patients will be required to orally take 0.5 mg once daily for the first 3 days and titrate up to 0.5 mg twice daily for days 4 - 7. From day 8 to the end of treatment patients should take 1 mg twice daily. Patients who cannot tolerate adverse effects of Champix may have the dose lowered temporarily or permanently to 0.5 mg twice daily. Patients should be treated for 12 weeks. Treatment should start 1 - 2 weeks prior to quitting smoking.
1810523|NCT00669253|Procedure|Er: YAG Laser|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using Er:YAG laser
1810524|NCT00669253|Procedure|Conventional treatment 1(ultrasonic and manual means)|Scaling and root planing at baseline and surgery for remaining deep pockets after 6 months both using conventional methods : ultrasonic and manual means
1810525|NCT00669253|Procedure|Conventional treatment 2 (ultrasonic and manual means)|Surgery at baseline for all deep pockets using conventional methods: ultrasonic and manual means
1993890|NCT03111303|Device|mechanical ventilation|Connection to mechanical ventilator
1810527|NCT00655174|Drug|fluvoxamine|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
1810528|NCT00655174|Drug|sertraline|Children will be started on 12.5 mg. If there is no therapeutic effectivenss observed after eight weeks, then the child may have their dose increased. In this case, the child will be followed for an additional eight weeks.
1810529|NCT00655174|Drug|Placebo|Patients in this study arm will receive capsules that appear identical to those of the two study drugs but will contain no active ingredient.
1810530|NCT00655187|Other|Collection of information|Information regarding demographic characteristics, medical history, previous participation in rotavirus clinical trials and vaccination history will be collected.
1810531|NCT00655187|Procedure|Collection of stool samples|Stools samples will be collected during hospitalisation for RV testing and genotyping of RV positive samples.
1810532|NCT00655200|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1810533|NCT00655213|Device|Symphony D 2450|
1810534|NCT00655213|Device|Symphony DR 2550|
1810535|NCT00655226|Behavioral|Hepatitis C educational support groups|Hepatitis C educational support groups
1810536|NCT00655226|Behavioral|Cognitive Behavioral Therapy skills based group sessions|Eight CBT group sessions tailored for hepatitis C patients conducted by a clinical psychologist: 3 sessions conducted prior to IFN/ribavirin initiation, 1 session the day of IFN/ribavirin initiation, and 4 sessions during IFN/ribavirin treatment.
1810537|NCT00655239|Behavioral|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
1810538|NCT00655239|Behavioral|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 8 weeks.
1810539|NCT00655252|Drug|Everolimus|
1810540|NCT00655265|Drug|Colesevelam hydrochloride film-coated tablets|tablets
1810541|NCT00655265|Drug|Placebo|Tablets
1810542|NCT00655278|Drug|T2000|T2000 at previous most effective, well-tolerated dose (600-1000mg daily)
1810543|NCT00655291|Drug|XP20B|
1810544|NCT00655291|Drug|Placebo|
1810545|NCT00655304|Device|Prometheus (R) liver support dialysis|6-8 hours of dialysis
1810546|NCT00655304|Device|CVVHDF (Continuously Veno-Venous Hemodiafiltration)|6-8 hours of dialysis with the CVVHDF system PrismaFlex offered by Gambro (Sweden).
1810547|NCT00655317|Other|Acupuncture|Treatment acupuncture group: therapeutic acupuncture treatment with actual needles
1810548|NCT00655317|Other|Sham acupuncture|SHAM (control) acupuncture group: non-therapeutic acupuncture treatment
1810549|NCT00655330|Drug|Valsartan|Valsartan (160mg/day)
1810552|NCT00655343|Drug|ATG-Fresenius S|"20 mg rabbit immunoglobulin (IgG) in 1 ml of sterile solution
20 mg/kg body weight per day diluted in 500 ml physiological saline, slow intravenous infusion at days -3, -2, -1 prior to transplantation"
1810553|NCT00655356|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of 3 mm post auricular skin punch biopsies.
Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
1810554|NCT00655356|Biological|Placebo|"Collection of 3 mm post auricular skin punch biopsies.
Three treatment visits with injections administered 5 ± 1 weeks apart on each side of the face."
1810555|NCT00655369|Drug|PD 0200390|oral 15 mg daily dose, 3 capsules per dose during a six week treatment period.
1810556|NCT00655369|Drug|PD 0200390|oral 25 mg daily dose, 3 capsules per dose during a six week treatment period.
1810557|NCT00655369|Drug|PD 0200390|oral 35 mg daily dose, 3 capsules per dose during a six week treatment period.
1810558|NCT00655369|Drug|PD 0200390|oral 5 mg daily dose, 3 capsules per dose during a six week treatment period.
1810559|NCT00655369|Drug|PD 0200390|oral 50 mg daily dose, 3 capsules per dose during a six week treatment period.
1810560|NCT00655369|Drug|Placebo|oral placebo daily dose, 3 capsules per dose during a six week treatment period.
1810561|NCT00655395|Drug|Laromustine (VNP40101M) and Ara-C|"Laromustine 300 mg/m2 (cohort 1), 400 mg/m2 (cohort 2), 500 mg/m2 (cohort 3) IV on day 1 over 30 - 60 minutes. Laromustine will be administered approximately 3-4 hours following the start of infusional Ara C.
Ara C at 100 mg/m2/day as a continuous infusion daily for 7 days. Appropriate antiemetics are given during the Ara C infusion."
1810562|NCT00655408|Drug|elemental iron|Iron supplementation.
1810563|NCT00655421|Other|Unaided Visual Inspection|Simple unaided visual inspection of the oral cavity with a bright white light source by trained Primary Health Care Worker
1810564|NCT00655421|Device|VelScope|Examination of the oral cavity through a VelScope by trained Primary Health Care Worker
1810565|NCT00655421|Other|Toluidine Blue Assisted Oral Examination|Examination of the oral cavity after the local application of Toluidine Blue dye by trained Primary Health Care Worker
1810566|NCT00655460|Procedure|glucose control with computer generated recommendations|Insulin dosing will be recommended by the computer tools based on subject glucose values. Bedside clinicians will have the ablity to accept or reject the suggested dose.
1810567|NCT00655473|Drug|Dalcetrapib (RO4607381)|600mg po daily for 24 months
1810568|NCT00655473|Drug|Placebo|po daily for 24 months
1810569|NCT00655486|Drug|lacosamide|Subjects' dose of lacosamide may be increased or decreased as needed to maintain a subject's effective and tolerable dose during the study. Tablets are 50 mg or 100 mg each; Dose is 100 mg/day up to 800 mg/day administered twice daily throughout the study (up to 2 years).
1996459|NCT02476084|Other|Biological samples collection|Draw of research blood samples.
1810576|NCT00655512|Drug|pimecrolimus 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
1810577|NCT00655512|Drug|hydrocortisonacetat 1% cream|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
1810578|NCT00655512|Drug|betamethasonvalerat 0,1% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
1810579|NCT00655512|Drug|clobetasol-17-propionat 0,05% cream|twice a day one fingertip at the testareas (forearm/back of the hand) for 4 weeks
1810580|NCT00655512|Drug|Placebo|twice a day one fingertip at the testareas (forehead and forearm/back of the hand) for 4 weeks
1810581|NCT00655525|Dietary Supplement|fish oil|2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months
1810582|NCT00655525|Dietary Supplement|placebo|placebo administered orally every day for 3 months
1810583|NCT00655538|Drug|Placebo|po daily for 36 weeks
1810584|NCT00655538|Drug|dalcetrapib|600mg po daily for 36 weeks
1810585|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 200 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 200 mg/day (100 mg twice daily) for 6.5 days
1810586|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 300 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 300 mg/day (150 mg twice daily) for 6.5 days
1810587|NCT00655551|Drug|lacosamide|Single loading intravenous (iv) lacosamide 400 mg dose administered over a 15 minute infusion duration followed by oral lacosamide 400 mg/day (200 mg twice daily) for 6.5 days
1810588|NCT00655564|Drug|Alefacept|"Alefacept's FDA indication is for the treatment of adult subjects with moderate to severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. The approved dosing regimen is 15mg once weekly as an intramuscular injection or 7.5mg given once weekly as an intravenous bolus. The recommended regimen is a course of 12 weeks.
Alefacept is supplied as a lyophilized powder. Alefacept contains LFA3-IgG1 Fusion Protein and excipient materials (citrate, glycine and sucrose)."
1810589|NCT00655577|Behavioral|Exercise|Supervised, mainly home-based balance, strength and jumping exercises
1810590|NCT00655590|Drug|Levitra (Vardenafil, BAY38-9456)|20 mg daily dosing
1810591|NCT00655590|Drug|Sildenafil|100 mg daily dosing
1810592|NCT00655590|Drug|Placebo|Matching placebos
1810593|NCT00655603|Other|Infusion of native hormones from the pancreas and gut (GLP-1)|Glucose-clamps at fasting levels during infusion of hormones in different combinations.
1810594|NCT00655616|Drug|Montelukast Placebo|"Seretide 100 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast
Seretide 250 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast
Seretide 500 Accuhaler 1 dose twice daily plus 1 tablet daily of placebo montelukast
Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
1810633|NCT00655863|Drug|Alogliptin and Pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone 30 mg, tablets, orally, once daily for up to 16 weeks.
1810634|NCT00655863|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
1810595|NCT00655616|Drug|Salmeterol, Montelukast|"Flixotide Accuhaler 50 micrograms per blister, 1 blister dose twice daily plus 1 tablet daily of montelukast
Flixotide Accuhaler 100 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast
Flixotide Accuhaler 250 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast
Flixotide Accuhaler 500 micrograms per blister; 1 blister dose twice daily plus 1 tablet daily of montelukast
Doses of montelukast or placebo: up to 6 years 4 mg once daily; 6-14 years 5 mg once daily; 15 years and above 10 mg once daily"
1810596|NCT00655629|Drug|Vardenafil ODT (STAXYN, BAY38-9456)|Subjects will receive 12 weeks of PRN (on demand) treatment with Vardenafil 10 mg orodispersible tablet (ODT)
1810597|NCT00655629|Drug|Placebo|Subjects will receive 12 weeks of PRN (on demand) treatment with matching placebo tablet
1810598|NCT00655642|Drug|Ondansetron|4 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
1810599|NCT00655642|Drug|Metoclopramide|10 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
1810600|NCT00655642|Drug|Promethazine|12.5 mg intravenous dose administered over 2 minutes through a peripheral intravenous catheter
1810601|NCT00655642|Drug|Normal Saline|Volume matched isotonic sodium chloride solution dose administered over 2 minutes through a peripheral intravenous catheter
1810602|NCT00655655|Drug|everolimus|Given orally
1810603|NCT00655655|Drug|vatalanib|Given orally
1810604|NCT00655655|Other|pharmacological study|Correlative study (Cohort IIA only)
1810605|NCT00655655|Other|laboratory biomarker analysis|Correlative study (Cohorts IIA and IIB)
1810606|NCT00655655|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Correlative study (Cohort IIA only)
1810607|NCT00655655|Procedure|ultrasound imaging|Correlative study (Cohorts IIA and IIB)
1810608|NCT00655668|Drug|Lenalidomide|Lenalidomide capsules, 25 mg daily for 21 days in each 28 day cycle
1810611|NCT00655694|Procedure|sputum, blood, urine, exhaled breath, lung function|
1810612|NCT00655707|Biological|Autologous Expanded CD34+ Haemopoietic cells|"Autologous expanded CD34+ cells obtained by leukapheresis on a single occasion by infusion into the hepatic artery or portal vein.
Patient numbers 01 and 02 will receive 1x109 cells Patient numbers 03 and 04 will receive 1x1010 cells Patient numbers 05 and 06 will receive 2x1010 cells Patient numbers 07 and 08 will receive 5x1010 cells"
1810613|NCT00655720|Other|infant formula|"hydrolyzed infant formula without probiotics
hydrolyzed infant formula with probiotics
hydrolyzed infant formula with probiotics"
1810614|NCT00655733|Drug|HMPL004|HMPL004 1200mg/d
1810615|NCT00655733|Drug|Placebo|Placebo
1810616|NCT00655746|Drug|Dasatinib + Omeprazole|Tablet/Capsule, Oral, (Dasatinib 100 mg)/(Omeprazole 40 mg), once daily, 7 days
1810617|NCT00655772|Other|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®): 0.16% sodium chlorite (NaClO2) with an efficacy of 0.1% chlorine dioxide (ClO2),Placebo mouthwash: glycerin, mint oil and distilled water, contents are almost the same as those in the experimental mouthwash except ClO2.
1810618|NCT00655785|Biological|VEGFR1-1084, VEGFR2-169|One mg of each peptide will be administered by subcutaneous injection on days 1, 8, 15, and 22 in group A, on days 3, 10, 17, 24 in group B, or 5, 12, 19, 26 in group C
1810619|NCT00655785|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 3, 10 and 17
1810620|NCT00655798|Dietary Supplement|Placebo|plain yogurt and capsules containing cellulose
1810621|NCT00655798|Dietary Supplement|Plain Yogurt + mix of anti-oxidants capsules|plain yogurt and capsules containing mix of anti-oxidants
1810622|NCT00655798|Dietary Supplement|Yogurt containing Lactobacillus helveticus|Yogurt containing the probiotic Lactobacillus helveticus
1810623|NCT00655798|Dietary Supplement|Yogurt containing Bifidobacterium animalis ssp.|Yogurt containing the probiotic Bifidobacterium animalis ssp.
1810624|NCT00655811|Drug|Capsaicin|Topical application, 0.1%, Capzasin HP; Chattem Inc., Chattanooga, TN, U.S.A
1810625|NCT00655811|Drug|Placebo moisturizing cream|Placebo moisturizing cream with no active ingredient (Cetaphil; Galderma Laboratories LP, Fort Worth, TX, U.S.A.)
1810626|NCT00655824|Drug|ofatumumab|1000 mL dilution of 35mls ofatumumab in sterile, pyrogen free, 0.9% NaCl
1810627|NCT00655837|Drug|SGN-40|4-12mg/kg IV; Days 1, 4, 8, 15 and 22 of Cycle 1 and Days 1, 8 and 15 of Cycles 2-8.
1810628|NCT00655837|Drug|rituximab|375 mg/m2 IV injection; Days -2, 8, 15 and 22 of Cycle 1 and Day 1 of Cycles 2-8.
1810629|NCT00655837|Drug|gemcitabine|1000 mg/m2 IV Injection; Days 1 and 15 of all Cycles.
1810630|NCT00655850|Drug|Paclitaxel|"Prior to receiving paclitaxel, all patients will receive the following premedications one hour before the infusion:
Dexamethasone 20mg, intravenously (IV)
Diphenhydramine 50 mg IV
Ranitidine 50 mg IV
Paclitaxel will be administered after the gemcitabine infusion as a 1 hour (IV) infusion.
The initial dose of paclitaxel is 80 mg/m2/weekly for 3 out of 4 weeks (Day 1, 8, 15)
Paclitaxel Dose Levels:
Dose Level 1 ________80 mg/m2/weekly
Dose Level -1 ________70 mg/m2/weekly"
1810631|NCT00655850|Drug|Gemcitabine|"Premedication
Prophylactic antiemetics: 5-HT3-receptor antagonist prior to infusion with gemcitabine.
Prior to receiving paclitaxel chemotherapy
Gemcitabine will be given at the initial dose of 200mg/m2/week (Dose Level 1) for 3 out of 4 weeks (Day 1, 8, 15), as a 30 minute (IV) infusion.
The dose of gemcitabine can be escalated to 300mg/m2/weekly (Dose Level 2) after the first cycle of treatment if no significant toxicity is experienced.
Gemcitabine Dose Levels:
Dose Level 2 ________300 mg/m2/weekly
Dose Level 1 ________200 mg/m2/weekly
Dose Level -1 ________150 mg/m2/weekly"
1810632|NCT00655850|Biological|Avastin|"The dose of Avastin is 10 mg/kg IV every 2 weeks
It will be administered following the administration of chemotherapy
The first infusion will be administered over 90 minutes; if well tolerated, the second and subsequent doses will be administered as a 60-minute and 30-minute infusion, respectively.
It should not be administered or mixed with dextrose solutions."
1996460|NCT02476084|Other|Questionnaires|Administration of validated patients' questionnaires.
1811269|NCT00660244|Drug|anastrozole|Oral
1810635|NCT00655863|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 16 weeks.
1810636|NCT00655876|Biological|cetuximab|Given IV
1810637|NCT00655876|Drug|cisplatin|Given IV
1810638|NCT00655876|Drug|paclitaxel|Given IV
1810639|NCT00655876|Radiation|radiation therapy|Given 5 days a week for 5½ weeks
1810640|NCT00655889|Biological|Autologous Human Fibroblasts (azficel-T)|"Collection of biopsy from palate
Papillary priming procedure
Seven injection treatments to target sites
Performance of study assessments (investigator and subject)"
1810641|NCT00655902|Dietary Supplement|Trans fat (soy bean oil)|Industrially produced trans fatty acid from soy bean oil (15 g/d for 16 weeks). The fat (a total of 25 g/d) will be baked into buns.
1810642|NCT00655902|Dietary Supplement|Control fat (sunflower oil)|Control fat from sunflower oil, with 60% oleic acid (in total 25 g/d for 16 weeks). The fat will be baked into buns.
1810643|NCT00655915|Other|Corticosteroid Injection- 1ml of Betamethasone and 1 ml of 1% Lidocaine|Patients will receive a carpal tunnel injection of 1 mg of betamethasone and 1 mL of 1% lidocaine will be infiltrated by small gauge (ie. 25- or 27-gauge) needle via attending surgeon preference. These are routinely performed by injecting 1cm proximal to distal wrist crease just ulnar to palmaris longus tendon although multiple techniques have been described. Elicitation of median nerve symptoms during needle placement requires redirecting needle prior to injection to avoid median nerve infiltration.
1810644|NCT00655928|Drug|N-acetylcysteine|N-acetylcysteine 240mg/kg in 1 litre 0.9% saline intravenous over 12 hours pre-operatively
1810645|NCT00655928|Drug|0.9% saline|0.9% saline 1 litre intravenous over 12 hours pre-operatively
1810646|NCT00655941|Behavioral|Dietary instruction|Weekly instruction by dieticians
1810647|NCT00655941|Other|Exercise|Supervised exercise in groups
1810648|NCT00655954|Procedure|sputum, blood, condensate|
1810649|NCT00655967|Drug|Acamprosate (Campral)|"During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance >50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
Treatment compliance will be monitored by counts of returned medication. Records of all concomitant medications will be taken at each study visit as well as reports of adverse events (as shown above)."
1810650|NCT00655967|Drug|Acamprosate|During the course of the study patients will be supplied with 333mg tablets of acamprosate provided by the Sponsor. The study medication will be administered at a dose of 666mg (=two tablets) three times a day for patients with a creatinine clearance >50. The dose will be 333mg three times a day for patients with a creatinine clearance in the range of 30-50.
1810651|NCT00655980|Drug|Vitamin B12 and folic acid|1 mg vitamin B12 IV 5 mg folic acid IV in 100 ml NS infusion
1810652|NCT00655980|Drug|Nitrous oxide and placebo|
1810653|NCT00655980|Other|standard of care|
1810654|NCT00655993|Drug|simvastatin|40 mg po daily
1810655|NCT00656006|Drug|Albuferon|
1810656|NCT00656006|Drug|Ribavirin|
1810658|NCT00656032|Other|paricalcitol|1 to 20 micrograms administered via IV; every other day, 3 days per week, for 8 weeks
1810659|NCT00656032|Other|cinacalcet|0 to 180 mg administered orally every day for either 8 weeks or 16 weeks
1810660|NCT00656045|Behavioral|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
1810661|NCT00656045|Behavioral|Physical Activity|The Physical Activity arm will receive an activity goal (200 minutes/week of moderate-intense physical activity).
1810662|NCT00656045|Behavioral|TV Watching|The TV Watching arm will receive a TV watching goal of watching less than 10 hours of TV/week.
1810663|NCT00656058|Drug|Singulair (Montelukast Sodium)|Singulair (Montelukast Sodium):5-10 mg (weight based dosing) by mouth (PO) hour of sleep (HS)
1810664|NCT00656084|Drug|gemcitabine|900 mg/m2 on Days 1 and 8 of each 21-day cycle The order of administration will be: Gemzar-->Novantrone-->Rituxan.
1810665|NCT00656084|Drug|mitoxantrone|"Novantrone 10 mg/m2on Day 1. The order of administration will be:
Gemzar-->Novantrone-->Rituxan."
1810666|NCT00656084|Drug|rituximab|"Rituxan 375 mg/m2 on Day 1. The order of administration will be:
Gemzar-->Novantrone-->Rituxan."
1810667|NCT00656097|Biological|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
1810668|NCT00656097|Biological|HRIG|HRIG 20 IU/kg intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
1810669|NCT00656097|Biological|Placebo matching CL184|Placebo intramuscularly on Day0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
1810670|NCT00656110|Drug|equal parts of 0.5% plain Marcaine and 2% lidocaine mixed with 0.8 mg Depo-medrol/4% absolute alcohol in a total injection volume of 1 ml|Bilateral 3rd/4th common digital nerve injections with neuroma treatment mixture given weekly for 3 weeks
1810671|NCT00656110|Drug|Normal saline - 1ml|Bilateral 3rd/4th common digital nerve injections with normal saline given weekly for 3 weeks
1810672|NCT00656123|Biological|GM-K562 cell vaccine|
1810673|NCT00656123|Biological|allogeneic tumor cell vaccine|
1810674|NCT00656123|Drug|cyclophosphamide|
1810675|NCT00656123|Genetic|gene expression analysis|
1810676|NCT00656123|Genetic|protein analysis|
1810677|NCT00656123|Other|immunoenzyme technique|
1810678|NCT00656123|Other|immunologic technique|
1810679|NCT00656123|Other|laboratory biomarker analysis|
1810680|NCT00656136|Drug|placebo|Patients receive placebo once daily
1810681|NCT00656136|Drug|BIBW 2992|Patients receive afatinib tablets once daily, and can reduce dose for adverse event management. Afatinib is given once daily, continuously until disease progression or unacceptable toxicity.
1810682|NCT00656149|Procedure|Telerehabilitation of hand function|6 weeks, 1 hr/day FES-assisted exercise therapy on a workstation, supervised over the Internet.
1810780|NCT00656838|Behavioral|Patients receives letter, phone call, office visit, educational materials|Behavioral
1812166|NCT00660894|Drug|folinate calcium|
1810683|NCT00656149|Procedure|Conventional exercise therapy|For one hour per day subjects perform range-of-motion tasks with a wristlet weight (20 min), precision tasks with a computer mouse (20 min) and receive cyclical electrical stimulation of hand muscles (20 min).
1810684|NCT00656175|Drug|raltegravir|raltegravir
1810685|NCT00656188|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 5mg or 10mg or 20mg taken orally on demand 1 hour prior to sexual intercourse
1810686|NCT00656188|Drug|Placebo|Matching placebo
1810687|NCT00656201|Drug|Crinone 8% Vaginal Gel|Crinone 8% (90 mg of micronized progesterone in a bioadhesive vaginal gel contained in a single use, one piece applicator) once a day beginning the second day following oocyte retrieval (Study Group A) continuing until the pregnancy test is negative or until the 10th week of pregnancy.
1810688|NCT00656201|Drug|Intramuscular Progesterone|Progesterone—50 mg intramuscularly once a day beginning the day after oocyte retrieval continuing until the pregnancy test is negative or if positive, switching to Crinone 8% intravaginal gel until the 10th week of pregnancy.
1810689|NCT00656214|Drug|Lycopene|08 mg/day in two divided dosage
1810690|NCT00656214|Drug|Placebo|Two divided dosage
1810691|NCT00656227|Drug|Avotermin|Comparison of different dose levels (20ng, 50ng, 100ng or 200ng/100 ul) versus placebo
1810692|NCT00656240|Drug|DE-104 ophthalmic solution|
1810693|NCT00656240|Drug|DE-104 vehicle|
1810694|NCT00656253|Drug|Herbal Medicinal Mixture (Roucongrong, Heshouwu etc.)|12 months period of Herbal Medicinal Mixture per day plus 1 month wash-out period without herbal medicine
1810695|NCT00656253|Drug|Placebo|12 months period of placebo plus 1 month period without placebo
1810696|NCT00656266|Drug|MMF (Cellcept)|
1810697|NCT00656266|Drug|placebo|
1810698|NCT00656279|Behavioral|Intensive dietary phosphorus education|Intensive dietary phosphorus education will be completed using the Phosphorus Point System Tool, a booklet listing phosphorus points for food items based on the phosphorus content. Patients will be allotted a maximum of 32-40 phosphorus points daily. Points consumed will be tracked by the patients via daily tracking sheets which require patients to list the phosphorus food items consumed, the number of points, and the time and amount of phosphate binders. Patients in this group will also receive intensive education about phosphorus additives. As a part of the program that supports the tool, patients will receive weekly telephone calls for the first 6 weeks to address any questions about the tool and find phosphorus point values of foods not listed within the tool.
1810699|NCT00656292|Drug|Simvastatin|40 mg po/nasogastric tube (NG) every day for 6 days
1810700|NCT00656292|Drug|Placebo|1 pill po/NG every day x 6 days
1810701|NCT00656305|Device|ExAblate 2000|MR guided focused ultrasound.
1810702|NCT00656305|Device|Sham|sham comparator
1810703|NCT00656318|Other|oral contraceptive pill (OCP; OCPs)|Daily administration of oral contraceptive pill for up to 3 months (2 months of daily administration required for the study).
1810704|NCT00656331|Drug|Amlodipine and Hydrocholorothiazide|Arm 1 gets Amlodipine and Arm 2 gets Hydrocholorothiazide
1810705|NCT00656344|Other|Cognitive behavioral treatment enhanced by virtual reality|A cognitive behavioral protocol with cognitive and behavioral techniques will be used to treat symptoms. The exposure part of the treatment will be enhanced with the use of a virtual environment.
1810706|NCT00656357|Drug|SYN117 Placebo|Placebo
1810707|NCT00656357|Drug|SYN117 80 mg|SYN117 80 mg
1810708|NCT00656357|Drug|SYN117 160 mg|SYN117 160 mg
1810709|NCT00656357|Drug|Cocaine 10mg|IV Cocaine 10mg
1810710|NCT00656357|Drug|Cocaine 20mg|IV Cocaine 20mg
1810711|NCT00656357|Drug|Cocaine 40mg|IV Cocaine 40mg
1810712|NCT00656357|Drug|Saline|IV Cocaine Placebo
1810713|NCT00656370|Drug|recombinant human hyaluronidase|150 Units in 1mL
1810714|NCT00656383|Other|Clients randomized to nurse-led clinic|Clients receive leg ulcer care in a nurse-led clinic; both groups are treated by the same health care providers using the same protocol
1810715|NCT00656383|Other|Clients receive leg ulcer care in their homes|Clients receive leg ulcer care in at home; both groups are treated by the same health care providers using the same protocol
1810716|NCT00656396|Device|Coagucheck XS Plus (Point of care monitor of coagulation intraoperative)|Coagucheck XS Plus® is used for intraoperative measurement of Prothrombin time
1810717|NCT00656396|Procedure|Control Intervention|Standard care
1810718|NCT00656409|Drug|Conjugated pneumococcal vaccine (Prevenar)|
1810719|NCT00656422|Drug|insulin Levemir|The participant will receive an insulin dose of insulin Levemir at dinner subcutaneously according to a dosing algorithm.
1810720|NCT00656422|Drug|insulin Lantus|The participant will receive an insulin dose of the insulin Lantus at dinner subcutaneously according to a dosing algorithm.
1810721|NCT00656435|Drug|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml) 7 to 9 days before vitrectomy
1810722|NCT00656448|Drug|Procrit|40,000 units sq every week starting within two weeks (before or after) from the start of induction chemotherapy.
1810723|NCT00656461|Drug|MKC-1|30 mg and 100 mg capsules, dosed BID daily on a continuous schedule
1810724|NCT00656474|Drug|Placebo gel|Administration of Placebo gel on Day 1, 3 and 5 post ablation.
1810725|NCT00656474|Drug|GLYC-101 gel (1.0 %)|Administration on Day 1, 3 and 5 post laser ablation.
1810726|NCT00656487|Drug|rimonabant|double blind, placebo controlled, single 90 mg dose
1810727|NCT00656487|Drug|placebo|matched placebo
1810728|NCT00656500|Behavioral|Standard brief advice|Brief general assistance with smoking cessation
1810729|NCT00656500|Behavioral|Quitline intervention|Brief intervention designed specifically to encourage quitline utilization
1810730|NCT00656513|Drug|Pilocarpine|5mg by mouth 3 times a day for 12 weeks
1810731|NCT00656513|Procedure|ALTENS|Acupuncture-like transcutaneous electrical nerve stimulation (ALTENS) twice weekly for 12 weeks via a Codetron unit
1810732|NCT00656526|Drug|Lidocaine, perineural injection, intraoperatively|0.5 cc lidocaine, one single injection over the dorsal root.
1810733|NCT00656526|Drug|Lidocaine|0.5 cc %2 lidocaine,single injection
1810734|NCT00656539|Drug|AzaSite®|Ophthalmic solution; 1 drop in each eye BID for two days, then 1 drop in each eye QD for ~26 days
1810781|NCT00656851|Drug|Pioglitazone|30mg/day for 16 weeks
1810735|NCT00656552|Drug|Escitalopram|Patient undergo a double- blind therapy of Escitalopram (10 mg) orally daily during breakfast (n=50) or placebo (n=50) for four weeks.
1810736|NCT00656578|Drug|4975|Single dose, solution
1810737|NCT00656578|Drug|Placebo|Single dose, solution
1810738|NCT00656591|Drug|Methotrexate|Methotrexate
1810739|NCT00656604|Genetic|proteomic profiling|at the time of each procedure.
1810740|NCT00656604|Procedure|lumpectomy or mastectomy|removal of breast tumor or removal of the entire breast in which the tumor is located
1810741|NCT00656604|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Prior to initiation of treatment
1810742|NCT00656604|Procedure|histopathologic examination|After the breast tumor has been removed, examination of the tumor under a microscope to determine the type and grade of breast cancer
1810743|NCT00656604|Procedure|magnetic resonance spectroscopy|Prior to initiation of treatment
1810744|NCT00656617|Drug|Idarubicin|12 mg/m^2 IV over 1 hour daily for 3 days (days 4 to 6)
1810745|NCT00656617|Drug|Cytarabine|1.5 g/m^2 IV as a continuous infusion over 24 hours daily (days 4 to 7)
1810746|NCT00656617|Drug|Vorinostat|Initial dose level 500 mg orally three times a day for 3 days (days 1 to 3).
1810747|NCT00656630|Drug|Acamprosate|Two 333mg capsules, 3 times daily (Total dose, 1998 mg daily), 1 week duration
1810748|NCT00656630|Drug|Naltrexone|50mg capsule, Once daily, 1 week duration
1810749|NCT00656630|Drug|Placebo|Matched placebo capsule, 1 week duration
1988429|NCT02830724|Drug|Cyclophosphamide|On days -7 and -6, Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
1988430|NCT02830724|Drug|Fludarabine|On days -7 to -3: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1988431|NCT02830724|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 4 days (maximum of 12 doses).
1810754|NCT00656656|Drug|Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine|"Protein A Immunoadsorption: performed on 3 consecutive days every 3 weeks
Rituximab: 1000 mg i.v. given twice at a 2-week interval
Dexamethasone pulse therapy: 100 mg i.v. given on 3 consecutive days every 3 weeks
Azathioprine: 2.5 mg/kg body weight daily p.o."
1810755|NCT00656669|Drug|sunitinib alone|sunitinib alone (segment 1): During the first segment, patients will receive single-agent sunitinib for 2 weeks.
1810756|NCT00656669|Drug|sunitinib plus paclitaxel|sunitinib plus paclitaxel (Segment 2): Following Segment 1, patients will begin the second segment, 4 cycles (16 weeks) of neoadjuvant treatment with the combination of sunitinib and paclitaxel.
1810757|NCT00656669|Drug|doxorubicin and cyclophosphamide|doxorubicin and cyclophosphamide (Segment 3): Following Segment 2, patients will receive 4 cycles (8 weeks) of neoadjuvant treatment with AC.
1810758|NCT00656682|Behavioral|Dietitian Counseling Alone|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian
1810759|NCT00656682|Behavioral|Dietitian Plus Community Group Lifestyle|Primary care-based identification of pre-diabetes with brief counseling by a dedicated registered dietitian, PLUS free-of-charge access to a group-based lifestyle intervention offered by the Community to prevent diabetes
1810760|NCT00656695|Drug|Iminoral|Iminoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
1810761|NCT00656695|Drug|Neoral|Neoral in form of capsules 25,50 and 100 mg giving in the dose of 3-7 mg/kg twice daily
1810762|NCT00656708|Other|Kerlix AMD gauze|Use Kerlix AMD gauze as the wound dressing for the entire burn unit
1810763|NCT00656721|Device|Flutter Valve|"Flutter Valve (Scandipharm, Birmingham, AL) is shaped like a pipe with a hardened plastic mouthpiece at one end, a plastic protective, perforated cover at the other end, and a high-density stainless steel ball resting in a plastic circular cone on the inside. When the patient expires, a vibratory effect is transmitted to airways by the steel ball oscillation in order to facilitate mucociliary clearance.
In our study, the use of the equipment was guided by a registered physical therapist, but the position (angle) was determined by the patient, according to his/her adaptation and perception of effectiveness of sputum clearance. The patients remained comfortably seated, breathing through the device for 15 minutes, starting from the total pulmonary capacity, and being free to cough. Thereafter, a 5-minute session of cough was done."
1810764|NCT00656734|Biological|MDX 1411|MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total
1810765|NCT00656747|Drug|Avelox (Moxifloxacin, BAY12-8039)|Subjects will be randomised to moxifloxacin 400 mg PO OD (5 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
1810766|NCT00656747|Drug|Amoxicillin clavulanic acid|Subjects will be randomised to amoxicillin-clavulanic acid 875/125 mg PO BID (7 days). Subjects will also take placebo tablets, so that each subject takes 3 tablets per day for 7 days. Prior to randomization, subjects are stratified based on co-administration of short-course systemic steroids.
1810767|NCT00656760|Other|PET/CT|PET/CT is being performed on all patients in the study.
1810768|NCT00656773|Drug|Sufentanil|0.15 μg/kg, IV following by 0.075 μg/kg every 3 minutes during 15 minutes
1810769|NCT00656773|Drug|Morphine|0.15 mg/kg, IV following by 0.075 mg/kg every 3 minutes during 15 minutes
1810772|NCT00656799|Drug|sugammadex|At 15 minutes after administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was administered.
1810773|NCT00656799|Drug|Rocuronium|After achieving stable anesthesia an IV single bolus dose of 0.6 mg/kg rocuronium was administered
1810774|NCT00656812|Drug|Rituximab|375 mg/m2 on day 1 of a 21-day treatment cycle
1810775|NCT00656812|Drug|2-CdA|0.1 mg/kg s.c. on days 1 - 4 of a 21-day treatment cycle
1810776|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 100 μg/mL
1810777|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 200 μg/mL
1810778|NCT00656825|Drug|P144 cream|P144 cream will be given at a dose of 300 μg/mL
1810779|NCT00656825|Drug|Placebo|Placebo will be randomly given to 4 subjects in each panel
1810782|NCT00656851|Behavioral|Exercise Training|Cardiorespiratory and resistance exercise training 3days/wk for 16 weeks
1810783|NCT00656864|Drug|Pioglitazone|Starting dose at 15 mg for two weeks, then titrated up to 45 mg in the subsequent 2 weeks.
1810784|NCT00656864|Drug|Placebo|placebo
1810785|NCT00656890|Biological|sterile saline for injection|10mg/kg/dose sterile saline injected every other week for a total of 4 doses
1810786|NCT00656890|Biological|MDX-1100|10mg/kg/dose MDX-1100 injected every other week for a total of 4 doses
1810787|NCT00656916|Drug|Fluticasone Propionate|440 micrograms twice daily by oral inhalation.
1810788|NCT00656929|Dietary Supplement|Vitamin D3|Vitamin D3 (cholecalciferol) 50 mcg (2000 IU) daily x 3 months
1810789|NCT00656929|Other|Placebo|Placebo tablets
1810790|NCT00656942|Device|Quantitative Sensory Testing (QST)|QST consists of a series of heat and cold stimulation tests.
1810791|NCT00656968|Drug|10-day sequential treatment|esomeprazole (40 mg daily) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 5, clarithromycin (500 mg, bid) from day 6 to day 10, metronidazole (500 mg, bid) from day 6 to day 10
1810792|NCT00656968|Drug|10-day concomitant therapy|esomeprazole (40 mg, bid) from day 1 to day 10, amoxicillin (1 g, bid) from day 1 to day 10, clarithromycin (500 mg, bid) from day 1 to day 10, metronidazole (500 mg, bid) from day 1 to day 10
1810793|NCT00656981|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|The study medication was packaged in 28-tablet blister packs. Each subject kit contained 6 blister packs plus 1 reserve blister pack.Subjects randomly assigned to the active treatment group received 24 consecutive days of hormonally active tablets (3mgDRSP/0.02mgEE) followed by 4 consecutive days of inactive tablets. The treatment period was 6 cycles (28 tablets per cycle).
1810794|NCT00656981|Drug|Placebo|The subjects randomly assigned to the placebo group received 28 inert but identical-appearing, color-matched tablets. The treatment period was 6 cycles (28 tablets per cycle)
1810795|NCT00656994|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 6 months.
1810796|NCT00656994|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 6 months
1810797|NCT00657007|Biological|belimumab|"1 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 1).
1 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 5)."
1810798|NCT00657007|Biological|belimumab|"4 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 2).
4 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 6)."
1810799|NCT00657007|Biological|belimumab|"10 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 3).
10 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 7)."
1810800|NCT00657007|Biological|belimumab|"20 mg/kg, IV (in the vein) once on Day 0, with a final evaluation at Day 84 (Cohort 4).
20 mg/kg, IV (in the vein) on Days 0 and 21, with a final evaluation at Day 105 (Cohort 8)."
1810801|NCT00657007|Biological|Placebo|"IV (in the vein) on Day 0 (Cohorts 1-4).
IV (in the vein) on Days 0 and 21 (Cohorts 5-8)."
1810802|NCT00657020|Drug|Nicotine|Nicotine lozenge containing 4 mg of nicotine
1810803|NCT00657020|Drug|Placebo|Placebo lozenge
1810804|NCT00657033|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (Vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
1810805|NCT00657033|Drug|Placebo|Identical placebo tablets will be matched for each vardenafil dosage and will be indistinguishable from active treatment
1810806|NCT00657046|Drug|Droxidopa|Capsules containing 200 mg droxidopa
1810807|NCT00657046|Drug|Placebo|Capsules with mannitol substituted for droxidopa
1810808|NCT00657059|Drug|irbesartan|In the ARB lead-in phase, each subject will be on a strict sodium-restricted diet ( < 5 g NaCl/day), and then given a stable dose (150mg ~ 300mg/day) of irbesartan (Aprovel) for 3 months until reaching the target blood pressure (BP) level of ≤ 125/75 mmHg. Patients will continue ARB treatment in the drug treatment phase and at lease 3 years in the follow-up phase.
1810809|NCT00657059|Drug|methylprednisolone (MP) or prednisone (pred)|Patients will take oral Pred ( 0.5 mg/kg/d) on alternate days, and on the first, third and fifth months of the drug treatment phase, patients will be given intravenous pulse therapy with methylprednisolone ( 0.5 g/day) for 3 successive days. And after 6 months, Pred should be tapered to be stopped until the end of the 12-month course of treatment.
1810810|NCT00657059|Drug|mycophenolate mofetil (MMF)|Patients will take MMF 1.0g bid (wt ≥ 50kg) or 0.75g bid (wt ＜ 50kg) for the first 6-month of drug treatment phase, then to 0.5 bid (wt ≥ 50kg) for the remaining 6-month.
1810811|NCT00657111|Drug|CS-8958 formulated as dry powder|CS-8958, formulated as a dry-powder and will be administered from capsules containing 5 mg CS-8958 and lactose to 25 mg (placebo) inserted into a FlowCaps inhaler device.
1810812|NCT00657111|Other|Placebo|placebo capsules containing 25 mg lactose
1810813|NCT00657124|Dietary Supplement|Aminolevan EN|The present study used carbohydrate and BCAA-enriched soft-powder nutrient-mixture for preoperative supplementation. Supplementation with Aminolevan EN (100 g per day) started at two weeks prior to the surgery under the careful monitoring of compliance.
1810814|NCT00657124|Dietary Supplement|Placebo|placebo
1989488|NCT02481154|Drug|AG881|AG-881 administered continuously as a single agent dosed orally on Days 1 to 28 of a 28-day cycle. Patients may continue treatment with AG-881 until disease progression or development of other unacceptable toxicity
1810817|NCT00657150|Drug|Enoxaparin|40 mg once daily
1810818|NCT00657150|Drug|Dabigatran etexilate|220 mg once daily
1810819|NCT00657163|Drug|fluoxetine|fluoxetine per os 20 mg daily
1810820|NCT00657163|Drug|placebo|placebo per os daily
1810821|NCT00657176|Drug|OPB-31121|"100mg tablet
oral administration, Qd"
1810822|NCT00657189|Drug|MEDI-545|100 mg once; SC Placebo × 12 doses on other weeks
1810823|NCT00657189|Drug|MEDI-545|100 mg every 4 weeks × 4 doses; SC Placebo × 9 doses on other weeks
1810824|NCT00657189|Drug|MEDI-545|100 mg every 2 weeks × 7 doses; SC Placebo × 6 doses on other weeks
1810825|NCT00657189|Drug|MEDI-545|100 mg every week × 13 doses
1810826|NCT00657189|Drug|Placebo|SC Placebo every week × 13 doses
1810827|NCT00657202|Drug|Ranibizumab|Given as an injection into three cutaneous neurofibromas on day 1 of the study treatment.
1812167|NCT00660894|Drug|tegafur-uracil|
1810828|NCT00669279|Drug|Carvedilol CR|Dose titration of 20mg by mouth once daily for 1 week, then 40mg by mouth once daily for 1 week, then 80mg by mouth once daily for 2 weeks
1810829|NCT00669279|Drug|Atenolol|Dose titration of 25mg by mouth once daily for 1 week, then 50mg by mouth once daily for 1 week, then 100mg by mouth once daily for 2 weeks
1810830|NCT00669292|Biological|URLC10-177, TTK-567, CpG-7909|peptide, peptide, TLR-9 agonist
1810831|NCT00669318|Biological|alemtuzumab|
1810832|NCT00669318|Biological|rituximab|
1810833|NCT00669318|Drug|pentostatin|
1810834|NCT00669318|Drug|sargramostim|
1810835|NCT00669331|Drug|Inhaled mannitol|400mg dose of Mannitol BD (twice a day) for 52 weeks
1810836|NCT00669331|Drug|Matched control|50mg dose of Mannitol BD (twice a day) for 52 weeks
1810837|NCT00669344|Drug|Exelon (rivastigmine)|Capsules, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
1810838|NCT00669344|Drug|Placebo|Capsule, twice daily orally. Dosage starts at 1.5mg bis diem to 4.5mg bis diem.
1810839|NCT00669357|Device|Abiocor Implantable Replacement Heart|Replacement of heart
1810840|NCT00669370|Drug|docetaxel and capecitabine|biweekly docetaxel iv (50 mg/m2) on day 1 and 15 and capecitabine po 1250 mg/m2 x 2/day days 1-7 and 15-21, treatment cycle consisting of 21 days
1810841|NCT00669383|Drug|betamethasone|12 mg IM q 24 hours x 2 doses
1810842|NCT00669383|Drug|placebo|Placebo IM q 24 hours x 2 doses
1810843|NCT00669396|Drug|Copper T380 IUD|Copper T380 IUD
1810844|NCT00669396|Drug|levonorgestrel|1.5 mg
1810845|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 10 mcg/kg IV
1810846|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 100 mcg/kg IV
1810847|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 200 mcg/kg IV
1810848|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 25 mcg/kg IV
1810849|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of 50 mcg/kg IV
1810850|NCT00669409|Drug|PF-04383119 (tanezumab)|single dose of Placebo IV
1810851|NCT00669435|Drug|Losartan + Simvastatin|"tablets; 50, 100 mg; od; 12 months
tablets; 20 mg; od; 6 months"
1810852|NCT00669435|Drug|Amlodipine + Simvastatin|"tablets; 5, 10 mg; od; 12 months
tablets; 20 mg; od; 6 months"
1810853|NCT00669448|Behavioral|Minfulness-based cognitive therapy|Mindfulness Based Cognitive Therapy (MBCT) is a group intervention that integrates elements from primarily Mindfulness-based Stress Reduction programme (MBSR)and cognitive therapy.The MBCT programme includes 2½ hours of training once a week for 8 weeks. In addition participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course.
1810854|NCT00669461|Drug|Lubiprostone|Lubiprostone 24 mcg BID orally for 4 weeks
1810855|NCT00669474|Procedure|Suction curettage|Suction curettage
1810856|NCT00669474|Drug|Treatment with Botox|Treatment with Botox
1810857|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|Truvada(FTC200mg+TDF300mg) every 24 hours + NVP 200 mg every 12 hours orally until week 72
1810858|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR S(D4T30mg+3TC150mg+NVP200mg)1 pill orally every 12 hours until week 24 and then switch to GPO-VIR Z
1810859|NCT00669487|Drug|AZT/3TC/NVP, AZT/D4T/NVP, Truvada/NVP|GPO-VIR Z(AZT250mg+3TC150mg+NVP200mg) 1 pill orally every 12 hours until week 72
1810860|NCT00669500|Behavioral|Lifestyle intervention|Alive!TM web-based, 12 week lifestyle intervention sent via NutritionQuest.
1810861|NCT00669513|Behavioral|Partial sleep deprivation|Partial sleep deprivation (less than 5 hours, but no less than 3 hours and 30 minutes)
1810862|NCT00669526|Behavioral|BCBT|Brief Cognitive Behavioral Therapy. This BCBT protocol consists of up to 8 CBT sessions to be conducted over a maximum of 12 weeks.
1810863|NCT00669526|Behavioral|SMHC referral|Referral to local Speciality Mental Health Care. Families were referred to local mental health care providers, and could freely choose any treatment or combination of treatments offered (e.g., anti-depressant medication, individual psychotherapy, family psychotherapy, etc.).
1810864|NCT00669552|Procedure|Percutaneous coronary intervention|PCI previously electively scheduled.
1810865|NCT00669565|Drug|Bavituximab|Receive weekly bavituximab at a dose of 3 mg/kg until disease progression, and carboplatin at a dose of AUC = 2 and paclitaxel 100 mg/m2 on days 1, 8, and 15 of a 28-day cycle for up to 6 cycles.
1810866|NCT00669578|Drug|CC-4047|CC-4047: taken orally each day in a 28 day cycle.
1810867|NCT00669591|Drug|Bavituximab|Weekly bavituximab infusion of 3 mg/kg combined with up to six 28-day cycles of docetaxel chemotherapy. After treatment phase, weekly bavituximab maintenance is continued until disease progression.
1810868|NCT00670449|Drug|Fingolimod|Fingolimod was supplied in capsules.
1810869|NCT00670462|Behavioral|Standard Behavioral Treatment (SBT)|SBT is state-of-the-art behavioral weight loss treatment, comprised of 6 months of weekly treatment meetings followed by 6 months of biweekly meetings and 6 months of monthly meetings. Topical coverage and behavioral assignments include typical combination of energy balance information and self-control skills training. MTT has the same number of treatment contacts, but the contacts are distributed in distinct 8-week segments, each of which have a unique topic and unique behavioral assignments. Between each segment, participants are left on their own for 4 weeks with instructions to continue regular weighing but otherwise to make their own choices about what to do for weight control.
1810870|NCT00670462|Behavioral|Maintenance-Tailored Treatment (MTT)|
1810871|NCT00670475|Drug|Piroxicam|In this interventional arm gel of piroxicam (manufactured by Iran najo co,Iran), repackaged in a 60 g anonymous tubes will be administered to the patients.
1810872|NCT00670475|Dietary Supplement|Olive Oil|"virgin olive oil prepared directly from olive fruit from olive gardens of north of iran, Gilan province will packaged in a 60 g anonymous tubes."
1810873|NCT00670488|Drug|MK2206|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 30 mg, 60 mg, 75 mg, and 90 mg on a schedule of once daily every other day in repeating 4 week cycles.
1810874|NCT00670488|Drug|MK2206|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 90 mg, 135 mg, 200 mg, 250 mg, and 300 mg on a schedule of once weekly in repeating 4 week cycles.
1810875|NCT00670501|Drug|teriparatide|40 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
1810876|NCT00670501|Drug|teriparatide|20 micrograms/day subcutaneous injection for 3 years with optional 2 year extension phase
1810877|NCT00670501|Drug|Placebo|Placebo for subcutaneous injection will be supplied in a prefilled injection device with a cartridge identical in appearance to the LY333334 device.
1810878|NCT00670501|Drug|Calcium Supplement|Approximately 1000 mg/day of elemental calcium will be supplied as open-label oral supplement
1810879|NCT00670501|Drug|Vitamin D Supplement|Approximately 400 to 1200 IU/day of vitamin D will be supplied as open-label oral supplement
1810880|NCT00670514|Behavioral|Nix Individual|Eight 40-minutes sessions at the local dental clinic during 4 months. Written material and counseling by a dental hygienist with special training in smoking cessation, according to a fixed program. A traditional smoking cessation program with a mixture of behavior therapy, coaching and pharmacological advises. Two questionnaires.
1810881|NCT00670514|Behavioral|Fimpa dig fri|"One 30-minute counseling session at the local dental clinic, focusing on explaining the content of a traditional self-help program (Fimpa dig fri). The leaflet contains an 8-week program with instructions and tasks to perform. Two questionnaires."
1810882|NCT00670527|Procedure|[18F] Fluorocholine PET/CT|"The patients fast 6 hours before the [18F]Fluorocholine PET/CT scan. [18F]Fluorocholine will be used as tracer with a dosage of 4 MBq per kg bodyweight. PET/CT imaging will be performed after 15 and 60 after the intravenous injection of the tracer. The patient will receive 2 full body FCH PET/CT. The CT scan is with contrast.
The radiation exposure from the CT scan is 9 mSv and from the PET scan it is 3 mSv, giving a total of 12 mSv, which equals 4 times the yearly background radiation in Denmark."
1810883|NCT00670540|Other|procedure of Deep Vein Thrombosis (DVT) and PE (Pulmonary Embolism) diagnosis|patients with a clinical suspicion of Venous ThromboEmbolism (VTE = Deep Vein Thrombosis or Pulmonary Embolism) were eligible
1810884|NCT00670553|Drug|panobinostat|
1810885|NCT00670566|Drug|irbesartan/hydrochlorothiazide|50/12.5mg for 4 weeks follow 300/12.5mg for 4 weeks and proceed to 300/25mg for 4 weeks
1810886|NCT00670592|Drug|HCD122|
1810887|NCT00670605|Other|medical chart review|
1810888|NCT00670605|Other|study of socioeconomic and demographic variables|
1810889|NCT00670618|Device|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
1810890|NCT00670618|Device|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
1810891|NCT00670618|Device|Fluoride (Elmex Medical Gel)|Fluoride
1810892|NCT00670631|Combination Product|tandem autologous transplantation|"DPACE: dexamethasone 20 mg days 1-4 and 8-11, cisplatin 10 mg/m2 days 1-4, Adriamycin 10 mg/m2 days 1-4, cyclophosphamide 400 mg/m2 days 1-4, etoposide 40 mg/m2 days 1-4.
Transplant 1: Dexamethasone 20 mg days -4 to -1 and +2 to +5. Velcade 1mg/m2 on days -4,-1, +2, and +5. Thalidomide 100mg on day -4 to day +5. Melphalan, 100 mg/m2 on days -4 and -1.
Transplant 2: Dexamethasone 20 mg on days -4 to -1 and +2 to +5. BCNU 300mg/m2 on day -4. Melphalan 140 mg/m2 on day -1. Velcade 1mg/m2 on days -4, -1, +2, +5. Gemcitabine 1000 mg/m2 on days -4 + -1.
Maintenance year 1: Bortezomib 1.0 mg/m2 on days 1, 4, 15,18 every cycle. Thalidomide, 100 mg . Dexamethasone,20 mg,on days 1-4 & 15-18 every cycle.
Maintenance year 2: Dexamethasone, 20 mg,days 1-4 every cycle."
1810893|NCT00670644|Other|questionnaire administration|Completed self-report form
1810894|NCT00670644|Other|survey administration|Completed self-report form-other
1810895|NCT00670644|Procedure|quality-of-life assessment|Completed self-report form qol
1810896|NCT00670657|Drug|AmBisome|Patients will receive 2mg/kg/day IV daily administration of AmBisome® over 30-60 minutes as a reaction to signs/symptoms and positive Candida culture
1810897|NCT00670670|Device|CPP-ACP (GC Tooth Mousse)|Calcium and phosphate
1810898|NCT00670670|Device|CPP-ACP (GC MI Paste Plus)|Calcium, phosphate and fluoride
1810899|NCT00670683|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1810900|NCT00670696|Drug|Rapydan|Topical anaesthetic plaster
1810901|NCT00670696|Drug|tetracaine gel|Topical tetracaine gel
1810902|NCT00670722|Drug|insulin aspart|Intervention at the discretion of the physician
1810903|NCT00670722|Drug|insulin detemir|Intervention at the discretion of the physician
1810904|NCT00670722|Drug|biphasic insulin aspart 30|Intervention at the discretion of the physician
1810905|NCT00670748|Biological|Anti-NY ESO-1 T-cell receptor PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 T-cell receptor (TCR) peripheral blood lymphocytes (PBL) and high dose aldesleukin. On day 0,cells (1x10e8 to 1x10e11)will be infused intravenously on the Patient Care Unit over 20-30 minutes.
1810906|NCT00670748|Drug|aldesleukin|Aldesleukin 720,000 IU/kg intravenous (IV) (based on total body weight)over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days(maximum of 15 doses)
1810907|NCT00670748|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
1810908|NCT00670748|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
1810909|NCT00670748|Biological|ALVAC NY ESO-1 vaccine|Approximately two hours prior to cell infusion, patients will receive 0.5 mL containing a target dose of 10e7 cell culture infectious dose 50 (CCID50) (with a range of approximately 10e6.4 to 10e7.9 / mL) of the ESO-1 ALVAC virus S.C. in each extremity (total of 4 x 10e7 CCID50/2 mL.
1810910|NCT00670761|Drug|misoprostol|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
1810911|NCT00670761|Procedure|MVA|comparison of orally administered 600mcg of misoprostol to either sublingually administered 400mcg or Manual Vacuum Aspiration (MVA)
1810942|NCT00671008|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1810943|NCT00671008|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1810944|NCT00671021|Other|Platelet aggregation|Platelet aggregation TxA2 formation
1810912|NCT00670774|Drug|Eculizumab|"Patients will be given 1200 mg of eculizumab intravenously over 30 minutes, 1 hour prior to surgery.
Patients will be given 900 mg of eculizumab on Day 1 post-transplant.
Patients will then be given 900 mg of eculizumab weekly through 4 weeks post-transplant
At week 4, patients will be assessed for B cell FCXM. Patients with B cell FCXM less than 200 will stop eculizumab treatment. Patients with B cell FXCM greater than or equal to 200 will continue eculizumab treatment every 14 days from week 5 through week 9. The dose will be increased to 1200 mg and dosing will now be every 2 weeks instead of weekly. Similar discontinuation assessments will be performed at week 9, 26, 39 and 52.
In addition, eculizumab 600 mg will be administered immediately after each plasmapheresis (PP) and immediately after any fresh frozen plasma (FFP) that is given post-transplant during the treatment period"
1810913|NCT00670787|Drug|Combination pill of losartan and hydrochlorothiazide|Combination pill of losartan potassium 50mg and hydrochlorothiazide 12.5mg in the morning
1810914|NCT00670800|Drug|Metformin|Following the baseline studies, PCOS affected women will be initiated on metformin at a dose of 500 mg orally after breakfast and the dose will be increased the following week to 500 mg twice daily (BID), adding a dose after lunch. On the third week, the dose will be increased to 500 mg three times daily (TID), adding a 500 mg tablet after supper. All subjects will be monitored for possible side effects such as nausea, vomiting, diarrhea, anorexia, and abdominal discomfort. These side effects tend to be mild, dose-related and improve with continued use of metformin. Hypoglycemia is rare and tends to occur in the setting of alcohol abuse or prolonged starvation. Malabsorption of vitamin B12 and folate occurs with long-term treatment, although it usually does not lead to anemia.
1810915|NCT00670813|Drug|Modafinil (Vigil)|Oral application of 2 x 100 mg Modafinil each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
1810916|NCT00670813|Drug|Placebo|Oral application of 2 x 100 mg Placebo each encapsulated in identical looking gelatine capsules at 12:00, 24:00 and again at 12:00 o' clock during the 40 h sleep deprivation period
1810917|NCT00670826|Device|vitalHEAT vH2 Temperature Management System|The vH2 system utilizes a combination of localized heat and vacuum application to one hand & forearm; this application opens AVAs in the palm of the hand and warms the extremity thus effectively warming the blood flowing to the body's core.
1810918|NCT00670826|Device|Arizant Healthcare Bair Hugger Temperature Management System|The Bair Hugger system is a forced air system providing convective warming via the circulation of warmed air through specially designed blanket which is placed over a portion of the body
1810919|NCT00670839|Biological|GenHevac-B|1 intramuscular injection of Genhevac-B® 20μg on day zero, month 1,and month 6
1810920|NCT00670839|Biological|GenHevac-B|2 intramuscular injections of Genhevac-B® 20μg on day zero, month 1,and month 6
1810921|NCT00670852|Procedure|X-rays and CT scan|CT Scan x-rays
1810922|NCT00670865|Other|Electronic discharge summary system|The customized electronic discharge summary program will be used to generate patient discharge summaries.
1810923|NCT00670878|Drug|3 x FEC 3 x DOC / Gemcitabine|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 75 mg/m² body surface area i.v. (D), and Gemcitabine 1000 mg/m² i.v. (30 min infusion) (G), administered on day 1, followed by Gemcitabine 1000 mg/m² i.v. (30 min infusion) on day 8, repeated on day 22
1810924|NCT00670878|Drug|3 x FEC 3 x DOC|3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicin 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22
1810925|NCT00670891|Procedure|oxygen (Hyperbaric Oxygen Therapy)|"Current Accepted Applications of HBOT (2008) Jan 2003, ANDI International
Air or Gas Embolus
Decompression Illness
Carbon Monoxide poising
Clostridial Myonecrosis (Gas Gangrene)
Necrotizing Fasciitis
Crush Injury (Compartment syndromes)
Selected Problem Wounds
Compromised Skin Flaps or Grafts
Refractory Osteomyelitis
Exceptional Anemia due to Blood loss
Osteoradionecrosis
Thermal Burns and Radiation Tissue Damage
Diabetic Wounds
Intra-Cranial Abscess
Brain Injury and other Head Trauma
Cerebral Palsy
High Altitude Sickness
Lyme disease"
1810926|NCT00670904|Other|Pharmacist-delivered group program for smoking cessation|Participants assigned to the treatment group participated in a pharmacist-delivered program at the clinic. The six-hour program consisted of three in-person sessions delivered at 2-week intervals over 5 weeks to a small group of smokers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
1810927|NCT00670904|Other|Brief standard care session for smoking cessation delivered over the telephone|Those assigned to the control group received one 5 to 10 minute session delivered by the clinical pharmacist over the telephone that included all the components of standard care recommended by the Clinical Practice Guidelines for brief interventions delivered by health care providers. Participants were offered their choice of one medication either bupropion IR or nicotine patch using doses and durations based on current medical practices. Participants receiving bupropion received a quantity sufficient to complete 12 weeks of therapy. Participants receiving nicotine patches received a quantity sufficient to complete 8 weeks of step-down therapy.
1810928|NCT00670917|Other|questionnaire administration|
1810929|NCT00670917|Procedure|acupressure therapy|
1810930|NCT00670917|Procedure|biopsy|
1810931|NCT00670917|Procedure|bone marrow aspiration|
1810932|NCT00670917|Procedure|pain therapy|
1810933|NCT00670930|Drug|omalizumab at a dose of 0.016mg/kg/IU/mL|
1810934|NCT00670930|Drug|Placebo|
1810935|NCT00670943|Other|Platelet function testing|
1810936|NCT00670956|Drug|Betamethasone|12 mg intramuscularly x 2 doses 24 hours apart
1810937|NCT00670956|Drug|Placebo|PLACEBO: IM x 2 doses 24 hours apart
1810938|NCT00670982|Drug|bevacizumab|Given intravenously every 2 weeks
1810939|NCT00670982|Drug|vinorelbine|Given intravenously once a week
1810940|NCT00670982|Drug|trastuzumab|Given intravenously once a week
1810941|NCT00670995|Behavioral|Interactive Tobacco Education|Increase perceived behavioral control (self-efficacy) Decrease willingness to use tobacco Decrease intentions to use tobacco
1958347|NCT01765725|Behavioral|Patient education program|Patient education program, 8 meetings, every other week, 2,5 hours per meeting.
1810961|NCT00671047|Other|non-interventional|SLE nature history observational
1810962|NCT00671060|Drug|Misoprostol|200 mcg buccal misoprostol administered every 6 hours for up to 48 hours until fetus is delivered.
1810963|NCT00671060|Drug|Misoprostol|100 mcg buccal misoprostol administered every 6 hours for upto 48 hours
1810964|NCT00671073|Drug|Oglemilast|Oglemilast low dose, oral administration, once daily for 12 weeks
1810965|NCT00671073|Drug|Placebo|Placebo, oral administration, once daily for 12 weeks
1810966|NCT00671073|Drug|Oglemilast|Oglemilast middle dose, oral administration, once daily for 12 weeks
1810967|NCT00671073|Drug|Oglemilast|Oglemilast high dose, oral administration, once daily for 12 weeks
1810968|NCT00671086|Drug|Ramelteon|Subjects 65 yrs of age and older will take Ramelteon 8 mg, tablets, orally, once nightly for up to one year.
1810969|NCT00671086|Drug|Ramelteon|Subjects between 18 and 64 years of age will take Ramelteon 16 mg, tablets, orally, once nightly for up to one year.
1810970|NCT00671099|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
1810971|NCT00671099|Dietary Supplement|Placebo|Placebo
1810972|NCT00671112|Drug|Bortezomib|"Patients will be assigned to one of the following dose levels of Bortezomib: 0.7mg/m2, 1.0 mg/m2, or 1.3mg/m2 on days 1,4,8,11 of a 21 day cycle.
The appropriate amount of bortezomib will be drawn from the injection vial and administered as an intravenous (IV) push or sub-cutaneously over 3 to 5 seconds followed by a standard saline flush or through a running IV line."
1810973|NCT00671112|Drug|Everolimus|Everolimus 5 mg PO every other day, 5 mg by mouth (PO) daily, or 10 mg PO daily
1810974|NCT00671125|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.
1810975|NCT00671125|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally, once nightly for up to 5 weeks.
1810976|NCT00671125|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.
1810977|NCT00671138|Biological|Necator americanus|10 necator americanus larvae will be inoculated at week 0 with a further 5 larvae inoculated at week 12
1810978|NCT00671138|Other|Sham inoculation|A diluted amount of McIlhenny & Co Tabasco Pepper Sauce will be applied via a gauze dressing at weeks 0 and 12.
1810979|NCT00671151|Drug|Theophylline|Theophylline 100 mg bid for 3 months
1810980|NCT00671177|Procedure|water immersion colonoscopy|instillation of 300cc of water in the rectum
1810981|NCT00671177|Procedure|standard air colonoscopy|air instillation in colon for visualization
1810982|NCT00671190|Drug|Ramelteon|Ramelteon 1 mg, tablets, orally once daily for up to 5 days
1810983|NCT00671190|Drug|Ramelteon|Ramelteon 2 mg, tablets, orally once daily for up to 5 days
1810984|NCT00671190|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally once daily for up to 5 days
1810985|NCT00671190|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally once daily for up to 5 days
1810986|NCT00671190|Drug|Placebo|Ramelteon placebo-matching tablets, orally once daily for up to 5 days
1810988|NCT00671216|Drug|GSK233705|Subjects will receive 200 (mcg) microgram once daily as a single dose
1810989|NCT00671216|Drug|GW642444|Subjects will receive 50 mcg once daily as a single dose
1810990|NCT00671216|Drug|GSK233705 and GW642444|Subjects will receive combination of GSK233705 200 mcg and GW642444 50 mcg as a single oral dose
1810991|NCT00671216|Drug|Placebo|Placebo matching study medication will be inhaled by subjects
1810992|NCT00671255|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
1810993|NCT00671255|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily for up to 5 weeks.
1810994|NCT00671255|Drug|Placebo|Ramelteon placebo-matching, tablets, orally, each night for up to 35 consecutive days.
1810995|NCT00671268|Biological|AL0704rP|strict subcutaneous
1810996|NCT00671268|Biological|Placebo|strict subcutaneous
1810997|NCT00671281|Drug|Tranexamic acid|Oral form, 100mg, tid (three times per day), 3 days before/the day of/6 days after the surgery
1810998|NCT00671281|Drug|Placebo|Placebo, Oral form, three times a day, 3 days before/day of/6 days after surgery
1810999|NCT00671294|Drug|Ramelteon and Placebo (9 possible combinations total)|"Randomized sequence over two consecutive nights for a total of three treatment periods to include the following:
Ramelteon 4 mg, tablets, orally over two nights
Ramelteon 8 mg, tablets, orally over two nights
Ramelteon placebo-matching tablets, orally over two nights"
1811000|NCT00671307|Drug|rhu-pGelsolin|IV formulation of recombinant plasma gelsolin formulated as 10 mg/ml given as a single IV infusion over 1 hour
1811001|NCT00671307|Drug|Placebo|Vehicle control given as IV infusion over 1 hour
1811002|NCT00671320|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth twice daily (BID) on Day 1 and then once daily (QD) on Days 2 to 7
1811003|NCT00671320|Drug|diclofenac|diclofenac 75 mg capsule by mouth twice daily (BID) for 7 days
1811004|NCT00671333|Procedure|LRTI|"Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, trapeziectomy using a cruciate osteotomy and rongeurs, creation of a metacarpal base bone tunnel using a high speed burr, harvesting of entire FCR tendon through two transverse volar incisions, ligament reconstruction and tendon interposition using Fibre Wire suture. Closure of capsule with Vicryl. Closure of skin with running Prolene suture."
1811322|NCT00660543|Other|Diffusion Weighted Imaging|Undergo DWI
1811005|NCT00671333|Procedure|Ascension PyroDisk|Dorsal radial incision, capsulotomy between EPB and APL protecting the radial artery, distal 2 mm of trapezium and dorsal cortex of both trapezium and metacarpal removed using osteotomes/rongeurs. A hole is drilled through the trapezium from dorsal to resected distal surface, and a second hole is drilled through the first metacarpal from the resected base to the dorsal surface. A slip of FCR is harvested. The tendon is woven through the trapezium, the central hole in the device, and the metacarpal tunnel then sutured back onto itself. Closure of capsule with Vicryl. Closure of skin with running Prolene suture.
1811006|NCT00671359|Drug|TR-701 600mg|TR-701 600mg
1811007|NCT00671372|Drug|FOLFIRI regimen|Intravenous repeating dose
1811008|NCT00671372|Drug|bevacizumab|Intravenous repeating dose (for Cohort 6 subjects not previously treated with bevacizumab)
1811009|NCT00671372|Drug|cetuximab|Intravenous repeating dose
1811010|NCT00671372|Drug|dulanermin|Intravenous repeating dose
1811011|NCT00671372|Drug|irinotecan|Intravenous repeating dose
1811012|NCT00671398|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally for one night only.
1811013|NCT00671398|Drug|Ramelteon|Ramelteon 16 mg, tablets, orally for one night only
1811014|NCT00671398|Drug|Placebo|Ramelteon placebo-matching tablets, orally for one night only
1811015|NCT00671411|Drug|Ultrasound with intravenous microbubble contrast injection|"Intravenous line will be inserted. After the ultrasound microbubble contrast has been suspended into solution, contrast will be injected intrav via hand bolus with a total activated suspension of 0.2 mL (30 uL octaflouropropane),followed by 10 mL saline flush, with option to rebolus 4 addit time's for tot dose of 150 uL. Post contrast cine images of renal mass will be obtained on commercially available US units primarily using low mechanical index settings & Contrast Pulsed Sequence (CPS®) technique. Images will be acquired at predetermined intervals, for up to 8 min post contrast admin. Manufacturer's guidelines incl immediate post flush image capture, as well as post admin image capture at intervals as 1 min, 2 , 4 & 8 mins. Additional, temporary higher mechanical index imaging of kidney for the purpose of flash bubble destruction may be optionally triggered using manufacturer's preset settings & energy w/i FDA guidelines. This will only be performed while imaging the kidney."
1811016|NCT00671424|Drug|Hydrochlorothiazide (HCTZ)|
1811017|NCT00671424|Drug|Remogliflozin etabonate (GSK189075)|
1811018|NCT00671424|Drug|Furosemide|
1811019|NCT00671437|Procedure|FDG-PET/CT|
1811020|NCT00671437|Drug|Cetuximab|
1811021|NCT00671463|Procedure|Pancreatic duct stenting|In the treatment arm, patients will have a pancreatic duct stent placed prior to having their distal pancreatectomy.
1811022|NCT00671476|Drug|pegylated liposomal doxorubicin hydrochloride|
1811023|NCT00671476|Genetic|DNA methylation analysis|
1811024|NCT00671476|Genetic|TdT-mediated dUTP nick end labeling assay|
1811025|NCT00671476|Genetic|fluorescence in situ hybridization|
1811026|NCT00671476|Genetic|loss of heterozygosity analysis|
1811027|NCT00671476|Genetic|polymerase chain reaction|
1811028|NCT00671476|Other|immunoenzyme technique|
1811029|NCT00671476|Other|immunohistochemistry staining method|
1811030|NCT00671476|Other|laboratory biomarker analysis|
1811031|NCT00671476|Procedure|breast duct lavage|
1811032|NCT00671476|Procedure|neoadjuvant therapy|
1811033|NCT00671476|Procedure|therapeutic conventional surgery|
1811034|NCT00671489|Dietary Supplement|Omega-3 Polyunsaturated Fatty Acid|A capsule of omega-3 Polyunsaturated Fatty Acid, 300mg (including 70% docosahexaenoic acid, 7% eicosapentaenoic acid and other), 7 capsules per day in 12 week.
1811035|NCT00671502|Drug|Carisoprodol SR|700 mg twice daily
1811036|NCT00671502|Drug|Carisoprodol SR|500 mg twice daily
1811037|NCT00671502|Drug|Placebo|Placebo tablet
1811038|NCT00671515|Drug|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
1811039|NCT00671528|Drug|Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate)|Betamethasone diproprionate 0.05%, clotrimazole 1%, and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area 2 times a day (BID), morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
1811040|NCT00671528|Drug|Cream (betamethasone diproprionate and gentamicin)|Betamethasone diproprionate 0.05% and gentamicin sulfate 0.1% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
1811041|NCT00671528|Drug|Cream (betamethasone diproprionate)|Betamethasone diproprionate 0.05% cream applied in a thin layer that covers the affected and surrounding area BID, morning and night for a maximum period of 28 days or until 5 days after total remission of the signs and symptoms, but never more than 28 days.
1811042|NCT00671541|Drug|Merogel Nasal Stent and Nasopore Stent|Merogel Nasal Stent and Nasopore Stent
1811043|NCT00671541|Drug|Nasopore Stent and either Gentamycin or Bacitracin|Nasopore Stent with Bacitracin (100,000 units in 10cc(NSS)or Gentamycin(80mg in 10cc NSS)
1811044|NCT00671554|Biological|Melaxin (autologous dendritoma vaccine) and BCG|Four 1 ml doses of 250,000 dendritomas SQ at 4 week intervals along with a separate SQ injection containing 1 million CFU of BCG. The dose of BCG will be decreased by 50% in subsequent dosing if there is injection site ulceration.
1811045|NCT00671567|Drug|Ramelteon|Ramelteon, 8 mg, tablets, orally, once daily for up to 5 weeks.
1811046|NCT00671567|Drug|Ramelteon|Ramelteon, 16 mg, tablets, orally, once daily for up to 5 weeks.
1811047|NCT00671567|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
1811048|NCT00671580|Drug|PZ-601|750 mg
1811049|NCT00671580|Drug|PZ-601|1000 mg
1811050|NCT00671580|Drug|Standard of Care|as directed
1811051|NCT00671593|Biological|House Dust Mite|"Dermatophagoides pteronyssinus: nebulized inhaled dosing is every 10 minutes per protocol limits at the following Allergen Concentration , (5 breaths of duration 0.8 seconds using a dosimeter) 0.0 AU, 0.3 AU/ml,
1 AU/ml, 3 AU/ml, 10 AU/ml, 30 AU/ml, 100 AU/ml, 300 AU/ml, 1000 AU/ml, 3000 AU/ml"
1811135|NCT00672230|Dietary Supplement|Lutein supplement|Subjects will be randomized to take a lutein supplement(12mg/day) lactation weeks 5-8 or to not take a lutein supplement
1811052|NCT00671593|Biological|Diluent|Greer lab allergen extract diluent (0.5% sodium chloride, 0.25% sodium bicarbonate, 50% glycerin (v/v), and 0.4% phenol)nebulized inhaled dosing is every 10 minutes per protocol limits at the following Diluent Concentration, (5 breaths of duration 0.8 seconds using a dosimeter)
1811053|NCT00671606|Procedure|Intraoperative Lymphatic Mapping|Intraoperative hysteroscopic injection of patent blue dye and radiocolloid for detection of sentinel lymph nodes.
1811054|NCT00671619|Drug|ESBA105|eye drops
1811055|NCT00671632|Drug|Ramelteon, triazolam, and placebo (56 possible combinations total)|"Randomized sequence over eight consecutive days to include the following:
Ramelteon 16 mg, tablets, orally, one day only;
Ramelteon 80 mg, tablets, orally, one day only;
Ramelteon 160 mg, tablets, orally, one day only;
Triazolam 0.25 mg, capsules, orally, one day only;
Triazolam 0.50 mg, capsules, orally, one day only;
Triazolam 0.75 mg, capsules, orally, one day only;
Ramelteon placebo-matching tablets, orally, one day only, OR Triazolam placebo-matching capsules, orally, one day only;
Additional dose of study medication or placebo, tablets or capsules, orally, one day only."
1811056|NCT00671645|Drug|capecitabine, bevacizumab|Capecitabine 825 mg/m2 bid (on each therapy day of first 4 Therapy weeks) Bevacizumab 5 mg/kg weight; day 1, 15, 29
1811057|NCT00671658|Drug|Rituximab|375 mg/m2 by vein
1811058|NCT00671658|Drug|Cyclophosphamide (CTX)|300 mg/m2 by vein
1811059|NCT00671658|Drug|Doxorubicin|50 mg/m2 by vein
1811060|NCT00671658|Drug|Vincristine|2 mg by vein
1811061|NCT00671658|Drug|Dexamethasone|40 mg by vein or by mouth (P.O.)
1811062|NCT00671658|Drug|Methotrexate (MTX)|"12 mg intrathecally (6 mg if via Ommaya reservoir) for Courses 1,3,5,7
200 mg/m2 by vein followed by 800 mg/m2 for Courses 2,4,6,8"
1811063|NCT00671658|Drug|Cytarabine|"100 mg intrathecal for Courses 1,3,5,7
3 gm/m2 by vein for Courses 2,4,6,8"
1811064|NCT00671658|Drug|G-CSF|10 ug/kg subcutaneous injection
1811065|NCT00671658|Drug|Mesna|600 mg/m2 a day by vein
1811066|NCT00671658|Drug|Pegylated asparaginase|2000 International units/m2 by vein
1811067|NCT00671658|Drug|Pegfilgrastim|6 mg (flat dose) within 72 hrs after completion of chemotherapy
1811068|NCT00671658|Drug|Solumedrol|40 mg by vein for Courses 2,4,6,8
1811069|NCT00671671|Drug|Small Molecule Agent (PF-868554)|Study drug will be administered 700mg BID in the fed state for three days.
1811070|NCT00671671|Drug|Small Molecule Agent (PF-868554)|Study drug will be given 450mg BID for a duration of 10 days.
1811071|NCT00671684|Procedure|Endoscopic Mucosal Resection (EMR)|EMR is a common procedure in gastroenterology. The technique involves placing a band around a piece of mucosa in the GI tract. The band and the tissue are then removed using a cautery snare. The technique can be used to obtain tissue for diagnostic purposes or to remove lesions for therapeutic purposes.
1811072|NCT00671697|Drug|Arsenic Trioxide|
1811073|NCT00671697|Drug|Decitabine|
1811074|NCT00671710|Drug|Aminolevulinic Acid|Escalating doses (10mg/kg, 20mg/kg, 30mg/kg) of Aminolevulinic Acid administered orally 3 hours prior to surgery to enhance visualization of malignant brain tumor.
1811075|NCT00671723|Drug|Normal saline:|Nebulized isotonic saline solution (4 ml of 0.9 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
1811076|NCT00671723|Drug|Hypertonic Saline|Nebulized hypertonic saline solution (4 ml of 7 % NaCl) twice daily, for a fixed period of 15 min, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
1811077|NCT00671723|Drug|Dornase alpha|2.5 mg of DNase (Dornase alpha, PULMOZYME® , Genentech, South San Francisco, CA), nebulized twice daily, after a 15 min premedication with nebulized albuterol (2.5 mg diluted in 3 ml of 0.9 % NaCl).
1811078|NCT00671736|Drug|Moli1901|2,5 ml inhalation solution, 8 weeks treatment period
1811079|NCT00671736|Drug|Moli1901 placebo|2,5 ml placebo solution, 8 weeks treatment period
1811080|NCT00671749|Drug|adapalene gel, 0.3%|Applied once daily at bedtime
1811081|NCT00671749|Drug|clindamycin/benzoyl peroxide gel|Applied once daily in the morning
1811082|NCT00671788|Drug|Dasatinib|Given orally
1811083|NCT00671788|Other|Laboratory Biomarker Analysis|Correlative studies
1811084|NCT00671801|Drug|Irinotecan|200 mg/m^2 by vein over 90 minutes once every 2 weeks on days 1 and 15.
1811085|NCT00671801|Drug|Lenalidomide|Given orally at escalating doses beginning 7.5 mg/day on Cycle 1 Days 1-21 and 10 mg/day on Cycle 2 Days 1-21.
1811086|NCT00671814|Drug|TR-701|TR-701 will be given as single oral doses in Cohorts 1-5 and as once daily oral doses for 21 days in cohorts 6-8.
1811087|NCT00671814|Drug|linezolid|Linezolid will be given at 600 mg twice daily for 21 days in cohort 10.
1811088|NCT00671814|Drug|placebo|Placebo will be given once for cohorts 1-5, once daily for 21 days for cohorts 6-8, and twice daily for 21 days for cohort 10.
1811089|NCT00671827|Behavioral|Questionnaire|Questionnaires each taking less than 10 minutes to complete.
1811090|NCT00671853|Drug|Quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
1811091|NCT00671853|Drug|Placebo for quetiapine XR|Days 1-2 - 50 mg/day; Days 3-4 - 150mg/day; Day 5-End of Study - 300mg/day
1811092|NCT00671879|Drug|Carisoprodol SR 700 mg|700 mg twice daily tablet
1811093|NCT00671879|Drug|Carisoprodol SR 500 mg|carisoprodol SR 500 mg tablet
1811094|NCT00671879|Drug|Placebo|placebo tablet
1811095|NCT00671892|Biological|Lipopolysaccharide endotoxin|"Delivered in nebulized form expressed in activity units(endotoxin units -EU).
Subjects receive each dose 30 min after completing the previous dose, dose duration is approximately 10 minutes:
Challenge One first saline then 5000 EU 10,000 EU 20,000 EU
Challenge 1 and 2 must be at least 2 weeks apart.
Challenge 2 Saline 40,000 EU 80,000 EU"
1811096|NCT00671905|Procedure|GP ablation|HF stimulation-guided and anatomic ablation of the main right and left atrial GP
1811097|NCT00671905|Procedure|PV isolation|Circumferential PV isolation
1811133|NCT00672217|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTI)|Six 15-30 minute in-person or phone sessions that incorporate cognitive, behavioral and psycho-educational techniques focused on modifying the perpetuating factors that maintain insomnia.
1811134|NCT00672217|Behavioral|Behavioral Placebo Treatment|Six 15-30 minute in-person or phone sessions that begin with a review of the sleep diary, a general discussion of treatment progress and tabulation of sleep parameters.
1812816|NCT00670397|Drug|HPPH|IV
1811098|NCT00671918|Drug|Lymphoseek|Breast Cancer: Intradermal admin of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site OR periareolar administration of Lymphoseek: Inject 0.2-.04 mL in multiple divided doses at the margin of the areola OR subareolar administration of Lymphoseek: Inject 0.2-0.4 in multiple divided injections or a single injection in subareolar area as a subcutaneous injection OR peritumor administration of Lymphoseek: Inject 2.0-4.0 mL in multiple divided injections, intraparenchemally surrounding the tumor or biopsy cavity. For melanoma pts intradermal administration of Lymphoseek: Inject 0.2-0.4 mL in multiple divided injections or a single injection overlying the intact primary tumor or excision biopsy site.
1811099|NCT00671931|Drug|low dexmedetomidine, low propofol|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 100 MCG/KG/M
1811100|NCT00671931|Drug|high dexmedetomidine, low propofol|Dexmedetomidine loading dose 1.1 MCG/KG ,Propofol infusion 100 MCG/KG/M
1811101|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.6 MCG/KG,Propofol infusion 200 MCG/KG/M
1811102|NCT00671931|Drug|Dexmedetomidin|Dexmedetomidine loading dose 1.1 MCG/KG.Propofol infusion 200 MCG/KG/M
1811103|NCT00671931|Drug|Dexmedetomidine|Dexmedetomidine loading dose 0.9 mcg/kg,Propofol infusion 140 mcg/kg/min
1811104|NCT00671944|Other|Low protein diet|Low protein diet for 6.5 weeks
1811105|NCT00671970|Drug|Bevacizumab and Erlotinib|"Bevacizumab administered intravenously at dose 10 mg/kg every 2 wks. Erlotinib administered orally, continuously once daily in fasting state for each 42-day cycle. Dose of erlotinib is based on prior erlotinib monotherapy trial in RMG. It will be 200 mg/day for pts not on cytochrome P450 3A4 (CYP3A4)-enzyme inducing anti-epileptic drugs & 500 mg/day for pts on EIAEDs.
It is possible that taking erlotinib w regular medications or supplements may change how erlotinib, subject's regular medications, or subject's regular supplements work. Treatment will continue until either evidence of progressive disease, unacceptable toxicity, non-compliance w study follow-up, or withdrawal of consent."
1811106|NCT00671983|Procedure|Neurocognitive Testing|
1811107|NCT00671996|Drug|Mangafodipir|"Treatment will be undertaken with a ready-to-use investigative drug formulation identical to what is in diagnostic use as a contrast medium for MRI.
Formulation content: MnDPDP 10 mmol/ml
Administered dose per cycle: 2 μmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an i.v. infusion over 5 min about 30 min prior to start of chemotherapy."
1811108|NCT00671996|Drug|Placebo treatment (0.9% NaCl)|Intravenous infusion, 2 micromol/kg, pretreatment 30 minutes before the start of FOLFOX treatment (during the first three FOLFOX treatments)
1811109|NCT00672009|Drug|Ixabepilone|Ixabepilone 35 mg/m^2 intravenously over 3 hours every 21 days for 4 cycles.
1811110|NCT00672022|Drug|Zavesca (Miglustat)|
1811111|NCT00672035|Biological|Biological: heat-labile enterotoxin of E. coli (LT)|LT patch applied on either the deltoid or the lower back.
1811112|NCT00672048|Other|Computer Tablet|A tablet computer based software application designed to collect structured clinical information from providers and patients at the point of care.
1811113|NCT00672048|Other|Continuing Education Course|Annual standard continuing education
1811114|NCT00672048|Other|Continuing education|Annual standard continuing education materials
1811115|NCT00672061|Drug|Ramelteon or Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
1811116|NCT00672074|Drug|Ipamorelin|IV
1811117|NCT00672074|Drug|placebo|IV
1811118|NCT00672087|Genetic|Genomic and proteomic biomarker discovery|Discovery of novel biomarkers for CP/CPPS and PBS/IC using genomic and proteomic methods
1811119|NCT00672100|Drug|Ropivacaine|Initial Bolus 5 ml Ropivacaine via interscalene injection
1811120|NCT00672100|Drug|Ropivacaine|Initial Bolus 10 ml Ropivacaine via interscalene injection
1811121|NCT00672100|Drug|Ropivacaine|Initial Bolus 20 ml Ropivacaine via interscalene injection
1811122|NCT00672113|Drug|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS 30 mg followed by Coracten 30 mg then back to nifedipine GITS 30 mg
1811123|NCT00672113|Drug|Coracten|Coracten 30 mg followed by nifedipine GITS 30 mg then back to Coracten 30 mg
1811124|NCT00672139|Drug|Methylnaltrexone bromide|Methynaltrexone subcutaneously as needed no more than 1 dose in a 24-hour period for a maximum of 10 weeks in this study)
1811125|NCT00672152|Biological|WT1 derived peptides|"WT1 derived peptides consisting of 0.3mg (cohort 1) or 1mg (cohort 2) of each of the following peptides mixed with 1ml Montanide ISA 51 and 100mcg GM-CSF in a total volume of 2ml:
WT peptide #1: HLA-A2 restricted: RMFPNAPYL
WT peptide #2: HLA-A24 restricted: CMTWNQMNL
WT peptide #3: HLA-DR15 restricted: QARMFPNAPYLPSCL
WT peptide #4: HLA-DRw53 restricted: LKGVAAGSSSSVKWT
Immunization with the peptide pools will be given as 200 microliter intradermal and 1.8ml subcutaneously in opposite thighs."
1811126|NCT00672165|Biological|ACTINIUM-225-LABELED HUMANIZED ANTI-CD33 MONOCLONAL ANTIBODY HuM195|A single infusion of 225Ac-HuM195 will be administered at a starting dose of 0.5 μCi/kg. Additionally, 100 mCi of 213Bi-HuM195 have been administered with full dose cytarabine (200 mg/m2 daily for 5 days) without dose-limiting toxicity.Serial sampling of blood, urine, and bone marrow will be performed following treatment to determine the toxicity, pharmacokinetics, immunogenicity, and antileukemic effects. Three to six patients will be treated at each dose level. Dose escalation will proceed if less than 33% of patients in a cohort experience dose-limiting toxicity.Patients will be followed until completion of therapy as outlined in the study, loss to follow-up, death, or until the day the patient is removed from the study.
1811127|NCT00672178|Radiation|Stereotactic body radiation|Stereotactic body radiotherapy will be given in three cohorts of increasingly higher dose levels: Cohort 1: 6 Gy/fraction x 3 fractions (total=18 Gy) over 5 days; Cohort 2: 8 Gy/fraction x 3 fractions over 5 days; Cohort 3: 10 Gy/fraction x 3 fractions over 5 days.
1811128|NCT00672191|Biological|AGS-004|HIV-1 Immune Therapy
1816263|NCT00695409|Drug|etoposide|Given IV
1811136|NCT00672243|Drug|Erlotinib + sirolimus|Erlotinib & sirolimus on a daily dosing schedule on a 28-day cycle. Dosing was 150 mg of oral erlotinib and 5mg of oral sirolimus for patients not on concurrent CY3PA-inducing anti-epileptics (EIAEDS) and 400 mg of oral erlotinib and 10 mg of oral sirolimus for patients on concurrent EIAEDS.
1811137|NCT00672256|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
1811138|NCT00672282|Drug|Bicalutamide|150mg p.o. daily
1811139|NCT00672282|Drug|Placebo|
1811140|NCT00672295|Drug|Dasatinib, Paclitaxel, and Carboplatin|"Dasatinib will be administered as an oral dose (tablet) as per the dose escalation (50 mg everyday - 250 mg everyday)continuously on days 2-21 in the first cycle (3 weeks) therapy and continuously (days 1-21) throughout the remainder of therapy.
Paclitaxel will be administered on a 21-day schedule. Paclitaxel (150-175 mg/m^2) IV infused over 3 hours on day #1 of each cycle.
Carboplatin (AUC=5-6 mg/,l/min) will be infused over 30-60 minutes every cycle via IV on day 1 of every cycle following the paclitaxel administration.
All patients will be followed until disease progression or study withdrawal. In addition, following disease progression, patients will be monitored for delayed toxicity and survival for a period of 5 years and data entered into eDC, unless is withdrawn."
1811141|NCT00672308|Other|Benefiber|
1811142|NCT00672308|Other|Benefiber with ORS|Benefiber (50 g/L)-supplemented, reduced-osmolarity WHO-ORS
1811143|NCT00672308|Other|Benefiber with ORS|
1811144|NCT00672308|Other|Benefiber with ORS|
1811145|NCT00672308|Other|the reduced-osmolarity WHO-ORS without added Benefiber|
1811146|NCT00672308|Other|the reduced-osmolarity WHO-ORS without added Benefiber|
1811147|NCT00672321|Genetic|gene expression analysis|
1811148|NCT00672321|Genetic|mutation analysis|
1811149|NCT00672321|Genetic|polymorphism analysis|
1811150|NCT00672321|Other|laboratory biomarker analysis|
1811151|NCT00672321|Other|questionnaire administration|
1811152|NCT00672334|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
1811153|NCT00672334|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
1811154|NCT00672347|Drug|Clonidine|1 mcg/kg
1811155|NCT00672347|Drug|Morphine|20 mcg/kg
1811156|NCT00672347|Drug|Bupivacaine plus clonidine and morphine|"bupivacaine 0,166% 1 ml/kg
clonidine 1 mcg/kg
morphine 20 mcg/kg"
1811157|NCT00672347|Drug|Bupivacaine|Caudal anesthesia with bupivacaine 0,166% 1 ml/kg
1811158|NCT00672360|Dietary Supplement|Folic acid|Compounded capsule, 7.6mg, taken orally, twice daily for 4 weeks.
1811159|NCT00672360|Dietary Supplement|Placebo|Compounded capsule of NaCl, taken orally, twice daily for 4 weeks.
1811160|NCT00672373|Drug|Extract of Ginkgo Biloba (EGb-761 capsules)|EGb-761 240mg/d, 1 capsule(80mg) tid,po,12 weeks; Each capsule contains 19.6mg flavonol glycosides and 4.8mg terpene lactones.
1811161|NCT00672373|Drug|Placebo|Wheat flour placebo capsule,1 capsule tid, po,12 weeks
1811162|NCT00672386|Drug|JNJ16269110|5 mg twice daily for 12 weeks
1811163|NCT00672386|Drug|JNJ16269110|10 mg twice daily for 12 weeks
1811164|NCT00672386|Drug|JNJ16269110|15 mg twice daily for 12 weeks
1811165|NCT00672386|Drug|Placebo|twice daily for 12 weeks
1811166|NCT00672386|Drug|Metformin|Participants will continue taking metformin at the same dose and according to the same dosing regimen as before the study.
1811167|NCT00672386|Other|Dietary Counseling|Participants will receive dietary counseling at Screening, Week 4, 8, 12, and will be instructed to remain on a calorically appropriate diet with a maximum of 30% of calories derived from fat (in accordance with local practice guidelines for the treatment of type 2 diabetes mellitus) during the entire study.
1811168|NCT00672399|Drug|exenatide|Subcutaneously injected, 10 mcg, single doses
1811169|NCT00672399|Drug|Moxifloxacin|oral, 400 mg tablet, single doses
1811170|NCT00672399|Drug|Placebo|Subcutaneously injucted in an amount equivalent to exenatide; or orally as a tablet identical in appearance to Moxifloxacin. Both are single doses
1811171|NCT00672412|Drug|GPO-Vir Z30 tablet|Tablet consisting of ZDV 30 mg/3TC 15 mg/NVP 28 mg taken orally twice daily
1811172|NCT00672412|Drug|Lamivudine|Oral suspension containing 10 mg 3TC in each mL. Dosage depends on weight.
1811173|NCT00672412|Drug|Nevirapine|Oral solution containing 10 mg NVP in each mL. Dosage depends on weight.
1811174|NCT00672412|Drug|Zidovudine|Oral solution containing 10 mg ZDV in each mL. Dosage depends on weight.
1811175|NCT00672438|Drug|Alfentanil|Target controlled intravenous infusion of alfentanil at a plasma concentration of 100ng/ml
1811176|NCT00672438|Other|Saline placebo infusion|Intravenous infusion of normal saline
1811177|NCT00672451|Dietary Supplement|rhubarb extract|titrate rhubarb extract titrated up to 6grams daily by mouth
1811178|NCT00672451|Dietary Supplement|placebo|placebo titrated up to 6 pills daily as patient tolerates
1811179|NCT00672464|Drug|Olanzapine|Olanzapine zydis 15 mg QHS for 28 days
1811180|NCT00672464|Drug|Metformin|Metformin capsules will be started at 500 mg twice a day (before breakfast and before dinner) for days 1-3, then 500 mg before breakfast and 1000 mg before dinner for days 4-7, and then 1000 mg twice a day thereafter.
1811181|NCT00672464|Drug|Simvastatin|Simvastatin will be started at 10 mg at bed time for the first week and 20 mg at bedtime thereafter.
1811182|NCT00672477|Drug|Methylnaltrexone bromide|Methylnatrexone (either 0.2ml, 0.4ml or 0.6ml) subcutaneously every other day for 14 days (ie, 7 doses)
1811183|NCT00672477|Drug|Placebo|Placebo (either 0.2ml, 0.4ml or 0.6ml) subcutaneously every other day for 14 days (ie, 7 doses)
1811226|NCT00672828|Behavioral|Interactive computer intervention|
1811323|NCT00660543|Other|MRI-Based Angiogram|Undergo TOF MR angiography
1816264|NCT00695409|Drug|melphalan|Given IV
1811184|NCT00672490|Drug|Quetiapine Fumarate|"Oral treatment, twice daily. 100 mg/day at Day 1, 200 mg/day at Day 2, 300 mg/day at Day 3, 400 mg/day at Day 4, from 400 mg/day to 600 mg/day before Day 8, from 600 mg/day to 800 thereafter, judged by the investigator.
Tablets"
1811185|NCT00672490|Drug|Lithium|Oral treatment, twice daily. 250 mg/day to 2000mg/day from Day1 to Day 7, 500mg/day to 2000mg/day thereafter, judged by the investigator.
1811186|NCT00672529|Dietary Supplement|Orthomolecular Therapy or Placebo Comparator|"The custom formulation proposed in this study comprises Vitamins C, E, B6 and B12, magnesium, selenium, quercetin and fish oil in relatively large doses. It is not at present registered as a natural health product or drug product.
Eligible patients will be randomized to an orthomolecular treatment regime or placebo with a 2:1 randomization ratio and will remain on their randomized treatment for 16 weeks. For the first 8 weeks of the intervention period inhaled corticosteroid treatment will be unchanged. In the remaining 8 weeks dose adjustment will occur every two weeks. Participants will be monitored closely for changes in their lung function."
1811187|NCT00672542|Biological|Proteasome siRNA and tumor antigen RNA-transfected dendritic cells|The safety and toxicity of vaccination with tumor antigen RNA-transfected dendritic cells (DC), derived from either untransfected or siRNA-transfected monocytes, will be evaluated in subjects with metastatic melanoma. Subjects will undergo leukapheresis and monocytes will be isolated. These monocytes will then be left untreated (Study Arm A) or transfected with either control siRNA (Study Arm B) or siRNA targeting immunoproteasome subunits LMP2, LMP7, and MECL1 (Study Arm C), then differentiated into DC in vitro . After the induction of maturation, these DC will be transfected with RNA encoding defined melanoma antigens MART, MAGE-3, tyrosinase, and gp100. These RNA-transfected autologous DC will be cryopreserved, then used to vaccinate subjects with metastatic melanoma, each of whom will receive a total of six intradermal (ID) injections using 1x10e7 DC at each cycle, administered weekly.
1811188|NCT00672555|Procedure|Limberg-flap|Complete excision of the pilonidal sinus and covering of the defect by a Limberg-flap from one buttock
1811189|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.5 mg, single dose, injection
1811190|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.75 mg, single dose, injection
1811191|NCT00672568|Drug|4975 - Highly purified capsaicin|Solution, 0.1 mg, Single dose, injection
1811192|NCT00672568|Drug|Placebo|Solution, single dose, injection
1811193|NCT00672581|Drug|ZD4054|10mg, Oral tablet, single dose
1811194|NCT00672594|Drug|Sunitinib Malate|Sunitinib Malate 50mg capsule by mouth once daily for 4 weeks
1811195|NCT00672607|Drug|extracts of Vitex agnus castus tablets|orally, one tablet daily. Apply for a period of 3 months. Do not interrupt during menses period.
1811196|NCT00672607|Drug|Placebo|Placebo
1811197|NCT00672620|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
1811198|NCT00672620|Drug|Duloxetine|Duloxetine capsules
1811199|NCT00672620|Drug|Placebo|Placebo-matching capsules
1811200|NCT00672633|Drug|Lovaza|Lovaza , 4 grams/day orally for 6 months
1811201|NCT00672633|Drug|Placebo|Corn Oil Pill, 4 pills/day orally for 6 months
1811202|NCT00672646|Drug|AZD1386|95mg, oral solution, single dose
1811203|NCT00672646|Drug|Naproxen|500mg, capsule, single dose
1811204|NCT00672646|Drug|Placebo|AZD1386 Placebo oral solution
1811205|NCT00672659|Drug|Citalopram + Pipamperone|Citalopram, 40 mg daily, 8 weeks Pipamperone, 5 mg twice daily, 8 weeks
1811206|NCT00672659|Drug|Citalopram|Citalopram, 40 mg daily, 8 weeks Placebo, dummy, twice a day, 8 weeks
1811207|NCT00672672|Biological|autologous platelet gel|Patients will receive APG to the surgical site in the operating room. The control site will receive no treatment.
1811208|NCT00672685|Dietary Supplement|omega-3|V0137 CA containing 400 mg docosahexaenoic acid (DHA) - 2 soft capsules once a day, i.e. 800 mg DHA per day for 36 months
1811209|NCT00672685|Behavioral|multi-domain intervention|multi-domain intervention = Nutrition, physical exercise, cognitive training and social activities, and preventive consultations
1811210|NCT00672685|Drug|Placebo|OMEGA-3 placebo
1811211|NCT00672698|Procedure|SURGERY|ELECTIVE SURGICAL PROCEDURES
1811212|NCT00672724|Drug|Ramelteon|Ramelteon 8 mg tablets, taken orally, once daily for up to 2 weeks.
1811213|NCT00672724|Drug|Placebo|Ramelteon placebo-matching tablets, taken orally, once daily for up to 2 weeks.
1811214|NCT00672737|Drug|Remifentanil|Remifentanil was administered as a computer-controlled infusion, targeting two different effect site concentrations, 1 and 2 mcg/mL, in randomized order.
1811215|NCT00672737|Procedure|Cold pain threshold and tolerance|Ice water was used to assess cold-related pain threshold and tolerance, defined as the time that the volunteers could keep their hands in the water before they started feeling pain or this feeling becomes unbearable, for threshold and tolerance, respectively.
1811216|NCT00672737|Device|Heat pain threshold and tolerance|TSAII Neuroanalyzer (Medoc Advanced Medical Systems, Durham, NC), was used to assess the heat-related pain and tolerance of the volunteers defined as the respective temperatures where they started feeling as painful or unbearable.
1811217|NCT00672737|Procedure|Polysomnography|All volunteers underwent a polysomnography study at home or at Stanford Sleep Center, approximately one week before their experimental pain assessment in the laboratory
1811218|NCT00672763|Drug|Colecalciferol D3 (Vigantol Oil)|"Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;
Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;
Colecalciferol 100,000iU orally once fortnightly for 4 weeks (2 doses)."
1811219|NCT00672763|Drug|Medium chain triglycerides|"Standard oral Prednisolone 40mg daily (or Budesonide 9mg daily) for 4 weeks;
Supplemental calcium and vitamin D3 (CalcichewD3Forte) 1000mg and 800iU respectively daily for duration of steroid treatment;
Migliol Oil 5ml oral fortnightly (2 doses)"
1811220|NCT00672776|Drug|paroxetine|
1811221|NCT00672776|Drug|placebo|
1811222|NCT00672789|Behavioral|Blood smear education|education at baseline and three month follow-up
1811223|NCT00672789|Other|standard education|standard education
1811224|NCT00672802|Drug|Ramelteon and Placebo|Ramelteon 16 mg, tablet, orally, once daily for Periods 1 or 2 and ramelteon placebo-matching tablets, orally, once daily for Periods 1 or 2.
1811225|NCT00672828|Behavioral|Non-tailored CRC screening brochure|Patients receive written educational material about colorectal cancer and prompting to talk to their doctor about getting tested.
1811227|NCT00672841|Drug|Preemptive Therapy with Anidulafungin|Subjects in the active surveillance arm who develop a single positive β-D-glucan test will receive preemptive anidulafungin intravenously. Preemptive therapy will include a loading dose of 200mg followed by 100mg maintenance therapy once a day. The loading and maintenance doses are derived from the FDA cleared schedule for Invasive Candidiasis and candidemia. Preemptive therapy will continue for 14 days.
1811228|NCT00672841|Drug|Empiric antifungal therapy based on physician discretion.|Patients in the standard care group may receive antifungal prophylaxis and/or treatment at any time based on the discretion of the treating physician.
1811229|NCT00672854|Drug|ClinOleic|TPN with ClinOleic (20%)
1811230|NCT00672854|Drug|Intralipid|TPN with Intralipid (20%)
1811231|NCT00672867|Drug|Clevudine|30mg
1811232|NCT00672867|Drug|Adefovir dipivoxil|10mg
1811233|NCT00672880|Behavioral|Self-System Therapy|12 sessions of structured Self-System Therapy
1811234|NCT00672880|Behavioral|Education|12 sessions of spine and muscle education including life style changes and medical treatments.
1811235|NCT00672880|Other|Standard Care|Study participants continue with their usual medical care, no changes.
1811236|NCT00672893|Other|Vibration Response Imaging|12 seconds of recording lung sounds
1811237|NCT00672906|Behavioral|Group Parent Training|Skills group for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
1811238|NCT00672906|Behavioral|Maudsley Family Therapy|Family therapy specifically adapted for the treatment of adolescent anorexia nervosa.
1811239|NCT00672919|Drug|Pioglitazone|Pioglitazone 30 mg to 45 mg, tablets, orally, once daily in combination with stable statin therapy for up to 17 weeks.
1811240|NCT00672932|Drug|raltegravir|400 mg two times daily for three months
1811241|NCT00672945|Drug|PRX-03140|
1811242|NCT00672945|Drug|Placebo|
1811243|NCT00672958|Drug|Vortioxetine|Encapsulated immediate-release tablets.
1811244|NCT00672958|Drug|Placebo|Vortioxetine placebo-matching capsules.
1811245|NCT00672971|Other|4% dimethicone foam|The dimethicone foam is applied to dry hair and left on the hair for approximately 15 minutes. The product is then removed by washing the hair with baby shampoo. The foam is applied two time, separated by an interval of 7-9 days.
1811246|NCT00672971|Other|1% permethrin|Nix® Cream Rinse is applied as indicated on the product labeling. The cream rinse is applied to wet hair and left on the hair for 10 minutes. The hair is then rinsed with tepid water to remove the product, toweled dry, and combed with a detangling comb. The product is applied two times, separated by an interval of 7-9 days.
1811247|NCT00660062|Drug|escitalopram|10 mg daily
1811248|NCT00660062|Drug|escitalopram|20 mg daily dosage
1811249|NCT00660062|Drug|escitalopram|30 mg daily dosage
1811250|NCT00660062|Drug|nortriptyline|100 mg daily dosage
1811251|NCT00660075|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
1811252|NCT00660075|Drug|Placebo|Placebo for 6 weeks
1811253|NCT00660088|Other|Ketasyn|10g for 7 days, 20g for 7 or 14 days
1811254|NCT00660101|Biological|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine|OVax: Autologous, DNP-Modified Ovarian Cancer Vaccine cells in suspension dosage - depends on arm route - intradermal frequency - weekly x7, booster at 6 months
1811255|NCT00660140|Drug|Gemcitabine|
1811256|NCT00660140|Drug|Carboplatin|
1811257|NCT00660153|Drug|Tivozanib (AV-951) plus FOLFOX6|"Investigational product, dosage and mode of administration (1 cycle = 4 weeks of treatment):
Tivozanib (AV-951): 0.5 mg, 1.0 mg, and 1.5 mg oral once daily On Day -5 (± 2 days) subjects will receive a single dose of tivozanib (AV-951) for pharmacokinetic sampling. Beginning on Day 1 of Cycle 1, subjects will receive tivozanib (AV-951) once daily for 3 weeks followed by 1 week off. Tivozanib (AV-951) dosing repeats every cycle in the absence of disease progression or unacceptable toxicity. On days when both tivozanib (AV-951) and the FOLFOX6 chemotherapy regimen are co-administered, tivozanib (AV-951) will be administered immediately prior to the start of the FOLFOX6 chemotherapy regimen.
Subjects will receive FOLFOX6 chemotherapy every 2 weeks starting on Day 1 of Cycle 1. Subjects will receive 2 treatments of FOLFOX6 in each treatment cycle, starting on Day 1 and Day 15."
1811258|NCT00660166|Biological|NK-Cell Infusion|The infusion of natural killer (NK) cells will be performed in the Infusion Center at New England Medical Center. The NK cells will be given to the subject intravenously (into a vein). In addition, a balanced salt solution will be infused beginning about two hours prior to and continuing for two hours after the infusion of NK cells to keep the fluid level in the body well balanced. The subject will also receive Benadryl by injection 15-30 minutes prior to infusion to counteract and prevent any unwanted allergic side effects. The subject will be observed for any side effects during this time. If the subject feels well, he/she can go home. However, there may be a requirement to keep him/her overnight.
1811259|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 3 mg dosage, once daily
1811260|NCT00660179|Drug|macitentan (ACT-064992)|Tablet, 10 mg dosage, once daily
1811261|NCT00660179|Drug|placebo|Matching placebo, once daily
1811262|NCT00660192|Drug|Botox|subjects randomized to receive Botox with have a series of injections of onobotulinumtoxinA totalling 200 to 300 units. Botox is prepared b adding 1cc of preservative free saline in 100 unit vial. Final dose is determined by bod and neck size.
1811263|NCT00660192|Other|Placebo|subjects randomized to receive Placebo will have a series of injections of saline solution totalling 2cc's to 3cc's injected into the scalp in a halo pattern; and into affected neck muscles.
1811264|NCT00660218|Drug|paclitaxel poliglumex|Phase I: 40 mg/m2 IV weekly in Cohort 1 (first 3 subjects), escalating in increments of 10 mg/m2 for Cohorts 2 through 5 (3 subjects each) until the maximum tolerated dose (up to 80 mg/m2 IV weekly) is established; Phase II: MTD mg/m2 IV weekly as established in Phase I (24 additional subjects)
1811265|NCT00660218|Biological|cetuximab|400 mg/m2 IV loading dose one week prior to starting other study treatments, then 250 mg/m2 IV weekly on same day as paclitaxel poliglumex
1811266|NCT00660218|Radiation|radiation therapy (IMRT or 3D-CRT)|radiation therapy to the head and neck, consisting of 33 daily fractions of 2.12 Gy for a total of 69.96 Gy, to begin the same day as paclitaxel poliglumex
1811267|NCT00660231|Drug|bexarotene|Bexarotene daily p.o. 150mg/sq m during week 1 and 2, then 300mg/sq m if tolerated.
1811268|NCT00660231|Drug|gemcitabine hydrochloride|Gemcitabine i.v. 1000mg/sq m day 1 and day 8 of four 21 day cycles.
1811270|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
1811271|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 2.5 ug per dose, intramuscular injection
1811272|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 5.0 ug per dose, intramuscular injection
1811273|NCT00660257|Biological|pandemic influenza vaccine (H5N1 strain NIBRG-14)|pandemic influenza vaccine (H5N1 strain NIBRG-14) booster (third) dose: 1.25 ug per dose, intramuscular injection
1811274|NCT00660270|Procedure|Pancreatic Surgery|
1811275|NCT00660270|Radiation|Radiation therapy|
1811276|NCT00660270|Drug|Cisplatin|
1811277|NCT00660270|Drug|5-FU|
1811278|NCT00660270|Drug|Alpha-interferon|
1811279|NCT00660270|Drug|Gemcitabine|
1811280|NCT00660283|Drug|Temozolomide|"(Stage I Treatment) Postoperative concomitant limited-field radiation therapy with daily temozolomide (75 mg/m2) must begin between 14 and 28 days from surgery.
7. (Stage II Treatment) temozolomide 150 mg/m2 to be given days 1-7 and 15-21 of a 28 day cycle to begin within 45 days of stop date of concomitant limited field radiation/daily temozolomide (Stage I treatment) up to a maximum of 12 cycles."
1811281|NCT00660296|Other|Air insufflation use in colonoscopy|Air insufflation for colonic distension
1811282|NCT00660296|Other|CO2 use in colonoscopy|Co2 insufflation for colonic distension
1811283|NCT00660309|Drug|Aliskiren|Aliskiren 300 mg tablets
1811284|NCT00660309|Drug|Irbesartan|Irbesartan 300 mg tablets
1811285|NCT00660309|Drug|Captopril|Captopril 25 mg tablet
1811286|NCT00660322|Behavioral|Telephone Asthma Program|"The parent will have access to a trained asthma coach for 12 months. The coach will call the parents at mutually convenient times (up to 12 times a year) to work on 4 targeted asthma behaviors:
Using asthma controller medications as prescribed
Having and Asthma Action Plan available to all who may need it.
Using asthma rescue medications with the child's first symptoms.
Having a collaborative relationship with the child's primary care provider that includes asthma check-ups at least twice a year."
1811287|NCT00660335|Drug|RG1068 (synthetic human secretin)|Single-dose, IV infusion
1811288|NCT00660348|Drug|morphine sulfate|This is morphine given in the traditional methods.
1811289|NCT00660348|Device|Medtronic intrathecal pump|This pump will be inserted into the research subject and then the pump will deliver morphine.
1811290|NCT00660374|Drug|insulin NPH|"Soft-treat-to-target dose titration scheme, injection s.c."
1811291|NCT00660374|Drug|EX1000|"Soft-treat-to-target dose titration scheme, injection s.c."
1811292|NCT00660387|Drug|Levodopa carbidopa intestinal gel (LCIG)|infusion should be kept within a range of 0.5-10 mL/hour (10-200 mg levodopa/hour) and is usually 2-6 mL/hour (40-120 mg levodopa/hour)
1811293|NCT00660387|Drug|Placebo Gel|
1811294|NCT00660387|Drug|Levodopa-carbidopa (LC) oral encapsulated immediate release (IR) tablets|
1811295|NCT00660387|Drug|Placebo (PBO) oral capsules|
1811296|NCT00660387|Device|CADD-Legacy® 1400 ambulatory infusion pump|
1811297|NCT00660387|Device|PEG tube|percutaneous endoscopic gastrostomy tube
1811298|NCT00660387|Device|J-tube|jejunal tube
1811299|NCT00660400|Drug|5-azacitidine|Once enrolled, the patients will receive pre-transplant 5-azacitidine (Vidaza) 75 mg/M^2/day subcutaneously for 5-7 days every 28 days). Adjustments in dose and timing may occur based on clinical and hematological parameters.
1811300|NCT00660400|Procedure|Allogeneic Hematopoietic Cell Transplantation (HCT)|"Patients will receive transplantation if there is either a suitable sibling or an unrelated donor.
Response will be evaluated by bone marrow biopsy after 4 cycles of 5-azacitidine or prior to HCT whichever comes first. Due to the very high risk of progression to AML or death in this patient population, the HCT will be done as soon as possible.
The patients may have additional cycles of 5-azacitidine per standard hematology practice until scheduled for transplant or until progression of disease.
All patients will be followed until time to progression of MDS, AML or death or a maximum of 1 year. For patients that are transplanted, follow up will be to one year post-transplant."
1811301|NCT00660413|Device|TOF-Watch SX (Acceleromyography)|Randomization of AMG to dominant or non-dominant arm. MMG at contralateral arm.
1811302|NCT00660426|Drug|Oxaliplatin|
1811303|NCT00660426|Drug|Gemcitabine|
1811304|NCT00660426|Drug|Capecitabine|
1811305|NCT00660439|Behavioral|Narrative Exposure Therapy|"Psychological treatment, with narration of positive and traumatic events in patients history, including in vivo exposure of traumatic events. The narrative is written down by the therapist."
1811306|NCT00660452|Drug|Staloral|Sublingual immunotherapy with Staloral dust mites solution
1811307|NCT00660478|Device|Endeavor|Comparison of two different drug eluting coronary stents
1811308|NCT00660478|Device|Cypher Select|Comparison of two different drug eluting coronary stents
1811309|NCT00660491|Other|exercise training|moderate intensity exercise group, and high intensity exercise group
1811310|NCT00660504|Drug|Amrubicin Hydrochloride|Amrubicin Hydrochloride combined with cisplatin
1811311|NCT00660504|Drug|Etoposide-Cisplatin combined chemotherapy|combined chemotherapy
1811312|NCT00660517|Drug|MP29-02|azelastine HCl 548 mcg / fluticasone propionate 200 mcg nasal spray one spray per nostril twice a day
1811313|NCT00660517|Drug|azelastine Hcl|azelastine Hcl nasal spray one spray per nostril two times a day
1811314|NCT00660517|Drug|fluticasone propionate|fluticasone propionate 200 mcg nasal spray one spray per nostril two times a day
1811315|NCT00660517|Drug|placebo|placebo nasal spray one spray per nostril two times a day
1811318|NCT00660543|Drug|Gadolinium|Given IV
1811319|NCT00660543|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
1811320|NCT00660543|Other|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE MRI
1811321|NCT00660543|Other|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC MRI
1811324|NCT00660582|Drug|Cetuximab (Erbitux)|500 mg/m² every second week, intravenous infusion, 8 cycles
1811325|NCT00660582|Drug|Oxaliplatin (Eloxatin) + Fluorouracil + folinic acid|Given in combination day 1 and 2, every second week, 8 cycles
1811326|NCT00660595|Drug|Quetiapine|Oral administration
1811327|NCT00660595|Drug|Risperidone|Oral administration
1811328|NCT00660621|Drug|Temozolomide and Bevacizumab|"Between 14 and 28 days after surgery, all subjects will begin a standard course of post-operative limited field radiation therapy to the tumor site and a surrounding margin with concomitant temozolomide at a daily dose of 75 mg/m2 (7 days/week).
No later than 45 days after date of completion of radiation therapy, all subjects will begin dose dense temozolomide at dose of 150 mg/m2 on Days 1-7 and 15-21 of a 28 day cycle with concomitant bevacizumab 10mg/kg administered intravenously every other week."
1811329|NCT00660634|Procedure|Endovascular Revascularization|Angioplasty/Stenting of femoro-popliteal lesions
1811330|NCT00660647|Drug|Adalimumab|Adalimumab injection 0.8 ml (40 mg) s.c. every second week in up to 2 years
1811331|NCT00660647|Drug|Placebo|Saline injection 0.9%, 0.8 ml s.c. every second week up to 2 years
1811332|NCT00660660|Drug|Esomeprazole|Nexium 20 mg administered once daily as 22.3 mg of esomeprazole magnesium hydrate
1811333|NCT00660660|Drug|Placebo|once daily
1811334|NCT00660673|Drug|Levodopa-carbidopa intestinal gel|should be kept within a range of 0.5-10 ml/hour (10-200 mg levodopa/hour) and is usually 2-6 ml/hour (40-120 mg levodopa/hour);
1811335|NCT00660673|Device|CADD-Legacy® 1400 ambulatory infusion pump|pump
1811336|NCT00660686|Behavioral|Resistance Exercise|60 minute sessions 3 times a week of moderate-vigorous lower and upper body free-weight strength training plus impact training (jumps). Two of the three sessions are conducted in a supervised setting at a university fitness facility and the third session is a modified version of the exercise program performed at home. Participants are in the exercise program for 12 months
1811337|NCT00660686|Behavioral|Flexibility Training|60 minute session 3 times a week focusing on whole body flexibility (stretching) and relaxation (progressive neuromuscular relaxation, focused breathing) exercises. Exercises are selected to be non-weight bearing and require minimal muscle strength in order to provide a contrast to the intervention arm. Two sessions are conducted in a supervised setting at a university fitness center and the third is a home-based version of the program performed at home.
1811338|NCT00660699|Drug|Gemcitabine|
1811339|NCT00660699|Drug|Docetaxel|
1811340|NCT00660699|Radiation|Radiation|
1811341|NCT00661180|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients will receive Bay 43-9006 400 mg po twice daily in a continuous, uninterrupted schedule. Treatment will continue until there is objective evidence of disease progression, or until evidence of toxicities that are unacceptable and thought to be related to study drug, which requires discontinuation of drug, or due to withdrawn patient consent.
1811342|NCT00661193|Drug|carboplatin|given IV
1811343|NCT00661193|Drug|erlotinib hydrochloride|given orally
1811344|NCT00661193|Drug|paclitaxel|given IV
1811345|NCT00661206|Drug|Clopidogrel|Patients on clopidogrel therapy at 6 months after implantation of a drug-eluting stent will be randomized to an additional 6 month period of clopidogrel 75mg per day
1811346|NCT00661206|Drug|Placebo|Patients randomized in this group will receive placebo for 6 months.
1811347|NCT00661219|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 (vardenafil) will be supplied as 5 mg tablets, 10 mg tablets, and 20 mg tablets.
1811348|NCT00661219|Drug|Placebo|Identical placebo will be matched for each vardenafil dosage form and will be indistinguishable from active treatment.
1811349|NCT00661245|Device|TOGA|Transoral Gastroplasty (TOGA®) System for gastric stapling.
1811350|NCT00661245|Device|Control|The control device (bougie dilator) is a FDA-cleared (Class II) device.
1811351|NCT00661258|Behavioral|Electronic drug monitoring feedback data|All patients were given electronic drug monitors that can monitor pill-taking behavior. In the intervention arm, patients and their attending doctors were given the electronic drug monitoring data on pill bottle openings at each monthly visit for use in adherence counseling sessions. Control arm patients were not given their electronic drug monitoring feedback data and their counseling sessions were based on self-reported adherence, as per standard of care in Dali.
1811354|NCT00661297|Drug|Levitra (Vardenafil, BAY38-9456)|10 mg Vardenafil to be taken 1 h prior to sexual attempt
1811355|NCT00661297|Drug|Placebo|Matching placebo
1811356|NCT00661310|Other|Drug review 80+ -To reduce usage of hospital care|drug review performed by multiprofessional team, including clinical pharmacist, in order to optimize drug therapy and reduce usage of hospital care. Also patient education and follow-up
1811357|NCT00661336|Drug|buthionine sulfoximine|
1811358|NCT00661336|Drug|melphalan|
1811359|NCT00661336|Genetic|microarray analysis|
1811360|NCT00661336|Other|high performance liquid chromatography|
1811361|NCT00661336|Other|laboratory biomarker analysis|
1811362|NCT00661336|Other|pharmacological study|
1811363|NCT00661336|Procedure|biopsy|
1811364|NCT00661349|Drug|Lopinavir/ritonavir|2 ITIAN (o 1 ITIAN+TDF)+ lopinavir/ritonavir, 2 tablet 200/50 mg to 12 hours
1811365|NCT00661349|Drug|Nevirapine|2 ITIAN (o 1 ITIAN+TDF)+ nevirapine, 2 tablet 200/50 mg to 12 hours
1811366|NCT00661362|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
1811367|NCT00661362|Drug|Placebo|oral tablet, once daily for 24 weeks
1811368|NCT00661362|Drug|Metformin|oral tablet, once daily for 24 weeks
1811369|NCT00661375|Drug|Nexavar (Sorafenib, BAY43-9006)|BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
1811370|NCT00661388|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
1811452|NCT00661947|Other|Dr Pepper sweetened with sucrose or high fructose corn syrup|Comparison of different formulations of fructose.
1816794|NCT00699049|Drug|Alpha blocker|oral
1811371|NCT00661401|Biological|gammaglobulin|They were administered a polyvalent, pasteurized liquid immune globulin subcutaneously (human 16% Beriglobin ®, Germany) with doses ranging from 57 to 132 mg/kg/week in order to maintain the same dosage they received by intravenous route monthly previous to this protocol. After a wash-out period (15 weeks) of the subcutaneous immunoglobulin administration, blood was collected every 4 weeks immediately before infusions. The infusions were administered using battery-powered ambulatory syringe drivers together with 10 or 20 ml syringe and infusions sets according to a pre-defined protocol (Gardulf et al, 2006).
1988432|NCT02830724|Biological|Anti-hCD70 CAR PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-hCD70CAR PBL cells and high dose aldesleukin. On day 0,cells will be infused intravenously on the Patient Care Unit over 20- 30 minutes.
1811375|NCT00661440|Drug|Neramexane mesylate|2 double-blind, cross-over treatment periods of 7 weeks separated by a wash-out phase, up to 75 mg Neramexane mesylate per day
1811376|NCT00661453|Drug|Valproic Acid and Levocarnitine|Drug: Valproic Acid and Levocarnitine; syrup; dosage is by weight
1811377|NCT00661466|Drug|Bupivacaine Collagen Sponge|
1811378|NCT00661466|Drug|Placebo|placebo
1811379|NCT00661479|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1.
1811380|NCT00661479|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1.
1811381|NCT00661479|Drug|100 µg Brimonidine Tartrate Implant|100 µg brimonidine tartrate implant in the study eye on Day 1.
1811382|NCT00661479|Other|Sham (no implant)|Sham in the fellow eye on Day 1.
1811383|NCT00661492|Drug|cetuximab|Erbitux (cetuximab) IV over 2 hours (loading dose) on Day 1 (Cycle 1 only), followed by Erbitux (cetuximab) IV over 1 hour weekly thereafter
1811384|NCT00661492|Drug|Mitoxantrone|Novantrone (mitoxantrone) IV Day 1 + Prednisone QD for ten (10) 21-day cycles Standard androgen deprivation therapy (ADT) will be continued in all patients who enter study on LHRH agonists
1811385|NCT00661505|Drug|methoxy polyethylene glycol-epoetin beta|120, 200 or 360 micrograms iv every 4 weeks (starting dose)
1811386|NCT00661531|Drug|Estrace|Estrace 10 mg three times daily will be administered for 3 months.
1811387|NCT00661531|Drug|Anastrozole|After 3 months of estrace, patients who do not have evidence of disease progression will then be switched to received Anastrozole 1 mg daily as long as their disease benefits from this treatment
1811388|NCT00661544|Drug|Arsenic Trioxide|Dose Level 1: None; Dose Level 2: 0.15 mg/kg days Intravenous (IV) Days -9 to -3; Dose Level 3: 0.25 mg/kg days IV Days -9 to -3.
1811389|NCT00661544|Drug|Melphalan|Dose Levels 1, 2, & 3: 100 mg/m2 IV Days -4, -3.
1811390|NCT00661544|Drug|Ascorbic Acid|Dose Levels 1, 2, & 3: 1000 mg IV Days -9 to -3.
1811392|NCT00661570|Device|Provox Vega voice prosthesis (20 Fr)|The current Provox2 voice prosthesis of laryngectomized patients will, when the patient comes in for a change, be replaced with a new, next generation Provox Vega voice prosthesis and insertion system
1811393|NCT00661583|Drug|Ranibizumab|0.5mg of ranibizumab intravitreally injected after surgery and at 1 month if needed
1811394|NCT00661583|Drug|Ranibizumab and MMC|Combination ranibizumab 0.5mg intravitreally injected and MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy
1811395|NCT00661583|Drug|MMC|MMC (0.4 mg/ml for 2 min) in eyes after trabeculectomy.
1811396|NCT00661596|Drug|Levitra (Vardenafil, BAY38-9456)|5 mg, 10 mg and 20 mg one hour prior to sexual intercourse
1811397|NCT00661596|Drug|Placebo|Matching placebo
1811398|NCT00661609|Drug|AZD4877|Intravenous (IV)25mg/weekly
1811399|NCT00661622|Drug|GM-CSF|2,000 mcg injected into the liver every 4 weeks alternating between right or left lobe when tumors present throughout liver.
1811400|NCT00661622|Procedure|Embolization|A catheter will be introduced to one of the hepatic arteries by way of the femoral artery (groin) to allow injection of GM-CSF in combination with ethiodized oil and gelatin sponge providing a temporary blockage of the blood supply from the hepatic (liver) artery
1811401|NCT00661635|Drug|placebo|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, placebo twice daily (BID) on Days 2 to 5
1811402|NCT00661635|Drug|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg once daily (QD)on Days 2 to 5.
1811403|NCT00661635|Drug|valdecoxib|valdecoxib 40 mg by mouth within 8 hours after the end of surgery, followed by a second dose of valdecoxib 20 mg within 1 to 12 hours (or by midnight on the Day 1, whichever was earlier); then, valdecoxib 20 mg twice daily (BID) on Days 2 to 5.
1811405|NCT00661661|Drug|CP-690,550|5 mg BID up to 10 mg BID until launch
1811406|NCT00661674|Drug|Palonosetron|"Over 3 study visits, patients will receive one of the following treatment regimens:
Placebo saline IV and sugar pill
0.75 mg Palonosetron IV and sugar pill
0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
1811407|NCT00661674|Drug|Hydroxyzine|"Over 3 study visits, patients will receive one of the following treatment regimens:
Placebo saline IV and sugar pill
0.75 mg Palonosetron IV and sugar pill
0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
1811408|NCT00661674|Other|Placebo|"Over 3 study visits, patients will receive one of the following treatment regimens:
Placebo saline IV and sugar pill
0.75 mg Palonosetron IV and sugar pill
0.75 mg Palonosetron IV and 100 mg hydroxyzine PO"
1811409|NCT00661687|Device|Currently Marketed PureVision Contact Lens.|Contact lens for continuous wear
1811410|NCT00661687|Device|Alternate Design of the PureVision Contact Lens.|Contact lens for continuous wear
1811411|NCT00661700|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg Vardenafil or down to 5mg Vardenafil followed by 14 weeks treatment at preferred dose.
1811641|NCT00663117|Drug|Naltrexone-HCl|naltrexone 4.5 mg
1811412|NCT00661700|Drug|Placebo|10mg placebo for 4 weeks followed by an 8 week titration period when subjects may be titrated up to 20mg placebo or down to 5mg placebo followed by 14 weeks placebo at preferred dose
1811413|NCT00661713|Biological|rMenB+OMV NZ|
1811414|NCT00661713|Biological|Placebo|
1811415|NCT00661726|Drug|Decitabine (USAN, INN)|Participants will receive 0.2 mg/kg of decitabine subcutaneously twice a week for 12 weeks. The dose will be reduced for toxicities as needed. The maximum dose of decitabine to be given will be 0.2 mg/kg.
1811416|NCT00661739|Drug|Bendamustine|Dose-level Bendamustine(mg/m²): I:50; II:60; III:60; IV:70; V:70 Dose-level Paclitaxel (mg/m²): I:60; II:60; III:80; IV:80; V:90 Treatment will be given on day 1,8,15 and repeated on day 29. When the recommended dose has been determined a total of 48 pts will be treated at this dose level.
1811417|NCT00661752|Device|quarter-time stress scans reconstructed by WBR (4SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of quarter-time WBR stress with stress studies generated via FBP and half-time WBR
1811418|NCT00661752|Device|quarter-time rest scans reconstructed by WBR (6/8/10 SPS) - Xpress3.Cardiac|Comparison of the diagnostic quality of 6 SPS quarter-time rest acquisitions with FBP and half-time WBR rest studies; simulated 8 SPS and 10 SPS quarter-time rest acquisitions are also compared to FBP and half-time WBR rest studies.
1811419|NCT00661765|Drug|varenicline tartrate|Single dose of 2.0 mg oral Chantix (varenicline) immediate release tablet formulation
1811420|NCT00661765|Drug|varenicline free base|A single 2.0 mg dose of varenicline transdermal delivery system applied to the skin for a 24 hour period.
1811421|NCT00661778|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
1811422|NCT00661778|Drug|Cisplatin|Bevacizumab was supplied as a sterile liquid in glass vials.
1811423|NCT00661778|Drug|Docetaxel|Bevacizumab was supplied as a sterile liquid in glass vials.
1811424|NCT00661791|Behavioral|Massage therapy without exercise|Infants will receive massage twice a day; 15 minutes each.
1811425|NCT00661791|Behavioral|Massage therapy with exercise|Infants will receive massage with exercise twice a day; 15 minutes each.
1811426|NCT00661817|Behavioral|Lifestyle Modification Program|"Participants will receive a behavior change prescription and skills training, offered via the Internet or through a combination of tailored print materials and an interactive voice response system, together with support strategies to enhance the intensity of the interpersonal and social-environmental support."
1811427|NCT00661817|Behavioral|Usual Care and Reading Materials|"Participants in this group will receive usual medical care provided by their own primary care providers. They will also receive the NHLBI's Aim for a Healthy Weight brochure at the baseline study visit and again at the beginning of Year 2."
1811428|NCT00661830|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 body surface i.v. first cycle at day 1, 8, 15, 22, 29, 36, 43. Next cycles at day 1, 8, 15.
1811429|NCT00661830|Drug|Placebo|Placebo
1811430|NCT00661830|Drug|Sorafenib|Sorafenib 400 mg bid orally continuously
1811431|NCT00661843|Other|Integrated Yoga style practice|Intervention constitutes of 2 supervised yoga style classes per week incorporating gentle postures,relaxation and meditation sequences. In addition daily home based sessions of yogic relaxation, and meditation a an audio CD
1811432|NCT00661856|Dietary Supplement|Soy protein|25g of Soy protein with or with out 90mg of isoflavones ones a day given for a period of 24 months
1811433|NCT00661869|Other|Wellness Program|36 weeks of educational and supportive interventions
1811434|NCT00661882|Other|medical chart review|"Medical information, called protected health information (PHI), which includes demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history will be accessed from the subject's medical record."
1811435|NCT00661882|Other|questionnaire administration|Provide or complete personal information about themselves, their medical history, their diet and lifestyle habits, any past or current environmental exposures and to re-create their family tree for any cancers that have occurred in any of their family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, age of death) will be recorded. This information will be collected by whichever method they prefer; completing the questionnaires on hardcopy (to then be entered into the PCCR by a data manager) or by logging on to the PCCR website to complete the questionnaires by obtaining a user id and password to enter their information directly into the PCCR. Study participants who are in the EDRN project are required to complete the questionnaires on hardcopy (to then be entered into the PCCR by a data manager).
1811436|NCT00661882|Other|study of socioeconomic and demographic variables|Share the information they provided with the PCCR research collaborators. This national group has formed the PCCR and is dedicated to pooling their efforts against pancreatic cancer.
1811437|NCT00661882|Procedure|biopsy|Release a portion of pancreatic tissue, tumor tissue and/or metastatic pancreatic cancer tissue and/or paraffin embedded tissue that has already been collected and saved from their previous surgery or biopsy for storage in the UNMC Solid Tumor Bank for future studies done here or at collaborating institutions. All studies will be proposed in future IRB submissions.
1811438|NCT00661895|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg tablets
1811439|NCT00661895|Drug|Lisinopril|Lisinopril 5mg Tablet, 10 mg tablet, 20 mg tablet
1811440|NCT00661895|Drug|Lisinopril and Hydrochlorothiazide|L 10 mg and H 12.5 mg tablets, L 20 mg and H 12.5 mg tablets, L 20 mg and H 25 mg tablets
1811441|NCT00661895|Drug|Nifedipine XL|30 mg extended release tablets, 60 mg extended release tablets
1811442|NCT00661895|Drug|Metoprolol tartrate|50 mg tablets & 100 mg tablets
1811443|NCT00661895|Drug|Atenolol|50 mg tablet
1811444|NCT00661895|Drug|Valsartan|80 mg tablets & 160 mg tablet
1811445|NCT00661895|Drug|Doxazosin|4 mg tablets
1811446|NCT00661895|Drug|Clonidine|0.2 mg tablets
1811447|NCT00661895|Drug|Hydralazine|50 mg tablets
1811448|NCT00661895|Drug|Metoprolol succinate|50 mg tablet & 100 mg tablet
1811449|NCT00661895|Drug|Amlodipine|5 mg tablets & 10 mg tablets
1811450|NCT00661921|Biological|AMG 108|IL-1 inhibitor, subcutaneous injection given every 2 weeks for the duration of the trial. Doses include 150 mg, 75mg, and 40 mg.
1811451|NCT00661921|Biological|Placebo|AMG 108 volume matching placebo
1811642|NCT00663117|Drug|Placebo|Placebo
1811453|NCT00661960|Drug|raltegravir|400mg tablet twice daily by mouth for nine months
1811454|NCT00661960|Drug|efavirenz|600mg capsule once daily by mouth without regard to food
1811455|NCT00661973|Drug|budesonide|inhaled budesonide (turbohaler) 400 micrograms twice a day for 4 weeks
1811456|NCT00661986|Dietary Supplement|dark chocolate 6 g/day|dark chocolate 6 g/day
1811457|NCT00661986|Dietary Supplement|dark chocolate 25 g/day|dark chocolate 25 g/day
1811458|NCT00661999|Biological|darbepoetin alfa|Given by injection
1811459|NCT00661999|Dietary Supplement|ferrous sulfate|Given by mouth
1811460|NCT00661999|Drug|sodium ferric gluconate complex in sucrose|Given by IV
1811461|NCT00661999|Other|placebo|Given by mouth
1811462|NCT00662012|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days for less responsive; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
1811463|NCT00662025|Drug|Capecitabine|Capecitabine 1000 mg/m2, twice daily, for 2 consecutive weeks, followed by a 1-week rest period and given as 3-week cycles
1811464|NCT00662025|Drug|Sunitinib|Sunitinib 37.5 mg daily, continuous dosing
1811465|NCT00662038|Drug|pirfenidone|Pirfenidone, 2403 mg/d, administered as 801-mg doses, three times daily.
1811466|NCT00662077|Drug|Ibandronate|Ibandronate endovenous 3 mg every 3 months
1811467|NCT00662077|Behavioral|Lifestyle modifications|Lifestyle modifications: counseling every 3 months
1811468|NCT00662103|Behavioral|exercise intervention|"Arm I (progressive, aerobic exercise program): Patients undergo aerobic exercise training over approximately 45 minutes (not including warm-up or cool-down exercises) 3 days a week for 18 months.
Arm II (progressive, resistance exercise program): Patients undergo resistance exercise training 3 days a week for 18 months."
1811469|NCT00662103|Other|laboratory biomarker analysis|All biomarkers will be measured from urine, blood and plasma obtained from participants by the Oregon Health & Science University (OHSU) General Clinical Research Center (GCRC). Upon exit from the study we will confirm the presence/absence of metastatic disease, via verbal verification by the subject, in order to ensure that biomarkers were primarily reflective of bone turnover changes and not to metastases.
1811470|NCT00662103|Other|questionnaire administration|Patients complete questionnaires at baseline and periodically during the study to assess demographic (i.e., age, income) and disease-specific (i.e., stage, treatment) variables, self-report mental and physical function, presence of chronic medical conditions, symptoms, fatigue, exercise outside the study exercise intervention, dietary intake, and psychosocial function.
1811471|NCT00662103|Other|survey administration|Administered at measured at baseline, 3, 6, 12, and 18 months
1811472|NCT00662103|Procedure|assessment of therapy complications|Follow-up every 6 months (measured at baseline, 3, 6, 12, and 18 months )
1811473|NCT00662103|Procedure|fatigue assessment and management|The Schwartz Cancer Fatigue (SCF) scale, a 6-item scale that specifically assesses the level of subjective fatigue that the participant is currently experiencing. The SCF has been used to measure fatigue in previous exercise studies. The Piper Fatigue Scale (PFS) consists of 22 items and four subscales: behavioral/severity, affective meaning, sensory and cognitive/mood. The scale has been shown to detect reductions in fatigue in cancer patients undergoing behavioral interventions to reduce fatigue, including exercise. Responses are averaged for subscale and total scores with higher scores indicating more fatigue. The PFS has been used to measure fatigue in previous studies of illness and/or medical treatments. 15 minute survey
1811474|NCT00662103|Procedure|management of therapy complications|An interim safety/efficacy review will occur after the first half of enrolled participants completes their 3 month testing appointment (or after 3 months of exercise). The interim safety review will be overseen by OHSU NCI-designated Cancer Institute, while the efficacy review will be conducted by an independent monitor, Dr. George Knafl, a biostatistician in the OHSU School of Nursing, who is not a member of the study personnel.
1811475|NCT00662103|Procedure|psychosocial assessment and care|We will include a 6-item measure of self-efficacy for exercise that has been validated in adults (Nigg, 2002) and has been used by Dr. Bennett (Co-I) in current work in cancer survivors. 5 min. survey
1811476|NCT00662116|Drug|alagebrium|200 mg (two 100 mg tablets) two times daily for 24 weeks
1811477|NCT00662116|Drug|placebo|placebo tablets - two tablets taken twice daily
1811478|NCT00662129|Biological|bevacizumab|
1811479|NCT00662129|Drug|gemcitabine hydrochloride|
1811480|NCT00662129|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1811481|NCT00662142|Dietary Supplement|docosahexaenoic acid|DHA 400 mg/day (200mg twice daily), vs DHA 1200 mg/day (400 mg three times daily), vs placebo; 1:1:1 ratio
1811482|NCT00662155|Drug|Zolpidem|sedative-hypnotic
1811483|NCT00662155|Drug|Placebos|Placebo
1811484|NCT00662207|Device|Vibrator|A vibrator will be applied to the patient's bottom to determine if it will induce a bladder contraction
1811485|NCT00662207|Procedure|Anal dilator|A balloon will be used for anal dilation to determine if it will result in relaxation of the pelvic floor and urethral sphincter. An anal dilator is being conduced with the balloon
1811486|NCT00662220|Drug|ribavirin|25-29 mg/kg/day
1811487|NCT00662220|Drug|ribavirin|12-15 mg/kg/day
1811488|NCT00662233|Drug|cyclophosphamide|
1811489|NCT00662233|Drug|doxorubicin hydrochloride|
1811490|NCT00662233|Drug|etoposide|
1811491|NCT00662233|Drug|ifosfamide|
1811492|NCT00662233|Drug|vincristine sulfate|
1811493|NCT00662233|Procedure|adjuvant therapy|
1811494|NCT00662233|Procedure|neoadjuvant therapy|
1811495|NCT00662233|Procedure|therapeutic conventional surgery|
1811496|NCT00662233|Radiation|brachytherapy|
1811497|NCT00662233|Radiation|intraoperative radiation therapy|
1811498|NCT00662233|Radiation|radiation therapy|
1811732|NCT00663884|Drug|Voglibose|voglibose 0.2mg three times a day before a meal
1811500|NCT00662259|Drug|Alprazolam (Xanax)|Drug dose will be fixed across patients: alprazolam 0.5 mg b.i.d escalating to 1.0 mg b.i.d. The treatment duration will be approximately 28 days (4 weeks).
1811501|NCT00662259|Drug|Placebo|Placebo, bid, p.o. for 28 +/- 2 days.
1811502|NCT00662272|Biological|Fluzone vaccine with JVRS-100 adjuvant|One vaccination on Day 0 with Fluzone vaccine at 22.5µg mixed with JVRS-100 adjuvant at one of four dose levels (7.5µg, 25µg, 75µg, 225µg) given by IM injection in the upper deltoid.
1811503|NCT00662272|Biological|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 22.5µg given by IM injection in the upper deltoid.
1811504|NCT00662272|Biological|Fluzone vaccine|One vaccination on Day 0 with Fluzone vaccine at 45µg given by IM injection in the upper deltoid.
1811505|NCT00662285|Dietary Supplement|Iron supplement: Niferex 100 mg|A: 100 mg pr day in 8 days
1811506|NCT00662298|Drug|prednisolone|40mg of prednisolone once a day for 14 days
1811507|NCT00662311|Drug|vorinostat|Given PO
1811508|NCT00662311|Drug|paclitaxel|Given IV
1811509|NCT00662311|Radiation|radiation therapy|Undergo radiation therapy
1811510|NCT00662324|Behavioral|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have taken part in clinical trials and other caregivers. This focus group will be audio recorded.
During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would have been useful to the patient you care for in his/her experience in a clinical trial.
The focus group to last from 60 to 90 minutes."
1811511|NCT00662324|Behavioral|focus groups|"Focus group with MSKCC patients with lung, breast and prostate cancer who have not taken part in clinical trials and other caregivers. This focus group will be audio recorded.
During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful if the patient you care for were ever to take part in a clinical trial sometime in the future.
We expect the focus group to last from 60 to 90 minutes."
1811512|NCT00662324|Behavioral|focus groups|"MSKCC clinicians who work with lung, breast and prostate cancer patients. This focus group will be audio recorded.
During the focus group, you will discuss a Question Prompt List that will be handed out to you. You will be asked about what you think of it and if you think it would be useful to your patients who take part in clinical trials.
Expect the focus group to last from 60 to 90 minutes."
1811513|NCT00662337|Drug|Diphenhydramine hydrochloride|After a ten-hour fast and a one-hour fluid restriction prior to each dosing period, subjects received supervised dosing of their first 25 mg treatment with approximately eight ounces of water. Following a seven-day washout, the comparison treatment was administered according to thye same procedure.
1811514|NCT00662350|Device|The Wallterm™ System|The Wallterm™ System is intended to ablate prostatic glandular and stromal tissue to relieve moderate to severe symptoms of outflow obstruction secondary to benign prostatic hyperplasia (BPH).
1811515|NCT00662363|Drug|Lubiprostone|24 µg po BID given with meals for 6 days
1811516|NCT00662363|Drug|Senna|2 tabs daily for 6 days
1811517|NCT00662376|Dietary Supplement|PreOP Booster (oral nutritional supplement, food for special medical purposes)|3 x 1 dosages of oral nutritional supplement / placebo are given prior to surgery: 2 the evening before the day of operation and 1 dosage 3-4 h before initiation of anaesthesia
1811518|NCT00662389|Device|Apsara Thermal Wand System|Single radiofrequency cycle to dermal tissue
1811520|NCT00662415|Device|mirror-box treatment|15 minutes daily for 4 weeks
1811521|NCT00662415|Behavioral|observation|observation
1811522|NCT00662428|Other|Symptom based discharge management|Depressive symptoms of patients are weekly assessed by Beck Depression Inventory (BDI II). Patients are discharged when BDI-score is under 20 points. Patients are treated in the same hospital for two more weeks as outpatients before being referred to outpatient care (general practitioner or specialist).
1811523|NCT00662428|Other|Treatment as usual|Treatment as usual is the usual stationary depression treatment which consists of a combination of several psychopharmacological and psychotherapeutical treatments. Duration of treatment is varying widely.
1811524|NCT00662441|Drug|Levitra (Vardenafil, BAY38-9456)|10mg taken 1 hours before sexual intercourse
1811525|NCT00662454|Drug|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
1811526|NCT00662454|Drug|ethinyl estradiol / levonorgestrel|Take one tablet daily of 20 mcg ethinyl estradiol/100 mcg levonorgestrel for 21 days plus 7 days of placebo tablets, repeat for two months total duration.
1811527|NCT00662467|Drug|aspirin + clopidogrel|Dual therapy
1811528|NCT00662467|Drug|aspirin + clopidogrel + warfarin|Triple therapy
1811529|NCT00662480|Procedure|Screening for hypertension, lower limb atherosclerosis and abdominal aortic aneurysm|Invited to vascular screening
1811530|NCT00662493|Behavioral|Motor control retraining program|Specific retraining of VMO activation in a low-load situation,and progressed to integrate more functional positions. Use of dual channel biofeedback was incorporated
1811531|NCT00662493|Behavioral|Quadriceps strengthening program|4 exercises focused on quadriceps strengthening commencing at a resistance of 60% 1 repetition maximum. Each exercise was performed for 3 sets of 10 repetitions
1811532|NCT00662506|Drug|Cediranib Maleate|Given PO
1811533|NCT00662506|Procedure|Diffusion Tensor Imaging|Undergo DTI
1811534|NCT00662506|Procedure|Diffusion Weighted Imaging|Undergo T1 weighted DCE-MRI
1811535|NCT00662506|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
1811536|NCT00662506|Radiation|Fludeoxyglucose F-18|Undergo 18 FDG PET
1811537|NCT00662506|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1811538|NCT00662506|Other|Laboratory Biomarker Analysis|Correlative studies
1811539|NCT00662506|Procedure|Perfusion Magnetic Resonance Imaging|Undergo PWI
1811540|NCT00662506|Procedure|Positron Emission Tomography|Undergo 18 F FDG-PET
1811541|NCT00662506|Drug|Temozolomide|Given PO
1811542|NCT00662519|Drug|Neulasta (Pegylated)|Subjects will receive 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
1811543|NCT00662519|Drug|Placebo|Placebo injections will be given in identical volumes in identical syringes in the identical subcutaneous manner. 6mg/dose given every 2 weeks for 12 weeks. Subjects less than 45kg will receive 100mcg/kg/dose every 2 weeks for 12 weeks.
1811544|NCT00662519|Dietary Supplement|Mixed Meal Tolerance Test (MMTT)|This is a 2 hour test to find out how much C-peptide is being produced. C-peptide is used to measure the insulin being made by the cells of the pancreas. Both groups will have this test performed.
1811545|NCT00662519|Other|Blood test|HbA1c is a blood test that measures the average blood sugar control and will be performed in both groups.
1811546|NCT00662519|Other|DNA Test|The HLA test looks at the different chromosomes (DNA) for diabetes and will be performed in both groups.
1811547|NCT00662532|Drug|Minocycline HCl|1mg microspheres for professional subgingival administration into periodontal pockets two times throughout the duration of the trial
1811548|NCT00662545|Drug|Entecavir with continued standard of care antiretroviral therapy|1 mg by mouth daily
1811549|NCT00662545|Drug|continued standard of care with tenofovir in addition to emtricitabine or lamivudine|continued standard of care with tenofovir in addition to emtricitabine or lamivudine
1811550|NCT00662558|Drug|celecoxib|200 mg capsules BID for 6 weeks
1811551|NCT00662558|Drug|tramadol HCL|50 mg capsules QID for 6 weeks
1811552|NCT00662571|Drug|acamprosate|acamprosate 333mg tabs, 2tabs 3times per day = 1998mg/day
1811553|NCT00662584|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|transcranial magnetic stimulation (TMS) at .5 HZ for 20s
1811554|NCT00662597|Drug|ASA404|
1811555|NCT00662597|Drug|Placebo|
1811556|NCT00662597|Drug|carboplatin|
1811557|NCT00662597|Drug|Paclitaxel|
1811558|NCT00662610|Drug|naproxcinod 375 mg -750 mg -1125 mg bid|naproxcinod 375 mg -750 mg -1125 mg bid
1811559|NCT00662610|Drug|naproxen 250 mg - 500mg -750 mg bid|naproxen 250 mg - 500mg -750 mg bid
1811560|NCT00662623|Behavioral|i-PAP|Internet Intervention based on wireless telemonitoring of CPAP data and patient-centered, collaborative care
1811561|NCT00662623|Behavioral|Usual Care (Standard Care)|Pre-determined clinic visits and telephone support
1811562|NCT00662636|Drug|dasatinib|Given orally
1811563|NCT00662636|Drug|lapatinib ditosylate|Given orally
1811564|NCT00662636|Other|pharmacological study|Correlative study (cohort II only)
1811565|NCT00662636|Other|laboratory biomarker analysis|Correlative study (cohort II only)
1811566|NCT00662649|Drug|Fingolimod 0.5 mg|Patients self-administered fingolimod 0.5 mg capsules orally once daily.
1811567|NCT00662649|Drug|Fingolimod 1.25 mg|Patients self-administered fingolimod 1.25 mg capsules orally once daily.
1811568|NCT00662662|Behavioral|Questionnaire|The questionnaire contains 18 questions and is estimated to take approximately 10-15 minutes to complete.
1811569|NCT00662675|Drug|Pancrease MT 10.5, or MT 21|Pancrease MT capsules for maximum dose of 10,000 lipase units / Kg / day
1811570|NCT00662675|Drug|Placebo for Pancrease MT 10.5 or MT 21|Capsules with Pancrease MT excipients without the active enzymes
1811571|NCT00662688|Drug|daltéparine|
1811572|NCT00662688|Drug|Chemotherapy at the investigator's discretion|
1811573|NCT00662701|Procedure|Catheter Ablation|RF ablation with complete circumferential ablation around the right and PVs, optional additional lines between the lower and upper PVs, and towards the mitral valve ring.
1811574|NCT00662701|Procedure|Surgical Ablation|Minimal invasive thoracoscopic surgery including isolation of the PVs by AtriCure and removal of the LAA.
1811575|NCT00662714|Drug|Repaglinide|oral; initial dose: 3x 0.5mg/d; 2 years
1811576|NCT00662714|Drug|short-acting Insulin (Actrapid)|initial dose: 3x 0.05E/kg/d, injected; 2 years
1811577|NCT00662727|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
1811578|NCT00662727|Device|Placebo|Placebo
1811579|NCT00662740|Drug|Tiotropium/Salmeterol QD|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule
1811580|NCT00662740|Drug|Placebo|Placebo Inhalation Powder, hard PE capsule / hard gelatine capsule
1811581|NCT00662740|Drug|Salmeterol|Salmeterol Inhalation Powder, hard PE capsule
1811582|NCT00662740|Drug|Tiotropium/Salmeterol QD+ Salmeterol|Tiotropium/Salmeterol Inhalation Powder, Hard Polyethylene Capsule, plus Salmeterol Inhalation Powder, hard PE capsule
1811583|NCT00662740|Drug|Tiotropium|Tiotropium
1811584|NCT00662753|Device|Home monitoring|Participants will receive a home blood pressure monitor and be taught how to use it. They will have an education session to review treatment goals, medications, diet and exercise. They will be asked to see their primary care provider at least every 3 months and the research nurse at 3, 6 and 12 months.
1811585|NCT00662753|Other|monitor & phone call|Participants will receive all of the same interventions of the home monitoring group plus they will receive scheduled telephone follow up by the research nurse
1811586|NCT00662766|Dietary Supplement|black currant seed press residue|Black currant seed press residue, baked into bread
1811587|NCT00662766|Dietary Supplement|Bread without black currant seed press residues|Same bread but without seeds
1811588|NCT00662766|Dietary Supplement|Baseline data|No supplement was administered.
1811589|NCT00662779|Drug|arformoterol|15 mcg arformoterol nebulizer
1811590|NCT00662779|Drug|formoterol|Formoterol 12 mcg/inhalation, dry powder inhaler
1811591|NCT00662779|Drug|placebo|placebo dry powder capsules ( lactose) and placebo normal saline for nebulization
1811592|NCT00662792|Drug|Tiotropium plus Salmeterol|
1811593|NCT00662792|Drug|Tiotropium|
1811594|NCT00662792|Drug|Salmeterol|
1811595|NCT00662805|Drug|Salmeterol/Fluticasone propionate|Open label, of Salmeterol/Fluticasone propionate (50/500 μg) twice daily via dry powder inhaler (DPI)
1811596|NCT00662818|Drug|Telcagepant|Telcagepant (MK-0974) (300 mg soft gel capsules or 280 mg tablets)
1811597|NCT00662818|Drug|Acetaminophen/Paracetamol|Acetaminophen/Paracetamol (500 mg X 2 dosage units)
1811598|NCT00662818|Drug|Placebo to Telcagepant|Placebo 300 mg soft gel capsules or placebo 280 mg tablet.
1811599|NCT00662818|Drug|Placebo to Acetaminophen/Paracetamol|Placebo to acetaminophen/paracetamol (500 mg X 2 dosage units)
1811600|NCT00662831|Drug|Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium.
1811601|NCT00662831|Drug|Placebo for Fragmin/ Dalteparin Sodium|Pre-filled syringes containing a single dose of placebo for 5000 IU Fragmin/ Dalteparin Sodium.
1811602|NCT00662844|Dietary Supplement|vitamin D3|Oral, one capsule daily of vitamin D3 (400IU, 800IU, 1600 IU, or 2400IU) plus calcium citrate (1-4 tablets) twice daily to reach a total calcium intake of 1000-1200 mg/day
1811603|NCT00662857|Drug|Technosphere® Insulin Inhalation Powder|TI Inhalation Powder, two 15 U cartridges
1811604|NCT00662857|Drug|Technosphere Insulin® Inhalation Powder|TI Inhalation Powder, one 30 U cartridge
1811605|NCT00662857|Drug|RAA Population|RAA Population: All subjects received a single 10 IU sc injection of insulin lispro.
1811606|NCT00662870|Biological|DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis vaccine)|0.5 mL, Intramuscular
1811607|NCT00662870|Biological|Pentacel: DTaP-IPV/Hib|0.5 mL, Intramuscular
1811608|NCT00662883|Drug|PMI-150 (intranasal ketamine HCl); mometasone furoate|"1 dose PMI-150 (intranasal ketamine HCl); day 1
mometasone furoate, daily; days 2-15
1 dose PMI-150 (intranasal ketamine HCl); day 15"
1811609|NCT00662896|Drug|naproxcinod 375 mg bid|naproxcinod 375 mg bid
1811610|NCT00662896|Drug|naproxcinod 750 mg bid|naproxcinod 750 mg bid
1811611|NCT00662896|Drug|naproxen 250 mg bid|naproxen 250 mg bid
1811612|NCT00662896|Drug|naproxen 500 mg bid|naproxen 500 mg bid
1811613|NCT00662896|Drug|ibuprofen 600 mg tid|ibuprofen 600 mg tid
1811614|NCT00662909|Drug|Mirabegron|Oral
1811615|NCT00662909|Drug|Placebo|Oral
1811616|NCT00662935|Procedure|setting-up of an electrode in deep brain|deep brain stimulation of the postero-inferoir hypothalamus
1811617|NCT00662948|Drug|Rituximab|375 mg/m2 every 8 weeks during 24 months
1811618|NCT00662948|Drug|Ibritumomab tiuxetan|One dose of 90Y Ibritumomab tiuxetan, 0,4 mCi/Kg
1811619|NCT00662961|Procedure|Periosteum|Periosteum fixation
1811620|NCT00662961|Procedure|Bone|Bone tunnel fixation
1811621|NCT00662974|Other|perineal massage with Wheat Germ Oil during the second stage of labor|30 ml of oil applied during labor
1811622|NCT00662974|Other|perineal massage with almond oil during the second stage of labor|30 ml of oil applied during labor
1811623|NCT00662987|Drug|7 days of amoxicillin|Received 7 days of amoxicillin (dosed 40mg/kg divided bid up to maximum daily dose of 800 mg)
1811624|NCT00662987|Drug|3 days of amoxcillin followed by 4 days of placebo|3 days of amoxicillin (40 mg/kg divided bid up to maximum daily dose of 800 mg) followed by placebo
1811625|NCT00663013|Other|Virtual Reality|Virtual reality (VR) gives patients an illusion of going into the 3-D computer generated environment/virtual world. During VR, the subject wears a head-mounted virtual reality helmet that positions two goggle-sized miniature LCD computer screens close to the subject's eyes. Position tracking devices keep the computer informed of changes in the patient's head location. An electro-magnetic head orientation device feeds the x, y, z coordinates of the patient's head to the computer, which can quickly change what the patient sees in virtual reality accordingly. The scenery in VR changes as the patient moves her head orientation (e.g., virtual objects in front of the patient in VR get closer as the patient, wearing the VR helmet, leans forward in the real world).
1811626|NCT00663026|Drug|bapineuzumab|5 mg bapineuzumab subcutaneous injection once per week for 6 months
1811627|NCT00663026|Drug|bapineuzumab|10 mg bapineuzumab subcutaneous injection once per week for 6 months
1811628|NCT00663026|Drug|placebo|Placebo subcutaneous injection once per week for 6 months
1811631|NCT00663052|Drug|Etanercept|ETN 50 mg QW + PBO QW for 12 weeks followed by ETN 50 mg QW for 12 weeks.
1811632|NCT00663052|Drug|Etanercept|ETN 50 mg BIW for 12 weeks folowed ETN 50 mg QW for 12 weeks.
1811633|NCT00663065|Drug|PAZ-417|
1811634|NCT00663078|Behavioral|Brief CBT Group therapy|CBT based therapy also expert patient programme
1811635|NCT00663091|Drug|Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
1811636|NCT00663091|Drug|WPP-201 Bacteriophage|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
1811637|NCT00663091|Drug|Bacteriophages|"WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing < 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants."
1811638|NCT00663104|Behavioral|exercise|exercise: 3 joint sessions/week for 12 months
1811639|NCT00663104|Behavioral|exercise + cimicifuga racemosa|exercise: 3 sessions/week for 12 months,cimicifuga racemosa (40 mg/d)
1811640|NCT00663104|Behavioral|wellness control, placebo|2x10 weeks with 1 session/week of low volume, low intensity wellness training over 12 months, placebo
1816795|NCT00699049|Drug|placebo|oral
1811643|NCT00663130|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10mg, taken orally within 1 hour prior to sexual intercourse
1811644|NCT00663130|Drug|Tadalafil|Tadalafil 10mg, taken orally within 1 hour prior to sexual intercourse
1811645|NCT00663143|Procedure|Stromal Cells Sample|Human Bone Marrow Stromal Cells will be obtained from 5 patients. Stromal cells will be obtained from subjects undergoing bone graft procedure to repair traumatic mandible fractures. Bone graft specimens will be obtained from the ileac crest. This will allow easy access to bone marrow specimen without additional pain or complications. A total of 5 ml of bone marrow will be obtained from each patient.
1811646|NCT00663156|Procedure|breast implants|patients will have breast augmentation using implants
1811647|NCT00663156|Procedure|Liposuction, fat grafting|Autologous fat will be harvested from the body (typically the abdomen or thighs) using syringe aspiration techniques and then infiltrated into the subcutaneous tissue around the breast as well as between the breast and the underlying musculature using blunt cannulas. These procedures will be done in an outpatient surgery setting in the Georgetown University Hospital under general anesthesia and sterile conditions.
1811648|NCT00663169|Biological|canakinumab|10 mg/kg intravenous infusion 250 mL over 2 hours.
1811649|NCT00663169|Drug|dexamethasone|12 mg intravenous infusion 50 mL over 30 minutes.
1811650|NCT00663169|Other|placebo matching canakinumab|5% glucose in water intravenous infusion.
1811651|NCT00663169|Other|placebo matching dexamethasone|Placebo intravenous infusion.
1811652|NCT00663182|Drug|Entecavir|Entecavir 0.5 mg/d
1811653|NCT00663195|Drug|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16 weeks
1811654|NCT00663208|Drug|Daclatasvir|Capsule, Oral, Approximately 182 days from initial dosing
1811655|NCT00663208|Drug|Placebo|Capsule, Oral, After 28 days from initial dosing and unblinding of the dose panel
1811656|NCT00663221|Dietary Supplement|Anthocyans, Calcium and Vitamin D|
1811657|NCT00663221|Dietary Supplement|placebo|
1811658|NCT00663234|Drug|Atorvastatin|10 mg to 20 mg atorvastatin taken orally once daily. Dosage is dependent on efficacy criteria.
1811659|NCT00663247|Device|Mesalazine|3 grams daily for 3 months
1811660|NCT00663247|Drug|Placebo|3 grams daily for 3 months
1811661|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once Daily, 104 weeks
1811662|NCT00663260|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once Daily, 104 weeks
1811663|NCT00663260|Drug|Placebo|Tablets, Oral, 0 mg, Once Daily, 104 weeks
1811664|NCT00663273|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
1811665|NCT00663286|Drug|IDP-110|Topical application for 12 weeks
1811666|NCT00663286|Drug|Clindamycin|Topical application for 12 weeks
1811667|NCT00663286|Drug|Benzoyl peroxide|Topical application for 12 weeks
1811668|NCT00663286|Drug|Vehicle|Topical application for 12 weeks
1811669|NCT00663299|Device|Endovascular Embolization Device|The TRUFILL DCS and TRUFILL DCS ORBIT Detachable Coils are each an embolic coil system that consists of a platinum detachable coil, a delivery system (delivery tube and coil introducer) and a syringe. Each system has been designed to deliver, position and detach embolic coils in order to embolize intracranial aneurysms
1811670|NCT00663312|Behavioral|e.g., Protein and calorie controlled diet; Self-hypnotic relaxation|Pilot description
1811671|NCT00663325|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
1811672|NCT00663338|Drug|Rotigotine|Rotigotine 9.0mg patch (equivalent to 4mg/24hr transdermal absorption) once daily during the treatment phase.
1811673|NCT00663351|Device|Reflection Ceramic-Ceramic Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
1811674|NCT00663351|Device|Reflection FSO V Total Hip Replacement|Intervention: all patients in study required (intervention) a total hip replacement, and were randomized to receive either the (Study Device)Reflection Ceramic Acetabular System or the(Control Device) Reflection FSO V (5 hole)acetabular system. Both arms received either a Synergy porous coated or Spectron EF stem.
1811675|NCT00663364|Drug|Physiogel AI Lotion, Physiogel Lotion|Physiogel AI Lotion and Physiogel Lotion is a cosmetic, applied twice daily to dry skin
1811677|NCT00663390|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in a small quantity, with abundantly rinse after use, during 21 days.
1811678|NCT00663403|Drug|Daptomycin|Daptomcyin 8 mg/kg infused intravenously every 48 hours
1811679|NCT00663416|Drug|NTx™-265: rhCG, then rEPO|"rhCG 10,000 IU, SC, on Day 1, 3, and 5 of study participation, then
rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
1811680|NCT00663416|Drug|Saline placebo|"Saline SC, on Day 1, 3, and 5 of study participation, then
Saline IV, on Day 7, 8, and 9 of study participation"
1811681|NCT00663429|Drug|Atiprimod|Oral, 14 days on / 14 days off; 30mg capsules
1811682|NCT00663442|Drug|OROS methylphenidate|18, 36, 54 mg
1811683|NCT00663455|Drug|Reduction of cyclosporine A (CSA)-dosing|Reduction of CSA-dosing over 4 months. Therapy control by safety parameters (serum creatinine, C2-monitoring, renal biopsy).
1811684|NCT00663481|Drug|CoFactor|
1811685|NCT00663481|Drug|Leucovorin|
1811686|NCT00663533|Device|Vas-X|mechanical vasectomy device
1811687|NCT00663559|Drug|Sunitinib|Sunitinib 50mg oral in the morning during 4 weeks with 2 weeks of break.
1811688|NCT00663585|Behavioral|Vipassana Meditation|12 day retreat where participants learn to meditate
1811689|NCT00663598|Drug|Levitra (Vardenafil, BAY38-9456)|Treatment according to US PI
1811690|NCT00663611|Drug|Norditropin|A polypeptide hormone of recombinant DNA origin.
1811691|NCT00663611|Drug|Placebo|
1811692|NCT00663624|Drug|aspart insulin|subcutaneous aspart insulin every 2 hours
1811730|NCT00663871|Dietary Supplement|Soybean Oil (Placebo)|Participants will take 2 grams of soybean oil supplements on a daily basis.
1811731|NCT00663884|Drug|Mitiglinide|mitiglinide 10mg three times a day before a meal
1811693|NCT00663624|Drug|Usual care as prescribed by the ED physicians.|Usual care can be oral anti-diabetic agents, subcutaneous insulin therapy or a combination of both. Subcutaneous insulin used for usual care could include NPH, 70/30 insulin, aspart insulin, regular insulin or insulin glargine
1811694|NCT00663637|Device|CAM (Complete Airway Management) Catheters|Prior to extubation, endotracheal tube lumen secretions are mechanically removed using CAM Rescue Cath followed by CAM Endotrach Cath.
1811695|NCT00663650|Procedure|Permanent Section Control|After surgical excision of the tumor, margins will be sent for permanent section pathologic control to determine if the tumor was completely excised
1811696|NCT00663650|Procedure|Frozen Section Control|After surgical excision of the tumor, tumor edges will be analyzed by frozen section at the time of surgery. If tumor margins are positive with the frozen section, additional tissue will be excised and analyzed again. This process will be repeated until all tissue edges are clear of tumor. Finally, the area of tumor excision will be surgically reconstructed.
1811697|NCT00663663|Behavioral|Telephone-Delivered Intervention 1|Intervention 1 will consist of eight 60-minute sessions conducted by phone over eight weeks. Intervention 1 will include: (1) education about the role of cognitions (particularly catastrophizing) and pain beliefs (including control) in chronic pain and adjustment; (2) instruction in how to identify negative thinking and cognitive distortions about pain; (3) instruction in thought-stopping and cognitive-restructuring techniques, including challenging negative thoughts and core beliefs about pain; (4) instruction in utilization of positive coping self-statements; (5) relaxation techniques; (6) activity pacing and scheduling; (7) coping with pain flare-ups; and (8) relapse prevention/maintenance of gains. Each intervention 1 session will include a brief relaxation exercise practiced over the phone.
1811698|NCT00663663|Behavioral|Telephone-Delivered Intervention 2|Intervention 2 will consist of eight 60-minute sessions conducted by phone over eight weeks (1 session/week on average), scheduled at times convenient for participants (including evenings and weekends if necessary). The sessions will cover a variety of topics, including the definition of chronic pain, the physiological processes underlying chronic pain, common pain-related conditions such as sleep disturbance, and the effects of chronic pain.
1811700|NCT00663702|Drug|Abatacept|Subcutaneous injection, 125 mg/mL, once weekly, 48 months
1811701|NCT00663715|Other|Observation of the Sciatic Nerve|Ultrasound will be used to determine the location of the Sciatic Nerve using a lateral mid-thigh approach.
1811702|NCT00663728|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1 hour prior to sexual intercourse
1811703|NCT00663728|Drug|Placebo|Matching placebo
1811704|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 2 weeks off) + CDDP (60 mg/m2 on Day 8) / 35 days / cycle
1811705|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (25 mg/m2 bid, 3weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days / cycle
1811706|NCT00663741|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib (400 mg bid) + S-1 (40 mg/m2 bid, 3 weeks on / 1 week off) + CDDP (75 mg/m2 on Day 1) / 28 days cycle
1811707|NCT00663754|Behavioral|Dissonance-based eating disorder prevention program|Participants will engage in verbal, written, and behavioral exercises in which they will critique the thin ideal. These exercises will be conducted in sessions and in homework activities. The exercises will aim to increase body image satisfaction by helping participants to think critically about the thin ideal and to discuss some of the problems associated with the pursuit of this ideal.
1811708|NCT00663754|Behavioral|Educational brochure|Participants will receive a mailed educational brochure about a healthy body image only.
1811709|NCT00663767|Drug|Placebo; oral|dose 1, dose 2
1811710|NCT00663767|Drug|Placebo; oral|dose 1
1811711|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels
1811712|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 1: multiple dose levels; dose 2
1811713|NCT00663767|Drug|Celecoxib, COX-2 inhibitor; oral|dose 1
1811714|NCT00663767|Drug|Placebo; oral|dose 2
1811715|NCT00663767|Drug|ARRY-371797, p38 inhibitor; oral|dose 2
1811716|NCT00663793|Drug|Acyline|300 mcg/kg
1811717|NCT00663793|Drug|Testosterone|"24 hours after acyline administration on Day 2 immediate release Testosterone (T) 300 mg po once (as a control), followed 24 hours later (Day 3) by external matrix fast release T 300 mg once, followed 24 hours later (Day 4) by external matrix slow release T 300 mg once, followed 96 hours later (Day 8) by immediate release T 600 mg, followed 24 hours later (Day 9) by external matrix fast release T 600 mg po once, followed 48 hours later (Day 11) by external matrix slow release T 600 mg once."
1811718|NCT00663793|Drug|Finasteride|1 mg PO once daily [day -2 to day 12) 14 days total
1811719|NCT00663806|Behavioral|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days and brochure about UTI
1811720|NCT00663806|Behavioral|Cipro XR (Ciprofloxacin, BAYQ3939)|Received Cipro XR (Ciprofloxacin, BAYQ3939) 500 mg once daily for 3 days; not given brochure about UTI
1811721|NCT00663819|Device|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement|Colorectal, coloanal, and ileoanal anastomotic staple line reinforcement with GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for circular stapler
1811722|NCT00663819|Procedure|Staple line without reinforcement|colorectal and coloanal anastomotic staple line without reinforcement
1811723|NCT00663832|Drug|LBH589 (i.v. panobinostat)|"i.v. LBH589 dose levels: 10, 15, or 20 mg/m2
i.v. docetaxel 75 or 60 mg/m2
oral prednisone 5mg bid.
LBH589 i.v. administered on days 1 and 8 in combination with docetaxel i.v. on day 1 and prednisone p.o 5mg bid every day of a 21-day cycle"
1811724|NCT00663845|Drug|Levitra (Vardenafil, BAY38-9456)|10mg Vardenafil taken orally 1h prior to sexual intercourse
1811725|NCT00663845|Drug|Placebo|Matching placebo
1811726|NCT00663858|Drug|Cetrorelix 78+78|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + 78 mg combining Week 26 (52 mg) and Week 28 (26 mg)
1811727|NCT00663858|Drug|Cetrorelix 78 + Placebo|Cetrorelix 78 mg combining Week 0 (52 mg) and Week 2 (26 mg) + Placebo on Week 26 and Week 28
1811728|NCT00663858|Other|Placebo|Placebo on Week 0, Week 2, Week 26 and Week 28
1811729|NCT00663871|Dietary Supplement|Fish Oil|Participants will take 2 grams (1400 mg EPA and DHA) of fish oil supplements on a daily basis.
1816796|NCT00699049|Drug|solifenacin|oral
1811733|NCT00663897|Drug|lansoprazole|lansoprazole, 30 mg, once daily for 14 days
1811734|NCT00663897|Drug|mosapride|mosapride, 5 mg, thrice daily for 14 days
1811735|NCT00663910|Drug|Aminolevulinic Acid|On Day 1, ALA will then be applied topically to the center of the tumor surface (at the location of its greatest diameter) in a standardized manner with great care not to include normal skin. The solution will be applied directly to the lesions by dabbing gently with a wet applicator tip. Enough solution will be applied to uniformly wet the exposed lesion surface. Once the initial application has dried, the ALA will be applied again in the same manner. The ALA will be left on for 2 hours under occlusion with Duoderm Extra Thin®.
1811736|NCT00663910|Procedure|biopsy|Then local anesthesia, lidocaine 1% with epinephrine 1:100,000, will be administered and before the tumor is excised by one of the Cleveland Clinic MOHS surgeons, a 2mm punch biopsy will be taken from the area where the ALA was previously applied. The punch biopsy will be full thickness, extending to the subcutaneous fat.
1811737|NCT00663910|Procedure|diagnostic imaging technique|Two hours after the amniolevlulenic acid was applied, the measurements of surface fluorescence will be repeated with the hand held dosimeter.
1811738|NCT00663910|Procedure|therapeutic conventional surgery|The non-melanoma skin cancer will be excised using the MOHS procedure.
1811739|NCT00663923|Procedure|photorefractive keratectomy (PRK)|comparison of PRK by cross-cylinder approach in one eye and conventional (single) method in the other eye for laser correction of astigmatism
1811740|NCT00663936|Drug|T-817MA|224 mg T-817 MA once daily
1811741|NCT00663936|Drug|Placebo|Placebo once daily
1811742|NCT00663949|Drug|Captopril|25 mg captopril tablet q8h
1811743|NCT00663949|Drug|Captopril + Pentoxifylline|patients takes captopril tablets 25 mg q8h and pentoxifylline 400 mg q8h
1811744|NCT00663962|Drug|Pregabalin|"PHASE 1 (N=3) Pregabalin 150mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op.
PHASE 2 (N=4) Pregabalin 300mg administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op."
1811745|NCT00663962|Drug|Placebo|An identical placebo administered one hour prior to surgery and 12 hours after surgery, then continued BID until day 7 post-op (N=8)
1811746|NCT00663975|Drug|DCI 1020|capsules (4,000 units of lipase) will be administered with meals and snacks
1811747|NCT00663988|Procedure|human transplantation|Allograft composite tissue transplantation. procedure. medication
1811748|NCT00664313|Drug|Linezolid|600 mg po daily for 112 doses (16 weeks)
1811749|NCT00664313|Drug|Placebo|Placebo given daily for 112 doses (16 weeks)
1811750|NCT00664326|Drug|Regorafenib (Stivarga, BAY73-4506)|Patients will be treated with BAY73-4506 160 mg po qd for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Patients will continue treatment with BAY73-4506 until disease progression, intolerable toxicity, or patient refusal to continue with the study or investigator decision to remove the patient from study.
1811751|NCT00664339|Biological|Flu Vaccine|Single dose of Flu vaccine by year (1)
1811752|NCT00664339|Other|Conventional medical therapy for heart failure|According with the international guidelines
1811753|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|"100µL of 300mM (8.46 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
1811754|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|"100µL of 600mM(16.93 mg/100μL) Juvidex will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
100µL of placebo will be injected intradermally into each cm2 of the other 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest."
1811755|NCT00664352|Drug|Mannose-6-Phosphate (Juvidex)|"300µL of 300mM (8.46 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
1811756|NCT00664352|Drug|Mannose-6-Phophate (Juvidex)|"300µL of 600mM (16.93 mg/100μL) Juvidex will be applied topically to one 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest.
300µL of placebo will be applied topically to the other 3cm2 donor site within 30 minutes of graft harvest and 24 hours after graft harvest."
1811757|NCT00664352|Drug|Placebo|"100µL of placebo will be injected intradermally into each cm2 of one 3cm2 donor site and into the 0.5cm border around the donor site no more than 20 minutes before graft harvest (total dose 750µL). A further 300µL of placebo will be applied topically within 30 minutes of graft harvest and 24 hours after graft harvest.
Standard Care (moist wound healing dressings alone) will be applied to the other 3cm2 donor site."
1811758|NCT00664365|Drug|GSK958108|GSK958108 oral tablets will be available with dosing strengths of 1 milligram, 5 milligrams, 25 milligrams and 50 milligrams. It will be a brownish-yellow film coated round shape tablet. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
1811759|NCT00664365|Drug|Placebo|Placebo tablets will be brownish-yellow film coated round shape tablets, administered orally. The tablets have to be swallowed completely with 240 milliliters of water, without chewing over a period of five minutes.
1811760|NCT00664378|Drug|CYT997|Intravenous infusion (24h); 202mg/m2 on days 1 and 8 of a 21 day cycle
1811761|NCT00664391|Drug|Lactic acid (Dermacid)|Liquid soup to be applied in the external genital area, in small quantity, with abundantly rinse after use, during 21 days
1811762|NCT00664404|Other|Functional Magnetic Resonance Imaging (fMRI)|Functional Magnetic Resonance Imaging (fMRI)of the Brain, one session while smoking, and one session while abstinent from smoking (not smoking).
1812116|NCT00666666|Drug|AT-101|AT101 will be administered orally 20 mg/day for 21 days of a 28 day cycle.
1811763|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 1
1811764|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 2
1811765|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 3
1811766|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 4
1811767|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 5
1811768|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Formulation 6
1811769|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 1
1811770|NCT00664417|Biological|Monovalent subvirion H5N1 influenza vaccine|0.5 mL, IM, 2 injections, Comparator 2
1811771|NCT00664417|Biological|Physiological saline|0.5 mL, IM, 2 injections
1811772|NCT00664430|Drug|Calcitriol|Initial doses determined according to the National Kidney Foundation's Kidney Disease Outcomes Quality Initiative (KDOQI) guideline (Am J Kidney Dis 2003;42(4)Suppl 3:S1-S201). During therapy, calcitriol dose may be modified by 0.5 - 1 mcg at 2- to 4-week intervals.
1811773|NCT00664430|Drug|Paricalcitol|Dose calculated by 0.04 to 0.1 microgram per kilogram (mcg/kg). Paricalcitol will be administered intravenously after the participants' dialysis. The paricalcitol dose will be titrated every 2 weeks until iPTH presents a reduction or up to 4 months, after which it will be adjusted monthly based on serum PTH, calcium, phosphorus and albumin measurements. Dosing may be modified by 2-4 mcg increments at 2- to 4-week intervals.
1811774|NCT00664443|Behavioral|Dispatch-assisted CPR Instructions|Pre and post assessment of bystander CPR frequency and impact on victim survival related to Dispatch-assisted CPR Instructions given since 2004
1811775|NCT00664456|Drug|Adjuvant therapy|AHT group receives 9 cycle of LHRH-A (goserelin acetate 3.6 mg/4 weeks or leuprorelin acetate 3.75 mg/4 weeks) after Iodine I-125 implantation (TPPB).
1811776|NCT00664456|Drug|Neoadjuvant therapy|3 cycle of LHRH-A (goserelin acetate 3.6mg/4 weeks or leuprorelin acetate 3.75mg/4 weeks).
1811777|NCT00664456|Radiation|Brachytherapy（iodine I 125）|Undergo Iodine I-125 transperineal prostatic brachytherapy (TPPB).
1811778|NCT00664469|Drug|ezetimibe|ezetimibe 10 mg/day over a 6-week course of treatment.
1811779|NCT00664469|Drug|Comparator: Simvastatin 20, 40 and 80 mg|Simvastatin 20, 40 and 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
1811780|NCT00664469|Drug|Comparator: Atorvastatin|Atorvastatin 20, 40 & 80 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
1811781|NCT00664469|Drug|Comparator: Rosuvastatin|Rosuvastatin 10, 20 & 40 mg; actual statin regimen for 6 weeks followed by another 6 weeks if at goal or statin dose can be doubled.
1811782|NCT00664482|Biological|AGS-006|Autologous Therapy for Pancreatic Cancer
1811783|NCT00664495|Behavioral|Diet Weight Loss|
1811784|NCT00664495|Behavioral|Exercise Weight Loss|
1811785|NCT00664495|Behavioral|Exercise Without Weight Loss|
1811786|NCT00664508|Procedure|Motion analysis|Motion analysis will be administered to each of the three groups: Lateral approach, anterior approach and posterior approach
1811787|NCT00664521|Biological|Rituximab|Rituximab will be administered as an intravenous infusion at a dose of 1000 mg at Weeks 1 and 3.
1811788|NCT00664521|Drug|Atacicept|Atacicept will be administered at a dose of 150 mg subcutaneously once a week from Week 7 to 32.
1811789|NCT00664521|Drug|Placebo matched to atacicept|Placebo matched to atacicept will be administered subcutaneously once a week from Week 7 to 32.
1811790|NCT00664534|Drug|Insulin Glargine|patient glucose-level dependent, injection, as needed per patient glucose level, 48 weeks
1811791|NCT00664534|Drug|Insulin Lispro Premix (mid-mixture and low-mixture)|patient glucose level dependent, injection, as needed per patient glucose level, 48 weeks
1811792|NCT00664547|Behavioral|Diet Weight Loss|
1811793|NCT00664547|Behavioral|Exercise Weight Loss|
1811794|NCT00664547|Behavioral|Exercise Without Weight Loss|
1811795|NCT00664560|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
1811796|NCT00664560|Drug|celebrex|200 mg celecoxib qd
1811797|NCT00664560|Drug|Placebo|sugar pill bid
1811798|NCT00664560|Drug|Rescue Antacid|Antacid Tablets
1811799|NCT00664573|Biological|Baminercept alfa (BG9924)|dosage administered as per Biogen-Idec protocol
1811800|NCT00664586|Drug|Terameprocol (EM-1421)|Weekly (3 of 4 consecutive weeks) 24 hour continuous intravenous infusion
1811803|NCT00664612|Device|AirTraq|Laryngoscopy with AirTraq
1811804|NCT00664625|Drug|BMS-791325|Capsules, Oral, Once Daily, Single Dose
1811805|NCT00664625|Drug|Placebo|Capsules, Oral, Once Daily, Single Dose
1811806|NCT00664638|Device|Symplicty(TM) Catheter System|Renal denervation using the Symplicity Catheter System
1811807|NCT00664664|Drug|APD125|soft gelatin capsule, 20 mg, daily dosing for up to 3 weeks
1811808|NCT00664664|Drug|APD125|soft gelatin capsule, 40 mg, daily dosing for up to 3 weeks
1811809|NCT00664664|Drug|Placebo|soft gelatin capsule, daily dosing for up to 3 weeks
1811810|NCT00664677|Drug|Terameprocol (EM-1421)|Terameprocol (EM-1421) as a single agent given intravenously over 6 hours three times a week for two weeks followed by one week rest (two weeks on, one week off.
1811811|NCT00664690|Drug|celebrex|400 mg celebrex given 1 hour preop and celebrex 200 mg BID postop
1811812|NCT00664690|Drug|placebo|placebo given preop and BID postop
1811813|NCT00664703|Drug|Lobeline sulfate|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
1811814|NCT00664703|Drug|Methylphenidate HCl|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
1811815|NCT00664703|Drug|Placebo|Each laboratory day, participants will receive one capsule containing either methylphenidate HCl (15 or 30 mg) or placebo, and one sublingual tablet containing either lobeline (7.5, 15, or 30 mg) or placebo.
1811816|NCT00664716|Biological|Baminercept alfa 1|experimental - one dose level
1811817|NCT00664716|Biological|Placebo|Placebo comparator
1811818|NCT00664716|Biological|Baminercept alfa 2|experimental - second dose level
1811819|NCT00664716|Biological|Baminercept alfa 3|experimental - third dose level
1811820|NCT00664716|Biological|Baminercept alfa 4|experimental - fourth dose level
1811821|NCT00664716|Biological|Baminercept alfa 5|experimental - fifth dose level
1811822|NCT00664729|Behavioral|Caloric Restriction|Reduced calorie diet (400 kcal/day deficit)
1811823|NCT00664729|Behavioral|Caloric Restriction + Low-Intensity aerobic exercise|400 kcal/day deficit plus 3 days/week aerobic exercise at 45-50% maximal aerobic fitness
1811824|NCT00664729|Behavioral|Caloric Restriction plus High-intensity aerobic exercise|400 kcal/day deficit and 3 d/week of aerobic exercise at 65-75% maximal fitness
1811825|NCT00664742|Drug|Fluvastatin XL®|Fluvastatin extended release 80 mg
1811826|NCT00664755|Drug|varenicline|"Day -7 thru -5: 0.5mg QD Day -4 thru -1: 0.5mg BID Day 0 onward: 1.0mg BID
Varenicline is taken for a duration of 4 weeks in this study."
1811827|NCT00664755|Device|transdermal nicotine patch|"Weeks 0-3: 21mg patch
Transdermal nicotine patch is used for a duration of 3 weeks in this study."
1811828|NCT00664768|Dietary Supplement|Neocate Infant|minimum of 8 fl. oz daily
1811829|NCT00664768|Dietary Supplement|new Neocate|minimum of 8 fl oz daily
1811830|NCT00664781|Drug|rucaparib (CO-338; formally AG-014699 or PF-01367338)|
1811831|NCT00664781|Genetic|protein expression analysis|
1811832|NCT00664781|Genetic|western blotting|
1811833|NCT00664781|Other|immunohistochemistry staining method|
1811834|NCT00664781|Other|liquid chromatography|
1811835|NCT00664781|Other|mass spectrometry|
1811836|NCT00664781|Other|pharmacological study|
1811837|NCT00664794|Procedure|without acromioplasty|This group will not have their acromion shaved - instead they will receive a repair of their rotator cuff with the scope using sutures or suture anchors.
1811838|NCT00664794|Procedure|with acromioplasty|This group will have Their rotator cuff repaired with sutures or suture anchors and additionally will have the tip of their acromion bone shaved slightly.
1811839|NCT00664820|Dietary Supplement|Probiotic capsules containing Lactobacillus rhamnosus GR-1 and L. reuteri RC-14|2 capsules daily for 3 months.
1811840|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|The Primary Care Physician (PCP) received the educational intervention
1811841|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|The Subject received the educational intervention
1811842|NCT00664833|Behavioral|Levitra (Vardenafil, BAY38-9456)|Both the Primary Care Physician (PCP) and the subject received the educational intervention
1811843|NCT00664833|Other|No Education|No education provided to either the Primary Care Physician (PCP) or the subject.
1811844|NCT00664846|Drug|Aspirin / Clopidogrel, Atorvastatin / Simvastatin|Standard Medical Management,including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
1811845|NCT00664846|Drug|Asprin / Clopidogrel, Atorvastatin / Simvastatin|Antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary
1811846|NCT00664859|Drug|LCP-AtorFen|All subjects will be assigned to receive open-label LCP-AtorFen combination therapy for 52 weeks. Subjects will take a single oral dose of study drug in the evening without regard to meals.
1811847|NCT00664872|Other|proactive psychosocial intervention by care managers|A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
1811848|NCT00664872|Behavioral|case management|
1811849|NCT00664885|Other|Culturally Sensitive Collaborative Treatment|a collaborative care model, for treating depressed patients in general medical care
1811850|NCT00664898|Drug|bortezomib|Escalating intravenous repeating dose
1811851|NCT00664898|Drug|SGN-40|Escalating intravenous repeating dose
1811852|NCT00664911|Other|chemotherapy|
1811853|NCT00664937|Drug|montelukast sodium|single oral dose, before exercise challenge, of montelukast 10mg; 7 week duration.
1811854|NCT00664937|Drug|Comparator: placebo (unspecified)|single oral dose, before exercise challenge, of Pbo; 7 week duration.
1811855|NCT00664950|Device|sliding hip screw|surgical repair of hip fracture using conventional sliding hip screw
1811856|NCT00664950|Device|IntertAn IM nail|interTAN IM nail
1811857|NCT00664963|Device|Implantation of YUKON Sirolimus-eluting Stent|Implantation of YUKON Sirolimus-eluting Stent
1811858|NCT00664963|Device|Implantation of YUKON Stent (uncoated)|Implantation of YUKON Stent (uncoated)
1811859|NCT00664976|Procedure|Electroconvulsive therapy|Electroconvulsive therapy
1811860|NCT00664976|Other|Treatment as usual|Pharmacological antidepressant as usual in the departments: Mood stabilizers as Lithium, lamotrigine, valproate, quetiapine, carbamazepine and olanzapine. Antidepressants + Psychosocial treatment as usual.
1812168|NCT00660894|Drug|tegafur-gimeracil-oteracil potassium|
1811861|NCT00665002|Biological|WT-1|Immune responses were to be evaluated at weeks 6 and 12 via delayed-type hypersensitivity, CD4 T cell proliferation, CD4 and CD8 T cell interferon release, as well as by bone marrow cytogenetics including polymerase chain reaction (PCR) to look for molecular evidence of disease. Patients who had an immunologic response and had not had disease progression could continue with up to 6 more vaccinations administered approximately every month. In that case, patients were to be reevaluated with bone marrows/immunologic studies after the 9th and 12th vaccination. In addition, patients would undergo evaluations for residual disease including immunohistochemistry and/or quantitative polymerase chain reaction (RQ-PCR) for WT-1 expression (on selected patients), and multiparameter flow cytometry (AML/ MDS).
1811862|NCT00665002|Drug|Montanide|The WT-1 vaccine is given with another substance, called Montanide, which clumps the WT-1 vaccine and thereby improves the immune response.
1811863|NCT00665002|Drug|Sargramostim (GM-CSF)|GM-CSF was administered at a dose 70 mcg (140ul) as a subcutaneous injection at the site of vaccination on day -2 and day 0.
1811864|NCT00665041|Drug|Quinagolide|"• Quinagolide 200 μg/day (dose titration from 50 μg/day to 100 μg/day to 200 μg/day), oral. Quinagolida tablets, 50 mcg.
placebo, oral."
1811865|NCT00665054|Drug|Levitra (Vardenafil, BAY38-9456)|5, 10, or 20 mg Vardenafil tablets orally prior to sexual activity
1811866|NCT00665054|Drug|Placebo|Matching placebo tablets orally prior to sexual activity
1811867|NCT00665093|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
1811868|NCT00665093|Drug|insulin detemir|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
1811869|NCT00665106|Drug|"NOVA63035 Corticosteroid"|Single injection in the study eye
1811870|NCT00665119|Drug|remifentanil|0.05 mcg.kg-1.min-1 for 30 minutes by continuous endovenous infusion
1811871|NCT00665119|Drug|placebo|NaCl 0.9 %
1811872|NCT00665132|Device|StimRouter System|Implanted with StimRouter System receive 6 hours (or less if not tolerated by the Subject)of electrical therapeutic stimulation each day for a total of 5 days (from start of successful programming)
1811873|NCT00665145|Drug|SB-509|Active drug
1811874|NCT00665145|Drug|SB-509|Active drug
1811875|NCT00665145|Drug|Placebo|Placebo
1811876|NCT00665145|Drug|SB-509|Active drug
1811877|NCT00665158|Behavioral|UC (Usual Care Group)|Usual Care Group - Treatment Implementation by Primary Care Physician
1811878|NCT00665158|Behavioral|BI (Behavioral Intervention Group)|Behavioral Intervention Group - Treatment Implementation by Health Educator
1811879|NCT00665184|Behavioral|Resistance Exercise via Negative Eccentric Work|High intensity resistance training delivered 2-3 times per week for 12 weeks
1811880|NCT00665184|Behavioral|Standard care exercise training|Evidence based exercise training (resistance training, aerobic training, flexibility training) 2-3 times per week for 12 weeks.
1811881|NCT00665197|Radiation|Protracted Course Radiotherapy|External Beam Radiation 30 Gy in 10 fractions
1811882|NCT00665197|Radiation|Short Course Radiotherapy|External Beam Radiation 20 Gy in 5 fractions
1811883|NCT00665223|Drug|ACR16|45 mg capsules Capsules will be swallowed whole with water. For the first four weeks, one capsule should be taken early in the morning before food. After four weeks, one capsule should be taken early in the morning before food and one in the early afternoon at least 1 hour after food.
1811884|NCT00665223|Drug|Placebo|Placebo capsules. Capsules will be swallowed whole with water. For the first four weeks, one capsule should be taken early in the morning before food. After four weeks, one capsule should be taken early in the morning before food and one in the early afternoon at least 1 hour after food.
1811885|NCT00665236|Other|Craniosacral therapy|Eight weekly 45-minute sessions with therapist
1811886|NCT00665236|Procedure|Low strength static magnets|Placement of magnets on/around subject body by therapist; frequency: weekly for 45-minutes x 8 weeks
1811887|NCT00665249|Behavioral|Motivational Interviewing|See MotivationalInterviewing.org
1811888|NCT00665249|Behavioral|Spirit-Only Motivational Interviewing|Non-directive elements encompass the use of MI-consistent, and avoidance of MI-inconsistent, behaviors, as well as attention to MI-spirit.
1811889|NCT00665249|Other|Self-Change|Participants are followed for 8 weeks, without therapeutic intervention. At end of assessment period, they receive 4 sessions of full MI.
1811890|NCT00665262|Drug|tramacet|2 tablets every 6 hours for 5 days
1811891|NCT00665314|Drug|Plerixafor (AMD3100)|0.24mg/kg SC for 2 to 7 days.
1811892|NCT00665314|Drug|Can be any registered nonpegylated form of G-CSF|10mcg/kg SC for 4 days followed by an additional 2 to 7 days.
1811893|NCT00665327|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg IV QD for a minimum of two doses followed by moxifloxacin 400 mg PO QD for a total treatment duration of 7 to 14 days
1811894|NCT00665327|Drug|Levofloxacin|Levofloxacin 500 mg IV QD for a minimum of two doses followed by Levofloxacin 500 mg PO QD for a total treatment duration of 7 to 14 days. For patients who have a documented or calculated creatinine clearance of 20 - 49 ml/minute, the IV and PO dose of Levofloxacin will be a 500 mg loading dose followed by 250 mg QD for a total treatment duration of 7 to 14 days
1811895|NCT00665340|Drug|Placebo|Matching placebo
1811896|NCT00665340|Drug|Levitra (Vardenafil, BAY38-9456)|5m, 10 mg and 20 mg 1 h prior to sexual intercourse
1811897|NCT00665353|Drug|pioglitazone|Traditionally used in the treatment of type 2 diabetes to increase insulin sensitivity. Participants will take 30 mg daily in tablet form.
1811898|NCT00665353|Drug|peginterferon|Used in the treatment of HCV. Participants will receive 180 mcg subcutaneously once a week.
1811899|NCT00665353|Drug|ribavirin|Used in the treatment of HCV. Participants will receive 1000 to 1200 mg orally per day depending on weight.
1811900|NCT00665366|Drug|Aripiprazole|5-, 10-, or 15-mg oral tablets in titrated doses for 12 weeks
1811901|NCT00665366|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
1811902|NCT00665366|Drug|Lithium|Participant's ongoing dose
1811903|NCT00665366|Drug|Valproate|Participant's ongoing dose
1811904|NCT00665379|Other|Regular Compression therapy (Trico bandages)|Application of marketed Trico compression bandages used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. The bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
1811905|NCT00665379|Other|New Compression therapy (C2L bandages)|Application of marketed compression bandages C2L used for treatment by trained specialists with assessment of the subbandage pressure and volume reduction. he bandages are applicated in patients with leg lymphedema at t=0 hour, t=2 hours. Comparison is made at t=2 hours, t= 24 hours
1811910|NCT00665405|Radiation|CT scan|Thoracic CT scan
1811912|NCT00665431|Drug|PN 400 (VIMOVO)|500 mg naproxen/20 mg esomeprazole bid
1811913|NCT00665431|Drug|celebrex|200 mg celecoxib qd
1811914|NCT00665431|Other|Placebo|sugar pill bid
1811915|NCT00665431|Drug|Rescue Antacid|Antacid Tablets
1811916|NCT00665444|Drug|Aripiprazole|All subjects will be assessed at baseline and then switched from their current antimanic agent to aripiprazole. Arpipirazole will be titrated from a starting dose of 5 mg/day up to a target dose of 15 mg/day over a period of up to 2 months (approximately 8 weeks). Concomitant medication will not be changed unless medically necessary. If a subject is taking an antipsychotic in addition to divalproex, aripiprazole will replace the antipsychotic.
1811936|NCT00665470|Drug|Aldesleukin|"High-dose aldesleukin intravenous (IV) over 15 minutes every 8 hours beginning within 24 hours after peripheral blood lymphocyte (PBL) infusion and continuing for up to 5 days (maximum of 15 doses).
Receive low-dose aldesleukin subcutaneously (SC) once daily 5 days a week for up to 6 weeks"
1811937|NCT00665483|Other|Skin Prick Test|Skin Prick Test
1811938|NCT00665496|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg and 20 mg orally once a day as needed
1811939|NCT00665496|Drug|Placebo|Matching Placebo
1811940|NCT00665509|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml, trivalent one injection at Day 1
1811941|NCT00665522|Drug|fentanyl iontophoretic transdermal system (40mcg) No Placebo|40 mcg per dose, maximum of 6 doses/hour
1811942|NCT00665522|Drug|IV PCA with standard of care opioid analgesia|total maximum 80 doses/24 hours
1811943|NCT00665535|Procedure|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3, or 4 hours
1811944|NCT00665535|Procedure|Turning or repositioning schedule|Turning schedule randomly assigned at 2, 3 or 4 hours
1811945|NCT00665548|Radiation|X-ray; magnetic resonance imaging|"Knee x-rays: acquired in both a standard or weight-bearing position and in non-weight-bearing position to measure joint space width and look at signs of osteoarthritis.
3 Tesla MRI: magnetic resonance imaging of the study knee during weight-bearing conditions and traditional non-loaded condition all acquired with the same sequences."
1811946|NCT00665561|Drug|Maraviroc along with an optimized background antiretroviral drug regimen|Maraviroc prescribed per approved local label.
1811947|NCT00665561|Drug|Optimized background antiretroviral drug regimen without maraviroc|Optimized background antiretroviral therapy prescribed per approved local label and treatment guidelines.
1811948|NCT00665574|Other|ActaVisc and ActaVisc Mx Intra-articular Injection|ActaVisc is a hyaluronan based device intended to alleviate the pain associated with osteoarthritis of the knee with a single injection and ActaVisc Mx is the same material combined with a corticosteroid.
1811950|NCT00665600|Drug|Levalbuterol HCl|Levalbuterol 0.63 TID
1811951|NCT00665600|Drug|Levalbuterol HCl|Levabuterol 1.25 mg TID
1811952|NCT00665600|Drug|Albuterol Sulfate|Racemic albuterol 2.5 mg TID
1811953|NCT00665600|Drug|Placebo|Placebo TID
1811954|NCT00665626|Drug|Fostamatinib disodium (R935788)|R935788 100 mg tablet, orally, twice-a-day
1811955|NCT00665626|Drug|Placebo|Placebo, orally, twice-a-day
1811956|NCT00665639|Drug|micafungin|IV
1811957|NCT00665639|Drug|caspofungin|IV
1811958|NCT00665652|Drug|Lenalidomide|Subjects will receive lenalidomide 25 mg per day for days 1-21 followed by 7 days rest (28-day cycle) for 12 cycles.
1811959|NCT00665665|Drug|NNC 0070-0002-0182|4mg initial dose (12 subjects active; 3 subjects placebo); 2mg weekly maintenance dose; for s.c. injection 20mg/vial
1811960|NCT00665665|Drug|placebo|Placebo for s.c. injection
1811961|NCT00665665|Drug|NNC 0070-0002-0182|12mg initial dose (12 subjects active; 3 subjects placebo); 6mg weekly maintenance dose; for s.c. injection 20mg/vial
1811962|NCT00665665|Drug|NNC 0070-0002-0182|32mg initial dose (12 subjects active; 3 subjects placebo); 16mg weekly maintenance dose; for s.c. injection 20mg/vial
1811963|NCT00665665|Drug|NNC 0070-0002-0182|60mg initial dose (12 subjects active; 3 subjects placebo); 30mg weekly maintenance dose; for s.c. injection 20mg/vial
1811964|NCT00665678|Drug|paroxetine|treatment for three months with paroxetine
1811965|NCT00665678|Drug|placebo|treatment for three months with placebo
1812120|NCT00666679|Drug|Comparator: montelukast|montelukast (inhalation powder, 1 mg once-daily, for approximately 2 weeks)
1811966|NCT00665691|Other|Nutritional Screening Tools|To compare the nutrition risk identification abilities of two nutrition screening tools: PEDSGA tool and the standard assessment tool.
1811967|NCT00665704|Behavioral|Tobacco Tactics website|Pilot test the Tobacco Tactics website tailored to the needs of veteran smokers
1811968|NCT00665717|Drug|Pravastatin|40 mg tablet; QD; 4 days
1811969|NCT00665717|Drug|Raltegravir|400mg tablet; BD 4 days
1811970|NCT00665717|Drug|Pravastatin and raltegravir|pravastatin 40mg tablet QD for 4 days; raltegravir 400mg tablet BD for 4 days
1811971|NCT00665730|Device|Sepraspray|
1811972|NCT00665743|Drug|PN400|naproxen 500 mg /esomeprazole 20 mg
1811973|NCT00665743|Drug|naproxen|naproxen 500 mg tablet
1811974|NCT00665743|Drug|naproxen|naproxen 500 mg
1811975|NCT00665756|Procedure|second Trabeculectomy|second trabeculectomy with mitomycin-c
1811976|NCT00665756|Procedure|Ahmed Implant|Ahmed silicone drainage device
1811977|NCT00665769|Other|Hypercapnia|transcutaenous CO2 50-60 mm Hg
1811978|NCT00665769|Other|Normocapnia|transcutaneous CO2 35-45 mm Hg
1811979|NCT00665782|Other|laboratory biomarker analysis|
1811980|NCT00665782|Other|questionnaire administration|
1811981|NCT00665782|Other|study of socioeconomic and demographic variables|
1811982|NCT00665782|Procedure|assessment of therapy complications|
1811983|NCT00665782|Procedure|psychosocial assessment and care|
1811984|NCT00665782|Procedure|therapeutic conventional surgery|
1811985|NCT00665808|Drug|insulin detemir|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
1811986|NCT00665808|Drug|isophane human insulin|"Observational study on treatment satisfaction of Levemir ® versus Protaphane® during real-life usage in Germany"
1811987|NCT00665821|Behavioral|Classic back pain prevention education, and cognitive behavioral management.|Classic education: postural hygiene, Back Guide. Cognitive behavioral management: active management, Back Book.
1811988|NCT00665821|Behavioral|General health education|General health education: a booklet describing general norms for maintaining good health
1811989|NCT00665834|Drug|rosuvastatin|rosuvastatin 20 mg from day 0 to (maximum) day 6
1811990|NCT00665834|Drug|placebo|placebo 20 mg from day 0 to (maximum) day 6
1811991|NCT00665834|Drug|rosuvastatin|rosuvastatin 20 mg from discharge until the end of the study
1811992|NCT00665834|Drug|atorvastatin|atorvastatin 80 mg from discharge until the end of the study
1811993|NCT00665847|Drug|Etravirine (TMC125)|Patients will be dosed by body weight , i.e. 5.2 mg/kg twice daily (b.i.d.) up to a maximum of 200 mg b.i.d. for 48 weeks.
1811994|NCT00665847|Drug|Optimized background regimen (OBR)|An investigator-selected optimized background regimen (OBR) comprising of a low-dose ritonavir (rtv)-boosted protease inhibitor (PI) (either lopinavir [LPV], darunavir [DRV], atazanavir [ATV] or saquinavir [SQV]) in combination with nucleos(t)ide reverse transcriptase inhibitor(s) (N[t]RTIs) to be dosed according to the drugs individual package inserts for 48 weeks.
1811995|NCT00665860|Dietary Supplement|Placebo|Three pills per day for two years
1811996|NCT00665860|Dietary Supplement|Soy isoflavones|Three pills that delivered 80 mg of aglycone isoflavones per day for two years
1811997|NCT00665860|Dietary Supplement|Soy isoflavones|Three pills that delivered 120 mg aglycone isoflavones per day for two years
1811998|NCT00665873|Device|PORT-A-CATH (Smiths Medical Inc., MN)|Port a Cath implanted by surgical cut-down
1811999|NCT00665873|Drug|Amoxicillin and clavulanic acid|1 gr i.v. before the procedure
1812000|NCT00665886|Device|Open Intravenous System - Vasocan®|Vasocan® Safety catheter 18 G x 45 mm (Ref. 4248139S), 20 G x 33 mm (Ref. 4248112S) y 22 G x 25 mm (Ref. 4248090S)with wings and a passive safety mechanism. To the control catheters a three-way tap ('stopcock') with extension tubing 10 cm long (Connecta® Extra 3) from BD (ref 394995)will be added.
1812001|NCT00665886|Device|Closed Intravenous System - Nexiva®|BD Nexiva® Catheter (18G x 45 mm, 20 G x 32 mm, 22 G x 25 mm) (Ref. 383609,Ref. 383606,Ref. 383602) BD QSyte®, Ref. 385100 Catheter material is Vialon®. The entire system is Latex and PVC free.
1812002|NCT00665899|Behavioral|Cancer-Focused Relationship Enhancement|Couples meet individually with a health educator for 6 sessions to learn about ways to support each other and communicate about breast cancer related issues.
1812003|NCT00665899|Behavioral|Couple's Cancer Education|Couples meet individually with a health educator for 6 sessions to discuss the medical aspects of breast cancer and treatment options.
1812004|NCT00665912|Procedure|Standard post-lobectomy wound care plus use of PRP and PPPc prepared by GPS and Plasmax respectively|GPS is used to create the platelet rich plasma (PRP). Plasmax is used to create the concentrated platelet-poor plasma (PPPc). Both PRP and PPPc will be used for wound care in the thoracic cavity post-lobectomy.
1812005|NCT00665912|Procedure|Standard post-lobectomy wound care|Standard post-lobectomy wound care
1812006|NCT00665925|Drug|Fostamatinib disodium (R935788)|100 mg tablet, orally, twice-a-day
1812007|NCT00665925|Drug|Fostamatinib disodium (R935788)|150 mg tablet, orally, once a day
1812008|NCT00665925|Drug|Placebo|Placebo, orally, either once a day, or twice a day
1812009|NCT00665938|Other|Infant formula|"Arm 1. extensively hydrolyzed infant formula without probiotics (Nutramigen LIPIL)
Arm 2. partially hydrolyzed infant formula with probiotics
Arm 3. extensively hydrolyzed infant formula with probiotics"
1812010|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 200/50mg; 2 tablets; single dose
1812011|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 sachets with granules; single dose
1812012|NCT00665951|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 100/25mg; 4 tablets; single dose
1812013|NCT00665964|Device|X-3 polyethylene|highly cross-linked polyethylene for knee arthroplasty
1812014|NCT00665964|Device|N2Vac polethylene|conventional polyethylene
1812015|NCT00665977|Drug|Thermosmart & placebo|a Fisher & Paykel 604 CPAP machine with Thermosmart™ heated humidity set at their prescribed pressure. Subjects will also be given nasal steroid placebo (purified water) and instructed to deliver two sprays in each nostril daily
1812117|NCT00666666|Drug|Bicalutamide|Daily bicalutamide 50 mg po is encouraged for the first month of LHRH agonist therapy to prevent a flare. Continued bicalutamide use is optional. Bicalutamide will be administered orally at a dose of 50 mg po daily, Day 1 to 28 of each cycle.
1812016|NCT00665977|Drug|Placebo Device & Nasacort|Visit 3 will be identical to visit 2, with the exception being the crossover of double-blind treatment. Subjects will now receive the Fisher & Paykel 604 CPAP machine with traditional heated humidity and a deactivated Thermosmart™ tube set to their prescribed pressure. Subjects will also be given the nasal steroid Nasacort AQ (triamcinolone acetonide) at a dosage of 220 mcg. They will be instructed to deliver two sprays in each nostril daily. Once again, phone follow-up will be made 7-10 days after the visit to assess compliance with study procedures and adverse events.
1812017|NCT00665977|Device|Placebo Arm|"To enter into the single-blind placebo phase, subjects will be setup with a Fisher & Paykel 604 CPAP unit with a heated humidifier and deactivated Thermosmart™ tube, thus, only traditional heated humidity will be available. The deactivated unit will still appear to function with intact heated humidity settings. The CPAP machine will be set to the patient's prescribed pressure. Subjects will also be given a nasal steroid spray placebo and instructed to deliver one spray in each nostril daily."
1812018|NCT00665990|Drug|Bevacizumab|Bevacizumab starting dose of 5 mg/kg every 3 weeks increasing in combination with Sorafenib and Cyclophosphamide until maximum tolerated dose
1812019|NCT00665990|Drug|Sorafenib|Sorafenib 90 mg/m2 PO every 12 hours increasing in combination with Bevacizumab and Cyclophosphamide until maximum tolerated dose
1812020|NCT00665990|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/m2 PO once daily increasing in combination with Bevacizumab and Sorafenib until maximum tolerated dose
1812021|NCT00666016|Drug|TRO19622|TRO19622 500 mg once a day before noon meal during 6 weeks
1812022|NCT00666029|Drug|atorvastatin|40 m.g. o.d. tablets for 6 months
1812023|NCT00666029|Drug|placebo|Placebo
1812024|NCT00666042|Drug|Vigamox - administration in spray form|Vigamox will be administered in a spray form
1812025|NCT00666042|Drug|Vigamox eye drops|Vigamox eye drops
1812026|NCT00666055|Drug|ARV regimen chosen by treating physician|"Women may also be naïve to either NNRTI or PIs and initiating their first, second or third HAART regimen (ARVs to be investigated: zidovudine, lamivudine, emtricitabine, abacavir, tenofovir, efavirenz, lopinavir/ritonavir, atazanavir with or without ritonavir).
Provided the ARV regimens contain one or more of the agents under study they may also include new agents such as maraviroc (CCR5 inhibitor), raltegravir (integrase inhibitor) and/or etravirine (NNRTI)."
1812027|NCT00666068|Other|corticotropin releasing hormone (CRH)|50 µg injected at 2200, 2300, 0000, and 0100
1812028|NCT00666068|Other|Placebo|injected at 2200, 2300, 0000, and 0100
1812029|NCT00666068|Other|Placebo|injected at 2200, 2300, 0000, and 0100
1812030|NCT00666081|Drug|GSK690693|Administered intravenously at a concentration between 0.1 - 4.8 mg/mL by slow infusion over 4 h.
1812031|NCT00666094|Behavioral|Endurance training|supervised endurance training. Three sessions per week in three months.
1812032|NCT00666094|Behavioral|strength training|Supervised strength training. Three sessions per week in three months.
1812033|NCT00666107|Biological|Gardasil|Intramuscular injections of Gardasil at Day 0, Month 2 and at Month 6
1812034|NCT00666120|Other|Enfamil LIPIL with iron|cow's milk based infant formula
1812035|NCT00666120|Other|Good Start Supreme with DHA and ARA|partially hydrolzed cow's milk protein
1812036|NCT00666133|Device|SpringFusor Pump|Women in Group I (Springfusor® arm) will receive loading and maintenance doses of magnesium sulfate administered via an IV infusion administered with the Springfusor pump, a simple, inexpensive flow-controlled pump system.
1812037|NCT00666159|Drug|tacrolimus ointment|topical
1812038|NCT00666159|Drug|pimecrolimus cream|topical
1812039|NCT00666172|Behavioral|Exercise|
1812040|NCT00666172|Behavioral|Weight Loss|
1812041|NCT00666185|Drug|Micafungin|IV
1812042|NCT00666185|Drug|Fluconazole|IV
1812043|NCT00666198|Drug|SILDENAFIL|"Revatio® Tablets 20 mg Dosage, Frequency: According to Japanese LPD, For oral use, the adult dose is 20 mg three times a day.
Duration: According to the protocol of A1481263, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 3 years after the first administration."
1812044|NCT00666211|Other|educational intervention|Participants will be educated on pain management.
1812045|NCT00666211|Other|Titrated pain management|Pain will be Monitored and Medication Titrated
1812046|NCT00666211|Other|questionnaire administration|Participants will be given questionnaires to complete.
1812047|NCT00666224|Drug|Glatiramer Acetate (DB)|Double blind period (DB): glatiramer acetate (GA) by subcutaneous injection, 20mg, once daily, for up to 36 months or until conversion to clinically definite multiple sclerosis (CDMS).
1812048|NCT00666224|Drug|Placebo|Double blind period (DB): subcutaneous injection of placebo, once daily, for up to 36 months or until conversion to CDMS
1812049|NCT00666224|Drug|Glatiramer Acetate (OL)|Open label period (OL): glatiramer acetate (GA), 20 mg, subcutaneous injection, once daily, given for up to an additional 24 months.
1812050|NCT00666237|Procedure|Tube shunt surgery|350mm2 Baerveldt glaucoma implant
1812051|NCT00666237|Procedure|Trabeculectomy with mitomycin C|Mitomycin C 0.4 mg/ml for 2 minutes
1812052|NCT00666250|Dietary Supplement|Xocai Activ drink|proprietary blend of cocoa powder and extracts of acai, grape and blueberry
1812053|NCT00666263|Biological|Immune Globulin Intravenous (human), 10%|Dose: Previous dose with 3, 4, or 6 cycles depending on previous schedule (patient specific)
1812054|NCT00666263|Biological|0.25% human albumin solution (Placebo)|Cross-over Period 1 (Randomized) / Cross-over Period 2 (opposite of the treatment received in Cross-over Period 1); Dose: Same volume/frequency as Stabilization Phase 1
1812055|NCT00666276|Drug|linezolid (Zyvox)|"Zyvox Tablets 600mg, Zyvox Injection 600mg Dosage, Frequency: According to Japanese Package Insert, In adults, administer usually 600mg of linezolid twice daily (q 12 hours) for a total daily dose of 1200 mg.
Duration: According to the protocol of A5951142, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 8 weeks after the first administration."
1812056|NCT00666302|Drug|tacrolimus ointment|topical
1812057|NCT00666302|Drug|pimecrolimus cream|topical
1812118|NCT00666666|Other|LHRH agent|An LHRH agonist(Leuprolide Acetate or Goserelin)can be administered at standard dosing appropriate to the agent used.
1812119|NCT00666679|Drug|Comparator: mometasone|mometasone (inhalation powder, 220 mcg once-daily, for approximately 6 weeks)
1812058|NCT00666328|Drug|clevidipine|"Clevidipine injectable emulsion (0.5 mg/mL) in 20% lipid emulsion in 100 mL bottles was administered intravenously to all patients via a single dedicated line.
Clevidipine was infused at an initial rate of 2.0 mg/h for the first 1.5 minutes. Thereafter, titration to higher infusion rates were to be attempted as needed to obtain the target systolic blood pressure (SBP) range (SBP ≤160 mmHg to ≥140 mmHg). Titration to effect was to proceed by doubling the dose every 1.5 minutes, up to a maximum of 32.0 mg/h, until the desired effect (SBP within the target range) was attained. The clevidipine infusion rate could be increased or decreased to maintain systolic blood pressure for up to a maximum of 96 hours."
1812059|NCT00666341|Drug|placebo|Placebo: Al(OH)3-Placebos with histamine-dihydrochloride analogue Allergen-Adsorbate rPhleum strengthes 1 to 4.
1812060|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 1 (20 μg)
1812061|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 2 (40 μg)
1812062|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 3 (80 μg)
1812063|NCT00666341|Biological|rPhleum|Cocktail of recombinant major allergens of Phleum pratense (timothy grass) with strength 4 (120 μg)
1812064|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 0.05% methotrexate per affected nail and adjacent skin folds applied daily for three months.
1812065|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 0.25% methotrexate per affected nail and adjacent skin folds applied daily for three months.
1812066|NCT00666354|Drug|Methotrexate|0.01 gram of topical amphimatrix containing 1.0% methotrexate per affected nail and adjacent skin folds applied daily for three months.
1812067|NCT00666367|Drug|D-cure|4 ml of D-cure (SMB oral intake) in syringe Exacta-Med Oral Dispenser.
1812068|NCT00666367|Drug|Placebo|4 ml of Arachidis oleum raffinatum Ph. Eur. in syringe Med Oral Dispenser.
1812069|NCT00666380|Biological|Plasmodium falciparum Malaria Protein 010 (FMP010)|Vaccine antigen is a recombinant protein based on merozoite surface protein-1 (MSP-1) of FVO strain of Plasmodium falciparum, and adjuvant AS01B is a proprietary adjuvant of GSK
1812070|NCT00666393|Drug|fentanyl iontophoretic transdermal system (40mcg) No placebo|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
1812071|NCT00666393|Drug|fentanyl iontophoretic transdermal system (40mcg)|40 mcg per dose, maximum of 6 doses/hour; total maximum 80 doses/24 hours
1812072|NCT00666406|Drug|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method (rAHF-PFM)|Infusion of 50 +/- 5 IU/kg bodyweight
1812073|NCT00666406|Drug|Recombinant Factor VIII (rAHF)|Infusion of 50 +/- 5 IU/kg bodyweight
1812074|NCT00666419|Other|Measurement, weight, and muscle strength test|10-12 year old schoolchildren will be weighed, measured for height, and tested for strength of their abdominal and paravertebral muscles
1812075|NCT00666432|Other|This is an observational study model that is family based|This is an observational study model that is family based
1812076|NCT00666458|Drug|saxagliptin|tablet, per oral, once daily
1812077|NCT00666458|Drug|sitagliptin|capsule, per oral, once daily
1812078|NCT00666471|Procedure|MICE|MICE
1812079|NCT00666471|Procedure|SPA ligation|SPA ligation
1812080|NCT00666484|Drug|cyclophosphamide|
1812081|NCT00666484|Drug|doxorubicin hydrochloride|
1812082|NCT00666484|Drug|etoposide|
1812083|NCT00666484|Drug|prednisolone|
1812084|NCT00666484|Drug|procarbazine hydrochloride|
1812085|NCT00666484|Drug|vincristine sulfate|
1812086|NCT00666484|Radiation|radiation therapy|
1812087|NCT00666497|Drug|Azacitidine|75 mg/m2/day for 5 days, subcutaneous (SC) injection, Days 1 - 5 of every 28-day cycle
1812088|NCT00666497|Drug|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 12 doses, 28-day cycle
1812089|NCT00666497|Drug|MGCD0103|90 mg, oral (PO) administration, 3 times per week for 10 doses, 28-day cycle
1812090|NCT00666523|Dietary Supplement|phytalgic|3/day
1812091|NCT00666523|Dietary Supplement|placebo|3/Day
1812092|NCT00666536|Drug|valsartan and amlodipine|
1812093|NCT00666536|Drug|valsartan and amlodipine|
1812094|NCT00666562|Dietary Supplement|Defined Green Tea Catechin Extract|Given orally
1812095|NCT00666562|Other|Laboratory Biomarker Analysis|Correlative studies
1812096|NCT00666562|Other|Pharmacological Study|Correlative studies
1812097|NCT00666562|Drug|Placebo|Given orally
1812098|NCT00666562|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1812099|NCT00666575|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime for 28 days
1812100|NCT00666575|Drug|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime for 28 days
1812101|NCT00666588|Drug|idarubicin|Given IV
1812102|NCT00666588|Drug|cytarabine|Given IV or IT
1812103|NCT00666588|Drug|bortezomib|Given IV
1812104|NCT00666588|Drug|etoposide|Given IV
1812105|NCT00666588|Other|laboratory biomarker analysis|Correlative studies
1812106|NCT00666601|Drug|TR-700 (active moiety)|A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
1812107|NCT00666601|Drug|TR-701 (pro-drug)|Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701
1812108|NCT00666614|Other|Sleep Environment Intervention|Patients randomized to the sleep environment intervention months will experience a relaxation period before nighttime sleep, white noise as selected by the patient, stimulus control strategies, a window covering to diminish hallway light from entering the room, and a nurse-protected 90-minute uninterrupted sleep period at night.
1812109|NCT00666614|Other|Normal Hospital Environment|Normal Hospital Environment
1812110|NCT00666627|Drug|Ibandronate|once monthly
1812111|NCT00666627|Drug|Risedronate|Risedronate 35mg once weekly
1812112|NCT00666627|Drug|Alendronate|Alendronate 70mg once weekly
1812113|NCT00666640|Device|DXA scan of hip|Dual-energy X-ray Absorptiometry scan
1812114|NCT00666640|Device|CT scan of hip|Computed Tomography scan
1812115|NCT00666653|Drug|pramipexole|
1812121|NCT00666679|Drug|Comparator: placebo (unspecified)|Placebo (Placebo once-daily, for approximately 2 weeks)
1812122|NCT00666692|Drug|M200 (Volociximab), Carboplatin, Paclitaxel, Bevacizumab|Volociximab will be administered via IV infusion once every three week at 10, 20, and 15 or 30 mg/kg with an additional loading dose in the 10, 20, and 15 mg/kg dose levels on Day 8 of the first cycle. Volociximab will be given for up to 6 cycles (3 weeks/cycle). Subjects who have stable disease or better and subjects who have disease that is not progressing at the end of 6 cycles may continue to receive volociximab alone until disease progression. Carboplatin is administered via IV infusion and dosed based on the Calvert formula (with a target area AUC of 6 mg/mL/min) for up to 6 cycles (3 weeks/cycle). Paclitaxel is administered via IV infusion and dosed at 200 mg/m2 for up to 6 cycles (3 weeks/cycle). All four drugs, when given in combination, will be infused on the same day in the following sequence: volociximab, paclitaxel, carboplatin.
1812123|NCT00666705|Drug|Maraviroc|300 milligrams(mg) every 12 hours Days 6-11
1812124|NCT00666705|Drug|Maraviroc|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
1812125|NCT00666705|Drug|Raltegravir|Days 12-14: Raltegravir 400 milligrams(mg) every 12 hours, maraviroc 300 milligrams(mg) every 12 hours (AM doses only on Day 14)
1812126|NCT00666705|Drug|Raltegravir|400 milligrams(mg) every 12 hours Days 1-3 Followed by washout Days 4-5
1812127|NCT00666718|Drug|Insulin Glargine|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
1812128|NCT00666718|Drug|Insulin Lispro Protamine Suspension (ILPS)|patient glucose-level dependent, injection, once daily in the evening, 24 weeks
1812129|NCT00666718|Drug|Insulin Lispro|subcutaneous injections prior to meals, 24 weeks
1812130|NCT00666731|Other|medical chart review|Demographic information (like address and birth date), the results of physical exams, blood tests, x-rays and other diagnostic and medical procedures and treatments, as well as medical and surgical history.
1812131|NCT00666731|Other|questionnaire administration|Collection of personal information, medical history, diet and lifestyle habits, any past or current environmental exposures and to re-create a family tree for any cancers that have occurred in any family members. In accordance with OPRR guidelines, no identifying information such as name, address, or date of birth will be used for relatives, but the affected status (cancer, age of onset, year of birth, age of death) will be recorded.
1812132|NCT00666731|Other|study of socioeconomic and demographic variables|Repository
1812133|NCT00666731|Procedure|Excess human biological tissue|Tissue procurement.
1812134|NCT00666731|Procedure|quality-of-life assessment|Cancer care.
1812135|NCT00666744|Other|Family Mediated Exercise Therapy|35 minutes of lower limb exercises to be completed by the person with stroke on a daily basis with the assistance of their family for a period of 8 weeks.
1812136|NCT00666757|Drug|duloxetine|30-120 milligrams (mgs) orally daily for 12 weeks
1812137|NCT00666757|Drug|fluoxetine|20-80 mgs orally daily for 12 weeks
1812138|NCT00666757|Drug|citalopram|20-40 mgs orally daily for 12 weeks
1812139|NCT00666757|Drug|paroxetine|20-50 mgs orally daily for 12 weeks
1812140|NCT00666757|Drug|sertraline|50-200 mgs orally daily for 12 weeks
1812141|NCT00666770|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
1812142|NCT00666770|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
1812143|NCT00666770|Drug|Placebo|Matched placebo 30 minutes prior to bedtime
1812144|NCT00666783|Drug|palonosetron|receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy.
1812145|NCT00666783|Drug|Granisetron|receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy.
1812146|NCT00660725|Drug|Vandetanib|Vandetanib is a pill that will be self-administered orally on Days 1-14 of each 14-day cycle. The dose of vandetanib each subject will receive will be determined by a dose escalation schedule (either 200 mg or 300 mg per day), which will be followed to determine the MTD of the study drug combination (vandetanib + GemOx). In the absence of disease progression, unacceptable toxicities, or other complications, the vandetanib and GemOx combination may continue per protocol for a maximum of 6 cycles, or 12 weeks. In subjects who show response or stable disease, vandetanib may be continued as a single agent beyond the 6 cycle maximum, at the investigator's discretion.
1812147|NCT00660725|Drug|Gemcitabine|30-minute IV infusion of 1000 mg/m^2 gemcitabine on Day 1 of each 14-day cycle.
1812148|NCT00660725|Drug|Oxaliplatin|Immediately following gemcitabine IV: 2-hour IV infusion of 85 mg/m^2 oxaliplatin on Day 1 of each 14-day cycle.
1812150|NCT00660764|Drug|Rosuvastatin|Oral
1812151|NCT00660777|Behavioral|Deep breathing, bilateral alternate chewing, nasal lavage|Deep breathing, bilateral alternate chewing, nasal lavage
1812152|NCT00660777|Behavioral|Oropharyngeal exercises|Oropharyngeal exercises (derived from speech language pathology) to the soft palate, tongue and facial muscles exercises as well as stomatognathic functions.
1812153|NCT00660803|Drug|Fulvestrant|
1812154|NCT00660816|Drug|erlotinib hydrochloride|Given orally once daily on days 2-19.
1812155|NCT00660816|Drug|pemetrexed disodium|Given IV over 10 minutes on day 1
1812156|NCT00660816|Drug|docetaxel|IV over 60 minutes on day 1.
1812157|NCT00660829|Drug|Placebo|Placebo
1812158|NCT00660829|Drug|0.15% Azelastine Hydrochloride|0.15% Azelastine Hydrochloride 822 mcg
1812159|NCT00660842|Procedure|carboplatin|AUC 6 IV day 1 every 21 days
1812160|NCT00660842|Drug|paclitaxel|175 mg/m2 IV day 1 every 21 days
1812161|NCT00660842|Drug|carboplatin|AUC 2 IV every week
1812162|NCT00660842|Drug|paclitaxel|60mg/m2 IV every week
1812163|NCT00660855|Drug|parecoxib/valdecoxib|parecoxib 40 mg intravenously after recovery from anesthesia; if pain persisted, the patient could receive an optional second drug dose on Study Day 1 (only) if more than 4 hours after the first dose. When the patient was able to tolerate oral medication, one valdecoxib 40 mg tablet was administered by mouth once daily in the morning until a maximum period of 7 days.
1812164|NCT00660868|Drug|Pentoxifylline retard 400mg|Agapurin retard 400mg 3/day per os for 3 weeks
1812165|NCT00660881|Biological|Epratuzumab|Epratuzumab at a concentration of 10 mg/mL prepared in 17.5 ml vials for slow intravenous infusion using only PBS as a vehicle/buffer for the infusion procedure.
1812169|NCT00660907|Drug|dapagliflozin|Tablet oral 2.5, 5, or 10 mg total daily dose once daily 208 weeks
1812170|NCT00660907|Drug|glipizide|Capsule oral 5, 10, or 20 mg total daily dose once or split/twice daily 208 weeks
1812171|NCT00660907|Drug|metformin hydrochloride|Tablet oral 1500, 2000, or 2500 mg total daily dose split/twice daily 218 weeks
1812172|NCT00660920|Drug|Ponatinib|Comparison of different dosages of drug given orally once per day.
1993585|NCT03170947|Device|Standardized insoles|Standardized insoles were done by EVA material with shore of 18 and 180 kg/cm3 and manufactured, with an extension of 3/4. It was in contact with heel and plantar arch.
1812175|NCT00660959|Drug|lixivaptan|oral capsule
1812176|NCT00660959|Drug|placebo|oral capsule
1812177|NCT00660972|Drug|Raltegravir|400 mg tablet taken orally twice daily
1812178|NCT00660972|Drug|Emtricitabine/tenofovir disoproxil fumarate|Fixed dose tablet containing 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate taken once daily. FTC/TDF will not be provided by the study and must be obtained by the particpant's health care provider.
1812179|NCT00660985|Drug|Adapalene|Gel, 0.3%, 2g, once daily for 30 days
1812180|NCT00660985|Drug|Adapalene|Gel, 0.1%, 2g, once daily for 30 days
1812181|NCT00660998|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1h before sexual intercourse
1812182|NCT00660998|Drug|Placebo|Matching placebo
1812183|NCT00661011|Procedure|Lobectomy followed by concomitant mediastinal chemoradiotherapy|Lobectomy Radiotherapy 66 Gy in 2 Gy/ fraction, 5 fractions/wk Chemotherapy Cisplatin 60 mg/m² on days 1 and 22 and Vinorelbine 15 mg/m² on days 1, 8, 22 and 29
1812184|NCT00661024|Procedure|intraoperative RLN visualization|intraoperative RLN visualization
1812185|NCT00661024|Procedure|intraoperative neuromonitoring of the RLN|IONM
1812186|NCT00661037|Device|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
1812187|NCT00661037|Device|Implantable defibrillator|Implantable defibrillator to reduce ventricular arrhythmias via shock.
1812188|NCT00661050|Procedure|Alternative Medicine|
1812189|NCT00661050|Procedure|Tai Chi instruction and class participation or walking exercise and sitting meditation|
1812190|NCT00661063|Drug|ketamine|ketamine 150 mcg/g bid
1812191|NCT00661063|Drug|vehicle gel|bid - 12 weeks
1812192|NCT00661063|Drug|ketamine + clonidine|ketamine 150mcg/g + clonidine 1% gel bid 12 weeks
1812193|NCT00661063|Drug|clonidine gel 1%|bid 12 weeks
1812194|NCT00661076|Drug|adefovir dipivoxil|10mg po daily for 96 weeks (arm 1) or 48 weeks (arm 2)
1812195|NCT00661076|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms weekly for 48 weeks
1812196|NCT00661089|Drug|Botulinum Toxin Type A - OnabotulinuntoxinA|100-200 units injected into the pectoralis major. The teres major may also be injected if tone is noted in shoulder extensors.
1812197|NCT00661102|Drug|Corticosteroids|As prescribed
1812198|NCT00661102|Drug|Placebo|As prescribed
1812199|NCT00661102|Drug|capecitabine [Xeloda]|As prescribed
1812200|NCT00661102|Drug|dexpantenol [Bepantol]|As prescribed
1812201|NCT00661115|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
1812202|NCT00661115|Drug|Placebo|Placebo. After a 4 week run-in period, subjects were randomized in order to enroll 3 times more subjects in the vardenafil group than in the placebo group. The duration of the active treatment phase was 12 weeks
1812203|NCT00661141|Drug|Antizol|
1812204|NCT00661141|Drug|Placebo|
1812205|NCT00661141|Other|Ethanol|oral dose of ethanol (0.5 g/kg)
1812206|NCT00661154|Drug|Bevacizumab|2-12microCi IV injection
1812207|NCT00661167|Drug|ABI-007|ABI-007 260 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
1812208|NCT00672984|Drug|immediate release guanfacine hydrochloride|Subjects will receive 2x2mg immediate-release guanfacine on day 1. Subjects will receive 4x2mg immediate-release guanfacine on day 6.
1812209|NCT00672984|Drug|moxifloxacin|Subjects will receive 400mg of moxifloxacin on day 1. Subjects will receive 400mg of moxifloxacin on day 6.
1812210|NCT00672984|Drug|Placebo|Subjects will receive placebo on Day 1. Subjects will receive placebo on Day 6.
1812211|NCT00672997|Drug|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
1812212|NCT00672997|Drug|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
1812213|NCT00673010|Radiation|131 I-iodine (131-I), 124 I-iodine (124-I)|Those who have demonstrated metastases which concentrate radioiodine will undergo routine testing to determine the MTA for blood and lung tissue. This will be performed with 124-I instead of 131-I. If the diagnostic scans (done with 123-I) show that the metastatic lesions concentrate radioiodine, the patient will be treated with 131-I based on standard of care discussions at a tumor board meeting. One week following the 131-I therapy, a whole body scan will be obtained and compared with the 124-I diagnostic scan. One year later, another extent of disease workup will be performed which will include 124-I dosimetry and scanning.
1812214|NCT00673023|Other|Dietary experiments|Dietary Supplement: high PUFA diet followed by high SFA diet
1812215|NCT00673036|Other|Blood sample|60 ml of whole blood
1812216|NCT00673049|Drug|CP 751,871 (Figitumumab)|CP 751,871 (20 mg/kg) will be administered as an IV infusion on study Days 1 and 2 in Cycle 1, and every three weeks (from Day 1) (Cycle) thereafter.
1812217|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO).
1812218|NCT00673049|Drug|Erlotinib|Erlotinib (one tablet of 150 mg/day PO). Erlotinib will be taken at least one hour before or two hours after the ingestion of food.
1812219|NCT00673062|Drug|SCH 900538|(4X50mg Capsules)
1812220|NCT00673062|Drug|Pseudoephedrine|Encapsulated pseudoephedrine (2X30 mg immediate release tablets)
1812221|NCT00673062|Drug|Placebo Capsules|Placebo
1812222|NCT00673075|Drug|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration once daily
1812223|NCT00673075|Drug|Carvedilol|Encapsulated Carvedilol 12.5 mg, 25 mg, 50 mg total daily dosage, oral administration twice daily
1812224|NCT00673088|Drug|Ropinirole Hydrochloride|Restless Leg Syndrome
1818220|NCT00717470|Drug|Advagraf®|oral
1812225|NCT00673114|Biological|haplo/cord transplant|T-cell depleted haplo-matched cells from related donor and unrelated umbilical cord blood
1812226|NCT00673127|Drug|Ketoconazole, Hydrocortisone and Dutasteride|"Ketoconazole: 200mg orally three times a day on an empty stomach. Hydrocortisone: 30mg in the morning and 10mg in the evening. Pills should be taken with food or milk.
Dutasteride: 0.5mg orally once a day on an empty stomach or after eating a meal"
1812227|NCT00673140|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
1812228|NCT00673140|Radiation|Far infrared radiation|Far infrared radiation at a frequency of 5 microns to 20 microns for 30 to 40 minutes per session.
1812229|NCT00673153|Drug|gemtuzumab ozogamicin|Given IV
1812230|NCT00673153|Drug|vorinostat|Given orally
1812231|NCT00673153|Other|laboratory biomarker analysis|Correlative studies
1812232|NCT00673166|Procedure|Staff incentive & supervision|Control & management of funds for incentive of staff; supervision
1812233|NCT00673166|Behavioral|Staff motivation|Supervision, control of funds
1812234|NCT00673179|Drug|Doxorubicin|Pre-Surgery, Regimen 1: IV Over 15 Minutes on Day 1 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV on Day 1 of Weeks 16, 21, and 26; Pre-Surgery, Regimen 2: IV over 15 Minutes on Day 1 of Weeks 1, 4, and 7. Dose 90 mg/m^2.
1812235|NCT00673179|Drug|Cisplatin|Pre-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 1 and 6; Post-Surgery, Regimen 1: IV Over 48 Hours, on Days 1 and 2 of Weeks 16, 21, and 26. Pre-Surgery, Regimen 2: Infusion through an artery over 4 hours on Day 1 of Weeks 1, 4, and 7. Dose 60 mg/m^2/day for 2 days continuous infusion.
1812236|NCT00673179|Drug|Methotrexate|Pre-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 4, 5, 9, and 10; Post-Surgery, Regimen 1: IV Over 4 Hours on Day 1 of Weeks 14, 15, 19, 20, 24, 25, 29, and 30; Post-Surgery, Regimen 2: IV Over 4 Hours on Day 1 of Weeks 14, 15, 20, 21, 26, 27, 32, 33, 38, and 39. Dose 12 gm/m^2, max 20 gm over 4 hours.
1812237|NCT00673179|Drug|Leucovorin|Pre- and Post-Surgery, Regimen 1: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours; Post-Surgery, Regimen 2: IV Over 5 minutes on the day after each methotrexate dose and then by mouth every 6 hours. Dose 10 mg IV, with 10 mg orally every 6 hours.
1812238|NCT00673179|Drug|Dexrazoxane|Dose 900 mg/m^2 IV Push with doxorubicin. Pre-Surgery, Regimen 2: IV Over 15 minutes on Day 1 of Weeks 1, 4, and 7.
1812239|NCT00673179|Drug|Ifosfamide|Post-Surgery, Regimen 2: IV continuously over 5 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2. Dose 2.8 grams m^2/day.
1812240|NCT00673179|Behavioral|Questionnaire|Questionnaires to be completed on 5 different days during the study.
1812241|NCT00673179|Drug|Gemcitabine|IV over 1 hour, every other week.
1812242|NCT00673179|Drug|Sargramostim|Inhaled aerosol (5 mcg/kg, maximum dose 300 mcg) twice a day for 7 days on, 7 days off, beginning the day receive gemcitabine.
1812243|NCT00673179|Procedure|Surgery|Planned limb salvage surgery after 3 courses of doxorubicin + cisplatin (IV) and High-dose methotrexate - at approximately week 12.
1812244|NCT00673179|Drug|Mesna|IV continuously over 6 days each time, on Weeks 16, 22, 28, and 34. Dose 2.8 gm/m^2/day.
1812245|NCT00673192|Procedure|peripheral blood isolation|to isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
1812246|NCT00673205|Drug|Bicalutamide|150mg p.o. daily
1812247|NCT00673205|Drug|Placebo|
1812248|NCT00673218|Drug|Placebo|Placebo, Q2 or 4 weeks depending on Ige level and weight as appropriate for active treatment.
1812249|NCT00673218|Drug|Xolair|150 to 375 mg is administered SC every 2 or 4 weeks
1812250|NCT00673231|Drug|Dapagliflozin|tablet oral 2.5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
1812251|NCT00673231|Drug|Dapagliflozin|Tablet oral 5 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
1812252|NCT00673231|Drug|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 48 weeks (= 24 week randomised treatment period + 24 week study extension period I)
1812253|NCT00673231|Drug|Placebo|Placebo
1812254|NCT00673231|Drug|Dapagliflozin|tablet oral 2.5 total daily dose once daily 56 weeks (= 56 week study extension period II)
1812255|NCT00673231|Drug|Dapagliflozin|tablet oral 10 mg total daily dose once daily 56 weeks (= 56 week study extension period II)patients that have been treated with 5 mg during the 24 week randomised treatment period and extension I period will during extension II period switched to 10 mg
1812256|NCT00673244|Drug|Furosemide|One dose: 1 mg/kg (iv)if the patient is furosemide naive or 1.5 mg/kg (iv) if patient is not furosemide naive.
1812257|NCT00673257|Drug|daunorubicin hydrochloride|Given IV
1812258|NCT00673257|Other|pharmacological study|pharmacological studies
1812259|NCT00673257|Procedure|dual x-ray absorptimetry|
1812260|NCT00673270|Drug|Fludrocortisone|50 µg of fludrocortisone per os
1812261|NCT00673270|Drug|Hydrocortisone|50 mg of intravenous hydrocortisone
1812262|NCT00673270|Drug|Placebo of Fludrocortisone|Tablet of placebo of Fludrocortisone
1812263|NCT00673270|Drug|Placebo of Hydrocortisone|2 ml of isotonic saline solution
1812264|NCT00673283|Device|bi-plane chest radiography|Bi-plane radiography of the thorax
1812265|NCT00673296|Drug|Intravitreal Bevacizumab|Intravitreal injection of bevacizumab (1.25 mg in 0.05 mL) and C3F8 (0.2-0.3 mL)
1812266|NCT00673309|Procedure|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
1812267|NCT00673309|Procedure|Stable Isotope Infusion study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
1812268|NCT00673309|Procedure|Radiology testing: DEXA, K+ counter, ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
1812269|NCT00673309|Drug|IGF-1|Administration of randomized drug daily throughout hospitalization to 95% wound healing
1812270|NCT00673309|Drug|Insulin|Insulin IV administered continuously to maintain serum glucose between 80-110 throughout hospitalization until wounds are 95% healed.
1812271|NCT00673309|Drug|oxandrolone|Oxandrolone given daily throughout hospitalization until 95% wound healing.
1818349|NCT00711230|Biological|DermaVir|
1812272|NCT00673309|Drug|Propranolol|Propranolol to be given daily to decrease HR and BP throughout hospitalization until 95% wound healing.
1812273|NCT00673309|Drug|Clonidine|Clonidine administered daily throughout hospitalization until 95% wound healing to decrease HR, BP, and anxiety.
1812274|NCT00673309|Drug|Ketoconazole|Ketoconazole administered PO every 12 hours throughout hospitalization until 95% wound healing.
1812275|NCT00673309|Drug|Dehydroepiandrosterone-sulfate|The hormone Dehydroepiandrosterone-sulfate will be given daily until 95% wound healing.
1812276|NCT00673309|Drug|Fenofibrate|Fenofibrate administered daily until 95% wound healing.
1812277|NCT00673309|Drug|Metformin|metformin to be administered daily throughout hospitalization until 95% wound healing.
1812278|NCT00673309|Drug|Byetta|Byetta administered daily throughout hospitalization until 95% wound healing.
1812279|NCT00673309|Drug|Growth Hormone|Recombinant Human Growth hormone to be administered daily until 95% wound healing.
1812280|NCT00673309|Drug|Pioglitazone|Pioglitazone administered daily throughout hospitalization until 95% wound healing
1812281|NCT00673686|Drug|YAZ (DRSP 3 mg/EE 0.02 mg, BAY86-5300)|SH T 00186 D in a 24-day regimen, i.e., 24 verum tablets, 4 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
1812282|NCT00673686|Drug|Yasminelle (SH T 00186 D)|SH T 00186 D in a 21-day regimen, i.e., 21 verum tablets, 7 placebo tablets Dose: 0.02 mg EE, 3 mg DRSPMode of administration: Oral, 1 tablet dailyDuration of treatment: 3 cycles of 28 days each
1812283|NCT00673699|Procedure|Gastric mucosal biopsy|Using upper gastrointestinal endoscopy with targeting biopsy in patients with dyspepsia
1812284|NCT00673712|Device|Continuous Sternal Block|Elastomeric Pump for Continuous Infusion of Local Anesthetic
1812285|NCT00673712|Drug|Opioid based analgesia|"Opioid Analgesic agents delivered by:
PCA on demand mode IV injections PRN IM injections PRN Oral PRN"
1812286|NCT00673725|Drug|Locobase® REPAIR|emollient
1812287|NCT00673738|Drug|Cetuximab|"Cetuximab dose: based on patient's actual weight. Loading phase dose of cetuximab is 400 mg/m2 IV administered over 120 minutes, on day 1 followed by; Concurrent phase, weekly infusion dose at 250 mg/m2 IV over 60 minutes, on days 8, 15, 22, 29, 36, 43, 50.
Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week complete blood counts (CBCs), differentials, and blood urea nitrogen (BUN) plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted."
1812288|NCT00673738|Radiation|Conformal Thoracic Radiotherapy (CTRT)|"Radiation will be accompanied by weekly Cetuximab. Weekly Cetuximab will start on 1st day of radiation (Day 8). So, total number of cetuximab administrations will vary from 7 to 8. Patients will have every other week CBCs, differentials, and BUN plus creatinine and Mg. If patient's ANC drops below 1,000 and/or the platelet count below 75,000 during CTRT, the corresponding, weekly dose of cetuximab will be omitted.
Radiation therapy will begin on day 8 (with window of ± 3 days). Adequate hematologic profile (ANC >1,000 and platelets >75,000) required. Patient may be delayed for a max. of 2 weeks. If > 2 week delay occurs, patient will come off study."
1812289|NCT00673751|Drug|GLP-2|450 nmol subcutaneous
1812290|NCT00673751|Drug|Placebo|
1812291|NCT00673764|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
1812292|NCT00673764|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops 1 drop each eye one time
1812293|NCT00673777|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), VEGFR1 peptide(1mg) and VEGFR2 peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
1812297|NCT00673803|Procedure|cataract surgery|cataract surgery with implantation of an IOL
1812298|NCT00673816|Drug|Sunitinib Malate|Participants were expected to receive 9 months of sunitinib malate therapy administered in 6 cycles. Each cycle consisted of a daily oral dose of 50 mg sunitinib malate for 4 weeks followed by a 2-week rest period).
1812299|NCT00673829|Biological|Gene Modified T Cells|Gene Modified T Cells Phase Ia: One time infusion Modified TCells given through a vein in the arm or a catheter over a 30-60 minute period
1812300|NCT00673829|Biological|Gene Modified T Cells and Interleukin 2|One time infusion Modified T Cells without or with (randomized) continuous infusion outpatient interleukin 2 (IL2) for two weeks
1812301|NCT00673842|Device|Implantable Cardioverter Defibrillator + Usual Care|Any Medtronic approved (in each geography) single chamber or dual chamber implantable cardioverter defibrillator (ICD)
1812302|NCT00673842|Other|Usual care|Usual post-MI care
1812303|NCT00673855|Other|Lubricant Eye Drops FID 112903|Lubricant Eye Drops FID 112903 1 drop each eye 1 time
1812304|NCT00673855|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops
1812305|NCT00673868|Biological|CMV Specific Cytotoxic T Lymphocytes|CMV Specific Cytotoxic T Lymphocytes will be infused between days 30 and 40 post-transplant at a dose ranging from 2- 5 x e5 cells/kg.
1812306|NCT00673881|Drug|choline fenofibrate|135 mg choline fenofibrate daily(oral, capsule)
1812308|NCT00673907|Other|Wood smoke particles|Subjects are exposed at rest to the exposures for 3 h in our climate chamber
1812309|NCT00673920|Drug|methotrexate|Oral or parenteral repeating dose
1812310|NCT00673920|Drug|ocrelizumab|Intravenous repeating dose
1812311|NCT00673920|Drug|placebo|Intravenous repeating dose
1812312|NCT00673933|Drug|Methyl aminolevulinate (MAL) PDT|Cream application followed by illumination with red light
1812313|NCT00673946|Other|True saturation values displayed|Physicians will be presented with real saturations.
1812314|NCT00673946|Other|Altered saturation values displayed.|Physicians will be presented with saturation measurements three percentage points above the true values.
1812315|NCT00673959|Other|Lubricant Eye Drop FID 111421|Lubricant Eye Drop FID 111421 1 drop each eye one time
1812316|NCT00673959|Other|Optive Lubricant Eye Drop|Optive Lubricant Eye Drop 1 drop each eye one time
1812317|NCT00673972|Radiation|gastric scintigraphy|"All tests start after overnight fast. Test meals consists of 120g scrambled egg, two slices of toasted bread, 30g of strawberry jam and 120ml of water. 12MBg (0.33mCi) of 99mTc sulfur colloid is mixed with egg thoroughly before the mixture cooked in a microwave oven for 2 minutes. All meals are prepared on the morning of examination and consumed within 20 minutes.
Anterior and posterior images of the gastric region are taken within one minute after completion of test meals. Subsequent images are taken every 2 minutes in the first 60 minutes and at 120 minutes and 180 minutes. One-min images of gastric region at upright position are taken in the 140keV 99mTc peak with a 20% window."
1812318|NCT00673985|Other|Percutaneous Transluminal Angioplasty|Balloon Angioplasty
1812319|NCT00673985|Device|LifeStent NT™ Self-Expanding Peripheral Stent|Balloon angioplasty plus stent
1812320|NCT00673998|Device|Isokinetic Dynamometer (Biodex system III)|Biodex system III Isokinetic Dynamometer (Biodex Medical, Inc., Shirley, NY).
1812321|NCT00674011|Drug|Bevacizumab|Given as part of standard of care or another research protocol
1812322|NCT00674024|Drug|Pazopanib|
1812323|NCT00674024|Drug|Pazopanib (GW786034)(GW786034)|
1812324|NCT00674037|Other|monetary incentive|75 euros for each patient included
1812325|NCT00674050|Drug|Technosphere Insulin (TI) Inhalation Powder|3.0 U of human insulin. 5 or 10 mg or Technosphere Inhalation Powder, containing 15 0r 30 U of insulin.
1812326|NCT00674050|Drug|Albuterol (Salbutamol)|2 puff= 200ug total dose
1812327|NCT00674050|Drug|Fluticasone|2 puffs= 500ug total dose
1812328|NCT00674063|Drug|alefacept|IV
1812329|NCT00674089|Dietary Supplement|Vitamin A|Vitamin A 50,000 IU
1812330|NCT00674089|Dietary Supplement|Placebo|Vitamin A Placebo
1812331|NCT00674102|Drug|ASA404|
1812332|NCT00674115|Drug|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate. Single dose per day for either 1 or 7 days.
1812333|NCT00674115|Drug|omeprazole magnesium|Omeprazole 20 mg tablet. Single dose per day for either 1 or 7 days.
1812334|NCT00674115|Drug|sodium bicarbonate|Sodium bicarbonate. Single dose.
1812335|NCT00674128|Device|Cyanoacrylate tissue adhesive (Dermabond)|Skin closure will be performed with cyanoacrylate tissue adhesive.
1812336|NCT00674128|Device|Polyglactin 910 suture (Vicryl)|Skin closure will be performed with polyglactin 910 suture.
1812337|NCT00674141|Drug|Dexamethasone soduim phosphate|nasale administation of Dexamethasone in 20mg dose/day (in two divided doses) fpr sevem days of treatment
1812338|NCT00674154|Drug|Cholecalciferol|2800 IE daily in 52 weeks
1812339|NCT00674167|Drug|Docetaxel|Three cycles of chemotherapy will be administered before surgery with docetaxel at 30 mg/m² on day 1 and 8 in a 21 day treatment cycles.
1812340|NCT00674167|Drug|Cisplatin|Three cycles of chemotherapy will be administered before surgery with cisplatin at 30 mg/m² on day 1 and 8 in a 21 day treatment cycle.
1812341|NCT00674167|Drug|Capecitabine|Three cycles of chemotherapy will be administered before surgery with capecitabine at 750 mg/m² twice daily from day 1 to 14 in a 21 day treatment cycle.
1812342|NCT00674180|Behavioral|Workbook|The workbook developed as a do-it-yourself program in which participants completed self-help sheets that guided them to sections of the workbook most salient to their needs.
1812343|NCT00674180|Behavioral|Computer Intervention|The computer intervention was provided using a network system that included a file server plus 5 multimedia computers with touch screens. The expert software program was written to guide participants in using the workbook and tail behavioral goals based on their prior computer use and the answers they provided on baseline questionnaires. The three primary paths in the computer addressed nutrition, fitness, and psychobehavioral content.
1812344|NCT00674180|Behavioral|Staff Consultation|The staff consultation component included 6 closed-group workshop sessions and up to 18 telephone or face-to-face consultations with a registered dietician and/or a cognitive behavioral therapist. The workshop curriculum focused on specific activities and assignments in the workbook, and it encouraged use of the computer to identify problems and issues.
1812345|NCT00674193|Other|pharmacological study|Correlative studies
1812346|NCT00674193|Other|laboratory biomarker analysis|Correlative studies
1812347|NCT00674206|Drug|Gemcitabine|Gemcitabine 1000mg/m^2 on day 1 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
1812348|NCT00674206|Drug|Oxaliplatin|Oxaliplatin 100mg/m^2 on day 2 every 14 days Cycles of treatment will be repeated every 2 weeks until disease progression, intolerable toxicity, or the development of any of the criteria for study removal
1812350|NCT00674232|Drug|600 mcg misoprostol|single dose of misoprostol taken orally
1812351|NCT00674232|Procedure|Surgical treatment|Either dilation and curettage or manual vacuum aspiration, as per local protocol
1812352|NCT00674245|Drug|Pantoprazole|40 mg once daily for 4 weeks
1812353|NCT00674245|Drug|Pantoprazole|40 mg once daily improves sleep quality in patients with GERD.
1812354|NCT00674245|Drug|placebo|40 mg once daily for 4 weeks
1812355|NCT00674258|Biological|URLC10, TTK and KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10-117 peptide(1mg), TTK- peptide(1mg) and KOC1- peptide(1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
1812357|NCT00674310|Drug|Ropinirole Hydrochloride|Restless Leg Syndrome
1812358|NCT00674323|Drug|Verteporfin Photodynamic Therapy|After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m^2 body surface area, light application of 50 J/cm^2 to the study eye was begun 15 minutes after the start of infusion.
1812359|NCT00674323|Drug|Ranibizumab|Ranibizumab at dose of 0.5 mg administered as an intravitreal injection.
1812360|NCT00674336|Procedure|High Hydrostatic Pressure Processing|High Hydrostatic Pressure Processing is a technology, used in the food service industry, where foods are subjected to high pressure. These high pressures kill many pathogens without affecting the quality of the food.
1812361|NCT00674349|Procedure|surgery|staging surgery
1812466|NCT00675090|Drug|Placebo|Placebo tablets to match once a day
1812364|NCT00674375|Other|Electronic risk alerts|Electronic risk alerts within the electronic medical record system will automatically calculate a patient's Framingham Risk Score during office visits for chest pain. These alerts will recommend electrocardiogram performance and aspirin therapy for patients with Framingham Risk Score at least 10%, and will recommend against exercise stress testing for patients with a Framingham Risk Score less than 10%.
1812365|NCT00674401|Procedure|Radiofrequency catheter ablation|"In case of Paroxysmal AF, patients will be randomized into one of 2 in the study:
Empirical pulmonary vein antrum circumferential isolation, or
High frequency sites ablation in the LA
In case of Persistent AF, patients will be randomized into one of 2 in the study:
Empirical circumferential PV antrum isolation w/out roof line, or
A combined approach involving PV antrum isolation w/out roof line and high frequency sites ablation."
1812366|NCT00674414|Biological|trastuzumab|Trastuzumab (Herceptin®) IV once weekly
1812367|NCT00674414|Drug|everolimus|Oral everolimus once daily
1812368|NCT00674414|Procedure|therapeutic conventional surgery|Patients undergo surgery
1812369|NCT00674427|Biological|CD3/CD28 Activated T cells|Subjects who are not in CR will receive one infusion of high dose aDLI
1812370|NCT00674427|Biological|CD3/CD28 Activated T cells|Subjects in CR 6-12 weeks after the first dose of Activated Donor Lymphocyte Infusion (aDLI) will continue to receive aDLI every 3 months for up to a year.
1812371|NCT00674440|Drug|F-DOPA|0.08-0.16 mCi/kg once
1812372|NCT00674440|Radiation|PET scan|
1812373|NCT00674453|Drug|Lasofoxifene|Oral tablet, 0.25 mg, daily, 2 years
1812374|NCT00674453|Other|Placebo|Matching placebo tablet given once daily for 2 years
1812375|NCT00674466|Drug|1.5 mg or 2.0 mg CJC-1134-PC|twice-a-week
1812376|NCT00674466|Drug|Placebo|twice-a-week
1812377|NCT00674479|Drug|INCB018424|Starting dose: 25 mg by mouth (po) twice daily for 7 days each week for 4 weeks.
1812379|NCT00674518|Behavioral|One on one counseling|Motivational Interviewing
1812380|NCT00674518|Behavioral|Group/team - based health education|peer led, scripted health promotion curriculum in groups of 4-5 individual, with team building activities and health education for 12, 1-hour sessions per year.
1812381|NCT00674518|Behavioral|PACE physician counseling|PACE format for physician exercise and nutrition counseling annually.
1812382|NCT00674531|Procedure|Artery resection|Artery resection
1812383|NCT00674544|Behavioral|Lifestyle intervention|Kindergarten and homebased increases in physical activity, healthy nutrition, sleep duration and decrease in media use: Involvement of parents and siblings
1812384|NCT00674557|Drug|SOD1 inhibitor ATN-224|
1812385|NCT00674557|Drug|exemestane|
1812386|NCT00674557|Genetic|protein expression analysis|
1812387|NCT00674557|Genetic|proteomic profiling|
1812388|NCT00674557|Other|laboratory biomarker analysis|
1812389|NCT00674557|Other|pharmacological study|
1812390|NCT00674570|Drug|Hydrocortisone|25 mg/oral one hour prior to extinction task
1812391|NCT00674570|Drug|D-Cycloserine|50 mg/oral one hour prior to extinction task
1812392|NCT00674570|Drug|Placebo|One hour prior to extinction task
1812395|NCT00674596|Drug|ramipril|ramipril 10 mg/day during 3 months
1812396|NCT00674609|Drug|Placebo|Containing colourants and excipients. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations in 24 hours.
1812397|NCT00674609|Drug|Sativex®|Containing D9 tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours.
1812398|NCT00674609|Drug|THC Alone|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
1812399|NCT00674622|Drug|Prolotherapy|Injection of 15% dextrose with lidocaine at the lateral epicondyle
1812400|NCT00674622|Procedure|Placebo|Saline/lidocaine
1812403|NCT00674648|Biological|CMV-Peptide-Specific T cells|"In this phase I trial, five escalating dose levels will be tested. Each dose will be administered to groups of at least 3 and up to 6 patients. Dose escalation will be based on the dose limiting toxicity (DLT) observed in each treatment group (Confer Biostatistics).
The patient groups and donors are outlined as follows: Group I will receive a single dose of 5 x 105 T cells/kg body weight/dose; Group II will receive a single dose of 1 x 106 T cells/kg/dose; and group III will receive a single dose of 2 x 106 T cells/kg/dose; group IV will receive 3 weekly doses of 1 x 106 T cells/kg/dose; group V will receive 3 weekly doses of 2 x 106 T cells/kg/dose."
1812404|NCT00674661|Drug|riboflavin ophthalmic solution|riboflavin 0.1% ophthalmic solution (approximately 32 drops, or 1.6 mL)
1812405|NCT00674661|Device|UVA Irradiation|UVA light (365 nm at an irradiance of 3 mW/cm2) for 30 minutes
1812406|NCT00674674|Drug|Topotecan|"Induction (4 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 3.
The Induction period is the first 4 weeks of therapy."
1812464|NCT00675077|Radiation|Far Infrared Radiation|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
1812407|NCT00674674|Drug|Topotecan|Consolidation (6 weeks): Patients will receive IT topotecan for 5 consecutive days during weeks 1 and 4. The Consolidation period is 6 weeks in duration. Consolidation begins immediately after completion of the 4th week of Induction.
1812408|NCT00674674|Drug|Topotecan|Maintenance (4 weeks for 11 courses): Patients will receive IT topotecan for 5 consecutive days during week 1. Each course of Maintenance is 4 weeks in duration. Maintenance begins immediately after completion of the 6th week of Consolidation.
1812409|NCT00674687|Drug|2-weeks placebo then gabapentin|Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
1812410|NCT00674687|Drug|1-week placebo then gabapentin|Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
1812411|NCT00674700|Drug|300 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
1812412|NCT00674700|Drug|500 IR house dust mites allergen extract tablet|One sublingual tablet daily for one year
1812413|NCT00674700|Drug|Placebo tablet|One sublingual tablet daily for one year
1812414|NCT00674713|Other|Acupuncture|
1812415|NCT00674713|Drug|Ondansetron|
1812416|NCT00674713|Drug|Physiological saline solution|
1812417|NCT00674713|Other|Sham acupuncture|
1812418|NCT00674713|Drug|Ondansetron|
1812419|NCT00674713|Other|Acupuncture at P6 point|
1812420|NCT00674713|Drug|Physiological saline solution|
1812421|NCT00674713|Other|Sham acupuncture|
1812422|NCT00674726|Other|Observation and measurement of axilo-rectal temperature|Measurement of axilo-rectal temperature
1812423|NCT00674739|Drug|Imiquimod|daily topical application for up to 8 weeks
1812424|NCT00674739|Drug|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks.
1812425|NCT00674739|Drug|placebo cream|placebo cream applied daily to wart areas for up to 8 weeks
1812426|NCT00674752|Drug|Gabapentin|Gabapentin 250 mg oral capsule 30 minutes prior to bedtime
1812427|NCT00674752|Drug|Gabapentin|Gabapentin 500 mg oral capsule 30 minutes prior to bedtime
1812428|NCT00674752|Drug|Placebo|Matched placebo oral capsule 30 minutes prior to bedtime
1812429|NCT00674765|Drug|Seroquel|400 mg/day
1812430|NCT00674765|Drug|Placebo|400 mg/day
1812431|NCT00674778|Procedure|Any percutaneous cardiovascular procedure|
1812432|NCT00674791|Biological|OCPM Immunotherapeutic Vaccine|Patients will receive 1 injection into each thigh at each of 6 visits: week 0, week 1, week 2, week 4, week 5, and week 6. The first 9 patients will receive a 100 microgram dose and the second 9 patients a 1 milligram dose of the peptide mixture.
1812433|NCT00674817|Drug|400 microgrammes GSK961081|Inhaled GSK961081 administered via Dry Powder Inhaler.
1812434|NCT00674817|Drug|1200 microgrammes GSK961081|Inhaled GSK961081 adminisntered via dry powder inhaler.
1812435|NCT00674830|Behavioral|professionally administered cognitive-behavioral therapy|professionally administered CBT-I consisting of six weekly sessions
1812436|NCT00674830|Behavioral|self-administered form of cognitive-behavioral therapy|self-administered CBT-I consisting of six short booklets and videotapes
1812437|NCT00674830|Behavioral|placebo|usual care
1812438|NCT00674843|Radiation|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
1812439|NCT00674856|Drug|naproxcinod|750mg
1812440|NCT00674869|Other|pit and fissure sealant|pit and fissure sealant on one randomized tooth by pair of permanent molar
1812441|NCT00674882|Other|Data Collection|Data Collection, Outcomes Research, Statistical Data Analysis, Longitudinal Study
1812442|NCT00674895|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Radiation: Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
1812443|NCT00674908|Biological|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
1812444|NCT00674908|Biological|Easy Five|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib conjugate pentavalent liquid combination vaccine
1812445|NCT00674921|Drug|cotrimoxazole|cotrimoxazole 800/160 mg once daily as indicated by the start and end times of the specified arms for continued prevention of HIV-related infections
1812446|NCT00674921|Drug|Placebo|starch, magnesium stearate, sodium lauryl sulphate
1812447|NCT00674934|Radiation|Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
1812448|NCT00674947|Drug|BIIB015|IV infusion once every 3 weeks until disease progression or unacceptable toxicity
1812449|NCT00674960|Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength)|Far Infrared Radiation (5μm to 20μm wavelength). Far Infrared radiation for 30 to 40 minutes per treatment session.
1812450|NCT00674973|Drug|Erlotinib|Participants received erlotinib 150 mg tablet orally once daily.
1812451|NCT00674973|Drug|Placebo|Participants received placebo matching to erlotinib 150 mg tablet orally once daily.
1812452|NCT00674986|Device|Accu-Chek 360° View Blood Glucose Analysis Tool|
1812453|NCT00674986|Device|Accu-Chek Aviva Glucose Meter|
1812454|NCT00674999|Biological|Amnion|Application of Amnion with processing procedures involving the use of trypsin-EDTA
1812455|NCT00674999|Biological|Amnion|Application of Amnion with processing procedures involving the use of Dispase II
1812456|NCT00674999|Drug|Polysporin/Bacitracin/Mycostatin|Application of Prepared antibiotic ointment: Polysporin, Bacitracin and Mycostatin combined
1812457|NCT00675012|Drug|NGR-hTNF|iv 0.8 or 45 mcg/sqm q3W
1812458|NCT00675012|Drug|Oxaliplatin|iv q3W 100 mg/sqm 60 minutes after NGR-hTNF infusion
1812459|NCT00675012|Drug|capecitabine|orally 825 mg/sqm 2qDx14
1993586|NCT03170882|Drug|Ixazomib|Ixazomib capsules
1812461|NCT00675038|Procedure|Liver Biopsy and MRI T2* MRI|Evaluation of iron overload with liver biopsy vs. MRI T2* MRI
1812462|NCT00675064|Drug|GSK369796|Anti-malarial
1812463|NCT00675064|Drug|Placebo|Placebo matching GSK369796
1812465|NCT00675090|Drug|GSK239512|GSK239512 oral tablets once a day
1812467|NCT00675103|Drug|pegloticase 8 mg i.v.|pegloticase 8 mg i.v. every 2 weeks for 24 weeks
1812468|NCT00675116|Drug|GW823296|
1812469|NCT00675129|Behavioral|Dialectical behavioral therapy for adolescents (DBT-A)|"Patients randomised to DBT-A will receive 16 weeks treatment, with one weekly session (60 minutes)of individual therapy, one weekly session of multifamily skills training (120 minutes), and telephone coaching outside therapy sessions.
The treatment has been developed by Marsha Linehan (Linehan, 1993a; 1993b)and adapted for adolescents by Alec Miller (Miller, Rathus & Linehan, 2007). Individual DBT therapists have been trained by drs Alec L Miller and Sarah K Reynolds and have a minimum of one year clinical practise as DBT therapists. The therapists are organised in two consultation teams supervised on a bimonthly basis throughout the entire study by drs Miller and Reynolds respectively."
1812470|NCT00675129|Behavioral|Treatment as usual|Patients randomised to EUC will received standard care (16 weeks) at five participating child and adolescent outpatient clinics from therapists not trained in or practising DBT. According to pilot study data EUC will most likely consist of psychodynamic therapy, various forms of family therapy and supportive therapy.
1812471|NCT00675142|Procedure|Intrauterine Insemination|Changing the time span between ovulation induction and IUI during fertility treatment.
1812472|NCT00675155|Radiation|Far Infrared Radiation|Radiation: Far Infrared Radiation (5μm to 20μm wavelength) Far Infrared radiation for 30 to 40 minutes per treatment session.
1812473|NCT00675168|Radiation|PET/CT (low-dose)|400 mBq 18F-flour-deoxyglucose given iv. 60 min. before PET/CT-scan
1812474|NCT00675181|Drug|Melatonin|5mg per os
1812475|NCT00675181|Drug|Placebo|per os
1812476|NCT00675194|Drug|Cisplatin, Irinotecan, Capecitabine|
1812477|NCT00675207|Drug|Brimonidine purite 0.15%|A single drop of brimonidine purite 0.15% ophthalmic solution administered topically in the eye 3 times daily.
1812478|NCT00675207|Drug|Dorzolamide 2%|A single drop of dorzolamide 2% ophthalmic solution administered topically in the eye 3 times daily.
1812479|NCT00675207|Drug|Brinzolamide 1%|A single drop of brinzolamide 1% ophthalmic solution administered topically in the eye 3 times daily.
1812480|NCT00675220|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1812481|NCT00675233|Drug|HPPH|Given IV
1812482|NCT00675233|Procedure|laser therapy|Escalating light doses with 665 nm light
1812483|NCT00675246|Drug|Betamethasone|IM administration of 12mg of betamethasone each 24 hours (total dose=24mg)
1812484|NCT00675259|Drug|bevacizumab|bevacizumab 10 mg/kg on days 1 and 15 administered every 28 days [1 cycle] for 5 cycles
1812485|NCT00675259|Drug|carboplatin|AUC 2 IV on days 1, 8, and 15
1812486|NCT00675259|Drug|nab-paclitaxel|100 mg/M2 IV
1812487|NCT00675259|Procedure|Surgery|lumpectomy or mastectomy along with axillary lymph node dissection approximately 4-5 weeks after completion of NCT.
1812488|NCT00675259|Drug|Adjuvant chemotherapy|All hormone receptor positive patients will receive endocrine therapy. All patients will receive 6 months of adjuvant bevacizumab at 15 mg/kg IV every 3 weeks. If using an adjuvant anthracycline-containing regimen then bevacizumab will be administered ≥ 3 weeks after completing the regimen.
1812489|NCT00675272|Drug|hydrocortisone|hydrocortisone 50mg iv. every 6 hours
1812490|NCT00675272|Drug|sodium chloride|sodium chloride every 6 hours iv
1993587|NCT03170882|Drug|Pomalidomide|Pomalidomide capsules
1993588|NCT03170882|Drug|Dexamethasone|Dexamethasone tablets
1812493|NCT00675311|Behavioral|DM-Standard|Device/t+ Medical Diabetes Management System
1812494|NCT00675311|Behavioral|Disease Management Plus|Plus is one of the randomized arms of the study. Patients assigned to this arm receive support from Disease Management nurses and technology.
1812495|NCT00675324|Drug|Laxabon|Laxabon 4 litres, starting the day (e.m.) before the colonoscopy
1812496|NCT00675324|Dietary Supplement|Fresubin Energy drink|30 kcal/kg*day five days before colonoscopy
1812497|NCT00675337|Procedure|perineum maintained|infants maintained at the level of the perineum until umbilical cord clamping
1812498|NCT00675337|Procedure|abdominal placement|infants placed on the maternal abdomen prior to umbilical cord clamping
1812499|NCT00675350|Drug|Omacetaxine|1.25 mg/m2 subcutaneous twice daily for 14 days
1812500|NCT00675363|Procedure|Protocolized Sedation|Nurse-directed protocol for administering sedation and/or analgesia.
1812501|NCT00675363|Procedure|Protocolized sedation, with daily interruption|Nurse-directed protocols for administering sedation and/or analgesia, with daily interruption of sedation/analgesia
1812502|NCT00675389|Behavioral|Peer Health Workers Intervention|Peer health workers are themselves PLWHA on ART who have demonstrated good ART adherence for at least 6 months. The peers are responsible for ~15-20 patients and are expected to visit the patients in their homes once every two weeks. At these visits, peers record a review of symptoms, client self-report of adherence, and a pill count. At the clinic, peers assist with patient organization and share their experiences, particularly with patients about to start ART. Peer health workers undergo an initial, intensive two day residential training course and are provided with a bike and basic supplies, and a modest amount of remuneration to encourage compliance with their responsibilities and promote a high program retention rate.
1812503|NCT00675389|Behavioral|Peer Health Workers and Mobile Phone Intervention|In addition to the peer health worker intervention, this arm adds a mobile phone intervention consisting of the following: during home visits, peers with mobile phones, using data collected on their home visit forms, send real-time text messages containing this clinical and adherence data back to the central clinic to be reviewed by clinical staff within a 24 hour period. Peers may also call, toll-free, back to a central clinic Warmline with any questions or concerns.
1812504|NCT00675402|Other|supervised treadmill exercise program|Supervised treadmill therapy consists of a walking exercise on a treadmill under supervision of a physiotherapist, 2-3 times a week. This program is combined with individual walking every other day and the total duration of the program is 6 months. Guided by the painfree walking distance, every month the angle and/or speed of the treadmill will increase. A standardized protocol for this type of therapy is already in use by many physiotherapists in Limburg (Willigendael, 2005).
1812505|NCT00675415|Diagnostic Test|Capnography|Capnography: Passive measurement of carbon dioxide via a special bite block which allows graphic assessment of the subject's respiratory activity
1812540|NCT00675701|Drug|placebo|capsules
1812506|NCT00675428|Drug|BG00002 (natalizumab)|
1812507|NCT00675441|Drug|Lenalidomide|10 mg (capsule) by mouth on days 1-21 of a 28-day cycle, for a total of 6 cycles.
1812508|NCT00675467|Behavioral|Focus Group - Parent/Caregiver|A 1 1/2 hour group session with other parents/caregivers.
1812509|NCT00675467|Behavioral|Focus Group - Pediatric Patient|A 1 1/2 hour group session with other pediatric patients.
1812510|NCT00675480|Procedure|Thrombectomy|Aspiration Thrombectomy prior to stent implantation in patients with ST segment elevation myocardial infarction
1812511|NCT00675480|Procedure|Primary angioplasty|Standard primary angioplasty with stent implantation
1812512|NCT00675493|Drug|biphasic insulin aspart 30|Start dose and frequency prescribed by the physician as a result of a normal clinical evaluation
1812513|NCT00675506|Drug|Growth hormone releasing hormone (GHRH) 1-44|2-mg sub-cutaneous injections once daily for 12 months
1812514|NCT00675506|Drug|Placebo|2-mg sub-cutaneous injections once daily for 12 months
1812515|NCT00675519|Behavioral|Motivational enhancement therapy|Motivational enhancement therapy begins with the assumption that the responsibility and capacity for change lie within the client. The therapist begins by providing individualized feedback about the effects of the patient's drinking. Working closely together, therapist and patient explore the benefits of abstinence, review treatment options, and design a plan to implement treatment goals.
1812516|NCT00675532|Behavioral|Primary Care Counseling|Subjects in this condition will attend bi-weekly 15 minute sessions with the study nurse for primary care counseling which is a brief manual-guided, medically focused counseling approach to the treatment of opioid dependent individuals seen in primary care settings. The brief counseling sessions involve repeated support for and monitoring of medication compliance, and the provision of advice regarding established methods for coping with psychological and social factors that lead to drug use.
1812517|NCT00675532|Behavioral|Cognitive-behavioral psychotherapy|Subjects in the CBT condition will participate in bi-weekly 50-minute-long individualized cognitive-behavioral psychotherapy sessions with a CBT trained clinician. The general purpose of the therapy is to: (1) acquire information about important concepts and aspects of recovery from opioid addiction; (2) increase self-awareness of specific problems and issues in relation to addiction and recovery, and (3) learn new coping skills to deal with problems contributing to or resulting from the addiction and to improve overall psychosocial functioning. The primary focus of this approach is to provide patients with frequent supportive contact and to teach cognitive-behavioral relapse prevention skills.
1812518|NCT00675545|Drug|Docetaxel, Carboplatin|"Docetaxel Form: A white, lyophilized powder in vials of 50, 150, and 450 mg each, which should be stored at room temperature in a light-protected area.
Carboplatin Form: Taxotere is supplied as a sterile, non-aqueous, viscous solution with an accompanying sterile diluent (13% ethanol in water for injection). 20 and 80 mg strengths are available."
1812519|NCT00675558|Procedure|Initial Surgery|"NO patients had initial abdominal laparoscopic surgery at study entry, during which research fat biopsies were obtained, completing their participation.
MO patients had initial laparoscopic bariatric surgery (gastric bypass, adjustable gastric band, or sleeve gastrectomy) and fat biopsies at entry, completing their participation.
All 30 SMO patients had initial laparoscopic bariatric surgery (sleeve gastrectomy) & fat biopsies. The first 10 to lose 100 lbs but who needed further surgery to reach optimal weight and who consented to further surgery underwent a 2nd laparoscopic bariatric surgery (either a biliopancreatic diversion with duodenal switch or a Roux-en-Y gastric bypass) and biopsies. The interval between surgeries averaged 15 mos. and the weight loss 55 kg. 30 SMO patients were initially enrolled to insure that 10 would complete 2 surgeries. When 10 had had their 2nd operation, the study was considered complete, and the remaining 20 SMO participants were so notified."
1812520|NCT00675558|Procedure|Second Bariatric Surgery|A second bariatric procedure was performed on only 10 of the original 30 Super-morbidly Obese (SMO) subjects.
1812521|NCT00675584|Drug|Budesonide|Participants in Arm 1 will receive 0.5 mg of budesonide once a day. Participants in Arm 2 will receive 1 mg of budesonide twice a day for 7 days at the onset of respiratory tract illnesses.
1812522|NCT00675584|Drug|Placebo Budesonide|Participants in Arm 1 will receive placebo budesonide each morning during respiratory tract illnesses for 7 days. Participants in Arm 2 will receive placebo budesonide once a day for the entire study, other than when they have a respiratory tract illness.
1812523|NCT00675597|Drug|Bevacizumab (Avastin), Taxotere (Docetaxel), Vinorelbine Tartrate (Navelbine)|Patients will be treated as follows: vinorelbine (45 mg/m2) + docetaxel (45 mg/m2) intravenously on day 1, followed by pegylated filgrastim 6mg subcutaneously on day 2, delivered every 2 weeks for 8 doses total. Patients who have already received one cycle of cisplatin-based adjuvant chemotherapy need only complete 3 cycles of vinorelbine+docetaxel for a total of 4 cycles of adjuvant chemotherapy. Patients who require post-operative radiation therapy (PORT) will begin PORT after completion of vinorelbine + docetaxel.
1812524|NCT00675610|Behavioral|communication training|providers are trained to communicate with patients about adherence and patients are coached to discuss adherence with providers
1812525|NCT00675623|Drug|Dimebon|Dimebon, 5 mg orally three times daily for six months
1812526|NCT00675623|Drug|Dimebon|Dimebon 20 mg orally three times daily for six months
1812527|NCT00675623|Drug|Placebo|Placebo three times daily for six months
1812528|NCT00675636|Other|study of socioeconomic and demographic variables|database, no intervention
1812529|NCT00675636|Procedure|evaluation of cancer risk factors|database, no intervention
1812530|NCT00675636|Procedure|study of high risk factors|database, no intervention
1812531|NCT00675649|Biological|CNTO 148 / Golimumab|100 mg sc injection every 4 weeks from week 0 to week 20
1812532|NCT00675649|Biological|placebo|placebo sc injection every 4 weeks from week 0 to week 20
1812533|NCT00675662|Behavioral|Lifestyle intervention|Lifestyle intervention with Trim Tots pre-school programme.
1812534|NCT00675662|Behavioral|waiting list control|waiting list control
1812535|NCT00675675|Behavioral|Comprehensive Behavioral Intervention for Tics (CBIT)|Habit Reversal Training plus functional assessment/intervention designed to identify and ameliorate tic triggers (antecedents) and maintaining consequences.
1812536|NCT00675675|Behavioral|Minimal Contact Waitlist|Bimonthly phone check-in to assess clinical status and enhance subject retention
1812537|NCT00675688|Drug|Bazedoxifene/Conjugate Estrogens (CE)|
1812538|NCT00675688|Drug|Raloxifene|
1812539|NCT00675688|Drug|Placebo|
1812541|NCT00675701|Drug|lixivaptan|capsules
1812542|NCT00675701|Drug|moxifloxacin|tablets
1812543|NCT00675714|Procedure|Stable Isotope Infusion Study|1-8 hour stable isotope infusion study to be done following each surgery. Tagged isotopes to assess uptake into blood and tissues.
1812544|NCT00675714|Procedure|Collection of blood and tissues|Blood draw with each stable isotope infusion study and weekly Tissue biopsy: skin, fat, muscle at stable isotope infusion study
1812545|NCT00675714|Procedure|Radiology testing: Dual-energy X-ray absorptiometry (DEXA), ultrasound, MRI|Testing to be done following every stable isotope infusion study to measure muscle, fat and bone tissues.
1812546|NCT00675714|Drug|Humatrope|Humatrope (Growth Hormone) dose:0.05mg - 0.2mg/kg/day SQ daily for up to 2 years post burn injury.
1812547|NCT00675714|Drug|Ketoconazole|Ketoconazole administration (or other glucocorticoid blocker--itraconazole or fluconazole) PO daily for up to 2 years post burn injury
1812548|NCT00675714|Drug|Oxandrolone|oxandrolone (or other anabolic steroid-testosterone or nandrolone) daily for up to 2 years post burn injury
1812549|NCT00675714|Drug|Propranolol|Propranolol (or other beta adrenergic blocker--metoprolol, inderol), PO administration daily for up to 2 years post burn injury.
1812550|NCT00675714|Drug|Oxandrolone and propranolol combined|Daily administration of oxandrolone and propranolol to be given for up to 2 years post burn injury.
1812551|NCT00675714|Drug|Humatrope and propranolol combined|Humatrope (growth hormone) and propranolol administration daily for up to 2 years post burn injury.
1812552|NCT00675714|Drug|Placebo|placebo to be given once a day for up to two years post burn injury.
1812553|NCT00675714|Behavioral|Exercise--Hospital supervised intensive exercise program|intensive exercise program supervised by trained personnel in the hospital environment for six up to twelve week program.
1812554|NCT00675714|Behavioral|Home exercise program|Home intensive exercise program: training occurs in hospital then patient sent home to continue exercise program for six weeks and up to 12 weeks at home.
1812555|NCT00675727|Biological|CADI-05|Two intradermal treatments each week for first 4 weeks followed by one intradermal treatment per week for second 4 weeks.
1812556|NCT00675740|Drug|rosiglitazone|tablets 4 mg daily
1812557|NCT00675740|Behavioral|physical exercise|stationary bike 5-6 times a week
1812558|NCT00675740|Other|control|control without intervention
1812559|NCT00675753|Genetic|Blood spot specimens will be drawn|Blood spot specimens will be drawn from mother-baby dyads in the control and experimental groups and sent for genotyping
1812560|NCT00675779|Drug|oral contraceptive (Mercilon)|oral contraceptive (20ug EE, 150ug DSG) 1 tablet a day p.o. for 21 days with 7 day break for 6 months
1812561|NCT00675779|Drug|atorvastatin + oral contraceptive|atorvastatin 20mg po a day for 6 months + oral contraceptive (20ug EE, 150ug DSG) 1 tablet po a day for 21 days with 7 day break for 6 months
1812562|NCT00675792|Drug|Sugammadex|Participants received 4 mg/kg sugammadex at 1-2 Post Tetanic Counts (PTCs) or better after the last dose of rocuronium bromide.
1812563|NCT00675792|Drug|Neostigmine|Participants received 50 µg/kg neostigmine combined with 10 µg/kg glycopyrrolate after the last dose of rocuronium bromide as per standard of care.
1812564|NCT00675792|Drug|Rocuronium|Participants received a single intubation bolus dose of 0.6 mg/kg rocuronium bromide, followed if necessary to maintain neuromuscular blockade by one or more single bolus dose(s) of 0.15 mg/kg rocuronium bromide.
1812565|NCT00675805|Device|Infusomat filter (Codan Duofilter-Set V86-P)|An approved filter system may be efficient in retaining complement activating IgG aggregates in IVIG preparations. This effect may reduce complement activation and consecutive inflammation thereby diminishing adverse events during application of intravenous immunoglobulins.
1812566|NCT00675805|Device|IVIG application without filter (Placebo)|Application Intravenous immunoglobulins without filter (Placebo)
1812567|NCT00675818|Device|Continuous venvenous hemofiltration (CVVH)|Continuous venovenous hemofiltration with a replacement fluid rate of 35 mL/kg/hr.
1812568|NCT00675818|Device|Continuous venovenous hemodialysis (CVVHD)|Continuous venovenous hemodialysis at a dialysate flow rate of 35 mL/kg/hr.
1812569|NCT00675831|Device|CliniMACS CD25 Reagent Device|Used to engineer CD25+ depleted donor lymphocytes which will be infused intravenously over 5-10 minutes
1812570|NCT00675844|Drug|elvucitabine|10 mg elvucitabine daily as part of an ART regimen
1812571|NCT00675857|Drug|NC-503 (eprodisate disodium)|capsules of 400 mg Dosage: 4 capsules (1600 mg) BID for 26 weeks
1812572|NCT00675857|Other|placebo|Dosage: 4 capsules BID for 26 weeks
1812573|NCT00675870|Drug|NRX 195183 Soft Gelatin Capsule|Daily oral NRX 195183 administration for 90 days to assess CR rate. Patients with CR may continue maintenance therapy after a 2-week drug holiday. Maintenance therapy will consist of two 3-month daily oral NRX 195183 administration separated by a 2-week drug holiday.
1812574|NCT00675896|Drug|Quetiapine Fumarate Sustained Release|50 mg/day for the first 2 days and then up to 150mg/day. After two weeks the dose will be doubled up to 300mg at night at the discretion of the investigator
1812575|NCT00675896|Drug|Placebo|1 tablet at HS for 2 days then 3 tablets at HS for 2 weeks
1812576|NCT00675909|Drug|Aerosolized Intranasal midazolam|"Midazolam will be administered via aerosolization (using atomizer) with half of dose in each nostril. Total dose is 0.3mg/kg."
1812577|NCT00675909|Drug|Aerosolized Buccal Midazolam|"0.3mg/kg total dose administered with aerosolization device (atomizer) sprayed onto buccal mucosa inside the cheek on both sides of mouth."
1812578|NCT00675909|Drug|Oral midazolam|oral midazolam 0.5mg/kg
1812579|NCT00675922|Drug|Sulfamylon 5% and Silver Nitrate Soaks|Application of Sulfamylon and Silver Nitrate Solution to burn wound daily
1812580|NCT00675935|Other|Fall Prevention Tool Kit prototype using a randomized design|Based on the results from Phase 1, Phase 2 and consistent with the literature that suggests that multifaceted, tailored interventions are most effective against inpatient falls, the FPTK prototype will be comprised of two interrelated components 1) The Fall Risk Alert and Communication Plan (translates an individual patient's fall risk assessment into a decision support intervention that communicates fall risk status to team members.) and 2) The Patient Safety Plan of Care PSPOC (translates an individual patient's fall risk assessment into a decision support intervention that creates a tailored evidence-based plan of care). The goal of the FPTK Intervention is to communicate risk status and recommended tailored discipline specific-interventions to prevent falls.
1812581|NCT00675948|Drug|Sativex|"Containing delta-9-tetrahydrocannabinol (THC), 27 mg/ml: cannabidiol (CBD), 25 mg/ml; both as extract of Cannabis sativa L.
Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours."
1812582|NCT00675948|Drug|GW-2000-02|Containing THC, 27 mg/ml, as extract of Cannabis sativa L. Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three hour period and 48 actuations (THC 130 mg) in 24 hours.
1812587|NCT00675974|Device|Jobst Pressure Garment|Pressure garment therapy for 18 months post burn injury. May be Jobst pressure garment or Medical Z pressure garment.
1812588|NCT00675974|Device|Medical Z pressure garment|Pressure garment to be worn for 18 months post burn. May be Jobst pressure garment or Medical Z pressure garment.
1812589|NCT00675987|Drug|losartan|losartan 100 mg tablets 1 tab po QD
1812590|NCT00675987|Drug|Placebo control|Placebo 1 po QD
1812591|NCT00676000|Procedure|Interrupted vaginal closure|Horizontal mattress closure of vaginal mucosa over mesh
1812592|NCT00676000|Procedure|Continuous vaginal closure|Running closure of vaginal mucosa over mesh
1812598|NCT00676026|Drug|Fluoxetine|Fluoxetine 20 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
1812599|NCT00676026|Drug|Zolpidem|Zolpidem 10 mg by mouth in the follicular and luteal phase of the menstrual cycle per participant.
1812600|NCT00676026|Drug|Progesterone|Progesterone 800 mg by mouth will be administered to each participant once in the follicular and luteal phases of the menstrual cycle.
1958357|NCT01746446|Other|Care team|Provides additional support to patients, family, and friends.
1958359|NCT01741389|Drug|"Melatonin (Circadin)"|
1812611|NCT00676091|Biological|13-Valent Pneumococcal Conjugate Vaccine (13vPnC)|
1812612|NCT00676091|Biological|7-Valent Pneumococcal Conjugate Vaccine (7vPnc)|
1812613|NCT00676104|Device|CoolSystems Discrete Cerebral Hypothermia System|The CoolSystems Discrete Cerebral Hypothermia System (DCHS) will be removed from the patients head after 48 hours.
1812614|NCT00676117|Drug|Esomeprazole (D961H)|20mg
1812615|NCT00676117|Drug|Loxoprofen|60mg tablet
1812616|NCT00676130|Drug|trimethoprim-sulfamethoxazole|"Weight-based dosing in capsule or suspension form according to the following scale:
15-19 kg (33-42 lbs): trimethoprim-sulfamethoxazole 40/200 mg four times daily
20-24 kg (42-53 lbs): trimethoprim-sulfamethoxazole 60/300 mg four times daily
25-29 kg (53-64 lbs): trimethoprim-sulfamethoxazole 72/360 mg four times daily
29-60 kg (64-132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily
60 kg (132 lbs): trimethoprim-sulfamethoxazole 80/400 mg four times daily
60-80 kg (132-176 lbs): trimethoprim-sulfamethoxazole 160/800 mg three times daily
> 80 kg (176 lbs): trimethoprim-sulfamethoxazole 160/800 mg four times daily"
1812617|NCT00676130|Drug|Cephalexin|"Weight-based dosing in capsule or suspension form according to the following scale:
15-19 kg (33-42 lbs): Cephalexin 300 mg four times daily
20-24 kg (42-53 lbs): Cephalexin 400 mg four times daily
25-29 kg (53-64 lbs): Cephalexin 500 mg four times daily
29-60 kg (64-132 lbs): Cephalexin 500 mg four times daily
60-80 kg (132-176 lbs): Cephalexin 1000 mg three times daily
> 80 kg (176 lbs): Cephalexin 1000 mg four times daily"
1812618|NCT00676143|Drug|bapineuzumab|Bapineuzumab 0.5 mg/kg administered by IV infusion approximately every 13 weeks through week 65.
1812619|NCT00676143|Drug|placebo|Placebo will be administered by IV infusion approximately every 13 weeks through week 65.
1812620|NCT00676156|Drug|oral lipoic acid (LA)|A single 1200 mg dose of oral LA will be administered.
1812621|NCT00676156|Drug|lipoic acid (LA) with fish oil and LA without fish oil|Subjects will be randomized to receive either 1 dose of 1200 mg LA with fish oil and then will be crossed-over to receive 1 dose of 1200 LA without fish oil. There will be a 1-week wash out period between the cross over.
1812622|NCT00676156|Drug|R lipoic acid|A single oral dose of 1200mg R enantiomer LA will be administered.
1812623|NCT00664001|Dietary Supplement|Anti-oxidant supplementation|Daily dose of 1g L-ascorbic acid, 400 IU of alpha-tocopherol acetate, and 600mg of alpha-lipoic acid in sealed capsules as anti-oxidant supplementation.
1812624|NCT00664001|Dietary Supplement|Matched placebo for anti-oxidant supplementation|Matched placebo for anti-oxidant supplementation
1812661|NCT00664261|Other|cancer prevention|
1812662|NCT00664261|Other|counseling intervention|
1812625|NCT00664014|Drug|Tolvaptan|Tablet;15mg/tab;15/30/60mg/day for 7days Plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
1812626|NCT00664014|Drug|Placebo|placebo plus conventional therapy according to each patient's underlying disease, such as congestive heart failure, hepatic cirrhosis and SIADH or others.
1812627|NCT00664027|Drug|RTA 402 (Bardoxolone Methyl)|Stratum 1: 25, 75, 150mg/day, orally, 28 consecutive days Stratum 2: 25 mg/day, orally, 28 consecutive days followed by 75 mg/day, orally, 28 consecutive days
1812628|NCT00664040|Other|Aspirin|The aspirin intervention (81 mg per day) will last a total of 14 days. Pills will be provided in a pre-loaded pillbox. The field team will visit the subject at his/her home at least once to insure adherence to the aspirin intervention and to monitor for adverse side effects. On day 14 of the aspirin intervention, the subject will visit the clinic for a fasting blood draw for platelet aggregation and inflammatory marker studies. A pill count will be performed to assess adherence. The subject can miss up to four aspirin doses over the two-week period; however, an aspirin must be taken each day for the three days prior to clinic visit 2. The aspirin intervention can be extended for up to three days (17 days total) to meet the latter criteria. If more than four doses were missed, then the physician should be contacted and the patient should be withdrawn from the aspirin intervention. Platelet aggregation will be measured 1 hour after the last dose of aspirin.
1812629|NCT00664040|Other|Cold Pressor Test|This intervention consists of the participant placing his or her hand and wrist into ice water for 2½ minutes. The blood pressure is taken before and after the arm is removed from the water. An ultrasound machine is used to take pictures of the brachial artery in the left arm before and after the arm is removed from the water.
1812630|NCT00664040|Other|High Fat Meal|The participants are given a high fat milk shake consisting of 83% fat. Blood samples are drawn from a catheter placed in the participant's arm prior to the test. The samples are drawn before the milk shake and at 1, 2, 3, 4, and 6 hours after the milk shake is consumed. Before and at 2, 4 and 6 hours following the meal the ultrasound is used to obtain images of the brachial artery.
1812631|NCT00664040|Other|Dietary Salt|The salt intervention will consist of 6 days of an isocaloric high salt diet (270 mmol/d) followed by a washout period of at least 8 days and then a low salt diet (40 mmol/d). All food will be prepared by a registered dietician and dietary technicians in a specially equipped kitchen. The specific foods will consist of approximately 50% carbohydrates, 35% fat, and 15% protein. Dietary potassium will remain constant at 120 mmol/d. A food diary will be kept for each diet and subjects will be instructed to eat only the food provided. A field nurse will visit the home on days 3 and 5 of each diet to insure that neither diet is acutely affecting the health status of the subject. A first AM void spot urine will be obtained to measure sodium, potassium and creatinine on the 4th, 5th, and 6th days of each diet to insure compliance. Blood pressure will be measured using an ambulatory blood pressure monitor for 24 hours on the last day of each diet.
1812632|NCT00664053|Dietary Supplement|DHEA|50mg daily for 6 months
1812633|NCT00664053|Behavioral|Yoga|2 sessions per week for 6 months
1812634|NCT00664053|Dietary Supplement|Placebo|Placebo supplement every day for 6 months
1812635|NCT00664053|Behavioral|Aerobics|Walking/chair aerobics program 2 sessions per week for 6 months
1812636|NCT00664066|Drug|DYNEPO (epoetin delta)|dose, dose frequency, route of administration (iv or sc) and duration will be determined by the investigator according to their normal prescribing habits, as this is an observational study
1812637|NCT00664079|Other|Blood draws|17 mls of blood will be drawn over a 5 day period from either a central venous catheter/arterial line or with scheduled phlebotomy. The following labs will be run tT3, fT3, rT#, tT4, fT4, TSH, and tyrosine.
1812638|NCT00664092|Other|Residential|living in a democratic, resident-run setting
1812639|NCT00664092|Other|Residential|Professionally-run substance abuse recovery setting
1812640|NCT00664105|Drug|Carboplatin|"Carboplatin will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.
Carboplatin will be given once every three weeks as a 30-minute intravenous infusion immediately following the infusion of docetaxel. Patients will receive two cycles of consolidation treatment."
1812641|NCT00664105|Drug|Docetaxel|"Docetaxel will be given weekly for seven weeks beginning on Day 1 of the study as a 30-minute intravenous infusion during concurrent therapy.
Docetaxel will be given once every three weeks administered as a one-hour IV infusion. Patients will receive two cycles of consolidation treatment (1 cycle = 3 weeks)."
1812642|NCT00664105|Radiation|radiation therapy|Radiotherapy will be administered daily X 5 day/week for 34 days beginning on Day 1 of the study. Radiotherapy will follow immediately after the infusions of docetaxel and carboplatin.
1812643|NCT00664118|Procedure|Doula combined analgesia|Doula combined epidural analgesia in the latent phase of first stage of labor in primiparas
1812644|NCT00664118|Procedure|Analgesia without doula|Epidural analgesia in the latent phase of first stage of labor without doula accompany in primiparas
1812645|NCT00664131|Other|Neurological Examination/Questionnaires|See Detailed Description section for description of treatment plan.
1812646|NCT00664144|Drug|Rasburicase (SR29142)|
1812647|NCT00664157|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decisiontest
1812648|NCT00664157|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
1812651|NCT00664183|Drug|Vitreosolve|Intravitreal injection
1812652|NCT00664196|Biological|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
1812656|NCT00664248|Drug|IDP-110|Topical application for 12 weeks
1812657|NCT00664248|Drug|Clindamycin|Topical application for 12 weeks
1812658|NCT00664248|Drug|Benzoyl peroxide|Topical application for 12 weeks
1812659|NCT00664248|Drug|Vehicle|Topical application for 12 weeks
1812660|NCT00664261|Behavioral|smoking cessation intervention|
1812663|NCT00664261|Other|educational intervention|
1812664|NCT00664261|Other|laboratory biomarker analysis|
1812665|NCT00664261|Other|questionnaire administration|
1812666|NCT00664261|Other|survey administration|
1812667|NCT00664261|Procedure|study of high risk factors|
1812668|NCT00664274|Behavioral|Cognitive remediation therapy|36 sessions of Computerized Cognitive Skills Training, 3 per week for 12 weeks.
1812669|NCT00664274|Genetic|COMT Genotyping|One time saliva sample is taken to genotype catechol-O-methyltransferase Val158/108Met alleles.
1812670|NCT00664287|Drug|niacin (+) laropiprant|Group 1: Patients will receive ER niacin/laropiprant 1 g/20 mg daily. After 4 weeks, ER niacin/laropiprant will be increased to 2 g/40 mg for remainder of study.
1812671|NCT00664287|Drug|placebo (unspecified)|Group 2: Patients will receive 1 placebo tablet daily. After 4 weeks, patients will be advanced to 2 placebo tablets for remainder of the study.
1812672|NCT00664300|Behavioral|Facial expression recognition of emotion|Facial expression recognition test Lexical decision test
1812673|NCT00669617|Drug|Indacaterol|Indacaterol 150 and 300 μg, delivered via single-dose dry-powder inhaler (SDDPI)
1812674|NCT00669617|Drug|Salmeterol/fluticasone (50/500 μg)|Salmeterol/fluticasone 50/500 μg fixed-dose combination delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
1812675|NCT00669617|Drug|Salbutamol (200 µg)|Salbutamol 200 μg delivered via manufacturer's proprietary Multi-Dose Dry-Powder Inhaler (MDDPI).
1812676|NCT00669617|Drug|Placebo to Indacaterol|Placebo to indacaterol delivered via SDDPI
1812677|NCT00669617|Drug|Placebo to Salmeterol/fluticasone|Placebo to salmeterol/fluticasone delivered via MDDPI
1812678|NCT00669617|Drug|Placebo to salbutamol|Placebo to salbutamol delivered via MDDPI
1812679|NCT00669630|Behavioral|Lay Health Promoter (LHP) with maintenance|Lay Health Promoters (LHPs) and their congregations will join an existing social and organizational support network, comprised of LHPs and congregations who are part of an active community health improvement collaborative.
1812680|NCT00669643|Drug|PB 6 doses - Rifampicin and Dapsone|"Adult: 6 doses;
1 monthly supervised dose: 600 mg Rifampicin + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone;
Children: 6 doses;
1 monthly supervised dose: 450 mg Rifampicin + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone"
1812681|NCT00669643|Drug|PB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses;
1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;
Children: 6 doses;
1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
1812682|NCT00669643|Drug|MB 12 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 12 doses;
1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine;
Children: 12 doses;
1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
1812683|NCT00669643|Drug|MB 6 doses - Rifampicin, Clofazimine and Dapsone|"Adult: 6 doses
1 monthly supervised dose: 600 mg Rifampicin + 300 mg Clofazimine + 100 mg Dapsone; 27 days: p/day - 100 mg Dapsone + 50 mg Clofazimine
Children: 6 doses
1 monthly supervised dose: Rifampicin 450 mg + 150 mg Clofazimine + 50 mg Dapsone; 27 days: p/day - 50 mg Dapsone + 25 mg Clofazimine"
1998696|NCT01087008|Other|No treatment control|Patients doesn't receive treatment
1812685|NCT00669669|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D conformal IMRT
1812686|NCT00669669|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
1812687|NCT00669669|Drug|Carmustine|Given IV
1812688|NCT00669669|Biological|Filgrastim|Given SC
1812689|NCT00669669|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplant
1812690|NCT00669669|Radiation|Intensity-Modulated Radiation Therapy|Undergo 3D conformal IMRT
1812691|NCT00669669|Other|Laboratory Biomarker Analysis|Correlative studies
1812692|NCT00669669|Drug|O6-Benzylguanine|Given IV
1812693|NCT00669669|Drug|Plerixafor|Given SC
1812694|NCT00669669|Radiation|Proton Beam Radiation Therapy|Undergo proton beam radiation therapy
1812695|NCT00669669|Drug|Temozolomide|Given PO
1812696|NCT00669682|Other|Congestive heart failure|Spontaneous occurrence of fluid overload.
1812697|NCT00669695|Drug|Atorvastatin treatment|Atorvastatin treatment: tablets of 40 mg Atorvastatin will be administered orally, respecting the dosage of 40 mg/day, for 6 months.
1812698|NCT00669695|Other|CPAP device|This device consists in a nasal continuous positive airway pressure (CPAP). It will be applied 3 months after the beginning of drug treatment and for 3 months.
1812699|NCT00669695|Other|sham CPAP treatment|This device consists in a sham CPAP. It will be applied 3 months after the beginning of drug treatment and for 3 months.
1812700|NCT00669708|Device|cooling compound (ph5 Eucerin)|application twice daily to the skin
1812701|NCT00669721|Drug|law molecular weigth heparin|administration of LMWH as anticoagulation for hemodialysis circuit;nadroparin is administred ad the dosage of 65 IU/kg on starting dialysis and in the arterial hemodialytic line after a washing phase with 2 litres of a heparin-free saline solution 0.9%.
1812702|NCT00669721|Drug|unfractioned heparin|administration of UFH as anticoagulation of hemodialysis circuit; standard heparin ( Sodic Heparin, Vister by Parke-Davis) 1500 IU on starting dialysis and 1500 ± 500 IU in continues intradialytic infusion per dialysis session
1812703|NCT00669734|Biological|Falimarev|Given intratumorally or SC
1812704|NCT00669734|Biological|Inalimarev|Given SC
1812705|NCT00669734|Other|Laboratory Biomarker Analysis|Correlative studies
1812706|NCT00669734|Biological|Sargramostim|Given SC
1812707|NCT00669747|Drug|Carboplatin i.d. Days 1 & 15|Carboplatin, 10 mg/ml, 10 ml (100 mg) infused into DCIS-involved duct on Days 1 & 15
1812708|NCT00669747|Drug|Carboplatin i.d. Day 1; Normal Saline i.d. Day 15|Carboplatin 10 mg/ml, 10 ml (100 mg) i.d. DCIS duct on Day 1 Normal Saline, 10 ml i.d. DCIS duct on Day 15
1812709|NCT00669747|Drug|Normal Saline|Normal Saline, 10 ml, i.d. on Days 1 and 15
1812710|NCT00669760|Other|non-interventional study|does not apply
1812711|NCT00669773|Drug|Adriamycin|Arm A: 4 cycles of adriamycin at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of docetaxel at 75mg/m2 3 weekly
1812712|NCT00669773|Drug|Docetaxel|Arm B: 4 cycles of docetaxel at 75mg/m2 3 weekly followed by surgery followed by 4 cycles of adriamycin at 75mg/m2 3 weekly.
1812713|NCT00669786|Drug|Human Menopausal Gonadotropin (HMG) & - Recombinant Follicle Stimulating Hormone (r-FSH)|
1812714|NCT00669799|Drug|gentamyacin|topical internasal
1812715|NCT00669799|Drug|gentamyacin|intranasal
1812716|NCT00669812|Drug|carmustine|
1812717|NCT00669812|Drug|cyclophosphamide|
1812718|NCT00669812|Drug|cytarabine|
1812719|NCT00669812|Drug|doxorubicin hydrochloride|
1812720|NCT00669812|Drug|epirubicin hydrochloride|
1812721|NCT00669812|Drug|etoposide|
1812722|NCT00669812|Drug|ifosfamide|
1812723|NCT00669812|Drug|melphalan|
1812724|NCT00669812|Drug|methotrexate|
1812725|NCT00669812|Drug|prednisolone|
1812726|NCT00669812|Drug|vincristine sulfate|
1812727|NCT00669812|Procedure|autologous hematopoietic stem cell transplantation|
1812728|NCT00669812|Procedure|biopsy|
1812729|NCT00669812|Procedure|peripheral blood stem cell transplantation|
1812730|NCT00669825|Drug|ALV003|Doses via intragastric tube at dosages of either 100 mg, 300 mg, 900 mg, or 1800 mg
1812731|NCT00669825|Drug|Placebo|Placebo to be administered via intragastric tube
1812732|NCT00669851|Drug|AI-700|
1812733|NCT00669864|Drug|biphasic insulin aspart 30|Subcutaneous (under the skin) injection, twice daily
1812734|NCT00669864|Drug|metformin|Tablets, 1000 - 2000 mg daily
1958365|NCT01738191|Drug|Atomoxetine|The study drug target dose is ATM 80mg per day; given as a once daily dose of an 80mg capsule. Patients will titrate up to target dose by starting on ATM 40mg capsules: 1 capsule daily for 14 days. Following study visit 3 (after 2 weeks on the titration dose), patients will increase the dose of ATM to 80mg daily.
1958366|NCT01738191|Drug|Placebo|
1993589|NCT03170622|Diagnostic Test|Intervention group|This group will provide a stool sample that will be analysed for VOCs and followed up after 3 months
1812743|NCT00669890|Drug|Gemtuzumab Ozogamicin|Dose Escalation
1812744|NCT00669890|Drug|Busulfan|Conditioning Regimen
1812745|NCT00669890|Drug|Cyclophosphamide|Conditioning Regimen
1812746|NCT00669890|Drug|Thymoglobulin|(Unrelated Donors only)
1812747|NCT00669890|Drug|Tacrolimus|GVHD Prophylaxis
1812748|NCT00669890|Drug|Mycophenolate Mofetil|GVHD Prophylaxis
1812749|NCT00669890|Drug|Methotrexate|GVHD Prophylaxis
1812750|NCT00669903|Drug|AZD0328|
1812751|NCT00669903|Drug|Placebo|
1812752|NCT00669916|Biological|AIN457|single infusion of 3 mg/kg
1812753|NCT00669916|Drug|Placebo|single infusion of placebo
1812754|NCT00669942|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
1812755|NCT00669942|Drug|Placebo|Placebo to AIN457
1812756|NCT00669955|Drug|Omeprazole, amoxicillin, clarithromycin|Triple therapy given for 7 days at a dose of omeprazole 20 mg BID, amoxicillin 500 mg 2 capsules BID, and clarithromycin 500 mg 1 tablet BID
1812757|NCT00669955|Drug|Pylera (Bismuth subcitrate potassium, metronidazole, tetracycline) given in combination with omeprazole|Pylera is a three in one capsule containing bismuth subcitrate potassium 120 mg, metronidazole 125 mg and tetracycline 125 mg given as 3 capsules QID, with omeprazole 20 mg BID.
1812758|NCT00669981|Behavioral|Cognitive behavioral couples therapy for post-traumatic stress disorder (CBCT for PTSD)|CBCT for PTSD is a 15-session manualized couples therapy that aims to both decrease individual PTSD symptoms and improve dyadic functioning.
1812759|NCT00669994|Drug|Ciprofloxacin|Cipro XR 500 mg tablets taken once daily
1812760|NCT00670007|Biological|Alpha1- proteinase inhibitor [human]|Lyophilized preparation of 60 mg/kg body weight intravenously once per week
1812761|NCT00670020|Procedure|supplemental perioperative oxygen|increased perioperative oxygen verses non-interventional oxygen
1812762|NCT00670033|Drug|Travoprost ophthalmic solution (new formulation)|
1812763|NCT00670033|Drug|Travoprost ophthalmic solution, 0.004%|
1812764|NCT00670033|Drug|Vehicle|Inactive ingredients used as a placebo
1812765|NCT00670046|Drug|valproic acid|given orally
1812766|NCT00670046|Procedure|standard follow-up care|no intervention
1812767|NCT00670059|Genetic|single embryo transfer without aneuploidy screening|without aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
1812768|NCT00670059|Genetic|single embryo transfer with aneuploidy screening|with aneuploidy testing for the chromosomes XY, 13, 16, 18, 21, 22
1812769|NCT00670098|Procedure|Bariatric surgery|patients receive either gastric bypass or lap-band
1812770|NCT00670098|Behavioral|lifestyle intervention (behavioral weight loss)|participants attend biweekly weight loss counseling group sessions
1812771|NCT00670111|Device|Insignia Plus / Ultra (Guidant/Boston Scientific)|Cardiac pacing using any Guidant/Boston Scientific Implantable Pacemaker System with rate-modulation and any compatible intracardiac lead system.
1812772|NCT00670124|Device|Hypothermia by the use of Blanketrol II, Cincinnati Sub-Zero|The patients are placed on a cooling mattress and body-core temperature is regulated to 33° C.
1812773|NCT00670150|Drug|NRX 195183 (retinoid analogue)|30mg/m2 PO daily x 3mo.in Induction, then daily with consolidation
1812774|NCT00670150|Drug|Arsenic Trioxide|0.15mg/kg/day over 2hrs VI on day 1-5 x 4 weeks. 2 weeks rest then repeat x 3 more cycles.
1812775|NCT00670163|Behavioral|Enhanced Partner Therapy (EPT)|EPT, a biomedical intervention, is designed to reduce the rate of sexually transmitted infection (STI) reinfection and, therefore, incident STIs. Men who have sex with men (MSM) with incident STIs will be given partner treatment packets that contain informational brochures, reference cards, prophylactic medications, and condoms for their sexual partners.
1993590|NCT03170466|Behavioral|Primary Palliative Care|The intervention will span 4 domains: symptom management (e.g., dyspnea), psychosocial support (e.g., anxiety), advance care planning (e.g., understanding prognosis and electing a proxy) and care coordination (e.g., communication across providers).
1993591|NCT03170271|Drug|Benralizumab (Medi-563)|30mg Benralizumab administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
1812776|NCT00670163|Behavioral|Communidades Positivas (CPOS)|The behavioral intervention, CPOS, is based on a combination of social-action theory and diffusion of innovation and is designed to reduce the frequency of unprotected sex with nonprimary partners. In CPOS, MSM who are recognized by their peers as leaders will be trained to implement a community center that provides information, support, and empowerment to MSM, their friends, and partners. CPOS will include a training program of at least 14 sessions. During these sessions, MSM leaders will be provided with information about HIV/STIs and their prevention and ways to strengthen leadership skills. The 2-hour group sessions will occur two times a week for 7 weeks. While the training sessions are underway, MSM leaders will be asked to work with community leaders to form a community center from which they will carry out HIV/STI prevention and promotion of sexual health activities for 18 months.
1812777|NCT00670163|Behavioral|Standard Care|Standard care will consist of usual care for STIs.
1812778|NCT00670176|Behavioral|REHAB (Pre- and postoperative cardiopulmonary rehabilitation)|
1812779|NCT00670189|Drug|BMS-833923 (XL139)|Capsules, Oral, 30 mg starting; dose escalation, Once daily, 37 days; additional days if receiving benefit
1812780|NCT00670202|Drug|Fasudil Hydrochloride|Fasudil 40 mg three times a day x 14 days
1812781|NCT00670202|Drug|Placebo Oral Tablet|Placebo oral tablet manufactured to mimic fasudil three times a day x 14 days
1812782|NCT00670215|Drug|Ciprofloxacin single dose|Patients randomized to this regimen will receive a single-dose of ciprofloxacin MR 1000 mg PO approximately 2 to 3 hours prior to the TRNBP. Patients will also receive two doses of matching placebo approximately 24 hours prior to and approximately 24 hours after the TRNBP.
1812783|NCT00670215|Drug|Ciprofloxacin triple dose|Patients randomized to this regimen will receive three doses of ciprofloxacin MR 1000 mg PO. The doses will be approximately 24 hours prior to the TRNBP, approximately 2 to 3 hours prior to the TRNBP, and approximately 24 hours after the TRNBP.
1812784|NCT00670228|Drug|Insulin Glargine (LANTUS)|Subcutaneous insulin glargine was initiated 90 prior to the insulin glulisine infusion discontinuation (i.e. 48 hours after randomization) and titrated as per physician preference to maintain the plasma glucose between 90-130 mg/dL
1812785|NCT00670228|Drug|Insulin Glulisine (Apidra)|"Prior PCI, subjects received a single IV bolus of insulin glulisine. The dose was 0.025 U/kg based upon patient reported weight.
Then IV insulin glulisine infusion was started within one hour of the IV insulin glulisine bolus and administered at a minimum rate of 2 U/h for 48 hours. The infusion was titrated in order to achieve and maintain the plasma glucose between 90 and 130 mg/dL."
1812786|NCT00670228|Drug|Standard Therapy|Standard insulin therapy titrated to blood sugar control
1812787|NCT00670241|Drug|calcipotriol and betamethasone (LEO 80185 gel)|Once daily application
1812788|NCT00670241|Drug|LEO 80185 vehicle|Once daily application
1812789|NCT00670241|Drug|Tacalcitol ointment|Once daily application
1812790|NCT00670254|Drug|Placebo|Application is identical to experimental arm
1812791|NCT00670254|Drug|Hydrocortisone|50 mg loading dose, continuous infusion of 200 mg/d for 5 d, 100 mg/d for 2d, 50 mg/d for 2 d, and 25 mg/d for 2 d.
1812792|NCT00670267|Drug|nadolol|Nadolol, oral taken daily, doses will be escalated every two weeks over 13 weeks following a 2 week run-in.
1812793|NCT00670280|Behavioral|Motivational Interviewing intervention|Those randomized to receive the Motivational Interviewing intervention will meet twice over a two-week period with a trained counselor while visiting the neonatal intensive care unit. Each visit will consist of a 45 minute session in which household smoking practices will be assessed and discussed. Two weeks after the child has been discharged from the hospital, the counselor will contact participants via telephone for a third 20-30 minute telephone meeting. After the third contact with the counselor, a letter will be mailed to participants summarizing information covered in the three meetings.
1812794|NCT00670280|Behavioral|Usual Care|Those randomized to receive the Usual Care intervention will receive written information on secondary smoke and infant health and will be assessed at 1 month, 3 months, and 6 months post-intervention.
1812795|NCT00670280|Behavioral|Usual Care - Reduced Measurement|Those randomized to the Usual Care - Reduced Measurement intervention will receive the same written information on secondary smoke and infant health as the Usual Care intervention but will be assessed only at the 6-month timepoint.
1812796|NCT00670293|Radiation|Positron Emission Tomography (PET) using [11C]raclopride|Participants with AN will undergo three PET scans at two separate time points. The first scan will occur when participants are underweight (but not less than 75% ideal body weight), and the second and third scans will occur 2 to 4 weeks after participants have accomplished weight restoration. Healthy participants will have two PET scans at a single timepoint.
1812797|NCT00670293|Drug|Methylphenidate|The second PET scan for healthy participants and third PET scan for participants with AN will be performed after administration of 60 mg of methylphenidate, a psychostimulant that allows for accumulation of dopamine (DA) extraneuronally.
1812798|NCT00670293|Procedure|Magnetic Resonance Imaging (MRI) scan|Participants with AN will undergo two MRI scans, and healthy participants will undergo one MRI scan. The scans will be conducted in conjunction with the PET scans.
1812799|NCT00670306|Drug|Cetrorelix Pamoate|Cetrorelix Pamoate IM, 52 mg week 0, 26 mg week 2,
1812800|NCT00670319|Drug|Raloxifene HCL|Raloxifene HCL 60 mg orally once daily
1812801|NCT00670319|Drug|Raloxifene HCL|Raloxifene HCL 120 mg orally once daily
1812802|NCT00670319|Drug|Placebo|Placebo one tab orally per day
1812803|NCT00670345|Drug|Tranexamic Acid|Patients will receive a slow endovenous infusion of 500 mg of tranexamic acid before surgical incision, followed by 250 mg/h of tranexamic acid by continuous infusion.
1812804|NCT00670345|Drug|Placebo|Patients belonging to the control group will receive the same volume of saline infusions.
1812805|NCT00670358|Biological|pegfilgrastim|
1812806|NCT00670358|Biological|rituximab|
1812807|NCT00670358|Drug|cyclophosphamide|
1812808|NCT00670358|Drug|doxorubicin hydrochloride|
1812809|NCT00670358|Drug|lenalidomide|
1812810|NCT00670358|Drug|prednisone|
1812811|NCT00670358|Drug|vincristine sulfate|
1812812|NCT00670358|Genetic|polymorphism analysis|
1812813|NCT00670358|Other|laboratory biomarker analysis|
1812814|NCT00670384|Biological|Standardized Allergenic Extract, Short Ragweed (Ambrosia artemisiifolia)|Sublingual drops
1812815|NCT00670384|Biological|Placebo|Sublingual drops
1812817|NCT00670410|Procedure|Related donor transplant|Patients with a related donor will get reduced intensity transplant conditioning with busulfan and fludarabine.
1812818|NCT00670410|Procedure|Cord blood transplant|Patients with a matched cord blood donor will get reduced intensity conditioning with busulfan, fludarabine, and ATG.
1812819|NCT00670410|Drug|Busulfan|Busulfan (Busulfex) [4mg/kg/dose for patients < 4 years; 3.2 mg/kg/dose for patients > 4 years] will be given IV in 0.9% sodium chloride or D5W to a final concentration > 0.5 mg/mL solution for infusion equal to 10 times the volume of diluent to Busulfex, through a central venous access device over 3 hours once daily.
1812820|NCT00670410|Drug|Thymoglobulin|Patients with an umbilical cord blood donor will also receive Thymoglobulin (ATG-rabbit) during the preparative regimen.
1812821|NCT00670410|Drug|Fludarabine|Fludarabine 30 mg/m2 x 5 days, total dose = 150 mg/m2. Patients < 12 kg will receive Fludarabine 1 mg/kg x 5 days, total dose = 5 mg/kg. Fludarabine will be given IV in 100 ml (or to a concentration of 1 mg/mL) of D5W or 0.9% sodium chloride, and infused over 30 min on Days -6 to 2.
1812822|NCT00670423|Drug|Tacrolimus|Tacrolimus as a continuous IV infusion will begin on day -3. (Levels will be monitored at least every 3 days to target 5-10 ng/mL)
1812823|NCT00670423|Drug|Sirolimus|Sirolimus oral loading dose on day -3, followed by oral daily dose. (Levels will be monitored at least every 3 days to target 3-12 ng/mL)
1812824|NCT00670423|Drug|Bortezomib|"Administered intravenously on day 0 (a minimum of 6 hours post-infusion of PBSC), and on day +3. The following dose levels will be used:
Cohort 1 (3-6 pts): 1 mg/m2 on days 0 and +3
Cohort 2 (3-6 pts): 1.3 mg/m2 on days 0 and +3
Cohort 3 (3-10 pts): 1.6 mg/m2 on days 0 and +3"
1812825|NCT00670436|Device|paclitaxel eluting PTCA balloon catheter (SeQuent Please)|paclitaxel eluting PTCA balloon catheter after bare-metal stenting of chronic total occlusion in a native coronary artery
1812826|NCT00670436|Device|paclitaxel eluting Taxus stent (Boston Scientific)|paclitaxel-eluting Taxus stents (Boston Scientific) in chronic total occlusion in native coronary arteries
1812827|NCT00676182|Other|Telerehabilitation|Rehabilitation via computer assisted internet capabilities
1812828|NCT00676195|Drug|N-Acetyl Cysteine|"Dosage of orally administered N-Acetyl Cysteine is as follows:
Days 1-30: 900 mg, once per day Days 31-60: 900 mg, twice per day Days 61-90: 900 mg, three times per day"
1812829|NCT00676208|Behavioral|Shared Medical Appointments|Participated in shared appointments for patients as part of interprofessional team providing care for diabetes
1812830|NCT00676221|Drug|Myfortic|"Mycophenolate Mofetil (Cellcept) discontinued at Baseline visit. Mycophenolate Sodium(Myfortic)commenced the following day at equimolar doses orally BID.
Cellcept 1000mg bid = Myfortic 720mg bid"
1812831|NCT00676234|Drug|epoetinum|Administration of intravenous rhu Epo on Day 0 20000 IU rhu Epo (20 patients) administered by the i.v. route 40000 IU rhu Epo (20 patients) administered by the i.v. route
1812832|NCT00676260|Drug|Pioglitazone|Pioglitazone 15 mg to 30 mg, tablets, orally, once daily for up to 10 weeks
1812833|NCT00676260|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 10 weeks
1993592|NCT03170271|Drug|Placebo|Placebo administered as a subcutaneous injection at Visit 4 (day 0), Visit 6 (day 28 +/- 3 days), Visit 7 (day 56 +/- 3 days) and Visit 9 (day 112 +/- 3 days)
1812836|NCT00676286|Procedure|3T MR Imaging|3TR Imaging
1812837|NCT00676286|Procedure|C-Choline PET Scanning|C-Choline PET Scanning
1812838|NCT00676286|Procedure|Gene Rearrangement|Gene Rearrangement
1812839|NCT00676299|Drug|JNJ-26483327|
1812840|NCT00676312|Drug|PTH134|
1812841|NCT00676325|Procedure|Surgical treatment of Anterior Vaginal Prolapse|seventy patients with greater anterior vaginal prolapse, whit stress incontinence or not, were randomly assigned to either colporrhaphy or polypropylene mesh repair (NAZCA TC™ POP REPAIR SYSTEM ) . The primary outcome was recurrent anterior vaginal prolapse, and secondary outcomes were effects on quality of life and sexual symptom scores, operative time, blood loss, length of hospitalization, and adverse events.
1812842|NCT00676325|Device|NAZCA TC™ POP REPAIR SYSTEM ,promedon® , argentina.|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not, requiring surgical correction .
1812843|NCT00676325|Procedure|surgical treatment for anterior vaginal wall prolapse|Women 50 years and older with greater anterior vaginal prolapse,whit stress incontinence or not requiring surgical correction were eligible for participation.
1812844|NCT00676338|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly plus placebo oral once daily
1812845|NCT00676338|Drug|metformin|oral, 1000-2500mg, daily plus placebo once weekly subcutaneous injection
1812846|NCT00676338|Drug|sitagliptin|oral, 100 mg, daily plus placebo once weekly subcutaneous injection
1812847|NCT00676338|Drug|pioglitazone|oral, 30-45mg, daily plus placebo once weekly subcutaneous injection
1812848|NCT00676351|Procedure|body plethysmography|Same tests were performed at 18 and 24 months. At 30 and 36 months, pulmonary function was evaluated by measuring respiratory resistances using an oscillometry system and an occlusion system
1812849|NCT00676364|Drug|4% lidocaine topical anesthetic cream|A dollop of 4% lidocaine cream was applied under occlusive dressing for 15 mins prior to venipuncture
1812850|NCT00676364|Drug|Placebo cream|A dollop of matching placebo cream was applied under occlusive dressing for 15 mins prior to venipuncture
1812851|NCT00676377|Drug|Neostigmine|2.5 mg of neostigmine intravenously in 250 ml normal saline over a period of thirty minutes ,Half Life 3 Hours
1812852|NCT00676377|Drug|Saline|Saline Placebo
1812853|NCT00676390|Other|doubly labelled water and questionnaire|0.075 g.kg-1 and 2H2O et 0.15 g.kg-1 de H218O per oral at inclusion visit. physical activity questionnaire at inclusion visit
1812854|NCT00676403|Drug|placebo|Placebo control (capsule), once a day, 1- 3 hours before bedtime for 6 weeks
1812855|NCT00676403|Drug|Pregabalin|50 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
1812856|NCT00676403|Drug|Pregabalin|100 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
1812857|NCT00676403|Drug|Pregabalin|150 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
1812858|NCT00676403|Drug|Pregabalin|300 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
1812859|NCT00676403|Drug|Pregabalin|450 mg (capsule) per day, 1 - 3 hours before bedtime for 6 weeks
1812860|NCT00676416|Drug|2,6-Diisopropylphenol|Propofol general anesthesia was performed in patients with asthma (1) and without asthma (2)
1812861|NCT00676429|Drug|Ziprasidone Hydrochloride|Ziprasidone Hydrochloride oral solution, individual titration 5 mg o.d. or 10 mg to 40 mg b.i.d
1812862|NCT00676429|Drug|Placebo|Placebo as oral solution, individually titrated
1812863|NCT00676442|Drug|PN400|naproxen/esomeprazole
1812864|NCT00676468|Other|Active Montelukast + Fish Oil Placebo|Montelukast (1 x 10 mg tablet) per day + 10 tablets of fish oil placebo (soy bean oil) per day for a duration of 3 weeks
1812865|NCT00676468|Other|Active Fish Oil + Montelukast Placebo|10 tablets (3.2 g EPA + 2.0 g DHA) per day and 1 x 10 mg Montelukast Placebo tablet per day for a duration of 3 weeks.
1812866|NCT00676468|Other|Active Montelukast + Active Fish Oil|1 x 10 mg Montelukast tablet per day and 10 tablets of active fish oil (3.2 g EPA + 2.0 g DHA) for a duration of 3 weeks.
1812867|NCT00676481|Behavioral|HIV risk education|Education for Phase III participants about potential risk of HIV infection before being asked to take a rapid HIV test in the ED
1812868|NCT00676494|Device|Pathway PV Atherectomy System|The Pathway PV Atherectomy System is a rotating, aspirating, expandable catheter for active removal of atherosclerotic debris and thrombus in lower limb peripheral vasculature during percutaneous interventional procedures.
1812869|NCT00676793|Drug|Polyphenon E|Four 200mg capsules daily taken with a meal, for the duration of the study.
1812870|NCT00676806|Biological|Umbilical Cord Blood After Myeloablative Conditioning|cyclophosphamide (60mg/m2 days -6 & -5), fludarabine (25 mg/m2 days -7, -6, & -5) and total body irradiation (days -3, -2, & -1, total 1200 cGy) followed by cord blood infusion on day 0.
1812871|NCT00676806|Biological|Umbilical Cord Blood After Reduced-Intensity Conditioning|Extracorporeal Photopheresis (days -8 & -7), cyclophosphamide 50 mg/kg (day -6) pentostatin 4 mg/kg/d (continuous infusion days -5 & -4), total body irradiation (days -3 & -2, total 600cGy) followed by Umbilical Cord Blood Infusion day 0.
1812872|NCT00676819|Drug|insulin aspart|
1812873|NCT00676819|Drug|human insulin|
1812876|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
1812877|NCT00676845|Drug|placebo|dosage form: tablet; frequency: daily; duration: 3 weeks
1812878|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
1812879|NCT00676845|Drug|olmesartan medoxomil|dosage form: oral tablet; frequency: daily; duration: 52 weeks
1812880|NCT00676871|Drug|MEDI-538|Dose one of MEDI 538 as a continuous IV infusion - dose level is 5 mg/m2/24h (Phase 1)
1812881|NCT00676871|Drug|MEDI-538|Dose two of MEDI 538 as a continuous IV infusion - dose level is 10 mg/m2/24h (Phase 1)
1812882|NCT00676871|Drug|MEDI-538|Dose three of MEDI 538 as a continuous IV infusion-dose level is 15mg/m2/24h (Phase 1)
1812883|NCT00676871|Drug|MEDI-538|Dose four of MEDI 538 as a continuous IV infusion - dose level is 30 mg/m2/24h(Phase 1)
1812884|NCT00676871|Drug|MEDI-538|Dose five of MEDI 538 as a continuous IV infusion - dose level is 45 mg/m2/24h (Phase 1)
1812885|NCT00676871|Drug|MEDI-538|Dose six of MEDI 538 as a continuous IV infusion - dose level is 60 mg/m2/24h (Phase 1)
1812886|NCT00676871|Drug|MEDI-538|Phase 2 part of the study, 20 to 60 patients will be treated with MEDI 538 as a continuous IV infusion through a central line catheter. The dose of MEDI-538 will be determined in the Phase 1 part of the study.
1812887|NCT00676884|Drug|Aeroderm (also known as pitrakinra, AER 001, BAY 16-9996)|30 mgs s.c. b.i.d.
1812888|NCT00676884|Drug|placebo|1.5 mL s.c. b.i.d.
1812889|NCT00676897|Drug|Simvastatin|Simvastatin 40mg PO or NGT
1812890|NCT00676897|Drug|Placebo|Corn Starch
1812891|NCT00676910|Drug|JNJ-26854165|
1812892|NCT00676936|Drug|Methylprednisolone|Custom made capsules, Methylprednisolone 16 mg twice daily, intervention period 7 days.
1812893|NCT00676936|Drug|Placebo|Custom made capsules, Lactose, administered twice daily, intervention period 7 days
1812894|NCT00676949|Biological|5 peptide vaccines of KOC1, TTK, CO16, DEPDC1, MPHOSPH1|1mg each of 5 peptides with IFA. 4 weekly s.c. administration.
1812895|NCT00676962|Behavioral|External facilitation|Study facilitator meets regularly with therapists to aid implementation of CBT
1812896|NCT00676975|Drug|Traditional Chinese Medicine|"A herbal extract 17g once daily for 8 weeks for lower dosage, and 34g for higher dosage.
The 20-herb formulation are Agastache rugosa,Fraxinus rhynchophylla, Angelica dahurica,Glycyrrhiza uralensis, Artemisia capillaris, Magnolia officinalis, Atractylodes macrocephala,Paeonia lactiflora, Aucklandia lappa, Plantago asiatica,Bupleurum chinense, Phellodendron amurense, Citrus reticulate, Poria cocos, Codonopsis pilosula, Saposhnikovia diraricata, Coix lacryma-jobi, Schisandra chinensis, Coptis chinensis, Zingiber officinale"
1812897|NCT00676975|Drug|Traditional Chinese Medicine Placebo|Placebo once daily for 8 weeks
1812898|NCT00677001|Drug|R306465|
1812899|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
1812900|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
1812901|NCT00677014|Device|AV Delay programming through cardiac resynchronization therapy|"All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm."
1819094|NCT00721656|Drug|Placebo|
1812902|NCT00677027|Other|lentinan|Five dose levels of escalating concentrations of the test substance will be tested during the study periode. All patients will recieve each dose, which is to be taken daily for two weeks.
1812903|NCT00677027|Other|placebo|Placebo
1812904|NCT00677053|Drug|TAK-442|Stage I: TAK-442 10 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
1812905|NCT00677053|Drug|TAK-442|Stage I: TAK-442 20 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
1812906|NCT00677053|Drug|TAK-442|Stage I: TAK-442 40 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
1812907|NCT00677053|Drug|TAK-442|Stage II: TAK-442 40 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
1812908|NCT00677053|Drug|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
1812909|NCT00677053|Drug|TAK-442|Stage II: TAK-442 80 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
1812910|NCT00677053|Drug|TAK-442|Stage III: TAK-442 160 mg, capsules, orally, once daily and standard care for recurrent ischemic events for up to 24 weeks.
1812911|NCT00677053|Drug|TAK-442|Stage III: TAK-442 120 mg, capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
1812912|NCT00677053|Drug|Placebo|Stages I, II & III: TAK-442 placebo-matching capsules, orally, twice daily and standard care for recurrent ischemic events for up to 24 weeks.
1812913|NCT00677066|Procedure|Home oxygen therapy|Administer oxygen at home or in hospital
1812914|NCT00677079|Drug|Iniparib|"Body weight adjusted dose
1 hour intravenous infusion"
1812915|NCT00677092|Drug|Imatinib mesylate|400 mg p.o. daily for 4 months. Dosage was reduced to 200 mg if participants develop gastrointestinal intolerance or alopecia.
1812916|NCT00677105|Drug|JNJ-26481585|
1812917|NCT00677118|Drug|Cisplatin,fluorouracil|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy, then receive cisplatin (80mg/m2 on day 1) and fluorouracil (800mg/m2 on Day 1 to 5) every four weeks for three cycles after completion of radiotherapy.
1812918|NCT00677118|Drug|Cisplatin|Patients receive radical radiotherapy and cisplatin (40mg/m2 on day 1) weekly during radiotherapy.
1812919|NCT00677131|Other|Reading the package insert of the drug|package insert of the drug
1812920|NCT00677131|Other|Reading the education information provided by the Pharmacy of NTUH|education information
1812921|NCT00677131|Other|Oral education provided by the pharmacist|Oral education provided by the pharmacist
1812922|NCT00677144|Drug|OS (oxalipaltin+S-1)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and S-1 80mg/m2/day PO [BSA <1.25 40mg bid (total 80mg/day); BSA ≥1.25 - <1.5 50mg bid (total 100mg/day); BSA ≥1.5 60mg bid (total 120mg/day)], divided by two on D1-14 every 21 days
1812923|NCT00677144|Drug|XELOX (oxalipaltin+capecitabine)|Oxaliplatin 130mg/m2 IV on D1 every 21 days and Capecitabine 2000mg/m2/day PO, divided by two on D1-14 every 21 days
1812924|NCT00677170|Drug|MLN4924|IV dose escalation for 5 consecutive days followed by a rest period of 16 days for a 21 day cycle. Treated may continue until disease progression or unacceptable toxicity develops.
1812925|NCT00677196|Device|The stonebreaker arm (LMA Stonebreaker)|The interventional device name is the LMA Stonebreaker pneumatic handheld lithotriptor.
1812926|NCT00677196|Device|Pneumatic Lithotripsy (Swiss LithoClastR)|Pneumatic lithotripsy, the Swiss LithoClastR during percutaneous nephrolithotripsy (PNL)
1812927|NCT00677209|Biological|Injection of autovaccine (Autovaccine Symbiopharm)|increasing dosage schedule, six different concentrations, application over six weeks, 2 weeks break, another six weeks, 2 weeks break, than challenge with inhalative house dust mite extract
1812928|NCT00677222|Biological|AMI MultiStem®|AMI MultiStem® administered via catheter into peri-vascular space of the target vessel, 2-5 days post PCI. There will be 3 dose escalation cohorts, 6 patients per cohort.
1812929|NCT00677235|Device|FLAIR Endovascular Stent Graft|Treatment of stenoses with primary PTA and placement of the FLAIR Endovascular Stent Graft
1812930|NCT00677235|Procedure|PTA|Treatment of stenoses with PTA only
1812931|NCT00677248|Drug|Ezetimibe and placebo|Placebo or three different doses of eprotirome added to ezetimibe treatment
1812932|NCT00677248|Drug|Eprotirome and ezetimibe|Placebo or three different doses of eprotirome added to ezetimibe treatment
1812933|NCT00677261|Procedure|Sciatic Nerve Block|Patients randomized to Group 1 will receive a single sciatic nerve block using the infragluteal parabiceps approach, using 20 ml of 0.5 % Ropivacaine. A sham injection of the posterior capsule and fat pad using 50 cc of normal saline will be conducted at the conclusion of the surgery.
1812934|NCT00677261|Procedure|Posterior capsule infiltration with local anesthetic|Patients randomized to Group 2 will receive a Sham sciatic nerve block using 20cc of normal saline as described above as well as extensive local anesthetic infiltration of the posterior capsule and fat pad with a solution of 50 ml of 0.2% ropivicaine.
1812935|NCT00677261|Procedure|Sham sciatic block and sham posterior infiltration|Patients randomized to group 3 will only receive a continuous femoral nerve catheter, A sham sciatic nerve block with 20cc of normal saline as well as a sham injection of the posterior capsule and fat pad will be performed with 50cc of normal saline.
1812936|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the onset of regular uterine contraction
1812937|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 0.5cm
1812938|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.0cm
1812939|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 1.5cm
1812940|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 2.0cm
1812941|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 3.0cm
1812942|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 4.0cm
1812943|NCT00677274|Procedure|Epidural labor analgesia|Epidural analgesia initiated at the cervix diameter 5.0cm
1813168|NCT00678990|Procedure|Transplantation of islets with heparin coating|Transplantation of islets with heparin coating
1813169|NCT00679003|Behavioral|SLCBT|Social learning and cognitive behavioral therapy
1812944|NCT00677287|Biological|RNF43, TOMM34, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, RNF43 peptide (1mg), TOMM34 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
1812945|NCT00677300|Drug|Raltegravir|400mg P.O. (orally) twice daily for 48 weeks
1812946|NCT00677300|Drug|Darunavir|800 mg P.O. (orally) once daily
1812947|NCT00677300|Drug|Ritonavir|100mg once daily
1812948|NCT00677300|Drug|Tenofovir/Emtricitabine|300 mg/200 mg P.O. (orally) once daily
1812950|NCT00677326|Biological|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
1812951|NCT00677339|Drug|L-arginine|L-arginine 6g orally daily
1812952|NCT00677339|Drug|Vitamin D|Cholecalciferol 50000 IU once monthly orally
1812953|NCT00677339|Drug|Placebo L-arginine|placebo L-arginine once daily
1812954|NCT00677339|Drug|Placebo Vitamin D|placebo vitamin D orally once monthly
1812955|NCT00677352|Drug|sertraline|dosage : 25mg , 50mg , placebo; dosage form : tablet; frequency : once daily after dinner; duration : 14 weeks
1812956|NCT00677352|Drug|Paroxetine|dosage : 10mg, placebo; dosage form : capsule; frequency : once daily after dinner; duration : 14 weeks
1812957|NCT00677365|Drug|MP-376|3 dose regimens of MP-376 administered twice daily (BID) or once daily (QD) for 28 days
1812958|NCT00677365|Drug|Placebo|same frequency as study drug using the same nebulizer
1812959|NCT00677391|Drug|Sibutramine|Capsules, Wk 0: 10mg, once daily; Wks 4-24: 10mg or 15mg, once daily, dosage escalation based upon investigator's assessment.
1812960|NCT00677391|Drug|Placebo|Capsules, once daily
1812961|NCT00677404|Biological|BM-MNC injection|Bone marrow aspiration A total volume of 400 ml bone marrow will be aspirated from the iliac crest under epidural anaesthesia
1812962|NCT00677430|Behavioral|Questionnaire|A brief questionnaire packet will be completed.
1812963|NCT00677430|Procedure|Digital Imaging|Photographs of the breast(s) will be taken with two different types of digital cameras (2D and 3D). The photos will be used to develop automated methods for evaluating the appearance and shape of the breasts.
1812964|NCT00677443|Drug|S-1 & Oxaliplatin|S-1 and Oxaliplatin : S-1 80 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
1812965|NCT00677443|Drug|Capecitabine & Oxaliplatin|COX : Capecitabine 1000 mg/m2/day, D1-14 Oxaliplatin, 130 mg/m2/day, D1 Repeated every 3 weeks
1812966|NCT00677456|Procedure|R-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
1812967|NCT00677456|Procedure|P-Y reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. The distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the P-Y.
1812968|NCT00677456|Procedure|Pouch reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels. To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border, the distance of the esophagojejunostomy to the jejunojejunostomy was 40 cm for the R-Y.
1812969|NCT00677456|Procedure|P-I reconstruction after total gastrectomy|Following curative total gastrectomy and systematic lymphadenectomy, the jejunum was divided 20 cm distal to the Treitz ligament with preservation of the nerve along the marginal vessels.To make the jejunal pouch, jejunojejunostomy was done with a linear stapler at the antimesenteric border,The pouch was 20 cm long, with a 10-cm jejunal loop with the P-I.
1812970|NCT00677469|Drug|Cholestyramine|2 grams BID
1812971|NCT00677469|Drug|Cholestyramine|1 gram BID
1812972|NCT00677469|Drug|Placebo powder|1 gram BID
1812973|NCT00677495|Dietary Supplement|Gluten-free diet|Gluten-free diet
1812974|NCT00677521|Drug|Acarbose|50mg tablet by mouth daily for the first 2 weeks, then twice a day for the next 2 weeks, and then three times a day for the next 8 weeks for a total of 12 weeks.
1812975|NCT00677534|Drug|Cholecalciferol|50,000 Units PO Twice weekly for 8 weeks
1812976|NCT00677573|Drug|Fostimon|450 IU for 4 days then adjusted
1812977|NCT00677586|Procedure|simultaneous resection of liver metastasis and the colorectal primary tumor|simultaneous resection of liver metastasis and the colorectal primary tumor
1812978|NCT00677586|Procedure|staged resection of liver metastasis and the colorectal primary tumor|Patients received resection of the colorectal tumor. 1 months later received resection of liver metastasis
1812979|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|Flavonoid compounds from cocoa (including epicatechin) and soy to be consumed for 365days in the experimental intervention (versus placebo consumption). 27g chocolate bar the vehicle for flavonoid enrichment.
1812980|NCT00677599|Dietary Supplement|Flavonoid enrichment (cocoa / soy compounds)|27g placebo chocolate bar to be consumed for 365 days.
1812981|NCT00677612|Biological|VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with Tegafur/Uracil/Folinate chemotherapy.
1812982|NCT00677638|Device|Ventor Embracer|Implantation of Ventor Embracer
1812983|NCT00677651|Procedure|Adipose Biopsy|Adipose tissue will be sampled from the abdomen and buttock
1812984|NCT00677651|Procedure|Blood sample|Blood will be sampled from an IV line
1812985|NCT00677651|Radiation|CT Scan|Single image at the level of the liver
1812986|NCT00677651|Radiation|DEXA|Whole body scan
1812987|NCT00677664|Drug|Glatiramer acetate (Copaxone)|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
1812988|NCT00677664|Drug|Mannitol|Drug was offered by subcutaneous administration one week prior and in the three sections of PRP, one per week.
1813173|NCT00679029|Biological|bevacizumab|Given IV
1812989|NCT00677677|Biological|Human papillomavirus quadrivalent vaccine|Patients meeting the inclusion / exclusion criteria will be enrolled from outpatient transplant clinics. Upon enrolment, baseline serum will be obtained and patients will be given the first dose of vaccine. Two months later, serum will again be obtained and the second dose of vaccine will be administered. Finally, at month 6, serum will be obtained and the third dose of vaccine will be given. The final serum samples will be collected at months 7, 12 and 36. At 48 hours and 7 days after each vaccination, patients will be contacted by telephone for local and systemic adverse effect reporting.
1812990|NCT00677690|Other|neuromuscular electrical stimulation (NMES)|NMES was applied by means of a commercially available four channel electrostimulator which generated a symmetrical biphasic pulsed current. Each session lasted 30 minutes and was performed 5 days/week for 5 weeks.
1812991|NCT00677690|Other|Sham electrical stimulation|Sham stimulation was performed with the same modality and time, but the stimulus was set up at 5 Hz.
1812992|NCT00677703|Other|Daily Text Messages|"Text message reminders to take oral contraception daily:
Each text message will be a short educational message listing the benefits of contraceptive use and providing instructions for avoiding common medication errors."
1812993|NCT00677716|Drug|131I-chTNT-1/B MAb (Cotara)|Given as a single interstitial infusion over approximately 25 hours at a dose of 2.5 mCi/cc.
1812994|NCT00677729|Drug|solution contains 1 mg salbutamol plus 3% hypertonic saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 3% hypertonic saline every 20 minutes for a total of 3 doses
1812995|NCT00677729|Drug|solution contains 1 mg salbutamol plus 0.9% saline|4 ml of nebulized study solution containing 1 mg salbutamol plus 0.9% saline (NaCl) every 20 minutes for a total of 3 doses
1812996|NCT00677742|Other|enhanced initial supply of oral contraception|7 packs of pills, or 1 pack of pills and a prescription for 6 refills
1812997|NCT00677742|Other|conventional initial supply of oral contraception|3 packs of pills, or 1 pack of pills and a prescription for 2 refills
1812998|NCT00677755|Drug|mifepristone combined misoprostol|women received a single dose of mifepristone (Mifepristone tablets; Xianju Pharmacy, Zhejiang, China) 200mg orally on day 1, and then returned to the clinic on day 3 and were given misoprostol (Cytotec tables; Searle,A Division of Monsanto.P.L.C, England )0.8mg orally
1812999|NCT00677755|Drug|misoprostol alone protocol|patients were only administered 0.8 mg of misoprostol orally on day 3.
1813000|NCT00677768|Other|No intervention|Sample collection
1813001|NCT00677794|Drug|Clear fluids|Clear fluids only after lunch.
1813002|NCT00677794|Drug|Picosalax|Two sachets the evening prior to Video Capsule Endoscopy (VCE).
1813003|NCT00677794|Drug|Polyethylene glycol|Two (2) litres the evening prior to Video Capsule Endoscopy (VCE).
1813004|NCT00677807|Drug|Indacaterol|Indacaterol once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
1813005|NCT00677807|Drug|Placebo|Placebo once-daily (o.d.) via single-dose dry-powder inhaler (SDDPI)
1813006|NCT00677820|Biological|Trivalent influenza virus vaccine|Trivalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 ml of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10:7 FFU (fluorescent focus units) of each of three cold-adapted, attenuated, 6:2 reassortant influenza strains A/South Dakota/6/07 (H1N1), A/Uruguay/716/07 (H3N2), and B/Florida/4/2006.
1813007|NCT00677820|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 ml of sucrose-phosphate buffer.
1813008|NCT00677833|Drug|Azithromycin plus Chloroquine|Combination of Azithromycin plus Chloroquine Azithromycin (~30 mg/kg) + chloroquine (~10mg base /kg) combination tablet(s) on weight basis, once daily for 3 days (Days 0,1,2) or Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
1813009|NCT00677833|Drug|Artemether-lumefantrine|Artemether-lumefantrine tablet(s) based on weight and labeling for 3 days (Days 0, 1, 2)
1813010|NCT00677859|Biological|MultiStem®|Patients will receive a single IV infusion of MultiStem® 2 days after HSCT.
1813011|NCT00677859|Biological|MultiStem®|Patients will receive either 3 weekly IV infusions or 5 weekly infusions of MultiStem®
1813012|NCT00677872|Drug|PRX-08066|
1813013|NCT00677898|Behavioral|Patient-centered computerized tool|A brief computer program that provides personalized health information to patients prescribed second-generation antipsychotic medications on adherence to guidelines for screening of metabolic side effects
1813014|NCT00677898|Behavioral|Written educational materials|Printed information on the metabolic side effects of second-generation antipsychotic medications and general recommendations for screening
1813015|NCT00677911|Behavioral|In-vivo pain catastrophizing induction|All participants underwent a 10-minute in-vivo pain castastrophizing induction.
1813016|NCT00677924|Drug|Zalutumumab|Solution for infusion
1813017|NCT00677937|Behavioral|Modified DESMOND education and ongoing support|6 hours of education with 1 month of inclusion, 3 years of ongoing support including annual refresher sessions
1813018|NCT00677950|Procedure|Spinal fusion|Surgical procedure for lumbar spinal posterior decompression with concomitant posterolateral intertransverse process arthrodesis
1813019|NCT00677963|Drug|sulphur hexafluoride, gadopentate dimeglumine|CE-US, using 2 x 2.4 ml sulphur hexafluoride and MRI, using 1 x 0.2 ml/kg gadopentate dimeglumine
1813020|NCT00677989|Procedure|Laparoscopic appendectomy|laparoscopic appendectomy:did appendectomy by laparoscopic manipulation
1813021|NCT00677989|Procedure|Open appendectomy|open appendectomy: did appendectomy by laparotomy
1813022|NCT00678015|Drug|Nordihydroguaiaretic Acid (NDGA)|NDGA 2000mg daily
1813023|NCT00678041|Drug|Nitrofurantoin|nitrofurantoin 100mg to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
1813024|NCT00678041|Drug|Placebo|Placebo capsule to be taken daily while performing clean intermittent self-catheterization (CISC) and for three more days after stopping CISC
1813025|NCT00678054|Drug|GM-CSF|Each cycle will consist of 28 days. Patients will receive 250 ug/m2/day of GM-CSF administered subcutaneously on days 1-14.
1813026|NCT00678067|Dietary Supplement|Docosahexaenoic acid|Soft capsules 500 mg/each; 1 capsule/day for 4 months
1813027|NCT00678067|Dietary Supplement|Docosahexaenoic acid (DHA)+ Eicosapentaenoic acid (EPA)|Soft capsules, 228 mg DHA + 208 mg EPA /each; 1 capsule/day for 4 months
1813028|NCT00678067|Dietary Supplement|Germ oil|Soft capsules, 275 mg linoleic acid + 35 mg linolenic acid + 65 mg oleic acid /each; 1 capsule/day for 4 months
1813029|NCT00678067|Other|National Cholesterol Education Program (NCEP) Step I Diet|Dietary counselling aimed at achieving NCEP Dietary Guidelines: Total fat intake <30% of total calories, Saturated fat intake <10% of total calories, Polyunsaturated fat intake up to 10% of total calories, monounsaturated fat intake 10-15% of total calories
1813032|NCT00678093|Other|Application of the SNAG technique|SNAG is a painless and gentle manual technique, mimicking a slide with concurrent active movement, performed in the lumbar spine (in this study) by an experienced manual therapist-physiotherapist.
1813033|NCT00678106|Drug|Dalbavancin|Subjects weighing > 60 Kg: 1 gram IV single dose Subjects weighing < 60 Kg: 15 mg/Kg IV
1813034|NCT00678119|Biological|AGS-003|Dendritic cell Immunotherapeutic
1813035|NCT00678119|Drug|Sunitinib|An approved drug for the treatment of RCC
1813036|NCT00678132|Drug|AZD 2281|
1813037|NCT00678132|Drug|Cisplatin|
1813038|NCT00678132|Drug|Gemcitabine|
1813039|NCT00678145|Drug|naloxone|Administering fructose or naloxone or exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
1813040|NCT00678145|Dietary Supplement|fructose|Administering fructose or naloxone or exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
1813041|NCT00678145|Behavioral|exercise|Administering fructose or naloxone or exercise on Day 1, and quantifying the counterregulatory responses to hypoglycemia on Day 2.
1813042|NCT00678158|Radiation|intensity modulated radiation therapy|Patients will be accrued at each dose level beginning at 22 Gy with increments of 2 Gy up to 28 Gy. Patients with a soft tissue mass, lymph nodes or focal bone metastases with lesions large enough to be imaged on CT scan will be accrued. Starting at 24 Gy, patients will be stratified in to 3 treatment categories: lesions involving bone, bowel, or spinal cord. Patients will be enrolled in each treatment category until 10 patients in that cohort reach an evaluable timepoint of 3 months post-RT. The maximum accrual is 20 for 22 Gy, and 90 (30 per treatment category) for each subsequent dose level (24-28 Gy). Some of these patients have participated in the optional FLT-PET scan portion of the study. Some of these patients have under gone an optional MRI scan which take place within one hour of the radiation treatment .
1813043|NCT00678171|Device|TLIF with a PEEK Spacer System and XIA Spinal System|TLIF with an AVS™TL PEEK Spacer System and XIA® Spinal System using either OP-1 Putty and/or Autograft.
1813044|NCT00678184|Drug|Atorvastatin|80 mg atorvastatin on two following days each
1813045|NCT00678197|Other|Access Intervention|
1813046|NCT00678197|Other|Bonus/Pay-for-Performance Intervention|
1813047|NCT00678210|Drug|CP-690,550|tablets, 2 mg BID for 12 weeks
1813048|NCT00678210|Drug|CP-690,550|tablets, 5 mg BID for 12 weeks
1813049|NCT00678210|Drug|CP-690,550|tablets, 15 mg BID for 12 weeks
1813050|NCT00678210|Drug|Placebo|tablets, BID for 12 weeks
1813051|NCT00678236|Other|Refobacin Bone Cement R|Insertion of a knee prosthesis fixed by Refobacin Bone Cement R
1813052|NCT00678236|Other|Refobacin Plus Bone Cement|Insertion of a knee prosthesis fixed by Refobacin Plus Bone Cement
1813053|NCT00678249|Device|FLAIR Endovascular Stent Graft|Primary balloon angioplasty followed by placement of the FLAIR Endovascular Stent Graft
1813054|NCT00678249|Procedure|PTA|Percutaneous Transluminal Angioplasty
1813055|NCT00678249|Device|FLAIR Endovascular Stent Graft|Primary PTA followed by placement of the FLAIR Endovascular Stent Graft. Roll-in participants were enrolled in the study for training purposes and were not randomized.
1813056|NCT00678275|Drug|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen with ATG: ATG FRESENIUS dosing: 10mg/kg/day, (day -3, -2,-1) when randomised Arm A
1813057|NCT00678275|Drug|ATG FRESENIUS (Anti-Lymphocyte-Globulin)|conditioning regimen WITHOUT ATG when randomised Arm B
1813058|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously
1813059|NCT00678288|Drug|Sorafenib (Nexavar, BAY43-9006) + Interferon|Sorafenib 400 mg (two 200 mg tablets) BID PO, continuously. IFN alpha-2a 3MIU FIW s.c., from Monday to Friday (total weekly dose 15 MIU) s.c., to start one week after commencing sorafenib.
1988470|NCT02825056|Drug|Bupivacaine|Intrathecal local anesthetic drug,Bupivacaine will be delivered in L3-L4 space.
1988471|NCT02825056|Drug|Bupivacaine + Morphine|Intrathecal local anesthetic drug,Bupivacaine and Morphine will be delivered in L3-L4 space.
1813063|NCT00678314|Drug|Ropivacaine 0.2%|10 ml
1813064|NCT00678314|Drug|Ropivacaine 0.75%|3 ml
1813065|NCT00678314|Drug|Normal saline|10 ml
1813066|NCT00678327|Biological|bleomycin sulfate|Given IV
1813067|NCT00678327|Biological|filgrastim|Given subcutaneously
1813068|NCT00678327|Biological|pegfilgrastim|Given subcutaneously
1813069|NCT00678327|Drug|cyclophosphamide|Given IV
1813070|NCT00678327|Drug|dacarbazine|Given IV
1813071|NCT00678327|Drug|doxorubicin hydrochloride|Given IV
1813072|NCT00678327|Drug|etoposide|Given IV
1813073|NCT00678327|Drug|prednisolone|Given orally
1813074|NCT00678327|Drug|procarbazine hydrochloride|Given orally
1813075|NCT00678327|Drug|vinblastine sulfate|Given IV
1813076|NCT00678327|Drug|vincristine sulfate|Given IV
1813077|NCT00678340|Device|WACA and PVI|Wide area circumferential ablation (WACA) in the pulmonary vein antrum with subsequent pulmonary vein isolation (PVI) with a single tip irrigated catheter.
1813078|NCT00678340|Device|PVAC|Circumferential ablation with a circular ablation catheter (Ablation Frontiers) to electrical silence.
1813079|NCT00678366|Procedure|addition of 4% oxygen|addition of 4% oxygen to the carbon dioxide pneumoperitoneum
1813080|NCT00678366|Procedure|carbon dioxde|classic pneumoperitoneum with 100 % carbon dioxide
1813081|NCT00678379|Drug|lidocaine (1%) + bupivacaine (0.5%)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.
B - lidocaine (1%) + bupivacaine (0.5%)"
1813082|NCT00678379|Drug|Normal saline|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.
A - normal saline"
1813083|NCT00678379|Drug|Lidocaine (1%) + Bupivacaine (0.5%) + Clonidine (25mcg)|"Submucosal injection of 1.5 mL into each tonsillar fossa prior to performing tonsillectomy.
C - lidocaine (1%) + bupivacaine (0.5%) + clonidine (25mcg)"
1813084|NCT00678392|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg twice daily [BID] with continuous dosing
1813085|NCT00678392|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg twice daily [BID] with continuous dosing
1813086|NCT00678405|Behavioral|Breathlessness Intervention Service|Breathlessness Intervention Service (BIS) consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease (cancer & non-cancer) using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. Thus BIS seeks to enhance the self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
1813087|NCT00678405|Behavioral|Best supportive care (Standard Care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory, cardiology, neurology or oncology) which may include specialist nurse input, and primary care services.
1813088|NCT00678418|Drug|VIVITROL® 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for 24 weeks during Part A, followed by once every 4 weeks for 52 weeks in Part B.
1813089|NCT00678418|Drug|Placebo|Administered via IM injection once every 4 weeks for 24 weeks during Part A, followed by VIVITROL® 380 mg via IM injection once every 4 weeks for 52 weeks in Part B.
1813090|NCT00678431|Dietary Supplement|Resveratrol with Glucose, and Malate|Dietary supplement delivered in grape juice
1813091|NCT00678431|Dietary Supplement|Placebo|Liquid placebo
1813093|NCT00678457|Drug|Ondansetron|ondansetron (4 μg/kg b.i.d.)
1813094|NCT00678457|Drug|Olanzapine|olanzapine (9, 18, and 36 μg/kg)
1813095|NCT00678457|Drug|Placebo|placebo
1813096|NCT00678470|Drug|Intralesional Alefacept|Patients enrolled in this study will receive intralesional alefacept injections to a single psoriatic plaque at week 0. After a two week observation period, patients will receive 15 mg intramuscular alefacept for 12 weeks.
1813097|NCT00678483|Drug|rimonabant (SR141716)|once daily
1813098|NCT00678496|Other|CBT Software|"Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one."
1813099|NCT00678496|Other|Treatment as usual|Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
1813100|NCT00678509|Biological|TTK peptide mixed with Montanide ISA 51|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
1813101|NCT00678522|Drug|Atorvastatin|80 mg atorvastatin daily on two following days
1813102|NCT00678535|Drug|Cetuximab|Single first dose of cetuximab 400 milligram per square meter (mg/m^2) will be administered intravenously over 120 minutes followed by weekly intravenous infusion of cetuximab 250 mg/m^2 over 60 minutes in each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
1813103|NCT00678535|Drug|Capecitabine|Capecitabine 1000 mg/m^2 will be administered orally twice daily from evening of Day 1 to morning of Day 15 for every 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
1813104|NCT00678535|Drug|Cisplatin|Cisplatin 80 mg/m^2 will be administered intravenously with infusion over 1 to 4 hours on Day 1 of each 3-week treatment cycle, until documented disease progression, unacceptable toxicity, or withdrawal of consent.
1813105|NCT00678548|Behavioral|Pleasant guided imagery|CD with pleasant guided imagery
1813106|NCT00678548|Behavioral|Pain diary|Filling out a pain diary
1813107|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
1813108|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
1813109|NCT00678561|Drug|CP-690,550|Topical treatment once daily for 28 days
1813110|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
1813111|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
1813112|NCT00678561|Drug|CP-690,550|Topical treatment twice daily for 28 days
1813113|NCT00678561|Drug|Placebo Vehicle|Topical treatment once daily for 28 days
1813114|NCT00678561|Drug|Placebo Vehicle|Topical treatment twice daily for 28 days
1813115|NCT00678574|Drug|fluoxetine|Fluoxetine 20 mg daily by mouth for 2-3 months.
1813116|NCT00678587|Drug|Eltrombopag|75 mg, once daily, oral
1813117|NCT00678587|Drug|Placebo|placebo, once daily, oral
1813118|NCT00678600|Other|Standard (static) Computer Alerts|Static Computer Alerts on Patient's EMR webpage.
1813119|NCT00678600|Other|Enhanced Computer Alerts|Population level and asynchronous alerts with enhanced functionality
1813120|NCT00678613|Drug|Probiotics and Placebo|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder. It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs and placebo will be given for one year or till the end points of the study.
1813170|NCT00679003|Behavioral|ES|Education and support (information about nutrition and gastrointestinal system)
1813171|NCT00679029|Drug|doxorubicin hydrochloride|Given IV
1813172|NCT00679029|Drug|cyclophosphamide|Given IV
1813121|NCT00678613|Drug|Probiotics and Norfloxacin|The Probiotics used in this study will be VSL#3. The control will be given similar looking capsules containing galactose powder.It will be used in the form of capsules. A total dose of 450 billions CFU will be used. Norfloxacin, 400 mg /day, will also be used as similar looking capsules. The drugs will be given for one year or till the end points of the study.
1813122|NCT00678626|Drug|CP-751,871|Docetaxel administered every 3 weeks. CP-751,871 administered every 3 weeks. CP-751,871 administration (20 mg/kg IV) will continue after the docetaxel is stopped.
1813123|NCT00678626|Drug|Docetaxel|Docetaxel only is administered every 3 weeks. After progression, administration with CP-751, 871 (20 mg/kg IV) is permitted.
1813124|NCT00678639|Other|Observation unit care, coupled with cardiac MRI|After Emergency Department (ED) evaluation, patients are randomized to Observation unit care or standard inpatient care. Patients in the observation unit will also undergo a stress cardiac MRI. Patients in the usual care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
1813126|NCT00678678|Device|Incentive Spirometry - RESPIRON|Device that stimulates the deep breathing, flow-oriented
1813127|NCT00678678|Device|Kit Epap®:|Device that providing constant positive pressure during expiration, given by spring load (cmH2O), using a face mask as an interface
1813128|NCT00678691|Drug|armodafinil|50-250mg/d
1813129|NCT00678691|Drug|placebo|matching placebo
1813130|NCT00678704|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 10 mg tablet prior to intercourse on demand
1813131|NCT00678704|Drug|Levitra (Vardenafil, BAY38-9456)|BAY 38-9456 20 mg tablet prior to intercourse on demand
1813132|NCT00678704|Drug|Placebo|Placebo tablet prior to intercourse on demand
1813133|NCT00678717|Device|"Sham"|Physiological stimuli
1813134|NCT00678717|Device|Medtronic or ANS spinal cord stimulator|Spinal cord stimulator implant
1813135|NCT00678730|Drug|delta 9 tetrahydrocannabinol|0.05 mg/kg of THC dissolved in ethanol intravenously over 20 minutes
1813136|NCT00678743|Drug|Omacor + simvastatin|Omacor 4 grams/day plus simvastatin 80 mg/day. Simvastatin dose adjusted at Investigator discretion after week 6.
1813137|NCT00678756|Drug|Ketokonazol 2% cream|twice a day at 2 times,2 out of 5 areas have to be treated for 4 weeks/7 days a week
1813138|NCT00678756|Radiation|UVB-radiation 311nm|3 out of 5 areas are radiated for 4 weeks every MO/DI/DO/FR starting MED orientated, intensified everytime 0,03 J/qcm
1813139|NCT00678769|Drug|Cixutumumab|Given IV
1813140|NCT00678769|Other|Laboratory Biomarker Analysis|Correlative studies
1813141|NCT00678769|Other|Pharmacological Study|Correlative studies
1813142|NCT00678769|Drug|Temsirolimus|Given IV
1813143|NCT00678782|Drug|etanercept|etanercept 12.5mg, intraarticular injection administered once every two weeks for an eight week period
1813144|NCT00678782|Drug|placebo|Placebo (NaCl) 0.5 ml intraarticular injection
1813145|NCT00678795|Drug|Sativex®|"Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.
Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours"
1813146|NCT00678795|Drug|Placebo|containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
1813149|NCT00678834|Dietary Supplement|To surgery patients, Tocopherol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
1813150|NCT00678834|Dietary Supplement|Tocotrienol to healthy subjects.|200 mg to take orally two times a day (400 mg a day).
1813151|NCT00678834|Dietary Supplement|To surgery patients, Tocotrienol capsules.|200mg (2 100mg capsules) to take by mouth twice daily to total 400mg daily
1813152|NCT00678847|Device|KFH NOVO (inactive) + SCT|inactive device (placebo) 2 x 1hour/day for total period of 8 weeks + standardized conventional therapy (SCT)
1813153|NCT00678847|Device|KFH Novo (BEST) + SCT|2 x 1 hour/day bio-electrical stimulation (BEST) for total period for total period of 8 weeks in combination with standardized conventional therapy (SCT)
1813154|NCT00678873|Procedure|Single Incision Laparoscopic Cholecystectomy|A single trans-umbilical incision laparoscopic cholecystectomy will be performed by standard fashion and under general anesthesia.
1813155|NCT00678886|Biological|otelixizumab infusion plus physician determined standard of care|infusion
1813156|NCT00678886|Biological|placebo infusion plus physician determined standard of care|infusion
1813157|NCT00678899|Device|Nucleus Hybrid L24|Implantation with Nucleus Hybrid L24 cochlear implant
1813158|NCT00678912|Device|Smartcare/PS|computer-driven protocol that adjusts pressure support level in pressure support mode to patient respiratory status
1813159|NCT00678925|Dietary Supplement|Phosphatidylcholine|850 mg per day from 18 weeks pregnancy through 90 days postpartum
1813160|NCT00678925|Dietary Supplement|Corn oil placebo|Placebo capsules containing corn oil given from 18 weeks pregnancy through 90 days postpartum
1813161|NCT00678938|Behavioral|Smoking abstinence oriented expert system intervention|Participants received up to three counselling letters targeting smoking cessation
1813162|NCT00678938|Behavioral|Smoking reduction oriented expert system intervention|Participants received up to three counselling letters targeting smoking reduction
1813163|NCT00678964|Drug|Erlotinib|Erlotinib 150 mg, p.o., once daily
1813164|NCT00678964|Drug|Vinorelbine and Carboplatin|Vinorelbine 25 mg/m2, i.v., day 1 and 8 of every cycle (21 days) plus carboplatin AUC 5, i.v., day 1 of every cycle
1813165|NCT00678977|Drug|Pazopanib (GW786034)|initial dose 400mg daily in 21-day cycles; increase in dose up to 800mg daily following evaluation of safety and tolerability
1813166|NCT00678977|Drug|Gemcitabine|Gemcitabine on Days 1 and 8 of each cycle; initial dose 600 mg/m2 increase to 1,000mg/m2 after evaluation of safety and tolerability; increase to 1250mg/m2 after evaluation of safety and tolerability
1813167|NCT00678977|Drug|Cisplatin|Cisplatin on Day 1 of each 21-day cycle initial dose 60mg/m2; increase to 80mg/m2 after evaluation of safety and tolerability
1819095|NCT00721656|Drug|KLS-0611|
1813174|NCT00679029|Drug|paclitaxel|Given IV
1813175|NCT00679029|Drug|gemcitabine hydrochloride|Given IV
1813176|NCT00679029|Other|laboratory biomarker analysis|Correlative studies
1813177|NCT00679029|Biological|pegfilgrastim|Given subcutaneously
1813178|NCT00679042|Drug|Islets of Langerhans transplantation|"Each subject may receive 1-3 transplantations of allogeneic human islets of Langerhans and the following medications:
Basiliximab 20 mg iv 2 hours before transplant and 20 mg iv 2 weeks post-transplant; Tacrolimus 1 mg p.o. bid adjusted to reach target trough levels of 3-6 ng/ml; Sirolimus 0.2 mg/kg loading dose, then 0.1 mg/kg p.o. daily adjusted to reach target trough levels of 10-15 ng/ml during the first 3 months post transplant and 7-10 ng/ml thereafter; Etanercept 50 mg iv 1 hour before transplant and 25 mg s.c. on days 3, 7,and 10 post-transplant; Exenatide 5-mcg s.c. bid for 1 week, then 10 mcg bid for 6 months after each transplant"
1813179|NCT00679055|Drug|MK-0736|MK-0736; 7mg once daily, orally at approximately the same time each morning for 12 weeks.
1813180|NCT00679055|Drug|Comparator: placebo (unspecified)|Matching Placebo once daily, orally at approximately the same time each morning for 12 weeks.
1813181|NCT00679068|Drug|Bosentan|62.5 mg b.i.d. for 4 weeks, then 125 mg b.i.d.for the remaining 8 weeks (if tolerated)
1813182|NCT00679081|Device|CelTx|Single application; split-mouth design
1813183|NCT00679081|Other|Autologous sub-epithelial connective tissue graft|Single application; split-mouth design
1813184|NCT00679094|Drug|Bowman-Birk inhibitor concentrate|Given orally
1813185|NCT00679094|Other|placebo|Given orally
1813186|NCT00679094|Other|pharmacological study|Correlative studies
1813187|NCT00679094|Other|laboratory biomarker analysis|Correlative studies
1813188|NCT00679107|Device|Use of OP-1 Putty in Uninstrumented posterolateral fusion|Use of OP-1 Putty in Uninstrumented posterolateral fusion
1813189|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
1813190|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery
1813191|NCT00679120|Device|Oxford Uni Knee|Oxford Uni Knee inserted at the time of surgery (porous coated and HA coated)
1813192|NCT00679133|Drug|MGCD265|Oral daily administration; 7 days on / 7 days off
1813193|NCT00679146|Drug|Thiocolchicoside+Ketoprofen|1 tablet TCC 8 mg + ketoprofen 100 mg b.i.d + 2 tablets TCC placebo b.i.d
1813194|NCT00679146|Drug|Thiocolchicoside|2 tablets TCC 4 mg b.i.d. + 1 tablet of FDC placebo b.i.d
1813195|NCT00679159|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from M. tuberculosis
1813196|NCT00679159|Biological|Prevenar|Streptococcus pneumoniae vaccine
1813197|NCT00679172|Biological|Dose of 5.0 x 10^9 CFU (Cohort 1)|S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration
1813198|NCT00679172|Biological|Dose of 7.5 x 10^9 CFU (Cohort 2)|S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration
1813199|NCT00679172|Biological|Dose of 1.1 x 10^10 CFU (Cohort 3)|S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration
1813200|NCT00679172|Biological|Dose of of 1.7 x 10^10 CFU (Cohort 4)|S. typhi (Ty2 aroC‾ssaV‾) ZH9 live attenuated typhoid vaccine, single dose, oral administration
1813201|NCT00679172|Other|Placebo (Cohorts 1-4 pooled)|Excipients only, single dose, oral administration
1813202|NCT00679185|Behavioral|expressive writing|four non-emotional writing assignments
1813203|NCT00679198|Behavioral|nurse-patient communication|"We will train home health nurses to act as patient advocates by communicating the risks and benefits of osteoporosis treatment to patients and their healthcare providers.
Thus, we will provide a comprehensive, integrated approach to the management of osteoporosis among patients with a history of insufficiency fractures that is highly generalizable to a national setting."
1813204|NCT00679211|Drug|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
1813205|NCT00679224|Drug|ambrisentan|ambrisentan
1813206|NCT00679237|Behavioral|smoking cessation|NRT and varenicline
1813207|NCT00679237|Drug|betablocker, diuretics, ACEI, ARB,|blood pressure control according to ESC guidelines
1813208|NCT00679237|Drug|statins, ezetimibe|Cholesterol reduction according to ESC guidelines
1813209|NCT00679237|Behavioral|training|daily walking
1813210|NCT00679237|Biological|influenza vaccine|vaccine (FLuarix, Influvac etc)
1813211|NCT00679237|Drug|metformin, glimepiride, insulin|s.glucose control according to ESC guidelines
1813212|NCT00679237|Behavioral|weight reduction|diet tips
1813213|NCT00679250|Drug|levocetirizine|5 mg once nightly before visit
1813214|NCT00679250|Drug|placebo to levocetirizine|1 tablet once nightly before visit
1813215|NCT00679263|Drug|MN-221|Initial dose: 16 μg/min for 15 minutes followed by 8 μg/min for 105 minutes (2-hour infusion with a total dose of 1,080 μg)
1813216|NCT00679263|Drug|MN-221|Subsequent dose: 30 μg/min for 15 minutes followed by 15 μg/min for 45 minutes (1-hr infusion with a total dose of 1,125 μg).
1813217|NCT00679263|Drug|Placebo|Placebo intravenous infusion with dosing volume equivalent to active treatment.
1813218|NCT00679276|Procedure|Prolift|surgical repair of vaginal prolapse
1813219|NCT00679289|Drug|Interferon alpha|20 MU/m2 IV QD x 5 Days for 4 weeks, then 10 MU/m2 SC TIW until disease progression
1813220|NCT00679289|Drug|KW2871|5 mg/m2 IV Q2W until disease progression
1813221|NCT00679289|Drug|KW2871|10 mg/m2 IV Q2W until disease progression
1813222|NCT00679289|Drug|interferon alpha|20 MU/m2 IV QD x 5 Days for 4 weeks, then 10 MU/m2 SC TIW until disease progression
1813223|NCT00679289|Drug|KW2871|20 mg/m2 IV Q2W until disease progression
1813224|NCT00679289|Drug|Interferon alpha|20 MU/m2 IV QD x 5 Days for 4 weeks, then 10 MU/m2 SC TIW until disease progression
1813225|NCT00673322|Biological|Gene Modified T Cells|One time infusion Modified T-Cells given through a vein in the arm or a catheter over a 30-60 minute period.
1813226|NCT00673335|Drug|letrozole|
1813227|NCT00673335|Drug|Placebo|
1813269|NCT00673634|Procedure|Standard preoxygenation|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes.
1813270|NCT00673634|Procedure|BiPAP assisted preoxygenation|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4cm H2O and a positive end-expiratory pressure of 4cm H2O, for 3 minutes.
1813228|NCT00673361|Drug|Concurrent decrescendo biochemotherapy regimen|"Temozolomide: 200mg/m^2, daily, PO, days 1-4
Vinblastine: 1.5mg/m^2, daily, IV, days 1-4
Cisplatin: 20mg/m^2, daily IV, days 1-4
IL (interleukin)-2: - 18 milli-International unit (MIU)/m^2, IVCI (intravenous continual infusion), day 1
9 MIU/m^2, IVCI, day 2
4.5 MIU/m^2, IVCI, days 3 & 4
Interferon (IFN) alpha: 5 MIU/m^2, daily, SC (subcutaneously), days 1-5
5-day inpatient regimen, to be repeated every 21 days"
1813229|NCT00673361|Drug|Low-dose Temozolomide plus Sorafenib|Temozolomide: 75mg/m^2, PO, QD (quaque die), 6 weeks on/2 weeks off Sorafenib: 400mg, PO, BID, 8 weeks
1813230|NCT00673374|Device|radio-opaque adhesive skin markers|The examining physician will place a radio-opaque skin marker (Beekley Corporation, Ortho-SPOTS® Order Code 187; 6mm spherical markers) at the point of maximal tenderness to direct abdominal palpation indicated by the patient. Additional markers will be placed at the cephalad and caudad limits of the region of tenderness, defined as the point at which the patient no longer complains of direct tenderness to palpation.
1813231|NCT00673387|Drug|pramlintide acetate|subcutaneous injection, twice a day
1813232|NCT00673387|Drug|metreleptin|subcutaneous injection, twice a day
1813233|NCT00673387|Drug|placebo-P|subcutaneous injection, twice a day
1813234|NCT00673387|Drug|placebo-M|subcutaneous injection, twice a day
1813235|NCT00673400|Procedure|Stapled transanal rectum resection|Contour Transtar-STR5G (Ethicon EndoSurgery Inc., Cincinnati, OH).The circular anal dilator is fixed to perianal skin.Rectal intussusception is evidenced with a swab.The first stitch is placed superficial on top of the intussusception. The procedure is performed 5to6 times counterclockwise.A final stitch for first radial cut at 3 o'clock.The device is introduced into the rectum. This cut opens the prolapse. Check with a finger the vagina. The device is then closed and fired. After replacing the cartridge, the device is introduced in the rectum, placed parallel to the circular anal dilator and moved counter clockwise with 4to6firings to complete the resection. Additional stitches across the staple line to assure haemostasis.
1813236|NCT00673426|Biological|Enoxaparin sodic|
1813237|NCT00673439|Drug|fondaparinux|Dosage form: subcutaneous injection; dosage: 7.5 to 10.0 mg; frequency and duration: daily until blood test results rule out confirmed HIT - for patients with confirmed HIT, continue daily until INR (blood clotting) measurement rises to at least 2
1813238|NCT00673439|Drug|warfarin|Dosage form: oral; dosage: 2.5 to 5.0 mg; frequency and duration: (for confirmed HIT only) once daily, to begin when blood platelet count reaches at least 100,000, and continue for approximately 4 weeks
1813239|NCT00673452|Drug|duloxetine hydrochloride|60-120 mg, oral, every day, 12 weeks (acute blinded phase followed by a 12 week blinded continuation phase).
1813240|NCT00673452|Drug|placebo|oral, daily, 12 weeks (acute blinded phase followed by 12 weeks of blinded duloxetine treatment)
1813241|NCT00673465|Drug|SCH 497079|SCH 497079 100 mg capsule, administered orally, once daily for 4 weeks
1813242|NCT00673465|Drug|Placebo|Placebo capsules matching SCH 497079, administered orally, once daily for 4 weeks
1813243|NCT00673465|Drug|Metformin|Metformin extended release 750 mg, 2 tablets administered orally, once daily for 4 weeks (1500 mg total daily dose)
1813244|NCT00673478|Drug|Tiotropium+Salmeterol|
1813245|NCT00673478|Drug|Salmeterol|
1813246|NCT00673478|Drug|Tiotropium|
1813247|NCT00673491|Other|Clinical Pathways|Clinical pathways are a methodology for the mutual decision making and organization of care for a well-defined group of patients during a well-defined period. Defining characteristics of clinical pathways includes: an explicit statement of the goals and key elements of care based on evidence, best practice, and patient expectations; the facilitation of the communication, coordination of roles, and sequencing the activities of the multidisciplinary care team, patients and their relatives; the documentation, monitoring, and evaluation of variances and outcomes; and the identification of the appropriate resources.
1813248|NCT00673504|Drug|Gemcitabine + Sunitinib|Gemcitabine 1.000 mg/m2, d1,8q3weeks Sunitinib 50 mg/day (2weeks on/1weeks off)
1813249|NCT00673504|Drug|Gemcitabine|1.000 mg/m2 d1,8,15q4weeks
1813250|NCT00673530|Behavioral|evidence based clinical nutrition concept|The evidence based nutrition concept comprise a routine malnutrition screening for hospitalized patients, the implementation of an evidence based guideline for clinical nutrition in the participating hospital, education training of the clinical staff and thereby optimal clinical nutrition for malnourished hospitalized patients.
1813251|NCT00673530|Behavioral|care as usual|Unchanged treatment of hospital patients without interference by the study.
1813252|NCT00673556|Drug|alefacept|Intramuscular (IM)
1813253|NCT00673556|Drug|placebo|Intramuscular (IM)
1813254|NCT00673569|Drug|erlotinib hydrochloride|
1813255|NCT00673569|Genetic|gene expression analysis|
1813256|NCT00673569|Genetic|protein expression analysis|
1813257|NCT00673569|Other|immunoenzyme technique|
1813258|NCT00673569|Other|immunologic technique|
1813259|NCT00673569|Other|laboratory biomarker analysis|
1813260|NCT00673569|Procedure|needle biopsy|
1813261|NCT00673582|Drug|Rosuvastatin|10 mg/day rosuvastatin
1813262|NCT00673582|Drug|Placebo|Placebo, 10 mg a day for 96 weeks
1813263|NCT00673595|Drug|Varenicline|"Smoking cessation assistance: study days 1-3: 0.5 mg once daily, study days 4-7: 0.5 mg twice daily, study days 8-15: 1 mg twice daily; study day 16: 1 mg once. The tablets should be taken orally after food intake with 200 ml of water.
The treatment phase may be prolonged up to a maximum of 2 weeks under the following conditions: 1) the participant voluntarily agrees to the prolongation of the study, 2) both the participant and investigator are confident that the participant will be able to completely refrain from smoking for at least 10 days until the final study day."
1813264|NCT00673595|Drug|Placebo|The pharmacy will prepare tablets that match the varenicline tablets. The tablets should be taken orally after food intake with 200 ml of water.
1813265|NCT00673608|Drug|deferasirox|Deferasirox up to 40mg/kg/day, PO, Dispersible tablets, taken once daily
1813266|NCT00673621|Drug|Technosphere Insulin Inhalation Powder|3.0 of human insulin. single dose cartridges filled with 5 or 10 mg of Technosphere Inhalation Powder, containing 15 or 30 u of insulin
1813267|NCT00673621|Drug|Salbutamol (Albuterol)|2 puff = 200 mcg total dose
1813268|NCT00673621|Drug|Methacholine chloride|5mls of methacholine; diluent sodium chloride 0.9%; formulation methacholine chloride in sodium chloride 0.9%
1813606|NCT00683436|Drug|Ambien CR|Ambien CR 12.5 mg
1813271|NCT00673647|Behavioral|Cognitive-behavioral treatment|10 sessions of individual psychotherapy including cognitive-behavioral treatment, motivational enhancement and a psychosocial problem training.
1813272|NCT00673660|Behavioral|Patient Compliance|Compliance of patients to statin treatment and reasons of compliance or non compliance will be obtained by Patient Reported Outcomes (PROs) every 3 months.
1813273|NCT00673673|Drug|FOLFOX|Oxaliplatin 85/mg/m2 IV infused over two hours followed by Leucovorin 400 mg/m2 IV over 2 hours, followed by 5-FU 400 mg/m2 IV bolus, then 2400 mg/m2 continuous IV infusion over 46-48 hours
1813274|NCT00673673|Drug|bevacizumab|bevacizumab will be used at a dose of 10 mg/kg administered every 2 weeks on day one of FOLFOX chemotherapy
1813275|NCT00679302|Drug|Trimethoprim-sulfamethoxazole|Participants were randomized to receive placebo or trimethoprim/sulfamethoxazole using a computer randomization program on the initial presentation. The placebo is a Maalox and tonic water combination that resembled the antibiotic in color, texture and taste. The antibiotic dose is a standard trimethoprim/sulfamethoxazole for bacterial infection (10-12mg trimethoprim/kg/day, with a maximum adult dose of 160mg trimethoprim/day, divided into two doses). The concentration of the liquid is 200mg sulfamethoxazole/40mg trimethoprim per 5mL. With a maximum dose of 160mg trimethoprim, this equates to 20mL.
1813276|NCT00679302|Drug|Placebo group|Placebo (Maalox with simethicone and bitter mixture) suspension was dispensed to study participants who were block randomized to receive the placebo.
1813277|NCT00679315|Drug|alfuzosin hydrochloride XL 10mg|One tablet to be taken daily after a meal before bedtime for 8 weeks.
1813278|NCT00679315|Drug|Placebo|One tablet to be taken daily after a meal before bedtime for 8 weeks.
1813279|NCT00679328|Device|Surgical implantation of OP-1 device or autograft bone graft material|Surgical implantation of OP-1 device or autograft bone graft material
1813280|NCT00679341|Drug|Trastuzumab emtansine [Kadcyla]|The total dose depended on the patient's weight on Day 1 of each cycle. Trastuzumab emtansine was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease (or until second disease progression for patients who crossed over), unacceptable toxicity, or study closure, whichever occurred first.
1813281|NCT00679341|Drug|Trastuzumab|The dose of trastuzumab was recalculated if body weight changed by more than ±10% from baseline. Trastuzumab was administered every 3 weeks until investigator-assessed radiographic or clinical progressive disease, or unmanageable toxicity. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
1813282|NCT00679341|Drug|Docetaxel|Docetaxel was given at a dose of 75 or 100 mg/m^2 based on the investigator's decision. Patients in the trastuzumab + docetaxel arm who discontinued study treatment because of progressive disease were eligible to cross-over to trastuzumab emtansine treatment until a second progressive disease event, clinical deterioration, and/or intolerance.
1813283|NCT00679354|Drug|cilengitide|Given IV
1813284|NCT00679354|Other|laboratory biomarker analysis|Correlative studies
1813285|NCT00679354|Other|pharmacological study|Correlative studies
1813286|NCT00679367|Drug|dexamethasone|40 mg once weekly
1813287|NCT00679367|Drug|lenalidomide|10 mg/day D1-21
1813288|NCT00679367|Drug|melphalan|5 mg/m2 D1-4
1813289|NCT00679380|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
1813290|NCT00679380|Drug|Budesonide MMX® 6 mg|6 mg/day, 6 mg tablets
1813291|NCT00679380|Drug|Budesonide MMX® 9 mg|9 mg/day, 9 mg tablets
1813292|NCT00679380|Drug|Entocort EC® 3 mg|9 mg/day, 3 mg tablets
1813293|NCT00679380|Drug|Placebo|Placebo
1813294|NCT00679393|Procedure|Open reduction internal fixation|Open reduction internal fixation surgery of severely comminuted calcaneal fracture (Sanders IV).
1813295|NCT00679393|Procedure|Fusion|Primary subtalar fusion of severely comminuted calcaneal fracture (Sanders IV)
1813296|NCT00679406|Behavioral|Brief Behavioral Treatment for Insomnia|Effective behavioral insomnia treatments are typically delivered over an 8-week period. This format may not be easily exportable to primary and community care settings where military returnees and veterans seek help. The goal here is to test the effects of a 4-week behavioral treatment that targets chronic insomnia (lasting >1 month) in service members returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF), and who present with the typical psychiatric comorbidities associated of combat-related anxiety and mood disorders and stress reactions.
1813297|NCT00679432|Procedure|Blood sampling, endoscopy|Blood sampling for hematology and biochemistry and endoscopy with biopsy for histological and endoscopic assessment scores
1813298|NCT00679432|Drug|budesonide-MMX® 6 mg|6 mg/day, 6 mg tablets
1813299|NCT00679432|Drug|budesonide-MMX® 9 mg|9 mg/day, 9 mg tablets
1813300|NCT00679432|Drug|Placebo|Placebo
1813301|NCT00679432|Drug|Asacol® 400 mg|2400 mg/day, 400 mg tablets
1813302|NCT00679445|Device|NeoVista Ophthalmic System|A single procedure using the NeoVioasta Ophthalmic System plus an injection of Lucentis.
1993594|NCT03169374|Device|Virtual Reality Technology|Patients in this arm will participate in virtual reality sessions planned for 5 minutes at a time, during which they are shown relaxing virtual environments.
1813305|NCT00679484|Drug|olmesartan medoxomil + candesartan cilexetil placebo|Dosage form: tablet; frequency: daily; duration: 24 weeks
1813607|NCT00683436|Drug|Adipiplon|bilayer tablets 9 mg
1993599|NCT03166540|Other|cup of espresso coffee|Subjects will consume the assigned treatment for one month. Espresso coffee will be prepared by using coffee capsules. Serving size: approximately 45 mL. The last day of the intervention is the sampling day.
1996625|NCT02432170|Device|Digital Tomosynthesis of Foot and Ankle|Imaging Technique
1813306|NCT00679484|Drug|olmesartan medoxomil placebo + candesartan cilexetil|Dosage form: tablets; frequency: daily; duration: 24 weeks
1813307|NCT00679497|Biological|MVA-B|"Modified Pox virus, strain MVA clade -B (expressing HIV-1 Bx08gp120 and IIIB gagpolnef)
-~ 1 x 10e8 pfu/ml
3 immunisations at week 0, 4 and 16"
1813308|NCT00679497|Biological|Placebo|-3 immunisations at week 0, 4 and 16
1813309|NCT00679510|Drug|rosuvastatin|tablet 10 mgs once daily
1813310|NCT00679510|Drug|placebo|placebo
1813311|NCT00679523|Drug|AN2690 Solution, 5.0%|Once daily application for 180 days
1813312|NCT00679523|Drug|AN2690 Solution, 7.5%|Once daily application for 180 days
1813313|NCT00679536|Drug|Busulfan|Patient will receive a Test Dose of Busulfan on either Day -10 or Day -9. Patient will receive their Regimen Dose of Busulfan on Day -5 to Day -2. The regimen dose of Busulfan will be based off of the findings from their Test Dose.
1813314|NCT00679536|Drug|Fludarabine|Patient will receive Fludarabine from Day -6 to Day -2. The dose of Fludarabine will be 30 mg/m^2/day.
1813315|NCT00679536|Drug|Thymoglobulin|The patient will also receive Thymoglobulin (rabbitATG) on Day -4 to Day -2. Each dose of rabbitATG will be 1.5 mg/kg/day.
1813316|NCT00679536|Radiation|Total Body Irradiation|On Day -1 the patient will receive a total of 400 cGy of Total Body Irradiation.
1813317|NCT00679549|Device|CPAP Therapy|CPAP therapy is provided as an inpatient.
1813318|NCT00679562|Drug|Lactic Acid|Application of occlusive patches containing test product. For 24 hours and repeat 2 weeks later for participants with no reaction to Lactacyd Radiance
1813319|NCT00679562|Other|Distilled water|Application of patches containing distilled water for 24 hours
1813320|NCT00679588|Drug|Semuloparin Sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection"
1813321|NCT00679588|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection"
1813322|NCT00679588|Drug|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component
Subcutaneous injection"
1813323|NCT00679601|Drug|AN2690|AN2690 7.5% Solution, once daily for 28 days
1813324|NCT00679614|Drug|tramacet, naloxone|Group A: oral tramacet 2 tablets preoperatively, then 2 tablets every 6 hours for 5 days then 1-2 tablets of tramacet prn to a maximum of 8 tablets per day. A naloxone infusion will started preop at 0.25ug/kg/hr and will continue during patient's stay in hospital (an equivalent of 400ug over 24 hours in a 70 kg man). Infusion discontinued 1 hour before patient discharge. All the patients in groups A and B will be provided Morphine PCA for the duration of their hospital stay. Use of morphine PCA will be noted.Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice.
1813325|NCT00679614|Drug|tramacet|Group B: oral tramacet 2 tablets preop,then 2 tablets every 6 hours for five days(or until discharge. Patient VAS after discontinuation of morphine PCA may dictate addition of oral narcotic oxycodone after discharge). Group also receives saline infusion at 4-6mls/hour during hospital stay.All patients in groups A and B will have Morphine PCA during hospital stay. Use of morphine PCA will be noted. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraopby the surgeon as per our standard practice.
1813326|NCT00679614|Drug|Acetaminophen|Group C will receive oral Acetaminophen tablets 1 gm preoperatively and subsequently 6 hourly plus an infusion of saline (placebo) at a rate of 4-6mls / hour for the duration of their stay. Oral celebrex 200mg will be given to all the patient twice a day for five days as per our standard practice. All patients will receive peri-articular infiltration with local anesthetic solution intraoperatively by the surgeon as per our standard practice. The Visual Analogue Scale, the Ramsay Sedation Score and the Mini Mental State Exam will be used to assess the patients for pain, sedation and confusion every 6 hours while in hospital.
1813327|NCT00679627|Drug|Galantamine|8mg/ day oral capsule increased to 16mg/day then to 24 mg per day
1813328|NCT00679627|Drug|Placebo|Matching placebo
1813329|NCT00681265|Drug|glycerin|Eye drop with active agent glycerin 1%, new topical ophthalmic formulation with polylysine-graft-polyethylene glycol as an excipient, single instillation.
1813330|NCT00681265|Drug|polyethylene glycol 400/propylene glycol|Eye drop with the active agents polyethylene glycol 400 0.4% /propylene glycol 0.3%, topical ophthalmic formulation, single instillation
1813331|NCT00681291|Device|Inguinal hernia repair with Ultrapro|surgical mesh (15x15cm) to support Lichtenstein repair
1813332|NCT00681291|Device|Inguinal hernia repair with Strattice|Surgical mesh (10x16) used to support Lichtenstein repair
1813333|NCT00681304|Other|ultrasound scan|The only study procedure involved in this project is for subjects to undergo an ultrasound scan during their radiation therapy simulation. The ultrasound is done at this time, so it can be co-registered to the routine breast treatment planning CT scan.
1813334|NCT00681317|Drug|AZD6280|oral
1813335|NCT00681330|Biological|URC10, TTK, KOC1|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg) and TTK peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
1813336|NCT00681343|Drug|Thymoglobulin|Induction
1813337|NCT00681343|Drug|Campath-1H|Induction
1813338|NCT00681343|Drug|Daclizumab|Induction
1813339|NCT00681356|Drug|4975, 15 and 5 mg|Direct instillation into the surgical site
1813340|NCT00681356|Drug|Placebo Comparator|Direct instillation into the surgical site
1813341|NCT00681356|Drug|4975 - 5 mg|Direct instillation into the surgical site
1813342|NCT00681395|Drug|ABT-143|once daily for 6 days
1813343|NCT00681395|Drug|ABT-335|once daily for six days
1813344|NCT00681395|Drug|Rosuvastatin|Once daily for 6 days
1813345|NCT00681408|Drug|Omega 3 Fish Oil supplements|Subjects in this arm will receive 3 grams daily Omega 3 fish oil supplements
1813346|NCT00681408|Drug|Placebo|Fish oil placebo pills
1813347|NCT00681421|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
1813348|NCT00681434|Behavioral|bilateral upper extremity training|Bilateral symmetrical upper extremity training for proximal control for three hours per week for eight weeks.
1813349|NCT00681434|Behavioral|Unilateral upper extremity training|Unilateral upper extremity training for proximal extremity for three hours a week for eight weeks.
1813350|NCT00681447|Procedure|Lumbar Interlaminar Epidural|"Lumbar interlaminar epidural injections under fluoroscopy
Epidural tray and needle
Drugs:
0.5% Xylocaine and non-particulate Celestone"
1813351|NCT00681447|Procedure|Lumbar Interlaminar Epidural injection|"Lumbar interlaminar epidural injections under fluoroscopy
Epidural tray and needle
Drugs:
0.5% Xylocaine and non-particulate Celestone"
1813352|NCT00681460|Drug|human recombined insulin|multiple injections protocol (functional intensive insulin therapy), variable doses following dietary conditions and current metabolic status
1813353|NCT00681460|Drug|metformin|pills given orally twice up to three times a day, a total daily dosage 1000-2400 mg
1813354|NCT00681473|Radiation|Proton Radiation Therapy|Once daily, Monday through Friday, for 6 weeks.
1813355|NCT00681486|Drug|Ghrelin|High dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
1813356|NCT00681486|Drug|Ghrelin|Low dose of ghrelin given as subcutaneous injection once a day for the duration of 8 weeks.
1813357|NCT00681512|Dietary Supplement|berry powder|"All subjects (lung cancer survivors and volunteers) will consume 20 grams of berry powder (blueberries, black raspberries, or a mixture of both) per day by mouth for the first 3 days, then 40 grams of berry powder by mouth every day for 4 to 5 weeks.
The berry powder is to be mixed in subject's routine intake of milk, yogurt, juice, or water.
All subjects will have the option to continue the berry regimen for an extended period. Subjects who choose to do so will not consume any berry powder for one week. After one week, subjects will begin consuming 40 grams of the berry powder every day for an additional 4 to 5 weeks."
1813358|NCT00681525|Drug|ABT-335|One ABT-335 135 mg capsule QD for 10 days
1813359|NCT00681525|Drug|Atorvastatin|One 80 mg tablet of atorvastatin QD for 10 days
1813360|NCT00681525|Drug|Ezetimibe|One ezetimibe 10 mg tablet QD for 10 days
1813361|NCT00681538|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum dose within any 24-hour interval is 12 sprays (THC 32.4 mg: CBD 30 mg)
1813362|NCT00681538|Drug|Placebo|containing ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring and colouring FD&C Yellow No.5 (E102 tartrazine) (0.0260%), FD&C Yellow No.6 (E110 sunset yellow) (0.0038%), FD&C Red No. 40 (E129 Allura red AC) (0.00330%) and FD&C Blue No.1 (E133 Brilliant blue FCF) (0.00058%).
1813363|NCT00681551|Drug|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg
1813364|NCT00681551|Drug|Magnevist (SH L 451A)|Magnevist at a dose of 0.1 mmol/kg and another 0.1 mmol/kg 30minutes later.
1813365|NCT00681564|Procedure|One-Stage Full-Mouth Disinfection|"Scaling and root planing, four quadrants in one session
Tongue brushing with a 1% chlorhexidine gel (1 minute)
Mouth rinsing with a 0.2% chlorhexidine solution for (2 minutes)
Subgingival chlorhexidine (1%) irrigation in all pockets
Twice daily rinsing with clorhexidine (1 minute) during fourteen days after the periodontal intervention
Basic oral hygiene instructions
Dental extractions will be performed at the end of patient followup (only in cases of teeth that could not be saved)"
1813366|NCT00681564|Procedure|Periodontal care|"Basic oral hygiene instructions
Supragingival plaque removal"
1813367|NCT00681577|Biological|URLC10, KOC1, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), KOC1 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
1813368|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|400 IU daily (low dose)
1813369|NCT00681590|Dietary Supplement|cholecalciferol (vitamin D)|2000 IU daily (high dose)
1813370|NCT00681603|Drug|subconjunctival injection of bevacizumab ( 1.25 to 2.50 mg)|subconjunctival injection of bevacizumab ( 1.25 to 2.50mg) according to the clinical judgment. Once per months for three times then reevaluate the drug effect, if the response was adequate, stop the trial; if no improvement, another three month intervention would be performed.
1813371|NCT00681616|Device|Compartment Monitoring System (CMS)|The CMS consists of an Introducer, Pressure Measurement & Fluid Collection (PMFC) catheter, a Fluid Collection (FC) catheter and Compartment Pressure Monitor. The PMFC catheter removes fluid and monitors pressure via a solid-state fiber optic transducer at the tip of the catheter. The FC catheter only removes fluid and does not have a pressure transducer at the tip. The CMS Monitor senses, displays and records compartment pressure as measured by up to two PMFC catheters. In addition, the CMS Monitor measures subject blood pressure using a provided cuff for calculating the perfusion pressure of the muscle compartment.
1813372|NCT00681616|Device|Compartment Monitoring System with Active Fluid Removal|Compartment Monitoring System with Active Fluid Removal
1813373|NCT00681616|Device|Compartment Monitoring System without fluid removal|Compartment Monitoring System without fluid removal
1813374|NCT00681629|Drug|Quetiapine XR|400-800 mg, oral, bid
1813375|NCT00681629|Other|Integrated Care Program (ICP)|Integrated care program (ICP), this is a legally based integrated care program covered by a contract according to §§ 140 a-d SGB-V (SGB: social security code); The ICP is not exclusively designed for this phase IV trial. Participation in the ICP is possible anytime for each patient in whom the services are covered by the individual health insurance.
1813376|NCT00681655|Drug|Alcohol 6%|Alcohol 6% infused for 2.8 hour long clamping session
1813377|NCT00681655|Drug|Placebo|1. Each subject will complete a total of 4 2.8 hr-long clamping sessions, conducted as two pairs of infusion sessions.Within each session, procedures differed only by the content of the infusate during the two clamping session. In one admission (AA), both sessions infused 6% ethanol; in the other (PA), the 1st session (always 1st) infused only the vehicle, quantifying the placebo response for every subject. The 2nd session of the PA was always another alcohol clamp.
1813378|NCT00681668|Drug|Quetiapine|150-800 mg, oral, twice a day (bid)
1813379|NCT00681694|Radiation|brachytherapy|An experimental arm using MRI imaging and excluding the transition zone from the target volume
1813380|NCT00681694|Radiation|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
1813381|NCT00681694|Radiation|brachytherapy|Standard ultrasound-guided brachytherapy with standard target volumes
1813382|NCT00681720|Drug|AZD7325|Single dose of oral solution or capsule. 3 times per subject.
1813383|NCT00681720|Drug|Radioligand (11C) flumazenil|Single dose of i.v solution. 4 times per subject. (3 times together with AZD7325)
1813384|NCT00681733|Drug|Pioglitazone|Pentoxifylline 1200mg/day in 3 divided doses. Pioglitazone 30 mg/day in single dose
1813385|NCT00681733|Drug|Pioglitazone|30 mg OD
1813386|NCT00681733|Drug|Pentoxifylline|1200 mg/d
1813387|NCT00681746|Drug|AZD6280|Single dose of oral solution or capsule(s). 3 times for the 2 subjects in Panel 1. Once for the 6 remaining subjects.
1813388|NCT00681746|Drug|(11C) flumazenil|Single dose of intravenous solution. 4 times for 2 subjects in Panel 1. 2 times for the remaining 6 subjects. (once together with AZD6280)
1813389|NCT00681772|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 1 hours before sexual intercourse
1813390|NCT00681785|Drug|dalteparine (Fragmin)|transurethrals surgery with and without dalteparine
1813391|NCT00681798|Drug|Vandetanib|100mg/300mg
1813392|NCT00681811|Drug|HGT-1111|Patients currently dosed with 100 U/kg or 200 U/kg will continue this treatment. Patients dosed with 50 U/kg will be equally randomized to treatment on 100 U/kg or 200 U/kg. The dose will be adjusted every 6-week to account for changes in body weight.The infusion length will be dependent on the dose. Infusion of 100 U/kg will be diluted in 50 ml isotonic sodium chloride and infused over 30 minutes. Infusion of 200 U/kg will be administered in the same manner except for an infusion time of 60 minutes.
1813393|NCT00681824|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/mL thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|Application of a thin layer of FS VH S/D 500 s-apr to the entire length of the suture loop and the adjacent area to at least 5 mm away from the suture line, including all suture holes. After application, the product is to be allowed to polymerize for 3 minutes.
1813394|NCT00681824|Procedure|Standard of care|Standard care: defined as the closure of a dura defect by suturing in a patch of autologous fascia, pericranium or suturable collagen-based dura substitute.
1813395|NCT00681863|Drug|pramipexole 0.125 mg BID|titrated dose for those patients whose symptoms were not controlled on the 0.0625 mg BID dose
1813396|NCT00681863|Drug|pramipexole 0.0625 mg QD|dose down titrated for those patients unable to tolerate the 0.0625 mg BID dosing
1813397|NCT00681863|Drug|pramipexole 0.125 mg TID|titrated up for those patients whose symptoms were not adequately controlled on 0.125 mg BID dose
1813398|NCT00681863|Drug|pramipexole 0.25 mg BID|titrated for those patients whose symptoms were not adequately controlled on 0.125 mg TID dose
1813399|NCT00681863|Drug|pramipexole 0.0625 mg BID|0.0625 mg BID given for first 4 wks of treatment
1813400|NCT00681876|Drug|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
1813401|NCT00681876|Drug|Avastin|Avastin (IV) 10 mgr/Kgr on day 1 every 2 weeks until progression
1813402|NCT00681876|Drug|Erbitux|Erbitux (IV)500 mg/m2 on day 1 every two weeks until progression
1813403|NCT00681889|Drug|Ranibizumab|10 Patients will receive treatment (Ranibizumab)
1813404|NCT00681902|Drug|Lidocaine|Jet lidocaine compared to jet placebo before needle insertion
1813405|NCT00681902|Drug|Placebo|Jet saline
1813406|NCT00681915|Drug|AZD7325|Oral
1813407|NCT00681928|Drug|anastrozole|As determined by the subject's physician
1813408|NCT00681928|Drug|letrozole|As determined by the subject's physician
1813409|NCT00681928|Other|questionnaire administration|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
1813410|NCT00681928|Procedure|cognitive assessment|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
1813411|NCT00681928|Procedure|psychosocial assessment and care|For cancer patients prior to starting medication and 6 months after starting medication. For healthy controls, one time administration.
1813412|NCT00681941|Drug|Sevelamer carbonate (Renvela®)|Sevelamer Carbonate Tablets Dosed Three Times A Day
1813413|NCT00681967|Drug|Gefitinib|250 mg; oral
1813414|NCT00681967|Drug|Gefitinib|250mg; oral
1813415|NCT00681980|Drug|Valproic acid|15 mg/kg/day
1813416|NCT00681980|Drug|costicosteroids|metypredsolone 1 g/day
1813417|NCT00681980|Drug|valproid acid plus corticosteroids|valporid acid 15 mg/kg/day plus corticosteroids 1 g/patient
1813418|NCT00681993|Other|Standard Dose Dense Doxorubucin and Cyclophosphomide|4 cycles of Standard Dose-Dense Doxorubucin and Cyclophosphomide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
1813419|NCT00681993|Other|Standard Doxorubucin and Cyclophosphomide|4 cycles of Standard Dose Doxorubucin and Cyclophosphomide and concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
1813420|NCT00681993|Other|Standard Docetaxel, Carboplatin, and Herceptin|6 cycles of Standard Docetaxel, Carboplatin and Herceptin chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
1813421|NCT00681993|Other|Standard Docetaxel, Doxorubucin and Cyclophosphomide|3 cycles of Standard Docetaxel, Doxorubucin and Cyclophosphomide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
1813422|NCT00681993|Other|Standard Docetaxel and Cyclophosphomide|4 cycles of Standard Docetaxel and Cyclophosphomide chemotherapy with concurrent radiation therapy at a dose of 270 cGy per fraction for 15 fractions to a total dose of 40.5 Gy. Treatments will be given Monday through Friday for three weeks. Radiation therapy may start 7 days before, but no later than 7 days after, day 1 of cycle 1 of chemotherapy (C1D1).
1813423|NCT00682006|Drug|4% Chlorhexidine|4% Chlorhexidine was provided to be applied in this arm to Mothers through TBAs.
1819366|NCT00723658|Drug|melphalan|
1813424|NCT00682006|Other|Hand washing Soap|Hand washing soap was provided to Mothers through TBAs.
1813425|NCT00682006|Drug|4% Chlorhexidine|4% Chlorhexidine was provided to be applied by Mothers through TBAs.
1813426|NCT00682019|Drug|Levitra (Vardenafil, BAY38-9456)|5mg, 10mg or 20mg taken 8 hours before sexual intercourse
1813427|NCT00682019|Drug|Placebo|matching placebo
1813428|NCT00682032|Dietary Supplement|beta-glucan|AIM 2: regimen to begin after baseline blood draw; AIM 3: regimen to begin after baseline blood draw and to be completed prior to surgery
1813429|NCT00682058|Other|Follow-up post-bariatric surgery|Follow-up of those subjects who had bariatric surgery (as part of the parent LABS trial) immediately following the collection of baseline measures (body composition) in this study. Follow-up body composition measures will be acquired at 60 months and 84 months post-baseline measures (post-surgery).
1813430|NCT00682084|Procedure|Surgery|Surgical removal of either a pituitary or ectopic ACTH producing tumor or an adrenal tumor
1813431|NCT00682097|Drug|RO4998452|Escalating oral doses
1813432|NCT00682097|Drug|placebo|Oral doses
1813433|NCT00682123|Dietary Supplement|19-norandrostendione|"Volunteers recieved 500mL of water containing 5g of creatine monohydrate and either 1.0μg, 2.5μg or 5.0μg of 19-norandrostendione in a single-blind crossover manner.
The amount of 19-norandrostendione administered was trivial, and far less than the amounts shown to be present in many popular dietary supplements. The recommended dosage according to the distributors is 100 mg 2-3 times daily, so the administered daily dose was not more than 0.05% of the recommended dose. This dose has no measurable physiological or pharmacological effects."
1813434|NCT00682136|Procedure|US-Guided Ropivacaine TAP Block|Bilateral injection of local anaesthetic into the Transversus Abdominis plane, guided by ultrasound.
1813435|NCT00682149|Dietary Supplement|PomGT (500 mg pomegranate extracts, 300 mg green tea and 60mg vitamin C)|1 tablet/day for 3 months
1813436|NCT00682162|Device|Acupuncture|The treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). The acupuncture treatment was semi-standardised. It consisted of a basic pool of 6 body acupuncture points. Five additional acupuncture body points together with auricular points formed an individual pool. After needle insertion, the needle was manipulated until the subject obtained the de-Qi response (a deep aching or full feeling at the needle, [22]). After obtaining the de-Qi response, there was no further manipulation of the needle. Each session lasted 20 minutes.
1813437|NCT00682162|Device|Sham-laser acupuncture|The sham-laser acupuncture treatment consisted of 5 sessions, all patients completed a recovery time after treatment of 30 min duration. The sessions were administered over a period of 5 weeks (one session per week). Sham-laser acupuncture was applied at the same points as the acupuncture treatment. A deactivated laser pen (Seirin, 3B Scientific GmbH, Hamburg, Germany) that could only beam normal red light rather than laser was used. The total number of acupuncture points utilized was equal to the acupuncture group. Every point was treated for 30 sec with the total treatment time of 20 minutes.
1813438|NCT00682175|Other|Observational|Pulmonary Artery pressure (PA), pulmonary capillary wedge pressure (PCWP), cardiac output (CO), and cardiac index (CI). This data will be collected after 24 ± 2 and 48 ± 2 hours of standard heart failure therapy
1813439|NCT00682188|Behavioral|Counseling Intervention|Six 30-minute individual student-centered counseling sessions based on the 5A approach to assist adolescents in making changes in their diet and level of physical activity delivered by school nurses over 2 months (weekly in month 1, biweekly in month 2)
1813440|NCT00682188|Behavioral|Information Intervention|Six individual sessions with the school nurse over 2 months to check weight and behavioral changes and provide a series of six pamphlets on weight and weight management
1813441|NCT00682214|Drug|Cholecalciferol|Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
1813442|NCT00682214|Drug|Lactose placebo|Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
1998697|NCT01084252|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1813444|NCT00682240|Procedure|laser treatment with PASCAL®|panretinal laser treatment - single-session
1813445|NCT00682240|Procedure|laser treatment with PASCAL®|panretinal laser treatment - multi-session
1813446|NCT00682240|Procedure|laser treatment with PASCAL®|grid / focal laser treatment
1813447|NCT00682240|Procedure|laser treatment with conventional laser system|panretinal laser treatment - multi-session according to the conventional protocol, using a conventional laser system
1813448|NCT00682266|Behavioral|intensity controlled interval training (AIT)|4 x 4 min intervals at 90% of maximal heart rate, each interval separated by 3 min at 70%, twice a week for 3 months
1813449|NCT00682266|Behavioral|Multidisciplinary approach (MTG)|exercise, dietary and psychological advice, twice a month for 12 months
1813450|NCT00682279|Drug|oral topotecan (SK&F-104864); lapatinib (GW572016)|This is a single-arm, dose escalation, Phase I study in which doses of oral topotecan will be escalated and lapatinib will be given initially as a fixed dose. This study will examine oral topotecan administered on a five-consecutive day schedule in combination with daily lapatinib. This study will be conducted in two parts. Part 1 of the study will investigate the impact of lapatinib on the bioavailability of oral topotecan (bioavailability phase) and Part 2 of the study will consist of dose finding to determine the MTD regimen of the combination (dose escalation phase).
1813451|NCT00682292|Drug|Thymoglobulin (ATG)|Thymoglobulin: 1.25 mg/kg per day from day 0 to day 7 post transplantation
1813452|NCT00682292|Drug|Daclizumab|Daclizumab: 1mg/kg at day 0, 14, 28, 42 and 56 post transplantation
1813453|NCT00682305|Procedure|Hematopoietic stem cell transplantation|"conditioning regimen:
day -7: 12g/m^2 Treosulfan
day -6: 12g/m^2 Treosulfan
day -5: 12g/m^2 Treosulfan
day -4: 30mg/kg BW Etoposide
day -3: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide
day -2: 20mg/kg ATG Fresenius (OPTIONAL), 60mg/kg BW Cyclophosphamide
day -1: 20mg/kg ATG Fresenius (OPTIONAL)
day 0: SCT"
1813608|NCT00683449|Drug|Dose Group 1|IV infusion of MN-221 16 mcg/min for 15 min; total dose of 240 mcg
1819367|NCT00723658|Drug|thalidomide|
1813454|NCT00682318|Drug|Fish Oil|"Part 1.1: Dose of 9.3 g/day EPA plus 7.5 g/day DHA;
Part 2a (run-in phase): Dose of 1 time 2 capsules per day of Lovaza (total of 1.7 g/d ω-3 PUFA consisting of 930 mg/day EPA and 750 mg/day DHA) for 29±1 days;
Part 2a (study arm): Dose of 3 times 4 capsules per day of Lovaza (total of 10.1 g/d ω-3 PUFA consisting of 5580 mg/day EPA and 4500 mg/day DHA) for 29±1 days"
1813455|NCT00682318|Dietary Supplement|Safflower Oil|Part 2a: (Study Arm): Omega-6 polyunsaturated fatty acids 3 times 4 capsules per day (total of 10.2 g/d ω-6 PUFA) for 29±1 days
1813456|NCT00682318|Dietary Supplement|Ethanol|"Part 1 & Part 1.1:
Dose of 0.9 g/kg body weight 98% alcohol solution
Part 2a:
Doses of 0.4 and 0.9 g/kg body weight 98% alcohol solution and a control placebo drinking solution
Part 2b, Part 3:
Doses of 0.4, 0.6 and 0.9 g/kg body weight 98% alcohol solution"
1813457|NCT00682318|Dietary Supplement|Omega-3 polyunsaturated fatty acids|"Part 2b:
Alimentary diet delivering ≈ 500 mg/day EPA/DHA,or Alimentary diet delivering ≈ 900-1000 mg/day EPA/DHA, or Alimentary diet delivering ≈ 1500-1800 mg/day EPA/DHA;
Part 3:
Alimentary diet delivering EPA/DHA in a quantity to be determined by Part 2b."
1813458|NCT00682318|Dietary Supplement|Omega-6 polyunsaturated fatty acid|"Part 2b:
Control omega-6 fatty acid alimentary diet (<130 mg/day EPA/DHA)"
1813459|NCT00682344|Drug|Levobupivacaïne|1,75mg/kg
1813460|NCT00682357|Drug|Methylprednisolone and Lidocaine|Methylprednisolone 80 mg, intra-articular and lidocaine 20 mg
1813461|NCT00682357|Drug|Methylprednisolone and Lidocaine|Methylprednisolone 16 mg intra-articular and lidocaine 20 mg
1813462|NCT00682357|Drug|Placebo and Lidocaine|Placebo and lidocaine 20 mg
1813463|NCT00682370|Drug|saline solution|intravenous infusion, single dose
1813464|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose
0.3 mg/kg heme arginate"
1813465|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose
1 mg/kg heme arginate"
1813466|NCT00682370|Drug|heme arginate|"intravenous infusion, single dose
3 mg/kg heme arginate"
1813467|NCT00682383|Drug|Cisplatin; Etoposide; Radiation therapy; Docetaxel; Neulasta|"Cisplatin 75 mg/m2 day 1 and 22
Etoposide 80mg/m2 days 1-3, 22-24
Radiation therapy: (initial fields 1.8gy/day (5 weeks) to 45Gy, then boost 2.0Gy/day (8 days) to a total of 61Gy) beginning day 1 (Total elapsed time: approximately 6 weeks, 3 days)
Filgrastim 5µg/kg* SQ injection days 4-13 and days 25-34
Docetaxel 75mg/m2 Q 3 Weeks X 3 Cycles
Pegfilgrastim 6 mg SQ injection day 2 of each cycle"
1813468|NCT00682409|Other|MR Imaging|MR imaging in the post operative follow-up of cholesteatoma in children
1813469|NCT00682435|Drug|Hydromorphone|"1mg IV hydromorphone, followed by an optional dose of 1mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
1993600|NCT03166540|Other|cocoa-based products containing coffee|Subjects will consume the assigned treatment (2 products per serving) for one month. Serving size: approximately 37 g. The last day of the intervention is the sampling day.
1813472|NCT00682461|Drug|Nicotine|Marketed nicotine replacement therapy formulation
1813473|NCT00682461|Drug|Nicotine|Nicotine prototype
1813474|NCT00682474|Behavioral|Counseling Intervention|Four 30-minute individual student-centered smoking cessation counseling intervention sessions delivered by school nurses to adolescent smokers in grades 9-12
1813475|NCT00682474|Behavioral|Information Intervention|Attention-control comparison condition consisting of four individual sessions with the school nurse to check smoking status and deliver a series of standardized pamphlets on smoking and cessation to adolescent smokers in grades 9-12
1813476|NCT00682487|Other|Hair sampling for cortisol|Hair sampling for cortisol
1813477|NCT00682487|Other|Hair sampling for cortisol|Hair sampling for cortisol
1813478|NCT00682500|Drug|Calfactant|Intratracheal Instillation of 0.5 mL/cm of height of 60 mg/mL suspension in two aliquots at study entry. Repeat dosing 12 hours later if criteria are met.
1813479|NCT00682500|Drug|Room Air (placebo)|Administration of 0.5 ml/cm height of air at study entry into the trachea. Repeat dosing at 12 hours if criteria are met
1813480|NCT00682526|Device|SmartLink Wireless Monitoring System (K033642)|All EMS transported patients age 18 or over who have their ECG attempted to be wirelessly transmitted and with the intention to treat with coronary reperfusion therapy (PCI or thrombolytics)based on their initial presentation.
1813481|NCT00682539|Drug|Bevacizumab (Avastin)|The intravitreal injection of Bevacizumab (Avastin®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
1813482|NCT00682539|Drug|Triamcinolone|The intravitreal injection of triamcinolone (Volon A®) is performed in the operating room under sterile conditions at baseline. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.1ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
1813483|NCT00682539|Drug|Sham|Patients receiving sham intravitreal injections do not receive an actual injection of study drug. The injecting physician performing the sham injection will be unmasked to the treatment to the treatment assignment regarding active versus sham. The injecting physician will perform the same pre-injection procedures for the patients receiving bevacizumab or triamcinolone, An empty syringe without a needle will be used in the sham injection. The injecting physician will mimic an intraocular injection by making contact with the conjunctiva and applying pressure without the needle. Immediately following the sham injection, the injecting physician will perform the same post-injection procedures as those performed on patients receiving bevacizumab or triamcinolone.
1813609|NCT00683449|Drug|MN-221 placebo|i.v. infusion of placebo for 15 minutes
1813484|NCT00682539|Procedure|Lucentis|The intravitreal injection of Ranibizumab (Lucentis®) is performed in the operating room under sterile conditions. The patient receives an initial drop of lidocaine 4% into the study eye followed by betaisodona solution. Then the lid margins, the lids and the periocular skin are washed carefully with betaisodona. The eye is draped in a sterile fashion. A sterile lid speculum is inserted by the surgeon. Another drop of betaisodona is applied into the eye. A circle is used to mark the injection site 3.5mm from the limbus in the inferior temporal quadrant. The injection is given at the marked site, slowly, at a 90 degree angle. After injecting the total volume of 0.05ml the needle is slowly withdrawn. Another drop of betaisodona is given as well as an antibiotic/steroid ointment.
1813485|NCT00682552|Procedure|A cervico-vaginal cervical smear|12 and 18 months after inclusion, a cervico-vaginal cervical smear will be realized and a new examination colposcopique with a new cervical taking for the search(research) and the detection of the HPV 16 and 18.
1813486|NCT00682565|Drug|CK-1827452|I.V. infusion for 2 hours at 24mg/hr followed by 18 hours at 6mg/hr
1813487|NCT00682565|Drug|CK-1827452|12.5mg oral immediate release capsule
1813488|NCT00682565|Drug|CK-1827452|I.V. infusion for 2 hours at 48mg/hr followed by 18 hours at 11mg/hr
1813489|NCT00682565|Drug|CK-1827452|25mg oral immediate release capsule
1813490|NCT00682565|Drug|Placebo|I.V. infusion for 20 hours
1813491|NCT00682565|Drug|Placebo|Matching placebo oral immediate release capsule
1813492|NCT00682565|Drug|Placebo|Matching placebo oral immediate release capsule
1813493|NCT00682578|Drug|Dihydroartemisinin + Piperaquine (Artekin)|An adult dose consists of four doses of two tablets, given at 0, 8, 24 and 48 h. The approximate total adult dose is 6/48 mg/kg (DHA/PPQ). For children, a dose of 1.6/12.8 mg/kg is given at the same time intervals; this dosage will be obtained by dissolving the tablets in 5 ml of water.
1813494|NCT00682578|Drug|artesunate-sulphadoxin/pyrimethamine, chloroquine|The standard treatment will be in accordance with that in Afghanistan
1813495|NCT00682617|Behavioral|Structured exercise program|Exercise intervention will consist of a three-month, supervised, facility-based, hip-specific strengthening, flexibility, and endurance exercise program. The intervention will consist of two phases and take place at OHSU rehabilitation services. Phase 1 will be a two-week orientation and general conditioning program. Phase 2 will be a ten-week progressive workload program. Subjects in both Phase 1 and Phase 2 will meet two to three times per week for 45 minutes per session. Phase 1 will be group sessions with more individualized orientation and attention by the exercise instructors. Phase 2 will begin progressive conditioning and utilize exercise groups of four to six subjects.
1813496|NCT00682617|Behavioral|Waitlist, delayed intervention|Due to limited space in exercise intervention classes, subjects may be placed on a waitlist for 3 months. When an opening becomes available, the subject will begin the exercise program identical to that of Group 2
1813497|NCT00682630|Drug|pyronaridine artesunate|720:240 mg of the reference tablet formulation; wash out period of 43 days; 720:240 mg of the to-be-marketed formulation; wash out period of 43 days
1813498|NCT00682643|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray
1813499|NCT00682643|Drug|vehicle placebo nasal spray|placebo
1813500|NCT00682656|Drug|Glucantime®|15mg Sb+5/Kg/day, during 20 days. Maximum dose:15ml/day
1813501|NCT00682656|Drug|Zithromax ®|Zithromax ®/ Pfizer, 500 mg - 1x day, during 20 days
1813502|NCT00682669|Behavioral|MBSR|A mindfulness-based stress reduction (MBSR) program consisting of an 8-week, 9-session intervention based on systematic and intensive training in mindfulness meditation and mindful hatha yoga and their application to every day life.
1813503|NCT00682669|Behavioral|HLC|An 8-week program consisting of lectures and discussion of health-related topics.
1813504|NCT00682682|Other|Virtual Reality video distraction|"Virtual Reality involves wearing a helmet and playing a game called Snow world. This game has sound and is presented in 3D format. This game has immersive qualities that help user feel as if they are in the game."
1813505|NCT00682682|Other|Virtual Reality video game|"Virtual Reality video games involve wearing a helmet with vision and sound. this game is presented in 3D which gives the user the feeling of being in the game. The game used for this study is Snow World"
1813506|NCT00682708|Dietary Supplement|PlumpyNut|
1813507|NCT00682708|Dietary Supplement|PlumpyDoz|
1813508|NCT00682721|Drug|Placebo|Matching placebo two pills once daily
1813509|NCT00682721|Drug|Valacyclovir|1 gram daily x number of days active in the study
1813510|NCT00682734|Drug|metoclopramide|metoclopramide 20 mg
1813511|NCT00682734|Drug|metoclopramide|metoclopramide 40 mg
1813512|NCT00682734|Drug|metoclopramide|metoclopramide 10 mg
1813513|NCT00682734|Drug|Diphenhydramine 25mg|Diphenhydramine 25mg, administered as an intravenous drip over 20 minutes
1813514|NCT00682747|Drug|Hyperbaric oxygen|40 treatments with hyperbaric oxygen once per day, five days per week, 2.4 ATA, 100 % oxygen (10-15 minutes compression with air, 90 min of oxygen breathing - two 10 minutes break for breathing air after each 30 minutes of oxygen, 10 minutes decompression with oxygen
1813515|NCT00682760|Drug|Korean Botulinum toxin type A (KbtxA) and Botox injection|Each vial of Botox and KbtxA contained 100 U of BTX-A in a sterile vacuum-derived form without preservatives. Each vial of KbtxA was identical to the placebo (Botox) vial, and all vials were reconstituted with 2.0 mL of 0.9% sterile nonpreserved saline solution to a final dilution of 5 U /0.1 mL. The dose of BTX-A per injection site was 2.5 U to 5 U, and the location, number of injection sites. Using a 30-gauge needle, injections were angled away from the center of lid to reduce the risk of spread into the levator muscle. Injection sites include the upper medial and lateral eyelid margins, lower lateral lid margins, and above the eyebrow.
1813516|NCT00682773|Other|SBAR|Educational intervention for nursing staff on effective communication regarding warfarin treatment/care; use of SBAR communication forms.
1813517|NCT00682786|Drug|5FU|
1813518|NCT00682786|Radiation|Radiation|
1813519|NCT00682786|Procedure|Surgery of resectable lesions|
1813520|NCT00682786|Drug|Irinotecan|
1813521|NCT00682812|Other|2 cervical takings and 2 sampling of blood|"2 cervical takings
2 sampling of blood before and after the total hysterectomy"
1813522|NCT00682812|Other|2 cervical takings and 2 sampling of blood|"cervical taking during the cervical conization
2 sampling of blood before and after the intervention"
1813953|NCT00686218|Other|laboratory biomarker analysis|Testing
1813523|NCT00682812|Other|2 cervical takings and 2 sampling of blood|"cervical taking during the pelvien examination under general anesthetic realized systematically during the balance sheet of pre-therapeutic evaluation
2 sampling of blood before and after the intervention"
1813524|NCT00682825|Behavioral|Bispectral index protocol|Aim to titrate anesthesia to maintain BIS between 40 and 60.
1813525|NCT00682825|Behavioral|End tidal anesthetic gas-guided|Aim to maintain anesthetic gas between 0.7 and 1.3 MAC equivalents
1813526|NCT00682838|Behavioral|Self-management|Self-management
1813527|NCT00682838|Behavioral|Telemonitored care|Telemonitored care
1813528|NCT00682851|Device|OSOM Trichomonas Rapid Test|Rapid test run using vaginal discharge collected via a cotton swab
1813529|NCT00682851|Device|OSOM BVBlue Test|Rapid test run using vaginal discharge collected using a cotton swab
1813530|NCT00682890|Drug|placebo|placebo birth control pill daily
1813531|NCT00682890|Drug|metformin|2000 mg per day for 3 months daily birth control pill
1813532|NCT00682903|Device|GuardianR|As self monitoring of capillary glucose level is needed to validate those algorithms, we postulate that using a device able to permanently control interstitial glucose readable by both medical team and patient himself (during the session and the 5 following days after discharge) could significantly improve safety and efficiency of such educative session.
1813533|NCT00682916|Dietary Supplement|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
1813534|NCT00682916|Dietary Supplement|Y288|Subjects will take 2 tablets per fat containing meal, 3 times a day, within one hour of consuming the meal
1813535|NCT00682929|Drug|Inhaled Cannabis|20 people will be enrolled in this arm of the study and will receive study drug for 7 weeks. Subjects in this arm of the study will be instructed to take their oral medication (placebo for this group) two and a half hours prior to the inhaled medication. Subjects will take two pills and smoke one cannabis cigarette, daily.
1813536|NCT00682929|Drug|Oral THC|20 people will be enrolled in this arm of the study and will receive study drug for 7 weeks. Subjects in this arm of the study will be instructed to take their oral medication (two 5mg dronabinol tablets) two and a half hours prior to the inhaled medication (placebo for this group). Subjects will take two pills and smoke one cigarette, daily.
1813537|NCT00682929|Drug|Placebo|20 people will be enrolled in this arm of the study and will receive study drug for 7 weeks. Subjects in this arm of the study will be instructed to take their oral medication (placebo) two and a half hours prior to the inhaled medication (placebo). Subjects will take two pills and smoke one cigarette, daily.
1813538|NCT00682955|Drug|Zinc Sulphate|20 mg per day, Zinc Sulphate tablet has been given to subjects.
1813539|NCT00682955|Drug|Zinc Sulphate|20 mg per day of Zinc Sulphate in suspension form has been given to subjects.
1813540|NCT00682981|Drug|Obatoclax|IV Infusions for 3 consecutive days of either 3-hours, 2 hours duration
1813541|NCT00682981|Drug|Carboplatin/etoposide|Carboplatin/etoposide combination
1813542|NCT00682994|Behavioral|Interview|Interview lasting about 5-10 minutes.
1813543|NCT00682994|Behavioral|Questionnaire|Questionnaires taking 20-30 minutes to complete.
1813544|NCT00683007|Other|Volume resuscitation (Crystalloid)|Crystalloid vs. Hypertonic Saline Solution
1813545|NCT00683007|Other|Volume resuscitation (Hypertonic Saline Solution)|Crystalloid vs. Hypertonic Saline Solution
1813546|NCT00683020|Behavioral|ATSM Intervention|"The ATSM system is designed to promote the efficiency of a care manager by having her focus outreach phone calls to patients who, by virtue of their responses to the ATSM system, report a need for further support. The purpose of these call-backs is to have the care manager directly engage patients in setting goals and developing an action plan to improve their overall health. The care manager is trained to perform motivational interviewing, assess and overcome barriers to health communication.
For some patients, the ATSM system as described above is augmented by additional phone communications from care manager to patient, triggered by health IT derived from 2 additional data sources: SFHP pharmacy claims data and CHNSF diabetes registry. The latter combines clinical data (labs and blood pressure). Based on clinical criteria, the ATSM system will alert care manager to make additional calls to patients."
1813547|NCT00683033|Behavioral|Contingency Management|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking is delivered. Expired carbon monoxide (CO) tests are conducted twice daily and urinary cotinine tests are conducted once each week. Participants earn the opportunity to win prizes for submitting samples that meet smoking abstinence criteria (e.g., CO ≤ 6ppm; cotinine ≤ 30ng/mL).
1813548|NCT00683033|Behavioral|Brief smoking cessation counseling|For 4 weeks starting on the quit date, daily brief (about 5 minutes) counseling based on public health service guidelines for quitting smoking. Expired carbon monoxide tests are conducted twice daily and urinary cotinine tests are conducted once each week.
1813549|NCT00683046|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3,.
1813550|NCT00683046|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
1813551|NCT00683046|Drug|Stem cells|Stem cell infusion on day 0.
1813552|NCT00683046|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
1813553|NCT00683059|Drug|Paclitaxel|total dose (mg) = body surface area in m2 x study dose (mg/m2) to be injected into a vein once every 3 weeks over 18 months.
1813554|NCT00683085|Biological|HLA-A*02:01-restricted VEGFR1-derived peptide vaccination|VEGFR1-derived HLA-A*02:01-restricted peptide (VEGFR1-A2-770; TLFWLLLTL)was vaccinated twice weekly for 8 weeks (total 16 doses) combined with conventional dose (1,000 mg/m^2 body surface area) of gemcitabine 6 doses for advanced stage pancreatic cancer to confirm the feasibility and efficacy of this type of peptide.
1813555|NCT00683111|Drug|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
1813556|NCT00683111|Drug|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for up to 12 months
1813557|NCT00683124|Drug|Losartan and nebivolol|"Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations.
Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations"
1813954|NCT00686218|Other|pharmacological study|Testing
1813558|NCT00683124|Drug|Losartan|Losartan is administered orally as pills. It is given preferentially once a day or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
1813559|NCT00683124|Drug|Nebivolol|Nebivolol is administered orally as pills. It is given preferentially once a day in the morning or, if not well tolerated because of hypotension, the total daily dosage is given in two administrations
1813560|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth once daily on Days 2 through 5
1813561|NCT00683137|Drug|valdecoxib|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then a valdecoxib 20 mg tablet by mouth twice daily on Days 2 through 5
1813562|NCT00683137|Drug|valdecoxib/placebo|valdecoxib 40 mg tablet by mouth followed by a valdecoxib 20 mg tablet by mouth after 1 to 12 hours of the initial dose on Day 1 then placebo on Days 2 through 5
1813563|NCT00683150|Other|Endothelial Function Test|Endothelial function tests performed within 20 days before surgery, when surgery begins (at the time of incision), every hour during surgery and then 1, 2, 3, and 5 days after surgery.
1813564|NCT00683163|Drug|PTH(1-84)|1.4 mg injected subcutaneously (in the abdomen) daily
1813565|NCT00683163|Drug|Ibandronate|150mg by mouth once monthly
1813566|NCT00683163|Other|Placebo injection|Daily injections as placebo for PTS 1-84
1813567|NCT00683163|Other|Placebo pills|Monthly pills as placebo for oral ibandronate
1813568|NCT00683176|Drug|Choline Fenofibrate|135 mg
1813569|NCT00683176|Drug|Placebo|Placebo
1813570|NCT00683189|Drug|Warfarin|Oral administration (QD), variable dosage: patients will undergo blood test for PT/INR at baseline and afterwards, at weekly bases for 4 weeks. The INR will be kept in a safe range of 2-2.5
1813571|NCT00683202|Drug|Acetylsalicylic acid|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
1813572|NCT00683202|Drug|Placebo|Acetylsalicylic acid 100 mg or placebo daily perorally started on the first day of ovarian gonadotrophin stimulation in in vitro fertilization or in intracytoplasmic sperm injection
1813573|NCT00683228|Behavioral|Counseling|Consecutive newborns exposed to secondhand smoke will be recruited into the study and randomized to have parents receive or not receive specific counselling on harmful effects of SHS exposure. Urine cotinine will be measured at several points during the study for each group
1813574|NCT00683241|Biological|DCVac-L|Subjects will receive three doses of intradermal vaccination with ~5-10 x 106 dendritic cells (DCVax-L) on days 0, 14 and 28
1813575|NCT00683267|Drug|4975, highly purified capsaicin|One dose administered by direct instillation into the surgical site
1813576|NCT00683267|Drug|Placebo|One dose administered by direct instillation into the surgical site
1813577|NCT00683280|Behavioral|contingency management|Prize-based contingency management, with the opportunity to earn prizes for expired carbon monoxide levels reading 6ppm or less and urinary cotinine levels reading 30ng/ml or less for 4 weeks.
1813578|NCT00683280|Drug|varenicline (smoking cessation medication)|0.5mg po daily Days 1-3, 0.5mg po twice daily Days 4-7, 1.0 mg po twice daily Days 8-84.
1813579|NCT00683280|Behavioral|Brief counseling for quitting smoking|Twice weekly brief counseling based on public health service guidelines for quitting smoking.
1813580|NCT00683293|Procedure|Conventional Laparoscopic Hysterectomy|Removal of uterus via standard laparoscopic techniques
1813581|NCT00683293|Procedure|Robot-assisted (Da Vinci®) laparoscopic hysterectomy|Removal of uterus by robot-assisted laparoscopic technique
1813582|NCT00683306|Drug|ZD1839 (Iressa)|Gefitinib supplied for oral use at the dose and schedule that the patient received in the previous gefitinib clinical study. In the case of placebo patients, the gefitinib dose will be as described in the protocol of their previous gefitinib clinical study.
1813583|NCT00683319|Drug|carboplatin|
1813584|NCT00683319|Drug|cisplatin|
1813585|NCT00683319|Drug|cyclophosphamide|
1813586|NCT00683319|Drug|methotrexate|
1813587|NCT00683319|Drug|vincristine sulfate|
1813588|NCT00683319|Procedure|adjuvant therapy|
1813589|NCT00683319|Procedure|cognitive assessment|
1813590|NCT00683319|Procedure|magnetic resonance imaging|
1813591|NCT00683319|Procedure|magnetic resonance spectroscopic imaging|
1813592|NCT00683319|Procedure|quality-of-life assessment|
1813593|NCT00683332|Drug|Tigecycline (Tygacil)|This is a non-interventional study; patients are administered Tygacil as prescribed by their doctor as per registered indications stated in product label/insert (50 mg by Intravenous Injection).
1813594|NCT00683345|Drug|Anakinra|Anakinra 0.67 ml (100 mg) daily subcutaneously for 4 weeks.
1813595|NCT00683345|Drug|Placebo|Saline 0.67 ml daily subcutaneously as placebo drug.
1813599|NCT00683384|Drug|Etanercept (Enbrel)|
1813600|NCT00683397|Other|Blood sampling|Screening of thrombophilia
1813601|NCT00683410|Biological|Pneumococcal Conjugate Vaccine, 7-valent (Prevenar)|
1813602|NCT00683423|Drug|BMS-741672|Tablets, Oral, 100 mg, once daily, 3 weeks
1813603|NCT00683423|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 3 weeks treatment period, 2 weeks washout, and 2 weeks follow-up
1813604|NCT00683436|Drug|Adipiplon|bilayer tablets 6 mg
1813605|NCT00683436|Drug|Placebo|Placebo
1813610|NCT00683449|Drug|Dose Group 2|i.v. infusion of MN-221 30 mcg/min for 15 minutes (total dose of 450 mcg)
1813611|NCT00683449|Drug|Dose Group 3|i.v. infusion of MN-221 16 mcg/min for 15 minutes followed by 8 mcg/min for 105 minutes (total dose = 1,080 mcg)
1993892|NCT03110991|Behavioral|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App (CCIA)
1998698|NCT01084252|Drug|Dexamethasone|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1813615|NCT00683475|Biological|IMC-A12|IMC-A12 is to be administered as an I.V. infusion, 6 mg/kg over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. IMC-A12 treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
1813616|NCT00683475|Drug|Mitoxantrone|Mitoxantrone is to be administered as an I.V. infusion, at 12 milligrams/square meter (mg/m^2) over 5-15 minutes on Day 1 during a 3-week (21-day) cycle. Mitoxantrone treatment is to be continued for a maximum of 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m^2) or until there is evidence of disease progression, death, or intolerable toxicity.
1813617|NCT00683475|Drug|Prednisone|Prednisone (5 mg) is to be self-administered PO BID, each day of the 21-day cycle.
1813618|NCT00683475|Biological|IMC-1121B (ramucirumab)|IMC-1121B (ramucirumab) is to be administered as an intravenous (IV) infusion, 6 milligrams/kilogram (mg/kg) over 1 hour on Days 1, 8, and 15 of each 3-week (21-day) cycle. Ramucirumab treatment is to continue until there is evidence of disease progression, death, intolerable toxicity, or other withdrawal criteria are met.
1813619|NCT00683488|Behavioral|Focus Group|Focus group using and collecting feedback on the CBT/CM intervention.
1813620|NCT00683488|Behavioral|First Intervention Trial|"Intervention will comprise of approximately 15 weekly sessions.
Exit interviews at the end of each session will assess acceptability, feasibility, and relevance of the intervention.
Quantitative assessment (ACASI) pre and post intervention will document immediate changes in substance use, sexual risk, and adherence to medical care.
Qualitative feedback from interviews with mental health providers and study coordinators will address acceptability and feasibility."
1813621|NCT00683488|Behavioral|Intervention Trial 2|Evaluations/assessments will be similar to those involved for the first intervention trial. Study participants will return for a follow-up visit 3 months after the last intervention session to complete the ACASI.
1813622|NCT00683501|Drug|DNB-001|four dosages of DNB-001, one placebo dosage
1813623|NCT00683514|Drug|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 28 days :
50 mg/m2 oral vinorelbine d1, d8, d15
20 mg/m2/d cisplatin from d1 to d4"
1813624|NCT00683514|Drug|Oral Vinorelbine and cisplatin with concomitant radiotherapy 66 Gy (total dose)|"q 21 days :
60 mg/m2 oral vinorelbine d1,d8 for cycle 1 or 80 mg/m2 oral vinorelbine d1,d8 for cycle 2
80 mg/m2 cisplatin d1"
1813625|NCT00683527|Drug|Elemental iron|Iron in the dose of 3-4 mg/kg/day (of elemental iron) PO once daily mixed with expressed breast milk from 14 days of life till the end of study period
1813626|NCT00683553|Drug|I5NP|Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
1813627|NCT00683553|Drug|Placebo|Single IV injection of saline
1813628|NCT00683566|Procedure|electrostimulation|Stimulate STN (at 0, 5, 10, 15, 20, 25, 30, 40, 70 and 130 Hz) in chronically implanted patients at rest and during simple and complex motor tasks
1813629|NCT00683579|Drug|Early Treatment with HAART|HAART with possibility of de-intensification
1813630|NCT00683579|Other|No treatment|No treatment. For group 2, participants do not yet meet DHHS guidelines. For group 4, treatment is not initiated due to unwillingness or providers' expectation of poor adherence.
1813631|NCT00683579|Drug|HAART Treatment - standard care|Initiation of HAART per DHHS guidelines, i.e. starting treatment and CD4+ T cells less than 350 cells/mm3 or HIV RNA >100,000 copies/ml
1813632|NCT00683592|Drug|vilazodone|titration to 40 mg tablets qd (once a day) for 8 weeks
1813633|NCT00683592|Drug|placebo|placebo
1813634|NCT00683618|Drug|Rosuvastatin|Capsule/Tablet, oral, qd, 6 or 12 weeks
1813635|NCT00683618|Drug|Atorvastatin|Capsule/Tablet, 10mg, oral, qd, 6 weeks
1813636|NCT00683631|Radiation|TheraSphere HUD|TheraSphere is FDA approved under a Humanitarian Use Device. It is considered a brachytherapy device that delivers intra-arterial radiation therapy using yttrium-90 microspheres directly to liver tumors.
1813638|NCT00683657|Drug|Saxagliptin|Tablets, Oral, 5mg, once daily, 4 weeks
1813639|NCT00683657|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 4 weeks
1813640|NCT00683670|Drug|cyclophosphamide|
1813641|NCT00683670|Biological|Mature dendritic cell vaccine|
1813642|NCT00683683|Behavioral|Knowledge Translation|The multifaceted KT strategy will include 1) local multidisciplinary champions in ED, ICU, and Cardiology 2) A simple protocol for application of hypothermia, tailored to local needs and policy; 3) Identification of perceived and actual barriers to knowledge use; 4) Development of an implementation tool kit and 5) Providing timely feedback on benchmarks for hypothermia and outcomes.
1813643|NCT00683696|Device|Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)|All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.
1813644|NCT00683709|Behavioral|Counselling as Usual|5 - 20 minutes, about the effects of clozapine on body weight, appetite, blood sugar and fats such as cholesterol and triglycerides in the blood, and how these might affect your health in the future.
1813645|NCT00683709|Behavioral|CBT|45 - 60 minutes individual treatment sessions focused on nutrition, exercise and weight control and will occur weekly for 4 weeks. After this, 10 group sessions focused on weight reduction will be held every 2 weeks. This will be followed by 6 group sessions focused on weight maintenance held every 2 weeks.
1813646|NCT00683722|Drug|PROCHYMAL™|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
1813647|NCT00683722|Drug|Placebo|Intravenous infusion of excipient of PROCHYMAL™
1813648|NCT00683735|Drug|Sitagliptin|100 mg once daily in the morning
1813649|NCT00683735|Drug|Metformin|up to 2000 mg/day
1813650|NCT00683735|Drug|Placebo|500mg 1-0-0-0
1813651|NCT00683735|Drug|Placebo|100mg 1-0-0-0
1815316|NCT00694317|Drug|Zaleplon|Short term treatment of insomnia
1813652|NCT00683761|Drug|131I-TM601|In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
1813653|NCT00683774|Drug|diazoxide|100mg orally three times per day for 10 days
1813654|NCT00683787|Drug|docetaxel|Given IV once every 3 weeks
1813655|NCT00683787|Drug|vandetanib|Oral vandetanib once daily
1813656|NCT00676507|Biological|Lucanix™|Treatment Arm: Subjects receive Lucanix™ (belagenpumatucel-L) intradermally (ID) once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
1813657|NCT00676507|Other|Placebo Comparator|Control Arm: Subjects receive placebo ID once monthly for 18 months and then once at 21 and 24 months in the absence of disease progression or unacceptable toxicity.
1813658|NCT00676520|Device|XIENCE V® Everolimus Eluting Coronary Stent|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
1813659|NCT00676533|Drug|Cipro XR (Ciprofloxacin, BAYQ3939)|3 tablets of Cipro XR 500 mg and were instructed to take 1 tablet per day for 3 days.
1813660|NCT00676559|Drug|Efalizumab|Efalizumab 1 mg/kg weekly subcutaneous self-administered injections for 48 weeks.
1813661|NCT00676559|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injections monthly for three months followed by criteria-guided monthly injections through Month 11 (inclusive).
1813662|NCT00676572|Other|Fiberoptic bronchoscopy; blood test|Fiberoptic bronchoscopy for obtention of alveolar macrophages and bronchial biopsies for histology and culture of airway smooth muscle cells
1813663|NCT00676585|Drug|Normal Saline|Normal Saline
1813664|NCT00676585|Drug|Hydrocortisone|Hydrocortisone 100mg
1813665|NCT00676637|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
1813666|NCT00676637|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
1813667|NCT00676650|Drug|Prednisone|5 mg BID, oral
1813668|NCT00676650|Drug|sunitinib|37.5 mg/day, oral, administered on a continuous daily dosing regimen
1813669|NCT00676650|Drug|Placebo|37.5 mg/day, oral, administered on a continuous daily dosing regimen
1813670|NCT00676650|Drug|Prednisone|5 mg BID, oral
1813671|NCT00676663|Drug|entinostat|SNDX-275 5mg tablet PO once/week
1813672|NCT00676663|Drug|exemestane|exemestane 25mg PO QD
1813673|NCT00676676|Drug|Testosterone|Testosterone atch delivering 300mcg daily for 8-weeks
1813674|NCT00676689|Device|SAPIEN Transcatheter Valve Implantation|Device Implantation
1813675|NCT00676702|Dietary Supplement|Ensure Plus|A high-fat liquid meal of 500 ml of Ensure Plus
1813676|NCT00676702|Drug|Pancrelipase in combination with Ensure Plus|3 pancrelipase MT 21 capsules containing a total of 63,000 USP units of lipase with a high-fat liquid meal of 500 ml of Ensure Plus.
1813682|NCT00676728|Drug|JNJ-26481585|In Part 1, Initial dose of JNJ-26481585 4 mg oral capsule is administered once daily on each day of a 21-day cycle. Dose will be escalated or de-escalated until Maximum tolerated dose (MTD) of JNJ-26481585 is determined in Part 1. MTD of JNJ-26481585 will be the initial dose in Part 2.
1813683|NCT00676741|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1813684|NCT00676741|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1813685|NCT00676741|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1813686|NCT00676754|Procedure|Statens Serum Institut RT23 2TU tuberculin|
1813687|NCT00676767|Dietary Supplement|Resistant Starch Type 4|
1813688|NCT00676767|Dietary Supplement|Dextrose|
1813689|NCT00676767|Dietary Supplement|Puffed wheat|
1813690|NCT00676780|Drug|Polyphenon E (EGCG)|4 capsules daily with a meal for the duration of the study
1813691|NCT00683800|Drug|desvenlafaxine succinate (DVS) SR|Titration with 50 mg tablets once daily for 7 days, then 100mg tablets once daily from day 8 to day 365, then taper with 50 mg tablets once daily for 7 days, followed by 25 mg tablets once daily for 7 days.
1813692|NCT00683800|Drug|Placebo|Titration with 50 mg placebo tablets once daily for 7 days, then 100mg placebo tablets once daily from day 8 to day 365, then taper with 50 mg placebo tablets once daily for 7 days, followed by 25 mg placebo tablets once daily for 7 days.
1813693|NCT00683813|Behavioral|vCRP|The vCRP includes online intake forms, one-on-one chat sessions with vCRP nurse, dietitian and exercise specialist, data collection (exercise heart rate, blood pressure, glucose- if diabetic), peer-support group chat sessions, ask-an-expert chat sessions, education, progress reports and online resources. VCRP patients will receive access to the website, a heart rate monitor and a blood pressure monitor and trained in their use. The heart rate monitors allow for exercise heart rate data to be stored and downloaded to their home computer and then uploaded to the vCRP webserver. The exercise data will be reviewed weekly. A letter to the patient's primary care physician will be sent to outline the vCRP intervention, the treatment algorithms to be used and indicate under what circumstances the vCRP nurse and/or patient may contact them with regards to their management. After the 4 month intervention, patients will be discharged into the care of their primary care physician.
1813732|NCT00684047|Biological|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Preliminary Part (I)
1819434|NCT00724126|Drug|Rifaximin|
1813694|NCT00683826|Dietary Supplement|L-Leucine 8gr|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 8 grams of leucine.
1813695|NCT00683826|Other|Liquid meal|Liquid meal preparation (contents): Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. The placebo group will have the same drinks listed above with no leucine incorporated.
1813696|NCT00683826|Dietary Supplement|L-Leucine 4g|Supplementation in the form of a liquid meal (premixed leucine powder solutions with flavor made by the Bionutrition Unit of the Irving Insitute for Clinical and Translational Research (IICTR)). Dosing of leucine will be a combination of 2 ounces of liquid per 1 gm of leucine. L-leucine was purchased (FCC quality) from Spectrum Chemical,California. Certificate of analysis enclosed (99.89% leucine).Liquid meal preparation: Grape juice and crystal light mixes will be used for the preparation of liquid meals that will be given to each participant each week. Participants will consume two 8 ounce drinks (packaged in two 10 ounce bottles) per day. Each drink will be individually prepared with 4 grams of leucine.
1813697|NCT00683839|Behavioral|Brief tobacco counseling|Public health dental professionals provide brief counseling during routine visits based on the Clinical Practice Guidelines 5 As (Ask, Advise, Assess, Assist, Arrange), including offering free Nicotine Replacement Therapy and referral to a Tobacco Quit Line. Pharmacologic: nicotine patch or lozenge maximum 12 week course.
1813698|NCT00683852|Drug|Aripiprazole 5mg|Tablet dose of aripiprazole will be 2 mg/day during the first phase (30 days) of the study, and 5 mg/day in the second phase (30 days)
1813699|NCT00683852|Drug|Aripiprazole 2mg|For patients randomly assigned to the placebo/drug sequence, the dose of aripiprazole will be 2 mg/day during the second phase of the study (30 days)
1813700|NCT00683852|Drug|Placebo|for patients randomly assigned to the placebo/placebo sequence, study medication will be placebo during both phases of the study (60 days)
1813701|NCT00683865|Drug|Ofloxacin|Ofloxacin 400 mg po bid plus metronidazole 500 mg po bid for 14 days
1813702|NCT00683865|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg po od for 14 days
1813703|NCT00683878|Drug|Dapagliflozin|Tablets, Oral, 5.0 mg, once daily, up to 48 weeks
1813704|NCT00683878|Drug|Dapagliflozin|Tablets, Oral, 10.0 mg, once daily, up to 48 weeks
1813705|NCT00683878|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, up to 48 weeks
1813706|NCT00683878|Drug|Thiazolidinedione (Pioglitazone)|Tablets, ≥ 30 mg, Once daily, up to 48 weeks
1813707|NCT00683891|Drug|FazaClo (clozapine, USP) ODT|
1813708|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 5 mg/min/mL|On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, intravenous (IV) solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 5 mg/min/mL, intravenous IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
1813709|NCT00683904|Drug|Ixabepilone, 32 mg/m^2 + Carboplatin, 6 mg/min/mL|After all participants in Dose Level 1 (ixabepilone, 32 mg/m^2 + carboplatin, 5 mg/min/mL) have been observed for 1 full 21-day cycle, Dose Level 2(ixabepilone, 32 mg/m^2 + carboplatin, 6 mg/min/mL) opened. On Day 1 of each 21-day cycle, ixabepilone, 32 mg/m^2, IV solution administered as a 3-hour infusion; 30 minutes after the end of ixabepilone infusion, carboplatin, 6 mg/min/mL, IV solution infused over 30 minutes. Repeated once every 3 weeks, for a maximum of 6 cycles.
1813710|NCT00683917|Drug|Proellex 25 mg|Proellex 25 mg, 1 capsule daily for 4 months
1813711|NCT00683917|Drug|Proellex 50 mg|Proellex 50 mg, 2 capsules daily for 4 months
1813712|NCT00683917|Drug|Lupron Depot|Lupron 3.75 mg monthly intramuscular injections for 4 months
1813713|NCT00683930|Drug|Mycophenolate Mofetil 2 g/Day|Mycophenolate mofetil 500 mg tablets; 4 tablets twice daily for 52 weeks
1813714|NCT00683930|Drug|Mycophenolate Mofetil (MMF) 3 g/Day|Mycophenolate mofetil 500 mg tablets; 6 tablets twice daily for 52 weeks
1813715|NCT00683930|Drug|Placebo|Placebo for MMF 2 g/day group: 4 tablets orally twice daily for 52 weeks; placebo for MMF 3 g/day group: 6 tablets orally twice daily for 52 weeks
1813716|NCT00683943|Drug|Lithium Carbonate|
1813717|NCT00683956|Device|ReinLoop control software for patient-specific induction and maintenance of anesthesia|
1813718|NCT00683956|Drug|Propofol|
1813719|NCT00683969|Drug|mycophenolate mofetil (CellCept)|1g bid for 36 weeks
1813720|NCT00683969|Drug|placebo|po bid for 36 weeks
1813721|NCT00683982|Drug|Nitazoxanide|Nitazoxanide 15mg/Kg/day twice day for 3 days
1813722|NCT00683982|Drug|Probiotic mix preparation|Probiotic preparation 1 gram twice a day for 5 days
1813723|NCT00683982|Other|Oral hydration solutions|Oral hydration solutions as needed
1813724|NCT00683995|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
1813725|NCT00684008|Drug|CYT107 - Recombinant glycosylated human interleukin 7.|Patients will be treated with CYT107 60 to 210 days post transplantation, in 3 successive cohorts of 3 patients. Escalating doses of CYT107 will be given to successive cohorts. Patients will receive 1 dose of CYT107 by the subcutaneous route, once a week for 3 weeks. Dose level 1: 10 mcg/kg/dose for 3 doses; Dose level II: 20 mcg/kg/dose for 3 doses; Dose level III: 30 mcg/kg/dose for 3 doses. Only 1 treatment course for this initial study.
1813726|NCT00684008|Drug|rhIL-7 (CYT107)|10, 20, or 30 mcg/kg once a week for 3 consecutive weeks via the subcutaneous route.
1813727|NCT00684021|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
1813728|NCT00684021|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
1813729|NCT00684034|Other|Sampling of blood|A sampling of blood will be made
1813730|NCT00684034|Other|Sampling of blood|A sampling of bood will be made before the dialysis
1813731|NCT00684034|Other|Sampling of blood|A sampling of blood will be made.
1813950|NCT00686218|Genetic|protein expression analysis|Testing
1813733|NCT00684047|Biological|FS Grifols|Fibrin Sealant Grifols (FS Grifols). Primary Part (II)
1813734|NCT00684047|Procedure|Manual Compression|Manual Compression. Primary Part (II)
1813735|NCT00684060|Biological|Adult stem cells|One time infusion of approximately 150 million total nucleated cells (TNC) in 30 ml of 5% HSA/saline solution
1813736|NCT00684060|Biological|Placebo|One time infusion of 30 ml of HSA (5%)
1813737|NCT00684073|Drug|buprenorphine|2 mg buprenorphine and 8 mg buprenorphine tablets at doses from 2 to 16 mg buprenorphine daily for first two days of study
1813738|NCT00684073|Drug|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone tablets at doses from 2/0.5 mg buprenorphine/naloxone to 16/4 mg buprenorphine/naloxone daily for last 3 days of study
1813739|NCT00684086|Behavioral|Diabetes Self Management Program|
1813740|NCT00684099|Drug|Docetaxel|Docetaxel at starting dose of 65 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
1813741|NCT00684099|Drug|Pemetrexed|Pemetrexed at starting dose of 400 mg/m2 IV on day 1 every 3 weeks for a total of 6 cycles
1813742|NCT00684112|Drug|Gabapentin|Patients in this arm of the study will receive two identical capsules, containing 300 mg of oral gabapentin each, 1 hour before surgery.
1813743|NCT00684112|Drug|Placebo|Patients in this arm of the study will receive two identical placebo capsules 1 hour before surgery.
1813744|NCT00684125|Device|Blake Drains (Blake drain, Ethicon USA)|19F Blake drain located in the posterior pericardial cavity
1813745|NCT00684125|Device|Standard mediastinal drainage|Mediastinal drainage will be accomplished using 28F or 32F chest tube located in the anterior mediastinum
1813746|NCT00684970|Drug|Hamsa-1™ TL-118|Once daily Hamsa-1™ TL-118
1813747|NCT00684983|Drug|Capecitabine|Given PO
1813748|NCT00684983|Biological|Cixutumumab|Given IV
1813749|NCT00684983|Other|Laboratory Biomarker Analysis|Correlative studies
1813750|NCT00684983|Drug|Lapatinib Ditosylate|Given PO
1813751|NCT00684983|Other|Quality-of-Life Assessment|Ancillary studies
1813752|NCT00684996|Drug|etaracizumab|Given IV
1813753|NCT00684996|Biological|bevacizumab|Given IV
1813754|NCT00685009|Drug|Estrogen hormone therapy|Estrogen pill daily
1813755|NCT00685009|Drug|Estrogen plus progesterone hormone therapy|Estrogen plus progesterone hormone therapy pill (Prempro) daily
1813756|NCT00685009|Drug|Placebo|Placebo pill daily
1813757|NCT00685022|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
Arm #A
Xopenex HFA MDI, albuterol HFA MDI"
1813758|NCT00685022|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|"Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
Arm #B
albuterol HFA MDI, Xopenex HFA MDI"
1813759|NCT00685035|Device|HFCWC with higher pressure/variable-frequency settings|Randomized crossover trial of airway clearance therapy comparing sine wave HFCWO with high pressures and variable frequency (pressure 10, frequencies 8,9,10 and pressure 6, frequencies 18,19,20) to low pressure and mid frequency (pressure 5, frequency 12). Subjects will have 2-day washout between airway clearance sessions. All sputum collected during sessions.
1813760|NCT00685035|Device|HFCWC with lower pressure/mid-frequency settings|Subjects will perform pulmonary function tests prior to and following each airway clearance therapy. All sputum produced during, and for 15 minutes following airway clearance therapy will be collected. Subjects will complete a questionnaire addressing the comfort of therapy upon completion of the session.
1813761|NCT00685048|Behavioral|10 minutes of psycho-education|Patients review with study therapist a brochure about types of gambling people engage in and relationships between gambling, drug use, moods, and legal problems.
1813762|NCT00685048|Behavioral|10 minutes of brief advice|Patients will review with study therapist a brochure and advice about problem gambling. It will also contain methods for reducing gambling.
1813763|NCT00685048|Behavioral|four 50-minute individual therapy sessions of MET & CBT|MET & CBT
1813764|NCT00685061|Drug|Thymoglobulin|Induction
1813765|NCT00685061|Drug|Campath-1H|Induction
1813766|NCT00685061|Drug|Daclizumab|Induction
1813767|NCT00685074|Behavioral|Computer-based Motivational Interviewing|The software includes three intervention components - pros and cons, feedback, and optional goal-setting in a fixed order.
1813768|NCT00685074|Behavioral|Time control|A series of therapeutically inactive videos and questions to (a) maintain RA blind, and (b) serve as a time control.
1813769|NCT00685100|Other|PDT plus intravitreal triamcinolone|PDT plus intravitreal triamcinolone
1813770|NCT00685113|Drug|DR-3001|4mg/day vaginal ring inserted vaginally and replaced every 4 weeks
1813771|NCT00685113|Drug|DR-3001|6mg/day vaginal ring inserted vaginally and replaced every 4 weeks
1813772|NCT00685113|Drug|Placebo|Placebo vaginal ring inserted vaginally and replaced every 4 weeks
1813773|NCT00685126|Drug|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, low dose (0.15 mg, 0.31 mg or 0.63 mg), adjusted for body weight
1813774|NCT00685126|Drug|Levalbuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, high dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
1813775|NCT00685126|Drug|Albuterol HCl Inhalation Solution|Nebulized unit dose vial for inhalation, dose (0.31 mg, 0.63 mg or 1.25 mg), adjusted for body weight
1813776|NCT00685139|Drug|Zonisamide 100 mg Capsule|100 mg capsule administered after an overnight fast.
1813777|NCT00685139|Drug|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered after an overnight fast.
1813778|NCT00685152|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) (MagPro, Medtronic)|6 weeks of either Active or Sham Repetitive Transcranial Magnetic Stimulation (rTMS). Active treatment comprises of stimulation with rTMS frequency 20Hz, intensity 110% of Motor Threshold, 20 trains, 9 seconds per train, 51 seconds of intertrain interval that is applied over the Right Dorsolateral Prefrontal Cortex by a figure eight shaped coil. Treatment will be given 5 times a week for 4 weeks, 3 times a week during Week 5 and 2 times a week during Week 6. Sham treatment will mimic active treatment; The rTMS machine used is MagPro and the company name is Medtronic.
1813779|NCT00685165|Drug|Primidone 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
1813780|NCT00685165|Drug|Primidone (Mysoline®) 50 mg Tablet|50 mg tablet administered after an overnight fast of at least 10 hours.
1813781|NCT00685178|Drug|topiramate|"topiramate powder 0mg - 150 mg with lactate in blind capsules. Two capsules dispensed daily. One capsule ingested under supervision at the methadone window. One capsule to be ingested at home at bedtime. Participant is expected to return the empty blister pack on the following day.
capsules are administered from week 4 through 25 of the trial"
1813782|NCT00685178|Behavioral|Contingency Reinforcement|monetary reward for self-reported cocaine abstinence confirmed by urine toxicology results
1813783|NCT00685178|Drug|placebo + NonCR|participant receives placebo capsules and monetary reinforcers by chance, irrespective of cocaine use or abstinence
1813784|NCT00685191|Drug|Salvage antiretroviral therapy including raltegravir|Initiation of raltegravir-including salvage antiretroviral therapy
1813785|NCT00685204|Drug|Milataxel|Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
1813786|NCT00685217|Procedure|TVT Secur (Gynecare)|Sling device for stress urinary incontinence
1813787|NCT00685217|Procedure|TVT (Gynecare)|Sling procedure for stress urinary incontinence
1994405|NCT03012607|Drug|Truvada|Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)
1813790|NCT00685243|Procedure|Laser treatment|Fraxel and pulsed dye laser
1813791|NCT00685256|Other|counseling intervention|subjects and parents will receive genetic counseling
1813792|NCT00685256|Other|educational intervention|subjects and parents will receive education re: genetic testing
1813793|NCT00685256|Other|survey administration|surveys will be administered to subjects and parents
1813794|NCT00685256|Behavioral|psychosocial assessment and care|psychosocial assessment and counseling will be provided
1813795|NCT00685256|Behavioral|supportive care|parents and children will be provided with supportive care
1813796|NCT00685269|Drug|Eszopiclone|Eszopiclone 3 mg QD
1813797|NCT00685269|Drug|Placebo|Placebo tablet
1813798|NCT00685282|Behavioral|Cognitive Behavioral Therapy|The intervention (CBT) will focus on teaching specific skills which are adapted for women undergoing fertility related problems. Through the sessions the participants will learn relaxation techniques such as breathing, progressive relaxation, and guided imagery. Furthermore, suggestions for making healthier choices for coping and for releasing tension will be reviewed and discussed, with an emphasis on making healthy lifestyle changes with balance and perspective rather than in a punishing or depriving way. Each session will consist of: 20 minutes of stress-reduction behavioral relaxation, 40 minutes of cognitive restructuring and 30 minutes personal tailoring of the behavioral homework between each session.
1813799|NCT00685295|Drug|Fentanyl|Fentanyl rapid dissolving tablet 100mcg
1813800|NCT00685295|Drug|Lansoprazole|lansoprazole 15mg rapidly dissolving tablet
1813801|NCT00685295|Drug|Oxycodone|Oxycodone 5/325 mg tablet
1813802|NCT00685308|Procedure|Stenting of atherosclerotic intracranial stenosis|"Patients will receive aspirin 300mg and clopidogrel 75mg per day for 3 days or more before stenting,and for at least 1 month after stenting. Modifiable risk factors will be controlled according to major international guidelines.
All stenting procedures will be performed in an elective setting, and under local or general anesthesia. The study will be terminated if stroke or death rate within 30 days of the stenting exceeds 15%."
1813803|NCT00685321|Device|H1 deep TMS coil|20 daily deep rTMS treatment
1813804|NCT00685321|Device|Sham|inactive treatment
1813805|NCT00685334|Drug|Olanzapine|Participants will take olanzapine daily for 12 weeks.
1813806|NCT00685334|Drug|Aripiprazole|Participants will take aripiprazole daily for 12 weeks.
1813807|NCT00685347|Drug|Levalbuterol HFA MDI|"levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).
Arm #A
Xopenex HFA MDI"
1813808|NCT00685347|Drug|Racemic Albuterol|"racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).
Arm #B
Proventil HFA MDI"
1813809|NCT00685360|Drug|OPC-67683|100 mg BID will be administered as two 50 mg tablets together with two matching placebo tablets for a total of four tablets administered twice a day (total daily dose of OPC-67683 is 200 mg) for 56 days. .
1813810|NCT00685360|Drug|OPC-67683|200 mg BID will be administered as four 50 mg tablets administered twice a day for (total daily dose of OPC-67683 is 400 mg) 56 days.
1813811|NCT00685360|Drug|Placebo|Placebo will be administered as four 50 mg tablets matching the OPC-67683 tablets administered twice a day for 56 days
1813812|NCT00685373|Drug|Canakinumab (ACZ885)|6 mL glass vial containing 150 mg lyophilized Canakinumab reconstituted with water for a subcutaneous injection every 8 weeks. Dosage based on body weight.
1813813|NCT00685386|Other|CO2 insufflation|The bowel lumen will be insufflated with CO2 during the endoscopy (as compared to room air).
1813814|NCT00685386|Other|Room air insufflation|During the ERCP, room air will be insufflated (current standard clinical practice) as a placebo comparator.
1813815|NCT00685399|Drug|AIN457|AIN457 subcutaneous dose
1813816|NCT00685399|Drug|AIN 457|AIN457 low dose (i.v)
1813817|NCT00685399|Drug|AIN457|AIN457 high dose (i.v)
1813818|NCT00685412|Biological|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
1813819|NCT00685425|Drug|Levalbuterol HFA MDI|"levalbuterol 45 µg (1 actuation of 45 µg); (b) levalbuterol 90 µg (2 actuation of 45 µg) and (c) levalbuterol 180 µg (4 actuations of 45 µg each).
Arm #A
Xopenex HFA MDI"
1813820|NCT00685425|Drug|Racemic Albuterol|"racemic albuterol 90 µg (1 actuation of 90 µg); (b) racemic albuterol 180 µg (2 actuations of 90 µg) and (c) racemic albuterol 360 µg (4 actuations of 90 µg).
Arm #B
Proventil HFA MDI"
1813821|NCT00685451|Behavioral|Cognitive Behavioral Therapy (CBT)|
1813822|NCT00685464|Drug|Abciximab|Intravenous.
1813823|NCT00685464|Drug|Abciximab|Intracoronary
1813824|NCT00685477|Drug|Experimental Sequence ABC|Drug will be given over 15 minutes, followed by infusion over 30 minutes, followed by infusion over 60 minutes
1819435|NCT00724126|Drug|Placebo|
1813825|NCT00685477|Drug|Experimental Sequence ACB|Drug infused over 15 minutes, followed by infusion over 60 minutes, followed by infusion over 30 minutes
1813826|NCT00685477|Drug|Experimental Sequence BAC|Drug will be given over 30 min infusion, followed by 15 minute infusion, followed by 60 minute infusion
1813827|NCT00685477|Drug|Experimental Sequence BCA|Drug will be given over 30 min infusion, followed by 60 minute infusion, followed by 15 minute infusion
1813828|NCT00685477|Drug|Experimental Sequence CAB|Drug will be given over 60 min infusion, followed by 15 minute infusion, followed by 30 minute infusion
1813829|NCT00685477|Drug|Experimental Sequence CBA|Drug will be given over 60 min infusion, followed by 30 minute infusion, followed by 15 minute infusion
1813830|NCT00685490|Procedure|Vitrectomy w/o ILM peeling for macular edema with BRVO|Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.
1813831|NCT00685503|Drug|Ranibizumab|
1993893|NCT03110991|Behavioral|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)|Multicomponent Cognitive Behavioral Intervention administered via a smartphone App+ telephone contact via conference call (CCIA+CC)
1813835|NCT00685529|Drug|Racemic formoterol|12 µg of racemic formoterol fumarate BID
1813836|NCT00685529|Drug|Arformoterol tartrate inhalation solution|15 µg of nebulized arformoterol tartrate inhalation solution BID
1813837|NCT00685529|Drug|Racemic formoterol|24 µg of racemic formoterol fumarate BID
1813838|NCT00685542|Drug|diacerein|Diacerein 50mg bid
1813839|NCT00685542|Drug|placebo|placebo
1813840|NCT00685555|Behavioral|Switch active lifestyles brought to you by MediaWise|The Switch™ Program is a unique community and family-based behavior change initiative that helps motivate children to change three critical health behaviors that are risk factors for childhood overweight and obesity.
1813841|NCT00685555|Behavioral|Switch active lifestyles from MediaWise|1300 students (male and female) were recruited through two separate school districts in Lakeville, Minnesota and Cedar Rapids, Iowa. Informed consents went to all students who chose to participate. Demonstration and Control school were randomly selected. Baseline data was collected regarding physical activity, screen time, and nutrition, standard body measurements, and baseline data, and salivary cortisol levels were taken. Parent and teacher surveys were also conducted. After baseline selected demonstration sites and students were provided with information focused on improving healthy behaviors while the control sites served as matched comparison groups.
1813842|NCT00685568|Drug|celecoxib|Orally, twice daily for 3 months; 50 mg tablets. Celecoxib escalating doses starting at 4 mg/kg/day.
1813843|NCT00685568|Other|placebo|Orally, twice daily for 3 months
1813844|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - lowest ratio|the lowest R-TFA/SFA ratio obtained from dairy cows in Winter period
1813845|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - medium ratio|the medium R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 4.1% flax seed
1813846|NCT00685581|Dietary Supplement|Ruminant trans fatty acid enriched diet - highest ratio|the highest R-TFA/SFA ratio obtained from dairy cows feeding with Winter diet supplemented with 9% flax seed
1813847|NCT00685594|Drug|cholecalciferol|20.000 IU cholecalciferol per week for 5 years versus placebo
1813848|NCT00685594|Drug|Placebo|Placebo capsule once a week, identical to cholecalciferol capsule
1813849|NCT00685607|Drug|loperamide-simethicone|Four caplets containing 2 mg loperamide HCl and 125 mg of simethicone each, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
1813850|NCT00685607|Drug|matching placebo|Four placebo caplets matching the caplets in Arm 1, administered orally with 4-8 oz. of water according to the labeled directions of the currently marketed product (i.e., 2 caplets after first loose stool, followed by 1 caplet after each subsequent loose stool, not to exceed 4 caplets in 24 hours). The treatment period will last six hours.
1813851|NCT00685620|Behavioral|Reinforcement Based Treatment|3 group random assignment to receive standard care, recovery housing alone, or recovery housing plus behavioral treatment
1813852|NCT00685633|Drug|bicalutamide|Given orally
1813853|NCT00685633|Drug|enzastaurin hydrochloride|Given orally
1813854|NCT00685646|Drug|antiandrogen therapy|Up to 24 courses of therapy
1813855|NCT00685646|Drug|zoledronic acid|Up to 24 courses of therapy
1813856|NCT00685659|Other|Intensive Outpatient Treatment|9 hours of group counseling per week for 2-3 months
1813857|NCT00685659|Other|Adaptive telephone-based counseling|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm is included
1813858|NCT00685659|Other|Adaptive telephone-based counseling plus incentives|In addition to IOP, patients receive telephone counseling calls, in which risk level is assessed and coping skills intervention delivered to address risk areas. Adaptive stepped care algorithm and monetary incentives for participation are included
1813859|NCT00685672|Drug|adrenalin|adrenalin 2 microgram pr ml placebo
1813860|NCT00685672|Drug|placebo|Saline instead of adrenaline in the epidural mixture
1813861|NCT00685685|Drug|Lovastatin 40 mg tablets|40 mg tablet administered after an overnight fast of at least 10 hours
1813862|NCT00685685|Drug|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered after an overnight fast of at least 10 hours
1813863|NCT00685698|Drug|TG-873870 (Nemonoxacin)|750 mg
1813864|NCT00685711|Biological|Cat-PAD|single, escalating dose intradermal and subcutaneous injections of Cat-PAD
1813865|NCT00685724|Behavioral|Motivational Enhancement Therapy (MET)|MET is a client-centered, directive form of therapy designed to enhance clients' intrinsic motivation to change.
1813866|NCT00685724|Behavioral|Cognitive-Behavioral Therapy (CBT)|In CBT, clients learn to modify their thoughts as well as their behaviors by increasing awareness of the relationship between thoughts, emotions, and actions.
1813867|NCT00685737|Drug|1-MNA|Capsule
1813868|NCT00685737|Drug|Placebo|Capsule
1813870|NCT00685763|Radiation|Proton radiation and chemotherapy|"Proton radiation 59.4 CGE in 33 fx at 1.8 CGE per fx over 7 weeks .
Chemotherapy:
Capecitabine (Xeloda ®) 1,000 mg by mouth twice a day, 5 days/week (M-F) Consolidation Chemotherapy: Suggested Regimen - Gemcitabine total of 12 doses"
1813871|NCT00685776|Drug|anacetrapib|Participants will receive one tablet of anacetrapib 100 mg once daily for 76 weeks.
1813872|NCT00685776|Drug|Comparator: placebo|Participants will receive one placebo tablet once daily for 76 weeks.
1813873|NCT00685789|Device|acupuncture, deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the deqi sensation.
1813874|NCT00685789|Device|acupuncture Non-manipulation|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
1813875|NCT00685802|Drug|Cilostazol 50 mg Tablets|Cilostazol (2 x 50 mg tablets) administered after an overnight fast of at least 10 hours
1813876|NCT00685802|Drug|Cilostazol (Pletal®) 50 mg Tablets|Cilostazol (Pletal® Tablets, 2 x 50mg) administered after an overnight fast of at least 10 hours.
1813877|NCT00685815|Drug|Ferric Carboxymaltose (FCM)|500mg FCM in 250cc NS IV over one hour, once on Day 3, once on Day 4
1813878|NCT00685815|Drug|Placebo|250cc NS IV over one hour, once on Day 3, once on Day 4
1813879|NCT00685828|Drug|imatinib mesylate|By mouth
1813880|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
1813881|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
1813882|NCT00685841|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
1813883|NCT00685841|Drug|Salmeterol MDI|Salmeterol MDI 42 mcg BID
1813884|NCT00685841|Drug|Placebo|Placebo BID MDI
1813885|NCT00685854|Drug|Ranibizumab|
1813886|NCT00685867|Other|Rapid molecular MRSA test|PCR-based rapid screening for MRSA carriage
1813887|NCT00685867|Behavioral|Hand hygiene promotion|"Promotion and monitoring of hand hygiene, with special emphasis on alcohol-based hand rubs and feedback of hand hygiene compliance
Standard precautions (e.g. use of gloves for contacts with wounds and body fluids)
Isolation precautions according to the hospitals' capacity and strategy
Additional basic infection control interventions (if necessary)"
1813888|NCT00685880|Drug|Prolotherapy (10% dextrose solution)|Dextrose diluted with sterile water.
1813889|NCT00685880|Drug|Betamethasone|CELESTONE® SOLUSPAN® * (betamethasone injectable suspension) Injectable Suspension is a sterile aqueous suspension containing 3 mg per milliliter betamethasone, as betamethasone sodium phosphate, and 3 mg per milliliter betamethasone acetate. Subjects will receive a 0.25 to 0.5 mL Celestone Soluspan injection.
1813890|NCT00685893|Behavioral|Education|We include information about end-of-life decision-making, communication skills, pain and symptom management, and withdrawal of life support. The primary methods of delivery will be a grand rounds lecture by one of the physician investigators and the viewing of an educational video for nurses and respiratory therapists. The content of the educational components will be structured to cover four topics: the principles of decision-making about end-of-life care in the ICU; communication with patients, families and the ICU team; pain and symptom management; and, the principles and practice of withdrawal of life support.
1813891|NCT00685893|Behavioral|Local Champions|We identify physicians, nurses and other clinicians from each hospital to serve as the local champions. The role of the local champions is to help implement the intervention and be a role model for end-of-life care in the ICU. Local champions participate in interactive education and training sessions with the investigators and the other local champions from their institution to discuss barriers to good end-of-life care at their location and to strategize about how to overcome those barriers.
1813892|NCT00685893|Behavioral|Institution Feedback|We provide feedback to the institution from the hospital specific family satisfaction data we collect. All feedback is presented as aggregated data for the institution without any personal identifiers.
1813893|NCT00685893|Behavioral|Academic Detailing|Study staff meet with ICU directors with 4 goals. The first goal is to familiarize the director with the educational content of the intervention. Secondly, the results of the family satisfaction data collected are shared without identifying information. The aggregated results of the other participating hospitals are disclosed, also without identifiers. Third, we elicit and discuss the institution-specific barriers to providing high quality end-of-life care in the ICU. Lastly, we hope that by educating the directors we can engage these clinical leaders to serve as role models in their institutions.
1813894|NCT00685893|Behavioral|Institutional Forms|We have developed a set of orders that encompass the various aspects of withdrawing life support from patients. Individual department directors at each hospital will decide if they want to implement a similar order form at their institution and whether they want to modify the form to fit their specific institutional needs. In addition to the order forms, we encourage hospitals to develop a family pamphlets and resources that can be given to families to provide education about the intensive care unit experience.
1813895|NCT00685906|Drug|AZD6140|90 mg tablet taken by mouth 2 times a day for 21 days per cycle
1813896|NCT00685906|Drug|Levonorgestrel and Ethinyl Estradiol (Nordette®)|1 tablet taken by mouth once a day for 28 days per cycle
1813897|NCT00685919|Drug|Carbidopa|200 mg every 6 hours for 5 doses given orally
1813898|NCT00685919|Drug|Placebo|every 6 hours for 5 doses, given orally, and matching Intervention 1
1813900|NCT00685945|Drug|Control (bradykinin)|Graded doses of bradykinin (Clinalfa AG, Läufelfingen, Switzerland) will be infused at 50, 100, and 200ng/min. Each dose will be infused for 5 minutes and FBF will measured during the last 2 minutes of infusion. Arterial and venous blood samples will be obtained for measurement of net t-PA release after each dose.
1813951|NCT00686218|Genetic|western blotting|Testing
1813952|NCT00686218|Other|flow cytometry|Testing
1813901|NCT00685945|Drug|L-NMMA + bradykinin|Thirty minutes after administration of bradykinin a continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be started started. While continuing the infusion of L-NMMA, baseline measurements and infusion of bradykinin will be repeated.
1813902|NCT00685945|Drug|Isosorbide + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 5mg isosorbide dinitrate (an exogenous NO donor; Major Pharmaceuticals Inc, Livonia MI). Sixty minutes after the administration of isosorbide the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
1813903|NCT00685945|Drug|Sildenafil + L-NMMA + bradykinin|Following the second bradykinin infusion, 12 subjects will receive 50mg sildenafil (phosphodiesterase type 5 (PDE5) inhibitor to increase cGMP without increasing NO; Pfizer, NY). Sixty minutes after the administration of sildenafil the continuous intra-arterial infusion of L-NMMA at 12 micromol/min will be restarted and baseline measurements and bradykinin infusion will be repeated.
1813904|NCT00685958|Drug|enoxaparin (XRP4563)|14 days of treatment
1813905|NCT00685971|Dietary Supplement|5000 IU of cholecalciferol|5 drops taken once daily for 12 weeks
1813906|NCT00685971|Dietary Supplement|placebo|5 drops once daily for 12 weeks
1813907|NCT00686010|Drug|Placebo|Placebo tablet, 3 tablets, oral, once daily after breakfast
1813908|NCT00686010|Drug|JTT-705 300mg|JTT-705 tablet, 1 tablet, oral, once daily, after breakfast. Placebo tablet, 2 tablets, oral, once daily, after breakfast.
1813909|NCT00686010|Drug|JTT-705 600mg|JTT-705 tablet, 2 tablets, oral, once daily, after breakfast. Placebo tablet, 1 tablet, oral, once daily, after breakfast
1813910|NCT00686010|Drug|JTT-705 900mg|JTT-705 tablet, 3 tablets, oral, once daily, after breakfast
1813911|NCT00686023|Procedure|internal fixation (DHS - richard nail)|internal fixation
1813912|NCT00686023|Procedure|internal fixation (inflatable PFN by DISCOTEC)|internal fixation
1813913|NCT00686036|Drug|vandetanib|300 mg orally, once daily for up to 18 months
1813914|NCT00686036|Drug|Placebo|
1813915|NCT00686062|Other|Control - computerized age-appropriate prenatal testing educational brochure|Computerized version of the age-appropriate prenatal testing educational brochure distributed by the State of California.
1813916|NCT00686062|Other|PT Tool - interactive, computerized, prenatal testing decision tool|An interactive, computerized prenatal testing decision-assisting tool (PT Tool).
1813917|NCT00686075|Biological|MEDI-534, Cohort 1|Participants aged 6 to less than (<) 24 months will receive MEDI-534, 10^5 median tissue culture infectious dose (TCID50) by intranasal route at Month 0, 2, and 4.
1813918|NCT00686075|Other|Placebo, Cohort 1|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
1813919|NCT00686075|Biological|MEDI-534, Cohort 2|Participants aged 6 to <24 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
1813920|NCT00686075|Other|Placebo, Cohort 2|Participants aged 6 to <24 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
1813921|NCT00686075|Biological|MEDI-534, Cohort 3|Participants aged 2 months will receive MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
1813922|NCT00686075|Other|Placebo, Cohort 3|Participants aged 2 months will receive placebo matched to MEDI-534, 10^4 TCID50 by intranasal route at Month 0, 2, and 4.
1813923|NCT00686075|Biological|MEDI-534, Cohort 4|Participants aged 2 months will receive MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
1813924|NCT00686075|Other|Placebo, Cohort 4|Participants aged 2 months will receive placebo matched to MEDI-534, 10^5 TCID50 by intranasal route at Month 0, 2, and 4.
1813925|NCT00686075|Biological|MEDI-534, Cohort 5|Participants aged 2 months will receive MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
1813926|NCT00686075|Other|Placebo, Cohort 5|Participants aged 2 months will receive placebo matched to MEDI-534, 10^6 TCID50 by intranasal route at Month 0, 2, and 4.
1813927|NCT00686088|Drug|PRX302|Determination of the therapeutic activity of different concentrations of PRX302 at increasing volumes and/or number of deposits per gram of prostate.
1813928|NCT00686114|Drug|Paclitaxel|135mg/m2, day 1 and day 29 of the radiotherapy.
1813929|NCT00686114|Drug|Cisplatin|20mg/m2, days 1-3,days 29-31 from the beginning of radiotherapy.
1813930|NCT00686114|Drug|Tarceva|150mg/day,oral administration, from day 1 to day 42 (at the beginning of therapy)
1813931|NCT00686114|Radiation|Radiotherapy|Enlarged field radiotherapy
1813932|NCT00686114|Radiation|Radiotherapy|Conventional field radiotherapy
1813933|NCT00686127|Drug|Lidoderm patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
1813934|NCT00686127|Drug|Placebo patch|1 patch was applied topically to the affected site(s) for 12 hours each day.
1813935|NCT00686140|Drug|celecoxib|400mg/day, twice a day, 12 weeks
1813936|NCT00686140|Drug|Placebo|twice a day, 12 weeks
1813937|NCT00686166|Biological|cetuximab|"Chemotherapy cycle 1: Cetuximab, 400 mg/m^2, IV, Day 1; Cetuximab, 250 mg/m^2, IV, Days 8,15,22,29
Chemotherapy+ Radiation Cycle 2: Cetuximab, 250 mg/m^2, IV, Days 50,57,64,71,78"
1813938|NCT00686166|Drug|capecitabine|"Chemotherapy Cycle 1: Capecitabine, 1650 mg/m^2/day, PO, Monday-Friday (Day 1-35)
Chemotherapy+ Radiation Cycle 2: Capecitabine, 1650 mg/m^1, PO, Monday-Friday (Day 50-84)"
1813939|NCT00686166|Drug|oxaliplatin|"Chemotherapy Cycle 1: Oxaliplatin, 50 mg/m^2, IV, Days 1,8,15,22,29
Chemotherapy+ Radiation Cycle 2: Oxaliplatin, 50 mg/m^2, IV, Days 50,57,71,78"
1813940|NCT00686166|Procedure|therapeutic surgical procedure|Surgical resection
1813941|NCT00686166|Radiation|radiation therapy|IMRT (intensity-modulated radiation therapy)
1813942|NCT00686179|Drug|AZD3480|Capsule, oral, single dose, 6 days
1813943|NCT00686179|Drug|Moxifloxacin|Capsule(encapsulated), oral, single dose
1813944|NCT00686179|Drug|PLACEBO|Capsule, oral, single dose
1813945|NCT00686192|Dietary Supplement|Calcium Carbonate|1500 mg per day
1813946|NCT00686205|Device|collection of follow-up sample based on PRISM HIV O Plus result|Test blood samples with investigational HIV assay. If results are reactive, donors may be deferred and asked to return for a follow-up blood draw.
1813947|NCT00686218|Drug|imatinib mesylate|Given orally
1813948|NCT00686218|Drug|panobinostat|Given orally
1813949|NCT00686218|Genetic|polymerase chain reaction|Testing
1813955|NCT00686231|Drug|Nitroglycerin|1 inch of Nitroglycerin vs 2 inches of Nitroglycerin
1813956|NCT00686231|Drug|Placebo|Sorbolene cream
1813957|NCT00686231|Drug|Lidocaine|Visit 2 lidocaine 1 inch + best dose Nitro vs Placebo + lidocaine
1813958|NCT00686244|Other|Combined 3-monthly endurance and strength training|"Combined 3-monthly endurance- (3x/week) and strength training (2x/week) with moderate beginning and continuous increase of volume, duration and intensity, orientated on metabolic equivalents (MET).
Main sport: walking, walk and cycling. Addition with other activities are possible up to once a week to achieve the basal metabolism"
1813959|NCT00686257|Device|Total face mask (interface for NPPV)|NPPV is applied by this mask, as long as NPPV is received.
1813960|NCT00686257|Device|Comfort full or RT040 oronasal mask (interface for NPPV)|NPPV is applied by one of these masks (Comfort full or RT040 masks used at Rhode Island Hospital and Tufts Medical Center respectively), as long as NPPV is received.
1813961|NCT00686270|Drug|apricitabine|Initially 1200mg apricitabine twice daily orally. Following the determination of the optimum dose (800mg or 1200mg twice daily) in the pre-ceeding study AVX-301,patients may be switched to the optimum dose,if required.
1813962|NCT00686283|Behavioral|PEP intervention|This study will explore the feasibility of adherence to a personalized exercise prescription (PEP) in adolescents with type 1 or type 2 diabetes. The PEP intervention consists of a 2-hour group education session and a 16-week personalized exercise plan implemented in the home or community setting with the use of parental support and care ambassadors. Care ambassadors will maintain consistency of interactions with specific families for the duration of the PEP intervention. This consistency will aid in establishing rapport with the adolescents and parents to answer any questions and provide guidance for adhering to the PEP plan. The PEP intervention will be mutually planned with each teen and parent based upon the assessment of the teen's personal and cultural choices, including family and community resources. Exercise frequency, duration, and intensity for the teen with diabetes will be documented with a MTI ActiGraph accelerometer (Fort Walton Beach, FL).
1813963|NCT00686296|Other|Taliderm™|taliderm™ dressing application once
1813964|NCT00686296|Other|Taliderm™|Taliderm™ dressing application up to three applications
1813965|NCT00686296|Other|standard wet to dry dressing with gauze|wet to dry dressing standard of care
1813966|NCT00686322|Drug|Concurrent chemoradiotherapy (paclitaxel plus cisplatin plus radiotherapy)|Induction one cycle of paclitaxel plus cisplatin (PC), concurrent 2 cycles of PC with radiotherapy, followed by 2 cycles of PC consolidation chemotherapy.
1813967|NCT00686335|Drug|Lodotra|Administered with food at approximately 10 pm during the 4 week treatment period; patients received the identical dose of Lodotra as received of IR prednisone during the run-in period.
1813968|NCT00686335|Drug|Cortancyl|Administered in the morning with food during the 4 week run-in period; patients remained on their respective pre-study dose of prednisone or equivalent standardized to 5 mg and 1 mg tablets of immediate release (IR) prednisone (Cortancyl).
1813969|NCT00686361|Drug|Choline supplementation|Chart data, height, weight, pulmonary function, dietary intake and a venous blood and urine sample will be collected at enrollment then every 3 months for 9 months. Choline supplementation will be from enrollment for 6 months, with follow up at 3 months post supplementation. To avoid additional hospital visits and blood draws, and to co-ordinate with pulmonary function, hematology, clinical chemistry tests as part of clinical care, each subject will be seen at routine scheduled clinic appointments, which are every 3 months.
1813970|NCT00686374|Biological|Adalimumab|Pre-filled syringe, 40mg (subjects >or =40kg) /20mg EOW (subjects <40kg)or 40mg(subjects >or =40kg)/20mg EW(subjects <40kg) for up to 408 weeks.
1813971|NCT00686400|Other|TAU = treatment as usual|medication and psychosocial interventions to be chosen by treating psychiatrist
1813972|NCT00686413|Drug|AZD3480|single dose, oral
1813973|NCT00686413|Radiation|2-[18F]-F-A85380|Single dose, IV
1813974|NCT00686426|Dietary Supplement|Dairy Foods|Adequate dairy (> 3 standard daily servings)
1813975|NCT00686426|Dietary Supplement|Dairy Foods|< 1 standard dairy serving/day
1813976|NCT00686439|Drug|adalimumab|subcutaneous injection 40mg on alternate weeks
1813977|NCT00686439|Drug|adalimumab|subcutaneous injection 40mg every other week
1813978|NCT00686465|Other|PET/CT scan|Patients will undergo whole body FDG-PET/CT imaging
1813979|NCT00686478|Drug|interferon alpha 2b|1 million IU of interferon alpha 2b (Intron A) subcutaneously once a day for 7 days, then 3 million IU of interferon alpha 2b (Intron A) subcutaneously three times a week for 23 weeks.
1813980|NCT00686504|Drug|AZD2066|single dose of oral dose, 3 times per subject
1813981|NCT00686504|Drug|radioligand [11C] AZ12713580|single dose of iv administered 4 times per subject (3 times together with AZD2066)
1813982|NCT00686517|Biological|Pegylated interferon alfa-2b|1.5 ug/kg/week SC for 12 or 24 weeks
1813983|NCT00686517|Drug|Ribavirin|Ribavirin at the dose of 10.6 mg/kg/day for 12 weeks
1813984|NCT00686530|Procedure|MR Imaging|Postmortem MR will be included as part of the autopsy examination in cases of suspected brain malformations. Imaging will be done using 1.5T GE CV/I MRI magnet. The specimen is scanned, following fixation, using an 8-channel head coil or 8-channel knee coil, depending on the size of the brain. Structural postmortem MR will include spin-echo T1, axial SPGR, and T2 imaging in three planes. Diffusion tensor imaging will be performed in the coronal plane.
1813985|NCT00686530|Procedure|Autopsy|Autopsy will be performed according to accepted standards, based on clinical indications. Macroscopic examination of the fetus will be performed initially , followed by organ removal for tissue fixation for a period of two weeks.
1813986|NCT00686543|Drug|Posaconazole|Posaconazole will be used for prophylaxis
1813987|NCT00686556|Drug|cyclophosphamide|60 mg/kg/day intravenous x 2 days pre-transplant, total dose 120 mg/kg
1813988|NCT00686556|Drug|cyclosporine|Beginning on Day -3 pre-transplant maintaining a level of >200 ng/mL. CSA dosing will be monitored and altered as clinically appropriate by Pharm D or physician, and discontinue at approximately day + 180 post-transplant.
1813989|NCT00686556|Drug|Fludarabine|25 mg/m2/day intravenous as a 1 hour infusion for consecutive 3 days pre-transplant, total dose 75 mg/m2
1813990|NCT00686556|Drug|mycophenolate mofetil|Beginning on day -3, use intravenous route between days -3 and +5, followed by oral administration on Day +6 through +30, if tolerated. 15mg/kg/dose for patients <40 kg, 3 gm/day for patients >40 kg.
1815434|NCT00696657|Drug|semaglutide|0.4 mg, once weekly, s.c. injection
1813991|NCT00686556|Radiation|total marrow irradiation|Dose escalating schedule per Cohort (TMI: 300 cGy) once daily.
1813992|NCT00686556|Procedure|umbilical cord blood transplantation|product will be infused via intravenous drip on Day 0 according to current University of Minnesota guidelines for Umbilical Cord Blood Grafts
1813993|NCT00686556|Biological|Granulocyte colony-stimulating factor|5 mcg/kg/day intravenous or subcutaneous based on body weight beginning on Day +1 after umbilical cord blood infusion until absolute neutrophil count exceeds 2.5 x 10^9/L for 3 consecutive days.
1813994|NCT00686556|Biological|HLA-matched related donor bone marrow|Related donor bone marrow or mobilized stem cells will be collected (target cell dose 5x10^8 nucleated cells/kg recipient weight, minimum 3x10^8 nucleated cells/kg recipient weight) and infused without processing on day 0 according to University of Minnesota Blood and Marrow Transplant Program guidelines.
1813995|NCT00686582|Biological|IMVAMUNE|1x 10E8_TCID50
1813996|NCT00686582|Biological|IMVAMUNE|1x 10E8_TCID50
1813997|NCT00686582|Procedure|Blood Draw Only|
1813998|NCT00686595|Biological|Infliximab|Infliximab 5 mg/kg IV infusion.
1813999|NCT00686608|Dietary Supplement|glucose|0.3mg/kg of glucose
1814000|NCT00686608|Dietary Supplement|fructose|fructose IV bolus
1814001|NCT00686608|Dietary Supplement|saline|IV saline
1814002|NCT00686621|Drug|Posaconazole|Posaconazole oral suspension 400 mg twice daily with meal or nutritional supplement. Alternatively, if meal or nutritional supplement is not tolerated, posaconazole should be administered at a dose of 200 mg four times a day.
1814003|NCT00686634|Drug|Sitagliptin|Sitagliptin 100 mg by mouth once daily
1814004|NCT00686647|Device|AngioSculpt® Scoring Balloon Catheter|Use of a stent for the main branch of a bifurcation lesion and use of a scoring balloon for the side branch of the same bifurcation lesion
1814005|NCT00686647|Device|AngioSculpt Scoring Balloon Catheter|Treatment of the side-branch vessel of true bifurcation lesions using the AngioSculpt device
1814006|NCT00686660|Behavioral|cycling, walking|"In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.
In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years."
1814007|NCT00686660|Behavioral|cycling, non-walking|"In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.
In non-training period, patients don't receive walk training."
1814008|NCT00686660|Behavioral|walking, walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.
In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years."
1814009|NCT00686660|Behavioral|walking, non-walking|"In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.
In non-training period, patients don't walking at community."
1814010|NCT00686673|Behavioral|Providing tailored message on disclosing terminal illness|an experimental intervention group that receives a decision aid consisting of targeted educational video and manual providing a protocol for disclosing terminal illness and aimed at improving communication between patients and their family
1814011|NCT00686673|Behavioral|Providing non-tailored message on pain control|an attention control group that receives non-tailored video and manual on pain control
1814012|NCT00686686|Biological|Infliximab|Intravenous infliximab 5 mg/kg given over a 2-hour period at Weeks 0, 2, and 6 and possibly at week 12.
1814013|NCT00686699|Drug|Preladenant|capsules
1814014|NCT00686699|Drug|Placebo|capsules
1814015|NCT00686712|Drug|1- Insulin glargine QHS|Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings <120 mg/dL)
1814016|NCT00686712|Drug|2 - Insulin glargine QAM|Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings <120 mg/dL)
1814017|NCT00686712|Drug|3 - NPH insulin QHS|NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses <120 mg/dL)
1994406|NCT03013673|Other|No intervention|No intervention
1814020|NCT00686751|Drug|paricalcitol|Dosage Form: Intravenous administration. Dosage: 0.01 micrograms/kilogram of body weight. Frequency: 2 HD treatments of each study week (depending on phase of study). Duration: 4 weeks.
1814021|NCT00686764|Other|Observational|"Using ultrasound, we will measure the cross-sectional area of the neuroma at its widest point and compare to the cross-sectional area of the same nerve at the lesser trochanter.
We will be using four different metrics for quantifying the pain experience of each subject: Questionnaire for Persons with Transfemoral Amputation (Q-FTA), Trinity Amputation and Prosthesis Experience Scales (TAPES), Visual Analog Scale (VAS), and the Short-Form 36 (SF-36)."
1814022|NCT00686777|Biological|Pegylated Interferon alfa-2b|Pegylated Interferon alfa-2b 1.5 ug/kg SC once weekly for 48 weeks
1814023|NCT00686777|Drug|Ribavirin|Ribavirin 400 mg/day orally
1814024|NCT00686790|Biological|Peginterferon alfa-2b (PegIntron, SCH 54031)|Peginterferon alfa-2b 1.5 mcg/kg/wk subcutaneously (SC) for 52 weeks.
1814025|NCT00686803|Drug|PL3994|Study drug
1814026|NCT00686803|Drug|Placebo|Placebo
1814027|NCT00686816|Dietary Supplement|Low calorie diet|low calorie diet
1814028|NCT00686816|Dietary Supplement|Olestra|low calorie Olestra diet
1814029|NCT00686829|Drug|Vicriviroc maleate|30 mg tablet for once daily oral administration until vicriviroc becomes commercially available.
1814030|NCT00686842|Drug|VEGF inhibitor PTC299|20 mg capsules to be taken by mouth BID. Three dose levels will be evaluated: 40 mg, 80mg, and 100mg BID. Subjects will receive PTC299 in consecutive 28-day cycles for a maximum of 12 cycles.
1814031|NCT00686842|Genetic|gene expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
1814032|NCT00686842|Genetic|polymerase chain reaction|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
1814033|NCT00686842|Genetic|protein expression analysis|To describe the effects of PTC299 on viral gene expression and cellular gene transcription in KS tumor biopsies using real-time QPCR-based profiling.
1815435|NCT00696657|Drug|semaglutide|0.8 mg, once weekly, s.c. injection
1814034|NCT00686842|Other|immunohistochemistry staining method|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
1814035|NCT00686842|Other|laboratory biomarker analysis|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
1814036|NCT00686842|Other|pharmacological study|To describe the pharmacokinetics of PTC299 in patients with HIV-associated KS. To describe the effects of PTC299 on circulating VEGF, VEGFR and cytokine levels in patients with HIV-associated KS.
1814037|NCT00686842|Procedure|biopsy|To describe the effects of PTC299 on KS tumor biopsies with respect to expression of VEGF, the VEGFR-2 and -3, phospho-Akt, p53, HIF-1α and proliferation, measured by Ki-67 staining.
1814038|NCT00686855|Drug|Tacrolimus|Tacrolimus elixir taken as an oral rinse four times a day for 4 weeks
1814039|NCT00686855|Drug|Dexamethasone|Dexamethasone elixir taken as an oral rinse 4 times a day for 4 weeks
1814040|NCT00686868|Other|placebo|placebo
1814041|NCT00686868|Drug|ofatumumab|fully human anti-CD20 monoclonal antibody
1814042|NCT00686881|Biological|Peginterferon alfa-2b (PegIFN-2b)|PegIFN-2b administered at a dose of 0.5 ug/kg SC once a week for 156 weeks
1814043|NCT00686881|Drug|Comparator: Stronger neo minophagen C (SNMC)|SNMC (as glycyrrhizin-containing compound) administered at 40 mL by intravenous (IV) injection or IV infusion 3 times weekly for 156 weeks .
1814044|NCT00686894|Procedure|PDUS|PDUS scored for each enthesitis every 2 weeks for 24 weeks.
1814045|NCT00686894|Drug|Infliximab|"5 mg/kg
IV
Frequency : weeks 0,2,6"
1814046|NCT00686907|Drug|Melatonin|Dose range: 0.01 mg - 20 mg, daily, up to 5 years (based on each subject's circadian rhythms and response to the dose).
1814047|NCT00686920|Drug|rifaximin|Tablets
1814048|NCT00686933|Drug|ABT-089|Subjects will take up to 80 mg daily for 24 months
1814049|NCT00686959|Drug|Pemetrexed|infusion over 10 minutes
1814050|NCT00686959|Drug|Cisplatin|infusion over 60 minutes with adequate anti-emetic treatment and appropriate hydration per local practice guidelines
1814051|NCT00686959|Drug|Etoposide|administered per local practice guidelines over a minimum of 30 minutes
1814052|NCT00686959|Drug|Vinorelbine|administered over 6-10 minutes infusion per local practice guidelines
1814053|NCT00686959|Drug|Paclitaxel|administered as a 3-hour infusion
1814054|NCT00686959|Drug|Carboplatin|administered per local practice guidelines over 30 minutes
1814055|NCT00686959|Radiation|Thoracic Radiation Therapy (TRT)|
1814056|NCT00686972|Drug|GLP-1|5 ng/kg/min, IV for 1 hour during each clamp study (7) over 2 year period.
1814057|NCT00686985|Drug|Carboplatin, docetaxel|Carboplatin AUC 5, Docetaxel 75 mg/m2, q 3 weeks, 4-6 cycles, 12-18 weeks
1814058|NCT00686998|Drug|AZD2624|Oral Suspension
1814059|NCT00686998|Drug|Olanzapine|PO BID
1814060|NCT00686998|Drug|Placebo|
1814061|NCT00687011|Drug|Palonosetron and Dexamethasone|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent, plus single IV dose of dexamethasone 8 mg administered 15 minutes before chemotherapy (in the event of a shortage of IV dexamethasone, a single oral dose of dexamethasone 20 mg or a single IV dose of methylprednisolone 125 mg could be administered).
1814062|NCT00687024|Procedure|Magnetoencephalography|MEG will be performed on a whole head Omega 151-channel gradiometer system. At least 15 2-minute periods of spontaneous data are recorded. The sampling rate for data acquisition is 625Hz, with a bandpass filter of 3 to 70 Hz and a notch filter of 60Hz.
1814063|NCT00687024|Procedure|MR imaging|MR imaging will be performed on a GE 1.5T system using a variety of sequences, including sagittal T1, axial T2, axial FLAIR, coronal dual echo, coronal FLAIR, axial 3D T2 frFSE and axial SPGR.
1814064|NCT00687024|Procedure|Diffusion Tensor Imaging|Diffusion tensor imaging will be performed on the same scanner, using single shot diffusion-weighted echo planar imaging. Twenty-five 'xial contiguous slices are obtained aligned to the anterior commissure line to cover the whole brain, giving a total imaging time of 4min 40sec.
1814065|NCT00687037|Drug|Cetylpyridinium chloride|
1814066|NCT00687050|Dietary Supplement|peroral high-caloric supplemental nutrition|HIV-positive hemodialysis patients will be given daily supplemental nutrition (125 ml, 2 kcal/ml) on top of recommended high-protein, high-caloric regular diet
1814067|NCT00687050|Dietary Supplement|peroral supplemental nutrition|Chronic hemodialysis patients will be given daily peroral supplemental nutrition (125 ml/d, 2 kcal/ml) on top of their recommended high-protein, high caloric diet
1814068|NCT00687063|Drug|insulin detemir|Start dose and frequency of insulin detemir is to be decided by physician. The choice of patient is also at the discretion of Physician
1814069|NCT00687076|Drug|Ezetimibe|Daily dose of 10 mg of Ezetimibe
1814070|NCT00687076|Drug|Niaspan|Daily dose of 1500 mg of Niaspan
1814071|NCT00687076|Drug|Statin therapy|Daily dose of 40 mg of Simvastatin (If unable to tolerate Simvastatin, participants will take a daily dose of Atorvastatin.)
1814072|NCT00687076|Behavioral|Standard care|Standard of medical care for PAD
1814073|NCT00687076|Drug|Aspirin|Daily dose of 325 mg of aspirin
1814074|NCT00687076|Drug|Clopidogrel|Daily dose of 75 mg of clopidogrel for 3 months or as recommended by the primary care physician
1814075|NCT00687076|Drug|Placebo Niaspan|Daily dose of 1500 mg of placebo Niaspan
1814076|NCT00687076|Drug|Placebo Ezetimibe|Daily dose of 10 mg of placebo Ezetimibe
1814077|NCT00687076|Procedure|Percutaneous transluminal angioplasty (PTA)|Participants who have not had an endovascular intervention in the 3 months before study entry will undergo PTA to mechanically open the artery blockages. This procedure will involve the inflation and deflation of a small balloon to open the blocked artery. Additionally, participants may have a metal mesh tube called a stent placed in the blocked area if deemed necessary by their physicians.
1814078|NCT00687089|Other|Sexual, cognitive functional tests and measurement weight|
1821186|NCT00738335|Other|mass spectrometry|
1814084|NCT00687128|Behavioral|Low-intensity treadmill exercise|Treadmill walking at 30% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
1814085|NCT00687128|Behavioral|Moderate-intensity treadmill exercise|Treadmill walking at 60% of VO2Reserve, 3-5 times per week at 20-60 minutes per session, progressive.
1814086|NCT00687128|Behavioral|Non-aerobic stretching exercise|Floor stretching exercise, 3-5 times per week at 20-60 minutes duration per session, progressive.
1814087|NCT00687141|Drug|AZD0328|Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.
1814088|NCT00687141|Drug|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 14.
1814089|NCT00687154|Procedure|Scatter Laser Photocoagulation in 1 Sitting|1 sitting with a minimum of 1200 to a maximum of 1600 burns, with one burn width separation of burns and scatter extending from the peripheral arcades to beyond the equator.
1814090|NCT00687154|Procedure|Scatter Laser Photocoagulation in 4 Sittings|4 sittings, each separated by four weeks (+4 days), with approximately 300 burns in each of the first two sittings and investigator judgment for number of burns for the third and fourth sittings as long as the total for the four sittings is between 1200 and 1600 burns.
1814091|NCT00687167|Drug|Zonisamide 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
1814092|NCT00687167|Drug|Zonisamide (Zonegran®) 100 mg Capsule|100 mg capsule administered 30 minutes after initiation of standardized, high-fat breakfast.
1814093|NCT00687180|Drug|Treatment with mycophenolat mofetil|
1814094|NCT00687180|Drug|Treatment with azathioprin|
1814095|NCT00687193|Drug|Placebo|Placebo BID, 3 blinded tablets administered BID for 12 weeks
1814096|NCT00687193|Drug|CP-690,550|10mg BID, 3 blinded tablets administered BID for 12 weeks
1814097|NCT00687193|Drug|CP-690,550|15mg BID, 3 blinded tablets administered BID for 12 weeks
1814098|NCT00687193|Drug|CP-690,550|1mg BID, 3 blinded tablets administered BID for 12 weeks
1814099|NCT00687193|Drug|CP-690,550|3mg BID, 3 blinded tablets administered BID for 12 weeks
1814100|NCT00687193|Drug|CP-690,550|5mg BID, 3 blinded tablets administered BID for 12 weeks
1814101|NCT00687206|Drug|Valsartan 160mg plus HCT 25mg|valsartan 160 mg once a day for 6 months plus hydrochlorothiazide 25 mg a tablet once a day for 6 months
1814102|NCT00687219|Biological|Peginterferon alfa-2b|Administered at 1.0 µg/kg/week SC for 48 weeks
1814103|NCT00687219|Drug|Ribavirin|Administered based on body weight and hemoglobin value at Screening: 600-1000 mg/day for subjects with hemoglobin value at screening >=14g/dL, and 400-800 mg/day for subjects with hemoglobin value at screening >=12g/dL and <14g/dL; treatment duration is 48 weeks
1814104|NCT00687232|Drug|AZD4818|Dry powder, inhalation, b.i.d, 10 + 1/2 days or 20 + 1/2 days
1814105|NCT00687232|Drug|Placebo|
1814106|NCT00687245|Drug|esomeprazole magnesium|capsules, oral, qd, one day
1814107|NCT00687258|Device|VitabranE ViE|Polysulfone dialyser with vitamin E alpha-tocopherol
1814108|NCT00687258|Device|APS-U (Asahi Polysulfone APS)|PS Polysulfone dialyser without vitamin E alpha-tocopherol
1814109|NCT00687271|Drug|MK6213|MK6213 160mg for 4 weeks.
1814110|NCT00687271|Drug|Comparator: atorvastatin calcium|atorvastatin calcium 20mg for 4 weeks.
1814111|NCT00687271|Drug|Comparator: placebo (unspecified)|Duration of Treatment: 4 Weeks
1814112|NCT00687284|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1814113|NCT00687297|Drug|vandetanib induction|100 mg daily by mouth
1814114|NCT00687297|Drug|Docetaxel|(75mg/m2) IV (in the vein) on day 1 of a 21-day cycle for 4 cycles or until disease progression
1814115|NCT00687297|Drug|Carboplatin|IV (in the vein) to area under the curve (AUC) of 6 on day 1 of a 21 day cycle, for 4 cycles or until disease progression
1814116|NCT00687297|Drug|Placebo|
1814117|NCT00687297|Drug|Vandetanib maintenance|300 mg daily by mouth
1814118|NCT00687310|Behavioral|Educational intervention|Tailored asthma education based on needs assessment
1814119|NCT00687323|Drug|temozolomide|
1814120|NCT00687336|Other|Empirical Hp eradication|Empirical Helicobacter pylori treatment initiated immediately after oral intake is resumed
1814121|NCT00687336|Other|Eradication treatment guided by a positive test|Eradication treatment given if there is at least one positive diagnostic test (URT, histological test, breath test or serology) for Helicobacter pylori.
1814122|NCT00687349|Behavioral|Training Program Intervention|Resident or NP Student receives the educational intervention during 8 half-day sessions.
1814123|NCT00687362|Biological|Infliximab|Infliximab 5 mg/kg of body weight given as an infusion at Weeks 0, 2, 6, 14, and 22.
1814124|NCT00687375|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using Transabdominal preperitoneal (TAPP) Approach
1814125|NCT00687375|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair using totally extra peritoneal (TEP) Approach
1814126|NCT00687388|Drug|selective alpha 1-blockers|Continued medication that the patient had before the enrollment of this study (tamsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks)
1814127|NCT00687388|Drug|celecoxib|200mg daily for 8 weeks
1814128|NCT00687388|Drug|alpha-blocker and NSAID|amsulosin 0.2mg, alfuzosin 10mg, doxazosin 4, 8mg, or terazosin 2-10mg daily for 8 weeks and celecoxib 200mg daily for 8 weeks
1814129|NCT00687401|Biological|Infliximab|Infliximab 5 mg/kg of body weight administered as an infusion at Weeks 0, 2, 6 (induction phase), and 14 (maintenance phase).
1814130|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|"Group A:
Full assessment (using the various measures described) will be carried out 0-3 weeks since referral.
Treatment will focus on the patient's needs and in accordance with the physicians requests.
Three months post initial treatment re-assessment will be conducted."
1814131|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group B Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
1814132|NCT00687427|Behavioral|Questionnaires and motor/sensitivity testing|Group C Researcher will contact by phone previous patients that were treated in the occupational therapy department in the past half year and a year, in order to get their permission to participate (retrospectively) in this research. After getting their consent, a questionnaire concerning their RTW will be posted to the subjects.
1814133|NCT00687440|Drug|Pegylated Liposomal Doxorubicin|"Stage 1: 25 subjects will be treated with Caelyx IV 30 mg/m^2 on day 1, every 3 weeks
Stage 2: 45 new patients will be treated at the recommended dose level (defined in the first step) on day 1, every 3 weeks."
1814134|NCT00687440|Drug|Docetaxel|Stage 1 and Stage 2: Docetaxel 60 mg/m2 IV as 1-hour infusion, on day 1, every 3 weeks.
1814135|NCT00687440|Drug|Trastuzumab|Stage 1 and Stage 2: 4 mg/kg IV 90-minute infusion loading dose. Then 2 mg/kg IV weekly during 6 cycles (18 weeks).
1814136|NCT00679640|Drug|Candesartan|Oral tablets
1814137|NCT00679653|Drug|sibutramine|8-wks, sibutramine, 10 mg, capsules, once daily
1814138|NCT00679653|Drug|sibutramine|8-wks, sibutramine, 15 mg, capsules, once daily
1814139|NCT00679653|Drug|verapamil/trandolapril|2 wk Run-in phase, antihypertensive therapy only
1814140|NCT00679653|Drug|metoprolol/HCT|2 wk Run-in phase, antihypertensive therapy only
1814141|NCT00679653|Drug|felodipine/ramipril|2 wk Run-in phase, antihypertensive therapy only
1814142|NCT00679666|Drug|Riboflavin|01% riboflavin drops for 30 minutes q 3 minutes before and during the procedure with exposure to UVA light for the second 30 minutes
1814143|NCT00679666|Drug|Placebo|Drops are given q 3 minutes before (30 minutes) and during the procedure (30 minutes) but without the use of UVA light. No activation of cross linking occurs.
1814146|NCT00679705|Drug|Ritodrine|Ritodrine (Pre-Par), maximum 400 µg/minute, IV
1814147|NCT00679705|Drug|Atosiban|Atosiban (Tractocile), maximum 300 µg/minute, IV
1814148|NCT00679705|Drug|Placebo|Glucose 5%, IV
1814149|NCT00679718|Drug|diquafosol tetrasodium (INS365) ophthalmic solution|
1814150|NCT00679731|Drug|ABT-874|200 mg at week 0 and 4 and 100mg at week 8 and every 4 weeks there after administered as aSQ injection
1814151|NCT00679731|Drug|Methotrexate|5.0 to 25 mg weekly
1814152|NCT00679744|Drug|Pyrimethamine|Pyrimethamine will be given PO once daily for 8 consecutive weeks.
1814153|NCT00679770|Drug|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
1814154|NCT00679770|Drug|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
1814155|NCT00679770|Drug|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
1814156|NCT00679770|Drug|Vehicle|Once daily application for 90 days and 3x weekly for 90 days
1814157|NCT00679783|Drug|AZD2281|PARP inhibitor
1814158|NCT00679796|Procedure|Varicella (chickenpox) lesion sampling|
1814159|NCT00679835|Drug|daptomycin|i.v. daptomycin given at 8 mg/kg or 10 mg/kg by a one or two hour infusion.
1814160|NCT00679848|Device|RS2 (RESTORe Suturing System)|Suturing in stomach
1814161|NCT00679861|Behavioral|Counselling Intervention|A personal counselling by the residing practitioner of up to 10 minutes. A follow-up counselling is included for the next regular patient consultation
1814162|NCT00679861|Behavioral|Expert-system intervention|Counselling letter of three to four pages will be generated by an expert-system base on the assessment of the patient. A second and third letter will be generated at follow-up consultations.
1814163|NCT00679874|Other|Cardio-vascular MRI|Contrast enhanced CMR studies at baseline, in the middle of chemotherapy and as follow-up
1814164|NCT00679887|Procedure|ischemic compression|Active Comparator, ischemic compression, 3 times a week,5 weeks
1814165|NCT00679900|Drug|eplivanserin (SR46349)|5 mg/day
1814166|NCT00679900|Drug|lormetazepam|1 mg/day
1814167|NCT00679913|Procedure|Standard pancreatoduodenectomy|Standard pancreatoduodenectomy
1814168|NCT00679913|Procedure|Extended pancreatoduodenectomy|Extended pancreatoduodenectomy
1814170|NCT00679939|Drug|Rosiglitazone|up to 8mg/day
1814171|NCT00679939|Drug|Metformin|up to 2000mg/day
1814172|NCT00679952|Procedure|closed suction drainage of pancreatic duct|A Fr 5-8 silastic polyethylene pediatric feeding tube with multiple side-holes is inserted 2 cm into the pancreatic duct. The catheter exited via a small enterotomy in the jejunal loop of the distal portion of the hepaticojejunostomy. Totally externalized pancreatic stents were connected to the aspiration bag of a Jackson-Pratt drain to generate negative pressure or to a bile bag for natural drainage.
1814173|NCT00679952|Procedure|natural drainage of pancreatic duct|Natural drainage group
1814174|NCT00679965|Drug|AN2690, 2.5%|Once daily application for 90 days and 3 x weekly for 90 days
1814175|NCT00679965|Drug|AN2690, 5%|Once daily application for 90 days and 3 x weekly for 90 days
1814176|NCT00679965|Drug|AN2690, 7.5%|Once daily application for 90 days and 3 x weekly for 90 days
1814177|NCT00679965|Drug|AN2690 Solution Vehicle|Once daily application for 90 days and 3x weekly for 90 days
1814178|NCT00679991|Drug|PRT-201|Applied topically to AVF during surgery
1814179|NCT00679991|Drug|PRT-201|Dose escalation study. Drug/placebo administered at the time of fistula creation
1814180|NCT00680017|Drug|ABT-335 plus rosuvastatin|ABT-335 45 mg plus rosuvastatin 5 mg for 8 weeks, then ABT-335 45 mg plus rosuvastatin 10 mg for 8 weeks
1814181|NCT00680017|Drug|Rosuvastatin|Rosuvastatin 5 mg for 8 weeks then rosuvastatin 10 mg for 8 weeks
1814182|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.04 milligram per kilogram (mg/kg); the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 grams per deciliter (g/dL).
1814183|NCT00680043|Drug|peginesatide|Participants received peginesatide by intravenous injection once every 4 weeks at the starting dose of 0.08 mg/kg; the dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
1814235|NCT00680433|Drug|Saline|Saline (placebo) will be administered after the normal anaesthetic agents in ECT.
1814184|NCT00680043|Drug|Epoetin Alfa|Participants received Epoetin alfa by intravenous injection three times a week at the starting dose of 50 Units/kg. The dose was adjusted throughout the study to maintain a hemoglobin target range of 11.0-12.0 g/dL.
1814185|NCT00680056|Drug|Formoterol plus Placebo (Tiotropium)|Formoterol 12mcg-capsules (2x/d) + Placebo (Tiotropium) (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
1814186|NCT00680056|Drug|Formoterol plus Tiotropium|Formoterol 12mcg-capsule (2x/dia) + Tiotropium 18mcg-capsule (1x/d). Double-blind medication will be dispensed in HandiHalers and Aerolisers during 2 weeks.
1814187|NCT00680069|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion influenza A/H5N1/Indonesia/05/05 (clade 2) vaccine administered via intramuscular injection. Low Dose Group will receive 15 mcg intramuscularly (IM), High Dose Group will receive 90 mcg IM. Subjects who received previous clade 1 vaccine will receive 1 dose, clade 1 vaccine-naive subjects will receive 2 doses 28 days apart.
1814188|NCT00680095|Drug|AN2690|AN2690 Solution, 2.5%, Daily for up to 21 days
1814189|NCT00680095|Drug|AN2690|AN2690 Solution, 7.5%, Daily for up to 21 days
1814190|NCT00680095|Drug|AN2690|AN2690 Solution, 5.0%, Daily for up to 21 days
1814191|NCT00680095|Other|AN2690 Solution, Vehicle|AN2690 Solution, Vehicle, Daily for up to 21 days
1814192|NCT00680095|Other|Sodium Lauryl Sulfate, 0.5%|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
1814193|NCT00680108|Drug|diquafosol tetrasodium (INS365) ophthalmic solution|
1814194|NCT00680121|Drug|Benfotiamine|Benfotiamine 600 mg
1814195|NCT00680121|Drug|Placebo|Placebo
1814196|NCT00680134|Drug|AN2690|AN2690 1% Solution, once daily for 180 days
1814197|NCT00680134|Drug|AN2690|AN2690 5% Solution, once daily for 30 days; 3x weekly for 150 days
1814198|NCT00680147|Behavioral|brief informational intervention to promote HPV vaccine acceptance|Teen and parent participants will receive a brief informational intervention that provides basic facts about the HPV vaccine, including the health benefits and three-dose requirements, along with information regarding where to go to receive the vaccination. A coupon for a free HPV vaccination will provided to the parent for use by their teenage daughter.
1814199|NCT00680160|Drug|AN2690|AN2690 7.5% Solution, once daily for 28 days
1814200|NCT00680173|Drug|pegylated interferon alpha 2a and plus ribavirin|pegylated interferon alpha 2a 180 mcg/week and Ribavirin 1000-1200 mg/day for 24 weeks, follow up for 24 weeks
1814201|NCT00680186|Drug|Warfarin|PRN (to maintain a target INR of 2.0-3.0)
1814202|NCT00680186|Drug|Dabigatran etexilate|150mg bid
1814203|NCT00680212|Dietary Supplement|dietary carotenoids|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene 0.5 mg oil capsule
1814204|NCT00680212|Dietary Supplement|spinach, rice, and synthetic beta-carotene|spinach containing 1 - 2 mg beta-carotene rice containing 0.5 mg beta-carotene synthetic beta-carotene, 0.5 mg oil dose
1814205|NCT00680225|Drug|Ranibizumab injection and TTT - ICG based|Intravitreal injection of ranibizumab (0.5mg) once a month for 6 months and transpupillary thermotherapy enhanced with Indocyanine Green (ICG) dye, once or twice starting at 2nd month.
1814206|NCT00680238|Drug|Human derived FSH|Customized for each patient
1994407|NCT03013218|Drug|ALX148|ALX148
1814209|NCT00680290|Procedure|Exercise|Exercise x 8 weeks
1814210|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
1814211|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
1814212|NCT00680303|Behavioral|The Lidcombe Program for early stuttering|
1814213|NCT00680316|Drug|Dornase alfa|2.5 mL (2.5 mg) dornase alfa nebulized once daily for 16 (+/-2) days
1814214|NCT00680316|Drug|Placebo|2.5 mL (2.5 mg) placebo nebulized once daily for 16 (+/-2) days
1814215|NCT00680329|Drug|Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)|One drop in study eye(s) once daily in the evening for four months
1814216|NCT00680329|Device|Travalert Dosing Aid|Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence
1814217|NCT00680342|Drug|Silymarin|700mg dose (5 pills, three times daily) for 24-week treatment period
1814218|NCT00680342|Drug|Silymarin|420mg dose (5 pills, three times daily) for 24-week treatment period
1814219|NCT00680342|Other|Placebo|Placebo (5 pills, three times daily) for 24-week treatment period
1814220|NCT00680355|Dietary Supplement|golden rice|An acute dose of cooked golden rice containing ~ 1 mg of ß-carotene
1814221|NCT00680355|Dietary Supplement|corn oil 0g|0 g of corn oil in the golden rice meal
1814222|NCT00680355|Dietary Supplement|corn oil 10g|10g corn oil in the golden rice meal
1814223|NCT00680355|Dietary Supplement|coren oil 5 g|golden rice meal with 5 g corn oil
1814224|NCT00680381|Behavioral|MTI, Minimal Transitional Intervention|Following 12 weeks of Functional Family Therapy (FFT), semi-weekly phone calls from a therapist for eight weeks.
1814225|NCT00680381|Behavioral|GTI, Group Transitional Intervention|Following 12 weeks of FFT, weekly one-hour sessions of group therapy for eight weeks.
1814226|NCT00680381|Behavioral|STI, Systems Transitions Intervention|Following 12 weeks of FFT, an individualized eight-week series of therapist meetings with the adolescent, family, police, teachers, coaches and others who can support the adolescent's reduced drug use.
1814227|NCT00680394|Drug|mifepristone|200 mg mifepristone
1814228|NCT00680394|Drug|misoprostol|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
1814229|NCT00680394|Drug|placebo|800 buccal misoprostol + matching placebo or 1600 buccal misoprostol
1814230|NCT00680407|Other|Placebo|Placebo (5 pills, three times daily) for 48-50 week treatment period
1814231|NCT00680407|Drug|Silymarin 700 mg|700 mg dose (5 pills, three times daily) for 48-50 week treatment period
1814232|NCT00680407|Drug|Silymarin 420 mg|420 mg dose (5 pills, three times daily) for 48-50 week treatment period
1814233|NCT00680420|Procedure|fine needle aspiration biopsy|One extra biopsy will be taken from the pancreas only in patients who are already undergoing biopsy of a mass or cyst.
1814234|NCT00680433|Drug|Ketamine|Ketamine IV will be administered after the administration of the normal anaesthetic agents for ECT.
1814236|NCT00680446|Drug|Immunoglobulin G (Ig NextGen 16%)|Weekly or Bi-weekly subcutaneous administration of Immunoglobulin G
1814237|NCT00680459|Drug|70% ethanol|70% ethanol lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. 70% ethanol solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
1814238|NCT00680459|Drug|heparin flush solution|heparin flush (10 units/ml) lock solution instilled into central venous line of patient with documented infection, in addition to usual care with antimicrobials and supportive therapy. Volume of solution instilled varies from 0.8-1.9ml depending on volume of the lumen and hub of the particular size line being treated. Heparin lock solution dwells for 4 hours, then is withdrawn and discarded. This procedure repeated daily for 5 consecutive days.
1814239|NCT00680472|Drug|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
1814240|NCT00680472|Other|Placebo Patch|Treatment with Placebo Patch
1814241|NCT00680485|Drug|GSK580416 oral tablets (250 mg) Ketoconazole oral tablets (200 mg)|
1814244|NCT00680511|Behavioral|Adolescent Methamphetamine Treament (AMT)|AMT Group Therapy plus Functional Family Therapy (FFT)
1814245|NCT00680511|Behavioral|Functional Family Therapy (FFT)|FFT
1814246|NCT00680524|Other|Phone-based outreach|Nurse care managers will use a phone call outreach intervention with structured templated notes to help deliver evidence-based care for PTSD
1814247|NCT00680537|Procedure|Exercises|Completion of a series of shoulder exercises for 6 weeks post device implant
1814248|NCT00680563|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose 1.2 micrograms/kg)
1814249|NCT00680576|Behavioral|CBT, Cognitive Behavioral Therapy|Eight weekly sessions of individual Cognitive Behavioral Therapy, to develop skills enabling adolescents stop or reduce their drug use.
1814250|NCT00680576|Behavioral|FFT, Family Functional Therapy|Eight weekly sessions of Functional Family Therapy designed to strengthen family relationships and build skills to help the adolescent stop or reduce his/her drug use.
1814251|NCT00680589|Biological|injection of mouse TYRP2 DNA|Cohorts of three patients will receive injections with mouse TYRP2 DNA delivered intramuscularly at four different dose levels (500, 2000, 4000 or 8000 μg) every three weeks for six injections.
1814252|NCT00680602|Behavioral|Group Cognitive Behavior Therapy|Structured protocol described by Cordioli et al., 2003
1814253|NCT00680602|Drug|SSRI (fluoxetine, sertraline, paroxetine, citalopram)|Fluoxetine (80mg/day or maximum tolerated dosage) Sertraline (200mg/day or maximum tolerated dosage) Paroxetine (60 mg/day or maximum tolerated dosage) Citalopram (60 mg/day or maximum tolerated dosage)
1814254|NCT00680615|Behavioral|Tailored, enhanced condition|Intervention will provide a personalized, interactive tobacco cessation Web application, based on existing empirically validated smokeless tobacco cessation programs.
1814255|NCT00680615|Behavioral|Usual Care|The Usual Care condition will provide access to typical smokeless tobacco cessation information and links to commonly available Web-based smokeless tobacco cessation resources.
1814256|NCT00680628|Drug|Tenecteplase + Enoxaparin|"Enoxaparin: 1 mg/kg within 12 hours before receiving tenecteplase.Subsequently, patients will receive 1 mg/kg enoxaparin SQ Q12 hours until discontinuation is clinically indicated.
Tenecteplase:will be administered using a tiered-dosing schedule according to patient weight: <60Kg=30mg; ≥60Kg to <70Kg=35mg; ≥70Kg to <80Kg=40mg; ≥80Kg to <90Kg=45mg; ≥90Kg=50mg"
1814257|NCT00680628|Drug|0.9% Saline + Enoxaparin|Enoxaparin: 1 mg/kg within 12 hours before receiving saline.
1814258|NCT00680641|Drug|Simvastatin|40mg of Simvastatin once daily
1814259|NCT00680641|Drug|Placebo|40mg of placebo once daily
1814260|NCT00680654|Drug|Riociguat (Adempas, BAY63-2521)|The investigational drug will be given twice per subject, as single dose administration of BAY 63-2521 (0.5 mg and 1.0 mg) during the hemodynamic investigation.
1814261|NCT00680667|Biological|Coriolus versicolor extract|Trametes versicolor (Tv) capsules at the assigned dose level (3 grams/day up to 24 grams/day) twice a day every day and continuing for weeks.
1814262|NCT00680680|Drug|Dutasteride|Patients will continue on their alpha blocker in addition to Dutasteride 0.5mg daily for a maximum of 3 months
1814263|NCT00680693|Behavioral|Mindfulness training|8 weekly 2-hour classes
1814264|NCT00680693|Behavioral|Psycho-educational support group for women with IBS|8 weekly 2-hour meetings
1814265|NCT00680706|Drug|Thiamine|Thiamine (100 mg) in 50 ml D5W, x 2.
1814266|NCT00680706|Drug|Placebo|D5W (50 ml)
1814267|NCT00680719|Behavioral|IBFT /HIV prevention|Integrated Behavioral and Family Therapy (IBGT) with HIV prevention.
1814268|NCT00680719|Behavioral|IBFT|Integrated Behavioral and Family Therapy (IBFT).
1814269|NCT00680732|Dietary Supplement|Multiple micronutrients supplements (MMS)|Vitamin A 800 mcg; vitamin E 10 mg; vitamin D 5 mcg; vitamin B1 1.4 mg; vitamin B2 1.4 mg;niacin 18 mg; vitamin B6 1.9 mg; vitamin B12 2.6 mcg; folic acid 400 mcg; vitamin C 70 mg; iron 30 mg; zinc 15 mg; copper 2 mg; selenium 65 mcg; iodine 150 mcg
1814270|NCT00680732|Dietary Supplement|Iron and folic acid (IFA)|Iron 60 mg and folic acid 400 mcg
1814271|NCT00680732|Drug|Chloroquine (CQ)|Tablets 100 mg of chloroquine base
1814272|NCT00680732|Drug|Sulphadoxyne-pyrimethamine (SP)|Tablets
1814273|NCT00680745|Drug|dapagliflozin|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
1814274|NCT00680745|Drug|Glimepiride|tablet oral 2.5, 5, or 10 mg total daily dose once daily 48 weeks
1814275|NCT00680745|Drug|metformin hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
1814276|NCT00680745|Drug|pioglitazone hydrochloride|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
1814277|NCT00680745|Drug|Rosiglitazone|rescue medication oral dosing in accordance with the manufacturer's recommendations and clinical practice
1814329|NCT00681174|Drug|Morphine|0.15 mg/kg i.v. bolus, 30 minutes before the expected end of anesthesia
1814330|NCT00681174|Drug|oxycodone|20 mg p.o. 1 h before the start of anesthesia
1814278|NCT00680758|Drug|cisplatin|"Dose Level: -3 20mg/m2/week 3-6 patients
Dose Level: -2 20mg/m2/week 3-6 patients
Dose Level: -1 25mg/m2/week 3-6 patients
Dose Level: 1 25mg/m2/week 3-6 patients
Dose Level: 2 25mg/m2/week 3-6 patients
Dose Level: 3 25mg/m2/week 3-6 patients"
1814279|NCT00680758|Drug|everolimus|"Dose Level: -3 20mg/m2/week 3-6 patients
Dose Level: -2 20mg/m2/week 3-6 patients
Dose Level: -1 20mg/m2/week 3-6 patients
Dose Level: 1 20mg/m2/week 3-6 patients
Dose Level: 2 25mg/m2/week 3-6 patients
Dose Level: 3 30mg/m2/week 3-6 patients"
1814280|NCT00680758|Drug|paclitaxel|"Dose Level: -3 65mg/m2/week 3-6 patients
Dose Level: -2 70mg/m2/week 3-6 patients
Dose Level: -1 70mg/m2/week 3-6 patients
Dose Level: 1 80mg/m2/week 3-6 patients
Dose Level: 2 80mg/m2/week 3-6 patients
Dose Level: 3 80mg/m2/week 3-6 patients"
1814281|NCT00680784|Drug|HKT-500 Ketoprofen Topical Patch|HKT-500 Ketoprofen Topical Patch
1814282|NCT00680784|Other|Placebo Patch|Placebo Patch
1814283|NCT00680797|Drug|Testosterone|Testosterone gel
1814284|NCT00680797|Drug|Estrogen|Estrogen patch
1814287|NCT00680836|Drug|Placebo|orally two times per day for 14 days
1814288|NCT00680836|Drug|Rifaximin|550 mg orally two times per day for 14 days
1814289|NCT00680875|Behavioral|Click City|School-based intranet delivery of tobacco use prevention program for 5th and 6th graders using interactive and engaging game-like multi-media technology.
1814290|NCT00680901|Drug|Lapatinib|5 pills at 250mg each once daily
1814291|NCT00680901|Drug|Placebo|5 pills once daily
1814292|NCT00680901|Drug|Capecitabine|1700mg/m2/day in two daily doses
1814293|NCT00680901|Drug|Oxaliplatin|130mg/m2 on day 1
1814294|NCT00680914|Biological|Pneumococcal vaccine GSK1024850A (Synflorix)|3 doses administered intramuscularly.
1814295|NCT00680914|Biological|Prevenar|3 doses administered intramuscularly.
1814296|NCT00680914|Biological|GSK Biologicals' Hiberix™|3 doses administered intramuscularly.
1814297|NCT00680927|Other|46 hrs Holter ECG recording|Maximum of 2 46 hrs external Holter ECG recordings are required.
1814298|NCT00680940|Drug|Paclitaxel & Cisplatin|Chemotherapeutic agent
1814299|NCT00680940|Biological|Mycobacterium w.|Immunomodulator
1814300|NCT00680953|Drug|Denosumab|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
1814301|NCT00680953|Drug|Placebo|Subcutaneous injection every 6 months for 24 months, followed by a 12-month period of denosumab (subcutaneously - every six months).
1814302|NCT00680953|Drug|Alendronate sodium hydrate|Oral tablet once a week for 24 months
1814303|NCT00680966|Behavioral|Adolescent Coping With Depression/Functional Family Therapy|ACWD- Cognitive behavioral group therapy for depressed adolescents FFT - Family therapy to address substance use disorders in adolescents
1814304|NCT00680979|Behavioral|Interpersonal Psychotherapy|
1814305|NCT00680979|Behavioral|Health Education|
1814306|NCT00680992|Drug|Denosumab|120 mg administered subcutaneously (SC) every 4 weeks (Q4W) with a loading dose of 120 mg SC on study days 8 and 15.
1989507|NCT02472470|Device|rTMS|Participants will receive 10 active TBS rTMS sessions once daily on weekdays for 2 weeks.
1814309|NCT00681018|Other|Liquid human milk fortifier|Liquid human milk fortifier added to human milk
1814310|NCT00681018|Other|Powder human milk fortifier|Powder human milk fortifier added to human milk
1814311|NCT00681031|Biological|ZOSTAVAX®|One dose (0.65 mL) contains: Varicella-zoster virus, Oka/Merck strain, (live attenuated) not less than 19400 PFU
1814312|NCT00681044|Biological|filgrastim|16 mcg/kg daily beginning 3 days prior to SCC through day before final SCC
1814313|NCT00681044|Drug|melphalan|70-100 mg/m2/day will be administered intravenously on Days -3 and -2
1814314|NCT00681044|Procedure|Stem Cell Infusion|infusion of previously collected stem cells on Day 0
1814315|NCT00681070|Other|Arm 2: Absorbable sutures|use of absorbable catgut sutures in pediatric facial lacerations
1814316|NCT00681070|Other|Arm 1: non-absorbable sutures|Use of non-absorbing sutures
1814317|NCT00681083|Device|Heated breathing tube (CPAP with ThermoSmart)|CPAP with ThermoSmart - heated passover humidifier, with heated breathing tube
1814318|NCT00681083|Device|Non heated breathing tube (CPAP with conventional humidification)|CPAP with conventional humidification - heated passover humidifier, no heated breathing tube
1814322|NCT00681135|Device|sonic toothbrush (Philips Sonicare® FlexCare, Typ HX6942/04)|toothbrushing with a sonic toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
1814323|NCT00681135|Device|manual toothbrush / interdental toothbrush (elmex® Inter X medium toothbrush / interdental brush Curaprox®)|toothbrushing with a manual toothbrush and interdental brush and sealant coating (ProSeal™) of the enemal surface around the brackets
1814324|NCT00681135|Device|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush and sealant coating (ProSeal™) of the enemal surface around the brackets
1814325|NCT00681135|Device|manual toothbrush (elmex® Inter X medium toothbrush)|toothbrushing with a manual toothbrush without sealant coating of the enemal surface around the brackets
1814326|NCT00681148|Drug|Botox injection|Intraprostatic injection of Botox (100 units for < 30 cc prostate; 200 units for > 30 cc prostate) administering 2 transperineal injections into both lateral lobes of the prostate (25-50 units per injection), just 5-10 mm proximal to the bladder neck.
1814327|NCT00681148|Drug|Saline injection|Saline injection, administering 2 transperineal injections into both lateral lobes of the prostate (1-2 cc per injection), just 5-10 mm proximal to the bladder neck.
1814328|NCT00681161|Other|continuous positive airway pressure (CPAP)|Standard of care treatment for OSA, requires a mask attached by tubing to a device providing continuous pressure of air at a given cm of water pressure, acting as a splint to open airway at night to relieve obstruction.
1814331|NCT00681174|Procedure|Paravertebral block|"Three injections of 0.5% ropivacaine, 5 ml each
Injections at the T5, T6 and T7 levels
A 22G spinal needle will be used to contact the ipsilateral transverse process; the needle will be walked off the process and the injection will be made 1 cm deeper."
1814332|NCT00681174|Drug|Propofol|"Plasma concentration target-controlled infusion based on bispectral index values
Acceptable range of concentrations: 2-4 µg/mL
Target bispectral index values: 40-60
Infusion starts at 4 µg/ml target, after pre-oxygenation (i.e., start of anesthesia)"
1814333|NCT00681174|Drug|Remifentanil|"50 µg/mL i.v. solution infused at 0.05-0.2 µg/kg/min
Infusion starts 7 min before propofol infusion (i.e., start of anesthesia)
Infusion rate adjusted to maintain mean arterial blood pressure within ±20% of baseline values.
Infusion stopped after end of surgery and after patients are brought back to the supine position (i.e., end of anesthesia)"
1814334|NCT00681174|Drug|Paracetamol|1 g i.v. bolus 30 min before the end of anesthesia; 1 g i.v. bolus q8h thereafter.
1814335|NCT00681174|Drug|Morphine|"Patient-controlled intravenous infusion pump (IV-PCA).
50 mg morphine in 50 ml saline solution (1 mg/ml)
Incremental dose: 1 mg
Lock-out time: 8 min
Limit: 40 mg in 4 h
Background infusion: none"
1814336|NCT00681187|Drug|lanreotide (Autogel formulation)|90 mg or 120 mg once every 28th day
1814337|NCT00681200|Behavioral|Enhanced health education|health education and social support
1814338|NCT00681200|Behavioral|Transcendental Meditation program|The TM program plus didactic-based health education classes
1814339|NCT00681213|Drug|Tacrolimus/Sirolimus|
1814340|NCT00681213|Drug|Tacrolimus/MMF|
1814341|NCT00681213|Drug|Neoral/Sirolimus|
1814342|NCT00681226|Drug|Ramipril or matching placebo|10 mg Ramipril or matching placebo once daily for 6 months
1814343|NCT00681239|Dietary Supplement|Modified Atkins diet and KetoCal|10 gram per day Modified Atkins diet and 10 oz per day of KetoCal shake.
1814344|NCT00681252|Biological|URLC10, VEGFR1 and VEGFR2|Patients will be vaccinated twice a week for 8 weeks. On each vaccination day, the URLC10 peptide (1mg), VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection in combination with S-1 chemotherapy.
1814345|NCT00687453|Drug|Insulin glargine at bedtime instead of NPH|Insulin glargine at bedtime substituting for NPH insulin at bedtime
1814346|NCT00687453|Drug|NPH twice-daily|Addition of morning NPH to bedtime NPH
1814347|NCT00687466|Drug|Insulin|"Insulin Glargine will be administered subcutaneously at the dosage of 0.1 U/Kg/die for three months. In case no hypoglycemic episodes occur during this period, the dosage will be increased to 0.15 U/Kg/die in occasion of the first control (T1) and will be scheduled for other three months. If even during this latter period no cases no hypoglycemic episodes occur, at the second control (T2) the dosage will be increased to the maximum of 0.2/U/Kg/die. It is generally accepted that the final dosage of glargine can be tailored to each patient, but it should be maintained between 0.1 and 0.2 U/Kg/die.
Glargine should be administered once daily in the morning and always at the same hour."
1814348|NCT00687505|Drug|FP-1039|Intravenous weekly administration
1814349|NCT00687518|Drug|Erythropoietin|Intravenous injection of 50 U/kg of erythropoietin
1814350|NCT00687518|Drug|Placebo|Intravenous injection of equivalent volume of saline serum
1814351|NCT00687531|Drug|Mometasone Furoate|Mometasone Furoate 400 mcg once daily, in the evening through 12 weeks.
1814352|NCT00687544|Biological|Peginterferon alfa-2b (SCH 054031)|Subjects will be given peginterferon alfa-2b (PEG-IFN) subcutaneously, at a dose of 1.5 ug/kg weekly. Treatment duration will be 48 weeks for subjects with Hepatitis C Virus (HCV) genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline Hepatitis C Virus-ribonucleic acid (HCV-RNA) below 800,000 IU/mL.
1814353|NCT00687544|Drug|Ribavirin (SCH 018908)|Subjects will be given ribavirin 800 mg/day orally(PO) when body weight is <65 kg, 1000 mg/day when body weight is between 65 kg and 85 kg, and 1200 mg/day when body weight is >85 kg. Treatment duration will be 48 weeks for subjects with HCV genotype 1 and 24 weeks for subjects with HCV genotype 2 or 3 and baseline HCV-RNA below 800,000 IU/mL.
1814354|NCT00687570|Dietary Supplement|Fresubin Energy Drink|Fresubin energy drink 30 kcal/kg*dag-1, seven days before surgery
1814355|NCT00687570|Drug|Laxabon®|Laxabon® 4 litres starting the day before surgery
1814356|NCT00687596|Drug|TAC-101|Patients randomized to TAC 101 will receive TAC 101 20 mg (administered as 2 10 mg formulated tablets) PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) for 14 days followed by a 7 day recovery period. This cycle will be repeated every 21 days.
1814357|NCT00687596|Drug|Placebo|Patients randomized to placebo will receive 2 placebo tablets (identical in appearance to the TAC 101 tablets) administered PO daily with approximately 240 mL (8 oz) of water under fed conditions (no later than 1 hour after a meal) in a regimen identical to that for TAC 101.
1814358|NCT00687609|Drug|Atomoxetine|0.5 milligrams per kilogram (mg/kg) daily for 1 week followed by 1.2 mg/kg daily for 11 weeks, orally, capsules.
1814359|NCT00687622|Drug|GSK1120212|Part 1-dose-escalation Part 2 - Recommended Part 2 dose Part 3 - characterize the range of biologically effective doses
1814360|NCT00687648|Drug|anastrozole|Given as previously prescribed
1814361|NCT00687648|Drug|cyclophosphamide|Given by mouth
1814362|NCT00687648|Drug|exemestane|Given as previously prescribed
1814363|NCT00687648|Drug|letrozole|Given as previously prescribed
1814364|NCT00687648|Drug|methotrexate|Given by mouth
1814365|NCT00687648|Drug|prednisolone|Given by mouth
1814366|NCT00687661|Drug|Bisphosphonate|35mg given orally once weekly for 24 months
1814367|NCT00687661|Drug|Placebo|identical placebo pill once weekly for 24 months
1814368|NCT00687674|Drug|dexamethasone|20 mg orally Days 1, 8, 15, 22 of 28 day cycle
1814369|NCT00687674|Drug|sorafenib tosylate|Phase I - dose escalating: 200mg once daily dose level -2, 200mg once daily dose level -1, 200mg once daily dose level 0, 200mg twice daily dose level 1, 200mg twice daily dose level 2, 400mg AM & 200mg PM daily dose level 2a, 400mg twice daily dose level 3 orally days 1-28 every 28 days until progression
1814370|NCT00687674|Drug|Lenalidomide|Phase I - dose escalating: 5mg level -2, 10mg level -1, 15mg level 0, 15mg level 1, 25mg level 2, 25mg level 2a, 25mg level 3 orally days 1-21 every 28 days until progression
1814371|NCT00687687|Drug|paclitaxel|Paclitaxel will be administered IV over 3 hours on Day 1 every 21 days.
1814504|NCT00689052|Drug|pramipexole ER|
1814372|NCT00687687|Drug|carboplatin|Carboplatin will be administered intravenously (IV) over 30 minutes on day 1 after pacitaxel administration, every 21 days.
1814373|NCT00687687|Drug|BSI-201 (Iniparib)|BSI-201 will be administered IV over one hour twice weekly beginning on day 1 (doses of BSI-201 must be separated by at least 2 days).
1814374|NCT00687700|Drug|GSK961081|GSK961081 multidose dry powder inhaler (Diskus inhaler) will be available with dosing strengths of 400 micrograms and 1200 micrograms administered once daily in the morning.
1814375|NCT00687700|Drug|GSK961081 matching placebo|GSK961081 matching placebo multidose dry powder inhaler (Diskus inhaler) will be available to be administered once daily in the morning.
1814376|NCT00687700|Drug|Propranolol|Propranolol over encapsulated tablet will be available with dosing strengths of 40 milligrams administered orally with 240 milliliters of water.
1814377|NCT00687700|Drug|Propranolol matching placebo|Propranolol matching placebo over encapsulated tablet will be available to be administered orally with 240 milliliters of water.
1814378|NCT00687713|Drug|Bupropion|150mg for the first 3 days of dosing. Increased to 150 mg b.i.d until taper.
1814379|NCT00687713|Other|Placebo|Placebo
1814380|NCT00687726|Behavioral|Standing balance exercise|Standing balance and mini squat exercise performed 30 times/day/side, 5 days/week, for 4 weeks.
1814381|NCT00687726|Behavioral|Isometric knee extension exercise|Isometric knee extension exercise performed 10 repetitions/set, 3 sets/day, 5 days/week for 4 weeks
1814382|NCT00687739|Drug|leuprolide acetate|3.75 mg for depot suspension delivered by monthly intramuscular injection for 5 months
1814383|NCT00687739|Drug|Estradiol Transdermal|0.075 mg patch per day for 5 months
1814384|NCT00687739|Behavioral|progressive resistance exercise training|45 minute exercise sessions 4 times per week for 5 months
1814385|NCT00687765|Drug|bsi-201 plus temozolomide|BSI-201 given iv. 2x weekly, temozolomide given orally
1814386|NCT00687791|Device|ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery|Study of the safety and effectiveness of the ologen™ Collagen Matrix Implant as an aid in phacotrabeculectomy surgery
1814387|NCT00687804|Drug|Ranibizumab|0.5 mg ranibizumab administered by intravitreal injection.
1814388|NCT00687804|Procedure|Laser|Laser photocoagulation treatment
1814389|NCT00687804|Procedure|Sham laser|Sham to laser procedure.
1814390|NCT00687804|Drug|Sham to ranibizumab|Sham to ranibizumab administered as an intravitreal injection.
1814391|NCT00688233|Device|Seifi's Functional|Patient with Class II Division 1 and Deepbite malocclusion will wear the Seifi's Functional to get the benefit of skeletal and dentoalveolar correction.
1814392|NCT00688246|Other|biologic sample preservation procedure|Increased bone turnover may be a risk factor for fracture [Lønning 2005]. However, it is uncertain whether markers of bone resorption and markers of bone formation are both associated with fracture risk [Looker 2000]. Therefore, we will measure bone formation and bone resorption markers at baseline, year 1 and year 5. Blood specimens will be shipped to and stored in a central laboratory for future assays of bone biomarkers. For markers of bone formation, the N-terminal Propeptide of Type I Collagen (PINP) will be measured. For bone resorption markers, serum levels of cross-linked N-telopeptides of type I collagen (NTx) will be measured. Note: Subjects must fast 12-14 hours prior to blood draw.
1814393|NCT00688246|Procedure|dual x-ray absorptometry|BMD of the spine (L1-L4) and total hip will be done within 12 months prior to randomization to the MAP.3 core protocol. BMD by DEXA of the spine (L1-L4) and total hip will be repeated at year 2 and year 5 of the MAP.3 core study on the same Lunar or Hologic scanner.
1814396|NCT00688272|Drug|Ciprofloxacin|Given 500mg BID x 6 days
1814397|NCT00688272|Drug|Eltrombopag|Given QD x 6 days
1814398|NCT00688272|Drug|Placebo|Given QD x 6 days
1814399|NCT00688285|Other|automated clinical alerts|automated clinical alerts in the electronic medical record
1814400|NCT00688285|Other|provider education|PCP education session on CKD
1814401|NCT00688298|Device|Prefyx PPS™ System|A mesh implant intended for use as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
1814402|NCT00688298|Device|Advantage ™ System|The Advantage Mesh implant is intended as a suburethral sling for the treatment of stress urinary incontinence resulting from hypermobility and/or intrinsic sphincter deficiency.
1814403|NCT00688311|Dietary Supplement|Synbiotic 2000|A preparation consisting of 4 species of probiotic bacteria (10^10 each) combined with 4 types of dietary fiber (2.5g each).
1814404|NCT00688311|Dietary Supplement|Placebo|Placebo
1814406|NCT00688350|Behavioral|Behavioral feedback|The medication adherence intervention consists of five components: medication feedback, hypertension feedback, medication-taking skills, habit adjustment, and succinct medication and disease information delivered over an 8-week period.
1814407|NCT00688363|Procedure|weekly blood glucose profile|once daily self-control of urinary-glucose
1814408|NCT00688363|Procedure|three-monthly haemoglobin A1c|once daily self-control of urinary-glucose
1814409|NCT00688363|Procedure|no blood-glucose self-control|once daily self-control of urinary-glucose
1814412|NCT00688389|Other|case/control|case: infected dengue fever people control:healthy people
1814413|NCT00688402|Drug|AZD3355|Single dose
1814414|NCT00688415|Drug|VTX-2337|Escalating doses of the investigational drug will be administered to cohorts of patients until the highest tolerated dose is identified.
1814415|NCT00688428|Drug|Esomeprazole 40mg/ASA 325mg|combination capsule, administered as a single oral dose
1814416|NCT00688428|Drug|Esomeprazole|40mg capsule, administered as a single dose
1814417|NCT00688428|Drug|ASA|325mg tablet, administered as a single oral dose
1814418|NCT00688441|Drug|Nasal CO2|Twice daily during the 14 day Treatment Period
1814419|NCT00688441|Drug|Placebo|Use of the study drug dispenser at the same frequency as the active arm
1814420|NCT00688467|Drug|Navarixin|30 mg capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
1814421|NCT00688467|Drug|Placebo|Matching capsule to be taken once daily in the morning for 10 days during Treatment Period 1 or Treatment Period 2
1814422|NCT00688480|Drug|Placebo|1 capsule, orally for 9 months
1814423|NCT00688480|Drug|Allopurinol|Allopurinol 300 mg once/day orally, 9 months
1814424|NCT00688493|Drug|Dapagliflozin|3 x 50 mg tablets, single oral dose
1814425|NCT00688493|Drug|Dapagliflozin|2 x 10 mg capsules, single oral dose
1814426|NCT00688493|Drug|Moxifloxacin|Overencapsulated 400 mg capsule, single oral dose
1814427|NCT00688493|Drug|Placebo to match moxifloxacin and dapagliflozin|Overencapsulated 400 mg capsule, single oral dose
1814428|NCT00688506|Device|combined sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
1814429|NCT00688506|Device|placebo therapy (Placebo Sonodyn Medico Star)|twice a day for 10 minutes during 12 weeks
1814430|NCT00688519|Drug|U0267|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
1814431|NCT00688519|Drug|Vehicle|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
1814432|NCT00688545|Drug|Celecoxib|Non-interventional: Treatment assignment as per treating physician's judgement
1814433|NCT00688545|Drug|nsNSAIDs|Non-interventional: Treatment assignment as per treating physician's judgement
1814434|NCT00688558|Drug|JTT-705 600 mg and simvastatin 40 mg|"JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment
Simvastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, immediately following breakfast and/or assessments"
1814435|NCT00688558|Drug|Placebo and simvastatin 40 mg|"Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments
Simvastatin 40 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
1814436|NCT00688571|Device|Melody Transcatheter Pulmonary Valve|Transcatheter valve implantation into a RV-PA conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs intervention
1814437|NCT00688584|Behavioral|Pamphlet-based personalized alcohol feedback (PAF)|participants in this condition will be mailed their respective pamphlets
1814438|NCT00688584|Behavioral|control pamphlet condition|The goal is to test if it is the specific content of the pamphlet that leads to the change or just the receipt of any pamphlet.
1814439|NCT00688597|Drug|AT2220|"low dose regimen 1
powder in a bottle for dissolution in water for oral administration"
1814440|NCT00688597|Drug|AT2220|high dose, regimen 1
1814441|NCT00688597|Drug|AT2220|high dose, regimen 2
1814442|NCT00688610|Other|laboratory value procalcitonin|"A. attending physician includes patient with acute respiratory infection in study, indicates antibiotic prescription and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is not recommended, patient shall not take antibiotic. In case of retention of decision: patient may take the antibiotic.
B. attending physician includes patient with acute respiratory infection in study, indicates NO antibiotic and collects procalcitonin-value. Waits for decision from laboratory either change of decision or retention of decision. In case of change decision: antibiotic is recommended, patient has to be informed about. In case of retention of decision: no change."
1814443|NCT00688623|Drug|Everolimus|
1814444|NCT00688636|Drug|infliximab|5 mg/kg IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
1814445|NCT00688636|Drug|placebo|placebo IV at baseline, 2 weeks, 6 weeks and then every 8 weeks x 6
1814446|NCT00688649|Dietary Supplement|Standard Oral Nutritional Supplement (ONS)|Standard energy, oral nutritional supplement (a milk style nutritional supplement (1.5kcal/ml, 200ml) containing protein, fat, carbohydrate and micronutrients)
1814447|NCT00688649|Dietary Supplement|High energy Oral Nutritional Supplement (ONS)|High Energy nutritional supplement (a milk style nutritional supplement (2.4kcal/ml, 125ml) containing protein, fat, carbohydrate and micronutrients)
1814448|NCT00688662|Procedure|ERCP with sphincterotomy|cutting the biliary sphincter muscle (sphincterotomy)
1814449|NCT00688662|Procedure|ERCP without sphincterotomy|ERCP with sphincter manometry, but no sphincterotomy
1814450|NCT00688688|Drug|Mirabegron|Tablets
1814451|NCT00688688|Drug|Tolterodine|Extended release capsules
1814452|NCT00688688|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
1814453|NCT00688688|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
1814454|NCT00688701|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1814455|NCT00688701|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1814456|NCT00688701|Device|Pen auto-injector|
1814457|NCT00688714|Drug|AZD6482|0,9-364,5 mg administrated through intravenous infusion over 3 hours
1814458|NCT00688714|Drug|Placebo|
1814459|NCT00688727|Behavioral|CBT|CBT, up to 12 sessions.
1814460|NCT00688727|Behavioral|Standard Care|Routine review by neuropsychiatrist in outpatient clinic
1814461|NCT00688740|Drug|Docetaxel|intravenous
1814462|NCT00688740|Drug|5-fluorouracil|intravenous
1814463|NCT00688740|Drug|Doxorubicin|intravenous
1814464|NCT00688740|Drug|Cyclophosphamide|intravenous
1814465|NCT00688753|Drug|RAD001|
1814505|NCT00689052|Drug|placebo|
1821669|NCT00741780|Drug|plerixafor|
1814466|NCT00688766|Drug|retaspimycin hydrochloride (IPI-504)|IPI-504 is a novel small molecule inhibitor of heat shock protein 90 (Hsp90). Patients will receive 400 mg/m2 of IPI-504 as a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
1814467|NCT00688766|Drug|placebo|Patients will receive a 30-minute IV infusion twice weekly for 2 weeks followed by 1 week off.
1814468|NCT00688766|Other|Best supportive care|Best supportive care will be according to institutional standard, but will not include administration of systemic cancer-specific therapies including chemotherapies, biologic therapies, investigational therapies, TKIs (e.g., imatinib, sunitinib, nilotinib, dasatinib), or local therapies such as surgery, radiotherapy, or lesion ablative therapies.
1814469|NCT00688779|Drug|AZD8848|Concentrate for nasal spray,solution 60 mg/g
1814470|NCT00688779|Drug|Placebo|
1814471|NCT00688805|Drug|Propranolol|40 mg given as a single oral administration in an opaque capsule
1814472|NCT00688805|Drug|Placebo|matching capsule containing no active medication
1814473|NCT00688818|Drug|Quetiapine|Patients will be initiated on 50 mg of Quetiapine XR and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
1814474|NCT00688818|Drug|Placebo|Patients will be initiated on 50 mg of Placebo and will be titrated to a maximum dose of 300 mg based on response and tolerability. Dosing will be flexible up to Week 8, and then will remain fixed for until the end of the 12 week period.
1814475|NCT00688831|Drug|AZD1305|Solution for iv infusion , single dose
1814476|NCT00688831|Drug|Placebo|NaCl solution for iv infusion, single dose
1814477|NCT00688844|Drug|KuvanTM Therapy|BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
1814478|NCT00688857|Drug|Diazoxide choline|Diazoxide choline controlled-release coated tablets versus Diazoxide choline controlled-release uncoated tablets administered orally once daily
1814479|NCT00688857|Drug|Diazoxide choline|Diazoxide choline controlled-release uncoated tablets versus Diazoxide choline controlled-release coated tablets administered orally once daily
1814480|NCT00688870|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|13vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
1814481|NCT00688870|Biological|7-valent pneumococcal conjugate vaccine (7vPnC)|7vPnC is given via intramuscular injection at approximately 2, 4, 6, and 15 months of age.
1814482|NCT00688883|Drug|Fludarabine Phosphate (Fludara)|Patients received Fludarabine Phosphate orally for 5 consecutive days, followed by a 23-day observation period. Setting this as 1 treatment cycle, 6 cycles will be given.
1814483|NCT00688896|Drug|JTT-705 600 mg and pravastatin 40 mg|"JTT-705 300 mg tablets, 600 mg dose, 2 tablets, oral, once daily, immediately following breakfast and/or assessment
Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
1814484|NCT00688896|Drug|JTT-705 300 mg and pravastatin 40 mg|"JTT-705 300 mg tablets, 300 mg dose, 1 tablet, oral, once daily, immediately following breakfast and/or assessment
Placebo tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments
Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
1814485|NCT00688896|Drug|Placebo and pravastatin 40 mg|"Placebo tablets, 2 tablets, oral, once daily, immediately following breakfast and/or assessments
Pravastatin 40 mg tablets, 40 mg dose, one tablet, oral, once daily, at bedtime"
1814486|NCT00688909|Drug|letrozole|2.5 mg daily by mouth for 6 months
1814487|NCT00688922|Drug|Pravastatin|Take an initial dose of pravastatin to start as 10mg/day, which is the recommended initial dose by Health, Labour and Welfare Ministry of Japan, and a diet counseling.
1814488|NCT00688935|Biological|Melatonin|0.1-3 mg, daily, up to 1 year (minimum duration of 6 weeks)
1814489|NCT00688948|Drug|Alfuzosin|Alfuzosin 10 mg once daily po for 12 weeks
1814490|NCT00688961|Drug|Aspirin|generic aspirin
1814491|NCT00688961|Drug|omega-3 acid ethyl esters|4, 1 g capsules q.d.
1814492|NCT00688974|Procedure|Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass
1814493|NCT00688974|Procedure|Adjustable gastric band|Laparoscopic adjustable gastric band
1814494|NCT00688987|Drug|Hydrocortisone|Subjects will receive in random order daily (split) dosing of hydrocortisone: a low dose of 15 mg (10 in AM, 5 in PM); a medium dose of 25 mg (15 in AM, 10 in PM) and high dose of 40 mg (30 in AM, 10 in PM) for 4 months.
1814495|NCT00688987|Dietary Supplement|Isocaloric Diet|Subjects will eat an isocaloric diet for 4 weeks while taking hydrocortisone
1814496|NCT00689000|Drug|CHR-2797 (tosedostat): Aminopeptidase inhibitor|"Phase I: Once daily, oral ingestion of CHR-2797 capsules (60mg, 90mg, 130mg or 180mg) depending on cohort
Phase II: Once daily, oral ingestion of 130mg CHR-2797 (recommended dose from Phase I) until progressive disease or withdrawal from the study"
1814497|NCT00689013|Other|Personalized letter|On Day 1 of the 2nd month, a personalized letter (addressing specific patient) was mailed to current pharmacy patients with indications for the Zostavax vaccine. Current patients were defined as those receiving at least one prescription medication from the pharmacy within 6 months. The personalized letter provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
1814498|NCT00689013|Other|Flyer advertisement|Beginning on Day 1 of the 2nd month, flyer advertisements were distributed with all pharmacy sales. Flyer advertisements provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
1814499|NCT00689013|Other|Newspaper press release|During the first week of the 2nd month, local newspapers published press releases. The press release provided detailed information about herpes zoster infection, the vaccine for herpes zoster prevention, indications for vaccine receipt and contraindications for vaccine receipt.
1814500|NCT00689026|Drug|Lubiprostone|Two 24 mcg lubiprostone capsules, which will be taken orally the morning and evening of the day of the 4L PEG prep (before and after the 4L PEG prep).
1814501|NCT00689026|Other|Polyethylene glycol with electrolytes|Standard oral dosing of 4L Polyethylene glycol colonoscopy preparation the day prior to their scheduled colonoscopy.
1814502|NCT00689039|Drug|AZD1305|ER tablet, administered as single and repeated doses.
1814503|NCT00689039|Drug|Placebo|Tablet, administered as single and repeated doses.
1814506|NCT00689065|Drug|CALAA-01|Subjects with solid tumors who satisfy the eligibility criteria will receive two, 21-day cycles of CALAA-01. A cycle will consist of four (4) 30-minute intravenous infusions administered on days 1, 3, 8, and 10 followed by 11 days of rest. If safe, a second 21-day cycle will be administered consisting of infusions on days 22, 24, 29 and 31 followed by 11 days of rest.
1958375|NCT01722448|Dietary Supplement|Choline|4 capsules with 480 mg choline per day
1958376|NCT01722448|Dietary Supplement|Placebo|
1814511|NCT00689091|Device|Bispectral Index Monitor|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
1814512|NCT00689091|Device|Electronic MAC alert|Comparison of two different alerting protocols. One using the bispectral index monitor and one using the MAC alerting protocols.
1814513|NCT00689104|Drug|Mirabegron|Tablets
1814514|NCT00689104|Drug|Tolterodine|Capsules
1814515|NCT00689104|Drug|Placebo to Mirabegron|Matching mirabegron placebo tablets.
1814516|NCT00689104|Drug|Placebo to Tolterodine|Matching tolterodine placebo capsules.
1814517|NCT00689117|Drug|CT Gel|Topical gel consisting of clindamycin 1% and tretinoin 0.025%, applied once daily in the evening for 12 weeks
1814518|NCT00689117|Drug|Clindamycin Gel (clindamycin )|Clindamycin 1% gel applied topically once daily in the evening for 12 weeks
1814519|NCT00689117|Drug|Tretinoin Gel (tretinoin)|Tretinoin 0.025% gel applied topically once daily in the evening for 12 weeks
1814520|NCT00689117|Drug|Vehicle Gel|Topical gel without clindamycin or tretinoin applied topically once daily in the evening for 12 weeks
1814521|NCT00689143|Drug|sargramostim|
1814522|NCT00689156|Drug|Epirubicin, cyclophosphamide and docetaxel|Epirubicin 90 mg/m2 iv day 1 every 3 weeks plus Cyclophosphamide 600 mg/m2 iv day 1 every 3 weeks times 3 followed by Docetaxel 100 mg/m2 iv day 1 every 3 weeks times 3
1814523|NCT00689156|Drug|docetaxel, cyclophosphamide|Docetaxel 75 mg/m2 plus cyclophosphamide 600 mg/m2 intravenously day 1 every 3 weeks times six
1814524|NCT00689169|Drug|ZBEAM (Zevalin, BCNU, Etoposide, Aracytine, Melphalan)|Zevalin 0.4 mCi/kg: D-14 BCNU 300 mg/m² : D-6 Etoposide 100 mg/m²/12h : D-6 D-5 D-4 D-3 Aracytine 200 mg/m²/12h : D-6 D-5 D-4 D-3 Melphalan 140 mg/m²: D-2
1814525|NCT00689169|Procedure|ASCT|ASCT : D0
1814526|NCT00689169|Drug|Rituximab|Rituximab 250 mg/m² :D-21 D-14
1814527|NCT00689182|Procedure|monthly phlebotomy x 12 months|All patients will receive monthly phlebotomies.
1814528|NCT00689195|Dietary Supplement|Curcumin powder|oral capsules containing the investigational agent
1814529|NCT00689195|Dietary Supplement|Ashwagandha extract|4.5% extract of ashwagandha
1814530|NCT00689208|Drug|Atropine|10 ug/kg bolus, 4 ug/kg/h infusion
1814531|NCT00689208|Drug|Physostigmine|0,12ug/kg/min
1814532|NCT00689208|Drug|Placebo Sodium|
1814533|NCT00689221|Drug|Cilengitide|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
1814534|NCT00689221|Drug|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] will be administered intravenously once daily from Weeks 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
1814535|NCT00689221|Radiation|Radiotherapy|Radiotherapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Weeks 1 to 6, total dose 60 Gy.
1814536|NCT00689234|Procedure|diaphragm plication 6 months after inclusion|thoracotomy
1814537|NCT00689234|Procedure|diaphragm plication at time of inclusion|thoracotomy
1814538|NCT00689247|Drug|AZD1305|oral solution, single dose
1814539|NCT00689247|Drug|AZD1305|iv infusion, single dose
1814540|NCT00689260|Device|easypod|Subjects is aware that the device records injection information that can be viewed by user
1814541|NCT00689260|Device|easypod|Subjects is not aware that the device records injection information that can be viewed by user
1814542|NCT00689273|Drug|PF-04136309|125 mg capsules. Dose will be 4 capsules BID for 2 weeks for a total of 500 mg for each dosing interval.
1814543|NCT00689273|Drug|Placebo|Placebo will be matched to PF-04136309. Dose, frequency, and duration same as PF-04136309.
1814544|NCT00689286|Device|BION|"They will be divided into three groups. Two groups of experimental subjects will receive stimulation using BIONs. The first group will have a stimulation paradigm like that used in a previous feasibility study that preceded the proposed trial, using low-frequency (1-5 PPS) twitch stimulation. The second group will have a stimulation paradigm in which tetanic-frequency stimulation (25-50 PPS) is used to produce fused muscle contractions. A third group of experimental subjects will have a standardized program of voluntary exercise.
In Groups 1 and 2, the femoral nerve will be stimulated electrically according to the assigned protocol during the 12 week experimental period after implantation of the devices. Individuals assigned to Group 3, receiving conventional exercise therapy for 12 weeks, will be allowed to receive BIONs at the end of the trial, providing they request BION therapy and they have been at least minimally compliant with the exercises."
1814545|NCT00689299|Biological|Standardized Allergenic Extract, Cat Hair|Standardized Cat Hair Allergenic Extract sublingual drops
1814546|NCT00689299|Biological|Placebo|Placebo Sublingual Drops
1814547|NCT00689312|Drug|Enfalyte|Each patient will receive one 250 ml dose.
1814548|NCT00689312|Drug|Pediatric Electrolyte|Each patient will receive one 250 ml dose.
1814549|NCT00689312|Drug|Pedialyte|Each patient will receive one 250 ml dose.
1814550|NCT00689338|Drug|Anidulafungin|Anidulafungin Intravenous Administration
1814551|NCT00689338|Drug|Fluconazole|Oral Administration of Fluconazole
1814552|NCT00689338|Drug|Voriconazole|Oral Administration of Voriconazole
1814553|NCT00689351|Biological|13-valent pneumococcal conjugate vaccine|13vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
1814554|NCT00689351|Biological|7-valent pneumococcal conjugate vaccine|7vPnC is given via intramuscular injection at approximately 2, 4, 6 and 12 months of age.
1814555|NCT00689390|Biological|Boceprevir|In previous treatment studies, boceprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
1814556|NCT00689390|Biological|Narlaprevir|In previous treatment studies, narlaprevir was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
1814557|NCT00689390|Biological|Peginterferon alfa-2b|In previous treatment studies, peginterferon alfa-2b was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
1814558|NCT00689390|Drug|Ribavirin|In previous treatment studies, ribavirin was administered as specified by the protocol. No treatment was administered on the current follow-up study (P05063, NCT00689390).
1814559|NCT00689390|Other|Blood/Plasma Collection|Blood samples were collected at all visits during the LTFU for blood chemistry and hematology. Plasma samples were collected at all visits as appropriate from participants who were sustained responders at the end of FU in the previous treatment protocol for HCV-RNA PCR and HCV sequence analysis.
1814560|NCT00689403|Drug|AZD1305|Extended release capsules, oral single doses
1814561|NCT00689403|Drug|AZD1305|Extended release capsules, oral single doses
1814562|NCT00689416|Drug|rosuvastatin|40 mg, tablet, once daily for 3 months.
1814563|NCT00689416|Drug|placebo|40 mg, tablet, once daily for 3 months
1814564|NCT00689442|Drug|JTT-705 600 mg and atorvastatin 20 mg|"JTT-705 300 mg tablets, 600 mg dose, oral, once daily, immediately following breakfast and/or assessment
Atorvastatin 20 mg tablets, 20 mg dose, oral, once daily, immediately following breakfast and/or assessments"
1814565|NCT00689442|Drug|Placebo and atorvastatin 20 mg|"Placebo tablet, 2 tablets, oral, once daily, immediately following breakfast and/or assessments
Atorvastatin 20 mg tablets, one tablet, oral, once daily, immediately following breakfast and/or assessments"
1814566|NCT00689468|Procedure|Cranial osteopathic manipulative treatment.|A series of five cranial osteopathic manipulative treatment sessions scheduled over three months, and provided by osteopathic physicians whose practices are limited to osteopathic manipulative treatment. Treatment modalities were limited to cranial osteopathy, balanced membranous/ligamentous tension, and/or myofascial release (applied directly or indirectly).
1814567|NCT00689468|Dietary Supplement|Echinacea purpurea|1:1 weight-to-volume 50% ethanol liquid extract of the fresh roots and dried mature seeds of Echinacea purpurea. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
1814568|NCT00689468|Procedure|Sham osteopathic manipulative treatment|Sham osteopathic treatment consisted of a series of five osteopathic examinations only (palpation of the cranial bones and muscles and other structures) without treatment maneuvers.
1814569|NCT00689468|Dietary Supplement|"Echinacea purpurea placebo"|An identically labeled placebo contained 50% ethanol, 45% filtered water, food coloring and thickeners. Dosage: 0.5 ml orally 3 times daily for 3 days at the onset of cold symptoms, followed by 0.25 ml orally 3 times daily for 7 more days.
1814570|NCT00689481|Drug|U0267 Foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
1814571|NCT00689481|Drug|Vehicle foam|All treatments will be administered topically twice daily (morning and evening) for 8 weeks to areas affected with psoriasis (excluding face and scalp).
1814572|NCT00689494|Other|Nanopaz contraception device|levonorgestrel and levonorgestrel device for cervical contraception-nantechnolgy method
1814573|NCT00689507|Biological|LY2127399|monoclonal antibody
1814574|NCT00689520|Drug|tinzaparin|tinzaparin (Innohep®) subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
1814575|NCT00689520|Drug|acenocoumarol|tinzaparin subcutaneously 175 IU anti-Xa/kg of body weight once daily for 7 days followed by acenocoumarol for 6 months
1814576|NCT00689559|Drug|AZD3480|AZD3480 capsules qd, oral, 22 days
1814577|NCT00689559|Drug|Placebo|Placebo qd, 12 days
1814578|NCT00689559|Drug|Aripiprazole|single dose on day 5
1814579|NCT00689572|Drug|Ondansetron|4 mg twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
1814580|NCT00689572|Drug|Placebo|twice a day + Cognitive Behavioral Therapy + Brief Behavioral Enhancement Therapy
1814581|NCT00689585|Drug|Placebo|250mg matching placebo capsules
1814582|NCT00689585|Drug|Ethosuximide|500-1500mg/day over a 1-5 week dose titration period until maximal tolerated dose (MTD) attained, followed by 1 week MTD plateau period.
1814583|NCT00689598|Drug|Spironolactone|25 mg po qd 25 mg po bid
1814584|NCT00689598|Drug|Placebo|Spironolactone 25 mg po qd
1814585|NCT00689611|Drug|Bupropion HCl ER|150 mg tablets po qd for 3 days and then 150 mg po bid for remainder of 9 weeks
1814586|NCT00689611|Drug|Placebo|Placebo
1814587|NCT00689624|Drug|Irinotecan|Irinotecan will be administered at a dose of 150mg/m2 as a 30 min IV infusion on day 1
1814588|NCT00689624|Drug|Leukovorin|Leukovorin will be administered at a dose of 200mg/m2 as a 2-hour IV infusion on days 2 and 3
1814589|NCT00689624|Drug|Oxaliplatin|Oxaliplatin will be administered on day 2 at the dose of 65mg/m2 as a 2-hours IV
1814590|NCT00689624|Drug|5-FLUOROURACIL|5-FLUOROURACIL at the dose of 400mg/m2 as IV bolus and then, 600mg/m2 as a 22-hour continuous IV infusion, on days 2 and 3
1814591|NCT00689624|Drug|Cetuximab|Cetuximab will be administered at the dose of 500mg/m2 as a 2-hour infusion on day 1 at least one hour before chemotherapy
1814592|NCT00689637|Drug|AZD3480|AZD3480 capsules qd, 12 days
1814593|NCT00689637|Drug|Placebo|Placebo capsules qd, 12 days
1814594|NCT00689637|Drug|Warfarin|Warfarin: single dose on day 6
1814595|NCT00689650|Device|1540 nm fractional laser|
1814596|NCT00689663|Procedure|Laparoscopic cholecystectomy|Randomized to three arm.
1814597|NCT00689689|Device|Fully coated Prodigy stem|Total hip arthroplasty with fully coated Prodigy stem
1814598|NCT00689689|Device|Cemented Endurance Stem|total hip arthroplasty with cemented endurance stem
1814642|NCT00689884|Drug|Pegfilgrastim|Pegfilgrastim: Sub Cutaneous, 6 mg on Day 3 of chemotherapy regimen or as otherwise indicated by chemotherapy regimen (ie., 24 hours after completion of chemotherapy).
1814599|NCT00689702|Drug|cetuximab, capecitabine|"Cetuximab 400mg/m2 in iv infusion as an initial dose on day 15, then a weekly dose of 250mg/m2 for 5 weeks during radiotherapy (days 22, 29, 36, 43, 50).
Capecitabine: 1250 mg/m² bd for 14 days (1 cycle); 825mg/m2 bd over 5 weeks during radiotherapy.
Radiotherapy: planned total dose of 45 Gy in 25 fractions using a four-field plan in 5 weeks."
1814600|NCT00689715|Procedure|Endoscopic ultrasonography-guided ethanol lavage with paclitaxel injection|A curvilinear-array echoendoscope and a 22 gauge needle were then used for cyst fluid aspiration, ethanol lavage and paclitaxel injection. The maximum possible volume of cyst fluid was aspirated, and the needle tip was carefully maintained inside the cyst to avoid parenchymal injury. Ethanol was injected into the collapsed cyst until the original shape was restored, and a lavage was then performed for 3-5 minutes. Pure ethanol (99%) was used for all patients except the first 2 in whom 88% ethanol was used. After reaspiration of the injected ethanol, the cyst cavity was injected with a solution containing 3 mg/mL paclitaxel and the needle then carefully retracted. The high viscosity of paclitaxel necessitated dilution in 0.9% normal saline for administration via a 22G needle. The volume of the paclitaxel solution administered was the same as the volume of the cyst fluid aspirated.
1814601|NCT00689728|Biological|LY2127399|30 mg of LY2127399 will be administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.
1814602|NCT00689728|Biological|LY2127399|80 mg of LY2127399 will be administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.
1814603|NCT00689728|Drug|Placebo|Placebo will be administered as a single IV infusion over 30 minutes at 0, 3, and 6 weeks.
1814604|NCT00689741|Biological|Cervarix|3 doses of IM injection
1814605|NCT00689741|Biological|placebo|3 doses of IM injection of Al(OH)3 placebo
1814606|NCT00689754|Procedure|nasogastric tube placement|standard nasogastric tube placement, aspiration and lavage up to 1L of normal saline
1814607|NCT00689767|Device|CINATRA™ Coronary Stent System|Bare metal cobalt chromium stent implantation
1814608|NCT00689767|Device|CINATRA™ ISA 247 Coated Coronary Stent System|Drug coated cobalt chromium stent implantation
1814609|NCT00689780|Drug|AZD1940|Oral solution Multiple ascending dose given orally once daily at day 1-12
1814610|NCT00689780|Drug|Midazolam|Oral solution given orally once daily on day -1 and day 14
1814611|NCT00689793|Drug|Ferrous sulphate|"Volunteers will receive 80 mg/day oral ferrous sulphate (Tardyferon®) for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
1814612|NCT00689793|Drug|Placebo|"Volunteers will receive 1 pill/day oral placebo for four weeks. Visual analogical scales and questionnaires will be performed at day 0 and 30 to quantify fatigue ( Fatigue Severity Scale). We will also check depression and anxiety symptoms ( Prime MD ) and health survey ( SF-12 ). An evaluation of the menstruation ( Pictorial Bleeding Assessment Chart  of Jansen) will be performed at day 0 to detect a possible hypermenorrhea (appendix 1-4). A physical test will be performed (Chester Step Test) to assess the VO2 max. Every side effect will be written on follow-up notes."
1814613|NCT00689806|Drug|Lovastatin|Lovastatin 20 mg extended release (or placebo) by mouth once daily for weeks 1-4. Liver function test will be checked at week 4 follow up visit. If LFTs are not > 3 times the upper limit of normal, then the subject will have the dose of extended release lovastatin increased to 60 mg once a day for weeks 4-12
1814614|NCT00689806|Drug|Placebo|Placebo by mouth once daily for weeks 1-4.
1814615|NCT00689819|Behavioral|Exercise|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
1814616|NCT00689819|Behavioral|Exercise|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
1814617|NCT00689819|Behavioral|Weight Loss|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
1814643|NCT00689897|Procedure|acupuncture, Deqi|Immediately after insertion of a needle, it is manually rotated backwards and forwards to induce the DeQi sensation.
1814644|NCT00689897|Procedure|acupuncture, Non-Deqi|After insertion of a needle, no manipulation is applied, and the needle is retained for 30 minutes.
1814846|NCT00690703|Device|RF ablation (Rita Medical Systems Model 1500x)|computed tomography-guided RF ablation with an expandable electrode needle
1814618|NCT00689819|Behavioral|Low Sodium Diet|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
1814619|NCT00689819|Behavioral|Smoking Cessation|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
1814620|NCT00689819|Drug|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target of < 140/90 mmHg (or < 130/80 mmHg for diabetics or with chronic kidney disease) as recommended by the 7th Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7). BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
1814621|NCT00689819|Behavioral|Weight Loss|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
1814622|NCT00689819|Behavioral|Low Sodium Diet|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
1814623|NCT00689819|Behavioral|Smoking Cessation|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
1814624|NCT00689819|Drug|Pharmaceutical Therapy (no specific therapy; approach guided by the JNC 7 protocol guidelines)|Blood pressure (BP) target will be < 120/80 mmHg. BP control efforts will be open-label and will include a combination of recommended life-style modifications (i.e., exercise, weight loss, low sodium diet, smoking cessation), and pharmaceutical therapy based on JNC 7 protocol driven guidelines with the following adaptations: 1) use of a diuretic that is appropriate to renal function (eGFR< 40 ml/min/1.73 m2: a loop diuretic; eGFR> 40 ml/min/1.73 m2: a thiazide); 2) use of automated reminders if BP exceeds target for > 4 weeks without a medication titration; 3) use of a second diuretic when taking 4 or more anti-hypertensives without adequate achievement of BP target level; and 4) automated alerts to study personnel for potential drug interactions.
1814625|NCT00689832|Drug|Tacrolimus 0.03%|ointment
1814626|NCT00689832|Drug|Fluticasone 0.005%|ointment
1814627|NCT00689845|Biological|bleomycin sulfate|Given IV
1814628|NCT00689845|Biological|filgrastim|Given subcutaneously
1814629|NCT00689845|Biological|rituximab|given IV
1814630|NCT00689845|Drug|cyclophosphamide|Given IV
1814631|NCT00689845|Drug|cytarabine|Given subcutaneously
1814632|NCT00689845|Drug|doxorubicin hydrochloride|Given IV
1814633|NCT00689845|Drug|etoposide phosphate|Given IV
1814634|NCT00689845|Drug|ifosfamide|Given IV
1814635|NCT00689845|Drug|methotrexate|Given IV
1814636|NCT00689845|Drug|prednisolone|Given orally
1814637|NCT00689845|Drug|prednisone|Given orally
1814638|NCT00689845|Drug|vincristine sulfate|Given IV
1814639|NCT00689845|Drug|vindesine|Given IV
1814640|NCT00689858|Drug|Cilostazol, Ginkgo biloba and placebo|dosing time
1814641|NCT00689871|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
1815100|NCT00693160|Drug|remifentanil|All subjects will receive a remifentanil infusion
1814648|NCT00689949|Dietary Supplement|folic acid|0.4 mg of folic acid per day
1814649|NCT00689962|Device|Linvatec 4.5 mm Smart Screw|Linvatec 4.5 mm Smart Screw to surgically fix the foot's Lisfranc ligaments
1814650|NCT00689962|Device|Synthes 4.0 mm steel screw|Standard steel screw use to surgically fix the foot's Lisfranc ligaments.
1814651|NCT00689975|Behavioral|behavioral dietary intervention|
1814652|NCT00689975|Behavioral|exercise intervention|
1814653|NCT00689975|Other|counseling intervention|
1814654|NCT00689975|Other|flow cytometry|
1814655|NCT00689975|Other|immunoenzyme technique|
1814656|NCT00689975|Other|laboratory biomarker analysis|
1814657|NCT00689975|Procedure|complementary or alternative medicine procedure|
1814658|NCT00689975|Procedure|standard follow-up care|
1814659|NCT00689988|Behavioral|speech-language therapy with AAC intervention|speech-language intervention in weekly 40-minutes sessions, without the presence of parents or caregivers, and 5 to 10-minutes to parents training and orientation
1814660|NCT00690014|Drug|probenecid|500 mg q 6 hrs
1814661|NCT00690027|Procedure|Emergency portacaval shunt|
1814662|NCT00690027|Procedure|Emergency and long-term endoscopic sclerotherapy|
1814663|NCT00690040|Device|Foley catheter|Single balloon catheter
1814664|NCT00690040|Device|Atad catheter|Double balloon catheter
1814665|NCT00690053|Procedure|Injection of HX-4|In step 1: 1 injection of HX-4 (max.6mCi (222MBq)) In step 2: 1 injection of HX-4 (max.12mCi 444MBq)
1814666|NCT00690066|Drug|PROCHYMAL®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
1814667|NCT00690066|Drug|Placebo|Intravenous infusion of excipients of PROCHYMAL®
1814668|NCT00690079|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period. Cmax = 16 mikromol/L and AUCmax = 98 mikromol*h/L
1814669|NCT00690079|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
1814670|NCT00690092|Biological|Spherule-derived coccidioidin|1.27 ug of sterile, injectable product (spherule-derived coccidioidin). Product was administered once by intradermal injection along with positive and negative control agents and results read after 48 hours.
1814671|NCT00690105|Drug|tacrolimus 0.1%|ointment
1814672|NCT00690105|Drug|fluticasone 0.005 %|ointment
1814673|NCT00690118|Drug|pioglitazone|45 mg/day, 18 months
1814674|NCT00690118|Drug|placebo|once daily, 18 months
1814675|NCT00690131|Behavioral|BTSCS|BTSCS includes: (1) A behavioral group emphasizing motivational enhancement, skills training, education, and relapse prevention; (2) Contingency management with financial incentives to reinforce reductions in smoking; (3) Supported use of Bupropion or nicotine replacement therapy that is integrated with clients' psychiatric care in participants who are interested; and (4) Smoking cessation care coordination to increase treatment engagement and retention.
1814676|NCT00690144|Device|High-fidelity high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).|Critical care training using high-fidelity simulation. The case scenarios were simulated by a high-fidelity mannequin simulator (SimMan, Laerdal, Stavanger, Norway).
1814677|NCT00690170|Drug|Ketamine|Ketamine: 0.23 mg/kg bolus over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes
1814678|NCT00690170|Drug|Nicotine|Nicotine: 13.5 µg/kg given over 10 min (1.35 µg/min/kg),IV (in the arm) followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg) Placebo: Normal saline (sodium chloride 0.9%)IV (in the arm)
1814679|NCT00690170|Drug|Placebo|Normal saline (sodium chloride 0.9%)administered via IV (in the arm) over 95 minutes
1814680|NCT00690170|Drug|Ketamine and Nicotine|"0.23 mg/kg of ketamine bolus IV (in the arm) over one minute followed by maintenance infusion at 0.58mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 64 minutes.
13.5 µg/kg of nicotineIV (in the arm) given over 10 min (1.35 µg/min/kg), followed by a constant infusion of 31.02 µg/kg given over 85 min (0.365 µg/min/kg)"
1814681|NCT00690196|Behavioral|Tai Chi Chih|"Tai Chi Chih (TCC) employs meditation through movement as a means of helping breast cancer survivors cope with fatigue, perceived physical limitations, and negative emotional states which are commonly associated with insomnia. In groups of 7-8, subjects will learn to perform 20 movements under the guidance of expert TCC teacher (K. Hollister, certified instructor) who will oversee treatment sessions throughout the 12 week treatment, consistent with our preliminary studies (9). Sessions will be taught over 120 minutes with 90 minutes of active TCC, 20 minutes of warm-up (e.g., stretching, breathing),10 minutes of cool down. Sessions will be mainly given in the late afternoon at 16:00 h. Thus, the TCC will be given once a week per week for a total of 120 minutes, similar in total time allocation with Cognitive Behavioral Therapy. The final week of treatment will include the development of a TCC adherence plan to ensure continuity of practice and skill maintenance during follow-up."
1814737|NCT00690651|Procedure|Standard mobilization|this group will rest in bed with their leg elevated above their heart for 48 hours post surgery to ankle fracture and will then mobilize with physiotherapist with aim to discharge home.
1814847|NCT00690716|Drug|Nasal CO2|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
1814848|NCT00690716|Drug|Inactive Placebo|Adaptive Randomization to a Dosing Regimen for Treatment of a Qualifying Headache
1815101|NCT00693160|Drug|Capsaicin|Topical capsaicin pain model utilized for each subject
1814682|NCT00690196|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) for insomnia will be supervised by a Ph.D. level psychologist, with specialty training in behavior therapy and behavioral medicine. The CBT sessions will be held once a week for 120 minutes (each session) over the 12-week treatment period, identical to the time schedule which was to be used for health education. Treatment will be given in small groups of 7-8 subjects. The content of the intervention will be organized around a series of modules that will be presented to patients in manualized form. For each session, the CBT treatment manual will outline objectives, patient skills, and treatment activities. Therapists will direct role-playing and other skill-development exercises that will be designed to increase patients' self-efficacy in managing their insomnia. Homework assignments will be planned weekly to ensure practice and skill application.
1814683|NCT00690209|Procedure|Autologous bone marrow derived stem cells myocardial transplantation|
1814684|NCT00690222|Procedure|Intracameral injection of mydriatic agent|A mixture of 0.2 % tropicamide and 2% phenylephrine will be injected into the anterior chamber at the beginning of surgery
1814685|NCT00690235|Drug|Pramlintide|180mg subcutaneous injections, twice daily
1814686|NCT00690235|Drug|Placebo|180mg subcutaneous injections, twice daily
1814687|NCT00690274|Drug|BF2.649|up to 20mg per day
1814688|NCT00690274|Drug|Placebo|up to 20mg per day
1814689|NCT00690287|Drug|AZD6370|Oral single doses a+b+c, o.d., suspension
1814690|NCT00690287|Drug|AZD6370|Oral single dose, o.d., b.i.d. and q.i.d., suspension
1814691|NCT00690287|Drug|Placebo|Placebo
1814692|NCT00690300|Drug|Docetaxel|75 mg/m2 IV on day 1 of each 22 day cycle
1814693|NCT00690300|Drug|Oxaliplatin|80 mg/m2 IV on day 2 of each 22 day cycle
1814694|NCT00690313|Drug|Vigamox|eye drops 3 times day either 1 or 3 days prior to intravitreal injection
1814695|NCT00690326|Behavioral|Behavioral change communication to promote physical activity|"treatment type: behavioral (lifestyle counseling)
treatment name: behavioral change communication to promote physical activity"
1814696|NCT00690326|Behavioral|Behavioral change communication to promote physical activity|"Arm B given placebo comparator ie pamphlet
Audiovisual module Physical activity frequency questionnaire"
1814697|NCT00690339|Device|Style 410 Silicone-Filled Breast Implants|Breast Implant Surgery
1814698|NCT00690352|Behavioral|Specialized Substance Abuse Supervision (SSAS)|Six months participation in SSAS which may include cognitive behavioral therapy (CBT) in groups; use of incentives, positive reinforcement, and/or motivational interviewing.
1814701|NCT00690404|Drug|AZD2066|single oral dose
1814702|NCT00690417|Dietary Supplement|Cholecalciferol (vitamin D3)|low calorie (~60 calories) cookie-like disc containing 2,500 IU of vitamin D3, taken by mouth daily for 4 months
1814703|NCT00690430|Drug|Pasireotide|Pasireotide LAR 60mg i.m. injection - patients may also receive pasireotide 600 µg s.c 3 times a day for symptom control as needed
1814704|NCT00690430|Drug|Octreotide|Octreotide LAR 40mg i.m. depot injection - Patients may also receive octreotide 100 µg s.c. 3 times a day for symptom control as needed
1814705|NCT00690443|Drug|Atorvastatin|atorvastatin 20 mg tablets, daily dosing, for 8 weeks.
1814706|NCT00690443|Drug|AEGR-733|2.5 mg AEGR-733 capsules, daily dosing, 4 weeks followed by 5 mg AEGR-733 capsules, daily dosing, 4 weeks
1814707|NCT00690456|Drug|Rimonabant|Tablet, oral administration
1814708|NCT00690456|Drug|Placebo (for Rimonabant)|Tablet, oral administration
1814709|NCT00690456|Drug|Metformin|Metformin continued at stable dose as background therapy
1814710|NCT00690469|Other|questionnaire administration|Ancillary studies
1814711|NCT00690469|Other|laboratory biomarker analysis|Correlative studies
1814712|NCT00690482|Drug|AZD1981|Oral tablet, twice daily
1814713|NCT00690482|Drug|Placebo|Placebo Oral tablet, twice daily
1814714|NCT00690495|Drug|Propofol|Propofol (drug), intravenous, induction of anesthesia
1814715|NCT00690495|Drug|Propofol 1%|Propofol (drug), intravenous, induction of anesthesia
1814716|NCT00690508|Procedure|Supra-Sternal Tube-Tip Palpation (SSTTP)|The supra-sternal palpation of the tube after tracheal intubation.
1814717|NCT00690521|Drug|metolazone or hydrochlorothiazide|The specific dose of hydrochlorothiazide will be determined by the individual's creatinine clearance. A creatinine clearance of 30-50 mL/min will indicate a dose of 50 mg per day. A creatinine clearance of > 50 mL/min will indicate a dose of 25 mg per day.5 If metolazone is added to their regimen, the specific dose will be determined using the equivalence ratio of 5 mg metolazone to 50 mg hydrochlorothiazide.
1814718|NCT00690534|Drug|Insulin Regular|insulin, 0.2 mU/kg/min for 3 hours
1814719|NCT00690534|Drug|L-NMMA|variable rate for 3 hours
1814720|NCT00690534|Drug|Sodium Nitroprusside|variable rate for 3 hours
1814721|NCT00690534|Other|mixed meal|mixed meal
1814722|NCT00690547|Other|muscle activation|activation of the muscle quadriceps femoris
1814723|NCT00690560|Biological|rituximab|
1814724|NCT00690560|Drug|cyclophosphamide|
1814725|NCT00690560|Drug|doxorubicin hydrochloride|
1814726|NCT00690560|Drug|prednisone|
1814727|NCT00690560|Drug|vincristine sulfate|
1814728|NCT00690560|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1814729|NCT00690573|Biological|Adalimumab|Adalimumab administered subcutaneously every other week, with dosage determined by body weight at study entry (20 mg for children weighing less than 30 kg, 40 mg for children weighing 30 kg or more).
1814730|NCT00690612|Drug|candesartan cilexetil|0.05, 0.2, 0.4 mg/kg, oral solution, single daily dose
1814731|NCT00690625|Drug|MyoRx Cream (6% Omega 3 Fatty Acid)|1/2 teaspoon 3 times per day for 30 days.
1814732|NCT00690625|Drug|Placebo cream, no Omega 3 fatty acid|Placebo cream, no Omega 3 fatty acid
1814733|NCT00690638|Drug|PHX1149T|200 mg
1814734|NCT00690638|Drug|PHX1149T|400 mg
1814735|NCT00690638|Drug|Placebo|Placebo
1814736|NCT00690651|Procedure|Early mobilization|pt to get out of bed and mobilize with physiotherapist within 24 hours of surgery. they will be allowed toilet privileges and will go home when safe (as per medical staff and allied health)
1815102|NCT00693186|Biological|HBVaxPRO® 5 µg / 0.5 mL|5 µg / 0.5 mL
1822439|NCT00747877|Drug|melphalan|Given IV
1814738|NCT00690677|Drug|LBH589|"LBH589 will be administered orally at a dose of 30mg (1 - 20mg capsule and 2 - 5g capsules) on Monday, Wednesday and Friday of each week (three times a week). Patients may continue treatment with oral LBH589 until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
The LBH589 capsules should be swallowed by mouth with a glass of water in the morning. The recommended way to take LBH589 is after not eating for at least 2 hours. You should also not eat for another 2 hours after taking your LBH589 capsules. The daily dose of LBH589 should be taken at approximately the same time each day. You should avoid eating grapefruit, seville oranges, or drinking grapefruit or seville orange juice during the study."
1814739|NCT00690690|Behavioral|Video (group-delivered video-based intervention)|group-delivered video-based intervention
1814740|NCT00690690|Behavioral|HCT|Offer of HIV counseling and testing
1814741|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +4.0 D Add Power Intraocular Lens|Intraocular Lens
1814742|NCT00684138|Device|ACRYSOF® ReSTOR® Aspheric +3.0 D Add Power Intraocular Lens|Intraocular Lens
1814743|NCT00684164|Drug|Conivaptan|20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
1814744|NCT00684164|Other|D5|Volume loading dose of D5 followed by an infusion of D5 over 24 hours for up to 4 days - or until the study endpoint of sodium ≥135mEq/L is reached.
1814745|NCT00684177|Drug|Retapamulin Ointment, 1%|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
1814746|NCT00684177|Drug|Placebo ointment|Provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse taper puncture tip caps.
1814747|NCT00684190|Drug|AZD3355|150 mg bid, oral, 7 days
1814748|NCT00684190|Drug|Esomeprazole|40 mg od, oral, 7 days
1814749|NCT00684203|Drug|Vorapaxar|Oral tablets; single 20-mg or 40-mg loading dose on first day followed by daily 1-mg or 2.5-mg maintenance dose for 59 days
1814750|NCT00684203|Drug|Placebo|Oral tablets; matching placebo for SCH 530348 loading and maintenance doses for 59 days
1814751|NCT00684203|Drug|Aspirin|Loading dose of 75-325 mg on Day 1, then 75-100 mg once daily for 60 days.
1814752|NCT00684203|Drug|Clopidogrel|100 mg two or three times daily for 60 days.
1814753|NCT00684216|Drug|capecitabine|200 mg, BID, PO, QD until progression of disease
1814754|NCT00684216|Drug|hormonal treatment (tamoxifen, exemestane, anastrozole or letrozole)|either tamoxifen or aromatase inhibitor (exemestane, anastrozole or letrozole), QD, until progression of disease
1814755|NCT00684229|Procedure|Regional anesthesia and analgesia|Post-operative analgesia will be epidural bupivacaine and fentanyl as well as intravenous morphine.
1814756|NCT00684229|Drug|general anesthesia followed by opioid analgesia|sevoflurane general anesthesia and postoperative opioid analgesia
1814757|NCT00684242|Drug|Lenalidomide|10 mg by mouth daily
1814758|NCT00684255|Procedure|Reduced Intensity Allogeneic Transplant|Eeduced intensity allogeneic stem cell transplantation with a fludarabine/busulfan/alemtuzumab conditioning regimen is anticipated to result in mixed and/or complete donor chimerism and potentially alter the natural history and outcome of patients with medically refractory Systemic Lupus Erythematosus (SLE) or Systemic Sclerosis (SSc).
1814759|NCT00684255|Drug|Fludarabine|Fludarabine 30 mg/m2 Day -7, -6, -5, -4, -3, -2
1814760|NCT00684255|Drug|Busulfan|Busulfan 3.2 mg/kg Days _8, -7, -6, -5
1814761|NCT00684255|Drug|Campath|Campath: 2 mg/m2 Day -5; 6 mg/m2 Day -4, -3; 20 mg/m2 Day -2
1814762|NCT00684268|Drug|Silibinin|"comparison of different dosing schedule of Silibinin infusions (20 mg/kg/d infused over 2 hours) A: 3x5days B: 14 days C: 21 days D: 28 days
sequential the infusion duration will be shortened - 2 hours, then 1 hr and then 1/2 hr/infusion"
1814763|NCT00684268|Drug|Silibinin|20 mg/kg Silibinin iv /d /21 days, antiviral combination therapy will be continued
1814764|NCT00684281|Other|Neurological and neuropsychological consultation, MRI|Neurological and neuropsychological consultation, MRI for the month 0, 18 and 36
1814765|NCT00684281|Other|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA|Neurological and neuropsychological consultation, MRI, Studies in imaging of drip, DNA, months 0/18/36
1814766|NCT00684294|Biological|TGFβ2 Antisense-GMCSF Gene Modified Autologous Tumor Cell (TAG) Vaccine|Patients with solid tumors will receive TAG Vaccine 1 x 10^7 cells/ injection or TAG Vaccine 2.5 X 10^7 cells/injection once a month for up to 12 doses via intradermal injection as long as sufficient material is available. Selection of cohort is dependent on the amount of tumor cell yield following harvest and processing.
1814767|NCT00684307|Drug|AZD0837|ER tablet, PO, once daily for a period of 3-9 months.
1814768|NCT00684307|Drug|Vitamin-K antagonist at INR 2-3|Tablet, PO for a period of 3-9 months.
1814769|NCT00684307|Drug|AZD0837|ER tablet, PO, twice daily for a period of 3-9 months
1814770|NCT00684320|Behavioral|Attention Disengagement Training (ADT)|Those assigned to ADT condition will receive a computer delivered attention retraining protocol designed to enhance attention disengagement from socially threatening stimuli. The ADT protocol includes eight 30-min sessions delivered over a 6-week period (i.e., bi-weekly sessions). During each session, participants will see 320 trials that consist of the various combinations of probe type (E or F) probe position (top or bottom), and emotion type (Neutral, Disgust, Anger). 256 trials will include one neutral face and one disgust face or one angry face: 2 (probe type) X 2 (probe position) X 16 (person) X 4 (repetitions). On trials where participants see one neutral face and one disgust or angry face (i.e., 80% of the trials), the probe will always follow the neutral face.
1814771|NCT00684320|Behavioral|Placebo Condition|The placebo condition (PC) will be identical to the AMP condition except that during the presentation of the trials where a threat picture is present, the probe will appear with equal frequency in the position of threat and neutral pictures. Thus, neither threat nor neutral pictures have signal value with regard to the position of the probe.
1814772|NCT00684333|Device|painless subcutaneous injection by EZ-Ject Injector|EZ-Ject Injector device employee cutaneous local anesthesia on the injection site by an electronic anesthetic system
1814773|NCT00684346|Other|18-FDG|The administered intravenous dose of 18-FDG is 0.14mCi/kg up to a maximum of 10mCi before each PET imaging scan is performed.
1814841|NCT00684918|Drug|Obatoclax|A 3-hour IV infusion for 3 consecutive days or a 24-hour infusion for 3 consecutive days every 2 weeks for up to 6 cycles.
1826111|NCT00774397|Drug|Placebo|Placebo
1814774|NCT00684372|Drug|leflunomide|"Screening: If BK viremia (BK PCR >10 000 copies/ml in serum) i. Reduced immunosuppression
MMF / AZA withdrawal
CNI reduction
Tacrolimus 5 ng/ml in serum
Cyclosporin 100 ng/ml in serum
Prednisolone to maintenance level
If effective => continue
Stable renal function (P-Krea)
>50% reduction in PCR (copies/ml) at 4 weeks after diagnosis
Negative PCR at > 3 months after diagnosis
If failure => add leflunomide
Deteriorating renal function (P-Krea) and positive PAD = BK nephropathy
<50% reduction in PCR at 4 weeks after diagnosis
Positive PCR at >3 months after diagnosis
Leflunomide dosing:
ii. Loading dose of 100 mgx1 PO daily for 5 days can be used or the patient can be directly started on iii. Maintenance dose (from day 1 or day 6)
Starting at 20 mgx1 PO daily
Thereafter adjusted between approximately 20-60 mgx1 PO daily according to serum levels of A77 1726 and the clinical situation a. Recommended level of A77 1726 >40 ug/ml"
1814775|NCT00684385|Drug|ZD1839|250mg administered daily for patients with NSCLC and500mg daily for patients with H&NC. Treatment dispensed to patients on Day 1 and every 12 weeks thereafter until the patient withdraws. Patients with NSCLC will take one tablet at each dose administration; patients with squamous cell H&NC will take two tablets at each dose administration.
1814776|NCT00684411|Drug|Imatinib mesylate|
1814777|NCT00684424|Other|Non-Interventional Study|Observational Only
1814778|NCT00684437|Behavioral|Focus Group|Focus group discussion and evaluation of various smoking risk informational messages. The focus group session should last about 1 hour and 30 minutes.
1814779|NCT00684437|Behavioral|Questionnaire|Questionnaires taking 15-30 minutes to complete.
1814780|NCT00684450|Procedure|Titration protamine|10. Study group: celite ACT will be performed every 3 minutes during protamine infusion until ACT values suggest reach of a plateau (defined as 2 similar ACT values, within 10% variability, and ACT ≤ to 160 seconds.), time at which infusion will be stopped. 2cc of blood is required per ACT test, for a maximum total of 10cc.
1814781|NCT00684450|Drug|Standard administration of protamine|1.3 mg of Protamine for 100u héparine
1814782|NCT00684463|Drug|Palonosetron|0.25 mg IV single dose, 30 minutes prior to the administration of the major chemotherapeutic agent.
1814783|NCT00684476|Drug|venom immunotherapy|
1814784|NCT00684489|Drug|clinical hypertension specialist-no specific med. Any anti-hypertension meds.|assignment to a clinical hypertension specialist. Drugs used were hypertension medications were: chlorothiazide, hydrochlorothiazide, polythiazide indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, ditiazem, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, clonidine, clonidine patch, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
1814785|NCT00684489|Drug|renin guided therapeutics-no specific med. Any anti-hypertensive med.|renin guided therapeutics-chlorothiazide, chlorthalidone, hydrochlorothiazide, polythiazide, indapamide, metolazone, bumetanide, furosemide, torsemide, amiloride, triamterene, eplerenone, spironolactone, atenolol, betaxolol, bisoprolol, metoprolol, nadolol, propranolol, timolol, acebutolol, penbutolol, pindolol, carvedilol, labetalol, benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, perindopril, quinapril, ramipril, trandolapril, candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, diltiazem, dilacor, verapamil, amlodipine, felodipine, isradipine, nicardipine, nifedipine, nisoldipine, doxazosin, prazosin, terazosin, chlonidine, methyldopa, reserpine, guanfacine, hydralazine, minoxidil.
1814786|NCT00684502|Drug|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12. Specific dose depends on dose panel.
1814787|NCT00684502|Drug|Placebo|Administered orally as a solution once per day on day 1, and then day 3 through to day 12.
1814788|NCT00684515|Drug|Vorapaxar 2.5 mg|Oral tablets; once daily for 60 days.
1814789|NCT00684515|Drug|Vorapaxar 1 mg|Oral tablets; once daily for 60 days
1814790|NCT00684515|Drug|Placebo|oral tablets; once daily for 60 days
1814791|NCT00684515|Drug|Aspirin 75-150 mg|oral tablets; once daily for 60 days
1814792|NCT00684528|Drug|Metformin 1500 mg daily|500 mg thrice daily
1814793|NCT00684528|Drug|Metformin + Janufer (Janumet)|Titration up to 1500/150 mg daily
1814794|NCT00684541|Behavioral|Interpretation Modification Program|"The IMP protocol includes twelve 30-min sessions delivered over a 6-week period. Each session will comprise 220 trials. In each trial, participants will first see either a non-threat or a threat (e.g. graceful or clumsy) word on the computer screen. They will then see an ambiguous sentence (e.g. You dance at the party) and will be asked to indicate if the word and sentence were related by pressing a corresponding key. Participants will receive positive feedback (i.e., You are correct!) when they endorse a non-threat interpretation or reject a threat interpretation of an ambiguous sentence. Participants will receive negative feedback (i.e., You are incorrect.) when they endorse a threat interpretation or reject a non-threat interpretation of an ambiguous sentence."
1814795|NCT00684541|Behavioral|Interpretation Control Condition|Participants assigned to the PC completed an identical procedure to the IMP procedure except that feedback about participants' performance was not contingent on the type of interpretation (i.e., non-threat or threat) endorsed. Thus, participants in the PC received positive feedback 50% of the time when viewing a threat interpretation and 50% of the time when viewing a non-threat interpretation.
1814796|NCT00684554|Drug|Buprenorphine|Dose is determined according to the participants' individual need.
1814797|NCT00684567|Radiation|Radiotherapy|Radiotherapy will be administered in combination with temozolomide during the concomitant radiotherapy phase. Radiotherapy will consist of a conventionally fractioned regimen, delivering a total dose of 60 Gy in 6 weeks, in a once daily schedule of 2 Gy per fraction, for a total of 30 fractions. Radiation will be provided by a linear accelerator of x ray energy of 4 MV or higher.
1814842|NCT00684931|Other|Imaging|neuropsychological evaluation and Imaging with magnetic resonance (MRI)
1814843|NCT00684944|Drug|TRx0014|Gelatin capsule, tid
1958381|NCT01708941|Biological|Ipilimumab|Given IV
1958382|NCT01708941|Other|Laboratory Biomarker Analysis|Correlative studies
1815103|NCT00693186|Biological|Engerix B® 10 µg / 0.5 mL|10 µg
1958383|NCT01708941|Biological|Recombinant Interferon Alfa-2b|Given IV or SC
1814798|NCT00684567|Drug|Temozolomide|During the concomitant radiotherapy phase (6 weeks), temozolomide will be administered in combination with radiotherapy, once daily at 75 mg/m2/day. Then, during the monotherapy phase, subjects will receive 6 cycles of temozolomide alone. Each cycle will last 28 days, and temozolomide will be administered once daily from Day 1 to Day 5 of each cycle. The dose of temozolomide in the first cycle will be 150 mg/m2/day, and may be increased to 200 mg/m2/day for Cycle 2 and subsequent cycles depending on nonhematologic toxicity observed and neutrophil and platelet count values. Capsules containing 5 mg, 20 mg, or 100 mg of temozolomide will be combined to achieve each subject's calculated dose.
1814799|NCT00684580|Other|Data Collection|Continuing review of outcomes and late toxicities
1814800|NCT00684593|Drug|Navarixin 10 mg|Navarixin capsules orally, once daily for 28 days.
1814801|NCT00684593|Other|Placebo|Matching placebo capsules to Navarixin orally, once daily for 28 days.
1814802|NCT00684606|Drug|Oxytocin IV|5 miu/1000ml Glu/Saline
1814803|NCT00684619|Drug|Nelarabine|1500 mg/m² i.v., duration 2 hrs, day 1, 3, 5
1814804|NCT00684632|Drug|Placebo|Placebo
1814805|NCT00684632|Drug|KW-2246 (fentanyl citrate)|KW-2246 (fentanyl citrate)
1814806|NCT00684645|Drug|SUTENT|SUTENT® hard gelatin capsules containing 12.5 mg, 25 mg or 50 mg equivalent of sunitinib malate; daily dosage of 50 mg for 4 consecutive weeks followed by a 2-week rest period. Sutent is administered until disease progression or occurrence of unacceptable toxicity.
1814807|NCT00684658|Behavioral|TeenCope|Teencope consists of a series of 5 sessions designed to increase children's sense of competence and mastery by retraining inappropriate or non-constructive coping styles and forming more positive styles and patterns of behavior. Each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth are grouped with 8-12 peers who complete the same weekly sessions in an asynchronous manner. Youth interact with each other on an online discussion board moderated by a clinical psychologist
1814808|NCT00684658|Behavioral|Managing Diabetes|Managing Diabetes consists of 5 sessions on educational content related to diabetes self management targeted to adolescents. As with the TeenCope program, each week a new 30-45 minute session is uploaded to a password-protected website on the Yale server for youth to complete. Youth complete educational sessions independently over 5 weeks. There is no online discussion board or peer interaction.
1814809|NCT00684671|Biological|Twinrix|Intramuscular injection, single dose in left deltoid.
1814810|NCT00684671|Biological|Engerix-B|Intramuscular injection, single dose in left deltoid.
1814811|NCT00684671|Biological|Havrix|Intramuscular injection, single dose in right deltoid.
1814812|NCT00684671|Biological|HBVAXPRO|Intramuscular injection, single dose in the left deltoid.
1814813|NCT00684671|Biological|Vaqta|Intramuscular injection, single dose in right deltoid.
1814814|NCT00684684|Device|Chartis System|Assessment of airway flow and pressure
1814815|NCT00684697|Dietary Supplement|iron|High, intermediate and low iron dosage orally for 2 months
1814816|NCT00684710|Drug|PAZ-417|
1814817|NCT00684710|Drug|Placebo|
1814818|NCT00684723|Drug|Lovastatin 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
1814819|NCT00684723|Drug|Lovastatin (Mevacor®) 40 mg Tablets|40 mg tablet administered 30 minutes following the start of a standardized high-fat, high-calorie breakfast
1814820|NCT00684762|Drug|Cilostazol 100 mg Tablets|Cilostazol (1 x 100 mg tablet) administered after an overnight fast of at least 10 hours
1814821|NCT00684762|Drug|Cilostazol (Pletal®) 100 mg Tablets|Cilostazol (Pletal® 1 x 100mg tablet) administered after an overnight fast of at least 10 hours.
1814824|NCT00684801|Other|questionnaire administration|Patients complete questionnaires.
1814825|NCT00684801|Procedure|quality-of-life assessment|Patients undergo quality-of-life assessments.
1814826|NCT00684814|Drug|Zolpidem Tartrate 10 mg tablet|10 mg tablet administered after an overnight fast of at least 10 hours
1814827|NCT00684814|Drug|Zolpidem Tartrate 10 mg tablet (Ambien®)|10 mg tablet administered after an overnight fast of at least 10 hours
1814828|NCT00684827|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|"Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
Arm #A
Xopenex HFA MDI, Pirbuterol HFA MDI"
1814829|NCT00684827|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|"Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
Arm #B
Pirbuterol HFA MDI, Xopenex HFA MDI"
1814830|NCT00684853|Drug|bevacizumab|1.25 mg of bevacizumab intravitreal
1814831|NCT00684853|Drug|vetaporfin|full fluence of vetaporfin
1814832|NCT00684866|Drug|Levalbuterol HFA MDI followed by Racemic albuterol HFA MDI|(a) Subjects will receive both treatments: (a) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses); followed by (b) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses)
1814833|NCT00684866|Drug|Racemic Albuterol followed by levalbuterol HFA MDI|(a) Subjects will receive both treatments: (a) racemic albuterol HFA MDI; 90 micrograms (16 cumulative doses) followed by (b) levalbuterol HFA MDI; 45 micrograms (16 cumulative doses)
1814834|NCT00684892|Device|Chartis System|Assessment of airway flow and pressure
1814835|NCT00684905|Drug|bicalutamide|
1814836|NCT00684905|Drug|leuprolide acetate|
1814837|NCT00684905|Procedure|adjuvant therapy|
1814838|NCT00684905|Procedure|neoadjuvant therapy|
1814839|NCT00684905|Procedure|quality-of-life assessment|
1814840|NCT00684905|Radiation|brachytherapy|
1814849|NCT00690729|Behavioral|Cognitive Behavioral Bibliotherapy|Minimal therapist direction for self-guided bibliotherapy involving exposure and response prevention
1814850|NCT00690729|Behavioral|Cognitive Behavioral Therapy|Therapist-directed exposure and response prevention
1814851|NCT00690768|Drug|Bevacizumab|Intravitreal bevacizumab (1.5 mg; 0,06 ml) 1 week after baseline; pars plana vitrectomy 3 weeks after baseline
1814852|NCT00690768|Procedure|pars plana vitrectomy|pars plana vitrectomy 3 weeks after baseline
1814853|NCT00690781|Dietary Supplement|Pulse casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
1814854|NCT00690781|Dietary Supplement|Spread casein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being casein. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
1814855|NCT00690781|Dietary Supplement|Pulse milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a pulse protein feeding pattern is used (8% protein in the morning, 80% for lunch, 4% at 1600 h and 8% in the evening).
1814856|NCT00690781|Dietary Supplement|Spread milk soluble protein feeding during energy restriction|Obese subjects are subjected to a 35% energy restriction during 6 weeks and during this period, 25% of energy is given as protein, these proteins being milk soluble proteins. In addition, a spread protein feeding pattern is used (25% of protein at each of the four meals of the day).
1814857|NCT00690794|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
1814858|NCT00690794|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanprost.
1814859|NCT00690807|Drug|PH-10|PH-10 will be applied daily for 28 days to skin areas affected by atopic dermatitis.
1814860|NCT00690820|Drug|Pancrelipase Delayed Release|12,000 unit Capsules, dosed individually based on fat intake.
1814861|NCT00690820|Drug|Placebo Comparator|Placebo
1814862|NCT00690833|Drug|topical desonide hydrogel 0.05%|apply the smallest amount of study medication possible that is just sufficient to cover all lesions of the standard cortisone-type medication twice daily (morning and evening) for up to 4 weeks to all of their AD lesions
1814863|NCT00690846|Drug|adalimumab|40 mg weekly adalimumab injection.
1814864|NCT00690872|Biological|autologous Epstein-Barr virus-specific cytotoxic T lymphocytes|
1814865|NCT00690872|Drug|carboplatin|
1814866|NCT00690872|Drug|gemcitabine hydrochloride|
1814867|NCT00690872|Genetic|polymerase chain reaction|
1814868|NCT00690872|Other|fluorescence activated cell sorting|
1814869|NCT00690872|Other|immunoenzyme technique|
1814872|NCT00690898|Drug|Lanreotide autogel 120 mg|12 months
1814873|NCT00690911|Drug|adalimumab|40mg dose subcutaneously using sterile technique. The site research staff will instruct and supervise subjects or a designee or nurse on proper injection technique during site visit evaluations. Subjects or a reliable designee will administer injectable study drug at home in between site visit evaluations.
1994408|NCT03013218|Drug|Pembrolizumab|Keytruda
1814877|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
1814878|NCT00690937|Drug|Enteric coated sevelamer|Drug treatment
1814879|NCT00690937|Drug|Colesevelam Cholestagel|Drug comparator
1814880|NCT00690937|Drug|Placebo|Placebo
1814881|NCT00690937|Drug|Placebo|Placebo
1814882|NCT00690950|Drug|Dutasteride|0.5mg capsule, taken once daily for 12 months
1814883|NCT00690963|Procedure|Radiotherapy|Dose excalation based on normal tissue toxicity using 5 dose bins ranging from 56.8 Gy/ 27 fractions to 67.3 Gy in 27 fractions.
1814884|NCT00690976|Behavioral|Proyecto SOL|Group intervention
1814885|NCT00690976|Behavioral|HCT|Offer of HIV counseling and testing
1814886|NCT00691002|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
1814887|NCT00691015|Biological|rituximab|Given IV
1814888|NCT00691015|Drug|busulfan|Given IV
1814889|NCT00691015|Drug|carmustine|Given IV
1814890|NCT00691015|Drug|cyclophosphamide|Given IV
1814891|NCT00691015|Drug|cytarabine|Given IV
1814892|NCT00691015|Drug|etoposide|Given IV
1814893|NCT00691015|Drug|fludarabine phosphate|Given IV
1814894|NCT00691015|Drug|melphalan|Given IV
1814895|NCT00691015|Radiation|total body irradiation (TBI)|Given once or twice daily
1814896|NCT00691015|Drug|anti-thymocyte globulin IV|Given IV
1814897|NCT00691028|Drug|TA-650 3 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
1814898|NCT00691028|Drug|TA-650 6 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6 weeks. Then 6 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
1814899|NCT00691028|Drug|TA-650 10 mg/kg|3 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 0, 2 and 6. Then 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at weeks 14, 22, 30, 38 and 46.
1814900|NCT00691522|Drug|Xerecept|
1815104|NCT00693199|Drug|amlodipine|amlodipine 5mg once daily for 28 days
1815105|NCT00693199|Drug|terazosin|terazosin 2 mg once daily for 28 days
1994409|NCT03013218|Drug|Trastuzumab|Herceptin
1994410|NCT03013218|Drug|Rituximab|Rituxan
1814901|NCT00691548|Drug|Cetuximab-Zr. 89|"Step 1: Determination of the toxicity of two low doses of 89Zr-cetuximab In three patients a standard loading dose of 400 mg/m2 of cetuximab will be administered, partly labelled with 89Zr (60 MBq, 2.5mg) on day 0.
On day 14, a second injection with dose of 250 mg/m2 of cetuximab, partly labelled with 89Zr (60 MBq, 2.5mg), will be given.
Step 2: Determination of the toxicity of one larger dose of 89Zr-cetuximab A standard loading dose of 400 mg/m2 of cetuximab will be administered in 3 patients, a part labelled with 89Zr (120MBq, 5mg)."
1814902|NCT00691561|Behavioral|Project ABLE|Participants will receive HIV counseling and testing. Those selected for the intervention arm will attend small groups consisting of 10 men who meet once a week for 8 consecutive weeks. The weekly two hour discussion sessions will address HIV risk behavior within a framework of contextual influences that may moderate men's risk reduction motivation and behavior. The factors include identity, stigma, connections to community, and situation factors.
1814903|NCT00691574|Dietary Supplement|Melatonin|up to 3 mg, daily, for up to 1 year
1814904|NCT00691574|Device|Enviro-light artificial light box|Subjects will sit in front of an artificial, fluorescent light box (10,000 lux) while completing 25-hours of hourly plasma samples. The light lux level will be well below that identified as safe by the FDA.
1958394|NCT01704352|Behavioral|Cognitive behavioral therapy for insomnia|CBT-I will be given during 3-6 sessions according to need by two therapists being either psychiatrists or psychologists with clinical experience in CBT-I.
1998699|NCT01084252|Drug|Dexamethasone|"Pharmaceutical form: tablet
Route of administration: oral"
1998700|NCT01076543|Other|Laboratory Biomarker Analysis|Correlative studies
1814912|NCT00691613|Drug|Epoetin alpha|The dosage (60.000 I/U Epoetin alpha) will be diluted in 10 ml of 0.9% sodium chloride solution and injected in a single dose intravenously in the dominant forearm (the non-dominant forearm will be used as ischemic model).
1814913|NCT00691613|Drug|NaCl|0.9% sodium chloride solution as placebo dosage is 10 ml, which will be administered in the same manner as the interventional medicinal product.
1814916|NCT00691639|Other|Blood Collection Only|Blood Collection Only
1814917|NCT00691652|Biological|rituximab|Administered weekly times 4 weeks and then monthly during the study for up to 8 cycles and will be given on day 1 of clofarabine. A peripheral or central intravenous (IV) line will be established. The initial dose rate at the time of the first infusion should be 50/mg/hr for the first hour. If no toxicity is seen, the dose rate may be gradually escalated (50 mg/hr increments at 30 minute intervals) to a maximum of 300 mg/hr. If the first dose of rituximab is well tolerated, the starting flow rate for the administration of subsequent doses will be 100 mg/hr then gradually increased (100 mg/hr increments at 30 minute intervals) not to exceed 400 mg/hr.
1814918|NCT00691652|Drug|clofarabine|Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
1814919|NCT00691652|Genetic|DNA methylation analysis|We will use an HPLC assay developed by Yu et al31 to determine the DNA methylation (DMI) index in peripheral blood and bone marrow of patients entering this trial and after treatment with clofarabine and rituxan
1814920|NCT00691652|Genetic|gene expression analysis|Total RNA will be processed for determination of gene expression by microarray
1814921|NCT00691652|Genetic|microarray analysis|we will scan the microarray slides with an Axon scanner, and quantify data using the GeneSight software. Local background is subtracted and data points with no signal, high background, or spot asymmetry are eliminated. We will adjust genes with low expression and low signal intensity to a minimal raw value of 5: This avoids unwarranted mathematical distortions due to division by decimals << 1. After calculating the ratio of the Cy5 /Cy3 fluorescence signal intensity for each gene, we normalize the data relative to the mean intensity from all genes.
1814922|NCT00691652|Genetic|polymerase chain reaction|
1814923|NCT00691652|Other|high performance liquid chromatography|Fifteen µg of DNA will be sonicated for 60 seconds on ice into 200 bp-1000 bp fragments. Samples are then denatured at 1000C for 5 minutes and cooled on ice to prevent re-annealing. Sixty units of nuclease S1 (Invitrogen) and 112.5 mu of snake venom phosphodiesterase I (Sigma) in 12 µl of S1 dilution buffer is then added to the samples and incubated at 370C for 18 hours. Samples are reheated to 1000C for 5 minutes, snap cooled again on ice, and another sixty units of nuclease S1 and 112.5 mu of snake venom phosphodiesterase I are added and incubated at 370C for another 4 to 6 hours. The pH of each sample was raised to 8.5 with 0.5 M Tris, pH 10. Two and a half units of alkaline phosphatase (Sigma) are added and incubated for 2 additional hours at 370C. One hundred µl of 0.05M potassium phosphate, pH 7 is added to final samples before 50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
1814924|NCT00691652|Other|laboratory biomarker analysis|50 µl of the clear supernatant is injected into the reverse-phase high performance liquid chromatography (HPLC).
1814925|NCT00691665|Drug|Olopatadine HCL Nasal Spray, 0.6%|Olopatadine HCL Nasal Spray, 0.6% 2 sprays per nostril twice daily
1814926|NCT00691665|Drug|Fluticasone Propionate Nasal Spray, 50 mcg|Fluticasone Propionate Nasal Spray, 50 mcg 2 sprays per nostril once daily
1814927|NCT00691678|Drug|Chondroitin|400mg chondroitin TID for twenty-four weeks
1814928|NCT00691678|Drug|Glucosamine|500mg glucosamine TID for twenty-four weeks
1815012|NCT00692354|Drug|CHR-2797 (tosedostat)|Drug was given orally, once daily, ensuring a dosing interval of approximately 24 hours. Dose escalations took place starting at 10mg and escalating (per protocol) as follows: 20, 40, 90, 130, 180, 240 and 320 mg
1815106|NCT00693199|Drug|amlodipine plus terazosin|amlodipine 5 mg plus terazosin 2 mg once daily for 28days
1998701|NCT01076543|Drug|Lenalidomide|Given PO
1998702|NCT01076543|Drug|Temsirolimus|Given IV
1998703|NCT01075412|Drug|[F18]Fluorothymidine|FLT PET scan 5 mCi (+/- 10%)
1998705|NCT01071512|Drug|Tysabri|Infuse TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP. Tysabri will be infused every four weeks.
1998706|NCT01071239|Device|CliniMACs device|Donor Peripheral blood progenitor cells will use CD34+ selection with the use of the CliniMACs device
1814929|NCT00691691|Radiation|Stereotactic Body Radiation Therapy|Radiation Dose: 48 Gy in 4 fractions in 2 weeks. A minimum of 48 hours should separate each treatment (e.g. every Tuesday and Friday). The dose is prescribed to the marginal isodose (80-90%) that encompasses the entire target lesion (GTV). Treatment will be delivered using a linear accelerator. For verification of the accuracy of these external skin fiducial markers, 10 patients will also have implanted internal gold coil markers. The implantable gold coil markers will be implanted into the liver in the proximity of the target lesions via a percutaneous transhepatic route under fluoroscopy guidance.
1814930|NCT00691704|Drug|Lenalidomide Induction|Induction: Lenalidomide 25 mg daily on Days 1-21 followed by 7 day rest and Dexamethasone 40 mg by mouth (po) daily on Days 1, 8, 15 and 22 every 28 days for 4 cycles.
1814931|NCT00691704|Drug|Sequential Maintenance Therapy|"Subjects who achieve >partial response (PR) following induction therapy will receive repeating triplet cycles of alternating low dose therapy until progression, poor tolerance or toxicity. Subjects who complete 24 months of maintenance will be removed from study unless they achieved > stable disease (SD) from maintenance (per discussion with physician):
325 mg aspirin for deep vein thrombosis (DVT) prophylaxis
Cycle 1, 4, 7, etc. - bortezomib 1.3 mg/m2 on day 1 and 8 of a 28-day cycle
Cycle 2, 5, 8 etc. - Melphalan 6 mg/m2 by mouth (po) daily on Days 1-7
Prednisone 60 mg /m2 po daily on Days 1-7 of a 28-day cycle
Cycle 3, 6, 9, etc. Lenalidomide 10 mg po daily on Days 1-21 of a 28 day cycle."
1814932|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 30 mg/mL|Single administration by anterior juxtascleral depot
1814933|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 60 mg/mL|Single administration by anterior juxtascleral depot
1814934|NCT00691717|Drug|Anecortave Acetate Sterile Suspension, 75 mg/mL|Single administration by anterior juxtascleral depot
1814935|NCT00691717|Other|Anecortave Acetate Vehicle|Single administration by anterior juxtascleral depot
1814936|NCT00691730|Other|laboratory biomarker analysis|Correlative studies
1814937|NCT00691730|Other|pharmacological study|Correlative studies
1814938|NCT00691756|Procedure|Cold blood renal perfusion|Both kidneys receive intermitent perfusion with cold (4 degrees C) autologous blood during thoracoabdominal aortic aneurysm repair.
1814939|NCT00691756|Procedure|Cold crystalloid renal perfusion|Both kidneys receive intermittent perfusion with cold (4 degrees C) lactated Ringer's solution during thoracoabdominal aortic aneurysm repair. This is the standard renal perfusion technique in our practice.
1814940|NCT00691782|Other|Survey of exercise practices|detailed questionnaire regarding the subject's race, income level; type(s), frequency, intensity, and amount of exercise; attitudes about exercise; hair style; hair care practices; attitudes about hair; hair and scalp health; and attitudes about exercise with regards to hair
1814941|NCT00691795|Drug|Clonidine or fentanyl|After obtaining consent, the patients will be randomized into two groups using a random allocation table. At the onset of late stage breakthrough pain one arm of patients will receive a mixture of 75 mcg clonidine and 10 mg bupivacaine in 8 ml of volume and the second group will receive 75 mcg fentanyl and 10 mg bupivacaine in 8 ml of volume.
1814942|NCT00691808|Drug|LX6171 High Dose|A high dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
1814943|NCT00691808|Drug|LX6171 Low Dose|A low dose of LX6171, using an oral suspension; daily oral intake for 28 days in the morning at approximately the same time.
1814944|NCT00691808|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days in the morning at approximately the same time.
1814945|NCT00691821|Other|Standard Dressings|Participants will receive standard dressings changes as needed. Different dressing types (e.g., silver, simple gauze, hydrogel, foam, creams, gels) will be used dependent on the type of the wound (e.g., dry, wet, and intermediate).
1814946|NCT00691821|Device|Negative Pressure Wound Therapy (Vacuum-Assisted Closure System [V.A.C.® Therapy™, KCI Medical Canada Inc., Mississauga, Ontario])|Participants will receive negative pressure wound therapy.
1814947|NCT00691834|Biological|Intracoronary delivery of unfractionated bone marrow mononuclear cells|Maximal intracoronary cell dose: 50 x 10e7 cells diluted in 10 ml Maximal intracoronary volume: 10 ml (diluted in plasma and culture medium)
1814948|NCT00691834|Biological|Placebo|Plasma and culture medium (10 ml)
1814949|NCT00691860|Device|Mesh (Ultrapro ®)|In the mesh group, the mesh was placed in the sublay position, above the peritoneum and the posterior rectus sheath of the rectus abdominis muscles, with a minimum of 5 cm of mesh around the colostomy
1814950|NCT00691860|Procedure|Conventional sigmoid end colostomy|Patients receiving conventional sigmoid end colostomy, without mesh
1814951|NCT00691873|Drug|Placebo|placebo
1814952|NCT00691873|Drug|Xolair|Xolair 150-375 mg SQ every 2 or 4 weeks based on body weight and pre treatment IgE level.
1814953|NCT00691886|Drug|dexmedetomidine hydrochloride|Dose of 0.4ug/kg/hr to 1.5ug/kg/hr to achieve a RASS score of -1 to-3 during the bronchoscopy procedure. Dexmedetomidine will infused a half hour before the proceudure is started and will continue throughout the procedure. Traditional sedatives (midazolam and or fentanyl) will be given prn.
1814954|NCT00691899|Drug|odanacatib|odanacatib; 5mg oral, once daily for Approximately 36 months.
1814955|NCT00691899|Drug|placebo (unspecified)|placebo; oral, once daily for Approximately 36 months
1814956|NCT00691912|Drug|liposomal Doxorubicin|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
1814957|NCT00691912|Drug|Myocet / Paclitaxel|20 mg/m² Myocet® as 30-minutes infusion on day 1,8,15 80 mg/m² Paclitaxel as 60-minutes infusion on day 1,8,15 q21d
1814958|NCT00691938|Drug|LBH589|
1814959|NCT00691938|Drug|Decitabine|
1814961|NCT00691964|Biological|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
1814962|NCT00691964|Biological|etanercept|SQ injection 50 mg BIW
1814963|NCT00691964|Drug|placebo|SQ placebo injections for ABT-874 and etanercept
1814964|NCT00691977|Radiation|Radiation Therapy followed by prostatectomy|Radiation Therapy
1814965|NCT00691990|Procedure|Total thyroidectomy|Comparison of the safety and cost-effectiveness of classic thyroidectomy with or without drains
1815052|NCT00692731|Other|Control beverage matched for energy and caffeine content|500 mL/day of a control beverage
1815053|NCT00692757|Drug|Hypochlorous acid|Hypochlorous acid for preoperative scrubbing to prevent surgical site infection in spray
1814966|NCT00692003|Drug|Zonisamide|"25-400 mg capsules orally once daily in the evening.
Maximum study duration of 28 weeks comprising:
Baseline Period (Week-8/-4 to Week 0) no treatment
Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg; >= 12 years old: 50 mg daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4
Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)
Down Titration Period (4 weeks)"
1814967|NCT00692003|Drug|Placebo|"25-400 mg Zonisamide Placebo capsules orally once daily in the evening.
Maximum study duration of 28 weeks comprising:
Baseline Period (Week-8/-4 to Week 0) no treatment
Titration Period (Week 0 to Week 4) <12 years old: 1 mg/kg Zonisamide Placebo; >= 12 years old: 50 mg Zonisamide Placebo capsules daily titrated weekly until a dose of 5 mg/kg or 300 mg was reached by Week 4
Maintenance Period (Week 4 to Week 16) dose from Week 4 to be maintained (4 mg/kg or 200 mg in the event of dose limiting adverse events)
Down Titration Period (4 weeks)"
1814968|NCT00692016|Drug|Naproxen sodium|Administered under fasting condition
1814969|NCT00692016|Drug|Naproxen sodium|Administered under fed condition
1814970|NCT00692042|Drug|AZD1704|One dose, by mouth
1814971|NCT00692055|Drug|PN400|naproxen 375 mg / esomeprazole 20 mg
1814972|NCT00692055|Drug|Naproxen|naproxen 375 mg
1814973|NCT00692081|Behavioral|Social competence training|8 group sessions multi-modal social competence training, 2-4 hours each, 2 trainers, 6-10 participants
1814974|NCT00692081|Behavioral|Special vocational training|as provided in German special centres for vocational training
1814975|NCT00692094|Biological|Melatonin|0.025 mg-0.5 mg, daily given at a time when it is expected to delay the timing of the body clock.
1814976|NCT00692094|Biological|Melatonin|0.025 mg - 0.5 mg, daily, at a time when melatonin should advance the timing of their body clock.
1814977|NCT00692094|Biological|Melatonin|0.025 mg - 10 mg, daily, at a time when melatonin should advance the timing of their body clock.
1814978|NCT00692094|Biological|Melatonin|0.025 mg - 20 mg, daily, at a time when the melatonin should advance the timing of the body clock.
1814979|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
1814980|NCT00692107|Radiation|Gray|68 Gy vs. 78 Gy
1814981|NCT00692120|Dietary Supplement|Cholecalciferol (vitamin D3)|50,000 IU once monthly for 12 months
1814982|NCT00692120|Dietary Supplement|Ergocalciferol (vitamin D2)|oral capsule 50,000 IU once monthly for 12 months
1814983|NCT00692120|Dietary Supplement|Ergocalciferol (vitamin D2)|oral capsule 1600 IU once daily for 12 months
1814984|NCT00692120|Dietary Supplement|Cholecalciferol (vitamin D3)|oral capsule 1600 IU once daily for 12 months
1814985|NCT00692120|Dietary Supplement|Placebo|oral placebo capsule once daily for 12 months
1814986|NCT00692146|Drug|AZD1386|Oral solution fixed dose (95 mg given orally on two occasions)
1814987|NCT00692146|Drug|Placebo|Oral solution fixed dose (95 mg given orally on two occasions)
1814988|NCT00692159|Drug|TRC102 + pemetrexed|Oral TRC102 solution + IV pemetrexed
1814989|NCT00692172|Drug|Alefacept|intramuscular injection (IM)
1814990|NCT00692185|Drug|Olanzapine|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of olanzapine once each evening for 8 weeks.
1814991|NCT00692185|Drug|Placebo|Participants will take 2.5 mg, 5.0 mg, or 10.0 mg of placebo once each evening for 8 weeks.
1814992|NCT00692198|Drug|Supplemental oxygen therapy|Oxygen dose at rest and during sleep will be 2 L/min via nasal cannula. The oxygen dose used while walking will be individually prescribed and will be sufficient to maintain oxygen saturation at 90% or above for at least 2 minutes while walking. Participants who have low blood oxygen levels at rest will be instructed to use oxygen 24 hours per day. Participants who have normal resting blood oxygen levels, but low or very low blood oxygen levels during exercise, will be instructed to use oxygen during physical activity and sleep.
1814993|NCT00692211|Other|Mailed fecal occult blood tests|Stool blood test
1814994|NCT00692211|Other|Mailed fecal immunochemical tests|Stool blood test
1814995|NCT00692224|Drug|zinc gluconate|zinc gluconate syrup - 10mg/day in two divided doses from day 2 to day 7 of life
1814996|NCT00692224|Drug|placebo|placebo was packed in similar looking bottles and ad similar taste as zinc gluconate drug
1814997|NCT00692237|Drug|Sildenafil|100 mg daily (3 capsules/day)
1814998|NCT00692237|Drug|Placebo|Placebo 100 mg (3 capsules/day)
1814999|NCT00692250|Drug|Colesevelam hydrochloride film-coated tablets (Cholestagel)|
1815000|NCT00692263|Drug|escitalopram and tramadol|10 mg escitalopram for 3 days 20 mg escitalopram for 6 days 150 mg tramadol as a single dose on day 9
1815001|NCT00692263|Drug|placebo|placebo identical for 10 mg/ 20 mg escitalopram and 150 mg tramadol
1815002|NCT00692263|Drug|placebo and tramadol|9 days of placebo equivalent to 10 / 20 mg escitalopram, one single dose of 150 mg tramadol on day 9
1815003|NCT00692276|Device|Superion™ Interspinous Spacer|Implantation of interspinous process spacer to treat lumbar spinal stenosis
1815004|NCT00692276|Device|X-STOP® IPD® Device|Implantation of interspinous process spacer to treat lumbar spinal stenosis
1815005|NCT00692302|Behavioral|SAFETY|Participants will receive a family-based cognitive behavioral therapy intervention called SAFETY for 12 weeks. The SAFETY intervention is an individually tailored intervention strategy that integrates (1) family- and community-based interventions aimed at mobilizing family and community networks that support youth safety, adaptive behavior, and reasons for living; (2) cognitive behavioral treatment modules that focus on decreasing suicidality and preventing repeat suicide attempts; and (3) an individualized care linkage strategy that links youth to needed services and resources.
1815006|NCT00692302|Behavioral|Enhanced usual care|Enhanced usual care will include treatment as usual enhanced by study support.
1815007|NCT00692315|Drug|Methylcobalamin (methylB12)|75 ug/Kg methylB12 every 3 days by subcutaneous injection
1815008|NCT00692328|Behavioral|Levodopa or acupuncture|Comparison of subject expectancy of receiving levodopa or acupuncture.
1815009|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
1815010|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
1815011|NCT00692341|Drug|AG-013736|Single oral 5-mg dose of AG-013736, administered as a film-coated, immediate-release tablet.
1815054|NCT00692757|Drug|Iodopovidone|Iodopovidone
1826389|NCT00777075|Drug|Placebo|
1815013|NCT00692367|Behavioral|Physical Activity|1. Physical activity group: Subjects will be progressed to 4-5 days per week, 30-45 min per session (120-180 min per week) of moderate intensity exercise. 2. Control (educational) group: Subjects will receive their usual care following surgery that in addition to their weight loss.
1815014|NCT00692380|Radiation|Fractionated radiation therapy followed by chemotherapy|Increasing doses of radiation therapy
1815015|NCT00692393|Procedure|Hartmann intervention|sigmoid resection, peritoneal and rectal lavage, terminal stoma
1815016|NCT00692393|Procedure|Protected anastomosis resection|sigmoid resection , peritoneal and rectal lavage, anastomosis, diverting stoma
1815017|NCT00692406|Behavioral|Smoking Abstinence|Smokers were scanned after having quitting smoking for 24 hours, and scanned after smoking as usual.
1815018|NCT00692419|Behavioral|Symptom management nurse intervention|A symptom management nurse will facilitate the management of pain, sexual dysfunction and depression in patients enrolled in one arm of the study
1815019|NCT00692419|Behavioral|Feedback intervention|Pain, sexual dysfunction and depression will be assessed monthly and feedback will be given to renal providers on the presence and severity of these symptoms. Treatment will be left at the discretion of the renal provider
1815020|NCT00692445|Drug|TC-5214 + citalopram|TC-5214 (as TC-5214-23) will be provided as white, opaque, hard-gelatin capsules in strengths of 1, 2, and 4 mg.
1815021|NCT00692445|Drug|Placebo + citalopram|Placebo will be provided with exactly the same shape, size and appearance. Subjects will take 2, 4, or 8 mg of study drug (or matching placebo), divided BID.
1815022|NCT00692458|Drug|Comparator: odanacatib|odanacatib; 5mg oral, once daily for approximately 60 months.
1815023|NCT00692458|Drug|Comparator: placebo|placebo; oral, once daily for approximately 60 months
1815024|NCT00692471|Device|Actigraphy Watch (motion sensors) with light sensors - ActiWatch from Minimitter|Watch to be worn on wrist for 7 days (except in water) that will measure activity/movement.
1815025|NCT00692484|Drug|Chlorhexidine gluconate|Chlorhexidine gluconate (2% w/v) in an aqueous base. Administered topically.
1815026|NCT00692484|Drug|Povidone iodine|Povidone iodine scrub and paint. Administer topically.
1815027|NCT00692497|Behavioral|one stop (Electronic standardised referrals and appointment bookings)|The one stop strategy is a set of interventions directed at GPs referring to the University Hospital. The interventions include: Guidelines for referral, standardised electronic referrals, booking for outpatient surgery and a patient information form.
1815028|NCT00692510|Drug|AZD3480|Capsule, oral, dose once daily, 7 days
1815029|NCT00692510|Drug|Placebo|Capsule, oral, dose once daily, 7 days
1815030|NCT00692510|Drug|Cocktail mix (Caffeine, Bupropion, Rosiglitazone, Omeprazole, Midazolam, Bilirubin)|"Cocktail mix which contains the following:
CYP1A2 (Caffeine), CYP2B6 (Bupropion), CYP2C8 (Rosiglitazone), CYP2C19 (Omeprazole), CYP3A4 (Midazolam), UGT1A1 (Bilirubin)
single dose of mix"
1815031|NCT00692523|Other|Recreational therapy activities|Recreational therapy sessions will include leisure activities such as playing cards and/or doing arts and crafts.
1815032|NCT00692523|Other|Nintendo Wii|The Nintendo Wii gaming system, released in 2005, introduced a new style of virtual reality by using a wireless controller that interacts with the player through a motion detection system. Nintendo Wii involves the incorporation of 3-dimensional accelerometer technology that can respond to changes in direction, speed, and acceleration, down to the most delicate movements. Specifically, the controllers use embedded acceleration sensors to enable players' wrist, arm, and hand movements to interact with the games. Tilt measurements allow users to move characters, while the accurate three-axis acceleration sensing easily transforms the controller into a virtual sword, gearshift, or musical instrument
1815033|NCT00692536|Behavioral|NNR (Nordic Nutrition Recommendations)|Diet with equal amounts of fat, protein and carbohydrates
1815034|NCT00692536|Behavioral|MPD (Modified paleolithic diet)|A diet high in protein and fat, but low in carbohydrates
1815035|NCT00692549|Device|ultrasound|
1815036|NCT00692562|Procedure|simultaneous islet-kidney transplantation|
1815037|NCT00692575|Behavioral|Problem-solving, education based telephone counseling|Caregivers are contacted every 2 weeks for 16-20 weeks after discharge of TBI survivor home. A caregiver support specialist provides telephone counseling based on a problem-solving, educational model.
1815038|NCT00692575|Other|No Intervention|The control group will receive standard of care, i.e., typical resources and/or supports offered to caregivers of persons with TBI.
1815039|NCT00692601|Dietary Supplement|Acute consumption of Capsiate Natura|10 capsules = 3 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. 3 active capsules containing 1 mg capsiate each and 7 placebo capsules.
1815040|NCT00692601|Dietary Supplement|Acute consumption of Capsiate Natura|10 capsules = 10 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
1815041|NCT00692601|Dietary Supplement|Acute ingestion of identical placebo capsules|10 mg placebo = 0 mg total capsiate. Consumed ONCE orally as capsules 30 minutes before starting to exercise. Each capsule contains 1 mg capsiate.
1815042|NCT00692614|Drug|triamcinolone acetonide|100 mcg; 500 mcg; 925 mcg triamcinolone acetonide on helical coil implant to elute over 12 months.
1815043|NCT00692640|Drug|XL147 (SAR245408)|Gelatin capsules supplied in 25-mg and 100-mg strengths; daily dosing for 21 days/7 days off
1815044|NCT00692640|Drug|Erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
1815045|NCT00692653|Behavioral|P4|Tailored online decision support system for prostate cancer treatment decision making
1815046|NCT00692692|Procedure|DermaMatrix|DermaMatrix acellular dermis with tissue expanders after mastectomy for breast reconstruction
1815047|NCT00692692|Procedure|standard of care tissue expander breast reconstruction surgery after mastectomy|standard of care muscle coverage over Tissue expander for breast reconstruction
1815048|NCT00692705|Drug|Radioligand (11C)AZD2995|Single dose of i.v solution. 1-2 times for AD patients. Once for healthy volunteers.
1815049|NCT00692705|Drug|Radioligand (11C)AZD2184|Single dose of i.v solution. Once for AD patients respective healthy volunteers.
1815050|NCT00692718|Drug|Epadel, Eicosapentaenoic acid|Epadel 900mg, 2 times a day, during hospitalization
1815051|NCT00692731|Dietary Supplement|500 mL/day of a beverage providing approximately 625 mg catechins|Subjects were asked to consume 500 mL/day of a beverage providing approximately 625 mg catechins
1815057|NCT00692796|Other|Pulmonary rehabilitation|Pulmonary rehabilitation is a multi-disciplinary program that includes exercise training, disease education, psychosocial education (e.g., stress management, coping with chronic illness) and nutrition education.
1815058|NCT00692835|Procedure|Total Thyroidectomy (Mini Video Assisted Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
1815059|NCT00692835|Procedure|Total Thyroidectomy (Classic Thyroidectomy)|Immediate postoperative course of patients with Thyroidectomy
1815060|NCT00692848|Other|Procalcitonin dosage PCT-Q test (Brahms, Germany)|Procalcitonin result available to the attending physician
1815061|NCT00692887|Device|PHP - Preferential Hyperacuity Perimeter (Foresee)|computerized test
1815062|NCT00692900|Drug|intravenous docetaxel with intraperitoneal oxaliplatin|IV docetaxel 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal oxaliplatin escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
1815063|NCT00692900|Drug|intravenous oxaliplatin with intraperitoneal docetaxel|IV oxaliplatin 75 mg/m2 over 1 hour on day #1 followed by intraperitoneal docetaxel escalating from 50 mg/m2 on day #2. Cycles of treatment will be repeated every 3 weeks until disease progression or intolerable toxicity occurs.
1815064|NCT00692913|Drug|FOSAVANCE 5600 (Alendronate Sodium (+) cholecalciferol)|FOSAVANCE 5600 international units (IU)(Alendronate Sodium 70 mg/Vitamin D 5600 IU) combination tablet once weekly for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
1815065|NCT00692913|Dietary Supplement|Calcium Supplement 500 mg|"Calcium supplied locally by the investigator (containing 500 mg
calcium supplement) daily for 52 weeks (unless the patient's dietary intake of
calcium exceeds 1000 mg per day)."
1815066|NCT00692913|Other|Referred-Care Model|Usual treatment for osteoporosis chosen and prescribed by patients' own physicians for 6 months (Week 26) during the base period and an additional 6-month extension period (Week 52).
1815067|NCT00692926|Biological|ALDHbr Umbilical Cord Blood Cells|ALDHbr sorted Umbilical Cord Blood Cells
1815069|NCT00692952|Drug|a novel Benzalkonium Chloride (BZK) contraceptive gel|insert 1 piece of the gel (containing 18mg BZK) into vagina before every coital act.
1815070|NCT00692952|Drug|LELEMI® contraceptive gel containing 50mg nonoxynol-9|insert 1 piece ofLELEMI® contraceptive gel within half an hour before every coital act
1815071|NCT00692978|Drug|Fluticasone Propionate|Dose 50 micrograms (total dose), Monodisperse aerosol with diofferemt particle size of drug (1.5, 3.0, 6.0 microns), inhaled
1815072|NCT00692978|Drug|Fluticasone Propionate|Inhaled, Metered dose inhaler, 250 micrograms dose (total dose)
1815073|NCT00693004|Drug|PRX-03140|
1815074|NCT00693004|Drug|Donepezil|
1815075|NCT00693004|Drug|Placebo|
1815076|NCT00693017|Drug|Zonisamide|"50-400 mg capsules once daily in the evening orally.
Maximum study duration 28 weeks comprising:
Baseline Period (Week -8 to Week 0): no treatment
Titration Period (Week 0 to Week 4): 50 mg daily titrated weekly until 300 mg was reached by Week 4
Maintenance Period (Week 4 to Week 16) 400 mg (or 350 mg in the event of dose limiting adverse events)
Down Titration Period (4 Weeks)"
1815077|NCT00693017|Drug|Placebo|"50-400 mg Zonisamide Placebo capsules once daily in the evening orally.
Maximum study duration 28 weeks comprising:
Baseline Period (Week -8 to Week 0): no treatment
Titration Period (Week 0 to Week 4): 50 mg Zonisamide Placebo daily titrated weekly until 300 mg was reached by Week 4
Maintenance Period (Week 4 to Week 16) 400 mg Zonisamide Placebo (or 350 mg in the event of dose limiting adverse events)
Down Titration Period (4 Weeks)"
1815078|NCT00693030|Device|sirolimus drug eluting coronary stent Cypher™ (Cordis Corp, Johnson & Johnson Co)|comparison of multiple drug eluting stents
1815079|NCT00693030|Device|paclitaxel polymer drug eluting stent Taxus Libertè™ (Boston Scientific, Natick MS)|comparison of multiple drug eluting coronary stents
1815080|NCT00693030|Device|zotarolimus drug eluting coronary stent Endeavor™ (Medtronic, Santa Rosa, CA)|comparison of multiple drug eluting coronary stents
1815081|NCT00693030|Device|Libertè bare metal coronary stent Libertè™ BMS(Boston Scientific, Natick, MS)|comparison of DES in overlap vs BMS in overlap
1815082|NCT00693043|Drug|lidocaine hydrochloride|Study group will have up to 2 mg/kg of Lidocaine administered to the skin and additional Lidocaine(3mg/kg)infused through an atomizer using a specialized tip attached to the sterile leur lock syringe into the pleural cavity. The Intrapleural lidocaine dose will be given in a fixed dose of 3 mg/kg. Serum levels will be obtained at 30, 60, and 120 minutes after initial intradermal administration
1815083|NCT00693056|Drug|Placebo|Placebo (w/o API)
1815084|NCT00693056|Drug|RX-10100 5mg|5 mg/dose of RX-10100
1815085|NCT00693056|Drug|RX-10100 10mg|10 mg/dose of RX-10100
1815086|NCT00693056|Drug|RX-10100 15mg|15 mg/dose of RX-10100
1815087|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg on the day prior to angiography
1815088|NCT00693069|Drug|Clopidogrel|clopidogrel 600 mg on the day prior to angiography
1815089|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg followed by 75 mg daily started one week prior to angiography
1815090|NCT00693069|Drug|Clopidogrel|clopidogrel 300 mg followed by 150 mg daily started one week prior to angiography
1815091|NCT00693082|Dietary Supplement|flaxseed|1 tablespoon a day for first three days, increasing to two tablespoons a day for the next three days. On the 7th day start with 3 tablespoons per day and maintain dose throughout the duration of the study (11 weeks).
1815092|NCT00693095|Biological|CMV-ALT + CMV-DCs|CMV-ALT (3 X 10e7) with CMV-DCs (2 X 10e7)
1815093|NCT00693095|Biological|CMV-ALT + Saline|CMV-ALT (3 X 10e7) with Saline
1815094|NCT00693108|Drug|Transdermal testosterone|
1815095|NCT00693121|Drug|Amantadine hydrochloride|100mg administered orally twice daily x 14 days
1815096|NCT00693121|Drug|Placebo capsule|capsule, identical to amantadine hydrochloride capsule, administered twice daily x 14 days
1815097|NCT00693147|Procedure|Total Thyroidectomy|Late postoperative course of patients with mini Video Assisted Thyroidectomy (miVAT) versus classic Thyroidectomy (T)
1815098|NCT00693160|Drug|ketorolac|single intrathecal injection of ketorolac 2 mg
1815099|NCT00693160|Drug|placebo|subject will receive a placebo (preservative free normal saline) spinal injection
1832179|NCT00820404|Drug|Placebo|
1815107|NCT00693212|Drug|methylphenidate|Dosing was flexible and dependent on clinical judgement, AEs and treatment response.
1815108|NCT00693212|Drug|methylphenidate|Patients were begun at 10 mg t.i.d. and the dose increased as necessary until a maximum dose of 60 mg/day was administered. Frequency could be increased and some patients had dosage schedules of 4 to 6 times per day
1815109|NCT00693212|Drug|placebo|Dosing is identical to the MPH arm except that the pills will contain no active medication.
1815110|NCT00693225|Drug|Omeprazole/sodium bicarbonate|Omeprazole/sodium bicarbonate powder for oral suspension 40 mg was supplied in individual packets that were emptied into a small cup containing 15-30 ml (1-2 tablespoons) of water, one per day, for 8 weeks.
1815111|NCT00693238|Radiation|Low Risk Proton Radiation|
1815112|NCT00693238|Radiation|Intermediate Risk Proton Radiation|
1815113|NCT00693251|Procedure|Crush technique|Crush technique
1815114|NCT00693251|Procedure|provisional T stenting|Provisional T stenting
1815115|NCT00693264|Dietary Supplement|Hoodia Gordonii|750 mg capsule will be taken one time
1815116|NCT00693264|Dietary Supplement|Placebo|Placebo capsule to be taken one time
1815117|NCT00693277|Behavioral|web-based nutritional educational intervention|
1815118|NCT00693290|Other|low residue diet|Fleet (usual preparation) plus diet sheet for low residue diet
1815119|NCT00693303|Behavioral|Training on My Scrivenor|Subjects received 20 minutes twice per week on the My Scrivenor
1815120|NCT00693316|Drug|ORM-12741|Alternating panel single dose escalation.
1815121|NCT00693342|Biological|immunological adjuvant OPT-821|Given subcutaneously
1815122|NCT00693342|Biological|polyvalent antigen-KLH conjugate vaccine|Given subcutaneously
1815123|NCT00693355|Other|Sodium butyrate|sodium butyrate
1815124|NCT00693355|Other|NaCl|NaCl
1815125|NCT00693381|Drug|Tacrolimus|oral
1815126|NCT00693381|Drug|Mycophenolate Mofetil|oral
1815127|NCT00693381|Drug|methylprednisolone and prednisone|IV and oral
1815128|NCT00693407|Procedure|gastric capsaicin with heterotopic stimulation/ distraction|The subjects are randomized to swallow either a capsaicin 0.50mg capsule or an identical placebo capsule with 100ml of water If after 15 minutes pain scores do not reach a minimum level of 30, a further double-blinded capsule of the same content will be swallowed with 100ml of water. This is repeated to a maximum of 8 capusles until pain with VAS >30 is reported.
1815129|NCT00693420|Drug|Bimatoprost 0.03% sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily.
1815130|NCT00693420|Drug|vehicle sterile solution|Apply one drop of study medication using single-use per eye applicator to upper eyelid margin once daily
1815131|NCT00693433|Drug|dexamethasone|Given orally
1815132|NCT00693433|Drug|temsirolimus|Given IV
1815133|NCT00693433|Other|laboratory biomarker analysis|Correlative studies
1815134|NCT00693446|Drug|Sirolimus|"In a first period, the patient will receive Tacrolimus. The time of first administration will be within the first 48H post transplantation. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.
In a second period, the patient will receive Sirolimus. The time of first administration of Sirolimus will be between day 60 and day 90 post transplant. Tacrolimus will be stopped at that time.
The initial dose will be 8 mg/day po. till a trough level is obtained and then titrated to maintain trough whole-blood concentrations between 5-15ng/ml.
The dose of sirolimus will be administrated once a day."
1815135|NCT00693446|Drug|Tacrolimus|"Patients receive Tacrolimus from day 0 to the end of the study. The time of first administration will be within the first 48 hours post transplant.
The dose of tacrolimus will be administrated twice a day. The initial dose will be 0,1 mg/day po. then titrated to maintain trough whole-blood concentrations between 5-15 ng/ml.
Patients receive also rATG , mycophenolate mofetil and corticosteroids."
1815136|NCT00693459|Device|Circular Anal Dilator for Transanal Hemorrhoidectomy|The Circular Anal Dilator for Transanal Hemorrhoidectomy (product #CAD01) allows the standard of care Ferguson hemorrhoidectomy to be performed and does not alter the steps of the operation. The presumed advantages are the ability of the dilator to guide an accurate dissection and also to decrease the overall time it takes to perform hemorrhoidectomy.
1815137|NCT00693472|Drug|Preladenant|Preladenant, one 25 mg capsule, administered orally every 12 hours
1815138|NCT00693472|Drug|Placebo|Matching placebo capsule administered orally every 12 hours
1815139|NCT00693472|Drug|Anticholinergic agents or propanolol|"Part 1 (as rescue therapy only): participants who develop akathisias may be treated with either anticholinergic agents or propranolol as a rescue medication at the discretion of the treating physician. Individual anticholinergic agents were not pre-specified per protocol.
Part 2 (standard of care): anticholinergic agents or propanolol at a dose determined by the investigator according to the local standard of care. Individual anticholinergic agents were not pre-specified per protocol."
1815140|NCT00693472|Drug|Haloperidol|Participants continued pre-study haloperidol, admistered orally, at a dose of at least 7.5 mg/day
1815141|NCT00693485|Drug|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
1815142|NCT00693485|Drug|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
1815143|NCT00693485|Drug|Sham (no implant)|Sham Posterior Segment Drug Delivery system; Applicator System at Day 1 in study eye.
1815144|NCT00693498|Biological|Standard leukoreduced irradiated blood cell transfusion|standard vs washed blood cell transfusions
1815145|NCT00693498|Biological|Washed leukoreduced irradiated blood cell transfusions|washed leukoreduced irradiated blood cell transfusions
1815146|NCT00693511|Behavioral|Circuit Training|Circuit Training (aerobic + strength training 2 times per week for 16 weeks)
1815147|NCT00693511|Behavioral|Circuit training + motivational interviewing|Circuit training (aerobic + strength training 2 times per week for 16 weeks) + motivational interviewing (4 individual + 4 group sessions)
1815148|NCT00693524|Drug|tacrolimus|oral
1815149|NCT00693524|Drug|Anti-IL2R AB|i.v.
1815150|NCT00693524|Drug|Mycophenolate mofetil|oral
1815151|NCT00693524|Drug|prednisone|oral
1815196|NCT00693836|Procedure|evaluation of cancer risk factors|
1815197|NCT00693849|Drug|Escitalopram|10 mg/day as a single dose, increased to max 20 mg/day
1815152|NCT00693537|Procedure|Coronary angiography|At baseline, 4 weeks, and 6 months changes in diameter of coronary arteries in response to intracoronary infusion of acetylcholine were analyzed by quantitative coronary angiography, mean peak flow velocity by Doppler velocimetry, and intramural plaques by intravascular ultrasound.
1815153|NCT00693537|Behavioral|Exercise training|4 weeks in-hospital exercise training (6x15 min bicycle/day, 5 days/week) followed by a 5 months ambulatory exercise program (30 min ergometer/day, 5 days/week, plus 1h group exercise/week)
1815154|NCT00693550|Other|metal patch tests|Twenty - seven (27) metal patch tests will be applied to the patient's back and left in place for 3 days
1815155|NCT00693563|Behavioral|Scheduled Telephone Intervention|Participants and their significant others will be contacted by telephone within 24 to 48 hours after discharge and 10 additional times at weeks 1, 2, 4, 6, and months 2, 3, 4, 6, 8, and 10. The frequent early telephone contacts are meant to address early concerns that frequently arise after discharge are expected to last between 30 and 45 minutes. Later phone calls may be brief if no concerns are raised and are expected to address resource needs as well as ongoing questions that arise through the first year after injury. Content of each phone call will be dependent on issues raised by each individual participant and their significant other and/or follow-up on concerns raised in prior phone contacts rather than a specific structured interview.
1815156|NCT00693576|Drug|simvastatin|20 mg simvastatin daily
1815157|NCT00693589|Drug|folic acid, vitamin B12 and B6 and rosuvastatin|Vitamin supplementation with folic acid 1mg/d, vitamin B12 0.4mg/d and B6 10mg/d po for 6 weeks alone vs. rosuvastatin 10mg/d for 6 weeks alone and thereafter combined treatment for 6 weeks
1815158|NCT00693602|Drug|Erwinase|Chemotherapy
1815159|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine|IM injection
1815160|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP vaccine with Al(OH)3|IM injection
1815161|NCT00693615|Biological|MEDI-517 HPV-16/18 VLP vaccine without adjuvant|IM injection
1815162|NCT00693628|Device|compression shrinker|Two levels of compression: 20-30 mmHg or 30-40 mmHg shrinker
1815163|NCT00693641|Other|Safe Sea sun lotion with jellyfish sting protection SPF 15|Prevent or significantly reduce jellyfish sting using sun lotion with a jellyfish sting inhibitor. The amount of lotion applied to the skin before spreading is the same as for regular sun lotion 2.00 mg.cm-²± 2.5%.
1815164|NCT00693641|Other|Nivea sun, caring sun lotion SPF 15|The amount of lotion applied to the skin before spreading is 2.00 mg.cm-²± 2.5%.
1815165|NCT00693654|Drug|Sarna|Active Ingredient: Pramoxine Hydrochloride Inactive ingredients:Benzyl Alcohol, Carbomer 940, Cetyl Alcohol, Dimethicone, Glyceryl Stearate (&) PEG-100 Stearate, Isopropyl Myristate, Petrolatum, PEG 8 Stearate, Purified Water, Stearic Acid, Sodium Hydroxide
1815166|NCT00693654|Drug|Cetaphil|Purified Water, Glycerin, Hydrogenated Polyisobutene, Cetearyl Alcohol, Ceteareth 20, Macadamia Nut Oil, Dimethicone, Tocopheryl Acetate, Stearoxytrimethylsilane, Stearyl Alcohol, Panthenol, Farnesol, Benzyl Alcohol, Phenoxyethanol, Acrylates/C10-30 Alkyl Acrylate Crosspolymer, Sodium Hydroxide, Citric Acid
1815167|NCT00693667|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient. Three tablets per day will be taken orally before bedtime.
1815168|NCT00693680|Dietary Supplement|Zincas Forte|25 mgZn/day + imipramine (100-200mg/day)
1815169|NCT00693680|Dietary Supplement|Placebo|placebo + imipramine (100-200mg/day)
1815170|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Cream preparation|Apply medication twice a day to affected areas of atopic dermatitis
1815171|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Ointment preparation|Apply medication twice a day to affected areas of atopic dermatitis
1815172|NCT00693693|Drug|hydrocortisone 17-butyrate 0.1% Lipocream preparation|Apply medication twice a day to affected areas of atopic dermatitis
1815173|NCT00693706|Biological|Trivalent influenza vaccine GSK 138842A|IM injection on Day 0
1815174|NCT00693706|Biological|Fluarix|IM injection on Day 0
1815175|NCT00693719|Drug|Etoposide|50 mg PO x14 days followed by 2 weeks off, 28 day/Cycle
1815176|NCT00693719|Drug|Irinotecan hydrochloride|Irinotecan 100 mg/m2 IV days 1 and 15, 28 day/Cycle
1815177|NCT00693732|Drug|Escitalopram treatment|On study inclusion at Visit 2, patients will be successively randomised using a computer generated randomisation list to either placebo or escitalopram (Lundbeck Export A/S, Singapore) 10mg given at bedtime in the first 2 weeks, followed by 20mg in the next 6 weeks. The treatments will be identical in appearance and will be administered in double-blind fashion. Treatment with any anticoagulants, antidiabetics, antimigraine drugs, antispasmodics, analgesics, psychoactive agents including antidepressants, Zelmac®, TCM or acupuncture for IBS and any drugs affecting nociception as judged by investigator are prohibited during the entire study.
1815178|NCT00693732|Behavioral|Quantitative sensory testing|Rectal Distention Stimulation
1815179|NCT00693758|Drug|adenosine|intravenous infusion of adenosine (140microgr./min/kg)
1815180|NCT00693758|Other|modified end-tidal forcing system|changes in partial pressures of O2 and CO2 in inspired air
1815181|NCT00693758|Other|arm cuff occlusion|3 min. lasting upper arm cuff occlusion
1815182|NCT00693758|Device|Breathing gas|Changes in pO2 and pCO2 in inspired air mix
1815183|NCT00693758|Device|Blood pressure cuff|supra-systolic arm occlusion with pressure cuff
1815184|NCT00693771|Drug|Insulin Glargine|Once daily and up-titrate accordingly
1815185|NCT00693784|Biological|Biostat® Disc Augmentation System|Delivery of Biostat BIOLOGX® Fibrin Sealant with the Biostat Delivery Device
1815186|NCT00693823|Procedure|Femoral-popliteal Bypass|Surgical placement of a prosthetic graft in the thigh from the groin to the knee
1815187|NCT00693823|Device|Angioplasty and stent placement with Viabahn covered stent-graft(W.L. Gore & Associates, Flagstff, Arizona) of superficial femoral artery|Placement of an ePTFE covered stent graft within the superficial femoral artery in the thigh through a needle hole percutaneously
1815188|NCT00693836|Genetic|genetic linkage analysis|
1815189|NCT00693836|Genetic|loss of heterozygosity analysis|
1815190|NCT00693836|Genetic|mutation analysis|
1815191|NCT00693836|Genetic|polymerase chain reaction|
1815192|NCT00693836|Genetic|polymorphism analysis|
1815193|NCT00693836|Other|biologic sample preservation procedure|
1815194|NCT00693836|Other|medical chart review|
1815195|NCT00693836|Other|questionnaire administration|
1815198|NCT00693849|Drug|Sertraline|50 mg/day as a single dose, increased to max of 200 mg/day
1815199|NCT00693849|Drug|Venlafaxine-XR|75 mg/day given once daily; increased to 150-225 mg/day
1815200|NCT00693862|Drug|levodopa, carbidopa, entacapone|
1815201|NCT00693862|Drug|levodopa, carbidopa|
1815202|NCT00693888|Behavioral|advice (e.g. medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives)|initial comprehensive assessment, stratified (city, suburbs) randomization into two groups: interventional group: individual comprehensive primary advice (medical and social aspects, care, support at home, residential advice, legal aspects, demonstration of help and support for the relatives), control group: standard support, observation over a period of 6 months, possibility of completing the diagnostic after final assessment
1815203|NCT00693901|Behavioral|Community-based participatory research (CBPR)|CBPR will involve park advisory boards and community members in the research process, including the park assessments and data analysis. The assessment research will be used to inform use of discretionary funds for park programming and facilities in the hopes of increasing community physical activity. Park directors will be provided with analysis of descriptive information and community feedback to help improve outreach, park programming, and features to attract more park users and increase physical activity.
1815204|NCT00693901|Behavioral|Director-only|Park directors will be provided with descriptive information on park use and community feedback. They will also receive assistance on how to improve outreach, programming, and park features that will increase park use and physical activity. These parks will not take part in any assessments.
1815205|NCT00693914|Behavioral|Series of tests/questionnaires|Developmental and Demographic, KINDL Health-Related Quality of Life, Adaptive Behavior Assessment System (ABAS-II),Behavior Rating Inventory of Executive Function (BRIEF), Wechsler Digit Span Task, Wide Range Achievement Test 3rd Edition (WRAT3),Wechsler Abbreviated Scale of Intelligence (WASI), Pediatric Immediate Post-Concussion Assessment and Cognitive Testing (ImPACT), Recognition Memory Task: Face Stimuli, Recognition Memory Task: Verbal Stimuli, Self Ordered Search: Object, Self Order Search: Verbal
1815206|NCT00693927|Procedure|Unmanipulated PBSC after nonmyeloablative conditioning|"Conditioning regimen with 2 Gy TBI with or without added fludarabine (90 mg/m2).
Unmanipulated PBSC from HLA-identical sibling or HLA-matched related or unrelated donor"
1815207|NCT00693927|Procedure|CD8-depleted PBSC after nonmyeloablative conditioning|
1815208|NCT00693940|Behavioral|Group mediated cognitive behavioral (GMCB) sessions|GMCB will include weekly group exercise sessions, lasting approximately 60 to 75 minutes each for a 6 month period. During these sessions, participants will be asked to exercise by walking around a track. There will also be a group discussion, led by a facilitator, who will help participants find ways to increase the frequency of their walking exercise at home. After completing the GMCB sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
1815209|NCT00693940|Other|Health education sessions|Health education will include weekly educational sessions on a health-related topic, lasting approximately 60 minutes each. After completing the health education sessions, which will last about 6 months, participants will be telephoned regularly by a study coordinator for another 6 months.
1815210|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 1)|IM injection
1815211|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 2)|IM injection
1815212|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP AS04 vaccine (Formulation 3)|IM injection
1815213|NCT00693966|Biological|MEDI-517 HPV-16/18 VLP with Al(OH)3 (Formulation 4)|IM injection
1815214|NCT00693979|Device|TAXUS Element Stent or TAXUS Express Stent|Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.
1815215|NCT00693992|Other|Laboratory Biomarker Analysis|Correlative studies
1815216|NCT00693992|Other|Placebo|Given PO
1815217|NCT00693992|Other|Quality-of-Life Assessment|Ancillary studies
1815218|NCT00693992|Drug|Sunitinib Malate|Given PO
1815219|NCT00694005|Procedure|kissing balloon|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
1815220|NCT00694005|Procedure|"without kissing balloon angioplasty leave alone"|simultaneous kissing balloon angioplasty during drug-eluting stent implantation for bifurcation coronary lesions
1815221|NCT00694018|Other|Education and standard care|Educational program for individuals with chronic back pain.
1815222|NCT00694018|Behavioral|Internet mediated enhanced pedometer intervention|Enhanced pedometer for uploading step information and website that provides step goals and feedback, tailored motivational messages and an online community.
1815223|NCT00694031|Procedure|Hemodialysis|3 times per week
1815224|NCT00694031|Procedure|On-line hemodiafiltration|3 times per week
1815225|NCT00687817|Drug|bavituximab plus paclitaxel and carboplatin|Weekly bavituximab dose of 3 mg/kg until disease progression, and up to 6 cycles of carboplatin at a dose of AUC=5 and paclitaxel 175 mg/m2 every 21 days (21-day cycles)
1815226|NCT00687830|Drug|Polyethylene Glycol afternoon|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Evening prep, between 5PM and 9PM
1815227|NCT00687830|Drug|Polyethylene Glycol morning|Prescribed the standard dose of 4L or 1 Gallon Polythylene Glycol to be taken over a period of 4 hours with water. For Morning prep, between 6AM and 10AM
1815228|NCT00687843|Drug|Tegafur-gimeracil-oteracil potassium (TS-1)|80 mg/m2, PO from day 1 to day 28 of each 42 day cycle. Number of Cycles: 8
1815229|NCT00687843|Drug|Krestin (PSK)|3 g, PO from day 1 to day 336
1815230|NCT00687856|Procedure|Echocardiogram (echo)|Participants will undergo a series of echoes to determine if they are eligible to be weaned from LVAD support. Each echo exam will involve the use of an ultrasound probe on the chest of participants to assess the pumping ability of their hearts.
1815231|NCT00687869|Behavioral|Case management|Case management with patient-information-notes, telephone hotline, individual counselling using home visits, e-mail and telephone contact, web portal
1815232|NCT00687869|Behavioral|Case management|Usual stroke aftercare plus patient-information-notes
1815233|NCT00687882|Other|Shortened duration (6 weeks) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 6 weeks.
1815234|NCT00687882|Other|Conventional duration (3 months) of anticoagulant therapy|Subjects with evidence of non-occlusive or resolved thrombus at 6 weeks time will be randomized to receive a total duration of anticoagulant therapy of 3 months.
1815235|NCT00687882|Other|No Intervention|Subjects with evidence of persistent thrombus at 6 weeks time will remain on anticoagulant therapy for 3-6 months at the discretion of their treating physician.
1815236|NCT00687882|Other|No Intervention|Subjects with evidence of persistent antiphospholipid antibody at 6 weeks will remain on anticoagulant therapy for 3 months to indefinite duration, at the discretion of their treating physician.
1815237|NCT00687895|Procedure|Clinical algorithm and microscopy diagnosis of malaria|"Clinical alogarithm
The content of the package included
description of signs and symptoms of malaria disease
history taking relevant to malaria and physical examination
identification of danger signs and severe illness for referral
appropriate treatment
counseling patients on the use of drugs.
Malaria microscopy. contents
make thick blood smears from patients with fever and stain with Giemsa
identify and count malaria parasites
maintain the microscope and store blood slides."
1815238|NCT00687908|Drug|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
1815239|NCT00687908|Drug|Vehicle Gel|Topical Gel to the face, once daily in the evening for 24 weeks.
1815240|NCT00687934|Drug|STA-9090|This is a dose-escalation study. The first cohort will consist of three patients who will receive STA 9090 (ganetespib)during a 1-hour infusion once per week for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive higher amounts of STA-9090 (gantespib) provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Dose escalation will continue until the maximum tolerated dose (MTD) is determined.
1815241|NCT00687947|Drug|CGRP|CGRP (0.5 ug/min) infused intravenously over 20 min
1815242|NCT00687960|Dietary Supplement|Resistant starch type 4 - raw|Dose: 80g bar containing Resistant Starch Type 4 - raw
1815243|NCT00687960|Dietary Supplement|Resistant Starch Type 4 - Cooked|Dose: 80g bar containing Resistant Starch Type 4 - cooked
1815244|NCT00687960|Dietary Supplement|Dextrose|Dose: 7 oz of oral glucose tolerance beverage
1815245|NCT00687960|Dietary Supplement|Puffed Wheat|Dose: 80g bar containing puffed wheat cereal
1815246|NCT00687973|Drug|Valsartan/amlodipine 80/5 mg tablets|
1815247|NCT00687973|Drug|Amlodipine 5 mg capsules|
1815248|NCT00687973|Drug|Amlodipine 10 mg capsules|
1815249|NCT00687973|Drug|Atenolol 50 mg tablets|
1815250|NCT00687973|Drug|Atenolol 100 mg tablets|
1815251|NCT00687986|Radiation|stereotactic radiotherapy|Either 3 fractions of 20 Gray or 5 fractions of 12 Gy
1815252|NCT00687986|Procedure|primary surgery|an anatomical surgical resection with lymph node dissection
1815253|NCT00687999|Drug|pegylated interferon alpha and ribavirin|standard pegylated interferon alpha and ribavirin
1815254|NCT00688012|Drug|SPC3649|
1815255|NCT00688038|Procedure|Laser Ablation|Laser ablation procedure taking about 1-3 hours, depending on the size and location of the tumor.
1815256|NCT00688038|Procedure|Magnetic Resonance Thermal Imaging|MRTI will be used to monitor the temperature within the ablation zone during the laser ablation.
1815257|NCT00688051|Other|My Life with CF game|Play the game My Life with CF
1815258|NCT00688064|Drug|Adapalene BPO Gel associated with Doxycyline Hyclate|Adapalene BPO Gel: Topical to the face, once daily in the evening Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
1815259|NCT00688064|Drug|Vehicle Gel associated with Doxycycline Hyclate|Vehicle Gel: Topical to the face, once daily in the evening; Doxycycline Hyclate: Oral, 1 tablet once daily in the morning. Both during 12 weeks.
1815260|NCT00688077|Drug|Calcitonin|Calcitonin 200 IU/ml, single subcutaneous injection, experimental group
1815261|NCT00688077|Drug|Placebo|NaCl 0,9 % 1ml, single subcutaneous injection, placebo group
1815262|NCT00688090|Biological|Biological: MKC1106-MT|Cancer Vaccine, Immunotherapy
1815263|NCT00688090|Biological|Biological: MKCC1106-MT|Cancer Vaccine, Immunotherapy
1815264|NCT00688103|Drug|ETN Alone|etanercept (25 mg, twice/week, s.c.)
1815265|NCT00688103|Drug|ETN+MTX|etanercept (25 mg, twice/week, s.c.) combined with methotrexate (6-8 mg/week)
1815266|NCT00688116|Drug|STA 9090 (ganetespib)|This is a dose-escalation study. The first cohort will consist of three patients who will receive 2 mg/m2 of STA 9090 (ganetespib) during a 1-hour infusion 2 times per week (e.g., [Monday, Thursday] or [Tuesday, Friday]) for three consecutive weeks followed by a 1 week dose-free interval. Subsequent cohorts will receive 4, 7, 10, 14, 19, 25, 33, 40 and 48 mg/m2 provided that the previous dose was well tolerated during cycle 1 (week 1 - 4). Further dose increments will be approximately 20% over the previous dose level, until the maximum tolerated dose (MTD) is determined.
1815267|NCT00688129|Behavioral|KITS Program|This is a 4-month psychosocial intervention for foster children entering kindergarten and their caregivers beginning the summer before kindergarten. The KITS intervention consists of: (a) child therapeutic play groups to facilitate the development of self-regulatory, social, and emergent literacy skills (2 times per week in summer, 1 times per week in the fall); (b) a bi-monthly psychoeducational support group to promote caregiver involvement in the child's emergent literacy and schooling and the use of effective parenting techniques; (c) home- and school-based behavioral consultation on an as needed basis.
1993894|NCT03110770|Biological|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is composed of a single closed-circular DNA plasmid (VRC 5283) that encodes with wild type (wt) precursor transmembrane M (prM) and envelope (E) proteins from the H/PF/2013 strain of ZIKV
1993895|NCT03110770|Other|VRC-PBSPLA043-00-VP|A sterile phosphate-buffered saline (PBS) prepared for human administration as a placebo
1815271|NCT00688168|Behavioral|Questionnaire|Questionnaires measuring pain and other symptoms, mood, and quality of life.
1815272|NCT00688168|Behavioral|Neurocognitive Testing|A neurocognitive exam (tests to check your memory and thinking abilities, for example) will be performed.
1815273|NCT00688168|Behavioral|Neurosensory Testing|Neurosensory testing will be performed to find out how sensitive you are to things such as touch, coolness, warmth, pinprick on the finger, and squeezing of the skin on the finger, hand, or arm.
1815275|NCT00688194|Drug|anastrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
1815276|NCT00688194|Drug|exemestane|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
1815277|NCT00688194|Drug|fulvestrant|Given intramuscularly
1815278|NCT00688194|Drug|lapatinib ditosylate|Given orally
1815279|NCT00688194|Drug|letrozole|Patients receive aromatase inhibitor therapy according to standard treatment regulations.
1815280|NCT00688194|Other|placebo|Given orally
1815281|NCT00688207|Drug|Rosiglitazone (Extended Release)|open-label, single, oral, 4mg dose
1815282|NCT00694044|Drug|varenicline|0.5 mg once daily for 7days followed by 0.5 mg twice daily for 7days followed by 1mg twice daily for 7 days
1815283|NCT00694044|Drug|varenicline|0.5 mg once daily for 14 days followed by 1 mg once daily for 7 days
1815284|NCT00694044|Drug|varenicline|0.5 mg once daily for 14 days followed by 0.5 mg twice daily for 7 days
1815285|NCT00694044|Drug|Placebo|Placebo for 21 days
1815286|NCT00694057|Drug|HE3286|HE3286 10 mg per day (5 mg BID)
1815287|NCT00694057|Drug|Placebo|Placebo capsules BID
1815288|NCT00694083|Drug|Ridaforolimus|Ridaforolimus (MK-8669), 20 or 40 mg administered orally on Day 1 followed by a washout of at least 6 days, then QD x5 (five consecutive days) followed by a 2-day holiday through Day 28 (Cycle 1), and QD x5 followed by a 2-day holiday for 21 days (Cycle 2 and subsequent cycles)
1815289|NCT00694096|Drug|Sunitinib|"Imaging studies with complete analyses will be provided on all patients prior to institution of sunitinib therapy as well as after therapy at various early time points (1 week in 5 patients, 2 weeks in 5 patients, 3 weeks in 5 patients or 4 weeks in 5 patients) after institution of sunitinib therapy at 37.5 mg orally/day.
Imaging studies include:
FDG-PET scans FLT-PET scans H215O-PET scans DCE-MRI scans"
1815290|NCT00694109|Drug|Mipomersen Sodium|Subcutaneous injection as a single injection directly into the abdomen, thigh, or outer area of the upper arm.
1815291|NCT00694122|Drug|Lantus (glargine)|Described in Arm Description
1815292|NCT00694135|Drug|EGP-437 1.6 mA-min at 0.4 with EyeGate® II System|Ocular Iontophoresis with EGP-437 1.6 mA-min at 0.4 mA delivered via EyeGate® II Drug Delivery System
1815293|NCT00694135|Drug|EGP-437 4.8 mA-min at 1.2 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 4.8 mA-min at 1.2 mA delivered via EyeGate® II Drug Delivery System
1815294|NCT00694135|Drug|EGP-437 10.0 mA-min at 2.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 10.0 mA-min at 2.5 mA delivered via EyeGate® II Drug Delivery System
1815295|NCT00694135|Drug|EGP-437 14.0 mA-min at 3.5 mA with EyeGate® II System|Ocular Iontophoresis with EGP-437 14.0 mA-min at 3.5 mA delivered via EyeGate® II Drug Delivery System
1815296|NCT00694148|Drug|NT 201|"A Botulinum neurotoxin type A, free of complexing proteins
Detailed described in study protocol"
1815297|NCT00694161|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsules once daily (at the same time each day) for 12 months
1815298|NCT00694174|Drug|sucrose 24% oral solution|sucrose 24% oral solution 2 ml one time only dose administered by mouth prior to heel lance
1815299|NCT00694174|Drug|sterile water|sterile water 2 ml single dose to be administered orally one time prior to heel lance
1815300|NCT00694187|Drug|Zaleplon|
1815301|NCT00694200|Drug|Vinorelbine|Vinorelbine per os 50 mg 3 times a week
1815302|NCT00694200|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV every 14 days
1815303|NCT00694213|Biological|VCL-IPM1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
1815304|NCT00694213|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
1815305|NCT00694213|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
1815306|NCT00694213|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
1815307|NCT00694226|Behavioral|brief motivational intervention|Brief intervention, consisting in an intervention with the adolescent and a session with parents or mentors. The session with the adolescent lasted 60 minutes. Materials related to the interview were developed according to previous reports on the subject. After building a good rapport the interviewer involved the patient in an initial discussion about the results of the evaluation. This led to a review of the drugs used by the subject and an elicitation of positives and negatives of drug use. The relationship between drug use and current and long-term goals was explored. Discrepancies and problems in the future related to substance use were examined, and information and counseling was offered. The basic components of the motivational interview approach were contemplated, and several skills were used by the interviewers. The individual session with parents or mentors consisted in the presentation of educational materials and a brief counseling intervention on parenting skills.
1815308|NCT00694226|Behavioral|treatment as usual|Treatment as usual (TTU): After completion of the intervention, individuals and their families went on to receive standard care at the Child and Adolescent Psychiatry and Psychology Department according to the primary diagnosis.Individuals assigned to this group and their parents or tutors received standard care and no further intervention other than completion of the assessment protocol.
1815309|NCT00694239|Behavioral|Knowledge of Cardiovascular Risk Assessment|Knowledge of Cardiovascular Risk Assessment and risk reduction at target BP, reviewed every 3-6 months.
1815310|NCT00694252|Drug|Lapatinib|Patients will receive lapatinib monotherapy 1500 mg/day for a period of at least one month depending on their response and the clinical status of their disease.
1815311|NCT00694265|Procedure|Decompression|Surgical decompression of the median nerve
1815312|NCT00694265|Procedure|Conservative treatment|Conservative treatment typically consisted of splinting and corticosteroid injections
1815313|NCT00694291|Drug|Sorafenib|400 mg orally twice daily
1815314|NCT00694291|Drug|Placebo|Matching Placebo
1815315|NCT00694304|Drug|Vortioxetine (Lu AA21004)|2.5, 5, or 10 mg/day; tablets; orally
1815317|NCT00694330|Biological|GM-K562 Vaccination|Lethally irradiated autologous glioma cells combined with GM-K562 cells as vaccine therapy given once a week for three weeks then every other week.
1815318|NCT00694343|Drug|HES 130/0.4 (6%) in sodium chloride (solution for infusion)|500 mL of HES 130/0.4 (6%) and 500 mL Ringer's Lactate Solution
1815319|NCT00694343|Drug|Ringer's Lactate solution|1000 mL Ringer's Lactate solution
1815320|NCT00694356|Biological|Dalotuzumab|IV infusion
1815321|NCT00694369|Drug|Comparator: etoricoxib|etoricoxib 90 mg; 120 mg (once daily) over three days.
1815322|NCT00694369|Drug|Comparator: ibuprofen|ibuprofen 2400 mg (600 mg Q6h) over three Days
1815323|NCT00694369|Drug|Comparator: acetaminophen + codeine|acetaminophen 2400 mg/codeine 240 mg (600/60 mg Q6h) over three Days
1815324|NCT00694369|Drug|Comparator: placebo|matching placebo over three Days
1815325|NCT00695786|Drug|Lenalidomide|"20 mg by mouth (PO) daily on days 1 - 21 followed by 7 days rest (28 day cycle). Following cycle 3, if patients fail to show a response (partial or complete) the dose will be increased to 25mg/day.
Schedule B: Lenalidomide will be administered orally at 20 mg total daily dose on days 2 to 22 of a 28 day cycle in patients with follicular lymphoma. Following cycle 3, if patients fail to show a response (partial or complete) the dose will be increased to 25mg/day. Patients with a diagnosis of small lymphocytic lymphoma (SLL) will begin at a dose of 10 mg total daily on days 2 to 22 of a 28 day cycle. This dose will be escalated by 5mg every 28 days up to 20mg if no toxicity is encountered. If no response is observed by cycle 3, the dose will be increased to 25 mg."
1815326|NCT00695786|Drug|Rituximab|375 mg/m^2 by vein over 4-8 Hours on day 1 of cycles 1-12 in schedule A, and day 1, 8,15, and 22 of cycle 1 and on day 1 of every subsequent cycle in schedule B.
1815327|NCT00695825|Dietary Supplement|Low GI+high GI|Consumption of low GI food product on day 1 Consumption of high GI food product on day 2
1815328|NCT00695825|Dietary Supplement|High GI+low GI|Consumption of high GI food product on day 1 Consumption of low GI food product on day 2
1815329|NCT00695851|Drug|PCK3145|i.v. bolus either 15 mg/m2 weekly of PCK3145.
1815330|NCT00695851|Drug|PCK3145|by i.v. bolus 7.5 mg/m2 twice per week of PCK3145
1815331|NCT00695864|Drug|Ondansetron and Placebo crossover|
1815332|NCT00695877|Biological|Ad5.ENVA.48 HIV-1 vaccine|Recombinant adenovirus serotype 5 HIV-1 vaccine
1815333|NCT00695903|Drug|daptomycin|daptomycin 10 mg/kg IV every 24 hours
1815334|NCT00695903|Drug|vancomycin|Vancomycin 15 mg/kg IV, dosed to maintain trough serum concentrations of 15 to 20 μg/mL
1815335|NCT00695916|Procedure|Breast MRI|
1815336|NCT00695929|Drug|Levosimendan|Intravenous injection
1815337|NCT00695929|Drug|Milrinone|Intravenous injection
1815338|NCT00695955|Drug|Azilsartan medoxomil with or without add-on chlorthalidone|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with chlorthalidone 25 mg, once-daily, if target blood pressure not achieved.
1815339|NCT00695955|Drug|Azilsartan medoxomil with or without add-on hydrochlorothiazide|Azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks; increased to azilsartan medoxomil 80 mg, tablets, orally, once daily for remainder of 56-week treatment period, if tolerated. Additional antihypertensive medications added, beginning with hydrochlorothiazide 12.5 to 25 mg, once-daily, if target blood pressure not achieved.
1815340|NCT00695981|Procedure|Rotator cuff repair|Rotator cuff repair + physical therapy according to a standardized protocol
1815341|NCT00695981|Procedure|Conservative treatment|Physiotherapy according to a standardized protocol
1815342|NCT00695994|Drug|Docetaxel|Docetaxel will be administered at a dose of 75 mg/m2 given as a 1-hour intravenous infusion on day 1 of a 21-day cycle. Docetaxel is re-constituted in 500 mL of normal saline and infused through a peripheral or central venous line. Docetaxel (Taxotere®, Sanofi-Aventis Inc.) is available in 80 mg and 20 mg in 2 mL polysorbate 80, 13% (w/w) ethanol in Water for Injection.
1815343|NCT00695994|Drug|gemcitabine and carboplatin|"Gemcitabine (Gemzar®, Lily Inc.) is available in vials containing 1000 mg or 200 mg of active drug formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder.
Carboplatin (Spectrum Pharmaceuticals, Inc.) is supplied as a 10 mg/mL aqueous solution. Unopened vials of gemcitabine are stable when stored at controlled room temperature at 25°C, protected from bright light. It can be diluted in normal saline or 5% dextrose. The solution remains stable for 8 hours at 25°C after reconstitution.
Carboplatin will be administered as a 1-hour infusion on day 1 of a 21-day cycle. It will be given before gemcitabine at the dose to achieve an AUC of 5 using the Calvert formula.
Gemcitabine will be administered as a 30-minute infusion at the dose of 1000 mg/m2 in 250 mL over 30 minutes, on day 1 and 8 of a 21-day cycle. It will be given after carboplatin infusion."
1815344|NCT00696007|Drug|Gemcitabine and cisplatin|"Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.
Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.
Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²"
1815345|NCT00696007|Other|Retrospective comparison|60 retrospective historical cohort group of subjects who have undergone a radical nephroureterectomy over the past five years
1815346|NCT00696020|Drug|BI 1744 CL/tiotropium bromide fixed dose combination|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
1815347|NCT00696020|Drug|tiotropium bromide|tiotropium bromide; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
1815348|NCT00696020|Device|Respimat® Inhaler|
1815349|NCT00696033|Drug|Diazepam|Diazépam drug (0,3 mg/kg) on a single oral intake
1815350|NCT00696033|Drug|Lorazepam|Lorazépam drug (0,038 mg/kg) on a single oral intake
1815351|NCT00696033|Drug|placebo|lorazépam placebo or Diazépam placebo
1815436|NCT00696657|Drug|semaglutide|0.8 mg with titration, once weekly, s.c. injection
1815437|NCT00696657|Drug|semaglutide|1.6 mg with titration, once weekly, s.c. injection
1815438|NCT00696657|Drug|placebo|0.1 mg, once weekly, s.c. injection
1815439|NCT00696657|Drug|placebo|0.2 mg, once weekly, s.c. injection
1815440|NCT00696657|Drug|placebo|0.4 mg, once weekly, s.c. injection
1815352|NCT00696046|Procedure|Intrabone Marrow Injection|Cord blood CB units will be thawed in a 37° CB cells will be resuspended in 20ml salinesolution + dextran/albumin, and aliquoted in 4 syringes of 5ml Pts were prepared in a surgical & steril room The anaesthesia consist in a short propofol sedation The injection will last 8-15 minutes. 1° sedation is established, a standard needle for bone marrow aspiration (14 gauge) was inserted few cms in the supero-posterior iliac crest then, an aspiration of about 0.5-1 ml will be performed to assess that the needle was securely introduced in the bone marrow cavity After, we will insert the syringe containing 4-5ml of CB cell suspension which will be gently infused This procedure will be then repeated for all the remaining aliquots at a distance of 2-3cm from the previous one following the iliac crest
1815353|NCT00696059|Drug|Adalimumab (Humira)|Adalimumab (Humira) 40 mg subcutaneously every other week
1815354|NCT00696072|Drug|Dasatinib|Tablets, Oral, 100 mg once daily, up to 2 years
1815355|NCT00696072|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, up to 2 years
1815356|NCT00696085|Behavioral|Brief motivational intervention|The women who have positive alcohol screening questionnaires and a random sample of women who screen negative are entered into the next phase of the study. They have blood drawn for the markers of alcohol use, are told of the results and are given brief intervention about alcohol use.
1815357|NCT00696098|Other|sodium butyrate|1 enema (60 ml) once daily containing 100mM
1815358|NCT00696098|Other|NaCl|1 enema (60 ml) once daily containing 0.9%NaCl
1815359|NCT00696111|Drug|Depot Lupron followed by estrogen plus placebo|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of estrogen (2mg) plus placebo for six weeks.
1815360|NCT00696111|Drug|Depot Lupron followed by progesterone plus placebo.|A single intramuscular dose of depot lupron (11.25 mg). Six weeks after injection, subjects will receive daily oral doses of progesterone (200mg) plus placebo for six weeks.
1815361|NCT00696111|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for six weeks.
1815362|NCT00696124|Genetic|VM202|2mg intramuscular injection with the first half of the total dose given on Day 1 and the second half on Day 15
1815363|NCT00696124|Genetic|VM202|4mg intramuscular injection, with half of the total dose given on Day 1 and the second half given on Day 15
1815364|NCT00696124|Genetic|VM202|8mg intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
1815365|NCT00696124|Genetic|VM202|16mg dose intramuscular injection. The first half of the total dose given on Day 1 and the second half on Day 15.
1815366|NCT00696137|Drug|BEMA Fentanyl|buccal soluble film; 200, 400, 600, 800, and 1200 mcg fentanyl; up to 4 times daily
1815367|NCT00696150|Procedure|determination of method with highest efficacy (ultrasound or nerve stimulator)|Use of ultrasound to guide the insertion of anterior psoas compartment block
1815368|NCT00696150|Procedure|nerve stimulator|The use of the nerve stimulator to guide insertion of the anterior psoas compartment block
1815369|NCT00696150|Procedure|loss of resistance|Use of ultrasound to guide the insertion of anterior psoas compartment block
1815370|NCT00696163|Drug|biphasic insulin aspart 30|Being an observational study, dose of NovoMix 30 will be according to treating physician's discretion
1815371|NCT00696176|Drug|STAT 3 DECOY|single administration to a head and neck tumor
1815372|NCT00696202|Drug|Mirena (BAY86-5028)|Intrauterine levonorgestrel containing device (market product)
1815373|NCT00696215|Drug|placebo|Placebo 1 mg once a day
1815374|NCT00696215|Drug|rasagiline|1mg
1815375|NCT00696228|Dietary Supplement|Placebo|Placebo
1815376|NCT00696228|Dietary Supplement|MUFA|MUFA
1815377|NCT00696228|Dietary Supplement|PUFA|PUFA
1815378|NCT00696228|Dietary Supplement|SFA|SFA
1815379|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 20 mg, tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
1815380|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, for up to 6 weeks.
1815381|NCT00696241|Drug|Azilsartan medoxomil and olmesartan|Azilsartan medoxomil 80 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and olmesartan 40 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
1815382|NCT00696241|Drug|Olmesartan|Olmesartan 40 mg, tablets, azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets and azilsartan medoxomil 80 mg placebo-matching tablets, orally, once daily for up to 6 weeks.
1815383|NCT00696241|Drug|Placebo|Azilsartan medoxomil 20 mg placebo-matching tablets, azilsartan medoxomil 40 mg placebo-matching tablets, azilsartan medoxomil 80 mg placebo-matching tablets, and olmesartan 40 mg placebo- matching tablets, orally, once daily for up to 6 weeks.
1815384|NCT00696254|Behavioral|Nerve excitability measurement|
1815385|NCT00696280|Behavioral|Functional Living Index - Emesis|
1815386|NCT00696293|Drug|Duloxetine|Duloxetine up to 120 mg/day + Clinical Management
1815387|NCT00696319|Other|Exercise protocol with perturbation exercises.|Perturbation exercises are exercises for balance and stability that involves perturbations of the surface through use of custom made equipment (a rollerboard, a rockerboard and a platform).
1815388|NCT00696319|Other|Exercise protocol with traditional exercises for stability and balance.|The exercise protocol will consist of exercises for balance and stability that do not include sudden disturbances or perturbations to the surface.
1815389|NCT00696332|Drug|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
1815390|NCT00696332|Drug|Talampanel|capsules Talampanel, 3 times per day, 52 weeks
1815391|NCT00696332|Other|placebo|capsules, placebo, 3 times a day, for 52 weeks
1815392|NCT00696358|Radiation|308nm excimer lamp|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks
1815393|NCT00696358|Radiation|308nm excimer laser|50 mJ/cm² below the MED (minimal erythemal dose) and progressive increase Twice a week for 12 weeks (same doses will be used between the 2 arms)
1815441|NCT00696657|Drug|placebo|0.8 mg with titration, once weekly, s.c. injection
1815442|NCT00696657|Drug|placebo|1.6 mg, once weekly, s.c. injection
1815394|NCT00696384|Drug|Azilsartan medoxomil|"All subjects initiated azilsartan medoxomil 40 mg, tablets, orally, once daily for four weeks, force-titrated to 80 mg, tablets, orally, once daily. After Week 8, chlorthalidone, 25 mg, tablets, orally, once daily as needed and other antihypertensive medications as needed to achieve target blood pressure (defined as <140/90 mm Hg for participants without diabetes or chronic kidney disease (CKD) and <130/80 mm Hg for participants with diabetes or CKD) for up to 26 weeks.
Study medication could have been up-titrated only after the subject had been at the previous dose level for a minimum of 2 weeks. Study medication could only have been up- or down-titrated by 1 dose level per scheduled or unscheduled visit."
1815395|NCT00696384|Drug|Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications.|Azilsartan medoxomil at the final dose received during the open-label phase: (20 mg, 40 mg or 80 mg), tablets, orally, once daily with or without chlorthalidone 25 mg, tablets, orally once daily and other non-ARB antihypertensive medications (if currently taking), for 6 weeks/Week 32.
1815396|NCT00696384|Drug|Placebo|Azilsartan medoxomil placebo-matching tablets, orally, once daily with or without chlorthalidone 25 mg or other non-ARB antihypertensive (if currently taking), tablets, orally, once daily for 6 weeks/Week 32.
1815397|NCT00696410|Drug|Zinc Acetate|Zinc acetate 50 mg po TID for 10 months. Dose will be titrated to achieve ceruloplasmin levels ~10-12.
1815398|NCT00696423|Biological|Infanrix™|Intramuscular injection, one dose
1815399|NCT00696423|Biological|Hiberix™|Intramuscular injection, one dose
1815400|NCT00696436|Drug|Azilsartan medoxomil|"Azilsartan medoxomil 20 mg, tablets and matching placebo comparator orally once daily for two weeks.
Increased to azilsartan medoxomil 40 mg tablets and matching placebo comparator orally, once daily for up to four weeks."
1815401|NCT00696436|Drug|Azilsartan medoxomil|"Azilsartan medoxomil 40 mg, tablets and matching placebo comparator orally, once daily for two weeks.
Increased to Azilsartan medoxomil 80 mg, tablets and matching placebo comparator orally, once daily for up to four weeks."
1815402|NCT00696436|Drug|Valsartan|"Valsartan 160 mg, tablets, and matching placebo comparator orally, once daily for two weeks.
Increased to Valsartan 320 mg, tablets, and matching placebo comparator, orally, once daily for up to four weeks."
1815403|NCT00696436|Drug|Olmesartan|"Olmesartan 20 mg, tablets and matching placebo comparator, orally, once daily for two weeks.
Increased to Olmesartan 40 mg, tablets and matching placebo comparator, orally, once daily for up to four weeks."
1815404|NCT00696436|Drug|Placebo|Matching placebo, orally, once daily for up to six weeks.
1815405|NCT00696449|Drug|Adapalene|All Subjects will treat the face once daily in the evening.
1815406|NCT00696449|Behavioral|frequent visits|This group will be asked to return to the study center on weeks 1, 2, 4 and 8 for office visits (to remind the Subject to apply the study medication); in addition to the study visits on Weeks 6 and 12.
1815407|NCT00696449|Behavioral|electronic reminder|This group will receive a daily electronic reminder by email, text pager, or phone message (approximately at the same time each day) to use the study medication within a 4-hour window after the reminder and will return to the study center for study visits on Weeks 6 and 12.
1815408|NCT00696449|Behavioral|Parent reminder|In this group parents will be prompted by a daily electronic message by email, text pager, or phone message (approximately at the same time each day) to remind the Subject to use the study medication within a 4-hour window after the reminder. Parents will be instructed to then verbally deliver the message to the study Subject. Subjects will return to the study center for study visits on Weeks 6 and 12.
1815409|NCT00696449|Behavioral|Standard of care|"This group is considered to be the standard of care arm and will return to the study center for study visits on Weeks 6 and 12. This group will not receive any kind of reminders other than the instructions provided by the study staff during the study visits."
1815410|NCT00696462|Device|forced-air warming|forced-air warming device
1815411|NCT00696475|Drug|Diazoxide choline|
1815412|NCT00696475|Drug|Diazoxide choline|
1815413|NCT00696475|Drug|Diazoxide choline|
1815414|NCT00696475|Drug|Placebo|
1815415|NCT00696488|Drug|Fluorouracil 0.5%|Subjects will apply the smallest amount of study medication possible that is just sufficient to cover all of the affected areas daily to AK lesions
1815418|NCT00696540|Drug|Inhalation of salbutamol diluted in hypertonic saline|The first of 3 nebulizations of 0.5 mg of Salbutamol is diluted in 3.5 ml of hypertonic (3%) saline. The second and the third are diluted in normal (0.9%) saline.
1815419|NCT00696540|Drug|Inhalation of salbutamol diluted in normal saline|The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
1815420|NCT00696553|Other|Tailored Nutrition Intervention|Provision of individualized nutrition counseling and nutrition support using oral liquid nutrition supplements and/or liquid enteral supplements
1815421|NCT00696553|Behavioral|Nutrition plus Exercise|Nutrition plus Exercise
1815422|NCT00696566|Drug|Clopidogrel and Rifampicin|"Clopidogrel: loading dose of 600 mg, then 75 mg o.d. for up to 28 days
Rifampicin: 300 mg b.d. for up to 28 days"
1815423|NCT00696579|Drug|BCG|6 weekly instillations of Tice-strain BCG (Organon Teknika Corp.) as induction chemotherapy, with a dose of 5 x 108 CFU diluted in 50 mL of saline held in the bladder for 2 hours.
1815424|NCT00696579|Drug|gemcitabine|14 days after II look-TURB the patients received 6 weekly instillations of Gemcitabine (Gemzar, Eli Lilly SpA), using a dose of 2000 mg diluted in 50 mL of saline held in the bladder for 2 hours
1815425|NCT00696592|Drug|Bevacizumab (Avastin), Verteporfin (Visudyne)|
1815426|NCT00696618|Drug|Fleet Enema|hyper-osmolar preparation
1815427|NCT00696618|Drug|tap water enema|hypo-osmolar preparation
1815428|NCT00696618|Drug|Normosol-R enema|iso-osmolar preparation
1815429|NCT00696631|Drug|Dronedarone (SR33589)|oral administration
1815430|NCT00696631|Drug|Placebo|oral administration
1815431|NCT00696644|Drug|Teriparatide|20 mcg daily subcutaneous for 18 months.
1815432|NCT00696657|Drug|semaglutide|0.1 mg, once weekly, s.c. injection
1815433|NCT00696657|Drug|semaglutide|0.2 mg, once weekly, s.c. injection
1843036|NCT00900042|Other|flow cytometry|
1815443|NCT00696657|Drug|liraglutide|1.2 mg with titration, once daily, s.c. injection
1815444|NCT00696657|Drug|liraglutide|1.8 mg with titration, once daily, s.c. injection
1815446|NCT00696696|Drug|Gemcitabine|1000 mg/m^2, intravenous, Days 1, 8, 15 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
1815447|NCT00696696|Drug|Erlotinib|150 mg, taken orally, once a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
1815448|NCT00696696|Drug|Sorafenib|400 mg, taken orally, twice a day, Days 1-28 for every 28-day cycle. In the absence of disease progression or toxicity, a patient may continue to receive gemcitabine, erlotinib, and sorafenib until disease progression.
1815449|NCT00696709|Biological|Comparator: V212|0.65 mL subcutaneous injection of heat-treated Varicella zoster virus (VZV) vaccine or alternative inactivation method VZV vaccine A, B, C; 4-dose regimen administered ~30 days apart
1815450|NCT00696709|Biological|Comparator: Placebo|Placebo; 4-dose regimen administered ~30 days apart.
1815451|NCT00696722|Drug|placebo + atazanavir|"Placebo treatment first, atazanavir treatment second
4 day treatment"
1815452|NCT00696722|Drug|atazanavir + placebo|"Atazanavir treatment first, placebo treatment second
4 day treatment"
1815453|NCT00696735|Procedure|chemotherapy|injection cyclophosphamide doxorubicin (25 mg/m2), and teniposide (60 mg/m2)(600 mg/m2)on day 1 and prednisone (40 mg/m2), administered orally on days 1 to 5.4,12 Treatment consisted of a 6-course induction phase administered monthly, followed, for responders and patients presenting a stable disease, by a maintenance phase that consisted of 1 cycle every 2 months for 1 year. Concomitant subcutaneous interferon alfa-2b was administered at 5 x 106 3 times a week for 18 months.
1815454|NCT00696735|Procedure|high dose therapy and autologous stem cell transplantation|VCAP regimen 3 cycles , less than PR: 2-3 DHAP, stem cell collection, in vitro purging autologous stem cell transplantation with TBI and cyclophosphamide
1815455|NCT00696748|Drug|Nebido (testosterone undecanoate)|Nebido (testosterone undecanoate) intramuscular 4 ml by scheme
1815456|NCT00696748|Drug|Placebo|Placebo 4 mL intramuscular
1815457|NCT00696761|Drug|alfuzosin|10mg, once daily, 12months
1815458|NCT00696761|Drug|alfuzosin|10mg, once daily, 12months
1815459|NCT00696761|Drug|alfuzosin|10mg, once daily, 12 months
1815460|NCT00696761|Drug|alfuzosin|10mg, once daily, 12months
1815461|NCT00696774|Drug|Duloxetine|"Study Period II (Acute Therapy): 60 mg capsules, QD, for 4 weeks.
Study Period III (Optimization): Responder group - 60 mg capsules, QD, for 4 weeks more. Non-responder group - 120 mg capsules, QD, for 4 weeks more."
1815462|NCT00696787|Drug|Desvenlafaxine Sustained Release (DVS SR)|
1815463|NCT00696787|Drug|Lyrica® (Pregabalin)|
1815464|NCT00696787|Drug|Placebo|
1815465|NCT00696800|Drug|Corifollitropin alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
1815466|NCT00696800|Biological|RecFSH / Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
1815467|NCT00696800|Drug|Placebo Corifollitropin alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
1815468|NCT00696800|Drug|Placebo RecFSH / follitropin beta|Identical ready-for-use solution, but without the active ingedient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
1815469|NCT00696800|Biological|RecFSH / Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
1815470|NCT00696800|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
1815471|NCT00696800|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
1815472|NCT00696800|Biological|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
1815473|NCT00696826|Drug|sitagliptin phosphate|sitagliptin phosphate 100 mg MK0431 (2 x 50 mg tablets) taken orally after overnight fast; Duration of Treatment: 5 Weeks
1815474|NCT00696839|Behavioral|Cognitive-behavioral therapy|3 sessions of CBT: introduction of CBT, training in relaxation and guided imagery, and troubleshooting/closure. 50 minute sessions with an HIV-experienced treating psychologist in Beck-type CBT. Participants will be given an audiorecording of the 2nd session to be used in private home practice, as desired.
1815475|NCT00696852|Behavioral|Mindfulness Meditation|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
1815476|NCT00696852|Behavioral|Yoga|The yoga and mindfulness classes will combine specific techniques of meditation, simple yoga postures, and breathing exercises.
1815477|NCT00696852|Behavioral|Exercise, Relaxation, and Health Education|The Exercise, Relaxation and Health Education program will consist of a 90 min group session that will include simple relaxation (such as progressive muscle relaxation) and light stretching exercises, group support, and discussions of various health topics and on stress reduction.
1815478|NCT00696865|Drug|AZD2624|oral suspension, 3 doses
1815479|NCT00696865|Drug|Placebo|
1815480|NCT00696878|Drug|Corifollitropin alfa|Corifollitropin alfa 150 µg administered as a single subcutaneous dose.
1815481|NCT00696878|Biological|FSH|FSH administerd subcutaneously at a dose not to exceed 225 IU/day.
1815482|NCT00696878|Biological|GnRH antagonist|GnRH antagonist administered subcutaneously at a dose of 0.25 mg/day.
1815483|NCT00696878|Biological|(rec)hCG|(rec)hCG administered subcutaneously at a dose of 5,000-10,000 IU/250 µg.
1815484|NCT00696878|Drug|Progesterone|Progesterone administered vaginally at a dose of at least 600 mg/day.
1815485|NCT00696891|Biological|HBV-MPL vaccine|3-dose intramuscular injection
1815486|NCT00696891|Biological|Engerix™-B|3-dose intramuscular injection
1815487|NCT00696904|Drug|ABT-333|Capsule, see arms for intervention description
1815488|NCT00696904|Drug|Placebo|Capsule, see arms for intervention description
1815489|NCT00696917|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection 3 different vaccine lots
1815490|NCT00696917|Biological|Engerix™-B|3-dose intramuscular injection
1815491|NCT00696930|Drug|90Y-SMT487|
1815492|NCT00696943|Drug|([18F]-ML-10)|[18F]-ML-10 was administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The radiation dose of [18F]-ML-10 administered at each session was 300-500 MBq (8.1-13.5 mCi).
1815493|NCT00696956|Device|Balloon angioplasty (uncoated conventional balloon)|endovascular therapy
1815494|NCT00696956|Device|Balloon angioplasty (conventional but coated with 3 µg/mm2 paclitaxel)|endovascular therapy
1815495|NCT00696969|Drug|Amphotericin B Deoxycholate|1 mg/kg e.o.d for 30 days
1815496|NCT00696969|Drug|Ambisome + Miltefosine|Ambisome (i.v. single dose 5 mg/kg)+ Miltefosine 7 days
1815497|NCT00696969|Drug|Ambisome and Paromomycin|Ambisome 5 mg/kg single dose + Paromomycin Sulphate 15mg/kg/day for 10 days
1815498|NCT00696969|Drug|Miltefosine and Paromomycin|Miltefosine (standard dose) and Paromomycin Sulphate 15mg/kg/day for 10 days
1815499|NCT00696982|Drug|sitagliptin|sitagliptin 100 mg once daily for 3 months
1815500|NCT00696982|Drug|glibenclamide|glibenclamide 5 mg once a day titrated as neede up to 20 mg a day
1815501|NCT00696995|Drug|biphasic insulin aspart 30|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
1815502|NCT00697021|Drug|Aspirin (200mg) and/or Plavix (150mg) dosage according to TEG|Non- responders to Aspirin or Plavix shown on TEG analysis will be treated by doubling of Aspirin (200mg) and/or Plavix (150mg) dosage
1815503|NCT00697021|Drug|Aspirin 100mg and Plavix 75mg|Responders to standard dual antiplatelet therapy as observed by TEG analysis will continue standard doses of Aspirin and Plavix
1815504|NCT00697034|Drug|Capsaicin|natural alkaloid derived from hot chili peppers and activates vanilloid receptors that are also activated by endogenous cannabinoid anandamide applied three times daily
1815508|NCT00697060|Drug|Imexon + docetaxel|Imexon at 1300 mg/m2 days 1-5 Docetaxel at 75 mg/m2 day 1
1815509|NCT00697073|Drug|Idebenone|Patients ≤ 45 kg/99 lbs: idebenone 1350 mg/day; Patients > 45 kg/99 lbs: idebenone 2250 mg/day
1815510|NCT00697086|Drug|Dronedarone (SR33589)|
1815511|NCT00697086|Drug|Placebo|
1815512|NCT00697099|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection"
1815513|NCT00697099|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection"
1815514|NCT00697099|Drug|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe strictly identical in appearance but without active component
Subcutaneous injection"
1815515|NCT00697112|Drug|Sirolimus|Non interventional. Sirolimus administered by Principal Investigator per standard practice and labeling.
1815516|NCT00697125|Biological|Engerix™-B|Intramuscular injection, 3 doses
1815517|NCT00697125|Biological|HBV-MPL vaccine (208129)|
1815518|NCT00697125|Biological|Hepatitis B vaccine, experimental formulation|Intramuscular injection, 3 doses
1815519|NCT00697138|Drug|d-Amphetamine; Atomoxetine|Dexedrine (0-60 mg/day); Strattera (0-80 mg/day)
1815520|NCT00697151|Drug|Warfarin|Warfarin once a day, titrated to obtain an INR of 1.4 to 2.8; placebo aspirin once a day
1815521|NCT00697151|Drug|Aspirin|Aspirin 325 mg once a day; placebo warfarin once a day
1815524|NCT00697190|Device|senofilcon A toric|silicone hydrogel contact lens for patients with astigmatism
1815525|NCT00697190|Device|galyfilcon A toric|silicone hydrogel contact lens for patients with astigmatism
1815526|NCT00697203|Drug|Placebo|po daily for 12 weeks
1815527|NCT00697203|Drug|Pravastatin|40mg po daily for 12 weeks
1815528|NCT00697203|Drug|dalceptrapib|300mg po daily for 12 weeks
1815529|NCT00697203|Drug|dalceptrapib|600mg po daily for 12 weeks
1815530|NCT00697203|Drug|dalceptrapib|900mg po daily for 12 weeks
1815531|NCT00697216|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
1815532|NCT00697216|Biological|Engerix™-B|3-dose intramuscular injection
1815533|NCT00697229|Biological|Engerix™-B|Intramuscular injection, 1 or 3 doses
1815534|NCT00697229|Biological|HBV-MPL vaccine|Intramuscular injection, 1 or 3 doses
1815535|NCT00697242|Biological|Engerix™-B|Intramuscular injection, 3 doses
1815536|NCT00697242|Biological|Recombinant HBsAg with different concentrations of Aluminium Salts and/or MPL|Intramuscular injection, 3 doses
1815537|NCT00697255|Drug|corifollitropin alfa|SC corifollitropin alfa on the 1st, 2nd or 3rd day after onset of a progestagen-induced withdrawal bleeding (Stage 1a: 15mcg, Stage Ib/II: 30 mcg).
1815538|NCT00697255|Biological|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
1815539|NCT00697255|Biological|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG (200 IU) administered as soon as the largest follicle reaches a size ≥12 mm 4 days after a corifollitropin alfa injection on stimulation day 5, 9 or 13.
1815540|NCT00697255|Biological|hCG Bolus injection|Bolus injection of SC hCG was administered to induce final oocyte maturation if at least one follicle is ≥18 mm and no more than two follicles ≥15 mm are observed.
1815606|NCT00697749|Biological|Engerix™-B|3-dose intramuscular injection
1815541|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days
Dose level 1"
1815542|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days
Dose level 2"
1815543|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days
Dose level 3"
1815544|NCT00697281|Drug|OC000459|"Tablets twice daily for 8 days
Dose level 4"
1815545|NCT00697281|Drug|Placebo|"Tablets twice daily for 8 days
Dose level 5"
1815546|NCT00697294|Dietary Supplement|Tri-Vi-Sol|All subjects will begin vitamin D supplementation at the first outpatient visit (at 1 week of life) and will continue through the second outpatient visit (at 3 months of age). Dosage will be 400 IU/day of vitamin D in the form of Tri-Vi-Sol vitamin drops.
1815547|NCT00697320|Drug|eptacog alfa (activated)|"A NON INTERVENTIONAL OBSERVATIONAL STUDY:
Doses and frequency of injections to be prescribed by the physician as a result of the normal clinical evaluation"
1815548|NCT00697333|Procedure|restriction of radiotherapy to FDG-PET positive areas only|Restriction of target volumes to areas positive in positron emission tomography using fluoro-deoxy-glucose
1815549|NCT00697346|Drug|Alisertib|Alisertib (MLN8237) PIC or ECT
1815550|NCT00697359|Device|Implantable loop recorder (ILR)|The ILR will be implanted subcutaneous following standard surgical procedure.
1815551|NCT00697372|Device|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
1815552|NCT00697372|Device|Everolimus eluting stent|Implantation of Everolimus eluting stent
1815553|NCT00697385|Drug|Cyclokapron|(2) 500mg tablets taken by mouth every 6-8 hours
1815554|NCT00697398|Other|Transcranial stimulation|Stimulation to white
1815555|NCT00697398|Other|Transcranial stimulation|Repetitive transcranial magnetic stimulation (rTMS)
1815556|NCT00697424|Device|SleepStyle 200 Auto Series CPAP Humidifier|The device will record on internal software perceived sleep disordered breathing events. Events will also be scored manually on the polysomnography (PSG. Results will then be compared.
1815557|NCT00697437|Drug|Docetaxel|70mg q3wx 1 dose
1815558|NCT00697437|Drug|Ketoconazole|6 doses of oral ketoconazole 200mg bid starting 2 days before, and with 1 dose to be completed after, docetaxel infusion
1815559|NCT00697450|Drug|insulin detemir|Start dose, frequency of dosing, dose titration to be prescribed by the physician as a result of a normal clinical evaluation
1993899|NCT03110601|Device|PM external modulator|Subjects with chronic back pain will be trialed with PM external modulator.
1815561|NCT00697476|Drug|topotecan, vorinostat|"Phase I study: vorinostat will be administered daily for a number of days per cycle variable from 7 to 14 according to the level of dose escalation; topotecan will be administered I.V. for 5 consecutive days every 3 weeks.
Phase II study: Patients will receive treatment at the recommended dose established by phase I part of the trial, for a maximum of 6 cycles or until disease progression, unacceptable toxicity or patient's refusal."
1815562|NCT00697489|Procedure|correction of POP plus preventive continence procedure|
1815563|NCT00697489|Procedure|POP surgery followed by eventual incontinence procedure|
1815564|NCT00697502|Drug|Capecitabine|"Capecitabine (XELODA) is supplied as biconvex, oblong film-coated tablets for oral administration and will be obtained from NUH Cancer Centre pharmacy.
Each light peach-colored tablet contains 150 mg capecitabine and each peach-colored tablet contains 500 mg capecitabine. Capecitabine is to be administered orally within 30 minutes after the end of a meal (breakfast, dinner). Tablets should be swallowed with about 200 mL of water (not fruit juices). Capecitabine will be administered for 14 days followed by a 7 day rest period."
1815565|NCT00697515|Drug|LDX|oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting
1815566|NCT00697515|Drug|Placebo|Placebo administered once-daily for one week during the adult workplace environment setting
1815567|NCT00697541|Drug|0.18% COL-118 facial gel (1.8 mg brimonidine)|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
1815568|NCT00697541|Drug|0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop)|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically.
1815569|NCT00697541|Drug|Advanced Eye Relief|One 1-g application of 0.18% COL-118 facial gel (1.8 mg brimonidine) administered topically plus one drop of Advanced Eye Relief™ in each eye, once in the morning. 1 g of 0.18% COL-118 facial gel is reapplied once after 4 hours
1815570|NCT00697541|Drug|COL-118 facial gel vehicle|One 1-g application of COL-118 facial gel vehicle (0.0 mg brimonidine tartrate) administered topically plus one drop of 0.2% brimonidine ophthalmic solution (0.1 mg brimonidine tartrate/drop) in each eye. Four hours after the first application 1-g of COL-118 facial gel vehicle (0.0 mg brimonidine) is administered topically
1815571|NCT00697554|Biological|HBV-MPL vaccine 208129|2-dose primary vaccination followed by 1 booster vaccination by intramuscular injection
1815572|NCT00697554|Biological|Engerix™-B|3-dose primary vaccination followed by 1 booster vaccination by intramuscular injection of double doses
1815573|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141 - non-MPL-containing adjuvant|Intramuscular injection, 3 doses
1815574|NCT00697567|Biological|Herpes simplex candidate vaccine GSK208141- MPL-containing adjuvant|Intramuscular injection, 3 doses
1815575|NCT00697580|Behavioral|Nutrition|Nutrition classes for 1 hour & 30 minutes once a week for 16 weeks + motivational interviewing (4 individual sessions)
1815576|NCT00697580|Behavioral|Strength Training & Nutrition|Strength Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
1815577|NCT00697580|Behavioral|Circuit Training & Nutrition|Circuit Training twice a week for 1 hour a day for 16 weeks + Nutrition once a week for 1 hour & 30 minutes for 16 weeks + motivational interviewing (4 individual & 4 group sessions)
1815578|NCT00697593|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody (mAb)|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1mg/kg/week for up to 12 weeks.
1815581|NCT00697619|Drug|Zometa (zoledronic acid)|Zometa 4 mg IV infusion every 4 weeks for 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
1815582|NCT00697632|Drug|MGCD265|Oral daily administration without interruption
1815583|NCT00697645|Device|Deep TMS (Transcranial magnetic stimulation)|All participants will receive standard medical and rehabilitation therapy for stroke without any restrictions. In addition, patients recruited for the study will receive 7 sessions of TMS with the Brainsway device delivered over the motor strip of the affected hemisphere. Each session will last for 15 minutes and the brain will be stimulated at 10Hz. Each TMS train will contain 20 pulses (2 seconds) and the inter train interval will be 20 seconds. Each session will contain 40 trains. Sessions will begin on day 3-5 after stroke onset and will be given every day, excluding weekends, for 10 days. All deep TMS will be performed in a dedicated room under the observation of an unblinded investigator. Patients will be monitored daily until discharge from the hospital, or until the end of the treatment, whichever is earlier. All assessments will be performed by investigators blinded to the therapy group.
1815584|NCT00697645|Device|Brainsway Deep TMS|Deep TMS applied over the motor strip
1815585|NCT00697658|Drug|Paliperidone ER|6 mg tablet once daily, variable treatment length.
1815586|NCT00697671|Other|NK Cell Infusion|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued
1815587|NCT00697671|Biological|Immunotherapy|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
1815588|NCT00697671|Device|Miltenyi Biotec CliniMACS device|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
1815589|NCT00697671|Drug|Interleukin-2 (IL-2)|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
1815590|NCT00697671|Drug|Clofarabine|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
1815591|NCT00697671|Drug|Cyclophosphamide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
1815592|NCT00697671|Drug|Etoposide|All participants will receive a 4 day regimen of chemotherapy (clofarabine, cyclophosphamide, and etoposide) followed by an infusion of HLA partially matched family member donor NK cells processed through the use of the investigational CliniMACS device. Interleukin-2 (IL-2) will be given three times per week post-infusion for a minimum of 2 weeks. IL-2 administration will continue until donor NK cells are no longer detectable in the recipient, and, at that time, will be discontinued.
1815593|NCT00697684|Drug|Antithymocyte Globulin|
1815594|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 20mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 100 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
1815595|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 30mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 150 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
1815596|NCT00697684|Drug|Clofarabine|Transplant conditioning will begin day -11 with 5 days of TLI at a dose of 80 cGy per day administered in conjunction with rabbit ATG at a dose of 1.5 mg/kg per day (day -11 to -7). Clofarabine will be given at 40mg/m2/d IV infused over 1 hour x 5 days (day -6 to -2), for a total dose of 200 mg/m(2). TLI will be completed at 80 cGy per day (day -4 to 0) for a total of 10 fractions (800 cGy).
1815597|NCT00697697|Drug|0.135mg MAP0010|0.135mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
1815598|NCT00697697|Drug|0.25mg MAP0010|0.25mg MAP0010 (unit dose budesonide) delivered by nebulization twice daily for 40 weeks
1815599|NCT00697710|Drug|50 mg S-777469|S-777469, 50 mg BID
1815600|NCT00697710|Drug|200 mg S-777469|S-777469, 200 mg BID
1815601|NCT00697710|Drug|800 mg S-777469|S-777469, 800 mg BID
1815602|NCT00697710|Drug|Placebo|Matching Placebo
1815603|NCT00697723|Procedure|Transit-time flowmetry|Transit-time flowmetry during 1:1 IABP assistance and when IABP is turned off
1815604|NCT00697736|Procedure|Echocardiography with myocardial tissular Doppler mode|Echocardiography with myocardial tissular Doppler mode during rest and exercise on a table equipped with a cyclo-ergometer
1815605|NCT00697749|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
1815607|NCT00697762|Drug|RWJ-333369|200 mg tablet twice daily for 12 weeks
1815608|NCT00697762|Drug|RWJ-333369|100 mg tablet twice daily for 12 weeks
1815609|NCT00697762|Drug|Placebo|Placebo tablet twice daily for 12 weeks
1815610|NCT00697775|Biological|HBV-MPL vaccine Formulation A|Single dose (when extemporaneously co-administered with Engerix™-B) or 2-dose (when administered alone) intramuscular injection
1815611|NCT00697775|Biological|HBV-MPL vaccine Formulation B|2-dose intramuscular injection
1815612|NCT00697775|Biological|Engerix™-B|Single dose (when extemporaneously co-administered with HBV-MPL) or 3-dose (when administered alone) intramuscular injection
1815613|NCT00697788|Drug|Dexmedetomidine|Dexmedetomidine bolus 1 ug/kg over 10 minutes, followed by ascending infusion as follows: Dexmedetomidine [in ug/kg/hr], each for 15 minutes: 0.7, 1.0, 1.3, 1.6, 1.9, 2.2, 2.5.
1815614|NCT00697801|Drug|MAP0010 low dose|a single dose of MAP0010 low dose delivered by nebulization twice daily for 6 weeks
1815615|NCT00697801|Drug|MAP0010 high dose|a single dose of MAP0010 high dose delivered by nebulization twice daily for 6 weeks
1815616|NCT00697801|Drug|Placebo|Placebo delivered by nebulization twice daily for 6 weeks
1815617|NCT00697814|Drug|Clomiphene citrate|Clomiphene 50 mg/day for 12 weeks
1815618|NCT00697827|Device|Interspinous Spacer device|Device: In-Space
1815619|NCT00697827|Device|Interspinous Process Distraction Device|Device: X STOP
1815620|NCT00697840|Biological|Engerix™-B|Intramuscular injection, 2 doses
1815621|NCT00697840|Biological|HBV-MPL 208129|Intramuscular injection, 2 doses
1815622|NCT00697840|Biological|Vaccine containing HBsAg absorbed on aluminium salts - experimental formulation|Intramuscular injection, 2 doses; experimental formulation
1815623|NCT00697853|Biological|Engerix™-B|3-dose intramuscular injection
1815624|NCT00697853|Biological|HBV-MPL vaccine 208129|2-dose intramuscular injection
1815625|NCT00697866|Biological|HBV-MPL vaccine 208129|3 consecutive lots; 3-dose intramuscular injection
1815626|NCT00697866|Biological|Engerix™-B|3-dose intramuscular injection
1815627|NCT00697879|Drug|CHR-3996|Once daily oral ingestion of capsules (5, 10, 20 or 40 mg), dose depending on cohort, treatment cycle of 28 days
1815628|NCT00697892|Drug|lopinavir/ritonavir|Two tablets of lopinavir 200mg / ritonavir 50mg orally twice daily with food for 26 days
1815629|NCT00697892|Drug|efavirenz|One 600mg tablet orally once daily before bedtime on an empty stomach for 26 days
1815630|NCT00697892|Drug|artemether/lumefantrine|4 tablets of artemether 20mg/lumefantrine 120mg twice daily with food. 2 three-day courses will be administered (with washout in between) during the duration of the trial.
1815631|NCT00697905|Drug|Gemcitabine|Intravenous administration on days 1, 8 of a 21-day cycle
1815632|NCT00697905|Drug|Carboplatin|Intravenous following Gemcitabine infusion on day 1
1815633|NCT00697905|Drug|Cisplatin|Intravenous on day 1 prior to 5-FU infusion on days 2 to 5 of a 28-day cycle
1815634|NCT00697905|Drug|5-fluorouracil (5-FU)|Intravenous infusion on day 2 to day 5
1815635|NCT00697918|Drug|RWJ-333369|100 mg to 400 mg twice daily
1815636|NCT00697931|Biological|Recombinant MPL- adjuvanted hepatitis B vaccine|Intramuscular injection, 3 doses
1815637|NCT00697931|Biological|Engerix™-B|Intramuscular injection, 3 doses
1815638|NCT00697944|Drug|Amphotericine in liposome (Ambisome®)|2 IV infusions separated by one week 10 mg/kg per injection
1815639|NCT00697957|Behavioral|Exercise|Progressive impact exercise
1815640|NCT00697970|Biological|HBsAg formulated with different concentrations of MPL and Aluminium Salts|Intramuscular injection, 3 doses
1815641|NCT00697970|Biological|Engerix™-B|Intramuscular injection, 3 doses
1815642|NCT00697996|Drug|Rituximab for transplant rejection|
1815643|NCT00698009|Drug|Fludarabine|25 mg/m^2 By Vein Daily Over 30 minutes Starting 6 days before the NK cell infusion (considered Day -6) and once a day through Day -2.
1815644|NCT00698009|Drug|Cyclophosphamide|60 mg/kg By Vein Daily Over 2 Hours On Days -5 and -4
1815645|NCT00698009|Biological|Natural Killer Cell Infusion|Natural Killer Cell Infusion on Day 0.
1815646|NCT00698009|Drug|Mesna|12 mg/kg By Vein, Over about 15 minutes, Five Times Per Day on Days -5 and -4.
1815647|NCT00698009|Drug|Interleukin-2|"Received under skin three times weekly for 9 total doses following NK Cell Infusion:
For patients weighing 45 kg or more, dose administered is 10 Million units three times weekly for 9 total doses. For patients less than 45 kg, dose administered is 5 Million units/m2 (max dose 10 Million units) three times weekly for 9 total doses."
1815648|NCT00698022|Drug|risperidone|daily risperidone plus mifepristone for 28 days
1815649|NCT00698022|Drug|risperidone matched placebo|risperidone-matched placebo plus mifepristone daily for 28 days
1815650|NCT00698022|Drug|risperidone-matched placebo|daily risperidone-matched placebo plus mifepristone for 28 days
1815651|NCT00698022|Drug|Mifepristone-matched placebo|daily mifepristone-matched placebo for 28 days
1815652|NCT00698035|Drug|Testosterone Cream|1% micronized in velvachol - 0.5 gm of cream vaginally each night for two weeks, then 3 times a week for total of 12 weeks of treatment
1815653|NCT00698035|Drug|Estring|2mg ring inserted vaginally once every 12 weeks
1815654|NCT00698061|Biological|HBV-MPL vaccine 208129|3-dose primary vaccination and booster vaccination by intramuscular injection
1815655|NCT00698061|Biological|Engerix™-B|3-dose primary vaccination and booster vaccination by intramuscular injection
1815656|NCT00698074|Device|Cardiac Resynchronisation Therapy|Biventricular Pacemaker Implant
1815657|NCT00698087|Biological|MPL-Adjuvanted recombinant hepatitis B vaccine|Intramuscular injection, 2 or 3 doses, 2 different formulations
1815658|NCT00698087|Biological|Engerix™-B|Intramuscular injection, 2 or 3 doses
1815659|NCT00698100|Biological|human tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
1815747|NCT00691483|Drug|varenicline|varenicline tablets, 1 mg taken orally twice daily for 12 weeks
1815660|NCT00698100|Biological|mouse tyrosinase|Patients will receive a total of 6 vaccinations. Each vaccination is given via the intramuscular route. Sites of injection should have intact lymphatic drainage. The vaccinations will be administered at three week intervals. Groups of six patients will be randomized at each dose level to receive either three immunizations with mouse tyrosinase followed by three immunizations with human tyrosinase or three immunizations with human tyrosinase followed by three immunizations with mouse tyrosinase
1815661|NCT00698113|Procedure|Massage|"Children will receive a 10-15 minute massage seated (clothed), or in bed (clothed or unclothed) each day using the following protocol: stroking, effleurage, petrissage, muscle squeezing, effleurage, stroking. Massaged areas can include the back, arms and legs.
Parents will receive a one hour educational session with a Massage Therapist, a DVD, and written materials that all illustrate the required protocol."
1815662|NCT00698113|Other|Journaling|Children will complete weekly journals about their feelings. These journals will either be drawn or written based on the preference of the child. Parents will complete a weekly journal outlining the number of massages given to their child, barriers that prevented massage, and their experience of giving the massage.
1815663|NCT00698126|Drug|soluble human insulin|Observational study; use of the products as in the normal clinical practice conditions
1815664|NCT00698126|Drug|biphasic insulin aspart|Observational study; use of the products as in the normal clinical practice conditions
1815665|NCT00698139|Device|Medtronic Pacemaker|Patients will come to clinic in the morning for baseline measurements. Subsequently, the atrial pacing rate will be increased to 85bpm for 6 hours. The control group will be given the illusion that their pacer has been adjusted, but the settings will remain unchanged. Patients will eat a standard breakfast provided by the hospital prior to the treatment session, and then will fast for the six-hour observation period. Patients will remain in supine position and will be clinically monitored for 6 hours. All patients will be on continuous cardiac monitors. Vital signs and symptoms of congestion/ischemia will be recorded every hour.
1815666|NCT00698178|Other|Anthropometric measurements|All patients undergo anthropometric measurements to record body weight, body height and waist circumference on the day of enrollment
1815667|NCT00698191|Biological|Allogeneic MSC (AlloMSC)|"Intervention:
Cyclophosphamide will be administered intravenously at at total dose of 0.8-1.8g 24 hours before transplantation.
Allogeneic bone marrow derived mesenchymal stem cells (matched family donors)will be infused intravenously at 106 cells/kg body weight"
1815668|NCT00698204|Drug|celecoxib|Subject was asked to take celecoxib each day that radiation therapy was given.
1815669|NCT00698204|Drug|placebo|Subject was asked to take placebo each day that radiation therapy was given.
1815670|NCT00698230|Drug|INCB013739|INCB013739 5 mg QD tablet
1815671|NCT00698230|Drug|INCB013739|INCB013739 15 mg QD tablet
1815672|NCT00698230|Drug|INCB013739|INCB013739 50 mg QD tablet
1815673|NCT00698230|Drug|INCB013739|INCB013739 100 mg QD tablet
1815674|NCT00698230|Drug|INCB013739|INCB013739 200 mg QD
1815675|NCT00698230|Drug|Placebo comparator matching INCB013739|Orally once daily tablet
1815676|NCT00698243|Drug|OSI-027|Administered orally
1815677|NCT00698256|Dietary Supplement|vegetable oil-based spread and oat-based drink (no brand name available)|spread and drink (9 g stanols/d)
1815678|NCT00698256|Dietary Supplement|vegetable oil-based spread and oat-based drink (no brand name available)|Spread and drink (not containing added stanols)
1815679|NCT00698269|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1815680|NCT00698269|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1815681|NCT00698269|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1815682|NCT00691041|Behavioral|Unity in Diversity|HIV/STI counseling and testing and a 7 session intervention to increase participants' level of knowledge and skills concerning HIV prevention (to decrease HIV acquisition or transmission) and to diffuse the information to their social network
1815683|NCT00691054|Drug|Abraxane|One treatment-cycle is 28 days with chemotherapy (Abraxane® 100 mg/m2) given on day 1, 8, and 15, followed by rest on week 4. Treatment cycles will be repeated every 28 days for as long as disease is not progressing and patient tolerates treatment
1815684|NCT00691067|Drug|mifepristone|200 mg po per day x 6 weeks
1815685|NCT00691067|Drug|Placebos|placebo
1815686|NCT00691093|Drug|fesoterodine|4 mg per 24 hours, possibility to increase to 8 mg depending on efficacy chronic treatment
1815687|NCT00691119|Behavioral|Relaxation and Visualization Therapy|Twenty minutes of facilitated relaxation and visualization therapy five days a week for six weeks. Self practice of 20 minutes per day for the next six weeks.
1815688|NCT00691119|Other|Health education|Facilitated health education sessions, twenty minutes, five times a week for six weeks.
1815689|NCT00691132|Drug|phenethyl isothiocyanate|Given orally
1815690|NCT00691132|Other|placebo|Given orally
1815691|NCT00691145|Drug|tacrolimus ointment|transdermal
1815692|NCT00691158|Drug|Pramlintide (Amylin)|4.7 mls of Amylin 15mcg/ml IV bolus.
1815693|NCT00691158|Drug|Placebo (Normal Saline)|4.7 mls normal saline IV bolus x1
1815694|NCT00691158|Drug|2 Metreleptin|Receive .06mg/kg of metreleptin IV bolus x1
1815695|NCT00691158|Drug|Leptin plus Pramlintide|receive leptin IV bolus x1 and pramlintide bolus at Timepoint +0 and +30 minutes.
1815696|NCT00691184|Drug|Placebo|0% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
1815697|NCT00691184|Drug|Terbinafine Hydrochloride|10% Terbinafine HCl Nail Lacquer for onychomycosis, twice daily for 28 days.
1815698|NCT00691184|Drug|Terbinafine Hydrochloride|1% Terbinafine Hydrochloride Cream, twice a day for 7 days.
1815699|NCT00691184|Drug|Terbinafine|Terbinafine tablet, 250mg, single dose in groups 1,2 and 3 at end of study.
1815700|NCT00691197|Device|Carboxymethylcellulose sodium and Glycerin|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
1815701|NCT00691197|Device|Carboxymethylcellulose sodium|Eye drops used at least 4 times per day, 1-2 drops in each eye while wearing contact lenses.
1815830|NCT00700063|Drug|PEP005 Topical Gel|0.01%, three days treatment
1815831|NCT00700063|Drug|PEP005 Topical Gel|0.015%, three days treatment
1815702|NCT00691210|Drug|Vorinostat|"Dose escalation scheme (400 mg)
Vorinostat is used to treat cutaneous T-cell lymphoma (CTCL, a type of cancer) in people whose disease has not improved, has gotten worse, or has come back after taking other medications. Vorinostat is in a class of medications called histone deacetylase (HDAC) inhibitors. It works by killing or stopping the growth of cancer cells."
1815703|NCT00691210|Drug|Niacinamide|"Dose escalation scheme (20, 40, 60, 80, 100 mg/kg rounded to 100 mg)
Niacinamide is a water soluble B-vitamin that has been evaluated for use in the treatment of pellagra, bullous pemphigoid, and as a radiation sensitizer in head and neck cancer."
1815704|NCT00691210|Drug|Etoposide|"Dose escalation scheme (0, 25, 50, 100 mg/m2)
Etoposide is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug. This medication is classified as a plant alkaloid and topoisomerase II inhibitor."
1815705|NCT00691236|Drug|Zoledronic acid|4mg IV 3 weekly for 6 doses
1815706|NCT00691236|Drug|Standard chemotherapy|Adriamycin + Cisplatinum and Ifosfamide
1815707|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|Low Dose- 70g bar
1815708|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Raw|High Dose- 100g bar
1815709|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|Low Dose- 70g bar
1815710|NCT00691249|Dietary Supplement|Resistant Starch Type 4-Cooked|High dose: 100g bar
1815711|NCT00691249|Dietary Supplement|Shredded Wheat|70g bar
1815712|NCT00691262|Drug|tacrolimus ointment|transdermal
1815713|NCT00691275|Drug|Ondansetron|
1815714|NCT00691275|Drug|Saline|
1815715|NCT00691288|Drug|Omega Pure followed by placebo|Subjects in this arm will begin the study on active capsules (containing Omega Pure). Subjects in the 5-11 age group will take 2 capsules containing 500mg EPA/DHA twice daily for 12 weeks. Subjects in the 12-18 age group will take 2 capsules containing 1.0g EPA/DHA twice daily, also for a period of 12 weeks. Both age groups will then be switched to the placebo capsules containing citrus-flavoured soybean and corn oil, identical in appearance to the active agent, to be taken on an identical regimen to the active pills, for a period of 12 weeks.
1815716|NCT00691288|Drug|Placebo followed by Omega Pure|Patients assigned to this arm of the study will begin on placebo followed by Omega Pure (identical dose and regimen as arm 1), also for a period of 12 weeks each.
1815719|NCT00691314|Device|Stent implantation (Wingspan, Coroflex, and TiTAN2)|"Stent Implantation:
Wingspan intracranial stent with Gateway PTA balloon Catheter; Coroflex&reg - balloon expandable stent system and Coroflex Blue - Coronary Stent System; TiTAN2 Bio-active coating stent
Standard Medical Management:including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide) .
Arms: 1"
1815720|NCT00691314|Drug|Standard medical treatment|Standard Medical Management:including antiplatelet agents(Aspirin 75~150mg/day or Clopidogrel 75mg/day),statins(Atorvastatin 20mg/day or Simvastatin 20mg/day),risk factor lowering agents (antihypertension agents:Amlodipine 5mg/day or Benazepril 10mg/day or Valsartan 80mg/day or Nifedipine 30mg/day or Indapamide 2.5mg/day,antidiabetic agents: Metformin 0.5 tid or Glipizide 5mg tid or Acarbose 50mg tid )if necessary,interactive education program (Online medical education program, health behavior guide)
1815721|NCT00691327|Device|Natrelle(TM) Silicone-Filled Breast Implants|Breast implant surgery
1815722|NCT00691379|Drug|Carboplatin|Carboplatin (IV) 2 AUC on day 1,8,15. Treatment repeats every 4 weeks until progression
1815723|NCT00691379|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1,15. Treatment repeats every 4 weeks until progression
1815724|NCT00691379|Drug|Paclitaxel|Paclitaxel (IV) 90 mg/m2,on day 1,8,15. Treatment repeats every 4 weeks until progression
1815725|NCT00691392|Drug|Linezolid|Linezolid 600 mg po daily for 16 weeks (112 doses) - over-encapsulated
1815726|NCT00691392|Drug|Microcrystalline Methylcellulose - Placebo|The placebo will be over-encapsulated microcrystalline methylcellulose
1815727|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 5 mcg BID
1815728|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg BID
1815729|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg BID
1815730|NCT00691405|Drug|Placebo|Placebo inhalation solution BID
1815731|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 15 mcg QD
1815732|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 25 mcg QD
1815733|NCT00691405|Drug|Arformoterol tartrate inhalation solution|Arformoterol 50 mcg QD
1815734|NCT00691405|Drug|Placebo|Placebo inhalation solution QD
1815735|NCT00691418|Dietary Supplement|docosahexaenoic acid (DHA)|600 mg per day of docosahexaenoic acid (DHA) starting at 22-24 weeks gestation until delivery.
1815736|NCT00691418|Dietary Supplement|placebo|placebo once per day starting at 22-24 weeks gestation until delivery.
1815737|NCT00691431|Device|LASIK|
1815738|NCT00691444|Dietary Supplement|Melatonin|"Subjects will be given up to 0.5 mg daily.
0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
1815739|NCT00691444|Dietary Supplement|Melatonin|"Subjects will be given up to 10 mg daily.
0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
1815740|NCT00691444|Biological|Melatonin|"Subjects will be given up to 20 mg daily.
0.005-20 mg, daily, up to 5 years (the exact duration depends on each subjects response to the dose and the specifics of their circadian rhythm patterns)."
1815741|NCT00691457|Device|Opti-Free contact lens solution|Solution
1815742|NCT00691457|Device|ReNu Multiplus contact lens solution|Solution
1815743|NCT00691457|Device|Clear Care contact lens solution|Solution
1815744|NCT00691470|Drug|ATI-5923|Dose Adjusted based on INR.
1815745|NCT00691470|Drug|Coumadin (warfarin)|Dose adjusted based on INR.
1815746|NCT00691483|Drug|placebo|placebo tablet taken orally twice daily for 12 weeks
1815832|NCT00700063|Drug|Vehicle gel|three days treatment
1815748|NCT00691496|Behavioral|Behavioral intervention to reduce sexual risk among African-American men who have sex with men|5 week intervention to increase skill level of participants with talking to their social networks and sexual partners about reducing high risk sexual behaviors while preparing a healthy meal
1815749|NCT00691509|Genetic|gene expression analysis|
1815750|NCT00691509|Genetic|polymorphism analysis|
1815751|NCT00691509|Other|high performance liquid chromatography|
1815752|NCT00691509|Other|laboratory biomarker analysis|
1815753|NCT00691509|Other|mass spectrometry|
1815754|NCT00691509|Other|questionnaire administration|
1815755|NCT00698282|Drug|AZD1981|Oral tablet, 250 mg single dose
1815756|NCT00698282|Drug|AZD1981|Suspension, 15, 75, 1000 and 2000 mg
1815757|NCT00698282|Drug|Placebo|
1815758|NCT00698321|Behavioral|HIV/STD prevention curriculum|The curriculum will include eight 1-hour HIV prevention modules administered weekly for 8 weeks. The modules will educate youth about risky sexual behaviors and will provide them with knowledge and skills necessary to reduce their risk of STDs, HIV, and pregnancy by abstaining from sex or using condoms if they choose to have sex. The curriculum is based on cognitive behavioral theories, focus groups, and the researchers' experience working with youth.
1815759|NCT00698321|Behavioral|General health promotion curriculum|The curriculum will include eight 1-hour general health modules administered weekly for 8 weeks. The curriculum will focus on teaching students healthful behaviors, including eating habits, physical activity, dental hygiene, and avoidance of cigarette smoking and substance abuse.
1815760|NCT00698334|Drug|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg [600 mg if more than 59 kg], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
1815761|NCT00698334|Drug|INH, Rifampicin, Ethambutol and Pyrazinamide|Directly Observed Treatment Short-course; Thrice weekly (INH 600 mg, Rifampicin 450 mg [600 mg if more than 59 kg], Ethambutol 1200 mg, Pyrazinamide 1500 mg)
1815762|NCT00698347|Device|M2a-Magnum™ Hip System|
1815763|NCT00698386|Dietary Supplement|Zinc supplement|Zinc miconutrient supplements have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.Each micronutrient capsule contains 50mg zinc (as zinc sulphate) in a lactose matrix.In this clinical trial one tablet of zinc as oral supplement will be given everyday during the entire course in line with the directly observed treatment, short-course (DOTS) strategy recommended by the World Health Organization.
1815764|NCT00698386|Dietary Supplement|Placebo|Placebo have been prepared by Cadila pharmaceutical Ltd., India, in the form of capsules.The placebo consisted of lactose alone. Supplement and placebo capsules were indistinguishable in appearance both externally and internally.
1815765|NCT00698412|Device|Cane|This group use the cane every day since the baseline
1815766|NCT00698425|Other|EyeGate II® Drug Delivery System|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
1815767|NCT00698425|Drug|Citrate buffer|Transscleral iontophoresis using citrate buffer delivered by EyeGate II® Drug Delivery System
1815768|NCT00698438|Device|Ex-PRESS implantation|"I. Mobility check of the device. II. Administration of a local or topical anesthetic. III. Preparation and coverage of the eye by conventional sterile procedures. IV. Injection of viscoelastic material into the AC through a paracenthesis. V. Creation of a scleral tunnel up to clear cornea. VI. Creation of a (5 mm) conjunctival tunnel fornix based. VII. Lifting of the conjunctiva and tenon. VIII. Formation of a 2mm scleral incision at 0.3mm depth, 1.5mm from the limbus. IX. Application of 0.5µg/ml MMC under the tunnel for one minute.
X. Penetration into the AC using a 0.65mm stiletto, inside the tunnel of the sclera-corneal junction.
XI. Implantation of the Ex-PRESSTM through that pre-incision at the sclerocorneal junction.
XII. Introducer withdrawal. XIII. Tucking the plate under the scleral tunnel, and verification of the position inside the tunnel.
XIV. Reposition the conjunctiva with 1 - 2 sutures at the limbus. XV. Closing the conjunctiva with a suture."
1815769|NCT00698438|Procedure|Trabeculectomy|standard trabeculectomy
1815770|NCT00698451|Drug|doxorubicin HCL liposome; bevacizumab; carboplatin|30 mg/m2 by intravenous infusion Day 1 of each 28 day cycle; 10 mg/kg by intravenous infusion Days 1 and 15 of each 28 day cycle; AUC=5 by intravenous infusion Day 1 of each 28 day cycle
1815771|NCT00698464|Drug|Pasireotide|Single subcutaneous injection of 600 µg of Pasireotide.
1815772|NCT00698490|Biological|Adjuvanted herpes simplex (gD) candidate vaccine GSK 208141|Intramuscular injection, 3 doses, 2 different formulations
1815773|NCT00698490|Biological|Herpes simplex virus containing gD-Alum|Intramuscular injection, 3 doses
1815774|NCT00698516|Drug|Oral Hycamtin (topotecan) Capsules + IV Avastin (bevacizumab)|2.3 mg/m2 daily x 5 oral topotecan and 15 mg/kg IV bevacizumab on day 1 of every 21 days cycle.
1815775|NCT00698529|Behavioral|Face-to-face training|NGOs will receive the POL intervention through face-to-face training. Staff will receive 2-day training on the POL intervention and individualized telephone follow-up consultations concerning POL implementation.
1815776|NCT00698529|Behavioral|Distance training|NGOs will receive the POL intervention through Web-based training. Staff will receive training delivered entirely by means of a Web-based, distance learning curriculum and through individualized telephone follow-up consultations concerning POL implementation.
1815777|NCT00698529|Behavioral|Popular Opinion Leader (POL)|POL is a community-level HIV intervention that recruits and trains opinion leaders in the community to promote safe sex behaviors through risk-reduction conversations with peers.
1815778|NCT00698555|Biological|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
1815779|NCT00698555|Biological|Engerix™-B|3-dose intramuscular injection
1815780|NCT00698568|Biological|Herpes simplex candidate vaccine- adjuvanted GSK 208141|Intramuscular injection, 3 doses
1815781|NCT00698568|Biological|Placebo|Intramuscular injection, 3 doses
1815782|NCT00698581|Drug|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
1815783|NCT00698581|Drug|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
1815784|NCT00698594|Biological|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old. receiving seasonally grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - seasonal SLIT group
1857785|NCT01005758|Drug|imatinib mesylate|
1815785|NCT00698594|Biological|sublingual allergen extract|Group of children with allergic rhinitis 6-18 years old receiving yearly grass pollens sublingual allergen extract (Staloral 300 IR, Stallergenes, France) (n=20) - yearly SLIT group
1815786|NCT00698594|Biological|placebo|Group of children with allergic rhinitis 6-18 years old receiving placebo in sublingual applicator (Staloral 300 IR, Stallergenes, France) (n=20) - placebo group
1815787|NCT00698607|Device|Everolimus-eluting stent (Xience or Promus)|Use everolimus-eluting stent in the treatment of coronary stenosis
1815788|NCT00698607|Device|Sirolimus-eluting stent (Cypher)|Use sirolimus-eluting stent in the treatment of coronary stenosis
1815789|NCT00698607|Drug|6-month clopidogrel therapy|Use clopidogrel for 6 months
1815790|NCT00698607|Drug|12-month clopidogrel therapy|Use clopidogrel for 12 months
1815791|NCT00699803|Drug|T-PRED|sterile ophthalmic solution at the first time point
1815792|NCT00699803|Drug|T-PRED|sterile ophthalmic solution at the second time point
1815793|NCT00699803|Drug|Pred Forte|sterile ophthalmic solution at the first time point
1815794|NCT00699803|Drug|Pred Forte|sterile ophthalmic solution at the second time point
1815796|NCT00699842|Drug|Lenalidomide|"Dose Level Lenalidomide Schedule
15mg/day for d1-21 out of 28 days
20mg/day for d1-21 out of 28 days
25mg/day for d1-21 out of 28 days"
1815797|NCT00699868|Other|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
1815798|NCT00699868|Other|Sampling of blood, phenotypic analysis sub-populations NK by cytometric of stream in multiple markings|Sampling of blood
1815799|NCT00699881|Drug|cetuximab|cetuximab 400mg/m2 as initial dose, subsequently at 250mg/m2 weekly dose. CPT-11 180 mg/m2 CF 200 mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
1815800|NCT00699894|Drug|aprepitant 40 mg|aprepitant 40 mg PO 1-3 hours prior to surgery
1815801|NCT00699894|Drug|ondansetron 4 mg|ondansetron 4 mg IV 2-5 minutes prior to induction of anesthesia
1815803|NCT00699920|Drug|Coarsucam|Oral route, once daily, dose according to bodyweight range Duration of treatment: 3 days
1815804|NCT00699920|Drug|Coartem|Oral route, twice daily, dose according to bodyweight range Duration of treatment: 3 days
1815805|NCT00699933|Other|CT-guided percutaneous drainage technique|Evaluation of different diagnostics and evaluation of outcome of patients who received percutaneous CT-guided drainage for necrotic debridement and analyze the further outcome
1815806|NCT00699946|Drug|olanzapine|5 mg preoperative and 5mg postoperative prior to discharge to inpatient nursing floor
1815807|NCT00699946|Drug|placebo|placebo administered preoperatively and postoperatively prior to discharge to inpatient nursing floor
1815808|NCT00699972|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
1815809|NCT00699972|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
1815810|NCT00699972|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
1815811|NCT00699998|Drug|Clopidogrel|300 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and 75 mg, oral, once daily as maintenance dose through end of study
1815812|NCT00699998|Drug|Prasugrel|30 milligrams (mg), oral, once as loading dose (in those subjects who initiate study drug with a loading dose); and either 5 mg or 10 mg (based upon weight and age), oral, once daily as maintenance dose through end of study
1815813|NCT00699998|Drug|Commercially-available Aspirin|Low-dose aspirin, oral, as prescribed by physician through end of study
1815814|NCT00700011|Drug|Clofarabine|10 mg/m2 x 5 days per 4 to 6 week cycles
1815815|NCT00700011|Drug|Clofarabine|5 mg/m2 x 5 days per 4 to 6 week cycles
1815816|NCT00700024|Drug|Testim|50 mg/dose7day
1815817|NCT00700024|Behavioral|Strength training|three times a week
1815818|NCT00700024|Drug|placebo|placebo
1815819|NCT00700037|Drug|high-dose atorvastatin|20mg/day
1815820|NCT00700037|Drug|low-dose atorvastatin|5mg/day
1815821|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 1 (females with cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, she will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
1815822|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 2 (females without cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, she will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
1815823|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 3 (males with cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, he will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
1815824|NCT00700050|Drug|Hypertonic saline|The subjects in this arm will be those from Group 4 (males without cystic fibrosis). They will be asked to inhale up to 2 puffs of salbutamol via Metered Dose Inhaler. Briefly, after the subject has performed post-bronchodilator spirometry, he will inhale increasing concentrations of 3, 4 and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
1815825|NCT00700063|Drug|PEP005 Topical Gel|0.005%, two days treatment
1815826|NCT00700063|Drug|PEP005 Topical Gel|0.01%, two days treatment
1815827|NCT00700063|Drug|PEP005 Topical Gel|0.015%, two days treatment
1815828|NCT00700063|Drug|Vehicle gel|two days treatment
1815829|NCT00700063|Drug|PEP005 Topical Gel|0.005%, three days treatment
1815833|NCT00700076|Drug|Ketamine and Org 25935|Oral administration of Org 25935 16 mg and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
1815834|NCT00700076|Drug|Placebo and Ketamine|Oral administration of placebo and intravenous administration of ketamine (0.23 mg/kg bolus over 1 minute, followed by 0.58 mg/kg/hour x 30 minutes, followed by 0.29 mg/kg/hour x 69 minutes)
1815835|NCT00700089|Behavioral|Assertive intervention|8-20 assertive contacts after suicide attempt
1815836|NCT00700089|Other|Standard treatment|In standard treatment there is no procedure for ensuring that the patient will actually receive the recommended treatment. Patients are often referred to available treatment modalities such as general practitioner, psychological treatment, treatment for alcohol abuse, and most often, the patients are themselves responsible for getting into contact with the treatment to which they are referred.
1815837|NCT00700102|Drug|Chemotherapy|As prescribed
1815838|NCT00700102|Drug|Bevacizumab|Bevacizumab, 5 mg/kg intravenously (IV) on days 1 and 14 of each 4 week cycle, or 7.5 mg/kg IV on days 1 and 22 of each 6 week cycle.
1815839|NCT00700115|Drug|Kaletra + Isentress|Kaletra 400/100 mg + Isentress 400 mg BID
1815840|NCT00700115|Drug|Pre-study antiretroviral regimen|Standard doses of pre-study antiretroviral regimen
1815841|NCT00700128|Drug|frovatriptan|Frovatriptan 2.5 mg or placebo given Bid starting on the last day of OC before taking the 4 day HFI. They will take a total of 10 pills max per HFI.
1815842|NCT00700128|Drug|frovatriptan|frovatriptan 2.5 mg bid or placebo starting on the last day of OC and continuing during the 4 day HFI.
1815843|NCT00700128|Drug|placebo|placebo
1815844|NCT00700154|Procedure|Insulin infusion|The infusion, a fast acting insulin analog in 1 Unit/ml of NaCl, starts prior the surgery the operation day for all patients and stops during the postoperative care in the control group (conventional therapy), the intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
1815845|NCT00700167|Biological|dendritic cell vaccine|"The vaccine will be split between as many as 10 injections, more or less. Each shot will be about 1/25th to 1/50th of a teaspoon (100 to 200 microliters). Each vaccine will be injected with a tiny needle just under your skin. This will usually cause a very small area of swelling at the injection site that may last for a few minutes to an hour or so. You will receive two additional booster doses of the same vaccine every 4-6 weeks. This would mean that you receive a total of three vaccines over about 2-3 months."
1815846|NCT00700180|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
1815847|NCT00700180|Drug|bevacizumab [Avastin]|15mg/kg iv on day 1 of each 3 week cycle
1815848|NCT00700180|Drug|Carboplatin-based chemotherapy|As prescribed
1815849|NCT00700193|Biological|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.25mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
1815850|NCT00700193|Biological|Influenza Virus Vaccine|2 dose vaccine regimen: 2 X 0.50mL vaccinations 30 days apart and a booster vaccination was administered 12 months after the first dose
1815851|NCT00700206|Drug|Ezatiostat Hydrochloride|"Dose Schedule 1-3000 mg orally per day in two divided doses for two weeks followed by 1 week with no treatment per three week cycle.
Dose Schedule 2-2000 mg orally per day in two divided doses for three weeks followed by 1 week with no treatment per four week cycle."
1815852|NCT00700245|Behavioral|Exercise-only (EXO-12 weeks of regular supervised exercise without diet restriction)|The exercise intervention for subjects in the EXO consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session. The subjects could choose between different modes of exercise; stationary bicycling, jogging on a treadmill or stair stepping.
1815853|NCT00700245|Behavioral|Diet-only (DIO-8 weeks of very low energy diet (VLED 600 kcal/d) followed by 4 weeks weight maintenance diet|Subjects in the DIO group were prescribed a liquid VLED(Nupo, Copenhagen) of respectively 600 and 800 kcal pr. day (proteins 41 g, carbohydrates 29 g, fat 5.6 g. pr 100 gram) for eight weeks followed by a weight maintenance diet for four weeks.
1815854|NCT00700245|Behavioral|Diet+exercise (DEX-8 weeks VLED 800 kcal/d + a four weeks weight maintenance diet combined with regular supervised exercise throughout the 12 weeks).|The exercise intervention for subjects in the DEX group consisted of supervised aerobic exercise three times per week with a duration of 60 -75 minutes pr. training session, with an estimated energy expenditure of 500-600 kcal per session
1815860|NCT00700271|Drug|Amlodipine|5 mg or 10 mg tablets.
1815861|NCT00700271|Drug|Valsartan|160 mg capsules.
1815862|NCT00700284|Drug|placebo vaginal ring|vaginal ring containing no TMC120 (dapivirine)
1815863|NCT00700284|Drug|TMC120 (dapivirine) vaginal ring|vaginal ring containing 120 mg TMC120 (dapivirine)
1815864|NCT00700297|Drug|Colchicine|100 mg Colchicine per day for 4 months
1815865|NCT00700297|Drug|Placebo|One tablet placebo per day for 4 months
1815866|NCT00700310|Drug|perampanel|2 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
1815867|NCT00700310|Drug|perampanel|4 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
1815868|NCT00700310|Drug|perampanel|8 mg perampanel or placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily and will be up-titrated weekly in 2-mg increments to their randomized dose.
1816126|NCT00694382|Drug|Semuloparin sodium|"0.4 mL solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection"
1815869|NCT00700310|Drug|Placebo|Placebo in a 1:1:1:1 ratio, 170 subjects/arm, a total of 680 subjects. All subjects will take a maximum of 6 tablets daily.
1815870|NCT00700323|Dietary Supplement|PS-Omega3 conjugate supplementation|
1815871|NCT00700323|Dietary Supplement|placebo|
1958402|NCT01690988|Drug|Ketamine (0.5 mg/kg)|Low dose (sub-anesthetic) 0.5 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
1815874|NCT00700349|Other|Small loan|Applicants in the treatment group were offered an interest rate, loan size, and maturity per the lender's standard underwriting criteria, involving a 4-month maturity at 11.75% per month, charged on the original balance (200% annual percentage rate).
1815875|NCT00700362|Procedure|Insulin infusion (aspart)|The insulin infusion, a fast acting insulin analog (aspart) in 1 Unit/ml of NaCl, starts when the patients full fill the eligibility criteria and has signed the informed consent. The intervention group continues for three full days with insulin infusion. After the transition day (the fourth day) multiple doses of mixinsulin continues until the study ends 4 weeks after the randomization.
1815876|NCT00700362|Procedure|Standard care|Glucose control according to standard care at the ward, i.e., sliding scale insulin at the discretion of responsible physician.
1815877|NCT00700375|Drug|Sodium bicarbonate|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
1815878|NCT00700375|Drug|Sodium Chloride|8.4%sodium bicarbonate 0.5ml/kg bolus injection before procedure and hydration with 154mEq/l sodium bicarbonate 1ml/kg/Hr for 6 hours after the procedure
1815879|NCT00700388|Device|TPEP device (UNIKO)|This technique is mainly based on a continuous low-pressure insufflation in the airways, which is likely to reduce (or even avoid) the potential pressure-related damages of other commonly used devices. This device should be used only in those individuals who are showing a normal competence of their cough reflex, thus it should be considered as a means which may help those techniques normally adopted for the individual's bronchial hygiene.
1815880|NCT00700388|Procedure|MABT (Manually assisted breathing techniques)|Conventionally manually assisted breathing techniques
1815881|NCT00700401|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms/week sc for 24 weeks
1815882|NCT00700401|Drug|ribavirin [Copegus]|800mg po daily for 24 weeks
1815883|NCT00700427|Drug|atomoxetine hydrochloride|Oral 40-100 mg/day
1815884|NCT00700427|Drug|Placebo|Oral delivery of matching placebo
1815885|NCT00700440|Drug|C225 (cetuximab)|one week before and then weekly during radiotherapy
1958403|NCT01690988|Drug|Normal Saline (placebo)|Normal saline IV following induction of anesthesia or administration of sedative medications
1958404|NCT01690988|Drug|Ketamine (1 mg/kg)|Low dose (sub-anesthetic) 1 mg/kg ketamine following induction of anesthesia or administration of sedative medications.
1815890|NCT00700466|Drug|i.v. beta-blocker infusion (metoprolol)|A beta-blocker (metoprolol) will be infused for treatment of hypertension and/or tachycardia prior to induction of anesthesia aiming at decrease of blood pressure and heart rate to normal limits
1815891|NCT00700479|Drug|aldosterone|4 hour infusion
1815892|NCT00700479|Dietary Supplement|low or high sodium diet|
1815893|NCT00700479|Drug|placebo|placebo
1815894|NCT00700492|Drug|progesterone|vaginal capsules 3X200mg daily
1815895|NCT00700505|Device|FlowPants(R) Garment|"The garment is shaped like a pair of boxer briefs. Garment heating is battery-powered.
The garment is activated and begins to heat up 5-15 minutes prior to voiding."
1815896|NCT00700518|Drug|placebo cream|placebo cream applied to 2 adjacent fingers of non-dominant hand one time
1815897|NCT00700518|Drug|Glyceryl Trinitrate|0.6mg of Glyceryl Trinitrate applied to 2 adjacent fingers on non-dominant hand one time
1815898|NCT00700518|Drug|Glyceryl Trinitrate|1.2mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
1815899|NCT00700518|Drug|Glyceryl Trinitrate|1.8mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
1815900|NCT00700518|Drug|Glyceryl Trinitrate|2.4 mg Glyceryl Trinitrate topically to 2 adjacent fingers of non-dominant hand one time
1815901|NCT00700531|Device|FLC removal HD (Gambro HCO 1100)|FLC removal HD using a extended dialysis schedule on the Gambro HCO 1100
1815902|NCT00700531|Procedure|Standard dialysis on a high flux ployflux dialyser|Standard dialysis on a high flux ployflux dialyser at a frequency determined by the duty nephrologist
1815903|NCT00700544|Drug|chemotherapy treatment (see arm) + norethandrolone|"oral form
Dosage:
10 mg in patients with a weight < 60 kgs 20 mg in patients with a weight > 60 kgs frequency: every day Duration: 2 years"
1815904|NCT00700544|Drug|chemotherapy treatment (see arms)|Induction chemotherapy + maintenance chemotherapy
1815905|NCT00700557|Dietary Supplement|Probiotics - Lactobacillus casei and Bifidobacterium breve|Experimental group:This group received enteral tube feeding or oral diet plus a juice containing 1 sachet (1g) of probiotics (Lactobacillus casei and Bifidobacterium breve - 6x 108 UFC/g) three times a day.
1815906|NCT00700557|Dietary Supplement|Maize starch|Placebo group: This groups received enteral tube feeding or oral diet plus a juice containing,approximately, 725mg of placebo three times a day.
1815907|NCT00700570|Drug|bevacizumab [Avastin]|5mg/kg iv on day 1 of each 2 week cycle.
1815908|NCT00700570|Drug|capecitabine [Xeloda]|1000mg/m2 iv on days 1-5 and 8-12 of each 2 week cycle
1815909|NCT00700570|Drug|oxaliplatin|85mg/m2 iv on day 1 of each 2 week cycle
1815910|NCT00700583|Drug|combination therapy of terazosin and hydrochlorothiazide|25 mg of hydrochlorothiazide eight hours before bedtime and 4 mg of terazosin at bedtime for 4 weeks
1815911|NCT00700596|Drug|Salvinorin A|Low dose: Active SA 250μg Medium Dose: Active SA 500μg High Dose: Active SA 750μg
1815912|NCT00700596|Drug|Placebo|Control or Placebo SA (30 % ethanolic solution)
1815913|NCT00700609|Behavioral|Attachment Based Family therapy (ABFT)|Attachment-Based Family Therapy (ABFT) is a brief manualized therapy designed exclusively for depressed adolescents and aims at reducing adolescent depression by improving family communication and trust.
1815914|NCT00700622|Drug|Technosphere Insulin|Technosphere Insulin Inhalation Powder 15U or 30U
1815915|NCT00700622|Drug|Insulin glargine|Lantus-injectible supplied as 3mL (300 units) pens
1815916|NCT00700622|Drug|Insulin lispro|Humalog autopen cartridges pre-filled with 3mL (300 units)
1815920|NCT00700648|Drug|insulin aspart|Intravenous NovoRapid dose & frequency as decided by treating physician
1815921|NCT00700661|Drug|montelukast|One montelukast 4-mg chewable tablet (CT) administered once daily at bedtime. Duration of Treatment: 48 Weeks
1815922|NCT00700661|Drug|placebo (unspecified)|Matching-image Montelukast placebo. Duration of Treatment: 48 Weeks
1815923|NCT00700687|Drug|PA32540|aspirin/omeprazole
1815924|NCT00700687|Drug|PA32540 and celecoxib|aspirin/omeprazole and celecoxib
1815925|NCT00700687|Drug|aspirin and [NSAID]|aspirin and [NSAID]
1815926|NCT00700700|Device|Active Cardiac Resynchronization Therapy (CRT)|"Initiation of active biventricular pacing/cardiac resynchronization therapy
Devices by Medtronic:
Insync Sentry 7298 & 7299
Concerto C174 ASK (Most frequently implanted)
Insync III 8042 (PM)
Devices by Guidant/Boston Scientific:
Contak Renewal 4 H190 & H199
Contak Renewal 3 H127
Devices by ELA/Sorin:
1. Ovatio CRT 6750"
1815927|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
1815928|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
1815929|NCT00700713|Biological|Meningococcal polysaccharide diphtheria toxoid conjugate|0.5 mL, IM
1815930|NCT00700739|Device|DISCOVER™ Artificial Cervical Disc|DISCOVER™ Artificial Cervical Disc
1815931|NCT00700739|Device|ACDF|Cervical CFRP I/F CAGE® and SLIM LOC(R) Anterior Cervical Plate System with allograft
1815932|NCT00700752|Device|senofilcon A|silicone hydrogel contact lens
1815933|NCT00700752|Device|balafilcon A|silicone hydrogel contact lens
1815934|NCT00700765|Drug|insulin detemir|For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
1815935|NCT00700778|Biological|recombinant human chorionic gonadotropin|
1815936|NCT00700778|Genetic|microarray analysis|
1815937|NCT00700778|Other|immunohistochemistry staining method|
1815938|NCT00700778|Other|laboratory biomarker analysis|
1815939|NCT00700778|Procedure|needle biopsy|
1815940|NCT00700791|Dietary Supplement|Natural Vitamin E Tocotrienol supplement (TCT)|Oral Vitamin E Tocotrienol Supplement (TCT)
1815941|NCT00700791|Device|Natural Vitamin E Tocotrienol Cream (TCT)|Natural Vitamin E Tocotrienol(TCT)Topical Cream
1815942|NCT00700791|Other|Placebo|Oral Placebo
1815943|NCT00700791|Other|Placebo Cream|Topical Placebo Cream
1815944|NCT00700804|Behavioral|High Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
1815945|NCT00700804|Behavioral|Low Protein Diet|High and low protein diets with meat as a primary protein source, tested in a cross-over design for each arm
1815946|NCT00700817|Drug|liraglutide|1.2 mg once daily, subcutaneous (under the skin) injection
1815947|NCT00700817|Drug|sitagliptin|Tablets, 100 mg daily
1815948|NCT00700817|Drug|metformin|Tablets, minimum 1500 mg daily
1815949|NCT00700817|Drug|liraglutide|1.8 mg once daily, subcutaneous (under the skin) injection
1815950|NCT00700830|Drug|insulin detemir|Initial dosage and the following dosages will be prescribed by the physician as a result of a normal clinical evaluation
1815951|NCT00700856|Drug|add-on pioglitazone|participants randomised to this arm will add pioglitazone 15 mg/die to therapy with metformin (2 gr/die)
1815952|NCT00700856|Drug|add-on sulphonylurea|participants randomized to this arm will add a sulphonylurea (glibenclamide 5 mg/die; gliclazide 30 mg/die or glimepiride 2 mg/die)to monotherapy with metformin (2 gr/die)
1815953|NCT00700869|Procedure|mechanical ventilation|mechanical ventilation
1815954|NCT00700882|Drug|dasatinib|
1815955|NCT00700882|Other|laboratory biomarker analysis|
1815956|NCT00700895|Drug|Warfarin Sodium|All predicted warfarin dose will be administered by rounding down to the nearest 0.5 mg. Warfarin (Marevan®) is available as 1mg (brown), 3 mg (blue) and 5 mg (pink) oral tablets from GlaxoSmithKline Pte. Ltd.
1815957|NCT00700908|Behavioral|automated telephone intervention vs. usual care|
1815958|NCT00700921|Drug|Lovastatin|40mg po once daily
1815959|NCT00700921|Drug|Placebo|One capsule, once daily
1815961|NCT00700960|Drug|insulin detemir|initiation of an long acting insulin treatment in association with OAD at the discretion of the physician/diabetologist
1815962|NCT00700973|Behavioral|Interpersonal Violence Prevention Intervention|This is a cognitive-behavioral approach incorporating cognitive restructuring and behavioral change.
1815963|NCT00700973|Other|Usual care|Substance use disorder usual care
1815964|NCT00700986|Drug|AZD9056|Oral tablet, 800mg, one single administration
1815965|NCT00700986|Drug|Placebo|Single dose
1815966|NCT00700999|Drug|Paroxetine|Paroxetine 20-40mg po QD for 12 weeks
1815967|NCT00701012|Procedure|preservation of nerve fibers around IMA|low ligation
1815968|NCT00701012|Procedure|resection of nerve fibers around IMA|high ligation
1815969|NCT00701038|Device|auto adjusting bi-level positive airway pressure device|auto adjusting bi-level positive airway pressure device is provided for treatment of obstructive sleep apnea.
1815970|NCT00701051|Behavioral|Aerobic exercise training|24 weeks of aerobic exercise training: 3 times per week, 60 minutes per session, at 70% of maximal aerobic capacity
1815971|NCT00701051|Behavioral|Detraining (cessation of exercise)|Cessation of exercise for 2 weeks
1815972|NCT00701064|Other|Bright Light Exposure|Administered via bright light box
1815973|NCT00701064|Other|Negative Ion Generator|Administered via Negative Ion Generatore
1815974|NCT00701077|Drug|3,4-Di-amino-Pyridine|a single 20 mg dosing
1815975|NCT00701077|Drug|placebo|placebo
1815976|NCT00701090|Drug|sitagliptin|Sitagliptin 100 mg q.d. (q.d. = once daily); Duration of Treatment: 30 weeks
1815977|NCT00701090|Drug|Comparator: glimepiride|glimepiride 1 mg per day to be up-titrated (up to week 18 of the double-blind treatment period) as considered appropriate by the investigator, based upon the results of patient's self blood glucose monitoring (SBGM). The maximum dose of glimepiride must not be higher than 6 mg/day.
1815978|NCT00701090|Drug|open-label metformin|open-label metformin oral tablets (≥1500 mg/day) in addition to Glimepiride or Sitagliptin treatment.
1815979|NCT00701103|Drug|Dalotuzumab|IV infusion
1815980|NCT00701129|Biological|Alglucosidase Alfa|Administered as IV infusion.
1815981|NCT00701129|Drug|Methotrexate|Administered subcutaneously.
1815982|NCT00701129|Drug|Rituximab|Administered as IV infusion.
1815983|NCT00701142|Biological|Haemocomplettan® P|Single intravenous infusion
1815984|NCT00701142|Biological|Saline solution|Single intravenous infusion
1815985|NCT00701155|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the actual clinical evaluation
1815986|NCT00701168|Device|yttrium Y 90 microspheres (Therasphere®)|This is a local therapy for unresectable liver tumors with limited treatment options. It may be repeated under special circumstances.
1815987|NCT00701181|Procedure|Laser Treatment|Necessity of laser treatment is assessed every three months.
1815988|NCT00701181|Drug|PF-04523655 high|3 mg intravitreal injection
1815989|NCT00701181|Drug|PF-04523655 middle|1 mg intravitreal injection
1815990|NCT00701181|Drug|PF-04523655 low|0.4 mg intravitreal injection
1815991|NCT00701194|Behavioral|Early Intervention Foster Care (EIFC)|The EIFC/MTFC-P intervention is delivered through a treatment team approach. Foster parents receive preservice training and ongoing consultation from program staff. Children receive individual therapy and attend a therapeutic playgroup. The intervention emphasizes the use of concrete encouragement for prosocial behavior; consistent, nonabusive limit-setting to address disruptive behavior; and close supervision of the child. The EIFC intervention employs a developmental framework in which the challenges of foster preschoolers are viewed from the perspective of delayed maturation and is oriented toward creating optimal environmental conditions to facilitate developmental progress. These conditions include a responsive and consistent caregiver and a predictable daily routine.
1815992|NCT00701207|Drug|nicotine patch|daily transdermal patch 7 mg, 14mg, 21 mg. 3 months
1815994|NCT00701233|Drug|Botulinum toxin|45 units Botox injected into Carpal Tunnel once
1815995|NCT00701233|Drug|Corticosteroid injection into Carpal Tunnel|40 mg Triamcinolone with one mL 1% lidocaine injected once into Carpal Tunnel
1815996|NCT00701246|Drug|ferrous sulfate|
1815997|NCT00701246|Drug|folic acid|
1815998|NCT00701246|Drug|placebo (folic acid)|
1815999|NCT00701259|Drug|Lansoprazole|Lansoprazole 15 mg once per day for 14 days
1816000|NCT00701259|Drug|Lansoprazole|Lansoprazole 30 mg once per day for 14 days
1816001|NCT00701259|Drug|placebo|
1816002|NCT00701285|Drug|pitavastatin|pitavastatin 4mg once daily
1816003|NCT00701285|Drug|pravastatin|pravastatin 10mg once daily
1816004|NCT00701298|Biological|peginterferon alfa-2b|Given SC
1816005|NCT00701298|Drug|decitabine|Given IV
1816006|NCT00701298|Other|laboratory biomarker analysis|Correlative studies
1816007|NCT00701311|Drug|CC-10004|CC-10004 20 mg per day
1816008|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm B (3 weeks)
1816009|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm A (day 1)
1816010|NCT00701324|Drug|BI 811283|dose escalation BI 811283, Arm A (day 15)
1816011|NCT00701337|Drug|oestradiol|oestradiol 2 mg oral route 30 days
1816012|NCT00701337|Drug|oestradiol|oestradio transdermal patch 60ug by 24 hours 30 days
1816013|NCT00701363|Drug|Lanreotide Autogel 120 mg|120mg, injections every 6 weeks, then depending on IGF-1 results at Week 24
1816014|NCT00701376|Other|liver biopsy|Subjects undergoing laparoscopic gastric surgery will be evaluated for liver function by comparing liver tissue biopsied during surgery with tissue biopsied after 60% weight loss
1816015|NCT00701389|Drug|telcagepant potassium|Single oral dose of 2 x 300 mg capsules.
1816016|NCT00701389|Drug|sumatriptan|single oral dose of 100 mg sumatriptan
1816017|NCT00701389|Drug|sumatriptan placebo|single oral dose
1816018|NCT00701389|Drug|telcagepant potassium placebo|single oral dose of 2 MK-0974 placebo capsules
1816019|NCT00701415|Biological|Agalsidase beta|Powder for concentrate for solution for infusion 1.0 mg/kg/4 weeks
1816020|NCT00701415|Biological|Agalsidase beta|Powder for concentrate for solution for infusion 0.5 mg/kg/2 weeks
1816021|NCT00701428|Drug|Losartan|Losartan 50 mg daily during 6 + 6 weeks
1816022|NCT00701428|Other|CPAP|CPAP during the second 6 week-period
1816023|NCT00701454|Other|No intervention|No intervention
1993941|NCT03101579|Drug|Pemetrexed|Pemetrexed,10-15 mg, intrathecal injection via lumbar puncture, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
1993942|NCT03101579|Drug|Dexamethasone|Dexamethasone, 5 mg, intrathecal injection via lumbar puncture, simultaneously with pemetrexed, twice per week for 2 weeks, followed by once per week for 2-4 weeks.
1816026|NCT00701493|Drug|Topiramate oral liquid formulation;Topiramate Sprinkle formulation|
1857786|NCT01005758|Drug|mercaptopurine|
1993943|NCT03101579|Drug|Folic Acid|Folic acid, 400 μg, oral, once per day, prior to the first intrathecal pemetrexed, until 21 days after the last intrathecal pemetrexed.
1816027|NCT00701506|Device|Patterned Electrical Neuromuscular Stimulation|"20-minute session, to each affected knee, 3 times per week for 12 weeks.
PENS for 20 minutes:
Tri-phasic Lower Extremity stimulation pattern based on activation timing of the quadriceps and hamstrings for strength training (50 Hz impulses for 200 ms every 1500 ms).
Minimal twitch for 5 minutes.
Moderate to strong, but well-tolerated twitch contractions for 15 minutes.
Electrodes placed on quadriceps and hamstrings"
1816028|NCT00701506|Device|Placebo PENS|"20-minute session, to each affected knee, 3 times per week for 12 weeks.
Placebo PENS for 20 minutes:
Electrodes placed on quadriceps and hamstrings."
1816029|NCT00701532|Drug|Modafinil and PET (brain imaging)|duration 90 days
1816030|NCT00701532|Drug|placebo|duration 90 days
1816031|NCT00701558|Drug|Erlotinib|150 mg po daily
1816032|NCT00701558|Drug|Gemcitabine|1000 mg/m^2 iv on days 1, 8, 15 of each 4 week cycle for 6 cycles
1816033|NCT00701571|Procedure|Virtual Reality distraction|"Virtual Reality involves the participant wearing a helmet with sight and sound. the visual provided is a type of immersive video game, the game used is Snow World. In some cases the participant will be exposed to 3D representation of the game, and in other cases a lower tech version with less immersive qualities."
1816034|NCT00701597|Drug|bosentan|Bosentan (Tracleer 125mg Tabletts), peroral, dose: 500mg for 8 days
1816035|NCT00701623|Drug|heparin|patients will receive the application of one of two types of heparin directly on the injured area
1816036|NCT00701623|Drug|heparin|patients will receive the application of one of two types of heparin directly on the injured area
1816037|NCT00701623|Drug|folder water|patients will receive the application of folder water directly on the injured area
1816038|NCT00701636|Drug|daptomycin|Subjects enrolled in the intervention group will receive a single intravenous administration of daptomycin 8 mg/kg 30-60 minutes prior to surgery (incision). The 500 mg vial will be reconstituted with 10 mL of 0.9% normal saline (NS) and further diluted in 50 mL of 0.9% NS to be given over a 30 minute infusion.
1816039|NCT00701649|Biological|CYT006-AngQb|s.c.
1816040|NCT00701649|Biological|Placebo|s.c.
1816041|NCT00701662|Biological|Vivaglobin|
1816042|NCT00701675|Drug|sertraline 50 mg daily|50 mg daily
1816043|NCT00701675|Drug|sertraline 100 mg daily|100 mg daily
1816044|NCT00701675|Drug|Placebo 50 or 100 mg|50mg or 100mg matching placebo
1816045|NCT00701688|Drug|Palifermin|Dose level 1 40 mcg/kg/day intravenous Dose level 2 60 mcg/kg/day intravenous Dose level 3 90 mcg/kg/day intravenous
1816046|NCT00701701|Biological|Myozyme (alglucosidase alfa)|Myozyme: Intravenous (IV) infusion of 20 mg/kg every other week (qow); Cyclophosphamide: 250 mg/m2 IV every 4 wks after Myozyme infusion for 6 months
1816047|NCT00701701|Biological|Myozyme (alglucosidase alfa)|Myozyme: IV infusion of 20 mg/kg qow; Rituximab: 375 mg/m2 IV weekly beginning the day after MZ infusion for 4 weeks (an optional additional 2nd cycle may be administered at the discretion of the investigator); Methotrexate: 15mg/m2 subcutaneous every other week on the day after Myozyme infusion for 6 months
1993944|NCT03101579|Drug|Vitamin B12|A single dose of vitamin B12 1000 μg, intramuscular injection, before the first intrathecal pemetrexed.
1816050|NCT00701727|Drug|ezetimibe|1 tablet,10mg, once a day, for 7 weeks
1816051|NCT00701727|Drug|Placebo|1 tablet, once a day, for 7 weeks
1816052|NCT00701740|Drug|oral isotretinoin and Mexoryl SX / XL|20mg, 3/week,continuously for three months
1816053|NCT00701740|Drug|Mexoryl XL / SX|11 subjects used only the same moisturizer and SPF 60 sunscreen
1816054|NCT00701766|Drug|BI 2536|
1816055|NCT00701779|Drug|Tamsulosin|Dutasteride 0.5mg once daily for one year and tamsulosin 0.4mg administered once daily for 3 months, followed by counseling on flexible dosing of tamsulosin on an as needed basis.
1816056|NCT00701792|Procedure|liver transplantation|liver transplantation
1816057|NCT00701792|Other|standard care for liver disease|"standard care for liver disease included therapy for ascitis (spironolactone, furosemide), portal hypertension (oesophageal varices ; propranolol), encephalopathy (lactulose), and bacterial infections whatever their localization (prophylaxis of spontaneous peritonitis with norfloxacin). All medical or instrumental procedures were allowed. Patients undergoing iterative paracentesis, variceal band ligation or sclerotherapy, peritoneojugular shunt (LeVeen), transjugular intrahepatic portosystemic shunt (TIPS) or surgical portocaval anastomosis were considered as receiving standard medical therapy."
1816058|NCT00701805|Drug|Paricalcitol|Intravenous (IV) paricalcitol, 3 times weekly, immediately before completion of hemodialysis.
1816059|NCT00701831|Drug|Insulin glargine|The dose is titrated according to patient needs
1816060|NCT00701844|Behavioral|Writing A (Experimental informative writing)|Experimental informative writing
1816061|NCT00701844|Behavioral|Writing B (Experimental noninformative writing)|Experimental noninformative writing
1816062|NCT00701844|Behavioral|Writing C (Control informative writing)|Control informative writing
1816063|NCT00701844|Behavioral|Writing D (Control noninformative writing)|Control noninformative writing
1816064|NCT00701857|Drug|cisplatin|Standard weekly dose
1816065|NCT00701857|Drug|Pemetrexed|Biweekly pemetrexed dose escalation
1816066|NCT00701857|Radiation|radiation therapy|Weekly standard dose radiation therapy
1816067|NCT00701870|Drug|ezatiostat hydrochloride (Telintra®)|4500 mg orally per day in two divided doses
1816068|NCT00701883|Drug|Placebo|2 capsules, once a day for 8 weeks
1816069|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
1816070|NCT00701883|Drug|MBX-8025|2 capsule, once daily for 8 weeks
1816071|NCT00701883|Drug|Atorvastatin|2 capsules, once daily for 8 weeks
1816072|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
1816073|NCT00701883|Drug|MBX-8025|2 capsules, once daily for 8 weeks
1816074|NCT00701896|Drug|Varenicline tartrate|1 mMg tablet form; daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12.
1816075|NCT00701896|Drug|Nicotine Replacement Therapy|Nicotine gum and nicotine patch
1816076|NCT00701896|Other|Biological Control|No treatment intervention only information and procedures.
1816077|NCT00701896|Behavioral|Motivational Interview|60 minute one-on-one Interview
1816164|NCT00694707|Drug|RGH-188|RGH-188 medium dose once daily for six weeks
1816262|NCT00695409|Drug|cytarabine|Given IV
1816078|NCT00701909|Drug|morphine plus saline|During the first wound care procedure, some patients will receive morphine 0.1 mg/kg (maximum dose of 8 mg) plus saline (MS), according to randomization, while other patients will receive morphine 0.05 mg/kg (maximum dose of 4 mg) plus ketamine 0.25 mg/kg
1816079|NCT00701909|Drug|morphine plus ketamine|Patients who received morphine 0.1 mg/kg (maximum dose of 8 mg)plus saline during the first wound care procedure will now receive ketamine 0.25 mg/kg IV plus morphine 0.05 mg/kg
1816080|NCT00701935|Drug|placebo|subcutaneous injection, twice a day
1816081|NCT00701935|Drug|exenatide|subcutaneous injection, twice a day, 10mcg
1816082|NCT00701961|Drug|Mefloquine-artesunate|Mefloquine-artesunate fixed dose combination comprised of 100 mg of artesunate and 220mg of mefloquine per tablet, developed by DNDi and manufactured by farmanguinhos (Brazil).
1816083|NCT00701974|Biological|collagenase (IRUXOL)|patients will be treated with collagenase one time per day.
1816084|NCT00701974|Biological|collagenase (Kollagenase)|patients will be treated with collagenase one time per day.
1816085|NCT00701987|Drug|ALS-357|Topical application of ALS-357
1816086|NCT00702026|Dietary Supplement|multispecies probiotic (Ecologic 801)|once daily, 5 gram [10e9 cfu/gram]
1816087|NCT00702026|Dietary Supplement|Placebo|once daily, 5 gram [10e9 cfu/gram]
1816090|NCT00702052|Drug|RAD001|
1816091|NCT00702078|Behavioral|closer collaboration between hospital and primary healthcare system|Follow-up from the hospital and the primary healthcare in cooperation
1816092|NCT00702078|Behavioral|usual care|follow-up according to todays best practice
1816093|NCT00702091|Drug|Ramipril|10 mg capsule
1816094|NCT00702104|Other|survey administration|
1816095|NCT00702117|Drug|flecainide|2 mg/kg iv in 10 minutes
1816096|NCT00702117|Drug|ajmaline|1 mg/kg iv in 10 minutes
1816097|NCT00702117|Drug|procainamide|10 mg/kg iv in 10 minutes
1816098|NCT00702130|Drug|Pravastatin|pravastatin 40mg per os once daily
1816099|NCT00702143|Drug|florbetapir F 18|IV injection, 370MBq (10mCi), single dose
1816100|NCT00702156|Drug|Bisoprolol|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
1816101|NCT00702156|Drug|Placebo|Titration. 1.25 mg 2 weeks, 2.5 mg 2 weeks, 5 mg 4 weeks, 7.5 mg 4 weeks, 10 mg 4 weeks.
1816102|NCT00702182|Drug|Vinorelbine (Navelbine)|Conventional Schedule Oral Vinorelbine on day 1 and day 8 of a 21 day schedule
1816103|NCT00702182|Drug|Vinorelbine (Navelbine)|Metronomic Schedule Oral Vinorelbine 3 times a week
1816104|NCT00702182|Drug|Erlotinib|Daily Oral Erlotinib 100 mg
1816105|NCT00702195|Drug|Org 36286 (corifollitropin alfa)|single dose of Org 36286 (corifollitropin alfa) administered under protocol 38805/38807
1816106|NCT00702195|Drug|Placebo|single dose of placebo (administered under protocol 38805)
1816107|NCT00702195|Drug|recFSH|150 IU recFSH daily (reference group administered under protocol 38807)
1816108|NCT00702208|Device|Delphi Screener|Self-sampling device for cervical vaginal lavage
1816109|NCT00702221|Biological|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant|Angiotensin Therapeutic Vaccine plus CoVaccine HT™ adjuvant given as 3 separate intramuscular injections into the arm, 21 days apart
1816110|NCT00702221|Biological|CoVaccine HT™ adjuvant|Given as three separate intramuscular injections into the arm, 21 days apart
1816111|NCT00702234|Biological|Corifollitropin alfa|Subcutaneous (SC) administration of corifollitropin alfa at a dose of 150 μg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
1816112|NCT00702234|Biological|GnRH antagonist|SC administration of a GnRH antagonist at a dose of 0.25 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
1816113|NCT00702234|Biological|(rec)hCG|SC administration of (rec)hCG at a dose of 5,000-10,000 IU/250 µg in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
1816114|NCT00702234|Biological|FSH|SC administration of FSH at a dose not to exceed 225 IU/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
1816115|NCT00702234|Drug|Progesterone|Vaginal administration of progesterone at a dose of at least 600 mg/day in base study P05714 (NCT00696878). In this follow-up study P05715, no study medications were administered.
1816116|NCT00702247|Procedure|Hematopoietic Stem Cell Transplantation|
1816117|NCT00702260|Drug|Ramipril|10 mg capsule
1816118|NCT00702273|Drug|150 µg Corifollitropin Alfa|On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
1816119|NCT00702273|Biological|200 IU RecFSH/Follitropin beta (Days 1 to 7)|Daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
1816120|NCT00702273|Drug|Placebo for Corifollitropin Alfa|Pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa. On the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection was administered in the abdominal wall.
1816121|NCT00702273|Drug|Placebo for RecFSH/Follitropin beta|Identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen. Daily SC injections were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
1816122|NCT00702273|Biological|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|From Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
1816123|NCT00702273|Drug|Ganirelix|On Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG
1816124|NCT00702273|Biological|hCG|When 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
1816125|NCT00702273|Biological|Progesterone|On the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
1816127|NCT00694382|Drug|Placebo (for semuloparin)|"0.4 mL solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component
Subcutaneous injection"
1816128|NCT00694408|Drug|methyl prednisolone, hydrocortisone, prednisolone|Will be specific dependant on weight of patients
1816129|NCT00694408|Other|No steroids|Children undergoing primary liver transplant will receive monoclonal antibodies and tacrolimus as per protocol
1816130|NCT00694447|Procedure|Acupuncture|
1816131|NCT00694460|Biological|Three 1 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 1.0 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
1816132|NCT00694460|Biological|Three 0.5 mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.5 mL intramuscularly on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
1816133|NCT00694460|Biological|Three 0.1mL doses of Rabies Vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0, Day 7 and Day 28 (a total of 3 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
1816134|NCT00694460|Biological|Two 0.1mL doses of Rabies vaccine and two JE vaccine|Vaccination with purified chick embryo cell rabies vaccine 0.1 mL intradermally at one site on Day 0 and Day 28 (a total of 2 doses) and Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL subcutaneously on Day 0 and Day 7 (a total of 2 doses)
1816135|NCT00694460|Biological|Two doses of JE vaccine|Vaccination with Beijing 1 strain of inactivated, lyophilized Japanese Encephalitis vaccine 0.25 mL only subcutaneously on Day 0 and Day 7 (a total of 2 doses)
1816136|NCT00694473|Device|Freestyle Navigator|Continuous glucose monitoring with the Freestyle Navigator for 72 hours or until discharge from the ICU
1816137|NCT00694512|Dietary Supplement|Low fat diet|20% fat diet
1816138|NCT00694512|Dietary Supplement|High fat diet|40% fat diet
1816139|NCT00694512|Dietary Supplement|MCT diet|Medium chain triglyceride diet
1816140|NCT00694538|Device|Interferential Laser therapy|Two GaAlAs laser (810 nm, 100mW)were used. In the interferential laser treatment, two probes were simultaneously applied. In the conventional laser group, only one probe was switched on. Laser was applied at five points over the pain area. The laser emission mode was continuous with an energy dose of 6 joules per point and session, a power density of 1.09 w/cm2 and an irradiation time per point of 60 s. The average output power was 100 mW and the total energy dose delivered in a patient session was 30 J. Every treatment was along 15 sessions. Hence, the accumulated energy delivered on the whole was 450 Joules for the conventional group of patients (using one beam) and 900 Joules for the interferential one (using two beams).
1816143|NCT00694564|Drug|S-adenosyl methionine|S-adenosyl methionine will be dosed as 200 mg tablets with doses ranging from 200 to 1400 mg daily.
1816147|NCT00694590|Drug|plerixafor|"Drug Course 1: plerixafor (20mg/mL). Dose escalation starting with 80 mcg/kg then 160, 240, 320, 420, and 540 mcg/kg, or to de-escalate to 40mcg/kg. Dosing 3 times/week for 3 weeks beginning at start of second week. Rituximab is also administered 3 times per week for 4 weeks using a fixed dose of 100 mg on Day 1 and a dose of 375 mg/m2 for all subsequent doses.
Drug Course 2: plerixafor (20 mg/m) same dose as course 1. Dosing 3 times/week for 4 weeks. Rituximab is also administered 3 times per week for 4 weeks using a dose of 375 mg/m2 for all doses."
1816148|NCT00694603|Drug|Cetuximab|Given intravenously once per week.
1816149|NCT00694616|Device|AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
1816150|NCT00694616|Device|Modified-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
1816151|NCT00694629|Drug|rifampin|tablet, 10 mg/kg, daily, 8 weeks
1816152|NCT00694629|Drug|rifapentine|tablet, 10 mg/kg, daily, 8 weeks
1816153|NCT00694629|Drug|rifapentine|tablet, 15 mg/kg, daily, 8 weeks
1816154|NCT00694629|Drug|rifapentine|20 mg/kg, daily, 8 weeks
1816155|NCT00694642|Biological|Selected CD 133+ cells|Endothelial progenitor cell CD 133
1816156|NCT00694655|Biological|Yellow fever vaccine|YFV will be given as injection
1816157|NCT00694668|Behavioral|Cognitive Behavioral treatment|Brief cognitive behavioral therapy (12 sessions)
1816158|NCT00694668|Behavioral|Mindfulness based cognitive therapy|9 sessions MBCT in a group-format (up to 8 persons)
1816159|NCT00694681|Behavioral|Telephonic care management|Individuals received intensive outreach from care managers, first to help them to enter treatment and then, if treatment began, to remain in it for an appropriate time. Treatment is based on the American Psychiatric Association's Evidence-Based Practice Guidelines for Major Depression, which includes psychotherapy and antidepressant medications. Outreach and care management took place by telephone.
1816160|NCT00694694|Drug|azithromycin + artesunate|Azithromycin 20mg/kg per day for three days (total 60 mg/kg) Artesunate 4mg/kg per day for 3 days
1816161|NCT00694694|Drug|artemether-lumefantrine|"Tablets are fixed-dose combinations and contain 20mg artemether and 120mg lumefantrine.
For children 5-14.9kg 1 tab 2x a day for 3 days For children 15-24.9kg 2 tablets 2x a day for 3 days For children 25-35kg 3 tablets 2x a day for 3 days"
1816162|NCT00694707|Drug|Placebo|Placebo oral administration once daily for 6 weeks
1816163|NCT00694707|Drug|RGH-188|RGH-188 low dose once daily for 6 weeks
1816165|NCT00694707|Drug|RGH-188|RGH-188 high dose oral administration once daily for six weeks
1816166|NCT00694707|Drug|Risperidone|Risperidone oral administration once daily for six weeks
1816167|NCT00694720|Drug|AVE0657|capsules once a day at bedtime
1816168|NCT00694720|Drug|placebo|capsules once a day at bedtime
1816169|NCT00694733|Drug|Placebo injection|Normal saline injection IM monthly for 4 months
1816170|NCT00694733|Drug|Depo Lupron/Aromatase inhibitor|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and aromatase inhibitor months 4-8.
1816171|NCT00694733|Drug|Depo Lupron/placebo|Depo Lupron injection 7.5mg IM monthly for 8 months, with addition of testosterone gel and placebo months 4-8.
1816172|NCT00694733|Drug|placebo|Placebo Cream 1ml applied twice daily for four months
1816173|NCT00694733|Drug|Estrogen cream|Estrogen cream 1 ml twice daily, dose titrated to maintain estradiol level between 60 and 280 pg/ml.
1816174|NCT00694746|Drug|Omega-3-acid ethyl esters|Participants will receive 2 capsules of 1 gram of fish oil with meals twice a day for a period of six months (including a ramp up period of three weeks)
1816175|NCT00694746|Drug|Placebo|Participants will receive 2 capsules of 1 gram of placebo with meals twice a day for a period of six months (including a ramp up period of three weeks)
1816176|NCT00694759|Drug|pioglitazone|30 mg for 2 weeks, then 45 mg daily
1816177|NCT00694759|Drug|metformin|500mg twice daily for 1 week, then 1000 mg twice daily
1816178|NCT00694759|Drug|placebo|capsule twice daily
1816179|NCT00694772|Procedure|Electrocautery-tonsillectomy|standard of care electrocautery tonsillectomy
1816180|NCT00694772|Procedure|Coblation-tonsillotomy|use of Arthrocare Coblation Technology to perform tonsillotomy
1816181|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.7 mg/kg given over the remaining 72 hours at a rate of 0.0004 mg/kg/min.
Group NT3"
1816182|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.14 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 1.3 mg/kg given over the next 72 hours.
Group T3"
1816183|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.8 mg/kg given over the remaining 72 hours at a rate of 0.0009 mg/kg/min.
Group NT6"
1816184|NCT00694785|Drug|ARC1779|"Initial stepwise infusion of 0.28 mg/kg given over 60 minutes and subsequent continuous infusion of an additional 3.0 mg/kg given over the remaining 72 hours.
Group T6"
1816185|NCT00694798|Biological|Mycobacterium w|Immunomodulator
1816186|NCT00694811|Behavioral|Re-feeding duration|1 or 6 weeks of re-feeding after VLED-induced weight loss
1816187|NCT00694837|Drug|nelfinavir|The start dose of nelfinavir in phase 1 is 1000mg BID. The maximum administered dose, if no DLT occurs, will be1250 mg BID (2500mg). Nelfinavir will be administered 1 week before start of the chemoradiotherapy until the last day of chemoradiotherapy.
1816188|NCT00694850|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521 will be up-titrated from 1,0 mg TID to 2,5 mg TID
1816189|NCT00694863|Drug|tetracosactide hexacetaat|Intramuscular injections with tetracosactide hexacetaat (Synacthen Depot) 1ml a 1mg/ml. Treatment for 9 months with an increasing dosage from once per 2 weeks to twice a week.
1816190|NCT00694889|Behavioral|Neuroadaptive cognitive training|Neuroadaptive cognitive training includes cognitive remediation exercises that participants will practice 1 hour per day, 5 days per week, for 8 weeks. The exercises are specifically designed to improve speed and accuracy in the perception of and response to verbal targets. The treatment will focus on TCT.
1816191|NCT00694889|Behavioral|Computer games|The control treatment involves commercially available computer games that participants will practice 1 hour per day, 5 days per week, for 16 weeks.
1816192|NCT00694902|Drug|GSK610677|GSK610677 Multi-Dose Powder Inhaler will be available in the strength of 10, 50, 100 and 25 microgram with dose levels of 10, 30, 50, 100, 250, 500 and 1000 microgram. Subjects will receive GSK610677 as single inhale dose.
1816193|NCT00694902|Drug|Placebo|Matching Placebo for GSK610677 will be available as Multi-Dose Powder Inhaler. Subjects will receive Placebo as single inhale dose.
1816194|NCT00694915|Biological|Mycobacterium w|Immunomodulator
1816195|NCT00694915|Biological|BCG (Bacillus Calmette-Guerin)|Immunotherapeutic agent
1816196|NCT00694928|Drug|clindamycin phosphate/butoconazole nitrate|semi-solid, single dose
1816197|NCT00694928|Drug|butoconazole nitrate|semi-solid, single dose
1816198|NCT00694941|Drug|ONO-2506PO|1200mg QD / 5 years
1816199|NCT00694954|Device|Diagnostic Test - Given Imaging Pillcam|"Procedure performed once only after randomization. If procedure is incomplete due to a number of variables, procedure may possibly need to be repeated.
Diagnostic possibilities: normal exam, active bleeding, potential source of bleeding (angiodysplasia, ulcer, tumor)"
1816200|NCT00694954|Other|Diagnostics|Any other diagnostic tests (if not already performed) that the referring or attending physician deems necessary aside from Wireless Capsule Endoscopy.
1816201|NCT00694967|Procedure|McDonald cerclage placement|Transcervical McDonald cerclage placement
1816202|NCT00694967|Drug|17 hydroxyprogesterone caproate|Weekly 250mg intramuscular injections
1816203|NCT00694980|Drug|placebo|Intravenous and subcutaneous escalating doses
1816204|NCT00694980|Drug|rhuMAb Beta7|Intravenous and subcutaneous escalating doses
1816205|NCT00694993|Drug|GSK1004723|GSK1004723 will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
1816206|NCT00694993|Drug|Placebo|Placebo will be supplied as intranasal sprays aqueous suspensions for intranasal spray administration.
1816207|NCT00695006|Other|Sham Traction|Traction <5lbs
1816208|NCT00695006|Other|Traction|Standard supine intermittent traction
1816209|NCT00695019|Drug|interferon-alpha lozenges|500 IU lozenges of natural human interferon-alpha for oral dissolution given once or three times per day for 24 weeks
1816210|NCT00695019|Drug|placebo lozenges|200 mg matching placebo lozenges
1816211|NCT00695032|Drug|cisplatin|
1816212|NCT00695032|Drug|ifosfamide|
1816213|NCT00695032|Other|laboratory biomarker analysis|
1816214|NCT00695045|Drug|intra thecal morphine|100 mcg intrathecal morphine given once .
1816215|NCT00695045|Drug|intra thecal morphine|200 mcg intrathecal morphine given once
1816216|NCT00695045|Drug|intra thecal morphine|300 mcg intrathecal morphine given once
1816217|NCT00695058|Device|Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)|"A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the perineum in women and the perineum or the frenulum in men.
In the women the stimulation will be performed with a vibration amplitude of 2 mm and a frequency of 100 Hz. In the men the vibration parameter/location will be determined by the results of the new pressure profile studies (aim 3).
A daily stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used through 6 weeks in both the women with stress incontinence and overactive bladder syndrome.
In the 3 groups of patients the subjects will be randomized to either active treatment or placebo treatment. The placebo treatment will be done with a vibration device with an amplitude of 0 mm. Subjects will be randomized by a draw."
1816218|NCT00695071|Drug|Itraconazole|Oral
1816219|NCT00695084|Behavioral|Constraint-Induced Movement Therapy|Intensive practice with the hemiparetic arm for 30 contact hours
1816220|NCT00695097|Drug|Rituximab|Rituximab infusion on Day 1 and Day 15
1816221|NCT00695097|Drug|No Rituximab|No Rituximab
1816222|NCT00695110|Drug|Testosterone undecanoate (TU)|300 mg T equivalents BID for 7 days
1816223|NCT00695110|Drug|TU + testosterone enanthate (TE)|400 mg T equivalents BID for 7 days
1816224|NCT00695110|Drug|Testosterone undecanoate (TU)|200 mg T equivalents BID for 8 days; pharmacokinetics determined when oral TU administered with and without food.
1816225|NCT00695110|Drug|TU + testosterone enanthate (TE)|300 mg T equivalents BID for 7 days
1816226|NCT00695136|Drug|Donepezil hydrochloride|
1816227|NCT00695136|Behavioral|Increase REM sleep percentage|
1816228|NCT00695149|Procedure|Transplantation of bone marrow stromal cell|
1816229|NCT00695162|Other|quiet|no noise
1816230|NCT00695162|Other|non-speech noise|noise without speech
1816231|NCT00695162|Other|speech noise|noise with speech present
1816232|NCT00695188|Drug|methotrexate|oral administration Escalating dose (15, 20, 25 mg)
1816233|NCT00695188|Drug|methotrexate|25 mg oral administration
1816234|NCT00695201|Drug|Floxuridine, Oxaliplatin, CPT-11|For patients on the 4-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin (which is used to prevent blood from clotting) and saline. Whether the pump contains drug or heparin and saline, it will need to be emptied and refilled about every two weeks. We will inject either the drugs or the saline and heparin into the pump through the skin using a needle and syringe. In summary, 2 weeks of drug in the pump is followed by 2 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day as the pump is filled and emptied, ie. Day 1 and Day 15 of each cycle.
1816235|NCT00695201|Drug|Floxuridine, Oxaliplatin, CPT-11|For patients on the 5-week cycle: On the first day of each cycle, the pump will be filled with FUDR and dexamethasone. The pump will be emptied of drugs after 2 weeks (on day 15 of each cycle) and filled with heparin and saline. This is repeated on day 29 of each cycle). In summary, 2 weeks of drug in the pump are followed by 3 weeks without drug in the pump. The systemic chemotherapy (Oxaliplatin/CPT-11) will be administered on the same day that the pump is emptied and filled with heparin and saline, i.e. Day 15 and Day 29 of each cycle.
1816236|NCT00695214|Drug|Propofol sedation|Patients receive an intravenous propofol infusion titrated to reach a target level of sedation, sleep with arousability to verbal stimuli.
1816237|NCT00695227|Drug|Proton Pump Inhibitor|Screened patients with extraesophageal reflux symptoms will be followed prospectively in order to gauge response to acid suppressing medication treatment. Non-responders will be tested with pharyngeal pH monitoring.
1816238|NCT00695240|Device|Continuous bupivacaine analgesia infusion (ON-Q PainBuster Post-Op Pain Relief System)|Patients assigned to the study group had an ON-Q PainBuster Post-Op Pain Relief System (270 ml x 4 ml/hr, dual catheter, 2 ml per site, 72 hours continuous) with dual five inch fenestrated catheters placed at the sacrospinous ligament. One half percent bupivacaine was utilized.
1816240|NCT00695279|Procedure|Venipuncture|Blood draw
1816241|NCT00695292|Drug|irinotecan|irinotecan 60 mg/m2 intravenously (IV) on Days 1, 8, and 15
1816242|NCT00695292|Drug|Carboplatin|carboplatin AUC=4 on Day 1
1816243|NCT00695292|Drug|sunitinib|sunitinib 25 mg orally (PO) daily after initial chemotherapy
1816247|NCT00695318|Drug|Fluocinolone Acetonide|0.2 µg/Day in study eye + Sham in fellow eye
1816248|NCT00695318|Drug|Fluocinolone Acetonide|0.5 µg/Day in study eye +Sham in fellow eye
1816249|NCT00695331|Drug|Misoprostol|Titrated Misoprostol Solution
1816250|NCT00695331|Drug|Oxytocin|Titrated Intravenous Oxytocin
1816251|NCT00695344|Drug|everolimus|Everolimus 2 times per day, v.o., 2 years treatment.
1816252|NCT00695344|Drug|azathioprine or mycophenolate mofetil|2 times per day during 2 years
1816253|NCT00695370|Drug|Pegfilgrastim (drug)|
1816254|NCT00695383|Behavioral|Bedside cycle exercise therapy|A 20-minute cycling exercise session is performed 5 days a week using a bedside cycle ergometer. Patients can cycle passively and actively against increasing resistance. Besides this, patients receive the standard physiotherapy program as in arm 2
1816255|NCT00695383|Behavioral|Standard physiotherapy program|The standard physiotherapy program consists of daily chest physiotherapy and a mobilization session on 5 days per week.
1816256|NCT00695396|Drug|Placebo|Matching volume 2 mLfor 48 weeks
1816257|NCT00695396|Drug|Epoetin alfa|40,000 IU subcutaneously once every week (1 mL dose) for 48 weeks
1816258|NCT00695396|Drug|Placebo|Matching volume 1 mL for 48 weeks
1816259|NCT00695396|Drug|Epoetin alfa|80,000 IU subcutaneously once every week (2 mL dose) for 48 weeks
1816260|NCT00695409|Biological|rituximab|Given IV
1816261|NCT00695409|Drug|carmustine|Given IV
1816265|NCT00695409|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
1816266|NCT00695409|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
1816267|NCT00695409|Radiation|yttrium Y 90 ibritumomab tiuxetan|Given IV
1816268|NCT00695422|Genetic|polymerase chain reaction|PCR for HPV DNA detection, performed on specimens collected at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
1816269|NCT00695422|Other|cytology specimen collection procedure|Detection of HPV-associated neoplasia at baseline, every 6 months while on parent protocol, treatment discontinuation on parent protocol, final visit on parent protocol.
1816270|NCT00695422|Other|histological technique|Detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
1816271|NCT00695422|Procedure|colposcopic biopsy|Where observed during HRA, collection of tissue for detection of HPV-associated neoplasia at baseline, treatment discontinuation on parent protocol, final visit on parent protocol.
1816272|NCT00695435|Drug|TOBRADEX Ophthalmic Suspension|TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline
1816273|NCT00695435|Drug|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension|Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline
1816274|NCT00695435|Drug|TOBREX Ophthalmic Solution|TOBREX Ophthalmic Solution 1 drop each eye at baseline
1816275|NCT00695448|Drug|GSK1059615|GSK1059615 is dosed orally once daily for 21 days of a 28-day cycle. Patients continue treatment for subsequent cycles as long as eligible and receiving benefit.
1816276|NCT00695461|Dietary Supplement|Lactobacillus plantarum 299v in oatmeal drink|Bacteria in a concentration of 10(9) CFU/ml
1816277|NCT00695461|Dietary Supplement|Oatmeal drink|Oatmeal drink as in arm 1 but without bacteria added.
1816278|NCT00695487|Drug|THC 9-d-tetra hydro cannabinol|0.125mg/kg iv one time
1816279|NCT00695500|Drug|Varenicline|Varenicline tablets, 2 mg per day for 3 weeks
1816280|NCT00695500|Drug|Placebo|Placebo tablets, 0 mg per day for 3 weeks
1816281|NCT00695513|Dietary Supplement|BENEO synergy1|50/50 v/v inulin/oligofructose 10 gram BID
1816282|NCT00695526|Dietary Supplement|cranberry|cranberry extractive in powder product (by Triarco Industries, Inc. NJ, USA) and encapsulated in dose of 500mg/capsule (by Topo digital tech co., Taiwan). By one capsule after each of three meals per day.
1816283|NCT00695552|Behavioral|Aerobic exercise|Aerobic exercise on stationary bikes. Three sessions/week for 3 three months. First month the workload is equivalent to 65% of HRmax, the second month the workload is equivalent to 70% of HRmax, and the third month the workload is equivalent to 75% of HRmax
1816284|NCT00695552|Behavioral|Low impact exercise|Participants meets 3 times/week for 3 months. They will engage in low impact activities such as stretching exercises
1816285|NCT00695565|Drug|Placebo Gel|TID x 12 weeks
1816286|NCT00695565|Drug|Clonidine Topical Gel (ARC-4558)|TID x 12 weeks
1816288|NCT00695591|Other|Evaluation for Nocturnal non invasive ventilation|Patients will be referred for evaluation for NNIV is indicated in patients with diurnal Pa,CO2 >6.0 Pa; and 2) nocturnal Sa,O2 <88% for 5 consecutive min. End tidal CO2 representing equivalent values will be referred for NNIV
1816289|NCT00695604|Drug|Placebo|Placebo via MDI.
1816290|NCT00695604|Drug|Fluticasone|Fluticasone MDI.
1993945|NCT03102034|Biological|D46/NS2/N/ΔM2-2-HindIII|10^5 plaque-forming units (PFU) per 0.5ml vaccine; administered as nose drops
1993946|NCT03102034|Biological|Placebo|Administered as nose drops
1816293|NCT00695630|Drug|Flumazenil|2 mL, 0.2 mg SM
1816294|NCT00695630|Drug|Placebo|2 mL sterile saline SM
1816295|NCT00695643|Drug|Mesalazine|3 g per day
1816296|NCT00695643|Drug|Placebo|0 g per day
1816297|NCT00695669|Biological|Influenza A (H5N1) Virus Monovalent Vaccine|Two doses administered intramuscularly (IM), the first in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm.
1993947|NCT03102554|Genetic|Return of Genetic Results|The results of testing for genetic causes of DSD/hypospadias will be returned to parents of subjects who elect to receive these results.
1816299|NCT00695708|Behavioral|Brain Fitness Program|Computer-aided cognitive program designed for intensive training of auditory perception, memory and attention
1816300|NCT00695708|Behavioral|Cogpack|Computer-aided cognitive program for cognitive abilities
1816301|NCT00695747|Procedure|2 Site procedure- Phacoemulsification/IOL and Trabeculectomy|2 Site Combined Procedure: in which a temporal clear cornea approach would be used for the cataract/IOL part of the procedure, and immediately thereafter the superior limbus would be employed for a limbus-based trabeculectomy
1816302|NCT00702299|Drug|cisplatin|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
1816303|NCT00702299|Drug|paclitaxel|IP cisplatin will be administered on day 2 of each cycle at 75mg per m2 and IP paclitaxel will be administered at 60mg per m2 on day 8 of each cycle. Courses will be repeated every 21 days for up to 6 cycles
1816304|NCT00702299|Drug|pemetrexed disodium|Escalate doses in groups of 3 patients to 60mg per m2, 120 mg per m2, 500 mg per m2, 750 mg per m2, 1000 mg per m2
1816305|NCT00702299|Other|biologic sample preservation procedure|Plasma samples will be collected on the 1st course at baseline, 30 minutes, 60 minutes, 2 hours, 4 hours, 6 hours (if possible) and 24 hours after the first IP Alimta® dose.
1816306|NCT00702312|Behavioral|Low-salt educational programme|Subjects will attend a health promotion cooking programme and receive written tailored low-salt Bengali educational tool. This tool has been developed specifically for this population group from Phase 1 and 2 study.
1816307|NCT00702312|Behavioral|Low-salt Bangladeshi educational programme|A multi-component low-salt educational programme tailored to the Bangladeshi kidney disease patients delivered in the community.
1816413|NCT00703131|Device|Anal Fistula Plug (SurgiSIS AFP)|Anal Fistula Plug
1816415|NCT00703144|Procedure|Pharmacokinetic|
1857787|NCT01005758|Drug|methotrexate|
1816308|NCT00702312|Behavioral|Low-salt Bangladeshi educational programme|A multi-component Low-salt educational programme tailored to the Bangladeshi kidney disease patients residents in Tower Hamlets delivered over 5 months.
1816309|NCT00702325|Drug|Budesonide / formoterol fumarate (SYMBICORT)|160/4.5 μg x 2 actuations twice daily (bid)
1816310|NCT00702325|Drug|Budesonide|inhalation powder 180 μg x 2 inhalations bid (PULMICORT)
1816311|NCT00702338|Drug|corifollitropin alfa|SC injection(s) of corifollitropin alfa (30 mcg) was administered the first, second or third day after onset of progestagen-induced withdrawal bleeding in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
1816312|NCT00702338|Biological|recombinant Follicle Stimulating Hormone (recFSH)|Daily injections of SC recFSH (50 IU/75 IU) were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
1816313|NCT00702338|Biological|human Chorion Gonadotropin (hCG)|Daily injections of SC hCG injection were administered as soon as the largest follicle reached a size ≥ 12 mm 4 days after a corifollitropin alfa injection (on stimulation day 5, 9 or 13) in base study P05693 (NCT00697255). No treatment was administered on the current follow-up study.
1816314|NCT00702338|Biological|hCG Bolus injection|Bolus injection of SC hCG was administered in base study P05693 (NCT00697255) to induce final oocyte maturation if at least one follicle was ≥18 mm and no more than two follicles ≥15 mm were observed. No treatment was administered on the current follow-up study.
1816315|NCT00702351|Drug|Org 36286 (corifollitropin alfa)|A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing >= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing <= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
1816316|NCT00702364|Drug|atomoxetine|
1816317|NCT00702364|Drug|placebo|
1816318|NCT00702377|Other|SYSTANE Ultra|SYSTANE Ultra Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
1816319|NCT00702377|Other|Optive|Optive Lubricant Eye Drops 1 drop each eye 4 times daily for 42 days
1816320|NCT00702403|Drug|nilotinib|Given PO
1816321|NCT00702403|Drug|imatinib mesylate|Given PO
1816322|NCT00702403|Other|pharmacological study|Correlative studies
1816323|NCT00702416|Procedure|Ultrasound-guided continuous interscalene brachial plexus block|"With patients in the supine position, a high-frequency (10-12 MHz) ultrasound transducer in a sterile sheath will be applied to explore the interscalene region and locate the brachial plexus. The transducer will be positioned so as to image the C5 and C6 roots in a single view. Visualization of the C7 root in the same scan will be sought, but will not be required.
A 50-mm, 20 G needle will be advanced in-plane from the postero-lateral side of the transducer. Injection of the local anesthetic will be performed in small aliquots while repositioning of the needle in order to optimize spread of the injectate around the nerve roots.
At the end of the injection, a catheter will be threaded through the needle. The catheter will be positioned to lie deep and close to the imaged nerve roots."
1816324|NCT00702416|Procedure|Continuous interscalene brachial plexus block using electrical nerve stimulation|"With patients in the supine position, the head will be rotated to the contralateral side. The interscalene groove will be palpated.
A 35-mm, 20 G needle will be inserted at the estimated C6 level (cricoid cartilage) with a 30-45° angle to the skin. The needle will be advanced along a line joining the insertion site to the axilla.
An electrical nerve stimulator will be used at an initial intensity of 1.0 mA (frequency: 2 Hz, pulse width: 0.2 ms). A musculocutaneous or axillary-nerve mediated twitch will be sought
Injection of the local anesthetic will start with a visible motor response at a current <0.5 mA. The catheter will be positioned to as to elicit a motor response at ≤0.4 mA."
1816325|NCT00702416|Drug|Ropivacaine|"Block induction [1% (wt/vol) solution]:
20 ml (200 mg)
Postoperative analgesia [0.2% (wt/vol) solution]:
Background infusion: 4 ml/h (8 mg/h)
Incremental on-demand dose: 2 ml (4 mg)
Lockout time: 15 min"
1816326|NCT00702416|Drug|Paracetamol|1 g iv q8h
1816327|NCT00702416|Drug|Morphine|5 mg im prn q1h (in the postoperative period)
1816328|NCT00702416|Drug|Fentanyl|50 µg iv prn (in the intraoperative period)
1816329|NCT00702416|Procedure|General anesthesia|"Will be given in case of block failure and/or patient discomfort intractable with fentanyl during the procedure.
The technique will be left at the discretion of the attending anesthesiologist. Monitored anesthesia care will also be acceptable; the block will be considered as failed in that case as well."
1816330|NCT00702429|Other|Blood sampling|Analysis of the PNN, analysis of the monocytes
1816331|NCT00702429|Other|Blood sampling|Analysis of the PNN, analysis of the monocytes
1816332|NCT00702442|Drug|Droperidol|0.625 mg droperidol administrated i.v prior to laparoscopic cholecystectomy
1816333|NCT00702442|Drug|Saline solution|Saline solution administrated i.v 30 min prior surgery
1816334|NCT00702455|Behavioral|Self-Directed (weight loss maintenance)|Self- Directed participants will receive a core set of print materials describing key behaviors and skills necessary for successful weight loss maintenance and will review these materials with an intervention coach in two sessions.
1816335|NCT00702455|Behavioral|Guided (weight loss maintenance)|Guided participants will receive 8 monthly check in calls and then bimonthly calls for the rest of the study. Guided participants are also asked to report their weight weekly, either via the Keep It Off website, email or voicemail. Those who experience weight gain will receive outreach calls to assist them in reversing their weight gain.
1816336|NCT00702468|Drug|Sativex|containing delta-9-tetrahydrocannabinol (THC)(27 mg/ml):cannabidiol (CBD)(25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Dose: 100 µl oromucosal spray, as required for symptom relief
1816337|NCT00702468|Drug|Placebo|Contains no active drug and is delivered in 100 microlitre actuations by a pump action oromucosal spray
1816338|NCT00702481|Drug|Nimotuzumab|Patients will receive nimotuzumab 200 mg weekly for 8 weeks. Nimotuzumab will be started together with concurrent chemoradiation, and continued 1 week after the completion of chemoradiation.
1816339|NCT00702481|Drug|Cisplatin|Concurrent chemotherapy with cisplatin 100 mg/m2 will be given on week 1, 4, and 7 of radiotherapy.
1816414|NCT00703144|Drug|piperacillin/tazobactam|piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
1816340|NCT00702481|Radiation|Radiation|Concurrent radiotherapy will be given to the primary tumor and upper neck at 2 Gy per fraction, once a day, five days a week to a total of 70 Gy in 35 fractions in seven weeks.
1816341|NCT00702494|Biological|TB-403|Multiple IV
1816342|NCT00702507|Drug|0.25 % Miconazole Nitrate Ointment|Topical Application
1816343|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 100 ug|Subcutaneous administration of corifollitropin alpha at a dose of 100 ug
1816344|NCT00702520|Drug|Corifollitropin alpha (MK-8962, Org 36286) 150 ug|Subcutaneous administration of corifollitropin alpha at a dose of 150 ug
1816345|NCT00702520|Drug|Triptorelin|Daily SC injections of 0.1 mg triptorelin started between Day 21 and 24 of the menstrual cycle (mid luteal phase).
1816346|NCT00702520|Biological|Recombinant follicle stimulating hormone (recFSH)|From stimulation Day 8 onwards, treatment was continued with daily SC of recFSH injections (maximally 200 IU) up to and including the day of administration of hCG.
1816347|NCT00702520|Biological|Human chorionic gonadotprophin (hCG).|HCG was administered as a single subcutaneous injection of 5,000 to 10,000 international units.
1816348|NCT00702546|Drug|corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
1816349|NCT00702546|Biological|recFSH (follitropin alfa)|Daily recFSH administered under protocol P05690
1816350|NCT00702546|Drug|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
1816351|NCT00702546|Drug|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC under protocol P05690
1816352|NCT00702546|Biological|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
1816353|NCT00702546|Drug|placebo-recFSH (follitropin alfa)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
1816354|NCT00702546|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
1816355|NCT00702546|Biological|open-label recFSH|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
1816356|NCT00702572|Drug|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|This dose escalating phase will enroll sequential cohorts of 3-6 patients to be entered at the following dose levels: Level -1: Days 1-14, Vorinostat 100 mg po QD; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 175 mg/m2. Level 1: Days 1-14, Vorinostat 200 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 2: Days 1-14, Vorinostat 300 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Level 3: Days 1-14, Vorinostat 400 mg po QD days 1-14; Day 3, Bevacizumab 15 mg/kg; Carboplatin 6 AUC; Paclitaxel 200 mg/m2. Treatment cycles will be repeated every 3 weeks. The highest dose level which <2 out of 5 patients experience dose limiting toxicity will be defined as the recommended phase II dose.
1816357|NCT00702572|Drug|Vorinostat, Bevacizumab, Carboplatin, Paclitaxel|Once the recommended phase II dose has been established from Phase I, 12 additional patients will be treated to evaluate the toxicities and safety profile of the 4-drug regimen.
1816358|NCT00702585|Drug|Org 36286|Org 36286 single-dose subcutaneous injection
1816359|NCT00702585|Drug|Placebo|Placebo to Org 36286 as a single-dose subcutaneous injection
1816360|NCT00702598|Behavioral|Telephone-based Cognitive Behaviour Therapy (CBT)|Telephone-based CBT: Eight sessions of telephone-based CBT (Tel-CBT) will be delivered over 8-10 weeks, based on a published manual (Simon et al, 2004). Tel-CBT has been modified to be briefer than traditional CBT (30-40 minutes instead of 60 minutes per session) and will be offered at convenient times (including evening sessions). The initial Tel-CBT session will occur within 2 weeks of randomization, with subsequent sessions occurring every 1-2 weeks depending on scheduling and patient preference. The initial session focuses on motivation enhancement exercises, subsequent sessions emphasize identifying, challenging and distancing from negative thoughts, and the final session focuses on a personal care plan and self-management skills.
1816361|NCT00702598|Behavioral|Telephone reminder calls|Telephone reminder calls: Weekly telephone calls for 8 weeks to inquire on progress and remind patients to take their medications properly
1816362|NCT00702611|Device|Granulocyte Monocyte Apheresis (GMA-Apheresis)|GMA Apheresis will be performed in a once per week during seven weeks only in experimental arm. Each apheresis will last 60 minutes at a blood flow rate of 30 ml/min.
1816363|NCT00702624|Drug|Corifollitropin alfa|Single injection of 100 μg corifollitropin alfa administered under protocol P05690
1816364|NCT00702624|Biological|recFSH (follitropin beta)|Daily recFSH administered under protocol P05690
1816365|NCT00702624|Drug|gonadatropin releasing hormone (GnRH) antagonist ganirelix|GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690
1816366|NCT00702624|Biological|human chorion gonadotropin (hCG)|hCG 5,000 IU/USP or 10,000 IU/USP administered under protocol P05690
1816367|NCT00702624|Biological|progesterone|Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
1816368|NCT00702624|Drug|placebo-recFSH (follitropin beta)|Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690
1816369|NCT00702624|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690
1816370|NCT00702624|Biological|open-label recFSH (follitropin beta)|Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P05690
1816371|NCT00702910|Drug|Placebo|comparator
1816372|NCT00702910|Drug|GW642444|investigational drug or placebo
1816373|NCT00702910|Drug|Magnesium Stearate|Magnesium Stearate
1816374|NCT00702923|Drug|Bicalutamide and CP-675,206 (Tremelimumab)|"Dose level -1 :
Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 3 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
1816375|NCT00702923|Drug|Bicalutamide, CP-675,206 (tremelimumab)|"Dose level 1:
Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 6 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
1816376|NCT00702923|Drug|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 2:
Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 10 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
1816377|NCT00702923|Drug|Bicalutamide, CP-675,206 (Tremelimumab)|"Dose level 3:
Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 15 mg/kg I.V. over 1 hour, day 29 Cycle repeated once at month 3 (beginning day 85 +/- 7)"
1816378|NCT00702923|Drug|Bicalutamide, CP-675,206|"Final Dose Level:
Bicalutamide 150 mg p.o. q.d. day 1-28, day 85-112
At month 9, if evidence of PSA progression:
Bicalutamide 150 mg p.o. q.d. day 1-28 CP-675,206 (MTD dose) I.V. over 1 hour, day 29"
1816379|NCT00702936|Drug|TELMISARTAN|80 mg daily
1816380|NCT00702936|Drug|RAMIPRIL|5 mg daily
1816381|NCT00702949|Drug|pregabalin|Given orally
1816382|NCT00702949|Other|placebo|Given orally
1958414|NCT01673646|Drug|SOM230LAR|Intramuscular administration of pasireotide LAR will be repeated every month (1 month = 28 days) for 12 months in core phase. It is permitted to increase the dose up to 60 mg in a patient showing the following biochemical test results after 3 and 6 months of study treatment: mean GH levels ≥2.5 µg/L and/or IGF-1 > ULN. In the event of any problem with tolerability, it is permitted to reduce the next lower dosage level at any time.
1816385|NCT00702975|Drug|Paclitaxel, Carboplatin and Bevacizumab,Erlotinib|4 cycles (or less in case of progression) with carboplatin AUC 6 -paclitaxel 200mg/m2 -bevacizumab 15 mg/kg i.v. At (early) progress Bevacizumab 15 mg/kg i.v. q 21 days plus Erlotinib 150 mg/day orally
1816386|NCT00702988|Drug|Org 36286|single dose of 60, 120, or 180 μg Org 36286 (experimental group administered under protocol 38826)
1816387|NCT00702988|Drug|recFSH|150 IU recFSH daily (reference group administered under protocol 38826)
1816388|NCT00703001|Behavioral|Educational Intervention|students in this arm will receive several oral health educational modules in class
1816389|NCT00703001|Behavioral|Referral Intervention|Parents of enrolled children will receive assistance in accessing oral health care for their child
1816390|NCT00703014|Drug|Corifollitropin Alfa 150 μg|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection of 150 μg (0.5 mL) Corifollitropin Alfa was administered in the abdominal wall.
1816391|NCT00703014|Biological|200 IU RecFSH/Follitropin beta (Days 1 to 7)|In the Base Trial P05787, daily SC injections with 200 IU fixed dose recFSH were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
1816392|NCT00703014|Drug|Placebo for Corifollitropin Alfa|In the Base Trial P05787, on the morning of day 2 or 3 of the menstrual cycle (Stimulation Day 1), a single SC injection from a pre-filled syringe containing an identical solution when compared to Corifollitropin Alfa was administered in the abdominal wall.
1816393|NCT00703014|Drug|Placebo for RecFSH/Follitropin beta|In the Base Trial P05787, daily SC injections of an identical ready-for-use solution, but without the active ingredient, supplied in cartridges for SC injection with the Follistim Pen, were started on Stimulation Day 1 and continued up to and including Stimulation Day 7.
1816394|NCT00703014|Biological|200 IU RecFSH/Follitropin beta (Days 8 to hCG)|In the Base Trial P05787, from Stimulation Day 8 onwards a daily SC dose of 200 IU recFSH was administered up to and including the Day of hCG.
1816395|NCT00703014|Drug|Ganirelix|In the Base Trial P05787, on Stimulation Day 5 a daily SC injection of 0.25 mg was started, which continued up to and including the day of hCG.
1816396|NCT00703014|Biological|hCG|In the Base Trial P05787, when 3 follicles >= 17 mm were observed by USS, a single dose of 10,000 IU/USP hCG was administered; or, for those at risk for Ovarian Hyperstimulation Syndrome (OHSS), a lower dose of 5,000 IU/USP
1816397|NCT00703014|Biological|Progesterone|In the Base Trial P05787, on the day of OPU, luteal phase support was started by administering micronized progesterone of at least 600 mg/day vaginally, or at least 50 mg/day intramuscular (IM), which continued for at least 6 weeks, or up to menses.
1816398|NCT00703053|Biological|A/Vietnam/1203/04|Inactivated subvirion influenza rg A/Vietnam/1203/04 (clade 1) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
1816399|NCT00703053|Biological|A/Indonesia/05/05|Inactivated subvirion influenza rg A/Indonesia/05/05 (clade 2) x PR8 A/H5N1 vaccine; dosages 45 mcg and 90 mcg.
1816400|NCT00703066|Biological|GMZ 2 vaccine (GLURP + MSP 3)|three doses of 30µg of GMZ 2 vaccine,
1816401|NCT00703066|Biological|GMZ 2 vaccine (GLURP + MSP 3)|100 µg of GMZ 2 vaccine
1816402|NCT00703066|Biological|Rabies vaccine|3 doses of Rabies vaccine
1816403|NCT00703079|Drug|Octreotide-LAR or lanreotide|Treated with octreotide-LAR will be given at dosages of 10-40 mg/q28d and treatment with lanreotide-SR at dosages of 60-120 mg/q28d. The dosages are up-titrated to control GH and IGF-I levels
1816404|NCT00703079|Procedure|Transsphenoidal adenomectomy|Removal of pituitary adenomas via one-nostril transsphenoidal approach and endoscopy-assisted.
1995579|NCT02716597|Drug|25% Albumin|
1816406|NCT00703105|Biological|Ontak DC|Administration of a single dose of Ontak at 18 µg/kg followed in 96 hours by DC vaccination with 1 x 10(6th) tumor lysate and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals (6 weeks)
1816407|NCT00703105|Biological|DC vaccination|DC vaccination with 1 x 10(6th) tumor lysate and KLH-loaded immature DCs into inguinal nodes identified by ultrasound guidance for a total of three injections at two week intervals; (6 weeks)
1816408|NCT00703105|Drug|Ontak|administration of Ontak 18 µg/kg without vaccination
1816409|NCT00703118|Drug|Telaprevir|Participants will receive telaprevir tablets of 750 mg orally eight hourly for 12 weeks in group A and B.
1816410|NCT00703118|Drug|Peg-IFN-alfa-2a|Participants will receive 180 µg subcutaneous (under the skin) injection of Peg-IFN-alfa-2a once weekly for 48 weeks in Group A, B and C.
1816411|NCT00703118|Drug|Ribavirin|Participants will receive ribavirin tablets of 1000-1200 mg orally twice daily for 48 weeks in Group A, B, and C.
1816412|NCT00703118|Drug|Placebo|Participants will receive telaprevir matching placebo tablets orally for 4 weeks in Group A and B. Participants will receive telaprevir matching placebo tablets orally for 16 weeks in Group C.
1857788|NCT01005758|Drug|methylprednisolone|
1995580|NCT02716597|Drug|Placebo|
1995581|NCT02715986|Device|3T MRI|Four visits will be conducted during the prospective follow during which will be carried out a 3T MRI examination, assessment of assessment of depressive symptomatology and anterograde memory: within 7 days prior to the first session of ECT, within 48 hours after the first ECT session, within 48 hours after the first effective ECT session and within 10 days of the last session of ECT.
1816416|NCT00703157|Procedure|Catheter Ablation|Patients undergoing left atrial circumferential pulmonary vein ostia ablation.
1816417|NCT00703157|Procedure|Surgical Ablation|patients undergoing left atrial circumferential pulmonary vein ostia ablation via minimal invasive surgery.
1816418|NCT00703170|Drug|Temsirolimus|
1816419|NCT00703170|Drug|Pegylated liposomal doxorubicin|
1816420|NCT00703183|Drug|ACU-4429|administered as a single dose, orally
1816421|NCT00703183|Drug|matching placebo|administered as a single dose, orally
1816422|NCT00703196|Dietary Supplement|folic acid|Given orally once daily
1816423|NCT00703196|Other|placebo|Given orally once daily
1816424|NCT00703209|Procedure|Nerve Decompression|"Nerve decompression on a randomized leg, with similar skin incisions on the opposite leg so that the patient is blinded to which leg received the decompression."
1816425|NCT00703222|Biological|SJNB-JF-IL2 and SJNB-JF-Lptn vaccine|"*SJNB-JF-IL2 and SJNB-JF-Lptn cells are each dosed at 1x10e7 cells/m2/vaccination. This will be given in conjunction with an escalating dose of SKNLP vaccine.
Dose Level 1: 1x10e6 cells/m2/vaccination dose of SKNLP Unmodified Neuroblastoma Cell Line Vaccine Component
Dose Level 2: 1x10e7 cells/m2/vaccination dose of SKNLP Unmodified Neuroblastoma Cell Line Vaccine Component"
1816426|NCT00703222|Biological|SKNLP Vaccine|"Dose Level 1: 1x10e6 cells/m2/vaccination
Dose Level 2: 1x10e7 cells/m2/vaccination"
1816427|NCT00703235|Drug|Bevacizumab|
1816428|NCT00703248|Procedure|Osteopathic Manipulative Treatments|"opening the thoracic inlet
pectoral traction for 1 minute bilaterally
rib raising for a total of 4 minutes- 2 minutes on each side of the thoracic spine ]
thoracic pump at a rate of 60 times per minute for a total of 5 minutes bilaterally
abdominal pump at a rate of 30 times per minute for a total of 5 minutes bilaterally."
1816429|NCT00703261|Drug|atorvastatin|Participants will be asked to self-administer one atorvastatin 10 mg or 80 mg tablet at approximately the same time each day.
1816430|NCT00703261|Drug|placebo|Participants will be asked to self-administer one tablet of placebo to atorvastatin 10 mg or 80 mg at approximately the same time each day.
1816431|NCT00703274|Behavioral|PROTECT DC|PROTECT DC facilitates the initiation of secondary prevention behaviors in an attempt to prevent the recurrence of stroke among participants. The program trains a lay person, called a stroke navigator, to provide participants with education on secondary prevention behavior and to navigate the health and human service system, which will assist participants in obtaining the necessary services and programs to engage in secondary prevention behaviors.
1816432|NCT00703287|Other|Physiotherapy|Specialized physiotherapy programme developed by Jean-Pierre Bleton
1816433|NCT00703287|Other|Physiotherapy|Generic physiotherapy
1816434|NCT00703300|Drug|bortezomib|Given IV
1816435|NCT00703300|Drug|decitabine|Given IV
1816436|NCT00703300|Other|pharmacological study|Correlative studies
1816437|NCT00703300|Other|laboratory biomarker analysis|Optional correlative studies
1816441|NCT00703326|Biological|ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B) is administered at a dose of 10 milligrams per kilogram (mg/kg) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
1816442|NCT00703326|Drug|docetaxel|Docetaxel is administered at a dose of 75 milligrams per square meter (mg/m²) as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
1816443|NCT00703326|Other|Placebo|Placebo comparator for ramucirumab (IMC-1121B) administered at a dose of 10 mg/kg as a 1-hour intravenous infusion on Day 1 of each 21-day cycle.
1816444|NCT00703339|Drug|Treprostinil sodium for inhalation|"Administration of inhaled treprostinil sodium 0.6 mg/ml in 3mL ampoules Duration of Treatment: single dose
Dose:
Cohort 1: dosed at 3 breaths (18 mcg)
Cohort 2: dosed at 6 breaths (36 mcg)
Cohort 3: dosed at 9 breaths (54 mcg)
Cohort 4: dosed at 12 breaths (72 mcg)
The decision to advance to the next cohort will be made after review of all safety information including vital signs, physical examination, clinical laboratory tests, ECGs, and adverse events."
1816445|NCT00703352|Drug|Eplerenone|Eplerenone (coated tablet) 50mg daily during 12 months.
1816446|NCT00703365|Drug|Sorafenib and Gemcitabine|Sorafenib 400 mg po bid daily and Gemcitabine IV 1,000 mg/m2 on day 1,8, 15 of a 28-day cycle (up to 6 cycles), then followed by Sorafenib 400 mg po bid daily maintenance until disease progression.
1816447|NCT00703378|Drug|Docetaxel (Taxotere®)|Phase 1 Cycle 1 and 2 Patients in group 1 receive 40mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 2 receive 30mg/m2/week of docetaxel in a 1-hour infusion. Patients in group 3 receive 20mg/m2/week of docetaxel in a 1-hour infusion.
1816448|NCT00703391|Drug|AZD9668|30mg oral tablets twice daily (bid) for 14 days
1816449|NCT00703391|Drug|Placebo|Matched placebo to 30mg oral tablet twice daily (bid) for 14 days
1816450|NCT00703417|Device|magnetic Resonance Imaging|MRI of the calcaneus, the distal tibia, the distal radius and also lower back.
1816451|NCT00703417|Device|Computed Tomography|CT scan of the lower back and hip
1816452|NCT00703417|Device|High resolution peripheral quantitative computed tomography|HR-pQCT of the distal radius and distal tibia
1816453|NCT00703430|Drug|Memantine|Initially Memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day, which is maintained for the following 2 months.
1816454|NCT00703456|Behavioral|Balance Training|balance training three days per week for 4 weeks during single limb standing
1816455|NCT00703469|Drug|MDX1106-02|Single dose
1816456|NCT00703469|Drug|Placebo|Placebo single dose
1816457|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 placebo
1816458|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate pbo/CoQ10 200 mg
1816459|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 placebo
1816460|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 80/CoQ10 100 mg
1816461|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 100 mg
1816462|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 80 /CoQ10 200 mg
1816463|NCT00703482|Drug|Fenofibrate/CoQ10|Fenofibrate 160mg/CoQ10 200 mg
1857789|NCT01005758|Drug|pegaspargase|
1816465|NCT00703508|Drug|Metformin 500 mg tablet|Metformin 500 mg tablets; two tablets every 12 hours for 9 months
1816466|NCT00703521|Biological|Rabies vaccine|1.0 mL IM day 0,7,28 and 1 year
1816467|NCT00703534|Drug|AZD3355|Immediate Release capsule administered as a single dose, 65mg, twice daily for 4 weeks
1816468|NCT00703534|Drug|Placebo|capsule. administered as a single dose twice daily for 4 weeks
1816469|NCT00703534|Drug|Gelusil®|Chewable tablets taken as needed
1816470|NCT00703547|Drug|GSK586529 capsules|GSK586529 will be provided as white gelatin capsule with a dose of 3 milligrams.
1816471|NCT00703547|Drug|GSK586529 tablets|GSK586529 will be provided as a yellow film-coated tablets for oral administration at three different strengths 10 milligrams, 60 milligrams and 120 milligrams.
1816472|NCT00703547|Drug|Placebo|Placebo tablets and capsules will be provided to subjects.
1816473|NCT00703573|Drug|S-777469 400 mg|S-777469 400 mg BID
1816474|NCT00703573|Drug|S-777469 800 mg|S-777469 800 mg BID
1816475|NCT00703573|Drug|Placebo|Placebo BID
1816476|NCT00703586|Drug|Maraviroc|"ARM A:
Addition of maraviroc to baseline ARV medications for 24 weeks at one of the following doses:
150 mg orally BID when coadministered with a ritonavir-boosted protease inhibitor
600 mg orally BID when coadministered with efavirenz or nevirapine
ARM B:
Addition of an additional NRTI to baseline ARV medications for 12 weeks then cross over to maraviroc intensification for an additional 12 weeks as above:
Addition of abacavir 600 mg orally once daily to a tenofovir containing regimen for 12 weeks then replacing the abacavir with maraviroc.
Addition of an alternate FDA approved NRTI [such as zidovudine (AZT) or didanosine (ddi)] at standard oral dosing to a tenofir containing regimen for 12 weeks (if the participant declines abacavir therapy) then replacing the alternate NRTI with maraviroc.
Addition of tenofovir 300 mg daily to an abacavir containing regimen for 12 weeks then replacing the tenofovir with maraviroc."
1816477|NCT00703599|Procedure|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
1816478|NCT00703612|Procedure|Autologous Adipose-derived Stem cells|Intravenous administration of autologous activated stromal vascular fraction derived from 100-120 ml lipoaspirate following mini-liposuction of abdominal adipose tissue.
1816479|NCT00703625|Drug|Temsirolimus|
1816480|NCT00703625|Drug|Docetaxel|
1816481|NCT00703638|Drug|cisplatin|Cisplatin administered intravenously, 75 mg/m^2 over 1-2 hours on day 1 of a 21 day cycle
1816482|NCT00703638|Drug|pemetrexed disodium|Pemetrexed 500 mg/m^2 intravenously (IV) will be given as a 10-minute intravenous infusion (after cisplatin) on day 1 of a 21 day cycle
1816483|NCT00703638|Drug|sorafenib|daily oral sorafenib (200 mg or 400 mg bid)
1816484|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years
1816485|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, ID. 1 injection/year for 3 years.
1816486|NCT00703651|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, IM. 1 injection/year for 3 years
1816490|NCT00703677|Drug|Lithium|All participants will receive lithium. The dosage will be titrated over a 5-week period and then continued for an additional 6 months.
1816491|NCT00703690|Drug|MK0767|MK0767 2.5, 5, and 10 mg/day supplied as tablets
1816492|NCT00703690|Drug|Comparator: fenofibrate|fenofibrate 200 mg supplied as capsules
1816493|NCT00703690|Drug|Comparator: Placebo (unspecified)|matching placebo will be supplied as tablets/capsules.
1816494|NCT00703703|Drug|Darifenacin|Darifenacin tablets 15 mg once daily
1816495|NCT00703703|Drug|Tolterodine|Tolterodine extended release (ER) 4 mg once daily
1816496|NCT00703703|Drug|Placebo|Placebo tablet once daily
1816497|NCT00703729|Device|Cold Compression (CC)|The device is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The device will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
1816498|NCT00703729|Other|Ice Wrap (IW)|The ice bag is applied to the shoulder within 60 minutes of arrival to the recovery room following surgery. The ice bag is placed on the shoulder and the elastic wrap is used to hold the bag in place. The ice will be applied at one hour intervals (60 minutes on the shoulder, 60 minutes off) during waking hours for the first 72 hours after surgery. For the remainder of the study period, therapy will be applied for one hour treatments 2-3 times a day during waking hours.
1816499|NCT00703742|Drug|Escitalopram|A,1: Escitalopram, oral, 20 mg/day, 8 weeks
1816500|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 850 mg bid (F160-M1700)
1816501|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin 500 mg bid (F160-M1000)
1816502|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 850 mg bid (F80-M1700)
1816503|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 40 mg bid + metformin 500 mg bid (F80-M1000)
1816504|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate 2 x 40 mg bid + metformin placebo (F160-M0)
1816505|NCT00703755|Drug|Fenofibrate /Metformin|fenofibrate placebo + metformin 850 mg bid (F0-M1700)
1816506|NCT00703755|Drug|Placebo|Placebo
1816507|NCT00703781|Drug|bromfenac ophthalmic solution|sterile ophthalmic solution
1816508|NCT00703781|Drug|placebo|sterile ophthalmic solution
1816509|NCT00703794|Device|The AXIUM Progressive Coil System|Embolization of aneurysm
1816510|NCT00703807|Drug|Topotecan|Dose escalation, 5 dose levels, 1.5 mg/m2 - 2.3 mg/m2, PO day 1-5 every 21 days
1816511|NCT00703807|Drug|RAD001|Dose level -1, 5 mg qod Dose level 1, 5 mg qod Dose level 2, 5 mg qd Dose level 3, 5 mg qd DOse level 4, 10 mg qd
1816512|NCT00703820|Drug|Cytarabine|See Detailed Description
1816513|NCT00703820|Drug|Daunorubicin|See Detailed Description
1816514|NCT00703820|Drug|Etoposide|See Detailed Description
1816515|NCT00703820|Drug|Clofarabine|See Detailed Description
1817015|NCT00708539|Drug|progesterone|90 mg, vaginal, once daily
1816516|NCT00703820|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
1816517|NCT00703833|Drug|MK0777|Days 1-3 3mg MK0777, Days 4-7 6 mg MK0777, Days 8-28 3, 6 or 9 mg MK0777
1816518|NCT00703833|Drug|Placebo (unspecified)|matching placebo
1816519|NCT00703846|Drug|Ketoconazole|Foam, 2%, Extina will be applied twice daily (morning and evening) to all seborrheic dermatitis lesions on the face, scalp, ears, neck, and chest. Study product should be applied at the first sign of a seborrheic dermatitis flare, and twice daily applications should continue until the area(s) has cleared. All symptom flares should be treated throughout the 12-month study period.
1816520|NCT00703859|Drug|Dichloroacetate (DCA)|DCA starting at an initial dose of 3mg/kg twice daily PO for consecutive days (days 1-5) on a 28 days cycle up to 6 cycles unless evidence of tumour progression. Each dose to be administered with food at the same time everyday 12 hours apart.
1816521|NCT00703872|Drug|Oral HDV-Interferon + ribavarin|Naive pateints
1816522|NCT00703872|Drug|Injectable HDV-Interferon + ribavarin|Nonresponders
1816523|NCT00703885|Drug|0.25 mg alprazolam|"0.25 mg alprazolam PO (liquid) to be administered 1 hour prior to fMRI scan
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
1816524|NCT00703885|Drug|1.0 mg alprazolam|"1 mg alprazolam PO (liquid) will be administered 1 hour prior to fMRI scan
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
1816525|NCT00703885|Drug|placebo|"Placebo (liquid) to be administered 1 hour prior to fMRI scan
Note that subjects receive all 3 treatments in randomized order (cross-over study), approximately 7-10 days apart."
1816526|NCT00703898|Drug|nevirapine|200 mg/day twice a day
1816527|NCT00703911|Drug|eptacog alfa (activated)|Treatment of patients experiencing bleeds at the discretion of the physician/caregiver
1816528|NCT00703924|Drug|WR 279,396|A topical cream containing 15% paromomycin and 0.5% gentamicin. Approximately 0.0005 mL per mm2 of skin lesion
1816529|NCT00703924|Drug|Placebo|Topical cream vehicle. Approximately 0.0005 mL per mm2 of skin lesion
1816530|NCT00703937|Drug|Ferric Carboxymaltose (FCM)|
1816531|NCT00703937|Drug|Standard Medical Care (SMC) for the treatment of IDA|
1816532|NCT00703950|Procedure|cup feeding|Method to feed: cup. This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using cup
1816533|NCT00703950|Procedure|bottle feeding|bottle feeding This is a method to feed preterm babies when breastfeeding is impossible. Feed is provided using bottle
1816534|NCT00703963|Device|INRatio monitor by Hemosense|Home testing monitor to test patients INR by placing a capillary drop of blood from the finger onto a test strip. The test strip is then inserted into the INRatio point-of-care self-testing coagulometer. After approximately 2 minutes of analysis, the INR value will be presented on the meter's display.
1816535|NCT00703963|Other|Usual Care|Usual care is defined as that care currently received by patients into whom mechanical heart valves are placed. Typically, these patients undergo frequent checks of their INR level until the therapeutic range is achieved. Then periodic INR levels are drawn at the discretion of the managing physician.
1816536|NCT00703976|Drug|Bevacizumab|Bevacizumab is approved by the Food and Drug Administration (FDA) for colorectal cancer and non-small cell lung cancer in combination of chemotherapy.
1816537|NCT00703976|Drug|Cetuximab|Cetuximab is approved by the FDA for head and neck cancers in patients who have failed other chemotherapy treatments.
1816538|NCT00703976|Drug|Pemetrexed|Pemetrexed is approved by the Food and Drug Administration (FDA) for head and neck cancer when used in combination with radiation therapy.
1816539|NCT00703976|Radiation|Radiation therapy|Radiation therapy standard fractionation 2 Gy/day without planned interruptions beginning on day 1 (Monday or Tuesday preferred). Radiation will be given 5 days/week, Monday through Friday, for 7 consecutive weeks
1816540|NCT00703989|Dietary Supplement|benfotiamine, α-lipoic acid|benfotiamine 300 mg twice a day, (Advanced Orthomolecular Research, Calgary, AB,CANADA) and slow-release α-lipoic acid (600 mg twice a day) (MRI, San Francisco, CA) for a total duration of four weeks
1816541|NCT00704002|Procedure|antegrade intramedullary splinting|antegrade intramedullary splinting with 2 to 3 small K-wires
1816542|NCT00704002|Procedure|conservative treatment|conservative treatment with 2-finger splint for one week
1816543|NCT00704015|Behavioral|Smoking cessation|Nurses, specifically trained for smoking cession program, contacted the patients at the orthopedic wards and initiated the intervention (stop smoking) within 1-2 days after acute hospitalization. The intervention included one or two personal meetings and weekly phone contacts during 6 weeks with a trained nurse. A phone number to a non-smoking hotline was provided for all patients. The patients were continuously encouraged not to smoke and free nicotine substitution (Nicorette®) was offered those who needed it. No other drug therapy was used.
1816544|NCT00704028|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg per minute weekly to a maximum cumulative dose of 2,250 mg.
1816545|NCT00704028|Drug|Iron Dextran|As determined by the investigator to a maximum cumulative dose of 2,250 mg.
1816546|NCT00704054|Drug|ridaforolimus|Ridaforolimus is given as an IV infusion over 30 minutes on days 1-5 and 15-19 of each 28 day cycle. For children less than 10 kg body weight, dosing will be adjusted.
1816547|NCT00704067|Behavioral|Supported employment plus cognitive training|Supported employment for 12 months plus cognitive training for the first 12 weeks
1816548|NCT00704067|Behavioral|Enhanced supported employment|Supported employment for 12 months plus one additional supported employment session per week for the first 12 weeks.
1816549|NCT00704080|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; continuous daily dosing
1816550|NCT00704080|Drug|Temozolomide|Capsules supplied in 5-mg, 20-mg, 100-mg, 140-mg, 180-mg, and 250-mg strengths; dosed at 200 mg/m2/day for 5 consecutive days, repeated every 28 days
1816551|NCT00704093|Device|Right ventricular pacing|Right ventricular pacing vs. sinus rhythm or atrial pacing at the same rate
1816552|NCT00704106|Drug|Entecavir|0.5 or 1 mg dose qd
1817169|NCT00709774|Device|Pacemaker Implantation|Implantation of right ventricular lead at septal or apex.
1816553|NCT00704119|Drug|RhuDex®|"Treatment A.1: 31.65 mg RhuDex® once N=12
Treatment A.2: 63.33 mg RhuDex® once N=12
Treatment A.3: 126.63 mg RhuDex® once N=12
Treatment A.4: 253.26 mg RhuDex® once N=12
Treatment B.1: 31.65 mg RhuDex® once N=12
Treatment B.2: selected dose of RhuDex® once N=12
Treatment C: selected dose of RhuDex® once N=12
Treatment D: selected dose of RhuDex® twice daily for 6 days N=12"
1816554|NCT00704132|Drug|Comparator: sitagliptin phosphate|Sitagliptin tablet 100 mg, administered once daily before the morning meal.
1816555|NCT00704132|Drug|Comparator: placebo (unspecified)|Matching placebo tablet, administered once daily before the morning meal.
1816556|NCT00704145|Device|Taxus Libertè™ paclitaxel drug-eluting stent|device:Taxus Libertè™ (Boston Scientific,Natick,MS)assessed at different time points after implant
1816557|NCT00704158|Drug|CR011-vcMMAE|administered as an intravenous infusion on Day 1 of a 21 day cycle.
1816558|NCT00704171|Procedure|Standard Tissue Closure Techniques|Standard Tissue Closure Techniques (sutures and staples only)
1816559|NCT00704171|Device|PleuraSeal Lung Sealant System|
1816560|NCT00704184|Drug|Comparator: Vaniprevir|Vaniprevir 300 mg b.i.d., 600 mg b.i.d., 600 mg q.d., or 800 mg q.d.; duration of treatment: 28 days
1816561|NCT00704184|Drug|Comparator: Pegylated-Interferon (Peg-IFN)|Peg-IFN 180 mcg once-weekly subcutaneous injection; duration of treatment: 48 weeks
1816562|NCT00704184|Drug|Comparator: Ribavirin|Ribavirin 200 mg tablet b.i.d. (dose based on body weight); duration of treatment: 48 weeks
1816563|NCT00704184|Drug|Comparator: placebo|Matching placebo to vaniprevir; duration of treatment: 28 days
1816564|NCT00704210|Device|SpineMed Table, Cert HealthSciences LLC|For Group A (the treated group) the following tension adjustments will be used: starting treatment tension will equal 1/4 body weight minus 10 lbs. Incremental increases of 4 lbs. per session will be implemented until optimum tensions are reached, which would be a maximum of ¼ body weight plus 25 lbs, unless distraction tensions cause discomfort, which would require a reduction of the tensions applied.
1816565|NCT00704210|Device|SpineMed Table, Cert HealthSciences LLC|Group B will receive sham decompression treatment (i.e. tension not exceeding 15 lbs) for 30 minutes and ice treatment for 15 minutes once a day during each treatment session. No incremental increases will be used for Group B.
1816566|NCT00704223|Drug|biphasic insulin aspart|Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation
1816567|NCT00704236|Drug|Coptis Chinensis, Astragalus mambranesceus, Lonicera Japonica (Traditional Chinese Treatment)|50 mg of Coptis Chinensis, 30 mg of Astragalus mambranesceus and 120 mg of Lonicera Japonica
1816568|NCT00704236|Drug|Placebo|
1816569|NCT00704249|Drug|nevirapine|Full-dose nevirapine from baseline (200 mg bid).
1816570|NCT00704249|Drug|nevirapine|Nevirapine with an increase in the initial dose (200 mg once daily for 14 days and 200 mg bid thereafter)
1816571|NCT00704262|Drug|Calcipotriol plus hydrocortisone (LEO 80190)|Once daily application
1816572|NCT00704275|Drug|0.05% cyclosporin eye drop|bid dosage for 4 months
1816573|NCT00704288|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths; continuous daily dosing
1816574|NCT00704301|Drug|Rivastigmine|Rivastigmine, two times 1,5 mg a day. The dosage will be increased every three days with 3 mg a day, until the CAM-ICU is negative or until the occurrence of presumed severe adverse effects or until a maximum of 12 mg a day.
1816575|NCT00704301|Drug|Placebo|Placebo, 2 times a day
1816576|NCT00704314|Drug|Simvastatin|80 mg Simvastatin daily for 8 weeks
1816577|NCT00704314|Drug|Placebo|The placebo was identical in appearance and was provided by the same manufacturer
1816578|NCT00704340|Device|DuraSeal Dural Sealant System|The DuraSeal™ Dural Sealant System is a polyethylene glycol (PEG) hydrogel that has been FDA approved as a dural sealant to achieve watertight dural closure in cranial and spinal surgery after primary repair with suturing is complete. It was developed as a means of providing a dural seal by covering small holes around the suture with an absorbable hydrogel. DuraSeal should only be used with autologous duraplasty material.
1816579|NCT00704340|Other|Standard of Care|Standard procedure to obtain intraoperative watertight dural closure. These methods could have included additional sutures, adhesive glue, absorbable gelatin sponge, dural substitute, soft tissue patch, or another method typically used by the investigator.
1816580|NCT00704353|Drug|Ferric Carboxymaltose|15 mg/kg up to a maximum of 750 mg at 100 mg/minute intravenously on Day 0.
1816581|NCT00704353|Drug|Standard Medical Care (SMC)|Per product label
1816582|NCT00704366|Drug|AZD0530|oral, tablet, once daily, dose will be variable
1816583|NCT00704379|Drug|Placebo|an inactive substance
1816584|NCT00704379|Drug|Sertraline|Sertraline and placebo will be given in a double blind fashion via an equal number of identical tablets administered once daily. Once stabilized in the targeted dosage (100 mg per day), sertraline serum levels will be monitored twice during the course of the intervention. Blood samples will be obtained randomly, one during the first and one during the second trimesters of the protocol.
1816585|NCT00704392|Drug|XL647|Tablets supplied at 50-mg strength administered orally daily
1816586|NCT00704392|Drug|XL147|Gelatin capsules supplied at 25-mg and 100-mg strengths administered orally daily
1816587|NCT00704405|Drug|Vaniprevir|Participants took capsules containing 100 mg Vaniprevir twice daily (b.i.d.), three in the morning (300 mg and 600 mg regimens) and three in the evening (600 mg regimen only), orally, for 24 or 48 weeks.
1816588|NCT00704405|Drug|Pegylated Interferon (Peg-IFN)|Participants used prefilled syringe containing 180 µg/0.5 mL Peg-IFN, for weekly subcutaneous injection, for 24 or 48 weeks
1816589|NCT00704405|Drug|Ribavirin (RBV)|Participants took tablets containing 200 mg RBV, 5 or 6 tablet dosage based on the participant's weight, with food, for 24 or 48 weeks. The dose was 1000 mg for participants weighing <=75 kg and 1200 mg for participants weighing >75 kg.
1816590|NCT00704405|Drug|Placebo (PBO)|Participants took PBO capsules matching Vaniprevir capsules, three in the morning and three in the evening, for 24 or 48 weeks.
1816591|NCT00704418|Drug|Bromfenac|sterile ophthalmic solution
1816592|NCT00704418|Drug|Placebo|sterile ophthalmic solution
1816593|NCT00704431|Drug|SB-480848 (darapladib)|160 mg darapladib
1816594|NCT00704444|Drug|Ezetimibe|Ezetimibe, 10-mg tablets
1816595|NCT00704444|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets + other lipid-lowering medication(s), as prescribed by attending physician
1816596|NCT00704470|Other|Medical simulator training|Contains seminars on airway management, general anesthesia, peri-arrest arrhythmias, and advanced life support. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss management of the critical incidents using videotapes of the scenarios.
1816597|NCT00704470|Other|Simulator based crew resource management course|Contains seminars on human error and non-technical skills. Furthermore, participants train in simulator scenarios. In the debriefing instructors discuss usage of non-technical skills as well as behaviour of the participants using videotapes of the scenarios.
1816598|NCT00704483|Drug|SBR759|Starting dose of 1g or 1.5g tid, with an increase of 1g tid every 2 weeks until serum phosphate level fall below target.
1816599|NCT00704483|Drug|Sevelamer HCl|0.8 g tid
1816600|NCT00704483|Drug|SBR759|1.5 g tid
1816601|NCT00704483|Drug|Sevelamer HCl|1.6 g tid
1816604|NCT00704509|Drug|Bifeprunox|20 mg daily, encapsulated tablets, orally, 12 months
1816605|NCT00704509|Drug|Placebo|Encapsulated tablets, orally, 12 weeks
1816606|NCT00704509|Drug|Quetiapine|600 mg daily, encapsulated tablets, orally, 12 months
1816607|NCT00704522|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
1816608|NCT00704522|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
1816609|NCT00704522|Behavioral|Patient assistance program|"Assistance programs will be classified as follows:
Medications used prophylactically or for treatment(Growth factors: RBC and neutrophil; Psychiatric medications; Other medications)
Other interventions (Psychotherapy, Patient Support Groups, Visiting Nurse, Nurse Telephone Calls, Nurse support in office, Other health care professional support, Educational Literature).
In Austria, sites with adherence nurses and side effect handouts will be compared with sites using side effect handouts only."
1816610|NCT00704535|Drug|Ezetimibe|1 tablet of 10 mg once daily
1816611|NCT00704548|Drug|Simvastatin 40mg|Simvastatin once daily, orally in the morning period, during eigth weeks
1816612|NCT00704548|Drug|Placebo|Placebo once daily, orally in the morning period, during eigth weeks
1816613|NCT00704561|Device|ENDEAVOR® drug-eluting stent (Medtronic, Santa Rosa, CA)|ENDEAVOR® drug-eluting stent implanted in acute myocardial infarction
1816614|NCT00704561|Device|DRIVER bare metal stent (Medtronic, Santa Rosa, Ca)|DRIVER bare metal stent implanted in acute myocardial infarction
1816615|NCT00704561|Device|Coronary stent implantation|Comparison of Drug Eluting versus Bare Metal Stent
1816616|NCT00704561|Device|Bare Metal Coronary Stent|Comaprison between Drug Eluting and Bare Metal Coronary Stents
1816617|NCT00704574|Drug|insulin detemir|No extra intervention, only normal clinical practise for treatment of type 1 diabetes
1816618|NCT00704600|Drug|nelfinavir|"Phase I:
take nelfinavir tablets (minimum 6, maximum 10) starting 7 days before start of chemoradiotherapy, for 45 days
day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample
day 0: PET-CT
Phase II:
take nelfinavir tablets (MTD from phase 1) starting 7 days before start of chemoradiotherapy, for 45 days
day 0 and day 7 and week 2-3-4-5-6-7 weekly blood sample
day 7 biopsy
day 7, 21 and week 15 :PET-CT + perfusion CT"
1816619|NCT00704626|Other|Blood Draw|A 5cc sample of serum will be drawn from each subject. Only one blood draw is required, but up to 8 additional blood draws can be obtained.
1816620|NCT00704626|Other|Cheek swab|A swab will be swished around the inside of the mouth to collect mouth (buccal) cells. This will be done with each blood draw.
1816621|NCT00704639|Drug|Cetuximab|Patients will receive weekly intravenous cetuximab (initial dose 400mg/m2 in the week prior to commencing radiotherapy, then weekly 250mg/m2)for the duration of the radiotherapy
1816622|NCT00704639|Drug|Carboplatin|Weekly intravenous carboplatin (AUC 2) for the duration of the RT
1816623|NCT00704639|Radiation|Radiotherapy|"The radiotherapy schedule will be the infield boost (IFB) regimen, that is 66 Gy in 35 fractions over 5 weeks: daily for 3 weeks, then twice daily for 2 weeks (or 70 Gy in 35 fractions over 7 weeks for a specific subgroup of patients where IFB is not recommended)."
1816624|NCT00704665|Drug|Relaxin|10 ug/kg/day or 25 ug/kg/day
1816625|NCT00704665|Drug|Relaxin|Placebo
1816626|NCT00704678|Drug|SBR759|1g tid
1816627|NCT00704678|Drug|Sevelamer HCl|1.6 g tid
1816628|NCT00704678|Drug|Sevelamer HCl|1.5 g tid
1816629|NCT00704678|Drug|Sevelamer HCl|0.8 g tid
1816630|NCT00704691|Drug|Lenalidomide|Lenalidomide 25 mg as a daily oral dose days 1-21 followed by a 7 day rest period (28 day cycle) for 1-6 cycles
1816631|NCT00704704|Drug|5-aza-cytidine and Thalidomide|5-AZA-Cytidine 75mg/m2 5 days a month. 12 months. Thalidomide 50mg orally daily for 6 months.
1816632|NCT00704717|Biological|PegIntron (peginterferon alfa-2b; SCH 54031) pen|PegIntron pen administered in accordance with approved labeling
1816633|NCT00704717|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling.
1816634|NCT00704730|Drug|XL184|Gelatin capsules supplied in 25-mg and 100-mg strengths administered orally daily
1816635|NCT00704730|Drug|Placebo|Gelatin capsules color and size-matched to XL184 capsules administered orally daily
1816636|NCT00704743|Device|Cylindrical cast|Arm cast/immobilization technique for wrist fracture
1816637|NCT00704743|Device|Modified sugar tong cast|Arm cast/immobilization technique for wrist fracture
1816638|NCT00704743|Device|Volar dorsal splint|Arm cast/immobilization technique for wrist fracture
1816639|NCT00704756|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at 1.5 μg/kg body weight/week subcutaneously for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
1816640|NCT00704756|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (<65 kg : 800 mg, 65 - 85 kg : 1000 mg, >85 kg : 1200 mg) orally for up to 24 wks (Genotype [G] 2,3/low viral load G 1) or 48 weeks for (G 1,4,5)
1816641|NCT00704769|Drug|Desloratadine (assigned by investigator as part of normal practice)|Desloratadine syrup, 2.5 mL (1.25mg) once daily for 2-5 year olds, 5 mL (2.5mg) once daily for 6-11 year olds, minimum 7 days of treatment, minimum of 2 visits
1816642|NCT00704782|Drug|dimebon|
1817170|NCT00709787|Other|Usual Care|Normal care for hypertensive patients with risk factors for CHD
1816643|NCT00704795|Other|Oral glucose tolerance test|50 g of waterfree glucose dissolved in 300 ml water is ingested over 5 minutes following a 10-h fast including liquids and medication (if any).
1816644|NCT00704795|Other|Isoglycemic iv glucose infusion|The plasma glucose curve obtained during a 50 g-OGTT (performed on a separate day) is copied using an adjustable iv glucose infusion (20% w/v) performed following a 10-h fast including liquids and medication (if any). The iv catheter is inserted into a peripheral vein in the hand/forearm.
1816645|NCT00704808|Procedure|Primary surgical treatment|Primary surgery for tumor resection.
1816646|NCT00704808|Radiation|Radiotherapy|Radiotherapy is given with concomitant temozolomide. Dosing according to European Summary of Product Characteristics.
1816647|NCT00704808|Drug|Temozolomide|Temozolomide is first given with concomitant radiotherapy, and then as monotherapy (adjuvant chemotherapy). Dosing according to European Summary of Product Characteristics.
1816648|NCT00704821|Drug|PTC299|PTC299 orally administered 2 or 3 times per day.
1816649|NCT00704834|Other|Blood Draw|35 cc of peripheral blood will be obtained by venipuncture from each subject.
1816650|NCT00704847|Drug|Oral Salmon Calcitonin|0.8mg SMC021, twice daily
1816651|NCT00704847|Drug|Oral Salmon Calcitonin (Placebo)|0.8mg Placebo, twice daily
1816652|NCT00704860|Other|Open label pharmacotherapy|"Dosage and drug types change based on patients need and response.
doxepin, clomipramine, amoxapine, amitriptyline, maprotiline, desipramine, nortriptyline, trimipramine, imipramine, protriptyline, isocarboxazid, phenelzine, tranylcypromine, moclobemide, fluvoxamine, paroxetine, fluoxetine, sertraline, citalopram, escitalopram, venlafaxine, atomoxetine, pramipexole, bromocriptine, quetiapine, clozapine, olanzapine, ziprasidone, aripiprazole, paliperidone, Risperidone, bupropion, mirtazapine, pindolol, topiramate, trazodone, Lithium,"
1816653|NCT00704886|Other|video|video of dementia
1816654|NCT00704899|Procedure|Physiotherapy|Structured exercise regimen
1816655|NCT00704899|Drug|Amitryptiline|Amitryptiline 25mg once daily
1816656|NCT00704912|Drug|Orlistat/Meal Replacement/Lifestyle Modification|Orlistat will be given at 60 mg three times per day (1 tablet 3 times a day) before meals, i.e., breakfast, lunch, and dinner.
1816657|NCT00704912|Drug|Loestrin 1/20|Patients will be started on a low dose containing OCP for a continuous 4 month period.
1816658|NCT00704912|Drug|Combination of treatments|Medications will be administered as described for the other 2 arms.
1816659|NCT00704925|Drug|3, 4 DAP|Patients with clinically-confirmed LEMS will receive 3, 4 DAP by mouth in slowly increasing doses. Treatment will begin with 5 mg three times a day and will increase by 50% every two weeks to 10-15 mg three to six times a day, as clinically needed, and if tolerated.
1816660|NCT00704938|Biological|aldesleukin|Intravenous (IV) aldesleukin 720,000 IU/kg every 8 hours for a maximum of 15 doses.
1816661|NCT00704938|Biological|anti-p53 T-cell receptor-transduced peripheral blood lymphocytes|Intravenous (IV) anti-p53 TCR transduced PBL will be administered at a a dose of 1 x 10^8 cells to 5 x 10^10 cells.
1816662|NCT00704938|Biological|autologous dendritic cell-adenovirus p53 vaccine|Ad-p53 DC vaccine, up to 2 x 10^8 ad-p53 DCs per dose will be administered subcutaneously, divided into 4 injections, one into each of the 4 extremities. Ad-p53 DCs will be administered subcutaneously on day 7 (± 2 days), day 14 (between day 14 and day 18), and day 28 (between day 25 and day 42) post T cell infusion.
1816663|NCT00704938|Biological|filgrastim|subcutaneously at a dose of 5 mcg/kg/day (not to exceed 300 mcg/day).
1816664|NCT00704938|Drug|cyclophosphamide|60mg/kg/day (Days-7,-6)
1816665|NCT00704938|Drug|fludarabine phosphate|25mg/m^2 (Days -5, -4, -3, -2, and -1)
1816666|NCT00704951|Drug|Posaconazole or alternative fungal treatment|"Dosage of Posaconazole:
Prophylactic dosing: 200mg tid (600mg/day) Treatment dosing: 400mg bid (800mg/day)"
1816667|NCT00704964|Biological|PegIntron|PegIntron (peginterferon alfa-2b) pen administered at a dose and frequency in accordance with approved labeling in Germany
1816668|NCT00704964|Drug|Rebetol|Rebetol (ribavirin) administered at a dose and frequency in accordance with approved labeling in Germany
1816669|NCT00704977|Procedure|pterygium surgery using alcohol 20% for tissue separation and bare sclera as wound closure technique|"The eye operated is disinfected and covered according routine protocol.
Tightly applying well above the pterygium area. Instilling alcohol 20% into the well and holding for 40-60 seconds. Absorbing alcohol by applicator and abundant irrigation with BSS.
Pterygium separation starting 2 mm centrally from the edges of the tissue. Excising the pterygium tissue at the base. Applying mytomycin C for 2.5 min+ abundant irrigation with BSS.
Wound closure by by technique described in each arm.
Bandage with chloramphenicol ointment or with Maxitrol ointment (Dexamethasone/Neomycin/Polymyxin B Eye Ointment.
Postoperative treatment include :antibiotic and steroid eyedrop treatment at least 2 weeks.
Follow up at 1 week, 1 month, 3 months, 6 months, 1 year. If additional follow upvisits are needed - they will be accomplished according the patients condition and needs."
1816670|NCT00704990|Dietary Supplement|Zinc, Magnesium, Vitamin B6, Vitamin C (Compound Natural Health Product for ADHD)|Weight based dosing of a chewable natural health product containing 15-35 mg zinc citrate, 150-350 mg magnesium lactate, 30-70 mg pyridoxine hydrochloride and 150-350 mg calcium ascorbate. Participants will take weight based dose two times during the day with meals for a 10 week period
1816671|NCT00705003|Drug|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and BCI-049: over-encapsulated Melatonin tablet 3 mg QD|BCI-024: over-encapsulated Buspirone tablet 15 mg QD and Drug BCI-049: over-encapsulated Melatonin tablet 3 mg QD taken in combination for 6 weeks
1816672|NCT00705003|Drug|BCI-024 (Buspirone)|Drug BCI-024 (Buspirone) taken once a day at bedtime for 6 weeks.
1816673|NCT00705003|Drug|Matching placebo|Placebo comparator once a day at bedtime for 6 weeks.
1816674|NCT00705016|Drug|Cilengitide 2000 mg once weekly|Cilengitide 500 milligram (mg) will be administered as an intravenous infusion over 60 minutes, daily from Day 1 to 4 of the first week of each 3-week cycle, subsequently followed by 2000 mg dose of cilengitide on Day 8 and 15 of every cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
1816742|NCT00698685|Biological|Alemtuzumab|Days - 5 through - 1: alemtuzumab 20 mg per dose intravenously over 8 hours daily for 5 doses (total cumulative dose, 100 mg)
1816743|NCT00698685|Procedure|Allogeneic hematopoietic stem cell transplantation|Infusion of related or unrelated donor peripheral blood progenitor cells on day 0.
1816675|NCT00705016|Drug|Cilengitide 2000 mg twice weekly|Cilengitide 2000 mg will be administered as an intravenous infusion over 60 minutes, twice weekly on Day 1, 4, 8, 11, 15, and 18 of each 3-week cycle for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants will receive cilengitide 2000 mg once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
1816676|NCT00705016|Drug|Cetuximab|Cetuximab will be administered as 250 milligram per square meter (mg/m^2) as infusion (initial starting dose of 400 mg/m^2) on Day 1, 8 and 15 of each 3-week treatment cycle. Cetuximab will be administered for a total of 6 cycles (18 weeks) or until PD, unacceptable toxicity or withdrawal for any other reason. After 6 cycles, participants received Cetuximab 250 mg/m^2 once weekly until PD, unacceptable toxicity or withdrawal for any other reason.
1816677|NCT00705016|Drug|5-fluorouracil (5-FU)|5-FU will be administered as an intravenous continuous infusion at a dose of 1000 mg/m^2 daily from Day 1 to 4 of each 3-week treatment cycle. 5-FU will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
1816678|NCT00705016|Drug|Cisplatin|Cisplatin will be administered as an intravenous infusion over 60 minutes, at a dose 100 mg/m^2 on Day 1 of each 3-week treatment cycle. Cisplatin will be administered for a total of 6 cycles (18 weeks), or until PD, unacceptable toxicity, or withdrawal for any other reason, whichever occur first.
1816679|NCT00705042|Drug|Etanercept|
1816680|NCT00705081|Drug|ezetimibe|10 mg once daily
1816681|NCT00705081|Drug|statin|
1816682|NCT00705107|Biological|PegIntron pen (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling.
1816683|NCT00705107|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
1816684|NCT00705120|Other|Bone Marrow Cell Transplantation|
1816685|NCT00705120|Radiation|Irradiation, Total Body|
1816686|NCT00705120|Drug|Cyclophosphamide|
1816687|NCT00705120|Drug|Cyclosporin|
1816688|NCT00705120|Procedure|Mesenchymal Stem Cell Transplantation|
1816689|NCT00705120|Drug|Busulfan|
1816690|NCT00705133|Drug|treprostinil|For both SQ and IV routes, treprostinil will be started in the hospital at 1ng/kg/min and titrated up by 1ng/kg/min per day initially as tolerated and then increased by 0.5ng/kg/min every 2 days as an outpatient. The maximum dose at 3 months will be 40ng/kg/min
1816691|NCT00705146|Device|Comfort Cool thumb splint by North Coast Medical|Comfort Cool(TM) splint, a prefabricated neoprene splint, fit according to the participant's size (S, M, M+, L). Participants instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Used for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
1816692|NCT00705146|Device|Custom made thermoplastic & neoprene splint|The Hybrid splint was based on Pat McKee's custom-made splint design, fabricated from neoprene and 1.6 mm Rolyan Aquaplast Watercolors (Bollingbrook, IL). Participants were instructed to wear the splint when symptomatic, during manual tasks, and at night if desired. Splint was worn for 4 weeks. Treating therapists did not provide exercises or joint protection education until the final outcome measurement session at 9 weeks.
1816693|NCT00705159|Drug|loteprednol etabonate and tobramycin|Topical ocular administration of loteprednol etabonate and tobramycin 4 times per day (QID) for 14 days.
1816694|NCT00705159|Drug|loteprednol etabonate|Topical ocular administration of Lotemax (loteprednol etabonate) QID for 14 days.
1816695|NCT00705159|Drug|Tobramycin|Topical ocular administration of Tobramycin QID for 14 days.
1816696|NCT00705159|Drug|Vehicle of Zylet|Topical ocular administration of the vehicle of Zylet QID for 14 days.
1816697|NCT00705172|Drug|somatropin|Prader-Willi syndrome children treated with at least one dose of Norditropin®
1816698|NCT00705198|Drug|Temozolomide (for newly diagnosed malignant glioma)|"Temozolomide treatment for newly diagnosed malignant glioma. The usual dose for adults in combination with radiotherapy is 75 mg/m2 orally once daily for 42 consecutive days. After a 4 week rest period, monotherapy at 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle is administered. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.
Temozolomide is administered as 20 mg and 100 mg capsules."
1816699|NCT00705198|Drug|Temozolomide (for relapsed malignant glioma)|"Temozolomide treatment for relapsed malignant glioma. The usual dose for adults is 150 mg/m2 orally once daily for 5 consecutive days per 28 day treatment cycle. The dose may be increased to 200 mg/m2 for the next 28 day treatment cycle.
Temozolomide is administered as 20 mg and 100 mg capsules."
1816700|NCT00705198|Radiation|Radiotherapy (for patients with newly diagnosed malignant glioma)|Although the study protocol does not clearly define how long this intervention is applied, radiotherapy is generally administered 5 days/week for 6 weeks to patients with newly diagnosed malignant glioma.
1816701|NCT00705211|Drug|Ezetimibe|Ezetimibe, 10-mg tablets,
1816702|NCT00705211|Drug|Ezetimibe + other lipid-lowering medication(s)|Ezetimibe, 10-mg tablets, other lipid-lowering medication(s) as prescribed by attending physician
1816703|NCT00705224|Biological|Pegylated Interferon|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.
The treatment course duration complied with the labeled dosage regimen. Each dose of pegylated interferon was administered as a subcutaneous
injection calculated as 1.5 mcg/kg once a week. Therapy duration varied from 24 to 48 weeks depending on Hepatitis C virus (HCV) genotype, viral load, activity and stage of hepatitis C.
The Sponsor did not provide formal drug supply."
1816704|NCT00705224|Drug|Ribavirin|"Routine treatment with a combination of any pegylated interferon and ribavirin was used according to the label/local practice in Russia.
The treatment course duration complied with the labeled dosage regimen. Ribavirin was taken orally as 200 mg gelatinous capsules. The daily dose varied from 800 to 1200 mg (depending on patient's body weight) twice daily in the
morning and in the evening with meal. Therapy duration varied from 24 to 48 weeks depending on HCV genotype, viral load, activity and stage of hepatitis C.
The Sponsor did not provide formal drug supply."
1816705|NCT00705237|Procedure|Functional Endoscopic Sinus Surgery with Balloon Dilatation|Luma lightwire technology will be utilized in conjunction with fluoroscopy for patients with sinusitis undergoing functional endoscopic sinus surgery with balloon dilatation. Trans-illumination of the sinus will be compared to fluoroscopy for accuracy
1816791|NCT00699036|Drug|avandia|4 mg twice daily
1816792|NCT00699036|Drug|metformin|500 mg twice daily for 48 weeks
1816706|NCT00705250|Drug|bendamustine hcl|Patients will receive bendamustine 120mg/m^2, administered as a 30-minute infusion, for two consecutive days. Cycles will be repeated every four weeks and a total of 6 cycles will be planned. Patients will receive pegfilgrastim with each cycle. Treatment will be delayed until the absolute neutrophil count is > 1000/ul and the platelet count is > 75,000/ul.
1816707|NCT00705263|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
1816708|NCT00705263|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
1816709|NCT00705276|Drug|Lactic acid (Dermacyd Femina Delicata)|
1816710|NCT00705289|Biological|Infliximab|Infliximab used in line with current clinical practice and local guidelines.
1816711|NCT00705302|Behavioral|Group training with self-help group|Combined educational and exercise program for pulmonary rehabilitation, with (1) or without(2 a self-help group. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group. Patients will instead of five of the group training sessions, participate in a self-help group.
1816712|NCT00705302|Behavioral|Group training|Combined educational and exercise program for pulmonary rehabilitation. The educational part consists firstly of two days with group meetings with information from medical doctor, pharmacist, psychologist, ergonomist, nurse, social worker, physiotherapist and a clinical nutritional physiologist. One more day will be held after 3 months and it is the participants themselves who decide on the content of these days. An experienced patient will participate throughout the course. The exercise part consists of group training twice a week for 3 months with 10-15 participants in each group.
1816713|NCT00705315|Drug|Docetaxel|Docetaxel as an IV infusion over 1h at the dose of 75mg/m2 every 3 weeks for 6 cycles
1816714|NCT00705315|Drug|Epirubicin|Epirubicin as an IV infusion over 10 min at the dose of 75mg/m2 every 3 weeks for 6 cycles
1816715|NCT00705315|Drug|Bevacizumab|Bevacizumab as an IV infusion over 1h at the dose of 15 mg/kg every 3 weeks for 6 cycles
1816716|NCT00705328|Behavioral|Primary Health Care Model (PRMHLTH)|Primary health care service delivery
1816717|NCT00705328|Behavioral|Recreation Coordination Model (REC)|Recreation coordination service delivery
1816718|NCT00705328|Behavioral|Comprehensive Model (COMP)|a comprehensive service delivery model consisting of PRMHLTH plus REC.
1816719|NCT00705341|Drug|fluticasone|Inhaled corticosteroid approved for treatment of asthma
1816720|NCT00705354|Drug|Bacitracin|Nasopore sponge soaked with Bacitracin, placed in middle meatus of the nose. No post-op oral antibiotics
1816721|NCT00705354|Procedure|Nasopore sponge soaked with saline|Nasopore sponge soaked with saline placed during surgery and will receive routine oral antibiotics post-operatively
1816722|NCT00705367|Drug|Placebo|Infusion, Intravenous, single dose, Day 1
1816723|NCT00705367|Drug|Abatacept|Infusion, Intravenous, 30mg/kg, single dose, Day 1
1816724|NCT00705367|Drug|Abatacept|Infusion, intravenous, 10 mg/kg, administered on Days 15 and 29 followed by doses every 4 weeks until the end of the study
1816725|NCT00705380|Behavioral|Cognitive behavioral therapy (CBT) with panic control treatment (PCT) for adolescents|CBT with PCT treatment will consist of 11 weekly sessions that are designed to be developmentally appropriate for a younger population. The primary aim of this treatment will be to directly influence three aspects of panic attacks and general anxiety: the cognitive/misinterpretational aspect, the hyperventilatory response, and the conditioned reactions to physical sensations. Throughout treatment, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks.
1816726|NCT00705380|Behavioral|Waitlist control|During the 12-week waitlist period, participants will keep daily records of their anxiety and will complete self-monitoring forms to monitor panic attacks. Participants will also meet with a therapist every other week to discuss the nature of any panic attacks or address any concerns.
1816727|NCT00705406|Drug|Peramivir|600 mg peramivir administered as bilateral 2-mL intramuscular injection
1816728|NCT00705406|Drug|Placebo|Placebo (buffered diluent) administered as bilateral 2-mL intramuscular injection.
1816729|NCT00705419|Drug|Vicriviroc maleate|Follow-up for subjects who previously received 30 mg tablet administered once daily according to the parent protocol.
1816730|NCT00705419|Drug|Vicriviroc maleate|Follow-up for subjects who previously received 20 mg tablet administered once daily according to the parent protocol.
1816731|NCT00705419|Drug|Placebo|Follow-up for subjects who previously received placebo tablet administered once daily according to the parent protocol.
1816732|NCT00705419|Drug|Emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg|Follow-up for subjects who previously received active control consisting of emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg combination tablet administered once daily according to the parent protocol.
1816733|NCT00698646|Drug|Valsartan + HCTZ|At week 0 patients received V+HCTZ 160+12.5 mg capsules. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 320+12.5 mg at week 4 and if needed to V+HCTZ 320+25 mg at week 8 or 12.
1816734|NCT00698646|Drug|Valsartan|At week 0 patients received Valsartan(V) 160 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
1816735|NCT00698646|Drug|HCTZ|At week 0 patients received HCTZ 12.5 mg capsule. Subjects not at BP goal <140/90 mmHg were uptitrated to V+HCTZ 160+12.5 mg at week 4 and if needed to V+HCTZ 320+12.5 mg at week 8, and V+HCTZ 320+25 mg at week 12.
1816736|NCT00698672|Device|charnley OGEE|charnley OGEE
1816737|NCT00698672|Device|Spectron Reflection CoCr|Spectron Reflection CoCr
1816738|NCT00698672|Device|Spectron XLPE CoCr|Spectron XLPE CoCr
1816739|NCT00698672|Device|Spectron Reflection Oxinium|Spectron Reflection Oxinium
1816740|NCT00698672|Device|Spectron XLPE CoCR|Spectron XLPE CoCR
1816741|NCT00698685|Drug|Pentostatin|Days - 8 through -6: pentostatin 4 mg/m2/24 hr as a continuous intravenous infusion (CIVI) (total cumulative dose, 12 mg/m2 over 3 days)
1816793|NCT00699036|Drug|losartan|losartan 50 mg once daily
1816744|NCT00698711|Biological|MUC-2-KLH|"The MUC-2-KLH conjugate will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4 week break and then a fourth vaccination during week 7, and 3 months later during week 19. Booster vaccinations may be given at or after week 50 and 100, and every 6 months thereafter to select patients who show no evidence of radiographic disease progression.
After 5 patients have been enrolled and completed two vaccinations without Grade II or greater toxicity, we will proceed to the next higher dose level. No dose escalations will be performed in the same patient."
1816745|NCT00698724|Drug|Xibrom, and Optive|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Optive: three times a day for 21 days after surgery.
1816746|NCT00698724|Drug|Xibrom and Pred Forte|Xibrom: two drops a day, three days before surgery and 21 days after surgery. Pred Forte: three times a day for 21 days after surgery.
1816747|NCT00698763|Drug|Levosimendan|from 0.125 mg to 2 mg in escalating doses
1816748|NCT00698763|Drug|Placebo|Placebo capsules are identical in appearance to active capsules
1816749|NCT00698776|Drug|Lenalidomide|10 mg/day in cohort 1, and 25 mg/day in cohort 2. LEN is administered orally in standard 21 day cycles starting one week before each DC injection and ending 14 days after each DC injection. All patients will receive a total of three cycles of LEN.
1816750|NCT00698776|Biological|Monocyte derived DCs loaded with KRN7000|10 million DCs injected intravenously
1816751|NCT00698789|Drug|INCB019602|5 mg of INCB019602 in AM with placebo administration in PM
1816752|NCT00698789|Drug|INCB019602|20 mg in AM with placebo administration in PM
1816753|NCT00698789|Drug|INCB019602|5 mg in PM with placebo administration in AM
1816754|NCT00698789|Drug|INCB019602|20 mg in PM with placebo administration in AM
1816755|NCT00698789|Drug|INCB019602|7.5 mg in PM QoD with placebo administration in AM as well as PM on non-active dose days
1816756|NCT00698789|Drug|Placebo|Placebo administration in AM or PM depending on treatment arm dosing regimen.
1816757|NCT00698789|Drug|Metformin|Stable dose metformin monotherapy
1816758|NCT00698802|Drug|EX1000|Treat-to-target titration scheme, s.c. injection
1816759|NCT00698802|Drug|biphasic human insulin|Treat-to-target titration scheme, s.c. injection
1816760|NCT00698815|Other|Laboratory Biomarker Analysis|Correlative studies
1816761|NCT00698815|Drug|Pemetrexed Disodium|Given IV
1816762|NCT00698815|Drug|Sunitinib Malate|Given PO
1816763|NCT00698828|Drug|Placebo comparator|Twice daily subcutaneous injections of placebo for 12 weeks.
1816764|NCT00698828|Drug|SUN11031|Twice daily subcutaneous injections of SUN11031 for 12 weeks.
1816765|NCT00698841|Drug|Cetuximab|Cetuximab administered by intravenous (IV) infusion at an initial dose of 400 mg/m^2 over 120 minutes on Day 1 followed by a weekly maintenance IV dose of 250 mg/m^2 over 60 minutes.
1816766|NCT00698854|Device|Vanguard™ Complete Knee System|Primary Total Knee System, Cruciate-Retaining (CR) or Posterior-Stabilized (PS)
1816767|NCT00698854|Device|Vanguard™ Patient-Specific Femur|Primary Total Knee System used with Signature technique to provide a patient-specific femur
1816768|NCT00698880|Procedure|Right hepatic vein embolization|Embolization of the right hepatic vein
1816769|NCT00698893|Biological|Herpes simplex candidate (gD) vaccine GSK208141|Intramuscular injection, 2 doses, 2 different formulations (with and without MPL)
1816770|NCT00698906|Biological|HBV-MPL vaccine|5 different formulations, 2-dose intramuscular injection
1816771|NCT00698906|Biological|Engerix™-B|3-dose intramuscular injection
1816772|NCT00698919|Other|Observational study|"This is not an interventional studies. We will just compare two methods of bacterial diagnosis. Of note the physicians will care of their patients with the classic bacterial analysis tools; so there is no modification of the care.
The new techniques used (DNA detection) will done later on and thus won't modify their decision."
1816773|NCT00698932|Drug|Saxagliptin|5mg, oral tablet, once daily for 24 weeks
1816774|NCT00698932|Drug|Placebo|oral tablet, once daily for 24 weeks
1816777|NCT00698958|Procedure|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days|Ambulatory adaptation to non- invasive mechanical ventilation for 7 days
1816778|NCT00698958|Procedure|Hospital based adaptation to non- invasive mechanical ventilation for 7 days|Hospital based adaptation to non- invasive mechanical ventilation for 7 days
1816779|NCT00698984|Dietary Supplement|BONISTEIN(R) bone blend|2 Capsules per day over a period of 6 months
1816780|NCT00698984|Dietary Supplement|Placebo|2 capsules per day over a period of 6 months
1816781|NCT00698997|Behavioral|Early Start Denver Model|"Phase 1 of ESDM intervention: 12 weekly, 1 to 1.5 hr. sessions focused on teaching & coaching parents to use the ESDM in all natural caretaking routines & play periods with their child. Parents are taught & coached on 1 aspect of the ESDM each week in the clinic session, & then practice it at home daily in natural family routines & play.
Phase 2: each child in the ESDM will receive 25 hrs. a week of ESDM intervention in their homes, 50 wks. a year, for 2 years. 20 hrs. weekly will be delivered by trained interventionists (ITs); 5 hrs. weekly will be delivered by parents. (ITs) will provide ten 2 hour teaching episodes involving play activities per week in the home. Parents will continue to deliver the ESDM in natural family routines & play activities. In addition, each child will receive additional services through public services, or other therapies that the parents may choose, for several more hrs. per week."
1816782|NCT00698997|Behavioral|Standard community care|Treatment and interventions, chosen by families, meeting current standards of community intervention for toddlers with autism and ASD
1816783|NCT00699010|Drug|Niacin|Niacin 240 mg every 48 hours
1816784|NCT00699010|Drug|Oxycodone HCL plus Niacin|Oxycodone HCL 40 mg plus Niacin 240 mg every 48 hours
1816785|NCT00699010|Drug|Placebo|Placebo every 48 hours
1816786|NCT00699010|Drug|Oxycodone HCL plus Niacin|Oxycodone HCl 40 mg plus Niacin 240 mg every 48 hours
1816787|NCT00699010|Drug|Oxycodone HCl|Oxycodone HCl 40 mg every 48 hours
1816788|NCT00699023|Drug|ezetimibe tablets|ezetimibe tablets 10 mg/die
1816789|NCT00699023|Drug|simvastatin tablets|simvastatin tablets 20 mg/die
1816790|NCT00699023|Drug|placebo|placebo
1816797|NCT00699062|Drug|singular|The participants randomized into this arm will receive singular 10mg q.n. plus combine therapy with inhaled ICS+LABA
1816798|NCT00699062|Drug|placebo|The participants allocated into this arm will receive placebo 10mg,q.n plus combine therapy with inhaled ICS+LABA
1816799|NCT00699101|Device|Conture Multi-Lumen Balloon|Placement of the balloon in a separate procedure using ultrasound guidance after surgery for breast cancer.
1816800|NCT00699114|Drug|Placebo|Lactose as powder in gelatine capsules, single dose
1816801|NCT00699114|Drug|Ibuprofen 400 mg|Ibuprofen 400 mg as powder in gelatine capsules, single dose
1816802|NCT00699114|Drug|Ibuprofen 600 mg|Ibuprofen 600 mg as powder in gelatine capsules, single dose
1816803|NCT00699114|Drug|Ibuprofen 800 mg|Ibuprofen 800 mg as powder in gelatine capsules, single dose
1816804|NCT00699114|Drug|Paracetamol (acetaminophen) 500 mg|Paracetamol (acetaminophen) 500 mg as powder in gelatine capsules, single dose
1816805|NCT00699114|Drug|Paracetamol (acetaminophen) 1000 mg|Paracetamol (acetaminophen) 1000 mg as powder in gelatine capsules, single dose
1816806|NCT00699114|Drug|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg|Paracetamol (acetaminophen) 1000 mg + codeine 60 mg as powder in gelatine capsules, single dose
1816807|NCT00699127|Behavioral|Lecture|Lecture of information regarding prematurity, NICU hospitalization, etc.
1816808|NCT00699140|Biological|IGIV3I Grifols|Immune Globulin Intravenous (Human)
1816809|NCT00699153|Drug|Loteprednol Etabonate|Loteprednol Etabonate in an ophthalmic base will be administered to study eye 4 times a day(QID) for 14 days.
1816810|NCT00699153|Drug|Vehicle of Ophthalmic Loteprednol Etabonate|Vehicle of ophthalmic loteprednol etabonate administered postoperatively to study eye 4 times a day(QID) for 14 days.
1816811|NCT00699166|Drug|DNK333|25 mg and 100 mg oral doses, each taken twice daily
1816812|NCT00699179|Drug|biphasic insulin aspart 30|There is no intervention in this trial. The trial is prepared to be non-interventional one. Start dose and frequency to prescribed by the physician as a result of a normal clinical evaluation.
1816813|NCT00699192|Drug|Amlodipine 5 mg|1 capsule amlodipine 5 mg orally once daily
1816814|NCT00699192|Drug|Valsartan 80 mg|1 capsule valsartan 80 mg orally once daily
1816815|NCT00699192|Drug|Valsartan 40 mg|1 capsule valsartan 40 mg orally once daily
1816816|NCT00699192|Drug|Placebo|1 capsule placebo to match valsartan orally once daily
1816818|NCT00699231|Biological|HBV-MPL vaccine 208129|IM injection
1816819|NCT00699231|Biological|Engerix™-B|IM injection
1816820|NCT00699244|Procedure|Peripheral placement of local anesthesia|Peripheral placement of local anesthesia
1816821|NCT00699244|Procedure|Central placement of local anesthesia|Central placement of local anesthesia
1816822|NCT00699283|Drug|Brivaracetam|25 mg tablet - 50 mg daily for 17 weeks (or 21 weeks if down-titrated (50 mg > 20 mg) for subjects not participating in the follow-up study)
1816823|NCT00699283|Drug|Brivaracetam|25 mg tablet - 100 mg daily for 17 weeks (or 21 weeks if down-titrated (100 mg > 50 mg > 20 mg) for subjects not participating in the follow-up study)
1816824|NCT00699296|Drug|Panobinostat (LBH589)|20mg/day p.o. on three times-a- week
1816827|NCT00699335|Drug|Fentanyl|Fentanyl transdermal patch. This was an observational study - therefore, the physician decided about dosage according to individual needs
1816828|NCT00699348|Drug|Methoxy polyethylene glycol-epoetin beta (C.E.R.A.)|Intravenous methoxy polyethylene glycol-epoetin beta (C.E.R.A.) at starting dose of 120, 200, or 360 micrograms every 4 weeks for 24 weeks.
1816829|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg I.V.
1816830|NCT00699361|Drug|Pantoprazole|Pantoprazole 160 mg intravenously (IV)
1816831|NCT00699374|Drug|sunitinib malate|sunitinib capsules at starting dose of 37.5 mg PO daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sunitinib dosing interruptions and/or reductions are allowed based on patient tolerability.
1816832|NCT00699374|Drug|sorafenib|sorafenib tablets at starting dose of 400 mg PO twice daily, until disease progression, occurrence of unacceptable toxicity, or other withdrawal criteria are met. Sorafenib dosing interruptions and/or reductions are allowed based on patient tolerability.
1816833|NCT00699387|Drug|Benznidazole|benznidazole (RADANIL®, Roche) 5-8 mg/kg/d bid PO for 60 days
1816834|NCT00699413|Drug|nutrition education plus active supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.
Active and inactive supplements will be identical in appearance and taste. Active supplements will contain 2,700 mgs/day of Super CitriMax (hydroxycitrate)and 400 µg per day of ChromeMate (niacin-bound Chromium). Supplements will be in powder and tablet form, and should be taken 30 minutes prior to each meal."
1816835|NCT00699413|Drug|nutrition education plus inactive supplement|"After all baseline measures have been completed, participants will be randomly assigned to either the nutrition education + supplement group, or the nutrition education + placebo group. The length of the intervention is twelve weeks. Nutrition classes will take place once a week for 1 1/2 hours. Subjects will be encouraged to increase fiber and decrease sugar intake. They will also be separated into gender-specific classes.
Active and inactive supplements will be identical in appearance and taste."
1816836|NCT00699426|Drug|nexium|40 mg once daily is tested together with Yoghurt
1816837|NCT00699426|Drug|nexium|nexium and placebo are tested
1816838|NCT00699426|Dietary Supplement|Yoghurt|Yoghurt
1816839|NCT00699426|Drug|placebo+placebo|placebo and placebo are tested.
1816840|NCT00699439|Other|Paper-based asthma flow diagram|If a patient is identified as having an asthma exacerbation by the Bayesian Network, the patients will be randomized to either arm A or B. If in A, the paper-based flow-chart will be printed out to place on the chart.
1817171|NCT00709800|Biological|VCL-IPT1|IM, 0.1 mg/mL, 2 injections, 0 and 21 days
1816841|NCT00699452|Drug|candesartan|Candesartan 8 mg/d for two weeks, then 16 mg/d until valve replacement surgery (approximately 3 months)
1816842|NCT00699452|Drug|placebo|placebo
1816843|NCT00699465|Drug|enoxaparin|20 mg enoxaparin (2 000 IU) s.c. will be given twice daily starting 24-48 h after onset of the stroke. Intermittent pneumatic compression will be started immediately after admission.
1816844|NCT00699465|Drug|enoxaparin placebo|Placebo will be given s.c. twice daily starting 24-48 h after onset of the stroke for 2 days. Thereafter, 20 mg enoxaparin (2 000 IU) s.c. will be given twice daily. Intermittent pneumatic compression will be started immediately after admission.
1816845|NCT00699478|Drug|mecobalamin|Methycobal Tab 0.5mg (contains 0.5 mg mecobalamin) for 3 times a day (Q8hrs) for three months
1816846|NCT00699491|Biological|cixutumumab|Given IV
1816847|NCT00699491|Drug|temsirolimus|Given IV
1816848|NCT00699491|Other|laboratory biomarker analysis|Correlative studies
1816854|NCT00699517|Drug|OMBRABULIN (AVE8062)|I.V. infusion followed by administration of cisplatin
1816855|NCT00699517|Drug|Placebo|I.V. infusion followed by administration of cisplatin
1816856|NCT00699530|Other|Cabergoline|Cabergoline 0,25 - 1,0 mg once a week, controlled by our outpatient clinic. The drug regimen is not influenced by participating in this study.
1816857|NCT00699543|Device|Coroflex Please stent implantation|Use Coroflex Please stent in the treatment of coronary stenosis
1816858|NCT00699543|Device|Taxus stent implantation|Use Taxus stent in the treatment of coronary stenosis
1816859|NCT00699556|Drug|21mg transdermal nicotine patch (Nicoderm CQ)|21mg transdermal nicotine patch
1816860|NCT00699556|Drug|1mg nicotine nasal spray|two 0.5mg/sprays, one to each nostril (dose = 1mg) The nicotine nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital. It is similar in concentration to Nicotrol.
1816861|NCT00699556|Drug|placebo nasal spray|saline combined with capsaicin to mimic the brief nasal irritation from active nicotine spray The placebo nasal spray is formulated by the Investigational Drug Service at Yale-New Haven Hospital.
1816862|NCT00699569|Dietary Supplement|hyperimmune colostrum|hyperimmune colostrum
1816863|NCT00699569|Dietary Supplement|Placebo|
1816864|NCT00699582|Drug|E2007 (perampanel)|8 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
1816865|NCT00699582|Drug|E2007 (perampanel)|12 mg perampanel in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study and will be up-titrated weekly in 2-mg increments to their randomized dose.
1816866|NCT00699582|Drug|Placebo|Placebo in a 1:1:1 ratio, 125 subjects/arm. All subjects will take a maximum of 6 tablets daily for the duration of the study.
1816867|NCT00699608|Drug|GSK1755165; placebo; zopiclone|Subjects receive either 3mg GSK1755165, matching placebo or 7.5mg zopiclone
1816868|NCT00699621|Biological|platelets|Four units of fresh platelets will be infused immediately
1816869|NCT00699634|Drug|Nabilone|Nabilone 0.5 mg at hs for 1 week, then 0.5 mg BID for 1 week. After a reassessment of the outcome measures, the dose is increased to 0.5 mg in the morning and 1 mg at hs for 1 week, followed by an increase to 1 mg BID in the last week of the study.
1816870|NCT00699660|Behavioral|CAPS/WHODAS|CAPS/WHODAS structured clinical PTSD interview
1816871|NCT00699660|Behavioral|Nonstructured Interview|Usual PTSD clinical PTSD interview, not CAPS or SCID
1816872|NCT00699686|Drug|Glargine|Daily bedtime subcutaneous insulin Glargine in individualized doses.
1816873|NCT00699686|Drug|Detemir|Daily bedtime subcutaneous insulin Detemir in individualized doses.
1816874|NCT00699712|Drug|CD-NP (Chimeric natriuretic peptide)|Infusion of CDNP at two of four doses
1816875|NCT00699738|Behavioral|Breastfeeding|Breastfeeding
1816876|NCT00699738|Behavioral|Bottlefeeding|Bottlefeeding
1816877|NCT00699751|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Radium-223 dichloride 50 kBq/kg b.w., 6 IV administrations separated by 4 weeks intervals.
1816878|NCT00699751|Drug|Placebo|Isotonic saline 6 IV administrations separated by 4 weeks intervals.
1816879|NCT00699751|Drug|Best standard of care (BSoC)|Best standard of care is regarded as the routine standard of care at each center, for example local EBRT (External Beam Radiation Therapy), corticosteroids, antiandrogens, estrogens (e.g., stilboestrol), estramustine or ketoconazole.
1816880|NCT00699764|Biological|Herpes simplex candidate vaccine- adjuvanted GSK208141|Intramuscular injection, 3 doses
1816881|NCT00699764|Biological|Placebo injection|Intramuscular injection, 3 doses
1816882|NCT00699777|Drug|Risedronate|1 risedronate 150 mg tablet administered orally
1816883|NCT00699777|Drug|Risedronate|2 risedronate 75 mg tablets administered as a single oral dose
1816884|NCT00699790|Drug|CCR2 Antagonist|Tablets, Oral, 50 mg, once daily, 12 weeks
1816885|NCT00699790|Drug|Placebo|Tablets, Oral, 0mg, once daily, 12 weeks
1816886|NCT00705432|Biological|Peginterferon alfa-2b (PEG)|Peginterferon alfa-2b 1.5 μg/kg/week subcutaneously (SC)
1816887|NCT00705432|Drug|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day administered orally, divided twice daily (BID).
1816888|NCT00705432|Drug|Placebo|Placebo to boceprevir, 800 mg (4 x 200mg capsules) administered orally three times a day (TID).
1816889|NCT00705432|Drug|Boceprevir|Boceprevir, 800 mg (4 x 200 mg capsules) administered orally TID.
1816890|NCT00705445|Dietary Supplement|Micronutrient Supplementation without Zinc|This will contain Micronutrient Supplements containing Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D and Folic Acid
1816891|NCT00705445|Dietary Supplement|Micronutrient Supplementation with Zinc|This will contain Microencapsulated Iron, Vitamin C, Vitamin A, Vitamin D, and Folic Acid. Additionally, this will also contain 10 mg elemental Zinc Sulphate.
1816892|NCT00705445|Other|Nutritional Counselling and Education|This will contain Nutritional Counselling and Education.
1816893|NCT00705458|Procedure|Coronary Computed Tomography Angiography|64-detector, retrospectively EKG-gated, computed tomography angiography of the coronary arteries during heart rate control (intravenous metoprolol, when necessary)
1816894|NCT00705458|Procedure|Stress Nuclear Myocardial Perfusion Imaging|Usually dual-isotope perfusion imaging at rest (201-Thallium) and at stress (99m-Technetium-MIBI). Some patients will have a 2-day MIBI protocol. Gated SPECT and attenuation-correction images will be obtained. Treadmill stress will be performed. If a patient is unable to exercise, adenosine or dobutamine will be given.
1816895|NCT00705471|Biological|Infliximab|None available in the protocol. This was a chart review study, therefore no Infliximab provided during the study.
1958422|NCT01660451|Drug|Copanlisib (BAY80-6946)|"BAY 80-6946 is administered in a normal saline solution, 100 mL, intravenously over 1h. No intravenous glucose preparations should be administered on the days of infusion. Dosing is weekly for the first 3 weeks (on Days 1, 8, and 15) of a 28-day cycle, followed by a 1-week break (i.e., no infusion on Day 22).
Part A: The individual dose will be 0.8 mg/kg (max. 65 mg) per infusion from Cycle 1 on. The maximum dose of 65 mg should never be exceeded.
Part B: The individual dose will be 60 mg per infusion from Cycle 1 on."
1816899|NCT00705497|Procedure|Radiofrequency Tumor Ablation|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
1816900|NCT00705510|Drug|0.05% cyclosporin eye drop|use the medication twice daily for 3 months
1816901|NCT00705523|Drug|varenicline|1.0 mg BID for 12 weeks
1816902|NCT00705523|Drug|placebo|BID 12 weeks
1816903|NCT00705536|Drug|Humalog|
1816904|NCT00705536|Drug|Humulin-R|
1816905|NCT00705536|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
1816906|NCT00705549|Drug|Gemcitabine|Gemcitabine I.V at the dose of 1000mg/m2 on Day 1 and Day 8
1816907|NCT00705549|Drug|Cisplatin|Cisplatin I.V at the dose of 75mg/m2 on Day 1
1816908|NCT00705549|Drug|Docetaxel|Docetaxel I.V at the dose of 75mg/m2 on Day 1
1816909|NCT00705549|Drug|Cisplatin|Cisplatin I.V at the dose of 80mg/m2 on Day 1
1816910|NCT00705549|Drug|Vinorelbine|Vinorelbine per os 50mg every Monday, Wednesday and Friday
1816911|NCT00705549|Drug|Pemetrexate|Pemetrexate I.V 500mg/m2 on Day 1
1816912|NCT00705562|Other|milk protein formulas, varying carbohydrate/protein sources|ad lib for 0-8 days of age until 28 days of age
1816913|NCT00705575|Drug|Aliskiren/hydrochlorothiazide (HCTZ) (300/25 mg)|During the titration period, patients received aliskiren/hydrochlorothiazide (HCTZ) 150/12.5 mg for 1 week.
1816914|NCT00705575|Drug|Aliskiren (300 mg)|During the titration period, patients received aliskiren 150 mg for one week. Subsequently, patients were up-titrated and received aliskiren 300 mg.
1816915|NCT00705588|Drug|Tadalafil|Orally, titrated to maximum 20mg od
1816916|NCT00705588|Drug|Vardenafil|Orally, titrated to 10 mg bid
1816917|NCT00705601|Procedure|PSG|PSG (polysomnography) for adaptation night, day 2 evening, and day 3 evening--used to identify suitable Nonrestorative Sleep candidates to participate in focus groups.
1816918|NCT00705614|Biological|Remicade|The treating physician will determine the treatment regimen and dose of Remicade.
1816919|NCT00705627|Drug|neoadjuvant chemotherapy plus concurrent chemoradiotherapy|Drug: cisplatin,fluorouracil. Patients received cisplatin 80mg/m2 on day 1,fluorouracil 4000mg/m2 civ 120 hours every three weeks for two cycles, then received radical radiotherapy, and cisplatin (80mg/m2 on day 1) every three weeks for three cycles during RT.
1816920|NCT00705640|Biological|incomplete Freund's adjuvant|Given subcutaneously and intradermally
1816921|NCT00705640|Biological|multi-epitope melanoma peptide vaccine|Given subcutaneously and intradermally
1816922|NCT00705640|Biological|tetanus toxoid helper peptide|Given subcutaneously and intradermally
1816923|NCT00705640|Procedure|biopsy|Patients undergo surgical biopsy at replicate vaccine site
1816924|NCT00705653|Drug|PG-11047|PG-11047 will be administered as a 60-minute intravenous infusion on days 1, 8 and 15 of each 28 day cycle. A treatment cycle will be defined as 4 weeks of therapy. The planned minimum treatment schedule is 2 cycles of PG-11047 treatment (8 weeks).
1816925|NCT00705666|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
1816926|NCT00705666|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b as monotherapy or in combination with ribavirin will be administered according to the products' labeling.
1816927|NCT00705679|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tablet
1816928|NCT00705679|Drug|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet
1816929|NCT00705679|Drug|Tenofovir disoproxil fumarate|300 mg tablet
1816930|NCT00705679|Drug|Tenofovir disoproxil fumarate placebo|placebo tablet
1816931|NCT00705679|Drug|Tenofovir 1% vaginal gel|1 gm/100 ml of 1% gel
1816932|NCT00705679|Drug|Tenofovir placebo|placebo gel
1816933|NCT00705692|Drug|Levamisole|
1816934|NCT00705692|Drug|Placebo|
1816935|NCT00705705|Behavioral|Network leader training|Network leaders will receive a nine-session training segment designed to enable them to motivate their peer networks to reduce sexual risk. The sessions will teach the identified leader of each network how to communicate HIV prevention messages to other members of his or her personal social network. Leaders will be asked to share these messages with other members of their groups.
1816936|NCT00705705|Behavioral|Standard HIV risk-reduction counseling|Participants will undergo interviews about their friendship groups, sexual behavior, substance abuse, STD treatment history, condom use, and beliefs about HIV/AIDS. Participants will undergo a brief session about HIV/AIDS prevention methods after the first interview.
1816937|NCT00705718|Device|Endurant Stent Graft System|Abdominal Aortic Aneurysm Repair
1816938|NCT00705744|Drug|Lactic acid (Dermacyd Femina)|
1816939|NCT00705757|Drug|latanoprost|Xalatan/latanoprost 0.005% ophthalmic solution one drop qhs for one year
1816940|NCT00705757|Drug|bimatoprost|Lumigan/bimatoprost 0.03% ophthalmic solution one drop qhs for one year
1817611|NCT00714753|Radiation|image-guided radiation therapy|
1816941|NCT00705757|Drug|travoprost|Travatan/travoprost 0.004% ophthalmic solution one drop qhs for one year
1816942|NCT00708019|Behavioral|PRO-SELF PLUS Pain Management Program|The psychoeducational intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve cancer pain management. Patients in both groups will be seen in their homes over the course of 10 weeks with phone calls conducted in between the home visits. Patients in the HIGH-DOSE group will receive 6 visits and 10 phone calls [total time 12.3 hours]. Patients in the LOW-DOSE group will receive 4 visits and 6 phone calls [8.0 hours]. Follow-up visits to assess the sustainability of the intervention will be done at 2 weeks, 1 month and 3 months after the intervention. Both quantitative and qualitative analyses will be conducted to evaluate patient outcomes.
1816943|NCT00708032|Device|spectacles|habitual spectacles
1816944|NCT00708032|Device|narafilcon A soft contact lenses|narafilcon A daily disposable contact lenses
1816945|NCT00708045|Procedure|Imaging assessments|FDG-PET scans, functional MRI (fMRI) scans, Neuropsychological Testing
1816946|NCT00708071|Biological|Fibrin Sealant with 4 IU/ml Thrombin, Vapor-Heated, Solvent Detergent Treated Containing Synthetic Aprotinin (FS VH S/D 4)|Each subject received fibrin sealant with 4 IU/mL thrombin, vapor heated, solvent detergent treated containing synthetic aprotinin (FS VH S/D 4 ) to one side of the face. The dosing volume to be applied is 0.02 mL/cm2 to 0.04 mL/cm2. The study product will be applied to the subcutaneous plane in both the neck and the face area. The product will be applied using the spray device provided by the sponsor. (The other side of the face will be treated using standard of care.)
1816947|NCT00708084|Biological|CL184|CL184 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
1816948|NCT00708084|Biological|HRIG|HRIG 20 IU/kg intramuscularly on Day 0; in conjunction with rabies vaccine on Days 0, 3, 7, 14, and 28
1816952|NCT00708110|Drug|GSK1349572|GSK1349572 is an experimental drug being developed for the treatment of HIV. It is in the class of integrase inhibitors.
1816953|NCT00708110|Drug|Placebo|Placebo is a tablet with no drug in it.
1816956|NCT00708136|Behavioral|water based training program to improve balance|
1816957|NCT00708149|Drug|lansoprazole OD|arm 1: lansprazole 30 mg qd from NG route or orally for 14 days
1816958|NCT00708149|Drug|placebo|takepron placebo
1816959|NCT00708162|Drug|Elvitegravir|Elvitegravir (EVG) tablet administered orally once daily with food
1816960|NCT00708162|Drug|Raltegravir|Raltegravir tablet administered orally twice daily according to prescribing information
1816961|NCT00708162|Drug|EVG placebo|Placebo to match elvitegravir administered orally once daily
1816962|NCT00708162|Drug|RAL placebo|RAL placebo administered orally twice daily.
1816963|NCT00708162|Drug|Background regimen|Background Regimen (administered according to prescribing information) contains 1 fully-active ritonavir-boosted protease inhibitor (PI/r) plus 1 or 2 additional agents. The ritonavir-boosted PIs include either ATV, darunavir, fosamprenavir, LPV (Kaletra®), or tipranavir; the additional agents include abacavir (ABC), Combivir® (lamivudine (LAM)/zidovudine (ZDV) coformulated), didanosine, emtricitabine (FTC), enfuvirtide, Epzicom® (ABC/LAM coformulated), etravirine, LAM, maraviroc, tenofovir disoproxil fumarate (TDF), Truvada®, (FTC/TDF coformulated), and/or ZDV.
1816964|NCT00708175|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for 4 weeks, then increased to Pioglitazone 45 mg, tablets, orally, once daily for up to 48 weeks.
1816965|NCT00708175|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to 52 weeks.
1816966|NCT00708188|Device|Multidetector raw CT|Multidetector raw CT
1816967|NCT00708201|Drug|Alvimopan|
1816968|NCT00708201|Drug|Placebo|
1816969|NCT00708214|Drug|BIBW 2992|BIBW 2992 at high and medium dosages
1816970|NCT00708214|Drug|BIBW 2992|BIBW 2992 at high and medium dosages
1816971|NCT00708214|Drug|Letrozole|Letrozole at standard dosage
1816972|NCT00708214|Drug|Letrozole|Letrozole at standard dosage
1816973|NCT00708227|Drug|fluticasone|Fluticasone propionate MDI(dose to be determined by patient's current treatment) for 2 weeks, followed by Advair(R)Diskus (same dose of fluticasone propionate) for 2 weeks; Ipratropium bromide MDI used for prn symptom relief
1816974|NCT00708227|Drug|Salmeterol|Fluticasone propionate MDI(dose to be determined by patient's current treatment) for 2 weeks, followed by Advair(R)Diskus (same dose of fluticasone propionate) for 2 weeks; Ipratropium bromide MDI used for prn symptom relief
1816975|NCT00708227|Drug|Ipratropium bromide|Fluticasone propionate MDI(dose to be determined by patient's current treatment) for 2 weeks, followed by Advair(R)Diskus (same dose of fluticasone propionate) for 2 weeks; Ipratropium bromide MDI used for prn symptom relief
1816976|NCT00708240|Drug|Escitalopram|Escitalopram will be provided in unit doses commercially available, with a starting dose, minimum effective dose, and maximum effective dose of 5 mg, 10 mg and 20 mg, respectively, given once daily.
1816977|NCT00708253|Device|Double-balloon procedure (DBE)|Double-balloon procedure (DBE): DBE is performed using the DBE T-type endoscope system (Fujinon Inc, Japan), as described in the literature. The DBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 8.5 mm and a flexible overtube with a length of 145 cm and an outer diameter of 12 mm. Latex balloons are attached to both the endoscope and the overtube. These balloons are inflated and deflated during insertion, as described elsewhere in detail (2,3).
1816978|NCT00708253|Device|Single-balloon procedure (SBE)|Single-balloon procedure (SBE): SBE is performed using the SBE endoscope system (SIF-Q180, Olympus Optical Co., Ltd., Tokyo, Japan). The SBE endoscope consist of a 200-cm long video endoscope with an outer diameter of 9.2 mm and a flexible overtube with a length of 140 cm and an outer diameter of 13.2 mm. One single balloon is attached to the the tip of the overtube. The insertion process follows the method used for DBE, but instead of inflation of the endoscope balloon, the tip of the endoscope is angulated at straightening
1816979|NCT00708266|Device|Openflow microperfusion catheter|Macro-perforated, double lumen catheter used to withdraw interstitial fluid samples from different tissues.
1857790|NCT01005758|Drug|prednisolone|
1816980|NCT00708266|Dietary Supplement|Intralipid 20%|"Lipid emulsion used in clinical practice as supplementary intravenous nutrition. 28 hours venous infusion during the treatment study visits."
1816981|NCT00708266|Other|0.9% Saline Solution|"0.9% sodium chloride solution, used in clinical practice for venous hydration. 28 hours infusion during the control study visits."
1816982|NCT00708279|Procedure|Osteopathic manipulation|Participant will be evaluated and treated for somatic dysfunction utilizing osteopathic manipulation once a week for 3 weeks, then once every 3 weeks for three more visits; a total of 6 interventions in 3 months.
1816983|NCT00708292|Drug|AUY922|
1816984|NCT00708292|Drug|Bortezomib|
1816985|NCT00708292|Drug|Dexamethasone|
1816988|NCT00708318|Drug|i.v. fentanyl and AeroLEF|"Period I: subjects received an intravenous dose of fentanyl (200 µg) (Treatment A).
Period II: subjects were randomly assigned to receive either 2 mL (Treatment B) or 3mL (Treatment C) of AeroLEF delivered by nebulization with an AeroEclipse BAN."
1816989|NCT00708331|Device|2 HEMA Hydrophilic Acrylic Intraocular Lens|2 HEMA Hydrophilic Acrylic Intraocular Lens implanted into the posterior capsule following cataract surgery for patient life duration.
1816990|NCT00708344|Drug|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Duration of treatment : 10 weeks
1816991|NCT00708344|Drug|Irbesartan - Hydrochlorothiazide|150/12.5 mg (1 tablet once daily) or 300/25 mg (1 tablet once daily) depending on the control of the blood pressure. Treatment duration : 10 weeks
1816992|NCT00708357|Drug|NG-monomethyl-L-arginine|intravenous administration, bolus over 5 minutes, dosage 6mg/kg
1816993|NCT00708370|Other|COACH|COACH Nurse will provide health tele-counselling to patients randomized to COACH arm fortnightly for 24 weeks.
1816994|NCT00708370|Other|No intervention for placebo|There will be no COACH health tele-counselling to patients randomized to Standard Care arm.
1816995|NCT00708383|Other|10% SSS embryo culture medium protein supplementation|10% SSS in addition to the 0.5% HSA already in the culture medium.
1816996|NCT00708383|Other|0.5% HSA embryo culture medium protein supplementation|0.5% HSA in the culture medium
1816997|NCT00708396|Drug|Escitalopram|First week; 10mg/d of Escitalopram Weeks 2-5; 20mg/d of Escitalopram After 4 weeks of 20mg treatment (2-5 weeks of the study) - if partial/no response according to YBOCS score and clinical judgment, the dose will be increased up to 30mg for 4 weeks (weeks 6-9) and in case of partial/ non response the dose will be increased up to 40 mg until the completion of the study (weeks 10-13).
1816998|NCT00708409|Procedure|Cardiac valve surgery|Different autograft implantation techniques.
1816999|NCT00708422|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
1817000|NCT00708422|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
1817001|NCT00708435|Biological|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body weight
1817002|NCT00708435|Biological|Fresh frozen plasma|Intravenous Infusion, dosage depending on baseline INR and body weight
1817003|NCT00708448|Radiation|PET Imaging|Patients will receive an FLT-PET scan, FDG-PET scan, a H215O-PET scan, and have a blood sample (15 cc, approximately 3 teaspoons) drawn for the genetic and protein studies. These studies will be done before patients begin taking erlotinib and bevacizumab.
1817004|NCT00708448|Drug|Erlotinib|150 mg/day
1817005|NCT00708448|Drug|Bevacizumab|15mg/kg q 21 days
1817006|NCT00708461|Behavioral|weight gain prevention|"Changes in the food environment that increase the availability of healthy foods and beverages, reduce food and beverage portion sizes, reduce prices on healthy food items, and increase prices on less healthy food items.
Changes in the activity environment that increase cues and incentives for walking at work and at home, using stairs, and to increase exposure of employees to information about active recreational opportunities at work and at home.
Changes to the environment to increase cues and incentives for regular weight monitoring by providing scales at convenient locations.
Changes in the informational environment that increase frequency of exposure of the employee population to accurate information about healthy food and activity choices."
1817007|NCT00708474|Device|OsseoFit™ Porous Tissue Matrix™|Bone void filler
1817008|NCT00708487|Other|Embryo incubator oxygen concentration|Two concentrations of oxygen are currently used to culture the embryos of infertile patients in commercial human IVF programs - 21% and 5%.
1817009|NCT00708500|Drug|Boceprevir (SCH 503034)|Boceprevir, 200 mg capsules, 800 mg TID PO
1817010|NCT00708500|Biological|Pegylated interferon alfa-2b (SCH 54031)|PEG2b 1.5 μg/kg/week subcutaneously (SC)
1817011|NCT00708500|Drug|Ribavirin (SCH 18908)|Ribavirin WBD 600 mg/day to 1400 mg/day by mouth (PO) divided twice daily (BID).
1817012|NCT00708500|Drug|Boceprevir placebo|Boceprevir placebo, 200 mg capsules, 800 mg three times daily (TID) PO.
1817013|NCT00708526|Other|standard of care for phase one anesthesia care|Patients received intravenous fentanyl at the discretion of the attending anesthesiologist. Anesthesia was induced with a remifentanil infusion, lidocaine, propofol, and rocuronium or succinylcholine at the anesthesiologist's discretion. Maintenance anesthesia was 6% end tidal desflurane with oxygen flows of 2 L/min (though clinicians could deviate from this at their discretion). Clinicians were directed to maintain blood pressure at ±20% of baseline. A baseline remifentanil infusion was used throughout each case, and both remifentanil and fentanyl were titrated at the anesthesiologist's discretion. Ventilation was adjusted to maintain an end tidal carbon dioxide concentration (EtCO2) of 35 mmHg. Ondansetron 4 mg was given prophylactically before the end of surgery.
1817014|NCT00708526|Device|Quick Emergence Device|The Quick Emergence Device is placed between the endotracheal tube and the anesthesia breathing circuit to enable hypercapnia when ventilation is increased. The end-tidal gas sampling line is connected between the device and the endotracheal tube connector. Minute ventilation is doubled and the EtCO2 is elevated to approximately 48 mmHg from the previous maintenance level of 35 mmHg.
1817016|NCT00708539|Drug|Progesterone|200 mg, vaginal, three times daily used in Denmark, 400 mg, vaginal, three times daily used in Sweden
1817020|NCT00708565|Drug|iloprost|Baseline echo measurements, cardiac output, pulse oximetry will be taken. Subjects will then be given one dose of inhaled iloprost. Post-inhalation, the measurements will be repeated at rest and with exercise.
1817021|NCT00708578|Drug|Glimepiride|Once a day before breakfast
1817022|NCT00708578|Drug|Metformin|After breakfast and supper
1817023|NCT00708578|Drug|Insulin Glargine|Injection in the morning
1817024|NCT00708591|Drug|Rapamycin|Oral Rapamycin once weekly at assigned dose in 4 week cycles. Dosing can continue until disease progression or severe side effects are seen.
1817025|NCT00708591|Drug|Ketoconazole|Twice daily (200mg each time) at the start of the second week of therapy for 4 consecutive days. Dosing continues every week after the second week of therapy.
1817026|NCT00708604|Procedure|Islet Transplantation|Islet Transplantation
1817027|NCT00708604|Biological|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
1817028|NCT00708630|Behavioral|Extended information on side effects|More detailed information on possible side effects of vaccine
1817029|NCT00708643|Device|Habitual Silicone Hydrogel Contact Lens|contact lens
1817030|NCT00708643|Device|narafilcon A|contact lens
1817031|NCT00708656|Drug|mesalazine (Asacol®)|800 mg tablets
1817032|NCT00708669|Device|TAXUS stent|Compared two kinds of stents:TAXUS stent, approved for commercialization in Japan(March 30th, 2007)
1817033|NCT00708669|Device|Cypher stent|CYPHER stent, approved for commercialization in Japan(March 25, 2004)
1817034|NCT00708682|Biological|13-valent pneumococcal conjugate vaccine|
1817035|NCT00708695|Behavioral|Nurse Home Visitation|Visits from nurses from mid-pregnancy to child age 2 years.
1817036|NCT00708708|Drug|etanercept (Enbrel®)|The patients will be treated in accordance with the requirements of the labeling of etanercept in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
1817037|NCT00708721|Drug|Clofarabine|Clofarabine is a rationally designed, second generation purine nucleoside analogue. Clofarabine was designed as a hybrid molecule to overcome the limitations and incorporate the best qualities of both fludarabine (F-ara-A) and cladribine (2-CdA, CdA) both of which are currently approved by various regulatory authorities for treatment of hematologic malignancies.
1817038|NCT00708734|Behavioral|functional exercise training|twice weekly group sessions for 5 weeks
1817039|NCT00708747|Drug|Albumin (5% serum-protein solution containing immunoglobulins)|5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
1817040|NCT00708747|Drug|Biseko|Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
1817041|NCT00708760|Behavioral|paper based training|read selected material, test skills learned in simulator lab
1817042|NCT00708760|Behavioral|web based training|read and view selected web based material, test skills learned in simulator lab
1817043|NCT00708773|Drug|Irinotecan|"90 minute IV infusion once every 3 weeks.
Dose will be based on sex and genotype determination."
1817044|NCT00708786|Device|ICD|Ventricular arrhythmia treatment
1817045|NCT00708786|Device|CRT-D|Ventricular arrhythmia treatment
1817046|NCT00708799|Other|Azithromycin on admission - not enrolled in the RCT|One dose of azithromycin prior to inclusion to the RCT
1817047|NCT00708812|Drug|Endostar(Recombinant Human Endostatin Injection)|Endostar 7.5mg/m2 on d8-d21 in each 21-day cycle
1817048|NCT00708812|Drug|paclitaxel-carboplatin|paclitaxel, 175mg/m2, iv, d1, q3w; carboplatin, AUC 5, iv, d1, q3w
1817049|NCT00708851|Other|LCD Solution with NB-UVB Phototherapy|"LCD Solution: 2 applications / day
NB-UVB Phototherapy: 3 light sessions / week"
1817050|NCT00708851|Device|NB-UVB Light Device (311-315 nm)|NB-UVB Phototherapy: 3 light exposures / week
1817051|NCT00708877|Procedure|Liver Transplantation|Transplantation will initially be performed with deceased donor livers using the technique of caval-sparing hepatectomy unless suspected caudate involvement or caudate atrophy is a concern regarding the resection margin. Patients will be assigned a provisional Model for End-Stage Liver Disease (MELD) score by the United Network for Organ Sharing (UNOS) Regional Review Board that will make a recipient eligible for transplantation within three months at the time of listing (typically 20-24). A segment of donor iliac artery will be used as an interposition graft to the recipient infrarenal aorta. The hilus will be avoided during dissection and the bile duct, hepatic artery, and portal vein will be divided as low as possible. A frozen section of the bile duct margin will be performed and patient will undergo pancreaticoduodenectomy if positive.
1817052|NCT00708890|Behavioral|Brief motivation to participate in TSG|The intensive intervention will consist of a boost motivational session on follow-up alternatives and particularly on attending TSGs. Efforts will be made to connect the patients with TSG volunteers via the AA/NA contact telephone. The patients are encouraged to invite AA/NA contact persons to visit them on the ward. The patient will then have the possibility to be followed to a meeting after treatment. The patients in the intensive referral group will get a phone call four weeks after discharge. The focus of this call will be on continued motivation to attend TSGs.
1817053|NCT00708903|Drug|neratinib|HKI-272
1817054|NCT00708903|Other|Placebo|Placebo
1817055|NCT00708903|Drug|Moxifloxacin|
1817057|NCT00708929|Procedure|Squatting|Squatting for 6 minutes
1817058|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Suppository HAL 100 mg for 3-7 hours application
1817059|NCT00708942|Drug|Placebo|Placebo suppository, for 3-7 hours application
1817060|NCT00708942|Drug|Hexaminolevulinate (HAL)|Drug: hexaminolevulinate (HAL) Ointment HAL 100 mg for 5 hours application
1817061|NCT00708942|Drug|Placebo|Placebo ointment for 5 hours application
1817062|NCT00708968|Behavioral|FOCUS Program|Supportive, educative sessions with patients and spouses.
1817612|NCT00714753|Radiation|intensity-modulated radiation therapy|
1817063|NCT00708981|Other|Multifactorial Intervention|"Study group will receive multifactorial intervention for advanced diabetic nephropathy:
Elements of multifactorial intervention:
BP control of <130/80mmHg and renal protection with reduction of proteinuria to <0.5g/day using therapy with ACE inhibitors and/or ARBs.
Tight glucose control with target of HbA1C of 7% and below using SMBG and Lantus/Apidra regimen.
Use of hypolipidemic therapy to achieve targets of LDL < 70 mg/dl, HDL > 40/50 mg/dl (M/F)and TG < 200 mg/dl.
Patient enhanced self-management provided by combined diabetes-renal education curriculum.
Behavior and social intervention
Intense case management that includes close follow-up of visits, laboratory monitoring and other self-adherence behaviors carried out by clinical research coordinators."
1817064|NCT00708994|Drug|THC|"Very low dose (0.0015 mg/kg = 0.21 mg in a 70kg individual) THC, dissolved in alcohol. Administered intravenously over 10 minutes.
Low dose (0.015 mg/kg = 1.05 mg in a 70kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. Administered intravenously over 10 minutes.
Medium dose (0.03 mg/kg = 2.1 mg in a 70 kg individual) THC, dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/2 of a marijuana cigarette, or joint. Administered intravenously over 10 minutes."
1817065|NCT00708994|Drug|Placebo|• Control: small amount of alcohol intravenous (quarter teaspoon), with no THC over 10 minutes
1817066|NCT00709007|Behavioral|Directly Administered Antiretroviral Therapy (DAART)|Participants are observed taking HIV medications by study staff on days when they receive opioid agonist therapy (sub-lingual buprenorphine) at the clinic.
1817067|NCT00709007|Behavioral|SAT|Participants take their HIV medications by themselves.
1817068|NCT00709020|Drug|white button mushroom extract|Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
1817069|NCT00709020|Other|flow cytometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
1817070|NCT00709020|Other|high performance liquid chromatography|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
1817071|NCT00709020|Other|laboratory biomarker analysis|Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.
1817072|NCT00709020|Other|mass spectrometry|Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
1817073|NCT00709020|Other|pharmacogenomic studies|Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.
1817074|NCT00709020|Other|pharmacological study|Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
1817075|NCT00709033|Biological|autologous or syngeneic PBTLs and EBV-CTLs|"Three dose levels are being evaluated namely:
GROUP 1
PBTL CD19CAR-28 zeta 2x10exp7 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp7 cells/m2
GROUP 2
PBTL CD19CAR-28 zeta 1x10exp8cells/m2 and EBV-CTL CD19CAR zeta 1x10exp8 cells/m2
GROUP 3
PBTL CD19CAR-28 zeta 2x10exp8 cells/m2 and EBV-CTL CD19CAR zeta 2x10exp8 cells/m2"
1817076|NCT00709046|Drug|High dose pantoprazole infusion|Pantoprazole 80mg iv bolus, 8mg/hr infusion for 72hrs
1817077|NCT00709046|Drug|Standard dose pantoprazole infusion|Pantoprazole 40mg iv bolus qd x 3 days
1817078|NCT00709059|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron 1.5 ug/kg body weight per week subcutaneously for 48 weeks
1817079|NCT00709059|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered based on body weight 800-1200 mg/day (<65 kg: 800 mg; 65 - 85 kg: 1000 mg; >85 kg: 1200 mg) orally for 48 weeks
1817080|NCT00709072|Behavioral|SMS (Short Message Service) reminders|SMS reminders sent every 2 weeks
1817081|NCT00709098|Drug|iloprost|Iloprost 5 mcg delivered by I-neb(R) adaptive aerosol delivery (AAD)(R) System power disc-6 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
1817082|NCT00709098|Drug|iloprost|Iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day for 12 weeks. If patient enters open label follow-up period, iloprost 5 mcg delivered by I-neb(R)AAD(R) System power disc-15 administered 6 to 9 times per day until the end of study.
1817083|NCT00709111|Drug|Maraviroc|The maraviroc doses were 150 mg orally twice daily, 300 mg orally twice daily, or 600 mg orally twice daily, depending on the pharmacokinetic interaction with a subject's pre-study ART and non-ART drug regimen according to the package insert.
1817084|NCT00709124|Device|Neuromuscular Electrostimulation (NMES) CareStim Muscle Stimulation Device (Care Rehab; McLean, VA)|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay.
1817085|NCT00709124|Device|Sham|60 minute NMES sessions will be applied to three muscle groups of the lower extremities (quadriceps, pretibial, and triceps surae). Sessions start at study entry, and will occur every day for the duration of subject's ICU stay. Sham groups will NOT have voltage applied.
1817086|NCT00709137|Drug|spironolactone|tablet form. doses used range from 12.5-50mg po QDAY. Total duration would be until completion or study or medication intolerance.
1817087|NCT00709137|Drug|amiloride|amiloride 2.5-10 mg po QDAY. Duration until completion of study or until tolerance
1817088|NCT00709150|Behavioral|Collaborative depression care management|Collaborative depression care management will include acute depression treatment with antidepressant medication and/or counseling sessions based on structured problem solving therapy. Participants will also receive supportive patient navigation services and maintenance/relapse telephone monitoring. Counseling treatment will include 8 weekly 45-minute counseling sessions that are socio-culturally adaptated for the study population. The length of medication treatment will depend upon participants' severity of depression and may last up to 12 months.
1817089|NCT00709150|Behavioral|Enhanced usual care|Participants will receive educational pamphlets on depression and a list of mental health resources in the community. Participants' primary care doctors will be free to prescribe antidepressant medication or provide other usual care.
1817172|NCT00709800|Biological|VCL-IPT1|IM, 0.5 mg/mL, 2 injections, 0 and 21 days
1817173|NCT00709800|Biological|VCL-IPT1|IM, 1 mg/mL, 2 injections, 0 and 21 days
1817174|NCT00709800|Biological|VCL-IPM1|IM, 1 mg/mL, 2 injections, 0 and 21 days
1817175|NCT00709800|Biological|PBS|IM, 1 mL, 2 injections, 0 and 21 days
1817090|NCT00709163|Drug|Nesiritide|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
1817091|NCT00709163|Drug|5% Dextrose|The patient will be given an initial bolus of 1mcg/kg and then placed on a continuous infusion of 0.01mcg/kg/min. Three hours after the start of the infusion the patient will be rebolused with 1mcg/kg and increase the continuous infusion to 0.015mcg/kg/min. This will occur again at 6 hours after the start with an increase in the continuous infusion rate to 0.02mcg/kg/min. Patients will continue on the study drug for a total of 24 hours.
1817092|NCT00709176|Behavioral|Brief FOCUS Program|Dyads randomized to this arm received the FOCUS Brief Program, two home visits and one phone call by a trained nurse.
1817093|NCT00709176|Behavioral|Extensive FOCUS Program|Dyads randomized to this arm received the FOCUS Extensive Program, 4 home visits and two phone calls by a trained nurse.
1817094|NCT00709189|Drug|Norgestimate/Ehinyl Estradiol; Folic acid.|
1817095|NCT00709202|Drug|Betahistine|Subjects will be started on 8 mg BID of Betahistine and titrated up to 24 mg BID.
1817096|NCT00709215|Drug|Cordycepin plus Pentostatin|Cordycepin Plus Pentostatin on days 1, 2 and 3 of a 21 day cycle. Number of cycles until progression or unacceptable toxicity
1817097|NCT00709228|Drug|PegIntron|1.5 ug/kg/week
1817098|NCT00709228|Drug|Rebetol|800-1200 mg/day
1817099|NCT00709254|Drug|i.v. fentanyl|single dose, 200 ug
1817100|NCT00709254|Drug|3 mL AeroLEF (500 µg/1 mL)|A single dose of 3mL (500 µg/1 mL) of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)
1817101|NCT00709254|Drug|3 mL AeroLEF (500 µg/1 mL)|A multiple doses of 3mL (500 µg/1 mL)of AeroLEF (Aerosolized Free and Liposome-Encapsulated Fentanyl)every 12 hours for a total of five doses over a 3 days
1817102|NCT00709267|Drug|Folic acid|
1817105|NCT00709293|Drug|Anti-Thymocyte Globulin|Thymoglobulin (1.5 mg/kg body weight) will be infused through a peripheral intravenous line over a minimum of 6 hours. The infusion will be started at the time of donor visualization (once it is confirmed the transplant is proceeding). The peri-operative nurse or anesthesiologist will be responsible for drug infusion.
1817106|NCT00709293|Drug|Normal Saline|Normal saline will be utilized as a placebo comparator. It will be infused in the same fashion as the Thymoglobulin in the intervention arm.
1817107|NCT00709306|Device|UV-Detect Instant Photos|UV-Detect Instant Photos
1817108|NCT00709306|Behavioral|Motivational Interviewing|Motivational Interviewing
1817109|NCT00709306|Behavioral|Education|Education
1817110|NCT00709332|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
1817111|NCT00709345|Behavioral|Cognitive behavioral sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on promoting healthy behaviors, dieting, and exercise.
1817112|NCT00709345|Behavioral|Time-matched attention control sessions|Participants will receive 26 weekly 1-hour small-group sessions and 26 weekly 30-minute individual sessions with a study facilitator. After completing treatment, participants will also receive 6 monthly 1-hour booster sessions. All sessions will focus on improving communications, developing healthy techniques for coping with stress, and resolving conflicts.
1817113|NCT00709358|Other|Detection of microbial DNA in blood by SeptiFast®|"The LightCycler® SeptiFast Test, the innovative real-time PCR test from Roche Diagnostics, is designed to detect and identify the 25 most important bacterial and fungal species causing bloodstream infections within just a few hours. The LightCycler® SeptiFast Test detects the pathogenic bacteria and fungi directly from whole blood without the need for prior incubation or culture steps.
Rapid detection and identification of bacterial and fungal DNA, directly from a 1.5 ml whole blood sample, without prior incubation or culture steps in less than 6 hours."
1817114|NCT00709358|Other|detection of microbial DNA in blood by blood culture|A blood culture is a test to find an infection in the blood. Most bacteria can be seen in the culture in 2 to 3 days, but some types can take 10 days or longer to show up. Fungus can take up to 30 days to show up in the culture.
1817115|NCT00709371|Drug|Zonisamide SR placebo/ bupropion SR placebo|2 placebo combination tablets twice daily for 16 weeks (maintenance period)
1817116|NCT00709371|Drug|Zonisamide SR placebo/ bupropion SR 360 mg/day|2 placebo and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
1817117|NCT00709371|Drug|Zonisamide SR 120 mg/day/ bupropion SR placebo|2 zonisamide SR 30 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
1817118|NCT00709371|Drug|Zonisamide SR 360 mg/day/ bupropion SR placebo|2 zonisamide SR 90 mg and placebo combination tablets, twice daily for 16 weeks (maintenance period)
1817119|NCT00709371|Drug|Zonisamide SR 120 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 30 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
1817120|NCT00709371|Drug|Zonisamide SR 360 mg/day/ bupropion SR 360 mg/day|2 zonisamide SR 90 mg and bupropion SR 90 mg combination tablets, twice daily for 16 weeks (maintenance period)
1817121|NCT00709384|Procedure|Prophylactic surgical lesion|A prophylactic peroperative linear lesions connecting the tricuspid annulus with a right atriotomy (surgical dissection plus cryoablation) and the atriotomy with the inferior caval vein (cryoablation alone).
1817122|NCT00709397|Other|blood drawing|Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
1817222|NCT00710203|Procedure|Curettage|A second lesion will be treated with curettage with or without anesthetic, depending on the patient's preference.
1817223|NCT00710203|Procedure|Electrodesiccation|A third lesion will be treated with electrodesiccation after infiltration of 1% lidocaine with epinephrine.
1817123|NCT00709410|Biological|rBS-WC vaccine|1 mg of recombinant cholera toxin B subunit and approximately 1 x 10^11 of inactivated whole cells of Vibrio cholerae O1 Inaba and Ogawa, classic and El Tor strains (6). The rBS-WC vaccine is supplied as 3 ml single-dose vials each with a sachet of sodium bicarbonate buffer. Buffer solution will be prepared by dissolving the sachets in drinking water (150 ml water for each sachet of sodium bicarbonate). The full dose of vaccine will be mixed with 40, 75, or 150 ml of buffer solution for persons 2 to 4 years, 5 to 11 years, and over 11 years old, respectively. The vaccine is recommended to be given in two doses with an interval of at least seven days and protection is conferred 7 to 10 days after the second dose.
1817124|NCT00709423|Drug|Moxaverine|
1817125|NCT00709423|Drug|Moxaverin 150mg|intravenous administration
1817126|NCT00709423|Drug|NaCl|intravenous administration
1817127|NCT00709436|Drug|PMI-150 (intranasal ketamine)|PMI-150 (intranasal ketamine) at time 0 and scheduled times thereafter.
1817128|NCT00709436|Drug|Placebo|Placebo (intranasal) at time 0 and scheduled times thereafter.
1817129|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
1817130|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
1817131|NCT00709449|Drug|moxaverine|intravenous infusion of 150 mg in 250 ml NaCl, applied over 30 minutes.
1817132|NCT00709462|Biological|CDX1307|
1817133|NCT00709475|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1817134|NCT00709488|Drug|Talaporfin sodium|LS11 (Talaporfin Sodium) dose is 1mg/kg administered intravenously slow push (3-5 minutes).
1817135|NCT00709488|Procedure|Placement of device in prostate urethra|Placement of device in prostate urethra
1817136|NCT00709488|Device|Transurethral illumination with light emitting diodes (Litx™ BPH Device)|Patients in Cohort A will receive 50 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort B will receive 70 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort C will receive 100 J of light treatment with 1 mg/kg LS11 administration; patients in Cohort D will receive 100 J of light treatment (with the active light emitting length increased from 10mm to 20 mm) with 1 mg/kg LS11 administration.
1817137|NCT00709501|Behavioral|Disseminating Effective Habits for Long-term Weight Loss|Comparison of weight change among those participants in the weight loss intervention (immediate access to the weight loss website) and those participants in the control group (delayed access to the weight loss website).
1817138|NCT00709501|Behavioral|Achieve Together website|access to the Achieve Together website immediately (Arm 1) or delayed (Arm 2)
1817139|NCT00709514|Drug|DCB-WH1 ointment|DCB-WH1 ointment (1.25%), topically applied twice daily
1817140|NCT00709514|Drug|Placebo|Placebo
1817141|NCT00709527|Drug|ARC1905|intravitreal injection
1817142|NCT00709540|Biological|ACE-011 or placebo|multiple administrations of ACE-011 given subcutaneously once per month for 3 months (4 administrations total)
1817143|NCT00709553|Drug|midazolam|
1817144|NCT00709553|Drug|ZD4054|ZD4054 10 mg od
1817145|NCT00709566|Behavioral|Exercise therapy|Participants will attend an exercise based programme once a week for 8 weeks. This will be supplemented by a home based exercise programme.
1817146|NCT00709566|Behavioral|Combined exercise and manual therapy|Patients will attend physiotherapy once a week for 8 weeks, where they will receive a combination of exercise therapy and manual therapy. Exercise will be supplemented by a home based exercise programme
1817147|NCT00709579|Drug|RV3391A|A standardized quantity of each product will be applied on the evening on anterior side of forearm. The side of application will be randomized.
1817148|NCT00709579|Drug|Placebo|placebo
1817149|NCT00709592|Biological|Thymoglobulin|Patients eligible for participation in this study will be randomized between receiving rabbit ATG for 3 days. Thymoglobulin will be administered according to VCU BMT standard of care starting day -9 and continued daily through day -7.
1817150|NCT00709592|Radiation|Total-Body Irradiation|Undergo TBI
1817151|NCT00709592|Procedure|Allogeneic PBSCT or BMT|Undergo allogeneic PBSCT or BMT
1817152|NCT00709592|Drug|Tacrolimus|Given PO
1817153|NCT00709592|Drug|Mycophenolate Mofetil|Given PO
1817154|NCT00709605|Drug|VRC-HIVADV014-00-VP|
1817155|NCT00709618|Drug|Lapatinib, Vinorelbine|Vinorelbine intravenously once weekly for 3 weeks, followed by a rest week in a 4-week cycle) plus lapatinib daily
1817156|NCT00709644|Drug|Norgestimate; Ethinyl Estradiol; Folic acid.|
1817157|NCT00709657|Drug|ranibizumab, bevacizumab or pegaptanib|measurements are performed one week before and after anti-VEGF intravitreal injection
1817158|NCT00709670|Procedure|MSCT and stress echocardiography|tests MSCT and stress echocardiography
1817159|NCT00709683|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1958429|NCT01646762|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1958430|NCT01646762|Other|Laboratory Biomarker Analysis|Correlative studies
1817162|NCT00709709|Procedure|multislice coronary scan|multislice coronary scan
1817163|NCT00709722|Drug|NKT-01|SC, 0.5 mg/kg/day, consecutive 14 days administrations, 1 week rest, 9 cycles.
1817164|NCT00709735|Drug|Propranolol|0.67 mg/kg short-acting propranolol combined with 1 mg/kg long-acting propranolol
1817165|NCT00709735|Drug|Placebo|Placebo (matching propranolol) short-acting and long-acting capsules
1817166|NCT00709748|Device|Empi Select TENS Device|The Empi Select TENS device delivers therapeutic electrical currents at various frequencies (intensities) and periods of time for the treatment of pain.
1817167|NCT00709748|Device|Placebo|Subjects in this study arm will receive control (not fully active) Empi Select TENS devices.
1817168|NCT00709761|Drug|Lapatinib/nab-Paclitaxel|This is an open-label, single-arm, multi-center, Phase II study to determine the activity of nab-paclitaxel plus lapatinib (TYKERB) in the first and second-line setting in women with ErbB2 overexpressing metastatic breast cancer (MBC). Sixty subjects will be enrolled in the study. Subjects will receive nab-paclitaxel (100 mg/m2 intravenously on Day 1, 8, 15, every 28 days (q28) days plus lapatinib (1000 mg once daily on a continuous basis).
1857791|NCT01005758|Drug|prednisone|
1817176|NCT00709813|Behavioral|Tailored assessments provided to physicians and nurses (CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA))|Both groups used CHOICE, the Computer-assisted Interactive Tailored Patient Assessment Tool (ITPA)for symptom assessments at in- and outpatient visits during and up-to nine months after treatment. In the intervention group physicians and nurses had assessment summaries available for care planning, displaying patients' symptoms, problems and concerns in rank-order of their needs for care. In the control group assessments were not available to care providers at any time.
1817177|NCT00709826|Drug|gemcitabine|Gemcitabine: per package insert.
1817178|NCT00709826|Drug|placebo|placebo: 100 mg tablets, 400 mg/day
1817179|NCT00709826|Drug|Erlotinib|Erlotinib - per package insert.
1817180|NCT00709826|Drug|apricoxib|apricoxib: 100mg tablets, given orally
1817181|NCT00709839|Drug|Hydrocortisone|0.6 mg/kg body weight, intravenous bolus given at time-point minus 4'
1817182|NCT00709839|Drug|Glucose 33%|1ml/kg body weight, intravenous bolus given at time-point 0'
1817183|NCT00709852|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|Participants received a single dose of gadobutrol 0.1 mmol/kg body weight (bw) via i.v. (intravenous)
1817184|NCT00709852|Drug|Gadoteridol (ProHance)|Participants received a single dose of gadoteridol at the approved dose, 0.1 mmol/kg bw, via i.v.
1817185|NCT00709865|Drug|tonapofylline|IV
1817186|NCT00709865|Drug|Placebo|IV
1817187|NCT00709878|Procedure|Skin Biopsy of Skin Rash Secondary to EGFRI Use|Patients who were treated with lapatinib, cetuximab, panitumumab or erlotinib who subsequently developed a skin rash have been biopsied as standard of care. The biopsies will be used for this study.
1817188|NCT00709891|Device|cobas® 4800 HPV Test|
1817189|NCT00709904|Drug|Open-label Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection once daily with an initial dose given 8 hours after surgery"
1817190|NCT00709904|Drug|Placebo (for Semuloparin sodium)|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance containing the same volume but without active component
Subcutaneous injection once daily"
1817191|NCT00709904|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection once daily"
1817192|NCT00709917|Drug|repaglinide|Start dose and freqency to be prescribed by the physician at his discretion following clinical practice
1817193|NCT00709930|Device|Magnetic field generator|dosage:Magnetic field generator Exposure to 1-μT 8/6-Hz ELF-EMF frequency:10min/day duration:1 month
1817194|NCT00709930|Device|Placebo magnetic field generator|Placebo device with no magnetic fields
1817195|NCT00709956|Drug|iloprost (5 µg)|Single dose of iloprost 5 µg using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
1817196|NCT00709956|Drug|placebo|Single dose of matching placebo using I-neb(R) Adaptive Aerosol Delivery (AAD(R)) System power setting 15 disc
1817197|NCT00709969|Drug|Artemether-lumefantrine|20mg artemether and 120 mg lumefantrine, tablet, dose based on body weight, 3 days treatment 5 - < 10kg (BWG 1) = 6 doses of 1 tablet / 10 - < 15kg (BWG 2) = 6 doses of 1 tablet / 15 - ≤ 25kg (BWG 3) = 6 doses of 2 tablets
1817198|NCT00709982|Drug|Norgestimate; Ethinyl Estradiol; Folic acid|
1817199|NCT00709995|Drug|Enzastaurin|Administered orally
1817200|NCT00709995|Drug|Sunitinib|Administered orally
1817201|NCT00709995|Drug|Placebo|Administered orally
1817202|NCT00710008|Other|exercise training|3 bouts of exercise at 90%RCP during one week
1817203|NCT00710021|Drug|Vitamin D3|8% vitamin D3 powder, 84% microcrystalline cellulose, 8% fumed silica by weight
1817204|NCT00710021|Drug|Vitamin D3 placebo|86% microcrystalline cellulose, 14% fumed silica by weight
1817207|NCT00710047|Drug|ZD4054|one single 10mg dose
1817208|NCT00710060|Behavioral|Community Popular Opinion Leader (C-POL)|The C-POL intervention will teach identified opinion leaders to share personalized HIV prevention messages in conversations with peers in an effort to change community norms. Opinion leaders will be taught skills for sharing HIV risk-reduction messages during four to five weekly training sessions. At least 15% of the community population will be trained as opinion leaders. After the initial training, opinion leaders will attend six to nine booster sessions over the next 2 years to reinforce and support continued conversation efforts.
1817209|NCT00710060|Behavioral|HIV/STD educational materials|Communities will receive HIV/STD educational materials and treatment referral information to distribute to community members.
1817210|NCT00710073|Device|sono-electro-magnetic therapy (Sonodyn Medico Star)|twice a day for 10 minutes during 6 or 12 weeks
1817211|NCT00710086|Drug|Hydromorphone|Intravenous administration of hydromorphone 1mg at the patient's request if they felt uterine contraction pain
1817212|NCT00710086|Drug|Remifentanil|Remifentanil intravenous PCA: 0.2μg/kg, lockout time interval 2 minutes, continuous infusion rate 0.2-0.8μg/kg/min.
1817213|NCT00710099|Drug|sildenafil|systemic absorption of sildenafil
1817214|NCT00710099|Drug|nitroprussiate iontophoresis|nitroprussiate iontophoresis
1817215|NCT00710112|Genetic|gene variations|comparing variations in genes in infants who develop chronic lung disease and other diseases of prematurity and those who do not.
1817216|NCT00710125|Drug|GPX-150 for Injection|Escalating doses starting at the dose of 14 mg/m2 and increasing to the dose of 265 mg/m2 will be administered IV once every 3 weeks for up to 8 cycles of treatment. Patients who have previously received an anthracycline are limited to 4 cycles of treatment.
1817217|NCT00710138|Dietary Supplement|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
1817218|NCT00710164|Drug|XSCR capsule (Composed of Traditional Chinese Medicine Huangqi, Chuanxiong, Chishao, Danggui, Dilong, Taoren, Honghua.)|14 days of XSCR capsule
1817219|NCT00710164|Drug|Placebo|14 days of Placebo
1817220|NCT00710190|Device|Rheos Baroreflex Hypertension Therapy System|This therapy uses implantable device-based electrical activation of the carotid sinus baroreflex to control blood pressure.
1817221|NCT00710203|Device|Pulsed dye laser|One lesion will be chosen for treatment with the pulsed dye laser with a 7 mm spot size. A single 10 J/cm2 pulse with 10 ms pulse duration will be used to treat the lesion.
1817224|NCT00710203|Other|No treatment|A fourth lesion will not be treated and will serve as a control.
1817225|NCT00710216|Drug|Lamivudine|100 mg/day
1817226|NCT00710216|Drug|Telbivudine|600 mg/day
1817227|NCT00710229|Drug|Ranibizumab|intravitreal injection
1817228|NCT00710229|Drug|Bevacizumab|intravitreal injection
1817229|NCT00710242|Drug|DF01|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
1817230|NCT00710242|Drug|Placebo|Once daily s.c. injections from approximately 3-7 days before expected delivery (maximum 2 weeks before) until delivery (maximum 2 weeks after expected delivery)
1817231|NCT00710255|Procedure|Hyperpnea challenge|5 minutes of dry air hyperpnea to induce bronchospasm
1817232|NCT00710268|Drug|AZD2281|Oral Capsule, Dose Escalation 50, 100, 200, 400 mgContinuous twice daily dosing
1817233|NCT00710268|Drug|Bevacizumab|IV administration10 mg/kg every 14 days
1817234|NCT00710281|Radiation|Additional scan time on standard MR angiography|"Procedure/Surgery: Additional 5 minutes scan time to standard MR angiography
Using the Nova® Software, an additional 5 minutes scan time will be required in order to identify aneurysm, select target artery, and complete measurements
Arms:"
1817235|NCT00710294|Device|CVRx Rheos Baroreflex Hypertension Therapy System|"The pulse generator, which is similar to a pacemaker, is typically implanted under the skin below the collarbone.
Two small leads from the device are wrapped around the carotid arteries on both sides of the neck and connected to the pulse generator."
1817236|NCT00710307|Procedure|Blood sampling|Blood samples will be collected at visit 1 (day 1) and at visit 2 (day 14 to 45).
1817237|NCT00710307|Genetic|Genetic analysis|The sample for genetic analyses may be taken at Visit 1. The blood sample volume will be 6 mL.
1817238|NCT00710320|Procedure|Covered and uncovered anesthesia induction|"We hypothesize that the core temperatures of:
the covered group during induction of general anesthesia will be greater by 0.5ºC than the uncovered group during induction of general anesthesia.
both groups, covered and uncovered, will be equal during surgery and post-operatively. In other words, due to the active warming procedures during surgery and post-operatively in the PICU, core temperatures of the uncovered group will catch up to the covered group."
1817239|NCT00710333|Drug|Avotermin|10 patients undergoing surgical revision of bilateral keloids will be dosed with 500ng Juvista/100µL per cm of wound margin to one ear lobe and placebo to the other and followed up for three months after dosing to assess the local and systemic tolerability.
1817240|NCT00710333|Drug|placebo|placebo
1817241|NCT00710359|Dietary Supplement|Hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma)|400 µg hydroxycobalamin (Vitamin B12 Depot, Nycomed Pharma), as a single intramuscular injection
1817242|NCT00710372|Biological|CYT006-AngQb|s.c. injection
1817243|NCT00710385|Drug|Heroin|Heroin (25 mg)
1817244|NCT00710385|Drug|Naloxone|.4 mg
1817245|NCT00710385|Drug|Low Bup Dose|4 and 8 mg
1817246|NCT00710385|Drug|High Bup Dose|8mg and 16 mg
1817247|NCT00710385|Drug|Low Bup/Nal Dose|Buprenorphine/Naloxone 4/1 mg, 8/2 mg
1817248|NCT00710385|Drug|High Bup/Nal Dose|Buprenorphine/Naloxone 8/2 mg, 16/4 mg
1817249|NCT00710385|Drug|Placebo (PCB)|Placebo control administration
1817250|NCT00710398|Behavioral|Exercise - Aerobic and Resistance|Subjects will perform exercise (aerobic and resistance) 7d/wk and will exercise supervised 5d/wk. Exercise will be carried out to expend 250 kcals/day. Supervised resistance training sessions will take place 2 days/wk and aerobic exercise will take place every day. During the resistance exercise sessions, subjects will engage in a circuit weightlifting routine using guided motion machines. During the aerobic sessions, subjects may choose whatever exercise modality they like (e.g. walking on track or treadmill, biking, elliptical, etc.). Subjects will wear devices that measure energy expenditure to get a better idea of the intensity and duration needed to expend 250 kcals with their exercise machine/modality of choice.
1817251|NCT00710398|Behavioral|Dietary - Caloric Restriction|"Subjects will be counselled on their respective hypocaloric diets during the 16 wk period. Adherence to the prescribed diet will be assessed via collection of assigned food records (biweekly), frequent contact with subjects, and regular dietary counseling sessions. The daily dietary energy deficit will be 500 kcal per day based on the subjects' estimated daily caloric requirements (based on height, weight, age, sex), multiplied by a sedentary activity factor.
Additionally, subjects will consume 2 drinks per day that will differ depending on their randomization allocation. Subjects in the Dairy Protein and High Dairy Protein group will be provided with dairy products (e.g. milk, cheese, yogurt) to consume on a weekly basis to help facilitate their prescribed dairy and dietary protein intake."
1817252|NCT00710424|Drug|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
1817253|NCT00710424|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
1817254|NCT00710437|Drug|Dexmedetomidine|Steady state infusion 0.007 mcg/kg/min
1817255|NCT00710463|Device|non invasive ventilation (Resmed VPAP III ST-A, Respironics Harmony)|non invasive ventilation was performed with commercially available ventilators from the manufacturers Resmed and Respironics.
1817256|NCT00710476|Procedure|Insemination|Insemination with a lower concentration of spermatozoa: 150 000 spermatozoa/ml
1817257|NCT00710502|Procedure|Transvaginal NOTES cholecystectomy|Under general anesthesia, patients will undergo Transvaginal NOTES cholecystectomy
1817258|NCT00710502|Procedure|Laparoscopic cholecystectomy|Under general anesthesia, patients will undergo standard Laparoscopic cholecystectomy
1817259|NCT00702637|Drug|Modafinil|
1817260|NCT00702650|Drug|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 120 days
1817261|NCT00702676|Drug|Quetiapine Fumarate|Tablet, Oral, once daily
1817262|NCT00702676|Drug|Quetiapine Fumarate|Tablet, Oral, once daily
1817263|NCT00702689|Drug|Gleevec, STI571(Imatinib Mesylate)|"Cohort 1 - Pts 1-8:Adults: 400mg imatinib mesylate daily; Children: 260mg/m^2 daily (400mg maximum), followed by dose de-escalation for adverse events.
Cohort 2 - Pts 9-20:Adults - 100 mg oral dose daily (increase to 200 mg daily after 28 days if well tolerated). Children - 65 mg/m^2 oral dose daily (increase to 130 mg/m^2 daily after 28 days if well tolerated)"
1817264|NCT00702702|Drug|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
1817265|NCT00702702|Drug|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
1817266|NCT00702702|Drug|Placebo|Placebo, 2 capsules daily for 3 months
1817267|NCT00702715|Drug|sugammadex|"Each subject will receive an
intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After
this dose, maintenance doses of 0.1 - 0.2 mg.kg-1
rocuronium may be given. In case of maintenance dosing, the target depth of
neuromuscular blockade has to be maintained at 1-2 post-tetanic counts (PTC). After the last dose of rocuronium has been administered, the subject will receive a single bolus dose of 4.0 mg.kg-1 sugammadex at a target depth of blockade of 1-2 PTC."
1817268|NCT00702728|Drug|Furosemide and matched saline hydration|Subjects will begin treatment approximately 90 minutes prior to the start of catheterization procedure. After a pre-hydration bolus of 250 ml of normal saline solution over 30 minutes the patient will receive 0.5 mg/kg of furosemide intravenously. Then, a replacement solution (saline) is given in an amount matched (ml for ml) to the volume of urine produced. Matched hydration will occur prior, during, and 4 hours post procedure.
1817269|NCT00702728|Drug|isotonic saline solution|Subjects will receive 1 ml/Kg/hr of intravenous saline solution for a minimum of 12 hours prior to catheterization. Hydration will continue to occur during the catheterization, and for a minimum of 12 hours post catheterization.
1817270|NCT00702741|Drug|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
1817271|NCT00702741|Drug|Chondrogen|Intra-articular injection of ex vivo cultured adult human mesenchymal stem cells
1817272|NCT00702741|Drug|Placebo|Intra-articular injection of Hyaluronan
1817273|NCT00702754|Biological|Botulinum Toxin Type B|Eligible patients could receive injections of MYOBLOC once every 12 weeks. Total Dose could range from 5,000 Units up to 25,000 Units.
1817274|NCT00702767|Drug|INTRALIPIDS|INTRAVENOUS FAT EMULSIONS
1817275|NCT00702780|Drug|escitalopram|5 mg/day for 2 weeks, 10 mg/day for 2 weeks and 20 mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
1817276|NCT00702780|Drug|placebo|5mg/day for 2 weeks, 10mg/day for 2 weeks and 20mg/day for 48 weeks (maintaining donepezil at the previous stable dose during the whole trial period)
1817277|NCT00702793|Drug|Varenicline|Varenicline 0.5 mg/d for days 1 to 3, 0.5 mg twice daily for days 4 to 7, then 1 mg twice daily through week 12. Administration of twice daily dosing should be at least 8 hours apart.
1817278|NCT00702806|Drug|Org 36286|Intra-abdominal injection of Org 36286
1817279|NCT00702806|Drug|Puregon®|Subcutaneous Puregon® 150 IU
1817280|NCT00702806|Drug|Orgalutran®|Subcutaneous Orgalutran® 0.25 mg
1817281|NCT00702806|Drug|Pregnyl®|Subcutaneous Pregnyl® 10,000 IU
1817282|NCT00702819|Drug|Bevacizumab|Dosage of 0.75mg/0.03ml injectable, one time only.
1817283|NCT00702832|Behavioral|Vestibular rehabilitation|Daily home training (4-6 specific exercises) 2-3 times per day. Group training led by a physiotherapist twice per week during the first 10 weeks and once per week from 10 weeks to 12 months or to symptoms are cured.
1817284|NCT00702832|Other|standard treatment|treatment as usual
1817285|NCT00702845|Drug|corifollitropin alfa (Org 36286)|100 µg corifollitropin alfa subcutaneous (SC) injection
1817286|NCT00702845|Drug|recFSH (follitropin beta)|150 IU recFSH SC injection
1817287|NCT00702845|Drug|gonadatropin releasing hormone (GnRH) antagonist (ganirelix)|GnRH antagonist (ganirelix) administered SC at a dose of 0.25 mg/day
1817288|NCT00702845|Drug|human chorion gonadatropin (hCG)|hCG 5,000 IU or 10,000 IU administered SC
1817289|NCT00702845|Biological|progesterone|Progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.
1817290|NCT00702845|Drug|placebo-recFSH (follitropin alfa)|Placebo-recFSH administered at the equivalent volume of 150 IU/day.
1817291|NCT00702845|Drug|placebo-corifollitropin alfa|Single SC injection of placebo-corifollitropin alfa administered on Day 2 or 3 of the menstrual cycle.
1817292|NCT00702845|Biological|open-label recFSH|Open-label recFSH administered up to a maximum dose of 200 IU/day.
1817293|NCT00702858|Drug|Blue Citrus|Five 700 mg Capsules three times a day to equal 15 capsules per day for 3 months
1817294|NCT00702858|Drug|Placebo|Five Placebo capsules three times a day to equal 15 capsules per day for 3 months
1817295|NCT00702871|Drug|Ranitidine|In arm 1 Ranitidine was given in dose of 50mg i.v. 8 hourly for entire duration of ICU stay.
1817296|NCT00702871|Drug|Sucralfate|In arm 2, Sucralfate was given in dose of 1gm via nasogastric tube 6 hourly for entire duration of ICU stay
1817297|NCT00702884|Drug|sunitinib malate|Sunitinib 37.5 mg daily for a 4 week cycle
1817298|NCT00710515|Drug|AZD6244|75mg
1817299|NCT00710528|Drug|CAL-101|CAL-101 50, 100, 150, 200, 350 mg capsules BID for 28 days CAL-101 150, 300 mg QD for 28 days CAL-101 150 mg BID 3 weeks on 1 week off for 28 days
1817300|NCT00710541|Device|ventilators designed for non invasive ventilation|Patients are advised to use the ventilator for non invasive ventilation as long term treatment for at least 6 hours per day over one year.
1817301|NCT00710554|Drug|Sativex|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
1817302|NCT00710554|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
1817303|NCT00710567|Device|DuraHeart Left Ventricular Assist System (LVAS)|The DuraHeart LVAS is implanated in using open heart surgery
1817304|NCT00710580|Biological|ABT-874|SQ injection 200 mg Weeks 0 and 4; 100 mg Week 8
1817305|NCT00710580|Biological|etanercept|SQ injection 50 mg BIW
1817306|NCT00710580|Drug|placebo|SQ placebo injections for ABT-874 and etanercept
1817307|NCT00710593|Biological|HPV vaccine for strains -6, -11, -16, and -18|All subjects will receive three doses of the HPV-6, -11, -16, -18 vaccine at the recommended dose and schedule (Day 0, Week 8, and Week 24).
1817397|NCT00713076|Other|Polyquaternium-preserved Multi-purpose Lens Cleaning Solution 109182|Lens Cleaning Solution Formulation Identification Number 109182
1817847|NCT00707187|Drug|Cialis|35 pills of study medication (20 mg)
1817308|NCT00710606|Drug|NuvaRing|Obese subjects (BMI 30-39.9) will receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
1817309|NCT00710606|Drug|NuvaRing|Normal weight subjects will also receive two contraceptive hormonal rings. During the second cycle of ring use, subjects will return to the study site for serial serum hormone measurements and transvaginal ultrasound twice weekly during four weeks of continuous use.
1817310|NCT00710619|Drug|activated recombinant human factor VII|This is an observation of how patients/caregivers dose bypassing agents at home for haemophilia with inhibitors
1817311|NCT00710619|Drug|Feiba VH|This is an observation of how patients/caregivers dose bypassing agents at home for hemophilia with inhibitors
1817312|NCT00710632|Other|laboratory biomarker analysis|
1817313|NCT00710632|Other|physiologic testing|
1817314|NCT00710632|Other|questionnaire administration|
1817315|NCT00710632|Procedure|management of therapy complications|
1817316|NCT00710645|Device|Lido Workset|The intervention will consist of spasticity testing on the Lido Workset device. The servo-controlled torque motor system will analyze resistance to passive movement of the knee.
1817317|NCT00710658|Behavioral|WebChoice|"Patients in the experimental group had over the study period access to the Internet support system WebChoice that allowed them to monitor symptoms over time, and provided access to evidence-based self-management options tailored to their reported symptoms as well as a communication area where patients could ask questions to a clinical nurse specialist in cancer care and exchange experiences with other cancer patients.
Patients in the control group received usual care"
1996759|NCT02385344|Device|Medistim device|This registry is intended to document surgical findings, procedural changes, and adverse events occurring prior to discharge
1817322|NCT00710697|Drug|Picoplatin|IV 150 mg/m2, IV (in the vein) on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1817323|NCT00710710|Drug|BI 2536|
1817324|NCT00710723|Procedure|vitrification|Vitrification using Hemi-straw carrier system.
1817325|NCT00710736|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
1817326|NCT00710736|Drug|Capecitabine, 5-fluorouracil prodrug; oral|multiple dose, single schedule
1817327|NCT00710749|Device|Disposable device|Disposable urine flow meter
1817328|NCT00710749|Device|Digital device|Digital urine flowmeter
1817329|NCT00710749|Device|Clinic flow measurement|Clinic gold standard flow measurement
1817330|NCT00710762|Drug|BIBF1120|
1817331|NCT00710762|Drug|Placebo|
1817332|NCT00710775|Procedure|surgical replacement of the aortic stenotic valve|Prior to surgical removal of the aortic valve, the native valve will be dilated under direct vision of the surgeon using a standard valve dilation balloon. The HLT valve will be loaded into a short version of the delivery catheter system and the catheter will be passed across the native valve.Measurements will be taken of the device relative to the anatomic structures of the heart. Once complete, the implant is removed from the native valve and the surgical valve replacement procedure is completed.
1817333|NCT00710788|Drug|sevelamer phosphate-binders|1600 mg/day for 2 years
1817334|NCT00710788|Drug|Calcium Carbonate|Calcium carbonate 1 g/day for 2 years
1817335|NCT00710814|Drug|Leptin|Leptin self-administered subcutaneously at 0.05 mg/kg body weight twice each day
1817336|NCT00710814|Other|Placebo|Sterile water equal in volume to that of the metreleptin dose calculated for each individual self-administered subcutaneously twice each day
1817337|NCT00710827|Drug|NEBIDO|Patients will receive 54 weeks of treatment with Nebido, 5 intramuscular injections of 4ml Nebido (at baseline, week 6, 18, 30, 42)
1817338|NCT00710827|Drug|PLACEBO|Patients will receive 54 weeks of treatment with placebo, 5 intramuscular injections of 4ml placebo (at baseline, week 6, 18, 30, 42)
1817339|NCT00710840|Procedure|Minimally Invasive Total Knee Arthroplasty [TKA Min]|TKA Min is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee. TKA Min, as opposed to TKA Traditional, employs smaller skin incisions and smaller instrumentation and avoids turning the knee cap out and dislocating the knee. This procedure also avoids disrupting the knee extensor mechanism and the suprapatellar pouch and minimizes extreme knee flexion during surgery.
1817340|NCT00710840|Procedure|Total Knee Arthroplasty (TKA) Traditional|TKA is a procedure in which diseased and painful joint surfaces of the knee are replaced by metal and plastic components shaped to allow continued motion of the knee.
1817341|NCT00712712|Drug|acetaminophen|
1817342|NCT00712712|Drug|morphine sulfate|
1817343|NCT00712712|Other|questionnaire administration|
1817344|NCT00712712|Procedure|quality-of-life assessment|
1817345|NCT00712712|Procedure|radiofrequency ablation|
1817346|NCT00712725|Drug|MK3207- 2.5 mg|Arm 1: MK3207 2.5 mg taken after migraine onset.
1817347|NCT00712725|Drug|MK3207- 5 mg|Arm 2: MK3207 5 mg taken after migraine onset.
1817348|NCT00712725|Drug|MK3207- 10 mg|Arm 3: MK3207 10 mg taken after migraine onset.
1817349|NCT00712725|Drug|MK3207- 20 mg|Arm 4: MK3207 20 mg taken after migraine onset.
1817350|NCT00712725|Drug|MK3207- 50 mg|Arm 5: MK3207 50 mg taken after migraine onset.
1817351|NCT00712725|Drug|MK3207- 100 mg|Arm 6: MK3207 100 mg taken after migraine onset.
1817352|NCT00712725|Drug|Comparator: placebo (unspecified)|Placebo taken after migraine onset.
1817353|NCT00712738|Drug|Nifedipine|
1817354|NCT00712738|Procedure|Phlebotomy|
1817355|NCT00712738|Procedure|Urinalysis|
1817356|NCT00712738|Procedure|Echocardiogram|
1817357|NCT00712738|Procedure|Electrocardiogram|
1817398|NCT00713115|Procedure|needlescopic adrenalectomy and laparoscopic adrenalectomy|Needlescopic instruments, defined as those with a diameter of no more than 3 mm. They result in smaller incisions than conventional 5- to 12-mm instruments.
1817399|NCT00713154|Drug|MTS-01|MTS-01 7% gel in 100 ml tubes, two 100 ml tubes prior to each radiation treatment
1817872|NCT00707421|Drug|artificial lacrimal tears|
1817358|NCT00712751|Behavioral|questionnaires|"Participants randomized to the Usual Care arm will receive standard care . For women, this is defined as the care that participants who are not in the intervention receive; we will ask these participants what psychosocial care they are receiving to track usual care. For men, usual care will consist of a standardized referral to the men's Sexual Medicine Program at MSKCC and written information in the form of the American Cancer Society (ACS) booklet on Sexuality after Cancer. Individuals randomized to Usual Care will not receive any additional counseling sessions from the study interventionists until they are done with the follow up interviews and then it will be offered to them. Follow up questionnaires will assess all study participants at 4 and 8 months after baseline."
1817359|NCT00712751|Behavioral|CSI-SH- Cancer Survivorship Intervention|This involves four 1-hour individual sessions with three additional telephone booster/review sessions provided in between the four sessions. Sessions can be completed in person or conducted over the phone. Although every effort will be made to complete the booster session in between counseling sessions, if the patient is unavailable to complete the booster calls they may be skipped. Sessions one and two will focus on rehabilitation techniques and tools will be provided and discussed with participants during these first two sessions.
1817360|NCT00712764|Drug|Adenosine|
1817361|NCT00712764|Drug|Placebo|
1817362|NCT00712777|Drug|Brimonidine 0.2 %|Brimonidine 0.2 % (Alphagan, Irvine, CA, USA), dose: 1 drop per eye
1817363|NCT00712790|Drug|Sorafenib|Tablet, 400mg orally, twice daily
1817364|NCT00712790|Radiation|SIR-Spheres|one time treatment and capped at 3.0 Gbq
1817365|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^3 dose of rDEN3-3'D4delta30 vaccine.
1817366|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^5 dose of rDEN3-3'D4delta30 vaccine.
1817367|NCT00712803|Biological|rDEN3-3'D4delta30|Live attenuated 10^1 dose of rDEN3-3'D4delta30 vaccine.
1817368|NCT00712816|Device|Game Ready Injury Treatment System (CoolSystems Inc.)|Cold with intermittent compression postoperatively for 2 weeks
1817369|NCT00712816|Other|Ice with compressive bandages|Cold with static compression postoperatively for 2 weeks
1817370|NCT00712829|Drug|123-I-MIP-1072|10 mCi intravenous injection given one time during the study
1817371|NCT00712829|Drug|123-I-MIP-1095|10 mCi intravenous injection given one time during the study
1817372|NCT00712842|Other|Ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters and laser Doppler velocimetry
1817373|NCT00712855|Biological|mapatumumab|3, 10, or 30 mg/kg IV (in the vein), on day 1 of each 21 day cycle
1817374|NCT00712855|Drug|sorafenib|400 mg orally, twice a day continuously in each cycle
1817375|NCT00712868|Drug|Lactic acid|Once a day
1817376|NCT00712881|Drug|MYOCET® Plus Cyclophosphamide and Trastuzumab, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles|MYOCET® (60 mg/m2) and cyclophosphamide (600 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg once every 3 weeks) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (6 mg/kg) once every 3 weeks for 4 cycles (MCH→TH).
1817377|NCT00712881|Drug|Free Doxorubicin Plus Cyclophosphamide, 4 cycles, followed by Docetaxel plus Trastuzumab, 4 cycles|Free doxorubicin (60 mg/m2) and cyclophosphamide (600 mg/m2) once every 3 weeks for 4 cycles followed by docetaxel (100 mg/m2) and trastuzumab (8 mg/kg loading dose followed by 6 mg/kg) once every 3 weeks for 4 cycles (AC→TH).
1817378|NCT00712894|Drug|Diltiazem|Intracoronary Infusion 400-2000ug
1817379|NCT00712894|Drug|Verapamil|Intracoronary Infusion 200-1000ug
1817380|NCT00712894|Drug|Nitroglycerin|Intracoronary Infusion 200-1000ug
1817381|NCT00712907|Dietary Supplement|vitamin C (Mayrhofer) 24mg/min i.v. for 64 min|Substance: Ascorbic acid (Mayrhofer) Manufacturer: Mayrhofer, Linz, Austria Dosage form: i.v. Dosage: 24mg/min over 64 min Dosage reference: Ting HH 1996
1817382|NCT00712907|Dietary Supplement|Placebo|Substance: Physiologic saline solution 0.9% (placebo) Dosage form: i.v. Dosage: 24ml/min over 64 min
1817383|NCT00712907|Other|100% O2 (AGA) two times for 12 min|"Substance: 100% oxygen (AGA, Vienna, Austria, gases for human use) Manufacturer: AGA, Vienna, Austria, gases for human use Dosage form: Inhalation through an oxygenmask over a period of 12 minutes two times per study day.
Dosage reference: Strenn K 1997"
1817384|NCT00712920|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 1644 mcg
1817385|NCT00712920|Drug|0.1% azelastine hydrochloride|0.1% azelastine hydrochloride 1096 mcg
1817386|NCT00712920|Drug|Placebo|Placebo
1817387|NCT00712933|Drug|belimumab|"Recombinant, fully human, monoclonal antibody
Comparison of the 1 mg/kg and 10 mg/kg dose of belimumab given IV every 28 days."
1817388|NCT00712959|Biological|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 ml, IM
1817389|NCT00712959|Biological|Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis (ADACEL®)|0.5 mL, IM
1817390|NCT00712985|Drug|Zometa|Zometa (Zoledronic Acid) 5 mg IV over 15 minutes in a one time dose
1817391|NCT00713011|Drug|Adalat XL|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Adalat XL at a starting dose of 20 or 30 mg. Adalat XL will be titrated during the 18 week treatment period in order to optimize blood pressure. Adalat XL will be supplied in 20 mg, 30 mg, 60 mg, and 90 mg.
1817392|NCT00713011|Drug|Tiazac XC|Patients will receive Avalide (Irbesartan/ hydrochlorothiazide; 300 mg/12.5 mg per day or 300 mg/25.0 mg per day) during the 12 week screening period and during the 18 week treatment period. At baseline, patients will be provided with Tiazac XC at a starting dose of 180 mg. Tiazac XC will be titrated during the 18 week treatment period in order to optimize blood pressure. Tiazac XC will be supplied in 180 mg, 240 mg, 300 mg and 360 mg.
1817393|NCT00713037|Procedure|Fluoromisonidazole-PET/CT|2 scans at different time intervals: 2 weeks before and 3 weeks after the participants first proton radiation treatment.
1817394|NCT00713050|Behavioral|Imitate Therapy|Imitation-based computer therapy
1817395|NCT00713063|Behavioral|aerobic exercise|12-week moderate intensity behavioral exercise intervention (MIBE) AND a 12-week standard smoking cessation program (including transdermal nicotine patch)
1817396|NCT00713063|Behavioral|Health Education Control|12-week health education control (HEC) AND a 12-week standard smoking cessation program (including transdermal nicotine patch).
1817529|NCT00714142|Procedure|Positron Emission Tomography|PET Scan
1817400|NCT00713154|Drug|Placebo|Placebo gel in 100 ml tube, two 100 ml tubes prior to each radiation treatment
1817401|NCT00713167|Drug|Grape Seed Extract (Vitagrape)|"Drug {Each Containing: Grape Seed Extract100 mg +...}
1 capsule twice daily for 2 months"
1817402|NCT00713167|Drug|Placebo of Grape Seed Extract|"Placebo {Each Containing: Gelatin 17mg + Cellulose Microcrystalline (Avicel) 67 mg + Dicalcium Phosphate 216mg}
1 capsule twice daily for 2 months"
1817403|NCT00713180|Procedure|Pterygium excision followed by grafting|Pterygium will be excised followed by either free conjunctival or limbal conjunctival graft obtained from the upper part of the globe. The graft will be kept in place by sutures
1817404|NCT00713193|Drug|Cyclosporine|2-3 mg/kg orally in a twice day divided dose for 6 months
1817405|NCT00713193|Drug|Prednisone|1 mg/kg orally, daily for at least 30 days, then tapered over 30 days after achieving remission.
1817406|NCT00713206|Device|Dental Implant (Osseotite)|Root form titanium dental implant
1817407|NCT00713219|Radiation|IMRT, cetuximab, docetaxel|IMRT will be administered in once daily fractions (2 Gy/day, Monday through Friday) over approximately 7 weeks to a goal of approximately 70 Gy. The chemotherapy regimen will begin with a loading dose of intravenous cetuximab (400 mg/m2) one week prior to the initiation of radiation therapy, followed by weekly administration of intravenous docetaxel (15 mg/m2) and intravenous cetuximab (250 mg/m2) for approximately 7 weeks concurrently with radiation. Patients will be evaluated weekly prior to their chemotherapy. All patients will be evaluated on an intention-to-treat basis.
1817408|NCT00713258|Drug|Parathyroid hormone (PTH) (1-84)|100 µg PTH(1-84) daily
1817409|NCT00713258|Drug|Alendronate|70 mg alendronate weekly
1817410|NCT00713271|Drug|AZD3199|"Low dose
Dry powder for inhalation, o.d., 1+12 days"
1817411|NCT00713271|Drug|Placebo|
1817412|NCT00713271|Drug|AZD3199|"intermediate dose
Dry powder for inhalation, o.d., 1+12 days"
1817413|NCT00713271|Drug|AZD3199|"high dose
Dry powder for inhalation, o.d., 1+12 days"
1817414|NCT00713284|Drug|sirolimus|Oral tablet(s) taken daily for 6 months; dose will be based on serum trough levels.
1817415|NCT00713297|Behavioral|satisfaction questionnaire|Satisfaction questionnaire
1817416|NCT00713310|Drug|Asacol 400 mg|"High dose:
17-<33 kg = 3 Asacol 400mg in morning and 2 Asacol 400 in PM, 33-<54 kg = 5 Asacol 400mg in morning and 4 Asacol 400 in PM, 54-<90 kg = 6 Asacol 400mg in morning and 6 Asacol 400 in PM"
1817417|NCT00713310|Drug|Asacol 400 mg|"Low dose:
17-<33 kg = 2 Asacol 400mg + 1 placebo in morning and 1 Asacol 400 +1 placebo in PM, 33-<54 kg = 3 Asacol 400mg +2 placebo in morning and 2 Asacol 400 + 2 placebo in PM, 54-<90 kg = 3 Asacol 400mg + 3 placebo in morning and 3 Asacol 400mg + 3 placebo in PM"
1817418|NCT00713323|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
1817419|NCT00713336|Drug|ZD4054|ZD4054 10mg Tablet
1817420|NCT00713336|Drug|Moxifloxacin|400 mg capsule
1817421|NCT00713336|Drug|ZD4054 Placebo|3 tablets
1817422|NCT00713336|Drug|Moxifloxacin placebo|1 capsule
1817423|NCT00713336|Drug|ZD4054 Placebo|2 tablets
1817424|NCT00713336|Drug|ZD4054|30mg tablet
1817425|NCT00713336|Drug|ZD4054|10mg tablet
1817426|NCT00713349|Drug|Xenaderm Vehicle|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
1817427|NCT00713349|Other|Placebo comparator|Ointment to be applied three times a day on cryo-surgery wound for 21 days.
1817428|NCT00713362|Procedure|Video-assisted thoracoscopic surgery|VATS for bullectomy and mechanical pleurodesis
1817429|NCT00713362|Procedure|chest tube drainage|Chest tube drainage for pneumothroax
1817430|NCT00713401|Drug|Tecadenoson|Tecadenoson administered intravenously (i.v.)
1817431|NCT00713401|Drug|Esmolol|Esmolol low dose infusion according to manufacturer's instructions
1817432|NCT00713427|Device|WallFlex™ Biliary Partially-Covered Stent|Implantable metal biliary stent intended for use in the palliative treatment of biliary strictures produced by malignant neoplasms. The stent is partially covered with a polymer to reduce the potential for tumor ingrowth through the stent.
1817433|NCT00713440|Other|Oral glucose test (OGTT); isoglycaemic iv. clamp; liquid meal test; Gastric Emptying Rate; Prednisolone; Paracetamol|"OGTT: The test is performed with 50 g of glucose deluded in 300 ml. of water. Isoglycaemic iv. clamp: Iv glucose infusion mimicking the glucose response curve of the OGTT.
Liquid Meal Test: The test is performed with 100g of formula milk in 300 ml. of water.
Gastric Emptying Rate: Paracetamol absorption test. Adrenocortical Steroids: Use of 37,5 mg./day of prednisolone during 10 days"
1817434|NCT00713479|Drug|Varenicline, then placebo|Subjects receive MA infusions on certain days first under varenicline (10 days) then under placebo (8 days) after a 14-24 day washout in order to determine study medication safety and tolerability
1817435|NCT00713479|Drug|Placebo, then varenicline|Subjects receive MA infusions on certain days first under placebo (10 days) then under varenicline(8 days) after a 14-28 day washout in order to determine study medication safety and tolerability
1817438|NCT00713505|Other|educational intervention|Parents receive face-to-face training sessions with a therapist over approximately 2-3 months. Phone support/assistance is provided by the therapist within 2-3 days following each training session and then every 2 weeks for up to 6 months after completion of the training sessions.
1817439|NCT00713505|Procedure|psychosocial assessment and care|Child participants and their families may access multidisciplinary psychosocial services (i.e., usual care).
1817440|NCT00713518|Drug|0.5 mg ranibizumab|
1817441|NCT00713518|Drug|3 mg PF-04523655|
1817442|NCT00713518|Drug|1 mg PF-04523655|
1817443|NCT00713544|Drug|AZD5672|20 mg oral, once daily
1817444|NCT00713544|Drug|Etanercept|50 mg, subcutaneous injection, weekly
1817445|NCT00713544|Drug|Placebo|placebo, oral, once daily
1817446|NCT00713544|Drug|AZD5672|50 mg oral, once daily
1817447|NCT00713544|Drug|AZD5672|100 mg oral, once daily
1817448|NCT00713544|Drug|AZD5672|150 mg oral, once daily
1817449|NCT00713557|Device|drug-eluting stent|drug-eluting stent, including sirolimus-eluting, paclitaxel-eluting and other types of China-made drug-eluting stent
1858951|NCT01016483|Drug|Gemcitabine|
1817450|NCT00713557|Drug|Tirofiban|upstream (in emergency room) versus downstream (in catheterization lab) intra-coronary loading versus conventional intravenous loading
1817451|NCT00713583|Drug|levodopa|800/200 mg/d levodopa carbidopa
1817452|NCT00713583|Drug|Placebo|Placebo
1817453|NCT00713596|Drug|Fibrinogen|One time application of 0.5 cc to 2.0 cc of fibrinogen following surgery.
1817454|NCT00713596|Procedure|Septorhinoplasty|Septorhinoplasty to correct nasal deviation.
1817455|NCT00713596|Procedure|Taping after septorhinoplasty.|Simple taping over the nose following nasal surgery.
1817456|NCT00713596|Procedure|Cast applied to the nose after nasal surgery|A molded cast will be placed on top of the nose following nasal surgery.
1817457|NCT00713596|Other|Saline|Approximately 0.5 cc to 2 cc normal saline will be applied after the operation before the nasal taping and casting.
1817458|NCT00713609|Drug|Benzoyl peroxide gel|5% benzoyl peroxide in a gel applied topically once a day
1817459|NCT00713609|Drug|Clindamycin gel|1% clindamycin phosphate applied topically once a day
1817460|NCT00713609|Drug|Tazarotene cream|0.1 % tazarotene in a cream applied topically once a day
1817461|NCT00713609|Drug|Vehicle gel|Vehicle gel is an identical gel without the active ingredients
1817462|NCT00713609|Drug|Vehicle cream|Vehicle cream is an identical cream without the active ingredients
1817463|NCT00713622|Drug|Zonisamide|Capsules of 25mg, 50mg and 100mg zonisamide will be supplied. Dosing will be twice a day.
1817464|NCT00713622|Drug|Sodium valproate|Crushable tablets of 100mg and enteric coated tablets of 200mg and 500mg will be supplied. Dosing will start at 600mg/day, increasing to the minimally effective dose, the maximum tolerated dose, or 2500mg/day, whichever is the lowest.
1817465|NCT00713648|Drug|catridecacog|35 IU/kg body weight, i.v. administration, once every 4 weeks
1817466|NCT00713661|Drug|TachoSil®|"Sterile, ready-to-use, absorbable sponge for intra-operative topical application. It consists of an equine collagen sponge coated with the fibrin glue components human fibrinogen and human thrombin.
Surgery was performed according to the hospitals' local standards. When the anastomosis was performed, all enrolled subjects had TachoSil® applied around the anastomotic line. TachoSil® was therefore an add-on therapy."
1817467|NCT00713674|Other|Theraworx|Theraworx swab intranasal BID for 5 days
1817468|NCT00713674|Drug|mupirocin antibiotic ointment|mupirocin antibiotic ointment swab intranasal BID for 5 days
1817469|NCT00713687|Drug|Gemcitabine, Oxaliplatin, Photodynamic therapy (Photosan®)|"Photodynamic therapy (PDT) after successful drainage:
Photosan® 2 mg/kg i.v. 48 hrs before laser activation
9 cycles of GemOx chemotherapy (start 4 weeks after PDT):
Gemcitabine 1000 mg/m² 100 min infusion on day 1 of chemotherapy
Oxaliplatin 100 mg/m² 2h infusion on day 2 of chemotherapy
iteration every 14 days
afterwards 4 weeks intermission
Iteration of 1. and 2. in case of good compatibility"
1817470|NCT00713700|Device|AMPLATZER Duct Occluder II|AMPLATZER Duct Occluder II
1817471|NCT00713713|Procedure|Mechanical ventilation with low and high tidal volume|Tidal volume of 6 or 12 ml.kg-1, calculated on ideal body weight
1817472|NCT00713726|Drug|FentanyL|Fentanyl: 1 µg/kg/h for preterm infants and 2 µg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
1817473|NCT00713726|Drug|Tramadol|Tramadol: 0.1 mg/kg/h for preterm infants and 0.2 mg/kg/h for term infants for 48 hours and than gradually decrease until interruption of the drug.
1817474|NCT00713739|Drug|Alfuzosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
1817475|NCT00713739|Drug|nifedipine|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
1817476|NCT00713739|Drug|doxazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
1817477|NCT00713739|Drug|prazosin|Patients who present to NMCSD with symptomatic ureteral stones visible on CT and KUB, and who are medically stable will be offered enrollment. The patients will be randomly assigned to one of 4 groups. Outpatient treatment groups will be randomized 1:1:1:1 and include; Group 1 - Alfuzosin 10 mg daily, Group 2 - Nifedipine 30 mg daily, Group 3 - Doxazosin 4 mg daily, or Group 4 - Prazosin 1 mg BID. The treatment regimens consist of daily medication until the stone passes or 21 days, whatever is shorter. Patients will also receive oral pain medication as needed.
1817478|NCT00713765|Drug|AZD3480|18 total doses of 40 mg, on days 1-18
1817479|NCT00713765|Drug|Donepezil|One single dose of mg on day 5
1817480|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using bipolar
1817481|NCT00713778|Procedure|Ovarian cystectomy|Laparoscopic ovarian cystectomy using ultrasonic scalpel electrocoagulation
1817482|NCT00713778|Procedure|Ovarian cystectomy|Laparotomic ovarian cystectomy using suture
1817483|NCT00713791|Drug|ZD4054|Treatment period 1: 10mg oral solution
1817484|NCT00713791|Drug|ZD4054|Treatment period 2: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
1817485|NCT00713791|Drug|ZD4054|Treatment period 3: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
1817486|NCT00713791|Drug|ZD4054|Treatment period 4: 3 of the 5 tablet variations (A-E) to be taken in a random sequence, but not the same tablet twice.
1858952|NCT01016483|Drug|Placebo|
1817487|NCT00713804|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required.
1817488|NCT00713804|Behavioral|Educational Booklet|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
1817489|NCT00713817|Drug|Sativex®|Containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavoring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
1817490|NCT00713817|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient
1817491|NCT00713830|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1817492|NCT00713830|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1817493|NCT00713830|Device|Pen auto-injector|
1817494|NCT00713830|Drug|Sulfonylurea|Sulfonylurea to be continued at maximum effective dose according to local labeling up to end of treatment.
1817495|NCT00713830|Drug|Metformin|Metformin if given to be continued at stable dose (at least 1.5 gram per day [except at least 0.75 gram per day in Japan and 1.0 gram per day in South Korea]) up to the end of treatment.
1817496|NCT00713843|Other|Manual Therapy Utrecht|Manual Therapy (6 weeks).
1817497|NCT00713843|Other|Physical Therapy|Physical Therapy (six weeks).
1817498|NCT00713856|Procedure|Custom PRK with iris registration|PRK
1817499|NCT00713856|Procedure|Conventional PRK|PRK
1817500|NCT00713895|Behavioral|stage-based expert system|an expert system intervention provided the Pathway-To-Change self-help manual and a series of 3 individualized feedback reports at baseline, 3, and 6 months.
1817501|NCT00713895|Behavioral|Standard self-help|standard smoking cessation self-help manual
1817502|NCT00713921|Drug|Detrol LA|Oral Detrol LA, 4mg daily for sim months
1817503|NCT00713934|Biological|CD133|portal vein infusion of CD133+ cells
1817504|NCT00713934|Biological|BM-MNC|portal vein infusion of BM-MNC
1817505|NCT00713947|Drug|during one week for the active treatments|during one week for the active treatments placebo during 25 weeks
1817506|NCT00713947|Drug|Pantoprazole|6 months at 20 mg
1817507|NCT00713947|Drug|Placebo Formula 515|26 weeks, one tablet per day
1817508|NCT00713986|Procedure|Water 2mL PO 2 minutes prior to intra-muscular injection|Sterile Water 2mL PO - single dose
1817509|NCT00713986|Procedure|skin-to-skin contact|neonates will receive skin-to-skin contact beginning 2 minutes before the intra-muscular injection and stopping 2 minutes afterwards.
1817510|NCT00713986|Procedure|Glucose 25% 2 mL PO 2 minutes prior to injection|Glucose 25% 2mL PO - single dose
1817511|NCT00713986|Procedure|neonates will receive skin-to-skin contact beginning 2 minutes after the intra-muscular injection and stopping 2 minutes afterwards.|neonates will receive 2 mL of glucose 25% PO (single dose) 2 minutes prior to the acute painful procedure. Skin-to-skin contact will start 2 minutes after the intra-muscular injection and will stop 2 minutes afterwards.
1817512|NCT00713999|Drug|Treatment with anti-STI and anti-schistosoma regimens|Anti-STI regimen: ciprofloxacin 500mg orally, doxycycline 100mg BID orally 7 days and metronidazole 2g orally (cefuroxime im and/or azithromycin alternatively for pregnant and breastfeeding women) Anti-schistosoma regimen: Praziquantel 40mg/kg
1817513|NCT00714012|Other|observational|presented with paper-based sets, web based sets or human simulator based set of questionnaires designed to identify the users' experience level and optimal visual or auditory elements for each specific domain.
1817514|NCT00714025|Drug|RAD001|RAD001 10mg, daily, PO
1817515|NCT00714051|Behavioral|fall prevention training|Training on a specialized treadmill that produced trip-simulating perturbations (movements.
1817516|NCT00714051|Behavioral|Attention Control|Participants walked on a treadmill at a self-selected speed once per week for four weeks.
1817517|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group A will receive 23vPPV during 3rd trimester and dTpa at delivery
1817518|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group B will receive 23vPPV at delivery and dTpa 7 months following delivery
1817519|NCT00714064|Biological|23vPPV, dTpa (Pneumovax, Boostrix)|Group C will receive dTpa at delivery and 23vPPV 7 months following delivery
1817520|NCT00714090|Other|active venlafaxine and active rTMS-repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed|"active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
active rTMS : 5 sessions per week for 2 to 6 weeks"
1817521|NCT00714090|Other|active rTMS -repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and sham venlafaxine|active rTMS : 5 sessions per week for 2 to 6 weeks sham venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
1817522|NCT00714090|Other|sham rTMS- repetitive transcranial magnetic stimulator, Inomed and Alpine Biomed and active venlafaxine|sham rTMS : 5 sessions per week for 2 to 6 weeks active venlafaxine LP 75 mg : 1 capsule per day for 3 days, then 2 per day for 2 to 4 weeks, if necessary 3 per day the next 2 weeks.
1817523|NCT00714103|Drug|8-Chloro-Adenosine|45 mg/m^2 intravenous over 1 hour daily for 5 days every 4 weeks (± 3 days).
1817524|NCT00714116|Drug|SBI-087|Single IV or SC dose of SBI-087
1817527|NCT00714142|Drug|62Cu-ethylglyoxal bis(thiosemicarbazone)|15-25 mCi, IV
1817528|NCT00714142|Drug|15O-water|10-20 mCi, IV
1817530|NCT00714155|Other|Questionnaires, Physical Examination|Questionnaires, Physical Examination
1817531|NCT00714168|Behavioral|Standard Behavioral Weight Loss Program|This program will include group sessions that will focus on modifying eating and physical activity behaviors to improve weight loss.
1817532|NCT00714168|Behavioral|Stepped-Care Weight Loss Program|In this program, increases in the intensity of treatment will be based on participants' abilities to achieve predetermined weight loss goals. Participants will initially receive less contact with program staff. The intensity and/or frequency of contact will then increase at 12-week intervals, based on weight loss progress until a 10% weight loss is attained and maintained. The program will stay constant, unless weight loss drops below the 10% level.
1817533|NCT00714181|Drug|hydroxychloroquine|
1817534|NCT00714181|Drug|temozolomide|
1817535|NCT00714181|Genetic|TdT-mediated dUTP nick end labeling assay|
1817536|NCT00714181|Genetic|western blotting|
1817537|NCT00714181|Other|electron microscopy|
1817538|NCT00714181|Other|high performance liquid chromatography|
1817539|NCT00714181|Other|immunoenzyme technique|
1817540|NCT00714181|Other|immunohistochemistry staining method|
1817541|NCT00714181|Other|laboratory biomarker analysis|
1817542|NCT00714181|Other|mass spectrometry|
1817543|NCT00714181|Other|pharmacological study|
1817544|NCT00714194|Procedure|Normal continuous sedation|Normal continuous sedation.
1817545|NCT00714194|Other|Daily interruption of continuous sedation|Withdrawal of normal continuous sedation with Lorazepam, Midazolam, and Propofol from 7:00 am to 8:00 am daily until continuous sedation discontinuation.
1817546|NCT00714207|Behavioral|NOT program|Students in this arm of the study received the reformatted NOT intervention
1817547|NCT00714207|Behavioral|NOT controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
1817548|NCT00714207|Behavioral|Kicking Butts intervention|Students in this arm of the study were randomized to receive the reformatted Kicking Butts intervention
1817549|NCT00714207|Behavioral|KB controls|Students in this arm were randomized to receive a single group session on smoking cessation and were given youth oriented informational pamphlets
1817550|NCT00714233|Drug|Metformin|Metformin 425mg. capsules, 2 capsules BID x 24 weeks
1817551|NCT00714233|Drug|Oral Contraceptive Pills (Yasmin)|Yasmin oral contraceptive tabs; 1 tab daily x 24 weeks
1817552|NCT00714233|Behavioral|Lifestyle Modification|weekly classes x 24 weeks for training in diet, exercise and behavior modification skills
1817553|NCT00714233|Drug|placebo|placebo to the active metformin arm. 2 capsules BID x 24 weeks.
1817556|NCT00714259|Drug|Fludarabine|Fludarabine 30 mg/m2/day x 3 days
1817557|NCT00714259|Radiation|Total Body Irradiation|TBI 200cGy x1 dose on transplant day
1817558|NCT00714259|Other|Infusion of Stem Cells|On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10*6 CD34+ cells per kilogram of recipient weight.
1817559|NCT00714285|Biological|GSK Biologicals' quadrivalent influenza vaccine|Single intramuscular dose on Day 0.
1817560|NCT00714285|Biological|GSK Biologicals' trivalent influenza vaccine|Single intramuscular dose on Day 0.
1817561|NCT00714298|Other|Measure of Initial heart fatty acid binding protein and ischemia modified albumin|Initial heart fatty acid binding protein and ischemia modified albumin will be measured after patient's arrival in the emergency room. The aim of the study is to analyse the predictive value of association of heart fatty binding protein and ischemia modified albumin for non ST segment elevation acute coronary syndrome diagnosis in the first hour of management in the emergency room.Treating physicians, biologist physician will be blinded to the results of the markers.
1817562|NCT00714311|Behavioral|Transference-Focused Psychotherapy|Outpatient psychotherapy according to the treatment manual, sessions of 50 minutes twice per week
1817563|NCT00714311|Behavioral|treatment by experienced community psychotherapists|Outpatient psychotherapy in private practices or outpatient units of psychiatric hospitals. Licensed psychotherapists with experience and special interest in the treatment of borderline patients are treating according to the method they have learned.
1817564|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (36mL of AZD1386 2.5mg/mL oral solution).
1817565|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (3 x 30mg AZD1386 capsules)
1817566|NCT00714337|Drug|AZD1386|One single oral dose of 90mg (6 x 15mg AZD1386 tablets)
1817567|NCT00714350|Behavioral|New ICU Display Visualization|
1817568|NCT00714363|Procedure|LASIK|Refractive surgery
1817569|NCT00714363|Procedure|SBK|Refractive surgery
1817570|NCT00714376|Drug|Docetaxel|75 mg/m2 iv every 3 weeks for 8 cycles
1817607|NCT00714727|Procedure|acupuncture|8 weeks of acupuncture, starting with twice a week for 4 weeks, followed by once a week for 4 weeks, using 8 standardized, bilateral acupuncture points.
1817608|NCT00714740|Drug|acetazolamide|acetazolamide 2 times 250mg per day
1817609|NCT00714753|Radiation|brachytherapy|
1868686|NCT01091623|Other|training|
1996626|NCT02431767|Biological|PENNVAX®-GP HIV-1 DNA vaccine|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
1996627|NCT02431767|Biological|Interleukin-12 (IL-12) DNA adjuvant|Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
1996628|NCT02431767|Biological|Placebo|Sterile Water for Injection, USP. Administered by intradermal (ID) injection in Groups 1, 2, and 3; administered by intramuscular (IM) injection in Group 4.
1996629|NCT02431884|Procedure|collect body fluids/tissues & med history|collect tissues/fluids & history
1996630|NCT02431000|Procedure|Sperm and blood collected for analysis|Sperm Collection and Freezing (Cryopreservation), Blood Collection for analysis
1996631|NCT02430896|Drug|Methylphenidate (MPH)|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
1996632|NCT02430896|Drug|Atomoxetine|Subjects of ADHD group will be taking methylphenidate or atomoxetine for 52 weeks.
1996633|NCT02430428|Device|Carl Zeiss Meditec VisuMax Femtosecond Laser|VisuMax femtosecond laser sphere-only or spherocylindrical treatment
1996634|NCT02428712|Drug|PLX8394|PLX8394 tablets, 75mg
1817572|NCT00714441|Behavioral|Lifestyle and Activities Education Program (LEAP-AHEAD)|Patients in the LEAP-AHEAD Program arm will be shown a 40-minute interactional DVD and given the Healthy Habits Health Risk Appraisal, at baseline and 20 weeks that asks questions about diabetes self care practices and other health behaviors and gives recommendations in those areas. A score sheet based on the participant's responses will be left with the participant. At intervals from 0 to 44 weeks, patients will receive emailed informational pamphlets on diabetes and its complications, along with live telephone calls to answer any questions and check-in.
1817573|NCT00714441|Behavioral|Computer Automated Self-Management (CASM)|CASM is a live and computer-assisted, low intensity, automated web and telephony based program that is directed at enhancing and sustaining diabetes self-management behavior over time. It provides education on the importance of healthy eating, physical activity and medication taking, and then asks patients to select an area for behavior change. At baseline patients will have a 45 minutes home visit to help them set goals and familiarize them with the website. A booster session is given at 20 weeks. Patients receive 8 ive phone calls over 12 months to support behavior change efforts.
1817574|NCT00714441|Behavioral|Computer Automated Self-Management and Problem Solving Therapy (CAPS)|Patients in the CAPS program receive all of the protocol included in the CASM program, and in addition receive a Problem Solving program. Problem solving is a process by which an individual attempts an adaptive solution to stressful, real life problem(s). At baseline there is a 45 minute home visit where the Counselor will introduce the patient to CASM and will go on to teach the patient about diabetes distress and PST. They will then generate a list of distress-related problems to teach the steps of PST. The steps of PST are: problem definition, goal setting, brain storming, decision making, action planning, and solution review. At 20 weeks there will be a booster session. Patients receive 8 live phone calls over 12 months to support behavior change efforts.
1817575|NCT00714454|Other|APS Topical Lotion|
1817576|NCT00714454|Other|Placebo|
1817577|NCT00714467|Behavioral|Expert System Only|expert system intervention only to the smoker participants which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters receive assessments only and no intervention.
1817578|NCT00714467|Behavioral|Family Assisted|The smoker participants received an expert system intervention (same intervention for those in the Expert system intervention) which includes a stage-based manual and a series of 3 individualized tailored feedback report at baseline, 3, and 6 months. The paired-supporters will receive a a self-help booklet based on the Transtheoretical Model of Change (TTM) that will aim at teaching the supporters how to use the stages of change framework to apply different strategies that best match with smokers' readiness to quit smoking.
1817579|NCT00714480|Drug|anti-thymocyte globulin|Administration of anti-thymocyte globulin at post-operative days -6, -4, -2 and 0
1817580|NCT00714480|Drug|anti-thymocyte globulin|anti-thymocyte globulin post-operative days -2, 0, 2 and 4
1817581|NCT00714480|Drug|anti-thymocyte globulin|Post-operative days 0, 2, 4 and 6
1817582|NCT00714493|Biological|Infliximab|3 mg/kg at week 0,2,6; Increase to 5mg/kg or 7 mg/kg based on EULAR response
1817583|NCT00714506|Behavioral|Diet and physical activity|lifestyle weight reduction - low fat eating, low calorie and physical activity
1817584|NCT00714506|Other|Physical activity control|physical activity plus successful aging health education
1817585|NCT00714519|Drug|Xenaderm® Ointment|Topical, BID or as needed
1817586|NCT00714519|Drug|Placebo Comparator|Topical, BID or as needed
1817587|NCT00714532|Behavioral|Expert System Only|Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
1817588|NCT00714532|Behavioral|Enhanced Expert System|"The intervention consists of 3 components:
Expert system which includes a stage-matched manual, and a series of 3 individualized tailored feedback reports at baseline, 1, and 3 months
scheduled smoking intervention, which includes a tailored-made 3-week smoking reduction schedule and a stage-matched tip guide to explain why and how to use the smoking reduction intervention
telephone check-in calls to provide brief counseling and technical support to motivate participants to use the intervention materials
a 2-week supply of nicotine gum or lozenge per participants' choice to use during smoking reduction"
1817589|NCT00714545|Radiation|Intracoronary brachytherapy|Beta irradiation with a 40-mm strontium/lytrium-90 source
1817590|NCT00714558|Drug|Fentanyl citrate; Naltrexone; Naloxone|
1817591|NCT00714571|Behavioral|Mnemonic strategy training (MST)|
1817592|NCT00714571|Behavioral|Repeated exposure (XP)|
1817593|NCT00714571|Behavioral|Subtracting Cues training|
1817594|NCT00714584|Drug|Naltrexone HCl.|
1817595|NCT00714597|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection"
1817596|NCT00714597|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection"
1817597|NCT00714623|Device|Sirolimus-Eluting Bx Velocity Coronary Stent (CypherTM Sirolimus-Eluting Stent)|Indications for use: The CYPHER™ Sirolimus-eluting Coronary Stent is indicated for improving coronary luminal diameter in patients with symptomatic ischemic disease due to discrete de novo lesions of length less than or equal to 30 mm in native coronary arteries with a reference vessel diameter between 2.5 and 3.5 mm. Long-term outcome (beyond 12 months) for this permanent implant is unknown at present.
1817598|NCT00714649|Drug|cetuximab|Cetuximab 250mg/m²/week IV before surgery till surgery
1817599|NCT00714662|Device|high flux hemodialyzer (FX-60, FX-80 or FX-100)|three sessions per week
1817600|NCT00714675|Dietary Supplement|Citrulline|1 unit of 10 g L-Citrulline, 1 time on morning during 21 days
1817601|NCT00714675|Dietary Supplement|Amino acids|1 unit of an equivalent quantity of iso nitrogenous of non-essential amino acids(alanine, aspartate, glycine, serine, histidine, proline), 1 time on morning during 21 days.
1817602|NCT00714688|Drug|prolonged release (PR) OROS methylphenidate 54 mg|18+36mg once daily for 13 weeks
1817603|NCT00714688|Drug|prolonged release (PR) OROS methylphenidate 72 mg|2x36mg once daily for 13 weeks
1817604|NCT00714688|Drug|Placebo|2xplacebo once daily for 13 weeks
1817605|NCT00714714|Drug|Adapalene Gel|adapalene gel 0.3% topically applied daily in a split-face model for two weeks
1817606|NCT00714714|Drug|Tretinoin Gel|Tretinoin 0.1% topically applied daily in a split face model for two weeks
1817610|NCT00714753|Radiation|hypofractionated radiation therapy|
1817613|NCT00714766|Procedure|Intravascular volume administration|Infusion of colloid to reestablish CVP under heat stress
1817614|NCT00714779|Drug|Fluoxetine|20-40 mg / day orally
1817615|NCT00714779|Behavioral|Short-term psychodynamic psychotherapy|1 session / week for 16 weeks
1817616|NCT00714818|Behavioral|Genetic Counseling|One face-to-face genetic counseling session of 1-2hours duration, with a board certified or board eligible genetic counselor which will involve, documentation of a detailed family history, discussion of: the contributors to mental illness pathogenesis, illness risk reduction strategies, chances for family members to develop mental illness (if required), supportive counseling around living with illness/risk of illness/managing illness vulnerability, and referral to support organizations as required
1817617|NCT00714818|Behavioral|Genetic Counseling|One educational booklet that provides information about the causes of mental illnesses, and the chances for relatives of affected individuals to develop mental illness will be provided to participants.
1817618|NCT00714831|Behavioral|Physical activity intervention|3-months physical activity intervention
1817619|NCT00714831|Behavioral|Health educational program|Health education sessions and stretching sessions
1817620|NCT00714857|Drug|Dexmedetomidine|The patients are given a normal loading dose (10 min infusion at a rate of 3-6 μg/kg/h) of dexmedetomidine followed by continuous infusion of 0.1 - 2.5 μg/kg/h for the period of time the responsible physician finds reasonable.
1817621|NCT00714870|Behavioral|Behavioral nutrition and exercise program|The intervention consists of a behavioral nutrition and exercise program. Meetings occur monthly on a Saturday afternoon and last 4 hours. During this time we cover: 1)registration: monitoring of sedentary activities and liquid choices, motivational interviewing, exercise testing;2)exercise: includes strength training; 3) educational lectures; 4) didactic games and projects.
1817622|NCT00714883|Device|NEVO™ Sirolimus-eluting Coronary Stent System|Intervention will consist of percutaneous coronary intervention for treatment of lesions in native coronary arteries using standard coronary intervention techniques. Intervention will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System.
1817623|NCT00714896|Behavioral|Stepped-Care|"stage-based expert system written intervention at baseline and 3 months
in-person stage appropriate counseling at baseline and 3 months
telephone counseling sessions at weeks 2,4 and 8,
as-needed brief check-in calls on or 2 days after quit date for those who have set a quit date; and/or check-in calls on days with anticipated high risk situations for former smokers or those who have quit smoking during the study
optional NRT nicotine replacement therapy in the forms of patch, gum or lozenge for current smokers who are ready to quit smoking and/or for former smokers who report significantly strong smoking urges"
1817624|NCT00714896|Behavioral|Control|Referral list to smoking cessation classes at Kaiser and the California Smokers Helpline
1817625|NCT00714922|Procedure|PRK|Laser refractive surgery
1817626|NCT00714922|Procedure|SBK|Laser refractive surgery
1817627|NCT00714935|Behavioral|Decision Counseling Program (DCP)|An individual decisional counseling program (DCP) to help them comprehend the information, adjust this information to their personal illness history and elicit their preferences for cardiac risk fctor modification behavior in light of this personalized information
1817628|NCT00714935|Behavioral|Coronary Artery Disease Decision Aid|"Coronary Artery Disease Decision Aid (CAD-DA) presented as a booklet called: Making Choices: Life Changes to Lower Your Risk of Heart Disease and Stroke
The CAD-DA is developed by the Ottawa Health Research Institute and Division of Clinical Epidemiology at Montreal General Hospital, in CAD patients facing the decision of making lifestyle changes to lower their cardiac risk factors and provides patients with information about what they can you do to prevent the disease from progressing."
1817629|NCT00714948|Drug|gemcitabine and cisplatin plus sorafenib|Gemcitabine 1000 mg/m 2 will be administered on days 1 and 8 and cisplatin 35 mg/m 2 will be administered on days 1 and 8. A total of six cycles of therapy will be administered at 21day intervals. Sorafenib 400 mg PO twice daily will be initiated on day 1 of cycle 1 and continued, as tolerated, until the time of disease progression or a maximum of 12 months. The total chemotherapy dose for gemcitabine and cisplatin (GC) may be modified for patients with severe obesity (e.g. body surface area (BSA) > 2.1), after consultation with the Principal Investigator.
1817630|NCT00714961|Drug|Clopidogrel (SR25990)|plus acetylsalicylic acid (ASA)
1817631|NCT00714961|Drug|Placebo|plus acetylsalicylic acid (ASA)
1817632|NCT00714974|Device|BIS|Sedation dosing based on BIS value, oer treating physician discretion.
1817633|NCT00715000|Procedure|Oral rehydration therapy|oral rehydration solution
1817634|NCT00715000|Procedure|classical hydration via intravenous infusion|intravenous infusion
1817636|NCT00715026|Device|Trilogy AB Acetabular Hip Implant System|Total hip replacement with ceramic on ceramic treatment surfaces.
1817637|NCT00715039|Drug|lorazepam|1.0 mg p.o. three times a day for three days, then 1.5mg p.o. three times a day for 25 days
1817638|NCT00715039|Drug|placebo|placebo p.o. t.i.d. for 28 days; placebo matching lorazepam and paroxetine
1817639|NCT00715039|Drug|paroxetine|20mg p.o. daily for 28 days; and matching placebo twice a day to maintain blind
1817640|NCT00715052|Procedure|Hyperbaric Oxygen Therapy (HBOT)|40 consecutive one hour treatments at 1.5 ATA with 100% O2
1817641|NCT00715065|Procedure|fMRI Scan|Subjects will undergo a functional MRI scan of the head lasting ~45 minutes. They will be repeatedly shown video clips of blood, other disgusting things, or are neutral.
1817642|NCT00715078|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
1817643|NCT00715091|Drug|diclophenac|continuous (daily) treatment of diclofenac cholestyramine 150 mg, divided into 75mg twice daily
1817644|NCT00715091|Drug|diclophenac|treatment on-demand (as needed) with diclofenac-cholestyramine 75 to 150 mg daily
1817645|NCT00715104|Biological|Sipuleucel-T with Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
1817686|NCT00705978|Drug|Pancreatin|Pancreatin with 40000 lipase units per capsule, 2 capsules per main meal (3 main meals) plus 1 capsule per snack (2-3 snacks)
1817646|NCT00715104|Biological|Sipuleucel-T without Booster|Sipuleucel-T is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. Sipuleucel-T consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
1817647|NCT00715117|Drug|Naltrexone|Naltrexone 0.1 mg/kg (not to exceed 4.5mg) once a day orally for 16 weeks
1817648|NCT00715117|Other|Placebo, sugar pill|Placebo -Sugar pill or liquid identical to active drug in appearance and taste given by mouth at bedtime once daily
1817649|NCT00715130|Behavioral|Energy Balance|We propose to develop and test a comprehensive intervention that will provide simple strategies related to dietary intake and energy expenditure that individuals can follow to achieve a balance in their energy intake and expenditure, while simultaneously changing structural and environmental cues to focus on promoting information, social support and opportunities for managing energy intake and increasing physical activity.
1817650|NCT00715143|Device|Novation Ceramic|This treatment is the study device (which will be compared to a similar historic control device)
1817651|NCT00715169|Drug|MLN1202|10 mg/kg dose of MLN1202 administered via IV infusion administered approximately 30 minutes to an hour
1817652|NCT00715169|Other|Placebo|Placebo consist of 0.9% saline solution administered as a 10 mg/kg dose via IV infusion administered approximately 30 minutes to an hour
1817653|NCT00715182|Drug|TKI258|
1817654|NCT00705770|Drug|Anecortave Acetate|"Low dose
Sustained release depot suspension"
1817655|NCT00705770|Drug|Anecortave Acetate|"Middle dose
Sustained release depot suspension"
1817656|NCT00705770|Drug|Anecortave Acetate|"High dose
Sustained release depot suspension"
1817657|NCT00705770|Drug|Placebo|Placebo treatment with vehicle
1817660|NCT00705796|Drug|MPP10, testosterone|Testosterone intranasal, 7.6 mg, twice daily to be taken immediately after waking up and washing/showering (approx. 7:00-8:00 AM) and at lunch time (approx. 12:00 AM).
1817661|NCT00705796|Drug|Testosterone|AndroGel® 50 mg, once daily in the morning after washing/showering.
1817662|NCT00705822|Drug|Docetaxel + Estramustine + Hydrocortisone|"Docetaxel iv 80 mg + Oral estramustine-pills 140 mg + Oral hydrocortisone-pills 20 mg.
Combination of these 3 drugs every 3 weeks"
1817663|NCT00705822|Drug|Docetaxel + Prednisone|Docetaxel iv 80 mg + oral prednisone-pills 5 mg. Combination of these 2 drugs every 3 weeks.
1817664|NCT00705835|Biological|rsPSMA protein plus Alhydrogel® vaccine|The assigned dose of rsPSMA protein plus Alhydrogel® vaccine will be administered subcutaneously to random sites on the upper arm and upper leg at weekly intervals for 3 weeks. This will be followed by a 4-week break and then a fourth vaccination during week 7. The vaccination site will rotate to a different quadrant with each administration.
1817665|NCT00705861|Drug|Placebo|Placebo as a substitute of SK3530 100mg
1817666|NCT00705861|Drug|SK3530|SK3530 100mg
1817667|NCT00705874|Drug|CGC-11047 and gemcitabine|Gemcitabine: (Closed to enrollment) 1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle. CGC-11047 will only be given on days 1 and 15 of each cycle and will start at dose level -1 (50 mg).
1817668|NCT00705874|Drug|CGC-11047 and docetaxel|Docetaxel: (Closed to enrollment) 75 mg/m2 administered IV over 60 minutes every 21 days. CGC-11047 will be administered only on Day 1 of each 21-day cycle and will start at dose level -1 (50 mg).
1817669|NCT00705874|Drug|CGC-11047 and bevacizumab|Bevacizumab: 5 mg/kg administered IV once every 14 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
1817670|NCT00705874|Drug|CGC-11047 and erlotinib|Erlotinib: 150 mg taken orally every day of each 28-day cycle. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
1817671|NCT00705874|Drug|CGC-11047 and cisplatin|Cisplatin: 80 mg/m2 administered IV over 1 hour once every 28 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
1817672|NCT00705874|Drug|CGC-11047 and 5-flurouracil / leucovorin|5-Flurouracil / Leucovorin: Leucovorin 500 mg/m2 IV over 2 hours with 5 - FU 500 mg/m2 IV bolus starting 1 hour into leucovorin infusion weekly for 6 wks, repeated every 56 days. CGC-11047 will be administered on Days 1, 8 and 15 of a 28 day cycle.
1817673|NCT00705874|Drug|CGC-11047 and sunitinib|Sunitinib: 50 mg orally once daily, 4 weeks on treatment followed by 2 weeks off (42 day cycle). CGC-11047 will be administered on Days 1 and 8 of a 21 day cycle.
1817674|NCT00705887|Behavioral|Brief Motivational Enhancement Intervention|The motivational enhancement intervention lasted 5-8 minutes and consisted of gaining the client's permission to address the topic of skin cancer prevention, exchanging information through the elicit-provide-elicit strategy of information exchange, and summarization/ conclusion based on verbal and nonverbal cues from the participant.
1817677|NCT00705913|Device|Mitroflow Aortic Pericardial Heart Valve (CarboMedics)|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Pericardial valve as compared to the Edwards Magna valve
1817678|NCT00705913|Device|Carpentier-Edwards Magna Tissue Valve|Study to compare sizing, implant techniques and hemodynamics of the Mitroflow Valve as compared to the Edwards Magna valve
1817679|NCT00705926|Drug|Highly Active Antiretroviral Therapy (HAART)|Participants in Groups A1 and A2 will receive HAART for either 12 or 32 weeks. Their medications will not be provided by the study.
1817680|NCT00705926|Other|No treatment|Participants in this group will not receive treatment at this stage of their infection.
1817681|NCT00705939|Drug|Taliglucerase alfa|Intravenous infusion every 2 weeks
1817682|NCT00705952|Other|Lifestyle intervention|Diet, exercise and behavioural change intervention.
1817683|NCT00705965|Behavioral|Psychotherapy|Stepwise, manualized individual and group psychotherapy in addition to usual cardiological care.
1817684|NCT00705965|Behavioral|Information session|One information session about living with heart disease.
1817685|NCT00705965|Other|Usual cardiological care|Usual cardiological care
1817687|NCT00705978|Drug|Placebo|placebo
1817688|NCT00705991|Procedure|ROTEM|
1817689|NCT00706004|Drug|lubiprostone|lubiprostone 24 microgram capsule taken twice daily for 4 weeks
1817690|NCT00706017|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1817693|NCT00706069|Drug|Vinorelbine oral|Vinorelbine at dose levels of 30mg, 40mg, 50mg, 60mg oral every Monday, Wednesday and Friday
1817694|NCT00706069|Drug|Capecitabine|Capecitabine at dose levels of 800 mg/m2, 950mg/m2, 1100mg/m2, 1250mg/m2 per os from day 1 to day 14 every 21 days
1817695|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.4 mg/m^2 for normal hepatic function.
1817696|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 1.1 mg/m^2 for mild hepatic impairment (Child-Pugh A)
1817697|NCT00706095|Drug|E7389|E7389 Intravenous injection starting dose on Day 1 is 0.7 mg/m^2 for moderate hepatic impairment (Child-Pugh B)
1817698|NCT00706108|Behavioral|Observational study|Observational (descriptive) study of technical and non-technical performance
1817699|NCT00706121|Drug|Vitamin E|400 IU daily by mouth for 7 - 12 years
1817700|NCT00706121|Drug|Selenium|200 mcg daily for 7 - 12 years
1817701|NCT00706121|Drug|Vitamin E placebo|1 pill by mouth daily for 7 - 12 years
1817702|NCT00706121|Drug|selenium placebo|1 pill by mouth daily for 7 - 12 years
1817703|NCT00706134|Drug|Placebo|Placebo tablet taken once daily in the morning with a light meal.
1817704|NCT00706134|Drug|Aliskiren 75 mg|Aliskiren 75 mg tablet taken once daily in the morning with a light meal.
1817705|NCT00706134|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet taken once daily in the morning with a light meal.
1817706|NCT00706134|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet taken once daily in the morning with a light meal.
1817707|NCT00706147|Drug|Arimoclomol|Drug: Arimoclomol capsules given three times per day
1817708|NCT00706147|Drug|Placebo|Drug: Placebo capsules given three times per day
1817709|NCT00706173|Drug|Hydrocortisone|Hydrocortisone 10-20 mg PO daily for 4 weeks.
1817710|NCT00706173|Drug|Placebo|"Placebo 10-20 mg PO daily for 4 weeks."
1817711|NCT00706186|Drug|Sodium Oxybate|The patient will maintain a dosage of 4.5 g/day for a duration of 7 days leading to Treatment Visit 1. After successful assessment at Treatment Visit 1, the dosage will be increased to 6 g/day for the duration of the trial. At Treatment Visit 2 (day 21), the dosage will be increased to a dosage of 9 g/day, if tolerated by the patient.
1817712|NCT00706199|Procedure|Bone marrow aspiration|Collection of a 2 ml bone marrow sample from an aspirate carried out for medical purposes.
1817713|NCT00706225|Drug|Bazedoxifene and conjugated estrogens|Bazedoxifene 20 mg tablet once daily for 7 days. Conjugated Estrogens 0.625 mg tablet, single doses one week apart.
1817715|NCT00706251|Device|Silicone tube|Silicone tube which is inserted into the tear duct through the punctum in the eyelid, then passed through the tear duct till it enters the nose and secured in place using a surgical knot. The tube remains in place for 3-6 months, than take out by the surgeon.
1817716|NCT00706264|Device|Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
1817717|NCT00706277|Drug|propofol|propofol 2mg/kg for induction of anesthesia; followed by propofol 6 mg/kg/hour
1817718|NCT00706277|Drug|propofol|propofol 2mg
1817719|NCT00706277|Drug|remifentanil|remifentanil 0,25mcg/kg/hour
1817720|NCT00706277|Drug|fentanyl|fentanyl 100mcg
1817721|NCT00706277|Drug|Sevoflurane/Nitrous Oxide|maintenance of anesthesia with sevoflurane and nitrous oxide
1817722|NCT00706290|Behavioral|Brief Cognitive Behavioral Therapy|The cognitive-behavioral intervention consists of 6-7 sessions lasting 60-90 minutes each focused on psycho-education; relaxation training; cognitive-restructuring and coping with cancer fears; and activity planning and pacing. Sessions are delivered by a licensed clinical psychologist or trained psychology fellow or graduate student.
1817723|NCT00706303|Behavioral|Supported self management training and support|Supported Self-management. This will consist of fortnightly individual patient sessions at home of approximately 40 minutes for two months, with home visits at a maximum frequency of 6 weeks thereafter for 1 year. Further details of the rubric of the initial training sessions are given in Appendix 1 and will use adapted versions of the Bourbeau self-management and education materials. Follow up visits will be less structured, and based on the patient's individual agenda as well as reviewing and reinforcing basic self-management messages. Patients will be provided with an individualised self-management plan and symptom diary cards to use as a monitoring aid. Patients will be trained to identify and treat exacerbations associated with purulent sputum with antibiotic and those associated with increased breathlessness, mucoid sputum and/or upper airway symptoms with Prednisolone.
1817724|NCT00706316|Biological|EBV-Specific CTLs and CD45 Mab|"One time infusion (IV) at one of the following dose levels:
Dose level I: 5 x 107 cells/m2
Dose level II: 1 x 108 cells/m2
Dose level III: 2 x 108 cells/m2"
1817725|NCT00706329|Device|Deflux|Patients undergo surgery using Deflux to correct umbilical hernia
1817726|NCT00706342|Drug|Fostamatinib Disodium / R935788|R935788 tablets
1817727|NCT00706355|Drug|PF-04217903|Escalating doses of PF-04217903 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 50 mg BID to 1000 mg BID. A cycle is considered to be 21 days
1817728|NCT00706368|Device|Point of care tests|Several point-of-care tests are offered: OSOM TV rapid trichomonas test; OSOM BV Blue rapid test; pHEMalert vaginal pH test. All subjects receive the OSOM TV test, while the other two are optional.
1817732|NCT00706394|Device|Endologix Powerlink 34 mm stent graft cuff|Endovascular abdominal aortic aneurysm repair
1817804|NCT00706901|Behavioral|Arm 3 TCC|TCC consisted of a 4-session psychoeducational group (75 minutes per session). Material was delivered using a power point presentation on topics
1817805|NCT00706914|Drug|Once-daily aclidinium/formoterol|Inhaled aclidinium bromide 200 µg/formoterol fumarate 12 µg fixed-dose combination once-daily in the morning
1868687|NCT01091623|Other|training|
1997026|NCT02277327|Behavioral|Plans of Action and Care Transitions|"Subjects randomized to the intervention will participate in action planning and care transitions (if hospitalized during the study period)"
1817734|NCT00706420|Procedure|Islet Transplantation + Immunosuppression|Islet Transplantation + Immunosuppression (Sirolimus/Tacrolimus, daclizumab)
1817735|NCT00706420|Biological|Islet cell transplantation|Islet cell transplantation will occur through the portal vein.
1817736|NCT00706433|Drug|aminolevulinic acid HCL (ALA)|Levulan Kerastick containing 20% aminolevulinic acid HCL (ALA). Up to 4 treatments will be given at 3 week intervals.
1817737|NCT00706433|Other|Vehicle (VEH)|Levulan Kerastick containing vehicle ingredients only (VEH). Up to 4 treatments will be given at 3 week intervals.
1958446|NCT01638013|Drug|peficitinib|oral
1958447|NCT01636011|Other|Osteopathic Manipulative Medicine Treatment|Osteopathic Manipulative Medicine Treatment
1958448|NCT01636011|Other|Light Touch sham|Light Touch sham
1958449|NCT01630616|Drug|Odanacatib|single oral dose, tablets, 10 or 50 mg
1958450|NCT01630616|Drug|Placebo|single oral dose, tablets
1817743|NCT00706459|Device|Magnetic Resonance Imaging|All study subjects will have a 3T MRI examination. The MRI exam will take approximately 90 minutes to complete and will involve the scanning o the spine.
1817744|NCT00706485|Device|Yttrium-90 Plaque Applicator|Placed on the dura during surgery for 10-17 1/2 minutes
1817745|NCT00706498|Drug|BI 2536|
1817746|NCT00706511|Device|CPAP|CPAP (continuous positive airway pressure) treatment at home for 6 weeks
1817747|NCT00706537|Drug|Active treatment|20 mg CP-945598 as 15 and 5 mg tablet once daily for 3 weeks
1817748|NCT00706537|Drug|Placebo|Placebo as two tablets once daily for three weeks
1817749|NCT00706550|Biological|(PV) 23-valent pneumococcal polysaccharide vaccine|Currently commercially available pneumococcal polysaccharide vaccine
1817750|NCT00706550|Biological|Placebo|Placebo
1817751|NCT00706563|Biological|Fluarix™|Single intramuscular dose on Day 0
1817752|NCT00706576|Drug|Infusion of opioid growth factor|Volunteers will be treated with an intravenous infusion of opioid growth factor(OGF) starting at 100 µg/kg with a 50 µg/kg dose escalation with each succeeding group. The investigational drug, OGF, will be diluted in sterile saline to its appropriate concentration based upon the body weight of the volunteer and administered in a volume of 60 ml over 45 minutes (rate of 2 ml/min)
1817753|NCT00706589|Drug|aripiprazole|Initial dose : 2mg, Maximum dose : 20mg
1817754|NCT00706589|Drug|placebo|Initial dose: 2mg, Maximum dose:20mg
1817755|NCT00706615|Biological|Ad-sig-hMUC-1/ecdCD40L vaccine|
1817756|NCT00706628|Drug|BIBF 1120|
1817757|NCT00706628|Drug|BIBW 2992|
1817758|NCT00706628|Drug|Sequential BIBF 1120 + BIBW 2992|
1817759|NCT00706641|Drug|Dasatinib|Dasatinib 100 mg administered orally once daily for 4 weeks duration (+/- 1 week)
1817760|NCT00706641|Procedure|Radical Cystectomy|Radical cystectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered Dasatinib dose. All attempts should be made for the patient to have their surgery after 8 hours but within 24 hours of their last dose of dasatinib. If surgery delay is imperative, dasatinib therapy should continue until at least 24 hours before planned surgery.
1817761|NCT00706654|Drug|Aripiprazole depot 300 or 400 mg|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
1817762|NCT00706654|Drug|Aripiprazole 10-30 mg orally|Aripiprazole was supplied as 10, 15, and 20 mg tablets. The dose that the patient received was based on the investigator's judgment and the subject's clinical need.
1817763|NCT00706654|Drug|Aripiprazole depot 25 or 50 mg|Aripiprazole depot was supplied in 200 mg lyophilized vials. Patients received aripiprazole 25 mg if they were unable to tolerate aripiprazole 50 mg.
1817764|NCT00706654|Drug|Placebo depot|Placebo depot was supplied in lyophilized vials.
1817765|NCT00706654|Drug|Placebo tablets|Placebo tablets were identical in appearance to the aripiprazole tablets.
1817766|NCT00706667|Drug|Ferinject ®|iv administration in Arm 1 placebo NaCl 0.9% In arm 2 iv administration of Ferinject ® and subcutaneous NaCl 0.9 % as an EPO placebo In arm 3 iv administration of Ferinject ® and subcutaneous EPO
1817806|NCT00706914|Drug|Twice-daily formoterol fumarate|Inhaled formoterol fumarate 12 µg twice-daily (BID)
1817807|NCT00706914|Drug|Placebo to formoterol fumarate|Inhaled placebo to formoterol fumarate once-daily in the evening
1817808|NCT00706914|Drug|Once-daily formoterol fumarate|Inhaled formoterol fumarate 12 μg once-daily in the evening
1817809|NCT00706927|Drug|latanoprost 0.005% + timolol 0,5% fixed combination|1 drop per day and eye for 6 weeks
1817810|NCT00706927|Drug|brimonidine 0,2% + timolol 0,5% fixed combination|1 drop twice a day per eye for 6 weeks
1958451|NCT01627821|Device|Jarvik 2000 VAS|Jarvik 2000 LVAD
1958452|NCT01627821|Device|HeartMate II|HeartMate II LVAD
1958453|NCT01627197|Procedure|Surgery of percutaneous catheter system|Intraarterial (IA) catheterization was done in the Department of Invasive Technology. All medications were administered using percutaneous catheter system via a modified Seldinger technique. An angiographic catheter was inserted through the femoral artery into the internal iliac artery. The catheter tips were located superior to the origin of bilateral common artery.
1817767|NCT00706680|Drug|Thymoglobulin|methyl prednisone intravenously pre-operatively, as per institutional practice. Thymoglobulin, initiated prior to completion of the anastomosis, or if not possible, within 24 hours of transplantation for a total dose of 6-7.5mg/kg given over 3-5 doses. Steroids initiated post-operatively at 1mg/kg/day for 2 days, then 0.5mg/kg/day for 2 days, then 0.25mg/kg/day for 2 days. Patients will be placed on 5mg daily for the remainder of the study. All patients will receive Mycophenolic acid at a dose of 2gm/day (Cellcept) or 1440mg/day (Myfortic) post-transplantation with dose adjustment as needed. Cyclosporine micro-emulsion will be initiated when renal function is established or no later than day 10 in a dose of 3mg/kg twice daily with adjustment to achieve a C2 target of 600-800 nanograms/ml.
1817768|NCT00706693|Dietary Supplement|Ingestion of BD glucose tablets (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with BD glucose tablets by giving 10g of glucose in children 10 and under. Children and teens over 10 will receive 15g of glucose.
1817769|NCT00706693|Dietary Supplement|Ingestion of Skittles (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Skittle by giving 10g of sucrose in children 10 and under. Children and teens over 10 will receive 15g of sucrose.
1817770|NCT00706693|Dietary Supplement|Ingestion of Fruit to Go (TM)|Hypoglycemia (blood glucose is less than 4.0 mmol/L as measured by a glucose meter) will be treated with Fruit to Go by giving 10g of fructose in children 10 and under. Children and teens over 10 will receive 15g of fructose.
1817771|NCT00706706|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
1817772|NCT00706719|Drug|25 mg Androxal|25 mg Androxal capsules, 1 capsule daily for 6 months
1817773|NCT00706719|Drug|Testim 1%|Testim 1% gel, dosage to be titrated according to manufacturer's instructions, once daily for 6 months
1817774|NCT00706732|Biological|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks via the IM route
1817775|NCT00706732|Biological|AVX502|2 doses at 2e8 IU given at T=0 and T=4 weeks given via the SC route
1817776|NCT00706732|Biological|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the IM route
1817777|NCT00706732|Biological|Placebo|2 doses of placebo given at T=0 and T=4 weeks via the SC route
1817778|NCT00706745|Dietary Supplement|oil rich in cis9, trans11 conjugated linoleic acid|An oil rich in cis9, trans11 conjugated linoleic acid (cis9,trans11-CLA). Of the total amount of CLA in the oil, 80% is cis9, trans11-CLA and 20% trans10, cis12-CLA. In total 4 grams of oil will be given daily. The oil will be taken in the form of soft gel capsules. Two capsules will be taken in the morning and two in the evening.
1817779|NCT00706745|Dietary Supplement|placebo|identical placebo capsules.
1817780|NCT00706758|Behavioral|IBS school|Structured patient group education
1817781|NCT00706758|Behavioral|IBS-guidebook|Written information - IBS-guidebook
1817782|NCT00706771|Drug|Sodium bicarbonate|Sodium bicarbonate: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
1817783|NCT00706771|Drug|Sodium chloride|0.9% sodium chloride: loading dose of 0.5 mmol/Kg and then continuous infusion of 0.2 mmol/Kg/hr
1817784|NCT00706784|Drug|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System|Ethylvinyl Acetate (EVA) Vaginal Ring Delivery System
1817785|NCT00706797|Drug|etanercept (EnbrelTM)|
1817786|NCT00706797|Drug|methotrexate|
1817787|NCT00706810|Drug|Hydroxyurea|Hydroxyurea inhibits DNA synthesis by inhibition of ribonucleotide diphosphate reductase and is a well-known drug used for the treatment of a number of tumor types including head and neck tumors and chronic myelogenous leukemia. It has also been used as an adjuvant for antiretroviral treatment for patients with HIV and as a treatment for polycythemia vera, essential thrombocythemia and sickle cell disease.
1817788|NCT00706810|Drug|Verapamil|Verapamil is another commonly used medication. It is used for the treatment of angina, hypertension, supraventricular arrhythmias, and migraine prophylaxis. Dosing with standard verapamil is 80-120 mg pox three times a day but the sustained release form can be given 120-480mg once or twice each day.
1817789|NCT00706823|Device|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
1817790|NCT00706823|Device|Laryngeal Mask Airway-Unique|supra-glottic airway device
1817791|NCT00706836|Drug|pregabalin|One dose of oral pregabalin (50 mg) to be administered one hour prior to fMRI scan
1817792|NCT00706836|Drug|pregabalin|One dose of oral pregabalin (200 mg) to be administered one hour prior to fMRI scan
1817793|NCT00706836|Drug|placebo|One dose of matched oral placebo to be administered one hour prior to fMRI scan
1817794|NCT00706849|Drug|mipomersen sodium|200 mg /mL
1817795|NCT00706849|Drug|placebo|1 mL matching placebo
1817796|NCT00706862|Drug|Talactoferrin|Oral, 1.5 grams twice per day
1817797|NCT00706862|Drug|Placebo|Oral, twice per day
1817798|NCT00706875|Behavioral|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:
In person at the medical appointment
Over the telephone
Mailed with self-addressed return envelope and prepaid postage
E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
1817799|NCT00706875|Behavioral|questionnaire|"A patient questionnaire, which includes validated instruments. Data collection methods are as follows:
In person at the medical appointment
Over the telephone
Mailed with self-addressed return envelope and prepaid postage
E-mailed and returned by e-mail, fax or self-addressed envelope and pre-paid postage"
1817800|NCT00706888|Dietary Supplement|Vitamins B6, B9 and B12 and polyphenols|
1817801|NCT00706888|Dietary Supplement|placebo|
1817802|NCT00706901|Behavioral|Arm 1 GMI|Participants randomized to GMI received four structured, back-to-back, 75-minute sessions in one week consistent with the central principles and spirit of MI (Miller & Rollnick 2013) and based on a manualized protocol (Martino & Santa Ana 2013; Santa Ana & Martino, 2009). Designed for dually diagnosed patients, a focus of the intervention is to examine the relationship between the substance use and the co-existing psychiatric disorder(s) and the importance of proactively treating both conditions.
1817803|NCT00706901|Behavioral|Arm 2 IHMD|Participants randomized to IHMD received a 27 day VA Care Coordination Home Telehealth (CCHT) program targeting acute recovery from alcohol and other drug disorders. IHMD consisted of daily assessment combined with dialogues consisting of motivational interviewing, cognitive behavioral therapy, and 12-step (mutual self-help) facilitation.
1817811|NCT00706953|Drug|bortezomib; pegylated liposomal doxorubicin|1.3 mg/m2 IV bolus on Days 1,4,8,11 of each 21-day cycle; 30 mg/m2 IV infusion on Day 4 of each 21 day cycle
1817812|NCT00706966|Drug|dutasteride|6 months of dutasteride 3.5 mg daily
1817813|NCT00706979|Other|Practice Quit Attempt plus nicotine lozenge|nicotine lozenge, 2 mg or 4 mg
1817814|NCT00706979|Behavioral|Practice Quit Attempt only|Practice Quit Attempts (PQA) message aided by brief advice and self-help materials
1817815|NCT00706992|Biological|ALVAC-MART-1 vaccine|Given subcutaneously
1817816|NCT00706992|Biological|MART-1:26-35(27L) peptide vaccine|Given subcutaneously
1817817|NCT00706992|Biological|Aldesleukin|Given subcutaneously
1817818|NCT00706992|Biological|autologous anti-MART-1 F5 T-cell receptor gene-engineered peripheral blood lymphocytes|Given intravenously (IV)
1817819|NCT00706992|Biological|incomplete Freund's adjuvant|Given subcutaneously
1817820|NCT00707018|Device|External rotation shoulder sling|The external rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 10 to 15 degrees of external rotation at the shoulder.
1817821|NCT00707018|Device|Internal rotation shoulder sling|The internal rotation sling will be adjusted to position the injured upper extremity in 90 degrees of elbow flexion, 0 degrees of shoulder abduction and flexion, and 70 to 80 degrees of internal rotation at the shoulder.
1817822|NCT00707031|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1817823|NCT00707031|Device|Pen auto-injector|
1817824|NCT00707031|Drug|Exenatide|Self administered by subcutaneous injections twice daily within the hour preceding breakfast and within the hour preceding dinner.
1817825|NCT00707031|Device|Prefilled pen injector|
1817826|NCT00707031|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
1817827|NCT00707044|Procedure|Control group (usual care)|control group, care as usual, 24 hours intensive care stay
1817828|NCT00707044|Procedure|Short-Stay Intensive Care treatment (SSIC)|Short-Stay Intensive Care treatment (SSIC), 8 hours of Intensive care treatment
1817829|NCT00707057|Drug|Ibuprofen 600 mg Extended-Release Tablets|Ibuprofen 600 mg Extended-Release Tablet: One 600 mg tablet taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
1817830|NCT00707057|Drug|Placebo|Placebo: One matching placebo tablet was taken orally every 12 hours or twice daily (BID). Each dose was administered with at least 6 ounces of water. Dose 1 was administered at hour 0, Dose 2 was administered at hour 12, Dose 3 was administered at hour 24 and Dose 4 was administered at hour 36.
1817831|NCT00707070|Drug|efalizumab plus placebo|1 mg/kg/week subcutaneous for 24 weeks
1817832|NCT00707070|Drug|efalizumab plus acitretin|1 mg/Kg/week for 24 weeks plus oral acitretin 0.4 mg/kg/day
1817833|NCT00707083|Drug|dexamethasone|Given oral
1817834|NCT00707083|Drug|mercaptopurine|Given orally
1817835|NCT00707083|Drug|methotrexate|Given orally
1817836|NCT00707083|Drug|vincristine sulfate|Given IV
1817837|NCT00707122|Other|Albumin and Crystalloids|"From day 2 to day 28 (or until ICU discharge, whichever comes first), fluid will be administered as follows:
1. treated group: albumin will be infused on a daily basis, aimed to maintain its serum concentration equal or above 30 g/l (8). In particular, after the daily determination of its serum level:
if lower than 25 g/l, 300 ml of 20% of albumin solution (total amount of 60 gr) will be infused;
if equal or higher than 25 g/l and below 30 g/l, 200 ml of 20% of albumin solution (total amount of 40 gr) will be infused;
if higher than or equal to 30 g/l, no albumin will be infused. Albumin solutions will be infused over a period of 3 hours. Further infusion of crystalloids will be allowed, when necessary, according to the clinical judgment. No infusion of colloids, other than albumin, will be admitted."
1817838|NCT00707122|Other|Crystalloids|"Volume replacement will be performed in both the treated and the control group according to the early-goal directed therapy.
control group: crystalloids infusion will be allowed whenever necessary on a clinical basis. Albumin administration will be restricted to emergency use, as clinically judged and documented according to the standard criteria of each participating unit. No other colloids will be allowed."
1817839|NCT00707135|Drug|Rapamycin|Rapamycin given once weekly in escalating doses. Higher dose levels will be split with the half the dose given on day 1 and half the dose on day 2 (24 hours later).
1817840|NCT00707148|Drug|Placebo|Saline (0.9% NaCl) administered as a single 0.5 mL intramuscular injection into the deltoid.
1817841|NCT00707148|Biological|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine adsorbed|Tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine absorbed (Tdap). Administered as a single 0.5 mL intramuscular injection into the deltoid.
1817842|NCT00707161|Radiation|Radiation Therapy|Radiation therapy will be delivered concurrent with cisplatin chemotherapy as outlined in table 2. Radiation therapy dose will be 50 Gy (2.5 Gy per day, 5 days per week, for 20 treatments).
1817843|NCT00707161|Drug|Cisplatin|Cisplatin dose will be 100 mg/m2 given i.v. every 3 weeks for a total of 2 doses (days 1 and 22) during radiation.
1817844|NCT00707161|Procedure|Surgical resection|Surgical resection of residual (or recurrent) melanoma for cure or for palliation may be performed following chemoradiation if deemed appropriate by the treating physicians (surgical resection may be planned following pre-operative chemoradiation or may be performed for salvage due to inadequate response to chemoradiation or for relapse following chemoradiation). Surgical resection will not be performed until at least 4 weeks following chemoradiation (unless deemed emergent by the treating physicians).
1817845|NCT00707174|Drug|Imiquimod Cream|Our current standard-of-care is to use imiquimod daily for 12 weeks followed by a staged-excision with 2mm margins per stage. These margins are justified because the standard-of care for lentigo maligna is continuing to evolve
1817846|NCT00707174|Drug|Tazarotene Cream 0.1%|Tazarotene is a topical retinoid cream that is commonly used to treat psoriasis and acne. It is known to help keratinocyte maturation and thinning of the stratum corneum (top layer of the epidermis). The stratum corneum functions as the primary barrier to the penetration of topical medications. The penetration of topical medications can be enhanced if the stratum corneum is thinned. We believe that the treatment of lentigo maligna with imiquimod, and staged-excision, will be improved by the addition of tazarotene cream.
1817848|NCT00707213|Procedure|Imaging study (FDG-PET/CT scan)|FDG-PET/CT scan-The scans that will be done with a radioactive sugar ([18F]fluoro-2-deoxy-D-glucose) and positron emission tomography (FDG-PET/CT). These scans will help to identify areas of possible infection.
1817849|NCT00707239|Drug|tigecycline|An initial intravenous (IV) loading dose of 150 mg of tigecycline, followed by 75 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
1817850|NCT00707239|Drug|tigecycline|An initial intravenous (IV) loading dose of 200 mg of tigecycline, followed by 100 mg of IV tigecycline approximately every 12 hours (q12h), for up to 14 consecutive days. Ceftazidime 2 g IV approximately every 8 hours, an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and vancomycin placebo given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
1817851|NCT00707239|Drug|imipenem/cilastatin|Imipenem/cilastatin 1g intravenous (IV) will be administered approximately every 8 hours, for up to 14 consecutive days. In addition vancomycin 15 mg/kg IV approximately every 12 hours (q12h), an aminoglycoside (tobramycin 7mg/kg daily or amikacin 20 mg/kg daily) and ceftazidime placebo will be given at the start of therapy (unless it is known at baseline that the subject does not have Pseudomonas aeruginosa or methicillin-resistant Staphylococcus aureus [MRSA]).
1817852|NCT00707252|Drug|Polyphenon E|Patients will be assigned to 3 sequential cohorts of three different dose levels of Polyphenon E (providing 200, 400 and 800mg of Polyphenon E given once daily) in a step-wise manner.
1817853|NCT00707252|Drug|Tarceva|All patients will also receive Erlotinib 150mg po/day from Day 1.
1817854|NCT00707265|Device|rhBMP-2/CRM/CD HORIZON® Spinal System|"The rhBMP-2/CRM component of the investigational device consists of recombinant human Bone Morphogenetic Protein-2 (rhBMP-2) and a compression resistant matrix (CRM) carrier consisting of an absorbable collagen sponge imbedded with biphasic calcium phosphate.
The posterior spinal fixation system, the CD HORIZON® Spinal System, is a commercially available rod-based spinal system intended for temporary stabilization of the spine in order to facilitate fusion. The CD HORIZON® Spinal System is available in either titanium or stainless steel. For this study, only titanium implant components will be used."
1817855|NCT00707265|Device|Autograft/CD HORIZON® Spinal System|The control will be autogenous bone taken from the iliac crest of the patient and placed bilaterally across two adjacent transverse processes and used in conjunction with the CD HORIZON® Spinal System. When used as a posterior spine thoracic/lumbar system, the CD HORIZON® CANNULATED M8 MULTI-AXIAL SCREW components are intended for several indications including degenerative disc disease.
1817856|NCT00707278|Radiation|Radiation Therapy|Radiation therapy will be delivered concurrently with capecitabine and oxaliplatin chemotherapy Radiation therapy dose will be 50.4 Gy (1.8 Gy per day, 5 days per week, for 28 treatments).
1817857|NCT00707278|Drug|Capecitabine|Capecitabine Dose (given twice daily concurrent with radiation therapy) Dose level 1: 400 mg/m2 Dose level 2:600 mg/m2 Dose level 3:600 mg/m2
1817858|NCT00707278|Drug|Oxaliplatin|Oxaliplatin Dose (given weekly concurrent with radiation therapy) Dose level 1: 50 mg/m2 Dose level 2: 50 mg/m2 Dose level 3: 60 mg/m2
1817859|NCT00707304|Drug|Talactoferrin|Oral, 1.5 grams twice per day
1817860|NCT00707304|Drug|Placebo|Oral, twice per day
1817861|NCT00707330|Drug|Clarithromycin|Prolonged release tablet, 500 mg, 1 tablet a day for a week
1817862|NCT00707343|Radiation|FLT-PET Imaging|radiopharmaceutical 3'-deoxy-3'-[F-18]fluorothymidine, [F-18]FLT, a radiopharmaceutical that directly assess tumor proliferation using Positron Emission Tomography(PET) in differentiating tumor recurrence from radiation necrosis in a group of patients with glial neoplasms.
1817863|NCT00707356|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2 mg/Kg,4 mg/Kg or 6 mg/kg, using 753 nm laser light at a fixed power (150mW/cm) and energy (200 J/cm) delivered through transperineal interstitial optical fibers. If deemed necessary and in consideration of the results of the patients treated with 200 J/cm, alternate power (200mW/cm) and alternate energy (300 J/cm) might be applied.The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The number of fibers and the total light energy will be adapted to each patient, taking into account the tumor localization and the volume of the prostate.
1817864|NCT00707369|Drug|Amoxicillin and Metronidazole|tablets: Amoxicillin 3H2O 574 mg and 400 mg metronidazole three times daily for 7 days
1817865|NCT00707369|Drug|Placebo|Placebo tablets (cellulose powder, lactose monohydrate, magnesium stearate, microcrystalline cellulose): three times daily for 7 days
1817866|NCT00707382|Genetic|(1) Genotyping for CYP4502D6 and 2C19 polymorphisms|"In this study arm (1), the genotype information is given to the physician in charge of treatment and can be used to direct the pharmacological treatment according to local guidelines. In the guidelines the genotype is translated to the clinical designation normal, slow or fast metabolizer of CYP2D6 or normal or slow metabolizer of CYP2C19. Different treatment options for the different genotypes are described."
1817867|NCT00707382|Other|(2) Intense clinical monitoring|In this study arm (2) the genotype information is not revealed. The intervention consists of an intensified clinical monitoring of treatment effect, side effects and patient perspective. Staffpersonnel is trained in the use of a clinical manual that builds on a selection of validated questions from the Scale for the Assessment of Positive Symptoms (SAPS), Side effect score (Udvalg af Kliniske Undersøgelser (UKU) and Rating of Medical Influences (ROMI). The manual has to be used at least once in a quarter (every third month), which is monitored by the study personnel. Data registered by the patients primary contact person are not used as outcome measures in the study but only as intervention tool for the optimisation of the medical antipsychotic treatment.
1817868|NCT00707382|Other|(3) Control|In this studyarm (3), (Control) treatment followed usual local practice. The genotype information was not revealed.
1817869|NCT00707408|Drug|Imatinib|Daily dosing of imatinib 600 mg/day is planned for one month or until progression of disease. Dose increase to 800 mg/ day imatinib is permitted for 2 additional months in the event of response failure. Novartis provided supplies of imatinib for all patients included in the study.
1817870|NCT00707421|Drug|ketorolac acetate|
1817871|NCT00707421|Drug|fluorometholone|
1869325|NCT01097096|Biological|CAD106|
1817874|NCT00707447|Behavioral|PREDIAS|Group programme aiming at modification of lifestyle: lifestyle changes, 12 lesson a 90 minutes, delivered in a group setting, consists of analysis of barriers against lifestyle changes, behavior analysis of eating and exercise behavior, modification of unhealthy lifestyle and relapse prevention
1817875|NCT00707447|Behavioral|Control|Written Information about diabetes risks. Brochure about the value of a healthy lifestyle, calorie table, suggestions for healthy food and daily exercise
1817876|NCT00707460|Behavioral|Dietary Intervention (Macronutrient composition)|"The Traditional Diet and Healthy Store-Bought arms differ from the control group and one another by their macronutrient composition. Please, see design section for more detail on this item.
All groups are exposed to nutrition education on serving size and portion size."
1817877|NCT00707473|Drug|Docetaxel|75 mg/m^2 IV on day 1 of each cycle.
1817878|NCT00707473|Drug|5-Fluorouracil|750 mg/m^2 continuous infusion on days 1 through 4 of each cycle.
1817879|NCT00707473|Drug|Cisplatin|75 mg/m^2 IV over 30-120 minutes on day 1 of each cycle.
1817880|NCT00707486|Device|Hemcon Dental Dressing|The Hemcon Dental Dressing is an oral wound dressing made of chitosan.
1817881|NCT00707486|Device|Gauze with Pressure and/or Gelfoam|Common practice for oral surgery patients involves the use of sterile dressing over the extraction site. The subject will provide the pressure by biting down on the sterile gauze. As previously discussed, other practices involve the use of Gelfoam prior to application of sterile gauze.
1817882|NCT00707499|Drug|BMS747158|Single dose administration.
1817883|NCT00707512|Drug|natalizumab|Administered as specified in the TOUCH Prescribing Program
1817884|NCT00707525|Procedure|Preimplantation Genetic Diagnosis|Preimplantation Genetic Diagnosis (PGD) is performed on the embryos resulting from these natural and stimulated cycles.
1817885|NCT00707538|Drug|BMS747158|2 IV injection of ~11 mCi (total) F-18 labeled compound
1817886|NCT00707551|Drug|Ketoconazole|Tablet, administered as repeated doses.
1817887|NCT00707551|Drug|Verapamil|Extended Release tablet, administered as repeated doses.
1817888|NCT00707551|Drug|AZD1305|Extended Release tablet, administered as a single dose.
1817889|NCT00707564|Device|HemCon Dental Dressing|The HemCon Dental Dressing is an oral wound dressing made of chitosan
1817890|NCT00707564|Device|Gauze with pressure|Gauze with pressure
1817891|NCT00707577|Behavioral|Internet-based maintenance program|The Be Fit maintenance program is a randomized controlled trial of a 9 month intervention to maintain weight loss and physical activity after completion of the 12 week wellness program. Six teams of 25 participants will be randomized to the intervention or to usual care. There are 2 key elements to the maintenance program: personal contact and Internet contact. The personal contact enables the participants to continue receiving face-to-face support from a Be Fit nutritionist and trainer. The Internet interface is an opportunity for the participants to self-monitor their own progress while still under the guidance of the program.
1817892|NCT00707590|Drug|BMS-767778 or Placebo|
1817893|NCT00707616|Other|Oral glucose tolerance test|one time 75g oral glucose tolerance test for measurement of insulin secretion and action
1817894|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [Low Dose of WN-80E API (5 µg) + Alhydrogel (3.5 mg)] given one month apart
1817895|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [Medium Dose WN-80E API (15 µg) + Alhydrogel (3.5 mg)] given one month apart
1817896|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [High Dose WN-80E API (50 µg) + Alhydrogel (3.5 mg)] given one month apart
1817897|NCT00707642|Biological|WN-80E|Three injections of the study vaccine [High Dose WN-80E API (50 µg)] given one month apart
1817898|NCT00707655|Drug|Zalutumumab|Eight weekly infusions
1817899|NCT00707681|Drug|MS-20|4 ml/vial
1817900|NCT00707681|Drug|Placebo|4ml/vial
1817901|NCT00707707|Drug|AZD2281|Dose finding study to establish the appropriate dose of AZD2281
1817902|NCT00707707|Drug|Paclitaxel|Intravenous infusion over 1 hour
1817903|NCT00707720|Device|TERIS procedure|The implantation of the restrictive implant
1817904|NCT00707746|Drug|mipomersen|
1817905|NCT00707746|Drug|placebo|
1817906|NCT00707759|Drug|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + Withdrawal Prednisone|"Arms A: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + withdrawal steroids over a six-days following randomization.
1°day: Methylprednisolone iv, 2-3 mg/kg/d 3 doses
2ºday: Methylprednisolone iv, 2-3 mg/kg/d 3 doses
3°day: Prednisone 2 mg/kg/d in 2 doses
4ºday: Prednisone 1 mg/kg/d in 2 doses
5ºday: Prednisone 0.5 mg/kg/d in 2 doses
6ºday: Prednisone 0.25 mg/kg/d in 2 doses
7ºday: Stop Prednisone"
1817907|NCT00707759|Drug|Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone|"Arms B: Tacrolimus (TAC)+ Mycophenolate Mofetil (MMF) + prednisolone (see schedule)/day
10°days after Tx: 2 mg/kg/d
Day 11 - 20: 1 mg/kg/d
Day 21 - 30: 0.5 mg/kg/d
Day 31 - 60: 0.3 mg/k/d
Week 8 - 12: 0.25 mg/k/d
Week 12 - 16: 0.20 mg/k/d
Week 16 - 20: 0.15 mg/k/d
Month 6 - 12: 0.10 - 0.12 mg/k/d"
1817908|NCT00707772|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: 800 milligram per day (PO)
1817909|NCT00707772|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)]
1817910|NCT00707785|Dietary Supplement|Vitamin A|50,000 IU of Vitamin A 50,000 IU of vegetable oil
1817911|NCT00707798|Biological|Pneumococcal vaccine GSK2189242A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2. Six different formulations of this vaccine will be tested
1817912|NCT00707798|Biological|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2
1817913|NCT00707824|Drug|nalbuphine|nalbuphine 5 mg epidural
1817914|NCT00707824|Drug|nalbuphine|nalbuphine 10 mg epidural
1817915|NCT00707824|Other|NSS|NSS
1817916|NCT00707837|Other|Preterm infant formulas and discharge formulas|Preterm infant formulas to be consumed per health care provider orders
1817917|NCT00707837|Other|Preterm infant formula with added soluble lipids|Preterm infant formula to be fed per healthcare provider instructions
1817918|NCT00707850|Drug|PEGASYS® (Peginterferon Alfa-2a (40KD)) Plus COPEGUS® (Ribavirin)|PEGASYS: 180 microgram per week (Injection) Plus Ribavirin: [=<75 kg: 1000 mg; >75 kg: 1200 mg per day (PO)]
1817919|NCT00707863|Drug|Escitalopram|10 mg of Escitalopram by mouth once a day for 8 weeks
1817920|NCT00707876|Drug|ferumoxytol|Dose 1 versus non-contrast MRA
1817921|NCT00707876|Drug|ferumoxytol|Dose 2 versus non-contrast MRA
1817922|NCT00707876|Drug|ferumoxytol|Dose 3 versus non-contrast MRA
1817923|NCT00707889|Drug|ABT-869|12.5 mg QD, tablets taken orally days 1-14 of every 14-day cycle
1817924|NCT00707889|Drug|bevacizumab|10 mg/kg QD, IV on Day 1 of each 14-day cycle
1817925|NCT00707889|Drug|oxaliplatin|85 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
1817926|NCT00707889|Drug|folinic acid|400 mg/m2 IV, 120 minutes on Day 1 of each 14-day cycle
1817927|NCT00707889|Drug|fluorouracil|400 mg/m2 IV bolus on Day 1 of each 14-day cycle; followed by 2400 mg/m2 IV infusion 46-48 hours
1817928|NCT00707889|Drug|ABT-869|7.5 mg QD tablets taken orally days 1-14 of every 14-day cycle
1817929|NCT00707902|Drug|chlorhexidine/lidocaine|
1817930|NCT00707902|Drug|echinacea/sage|
1817931|NCT00707915|Drug|Drug: Benzodiazepine (listed out below)|"The benzodiazepine (BZD) dose will be discontinued in 4 weeks by a weekly 25% reduction. BZD-derivative hypnotics will include brotizolam, flunitrazepam, etizolam, quazepam, estazolam, nitrazepam, flurazepam, and diazepam.
All psychotropic agents other than the BZD-derivative hypnotics will be kept constant throughout the study. In addition, the use of trazodone (25-100 mg/day) will be allowed anytime throughout the study period. Subjects will be observed for 8 weeks."
1817932|NCT00707928|Drug|nitroglycerine|nitroglycerine 100 microgram intravenous.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
1817933|NCT00707928|Other|NSS|NSS.Once the placenta had been delivered, oxytocin or ergometrine will be administered. Fentanyl 50-100 microgram can be given if the cord traction is considered painful.
1817934|NCT00707941|Drug|Oseltamivir|"Children ≤12 years: Suspension by Weight (Kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)
Patients≥12 years: 75 mg capsules as follows:
1 cap (75 mg) PO BID X 5 days
≥ 40 75 mg PO BID 6.25"
1817935|NCT00707941|Drug|Placebo|"Children < 12 years, suspension by weight (kg) as follows: Dose X 5 days Volume (ml) < 15kg = 30 mg PO BID (2.5 ml) 15kg - 22kg = 45 mg PO BID (3.75 ml) 23kg - 39kg = 60 mg PO BID (5 ml)
Patients≥12 years: 75 mg capsules as follows 1 cap (75 mg) PO BID X 5 days
≥ 40 75 mg PO BID 6.25"
1817936|NCT00707954|Drug|TA-7284|Patients will receive single ascending dose of TA-7284 in each step (4 doses planned: 25, 100, 200 and 400 mg), once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
1817937|NCT00707954|Drug|Placebo of TA-7284|Patients will receive placebo tablets in each step, once daily, 15 days (1 day followed by a 1 day washout period and then 14 consecutive days)
1817938|NCT00707967|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
1817939|NCT00707967|Biological|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
1817940|NCT00707967|Biological|Control vaccine with physiological saline|Intramuscular injection, 2 doses at 0, 1 month
1817941|NCT00707980|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
1817942|NCT00707993|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily and glipizide placebo matching tablets, orally, once daily for up to 52 weeks.
1817943|NCT00707993|Drug|Glipizide|Alogliptin placebo-matching tablets, orally, once daily and glipizide 5 mg to 10 mg, tablets, orally, once daily up to 52 weeks.
1817944|NCT00708006|Drug|HGS1029|Escalating doses by IV (in the vein), on days 1, 8 and 15 of each 28-day cycle. Number of cycles: until disease progression or unacceptable toxicity
1817945|NCT00715195|Behavioral|Plurifocal educational program|intensive group program of 8 weeks, including, in addition to the briefing, measures and exercises for the implementation of the principles of managing fibromyalgia, and cognitive-behavioral therapy
1817946|NCT00715208|Drug|rituximab|
1817947|NCT00715208|Drug|cyclophosphamide|
1817948|NCT00715208|Drug|doxorubicin|
1817949|NCT00715208|Drug|VELCADE|
1817950|NCT00715208|Drug|prednisone|
1817951|NCT00715234|Other|Reminder/recall notices for vaccines|"Receive a generic letter reminding them to make an appointment to get vaccines.
Receive a computer-generated telephone message at 1 week post initial letter.
Receive a computer-generated telephone message at 2 months post initial letter.
Receive a letter at 3 months post initial letter."
1817952|NCT00715273|Drug|Atorvastatin|10 to 80 mg of atorvastatin each day
1817953|NCT00715273|Drug|Niacin|2000 mg of niacin each day
1817954|NCT00715273|Drug|Colesevelam|3.8 g of colesevelam each day
1817955|NCT00715273|Drug|Placebo Niacin|Placebo niacin each day
1817956|NCT00715273|Drug|Placebo Colesevelam|Placebo colesevelam each day
1817957|NCT00715286|Other|timing of surgery|Surgery is followed by chemotherapy
1817958|NCT00715286|Other|timing of surgery|Chemotherapy is followed by surgery
1817959|NCT00715299|Behavioral|locomotor training|Persons will train 3 times a week for 12 weeks. The training sessions will each last about an hour to an hour and a half. Therapists will manipulate the participant's body to generate stepping and walking that is more consistent with normal walking. Someone will manipulate the trunk by standing at the waist and helping with weight shift and proper upper body mechanics. The other two therapists will sit at the legs and bend and extend them as they should in a more normal gait pattern.
1817960|NCT00715312|Other|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which accounts for 30-35% of calorie intake
1817961|NCT00715312|Other|Novel Olein|A total of 70g of test oil is incorporated into cooked meal which provides 30-35% of calorie
1817962|NCT00715325|Device|Protectiscop CS|Patients who are indicated for screening colonoscopy will be recruited into the trial. The ProtectiScope CS sleeve is assembled on the colonoscope.standard colonoscopy is performed. Subjects will be followed for 1-month post procedure.
1817963|NCT00715351|Drug|insulin detemir|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
1869326|NCT01097096|Biological|CAD106|
1817964|NCT00715351|Drug|insulin NPH|Physician decides which insulin should be prescribed, selection of subjects will be at the discretion of participating physician
1817965|NCT00715364|Drug|NTx™-265: rhCG, then rEPO|"rhCG 385 µg, SC, on Day 1, 3, and 5 of study participation, then
rEPO 30,000 IU, IV, on Day 7, 8, and 9 of study participation"
1817966|NCT00715364|Drug|Saline Placebo|"Saline SC, on Day 1, 3, and 5 of study participation, then
Saline IV, on Day 7, 8, and 9 of study participation"
1817967|NCT00715377|Drug|Benztropine|Patients aged ≥ 50 years suffering from a primary psychotic disorder treated with a SGA and benztropine concomittantly at any dose steadily for at least 3 months will be eligible to participate in this study. The dose of benztropine will be reduced by 0.5mg per week. During this 8-week study period, extrapyramidal symptoms will be assessed on a weekly basis. The clinical assessments will be repeated 8 weeks after the initial assessments.
1817968|NCT00715403|Drug|BIBF 1120|
1817969|NCT00715416|Device|Nitinol stent|Interventions are performed percutaneously from either an antegrade or an over-the-bifurcation approach. After insertion of an 6 French sheath, 5000 IU of heparin are administered intra-arterially. After passage of the stenosis/occlusion with the guide wire, patients are randomized to either PTA or primary stent implantation. For standardized documentation of the lesion morphology and comparability during follow-up, a ruler is fixed at the patients thigh with the distal end exactly overlapping at the upper edge of the patella. As a bail-out procedure in the PTA group, stent placement is performed in cases with a residual stenosis of more than 30% in the worst view angiogram.
1817970|NCT00715416|Procedure|Nitinol Stent Placement|Balloon angioplasty compared to primary stent implantation for long segment superficial femoral artery lesions
1993601|NCT03166995|Other|Low impact aerobic exercise|The intervention will consist of working the muscles that are most affected by FMS through group exercises, which will be dynamic, fluid and aimed at improving functionality. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); games, group dynamics and aerobics (30 minutes); and cool down with stretching for 15 minutes.
1817973|NCT00715442|Drug|Sunitinib|50 mg by mouth daily for 28 consecutive days
1817974|NCT00715442|Procedure|Nephrectomy|Nephrectomy will occur approximately 24 hours after the last dose of sunitinib.
1817975|NCT00715455|Drug|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at approximately 10% the total reversal dose followed by the remaining dose several hours later to counteract RB006 induced anticoagulation.
1817976|NCT00715455|Drug|REG1|ii. The REG1 anticoagulation system consists of a drug (RB006) and antidote (RB007). The drug (RB006) is administered via IV bolus to achieve anticoagulation. The antidote (RB007) is administered as an IV bolus dose at 100% of the total reversal dose to counteract RB006 induced anticoagulation.
1817977|NCT00715455|Drug|Unfractionated Heparin|Heparin will be administered per standard of care at sites
1817978|NCT00715494|Behavioral|Cognitive, physical, and functional rehabilitation|A multicomponent program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients in their home environments over a focused 12 week period with the aid of tele-technology to utilize the expertise of physical therapy, occupational therapy, and neuropsychology.
1817979|NCT00715507|Device|medication monitor|the medication monitor will aid in expertise and decision-making.
1993602|NCT03166995|Other|Postural exercises|The intervention will consist of performing postural exercises in prone, supine, sitting and standing position, as well as in quadrupedia. Each session will consist of 60 minutes and will be divided into three parts: warm up (15 minutes); postural exercises (30 minutes); and cool down with stretching for 15 minutes.
1993603|NCT03166813|Procedure|Remote Ischaemic Preconditioning|The intervention RIPC protocol will be performed each time by three cycles of inflation of a blood pressure cuff placed over the arm or leg of your child, where deemed to cause minimal discomfort, to 15 mmHg above the systolic blood pressure for 5 minutes followed by 5 minutes of cuff deflation to 0 mmHg.
1993604|NCT03166813|Other|Control|Placement of blood pressure cuff without inflation for 30 minutes.
1817983|NCT00715689|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
1817984|NCT00715689|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
1817985|NCT00715689|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
1817986|NCT00715689|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
1817987|NCT00715689|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
1817988|NCT00715689|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
1817989|NCT00715689|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
1817990|NCT00715689|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
1817991|NCT00715702|Drug|AZD5672|100 mg oral single dose
1817992|NCT00715715|Drug|Prednisone Priming|For randomly selected patients treated with steroids: The patients will receive prednisone 30 mg daily for 3 weeks, 15 mg daily for 1 week, no treatment for 2 weeks, followed by Adefovir dipivoxil (Hepsera) 10 mg daily for a minimum of 52 weeks.
1817993|NCT00715741|Other|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3 -5 cm water|FiO2 (fraction of inspired oxygen) 0.3 plus PEEP (positive end expiratory pressure) 3-5 cm water
1817994|NCT00715741|Other|FiO2 0.3 without PEEP|FiO2 0.3 without PEEP
1817995|NCT00715741|Other|FiO2 >0.9 with 3-5 cm water PEEP|FiO2 >0.9 with 3-5 cm water PEEP
1817996|NCT00715741|Other|FiO2 >0.9 without PEEP|FiO2 >0.9 without PEEP
1818029|NCT00715962|Other|Friendly visits|The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
1818030|NCT00715975|Drug|halobetasol|The patients will be treated with halobetasol once a day for 15 days.
1818031|NCT00715975|Drug|clobetasol|The patients will be treated with clobetasol once a day for 15 days.
1818032|NCT00715988|Drug|Methadone HCl Inject 10 mg/ml (will require dilution)|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 mg/ml (will require dilution)
1817997|NCT00715767|Behavioral|Assessment|"Cognitive Assessment:
Knowledge base and critical thinking will be evaluated by a 50-question BLS multiple-choice examination. At the designated 4 cognitive assessments in the study (pre-course, immediately post course, 3 months and 6 months) 50 equivalent questions will be used to cover all core BLS objectives. Technical Skills Assessment:
Primary outcome measures of adequacy of chest compressions and ventilations as well as key actions for each of the 3standardized basic life support skill tests during 3-minute testing scenarios. Video review by 2independent experts will be utilized for objective assessment of time and order dependent skills, and manikin output will be utilized to assess qualitative effectiveness of skills (adequate ventilation, compression, and defibrillation).
Survey Instrument for Barriers to Acute Medicine Education:
A survey tool will be used to identify barriers to acute medicine education implementation and efficacy."
1817998|NCT00715780|Drug|soluble human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1817999|NCT00715780|Drug|biphasic human insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1818000|NCT00715780|Drug|insulin NPH|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1818001|NCT00715780|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1818002|NCT00715780|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1818003|NCT00715780|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1818004|NCT00715793|Drug|Decitabine|"In Part I patients will be treated on a standard 3+3 phase I dose-escalation design starting at 0.075 mg/kg until a decitabine dose level of 0.15 mg/kg is reached, or, in case unacceptable toxicities are observed, at the maximum tolerated dose (Phase II recommended dose). Decitabine will be administered at the specified dose level, intravenously, daily 5 days a week for the first 2 weeks of a 6-week cycle."
1818005|NCT00715793|Drug|Temozolomide|Temozolomide is available in 25 mg and 100 mg tablets that will be administered orally; doses will be rounded to the nearest 25 mg. Temozolomide will be administered orally at 75 mg/m2 daily for 4 weeks starting on week 2 of a 6-week cycle.
1818006|NCT00715793|Procedure|biopsy|Fine needle aspirates (FNA) and/or core biopsies of tumor samples will be obtained from consenting patients with accessible, evaluable disease, on days 1, 8, 15, and 29 of the first cycle and when patients go off study. Biopsies are optional in Phase I and required for all consenting subjects in Phase II.
1818007|NCT00715806|Device|Open MRI scanner.|Imaging in an Open MRI scanner.
1818008|NCT00715806|Device|Closed MRI scanner.|Imaging in a short-bore closed MRI scanner.
1818009|NCT00715832|Biological|Dendritic Cell Vaccination|Autologous dendritic dells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally
1818010|NCT00715845|Procedure|Carbon dioxide insufflation|For baseline evaluations, all patients will undergo a battery of neuropsychological testing after obtaining written informed consent and before cardiac surgery. A transesophageal echocardiography and a transcranial doppler will be performed for intraoperative evaluations. For post-operative evaluations, patients will undergo a diffusion-weighted magnetic resonance imaging three to seven days after surgery and have a repeat neuropsychological assessment at six to eight weeks post cardiac surgery. All patients will undergo cardiopulmonary bypass using the same equipment and technique. Patients in both groups will receive a jackson-pratt drain as a gas diffuser. The jackson-pratt drain will be placed 5 cm below the cardiothoracic wound opening adjacent to the diaphragm and if the patient is randomized to carbon dioxide, the flow will be set at 2 litre/min.
1818011|NCT00715858|Drug|doxycycline|capsule, 100 mg, b.i.d., 12 months
1818012|NCT00715858|Drug|rifampin|capsule, 300 mg, od, 12 months
1818013|NCT00715858|Drug|placebo|placebo matched to rifampin; placebo matched to doxycycline
1818014|NCT00715871|Drug|Nicotine|"Subjects received an amount of liquid nicotine cigarettes (containing 1.5mg of nicotine each) based on the amount of nicotine the subjects had been receiving from cigarettes. The number of liquid nicotine cigarettes received by each subject was reviewed, and adjusted (if necessary), every two weeks for the duration of the 12-week study."
1818015|NCT00715871|Device|Smoke-Break nicotine delivery device|"The Smoke-Break nicotine delivery device is a liquid nicotine cigarette designed to mimic the act of smoking. It is an NRT (nicotine replacement therapy) similar in concept to the nicotine patch, gum, and lozenge, except the nicotine is delivered in a way designed to duplicate the cigarette smoking experience. The Smoke-Break nicotine delivery device is non-invasive."
1818016|NCT00715884|Device|CYPHER® ELITE™ Sirolimus-Eluting Stent System|Drug eluting stent
1818017|NCT00715884|Device|CYPHER® Bx VELOCITY® Sirolimus-eluting Stent System|Drug eluting stent
1818018|NCT00715897|Procedure|Hyperbaric Oxygen Therapy (HBOT)|8-week, 5 times a week administration of 100% O2 for 90 minutes at a pressure of 2 ATA.
1818019|NCT00715910|Biological|Nimenrix|One dose, as intramuscular injection
1818020|NCT00715910|Procedure|Blood sampling|Blood samples will be collected from subjects 10-25 years of age as per enrollment in primary study and from subjects in the Nimerix Naive Group at Month 60 (Year 5) and 1 month post booster vaccination (Month 61).
1818021|NCT00715923|Other|Modified consent form|modified consent form used
1818022|NCT00715923|Other|Standard consent form|standard consent form used
1818023|NCT00715936|Behavioral|Control|
1818024|NCT00715936|Behavioral|ECD|
1818025|NCT00715936|Behavioral|Enhanced Nutrition|
1818026|NCT00715949|Other|Immediate Post-concussion Assessment and Cognitive Testing|ImPACT© utilizes a battery of neurocognitive tests to assess neurologic deficits.
1818027|NCT00715962|Behavioral|Behavioral intervention|Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
1818028|NCT00715962|Other|Walking Intervention|Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
1818172|NCT00717080|Procedure|IOL surgery|IOL surgery without CTR
1818033|NCT00715988|Drug|Methadone|Methadone HCl oral solution 5 mg/ml Methadone HCl inject 10 ml/ml (will require dilution) Single dose
1818034|NCT00716001|Drug|N-acetylcysteine|
1818035|NCT00716014|Drug|TD101|TD101 is injection into a callus on the bottom of one of the patient's feet
1818036|NCT00716014|Drug|Normal saline (placebo)|A normal saline solution (placebo) is injected into one of the patient's feet.
1818037|NCT00716027|Behavioral|Standard behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity.
1818038|NCT00716027|Behavioral|Modified behavioral treatment for weight loss|A 24-week intervention in which individuals will meet weekly to be instructed on behavioral change associated with weight loss, including modifying dietary intake, self-monitoring weight and eating behaviors, and increasing physical activity. In this intervention, individuals not meeting weight loss goals will be given one-on-one treatment.
1818039|NCT00716040|Behavioral|Social-psycho intervention to improve adherence to HAART|The intervention focus on the notion of scenes and scenarios to examine and discussing the experience of taking ARV medicines. In principle, such an approach provides a tool for conscientization, action and the invention of novel group and individual repertoires that may result in individual mobilization for improving adherence to treatment and reducing his/her vulnerability.
1818040|NCT00716040|Other|Usual care|The control group will be submitted to the usual care of the health service
1818041|NCT00716053|Drug|BLVR|BLVR 20 mL
1818042|NCT00716066|Biological|Anti-Thymocyte Globulin|Given IV
1818043|NCT00716066|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous or syngeneic peripheral blood stem cell transplantation
1818044|NCT00716066|Drug|Carmustine|Given IV
1818045|NCT00716066|Drug|Cytarabine|Given IV
1818046|NCT00716066|Drug|Etoposide|Given IV
1818047|NCT00716066|Other|Laboratory Biomarker Analysis|Correlative studies
1818048|NCT00716066|Drug|Melphalan|Given IV
1818049|NCT00716066|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous or syngeneic peripheral blood stem cell transplantation
1818050|NCT00716066|Drug|Prednisone|Given PO
1818051|NCT00716066|Procedure|Syngeneic Bone Marrow Transplantation|Undergo syngeneic bone marrow transplantation
1818052|NCT00716079|Other|Blood pressure management policies|The trial is an assessment of BP lowering management strategies, using routinely available drugs. There is some flexibility in the use of particular BP lowering agents to achieve BP targets.
1818053|NCT00716092|Drug|Placebo (linagliptin)|once daily for 28 days
1818054|NCT00716092|Drug|Placebo (linagliptin)|once daily for 28 days
1818055|NCT00716092|Drug|Sitagliptin|100 mg once daily for 28 days
1818056|NCT00716092|Drug|Placebo (sitagliptin)|once daily for 28 days
1818057|NCT00716092|Drug|Placebo (sitagliptin)|once daily for 28 days
1818058|NCT00716092|Drug|Linagliptin|5mg once daily for 28 days
1818059|NCT00716105|Other|Standard infant formula|From 3 to 12 months of age. As per standard requirement
1818060|NCT00716105|Other|Infant formula with different level of proteins|From 3 to 12 months of age. As per standard requirement
1993605|NCT03166670|Diagnostic Test|stool examination|collection of stool specimen and microscopic examination for parasites
1818062|NCT00716170|Biological|Glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2)|"Day A: Oral glucose tolerance test (50g glucose)
Day B: Isoglycemic intravenous (iv) glucose infusion
Day C: Isoglycemic iv glucose infusion + iv GIP infusion (0-20 min: 4 pmol/kg body weight/min; 20-50 min: 2 pmol/kg body weight/min)
Day D: Isoglycemic iv glucose infusion + iv GLP-1 infusion (0-20 min: 0,6 pmol/kg body weight/min; 20-50 min: 0,3 pmol/kg body weight/min)
Day E: Isoglycemic iv glucose infusion + iv GLP-2 infusion (0-20 min: 1 pmol/kg body weight/min; 20-50 min: 0,5 pmol/kg body wight/min)
Day F: Isoglycemic iv glucose infusion + iv infusion of GIP, GLP-1 and GLP-2 in doses as Day C, D and E."
1818063|NCT00716183|Biological|Lactobacillus salivarius HN6|9 log colony-forming units, capsules, daily, four weeks
1818064|NCT00716183|Biological|Lactobacillus reuteri CR20|9 log colony-forming units, capsules, daily, four weeks
1818065|NCT00716183|Biological|Lactobacillus fermentum LC40|9 log colony-forming units, capsules, daily, four weeks
1818066|NCT00716183|Drug|Beta-lactam antibiotic|Use of amoxicillin, cloxacillin or amoxicillin/clavulanic acid(500-750 mg), orally, every 8-12 h, for 2-3 weeks (as prescribed by the physician responsible for the clinical diagnosis of lactational mastitis)
1818067|NCT00716248|Drug|bucillamine|bucillamine 100 mg, twice a day
1818068|NCT00716248|Drug|methotrexate|methotrexate 6 mg or more per week
1818069|NCT00716261|Device|McROB Hybrid node 3-axes accelerometers and 3-axes gyroscopes|Training with the Audio-feedback device for about 30 minutes, 3 times per week for 6 weeks
1993606|NCT03166670|Diagnostic Test|real time polymerase chain reaction|evaluation of genotype of cryptosporidium in stool specimen
1818072|NCT00716326|Device|Transcutaneous Nerve Stimulation (TENS)|Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises. The TENS will be used during 3-4 weeks of hospitalization. If patients want to continue the use of TENS/placebo-TENS at home, they will be offered to borrow equipment for 4 months.
1818073|NCT00716326|Device|Cefar Primo Pro TENS device|"Patients will be randomly allocated to a group with active-TENS and exercises, or to a group with placebo-TENS and exercises.
Active TENS: high-frequency modulated pulse duration stimulation Placebo TENS: manipulated device with impulses near sensory threshold."
1818074|NCT00716339|Behavioral|motivation|
1818075|NCT00716352|Behavioral|Educational intervention programme|
1818076|NCT00716365|Device|HemCon bandage|5 cm X 5 cm
1818077|NCT00716378|Behavioral|Teen Passenger Presence|
1818078|NCT00716391|Other|TPF, radiotherapy and cisplatin.|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cisplatin: 100 mg/m2, i.v., 1 hour, 3 days
1818218|NCT00717457|Drug|taspoglutide|10mg once weekly for 4 weeks followed by 20mg once weekly
1818219|NCT00717470|Drug|Prograf®|oral
1818079|NCT00716391|Other|TPF, radiotherapy and cetuximab.|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
1818080|NCT00716404|Device|Targeted Renal Therapy|Patient diagnosis, treatment, and follow-up are left to the discretion of the participating investigator. There are no requisites as to how patients should be managed as this is intended to be an observational study. No procedures other than usage of the Benephit Infusion System per its Instructions for Use are specifically required for participation in this study.
1818081|NCT00716417|Drug|BIBW 2992|In each arm, BIBW 2992 dose will be escalated to determine MTD. Starting dose will be 20mg daily followed by 40 mg (with the option of an intermediary dose of 30 mg) then 50mg daily. Dose escalation will stop at 50 mg. No intra patient dose escalation.
1818082|NCT00716417|Drug|BIBW 2992|low to high dose, daily
1818083|NCT00716430|Behavioral|Quality Improvement Programme|Quality Improvement training programme
1818084|NCT00716443|Drug|tetracaine 7% / lidocaine 7% cream (Pliaglis® Cream)|Apply tetracaine/lidocaine cream once on one side of the face prior to Restylane® injections
1818085|NCT00716443|Drug|benzocaine 20% / lidocaine 6% / tetracaine 4% ointment|apply benzocaine / lidocaine / tetracaine ointment once on the other side of the face prior to Restylane® injections
1818086|NCT00716456|Drug|erlotinib with cetuximab|The phase I portion will accrue as many as 3 cohorts of 3-6 patients; receiving erlotinib 100 mg daily along with escalating doses of cetuximab administered every 2 weeks beginning at 250mg/m2 IV without a loading dose. Subsequent cetuximab dose levels will be 375 mg/m2, and 500 mg/m2, administered IV every 2 weeks. Patients will have baseline CT, labs and ECG done within 2 weeks of study entry. Three patients will be enrolled per dose level. Patients will be monitored for toxicity weekly for the first 5 weeks, and every 2 weeks thereafter. Patients will be monitored for response by CT in the fourth week of combined therapy and every 8 weeks. All patients in this portion of the trial will receive intravenous cetuximab every two weeks at the MTD (to be determined in phase I portion) and daily erlotinib on an outpatient basis and will obtain clinical re-evaluation and radiographic re-imaging on a schedule similar to that followed in the phase I portion
1818087|NCT00716469|Drug|LS11|LS11 will be given as a one-time IV infusion over 3-5 minutes.
1818088|NCT00716495|Biological|AGI-101H Vaccine|Each patient will receive one dose of AGI - 101H containing 5 x 107 viable cells, administered s.c. for up to 26 weeks.
1818089|NCT00716508|Procedure|Repair with transpatellar tunnels|Repair with transpatellar tunnels: We will make a small horizontal trough at the inferior pole of the patella. Multiple, braided Krackow sutures will then be placed through the substance of the tendon using no. 5 Fiberwire (Arthrex, Naples FL) suture. Three to four drill holes will then be made through the patella. Using a suture passer, the sutures will then be brought from distal to proximal and tied over the superior pole. The knee will be flexed to 45 degrees. The tendon will be repaired adjacent to the articular surface and not to the anterior surface of the patella.
1818090|NCT00716508|Procedure|Repair with suture anchors.|Repair with suture anchors: The insertion points for the three suture anchors will be marked with electrocautery. The anchors will be placed approximately 2 mm from the articulate surface; placing them too superficially may increased the joint reactive force and lead to abnormal patella femora joint mechanics. Pilot holes will be drilled with a 3.2-mm drill bit parallel to the patella, avoiding penetration of the articular surface. Three Suture anchors (Arthrex, Naples FL) will be threaded with two No. 5 Fiberwire (Arthrex, Naples FL) sutures and will be inserted and deployed in the pilot holes in the usual manner.
1818091|NCT00716521|Drug|placebo|single oral dose placebo
1818092|NCT00716521|Drug|zolpidem|single oral dose, 5 mg zolpidem
1818093|NCT00716521|Drug|zolpidem|single oral dose, 10 mg zolpidem
1818094|NCT00716534|Drug|ABT-869|12.5 mg ABT-869
1818095|NCT00716534|Drug|Placebo for ABT-869|Placebo Comparator (12.5 mg or 7.5 mg)
1818096|NCT00716534|Drug|ABT-869|7.5 mg ABT-869
1818097|NCT00716534|Drug|Carboplatin|Carboplatin (AUC 6 mg/mL/min)
1818098|NCT00716534|Drug|Paclitaxel|Paclitaxel (200 mg/m2)
1818099|NCT00716547|Drug|ketoprofen in Diractin®|50 mg (b.i.d.)
1818100|NCT00716547|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
1818101|NCT00716547|Drug|Placebo|b.i.d.
1818102|NCT00716547|Drug|celecoxib|100 mg (b.i.d.)
1818103|NCT00716573|Drug|everolimus|0,75 mg bid, 24 months
1818104|NCT00716586|Drug|dorzolamide|2% dorzolamide- 1 Gtt TID
1818105|NCT00716599|Device|training in use of rapid diagnostic tests (RDTs) for malaria|training program and introduction of RDTs for use in case management of patients presenting for routine care at government health centers
1818106|NCT00716612|Drug|Coenzyme Q 10|PO Coenzyme Q 10 120 mg QD
1818107|NCT00716612|Drug|Placebo control|po Placebo QD
1818108|NCT00716625|Drug|sunitinib malate|"SUTENT® Capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.
The dosage may be decreased according to the patient's clinical condition."
1818109|NCT00716638|Behavioral|Trauma-focused Cognitive Behavior Therapy|This intervention comprises 10 sessions of trauma-focused cognitive behavior therapy for PTSD with the components (a) prolonged imaginal exposure, (b) in vivo exposure, and (c) cognitive restructuring.
1818110|NCT00716638|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|This intervention comprises 10 sessions of EMDR according to the standard protocol.
1818111|NCT00716651|Drug|mepolizumab|750 mg mepolizumab iv q4wk until week 32
1818112|NCT00716664|Other|A treatment series of gentle joint and muscle movements|Undertaken by a physiotherapist, weekly, for six weeks
1818113|NCT00716664|Other|Control group measurements|The control group are measured using the same outcome measures at the same time intervals, but receive no active intervention
1818114|NCT00716690|Procedure|Multi donor stem cell transplantation|stem cell transplantation from 2 donors
1818115|NCT00716703|Other|CT Scan using IV contrast alone|CT scan using IV contrast alone
1818116|NCT00716716|Drug|rFIXFc|As specified in the treatment arm
1818117|NCT00716742|Drug|bimatoprost 0.03%, latanoprost 0.005%, and travoprost 0.004%|1 drop in eye(s) every evening
1818118|NCT00716755|Drug|Risperidone/Olanzapine and PET scans|Current risperidone/olanzapine users who are 50 or older will be recruited. Dopamine D2 dopamine receptors using a selective D2 dopamine receptor ligand, [11C]-raclopride, and plasma levels of risperidone and 9-OH-risperidone, or of olanzapine, and prolactin will be measured on the 1st PET visit. Subsequently, there will be gradual dose reductions of risperidone or olanzapine by 0.5 and 2.5 mg per week, respectively (as long as the total reduction does not exceed 40%). At least 5 days after the termination of the dose taper, participants will have the second PET scan. Participants will be followed up for 24 weeks after the termination of the dose reduction.
1818119|NCT00716768|Procedure|Laparoscopic Inguinal Hernia Repair|Laparoscopic Inguinal Hernia Repair
1818120|NCT00716768|Procedure|Open Inguinal Hernia Repair|Open Inguinal Hernia Repair
1818121|NCT00716794|Drug|HE3235|HE3235 will be administered orally in 28 day cycles.
1818122|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
1818123|NCT00716807|Drug|nalbuphine plus placebo|Patient group: temporomandibular disorders. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
1818124|NCT00716807|Drug|nalbuphine plus naloxone|Patient group: burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Naloxone 0.4 mg administered by nasal spray (one time only).
1818125|NCT00716807|Drug|nalbuphine plus placebo|Patient group: Burning mouth syndrome. Nalbuphine 5 mg administered by nasal spray (one time only). Placebo (naloxone vehicle) administered by nasal spray (one time only).
1818126|NCT00716820|Drug|SUNITINIB MALATE|"SUTENT capsule 12.5 mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral sunitinib is 50 mg once daily, 4 weeks on followed by 2 weeks off (Schedule 4/2). This comprises 1 treatment cycle, which may be repeated.
The dosage may be decreased according to the patient's clinical condition."
1818127|NCT00716833|Drug|Etoricoxibe|Preemptive group patients get Etoricoxibe either twice (before and after surgery) or just a single preoperative dose.
1818128|NCT00716833|Drug|Placebo|Postoperative group patients get placebo before surgery and either a drug application or a placebo again after surgery (so called 2x2 factorial study design).
1818129|NCT00716846|Drug|simvastatin|10mg, 2 weeks
1818130|NCT00716846|Drug|atorvastatin|10mg
1818131|NCT00716846|Drug|pitavastatin|2mg
1818132|NCT00716859|Drug|Timolol|Timolol 0.5% dosed twice-daily
1818133|NCT00716859|Drug|latanoprost|Latanoprost 0.005% ophthalmic solution dosed once-daily
1818134|NCT00716872|Behavioral|Sleep Healthy Using the Internet (SHUTi)|"SHUTi is an Internet program based on cognitive-behavioral therapy for insomnia (CBT-I). Users complete daily online sleep diaries in addition to receiving weekly access to six interactive Cores of information. As they progress through the program, users receive tailored instructions for how to improve their sleep."
1818135|NCT00716872|Behavioral|Hypnosis recordings|Subjects listen to self-hypnosis recordings designed to improve their disturbed sleep.
1818136|NCT00716911|Drug|ganciclovir|
1818137|NCT00716911|Genetic|polymerase chain reaction|
1818138|NCT00716911|Other|flow cytometry|
1818139|NCT00716911|Other|immunologic technique|
1818140|NCT00716911|Procedure|allogeneic bone marrow transplantation|
1818141|NCT00716911|Procedure|allogeneic hematopoietic stem cell transplantation|
1818142|NCT00716911|Procedure|assessment of therapy complications|
1818143|NCT00716911|Procedure|peripheral blood stem cell transplantation|
1818144|NCT00716924|Drug|Clopidogrel|300 mg
1818145|NCT00716924|Drug|Clopidogrel|600 mg
1818146|NCT00716937|Procedure|karydakis flap|Karydakis flap is a type of primary repair of the wound, after complete excision of sacral pilonidal cyst with 2 characteristics 1)lateralization of final scar 2)flattening of natal cleft
1818147|NCT00716937|Procedure|laying open|laying open the site of excision of sinus or cyst without any flap
1818148|NCT00716950|Drug|valsartan/amlodpine|tablets; 160mg/5mg; od; 4 weeks
1818149|NCT00716950|Drug|losartan/amlodpine|tablets; 100mg/5mg; od; 4 weeks
1818150|NCT00716963|Drug|Fluticasone propionate (Flovent Diskus) 250 mcg|Flovent Diskus 250 mcg
1818151|NCT00716963|Drug|budesonide 400 mcg|budesonide 400 mcg
1818152|NCT00716963|Other|Placebo|Placebo
1993607|NCT03165981|Biological|PCV13|ACIP Recommended vaccine
1993608|NCT03165981|Biological|DTaP|ACIP Recommended vaccine
1818155|NCT00716989|Biological|Tuberculin antigen|2 intradermal injection of 50µl of antigen + 2 intradermal injection of 50µl of physiological serum
1818156|NCT00717054|Drug|Aprepitant|Aprepitant 40mg PO one time at least one hour prior to induction of anesthesia
1818157|NCT00717054|Drug|Scopolamine|Scopolamine transdermal applied to skin behind the ear one hour prior to surgery
1818158|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
1818159|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet twice daily x 7 days
1818160|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
1818161|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
1818162|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet once daily x 7 days
1818163|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
1818164|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
1818165|NCT00717067|Drug|Maraviroc|Maraviroc 150 mg tablet once every 48 hours x 7 days
1818166|NCT00717067|Drug|Ritonavir|Ritonavir 100 mg capsule twice daily x 7 days
1818167|NCT00717067|Drug|Saquinavir|Saquinavir 1000 mg (500 mg x 2 tablets) twice daily x 7 days
1818168|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose
1818169|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose one hour following completion of hemodialysis
1818170|NCT00717067|Drug|Maraviroc|Maraviroc 300 mg (150 mg x 2 tablets) x single dose three hours prior to start of hemodialysis
1818171|NCT00717080|Procedure|IOL surgery|IOL surgery using capsular tension ring (AURORING)
1818173|NCT00717093|Drug|Varenicline Tartrate|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
1818174|NCT00717093|Drug|Placebo|Subjects will be up-titrated during the first week of treatment in the following manner: 0.5 mg once daily for 3 days followed by 0.5 mg twice daily for 4 days, and then 1 mg twice daily for the following 11 weeks of the treatment period.
1818175|NCT00717132|Behavioral|Individual Behavior Modification|Individual behavioral treatment for obesity. Children and parents meeting individually for 15 total behavioral modification intervention sessions.
1818176|NCT00717132|Behavioral|Family-based behavior modification|Family-base behavior treatment for obesity. Children and parents meeting together for 15 total behavioral modification intervention sessions.
1818177|NCT00717145|Drug|risedronate|one risedronate 20 mg DR tablet
1818178|NCT00717145|Drug|risedronate|One risedronate 20 mg DR tablet
1818179|NCT00717145|Drug|risedronate|One risedronate 35 mg DR tablet
1818180|NCT00717145|Drug|risedronate|One risedronate 35 mg IR tablet
1818181|NCT00717158|Behavioral|Usual medical care|
1818182|NCT00717158|Behavioral|Lifestyle Case management|Intervention participants were assigned to one registered dietitian who they met with over a one year period for 6 session (four hours) of individual care, 6- one-hour group classes, and had monthly email contact for follow up and checking in
1818183|NCT00717171|Device|SurgiStim3|Electrical stimulation device that provides interferential, high voltage pulsed current and neuromuscular waveforms in sequence. The device runs continuously for the first 2 days following surgery, then runs 3 times a day for 1 hour on days 3 through 42.
1818184|NCT00717171|Device|SurgiStim3|The placebo device is programmed to run for the same amount of time, at the same schedule, using the same waveforms as the functional device over the course of the 42 days. The placebo device, however, will only increase to 80% of the patient-set amplitude after a one minute set-up period and will only turn on for 6 seconds of every minute (3s ramp up, 1s on time, 2s ramp down).
1818185|NCT00717184|Drug|Interleukin, NK cells|
1818186|NCT00717197|Drug|Capecitabine|1,000-1,250 mg/m2 taken by mouth twice daily for 14 out of 21 consecutive days until progression or unacceptable toxicity.
1818187|NCT00717210|Drug|Temozolomide|200 mg/m2 body surface on days 1-5 every 28 days for 8 cycles; and again for another 4 cycles at primary progression
1818188|NCT00717210|Radiation|Focal radiotherapy|54-60 Gy in 28-30 fractions over 6-7 weeks
1818189|NCT00717236|Drug|Certolizumab pegol (CZP)|400 mg CZP given as two 200 mg subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by 200 mg CZP given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
1818190|NCT00717236|Other|Placebo|Placebo (0.9% saline) given as 2 subcutaneous (sc) injections at Weeks 0, 2, and 4, followed by placebo given as 1 sc injection on Weeks 6, 8, and 10. At Week 12 subjects enter the open label phase and receive 200 mg of CZP every other week for a minimum 16 additional weeks until CZP is commercially available.
1818191|NCT00717249|Device|galyifilcon A control lens|Marketed daily wear contact lens
1818192|NCT00717249|Device|galyfilcon A with a silver additive|Investigational daily wear contact lens
1818193|NCT00717262|Drug|HQK-1001|HQK-1001 (5, 10 or 15 mg/kg) capsules administered once a day, orally, for 14 days.
1818194|NCT00717262|Drug|placebo|Matching placebo capsules administered once a day, orally, for 14 days.
1818195|NCT00717275|Drug|Temozolomide|75 mg/m2 taken by mouth once a day for 14 out of 28 consecutive days until progression or unacceptable toxicity.
1818196|NCT00717288|Drug|Detemir|Detemir dosed at 50% of calculated basal insulin infusion requirements
1818197|NCT00717288|Drug|Detemir|Detemir dosed at 65% of calculated basal insulin infusion requirements
1818198|NCT00717288|Drug|Detemir|Detemir dosed at 80% of calculated basal insulin infusion requirements
1818199|NCT00717314|Drug|Mycophenolate mofetil|1.5 to 2.0 g daily PO BID
1818200|NCT00717314|Drug|CNI (50%)|50% reduction from BL
1818201|NCT00717314|Drug|CNI (≥75%)|≥75% reduction from BL
1818202|NCT00717327|Other|Counseling for subjects who do not know their medications|Physician interviewer will provide counseling to subjects who indicate through answers that they do not know their medication names.
1818203|NCT00717340|Drug|tivozanib (AV-951) + paclitaxel|"Tivozanib (AV-951):
Subjects in the Phase 1b study will receive 1 dose of tivozanib (AV-951) on Day -5 (± 2 days) for PK sampling prior to Cycle 1 only.
Thereafter in the Phase 1b and 2a study, subjects will receive tivozanib (AV-951) once daily for 3 weeks beginning on Day 1, followed by 1 week off treatment (1 cycle = 4 weeks). On days when paclitaxel and tivozanib (AV-951) are co-administered, AV-951 will be administered immediately following the end of the paclitaxel infusion.
Paclitaxel: Phase 1b study and Phase 2a study:
All subjects will receive IV paclitaxel 90 mg/m2, administered over 1 hour once a week for 3 weeks, followed by 1 week off (1 cycle = 4 weeks)."
1818204|NCT00717366|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|Will be administered IV, every 4 weeks.
1818205|NCT00717379|Drug|Tacrolimus|oral
1818206|NCT00717379|Drug|Mycophenolate Mofetil|oral
1818207|NCT00717379|Drug|Methylprednisolone or equivalent|oral
1818208|NCT00717379|Drug|Prednisone|oral
1818209|NCT00717405|Drug|Standard chemotherapy|As prescribed
1818210|NCT00717405|Drug|bevacizumab [Avastin]|15mg/kg iv 3 weekly in cycles 1-8
1818211|NCT00717405|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose followed by 6mg/kg iv 3 weekly in cycles 5-8.
1818212|NCT00717418|Drug|cyclosporine ophthalmic emulsion 0.05%, artificial tears|one drop, twice a day in each eye
1818213|NCT00717431|Procedure|Hippocampal Electrical Stimulation|Surgical Implantation of electrode and stimulator
1818214|NCT00717444|Behavioral|contingency management|"contingency management for abstinence plus 12-step facilitation therapy
prizes awarded for target behaviors"
1818215|NCT00717444|Behavioral|contingency management|"contingency management for abstinence plus 12-step facilitation therapy and contingency management for completing healthy activities
prizes awarded for target behaviors"
1818216|NCT00717457|Drug|exenatide|5mg twice daily for 4 weeks followed by 10mg twice daily
1818217|NCT00717457|Drug|taspoglutide|10mg once weekly
1818221|NCT00717470|Drug|Mycophenolate Mofetil|oral
1818222|NCT00717470|Drug|Simulect|oral
1818223|NCT00717470|Drug|methylprednisolone / prednisone|oral
1818224|NCT00717496|Other|Telephone Support Intervention to Improve Breastfeeding|The intervention will consist of outreach telephone calls daily by bilingual trained nursing staff for the first 2 weeks postpartum using the scripted protocols developed for this program. Both groups will receive a small bag with reading materials, illustrations of breastfeeding positions and latch, hand breast pump, and lanolin cream. The intervention nurse will ask the mothers on their initial intake call for the best time to call each day to minimize time needed to reach the mother.
1818225|NCT00717522|Drug|Pomalidomide|
1818226|NCT00717535|Other|cryopreservation|
1818227|NCT00717535|Other|questionnaire administration|
1818228|NCT00717535|Other|study of socioeconomic and demographic variables|
1818229|NCT00717548|Behavioral|Narrative Exposure Therapy|Trauma-Focused short term intervention (8-12 sessions)
1818230|NCT00717561|Drug|Avelox (Moxifloxacin, BAY12-8039)|IV therapy: every 24 hours, patients will be administered a 400 mg moxifloxacin infusion over 60 minutes. Oral therapy: patients will be administered a single moxifloxacin 400 mg tablet, every 24 hours
1818231|NCT00717561|Drug|Ceftriaxone; Azithromycin; Amoxicilline/clavulanate; Clarithromycin|IV therapy: every 24 hours patients will be administered a 2 g ceftriaxone infusion over 30 minutes. Following the infusion with ceftriaxone, patients will be administered a 500 mg azithromycin infusion over 180 minutes.Oral therapy: every 8 hours patients will be administered a 1000 mg amoxicillin/clavulanic acid tablet. Every 12 hours patients will be administered a 500 mg clarithromycin tablet.
1818232|NCT00717574|Drug|Sevoflurane group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
1818233|NCT00717574|Drug|Propofol group|Addition of 60% nitrous oxide for 20 minutes duration, then back to 1:1 oxygen/air mixture.
1818234|NCT00717587|Drug|motexafin gadolinium|
1818235|NCT00717587|Drug|sunitinib malate|
1818236|NCT00717587|Genetic|comparative genomic hybridization|
1818237|NCT00717587|Genetic|gene expression analysis|
1818238|NCT00717587|Genetic|mutation analysis|
1818239|NCT00717587|Genetic|polymorphism analysis|
1818240|NCT00717587|Other|immunohistochemistry staining method|
1818241|NCT00717587|Other|iodine I-124 girentuximab|
1818242|NCT00717587|Other|laboratory biomarker analysis|
1818243|NCT00717587|Other|pharmacological study|
1818244|NCT00717587|Procedure|adjuvant therapy|
1818245|NCT00717587|Procedure|neoadjuvant therapy|
1818246|NCT00717587|Procedure|therapeutic conventional surgery|
1818247|NCT00717600|Dietary Supplement|Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1|2x10^9 cfu of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1 administered daily via a single orally ingested freeze-dried capsule.
1818248|NCT00717626|Drug|Kogenate FS, Advate, or Humate-P, Recombinate, Helixate FS|Starting at the 4-month visit, subjects will receive 250 units per day (if their weight is < 50 kg.) or 500 units per day (weight ≥ 50 kg.) of their usual preparation of factor VIII.
1818249|NCT00717639|Procedure|Diagnostic MR-Angiography|Single MR-Angiography of the lower extremity after the bolus injection 0.03mmol/kg BW Vasovist
1818250|NCT00717652|Drug|arbutin, tretinoin, triamcinolone|arbutin, tretinoin, triamcinolone
1818251|NCT00717652|Drug|Triluma|Hydroquinone, Fluoncinolone, Tretinoin
1818252|NCT00717665|Device|Home blood pressure tele-management system.|Scheduled blood pressure monitoring with transmission of information to a central server for processing and disbursement.
1818253|NCT00717665|Other|Usual care.|Patient self-monitoring of blood pressure with results taken by patient to the doctor at scheduled visits.
1818254|NCT00717678|Drug|Prograf-XL|oral
1818255|NCT00717678|Drug|Prograf|oral
1818256|NCT00717678|Drug|MMF|oral
1818257|NCT00717691|Device|Metatarsophalangeal Extension Dynasplint System|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. This unit is worn for 30 minutes, three times per day, (while seated or resting in bed) totaling 1.5 hours per day.
1818258|NCT00717691|Other|Standard of Care|The current standard of care in treating Hallux Limitus will be given to all patients regardless of randomized categorization, and this includes: analgesic and nonsteroidal anti-inflammatory drugs (NSAIDs), orthotics with medial stiffness, and reduction of great toe movement in motions such as kneeling or squatting with the toes in an extended position.
1818259|NCT00717704|Drug|ixabepilone|by vein once every 3 weeks
1818260|NCT00717704|Drug|Dasatinib|by mouth once daily
1818261|NCT00717717|Behavioral|Intervention|One-year rehabilitation program including weekly supervised and group-based physical exercise, home-based physical activity, individual and group-based coaching (narrative therapy), and expert educational talks/lectures
1818262|NCT00717730|Dietary Supplement|Folic Acid|150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months.
1818263|NCT00717730|Dietary Supplement|Vitamin B12|1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
1818264|NCT00717730|Dietary Supplement|Placebo|Placebo with no active ingredients
1818265|NCT00717730|Dietary Supplement|Folic acid and vitamin B12|Folic acid 150µgm/day for 6 months in children older than 11 months and 80µgm in 6 to 11 months vitamin B12 1.8µgm/day for 6 months in children older than 11 months and 0.5µgm in 6 to 11 months.
1818266|NCT00717756|Drug|lenalidomide|25 mg po qd x 21 days then 1 week off equals one cycle
1818267|NCT00717769|Drug|SUN13834|Daily oral doses, low dose, for 28 days of SUN13834
1818268|NCT00717769|Drug|Placebo|Daily oral doses, placebo, for 28 days of SUN13834
1818269|NCT00717782|Procedure|injection of botulinum toxin|Patients received a 0·6-ml injection of a solution containing 30 units botulinum toxin into the internal anal sphincter
1818270|NCT00717782|Procedure|injection of saline|Patients received a 0·6-ml injection of a saline solution into the internal anal sphincter
1818271|NCT00717795|Behavioral|interview and physical activity|For Arm 1 participants in the Physical Activity intervention condition will be assessed at baseline, and postintervention Follow-up (at 12 weeks post baseline).
1818350|NCT00711230|Biological|Placebo|glucose/dextrose
1818272|NCT00717795|Behavioral|interview and wait list|Participants in the control condition (Arm 2)will be assessed at baseline and 12 weeks post baseline (Follow-up). At this time, the PA intervention will be offered at no cost to the participants in the control condition. If the waitlist participant chooses to complete the PA intervention after the 12 week waitlist period, program satisfaction will be assessed after study completion.
1818273|NCT00717808|Drug|Tranilast|Tranilast (300mg twice a day) for a period of seven days whilst taking their weekly prescribed dose of methotrexate. Followed by a 7 day washout period before starting arm 2
1818274|NCT00717808|Drug|Placebo comparator|The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
1818275|NCT00717821|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120 micrograms or 200 micrograms iv or sc (starting dose)
1818276|NCT00717821|Drug|Epoetin beta or darbepoetin alfa|As prescribed
1818277|NCT00717834|Biological|Formalin-treated, UV-inactivated, whole-virion, Vero cell-derived, preservative free Ross River Virus (RRV) vaccine with or without an Al(OH)3 adjuvant|Two intramuscular injections of either 1.25 µg, 2.5 µg, 5 µg or 10 µg on Days 0 and 21, with a booster vaccination to follow 180 days after the first.
1818278|NCT00717860|Drug|caspofungin acetate|Caspofungin acetate (50 mg/day for participants with esophageal candidiasis and 50 mg/day for participants with invasive candidiasis or aspergillosis after a 70 mg loading dose on Day 1), once daily intravenously (IV) for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
1818279|NCT00717860|Drug|Comparator: Micafungin sodium|Micafungin sodium 150 mg/day, once daily IV, for 1-4 weeks for esophageal candidiasis, 2-8 weeks for invasive candidiasis, 2-12 weeks for aspergillosis.
1818280|NCT00717873|Device|Airway clearance Device|Provided by the Vest Airway clearance system
1818281|NCT00717886|Radiation|isosulfan blue dye|"At the time of surgery, each patient will undergo a subareolar injection of isosulfan blue dye into the ipsilateral breast as routinely performed during a sentinel lymph node mapping for breast cancer. The surgeon will then perform an axillary lymph node dissection in the usual, routine manner. The above differs from standard of care in that patients scheduled for an upfront axillary dissection do not routinely undergo sentinel lymph node mapping- therefore these patients would not normally get any isotope or TSC injections since they already need an ALND. Second, standard sentinel lymph node mapping involves injection of TSC into the affected breast the day prior to surgery or 3 hours before surgery versus injection of TSC into the ipsilateral upper extremity. The protocol specifies day of mapping for patient convenience."
1818282|NCT00717899|Device|Spirometry (Pony spirometer)|Spirometry at rest
1818283|NCT00717912|Other|Experimental sweetener syrup|3 glucose and insulin responses with experimental sweetener syrup : 50 grams of digestible carbohydrate plus fiber
1818284|NCT00717912|Other|Classical sweetener syrup|1 glucose and insulin responses with classical sweetener syrup : 50 grams of digestible carbohydrate plus fiber
1818285|NCT00717912|Other|Classical sugar syrup|3 glucose and insulin responses with classical sugar syrup : 50 grams of digestible carbohydrate plus fiber
1818286|NCT00717925|Drug|Inotuzumab Ozogamicin (CMC-544)|Intravenous (IV) infusion, 1.3 - 1.8 mg/m2, every 28 days, 4 cycles
1818287|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide.|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. Used drugs=cisplatinum or carboplatin and e.g.etoposide. Treatment will be given every three weeks for 4-6 cycles according to local variants.
1818288|NCT00717938|Drug|cisplatinum or carboplatin and e.g.etoposide+enoxaparin|Standard chemotherapy treatment for patients with small cell lung cancer. Chemotherapy regimen contains a platinum drug and a topoisomerase inhibitor. Numbers of cycles 4-6 according to local variants. In addition to this, subjects will receive daily subcutaneous injections of enoxaparin during chemotherapy treatment.
1818289|NCT00717951|Drug|docetaxol, cisplatin, capecitabine|docetaxol(75mg/m2 d1 every 21 days) combined with cisplatin(75mg/m2 d1 every 21 days) VS docetaxol( 75mg/m2 d1 every 21 days) combined with capecitabine(2000mg/m2 d1-14 every 21 days)
1818290|NCT00717977|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor for 3-7 days
1818291|NCT00717990|Drug|Capecitabine|Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
1818292|NCT00717990|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
1818293|NCT00717990|Drug|Irinotecan|Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
1818294|NCT00718042|Device|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with ABBOTT PRISM Chagas assay. If results are reactive, donor sample will be tested with Chagas Confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
1818295|NCT00718042|Device|ABBOTT PRISM Chagas Assay and Chagas Confirmatory Assay|Test blood donor sample with investigational Chagas assay. If results are reactive, donor samples will be tested with Chagas confirmatory assay. Donors reactive with screening assay or positive with confirmatory assay will be deferred and asked to return for a follow-up blood draw.
1818296|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|Continuous infusion, 40mmol in 40ml, starting at 10ml/hr, rate altered according to serum potassium level checked 2 hourly
1818297|NCT00718068|Drug|Sterile Potassium Chloride Concentrate|By intermittent infusion, 20mmol diluted in 100ml 0.9% NaCl, administered over 60 mins, serum potassium level checked 2 hourly, and repeat doses administered as appropriate
1818298|NCT00718081|Drug|Oral sufentanil|Oral dosage of sufentanil
1818299|NCT00718081|Drug|Placebo|Oral dosage of placebo
1818301|NCT00718120|Biological|Fluviral®|One intramuscular injection into the deltoid region of the non-dominant arm
1818302|NCT00718133|Device|Spirometry (Pony spirometer)|Spirometry at rest
1818303|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
1818304|NCT00718146|Biological|Split virion, inactivated Influenza vaccine|0.5 mL, Intramuscular (IM)
1818345|NCT00711191|Drug|chemotherapy|gemcitabine 1000 mg/m^2 intravenous administration [IV] q week [wk]x3 of 4-week cycles
1818346|NCT00711204|Drug|Donepezil Hydrochloride (Aricept)|5mg (or 10mg) tablet, once daily, with a full glass of water.
1818347|NCT00711217|Other|Medical Food|twice daily
1818305|NCT00718159|Drug|LY573636-sodium|Individualized dose is dependent on patient's height, weight, gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Dosing will be done on Day 1 of a 35-day cycle for AML and Day 1 of a 28-day cycle for ET for at least one cycle. A patient may have additional cycles of LY573636 if he or she is receiving benefit from the study drug and does not fulfill any of the criteria for study discontinuation.
1818306|NCT00710853|Other|YiRen Qi gong|One hour weekly class for 8 week duration
1818307|NCT00710853|Other|Tai Chi|One hour weekly class for 8 week duration
1818308|NCT00710853|Other|Hatha yoga|One hour weekly class for 8 week duration
1818309|NCT00710866|Biological|Inactivated Influenza Vaccine Trivalent Types A and B (Split Virion)|Arm 1 (experimental group) received two spaced injections of the 0.5 mL (full) dose while arm 2 (comparison group) received the currently recommended two spaced injections of 0.25mL (half) dose of trivalent inactivated split virion influenza vaccine (VAXIGRIP®) manufactured by Sanofi Pasteur, Lyon, France.
1818310|NCT00710879|Device|Bausch & Lomb Multi-Purpose Solution|Daily care for contact lenses.
1818311|NCT00710892|Biological|Allodepleted T Cells|"Dose Level 1 = 1 x 10e6 T cells/kg; Dose Level 2 = 3 x 10e6 T cells/kg; Dose Level 3 = 1 x 10e7 T cells/kg.
Patients may be enrolled at the next dose level of T cells when all patients at the previous dose level have reached Day 42 post-T cell infusion without unacceptable toxicity."
1818312|NCT00710905|Device|AcrySof ReSTOR Aspheric IOL models SN6AD1 and SN6AD3|Contralateral implantation of AcrySof ReSTOR +3 Intraocular Lens (IOL) in one eye, AcrySof ReSTOR +4 IOL in the other eye following cataract removal.
1818313|NCT00710931|Device|AcrySof ReSTOR Aspheric IOL model SN6AD1|Bilateral implantation of the AcrySof ReSTOR +3 Intraocular Lens (IOL) following cataract removal.
1818314|NCT00710944|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™: Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm.
1818315|NCT00710970|Drug|Tamoxifen|Tamoxifen is administered at 20 mg/day as a single daily oral dose. Tamoxifen is continued until progressive disease or intolerable grade 3 or 4 side effects occur due to tamoxifen.
1818316|NCT00710983|Biological|Oral polio vaccine|
1818317|NCT00711009|Drug|lopinavir/ritonavir (LPV/r)|LPV/r 400/100 mg BID
1818318|NCT00711009|Drug|emtricitabine/tenofovir disoproxil fumarate (FTC/TDF)|FTC/TDF 200/300 mg QD
1818319|NCT00711009|Drug|raltegravir (RAL)|RAL 400 mg BID
1818320|NCT00711022|Device|ASTRA TECH Implant System, OsseoSpeed™, all dimensions.|
1818321|NCT00711035|Biological|Trivirus Specific CTLs for EBV, CMV and Adenovirus Infection|"Follow-up Assessments: The timing of follow-up visits is based on the date of CTL infusion. If a patient has multiple CTL doses the schedule resets again at the beginning so follow up relates to the last CTL dose.
Follow up will occur at 7 days, 14 days, 21 days, 28 days, 42 days, 90 days, 180 days, and 365 days post enrollment."
1818322|NCT00711048|Drug|AZD1386|oral, single dose
1818323|NCT00711048|Drug|Placebo|Oral solution, single dose
1818324|NCT00711074|Drug|AZD5672|single dose 200mg aqueous solution
1818325|NCT00711087|Drug|BOTOX-A|Group 1-100 units of BTX-A (Botox®, Allergan Inc., Irvine, CA) on Day 0 and 100 units of BTX-A on Day 90
1818326|NCT00711087|Other|Saline injection|Group 2-sham saline injections on both Day 0 and Day 90.
1818327|NCT00711100|Other|Camel Snus|All subjects will sample Camel Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Camel Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Camel Snus is chosen for use) during abstinence phase.
1818328|NCT00711100|Other|Marlboro Snus|All subjects will sample Marlboro Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Marlboro Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Marlboro Snus is chosen for use) during abstinence phase.
1818329|NCT00711100|Other|Stonewall|All subjects will sample Stonewall and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Stonewall. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Stonewall is chosen for use) during abstinence phase.
1818330|NCT00711100|Other|Ariva|All subjects will sample Ariva and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of Ariva. Intervention period (duration: 2 weeks) involves ad libitum daily use (if Ariva is chosen for use) during abstinence phase.
1818331|NCT00711100|Other|General Snus|All subjects will sample General Snus and determine if they would prefer to use this product during the abstinence phase over the other products sampled. Sampling period (duration: 1/2 day) requires use of at least 3 samples of General Snus. Intervention period (duration: 2 weeks) involves ad libitum daily use (if General Snus is chosen for use) during abstinence phase.
1818332|NCT00711113|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
1818333|NCT00711126|Drug|GW642444|2.5mcg IV
1818334|NCT00711126|Drug|GW642444|5mcg IV
1818335|NCT00711126|Drug|GW642444|10mcg IV
1818336|NCT00711126|Drug|GW642444|100mcg inhaled
1818337|NCT00711126|Drug|GW642444|20mcg IV
1818338|NCT00711126|Drug|GW642444|500mcg oral
1818339|NCT00711152|Other|Protocol-driven care under JADE Program|The JADE Program uses the state of the art of information technology to facilitate evidence-based clinical protocol by a multidisciplinary team. There is an internet on-line and computer record system to facilitate the day-to-day management of people with diabetes.
1818340|NCT00711152|Other|Additional support by CHW|Patients will receive additional support by a trained community health worker (CHW). Guided by the personalized report with embedded decision support, the CHW will reinforce treatment adherence and self care after each clinic visit.
1818341|NCT00711165|Drug|Placebo|2 puffs, qd
1818342|NCT00711165|Drug|Mometasone Furoate|400 mcg, qd for 8 weeks
1818343|NCT00711178|Procedure|Photodynamic therapy with methyl aminolevulinate|daylight mediated photodynamic therapy
1818344|NCT00711191|Biological|monoclonal antibody|CP-870,893 intravenous administration [IV] on day 3 of 4-week cycles
1818348|NCT00711217|Other|Drink mix calorically similar to experimental product|twice daily
1818351|NCT00711243|Drug|docetaxel|Docetaxel at the dose indicated by the patient cohort, administered intravenously in 5% dextrose over 1 hour on day 1 of each cycle.
1818352|NCT00711243|Drug|fluorouracil|Intravenous infusion at 85 mg/m2 continuously over 46 hours beginning each cycle after docetaxel administration.
1818353|NCT00711243|Drug|oxaliplatin|Oxaliplatin 2.4 gm/m2 administered intravenously in 5% dextrose over 2 hours each cycle beginning immediately following docetaxel
1818354|NCT00711256|Other|sunscreen MATAS sunlotion SPF 8|
1818355|NCT00711256|Radiation|UVB light|duration 4 times 1 minute radiation on the trunk.
1993609|NCT03165981|Biological|IIV|ACIP Recommended vaccine
1993610|NCT03165565|Behavioral|Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT)|Participants will receive Motivational Interviewing (MI) and Acceptance and Commitment Therapy (ACT).
1818360|NCT00711282|Device|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 3.5 and 4.0 mm.
1818361|NCT00711282|Device|OsseoSpeed™|OsseoSpeed™ MicroThread™, diameters of 4.5 and 5.0 mm.
1818362|NCT00711295|Biological|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 7.5 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
1818363|NCT00711295|Biological|H5N1 Influenza Vaccine Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted|Intramuscular injection of 3.75 µg hemagglutinin antigen (A/Vietnam/1203/2004 strain) in a non-adjuvanted formulation on Days 0 and 21.
1818364|NCT00711308|Drug|tinzaparin|tinzaparin (innohep®)subcutaneously in a fixed dose of 175 IU anti-Xa/kg of body weight once daily for 6 months
1818365|NCT00711308|Drug|acenocoumarol|acenocoumarol for 6 months
1818366|NCT00711347|Device|DisCoVisc|Use of Alcon's DisCoVisc Ophthalmic Viscosurgical Device(4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery with intraocular lens implantation.
1818367|NCT00711347|Device|Healon5|Use of Abbott Medical Optics (AMO) Healon5 Ophthalmic Viscosurgical Device (2.3% Sodium Hyaluronate) during cataract surgery with intraocular lens implantation.
1818368|NCT00711360|Device|Intrathoracic impedance measurement|Intrathoracic impedance measurement by cardiac resynchronization therapy (CRT) devices and implantable cardioverter defibrillators (ICDs) (Lumax 540)
1818369|NCT00711373|Procedure|Allogeneic hand transplantation|Surgical reconstruction of part or all of the hands and/or hands and forearm using tissue from a non-living donor
1818370|NCT00711386|Drug|GSK706769|50mg, 100mg, 200mg, or 400mg
1818371|NCT00711386|Other|Placebo|Placebo
1818372|NCT00711399|Device|PulmoTrack® 2010 with WIM-PC™ and WIM-CC™ Technologies|wheeze and cough detection in hospitalized patients.
1818373|NCT00711412|Drug|Capecitabine - Induction Therapy|Two 21-day cycles will be given as induction. Capecitabine will be given at 1000 mg/m2 twice daily approximately 12 hours apart for 14 days, followed by seven days off.
1818374|NCT00711412|Drug|Oxaliplatin - Induction Therapy|Two 21-day cycles will be given as induction. Oxaliplatin will be given at 70 mg/m2 intravenously in 5% dextrose over two hours on days 1 and 8 of each cycle.
1818375|NCT00711412|Drug|Capcitabine - Combination Therapy|Two 21-day cycles will be given for combination therapy. Capecitabine will be given at 825 mg/m2 twice daily approximately 12 hours apart for five days (Monday through Friday) followed by two days off for 51/2 weeks.
1818376|NCT00711412|Drug|Oxaliplatin - Combination Therapy|Two 21-day cycles will be given. Oxaliplatin will be given at 50 mg/m2 intravenously in 5% dextrose over two hours on days 1, 8 and 15 of each cycle.
1818377|NCT00711412|Radiation|Radiation - Combination Therapy|1.8 Gy daily Monday through Friday to a total of 50.4 Gy for 6 weeks during combination therapy.
1818378|NCT00711425|Device|OsseoSpeed™|OsseoSpeed™, all dimensions
1818379|NCT00711438|Behavioral|Breathlessness Intervention Service (BIS)|BIS consists of a clinical specialist physiotherapist & palliative care consultant. It aims to manage the symptom of breathlessness in patients with any disease using a rehabilitative approach. Interventions include: evidence-based non-pharmacological interventions (psychological, social & physical); palliative care input (e.g. end of life issues, psychosocial issues, family concerns); & pharmacological review. This BIS seeks to enhance self-management of breathlessness. Uniquely, care is located in clinic or in patients' own homes, as appropriate. Referrals come from medical specialists, GPs & allied health professionals (with medical consent).
1818380|NCT00711438|Behavioral|Best supportive care (Standard care)|Standard care: specialist outpatient appointments in secondary care (e.g. respiratory) which may include specialist nurse input, and primary care services.
1818381|NCT00711451|Behavioral|Manual removal|Manual removal of placenta during cesarean delivery
1818382|NCT00711451|Procedure|Expressed removal|Surgeon will perform an expressed delivery of the placenta
1818383|NCT00711464|Drug|modafinil (M1, M2, M4)|modafinil 100, 200, and 400 mg oral dose
1818384|NCT00711477|Drug|Naltrexone SR 32 mg/bupropion SR 360 mg/day|
1818385|NCT00711477|Drug|Placebo|
1818386|NCT00711477|Other|fMRI scan|fMRI to assess the effects of the drug/placebo on areas of the brain
1818387|NCT00711490|Drug|Sirolimus|20 μL (440 μg) of sirolimus were injected at baseline, Month 2, and every 2 months thereafter if re-treatment criteria were satisfied.
1818388|NCT00711503|Drug|anakinra|The patients are instructed to administer anti-IL-1 therapy in the form of recombinant human non-glycosylated interleukin-1 receptor antagonist (IL-1Ra, anakinra, Kineret®, Amgen, CA, USA) [13] at a dose of 100 mg once daily by subcutaneous injection
1818389|NCT00711503|Drug|saline|The patients are instructed to administer placebo (saline) once daily by subcutaneous injection
1818390|NCT00711516|Drug|Armodafinil|Armodafinil once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
1818391|NCT00711516|Drug|Placebo|Matching Placebo dosed once-daily (50 mg/day (1 tablet) on Day 1; increased to 100 mg/day (2 tablets) starting on Day 2; increased to 150 mg/day (3 tablets) starting on Day 5; increased to 200 mg/day (4 tablets) starting on Day 8). Then continue 200 mg/day dosage through Day 14.
1818433|NCT00711854|Drug|Rifampicin|Rifampicin (600 mg IV or PO once daily)
1818434|NCT00711867|Device|VH2|Dynatherm vitalHeat2 (VH2) temperature management system.
1869327|NCT01097096|Biological|CAD106|
1818392|NCT00711529|Behavioral|Hypnotherapy|Patients randomized to the hypnosis arm of the study will undergo individually three one-hour sessions with a certified hypnotherapist. These sessions will be one week apart. surveys. The therapist will be prohibited from asking subjects about clinical responses to the hypnosis sessions. The patients will also be instructed on self-hypnosis techniques to be used at home.
1818393|NCT00711529|Drug|gabapentin|Patients randomized to the gabapentin arm will be prescribed 900mg of the drug daily (300 mg by mouth three times daily). This dose has been shown to be more effective than 300mg daily. Larger doses have not been evaluated in this population, and may be associated with a more significant side-effect profile. The prescription for gabapentin will be provided at the patient's enrollment appointment. The patients will take gabapentin as prescribed daily for the study-enrollment period, which is 8 weeks.
1818394|NCT00711542|Biological|autologous bone marrow-derived progenitor cells|intracoronary infusion of autologous bone marrow-derived progenitor cells isolated from 50 ml bone marrow aspirate
1818395|NCT00711542|Biological|placebo medium|intracoronary infusion of placebo medium
1818396|NCT00711555|Drug|aprepitant, ondansetron, dexamethasone|"On day 1, the subject will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 125mg. On days 2 to THE LAST DAY OF THE MODERATELY-HIGH TO HIGHLY EMETOGENIC CHEMOTHERAPY, subjects will receive a total daily dose of oral dexamethasone 12mg, oral ondansetron 24mg, and oral aprepitant 80mg. All anti-emetics should be give one hour before starting chemotherapy administration.
FOR TWO DAYS AFTER RECEIVING CHEMOTHERAPY, the subject will be prescribed oral dexamethasone 4mg every 12 hours and oral aprepitant 80 mg every day.
FOR RESCUE, the subject will be prescribed prochlorperazine 10 mg oral every 4 hours as needed for nausea and prochlorperazine 10 mg intravenous every 4 hours as needed for vomiting."
1818397|NCT00711568|Procedure|Repetitive transcranial magnetic stimulation (rTMS)|20 Hz rTMS delivered for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli (25 minutes)
1818398|NCT00711568|Procedure|Sham rTMS|20 Hz sham rTMS delivered to L or R frontal region for 2 seconds (40 stimuli) every 30 seconds for a total of 2000 stimuli
1818399|NCT00711568|Device|Repetitive Transcranial Magnetic Stimulator|Repetitive Transcranial Magnetic Stimulator
1818400|NCT00711581|Device|Gallbladder retraction|The gallbladder will be retracted using the Endograb retractor
1818401|NCT00711594|Drug|BIBW 2992 MA2 40mg/day|Phase I step: Increased dose cohorts from low dose to MTD
1818402|NCT00711594|Drug|BIBW 2992 MA2 50mg/day|Phase I step: Increased dose cohorts from low dose to MTD
1818403|NCT00711594|Drug|BIBW 2992 MA2 20mg/day|Phase I step: Increased dose cohorts from low dose to MTD
1818404|NCT00711594|Drug|BIBW 2992 QD|Phase II step: This is an open label study. Patients are treated with BIBW 2992 until disease progression or undue AEs.
1818405|NCT00711607|Drug|nomegestrol acetate and estradiol|Group 1: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 and day 35; Group 2: one tablet of 2.5 mg NOMAC-E2 and 1.5 mg E2 per day on days 1-24 followed by one Placebo tablet on day 35
1818406|NCT00711620|Drug|Thymosin alpha 1|1.6 mg s.c injection twice per day for 5 days, then 1.6 mg s.c injection once per day for 2 days.
1818407|NCT00711633|Dietary Supplement|Milk with probiotic and prebiotic activities|Comparison of two different formula for preterm infants
1818408|NCT00711633|Dietary Supplement|Milk without probiotic and prebiotic activities|Comparison of formula for preterm infants
1818409|NCT00711646|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
1818410|NCT00711646|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
1818411|NCT00711685|Procedure|coronary artery bypass grafting via midline sternotomy|
1818412|NCT00711698|Procedure|Patient controlled analgesia|Patients in this arm will be treated with a bolus of narcotic followed by PCA
1818413|NCT00711698|Drug|nurse-administered intermittent IV bolus opioid therapy (NAIBOD)|In this arm patients will receive the current standard of care of IV bolus narcotic therapy
1993611|NCT03165565|Behavioral|Conventional Care|Conventional care from the hospital for NICU mothers who test positive for drug use, which includes visits and resources from hospital social workers.
1996846|NCT02345772|Drug|Docetaxel (T) 75 mg/m2 (Taxotere)|Docetaxel (T) 75 mg/m2 every 3 weeks will be given for four cycles.
1818416|NCT00711776|Drug|New formulation|New formulation of Aciclovir Cream 5% scheduled to be substituted to Current formulation in Japan
1818417|NCT00711776|Drug|Current formulation|Current formulation of Aciclovir Cream 5% in Japan
1818418|NCT00711789|Drug|Angiotensin II|Angiotensin II will be given by continuous infusion for 24 hours starting at a dose of 5ng/kg/min and then titrated to a maximum dose of 15 ng/kg/min according to a blood pressure based protocol
1818419|NCT00711789|Drug|Saline placebo|Saline placebo will be given by continuous infusion according to a blood-pressure base protocol. This protocol will also incorporate noradrenaline for blood pressure control (as is true in the active drug arm), such that blood pressure targets will be rapidly achieved in both arms of the study; the only difference being that in the active drug arm, at least part of the pressor effect will be provided by angiotensin II.
1818420|NCT00711802|Drug|Daptomycin|
1818421|NCT00711802|Drug|Standard of Care (SOC)|
1818422|NCT00711828|Drug|Bortezomib|Given IV
1818423|NCT00711828|Biological|Rituximab|Given IV
1818424|NCT00711828|Drug|Cyclophosphamide|Given PO
1818425|NCT00711828|Drug|Dexamethasone|Given PO
1818426|NCT00711828|Other|Questionnaire Administration|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
1818427|NCT00711828|Other|Quality-of-Life Assessment|Complete a quality of life questionnaire (FACT/GOG neurotoxicity questionnaire, version 4.0)
1818428|NCT00711841|Drug|dexamethasone|Dexamethasone, 10mg (2mL), intravenous, every 12 hours, for 48 hours
1818429|NCT00711841|Drug|Placebo|Saline solution, 2 mL, intravenous, every 12 hours, for 48 hours
1818430|NCT00711841|Drug|dexamethasone|dexamethasone, 10mg, 2 mL, intravenous solution, every 12 hours , for 48 hours
1818431|NCT00711854|Drug|trimethoprim-sulfamethoxazole (TMP-SMX)|TMP-SMX (160 mg TMP/ 800 mg SMX IV or PO 3x daily)
1818432|NCT00711854|Drug|Linezolid|Linezolid (600 mg IV or PO twice daily)
1818435|NCT00711867|Device|Bair Hugger|Arizant Bair Hugger temperature management system.
1818436|NCT00711880|Drug|Sativex®|containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
1818437|NCT00711880|Drug|Placebo|containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
1818438|NCT00711893|Device|Cognis 100-D, Teligen DR and VR 100 HE|Teligen is an implantable defibrillator for detection and termination of life threatening arrhythmias. Cognis includes in addition to these capabilities cardiac resynchronization therapy for patients having heart failure.
1818439|NCT00711906|Drug|Cotrimoxazole|Cotrimoxazole
1818440|NCT00711906|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine
1818441|NCT00711919|Drug|Pitavastatin|"comparison of different target levels of lipid lowering using Pitavastatin
Subjects are receiving Pitavastatin, starting at 2 mg, for 12 months."
1818442|NCT00711919|Drug|Pitavastatin|Subjects are receiving Pitavastatin, starting at 4 mg, for 12 months.
1818443|NCT00711958|Drug|HX575, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of rh erythropoiethin
1818444|NCT00711958|Drug|ERYPO®, Janssen-Cilag, solution for injection (s.c.)|1000, 2000, 4000, 8000 and 10.000 IU of epoetin alfa
1818445|NCT00711971|Drug|EPA-rich fish oil supplement|1060 mg EPA plus 274 mg DHA
1818446|NCT00711971|Drug|DHA-rich fish oil supplement|900 mg DHA plus 180 mg EPA
1818447|NCT00711971|Drug|placebo|control arm
1818448|NCT00711984|Device|Herkulink renal artery Stent|renal artery stent
1818449|NCT00711984|Other|best medical therapy|All patients will receive best medical therapy according to current guidelines consisting in antihypertensive, antiplatelet, antidiabetic and lipid-lowering medication and in recommendation of lifestyle modification
1818450|NCT00711997|Biological|DTA-H19|Cohort #1: 4 mg DTA-H19 intratumorally 2 times per week for 2 weeks Cohort #2: 8 mg DTA-H19 intratumorally 2 times per week for 2 weeks
1818451|NCT00712010|Other|Whey protein native|Whey protein native against the 6 other arms
1818452|NCT00712010|Other|Whey protein microgels|Whey protein microgels versus the six other arms
1818453|NCT00712010|Other|Hydrolyzed whey protein|versus the six other arms
1818454|NCT00712010|Other|Casein native|versus the six other arms
1818455|NCT00712010|Other|Hydrolyzed casein|versus the six other arms
1818456|NCT00712010|Other|Total milk protein native|versus the six other arms
1818457|NCT00712010|Other|Hydrolyzed milk protein|versus the six other arms
1818458|NCT00712023|Device|warming device (a reusable, custom-made forced- air warming mattress)|"2=forced-air warming mattress
1=circulating-water mattress"
1818459|NCT00712036|Behavioral|Interim|Methadone maintenance with emergency counseling only for up to 4 months
1818460|NCT00712036|Behavioral|Comprehensive|Methadone treatment with counseling as usual
1818461|NCT00712036|Behavioral|Restored|Methadone maintenance with counseling provided by a clinician with a lower than usual caseload
1818462|NCT00712049|Drug|simvastatin|simvastatin 40 mg
1818463|NCT00712049|Drug|Nicotinic Acid|daily dose starting with 500 mg, up to 2000mg
1818464|NCT00712062|Drug|Pemetrexed|500 mg/m2 given as an injection into a vein over 10 minutes once every 21 days until progression or unacceptable toxicity.
1818465|NCT00712075|Behavioral|CBSST+PDA|PDA-Assisted Cognitive Behavioral Social Skills Training (CBSST+PDA) includes weekly group therapy sessions, each 90 minutes in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis. Participants utilized PDAs to assist with homework completion and compliance.
1818466|NCT00712075|Behavioral|Cognitive Behavioral Social Skills Training|Cognitive Behavioral Social Skills Training includes weekly group therapy sessions, each 2.5 hours (30 min lunch break) in length, with 6-8 patients (maximum of 10) were held for 24 weeks. The intervention integrated cognitive behavioral and social skills training interventions modified for use with older patients with psychosis.
1818467|NCT00712075|Behavioral|PDA-only|To control for the effects of having a PDA, a third group was provided PDAs for the same duration as the other two groups. Participants had access to the same basic functions (calendar, contact list, etc.) as the CBSST+PDA group, but did not have any homework or weekly group meetings.
1818468|NCT00712088|Behavioral|Project ICARE|Group-level intervention (Project ICARE)
1818469|NCT00712088|Behavioral|HCT|Offer of HIV counseling and testing
1818470|NCT00712101|Drug|abciximab intracoronary|administer abciximab bolus intracoronary during primary percutaneous coronary intervention
1818471|NCT00712101|Drug|abciximab intravenously|administer abciximab bolus intravenously during primary percutaneous coronary intervention
1818475|NCT00712127|Other|Diet and Exercise|The participants in this intervention will receive 12 months of weight loss through diet and exercise
1818476|NCT00712127|Other|Diet and Exercise-Delayed|Participants in this intervention will receive six months of weight loss through diet followed by six months of diet and exercise
1818477|NCT00712140|Biological|trastuzumab|Given IV
1818478|NCT00712140|Drug|parenteral chemotherapy|per the local institutional protocols either concurrently with or sequentially to trastuzumab
1818479|NCT00712166|Drug|AZLI 75 mg three times daily (TID)|
1818480|NCT00712166|Drug|Placebo three times daily (TID)|
1818481|NCT00712192|Procedure|coronary artery bypass grafting|patient with coroary artery diseases underwent coronary artery bypass grafting surgery
1818482|NCT00712205|Drug|Placebo|once daily 1mcg Placebo for 28days followed by crossover treatment
1818483|NCT00712205|Drug|Calcitriol|once daily 1mcg Calcitriol / Placebo for 28days followed by crossover treatment
1818484|NCT00712218|Procedure|No Lymphadenectomy (LNE)|No lymphadenectomy is performed in patients of the control group
1818918|NCT00720538|Drug|placebo|placebo capsules
1818485|NCT00712218|Procedure|Lymphadenectomy (LNE)|Patients allocated to the lymphadenectomy group undergo systematic lymphadenectomy in addition to surgery for complete resection. Complete mobilization of the colon by resection of the paracolic gutters is necessary for the preparation of the lymphadenectomy. Afterwards the peritoneum has to be opened until the Treitzsche's Band for visualization of the renal vein. Systematic pelvic and para-aortic lymphadenectomy is based on anatomical studies and defined according to a recently published single centre series as systematic resection of lymph nodes in the following regions [24, ].
1818486|NCT00712244|Device|DisCoVisc|Use of DisCoVisc Ophthalmic Viscosurgical Device (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) during cataract surgery.
1818487|NCT00712244|Device|DuoVisc|Use of DuoVisc viscoelastic system consisting of Viscoat (3% sodium hyaluronate, 4% chondroitin sulfate)and Provisc(1% sodium hyaluronate) during cataract surgery.
1818488|NCT00712244|Device|Healon5|Use of Healon5 ophthalmic viscosurgical device (2.3% Sodium Hyaluronate) during cataract surgery.
1818489|NCT00712244|Device|Amvisc Plus|Use of Amvisc Plus ophthalmic viscosurgical device (1.6% Sodium Hyaluronate) during cataract surgery.
1818491|NCT00712270|Drug|Aripiprazole|Target dose = 15mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
1818492|NCT00712270|Drug|Risperidone|Target Dose = 2mg by mouth per day for 16 weeks. The dosage will be titrated in accordance with the treating physician's clinical judgment, generally reaching full dosage within one week of initiation. The dosage may be increased as clinically indicated, by the treating physician. Any deviation from these target dosing schedules must be reviewed and approved by the principal investigator, generally prior to the adjustment unless clinical circumstances require more immediate adjustment (in which case the treating physician should consult with the principal investigator as soon as is practically possible).
1818493|NCT00712283|Drug|Neramexane mesylate|tablets Group A: duration: 12,5 mg for 7 days and 25 mg for 8 days Group B: duration: 25 mg for 7 days and 50 mg for 8 days Group C: duration: 50 mg for 7 days and 75 mg for 8 days Group D: duration: placebo for 15 days
1993614|NCT03164447|Biological|UB-421|Monoclonal antibody by IV infusion
1993615|NCT03164447|Drug|Optimized background therapy (OBT)|The prescribed OBT must contain at least one agent to which the participant's virus is known to be fully sensitive.
1818497|NCT00712309|Device|Lifestent|Stent for endovascular treatment of popliteal artery lesions
1818498|NCT00712309|Device|balloon-angioplasty (PTA)|PTA for endovascular treatment of popliteal artery lesions
1818499|NCT00712322|Drug|Darifenacin|(0.030 mg/kg/day)
1818500|NCT00712322|Drug|Darifenacin|(0.0625 mg/kg/day)
1818501|NCT00712322|Drug|Darifenacin|(0.125 mg/kg/day)
1818502|NCT00712322|Drug|Darifenacin|(0.250 mg/kg/day)
1818503|NCT00712335|Drug|Fluticasone Propionate|DPI 250 mcg BID for 3 weeks
1818504|NCT00712335|Drug|Montelukast|PO 10 mg QHS for 3 weeks
1818505|NCT00712335|Drug|Salmeterol|DPI 50mg BID for 3 weeks
1818506|NCT00712348|Drug|Taliglucerase alfa|Intravenous infusion every 2 weeks
1818507|NCT00712361|Device|Non Invasive peripheral blood screening (Cnoga Medical Ltd.,SofTouch,OnlyTouch, CM-CL-R-007, CMC 07015922,HT 4502, HTA 4502)|Non Invasive screening of various independent peripheral blood parameters: Glucose, hemoglobin, Hematocrit, blood pressure, pulse, SpO2, CO2, pH.
1818508|NCT00712374|Drug|sulfadoxine-pyrimethamine plus amodiaquine|"SP+AQ on three occasions during the malaria transmission season
Intermittent Preventive Treatment with sulfadoxine-pyrimethamine plus amodiaquine"
1818509|NCT00712387|Behavioral|LapSim simulator|Group B will be required to train on the LapSim simulator until they reach predefined levels of proficiency
1818510|NCT00712400|Drug|Latanoprost 0.005%, Xalatan®|Substance: Latanoprost 0.005%, Xalatan® (Pharmacia Austria Ges.m.b.H. Oberlaaer Straße 251, 1101 Vienna) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
1818511|NCT00712400|Drug|Placebo|Substance: Vehicle to latanoprost (eyedrops containing the same stabilizers as latanoprost, but no active drug) Dosage form: topical application in one eye Dosage: 1 drop in the evening for 14 days
1818512|NCT00712413|Drug|OBMT|Omeprazole 20 mg twice daily, in combination with bismuth subcitrate potassium (40 mg), metronidazole 125 mg and tetracycline 125 mg HCl. All patients must take 6 capsules of Pylera, in addition to 1 omeprazole twice daily
1818513|NCT00712426|Drug|Creatine Monohydrate|Up to 40 grams daily, powder form creatine monohydrate, taken for the trial duration
1818514|NCT00712426|Drug|Placebo|Up to 40 grams daily, powder form placebo (inactive substance), taken for the trial duration
1818515|NCT00712439|Drug|Gabapentin Extended Release tablets|
1818516|NCT00712439|Drug|Placebo|
1818517|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
1818518|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
1818519|NCT00712452|Other|Biology and ultrasonography after chemotherapy|Study of markers of ovarian reserve: Estradiol, LH, FSH and progesterone levels and ultrasonographic antral follicle count (no made in current practice)
1818520|NCT00712465|Drug|AZD1305|Extended Release tablet, repeated administration
1818521|NCT00712465|Drug|Digoxin|Tablet, repeated administration
1818522|NCT00712478|Drug|insulin|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1818525|NCT00712504|Drug|sunitinib|25, 37.5 and 50 mg/day, oral, administered on an outpatient basis in two different dosing regimens: schedule 2/1 (2 weeks on, 1 week off) and schedule 4/2 (4 weeks on, 2 weeks off)
1818526|NCT00712504|Drug|docetaxel|60, 75, and 100 mg/m2 docetaxel administered every 21 days as a 1-hr IV infusion
1818527|NCT00712517|Drug|propofol|propofol anesthesia 3-5mg/kg
1818528|NCT00712517|Drug|sevoflurane|sevoflurane anesthesia
1818529|NCT00712530|Biological|DermaVir|DermaVir is a synthetic pathogen-like nanomedicine. The active pharmaceutical ingredient is a plasmid DNA expressing fifteen HIV proteins that assemble into HIV-like particles. These particles are safe, cannot replicate, integrate or reverse transcribed. DermaVir is targeted to Langerhans cells with DermaPrep medical device. These DermaVir-containing Langerhans cells migrate to the lymph nodes, where induce HIV-specific cytotoxic T cells that can recognize and kill HIV-infected cells.
1818530|NCT00712530|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
1818531|NCT00712543|Drug|lactulose (Kristalose®)|Crystals to be dissolved in water and taken as prescribed.
1818532|NCT00712543|Drug|liquid lactulose|Liquid to be taken as prescribed.
1818533|NCT00712556|Radiation|fluorine 18-fludeoxyglucose positron emission tomography|fluorine 18-fludeoxyglucose is a radioactive isotope used in PET to detect cancer tumors
1818534|NCT00712569|Behavioral|questionnaires|Patients in Category 1 are those who report before the visit that they intend to discuss cancer-related internet information and report after the visit that they did discuss such information. The coding of these patients' consultations with their physicians and analysis of their pre- and post-consultation questionnaires will address Aims 1 and 2.
1818535|NCT00712569|Behavioral|audio recordings , questionnaires|"Patients in Category 2 are those who report before the visit that they intend to discuss cancer-related internet information, but report after the visit that they did not discuss such information. This category is important as our previous research indicates that sometimes patients do not discuss information because they feel there is not enough time or because the information is irrelevant or repetitive. These patients' audio recordings will be checked to verify that there was no internet information discussion. These audio recordings will not be coded.
However, assessment of these patients' questionnaires will aid in addressing Aim 3 and may provide some pilot data on why patients who initially intend to discuss internet information do not."
1818536|NCT00712569|Behavioral|audio recorded questionnaires|Patients in Category 3 are those who report before the visit that they do not intend to discuss cancer-related internet information and do not discuss it. Assessment of these patients' questionnaires will aid in addressing Aim 3. These audio recordings will not be coded. It is important, however, that these consultations be audio recorded for two reasons: First, it allows the physician to remain blinded to the intent of the patient to discuss internet information. Second, it provides a method of verifying that the patient really did not discuss internet information. Although not expected, it is possible for a patient to go into a consultation without intending to discuss internet information, but does end up discussing it. We will note if this occurs.
1818537|NCT00712582|Drug|Etoposide, carboplatin, ifosfamide|Patients in consolidation A will receive three drugs in a regimen called ICE. You will have 3 cycles. Each new cycle begins 2 to 3 weeks after the last one.
1818538|NCT00712582|Drug|Rituximab, Ifosfamide, Etoposide, Carboplatin|It consists of four drugs in a regimen called augmented RICE (augRICE). It is given every 3 weeks for 2 cycles.
1818539|NCT00712582|Drug|Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine|"It consists of four drugs in a regimen called augRICE. It is given every 3 weeks for 2 cycles. After the rituximab on day 3, you will then be admitted to the hospital for 2 to 3 nights.
Part 2: Stem Cell Collection, Part 3: High dose chemoradiotherapy and stem cell transplant. Your doctor may want you to get radiation therapy. If so, it will start 2 weeks before the highdose chemotherapy. This regimen is called CBV-N chemotherapy. It is given by vein in the hospital."
1818540|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 10 mg daily for three months
1818541|NCT00712595|Drug|Mifepristone|Oral administration of Mifepristone 5 mg, daily for three months
1818542|NCT00712608|Other|Infant formula|Marketed cow's milk base infant formula 20 kcal/oz
1818543|NCT00712608|Other|Infant formula|cow's milk based infant formula with prebiotics, different level of fatty acids and fat and a different calcium source
1818544|NCT00712608|Other|Cow's milk infant formula|Cow's milk based formula with prebiotics, different level of fatty acids and fat and a different calcium source
1818545|NCT00712621|Behavioral|Counseling|• Arm II: Patients receive audio visual aids and weekly counseling sessions by the expert counselors and breast cancer survivors over 8 weeks for a total of 8-16 sessions. Patients receive written materials from the counseling group after the completion of the sessions
1818546|NCT00712621|Behavioral|Written materials|• Arm I: Patients receive the support by providing existing resources. Patients receive standard written materials from the counseling group after enrolling in the study.
1818547|NCT00712634|Biological|CMVpp65-A*0201 peptide vaccine|Vaccine received on either days 0 and 28 or on days 0, 28, and 56 and perhaps day 90
1818548|NCT00712647|Drug|Beta Carotene and Retinol|"Pilot participants (ppts):
Asbestos-Exposed--15 mg/day beta-carotene + 25,000 IU/day retinol Heavy Smokers--30 mg/day beta-carotene + 25,000 IU/day retinol
Vanguard & Efficacy ppts:
Asbestos-exposed AND heavy smokers--30 mg/day beta-carotene + 25,000 IU/day retinol"
1818549|NCT00712647|Other|Placebo|Two placebos, one each/day
1818550|NCT00712660|Drug|antipsychotic dose increase|20% increase in the dose of current antipsychotic medication
1818551|NCT00712660|Other|no intervention|Treatment as usual
1818552|NCT00712673|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
1818553|NCT00712673|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding meal (either breakfast or dinner).
1818554|NCT00712673|Device|Pen auto-injector|
1818555|NCT00712673|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
1818556|NCT00712686|Drug|Aripiprazole|Tablets, Oral, 15-30 mg, once daily, 140 weeks
1818557|NCT00712686|Drug|Olanzapine|Capsule, Oral, 10-20 mg, once daily, 140 weeks
1818603|NCT00718679|Drug|IVN201|Intralymphativ injection of the study drug
1818604|NCT00718679|Drug|Placebo|
1818560|NCT00718172|Procedure|Liver Biopsy|
1818561|NCT00718172|Drug|Peginterferon &amp; Ribavirin for Hepatitis C|
1818562|NCT00718172|Drug|Pre-treatment Ribavirin|
1818563|NCT00718185|Procedure|Obtain blood specimens|Obtain blood samples at multiple timepoints.
1818564|NCT00718224|Drug|Semuloparin sodium|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe
Subcutaneous injection"
1818565|NCT00718224|Drug|Enoxaparin|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 mL pre-filled syringe
Subcutaneous injection"
1818566|NCT00718224|Drug|Placebo|"0.3 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component
Subcutaneous injection"
1818567|NCT00718237|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™)|Rotateq orally administered 3 times
1818568|NCT00718237|Biological|Comparator: Comparator: Placebo (unspecified)|Placebo orally administered 3 times
1818569|NCT00718250|Biological|RFUSIN2-AML1|AML cell vaccine alone. x4 doses 3 weeks apart
1818570|NCT00718250|Biological|Donor leukocyte infusion (DLI)|1 dose 1x107/kg
1818571|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x 4 doses 3 weeks apart Donor leukocyte infusion 1x107/kg x 1 dose
1818572|NCT00718250|Biological|RFUSIN2-AML1 and donor leukocyte infusion|AML cell vaccine x4 doses 3 weeks apart Donor leukocyte infusion 1x108/kg x1 dose
1818575|NCT00718276|Drug|25(OH)D|daily (20ug), weekly (140 ug), Bolus (140 ug)
1818576|NCT00718276|Dietary Supplement|vitamin D3|daily (800 IU), weekly (5600 IU), Bolus (5600 Iu)
1818577|NCT00718289|Other|Citrate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
1818578|NCT00718289|Other|Acetate dialysate|dialysis fluid composition for Citrate (C) and Acetate (A): acetate [3.0 mmol/L in A and 0.3 in C], citrate [0 mmol/L in A and 0.8 in C]
1818579|NCT00718302|Device|Antiglide Plate|A plate is placed behind the broken ankle and secured with screws
1818580|NCT00718302|Device|Lateral Plate|A metal plate is placed to the side of the broken ankle and is secured with screws
1818581|NCT00718315|Drug|erlotinib [Tarceva]|150mg po daily
1818582|NCT00718315|Drug|fusidic acid [Verutex]|topical, daily for 30 days.
1818583|NCT00718315|Drug|erythromycin [Eritex]|topical, daily for 30 days.
1818584|NCT00718315|Drug|Fisiogel|topical, daily for 30 days
1818587|NCT00718341|Drug|AF056|
1818588|NCT00718341|Drug|Placebo|
1818589|NCT00718354|Drug|Enoxaparin|Once daily dose of 1mg/Kg of body weight for 6 months
1818590|NCT00718354|Drug|Standard Chemotherapy|Investigator's discretion
1818591|NCT00718380|Drug|ABT-869|2.5 mg or 10 mg tablet, Once a day, oral dose, dose per body weight (dose determined by group; 2.5mg or 10mg tablet) until evidence of uncontrolled unacceptable toxicity or disease progression. For more information, please see Arm Description.
1818592|NCT00718406|Drug|Metoprolol|
1818593|NCT00718406|Drug|metoprolol plus morphine|
1818594|NCT00718419|Drug|Enzastaurin|Enzastaurin: Cycle 1 Day 1 only: 3, 125-mg tablets three times on Day 1 (Day 1 total dose = 1125 mg) Day 2 onwards and subsequent Cycles: 2, 125-mg tablets orally BID (500 mg total per day) Cycle length (all cycles): 28 Days Patients may stay on drug past 8 cycles, (until the study is closed) or until disease progression.
1818595|NCT00718432|Behavioral|Exercise and nutritional integrated care|Besides the information sharing and the educational booklets, the ENIC group subjects are invited to take a structured exercise course at the participating hospital 3 times a week for 3 months. (twice a week for 24 weeks in 2009 study) The exercise program included warm up; a range of motion, stretching, and postural-correction activities; aerobic strengthening; balance; and cool down. The research team also inquired about the subjects' dietary compliance and responded to their dietary questions during the exercise sessions.
1818596|NCT00718432|Behavioral|Usual care with education|The study educational booklet (plus CD-ROM in 2009 study) on frailty, depression, osteoporosis, healthy diets, exercise protocols, and coping strategies are given to the participants. UC group subjects will receive a 2-hour education based on the content of study booklet including 1-hour demonstration of study exercise program in 2009 study. Subjects are contacted monthly (bimonthly in 2009 study ) for frequencies of reading this booklet and the compliance on the suggested diet and exercise protocols. Subjects are also encouraged to follow with their primary care physicians for abnormal results identified from our assessments.
1818597|NCT00718432|Behavioral|Problem solving therapy (PST) integrated care|Besides the information sharing and the educational booklets, the PSTIC group subjects will receive 6 sessions of PST (within 12 weeks in pilot study, within 24 weeks in 2009 study) aiming at solving the 'here-and-now' problems contributing to their mood-related condition and helps increase their self-efficacy. If major depressions are found, subjects are referred to their primary care physicians for further medical managements.
1818598|NCT00718471|Drug|Enoxaparin|ENOXAPARIN IV 0.5 mg.kg
1818599|NCT00718471|Drug|UFH (unfractionated heparin)|UFH IV 50-70 IU if GP IIbIIIa or 70-100IU if no GP IIbIIIa
1818600|NCT00718484|Drug|Palifosfamide Tris and Doxorubicin|On Day 1 of each cycle (21 days), 150 mg/m2 IV (intravenous) palifosfamide tris and 75 mg/m2 IV doxorubicin are administered on the same day. Doxorubicin administration will be initiated approximately 60 minutes after the completion of palifosfamide tris dosing. Palifosfamide tris alone is administered on Days 2 and 3, every 3 weeks (one 21-day cycle).
1818601|NCT00718484|Drug|Doxorubicin|On Day 1 of each cycle, 75 mg/m2 doxorubicin is administered IV.
1818605|NCT00718692|Drug|Sym001|Each cohort will receive one single dose of Sym001 according the assigned dose level.
1818606|NCT00718705|Drug|Josamycin|josamycin with posology of 2 grams per day by oral way during 10 days
1818607|NCT00718705|Drug|Placebo|Placebo with posology of 2 grams per day by oral way during 10 days
1818613|NCT00718731|Drug|GSI-136|
1818614|NCT00718731|Other|Placebo|
1818615|NCT00718744|Other|Standardization of allergenic extract (Ch. arcuatus)|Allergenic extract for cutaneous prick-test
1818616|NCT00718757|Drug|Dexamethasone|5 doses given on Days 6-10
1818617|NCT00718757|Drug|Irinotecan|20 mg/m2/day IV, 10 doses given on Days 1-5, 8-12
1818618|NCT00718757|Drug|Vincristine|"1.5 mg/m2/day IV (max 2 mg), 2 doses given on Days 1,8
* Patients < 1 year of age or < 10kg in weight: Vincristine 0.05 mg/kg"
1818619|NCT00718770|Drug|Bexarotene|Bexarotene will be given by mouth once a day every day for 1 year. The dose to be used will be 300 mg/m2.
1818620|NCT00718783|Other|Tissue samples taken from retinoblastoma|Tissue banking
1818621|NCT00718783|Other|5 ml peripheral blood|White blood cells will be isolated from the blood sample as a source of genomic DNA.
1818622|NCT00718796|Other|Naturopathic medicine. May include: fish oil, plant sterols, soluble fiber, cinnamon, coQ10 and exercise|Individualized according to needs of each participant and willingness to comply. Intervention to include lifestyle modification, dietary changes and supplementation using natural health products as recommended by naturopathic practitioner.
1818623|NCT00718796|Other|Conventional medical treatment (Atorvastatin,Fluvastatin,Lovastatin,Pravastatin,Rosuvastatin,Simvastatin)|Will vary according to individual - not standardized and likely to include statins.
1818624|NCT00718809|Drug|saracatinib|Given orally
1818625|NCT00718822|Other|oxygen concentration in the culture atmosphere|
1818626|NCT00718835|Behavioral|incentive-based contingency management|Direct comparison of Contingent versus Noncontingent incentives in promoting abstinence from smoking among opioid-treatment patients. The biochemical measures of breath carbon monoxide levels and urinary cotinine are used to confirm smoking status. Participants receive voucher-based incentives either contingent upon demonstrating abstinence from recent smoking (Contingent condition) or independent of smoking status (Noncontingent control condition).
1818627|NCT00718848|Procedure|Incentre nocturnal hemodialysis|This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
1818628|NCT00718848|Procedure|Remaining on conventional hemodialysis|These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
1818629|NCT00718861|Drug|Placebo|
1818630|NCT00718861|Drug|Zoledronic acid|
1818631|NCT00718874|Other|Dietary|modification of macronutrient content
1818632|NCT00718887|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily (QD), 52 weeks
1818633|NCT00718887|Drug|Adefovir/Entecavir|Tablets, Oral, 10-mg adefovir QD for 12 weeks followed by 0.5-mg entecavir QD for a maximum of 52 weeks
1818634|NCT00718913|Drug|Docetaxel|Docetaxel will be given at 60 mg/m2, as a 60-minute infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Docetaxel 60 mg/m2.
1818635|NCT00718913|Drug|Cisplatin|Cisplatin will be given at 60 mg/m2, as 2-hour infusion every 3 weeks for 2 cycles before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Cisplatin at 60 mg/m2.
1818636|NCT00718913|Drug|Capecitabine|Capecitabine will be given orally at 1800 mg/m2 days 1 through 14 divided in two daily doses before chemo-radiation. Four to five weeks after completion of chemo-radiation therapy, all patients will receive two more cycles of Capecitabine at 1800 mg/m2 days 1 through 14 (divided in two daily doses).
1818637|NCT00718913|Radiation|Radiation|At the end of the second cycle of chemotherapy and one week of rest (day 27), a total of 45 Gy (1.8 Gy fx/d) of radiotherapy will be given.
1818638|NCT00718913|Drug|Capecitabine|Capecitabine will be administered orally during radiotherapy for radiosensitization(1650 mg/m2 per day divided in two daily doses, 5 days/week, on Monday through Friday).
1818639|NCT00718939|Device|Rheos Baroreflex Activation Therapy System|The two (2) Rheos Carotid Sinus Leads conduct the activation energy from the Rheos Implantable Pulse Generator to the baroreceptors located on the left (Left Carotid Sinus Lead) and right (Right Carotid Sinus Lead) carotid sinus. This energy activates the baroreflex by inducing signals that the brain interprets as elevated blood pressure.
1818640|NCT00718952|Drug|Vardenafil|vardenafil tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
1818641|NCT00718952|Drug|Placebo|Placebo tablet 5mg once-daily orally in the first 4 weeks while 5mg twice-daily orally in the following 8 weeks.
1818642|NCT00718952|Drug|Vardenafil|Patients in all the 2 arms will take vardenafil tablet 5mg twice-daily orally from week 13 to week 24(open-label).
1818643|NCT00718965|Drug|AVE5530|one tablet in the evening with dinner
1818644|NCT00718965|Drug|Placebo|one tablet in the evening with dinner
1818645|NCT00718978|Procedure|CSS grafting|grafting of autologous three-cellular cultured skin substitutes (CSS) consisting of cultured keratinocytes, melanocytes and fibroblasts attached to a scaffold of hyaluronic acid (HYAFF11® and HYAFF11p80®) obtained from full-thickness skin biopsies to repair full-thickness loss of substance
1818692|NCT00719290|Procedure|Phacoemulsification and goniosynechialysis (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant and goniosynechialysis
1818693|NCT00719303|Behavioral|Behavioral Dietary Intervention|Receive dietary intervention
1818694|NCT00719303|Behavioral|Compliance Monitoring|Complete daily fat gram and step diaries
1818646|NCT00718991|Device|Spectranetics Turbo elite™ excimer laser catheter|The Spectranetics Turbo elite™ excimer laser catheters are percutaneous intravascular devices constructed of multiple optical fibers around a guidewire lumen. The laser catheters transmit ultraviolet energy from the Spectranetics CVX-300® Excimer Laser System to the obstruction in the artery. The ultraviolet energy is delivered to the tip of the laser catheter to photo-ablate fibrous, calcific and atheromatous lesions, thus recanalizing diseased vessels.
1818647|NCT00719004|Procedure|Ultrasound of the foot|These volunteers will have one ultrasound scan of each foot
1818648|NCT00719017|Procedure|Upper vaginectomy|Laparoscopic surgery with upper vaginectomy
1818649|NCT00719017|Radiation|Post-operative brachytherapy|Laparoscopic surgery followed by brachytherapy
1818650|NCT00719017|Procedure|Standard procedures|Laparoscopic surgery +/- brachytherapy +/- pelvic radiation
1818651|NCT00719030|Dietary Supplement|Pomegranate pill|Pomegranate extract pill
1818652|NCT00719030|Dietary Supplement|Pomegranate pill placebo|Pomegranate pill placebo
1818653|NCT00719043|Biological|A/turkey H5N1 vaccine|Administered as an intramuscular (IM) injection
1818654|NCT00719043|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted (A/Indonesia)|Administered as an intramuscular (IM) injection
1818655|NCT00719043|Biological|Placebo|Administered as an intramuscular (IM) injection
1818656|NCT00719056|Drug|Teicoplanin|The selected dose was 10mg/kg and it was given intravenously by a catheter inserted under aseptic conditions in a forearm vein within 15 minutes; it was diluted in one 5% glucose solution of a 50 ml final volume
1818657|NCT00719056|Drug|β-lactams or ciprofloxacin|Multiple doses for up to six consecutive days
1818658|NCT00719069|Drug|PSI-697|
1818661|NCT00719108|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
1818662|NCT00719108|Biological|Actrapid|Total dose per subject will be 0.3 IU/Kg given IV over 5 hrs.
1818663|NCT00719121|Drug|Talarozole|Topical Application (20 mg)
1818664|NCT00719121|Drug|Differin™, 0.1% adapalene gel|Topical Application (20 mg)
1818665|NCT00719134|Drug|Maxalt|anti-migraine drug
1818666|NCT00719134|Drug|placebo pill|placebo pills
1818667|NCT00719134|Drug|placebo pills|placebo pills
1818668|NCT00719147|Procedure|MRI|Not performed for study purposes, MRI will be done as part of routine clinical visit. Findings will be used for study.
1818669|NCT00719147|Other|Functional Status and Symptom Questionnaire|Questionnaire
1818670|NCT00719160|Drug|esomeprazole|2 Interventions with esomeprazole 20 mg twice a day for 9 days vs. a placebo for 9 days while on a high protein diet
1818671|NCT00719160|Drug|Placebo|Placebo 20 mg twice a day for 9 days
1818672|NCT00719173|Drug|aprepitant|Given orally
1818673|NCT00719173|Drug|cyclophosphamide|Given IV
1818674|NCT00719173|Other|placebo|Given orally
1818677|NCT00719199|Drug|IMO-2055|SC weekly injections
1818678|NCT00719199|Drug|Cetuximab|given weekly through intravenous administration. Cycle 1 Day 1 dose given at 400mg/m2, all subsequent doses given at 250 mg/m2.
1818679|NCT00719199|Drug|FOLFIRI|Given day 1 of each cycle
1818680|NCT00719212|Biological|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
1818681|NCT00719225|Drug|Belatacept|IV, 5 mg/kg, once monthly, until BMS terminates trial or Belatacept is available commercially
1818682|NCT00719238|Behavioral|Nutrition plus education|Nutritional instruction in small groups plus education
1818683|NCT00719238|Behavioral|Education only|Educational video and pamphlets
1818684|NCT00719251|Device|High voltage pulsed current|The patient´s wounds were treated for 45 minutes with HVPC three times a week for 16 weeks or until their ulcers closed. The active electrode made of aluminum foil was secured directly over the wound, which previously had been loosely packed with sterile gauze soaked with 0.9% saline solution. The dispersive electrode was placed 5 cms proximal to the wound.The electrical stimulator Intelect 340 stim model (Chattanooga Group) produces a twin peaked pulse and was applied with the following parameters: continuous mode, submotor level, 100 Hz pulse frequency and 100microseconds pulse duration. Prior to the beginning the study the electrical stimulator was calibrated with oscilloscope (Tektronix TDS 1002 model).
1818685|NCT00719251|Device|Low level laser|Wavelenght 633 nm (DMC - Brazil), power 30 mW, continuous, 2 J/cm2 in the edge of the ulcer and 1.5 J/cm2 in the bed, punctual application in direct contact, 3 times a week, 1 every alternate day, for 16 weeks or until the ulcer closed. The laser device was calibrated before each treatment session with a research radiometer (International Light).
1818686|NCT00719251|Other|Standard nursing care|It was based to nursing intervention classification (NIC)46. These interventions were performed by a qualified nurse and included ulcer irrigation with physiological saline, sharp debridement as needed and maintenance of a moist wound environment with appropriate wound dressing. Patients were all educated regarding pressure off loading of the involved foot. All patients received standard wound care seven times a week for 16 weeks or until their ulcers closed.
1818687|NCT00719264|Drug|RAD001(everolimus)|10 mg qd
1818688|NCT00719264|Drug|interferon alfa-2a|dose escalated from 3 MIU (million international unit) during week 1, 6 MIU during week 2, and 9 MIU during week 3
1818689|NCT00719264|Drug|bevacizumab|10 mg/kg every 2 weeks
1818690|NCT00719277|Device|Sleuth Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
1818691|NCT00719290|Procedure|Phacoemulsification (Acrylic Foldable Intraocular Lens (Acrysoft)), (Healon5)|Phacoemulsification of the lens with intraocular lens implant
1818753|NCT00719706|Drug|Placebo|Placebo
1818695|NCT00719303|Other|Counseling|Undergo face-to-face and telephone counseling
1818696|NCT00719303|Other|Educational Intervention|Receive educational materials
1818697|NCT00719303|Behavioral|Exercise Intervention|Undergo physical activity intervention
1818698|NCT00719303|Other|Laboratory Biomarker Analysis|Correlative studies
1818699|NCT00719303|Other|Quality-of-Life Assessment|Ancillary studies
1818700|NCT00719303|Other|Questionnaire Administration|Ancillary studies
1818701|NCT00719316|Drug|Aliskiren|Aliskiren 300mg per day for 6 weeks
1818702|NCT00719329|Drug|Chlorhexidine 4.0%|Solution (4.0%, 7.1% CHX-D)
1818703|NCT00719329|Behavioral|Dry Cord Care|Educational messages regarding clean cord care
1818704|NCT00719342|Drug|Oxygen + Carbondioxide|Mixture of 92 % oxygen and 8 % carbon dioxide for inhalation
1818705|NCT00719342|Other|full field flickering light at 12.5 Hz|1 minute stimulation with full field flickering light at 12.5 Hz during measurement of vessel diameters and measurement of blood flow.
1818706|NCT00719355|Behavioral|Walking with poles|Patients walked with poles, 20-45 minutes, 3 times/week for 24 weeks.
1818707|NCT00719355|Behavioral|Walking exercise|Patients walked for 20-45 minutes, 3 times/week for 24 weeks.
1818708|NCT00719381|Drug|Pioglitazone|Treatment of pioglitazone will consist of 15 mg once daily for 28 days followed by 30 mg once daily for 28 days (N=12)
1818709|NCT00719394|Drug|GSI 136|
1818710|NCT00719394|Drug|placebo|
1818711|NCT00719407|Drug|erythropoietin|250 U/kg/dose x 6 doses (n=3); 500 U/kg/dose x 6 doses (n=6); 1,000 U/kg/dose x 6 doses (n=7) 2,500 U/kg/dose x 6 doses (n=8)
1818712|NCT00719420|Drug|Clarithromycin, Metronidazole, Amoxicillin (+Omeprazole)|Clarithromycin 500 mg bid, metronidazole 500 mg tid, and amoxicillin 500mg tid with or without omeprazole 20 mg bid for 14 days
1818713|NCT00719420|Drug|Clarithromycin, Amoxicillin, Omeprazole|Clarithromycin 500 mg bid, amoxicillin 1 g bid, and omeprazole 20 mg bid for 10 days
1818714|NCT00719433|Device|robot therapy (ARMin)|therapy of the affected arm with a robot for eight weeks, three times weekly for one hour
1818715|NCT00719433|Other|conventional therapy|physical and occupational therapy of the affected arm for eight weeks, three times weekly for one hour
1818716|NCT00719459|Drug|Iron Sucrose|Venofer 20 mg/mL
1818717|NCT00719459|Drug|Iron Sucrose|Iron sucrose 20 mg/mL
1818718|NCT00719472|Drug|Rituximab|During Cycle 1 rituximab was administered at an initial rate of 50 mg/hour. In the absence of infusion toxicity during Cycle 1, the infusion rate was escalated by 50 mg/h increments every 30 minutes to a maximum rate of 400 mg/hour. In case of infusion-related reactions, the infusion was interrupted or the infusion rate reduced. In case of Grade 3/4 infusion reactions, the rituximab infusion was discontinued and medical treatment provided. If the rituximab infusion in Cycle 1 was tolerated without a serious adverse event (AE) or Grade 3/4 infusion-related AE, as judged by the investigator, infusions in Cycle 2 onwards were administered as follows: 20% of the total dose was given over 30 minutes and the remaining 80% of the dose was given over the next 60 minutes, for a total infusion time of 90 minutes. Commercial preparations of rituximab were used.
1818719|NCT00719472|Drug|CHOP (cyclophosphamide, hydroxydaunorubicin [doxorubicin], Oncovin [vincristine], prednisone)|Commercial preparations of CHOP were used. Prednisone was administered prior to rituximab infusion.
1818720|NCT00719472|Drug|CVP (cyclophosphamide, vincristine, prednisone)|Commercial preparations of CVP were used. Prednisone was administered prior to rituximab infusion.
1818721|NCT00719472|Drug|Analgesic/antipyretic and antihistamine drugs|An analgesic/antipyretic (eg, acetaminophen) and an antihistamine (eg, diphenhydramine) were administered 30 minutes before each infusion of rituximab.
1818722|NCT00719485|Other|Educational program|Informing patients about their condition, treatment options, prioritization on the wait list, and post-operative care
1818723|NCT00719498|Drug|Epo-alpha|
1818724|NCT00719511|Drug|Purified allergen dose 1 integrated in a Patch system|Epicutaneous application of a patch
1818725|NCT00719511|Drug|Purified allergen dose 2 integrated in a Patch system|Epicutaneous application of a patch
1818726|NCT00719511|Drug|Purified allergen dose 3 integrated in a Patch system|Epicutaneous application of a patch
1818727|NCT00719511|Drug|Purified allergen integrated in a Patch system|Epicutaneous application of a patch
1818728|NCT00719524|Drug|OMBRABULIN (AVE8062)|Dose escalation study with combination chemotherapy
1818729|NCT00719537|Drug|Aspirin|Aspirin 81 mg once a day
1818730|NCT00719537|Drug|Placebo Oral Tablet|Placebo 1 tab Daily
1818731|NCT00719537|Drug|Progesterone|Oral Progesterone 200 mg Twice Daily
1818732|NCT00719550|Drug|Capecitabine|Administered at 625mg/m2 BID orally every day while on study.
1818733|NCT00719550|Drug|Epirubicin|Administered day 1 of each cycle at 50mg/m2 IV.
1818734|NCT00719550|Drug|AMG 102|Investigation product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment.
1818735|NCT00719550|Drug|Cisplatin|Administered day 1 of each cycle at 60mg/m2 IV.
1818736|NCT00719550|Drug|Placebo|AMG 102 placebo will be provided in similar vials as clear, colorless, sterile protein-free solution
1818737|NCT00719563|Drug|American ginseng|Given orally
1818738|NCT00719563|Other|placebo|Given orally
1993616|NCT03164057|Drug|Azacitidine|Azacitidine solution is administered intravenously (IV) over a period of 10-40 minutes.
1818741|NCT00719602|Drug|Lamivudine|Taken orally twice daily
1818742|NCT00719602|Drug|Lopinavir/Ritonavir|Taken orally twice daily
1818743|NCT00719602|Drug|Nevirapine|Taken orally twice daily
1818744|NCT00719602|Drug|Zidovudine|Taken orally twice daily
1818745|NCT00719641|Procedure|Colonoscopy|
1818746|NCT00719641|Procedure|Colon Cancer Screening|
1818747|NCT00719641|Device|Segmental Stiffening Wire|
1818748|NCT00719667|Other|coronary artery bypass grafting|on pump off pump
1818749|NCT00719680|Biological|IgPro20|
1818750|NCT00719693|Drug|ABT-143 ( rosuvastatin calcium and fenofibric acid )|one dose under low-fat meal condition
1818751|NCT00719693|Drug|ABT-143 (rosuvastatin calcium and fenofibric acid )|one dose under fasting meal condition
1818752|NCT00719706|Drug|acetyl-l-carnitine PLUS alpha-lipoic acide|1000-3000 mg/day of acetyl-l-carnitine in addition to 600-1800 mg/day of alpha-lipoic acid.
1818754|NCT00719732|Device|ReSTOR|Enrolled subjects receive implantation of ReSTOR +3 intraocular lenses (IOLs) for replacement of cataract in the natural lens of the eye. The patients were to be implanted bilaterally (in both eyes).
1818755|NCT00719745|Drug|Prograf|oral
1818756|NCT00719745|Drug|MR4|oral
1818757|NCT00719758|Drug|TRK-100STP (BERASUS LA)|oral
1818758|NCT00719758|Drug|AST-120 (Kremezin®)|oral
1818759|NCT00719771|Device|Global® AP™ Total shoulder arthroplasty|Total shoulder arthroplasty
1818760|NCT00719784|Device|Vibration Response Imaging|Recordings will be then performed using the VRI device (Deep Breeze™, Or Akiva, Israel). Forty-two sensors that are assembled on 2 planar arrays will be placed on subject's back. Each row of 3 sensors is held in place by silicone cups that are coupled to the patient's back by a computer-controlled low vacuum seal.
1818761|NCT00719797|Biological|bevacizumab|Given IV
1818762|NCT00719797|Drug|fluorouracil|Given IV
1818763|NCT00719797|Drug|irinotecan hydrochloride|Given IV
1818764|NCT00719797|Drug|leucovorin calcium|Given IV
1818765|NCT00719797|Drug|oxaliplatin|Given IV
1818766|NCT00719810|Drug|delafloxacin|300 mg intravenous every 12 hours
1818767|NCT00719810|Drug|delafloxacin|450 mg intravenous every 12 hours
1818768|NCT00719810|Drug|tigecycline|100 mg then 50 mg intravenous tigecycline every 12 hours
1818769|NCT00719823|Drug|Maraviroc|Maraviroc 150mg, 300 mg or 600 mg twice daily administered orally with or without food in combination with other antiretroviral agents. The recommended dose of Maraviroc differs based on concomitant medications due to drug interactions as outlined in the Prescribing Information.
1818770|NCT00719836|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
1818771|NCT00719849|Biological|anti-thymocyte globulin|30mg/Kg Days -6 to -4
1818772|NCT00719849|Drug|cyclophosphamide|50 mg/Kg Day -6
1818773|NCT00719849|Drug|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on Day -3 maintaining a trough level between 250 and 500 ng/mL. For adults the initial dose will be 2.5 mg/kg IV over 1 hour every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 1 hour every 8 hours.
1818774|NCT00719849|Drug|fludarabine phosphate|40mg/m2 Days -6 to -2
1818775|NCT00719849|Drug|mycophenolate mofetil|1 gram every 8 hours for patients who are ≥ 40 kg. Pediatric patients (<40 kilograms) will receive MMF at the dose of 15 mg/kg/dose every 8 hours. Stop MMF at Day +30 or 7 days after engraftment, whichever day is later, if no acute GVHD.
1818776|NCT00719849|Procedure|umbilical cord blood transplantation|Single or double unit umbilical cord blood transplant
1818777|NCT00719849|Radiation|total body irradiation|200 cGy Day -1
1818778|NCT00719862|Drug|Placebo nasal spray|Placebo
1818779|NCT00719862|Drug|0.15% azelastine hydrochloride Nasal Spray|0.15% azelastine hydrochloride 822 mcg
1818780|NCT00719875|Drug|Vorinostat|BID days -7, 1-7 and 15-21, 200 mg
1818789|NCT00719901|Drug|obatoclax mesylate|Given IV
1818790|NCT00719901|Drug|bortezomib|Given IV
1818791|NCT00719901|Other|laboratory biomarker analysis|Correlative studies
1818792|NCT00719914|Drug|eptifibatide|Intra-coronary injection, weight based, of eptifibatide.
1818793|NCT00719914|Drug|eptifibatide|Intra-coronary injection, based on weight, of eptifibatide
1818794|NCT00719914|Drug|normal saline|Intra-coronary injection, weight based, of normal saline.
1818795|NCT00719927|Behavioral|Comadres Weight Loss Pilot Program|The first condition will consist of women participating with a female friend (comadre), while the second condition will consist of women participating without a support partner.
1818796|NCT00719940|Behavioral|Cognitive behavioral therapy|1-15 individual sessions of 50-60 min. to apply 1-15 manualized tinnitus specific cognitive behavioral therapy interventions structured by the tinnitus care disease management program
1818797|NCT00719940|Other|Waiting group|No intervention
1818798|NCT00719953|Dietary Supplement|Cognitex|Treatment will consist of one capsule of Cognitex (Life Extension, USA), three times a day, with meals, delivering a total of 600 mg GPC, 100 mg PS-omega 3, 20 mg vinpocetine, 50 mg uridine-5'-monophosphate (disodium), 550 mg plant extracts (150 mg wild blueberry, 125 mg ashwagandha, 150 mg grape seed, 125 mg hops, ginger and rosemary). Duration: 15 weeks
1818799|NCT00719966|Drug|anastrozole|Patients receive aromatase inhibition therapy.
1818800|NCT00719966|Drug|exemestane|Patients receive aromatase inhibition therapy.
1818801|NCT00719966|Drug|letrozole|Patients receive aromatase inhibition therapy.
1818802|NCT00719966|Procedure|assessment of therapy complications|Endothelial function is measured
1818803|NCT00719979|Behavioral|Behavioral intervention (iCBT + TeleCoach)|TABI will include 12 weeks of Internet-based cognitive behavioral therapy (iCBT) combined with brief telephone and email support from a coach.
1818804|NCT00719979|Behavioral|Internet-based cognitive behavioral therapy (I-CBT)|I-CBT will include access to an interactive Web-based intervention designed to teach and facilitate the use of cognitive behavioral skills. The intervention will last 12 weeks.
1818805|NCT00719979|Behavioral|Treatment as usual / Wait-list control|TAU will include standard treatment from participants' primary care physicians. Participants will be able to choose between TABI and I-CBT treatment options after a 6-week wait-list period.
1818806|NCT00719992|Procedure|coronary angiography|effect of level of HS-CRP
1818807|NCT00720005|Device|Aspheric Acrysof ReSTOR intraocular lens|Bilateral implantation of Aspheric Acrysof ReSTOR
1818808|NCT00720018|Drug|NP101 Sumatriptan Iontophoretic Transdermal Patch|NP101 transdermal patch delivering sumatriptan for 4 hours.
1818913|NCT00720512|Drug|fluorouracil|Given IV
1818914|NCT00720512|Drug|irinotecan hydrochloride|Given IV
1818809|NCT00720031|Biological|autologous Melan-A/MART-1 specific CTL clones|"By using patients' blood, several million to several billion of Melan-A/MART1 tumor reactive T cell clone(s) will be produced in vitro, then infused to the patient, 3 to 6 months after collecting blood sample. During this production period of the T cell clone, the patient will be treated with deticene at the dose of 250mg/m2/j by IV for 4 days each month.
After each T cell clone infusion (J1), the patient will receive IFN-α at the dose of 9 M/U 3 times a week for 4 weeks and Interleukin-2 at the dose of 9 M/U from Day 1 to day 5 and from Day 8 to Day 12."
1818810|NCT00720057|Drug|Naproxen Sodium ER (BAYH6689)|Analgesic efficacy in dental pain; per oral; 1 tablet extended release Naproxen Sodium; with a full glass of water within 4 hours post surgery
1818811|NCT00720057|Drug|Placebo|Inactive ingredient; per oral; 1 lactose based tablet; with a full glass of water within 4 hours post surgery
1818812|NCT00720070|Procedure|positron emission tomography/computed tomography|Patients undergo PET/CT scan
1818813|NCT00720070|Procedure|therapeutic conventional surgery|Patients undergo neck dissection
1818814|NCT00720083|Drug|cisplatin|Given IV
1818815|NCT00720083|Drug|vandetanib|Given orally
1818816|NCT00720083|Radiation|radiation therapy|Patients undergo radiotherapy 5 times a week for up to 6.5 weeks.
1818819|NCT00720109|Drug|Asparaginase|Given IT
1818820|NCT00720109|Drug|Cyclophosphamide|Given IV
1818821|NCT00720109|Drug|Cytarabine|Given IT or IV
1818822|NCT00720109|Drug|Dasatinib|Given PO
1818823|NCT00720109|Drug|Daunorubicin Hydrochloride|Given IV
1818824|NCT00720109|Drug|Dexamethasone|Given IV or PO
1818825|NCT00720109|Drug|Etoposide|Given IV
1818826|NCT00720109|Biological|Filgrastim|Given IV or SC
1818827|NCT00720109|Drug|Hydrocortisone Sodium Succinate|Given IT
1818828|NCT00720109|Drug|Ifosfamide|Given IV
1818829|NCT00720109|Other|Laboratory Biomarker Analysis|Correlative studies
1818830|NCT00720109|Drug|Leucovorin Calcium|Given IV or PO
1818831|NCT00720109|Drug|Mercaptopurine|Given PO
1818832|NCT00720109|Drug|Methotrexate|Given IT, PO, or IV
1818833|NCT00720109|Drug|Methylprednisolone|Given IV
1818834|NCT00720109|Drug|Pegaspargase|Given IM
1818835|NCT00720109|Drug|Prednisone|Given PO or IV
1818836|NCT00720109|Radiation|Radiation Therapy|Some patients undergo cranial RT
1818837|NCT00720109|Drug|Vincristine Sulfate|Given IV
1818838|NCT00720122|Drug|Recombinant human insulin like growth factor-1 (rhIGF-1)|Twice daily
1818839|NCT00720135|Biological|DI-Leu16-IL2 immunocytokine|Given IV
1818840|NCT00720135|Biological|rituximab|Given IV
1818841|NCT00720135|Other|flow cytometry|Correlative studies
1818842|NCT00720135|Other|immunohistochemistry staining method|Correlative studies
1818843|NCT00720135|Other|pharmacological study|Correlative studies
1818844|NCT00720135|Other|laboratory biomarker analysis|Correlative studies
1818845|NCT00720135|Other|enzyme-linked immunosorbent assay|Correlative studies
1818846|NCT00720135|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
1818847|NCT00720148|Drug|Sunitinib and Bortezomib|50 mg/m2, IV (in the vein)on day 5 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops
1818848|NCT00720161|Drug|Metformin|daily 850 mg
1818849|NCT00720161|Drug|placebo|placebo
1818850|NCT00720174|Biological|Cixutumumab|Given IV
1818851|NCT00720174|Drug|Doxorubicin Hydrochloride|Given IV
1818852|NCT00720174|Other|Laboratory Biomarker Analysis|Correlative studies
1818853|NCT00720200|Behavioral|Facilitator-Based intervention|Family Members receiving facilitator-based intervention
1818854|NCT00720200|Behavioral|Usual Care|Family Members receiving usual care/clinical interaction
1818855|NCT00720226|Drug|Losartan|Losartan 100 mg daily
1818856|NCT00720226|Drug|Placebo|Placebo pill daily
1818857|NCT00720239|Other|Taliderm wound healing dressing|"Taliderm wound healing dressing will be applied to the wound site as follows depending on assignment to group:
Control group receives no intervention. Experimental Group 1 (n = 10) will receive TalidermR only one time at the beginning of the treatment phase.
Experimental Group 2 (n = 10) will receive TalidermR to the wound every other week during the treatment phase.
Experimental Group 3 (n = 10) will receive TalidermR to the wound every three weeks during the treatment phase."
1818858|NCT00720252|Device|Ultrasound|To measure intratracheal flow volume (and peak velocity) displaced during breathing cycle in premature fetuses.
1818859|NCT00720265|Drug|Prograf|oral
1818860|NCT00720265|Drug|MR4|oral
1818861|NCT00720278|Drug|0.15% azelastine hydrochloride 1644 mcg daily|0.15% azelastine hydrochloride 1644 mcg daily
1818862|NCT00720278|Drug|0.1% azelastine hydrochloride 1096 mcg daily|0.1% azelastine hydrochloride 1096 mcg daily
1818863|NCT00720278|Drug|Placebo|0 mcg Placebo daily
1818864|NCT00720291|Drug|Metronidazole|Patients who are randomly assigned to receive Metronidazole will receive 500 mg po bid Metronidazole for 7 days
1818865|NCT00720291|Drug|Placebo|Patients who are randomly assigned to receive a placebo will receive a placebo pill po bid for 7 days.
1818866|NCT00720304|Drug|docetaxel|Beginning on week 3, patients receive docetaxel IV over 1 hour once a week
1818867|NCT00720304|Drug|erlotinib hydrochloride|oral erlotinib hydrochloride once daily for up to 2 years in the absence of disease progression or unacceptable toxicity
1818868|NCT00720304|Genetic|fluorescence in situ hybridization|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
1818915|NCT00720512|Drug|leucovorin calcium|Given IV
1818916|NCT00720512|Drug|oxaliplatin|Given IV
1818917|NCT00720538|Drug|Thalidomide|Thalidomide 1.5-2.5 mg/kg/die once a day, at evening.
1818869|NCT00720304|Genetic|polymerase chain reaction|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
1818870|NCT00720304|Other|immunoenzyme technique|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
1818871|NCT00720304|Other|immunohistochemistry staining method|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
1818872|NCT00720304|Other|laboratory biomarker analysis|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
1818873|NCT00720304|Other|pharmacological study|Patients undergo blood sample, tissue biopsy, mucosal scraping, and saliva collection at baseline and periodically during study. Samples are analyzed for markers of angiogenic activity (VEGF, sVEGFR-2, sKIT, ICAM, and PDGF), pharmacokinetic studies, gene expression profile, and human papilloma virus DNA by enzyme linked immunosorbent assay (ELISA), immunohistochemistry, fluorescence in situ hybridization (FISH), and PCR.
1818874|NCT00720304|Procedure|therapeutic conventional surgery|At 6-8 weeks after completion of chemoradiotherapy, patients with N2 or greater cervical lymph node involvement at baseline or with residual disease may undergo surgery.Patients with persistent disease during study therapy undergo salvage surgery 6-12 weeks after completion of chemoradiotherapy.
1818875|NCT00720304|Radiation|intensity-modulated radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
1818876|NCT00720304|Radiation|radiation therapy|radiotherapy (may be intensity-modulated) once daily for 8 weeks in the absence of disease progression or unacceptable toxicity.
1818877|NCT00720330|Drug|ropivacaine|10 ml 0.5% ropivacaine plus epinephrine will be injected at T11 and L1 as described above (20 ml total) using intravenous midazolam (1-2 mg) and fentanyl (0.5-1 mcg/kg) for sedation
1818878|NCT00720330|Drug|Lidocaine/Ketamine|Patients will receive a general anesthetic consisting of intravenous induction with lidocaine (1.5 mg/kg), propofol (1.5-2.5 mg/kg), ketamine (0.25 mg/kg), fentanyl (1 mcg/kg), and midazolam (1-2 mg).
1818879|NCT00720330|Other|placebo|placebo
1818880|NCT00720343|Drug|Choline|Oral Choline 20 grams before surgery
1818881|NCT00720343|Drug|Placebo|Gelatin Capsule
1818882|NCT00720356|Drug|bevacizumab|10mg/kg administered intravenously every 2 weeks
1818883|NCT00720356|Drug|erlotinib hydrochloride|150 mg/daily orally
1818884|NCT00720369|Drug|CoEnzyme Q10|CoEnzyme Q10 with dosage range from 400 mg to 1200 mg per day
1818885|NCT00720382|Drug|0.15% azelastine hydrochloride|1644 mcg (205.5 mcg/spray) 2 sprays per nostril twice a day/AM and PM
1818886|NCT00720382|Drug|Mometasone furoate|200 mcg (50 mcg/spray) 2 sprays per nostril Once a day (AM)
1818887|NCT00720408|Drug|Prograf-XL|oral
1818888|NCT00720408|Drug|Prograf|oral
1818889|NCT00720408|Drug|MMF|oral
1818890|NCT00720421|Drug|AZD7325|AZD7325 10 mg oral 2 capsules
1818891|NCT00720421|Drug|AZD7325|AZD7325 1 mg oral 2 capsules
1818892|NCT00720421|Drug|AZD7325|AZD7325 Placebo oral 2 capsules
1818893|NCT00720421|Drug|Lorazepam|Lorazepam 1 mg oral 2 tablets
1818894|NCT00720421|Drug|Lorazepam|Lorazepam Placebo oral 2 tablets
1818895|NCT00720434|Drug|PF-00868554|500 mg BID administered as 5x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks.
1818896|NCT00720434|Drug|PF-00868554|300 mg BID administered as 3x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
1818897|NCT00720434|Drug|PF-00868554|200 mg BID administered as 2x100 mg tablets for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
1818898|NCT00720434|Drug|Placebo|Placebo administered for 4 weeks in combination with standard of care; standard of care continued for an additional 44 weeks
1818899|NCT00720447|Biological|alemtuzumab|
1818900|NCT00720447|Biological|donor lymphocytes|
1818901|NCT00720447|Drug|carmustine|
1818902|NCT00720447|Drug|cytarabine|
1818903|NCT00720447|Drug|etoposide|
1818904|NCT00720447|Drug|melphalan|
1818905|NCT00720447|Procedure|allogeneic bone marrow transplantation|
1818906|NCT00720447|Procedure|peripheral blood stem cell transplantation|
1818907|NCT00720473|Drug|Lamotrigine|Lamotrigine with dosage range from 25 mg to 200 mg per day.
1818908|NCT00720486|Behavioral|Juvenile Justice Anger Management (JJAM) for Girls|JJAM will include two 1.5-hour group treatment sessions per week for 8 weeks. JJAM sessions will be manual based and will be designed to help youth develop skills in the following areas: identifying different types of physical and relational aggression, recognizing early warning signs of anger, avoiding anger-provoking situations, managing anger to prevent aggression, solving problems, communicating about anger-related events, and repairing relationships damaged by anger-related behaviors.
1818909|NCT00720486|Behavioral|Treatment as usual|Treatment as usual will include standard activities in the female juvenile justice program.
1818910|NCT00720499|Drug|BI 1744 CL plus tiotropium bromide|BI 1744 CL plus tiotropium bromide fixed dose combination; Solution for inhalation via Respimat® Inhaler (A5); Oral inhalation
1818911|NCT00720499|Device|Respimat® Inhaler|
1818912|NCT00720512|Biological|bevacizumab|Given IV
1818919|NCT00720551|Other|alcohol|alcohol 0.05%, 0.08% or 0.11% or placebo
1818920|NCT00720564|Drug|arsenic trioxide|
1818921|NCT00720564|Drug|temozolomide|
1818922|NCT00720564|Procedure|adjuvant therapy|
1818923|NCT00720564|Radiation|intensity-modulated radiation therapy|
1818924|NCT00720564|Radiation|radiation therapy|
1818925|NCT00720577|Drug|Simvastatin|40 Mg. tablet, 1 tablet daily
1818926|NCT00720577|Drug|Losartan|50 mg., tablets, 1 tablet once daily
1818927|NCT00720577|Drug|Pioglitazone|30 mg, tablet, 1 tablet once daily
1818931|NCT00720603|Drug|Plerixafor|Subcutaneous injection of 240 mcg/kg on the evening prior to each apheresis session
1818932|NCT00720616|Drug|Norditropin|Norditropin 0.1 mg/day self-administered once a day subcutaneously
1818933|NCT00720629|Drug|Visilizumab|3 mg/m^3, IV (in the vein) on day 0, prior to hematopoietic cell infusion (transplant).
1818934|NCT00720629|Drug|Tacrolimus|0.02 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 4 after transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
1818935|NCT00720629|Drug|Methotrexate|15 mg/m^2 intravenously (IV) on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
1818936|NCT00720629|Drug|Antithymocyte globulin (ATG)|1 mg/kg IV over 6 hours on Day 3 before transplant; 3.25 mg/kg IV over 4 hours on days 2 and 1 before transplant.
1818937|NCT00720629|Drug|Tacrolimus|0.03 mg/kg/24h (based on ideal body weight) continuous infusion (over 24 hours) beginning on day 3 before transplant up to approximately day 180 after transplant. Switch to oral tacrolimus as able. Dose adjusted based on levels. In the absence of GVHD, the dose to be tapered beginning 100 days after transplant.
1818938|NCT00720629|Drug|Methotrexate|15 mg/m^2 IV on Day 1 after transplant; 10 mg/m^2 IV on Days 3, 6 and 11 after transplant.
1818939|NCT00720655|Other|Dietary intervention|Fatty fish at least 4 meals per week.
1818940|NCT00720655|Other|Dietary intervention|Lean fish at least 4 meals per week.
1818941|NCT00720655|Other|Dietary intervention|Control diet with lean meat and chicken.
1818942|NCT00720668|Procedure|radiofrequency ablation|radiofrequency ablation for HCC
1818943|NCT00720707|Procedure|CAF+ADM+EMD|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) with enamel matrix derivatives (EMD).
1818944|NCT00720707|Procedure|CAF+ADM|using coronally advanced flap (CAF) in combination with acellular dermal matrix (ADM) without enamel matrix derivatives (EMD) for root coverage procedures.
1818945|NCT00720720|Dietary Supplement|plant sterol enriched margarine|Each group will have to consume 20 grams of margarines (either placebo or enriched in plant sterols) in one or two catches per day, for 8 weeks.
1818946|NCT00720720|Dietary Supplement|placebo margarine|
1818947|NCT00720733|Behavioral|Skills-Building Intervention|A 5-week intervention including 5 weekly sessions covering 8 varied coping skills with daily home practice. The skills are: 1) noting daily positive events; 2) capitalizing on positive events; 3) gratitude; 4) mindfulness; 5) positive reappraisal; 6) focusing on personal strengths; 7) setting and working toward attainable goals; and 8) small acts of kindness. Sessions are 1 hour long and include approximately 30 minutes per day.
1818948|NCT00720733|Behavioral|Personal Interview Group|There are 5 weekly sessions which will be approximately one hour long and will consist of personal interview. The interviews will include both quantitative and qualitative questions. Each session will have a separate theme including: Life 1) History; 2) Health History; 3) Personality; 4) Social Networking; and, 5) Meaning & Purpose.
1818949|NCT00720759|Drug|D-cycloserine + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
1818950|NCT00720759|Behavioral|D-cycloserine + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with d-cycloserine 50 mg PO administered before each treatment session
1818951|NCT00720759|Drug|Placebo + distributed treatment|Subjects will receive CIMT 2 hours/day, 3 days a week, for 10 weeks, in conjunction with placebo administered before each treatment session
1818952|NCT00720759|Behavioral|Placebo + condensed treatment|Subjects will receive CIMT 6 hours/day, 5 days a week, for 2 weeks, in conjunction with placebo administered before each treatment session
1818953|NCT00720772|Drug|25% intravenous (IV) sodium thiosulfate|50 ml IV drip twice/week post hemodialysis
1818955|NCT00720798|Drug|Tocilizumab|For participants weighing > 100 kg, the maximum dose of tocilizumab was 800 mg. Tocilizumab was supplied as a sterile solution in vials.
1818956|NCT00720798|Drug|Disease-modifying anti-rheumatic drugs|Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide. These drugs could be used alone or in combination, except for the combination of methotrexate and leflunomide, which was not allowed.
1818957|NCT00720798|Drug|Non-steroidal anti-inflammatory drugs|Participants could be treated with non-steroidal anti-inflammatory drugs up to the maximum recommended dose throughout the study. The choice and doses of non-steroidal anti-inflammatory drugs were at the discretion of the investigator.
1818958|NCT00720798|Drug|Oral corticosteroids|Oral corticosteroids (≤ 10 mg/day) were permitted during the study.
1818959|NCT00720811|Drug|Artemether-lumefantrine combination|20/120mg Artemether-lumefantrine 4-35 months: 1 tablet twice daily for 3 days; 36-59 months: 2 tablets twice daily for 3 days
1818960|NCT00720811|Drug|amoxycillin|amoxycillin 250mg tab 4-12 months: 1/2x2; 13-35 months: 1x2; 36-59 months: 11/2x2
1818961|NCT00720811|Drug|paracetamol|paracetamol 500mg tablet <36months: 1/4x4 for 2 days; 36-59months: 1/2x4 for 2 days
1818962|NCT00720811|Device|malaria rapid diagnostic test, respiratory rate timer|malaria dipstick, and breath timer
1818963|NCT00720811|Drug|Artemether-lumefantrine combination|20/120mg tablet arthermether-lumefantrine 4-35months: 1x2; 36-59months: 2x2
1818964|NCT00720824|Behavioral|Topical anesthetic and hypnotic distraction|Ethyl chloride spray, plastic arm gripper, vibrating instrument, hypnotic suggestions.
1818965|NCT00720824|Behavioral|Office routine|Standard vaccine administration
1818966|NCT00720837|Procedure|Visualase® Thermal Therapy System|An intraoperative biopsy and placement of applicator for laser treatment. Treatment will last between 5 and 10 minutes.
1818967|NCT00720850|Drug|lenalidomide|p.o. 10 mg/d for 21 days every 4 weeks for 1 year (12 cycles) after HSCT
1818968|NCT00720876|Biological|rituximab|Rituximab will be administered at a dose of 375 mg/m2 on day 1 of every cycle, every 3 weeks.
1818969|NCT00720876|Drug|vorinostat|200 mg twice daily, orally for 14 days followed by a seven day break on a 21 day cycle.
1818975|NCT00720915|Other|Discontinue anticoagulant therapy (Negative d-dimer)|Patients with negative d-dimer discontinue long-term anticoagulant therapy.
1818976|NCT00720915|Other|Continue on anticoagulant therapy (positive d-dimer)|Patients with positive d-dimer continue or re-start on anticoagulant therapy
1818977|NCT00720928|Drug|flucinolone acetonide|Intra-vitreal implantation of RETISERT on the study eye. The implant is a sustained-release delivery system containing 0.59 mg of flucinolone acetonide designed to deliver the drug for approximately 3 years.
1818978|NCT00720941|Drug|Pazopanib|800 mg administered once daily orally continuous dosing
1818979|NCT00720941|Drug|Sunitinib|50 mg sunitinib to be administered in 6-week cycles: 50mg orally daily for 4 weeks followed by 2 weeks off treatment
1818980|NCT00720954|Procedure|Ct-guided pleural needle biopsy|Biopsy of pleura
1818981|NCT00720954|Procedure|Thoracoscopy|Biopsy of pleura
1818982|NCT00720967|Procedure|Open Heart Surgery (OHS)|General anesthesia, use of iodine impregnated adhesive dressing, median sternotomy and/or thoracotomy incision, full heparinization (300-400 ui/kg), arterial and venous cannulation, initialization of CPB with or without aortic cross-clamping and high-potassium cold cardioplegia, surgical repair under mild-moderate hypothermia. De-clamping (if cross clamp was applied), neutralization of heparin by protamin, de-cannulation and hemostasis after surgical repair. Insertion of drain(s) and pacing wire(s). Closure of all layers in anatomical plan.
1818983|NCT00720967|Procedure|Intraoperative Modified Ultrafiltration (MUF)|Once the surgical repair is finished, and CPB will be stopped after aortic declamping. The arterial and venous cannulae will be connected to each other using 3-way connectors and a cardioplegia line. When hemodynamic stability is established (MAP >75 mmHg, CVP > 12 mmHg, Htc > 25%), blood will be drained from the arterial cannula using a roller pump, driven to the ultrafilter, and eventually to the venous cannula. The blood flow will be maintained at ~150 mL/min, and suction will be applied to the filtrate port to achieve an ultrafiltration of 100-120 mL/min. Heat exchanger and bubble trap of the cardioplegia line will be used to maintain the filtered blood at body temperature and to prevent air embolism, respectively. MUF will continue 20 minutes. The filtered volume will be collected.
1818984|NCT00720967|Procedure|Hemodialysis (HD)|Two HD sessions will be performed at 3 days and 1 day prior to surgery. Each session will last 3 hours if the patient weighs < 75 kg, and 4 hours if > 75 kg. Conventional HD will be carried out using a volume-controlled dialysis machine. A bicarbonate dialysate containing K (3 mmol/L), Ca (1.5 mmol/L) and HCO3 (31 mmol/L) will be used. Sodium conductivity will be set at 138 mmol/L. Medium-flow filters will be used as artificial kidney devices. Dialysate temperature will be set at 36oC. Dialysate and blood flow rate will be set at 500 mL/min and 250-300 ml/min, respectively. Intradialytic ultrafiltration will not be used routinely unless the patient has volume overload. The decision to use intradialytic ultrafiltration will be taken with the anaesthesiologist and the cardiac surgeon. If intradialytic ultrafiltration is indicated, maximal rate of ultrafiltration will be 10 ml/kg/hour. These patients will undergo open heart surgery after two sessions of HD.
1818985|NCT00721006|Biological|MESENDO|40 subcutaneous injections of biological product
1818986|NCT00721006|Biological|Placebo|40 subcutaneous injections of placebo
1818987|NCT00721019|Other|5-hour bedtime|10 days with sleep restricted only to a 5-hour bedtime period at night
1818988|NCT00721019|Other|8.5-hour bedtimes|10 days with sleep allowed only during a 8.5-hour period at night
1818989|NCT00721032|Procedure|MRI guided VT ablation|Magnetic resonance imaging (MRI)-guided ablation of ventricular tachycardia (VT)
1818990|NCT00721032|Drug|Increased dose of amiodarone|"Increase the dose of amiodarone according to the following scheme:
current dose -> new dose 100 once daily (QD) -> 200 QD; 200 QD -> 400 QD; 300 QD -> 600 QD; 400 QD -> 600 QD"
1818991|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|25 M allogeneic MPCs by transendocardial injection and mapping.
1818992|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|75 M allogeneic MPCs by transendocardial injection and mapping.
1818993|NCT00721045|Biological|Mesenchymal Precursor Cells (MPCs)|150 M allogeneic MPCs by transendocardial injection
1818994|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
1818995|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
1818996|NCT00721045|Procedure|standard-of-care treatment with mock mapping and injection procedures.|Mock
1818997|NCT00721058|Other|CT-scan|A pre-operative CT-scan will be made
1818998|NCT00721071|Drug|Hypertonic Saline|After each subject has performed post-bronchodilator spirometry, he/she will inhale increasing concentrations of 3, 4, and 5% of hypertonic saline for 7 minutes each for 3 cycles until expectorating a sufficient sputum sample.
1818999|NCT00721097|Other|spirometry, and blood taken|each month during one year
1819000|NCT00721110|Drug|Lidocaine|Upon general anesthesia induction, lidocaine (1.5 mg/kg) will be given. Lidocaine infusion of 2 mg/kg/hour, to a maximum of 200 mg/hour during The lidocaine infusion will be reduced to 1.3 mg/kg/hour, to a maximum of 133 mg/hour, at skin closure and discontinued 24 hours postoperatively.
1819001|NCT00721110|Drug|Placebo|Placebo boluses and infusions will be substituted
1819002|NCT00721110|Drug|Ketamine|Ketamine (0.25 mg/kg) will be given followed by an infusion of ketamine (0.25 mg/kg/hour) up to 25 mg/hour. The ketamine infusion will be reduced to 0.12 mg/kg/hour up to a maximum of 12 mg/hour at skin closure and discontinued 24 hours postoperatively.
1819003|NCT00721110|Drug|Ketamine + Lidocaine|both Ketamine and Lidocaine will be given
1819004|NCT00721123|Drug|Tocilizumab|Tocilizumab (myeloma receptor antibody [MRA]) was supplied in sterile solution of 20 mg TCZ/mL for aseptic preparation of infusion bags for IV administration.
1819005|NCT00721136|Drug|continue warfarin through the procedure|The usual dose of warfarin (resulting in a therapeutic INR) is taken throughout the peri-procedural period.
1819006|NCT00721136|Drug|Hold warfarin|For moderate risk patients, warfarin will be held for 4-5 days prior to the procedure.
1819007|NCT00721136|Drug|Warfarin held with heparin transition.|For high risk patients, warfarin is held for 4-5 days prior to the procedure and heparin is given to provide anticoagulation while the INR is subtherapeutic.
1819008|NCT00721149|Device|Radiofrequency Ablation|The Biosense Webster® NAVISTAR THERMOCOOL Diagnostic/Ablation Deflectable Tip Catheter is a luminal catheter with a deflectable tip designed to facilitate electrophysiological mapping of the heart and to transmit radiofrequency current to the catheter tip electrode for ablation purposes.
1819009|NCT00721162|Biological|Ramucirumab|Participants will receive ramucirumab at 8 milligrams/kilogram (mg/kg) administered over 1 hour every other week (every 14 days). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
1819010|NCT00721175|Device|biliary stent (self expandable metallic stent)|metallic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
1819011|NCT00721175|Device|PS|plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
1819012|NCT00721188|Drug|Venofer|Single dose of 7mg intravenous (IV) of iron per kg of body weight for a maximum of 200mg iron IV.
1819013|NCT00715546|Procedure|autologous transplantation of liposuction material enriched with adipose-derived stem cells|Lipoinjection enriched with adipose-derived stem-cells.
1819014|NCT00715559|Drug|cysteamine bitartrate|All enrolled participants will begin open treatment with cysteamine on the first visit of the experimental period (after screening, medical clearance and medication washout period if necessary). The dosing schedule is a flexible regimen starting at 150 mg PO three times daily. After one week, patients without intolerable side effects will increase the dose to 300 mg three times daily. The titration schedule will continue up to a maximum of 1800 mg a day. In case of adverse events, the investigator may decrease the dose by 150 mg daily.
1819015|NCT00715572|Drug|thyroxine|monotherapy with thyroxine
1819016|NCT00715572|Drug|thyroxine and triiodothyronine|combination with thyroxine and triiodothyronine
1819017|NCT00715585|Behavioral|Active Control|patients receive 3 individualized visits with a health educator focused on general diabetes education and health promotion
1819018|NCT00715585|Behavioral|int arm 1|VVpatients receive 3 individualized visits with an rd-cde for education focused on modified plate method
1819019|NCT00715585|Behavioral|int arm 3|patients receive 3 individualized visits with an rd-cde for education focused on carb counting
1819023|NCT00715624|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1819024|NCT00715624|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1819025|NCT00715624|Drug|Basal Insulin|Dose to be kept stable.
1819026|NCT00715624|Drug|Metformin|Metformin if given to be continued at stable dose (1.5 gram per day) up to the end of treatment.
1819027|NCT00715624|Device|Pen auto-injector|
1819028|NCT00715637|Drug|Daunorubicin and Cytarabine|Daunorubicin: 45 mg/m2 over 30 minutes daily on days 1-3 (up to max. of 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on days 1-7 (up to max. of 2 courses)
1819029|NCT00715637|Drug|Amonafide and Cytarabine|Amonafide: 600 mg/m2 IV over 4 hours daily on Days 1-5 (up to max. 2 courses) Cytarabine: 200 mg/m2 IV continuous infusion daily on Days 1-7 (up to max. 2 courses)
1819030|NCT00715650|Behavioral|Benefits Counseling|Benefits counseling is designed to improve the quality of life of disability applicants by accomplishing two functions: 1) Providing information concerning what vocational rehabilitation services are available and how they will affect receipt of disability payments, 2) Amplifying applicants' existing motivation to engage in work and related-activities, using a Motivational Interviewing approach.
1819031|NCT00715650|Behavioral|VA Orientation|VA Orientation is designed to provide the Veteran with information regarding the services available, how to access the services and where the service is located on the VA campus.
1819032|NCT00715663|Drug|biphasic insulin aspart 30|No intervention is done. For study drug, start dose and frequency of administration to be prescribed by the physician as a result of normal clinical evaluation
1819033|NCT00715676|Drug|Placebo|oral, once daily
1819034|NCT00715676|Drug|DP001|oral, once daily
1819035|NCT00721201|Drug|Mifepristone|Use of mifepristone 200mg bd for 8 weeks
1819036|NCT00721214|Drug|5-azacytidine|The recommended starting dose for the first treatment cycle, for all patients regardless of baseline hematology laboratory values, is 75 mg/m2 subcutaneously or intravenously, daily for 7 days.
1819037|NCT00721227|Procedure|Reduction Gastroplasty|"Subjects will undergo reduction gastroplasty by gastric plication
Subjects are followed for 12 months to evaluate outcomes and potential complications."
1819038|NCT00721240|Drug|montelukast|5mg montelukast once daily for 12 weeks
1819039|NCT00721253|Device|ReSTOR|Implantation of the ReSTOR Aspheric +4 (SN6AD3) multifocal intraocular lens (IOL)
1819040|NCT00721253|Device|Tecnis|Implantation with the Tecnis multifocal (ZM900) intraocular lens (IOL)
1819041|NCT00721253|Device|Acri.LISA|Implantation with the Acri.LISA 366D multifocal intraocular lens (IOL)
1819042|NCT00721266|Drug|RO5083945|Administered iv, either weekly, every 2 weeks or every 3 weeks, at escalating doses (with a starting dose of 50mg weekly (Part 1)). Recommended dose administered iv, either weekly, every 2 weeks or every 3 weeks (Part 2).
1819043|NCT00721279|Drug|Sifrol® (pramipexole dihydrochloride)|
1819044|NCT00721305|Drug|Lovastatin|Lovastatin 40 mg daily (2 tablets of 20 mg each, p.o.), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
1819045|NCT00721305|Other|placebo|Placebo will be administered daily (2 tablets which will look externally identical to intervention: wrapped in the same way, with the same size, shape and color), during twelve months until the end of the study, or before the end of the study if any AIDS defining disease or toxicity appear
1819046|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
1819047|NCT00721331|Drug|nortriptyline HCl + loratadine|Topical
1819048|NCT00721331|Drug|nortriptyline HCl|Topical
1819049|NCT00721331|Drug|mometasone furoate|Topical
1819050|NCT00721331|Drug|Active ingredient free vehicle cream of CRx-197|Topical
1819051|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 20mg
1819052|NCT00721344|Drug|Moxifloxacin|Tablets 400mg
1819053|NCT00721344|Drug|Technosphere Inhalation Powder (FDKP)|Technosphere® Inhalation Powder 40mg
1819054|NCT00721344|Drug|Placebo|Placebo cartridges
1819055|NCT00721357|Behavioral|Treadmill walking|Subjects will perform treadmill walking at a self-selected velocity
1819056|NCT00721357|Other|Magnetic resonance spectroscopy|Muscle oxidative capacity will be assessed via Magnetic resonance spectroscopy (31P-MRS)
1819057|NCT00721370|Device|NIR imaging system|Optical imaging parameter optimization (field-of-view, NIR excitation fluence rate, camera integration time) and system ergonomics.
1819058|NCT00721383|Behavioral|Enhancing Physical Activity Intervention|Physical activity and caregiver skill-building
1819059|NCT00721383|Behavioral|CSBI|Caregiver skill-building
1819060|NCT00721396|Biological|rMenB+OMV NZ|
1819061|NCT00721396|Biological|combined diphtheria,tetanus,pertussis+polio+Hepatitis B+Haemophilus influenzae B vaccine|
1819062|NCT00721396|Biological|Pneumococcal vaccine|
1819066|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
1819067|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
1819068|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
1819069|NCT00721422|Drug|PD 0332334|50 mg (two 25 mg capsules), single, oral dose
1819070|NCT00721435|Procedure|3D Tomosynthesis and ultrasound imaging|3D tomosynthesis & ultrasound imaging for scanning masses or healthy breast tissue
1819071|NCT00721448|Drug|AZD6140|90mg tablet, oral, once daily for the first day and twice daily from day 4 to 9
1819072|NCT00721448|Drug|AZD6140|90 x 2 mg tablets, oral, once daily for the first day and twice daily from day 4 to 9
1819073|NCT00721461|Biological|V930|Intramuscular injection of phosphate buffered saline solution will be given and within 2 - 5 minutes will be followed by an electrostimulation pulse with the MedPulser DDS in the deltoid muscle of the right arm. 15 days later, the same procedure will take place using the left arm.
1819074|NCT00721474|Drug|Bosutinib|Bosutinib fasting
1819075|NCT00721474|Drug|Bosutinib|Bosutinib fed
1819076|NCT00721487|Drug|Fluconazole|Patients hospitalized with severe infection caused by C. albicans, documented by standard clinical signs, symptoms, and radiology, and having failed at least four days of fluconazole therapy
1819077|NCT00721500|Device|etafilcon A|contact lens
1819078|NCT00721500|Device|narafilcon A|contact lens
1819079|NCT00721513|Biological|cetuximab|
1819080|NCT00721513|Drug|cisplatin|
1819081|NCT00721513|Drug|docetaxel|
1819082|NCT00721513|Drug|fluorouracil|
1819083|NCT00721513|Procedure|computed tomography|
1819084|NCT00721513|Procedure|positron emission tomography|
1819085|NCT00721513|Procedure|quality-of-life assessment|
1819086|NCT00721513|Radiation|3-dimensional conformal radiation therapy|
1819087|NCT00721513|Radiation|intensity-modulated radiation therapy|
1819088|NCT00721526|Drug|disulfiram plus lorazepam|Disulfiram 500mg three times weekly lorazepam 0.5-2.0 mg three times daily
1819089|NCT00721539|Device|da Vinci Surgical Robot Platform|daVinci Surgical Robot Platform is a surgical device that enhances transoral access to the upper aerodigestive tract through miniaturization of endoscopes and micromanipulators that can be introduced through the mouth.
1819090|NCT00721539|Procedure|Transoral Robotic Surgery|Eligible patients will undergo transoral treatment of neoplastic disease of the upper aerodigestive tract using the daVinci Surgical Robot Platform as opposed to traditional (TOL - transoral laser; TEC - transoral electrocautery) methods.
1819091|NCT00721630|Drug|capecitabine, lapatinib|Capecitabine 2,000mg twice daily for 7 days followed by a 7-day rest in combination with lapatinib 1,250mg orally daily. Cycle length is 28 days (+/- 2 days).Toxicity assessment will occur q2 weeks for the first 4 weeks, then q4 weeks(+/- 2 days). Radiographic response assessment will take place q12 weeks (+/- 1 week). LVEF assessment will be repeated q12 weeks (+/- 1 week).
1819092|NCT00721643|Dietary Supplement|angel's plant (Angelica keiskei)|Healthy control, one time dose of 5g dry power of Angelica keiskei
1819093|NCT00721643|Dietary Supplement|Angel's plant (Angelica keiskei)|Metaboic syndrome subjects, one time dose of 5g dry powder of angel's plant (Angelica keiskei)
1819096|NCT00721669|Drug|IMGN388|IMGN388 is a human IgG1 anti-integrin antibody conjugated to the maytansinoid, DM4.
1819097|NCT00721695|Drug|OMS302|OMS302 Irrigation Solution
1819098|NCT00721695|Drug|OMS302-PE|OMS302-PE HCI Irrigation Solution
1819099|NCT00721695|Drug|Vehicle|Standard topical mydriatics and Balanced Salt Solution Irrigation Solution
1819100|NCT00721708|Dietary Supplement|pure carnosine|one time dose of pure carnosine (450 mg)
1819101|NCT00721708|Other|Beef|one time dose, 150 g of beef
1819102|NCT00721708|Other|Chicken|One time dose, 150g of chicken breast
1819103|NCT00721708|Other|Chicken broth|one time dose of chicken broth obtained from 150g of chicken breast
1819104|NCT00721721|Behavioral|Low Sodium Diet|3 grams of salt or 51.3 mmol of sodium per day
1819105|NCT00721721|Behavioral|High Sodium Diet|18 grams of salt or 307.8 mmol of sodium per day
1819106|NCT00721721|Dietary Supplement|Potassium Supplementation|60 mmol potassium supplement
1819107|NCT00721734|Drug|Carfilzomib|Carfilzomib was administered intravenously (IV) at a rate of approximately 10 mL/minute.
1819108|NCT00721747|Drug|Docetaxel, Liposomal doxorubicine and Cyclophosphamide|4 cycles of Docetaxel 100mg/m2 iv followed by 4 cycles of Liposomal doxorubicine 60mg/m2/iv and Cyclophosphamide 600mg/m2/iv
1819109|NCT00721760|Drug|Enoxaparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection"
1819110|NCT00721760|Drug|Semuloparin sodium|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml pre-filled syringe
Subcutaneous injection"
1819111|NCT00721760|Drug|Placebo|"0.4 mL (0.2 mL if SRI) solution in ready-to-use 0.5 ml prefilled syringe strictly identical in appearance but without active component
Subcutaneous injection"
1819112|NCT00721773|Drug|Benazepril|Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
1819113|NCT00721773|Drug|Valsartan|Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
1819114|NCT00721773|Drug|Benazepril+Valsartan|Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
1819115|NCT00721773|Drug|Control|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
1819116|NCT00721786|Behavioral|UCSF/SFGH Internet Stop Smoking Study site|Internet stop smoking site in Spanish and English
1819117|NCT00721799|Drug|18F-Fluorothymidine PET scan|18F-Fluorothymidine (0.04 - 0.08 mCi / kg to a maximum dose of 5 mCi) administered once intravenously for a positron emission tomography (PET) scan.
1819118|NCT00721812|Drug|GSK1399686|Safety and tolerability dose escalation in normal human volunteers
1819119|NCT00721825|Drug|Neuroaid|Neuroaid capsules, 4 capsules, three times per day, during one month
1819120|NCT00721825|Drug|Neuroaid matched Placebo|Neuroaid matched placebo 4 capsules three times per day during one month
1819121|NCT00721877|Drug|resveratrol|Given orally
1819122|NCT00721877|Other|pharmacological study|Correlative studies
1819123|NCT00721877|Other|laboratory biomarker analysis|Correlative studies
1819124|NCT00721890|Dietary Supplement|Double-Brewed Green Tea|liquid, 4 celsius; 500 mL ID, 3 hours after meals and 1 hour before next meal; duration: to the first of the following events: 18 months or relapse
1819125|NCT00721903|Procedure|Ultrasound Scan|10 female volunteers with normal breast who will be studied to refine imaging techniques and for comparison with patients. To the degree possible, the volunteer group will be age-matched to patients with symptoms, initially 30 to 70 years of age.
1819126|NCT00721903|Procedure|Mammography and Ultrasound|To determine how well from ultrasound scans, changes in malignant masses can be measured, and to whether the use of a dye visible by ultrasound will be useful in evaluating different therapies for breast cancer.
1819127|NCT00721916|Drug|SOL(The combination therapy of S-1, Leucovorin, and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
1819128|NCT00721916|Drug|mFOLFOX6(The combination therapy of 5-FU, l-LV and Oxaliplatin)|L-OHP 85 mg/m2 iv. for 2 hr on day 1 of each 2 weeks cycle l-LV 200 mg/m2 iv. for 2 hr on day 1 5-FU 400 mg/m2 bolus on day 1 5-FU 2400 mg/m2 ci for 46 hr (day 1, 2hr～48hr)
1819129|NCT00721929|Procedure|MRI|Magnetic Resonance Imaging
1819130|NCT00721955|Drug|Inhaled Placebo|Inhaled loxapine Placebo, may repeat after 2 hours x 2
1819131|NCT00721955|Drug|Inhaled loxapine 5 mg|Inhaled Staccato loxapine 5 mg, may repeat after 2 hours x 2
1819132|NCT00721955|Drug|Inhaled loxapine 10 mg|Inhaled Staccato loxapine 10 mg, may repeat after 2 hours x 2
1819133|NCT00721968|Device|Glaucoma Stent Surgery (GTS400 Stent)|ab interno trabecular bypass stent surgery
1819134|NCT00721968|Procedure|cataract surgery alone|Cataract surgery alone
1819135|NCT00721994|Device|Cormet Hip Resurfacing System|Cormet Hip Resurfacing System
1819136|NCT00722007|Device|Cormet Hip Resurfacing|Cormet Hip Resurfacing implant
1819137|NCT00722020|Device|VEST|15 minutes of HFCWO via the Vest 2-3 times daily
1819138|NCT00722033|Drug|3 protocols of Indomethacin administration|Indomethacin will consecutive be infused in 30, 60 and 120 minutes in each patient who requires it.
1819139|NCT00722046|Biological|PF-04360365 0.1 mg/kg|0.1 mg/kg every 60 days (10 doses total)
1819140|NCT00722046|Biological|PF-04360365 0.5 mg/kg|0.5 mg/kg every 60 days (10 doses total)
1819141|NCT00722046|Biological|PF-04360365 1 mg/kg|1 mg/kg every 60 days (10 doses total)
1819142|NCT00722046|Drug|Placebo|Placebo every 60 days (10 doses total)
1819143|NCT00722046|Biological|PF-04360365 3 mg/kg|3 mg/kg every 60 days (10 doses total)
1819144|NCT00722046|Biological|PF-04360365 8.5 mg/kg|8.5 mg/kg every 60 days (10 doses total)
1819145|NCT00722059|Procedure|Breast Tomosynthesis|3D breast imaging
1819323|NCT00723398|Drug|Raloxifene|60 mg orally every day for two years
1819146|NCT00722072|Drug|fulvestrant|Loading dose for cycle 1: 500 mg intramuscular(IM) on Day 1;250 mg IM on Day 15 Upon completion of the loading dose, a fixed dose of fulvestrant 250 mg IM will be administered on day 1 of the next 28 day cycle and every consecutive cycle until tumor progression or until unacceptable toxicity occurs requiring discontinuation of study therapy
1819147|NCT00722072|Drug|sorafenib tosylate|Subjects will take sorafenib 800 mg/day administered as 400 mg bid (twice daily) each morning and evening approximately 12 hours apart. Treatment will begin on Day 1 of the study and continue daily until tumor progression or until an unacceptable toxicity occurs which would require delay, modification or discontinuation of study therapy
1819154|NCT00722124|Drug|S-Adenosyl-L-Methionine|800 mg dose per day for 8 weeks
1819155|NCT00722124|Drug|S-Adenosyl-L-Methionine|1600 mg per day for 8 weeks
1819156|NCT00722124|Other|placebo|4 pills (2 in the AM and 2 in the PM) of placebos for 8 weeks
1819157|NCT00722137|Drug|Rituximab 375 mg/m^2|Intravenous rituximab 375 mg/m^2 on Day 1 of a 21 day (3 week) cycle for 6 cycles.
1819158|NCT00722137|Drug|Cyclophosphamide 750 mg/m^2|Intravenous cyclophosphamide 750 mg/m^2 on Day 1 of a 21 day (3 week) cycle for 6 cycles
1819159|NCT00722137|Drug|Doxorubicin 50 mg/m^2|Intravenous doxorubicin 50 mg/m^2 on Day 1of a 21 day (3 week) cycle for 6 cycles
1819160|NCT00722137|Drug|VELCADE 1.3 mg/m^2|Intravenous VELCADE 1.3 mg/m^2 on Days 1,4,8, and 11of a 21 day (3 week) cycle for 6 cycles
1819161|NCT00722137|Drug|Prednisone 100 mg/m^2|Oral prednisone 100 mg/m^2 on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
1819162|NCT00722137|Drug|Vincristine 1.4 mg/m^2|Intravenous vincristine 1.4 mg/m^2 on Day 1of a 21 day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.
1819163|NCT00722150|Drug|Artesunate|2 mg/kg/day x 7 days
1819164|NCT00722150|Drug|Artesunate|4 mg/kg/day x 7 days
1819165|NCT00722150|Drug|Artesunate|6 mg/kg/day x 7 days
1819166|NCT00722163|Other|Cognitive Behavioural Therapy|
1819167|NCT00722163|Other|befriending|
1819171|NCT00722202|Drug|ERB-257|
1819172|NCT00722202|Other|placebo|
1819173|NCT00722215|Drug|BQ-123 (selective endothelin A receptor antagonist)|Single dose of BQ-123 given at a dose of 1000 nmol/min for 15 min intravenously.
1819174|NCT00722215|Drug|0.9 % saline|Single 15ml 0.9% saline infused for 15 mins as placebo control
1819175|NCT00722215|Drug|Nifedipine|Single dose of nifedipine 10 mg given orally as active control
1819176|NCT00722228|Biological|Allogeneic whole epithelial tumor cells, DNP-conjugated and irradiated|
1819178|NCT00722293|Drug|Doxorubicin|Arm D - doxorubicin given as a intravenous bolus injection on Day 1 or Day 3 depending on schedule selected from Arm A, B or C - starting dose 60 mg/m2 and increase to 75mg/m2
1819179|NCT00722293|Drug|Pazopanib (GW786034)|Arm A - daily administration of pazopanib on Days 1 through 21 starting at 200mg with a maximum dose of 800mg; Arm B daily administration of pazopanib on Days 1 through 8 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm C daily dose of pazopanib on Days 14 through 21 of a 3-week cycle starting at 200mg escalating to a maximum dose of 800mg; Arm D once daily administration of pazopanib (according to schedule selected from Arm A, B, or C) starting at 400mg escalating to a maximum dose of 800mg
1819180|NCT00722293|Drug|Epirubicin|Arm A and Arm B - epirubicin given as a bolus intravenous injection on Day 3 starting dose 60mg/m2 increase to 90mg/m2 if tolerated; Arm C - epirubicin given as a bolus intravenous injection on Day 1 starting dose 60mg/m2 increase to 90mg/m2 if tolerated
1819181|NCT00722306|Drug|PD 0200390|Extemporaneous solution of C14 Labelled PD 0200390 60 mg single dose
1819182|NCT00722332|Biological|HepaGam B|Hepatitis B Immunoglobulin
1819183|NCT00722345|Behavioral|"review of Canada's Physical Activity Guide for Youth"|"The contents of the exercise booklet was reviewed with each participant of the control group by the research fellow. Health Canada's Canada's Physical Activity Guide for Youth was used for the exercise booklet"
1819258|NCT00722917|Drug|TAK-379|TAK-379 100 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
1993617|NCT03164057|Drug|Decitabine|Administered by IV injection over approximately one hour.
1993618|NCT03164057|Drug|Cytarabine|Given IV or intrathecally (IT).
1993619|NCT03164057|Drug|Daunorubicin|Given IV.
1993620|NCT03164057|Drug|Etoposide|Given IV.
1993621|NCT03164057|Combination Product|ITMHA|Given IT.
1993622|NCT03164057|Drug|Idarubicin|Given IV.
1993623|NCT03164057|Drug|Fludarabine|Given IV over approximately 30 minutes.
1993624|NCT03164057|Drug|Mitoxantrone|Given IV.
1993625|NCT03164057|Drug|Erwinia asparaginase|Given IV or intramuscularly (IM).
1993626|NCT03164057|Drug|Sorafenib|Given PO. Used only for participants with FLT3 ITD and NUP98-NSD1.
1993627|NCT03164057|Drug|G-CSF|Given IV.
1993628|NCT03164057|Drug|Dexrazoxane|Given IV immediately before idarubicin administration.
1993629|NCT03164057|Biological|Stem Cell Transplant|The transplant protocol will depend on the patient's donor and transplant physician's preference.
1993990|NCT03093532|Other|ED SBIRT-HTN|"Participants in the ED-SBIRT-HTN group will receive the following interventions:
1) screening (risk assessment/stratification), 2) a limited bedside echocardiogram (looking for evidence of subclinical cardiac disease), and 3) a urine microalbumin test (marker of early cardiovascular disease)."
1819184|NCT00722345|Behavioral|Exercise consultation|The exercise consultation consisted of a one-to-one discussion designed to educate the participant, strengthen his/her motivation and develop realistic goals and strategies to promote physical activity based on the patient's stage of change. The consultation was based upon the standardized protocol previously published by Loughlan and Mutrie. The Consultation Guidelines describe the 5 steps involved in an exercise consultation, including: 1) discussing current & past activities; 2) reviewing the pros & cons of exercising; 3) discussing the barriers to exercising and strategies for overcoming them; 4) determining the social support available to the patient; and finally, 5) setting realistic, attainable short term and long term goals to enhance physical activity.
1819185|NCT00722358|Drug|BMS-650032|"Capsule, Oral, Q12h, 3/5 days
Panel 1: 200 mg
Panel 2: 400 mg
Panel 3: 600 mg"
1819186|NCT00722358|Drug|Placebo|"Capsule, Oral, Q 12h, 3/5 days
Panel 1: matching placebo
Panel 2: matching placebo
Panel 3: matching placebo"
1819187|NCT00722371|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet (blinded) orally once daily for 54 weeks.
1819188|NCT00722371|Drug|Pioglitazone hydrochloride|Pioglitazone 15 mg, 30 mg, or 45 mg tablets or capsules (blinded) orally once daily for 54 weeks. Participants randomized to receive pioglitazone 45 mg as monotherapy or in combination with sitagliptin were to start on pioglitazone 30 mg at Week 1 and undergo uptitration to pioglitazone 45 mg at Week 4.
1819189|NCT00722371|Drug|Matching placebo to sitagliptin|Matching placebo to sitagliptin orally once daily for 54 weeks.
1819190|NCT00722371|Drug|Matching placebo to pioglitazone|Matching placebo to pioglitazone tablets or capsules orally once daily for 54 weeks.
1819191|NCT00722371|Drug|Metformin|Metformin 500 mg (open-label) was to be initiated as rescue therapy to participants not meeting specific glycemic goals. The dose of metformin may have been uptitrated and adjusted, at the discretion of the investigator, up to the maximum approved dose in the country of origin.
1819192|NCT00722384|Drug|bevasiranib|
1819193|NCT00722384|Drug|bevasiranib|The first three patients enrolled will receive 0.1 mg Cand5 in the study eye, the next three patients enrolled will receive 0.33 mg Cand5 in the study eye, the following three patients enrolled will receive 1.0 mg Cand5 in the study eye, the following three patients enrolled will receive 1.5 mg Cand5 in the study eye, and the remaining three patients enrolled will receive 3.0 mg Cand5 in the study eye. The third patient enrolled at each dose level will complete their two-week visit before the next dose level group may be treated.
1819194|NCT00722410|Dietary Supplement|VSL#3|A probiotic preparation.
1819195|NCT00722410|Drug|Polyethylene glycol|Oral ingestion of 3 liters of polyethylene glycol solution.
1819196|NCT00722423|Behavioral|Integrated care model|The integrated care intervention follows a manualized protocol consisting of a series of brief intervention tailored to the patients' main barriers to treatment along with a case management approach in which the integrated care mental health provider actively tracks each patients progress through the evaluation and treatment process. The integrated care mental health provider can be a clinical nurse specialist, psychologist, or licensed clinical social worker that has experience and training in the provision of psychiatric and SUD interventions. They will receive additional training on the integrated care protocol. Data will be collected at baseline, pre-treatment, and post-treatment intervals.
1819197|NCT00722423|Behavioral|Usual Care Model|
1819198|NCT00722436|Drug|Tranexamic acid|100 mg/kg load, then 10 mg/kg/hr
1819199|NCT00722436|Drug|saline|Placebo
1819200|NCT00722462|Procedure|Active acupuncture|Acupuncture 25 minutes before and after embryo transfer
1819201|NCT00722462|Procedure|Sham acupuncture|Acupuncture at neutral points, 25 minutes before and after embryo transfer
1819202|NCT00722475|Drug|Intravenous immunoglobulin|Intravenous infusions, 25-35 g each time, 4th to 15th gestational week
1819203|NCT00722475|Drug|Human albumin|Repeated infusions of Human Albumin 5%, 250-350 ml between 4th and 15th gestational week
1819204|NCT00722488|Drug|MLN4924|Intravenous dose 100 mg/m2 on a Days 1,4,8,11 schedule within a 21-day treatment cycle. Treatment may continue until disease progression or unacceptable toxicity develops.
1819205|NCT00722501|Drug|ERB-257|
1819206|NCT00722501|Other|placebo|
1819207|NCT00722514|Behavioral|patient education|"complex individual antiinflammatory rehabilitation program during inpatient rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally
Patient education 6 x 90 Minutes"
1819208|NCT00722514|Behavioral|Standard Care|"complex individual antiinflammatory rehabilitation program during inpatient
complex individual medical rehabilitation (physiotherapy, physical therapy, occupational therapy, health-promoting measures and more) and additionally
further 6 treatments from available disciplines(e.g. massage, electrotherapy, bath)"
1819209|NCT00722540|Drug|NNC126-0083|Dose level 1; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
1819210|NCT00722540|Drug|NNC126-0083|Dose level 2; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
1819211|NCT00722540|Drug|NNC126-0083|Dose level 3; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
1819212|NCT00722540|Drug|NNC126-0083|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
1819213|NCT00722540|Drug|placebo|Dose level 1; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
1819214|NCT00722540|Drug|placebo|Dose level 2; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
1819215|NCT00722540|Drug|placebo|Dose level 3; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
1819216|NCT00722540|Drug|placebo|Dose level 3 repeated; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
1819217|NCT00722540|Drug|NNC126-0083|Dose level 4; (6 subjects active, 2 subjects placebo); s.c. injection once weekly for 3 weeks
1819218|NCT00722540|Drug|placebo|Dose level 4; NNC126-0083 placebo for s.c. injection once weekly for 3 weeks
1819219|NCT00722553|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes via a peripheral IV line containing normal saline (0.9% sodium chloride).
Initial dose: 190 mg/m2
Dose reductions per protocol: 150 mg/m2, 120 mg/m2 and 100 mg/m2 will be allowed for defined toxicity.
Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
1819220|NCT00722553|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection
Administered within 10 weeks of enrollment, every 8-10 weeks throughout the study and for at least 30 days after last dose of pralatrexate."
1819221|NCT00722553|Dietary Supplement|Folic Acid|"1-1.25 mg orally
Administered daily for at least 7 days prior to enrollment, throughout the study and for at least 30 days after last dose of pralatrexate."
1819222|NCT00722566|Drug|VELCADE Administered by subcutaneous injection|Patients will receive a 1.3mg/meters(squared)/dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle
1819223|NCT00722566|Drug|VELCADE Administered by intravenous infusion|Patients will receive a 1.3mg/meters(squared) dose of VELCADE on Days 1,4,8, and 11 of a 3-week cycle.
1819224|NCT00722579|Device|PRESILLION cobalt chromium stent|PTCA with bare-metal stent
1819225|NCT00722592|Drug|Vintafolide|2.5 mg IV bolus on Days 1,3,5 and 15,17,19 of a 4-week cycle
1819226|NCT00722592|Drug|pegylated liposomal doxorubicin (PLD)|50 mg/m^2 (with dose based on ideal body weight for participants whose measured body weight is greater than their ideal body weight) intravenous infusion on Day 1 of a 4 week cycle. Dose reductions permitted for toxicity.
1819227|NCT00722592|Other|EC20|During the screening period, participants at centers with EC20 imaging capability will receive a single intravenous injection of 0.1 mg EC20 labeled with 20-25 mCi technetium-99m followed by an imaging procedure. A second injection and imaging may be done after all therapy with the study drugs is done.
1819228|NCT00722605|Procedure|cone-beam CT|"You will have the following CT scans along with the standard weekly portal images:Before treatment you will have a CT scan (a respiratory-correlated CT scan) at the time of the radiation planning, or simulation planning.During the first week of treatment - you will have 5 cone-beam CT scans at days 1 through 5 of your radiation treatment schedule.
During the remaining weeks of treatment - you will have a cone-beam CT scan every week. Depending on the number of treatments that your study doctor has prescribed for you, the number of weekly scans can be between 3 and 7.
For all scans, an external monitor will be used to record your breathing.
If needed, you will be repositioned by adjusting the radiation machine's treatment couch position."
1819229|NCT00722618|Behavioral|Written materials, telephone based education|4 new written materials, 15-20 minute educational session by telephone
1819230|NCT00722618|Other|Written materials|2 written materials available on public website
1819231|NCT00722631|Drug|Pioglitazone|Subjects who meet eligibility criteria will be titrated up to a maximum of 30 mg/day pioglitazone.
1819232|NCT00722631|Drug|Glimepiride|Subjects who meet eligibility criteria will be titrated up to a maximum of 4 mg/day glimepiride.
1819233|NCT00722644|Behavioral|Cognitive Behavioral Stress Management|
1819234|NCT00722670|Behavioral|Woman-focused intervention|Participants in this group received a four individual sessions of the woman-focused intervention, in addition to services that were part of their substance abuse treatment program
1819235|NCT00722670|Behavioral|Treatment as Usual|Participants in this group only received services that were part of their substance abuse treatment program
1819237|NCT00722696|Other|physical training|8 weeks of hiking downwards. For the opposite way, a cable car will be used.
1819238|NCT00722709|Drug|Ropivacaine|"In the treatment arm patients will receive 10mls 0.75% ropivacaine diluted to 50mls with saline immediately before closure.
At closure, two small 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump (On-Q pain buster). This pump will contain 270mls of 0.2% ropivacaine. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
1819239|NCT00722709|Drug|0.9% Saline|"In the placebo arm patients will receive 50 ml 0.9% saline into the peritoneum soon after the creation of the laparotomy.
At closure, two 2 mm catheters will be placed in the peritoneal cavity at the site of the operation to infuse local anaesthesia. This will penetrate through the skin once closure is complete. This will be attached to a small infusion pump on-Q pain buster). This pump will contain 0.9% saline. After 68 hours the pump will be stopped and the catheter will be removed in a similar fashion as routine drain removal."
1819240|NCT00722722|Drug|Bortezomib|Velcade given in four-dose cycles intravenously (through a vein).
1819241|NCT00722735|Drug|Finafloxacin|Finafloxacin tablets, 300 mg b.i.d., oral administration; Ciprofloxacin placebo capsule, 1 capsule b.i.d.,oral administration; duration: 3 days
1819242|NCT00722735|Drug|Ciprofloxacin|Finafloxacin placebo, 6 tablets b.i.d., oral administration; Ciprofloxacin capsule, 250 mg b.i.d., oral administration; duration: 3 days
1819243|NCT00722761|Drug|drospirenone and ethinyl estradiol|Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks
1819244|NCT00722761|Drug|Placebo tablet|Placebo tablet (no active drug) given once daily for 24 weeks
1819245|NCT00722774|Biological|H2N2 1960 AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
1819246|NCT00722800|Drug|drospirenone and ethinyl estradiol (YAZ)|1 tablet daily for 24 weeks
1819247|NCT00722800|Drug|Placebo|1 tablet daily for 24 weeks
1819248|NCT00722813|Other|Survey|To determine patient preference for the two tests CT angiography (CTA) and catheter coronary angiography (CCA).
1819249|NCT00722839|Biological|PADRE-CMV fusion peptide vaccine|Given subcutaneously
1819250|NCT00722839|Biological|tetanus-CMV fusion peptide vaccine|Given subcutaneously
1819251|NCT00722839|Drug|agatolimod sodium|Given subcutaneously
1819252|NCT00722852|Drug|ketoprofen in Diractin®|100 mg (b.i.d.)
1819253|NCT00722852|Drug|Placebo|100 mg (b.i.d.)
1819255|NCT00722891|Device|Balafilcon A Lenses with ReNu Multiplus|Balafilcon A lenses using ReNu Multiplus lens solution for 28 days
1819256|NCT00722891|Device|Balafilcon A Lenses with Optifree RepleniSH|Balafilcon A lenses using Optifree RepleniSH lens solution for 28 days
1819257|NCT00722917|Drug|TAK-379|TAK-379 25 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
1819322|NCT00723398|Dietary Supplement|Lovaza|dietary supplement
1819259|NCT00722917|Drug|TAK-379|TAK-379 200 mg, tablets, orally, once daily and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
1819260|NCT00722917|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily and TAK-379 placebo-matching tablets, orally, once daily for up to 12 weeks
1819261|NCT00722917|Drug|Placebo|TAK-379 placebo-matching tablets, orally, and pioglitazone placebo-matching tablets, orally, once daily for up to 12 weeks
1819262|NCT00722930|Drug|Y90 Ibritumomab Tiuxetan|Consolidation with Y90 Ibritumomab Tiuxetan
1819263|NCT00722943|Other|Developmental Massage Therapy|Tactile stimulation and massage will be done by a licensed therapist
1819264|NCT00722943|Other|no intervention|The infant will not be touched by the therapist.
1819265|NCT00722956|Drug|AZD5672|100 mg once daily, 10 days
1819266|NCT00722956|Drug|atorvastatin|one single dose of 40 mg on day 10
1819267|NCT00722969|Drug|sorafenib + erlotinib|sorafenib 400mg b.i.d oral Erlotinib 150 mg o.i.d oral
1819268|NCT00722995|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy is a restrictive procedure for the treatment for morbid obesity
1819269|NCT00722995|Procedure|Gastric Bypass|Laparoscopic gastric bypass is a restrictive and difficult absorption procedure for the treatment of morbid obesity
1819270|NCT00723008|Device|Alpha Stim 100 (Cranial Electrotherapy Stimulation)|cranial electrical stimulation 100 microamps
1819271|NCT00723021|Drug|PF-04191834|30mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets.
1819272|NCT00723021|Drug|PF-04191834|100mg PF-04191834, single dose, oral dispersion + 2 x placebo tablets, single dose.
1819273|NCT00723021|Drug|PF-04191834|2000mg PF-04191834, single dose, oral dispersion + 2 x placebo tables, single dose
1819274|NCT00723021|Drug|zileuton|1200mg, 2 x 600mg tablets, single dose + placebo oral dispersion, single dose.
1819275|NCT00723021|Drug|Placebo|2 x placebo tablets + placebo oral dispersion, single dose.
1819276|NCT00723047|Procedure|Fibrin glue injection in fistula|
1819277|NCT00723060|Drug|escitalopram|escitalopram high dose group (40mg) escitalopram conventional dose group (20mg)
1819278|NCT00723086|Drug|docetaxel (XRP6976)|combined treatment with prednisolone
1819279|NCT00723099|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo umbilical cord blood transplant
1819280|NCT00723099|Drug|Cyclophosphamide|Given IV
1819281|NCT00723099|Drug|Cyclosporine|Given IV
1819282|NCT00723099|Drug|Fludarabine Phosphate|Given IV
1819283|NCT00723099|Other|Laboratory Biomarker Analysis|Correlative studies
1819284|NCT00723099|Drug|Mycophenolate Mofetil|Given IV or PO
1819285|NCT00723099|Radiation|Total-Body Irradiation|Undergo TBI
1819286|NCT00723099|Procedure|Umbilical Cord Blood Transplantation|Undergo umbilical cord blood transplant
1819287|NCT00723125|Drug|Abraxane|Abraxane 100 mg/m2 IV over 30 minutes weekly x 12 weeks
1819288|NCT00723125|Drug|Carboplatin|Carboplatin at AUC 6 over 30 min IV weeks 1,4,7, and 10
1819289|NCT00723125|Drug|Avastin|Avastin 15 mg/kg IV over 30-90 minutes weeks 1,4,7, and 10 (in Cohort 2, omit dose of Avastin on week 10)
1819290|NCT00723151|Behavioral|Milieu Communication Teaching|Communication intervention targeting intentional communication and language skills provided either one hour per week or one hour per day, five days per week
1819291|NCT00723164|Drug|Fentanyl and Midazolam|A combination of fentanyl 0.6 ug/kg and midazolam 9 ug/kg, to which NaCl was added to obtain a volume of 2.5 mL (group FM) injected IV, 5 minutes prior inhalation induction of anesthesia with sevoflurane
1819292|NCT00723164|Drug|NaCl|NaCl 0.9% 2.5 ml intravenous (IV), 5 minutes prior inhalation induction of anesthesia with sevoflurane.
1819293|NCT00723177|Drug|AV411|Low (20 mg), and high dose (40 mg) of AV411 will be administered orally twice a day (BID) for two consecutive weeks
1819294|NCT00723177|Drug|Placebo (PCB)|Placebo drug will be administered orally twice a day (BID) for two consecutive weeks
1819295|NCT00723190|Drug|CLONICEL (Clonidine HCl sustained release)|0.1 mg for 1 week; the dose may be escalated to 0.2 mg/day at week 2, 0.3 mg/day at week 3, and 0.4 mg/day at week 4
1819296|NCT00723203|Drug|panobinostat|40 mg Monday, Wednesday and Friday of every week in a 28 day cycle
1819297|NCT00723203|Genetic|gene expression analysis|Day 1 and day 28 samples
1819298|NCT00723203|Genetic|reverse transcriptase-polymerase chain reaction|Day 1 and day 28 samples
1819299|NCT00723203|Other|laboratory biomarker analysis|Day 1 and day 28 samples
1819300|NCT00723216|Drug|enoxaparin|20 mg twice a day
1819301|NCT00723216|Other|Physical prophylaxis|
1819302|NCT00723229|Drug|acyclovir|Acyclovir 400 mg PO BID for 28 days
1819303|NCT00723242|Drug|Viraferon-peg and Rebetol|
1819304|NCT00723255|Biological|bevacizumab|Given IV
1819305|NCT00723255|Drug|temsirolimus|Given IV
1819306|NCT00723268|Drug|Prednisolone|5MG Prednisolone per day for 3 months
1819307|NCT00723268|Drug|Colchicine|0.5 MG Colchicine per day for 3 months
1819308|NCT00723294|Procedure|cryosurgery|
1819309|NCT00723294|Procedure|therapeutic conventional surgery|
1819310|NCT00723307|Drug|Metformin|White film-coated tablets, 850mg tablet twice daily, 1.5 years duration
1819311|NCT00723307|Drug|Placebo|White coated tablet; one tablet twice daily; 1.5 years duration
1819312|NCT00723320|Drug|Atorvastatin|atorvastatin 10mg/d
1819313|NCT00723320|Behavioral|Aggressive lifestyle intervention|aggressive lifestyle intervention
1819314|NCT00723333|Procedure|Reduced Intensity Conditioning (RIC) Allogenic Transplant|Reduced Intensity Conditioning (RIC) Regimen Allogenic Stem Cell Transplant
1819315|NCT00723346|Biological|GRASPA|50 UI/Kg
1819316|NCT00723346|Biological|GRASPA|100 UI/Kg
1819317|NCT00723346|Biological|GRASPA|150 UI/Kg
1819318|NCT00723346|Drug|native L asparaginase|10000UI/m2, 14 infusions during 4 chemotherapy cycle
1819319|NCT00723359|Drug|BT062|biologic
1819320|NCT00723385|Dietary Supplement|Vitamin D (1000 or 2000 IU/day)|Dose titration beginning with 1000 IU/day and either remaining at 1000 IU/day for weeks 7-12 if normalized D levels at 6 weeks or increasing to 2000 IU/day for weeks 7-12 if levels not normalized at week 6
1819321|NCT00723385|Other|Placebo|Administration of placebo for 12 weeks with repeated D measurements
1819365|NCT00723658|Drug|etoposide|
1819324|NCT00723398|Drug|Raloxifene 30 mg|30 mg orally daily for two years
1819325|NCT00723398|Drug|Lovaza plus Raloxifene|Lovaza 4 gm daily plus Raloxifene 30 mg daily for two years
1819326|NCT00723411|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
1819327|NCT00723411|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
1819328|NCT00723411|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270
1819329|NCT00723424|Drug|AZD5672|50 mg, for 13 days
1819330|NCT00723424|Drug|Digoxin|0.5mg dose
1819331|NCT00723437|Drug|acitretin|Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.
1819332|NCT00723450|Drug|lamictal|Flexible Dosing
1819333|NCT00723463|Procedure|3T MRI scan|Establishing/evaluating apparent diffusion coefficient (ADC) values using a 3T MRI scan to differentiate tumors from normal tissue.
1819334|NCT00723476|Behavioral|Family Centered Advanced Care Planning (FCACP) sessions|FCACP will include three 60- to 90-minute weekly sessions. Sessions consisting of structured conversations with HIV infected adolescents, their proxies, and trained facilitators will aim to enhance quality of life by integrating effective end-of-life (EOL) care and minimizing depression and anxiety. The three sessions will consist of a structured EOL survey, an FCACP interview, and a family problem-solving lesson.
1819335|NCT00723476|Behavioral|Health education control sessions|Health education control sessions will include three 60- to 90-minute sessions and will involve adolescents with HIV/AIDS and their proxies. Topics covered during sessions will include developmental history, planning for the future, and safety tips.
1819336|NCT00723489|Biological|Live Yellow Fever Vaccine (YFV-17D)|
1819337|NCT00723489|Drug|YFV-17D Placebo|
1819338|NCT00723502|Drug|Finafloxacin + Amoxicillin|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Amoxicillin, tablet 1000 mg b.i.d. (1 X 1000 mg tablet), oral administration
1819339|NCT00723502|Drug|Finafloxacin + Esomeprazole|Finafloxacin, tablets, 400 mg b.i.d. (8 X 50 mg tablets), oral administration; Esomeprazole, tablet, 40 mg b.i.d. (1 X 40 mg tablet), oral administration
1819340|NCT00723515|Drug|sodium fluoride|sodium fluoride 5%
1819341|NCT00723515|Drug|sodium fluoride calcium fluoride|sodium fluoride 5% + calcium fluoride
1819342|NCT00723528|Drug|Placebo (CP)|Placebo 0.5 ml and 1.0 ml will be administered subcutaneously (SC) on Weeks 0 and 4 respectively during the controlled period (Weeks 0-12).
1819343|NCT00723528|Drug|Ustekinumab 45 mg (CP)|Ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
1819344|NCT00723528|Drug|Ustekinumab 90 mg (CP)|Ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC on Weeks 0 and 4 during controlled period (Weeks 0-12).
1819345|NCT00723528|Drug|Placebo A (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo A, in which ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
1819346|NCT00723528|Drug|Placebo B (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), the placebo group will be randomized into 2 groups, including Placebo B, in which ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) will be administered SC at Weeks 12, 16, 28, 40, and 52.
1819347|NCT00723528|Drug|Ustekinumab 45 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 45 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 45 mg (0.5 ml) and placebo (1.0 ml) SC at Weeks 16, 28, 40 and 52.
1819348|NCT00723528|Drug|Ustekinumab 90 mg (After CP)|After the controlled period (i.e., during the active drug treatment period [Weeks 12-64]), participants in the ustekinumab 90 mg group will receive placebo (0.5 ml and 1.0 ml) SC at Week 12 followed by ustekinumab 90 mg (1.0 ml) and placebo (0.5 ml) SC at Weeks 16, 28, 40 and 52.
1819349|NCT00723541|Procedure|Computer aided analysis of breast lesions|Tomosynthesis mammography and computer aided analysis of breast lesions to aid in detection of breast cancer.
1819350|NCT00723554|Drug|Iloprost PD-6|Period 1 (PD-6): study period defined as the 14 days prior to the first dose of study iloprost inhalation with PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-6 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day
1819351|NCT00723554|Drug|Iloprost PD-15|"Period 2 (PD-15): study period between the administration of the first dose with PD-15 on Day 1 until Day 28 inclusive.
Period 3 (PD-15): study period from Day 29 until discontinuation of the PD-15. Commercial iloprost inhalation solution delivered using the Power Disc-15 with the I-neb® Adaptive Aerosol Delivery (AAD®) system administered 6 to 9 times per day"
1819352|NCT00723580|Drug|risperidone|Five treatment conditions: 1. Baseline no medication 2. Risperidone .25 mg at bedtime (q.h.s.) x 7 days 3. Risperidone .25 mg twice daily (b.i.d.) 4. Risperidone .25 mg three times a day (t.i.d.) and 5. Risperidone .5 mg three times a day (t.i.d.).
1819353|NCT00723606|Drug|Intramuscular ziprasidone mesylate|The recommended dose is 10 to 20 mg administered as required up to a maximum dose of 40 mg per day. Doses of 10 mg may be administered every two hours; doses of 20 mg may be administered every four hours up to a maximum of 40 mg/day for 3 days.
1819354|NCT00723606|Drug|Intramuscular haloperidol|The haloperidol group will receive an initial intramuscular injection of haloperidol 5mg, following on which 5mg haloperidol may be repeated every 4-8 hours to a maximum of 20 mg /day for 3 days.
1819355|NCT00723632|Biological|peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling, ie, 1.5 μg/kg weekly SC for 48 weeks for participants with hepatitis C virus (HCV) genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
1819356|NCT00723632|Drug|ribavirin|Ribavirin administered in accordance with approved labeling, ie, 800 mg/day for participants <65 kg, 1000 mg/day for participants >65 to <85 kg, and 1200 mg/day for participants >=85 kg, administered orally for 48 weeks for participants with HCV genotype 1 or for 24 weeks for participants with HCV genotype 2, 3.
1819357|NCT00723658|Biological|rituximab|
1819358|NCT00723658|Drug|bortezomib|
1819359|NCT00723658|Drug|carmustine|
1819360|NCT00723658|Drug|cisplatin|
1819361|NCT00723658|Drug|cyclophosphamide|
1819362|NCT00723658|Drug|cytarabine|
1819363|NCT00723658|Drug|dexamethasone|
1819364|NCT00723658|Drug|doxorubicin hydrochloride|
1819368|NCT00723658|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|
1819369|NCT00723658|Procedure|peripheral blood stem cell transplantation|
1819370|NCT00723671|Procedure|MRI|
1819371|NCT00723684|Other|Placebo EEG Neurofeedback|"The placebo EEG-neurofeedback group will get an identical procedure as the real EEG-Neurofeedback, but with feedback on a EEG signal simulation. The placebo group will not be rewarded on their real-time EEG but on a random, simulated EEG; known to be effective for this purpose (Utrecht University, study in progress).
In the protocol selection the electrode position and rewarding versus inhibition of the treatment frequency band or bands will be individually created. The first 30 seconds of the treatment will start on a predetermined fixed threshold value for all treatment subjects."
1819372|NCT00723684|Other|EEG-Neurofeedback|The EEG-neurofeedback group will receive feedback on their real-time EEG-signal (brain activity). The treatment group will be rewarded, by brightening (i.e. not being blackened of) the feedback screen. Rewards will be given to the subjects when their digitally filtered frequency EEG activity meets the criteria in the 'percentage time over threshold' parameter. The 'percentage time over threshold' parameter will be auto-adjusted on the digitally filtered real-time EEG every 30 seconds, and the percentage parameter will be kept as a constant over all participants during the entire study (i.e. not adjusted during treatment based on individual capabilities).
1819373|NCT00723697|Drug|buprenorphine|0.4, 2, or 8 mg sublingual tablets
1819374|NCT00723710|Biological|Intron A (interferon alfa-2b; SCH 30500)|The recommended regimen includes an induction treatment of 5 consecutive days per week for 4 weeks as a 20-minute intravenous (iv) infusion at a dose of 20 million international units per square meter (MIU/m^2). The induction treatment should be followed by a maintenance treatment of 3 times per week for 48 weeks as a subcutaneous (sc) injection at a dose of 10 MIU/m^2. Therapy should be administered for a total of one year unless the disease progresses or the treatment has lead to recurrent unmanageable serious adverse effects.
1819375|NCT00723723|Drug|Statin|Statin
1819376|NCT00723736|Drug|Desloratadine|2.5 ml (1.25 mg) once daily
1819377|NCT00723749|Drug|Buprenorphine/Naloxone|"Sublingual combination tablet containing buprenorphine and naloxone at a ration of 4:1, respectively. It is available in two tablet strengths: 2 mg buprenorphine & 0.5 mg naloxone and 8 mg buprenorphine & 2 mg naloxone.
The only effective and safe use is sublingual administration. SUBOXONE® use will occur on the basis of SPC and is solely aimed at medical-therapeutic necessity."
1819378|NCT00723762|Procedure|Specimen collection|A blood sample and a spot urine sample will be obtained from all eligible patients receiving VPA at the start of the study.
1819379|NCT00723775|Drug|GSK706769 & KALETRA|GSK706769 alone and GSK706769 + Kaletra
1819380|NCT00723788|Device|MRI of the abdomen|Multiple MRI pulse sequences of the abdomen
1819381|NCT00723801|Drug|Atenolol|Atenolol 50mg PO QD
1819382|NCT00723801|Drug|Losartan|Losartan 100mg PO QD
1819383|NCT00723827|Drug|Temozolomide|Administration of temozolomide based on the product labeling.
1819384|NCT00723827|Radiation|Radiotherapy|Radiotherapy given concomitantly with temozolomide for newly diagnosed glioblastoma multiforme.
1819385|NCT00723840|Other|Observational Studies: participants treated according to the real clinical practice.|No intervention was administered to the participants specifically for the purpose this study. Participant could be on any drug therapy.
1819386|NCT00723853|Behavioral|Reach-Out Program, nutritional and exercise program|"This group will participate in the Reach-Out nutritional and exercise program. This includes 14 weekly, group sessions involving both parents and children.
During these sessions, participants will receive hands-on education regarding food and exercise habits. Sample nutrition activities include learning to read nutrition labels on foods, a tour of a grocery store and practicing a recipe substituting low fat for high fat ingredients. Exercise activities involve physical activities appropriate for children and adults, respectively. Session leaders will help subjects set personal goals in the areas of nutrition and physical activity, and follow up on subjects' progress each week at sessions and with telephone calls between sessions. At the end of the 14-week program, subjects will be asked to attend four bi-monthly and 18 monthly follow-up sessions in which subjects will continue to meet as a group to work on goals in the areas of nutrition and exercise."
1819387|NCT00723853|Behavioral|Reach-In Program, standard of care|This group will received standard medical care for their health condition. This includes meeting individually with a dietician to learn about diet, exercise and diabetes. This also includes developing an individualized meal plan.
1819388|NCT00723866|Other|BtxA+mCIMT|The combination group receive BtxA+mCIMT for 2 hours/day, 3 days/week for 3 months.
1819389|NCT00723866|Other|BtxA+ conventional rehabilitation|The control group received for 2 hours/day, 3 days/week for 3 months.
1819390|NCT00723879|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
1819391|NCT00723879|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b and ribavirin will be administered according to the products' labeling.
1819392|NCT00723879|Behavioral|Patient assistance program|"Patient assistance programs will be classified as follows:
medications, including psychiatric medications (antidepressants);
other interventions, including nurse telephone calls and nurse support in the office: and
educational literature about hepatitis C containing information about the disease, mode of transmission, complications, and treatment and treatment drawbacks that will be given to each patient at the start of treatment."
1819393|NCT00723892|Biological|Peginterferon alfa-2b (PegIntron)|Peginterferon alfa-2b (PegIntron) was administered based on the prescribed dose. The average dose for PegIntron was a weekly injection of 1.5 ± 0.3 μg^kg^week
1819394|NCT00723892|Drug|Rebetol (Ribavirin)|Rebetol was administered orally based on the prescribed dose. The average dose for Rebetol was 950 ± 167.2 mg^day
1819395|NCT00723892|Behavioral|Psychotherapy support program|Each site has implemented a psychotherapy support program.
1819396|NCT00723918|Drug|SAB378|SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
1819397|NCT00723918|Drug|methadone|Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
1819398|NCT00723918|Drug|SAB placebo|an inactive substance
1819399|NCT00723918|Drug|Methadone placebo|Methadone placebo
1819400|NCT00723931|Biological|Peginterferon alfa-2b (SCH 54031)|Surveillance will be conducted after administration of peginterferon alfa-2b (administered according to the directions on the products' labeling). PegIntron Injection for surveillance is a weight-based dosing product administered at a dose of 0.5/1.0 ug/kg or 1.5 ug/kg. Administration of treatment is not part of this study.
1819401|NCT00723944|Device|Osseotite Certain Prevail|Root form titanium dental implant
1819402|NCT00723944|Device|Osseotite Certain|Dental implant without the lateralized design
1819403|NCT00723957|Drug|Ixabepilone, 32 mg/m^2|Intravenous (IV) solutions, ixabepilone, 32 mg/m^2
1819404|NCT00723957|Drug|Paclitaxel, 200 mg/m^2|IV solutions, paclitaxel, 200 mg/m^2
1819405|NCT00723957|Drug|Carboplatin (area under the concentration curve [AUC] 6)|Carboplatin (AUC 6) day 1, every 21 days, 6 cycles
1819406|NCT00723970|Drug|Quetiapine Extended Release|Quetiapine XR, 150-300 mg QHS, for 8 weeks
1819407|NCT00723983|Drug|Sumatriptan succinate|Sumatriptan succinate 50 mg taken orally
1819408|NCT00723983|Drug|NP101 Study Patch|NP101 study patch 4 hour application
1819409|NCT00723996|Behavioral|Behavioral Study in Women|A Randomized study to assess the knowledge of womens health related issues
1819410|NCT00724009|Drug|Clofarabine|Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
1819411|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF, Prednisolon|Control group. Therapy with Prednisolon.
1819412|NCT00724022|Drug|Basiliximab, Tacrolimus, MMF|No Prednisolon after 7 days
1819413|NCT00724022|Drug|Tacrolimus, MMF, rATG|Induction therapy: rATG instead of Basiliximab. No Prednisolon.
1819414|NCT00724035|Drug|Midazolam|"Procedural sedation before the execution of the block.
0.03 mg/kg iv bolus"
1819415|NCT00724035|Drug|Ropivacaine|0.75% (wt/vol) solution, 20 ml perineural injection
1819416|NCT00724035|Drug|Fentanyl|50 µg iv bolus prn for pain during surgery, up to 150 µg
1819417|NCT00724035|Procedure|General anesthesia|General anesthesia will be induced if pain during surgery develops which is intractable with iv fentanyl ≤150 µg.
1819418|NCT00724035|Procedure|Axillary brachial plexus nerve block|"Blocks will be performed under high-resolution real-time ultrasound guidance.
Patients will be in the supine position. With the abducted arm flexed 90° at the elbow, the transducer will scan for the axillary artery in its short-axis. Individual nerves will be sought for around the artery.
A 22G, 17°-bevel needle will be advanced in-plane to inject aliquots of local anesthetic around each nerve structure up to the prescribed dose."
1819419|NCT00724035|Procedure|Infraclavicular brachial plexus block|"Blocks will be performed under high-resolution real-time ultrasound guidance.
Patients will be in the supine position. The linear transducer will be initially positioned between the middle and lateral third of the clavicle, scanning on a parasagittal plane.
The axillary artery and veins will then be sought for. We will try to visualize the three cords of the brachial plexus separately, and to inject local anesthetic around each of them. If this is not possible, the needle will be positioned cranially and posteriorly to the artery, and the injection will be made from there. A 20 G, 17°-bevel needle will be used for all blocks."
1819420|NCT00724048|Drug|ACR16 10 mg|ACR16 capsules: 10mg twice daily
1819421|NCT00724048|Drug|ACR16 22.5 mg|ACR16 capsules: 22.5mg twice daily
1819422|NCT00724048|Drug|ACR16 45 mg|ACR16 capsules: 45mg twice daily
1819423|NCT00724048|Other|Placebo|Placebo capsules
1819424|NCT00724061|Biological|Pegylated interferon α-2b|PEG-IFN-α-2b will be administered subcutaneously once a week. The starting dose of PEG-IFN-α-2b will be 1.5μg/kg. Each patient will undergo dose escalation to 3, 4.5, 6, 7.5, and up to 9μg/kg every 2 weeks or to maximum tolerated dose will be allowed. If no dose limiting toxicity (DLT) is observed, the maximum dose reached will be expanded. Once this dose has been given weekly for 2 weeks with no DLT, therapy will continue at this dose for up to 1 year depending on response.
1819425|NCT00724061|Other|Psoralens with ultraviolet light A|Oral psoralen (8-methoxypsoralen, 0.6-1.0 mg/kg) will be taken 1.5 to 2 hours prior to UVA treatment. The initial UVA dosage will be approximately 0.5 to 1.5 J/cm2, and will be increased in increments as determined by skin type and tolerability. PUVA therapy will be given 2-3 times per week until complete remission (CR) is achieved. Afterwards, additional maintenance therapy will be given with a gradual reduction from once a week to every 4-6 weeks up to 1 year after CR was achieved.
1819426|NCT00724061|Other|Narrowband-ultraviolet light B|The initial NB-UVB dose will be 70% of the patient's MED and approximately 0.2 J/cm2 and will be increased by 15% of each subsequent treatment as determined by skin type and/or tolerability. Therapy will be given 3 times per week until complete remission (CR) is achieved. Additional maintenance therapy will be administered while gradually reducing NB-UVB from thrice weekly to once a week. All patients will continue maintenance NB-UVB therapy until 1 year after they have achieved CR.
1819427|NCT00724074|Device|On-Q PainBuster with Bupivacaine|On-Q PainBuster continuous wound infusion analgesia system, using bupivacaine as the local anaesthetic
1819428|NCT00724074|Device|Usual Care|Usual Care
1819429|NCT00724087|Other|5.5-hour bedtime|16 days with sleep allowed only during a 5.5-hour bedtime period at night
1819430|NCT00724087|Other|8.5-hour bedtime|16 days with sleep allowed only during a 8.5-hour bedtime period at night
1819431|NCT00724100|Drug|ALB 109564(a) (12´-methylthiovinblastine dihydrochloride)|Starting dose is 1.2 mg/m2. Standard dose increase, in the absence of limiting toxicity, is 50%. Each dose of ALB 109564(a) will be administered by intravenous infusion once every 3 weeks (21-day cycle) over a period of time up to approximately 30 minutes. Number of cycles: Maximum of 12, until disease progression, or unacceptable toxicity develops. Greater than 12 cycles if disease has not progressed after 12 cycles, with Investigator's and Sponsor's approvals.
1819432|NCT00724113|Procedure|infiltration intra articular|infiltration intra articular at inclusion with XYLOCAINE 1%
1819433|NCT00724113|Procedure|ARTHRO distension plus intensive mobilisation|ARTHRO distension plus intensive mobilisation
1819436|NCT00724139|Device|: APOS biomechanical gait system, Apos - Sports and Medical Technologies Ltd. Hertzlia, Israel|training program utilizing a novel biomechanical system comprising four modular elements attached onto foot-worn platforms which conveys perturbation throughout the gait cycle
1819437|NCT00724152|Behavioral|Cognitive Behavioral Therapy|A psychotherapeutic approach to tinnitus management which includes tinnitus education
1819438|NCT00724152|Behavioral|Tinnitus Education|An audiologic rehabilitative approach to tinnitus education.
1819439|NCT00724165|Behavioral|Intervention|Culturally-modified, individually tailored physical activity print materials
1819440|NCT00724165|Behavioral|Control|Bilingual health education booklets
1819441|NCT00718510|Drug|L-Arginine|3 grams, twice daily, oral administration
1819442|NCT00718523|Drug|AMG 479|Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle
1819443|NCT00718523|Drug|AMG 479 Placebo|Matching placebo administered Day 1 of each 21 day cycle.
1819444|NCT00718536|Drug|Addition of raltegravir 800 mg QD to HAART|Addition of raltegravir 800 mg QD to HAART
1958499|NCT01588990|Drug|Oxaliplatin|Participants will receive oxaliplatin 85 milligrams per square meter (mg/m^2) intravenous (IV) on Day 1 of every 2 weeks cycle during alternative phase A treatment or 130 mg/m^2 on Day 1 of every 3 weeks cycle during Phase A treatment.
1958500|NCT01588990|Drug|Capecitabine|Participants will receive capecitabine 1000 mg/m^2 per oral (PO) twice daily on Days 1-14 of 3 weeks cycle.
1819450|NCT00718562|Drug|AMN107|
1819451|NCT00718575|Procedure|Glucose/Ischemic Preconditioning Pre-treatment|A 20% dextrose+insulin infusion is administered to the liver via the mesenteric vein beginning after cannulation of the mesenteric vein and ending immediately prior to flushing with cold preservation fluid. Also, after completion of the visceral dissection but prior to cross-clamping, ischemic precondition will occur. This involves occluding the portal vein and hepatic artery to stop blood flow for 10 minutes, then restoring blood flow for 10 minutes.
1819452|NCT00718588|Drug|MTRX1011A|Subcutaneous and intravenous single and repeating dose
1819453|NCT00718601|Drug|Imetelstat Sodium (GRN163L)|25% dose escalation infused over 2 hours weekly
1819454|NCT00718614|Procedure|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.|Light will be switched from 0.5µW/cm2/sr to 115µW/cm2/sr.
1819455|NCT00718627|Biological|Human Heterologous Liver Cells|Multiple applications of liver cell suspension for infusion
1819456|NCT00718640|Drug|Dexamethasone|Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).
1819457|NCT00718640|Drug|Bortezomib|Bortezomib 1.3 milligram per meter^2 (mg/m^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.
1819458|NCT00718653|Dietary Supplement|Lutein|Lutein (12 mg/d)
1819459|NCT00718653|Dietary Supplement|Lutein plus green tea extract|lutein (12 mg/d) plus green tea extract (200 mg/d)
1819460|NCT00724178|Dietary Supplement|cholecalciferol plus calcium carbonate|oral calciferol 100,000 IU by mouth bimonthly and calcium carbonate (1 gr) by mouth daily
1819461|NCT00724191|Procedure|MRI|New MRI methods which measure information related to water, blood, and chemical makeup in the brain.
1819462|NCT00724204|Dietary Supplement|follow on formula without probiotics|A follow on formula without probiotics
1819463|NCT00724204|Dietary Supplement|follow on formula with Lactobacillus salivarius CECT5713|follow on formula with Lactobacillus salivarius CECT5713 in a dose of 2x10E8 cfu/day
1819464|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based supplements.
1819465|NCT00724217|Other|Standard Process 21 Day Purification Program (SPPP)|The Standard Process 21 Day Purification Program (SPPP) consists of a controlled food intake regimen of mostly fruit and vegetables with restricted calories, protein and fats plus daily use of herbal and whole food based
1819466|NCT00724230|Drug|PegIntron (peginterferon alfa-2b; SCH 54031)|"PegIntron administered in accordance with approved labeling
Subcutaneous injection once weekly for 24 weeks."
1819467|NCT00724230|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered orally twice daily in accordance with approved labeling. Dosing duration 24 weeks.
1819468|NCT00724243|Drug|Infliximab|Infliximab given in accordance with the local summary of product characteristics
1819469|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 7 days.
1819470|NCT00724256|Drug|ceftibuten|ceftibuten 9mg/kg once a day for 10 days.
1819471|NCT00724269|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
1819472|NCT00724269|Device|ReNu MultiPlus MPS|Multi-Purpose Solution for soft contact lenses
1819473|NCT00724282|Drug|Eszopiclone|Eszopiclone 3 mg by mouth daily at bedtime for 9 days
1819474|NCT00724282|Drug|Placebo|Placebo by mouth daily at bedtime for 9 days
1819475|NCT00724295|Drug|peginterferon alfa-2b|PegIntron powder (reconstituted) administered in accordance with approved labeling; Subcutaneous injection of 1.5 ug/kg once weekly for 48 weeks.
1819476|NCT00724295|Drug|ribavirin|Rebetol capsule administered orally twice daily in accordance with approved labeling (weight based dosing). Dosing duration 48 weeks.
1819477|NCT00724308|Other|Telephone Care Coordination|The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from TeleQuit MH study counselors; and (4) follow-up at 2 and 6 months to check the patient's smoking status.
1819478|NCT00724308|Other|Telephone Care Coordination with state Quitline|"The telephone care coordination program involves the following steps: (1) brief counseling and referral from a mental health provider; (2) prescribing and mailing of smoking cessation medications; (3) proactive multi-call counseling from the patient's state Quitline; and (4) follow-up at 2 and 6 months to check the patient's smoking status."
1873129|NCT01112137|Drug|Clopidogrel|
1819479|NCT00724321|Drug|iloprost|A dose of inhaled iloprost (or placebo) will be given once at baseline and then at altitude. Measurements will be obtained before and after inhalation. Patients will then cross over and be given a dose of placebo (or iloprost)and measurements will be repeated.
1819480|NCT00724334|Drug|SAR302503 (TG101348)|orally administered, once a day
1819481|NCT00724347|Behavioral|Consonant Identification Training|Subjects received psychophysically adaptive, consonant identification training in consonant discrimination on PCs in their homes.
1819482|NCT00724360|Drug|Herceptin (trastuzumab)|Administered as a 4 mg/kg intravenous loading dose followed by 2 mg/kg weekly for at least 2 months and/or until progression
1819483|NCT00724373|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
1819484|NCT00724373|Drug|Ribavirin (SCH 18908)|Peginterferon alfa-2b plus ribavirin will be administered according to the products' labeling.
1819485|NCT00724386|Drug|Paclitaxel|1-hour IV infusion once weekly for 12 to 14 weeks
1819486|NCT00724386|Drug|Vinorelbine|escalating doses administered intravenously over 6-10 minutes for 12-14 weeks
1819487|NCT00724386|Drug|Filgrastim|"daily injections for 6 days beginning on day 2 of second week on study and then every other week (weeks 2, 4, 6, 8, 12).
For the final dose cohort, administration on chemotherapy only weeks, only if dose reduction or dose delay required by subject"
1819488|NCT00724386|Radiation|Radiation|Radiotherapy for 5 consecutive days every other week (weeks 1, 3, 5, 7, 9, 11, 13)starting on same day as first dose of protocol chemotherapy
1819489|NCT00724399|Behavioral|Survey on womens health Issues.|Cardiovascular health.
1819490|NCT00724412|Other|Systane|Dry Eye relief eye drops
1819491|NCT00724412|Other|Optive|Dry Eye relief eye drops
1819492|NCT00724425|Drug|IPI-493|Capsules, Multiple Schedules
1819493|NCT00724451|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b administered in accordance with approved labeling
1819494|NCT00724451|Drug|Ribavirin|Ribavirin administered in accordance with approved labeling
1819495|NCT00724451|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a administered in accordance with approved labeling
1819496|NCT00724464|Biological|PegIntron (peginterferon alfa-2b, pegylated interferon alfa-2b)|Prior to enrollment in the study, PegIntron was to be administered at a dose of 1.5 μg/kg/week subcutaneously in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
1819497|NCT00724464|Drug|Rebetol (ribavirin)|Prior to enrollment in the study, Rebetol was to be administered at a dose of 800-1200 mg/day orally in accordance with approved labeling. Therapy duration varied from 24 to 48 weeks depending on HCV viral load and genotype followed by a 24-week post-treatment follow-up.
1819498|NCT00724477|Drug|INEGY|Ezetimibe 10mg - Simvastatine 20 mg or 40 mg; Tablet - OD; Patient currently treated for INEGY for at least 4 weeks
1819499|NCT00724490|Procedure|Deep Brain Stimulation|Unilateral Deep Brain Stimulation in the right Nucleus Accumbens
1819500|NCT00724503|Drug|Systemic chemotherapy (FOLFOX)|"Oxaliplatin 85 mg/m2, IV infusion, q two weeks
Leucovorin 200 mg/m2, IV infusion, q two weeks
5-Fluorouracil 400 mg/m2, IV bolus, q two weeks
5-Fluorouracil 2.4 g/m2, IV infusion, q two weeks"
1819501|NCT00724503|Device|SIR-Spheres yttrium-90 microspheres|SIR-Spheres microspheres implanted once on the 3rd or 4th day of the first week of the first chemotherapy cycle
1819502|NCT00724503|Drug|Systemic chemotherapy (FOLFOX)|"Oxaliplatin 60 mg/m2,IV infusion, q two weeks for first 3 cycles
Oxaliplatin 85 mg/m2, IV infusion, q two weeks from cycle 4 onwards
Leucovorin 200 mg/m2, IV infusion, q two weeks
5-Fluorouracil 400 mg/m2, IV bolus, q two weeks
5-Fluorouracil 2.4 g/m2, IV infusion, q two weeks"
1819503|NCT00727272|Drug|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered after an overnight fast of at least 10 hours.
1819504|NCT00727272|Drug|Quinine Sulphate Tablets 300 mg|One 300 mg tablet administered after an overnight fast of at least 10 hours.
1819505|NCT00727272|Drug|Quinine Sulfate Capsules 324 mg|One 324 mg capsule administered thirty minutes after the initiation of a standardized, high-fat breakfast.
1819506|NCT00727298|Biological|Infliximab|Infliximab administered at a dose of 3-10 mg/kg at Week 0, Week 2, and Week 6, and every 4-8 weeks thereafter for 24 months for the treatment of chronic inflammatory disease.
1819507|NCT00727311|Biological|PegIntron (peginterferon alfa-2b; SCH 54031) injector|PegIntron administered at a dose 1.5 μg/kg/week, according to the Summary of Product Characteristics (SPC) and approved European labeling
1819508|NCT00727311|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 800-1200 mg/day (on a weight-basis) according to the SPC and approved European labeling
1819509|NCT00727324|Drug|bovine intestinal alkaline phosphatase (BIAP)|30,000U/24h for 7 consecutive days via a duodenal catheter
1819510|NCT00727337|Behavioral|LACE-computer|Computerized Auditory Training
1819511|NCT00727337|Behavioral|PLACEBO-Directed listening|Subjects will be asked to listen to books on tape for 20 minutes a day and answer questions as they go along
1819512|NCT00727337|Behavioral|CONTROL|No specialized treatment will be provided in addition to standard of care audiology treatment provided with the provision of hearing aids
1819513|NCT00727337|Behavioral|Lace-DVD|DVD based Auditory Training
1819514|NCT00727350|Radiation|Fractionated stereotactic body radiation therapy|For centrally located T1 and T2 lesions 4 x 15 Gy over 2 weeks will be delivered. Lesions located peripherally will be treated with 3 x 20 Gy, also delivered within 2 weeks. For both schedules, there should be a minimum of 40 hours and a maximum of 8 days between 2 separate fractions. There should be a maximum of 2 fractions per week.
1819515|NCT00727363|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri DSM 17938 will be administered at a dose of ten to the eighth colony-forming units in 5 drops of a commercially available oil suspension once per day until discharge from the hospital.
1819516|NCT00727363|Dietary Supplement|Placebo|5 drops of an available oil suspension without Lactobacillus reuteri will be given once per day until discharge from the hospital.
1819517|NCT00727389|Behavioral|Physiotherapy|Exercise two days a week for six month
1819518|NCT00727415|Drug|Cyclophosphamide|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
1873130|NCT01112137|Drug|Clopidogrel|
1819519|NCT00727415|Drug|Fludarabine phosphate|All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
1819520|NCT00727415|Drug|Lenalidomide|"All patients will receive six monthly courses of FCL schedule consisting of three days of Fludarabine and Cyclophosphamide administration (d1-d3) combined with 14 days of Lenalidomide administration (d1-d14).
In the first phase of the study, the dose of Lenalidomide given with FC will be gradually escalated to reach the MTD. In the second phase of the study, FC will be given in combination with the Lenalidomide escalated to the MTD or the maximum planned dose."
1819521|NCT00727428|Biological|FluLaval® TF|One IM injection.
1819522|NCT00727441|Biological|GVAX pancreatic cancer vaccine|Given intradermally
1819523|NCT00727441|Drug|cyclophosphamide|Given IV
1819524|NCT00727454|Device|CPAP|Continuous Positive Airway Pressure (CPAP) during sleep for 3 months.
1819525|NCT00727454|Device|No treatment|No treatment
1819526|NCT00727467|Device|Auditory Cueing Device|Each participant will be given an iPod containing an auditory cue in the form of a continuous metronome beat, individualised to the patient's walking frequency (less 10%).Participants will be instructed to listen to the cueing when they are performing any mobility related tasks.
1819527|NCT00727480|Procedure|Ultrasound|Ultrasound scanning of fingertips for assessment of possible imaging modes with Gray scale ultrasound, color flow vascularity imaging, and color flow vascularity imaging before and after exercise.
1819528|NCT00727493|Drug|alendronate once weekly 70mg|alendronate once weekly 70mg, calcium 1000mg and Vitamin D 800 IU daily for 12 months, dental implant
1819529|NCT00727493|Drug|placebo|placebo once weekly; calcium 1000mg and Vitamin D 800 IU daily, dental implant
1819530|NCT00727506|Drug|BIBW 2992|BIBW 2992 once daily
1819531|NCT00727506|Drug|TMZ|TMZ 21/28
1819532|NCT00727506|Drug|BIBW 2992 plus TMZ|BIBW 2992 once daily plus TMZ 21/28 days
1819533|NCT00727519|Dietary Supplement|Pomegranate juice|
1819534|NCT00727519|Dietary Supplement|Placebo|
1958501|NCT01588990|Drug|Bevacizumab|Participants will receive 7.5 mg/kg IV on Day 1 every 3 weeks (Phase A treatment) or 5 mg/kg IV on Day 1 every 2 weeks (Alternative Phase A treatment and Phase B).
1819537|NCT00727545|Other|iron bisglycine chelate|
1819538|NCT00727545|Other|placebo|
1819539|NCT00727558|Device|nelfilcon A|spherical soft contact lens
1819540|NCT00727558|Device|narafilcon A|spherical soft contact lens
1819541|NCT00727571|Other|Observations|This is a non-interventional, observational study; no investigational product is being used
1819542|NCT00727584|Radiation|radiation therapy|Patients undergo external beam radiotherapy
1819543|NCT00727597|Drug|Efavirenz 600mg|"QD regimen of Sustiva (efavirenz 600 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
The intervention may be switched for the following reasons:
To resolve a Grade 3 or 4 Adverse Event
The subject experienced a virologic failure (as defined in section 3.6.2)
The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue
The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
1819544|NCT00727597|Drug|Boosted Lexiva|"Once daily (QD) regimen of Lexiva (fosamprenavir 1400 mg) + Norvir (ritonavir 100 mg) + Epzicom (abacavir 600 mg / lamivudine 300 mg)
The intervention may be switched for the following reasons:
To resolve a Grade 3 or 4 Adverse Event
The subject experienced a virologic failure (as defined in section 3.6.2)
The investigator believes the subject is at a significant risk for failing to comply with the protocol AND the investigator believes a regimen substitution is likely to resolve the compliance issue
The investigator believes there is any other significant safety concern for the subject associated with remaining on the current regimen (e.g., hypersensitivity reaction, increased risk of suicide)"
1819545|NCT00727636|Biological|Gardasil vaccine|standard 0.5 mL dose of Gardasil vaccine given at Day 0, Month 2, and Month 6
1819546|NCT00727649|Drug|Psyllium powder|2 teaspoons with 8 ounces of liquid daily for 28 days (weekly adjusted dose)
1819547|NCT00727649|Drug|Loperamide|1 capsule daily for 28 days (weekly adjusted dose)
1819548|NCT00727662|Other|Iyengar Yoga|The poses and breathing techniques to be used in this study are based on sequences developed by B.K.S. Iyengar for breast cancer survivors who suffer from fatigue. Women will start with simple versions of the poses and progress to more advanced versions over the course of the intervention.
1819549|NCT00727662|Other|Wellness Seminar Series|The Wellness Seminar Series consists of lectures on key topics, followed by group discussion. This series will focus entirely on cancer survivorship, including sessions on quality of life, side effects of cancer treatment, stress, nutrition and psychosocial issues.
1819550|NCT00727675|Behavioral|Integrated Cognitive Behavioral Therapy|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
1819551|NCT00727701|Behavioral|Aftercare summary|A personalized, targeted set of self-care instructions for venous ulcer prevention, including a graphical depiction of patient adherence to self-care goals.
1819552|NCT00727727|Drug|Piribedil|
1819553|NCT00727740|Drug|Indomethacin|Indomethacin 100 mg liquid suspension (25 mg/5 ml) which is 20 cc of suspension is instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the suspension, the catheter is flushed with 5 cc of normal saline.
1819554|NCT00727740|Drug|Placebo suspension|A placebo suspension which is made by the Investigational Drug Service (IDS) by adding the appropriate dye coloring to normal saline so that the appearance is identical to the indomethacin suspension. The placebo solution is also instilled via a Teflon catheter (the end of which is passed through the biopsy channel of the endoscope) and situated into the duodenum. Following instillation of the placebo suspension, the catheter is flushed with 5 cc of normal saline.
1819555|NCT00727753|Drug|Ranibizumab|ranibizumab (0.5 mg) will be injected intraocular
1819556|NCT00727753|Drug|Bevacizumab|Bevacizumab (1.25 mg) will be injected intraocular
1819557|NCT00727753|Other|No treatment|No treatment
1819558|NCT00727766|Drug|Clofarabine|
1821187|NCT00738335|Other|pharmacological study|
1819559|NCT00727779|Behavioral|strength training|eight weeks of progressively increasing resistance training will be done in both groups side-by-side
1819560|NCT00727792|Procedure|MRI -Clinical|MRI done is standard of care
1819561|NCT00727792|Procedure|MRI-Research|MRI includes extra sequences
1819562|NCT00727818|Device|guided bone regeneration|
1819563|NCT00727831|Drug|glucarpidase|
1819564|NCT00727831|Drug|leucovorin calcium|
1819565|NCT00727831|Drug|methotrexate|
1819566|NCT00727831|Other|laboratory biomarker analysis|
1819567|NCT00727831|Procedure|quality-of-life assessment|
1819568|NCT00727831|Radiation|radiation therapy|
1819569|NCT00727844|Drug|Immediate Start Linezolid|
1819570|NCT00727844|Drug|Delayed Start Linezolid|
1819571|NCT00727857|Drug|Pioglitazone and metformin|Pioglitazone 15 mg /metformin 850 mg combination, tablets, orally, twice daily for up to 24 weeks.
1819572|NCT00727857|Drug|Pioglitazone|Pioglitazone 15 mg, tablets, orally, twice daily for up to 24 weeks.
1819573|NCT00727857|Drug|Metformin|Metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
1819574|NCT00727870|Device|Shapes by PolyMem dressing|Shapes by PolyMem dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
1819575|NCT00727870|Device|Shapes by PolyMem Silver Dressing|Shapes by PolyMem Silver dressing on one site compared to antibiotic ointment covered with band-aid type dressing on second site
1819576|NCT00727870|Device|Shapes by PolyMem on one site and Shapes by PolyMem Silver dressing on second site|Shapes by PolyMem dressing on one site. Shapes by PolyMem Silver dressing on other site.
1819577|NCT00727896|Behavioral|Pre-coded messages|Earlier life style modification and existing drug therapy was used and now SMS is added as a tool for reminder
1819578|NCT00727896|Drug|Diabetes Treatment|Life style modification and drug therapy
1819579|NCT00727909|Device|Hearing Aid Treatments|"Hearing aid treatments:
Traditional Custom (TC), Receiver-in-the Aid (RITA) and Receiver-in-the-Ear (RITE)"
1819580|NCT00727922|Drug|Mangafodipir|Mangafodipir (0.5 ml/kg) is administered as a 30 minutes infusion just after each administration of oxaliplatin. The oxaliplatin dose (85 to 100 mg/m²) and the length of the infusion (2 hours) are the same that before the inclusion and modifications are not authorized during all the study participation. During 4 months (8 administrations).
1819581|NCT00727935|Drug|Lidocaïne|
1819582|NCT00727935|Drug|Ropivacaïne|
1819583|NCT00727935|Drug|Placebo|
1819584|NCT00727948|Drug|Aspirin|325 mg tablets, once daily for 45 days
1819585|NCT00727961|Drug|Pegylated Liposomal Doxorubicin hydrochloride|Caelyx Intravenous, 50 mg/m^2 (60 minute infusion) on day 1, every 4 weeks, during 6 cycles
1819586|NCT00727987|Drug|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 152.
1819587|NCT00727987|Drug|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 24.
1819588|NCT00727987|Drug|Methotrexate (MTX)|6 mg/week to 8 mg/week taken orally (by mouth) from at least 4 weeks before the initial investigational treatment to the completion of assessment at Week 52.
1819589|NCT00728000|Drug|Gemcitabine|Gemcitabine 1000mg/m2 IV on day 1 and day 15 over 30mins.
1819590|NCT00728000|Drug|Oxaliplatin|100mg/m2 IV on days 1 and 15 given over 120 mins.
1819591|NCT00728000|Drug|Erlotinib|100mg/day PO on days 1-14 and 15-28
1819592|NCT00728013|Drug|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to intensive statin therapy (atorvastatin, 20 or 40 mg/d, or equivalent dose of other statins)
1819593|NCT00728013|Drug|Atorvastatin|Eligible patients are randomly assigned (1:1 ratio) by center to moderate therapy (atorvastatin, 10 mg/d, or equivalent dose of other statins).
1819594|NCT00728052|Drug|GSK598809|GSK598809 capsules will be available with dose strengths of 5 milligrams and 25 milligrams, administered orally with water.
1819595|NCT00728052|Drug|Placebo|Placebo capsules will be administered orally with water.
1819596|NCT00728065|Dietary Supplement|White Bread|About 100g of white bread consisting of 50g of available carbohydrates, served with 250mL water
1819597|NCT00728065|Dietary Supplement|White bread with added 7.32g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
1819598|NCT00728065|Dietary Supplement|White bread with added 15.58g Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 7.32g Salvia hispanica, served with 250mL water
1819599|NCT00728065|Dietary Supplement|White bread with added Salvia hispanica|About 100g of white bread consisting of 50g of available carbohydrates and 24g Salvia hispanica, served with 250mL water
1819600|NCT00728065|Dietary Supplement|Rice milk|Rice milk containing 50g of available carbohydrates
1819601|NCT00728065|Dietary Supplement|Enriched rice milk containing 7.32g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 7.32g added Salvia hispanica
1819602|NCT00728065|Dietary Supplement|Enriched rice milk containing 15.58g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 15.58g added Salvia hispanica
1819603|NCT00728065|Dietary Supplement|Enriched rice milk containing 24g Salvia hispanica|Rice milk containing 50g of available carbohydrates with 24g added Salvia hispanica
1819604|NCT00728078|Drug|thalidomide|thalidomide 50mg tid for 6 months
1819605|NCT00728091|Drug|Satavaptan|tablets
1819606|NCT00728091|Drug|placebo|tablets
1819607|NCT00728117|Other|feeding|Study infants will receive trophic enteral nutrition (15 ml/kg/day) during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
1819608|NCT00728117|Other|fasting|Study infants will be fasted during the study drug period.The study drug period is defined as the interval between administration of the first dose of ibuprofen or indomethacin and 24 hours after the last dose of ibuprofen or indomethacin.
1819609|NCT00728130|Procedure|neck dissection of at least the ipsilateral sub-level 1B|neck dissection of at least the ipsilateral sub-level 1B
1819610|NCT00728143|Dietary Supplement|Highly viscous polysaccharide enriched biscuits|10 g of highly viscous polysaccharide
1821188|NCT00738335|Radiation|stereotactic radiosurgery|
1819611|NCT00728156|Drug|clopidogrel|75 milligrams, oral, clopidogrel, one tablet daily, for seven days after the baseline chamber study.
1819612|NCT00728156|Drug|placebo|Placebo: Hydroxy methyl cellulose, similar in weight to the active medication 75 mgs, oral tablets, once a day
1819613|NCT00728182|Drug|NA-1|single intravenous dose of 2.6 mg/kg of NA-1 administered as a 10-minute infusion
1819614|NCT00728182|Drug|Placebo|single intravenous dose of 2.6 mg/kg of placebo administered as a 10-minute infusion
1819615|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 10 mg orally twice a day for 12 consecutive weeks.
1819616|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 20 mg orally twice a day for 12 consecutive weeks.
1819617|NCT00728195|Drug|JNJ-37822681|Participants will receive JNJ-37822681 capsule 30 mg orally twice a day for 12 consecutive weeks.
1819618|NCT00728195|Drug|Olanzapine|Participants will receive olanzapine 10 mg capsule alone or in combination with olanzapine 5 mg capsule orally for 6 or 12 weeks.
1819619|NCT00728195|Drug|Placebo|Participants will receive matching placebo capsules orally for 12 weeks.
1819620|NCT00728208|Drug|GSK372475|1.5mg for 28 days
1819621|NCT00728221|Dietary Supplement|Korean Red Ginseng|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: whole root in capsules (3g)"
1819622|NCT00728221|Dietary Supplement|Korean Red Ginseng (Panax ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: total ginsenoside fraction in capsules"
1819623|NCT00728221|Dietary Supplement|Cornstarch|Placebo
1819624|NCT00728221|Dietary Supplement|Korean Red Ginseng (Panax Ginseng)|"Cultivated KRG-B (central body Korean Red Ginseng) obtained from Kyonggi-do Farm, Kyonggi-do Province, Korea.
Dosage form: total polysaccharide fraction (panaxans) in capsules"
1819625|NCT00728234|Device|aEEG recording|weekly recordings with aEEG
1819626|NCT00728247|Procedure|Manual Therapy Techniques|One of the following will be selected(1) soft-tissue stretch, (2) myofascial release, (3) muscle energy, or (4) functional (indirect) method
1819627|NCT00728260|Biological|None administered in this study|N/A in this study
1819628|NCT00728273|Dietary Supplement|worm treatment and multiple micronutrient fortified biscuits|"A single dose of intestinal anthelminthic treatment as orange-flavored chewable tablets containing 400 mg Albendazole (Vidoca, Thephaco, Vietnam) was given. Deworming was repeated with Albendazole for all children at the end of the study (after 4 months).
The composition and amount of nutrients in each serving of fortified biscuit were 6 mg iron, 5.6 mg zinc, 35µg iodine, 300 µg RAE vitamin A, 1.0 mg thiamin, 0.9 mg riboflavin, 1.1 mg vitamin B6, 10.5 mg NE niacin, 1.5 µg vitamin B12, 120 µg folic acid, 28 mg vitamin C, 150 mg calcium, 74 IU vitamin D, 40 mg magnesium, 6.8 µg selenium, 378 mg potassium, 70 mg phosphorus, 3.0 mg pantothenic acid, 2.8 µg vitamin E, 10 µg vitamin K and 18 µg biotin."
1819629|NCT00728299|Drug|PomWonderful Juice|8 oz per day each day for 78 weeks
1819630|NCT00728299|Drug|Placebo juice|8 oz per day for 78 weeks
1819631|NCT00728312|Drug|Aripiprazole|12 week comparison of active medication (aripiprazole 5-15 mg per day) versus Placebo (placebo look-alike 5-15 mg per day)
1819632|NCT00728312|Drug|Placebo|12 week comparison of placebo 5-15 mg per day (pill which contains no active medication) versus active medication (aripiprazole 5-15 mg per day)
1819633|NCT00728325|Behavioral|Supported Employment (SE)|SE(IPS)involves: a vocational rehabilitation employment specialist who is integrated into the clinical treatment team, carries out all phases of the vocational services, provides predominantly community-based services, provides assertive engagement and outreach, has a case load of ≤ 25 clients; engages in rapid job search, individualized placement in diverse and potentially permanent competitive job(s), ongoing work-based vocational assessment, and assistance in finding subsequent jobs if needed with the view that all jobs are positive learning experiences; continuous time-unlimited follow-along supports to provide vocational services; and weekly group supervision with IPS/VRP team and with IPS supervisor/trainer monthly.
1819634|NCT00728325|Behavioral|Standard Vocational Rehabilitation (VRP)|Standard Vocational Rehabilitation (VRP) includes 1) the Vocational Assistance Program (includes routine prevocational testing and evaluation for all patients upon referral to VRP), 2) Vocational Rehabilitation Therapy that operates under the Compensated Work Therapy/Veterans Industries (CWT) and provides a work regimen with monetary incentives derived from contracts whereby participants are paid on a piece rate basis related to their production, and 3) Transitional Work Program (TWP) that includes a temporary work experience either within the VAMC or in community settings (called the Transitional Work External or TWE).
1819635|NCT00728338|Dietary Supplement|Docosahexenoic acid (DHA)|The DHA group received 7.5 g/d DHA oil (DHA 3.0 g/d) which is produced in the microalga Crypthecodinium cohinii.
1819636|NCT00728338|Dietary Supplement|Olive oil|7.5 g olive oil/day
1819637|NCT00728351|Drug|vildagliptin + metformin|
1819638|NCT00728351|Drug|metformin|1000 bid metformin
1819639|NCT00728377|Behavioral|Physical activity|Individually Tailored (IT) Exercise Intervention This intervention is designed to increase the amount of physical activity incorporated into the daily lifestyle of pregnant women, primarily through increased walking, with the ultimate goal of achieving the American College of Obstetricians and Gynecologists (ACOG) exercise goals for pregnant women. These goals are the same as the Surgeon General's Guidelines for physical activity for nonpregnant individuals (30 minutes or more or moderate activity on most days of the week).The intervention includes: 1) individually tailored print-based materials (i.e., individually-tailored reports and stage-matched manuals), 2) self-monitoring materials, and 3) goal setting.
1819640|NCT00728377|Behavioral|Heath & Wellness|The comparison intervention consists of a series of informational booklets published by the American College of Obstetricians and Gynecologists on general issues related to health and wellness during pregnancy. These include alcohol and drug use during pregnancy, easing back pain, as well as the Pregnancy Fitness brochure on the safety of exercise during pregnancy. These booklets are selected to represent high-quality, standard, low-cost, self-help material currently available to the public.
1819641|NCT00728390|Drug|PF-00299804|CP-751,871 at recommended dose on Day 1 and 2 of cycle 1, then on Day 1 every 3 weeks; and PF-00299804 orally at recommended dose once daily.
1819681|NCT00728637|Behavioral|General Educational Materials|Participants in the control group received an educational brochure about heart health at the baseline study visit.
1819642|NCT00728403|Dietary Supplement|American Ginseng (Panax quinquefolius L.) and Korean Red Ginseng (steamed Panax C.A. Meyer)|1.5 grams American Ginseng and 1.5 grams Korean Red Ginseng are to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
1819643|NCT00728403|Dietary Supplement|American Ginseng (Panax quinquefolius L.)|3 grams of American Ginseng is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
1819644|NCT00728403|Dietary Supplement|Wheat Bran|3 grams of Wheat Bran is to be taken in capsulated form. Two capsules are taken with every meal, for a total of 6 capsules per day for 12 weeks
1819645|NCT00728416|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
1819646|NCT00728416|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
1819647|NCT00728429|Behavioral|exercise intervention|24 week program of exercise
1819648|NCT00728442|Device|ONCODOC LOGICIEL|Introduction of a computer-based decision support system in the medical decision process
1819649|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 1: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
1819650|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 2: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
1819651|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 3: (6 subjects active, 2 subjects placebo). Subjects administered NNC 0070-0002-0349 will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
1819652|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 4 for s.c. injection (6 subjects active, 2 subjects placebo)
1819653|NCT00728455|Drug|NNC 0070-0002-0349|Dose level 5 for s.c. injection (6 subjects active, 2 subjects placebo)
1819654|NCT00728455|Drug|placebo|Dose level 1: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
1819655|NCT00728455|Drug|placebo|Dose level 2: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
1819656|NCT00728455|Drug|placebo|Dose level 3: NNC 0070-0002-0349 placebo. Subjects administered placebo will receive a subcutaneous injection. Subjects in the first 3 dose groups will receive two injections: one of randomized treatment (drug or placebo) and placebo
1819657|NCT00728455|Drug|placebo|Dose level 4: NNC 0070-0002-0349 placebo for s.c. injection
1819658|NCT00728455|Drug|placebo|Dose level 5: NNC 0070-0002-0349 placebo for s.c. injection
1819659|NCT00728468|Drug|PF-00299804|PF-00299804: Patients take oral 45 mg PF-00299804 once daily starting on Cycle 1 Day 1 until disease progression or unacceptable toxicities occur. One cycle equals 21 days. Dextromethorphan: Patient take a single 30 mg oral dose of dextromethorphan HBr three days prior to Cycle 1 Day 1, and then on Cycle 2 Day 7.
1819660|NCT00728481|Drug|Esomeprazole|Proton pump inhibitor; Nexium 40mg capsule taken twice daily by mouth for 6 weeks
1819661|NCT00728481|Drug|Budesonide|Corticosteroid therapy; oral viscous Pulmicort Respules 1 gram taken by mouth orally twice daily (mixed with 1 gram packet of Sucralose [Splenda-registered trademark]) for 6 weeks in subjects with negative 24 hour pH studies (without GERD)
1819662|NCT00728494|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|Peginterferon alfa-2b will be administered according to the product's labeling.
1819663|NCT00728494|Drug|Rebetol (ribavirin; SCH 18908)|Ribavirin will be administered according to the product's labeling.
1819664|NCT00728494|Behavioral|Patient Assistance Program|"The patient assistance program includes the following:
Training by physicians or specialized nurses.
Informational materials based on the To beat HCV program.
Management of specific side effects."
1819665|NCT00728507|Drug|Rifapentine, Moxifloxacin, Pyrazinamide, Isoniazid|Rifapentine:150mg tablets, dose = 300mg for subjects <= 45kg and 450mg for those >45kg by mouth once a day for 8 weeks; Moxifloxacin 400mg tablet by mouth once a day for 8 weeks, Isoniazid and Pyrazinamide per standard of care for TB treatment.
1819666|NCT00728507|Drug|Isoniazid, Rifampin, Pyrazinamide, Ethambutol|Administered per standard of care for TB treatment
1819667|NCT00728520|Drug|Azacitidine|Azacitidine 75 mg/m2 daily IV or subcutaneously (SQ) for 5 days, every 4 weeks for a minimum of 4 cycles.
1819668|NCT00728533|Drug|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
1819669|NCT00728533|Drug|Degarelix|Prostate Cancer - Degarelix powder and solvent for suspension for injection. Three-month depot in two dosing regimens.
1819670|NCT00728546|Drug|Isoniazid (Rifinah)|The dose of the re-challenged INH is followed by the results of the genotyping of NAT2 in each patient.
1819671|NCT00728559|Drug|bupivacain 0.5%|trocar site injection
1819672|NCT00728572|Procedure|Logan Basic Technique and Surface EMG|Participant will receive a brief Basic Technique and Surface EMG examination and Basic Technique treatment.
1819673|NCT00728572|Other|Surface EMG|Surface EMG only, no intervention
1819674|NCT00728572|Procedure|Logan Basic Technique Sham|Participants will receive a sham Basic Technique treatment, not indicated by examination.
1819675|NCT00728585|Biological|palifermin|Given IV
1819676|NCT00728585|Other|placebo|Given IV
1819677|NCT00728611|Biological|PRGF|intra auricular injection 6mg
1819678|NCT00728611|Drug|hyaluronic acid|20 mg / 2 ml
1819679|NCT00728611|Drug|placebo|physiological water 3cc + lidocain 3cc
1819680|NCT00728637|Behavioral|Family Passport to Heart Health Program|Participants in this group received personalized heart disease risk factor screening at the baseline study visit. They were taught lifestyle approaches to risk reduction based upon national heart disease prevention guidelines, including the Adult Treatment Panel (ATP) III recommendations for improving blood cholesterol levels with a TLC diet. Participants had regular contact with study staff and will receive individualized feedback throughout the study.
1873131|NCT01112137|Drug|Clopidogrel|
1819682|NCT00728663|Biological|cetuximab|"Cetuximab: 400 mg/m2 initial dose on day 1, then 250 mg/m2 weekly starting on day 8
--- for max. 24 weeks or until progression or unacceptable toxicity ---"
1819683|NCT00728663|Drug|docetaxel|"75 mg/m2 day 1 of a 21 day cycle or 35 mg/m2 day 1,8,15 of a 28 day cycle
--- for max. 24 weeks or until progression or unacceptable toxicity ---"
1819684|NCT00728689|Drug|ST-246 Days 1 - 3|First Intervention is on Days 1 - 3, and includes 6 patients dosed once orally with ST-246 Form I (Arm 1), and 6 patients dosed once orally with ST-246 Form V (Arm 2).
1819685|NCT00728689|Drug|ST-246 Days 11 - 13|Second Intervention is on Days 11 - 13 (after a 3 day post-treatment monitoring and 7 day wash-out period) where the 6 patients previously given ST-246 Form I (Arm 1) are now dosed once orally with ST-246 Form V, and the 6 patients previously given ST-246 Form V (Arm 2) are now dosed once orally with ST-246 Form I.
1819686|NCT00728715|Drug|budesonide-formoterol single inhaler|High dose budesonide:Budesonide (Pulmocort turbuhaler) 400 mcg (2 inhalations bid) Medium dose budesonide plus formoterol (Rilast turbuhaler) 4,5 mcg of formoterol plus 400 mcg of budesonide: 2 inhalations bid
1819687|NCT00728715|Drug|High dose of budesonide|1600 mcg/d of budesonide
1819688|NCT00728715|Drug|A|medium dose of budesonide-formoterol
1819689|NCT00728715|Drug|B|High Dose Inhaled Budesonide
1819690|NCT00728728|Drug|Dietary Supplement: Pregnenolone|Pregnenolone 50mg BID x 14 days, followed by Pregnenolone 150 x 14 days, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial.
1819691|NCT00728728|Dietary Supplement|Placebo|Placebo
1819692|NCT00728754|Device|Dental implant Osseotite Prevail|Root form titanium dental implant
1819693|NCT00728754|Device|Dental implant Osseotite|root form titanium dental implant
1819694|NCT00728767|Other|Brief intervention|"The intervention consists of a brief conversation based on the principles of motivational interviewing, including Rollnicks scales to assess the motivation and importance for change. The intervention has duration of about 10 minutes and qualifies as a hybrid between a minimal intervention and a brief intervention.
The intervention also consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol above recommended limits, and a sheet about local alcohol treatment possibilities.
The Intervention group is also offered a brief telephone follow up call 4 weeks later. The purpose of this is to maintain the participant's motivation to reduce drinking.
Employees had been instructed to ask these questions during the intervention: What are you already doing to restrain your drinking? And What can you do more?"
1819695|NCT00728767|Other|Control group|The intervention consists of two leaflets ('Good advice about drinking less' and 'Learn more about alcohol') on the harmful in having an alcohol use above the recommended limits, and a sheet about local alcohol treatment possibilities.
1819696|NCT00728780|Drug|ABT-143|once
1819697|NCT00728780|Drug|ABT-335 and rosuvastatin|once
1958502|NCT01588990|Drug|Leucovorin|Participants will receive leucovorin 400 mg/m^2 IV on Day 1 every 2 weeks. Investigators may elect to chose low dose of leucovorin (either 20 mg/m^2 or 50 mg total dose).
1819699|NCT00728819|Device|Tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
1819700|NCT00728819|Device|Non-tapered PICC|Standard peripheral central catheter placement in the Brachial, Basilic or Cephalic veins
1819701|NCT00728832|Drug|DepoDur (extended-release epidural morphine)|DepoDur with on demand boluses of IV fentanyl PCA
1819702|NCT00728845|Biological|bevacizumab|Only patients eligible for bevacizumab will receive bevacizumab. Dose is at 15 mg/kg on day 1 of each cycle.
1819703|NCT00728845|Drug|carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel
1819704|NCT00728845|Drug|hydroxychloroquine|200 mg orally BID (total daily dose of 400 mg)
1819705|NCT00728845|Drug|paclitaxel|Dose of 200 mg/m2 IV on day 1 of each cycle
1819706|NCT00728871|Procedure|peripheral blood isolation|To isolate serum from patient peripheral blood to test the titer of HPV infection and cytokine expression
1819707|NCT00728897|Drug|GSK598809 new formulation|GSK598809 new formulation will be available as an immediate release capsule with a single dose of 100 milligrams, administered orally with 240 milliliters of water.
1819708|NCT00728897|Drug|GSK598809 old formulation|GSK598809 old formulation will be available as an immediate release capsule with a single dose of 25 milligrams, administered orally with 240 milliliters of water.
1819709|NCT00728910|Drug|Atorvastatin|10 mg QD for 4 weeks
1819710|NCT00728910|Drug|ABT335|135 mg QD added to atorvastatin for 8 weeks
1819711|NCT00728910|Drug|ER Niacin|2000 mg QD added to atorvastatin and ABT335 for 10 weeks
1819712|NCT00728923|Drug|NPL-2003|Minocycline (NPL-2003) daily for 12 weeks
1819713|NCT00728936|Drug|IMO-2125|IMO-2125 is a synthetic DNA-based agonist of Toll-like receptor 9 (TLR9), TLR9 is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system
1819714|NCT00728936|Drug|placebo|saline placebo
1819715|NCT00728949|Biological|IMC-A12 (cixutumumab)|10 mg/kg I.V.
1819716|NCT00728949|Drug|tamoxifen|Daily 20 mg, oral
1819717|NCT00728949|Biological|Anastrozole|Daily 1 mg, oral
1819718|NCT00728949|Biological|Letrozole|Daily 2.5 mg, oral
1819719|NCT00728949|Drug|Exemestane|Daily 25 mg, oral
1819720|NCT00728949|Drug|Fulvestrant|Monthly 250 mg, intramuscularly
1819721|NCT00728988|Drug|Atorvastatin|80mg 12 hours pre-Percutaneous Coronary Intervention (PCI), 40mg 2 hours pre-PCI and 40mg daily after PCI for 30 days.
1819722|NCT00728988|Drug|Atorvastatin|40mg daily after PCI for 30 days.
1819723|NCT00729001|Biological|Human Rotavirus Vaccine - two different formulations|Two oral doses
1819724|NCT00729001|Biological|Prevnar|Three-dose intramuscular injection (US subjects only)
1819725|NCT00729001|Biological|IPOL|Two-dose intramuscular injection (US subjects only)
1819726|NCT00729001|Biological|Infanrix|Three-dose intramuscular injection (US subjects only)
1819727|NCT00729001|Biological|OmniHIB|Three-dose intramuscular injection (US subjects only)
1819728|NCT00729001|Biological|Pentacel|Three-dose intramuscular injection (Canada only)
1819777|NCT00729391|Behavioral|VCT Only|Participants in this group will receive VCT only.
1819729|NCT00729027|Drug|25 mg/day AVE5530|"one tablet in the evening with dinner
in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
1819730|NCT00729027|Drug|50 mg/day AVE5530|"one tablet in the evening with dinner
in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
1819731|NCT00729027|Drug|placebo|"one tablet in the evening with dinner
in addition to statin treatment (HMG-CoA Reductase Inhibitors)"
1819732|NCT00729040|Behavioral|Stepping Up to Health|Internet-mediated walking program with pedometers, goal-setting and tailored messaging
1958503|NCT01588990|Drug|5-Fluouracil|Participants will receive 5-fluouracil loading dose of 400 mg/m^2 IV on Day 1 followed by 2400 mg/m^2 continuous IV infusion over 46 hours Day 1.
1819734|NCT00729079|Behavioral|DPP|"The primary outcome measure is weight loss with a goal of 7% of initial weight.
Secondary outcomes are adherence to behavior changes:
Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week
Fat intake less than 25% and saturated fat less than 10%
Fiber intake of at least 25 grams per day
Fasting blood sugar < 100 mg/dL
Absence of tobacco use"
1819735|NCT00729079|Behavioral|DPP|"The primary outcome measure is weight loss with a goal of 7% of initial weight.
Secondary outcomes are adherence to behavior changes:
Exercising a minimum of 150 minutes per week at a moderate level to maintain an energy expenditure of 700 kcals per week
Fat intake less than 25% and saturated fat less than 10%
Fiber intake of at least 25 grams per day
Fasting blood sugar < 100 mg/dL
Absence of tobacco use"
1819736|NCT00729118|Drug|lenalidomide|combined with Vorinostat (SAHA) days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
1819737|NCT00729118|Drug|vorinostat|Vorinostat (SAHA) will be administered orally beginning at dose level 1 starting day +90 ±6 days after HSCT for days 1 and 15-21 of a 28-day cycle combined with lenalidomide days 1-21 of a 28-day cycle until progression or clinically significant toxicity.
1819738|NCT00729131|Drug|Etanercept inhibition of ozone-induced airway hyper-responsiveness.|Single dosage of etanercept(50 mg, subcutaneous) given 2 days prior to a laboratory ozone exposure.
1819739|NCT00729157|Radiation|Fludeoxyglucose F-18|Correlative studies
1819740|NCT00729157|Other|Laboratory Biomarker Analysis|Correlative studies
1819741|NCT00729157|Other|Pharmacological Study|Correlative studies
1819742|NCT00729157|Procedure|Positron Emission Tomography|Correlative studies
1819743|NCT00729157|Biological|Ziv-Aflibercept|Given IV
1819744|NCT00729170|Dietary Supplement|Supplementation of milk (35% more calcium)|The supplement provides 1000 mg of calcium and 250 kcal daily.
1819745|NCT00729183|Drug|Odanacatib|Odanacatib 50 mg tablets, taken orally once weekly for 24 months.
1819746|NCT00729183|Drug|Placebo|Matching placebo tablets to odanacatib taken orally once weekly for 24 months.
1819747|NCT00729183|Drug|Vitamin D3|Vitamin D3 tablets (5600 IU) taken orally once weekly for 24 months.
1819748|NCT00729183|Drug|Calcium supplement|Calcium supplement 500 mg tablet taken orally once daily (up to ~1200 mg total) for 24 months.
1819749|NCT00729196|Behavioral|Lifestyle Modification|Weekly group therapy for 20 weeks, followed by bi-weekly group therapy for 20 weeks
1819750|NCT00729209|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
1819751|NCT00729209|Drug|Placebo; oral|matching placebo
1819752|NCT00729222|Drug|Comparator: Placebo|rolofylline placebo IV infusion over 4 hours.
1819753|NCT00729222|Drug|rolofylline|rolofylline 30 mg IV infusion over 4 hours.
1819754|NCT00729235|Device|Ovatio CRT 6750|"Slow VT zone programmed as a Monitoring zone (Monitoring arm)"
1819755|NCT00729235|Device|Ovatio CRT 6750|Slow VT zone programmed with ATP therapies (therapy arm).
1819756|NCT00729261|Procedure|extubation|Brian injured patients that remained intubation solely because of a depressed level of consciousness were randomized into immediate extubation or delayed extubation until their level of consciousness improved.All patients met standard ventilatory, and airway criteria for extubation.
1819757|NCT00729261|Procedure|continued intubation|patients remain intubated until their Glasgow coma scores improve to greater than 8.
1819758|NCT00729274|Drug|normal saline solution|Two 4ml nebulizations with 30 minute interval
1819759|NCT00729287|Dietary Supplement|selenium|Given orally
1819760|NCT00729287|Other|placebo|Given orally
1819761|NCT00729300|Drug|placebo|placebo daily
1819762|NCT00729300|Drug|disulfiram|250mg daily
1819763|NCT00729313|Drug|Lanreotide microparticles|
1819764|NCT00729313|Drug|Placebo|
1819765|NCT00729326|Drug|exenatide|subcutaneous injection (5mcg or 10mcg), twice a day
1819766|NCT00729326|Drug|sitagliptin|oral administration (100mg), once a day in the morning
1819767|NCT00729326|Drug|placebo|subcutaneous injection (5mcg or 10mcg), twice a day
1819768|NCT00729326|Drug|placebo|oral administration (100mg), once a day in the morning
1819769|NCT00729339|Drug|mosapride for the first month and placebo for the 2nd month|lansoprazole 30 mg once per day for 2 months mosapride 5 mg thrice per day, for the first month placebo thrice per day, for the second month
1819770|NCT00729339|Drug|placebo for the first and mosapride for the second month|lansoprazole 30 mg once per day for 2 months placebo thrice per day, for the first month mosapride 5 mg thrice per day, for the second month
1819771|NCT00729365|Drug|Ramipril|"ACE inhibitor known as Ramipril
Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into this group and given an ACE inhibitor (study medication). Therefore, the Non-Dippers groups II and III will be randomized to receive either drug or placebo."
1819772|NCT00729365|Drug|Placebo|Dippers (category of subjects with a nighttime dip in blood pressure) will all be given Placebo. Control group.
1819773|NCT00729365|Drug|Placebo|"Subjects with nighttime blood pressure that does not drop during the night (non-dippers) maybe randomized into the control group and given Placebo."
1958504|NCT01588990|Drug|Irinotecan|Participants will receive irinotecan 180 mg/m^2 IV on Day 1 every 2 weeks.
1819775|NCT00729391|Behavioral|Woman-Focused Intervention (Women's Health CoOp)|Participants in this group will receive VCT and participate in two group sessions of the woman-focused intervention.
1819776|NCT00729391|Behavioral|Nutrition (Attention-Control)|Participants in this group will receive VCT and participate in two group sessions of the nutrition intervention.
1819778|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+2.1mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles)
1819779|NCT00729404|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|transdermal patch: 0.55mg EE+1.05 mg GSD; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles
1819780|NCT00729430|Drug|Omega-3 Fatty Acids (Fish Oil Supplements)|4 grams of omega-3 fatty acids taken orally once per day for 6 months
1819781|NCT00729430|Drug|Placebo|Placebo tablets taken orally once per day for 6 months
1819782|NCT00729443|Drug|AZD3241|single oral dose
1819783|NCT00729443|Drug|Placebo|
1819784|NCT00729456|Other|Education|Patients receive a single session, one-to-one workshop (carers may be included if appropriate) in their own home, lasting 60 - 120 minutes.
1819785|NCT00729469|Drug|Ospemifene 60 mg|60 mg/day oral dose of ospemifene for 12 weeks - from Visit 2 (Randomization, Day 1) to Visit 4 (Week 12)
1819786|NCT00729469|Drug|Placebo|
1819787|NCT00729469|Drug|Non-hormonal vaginal lubricant|Vaginal lubricant should be used as needed
1819788|NCT00729482|Drug|RAD001|RAD001 (everolimus) 10mg daily administration orally until disease progression and/or intolerability
1819789|NCT00729495|Drug|celecoxib|dose form
1819790|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 2X 4 administrations 2 weeks apart
1819791|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 4 administrations 2 weeks apart
1819792|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 4 administrations 4 weeks apart
1819793|NCT00729508|Biological|Cat-PAD|Cat-PAD dose 1X 8 administrations 2 weeks apart
1819794|NCT00729508|Biological|Cat-PAD|Placebo
1819795|NCT00729521|Other|facilitative system|The facilitative system links communities with academic partners to provide communities with the skills and resources needed to help facilitate the community health improvement process. The system identifies what assets are available within communities, as well as the skills and resources needed to work through the community health improvement process. The facilitative system will then provide technical assistance, best practices guides, and direct consultation in carrying out all phases of the community health improvement process. This information is designed to increase community capacity in community assessment, coalition development, accessing and interpreting local injury prevention data, searching and selecting evidence-based research, and program planning and evaluation.
1819796|NCT00729521|Other|Standard Program|"a Standard Program group receiving modest funding to implement an evidence-based fall prevention program in their local community;"
1819797|NCT00729547|Behavioral|Neurofeedback|enhance relative activity level of left frontal activity
1819798|NCT00729547|Behavioral|Psychotherapy placebo|These sessions consisted of additional assessment, interpretation of the test results and providing information on course and treatment of mood disorder.
1819799|NCT00729560|Drug|Flutamide|250 mg twice daily for 4 weeks
1819800|NCT00729560|Drug|Placebo|Placebo twice daily for 4 weeks
1819801|NCT00729573|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg/300 mg tabletas a part of MTN-003
1819802|NCT00729573|Drug|Emtricitabine/tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
1819803|NCT00729573|Drug|Tenofovir disoproxil fumarate|300 mg tablet as a part of MTN-003
1819804|NCT00729573|Drug|Tenofovir disoproxil fumarate placebo|placebo tablet as a part of MTN-003
1819805|NCT00729586|Other|Laboratory Biomarker Analysis|Correlative studies
1819806|NCT00729586|Drug|Megestrol Acetate|Given PO
1819807|NCT00729586|Drug|Tamoxifen Citrate|Given PO
1819808|NCT00729586|Drug|Temsirolimus|Given IV
1819809|NCT00729599|Drug|Cetylpyridinium chloride|Cetylpyridinium chloride during 21 consecutive days.
1819810|NCT00729612|Drug|carboplatin|
1819811|NCT00729612|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1819812|NCT00729612|Genetic|protein expression analysis|
1819813|NCT00729612|Other|immunoenzyme technique|
1819814|NCT00729612|Other|immunohistochemistry staining method|
1819815|NCT00729612|Other|laboratory biomarker analysis|
1819816|NCT00729625|Device|robotic device|"The device has a small air muscle that when activated will slowly lift their fingers and wrist from your resting wrist position. This device is classified as a non-significant risk device by the FDA (see attached letter dated 1-15-05). The patient should not experience any pain or discomfort during this stretching activity. If they do experience any pain or discomfort they can activate a stop switch located on the control box with their unimpaired hand."
1819817|NCT00729638|Drug|RAD001|Dose levels will change: Taken orally either every other day for the first three weeks of each cycle or taken every day for the first three weeks of each cycle.
1819818|NCT00729638|Drug|lenalidomide|Dose level will vary: taken orally 30-60 minutes after taking RAD001 every day for the first three weeks of each cycle.
1819819|NCT00729651|Drug|alendronate sodium (+) cholecalciferol|Alendronate sodium/Cholecalciferol; tablet, once weekly, for 16 weeks
1819820|NCT00729651|Drug|Comparator: Alendronate sodium (Fosamax)|Alendronate sodium; tablet, once weekly, for 16 weeks
1819821|NCT00729651|Dietary Supplement|Comparator: Calcium|500 mg oral tablet calcium once daily, for 16 weeks
1819822|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 0.1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
1819823|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 0.3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
1819824|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 1 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
1819825|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 3 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
1819826|NCT00729664|Biological|Anti-PDL-1 antibody|Solution, Intravenous, 10 mg/kg, Every 14 days, 3 doses per each cycle of 42 days, 16 cycles/48 doses depending on response
1819869|NCT00729846|Drug|Bevacizumab|Patients will receive intravitreal bevacizumab (1.25mg) on same day following photodynamic therapy.
1819908|NCT00730067|Drug|placebo|tablet with Laetose mono hydrat, talc,Potato tarch, Gelatin, Magnesium stearate.
1819827|NCT00729690|Drug|Pregabalin|"Group 1 (n=16, multi-dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery and then repeat 150 mg doses at 12 and 24 hours after initial dose.
Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2."
1819828|NCT00729690|Drug|Pregabalin|Group 2 (n=16, single dose pregabalin): patients receive pregabalin 150 mg orally 1 hour prior to surgery, and then placebo doses at 12 and 24 hours after initial dose.
1819829|NCT00729690|Drug|Placebo|Group 3 (n=16, placebo): patients receive matching placebo at the same 3 time points as Groups 1 and 2.
1819830|NCT00729703|Device|Ovatio DR 6550|Dual-chamber ICD therapy with minimized ventricular pacing
1819831|NCT00729703|Device|OVATIO DR 6550|Single-chamber device therapy with settings which are common in clinical practice.
1819832|NCT00729716|Biological|BioCart™II|A cartilage biopsy will be harvested from patients during arthroscopy and used for chondrocyte isolation, culture and future implantation. Subjects will also have about 80 ml venous blood drawn for autologous cell culture medium. Two-four weeks following biopsy harvest, BioCart™II will be implanted into the cartilage defect after careful debridement via miniarthrotomy.
1819833|NCT00729716|Procedure|Microfracture|MF procedure will be carried out according to accepted practice. After careful debridement multiple perforations, or microfractures, are made in the subchondral bone using an awl. The released bone marrow forms a clot at the lesion site which is an enriched environment for new tissue formation. With the subject's consent a cartilage biopsy will be taken (at least 150 mg) and about 80 ml venous blood withdrawn. This will be used for chondrocyte culture and cryopreservation in case a later BioCart™II implantation is required after failure of the microfracture procedure.
1819834|NCT00729729|Drug|PCA|Placebo tablet, once
1819835|NCT00729729|Drug|PCA|PO, 700mg, once
1819836|NCT00729729|Drug|PCA|PO, 1000mg, once
1819837|NCT00729742|Drug|Comparator: erlotinib + dalotuzumab|"Part II: All patients will receive 1 week of erlotinib 150 mg tablets per day.
Arm 1: Patients who experience a PET response will continue on erlotinib monotherapy until disease progression.
Arm 2: Patients who fail to receive a PET response will continue to take erlotinib in combination with dalotuzumab 10 mg/kg IV infusion once weekly. At the time of disease progression, patients on erlotinib monotherapy will be offered to crossover to dalotuzumab 10 mg/kg IV infusion once weekly in combination with erlotinib."
1819838|NCT00729742|Drug|Comparator: erlotinib monotherapy|Part I: All patients will receive erlotinib 150 mg tablets per day until disease progression.
1819839|NCT00729755|Dietary Supplement|Creatine monohydrate|In addition to 10-20mg escitalopram, the subjects will be given total 3 gram of creatine (500mg/capsule) a day in first week and then, 5 gram a day in the rest of the weeks.
1819840|NCT00729755|Dietary Supplement|Placebo|In addition to 10-20mg escitalopram, the subjects will be given total 6 capsules of placebo (equal quantities to those of creatine group) a day in first week and then, 10 capsules a day in the rest of the weeks.
1819841|NCT00721552|Drug|Sitagliptin 100 mg|28 days administration of 100 mg daily
1819842|NCT00721552|Drug|Prednisolone 30 mg|14 days administration of 30 mg daily
1819843|NCT00721552|Drug|Sitagliptin-placebo|28 days administration once daily
1819844|NCT00721552|Drug|Prednisolone-placebo|14 days administration once daily
1819845|NCT00721565|Behavioral|Exercise Behavior Change|attend 12 supervised exercise sessions, attend 6 group sessions with psychologist, attend 3 counseling sessions with exercise specialist
1819846|NCT00721578|Drug|voriconazole|Patients must have received (in the Intensive Care Unit [ICU] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection. The decision regarding choice of antifungal agent would lie with the treating physician and will necessarily precede and be independent of the decision to enroll a patient into the study.
1819847|NCT00721604|Drug|fluid administration|two consecutive infusions of 6% hydroxyethyl starch at the dosage 7 ml/kg over 30 minutes (total 14 ml/kg in 60 minutes)
1819848|NCT00721617|Other|Intralipid 20%|Lean and obese normotensive subjects will receive Intralipid 20% infusion. Intralipid is an oil-in-water emulsion derived from egg phospholipids, soybean, and glycerol. The Intralipid 20% long-chain triglyceride emulsion contains: 200 g of soy bean oil; 12 g of egg yolk; 25 g of glycerol. The emulsion is composed of the following free fatty acids (FFAs): linoleic acid: 50%, oleic acid: 26%, palmitic acid: 10%, stearic acid: 9%, egg yolk, phospholipids: 3.5% It will be given intravenously at 20 ml/hr (96 g/24 h) for 24 hours.
1819849|NCT00721617|Other|Normal Saline|Lean and obese normotensive subjects will receive normal saline at 20 ml/hr for 24 hours.
1819850|NCT00721617|Other|Oral fat load|Lean and obese normotensive subjects will receive an oral fat load at 96 g/24hr. The oral liquid fat load will be given in equal amounts (16 g) every 4 hours (total 96 g over 24 hours).
1819851|NCT00729768|Drug|basiliximab|2 intravenous doses
1819852|NCT00729768|Drug|efalizumab|Subcutaneous repeating dose
1819853|NCT00729768|Drug|mycophenolate mofetil|Oral repeating dose
1819854|NCT00729768|Drug|corticosteroids|Repeating doses
1819855|NCT00729768|Drug|cyclosporine|Oral repeating dose
1819856|NCT00729781|Device|Polyester Implants|Three polyester (PET) implants will be implanted in each side of the nose affected by external NVC. See the detailed description for information about the implant procedure.
1819857|NCT00729794|Drug|Vasopressin, Epinephrine, Methylprednisolone, Hydrocortisone|"Combination Treatment
Administration of vasopressin, epinephrine, and methylprednisolone during CPR, and of stress dose hydrocortisone after CPR"
1819858|NCT00729794|Drug|Standard CPR Protocol with Epinephrine and two Placebos|Patients receive advanced life support according to the Guidelines for Resuscitation 2005
1819859|NCT00729807|Drug|pentamidine|
1819860|NCT00729807|Genetic|gene expression analysis|
1819861|NCT00729807|Genetic|polymerase chain reaction|
1819862|NCT00729807|Genetic|western blotting|
1819863|NCT00729807|Other|bioluminescence|
1819864|NCT00729807|Other|immunoenzyme technique|
1819865|NCT00729807|Other|immunohistochemistry staining method|
1819866|NCT00729807|Other|laboratory biomarker analysis|
1819867|NCT00729833|Drug|CP-751,871|CP-751,871 IV, every 3 weeks
1819868|NCT00729833|Drug|Sunitinib|Sunitinib - daily dosing
1819870|NCT00729846|Device|verteporfin photodynamic therapy reduced fluence|Patients will receive combination verteporfin photodynamic therapy with stand fluence [600mW/cm2].
1819871|NCT00729846|Device|verteporfin photodynamic therapy standardfluence|Patients will receive combination verteporfin with photodynamic therapy at standard fluence [600mw/cm2].
1819872|NCT00729859|Drug|Acyline|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + placebo Testosterone gel daily for 28 days + placebo oral anastrozole pill daily for 28 days
1819873|NCT00729859|Drug|Acyline + Testosterone gel|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + placebo oral pill 1 mg daily for 28 days
1819874|NCT00729859|Drug|Acyline + testosterone gel + anastrozole|Acyline 300 μg/kg injections every two weeks (2 doses) for 28 days + Testosterone gel 100 mg daily for 28 days + oral anastrozole pill 1 mg daily for 28 days
1819875|NCT00729872|Biological|AG011|Capsules (low, mid or high dose), twice daily for 28 days, combined with Enema (low, mid or high dose respectively), once daily for 28 days.
1819876|NCT00729872|Other|Placebo|Capsules (matching placebo for low, mid or high dose), twice daily for 28 days, combined with Enema (matching placebo for low, mid or high dose respectively), once daily for 28 days.
1819877|NCT00729885|Device|Goggle with 20 degree error|The Vertigone Goggle is modified such that the head positions and visual feedback indicators are offset 20° from the classic Epley positions.
1819878|NCT00729885|Device|Optimized Goggle|The classic Epley maneuver involves 3 head positions: 1) the patient supine, the neck is extended 20°and the head turned 45° towards the affected ear, 2) the patient rotates his head 90° to the contralateral side, with the final head position 45° from vertical, 3) the patient turns his head 135° towards the floor on the contralateral side. For the classic Epley maneuver, the goggle coach ball markings will be set for correct positioning.
1819879|NCT00729898|Drug|biphasic insulin aspart 30|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1819882|NCT00729924|Drug|Raltegravir|400mg orally every 12 hours for 7 days
1819883|NCT00729937|Drug|Cephalexin|500 mg, four times per day.
1819884|NCT00729937|Drug|Clindamycin|300 mg, four times per day.
1819885|NCT00729937|Other|Placebo|Placebo tablet administered orally.
1819886|NCT00729937|Drug|Trimethoprim-sulfamethoxazole|4 single strength Trimethoprim/Sulfamethoxazole (TMP/SMX), 80 mg/400 mg each, twice per day.
1819887|NCT00729950|Biological|MDX-010|Subjects will be treated with transfectoma-derived MDX-010 at 2.8 or 5 mg/kg/dose, or with hybridoma-derived MDX-010 at 3 mg/kg/dose administered on Days 1, 57, and 85. The 2.8, 3, and 5 mg/kg dosage cohorts may be initiated concurrently. Additionally, 6 subjects per cohort will receive single doses of transfectoma-derived MDX-010 at 7.5, 10, 15, and 20 mg/kg.
1819888|NCT00729963|Drug|Sibutramine|The first group received sibutramine 10 mg for the first 4 weeks, at which time consideration of increasing dosage to 15 mg was re-evaluated in the case of insufficient weight loss (< 1.8 kg) over the first month of treatment.
1819889|NCT00729963|Device|CPAP|
1819890|NCT00729976|Drug|Ibuprofen suppository|5-10mg/Kg of ibuprofen
1819891|NCT00729976|Drug|Ibuprofen Suspension|5-10mg/Kg
1819892|NCT00729989|Procedure|Gastric suctioning|The stomach will be suctioned shortly following birth with an orogastric tube
1819893|NCT00730002|Procedure|Magnetic Resonance Angiography (MRA)|As part of the Magnetic Resonance(MR) scan, you will need to lie still on a padded MR table inside the MR machine for about 15 minutes at a time while MR studies are being performed on you. The total time for the clinical portion of the MR study is approximately 35-40 minutes and there will be an additional 30 minutes for the research related MR studies. The total time you will spend on the MR table for this research will seldom be more than one hour.
1819894|NCT00730002|Procedure|Magnetic resonance imaging|MR spectroscopy
1819895|NCT00730002|Procedure|MRA|MRA of the brain
1819896|NCT00730002|Procedure|MRA|
1819897|NCT00730002|Procedure|diffusion Imaging|MRA of the Brain
1819898|NCT00730002|Procedure|perfusion imaging.|MRA of the brain
1819899|NCT00730015|Drug|Matching Placebo|Oral, once daily
1819900|NCT00730015|Drug|Linaclotide|Oral, once daily
1819901|NCT00730028|Drug|Trimethoprim-sulfamethoxazole|Trimethoprim-sulfamethoxazole (TMP-SMX) will be administered orally at a dose of 160 mg TMP and 800 mg SMX (as 2 single strength over encapsulated tablets) twice daily (adult or child > 40 kg dose) or 8-10 mg TMP, 40-50 mg SMX per kg daily, divided into 2 daily doses (child < 40 kg dose). Study drug will be administered for 10 days.
1819902|NCT00730028|Other|Placebo|Placebo capsules will be identical in appearance to the CLINDA and TMP-SMX. Administered 3 times daily for 10 days.
1819903|NCT00730028|Drug|Clindamycin|CLINDA (adult dose of 300 mg three times daily; pediatric dose of 25-30 mg/kg/day divided three times daily up to a maximum dose of 900 mg/day). Study drug will be administered for 10 days.
1819904|NCT00730041|Device|Pillar Palatal Implant System|The Pillar system is intended as an initial treatment option for mild to moderate OSA. It consists of a delivery system and an implant. The delivery system is comprised of a disposable handle and needle assembly that allows for positioning and placement of the implant within the soft palate of the mouth. The 18mm x 2mm implant is a cylindrical shaped segment of braided polyester filaments that is intended for permanent implantation into the soft palate. The implant is pre-loaded into the needle. Three implants are placed in each subject under local anesthesia. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
1819905|NCT00730041|Device|Sham system|The Pillar system consists of a delivery system and an implant. The only difference between the treatment and sham arm in this study is that the sham delivery device is not pre-loaded with the implant. Otherwise the appearance, manufacturing and function of the delivery devices are identical. Three insertions are made, but no implants are actually deployed during the procedure. Because implants are not able to be seen in the soft palate tissue, the physician is unable to see if an implant is placed or not placed and thus is blinded to the intervention type.
1819906|NCT00730054|Drug|Remifentanil+clonidine|iv Remifentanil+ iv clonidine
1819907|NCT00730067|Drug|sildenafil|Sildenafil 50 mg three times daily
1819909|NCT00730080|Drug|Sapropterin (Kuvan)|20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
1819910|NCT00730093|Dietary Supplement|B12 vitamin (Cyanocobalamin)|Arm A: B12 vitamin (Cyanocobalamin)
1819911|NCT00730730|Device|Complete SE Iliac Stent|Iliac stenting
1819912|NCT00730730|Device|Complete SE Iliac Stent|Self-expanding stent
1819913|NCT00730743|Procedure|Intermittent Pringle maneuver|Pringle maneuver is performed by isolation of the hepatoduodenal ligament which is then encircled and occluded with atraumatic vascular clamp. The clamp is applied for 15 minutes followed by unclamping for 5 minutes and repeated till end of liver transection. Limits of clamp cycle: 3 cycles for cirrhotic liver; 4 cycles for non-cirrhotic liver.
1819914|NCT00730756|Drug|Fluticasone Furoate Nasal Spray|Fluticasone furoate nasal spray 110mcg intranasally once daily for 4 weeks
1819915|NCT00730756|Other|Placebo Nasal Spray|Matching placebo nasal spray intranasally once daily for 4 weeks
1819916|NCT00730769|Drug|Single arm (ganciclovir and valganciclovir)|Patients received a short induction of IV ganciclovir at 5 mg/kg bid for 5 days (1 hour infusion) , followed by treatment with oral valganciclovir at 900 mg bid (after meals) for 16 days up to complet 21 days of treatment. In patients with impaired renal function, IV ganciclovir and oral valganciclovir doses were adjusted at each visit according to estimated GFR (Cockroft-Gault equation)
1819917|NCT00730782|Biological|PfAMA-1-FVO[25-545]|Subcutaneous vaccination of 0.5ml of two dosage 10 and 50ug PfAMA1
1819918|NCT00730795|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 3 doses at 0, 1, 2 months Different antigen doses (low and high)
1819919|NCT00730808|Dietary Supplement|PreOP Booster (food for special medical purposes)|3x1 dosage is given prior to surgery: 2x1 the day prior to surgery; 1x1 3-4h prior to initiation of anaesthesia;
1819920|NCT00730821|Drug|BIBW 2992|
1819921|NCT00730821|Drug|BIBF 1120|
1819922|NCT00730834|Device|Oasis|Digital sound player that provides customized acoustic stimulus based on subjects hearing thresholds
1819923|NCT00730847|Biological|Cervarix|Subjects received three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
1819924|NCT00730860|Procedure|radiofrequency ablation associated with TACE|treatment of hepatocellular carcinoma by radiofrequency ablation associated with postoperative transhepatic arterial chemoembolization
1819925|NCT00730860|Procedure|radiofrequency ablation only|treatment of hepatocellular carcinoma by radiofrequency ablation only
1819926|NCT00730873|Device|Continuous positive airway pressure|
1819927|NCT00730886|Device|ExAblate 2000|Magnetic resonance image guided focused ultrasound (MRgFUS) for fibroid ablation
1819928|NCT00730886|Procedure|Myomectomy|Invasive surgical procedure for fibroid removal
1819929|NCT00730912|Drug|loratadine|Loratadine (SCH 29851) dry syrup 1% 5 mg/day for 4 weeks
1819930|NCT00730912|Drug|loratadine|loratadine 10 mg tablet once daily for 4 weeks
1819931|NCT00730912|Drug|loratadine|loratadine 10 mg tablet once daily for 4 weeks
1819932|NCT00730925|Drug|BIBW2992|tablet BIBW high dose
1819933|NCT00730925|Drug|BIBW2992 + paclitaxel|tablet BIBW 2992 in combination with i.v. paclitaxel 3 weekly
1819934|NCT00730938|Drug|cefuroxime|intracameral cefuroxime 0.1 ml
1819935|NCT00730938|Drug|Saline placebo|0.1 ml of Ringers lactate
1819936|NCT00730951|Dietary Supplement|Korean Red Ginseng|500mg Capsulated Ground Dried Korean Red Ginseng Root
1819937|NCT00730951|Dietary Supplement|Corn Starch|500mg Capsulated Corn Starch
1819938|NCT00730964|Drug|Perflutren Protein-Type A Microspheres Injectable Suspension, United States Pharmacopeia (USP)|"The recommended dose of Optison is 0.5mL injected into a peripheral vein. This may be repeated for further contrast enhancement as needed.
The injection rate should not exceed 1mL per second. Follow the Optison injection with a flush of 0.9% sodium chloride injection, USP or 5% dextrose in water injection, United States Pharmacopeia (USP) .
The maximum total dose should not exceed 5.0mL in any 10 minutes period. The maximum total dose should not exceed 8.7mL in any one patient study."
1819939|NCT00730977|Drug|dry powder inhaled mannitol|single doses of 40 mg, 70 mg and 100 mg
1819940|NCT00730990|Other|Positron Emission tomography|Positron Emission tomography scans. Part 1of the study : 4 subjects will receive 2 scans a day for 1 day with PET ligand administered in tracer quantities.
1819941|NCT00730990|Other|PET Scan with PF-03654746|If none of the data from Cohort 2 is informative, then: 2) an additional 3 subjects will receive 2 Scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746. Doses will be determined based upon the outcome of the first intervention.
1819942|NCT00730990|Other|PET Scan with PF-03654746|If none of the data from the previous interventions are informative, then: 3) an additional 3 patients will receive 2 scans on Day 1 and 1 scan on Day 2 following three different doses of PF-0365476. Doses will be determined based upon the outcomes of the previous interventions.
1819943|NCT00730990|Other|PET Scan with PF-03654746|"Part 2 of the study will have 3 possible interventions:
1) 3 subjects in Cohort 2 will receive 2 scans on Day 1 and 1 scan on Day 2 following 3 different doses of PF-03654746 (0.5 mg, 1.5 mg, 4 mg)."
1819944|NCT00731003|Drug|Oxitriptan|100 mg 5-Hydroxytryptophan will be administered orally.
1819945|NCT00731003|Other|Acute tryptophan depletion|Acute tryptophan depletion employs the oral ingestion of an amino acid mixture devoid of tryptophan, the precursor of serotonin, which results in lowered serotonin levels.
1819946|NCT00731003|Other|Amino acid drink with tryptophan|Amino acid drink with tryptophan, placebo for the ATD procedure
1819947|NCT00731003|Drug|Placebo capsule|Placebo for 5-HTP
1819948|NCT00731016|Drug|Zoledronic acid, pravastatin|"Pravastatin : 10 mg daily
Zoledronic acid : slow (30 mn) intravenous injections, diluted into 50 ml of saline solution following this schedule :
injection 1, S1: 0.0125 mg/kg of zoledronic acid
injection 2, S6: 0.025 mg/kg of zoledronic acid
injection 3, S12 and following, trimestrial basis, 0.05 mg/kg of zoledronic acid"
1819949|NCT00731029|Biological|Thiomersal free trivalent influenza split vaccine 2002/2003|Single dose, intramuscular injection
1819950|NCT00731029|Biological|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003|Single dose, intramuscular injection
1819951|NCT00731042|Drug|Avagard|Topical solution, 6 mL, 6 applications/day for 14 days.
1819952|NCT00731042|Drug|Purell Surgical Scrub|Topical solution, 4 mL, 6 applications/day for 14 days.
1873132|NCT01112137|Drug|Clopidogrel|
1819953|NCT00731055|Drug|Varenicline|4 doses of Varenicline. 1 capsule of either dose (0mg, 0.5mg, 1mg, 2 mg) in the morning on days at least 5 days apart.
1819954|NCT00731055|Drug|Placebo|1 dose of placebo
1819955|NCT00731068|Biological|PRGF|injection of 6cc into injured area of tendon
1819956|NCT00731068|Biological|placebo|injection of 6 cc of saline into injured area
1819957|NCT00731094|Behavioral|Expert system-based physical activity counseling|The intervention included 14 mailings to participants that involved completion of physical activity questionnaires printed on forms that were scanned into a computerized expert system program to generate individually-tailored feedback messages and related manuals based on the Stages of Motivational Readiness for Change Model. Newsletters providing additional support and suggestions for increasing physical activity were also part of the mailing program.
1819958|NCT00731107|Procedure|laparoscopic surgery|XCEL bladeless trocar laparoscopic entry
1819959|NCT00731107|Procedure|laparoscopic surgery|Veress Needle laparoscopic entry
1819960|NCT00731120|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
1819961|NCT00731120|Drug|Placebo|Vortioxetine placebo-matching capsules
1819962|NCT00731133|Drug|Disulfiram|250 mg/day
1819963|NCT00731146|Other|Ultrasound Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
1819964|NCT00731146|Other|Nerve Stimulator Minimum Effective Anesthetic Volume|Each sequential participant in this group will be assigned a dose based on the success or failure of the previous participant's block. The starting dose will be 10mL of 0.5% ropivacaine. Each success will decrease the dose by 2.5mL and each failure will subsequently increase the dose by 2.5mL.
1819965|NCT00731159|Biological|sperm capacitation|sperm capacitation measured at Bar Ilan University
1819966|NCT00731159|Other|biologic|sperm synthesis of G-actine to F-actine
1819967|NCT00731159|Other|sperm capacitation|sperm synthesis of G-actine to F-actine
1819968|NCT00731172|Drug|glatiramer acetate|20 mg daily subcutaneous injection through week 12
1819969|NCT00731172|Drug|placebo|subcutaneous daiky injection through week 12
1819970|NCT00731185|Drug|Mometasone Furoate Nasal Spray|MFNS 200 mcg (2 sprays of 50 mcg in each nostril) once daily in the morning for up to 24 weeks or until relapse
1819971|NCT00731185|Drug|Placebo|
1819972|NCT00731198|Drug|Drotaverine hydrochloride|Drotaverine hydrochloride 40mg was administered intravenously 15 minutes before ERCP
1819973|NCT00731198|Drug|Hyoscine-N-butylbromide|Hyoscine-N-butylbromide 20mg was administered intravenously 15 minutes before ERCP.
1819974|NCT00731211|Drug|Pazopanib|800 mg of pazopanib orally each day continuously
1819975|NCT00731224|Drug|Rivastigmine transdermal patch|
1819976|NCT00731250|Drug|SB-705498|Subjects will be administered a single dose of 400 mg SB-705498
1819977|NCT00731250|Drug|Placebo|Subjects will be administered SB-705498 matching placebo tablets
1819978|NCT00731250|Other|Caspaicin|Subjects will be challenged with 0.5 µg, 5.0 µg and 50 µg intranasal dose
1819979|NCT00731263|Drug|AZD8055|Oral solution or tablet, single dose on Day 1 Part A, twice daily ascending dosing from day 8 onwards (until maximum tolerated dose is reached), cycles of 28 days treatment.
1819980|NCT00731276|Drug|irinotecan hydrochloride|
1819981|NCT00731276|Other|pharmacogenomic studies|
1819982|NCT00731276|Other|pharmacological study|
1819983|NCT00731289|Drug|hyaluronic acid|one intraarticular injection of hyaluronan (HA) 3 ml (Durolane®, 20 mg/ml non-animal stabilized hyaluronic acid (NASHA) in buffered physiological sodium chloride solution pH 7 in one pre-filled glass syringe in sterile pack
1819984|NCT00731289|Drug|triamcinolone|"one intraarticular injection of triamcinolone 1 ml (Volon A10®, 10mg triamcinolone acetonide, 10mg/ml)
antiinflammatory intervention"
1819985|NCT00731302|Drug|aspirin and meloxicam|aspirin 81 mg daily then aspirin 81 mg plus meloxicam 7.5 mg daily
1819986|NCT00731315|Other|Computer-assisted treatment group|This group will receive computer-assisted expedited treatment for uncomplicated UTI or complicated cystitis based on their symptoms and past medical history reported on the computer.
1819987|NCT00731315|Other|Usual care group|This group will receive usual care for an uncomplicated UTI or complicated cystitis in the Emergency Department or Community Health Center.
1819988|NCT00731328|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|infusion of mobilized donor hematopoietic progenitor cells
1819989|NCT00731341|Procedure|Cryoablation for the treatment of uterine fibroids|Needle will be inserted into the fibroid via the cervix through a hysteroscope channel. Gas is circulated through the sealed needle to form an iceball at the tip. After insertion, the needle will be cooled to a temperature of below -100°C to freeze the tissue of the fibroid.
1819990|NCT00731354|Device|Suction-assisted Lipoplasty|Standard Suction-assisted lipoplasty will be performed on one side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
1819991|NCT00731354|Device|VASER-assisted lipoplasty|VASER-assisted lipoplasty will be performed on the opposite side of the body to remove excess fat and contour the body in one or more of the following body areas: arm, inner thigh, outer thigh, back
1819992|NCT00731367|Device|Aquacel Ag Gelled|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
1819993|NCT00731367|Device|Aquacel Ag Adherent|AQUACEL Ag is produced by changing a small fraction of the sodium ions present in AQUACEL for silver ions and then stabilizing the complex formed by adding chloride. This produces a characteristic silver gray product. There are no counter ions (such as nitrate or sulphadiazine ions) present: these compounds, found in many silver containing products, are known to retard wound healing. AQUACEL Ag maintains a moist wound-healing environment while, at the same time, killing wound pathogens that are immobilized within the dressing. It also reduces bioburden at the wound-dressing surface, thus minimizing the risk of wound infection and facilitating wound healing.
1819994|NCT00731380|Drug|ABI-007|Dose escalation beginning with ABI-007 75 mg/m2 day 1 + day 8, Cisplatin 100 mg/m2 day 1, 5-Fluorouracil (5-FU) 1000 mg/m2/d continuous infusion x 96 hours on day 1-4, for 3 weeks x 3 cycles. Followed by Concurrent weekly Carboplatin (AUC 1.5) with radiotherapy for 7 weeks. Carboplatin should be given on Monday or Tuesday of each week, if possible.
1819995|NCT00731393|Biological|Thiomersal free trivalent influenza split vaccine 2003/2004|2 doses, intramuscular injection
1819996|NCT00731393|Biological|GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2003/2004|2 doses, intramuscular injection
1819997|NCT00731419|Device|SEMS|Comparing plastic and metal stents
1819998|NCT00731432|Drug|Transmucosal Herbal Periodontal Patch (THPP)|Patch applied to oral gingiva
1819999|NCT00731432|Drug|Placebo Patch|Identical in shape and texture to treatment patch
1820000|NCT00731445|Drug|Z-208|Oral pills taken daily; 8mg, 12mg, 16mg, 4mg
1820001|NCT00731458|Device|Optical coherance tomography ( Cirrus; Stratus)|Non-contact retinal thickness analyzer
1820002|NCT00731471|Biological|MVA85A|Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.
1820003|NCT00731497|Device|Solar Water Disinfection (SODIS)|Intervention group has SODIS implemented at the household level as a way to disinfect drinking water
1820004|NCT00731510|Dietary Supplement|Carbohydrate energy drink|Complex carbohydrates including maltodextrin (97%) dissolved in water to make a a 10% solution, or dissolved in 25mL gels. Ad libitum. Twenty two days.
1820005|NCT00731510|Dietary Supplement|Aspartame|Aspartame dissolved in water, ad libitum, 22 days.
1820006|NCT00731523|Drug|fingolimod (FTY720)|
1820007|NCT00731536|Other|No intervention|This is an observational study. Medical records of patients with the diagnosis of HSTCL in the PALGA database will be analyzed.
1820008|NCT00731549|Drug|Aripiprazole IM Depot|300mg or 400mg
1820009|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fasted conditions
1820010|NCT00731562|Drug|Varenicline Tartrate Controlled Release|A single, 2.4 mg dose of a varenicline controlled release tablet administered orally under fed conditions
1820011|NCT00731575|Drug|prednisolone|First dose 2 mg/kg (max 60 mg) p.o., then 2 mg/kg/d (max 60 mg/d) p.o. in 3 divided doses for 3 days.
1820012|NCT00731588|Biological|Transfused Biotin RBCs - Adults Phase I|A 3 mL venous blood sample is obtained. 250 mL of blood will be drawn to a blood collection bag containing the anticoagulant CPD. Separate equal volumes of RBCs are labeled with up to five different densities of biotin. The biotinylated RBCs are resuspended in autologous plasma to achieve a 60 to 70% hematocrit. An IV is inserted for the reinfusion of the biotinylated RBCs. Three mL aliquots of blood are sampled at 5, 10, 20, and 60 minutes after infusion. The subject returns ~24 hours and 3 days after the RBC infusion to obtain a 3 mL venous blood sample. Subjects return for weekly 3 mL blood sampling.
1820013|NCT00731588|Biological|Transfused Biotin RBCs - Infants Phase II|After the infant's clinical care team decides that a RBC transfusion is needed, a 15mL/kilogram of body weight is ordered. Transfusion will be given in 2 parts: 1) approximately 80% of the total transfusion to be transfused over 3-4 hours and 2) approximately 20% of the total transfusion will be marked with biotin to be transfused upon completion of the first part. The bedside nurse maintains constant observation of the infant as appropriate for the infant's condition, assessing for signs and symptoms of a transfusion reaction.
1820014|NCT00731588|Biological|Transfused Biotin RBCs - Infants Phase III|Phase III (infants) to be determined upon completion of Phase II (infants).
1820015|NCT00731601|Drug|pantoprazole|pantoprazole 40 mg/q6h IV infusion for three days
1820016|NCT00731601|Drug|pantoprazole|pantoprazole 8 mg/h IV infusion for three days
1820017|NCT00731614|Behavioral|Cognitive Behavioral Therapy and Mirror Retraining|Cognitive Behavioral Pain Management treatment administered in 8 weeks of individual treatment, combined with training in use of a mirror device to reduce phantom limb pain.
1820018|NCT00731614|Behavioral|Supportive therapy|Non-directive, emotion focused psychotherapy to facilitate coping with pain, delivered in weekly individual sessions.
1820019|NCT00731614|Behavioral|Mirror retraining|Use of a mirror to produce an illusion of the missing limb. By attending to the reflected limb while moving the existing limb, the patient provides visual feedback that helps correct changes in the neural organization of the somatosensory cortex resulting from the amputation and contributing to the phantom limb pain
1997027|NCT02277327|Behavioral|Routine Care|"Subjects randomized to the control group will continue to receive routine care within the medical home program"
1820022|NCT00731640|Device|ReSTOR|AcrySof ReSTOR +4 Intraocular Lens (IOL) unilaterally implanted
1820023|NCT00731653|Drug|Combination Product: BCI-024 + BCI-049|BCI-024 and BCI-049 once a day at bedtime for 6 weeks
1820024|NCT00731666|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction. The implant provides the participant with voluntary control over the erect and flaccid states of the penis.
1820025|NCT00731679|Drug|Rifaximin|
1820026|NCT00731679|Drug|Placebo|
1820027|NCT00731692|Drug|FTY720|Fingolimod capsules at doses of 1.25 mg (prior to implementation of Amendment 5) and 0.5 mg (after Amendment 5) were administered orally once daily
1820028|NCT00731692|Drug|Placebo|Matching placebo capsules were administered orally once daily
1820029|NCT00731705|Procedure|collection of peripheral blood and apheresis samples|Sixty mL of peripheral blood will be collected from consenting eligible donors. Additionally, after the laboratory techniques have been fully evaluated, leukopheresis samples will also be collected.
1820030|NCT00731718|Device|lousebuster|Subject serves as own control the length of treatment is approximately 30 minutes for full head treatment
1820036|NCT00731744|Procedure|Normal full-term deliveries|Normal full-term deliveries by standard procedures according to institutional guidelines
1820037|NCT00731757|Drug|Humira|80 mg at week 0, then 40 mg weekly from week 1-week 23.
1820040|NCT00731783|Drug|2% Mupirocin Ointment|Apply ointment to the anterior nares twice daily for 5 days.
1820041|NCT00731783|Drug|4% Chlorhexidine liquid soap|Bathe with liquid soap daily for 5 days.
1820042|NCT00731783|Behavioral|Hygiene protocol|"Follow key hygiene tips indefinitely. Tips are:
Throw out all lotions or creams that you dip your hands into and replace with pumps or pour bottles.
Use liquid(pour or pump) soaps instead of bar soaps.
Wash hands frequently or use hand sanitizer(with more than %60 alcohol) such as Germ-X or Purell.
Do not share personal care items such as razors and brushes.
Wash all sheets and towels in hot water. Wash sheets every week.
Use towels and wash cloths only once before washing and do not share."
1820043|NCT00731796|Device|Functional Outcome Measure|Functional Outcome Measure is a computerized test performed by the subject. The subject sits at a computer and answers questions about their visual deficit and its impact. The patient then performs a Vision Preference Scale test intended to rate the overall quality of life. A reading test is performed that measures reading speed, accuracy, and comprehension. Finally a Visuospatial Attention test is given to measure object localization, object recognition,and motion recognition.
1820044|NCT00731809|Radiation|FDG PET CT|FDG PET CT
1820045|NCT00731822|Drug|GW685698/GW642444|GW685698/GW642444
1820046|NCT00731835|Procedure|Endovascular Revascularization|"angioplasty, also called percutaneous transluminal angioplasty (PTA) and/or
stent placement
atherectomy"
1820047|NCT00731848|Dietary Supplement|pomegranate liquid extract|Pomegranate liquid extract, 8 oz per day, for 52 weeks
1820048|NCT00731861|Drug|Paclitaxel plus PTK787|"Paclitaxel will be given on days 1 and 15 over 28 days in cycle 1 with PTK787 on days 3 to 28. PTK787 WILL BE TAKEN AT NIGHT.
In cycle 2 and beyond, paclitaxel will be given on days 1, 8 and 15 every 28 days . PTK787 will be taken orally NIGHTLY."
1820049|NCT00731874|Drug|Tacrolimus|Dosed to achieve target trough concentrations.
1820050|NCT00731887|Procedure|Blood and urine testing|complete blood count, routine chemistries, liver function test, retinol binding protein, transferrin, prothrombin time, partial thromboplastin time, fibrinogen, Vitamin A and Zinc, Insulin Growth Factor levels and binding proteins, cytokines (interleukins 1, 6, 12), insulin, thyroid hormones, cortisol, 25-hydroxyvitamin D, and osteocalcin.
1820051|NCT00731913|Other|Absorable, monofilament sutures: Monosyn and Monocryl|Subjects were randomized to Monosyn vs. Monocryl suture arms. The designated skin lesion was removed surgically. The surgical repair of the defect was performed by dividing the wound in half by a single Prolene suture. The appropriate suture was opened by the Study Coordinator and passed sterilely to the surgical technician. The surgical technician loaded the suture, and passed it in a blinded fashion to the physician who closed the appropriate half of the surgical defect. One half of the wound was closed with one suture and the other half was closed with the other suture. Each patient served as their own control, as both sutures were used in each study patient.
1820052|NCT00731926|Dietary Supplement|Oligomerized litchi fruit extract|100mg at once twice a day for 1 month
1820053|NCT00731926|Dietary Supplement|VItamin C + Vitamin E mixture|Vitamin C 400mg + Vitamin E 160IU at once twice a day for 1 month
1820054|NCT00731926|Other|placebo|twice a day for 1 month
1820055|NCT00731939|Device|Inflatable Penile Prosthesis|Hydraulic system designed to be surgically implanted into the penis for the management of erectile dysfunction.
1820056|NCT00731952|Drug|Velcade and Vorinostat|Subjects will receive one of 3 doses of Velcade (at a dose of 1.0 - 1.6 mg/m2 once weekly for 3 weeks) and one of 4 doses of Vorinostat (at a dose of 100mg every day 3 times a week for 3 weeks to 300mg twice per day, 3 times per week for 3 weeks). Doses determined by a predetermined escalation schedule.
1820057|NCT00731965|Biological|Measles, Mumps, Rubella vaccination|Dosage: 1 dose MMR vaccine, containing 5000 p.f.u. (plaque forming unit) life attenuated mumps virus (Jeryl-Lynn-strain), 1000 p.f.u. life attenuated measles virus (Moraten-strain) and 1000 p.f.u. life attenuated rubella virus (Wistar RA 27/3-strain) + 0.5 ml solution fluid Dosage form: subcutaneously frequency: once
1820058|NCT00731978|Procedure|Restricted intraoperative fluid management|Intraoperative fluid management guided by Sto2.
1820059|NCT00731991|Other|ART|ART to the levator scapulae.
1820060|NCT00731991|Other|PNF|PNF to the levator scapulae.
1820061|NCT00731991|Other|No Treatment|No treatment will be given. The participant will sit in the treatment room with the doctor for 4 minutes.
1820062|NCT00732004|Device|Silicone Hydrogel Contact Lenses|
1820063|NCT00732004|Device|1x PMBH preserved MPS|
1820064|NCT00732004|Device|1x Polyquad/Aldox MPS|
1820065|NCT00732017|Device|Standard physical therapy and HVPC with positive polarity|A high voltage stimulator with positive polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
1820066|NCT00732017|Device|high voltage pulse stimulation with negative polarity|A high voltage stimulator with negative polarity was used with a direct pulsed monophasic current, double peak, 5 and 8micros duration and separated by a pulsate interval of 75micros and monopolar application with a dispersive electrode in the lumbar region and two transarticular active electrodes. The intensity of the current was under motor level, that is, just before a visible motor response could be observed. The frequency used was 120pps, in a continuous mode and was applied once a day with thirty-minute duration.
1820106|NCT00732277|Drug|hydrocortisone|Patients will be assigned to treatment with hydrocortisone at 100mg/m2/24 hours in 4 divided doses (25 mg/m2/q 6 hourly) for 8 doses (48 hours) in phase 1 of study (45 patients, 30 receive IMP) or 20 doses (120 hours) in phase 2 (45 patients, 30 receive IMP).
1820107|NCT00732290|Drug|Clopidogrel then fluoxetine+clopidogrel|D1 : clopidogrel (Plavix) 600mg (8 tablets) one time D45 to D48 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D49 : 20mg Fluoxetine + 600mg Clopidogrel
1820194|NCT00732797|Behavioral|Self-treatment booklet|A booklet outlining vestibular rehabilitation exercises
1820067|NCT00732017|Other|standard physical therapy treatment|"Initial phase: Application of crushed ice on the ankle for 20 minutes. The subject performed isometric and active exercises of the ankle in all freedom degrees, with no weight bearing.
Intermediate phase: Application of cryotherapy continued and once mobility was completed and painless, progressive use of weight and reeducation of the walking pattern were initiated. Then, exercises with manual resistance of muscles of ankle and balance in stable surfaces were done.
Advanced phase: Balance exercises on unstable surfaces as well as strengthening ankle muscles with proprioceptive neuromuscular facilitation techniques and elastic band were performed. At the end, the patient did activities like trotting in S or Z and jumping in all directions."
1820068|NCT00732030|Device|Toric IOL (SN60T3)|Each enrolled eye implanted with the AcrySof Toric Model SN60T3 intraocular lens (IOL) for the treatment of cataract.
1820069|NCT00732043|Dietary Supplement|pomegranate extract|8 oz per day, 48 months
1820070|NCT00732043|Dietary Supplement|pomegranate juice|8 oz per day, 48 months
1820071|NCT00732043|Dietary Supplement|placebo|8 oz per day, 48 months
1820072|NCT00732056|Drug|GRN163L|25% dose escalation infused over 2 hours weekly
1820073|NCT00732069|Drug|Placebo|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
1820074|NCT00732069|Drug|Ramipril|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
1820075|NCT00732069|Drug|Valsartan|Patients receiving an angiotensin converting enzyme inhibitor or angiotensin receptor blocker before the study underwent washout for 3 weeks. Subjects were treated with study drug for 7 days and each treatment period was separated by a 3-week washout period. Ramipril was given at dose of 2.5mg/d for two days, then 5mg/d for 5 days. Valsartan was given at 80mg/d for 2 days followed by 160mg/d for 5 days. On the seventh day of each treatment blood samples were collected prior two, during and two hours after dialysis
1820076|NCT00732082|Drug|Gemcitabine|
1820077|NCT00732082|Biological|LAG-3|
1820078|NCT00732095|Behavioral|Promoting Self-Change with Ads|Use of Ads immediate or delayed or no ad
1820079|NCT00732108|Drug|topiramate|50mg orally for 2 weeks, then 100mg orally for 6 weeks
1820080|NCT00732108|Drug|lactulose placebo pill|1 placebo pill orally for 2 weeks, then 2 placebo pills orally for 6 weeks
1820081|NCT00732121|Drug|Sitagliptin|100 mg daily for 4 weeks
1820082|NCT00732121|Drug|Placebo|Placebo
1820083|NCT00732147|Drug|Pramlintide acetate|120 micrograms given subcutaneously before each meal X 3.
1820084|NCT00732147|Drug|Placebo|120 micrograms given subcutaneously before each meal x 3.
1820085|NCT00732160|Drug|Aldosterone infusion (A)|Infusion of exogenous aldosterone (0.7 mcg/kg/hr for 12.5 hrs)
1820086|NCT00732160|Drug|Vehicle Infusion (V)|Vehicle infusion for 12.5 hours
1820087|NCT00732160|Other|High Sodium Diet (HS)|160 mmol/d sodium diet for 7 days
1820088|NCT00732160|Other|Low Sodium Diet (LS)|20 mmol/d sodium diet for 9 days
1820089|NCT00732173|Behavioral|behavioral dietary intervention|Undergo SUCCEED lifestyle intervention
1820090|NCT00732173|Behavioral|exercise intervention|Undergo SUCCEED lifestyle intervention
1820091|NCT00732173|Other|counseling intervention|Undergo SUCCEED lifestyle intervention
1820092|NCT00732173|Other|educational intervention|Receive information
1820093|NCT00732173|Other|survey administration|Undergo SUCCEED lifestyle intervention
1820094|NCT00732186|Biological|Ipilimumab|IV Solution, IV, 10 mg/kg, (if dose reduction necessary at 3 mg/kg), Every three weeks for the first 10 weeks, with a booster at week 22, Up to 38 weeks depending on response
1820095|NCT00732199|Other|1) hyperventilation via noninvasive positive pressure ventilation 2) multiple trials of episodic hypoxia|1) noninvasive hyperventilation to determine apneic threshold; 2) episodic hypoxia to determine ventilatory long term facilitation
1820096|NCT00732212|Device|Doppler endoscopic ultrasound probe for blood flow detection|Used for blood flow detection
1820097|NCT00732212|Other|Standard endoscopic hemostasis|Per current treatment guidelines for non-variceal UGI lesions - based upon stigmata of hemorrhage & visual cues for risk stratification and completion of endoscopic treatment.
1820098|NCT00732225|Device|DisCoVisc|DisCoVisc Ophthalmic Viscosurgical Device (OVD) (4% sodium chondroitin sulfate, 1.65% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
1820099|NCT00732225|Device|DuoVisc|DuoVisc Ophthalmic Viscosurgical System (1% sodium hyaluronate, and 3% sodium hyaluronate, 4% chondroitin sulfate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
1820100|NCT00732225|Device|BioVisc|BioVisc Ophthalmic Viscosurgical Device (OVD) (1% sodium hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
1820101|NCT00732225|Device|Healon5|Healon5 Ophthalmic Viscosurgical Device (OVD) (2.3% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
1820102|NCT00732225|Device|Amvisc Plus|Amvisc Plus Ophthalmic Viscosurgical Device (OVD) (1.6% Sodium Hyaluronate) as utilized throughout cataract removal and intraocular lens (IOL) insertion procedure.
1820103|NCT00732238|Other|Shortened course of antibiotic therapy|By obtaining a urine culture from a newly inserted catheter we hope to find the true urinary pathogen. In so doing we feel a shorter but pathogen specific course of antibiotic therapy will more successfully prevent urinary tract infection relapse.
1820104|NCT00732238|Other|Standard Therapy|Patients entered into this arm of the study will receive the standard duration of antibiotic therapy, which will be determined by urine culture results obtained from existing urinary catheter.
1820105|NCT00732251|Drug|Allopurinol|Allopurinol: 300-600 mg/day over a 4 week period
1820108|NCT00732290|Drug|Fluoxetine+clopidogrel then clopidogrel|D1 to D4 : Fluoxetine (Fluoxetine EG 20mg) 20mg (1 tablet) per day D5: 20mg Fluoxetine + Clopidogrel (Plavix) 600mg (8 tablets) one time D49 : Clopidogrel 600mg one time
1820109|NCT00732303|Drug|Pemetrexed|Pemetrexed (Alimta) 500mg/^2 administered intravenously over approximately 10-minutes on Day 1 of a 21-day cycle x 3 cycles
1820110|NCT00732303|Radiation|Radiation Therapy|"Radiation will start between days -1 to 2 from day 1 of cycle 1. Day 1 radiotherapy must be a Monday, Tuesday, or Wednesday.
The planned radiation dose is 60 Gy in 2.0 Gy fractions. The entire PTV, including primary tumor and areas of known nodal disease, shall receive 60 Gy at 2.0 Gy fractions, 5 fractions/week for 30 fractions over 6 weeks."
1820111|NCT00732316|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|administration of conditioning therapy including immunosuppressive agents plus alkylating agents and infusing hematopoietic progenitor cells collected from the donor
1820112|NCT00732316|Procedure|peripheral blood stem cell transplantation|infusion of donor hematopoietic cells collected by leukapheresis after mobilization with growth factor
1820113|NCT00732329|Behavioral|Occupational Therapy|"optimized home Based Occupational Therapy including:
diagnostic assessment
patient-centered definition of targets involving the care giver
occupational therapy"
1820114|NCT00732342|Behavioral|Contingency Management|Prizes given for targeted behavior of abstinence
1820115|NCT00732355|Device|Syph-Check POC|Rapid membrane test for syphilis antibodies
1820116|NCT00732368|Drug|Mometasone furoate|Two sprays mometasone nasal spray per nostril once daily (200 mcg/day). After 4 weeks, dose can be decreased to one spray per nostril daily or increased to 4 sprays per nostril daily.
1820117|NCT00732381|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
1820118|NCT00732381|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
1820119|NCT00732394|Other|MSDR|"The MSDR® questionnaire establishes an individual's musculoskeletal functional status using information gathered from 1) a questionnaire the patient fills out regarding medical history, chronic medical conditions, and health risk factors; 2) anatomic pain survey completed by the patient; and 3) evaluation by a trained researcher of various patient biometric parameters related to range of motion. Stratifying an individual into a risk category with this evidence-based assessment tool then permits an assessment of which patients respond long term to therapy.
MSDR® demonstrates the ability to benchmark specific musculoskeletal findings (both clinical and sub-clinical) to ICD-9 Diagnoses supported by diagnostic, radiographic and/or MRI findings where clinically indicated."
1820120|NCT00732407|Drug|aliskiren|Aliskiren will be given in a preliminary dosage of 150 mg per day, after a follow up of two weeks dosage will be increased to 300 mg per day.
1820121|NCT00732407|Drug|losartan|Losartan will be given in a preliminary dosage of 50 mg per day and after a two weeks follow up dosage will be increased to 100 mg per day
1820122|NCT00732420|Drug|topotecan|Topoisomerase I inhibition.
1820123|NCT00732420|Drug|pazopanib|Tyrosine kinase inhibitor
1820124|NCT00732433|Procedure|digital mammography|Using non-invasive digital mammography with computer aided programs to screen, detect and characterize breast lesions/cancer.
1820125|NCT00732446|Drug|Moxifloxacin and Dexamethasone combined|moxifloxacin 0,5% qid and dexamethasone 0,1% qid combined
1820126|NCT00732446|Drug|Moxifloxacin|moxifloxacin 0,5% qid and
1820127|NCT00732446|Drug|Dexamethasone|dexamethasone 0,1% qid
1820128|NCT00732459|Device|Electro-acupuncture preconditioning|electro-acupuncture
1820129|NCT00732472|Drug|GSK573719|7 day repeat dose
1820130|NCT00732485|Drug|fenofibrate|Fenofibrate, PO, 5 mg/kg/day from admission to 6 months post burn
1820131|NCT00732485|Drug|placebo|Placebo, sugar pill, from admission to 6 months post burn
1820132|NCT00732498|Drug|Methylprednisolone|250 mg/m2/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
1820133|NCT00732498|Drug|Etoposide|40 mg/day IV over 1 hour days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
1820134|NCT00732498|Drug|Cytarabine|2000 mg/m2 IV over 2 hours days 4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
1820135|NCT00732498|Drug|Cisplatin|25 mg/m2/day IV at 1mg/min days 1,2,3,4 every 28 days for 2 cycles. If bone marrow <25% involved and expected biodistribution after 2 cycles yttrium-90-ibritumomab tiuxetan (Zevalin) to be administered.
1820136|NCT00732498|Drug|Rituximab|250 mg/m2 slow IV over days 1, then 7,8 or 9 prior to In Zevalin. Rituximab + Zevalin regimen is given 4-6 weeks after completion of 2 cycles of ESHAP. Treatment can be completed within 7-9 days in an outpatient setting.
1820137|NCT00732498|Drug|In-Zevalin|5 mCi slow IV push over 10 minutes days 1. Given within 4 hours after Rituximab.
1820138|NCT00732498|Drug|Y-Zevalin|Platelet counts from 100,000/mm3 to 149,000/mm3 will receive 0.3 mCi/kg. Platelet counts from >/= 150,000/mm3 will receive 0.4 mCi/kg, not to exceed 32 mCi Y Zevalin. Slow IV push over 10 minutes, days 7,8 or 9 given within 4 hours after Rituximab.
1820139|NCT00732511|Drug|carvedilol|capsules in doses of 20, 40, and 80 mg; once daily; 12 weeks duration
1820140|NCT00732511|Drug|metoprolol extended release|tablets in doses 50, 100, and 200 mg; once daily; 12 weeks duration
1995582|NCT02715856|Other|Physical Tasks|About 2, 6, 12, and 24 weeks after surgery, participant has standard follow-up visits. At these visits, participant asked to perform different physical tasks. Physical therapist will observe one of the walking tests.
1820189|NCT00732758|Dietary Supplement|Vitamin D3 1000 IU|Vitamin D3 1000 IU Tablet once daily for 6 months
1820190|NCT00732758|Dietary Supplement|Placebo Tablet|Placebo Tablet once daily for 6 months
1820191|NCT00732771|Drug|LCI699|
1820192|NCT00732784|Drug|Imatinib mesylate|Dosage form: tablets Dosage: 400 mg Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
1820193|NCT00732784|Dietary Supplement|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
1876896|NCT01154036|Drug|ezetimibe 10 mg|
1820143|NCT00732537|Drug|inhaled Nitric Oxide|"iNO started at 20 ppm for 1 hour, then weaned hourly over the next 4 hours (20 ppm to 10 to 5 to 2.5 to 1 to off). If >5% drop in oxygen saturation was observed during weaning, study gas was increased to the previous concentration and weaning done 2 hourly. If > 5% drop in oxygen saturation or >5% Methemoglobin was observed during initial administration, the study gas would be weaned over 30 minutes and the infant would exit. The iNO was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. Monitoring of O2, NO2, NO was done by placing the end of the sample line inside the oxyhood. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
1820144|NCT00732537|Drug|Oxygen (>90% by hood) - standard therapy|"Oxygen (>90% by hood, standard therapy for PPHN prior to intubation) was introduced into an oxygen hood (Oxydome ™ disposable hood from Maxtex ® Inc.) using an INOvent (Datex-Ohmeda). The INOvent ® was connected to the oxyhood by placing the injector module inline on the dry side of the humidifier chamber. If the baby was randomized to the control group and did not receive NO, the INOmax® cylinder was opened and used only to pressurize the system, which prevented the Low NO Pressure alarm. A Masking Shield covered the Display/Control Panel and Cylinder Gauges, in order to maintain masking of the intervention. Only the respiratory therapist and research coordinator was aware of the allocation assignment."
1820145|NCT00732550|Procedure|Single trocar cholecystectomy|Patients with symptomatic cholelithiasis will be operated using the single trocar surgery approach
1820146|NCT00732550|Procedure|Standard laparoscopic cholecystectomy|Patients with symptomatic cholelithiasis will undergo a standard laparoscopic cholecystectomy
1820155|NCT00732576|Dietary Supplement|menaquinone-7|capsule consisting of 10, 20 or 45 µg menaquinone-7 per day during 8 weeks
1820156|NCT00732576|Dietary Supplement|fish oil|9 fish oil capsules equivalent to 3 gram per day of n-3 polyunsaturated fatty acids during 12 weeks
1820157|NCT00732576|Dietary Supplement|krill oil|9 krill oil capsules, equivalent to 1,5 gram per day of n-3 polyunsaturated fatty acids (PUFA) during 12 weeks
1820158|NCT00732589|Drug|1% xylocaine|10 cc. of 1%xylocaine, once a week
1820159|NCT00732589|Other|ultrasound|ultrasound at shoulder area about 10 mins.
1820160|NCT00732602|Other|GIP-infusion|
1820161|NCT00732602|Other|Sodium-chloride|
1820162|NCT00732602|Other|GLP-2 infusion|
1820163|NCT00732615|Drug|Placebo|Placebo for subcutaneous injection
1820164|NCT00732615|Drug|NPSP558|Parathyroid hormone 50, 75, or 100 mcg injectable subcutaneously daily
1820165|NCT00732628|Device|Boomerang closure device|Use of percutaneous of Boomerang closure device. Follow up outcomes evaluated after the use of Boomerang closure device.
1820166|NCT00732641|Drug|Peginterferon|Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.
1820167|NCT00732654|Drug|Milk Protein Extract Immunotherapy goal of 4mg/day|Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
1820168|NCT00732654|Drug|Milk Protein Extract Immunotherapy goal of 7mg/day|Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
1820169|NCT00732654|Drug|Milk Powder Immunotherapy goal dose 2000 mg/day|Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
1820170|NCT00732654|Drug|Milk Powder Immunotherapy goal dose 1000mg/day|Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
1820171|NCT00732680|Drug|Botulinum Toxin Type A|10 Units of Botulinum Toxin Type A injected into the dilator nasalis muscle on each side of the nose.
1820172|NCT00732693|Drug|Ethinylestradiol / Norethisterone|"Oral ethinylestradiol 30mcg and norethisterone 1.5mg daily for weeks 1-3, followed by 7 pill free days"
1820173|NCT00732693|Drug|Estradiol / Progesterone|Transdermal estradiol 100mcg daily for week 1, then 150mcg daily for weeks 2-4; and vaginal progesterone pessaries 200mg twice daily for weeks 3-4
1820174|NCT00732706|Procedure|Sartorius Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Sartorius Muscle fascia with the lowest possible current.
1820175|NCT00732706|Procedure|Quadriceps Muscle Twitch|Stimulation of the femoral nerve branch responsible for activating the Quadriceps Muscle fascia with the lowest possible current.
1820176|NCT00732719|Device|Prototype device (unnamed) worn-no pressure given (placebo) from inflatable cuffs|
1820177|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
1820178|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
1820179|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
1820180|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
1820181|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
1820182|NCT00732719|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
1820183|NCT00732732|Dietary Supplement|Green banana powder|Green banana in powder form, 10 grams/ day for children below 10 kg, 20 grams for those weighing 10 Kg or more. Protocol Modified on Aug 5th 2009 to give 20 grams irrespective of age.
1820184|NCT00732732|Other|Microcrystalline cellulose|Microcrystalline cellulose 10 gm/ day for subjects below 10 kg in weight, 20 gms/ day for those weighing 10 Kg or more
1820185|NCT00732745|Drug|docetaxel|Given IV
1820186|NCT00732745|Drug|oxaliplatin|Given IV
1820187|NCT00732745|Drug|vandetanib|Given orally
1820188|NCT00732745|Other|placebo|Given orally
1876897|NCT01154036|Drug|atorvastatin|
1820195|NCT00732797|Behavioral|Remote telephone support|Up to an hour's remote support from an expert vestibular therapist
1820196|NCT00732810|Drug|SCH 727965|SCH 727965 50 mg/m^2 IV on Day 1 of each 21 day cycle until disease progression.
1820197|NCT00732810|Drug|Capecitabine|Capecitabine 1250 mg/m^2 orally twice daily from Day 1 to Day 14 of each 21 day cycle until disease progression.
1820198|NCT00732810|Drug|Erlotinib|Erlotinib 150 mg orally once daily until disease progression.
1820199|NCT00732823|Device|Placebo - No device worn|
1820200|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
1820201|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
1820202|NCT00732823|Device|Prototype device(unnamed)-A battery operated inflatable pneumatic cuffs|
1820203|NCT00732836|Drug|HAI Abraxane|Escalating doses (beginning dose 180 mg/m^2) starting Day 1, Cycle 2 and later via hepatic arterial infusion (HAI) following IV Abraxane in Day 1, Cycle 1 for 21 day cycles.
1820204|NCT00732836|Procedure|Hepatic Artery Catheter|On each day of treatment for Cycles 2-4, hepatic artery catheter placement completed by interventional radiology.
1820205|NCT00732836|Drug|IV Abraxane|Intravenous (IV) Abraxane only in Cycle 1 (up to Dose Level 4 of 260 mg/m^2), infused over 60 minutes or 4 hours Day 1 of 21 day cycle.
1820206|NCT00732849|Drug|Reconvan, Dipeptiven, Omegaven|Reconvan (1ml=1 kcal), 30 kcal/kg b.w. Omegaven 1 ml/ kg b.w. Dipeptiven 1 ml/ kg b.w.
1820207|NCT00732862|Procedure|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
1820208|NCT00732862|Procedure|glucose clamp|Hyperinsulinemic Hypoglycemic clamp
1820209|NCT00732875|Biological|Infliximab + methotrexate (MTX)|Open label Infliximab infusions at weeks 0, 2, and 6 and every 8 weeks + methotrexate (MTX)
1820210|NCT00732888|Drug|Nilotinib Hydrochloride|Dosage form: capsules Dosage: 400 mg (2 x 200 mg capsule) Frequency & duration: On an 18-day schedule, one dose administered once on day 1 and once on day 15 (2 doses total)
1820211|NCT00732888|Dietary Supplement|calcium carbonate|Dosage form: tablets Dosage: 4000 mg (4 x 1000 mg tablet) Frequency: On an 18-day schedule, once daily day 15 (for Arm 1); or once daily day 1 (for Arm 2)
1820212|NCT00732901|Drug|Escitalopram|Escitalopram: once daily 10 mg on days 1-3, 20 mg on days 4-24 and 10 mg on days 25-28
1820213|NCT00732901|Drug|Placebo|Once daily days 1-28
1820214|NCT00732914|Drug|Sunitinib (Sutent)|Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity), followed by sorafenib 400 mg BID
1820215|NCT00732914|Drug|Sorafenib (Nexavar)|Sorafenib 400 mg BID, followed by Sunitinib 50 mg once daily 4 weeks on, 2 weeks off, and after discontinuation (due to PD or toxicity)
1820216|NCT00732927|Drug|parnaparin|vials, 6.400 IU sc twice daily for 7 days, then once daily for a total of 3 months
1820217|NCT00732927|Drug|aspirin|tablets, 100 mg for 3 months
1820218|NCT00732940|Drug|Belimumab 100 mg SC|Belimumab 100 mg SC for 1 injection on Days 0, 7, 14, and then every two weeks.
1820219|NCT00732940|Drug|Belimumab 100 mg SC|Belimumab 100mg SC for 2 injections (of 100mg each) on Days 0, 2, and 4, then 100 mg (1 injection) three times per week.
1820220|NCT00732953|Device|Genous stent implantation with paclitaxel-eluting balloon dilation|Genous stent implantation with paclitaxel-eluting balloon therapy
1820221|NCT00732953|Device|Genous stent implantation|Genous stent implantation
1820222|NCT00732966|Drug|losartan|with losartan 50 mg once daily for one month
1820223|NCT00732966|Drug|valsartan|valsartan 160 mg once daily
1820224|NCT00732979|Procedure|Infrahepatic inferior vena cava clamping|The inferior vena cava is circumferentially dissected below the liver and clamped with a vascular clamp. Patients in this study group will receive intravenous volume for maintenance of fluid hemostasis according to local standards.
1820225|NCT00732979|Procedure|No infrahepatic inferior vena cava clamping|Patients in this study group undergo hepatic resection following current standards of the Departments of Surgery and Anesthesiology, University of Heidelberg. Current practice consists of no type of vascular control in combination with CVP reduction below < 5mmHg. CVP reduction is mainly attained using restricted intravenous fluid administration.
1820226|NCT00732992|Drug|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule in a continuous daily dosing regimen with pemetrexed every 3 weeks until progression or unacceptable toxicity.
1820227|NCT00732992|Drug|Sunitinib, Pemetrexed|Sunitinib daily by oral capsule administered for 2 weeks out of every 3 weeks with pemetrexed every 3 weeks until progression or unacceptable toxicity.
1820228|NCT00733005|Drug|Mometasone furoate nasal spray (MFNS)|MFNS 50 mcg/spray: two sprays in each nostril once daily (ie, 200 mcg QD) for 15 days
1820229|NCT00733005|Drug|Matching placebo nasal spray|Matching placebo nasal spray: 2 sprays in each nostril once daily for 15 days
1820230|NCT00733018|Behavioral|"Western versus balanced macro nutrient diet composition"|Randomized crossover diet intervention. 6 days on solely one of two isocaloric diets, 8 days washout, and then the other diet for 6 days. Fasting blood sampling before and after each diet intervention period.
1820231|NCT00733031|Drug|AZD6918|liquid suspension, daily, oral dose
1820232|NCT00733031|Drug|gemcitabine|intravenous, doses are on an intermittent schedule
1820233|NCT00733031|Drug|pemetrexed|intravenous, dose administered every 21-days
1820234|NCT00733044|Behavioral|Specialized Care|The intervention consists of the integration of integral tinnitus management provided by a specialized tinnitus centre in the health care system. The tinnitus centre offers care following a stepped-care approach with two levels. The first level of intervention consists of audiological diagnostics and intervention, a tinnitus educational group session and a individual consult with a clinical psychologist. For patients with mild complaints this basic intervention is expected to suffice. For patients with moderate to severe complaints a second level of intervention exists. This level of intervention consists of combinations of the following therapies: Cognitive Behavioural Therapy (CBT), Attention Diversion (AD), exposure techniques, and Relaxation Therapy (RT).
1820324|NCT00725296|Biological|Remicade (Infliximab)|Induction infusions of Remicade will be administered at weeks 0, 2, and 6 given in a dosage due to the decision of the physicians. A maximum of 6 maintenance infusions will be administered with the dosage and interval due to the discretion of the physicians.
1877848|NCT01161602|Drug|Pumosetrag|
1820235|NCT00733044|Other|Usual Care|Usual care consists of a standardized version of treatment that is currently applied in peripheral audiological centres throughout the Netherlands. A telephone survey was conducted amongst all audiological centres (n=28) in the Netherlands. The results of this survey determined the content of the usual care treatment protocol in the current study. The treatment consists of audiological diagnostics and intervention and, if necessary, one or more consults with a social worker with a maximum of ten one hour sessions.
1820236|NCT00733057|Drug|Minocycline|Minocycline as an add-on drug (200 mg/day)
1820237|NCT00733057|Drug|Placebo (200 mg/day)|
1820238|NCT00733070|Device|CiTop™ ExPander™ Guidewire|Chronic Total Occlusion guidewire
1820239|NCT00733083|Drug|0,1 mg/kg of oxycodone|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
1820240|NCT00733083|Drug|Morphine 0,1 mg/kg|solution for injection, 0,1 mg/kg, one injection in the beginning of anesthesia
1820241|NCT00733083|Drug|Dexamethasone 0,5 mg/kg|solution for injection, 0,5 mg/kg, one injection in the beginning of anesthesia
1820242|NCT00733083|Drug|NaCl 0,9%|solution for injection one injection in the beginning of anesthesia
1820243|NCT00733096|Drug|etanercept|Two transforaminal epidural injections of 4 mg, two weeks apart
1820244|NCT00733096|Drug|methylprednisolone|Two transforaminal epidural steroid injections with 60 mg, two weeks apart
1820245|NCT00733096|Drug|normal saline|Two transforaminal epidural saline injections, two weeks apart
1820246|NCT00733109|Procedure|Excision of the lesion|Surgery with Large Loop Excision of Transformation Zone (LLETZ)
1820247|NCT00733109|Other|Follow-up for spontaneous regression of the lesion|Follow-up at last 12 months
1820248|NCT00733122|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine 0.5 mL of GARDASIL as intramuscular injections at the Day 1, Month 2, and Month 6 visits.
1820249|NCT00733135|Device|SilverHawk™ LS-C, TurboHawk™ LS-C, TurboHawk™ LX-C plaque excision systems and SpiderFX™ embolic protection device|Catheter-based excision of moderate to severely calcified plaque located in the SFA and/or popliteal artery.
1820250|NCT00733148|Drug|dosing of insulin|Dosing od insulin is calculated by a computer based algorithm
1820251|NCT00733161|Other|Passive leg cycle exercise with stretching and resistance training|Passive leg cycle exercise for 15 minutes everyday as well as stretching and resistance training
1820252|NCT00733161|Other|Stretching and resistance training|Stretching and resistance training everyday but no Passive leg cycle exercise
1820253|NCT00733174|Drug|Rosiglitazone|tablet
1820254|NCT00733174|Drug|Placebo|
1820255|NCT00733187|Drug|ABT-869|0.25 mg/kg
1820256|NCT00733200|Procedure|Minor or Major Liver Resection|
1820257|NCT00724776|Biological|Albinterferon alfa 2b|recombinant human albumin-interferon alfa fusion protein, 600-1800mcg single dose by S.C. on Day 0
1820258|NCT00724789|Drug|ganirelix|Daily 0.25 mg ganirelix administered to prevent premature LH surges during COS in order to achieve a pregnancy
1820259|NCT00724789|Drug|GnRH agonist|Long protocol of GnRH agonist administered to prevent premature LH surges during COS in order to achieve a pregnancy
1820260|NCT00724802|Dietary Supplement|GTA (Glyceryl triacetate)|0.5 gr/kg x2/day syrup two times a day with increasing dose each 3 days till max 5gr /kg each day for 6 months
1820261|NCT00724802|Drug|GTA glyceryl triacetate|0.5 gr/kg twice a day with increase of 0.5 gr/kg every 3 days up to 5 gr/kg
1820262|NCT00724815|Drug|NP101 - Sumatriptan iontophoretic transdermal patch|Sumatriptan iontophoretic transdermal patch
1820263|NCT00724815|Drug|Placebo|NP101 Placebo iontophoretic transdermal patch
1820264|NCT00724841|Drug|Obatoclax Mesylate|Obatoclax Mesylate (GMX1777) at various doses in combination with temozolomide
1820265|NCT00724841|Drug|Temozolomide|
1820266|NCT00724854|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered in accordance with approved labeling
1820267|NCT00724854|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered in accordance with approved labeling
1820268|NCT00724867|Biological|Belimumab 1 mg/kg|Belimumab 1 mg/kg IV over one hour every 28 days
1820269|NCT00724867|Biological|Belimumab 10 mg/kg|Belimumab 10 mg/kg IV over one hour every 28 days
1820270|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 5 days prior to surgery
1820271|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 3 days prior to surgery
1820272|NCT00724880|Drug|Clopidogrel|Clopidogrel is stopped 0 days prior to surgery
1820273|NCT00724893|Biological|PegIFN-2b|PegIFN-2b powder for solution adminstered subcutaneously using the newly approved Redipen. Dosing per approved labeling
1820274|NCT00724893|Drug|Ribavirin|Ribavirin capsules administered orally. Dosing in accordance with approved labelling.
1820275|NCT00724906|Drug|123 I - ALTROPANE®|8.0 mCi (±1.0 mCi) will be administered intravenously to each subject.
1820276|NCT00724932|Drug|Rocuronium|Participants will receive an intravenous (i.v.) single bolus dose of 0.6 mg.kg-1 rocuronium. After this dose, maintenance doses of 0.1-0.2 mg.kg-1 rocuronium may be given.
1820277|NCT00724932|Drug|Sugammadex|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, a single bolus dose of 4.0 mg.kg-1 sugammadex at 1-2 PTC.
1820278|NCT00724932|Drug|Neostigmine|After the last dose of rocuronium has been administered, participants will receive, according to the randomization, 50 μg.kg-1 neostigmine (with atropine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
1820279|NCT00724932|Drug|Atropine|After the last dose of rocuronium has been administered, participants will receive, according to randomization, 10 μg.kg-1 atropine (with neostigmine in a ratio of 5:1 for neostigmine:atropine) at reappearance of T2.
1820280|NCT00724945|Device|balafilcon A|multifocal contact lens
1820281|NCT00724945|Device|senofilcon A|multifocal contact lens
1820282|NCT00724958|Biological|Infliximab|Not specified in the protocol.
1993991|NCT03093532|Other|PACHT-c|Participants randomized to the SBIRT-HTN +PACHT-c (Post-Acute Care Hypertension Transition Clinic) arm will receive all interventions of the ED SBIRT-HTN arm plus a 48-72 hour follow-up in the Post-Acute Care Hypertension Transition Clinic for repeat blood pressure assessment, review of screening assessments, and secured PCP appointment with a federally qualified health center within the study site's health system.
1820285|NCT00724984|Drug|PCI-24781|"Phase I Dose Escalation: Up to 5 cohorts will receive PCI-24781 orally at doses starting at 30mg/m2 two times a day approximately 4-6 hours apart (BID), up to 90mg/m2 administered 5 days/week during the first 21 days of each 28 day cycle until the maximum tolerated dose (MTD) is reached. If a dose limiting toxicity (DLT) occurs, then the next cohort will receive PCI-24781 BID for 7 days every other week (2 times in a 28 day cycle).
Phase II Efficacy Evaluation: All patients will receive PCI-24781 orally at the dosage and regimen determined in Phase I."
1820286|NCT00724997|Biological|GHB01L1|Study medication administered as a single intranasal aerosol (520ul) at doses of 6.4 log10, 6.7 log10, 7.0 log10, 7.4 log10 and 7.7 log10 TCID50/volunteer
1820287|NCT00725010|Drug|Temozolomide|Temozolomide will be administered orally at 75 mg/m^2 with radiotherapy during the concomitant treatment phase. After four weeks, temozolomide will be administered at 150 mg/m^2 to 200 mg/m^2 from Day 1 to Day 5 of six therapy cycles during the monotherapy phase.
1820288|NCT00725010|Radiation|Radiotherapy|Radiotherapy will consist of fractionated focal irradiation at a dose of 2 Gy per fraction given Monday through Friday for a total dose of 60 Gy, administered with temozolomide during the concomitant treatment phase.
1820289|NCT00725023|Device|TDP© Lamp|TDP© heat lamp is an electrical device with a heating element sitting behind a ceramic plate made of clay and minerals
1820290|NCT00725023|Device|Dummy TDP© Lamp|The dummy TDP© heat lamp is an electrical device with the heating element removed.
1820291|NCT00725036|Drug|inhaled human insulin|
1820292|NCT00725036|Drug|insulin aspart|
1820293|NCT00725036|Drug|insulin NPH|
1820294|NCT00725049|Device|Dental Implant (Nanotite)|Root form titanium dental implant
1820295|NCT00725062|Biological|CD4+CD25+ regulatory T cells|Cohort 1 will receive 3 x 10^6 CD4+CD25+ cells/kg, Cohort 2 will receive 1 x 10^7 CD4+CD25+ cells/kg, Cohort 3 will receive 3 x 10^7 CD4+CD25 cells/kg
1820296|NCT00725062|Procedure|allogeneic hematopoietic stem cell transplantation|Occurs on Day 0 of study - HLA-identical sibling donor peripheral blood progenitor cell (PBPC) transplantation
1820297|NCT00725075|Drug|MK-8435 (Org 25935) 4-8 mg|Administered orally 2 times a day (BID) for a final concentration of 8-16 mg/day
1820298|NCT00725075|Drug|Placebo|Matching placebo for MK-8435 (Org 25935) administered orally BID
1820299|NCT00725075|Drug|MK-8435 (Org 25935) 12-16 mg|Administered orally BID for a final concentration of 24-32 mg/day
1820300|NCT00725088|Behavioral|Exercise training|Exercise training
1820301|NCT00725101|Drug|Treatment for Fibromyalgia|FM participants starting any new pharmacologic FM agent.
1820302|NCT00725114|Biological|Tetrodotoxin|30 µg twice daily for 4 days
1820303|NCT00725114|Biological|Placebo|2 mL subcutaneous injection twice daily for 4 days
1820304|NCT00725127|Drug|aspirin|100 mg/day upon awakening for five years
1820305|NCT00725127|Drug|aspirin|100 mg/day at bedtime for five years
1820306|NCT00725153|Device|Balafilcon A contact lenses (PureVision)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
1820307|NCT00725153|Device|Etafilcon A contact lenses (Acuvue2)|Commercially marketed, soft contact lenses worn bilaterally for 10 hours
1820308|NCT00725166|Other|Skeletal muscle aging|"W1 - Blood test
Maximal voluntary contraction of quadriceps
Hydrostatic weighing
W2 - Maximal metabolic test using a cycloergometer
W3 - Muscular biopsy"
1820309|NCT00725192|Behavioral|Cognitive Processing Therapy|Clients will receive between 12 sessions of Cognitive Processing Therapy.
1820310|NCT00725192|Behavioral|Hypnosis|PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
1820311|NCT00725205|Biological|PegIntron (Peginterferon alfa-2b)|Peginterferon alfa-2b (injection pen) administered according to the product's labeling and current practice in Hungary (1.5 micrograms [mcg]/killogram [kg]) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
1820312|NCT00725205|Drug|Rebetol (Ribavirin)|Ribavirin capsules administered according to the product's labeling and current practice in Hungary (weight based daily) for 12 weeks. Those participants whose continued treatment was warranted beyond week 12 based on response received therapy for 24 or 48 weeks depending on the viral genotype.
1820313|NCT00725218|Drug|Saline|Saline 5 ml injection 10 min prior to propofol administration.
1820314|NCT00725218|Drug|Flurbiprofen Axetil|Flurbiprofen Axetil 50 mg in 5 ml injection 10min prior to propofol administration.
1820315|NCT00725231|Biological|alemtuzumab|Addition of 30 mg Alemtuzumab by subcutaneous application for the first 4 cycles
1820316|NCT00725231|Drug|chemotherapy|dose dense chemotherapy with CHOP-14, 6 cycles, + G-CSF
1820317|NCT00725244|Device|Bipolar eletrocoagulation|Bipolar Eletrocoagulation was performed with a high-frequency electrosurgical generator (ERBE® ICC 200 Eletromedizin, Tubingen, Germany), using Gold probe (Wilson- Cook®) with 7 Fr diameter and 300 cm length. The power setting was 50 W. Coagulation of each telangiectasia was achieved with the probes by applying light pressure directly on the telangiectasia.
1820318|NCT00725244|Device|Argon Plasma Coagulation|"Argon plasma coagulation was delivered using a spray-painting technique, with short applications at 40 W power with a gas flow of 1.0l per minute. APC equipment was an argon delivery unit (ERBE® ICC 300) coupled a high frequency surgery unit (ERBE® ICC 200). Only the end-firing probe with 2.3 mm and 220 cm length was used. The probe was purged with argon, tested and passed though the endoscope until it extends approximately 1 cm from the tip. The probe was hold just above the mucosal surface and the contact was avoided. During the procedure periodic suction was made to prevent over-distention with gas and consequently patient discomfort."
1820319|NCT00725257|Other|Mediterranean diet|The recommended composition of the dietary regimen was as follows: Carbohydrate 40 to 50%, protein 15 to 20%; fat 30 to 40%; saturated fat less than 10%.
1820320|NCT00725257|Other|Low-fat diet|The recommended composition of the dietary regimen was as follows: Fat less than 30%; carbohydrate 50 to 60%, protein 15 to 20%; saturated fat less than 10%.
1820321|NCT00725270|Drug|Mifepristone|600 mg of mifepristone
1820322|NCT00725270|Drug|Placebo Oral Tablet|Placebo comparator
1820327|NCT00725335|Procedure|curative resection without Pringle|Radical excision of liver cancer without the procedure of pringle manoeuvre
1820328|NCT00725335|Procedure|curative resection with Pringle manoeuvre|curative resection liver cancer under pringle manoeuvre
1820329|NCT00725348|Drug|Talarozole|1.0 mg oral dose per day
1820330|NCT00725361|Drug|Ambrisentan|
1820331|NCT00725374|Drug|tibolone|one tablet of 2.5 mg tibolone, per day, every day, for 14 ± 2 days (until the day before surgery).
1820332|NCT00725374|Drug|placebo|Subjects were to take one tablet of tibolone-matched placebo, per day, every day, for 14 ± 2 days (until the day before surgery).
1820333|NCT00725400|Other|Cetuximab and Radiation Therapy|Patients will receive Cetuximab and Radiation Therapy. Patients will receive a dose of Cetuximab through Intravenous (IV). The initial dose is 400 mg/m2 administered as a 120-minute intravenous infusion (maximum infusion rate 10 mg/min) and weekly dose is 250 mg/m2 infused over 60 minutes (maximum infusion rate 10 mg/min) until disease progression or unacceptable toxicity. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
1820334|NCT00725400|Procedure|Surgery and Radiation Therapy|Patients will undergo Surgery before or after Radiation Therapy. Colorectal Cancer Surgery are Colon resection (Colectomy), Rectum resection (Proctectomy), Colostomy, and Radiofrequency ablation. Radiation treatment for Colorectal Cancer are Intensity Modulated Radiation Therapy (IMRT). IMRT delivers radiation directly to the tumor and modulates the intensity of the radiation with laser accuracy.
1820335|NCT00725413|Drug|etonogestrel implant (Implanon)|subdermal etonogestrel implant
1820336|NCT00725426|Drug|Bosutinib|
1820337|NCT00725439|Drug|Talarozole|Oral Dose 1.0 mg once daily
1820338|NCT00725452|Biological|Infliximab|Infliximab initial induction therapy consisting of 3 Infliximab infusions at weeks 0, 2, and 6 given in specialized centers. A maximum of 6 maintenance infusions will be given in doses and intervals due to the discretion of the physicians.
1820339|NCT00725478|Drug|Piribedil|
1820340|NCT00725491|Drug|ganirelix|On day 6 of recFSH treatment, Org 37462 treatment will start by daily SC administration (0.25 mg) up to and including the day of hCG administration.
1820341|NCT00725491|Drug|triptorelin|a daily dose of 0.05 mg SC is to be injected. Triptorelin treatment will start in the luteal phase at day 21-24 of the menstrual cycle. Treatment with recFSH will start 14 days later if treatment with triptorelin has resulted in downregulation, i.e. serum E2 <= 50 pg/ml (<= 200pmol/l). In case the hypogonadotropic state is not reached after 14 days of pretreatment, the dose of triptorelin will be increased to 0.1 mg. If downregulation is not reached within 28 days of pre-treatment with triptorelin, the subject will be discontinued from further hormonal treatment. The daily dose of triptorelin is sustained up to and including the day of hCG.
1820342|NCT00725504|Drug|Intravenous lidocaine|Intravenous lidocaine administered up to 5 µg/ml.
1820343|NCT00725517|Drug|Icodextrin|Icodextrin was used instead of Dianeal for long dwell time every day for 5 weeks.
1820344|NCT00725530|Device|balafilcon A contact lens (PureVision)|Commercially marketed, silicone hydrogel contact lens
1820345|NCT00725530|Device|etafilcon A contact lens (Acuvue2)|Commercially marketed, hydrogel contact lens
1820346|NCT00725543|Biological|Infliximab|Remicade induction therapy consists of 3 infusions given at weeks 0, 2, and 6 in specialized centers. Maintenance therapy will consist of a maximum of 6 infusions given in doses and intervals due to discretion of physicians.
1820347|NCT00725556|Other|Speech Therapy|Speech Therapy
1820348|NCT00725569|Drug|Bellis perennis and Staphysagria (C6)|homeopathic remedy
1820349|NCT00725569|Drug|Bellis perennis and Staphysagria (C30)|Homeopathic Remedy
1820350|NCT00725569|Drug|Placebo|Placebo remedy, identical in size, shape and taste to treatment remedies
1820351|NCT00725582|Drug|IMA-026|
1820352|NCT00725582|Other|Placebo|
1820353|NCT00725608|Drug|buprenorphine/naloxone|2/0.5 mg buprenorphine/naloxone and 8/2 mg buprenorphine/naloxone sublingual tablets; dosage and frequency are subject specific; subjects will receive treatment for up to 12 months
1820354|NCT00725621|Biological|Infliximab|Remicade induction therapy consisting of three Remicade infusions in weeks 0, 2, and 6 given in specialized centers. Maintenance therapy will consist of another maximal 6 infusions given in doses and intervals due to discretion of physicians.
1820355|NCT00725634|Biological|AV-299|AV-299 monotherapy will be given as intravenous infusion in dose-escalation cohorts at 2, 5, 10, and 20 mg/kg. Once the RP2D has been determined the cohort may be expanded to include up to 12 patients for safety assessment and enriched with up to 12 additional Multiple Myeloma patients.
1820356|NCT00725634|Biological|AV-299 + erlotinib|AV-299 will be given as intravenous infusion at RP2D in combination with erlotinib (150 mg daily). Once the combination-RP2D has been determined the cohort may be expanded to include up to 12 additional patients.
1820357|NCT00725686|Drug|PF-04523655|This is a dose-escalation study (50, 100, 200, 400, 670, 1000, 1500, 2250, 3000 microgram) given at baseline and then the subject is followed up for 24 months
1820358|NCT00725712|Drug|GSK1363089 (formerly XL880)|c-MET tyrosine kinase inhibitor
1820359|NCT00725725|Behavioral|Cognitive-behavioral therapy|Participants underwent 5 weekly CBT session (sessions were 60-90 minutes in duration).
1820360|NCT00725725|Drug|Org 25935|4 mg Org 25935 is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
1820361|NCT00725725|Drug|Org 25935|12 mg Org 25935 is given in tablet form, a single dose two hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a two-week period.
1820362|NCT00725725|Drug|Placebo|Placebo is given in tablet form, a single dose 2 hours prior to 3 CBT sessions. A total of 3 doses of trial medication is given over a 2-week period.
1820363|NCT00725738|Genetic|Stem Cell Transplantation|"1-2 million of CD34 cells injected through the infarct related artery by PTCA over-the-wire catheter during multiple sequences of balloon artery occlusion with a mean duration of 30 minutes."
1820364|NCT00725751|Biological|Pegylated interferon alfa-2b (PegIFN-2b)|PegIFN-2b administered according to European labeling.
1820365|NCT00725751|Drug|Ribavirin|Ribavirin administered according to European labeling.
1997030|NCT02268331|Other|Active Surveillance|
1820367|NCT00725777|Drug|artemether-lumefantrine|Standard artemether-lumefantrine treatment
1820566|NCT00733382|Drug|dexamethazone|injection form, 8 miligram, injected once
1997031|NCT02268331|Other|Passive Surveillance|
1820368|NCT00725790|Drug|Vardenafil|"10 mg vardenafil on demand treatment for first 4 weeks.
A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period.
A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of vardenafil or down-titrate to 5 mg per dose of vardenafil during the subsequent 4 week double-blind treatment period."
1820369|NCT00725790|Drug|Placebo|"10 mg placebo on demand treatment for first 4 weeks.
A decision is made at week 4 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period.
A decision is made at week 8 to either maintain the previous dosage regimen or to up-titrate to 20 mg per dose of placebo or down-titrate to 5 mg per dose of placebo during the subsequent 4 week double-blind treatment period."
1820370|NCT00725803|Drug|GS-9450|GS-9450 capsules administered orally once daily
1820371|NCT00725803|Drug|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
1993998|NCT03092193|Drug|Naproxen|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen (500mg) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
1820375|NCT00725842|Biological|Peg-IFN alfa-2b|Peg-IFN alfa-2b administered in accordance with approved labeling
1820376|NCT00725842|Drug|Ribavirin|Ribavirin administered in accordance with approved labeling
1820377|NCT00725855|Drug|MEM 3454|1 mg dose
1820378|NCT00725855|Drug|MEM 3454|5 mg dose
1820379|NCT00725855|Drug|MEM 3454|15 mg dose
1820380|NCT00725855|Drug|MEM 3454|50 mg dose
1820381|NCT00725855|Drug|Placebo for MEM 3454|Placebo dose
1820382|NCT00725868|Other|Data private hospitals, angioplasty, sampling of blood|"Data private hospitals : Age, sex, index of body mass, factors of cardiovascular risk, medical surgical histories, treatment before and after the angioplasty, the renal insufficiency
coronary angioplasty
Sampling of blood : Before the angioplasty, 6 hours after the angioplasty and 24 hours after the angioplasty. A numeration of the proparents circulants (hématopoietics, PEC) and a numeration of CEC are made"
1820383|NCT00725881|Drug|Trans sodium crocetinate (TSC)|Once-daily bolus intravenous injections in a superficial vein of the arm via syringe over a period of up to 2 minutes. Each patient will receive up to 5 doses given on 5 consecutive days
1820384|NCT00725881|Drug|0.9% normal saline|A total volume of 5.0 mL normal saline will be dosed in a superficial vein of the arm via syringe over a period of up to 2 minutes.
1820385|NCT00725894|Device|Pediatric Locking Nail|The nail is pre contoured with a nine-degree anterior bow and is universal for right and left femoral.
1820386|NCT00725907|Biological|PGRF|injection of 6cc into injured area
1820387|NCT00725907|Biological|placebo saline|injection of 6cc into injured area
1820388|NCT00725920|Drug|Topiramate|patients will receive the active drug. The starting dose was 25 mg/day, with weekly increments of 25 mg/day, according to clinical status. The maximum dose considered was 200 mg/day
1820389|NCT00725920|Drug|placebo control group|initial dose 25 mg day, increments of 25 mg each 2 weeks. Up to 100 mg/day Those with no intolerance and no response dose could be up to 200 mg day
1820390|NCT00725933|Drug|BIIB028|IV infusion administered twice weekly until disease progression or unacceptable toxicity
1820393|NCT00725972|Other|Augment O2 Delivery by hemodynamic protocol|Hemodynamic management to a goal of O2 delivery of 600 ml/m2/min utilizing cardiac stroke volume variation with positive pressure ventilation to optimize fluid management.
1820394|NCT00725972|Procedure|High Risk Surgery|Patients with same characteristics as Experimental Group having same types of Surgery but no change to usual anesthetic care
1820395|NCT00725985|Drug|Cladribine|Cladribine tablets will be administered as cumulative dose of 0.875 milligram per kilogram (mg/kg) over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48, and 52 resulting in total cladribine dose of 5.25 mg/kg during the initial treatment period (ITP) of 96 weeks or until CDMS conversion, whichever occur first
1820396|NCT00725985|Drug|Cladribine|Cladribine tablets will be administered as cumulative dose of 0.875 mg/kg over a course of 5 consecutive days at Weeks 1, 5, 48, 52 and placebo matched to cladribine tablets will be administered at Week 9 and 13 resulting in total cladribine dose of 3.5 mg/kg during the ITP of 96 weeks or until CDMS conversion, whichever occur first
1820397|NCT00725985|Drug|Placebo|Placebo matched to cladribine tablets will be administered over a course of 5 consecutive days at Weeks 1, 5, 9, 13, 48 and 52 during the ITP of 96 weeks or until CDMS conversion, whichever occur first
1820398|NCT00725985|Drug|Rebif® new formulation (RNF)|Participants who will convert to CDMS during ITP will enter in open-label maintenance period (OLMP) and receive RNF subcutaneously at a dose of 44 microgram (mcg) three times a week. Participants who will convert to CDMS during long-term follow-up (LTFU) period, will also receive RNF subcutaneously at a dose of 44 mcg three times a week
1820399|NCT00726011|Biological|Tetrodotoxin|30 µg twice daily for 4 days; repeated every two weeks as long as there is a meaningful analgesic response
1820400|NCT00726037|Drug|Ontak|One dose of Ontak 9 mcg/Kg IV over 30 minutes times 3 doses. 1 dose every other day
1820401|NCT00726063|Device|Nanotite dental implant|Nanotite root form titanium dental implant
1820402|NCT00726063|Device|Osseotite dental implant|Osseotite Root form titanium dental implant
1820403|NCT00726076|Behavioral|WebEase|"Computer-based epilepsy self-management program
The Treatment Group received the WebEase Intervention immediately after completing the Baseline Assessment"
1820404|NCT00726076|Behavioral|WebEase|Control Group also received the WebEase Intervention. However, Control Group participants began the Intervention 6 weeks after completing the Baseline Assessment.
1820405|NCT00726102|Other|Meat|2 0z of locally available meat per day
1820406|NCT00726102|Other|Cereal|Daily provision of cereal to infants from 6-18 mos
1820407|NCT00726102|Other|fortified rice cereal|Daily provision of fortified cereal to infants 6-18 months of age
1820408|NCT00726115|Drug|SAM-531|
1820409|NCT00726115|Drug|placebo|
1820410|NCT00726128|Device|VueLock™ Anterior Cervical Plate|Implanted in subjects having an ACDF
1880646|NCT01182636|Drug|Placebo|Gel Base
1820411|NCT00726141|Behavioral|Brief intervention, Motivational Interviewing, Expert System|Motivational Interviewing, stage-tailored self-help manual, physician letter, expert system feedback letter
1820412|NCT00726154|Behavioral|IPSRT|Interpersonal and social rhythm therapy (IPSRT) focuses specifically on rhythmicity. IPSRT is based on the social zeitgeber hypothesis (Ehlers et al., 1988; 1993) and the conviction that regularity of social routines and stability of interpersonal relationships have a protective effect in recurrent mood disorders. In IPSRT, resolution of depressive symptoms is theorized to come about through the exploration of the links among mood symptoms, stability of social rhythms and quality of social relationships and social role performance, and the identification and management of potential precipitants of rhythm disruption.
1820413|NCT00726154|Behavioral|Collaborative Care|The collaborative care (CC) condition is a less intensive psychosocial intervention that was employed as the control condition in the STEP-BD study of psychosocial treatment (see Miklowitz et al., 2007). Participants assigned to this condition will receive a psychoeducational videotape and a workbook including information about: 1) the diagnosis, management, and treatment of bipolar illness; 2) the importance of medication adherence; 3) schedule management including daily mood charting; 4) typical biases in thinking relevant to mood states; 5) improving relationships through communication skills; and 6) developing a treatment contract geared toward preventing episodes.
1820414|NCT00726167|Device|Procalcitonin Level|Procalcitonin concentrations will be determined every day and will be compared with the clinical diagnosis based upon standard clinical practice. All subjects enrolled will be followed until the patient is either extubated or discharged from the SICU.
1820415|NCT00726180|Drug|trastuzumab (Herceptin®)|About 1 week (4 - 7 days) before scheduled breast surgery, consisting of lumpectomy or mastectomy, subjects will receive a dose of trastuzumab (Herceptin®). Trastuzumab will be given through an IV or port for approximately 90 minutes. During this time, subjects will be closely monitored by a chemotherapy nurse to make sure that subjects do not have a reaction to the medication. It is possible that the infusion of the medication will need to be slowed down, in which case, the time for the infusion will be longer than 90 minutes. The one dose of the trastuzumab drug will be provided by the study (not billed to insurance), but the charges to administer the drug will be billed to subjects or subjects health insurance.
1820416|NCT00726193|Device|OsteoGen|OsteoGen Implatable stimulator
1820417|NCT00726206|Other|Electroencephalogram, recording the movements|Electroencephalogram, recording the movements of the child, RMI, Transfontanel Imaging
1820418|NCT00726219|Other|Femoral perineural catheter|Comparison of 2 insertion distances (3 vs 7 cm) for a femoral perineural catheter in the context of major knee surgery.
1820419|NCT00726232|Drug|Ruxolitinib|Ruxolitinib was administered orally and supplied as 5 mg and 25 mg tablets.
1820420|NCT00726245|Biological|PRGF|3-6mg IM (to area of muscle tear)
1820421|NCT00726245|Biological|Placebo|3cc IM of physiological saline
1820422|NCT00726258|Drug|ketamine|ketamine with various concentrations
1820423|NCT00726258|Drug|placebo|physiological serum
1820424|NCT00726271|Dietary Supplement|light olive oil, fish oil capsules, flax seed oil capsules|fish oil 1000 mg capsules three daily flax seed oil 1000 mg capsules three daily light olive oil 30 ml to 60 ml daily(weight less than 160 pounds, 30 ml/ weight 160-200 pounds 45 ml/ weight over 200 pounds 60 ml)
1820425|NCT00726310|Device|SpineLink® , SpineLink® II|Spine plate system for lumbar spinal fusions
1995583|NCT02715856|Other|Follow Up with Mobile Device|At weeks 3, 7, 13, and 25 participant uses a mobile device to send the study staff photos of their surgical wound and videos of their walking tests.
1820427|NCT00726336|Drug|GSK1349572 and tenofovir|
1820428|NCT00726349|Other|No intervention|Observational study.
1820429|NCT00726375|Drug|Etanercept (Enbrel)|Etanercept will begin within 72 hours of the diagnosis of Grade I acute GVHD and after consent for this study. Subjects receive eight doses of etanercept over four weeks. All doses will be administered by SQ injection. All subsequent doses will be given as subcutaneous injections into the skin. Injections will be given twice weekly with at least one day in between injections. The injections can be given in clinic, in the hospital, or self administered injections.
1820430|NCT00726388|Drug|DIC075V (intravenous diclofenac sodium)|multiple doses up to 5 days
1820431|NCT00726401|Drug|COLD-fX|200mg BID for 4 weeks
1820432|NCT00726401|Drug|Placebo|200mg BID for 4 weeks
1820433|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered after an overnight fast of at least 10 hours.
1820434|NCT00726414|Drug|Quinine Sulfate 2 x 324 mg Capsules|Quinine Sulfate (2 x 324 mg capsules) administered 30 minutes after a standardized, high fat breakfast.
1820435|NCT00726427|Drug|AZD1656|Dose escalation to achieve maximum tolerated dose
1820436|NCT00726427|Drug|AZD1656|Oral single dose
1820437|NCT00726440|Device|Navigator®|Patients will be encouraged to use the Navigator® all the time and to modify their treatment according to the device measurments. Patients will also follow and educational process in order to adapt insulin doses according to each sensor data
1820438|NCT00726440|Device|Navigator®|Patients will follow the same educational process as group1 concerning insulin doses adaptation.The duration of the use of the devicewill be determined at the consultation every each 3 months.
1820439|NCT00726440|Device|Placebo|Patients will have their usual follow up with self-monitoring blood glucose
1820440|NCT00726453|Device|Resolute Zotarolimus-Eluting Coronary Stent|Implantation of a Resolute Zotarolimus-Eluting Coronary Stent
1820441|NCT00726466|Drug|Efalizumab, Ranibizumab|
1820442|NCT00726479|Drug|BIBW 2948 BS|7.5 mg b.i.d, 15mg q.d, 15mg b.i.d
1820443|NCT00726492|Other|Continuous short wave diathermy (CSWD)|CSWD applied twice a week for 4 weeks
1820444|NCT00726492|Other|Hydrotherapy|Hydrotherapy (exercise in water) attended twice a week for 4 weeks
1820445|NCT00726505|Drug|Dapagliflozin|Tablets, Oral, Once Daily, up to 29 days:
1820483|NCT00726726|Drug|BMS-708163 + Cooperstown Cocktail|Capsules + tablets + Oral solution, Oral, BMS-708163: 150 mg + Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg, BMS-708163, once daily, days 16-20 midazolam,warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan once daily on Day 16, 5 Days
1820618|NCT00733902|Biological|tanezumab|IV tanezumab 2.5 mg at 1 dose every 8 weeks
1885759|NCT01222650|Drug|KSO-0400|
1820446|NCT00726531|Behavioral|Otago Exercise Programme|Home based exercise programme (OEP) This exercise programme consists of a 30 minute programme of leg muscle strengthening and balance retraining exercises progressing in difficulty to be performed at home at least three times per week, and a walking plan to be undertaken at least two times per week for 24 weeks. . Trained peer mentors will contact and visit the patients at their home to start the exercise programme with them and will follow-up with up to three more home visits / exercise sessions as the participants require
1820447|NCT00726531|Behavioral|Fame|Community based exercise programme (FaME) FaME includes and extends the OEP. It will comprise one hour PSI delivered group exercise class in a local community centre for a maximum of 15 participants, and two 30 minute home exercise sessions (based on the extended OEP) per week for 24 weeks. Participants will also be advised to walk at least twice per week for up to 30 minutes at a moderate pace.
1820448|NCT00726531|Other|Treatment As Usual|Treatment as usual by the general practitioner
1820449|NCT00726544|Drug|ARC 1779 Placebo|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper.
1820450|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 3μg/mL.
1820451|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 6μg/mL.
1820452|NCT00726544|Drug|ARC1779 Injection|ARC1779 Injection or placebo is administered intravenously to patients as an initial loading dose followed by continuous infusion of up to 14 days plus 2 day taper. Treatment with ARC1779 Injection is to be given at low dosage that is intended to produce target steady-state ARC1779 plasma concentrations during infusion of 12μg/mL.
1820453|NCT00726557|Biological|PegIntron (pegylated interferon alfa-2b; SCH 54031)|PegIntron 1.5 μg/kg/week administered for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue PegIntron therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
1820454|NCT00726557|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at 10.6 mg/kg/day for a minimum of 12 weeks. Patients who achieve early virologic response at Treatment Week 12, will continue Rebetol therapy for a total of 24 weeks for subjects infected with HCV genotype 2 or 3, and for a total of 48 weeks for subjects infected with HCV genotype 1 or 4
1820455|NCT00726570|Device|Sequential compression device therapy|"Pneumatic stockings will be applied to patients.
Pressures ranging from 12 to 40 mmHg will be applied at different levels of the lower limb for 40-second cycles at 2-minute intervals. Therapy will continue until the morning after surgery."
1820456|NCT00726570|Drug|Dalteparin|"2500 UI qd if ≤ 50 kg body weight
5000 UI qd if > 50 kg"
1820457|NCT00726570|Procedure|TEG|"A 2-ml blood sample will be used for each exam. A full analysis will be run both with and without heparinase at each time point.
TEG analyses will be run at:
Patient admission (before SCD start)
40-60 min after admission
Morning after surgery"
1820458|NCT00726583|Drug|PX-866|Oral solution, dose escalation, once per day on days 1 to 5 and 8 to 12 or days 1-28 of a 28 day cycle, until progression or development of unacceptable toxicity
1995584|NCT02715856|Behavioral|Surveys|After each visit, participant completes a survey about their physical and emotional health as well as their pain. At the end of the study, participant completes a survey regarding the study.
1820460|NCT00726609|Drug|Posaconazole|The usual dose of NOXAFIL® is 400 mg twice daily (10 mL) at meals or with 240 mL of a food supplement. For patients unable to take meals or food supplements, NOXAFIL® is administered at a dose of 200 mg (5 mL) four times daily.
1820461|NCT00726622|Procedure|Open laparotomy and rectal resection|Patients undergo open laparotomy and rectal resection.
1820462|NCT00726622|Procedure|Laparoscopic-assisted rectal resection|Patients undergo laparoscopic-assisted rectal resection.
1820463|NCT00726635|Behavioral|Cognitive intervention|The intervention will last one hour and will include cognitive technique (self-talk). The technique will be demonstrated to the woman, practiced with her, and taped so as to encourage further practice at home.
1820464|NCT00726635|Other|Control group|A one hour conversation with a nurse
1820465|NCT00726635|Other|psycho-physiological intervention|The intervention will last an hour and will include a psycho-physiological intervention (relaxation and guided imagery). The technique will be demonstrated to the woman, practiced with her, and taped so as to assure further practice at home
1820466|NCT00726648|Drug|CDP323|50mg capsules, 100mg bid for 4 weeks
1820467|NCT00726648|Drug|CDP323|250mg capsules, 500mg bid for 4 weeks
1820468|NCT00726648|Drug|CDP323|250mg capsules, 1000mg bid for 4 weeks
1820469|NCT00726648|Drug|CDP323|250mg capsules, 1000mg daily for 4 weeks
1820470|NCT00726648|Drug|Placebo|placebo capsules for 4 weeks
1820471|NCT00726687|Drug|indibulin|indibulin, dose escalation, 400-600 mg taken twice every day
1820472|NCT00726687|Drug|capecitabine|capecitabine, dose escalation, 875 mg/m2- 1250 mg/m2, taken twice daily for 14 days per 21 day cycle
1820473|NCT00726700|Biological|pegfilgrastim|Given subcutaneously
1820474|NCT00726700|Biological|rituximab|Given IV
1820475|NCT00726700|Drug|cyclophosphamide|Given IV
1820476|NCT00726700|Drug|doxorubicin hydrochloride|Given IV
1820477|NCT00726700|Drug|prednisone|Given orally
1820478|NCT00726700|Drug|vincristine sulfate|Given IV
1820479|NCT00726713|Other|Metanx (a medical food)|Metanx one tablet twice a day
1820480|NCT00726713|Other|Metanx placebo|Metanx placebo one tablet twice a day
1820481|NCT00726726|Drug|Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)|Capsules + Tablets + Oral solution, Oral, Midazolam: 5 mg, Warfarin: 10 mg (vitamin K 10 mg), caffeine: 200 mg, omeprazole: 40 mg, dextromethorphan: 30 mg once daily, Day 1, 1 Day
1820482|NCT00726726|Drug|BMS-708163|Capsules, Oral, 150 mg, once daily, days 6-15, 10 Days
1885760|NCT01222650|Drug|KSO-0400|
1820484|NCT00726739|Biological|aldesleukin|IL-2 Alone - administer 10 x 10^6 International Units subcutaneously (SQ) will be given on day 1 and day 2 every 4 weeks until disease progression or for a maximum of 12 treatment cycles.
1820485|NCT00726739|Biological|allogeneic large multivalent immunogen vaccine|Allogeneic tumor cell membrane-coated large multivalent immunogen (LMI [1 x 10^7, 5-μm silica spheres]) will be given as an intradermal injection every 4 weeks for up to 12 injections. Each vaccine dose will be 0.2 ml.
1820486|NCT00726752|Drug|Axitinib (AG-013736)|Three single dose level of AG-013736 (5 mg, 7 mg and 10 mg) will be given for all patient. After single dosing at each dose level, multiple doses of 5 mg twice a day (BID) will be started.
1820487|NCT00726791|Device|repetitive Transcranial Magnetic Stimulation (rTMS)|Patients receive high frequency rTMS applied to the motor cortex (M1 area). The treatment protocol consists of 10 sessions of rTMS. At each session, patients receive 30 stimulation trains (10 Hz, 4 sec, 100% motor threshold) with 26 sec inter-train interval, resulting in a total of 1200 pulses per session.
1820488|NCT00726804|Drug|Discontinuation of TNF-alpha inhibitor and re-starting it if flare-up in disease activity (etanercept or adalimumab)|Discontinuation of infusion infliximab (Remicade) 3-5mg/kg every 6-8 week, injection of etanercept (Enbrel) 25 mg x 2/week or injection of adalimumab (Humira) 40 mg eow.
1820489|NCT00726817|Drug|Butyrate|
1820490|NCT00726830|Drug|methadone hydrochloride|Given orally
1820491|NCT00726830|Drug|morphine sulfate|Given orally
1820492|NCT00726830|Drug|oxycodone hydrochloride|Given orally
1820493|NCT00726843|Other|8 weeks of Iyengar Yoga|Participants will attend 8 weekly, 75 min. yoga sessions, followed by 8 weeks of follow-up (will provide headache frequency/intensity)
1820494|NCT00726843|Other|8 weeks of Iyengar Yoga|Participants will provide headache frequency/intensity for 8 weeks, followed by 8 weekly, 75 min. yoga sessions
1820495|NCT00726856|Drug|Ezetimibe 10 mg plus statin or ezetimibe 10 mg plus fenofibrate|Ezetimibe 10 mg taken daily for 3 months
1820496|NCT00726869|Drug|Elotuzumab (HuLuc63)|Cohort 1 - 2.5 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 2 - 5.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; Cohort 3 - 10.0 mg/kg elotuzumab IV withbortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8; and Cohort 4 - 20.0 mg/kg elotuzumab IV with bortezomib on Days 1 & 11, with only Bortezomib IV on Days 4 & 8.
1820497|NCT00726882|Procedure|Blood sample collection only|Approximately monthly collection of blood samples.
1820498|NCT00726882|Drug|ABT-333|Previous treatment in prior ABT-333 studies.
1820499|NCT00726895|Drug|Quinine Sulfate Capsules 324 mg|1 x 324 mg capsule
1820500|NCT00726895|Drug|Quinine Sulfate Capsules 324 mg|2 x 324 mg capsules
1820501|NCT00726908|Dietary Supplement|Low carbohydrate|43% CHO
1820502|NCT00726934|Other|Food Safety Guidelines|Participants will be randomized to the food safety guidelines will receive information and recommendations regarding Food Shopping, Food Storage, Food Preparation, Safe Cooking, and Safe Serving of Food.
1820503|NCT00726934|Other|Neutropenic Diet|"The Neutropenic Diet Guideline includes all information contained in the FDA Food Safety Guidelines with the addition of the following recommendations:
Avoid raw vegetables and fruit (Oranges and bananas are okay.)
Avoid take-out foods and fast foods and fountain drinks.
Avoid aged cheese (blue, Roquefort, Brie).
Cook all produce to well done. Eggs must be hard-boiled.
Avoid deli meats.
No raw nuts, nuts roasted in shell, or freshly ground nut butters from a health food store.
No well water
No yogurt"
1820504|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Acute DVT
1820505|NCT00726947|Procedure|Ultrasound|Ultrasound imaging of Chronic DVT
1820506|NCT00726960|Drug|aprepitant|Oral, 125 mg once daily for one week
1820507|NCT00726960|Drug|Pseudo-placebo - buprenorphine|Randomized to receive either 8 mg sublingual tablets or 0.4 mg sublingual tablets
1820508|NCT00726973|Drug|Ranibizumab|Ranibizumab, and reduced fluence PDT or sham PDT and Ranibizumab. For 2 months injected intravitreal Ranibizumab will be given. At month 3 subjects will receive combination reduced fluence PDT and intravitreal Ranibizumab. If they develop recurrence of subretinal fluid, cystoid macular edema, increased pigment epithelial detachment (PED), or increased retinal thickness >100 microns compared to best thickness measure of OCT, subjects will be eligible for repeat combination reduced fluence PDT + intravitreal Ranibizumab every 3 months thereafter.
1820509|NCT00726973|Drug|Ranibizumab monotherapy|3 monthly intravitreal injections of Ranibizumab monotherapy. After month 2 they are eligible for retreatment with Ranibizumab if retreatment criteria are met (same as arm 1) At intervals of no less than 3 months from the previous sham PDT they will receive sham PDT if retreatment criteria are met.
1820510|NCT00726986|Drug|cisplatin|Cisplatin IV over 30-60 minutes on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
1820511|NCT00726986|Drug|etoposide|Etoposide IV over 60 minutes on days 1-3. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.
1820512|NCT00726986|Drug|sorafenib tosylate|Oral sorafenib tosylate twice daily beginning on day 1 of course 1 and continuing for up to 1 year in the absence of disease progression or unacceptable toxicity.
1820513|NCT00726999|Drug|Gabapentin|oral gabapentin in load pre-op (15mg/kg) and maintenance 5mg/kg TID for 5 days or discharge
1820514|NCT00726999|Drug|Placebo|
1820515|NCT00726999|Drug|Morphine|Administered as needed
1820516|NCT00727012|Device|mitral valve repair (SJM® Rigid Saddle Ring)|mitral valve repair due to mitral degenerative or functional disease
1820517|NCT00727025|Device|wound closure device (Steri-Strip™)|wound closure with steri-strip S
1820518|NCT00727038|Drug|Ranibizumab (Lucentis)|0.5 mg ranibizumab intravitreal injection single dose administration
1820519|NCT00727064|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
1820520|NCT00727064|Drug|Venlafaxine Extended Release (VEN ER)|
1820521|NCT00727077|Biological|IntronA (interferon alfa-2b; SCH 30500)|IntronA (3 Mio I.E./m2, 3 times per week) administered in accordance with the SPC and approved European labeling
1820522|NCT00727077|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol (15 mg/kg/day) administered in accordance with the SPC and approved European labeling
1820523|NCT00727090|Drug|Conivaptan|Conivaptan 20 mg once, followed by conivaptan 20 mg over 24 hours
1821189|NCT00738348|Drug|sivelstat|sivelstat sodiumhydrate
1820524|NCT00727103|Drug|Varenicline|Varenicline will be dispensed in 0.5 mg and 1 mg tablets taken orally. During the first 3 days of medication, participants will take one 0.5 mg tablet of varenicline daily. If the medication is well-tolerated, the dose will be increased to 0.5 mg po twice daily for 4 days. On day 8, the dose will be increased again to the standard dosing schedule of 1 mg (1 tablet) po twice daily. At the end of the 8th week, varenicline will be discontinued.
1820525|NCT00727103|Drug|Placebo|Placebo will be dispensed in color-coded capsules. Blue capsules will contain 0.5 mg glucose (placebo), red capsules will contain 1 mg glucose (placebo).
1820526|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program: State-wide|Upon the birth of the child in a Pennsylvania hospital, all parents (mothers, and whenever possible, fathers or father figures) will be asked to read written materials and view an 8-minute video on the dangers of violent infant shaking. Parent education materials contain four key messages: crying is a normal infant behavior, how to keep calm when an infant is crying, how to help calm a crying infant, how to select other caregivers for your infant. Parents will be asked to voluntarily sign a commitment statement affirming their receipt and understanding of the materials.
1820527|NCT00727116|Behavioral|PA Abusive Head Trauma Prevention Program Booster: Central PA|All primary care providers serving families of newborns in half of the counties in Central PA will be asked to provide all parents of newborns at the 2-, 4-, and 6-month immunization visits another set of written materials about violent infant shaking and voluntarily sign a response form that they read and understood the materials.
1820528|NCT00727129|Drug|Divigel|
1820529|NCT00727142|Procedure|Surgical treatment|Insertion of a functioning shunt
1820530|NCT00727155|Behavioral|Adjusting to Chronic Conditions Using Education Support and Skills|This psychosocial intervention uses a combination of cognitive-behavioral therapy and disease self-management techniques.
1820531|NCT00727181|Device|Trifecta aortic heart valve|Replacement of a diseased, damaged, or malfunctioning aortic heart valve
1820532|NCT00727194|Drug|eculizumab|eculizumab 600 mg IV weekly for 4 doses followed by eculizumab 900 mg IV every two weeks for 7 doses
1820533|NCT00727194|Drug|Placebo|Placebo IV weekly for 4 doses then every two weeks for 7 doses
1820534|NCT00727207|Drug|everolimus|
1820535|NCT00727233|Drug|Nexavar (BAY 43-9006) (Sorafenib)|
1820536|NCT00727233|Drug|Toxicity, Pharmacokinetics|
1820537|NCT00727233|Drug|Pharmacodynamics|
1820538|NCT00727233|Drug|Radiographic Evaluation|
1820539|NCT00727233|Drug|QOL assessment, Neuropsychological|
1820540|NCT00727233|Drug|Bony Toxicity|
1820541|NCT00727246|Drug|CDP-Choline|1000 mg CDP-Choline 2 x per day for 6 weeks.
1820542|NCT00727246|Drug|Placebo|Treatment with placebo for 6 weeks
1820543|NCT00727259|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b will be administered according to the products' labeling.
1820544|NCT00727259|Drug|Ribavirin (SCH 18908)|Ribavirin will be administered according to the products' labeling.
1820545|NCT00733226|Drug|OM-85 BV (Broncho-Vaxom)|3.5 mg capsule, 1 capsule per day for first 10 day of the month, for 3 months
1820546|NCT00733226|Drug|OM-85 BV (placebo)|3.5 mg oral placebo capsule, 1 placebo capsule per day for first 10 days of the months for 3 months
1820547|NCT00733239|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsule may possibly be given Diltiazem: 30, 60, 120 mg oral capsule may possibly be given Gabapentin: 100, 200, 400 mg oral capsule may possibly be given Isradipine: 5, 10 mg oral capsule may possibly be given Naloxone: 0.15 mg/70 kg or 0.2 mg I.M. injection may possibly be given Nifedipine: 5, 10, 20 mg oral capsule may possibly be given Placebo (sugar pill or microcrystalline cellulose): oral capsule may possibly be given Saline: I.M. injection may possibly be given Verapamil: 30, 60, 120 mg oral capsule may possibly be given
1820548|NCT00733252|Procedure|bronchoscopic and lung imaging studies|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
1820549|NCT00733252|Procedure|diagnostic bronchoscopy|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
1820550|NCT00733252|Procedure|histopathologic examination|All imaged areas are marked. The marked areas are then excised and fixed in formalin for histopathologic analysis.
1820551|NCT00733252|Procedure|optical coherence tomography|Bronchoscopic imaging and optical coherence tomography are performed on lung tissue samples collected during surgery.
1820552|NCT00733265|Drug|AZD6140|single oral dose
1820553|NCT00733278|Device|Copper IUD ( ParaGard Intrauterine Contraceptive Device)|Intraoperative placement of copper IUD at time of C-section
1820554|NCT00733291|Device|Nelfilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
1820555|NCT00733291|Device|Etafilcon A contact lens|Commercially marketed, single vision, soft contact lens for daily disposable wear
1820556|NCT00733291|Device|FID 107027 solution|Commercially marketed solution for contact lens disinfection
1992233|NCT03322904|Diagnostic Test|iris photography|"The LF (0.04-0.15 Hz) and HF (0.16-0.4 Hz) ratings were recorded for 24 hours (day and night average) by Holter recording system
Photographs of both irises of the healthy volunteers were taken . An image software program was used to draw circular limits over the iris exterior circle (IEC), coloretta circle (CC), and pupil circle (PC) on digital photographs. The areas between the circles were measured. The likelihood that the IRIS ratio was equal to the LF/HF ratio was calculated using the formula [IEC-PC¬] ‒ [CC-PC] / [CC-PC]."
1820558|NCT00733317|Drug|0.5 mg/ml budesonide nebules|Children will receive 0.5 mg/ml budesonide nebules every 20 minutes for 3 times
1820559|NCT00733317|Drug|Saline|Children will receive 2 ml of saline every 20 minutes for 3 times
1820560|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using the conventional surgical approach and manual surgical technique|Orthopaedic implants for total knee replacement implanted with a standard approach using standard instrumentation
1820561|NCT00733330|Device|Either P.F.C. Sigma or L.C.S. Complete knee replacement using minimally invasive surgical approach and computer navigation|Orthopaedic implants for total knee replacement implanted with a minimally invasive approach and computer navigation
1820564|NCT00733369|Device|PFC Sigma RP-F|An orthopaedic implant for total knee replacement with a high flexion rotating platform bearing
1820565|NCT00733369|Device|PFC Sigma RP|An orthopaedic implant for total knee replacement with a standard flexion rotating platform bearing
1820567|NCT00733395|Dietary Supplement|Tart Cherry Juice|Participants will ingest 10.5 fl oz of cherry juice twice a day for 7 days prior to the race, and the day of the race (8 days total).
1820568|NCT00733395|Dietary Supplement|Fruit juice|Participants will ingest 10.5 fl oz of fruit juice twice a day for 7 days prior to the race, and the day of the race (8 days total), which will serve as a 'placebo' juice.
1820569|NCT00733408|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1820570|NCT00733408|Biological|bevacizumab|Given IV
1820571|NCT00733408|Drug|erlotinib hydrochloride|Given PO
1820572|NCT00733408|Other|laboratory biomarker analysis|Correlative studies
1820573|NCT00733421|Drug|etoricoxib|90 mg once daily
1820574|NCT00733421|Drug|tramadol|100 mg twice daily
1820575|NCT00733434|Drug|Prostaglandin E1|PGE 1 80mcg/500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
1820576|NCT00733434|Other|Saline|500 ml saline continuous intravenous infusion per day after head and neck microsurgery for 5 days
1820577|NCT00733447|Device|CardioWest temporary Total Artificial Heart (TAH-t) System|The SynCardia CardioWest temporary Total Artificial Heart (TAH-t) System is a pulsatile biventricular device that replaces a patient's native ventricles and valves, and pumps blood to both pulmonary and systemic circulation. The system consists of the implantable CardioWest TAH-t and an external pneumatic driver connected by drivelines.
1820578|NCT00733460|Drug|BFPET|
1820579|NCT00733473|Drug|Budesonide 0.5 mg/ml nebules|Children will receive 1 mg nebulized budesonide 2 times a day up to 5 days
1820580|NCT00733473|Drug|% 0.9 Saline solution|Children will receive 2 ml of nebulized saline 2 times a day up to 5 days
1820581|NCT00733486|Device|L.C.S. APG Knee Anterior Posterior Glide knee|Orthopaedic implant for primary knee replacement
1820582|NCT00733499|Device|LCS Complete Duofix|Orthopaedic implant for total knee replacement with Duofix biological fixation surfaces
1820583|NCT00733499|Device|LCS Complete Porocoat|Orthopaedic implant for total knee replacement with Porocoat biological fixation surfaces
1820584|NCT00733512|Device|ReSTOR|Patients were implanted with the AcrySof ReSTOR Aspheric +4 Intraocular Lens (IOL) in one or both eyes for treatment of cataract.
1820585|NCT00733525|Behavioral|Cognitive Behavioral Therapy|Therapy focusing on skills needed to alter eating patterns
1820586|NCT00733525|Drug|Fluoxetine|20 mg/day of fluoxetine, which can be incrementally increased to 80 mg/day
1820587|NCT00733525|Behavioral|Guided Self-Help|Manual designed to impart teachings of cognitive behavioral therapy
1820588|NCT00733538|Drug|zometa|patients receiving treatment during their follow-up
1820589|NCT00733551|Drug|GSK962040|GSK962040 tablets will be available in dosing strengths of 1 milligram, 5 milligrams, 25 milligrams given orally, once daily, in the morning, in a fasted state.
1820590|NCT00733551|Drug|Placebo|Placebo tablets will be given orally, once daily, in the morning, in a fasted state.
1820591|NCT00733681|Device|PFC Sigma RP TC3 Revision knee system|Orthopaedic implant system for revision total knee replacement
1820592|NCT00733694|Device|LCS® Complete™ Mobile Bearing Knee Systems|An orthopaedic implant for primary total knee replacement with a mobile bearing knee
1820593|NCT00733707|Behavioral|Text messaging reminders|Subjects in this arm will receive daily text message reminders once per day at the same time each day. Messages will remind the subject to take their oral contraceptive pill.
1820594|NCT00733720|Drug|Suboxone|4/1mg, 8/2mg 16/4mg
1820595|NCT00733733|Drug|ATG Fresenius|One gift of ATG Fresenius (9 mg/kg body weight) intravenously during the transplantation procedure. ATG is given in addition to standard immunosuppressive treatment (tacrolimus/MMF/prednisolone)
1820596|NCT00733746|Drug|erlotinib hydrochloride|oral administration
1820597|NCT00733746|Drug|gemcitabine hydrochloride|Intravenous administration
1820598|NCT00733746|Procedure|therapeutic conventional surgery|
1820599|NCT00733772|Dietary Supplement|flaxseed|30 grams/day of flaxseed for 12 weeks
1820600|NCT00733772|Behavioral|Health lifestyle counseling|Health lifestyle counseling accroding to AHA reccommendation
1820601|NCT00733785|Drug|Rosiglitazone XR|Rosiglitazone extended release formulation
1820602|NCT00733798|Drug|131I-TM601|After a single 20mCi/0.4 mg Imaging Dose of 131I-TM601, patients in the Dose Escalation Phase will be administered between 2-5 weekly doses of 131I-TM601 at 1.2 mCi/kg of lean body mass (specific activity of 131I-TM601 will be maintained at 50 mCi 131I/mg TM601 for all doses administered in this study.) Patients in the Efficacy Phase of the study will be treated at the Maximum Tolerated Dose established in the Dose Escalation Phase.
1820603|NCT00733811|Drug|Deferiprone (DFP) and Deferoxamine (DFO)|Sequential treatment including DFP at 75 mg/kg for four days per week and DFO by subcutaneous infusions (8-12h) at 50mg/kg/day for the remaining three days per week
1820604|NCT00733811|Drug|Deferiprone (DFP)|DFP alone at 75 mg/kg divided into three oral daily doses
1820605|NCT00733824|Drug|AMD3100|
1820606|NCT00733824|Drug|G-CSF|
1820607|NCT00733824|Procedure|Apheresis|
1820608|NCT00733837|Other|Nonspecific, Innocuous, Mechanoreceptor Stimulation|A custom device will be used to provide light manual cervical traction
1820609|NCT00733850|Drug|Kanglaite Injection plus gemcitabine|Intravenous repeating dose
1820610|NCT00733850|Drug|Gemcitabine|Intravenous repeating dose
1820611|NCT00733863|Biological|Placebo|
1820612|NCT00733863|Biological|CAD106|
1820613|NCT00733876|Biological|Multipotent Stromal Cells|Post-operative administration of MSC
1820614|NCT00733876|Biological|Administration of MSC|Dose escalation protocol
1820615|NCT00733889|Drug|cetuximab and chemotherapy (docetaxel, cisplatin, 5-fluorouracil)|"Neoadjuvant chemotherapy plus cetuximab:
3 cycles of chemotherapy (Docetaxel: 75 mg/m2; day1; Cisplatin :75 mg/m2, day 1; 5-FU: 750 mg/m2; 24-hour infusion; day1-5) administered every 3 weeks, plus cetuximab (250 mg/m2; day 1, 8 and 15) Cetuximab will be maintained from the beginning of chemotherapy until the end of radiotherapy.
Radio-chemotherapy plus cetuximab:
The radiotherapy treatment: A dose of 50.4 Gy will be administered in 28 fractions of 1.8 Gy / day, 5 days a week (a total of 5.6 weeks).
Cetuximab:250 mg/m2 and Cisplatin: 40 mg/m2, day 1, 8, 15, 22, 29 and 36"
1820616|NCT00733902|Biological|tanezumab|IV tanezumab 10 mg at 1 dose every 8 weeks
1820617|NCT00733902|Biological|tanezumab|IV tanezumab 5 mg at 1 dose every 8 weeks
1820619|NCT00733902|Biological|Placebo|IV placebo to match tanezumab at 1 dose every 8 weeks
1820620|NCT00733915|Device|L.C.S. Complete Knee (DePuy Low Contact Stress Complete Knee System)|L.C.S. Complete mobile-bearing total knee system
1820621|NCT00733928|Device|PFC Sigma knee with all-poly tibial component|Orthopaedic implant for total knee replacement with an all-polyethylene tibial component
1820622|NCT00733928|Device|PFC Sigma knee with metal backed tibia|Orthopaedic implant for total knee replacement with a metal-backed tibial component
1820623|NCT00733941|Behavioral|High frequency training|24 training sessions, 8x weekly, followed by detraining phase 8 weeks, and retraining
1820624|NCT00733941|Behavioral|normal frequence training|24 training sessions, 3x weekly, followed by detraining phase 8 weeks, and retraining
1820625|NCT00733954|Drug|clobetasol propionate spray|Apply twice daily
1820626|NCT00733954|Drug|clobetasol propionate ointment|Apply twice daily
1820627|NCT00733967|Drug|Varenicline|Varenicline (oral capsule): 0.5 mg once daily for 3 days; 0.5 mg twice daily for 2 days; 1 mg twice daily for one day; 1 mg once daily for one day.
1820628|NCT00733967|Drug|Placebo|Matching oral placebo capsules as control.
1992234|NCT03322891|Other|Educational Supplement|Participants will receive education about prostate cancer and treatments using models and props during a face-to-face interview. During the interview, participants will also be asked about medical terms and treatments regarding prostate cancer. The interview will last 45 to 60 minutes.
1997033|NCT02267603|Other|Laboratory Biomarker Analysis|Ancillary studies
1820631|NCT00733993|Drug|Caffeine 150 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
1820632|NCT00733993|Drug|Placebo|Across five separate testing days, subjects were administered two placebo doses, 20 mg amphetamine, 150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
1820633|NCT00733993|Drug|Amphetamine|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
1820634|NCT00733993|Drug|Caffeine 300 MG|Across five separate testing days, subjects were administered two placebo doses, 20 mg damphetamine,150 mg caffeine, and 300 mg caffeine in counterbalanced fashion
1820635|NCT00734019|Device|P.F.C. Sigma Knee|Orthopaedic implant for primary total knee replacement with a cobalt-chrome tibial tray and a moderately cross-linked polyethylene tibial insert
1820640|NCT00734058|Device|Laser MAZE by Ablation of Cardiac Tissue|The protocol calls for the creation of the pulmonary vein isolation lesion through the use of the SOLAR™. The additional lesions are to be created using the ATRILAZE™. At surgeon discretion, the ganglia may be ablated and left and right atrial appendages may be removed.
1820641|NCT00734071|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets
1820642|NCT00734071|Drug|Placebo|Vortioxetine placebo-matching capsules
1820643|NCT00734084|Device|Preservation Unicompartmental Knee|Minimally invasive orthopaedic implant for single compartment knee arthritis
1820644|NCT00734097|Drug|Esomeprazole 40 mg|Once a day
1820645|NCT00734097|Procedure|Physical Exam|every visit
1820646|NCT00734097|Other|Quality of Life Questionnaires|every visit
1820647|NCT00734097|Procedure|pregnancy test, if applicable|as needed
1820648|NCT00734110|Device|P.F.C. Sigma Total Knee System|An orthopaedic implant for total knee replacement
1820649|NCT00734123|Drug|Simvastatin or Atorvastatin|Simvastatin 10-40 mg or Atorvastatin 20-40 mg will be prescribed according to LDL cholesterol reduction target.
1820650|NCT00734123|Drug|Enalapril|Enalapril 10 mg/day will be prescribed as the initial treatment. Doses and adding drugs will be titrated accordingly
1820651|NCT00734123|Drug|Aspirin or clopidogrel|Aspirin 100 mg or clopidogrel 75 mg/ per day
1820652|NCT00734123|Drug|Rimonabant|"In both arms, we will follow the standard clinical care in terms of treatments, as far as obesity and diabetes mellitus is concerned.
Drugs will be prescribed as the standard clinical care"
1820653|NCT00734136|Procedure|Blood Draws and a hepatectomy specimen|"Pre operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons).
Blood draw during surgery(1.5 ml serum, 1.5 ml EDTA)from Hepatic Artery, Hepatic Vein, and Portal Vein.
Wedge section of Hepatectomy specimen following resection in surgical subjects(tested for the same factors)"
1820654|NCT00734136|Procedure|Blood draw - pre operative standard of care|Pre-operative blood draw(1.5 ml serum, 1.5 ml EDTA)(approximately 2 teaspoons) from peripheral vein
1820655|NCT00734149|Drug|Bortezomib|
1820656|NCT00734149|Drug|Melphalan|
1820657|NCT00734149|Drug|Prednisone|
1820658|NCT00734162|Drug|Tenofovir disoproxil fumarate (TDF)|TDF administered as a 300-mg tablet once daily
1820659|NCT00734162|Drug|Placebo|TDF placebo tablet once daily
1820660|NCT00734175|Biological|H6N1 Teal HK 97/AA ca recombinant vaccine|Approximately 0.2 ml of 10^7 TCID50 doses of vaccine administered intranasally
1820661|NCT00734188|Drug|PTI-6D2|monoclonal antibody
1820662|NCT00734201|Drug|V24343|Oral, 1mg, 2 mg, 5 mg or 25 mg, or placebo, once daily for 28 days
1820663|NCT00734214|Drug|0.9% NaCl|"Intravenous Fluid
Isotonic Parenteral Fluid"
1820664|NCT00734214|Drug|0.45%NaCl|"Intravenous Fluid
Hypotonic Parenteral Fluid"
1820665|NCT00734227|Procedure|Emergency portacaval shunt|
1820666|NCT00734227|Other|Emergency TIPS|
1820667|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, single dose
1820668|NCT00734240|Drug|ISIS 353512|50 mg via 2 hour IV infusion, 6 doses over 22 days
1820669|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, single dose
1820670|NCT00734240|Drug|ISIS 353512|50 mg via SC injection, 6 doses over 22 days
1820671|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 3, 100 mg on day 5, and 200 mg on day 8
1820672|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, single dose
1820673|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, single dose
1820674|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, single dose
1820675|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, single-dose
1820676|NCT00734240|Drug|ISIS 353512|100 mg via 2 hour IV infusion, 6 doses over 22 days
1821190|NCT00738348|Drug|glucose|glucose
1820677|NCT00734240|Drug|ISIS 353512|200 mg via 2 hour IV infusion, 6 doses over 22 days
1820678|NCT00734240|Drug|ISIS 353512|100 mg via SC injection, 6 doses over 22 days
1820679|NCT00734240|Drug|ISIS 353512|200 mg via SC injection, 6 doses over 22 days
1820680|NCT00734240|Drug|ISIS 353512|100 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or oral placebo
1820681|NCT00734240|Drug|ISIS 353512|200 mg via SC injection PLUS an oral treatment of a NSAID, acetaminophen, or steroid
1820682|NCT00734240|Drug|ISIS 353512|2 hour IV infusion, 50 mg on day 1, 100 mg on day 3, 100 mg on day 5 and 200mg on day 8
1820683|NCT00734253|Drug|Pyridoxamine Dihydrochloride|150 mg capsules taken orally twice a day for 1-year.
1820684|NCT00734253|Drug|Pyridoxamine Dihydrochloride|300 mg capsules taken twice a day for 1-year.
1820685|NCT00734253|Drug|Placebo|Placebo capsules taken twice a day for 1-year
1820686|NCT00734279|Drug|Leuprolide Acetate - Early Puberty Leuprolide Visit|Dose of 10 mcg/kg Sub cutaneous once at 0800 on day 2 of the Early Puberty Luprolide Visit
1820687|NCT00734279|Drug|Ganirelix - Early Puberty Ganirelix Visit|Dose of 2.5 mcg/kg Sub-cutaneous once at 17:30 on day 1 of the Early Puberty Ganirelix Visit and once at 08:00 on day 2 of the Early Puberty Ganirelix Visit
1820688|NCT00734279|Drug|Ganirelix - Delayed Puberty Ganirelix Visit|Ganirelix is administered at a dose of 2.5 mcg/kg sub cutaneous at 17:30 on day 1 and once at 08:00 on day 2 of the Ganirelix Delayed Puberty Visit
1820689|NCT00734279|Drug|Leuprolide Acetate- Delayed Puberty Leuprolide Visit|Leuprolide acetate is given at a dose of10 mcg/kg at 0800 on day 2 of the Delayed Puberty Leuprolide Visit
1820690|NCT00734292|Drug|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen A: FlutiForm 250/10 ug
FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)
● Period 2 Treatment Regimen B: FlutiForm 100/10 ug
FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)
● Period 3 Treatment Regimen C: placebo
SKP placebo; (two actuations)"
1820691|NCT00734292|Other|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen B: FlutiForm 100/10 ug
FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)
● Period 2 Treatment Regimen C: placebo
SKP placebo; (two actuations)
● Period 3 Treatment Regimen A: FlutiForm 250/10 ug
FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)"
1820692|NCT00734292|Other|fluticasone propionate, formoterol fumarate|"● Period 1 Treatment Regimen C: placebo
SKP placebo; (two actuations)
● Period 2 Treatment Regimen A: FlutiForm 250/10 ug
FlutiForm HFA pMDI (250/10 ug); (two actuations of FlutiForm HFA pMDI 125/5 ug/actuation)
● Period 3 Treatment Regimen B: FlutiForm 100/10 ug
FlutiForm HFA pMDI (100/10 ug); (two actuations of FlutiForm HFA pMDI 50/5 ug/actuation)"
1820693|NCT00734305|Drug|MM-121|Dose escalation Frequency - once weekly
1820694|NCT00734318|Drug|Flutiform 250/10 micrograms|
1820695|NCT00734318|Drug|Flutiform 50/5 micrograms|
1820696|NCT00734318|Drug|Flixotide pMDI 250 mcg + foradil pMDI 24 micrograms|
1820697|NCT00734318|Drug|Flixotide pMDI 250 micrograms|
1820698|NCT00734344|Drug|Raltegravir|Raltegravir 400 mg. BID
1820699|NCT00734344|Drug|Efavirenz|600 mg once daily
1820700|NCT00734344|Drug|Emtricitibine|200mg once daily
1820701|NCT00734344|Drug|Tenofovir disoproxil once daily|300mg once daily
1820702|NCT00734344|Drug|Tenofovir disoproxil twice daily|300mg twice daily
1820703|NCT00734357|Procedure|Blood work|Prior to having the clinically scheduled CT examination the subject will have blood work drawn. This blood work will give the investigators a baseline value of the basic kidney function of the subject. They will then have blood work done again at 2 days and again at 3 days following the CT examination. Some patients, based on their blood work obtained at 2 and 3 days after the CT examination, will be asked to have blood work performed at 7 days after their CT examination.
1820704|NCT00734370|Behavioral|Virtual Reality Exposure Therapy for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of
Psycho-education, breathing training and cognitive restructuring
Virtual reality Exposure to agoraphobic situations and interoceptive exposure
Relapse prevention"
1820705|NCT00734370|Behavioral|Standard exposure in vivo for agoraphobic participants|"This intervention is comprised of 10 sessions of cognitive behavior therapy for panic disorder and agoraphobia with components of
Psycho-education, breathing training and cognitive restructuring
Standard exposure in vivo to agoraphobic situations and interoceptive exposure
Relapse prevention (according to the protocol of Craske & Barlow)"
1820706|NCT00734383|Drug|Propofol|Propofol cardioprotection : Ten minutes prior to initiation of CPB, we will stop delivery of isoflurane, inject 1 mg/kg iv and then continuously infuse propofol at 120µg/kg/min IV until 15 min after release of the aortic cross clamp (reperfusion).
1820707|NCT00734383|Drug|Propofol|Volatile Anesthetic preconditioning : Anesthesia will be maintained using an inspired concentration of isoflurane between 0.5-2% before, during, and after CPB, without administration of propofol. For ten minutes prior to the initiation of CPB we will deliver Isoflurane 2.5% end tidal then resume maintenance anesthesia as described.
1820708|NCT00734396|Procedure|Mesenchymal stem cell infusion|MSC infusion: two doses of 1-2x106 MSCs per kilogram body weight, intravenously, 7 days apart.
1820709|NCT00734409|Device|Bispectral Index (BIS) Monitor|BIS monitoring in addition to RASS assessments
1820710|NCT00734422|Behavioral|Virtual Reality Exposure Therapy|Standard virtual reality exposure therapy for fear of flying will be combined with the administration of either yohimbine hydrochloride or an inactive placebo pill.
1820711|NCT00734435|Drug|zonisamide SR plus olanzapine|zonisamide SR 90 mg given twice daily and olanzapine 10 mg to 20 mg daily for 10 weeks (maintenance period)
1820712|NCT00734435|Drug|Placebo plus olanzapine|Placebo given twice daily and olanzapine 10-20 mg for 10 weeks (maintenance period)
1820713|NCT00734448|Dietary Supplement|myo-inositol|2 g twice a day until delivery
1820714|NCT00734461|Drug|oxycodone and naltrexone|"tablets containing 20 mg or 40 mg oxycodone
/ tablets containing 20 mg or 40 mg oxycodone combined w/0.001 mg or 0.0001 mg naltrexone"
1820715|NCT00734474|Drug|LY2189265|
1820716|NCT00734474|Drug|Sitagliptin|
1820717|NCT00734474|Drug|Placebo solution|
1820718|NCT00734474|Drug|Placebo tablet|
1820719|NCT00734474|Drug|Metformin|
1821509|NCT00740649|Drug|HSD-016|
1820720|NCT00734500|Drug|Anidulafungin|Intravenous form. Loading Dose: 3 mg/kg/dose. Maintenance dose: 1.5 mg/kg/dose. Treatment duration: 5 days total.
1820721|NCT00734513|Behavioral|Partner-assisted emotional disclosure|Patients and partners in the partner-assisted emotional disclosure condition will attend four weekly face-to-face sessions with a therapist. The first session will last 75 minutes and will focus on training in skills to facilitate the patient's disclosure. The subsequent 3 sessions will last 45 minutes each. In these sessions, the therapist will briefly review the strategies and provide feedback from the previous session and the patient will spend 30 minutes talking about their cancer-related concerns to the partner.
1820722|NCT00734513|Behavioral|Cancer Education|The cancer education protocol consists of four weekly face-to-face sessions for education about living with GI cancer. The cancer education sessions will be delivered to patients and their partners and use a presentation and discussion format. Handouts and discussion sessions will center on the following topics: Orientation to Duke Cancer Care and the treatment team; suggestions for communicating with health care providers; resources for health information, psychosocial support, and financial concerns; evaluating health information on the internet; the impact of cancer on different domains of quality of life; and suggestions for maintaining quality of life.
1820723|NCT00734526|Drug|Temozolomide|"Groups 1 & 2: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 150-200 mg/m^2 Once Daily by Mouth Days 1-5 of 1st 28-Day Cycle, then 75 mg/m^2 Once Daily by Mouth Days 1-5 for Subsequent 28-Day Cycles.
Groups 3 & 4: 75 mg/m^2 Once Daily by Mouth During Radiation; 4 Weeks after Completion of Radiation, 75-100 mg/m^2 Once Daily by Mouth Days 1-21 every 28-Day Cycle."
1820724|NCT00734526|Radiation|Radiation|Total of 60 Gy delivered over 30 Days (approximately 6 weeks).
1820725|NCT00734526|Drug|Sorafenib|"Group 1: 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
Group 2: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth.
Group 3: 200 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 200 mg Twice Daily by Mouth.
Group 4: 400 mg Twice Daily by Mouth during Radiation; 4 Weeks after Completion of Radiation, 400 mg Twice Daily by Mouth."
1992235|NCT03322891|Other|Standard Practice Education|Participants will receive traditional standard of care education regarding prostate cancer treatments and side effects provided by their physician.
1997034|NCT02267603|Biological|Pembrolizumab|Given IV
1820728|NCT00734552|Dietary Supplement|α-Keto Acid with low protein diet|"Compound α-Keto Acid: The daily dose of compound α-Keto Acid is 0.1/kg/d. The total daily dose will be divided into three times a day.
Low Protein Diet: Diet contain protein 0.8g/kg/d."
1820729|NCT00734552|Dietary Supplement|Normal protein diet|Diet contain protein 1.0-1.2 g/kg/d.
1820730|NCT00734565|Biological|Haemophilus influenzae type b|1 dose monovalent conjugated vaccine against Haemophilus influenzae type b in children aged 16 - 20 months and infants aged 2 - 4 months
1820731|NCT00734578|Drug|SPD503-AM|SPD503 (Guanfacine Extended Release)-AM Optimized 1-4mg
1820732|NCT00734578|Drug|SPD503-PM|SPD503 (Guanfacine Extended Release)-PM Optimized 1-4mg
1820733|NCT00734578|Drug|Placebo|Placebo matched to Guanfacine Hydrochloride Extended Release
1820734|NCT00734591|Drug|Exubera|Subjects who had been treated with Exubera in a prior Exubera controlled trial. Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice).
1820735|NCT00734591|Other|Randomized diabetes therapy|"Subjects who had been treated with a comparator (other diabetes treatment including one or more of: subcutaneous insulin, sulfonylureas, biguanides, or thiazolinediones) in a prior Exubera controlled trial.
Following initial use of randomized treatment, physicians and subjects were free to change regimens and dosing based on subject response to assigned treatment (as consistent with routine practice)."
1820736|NCT00734604|Drug|tadalafil once a day [T(OaD)]|5 mg tablet taken once a day (OaD) by mouth for 8 weeks
1820737|NCT00734604|Drug|sildenafil citrate as needed [S(PRN)]|100 mg tablet taken as needed (PRN) by mouth for 8 weeks
1820738|NCT00734604|Drug|tadalafil as needed [T(PRN)]|20 mg tablet taken as needed (PRN) by mouth for 8 weeks
1820739|NCT00734617|Drug|Nicotine Patch|"Groups 1 & 3 1-21mg Nicotine patch and 1-placebo for 2 wks pre quit day and 4 wks post quit day
Groups 2 & 4 2-21mg Nicotine Patches for 2 wks pre quit day and 4 wks post quit day"
1820740|NCT00734630|Drug|nebivolol|"Encapsulated Nebivolol 5mg, 10mg, 20mg, or 40mg total daily dosage, oral administration once daily
Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration"
1820741|NCT00734630|Drug|Placebo|Lisinopril 10mg, 20mg total daily dosage, oral administration Losartan 50mg, 100mg total daily dosage, oral administration
1820742|NCT00734656|Drug|dutasteride + ethanol|4 mg dutasteride administered 2-4 days prior to ingestion of 0.8 mg/kg ethanol divided between three drinks consumed over 36 minutes
1820743|NCT00734656|Drug|placebo medication + ethanol|placebo medication administered 2-4 days prior to ingestion of 0.8 gr/kg ethanol divided between three drinks consumed over 36 minutes
1820744|NCT00734656|Drug|dutasteride + placebo alcohol|4 mg dutasteride administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
1820745|NCT00734656|Drug|placebo medication + placebo alcohol|placebo medication administered 2-4 days prior to ingestion of three drinks each containing 1 cc ethanol consumed over 36 minutes
1820746|NCT00734669|Drug|Glibenclamide|Taking a single dose of 3.5 mg glibenclamide
1820747|NCT00734682|Drug|Nanoliposomal CPT-11|Depending on UGT1A1 genotyping status, patients are either given a starting dose of 120 mg/m^2 (wild type) or 60 mg/m^2 IV q3 weeks.
1820748|NCT00734695|Dietary Supplement|vitamin c|Subconjunctival daily or bid
1820749|NCT00734695|Dietary Supplement|vitamin c|topical and systemic
1820750|NCT00734695|Dietary Supplement|vitamin c|topical systemic
1820751|NCT00734708|Drug|Trafermin (genetical recombination)|Administered to the bone defect during flap operation
1820752|NCT00734708|Drug|Placebo|Control
1820753|NCT00734721|Behavioral|Preoperative information and perioperative care|Patients receive different information and care in addition to the basic medical consultation.
1820754|NCT00734734|Biological|Seasonal Influenza Vaccine|1 single intramuscular dose of influenza vaccine, 2008/2009 NH formulation
1821510|NCT00740649|Drug|placebo|
1820755|NCT00734747|Device|Medigus SRS endoscopic stapling system|The system is designed to staple the stomach to the esophagus in 2 or 3 locations using a quintuplet of standard B shaped, 4.8 mm titanium staples in each location.
1820756|NCT00734760|Behavioral|education|face-to-face education and counseling intervention
1820757|NCT00734773|Biological|Rituximab|Infusion will be given at week 2, week 4, week 6 and week 8. Infusions can be administered at an initial rate of 100 mg/hr, and increased by 100 mg/hr increments at 30-minute intervals, to a maximum of 400 mg/hr as tolerated.
1820758|NCT00734773|Drug|Cytarabine|Administered by IV over 3 hours at a dose of 3 g/m2/day for 2 days given at week 17 and week 21.
1820759|NCT00734773|Drug|Methotrexate|Administered by IV at dose of 3.5 grams/m2 on day 1 of week 1, week 3, week 5, week 7 and week 9; if CSF was positive it will also be given intrathecally on day 8 of week 1, week 3, week 5, week 7 and week 9.
1820760|NCT00734773|Drug|Motexafin gadolinium|"Administered to the first five patients enrolled on trial, MGd will be given at 5 mg/kg q day x2 doses (completed on 2 consecutive days 1 to 2 weeks prior to day of cycle 1) to be followed by a non-infused MRI (without contrast) 1-5 hours after 2nd MGd dose (to evaluate for MGd tumor selective uptake).
For induction chemotherapy, MGd 10 mg/kg will be given intravenously on day 8 of each cycle. MGd will be given immediately after Rituxan.
During radiation therapy, MGd will be administered at 5 mg/kg 2-5 hours prior to WBRT, daily for the first 10 days (fractions) and then every other day of radiation thereafter."
1820761|NCT00734773|Drug|Procarbazine hydrochloride|Taken orally, 100 mg/m2 days 1-7 of the 1st, 3rd, and 5th cycles of induction therapy.
1820762|NCT00734773|Drug|Vincristine sulfate|Administered by IV at a dose of 1.4mg per meter squared on weeks 1, 3, 5, 7 and 9.
1820763|NCT00734773|Radiation|Radiation therapy|Given at weeks 11 through 16.
1820764|NCT00734786|Other|Wrinkle cream application|Single application on the crow's feet wrinkles. Placebo cream will be applied on one side, the active cream on the other side.
1820765|NCT00734799|Behavioral|Sleep Intervention for PTSD (SIP).|"Patients in the SIP condition will receive the same elements as the Usual Care patients. In addition, these patients will receive six, bi-weekly, 1-hour individual sessions with the PI, including 3 sessions of Cognitive-Behavioral Therapy for Insomnia (CBT-I) and 3 sessions of Imagery Rehearsal Therapy (IRT). CBT-I consists of education designed to correct unrealistic sleep expectations, a prescription for an individually-tailored behavioral regimen, standard sleep hygiene recommendations, and the identification and restructuring of dysfunctional beliefs and attitudes regarding sleep. IRT is a brief intervention designed to facilitate the patient's rescripting of reoccurring nightmares to decrease their associated affective distress."
1820766|NCT00734812|Procedure|Laparoscopic supracervical hysterectomy|Patients will be randomized to LSH (retaining the cervix) and TLH (cervix removal)
1820767|NCT00734812|Procedure|Total laparoscopic hysterectomy|Patients will be randomized to either removal or retention of cervix
1820768|NCT00734825|Other|Omnipaque|oral contrast for CT scan
1820769|NCT00734838|Device|High Resolution Microendoscope|Using core biopsy and reduction mammoplasty tissue
1820770|NCT00734851|Drug|Docetaxel|Docetaxel 70 mg/m2 day 1 every 3 weeks for 4 cycles with prednisone 5 mg orally twice daily
1820771|NCT00734851|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily for 14 days followed by 7 days off, for 4 cycles, concurrent with docetaxel and prednisone
1820772|NCT00734851|Radiation|EBXRT|External beam radiotherapy to the prostate bed, started on day 100, after completion of chemotherapy. 66 Gy over 6-7 weeks.
1820773|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects taking EIAEDs (CYP3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
1820774|NCT00734864|Drug|enzyme-inducing anti-epileptic drugs|Subjects NOT taking EIAEDs (CYP-3A enzyme-inducing anti-epileptic drugs Phenytoin/Dilantin, Fosphenytoin/Cerebyx, Phenobarbital, Primidone/Mysoline, Oxcarbazepine/Trileptal, Carbamazepine/Tegretol).
1958505|NCT01586624|Drug|Vandetanib, Selumetinib|"Dose escalation phase This phase consists of various cohorts, each investigating an increasing dose level of vandetanib and/or selumetinib. Vandetanib steady state dose levels investigated include 100, 200 or 300mg OD. Selumetinib dose levels are 25mg bd, 50mg bd and 75mg bd or 100 and 125mg OD.
All patients in this phase will take the study treatment as follows:
Cycle 1
Vandetanib higher (lead in) dose once daily (2 or 4 days) followed by vandetanib steady state dose once daily (10 or 12 days) followed by vandetanib steady state dose once daily in combination with selumetinib once/twice daily (28 days).
Cycle 1 is 42 days in length."
1958506|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 2 onwards
Vandetanib steady state once daily in combination with selumetinib once/twice daily(28 days).
Cycle 2 and subsequent cycles are 28 days in length. From this phase, we will establish what the maximum tolerated dose (MTD) of the combination treatment is, which can safely be given to patients."
1820777|NCT00734890|Biological|bevacizumab|
1820778|NCT00734890|Drug|vandetanib|
1820779|NCT00734890|Other|laboratory biomarker analysis|
1820780|NCT00734890|Other|pharmacological study|
1958507|NCT01586624|Drug|Vandetanib, Selumetinib|"Expansion cohort (patients with non small cell lung cancer).
All patients will receive the same dose of combination treatment (the MTD established during dose escalation phase). As follows:
All patients in the expansion cohort will take the study treatment in the same way as follows:
Cycle 1
Vandetanib higher dose (lead in) once daily (2 or 4 days) followed by vandetanib steady state dose once daily (10 or 12 days) followed by vandetanib steady state dose once daily in combination with selumetinib once/twice daily (28 days).
Cycle 1 is 42 days in length."
1820783|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Omegaven)|Omegaven 10%, 0.2g/kg/hr i.v.during 1 hour on 3 consecutive days
1820784|NCT00734916|Dietary Supplement|Parenteral lipid emulsion (Intralipid)|Intralipid 10%, 0.2g/kg/hr i.v. during 1 hour on 3 consecutive days
1820785|NCT00734916|Dietary Supplement|Parental lipid emulsion (Saline 0.9%)|Placebo (Saline 0.9%), same volume/hr as lipid emulsions
1820786|NCT00734929|Drug|Aprepitant + Dexamethasone|Aprepitant 40 mg + Dexamethasone 10 mg
1820787|NCT00734929|Drug|Ondansetron + Dexamethasone|Ondansetron 4 mg + Dexamethasone 10 mg
1820870|NCT00735527|Drug|Lorazepam|Intra-nasal 0.1 mg/kg (maximum 4 mg) once
1885761|NCT01222650|Drug|Silodosin|
1820788|NCT00734942|Other|support service|"professional partners for communication
befriending with other families concerned
information and education (about illness, symptoms, first aid, caring)
free-time activities and time out
homework assistance
administrative advise
support for everyday life"
1820789|NCT00734955|Device|49-channel optical spectrometer|
1820790|NCT00734968|Drug|Nitrofurantoin|Nitrofurantoin 100mg PO BID for 3 days post operatively following the placement of a sub-urethral sling for the treatment of stress urinary incontinence
1820791|NCT00734968|Other|Placebo|6 tablets to be taken 1 tablet PO BID. These tablets are identical to nitrofurantoin 100mg tablets.
1820792|NCT00734994|Device|Hyperthermia System|Hyperthermia applied to heat the bladder to a temperature of 42 degrees Celsius for 40-60 minutes concurrent with mitomycin Treatment Schedule: 6 Weekly Sessions (Induction) followed by 4 Monthly Sessions (Maintenance) until documented second recurrence
1820793|NCT00734994|Drug|Mitomycin C|40 mg in 40 ml sterile water instilled into bladder
1820794|NCT00735007|Drug|Rebif® New Formulation (RNF) using RebiSmartTM|RNF 44 mg, 3 times a week by subcutaneous injection.
1820795|NCT00735020|Biological|Adjuvanted Influenza Vaccine|1 dose of Adjuvanted Influenza Vaccine
1820796|NCT00735020|Biological|Influenza Vaccine|1 dose of Influenza Vaccine
1820797|NCT00735033|Other|Physiotherapy with Swiss Ball|
1820798|NCT00735046|Behavioral|Cognitive behavioral therapy for early Alzheimer's disease|12 weekly individual sessions, total duration 3 months, regular involvement of patient's proxy ever second session. Intervention is manualized but is flexible with regard to individual resources and needs.
1820799|NCT00735046|Other|Control|Patients and proxies who are assigned to treatment as usual
1820800|NCT00735059|Device|treatment with the dialyzer ELISIO 170H|one week of three consecutive dialysis treatments, > 3 hours
1820801|NCT00735059|Device|treatment with the dialyzer PES-170DS|one week of three consecutive dialysis treatments, > 3 hours
1820802|NCT00735072|Drug|Placebo|Dose based on current medications in regimen: 150mg PO BID for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
1820803|NCT00735072|Drug|Maraviroc|Dose based on current medications in regimen: 150mg orally (PO) twice daily (BID) for those on a protease inhibitor-based regimen other than Tipranavir; 600mg PO BID for efavirenz-containing regimens; or 300 mg PO BID for all other regimens.
1820804|NCT00735085|Drug|SLV334|1000mg SLV334 as a single dose
1820805|NCT00735085|Drug|SLV334|1000mg SLV334 b.i.d. for one day
1820806|NCT00735085|Drug|SLV334|2000mg SLV334 b.i.d. for one day
1820807|NCT00735085|Drug|SLV334|2000mg SLV334 b.i.d. for three days
1820808|NCT00735085|Drug|Placebo|SLV334 Placebo arm
1820809|NCT00735098|Other|KBA exercise|KBA exercise protocol, 3 times per week for 8 weeks
1820810|NCT00735098|Other|strength training exercise|strength training exercise, 3 times per week for 8 weeks
1820811|NCT00735098|Other|KBA and strength training|KBA and strength training exercise, 3 times per week for 8 weeks
1820812|NCT00735098|Other|Control group|8 week control group
1820813|NCT00735111|Other|Karnofsky Performance Status Score|Karnofsky Performance Status scores will be independently completed by both the patient and their health-care provider at each routine clinic visit.
1820814|NCT00735124|Drug|Gabapentin|1200 mg single dose gabapentin
1820815|NCT00735124|Other|placebo|Injection of placebo/sham
1820816|NCT00735137|Device|Vaginal pessary (CE0482, MED/CERT ISO 9003 / EN 46003)|Inserted from randomization till 36-37 weeks of gestation
1820817|NCT00735150|Behavioral|questionnaire, interview|You will be asked to make a one-time visit to MSKCC. At that research visit, you will be asked to complete a short questionnaire about your knowledge of various reproductive technologies relevant to individuals at hereditary risk. Then you will watch a short presentation about these reproductive technologies and complete a second brief questionnaire to assess your understanding of the presentation. Afterwards, you will meet with an interviewer one-on-one for about one hour, during which time you may share your thoughts and feelings about the use of these reproductive technologies.
1820818|NCT00735163|Other|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
1820819|NCT00735176|Procedure|Cervical arthroplasty|Anterior cervical discectomy, followed by insertion of the Discover™ Artificial Cervical Disc
1820820|NCT00735176|Procedure|Anterior cervical discectomy and fusion (ACDF)|Anterior cervical discectomy and decompression, followed by insertion of a PEEK cage, which induces fusion.
1820821|NCT00735189|Other|anticoagulation clinic care|Patient receives care from the outpatient anticoagulation management service
1820822|NCT00735189|Other|usual care|patient receives usual anticoagulation care from their regular primary care physician
1958508|NCT01586624|Drug|Vandetanib, Selumetinib|"Cycle 2 onwards •o Vandetanib steady state dose once daily in combination with selumetinib once/twice daily (28 days).
o Cycle 2 and subsequent cycles are 28 days in length. Number of cycles: Patients will be allowed to receive 6 cycles of study treatment. If the patient is still benefiting clinically and experiencing no unacceptable toxicity, then the Investigator can make a request to the Sponsor for continuation of treatment."
1820824|NCT00735241|Device|SIR-Spheres microspheres|SIR-Spheres yttrium-90 microspheres
1820825|NCT00735241|Drug|FOLFOX6 cycles 1-3|Oxaliplatin 60 mg/m2, IV infusion, q 2 weeks Leucovorin 200 mg/m2, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
1820826|NCT00735241|Drug|FOLFOX6 cycles 4 onwards|Oxaliplatin 85 mg/m2 given, IV infusion, q 2 weeks Leucovorin 200 mg/m2 given, IV infusion, q 2 weeks 5-Fluorouracil 400 mg/m2, IV bolus, q 2 weeks 5-Fluorouracil 2.4 g/m2, IV infusion, q 2 weeks
1820827|NCT00735241|Drug|Bevacizumab cycles 3 onwards|Bevacizumab 10 mg/m2, IV infusion, q 2 weeks commencing with the third cycle of chemotherapy
1820832|NCT00735267|Drug|PD 0332334|Dosage Form: 25 or 100 mg oral capsules Dosage and frequency: 350-600 mg twice a day Duration: 1 year
1820833|NCT00735280|Drug|unfractionated heparin|bolus of 100 U/kg of unfractionated heparin
1820871|NCT00735527|Drug|Lorazepam|Intra-venous 0.1 mg/kg (maximum 4 mg) once
1820872|NCT00735540|Other|Observational|Data summary only
1885762|NCT01222650|Drug|Placebo|
1820834|NCT00735293|Device|VASER|A small incision will be made in the underarm. A VASER probe will be inserted under the skin to break apart fat and sweat glands under the skin. A small hollow tube will be used to draw out the broken-down skin and the incision will be closed with a stitch.
1820835|NCT00735306|Drug|Avastin|Avastin 10 mg/kg IV on days 1, 15 and 29 Begins the first day of radiation therapy
1820836|NCT00735306|Drug|Tarceva|Daily by mouth per assigned dose, for 5.5 weeks Begins the first day of radiation therapy
1820837|NCT00735306|Radiation|Radiation Therapy|Radiation to the pancreas Monday through Friday for 28 treatments
1820838|NCT00735319|Device|Transcutaneous Bilirubinometer|For all eligible babies living in the 7 intervention community health centers, a Transcutaneous Bilirubinometer will be routinely used by all community nurses in conjunction with an algorithm that will guide the nursing management of the neonates based on the values obtained
1820839|NCT00735332|Drug|TLN-232|21 day continuous IV administration of TLN-232 followed by a 7-day recovery period
1820840|NCT00735345|Drug|5-FU|750 mg/m2/d C.I. i.v.d1-5, d29-33 and 300 mg/m2/d C.I. i.v. on the days of radiotherapy
1820841|NCT00735345|Drug|Cisplatin|15 mg/m2/d i.v. d1-5, d29-33
1820842|NCT00735345|Drug|Taxotere|75 mg/m2/d i.v. d1 and d29, 15 mg/m2/d i.v. on d57, d64, d71 and d78
1820843|NCT00735345|Biological|Cetuximab|Cetuximab: 400 mg/m2 i.v. d1; 250mg/m2 weekly d8 through d85
1820844|NCT00735345|Radiation|Radiation during chemoradio-immunotherapy|39.6 Gy total dose
1820845|NCT00735358|Procedure|Cyanoacrylate|Cyanoacrylate 0.5 ml, endoscopic injection of gastric varix at each shot
1820846|NCT00735358|Procedure|Cyanoacrylate|Cyanoacrylate 1 ml, endoscopic injection for gastric varices at each shot
1820847|NCT00735371|Drug|LDX 30 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
1820848|NCT00735371|Drug|LDX 50 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
1820849|NCT00735371|Drug|LDX 70 mg|Eligible subjects will be randomized in a 1:1:1:1 ratio to a daily morning dose of LDX (30, 50, or 70mg/day) or placebo for a double-blind stepwise forced dose titration (3 weeks) followed by a 1-week Dose Maintenance Period. The test product is LDX, available in 30, 50, and 70mg capsules. All test products will appear identical to placebo to protect the study blind.
1820850|NCT00735371|Drug|Placebo|Placebo will be identical to test product.
1820851|NCT00735397|Drug|perampanel|Perampanel 2 mg to 12 mg, once daily in the Open-Label Extension (OLE) study up to approximately 5 years
1820852|NCT00735410|Biological|Seasonal Influenza Vaccine|1 dose of Split influenza vaccine
1820853|NCT00735423|Device|No intervention|IDE used for outcome measurement not intervention
1820854|NCT00735436|Drug|Gliadel/Avastin/CPT-11|
1820855|NCT00735449|Drug|Fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5%|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
1820856|NCT00735449|Drug|timolol maleate 0.5%|1 drop of timolol maleate 0.5% taken approximately 12 hours apart, up to 2 times a day.
1820857|NCT00735449|Drug|latanoprost 0.005%|1 drop of latanoprost 0.005% once nightly.
1820858|NCT00735462|Drug|2.5% imiquimod cream|2.5% imiquimod cream applied daily to wart areas for up to 8 weeks.
1820859|NCT00735462|Drug|3.75% imiquimod cream|3.75% imiquimod cream applied daily to wart areas for up to 8 weeks
1820860|NCT00735462|Drug|Placebo cream|Placebo cream applied daily to wart areas for up to 8 weeks
1820861|NCT00735475|Biological|CSL Limited Influenza Virus Vaccine (Afluria®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
1820862|NCT00735475|Biological|US Licensed Influenza Virus Vaccine (Fluzone®)|A single 0.5 mL, intramuscular injection in the deltoid region of the arm on day 0.
1820863|NCT00735488|Other|Observational|Summary of data
1820864|NCT00735501|Drug|insulin detemir|Start dose and frequency as well as dose alterations to be determined by the physician according to normal clinical evaluation
1820865|NCT00735514|Behavioral|compliance monitoring|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
1820866|NCT00735514|Other|questionnaire administration|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
1820867|NCT00735514|Procedure|assessment of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
1820868|NCT00735514|Procedure|management of therapy complications|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
1820869|NCT00735514|Procedure|psychosocial assessment and care|Patients from the IMPAC registry in Radiation Oncology at the University Hospitals Case Medical Center, Ireland Cancer Center complete questionnaires online or by mail. Questionnaires include the Vaginal Dilation Adherence questionnaire, the Sexual Function-Vaginal Changes Questionnaire, the Dyadic Satisfaction questionnaire, and the Physician/Nurse Recommendation of Vaginal Dilation questionnaire.
1820873|NCT00735553|Drug|Proellex|One 25 mg capsule of Proellex® and one placebo capsule orally daily for up to four months
1820874|NCT00735553|Drug|Proellex|Two 25 mg mg capsules of Proellex® orally daily for up to four months
1820875|NCT00735553|Drug|Placebo|Two placebo capsules orally daily for up to four months
1820876|NCT00735592|Other|Observational|Retrospective data obtained from electronic files
1820877|NCT00735605|Other|BFD|The investigators used pressure based biofeedback training, using a perfused eight-channel polyvinyl catheter with a compliant balloon at the tip
1820878|NCT00735605|Procedure|PDPR|A 2-3 cm curved incision is made on either side of the anal canal along its posterolateral aspect, each about 2.5 cm distance from the anal verge Fig(2). After that dissection in ischiorectal fossa was done till reaching the puborectalis sling from outside i.e. extrasphincteric approach . Using a right angle forceps the puborectalis sling is lifted up, guided by the contralateral index finger in the anal canal Fig(3). Nearly the inner half of puborectalis sling was divided on each side by using a scalpel NO. 11 Fig(4). Complete haemostasis was followed by skin closure without drain
1820879|NCT00735605|Other|BTX A|A vial of Dysport, 500 u, (Dysport, Ipsen, United Kingdom) is dissolved in 2.5 ml isotonic saline Fig(1). A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient
1820880|NCT00735618|Other|Guided Relaxation|Following 5 minute questionnaire, 15 minute rest and 5 minute heart rhythm recording, 15 minute relaxation program (listening via headphone to audio recording) to be completed by second heart rhythm recording and same questionnaire. Entire procedure 45-60 minutes.
1820881|NCT00735631|Device|SISO model-based predictive closed-loop system|The single-input-single-output (SISO) model-based predictive closed-loop system will be used to guide patient-individualized ICU sedation with propofol
1820882|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
1820883|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
1820884|NCT00735644|Biological|Japanese encephalitis vaccine|0.5 mL, Subcutaneous
1820885|NCT00735644|Biological|Japanese encephalitis vaccine (Acambis)|0.5 mL, Subcutaneous
1820886|NCT00735644|Biological|Hepatitis A vaccine|0.5 mL, Intramuscular
1820887|NCT00735657|Device|needle|Peribulbar blockade with standard (25 mm) needle
1820888|NCT00735657|Device|needle|Peribulbar blockade with short (12.5 mm) needle
1820889|NCT00735657|Procedure|Pars Plana Vitrectomy|Peribulbar block
1820890|NCT00735670|Drug|Venlafaxine HCl|Starting dose is 37.5 mg and ending dose is 150 mg at 13 weeks. From weeks 13 to 26 subjects no longer will receive the drug
1820891|NCT00735670|Other|Placebo|Subjects received a placebo instead of Venlafaxine HCl until week 13 as did the Venlafaxine group.
1820892|NCT00735683|Drug|ATHX-105 phosphate|includes diet, physical activity, and lifestyle modification
1820893|NCT00735683|Drug|Placebo|includes diet, physical activity, and lifestyle modification
1820894|NCT00735696|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg), intravenous (IV) infusion, on Day 1 of each 21-day cycle.
1820895|NCT00735696|Drug|Paclitaxel|200 milligrams per meter squared (mg/m^2), administered intravenously (IV) following the ramucirumab infusion, on day 1 of each 21-day cycle, for up to six cycles.
1820896|NCT00735696|Drug|Carboplatin|Administered after paclitaxel, as an intravenous infusion (IV), over 30 minutes on day 1 of each 21-day cycle, for up to six cycles. The dose to be administered is calculated based on the participant's actual body weight at time of treatment and the area under the curve (AUC) dosing. The target AUC for carboplatin treatment is AUC=6.
1820897|NCT00735709|Drug|Vortioxetine|Encapsulated immediate-release vortioxetine tablets
1820898|NCT00735709|Drug|Placebo|Vortioxetine placebo-matching capsules
1820899|NCT00735722|Device|HIFU AF Ablation|Concomitant left atrial ablation using High Intensity Focused Ultrasound (HIFU)
1820900|NCT00735735|Other|The taking of a saliva sample from each subject.|After taking the sample, the saliva will be transferred via a pipette to a clean tube which will be labeled with the subject's name, the date and the hour. Once a month the tubes will be sent to the collaborating laboratory for analysis.
1820901|NCT00735748|Drug|Tramadol per os (Tradonal Odis® orodispersible tablets)|Administration of 1 unit dose of 50 mg tramadol perorally given in 3 unit dosages
1820902|NCT00735748|Drug|Tramadol IV (Tradonal® IV)|Administration of tramadol IV given in 3 unit dosage of 35 mg
1820903|NCT00735761|Drug|ME-609|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
1820904|NCT00735761|Drug|Acyclovir in ME-609 vehicle (5% acyclovir)|Dosage form: Cream Dose and regimen: 5 times daily during 5 days Route of administration: Topical application
1820905|NCT00735774|Drug|11C-ORM-13070|Single dose of i.v. solution
1820906|NCT00735787|Biological|Placebo|Loading dose of 2 placebo subcutaneous (SC) injections (0.8 ml) at Week 0 followed by 1 injection SC eow from Week 1 to Week 15.In second period of study, subjects who continued in the study received 80 mg adalimumab at Week 16 followed by open-label 40 mg adalimumab eow from Week 17 to Week 27.
1820907|NCT00735787|Biological|Adalimumab|Loading dose of 80 mg adalimumab SC (two 40 mg injections) followed by 40 mg adalimumab SC eow.
1820908|NCT00735800|Behavioral|Family Intervention:Telephone Tracking Support- Caregiver|Family-based problem solving treatment
1820909|NCT00735800|Behavioral|Telephone Support|Supportive telephone counseling about caregiving
1820910|NCT00735813|Device|Taurolock|When not in use the childrens tunneled central venous catheters are locked with the liquid Taurolock instead of heparin.
1820911|NCT00735813|Device|Heparin|When not in use the childrens tunneled central venous catheters are locked with heparin
1820913|NCT00735839|Biological|V710|V710 vaccination (60 mcg, 0.5 ml) single injection on Day 1
1820914|NCT00735839|Biological|Placebo|Saline placebo (0.5 ml) single injection on Day 1
1820915|NCT00735852|Drug|Decapeptyl SR 11.25mg|11.25 mgs, Intra muscular (IM) every 3 months for 2 years
1821010|NCT00730236|Drug|AEGR-733|5-80 mg daily by mouth for 1.5 yrs
1820916|NCT00735865|Procedure|Punctal plugs, punctal cautery|25 subjects(20 silicone punctal plugs, 5 punctal cautery) The procedure will be based on clinical indication. Randomized one eye for study. Baseline cultures of lid margin & tarsal/inferior fornix conjunctiva obtained & plated according to protocol
1820917|NCT00735865|Procedure|Punctal Plug, Punctal thermocauterization|"Up to 5 subjects. Subjects in need of punctal occlusion(No preference for punctal thermocauterization or punctal occlusion by silicone plug). Randomize one eye to silicone punctal plug occlusion, the other eye to punctal thermocauterization.
This group ONLY, cultures will be obtained of the lid margin & conjunctiva/inferior fornix of BOTH eyes"
1820918|NCT00735865|Procedure|Silicone plug or thermodynamic hydrophobic acrylic plug|"Up to 5 subjects. Subjects in need of punctal occlusion(not preference for punctal occlusion by silicone plug or by the thermodynamic hydrophobic acrylic plug). Randomize one eye to silicone punctal plug occlusion, the other eye to acrylic punctal plug occlusion.
In this group ONLY cultures will be obtained of the lid margin and conjunctiva/inferior fornix of BOTH eyes"
1820919|NCT00735865|Other|Previous subjects with Punctal occlusion|"Up to 20 subjects(15 subjects with silicone punctal plug closure and 5 subjects with punctal closure by thermocauterization)Subjects who have previously had punctal occlusion who have symptoms and/or signs thought to be secondary to punctal occlusion.
Lid margin and conjunctiva/inferior fornix of eye with greatest sign or symptoms will be cultured/plated according to standard protocol."
1820924|NCT00735904|Drug|AG-013736|AG-013736 5 mg tablets orally, twice daily, until disease progression
1820925|NCT00735904|Drug|gemcitabine|200-mg or 1 g lyophilized powder, to be administered as 1250 mg/m^2 IV infusion on Day 1 and Day 8 of 21-day cycle. For a maximum of 6 cycles
1820926|NCT00735904|Drug|cisplatin|1mg/ml solution or as lyophilized powder, to be administered as 80 mg/m^2 IV infusion on Day 1 of 21-day cycle. For a maximum of 6 cycles
1820927|NCT00735917|Drug|saracatinib|Given PO
1820928|NCT00735917|Other|pharmacogenomic studies|Optional correlative studies
1820929|NCT00735917|Other|pharmacological study|Optional correlative studies
1820930|NCT00735917|Procedure|positron emission tomography|Optional correlative studies
1820931|NCT00735917|Radiation|fludeoxyglucose F 18|Optional correlative studies
1820932|NCT00735917|Other|laboratory biomarker analysis|Optional correlative studies
1820933|NCT00735930|Drug|Alvocidib Hydrochloride|Given IV
1820934|NCT00735930|Drug|Lenalidomide|Given PO
1820935|NCT00735930|Other|Pharmacological Study|Correlative studies
1820936|NCT00735930|Other|Laboratory Biomarker Analysis|Correlative studies
1820937|NCT00735943|Other|No intervention|No intervention
1820938|NCT00735956|Behavioral|Counseling|Handouts, referrals and brief counseling sessions are given after determination of early alcohol abuse has been assessed.
1820939|NCT00735969|Drug|Peginterferon|
1820940|NCT00735969|Drug|Ribavirin|
1820941|NCT00735995|Behavioral|Cognitive behavioral therapy (individual)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
1820942|NCT00735995|Behavioral|Cognitive behavioral therapy (group)|The Coping Cat program, 12 weekly sessions, two additional parent meetings
1820943|NCT00736008|Other|Observational|Data summary only
1820944|NCT00736021|Drug|Escitalopram|Up to 40 mg oral dose in 10 or 20 mg tablets taken twice daily
1820945|NCT00736034|Dietary Supplement|Phosphatidylserine-Omega3 (SharpPS™-Gold)|Treatment will consist of capsules containing 100 mg phosphatidylserine-Omega3. Dosage: 1 capsule X 3 times daily, with meals. Duration: 15 weeks
1820946|NCT00736047|Biological|NIC002|
1820947|NCT00736047|Biological|Placebo|
1820948|NCT00736060|Other|Observational|Summary of clinical and laboratory data
1820949|NCT00736073|Drug|aprepitant|one dose of aprepitant (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
1820950|NCT00736073|Drug|Placebo|one dose of placebo (125 mg PO 4 hours) prior to their ERCP and one dose (80 mg PO) 18 hours after the first dose
1820951|NCT00736086|Device|Vessel Closure (StarClose™)|
1820952|NCT00736099|Drug|linagliptine 5 mg|safety and efficacy of linagliptine 5 mg open label
1820953|NCT00736099|Drug|linagliptine 5 mg and pioglitazone 30 mg|efficacy and safety of the combination linagliptine and pioglitazone
1820954|NCT00736112|Other|Food Allergy Testing|Food Allergy Diagnosis - blood drawn for food allergy testing at the time of surgery (bilateral myringotomy with tympanostomy tubes +/- adenoidectomy)
1820955|NCT00736112|Procedure|Adenoidectomy|Adenoidectomy to remove adenoid tissue. (Are adenoids a factor in OME (otitis media with effusion) or is food allergy diagnosis and treatment able to significantly prevent ROM (recurrent otitis media) after the tubes fall out?)
1820956|NCT00736112|Procedure|BMT|The standard protocol for children presenting with initial Chronic OME is to perform a BMT
1820957|NCT00736125|Device|pulsatile saline lavage|Prior to cement application, cut bone surfaces are cleaned using pulsatile saline lavage
1820958|NCT00736125|Device|carbon dioxide lavage|Prior to cement application, cut bone surfaces are cleaned using carbon dioxide lavage
1820959|NCT00736138|Procedure|training and pellots|training and pellots
1820960|NCT00736151|Drug|Ralfinamide|Oral tablets administered at rising doses of 80 - 320 mg/day
1820961|NCT00736164|Dietary Supplement|selenomethionine|Given orally
1820962|NCT00736164|Other|placebo|Given orally
1998506|NCT01310296|Drug|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
1998507|NCT01310296|Drug|Lofexidine hydrochloride|Single Dose = 200 μg lofexidine in phosphate-buffered saline administered intravenously via infusion pump at a rate of 1 μg/min for 200 min
1998508|NCT01307891|Drug|Abraxane alone|100 mg/m2 weekly X 3 doses (Days 1, 8, 15) at 28-day intervals until disease progression or unacceptable toxicity. Abraxane will be administered on an outpatient basis by an IV infusion over 30 minutes. Patients will be evaluated for response every 2 cycles (every 8 weeks).
1998509|NCT01307891|Drug|Abraxane + Tigatuzumab|Tigatuzumab will be administered as a loading dose of 10 mg/kg on Day 1, then 5 mg/kg on Day 15 and then every other week on Days 1 and 15 of subsequent cycles. It will be given as an IV infusion over 60 minutes or less. No dose reductions will be allowed. Tigatuzumab will be administered in combination with the Abraxane according to the intervention described for it.
1820963|NCT00724516|Device|Novel Breast Compression Paddle|Instead of using the regular wire localization mammography compression paddle, a new breast compression paddle will be used. The new breast compression paddle is similar to a tennis racquet. It consists of crossing plastic strings that are strung tightly in a frame. The needle/wire can be inserted anywhere between the strings.
1820964|NCT00724529|Biological|Infliximab|Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
1820965|NCT00724542|Drug|Voglibose tablets|0.2mg Tid
1820966|NCT00724568|Drug|Lenalidomide|Patients will be treated with Revlimid on days 1-14 in 3-week cycles for 4-8 cycles.
1820967|NCT00724568|Drug|Bortezomib|Patients will be treated with Velcade at 1.3 mg/m2 on days 1, 4, 8, and 11
1820968|NCT00724568|Drug|Dexamethasone|Patients will be treated with Dexamethasone at 20 mg orally on days of Velcade and the day after for all dose levels.
1820969|NCT00724568|Drug|Doxil|Patients will be treated with Doxil on day 4.
1820970|NCT00724581|Drug|Amiodarone|intravenous bolus of 300 mg oral treatment og 600 mg twice a day for five days
1820971|NCT00724594|Drug|N-acetylcysteine|NAC (100 mg/kg/dose) was given intravenously to mothers within 4 hours of diagnosis of chorioamnionitis, and every 6 hours until delivery. NAC was given to preterm (12.5 mg/kg/dose) and term infants (25 mg/kg/dose) every 12 hours for 5 doses after birth.
1820972|NCT00724594|Drug|Control|Saline was given in the same volume, at the same timing as NAC infusions
1820975|NCT00724633|Other|Lowering the dialysate sodium|Please see above
1820976|NCT00724646|Other|Survey|3 individual surveys
1820977|NCT00724646|Other|Focus group|Focus group discussions facilitated by a psychologist
1820978|NCT00724659|Procedure|Ultrasound|Ultrasound of the joint(s) before the clinically scheduled arthrogram of the same joint(s)
1820979|NCT00724659|Procedure|Ultrasound|Ultrasound of the joint(s) after a clinically scheduled arthrogram is performed. Ultrasound images will then be compared to the arthrogram findings, other imaging findings such as MRI and surgical pathological findings such as arthroscopy (if any.)
1820980|NCT00724672|Drug|etanercept|etanercept 50 mg subcutaneously once weekly
1820981|NCT00724672|Drug|infliximab|infliximab 3 mg/kg IV at Weeks 0, 2, and 6
1820982|NCT00724672|Drug|adalimumab|adalimumab 40 mg subcutaneously biweekly
1820983|NCT00724685|Drug|Naropeine (Ropivacaine)|
1820984|NCT00724685|Drug|Placebo|saline
1820985|NCT00724698|Drug|Desloratadine|Desloratadine 5 mg once daily
1820986|NCT00724711|Drug|emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF)|FTC 200 mg/TDF 300 mg tablet, once a day
1820987|NCT00724711|Drug|abacavir (ABC)/lamivudine (3TC)|ABC 600 mg/3TC 300 mg tablet, once a day
1820988|NCT00724724|Drug|Butylphthalide Soft Capsules|Butylphthalide Soft Capsules: 2 tablets Bid for 1 year Aspirin: 100mg for 1 year
1820989|NCT00724724|Drug|Aspirin|Aspirin 100mg Qd for 1 year
1820990|NCT00724737|Procedure|Presurgical MRI|"People who are scheduled to have brain surgery with undergo a fMRI of the brain before surgery. This is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
1820991|NCT00724737|Procedure|functional MRI (fMRI) of the brain|"Healthy subjects will be undergo a brain fMRI of the brain. fMRI is a functional scan, meaning that subjects will be asked to perform tasks (such as finger tapping or picture identification) during the MRI scan."
1820992|NCT00724750|Device|Gauze suction (G-SUC)|Negative pressure wound therapy
1820993|NCT00724750|Device|Vacuum Assisted Closure Device (VAC)|Negative Pressure Wound Therapy
1820994|NCT00724763|Device|acupuncture|to Liv 3 and PE 9.
1820995|NCT00724763|Device|sham needle treatment|needle not in meridian area
1820996|NCT00730132|Drug|Ezetimibe|Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
1820997|NCT00730132|Drug|Statin|Statin titration for the Statin Dose Titration group, and new statin treatment and dosage for the New Statin group, determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
1820998|NCT00730145|Drug|PD-0332334|A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject
1820999|NCT00730158|Drug|KD018|Traditional Chinese Medicine formulation administered orally twice a day for 4 days on days 1-4 every 2 weeks from the second cycle, beginning at a dose of 1,800 mg twice a day, and escalating to 2,400 mg twice a day in dose level 2-4.
1821000|NCT00730158|Drug|Irinotecan|Irinotecan will be administered intravenously once every 2 weeks from the first cycle, beginning at a dose of 180 mg/m², and escalating to 215 mg/m²in dose level 3 and 250 mg/m² in dose level 4.
1821001|NCT00730158|Drug|Placebo|Placebo capsules will be administered orally twice a day for 4 days on days 1-4 every 2 weeks.
1821002|NCT00730171|Drug|Linaclotide|Oral, once daily
1821003|NCT00730184|Dietary Supplement|potassium bicarbonate|90 mmol/d given as 4 tablets after each meal, with a full glass of water
1821004|NCT00730184|Dietary Supplement|Placebo (microcrystalline cellulose)|Given as 4 tablets after each meal, with a full glass of water
1821005|NCT00730197|Drug|Albuterol Sulfate Extended-Release Tablets 8 mg|8mg, single dose fed
1821006|NCT00730197|Drug|VoSpire® ER Tablets 8 mg|8mg, single dose fed
1821007|NCT00730210|Drug|a: PTH (1-84)|preotact 100 microgram subcutaneous a day in 6 months
1821008|NCT00730210|Drug|b:placebo|100 microgram placebo subcutaneous a day for 6 months
1821009|NCT00730223|Drug|Nevirapine and Efavirenz|single oral dose 200mg of nevirapine and single oral dose 600 mg of efavirenz
1998510|NCT01296178|Drug|IDARUBICINE|"Administration of chemotherapy induction
Idarubicin IV Dose of 12 mg/m2/day days 1 to 3"
1998511|NCT01296178|Drug|ARA-C|ARA-C 200 mg/m2/day dose continuous infusion of IV days 1 to 7
1821011|NCT00730249|Drug|methylphenidate hydrochloride|sustained release, twice daily, dosage according to an individual titration schedule
1821012|NCT00730249|Drug|Placebo|twice daily according to an individual titration schedule
1821014|NCT00730275|Drug|Sitagliptin phosphate|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of sitagliptin 50 mg tablet, sitagliptin 100 mg tablet, or sitagliptin 200 mg.
1821015|NCT00730275|Drug|Comparator: matching placebo|Participants will fast 8 hours prior to dosing. All doses will be given with 240 ml of water. Participants received either a single oral dose of matching placebo to sitagliptin 50 mg, 100 mg, or 200 mg.
1821016|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
1821017|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5 mL, Subcutaneous, 1 dose
1821018|NCT00730288|Biological|Chimeric dengue serotype (1, 2, 3, 4)|0.5mL, Subcutaneous, 1 dose
1958524|NCT01564784|Drug|inotuzumab ozogamicin|Dose: inotuzumab ozogamicin 0.8-0.5 mg/m^2 IV, weekly, 3 times per cycle Cycle length: 21-28 days Total number of cycles: 6
1821020|NCT00730314|Procedure|Hematopoietic stem cell transplantation|hematopoietic stem cell transplantation conditioning regimen depending on graft source
1821021|NCT00730327|Device|BioEnterics® Intragastric Balloon|Inflatable balloon inserted into the stomach.
1821022|NCT00730327|Other|Behavioral modification|Low-calorie diet, food/exercise diary, eating plan, emphasis on exercise
1821023|NCT00730340|Procedure|Closure of the Tonsillar Fossa|We hypothesize that closure of the tonsillar fossa decreases the morbidity of pain by decreasing exposure of the raw operative bed to oral secretions, mediation, and oral intake, and decreases the morbidity of post-operative hemorrhage by having the operative wound closed.
1821024|NCT00730340|Procedure|Tonsillectomy with open fossa|SOP for a tonsillectomy.
1821025|NCT00730353|Drug|Sunitinib malate|Sunitinib malate 37.5 mg orally, daily
1821026|NCT00730353|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 1, 8 and 15.
1821027|NCT00730366|Drug|sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine given as intermittent therapy, at the dosage of 1500/75 mg per administration (3 tablets), Twice during pregnancy
1821028|NCT00730366|Drug|Chloroquine|Chloroquine tablets 100 mg. First administration of 1500 mg given over three days, followed by weekly doses of 300 mg/week
1821029|NCT00730379|Drug|Comparator: ridaforolimus + dalotuzumab|Starting dose of oral ridaforolimus is 10 mg/day, QD, for five days. Dose rising up to 40 mg/day, QD for five days. Dose range for intravenous dalotuzumab is 7.5 mg/kg/week, 10 mg/kg/week or 7.5 mg/kg/every 14 days. Dalotuzumab will be given as an IV infusion over 1 or 2 hour(s).
1821030|NCT00730392|Drug|Etanercept|The study drug was provided in lyophilized 10 mg vials to be reconstituted with 1 ml of diluent/vial and was administered at a dose of 0.4 mg/Kg up to maximum dose of 25 mg/dose SC twice weekly
1821031|NCT00730392|Drug|Placebo|administered at 0.4 mg/Kg/dose SC up to 25 mg max twice weekly
1821032|NCT00730405|Drug|Albaconazole 100mg|Albaconazole for 36 weeks
1821033|NCT00730405|Drug|Albaconazole 200mg|Albaconazole for 36 weeks
1821034|NCT00730405|Drug|Albaconazole 400mg|Albaconazole for 36 weeks
1821035|NCT00730405|Drug|Albaconazole 400mg|Albaconazole for 24 weeks, Placebo for 12 weeks
1821036|NCT00730405|Drug|Placebo 400 mg|Placebo for 36 weeks
1821037|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 4mg daily for 24 mos
1821038|NCT00730418|Drug|Doxazosin|Treatment with doxazosin 8mg daily for 24 mos
1821039|NCT00730431|Drug|IDX184|IDX184 supplied as size 3, white opaque capsules containing either 5 mg or 25 mg.
1821040|NCT00730431|Drug|Placebo|Placebo supplied as size 3, white opaque capsules matching IDX184 capsules.
1821041|NCT00730444|Drug|Iobenguane I 123 Injection|1-10 mCi administered intravenously
1821042|NCT00730457|Biological|VAX125|Single intramuscular dose
1821043|NCT00730470|Drug|U3-1287 (AMG888)|IV Infusion Dose Escalation (Part 1) - 5 Dose Cohorts Dose Expansion (Part 2) - 30 patients
1821044|NCT00730483|Drug|PVA microporous hydrospheres/doxorubicin hydrochloride|
1821045|NCT00730496|Procedure|uterine cavity injection of day 2 embryo culture supernatant|On the day 2, the embryos were translated from the old dish to a new dish with fresh media and cultured continuously. In study group, the embryo culture supernatant at the old dish were aspirated by using embryo transfer catheter (COOK-5000, Australia) and injected into the patient's uterine cavity. But in the control group, this intervention was not done. Conventional ET was performed on the third day of embryo culture for both groups.
1821046|NCT00730509|Dietary Supplement|5-methyltetrahydrofolate and vitamin B12|children with cystic fibrosis were supplementated for 6 months with 5-MTHF, 7,5 mg/day ; vitamin B12, 0,5 mg/day
1821047|NCT00730522|Drug|CPP-109 vigabatrin|tablets, bid for 12 weeks
1821048|NCT00730522|Drug|Matching Placebo|tablets, bid, 12 weeks
1821049|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 1 months
1821050|NCT00730535|Drug|Tolterodine|Extended release tolterodine tartrate 4 mg, once daily, for 3 months
1821051|NCT00730535|Drug|Tolterodine 6|Extended release tolterodine tartrate 4 mg, once daily, for 6 months
1821052|NCT00730548|Behavioral|Device triggered remote telephone contact because of Care Alert|Care Alerts on, physician will be notified in case of an Care Alert. Depending on the outcome of the telephone contact drug adjustment and / or further interventions can be prescribed
1821053|NCT00730561|Biological|Hematopoietic stem cell transplantation|Intramuscular application of CD34+ hematopoietic stem cells (with a minimum of 2 million CD34+ cells/kg) into the gastrocnemius muscles after stimulation with subcutaneous filgrastim 600 micrograms/kilogram a day for 4 days
1821054|NCT00730574|Dietary Supplement|Vitamin B12 + Folic Acid|Trial group would get daily treatment of 1 mg Vitamin B12 combined with 5 mg Folic Acid
1821055|NCT00730600|Procedure|Thai Traditional massage|Thai traditional massage for 2 hours by a single masseuse.
1821059|NCT00730626|Dietary Supplement|Yogurt with 1X10E9 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E9 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
1821060|NCT00730626|Dietary Supplement|Yogurt with 1X10E10 BB-12 and LA-5|100g of yogurt containing the probiotics L.acidophilus and B.lactis (concentrations of 1x10E10 of each probiotics) with 40 mg of green tea extract, once a day for 10 weeks.
1821061|NCT00730626|Dietary Supplement|Yogurt Placebo|100g of yogurt placebo containing no probiotics and no green tea extract, once a day for 10 weeks.
1821062|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 0.1 mg/kg - 10 mg/kg, Every 2 weeks, 3 years depending on response
1821063|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
1821064|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
1821065|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 1 - 10 mg/kg, Every 2 weeks, 3 years depending on response
1821066|NCT00730639|Biological|BMS-936558 (MDX-1106)|Solution, Intravenous, 10 mg/kg, Every 2 weeks, 3 years depending on response
1821067|NCT00730652|Biological|MDX-1411|Single dose of MDX-1411 (fully human monoclonal antibody) will be administered as an intravenous (i.v.) infusion every 7 days for up to a total of 5 doses.
1821068|NCT00730665|Drug|PF-00885706|Capsule, 100ug, every 12 hours (twice a day)
1821069|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
1821070|NCT00730665|Drug|PF-00885706|Capsule, 300ug, every 12 hours (twice a day)
1821071|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
1821072|NCT00730665|Drug|PF-00885706|Capsule, 1mg, every 12 hours (twice a day)
1821073|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
1821074|NCT00730665|Drug|PF-00885706|Capsule, 3mg, every 12 hours (twice a day)
1821075|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
1821076|NCT00730665|Other|Placebo|Capsule, Placebo, every 12 hours (twice a day)
1821077|NCT00730665|Drug|Esomeprazole|Patients entering the run-in phase lasting 6 weeks (42 days) will be switched from their current proton pump inhibitor (PPI) treatment and maintained on a standard background PPI - open label esomeprazole 20 mg to be taken once daily 1 hour before breakfast. Subjects meeting randomization criteria at Visit 4 are randomly assigned to one of the active arms of PF-00885706 or matching placebo, in addition to esomeprazole.
1821078|NCT00730691|Drug|Placebo|Placebo-matching capsules
1821079|NCT00730691|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
1821080|NCT00730691|Drug|Duloxetine|Overencapsulated duloxetine capsules
1821081|NCT00730717|Drug|Humira|Will receive 80 mg of Humira injection at week 0 followed by 40 mg weekly Humira injection from Week 1 to Week 23
1821082|NCT00730717|Drug|Humira|Will receive 40 mg Humira injection every other week from Week 0 to Week 23
1821083|NCT00736177|Procedure|Embryo cryopreservation|Subjects in the Test group will have their embryos cryopreserved for transfer in a subsequent cycle.
1821084|NCT00736177|Procedure|Fresh embryo transfer|Subjects in the Control group will receive fresh embryo transfer.
1821085|NCT00736190|Drug|Tenofovir disoproxil fumarate|300-mg tablet (marketed formulation) taken orally once daily
1821086|NCT00736216|Other|survey administration|Participants complete the Young Adult Survey online documenting demographic data; sexual history (i.e., whether they ever had sex, age of first sexual encounter, number of life time partners, condom use, sexually transmitted diseases [STDs], and pregnancy history); cigarette use; current and past drug use; knowledge of human papillomavirus (HPV) and cervical cancer; past history of Pap tests and STD screenings; attitudes towards HPV testing; vaccine knowledge and acceptability; sources of information about HPV; source of information about cervical cancer; identification of common STDs; perceived risk of acquiring STDs; perceived risk of acquiring HPV; social support; and religion.
1821087|NCT00736229|Drug|Exenatide|0.05 µg/min bolus of open-label exenatide followed by a constant infusion of 0.025 µg/min for 24-48 hours
1821088|NCT00736242|Biological|PEG-IFN alfa-2b|Peginterferon alfa-2b administered subcutaneously at a dose 1.5 ug/kg/week, according to the European Medicines Agency (EMEA)-approved labeling
1821089|NCT00736242|Drug|RBV|Ribavirin administered at a dose of 800-1200 mg/day (on a weight-basis) according to the EMEA-approved labeling
1821090|NCT00736255|Drug|Lis-dexamphetamine (LDX; Vyvanse) and Transdermal Nicotine Patch|Subjects on this arm will receive Lis-dexamphetamine day after the identified quit date. All subject will start with 30mg once a day and will be titrated up to 50mg then to 70mg over a 3 week period to reach an optimized dose. They will then be maintained on this optimized dose until the 4th week. All subjects will continue to receive transdermal nicotine patch during these weeks. The dose will be tapered down from 21 mg to 14mg after week 1,then to 7 mg after week 2. Subjects will remain at 7mg until the 4th week.
1821091|NCT00736255|Drug|Placebo and transdermal nicotine patch|Subjects on this arm will receive matching placebo and NRT.
1821183|NCT00738335|Other|immunoenzyme technique|
1821184|NCT00738335|Other|laboratory biomarker analysis|
1821092|NCT00736268|Behavioral|Telephone-based Enhanced Coping Skills Training (CST)|Telephone-based Enhanced Coping Skills Training (CST) intervention will systematically train participants (and caregivers) in the use of coping skills for symptom management (i.e. activity pacing, pleasant activity scheduling, communications, relaxation, goal setting, imagery, calming self-statements, problem solving, and preventing and dealing with setbacks). Participants in the CST condition will receive 12 weekly 30 minute telephone sessions followed by 2 bi-weekly booster sessions for training in symptom management strategies. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
1821093|NCT00736268|Other|Usual Medical Care and COPD education and symptom monitoring (UMC)|COPD usual care plus education and symptom monitoring control condition will participate in a weekly 15 minute phone call followed by 2 bi-weekly phone calls, assessing their health status and providing them with support and COPD education. COPD Education topics include types of lung disease, oxygen use, medication management, preventing infection, managing daily activities, and nutrition. Participants and caregivers will be evaluated at baseline, at the conclusion of 4 months of treatment, and at annual follow-up intervals for up to 4 years.
1821094|NCT00736281|Other|Food Drops: Food Allergens (peptides)|The patients enrolled in our study will present with food allergy symptoms and diagnostic tests will provide the specific information regarding their food allergies. Once the diagnosis has been made and consent for treatment has been obtained, participants will be randomly assigned to either the group that receives the food allergy intervention with SLIT ( food allergens mixed with 50% glycerin in a vial) or the group that receives the control SLIT (glycerin only). The patients are truly blinded to their treatment because all the SLIT food allergy vials are identical and contain no distinguishing features that could reveal their contents. There is also no difference in taste between a vial containing glycerin and food allergens and a vial containing only glycerin.
1821095|NCT00736294|Drug|Ramipril|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
1821096|NCT00736294|Drug|Placebo|5 mg/d from D1 to M3 10 mg/d from M3 to M12 Tablets
1821097|NCT00736307|Procedure|Cultured limbal stem cells Transplantation|Transplantation of cultivated limbal epithelium on amniotic membrane
1821098|NCT00736320|Drug|ABVD (Adriamycin, Bleomycin, Vincristine, Dacarbazine)|chemotherapy with 2 cycles of ABVD (day 1 + 15)
1821099|NCT00736320|Radiation|20 Gy IFRT (Involved Field Radiotherapy)|20 Gy Involved Field Radiotherapy
1821100|NCT00736333|Drug|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) 50 mg/m^2, given for up to 6 cycles
1821101|NCT00736346|Behavioral|Brief cognitive-behavioral treatment for Panic Disorder|One two-hour session of cognitive-behavior therapy for panic disorder
1821102|NCT00736346|Behavioral|Cognitive-Behavior Therapy for Panic Disorder|Seven one-hour sessions of cognitive-behavior therapy for panic disorder
1821103|NCT00736346|Drug|paroxetine|40 mg die, for 6 months
1821104|NCT00736372|Drug|PX-12|Intravenous infusion, dose escalation, infused over a 72 hour period on days 1, 2 and 3 of a 21-day cycle until progression or development of unacceptable toxicity
1821105|NCT00736385|Drug|Glucophage (Metformin)|metformin XR 2000 mg daily for 12 months
1821106|NCT00736385|Drug|Placebo|placebo 2000 mg daily for 12 months
1821107|NCT00736398|Procedure|Spinal fusion|Spinal fusion
1821108|NCT00736411|Procedure|acupuncture|16 treatments over 8 weeks
1821109|NCT00736411|Procedure|IVF|one 4 week IVF cycle
1821110|NCT00736424|Device|Itrel II™ and Soletra™ Epilepsy Control System|Bilateral neurostimulation of the anterior nucleus of the thalamus
1821111|NCT00736437|Drug|ME-609|Cream applied topically 6 times daily over the UVR exposed area
1821112|NCT00736437|Drug|Vehicle|Treatment applied 6 times daily over the UVR exposed area
1821113|NCT00736450|Biological|oblimersen sodium|Given IV
1821114|NCT00736450|Biological|rituximab|Given IV
1821115|NCT00736450|Drug|cyclophosphamide|Given IV
1821116|NCT00736450|Drug|doxorubicin hydrochloride|Given IV
1821117|NCT00736450|Drug|vincristine sulfate|Given IV
1821118|NCT00736450|Drug|prednisone|Given orally
1821119|NCT00736450|Procedure|biopsy|Correlative studies
1821120|NCT00736450|Genetic|microarray analysis|Correlative studies
1821121|NCT00736450|Other|immunohistochemistry staining method|Correlative studies
1821122|NCT00736450|Genetic|gene expression analysis|Correlative studies
1821123|NCT00736450|Genetic|cytogenetic analysis|Correlative studies
1821124|NCT00736463|Drug|Simvastatin|One arm of randomized crossover
1821125|NCT00736463|Drug|Atorvastatin 80 mg|Second arm of randomized crossover
1821126|NCT00736476|Biological|H.pylori vaccines|1 dose of H.pylori vaccine at 0, 1, and 2 months
1821127|NCT00736476|Biological|Placebo Vaccine|Placebo Vaccine at 0, 1, and 2 months
1821128|NCT00736489|Drug|AZD3199|Dry powder for inhalation, single dose
1821129|NCT00736489|Drug|Formoterol|Dry powder for inhalation, single dose
1821130|NCT00736489|Drug|Placebo|Dry powder for inhalation, single dose
1958525|NCT01564784|Drug|FLAG (fludarabine, cytarabine and G-CSF)|Dose: cytarabine 2.0 g/m^2/day IV days 1-6 fludarabine30 mg/m^2/day IV days 2-6 Cycle length: 28 days Total number of cycles: 4
1958526|NCT01564784|Drug|HIDAC (high dose cytarabine)|cytarabine 3 g/m^2 IV every 12 hours for up to 12 times
1821133|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
1821134|NCT00737867|Drug|Gemcitabine|Day 1: Gemcitabine infusion 1000 mg/m2 Day 8: Gemcitabine infusion 1000 mg/m2
1821135|NCT00737867|Drug|Vinorelbine|Day 1: Vinorelbine capsules 60 mg/m2 Day 8: Vinorelbine capsules 60 mg/m2
1821136|NCT00737867|Drug|Carboplatin|Day 1: Carboplatin infusion AUC = 5 (Calvert`s formula)
1821137|NCT00737880|Other|Organ perfusion during pancreas procurement|Usage of UW or HTK perfusion solution during in situ abdominal organ perfusion in multi-organ procurement
1821138|NCT00737893|Drug|Placebo|Saline injection (solution prepared by research pharmacy) subcutaneously given the day before surgery, day of surgery, and the day after surgery.
1821185|NCT00738335|Other|liquid chromatography|
1958527|NCT01564784|Drug|cytarabine and mitoxantrone|mitoxantrone 12 mg/m^2 IV days 1-3 cytarabine 200 mg/m^2/day IV over 7 days cycle length: 15-20 days Total number of cycles: 4
1821139|NCT00737893|Drug|Erythropoietin (EPO)|Erythropoietin (EPO)-induced Protein 29, Human; 20,000 units subcutaneously given the day before surgery, day of surgery, and the day after surgery.
1821140|NCT00737906|Procedure|Surgical turbinate reduction procedure|Surgical turbinate reduction using the COBLATION device
1821141|NCT00737919|Dietary Supplement|Plant Stanol|Plant stanols in margarines daily 2 grams
1821142|NCT00737919|Dietary Supplement|Plant Sterol|Plant sterols in margarines daily 2 grams
1821143|NCT00737932|Drug|Laquinimod|Laquinimod 0.5mg/day, 1mg/day, 1.5mg/day, 2mg/day, oral, for 8 weeks of treatment
1821144|NCT00737932|Other|placebo|Matching placebo for 8 weeks of treatment
1821145|NCT00737971|Drug|Bevacizumab intravitreal|Bevacizumab intravitreal 0.05 ml/1.25 mg - administered on D0, Week 4, Week 8
1821146|NCT00737971|Drug|Triamcinolone|Intravitreal 0.1 ml/4 mg, D0, Week 4 and Week 8
1821147|NCT00737971|Drug|Triamcinolone + Bevacizumab|Intravitreal triamcinolone 0.1 ml/4 mg + bevacizumab 0.05 ml/1.25 mg simultaneously on D0, week 4, Week 8
1821148|NCT00737984|Procedure|Endometrial sampling|Endometrial sampling performed in the preceding cycle. It will be done in the follicular phase not later than day 10 of the cycle
1821149|NCT00737997|Drug|Morphine|150 mcg/kg diluted in normal saline to a volume of 10 ml at time of induction of anesthesia
1821150|NCT00737997|Other|Saline|10 ml saline alone
1821151|NCT00738010|Device|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
1821152|NCT00738010|Device|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
1821153|NCT00738010|Behavioral|Control|Voluntary quadriceps muscle contractions.
1821154|NCT00738023|Drug|Rosiglitazone|Diabetic subjects will be receive rosiglitazone for 6 weeks
1821155|NCT00738023|Drug|Normal saline 0.9%|Normal saline 0.9% intravenous infusion at 40ml/hr for 48 hours
1821156|NCT00738023|Drug|Intralipid 20%|Intralipid 20% at 40ml/hr intravenously for 48 hours
1821157|NCT00738049|Drug|darusentan 100 mg|All subjects will receive oral darusentan 100 mg for a total of 2 weeks and placebo for 2 weeks.
1821158|NCT00738062|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
1821159|NCT00738062|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
1821160|NCT00738075|Device|Auditory cue|When device recognizes automatically freezing episode it will generate auditory cue
1821161|NCT00738088|Drug|gliclazide|Gliclazide 80mg bd for 6 weeks
1821162|NCT00738101|Drug|Omegaven|Therapy with Omegaven will be provided at a dose of 1 gm/kg/day (by continuous infusion). Omegaven will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition. Treatment will be given for as long as the child needs any TPN AND has a conjugated bilirubin greater than 2 mg/dL for a maximum of 5 years. If the infant no longer is requiring any TPN, then the Omegaven will be stopped regardless of bilirubin. If the bilirubin is less than 2 mg/dL but the child still requires TPN, then the Omegaven will be continued until the infant no longer requires TPN.
1821163|NCT00738127|Procedure|Open reduction and internal fixation|Inoue et al.'s technique is most commonly used which required placing three K-wires to immobilize both midcarpal joint and radiocarpal joint. This technique is effective, however, it has some problems. In the study, we improve the surgical technique.
1821164|NCT00738140|Behavioral|Diabetes Prevention Program|12-lesson program which will cover diet, exercise, and behavior modification.
1821165|NCT00738153|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1821166|NCT00738166|Other|Organic or conventional diet|12 days on fully controlled organic 1 diet, organic 2 diet and conventional diet
1821167|NCT00738166|Other|Diet (organic or conventional)|organic or conventional diet
1821168|NCT00738179|Device|Continuous Positive Airway Pressure (CPAP)|CPAP worn nightly
1821169|NCT00738179|Other|Standard care|Standard care of cardiovascular risk factors
1821170|NCT00738192|Drug|Fentanyl citrate|Fentanyl 0.5 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
1821171|NCT00738192|Drug|Sufentanil citrate|Sufentanil 0.05 μg/kg delivered intravenously immediate at the end of remifentanil pump finished
1821172|NCT00738192|Drug|Butorphanol tartrate|Butorphanol 0.01 mg/kg delivered intravenously immediate at the end of remifentanil pump finished
1821173|NCT00738218|Other|Multidetector Computed Tomography - 64 detectors|Multidetector computed tomography angiography
1821174|NCT00738231|Behavioral|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
1821175|NCT00738231|Behavioral|Training|The training materials were randomly distributed to study participant groups. The list of names was systematically divided into two groups: odd-numbered individuals were given brochures only, and even-numbered individuals were given both letters and brochures. Since we could not have prevented an illustrated material to be passed by in a closed environment, it was deemed appropriate to distribute both the letter and brochure instead of just the brochure.
1821176|NCT00738257|Drug|Pamidronate|
1821177|NCT00738296|Drug|ezetimibe (+) simvastatin|Patients will receive the combination of ezetimibe/simvastatin 10/20 mg o.d. with the possibility to increase the dose to 10/40 mg o.d. for 1 year. Tablets
1821178|NCT00738296|Drug|simvastatin|Patients will receive 40mg od. With the possibility to escalate the dose to 80 mg o.d. if therapeutic goals not attained; for 1 year. Tablets
1821179|NCT00738296|Drug|pravastatin|Patients will receive pravastatin 40 mg o.d. with the possibility to add up 10mg of ezetimibe daily if LDL-C goal is not achieved; for 1 year. Tablets
1821180|NCT00738322|Drug|AZD1305|Solution for iv infusion, single dose
1821181|NCT00738322|Drug|Placebo|NaCl solution for iv infusion, single dose
1821182|NCT00738335|Drug|erlotinib hydrochloride|
1821191|NCT00738361|Drug|nab-paclitaxel|150 mg/m2 weekly for 3 of 4 weeks every 28 days.
1821192|NCT00738374|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv on day 1 of course 3; 500mg/m2 iv on day 1 of courses 4-8 (induction phase); 375mg/m2 iv every 8 weeks (maintenance phase).
1821193|NCT00738374|Drug|chlorambucil|8mg/m2 po on days 1-7 of courses 1-8
1821194|NCT00738387|Drug|ASA404|1800 mg/m2 of ASA404 i.v. on day 1 of each 21 day cycle
1821195|NCT00738387|Drug|Placebo|Placebo i.v. on day 1 of each 21 day cycle
1821196|NCT00738387|Drug|docetaxel|75 mg/m2 of docetaxel intravenous (IV) an hour for 1st 6 cycles; cycle: every 21 days
1821197|NCT00738400|Drug|Vardenafil (Levitra, BAY38-9456)|Vardenafil 10 mg tablets daily for 4 weeks, vardenafil 5 mg / 10 mg / 20 mg tablets for consecutive 4 weeks
1821198|NCT00738400|Drug|Placebo|Matching placebo tablets daily for 4 weeks, placebo tablets daily for consecutive 4 weeks
1821199|NCT00738413|Drug|Deferoxamine|Deferoxamine will be administered subcutaneously over 8 hours for 6 days at a dose of 40 mg/kg.
1821200|NCT00738413|Drug|Deferasirox|Deferasirox will be orally administered at a dose of 30 mg/kg once daily for 6 days.
1821201|NCT00738426|Device|Erchonia ML Scanner (MLS)|Red diode low level laser light energy.
1821202|NCT00738426|Device|Sham device|non-therapeutic light energy output
1821203|NCT00738452|Other|high performance liquid chromatography|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
1821204|NCT00738452|Other|pharmacological study|Blood evaluation 0 minutes, 1 hour, 4 hours, 1 day, 2 days, 3-5 days and 6-7 days post start of antibody infusion. 24 hour urine sample evaluation daily for 5 consecutive days post antibody infusion.
1821205|NCT00738452|Procedure|radionuclide imaging|Approximately 1-3 hours, 1 day, 2 days, 3-5 days and 6-7 days post infusion.
1821206|NCT00738452|Procedure|single photon emission computed tomography|Approximately 2 days and 3-5 days post infusion
1821207|NCT00738452|Radiation|radiation therapy|3-6 mCi Indium-111 labeled cT84.66(5mg) and dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
1821208|NCT00738452|Radiation|yttrium Y 90 anti-CEA monoclonal antibody cT84.66|Dose escalation (depending on toxicities observed from previous dosages) from a starting dose of 8mCi/m2 Y-90-cT84.66.
1821209|NCT00738478|Device|nasogastric tube|insertion of nasogastric tube for 2 days after operation
1821210|NCT00738478|Device|without nasogastric tube|without nasogastric tube after operation
1821211|NCT00738517|Device|Immunoadsorption / Immunoglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
1821212|NCT00738530|Drug|Bevacizumab [Avastin]|10 mg/kg IV every 2 weeks
1821213|NCT00738530|Drug|Interferon alfa 2a [Roferon]|9 MIU SC 3 times/week
1821214|NCT00738530|Drug|Placebo|IV every 2 weeks
1821215|NCT00738543|Other|WHOLE GROUP OF 48 VOLUNTEERS|Two antiseptics (10% povidone iodine and 10% sodium hypochlorite) and one control were tested as skin antiseptics. The intervention consisted of preparing the skin with the antiseptic or the control. The areas were approximately 25 cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was then kept on the skin for 60 seconds before the bacterial culture was conducted. All volunteers were instructed to continue the use of neutral soap and shampoo without antiseptics during the follow-up period.
1821216|NCT00738556|Device|Drug-eluting stents (Cypher and Taxus)|Spot or full length stenting of a coronary lesion
1821217|NCT00738569|Drug|Raltegravir|Raltegravir 400 mg PO BID for 12 months
1821218|NCT00738582|Drug|MORAb-009 (Amatuximab)|MORAb-009 (Amatuximab) by IV on Days 1 and 8 every 21 days for 6 cycles.
1821219|NCT00738582|Drug|Pemetrexed|Pemetrexed 500 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
1821220|NCT00738582|Drug|Cisplatin|Cisplatin 75 mg/m2 on Day 1 of each 21-day cycle for 6 cycles
1821221|NCT00738595|Drug|EVT 302|EVT 302 5 mg once daily
1821222|NCT00738595|Drug|Placebo|Placebo to match EVT 302, 5 mg
1821223|NCT00738595|Drug|EVT 302 plus open label Nicotine replacement|Double-blind EVT 302 plus open label nicotine replacement
1821224|NCT00738595|Drug|Placebo plus open label Nicotine Replacement|Double-blind placebo plus open label Nicotine replacement patch 21 mg once daily.
1821225|NCT00738621|Drug|Aprepitant, Dexamethasone, Ondansetron|Aprepitant oral 40mg one dose, dexamethasone IV 4mg one dose, ondansetron 4 mg one dose
1821226|NCT00738621|Drug|Aprepitant, Dexamethasone, Placebo|Aprepitant 40mg oral one time, dexamethasone IV 4mg one time placebo one time
1821227|NCT00738634|Behavioral|Self-motivated physical activity|"Components:
Physical activity education in the form of a brief booklet (double sided A4 page).
Physical activity motivation tips (one sided A4 page).
Pedometer
Monitoring chart
Online presentation of common obstacles and ways to overcome these obstacles"
1821228|NCT00738634|Behavioral|Nutrition|"Components:
Nutrition education booklet (Double-sided A4 page)
Nutrition motivation tips (single-sided A4 page)
Nutrition monitoring chart
Online presentation of common obstacles and ways to overcome these obstacles"
1821229|NCT00738634|Behavioral|Physical activity researcher contact|"Behavioral: Self-motivated physical activity
Components:
Physical activity education in the form of a brief booklet (double sided A4 page).
Physical activity motivation tips (one sided A4 page).
Pedometer
Monitoring chart
Online presentation of common obstacles and ways to overcome these obstacles"
1821230|NCT00738647|Procedure|Tooth restorations with composite|The cavity is excavated and filled according to the guidelines for composite restorations
1821231|NCT00738660|Drug|Telmisartan, Ramipril|80 mg of telmisartan administered for 8weeks,followed by addition of ramipril 10 mg for further 8weeks
1821232|NCT00738673|Drug|degarelix|Starting dose of 240 mg (40 mg/mL). Maintenance doses of 80 mg (20 mg/mL).
1821233|NCT00738686|Device|Intracoronary stent implantation|Taxus stent implantation in patients with multivessel coronary artery disease
1821234|NCT00738699|Drug|MORAb-003 (farletuzumab)|Farletuzumab (FAR) at 2.5 mg/kg was administered by intravenous (IV) infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
1821511|NCT00740662|Procedure|Distal gastric bypass|Distal gastric bypass
1821235|NCT00738699|Drug|0.9% Saline|Placebo (0.9% normal saline) was administered by IV infusion weekly on Day 1 of Weeks 1 to 12 (Cycle 1) and then in 4-week cycles with treatment administered on Day 1 of Weeks 1 to 3 for all subsequent cycles.
1821236|NCT00738699|Drug|Paclitaxel|
1821237|NCT00738712|Procedure|MRI Magnetic Resonance Imaging|MRI
1821238|NCT00738738|Drug|PD-0332334|Dosage from: 50-100 mg oral capsule Dosage and frequency: 50-350 mg once or twice a day Duration: 6 months
1821239|NCT00738751|Drug|Panobinostat (LBH589)|Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Each cycle was defined as a 21-day period. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
1821240|NCT00738751|Drug|erlotinib|Erlotinib was taken daily without interruption. Each cycle was defined as a 21-day period. Panobinostat was taken twice weekly, for 2 out of 3 weeks of each cycle. Four dose levels of panobinostat in combination with erlotinib were planned: 1) dose level 1 (DL1) = panobinostat 20 mg by mouth (PO) twice weekly for 2 out of 3 weeks + erlotinib 100 mg PO daily; 2) dose level 2 (DL2) = panobinostat 30 mg and erlotinib 100 mg; 3) dose level 3 (DL3) = panobinostat 30 mg and erlotinib 150 mg; and 4) dose level 4 (DL4) = panobinostat 40 mg and erlotinib 150 mg. Doses were not escalated over the course of treatment of an individual participant.
1821241|NCT00738764|Biological|PDL192|Humanized anti-TWEAK receptor monoclonal IgG1 antibody
1821242|NCT00738777|Drug|Anastrozole|1 mg,QD,PO
1821243|NCT00738777|Drug|Anastrozole+Fulvestrant|Anastrozole; 1 mg, QD, PO Fulvestrant; 500 mg, IM, day 1, 15, 29 and monthly thereafter
1821244|NCT00738777|Drug|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
1821245|NCT00738777|Drug|Tamoxifen|loading dose of 40 mg, TID, PO, during 7 days, Thereafter 20 mg, QD, PO
1821246|NCT00738790|Radiation|Short course of radiotherapy|5 x 5 Gy plus boost 4 Gy
1821247|NCT00738790|Radiation|Radiochemotherapy|28 x 1,8Gy plus boost 3 x 1,8 Gy with three 2-days cycles of chemotherapy during weeks 1, 3 and 5 of irradiation (the each cycle consisted of leukovorin 20 mg/m2 per day and 10-20 minutes later of 5-fluorouracil 400 mg/m2 per day, both administrated as rapid intravenous infusion)
1821248|NCT00738803|Procedure|Total hip replacement|Total hip replacement typically preformed for hip arthritis
1821249|NCT00738816|Other|Systematic medication review and advisory notes|Within 24 hours of admission a pharmacist retrieve medication histories from patients included in the intervention group. Medication histories will be obtained from - medical records, medication charts, patients electronical medication profile, interview with patients and if necessary contact to the patients general practitioner. The obtained medication history will be discussed with a physician specialized in pharmacology and an advisory note with suggested changes to the patients medication is added to the medical record. The orthopedic physicians are not obliged to follow the suggested changes
1821250|NCT00738829|Drug|Lenalidomide|"Dose escalation stage: starting dose 2.5mg/d, dose escalation via 5/10/15/20/25 mg/d every 28 days if no dose-limiting toxicity.
During maintenance stage dosing on days 1-28 for max. 6 months at maximum tolerated dose reached during dose escalation stage."
1821251|NCT00738829|Drug|Fludarabine|25 mg/m2 i.v. d1-3 or 40 mg/m2 po d1-3 every 28 days for 6 cycles during dose escalation stage.
1821252|NCT00738829|Biological|Rituximab|"Dose escalation stage: 375 mg/m2 i.v. d4 Cycle 1, 500 mg/m2 i.v. d1 Cycles 2-6.
Maintenance stage: 375 mg/m2 i.v. at 2/4/6 months after end of escalation stage."
1821253|NCT00738842|Drug|AZD6140|Oral tablets taken bid for 5 days
1821254|NCT00738842|Drug|Placebo to match AZD6140|Oral tablets taken bid for 5 days
1821255|NCT00738855|Other|Oral Gastrografin|100 ml of the dye administered through a nasogastric tube
1821256|NCT00738855|Other|Nothing per os|A nasogastric tube
1821257|NCT00738868|Biological|cetuximab|
1821258|NCT00738868|Radiation|stereotactic body radiation therapy|
1821259|NCT00738881|Drug|Erlotinib Hydrochloride|Given PO
1821260|NCT00738881|Drug|Pemetrexed Disodium|Given IV
1821261|NCT00738894|Device|GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder|PFO closure with GORE® HELEX® Septal Occluder / GORE® CARDIOFORM Septal Occluder
1821262|NCT00738894|Other|Antiplatelet Medical Therapy|Investigator's choice of one of three regimen options specified in protocol
1821263|NCT00738920|Behavioral|Self Administered Cognitive Behavior Therapy|This 4 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
1821264|NCT00738920|Behavioral|Therapist Administered Cognitive Behavior Therapy|This 10 session treatment is aimed at controlling symptoms by changing specific behaviors found to aggravate IBS
1821265|NCT00738920|Behavioral|Behavioral Education and Supportive Therapy|This 4 session treatment aims at controlling symptoms through support and the provision of information about IBS symptoms, how it is diagnosed, its causes, and treatment options and a collaborative, relationship between the patient and doctor
1821266|NCT00738933|Dietary Supplement|Dietary plant stanols|Daily 2 grams of plant stanols in a margarine preparation for 4-8 weeks before the operation
1821267|NCT00738933|Dietary Supplement|Dietary plant sterols|Daily 2 grams of plant sterols in a margarine preparation for 4-8 weeks before the operation
1821268|NCT00738933|Dietary Supplement|placebo|Margarine product without plant stanol or sterol esters
1821269|NCT00738946|Drug|Intermittent preventive treatment with AQ+ SP|Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
1821270|NCT00738959|Drug|AZD0328|Oral solution A single dose Day 1 followed by once daily doses on Day 3-7
1958528|NCT01561976|Drug|Metformin hydrochloride prolonged release|1000mg in fasting state
1958529|NCT01561976|Drug|metformin hydrochloride prolonged release|1000mg in fed state
1958530|NCT01561976|Drug|Metformin hydrochloride sustained release/Glimepiride|1000/2mg in fed state
1821275|NCT00738985|Drug|ezetimibe/simvastatin 10/20 mg + placebo|Patients will receive placebo (sugar tablets) for up to 22 weeks.
1894209|NCT01289054|Drug|Gleevec|
1821276|NCT00738985|Drug|ezetimibe/simvastatin 10/20 mg + MK0524A|ezetimibe (+) simvastatin 10/20 mg for 18 weeks. Tablets
1821277|NCT00738998|Behavioral|Questionnaire|Questionnaires about pain and other symptoms, quality of life, and ability to work will be completed.
1821278|NCT00738998|Other|Phone Calls|A telephone system will call every 2 weeks so that you can rate your symptoms and how they interfere with daily activities. Each call will take about 5 minutes.
1821279|NCT00739011|Device|SleepStyle 254/244 CPAP series CPAP humidifier|Therapeutic CPAP pressure will be determined for individual subjects during the titration portion of an overnight sleep study. This pressure will range from 4 to 20 cmH20
1821280|NCT00739024|Drug|Ramelteon|8 mg tablet, oral, once daily
1821281|NCT00739024|Drug|Placebo|Placebo tablet, oral, once daily
1821282|NCT00739037|Drug|Placebo|
1821283|NCT00739037|Drug|PAZ-417|
1821284|NCT00739050|Drug|simvastatin|simvastatin 20mg daily at nights for 12 weeks. Tablets
1821285|NCT00739050|Drug|Comparator: Placebo|placebo daily at nights for 12 weeks. Tablets
1821286|NCT00739063|Drug|Tarceva|Tarceva (erlotinib hydrochloride) given alone, at 150 mg by mouth daily.
1821287|NCT00739076|Behavioral|Virtual Reality|Using Virtual Reality for pain control
1821288|NCT00739102|Device|S.M.A.R.T. ® Stent|The Cordis S.M.A.R.T.® Nitinol Stent System is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
1821289|NCT00739115|Other|Heliox gas|Heliox gas used in conjunction with nasal CPAP
1821290|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscular at zero, one and six months intervals
1821291|NCT00739128|Biological|hepatitis B vaccine (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intradermally in the deltoid region at zero, one and six months intervals
1821292|NCT00739141|Other|fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft|Cyclophosphamide 50 mg/kg/dose x 1 IV day -6 (1 dose) Fludarabine 30 mg/m2/dose x 5 IV days -6 to -2 (5 doses) Thiotepa 5 mg/kg/dose x 2 IV days -5 to -4 (2 doses) TBI 200 cGy/dose x 2 days -2 to -1 (2 doses). On transplant day, the cord blood cells will be given through your catheter. The immune suppressing drugs you will receive are called cyclosporine-A (CSA) and mycophenolate mofetil (MMF). These will be started 3 days before the transplant and will be given through your catheter. Later they can be given as tablets.
1821293|NCT00739180|Other|Control|Standard care control (no exercise)
1821294|NCT00739180|Other|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
1821295|NCT00739180|Other|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
1821296|NCT00739193|Drug|amiodarone|
1821297|NCT00739206|Drug|SAR97276A|Dose based on body weight
1821298|NCT00739219|Device|Apieron Insight eNO monitor|The Apieron Insight(tm) eNO monitor is used to measure exhaled nitric oxide, and asthma is managed to keep eNO below an individualized target.
1821299|NCT00739232|Drug|HSD-016|
1821300|NCT00739232|Other|placebo|
1821301|NCT00739271|Other|Early feeding|
1821302|NCT00739271|Other|late feeding after bowel sounds return|Traditional method
1821303|NCT00739284|Device|nephrostomy tube and ureteral stent|
1821304|NCT00739297|Drug|Comparator: montelukast|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
1821305|NCT00739297|Drug|Comparator: placebo|5 Period, Cross-over, Dose-Ranging study. Period I: no treatment. Periods II-V: Single-dose administration of inhaled montelukast (using doses as low as 25 mcg, to as high as 1000 mcg), or montelukast placebo. Two puffs of albuterol or albuterol placebo will be given four hours after montelukast/montelukast placebo.
1821306|NCT00739310|Device|Vest Treatment (high frequency chest wall oscillation)|twice daily for 15-20 minutes
1821307|NCT00739336|Behavioral|Diabetes Prevention and Control|The program will be delivered over 3 months in 12 one hour weekly mid-day sessions at the worksite. The curriculum has been adapted from the Diabetes Prevention Program, the National Diabetes Education Program and Conversation maps from Healthy Interactions Inc. Topics relate to healthy eating, physical activity, coping with disease and depression, and cardiovascular disease prevention. Additional topics may be included per feedback and need of the participants. After completion of the 3 month program, there will be monthly meetings.
1821308|NCT00739349|Drug|NOVA22007 ''Cyclosporine''|Cyclosporine 0.05% Ophthalmic Cationic Emulsions
1821309|NCT00739349|Drug|NOVA22007 ''Cyclosporine''|Cyclosporine 0.1% Ophthalmic Cationic Emulsions
1821310|NCT00739349|Drug|vehicle/placebo|vehicle/placebo
1821318|NCT00739375|Procedure|Primary arterio-venous vascular access creation|Primary arterio-venous vascular access creation, ECHO with pulmonary artery pressure measurements, Assessment of blood NO metabolite levels
1821319|NCT00739388|Drug|azacytidine|100 mg/m2/day s.c. on days 1-5 of a 28-day cycle
1821320|NCT00739401|Device|Suprarenal Proximal Cuff Extension|Powerlink 25 and 28mm Suprarenal Proximal Extensions augmenting the 25 and 28mm Powerlink bifurcated stent graft
1821321|NCT00739414|Drug|LBH589|10, 15, 20 mg/m2, i.v. on day 1 and 8 of each 21 day cycle
1821322|NCT00739440|Biological|serum antiscorpion|The dose may be required for the patient according to clinical manifestations and evolution
1821323|NCT00739453|Drug|OSI-906|administered orally
1821324|NCT00739453|Drug|erlotinib|administered orally
1821325|NCT00739466|Drug|Liposomal Alendronate|IV in a single low dose during the index procedure (coronary stent implantation) over 2 hours
1821326|NCT00739466|Drug|Liposomal Alendronate|IV in a single high dose during the index procedure (coronary stent implantation) over 2 hours
1821327|NCT00739466|Drug|Saline infusion (placebo)|IV saline infusion during the index procedure (coronary stent implantation) over 2 hours
1821328|NCT00739479|Dietary Supplement|Weight Loss|Participants will reduce their total dietary intake by ~800 kcal/day. ~100 kcal will be replaced by either the PHWP of PHG protein supplement, resulting in a total energy restriction of ~700 kcal/day.
1821329|NCT00739492|Behavioral|financial incentives|financial incentives based on attaining weight loss goals
1821330|NCT00739505|Biological|Asfotase Alfa|"The initial IV dose to be administered to patients was set at one-tenth the no adverse effect level (NOAEL) as determined by one month toxicology studies in animals in which Asfotase Alfa was administered as a single weekly IV dose. The SC doses to be administered are lower than the IV doses and are thought to be near or at the anticipated daily efficacious dose. Dosing will be as follows:
Cohort 1: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 3 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1 mg/kg SC."
1821331|NCT00739505|Biological|Asfotase Alfa|Cohort 2: In Week 1, patients will receive an IV infusion of Asfotase Alfa at a dose of 7 mg/kg. In Weeks 2, 3 and 4, patients will receive weekly SC injections of Asfotase Alfa at a dose of 1.5 mg/kg SC.
1821332|NCT00739518|Procedure|MRI|Neurological MRI with new technology evaluation. The new technology may involve software or MRI scanning sequences. This is a long term research study that focuses on new technology that is constantly being created.
1821333|NCT00739531|Device|Exhaled nitric oxide (eNO)|Subjects will perform a controlled breath maneuver using both the Apieron and NIOX devices. The devices will measure nitric oxide in the subjects' exhaled breath.
1821334|NCT00739544|Other|1|Testing with thermal sensor testing device, von Frey filaments, cotton wisp, turning fork, pressure gauge device
1821335|NCT00739570|Device|AAI signature IV AMCT|Chiropractic adjustments of the lumbar spine following the activator basic scan protocol
1821336|NCT00739583|Drug|CHG 2% w/v and IPA 70% v/v|Skin preparation of the surgical site per label of the product. The area for surgery will be prepared for 30 seconds
1821337|NCT00739583|Drug|Iodophor 0.7% and IPA 74% w/w|Skin preparation of the surgical site per product labeling. The area will be painted with the solution.
1821338|NCT00739596|Drug|Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Aliskiren HCTZ (150/12.5 mg) for 1 week followed by forced titration to Aliskiren HCTZ (300/25 mg) for remaining 7 weeks
1821339|NCT00739596|Drug|Amlodipine: 8 weeks|Amlodipine 5 mg for 1 week followed by forced titration to Amlodipine 10 mg for remaining 7 weeks
1821340|NCT00739609|Drug|1-methyl-D-tryptophan|D-1MT will be administered in escalating doses. Initial dosing will be 200 mg by mouth daily with escalation planned to 2000 mg by mouth daily and potentially higher doses in subsequent cohorts if tolerated and pharmacokinetic and biologic data support further dose escalation.
1821341|NCT00739622|Drug|TMC278|
1821342|NCT00739635|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day
1821343|NCT00739635|Drug|Placebo|Double-blind treatment period of 17 weeks placebo
1821344|NCT00739648|Drug|MP-376|MP-376 administered via inhalation for 5 consecutive days within 28-day treatment cycles for up to 12 cycles
1821345|NCT00739648|Drug|Placebo|same frequency as study drug using the same method of delivery
1821346|NCT00739661|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
1821347|NCT00739661|Drug|Placebo to vismodegib|Placebo to vismodegib consisted of the excipients for vismodegib without the active molecule in hard gelatin capsules matching the active drug product in color and size.
1821348|NCT00739674|Drug|losartan potassium (+ hydrochlorothiazide [HCTZ] + calcium channel blocker [CCB])|"Losartan 50 mg or 100 mg once daily for 40 weeks with sequential titration including HCTZ 12.5 mg or 25 mg and CCB only as needed to achieve target blood pressure, as follows:
Patients with mild-moderate hypertension, uncontrolled hypertension on monotherapy, or diabetes:
Losartan 50 mg
Losartan 100 mg
Losartan 100 mg/HCTZ 12.5 mg
Losartan 100 mg/HCTZ 25 mg
Losartan 100 mg/HCTZ 25 mg + CCB
Patients with severe hypertension:
Losartan 50 mg/HCTZ 12.5 mg
Losartan 100 mg/HCTZ 12.5 mg
Losartan 100 mg/HCTZ 25 mg
Losartan 100 mg/HCTZ 25 mg + CCB
Losartan 100 mg/HCTZ 25 mg + increasing CCB"
1821349|NCT00739674|Behavioral|Low Salt Diet|"Low-salt intake diet (Dietary Approaches to Stop Hypertension [DASH]) including:
Healthy diet
Reduction in sodium intake to less than 2300 mmol/day
Low alcohol consumption (less than 2 standard drinks/day)"
1821350|NCT00739687|Drug|ALT-711|200 mg tablet BID for 9 months.
1821351|NCT00739687|Drug|Placebo|200 mg tablet BID for 9 months.
1821352|NCT00739713|Dietary Supplement|Sea buckthorn (Hippophaë rhamnoides) oil|Dosage 2 g/d, frequency twice/d, duration 3 months
1821353|NCT00739713|Dietary Supplement|Placebo comparison|Placebo comparison, dosage 2 g/d, frequency twice/d, duration 3 months
1821354|NCT00739739|Drug|PD 0299685 at 15mg BID|5 mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study
1821355|NCT00739739|Drug|PD 0299685 at 30mg BID|10mg Capsules, 3 to be taken in the morning and at bedtime for the duration of the study. Initial 2 week titration period at 15mg BID.
1821356|NCT00739739|Drug|placebo for PD 0299685|Capsules identical in appearance to PD 0299685, 3 to be taken in the morning and at bedtime for the duration of the study
1958531|NCT01561833|Drug|Sorafenib|Intrapatient dose reduction to 400 mg once daily and then 400 mg every other day will be allowed depending on the type and severity of toxicity encountered provided that criteria for patient withdrawal from study treatment have not been met.
1993999|NCT03092193|Drug|Naproxen-esomeprazole|20 phenotyped for CYP2C9 and CYP2C19 (by PCR) and for the pharmacokinetics of naproxen-esomeprazole, saliva samples will be collected of these patients at different times after ingestion of a tablet of naproxen-esomeprazole (500mg+20mg) (after one month of the first collection) (before, 0,25; 0,5; 0,75; 1; 1,5; 2; 3; 4; 5; 6; 8; 11; 24; 48; 72 e 96 hours after ingestion).
1821360|NCT00739765|Behavioral|Interpersonal Psychotherapy|14 weekly 50-minute sessions of interpersonal psychotherapy, a time-limited treatment that focuses on interpersonal functioning and social supports
1821361|NCT00739765|Behavioral|Prolonged Exposure Therapy|Ten 90-minute sessions, distributed over 14 weeks, of prolonged exposure, which involves the repeated, detailed recounting of the trauma to develop a coherent narrative and repeated exposure to reminders of the trauma
1821362|NCT00739765|Behavioral|Relaxation Therapy|Nine 90-minute sessions and one 30-minute session, distributed over 14 weeks, that focus on muscle relaxation to address the physical symptoms of PTSD
1821363|NCT00739778|Other|food - novel sweetener|concentration to be isosweet with 4.7% sucrose
1821364|NCT00739778|Other|food vehicle blank|water blank
1821365|NCT00739778|Other|food - sweetener, positive control|4.7% sucrose in water
1821366|NCT00739778|Other|food - sweetener, negative control|non-cariogenic sweetener at concentration isosweet with 4.7% sucrose
1821367|NCT00739791|Behavioral|exercise intervention|
1821368|NCT00739791|Genetic|gene expression analysis|
1821369|NCT00739791|Genetic|polymerase chain reaction|
1821370|NCT00739791|Genetic|proteomic profiling|
1821371|NCT00739791|Genetic|reverse transcriptase-polymerase chain reaction|
1821372|NCT00739791|Other|laboratory biomarker analysis|
1821373|NCT00739791|Other|medical chart review|
1821374|NCT00739791|Other|questionnaire administration|
1821375|NCT00739791|Procedure|psychosocial assessment and care|
1821376|NCT00739791|Procedure|quality-of-life assessment|
1821377|NCT00739791|Procedure|support group therapy|
1821378|NCT00739791|Procedure|therapeutic dietary intervention|
1821379|NCT00739830|Drug|ridaforolimus|40 mg once daily oral tablets for 5 days followed by 2 days without ridaforolimus
1821380|NCT00739830|Drug|medroxyprogesterone acetate tablets OR megestrol acetate|oral medroxyprogesterone acetate tablets 200 mg daily OR oral megestrol acetate tablets 40 mg 4 times per day (160 mg daily)
1821381|NCT00739830|Drug|chemotherapy|Chemotherapy - carboplatin, paclitaxel, doxorubicin, pegylated liposomal doxorubicin or topotecan administered as a single agent or as a doublet, and will be administered at doses and schedules chosen by the investigator
1821382|NCT00739856|Procedure|Electroconvulsive Therapy|ECT was administered using the MECTA-SR1 apparatus. The current amplitude was 800 mA, pulse width was 1.5 ms, and pulse frequency was 50 Hz. Stimulus duration was increased as required to elicit an adequate seizure, defined as at least 25 s with EEG monitoring. The ECT course was fixed, and comprised 6 treatments administered with bitemporal electrode placement at a twice-weekly frequency
1821383|NCT00739882|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody|Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week. The treatment period will be 24 weeks divided into two phases: 1) double-blind for 12 weeks, and 2) open-label for 12 additional weeks, in which all subjects from the placebo group and those subjects from the Raptiva ® group with ≥ 50% of improvement will be allocated to extended treatment with Raptiva ® for 12 additional weeks while non-responders to Raptiva ® (improvement ≤ 50%) will be followed in an observational manner for 12 additional weeks without treatment.
1821384|NCT00739882|Drug|Placebo|Placebo will be administered at Study Day (SD) 1, Week (W) 1, W 4, W 8 and W 12. Each subject will receive an initial conditioning dose of 0.7 mg/kg/week and then will continue treatment at a dose of 1.0 mg/kg/week for 12 weeks (double-blind phase)
1821385|NCT00739895|Procedure|Cardiac magnetic Resonance study|follow-up studies
1821386|NCT00739895|Procedure|Blood testing|Blood sample tested for myocardial biomarkers
1821387|NCT00739908|Drug|CX157 (TriRima)|Six capsules administered three times a day for six weeks.
1821388|NCT00739908|Drug|Placebo|Six capsules administered three times a day for six weeks.
1821389|NCT00739921|Procedure|Nasal swab under endoscopic guidance|"After the application of pontocaine and neosynephrine spray, the following will be done:
A small sponge applicator will be used to swab the inside of your mouth for saliva collection
A blood sample (6cc - one tube) will be collected
A small brush applicator called a cytology brush and an instrument called an endoscope will be used to swab the inside of your nose (middle meatus)
Subjects will be asked to complete 2 standard quality of life questionnaires regarding how much your symptoms bother you
You will be asked to bring in a vacuum cleaner bag from home at a follow-up appointment which will be swabbed as well
The samples will be refrigerated and analyzed using PCR to detect and speciate fungus."
1821390|NCT00739934|Drug|voriconazole (Vfend)|"Study Days 1 to 7: IV voriconazole 7 mg/kg q12h. Study Days 8 to 14: Oral voriconazole (POS) 200 mg q12h
Notes:
If unable to switch to oral medication on Day 8, subjects can continue with IV treatment up to Day 20 before switching to oral dose.
Only morning oral dose will be given on Day 14 (or the seventh day of oral dosing if IV regimen is extended). However, if clinically indicated, voriconazole treatment may be continued up to Day 30.
(IV = Intravenous; POS = Powder for oral suspension)"
1821391|NCT00739947|Other|Observational study of the surgical outcome|Subjects return for 7 follow-up visits following arthroscopic repair of their rotator cuff. During the follow-up visits subjects undergo imaging with MRI and ultrasound.
1994000|NCT03090971|Drug|Diclofenac Sodium|Following microporation, treatment neurofibromas will receive treatment with topical diclofenac
1821393|NCT00739973|Drug|Placebo|
1821394|NCT00739973|Drug|Aliskiren 150 mg tablet|
1821395|NCT00739973|Drug|Aliskiren 300 mg tablet|
1821396|NCT00739973|Drug|Amlodipine 5 mg capsule|
1821397|NCT00739973|Drug|Amlodipine 10 mg capsule|
1821398|NCT00739973|Drug|Aliskiren/amlodipine 150/5 mg tablet|
1821399|NCT00739973|Drug|Aliskiren/amlodipine 150/10 mg tablet|
1821400|NCT00739973|Drug|Aliskiren/amlodipine 300/5 mg tablet|
1821401|NCT00739973|Drug|Aliskiren/amlodipine 300/10 mg tablet|
1821402|NCT00739986|Drug|Semapimod|semapimod 60 mg IV x 1 day, placebo x 2 days
1821403|NCT00739986|Drug|Semapimod|Semapimod 60 mg IV x 3 days
1821404|NCT00739986|Drug|Placebo|placebo IV x 3 days
1821405|NCT00739999|Drug|Atorvastatin|6-10 years Tanner Stage 1 will be administered 5-mg daily dose of an atorvastatin pediatric tablet formulation. Dose may be doubled if subjects have not attained target LDL (<3.35 mmol/L) after 4-week treatment.
1821406|NCT00739999|Drug|Atorvastatin|10-17 years Tanner Stage 2 will be administered 10-mg daily dose of atorvastatin tablet formulation. Dose may be doubled if subjects have not attained target LDL (<3.35 mmol/L) after 4-week treatment.
1821407|NCT00740012|Other|Continuous glucose monitoring|Glucoday S (microdialysis system). Continuous glucose monitoring all three nights
1821408|NCT00740012|Other|alarm- clock intervention, patient perform blood glucose self monitoring|Alarm clock intervention at midnight, 2 a.m., 4 a.m. and 6:45 a.m.
1821409|NCT00740012|Other|nurse intervention|Nurse intervention: gently drawing capillary sample (blood glucose)at midnight, 2 a.m., 4 a.m. and 6:45 a.m. .
1821410|NCT00740012|Other|Taking the patients pulse|In nights (a) and (b) the doctoral candidate takes the patients pulse 5-7 minutes after the alarm clock or the nurse.
1821411|NCT00740012|Other|Venous blood drawing|Venous blood drawing for the determination of epinephrine, norepinephrine, cortisol, glucagon, growth hormone, and prolactin (determined by specific immunoassays at Biocientia laboratories, Jena, Germany) (6-10 minutes after midnight, 2 a.m., 4 a.m. and 6:45 a.m.)in night (a) and (b)
1821412|NCT00740012|Other|Other capillary sample|5-7 minutes after the alarm clock or the nurse the doctoral candidate takes another capillary sample for a laboratory glucose determination (EBIOS, Eppendorf, Hamburg, Germany) analyzer.
1821413|NCT00740038|Behavioral|Stress Management training|Self-administered stress management training comprising 10 minute introduction by staff, & provision of DVD, CD,brochure, and workbook. Materials provide overview of sources of stress during chemotherapy, and instruction in cognitive-behavioral stress management techniques (paced abdominal breathing, progressive muscle relaxation with guided imagery, and use of coping self-statements). Daily use is encouraged over 13-14 weeks of the study.
1821414|NCT00740038|Behavioral|Exercise Training|Home-based exercise (walking) program: brief introduction by staff (10 minutes) and provision of packet with DVD, brochure, workbook, pedometer (electronic step counter) along with instructions on initiating and maintaining a walking program. Dose Recommendations: 3-5 exercise session per week for at least 20-30 minutes at maximum intensity of 50 to 75% of their estimated heart rate reserve (RPE of 11-13) which is calculated based on their age and resting pulse.
1821415|NCT00740038|Behavioral|Usual care|Usual psychosocial care and provision of NCI booklet, Chemotherapy and You (NCI, 1999) which gives general feedback about fitness testing, exercise and stress management during chemotherapy. Recommended to read booklet at least once.
1821416|NCT00740038|Behavioral|Combined stress management and exercise training|Home-based, self-administered stress management and exercise (walking) program: brief introduction by staff and provision of DVD, CD, brochure, pedometer, workbook. Dose Recommendations: walking/exercise program (3-5 times per week for at least 20-30 minutes) and use of CD (progressive muscle relaxation with guided imagery) and coping statements once per day.
1821417|NCT00740051|Drug|Linagliptin|5mg once daily
1821418|NCT00740051|Drug|Linagliptin Placebo|0 mg placebo comparator for part 1 of study (to 18 weeks)
1821419|NCT00740051|Drug|Glimepiride|1-4mg for part 2 of study (weeks 19-52)
1821420|NCT00740064|Drug|Raltegravir and Abacavir/Lamivudine|Raltegravir 400mg BID Abacavir/Lamivudine 1 tablet QD
1821421|NCT00740077|Other|Low calorie, sugar-free cranberry juice cocktail (54% juice)|Single-dose, 24 hour pharmacokinetic trial of 8 oz dose administered orally.
1821422|NCT00740090|Drug|AMA1-C1/Alhydrogel plus CPG 7909|
1821423|NCT00740103|Drug|Semapimod|60 mg IV x 3 days q 6 - 8 weeks
1821424|NCT00740116|Drug|Tranexamic acid|Tranexamic acid, 100 mg/ml; 15 mg/kg body weight added to 100 ml 0.9% NaCl solution given as a single dose intravenously immediately prior to scin incision at surgery
1821425|NCT00740116|Drug|0.9% NaCl solution|0.9% NaCl solution; 0.15 ml/kg body weight added to 100 ml 0.9% NaCl solution. The volume is given intravenously immediate before scin incision at surgery.
1821426|NCT00740129|Drug|Zoledronic Acid|Zoledronic acid 5 mg intravenous infusion once
1821427|NCT00740142|Drug|L-ornithine-L-aspartate and lactulose|L-ornithine-L-aspartate 1 sachet(3 grams)3 times a day for 7 days
1821428|NCT00740142|Drug|placebo and lactulose|placebo 3 times a day for 7 days
1821429|NCT00740155|Biological|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 Day 0; CYD-2,4 Day 105)
1821430|NCT00740155|Biological|Bivalent CYD-1,3 Dengue (Vero) + Bivalent CYD-2,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (CYD-1,3 + CYD-2,4 on Day 0 and Day 105)
1821431|NCT00740155|Biological|Tetravalent blending VDV-2/CYD-1,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
1821432|NCT00740155|Biological|Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (Day 0 and Day 105)
1821433|NCT00740155|Biological|JE-VAX®: Japanese encephalitis virus vaccine inactivated + Tetravalent CYD-1,2,3,4 Dengue (Vero)|0.5 mL, Subcutaneous (SC) (JE-VAX® Day 0 + Tetravalent CYD-1,2,3,4 on Day 105)
1821434|NCT00740168|Drug|bevacizumab treatment|single infusion 10 mg/kg
1821435|NCT00740181|Drug|chemotherapy|
1821436|NCT00740194|Drug|Aromatase inhibition|Letrozole
1821437|NCT00740194|Drug|Estradiol|Dermestril
1821438|NCT00740207|Drug|VISIPAQUE 270|VISIPAQUE 270 (Iodixanol Injection) is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
1821439|NCT00740207|Drug|Isovue 250|ISOVUE-250 (Iopamidol Injection) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
1821441|NCT00740259|Drug|Flunarizine|For 1 week, 40 mg/day. From week 2 to 3, 20 mg/day. Form week 4 onwards, dosage increment or reduction of 10mg/day was allowed according to efficacy and tolerability.
1821442|NCT00740272|Procedure|AF ablation + pacemaker implantation|regular pacemaker implantation and concomitant AF ablation procedure (PV isolation)
1821443|NCT00740272|Procedure|Pacemaker implantation|regular pacemaker implantation
1821444|NCT00740285|Drug|Lidocaine 2% without vessel constrictor|"first 5 days: 20ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours
next 5 days: 30ml lidocaine 2% without vessel constrictor + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days"
1821445|NCT00740285|Other|Placebo - physiological solution 0,9%|first 5 days: 20ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours next 5 days: 30ml of physiological solution 0,9% 500ml + physiological solution 0,9% 500ml intravenously during 4 hours total: 10 days
1821446|NCT00740298|Other|sucrose|sweet taste
1821447|NCT00740298|Other|warmth|warmth
1821448|NCT00740311|Device|MBCP gel TM|alveoli filling with an injectable calcium phosphate after extraction of mandibular molar or pre molar
1821449|NCT00740324|Drug|NPO-11|20 mg butylscopolammonium bromide after administration of NPO-11
1821450|NCT00740324|Drug|NPO-11|NPO-11 after administration of NPO-11
1821451|NCT00740324|Drug|NPO-11|1 mg glucagons after administration of NPO-11
1821452|NCT00740350|Procedure|Logan Basic|Logan Basic chiropractic adjustments during pregnancy.
1821453|NCT00740363|Drug|sitagliptin|Once daily sitagliptin. If GFR>50 ml/min/1.73m2: 100 mg/day. If GFR from 25 to 49 ml/min/1.3m2: 50 mg/day
1821454|NCT00740363|Drug|placebo|No active sitagliptin treatment for 4 weeks
1821455|NCT00740376|Device|Uniglide Mobile Bearing Unicondylar Knee System|Uniglide Mobile Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo)that articulates with a mobile bearing tibial construct comprised of a cobalt chromium molybdenum (CoCrMo)tibial base plate and ultra high molecular weight polyethylene (UHMWPE) meniscal insert. The femoral component has been cleared as part of the fixed bearing version in K050764. The investigational portion of this device is the mobile bearing tibial construct (tibial tray and meniscal insert).
1821456|NCT00740376|Device|Uniglide Fixed Bearing Unicondylar Knee System|Uniglide Fixed Bearing Knee System includes a femoral component made of cobalt chromium molybdenum (CoCrMo) that articulates with a one piece ultra high molecular weight polyethylene (UHMWPE) tibial bearing (K050764).
1821457|NCT00740389|Drug|TMC125|
1821458|NCT00733564|Drug|Lidocaine|Paracervical injection of 2% Lidocaine to block associated nociception input
1821459|NCT00733564|Drug|Propofol|Propofol 3mg/kg will be injected intravenously; 1 mg/kg will be added additionally for incomplete anesthesia
1821460|NCT00733564|Drug|Sevoflurane|Sevoflurane 8% for anesthesia induction, 2-3% as the maintenance
1821461|NCT00733577|Drug|SB756050|doses are planned to be 15mg to 600mg doses may be altered based on plasma concentrations
1821462|NCT00733603|Other|Global Therapeutic Massages (GTM)|Non-specific somatic treatment with full-body Western massage.
1821463|NCT00733603|Other|Myofascial Tissue Manipulation (MTM)|Targeted internal and external Connective Tissue Manipulation focusing on the muscles and connective tissues of the pelvic floor, hip girdle, and abdomen.
1821464|NCT00733616|Drug|DOX: Docetaxel, oxaliplatin, Capecitabine|"Docetaxel 40 mg/m2, iv infusion 60 minutes, day 1
Oxaliplatin 80 mg/m2, iv infusion 120 minutes, day 1
Capecitabine 625 mg/m2, bid, oral, continuous
6 cycles, every 3 weeks
Capecitabine will be given same dose (625mg/m2/bid) continuous in case no toxicity (no dose adjustment)"
1821465|NCT00733642|Biological|PF-04360365 1 mg/kg|PF-04360365 1 mg/kg infused as a single dose
1821466|NCT00733642|Biological|PF-04360365 3 mg/kg|PF-04360365 3 mg/kg infused as a single dose
1821467|NCT00733642|Biological|PF-04360365 5 mg/kg|PF-04360365 5 mg/kg infused as a single dose
1821468|NCT00733642|Biological|PF-04360365 10 mg/kg|PF-04360365 10 mg/kg infused as a single dose
1821469|NCT00733668|Drug|Quetiapine fumarate (Seroquel)|300 mg, PO, 100 mg morning, 200 mg evening, 4 weeks
1821470|NCT00740415|Biological|rituximab|Rituximab, 375 mg/m2 Intraveinous
1821471|NCT00740415|Drug|bortezomib|-Velcade®, 1,3 mg/m2 Intraveinous on days 1, 4, 8 and 11
1821472|NCT00740415|Drug|dexamethasone|day - Dexamethasone, 40 mg Intraveinous
1821473|NCT00740415|Drug|Bendamustine|-Day 1 and day 2 Bendamustine/Levact ®,, 90 mg/m2 Intraveinous
1821474|NCT00740428|Procedure|Pregnants for receive the physical therapy guide|pregnants for the first time who will receive the physical therapy guide, perform the exercises under the supervision of a physical therapist, and complete an exercise compliance form and a log with information on urinary losses.
1821475|NCT00740441|Drug|AS1411|AS1411 40 mg/kg/day) will be administered on days 1-4 via a continuous iv infusion every 28-day cycle for up to 2 cycles
1821476|NCT00740454|Other|Lower limb veins compression ultrasonography|Distal and proximal lower limb veins compression ultrasonography
1821477|NCT00740467|Biological|anti-thymocyte globulin|
1821478|NCT00740467|Drug|busulfan|
1821479|NCT00740467|Drug|cyclophosphamide|
1821480|NCT00740467|Drug|cyclosporine|
1821481|NCT00740467|Drug|fludarabine phosphate|
1821482|NCT00740467|Drug|mycophenolate mofetil|
1821483|NCT00740467|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1821484|NCT00740493|Drug|warfarin|18 months of warfarin therapy
1821485|NCT00740493|Drug|placebo of warfarin|18 months of placebo of warfarin therapy
1821486|NCT00740506|Behavioral|Frequency of Intercourse|
1821487|NCT00740519|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation.
1821488|NCT00740532|Genetic|Gene mutation analyses and FISH|FISH and mutation analyses of multiple genes
1821489|NCT00740545|Drug|enoxaparine 40 mg daily|Women inject ourselves every days with 40 mg of enoxaparine
1821490|NCT00740545|Drug|placebo|Women inject ourselves every days with placebo
1821491|NCT00740558|Procedure|Activator methods technique|Chiropractic adjustment by a manually assisted mechanical force
1821492|NCT00740558|Procedure|Traditional chiropractic adjustment|Lumbar roll according to the Diversified technique of chiropractic adjusting
1821493|NCT00740571|Drug|amitriptyline|strategy in which the patient starts with amitriptyline, during 8 weeks
1821494|NCT00740571|Drug|pregabalin|Strategy in which patient starts with pregabalin
1821495|NCT00740584|Drug|3% SPL7013 Gel (VivaGel)|A single application of VivaGel applied to the vagina on five separate occasions, each occasion separated by a minimum of 5 days.
1821496|NCT00740597|Genetic|gene expression analysis|
1821497|NCT00740597|Genetic|polymerase chain reaction|
1821498|NCT00740597|Genetic|western blotting|
1821499|NCT00740597|Procedure|neoadjuvant therapy|
1821500|NCT00740597|Procedure|therapeutic conventional surgery|
1821501|NCT00740597|Radiation|intensity-modulated radiation therapy|
1821502|NCT00740610|Drug|GS-9450|GS-9450 capsules at a dose of 1, 5, 10, and 40 mg administered orally once daily
1821503|NCT00740610|Drug|GS-9450 Placebo|Placebo to match GS-9450 administered orally once daily
1821504|NCT00740623|Drug|Carisbamate|800 mg/day for 14 weeks
1821505|NCT00740623|Drug|placebo|placebo for 14 weeks
1821506|NCT00740623|Drug|Carisbamate|1,200 mg/day for 14 weeks
1821507|NCT00740636|Drug|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 75 mg/m2/day.
1821508|NCT00740636|Drug|Temozolomide|Temozolomide will be administered orally once per day on days 1 through 5 of a 28 day cycle. The dose will be 200mg/m2/day.
1821512|NCT00740675|Other|Outpatient Medication Reconciliation|"The post-discharge medication reconciliation module has the following features:
Presents the (preadmission) ambulatory medication list and the hospital discharge medication list side-by-side, sorted by class, with all identical medications lined up next to each other and all differences in the two regimens highlighted.
Allows users to update the ambulatory medication list with a few keystrokes (i.e., to accept individual changes made during the hospitalization).
Allows reconciliation to be performed in full (e.g., for PCPs who are responsible for the entire medication list) or in part (e.g., for specialists)."
1821513|NCT00740688|Procedure|Logan Basic Apex Contact|A Logan Basic Apex Contact, which is a contact that is placed on the anterior surface of the sacrotuberous ligament with a light force directed posterior with varying degrees of laterality.
1821514|NCT00740688|Procedure|Sham Logan Basic apex contact|light force contact applied to the inferior surface of the sacrotuberous ligament, directed straight superiorly.
1821515|NCT00740701|Device|Cerebellar transcranial magnetic stimulation|single pulse TMS or repetitive TMS at 1 Hz frequency
1821516|NCT00740714|Drug|Coenzyme Q10 with vitamin E|2400 mg dose - eight 300 mg Coenzyme Q10 chewable wafers taken orally four times a day; 1200 mg dose - four 300 mg Coenzyme Q10 and four placebo chewable wafers taken orally four times a day.
1821517|NCT00740714|Drug|placebo with vitamin E|placebo or an inactive substance (with vitamin E 1200 IU/day); Placebo - eight chewable wafers taken orally four times a day.
1821518|NCT00740727|Drug|Human recombinant hyaluronidase (HRH)|150u HRH administered via EASI access line, prior to infusion of 250 D5W (5% dextrose in water)
1821519|NCT00740727|Procedure|Enzymatically Augmented Subcutaneous Infusion (EASI) line placement|Subjects will under placement of an EASI line. This entails placement of a small (20-gauge) catheter in the upper back, in the subcutaneous space.
1821520|NCT00740753|Device|Yttrium 90 (TheraSphere)|Y-90 embedded glass microspheres
1821521|NCT00740766|Behavioral|Food diary and behavioral model|"The monitored group is to be placed on a prenatal nutritional program consisting of 18 to 24 kcal. per kg. (according to the patient's actual weight) with monitoring each visit.
The patients will be weighed each prenatal visit with the monitored patients weighed and blinded to their actual weight (being weighed with her back to the scale). The monitored patients will be requested not to weigh at home and all patients will be asked to wear similar clothing at each visit.
All intervention (monitored) group women will be asked to record in a diary all of the foods eaten during each day. These records will be reviewed at each prenatal visit. Six weeks after delivery, the patient will be weighed and will then exit the study. The food diary notebooks will be collected from each patient at the end of the study."
1821522|NCT00740779|Drug|Silodosin 8 mg|Silodosin 8 mg daily
1821523|NCT00740779|Drug|Placebo|Placebo
1821524|NCT00740779|Drug|Silodosin 4 mg|Silodosin 4 mg daily
1821525|NCT00740792|Drug|azelastine HCl/fluticasone propionate|azelastine HCl 548 mcg/ fluticasone propionate 200 mcg one spray per nostril BID
1821526|NCT00740792|Drug|azelastine Hcl|azelastine Hcl 548 mcg one spray per nostril BID
1821527|NCT00740792|Drug|fluticasone propionate|fluticasone propionate 200 mcg one spray per nostril BID
1821528|NCT00740792|Drug|placebo|placebo one spray per nostril BID
1821534|NCT00740818|Other|No Intervention|The patient will lay prone on the adjustment table 5 minutes, the approximate equivalency of a Logan Basic adjustment. Table will be in proper position according to Logan Basic protocol.
1821535|NCT00740818|Procedure|Sham Logan Basic Adjustment|A thumb contact will be used against the sacrotuberous ligament as opposed to underneath the ligament. Auxiliary contacts will also be sham adjustments; the spine will be contacted but no force applied.
1821536|NCT00740818|Procedure|Logan Basic adjustment|Logan Basic adjustment, as well as auxiliary and abdominal contacts, based on the Logan Basic protocol.
1821537|NCT00740831|Drug|PGL4001|tablets
1821538|NCT00740831|Drug|leuprorelin|solution for injection
1821539|NCT00740844|Device|Intermittent pneumatic compression of the lower limbs|Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
1821540|NCT00740857|Drug|placebo|2 placebo gels capsules delivered as a single dose.
1821541|NCT00740857|Drug|ibuprofen Formulation 1|2 marketed ibuprofen gels
1821542|NCT00740857|Drug|ibuprofen Formulation 2|2 marketed ibuprofen gels
1821544|NCT00740883|Drug|warfarin|18 months of warfarin therapy, once daily
1821545|NCT00740883|Drug|placebo of warfarin|18 months of placebo of warfarin therapy, once daily
1821546|NCT00740896|Behavioral|Smoking|Active Comparator: Participants smoke 8 cigarettes in 4 hours.
1821547|NCT00740896|Behavioral|Smoking|Sham Comparator: Participants are not allowed to smoke for 4 hours.
1821548|NCT00740909|Behavioral|Cognitive Behavioral Therapy|A therapy designed to help patients with response prevention skills.
1821549|NCT00740922|Drug|Sterile becaplermin gel vs. sterile placebo gel treatment 1|Becaplermin gel 100 µg/g versus placebo gel (up to 12 applications).
1821550|NCT00740935|Biological|Rotateq vaccine|"Vaccination against rotavirus
Three oral doses (2 mL) between 6 to 26 weeks of life with at least 4 weeks between each dose."
1821551|NCT00740948|Drug|Rituximab (mabthera) Injection|2 * 1g of Rituximab at the 1st day and at the 14th day.
1821552|NCT00740948|Drug|Placebo: NaCl 0.9% or Glucose 5%|2* 250ml of NaCl 0.9% or Glucose 5% at the 1st day and at the 14th day.
1821553|NCT00740961|Behavioral|compliance monitoring|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
1821554|NCT00740961|Drug|systemic chemotherapy|Learning about changes over time in older patients' ability to function after receiving chemotherapy for breast or colon cancer
1821555|NCT00740961|Other|medical chart review|A limited review of medical records for the sole purpose of evaluating patients for study eligibility will be undertaken by the research team.
1821556|NCT00740961|Other|study of socioeconomic and demographic variables|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
1821557|NCT00740961|Other|survey administration|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
1821558|NCT00740961|Procedure|cognitive assessment|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
1821559|NCT00740961|Procedure|psychosocial assessment and care|Patients complete the Vulnerable Elders Survey (VES-13) and a Comprehensive Geriatric Assessment at baseline and 12 months later. Variables collected include sociodemographics; cognitive, nutritional, psychosocial, and emotional status; tumor characteristics; therapy; and mortality.
1821560|NCT00740987|Device|Intermittent pneumatic compression of the lower limbs|No Intermittent pneumatic compression of the lower limbs during hospitalisation in reanimation unit
1821561|NCT00741000|Procedure|Cervical Stairstep|Cervical low force mobilization procedure.
1821562|NCT00741013|Drug|placebo pill and placebo IV|"Placebo pill every four hours, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
1821563|NCT00741013|Drug|Lovastatin pill and placebo IV|"lovastatin pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
Placebo IV starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
1821564|NCT00741013|Drug|placebo pill and recombinant human activated protein C IV|"placebo pill every four hours, total of 80 milligrams a day, starting 16 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS
recombinant human activated protein C IV 24 micrograms per kg per hour starting 2 hours before intrabronchial LPS and ending 24 hours after intrabronchial LPS"
1821565|NCT00741013|Biological|Endotoxin|Endotoxin 4 ng/kg instilled bronchoscopically in all volunteers 12 hours after starting lovastatin treatment and 2 hours after starting recombinant human activated protein C treatment.
1821566|NCT00741026|Drug|Olanzapine 10 mg po qhs for 3 days|(1) 10 mg tablets administered orally before bed for three consecutive evenings (Total Dose = 30 mg, 3 tablets)
1821567|NCT00741026|Drug|Placebo|(1) placebo tablets administered orally before bed for three consecutive evenings (Total Dose = 3 tablets)
1821568|NCT00741039|Biological|inactivated influenza vaccine and the 23- valent pneumococcal vaccine|Patients >65 years of age with a diagnosis of prostate, lung, and/or breast cancer will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly) and/or the 23-valent pneumococcal vaccine (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured, as will serum IgG levels and IgG subtypes. At 8-16 weeks after vaccination, post vaccine titers, CBC, lymphoid phenotype and function will be assessed.
1821569|NCT00741039|Biological|inactivated influenza vaccine and the PPV23 vaccine (Pneumovax)|MSKCC employee volunteer controls > or = to 65 years of age without a cancer diagnosis will be immunized with the inactivated influenza vaccine (0.5 ml intramuscularly)and/or PPV23 vaccine (Pneumovax), (0.5 ml subcutaneously or intramuscularly). Prior to vaccination, titers against influenza and pneumococcus will be measured. At approximately 8-16 weeks after vaccination, post vaccine titers will be measured again.
1821570|NCT00741052|Drug|Ciprofloxacin|12 hourly oral dose of ciprofloxacin for 3 days
1821571|NCT00741052|Drug|Azithromycin|1 gm Azithromycin single dose
1821572|NCT00741065|Procedure|Direct Epicardial Shock Wave Therapy|performed in adjunct to a standard coronary artery bypass grafting procedure Prior to aortic cross clamping direct epicardial shock wave therapy - applied directly to the myocardium
1821573|NCT00741078|Drug|statin, amlodipine|
1821574|NCT00741091|Device|Carotid WALLSTENT Monorail Endoprosthesis|A carotid artery stent for use in subjects at high risk for adverse events from Carotid endarterectomy (CEA) due to either anatomic or comorbid conditions who require carotid revascularization in the treatment of ipsilateral or bilateral carotid artery disease.
1821575|NCT00741091|Device|FilterWire EZ™ System™|Embolic protection device used in conjunction with the Carotid WALLSTENT Endoprosthesis.
1821576|NCT00741104|Drug|Infliximab|Treatment of RA with Infliximab according to and under normal routine clinical practice.
1821577|NCT00741117|Procedure|Arterial Blood Gas|One blood gas sample will be obtained from an artery in the arm.
1821578|NCT00741117|Procedure|Pulse Oximetry Machine|A pulse oximetry machine will be used at one time point to obtain an oxygen saturation reading. This is done by placing a clip onto the finger. The pulse oximetry value displays on the pulse oximeter machine within seconds.
1821579|NCT00741117|Procedure|Direct and Indirect Serum Bilirubin Measurement|One tube of blood will be drawn from a vein in the arm at one timepoint to measure the direct and indirect serum bilirubin levels.
1821580|NCT00741143|Other|Fortification of wheat flour with NaFeEdta|NaFeEdta Fortified Wheat Flour (100g)provided as a lunch meal. Fortification level of 6mg Fe/100g/day/child for 7 months
1821581|NCT00741156|Drug|Enalaprilat|Enalaprilat will be administered intravenously i.v. 0.005 - 0.01 mg/kg i.v. over 1 minute
1821582|NCT00741169|Drug|TMC435350|200 mg taken by mouth once daily for 7 days
1821583|NCT00741169|Drug|Rifampin|600 mg taken by mouth once daily for 7 days
1821584|NCT00741169|Drug|TMC435350+rifampin|The combination of TMC435350 200 mg + rifampin 600 mg both taken by mouth once daily for 7 days.
1821585|NCT00741182|Drug|rhPTH(1-34)|Injection of 20 micrograms per day in eight weeks
1821586|NCT00741195|Drug|Docetaxel|Docetaxel at the dose of 75 mg/m2 IV on days 1 every 3 weeks for 6 consecutive cycles.
1821587|NCT00741195|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles
1821629|NCT00741468|Drug|CYP3A4 probe|Midazolam (2mg)
1821588|NCT00741208|Dietary Supplement|Soy Isoflavone|50mg soy isoflavone supplement consumed twice daily for a total of 100mg of soy isoflavones per day.
1821589|NCT00741221|Drug|Pemetrexed|Pemetrexed (IV) 500 mg/m2 on day 1 every 3 weeks for 6 cycles
1821590|NCT00741221|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks for 6 cycles After the end of the 6 cycles Bevacizumab will be administered alone at the dose of 15 mgr/Kgr (IV) every 3 weeks until disease progression
1821591|NCT00741234|Drug|SB939|SB939 taken orally in a 4-week cycle.
1821592|NCT00741234|Drug|Azacitidine|Azacitidine taken orally with SB939 in a 4-week cycle
1821593|NCT00741247|Procedure|EBUS-TBNA, EUS-B-FNA (EUS-FNA with bronchoscope)|EBUS-TBNA is a bronchoscopic diagnostic method that enables real time aspiration of paratracheal and peribronchial lesions. EUS-FNA is a procedure to obtain samples through the esophagus under real-time ultrasound guidance. In this study, EUS-FNA will be applied using a ultrasonic bronchoscope (EUS-B-FNA).
1994001|NCT03090971|Drug|Saline Solution|Following microporation, control neurofibromas will receive treatment with topical saline
1821596|NCT00741273|Drug|Proellex|Proellex 25 mg capsule, single dose
1821597|NCT00741286|Drug|Aspirin|Asprin (100mg) plus placebo
1821598|NCT00741286|Drug|cilostazol|Aspirin (100mg) plus cilostazol (200mg)
1821599|NCT00741312|Behavioral|Regular aerobic physical exercise|"Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
The exercise-program follows the ACOG and ACSM exercise prescription. Aerobic activities will be performed at moderate intensity (60-70% of maximal heart rate) measured by the 6-20 Borg's rating scale. Each session starts with a 5 minutes of warm up, followed by 30 minutes of aerobic activity, including 5 minutes cool down. This is followed by 15 minutes of circuit strength training of the upper limbs, lower limbs, and deep abdominal stabilization muscles. The last 5 minutes consists of stretching and relaxation exercises."
1821600|NCT00741312|Behavioral|Activities of daily living|Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist.
1821601|NCT00741325|Drug|granulocyte colony-stimulating factor (G-CSF)|
1821602|NCT00741325|Drug|plerixafor|
1821603|NCT00741325|Drug|Placebo|
1821604|NCT00741338|Biological|Laronidase|0.058 mg/kg - 0.58 mg/kg IV infusion weekly.
1821605|NCT00741338|Drug|Cyclosporine A (CsA)|Orally three times daily.
1821606|NCT00741338|Drug|Azathioprine (Aza)|Orally either every day for Cohort 1 or every other day for Cohort 2.
1821607|NCT00741351|Drug|Sevoflurane + Fentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and fentanyl (2-3 microg/kg/hr or 0.7 microg/kg boluses). Just before incision of the scalp, fentanyl (1-2microg/kg/hr) can be supplemented, if necessary
1821608|NCT00741351|Drug|Sevoflurane + Remifentanyl|Sevoflurane is maintained in a MAC range (0.75% to 1.25%) and remifentanil (0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening). Just before incision of the scalp, remifentanil can be supplemented, if necessary
1821609|NCT00741351|Drug|Propofol + Remifentanyl|Propofol is maintained with continuous infusion at 10 mg/kg/h for the first 10 minutes, then reduced to 8 mg/kg/h for the following 10 minutes and reduced to 6mg/kg/h thereafter and remifentanil 0.5-0.25 microg/kg/min reduced to 0.05-0.1 microg/kg/min after dural opening. Just before incision of the scalp, remifentanil could be supplemented, if necessary
1821610|NCT00741364|Dietary Supplement|vitamin D3 (cholecalciferol)|liquid vitamin D solution (vitamin D3 in ethanol) taken daily at one of three possible doses (400, 10000, or 40000 IU/d) for 4-6 weeks prior to radical prostatectomy
1821611|NCT00741377|Drug|BHQ880|
1821612|NCT00741377|Drug|Zoledronic acid|
1821613|NCT00741390|Device|BD/33G|BD Lancet device/BD 33G lancets (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
1821614|NCT00741390|Device|OTM / 33G|OneTouch® Mini Lancet device / BD 33G lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
1821615|NCT00741390|Device|OTU/28G|OneTouch® UltraSoft® Lancet device/OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ BGM) and OneTouch® Ultra® test strips)
1821616|NCT00741390|Device|ACC/28G|Accu-Chek® Softclix Lancet device/Accu-Chek® Softclix 28G Lancet (BGM measured with Accu-Chek® Advantage BGM and Accu-Chek® Comfort Curve test strip)
1821617|NCT00741390|Device|OTM/28G|OneTouch® Mini Lancet device / OneTouch® UltraSoft® 28G Lancet (BGM measured with the OneTouch® UltraMini™ (BGM) and OneTouch® Ultra® test strips)
1821618|NCT00741403|Drug|CPI-613|CPI-613, the investigational drug, is a novel anti-tumor compound believed to operate via a novel mechanism of action that does not belong to any existing pharmacological class of anticancer agents currently being used in the clinics. Specifically, CPI-613 is Cornerstone Pharmaceutical Inc.'s lead drug from its Altered Energy Metabolism-Directed (AEMD) technology platform. It is selective against tumor cells (but not normal cells)according to preclinical studies
1821619|NCT00741429|Drug|Technosphere Insulin Inhalation Powder|Subjects previously treated with Technosphere Insulin Inhalation Powder
1821620|NCT00741429|Drug|Comparator|Subjects previously treated with other anti-diabetic medications
1821621|NCT00741442|Drug|RDEA806|Uricosuric agent for the treatment of gout
1821622|NCT00741442|Drug|Placebo|Matching Placebo.
1821623|NCT00741455|Procedure|Chemotherapy followed by Stem Cell Transplantation|"Donor: Prior to mobilization, leukapheresis to collect CD3+ cells. The donor will then receive G-CSF (10 mcg/kg/day) with leukapheresis collection of peripheral blood stem cells on days 5, 6 and 7 as needed. Goal of leukapheresis will be > 5 x 106 CD34+cells/kg of recipient.
Patient: Peripheral Blood Stem Cell (PBSC) Transplant. Fludarabine 25mg/m2/d IV over 30 minutes on days -6 to -2, followed by cyclophosphamide 1g/m2/d IV on days -3 and -2. This will be followed by allogeneic stem cell infusion 48 hours later.
Donor Lymphocyte Infusion (DLI) and Adjustment of Immunosuppression: Cyclosporine (CSA) and methotrexate (MTX) will be used for GvHD prophylaxis with target CSA levels of 200-400 ng/ml."
1821624|NCT00741468|Drug|Proellex|2, 25 mg Proellex capsules administered daily
1821625|NCT00741468|Drug|CYP1A2 probe|Caffeine (200 mg)
1821626|NCT00741468|Drug|CYP2C9 probe|Tolbutamide (250 mg)
1821627|NCT00741468|Drug|CYP2C19 probe|Omeprazole (20 mg)
1821628|NCT00741468|Drug|CYP2D6 probe|Dextromethorphan (30 mg)
1821630|NCT00741481|Procedure|FDG-PET imaging|FDG-PET imaging at D0 and D14 of first course of a new chemotherapy for advanced colorectal cancer
1821631|NCT00741494|Device|PICSI dish|Sperm are added to the PICSI dish. Only those that bind to the hyaluronan microdots are selected for ICSI
1821632|NCT00741507|Behavioral|Alcohol drinking|Never drinking of alcohol
1821633|NCT00741507|Behavioral|Alcohol drinking|"Mild drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
1821634|NCT00741507|Behavioral|Alcohol drinking|"Moderate drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
1821635|NCT00741507|Behavioral|Alcohol drinking|"Severe over drinking of alcohol assessed by alcohol use disorders identification test (AUDIT)"
1821636|NCT00741507|Behavioral|Alcohol drinking|"Alcohol-dependent assessed by alcohol use disorders identification test (AUDIT)"
1821637|NCT00741520|Device|CPAP|Control - no treatment
1821638|NCT00741520|Device|CPAP|CPAP: The airway pressure will be determined by an overnight sleep study titration.
1821639|NCT00741546|Procedure|Cardiac Surgery|Cardiac Surgery
1821640|NCT00741559|Device|magnetoencephalography|MEG studies are performed using a whole-head Omega 151-channel gradiometer system.
1821641|NCT00741559|Device|Positron emission tomography (PET)|An interictal FDG(fluoro-D-glucose)-PET will be obtained in a single 10 minute scanning session. PET scans will be obtained using a 3D acquisition technique, which will allow the use of a lower dose of radiotracer.
1821642|NCT00741559|Device|Magnetic resonance imaging|MR will be performed on a 1.5T or 3T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
1821643|NCT00741585|Drug|Any antihypertensive medication alone or in combination|All drugs on awakening
1821644|NCT00741585|Drug|Any antihypertensive medication alone or in combination|One or more drugs at bedtime
1821645|NCT00741585|Device|Ambulatory blood pressure monitoring|Sampling at 20-min intervals from 07:00 to 23:00 and at 30-min intervals at night for 48 consecutive hours
1821646|NCT00741598|Drug|Galantamine-ER|Galantamine-ER 8 to 24 mg per day for 16 weeks
1821647|NCT00741598|Drug|Galantamine placebo|Galantamine placebo 8 to 24 mg per day for 16 weeks
1821648|NCT00741611|Device|HD Mesh Ablation System|Ablation using the HD Mesh Ablation System
1821649|NCT00741611|Drug|Anti-arrhythmic drugs|5 anti-arrhythmic drugs administered at the labeled dosage for atrial fibrillation
1821650|NCT00741624|Other|Bandage|one application for one week
1821651|NCT00741637|Biological|CholeraGarde®|"Live attenuated oral Cholera vaccine
Each vial of CholeraGarde® contains 5x107 to 1x109 CFU of Peru-15, 6.75 mg KH2PO4, and 300 mg trehalose as a lyophilized cake in 5 mL single-dose vials"
1821652|NCT00741637|Biological|Placebo|A buffer solution containing 2.5 g sodium bicarbonate, and 1.65 g ascorbic acid.
1821653|NCT00741650|Behavioral|Information and Peer advisor|Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
1821654|NCT00741650|Behavioral|Information, peer advisor and fast referral|"Information at work place and recruitment and training of one employee as a peer advisor who help colleagues who experience musculoskeletal pain with reasons to stay active, help with adjustment in the work situation to allow individuals to stay at work.
In addition, the peer advisor can refer employees who do not improve to a two day educational program that also includes a medical exam and individual counselling.
In addition,"
1821655|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm A will receive potassium canrenoate at the initial dose of 200 mg/day, then increased up to 400 mg/day. Non responders will be treated with 400 mg/day of potassium canrenoate and furosemide at an initial dose of 50 mg/day, then increased up to 150 mg/day.
1821656|NCT00741663|Drug|Spironolactone and furosemide|Patients in arm B will receive at first 200 mg/day of potassium canrenoate and 50 mg/day of furosemide, then increased up to 400 mg/day and 150 mg/day, respectively.
1821657|NCT00741676|Procedure|laparoscopy-assisted distal gastrectomy|10 mm trocar under umbilicus, 12 mm and 5 mm trocar at the right flank area are inserted into abdominal wall. Another two 5 mm trocar are inserted into the both midline of subcostal line. The devices for operation are inserted through the trocars. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.Dissected stomach and lymph node are collected through additional 3~5 cm incision at the preexisting epigastric incision.Finally, Billroth II reconstruction is performed.
1821658|NCT00741676|Procedure|open distal gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal gastrectomy (dissect more than 2/3 of stomach and total omentectomy) and D2 lymph node dissection (around common hepatic artery, celiac artery, proximal part of splenic artery, hepatoduodenal ligament, superior mesenteric vein) will be performed basically. As a general rule, Billroth II method was used for gastric reconstruction for all cases.
1821659|NCT00741689|Drug|AZD1656|Dose escalation of oral single doses of AZD1656 to achieve maximal tolerated dose
1821660|NCT00741702|Other|Nurse administered treatment algorithm|Start with Irbesartan 150 mg/d; check BP in 6 wks, if BP >=130/80 mm HF, 300 mg/d irbesartan; check BP at next visit, if BP>= 130/80 mm Hg, add HCTZ 12.5 mg/d; check BP at next visit, if BP>=130/80 mm Hg, add verapamil 180 mg/d; check BP at next visit, if BP>=13/80 mm Hg, increase verapamil to 240 mg/d
1821661|NCT00741715|Drug|AVE5530|oral administration once daily in the evening with dinner
1821662|NCT00741715|Drug|atorvastatin|oral administration once daily in the evening with dinner
1821663|NCT00741715|Drug|placebo|oral administration once daily in the evening with dinner
1821664|NCT00741728|Other|Spider flash EKG, echocardiography tracking, step test|cardiac rhythm recorded during health check up, echocardiography tracking of the right common carotid, step test during 2 minutes
1821665|NCT00741741|Drug|TMC278|
1821666|NCT00741754|Other|Mouthrinse with HcT20|Mouthrinse for 1 minute with 10ml, twice a day. During seven weeks
1821667|NCT00741767|Drug|salmeterol-fluticasone|250ug salmeterol/50ug fluticasone inhaled via an oral inhaler twice daily
1821668|NCT00741780|Drug|Placebo|
1821670|NCT00741780|Drug|granulocyte colony-stimulating factor (G-CSF)|
1821671|NCT00741806|Biological|GHB04L1|single dose intranasal administration of GHB04L1
1821672|NCT00741806|Other|Placebo|SPGN buffer
1821673|NCT00741819|Drug|Inhaled treprostinil|
1821677|NCT00741858|Procedure|Duragen duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duragen)
1821678|NCT00741858|Procedure|Duraguard duraplasty|Posterior cranial fossa repair and enlargement with application of dural patch (Duraguard)
1821679|NCT00741871|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle
1821680|NCT00741884|Drug|Varenicline Controlled Release 1.2 mg|Varenicline CR tablet 1.2 mg BID for 7 weeks
1821681|NCT00741884|Drug|Varenicline Controlled Release 1.8 mg|Varenicline CR tablet 1.8 mg BID for 7 weeks
1821682|NCT00741884|Drug|Varenicline Controlled Release 2.4 mg|Varenicline CR tablet 2.4 mg BID for 7 weeks
1821683|NCT00741884|Drug|Varenicline Immediate Release 1 mg|Varenicline IR tablet 1 mg BID for 7 weeks
1821684|NCT00741884|Drug|Placebo|Placebo BID for 7 weeks
1821685|NCT00741897|Drug|Fexofenadine|Fexofenadine: One 30 mg Tablet once daily for two weeks
1821686|NCT00741910|Drug|Semapimod|semapimod IV 60 mg x 3 days q 6 - 10 weeks
1821687|NCT00741923|Other|navy beans added to regular diet|5 cups per week of commercially available white beans for 4-weeks
1821688|NCT00741936|Drug|MaZiRenWan (MZRW)|MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
1821689|NCT00741936|Drug|Placebo|Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
1821690|NCT00741949|Drug|Propofol|Sedation in TCI with propofol
1821691|NCT00741949|Drug|Placebo|Isotonic saline solution infusion
1821692|NCT00741962|Dietary Supplement|VR-3 Herbal Blend|This is a liquid blend of various reputed adaptogenic herbs. The dosage will be 2ml of liquid per day.
1821693|NCT00741962|Dietary Supplement|Placebo|The placebo will be a similar tasting liquid as VR-3 Herbal blend. The dosage will be 2ml of liquid per day.
1821694|NCT00741975|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training
1821695|NCT00741975|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics
1821696|NCT00741988|Drug|Ixabepilone|ixabepilone 30 mg/m2
1821697|NCT00741988|Drug|Carboplatin|carboplatin AUC = 6 intravenously (IV) on Day 1 of one 21-day treatment cycle.
1821698|NCT00741988|Drug|Bevacizumab|bevacizumab 15 mg/kg on Day 1 of one 21-day treatment cycle.
1821699|NCT00742001|Biological|Mirasol System for Whole Blood.|Treatment of whole blood with the Mirasol system at 3 experimental illumination energies for testing of autologous RBC recovery and survival in healthy subjects
1821700|NCT00742014|Drug|Sildenafil|One oral dose of Sildenafil (0.5 mg/kg) will be administered nia a nasogastric tube
1821701|NCT00742027|Drug|Panobinostat|Oral 40 mg/dose, three times per week, every week dosing on a 21-day cycle
1821702|NCT00742040|Drug|Captopril|A rapid 3-day up-titration protocol
1821703|NCT00742040|Drug|Captopril|A slower 9-day up-titration protocol
1821704|NCT00742053|Device|ECG-guided PICC placement|Patients undergoing PICC placement will have ECG data collected as a function of tip location.
1821705|NCT00742066|Drug|Irbesartan|Single dose 600mg orally
1821706|NCT00742066|Drug|Felodipine|single dose 10mg Felodipine ER
1821707|NCT00742066|Drug|Placebo|Single dose tablet orally
1821708|NCT00742079|Drug|D-cycloserine|Single, fixed 50-mg dose of D-cycloserine administered 1 hour prior to a CBT session
1821709|NCT00742079|Behavioral|Cognitive Behavioral Therapy|One-hour talk therapy session with a trained clinician aimed at increasing cognitive flexibility by examining alternative explanations to everyday situations
1821710|NCT00742092|Drug|miglustat|Oral miglustat capsules 200 mg t.i.d. (three times a day) for 7 days and a single 200 mg dose on Day 8
1821711|NCT00742092|Drug|placebo|Oral placebo capsules matching in appearance miglustat capsules given t.i.d. (three times a day) for 7 days and a single dose on Day 8
1821712|NCT00742105|Drug|BGT226|
1821713|NCT00742118|Procedure|Colic biopsies|colic biopsies and analysis
1821714|NCT00742131|Drug|GSK1363089|GSK1363089 will be administered orally as a cinnamon-flavored liquid (250 milligrams of GSK1363089 in 50 milliliters liquid [5 milligrams/milliliter] or 1000 milligrams of GSK1363089 in 50 milliliters liquid [20 milligrams/milliliter]) or as solid capsules of 20, 100, and/or 200 milligrams.
1821715|NCT00742144|Drug|ofatumumab|Ofatumumab (GSK1841157), a clear colorless liquid, is supplied in a glass vial. Each vial contains 100mg of ofatumumab in 5mL.
1821716|NCT00742157|Drug|Growth Hormone|dosage = 0.05mg/kg/day, in diluent for injection, once a day, for 23 - 54 days.
1821752|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
1821717|NCT00742170|Device|Electroacupuncture|Participants are randomly assigned to receive either active or sham electroacupuncture using the Han's Acupoint Nerve Stimulator (HANS) device. The HANS method uses a non-invasive device that emits a constant electric current transcutaneously via skin electrodes to stimulate relevant acupoints: Heku (LI4) / Laogong (P8) on one hand and Neiguan (P6) / Waiguan (TE 5) on the opposite arm. Stimulation is delivered in the dense-and-disperse mode, alternating between 2 and 100 Hz at 3-second intervals. Participants receive thrice daily treatments for 4 days during inpatient opioid detoxification.
1821718|NCT00742183|Device|Mepilex|Mepilex Ag - dressing changes every 5-7 days, more frequently if needed
1821719|NCT00742183|Device|Silvadene|Silvadene - dressing changes every day, more frequently if needed
1821720|NCT00742209|Drug|GSK1838262|Flexible dosing: 1200 mg/day, 1800 mg/day, 2400 mg/day and 3000 mg/day
1821721|NCT00742209|Drug|Placebo|Placebo-control
1821722|NCT00742222|Radiation|Electronic Brachytherapy|34 Gy administered over 10 fractions, twice a day times five days. The radiation therapy treatment will be complete upon the 5th day.
1821723|NCT00742222|Radiation|Intracavitary accelerated partial breast irradiation|3.4 Gy BID x 5 days
1821724|NCT00742235|Drug|ergocalciferol|Ergocalciferol 50,000 IU given every other day for 5 total doses
1821725|NCT00742248|Drug|Formoterol|pMDI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
1821726|NCT00742248|Drug|Formoterol|DPI 12 mcg/dose 1 dose in the morning and 1 dose in the evening
1821727|NCT00742248|Drug|Placebo|Placebo pMDI/DPI 1 dose in the morning and 1 dose in the evening
1821728|NCT00742261|Drug|GSK1363089|Two-part study to evlauate the relative bioavailability of GSK1363089 from a free base formulation (GSK1363089G) compared with the biophosphate salt formulation (GSK1363089A) (Part 1) and to assess the safety of the GSK1363089 biophosphate formulation when administered three times a week until disease progression (Part 2).
1821729|NCT00742274|Device|Gore TAG Endoprosthesis|Implant Gore TAG device with Best Medical therapy per physician discretion
1821730|NCT00742274|Other|Best Medical Therapy|Best Medical therapy is regimen of antihypertensive medications used to maintain blood pressure below 125/80 mm/Hg throughout the entire follow-up period. Because BMT is assessed by blood pressure response to medication, specific medication regimens for each patient will differ. The typical regimen consists of 1 to 4 concomitant antihypertensive medications that may include angiotensin converting enzyme (ACE) inhibitors, alpha blockers, beta blockers, calcium channel blockers, diuretics, and/or vasodilators.
1821731|NCT00742287|Dietary Supplement|oligomeric proanthocyanidins (MASQUELIER'S Original OPCs)|200 mg oligomeric proanthocyanidins (MASQUELIER'S Original OPCs) per day over 8 weeks
1821732|NCT00742287|Dietary Supplement|Placebo|placebo
1821733|NCT00742300|Procedure|Autologous hematopoietic stem cell transplantation|Transplantation of CD34-selected autologous hematopoietic stem cells after high-dose chemotherapy with cyclophosphamide (200mg/kg) and rabbit-antithymocyteglobulin (90mg/kg)
1821734|NCT00742313|Biological|FloSeal Matrix|10 ml of FloSeal Matrix will be applied to the endoscopic wound bed.
1821735|NCT00742326|Drug|Pioglitazone|45 mg/daily
1821736|NCT00742326|Drug|Placebo|one capsule daily
1821737|NCT00742339|Drug|Terlipressin plus albumin|The terlipressin will be give at the initial dose of 3 mg/24 hours by intravenous continuous infusion. If during the following 48 hours the serum value of creatinine will not change or will go down less than 25%, the dose of terlipressin will be increased to 6 mg/24 hours. If no response will ensue, the dose of terlipressin will be increased to the maximal dose of 12 mg/24 hours. Twenty percent human albumin solution will be administrate together with terlipressin at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
1821738|NCT00742339|Drug|Midodrine plus octreotide plus human albumin|Midodrine will be give orally at the initial dose 7.5 tid together with octreotide at the initial dosage of 100 µg subcutaneously tid. If during the following 96 hours the serum value of creatinine will not change or will go down less than 25%, the dose of midodrine will be increased to 12.5 mg tid Twenty percent human albumin solution will be administrate together with midodrine and octreotide at the dosage of 1 g/Kg of body weight, on first day, and then, to the dosage of 20-40 g/Kg in order to maintain the central venous pressure (CVP) between 10 and 15 cm H2O.The treatment with terlipressin and albumin will be maintained for 24 hours after complete or incomplete resolution. The length of the study in patients with complete and incomplete resolution will reach a maximum of 15 days. In the patients without response the treatment with the high dosage of terlipressin will go on for a maximum of 7 days.
1821739|NCT00742365|Device|Bright light|One hour of exposure to bright light daily upon awakening for 6 weeks.
1821740|NCT00742365|Device|Red light placebo|One hour of exposure to red light.
1821741|NCT00742391|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
1821742|NCT00742391|Drug|Vehicle gel|two day treatment
1821743|NCT00742404|Drug|bortezomib|
1821744|NCT00742404|Drug|dexamethasone|
1821745|NCT00742404|Drug|pegylated liposomal doxorubicin hydrochloride|
1821746|NCT00742404|Genetic|protein analysis|
1821747|NCT00742404|Other|immunologic technique|
1821748|NCT00742417|Biological|Albutein 5%|"18 Plasma Exchanges using Albutein 5%:
three weeks of intensive treatment with two plasma exchanges per week
six weeks of maintenance treatment with one weekly plasma exchange
three months of maintenance treatment with one plasma exchange every two weeks"
1821749|NCT00742417|Other|Control|Control group followed the same schedule; however, they did not undergo plasma replacement (it was subjected to simulated plasma replacements)
1821750|NCT00742430|Procedure|PCI|percutaneous coronary intervention in stable coronary artery disease
1821751|NCT00742443|Drug|Juvista (avotermin)|100ng/100µL Juvista administered to each linear centimetre of the margins of one wound segment by intradermal injection immediately after and then 24h after wound closure versus 100μL of placebo administered to each linear centimetre of the margins of the other wound segment by intradermal injection immediately after and then 24h after wound closure
1821976|NCT00737256|Drug|Perphenazine|8-16 mg
1821753|NCT00742443|Drug|Juvista (avotermin)|250ng/100µL Juvista administered to each linear centimetre of the margins of both wound segments by intradermal injection immediately after and then 24h after wound closure
1821754|NCT00742456|Dietary Supplement|Glucose solution|single oral intake of 250 ml glucose solution (75gr sugar in 250ml of water)
1821755|NCT00742456|Dietary Supplement|Placebo|single intake of placebo solution (250ml of sweet flavored water, no sugar added), orally
1821756|NCT00742469|Drug|Rifaximin|
1821757|NCT00742469|Drug|Placebo|
1821758|NCT00742482|Drug|HL 10|Freeze dried HL 10
1821759|NCT00742495|Drug|Forodesine|PK study
1821760|NCT00742508|Drug|SK&F-105517-D 10 mg capsule|1 capsule once a day
1821761|NCT00742508|Drug|Carvedilol-immediate release (IR) 2.5 mg tablet|1 or 2 tablet(s) twice a day
1821762|NCT00742508|Drug|SK&F-105517-D 20 mg capsule|1 capsule once a day
1821763|NCT00742508|Drug|SK&F-105517-D 40 mg capsule|1 or 2 capsule(s) once a day
1821764|NCT00742508|Drug|Carvedilol-IR 10 mg tablet|1 tablet twice a day
1821765|NCT00742521|Procedure|glucose clamp|Day 1 hyperinsulinemic euglycemic glucose clamp procedure x 2 and Day 2 hyperinsulinemic hypoglycemic glucose clamp procedure
1821766|NCT00742521|Procedure|glucose clamp|Hypoglycemic glucose clamp procedure x 2 on Day 1 and hypoglycemic glucose clamp procedure on Day 2. Control study
1821767|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 2 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
1821768|NCT00742521|Procedure|glucose clamp|Hyperinsulinemic euglycemic glucose clamp procedure x 2 with cortisol infusion at 1 ug/kg on Day 1 and hyperinsulinemic hypoglycemic glucose clamp procedure on Day 2.
1821769|NCT00742534|Drug|Intravenous L-Citrulline|This is a classic dose escalation using initial doses of 10 mg/kg of intravenous citrulline and advancing the dose by 10 mg/kg every 3 patients for a target peak plasma citrulline concentration of 100 umol/L. This regimen will be adjusted with pharmacokinetic data as it becomes available so that it may be adjusted to maintain appropriate serum levels of the urea cycle precursors and NO metabolites of interest.
1821770|NCT00742547|Other|Telephone counseling|Telephone counseling is provided once a month by the medical secretary of the general practitioner's practices
1989519|NCT02466568|Drug|Nivolumab|Participants will receive treatment with nivolumab as a 60-minute +/-5 minutes intravenous (IV) infusion on Day 1 and 15 of each 28-day cycle.
1989520|NCT02466568|Biological|GM.CD40L Vaccine|GM.CD40L will be injected intradermally every 2 weeks for 4 injections, then every month for 4 injections, then every 3 months until the patient is off treatment.
1821774|NCT00742573|Drug|Antidepressants through Texas Medication Algorithm (TMA)|Treatment with medication will follow the TMA for depression. Antidepressant medications may include any of the following: citalopram, escitalopram, paroxetine, sertraline, venlafaxine XR, bupropion SR, duloxetine, nortriptyline, and mirtazapine.
1821775|NCT00742573|Behavioral|Brief Interpersonal Psychotherapy (IPT-B)|IPT-B consists of twelve 50-minute sessions, divided into three phases, focusing on an interpersonal problem or problems.
1821776|NCT00742599|Drug|NPO-11|20 ml NPO-11
1821777|NCT00742599|Drug|Placebo|20 ml NPO-11(Placebo)
1821778|NCT00742612|Drug|ARC1779 Injection|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The ARC1779 treatment group will be dosed to achieve a target ARC1779 steady-state plasma concentration of 3 Ug/mL, using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
1821779|NCT00742612|Drug|Placebo (normal saline)|Study drug treatment will be initiated 1 hour prior to the induction of anesthesia with a loading dose given over 1 hour in 3 successively increasing, 20-minute step infusions. The placebo group will be dosed to a steady-state plasma concentration using a loading dose infusion sequence of 0.0015 mg/kg/min for 20 minutes, 0.003 mg/kg/min for the next 20 minutes, and then 0.006 mg/kg/min for the final 20 minutes; thereafter, their maintenance infusion rate is to be 0.0006 mg/kg/min.
1821780|NCT00742625|Drug|daunorubicin hydrochloride|Given IV
1821781|NCT00742625|Drug|cytarabine|Given IV
1821782|NCT00742625|Drug|bortezomib|Given IV
1821785|NCT00742664|Behavioral|Cognitive-behavioral therapy|The manual is informed by behavioral principles and provides a structured, replicable manner of treating OC symptoms in youth with PWS. The treatment is individual in nature, includes a strong family component (i.e., teaching parents to be their child's coach/therapist), and lasts for approximately 12 sessions, held in a twice-weekly format. In addition, the protocol includes several specific components: education about OC symptoms (i.e., etiology, behavioral function, etc.), developing a hierarchy of rituals to target, exposure and response prevention exercises, promoting adaptive familial responses to child behaviors, and relapse prevention and problem solving future situations.
1821786|NCT00742664|Behavioral|Wait-list control|The subject will not receive active treatment during this interval.
1821787|NCT00742677|Procedure|nutritional support|Given orally
1821788|NCT00742690|Drug|terlipressin given by intravenous boluses and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given by intravenous boluses at the initial dose of terlipressin was 0.5 mg/4 hr. In case of non response, the dose of terlipressin was progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given intravenously at the dose of 1 g/kg of body weight on the first day followed by 20-40 g/day.
1821789|NCT00742690|Drug|terlipressin given by continuous intravenous infusion and albumin|Patients who will be randomly assigned to arm 1 will received terlipressin given as intravenous boluses at the initial dose of 0.5 mg/4 hr. In case of non response, the dose of terlipressin will be progressively increased up to a maximum of 2 mg/4 hr. Human albumin will be given at the dose of 1 g/kg of body weight at the first day followed by 20-40 g/day.
1821790|NCT00742703|Other|Mineralized water|
1821791|NCT00742703|Other|Low mineralized water|
1821792|NCT00742716|Drug|CTA018 Injection|Comparison of different dosages of drug
1821793|NCT00742729|Behavioral|Arm 1|Educational small group session with free FOBT kit
1821794|NCT00742729|Behavioral|Arm 2|Educational small group session with no FOBT kit
1821795|NCT00742729|Behavioral|Arm 3|Educational small group session, exercise
1821796|NCT00742742|Behavioral|healthy life style education|healthy life style education
1821797|NCT00742755|Behavioral|Prospective intervention|Prospective Intervention: Peer navigator who assists with appointment making, transportation, translations, completing forms, etc.
1821798|NCT00742768|Dietary Supplement|Vitamin K2 in softgel|4 softgel capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 softgel capsules containing 30 µg MK-4 per capsule
1821799|NCT00742768|Dietary Supplement|Vitamin K2 in Gelpell|4 Gelpell capsules containing 45 µg MK-7 and 5 µg vitamin D3 per capsule and 4 Gelpell capsules containing 30 µg MK-4 per capsule
1821800|NCT00742781|Dietary Supplement|Vitamin D|Oral supplementation daily with up to 5000 IU over 6 months.
1821801|NCT00742794|Other|Observation|Observation of sting frequency
1821802|NCT00742807|Drug|Low dose of alfentanil hydrochloride|Administration of low dose alfentanil hydrochloride before paracervical block
1821803|NCT00742807|Drug|Normal dose of alfentanil hydrochloride|Normal dose of alfentanil hydrochloride is administered after paracervical block
1821804|NCT00742820|Drug|Calcium Acetate Oral Solution 667 mg per 5 mL|Drug: Calcium acetate oral solution 667 mg calcium acetate, USP per 5 mL (169 mg of elemental calcium per 5 mL); Dosage: 30 mL of calcium acetate oral solution; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
1821805|NCT00742820|Drug|Calcium Acetate 667 mg GelCaps|Drug: PhosLo GelCaps (calcium acetate) 667 mg (169 mg of elemental calcium per gelcap); Dosage: 6 gelcaps; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses.
1821806|NCT00742820|Dietary Supplement|Calcium Citrate 950 mg Caplets|Drug: Calcium Citrate 950 mg Caplets (200 mg of elemental calcium per caplet); Dosage: 5 caplets; Dosage frequency: three times per day with meals; Duration: 3 days and the morning of day 4, in total ten doses
1821807|NCT00742833|Drug|KUC-7483|
1821808|NCT00742833|Drug|Placebo|
1821809|NCT00742846|Drug|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog®-10 into the shoulder joint
Intra-articular injection with local anesthetic and steroid"
1821810|NCT00742846|Drug|Lidocaine + Kenalog|"5ml 1% Lidocaine + 1ml 40mg Kenalog-10 into the subacromial space
Local anesthetic and steroid in to the subacromial space"
1821811|NCT00742846|Drug|Lidocaine|"5ml 1% Lidocaine alone into the shoulder joint.
intra-articular local anesthetic injection"
1821812|NCT00742846|Drug|Lidocaine|"5ml 1% Lidocaine alone into the subacromial space.
subacromial local anesthetic injection"
1821815|NCT00742872|Drug|Mosapride Citrate|One 5 mg tablet taken orally three times per day (15 min before meals) for 8 weeks.
1821816|NCT00742872|Drug|Placebo|One tablet (identical in shape and form to the actual drug) taken orally three times per day (15 min before meals) for 8 weeks.
1821817|NCT00742885|Biological|Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
1821818|NCT00742898|Other|Non-targeted opt-out rapid HIV screening|Experimental Arm: Integrated non-targeted opt-out rapid HIV screening Active Comparator Arm: Integrated diagnostic rapid HIV testing
1821819|NCT00742911|Drug|Disulfiram|"Patients will take a pill of disulfiram at a fixed dose of 250 mg with their evening meal. This dose of disulfiram used to treat alcoholism. We will start by administering 2 mg of copper as copper gluconate along with 250 mg disulfiram.
Patients must not consume beverages containing alcohol while taking disulfiram."
1821820|NCT00742911|Drug|Copper Gluconate|"Commercially available. Copper gluconate has long been manufactured and sold as a food supplement. Copper gluconate should be taken separately from disulfiram, and if possible with breakfast.
Copper gluconate should not be administered to individuals with Wilson's disease or a family history of Wilson's disease.
Patients will receive 2 mg, 4mg, 6mg or 8mg daily"
1821821|NCT00742924|Drug|cisplatin|Given IV
1821822|NCT00742924|Drug|dexrazoxane hydrochloride|Given IV
1821823|NCT00742924|Drug|doxorubicin hydrochloride|Given IV
1821824|NCT00742924|Drug|etoposide|Given IV
1821825|NCT00742924|Drug|ifosfamide|Given IV
1821826|NCT00742924|Drug|leucovorin calcium|Given IV or orally
1821827|NCT00742924|Drug|methotrexate|Given IV
1821828|NCT00742924|Drug|zoledronic acid|Given IV
1821829|NCT00742924|Procedure|adjuvant therapy|
1821830|NCT00742924|Procedure|neoadjuvant therapy|
1821831|NCT00742924|Procedure|therapeutic conventional surgery|Surgery of the primary tumor is scheduled for 12 weeks after the commencement of chemotherapy.
1821832|NCT00742924|Biological|filgrastim|Given SC
1821833|NCT00742924|Drug|Mesna|Given IV
1821834|NCT00742937|Dietary Supplement|vitamin A|second capsule 200,000 UI of retinol palmitate (vitamin A)plus vitamin E, eight days after delivery.
1821835|NCT00742937|Dietary Supplement|Placebo|second capsule with vitamin E, eight days after delivery.
1821836|NCT00742950|Procedure|Nasal 2.8-mm corneal incision|Phacoemulsification through a nasal 2.8-mm incision
1821837|NCT00742950|Procedure|Temporal 2.8-mm corneal incision|Phacoemulsification through a 2.8-mm temporal incision
1821838|NCT00742950|Procedure|Superior 2.8-mm incision|Phacoemulsification through a superior 2.8-mm corneal incision
1821840|NCT00742976|Drug|Insulin Detemir; Insulin Insulatard|Dosage is individual but fixed in study period (if possible). Detemir is given once daily, Insulatard is given twice daily.
1821841|NCT00742976|Drug|Insulin Detemir, Insulin Insulatard|Fixed doses in study period (if possible). Insulin Detemir once daily, Insulin Insulatard twice daily.
1821923|NCT00736944|Drug|Abraxane|100 mg/m2 IVPB, Day 1, 8 and 15 of cycles 1, 2, and 3
1821924|NCT00736944|Drug|Cetuximab|400 mg/m2 IVPB, Day 1, cycle 1
1821925|NCT00736944|Drug|Cetuximab|250 mg IVPB, Day 8 and 15 cycle 1, Day 1, 8 and 15 of cycles 2 and 3
1821842|NCT00742989|Other|OLT maneuver|direct myofascial release for the thoracic inlet for 30 seconds, supine rib raising for 1 minute on each side of the body, thoracic pumping for one minute, thoracic vacuum for 30 seconds, doming of the abdominal diaphragm for 30 seconds, abdominal pumping for 1 minute, pedal pumping for 1 minute, a second thoracic pump for 1 minute, a second thoracic vacuum for 30 seconds, and a final direct myofascial release for the thoracic inlet lasting 30 seconds
1821843|NCT00742989|Other|Sham OLT|Therapeutic massage performed
1821844|NCT00743002|Drug|TT223 with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
1821845|NCT00743002|Drug|Placebo with Metformin and/or TZD|Daily subcutaneous injection: 1 mg for 1 week; followed by 2 mg for 1 week; followed by 3 mg for 10 weeks
1821846|NCT00743015|Drug|BI 44370 TA tablet|
1821847|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2 studies vs. a single dose of one of the new ABT-263 formulation
1821848|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
1821849|NCT00743028|Drug|ABT-263|Single dose of the current ABT-263 formulation being assessed in ongoing Phase 1/2a studies vs. a single dose of a new ABT-263 formulation followed by QD dosing with a new ABT-263 formulation for 7 days.
1821850|NCT00743041|Behavioral|Emotional Freedom Techniques (EFT)|EFT is an exposure therapy with a cognitive component, consisting of recall of a trauma along with a statement of self-acceptance, in combination with touching or tapping on a series of stress reduction points on the body
1821851|NCT00743067|Drug|GSK1363089 (formerly XL880)|GSK1363089 will be available as solid capsules with dose unit of 20, 100 and 200 mg. Subjects will administer GSK1363089 capsules orally
1821852|NCT00743080|Procedure|Laparoscopic myomectomy and supracervical hysterectomy with GYNECARE MORCELLEX|"Laparoscopic myomectomy with GYNECARE MORCELLEX: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (GYNECARE MORCELLEX).
Laparoscopic supracervical hysterectomy using GYNECARE MORCELLEX: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of GYNECARE MORCELLEX. Abdominal cavity irrigation."
1821853|NCT00743080|Procedure|Laparoscopic myomectomy and supracervical hysterectomy with ROTOCUT G1|"Laparoscopic myomectomy with ROTOCUT G1: Laparoscopic approach. Longitudinal incision close to the midline of myoma. Identification of cleavage plane. Enucleation of myoma. Suturing myometrial. Removal of myoma with a automatic morcellator (ROTOCUT G1).
Laparoscopic supracervical hysterectomy using ROTOCUT G1: Laparoscopic approach. Use of bipolar diathermy and scissor starting with the round ligament and then the utero-ovarian ligament, otherwise the infundibulopelvic ligament in case of removal of adnexa. Identification, desiccation with polar diathermy, and transection of the uterine vessels. Repetition of the procedure on the contra-lateral side. Opening of vagina just below uterine vessels using an unipolar needle. Removal of uterus by means of ROTOCUT G1. Abdominal cavity irrigation."
1821854|NCT00743093|Drug|acetaminophen|500 mg caplets; 2 caplets (1 g)/dose; 4 doses (4 g)/day, 4 hours apart for 16 to 40 days.
1821855|NCT00743093|Drug|placebo|placebo caplets, 2 caplets per dose, 4 doses per day, 4 hours apart for 16 to 40 days
1821856|NCT00743106|Drug|Fenoldopam|Fenoldopam (0.1 ~g/kg/min)started during surgery and lasting for a total of 24 hours
1821857|NCT00743106|Drug|Placebo|Placebo infusion(0.9% Nacl) beginning during surgery and lasting for up 24 hours post surgery
1821862|NCT00743184|Drug|ozarelix|One single-dose vial contains 16.5 mg of ozarelix. The drug is reconstituted with 1.3 mL of diluent.
1821863|NCT00743184|Drug|Placebo|Identical placebo is also provided and reconstituted using diluent containing 0.1% saline solution
1821864|NCT00743197|Drug|Aspirin|Aspirin 81 mg daily
1821865|NCT00743197|Drug|Lisinopril|Lisinopril 10 mg every night
1821866|NCT00743197|Drug|Simvastatin|Simvastatin 20 mg every night
1821867|NCT00743197|Drug|Lovaza|Lovaza 1 gram daily
1821868|NCT00743197|Behavioral|Therapeutic Lifestyle Changes|Therapeutic lifestyle changes will be initiated with the assistance of a dietician, including diet counseling, exercise recommendation, and weight maintenance/weight loss.
1821869|NCT00743210|Drug|L-citrulline|Oral L-citrulline, 3 grams once per day for 3 weeks.
1821870|NCT00743210|Drug|Placebo|Placebo, 3 grams once per day for 3 weeks.
1821871|NCT00736528|Drug|PF-04447943|05 mg BID for 14 days
1821872|NCT00736528|Drug|PF-04447943|15 mg BID for 14 days
1821873|NCT00736528|Drug|PF-04447943|45mg BID for 14 days
1821874|NCT00736528|Drug|Placebo|Placebo for 14 days
1821875|NCT00736541|Drug|N-acetylcysteine|The patients in the NAC group will receive a loading dose of 140 mg/kg IV of NAC over one hour at the start of the surgery. Thereafter, NAC will be repeated every 4 hours at a dose of 70 mg/kg IV, for a total of 13 doses
1821876|NCT00736580|Other|Blunt tipped needle|The Cesarean delivery is performed using blunt tipped needles.
1821877|NCT00736580|Other|Sharp needles|The cesarean is performed using standard sharp surgical suture needles.
1821878|NCT00736593|Drug|Nexagon™ or Nexagon™ vehicle|
1821879|NCT00736606|Drug|simvastatin|One single dose of 40mg
1821880|NCT00736606|Drug|AZD9056 + simvastatin|AZD9056: 400 mg od, 8 days simvastatin: one single dose of 40 mg on day 7
1821926|NCT00736944|Drug|Cisplatin|75 mg/m2 IVPB Day 1, cycles 1, 2 and 3
1821927|NCT00736944|Drug|5-FU|750 mg/m2 CIVI Day 1, 2 and 3, cycles 1, 2 and 3
1821928|NCT00736944|Radiation|Radiation (Post induction)|Monday-Friday, weeks 1-7
1821929|NCT00736944|Drug|Cisplatin|(Post induction) Cisplatin 100 mg/m2 IVPB on radiation day 1, 22 and 42
1822015|NCT00737646|Behavioral|Usual care|No intervention will be conducted in this arm of the study.
1821881|NCT00736619|Other|Cetuximab, IMRT, Albumin-bound paclitaxel (Abraxane®)|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity-modulated radiation therapy) administered concurrently with cetuximab (400 mg/m2 intravenous loading dose one week prior to radiation therapy, followed by 250 mg/m2 weekly intravenous infusions). To explore different dose levels of nanoparticle albumin-bound paclitaxel (Abraxane®) given intravenously weekly with the standard regimen of weekly cetuximab + daily radiation therapy.
The total number of planned cetuximab infusions is 8 (loading dose, plus 7 weekly infusions concurrent with radiation therapy). The total number of planned albumin-bound paclitaxel infusions is 7 (all concurrent with radiotherapy). Five dose levels of weekly intravenous (IV) albumin-bound paclitaxel will be explored."
1821882|NCT00736632|Drug|Vitamin D3|Cholecalciferol 4000 units orally daily Calcium carbonate 500 mg orally twice daily
1821883|NCT00736632|Drug|Placebo|Placebo pill orally daily Calcium carbonate 500 mg twice daily
1821887|NCT00736658|Drug|AZD1386|Oral admin. of doses at 11 days through a 12 days period.
1821888|NCT00736658|Drug|Placebo|Oral admin. of doses at 11 days through a 12 days period.
1821889|NCT00736684|Device|Proximal Femoral Nail AntirotationTM (PFNA)|intramedullary nailing
1821890|NCT00736684|Device|Gamma Nail 3TM (Gamma3)|intramedullary nailing
1821891|NCT00736697|Drug|moxidectin|
1821892|NCT00736710|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
1821893|NCT00736710|Procedure|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|The rTMS procedures will be delivered in a single-blind fashion by the rTMS technician at the CAMH rTMS Laboratory. All subjects would be enrolled in a 10-week smoking cessation program using weekly group behavioral therapy which will emphasize psychoeducation about the effects of smoking on psychiatric and medical aspects of schizophrenia, social skills training, relapse-prevention skills training and benefits of quitting smoking. All subjects would start group therapy interventions in Week 1 of the trial, and begin rTMS procedures in a separate session on Week 2. The transdermal nicotine patch (TNP; 21 mg/24h) would be applied during the quit date at Week 3 (Day 15). At the end of the 10-week trial, TNP and group therapy would be discontinued.
1821894|NCT00736736|Other|Additional Hip Muscle Strengthening to Leg Press Exercise|
1821895|NCT00736736|Other|Leg Press Exercise|
1821898|NCT00736762|Other|GPR|The subjects randomised to the GPR program will participate in posture retraining techniques of approximately forty minutes, one time a week for ten weeks.
1821899|NCT00736775|Drug|anti-Abeta|Intravenous single and multiple doses
1821900|NCT00736775|Drug|placebo|Intravenous single and multiple doses
1821901|NCT00736788|Drug|AZD1704|single dose oral suspension, 4 different dose levels
1821902|NCT00736788|Drug|Placebo|single dose oral suspension
1821903|NCT00736801|Drug|Salmeterol and Salmeterol / Fluticasone|Patients inhale salmeterol for 2 weeks, followed by an inhalation of both salmeterol and fluticasone for 2 weeks.
1821904|NCT00736814|Drug|carboplatin|Given intravenously
1821905|NCT00736814|Drug|docetaxel|Given intravenously
1821906|NCT00736814|Drug|gemcitabine hydrochloride|Given intravenously
1821907|NCT00736814|Drug|vinorelbine tartrate|Given intravenously
1821908|NCT00736840|Device|c13 methacetin solution with breath analyzer|Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver
1821909|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Open-Label)|Fixed dose combination of tramadol 37.5 milligram (mg)/acetaminophen 325 mg, 1 or 2 tablets 4 times daily will be given for one week; dose level will be fixed for each participant during the second week based on analgesic efficacy and tolerability (maximum daily dose will be 8 tablets).
1821910|NCT00736853|Drug|Tramadol Hydrochloride Plus Acetaminophen (Double-Blind)|Fixed dose combination of tramadol 37.5 mg/acetaminophen 325 mg, 1 or 2 tablets (same dose [number of tablets] as that for the second week in the open-label period) will be given 4 times daily up to 4 weeks.
1821911|NCT00736853|Drug|Placebo (Double-Blind)|Matching placebo will be given up to 4 weeks.
1821912|NCT00736866|Drug|Acetylcysteine|Acetylcysteine: 1200 mg every 12 hours for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
1821913|NCT00736866|Drug|Placebo|Placebo of Acetylcysteine: every 12 hours PO, for a total of 4 doses. Treatment is to be started 12 hours before angiography, that is, two doses should be administered before it. When this is not achievable, at least one dose should be administered before angiography.
1821914|NCT00736879|Drug|Dapagliflozin|Tablets, Oral, Once Daily, Up to 24 weeks
1821915|NCT00736879|Drug|Placebo|Tablets, Oral, Once Daily, Up to 24 weeks
1821916|NCT00736905|Drug|TMC278|
1821917|NCT00736918|Behavioral|Case management|Case management, Usual clinical practice and Providing paper based information for suicide prevention
1821918|NCT00736918|Other|Enhanced usual care|Usual clinical practice and Providing paper based information for suicide prevention
1821919|NCT00736931|Drug|Brivaracetam|Brivaracetam 10 mg tablets
1821920|NCT00736931|Drug|levetiracetam|500mg tablets
1821921|NCT00736931|Drug|lorazepam|lorazepam 2 mg over encapsulated tablets
1821922|NCT00736931|Other|placebo|placebo capsules
1821930|NCT00736944|Drug|Cetuximab|(Post-induction) Cetuximab (for patients who cannot receive cisplatin) will begin (+/- 3 days) before starting radiation therapy at 400 mg/m2 IVPB. Subsequent doses of cetuximab will be given weekly at 250 mg/m2 IVPB
1821931|NCT00736957|Drug|Tramadol Hydrochloride (HCL) plus Acetaminophen (JNS013)|Tramadol hydrochloride 37.5 milligram (mg) plus acetaminophen 325 mg (JNS013) one or two tablets will be given orally four times daily (maximum dose is 8 tablets per day) for 4 weeks during treatment period 1 (restrictions on concomitant treatments will be established) and for 48 weeks during treatment period 2 (permitting modifications to the concomitant drugs/therapies). The dosing interval will be of at least 4 hours.
1821932|NCT00736970|Drug|ridaforolimus|10 mg oral tablets administered at 40 mg once daily for 5 consecutive days each week, followed by 2 days without ridaforolimus.
1821933|NCT00736970|Drug|trastuzumab|single intravenous infusion every week; initial dose of 4 mg/kg over 90 minutes, then 2 mg/kg over 30 minutes
1821934|NCT00736983|Drug|adalimumab|24 weeks: 160 mg, 80 mg, and than 40mg every 2 weeks
1821935|NCT00736983|Drug|ciprofloxacin|12 weeks; daily 2 x 500mg
1821936|NCT00736996|Drug|Pioglitazone|30 - 45mg tablet daily for 6 months
1821937|NCT00736996|Drug|Placebo|Matching tablet daily for 6 months
1821938|NCT00736996|Behavioral|Endurance Exercise Training|Individualized exercise prescription, 45-75 minutes (progressive increments) three times a week
1821939|NCT00737035|Behavioral|Interactive Healthcare Communication Application|"The IHCA is an Internet-based tool that integrates multiple resources for guardians of survivors of interparental homicide. The IHCA will have six components: (1) an instant library of articles on topics of interest; (2) a resource directory of both national and local support and service organizations; (3) access to a peer communication system; (4) a Frequently Asked Questions section, updated with responses to user generated questions; (5) an Ask an Expert system staffed by researchers; and (6) personal stories of others dealing with IPH."
1821940|NCT00737035|Behavioral|Control Web sites|Only publicly available Web sites on parenting, child development, and trauma will be used.
1821941|NCT00737048|Drug|Tramadol Hydrochloride|Tramadol hydrochloride two oral capsules will be administered once as 75 milligram (mg).
1821942|NCT00737048|Drug|Acetaminophen|Acetaminophen two oral capsules will be administered once as 650 mg.
1821943|NCT00737048|Drug|Placebo|Two oral tablets or capsules of matching Placebo will be administered once along with Tramadol Hydrochloride and/or acetaminophen.
1821944|NCT00737048|Drug|Tramadol plus Acetaminophen|Tramadol hydrochloride and acetaminophen combination tablet will be administered as single oral dosing of two tablets at a dose of 75 and 650 milligram respectively.
1821945|NCT00737061|Device|Adiana Transcervical Sterilization System|Implantation of silicone matrix in fallopian tubes
1821946|NCT00737087|Device|Delta Xtend Reverse Total Shoulder|Orthopaedic implant for total shoulder replacement
1821947|NCT00737100|Drug|Placebo Respimat|patient to receive placebo matching active drug once daily
1821948|NCT00737100|Drug|Tiotropium bromide 5 mcg|patient to recieve high dose tiotropium once daily
1821949|NCT00737100|Drug|tiotropium bromide-low dose-2.5mcg|patient to receive low dose tiotropium once daily
1821950|NCT00737113|Drug|Genotropin (Recombinant Human Growth Hormone)|Patients will begin daily subcutaneous (SC) therapy at a starting dose of ~0.02mg/kg body weight. The study drug will continue for 90 days post enrollment.
1821951|NCT00737126|Drug|Folic acid|Administration of a daily tablet containing 5 mg of folic acid for 4 months.
1821952|NCT00737126|Drug|Placebo|Administration of an oral placebo pill
1821953|NCT00737139|Procedure|Peri-articular injection of marcaine/epinephrine|60ml of 0.5% Bupivacaine and Epinephrine 1:200,000 Inj
1821954|NCT00737139|Procedure|Peri-articular injection of marcaine alone|60ml of 0.5% Bupivacaine
1821955|NCT00737152|Other|RAS 130 with diet and exercise|Entire population, which will also include existing patients, will be treated with RAS 130 along with diet and exercise. By the end of 6 months: 3 months of study and 3 months of follow-up, the entire population will be divided into two groups which will be determined through endpoints. The first group will be subjects with diet and exercise and the second group will be subjects without diet and exercise. The endpoints for the division of the groups are given in the design of the study.
1821956|NCT00737165|Behavioral|Multimodal suicide prevention program|"A community intervention of multimodal suicide prevention program includes following components:
Building support networks for suicide prevention and mental health promotion in public health system
Primary prevention of suicide and suicide related behaviors
Secondary prevention of suicide and suicide related behaviors
Tertiary prevention; after care for suicide survivors
Suicide prevention targeting for people with substance/alcohol- related disorders , schizophrenia and other mental health disorders
Suicide prevention targeting for people with work-related problems"
1821957|NCT00737165|Behavioral|Suicide prevention program as usual|Usual suicide prevention program
1821958|NCT00737178|Device|CuT380A|Comparison of different timing of IUD insertion
1821959|NCT00737191|Drug|olanzapine|Given orally
1821960|NCT00737191|Other|placebo|Given orally
1821961|NCT00737204|Drug|Armodafinil|Participants will receive 50 mg of armodafinil per day, increasing to 250 mg per day as clinically indicated.
1821962|NCT00737204|Drug|Placebo|Participants will receive placebo pills matched to the active armodafinil and according to the same dosing strategy
1821963|NCT00737217|Behavioral|Behavioral assessment/questionnaire|Complete behavioral assessment/questionnaire
1821964|NCT00737230|Other|educational intervention|
1821965|NCT00737230|Other|questionnaire administration|
1821966|NCT00737230|Procedure|assessment of therapy complications|
1821967|NCT00737230|Procedure|gastrointestinal complications management/prevention|
1821968|NCT00737230|Procedure|management of therapy complications|
1821969|NCT00737230|Procedure|quality-of-life assessment|
1821970|NCT00737243|Drug|Paclitaxel|175 mg/m2, 1-3 hour IV infusion Day 1
1821971|NCT00737243|Drug|Carboplatin|AUC 6.0 IV Day 1
1821972|NCT00737243|Drug|Bevacizumab|15 mg/kg IV infusion Day 1
1821973|NCT00737243|Drug|Erlotinib|150 mg PO
1821974|NCT00737243|Other|Treatment determined by physician|Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy
1821975|NCT00737256|Drug|Aripiprazole|15-30 mg
1821977|NCT00737282|Drug|Proellex 25 mg|One capsule Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
1821978|NCT00737282|Drug|Proellex 50 mg|Two capsules Proellex 25 mg administered as daily oral doses for four (4) consecutive months during each treatment cycle
1821979|NCT00737295|Procedure|CCK Injection and Ultrasound|"All subjects, whether they participate in this study or not, will undergo the HIDA scan as this is the accepted standard of care for diagnosing biliary dyskinesia. If a given subject agrees to participate in this study, he/she will be asked to undergo the following study procedures:
If a pregnancy test has not already been done, a urine pregnancy test will be done for women of childbearing potential.
An intravenous line (IV) will be inserted (if not already in place), and a standard dose of CCK (Kinevac®- 0.02 µg/kg) will then be injected according to the package insert. Ultrasound will be used to measure dimensions of the gallbladder (length, width and height) every minute for 35 minutes following injection of the CCK. This will be done by applying ultrasound jelly to the upper part of the abdomen and ultrasound probe will be used to obtain optimal images for three dimensional analysis of the subject's gallbladder."
1821980|NCT00737308|Other|ceramic crown|Zirconia
1821981|NCT00737321|Procedure|Samples will be collected|wound tissue biopsy, blood samples, saliva collection and wound VAC sponge (if applicable).
1821982|NCT00737334|Device|EEGo, BIS, FORE-SIGHT cerebral oximeter|"The EEGo monitor, BIS monitor, and FORE-SIGHT cerebral oximeter will be used for cerebral monitoring of all patients. A comparison of the three monitors will be done. For EEGo monitoring, five bipolar electrodes will be placed per International 1020 system. For BIS monitoring, the BIS quattro sensor will be placed on the forehead in usual fashion. For FORE-SIGHT monitoring, the two sensor strips will be placed on the forehead in usual fashion.
All patients will have their ipsilateral Internal Jugular vein cannulated by the surgeon intraoperatively with a 16g IV cannula, through which a Portex multi-orifice epidural catheter will then be placed."
1821983|NCT00737347|Behavioral|Lifestyle modification|lifestyle intervention includes meal planning, food preparation, food label reading, dining out, and physical activity counseling
1821984|NCT00737360|Drug|TAS-106|6.5 mg/m2, IV on day 1 of each 21 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
1821985|NCT00737373|Drug|Docetaxel|50mg/m2 qd15
1821986|NCT00737373|Drug|5-Fluorouracil|2600mg/m2 qd15
1821987|NCT00737373|Drug|Oxaliplatin|85mg/m2 qd15
1821988|NCT00737373|Drug|folinic acid|200mg/m2 qd15
1821989|NCT00737399|Behavioral|Lifestyle Counseling with Emotional Freedom Techniques (EFT)|Two series of four sessions of phone support group coaching instruction in the use of EFT
1821992|NCT00737425|Device|PainShield|
1821993|NCT00737425|Device|Sham PainShield|
1821994|NCT00737438|Drug|epirubicin, cisplatin, capecitabine, bevacizumab, docetaxel and irinotecan|"Patients with FDG avid locally advanced but resectable gastric or GEJ adenocarcinoma will receive preoperative therapy with epirubicin, cisplatin, capecitabine (ECX), and bevacizumab. Each cycle of therapy is 21 days. Near the completion of cycle 1 of therapy (eg during week 3, target days 18-21), patients will undergo a second FDG-PET/CT scan. Note, patients will hold capecitabine for 48 hours prior to the FDG-PET/CT scan.
Patients with a good metabolic response (eg. > 35% reduction in FDG uptake at the primary tumor on the week 3 PET scan as compared with baseline FDG uptake) will continue ECX for 2 additional cycles (cycle 2 and 3).
Cycle 2 will be administered with bevacizumab and cycle 3 will be administered without bevacizumab. Patients will then proceed to surgery approximately 4-6 weeks following the completion of cycle 3. There is a 10-12 week time interval (eg. 70-84 days) between the last bevacizumab treatment and surgery."
1821995|NCT00737451|Behavioral|blood sampling|blood sampling 10ml from the study subjects
1821996|NCT00737464|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv (120, 200 or 360 micrograms) every 4 weeks for 12 weeks.
1821997|NCT00737477|Drug|Methoxy polyethylene glycol-epoetin beta|Mircera will be administered SC every 4 weeks for a total of 48 weeks. The first dose of 120 or 200 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within the target range.
1821998|NCT00737490|Other|"Sequential Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"Echocardiographically guided optimized device programming: specifically sequential BiV pacing. Sequential Arm
Using one of the FDA approved St. Jude devices, depending on MD preference."
1821999|NCT00737490|Other|"Simultaneous Arm (Promote , model # 2207-36 or Atlas HF , model # V-343)"|"simultaneous BiV pacing.
Using one of the FDA approved St. Jude devices, depending on MD preference."
1822000|NCT00737503|Biological|Rotavirus Vaccine (ROTARIX)|Rotavirus Vaccine two doses four weeks apart
1822001|NCT00737516|Biological|HPC, Cord Blood|Search for HLA compatible cord blood units using the NMDP registry
1822002|NCT00737529|Drug|lenalidomide|25mg oral capsules continuous days 1-21 each of a 28 day cycle
1822005|NCT00737555|Drug|CHR-2797|Oral once daily administration of capsules of CHR-2797, to determine safety and tolerability in patients being treated with paclitaxel infusion every 3 weeks for up to 18 weeks.
1822006|NCT00737568|Drug|TDF|Tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg tablet administered orally once daily
1822007|NCT00737568|Drug|FTC/TDF|Emtricitabine (FTC)/TDF 200/300 mg fixed-dose combination tablet administered orally once daily
1822008|NCT00737568|Drug|TDF Placebo|TDF placebo tablet administered orally once daily
1822009|NCT00737568|Drug|FTC/TDF Placebo|FTC/TDF placebo tablet administered orally once daily
1822010|NCT00737594|Drug|Placebo|0 mcg capsules three times daily (TID)
1822011|NCT00737594|Drug|Cobiprostone|12 mcg cobiprostone (capsules) three times daily (TID)
1822012|NCT00737594|Drug|Cobiprostone|18 mcg cobiprostone (capsules) three times daily (TID)
1822014|NCT00737633|Drug|VI-0521|Phentermine 15 mg/Topiramate controlled release (CR) 92 mg, oral capsule, once daily, 58 weeks
1822231|NCT00746122|Procedure|EVAR|Emergency endovascular aneurysm repair
1822016|NCT00737646|Behavioral|Clinic-focused intervention|The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff. The provider training sessions will include the presentation of CRC screening statistics and information, and will be heavily interactive and skills-based. The provider training sessions will also focus on the provision of tools for improving clinical staff- and clinician-patient interactions about CRC screening and for office system changes/improvements to identify eligible patients and to track screening.
1822017|NCT00737646|Behavioral|Clinic- and patient-focused|This arm will combine the clinic-focused intervention and the patient-focused intervention. The clinic-focused intervention consists of CRC screening training sessions for clinicians and clinical staff as described in Arm 2. The patient-focused intervention includes sending a CRC screening education packet (CDC-developed educational text tailored for use within the study sites), accompanied by a letter from the patient's physician, to patients meeting study inclusion criteria.
1822018|NCT00737659|Drug|Mycophenolate mofetil (CellCept® )|Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg*h\L) measured on Days 7,14,Months 1,3,6 and 12.
1822019|NCT00737659|Drug|Mycophenolate mofetil (CellCept® )|Fixed Dose group, MMF dosage will be adjusted based on standard care
1822022|NCT00737685|Drug|cyclophosphamide, fludarabine , thymoglobulin|cyclophosphamide (50 mg/kg once daily i.v. on days -9, -8, -7 & -6) fludarabine (30 mg/m2 once daily i.v. on days -5, -4, -3 & -2) thymoglobulin (2.5 mg/kg once daily i.v. on days -3, -2 & -1)
1822023|NCT00737698|Other|Exercise|Physiotherapist-supervised exercise course (endurance and resistance exercises) for 2 hours twice a week for 8 weeks
1822024|NCT00737698|Other|Repetitive magnetic stimulation|Repetitive magnetic stimulation of the intramuscular branches of the femoral nerve for 3 hours twice a week for 8 weeks
1822025|NCT00737711|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|iv 0.6 micrograms/kg every 2 weeks
1822026|NCT00737724|Drug|Simultaneous ARV and antiMTB|Receives both, simultaneously antiretroviral therapy and antituberculosis therapy
1822027|NCT00737724|Drug|Deferred RV and antiMTB treatment|Receives only antituberculosis therapy and 2 months afterwards antiretroviral therapy
1822028|NCT00737737|Drug|MS Contin|
1822029|NCT00737737|Drug|Placebo|
1822030|NCT00737750|Device|Kneehab|Program of NMES 3 times per day, five days per week for 12 weeks.
1822031|NCT00737750|Device|Poli-Stim|Poli-Stim is standard NMES which the patients used for 20 minutes, 3 times per day, 5 days per week for 12 weeks.
1822032|NCT00737750|Behavioral|Control|Voluntary quadriceps muscle contractions.
1822033|NCT00737763|Drug|efalizumab|Enrollees randomized to efalizumab will receive the first dose of 0.7mg/kg subcutaneously given at enrollment, and 1.0 mg/kg subcutaneously weekly for 26 weeks self or family-administered after injection training. This is the FDA-approved initial and subsequent doses of efalizumab used for psoriasis treatment
1822034|NCT00737763|Drug|placebo|Enrollees receiving placebo will be given a subcutaneous injection of equal volume and appearance to treatment on the same schedule.
1822035|NCT00737776|Drug|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1822036|NCT00737789|Drug|Mesalazine slow-release granules|Mesalazine 2g Sachet prolonged release granules, administered orally.
1822037|NCT00737789|Drug|Mesalazine liquid enema|1g mesalazine liquid enema, administered topically once a day in the evening.
1822038|NCT00737815|Dietary Supplement|Magnesium Citrate: a total of 500 mg elemental magnesium|500 mg elemental magnesium
1822039|NCT00737815|Other|Placebo|Inactive placebo pill
1822040|NCT00737828|Other|Perioperative care pathway guided by CPX results|"AT > 11ml/min/kg no myocardial ischaemia or Ve/VO2 <35 - Level 1 Ward Care
AT > 11ml/min/kg with myocardial ischaemia or Ve/VO2 >35 - Level 2/3 (ITU) Critical Care Unit
AT <11mls/min/kg - Level 2/3 Critical Care Unit
AT <8mls/min/kg - Level 2/3 Critical Care Unit/ consider cancellation or alternative procedure"
1822043|NCT00737854|Procedure|Surgical resection|20 patients with OLP will be selected for this study. Before this routine treatment modalities had been attempted. Removal of possible triggering drug was also considered. Local ethical committee approval will be obtained before the trial starts. Surgical procedure includes: removal of the tissue up to submucosa (containing antigenic properties that caused OLP). A specimen will be sent for histopathologic analysis. The graft sliced from healthy mucosa also up to submucosa. Then the graft trimmed on a gauze soaked in saline and adapted to recipient site. The graft was sutured in position. Checking will be done after 1 week and every two months up to 1 year. Punch biopsy will be done in 1 year after surgery for histopathologic investigations.
1822044|NCT00743223|Other|The measure of the cervical posture|The investigation of the cervical position consisted of locating the individual in side view with the parallel feet in erect position and tracing an imprisoned plumb wire to the ceiling and tangent to the kyphosis curve of the thoracic column. With a ruler it was verified at a distance of this line until the point deepest of the cervical lordosis curve.
1822045|NCT00743236|Procedure|cold ischemia procedure|Cold ischemia followed by partial nephrectomy
1822046|NCT00743236|Procedure|warm ischemia procedure|Warm ischemia followed by partial nephrectomy
1822047|NCT00743249|Device|MINI MONOKA canalicular stent, 10 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 10 mm length
1822048|NCT00743249|Device|MINI MONOKA canalicular stent, 20 mm|40 mm hollow intubation stent composed of a silicon tube and an oval collarette head (plug), cut to 20 mm length
1822049|NCT00743262|Device|Provox voice prosthesis|The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
1822050|NCT00743275|Biological|Split, Inactivated, Trivalent Influenza vaccine (Fluzone®)|0.5 mL, intramuscular
1822051|NCT00743288|Drug|Melphalan|Same as above
1822052|NCT00743288|Drug|Panobinostat|
1822053|NCT00743301|Other|Palm olein vs olive oil and lard|17E% from test fat is incorporated into three rolls and a piece of cake
1822054|NCT00743314|Other|screening questionnaire administration|
1822055|NCT00743314|Procedure|computed tomography|
1822056|NCT00743314|Procedure|lymphoscintigraphy|
1822057|NCT00743314|Procedure|single photon emission computed tomography|
1822058|NCT00743314|Radiation|intensity-modulated radiation therapy|
1822059|NCT00743314|Radiation|technetium Tc 99m sulfur colloid|
1822060|NCT00743327|Drug|Pioglitazone|45mg capsule, once daily for 1 year
1822061|NCT00743340|Drug|Emtricitabine|Emtricitabine (FTC) administered based on body weight at a dose of 6 mg/kg once daily, with a maximum dose of 200 mg once daily with the capsule formulation (for children weighing ≥ 33 kg) or a maximum dose of up to 240 mg once daily with the oral solution formulation.
1822062|NCT00743353|Drug|F-18 RGD-K5|Study Drug F-18 RGD-K5 administered for diagnostic PET Imaging to be observed for a maximum of 4 hours, followed by 24 hour follow up
1822063|NCT00743366|Drug|Marijuana|0,6.2% THC
1822064|NCT00743366|Drug|Quetiapine|200 mg/day
1822065|NCT00743366|Drug|Placebo oral capsule|
1822067|NCT00743405|Drug|GSK1034702|Oral or liquid
1822068|NCT00743405|Drug|Placebo|To match GSK1034702
1822069|NCT00743418|Device|GPS modem and RFID|The participant will take the GPS kit with him/her everywhere during the whole day for a period of 4 weeks. The GPS tracking kit consists of a GPS receiver with a GSM modem, an RF transmitter contained in a wrist-watch and a monitoring unit located in the home that enables researchers to know whenever the tracked person leaves home. The waterproof RF transmitter will allow researchers to know whether or not research subjects leave home with the GPS device and if they are carrying the device or not at a given moment.
1822070|NCT00743431|Drug|Caelyx (Pegylated Lyposomal Doxorubicin)|Pegylated Lyposomal Doxorubicin, 50 mg/m2 every 4 weeks for 6 cycles.
1822071|NCT00743444|Drug|AZD3355|65 mg capsules, oral, 3 single doses
1822072|NCT00743444|Drug|Placebo|capsules, oral, 3 single doses
1822073|NCT00743457|Device|Ocular Ultrasound|B-mode ultrasound of the eye with 90 and 30 degree view of optic nerve sheath
1822074|NCT00743470|Drug|lopinavir/ritonavir|lopinavir/ritonavir tablet; see arm for intervention description
1822075|NCT00743470|Drug|rifabutin|rifabutin capsule; see arms for intervention description
1822076|NCT00743483|Drug|rhBSSL|oral suspension, 170 mg BSSL, 3 times daily for 5-6 days
1822077|NCT00743496|Biological|Anti-GD2 antibody|Anti-GD2 antibody
1822078|NCT00743509|Drug|Cyclophosphamide and Sirolimus|"The dose of cyclophosphamide will start at 200 mg (4 tablets) per day on day 1 and will be taken for 7 days every other week of a 28 day cycle.
Subjects will take 12 mg (12 tablets) of sirolimus on day 1 of treatment as a loading dose followed by 4 mg (4 tablets) daily continuously"
1822079|NCT00743522|Device|ICD/ CRT-D|Cardiac device
1822080|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TOT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.
Small incision sites in the femoral/pelvic fold. Bilateral transobturator insertion of mesh by means of mono-use needle"
1822081|NCT00743535|Procedure|Transobturatory correction of anterior defect plus TVT|"Longitudinal vaginal incision 1 cm far from esternal urethral meatus. Bladder dissecting and identification of ischiatic spines. Bilateral transobturator insertion of anterior mesh through high and low trans-obturatory approach. Mesh anchorage.
Small incision sites at sovrapubic level. Bilateral retropubic insertion of mesh by means of mono-use needle."
1822082|NCT00743548|Device|IB = Interdental brush, the intervention|IB is a small multi-tufted brush on a wire attached to a long angled handle that is inserted in a horizontal plane between the teeth. The IB is inserted once and removed.
1822083|NCT00743548|Device|DF = Dental floss, the positive control|DF is waxed dental floss; nylon covered with a water soluble unflavoured wax to facilitate easier access the contact points of teeth. DF is rubbed against the interproximal surfaces of the teeth 2-4 times on each surface.
1822084|NCT00744653|Procedure|Electrochemotherapy|Electric pulses , duration 100 microseconds, about 400 V given at 5000 Hz. Drug used is Bleomycin.
1822085|NCT00744666|Drug|Prednisolone 1% topical eye drops|Prednisolone 1% 1gtt qid to the eye requiring IVTA
1822086|NCT00744679|Drug|Natalizumab|Participants continue to receive regularly-scheduled doses of Tysabri (300 mg infusion every 28±7 days) through the Tysabri Outreach: United Commitment to Health Prescribing Program (TOUCH) throughout the screening and assessment periods. Participants must continue to be dosed every 28±7 days in order to maintain steady-state pharmacokinetics.
1822087|NCT00744692|Biological|Unrelated Umbilical Cord Blood Transplant|Reduced Intensity Conditioning for unrelated umbilical cord blood transplant
1822088|NCT00744692|Drug|Reduced Intensity Conditioning|
1822089|NCT00744718|Drug|Bevacizumab|Bevacizumab 10 mg/kg every 3 weeks
1822090|NCT00744718|Drug|Carboplatin|Carboplatin AUC 5 every 5 weeks
1822091|NCT00744731|Drug|placebo|placebo for 1 week
1822092|NCT00744731|Drug|carisbamate|400 mg/day to 1,200 mg per day
1822093|NCT00744744|Other|informational intervention|Patient educational information
1822094|NCT00744744|Other|questionnaire administration|Survey
1822095|NCT00744744|Procedure|management of therapy complications|Survey
1822096|NCT00744744|Procedure|psychosocial assessment and care|Survey
1822097|NCT00744744|Procedure|quality-of-life assessment|Survey
1822098|NCT00744757|Drug|Decitabine|Decitabine 20 mg per m^2 will be administered intravenous infusion over 1 hour, once daily for 5 consecutive days of a 28 days cycle up to 8 cycles or continued until disease progression or unacceptable toxicity.
1822099|NCT00744770|Drug|TMC278|
1822100|NCT00744796|Procedure|DSEAK|Endothelial Keratoplasty
1822101|NCT00744809|Drug|TMC278; Moxifloxacin; Efavirenz|
1822102|NCT00744835|Procedure|Ablation procedure and/or cardioversion|Ablation Frontiers Cardiac Ablation System
1822103|NCT00744848|Drug|Bupivacaine HCl|100 mg Bupivacaine HCl
1822104|NCT00744848|Drug|SKY0402|Single administration 300 mg SKY0402 in a 40-mL injection volume
1822107|NCT00744874|Procedure|RF Ablation procedure|Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
1822108|NCT00744887|Drug|Darunavir|
1822109|NCT00744900|Drug|Pemetrexed, cisplatin|Alimta 500mg/m² IV 10 min infusion and Cisplatin 75mg/m² IV 60 min on day 1. Cycle will be repeated each 21 days.Folic acid orally 400µg should begin 5-7days prior to the first dose of pemetrexed and continuing daily until 3 weeks after the last dose of pemetrexed. Vitamin B12 will be administered as a 1000 mg intramuscular injection, approximately one week before Day 1 of cycle 1 and should repeat approximately every 9 weeks Dexamethasone, 4 mg or equivalent, should be taken orally twice per day on the day before, the day of, and the day after each dose of pemetrexed.WBRT will be administered with high energy photons systematically after cycle 6 or in case of stable disease (SD) after cycle 4 or progressive disease (PD) at any time. The dose will be 3Gy by fraction, 1 fraction per day, for 10 days.
1822110|NCT00744913|Drug|Nicoderm patches|Women in this group will receive standard counselling and NRT (Nicoderm patches) starting with a dose of 14 mg/day that can be increased to 21 mg/day based on response (smoking cessation) and potential side effects
1822111|NCT00744913|Other|Counselling|Women in this arm of the study will receive standard counseling only.
1822112|NCT00744926|Drug|placebo|sc, once weekly
1822113|NCT00744926|Drug|taspoglutide|10mg sc, once weekly
1822114|NCT00744926|Drug|taspoglutide|20mg sc, once weekly (after 4 weeks of taspoglutide 10mg sc once weekly)
1822115|NCT00744939|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-4882)|Patients will be followed for 2 years after the administration of Magnevist at the approved dose to see if symptoms consistent with NSF develop
1822116|NCT00744965|Drug|Glyburide|Starting dosage is 2.5 mg once daily. This dose will be titrated as necessary during the pregnancy to achieve glycemic control.
1822117|NCT00744965|Drug|Placebo|Sham dose adjustments of the placebo will be made.
1822118|NCT00744978|Drug|Varenicline|0.5 mg once daily for 1 week followed by 0.5 mg twice daily for 1 week followed by 1 mg twice daily for 4 weeks
1822119|NCT00744978|Drug|Placebo|Placebo once daily for 1 week followed by placebo twice daily for 5 weeks.
1822120|NCT00744991|Drug|Enzastaurin|1125 mg loading dose then 500 mg, oral, daily, until disease progression
1822121|NCT00745004|Drug|Ondansetron|Over-encapsulated 4mg ondansetron tablets. Ondansetron 4mg OD, dose titrated up to a maximum of 8mg tds or down to a minimum of 4mg alternate days. For 5 weeks.
1822122|NCT00745004|Drug|Placebo|Capsule matching over-encapsulated experimental drug. 1 capsule OD, dose titrated up to a maximum of 2 capsules tds or down to a minimum of 1 capsule alternate days. For 5 weeks.
1822123|NCT00745017|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
1822124|NCT00745017|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
1822125|NCT00745017|Drug|Antidepressant medication|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
1822126|NCT00745030|Drug|Rozerem|Subjects take 1 8mg tablet 30 minutes before bedtime everyday for 8 weeks.
1822127|NCT00745030|Drug|Placebo|Placebo 8 mg tablets
1822128|NCT00745043|Drug|bronchodilator response|
1822129|NCT00745069|Drug|tapentadol HCl|
1822130|NCT00745095|Drug|Neostigmine|Neostigmine will be administered in 20, 40, and 60mg doses until an individualized dose-response relationship is established
1822131|NCT00745108|Drug|tibolone|oral 1.25 mg tablet, once daily, for 2 years
1822132|NCT00745108|Drug|Tibolone 2.5 mg|oral 2.5 mg tablet, once daily, for 2 years
1822133|NCT00745108|Drug|CE/MPA|oral, 0.625 mg tablet conjugated equine estrogen and 2.5 mg medroxyprogesterone acetate tablet placed together in a single capsule, once daily, for 2 years
1822134|NCT00745121|Device|OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ implants Ø 3.5, 4, 4.5, 5.0 mm in lengths of 8, 9, 11, 13, 15, 17 and 19 mm
1822135|NCT00745134|Drug|Curcumin|4 gm tablets by mouth twice a day
1822136|NCT00745134|Drug|Placebo|Tablets by mouth twice a day
1822137|NCT00745134|Radiation|Radiotherapy|45 Gy once a day, for 5 days in a row for 5-6 weeks (up to 28 treatments in all)
1822138|NCT00745134|Drug|Capecitabine|825 mg/m^2 by mouth twice a day only on days of radiation (Monday through Friday).
1822139|NCT00745147|Drug|Chinese herbal formula (CCH1)|initial dose of 1.5/3.0/4.5gm herbal powder with 15/30/45ml placebo of duphalac, respectively, per day for mild/moderate/severe constipation, then titrated
1822140|NCT00745147|Drug|Duphalac|initial dose of 15/30/45ml duphalac with 1.5/3.0/4.5gm placebo of herbal powder, respectively, per day for mild/moderate/severe constipation, then titrated
1822141|NCT00745160|Other|blood sample and questionnaire|After giving informed consent, all patients will be asked to complete questionnaire and will be asked to provide a blood sample for DNA analysis. The questionnaire will consist of a detailed smoking questionnaire, based on the most recent Centers for Disease Control and Prevention (CDC) Behavioral Risk Factor Surveillance System Survey Questionnaire.
1822142|NCT00745173|Drug|Premarin|
1822143|NCT00745186|Drug|Glucagen|0.2 mg or 1 mg Glucagen single injection
1822144|NCT00745186|Drug|Mayne Glucagon|0.2 mg or 1 mg Mayne Glucagon
1822147|NCT00745225|Drug|Pioglitazone|pioglitazone 15mg daily for 12 weeks, then 30mg daily for 84 weeks
1822148|NCT00745225|Drug|placebo comparator|1 capsule daily, 96 weeks.
1822149|NCT00745238|Other|withdrawal of non-invasive ventilation|Four weeks withdrawal of non-invasive ventilation
1822150|NCT00745251|Drug|VI-0521|15 mg Phentermine and 92 mg Topiramate
1822151|NCT00745251|Drug|placebo|placebo
1822152|NCT00745264|Drug|Diractin|100 mg Ketoprofen to 2 joints
1822153|NCT00745264|Drug|Diractin|400 mg ketoprofen to 4 joints
1822154|NCT00745264|Drug|Diractin|100 and 400 mg Ketoprofen used concomittant with heat
1822155|NCT00745264|Drug|Diractin|100 and 400 mg Ketoprofen concomittant with moderate exercise
1822156|NCT00745277|Drug|Carbidopa-Levodopa|"For the first four weeks, the patient will receive carbidopa 75mg daily plus placebo, plus levodopa at level the patient was taking prior to start of study.
For the last 4 weeks, the patient will receive carbidopa 450mg daily plus previous dose of levodopa"
1822157|NCT00745277|Drug|Carbidopa- Levodopa|"For the first four weeks, the patient will receive carbidopa 450mg daily plus levodopa at level the patient was taking prior to start of study.
For the last 4 weeks, the patient will receive carbidopa 75mg daily plus placebo, plus previous dose of levodopa"
1822158|NCT00745290|Drug|Bupivacaine HCl|200 mg bupivacaine HCl
1822159|NCT00745290|Drug|SKY0402|600 mg SKY0402 (study drug).
1822160|NCT00745303|Procedure|Tai Chi Cuan|Tai Chi Cuan training for 3 months
1822161|NCT00745316|Drug|Tonapofylline|Oral Tonapofylline - 2 capsules bid
1822162|NCT00745316|Drug|Placebo|Oral placebo - 2 capsules bid
1822163|NCT00745329|Other|sperm quality test|All participants will undergo sequential sperm quality tests and blood tests
1822164|NCT00745342|Behavioral|Family Teamwork Intervention|Families in the teamwork group received quarterly psychoeducational interventions at regular clinic visits, focusing on promoting family teamwork and reducing diabetes-specific family conflict and diabetes burnout.
1822165|NCT00745355|Behavioral|Quality Of Life questionnaires|All patients who agree to participate will be interviewed using a baseline idiographic quality of life assessment prior to surgery and at approximately 6, 12, 18 and 24 months postoperatively. All patients will also be asked to respond to a questionnaire including all standard measures (closed-ended, multiple choice items) before surgery and at approximately 3, 6, 12, 18 and 24 months post-surgery.
1822166|NCT00745368|Drug|Raltegravir|400 mg tablets twice daily during duration of trial
1822167|NCT00745381|Other|questionnaire, Blood specimens|All participants will complete an epidemiology study questionnaire as well as a quality of life questionnaire. They will also be asked to donate blood samples. We will request participation in a tissue repository consisting of fresh frozen or paraffin embedded tissue. The repository will be of serum, plasma and tumor tissue. Follow-up will occur on patients every 6 months for the first year after consent and then annually.
1822168|NCT00745407|Drug|fenofibrate|
1822170|NCT00745433|Drug|repaglinide|Start dose and frequency at the discretion of the physician following clinical practice
1822171|NCT00745433|Drug|metformin|Start dose and frequency at the discretion of the physician following clinical practice
1822172|NCT00745446|Procedure|Forearm Venous Occlusion Plethysmography|Forearm venous occlusion plethysmography with intra-arterial infusion of Acetylcholine (5-20mcg/min), bradykinin (30-300mcg/min), sodium nitroprusside (2-8mcg/min) and Verapamil (2-10 mcg/min) into non-dominant brachial artery
1822173|NCT00745459|Drug|NPO-11|20 mL NPO-11
1822174|NCT00745485|Drug|zoledronic acid|
1822175|NCT00745498|Drug|Bevacizumab|Patients will receive intravitreal injection of 1.25 mg of bevacizumab (0.05 ml)
1822176|NCT00745511|Drug|ORA102 and Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)and ORA102
1822177|NCT00745511|Drug|Avastin|treatment with intravitreal injections of Avastin 1.25mg (0.05ml)
1822178|NCT00745537|Other|repeated mood measures and phone depression care management|The adolescent mothers will be assigned a depression care management who will support the mother in making choices about depression treatment, educate about treatment options, discuss barriers and solutions, counsel to comply with treatment recommendations, and assisted to problem-solve if failure to respond occurs.
1822179|NCT00745550|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28-day cycle
1822180|NCT00745563|Device|Fertiligent|Fertility treatment by using the EVIE - Slow Release Insemination method
1822181|NCT00745576|Drug|SAM-531|
1822182|NCT00745589|Drug|sevelamer hydrochloride|First-line high dose (that is, 800mg TDS and up to a maximum of 1200mg TDS) sevelamer hydrochloride will be compared against low dose second-line sevelamer hydrochloride (that is, fixed dose of 400mg TDS)
1822183|NCT00745602|Procedure|non-invasive testing|non-invasive tests including Transcranial Doppler ultrasound (TCD), manual cuff blood pressure (BP), beat to beat BP monitoring by a Portapress monitor, and respiratory tidal CO2
1822185|NCT00745667|Procedure|laparoscopic surgery|laparoscopic correction perforated peptic ulcer
1822186|NCT00745667|Procedure|Upper laparotomy|upper laparotomy for correction of perforated peptic ulcer
1822187|NCT00745693|Drug|Endothelin-1|Intra-arterial infusion of Endothelin-1 at 5pmol/min for 1 hour during venous occlusion plethysmography
1822188|NCT00745693|Drug|BQ-123 and BQ-788|1 hour intra-arterial infusion of BQ-123 at 10nmol/min followed by co-infusion of BQ-788 at 1nmol/min for a further hour during forearm venous occlusion plethysmography
1822229|NCT00746109|Procedure|NoPacking|This is a routine incision and drainage procedure but without the use of packing. Sterile gauze dressing will be placed over the abscess cavity.
1822189|NCT00745706|Device|Implantable Loop Recorder (ILR)|Insertion of ILR 3 months prior to clinical ablation procedure to collect data on actual Atrial Fibrillation episodes and correlation with patient symptoms through patient diary entry. Then patient undergoes their previously indicated clinical ablation procedure and is then followed up with ILR insitu for 30 months post-ablation for the same as mentioned above.
1822190|NCT00745719|Procedure|parathyroidectomy|total parathyroidectomy with forearm autografting
1822191|NCT00745732|Drug|ZD6474 (ZACTIMA)|ZD6474 (ZACTIMA) beginning at 100 mg once a day by mouth
1822192|NCT00745732|Radiation|Radiation Therapy|"Phase I: 45 Gy at 3 Gy per fractions once a day.
Phase II: 45 Gy at 3 Gy per fraction once a day or 66-70 Gy at 2 Gy per fraction once a day."
1822193|NCT00745745|Device|Device Implantation|ICD lead implantation
1822194|NCT00745771|Drug|Diractin|
1822195|NCT00745771|Drug|Diractin|
1822196|NCT00745784|Behavioral|in-person or telephone interview|Participants will be administered one battery of questionnaires that should take 50- 55 minutes, which may be broken down into two or more segments if necessary. They may choose to have these questionnaires administered to them in person at the hospital, in person at their home, or via telephone by a trained master's level research assistant.
1822197|NCT00745797|Radiation|Radiotherapy|blood transfusions, platelet transfusions, antibiotics, antipyretic analgesics and anesthetics
1822198|NCT00745810|Other|Cardiopulmonary bypass|sequential changes of oxidative injuries before and after cardiopulmonary bypass
1958537|NCT01552213|Other|Minimum intervention control group|A single visit with a dietician or health educator to discuss general health risks, good eating habits, and appropriate weight gain. This will be followed by routine prenatal care per provider.
1958538|NCT01552213|Other|Treatment for glucose intolerance|Diet, exercise glucose monitoring, insulin if necessary
1822202|NCT00745836|Drug|statin|
1822203|NCT00745849|Drug|esomeprazole|40mg by mouth twice daily
1822204|NCT00745849|Drug|placebo|
1822205|NCT00745862|Behavioral|questionnaire on-line or if uncomfortable with a computer interface, paper copies will be provided|This pilot study will measure illness related distress in female patients undergoing surgical treatment of cutaneous melanoma within two years of diagnosis and treatment. Areas of particular focus will be survival anxiety, family functioning/childbearing concerns, and aesthetic impact of surgery. Patients will complete a one time only set of quality of life assessments these questionnaires will take 30-45 minutes to complete.
1822206|NCT00745875|Drug|ZD4054|10mg oral tablet, once daily
1822207|NCT00745875|Drug|Pemetrexed|500mg2/m IV infusion
1822208|NCT00745875|Drug|Placebo|10mg oral tablet, once daily
1822209|NCT00745888|Other|Chemiluminescence Analyzer|measure reactive oxygen species
1822210|NCT00745901|Drug|Norgestimate/ethinyl estradiol; Drospirenone/ethinyl estradiol|
1822211|NCT00745914|Drug|Pioglitazone|oral Pioglitazone 15mg daily for 12 weeks, then 30mg daily for 36 weeks
1822212|NCT00745914|Drug|Placebo comparator|Placebo comparator
1822213|NCT00745927|Other|CO2 insufflations|CO2 insufflations during whole procedure of colonoscopy
1822214|NCT00745940|Behavioral|MBCT for TBI|Subjects will participate in a 10-week Mindfulness-Based Cognitive Therapy Program led by two trained facilitators. Weekly one-and-a-half hour group sessions will guide subjects through exercises such as meditation, awareness, and breathing techniques aimed at developing skills to help with tension, stress, anxiety and depression. Subjects will be encouraged to practice skills at home and in daily life.
1822215|NCT00745953|Drug|Valsartan|Valsartan 320mg PO daily for 8 months
1822216|NCT00745953|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg PO daily for 8 months
1822217|NCT00745992|Other|Blood drawn (lab data)|"Check drug blood level 3-5 days after start of drug, treatment failure, occurence of adverse events, or clinically indicated
Check genetic polymorphism of liver enzyme 3-5 days after start of drug"
1822218|NCT00746005|Dietary Supplement|fish oil|3 g fish oil (3078 mg) total EPA 1512 mg and total DHA 1026 mg
1822219|NCT00746005|Dietary Supplement|placebo, sunflower oil|3 g of sunflower oil
1822220|NCT00746018|Device|LigaSure vessel sealing system|The investigators intend to enroll a total of 60 patients planned to undergo a total hysterectomy and bilateral salpingo-oophorectomy. There will be two techniques compared in this protocol. The first 30 patients will have the right tube removed with one application of the LigaSure. The LigaSure will be placed and the most proximal portion of the right fallopian tube adjacent to the uterine cornua and will be used to coagulate and cut the tube. The next 30 patients will have the tube ligated in the same fashion as group A however an additional step will be added once the fallopian tube has been removed. The LigaSure will be used to cauterize the remaining medial tissue on the cornua region of the uterus.
1822221|NCT00746031|Drug|GnRH analogue (Zoladex)|3.6mg subcutaneous implant. Monthly doses x 3.
1822222|NCT00746031|Drug|GnRH antagonist-Cetrorelix|Subcutaneous injection 3mg x3 over 7 days
1822223|NCT00746057|Biological|DNA chip|One biopsy is realized before graft, another biopsy is realized one year after graft and a blood sample is collected 3 months after graft to realize DNA chip. Blood samples are also collected at day 0, day 1, month 3, month 6 and month 12 to analyze biochemistry, proteinuria, haematology, creatinine clearance and immunology at day 0, month 3 and month 12.
1822224|NCT00746070|Other|with the clinical treatment ( ex adrenalectomy or spironolactone|with the clinical observational study
1822225|NCT00746083|Behavioral|Challenge!|"Each adolescent in the intervention group received 12 lessons administered in adolescent's home or community by a personal trainer (a college-aged mentor). The lessons focused on behavior change relating to diet and physical activity and was based on social cognitive theory. At the end of each lesson the adolescent set a behavior change goal for themselves. The adolescents were taught how to track their goals and they discussed thir ability/inability to meet their goals at each meeting with their personal trainer."
1822226|NCT00746096|Drug|IKH-01|ethinyl estradiol 0.035mg and norethisterone 1mg
1822227|NCT00746096|Drug|Placebo|Placebo for ethinyl estradiol 0.035mg and norethisterone 1mg
1822228|NCT00746109|Procedure|Wound packing|"1/4 non-iodoform packing loosely placed inside abscess cavity."
1822230|NCT00746122|Procedure|Open repair|Standard treatment of emergency open surgery
1822232|NCT00746135|Device|Device Implantation|RV apical pacing lead, RV pacing lead at HIS bundle position, LV pacing lead implantation
1822233|NCT00746148|Other|Reflexology|10 weekly sessions of 45 minutes each
1822234|NCT00746161|Procedure|Reconstruction after total gastrectomy|Roux-en-Y
1822235|NCT00746161|Procedure|Reconstruction after total gastrectomy|double tract reconstruction
1822236|NCT00746174|Drug|Rosiglitazone|Rosiglitazone 8mg PO daily for 16 weeks
1822237|NCT00746174|Drug|Placebo|Placebo 1 tablet PO daily for 16 weeks
1822238|NCT00746187|Device|ASTRA TECH Implant System; Fixture ST: Ø 4.5 cm in lengths of 9, 11 and 13 mm.|
1822239|NCT00746187|Device|3i Osseotite® implant: Ø 4.0 in lengths of 8.5, 10, 11.5 and 13 mm|
1822240|NCT00746200|Procedure|(electro)acupuncture|Frequency of electrostimulation: 15Hz; Duration of electrostimulation: 20min;
1822241|NCT00746200|Procedure|sham acupuncture|Superficial acupuncture needle stimulation at non-acupoints with TENS applied for seconds
1822242|NCT00746226|Biological|Lactobacillus acidophilus and Bifidobacterium lactis|Daily 5x10^9 CFU of a combination of L. acidophilus and B. lactis
1822243|NCT00746226|Biological|Placebo|"Microcrystalline cellulose
As capsule which could be opened"
1822244|NCT00746239|Drug|Placebo and Escitalopram|Placebo and Escitalopram (5 to 40 mg)
1822245|NCT00746239|Drug|Ramelteon and Escitalopram|Ramelteon 8 mg and Escitalopram (5-40 mg)
1822248|NCT00746265|Behavioral|Behavioral weight loss intervention|Participants in both conditions are provided nutritional education and behavioral strategies for weight loss (consistent with the LEARN program). Participants in SBT are taught the cognitive and motivational strategies used in LEARN while participants in ABT are taught acceptance-based strategies (e.g., acceptance, mindfulness).
1822249|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using bipolar|Laparoscopic ovarian cystectomy using bipolar
1822250|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using ultrasonic scalpel|Laparoscopic ovarian cystectomy using ultrasonic scalpel
1822251|NCT00746278|Procedure|Laparoscopic ovarian cystectomy using suture|Laparoscopic ovarian cystectomy using suture
1822252|NCT00746291|Other|6 min walk test, Step climbing|walking for 6 minute and climbing steps
1822253|NCT00746317|Drug|GC33|IV administration at 4 escalating dose levels.
1822254|NCT00746330|Drug|Mometasone furoate/formoterol fumarate (MFF)|Formoterol fumarate dihydrate / mometasone furoate combination product 10 μg / 100 μg delivered via Pressurized Metered Dose Inhaler (pMDI). One dose consisted of 2 puffs x 5 μg / 50 μg.
1822255|NCT00746330|Drug|Formoterol fumarate 12 μg pMDI (F12M)|Formoterol fumarate dihydrate 12 μg delivered via Pressurized Metered Dose Inhaler (pMDI) (1 dose = 2 puffs x 6 μg).
1822256|NCT00746330|Drug|Formoterol fumarate 12 μg DPI (F12D)|Formoterol fumarate dihydrate 12 μg delivered via Dry Powder Inhaler (DPI).
1822257|NCT00746330|Drug|Placebo to F12D|Placebo to formoterol fumarate DPI delivered via DPI
1822258|NCT00746330|Drug|Placebo to F12M/MFF|Placebo to formoterol fumarate pMDI and formoterol fumarate / mometasone furoate delivered via pMDI
1822259|NCT00746343|Behavioral|IRRI|Subjects will remain in their assigned treatment condition for 24 months. IRRI subjects will meet with the lifestyle coach 25-27 times throughout the duration of the study.
1822260|NCT00746343|Behavioral|PCCM|Subjects will remain in their assigned treatment condition for 24 months.
1822261|NCT00746356|Device|Testing of the autocapture features of the device|Patients receiving cardiac resynchronization therapy will have new autocapture features tested on right atrial, right ventricular and left ventricular leads.
1822262|NCT00746356|Device|Testing of the autocapture features of the device|Patients with an Implantable Cardioverter Defibrillator will have new autocapture features tested on the right atrial and right ventricular leads.
1822263|NCT00746369|Behavioral|IMARA HIV Prevention Intervention|Three individual sessions- behavioral intervention for incarcerated female adolescents.
1822264|NCT00746382|Drug|Roflumilast cream|Roflumilast cream 0.5% versus Placebo cream
1822265|NCT00746382|Drug|Placebo cream|Placebo cream
1822266|NCT00746395|Drug|Lubiprostone|24 mcg oral administration
1822267|NCT00746395|Drug|Placebo|Oral administration
1822269|NCT00746421|Drug|Quetiapine XR|oral doses, 200 mg, 300 mg, 400 mg
1822270|NCT00746421|Drug|Placebo|200mg, 300mg or 400mg
1822271|NCT00746434|Drug|Roflumilast cream|Roflumilast cream 0.5%
1822272|NCT00746434|Drug|Placebo cream|Placebo cream
1822273|NCT00746447|Drug|mesalamine granules|3.0g mesalamine in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
1822274|NCT00746447|Drug|mesalamine granules|1.5g mesalamine and 1.5g placebo in the morning, 0.5g placebo at lunch, 0.5g placebo in the evening;
1822275|NCT00746447|Drug|mesalamine granules|0.5g mesalamine and 2.5g placebo in the morning, 0.5g mesalamine at lunch, 0.5g mesalamine in the evening
1822276|NCT00746460|Behavioral|CVD risk profile|Cardiovascular risk assessment and behavioral counselling
1822277|NCT00746486|Drug|budesonide|One budesonide 3 mg capsule TD or one budesonide 3 mg capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
1822278|NCT00746486|Drug|budesonide placebo|One placebo capsule TD or One placebo capsule BD and 12-16 mg ursodeoxycholic acid/kg BW/d for 3 years
1822279|NCT00746499|Drug|Raltegravir|400mg raltegravir BID x 7 days
1822280|NCT00746512|Drug|Prednisone 15 mg|Prednisone 15 mg tablets once daily for 15 days.
1822281|NCT00746512|Drug|Placebo Tablets|Prednisone placebo tablets once daily for 15 days.
1822282|NCT00746512|Drug|Prednisone 7.5 mg|Prednisone 7.5 mg over-encapsulated tablets once daily for 15 days
1822283|NCT00746512|Drug|Placebo Over-Encapsulated Tablets|Prednisone 7.5 mg placebo over-encapsulated tablets once daily for 15 days
1822284|NCT00746525|Other|Surface functional electrical stimulation (FES)|FES is a technique that electrically stimulates a muscle in a comfortable manner in order to contract the muscle. It uses an electrode placed on the surface of the skin. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
1822285|NCT00746525|Other|Motor learning|Motor learning is an exercise that uses movements needed for everyday tasks such as picking up a glass or opening a book. This study will use BCI, FES, and motor learning interventions to address upper extremity motor deficits following stroke.
1822286|NCT00746525|Other|Brain computer interface (BCI) training|BCI training uses signals produced by the brain to help individuals with stroke move their weak arm. This study will use BCI, FES and motor learning interventions to address upper extremity motor deficits following stroke.
1822287|NCT00746538|Device|biliary stent|Metallic stent of plastic stent was inserted into right or left hepatic duct which was planed before intervention using CT scan or MRCP
1822288|NCT00746551|Drug|Ferli-6® (Continental Pharm co., ltd.)|In the O-group, women had to take 3 ferrous fumarate tablets (Ferli-6®) everyday with a total of 200 mg of elemental iron per day from 33 weeks gestation until delivery. Emphasizing and monitoring for compliance to the treatment protocol were carried out.
1822289|NCT00746551|Drug|Venofer® (Vifor AG, St. Gallen, Switzerland)|Women in the IV-group received 500 mg iron sucrose (Venofer®, Vifor International AG, St. Gallen, Switzerland) divided into three weekly administrations. Two doses of 200 mg iron sucrose were given at 33 and 34 weeks gestation while the remaining (100 mg) was infused at gestation of 35 weeks. Thereafter, women in this group received no further iron therapy until delivery. In preparation, 200 mg of iron sucrose was diluted into 100 ml of 0.9% saline solution.
1822290|NCT00746564|Device|SJM Confirm|All patients in this study will receive the SJM Confirm device.
1822291|NCT00746577|Other|Organizational change to improve the implementation of evidence-based practices.|Some sites will receive assistance with the creation and implementation of an organizational development plan.
1822292|NCT00746590|Drug|Prolarix (tretazicar co-administered with caricotamide)|Prolarix (26.6 mg/m2 tretazicar co-administered with 200 mg/m2 caricotamide) administered intravenously every 21 days until disease progression
1822294|NCT00746616|Device|Durom Hip Resurfacing System|Hip resurfacing devices in the young, active patient with advanced hip disease instead of traditional total hip arthroplasty.
1822295|NCT00746629|Behavioral|FOCUS|"Treatment will be delivered over a 20-week period. Participating children and at least one of their parents will attend weekly in-person clinic sessions. Treatment will consist of 20-25 minute meetings between the assigned interventionist and each child/parent pair to individualize treatment, with an emphasis on helping the family change eating and activity behaviors. Family meetings will be followed by separate child and parent group meetings lasting approximately 35-45 minutes. In both approaches, parents serve as primary implementers of the treatment for the child and, if overweight, for themselves. Group sessions provide education in diet and physical activity, parenting, and behavioral skills, although conditions differ in whether skills are prescribed or self-directed. Children and parents will be weighed at each clinic visit."
1822296|NCT00746642|Device|Mellitor device for glucose measurement|"Glucose measurement using Mellitor device"
1822297|NCT00746655|Radiation|Stereotactic Body Radiation Therapy (SBRT)|The first four patients will receive 50 Gy in 5 fractions (10 Gy /fx) over a 2 week period. The next four patients will be treated to a total dose of 60 Gy in 5 fractions (15 Gy/fx) over two weeks. The final four patients will receive 75 Gy in 5 fractions (15 Gy/fx) delivered over a 2-week period,
1822298|NCT00746655|Procedure|Transcatheter Arterial Chemoembolization (TACE)|. Intra-arterial cisplatin treatment will be given at a dose of 125 mg/m2. After delivery of the drug(s) to the tumor, embolization will be accomplished with Embospheres (Biosphere Medical, Inc.,Rockland, MA, USA) until moderate to marked stasis of antegrade flow is seen in the artery.
1822299|NCT00746668|Behavioral|Module 1: Visual Awareness and Eccentric Viewing|"In this module, awareness of the PRL location and eccentric viewing were trained. Exercises based on published sources were administered. One example of these exercises is the clock face display adapted from Holcomb and Goodrich and Maplesden.
This module also focused on awareness of the perceptual consequences of using a PRL. The purpose of these training exercises was to allow the subjects to appreciate perceptual alterations that occur when using a PRL and to practice making perceptual discriminations with the peripheral retina. Previously published work has demonstrated that perception in the peripheral retina can be affected by practice."
1822300|NCT00746668|Behavioral|Module 2: Control of Reading Eye Movements|In this module, control of eye movements was trained. These exercises began with a series of saccade tasks to nonalphabetical stimuli and then progressed to single letter, letter pairs, and word stimuli. Subjects were instructed to make a saccade between the dots. The experimenter provided feedback concerning the appropriateness of the saccades, and the alternation rate of the dots was increased as performance improved.
1822301|NCT00746668|Behavioral|Module 3: Reading Practice with RSVP|In module 3, we wanted to assess only the higher-level effects of reading practice. Subjects practiced reading using stimuli that did not require reading eye movements. An example is short sentences that were presented one word at a time at a single location on a screen (Rapid Serial Visual Presentation [RSVP]). At the end of the sentence, subjects reported whether the sentence made sense or not. We also had our subjects practice reading scrolled text. Although, eye movements and saccades may spontaneously occur under the text presentation conditions of this module, they are not the efficient saccades necessary for reading.
1822302|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 2mg, once daily for 4 weeks Pregabalin, Oral, 75 mg, twice daily for 4 weeks
1822303|NCT00746681|Drug|Tolterodine|Tolterodine SR, Oral, 4 mg, once daily for 4 weeks
1822304|NCT00746681|Drug|Placebo|Placebo, Oral, twice daily for 4 weeks
1822305|NCT00746681|Drug|Tolterodine & Pregabalin|Tolterodine SR Oral, 4mg, once daily for 4 weeks Pregabalin, Oral, 150 mg, twice daily for 4 weeks
1823856|NCT00757991|Genetic|polymorphism analysis|
1822306|NCT00746681|Drug|Pregabalin|Pregabalin, Oral, 150 mg twice daily for 4 weeks
1822307|NCT00746707|Device|1. Dermabond Topical Skin Adhesive 2-Octyl Cyanoacrylate|adhesive of perineal tears
1822308|NCT00746707|Procedure|3. traditional suturing with vicryl rapid 2X0|suturing of perineal tears grade one with vicryl rapid 2X0
1822309|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet 60 mg (orally), 120 mg (= 2 tablets a 60 mg) once daily, on day one post surgery
1822310|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), two tablets once daily, on day one post surgery
1822311|NCT00746720|Drug|Etoricoxib 60 mg|film coated tablet (orally), 120 mg (= 2 tablets a 60 mg) once daily, two hours before and 24 hours after surgery
1822312|NCT00746720|Drug|Placebo for Etoricoxib 60 mg|film coated tablet (orally), 2 tablets once daily, two hours before and 24 hours after surgery
1822313|NCT00746733|Drug|Lisdexamfetamine Dimesylate|50mg capsule
1822314|NCT00746733|Drug|Adderall XR (mixed salts amphetamine)|20mg capsule
1822315|NCT00746746|Biological|HyperAcute vaccine|1.8 mL weekly
1822316|NCT00746746|Drug|Pegylated Interferon-Alpha 2b|6.0 mcg/kg weekly
1822317|NCT00746759|Device|Biomarker (not used as an intervention)|This study is an observational study. There is no intervention.
1822318|NCT00746772|Drug|Purslane 235mg/day in one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months
1822319|NCT00746772|Drug|Placebo : one dosage|Patients had been clinically with OLP and confirmed by histopathological findings were selected for the study. Gender, age, medical history, symptoms, types, size, and site of the lesions , duration of disease and other treatment used for this disease were recorded. Local ethical committee approval was obtained before the trial started and all patients gave written informed consent. Patients were randomly divided into two groups .First group received systemic Purslane CAP with concentration antioxidant 235 mg/day in 1 dosage and second group used placebo CAP for 3 month. Each patients was examined at the beginning of the therapy ,and then 2 weeks after therapy and every 1 month up to 6 months .
1822320|NCT00746785|Drug|2.5 mg Olanzapine|2.5 mg
1822321|NCT00746785|Drug|5mg Olanzapine|5 mg
1822322|NCT00746785|Drug|placebo|placebo
1822323|NCT00746798|Biological|ChimeriVax-WN02 vaccine|low dose, approximately 4 x 3log10, given one time subcutaneously
1822324|NCT00746798|Biological|ChimeriVax-WN02 vaccine|medium dose, approximately 4 x 4log10, given one time
1822325|NCT00746798|Biological|ChimeriVax-WN02 vaccine|high dose, approximately 4 x 5log10, given one time subcutaneously
1822326|NCT00746798|Biological|Placebo|0.9%Normal Saline for Injection, given one time subcutaneously
1822329|NCT00746824|Drug|TM30339 and/or placebo|The drug and/or placebo will be injected in the abdominal area (site to vary for each injection). Injections will be administered twice daily for 28 days.
1822330|NCT00746837|Drug|AZD5672|single IV doses starting at 7 mg, subsequent doses to be confirmed following review of PK and safety data after each treatment period
1822331|NCT00746837|Drug|AZD5672|50 mg od, 12 days
1822332|NCT00746837|Drug|AZD5672|150mg od, 12 days
1822333|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with H (Harmonic)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with H (Harmonic scalpel)
1822334|NCT00746850|Procedure|early LC within 72 hours after the diagnosis with MD (Monopolar Diathermy)|early laparoscopic cholecystectomy within 72 hours after the diagnosis of acute cholecystitis with MD (Monopolar Diathermy)
1822335|NCT00746863|Drug|0.125% Marcaine|Patients randomized to the intervention arm will receive 60 cc of 0.125% Marcaine injected into the retropubic space along the tract that the suprapubic mid-urethral trocar will follow (one on each side) for a total of 120 cc of 0.125% Marcaine, prior to the placement of the mid-urethral sling via the suprapubic approach.
1822336|NCT00746876|Device|Unipolar hip hemiarthroplasty|Unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
1822337|NCT00746876|Device|Bipolar hip hemiarthroplasty|Bipolar hip hemiarthroplasty for the treatment of femoral neck fractures
1822338|NCT00746889|Drug|triamcinolone acetonide|single intraarticular injection of 40 mg of triamcinolone acetonide
1822339|NCT00746889|Drug|saline|Single intraarticular injection of 1 ml of 0.9% saline
1822340|NCT00746902|Device|nCPAP|Active nCPAP
1822341|NCT00746915|Device|EpiDetect|During the epidural needle insertion, data will be collected to characterize in real-time the electrical bioimpedance properties of the types of tissue along the path of the needle.
1822342|NCT00746928|Other|Chronic Intermittent Hypoxia|Chronic Intermittent Hypoxia mimicking the CIH undergone by patients suffering from Sleep Apnea Syndrome, is applied to Healthy subject during 8 hours a day (nights) for a 14 days period. The cycle of intermittent Hypoxia is 30 drop in SaO2 per hours with a 10% decrease in SaO2.
1822343|NCT00746941|Drug|mefloquine|250 mg orally each day for 3 days and then weekly up to 6 months.
1822344|NCT00746954|Drug|Acetazolamide|Cabonic Anhydrase inhibitor
1822345|NCT00746954|Drug|Buspirone|Agonist of a 5-HT1a receptor with some D2 agonist properties.
1822346|NCT00746967|Drug|sildenafil|sildenafil 50 mg (starting dose) tablet by mouth taken as needed 1 hour before anticipated sexual activity; the dose could be increased to 100 mg or decreased to 25 mg; the duration of therapy in this open-label study was 52 weeks
1822347|NCT00746980|Drug|efalizumab|1 mg/kg subcutaneously once weekly for 48 weeks, following an initial conditioning dose of 0.7 mg/kg at week 0.
1822348|NCT00746993|Other|Structured contraceptive counseling|Uniform set of visual information about contraception which a counselor will read out loud with each participant and answer questions.
1822395|NCT00747331|Drug|Placebo|"Intravenous infusion (saline)
Infused at the same rate (ml/h) as the experimental drug"
1822349|NCT00747006|Drug|TI Inhalation Powder and Humalog (Amendment 1)|Subcutaneous (sc) rapid acting analog to be administered at one half of the meal challenge visits 15 minutes before a meal. Only the last 5 - 10 patients (Type 2) will be undergoing this amendment to the protocol.
1822350|NCT00747006|Drug|TI Inhalation Powder (original protocol)|Inhaled insulin technology to be administered immediately before a meal (prandially) for glucose control in Type 1 or Type 2 diabetics
1822351|NCT00747019|Behavioral|Prosocial Behavior Physical Activity (PBPA)|The PBPA condition involves a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9. PBPA participants also earn boxes of food for donation to the Second Harvest Food Bank (SHFB) of Northwest North Carolina based upon their weekly physical activity.
1822352|NCT00747019|Behavioral|Physical Exercise (PE)|The PE condition is a center-based cognitive-behavioral intervention to teach participants the behavioral skills to engage in long-term (9-month) independent physical activity; delivered three times a week months 1-3; independent physical activity months 4-9.
1822353|NCT00747032|Drug|NYC 0462 Ointment|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
1822354|NCT00747032|Drug|Placebo|To assess the efficacy of NYC 0462 Ointment versus Placebo in the treatment of Plaque Psoriasis
1822355|NCT00747045|Other|Ventilation Strategy|Comparison of low vs standard tidal volumes in patients undergoing PTE
1822356|NCT00747058|Drug|PF-3864086|The dosage form is POS (powdered oral suspension). Each subject will have 5 periods and the frequency (and duration) is once per period. The doses have been left flexible within the protocol but are listed as: 3, 10, 30, 60, 120, 240, 480 and 720 mg with an option to insert an additional dose cohort as well.
1822357|NCT00747058|Drug|Placebo|Placebo
1822358|NCT00747071|Drug|Colostrum|Daily administration of Colostrum derived antibodies against C. difficile.
1822359|NCT00747084|Procedure|Colonoscopy|The purpose of the study is to conduct an RCT study to determine the effectiveness of loading the sigmoid colon with warm water and warm water irrigation for dealing with colonic spasms in enhancing patient abdominal comfort during unsedated colonoscopy.
1822360|NCT00747097|Drug|gemcitabine + cetuximab|gemcitabine 1g/m² 3weeks/4 cetuximab 400 mg/m² the first week, then 250 mg/m², every week Every cycle is 8 weeks treatment
1822361|NCT00747110|Drug|budesonide|3x 3mg budesonide capsules once daily
1822362|NCT00747110|Drug|mesalazine|3x 1000mg mesalazine onc daily
1822363|NCT00747123|Biological|ACE-011|ACE-011 given by the subcutaneous route of administration monthly for 4 doses.
1822364|NCT00747123|Biological|Placebo|Placebo given by the subcutaneous route of administration monthly for 4 doses.
1822365|NCT00747149|Drug|Rosuvastatin|Oral
1822366|NCT00747162|Device|Measure of muscle oxygenation|The investigators will use an INVOS oxymeter for muscle oxygenation measure.
1822367|NCT00747162|Device|Skin pigmentation determination|The investigators will use a DermaSpectrometer to get a reading from subjects' skin color
1822368|NCT00747175|Drug|AZD1656|Dose titration to 3 (alt 4) increasing dose-steps with oral suspension, 8 days treatment
1822369|NCT00747175|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose, 1 month treatment
1822370|NCT00747188|Behavioral|PBL|
1822371|NCT00747201|Behavioral|Replicating Effective Programs Framework for the Bipolar Care Model|Health care providers will receive adapted manuals, training, and technical assistance in the bipolar care model.
1822372|NCT00747201|Behavioral|Bipolar Care Model Package Only|Health care providers will receive only the adapted manuals.
1822373|NCT00747214|Drug|CRx-102|
1822374|NCT00747214|Drug|Placebo|
1822375|NCT00747214|Drug|DMARD Therapy|DMARD therapy can include methotrexate or other DMARD therapy
1822376|NCT00747227|Device|modified light transmission intraocular lens|violet visible light blocking acrylic intraocular lens
1822377|NCT00747227|Device|monofocal acrylic intraocular lens|conventional hydrophobic acrylic intraocular lens
1822378|NCT00747253|Device|AutoLITT system|laser treatment with the AutoLITT system
1822379|NCT00747279|Other|Carbohydrate restrictive strategy|Patients will receive intravenous hydration with a glucose free solution (Ringer III) and enteral nutritional formula containing 33.3% carbohydrates, 16.7% proteins and 50% lipids. These patients will receive regular insulin subcutaneously four times daily, aiming to maintain blood glucose levels at least below 180 mg/dl, and in stable patients, ideally below 150 mg/dl.
1822380|NCT00747279|Drug|Intensive insulin therapy|Continuous intravenous regular insulin infusion will be adjusted to maintain glycemic levels at least below 150 mg/dl, and, in stable patients and ideally, between 80 and 120 mg/dl. Patients will be submitted to capillary glycemic measurements every 2 hours. The insulin dose is adjusted according to an algorithm run by nurses and overseen by physicians. These patients will receive glucosaline (5% glucose + 0.9 NaCl) hydration and enteral nutrition with a formula containing 45% carbohydrates, 17% proteins and 38% lipids.
1822381|NCT00747292|Procedure|epidural|Patients in this limb receive epidural analgesia
1822382|NCT00747292|Procedure|PCA|Patients in this limb receive a PCA for their pain control
1822383|NCT00747292|Procedure|Spinal|Patients in limb will receive spinal analgesia
1822384|NCT00747305|Drug|sunitinib malate|
1822385|NCT00747305|Genetic|gene expression analysis|
1822386|NCT00747305|Genetic|reverse transcriptase-polymerase chain reaction|
1822387|NCT00747305|Genetic|western blotting|
1822388|NCT00747305|Other|immunohistochemistry staining method|
1822389|NCT00747305|Other|laboratory biomarker analysis|
1822390|NCT00747305|Procedure|adjuvant therapy|
1822391|NCT00747305|Procedure|neoadjuvant therapy|
1822392|NCT00747305|Procedure|therapeutic conventional surgery|
1822393|NCT00747318|Drug|SKP FlutiForm HFA pMDI|Each subject will receive SKP FlutiForm HFA pMDI 250/10 microgram twice daily for 60 weeks (two actuations of SKP FlutiForm HFA pMDI 125/5 microgram/actuation) for a total daily dose of 500 microgram fluticasone propionate and 20 microgram formoterol fumarate.
1822394|NCT00747331|Drug|Fenoldopam mesilate|Continuous intravenous infusion at 0.1 mcg/kg/min starting immediately before CPB and ending after 12 hours from the end of the operation
1822438|NCT00747877|Drug|cyclophosphamide|Given orally
1822396|NCT00747344|Drug|Placebo - Controlled Period (CP)|Placebo, Weeks 0-12
1822397|NCT00747344|Drug|Ustekinumab 45 mg - CP|Ustekinumab 45 mg, Weeks 0-12
1822398|NCT00747344|Drug|Placebo to ustekinumab 45 mg - after CP|Placebo at Weeks 0 and 4, then ustekinumab 45 mg at Week 12 and Week 16
1822399|NCT00747344|Drug|Ustekinumab 45 mg - after CP|Ustekinumab 45 mg at Weeks 0 and 4, then placebo at Week 12 and ustekinumab 45 mg at Week 16
1822400|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Drug Eluting Balloon is followed by Bare Metal Stent
1822401|NCT00747357|Device|Drug Eluting Balloon SeQuent Please|Bare Metal Stent followed by Drug Eluting Balloon
1822402|NCT00747370|Procedure|movement of midurethra, bladder neck, cervix and rectum|
1822403|NCT00747383|Drug|Glimepiride|3mg oral tablet.
1822404|NCT00747383|Drug|Sitagliptin|100mg oral tablet.
1822405|NCT00747396|Other|Foster Care Placement|A group of children living in institutions for children in Bucharest, Romania was randomly assigned to placement in foster care. Foster parents were recruited, consented to background checks, and received training in Romanian. Prior to placement, foster parents visited their children to begin developing a relationship with the child. Once hired, foster parents were supported and monitored by project social workers. Foster parents in the BEIP network received frequent visits from the social workers, with visits occuring weekly for several months after initial placement of the child, then biweekly and later monthly. Foster parents also had the opportunity to participate in a support group organized by project social workers. Project social workers received weekly consultation from US staff experienced in dealing with young children in foster care.
1822406|NCT00747409|Drug|insulin aspart and detemir (NovoRapid, Levemir)|use of basal-bolus therapy with insulin aspart and detemir
1822407|NCT00747409|Drug|human regular insulin and NPH insulin (Actrapid, Protaphne)|basal-bolus therapy with human regular and NPH insulin
1822408|NCT00747422|Device|Ulthera™ System|ultrasound treatment
1822409|NCT00747435|Device|Electric Acoustic System|Combination of a cochlear implant and a hearing aid
1822410|NCT00747461|Device|CryoSpray Ablation|Cryospray Ablation up to 4 -5 second cycles for up to 4 treatments in the first 30 days
1822411|NCT00747474|Drug|Lipotecan|Lipotecan IV day 1, 8, 15
1822412|NCT00747487|Drug|Idebenone|Idebenone 900 mg/day
1822413|NCT00747487|Drug|Placebo|Placebo
1822414|NCT00747526|Drug|Rabeprazole sodium 5 mg|Type= exact number, unit= mg, number= 5, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to Day 5; possible extension using 5 mg once daily up to 28 consecutive days.
1822415|NCT00747526|Drug|Rabeprazole sodium 10 mg|Type= exact number, unit= mg, number= 10, format= bead suspension formulation, route= oral use. Rabeprazole sodium 0.5 mg/kg (using increments of 1 mg dose) once daily from Day 1 to up to Day 14; possible extension using 10 mg once daily up to 28 consecutive days.
1822416|NCT00747539|Drug|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV)|Pegylated interferon alfa and ribavirin (PEG-IFN/RBV), considered standard care for patients with chronic HCV, will be given to participants.
1822417|NCT00747565|Device|Tecnis ZM900 Multifocal Intraocular Lens|Investigational intraocular lens
1822418|NCT00747565|Device|CeeOn 911A monofocal IOL|Monofocal Control IOL
1822419|NCT00747604|Biological|mecasermin [rDNA origin] injection|As prescribed by the physician.
1822420|NCT00747617|Drug|recombinant human chorionic gonadotropin|Each subject will receive a dose (1, 10, 25, 100, or 250 micrograms) of human chorionic gonadotropin administered intravenously on 5 separate occasions.
1822421|NCT00747630|Other|An educational video about Fetal Alcohol Syndrome|A 20 minute video about FAS
1822422|NCT00747643|Drug|varenicline|Participants in this group received varenicline according to the schedule in the Arm Description.
1822423|NCT00747643|Drug|placebo|Participants in this group received a placebo and did not receive any active medication according to the schedule in the Arm Description.
1822424|NCT00747669|Drug|lidocaine 70mg and tetracaine 70mg topical patch|One Synera Patch applied for 30 minutes.
1822425|NCT00747695|Drug|Rabeprazole sodium|
1822426|NCT00747708|Drug|Granulocyte-colony stimulating factor|5 days subcutaneous injection
1822427|NCT00747708|Procedure|Percutaneous intracoronary injection|Bone marrow derived stem/progenitor cells or placebo infusion is delivered through an over-the-wire balloon catheter into the target coronary vessels using a stop-flow technique.
1822428|NCT00747708|Procedure|Percutaneous intramyocardial injection|Direct intramyocardial injections of bone marrow derived stem/progenitor cells or placebo will be delivered using the electromechanical NOGA mapping and injection system
1822429|NCT00747721|Drug|Dexmedetomidine|2 ml ampoule containing 200 micrograms dexmedetomidine for dilution with 48 ml 0/9% sodium chloride injection. Titrated to efficacy.
1822430|NCT00747734|Drug|MNRP1685A|Escalating intravenous dose
1822431|NCT00747747|Biological|Saline solution|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
1822432|NCT00747747|Device|Sinuclean DM Spray|3 sprays per nostrils twice a day (morning and evening); in case of need a third nebulization between the two is allowed
1958545|NCT01535001|Other|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
1822434|NCT00747799|Drug|Sorafenib plus Cisplatin and 5-fluorouracil|"Sorafenib with Cisplatin and 5-fluorouracil as first-line treatment of recurrence after radiotherapy patients who failed with radiotherapy in recurrent or metastatic nasopharyngeal carcinoma (NPC)
Sorafenib 400 mg bid per daily . Every 21-day cycles.
Cisplatin 80 mg/m2 day d1, every 21 days cycle.
5-fluorouracil 1000 mg/m2 day CIV 4days, repeat 21-day cycles"
1822435|NCT00747812|Device|Precision|Implantable Neurostimulator
1822436|NCT00747825|Drug|131-I-MIP-1145|IV injection between 4.0 to 6.0 mCi (148-222 MBq) of 131-I-MIP-1145
1822437|NCT00747838|Procedure|Minimally Invasive Maze Procedure|Minimally Invasive Surgical Correction of Atrial Fibrillation.
1958546|NCT01535001|Behavioral|Information|"Information on knee osteoarthritis, and on what they can do to treat the disorder and prevent it from being worse.
Information will be given in a leaflet."
1958547|NCT01535001|Drug|Paracetamol|1 g x 4/day
1958548|NCT01535001|Drug|Burana|400 mg x 3/day for three weeks
1822440|NCT00747877|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous hematopoietic stem cell transplantation on day 0.
1822441|NCT00747890|Procedure|Modified tonsillectomy|"Tonsillectomy
Uvulectomy
Soft palatal resection
Lifestyle counselling by physician: General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance"
1822442|NCT00747890|Other|Lifestyle counselling by physician|General (e.g. avoidance of smoking, alcohol drinking) and nutritional education, and sleeping positional guidance.
1822443|NCT00747903|Drug|aminolevulinic acid hydrochloride|
1822444|NCT00747916|Device|CryoSpray Ablation (TM) System|Subjects will be treated with spray cryotherapy using the CryoSpray Ablation (TM) System at Day 0 using up to 3 cycles of 10-40 second sprays as the studied dosimetry and will cover the affected area, including the tumor and the parietal pleural surface. If disease exists bilaterally, only one side will be sprayed. Subjects will be assessed 2-5 days from the initial treatment (Day 0) to check for mucosal sloughing, to reassess tumor burden and for additional CSA therapy as needed.
1822445|NCT00747929|Drug|Placebo|Total of 54 weeks, four placebo tablets (total dose = 0 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet
1822446|NCT00747929|Drug|S-2367 800 mg|Total of 54 weeks, two 400 mg S-2367 tablets and two placebo tablets (total dose = 800 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet
1822447|NCT00747929|Drug|S-2367 1600 mg|Total of 54 weeks, four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once-a-day with morning meal while on a reduced calorie diet
1822448|NCT00747942|Behavioral|Support for Increased Physical Activity|Exercise referral combined with individual support, access to structured group exercise programs, and motivational support
1822449|NCT00747968|Drug|Byetta, Exenatide|Drug: Exenatide or placebo Dosage form: Infusion Dosage: Exenatide (Eli Lilly/Amylin Pharmaceuticals) 0.066 pmol*kg-1*min-1 Duration: 5 hours Frequency: Drug given once, placebo given once
1822450|NCT00747981|Procedure|Thoracic CT Scan|Perform a CT Scan and an endoscopy
1822451|NCT00748007|Drug|Rivastigmine|Exelon (1.5mg/cap) 1.5 mg bid
1822452|NCT00748020|Procedure|UVB phototherapy|Group 1: every irradiation an increase of 40%, starting with 70% of the minimal erythema dose
1822453|NCT00748020|Procedure|UVB phototherapy|Group 2: every irradiation an increase of 20%, starting with 30% of the minimal erythema dose
1822454|NCT00748046|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight.
1822455|NCT00748059|Procedure|Standing or upright tilt|stand upright or tilt table test
1822456|NCT00748059|Procedure|Microneurography|Recording from sympathetic nerve
1822457|NCT00748059|Procedure|QSweat|quantitative sweat testing
1822458|NCT00748059|Device|neck cuff stimulation|Blood pressure receptors in the neck arteries may be stimulated by applying suction through a collar around the neck.
1822459|NCT00748059|Drug|phenylephrine,isoproterenol,nitroprusside,propranolol,edrophonium,atropine,tyramine|"IV Pharmacological Testing
phenylephrine 12.5 - 400 ug, isoproterenol 0.1 - 0.4 ug or higher until desired effect, nitroprusside 0.1 - 1.6 ug/kg, propranolol 1.1 mg/min, edrophonium maximum of 10 mg, atropine .01 mg/kg, tyramine 250-4000 ug or higher until desired effect"
1822460|NCT00748059|Drug|clonidine,yohimbine,metoclopramide,alpha-methyldopa|"Oral Pharmacological Testing
clonidine 0.1-0.3 mg, yohimbine 5-10 mg, metoclopramide 10 mg, alpha-methyldopa 62.5 mg, placebo"
1822461|NCT00748059|Procedure|BodPod|Determination of body composition
1822462|NCT00748059|Procedure|Eye exam|"Examination of pressure in the eye and eyelid fatiguability. The following eyedrops might be used:
0.5% proparacaine (Alcaine, Allergan, Inc)
Fluress (0.4% benoxinate hydrochloride, fluorescein sodium, Akorn, Inc)
0.5%, 1% tropicamide (Mydriacyl, Alcon)
Over-the-counter preservative-free artificial tears
0.25%, 2.5% and 10% phenylephrine (Bausch and Lomb)
1% cyclopentolate hydrochloride (Alcon)"
1822463|NCT00748059|Procedure|Sleep study|Recording of sleep pattern overnight
1822464|NCT00748059|Procedure|Pain response testing|Subjects will rate the quality and intensity of 2 pain tasks.
1822465|NCT00748059|Procedure|Metabolic chamber|Determination of metabolic rate via 24hr stay in whole-room indirect calorimeter
1822466|NCT00748059|Procedure|Brain function studies|Questionnaires and computer tasks, an EEG and an MRI may be used to assess brain function.
1822467|NCT00748059|Procedure|Bicycle Exercise Test|Blood pressure and heart rate may be monitored while exercising on a stationary bicycle.
1822468|NCT00748072|Drug|DDAVP|0.3 mcg/kg subcutaneous
1822469|NCT00748072|Drug|saline solution|saline solution 1 ml subcutaneous
1822470|NCT00748085|Device|CryoSpray Ablation|Treatment dosimetry will be up to 4, 5-second spray cycles. Subjects will have initial cryospray treatment. Subjects may undergo up to one bronchoscopy with CryoSpray Ablation every seven days for a total of four (4) treatments in the first month.
1822471|NCT00748098|Drug|GSK1838262 Extended Release Tablets|GSK1838262 extended release tablets
1822472|NCT00748098|Drug|Placebo|Placebo
1822473|NCT00748111|Other|Blood sample|Blood sample and thrombus sample
1822474|NCT00748124|Device|PleuraSeal Sealant System|Lung Sealant Device + standard tissue closing techniques (sutures/staples)
1822475|NCT00748124|Procedure|Standard Tissue Closure Techniques|Standard tissue closure techniques (sutures/ staples) alone
1958549|NCT01535001|Drug|Pantoprazole|20mg x 1/day for three weeks
1958550|NCT01535001|Behavioral|Dietary counseling|For participants with a BMI equal to or >25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
1822478|NCT00748150|Biological|Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009|1 dose, 0.5 mL of Flu Vaccine Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2008-2009
1822479|NCT00748163|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1822480|NCT00748163|Drug|sunitinib malate|
1822481|NCT00748176|Procedure|spinal anesthesia|spinal anesthesia with bupivacaine
1822482|NCT00748189|Drug|chlorambucil, tablets|2mg tablets, chlorambucil dose: 10mg/m2 PO at days 1-7 every 28 days; duration: minimum of 3 cycles until best response or maximum of 12 cycles
1822483|NCT00748189|Drug|ofatumumab (GSK1841157) infusion|iv infusion; dose: cycle 1 300mg day 1 and 1000mg day 8, subsequent cycles: 1000mg at day 1 every 28 days;
1822484|NCT00748202|Drug|C1-Esterase Inhibitor|1000 I.E.
1822485|NCT00748215|Drug|calcium aluminosilicate anti-diarrheal|Given orally
1822486|NCT00748215|Other|placebo|Given orally
1822487|NCT00748228|Dietary Supplement|dietary sodium|10 mEq/day
1822488|NCT00748228|Dietary Supplement|dietary sodium|300 mEq/day
1822489|NCT00748228|Dietary Supplement|dietary sodium|150 mEq/day dietary sodium
1822490|NCT00748241|Device|Astra Tech Fixture ST|Astra Tech Fixture ST Ø 3.5 and 4.5 cm in lengths of 9, 11, 13, 15, 17 and 19 mm.
1822491|NCT00748254|Procedure|Laser Based Photoacoustic Tomography, MRI, Ultrasound|Healthy subjects will have scans on all finger joints of the hand with the scanning methods described above.
1822492|NCT00748254|Procedure|laser based photoacoustic tomography, MRI, ultrasound|Subjects with arthritis will have scans on all finger joints of the hand with the scanning methods described above.
1822493|NCT00748267|Other|questionnaire administration|
1822494|NCT00748267|Procedure|hypnotherapy|
1822495|NCT00748267|Procedure|therapeutic conventional surgery|
1822496|NCT00748280|Procedure|One-visit root canal therapy|Teeth were isolated, caries was removed and access cavities were prepared. Canal preparation was conducted using step-back technique. The working lengths were determined and confirmed by radiographs. The minimum size file for preparing the working length was size ISO #25 K-file to within 0.5-2 mm of the radiographic apex of the root. During hand instrumentation, canals were frequently irrigated with adequate amount of sterile normal saline solution. The root canals were filled with multiple gutta-percha cones and sealer using lateral condensation technique. Placing a cotton pellet in the pulp chamber, the access cavity was temporarily filled. The treatments of all samples were performed one-visit.
1822497|NCT00748280|Procedure|pulpotomy|Pulpotomy was performed with a large round bur in a high-speed handpiece with copious irrigation; removing inflamed pulp tissue to stump level. Hemostasis was achieved by irrigation of the cavity with sterile normal saline and application of small pieces of sterile cotton pellets. The blood clot-free pulpal wound was covered with approximately 2 mm layer of endodontic bio-materials, a sterile wet cotton pellet was then placed over the MTA/CEM cement and the cavity sealed with Cavit.
1822498|NCT00748293|Other|Low-residue diet|Commercialized (not yet marketed)low-residue diet
1822501|NCT00748319|Other|Detection of KIR receptor by RT PCR|Detection on biopsy cutaneous (3mm) and on blood sample of 30 ml
1822502|NCT00748332|Dietary Supplement|Fortimel Extra®|2 bottles (600 kcal, 40 g proteins) per day
1822503|NCT00748332|Dietary Supplement|Fortimel Care®|Fortimel Care® : 2 bottles (660 kcal, 36 g proteins, 2.38 g EPA) per day
1822504|NCT00748345|Drug|Caspofungin (drug)|pharmacokinetics of caspofungin in burn patients after a single usual dose (70 mg i.v.), in order to determine the optimal dose in this population
1822505|NCT00748358|Drug|sunitinib|37.5 mg orally once daily, continuously, for 6 cycles of 6 consecutive weeks.Dose increase or reduction of 12.5 mg increments and change of schedule is recommended based on individual safety and tolerability.
1822506|NCT00748371|Drug|aspirin|40mg aspirin: one 40-mg aspirin capsule by mouth each morning + one Avicel capsule by mouth each evening
1822507|NCT00748371|Drug|aspirin|1300mg aspirin: one 650-mg capsule by mouth twice daily
1822508|NCT00748371|Drug|placebo|Placebo: one Avicel (cellulose) capsule by mouth twice daily
1822509|NCT00748397|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
1822511|NCT00748423|Drug|Nitric Oxide|NO in inhalation for 3 days
1822512|NCT00748423|Drug|Placebo|Placebo in inhalation for 3 days
1822513|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + placebo tablet) BID per os 12 weeks
1822514|NCT00748436|Drug|betahistine dihydrochloride|(24mg tablet Betahistine + 24mg tablet Betahistine) BID per os 12 weeks
1822515|NCT00748436|Drug|placebo|(placebo tablet + placebo tablet) BID per os 12 weeks
1822516|NCT00748449|Procedure|Colonoscopy|1 Colonoscopy
1822517|NCT00748449|Procedure|CT-colonography|1 CT-colonography; Procedure/Surgery/Radiation
1822518|NCT00748462|Device|Fractional CO2 Laser|"the treatment settings:
Pulse duration : 5 to 7ms depending on skin reaction
Spot Density: 49 MTZ/cm2 (Low density)
Power: 15 W = (75 - 105) mJ/MTZ"
1822519|NCT00748475|Behavioral|Neurofeedback|
1822520|NCT00748488|Other|Physical therapy aimed to move safely|"Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease solely focused on safety of movement.
Duration program: 2 years Maximum number of sessions: 35 per year Duration sessions: 30 minutes"
1822521|NCT00748488|Other|Physical Therapy aimed to improve Physical Activity|Physical Therapy according to the Dutch guidelines for Physical Therapy in Parkinson's Disease combined with a coaching program aimed to promote the level of physical activity Duration program: 2 years Maximum number of sessions: 35 per year Duration of sessions: 30 minutes
1822522|NCT00748501|Drug|SB-509|Intramuscular injection of 60 mg of SB-509. Two doses on Day 0 and Day 90.
1822523|NCT00748527|Drug|carboplatin|Given IV
1822524|NCT00748527|Drug|decitabine|Given IV
1822525|NCT00748540|Device|Vibrant Soundbridge|Mixed and conductive hearing loss using round window stimulation
1822526|NCT00748553|Drug|Azacitidine (Vidaza)|50mg/m2, 75mg/m2 or 100mg/m2 daily for 5 days for each 4-week cycle
1822527|NCT00748553|Drug|Nab-paclitaxel (Abraxane)|100mg/m2 weekly for 3 weeks of each 4-week cycle
1822528|NCT00748566|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40 to 160 mg total daily dose) for up to 1 year.
1822529|NCT00748579|Drug|CK-1827452|I.V. infusion for 0.5 hour at 54mg/hr followed by 1 hour at 21mg/hr
1822530|NCT00748579|Drug|CK-1827452|I.V. infusion for ≤ 1 hour at 72mg/hr followed by 1 hour at 36mg/hr
1822531|NCT00748592|Drug|Placebo|Subjects in this arm will be administered 3 capsules of placebo 30 minutes before bedtime for two consecutive nights in the sleep lab.
1822532|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 5 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
1822533|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 15 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
1822534|NCT00748592|Drug|PD 0200390|Subjects in this arm will be administered 3 capsules totaling 30 milligrams 30 minutes before bedtime for two consecutive nights in the sleep lab.
1822535|NCT00748605|Drug|Placebo|Total of 60 weeks of double-blind dosing, four placebo tablets (total dose = 0 mg/day S-2367) administered orally once daily with AM (ante meridiem) meal while on both LCD (low calorie diet) and RCD (reduced calorie diet)
1822536|NCT00748605|Drug|Placebo plus S-2367|Total of 6 weeks of double-blind dosing, with four placebo tablets (total dose = 0 mg/day S-2367) during LCD and 54 weeks of four 400 mg S-2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on RCD
1822537|NCT00748605|Drug|S-2367|Total of 60 weeks of double-blind dosing, four 400 mg S- 2367 tablets (total dose = 1600 mg/day S-2367) administered orally once daily with AM meal while on both LCD and RCD
1822538|NCT00748618|Dietary Supplement|vitamin D3|10,000 I.U./wk of vitamin D3 orally for 6 months
1822539|NCT00748618|Dietary Supplement|vitamin D3|50,000 I.U./wk of vitamin D3 orally for 6 months
1822540|NCT00748631|Device|balloon kyphoplasty|A bilateral approach is chosen to insert working cannulas into the posterior part of the vertebral body through a posterior transpedicular approach.Once inserted, the balloons are inflated using visual, volume and pressure control to create a cavity.The balloons are then deflated and removed. The Bone Filler Device is then advanced through the working cannula towards the anterior part of the cavity and cement is slowly extruded by a stainless steel stylet, acting as a plunger. When the amount of cement from the first Bone Filler Device is delivered in the cavity, it is removed and another Bone Filler Device is advanced through the working cannula.
1822541|NCT00748644|Drug|Rituximab|"rituximab infusion will be performed at J1, J15, M6, M12 and M18(i.e. a total of 5 infusions), at the dose of 500 mg at a fixed dosage.
All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
1822542|NCT00748644|Drug|Azathioprine|"azathioprine (2 mg/kg/d) for 12 months, then progressively tapered until its discontinuation at month 22.
All patients received corticosteroids, starting from induction with prednisone (or equivalent) at a dose of 1 mg/kg/day with gradual tapering according to a regimen adjusted to body weight over a mean of 18 months since diagnosis."
1822543|NCT00748657|Biological|Bevacizumab|Given IV
1822544|NCT00748657|Other|Laboratory Biomarker Analysis|Correlative studies
1822545|NCT00748670|Device|Fixture MicroThread (Micro-Macro)|Fixture MicroThread (Micro-Macro) Ø 3.5 and 4.0 mm in lengths of 9, 11, 13, 15 and 17 mm.
1822546|NCT00748683|Other|RFID|A RFID tag attached on subjects' clothes 24hr a day during 1 month.
1822547|NCT00748696|Dietary Supplement|Fortimel Extra®|260kcal and 20g protein per day
1822548|NCT00748696|Other|resistance training|3 sessions of resistance training per week
1822549|NCT00748696|Other|combined treatment|260kcal and 20g protein per day 3 sessions of resistance training per week
1822550|NCT00748709|Drug|BIBW 2992 (Afatinib)|BIBW 2992 (Afatininb) for patients FISH positive for/or harboring EGFR or HER2 Mutation
1822551|NCT00748722|Device|CT Angiography|Injection of contrast material (iodine)
1822552|NCT00748735|Procedure|Implantation of a cardiac resynchronization therapy device|
1822553|NCT00748735|Procedure|Echocardiography (myocardial deformation imaging)|
1822554|NCT00748748|Biological|Culturelle|10^10 Lactobacillus rhamnosus GG per capsule
1822555|NCT00748761|Behavioral|Cognitive Behavioral Therapy (CBT)|Nondrug psychotherapy administered weekly for 12 weeks
1822556|NCT00748761|Behavioral|Waitlist|Contact waitlist weekly for 12 weeks
1822557|NCT00748774|Behavioral|Questionnaire|Two questionnaires taking about 10 minutes to complete.
1822558|NCT00748787|Drug|Ispaghula husk|1 sachet of effervescent powder containing 5 gr of product (3.5 g of Ispaghula husk), b.i.d. during 16 weeks. Oral route.
1822559|NCT00748787|Drug|Placebo|1 sachet of effervescent powder b.i.d. during 16 weeks, oral route.
1822560|NCT00748800|Behavioral|Affect Management|5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
1822561|NCT00748800|Behavioral|General Health Promotion|5 session group focused on delivering general health promotion information in didactic format
1822562|NCT00748813|Biological|Influenza Vaccine, Formulation 2008-2009|1 dose of Surface Antigen, Inactivated, Influenza Vaccine, Formulation 2008-2009
1822563|NCT00748826|Biological|Infliximab|"Patients with active rheumatoid arthritis (RA) confirmed with American College of Rheumatology (ACR) criteria could take part in the project if they did not respond sufficiently to disease-modifying products, including methotrexate, received Infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of
Infliximab therapy with additional infusions of 5 mg/kg at week 2"
1822564|NCT00748852|Drug|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
1822565|NCT00748865|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops 1 drop each eye one time
1822566|NCT00748865|Other|Systane Lubricant Eye Drops|Systane Lubricant Eye Drops 1 drop each eye one time
1822567|NCT00748891|Drug|Recentin (Cediranib)|30mg once daily, oral dose
1822568|NCT00748904|Drug|Rifaximin|400 mg orally
1822569|NCT00748904|Drug|Lactulose|20 grams titrate to 2-3 bowel movements in one day
1822570|NCT00748930|Other|Retrospective Chart Review and Data collection|Retrospective Chart Review and Data collection
1822571|NCT00748943|Other|Chlorine Dioxide|Experimental mouthwash (ClO2 Fresh®) contained 0.16% sodium chlorite (NaClO2)
1822572|NCT00748956|Drug|Low dose NPY|50nmol, administered intranasally
1822573|NCT00748956|Drug|High dose NPY|100nmol administered intranasally
1822574|NCT00748956|Drug|Placebo|placebo comparator (0nmol)) administered intranasally
1822618|NCT00749385|Drug|PN 400|A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)
1822575|NCT00748969|Drug|Somatropin (DNA origin)|The study starting dose of Nutropin AQ® will be 0.48 mg/kg/week divided into daily SC injections. Nutropin AQ® will be administered by either the subject or, if unable to demonstrate competency in this, then by the guardian. To decrease the risk of increased intracranial hypertension, the dose in the first month of treatment will be decreased by 50% (0.24 mg/kg/week), and then increased to 0.48 mg/kg/week if tolerated well after 1 month.
1822576|NCT00748982|Drug|AZD1305|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
1822577|NCT00748982|Drug|Placebo|iv single infusion: initial iv loading dose which will be followed by a maintenance dose given for a maximum of 90 minutes
1822578|NCT00749021|Drug|Ranibizumab|0.5 mg of intravitreal ranibizumab monthly for 12 months
1822579|NCT00749021|Drug|Ranibizumab|0.5 mg intravitreal injection of ranibizumab for 4 months followed by PRN dosing
1822580|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal ranibizumab monthly for 12 months
1822581|NCT00749021|Drug|Ranibizumab|2.0mg of intravitreal injection of Ranibizumab for 4 months followed by PRN dosing
1822582|NCT00749034|Biological|VPM1002|live vaccine
1822583|NCT00749034|Biological|BCG|commercially available live vaccine BCG
1822584|NCT00749047|Drug|Pioglitazone|15-45 mg/day
1822585|NCT00749060|Other|conventional treatment|with our without brace
1822586|NCT00749060|Procedure|kyphoplasty with balloons|Balloon Kyphoplasty which consists of placing through a percutaneous posterior approach under radiological guidance, into the fractured vertebra a balloon which is inflated with fluid and creates a cavity. This may restore part of the vertebral height loss due to the fracture. In addition, after balloon deflation, polymethylmetacrylate cement is injected with low pressure into the created cavity.
1822587|NCT00749060|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
1822588|NCT00749073|Device|Minimally Invasive Lumbar Decompression (MILD™)|The arthroscopic devices in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
1822589|NCT00749086|Device|balloon kyphoplasty|Balloon Kyphoplasty, a variant of Vertebroplasty, in which a balloon is first placed into the fractured vertebra and inflated with fluid in order to create a cavity. Then, the balloon are deflated and removed. This may restore part of the vertebral height loss due to the fracture and facilitate the injection of the cement with low pressure.
1822590|NCT00749086|Procedure|vertebroplasty|Vertebroplasty consisting in the percutaneous injection into the fractured vertebra of polymethylmetacrylate cement (the cement used to fix prosthesis in joint replacement) through a posterior route through the vertebral pedicles under radiological guidance
1822591|NCT00749099|Drug|pancrelipase|"The test drug (PANCRECARB® [pancrelipase] - Phase II) with a standardized Lundh meal.
Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
1822592|NCT00749099|Drug|placebo|"5 capsules of a placebo drug (Phase I) with a standardized Lundh meal.
Gastric samples are collect once an hour and duodenal samples are collected every 15 minutes for each phase (4 hours each)."
1822593|NCT00749112|Drug|Alemtuzumab, Rituximab|Alemtuzumab 10 mg each 24 hrs subcutaneous for 3 days. Rituximab 100 mg IV every week for 4 weeks.
1822595|NCT00749138|Drug|tamoxifen|giving drug tamoxifen
1822596|NCT00749151|Behavioral|telephone counseling|First time callers to telephone help line agreed to one year follow-up on smoking cessation.
1822597|NCT00749164|Procedure|MSC transplantation|1-2X10^6 MSC per kg
1822598|NCT00749177|Other|Traditional Healing options|Dream work, energy healing, healing circles, pipe ceremonies, self care, smudging, sweat lodges and traditional learning.
1822599|NCT00749190|Drug|BI 10773|
1822600|NCT00749190|Drug|placebo|
1822601|NCT00749190|Drug|sitagliptin|
1822604|NCT00749216|Drug|Solanezumab|
1822605|NCT00749229|Device|balloon kyphoplasty|During the same surgery or some days later on, percutaneous Balloon kyphoplasty of the fractured vertebral body (ies) using polymethylmetacrylate cement injection through a posterior transpedicular approach will be carried out in replacement of anterior spine surgery to restore vertebral body strength
1822606|NCT00749242|Other|orthopedic brace|antalgic drugs and orthopedic brace
1822607|NCT00749242|Device|balloon kyphoplasty|introduction of balloon into the vertebral body, inflation of the balloon which creates a cavity, then balloon is deflated and removed , then introduction of the cement into the cavity.
1822608|NCT00749268|Device|AbsorbaTack|Comparison of different devices for mesh fixation. This intervention arm has absorbable tacks as the method of hernia mesh fixation. Application is during hernia repair and tacks will essentially absorb within the body after 1 year.
1822609|NCT00749268|Device|ProTack|Comparison of different devices for mesh fixation. This intervention is a permanent tack for hernia mesh fixation. Application is during hernia repair and the tacks will remain in the body.
1822610|NCT00749307|Dietary Supplement|Docosahexaenoic acid (DHA)|
1822611|NCT00749307|Dietary Supplement|Placebo|
1822612|NCT00749320|Other|Arterial Spin Labeling Magnetic Resonance Imaging|ASL MRI performed at different time intervals on participants receiving sunitinib or pazopanib for treating RCC
1822613|NCT00749333|Drug|AZD8566|solution. Specific dose will be selected by the safety review committee
1822614|NCT00749333|Drug|Placebo|Single 10ml oral solution.
1822615|NCT00749346|Device|NovoTTF-100L|TTFields treatment 12h/d for the duration of the study (until progression)concomitant to standard Alimta dosing
1822616|NCT00749359|Drug|Paxil CR|Paxil CR 37mg tablet manufactures at two different sites
1822617|NCT00749372|Other|T2* Cardiac and Liver MRI|Patients will undergo an MRI of the heart and liver.
1822868|NCT00750113|Drug|Nifidipine|Tablets 20 Mg daily for 4 weeks then combination therapy
1822619|NCT00749385|Drug|EC naproxen plus EC esomeprazole|Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)
1822620|NCT00749385|Drug|EC naproxen|Enteric-coated naproxen tablet (500mg)
1822621|NCT00749385|Drug|EC esomeprazole|Enteric-coated esomeprazole capsule (20mg)
1822622|NCT00749398|Biological|Infliximab|According to local country regulations.
1958551|NCT01535001|Behavioral|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
1958552|NCT01535001|Other|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes."
1822625|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
1822626|NCT00749424|Device|SES|CYPHER SELECT™ Sirolimus-eluting Balloon-expandable Coronary Stent
1822627|NCT00749437|Radiation|3-dimensional conformal accelerated partial breast irradiation|Accelerated partial breast irradiation following lumpectomy with placement of Acculoc fiducial markers.
1822628|NCT00749450|Drug|capecitabine|Given orally
1822629|NCT00749450|Drug|fluorouracil|Given IV
1822630|NCT00749450|Drug|oxaliplatin|Given IV
1822631|NCT00749463|Drug|Nicotine Gum|2 mg or 4 mg for 12 week treatments and followed by 12 week off-treatment follow-up. Recommend subject to use 8-12 pieces daily for first 8 weeks and 4-6 pieces daily the next 2 weeks, then reduce to 1-3 pieces each day in last 2 weeks
1822632|NCT00749463|Drug|Nicotine Patch|Each will use 15 mg/16 h patch for the first 8 weeks, 10 mg/16 h for the following 2 weeks and 5 mg/16 h for the last 2 weeks. Then followed by 12 week off-treatment follow-up.
1822633|NCT00749476|Biological|Factor IX recovery|
1822634|NCT00749489|Procedure|Femoral Nerve Block|Patients assigned to the intervention group will have a femoral nerve block administered by the attending emergency department physician. Twenty-four hours after the femoral nerve block or at the time of surgery, an anesthesiologist will insert a continuous fascia iliaca block. Both procedures (femoral nerve block and fascia iliaca blocks) are standard anesthetic techniques that are used in orthopedic procedures but their efficacy as compared to standard opioid therapy has not been evaluated in controlled clinical trials in hip fracture. The medications that will be used in each procedure are as follows: 1) femoral nerve block: 0.5% bupivacaine with 1:300,000 epinephrine; 2) fascia iliaca block: 0.2% ropivacaine will be infused at 5ml/hr.
1822635|NCT00749502|Drug|MK-4827|MK-4827 in 10 mg and 100 mg capsules given daily in a 21 day dosing cycle (dose escalation to RP2D).
1958554|NCT01528592|Drug|Carbidopa-Levodopa|Equivalent amount of carbidopa-levodopa will be provide to you
1822639|NCT00749554|Device|Disc biacuplasty|The lesion duration will be 15 minutes with a ramp rate of 2°C per minute and a peak set temperature of 45°C (Temperature in posterior annulus of disc reaches 65°C).
1822640|NCT00749554|Device|Sham biacuplasty|Probes not inserted into disc, no RF electricity applied.
1822641|NCT00749567|Drug|Erlotinib|Erlotinib 150mg daily, continuously, until disease progression or the appearance of unacceptable toxicity
1822642|NCT00749567|Drug|Bevacizumab|Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression or the appearance of unacceptable toxicity
1822643|NCT00749580|Drug|Switch NRTIs as a Backbone to Raltegravir|This is a multicenter, pilot randomized, controlled study to evaluate the safety and efficacy of raltegravir in patients switched from a stable boosted PI-based regimen with a NRTI backbone to raltegravir instead of their current NRTIs. A stable boosted PI-based regimen is defined as having a documented HIV RNA <75 copies/mL for ≥ 3 months prior to study entry, while receiving a boosted PI-based with NRTI backbone. Additionally, patients must not have had HIV RNA ≥ 75 copies/mL during the three months prior to study entry. Approximately 25 patients will be enrolled in the raltegravir treatment arm (Group 1) and approximately 25 patients in the continuation of the current NRTI backbone regimen treatment arm (Group 2). Patients will be randomly assigned 1:1 to a treatment group.
1822646|NCT00749619|Other|Catheter Lock Solution Taurolidine and Citrate|
1822647|NCT00749619|Other|Catheter Lock Solution :Taurolidine and Citrate and Heparin|
1822648|NCT00749619|Other|Catheter Lock Solution : Heparin|
1822649|NCT00749632|Drug|oxybutynin|low dose oxybutynin administered daily
1822650|NCT00749632|Drug|oxybutynin|middle dose oxybutynin administered daily
1822651|NCT00749632|Drug|oxybutynin|high dose oxybutynin administered daily
1822652|NCT00749645|Drug|FANG(30)|Andrographolide formula Oral tablets, 30mg, three times per day, during a total of 105 continuous days.
1822653|NCT00749645|Drug|Placebo|Placebo 30mg tabs, 3/day, 105 days continuously.
1822654|NCT00749658|Drug|Bupropion SR|Form: tablet, Dosage, Frequency, Duration: Days 1-3, 150 mg, q.d., Days 4-11, 150 mg, b.i.d.
1822655|NCT00749658|Drug|Varenicline|Form: tablet, Dosage, Frequency, Duration: Days 1-3, .5 mg, q.d., Days 4-7, .5 mg, b.i.d., Days 8-11, 1 mg, b.i.d.
1822656|NCT00749671|Device|Bispectral index monitoring|The monitoring of the EEG signal is designed to determine if the sedation is adequate.
1822657|NCT00749671|Other|Ramsey Sedation Scale|The determination of the degree of sedation is accomplished using an established sedation scale.
1822658|NCT00749684|Biological|Interferon α-2b|20 mio IU/m² interferon-α-2b 5x/week intravenously (IV) over the course of 1 month, followed by 10 mio IU/m² interferon-α-2b 3x/week subcutaneously (SC) for 11 months.
1822659|NCT00749697|Other|SPECT scan|SPECT scan measures the amount of radio activity that is remaining in patients' body after the consumption of radio iodine for therapeutic purpose
1822660|NCT00749710|Procedure|clopidogrel|ORIF - surgical treatment
1822661|NCT00749710|Procedure|no antiaggregant therapy|ORIF - surgical treatment
1822662|NCT00749723|Drug|carboplatin|200 mg/m²/d continuously IV on day 1-4 of each 21-28-day-cycle. Number of cycles: until disease progression, maximum 4 cycles
1822663|NCT00749723|Drug|etoposide|100mg/m²/d continuously IV on day 1-4 of each 21-28 day cycle. Number of cycles: until disease progression, maximum 4 cycles
1822664|NCT00749723|Drug|temozolomide|150mg/m²/d p.o. on day 1-5 of a 21-28-day-cycle. Number of cycles: until progression or maximum up to 2 years
1822665|NCT00749723|Drug|thiotepa, carboplatin, etoposide|HD-chemotherapy prior to stem cell transplantation
1822666|NCT00749723|Drug|temozolomide, thiotepa|HD-chemotherapy prior to autologous stem cell transplantation
1822667|NCT00749723|Procedure|autologous stem cell transplantation|autologous stem cell transplantation following HD-chemotherapy
1822668|NCT00749723|Drug|etoposide|prior to systemic chemotherapy as single agent in patients with neoplastic meningitis, in addition to systemic chemotherapy if proven effective in phase II study, intraventricularly age-dependent daily dose (>3m to <3y 0.7 mg; >3y 1.0 mg) for 5 days every 2 two 4 weeks. Number of cycles: at least 3 courses, maximum up to 2 years
1822669|NCT00749723|Drug|trofosfamide/etoposide|maintenance therapy: trofosfamide/etoposide: 25 and 100 mg/m²/d for 21 days every 4 weeks. Number of cycles: until progression or maximum up to 2 years
1822670|NCT00749736|Dietary Supplement|cholecalciferol|"4000 IU of cholecalciferol per day
15 patients will be enrolled in each arm."
1822671|NCT00749736|Dietary Supplement|doxercalciferol|1 mcg of doxercalciferol per day
1822672|NCT00749736|Dietary Supplement|placebo|"placebo for 6 months; with stratification based on stage of CKD by modified MDRD formula.
15 patients will be enrolled in each arm."
1822673|NCT00749749|Device|Bupivacaine Collagen Sponge (CollaRx Bupivacaine Implant)|The bupivacaine collagen sponge contains 70mg Type I bovine collagen and 50mg bupivacaine hydrochloride
1822674|NCT00749749|Device|ON-Q PainBuster Post-op Pain relief System|5 mL/hr per catheter of 0.25% bupivacaine (12.5 mg) for 72 hours(total dose 360 mL [900 mg])
1822675|NCT00749775|Drug|Selara|Treatment should be initiated at 25 mg once daily and titrated to the recommended dose of 50 mg once daily, preferably within 4 weeks as tolerated by the patient. Selara may be administered with or without food.
1822676|NCT00749788|Drug|JTT-302|JTT-302, 100 mg tablets, 200 mg dose, oral, 30 minutes after the start of the morning meal
1822677|NCT00749788|Drug|JTT-302|JTT-302, 100 mg tablets, 400 mg dose, oral, 30 minutes after the start of the morning meal
1822678|NCT00749788|Drug|Placebo|Matching placebo tablets, oral, 30 minutes after the start of the morning meal
1822680|NCT00749814|Dietary Supplement|Melatonin|Melatonin slow release tablets, 2 mg, 1 hour before bedtime for 7 days prior to admission to the hospital and up to 7 days after surgery.
1822681|NCT00749814|Other|Placebo tablets|Placebo
1822682|NCT00749827|Drug|Bicarbonate Hydration|"Intravenous sodium bicarbonate (130 mEq/L) in 4.35% dextrose at 3.5 ml/Kg over 1 hour pre-contrast, followed by the same solution intravenously at 1 ml/Kg/hr for 6 hours. In all cases the maximum rate of fluid permitted is that for a body weight of 110 Kg. Intra-vascular low-osmolal or iso-osmolal contrast (according to operator or institution choice) will be used in the minimal dose needed to complete the required imaging.
Hypotonic hydration arm. Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours."
1822683|NCT00749827|Drug|Hypotonic hydration|Intravenous 5% dextrose in water at 3.5 ml/Kg over 1 hour pre-contrast followed by 0.9% saline intravenously at 1 ml/Kg/hr for 6 hours.
1822684|NCT00749840|Behavioral|Questionnaire|Questionnaire taking 60-90 minutes.
1822685|NCT00749853|Drug|follicle stimulating hormone|Pituitary down-regulation will be achieved using buserelin (Suprefact®, Hoechst, Frankfurt, Germany) at a fixed daily dose of 200 mg s.c., according to a long agonist protocol, starting on day 2 of the normal menstrual cycle. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The initial r-hFSH dose will be 250 IU s.c. daily for 5 days, after which the dose will be increased to a maximum of 450 IU per day using a step-up protocol with steps of 50 IU/day.
1822686|NCT00749853|Drug|follicle stimulating hormone|No pituitary down-regulation will be performed. Treatment with r-hFSH (Gonal-F®, Serono Austria GmbH, Vienna, Austria) will be started in women with serum E2 concentrations <200 pmol/l and no follicles >15 mm in diameter or ovarian cysts on ultrasonographic examination. The r-hFSH dose will be 150 IU s.c. daily for 11 consecutive days.
1822687|NCT00749866|Drug|Gentamicin|Nebulised 80mg twice daily
1822688|NCT00749866|Drug|Saline|Nebulised 4mls 0.9% Saline twice daily
1822690|NCT00749892|Drug|Erlotinib Hydrochloride|150 mg (pill) by mouth daily for 3 to 5 weeks prior to surgery
1822691|NCT00749905|Other|low fiber diet|Low fiber diet for 5 days prior to colon capsule
1822692|NCT00749905|Other|regular diet|Regular diet until 1 day before colon capsule
1822693|NCT00749918|Dietary Supplement|Cholecalciferol (vitamin D3)|Oral capsules of cholecalciferol, 5000 IU/ capsule, two capsules daily for one month.
1822694|NCT00749931|Device|MarginProbe|Device use to assess margin status of the excised specimen surface.
1822695|NCT00749931|Procedure|Lumpectomy|Standard of care lumpectomy procedure
1822696|NCT00749944|Drug|varenicline|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
1823857|NCT00757991|Other|laboratory biomarker analysis|
1822697|NCT00749944|Drug|placebo|1 mg tablets twice daily by mouth (after one week of uptitration: 0.5mg once daily for three days, 0.5mg twice daily for four days)
1822698|NCT00749957|Biological|rAAV2-CB-hRPE65|Recombinant adeno-associated virus vector expressing RPE65
1822699|NCT00749983|Dietary Supplement|Creatine supplementation|
1822700|NCT00749983|Dietary Supplement|Dextrose supplementation|
1822701|NCT00743561|Device|Polysomnography|Simultaneous recording of electro-encephalography, tibial and submental electro-myography, electro-oculography, nasal air flow, oxygen saturation, as well as the thoracic and abdominal respiratory effort
1822702|NCT00743561|Device|ambulatory polygraphy|Simultaneous recording of nasal air flow, oxygen saturation, as well as the abdominal and thoracic respiratory effort.
1822703|NCT00743574|Dietary Supplement|Vitamin D2 (Ergocalciferol)|50,000IU (or 1 tablet), PO, monthly (supplements to be taken for three months)
1822704|NCT00743574|Drug|Medroxyprogesterone (Provera)|10mg, PO, daily for ten days
1822705|NCT00743574|Dietary Supplement|Vitamin D3 (Cholecalciferol)|2,000IU (or 2 tablets), PO, daily (supplements taken for three months)
1822706|NCT00743574|Dietary Supplement|Elemental Calcium|1,000mg (or 2 tablets), PO, daily (supplements taken for three months)
1822707|NCT00743587|Drug|Placebo|Oral, a double-dummy approach will be used to maintain the blind between active tablet and capsule doses
1822708|NCT00743587|Drug|Oxycodone|Oral, 1 x 20mg controlled-release tablets
1822709|NCT00743587|Drug|Tramadol|Oral, 2 x 50mg immediate release capsules
1822710|NCT00743587|Drug|Naproxen|Oral, 1 x 500mg enteric-coated
1822711|NCT00743600|Other|ultrasound of painful shoulder|Patients who have a shoulder that is painful or has limited movement who were referred to Radiology will have an ultrasound exam of their shoulder.
1822712|NCT00743600|Other|ultrasound|Healthy volunteers who do not have pain or limited movement will have an ultrasound exam of their shoulder.
1822713|NCT00743613|Behavioral|Sexual Health Inventory for Men (SHIM)|Five question test with maximum score of 25 points administered on the initial visit. Erectile dysfunction is indirectly related to the score.
1822714|NCT00743613|Procedure|Ankle-Brachial Index (ABI)|Measure Ankle-Brachial Index with a hand held doppler and sphygmomanometer to determine the ABI.
1822715|NCT00743626|Other|Diagnostic cervical cancer screening tests (Pap smear, HPV and/or p16)|If positive (Pap smear, HPV and/or p16) patients will be scheduled for 3 colposcopy follow up visits (1,12,18 months)
1822716|NCT00743639|Procedure|intramyocardial bone marrow stem cells implantation|"Control group: the patients will be monitored with regular medical visits. Echocardiography: baseline,3,6,9 months. Cardiac NMR at baseline, 3 and 9 months.
Interventional group: Bone-marrow was collected from in the anterior-superior iliac crest and mononuclear stem cells were isolated by centrifugation in the density rate Ficoll-Hypaque 1.077 media. Technique - The approach was through a left mini-thoracotomy. Twenty small injections of cellular suspension were directly made through a 21F butterfly needle(total=5ml), in the anterior, lateral, posterior and apical faces of the LV ((average 9.6±2.6 x 10[7] cells). After the procedure, the patients were kept in the p.o. for a minimum period of 24hrs. They were released from the hospital in a period that varied from 5-7 days."
1822717|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|4 doses of 13vPnC (0.5ml, IM) will be administered. (3 doses infant series, and 1 toddler dose)
1822718|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|3 doses of 13vPnC (0.5ml, IM) will be administered. (2 doses for infant series catch-up, and 1 toddler dose)
1822719|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (1 dose infant series catch-up, and 1 toddler dose)
1822720|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|2 doses of 13vPnC (0.5ml, IM) will be administered. (2 catch-up dose(s) greater than 60 days apart )
1822721|NCT00743652|Biological|13-valent Pneumococcal Conjugate Vaccine|1 dose of 13vPnC (0.5ml, IM) will be administered. (1 catch-up dose)
1822722|NCT00743678|Drug|FOLFOX6/cetuximab|Neoadjuvant FOLFOX6/cetuximab
1822723|NCT00743691|Other|Community Based|In Arm 2 health extension workers will make a diagnosis of Neonatal infection and treat with antibiotics
1822724|NCT00743704|Other|ozoneexposure|subjects will be exposed to either ozone (250 ppb) or filtered air in an ozone challenge chamber for three hours. Ventilation will be increased to 20 l/min/m2 by intermittent exercise on a bicycle ergometer.
1822725|NCT00743717|Device|zirconia femoral component|total knee arthroplasty performed using implant with zirconia femoral component
1822726|NCT00743717|Device|cobalt chrome femoral component|total knee arthroplasty performed using implant with cobalt chrome femoral component
1822727|NCT00743730|Other|Pain and standard side effect management for PNCA with basal method.|"Comparing pain management and parent and nurse satisfaction with medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.
Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
1822728|NCT00743730|Other|Pain and standard side effect management with PNCA without basal|"Comparing pain management and parent nurse satisfaction with pain mediation delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.
Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol. PCA teaching will be done per Policy and Procedure."
1822729|NCT00743730|Other|Pain and standard side effect management with IV on an as needed basis method.|"Comparing pain management and parent and nurse satisfaction with pain medication delivery. Standard side effects of nausea, vomiting and pruritis can be expected although not always present. Protocol is in place to treat and manage these side effects.
Only PAIN TEAM will be writing analgesic orders and will make medication adjustment per protocol."
1822730|NCT00743743|Dietary Supplement|Longevinex brand resveratrol supplement|1 capsule daily for 52 weeks containing 215 mg of resveratrol active ingredient
1822731|NCT00743743|Dietary Supplement|placebo|1 capsule of placebo daily for 52 weeks
1822732|NCT00743756|Dietary Supplement|home-delivered meals|3 diabetic meals per day, 7 days per week for 12 months
1822733|NCT00743756|Dietary Supplement|home-delivered meals|diabetic meals 3 times per day, 7 days a week for six months
1822869|NCT00750113|Drug|Telmisartan|Tablets 80 Mg daily for 4 weeks then combination therapy
1822734|NCT00743756|Behavioral|diabetes education for 12 months|subjects in this group received diabetes education for 12 months
1822735|NCT00743769|Drug|thymosin beta 4|Single bolus injections of ascending doses of 42 mg, 140 mg, 420 mg or 1,260 QD of thymosin beta 4
1822736|NCT00743769|Other|Placebo|Single bolus injections of ascending doses of 0.00 mg QD of thymosin beta 4
1822737|NCT00743782|Drug|Synthetic Human Parathyroid Hormone 1-34|
1822738|NCT00743795|Drug|placebo|oral BID
1822739|NCT00743795|Drug|GS-9190|40 mg oral BID
1822740|NCT00743795|Drug|Peginterferon Alfa 2a|All subjects received a fixed dose of 180 μg PEG via subcutaneous injection on a weekly basis.
1822741|NCT00743795|Drug|Ribavirin|Ribavirin supplied as 200 mg Copegus® tablets (1000 mg for subjects weighing < 75 kg and 1200 mg for subjects weighing ≥ 75 kg) were given in a divided daily dose.
1822742|NCT00743808|Other|quality improvement|3-phase quality improvement intervention
1822743|NCT00743834|Drug|Luvox CR|In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
1822744|NCT00743834|Behavioral|Behavioral Therapy|The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
1822745|NCT00743847|Drug|placebo|Subjects randomized to placebo will receive matching placebo and follow the titration schedule and dosing schedule of those randomized to varenicline.
1822746|NCT00743847|Drug|varenicline|Subjects randomized to the 0.5 mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 7 days, then 0.5mg BID for the remainder of the 6 week trial.
1822747|NCT00743847|Drug|varenicline|Subjects randomized to the 1mg arm will be titrated to the full dose during the first week in the following manner: 0.5mg QD x 3 days, 0.5mg BID x 4 days, then 1mg BID for the remainder of the 6 week trial.
1822748|NCT00743860|Drug|darapladib|experimental drug
1822749|NCT00743873|Biological|Plasma Rich in Growth Factors (PRGF)|US guided IM injection 3-6mg
1822750|NCT00743873|Drug|placebo|injection of 6 cc of saline into injured area
1822751|NCT00743886|Biological|Plasma Rich in Growth Factors (PRGF)|injection onto injured area in ligament dose: 3-6mg
1822752|NCT00743886|Drug|saline|injection of 6 cc of saline into injured area
1822753|NCT00743899|Procedure|The aggressive group|Stents were implanted in lesions with diameter stenosis >50% and RD ≥2.25 mm and balloon angioplasty was performed in lesions with diameter stenosis >50% and RD ≥2.0 mm and <2.25 mm.
1822754|NCT00743899|Procedure|The conservative group|Stenting was performed only in lesions with diameter stenosis >70% and reference diameter (RD) ≥2.25 mm
1822755|NCT00743912|Drug|rifaximin|550 mg TID
1822756|NCT00743925|Drug|Varespladib Methyl (A-002)|2 Tablets (250 mg each) once daily for at least 24 weeks in combination with Atorvastatin (80 mg tablet once a day).
1822757|NCT00743938|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, Until disease progression or toxicity
1822758|NCT00743938|Drug|Erlotinib|Capsules, Oral, 150 mg, once daily, Until disease progression or toxicity
1822759|NCT00743951|Behavioral|1 Patient decision aid|"Patients will receive:
i)patient education booklet ii) a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.
iii) a personal decision form is an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.
iv) Referral to the surgeon with a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
1822760|NCT00743951|Behavioral|2 Usual care|"Patient will be given i) education booklet from local hospital which is a standardized teaching booklet given to all patients describing preparation for surgery, recovery after surgery, discharge plans.
ii) Referral to the surgeon with a standardized report of their clinical findings."
1822761|NCT00743964|Drug|Epirubicin|Epirubicin 50 mg/m2 iv on day 1
1822762|NCT00743964|Drug|Cisplatin, capecitabine|Cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Capecitabine 2000 mg/m2 on days 1 to 14.
1822764|NCT00743990|Other|Ointment containing camphor, eucalyptus oil, and menthol|One time use
1822765|NCT00743990|Other|Petroleum jelly|One time use
1822766|NCT00744016|Drug|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning
1822767|NCT00744016|Drug|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning
1822768|NCT00744029|Behavioral|educational material|Educational letter indicating stroke symptoms and emphasizing the importance of calling the emergency medical services (EMS) as well as a bookmark and sticker with the EMS telephone number.
1822769|NCT00744042|Biological|asfotase alfa|
1822770|NCT00744055|Drug|Prazosin|prazosin (16mg/day) 2 times a day
1822771|NCT00744055|Drug|Placebo|Placebo
1822772|NCT00744068|Behavioral|Continuing Care Telephone Support|Counselor-provided telephone support as strategies to promote patient aftercare attendance and sustained abstinence from stimulant use. To this end, we will develop and compare the efficacy of four low-cost telephone support protocols for patients who have completed the intensive phase of a structured, outpatient stimulant abuse treatment program.
1822773|NCT00744081|Drug|Glivec|
1822774|NCT00744081|Drug|Mitoxantrone|
1822775|NCT00744081|Drug|Topotecan|
1822776|NCT00744081|Drug|AraC|
1822777|NCT00744094|Dietary Supplement|protein drink|250 ml protein hydrolysate solution
1822778|NCT00744094|Behavioral|Resistance training|12 weeks resistance training, 3 days per week
1822779|NCT00744107|Device|PCI with the Cobra™ Cobalt Super Alloy Coronary Stent System|stent placement, single-arm study
1822870|NCT00750113|Drug|Nifedipine/Telmisartan|2 drugs (20 Mg Nifedipine/80 Mg Telmisartan) Combination therapy since the beginning
1822780|NCT00744133|Biological|NF54 P. falciparum isolate|1, 3, 5 or N bites from aseptically-raised Anopheles stephensi female mosquitoes infected with Plasmodium falciparum parasites of the NF54 strain.
1822781|NCT00744146|Biological|Protexia|Single 50 mg IM dose
1822782|NCT00744146|Biological|Protexia|Single 100 mg dose
1822783|NCT00744146|Biological|Protexia|Two 250 mg doses, IM, one at Day 1 and one at Day 72
1822784|NCT00744146|Biological|Protexia|Single 500 mg dose, IM
1822785|NCT00744146|Biological|Protexia|Single 750 mg dose, IM
1822786|NCT00744172|Procedure|laparoscopy|laparoscopic hysterectomy
1822787|NCT00744172|Procedure|vaginal|vaginal hysterectomy
1822788|NCT00744172|Procedure|abdominal|abdominal hysterectomy
1822789|NCT00744185|Drug|propranolol treatment|30 days-propranolol treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
1822790|NCT00744185|Drug|placebo treatment|30 days-placebo treatment : 3 mg/kg 15 days + 4 mg/kg 15 days
1822791|NCT00744198|Procedure|Autologous transobturator tape procedure|A strip of rectus fascia is harvested. Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of the autologous strip by means of reusable needles
1822792|NCT00744198|Procedure|Synthetic transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of synthetic mesh by means of mono-use needles.
1822793|NCT00744198|Procedure|Biological transobturator tape procedure|Small incision sites in the vagina and in the femoral/pelvic fold. Bilateral transobturator insertion of biological mesh by means of mono-use needle
1822794|NCT00744224|Drug|Placebo|Single dose of placebo with saline infusion
1822795|NCT00744224|Drug|Prednisolone|Single dose of 80 mg prednisolone with saline infusion
1822796|NCT00744224|Drug|Prednisolone and Exenatide|Prednisolone 80 mg single dose Exenatide infusion 20 mg/min
1822797|NCT00744237|Drug|Nebivolol|"Nebivolol 5 mg (overencapsulated 5-mg marketed tablet), oral administration
Nebivolol 10 mg (overencapsulated 10-mg marketed tablet), oral administration
Nebivolol 20 mg (overencapsulated 20-mg marketed tablet) oral administration
Nebivolol 40 mg (two overencapsulated 20-mg tablets) oral administration"
1822798|NCT00744237|Drug|Metoprolol ER|"Metoprolol ER 50 mg (overencapsulated 50-mg tablet) oral administration
Metoprolol ER 100 mg (two overencapsulated 50-mg tablets) oral administration
Metoprolol ER 200 mg (overencapsulated 200-mg tablet) oral administration
Metoprolol ER 400 mg (two overencapsulated 200-mg tablets) oral administration"
1822799|NCT00744237|Drug|HCTZ|"HCTZ 12.5 mg (overencapsulated 12.5 capsule), oral administration
HCTZ 25 mg (two capsules, overencapsulated 12.5-mg capsules), oral administration"
1822800|NCT00744250|Drug|Pancrelipase|PANCRECARB MS-16
1822801|NCT00744263|Biological|VACCINE: placebo|0.5 mL, single intra-muscular injection
1822802|NCT00744263|Biological|VACCINE: 13-valent pneumococcal conjugate vaccine|0.5 mL, single intra-muscular injection
1822803|NCT00744276|Drug|danazol|danazol applied topically once per day for 4 treatment cycles
1822804|NCT00744276|Drug|Placebo|placebo topically applied once daily for 4 treatment cycles
1822805|NCT00744289|Other|Incentive condition|Receipt of a small financial incentive after the second and third dose of the hepatitis B vaccine
1822806|NCT00744302|Drug|physiological (1.25 mmol/L ) calcium dialysate|Using the physiological calcium dialysate (1.25 mmol/L calcium dialysate)for Stable haemodialysis treatment for more than 3 months, undergoing 2 to 3 times haemodialysis a week for 4 to 5 hours per session
1822808|NCT00744328|Drug|Transdermal Estradiol|Estradiol patch ranging in dose from 50 to 200 mcg/day
1822809|NCT00744328|Drug|Sertraline|Sertraline dose will range from 50 - 200 mg/day
1822810|NCT00744328|Other|Placebo|Placebo patches and pills that are identical to transdermal estradiol and oral sertraline, respectively, will be used.
1822811|NCT00744341|Drug|SLV320|1.25mg i.v. bid
1822812|NCT00744341|Drug|SLV320|3.75mg i.v. bid
1822813|NCT00744341|Drug|SLV320|7.5mg i.v. bid
1822814|NCT00744341|Drug|SLV320|15.0mg i.v. bid
1822815|NCT00744341|Drug|Placebo|
1822816|NCT00744354|Drug|bortezomib|Intravenous Push 1.3 mg/m2 Days 1, 4, 8, and 11
1822817|NCT00744354|Drug|pegylated liposomal doxorubicin hydrochloride|Intravenous infusion, 30mg/m2, Day 4, each cycle
1822818|NCT00744354|Drug|vorinostat|Oral, 300mg, Days 1, 2, 4, 5, 8, 9, 11, 12, every cycle.
1822819|NCT00744367|Drug|metformin|>1500 mg/day or maximum tolerated dose (MTD)
1822820|NCT00744367|Drug|pioglitazone|>= 30 mg/day
1822821|NCT00744367|Drug|placebo|sc once weekly
1822822|NCT00744367|Drug|taspoglutide|10 mg sc once weekly;
1822823|NCT00744367|Drug|taspoglutide|20 mg sc once weekly (after 4 weeks of taspoglutide 10 mg sc once weekly)
1822824|NCT00744380|Drug|Midazolam|Midazolam infusion of 1 mg/hour (final infusion concentration of 0.5 mg/mL) and adjusted by 1 mg/hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
1822825|NCT00744380|Drug|Dexmedetomidine|Dexmedetomidine 0.15 µg/kg per hour (final infusion concentration of 0.075 µg/kg per mL) and adjusted by 0.15 µg/kg per hour by the bedside nurse as needed for the desired level of sedation (Riker sedation-agitation score of 3 - 4)
1822826|NCT00744393|Drug|sodium oxybate|The dose of sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and crossed over the next day
1822827|NCT00744393|Drug|placebo|The dose of placebo sodium oxybate will be 4.5g every 4 hours x 2 doses. The first dose of study medication will be given at 10pm followed by the next dose four hours later and then crossed over the next day
1822990|NCT00751647|Other|Physical Therapy|Treatment
1822828|NCT00744406|Behavioral|Cognitive Behavioral Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized cognitive-behaviour therapy provided by either M.S.W or Ph.D. psychotherapists trained and certified in CBT. Treatment will be conducted according to the manualized CBT treatment for depression outlined by Beck and colleagues (Beck et al., 1979), and consistent with the protocol administered in the NIMH study.
1822829|NCT00744406|Behavioral|Interpersonal Therapy|All patients randomized to this condition will receive 16 consecutive weeks of manualized interpersonal psychotherapy conducted by M.S.W., Ph.D., or M.Ed. psychotherapists trained and certified in IPT.
1822830|NCT00744406|Drug|Antidepressant medication (sertraline ,paroxetineor or venlafaxine)|Patients patients randomized to this condition will be treated for 16 weeks with different classes of anti-depressant medications, using standardized protocols. Patients will receive 16 weeks of treatment with either a SSRI (sertraline or paroxetine) or a SNRI (venlafaxine). The dose range is as follows: sertraline 50-200 mg/day, paroxetine 20-40 mg/day, venlafaxine 75-375 mg/day. Patients unable to continue with the prescribed medication due to side effects and/or lack of response will be prescribed an alternate medication during the first two weeks of the protocol.
1822831|NCT00744419|Drug|pantoprazole|Intravenous pantoprazole will be administered daiy for 6 (+/- 1 day). The first 6 subjects in each age group will receive low dose [0.4 mg/kg (< 44 wks PMA) or 0.8 mg/kg (44 wks to < 1 yr)] and the last 6 subjects in each age group will receive high dose [0.8 mg/kg(< 44 wks PMA) or 1.6 mg/kg(44 wks to < 1 yr)]
1822832|NCT00744445|Drug|r-HuEPO|r-HuEPO 50 U/kg s.c. three times per week. The dose is rounded to the nearest 2000 unites.
1822833|NCT00744458|Other|Treatment contract|Patients signs in for a agreement - to respect a regular follow-up at the health facility.
1822834|NCT00744458|Other|Tracing and recall at home by a community worker|The local health committee sends out a member to trace the patient and to motivate him to take up again regular treatment visits.
1822835|NCT00744458|Other|Incentive|Incentive by giving free treatment after a 4-month regular follow-up
1822836|NCT00744471|Biological|tanezumab|Tanezumab 10 mg IV every 8 weeks
1822837|NCT00744471|Biological|tanezumab|Tanezumab 5mg IV every 8 weeks
1822838|NCT00744471|Biological|tanezumab|Tanezumab 2.5 mg IV every 8 weeks.
1822839|NCT00744471|Biological|Placebo|Placebo to match tanezumab IV every 8 weeks
1822840|NCT00744484|Behavioral|Training in water|45 minutes interval training in water, submaximal intensity, twice a week
1822841|NCT00744484|Behavioral|Training on land|45 minutes interval training on land, submaximal intensity, twice a week
1822842|NCT00744497|Drug|Placebo|
1822843|NCT00744497|Drug|Dasatinib|
1822844|NCT00744497|Drug|Docetaxel|
1822845|NCT00744497|Drug|Prednisone|
1822846|NCT00744510|Other|Reflexology|10 weekly sessions of 45 minutes each
1822847|NCT00744523|Device|Mo.Ma cerebral protection device|Proximal embolic protection based on the principle endovascular clamping consisting of a catheter with two compliant balloons. Mo.Ma is designed to achieve cerebral protection by proximal blood flow blockage at the carotid bifurcation: antegrade and retrograde flow blockage are achieved by proximal balloon occlusion of the CCA and distal balloon occlusion of the ECA. Cerebral protection is established prior to the initial wire passage through the stenosis and maintained during the entire procedure. Mo.Ma provides withdrawal of embolic particles by allowing manual syringe aspiration of any micro-emboli at the end of the procedure before restoring blood flow through the stented vessel.
1822848|NCT00744536|Drug|Lenalidomide and melphalan|Lenalidomide (Revlimid) 10 mg po daily for 21d/28 Melphalan (Melphalan) 2 mg po daily for 21d/28
1822849|NCT00744549|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
1822850|NCT00744549|Drug|Placebo|Twice a day with meals.
1822851|NCT00744562|Drug|OMP-21M18|0.5, 1, 2.5, 5, and 10 mg/kg weekly until day 56. If patient has not progressed may continue with original dose administered every other week until progression
1822852|NCT00744614|Procedure|Capnography|A technique for monitoring the concentration or partial pressure of CO2 levels in respiratory gases
1822853|NCT00744627|Drug|Vortioxetine|Encapsulated vortioxetine immediate-release tablets.
1822854|NCT00744627|Drug|Placebo|Vortioxetine placebo-matching capsules
1822855|NCT00744640|Drug|gemcitabine, oxaliplatin, capecitabine|gemcitabine day 1 and 8, oxaliplatin day 1, capecitabine days 1-14, q3weeks
1822856|NCT00749996|Device|DIAM™ Spinal Stabilization System|The DIAM™ Spinal Stabilization System is a spacer that is inserted between adjoining spinous processes after doing a standard herniectomy procedure using a posterior surgical approach.
1822857|NCT00749996|Procedure|Herniectomy|"Herniectomy is defined as the removal of the extruded/protruded/sequestrated disc material. This is done by probing the annulus and disc space and removing all mobile disc fragments."
1822858|NCT00750009|Other|educational intervention|Patients receive a tailored intervention or generic information
1822859|NCT00750022|Behavioral|Individualized IC treatment|Individuals will receive IC measurement at baseline and three months. Nutrition and physical activity plan will be developed and adjusted from measured RMR and lifestyle.
1822860|NCT00750022|Behavioral|Usual Care|Individuals will receive standard dietary plan. Women will receive 1200 Kcal/day and men will receive 1600 Kcal/day. Individuals will receive RMR measurement at three months. RMR information will be used to help improve eating behavior.
1822861|NCT00750035|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy and Subtotal abdominal hysterectomy
1822862|NCT00750035|Procedure|Subtotal abdominal hysterectomy|
1822863|NCT00750048|Drug|Naloxone and paracetamol|to check if naloxone induce an inhibiting effect on the analgesic effect of paracetamol in healthy volunteer, using evoked potentials
1822864|NCT00750061|Drug|Lithium Carbonate|"The subject start at a dosage regime of three times a day and one tablet of lithium carbonate, 250mg/table, oral administration each time for three days. The daily dose will be adjusted according to the serum lithium level and the clinical findings. Target serum lithium level is 0.6-1.2mM.
The course of medication is 6 weeks."
1822865|NCT00750061|Drug|Placebo|Matching placebo
1822866|NCT00750100|Drug|human chorionic gonadotropin|hCG 200IU in the late follicular phase
1822867|NCT00750100|Drug|recombinant gonadotropins|200 IU per day during controlled ovarian stimulation
1822871|NCT00750126|Drug|Fludarabine, Busulfan, Thymoglobulin|"study :
acute and/or chronic graft-versus-host reaction (incidence and severity) and immune reconstitution, post transplantation
the effectiveness of the protocol on tumor response
overall survival"
1822872|NCT00750139|Drug|NAFT-500|topical cream 1 application every day up to 4 weeks weeks
1822873|NCT00750139|Drug|Placebo 2-weeks|placebo cream 1 application every day for up to 4 weeks
1822874|NCT00750139|Drug|Naftin 1%|topical allylamine cream applied once a day for up to 4 weeks
1822875|NCT00750139|Drug|Placebo 4-weeks|topical placebo cream applied once a day for up to 4 weeks
1822876|NCT00750152|Drug|NAFT-500|topical cream application up to 4 weeks
1822877|NCT00750152|Drug|Placebo|placebo cream applied for up to 4 weeks
1822878|NCT00750165|Device|SleepStyle 200 Auto Series CPAP Humidifier|The device is a standard CPAP machine with a built in computer controller that incorporates software for evaluation of the flow signal obtained from the CPAP machine
1822879|NCT00750178|Drug|vorinostat (MK0683 )|"Panel A: vorinostat 400 mg capsules once daily on Days 1, 5, 7-28
Total treatment period is 28 days"
1822880|NCT00750191|Device|The Transdiscal Radiofrequency Annuloplasty|Adjustment in dosage form, frequency and or duration.
1822881|NCT00750191|Device|The Transdiscal Radiofrequency Annuloplasty|interventions include adjustment to dosage form,frequency,duration or switching to treatment arm A
1822882|NCT00750204|Device|APRV|"APRV Protocol
Set fraction of inspired oxygen (FiO2) at 0.1 higher than the setting on conventional MV currently used
Tlow = 1.0 second (this setting shall remain unchanged throughout the trial).
Respiratory rate (RR) to equal 60-65% of RR on conventional MV.
P high = the inspiratory plateau pressure. Maximum P high = 30 cm H20.
Plow = 5 cm water (H2O). Adjust Plow to achieve pressure release volumes 5.5-6.5 ml/kg of percent body weight (PBW).
If release volumes on APRV are greater than desired, increase Plow by 2-4 cm H2O increments to a maximum of Plow = 12 cm H2O. If release volumes are larger than desired despite raising Plow to 12 cm H20, decrease P high in increments of 2-4 cm H20 to achieve desired release volumes (minimum P high = 12 cm H20). If release volumes on APRV still remain larger than desired,the participant will be excluded from the study and placed on conventional MV."
1822883|NCT00750204|Device|Conventional MV|Low tidal-volume mechanical ventilation
1822885|NCT00750230|Dietary Supplement|NEM|see Treatment Arm
1822886|NCT00750243|Drug|LT-NS001|1200 mg b.i.d. p.o. for 7.5 days
1822887|NCT00750243|Drug|Naprosyn®|500 mg b.i.d. p.o. for 7.5 days
1822888|NCT00750256|Drug|GSK1278863A|GSK1278863A planned doses from 2mg to 450mg which may change based on safety or PK from previous cohorts.
1822889|NCT00750269|Radiation|SBRT 40.0 Gy|SBRT delivered in 5 fractions of 8.0 Gy/fraction over 1.5 to 2 weeks for a total of 40.0 Gy
1822890|NCT00750269|Radiation|SBRT 42.5 Gy|SBRT delivered in 5 fractions of 8.5 Gy/fraction over 1.5 to 2 weeks for a total of 42.5 Gy
1822891|NCT00750269|Radiation|SBRT 45.0 Gy|SBRT delivered in 5 fractions of 9.0 Gy/fraction over 1.5 to 2 weeks for a total of 45.0 Gy
1822892|NCT00750269|Radiation|SBRT 47.5 Gy|SBRT delivered in 5 fractions of 9.5 Gy/fraction over 1.5 to 2 weeks for a total of 47.5 Gy
1822893|NCT00750269|Radiation|SBRT 50.0 Gy|SBRT delivered in 5 fractions of 10.0 Gy/fraction over 1.5 to 2 weeks for a total of 50.0 Gy
1822894|NCT00750269|Radiation|SBRT 52.5 Gy|SBRT delivered in 5 fractions of 10.5 Gy/fraction over 1.5 to 2 weeks for a total of 52.5 Gy
1822895|NCT00750269|Radiation|SBRT 55.0 Gy|SBRT delivered in 5 fractions of 11.0 Gy/fraction over 1.5 to 2 weeks for a total of 55.0 Gy
1822896|NCT00750269|Radiation|SBRT 57.5 Gy|SBRT delivered in 5 fractions of 11.5 Gy/fraction over 1.5 to 2 weeks for a total of 57.5 Gy
1822897|NCT00750269|Radiation|SBRT 60.0 Gy|SBRT delivered in 5 fractions of 12.0 Gy/fraction over 1.5 to 2 weeks for a total of 60.0 Gy
1822898|NCT00750282|Drug|Florbetaben (BAY94-9172)|Healthy volunteers and patients with probable Alzheimer's disease receiving single injection of investigational medicinal product BAY 94-9172 followed by subsequent PET imaging sessions
1822899|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
1822900|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
1822901|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
1822902|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
1822903|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
1822904|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
1822905|NCT00750295|Drug|SBR759|Four weeks of treatment with different doses of SBR759. Patients maintain their prescribed dose of other phosphate binders during the run-in period.
1822906|NCT00750308|Drug|Ramipril|Ramipril 10 mg per day for three weeks
1822907|NCT00750308|Drug|Tadalafil|tadalafil 10 mg every other day for three weeks
1822908|NCT00750308|Drug|placebo|placebo matching ramipril
1822909|NCT00750308|Drug|placebo|placebo matching tadalafil
1822910|NCT00750334|Drug|clofarabine|Drug given Daily x 14 days and 7 days of rest for 21 day cycle
1822911|NCT00750334|Drug|clofarabine|Drug given Daily X 14 days and 7 days of rest for 21 day cycle
1822912|NCT00751075|Drug|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
1822913|NCT00751075|Drug|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
1822914|NCT00751075|Drug|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
1822915|NCT00751075|Drug|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
1822916|NCT00751088|Procedure|MiniArc positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. MiniArc will be placed by means of curved single use needle. Incision closure."
1822917|NCT00751088|Procedure|TVT secur system positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. TVT Secur System will be placed by means of two curved, stainless steel, single use introducers. Incision closure."
1822918|NCT00751088|Procedure|Ajust positioning|"Patient placed in lithotomic position. 1.5 cm incision made, starting 1 cm down to the urethral meatus. Tunneling wide to 12-15 mm up to the bonny edge horizontally to the inferior pubic arm by spreading the scissors blades while withdrawing it, at a plane parallel to the vaginal wall. Mucosal undermining performed at the level of the upper and lower frenulum attaching the sub-urethral tissue to the vaginal wall. Insertion of the device to the bonny edge, horizontaly to the inferior pubic arm, and behind the bone edge to the internal obturator muscle. Ajust will be placed by means of a safe hook geometry introducer. Incision closure."
1822919|NCT00751088|Procedure|Tension free vaginal ttape|Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
1822920|NCT00751101|Drug|nicotine|Nicotine patch applied prior to and concurrently with capecitabine chemotherapy or beginning during the first course of capecitabine after the onset of hand-foot syndrome symptoms
1822921|NCT00751114|Drug|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a pre-filled SoloStar® pen (3 mL).
1822922|NCT00751114|Drug|Sitagliptin|Oral administration. 100 mg film-coated tablets.
1822923|NCT00751114|Drug|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
1822924|NCT00751127|Drug|PhXA41|One drop in the affected eye once daily for six months.
1822925|NCT00751127|Drug|timolol|One drop in the affected eye twice daily for six months.
1822926|NCT00751140|Procedure|Lymph Node Dissection|The lymph nodes will be sent to pathology for review.
1822927|NCT00751153|Drug|Raltegravir and Atazanavir|Rategravir 400 BID, Atazanavir 400 mg daily
1822928|NCT00751166|Drug|Desloratadine|Desloratadine 5 mg, oral tablet, once daily in the morning, 28 days
1822929|NCT00751166|Drug|Cetirizine|Cetirizine 10 mg, oral tablet (over encapsulated), once daily in the morning, 28 days
1822930|NCT00751166|Drug|placebo|placebo once daily for 28 days
1822931|NCT00751179|Drug|rocuronium|A single bolus intubation dose of 0.6 mg/kg rocuronium will be administered following induction of anesthesia and if required, single bolus dose(s) of 0.15 mg/kg rocuronium will be administered to maintain the neuromuscular block.
1822932|NCT00751179|Drug|sugammadex|At the end of the surgical procedure at a target depth of neuromuscular blockade of at least 1-2 Post-Tetanic Count (PTC), 4.0 mg/kg of sugammadex will be administered.
1822933|NCT00751179|Drug|succinylcholine|A single bolus intubation dose of 1.0 mg/kg succinylcholine will be administered following induction of anesthesia and the subject is allowed to recover spontaneously from the neuromuscular blockade.
1822934|NCT00751192|Device|HIV-testing motivational videos|
1822935|NCT00751192|Device|Standard public health text|
1822936|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. In addition, subjects will receive Acetyl-L-Carnitine (ALC) 1000 mg tid. Treatment with Sagopilone and ALC will be continued as long as there is benefit. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
1822937|NCT00751205|Drug|Sagopilone 16 mg/m^2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid|Subjects will receive intravenous (i.v.) infusion of Sagopilone for 3 hours on day 1 of a 3-weeks cycle. Treatment will be continued as long as there is benefit. In addition, subjects will receive 21 weeks of placebo 1000 mg tid. After all patients have completed 6 cycles of treatment, an analysis will be performed to see whether ALC was better than placebo. If this is the case, patients still under placebo treatment will be offered to switch to ALC. Subjects with HRPC will also receive Prednisone or Prednisolone 5 mg bid, throughout the treatment with Sagopilone.
1822941|NCT00751231|Drug|clopidogrel|Loading dose of 300mg or 600mg, followed by once daily dosing of 75 mg
1822942|NCT00751231|Drug|PRT060128|80-120 mg IV bolus administered prior to PCI, followed by twice daily dosing of oral 50mg, 100mg or 150mg
1822991|NCT00751660|Other|laboratory biomarker analysis|
1822992|NCT00751660|Other|screening questionnaire administration|
1822993|NCT00751660|Procedure|bronchoscopic and lung imaging studies|
1822994|NCT00751660|Procedure|computed tomography|
1822995|NCT00751660|Procedure|endoscopic biopsy|
1822996|NCT00751660|Procedure|quality-of-life assessment|
1822943|NCT00751244|Behavioral|Trauma Affect Regulation: Guide for Education and Therapy|"Trauma Affect Regulation: Guide for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences, summarized by a mnemonic (FREEDOM), e.g., Focusing (F), Recognizing current triggers. TARGET also involves creative arts activities, i.e., personalized lifelines via collage, drawing, poetry, and writing that may include traumatic experiences but emphasize life story narrative reconstruction with no exposure therapy."
1822944|NCT00751244|Behavioral|Present Centered Therapy (PCT) - psychotherapy|"Present Centered Therapy (PCT) is a 12-session supportive therapy adapted a 14-session version co-developed by the first author (McDonagh-Coyle et al., 2005). Psychoeducation is provided about the link between traumatic events, PTSD symptoms, and problems in relationships, and social problem solving skills are taught to address the traumagenic dynamics of betrayal, stigma, powerlessness, and sexualization (Finkelhor, 1987). PCT focuses on addressing current problems rather than trauma memory-based exposure therapy, and uses a distinctive mnemonic to organize the skill set. PCT has clients keep a journal of relational stressors and responses as between-session homework."
1822945|NCT00751244|Other|"No-treatment waitlist group"|After a 90 day wait-list period, participants were invited to choose one of the treatment approaches (PCT or TARGET) and engage in 12 sessions of therapy.
1822946|NCT00751257|Drug|N-acetylcysteine|2400mg (1200mg b.i.d., 600mg capsules, p.o.)
1822947|NCT00751257|Drug|Placebo|"Identically appearing placebo capsules, packaged in an N-acetylcysteine slurry so that placebo has similar odor as active NAC capsules"
1822948|NCT00751270|Biological|AdV-tk|Three different dosing levels of AdV-tk (3x10e10, 1x10e11, 3X10e11) were evaluated. A single injection of AdV-tk at the assigned dose level was administered, followed by 14 days of the oral prodrug valacyclovir. Patients then received standard of care radiation therapy and chemotherapy.
1822949|NCT00751270|Drug|Valacyclovir|The oral prodrug valacyclovir was given beginning 1-3 days following the AdV-tk. Valacyclovir tablets were taken three times a day for a total of 14 days.
1822950|NCT00751283|Device|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
1822951|NCT00751296|Drug|Lenalidomide|Subjects will receive lenalidomide, starting at 2.5 mg daily x 3 weeks (days 1-21) and escalating up to a target dose of 10 mg daily X 3 weeks (days 1-21) followed by 1 week off therapy (days 22-28) on a 28 day cycle.Patients will be treated with lenalidomide until disease progression or 2 cycles past CR. (no maximum of cycles).
1822952|NCT00751309|Other|Non-interventional|Post-transplantation observational study
1822953|NCT00751322|Other|RBC transfusion of 5 days or less storage age|RBC transfusion of 5 days or less storage age
1822954|NCT00751322|Other|RBC transfusion of conventional storage age|RBC transfusion of conventional storage age
1822955|NCT00751335|Device|Heated breathing tube (CPAP with ThermoSmart)|heated humidification with a heated breathing tube.
1822956|NCT00751335|Device|Non heated breathing tube (CPAP with conventional humidification)|Heated humidification without a heated breathing tube
1822957|NCT00751348|Biological|PriorixTM|Subcutaneous administration in left upper arm
1822958|NCT00751348|Biological|VarilrixTM|Subcutaneous administration in right upper arm
1822959|NCT00751348|Biological|Priorix-Tetra®|Subcutaneous injection in left upper arm
1822960|NCT00751361|Device|Rheopheresis / double filtration plasmapheresis|Rheopheresis is a specific method of therapeutic apheresis, using the methodology of double filtration plasmapheresis.
1822961|NCT00751374|Drug|gentamicin|topical gentamicin cream on daily basis
1822962|NCT00751374|Drug|gentamicin cream alternating with mupirocin cream|topical gentamicin cream alternating with mupirocin cream at monthly basis
1822963|NCT00751400|Drug|Naproxen Sodium ER (BAYH6689)|Consumer use of Extended Release Naproxen Sodium
1822964|NCT00751413|Drug|Comparator: MK0633|A single dose of MK0633 10 mg or 25 mg film coated tablet. Dose will be based on patient weight.
1822965|NCT00751465|Behavioral|Task Concentration Training|Task Concentration Training TCT following Bögels et al. (1997).
1822966|NCT00751465|Behavioral|Standard CBT|Standard CBT following the Clark-and-Wells (1995) model of social anxiety disorder, relying on the German manual for SAD (stangier et al., 2006). Includes the model, role-plays with and without safetey behavior, video-feedback.
1822967|NCT00751478|Drug|ALO-01|ALO-01 capsules
1822968|NCT00751478|Drug|MSIR|immediate release morphine sulfate
1822969|NCT00751478|Drug|Placebo|Placebo
1822973|NCT00751504|Drug|Quetiapine|Dosage form: tablets Dosage: between 300 mg/die and 600 mg/die Frequency: once daily Duration: 6 weeks
1822974|NCT00751517|Drug|Methotrexate|
1822975|NCT00751517|Drug|Cyclophosphamide|
1822976|NCT00751530|Drug|raltegravir|New combination ART incorporating raltegravir with other ARVs.
1822977|NCT00751543|Radiation|CT, radiation therapy|Computed tomography (CT) is the mainstay for evaluating lung cancer. The advance of multi-row detector CT (MDCT) provides volumetric acquisition within a breath hold, and enables detailed evaluation of tissue and organ perfusion with excellent resolution
1822978|NCT00751556|Drug|Naproxen Sodium 660mg|Extended release Naproxen Sodium (660mg) administered once a day
1822979|NCT00751556|Drug|Commercial Aleve 220 mg|Immediate release commercial Aleve (220 mg) administered in a 2 (440 mg) plus one (220 mg) dosing schedule, 660 mg total
1822980|NCT00751569|Other|blood donation|obtaining cord blood
1822981|NCT00751582|Dietary Supplement|Food supplementation and nutrition education|Food supplementation and nutrition education for three months
1822982|NCT00751582|Behavioral|Nutrition education|Nutrition education for children for three months
1822983|NCT00751582|Other|Control Group|No Nutrition Education
1822984|NCT00751595|Biological|Tat protein|Biologically active recombinant Tat protein
1822985|NCT00751608|Drug|APL180|
1822986|NCT00751608|Drug|APL180|
1822987|NCT00751608|Drug|Placebo|
1822988|NCT00751621|Biological|IgPro20|
1822989|NCT00751634|Device|Gaymar Rapr-Round (external cooling blanket)|Application of the device per its approved labeling
1822997|NCT00751686|Procedure|Stool sample|Collection of the stool at least 48 hours after hospitalisation. Stool samples should be obtained preferably within 4 and no later than 10 days after the onset of the GE symptoms.
1822998|NCT00751686|Other|Data collection|Logbook, Health Economic Questionnaire, Telephone call.
1822999|NCT00751699|Drug|Asacol|Asacol tablets, 6 tablets per day at 7 am for 7 days
1823000|NCT00751699|Drug|Asacol|Asacol tablets, 400 mg, 2 tablets at 7 am, 3 pm, and 11 pm for 7 days
1823001|NCT00751699|Drug|Lialda|Lialda tablets 1.2 g, 2 tablets once a day at 7 am for 7 days
1823002|NCT00751712|Device|Cerebral oximeter sensor|The INVOS Cerebral Oximeter utilizes two electrodes to monitor cerebral oxygenation. The recommended placement of these electrodes is on the forehead to monitor the frontal cortex. In this study, one electrode will be placed in the normal position on the forehead, and the other will be placed at the base of the skull. The stickers will be placed on the patient at the beginning of surgery and removed at the end. The maximum amount of time that they will be on the patient's skin is approximately six hours. Application of the stickers and the data they provide will not alter the provider's treatment plan. This procedure will be used for all enrolled patients, whether they are enrolled in Part I or Part II.
1823003|NCT00751738|Drug|azimilide dihydrochloride|oral, once daily until sponsor stopped the study
1823004|NCT00751751|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets taken once daily for 52 weeks + oral hydrochlorothiazide tablets, once daily, after 12 weeks if needed to control BP
1823005|NCT00751751|Drug|losartan + hydrochlorothiazide, if necessary|oral losartan capsules, 50 or 100 mg taken once daily for 52 weeks + 12.5 or 25 mg oral hydrochlorothiazide tablets, after 12 weeks, if needed to control BP.
1823006|NCT00751764|Drug|Moxidectin|
1823007|NCT00751777|Biological|heat-labile enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
1823008|NCT00751777|Biological|Placebo|Travelers' Diarrhea Vaccine System
1823009|NCT00751790|Drug|triptorelin embonate (INN)|Triptorelin embonate 22.5 mg 6 month formulation to be injected every 24 weeks
1823010|NCT00751803|Drug|BI 44370 TA Low Dose|
1823011|NCT00751803|Drug|Eletriptan|
1823012|NCT00751803|Drug|Placebo|
1823013|NCT00751803|Drug|BI 44370 TA Medium Dose|
1823014|NCT00751816|Drug|systemic chemotherapy|Not specified
1823015|NCT00751816|Other|survey administration|will be administered before, during, and after medical intent-to-cure treatment to describe head and neck cancer survivors' physical and functional well-being.
1823016|NCT00751816|Procedure|adjuvant therapy|not specified
1823017|NCT00751816|Procedure|management of therapy complications|not specified
1823018|NCT00751816|Procedure|musculoskeletal complications management/prevention|Not specified
1823019|NCT00751816|Procedure|physical therapy|weekly visits coordinated with adjuvant treatment as part of standard care
1823020|NCT00751816|Radiation|radiation therapy|not specified
1823021|NCT00751829|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary|oral olmesartan medoxomil tablets 20 mg or 40 mg once daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
1823022|NCT00751829|Drug|nitrendipine + hydrochlorothiazide, if necessary|oral nitrendipine tablets 10 or 20 mg taken twice daily for 24 weeks + oral hydrochlorothiazide tablets 12.5 or 25 mg once daily after 12 weeks, if needed to control BP
1823023|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1, 30, 90 and 270.
1823024|NCT00751842|Drug|rhGAD65|Diamyd (rhGAD65) 20 µg injected subcutaneously at days 1 and 30, followed by placebo injections at days 90 and 270.
1823025|NCT00751842|Drug|Placebo|Placebo injected subcutaneously at days 1, 30, 90 and 270.
1823029|NCT00751868|Drug|Ixabepilone|Ixabepilone is administered as 3-hour intravenous infusion (iv) at the dose of 40 mg/mq, every 14 days for 4 cycles (with G-CSF support), sequentially to Fluorouracil 600 mg/mq as intravenous (iv) infusion, Epirubicin 90 mg/mq as intravenous (iv) bolus and Cyclophosphamide 600 mg/mq as intravenous (iv) infusion every 14 days for 4 cycles (with G-CSF support)
1823030|NCT00751881|Drug|Placebo|"Film-coated tablet
Oral administration"
1823031|NCT00751881|Drug|Teriflunomide|"Film-coated tablet
Oral administration"
1823032|NCT00751894|Drug|Pegfilgrastim (Neulasta, Amgen)|sequential Bayesian study
1823035|NCT00751920|Procedure|Enhanced MRI Scan|Following the detection of a pulmonary nodule(s) with the unenhanced MRI scan, the subjects will then be injected with the contrast agent, Magnevist, and have a dynamic enhanced MRI scan of the largest pulmonary nodule.
1823036|NCT00751933|Biological|Vaccine Vivotif + Vaccine Dukoral + oats|"Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months."
1823037|NCT00751933|Biological|Vaccine Vivotif + Vaccine Dukoral|Vivotif 1 capsule at study day 1,3,5 and 7. Dukoral oral mixture taken with sodium hydrogen carbonate in water at study day 1 and 14.
1823038|NCT00751933|Dietary Supplement|Oats|One daily portion of oats porridge made from oats grain 1dL and water, 6 days a week for 6 months.
1823039|NCT00751933|Other|Placebo|Placebo capsules instead of Vivotif capsules Placebo mixture instead of liquid Dukoral vaccine
1823064|NCT00752115|Drug|sildenafil|50mg, day1,8 and 15 in each cycle
1823065|NCT00752115|Drug|placebo|1 tab, day 1,8 and 15 in each cycle.
1823066|NCT00752115|Drug|paclitaxel (taxol)|paclitaxel; 70mg/m2 div on day 1, 8 and 15, every 28 days
1823067|NCT00752115|Drug|carboplatin (palaplatin)|carboplatin; AUC=6 on day 1, every 28 days
1823068|NCT00752128|Device|Endeavor Resolute Zotarolimus-Eluting Coronary Stent System|Stent implantation
1823069|NCT00752141|Drug|oxybutynin chloride immediate-release|capsule containing oxybutynin chloride immediate-release 5 mg tablet administered three times daily, and placebo gel administered once daily
1823040|NCT00751946|Behavioral|Trauma Adaptive Recovery Group Education and Therapy|"Trauma Affect Regulation: Guidelines for Education and Therapy (TARGET; Ford & Russo, 2006) is a manualized gender-specific treatment for PTSD. The 12-session individual therapy version in the present study is being adapted for adolescent girls based on a parallel version for young mothers and a group version that has been field tested with more than 20 adolescent girls.
TARGET teaches a practical 7-step sequence of skills for processing and managing trauma-related reactions to current stressful experiences. The skills are designed in a sequence mirroring the three phases of complex traumatic stress disorder treatment (Ford, Courtois, Van der Hart, Nijenhuis & Steele, 2005), summarized by an acronym FREEDOM. TARGET also uses creative arts activities: personalized lifelines via collage, drawing, poetry, and writing."
1823041|NCT00751946|Behavioral|Enhanced Treatment As Usual|Enhanced Treatment as Usual (ETAU) is a 12-session supportive therapy adapted from the Present Centered Therapy co-developed by the first author (McDonagh-Coyle, Friedman, McHugo, Ford, Mueser, & Sengupta, 2005). In ETAU therapists invite the participant to talk about goals or problems that are important to her. The therapist's focus is on providing the core conditions of client centered psychotherapy (nonjudgmental acceptance, empathy, interpersonal warmth) and engaging the participant in a strengths-based solution-focused reflection on how she is successful (or has been in the past) in managing stressors, handling problems, achieving personal goals, and developing healthy relationships with peers, family, and other community members.
1823042|NCT00751959|Drug|Curosurf|Surfactant application via a thin endotracheal catheter during spontaneous breathing with CPAP, followed by respiratory support with CPAP
1823043|NCT00751959|Drug|Curosurf|Conventional therapy with intubation, initiation of mechanical ventilation and surfactant application
1823044|NCT00751972|Device|HeartWare® VAS|The HeartWare® LVAD is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device which is both lightweight and simple to use.
1823045|NCT00751985|Other|Personalised normative feedback (PNF)|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.
The brief personalised normative feedback will comprise the result of the participant's amount of alcohol consumption, previously given in an online questionnaire.
Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. The feedback is also comparing their drinking, in graphical format, to the average drinking in the municipality concerned. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
1823046|NCT00751985|Other|Self-help material|"The intervention can be classified as a minimal ultra-brief intervention consisting of only a single session.
The intervention comprises of on-line self-help material informing about the participant's response from an online questionnaire shows that the participant's alcohol consumption exceeds the recommended limits.
Alongside, information about alcohol and how it might affect them at their current drinking levels is provided. Contact details are also provided about local alcohol treatment possibilities if the participants feel they need further help."
1823047|NCT00751985|Other|Control|The participant is being informed about their allocation to the control group.
1823048|NCT00751998|Device|SpyGlass|The SpyGlass Direct Visualization System is an integrated product platform that is designed to provide a direct intraluminal view of the biliary duct system and direct therapeutic devices.
1823049|NCT00752011|Drug|TAS-106|Starting dose 2.0 mg/m^2 by vein over 24 hours, Day 1 of 3 Week Cycle.
1823050|NCT00752011|Drug|Carboplatin|Starting dose AUC of 4, administered by vein over 60 minutes, Day 1 of 3 Week Cycle.
1823051|NCT00752024|Device|YL-1 type of intracranial hematoma puncture needle|"YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.
To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
1823052|NCT00752024|Drug|dehydrating agent, haemostatic|In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
1823054|NCT00752050|Drug|Mentor Purified Toxin Botulinum Toxin Type A|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 30 U of the Active Comparator Mentor Purified Toxin.
1823055|NCT00752050|Drug|Preservative-free Saline|For Part II, subjects in this arm will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
1823056|NCT00752063|Drug|Sorafenib with Capecitabine and Oxaliplatin|Regimen 1: Oxaliplatin 85 mg/m2 (50 mg per vial) administered intravenously on day 1 of each cycle Regimen 2: Capecitabine 1700 mg/m2 p.o. (850 mg/m2 BD) day 1 to 7 Regimen 3: Sorafenib 400 mg (200 mg/tablet) orally BD day 1 to 14
1823057|NCT00752076|Other|cancer cell lines establishment|Detection of epithelial growth factor receptor (EGFR) mutation in malignant pleural effusion of lung cancer patients and cancer cell lines establishment
1992297|NCT03322423|Device|Multifocal Contact Lens 1|Dailies Total 1 Multifocal Contact Lens
1992298|NCT03322423|Device|Multifocal Contact Lens 2|Biotrue ONEday for Presbyopia Contact Lenses
1992299|NCT03322423|Device|Spherical Contact Lens 2|Spherical Contact Lens 2
1992300|NCT03322410|Biological|modified Peritoneal Equilibration test|"Peritoneal permeability status determined by modified Peritoneal Equilibration test with complete drainage at 60 minutes as described for TwardowskyHigh : D/P creatinine>0,8; D/D0 glucose<0,25High average : 0,65< D/P creatinine <0,8; 0,25< D/D0 glucose <0,38Low average : 0,5< D/P creatinine <0,65; 0,39< D/D0 glucose < 0,48Low  : D/P creatinine<0,5 ; D/D0 glucose>0,49."
1992301|NCT03322397|Behavioral|Self-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for themselves three times per week. These acts should require effort and be outside of an individual's normal routine.
1823070|NCT00752141|Drug|oxybutynin chloride topical gel|oxybutynin chloride topical gel applied once daily, and capsule containing placebo tablet administered three times daily
1823071|NCT00752141|Other|placebo|capsule containing placebo tablet administered three times daily, and placebo gel administered once daily
1823072|NCT00752154|Drug|Curcumin (Longvida™)|Curcumin (Longvida™) or matching placebo. They will begin by taking 4 capsules (approximately 2 grams) once a day for 2 weeks and then the dose will be increased to 4 capsules twice a day (4 gram per day) beginning at week 3. Subjects will remain at this dose for an additional 13 weeks for a total 16 weeks. After 16 weeks, the same procedures will be repeated for another 16 weeks
1823073|NCT00752180|Biological|Wosulin R|Total dose per subject will be 0.3 IU/Kg given Subcutaneously.
1823074|NCT00752180|Biological|Actrapid|Total dose per subject will be 0.3 IU/kg given Subcutaneously.
1823075|NCT00752193|Other|Probiotic lactobacilli|Probiotic lactobacilli in combination with antibiotic therapy
1823076|NCT00752193|Other|Placebo|Placebo in combination with antibiotic therapy
1823079|NCT00752219|Drug|ceftazidime/NXL104 + metronidazole|IV TID
1823080|NCT00752219|Drug|meropenem|IV TID
1823081|NCT00752232|Biological|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
1823082|NCT00752232|Other|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
1823083|NCT00752232|Biological|ACC-001|IM injection, dose of 3, 10, 30 micrograms, Day 1, month 3, 6, 9, 12
1823084|NCT00752232|Other|QS-21|IM injection, dose of 50 micrograms, Day 1, month 3, 6, 9, 12
1823085|NCT00752232|Other|PBS|IM injection, Day 1, month 3, 6, 9, 12
1823086|NCT00752245|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
1823087|NCT00752245|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
1823088|NCT00752245|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
1823089|NCT00752258|Drug|Mentor Purified Toxin Botulinum Toxin Type A|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of Mentor Purified Toxin. Subjects will have many Treatment Visits throughout the course of the three-year study.
1823090|NCT00752284|Procedure|Coronectomy|Coronectomy Group. Removal of crown of lower wisdom tooth, trim down root below crestal bone and primary closure
1823091|NCT00752284|Procedure|Total Excision|Total excision of lower third molar
1823092|NCT00752297|Drug|Preservative-free Saline|Subjects will receive five 0.1 mL intramuscular injections at the Day 0 Treatment Visit: two in each corrugator and one in the procerus muscle. The total treatment dose (sum of the five injections) to be administered will be 0.5 mL of the placebo (preservative-free saline).
1823093|NCT00752297|Drug|Mentor Purified Toxin|All subjects will receive five 0.1 mL intramuscular injections (two in each corrugator and one in the procerus muscle) at each Treatment Visit. The total treatment dose (sum of the five injections) to be administered will be 30 U of PurTox. Subjects will have many Treatment Visits throughout the course of the three-year study.
1823094|NCT00752310|Drug|Darunavir|
1823095|NCT00752323|Drug|aminolevulinic acid|Given orally
1823096|NCT00752336|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day
1823097|NCT00752349|Procedure|Ultrasound|To evaluate oral phase swallowing function using submental ultrasound
1823098|NCT00752362|Device|Milennium Matrix® (Control)|Percutaneous coronary intervention with bare metal stent
1823099|NCT00752362|Device|Infinnium®|Percutaneous coronary intervention with paclitaxel-eluting stent
1823100|NCT00752362|Device|Supralimus®|Percutaneous coronary intervention with sirolimus-eluting stent
1823101|NCT00752375|Drug|Trimethoprim Sulfamethoxazole|"Children >3months of age will receive Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)per day for one year.
Children under 3 months of age will receive amoxicillin 10mg/kg once per day for one year.
Those children with a Sulfa allergy will receive nitrofurantoin (1mg/kg) once per day for one year."
1823102|NCT00752375|Drug|placebo|"Placebo matching Trimethoprim Sulfamethoxazole (2mg/kg Trimethoprim component)for children more than 3 months of age
Placebo matching amoxicillin 10mg/kg once per day for children under 3 months of age
Placebo matching nitrofurantoin (1mg/kg) once per day for children with a sulfa allergy."
1823103|NCT00752401|Drug|Cholecalciferol|6800 IU of Cholecalciferol will be administered in the form of Oleovit® D3-drops once a day for one year. Treatment starts on day 5 after kidney transplantation. At serum calcium levels >2,65 mmol/l vitamin D3 administration will be reduced to 3600 IU per day. If calcium levels persist above 2,85 mmol/l over a period of four weeks vitamin D3 administration will be discontinued and restarted when serum calcium levels declined to ≤ 2,65 mmol/l with only 3600 International Units per day.
1823104|NCT00752401|Drug|Placebo|An oral placebo solution matching Cholecalciferol in terms of appearance, smell and taste will be administered once a day for one year. Treatment starts on day 5 after kidney transplantation.
1823105|NCT00752414|Drug|MP-376 (Levofloxacin solution for Inhalation)|Daily for 5 days
1823106|NCT00752414|Drug|Placebo|same frequency as MP-376
1823107|NCT00752427|Drug|Paliperidone ER OROS®|
1823108|NCT00752440|Other|Inspiratory muscle training (IMT)|IMT (30 min 7 times per week, for 8 weeks)
1823109|NCT00752453|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
1823110|NCT00752453|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
1823111|NCT00752453|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
1823112|NCT00752466|Drug|Topiramate; flunarizine|
1823113|NCT00752479|Biological|Mesenchymal stem cells infusion, Basiliximab,Methylprednisolone,RATG ,Cyclosporine ,Mycophenolate mofetil|"Cell therapy
Mesenchymal cells infusion.
Induction therapy:
Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).
Maintenance therapy:
Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
1823195|NCT00753103|Drug|Azathioprine|Daily oral 2 mg/kg started once patient is in remission and cyclophosphamide has been discontinued.
1823858|NCT00757991|Other|questionnaire administration|
1823114|NCT00752479|Drug|Basiliximab, Methylprednisolone,RATG,Cyclosporine,Mycophenolate mofetil|"Routine immunosuppressive therapy
Induction therapy:
Basiliximab (20 mg i.v.day 0 and day 4 post-tx). Low dose RATG (0.5 mg/kg/day i.v. day 0-6 post-tx). Methylprednisolone (500 mg to 25 mg from day 0 to 6 post-tx. Then stop).
Maintenance therapy:
Cyclosporine (from day 0: dose according to target trough blood level). Mycophenolate mofetil (750 mg b.i.d. from day 1 post-tx)."
1823115|NCT00752492|Other|Isocapnic Hyperpnoea|IH is a method of increasing alveolar ventilation (Va) while preventing the unwanted hypocapnia by addition of CO2 to the inhaled mixture.
1823116|NCT00752505|Drug|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
1823117|NCT00752505|Drug|Esreboxetine|Tablet once daily either placebo, 4mg or 8mg per day. Subjects will be on active treatment for 4 weeks out of a total of 11 weeks in a crossover dosing
1823118|NCT00752518|Drug|bortezomib|
1823119|NCT00752531|Behavioral|Home Automated Telemanagement (HAT)|The HAT was designed as an Internet-based telemedicine system that (1) provides ongoing education to patients about their chronic disease, (2) helps patients follow their self-care plans, and (3) helps health care practitioners monitor their patients' self-management processes according to current clinical guidelines. During each telecommunication session, patients perform self-testing and receive structured disease-specific education, patient-tailored counseling, and advice on how to follow their individual self-care plans based on the current results of self-testing.
1823120|NCT00752544|Drug|TMC435350|
1823124|NCT00752570|Drug|AMG 386|AMG 386 (10 mg/kg QW) will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
1823125|NCT00752570|Drug|AMG 386 Placebo|AMG 386 placebo QW will be administered until subject develops disease progression, clinical progression, unacceptable toxicity, or withdraws consent.
1823126|NCT00752570|Drug|FOLFIRI|"Administration of FOLFIRI chemotherapy will commence on day 1 of each dosing week following the administration of AMG 386.
FOLFIRI Q2W regimen: irinotecan 180 mg/m2 IV over 90 (+-15) minutes on Day 1, leucovorin 400 mg/m2 IV over 2 hrs on Day 1, 5 FU 400mg/m2 IV bolus, followed by 2400 mg/m2 continuous IV infusion over 46 hrs +- 2 hours.
FOLFIRI will be administered until disease progression, FOLFIRI intolerability, death, or study withdrawal by the subject, investigator, or sponsor, whichever occurs earliest."
1823127|NCT00752583|Procedure|Peritoneal dialysis|Blood, urine and dialysate sampling
1823128|NCT00752583|Procedure|Haemodialysis|Blood, urine and dialysate sampling
1823129|NCT00752596|Drug|Azimilide 2HCl|One tablet of 125 mg/day azimilide 2HCl, taken until the study is terminated
1823130|NCT00752609|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous or intravenous injection, once every 4 weeks for up to 24 weeks. Initial dose based on patient's previous total weekly darbepoetin alfa dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
1823131|NCT00752622|Biological|Infliximab 5 mg/kg|Participants received Infliximab 5 mg/kg intravenously (IV) at weeks 0, 2 and 6 during the induction phase. At Week 10, those who were in clinical response received further treatment every 8 weeks during the observational phase
1823132|NCT00752622|Biological|Infliximab 5 mg/kg every 6 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 5 mg/kg IV every 6 weeks (shortened interval group)
1823133|NCT00752622|Biological|Infliximab 7 mg/kg every 8 weeks|Participants with loss of response in the observational phase were randomized at entry into the interventional phase received 7 mg/kg IV every 8 weeks (increased dose group)
1823134|NCT00752635|Drug|Norgestimate-ethinyl estradiol; Cyproterone acetate-ethinyl estradiol|
1823135|NCT00752648|Drug|TMC435350|
1823136|NCT00752661|Drug|Tramadol Hydrochloride; JNS013|
1823137|NCT00752674|Other|Neuromuscular balance|
1823138|NCT00752687|Drug|ABT-072|Capsule or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
1823139|NCT00752687|Drug|placebo|Capsule, or powder drug substance from the capsule mixed in an alternative vehicle. For additional information refer to Arm Description.
1823140|NCT00752700|Other|Conventional resistance training|Conventional resistance training program (CRT)
1823141|NCT00752700|Other|Whole body vibration resistance training|Whole body vibration resistance training (WBV) on the FITVIBE-platform
1823142|NCT00752713|Procedure|cardiac MRI|cardiac MRI at one time point for group 1 after intervention for group 2 at any time point
1823143|NCT00752726|Drug|Orlistat|Weight loss treatment
1823144|NCT00752726|Drug|Placebo|Inactive
1823145|NCT00752739|Dietary Supplement|selenium|Given orally
1823146|NCT00752739|Other|placebo|Given orally
1823147|NCT00752778|Other|pet-scan FDG-F18|
1823148|NCT00752791|Drug|Peginesatide|Peginesatide 0.04 to 0.16 mg/kg, subcutaneous injection, once every 4 weeks for up to 25 weeks. Initial dose based on patient's previous total weekly Epoetin dose, and thereafter could be adjusted to maintain hemoglobin values in the target range of 10 to 12 g/dL and ±1.5 g/dL from Baseline.
1823149|NCT00752804|Procedure|Dialysis during 4 hours|Blood and dialysate sampling
1823150|NCT00752804|Procedure|Dialysis during 6 hours|Blood and dialysate sampling
1823151|NCT00752804|Procedure|Dialysis during 8 hours|Blood and dialysate sampling
1823152|NCT00752817|Other|Proficiency-based virtual reality simulation training|Subjects (surgical trainees) will be trained under a proficiency-based virtual reality simulation training programme before performing their first live case
1823153|NCT00752817|Other|Training under the current surgical training programme|Subjects (surgical trainees) will continue to train under the current training methodology offered at their institution before they perform their first live case.
1823154|NCT00752830|Drug|AZD0328|Oral capsule, single dose
1823155|NCT00752843|Drug|mifepristone + fluvastatin|Subjects will receive a single oral dose of 40 mg PO of fluvastatin on three occasions: alone (Day 1), at the same time as a single dose of CORLUX 1200 mg (Day 8) and during concomitant administration of CORLUX 1200 mg/day (CORLUX on Days 8-14, fluvastatin on Day 14).
1823156|NCT00752856|Drug|Kaletra + Isentress|kaletra 2 tabs twice a day + Raltegravir 1 tab twice a day
1823157|NCT00752856|Drug|Atripla|Atripla 1 tab once a day
1823160|NCT00752882|Drug|ceftazidime|
1823161|NCT00752895|Dietary Supplement|American ginseng|Given orally
1823162|NCT00752895|Dietary Supplement|Placebo|Given orally
1823163|NCT00752921|Drug|etoricoxib|120 mg
1823164|NCT00752921|Drug|placebo|placebo
1823165|NCT00752934|Drug|oral baclofen + placebo|"Group A will be given 13 weeks of oral baclofen followed by a 2-week non-treatment (washout) period, and then 13 weeks of oral placebo.
For participants who with weight under 15 Kg at the time of enrolment, the initial oral baclofen dose will be 2.5 mg daily, increasing weekly over a 7-week period to 10 mg three times a day, and will be continued at that dose for the following 5 weeks.
For those participants who will be over 15 Kg at the time of enrollment, the starting oral baclofen dose will be 5 mg daily, increasing over a 9-week period to 20 mg three times a day, and will be continued for the next 3 weeks at that dose. At the end of each 12-week period, the drug (either baclofen or placebo) will be tapered over 6 days.
Children's carers will given information on possible side effects, and asked to contact one of the researchers if any adverse events occur."
1823166|NCT00752934|Drug|placebo + oral baclofen|Group B will receive 13 weeks of oral placebo followed by 2-week nontreatment, and then 13 weeks of oral baclofen
1823167|NCT00752947|Drug|moxifloxacin|Moxifloxacin 400mg iv. OD followed by moxifloxacin 400mg OD orally, 2-4 weeks.
1823168|NCT00752947|Drug|levofloxacin|Levofloxacin 400mg i.v. OD followed by oral levofloxacin 400mg OD, 2-4 weeks
1823169|NCT00752947|Drug|metronidazole|metronidazole 0.5g i.v. bid followed by oral metronidazole 0.2g tid, 2-4 weeks
1823170|NCT00752973|Drug|MALG (malathion) Treatment|MALG applied for 30 minutes
1823171|NCT00752986|Drug|ZD6474 (Vandetanib at the dose of 100 mg)|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
1823172|NCT00752986|Drug|Placebo to match ZD6474 (Vandetanib at the dose of 100 mg)|Placebo of 300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
1823173|NCT00752986|Drug|Fulvestrant|All patients will receive fulvestrant Loading Dose (LD). The Loading Dose regimen is 500mg (2 injections) at day 1, followed by 250mg at day 14, 28 and every 28 days thereafter.
1823174|NCT00752986|Drug|ZD6474 (Vandetanib at the dose of 300 mg)|300 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first.
1823175|NCT00752986|Drug|Placebo to match ZD6474 (Vandetanib at the dose of 300 mg)|Placebo of 100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
1823176|NCT00752999|Drug|Fostamatinib Disodium (R935788)|150 mg tablet, oral, twice-a-day
1823177|NCT00752999|Drug|Placebo|Placebo tablet, oral, twice-a-day
1823178|NCT00753012|Drug|Lisdexamfetamine|Lisdexamfetamine daily until the completion of participation in the clinical trial (up to Week 11 or final study visit). Subjects will start on 30 mg of LDX per day for the first week of treatment. The dose will be increased weekly in 20 mg increments, up to a 70 mg daily (maximum). If significant adverse effects (AE) occur, the daily dose may be reduced by 20 mg. At subsequent visits, a higher dose may be resumed if tolerated. Both cohorts of the study will follow the same treatment plan.
1823179|NCT00753025|Procedure|Bone marrow aspiration, injection of cells|"Bone marrow is aspirated at patients in all arms.
Arm TNC receives injection of total nucleated cells into ischemic muscle"
1823180|NCT00753025|Procedure|Bone marrow aspiration , injection of isolated CD 133+ cells|"arm CD133 receives injection of isolated CD 133+ cells"
1823181|NCT00753025|Procedure|Bone marrow aspiration, injection of saline|"arm placebo receives injection of saline"
1823182|NCT00753038|Biological|REOLYSIN®|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
1823183|NCT00753038|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
1823184|NCT00753038|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
1823185|NCT00753051|Drug|clozapine+haloperidol|clozapine 300-900 mg/d haloperidol 4-60 mg/d
1823186|NCT00753051|Drug|clozapine,electroconvulsive therapy|clozapine 300-900 mg/d electroconvulsive therapy 4-12 times
1823187|NCT00753064|Drug|Antiscorpion venom serum(AScVS).|"AScVS therapy group
If the score is 5 and if the patient belongs to pediatric group(>12-14): 1 vial AScVS as i.v. slow bolus after test dose If the score is 5 and if the patient is adult: 2 vials of AScVS as i.v. slow bolus after test dose. For injection, 1 vial will be dissolved in 10 ml distilled water and given over a period of 4 to 5 minutes.
According to the scores 1 vial for pediatric and 2 vials for adult patient will be increased as shown below:
Vials of AScVS Composite score Child Adult 5-10 2 4 > 10-15 3 6 >15- 21 4 8"
1823188|NCT00753064|Drug|T.Prazosin|Prazosin therapy Prazosin (30 micrograms/Kg/dose): 500 micrograms for pediatric patient, and 1mg for adult patients) will be given every 3 hourly orally till complete recovery.
1823189|NCT00753064|Drug|AScVS + Prazosin|Combination AScVS and Prazosin therapy In this group, AScVS therapy will be given as mentioned in AScVS therapy group and in addition, prazosin(500 micrograms for pediatric patient and 1mg for adult patients,30 micrograms/Kg/dose) every 3 hourly will be given.
1823190|NCT00753090|Device|Vanguard™ Deep Dish Rotating Platform Knee|Vanguard™ Deep Dish Rotating Platform Knee
1823191|NCT00753090|Device|Vanguard™ Cruciate Retaining Knee|Vanguard™ Cruciate Retaining Knee
1823192|NCT00753103|Biological|Infliximab|5 mg/kg intravenous infusion at weeks 0, 2, 6 and 10 of study
1823193|NCT00753103|Drug|Cyclophosphamide|Daily oral 2 mg/kg or pulsed intravenous 15mg/kg every 2-3 weeks for 3-6 months (until patient has been in remission for 3 months).
1823194|NCT00753103|Drug|Prednisolone|Daily oral 1mg/kg tapered over 12 months
1824397|NCT00762515|Drug|Fluoride|Brush two times daily for 6 weeks
1823196|NCT00753103|Procedure|Plasma exchange|Additional therapy for patients with severe vasculitis (creatinine > 500 mcmol/L or pulmonary haemorrhage). 7x 4L exchanges over 10 days.
1823197|NCT00753103|Drug|Mycophenolate mofetil|Daily oral up to 1.5 g twice daily as tolerated. Used as alternative to azathioprine at lead physicians discretion.
1823198|NCT00753103|Drug|Methylprednisolone|500 mg intravenous infusion daily for three days at lead physicians discretion.
1823199|NCT00753116|Device|Renal Denervation with a catheter-based procedure|Disruption of the renal nerves with a catheter-based procedure
1823200|NCT00753129|Procedure|Prone position with head elevation|Head elevation of 30° in prone position (Ant-Trendelenburg position of the whole bed)
1823201|NCT00753142|Drug|Intralipid 20%|48hr infusion with intralipid at 40ml/hr
1823202|NCT00753142|Drug|Glucose infusion|Glucose infusion for 20 hours at 200 mg/m2/min
1823203|NCT00753155|Behavioral|exercise training; psychosocial support|supervised home-based endurance training; recommendation to exercise every other day; psychosocial support
1823204|NCT00753168|Drug|OT-730 ophthalmic solution|one eye drop twice daily
1823205|NCT00753168|Drug|timolol maleate ophthalmic solution|one eye drop twice daily
1823206|NCT00753168|Drug|OT-730 placebo|one eye drop twice daily
1823207|NCT00753181|Other|Nutritional Formula|nutritional shake daily
1823208|NCT00753181|Other|Usual diet|usual dietary habits
1823209|NCT00753181|Other|Diabetes Meal Plan with experimental diabetes-specific nutritional shake, diabetes specific cereal, and diabetes specific snack bars.|nutritional shake, diabetes specific cereal and diabetes snack bar daily
1823210|NCT00753207|Drug|epirubicin hydrochloride|
1823211|NCT00753207|Drug|lapatinib ditosylate|
1823212|NCT00753207|Other|biomarker analysis|
1823213|NCT00753207|Other|immunohistochemistry staining method|
1823214|NCT00753207|Other|liquid chromatography|
1823215|NCT00753207|Other|mass spectrometry|
1823216|NCT00753220|Biological|VDC2008|"Intratumoral injection of VDC2008 post-cryotherapy.
Dosage will depend on cohort: 2.5 x 10^7, 7.5 x 10^7 or 1.0 x 10^8 cells"
1823217|NCT00753220|Drug|Cyclophosphamide|Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles [1 cycle = 4 weeks] starting Week 2 after cryoablation and going to Week 26)
1823218|NCT00753246|Drug|nimotuzumab|monoclonal antibody
1823219|NCT00753259|Other|AF Clinic|Treatment of atrial fibrillation patients by specialized nurses, supervised by cardiologists, using dedicated software to ensure maximal adherence to AHA/ACC/ESC guidelines on atrial fibrillation treatment
1823220|NCT00753259|Other|Care as Usual|Routine clinical care of atrial fibrillation patients, provided by cardiologists, without the help of specialized nurses or dedicated software.
1823221|NCT00753272|Biological|GSK Bio's influenza vaccine GSK2186877A|IM administration, two times one annual dose, 3 different lots will be tested
1823222|NCT00753272|Biological|Fluarix TM|IM administration, two times one annual dose
1823223|NCT00753285|Device|Renal Denervation|
1823224|NCT00753298|Device|LoFric Primo (POBE) single-use urinary catheter|LoFric Primo (POBE) single-use urinary catheter
1823225|NCT00753298|Device|LoFric Primo (PVC) single-use urinary catheter|LoFric Primo (PVC) single-use urinary catheter
1823226|NCT00753311|Drug|rizatriptan or placebo|Patient took 1 rizatriptan 10 mg wafer or placebo as soon as their migraine headache became of moderate or severe intensity.
1823227|NCT00753324|Drug|Routine three-drug antiretroviral prophylaxis|Women who are identified as HIV-infected will be offered routine combination antiretroviral prophylaxis starting at 28 weeks gestation (timing consistent with Zambian national guidelines for short-course ZDV). The first-line combination provided to pregnant women will be standardized following consultation with the Ministry of Health, but will likely include ZDV, lamivudine (3TC) and either NVP or lopinavir / ritonavir. In women who with moderate to severe anemia, ZDV is substituted with stavudine (d4T). In accordance with the Zambian national guidelines, any patients who are started on NVP will begin with a once daily dose for two weeks before increasing to the regular twice daily schedule
1823228|NCT00753337|Device|Assurant® Cobalt Iliac Stent System|Iliac Stenting
1823229|NCT00753350|Device|Sensate™ anchored gastric device|Delivery/anchoring of the Sensate™ device in the stomach. Withdrawal of the Sensate™ device and its anchoring components after 8 weeks.
1823230|NCT00753363|Other|Weight Loss|6 months of weight loss
1823231|NCT00753363|Other|Aerobic Exercise Training|6 months of aerobic exercise training
1823232|NCT00753389|Other|None (anesthesia)|anesthesia
1992302|NCT03322397|Behavioral|Other-Focused Acts of Kindness Intervention|Participants engage in positive behaviors by completing acts of kindness for others three times per week. These acts should require effort and be outside of an individual's normal routine.
1823235|NCT00753415|Biological|V935|A 0.5 mL vaccine administered IM every 2 weeks as either a LD (1 x 10^9 vector genomes/mL) or a HD (1 x 10^11 vector genomes/mL).
1823236|NCT00753415|Biological|V934-EP|A 0.5 mL vaccine administered by EP as either a LD (0.5 mg plasmid/mL) or a HD (5.0 mg plasmid/mL).
1823237|NCT00753428|Other|Community-based Survey|"Questionnaires will be used to record detailed information regarding demographic and socioeconomic characteristics, maternal medical history, recent obstetrical history (including access to preventive services for mother-to-child HIV transmission), and infant medical history. Infant deaths will also be recorded as part of the survey. In cases where either the mother or infant has died, we will perform verbal autopsy interviews (Appendix 5) with surviving family members to determine cause of death and gather information regarding HIV infection and/or exposure.
Heel/finger pricks will be taken so as to perform dried blood spot cards, and test for HIV in children and adults."
1823240|NCT00753454|Drug|Certolizumab pegol|Liquid certolizumab pegol administered every two weeks as a single injection (400 mg at Entry, Week 2 & Week 4, followed by 200 mg every 2 weeks).
1823241|NCT00753467|Drug|IFN-γ 1b (Actimmune)|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose
1823242|NCT00753467|Drug|Adefovir dipivoxil|Adefovir dipivoxil: 1 tablet of 10mg given orally QD
1823243|NCT00753467|Drug|IFN-γ 1b and Adefovir dipivoxil combination|IFN-γ 1b: 200μg given SC ED = 2 vials of active drug (0.5 mL from each vial) will be mixed for a total volume of 1.0 mL per dose Adefovir dipivoxil: 1 tablet of 10mg given orally QD
1823244|NCT00753480|Drug|D4064A|
1823245|NCT00753493|Drug|intravenous topiramate|Single 25 mg IV dose given in addition to subject's normal morning dose of topiramate
1823246|NCT00753506|Dietary Supplement|Artemisinin|100 mg of artemisinin twice per day for 10 weeks
1823247|NCT00753506|Dietary Supplement|Identical looking placebo capsule|Identical looking placebo twice per day for 10 weeks
1823248|NCT00753519|Device|Real iTBS|Real iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
1823249|NCT00753519|Device|Sham iTBS|Sham iTBS was performed in 8 sessions over 2 successive weeks, a session/day for 4 consecutive days/week.
1823250|NCT00753532|Dietary Supplement|200mg of Palm vitamin E (tocotrienols) or placebo|Individuals randomized in the (MRI+ve) and (MRI -ve) cohort received either 200 mg softgels of Palm Vitamin E (tocotrienols) or placebo taken orally twice a day.
1823251|NCT00753545|Drug|AZD2281|Oral 400mg bid
1823252|NCT00753545|Drug|matching placebo|matching placebo bid
1823253|NCT00753558|Drug|Arm #1 :Oral solution and buccal gel of gentamicin and polymyxin E. Arm #2: Placebo.|"Arm #1: Oral gentamicin & polymyxin E, gentamicin & polymyxin E buccal gel.
Arm #2: Oral placebo solutions, placebo buccal gel."
1823254|NCT00747513|Behavioral|lifestyle program|a comprehensive program designed to encourage healthier food choices and eating habits and increased physical activity among children, by use of school, family and community measures.
1823255|NCT00753571|Drug|Cistanche Total Glycosides|"Drug: Cistanche Total Glycosides Cistanche Total Glycosides ,1.8g/day(6 capsules) po Qd*9months Arms: 1 Drug: blank capsules 6 capsules po Qd*9months
Arms: 2"
1823256|NCT00753597|Drug|Solu-medrone, Mabthera|125mg, 1gram, twice day 1 and day 15
1823257|NCT00753623|Drug|Ramelteon|ramelteon (8 mg)
1823258|NCT00753623|Drug|Placebo|In a crossover design, a subject will be first assigned to the ramelteon or placebo arm and then switched over to the opposite arm.
1823259|NCT00753636|Drug|Dynacirc CR (Isradipine)|Dynacirc CR is given by the recommended schedule for titration. Subjects start on a 5mg dose and are increased in increments of 5mg every 2 weeks provided that the subjects do not have significant adverse events or symptomatic orthostatic hypotension.
1823260|NCT00753649|Biological|Infanrix™ hexa|Intramuscular, three doses
1823261|NCT00753662|Device|1Hz TMS with H2 coil|1Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
1823262|NCT00753662|Device|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex|10Hz TMS with H2 coil to prefrontal and parieto-temporal cortex
1823263|NCT00753662|Device|SHAM TMS with H2 coil|SHAM TMS with H2 coil to prefrontal and parieto-temporal cortex
1823264|NCT00753675|Drug|ZD6474, Vandetanib|300 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
1823265|NCT00753675|Drug|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
1823266|NCT00753675|Drug|Gemcitabine|administered intravenously at 1000 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle up to 6 cycles or until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
1823267|NCT00753675|Drug|Placebo matching ZD6474|Placebo to match ZD6474 100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
1823268|NCT00753688|Drug|PAZOPANIB|800 mg once daily orally
1823269|NCT00753688|Drug|Placebo|matching placebo 800 mg once daily orally
1823270|NCT00753714|Drug|ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 until disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
1823271|NCT00753714|Drug|Placebo to Match ZD6474, Vandetanib|100 mg as a once daily oral dose, from Day 1 UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
1823272|NCT00753714|Drug|Gemcitabine|administered intravenously at 1200 mg/m2 over 30 minutes on Days 1 and 8 of each 21-day cycle UP to 6 cycles or UNTIL disease progression or unacceptable toxicity or consent withdrawal whichever occurs first
1823273|NCT00753727|Drug|Sunitinib malate|Sunitinib dose 50 mg/day orally for 2 weeks prior to radiotherapy. Treatment Dose Levels during radiotherapy: Dose level 0: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 25mg/day given concurrently with radiotherapy; Dose level 1: Sunitinib 50mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy; Dose level -1: Sunitinib 37.5mg/day for 2 weeks prior to radiotherapy, followed by 37.5mg/day given concurrently with radiotherapy. Dose escalation/de-escalation: first 6 patients will be accrued at dose level 0. The dose levels at which subsequent patients will be accrued will be determined using a dose modification schedule.
1823274|NCT00753727|Radiation|Radiotherapy|Preoperative radiotherapy consisting of external beam radiotherapy at a dose of 50.4 Gy given in 28 fractions, five days a week, over five weeks and 3 days to the planning target volume.
1823275|NCT00753740|Drug|IT-101 (12mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive a blinded infusion of IT-101 (12mg/m2/dose) every other week until disease progression.
1823276|NCT00753740|Drug|IT-101 (15mg/m2/dose)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of IT-101 (15mg/m2) every other week until disease progression.
1823277|NCT00753740|Drug|5% Dextrose (Placebo)|Patients who satisfy the inclusion/exclusion criteria will receive an infusion of placebo every other week until disease progression.
1823278|NCT00753766|Other|Multifactorial Intervention|
1823279|NCT00753779|Drug|colesevelam HCl tablets, and simvastatin tablets|colesevelam HCl tablets, 6/day simvastatin tablet, 1/day
1823280|NCT00753779|Drug|simvastatin tablets and colesevelam HCl placebo|simvastatin tablet, 1/day; Welchol placebo tablets, 6/day
1823281|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.000 mg/day intravenous administration during three days
1823282|NCT00753792|Drug|methylprednisolone|methylprednisolone 1.250 mg/day orally administered during three days
1823283|NCT00753792|Drug|Placebo|Placebo of methylprednisolone administered intravenously (Arm 2) or orally (Arm 1)
1823284|NCT00753805|Dietary Supplement|mare's milk|The participants received 250 ml mare's milk or placebo daily. The placebo drink was based on a hypoallergenic infant formula.
1823285|NCT00753818|Other|DHA and ARA|various levels of DHA and ARA
1823286|NCT00753818|Other|Control|
1823287|NCT00753831|Procedure|Aurosling|Silicon rod to be used in frontalis suspension surgery
1823288|NCT00753844|Biological|URLC10|Biological: URC10 Patients will be vaccinated once in one week to the eighth vaccine and will be vaccinated once in two weeks from the ninth vaccine. On each vaccination day, the URLC10 peptide (1mg) mixed with Montanide ISA 51 will be administered by endodermic injection.
1823289|NCT00753857|Other|Drug Facts Box|Educational intervention of 1 page summary of drug efficacy and side effects
1823290|NCT00753857|Other|Standard Brief Summary|Ads consisted of the standard second page called the brief summary
1823291|NCT00753870|Biological|CCRE inhalation|20,000 EU CCRE given as a one-time challenge
1823292|NCT00753883|Drug|simvastatin|simvastatin 20 mg/QD for 6 Weeks.
1823293|NCT00753883|Drug|Ezetimibe|Ezetimibe 10 mg/QD for 8 weeks.
1823294|NCT00753896|Drug|exenatide|subcutaneous injection, 2.0mcg, once weekly
1823295|NCT00753909|Drug|Carboplatin|Carboplatin (IV) 3 AUC on day 1 and day 15 every 4 weeks for 6 cycles
1823296|NCT00753909|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15 every 4 weeks for 6 cycles Followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
1823297|NCT00753909|Drug|Paclitaxel|Paclitaxel (IV) 140 mg/m2,on day 1 and day 15 every 4 weeks for 6 cycles
1823298|NCT00753922|Device|Mentor Round Low Bleed Gel-filled Mammary Protheses, both Siltex and Smooth Surface|Two types of Mentor Round Low-Bleed Silicone Gel-filled Mammary Prostheses will be used in the study: the Siltex textured surface device and the smooth surface device. Each implant is a silicone elastomer (rubber) mammary device that is supplied individually packaged in a doubled wrapped packaging system, sterile, and non-pyrogenic (does not cause fever). Each device consists of a silicone shell encasing a silicone gel filler material with a patch on the posterior side of the device. The basic smooth device shell consists of a silicone layer sandwiched in between two other silicone layers. This construction acts as a barrier to slow the diffusion of (spread) any gel filler materials through the shell. The Siltex textured shell consists of a smooth shell to which is bonded an additional layer of silicone with a textured pattern imprinted into its surface. The Siltex shell is intended to prevent tissue ingrowth. The implants will be available in sizes 100cc through 800ccs.
1823299|NCT00754221|Drug|[S,S]-Reboxetine|Once a day, oral treatment, of 4, 6, 8 or 10 mg
1823300|NCT00754234|Behavioral|My Pyramid menu days 1, 2, 3, 4, 5, 6 or 7|Iron absorption measured from one of seven different menus fed for 1 day each, in randomized order for each subject, with feedings separated by 2 weeks
1823301|NCT00754247|Drug|0.5% hydrocortisone, silicone, vitamin E lotion|0.5% hydrocortisone, silicone, vitamin E lotion will be applied topically to cover the selected scar twice daily for 16 weeks. The lesion will be cleansed with soap and water and dried thoroughly. The medication will be applied with a brush and allow it to dry for one minute before contact with clothing.
1823302|NCT00754247|Drug|Onion extract gel|Onion extract gel is applied and massaged into the selected scar 3 to 4 times daily according to product instructions for 16 weeks.
1823303|NCT00754247|Drug|Cetearyl alcohol lotion|Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
1823304|NCT00754260|Behavioral|Caffeine reduction|patients are randomized to receive caffeine reduction counseling versus no caffeine reduction counseling
1823305|NCT00754273|Other|etest susceptability testing|E-test methodology is performed on all MRSA samples using standardized inoculum (0.5 McFarland) for Tigecycline, Vancomycin, Teicoplanin, and Linezolid. E test is performed using heavy inoculum for Vancomycin and Teicoplanin (2.0 McFarland).
1823306|NCT00754286|Other|Aromatherapy Scented Wand|"The aromatherapy used in this will be Quease Ease™, manufactured by Soothing Scents, Inc. Quease Ease is a blend of lavender, spearmint, ginger, and peppermint soaked into a pad placed within a wand dispenser that emits a fragrance when placed within a few inches of the nares. Participants will be given aromatherapy wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the aromatherapy treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety."
1823307|NCT00754286|Other|Placebo wand|Placebo wands will look identical to the scented wands but will not contain a scent. Participants will be given the placebo wand at the onset of their chemotherapy treatment. Participants will be instructed how to self-administer the placebo treatment. Specifically, they can hold the wand under their nose and breathe in deeply five times when they feel symptoms of nausea or anxiety.
1823308|NCT00754312|Drug|SNDX-275|
1823309|NCT00754325|Drug|Dasatinib|Tablets, Oral, 100 mg, once daily (QD), upto 2 years
1823310|NCT00754325|Drug|Fulvestrant|Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1. In subsequent cycles, 500 mg IM administered on Day 1. IM day 1 and 15 first cycle then IM Day 1 for all other cycles for 2 years
1823311|NCT00754338|Drug|Alcon Opti-Free® RepleniSH® with Supraclens®|Marketed Multipurpose Disinfecting Care System + Marketed contact lens protein remover
1823312|NCT00754338|Drug|Alcon Opti-Free® RepleniSH®|Marketed Multipurpose Disinfecting Care System
1823313|NCT00754338|Drug|B&L ReNu MultiPlus™|Marketed Multipurpose Disinfecting Care Systems
1823314|NCT00754351|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on days 1 and 15 every 4 weeks for 6 cycles followed by Bevacizumab (IV) 15 mgr/Kgr on day 1 every 3 weeks until disease progression
1823315|NCT00754351|Drug|Docetaxel|Docetaxel (IV) 65 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
1823316|NCT00754351|Drug|Gemcitabine|Gemcitabine (IV) 1500 mg/m2 on days 1 and 15 every 4 weeks for 6 cycles
1823362|NCT00754741|Behavioral|Adherence information|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system.
1823627|NCT00756470|Drug|Cyclophosphamide|500 mg/m^2 intravenously over 45-60 minutes every three weeks of Weeks 13-24.
1823317|NCT00754364|Drug|Pemetrexed/Carboplatin|"Patients will receive Pemetrexed intravenous infusion (i.v.) via infusion pump or gravity drip, at a dose of 500 mg/m2 (over a target of 10 minutes). Pemetrexed should be administered every 21 days on the same day.
Patients will receive carboplatin intravenous continuous infusion (i.v.) over 30 minutes via infusion pump or gravity drip, at a dose of AUC5. Carboplatin should be administered every 21 days on the same day."
1823318|NCT00754364|Drug|Gemcitabine|Patients will receive gemcitabine 1250 mg/m2 as a 30 minutes intravenous infusion on days 1 and 8 and of a 21-day cycle.Patients may continue to receive gemcitabine for up to a maximum of 6 cycles.
1823319|NCT00754377|Other|PBLI Curriculum|PBLI curriculum was offered on alternate rotations
1823320|NCT00754390|Dietary Supplement|Moderate Calcium, Low phytate Diet|Participants consumed diet containing 700 milligrams calcium and 440 milligrams of phytate for 4 weeks
1823321|NCT00754390|Dietary Supplement|Moderate Calcium, High Phytate Diet|Participants consumed diet containing 700 milligrams calcium and 1800 milligrams of phytate for 4 weeks
1823322|NCT00754390|Dietary Supplement|High Calcium, Low Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 440 milligrams of phytate for 4 weeks
1823323|NCT00754390|Dietary Supplement|High Calcium, High Phytate Diet|Participants consumed diet containing 1900 milligrams calcium and 1800 milligrams of phytate for 4 weeks
1823324|NCT00754403|Drug|Pioglitazone and metformin|Pioglitazone 30 mg, tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
1823325|NCT00754403|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, once daily and metformin 1000 mg, tablets, orally once daily for up to 16 weeks.
1823326|NCT00754429|Drug|losartan|losartan 50mg qd for 30 weeks.
1823327|NCT00754429|Drug|amlodipine|amlodipine 5 mg q.d for 30 weeks.
1823328|NCT00754442|Drug|Teriparatide|"Teriparatide will be given by continuous intravenous infusion at a rate of 12 pmol/kg/hr for 8 hours to both patients and controls"
1823329|NCT00754455|Biological|Influenza VLP Vaccine (recombinant)|Single injection Day 0; 0.5mL
1823330|NCT00754455|Biological|Placebo|Placebo as a single injection of 0.5 mL.
1823331|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 4 cycles x 10 seconds treatment
1823332|NCT00754468|Device|Cryo Spray Ablation|Cryo Spray Ablation 2 cycles x 20 seconds
1823333|NCT00754481|Other|Normothermia|Patients randomized to the Normothermia arm (esophageal temp 36.5-37.5 ºC) will be maintained at an esophageal temperature of 36.5-37.5ºC for 48 hours. Patients who are hypothermic (temperature < 35 ºC) when randomized to the normothermia group will be rewarmed slowly using the servo-controlled mattress. Patients who are hyperthermic following randomization to the normothermia group will be actively cooled to normothermia using the servo-controlled mattress. Neuromuscular blockers will be administered as needed intravenously in both groups of patients to prevent shivering.
1823334|NCT00754481|Other|Hypothermia|Patients randomized to the Hypothermia arm (esophageal temp 33º to 34 °C) will be cooled rapidly using the cooling protocol developed for the Hypothermia Paediatric Head Injury Trial. A temperature probe will be placed in the esophagus and its position confirmed using a chest radiograph. Patients will be placed on a servo-controlled cooling blanket and covered in crushed ice (in sealed plastic bags covered by pillow cases) and a second cooling blanket. Once the esophageal temperature reaches 34.0ºC, the ice and second cooling blanket will be removed and esophageal temperature will be maintained at 33º to 34 °C for 48 hours using the servo-controlled cooling mattress. Patients treated with ECMO will be cooled using the extracorporeal circuit cooling-device. Rewarming will be done at a rate of 0.5 ºC every 2 hours until an esophageal temperature of 36.5 ºC is reached. Thereafter temperature will be recorded but not controlled by surface cooling.
1823335|NCT00754494|Drug|erlotinib hydrochloride|Given PO
1823336|NCT00754494|Other|placebo|Given PO
1823337|NCT00754494|Other|laboratory biomarker analysis|Correlative studies
1823338|NCT00754507|Drug|colesevelam HCl tablets, and atorvastatin tablets|colesevelam HCl tablets,6 tablets/day; atorvastatin tablets, 1 tablets/day for 6 weeks
1823339|NCT00754507|Drug|colesevelam HCl placebo tablets and atorvastatin tablets|colesevelam HCl placebo tablets, 6 tablets/day for 6 weeks atorvastatin tablets, 1 tablet/day for 6 weeks
1823340|NCT00754520|Device|Ceramic On Metal|Ceramic on Metal articulation using M2a-38™ mm cup
1823341|NCT00754520|Device|Metal on Metal|Metal on Metal articulation using M2a-38™ mm cup
1823342|NCT00754533|Other|Continuous versus interval training|Influence of different exercise training programs
1823343|NCT00754546|Drug|Arformoterol tartrate|15 mcg in two ml solution administered via nebulizer
1823344|NCT00754546|Drug|Placebo: Normal Saline|Normal saline was nebulized.
1823345|NCT00754546|Other|Treadmill Exercise|
1823346|NCT00754546|Other|Cycle Exercise|
1823347|NCT00754559|Drug|Tocilizumab|8mg/kg iv every 4 weeks
1823348|NCT00754572|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv, every 4 weeks
1823349|NCT00754572|Drug|methotrexate|10-25mg oral or parenteral weekly.
1823350|NCT00754585|Device|Logic Back Grahl Duo Back Model DB11‐01|The device is placed against the back rest of a chair. The tension of the straps are adjusted for each participant to obtain the ENP.
1823351|NCT00754624|Drug|Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler|Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
1823352|NCT00754650|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in single-use vials.
1823353|NCT00754663|Behavioral|exercise training|walking training at least 3 times a week
1823354|NCT00754689|Drug|Rimonabant|Tablet, oral administration
1823355|NCT00754689|Drug|Metformin|Tablet, oral administration
1823356|NCT00754689|Drug|placebo|Tablet, oral administration
1823357|NCT00754702|Drug|Vinorelbine|Vinorelbine p.o (50 mg 3 times a week) until disease progression or appearance of unacceptable toxicity
1823358|NCT00754702|Drug|Lapatinib|Lapatinib p.o every day without interruption disease progression or appearance of unacceptable toxicity
1823359|NCT00754715|Drug|AZD2516|Solution administered once orally
1823360|NCT00754715|Drug|Placebo|Solution administered only once
1823361|NCT00754728|Device|JACTAX DES|Drug Eluting Stent
1824485|NCT00763139|Drug|Placebo|By mouth once a day for 8 weeks
1823363|NCT00754741|Behavioral|Adherence information plus motivational interviewing|Physicians, of the patients randomized to this arm, will have medication adherence information displayed when using the electronic prescribing system. Moreover, patients randomized to this arm will be recruited into a clinic run by pharmacists and nurses with delegated prescription power. The clinic personnel will use motivational interviewing techniques with patients to improve adherence to medications and/or to intensify medical treatment if adherence is optimal.
1823364|NCT00754754|Procedure|Brain Retraction Monitoring Sensor|This is a sensor incorporated into a brain retractor blade to monitor electrical activity and pressure applied to the brain during retraction required for the selected skull base operations.
1823365|NCT00754767|Drug|L-carnitine L-tartrate|Given orally
1823366|NCT00754767|Other|placebo|Given orally
1823367|NCT00754780|Drug|Pirfenidone|Capsule 800 mg TID, oral
1823368|NCT00754793|Drug|escitalopram|10mg - 30mg daily titrated as tolerated over 12 weeks
1823369|NCT00754793|Drug|placebo|inactive comparator; titrated as per protocol over 12 weeks
1992303|NCT03322397|Behavioral|Daily Reports|Participants will report their daily activities three times per week. Aside from reporting at the end of the day, no changes should be made to the individual's normal routine.
1823372|NCT00754832|Drug|American ginseng extract HT-1001|Ginseng HT-1001 was dosed at 100 mg orally per day initially, increased after one week to 200 mg per day, then further increased the next week to 400 mg per day as tolerated. Subjects were then maintained on 400 mg per day or the maximum tolerated dose for the remainder of the 6 week treatment period.
1823373|NCT00754832|Drug|placebo|Placebo capsules were identical to the study drug and were dose escalated to match the study drug. Subjects were maintained on placebo capsules for the remainder of the 6 week treatment period.
1823376|NCT00754858|Drug|belotecan hydrochloride|
1823377|NCT00754858|Drug|cisplatin|
1823378|NCT00754871|Drug|Dienogest (81150037)|daily oral intake of 0.5 mg dienogest over two cycles or a max. of 72 days
1823379|NCT00754871|Drug|Dienogest (81150231)|daily oral intake of 1.0 mg dienogest over two cycles or a max. of 72 days
1823380|NCT00754871|Drug|Dienogest (SH T00660A)|daily oral intake of 2.0 mg dienogest over two cycles or a max. of 72 days
1823381|NCT00754871|Drug|Dienogest (81150746)|daily oral intake of 3.0 mg dienogest over two cycles or a max. of 72 days
1823382|NCT00754884|Drug|salmon calcitonin|daily intranasal 200 U.I. salmon calcitonin for periods of 14 days at a time
1823383|NCT00754884|Drug|intranasal saline solution plus glycerol|daily intranasal (one shot) saline solution plus glycerol for a period of 14 days
1823384|NCT00754910|Drug|porfimer sodium|Given IV
1823385|NCT00754910|Procedure|bronchoscopy|Patients undergo bronchoscopy
1823386|NCT00754923|Drug|sorafenib|administered orally at 400 mg taken twice daily , continuously on a 28 day cycle as an outpatient.
1823387|NCT00754936|Drug|Escitalopram|20 mg by mouth daily
1823388|NCT00754949|Drug|1% Azithromycin and 0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
1823389|NCT00754949|Drug|1% Azithromycin|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
1823390|NCT00754949|Drug|0.1% Dexamethasone|Subjects will dose topically to the eye and eyelid BID at approximately 12 hour intervals for 14 days in both eyes.
1823391|NCT00754962|Drug|protriptyline|10 mg tablet
1823392|NCT00754975|Device|JACTAX LD DES|Drug Eluting Stent
1823393|NCT00754975|Device|TAXUS™ Libertè™ DES|Drug Eluting Stent
1823394|NCT00754988|Drug|Metformin|As prescribed
1823395|NCT00754988|Drug|Placebo (matching sitagliptin)|Once daily oral administration of placebo (matching sitagliptin).
1823396|NCT00754988|Drug|Placebo (matching taspoglutide)|Once weekly subcutaneous (sc) injection of placebo (matching taspoglutide).
1823397|NCT00754988|Drug|Sitagliptin|Once daily oral administration of 100 mg of sitagliptin.
1823398|NCT00754988|Drug|Taspoglutide|Once weekly subcutaneous (sc) injection of 10 mg or 20 mg of taspoglutide.
1823399|NCT00755001|Device|BiHapro hip stem with PPS Ti+Plasma HA|BiHapro hip stem with PPS Ti+Plasma HA
1823400|NCT00755001|Device|BiHapro hip stem with PPS Ti+BoneMaster HA|BiHapro hip stem with PPS Ti+BoneMaster HA
1823401|NCT00755014|Other|red wine|One group (n=20) that consumed red wine (100 ml) daily for 3 weeks Another group (n=20) that consumed beer (250 ml) daily for 3 weeks
1823402|NCT00755027|Drug|Rasagiline|rasagiline 1 mg daily, oral use, during 12 weeks
1823403|NCT00755040|Drug|cyclosporine ophthalmic emulsion|Given as eye drops
1823404|NCT00755040|Other|placebo|Given as eye drops
1823405|NCT00755053|Drug|Clotrimazole, vaginal ovule|Single intravaginal dose of 500 mg clotrimazole ovule at Visit 1 (Day 0).
1823406|NCT00755053|Drug|Clotrimazole, vaginal tablet|Single intravaginal dose of 500 mg clotrimazole tablet at Visit 1 (Day 0).
1823407|NCT00755066|Drug|Fluticasone propionate|200 µg intranasal, 4 weeks, od.
1823408|NCT00755066|Drug|Placebo|Placebo intranasal spray
1823409|NCT00755079|Drug|extended release beta-2 adrenergic agonist|Albuterol extended release belongs to a class of drugs known as bronchodilators. It works in the airways by opening breathing passages and relaxing muscles.
1823410|NCT00755079|Drug|placebo|An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
1823411|NCT00755092|Behavioral|Doula|Doula support for nulliparous women from the beginning of regular contraction of uterus to the end of delivery
1823412|NCT00755092|Behavioral|Doula|Doula support for multiparous women from the beginning of regular contraction of uterus to the end of delivery
1823413|NCT00755118|Drug|Oxaliplatin|Oxaliplatin (I.V) 85mg/m2 on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
1823414|NCT00755118|Drug|5-Fluorouracil|5-Fluorouracil (I.V) 1750mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
1823415|NCT00755118|Drug|Leucovorin|Leucovorin (I.V) 500mg/m2 on week 1,2,3 and 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
1823753|NCT00756990|Drug|Depot Naltrexone|228mg of injectable naltrexone
1823416|NCT00755118|Drug|Bevacizumab|Bevacizumab (I.V) 10mg/Kg on week 1 and week 3 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
1823417|NCT00755118|Drug|Irinotecan|Irinotecan (I.V) 110mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
1823418|NCT00755118|Drug|Cetuximab|Cetuximab (I.V) 500mg/m2 on week 2 and week 4 every six weeks for 2 continuously until disease progression or the appearance of unacceptable toxicity
1823419|NCT00755131|Other|Exercise-based Cardiac Rehabilitation program|Trained patients attend the exercise training protocol for 6 months on hospital ambulatory-based regimen 3 times/week. Training sessions are supervised under continuous electrocardiography monitoring by a cardiologist, a physiotherapist and a graduate nurse. Each session is preceded by a 5-min warming-up and followed by a 5-min cooling-down. Exercise is performed for 30 min on a bicycle ergometer with the target of 60-70% of the peak oxygen consumption achieved at the initial symptom-limited cardiopulmonary exercise test. Exercise protocol is performed with a gradual increase in exercise workload until the achievement of the predefined target.
1823420|NCT00755144|Device|LCS Knee|Cementless total knee arthroplasty with LCS Knee
1823421|NCT00755144|Device|ROCC Knee|Cementless total knee arthroplasty with ROCC Knee
1823422|NCT00755157|Drug|Docetaxel|Metronomic docetaxel (IV) 30 mg/m2 on days 1, 8, 15 every 4 weeks for 6 cycles maximum
1823423|NCT00755157|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by (not compulsory) Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
1823424|NCT00755170|Drug|Vinorelbine|Metronomic vinorelbine (p.o) 30 mg total dose/day, every Monday, Wednesday and Friday of each week, continuously without intervals for the equivalence of 6 cycles maximum
1823425|NCT00755170|Drug|Bevacizumab|Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks for 6 cycles maximum followed by Bevacizumab (IV) 10 mgr/Kgr on day 1 and 15 every 4 weeks until disease progression
1823426|NCT00755183|Drug|testosterone ophthalmic solution|testosterone ophthalmic solution for 128 days
1823427|NCT00755183|Drug|vehicle of testosterone ophthalmic solution|vehicle of testosterone ophthalmic solution for 128 days
1823428|NCT00755196|Drug|AN2728|AN2728 Ointment, 5%, twice daily for 12 weeks
1823429|NCT00755196|Drug|Ointment vehicle|Ointment vehicle, twice daily for 12 weeks
1823430|NCT00755209|Drug|tranexamic acid|Loading 1 gram (~20 mg/kg) 100cc solution infuses in 30 minutes Maintenance 1 gram (~2.5 mg/kg/hr) 1000cc solution infuses in 8 hours
1823431|NCT00755222|Biological|AA4500|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series was separated by 6 weeks.
1823432|NCT00755222|Biological|Placebo|2 single injections of study drug per each treatment series up to three treatment series total in study. Each treatment series is separated by 6 weeks.
1823433|NCT00755235|Other|Depression care management by secure messaging|Participants will receive electronic messages welcoming them and monitoring their antidepressant treatment. Care managers will use monitoring data to aid participants' physicians, coordinate physician follow-ups, facilitate emergency care, and facilitate specialty referrals. Care managers will also provide motivation and education to participants.
1823434|NCT00755248|Procedure|Coronary Artery Bypass Grafting|Coronary Artery Bypass Grafting on- or off-pump
1823435|NCT00755261|Drug|Avastin|Combination of Avastin and doxorubicin. If initial 90 +/- 15 minute infusion of Avastin is tolerated without fever and chills, the 2nd dose may be infused over 60 +/- 10 minutes. If well tolerated, all subsequent infusions may be delivered over 30 +/- 10 minutes.
1823436|NCT00755261|Drug|Doxorubicin|The Day 1 6- hour continuous IV infusion must be done through a central venous catheter.
1823437|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
1823438|NCT00755274|Biological|Influenza Virus Vaccine No Preservative: Pediatric Dose|0.25 mL, IM (age 6-35 months) or 0.5 mL, IM (age 36-59 months)
1823439|NCT00755287|Drug|insulin glargine|starting dose 10 IU daily
1823440|NCT00755287|Drug|metformin|As prescribed
1823441|NCT00755287|Drug|taspoglutide|10 mg once weekly
1823442|NCT00755287|Drug|taspoglutide|20 mg once weekly (after 4 weeks of taspoglutide 10 mg once weekly)
1823443|NCT00755300|Procedure|Measurement of total thrombolic load|A video recording of the right atrium using TE echo will be used to quantitate the total thromboembolic load
1823444|NCT00755313|Biological|trastuzumab|
1823445|NCT00755313|Drug|aromatase inhibition therapy|
1823446|NCT00755313|Drug|carboplatin|
1823447|NCT00755313|Drug|cyclophosphamide|
1823448|NCT00755313|Drug|docetaxel|
1823449|NCT00755313|Drug|doxorubicin hydrochloride|
1823450|NCT00755313|Other|metabolic assessment|
1823451|NCT00755313|Other|questionnaire administration|
1823452|NCT00755313|Other|study of socioeconomic and demographic variables|
1823453|NCT00755313|Procedure|cognitive assessment|
1823454|NCT00755313|Procedure|positron emission tomography|
1823455|NCT00755313|Radiation|fludeoxyglucose F 18|
1823456|NCT00755326|Drug|HLXL|Three daily dosages will be investigated. The lowest dosage condition will be 6 capsules (2,400 mg) daily, followed by an escalation to the 10 capsule condition (4,000 mg), and then to the 14 capsule (5,600 mg) condition. Participants will be treated for 6 weeks
1823457|NCT00755352|Drug|pravastatin tablets and Welchol tablets|pravastatin tablets, 1 tablet/day for 6 weeks; Welchol Tablets, 6 tablets/day for 6 weeks
1823458|NCT00755352|Drug|pravastatin tablets and Welchol placebo tablets|pravastatin tablets, 1 tablet/day; Welchol placebo tablets, 6 tablets/day
1823459|NCT00755378|Drug|AZD8529|Oral
1823460|NCT00755378|Drug|Placebo|Oral
1823461|NCT00755391|Behavioral|cognitive behavior therapy|The cognitive behavioral therapy used in this study will focus on developing patterns of regular eating, addressing body image issues, and ways to cope with situations that trigger eating disordered behaviors.
1823462|NCT00755391|Behavioral|Supportive Psychotherapy|The supportive psychotherapy treatment used in this study will involve identifying issues underlying your child's eating disorder and giving your child information about the psychological processes that tend to maintain or continue eating disorder symptoms.
1823463|NCT00755404|Drug|PD Solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 180 days.
1823464|NCT00755404|Drug|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 180 days.
1823465|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
1823466|NCT00755417|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
1823467|NCT00755417|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
1823468|NCT00755443|Device|Drug eluting stent|Drug eluting stent implantation
1823469|NCT00755443|Device|Bare metal stent|
1823470|NCT00755456|Drug|PD solution|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchange. PD solutions are instilled for 120 days.
1823471|NCT00755456|Drug|PD solution containing L-carnitine|Instillation of PD solutions containing Glucose (1.5 or 2.5%, w/v) and L-carnitine (0.1%, w/v) for the diurnal exchanges, and 1 PD solution containing icodextrin (7.5 w/v) for nocturnal exchanges. PD solutions are instilled for 120 days.
1823472|NCT00755469|Procedure|Post-conditioning|The post-conditioning protocol consists of performing 4, 30-second PTCA balloon occlusions followed by 30 seconds of reperfusion for a total of 4 minutes. The first balloon inflation occurs immediately after an angioplasty guidewire is placed through the obstruction in the artery and flow is restored. Following this protocol the vessel will be stented as part of usual practice for treatment of acute MI.
1823473|NCT00755482|Drug|Aquamin F|
1823474|NCT00755482|Drug|Placebo (maltodextran)|
1823475|NCT00755495|Drug|Ramelteon and doxepin|Ramelteon 8 mg, tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
1823476|NCT00755495|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
1823477|NCT00755495|Drug|Doxepin|Ramelteon placebo-matching tablets, orally, once daily and doxepin 3 mg, liquid, orally, once daily for up to five weeks.
1823478|NCT00755495|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and doxepin placebo-matching liquid, orally, once daily for up to five weeks.
1823479|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 4 mg, tablets, orally, once daily and gabapentin 400 mg, capsules, orally, once daily for up to one week.
1823480|NCT00755508|Drug|Ramelteon and gabapentin|Ramelteon 8 mg, tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
1823481|NCT00755508|Drug|Ramelteon|Ramelteon 8 mg, tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
1823482|NCT00755508|Drug|Gabapentin|Ramelteon placebo-matching tablets, orally, once daily and gabapentin 800 mg, capsules, orally, once daily for up to one week.
1823483|NCT00755508|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily and gabapentin placebo-matching capsules, orally, once daily for up to one week.
1823484|NCT00755521|Drug|etoricoxib|"Treating Fibromyalgia with etoricoxib
etoricoxib - 90mg"
1823485|NCT00755534|Drug|Irinotecan|Irinotecan (IV) 150 mg/m2 on day 1 every two weeks until progression
1823486|NCT00755534|Drug|Capecitabine|Capecitabine (p.o) 2000 mg/m2 (1000 mg/m2 x 2) on day 1-7 every 2 weeks until progression
1823487|NCT00755534|Drug|Cetuximab|Cetuximab(IV) 500 mg/m2 on day 1 every two weeks until progression
1823488|NCT00755534|Drug|Oxaliplatin|Oxaliplatin (I.V) 85 mg/m2 on day 1 every two weeks until progression
1823489|NCT00755547|Other|Aerobic Exercise Training|All sessions will be designed to elicit a certain degree of energy expenditure that will progressively increase throughout the trial. Adolescents randomized to the vigorous activity group will perform interval sessions that ensure an average heart rate between 70 and 85% of maximal heart rate reserve while those randomized will perform aerobic activity between 40 and 50% of heart rate reserve. The goal for the trial will be to expend a minimum of 350 kcal. The type of exercise will depend on the preference of each participant however, during the supervised sessions walking/jogging on a treadmill or outdoors will be used to elicit exercise intensities. The three activity sessions held at the YMCA-YWCA facilities in Winnipeg and be supervised by a trained kinesiologist who will record heart rate and perceived exertion for each session.
1823490|NCT00755560|Drug|Albendazole|Albendazole 10 - 15 mg/kg/day BID for 15 days
1823491|NCT00755560|Drug|Placebo|Placebo BID for 15 days
1823492|NCT00755573|Drug|Pregabalin|Pregabalin 300 mg - 600 mg BID
1823493|NCT00755573|Drug|placebo|Regime as described for pregabalin
1823494|NCT00755586|Procedure|Mononuclear cell injection: 4 * 10e8 cells|350 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 4 * 10e8 cells in the m. biceps brachii.
1823495|NCT00755586|Procedure|Mononuclear cell injection: 8 * 10e8 cells|650 ml bone marrow will be aspirated from the posterior iliac crest under general anesthesia in combination with a muscle tendon transposition surgery. Next, the patients will receive a bone marrow derived mononuclear cell injection of 8 * 10e8 cells in the m. biceps brachii.
1823496|NCT00755586|Procedure|No mononuclear cell injection|Patients will receive a muscle tendon transposition surgery without bone marrow aspiration or mononuclear cell injection.
1823497|NCT00755599|Procedure|no-stirrup vaginal examination|Vaginal speculum examination done with feet on table extender.
1823498|NCT00755599|Procedure|Vaginal speculum examination done with stirrups.|Speculum examination done with feet in stirrups.
1823499|NCT00755638|Biological|ACE-031|single subcutaneous dose of ACE-031
1823500|NCT00755651|Procedure|Endometrial biopsy|Endometrial biopsy taken on completion of office/outpatient diagnostic hysteroscopy
1823542|NCT00755898|Drug|Ingestion of a 200 mg dose of amantadine hydrochloride|Healthy subject ingests 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper
1823501|NCT00755664|Dietary Supplement|Low-dose complex B-vitamins|The complex B vitamins supplement has been made as capsule and packaging 31 capsules in 1 bottle with a pre-determined code number on its cover. The main content contains either vitamin C 50mg alone or combination with folate 0.4 mg, vitamin B6 2mg, vitamin B12 10μg and vitamin C 50 mg. Two kinds of the supplements could not be discriminated by appearance, smell, taste, size and package.volunteers in either arms are required to take 1 capsule per day and last for 48 weeks.
1823502|NCT00755677|Other|Pulses|subjects consume 1 pulse food daily for eight weeks
1823503|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day).
1823504|NCT00755690|Behavioral|High/ Low Phosphate diet|Low phosphate diet (750mg/day) with the addition of the phosphate binder aluminum hydroxide (500mg three times per day).
1823505|NCT00755690|Behavioral|High/ Low Phosphate diet|III. High phosphate diet (2000mg /day).
1823506|NCT00755703|Biological|Pandemic Influenza Vaccine|Undetermined
1823507|NCT00755703|Biological|Placebo|
1823511|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in OCH group consumed 400 ml Nutricia preOp® (12.5% carbohydrates, 0.5 kcal/ml, 240 mOsm, pH 4.9, Nutricia Zoetermeer, The Netherlands) 3 hours prior to induction of anaesthesia and finished the ingestion within 1 hour
1823512|NCT00755729|Dietary Supplement|Preoperative Oral Carbohydrate|Patients in FSD group were fasted from midnight the night before surgery, and no preoperative oral carbohydrate loading
1823513|NCT00755742|Other|Lifestyle intervention|"The 3-pronged lifestyle intervention is designed to deliver a period of intensive contact (week 0-12) and less-intensive contact (weeks 12-24):
i) Behavior Modification Counseling: The principles of motivational enhancement and cognitive-behavior therapy (MET/CBT) will be utilized at each visit and telephone contact to provide individually tailored counseling. The goal is to enhance internal motivation and facilitate changes in lifestyle that are adaptable to each participant's usual habits.
ii) Physical activity target: increment in activity of at least 3000 steps/day above the baseline, or total activity of 10,000 steps/day (whichever is greater).
iii) Dietary assessment and nutritional plan: A diet plan designed to both lose weight and improve insulin resistance will be provided."
1823514|NCT00755755|Drug|PGL4001 (ulipristal) and iron|tablets
1823515|NCT00755755|Drug|PGL4001 matching placebo and iron|tablets
1823516|NCT00755755|Drug|PGL4001 (ulipristal) and iron|Tablets
1823517|NCT00755768|Behavioral|additional review by dietician|
1823518|NCT00755781|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration (up to 3 years)
1823519|NCT00755794|Drug|montelukast sodium|Montelukast Tablet, 10 mg, 8 weeks, daily
1823520|NCT00755807|Drug|Duloxetine Hydrochloride (HCI)|Participants received 30 mg duloxetine (po, QD) for 1 week followed by 5 weeks at 60 mg in the acute placebo-controlled period. If the participant completes the double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 mg QD for 12 weeks).
1823521|NCT00755807|Drug|Placebo|Participants received placebo oral (po), once daily (QD) for 6 weeks (acute phase). If the participant completes the 6-week double-blind portion of the trial, the participant will be offered the option to participate in the open-label extension period (given 60, 90, or 120 milligrams [mg] QD for 12 weeks).
1823522|NCT00755820|Behavioral|Exposure Therapy + D-Cycloserine|Exposure therapy with d-cycloserine medication
1823523|NCT00755820|Behavioral|Exposure Therapy + Placebo|Exposure therapy with placebo medication
1823524|NCT00755820|Behavioral|Supportive Psychotherapy|Supportive psychotherapy
1823525|NCT00755833|Drug|biphasic insulin aspart 50|Efficacy and safety data collection in connection with the use of the drug NovoMix® 50 in daily clinical practice.
1823526|NCT00755846|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
1823527|NCT00755846|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
1823528|NCT00755846|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
1823529|NCT00755846|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks.
1823530|NCT00755846|Drug|Alogliptin|Alogliptin 100 mg, tablets, orally, once daily for up to 12 weeks.
1823531|NCT00755846|Drug|Placebo|Alogliptin placebo-matching tablets, orally, once daily for up to 12 weeks.
1823532|NCT00755859|Drug|steroids plus azathioprine|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day plus azathioprine 1.5 mg/kg/day for six months
1823533|NCT00755859|Drug|steroids|methylprednisolone 1 g i.v. for three consecutive days at the beginning of months 1, 3 and 5, followed by oral prednisone 0.5 mg/kg every other day for six months
1823534|NCT00755872|Drug|Risedronate|Treatment A (35 mg DR Fasted): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
1823535|NCT00755872|Drug|Risedronate|Treatment B (35 mg DR Fed): One risedronate tablet (35 mg DR) taken following an overnight (10-hour) fast, within 5 minutes after ingesting a high-fat meal.
1823536|NCT00755872|Drug|Risedronate|Treatment C (35 mg IR Fasted): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, followed by a 4-hour fast.
1823537|NCT00755872|Drug|Risedronate|Treatment D (35 mg IR Per-label): One risedronate tablet (35 mg IR) taken following an overnight (10-hour) fast, 30 minutes before ingesting a high-fat meal.
1823538|NCT00755885|Drug|abiraterone acetate|
1823539|NCT00755885|Other|laboratory biomarker analysis|
1823540|NCT00755885|Other|pharmacogenomic studies|
1823541|NCT00755898|Drug|Ingestion of a 200 mg dose of amantadine hydrochloride|Volunteer cancer patients ingest 2 x 100 mg tablets of amantadine hydrochloride with a glass of cold water 2 hours after supper.
1823859|NCT00758004|Drug|Atorvastatin|A single dose of 80 mg atrovastatin tablet
1823543|NCT00755911|Biological|Tissue Repair Cells (TRC)|30-50 ml of bone marrow is aspirated from subject and processed into TRC autologous bone marrow tissue graft. 10ml of TRC will be absorbed onto gelfoam carrier and placed in extraction socket.
1823544|NCT00755911|Device|Control|Control subjects only receive standard gelfoam carrier. It promotes healing after tooth extraction
1823545|NCT00755924|Dietary Supplement|Vinegar|Apple cider vinegar 2 TBlsp/day
1823546|NCT00755924|Other|Placebo|Water placebo colored with balsamic vinegar
1823547|NCT00755937|Other|Data collection post infusion|
1823548|NCT00755950|Dietary Supplement|Silymarin|280 mg three times daily for four weeks
1823549|NCT00755950|Dietary Supplement|Silymarin|420 mg three times daily for four weeks
1823550|NCT00755950|Other|Lactose monohydrate|Lactose monohydrate 326.95 mg three times daily for four weeks
1823551|NCT00755963|Drug|estradiol valerate|Progynova® 21; 2mg/d
1823552|NCT00755963|Drug|micronized progesterone|Utrogestan®; 200mg/d
1823553|NCT00755963|Drug|placebo|maltodextrin
1823554|NCT00755976|Drug|epirubicin hydrochloride|
1823555|NCT00755976|Drug|sulindac|
1823556|NCT00755976|Other|immunologic technique|
1823557|NCT00755989|Drug|morphine topical gel|morphine gel 0.1%, applied every 12 hours to stage 2-3 wound, during their hospital stay
1823558|NCT00755989|Drug|placebo|topical gel without morphine
1823559|NCT00756002|Drug|Ramelteon|Ramelteon 4 mg, tablets, orally, once daily for up to 5 weeks.
1823560|NCT00756002|Drug|Placebo|Ramelteon placebo-matching tablets, orally, once daily for up to 5 weeks.
1823561|NCT00756015|Other|Early Motion Protocol|Early range of motion group: Shoulder pendulum exercises will be allowed from the time of surgery. Immediate range of motion of the elbow, forearm, wrist and hand. At the first postoperative visit, PROM of the shoulder will be permitted under therapist direction. Patients will avoid IR and behind the back stretching. At 6 weeks, AAROM and AROM will be advanced as tolerated. Capsular stretching will be advanced until full range of motion is achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 3 months post surgery.
1823562|NCT00756015|Other|Immobilization|Immobilization group: 6 weeks of sling shoulder immobilization. Immediate range of motion of the elbow, forearm, wrist and hand. At 6 weeks, PROM and stretching of the shoulder allowed under therapist direction. At 12 weeks, AAROM and AROM exercises will be initiated and capsular stretching advanced until full ROM achieved. Strengthening activities of the rotator cuff, deltoid and scapular stabilizers will be permitted at 4 months post surgery.
1823563|NCT00756028|Drug|Patients receiving short protocol IVF/ICSI-treatment.|Injection s.c. Orgalutran® (Ganirelix)0.25 mg once daily from day 5 of FSH-stimulation until HCG-day
1823564|NCT00756028|Drug|Long protocol|Patients receiving long protocol IVF/ICSI-treatment. Intervention pharmacon: GnRH-agonist (Synarela®:Nafarelin)
1823565|NCT00756041|Drug|TAK-128|TAK-128 100 mg tablet, orally, once daily for up to 1 year.
1823566|NCT00756067|Biological|Pneumococcal vaccine GSK2189241A|Two doses of 0.5 ml will be administered intramuscularly; one dose at Month 0 and another at Month 2.
1823567|NCT00756067|Biological|Pneumo 23™|One dose of 0.5 ml will be administered intramuscularly at Month 0, and a placebo dose to keep the blinding at Month 2.
1823568|NCT00756080|Drug|citrulline|0.06 G/kg three times/day during 7 days
1823569|NCT00756080|Drug|placebo|placebo (equimolar mixture of 6 non essential amino acids: alanine, aspartate, glycine, histidine, proline, serine) 0,006 g/kg 3 times/day during 7 days
1823570|NCT00756093|Other|Systane Ultra Lubricant Eye Drops|Systane Ultra Lubricant Eye Drops one drop each eye one time
1823571|NCT00756093|Other|Optive Lubricant Eye Drops|Optive Lubricant Eye Drops one drop each eye one time
1823572|NCT00756093|Other|Blink Tears|Blink Tears one drop each eye one time
1823573|NCT00756093|Other|GenTeal Moderate Lubricant Eye Drops|GenTeal Moderate Lubricant Eye Drops one drop each eye one time
1823574|NCT00756106|Drug|temozolomide|chemotherapy
1823575|NCT00756106|Other|imaging biomarker analysis|MRI
1823576|NCT00756145|Procedure|At start of the session, at the inlet line|Injection of LMWH at the inlet line, at the start of the hemodiafiltration session
1823577|NCT00756145|Procedure|5 minutes after the start of the session, at the inlet line|Injection of LMWH at the inlet line, 5 minutes after the start of the hemodiafiltration session
1823578|NCT00756145|Procedure|At the start of the session, at the outlet line|Injection of LMWH at the outlet line, at the start of the hemodiafiltration session
1823579|NCT00756171|Drug|colesevelam|2 times 3 625 mg tablets daily, 3 weeks
1823580|NCT00756171|Drug|placebo|2 times 3 625mg tablets daily
1823581|NCT00756184|Device|TDA adherence monitor for travoprost therapy|monitoring adherence to travoprost therapy
1823582|NCT00756184|Device|TDA and travoprost monotherapy|Patients will be prescribed travoprost therapy and will be followed up in a standard clinical fashion with a attention placebo at both baseline and 6 months
1823583|NCT00756197|Device|Cryo Spray Ablation Group 1|Cryo Spray Ablation
1823584|NCT00756197|Device|Cryo Spray Ablation Group 2|cryo spray ablation
1823585|NCT00756210|Other|Whole body vibration|Frequence: 35 Hz Amplitude: 'high' (approx. 4 mm)
1823586|NCT00756223|Drug|Arm A|Dose escalation Arm A (4 weeks)
1823587|NCT00756223|Drug|Arm B|Dose escalation Arm B (3 weeks)
1823588|NCT00756236|Drug|Metoprolol|60ml syringes of 0.9% NaCl, 5ml syringes of metoprolol at 1mg/ml concentration
1823589|NCT00756236|Drug|Esmolol|60ml syringes of esmolol at 10 mg/ml concentration, 5ml syringes of 0.9% of NaCl
1823590|NCT00756236|Drug|P-Group|0.9%NaCl dispensed in 60ml & 5ml syringes
1823591|NCT00756249|Drug|Lu AA24493 (CEPO)|0.005 - 50.0 mcg/kg body weight, IV, within 12-48 hrs from symptom onset
1823592|NCT00756249|Drug|Placebo|Vials with solution for IV infusion
1823593|NCT00756262|Biological|Lactobacillus GG or Culturelle|Drug to be administered orally (capsule form). Dose=2 capsules/day for 14 days. Dosage strength= 1x10^10 bacteria
1992304|NCT03322384|Drug|epacadostat|Epacadostat will be administered orally, in pill form, twice daily until disease progression.
1992305|NCT03322384|Drug|SD-101|Four milligrams of SD-101 will be delivered into the treatment lesion by intralesional injection on days 1, 8, 15, 22, and 29.
1823599|NCT00756288|Procedure|Topical retinoid and blue-light therapy with photosensitizing agent|Topical Retinoid - Apply to AKs for 4 weeks Photo-therapy with photosensitizing agent- Apply to AKs at week 4
1823600|NCT00756288|Procedure|Photodynamic Therapy (PDT)|Photo-therapy with sensitizing agent - apply to AKs at week 4
1823601|NCT00756301|Other|Lidocaine local anesthesia- Alternative|Local anesthetic (Lidocaine) injected using traditional technique (involves injecting Lidocaine into the skin first, then into the deeper tissues).
1823602|NCT00756314|Behavioral|Personalized contraceptive counseling|The intervention comprised a personalized and comprehensive (face-to-face) contraceptive counseling regarding to individual contraceptive history and needs. The counseling intervention was conducted by three trained gynecologists according to standard one day training.
1823603|NCT00756340|Drug|Bevacizumab|"Bevacizumab IV every 2 weeks
Dose Level 0- 8 mg/kg
Dose Level 1 (starting dose)- 10 mg/kg
Dose Level 2- 10 mg/kg"
1823604|NCT00756340|Drug|Everolimus|"Everolimus
Dose Level 0- 4 mg/m2
Dose level 1 (starting dose)- 4 mg/m2
Dose Level 2- 5 mg/m2"
1823605|NCT00756366|Other|Positron Emission Tomography|PET imaging at baseline, 1 week and 6-8 weeks. CPAP begins after baseline PET scan.
1823606|NCT00756366|Other|Positron Emission Tomography|PET imaging at Baseline, 1 week and 6-8 weeks. CPAP begins after 6-8 week PET scan.
1823607|NCT00756366|Other|Positron Emission Tomography|PET scan at baseline and 6-8 weeks, no CPAP therapy
1823608|NCT00756379|Other|Comprehensive therapy program for risk factor modification|Patients enrolled in the comprehensive therapy arm will have a baseline myocardial perfusion PET and the support of a team of professionals aiming to modify and minimize all the known CAD risk factors. During the 5 year follow-up they will be educated and guided toward a healthy lifestyle by a dietician, an exercise physiologist/cardiovascular physician specialist.
1823609|NCT00756392|Procedure|3T MR Spectroscopy|A Magnetic Resonance Spectroscopy (MRS)study of a patient's prostate will be conducted with the 3 Tesla Philips Intera Nuclear Magnetic Resonance (NMR) scanner before and after filling the rectum with barium. Scan duration from Preparation to Completion will be approximately 30 minutes. The spectra will be acquired without and with the presence of Barium solution to compare to see if the latter is advantageous.
1823610|NCT00756405|Behavioral|Antioxidant diet|Participants were asked to increase antioxidant-rich food intake to approximately double their daily habitual intake and take a placebo pill.
1823611|NCT00756405|Dietary Supplement|Antioxidant supplement|Participants were asked to consume their usual diet and take a supplement containing carotenoids, mixed tocopherols, vitamin C and selenium, designed to approximately double their daily habitual intake.
1823612|NCT00756405|Dietary Supplement|Placebo|Participants were asked to consume their usual diet and take a placebo pill.
1823613|NCT00756418|Drug|montelukast|montelukast 5 mg QD 4-weeks.
1823614|NCT00756418|Drug|Theophylline|Theophylline 100 to 200 mg BID 4-weeks.
1823615|NCT00756431|Device|Hip Fracture reduction Screw without HA Coating (Hiploc)|Hip Fracture reduction Screw without HA Coating (Hiploc)
1823616|NCT00756431|Device|Hip Fracture reduction Screw with HA Coating (Hiploc)|Hip Fracture reduction Screw with HA Coating (Hiploc)
1823617|NCT00756444|Drug|Panitumumab|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
1823618|NCT00756444|Drug|Cisplatin|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
1823619|NCT00756444|Drug|5FU|This is a PK study comparing Panitumumab plus Chemotherapy to Chemotherapy alone
1823620|NCT00756457|Device|Bracing|Participants will wear a brace that includes ankle stirrup support and medial longitudinal arch support. The brace will be worn during weight-bearing tasks throughout the 12-week study.
1823621|NCT00756457|Other|Strengthening exercises|"Participants performed strengthening exercises progressively longer each time for up to 3 sets of 30 repetitions twice daily by the third visit. Exercises included bilateral heel raises, foot adduction/rear foot inversion with thera-tubing, and unilateral heel raises. Participants increased resistance by using thera-bands with higher levels of resistance over the 12 week period. The amount of resistance was progressed according to patient tolerance at each visit. Strengthening exercises were preceded by the control stretching exercises which constituted a warm up."
1823622|NCT00756457|Other|Stretching exercises|Subjects were provided with written descriptions and pictures demonstrating 2 range-of-motion exercises which included a wall calf stretch, and a supine ankle active range-of-motion exercise. Subjects were instructed to perform 3 sets of the stretching exercises, 2 times a day, similar to the intervention group. Each stretching exercise was performed twice and held for 30 seconds.
1823623|NCT00756470|Drug|Lapatinib|1000 mg taken by every day by mouth (PO) weeks 1 and 2; then starting day 15 for 12 weeks (weeks 3 to 14) daily 750 mg PO. Week 15, second combination treatment consisting of lapatinib (1,000 mg orally once daily) combined with FEC7.
1823624|NCT00756470|Drug|Paclitaxel|80 mg/m^2 intravenously over 1 hour weekly for 4 cycles administered on Day 1, Day 8, and Day 15 of each cycle then weekly starting day 15 for 12 weeks.
1823625|NCT00756470|Drug|5-Fluorouracil (5-FU)|500 mg/m^2 intravenously over 3-5 minutes every three weeks of Weeks 13-24.
1823626|NCT00756470|Drug|Epirubicin|75 mg/m^2 intravenously over 5-10 minutes every three weeks of Weeks 13-24.
1823907|NCT00758394|Drug|Fluoride|Brush two times a day for 4 days.
1823629|NCT00756522|Other|There is no intervention. Study is observational.|There is no intervention. Study is observational.
1823630|NCT00756535|Procedure|Exercise training|Group-based exercise training 5 days a week during hospitalization
1823631|NCT00756535|Procedure|usual treatment and rehabilitation|usual treatment and rehabilitation
1823632|NCT00756548|Drug|BLI850|multi-dose preparation for oral administration prior to colonoscopy
1823633|NCT00756548|Drug|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
1823634|NCT00756574|Device|Surgical mask|Surgical mask worn for patients with febrile respiratory illness
1823635|NCT00756574|Device|N95 mask|N95 mask worn for patients with febrile respiratory illness
1823636|NCT00756587|Device|Cup Feeding|using a cup feeding technique for feeding the preterm infants during NICU stay
1823637|NCT00756587|Device|Bottle Feeding|receiving all feeding by bottle
1823638|NCT00756600|Drug|Regional Anesthesia|Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.
1823639|NCT00756600|Drug|General Anesthesia|Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.
1823640|NCT00756626|Behavioral|Bottle Weaning Intervention|WIC Nutritionist will deliver bottle weaning intervention education with participants in intervention group at 12 month baseline and at 15, 18, 21, and 24 month follow-up as needed
1823641|NCT00756639|Radiation|Prophylactic Cranial Irradiation (PCI)|Prophylactic cranial irradiation (PCI) treatments to be started within 4 months after the end of chemotherapy or surgery to a total dose of 30 Gy, given at 2 Gy per fraction, 5 days per week for 3 weeks.
1823642|NCT00756639|Other|Brain X-ray|On the first day of each week of therapy, a brain X-ray will done to see if the radiation is being given to the best area.
1823643|NCT00756652|Device|Mentor Silicone Gel-Filled Breast Implants|
1823644|NCT00756652|Device|Saline Breast Implants|
1823645|NCT00756678|Drug|Lubricant Eye Drops (Optive™)|1 drop in both eyes as needed for 7 days`
1823646|NCT00756678|Drug|Lubricating Eye Drops (blink® Tears)|1 drop in both eyes as needed for 7 days
1823647|NCT00756691|Other|18F-FAZA|Radioactive dose of 110-600 MBq per injection. A single pre-treatment injection of 18F-FAZA will be permitted per patient
1823648|NCT00756704|Behavioral|Smoking cessation guideline implementation|"a tutorial on brief cessation counseling for ED nurses and physicians
use of an ED algorithm that includes recommended tobacco counseling items
fax referral of motivated smokers to Quitline Iowa for proactive telephone counseling plus free nicotine replacement therapy
group feedback to ED staff"
1823649|NCT00756717|Drug|MK-0752|Women who are post menopausal will receive letrozole 2.5 mg by mouth one time per day for 24 days. Women who are pre menopausal, or who have a contraindication to letrozole will receive tamoxifen 20 mg orally one time per day for a period of 24 days. Starting on day 15 of this 24 day period all patients will receive the oral gamma-secretase inhibitor drug MK-0752 at a dose of 350 mg for three days on, then off four days, then three days on, for a total of 6 doses over a period of 10 days.
1823650|NCT00750347|Drug|Rimonabant and Paracetamol and placebo|evaluation of an possible inhibiting effect of rimonabant on the analgesic effect of paracetamol in healthy volunteers
1823651|NCT00750360|Biological|FluarixTM|All subjects will receive a single dose of FluarixTM. For children less than 9 years of age who have not previously been vaccinated against influenza, a second dose will be given after an interval of at least 4 weeks (Group B).
1823652|NCT00750373|Procedure|Valve surgery with removal of vegetations|Early valve repair or replacement with removal of vegetations within 48 hours of randomization
1823653|NCT00750386|Drug|Paclitaxel|175 mg/m2, I.V, every 2 weeks
1823654|NCT00750386|Drug|Carboplatin|Carboplatin AUC, I.V, 5 every 2 weeks
1823655|NCT00750399|Drug|Ranibizumab|intravitreal ranibizumab monthly for 4 months, and then every month thereafter until month 12.
1823656|NCT00750399|Drug|ranibizumab|intravitreal ranibizumab 0.5 mg
1823657|NCT00750412|Behavioral|TeenScreen Program|Adolescents who are randomized into the TeenScreen program and their parent/guardian will receive post-screening information, a facilitated referral, and case management services from a research social worker.
1823658|NCT00750425|Drug|cediranib (RECENTIN TM, AZD2171)|20 mg cediranib once daily from Days 1 to 7; then 20 mg cediranib plus 400 mg ketoconazole from Days 8-10; then 20 mg cediranib once daily from Days 11-23. At Day 24 patients may dose escalate to 30 mg tablet once daily providing the treatment is well tolerated (this may be escalated up to 45 mg if the 30mg dose is tolerated for a minimum of 14 days)
1823659|NCT00750438|Dietary Supplement|Propionate ester|The subject will take propionate ester at the dose specified by the dose finding study, three times a day for 24 weeks
1823660|NCT00750438|Dietary Supplement|Inulin|The subjects in this group will take inulin at a comparable dose, three times a day for 24 weeks
1823661|NCT00750438|Dietary Supplement|Cellulose|The subjects in this group will take the non fermentable carbohydrate, cellulose, at a comparable dose for 24 weeks.
1823662|NCT00750451|Drug|low molecular weight heparin (enoxaparine sodium)|1 mg/kg/day subcutaneously in the luteal phase after IVF treatment
1823663|NCT00750451|Drug|crinone 8% gel|routine luteal phase support with progesterone gel
1823664|NCT00750477|Dietary Supplement|NEM|see Treatment Arms
1823665|NCT00750477|Dietary Supplement|Placebo|Placebo comparator containing inactives
1823667|NCT00750529|Drug|Galantamine and Donepezil|the analysis of two inhibitors of Ach-E : galantamine and donézepil in over 65 years old patients suffering from Alzheimer's disease (MMSE between 20 and 26) without Alzheimer's medication
1992306|NCT03322384|Radiation|Radiotherapy|Radiotherapy will be delivered to the treatment lesion during the first week of ERS therapy.
1992308|NCT03322358|Other|Naps|"After a baseline period, participants in this condition will be provided with the opportunity to nap in a quiet comfortable nap cabin in the study office for 30 minutes each afternoon on all work days."
1823668|NCT00750555|Drug|Erlotinib|150 mg per day orally until disease progression occurs, up to a maximum of 12 months
1823669|NCT00750581|Drug|Indomethacin|Infants randomized to Escalating Dose group will receive indomethacin (0.2 mg/kg/dose) at 12 hr intervals for 2 doses, followed by indomethacin (0.3 mg/kg/dose) at 12 hr interval for 2 doses, then Indomethacin (0.4 mg/kg/dose) at 12 hr interval for 2 doses, increased to indomethacin (0.5 mg/kg/dose) at 12 hour interval for 2 doses and finally indomethacin 0.6 mg/kg/dose at 12 hourly interval for 2 doses.
1823670|NCT00750620|Drug|YM178|oral
1823671|NCT00750633|Drug|Moxidex otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
1823672|NCT00750633|Drug|Moxifloxacin otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
1823673|NCT00750633|Drug|Dexamethasone phosphate otic solution|4 drops in the infected ear(s) twice daily (morning and evening) for 7 days
1823674|NCT00750633|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media with effusion in children
1823675|NCT00750646|Device|MEMS cap|The Medication Event Monitoring System will be used to assess the level of subject adherence to recommended topical eye drop therapy.
1823676|NCT00750659|Drug|Nilotinib|Nilotinib 400 mg po/BID until transplant. Nilotinib 200-400 mg po/BID post transplant in escalated doses.
1823677|NCT00750685|Device|Mentor Smooth Becker 50 Expander/Breast Implant|The Mentor Becker Expander/Breast Implant is comprised of two components: the Becker implant and the injection dome/fill tube. The breast implant is available in a smooth surface. It has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The silicone elastomer fill tube is pre-inserted into the dual self-sealing valve system at the time of manufacture and is joined to the injection dome by the connector system at the time of surgery. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
1823678|NCT00750698|Drug|SNDX-275|SNDX-275 (10 mg fixed dose PO Q2W) on days 1 and 15 of a 28-day cycle for up to 6 cycles
1823679|NCT00750698|Drug|erlotinib|erlotinib (150 mg PO QD) for up to six (6) 28-day cycles
1823680|NCT00750711|Procedure|Radiofrequency ablation for atrial flutter by catheters|
1823681|NCT00750724|Drug|"25 mg sodium hyaluronate GO ON"|25 mg sodium hyaluronate, 2 ml., intraarticular weekly for 5 weeks
1823682|NCT00750724|Drug|normal saline,2 ml., intraarticular weekly for 5 weeks|
1823683|NCT00750737|Drug|Posaconazole|200 mg three times daily by mouth up to 6 weeks (Days 1-42)
1823684|NCT00750737|Drug|ABLC|7.5 mg/kg of ABLC intravenously infused over 4-6 hours once per week, for up to 6 weeks (from Day 1 through Day 42)
1823685|NCT00750750|Drug|mometasone furoate nasal spray (MFNS)|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril once daily in the morning and placebo nasal spray once daily in the evening for 15 days, followed by 14-day no-treatment observation period
1823686|NCT00750750|Drug|MFNS|Placebo capsules three times daily for 10 days, and MFNS 50 mcg/spray, 2 sprays in each nostril twice daily for 15 days followed by 14-day no-treatment observation period
1823687|NCT00750750|Drug|Amoxicillin|Amoxicillin 500 mg/capsule, one capsule 3 times a day for 10 days and placebo nasal spray twice daily for 15 days, followed by a 14-day no-treatment observation period
1823688|NCT00750750|Drug|Placebo|Placebo capsule three times daily for 10 days and placebo nasal spray twice daily for 15 days, followed by 14-day no-treatment observation
1823689|NCT00750763|Drug|Colonlytely|Bowel preparation
1823690|NCT00750763|Drug|Picolax/Picoprep|Bowel preparation
1823691|NCT00750763|Drug|Fleet|Bowel preparation
1823692|NCT00750789|Dietary Supplement|dates|5 maedjool dates or 7 emery dates per day for 2 weeks each with a washout period of 2 weeks between
1823693|NCT00750802|Drug|AZD6280|10mg Capsule, oral, single-dose
1823694|NCT00750802|Drug|AZD6280|40mg Capsule, oral, single-dose
1823695|NCT00750802|Drug|Lorazepam|2mg tablet, oral single-dose
1823696|NCT00750802|Drug|Placebo|
1823697|NCT00750815|Drug|Cyclophosphamide|Enroll patients into 4 different dose levels. The dose of Cyclophosphamide they receive will depend on how many patients have been treated.
1823698|NCT00750815|Drug|Bortezomib; Pegylated Liposomal Doxorubicin; Dexamethasone (VDD)|Patients will receive Bortezomib, Pegylated Liposomal Doxorubicin and Dexamethasone at standard doses.
1823699|NCT00750841|Drug|cediranib|45 mg cediranib once daily from Days 1-7; cediranib 45 mg plus 600 mg rifampicin from Days 8-14; 45 mg cediranib once daily from Days 15-28; from Day 29 patients may continue on 45 mg cediranib or dose reduce.
1823700|NCT00750854|Dietary Supplement|NEM Formulation X|see Treatment Arms
1823701|NCT00750854|Dietary Supplement|NEM Formulation Y|see Treatment Arms
1823702|NCT00750867|Drug|intravenous immunoglobulin (IVIg)|The intravenous immunoglobulin (brand Privigen) will be infused intravenously, monthly, 6 times, for 6 months the dose will be 0.4 gram/kg for each infusion.
1823703|NCT00750880|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv (60 minute infusion)
1823704|NCT00750893|Biological|Rotarix™ or Rotarix™ liquid formulation (oral suspension or prefilled syringe)|GSK Biologicals' oral live attenuated human rotavirus (HRV) vaccine.
1823705|NCT00750919|Drug|esmirtazapine|
1823706|NCT00750945|Other|Music and treadmill walking program|Treadmill with Music cueing training 3 days/wk, plus home music cueing 3 days/wk x 4 weeks
1823707|NCT00750945|Other|Treadmill walking program|Treadmill training 3 days/wk, plus home walking 3 days/wk x 4 weeks
1823708|NCT00750945|Other|Home program|Home walking program 6 days/wk x 4 weeks
1823709|NCT00750958|Procedure|NetGuard Automated Clinician Alert System|Monitoring System for in-hospital patients who are typically unmonitored. Identifies and alarms for cardiac rhythm changes.
1823710|NCT00750971|Procedure|Immunoablation and Autologous Hematopoietic Stem Cell Transplantation|Transplantation of purified CD34+ autologous hematopoietic stem cells mobilized with cyclophosphamide (200mg/m2)and G-CSF (10µg/kg/d) after immunoablation with cyclophosphamide (200mg/kg)and rabbit-antithymocyteglobulin (90mg/kg)
1823754|NCT00757003|Device|Endovascular Stent-graft repair of descending thoracic aorta|A TAG device will be used to repair the pathology in the thoracic aorta
1823711|NCT00750984|Procedure|Anterolateral approach|The anterolateral approach is performed with the patient positioned on the side. The blood supply to the femoral neck from the medial circumflex artery is regarded preserved by this surgical method.
1823712|NCT00750984|Procedure|Posterior approach|The posterior approach is performed with the patient positioned on the side. The medial circumflex artery is cut at the lower border of the short external rotators risking a compromised blood supply to the femoral head.
1823713|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the anterolateral approach using the ReCap® Total Hip Resurfacing System.
1823714|NCT00750984|Device|ReCap Total Hip Resurfacing|This arm utilizes the posterior approach using the ReCap® Total Hip Resurfacing System.
1823715|NCT00750997|Drug|hypertonic saline|patients in parent trial were randomized to 250cc 7.5% saline, 7.5%saline with 6%dextran or normal saline as control as the initial resuscitation fluid after injury with signs of either hemorrhagic shock or severe traumatic brain injury
1823716|NCT00751023|Drug|Modafinil|400 mg daily for four weeks
1823717|NCT00751023|Drug|Placebo|Placebo 2 tablets daily for 4 weeks
1823718|NCT00751036|Drug|Nilotinib|Nilotinib hard gel capsules were supplied to the Investigators at dose strengths of 200 mg. Nilotinib is a novel agent, which has been approved for the treatment of chronic phase and accelerated phase Philadelphia-chromosome-positive CML in adult patients resistant to or intolerant to prior therapy that included imatinib.
1823719|NCT00751036|Drug|Imatinib|Imatinib tablets were supplied at 100 mg and/or 400 mg dose strength. Imatinib is an approved agent for GIST. Efficacy of imatinib at a dose of 400 mg bid has been established in the setting of disease progression after the use of the conventional dose (400 mg qd).
1823720|NCT00751049|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
1823721|NCT00751049|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
1823722|NCT00751062|Drug|timolol|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle.
1823723|NCT00751062|Drug|PhXA41|One drop in the affected eye every morning from the morning bottle and one drop every evening from the evening bottle
1823724|NCT00756730|Drug|ATV/r|Switch to ATV/r at a dose of 300mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
1823725|NCT00756730|Drug|DRV/r|We designed a study to determine if switching virologically suppressed patients on a regimen containing LPV/r or FPV/r to either DRV/r or ATV/r would result in improved TGs while maintaining virological suppression. Switch to DRV/r at a dose 800mg/100mg QD for 24 weeks. Subjects will continue to maintain their background NRTI drugs throughout the screening period and during the entire study.
1823726|NCT00756743|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include 5, 10 and 15 mg capsules q12 hours, doses may be adjusted based on accumulating data
1823727|NCT00756743|Drug|Placebo|Placebo capsules q12 hours for 10 days
1823728|NCT00756756|Drug|G-CSF|after 2 week post MI an d PCI G-CSF was infused for 5 days at dose of 10 microgram/Kg
1823729|NCT00756756|Drug|placebo infusion of normal saline|2 week post MI and PCI normal saline was infused
1823730|NCT00756782|Drug|TAC-101|Patients will receive TAC-101 20 mg (2 x 10-mg formulated tablets) administered orally every day with approximately 8 oz. water within 1 hour following a morning meal for 14 days followed by a 7-day recovery period, repeated every 21 days.
1823731|NCT00756782|Drug|Placebo|Patients will receive placebo (two matching tablets) at same frequency and duration of active treatment
1823732|NCT00756795|Behavioral|Intervention group|"5ml of blood will be collected from each blood draw at baseline and post-intervention to assay for Interleukin-6 level.
Structured Interview will be conducted at baseline and post-intervention.
Patients assigned to the Intervention group will be given pedometers to obtain distance walked. In addition, patient will be taught how to keep the Exercise diary to record walking and physical activities.
All patients will receive 3 reminder phone calls during the first week of study and 10 minutes social visits in the following weeks by study coordinator on a weekly basis."
1823733|NCT00756847|Drug|XL147 (SAR245408),|Gelatin capsules supplied in 25- and 100-mg strengths; daily dosing
1823734|NCT00756847|Drug|paclitaxel|Intravenous injection dosed once every three weeks
1823735|NCT00756847|Drug|carboplatin|Intravenous injection dosed once every three weeks
1823736|NCT00756860|Drug|AMG 223|2 g AMG 223 (4 x 500 mg capsules ) TID on Days 1 through 7
1823737|NCT00756860|Drug|Renagel® (sevelamer hydrochloride)|2g Renagel® (2 x 800 mg capsules + 1 x 400 mg capsule) TID on Days 1 through 7
1823738|NCT00756873|Drug|Administration of placebo|Placebo qd orally day 0-14
1823739|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 90 mg qd orally day 0-14
1823740|NCT00756873|Drug|Administration of etoricoxib|Etoricoxib 120 mg qd orally day 0-7 Etoricoxib 90 mg qd orally day 8-14
1823741|NCT00756886|Drug|Atorvastatin|40 mg QD 7 day continue after procedure for 14 days
1823742|NCT00756886|Drug|Placebo|40 mg QD for 7 days prior to surgery, and then continue at same dosage for 14 days after surgery.
1823743|NCT00756912|Drug|E5564|Three dose levels of Eritoran IV over 14 days for a total of 32, 96, and 224 mg over 14 days.
1823744|NCT00756925|Drug|Acthrel|1 ug/kg, i.v., 1 minute
1823746|NCT00756951|Drug|Placebo|Placebo
1823747|NCT00756951|Drug|SCV-07|0.02 mg/kg
1823748|NCT00756951|Drug|SCV-07|0.10 mg/kg
1823749|NCT00756964|Drug|Rasburicase|Rasburicase (Dose: 7.5mg in 50ml of normal saline administered over 30 minutes) or identical placebo will be administered as an (dosage form)intravenous infusion preoperatively.
1823750|NCT00756964|Drug|Placebo|Placebo drug (color-coded to appear identical to study drug) administered as an (dosage form) intravenous infusion preoperatively.
1823751|NCT00756977|Drug|BLI850|multi-dose preparation for oral administration prior to colonoscopy
1823752|NCT00756977|Drug|polyethylene glycol 3350 based bowel preparation|multi-dose preparation for oral administration prior to colonoscopy
1823755|NCT00757016|Drug|Triamcinolone|1 ml triamcinolone 20mg/ml will be given once to the insertion of the sacrospinous ligament bilaterally.
1823756|NCT00757016|Drug|Saline solution|Saline solution
1823757|NCT00757029|Genetic|norepinephrine transporter polymorphism,|OROS methylphenidate (Concerta) monopharmacotherapy dose : 18-54mg duration : 8 weeks genotyping : norepinephrine transporter (SLC6A2) polymorphism
1823758|NCT00757042|Drug|AMG 157|Part A (healthy subjects): 6 subcutaneous (SC) cohorts and 2 intravenous (IV) cohorts receiving a single dose of either AMG 157 (dose escalating by cohort) or placebo. Part B (subjects with moderate to severe atopic dermatitis):two cohorts receiving a single dose (SC or IV; dose to be determined) of AMG 157 or placebo.
1823759|NCT00757055|Drug|Ivabradine|Ivabradine titrated to heart rate starting at 5 mg bd and increasing to maximum of 7.5 mg bd or reducing to 2.5 mg if heart rate < 60 bpm.
1823760|NCT00757055|Drug|Placebo|No active treatment given
1823761|NCT00757289|Biological|PRP Injection|PRP Injection
1823762|NCT00757289|Biological|Corticosteroid Injection|Corticosteroid Injection
1823763|NCT00757302|Device|SLN procedure (CarolIReS camera)|"Group I : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²).
Group II : The SLN procedure will be initiated 18 hours before surgery using a preoperative injection of colloidal rhenium sulphur and technetium (0.4 ml, 20 MBq of Nanocis®; CIS Bio International, France) at the four cardinal points in the subareolar area. Lymphoscintigraphy will be obtained 3 hours after the injection. Immediately before surgery, the axillary drainage will be checked using the CarolIReS camera (FOV 10x10 cm²)."
1823764|NCT00757315|Device|NdYag Laser(hair removal laser) plus topical corticosteroid|NdYag laser and topical corticosteroid are applied to one half of the scalp.
1823765|NCT00757315|Drug|Topical corticosteroid alone|topical corticosteroid alone is applied to one half of the scalp
1823766|NCT00757341|Drug|SKI-606|
1823767|NCT00757354|Procedure|Metal on Metal cementless hip|Metal on Metal hip arthroplasty
1823768|NCT00757367|Drug|TI Inhalation Powder|1 60-U dose of TI Inhalation Powder before the bronchoscopy. Cohort 1 will undergo bronchoscopies at 30 minutes and again at 6 hours after the 60-U dose inhalation of TI Inhalation Powder. Cohort 2 bronchoscopies will occur at 4 hours and again at 8 hours after TI Inhalation Powder. The need to run and the timepoints for bronchoscopies for Cohort 3 will be determined based on the results from Cohort 1 and 2. All subjects will undergo 2 bronchoscopies at Visit 2.
1823769|NCT00757380|Procedure|Trypan Blue|Membranepeeling with TB
1823770|NCT00757380|Procedure|Brillant Blue|Membranepeeling and membrana limitans interna peeling with BB
1823771|NCT00757393|Dietary Supplement|Vitamin D + Calcium + Exercise program|Subjects is this arm of the study will receive a) a supplementation with vitamin D3, 1000 IU daily b) a dietary calcium intake set at DRI for age and a supplement used as needed to meet the requirement and c) a weight bearing exercise program appropriate for the underlying medical condition
1823772|NCT00757393|Drug|Vitamin D + Calcium + Exercise program + Humatrope|Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
1823773|NCT00757419|Drug|AZD3355|capsules, oral, single or twice daily dose
1823774|NCT00757419|Drug|Placebo|To match dosing of AZD3355
1823775|NCT00757458|Drug|EDTA without re-filling|Target controlled infusion of propofol containing EDTA (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca), without re-filling of syringe.
1823776|NCT00757458|Other|Propofol syringe re-filling with propofol containing EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol containing EDTA.
1823777|NCT00757458|Other|Target controlled infusion of propofol without EDTA|Target controlled infusion of propofol without EDTA using Marshal´s technic with Alaris® or Fresenius® equipment
1823778|NCT00757458|Other|Re-filling of syringe with propofol without EDTA|Target controlled infusion of propofol (Diprivan®-Astra Zeneca) using equipment Diprifusor® (Astra Zeneca) with re-filling of syringe with propofol not containing EDTA.
1823779|NCT00757471|Procedure|Brillant Blue|Membrane Peeling with Brillant Blue
1823780|NCT00757471|Procedure|Indocyanine Green|Membrane Peeling with indocyanine Green
1823781|NCT00757497|Behavioral|Electrical Polarization|
1823784|NCT00757536|Procedure|Encircling Band|ppVE and encircling band
1823785|NCT00757536|Procedure|Endolaser Photocoagulation|ppVE and endolaser photocoagulation
1823794|NCT00757562|Drug|desloratadine|desloratadine syrup: 1.25 mg (2.5 mL) for subjects >=2 to <6 years, 2.5 mg (5 mL) for subjects >=6 to <12 years, orally once daily in the morning for 36 days.
1823795|NCT00757562|Drug|Placebo|placebo syrup: 2.5 mL for subjects >=2 to <6 years, 5 mL for subjects >=6 to <12 years, orally once daily in the morning for 36 days.
1823796|NCT00757588|Drug|Saxagliptin, 5 mg + insulin|Saxagliptin, 5-mg tablets (plus stable insulin dose), given orally once daily (24 weeks short-term, 28 weeks long-term); participants stratified by use of stable metformin dose; flexible insulin dose (as needed for rescue)
1823797|NCT00757588|Drug|Placebo + insulin|Placebo tablets given orally once daily for 24 weeks (short-term period)+ insulin with metformin
1823855|NCT00757978|Drug|placebo|1 capsule of placebo twice a day
1823798|NCT00757601|Drug|MK1006|"MK1006 capsules: 1 mg, 10 mg, and 20 mg.
Panel A: MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg
Panel B: MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.
Panel C: MK1006 capsules in five doses beginning at 140 mg and rising to 260 mg.
There will a 7-day interval between each dose"
1823799|NCT00757601|Drug|Placebo|"Placebo capsule to match MK1006 1, 10, and 20 mg.
Panel A: Placebo to MK1006 capsules in five doses beginning at 15 mg and rising to 60 mg
Panel B: Placebo to MK1006 capsules in five doses beginning at 60 mg and rising to 140 mg.
Panel C: Placebo to MK1006 capsules in 5 doses beginning at 140 mg and rising to 260 mg.
There will a 7-day interval between each dose"
1823800|NCT00757614|Genetic|DNA analysis|
1823801|NCT00757614|Genetic|polymorphism analysis|
1823802|NCT00757614|Other|laboratory biomarker analysis|
1823803|NCT00757614|Other|questionnaire administration|
1823804|NCT00757627|Drug|etoricoxib|etoricoxib 60 mg QD for 4 weeks.
1823805|NCT00757640|Procedure|cholecystectomy|prophylactic cholecystectomy during standard gastric surgery for cancer
1823806|NCT00757653|Device|Hip stem with plasma sprayed porous Ti 6Al4V alloy + plasma sprayed HA|Hip stem with plasma sprayed porous Titanium 6Al4V alloy + plasma sprayed HA
1823807|NCT00757653|Device|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA|Hip stem with plasma spayed porous Titanium 6Al4V alloy + Bonemaster HA
1823808|NCT00757653|Device|Hip stem with Interloc Titanium surface + Bonemaster H.A|Hip stem with Interloc Titanium surface + Bonemaster H.A
1823809|NCT00757666|Device|Rate adaptive pacemaker|Accelerometer sensor
1823810|NCT00757666|Device|Rate adaptive pacemaker|Minute ventilation sensor
1823811|NCT00757679|Drug|Milnacipran|capsules
1823812|NCT00757679|Drug|Placebo|capsules
1823813|NCT00757692|Drug|Vandetanib|Vandetanib at 300 mg in combination with Bicalutamide at 50 mg will be administered orally, daily and continuously
1823814|NCT00757692|Drug|Bicalutamide|Bicalutamide at 50 mg will be administered orally, daily and continuously.
1823815|NCT00757705|Drug|Paliperidone ER|Participants will receive paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day orally once daily for 24 weeks as per Investigator's discretion based on the individual participant's clinical response to and tolerability of the study drug.
1823816|NCT00757718|Device|CPAP|One half of the subjects will be randomly assigned to wear continuous a positive airway pressure device on the second night of the study. Portable polysomnography will be repeated for this night and morning bloodwork for inflammatory markers will be repeated.
1823817|NCT00757718|Device|Oral Appliance|Half of the subjects will be assigned to wear an oral appliance and nasal strip on the second night of the study. Repeat portable polysomnography will be performed and morning bloodwork will again be drawn for inflammatory markers.
1823818|NCT00757731|Drug|milnacipran|hard capsule
1823819|NCT00757731|Drug|Placebo|hard capsule
1823820|NCT00757744|Behavioral|Behavioral Drug and HIV Risk Reduction Counseling (BDRC)|once weekly individual counseling
1823821|NCT00757744|Behavioral|Drug counseling|individual drug counseling
1823822|NCT00757757|Drug|MCS110|Anti-M-CSF antibody
1823823|NCT00757770|Biological|Rotarix|Two oral doses.
1823824|NCT00757770|Biological|Placebo|Two oral doses; The placebo consist of all components of the study vaccine i.e. excipients and buffer, but no RV particles.
1823825|NCT00757783|Drug|ritonavir|100 mg capsule or tablet once daily for 48 weeks
1823826|NCT00757783|Drug|ritonavir|100 mg capsule or tablet once daily for 48 weeks
1823827|NCT00757783|Drug|darunavir|800 mg tablet once daily for 48 weeks
1823828|NCT00757783|Drug|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg tablet once daily for 48 weeks
1823829|NCT00757783|Drug|emtricitabine [FTC]/tenofovir [TDF]|200/300 mg once daily for 48 weeks
1823830|NCT00757783|Drug|atazanavir|300 mg capsule once daily for 48 weeks
1823831|NCT00757809|Drug|neratinib|HKI-272
1823832|NCT00757822|Drug|Dronabinol|Dronabinol (5mg) will be administered orally (p.o.) 20-60 min pre-operatively.
1823833|NCT00757822|Drug|Ondansetron|Ondansetron (4mg) will be administered intravenously (iv) intraoperatively in those patients not receiving Dronabinol.
1823834|NCT00757835|Drug|treatment with latanoprost/timolol fixed combination|dosing in the evening with the two fixed combinations
1823835|NCT00757835|Drug|latanoprost/timolol fixed combination drops|once in the evening
1823836|NCT00757848|Drug|AZD9668|60 mg, oral tablet, twice daily for 28 days
1823837|NCT00757848|Drug|AZD9668 Placebo equivalent|Match placebo to 60 mg, oral tablet, twice daily for 28 days
1823838|NCT00757874|Drug|Tacrolimus cream|0.5 g per day at bed time for 3 months or less.
1823839|NCT00757874|Drug|Clobetasol cream|0.5 gram each day at bed time during 3 months or less.
1823840|NCT00757887|Biological|Exposure to 5 P. falciparum infected mosquitoes|Five Anopheles Stephensi mosquitoes are infected with NF54 P.falciparum. volunteers are exposed to bites for 10 minutes.
1823841|NCT00757900|Biological|MUTAGRIP|Purified polyvalent vaccine for active immunisation against influenza.The vaccine is an inactivated split virus mixture of different group A and B viral strains. One 0.5 ml dose, intramuscular route.
1823842|NCT00757913|Dietary Supplement|n-3 enriched nutrition|
1823843|NCT00757926|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine [BRV-TV]|Three oral doses of the vaccine (0.5 ml each) following oral administration of antacid.
1823844|NCT00757926|Other|Placebo|Three oral doses of the placebo (0.5 ml each)following oral administration of antacid.
1823845|NCT00757939|Other|MRI|During the study all participants will have 4 total MRI scans: baseline, 1 week, 6 and 12 months.
1823846|NCT00757939|Other|FDG-PET|2 to 4 PET scans will be done over 12 months, 2 planned and 2 more if data from any of these are un-interpretable
1823847|NCT00757952|Other|Fourier transform ion cyclotron resonance mass spectrometry|
1823848|NCT00757952|Other|chromatography|
1823849|NCT00757952|Other|diagnostic laboratory biomarker analysis|
1823850|NCT00757952|Other|questionnaire administration|
1823851|NCT00757965|Genetic|polymorphism analysis|
1823852|NCT00757965|Other|laboratory biomarker analysis|
1823853|NCT00757965|Other|questionnaire administration|
1823854|NCT00757978|Drug|memantine|memantine 10mg twice a day
1823860|NCT00758004|Drug|Atorvastatin pediatric appropriate formulation|A single dose of pediatric appropriate atorvastatin 80 mg formulation
1823861|NCT00758017|Other|Acupuncture 1|Application of individualised acupuncture
1823862|NCT00758017|Other|Acupuncture 2|Application of standardised acupuncture
1823863|NCT00758030|Drug|Paliperidone ER OROS|
1823864|NCT00758043|Drug|telaprevir|750 mg every 8 hours (q8h) for 12 weeks
1823865|NCT00758043|Drug|ribavirin|1000 - 1200 mg/day based on body weight for either 24 or 48 weeks
1823866|NCT00758043|Biological|peginterferon alfa-2a|180 mcg/week for either 24 or 48 weeks
1823867|NCT00758056|Genetic|polymorphism analysis|
1823868|NCT00758056|Other|laboratory biomarker analysis|
1823869|NCT00758056|Other|questionnaire administration|
1823870|NCT00758069|Drug|sitagliptin phosphate|100 mg once daily (QD), taken orally for 4 weeks
1823871|NCT00758069|Drug|Comparator: Placebo|Placebo tablet, QD, taken orally for 4 weeks
1823872|NCT00758069|Drug|Comparator: Sitagliptin|50 mg twice daily (BID), taken orally for 4 weeks
1823873|NCT00758082|Device|paper support|Patients will have face to face visits at 3 months and no PDA-phone. Patients will record glycemia on paper support.
1823874|NCT00758082|Device|PDA-phone + telemonitoring|Patients will received PDA-phone + a telephone follow up + standard visit at 3 months
1823875|NCT00758121|Device|Cardiac Resynchronization Therapy Defibrillator|CRT-D observational study
1823876|NCT00758134|Drug|Trastuzumab (Herceptin)|Trastuzumab 6 mg/Kg every 3 weeks i.v. (loading dose 8 mg/Kg i.v.)
1823877|NCT00758147|Device|Exercise with force feedback joystick|System consists of a commercially available force feedback joystick, and specially written software. Patients will work with the system 5 times a week for 4 weeks, a half hour each time, 2 weeks with visual and haptic feedback and 2 weeks without the feedback.
1823878|NCT00758160|Drug|OROS Methylphenidate|Participants will receive Osmotic Release Oral Delivery System (OROS) methylphenidate (MPH) 18 milligram (mg), 36 mg or 54 mg once daily for 8 weeks. Dose will be adjusted for each participant based on clinical responses and/or side effects.
1823879|NCT00758173|Genetic|polymorphism analysis|
1823880|NCT00758173|Other|laboratory biomarker analysis|
1823881|NCT00758173|Other|questionnaire administration|
1823882|NCT00758186|Procedure|Emergency endoscopic colonic stenting|Colonic-stenting and elective surgery: Emergency endoscopic colonic stenting followed by elective surgery at a later date for acute left-sided malignant colonic obstruction. Patients who had successful stenting were discharged and re-admitted for elective surgery. Patients in whom stenting was unsuccessful underwent emergency surgery. The choice of surgery performed was up to the individual consultant colorectal surgeon.
1823883|NCT00758186|Procedure|Emergency surgery|Patients underwent emergency surgery for acute left-sided malignant colonic obstruction. The choice of surgery performed was up to the individual consultant colorectal surgeon. Surgery included primary resection with or without defunctioning stoma and palliative diverting stoma only.
1823884|NCT00758199|Drug|Bromfenac|Group 1: Bromfenac BID for 3 weeks Group 2: Bromfenac BID for 6 weeks
1823885|NCT00758199|Drug|Moxifloxacin hydrochloride|Group 1 and Group 2:Moxifloxacin hydrochloride 1 day prior to surgery-continue for six days after surgery.
1823886|NCT00758199|Drug|Prednisolone Acetate|Group 1 and Group 2:Prednisolone Acetate for 3 weeks in a tapering schedule (week 1: TID; week 2: BID, week 3:QD).
1823887|NCT00758212|Biological|Mesotherapy|The regular seasonal trivalent Influenza vaccine( Vaxigrip) will be diluted 1:10 in saline.The diluted vaccine will be given intra-dermally using Mesotherapy,namely multiple injections given at one time in the torso, back and axillae.
1823888|NCT00758225|Drug|Idebenone|Patients ≤ 45 kg: 450 mg/day (1 tablet 3 times a day) Patients > 45 kg: 900 mg/day (2 tablets 3 times a day)
1823889|NCT00758238|Other|myBP facilitated e-health self-management|MyOSCAR, a web-based patient-controlled personal health record, provides a mechanism for patients to enter/track health information and can encourage longitudinal patient engagement, better interaction between patients and health care providers, and patient self management. The intervention will provide access via MyOSCAR to a cardiovascular risk profile and BP tracker with sharing to providers enabled. Patients can receive general information about hypertension management; tailored messages related to their modifiable risk factors; and secure messaging with multiple providers. Providers can draw on a 'menu' of links/resources to share with patients. A lifestyle changes planner/checklist and an enhanced medication diary are additional components.
1997151|NCT02206035|Drug|Tacrolimus|Patients enrolled in the clinical trial will receive tacrolimus per institutional guidelines at doses to maintain therapeutic levels and continued until at least Day 90 posttransplant
1823892|NCT00758277|Drug|levetiracetam (Keppra)|levetiracetam daily application 1500-2000 mg
1823893|NCT00758277|Drug|Placebo|Sugar Pill
1823894|NCT00758290|Drug|Triclosan/Fluoride|Brush twice daily for 3 weeks
1823895|NCT00758290|Drug|Fluoride/triclosan|Brush daily for 3 weeks
1823896|NCT00758303|Drug|Low Dose TRIA-662|One Capsule 3 times a day
1823897|NCT00758303|Drug|High Dose TRIA-662|3 Capsules 3 times daily
1823898|NCT00758303|Drug|Placebo for TRIA-662|Matching Placebo for TRIA-662 taken 3 times a day
1823899|NCT00758316|Other|Thoracoscopy and Pleurx|Talc poudrage and tunneled pleural catheter
1823900|NCT00758316|Procedure|Thoracoscopy|Talc poudrage
1823901|NCT00758329|Device|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
1823902|NCT00758342|Drug|Travoprost 0.004% + Brinzolamide 1.0%|Travoprost 0.004% (once daily) + Brinzolamide 1.0% (twice daily)
1823903|NCT00758342|Drug|Travoprost 0.004% + Tears Natural|Travoprost 0.004% (once daily) + Tears Naturale (twice daily)
1823904|NCT00758368|Drug|Apomorphine|Participants in both arms will receive the study drug apomorphine for 6 months. One group will receive it continuously using a portable pump during waking hours, and the other group will receive it intermittently by bolus injections. The continuous delivery group will receive up to 100 mg apomorphine per 24 hours, delivered subcutaneously by ambulatory pump. The intermittent delivery group will receive up to 5 subcutaneous injections totaling up to 20 mg daily.
1823905|NCT00758381|Drug|Sorafenib 400 mg po bid, continuously|"NEXAVAR*112CPR RIV 200MG
Titolare AIC:
BAYER SpA
Numero di AIC dell'IMP:
037154010"
1823906|NCT00758381|Drug|Gemcitabina, Cisplatino|Gemcitabina 1000 mg/mq, Cisplatino 25 mg/mq day 1 and 8 every 21 days
1823908|NCT00758394|Drug|Triclosan/Fluoride|Brush two times daily for 4 days
1823909|NCT00758394|Drug|Triclosan/Fluoride|Brush twice daily for 4 days
1823910|NCT00758394|Drug|Triclosan/Fluoride|Brush twice daily for 4 days
1823911|NCT00758407|Drug|Methylphenidate hydrochloride|sustained release, dosage according to an individual titration schedule
1823912|NCT00758407|Drug|Placebo|dosage according to an individual titration schedule
1823913|NCT00758420|Drug|Varisolve (Polidocanol Endovenous Microfoam)|1% polidocanol, up to 15 mL, one treatment session (initially up to 30 ml, reduced to up to 15 ml in Amendment #2)
1823914|NCT00758420|Drug|Agitated Saline|10 u/mL normal heparinized saline solution, up to 20 mL, one treatment session
1823915|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0075% q.d. 24 hours for 7 days
1823916|NCT00758433|Drug|Zucapsaicin|Civamide patch 0.0150% q.d. 24 hours for 7 days
1823917|NCT00758433|Drug|Placebo patch|Placebo patch q.d. 24 hours for 7 days
1823918|NCT00758446|Drug|BLX-028914|50 mg capsules, p.o, daily, 14 days
1823919|NCT00758446|Drug|BLX-028914|15 mg capsules, p.o, daily, 14 days
1823920|NCT00758446|Drug|placebo|capsules, p.o, daily, 14 days
1823921|NCT00758459|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
1823922|NCT00758459|Drug|Placebo|Dosing to match AZD1236
1823923|NCT00758472|Device|ReCap Total Hip Resurfacing|ReCap Total Hip Resurfacing
1823924|NCT00758485|Drug|Sugammadex|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of 4.0 mg.kg-1 sugammadex (volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
1823925|NCT00758485|Drug|0.9% sodium chloride (NaCl)|At a target depth of NMB of 1-2 PTC after the last dose of rocuronium, a bolus dose of placebo (0.9% NaCl, volume based on the actual body weight of the participant) will be administered, within 10 seconds into a fast running venous infusion.
1823926|NCT00758498|Drug|armodafinil|50 mg/day orally, once daily in the morning for 3 days
1823927|NCT00758498|Drug|armodafinil|150 mg/day orally, once daily in the morning for 3 days
1823928|NCT00758498|Drug|placebo|placebo tablets, once daily in the morning for 3 days
1823929|NCT00758511|Procedure|25% Sucrose|orally administrated 25%Sucrose before, during and after heel stick
1823930|NCT00758511|Procedure|facilitated tucking|facilitated tucking before, during and after heel stick
1823931|NCT00758511|Procedure|Sucrose and facilitated tucking|orally administrated 25%sucrose and facilitated tucking before, during and after heel stick
1823932|NCT00758524|Drug|LCI699|
1823933|NCT00758524|Drug|Eplerenone|
1823934|NCT00758524|Drug|Placebo|Placebo
1823935|NCT00758550|Device|AcrySof® Toric IOL|AcrySof® Toric Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
1823936|NCT00758550|Device|AcrySof Natural|AcrySof Natural Intraocular Lens (IOL) implanted into the study eye following cataract extraction surgery
1823937|NCT00758563|Drug|Fluoride|Brush twice daily
1823938|NCT00758563|Drug|Triclosan/Fluoride|Brush twice daily
1823939|NCT00758576|Device|ACRYSOF Multifocal Single-piece Intraocular Lens (IOL) Model SN6AD1|Implantation with the AcrySof ReSTOR Intraocular Lens (IOL) Model SN6AD1 following cataract removal.
1823940|NCT00758589|Drug|AZD1981|Oral tablet, 50 mg twice daily
1823941|NCT00758589|Drug|AZD1981|Oral tablet, 400 mg twice daily
1823942|NCT00758589|Drug|AZD1981|Oral tablet, 1000 mg twice daily
1823943|NCT00758589|Drug|Placebo|
1823944|NCT00758602|Drug|mycophenolate mofetil|0.75-1 g PO BID from Day 0 through Month 12
1823945|NCT00758602|Drug|tacrolimus, standard dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8-10 ng/mL from Day 0 through Month 3; the dose was adjusted to reach a target trough level of 7-10 ng/mL in Month 3 and continued through Month 12.
1823946|NCT00758602|Drug|tacrolimus, low dose|Initial dose of 0.1-0.15 mg/kg PO BID to reach a target trough dose of 8 to 10 ng/mL from Day 0 through Month 3; 0.05-0.08 mg/kg PO BID to reach a target trough dose of 2-5 ng/mL in Month 3 and continued through Month 12.
1823947|NCT00758602|Drug|corticosteroids|According to center's practice
1823948|NCT00758615|Behavioral|Walking School Bus|Students are chaperoned to and from school by adults (study staff or parent volunteers) along set routes.
1823949|NCT00758628|Drug|Bromefenac|Bromfenac BID 3 months
1823950|NCT00758628|Drug|Blink|Blink BID for 3 months
1823951|NCT00758641|Device|L-PRP Injection|L-PRP produced with Biomet Recover L-PRP Platelet Separation Kit
1823952|NCT00758641|Drug|Corticosteroid Injection|kenacort 40 mg/ml triamcinolon acetonide
1823953|NCT00758667|Drug|Mesna|B. Mesna will be used to aid in the removal of the capsule when capsulectomy is performed
1823954|NCT00758680|Drug|MK-1006|MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
1823955|NCT00758680|Drug|Comparator: Placebo comparator|Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
1823956|NCT00758693|Drug|Bendamustine|Bendamustine 100 mg/m2 intravenously on days 1 and 2 on a 28-day cycle for 6 cycles
1823957|NCT00758693|Drug|Rituximab|Rituximab 500 mg/m2 on a 28-day cycle for 6 cycles
1823958|NCT00758706|Drug|AZD1236|oral tablet, 75 mg, twice daily during 6 weeks
1823959|NCT00758706|Drug|Placebo|Dosing to match AZD1236
1823960|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 75mg/m2 over a 60 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
1823961|NCT00758732|Drug|Carboplatin|Carboplatin 5 AUC over a 90 min intravenous infusion every 3 weeks for a maximum of 6 consecutive cycles
1823962|NCT00758732|Drug|Docetaxel|Docetaxel at the dose of 40mg/m2 over a 60 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
1823963|NCT00758732|Drug|Liposomal doxorubicin|Liposomal doxorubicin at the dose of 20 mg/m2 over a 90 min intravenous infusion every 2 weeks in 28 days cycle for a maximum of 6 consecutive cycles.
1823964|NCT00758745|Device|Model SN60WF|Implantation with the AcrySof Model SN60WF Single-piece intraocular lens (IOL) following cataract removal.
1823965|NCT00758745|Device|Model MA60AC|Implantation with the AcrySof Model MA60AC multi-piece intraocular lens (IOL) following cataract surgery.
1823966|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Hedrocel
1823967|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Allograft
1823968|NCT00758758|Device|Anterior Cervical Discectomy and Fusion|Implantation of Autograft
1823969|NCT00758784|Drug|Refresh Tears|sterile ophthalmic solution
1823970|NCT00758797|Other|Photoimmunotherapy|DIOMED laser + photosensitizing agent injected intralesionally and topical immuno-modulating cream
1823971|NCT00758823|Device|Paranix|pediculicide product
1823972|NCT00758836|Drug|placebo|
1823973|NCT00758836|Drug|ibuprofen|
1823974|NCT00758836|Drug|acetominophen|
1823975|NCT00758836|Drug|telcagepant|
1823976|NCT00758849|Drug|Placebo|One placebo tablet administered tid for 12 days in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
1823977|NCT00758849|Drug|Fipamezole|One 30-mg tablet of Fipamezole tid from day 1 to 3; one 60-mg tablet of Fipamezole tid from Day 4 to 6; and one 90-mg tablet of Fipamezole tid from Day 7 to 12 in each of the three crossover treatment blocks, each block separated by 2-days placebo washout
1823978|NCT00758862|Drug|2% TD1414 Cream|Application 3 times daily for 7 days
1823979|NCT00758888|Procedure|Orthopedic Blocking|Place the blocks under the pelvis for 2 minutes
1823980|NCT00758888|Procedure|Trochanter Belt|Participant is fitted with trochanter belt on the adjusting table and wear it while Investigator checks their flexion and extension strength.
1823981|NCT00758888|Other|Blocking Sham|Participant lies on adjusting table, blocks are placed in a similar configuration but distant to actual points of leverage.
1823982|NCT00758901|Device|Knee Replacement (with ROCC Knee prosthesis)|Knee Replacement (with ROCC Knee prosthesis)
1823983|NCT00758914|Dietary Supplement|Vitamin E|200 IU alpha-tocopherol or placebo for 1 year.
1823984|NCT00758927|Drug|Omega-3 acid 4 grams per day|OMACOR 4 grams per day is administered simultaneously with exercise and diet therapy
1823985|NCT00758927|Drug|Placebo control|Placebo will be administered simultaneously with exercise and diet therapy in same intensity with the experimental arm
1823986|NCT00758940|Device|Acrysof ReSTOR multifocal IOL|Implanted into the study eye following cataract extraction surgery
1823987|NCT00758953|Drug|Danazol Once Weekly|semi-solid
1823988|NCT00758953|Drug|Danazol Twice Weekly|semi-solid
1823989|NCT00758953|Drug|Placebo Once Weekly|semi-solid
1823990|NCT00758953|Drug|Placebo Twice Weekly|semi-solid
1823991|NCT00758966|Drug|Fluoxetine 60 mg|Two week titration followed by daily dosing of fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on fluoxetine 60 mg for an additional 6 weeks. Non-responders will have naltrexone SR 32 mg added to their therapy.
1823992|NCT00758966|Drug|Naltrexone 32 mg and fluoxetine 60 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg and fluoxetine 60 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on a daily dose of naltrexone SR 32 mg and fluoxetine 60 mg for an additional 6 weeks. Non-responders will have their daily dose adjusted to naltrexone SR 48 mg and fluoxetine 80 mg.
1823993|NCT00758966|Drug|Naltrexone SR 32 mg|Two week titration followed by daily dosing of naltrexone SR 32 mg for 8 weeks. Response is assessed at after 8 weeks. Responders will continue on naltrexone SR 32 mg for an additional 6 weeks. Non-responders will have fluoxetine 60 mg added to their therapy.
1823994|NCT00759005|Drug|propranolol and cortisol|
1823995|NCT00759018|Biological|remestemcel-L|Patients will be treated with Prochymal® twice per week at a dose of 2 x 10^6 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
1823996|NCT00759031|Drug|Sodium Monofluorophosphate|Brush teeth and evaluate plaque score after one use of the study toothpaste
1823997|NCT00759031|Drug|Triclosan/Fluoride/Copolymer|Brush teeth and evaluate plaque score after one use of the study toothpaste
1823998|NCT00759057|Device|Posterior Pedicle Screw System|Implantation of Posterior Pedicle Screw System
1823999|NCT00759070|Drug|Tenofovir + emtricitabine + efavirenz|"Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)
+ Efavirenz 600 mg, (Sustiva, Bristol-Myers Squibb) once daily"
1824000|NCT00759070|Drug|Tenofovir + emtricitabine + lopinavir/ritonavir|Tenofovir 300 mg + emtricitabine 200 mg, (Truvada, Gilead Sciences)QD Lopinavir/ritonavir 400 mg/100 mg, (Kaletra, Abbott) BID
1824001|NCT00759083|Drug|bivalirudin|Bivalirudin; 0.75mg/kg/h IV bolus followed immediately by 1.75 mg/kg/h infusion for the duration of the procedure
1824002|NCT00759096|Device|RESTOR IOL Model SA60D3|Implanted into the study eye following cataract extraction surgery
1824005|NCT00759122|Drug|venlafaxine (Effexor)|Matching capsules containing venlafaxine 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
1824006|NCT00759122|Drug|placebo|Matching capsules containing placebo 37.5 mg. WERE prepared by the UCLA Pharmacy for the initial phase of the study. After a one-week placebo lead-in, subjects WERE randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects received four capsules daily (subjects achieved a dose of 150 mg. of venlafaxine after 10 days). The first dose was administered in the morning, with subsequent capsules added on a b.i.d. schedule.
1824007|NCT00759135|Drug|2.5 mg NX-1207|Therapeutic dose; single intraprostatic injection of 2.5 mg NX-1207
1824008|NCT00759135|Drug|0.125 mg NX-1207|Low dose; single intraprostatic injection of 0.125 mg NX-1207
1824009|NCT00759135|Drug|finasteride|Active comparator; 5.0 mg finasteride p.o. q.d. for duration of study (180 days)
1824010|NCT00759148|Drug|Moxifloxacin eye drops|eyedrops; 1 drop in each eye, twice daily for 3 days
1824011|NCT00759148|Drug|Moxifloxacin AF Ophthalmic Solution Vehicle (placebo)|Eyedrops; 1 drop in each eye, twice daily for 3 days
1824012|NCT00759161|Drug|AN2728|AN2728 Ointment, 5%, twice daily for 4 weeks
1824013|NCT00759161|Drug|AN2728 Ointment Vehicle|AN2728 Ointment Vehicle, twice daily for 4 weeks.
1824014|NCT00759174|Drug|No intervention|No intervention occurs in this observational study.
1824015|NCT00759187|Drug|Fluoride|Brush twice daily
1824016|NCT00759187|Drug|Triclosan/Fluoride|Half mouth toothbrushing twice daily for 4 days
1824017|NCT00759187|Drug|Chlorhexidine Gluconate|Mouth rinsing twice a day for 4 days
1824018|NCT00759200|Drug|alb-interferon alfa 2b|900 mcg every 4 weeks
1824019|NCT00759200|Drug|alb-interferon alfa 2b|1200 mcg every 4 weeks
1824020|NCT00759200|Drug|alb-interferon alfa 2b|1500 mcg every 4 weeks
1824021|NCT00759200|Drug|alb-interferon alfa 2b|1800 mcg every 4 weeks
1824022|NCT00759200|Drug|peg-interferon|Peg-interferon alfa 2a: 180 mcg 1x per wk.
1824023|NCT00759226|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 (30 min)
1824024|NCT00759226|Drug|Cisplatin|Cisplatin 30 mg/m2 (90 min)
1824025|NCT00759226|Drug|5-FU|5-FU 750 mg/m2 (24h CI)
1824026|NCT00759226|Drug|Folinic Acid|Folinic Acid 200 mg/m2 (30 min)
1824027|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, morning dosing
1824028|NCT00759239|Drug|Travoprost 0.004% / Timolol maleate 0.5%|Solution, evening dosing
1824029|NCT00759265|Other|resistance training|"During 24 weeks, the patients of the intervention group will participate in a resistance training program. Two subsequent intervention programmes will be offered. Initially the first 12 week resistance trainings stage will aimed at improving function of lower leg muscles; subsequently a more extended programme affecting total limb musculature (lower- and upper leg) will be provided (also 12 weeks).
During these trainings period, patients will train 3 times a week; once a plenary training session of 1,5 hour provided by a physical therapist. And 2 trainings sessions of half an hour each, by them selves at home."
1824030|NCT00759278|Procedure|ultrasound evaluation in pregnancy|Subjects enrolled will have a series of ultrasound evaluations to assess parameters in the study. Ultrasound is a non-invasive technique for creating images that does not use radiation and is routine in obstetrical practice
1824031|NCT00759291|Drug|acipimox|250 mg tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
1824032|NCT00759291|Drug|matching placebo|1 tablet orally every 6 hours for 7 days, with a dose at 7 am on the morning of the study visit
1824033|NCT00759317|Drug|venlafaxine (Effexor)|Matching capsules containing either venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule.
1824034|NCT00759330|Drug|Placebo Tape (Arm 1)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
1824035|NCT00759330|Drug|Flurbiprofen Tape (Arm 2)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
1824036|NCT00759330|Drug|Placebo Tape (Arm 3)|Two placebo tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days.
1824037|NCT00759330|Drug|Flurbiprofen Tape (Arm 4)|Two flurbiprofen tapes (one on each side of the spine) were applied on the lower back area once daily for 7 days. Each tape contained 31.5 mg flurbiprofen for a total daily dose of 63 mg.
1824038|NCT00759356|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
1824039|NCT00759356|Drug|KADIAN|2 x 100 mg, single-dose capsule
1824040|NCT00759369|Other|Water prescription|Water prescription in 12 to 16 equally divided doses
1824041|NCT00759395|Drug|AZD2327|Tablet, Oral, Daily
1824042|NCT00759395|Drug|Placebo|Tablet, Oral, Daily
1824044|NCT00759421|Drug|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
1824045|NCT00759421|Drug|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
1824046|NCT00759434|Procedure|Surgery - Saphenofemoral ligation, saphenous strip and avulsions|Patients undergo Saphenofemoral ligation, inversion stripping of the Long Saphenous Vein and avulsion of varicosities if necessary under a general anaesthetic.
1824047|NCT00759434|Procedure|EVLT|Patients undergo endovenous laser treatment, using a 810nm laser aiming to occlude the incompetent long saphenous vein from the saphenofemoral junction to the knee. This may then be followed by ambulatory phlebectomy as appropriate. All procedures are to be performed under a local anaesthetic.
1824048|NCT00759460|Drug|Sertindole|12 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
1824049|NCT00759460|Drug|Olanzapine|10 to 20 mg daily after initial up-titration, encapsulated tablets, orally, 84 days
1824050|NCT00759473|Drug|D-Cycloserine (DCS)|50 mg d-cycloserine or placebo taken orally
1824051|NCT00759473|Drug|Placebo|
1824052|NCT00759512|Other|Therapeutic Touch|
1824053|NCT00759525|Drug|Glycyrrhetic Acid|130 mg daily for fourteen days
1824054|NCT00759525|Drug|Placebo|Placebo daily for fourteen days
1824055|NCT00759551|Drug|Azilsartan|Azilsartan 2.5 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
1824056|NCT00759551|Drug|Azilsartan|Azilsartan 5.0 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
1824057|NCT00759551|Drug|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
1824058|NCT00759551|Drug|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
1824059|NCT00759551|Drug|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily and olmesartan placebo-matching capsules and tablets, orally, once daily for up to 8 weeks.
1824060|NCT00759551|Drug|Placebo|Azilsartan placebo-matching tablets, orally, once daily and olmesartan placebo-matching capsules, orally, once daily for up to 8 weeks.
1824061|NCT00759551|Drug|Olmesartan|Azilsartan placebo-matching tablets, orally, once daily and olmesartan 20 mg, capsules, orally, once daily for up to 8 weeks.
1824062|NCT00759564|Drug|CP-70,429 and PF-03709270|Study Periods 1 and 2 will be separated by a minimum of 14 days. In Period 1, subjects will receive a single dose of CP-70429 (800 mg given as a 1.5 hour intravenous infusion), while in Period 2, subjects will receive a single oral dose of PF-03709270 (1000 mg).
1824063|NCT00759577|Drug|Solifenacin|5mg and 10 mg, oral once daily
1824064|NCT00759590|Procedure|CT scan and Pressure volume curve|CT scan
1824065|NCT00759603|Drug|Lenalidomide|Started on Day 9 of Cycle 1 at the dose of 10 mg/day and continued daily. Treatment duration will be twelve cycles.
1824066|NCT00759603|Drug|Rituximab|Dose of 375 mg/m^2 given intravenously on Day 1, Day 8, Day 15 and Day 22 then continued once every four weeks during cycles 3-12 (+ 7 days). Rituximab not given in Cycle 2.
1824067|NCT00759616|Device|Oxford Partial Knee|Oxford Partial Knee
1824068|NCT00759629|Other|Interventional treatment group|Patients assigned to PCI will receive the loading dose of clopidogrel (300 mg), 500 mg aspirin plus a bolus of 70 U/kg heparin i.v. and be transferred immediately for interventional treatment. They will receive abciximab as a bolus of 0.25 mg/Kg of body weight followed by a continuous infusion of 0.125 µg/Kg/minute (up to a maximal dose of 10 µg/minute) for 12 hours. All patients will undergo coronary angiography and left ventriculography in the conventional way. During the procedure patients will receive the weight-adjusted heparin doses (70 U/ kg). Post-procedural antithrombotic therapy will consist of clopidogrel in a daily dose of 75 mg for at least 4 weeks (6 months recommended) and aspirin, 100 mg to 350 mg daily, indefinitely.
1824069|NCT00759629|Other|Conservative treatment group|Patients assigned to this group will receive the usual therapy in the intensive care unit of the admitting hospital according to local standards. Per protocol, all patients in this arm will receive a loading dose of clopidogrel (300 mg) followed by 75 mg/day for at least 4 weeks (6 months recommended) after randomization and aspirin, indefinitely. Recommended additional regimen will include heparin, ß-blockers, ACE inhibitors and statins
1824070|NCT00759642|Drug|lapatinib|lapatinib 1500 mg PO daily
1824071|NCT00759655|Biological|Moroctocog alfa|Patients will receive Moroctocog alfa according to their investigator's prescription.
1824072|NCT00759668|Device|Acrysof Natural ReSTOR SN60D3|Bilateral implantation with the AcrySof Natural ReSTOR Intraocular Lens (IOL) SN60D3 following cataract removal.
1824073|NCT00759668|Device|Acrysof Natural Monofocal SN60AT|Bilateral implantation with the AcrySof Natural Intraocular Lens (IOL) Model SN60AT following cataract removal.
1824074|NCT00759681|Device|ArterX Surgical Sealant|Apply at the suture site.
1824075|NCT00759681|Device|Gelfoam and Thrombin|Apply at the suture site.
1824076|NCT00759707|Drug|L-N^G monomethyl arginine (L-NMMA)|L-NMMA was infused at a dose of 1 mg/kg over 10 minutes to competitively inhibit the production of nitric oxide. Ultrasound imaging of the saphenous vein [arterial] bypass at baseline, and following an ischemic stimulus, administration of sublingual nitroglycerin, and intravenous administration of L-NMMA.
1824077|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 16 mg, tablets, orally, once daily and glyburide stable dose orally, once daily for up to 26 weeks.
1824078|NCT00759720|Drug|TAK-559 and glyburide|TAK-559 32 mg, tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
1824079|NCT00759720|Drug|Glyburide|TAK-559 placebo-matching tablets, orally, once daily and glyburide stable dose, orally, once daily for up to 26 weeks.
1824080|NCT00759733|Procedure|echocardiography|A non-invasive assessment of cardiac function using sound waves to create a picture of the pregnant woman's heart. There is no radiation involved.
1824081|NCT00759733|Procedure|blood draw for serum B-type natriuretic peptide|A simple, minimally invasive standard blood draw for assessment of serum B-type natriuretic peptide, to be measured in a standard hospital laboratory and recorded for research purposes only
1824082|NCT00759746|Behavioral|SFM+ Low Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet less often than families that receive the Social Facilitation Maintenance (SFM) - High Dose intervention, giving them more opportunities to practice new skills between clinic visits.
1824083|NCT00759746|Behavioral|Weight Maintenance Education|The Weight Maintenance Education intervention will help participants in parent and child groups to learn more about healthy eating and physical activity in a group setting. Participants will also learn about exercise and exercise safety, hydration during exercise, and stress management. Parent and child groups will combine for particular on-site and off-site activities, such as cooking demonstrations, grocery store tours, gym tours, and dance lessons.
1824084|NCT00759746|Behavioral|SFM+ High Dose|The SFM intervention assumes people need a social environment that supports changes in eating and physical activity for continued weight maintenance. Therefore, the SFM intervention will focus on helping families create a social environment that supports weight maintenance (e.g., children being friends with physically active peers). Participants in this group will meet more often than families that receive the Social Facilitation Maintenance (SFM) - Low Dose intervention, allowing for more in-depth discussion and practice of key skills and concepts related to creating a social environment that supports a healthy lifestyle. These participants will receive more feedback and reinforcement from fellow group members, family interventionists, and group leaders for practicing their new behaviors.
1824085|NCT00759759|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
1824086|NCT00759759|Drug|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
1824089|NCT00753948|Drug|N-Nitro L-arginine-methylester (L-NAME)|A non-specific inhibitor of the nitric oxide synthase enzyme.
1824090|NCT00753961|Other|fermented dairy product|fermented dairy product (2 bottles/day during 16 weeks)
1824091|NCT00753961|Other|non fermented dairy product|non fermented dairy product (2 bottles/day during 16 weeks)
1824092|NCT00753987|Drug|Hypertonic Saline|5 ml of 7% saline will be administered via mask with Pari LC Plus nebuliser and a Pari Ultra Ned compressor.
1958585|NCT01498978|Biological|ipilimumab|Given IV
1824094|NCT00754013|Drug|Aricept (Donepezil hydrochloride)|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) donepezil.
All doses will be administered orally."
1824095|NCT00754013|Drug|Placebo|"All subjects will start with a dose of 1.25 mg/day (1.25 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 5 mg/day (5 ml) placebo.
All doses will be administered orally."
1824096|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 2cm
1824097|NCT00754026|Procedure|Insertion of interscalene catheter for shoulder surgery|Distance of interscalene catheter: 6cm
1824098|NCT00754039|Drug|colesevelam HCl tablets and fenofibrate tablets|Colesevelam 625 mg tablets - 6 tablets/day Fenofibrate 160 mg tablet - 1/day
1824099|NCT00754039|Drug|fenofibrate tablets and Welchol placebo tablets|fenofibrate tablets 160 mg - 1/day + Welchol placebo tablets - 6/day
1824100|NCT00754039|Drug|fenofibrate tablets and Welchol placebo tablets|fenofibrate 160 mg tablet - 1/day and Welchol placebo tablets - 6/day
1824101|NCT00754052|Drug|Aricept (donepezil hydrochloride)|All subjects will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalation will occur at 2 weeks to a maximum of 5 mg/day (5 ml) donepezil. All doses will be administered orally.
1824102|NCT00754052|Drug|Aricept (donepezil hydrochloride)|All subjects will start with a dose of 2.5 mg/day (2.5 ml) donepezil ; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) donepezil. All doses will be administered orally.
1824103|NCT00754052|Drug|Placebo|All subjects will start with a dose of 2.5 mg/day (2.5 ml) placebo; dose escalations will occur every 2 weeks to a maximum of 10 mg/day (10 ml) placebo. All doses will be administered orally.
1824104|NCT00754065|Drug|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated BAY86-5027 for 28 days per Cycle, for 13 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo
1824105|NCT00754065|Drug|Ortho Tri Cyclen Lo|Dose--Ethinylestradiol (EE) + Norgestimate (NGM) Triphasic 21-day regimen. Daily oral administration of one encapsulated Ortho Tri-Cyclen Lo for 28 days per Cycle, for 13 treatment cycles: Days 1-7, 0.025 mg EE+0.180 NGM; Days 8-14, 0.025 mg EE+0.215 NGM; Days 15-21, 0.025 mg EE+0.250 NGM; Days 27-28, placebo
1824106|NCT00754078|Radiation|Tomotherapy|30 fractions of tomotherapy treatment
1824107|NCT00754104|Drug|ABT-869|0.25 mg/kg. daily.
1824108|NCT00754104|Drug|Tarceva|150mg, daily.
1824109|NCT00754130|Drug|Placebo|Placebo tablets before every meal (q.a.c) Treatment period is 5 days.
1824110|NCT00754130|Drug|MK-0941|MK-0941 5 mg tablets q.a.c.; 10 mg tablets q.a.c.; 20 mg tablets q.a.c.; or 40 mg tablets q.a.c. Treatment period is 5 days.
1824111|NCT00754143|Drug|FG-3019|Placebo every 2 weeks IV for all infusions
1824112|NCT00754143|Drug|FG-3019|FG-3019 5 mg/kg every 2 weeks IV for all infusions
1824113|NCT00754143|Drug|FG-3019|FG-3019 10 mg/kg IV for infusions on Days 1, 15, 29 and 57 and Placebo IV on Days 43 and 71
1824114|NCT00754156|Device|ABRA Abdominal Closure System|ABRA Abdominal Closure System
1824115|NCT00754156|Device|V.A.C. Therapy|V.A.C. Therapy Alone
1824116|NCT00754156|Device|KCI ABThera|KCI ABThera
1824117|NCT00754182|Device|Octylcyanoacrylate (Dermabond)|Synthetic glue for surgical use (skin closure)
1824118|NCT00754182|Device|Subcuticular reabsorbable suture (Caprosyn)|Every stitch is positioned in the subcuticular tissue by a continuous technique
1824119|NCT00754195|Other|Thoracic epidural catheter|Comparison of 3 insertion distances (3,5 and 7 cm) for a thoracic epidural catheter in the context of thoracic surgery.
1824120|NCT00754208|Drug|methylphenidate|Starting dose: methylphenidate (immediate-release pill) or Methylin (immediate-release chewable tablet for those unable to swallow pills) 2.5mg Q AM and Q noon. Target dose of 1mg/kg/day. Titration will occur as follows: 5mg Q AM and Q noon, then 7.5mg Q AM and Q noon, then 10mg Q AM and Q noon, as tolerated, not to exceed 30mg per day. Once each child arrives at a stable dose with a good response and good tolerability, they will be converted to the closest Ritalin LA dose, with a target dose of 1mg/kg/day.
1824121|NCT00759772|Drug|Placebo|sc daily for 6 months
1824122|NCT00759772|Drug|Teriparatide|20 mcg sc daily for 6 months
1824123|NCT00759785|Drug|dalotuzumab (MK0646)|Single intravenous infusion
1824124|NCT00759798|Drug|Fludarabine|25 mg/m^2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
1824125|NCT00759798|Drug|Cyclophosphamide|250 mg/m2 given intravenously on Days 2-4 of Cycle 1 and Days 1-3 of Cycles 2 and beyond.
1824126|NCT00759798|Drug|Rituximab|"375 mg/m2 given intravenously on Day 1 of Course 1
All subsequent Courses: 500 mg/m2 given intravenously on Day 1 (Weeks 5,9,13,17,21)"
1824127|NCT00759811|Drug|Methotrexate|"Patients receiving conventional treatment to heart failure who will receive methotrexate 7.5mg oral plus folic acid 5mg oral once a week for 12 weeks.
All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
1824128|NCT00759811|Drug|Placebo|"Patients receiving conventional treatment to heart failure who will receive placebo oral plus folic acid 5mg oral once a week for 12 weeks.
All patients will have evaluated at the baseline and after 12 weeks: physical capacity by the 6-minutes walk test, quality of life by the Brazilian edition SF-36 and inflammatory marker by C-reactive protein. They also will be tested for ALT, AST, blood cell count, creatinine, and prothrombin time at baseline, after 6 weeks and after 12 weeks."
1824129|NCT00759824|Drug|Adriamycin, cyclophosphamide, vindesine, valproic acid|Adriamycin 45 mg/m² day 1 IV Cyclophosphamide 1 g/m² day 1 IV Vindesine 3 mg/m² day 1 IV Valproic acid 20-30 mg/kg/day from day -7 until the end of treatment, orally
1824130|NCT00759837|Drug|Bosutinib|
1824264|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose step 2 (3 subjects)
1825071|NCT00769470|Drug|carboplatin|Given IV
1824131|NCT00759850|Device|Drug Eluting Stent (DES)|Open-label randomization was performed after initial angiography by the treating physician when eligibility criteria were met. All patients received in the CCU 70U/Kg i.v. bolus of UFH plus 1000U/h infusion (to maintain an ACT of at least 200 seconds), aspirin intravenously (500 mg) and clopidogrel (300 mg loading dose). All patients received upstream Gp IIb-IIIa inhibitors administration as a routine adjunctive therapy before primary PCI. Postinterventional antiplatelet therapy for all patients included in the three study group, consisted of aspirin (100 mg) indefinitely and clopidogrel (75 mg for six months). Stenting procedures were performed according to standard techniques. The number and length of stents, and the type of BMS to be implanted, were left to the operator's discretion. The operator was allowed to implant DES to cover the entire length of the lesion with coverage of the entire stented segment and of 5 mm proximal and distal segments.
1824132|NCT00759863|Behavioral|Lifezig|Personalized Reminiscence Video
1824133|NCT00759876|Drug|Ataluren|Oral powder in a sachet taken 3 times per day with dosing based on subject body weight. Doses are 20 mg/kg with breakfast, 20 mg/kg with lunch, and 40 mg/kg with dinner.
1824134|NCT00759902|Drug|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
1824135|NCT00759902|Drug|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
1824136|NCT00759915|Drug|morphine sulfate extended-release capsules|2 x 10 mg, single-dose capsule
1824137|NCT00759915|Drug|KADIAN (morphine sulfate extended-release) capsules|1 x 20 mg, single-dose capsule
1824138|NCT00759928|Drug|Erlotinib|150 mg once daily by mouth
1824139|NCT00759928|Drug|Sorafenib|400 mg twice daily by mouth
1824140|NCT00759941|Drug|Brinzolamide 1% ophthalmic solution (Azopt)|One drop three times a day in both eyes for 3 months
1824141|NCT00759941|Drug|Placebo eye drops|One drop three times a day in both eyes for 3 months
1824142|NCT00759941|Drug|Latanoprost 0.005% ophthalmic solution (Xalatan)|One drop once a day in both eyes for 3 months
1824143|NCT00759954|Drug|morphine sulfate sustained-release capsules|1 x 200 mg, single-dose capsule
1824144|NCT00759954|Drug|KADIAN (morphine sulfate sustained-release) capsules|2 x 100 mg, single-dose capsule
1824145|NCT00759967|Procedure|Microneurography|Muscle sympathetic nerve activity measurement will be obtained using microneurography. Approximately 10-20% of microneurography recordings are not interpretable due to technical problems. For this reason, blood samples will be collected at the same time that the microneurography is to be done. These test will be done at 3 time points throughout the study.
1824146|NCT00759967|Procedure|Bioimpedance testing|bioimpedance measurement of extracellular fluid volume will be measured at the end of each 3 month period. This test will be done at 3 time points throughout the study.
1824147|NCT00759993|Drug|chromium piccolinate|1000mg tab
1824148|NCT00759993|Drug|placebo for chromium piccolinate|
1824151|NCT00760019|Drug|salsalate|1.5 grams orally 3 times daily
1824152|NCT00760019|Drug|placebo|matching placebo
1824153|NCT00760032|Drug|Ciprofloxacin|Ciprofloxacin oral, 500 mg capsules, one capsule per day during four weeks.
1824154|NCT00760032|Drug|Placebo|Placebo capsules, one capsule per day during four weeks.
1824155|NCT00760045|Drug|Hydroxypropyl Guar Galactomannan|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
1824156|NCT00760045|Drug|0.1% sodium hyaluronate ophthalmic solution|One drop per one time in both eyes, once daily (at each visit).One instillation daily in one period and a total of 4 instillations over 4 periods.
1824157|NCT00760058|Device|AcrySof® IQ IOL|Replacement of natural crystalline lens in cataract surgery
1824158|NCT00760058|Device|Tecnis® Aspheric intraocular lens|Replacement of natural crystalline lens in cataract surgery
1824159|NCT00760058|Device|Akreos® MI60 intraocular lens|Replacement of natural crystalline lens in cataract surgery
1824160|NCT00760084|Drug|Decitabine|Decitabine is administered at a dose of 20 mg/m² over a 1-hour intravenous infusion for 5 consecutive days every 4 weeks in patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML; ≥ 30% blasts).
1824161|NCT00760097|Device|Transcranial direct stimulation|sessions of 20 minutes each
1824162|NCT00760916|Drug|UT-15C 1 mg|UT-15C 1 mg
1824163|NCT00760916|Drug|UT-15C 0.25 mg|UT-15C 0.25 mg
1824164|NCT00760916|Drug|UT-15C 5 mg|UT-15C 5 mg
1824165|NCT00760916|Drug|Placebo|Placebo
1824166|NCT00760929|Drug|Placebo|iv 9mg/kg weekly
1824167|NCT00760929|Drug|Placebo|iv 16mg/kg every 3 weeks
1824168|NCT00760929|Drug|RG1507|iv 9mg/kg weekly
1824169|NCT00760929|Drug|RG1507|iv 16mg/kg every 3 weeks
1824170|NCT00760929|Drug|erlotinib [Tarceva]|150mg oral daily
1824171|NCT00760942|Dietary Supplement|Similac special care 30|Liquid pre-term formula 30Kcals/oz. used as human milk fortifier.
1824172|NCT00760942|Dietary Supplement|Similac human milk fortifier|Powdered human milk fortifier.
1824173|NCT00760955|Drug|TAK-583|TAK-583 5 mg, tablets, orally, once daily for up to 6 months.
1824174|NCT00760955|Drug|TAK-583|TAK-583 50 mg, tablets, orally, once daily for up to 6 months.
1824175|NCT00760955|Drug|TAK-583|TAK-583 100 mg, tablets, orally, once daily for up to 6 months.
1824176|NCT00760955|Drug|Placebo|TAK-583 placebo-matching tablets, orally, once daily for up to 6 months.
1824177|NCT00760968|Drug|TAK-783 and methotrexate|TAK-783 100 mg, tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
1824178|NCT00760968|Drug|Methotrexate|TAK-783 placebo-matching tablets, orally, once daily and methotrexate stable dose therapy for up to 12 weeks.
1824179|NCT00760981|Drug|Imatinib|
1825072|NCT00769470|Drug|docetaxel|Given IV
1824180|NCT00760994|Behavioral|Experiential acceptance|The experiential acceptance coping condition will focus on changing one's relationship to one's internal events by learning to remain in contact with negative and positive thoughts and feelings and cravings as they are, without defense or judgment or attempting to cling to them (Eifert & Forsyth, 2005; Hayes, Strosahl, & Wilson, 1999; Kadden et al., 1992; Levitt, Brown, Orsillo, & Barlow, 2004).
1824181|NCT00760994|Behavioral|Cognitive restructuring|The cognitive restructuring coping condition will focus on how to change the content and frequency of internal events by changing one's thinking patterns (Kadden et al., 1992).
1824182|NCT00760994|Other|No-intervention control: Nutrition information|The no-intervention condition will be taught the plate method, a nutritional servings guideline, which will have no content related to AUD or PTSD, in order to control for time and contact with a research assistant.
1824183|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 1 (10 mg), once daily
1824184|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 2 (30 mg), once daily
1824185|NCT00761007|Drug|Ibodutant|Oral tablet, dose level 3 (60 mg), once daily
1824186|NCT00761007|Drug|Placebo|Oral tablet matching the three dose levels of ibodutant, once daily
1824187|NCT00761020|Other|Mefloquine and Control Cohort|To determine the seroconversion rate (sensitivity) to Plasmodium falciparum Merozoite Surface Protein 1 (Pf MSP-1) antigen by ELISA assay in the infectivity control and mefloquine cohorts as part of a larger project to support the qualification of anti-MSP-1 antigen-specific antibody assays as valid surrogate endpoints for malaria infection.
1824188|NCT00761033|Behavioral|music|
1824189|NCT00761059|Drug|Glucose 20%|The oral application of 0,3 ml/kg Glucose 20% 3 minutes before nasopharyngeal suctioning
1824190|NCT00761059|Drug|Aqua|The oral application of 0,3 ml/kg Aqua 3 minutes before nasopharyngeal suctioning
1824191|NCT00761085|Drug|Morphine|Standard of care for pain management of acute episode of pain
1824192|NCT00761085|Drug|Methadone|Methadone given to compare to standard of care for pain management
1824193|NCT00761098|Drug|Standard Care|Standard Care: 25% salt poor albumin administered day 1 (1.5g/kg) and day 3 (1.0g/kg)
1824194|NCT00761098|Drug|Experimental|25% Salt Poor Albumin administered per standard care on day 1 (1.5g/kg). Second dose administered on day 2 only to those individuals with renal insufficiency and risk for renal failure.
1824195|NCT00761111|Behavioral|Assessment of the Your Back Operation|to translate and assess an evidence based educational booklet on low back pain patients beliefs after lumbar discectomy
1824196|NCT00761124|Behavioral|Intervention Session|A one-hour discussion group composed of 8-10 Latino men. The session includes an interactive, multimedia presentation led by a facilitator to guide participant interaction.
1824197|NCT00761124|Behavioral|Printed Material|General prostate cancer pamphlet
1824198|NCT00761137|Drug|0.3 mg tropicamide|0.3 mg tropicamide in intra-oral thin film
1824199|NCT00761137|Drug|1 mg tropicamide|1 mg tropicamide in intra-oral thin film
1824200|NCT00761137|Drug|3 mg tropicamide|3 mg tropicamide in intra-oral thin film
1824201|NCT00761137|Drug|0 mg tropicamide|0 mg tropicamide (placebo) in intra-oral thin film
1824202|NCT00761150|Drug|ABT-712|ABT-712 extended-release tablet
1824203|NCT00761150|Drug|Placebo|Placebo tablet
1824204|NCT00761163|Other|Resistance Exercise|The subjects will complete 2 resistive exercise sessions on non-consecutive days that will be supervised by our laboratory staff. The following exercises will be performed using the Keiser Sports Health equipment in Ismail Health, Exercise, and Nutrition Center: seated row, double leg press, seated leg curl, chest press, and leg extension. The subjects will individually perform 3 sets of 8-10 repetitions at an exercise intensity of 70% of pre-determined maximal strength for these exercises. Each repetition will be performed in a slow (six to eight seconds) uniform fashion, giving equal time to the concentric (muscle shortening) and eccentric (muscle lengthening) portions. One minute of rest will be allowed between sets. The last repetition of the third set of each exercise will be done to voluntary fatigue or the performance of 12 repetitions.
1824205|NCT00761163|Other|Aerobic Exercise|The subjects will complete 2 aerobic exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. The subjects will perform 45 minutes of aerobic exercise on a stationary bike at an exercise intensity of 70% of their heart-rate reserve.
1824206|NCT00761163|Other|Control (Non-exercise)|The subjects will also complete 2 non-exercise sessions on non-consecutive days that will also be supervised by our laboratory staff. These sessions will consist of incorporating diversionary tasks throughout a 45 minute period consisting of a variety of motor and psychological tasks (tests of hand steadiness, alertness, optical illusions, mental acuity, etc.)
1824207|NCT00761176|Device|The Provant Therapy System|The Provant Wound Therapy System is a safe adjuvant non-invasive medical device.
1824208|NCT00761189|Drug|Paliperidone|Paliperidone extended-release (ER) tablet will be administered orally in dose range of 3 to 12 milligram (mg) per day for 12 weeks as per Investigator's discretion.
1824209|NCT00761202|Drug|A sterile solution containing sodium carboxymethylcellulose and glycerin, preserved with PURITE®|Eyedrops as required, but at least 3 times per day
1824210|NCT00761202|Drug|Sodium hyaluronate|Eyedrops as required, but at least 3 times per day
1824211|NCT00761215|Drug|TR-701 200 mg|oral TR-701 200 mg for 5 to 7 days
1824212|NCT00761215|Drug|TR-701 300 mg|oral TR-701 300 mg for 5 to 7 days
1824213|NCT00761215|Drug|TR-701 400 mg|TR-701 400 mg for 5 to 7 days
1824214|NCT00761228|Drug|Apomorphine|Patients will receive an ascending dosing schedule of continuous subcutaneous apomorphine to reach a maximum infusion rate of up to 6 mg/hour for 12 hours a day.
1824215|NCT00761228|Drug|Placebo|Patients will receive a continues subcutaneous infusion of saline solution.
1824216|NCT00761241|Drug|Gemcitabine, Docetaxel, 5FU, Oxaliplatin|Gemcitabine: 1000 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8cycles Docetaxel: 40 mg/m2 IV bolus days 1 and 8, repeated every 21 days x 8 cycles Gemcitabine/docetaxel will be repeated (based upon initial response) Oxaliplatin: 40 mg/m2 IV on day 1 of each week of radiation 5-FU: 175 mg/m2 continuous infusion on days 1-18 and 29-46 of radiation
1824217|NCT00761241|Biological|Alpha-interferon|Alpha-interferon: injected subcutaneously on days 1, 3, 5, 8, 10, 12, 15, 17, 29, 31, 33, 36, 38, 40, 43 and 46 during radiation therapy
1824265|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (9 subjects)
1824218|NCT00761241|Radiation|Abdominal/pelvic radiation therapy|3-D conformal technique. The dose per fraction will be 180cGy, with a total dose of 5040 cGy in 28 fractions. Radiation therapy will be delivered on days 1-18 and days 29-46
1824219|NCT00761241|Procedure|Pancreaticoduodenectomy|Surgery performed if subject is considered candidate by protocol definition.
1824220|NCT00761254|Drug|Domperidone|Initially, 10mg of oral Domperidone will be administered 2-4 times a day as needed. This dosage may be increased or decreased depending on how the subject responds to the drug.
1958586|NCT01498978|Other|laboratory biomarker analysis|Correlative studies
1958587|NCT01492582|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine or nonavalent human papillomavirus vaccine (HPV 6, 11, 16, 18, 31, 33, 45, 52, 58)|Given IM
1958588|NCT01492582|Other|laboratory biomarker analysis|Correlative studies
1958589|NCT01492582|Other|survey administration|Ancillary studies
1958590|NCT01492582|Other|medical chart review|Ancillary studies
1824229|NCT00761306|Drug|Vortioxetine (Lu AA21004)|5 or 10 mg/day; tablets; orally
1824230|NCT00761319|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as travoprost.
1824231|NCT00761319|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 90 days. Referred to as latanoprost.
1824232|NCT00761332|Drug|teriparatide|treatment will be prescribed according to usual standard of care
1824233|NCT00761332|Drug|antiresorptives|treatment will be prescribed according to usual standard of care
1824234|NCT00761345|Drug|gemcitabine|gemcitabine 1000mg/m2 days 1 and 8 of each 21 day cycle.
1824235|NCT00761345|Drug|Erlotinib|Erlotinib 100mg or 150mg daily of each 21 day cycle
1824236|NCT00761345|Radiation|low dose fractionated radiotherapy|low dose fractionated radiotherapy day 1 and 2, day 8 and 9 of each 21 day cycle
1824237|NCT00761358|Drug|Z-338|Oral
1824238|NCT00761358|Drug|Placebo|Oral
1824239|NCT00761371|Drug|Imiquimod 5% cream|Subjects were treated with imiquimod (one sachet/20 cm2), three applications per week, for up to 16 weeks, or fewer in the case of total clearance of initial warts. At the visit at the end of treatment, a second scraping of the lesion area was carried out to determine the sub-type of HPV.
1824240|NCT00761384|Drug|90Y-ibritumomab|90Y-ibritumomab given with stem cells support, based on absorbed dose escalation to the liver. Absorbed dose escalation starts at 12 Gy and is capped at 36 Gy to the liver.
1824241|NCT00761397|Behavioral|Interview|15-30 Minute Weekly meeting w/Staff to discuss swallowing exercises
1824242|NCT00761397|Behavioral|Phone Call|Phone call follow ups for 4 weeks after last radiation treatment
1824243|NCT00761397|Other|Brochure|Detailed brochure explaining the purpose of the swallowing exercises and a description of how to perform the exercises
1824244|NCT00761397|Other|Questionnaire|Day 1 of study, 10 weeks after starting study, & 12 months after starting study
1824245|NCT00761410|Device|P.F.C. Sigma RP-F Total Knee Replacement|An orthopaedic implant for total knee replacement with a mobile-bearing and a high flexion design
1824246|NCT00761423|Biological|PRP Injection with eccentric exercises|PRP Injection with eccentric exercises
1824247|NCT00761423|Biological|Placebo Injection with eccentric exercises|Placebo Injection with eccentric exercises
1824248|NCT00761436|Biological|Spheramine (BAY86-5280)|Stereotactic Intrastriatal Implantation
1824249|NCT00761449|Drug|lenalidomide|Initial dose is oral lenalidomide 10 mg daily continuously. The dose should be increased to 20 mg day 1 in week 6 and to 30 mg day 1 in week 10. This dose should be kept for seven weeks. Thus, the total study period is 16 weeks.
1824250|NCT00761462|Drug|Ciprofloxacin|Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label
1824251|NCT00761462|Drug|Non-quinolone antibiotic|Common used dose and route
1824252|NCT00761475|Procedure|mesh supported closure|onlay mesh supported closure midline laparotomy
1824253|NCT00761475|Procedure|primary closure|primary closure of the midline
1824254|NCT00761475|Procedure|mesh supported closure|sublay mesh supported closure midline laparotomy
1824255|NCT00761488|Device|AcrySof® Toric IOL|Implanted into the study eye
1824256|NCT00761501|Drug|PN400|Oral
1824257|NCT00761501|Drug|Naproxen (Proxen S)|Oral
1824258|NCT00761501|Drug|Naproxen (Naprosyn E)|Oral
1824259|NCT00761514|Drug|Humira (adalimumab)|40 mg eow
1824260|NCT00761527|Drug|Desloratadine Syrup|"Desloratadine (Aerius) Syrup;
Dose selection was based upon the age of the participant, and the timing of dose for each participant was once daily (QD) as described in the Product Insert for 14 days:
Children 6 through 11 years of age, 5 mL (milliliters) of Aerius Syrup (2.5 mg [milligrams] of desloratadine)
Children 1 through 5 years of age, 2.5 mL of Aerius Syrup (1.25 mg of desloratadine)
Children 6 months to 11 months of age, 2 mL of Aerius Syrup (1 mg of desloratadine)"
1824261|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1 (9 subjects)
1824262|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1 (3 subjects)
1824263|NCT00761540|Drug|liraglutide|Liraglutide for s.c. injection once daily: dose step 1, followed by dose step 2 (9 subjects)
1824398|NCT00762528|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
1958595|NCT01470599|Drug|CP-690,550|ORAL TABLET, TWICE DAILY
1958596|NCT01470599|Drug|CP-690,550|ORAL TABLETS, TWICE DAILY
1824266|NCT00761540|Drug|placebo|Liraglutide placebo for s.c. injection once daily: dose step 1, followed by dose steps 2 and 3 (3 subjects)
1824267|NCT00761553|Other|Dietary supplements with exercise|Resistive exercise along with consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
1824268|NCT00761553|Dietary Supplement|Dietary supplement without exercise|Consuming two dietary supplements every day during both 8 week intervention periods, for a total of 16 weeks.
1824269|NCT00761566|Other|Real preconditioning followed by Sham preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure. The subjects will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg.
1824270|NCT00761566|Other|Sham preconditioning followed by Real preconditioning|Subjects in this arm of the study will first receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a sham procedure consisting of inflating the blood pressure cuff to 10 mmHg. They will then cross-over to the other arm of the study and receive four 5 minute cycles of upper limb ischemia interspaced with 5 minutes of reperfusion by using a blood-pressure cuff inflated to a pressure of 15 mmHg greater than systolic arterial pressure.
1824271|NCT00761579|Drug|Paliperidone|Paliperidone oral tablet was administered once daily at a starting dose of either 3 milligram (mg), 6 mg or 9 mg for 48 weeks, wherein recommended dose was 6 mg and dose range was 3 to 12 mg per day.
1824272|NCT00761592|Biological|Botulinum Toxin Type A 900kDa|6 to 16 injections, with maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
1824273|NCT00761592|Biological|Botulinum Toxin Type A 150kDa|6 to 16 injections, with a maximum of 21, at a dose of ≥20U/eye (≥40U total dose)
1824274|NCT00761605|Drug|Paliperidone|Paliperidone oral tablet will be administered once daily at a dose of 6 milligram (mg) for 24 weeks, wherein dose range was 3 to 12 mg per day.
1824275|NCT00761618|Procedure|Intrapleural catheter (IPC) drained|IPC drained daily (Group 1) or 3 times per week (Group 2)
1824276|NCT00761618|Procedure|IPC Placement|IPC placed in chest cavity to drain excess fluid
1824277|NCT00761618|Radiation|Chest X-Ray|Chest X-Rays at 3 and 6 month follow up visits
1824278|NCT00761631|Biological|13 valent pneumococcal conjugate vaccine|Intramuscular injection of 0.5mL at visit 1 and visit 2 for group 1 and and visit 1 for groups 2, 3, and 4.
1824279|NCT00761644|Drug|Doxil|Day 1 of each 21 day cycle, beginning dose level 10 mg/m^2 by vein over 3 hours.
1824280|NCT00761644|Drug|Bevacizumab|Day 1 of each 21 day cycle, beginning dose level 5 mg/kg by vein over 90 minutes.
1824281|NCT00761644|Drug|Temsirolimus|Days 1, 8 & 15 of 21 Day Cycle, beginning dose level 12.5 mg by vein over 30 to 60 minutes.
1824282|NCT00761657|Drug|FG-4592|FG-4592 1.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
1824283|NCT00761657|Drug|FG-4592|FG-4592 1.5 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
1824284|NCT00761657|Drug|FG-4592|FG-4592 2.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
1824285|NCT00761657|Drug|FG-4592|FG-4592 2.5 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
1824286|NCT00761657|Drug|FG-4592|FG-4592 3.0 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
1824287|NCT00761657|Drug|FG-4592|Placebo Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
1824288|NCT00761657|Drug|FG-4592|FG-4592 0.7 mg/kg Two times weekly dosing for 29 days or Three Times weekly dosing for 26 days
1824289|NCT00761670|Drug|amisulpride and risperidone|amisulpride tablet 400-800 mg/day risperidone tablet 4-8 mg/day
1824290|NCT00761696|Drug|IPI-926|Oral daily dosing
1824291|NCT00761709|Drug|AL-39256 Ophthalmic Suspension, 1%|
1824292|NCT00761709|Drug|Latanoprost Ophthalmic Solution, 0.005%|
1824293|NCT00761709|Drug|Vehicle|Inactive ingredients used as a placebo comparator
1824294|NCT00761722|Drug|azacitidine|"Arm 1:
Cycle 1 (PK Phase) - Subjects will receive a single SC dose of 75 mg/m2 on Days 1 and 15. Single oral doses of a given formulation of azacitidine will be administered in increasing doses on Days 3 and 5, and at doses calculated to deliver 80% and 120% of the SC exposure, up to a maximum dose of 600 mg on Days 17 and 19.
Cycles 2 and beyond - (Treatment phase) Oral azacitidine will be administered in a dose calculated to deliver 100% of the SC exposure up to a maximum of 600 mg on days 1 - 7 of a 28 day cycle.
Arm 2:
All Cycles - Oral azacitidine will be administered a maximum of 600 mg on Days 1 - 7 of a 28 days cycle."
1824295|NCT00761735|Biological|Peginterferon alfa-2b|In the previous treatment protocol (P02538 Part 1), peginterferon alfa-2b was administered at a dose of 60 μg/m^2 by subcutaneous injection weekly for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
1824296|NCT00761735|Drug|Ribavirin|In the previous treatment protocol (P02538 Part 1), ribavirin was administered at a dose of 15 mg/kg/day orally in two divided doses for up to 48 weeks. No treatment was administered on the current follow-up study (P02538 Part 2).
1824297|NCT00761748|Device|Convatec Uro 2-piece|"Specific name of the device: 'Combihesive Natura® with a Durahesive Convex-It® base plate, 45 mm coupling, moldable (13-22 and 22-33 mm) hole size with boarder tape'.
The subjects are asked to test each of the two products for 21 days plus/minus 3 days in a randomised order and in accordance with their normal frequency of change and normal use pattern. The duration of the clinical investigation should be enough time to identify any difference in user-preference. If the subject is in the middle of testing an urostomy base plate when the test period is turning into the next period, the urostomy base plate can be worn until it needs to be changed. It is not possible to blind the investigation as the appearance of the test- and refer-ence products are very different in the look."
1824298|NCT00761748|Device|SenSura Uro 2-piece|SenSura URO 2-piece Extended Wear, convex light, 50 mm coupling, cuttable (15-33 mm)
1824299|NCT00761761|Drug|Sensoril|
1824300|NCT00761761|Other|Placebo|
1824346|NCT00762125|Behavioral|AC treatment|Provides support and controls for nonspecific factors associated with exposure to therapists and other FMS sufferers, but does not directly address either maladaptive beliefs or emotional arousal
1824399|NCT00762528|Drug|Sodium monofluorophosphate toothpaste|Twice daily usage
1824301|NCT00761774|Drug|Brivaracetam|Subjects will begin at a recommended dose of Brivaracetam 100 mg/day. Subjects will continue treatment at a dose up to a maximum of 200 mg/day with a twice per day administration. Up- and down-titration steps may be performed in steps of a maximum of 50 mg/day on a weekly basis. Full down-titration should include a one week step on 20 mg/day. The study medication will come in 10 mg and 25 mg tablet strengths.
1824302|NCT00761800|Drug|Lactic acid|
1824303|NCT00761813|Device|Open reduction internal fixation (ORIF) with single sliding hip screw|The ORIF will be performed using a single large diameter partially threaded screw that is affixed to the proximal femur with a side plate (with a minimum of two holes and a maximum of four holes) and no supplemental fixations. Surgeons will use any commercially available sliding hip screw implant and will insert implants as per the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
1824304|NCT00761813|Device|ORIF with multiple cancellous screws|ORIF will be performed using multiple small diameter threaded screws (with a minimum of two screws and a minimum diameter of 6.5 mm). Surgeons will use any threaded screw or hook pin and will follow the manufacturers' technical guides. Other surgical factors will be based on surgeon preference and noted.
1824305|NCT00761826|Device|MEL 80 Mixed Astigmatism Treatment|Treatment of Naturally Occuring Mixed Astigmatic corrections up to 6.0 D.
1824306|NCT00761839|Behavioral|After-care summary|"The wound care NP will measure the wound and assess adherence to the following self-management activities: visiting the wound care clinic as scheduled; offloading; applying dressings; obtaining assistance at home; and participating in social activities. This information will be entered into a computer database on a VA computer that will generate a summary chart showing the relationship between adherence and wound healing. The generated after-care summary will be discussed with the patient and used to set self-management goals."
1824307|NCT00761839|Behavioral|Control group|Patients in the control group will receive usual counseling for self-management.
1824308|NCT00761852|Drug|Ruboxistaurin|32 mg daily for 2 weeks
1824309|NCT00761852|Drug|Placebo|1 tab po QD for 2 weeks
1824310|NCT00761865|Device|Air Cast Stirrup Brace & High Tide Fracture Boot|Subjects will be randomly assigned to one of two treatment braces. All patients will be given instructions to use fracture boot or air cell brace at all times of ambulatory activity until follow-up until 2 week post-strain follow-up.
1824311|NCT00761878|Procedure|Exposure to plasma energy|Non-invasive exposure to pulsed plasma to the unbroken skin over half of the facial area
1824314|NCT00761904|Behavioral|Free Generic Samples (hydrochlorothiazide, simvastatin)|Free samples of generic hydrochlorothiazide (12.5 mg tabs) and simvastatin (20 mg tabs)
1824315|NCT00761917|Device|Tear Film Analyzer|tear film images
1824316|NCT00761930|Drug|Fluoride|Brush twice daily
1824317|NCT00761930|Drug|Triclosan and fluoride|Brush twice daily
1824318|NCT00761930|Drug|Herbal Ingredient and fluoride|Brush twice daily
1824319|NCT00761956|Device|NexGen CR-Flex Fixed Bearing Knee|NexGen CR-Flex Fixed Bearing femoral component
1824320|NCT00761956|Device|NexGen CR Knee|NexGen Complete Knee Solution Cruciate Retaining femoral component
1824321|NCT00761969|Other|Implementation of the European Guidelines on cardiovascular Disease Prevention in Clinical Practice|Life-style modification advice and prescribing standard cardioprotective medication (antiplatelet agents, statins, antihypertensive agents) according to the European Guidelines on Cardiovascular Disease Prevention in Clinical practice.
1824322|NCT00761982|Procedure|Infusion on autologous CD34+ stem cells into middle cerebral artery|Intraarterial infusion of autologous bone marrow stem cells into middle cerebral artery of acute stroke patients
1824323|NCT00761995|Drug|Azopt|topical eye drop dosed 1 drop 3 times daily
1824324|NCT00761995|Drug|Cosopt|topical eye drop dosed 1 drop 2 times daily
1824325|NCT00762021|Device|SN60AT|Implantation with the AcrySof Intraocular Lens Model SN60AT following cataract removal.
1824326|NCT00762021|Device|SN60WF|Implantation with the AcrySof Intraocular Lens Model SN60WF following cataract removal.
1824327|NCT00762034|Drug|Pemetrexed|Induction therapy 500 milligram per meter squared (mg/m^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
1824328|NCT00762034|Drug|Pemetrexed|Maintenance therapy 500 mg/m^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
1824329|NCT00762034|Drug|Paclitaxel|Induction therapy 200 mg/m^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
1824330|NCT00762034|Drug|Carboplatin|Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
1824331|NCT00762034|Biological|Bevacizumab|Induction therapy 15 milligrams per kilogram (mg/kg) IV every 21 days for up to 4 cycles of 21 days
1824332|NCT00762034|Biological|Bevacizumab|Maintenance therapy 15 mg/kg IV every 21 days until progressive disease or treatment discontinuation.
1824333|NCT00762047|Device|Durasphere FI|Durasphere Injection
1824334|NCT00762047|Device|Sham|Sham injection with anesthesia
1824335|NCT00762060|Device|ON-Q Silver soaker System|Continuous infusion of local anesthetic to surgical site
1824336|NCT00762060|Drug|Patient controlled analgesia|IV opioids delivered via PCA
1824337|NCT00762073|Drug|budesonide|oral suspension
1824338|NCT00762073|Drug|placebo|oral suspension matching budesonide
1824339|NCT00762086|Device|AngioPress Intermittent pneumatic compression (IPC) Device|Treatment with Intermittent pneumatic compression (IPC) for PAD
1824340|NCT00762086|Other|Medications and Standard walking exercises|Aspirin/Clopidegrol and Standard walking exercises
1824341|NCT00762099|Drug|Pregabalin|Pre-operative dose 150 mg Post-operative dose 75 mg BID
1824342|NCT00762099|Drug|Placebo|Placebo/sugar tabs will look identical to active drug.
1824343|NCT00762112|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 24 months.
1824344|NCT00762125|Behavioral|CR+ST|Addresses maladaptive beliefs in general and includes education and training in the use of specific coping strategies
1824345|NCT00762125|Behavioral|ET|Addresses beliefs and emotional arousal during confrontations with feared element (exercising) through use of counter-conditioning and corrective feedback
1824347|NCT00762138|Device|AutoloGel System|"The AutoloGel™ System may be used for chronic or surgically-debrided wounds up to twice a week for eight (8) weeks. The treating health care practitioner may elect to continue the treatment up to twelve (12) weeks. The AutoloGel™ System should be used in conjunction with standard of care procedures for comprehensive wound management , such as:
Removal of necrotic or infected tissue Off-loading Compression therapy for venous stasis ulcers Establishment of adequate blood circulation Maintenance of a moist wound environment Management of wound infection Wound cleansing Nutritional support, including blood glucose control for subjects with diabetic ulcers Bowel and bladder care for subjects with pressure ulcers at risk for contamination Management of underlying disease"
1824348|NCT00762151|Other|Negative Control (Regular Toothpaste)|Regular Toothpaste
1824349|NCT00762151|Other|Positive Control (anti-plaque/anti-bacterial toothpaste)|Standard anti-plaque and anti-bacterial toothpaste
1824350|NCT00762151|Drug|Prototype (AN0128 Toothpaste)|AN0128 Toothpaste
1824351|NCT00762164|Drug|Vytorin|Vytorin 10/80 split into 4
1824352|NCT00762164|Drug|Simvastatin|Simvastatin 20 milligrams
1824353|NCT00762177|Drug|Fluoride|Brush twice a day for 14 days
1824354|NCT00762177|Drug|Fluoride, Triclosan|Brush twice daily for 14 days
1824355|NCT00762177|Drug|Stannous Fluoride|Brush twice daily for 14 days
1824356|NCT00762190|Drug|TAK-559 and insulin|TAK-559 32 mg, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
1824357|NCT00762190|Drug|Insulin|TAK-559 placebo-matching, tablets, orally, once daily and insulin stable dose injection for up to 54 weeks.
1824358|NCT00762216|Device|AcrySof® Toric intraocular lens|Implantation of the AcrySof Toric intraocular lens (IOL) into the eye following cataract extraction surgery
1824359|NCT00762229|Drug|Ezetimibe 10 mg|Ezetimibe 10 mg daily for 4 weeks
1824360|NCT00762229|Drug|Ezetimibe 5 mg|"Ezetimibe 5 mg daily for 4 weeks, formulated as a 10 mg tablet split in half"
1824361|NCT00762242|Procedure|blood sampling and brachial artery ultrasound|"Intravenous blood sampling will be performed before and 15 seconds, 30 seconds, 1,2,5,10,and 30 minutes following an ischemic stimulus (inflation of a blood pressure cuff to suprasystolic pressure for 5 minutes)
Brachial artery ultrasound imaging will be performed before and 1 minute after a 5 minute ischemic stimulus, to assess endothelium-dependent vasodilation of the brachial artery.
Following completion of blood sampling, an additional resting image of the brachial artery will be obtained. Sub-lingual nitroglycerin will be administered, and the artery will be imaged again after 3 minutes, to assess endothelium-independent vasodilation."
1824362|NCT00762255|Drug|Vorinostat|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
1824363|NCT00762255|Drug|Bevacizumab|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
1824364|NCT00762255|Drug|Irinotecan|Vorinostat, Bevacizumab and Irinotecan Study. Determine maximum tolerated dose for treatment.
1824365|NCT00762268|Drug|SAMe|"SAMe tablets will be administered intermittently and in steadily increasing dosages. Subjects will receive oral SAMe for only 3 days per week, followed by a 4 day rest-period, before the next dosage increase. SAMe dosage will be progressively increased each week to a maximum of 1600 mg per day over a 4-week period."
1824366|NCT00762268|Drug|Placebo|
1824367|NCT00762281|Device|MEL 80 Hyperopic LASIK Treatment|Treatment of Hyperopic corrections ≤ +6.0 D with or without Astigmatism of +0.50 to +3.50 D and MRSE ≤ +6.50 D.
1824368|NCT00762307|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
1824369|NCT00762320|Drug|Low dose Kaletra tablets|Lopinavir/Ritonavir tablets 100mg/25mg
1824370|NCT00762346|Drug|zometa|zometa 4mg i.v. every 4 weeks for up to 2 years
1824371|NCT00762359|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 12 to 30 months.
1824372|NCT00762359|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 12 to 30 months.
1824373|NCT00762372|Drug|desflurane|volatile liquid for inhalation
1824374|NCT00762372|Drug|desflurane/nitrous oxide|volatile liquid for inhalation with gas for inhalation
1824375|NCT00762372|Drug|sevoflurane/nitrous oxide|volatile liquid for inhalation and gas for inhalation
1824376|NCT00762385|Device|galyfilcon A|galyfilcon A
1824377|NCT00762385|Device|comfilcon A|comfilcon A
1824378|NCT00762398|Device|Masimo hemoglobin-meter|Placing a probe on the finger
1824379|NCT00762398|Biological|drawing blood sample|drawing a blood sample less that 0.5 mL each time, for around 10-12 times along the surgery (depends on surgical time)
1824380|NCT00762411|Drug|LY450139|Administered orally once daily.
1824381|NCT00762411|Drug|Placebo|Administered orally once daily.
1824382|NCT00762424|Drug|Flowmax|0.4 mg once a day until stone passage total = 9 tablets
1824383|NCT00762424|Drug|placebo|cornstarch
1824384|NCT00762437|Device|Zeltiq Dermal Cooling Device|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
1824385|NCT00762450|Drug|Triclosan, Fluoride|Rinse 3 times daily with assigned toothpaste slurry
1824386|NCT00762450|Drug|fluoride|Rinse 3 times daily with assigned toothpaste slurry
1824387|NCT00762450|Drug|Fluoride, triclosan, amino acid|Rinse 3 times daily with assigned toothpaste slurry
1824388|NCT00762463|Drug|Celecoxib|capsule, 200 mg QD, 6-12 weeks
1824389|NCT00762463|Drug|Diclofenac SR|tablet, 75 mg QD,6-12 weeks
1824390|NCT00762476|Drug|3804-250A|"topical product
apply 2 pumps
apply at least every 4 hours or after hand washing"
1824391|NCT00762476|Drug|3804-291|"topical
apply 2 pumps
apply at least every 4 hours or after hand washing"
1824392|NCT00762489|Other|Temporal artery thermometer temperature|Newborn infants had a temporal artery temperature taken within a few minutes of the axillary and rectal temperatures. The axillary and rectal temperatures are taken via methods which are standard of care.
1824393|NCT00762502|Device|senofilcon A toric contact lens|soft contact lens
1824394|NCT00762502|Device|balafilcon A toric contact lens|soft contact lens
1824395|NCT00762515|Drug|Fluoride|Brush teeth two times daily for 6 weeks
1824396|NCT00762515|Drug|Triclosan|Brush two times daily for 6 weeks
1824400|NCT00762541|Device|MEL 80 Treatment of High Myopia|The reduction or elimination of myopia > -7.00 D to -12.00 D, and astigmatism less than or equal to -6.00 D at the spectacle plane (myopia with or without astigmatism), with a maximum MRSE ≤ -12.00 D.
1824401|NCT00762554|Drug|Depodur|Depodur 10mg given epidurally at end of cesarean section.
1824402|NCT00762554|Drug|Depodur|Depodur 10mg given epidurally at end of cesarean section after patient received spinal bupivacaine at the beginning of the case.
1824403|NCT00762554|Drug|Fentanyl|Epidural fentanyl infusion started after epidural lidocaine or spinal bupivacaine used for the cesarean section.
1824404|NCT00762567|Drug|phenylephrine HCl|A single dose of a liquid dosage form of phenylephrine HCl 2.5mg/5mL, using a weight-age dosing schedule
1824405|NCT00762593|Device|transvaginal placebo device|Use of a transvaginal placebo home use programmable device used 30 minutes every day during 8 weeks
1824406|NCT00762593|Device|transvaginal electrical stimulation device|Use of a transvaginal electrical stimulation home use programmable device used 30 minutes every day during 8 weeks
1824407|NCT00762606|Procedure|Phacoemulsification cataract extraction surgery|Surgical removal of cataract using phacoemulsification followed by implantation of an AcrySof Intraocular Lens (Model SN60WF)
1824408|NCT00762606|Procedure|Small incision cataract surgery|Surgical removal of cataract using small incision cataract surgery (SICS) followed by implantation of a Polymethyl methacrylate(PMMA) Intraocular Lens (Model MZ60BD).
1824409|NCT00762619|Drug|Fluoride|Brush twice daily
1824410|NCT00762619|Drug|Triclosan, fluoride|Brush twice daily
1824411|NCT00762632|Drug|NILOTINIB|400 mg Nilotinib bid (total daily dose 800 mg) should be continued 25 weeks
1824412|NCT00762632|Drug|EVEROLIMUS|Everolimus at 2,5 mg/day should be continued 25 weeks.
1824413|NCT00762645|Drug|Travoprost 0.004% (Travatan)|One drop in each eye, once daily at 9 AM
1824414|NCT00762645|Drug|Pilocarpine 1%|One drop in each eye, forth times daily at 7 AM, 11 AM , 4 PM and 9 PM for twelve (12) weeks
1824415|NCT00762658|Drug|AN2728 Ointment, 5%|
1824416|NCT00762658|Drug|AN2728 Ointment, 2%|
1824417|NCT00762658|Drug|AN2728 Ointment, 0.5%|
1824418|NCT00762658|Drug|AN2728 Ointment Vehicle|
1824419|NCT00762658|Drug|Betnesol®-V Creme, 0.1%|
1824420|NCT00762658|Drug|Protopic® Ointment, 0.1 %|
1824421|NCT00762671|Drug|Ebselen|150 mg BID for 2 weeks
1824422|NCT00762671|Drug|Placebo|Placebo 1 po BID for 2 weeks
1824423|NCT00762684|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
1824424|NCT00762684|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
1824425|NCT00762710|Drug|Prazosin medication|"Form: Prazosin will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg"
1824426|NCT00762710|Drug|Placebo medication|"Form: Placebo will be taken orally, in the form of pills.
Dosing: 9 AM, 3 PM, 9 PM
Days 1-2: 0 mg, 0 mg, 1 mg
Days 3-4: 1 mg, 1 mg, 1 mg
Days 5-7: 2 mg, 2 mg, 2 mg
Day 8-10: 2 mg, 2 mg, 6 mg
Day 11-14: 4 mg, 4 mg, 6 mg
Day 15-84: 4 mg, 4 mg, 8 mg"
1824427|NCT00762723|Device|Trinica Anterior Lumbar Plate System|Trinica Anterior Lumbar Plate System accommodates the use of either fixed- or variable-angle screws. This study is a comparison of clinical outcomes from anterior lumbar interbody fusion patients receiving the Trinica Anterior Lumbar Plate system with either all fixed-angle screws, variable-angle screws, or a hybrid configuration.
1824428|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
1824429|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
1824430|NCT00762736|Drug|Pioglitazone|Pioglitazone 15 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
1824431|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 5 mg, tablets, orally, once daily for up to 24 weeks.
1824432|NCT00762736|Drug|Pioglitazone and azilsartan|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan 40 mg, tablets, orally, once daily for up to 24 weeks.
1824433|NCT00762736|Drug|Pioglitazone|Pioglitazone 45 mg, tablets, orally, once daily and azilsartan placebo-matching tablets, orally, once daily for up to 24 weeks.
1824434|NCT00762749|Drug|diphenhydramine HCl|A single liquid dose of diphenhydramine HCl (12.5 mg /5 mL) followed by water, according to an age-weight dosing schedule
1824435|NCT00762762|Drug|Triclosan and fluoride|Brush twice daily
1824436|NCT00762762|Drug|Fluoride|swished twice daily
1824437|NCT00762775|Dietary Supplement|Calcium and vitamin D supplementation|Arm 1: 1,200 mg daily of calcium supplementation and placebo; Arm 2: 100 microgram daily of Vitamin D and placebo; Arm 3: 1,200 mg of calcium and 100 microgram of Vitamin D daily; Arm 4: placebos only.
1824438|NCT00762788|Device|senofilcon A|1 week extended wear contact lens
1824439|NCT00762788|Device|lotrafilcon A|1 week extended wear contact lens
1824440|NCT00762788|Device|lotrafilcon B|1 week extended wear contact lens
1824441|NCT00762788|Device|balafilcon A|1 week extended wear contact lens
1824442|NCT00762788|Device|comfilcon A|1 week extended wear contact lens
1824443|NCT00762788|Device|etafilcon A|1 week extended wear contact lens
1824444|NCT00762814|Device|Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)|Eligible subjects will be perform walking tests involving the use of the TENS device (Select Unit by Empi) on the lower leg bilaterally during gait: uncued (wearing the unit but, but with the device turned off) or with a tactile cue (wearing the device with it turned on until a tactile stimulus is felt). The TENS unit is a battery-operated, single-channel electrical stimulator worn around the proximal calf that can used to provide a constant tactile stimulus. All subjects will undergo a single visit in which the two walking conditions are tested. During these visits, the patient will perform the same gait assessments measured with the device turned off as well as turned on. Testing the two conditions on the same day/time will provide the investigators with a consistent comparison of the two tested conditions, as mobility and function in patients with PD can vary significantly within and between days.
1824484|NCT00763139|Drug|Pioglitazone|45 mg by mouth once a day for 8 weeks
1824445|NCT00762840|Device|the Apexum Protocol|using the apexum kit for minimally invasive removal of periapical lesion tissue.
1824446|NCT00762840|Procedure|Conventional endodontic procedure|Standard root canal treatment
1824447|NCT00762853|Drug|Fluoride|Brush half mouth once with assigned study treatment
1824448|NCT00762853|Drug|Fluoride and triclosan|Brush half mouth once with assigned study treatment
1824449|NCT00762892|Drug|Raltegravir and truvada|Raltegravir 400 mg po bid, truvada 1 tab q daily
1824450|NCT00762892|Drug|Atazanavir, Norvir and Truvada|Atazanavir 300 mg po q daily, Norvir 100 mg po q daily and Truvada 1 tablet po q daily
1824451|NCT00762905|Device|LiquiBand Laparoscopic|LiquiBand Laparoscopic™ is a sterile, liquid adhesive made up of a blend of n-butyl and 2-octyl cyanoacrylate intended for soft tissue approximation of skin wounds. It is packaged in a sterile, single-use, nylon applicator with internal glass ampoule containing 0.8g of adhesive and sealed in a PETG/Tyvek blister pack. LiquiBand Laparoscopic™ is intended to be applied topically to pre-apposed wound edges. The tissue adhesive sets rapidly (5 - 10 seconds) to hold the wound closed. Following wound closure the product is designed to apply a broad coverage of adhesive to act as a liquid dressing to protect the wound.
1824452|NCT00762905|Device|Dermabond|High viscosity DermaBond Topical Skin Adhesive is a sterile, liquid topical skin adhesive containing a monomeric (2-octyl cyanoacrylate) formulation and the colorant D & C Violet #2. It is provided in a single use applicator packaged in a blister pouch. The applicator is comprised of a crushable glass ampule contained within a plastic vial with attached applicator tip. As applied to skin, the liquid is syrup-like in viscosity and polymerizes within minutes.
1824453|NCT00762918|Dietary Supplement|cholecalciferol|cholecalciferol 5000 IU capsule by mouth daily for 3 months
1824454|NCT00762931|Device|Neurostimulation|An electrical neurostimulation signal will be applied to the neck.
1824455|NCT00762931|Device|Neurostimulation|Subcutaneous lead placement for vagal nerve stimulation
1824456|NCT00762957|Drug|TAK-559 and metformin|TAK-559 16 mg, tablets, orally, once daily and metformin stable dose orally, once daily for up to 26 weeks.
1824457|NCT00762957|Drug|TAK-559 and metformin|TAK-559 32 mg, tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
1824458|NCT00762957|Drug|Metformin|TAK-559 placebo-matching tablets, orally, once daily and metformin stable dose, orally, once daily for up to 26 weeks.
1824459|NCT00762970|Device|Test Lens 1|Investigational soft contact lens with asperic optical design to control myopia progression.
1824460|NCT00762970|Device|Test Lens 2|Investigational soft contact lens with asperic optical design to control myopia progression.
1824461|NCT00762970|Device|Control Lens|Spectacle Lenses.
1824462|NCT00762983|Drug|loratadine|"Claritin Tablet 10 mg, Claritin RediTabs 10 mg: For pediatric patients aged 7 years and older, 10 mg of loratadine is orally administered once daily after a meal in usual cases.
Claritin Dry Syrup 1%: For pediatric patients aged 3 to < 7 years, 5 mg loratadine (0.5 g dry syrup); and for pediatric patients aged 7 years and older, 10 mg of loratadine (1 g dry syrup) is dissolved immediately before use and orally administered once daily after a meal in usual cases.
The observation period will not be specified."
1824463|NCT00762996|Device|etafilcon A|contact lens
1824464|NCT00762996|Device|omafilcon A|contact lens
1824465|NCT00763009|Drug|dipyridamole|0.28mg/kg over 4 minutes intravenously x three doses; totalling 0.84mg/kg intravenously
1824466|NCT00763022|Drug|TAK-559|TAK-559 16 mg, tablets, orally, once daily for up to 26 weeks.
1824467|NCT00763022|Drug|TAK-559|TAK-559 32 mg, tablets, orally, once daily for up to 26 weeks.
1824468|NCT00763022|Drug|Placebo|TAK-559 placebo-matching tablets, orally, once daily for up to 26 weeks.
1824470|NCT00763048|Drug|Fluoride|Brush twice daily for 6 weeks
1824471|NCT00763048|Drug|Fluoride, triclosan|Brush twice daily
1824472|NCT00763061|Drug|Travoprost 0.004% Ophthalmic Solution (Travatan)|Travoprost at 9 AM + Placebo & 9 PM
1824473|NCT00763061|Drug|Timolol 0.5% Ophthalmic Solution (Timoptic)|Timolol in each eye, twice daily at 9 AM & 9 PM
1824474|NCT00763074|Behavioral|Standard life style modification for type 2 diabetes|"Two session of education for exercise and diet.
----------- Exercise: 30min/day x 4/week Diet: ideal body weight x 30~35kcal/day"
1824475|NCT00763074|Behavioral|Diet restriction|"Education for diet and exercise every 2 weeks
----------- Dietary calorie restriction: reduce their usual intake by -500kcal/day"
1824476|NCT00763074|Behavioral|Exercise|"Education for diet and exercise every 2 weeks
----------- Exercise: more than 60min/day of exercise with moderate activity level twice per day"
1824477|NCT00763074|Behavioral|Diet and exercise|"Education for diet and exercise every 2 weeks
----------- Exercise education like as exercise group and diet education like as diet group"
1824478|NCT00763087|Behavioral|weightbearing exercise|All subjects in the exercise group will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Walking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
1824479|NCT00763087|Behavioral|nonweightbearing exercise|All subjects in the 2 exercise groups will participate, as able, in 3 supervised 1 hour exercise sessions per week for the first month and 2 supervised and 1 unsupervised exercise session per week for the remaining 2 months. Subjects in each exercise group will be seen on alternating times to avoid cross contamination of treatment intervention. Biking intensity for all subjects will be applied with the intent to exceed their routine physical stress level, and therefore incur positive adaptations to physical stress, but not exceed their threshold for injury.
1824480|NCT00763087|Behavioral|nonexercising control|All subjects will be instructed, verbally and with written documents, regarding appropriate foot and skin care twice per month.
1824481|NCT00763113|Device|Vanguard PS Knee|Vanguard PS Knee
1824482|NCT00763113|Device|Vanguard CR Knee|Vanguard CR Knee
1824483|NCT00763126|Behavioral|stress level|Stress levels
1824486|NCT00763152|Other|Observation of transponder stability|Observation of transponder stability and placement in the prostatic bed following radical prostatectomy
1824487|NCT00763165|Drug|Triclosan|Brush twice daily
1824488|NCT00763165|Drug|Fluoride|Brush twice daily
1824489|NCT00763165|Drug|Fluoride|Brush twice daily
1824490|NCT00763178|Drug|Duloxetine|"Dosage given according to the following schedule:
Week 1: 30mg QD, Week 2: 60mg QD, Week 3: 60mg QD, Week 4-6: Flexible dosing according to clinical situation, dose range between 60-120mg QD, Weeks 7 + 8: fixed dose"
1824491|NCT00763191|Other|examination of ocular movements|
1824492|NCT00763191|Other|MATTIS test|
1824493|NCT00763191|Other|UPDRS test|
1824494|NCT00763191|Other|CRST test|
1824495|NCT00763204|Drug|AN2728 Cream, 2%|
1824496|NCT00763204|Drug|AN2728 Cream, 1%|
1824497|NCT00763204|Drug|AN2728 Cream, 0.3%|
1824498|NCT00763204|Drug|AN2728 Cream Vehicle|
1824499|NCT00763204|Drug|Betnesol®-V Creme, 0.1%|
1824500|NCT00763230|Device|Transcranial direct current stimulation|tDCS will be given every weekday. For each session, tDCS will be given continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash as described in the safety section above). For sham stimulation, the current will be left on for another 30s, then gradually reduced to zero over another 30 seconds, so that the initial tingling sensation experienced by subjects will be identical for the two groups. The stimulator will be placed behind the subject's head so any adjustments to the current by the operator are not evident. This sham procedure resulted in successful blinding in our pilot study.
1824501|NCT00763243|Behavioral|Cogmed Working Memory Training Program|The Cogmed Working Memory Training program is a 5-week program of computer-based exercises that require the user to complete tasks involving verbal, visual, or combined verbal-visual memory skills. In addition to memory skills, Cogmed tasks demand attention, concentration, and reasoning skills. Users are expected to practice Cogmed exercises at home for 40 minutes/day, 5 days/week, during the 5-week training period. The program uses an adaptive algorithm that presents users with problems of increasing difficulty at a level slightly higher than that at which they have recently achieved success.
1824502|NCT00763256|Drug|Triclosan, Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned treatment period.
1824503|NCT00763256|Drug|Fluoride|subjects brushed their teeth twice daily with the study toothpaste for the assigned study treatment period.
1824504|NCT00763269|Drug|Triclosan, Silicon dioxide, fluoride|Brush twice daily
1824505|NCT00763269|Drug|Triclosan, fluoride|Brush twice daily
1824506|NCT00763282|Behavioral|Self Management (SM)|Self Management (SM) consists of: 1) on-site decisional support to promote provider adherence to ulcer management guidelines, 2) enhanced, interactive PrU education, 3) chronic disease self-management skill building via telephone based groups, 4) proactive care management using MI to support ongoing self-management activities, and 5) distance technology.
1824507|NCT00763282|Behavioral|Motivational Interviewing (MI)|Self Management and Motivational Interviewing (SM+MI) participants were assigned to both a self-management and motivational interview group. An education control intervention (ED) designed to be a credible intervention that is comparable to the SM will control for potential effects of natural history/time, treatment dosing, measurement processes, attention, the non-specific effects of therapeutic alliance, social support, and of receiving a manualized treatment with specific therapist procedures.
1824508|NCT00763282|Behavioral|Education (ED)|The ED intervention differs only in that subjects will not be instructed in any specific problem solving, self-monitoring, or SM techniques, with the exception of encouraging them to become informed consumers of SCI care.
1824509|NCT00763295|Other|T-Spot.TB test|diagnostic test
1824510|NCT00763308|Behavioral|Web-based Heart Healthy Program|The Heart Healthy program will be developed during the course of the study based on goals set by researchers and based on feedback from focus groups. The goals of the program are to educate users in the fundamentals of heart health and risk factors for heart disease and to provide a system for starting and sustaining lifestyle changes that reduce risk of heart disease.
1824511|NCT00763321|Drug|ABT-712|ABT-712 extended-release tablet
1824512|NCT00763321|Drug|Placebo|Placebo tablet
1824513|NCT00763347|Drug|SYR-619|SYR-619 12.5 mg, tablets, orally, once daily for up to 12 weeks.
1824514|NCT00763347|Drug|SYR-619|SYR-619 50 mg, tablets, orally, once daily for up to 12 weeks.
1824515|NCT00763347|Drug|SYR-619|SYR-619 100 mg, tablets, orally, once daily for up to 12 weeks.
1824516|NCT00763347|Drug|SYR-619|SYR-619 200 mg, tablets, orally, once daily for up to 12 weeks.
1824517|NCT00763347|Drug|Placebo|SYR-619 placebo-matching tablets, orally, once daily for up to 12 weeks.
1824518|NCT00763347|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
1824519|NCT00763360|Device|DisCoVisc®|Injection of DisCoVisc® Ophthalmic Viscosurgical Device (OVD) into the anterior chamber prior to and throughout the cataract surgery procedure
1824520|NCT00763360|Drug|Healon|Injection of Healon into the anterior chamber prior to and throughout the cataract surgery procedure
1824521|NCT00763360|Drug|Amvisc Plus|Injection of Amvisc Plus into the anterior chamber prior to and throughout the cataract surgery procedure
1824522|NCT00763373|Other|Implementation of antibiotic switch guidelines|Implementation of antibiotic switch guidelines
1824523|NCT00763386|Device|NexGen LPS-Flex Fixed Bearing Knee|NexGen LPS-Flex Fixed Bearing femoral component
1824524|NCT00763386|Device|NexGen Legacy Posterior Stabilized Knee|NexGen Legacy Posterior Stabilized femoral component
1824525|NCT00763399|Dietary Supplement|probiotics (antibiophilus(Lactobacillus casei), bio-three)|probiotics (antibiophilus(Lactobacillus casei), bio-three) 4x 10^8CFU/day
1824526|NCT00763412|Drug|placebo|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with placebo by taking 1 pill before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
1824619|NCT00766493|Device|GORE® Embolic Filter|Embolic protection during carotid stenting
1824655|NCT00766792|Procedure|Standard dialysis|Standard dialysis (3 times 240-270 min/week)
1824527|NCT00763412|Drug|repaglinide|CF pancreatic insufficient patients with impaired glucose tolerance (IGT) or CFRD without fasting hyperglycemia (CFRD-No FH) by OGTT will be treated with repaglinide 0.5 mg before each meal that contains more than 20 grams of carbohydrate 3-4 times a day for 2 years.
1824528|NCT00763425|Procedure|cold polypectomy|The removal of small colorectal polyps up to 8 mm is performed using cold snare polypectomy.
1824529|NCT00763425|Procedure|conventional polypectomy|The removal of small colorectal polyps up to 8 mm is performed using conventional polypectomy.
1824530|NCT00757068|Behavioral|CBT addressing postpartum mood and weight concerns|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. In these treatment sessions, the counselor will address postpartum mood and weight concerns.
1824531|NCT00757068|Behavioral|Supportive Behavioral Therapy|Women will be assigned an individual counselor who will meet with them face-to-face six times and telephone them seven times. A non-specific, supportive condition will be delivered to women who want to remain smoke-free after they give birth.
1824532|NCT00757081|Drug|phosphatidylcholine and deoxycholate|50 mg phosphatidylcholine, 42 mg deoxycholate subcutaneous injection Every 8 weeks x 2 with additional 2 treatments optional
1824533|NCT00757107|Device|Taperloc Microplasty|primary total hip arthroplasty
1824534|NCT00757107|Device|Taperloc standard|primary total hip arthroplasty
1824535|NCT00757133|Procedure|Conventional laparotomy closure|Recommended technique: The laparotomy is closed with a slowly resorbable running suture (f.e. PDS) in a single layer. The length of the suture should approximately be four (4) times the length of the fascial incision. The skin is closed with the usual technique of the department
1824536|NCT00757133|Procedure|Laparotomy closure with mesh augmentation|"Recommended technique: Mesh augmentation can be done in a retromuscular or a prefascial position. By consensus of the initial primary investigators a retromuscular (sublay) position of the mesh was chosen and as a mesh a light weight polypropylene mesh will be used. Retromuscular (sublay): (see reference no. 11: Rogers et al.) At the end of the vascular procedure the plane behind the rectus muscles (retromuscular-preperitoneal) is dissected as in a Stoppa repair for incisional hernias"
1824537|NCT00757159|Device|Ostim|Ostim® is synthetically manufactured and comprises nanocrystalline hydroxyapatite. The small particle size facilitates resorption. Ostim is an aqueous watery paste and can be used to fill bone defects or to build up bony structures in the region of the jaws. Ostim is osteoconductive, facilitating bone growth. It will act as a scaffolding for the new bone. Ostim is absorbed during the healing process, in the beginning it is osseously interweaved and finally replaced by natural bone.
1824538|NCT00757159|Device|Emdogain|Emdogain® consists of sterile lyophilised Enamel Matrix Derivative with sterile aqueous solution of Propylene Glycol Alginate, 30 mg/ml.
1824539|NCT00757172|Biological|panitumumab|
1824540|NCT00757172|Drug|cisplatin|
1824541|NCT00757172|Drug|docetaxel|
1824542|NCT00757172|Procedure|neoadjuvant therapy|
1824543|NCT00757172|Procedure|therapeutic conventional surgery|
1824544|NCT00757172|Radiation|radiation therapy|
1824545|NCT00757185|Drug|ganirelix acetate|GnRH antagonist, subcutaneous injection, 0.25 mg/day for 21 days
1824546|NCT00757185|Drug|methyl testosterone|testosterone, oral administration, day 5 of GnRH administration, 2.5 mg/day
1824547|NCT00757198|Drug|remifentanil|remifentanil infusion
1824548|NCT00757198|Drug|remifentanil|remifentanil infusion
1824549|NCT00757211|Genetic|polymorphism analysis|
1824550|NCT00757211|Other|laboratory biomarker analysis|
1824551|NCT00757211|Other|questionnaire administration|
1824552|NCT00757224|Behavioral|Guidance|Smoking parents will receive education on the association between parental smoking and respiratory morbidity in the infant. They will also be offered ways to reduce smoke exposure of their infants.
1824553|NCT00757237|Drug|Aztreonam for Inhalation Solution (AZLI)|Aztreonam for inhalation solution (75 mg) was administered 3 times a day (TID) for 28 days for each treatment cycle via the PARI eFlow electronic nebulizer.
1824554|NCT00757237|Drug|Tobramycin Inhalation Solution (TIS)|Tobramycin inhalation solution (300 mg) was administered 2 times a day (BID) for 28 days for each treatment cycle via the PARI LC Plus nebulizer with compressor or via another nebulizer compatible with country-specified labeling.
1824555|NCT00757250|Drug|Angiotensin 1-7|Once daily subcutaneous injection of 50, 100, 200 or 300 mcg/kg/day
1824556|NCT00757263|Genetic|polymorphism analysis|
1824557|NCT00757263|Other|laboratory biomarker analysis|
1824558|NCT00757263|Other|questionnaire administration|
1824559|NCT00763438|Drug|Sertindole|Flexible dose
1824560|NCT00763451|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
1824561|NCT00763451|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
1824562|NCT00763451|Device|Pen auto-injector|
1824563|NCT00763451|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
1824564|NCT00763464|Procedure|stress-echocardiography|stress-echocardiography will be performed once using Adenosin (140 µg/kg/min over 6 Minutes) and a contrast agent (SonoVue)
1824565|NCT00763464|Procedure|stress-MRI|stress-MRI will be performed once using Adenosin (140 µg/kg/min over 6 Minutes)and a contrast agent (Gadovist)
1824566|NCT00763477|Biological|ghrelin|subcutaneous injection
1824567|NCT00763490|Procedure|Full intensity, double umbilical cord, stem cell transplant|stem cell transplant using two umbilical cord blood units, combined with a Flu/Bu4 conditioning regimen prior to transplantation
1824568|NCT00763490|Drug|Flu/Bu4 conditioning regimen|"Fludarabine: 40 mg/m² daily on days -5, -4, -3, -2
Busulfan: 3.2 mg/kg IV daily on days -5, -4, -3, -2"
1824569|NCT00763490|Radiation|Total Lymphoid Irradiation (TLI)|one dose, 400 cGy,on day -1 or day 0, prior to cord blood infusion
1824570|NCT00763490|Drug|Graft versus Host Disease prevention (GVHD prophylaxis)|Tacrolimus for GVHD (Graft Versus Host Disease Prevention) Tacrolimus - will begin on day -3 (IV or oral) for at least 180 days. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant.
1824654|NCT00766792|Procedure|Nocturnal dialysis|Switch to nocturnal dialysis (3 times 480 min/week)
1824571|NCT00763490|Drug|Mycophenolate Mofetil|"Mycophenolate Mofetil (MMF) for GVHD prophylaxis. MMF - will be given at a dose of 10mg/kg IV q 8 hours if the patient weight is more than 50 kg, or 15 mg/kg IV q 8 hours if less than 50 kg, beginning the morning of day -3. (If renal failure and Glomerular Filtration Rate (GFR) < 25 mL/min, the dose should not exceed 1 gm every 8 hours. (No dose adjustment for liver disease is required.) MMF should be given via IV until oral medications are tolerated.
MMF will be stopped at Day +28 if no acute GVHD is seen by that time. If there is not any donor cell engraftment, MMF will be continued as directed by the attending physician. If the patient has active acute GVHD requiring systemic therapy, MMF may be continued."
1824572|NCT00763503|Drug|CD 2027|3µg/g Oily Spray
1824573|NCT00763516|Radiation|Proton radiation and chemotherapy|"Neoadjuvant Chemotherapy Capecitabine (Xeloda®) 1,000 mg by mouth twice a day 5 days/week (M-F) on radiation days only
Proton radiation 50.4 cobalt gray equivalent(CGE) in 28 fractions over 6 weeks
Surgery: Gross total resection of primary tumor and regional lymph nodes done 6 weeks after completion of radiation
Adjuvant Chemotherapy starting 2-8 weeks after surgery Suggested Regimen: Gemcitabine (Gemzar®) 1,000 mg/m2 IV total of 18 doses"
1824574|NCT00763529|Drug|Mometasone|Mometasone furoate cream 0.1% applied once daily
1824575|NCT00763529|Drug|Fluticasone|Fluticasone propionate cream 0.05% applied twice daily
1824576|NCT00763542|Behavioral|CBT for SUD|CBT for SUD focuses on patient-motivation, self-control strategies and relapse-prevention.
1824577|NCT00763542|Behavioral|Structured writing therapy for PTSD|Patients progress through three stages, in which instructions for writing and feedback by therapists are successively aimed at achieving trauma processing, cognitive restructuring and social sharing of a traumatic event.
1824578|NCT00763555|Drug|CD 2027|3 µg/g Oily Spray, twice a day for 8 weeks
1824579|NCT00763555|Drug|Vehicle (placebo)|placebo spray, twice a day for 8 weeks
1824580|NCT00763568|Drug|Nitazoxanide|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
1824581|NCT00763568|Biological|Peginterferon alfa-2a|One nitazoxanide 500 mg tablet orally twice a day for 4 weeks followed by one nitazoxanide 500 mg tablet orally twice a day plus weekly injections of 180µg peginterferon alfa-2a for 36 weeks.
1824582|NCT00763594|Behavioral|Brief Relational Therapy|16 weeks of psychodynamically informed and therapy alliance focussed psychotherapy adapted for treating Major Depressive Disorder.
1824583|NCT00763594|Behavioral|Interpersonal Psychotherapy|16 weeks of Interpersonal Psychotherapy for Major Depressive Disorder
1824584|NCT00763607|Genetic|Protein expression by immunohistochemistry and immunofluorescence|Protein expression by immunohistochemistry and immunofluorescence
1824585|NCT00763620|Device|catheter for mini bronchoalveolar lavage|For each patient included an endotracheal aspiration and a mini bronchoalveolar lavage will be performed. After local anaesthesia, a suction catheter will be introduced in trachea by nasotracheal way. An endotracheal aspirate will be performed. Then, the mini bronchoalveolar lavage will be performed with the specific catheter introduced through the suction catheter. Expectorated sputum will also be ordered. This procedure will be performed once at the admission patient in intensive care unit.
1824588|NCT00763646|Drug|Taxotere, Cisplatin, and 5-FU|Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total), 1 - 2 weeks, Taxotere/Cisplatin/5-FU x 3 cycles (3 weeks per cycle or 9 weeks total)
1824589|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|20mg Lutein, 2mg Zeaxanthin, 510 mg Omega-3-FA; daily supplementation about one year
1824590|NCT00763659|Dietary Supplement|Lutein/ Zeaxanthin + Omega-3-FA|10mg Lutein, 1mg Zeaxanthin, 255 mg Omega-3-FA; daily supplementation about one year
1824591|NCT00763659|Dietary Supplement|Placebo|0 mg Lutein, Zeaxanthin, Omega-3-FA
1824592|NCT00763672|Other|Transmission of sFlt-1 results to the investigator|Transmission of sFlt-1 results by the laboratory to the investigator
1824593|NCT00763672|Other|No transmission of the sFlt-1 results to the investigator|The laboratory do not transmit the sFlt-1 results to the investigator before the end of the study.
1824594|NCT00763685|Drug|etoricoxib|etoricoxib 120 mg, paracetamol 1 g
1824595|NCT00763698|Device|QuickFlex Micro Model 1258T Left Heart Lead|Implantation of QuickFlex Micro 1258T left heart lead in combination with a CRT-D system.
1824596|NCT00763711|Device|Needle Guided Periurethral Injection|Bulking Agent injection using a needle guide
1824597|NCT00763737|Procedure|Fetoscopic Endoluminal Tracheal Occlusion|prenatal balloon placement at 30-32+6 weeks and removal at 34-34+6 wks
1824598|NCT00763750|Drug|PPX +TMZ+XRT|PPX 50 mg/m2/week x 6 weeks (Days #1, 8, 15, 22, 29, 36) XRT: 60 Gy at 2 Gy/fraction x 30 fractions Temozolomide 75 mg/m2/day: Day #1 of XRT until completion (including weekends and holidays)
1824599|NCT00763763|Drug|Imatinib mesylate|imatinib 600 mg/day for 2 years
1824600|NCT00763763|Drug|Interferon|45 micrograms per week during 2 years
1824601|NCT00763763|Drug|Vincristine|2 mg IV injection repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
1824602|NCT00763763|Drug|Dexamethasone|40 mg PO repeated weekly for 4 weeks as induction and then monthly for 4 months as consolidation
1824603|NCT00766415|Drug|AZD1981|Oral tablet, twice daily, 4 weeks treatment
1824604|NCT00766415|Drug|Placebo|Placebo
1824605|NCT00766441|Drug|Sitagliptin|tablet, 100mg, once daily, 4 weeks
1824606|NCT00766441|Drug|sulphonylurea|sulphonylurea, variable, od or bd, during ramadan
1824607|NCT00766454|Genetic|DNA analysis|
1824608|NCT00766454|Genetic|mutation analysis|
1824609|NCT00766454|Genetic|polymorphism analysis|
1824610|NCT00766454|Other|laboratory biomarker analysis|
1824611|NCT00766454|Other|medical chart review|
1824612|NCT00766454|Other|questionnaire administration|
1824613|NCT00766454|Procedure|evaluation of cancer risk factors|
1824614|NCT00766467|Drug|Armodafinil|Taken orally once a day in the morning. Dose will change depending upon level of fatigue
1824615|NCT00766467|Other|Placebo|Placebo taken once a day in the morning
1824616|NCT00766480|Drug|cisplatin|Given IV
1824617|NCT00766480|Drug|fluorouracil|Given IV
1824618|NCT00766480|Radiation|radiation therapy|Patients undergo radiotherapy
1824620|NCT00766506|Device|Fentanyl IONSYS|Participants will receive 40 mcg of fentanyl dose up to a maximum of 240mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 80 doses within a 24 hour period from an Iontophoretic Transdermal System (IONSYS).
1824621|NCT00766506|Device|Morphine IV PCA|Morphine sulphate solution will be administered intravenously (IV) by a patient-controlled analgesia (PCA) pump using set bolus doses with a fixed lock out period as per physician's discretion (maximum total dose of 20 milligram per 2 hours) for 72 hours.
1824622|NCT00766519|Other|volume optimization|"Fluid management:
basal fluid administration = 5 ml/kg/h lactated Ringer's solution
+ systematic minimization of the arterial pulse pressure variation (PPV) to 10% or less by volume loading (6% hydroxyethyl starch) throughout surgery
hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) only if PPV is > 10%"
1824623|NCT00766519|Other|standard volume administration|"Fluid management:
basal fluid administration = 5 ml/kg/h lactated Ringer's solution
hypovolemia suspected : fluids (1. crystalloids, 2. 6% hydroxyethyl starch) according to predetermined algorithm primarily based on mean arterial pressure, heart rate, and urine output, and secondary on PPV"
1824624|NCT00766532|Drug|Aromatase Inhibitor|Any aromatase inhibitor started as initial adjuvant therapy
1824625|NCT00766545|Drug|cilostazol|oral tablet 100 mg, twice daily, over 1 year
1824626|NCT00766545|Drug|placebo of cilostazol|oral tablet, 0 mg twice daily, over 1 year
1824627|NCT00766584|Other|Sleep apnea/hypopnea detection|Simultaneous 24-hour ambulatory electrocardiogram and polygraphic recordings performed at home during a night.
1824628|NCT00766597|Drug|Vicriviroc|Administered orally in either tablet or liquid form at a dosage of approximately 0.8/mg/kg every 24 hours, with a ritonavir boosted protease inhibitor containing background regimen
1824629|NCT00766623|Dietary Supplement|high fat meal|milkshake containing 95g fat
1824630|NCT00766623|Dietary Supplement|control meal|milkshake comparable with a normal breakfast
1824631|NCT00766636|Drug|Gemcitabine|"Arm A:
1000 mg/M^2 given intravenously over 100 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day.
Arm B:
400 mg/M^2 given intravenously over 40 min. every week for 6 doses beginning day 1 (days 1, 8, 15, 22, 29, 36) +/- 1 day."
1824632|NCT00766636|Radiation|Radiation Therapy|1 time each day for 5 days in a row for 5 1/2 weeks starting on Day 1 for a total of 50.4 Gy.
1824633|NCT00766636|Drug|Erlotinib|100 mg daily by mouth on days 1-42.
1824634|NCT00766636|Procedure|Surgery|Surgical removal of the pancreas and duodenum
1824635|NCT00766649|Drug|Sirolimus|Participants receive a 20 μL (440 μg) subconjunctival injection of sirolimus in the study eye at baseline and every three months thereafter.
1824636|NCT00766662|Drug|Sulfadoxine pyrimethamine|
1824637|NCT00766675|Drug|Tramadol hydrochloride|Tramadol hydrochloride oral tablet will be administered at a dose of 37.5 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
1824638|NCT00766675|Drug|Acetaminophen|Acetaminophen oral tablet will be administered at a dose of 325 milligram as, once daily for Day 1-3, twice daily for Day 4-6 and thrice daily for Day 7-56.
1824639|NCT00766688|Drug|AVE5530|"one tablet in the evening with dinner
in addition to high doses of statin treatment"
1824640|NCT00766688|Drug|Placebo|"one tablet in the evening with dinner
in addition to high doses of statin treatment"
1824641|NCT00766701|Procedure|Procedure: Spectroscopy and Digital Imaging|Procedure: Spectroscopy and Digital Imaging
1824642|NCT00766714|Device|Cook K-SOFT-5100 catheter|A Cook K-SOFT-5100 catheter was used for embryo transfer in human IVF/ICSI
1824643|NCT00766714|Device|Frydman classical catheter|A Frydman classical catheter was used for embryo transfer in human IVF/ICSI
1824644|NCT00766740|Device|thrombectomy devices|mechanical or manual devices able to remove thrombus from the coronary arteries.
1824645|NCT00766740|Device|angioplasty|percutaneous coronary angioplasty with use of balloon catheters and bare metal stents or drug eluting stents.
1824646|NCT00766753|Biological|Dendritic vaccine pulsed with multiple peptides|Subjects will receive four (4) injections of the vaccine into the lymph nodes. Injection is guided by ultrasonography. Subjects will receive the first cycle of vaccine in the right groin. Two weeks after the first vaccine, subjects receive the same vaccine at the left groin, followed by the 3rd and the 4th vaccines in the left and right armpits, respectively, with two-week intervals. Each injection contains 0.2cc (less than 1/20th of a teaspoon) of a saline solution containing the vaccine cell mixture.
1824647|NCT00766753|Biological|The first booster vaccine phase:|This phase will begin at week 13. These subjects will be treated with additional vaccinations every 4 weeks to a maximum of 5 vaccine injections and, if poly-ICLC is available from the supplier starting on the day of the first additional vaccine and twice/week for 8 injections following each additional vaccine. If poly-ICLC supply is not available from the supplier, DC vaccines only will be given in the booster phases.
1824648|NCT00766753|Biological|The second booster vaccine phase:|"At week 33, following the completion of 5 additional vaccines, if participants demonstrate stable disease or positive clinical response, if poly-ICLC supply is still available, participants will be offered additional DC-vaccines and poly-ICLC treatment. The second phase booster vaccines can be continued as long as the patient shows continued positive response or stable disease (both radiological and clinically) with no major adverse events, and as long as funding is available for the study. DC vaccines in this phase will be administered every 6 months+/- 2 weeks.
2). Poly-ICLC at 10µg/kg and up to 1640 µg/injection will be administered intramuscularly (i.m.) on the day of each booster DC vaccine. Poly-ICLC will be administered weekly thereafter for twice (at one week and two weeks after each vaccine) (e.g. if the previous DC vaccine was administered on a Thursday, subsequent poly-ICLC will be administered on the next two Thursdays"
1824649|NCT00766766|Behavioral|Health Risk and Behavioral Skills Coaching Sessions|Health Risk and Behavioral Skills Coaching Sessions
1824650|NCT00766766|Behavioral|Telephone Coaching Sessions|Telephone Coaching Sessions
1824651|NCT00766766|Behavioral|Physician Feedback Letter|Physician Feedback Letter
1824652|NCT00766779|Procedure|hematopoietic cell transplantation|low dose total body irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors
1824653|NCT00766779|Drug|Non-Transplant treatment approach for consolidation|Patients will receive the treatment that would be otherwise applied at the local institution. The consolidation or maintenance therapy is according to the study group protocol.
1824656|NCT00766805|Drug|EVL + Propranolol + Isosorbide 5 mononitrate|Treatment was started with propranolol at a dose of 40 mg twice a day. The heart rate and blood pressure were checked after 12 to 24 hours. The dose of propranolol was increased at increments of 20 to 40 mg per day until the patient achieved a heart rate of 55 bpm, or a maximum dose of 320 mg/day was achieved.ISMN was added at a dose of 10 mg twice a day. The dose was escalated at increments of 10-20 mg/day till a maximum dose of 40 mg/day was reached.
1824657|NCT00766805|Other|EVL alone|
1824658|NCT00766818|Drug|Kaletra|Kaletra 400/100mg BID, then increase at 30weeks to 500/125mg BID
1824659|NCT00766831|Drug|Hydromorphone|Participants will receive hydromorphone OROS (8 milligram [mg] to greater than or equal to 32 mg) once daily for 2 weeks, in a dose adjusted according to previously administered strong oral opioid analgesic (dose with equivalent analgesic effect; hydromorphone OROS dose: oral morphine dose=1:5) hydromorphone OROS will be continued as per Investigator's discretion for additional 84 days of extension phase.
1824660|NCT00766844|Device|spinal cord stimulation|electrode is inserted into cervical epidural space for continuous spinal cord stimulation
1824661|NCT00766857|Drug|exenatide|Exenatide 5 mcg BID for 4 weeks, subsequently increased to 10 mcg BID for the remainder of the study (total of 26 weeks).
1824662|NCT00766857|Drug|Insulin glargine|Insulin glargine will be initiated at 10 IU QD, titrated according to fasting blood glucose concentrations based on general protocol-defined guidance.
1824663|NCT00766870|Drug|Lu AA34893|Per oral doses, divided in twice daily administrations as capsules during 8 weeks, followed by a two-week tapering period
1824664|NCT00766870|Drug|Venlafaxine extended release|Per oral, once daily, during 8 weeks, followed by a two-week tapering period
1824665|NCT00766870|Drug|Placebo|Per oral doses, twice daily as capsules during 10 weeks
1824666|NCT00766883|Behavioral|Problem Solving Education|
1824667|NCT00766896|Drug|Aspirin (platelet sensitive versus platelet hyperreactivity)|"The dose of aspirin to be prescribed in this study will be 300 mg orally or by nasogastric tube once a day (assisted therapy), with first dose tomography soon after admission if the patient has no indication of thrombolytic therapy. After the acute phase, patients will receive aspirin at a dose of 200 mg/day. Aspirin will be administered in a simple preparation (no buffer, no extended release)."
1824668|NCT00766909|Drug|cyclosporine|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.
For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days."
1824669|NCT00766909|Drug|tacrolimus|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.
For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days."
1824670|NCT00766909|Other|Capsules and isotonic saline|"For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.
For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days."
1824671|NCT00766948|Other|There is no intervention, this is a biorepository.|There are no interventions in this study.
1824672|NCT00766961|Procedure|Trans-catheter arterial embolization|Trans-catheter arterial embolization
1824673|NCT00766961|Procedure|Surgery|Surgery
1824674|NCT00766974|Device|Anti-embolism Knee High Stocking|Anti-embolism Knee High Compression Stocking
1824675|NCT00766974|Device|20-30 Knee High Compression Stocking|20-30 mmHg Knee High COmpression Stocking
1824676|NCT00767000|Drug|MK-0941|MK-0941 tablets three times daily
1824677|NCT00767000|Drug|Comparator: Placebo|Matching placebo to MK-0941 three times daily
1824678|NCT00767000|Biological|Lantus|Lantus injection once daily
1824679|NCT00767000|Drug|Metformin|Metformin ≥1500 mg/day at a stable dose for at least 6 weeks before Screening and for the duration of the study. The number of randomized participants who receive metformin will be capped at 70% of enrollment.
1824680|NCT00767013|Other|DSCT, TTE|One assessment each
1824681|NCT00767026|Behavioral|COPE (Creating Opportunities for Parent Empowerment)|Twenty-four hours after admission to the hospital, this group will receive Phase I of the study which includes information focusing on what parents can expect during their child's hospital stay, and how they can help their child cope with the experience. Prior to discharge parents will receive additional information pertaining to Phase II of the study. At 3 days post discharge, the participants will receive a follow up phone call to reiterate the information provided in Phase II and ask parents about questions or problems since discharge. One week following, participants will be asked to complete assessments. At 6 weeks after the hospitalization they will receive Phase III, which includes, additional information on behaviors parents can expect to see in their children following a hospitalization. Parents will be given a workbook that will teach them techniques to help their child cope. Then at 6 weeks after the last intervention phase, participants will again complete assessments.
1824682|NCT00767026|Behavioral|Standard education|This group will receive standard education regarding medication management and seizure first aid. This group will also receive information, oral and written, that will discuss tests to be administered during the hospitalization. The usual care group also receives a call at home within one week after discharge from a nurse to ask if they had any problems with their stay, and if they have any further needs or questions.
1824683|NCT00767039|Drug|Survanta (beractant)|beractant 4.0 ml/kg/dose (100 mg phospholipid/kg/dose, intratracheal, every 6-12 hours as needed for respiratory distress syndrome for initial and subsequent doses, maximum of 4 doses)
1824684|NCT00767039|Drug|Curosurf (poractant)|poractant alfa 2.5 ml/kg/dose initial (200 mg phospholipid/kg), and 1.25 ml/kg/dose subsequent (100 mg/kg/subsequent dose), intratracheal, every 12-24 hours as needed for respiratory distress syndrome, maximum of 3 doses)
1824685|NCT00767052|Drug|AZD1236|75mg once daily or 75mg twice daily will be administered in multiple dose part.
1824686|NCT00767052|Drug|Placebo|Placebo tablet matching to the active in multiple dose part.
1824687|NCT00767052|Drug|AZD1236|75mg single dose will be administered in relative bioavailability part.
1824688|NCT00767052|Drug|AZD1236|75mg oral suspension single dose will be administered in relative bioavailability part.
1824729|NCT00767416|Biological|MEDI-559|Cohort 1 (5 to <24 months): N=80 MEDI-559 at 10^5 FFU at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains 10^5 FFU MEDI-559 in a sucrose phosphate glutamate buffer.
1824689|NCT00767065|Radiation|Cardiac Computed Tomography|Patients randomised to the CCT arm will undergo 128-channel cardiac computed tomography with delayed acquisition. Patients will receive beta-blockade if necessary prior to the scan to achieve a heart rate of less than 70/min. An unenhanced scan will be performed in all patients to assess coronary artery calcium score. Patients will then undergo contrast enhanced CCT. After a bolus tracking acquisition, injection of 120mls iodinated contrast at 5ml/s will be followed by 40ml normal saline/contrast (in 50:50 proportion), also at 5ml/s. Imaging will be performed with a gated cardiac CT protocol. Where possible (stable rhythm and heart rate <70bpm) a low dose technique will be utilised. When not possible a retrospective gating method will be employed. In the latter case the ECG will be used to assign the images to their respective phases of the cardiac cycle. 10 minutes after contrast injection, a second prospectively gated scan will be acquired to assess myocardial enhancement patterns.
1824690|NCT00767065|Other|Standard care|Further investigations as decided by the patient's clinical team, according to best normal practice. These may include some or all of: further blood tests, exercise stress testing and myocardial perfusion scintigraphy. These may be conducted either during the initial hospital admission, or subsequently as an outpatient.
1824691|NCT00767091|Drug|rivastigmine|transdermal patch of rivastigmine of 9.5 mg/day
1824692|NCT00767091|Drug|placebo|transdermal patch of placebo
1824693|NCT00767104|Other|Silk like Pillowcase|sleep on silk-like pillowcase each night
1824694|NCT00767104|Other|Cotton Pillowcase|Sleep on placebo cotton pillowcase each night
1824695|NCT00767117|Drug|Etravirine; Lopinavir; Ritonavir|
1824696|NCT00767156|Other|Omega7 Sea Buckthorn Oil Cream|The subjects use Omega7 Sea Buckthorn Oil Cream on the face, twice per day
1824697|NCT00767156|Other|Base cream|The subjects use the base cream on the face, twice per day
1824698|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|The subjects take SBA24 sea Buckthorn Oil Capsules, 2 x 2 capsules (2.0 g oil) per day and use topically Omega7 Sea Buckthorn Oil Cream, twice per day.
1824699|NCT00767156|Dietary Supplement|SBA24 Sea Buckthorn Oil Capsule|Teh subjects took SBA24 Sea Buckthorn Oil Capsule, 2 x 2 capsules (2 g oil) per day and use topically the base cream, twice per day
1824700|NCT00767169|Device|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate|Dental implant coating with a fibrinogen carrier for pamidronate and ibandronate compared with uncoated controls in the same mouth.
1824701|NCT00767182|Other|blood sample|biological markers evaluated : D-Dimer, sEPCR
1824702|NCT00767208|Other|oral glucose load|oral ingestion of 13C labeled glucose
1824703|NCT00767221|Drug|Budesonide|8 mg PL-56 once daily for six months
1824704|NCT00767234|Procedure|Observation|Standard of Care
1824705|NCT00767260|Drug|BM-MNC+HOT|Autologous Bone Marrow Mononuclear cell Infusion Combined With Hyperbaric Oxygen Therapy
1824706|NCT00767260|Drug|BM-MNC|Autologous Bone Marrow Mononuclear cell Infusion
1824707|NCT00767260|Device|HOT|Hyperbaric Oxygen Therapy
1824708|NCT00767260|Drug|SMT|hypoglycemic drugs or exogenous insulin
1824709|NCT00767273|Procedure|PET Scan|
1824710|NCT00767273|Drug|FLT|
1824711|NCT00767273|Drug|FDG|
1824712|NCT00767286|Drug|flutamide|
1824713|NCT00767286|Drug|goserelin acetate|
1824714|NCT00767286|Radiation|low-LET cobalt-60 gamma ray therapy|
1824715|NCT00767286|Radiation|low-LET photon therapy|
1824716|NCT00767299|Drug|arzoxifene|20 mg, QD, PO,24 weeks
1824717|NCT00767299|Drug|Placebo|QD, PO, 24 weeks
1824718|NCT00767325|Drug|Abatacept|Abatacept, 10 mg/kg, solution given intravenously on Days 1, 15, 29,57, 85, 113, 141, and 169
1824719|NCT00767325|Drug|Methotrexate|Methotrexate administered in a dose of 15 mg/week or higher for at least 3 months and at a stable dose for at least 28 days prior to baseline
1824720|NCT00767338|Behavioral|Timed intercourse|Timed intercourse
1824721|NCT00767338|Procedure|Microsurgical varicocelectomy|Microsurgical varicocelectomy
1824722|NCT00767338|Procedure|Intrauterine insemination|Intrauterine insemination
1824723|NCT00767364|Biological|Oral, live, pentavalent rotavirus vaccine; RotaTeq(R)|Oral vaccine for prevention of rotavirus infection, 3 dose series
1824724|NCT00767377|Drug|EOF5|epirubicin 50 mg/m2 day 1, oxaliplatin 130 mg/m2 day 1, and 5-FU 375-425 mg/m2/d day 1 through 5 continuous infusion, repeated every 3 weeks
1824725|NCT00767390|Device|ACL Patch|Observe and characterize the changes in relative conductivity between the six ACL patches over period of six hours. Investigation only involves passive data collection on pressure impact and adhesiveness properties of ACL patches.
1824726|NCT00767403|Behavioral|Internet Intervention + Stepped Care|"Participants will spend about 1 hour each week for 6 weeks using the Internet Intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program then assigns additional intervention modules based on the difficulties the participants endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses. In addition to automatic emails, participants in this group will also receive additional support based on whether they complete specific intervention milestones."
1824727|NCT00767403|Behavioral|Internet Intervention|"As described in Arm 1 above, participants will spend about 1 hour each week for 6 weeks using the Internet intervention. In the first week, users will complete tutorials covering the three main components of treatment: 1) anatomy, physiology and pathophysiology of digestion; 2) education on clean-out and laxative treatments; and 3) behavioral treatment for encopresis. In subsequent weeks, users will complete weekly follow-ups, where they answer a series of questions about their progress and needs. The program will then assign additional intervention modules based on the difficulties the participant endorses. The 22 modules target a variety of issues including fears of toilet use; social isolation; administering, adjusting, and tapering laxatives; diet; hygiene; and preventing relapses."
1824728|NCT00767403|Behavioral|Patient Education Website|Participants will be given access to a relevant patient education website. It will contain material on managing and treating the behaviors and symptoms of childhood encopresis.
1824730|NCT00767416|Other|Placebo|Cohort 1 (5 to < 24 months); N = 80 placebo at 0, 2, and 4 months; frozen preparation filled into 0.5 ml luer slip-tip syringes. Each 0.2 ml dose contains sucrose phosphate buffer.
1824731|NCT00767429|Device|fall risk detector|fall risk detector: stumbles, specific fall related movements, falls
1824732|NCT00767455|Device|HP828-101|21 day patches
1824733|NCT00767468|Drug|sorafenib tosylate|Sorafenib 400mg BID until disease progression or patient withdrawal.
1824734|NCT00767481|Drug|Travoprost/Brinzolamide|Eye drop suspension, once daily
1824735|NCT00767481|Drug|Cosopt|Eye drop solution, one drop BID
1824736|NCT00767494|Drug|Travoprost/Brinzolamide fixed combination|Eye Drops, suspension once daily
1824737|NCT00767494|Drug|Azopt|Eye Drop Suspension, 1 drop BID
1824738|NCT00767494|Drug|Travatan|Eye Drop Solution, 1 drop BID
1824739|NCT00767507|Drug|cangrelor|
1824740|NCT00767507|Other|Placebo|Placebo IV infusion administered in the same fashion as the active study drug in order to maintain the blind in the study.
1824741|NCT00767520|Drug|Exemestane + Dasatinib|Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity
1824742|NCT00767520|Drug|Exemestane + Placebo|Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity
1824743|NCT00767546|Drug|Botulinum toxin|60- 100 units Local injection to the rash area
1824744|NCT00767559|Drug|warfarin|5 mg beginning the night before surgery, followed by 5 mg the PM of surgery*, and then variable daily dose, until day 28 (+/-2 days) from day of surgery follow-up. (target INR 2.0 -2.5)
1824745|NCT00767559|Drug|Fondaparinux:|2.5 mg daily starting more than 6 hours following surgery and no later than 6 AM the next day*, or 6-8 hours after epidural catheter removal, and continued until follow up day 28 (+/-2 days) from day of surgery.
1824746|NCT00767559|Drug|warfarin|"Fixed Low Dose warfarin
1 mg daily beginning 7 days preoperative, and continued at 1 mg daily until follow-up 28 day (+/- 2 days) from day of surgery."
1824747|NCT00767572|Drug|atorvastatin|Atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout period, then cross over groups to complete another 12 weeks. (Total study time is 28 weeks (12+4+12)
1824748|NCT00767572|Drug|Sugar pill|atorvastatin 80mg daily vs. placebo daily X 12 weeks, then 4 week washout, then cross over groups X 12 weeks. Total study time is 28weeks (12+4+12).
1824749|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 20mg vardenafil
1824750|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 100mg sildenafil
1824751|NCT00767598|Drug|phosphodiesterase type 5 inhibitor|single oral administration of 200mg udenafil
1824752|NCT00767624|Drug|Antidepressant|Possible antidepressants are sertraline, escitalopram, desvenlafaxine, based on past history, response and tolerance
1824753|NCT00767624|Behavioral|Desensitization Therapy for Insomnia|
1824754|NCT00767624|Behavioral|Cognitive Behavioral Therapy for Insomnia|
1824755|NCT00767637|Drug|Lanthanum Carbonate (BAY77-1931)|BAY77-1931 750mg, in the morning, day and evening
1824756|NCT00767663|Drug|dipyridamole|dipyridamole slow release 200mg twice daily, minimal 3 days pretreatment
1824757|NCT00767663|Drug|placebo|placebo twice daily, minimal three days pretreatment
1824758|NCT00767676|Device|HP828-101|Nine topical patch applications over 3 weeks, rest period of 2 weeks and challenge after 48 hours.
1824759|NCT00767689|Drug|vitamin b6|vitamin b6 100 mg po daily
1824760|NCT00767689|Drug|placebo|placebo is given in the placebo arm
1824761|NCT00767715|Drug|olanzapine|physician determined dose, oral, daily, 5 months
1824762|NCT00767715|Drug|haloperidol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
1824763|NCT00767715|Drug|zuclopentixol|physician determined dose, oral, parenteral (<= 3 days), daily, 5 months
1824764|NCT00767728|Drug|Granulated mesalamine|0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning.
1824765|NCT00767728|Drug|Placebo|Matching placebo capsules (4 capsules) were administered orally QD, in the morning.
1824766|NCT00767741|Device|with heat and massage|For the with intervention group a treatment to the injection site is applied after each insulin bolus injection.
1824767|NCT00767754|Drug|Paxil CR|12 week treatment of Paxil(20-40mg)
1824768|NCT00767767|Drug|Placebos|IV Saline infusion for 2 hours.
1824769|NCT00767767|Drug|Propofol 0.45mcg/mL|IV Propofol infusion for 2 hours.
1824770|NCT00767767|Drug|Propofol 0.90mcg/mL|IV Propofol infusion for 2 hours.
1824771|NCT00767767|Drug|Thiopental 1.5mcg/mL|IV Thiopental 1.5mcg/mL infusion for 2 hours
1824772|NCT00767767|Drug|Thiopental 3mcg/mL|IV Thiopental 3mcg/mL infusion for 2 hours
1824773|NCT00767780|Device|APOS biomechanical gait system|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
1824774|NCT00767793|Drug|Placebo|One drop in each eye every 12 hours for seven days
1824775|NCT00767793|Drug|INS117548|One drop of Concentration #1 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
1824776|NCT00767793|Drug|INS117548|One drop of Concentration #2 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
1824777|NCT00767793|Drug|INS117548|One drop of Concentration #3 in one eye and one drop of placebo in contralateral eye every 12 hours for seven days
1824778|NCT00767806|Drug|Duloxetine|60 mg orally once daily for 12 weeks
1824779|NCT00767806|Drug|Placebo|Placebo once daily orally for 12 weeks
1824780|NCT00767819|Drug|Everolimus/RAD001|10 mg orally
1824781|NCT00767845|Other|questionnaire/survey administration|
1824782|NCT00767871|Drug|Lexapro|12 week treatment with lexapro
1824783|NCT00767897|Drug|Human Papillomavirus Vaccine|The HPV vaccination will be administered by intramuscular injection in three separate 0.5mL doses. The recommended schedule is a 3-dose series with dose #2 and #3 administered 2 and 6 months after dose #1, respectively. The minimum interval between dose #1 and #2 of the vaccine is 4 weeks. The minimum recommended interval between dose #2 and #3 of the vaccine is 12 weeks.
1824785|NCT00767962|Other|talc pleurodesis under medical thoracoscopy|talc pleurodesis under medical thoracoscopy for recurrent primary spontaneous pneumothorax
1824786|NCT00767962|Other|pleurodesis under video-assisted thoracoscopy surgery|pleurodesis under video-assisted thoracoscopy surgery for recurrent primary spontaneous pneumothorax
1824787|NCT00767975|Drug|isoniazid , randomized, open label|isoniazid 300mg/tab 1 tab qd, 6 months (the other treatment arm is rifampin)
1824788|NCT00767975|Drug|rifampin, randomized, open label|rifampin 300mg/capsule 2 caps qd, 4 months (the other treatment arm is isoniazid)
1824789|NCT00767988|Dietary Supplement|Urex-cap-5 (2x10^9 cfu each of Lactobacillus reuteri RC-14 and Lactobacillus rhamnosus GR-1)|Capsules once daily at approximately the same time each day for 6 months.
1824790|NCT00767988|Other|Placebo|Capsule once daily at approximately the same time each day for 6 months.
1824791|NCT00768040|Drug|Aliskiren|300 mg once daily
1824792|NCT00768040|Drug|Placebo|Matching placebo once daily
1824793|NCT00768053|Drug|Etanercept|Etanercept 50 mg once a week
1824794|NCT00768066|Biological|Autologous human mesenchymal cells (hMSCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hMSCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
1824795|NCT00768066|Biological|Autologous human bone marrow cells (hBMCs)|Participants will receive 40 million cells/mL delivered in either a dose of 0.25 mL per injection for a total of 1 x 108 (100 million) hBMCs x 10 injections or a dose of 0.5 mL per injection for a total of 2 x 108 (200 million) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
1824796|NCT00768066|Biological|Placebo|Participants will receive 0.5 mL injections of phosphate-buffered saline (PBS) and 1% human serum albumin (HAS) x 10 injections. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
1824797|NCT00768079|Other|Placebo|Placebo on Study Day 0 (3mL vials filled with 1.2 mL solution of 10mM histidine, 300 mM glycine, 0.02% polysorbate 20, pH 6.0.)
1824798|NCT00768079|Biological|MEDI-563|0.3 mg/kg IV MEDI-563 on Study Day 0
1824799|NCT00768079|Biological|MEDI-563|1.0 mg/kg IV MEDI-563 on Study Day 0
1824800|NCT00768105|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose in 2-3 dose steps. Investigational product given twice daily for eight days.
1824801|NCT00768105|Drug|Placebo|Dosing to match AZD1656
1824802|NCT00768118|Dietary Supplement|curcumin/green tea extract/Polygonum cuspidatum extract/soybean extract capsule|
1824803|NCT00768118|Genetic|electrophoretic mobility shift assay|
1824804|NCT00768118|Other|laboratory biomarker analysis|
1824805|NCT00768131|Drug|Cetuximab|Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision
1824806|NCT00768131|Drug|Paclitaxel|Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum
1824807|NCT00768131|Drug|Carboplatin|Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
1824808|NCT00768144|Drug|Sunitinib|
1824809|NCT00768157|Drug|antiviral treatment (lamivudine or entecavir)|antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
1824810|NCT00768157|Procedure|radical resection of HBV-related HCC|Procedure/Surgery - radical resection of HBV-related HCC
1824811|NCT00768170|Drug|MK0633|MK0633 (50 mg) Oral, single dose
1958602|NCT01462565|Drug|current marketed FLOLAN (epoprostenol sodium)|continuous intravenous infusion
1958603|NCT01462565|Drug|new thermo stable formulation of epoprostenol sodium|continuous intravenous infusion
1824815|NCT00768209|Drug|Phentermine and Topiramate|Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
1824816|NCT00768222|Device|silk suture|skin closure
1824817|NCT00768222|Device|VICRYL* Plus suture|skin closure
1824818|NCT00768235|Other|yoga practice|The yoga program comprised 70 min sessions, 3 times/week during 12 weeks
1824819|NCT00768248|Drug|perineural ropivacaine|ropivacaine 0.4%; the basal rate will be set at 7 mL/h
1824820|NCT00768248|Drug|normal saline (placebo)|the basal rate will be set at 7 mL/h
1824821|NCT00768261|Drug|Memantine (Namenda®)|Drug treatment will begin with 5 mg/day of donepezil for six weeks. After six weeks of such treatment, the subjects symptoms will be re-evaluated and any side-effects of treatment assessed and recorded. If no serious side-effects of donepezil are encountered, the dose of donepezil will be increased to 10 mg/day. For subjects prescribed the combination of donepezil and memantine, memantine (20 mg/day) will be added to the drug treatment regimen after the dose of donepezil has been established (i.e., at six weeks). Again, memantine will be initially started at 10 mg/day and increased to its full dose only if no serious side-effects are encountered.
1824822|NCT00768261|Drug|Memantine (Namenda®)|Initial dose of 10mg/day and increased to full dose of 20mg/day if no serious side-effects
1824823|NCT00768261|Drug|Donepezil (Aricept®)|5mg/day for six weeks and if no serious side-effects increased to 10mg/dy.
1824824|NCT00768274|Drug|RVX000222|RVX000222 twice daily (b.i.d.) for 28 days
1824825|NCT00768274|Drug|Placebo|Placebo twice daily (b.i.d.) for 28 days
1824826|NCT00768287|Biological|IB1001 (On-Demand)|use as needed
1824827|NCT00768287|Biological|IB1001 (Prophylaxis)|use on a prophylaxis basis
1824828|NCT00768300|Drug|Ambrisentan|Ambrisentan (5mg or 10 mg tablet) was administered orally once daily.
1824829|NCT00768300|Drug|Placebo|Placebo to match ambrisentan was administered orally once daily.
1824830|NCT00768313|Device|titanium rod|comparison of rods of varying yield strengths and their ability to hold correction of scoliosis.
1824831|NCT00768313|Device|ultra strength stainless steel rod|interventions involving rods of various strength to treat scoliosis
1824832|NCT00768326|Drug|Zicronapine|"Study Part A:
3mg; orally, film-coated tablets, once daily, 8 weeks"
1824833|NCT00768326|Drug|Zicronapine|"Study Part B:
5mg; orally, film-coated tablets, once daily, 8 weeks"
1824834|NCT00768326|Drug|Zicronapine|"Study Part C:
7mg; orally, film-coated tablets, once daily, 8 weeks"
1824835|NCT00768326|Drug|Zicronapine|"Study Part D:
2 x 5mg; orally, film-coated tablets, once daily, 8 weeks"
1824836|NCT00768326|Drug|Zicronapine|"Study Part E:
2 x 7mg; orally, film-coated tablets, once daily, 8 weeks"
1824837|NCT00768326|Drug|Placebo|"Study Part A, B, C, D and E:
Placebo; orally, film-coated tablets, once daily, 8 weeks"
1824838|NCT00768339|Drug|AEG35156 antisense IV infusion|"AEG35156 will be given as a 2-hour intravenous infusion (escalating dose 50, 100, 150, 200, 250 and 300 mg) once weekly on Day 1, Day 8 and Day 15. One cycle of therapy will consist of 21 days. Patients will be treated until disease progression.
Patients must be pretreated for at least three days with allopurinol prior to the first dose of AEG35156 and throughout protocol therapy.
Patients must be hydrated with 1 L of normal saline prior AEG35156 infusion"
1824839|NCT00768352|Other|Educational intervention|An educational intervention which will consist of a standardized PowerPoint presentation that will cover general mental health topics such as depression and substance abuse. The presentation will also include discussion of common and validated mental health screening and assessment tools, as well as how to use these tools in a clinical setting. An educational packet will be provided to the residents and will include the screening tools, information on motivational interviewing and the behavioral stages of change, information on common medications prescribed for mental health disorders, and a bibliography of reputable resources for mental health topics.
1824840|NCT00768378|Device|Training with the BrainPort balance device|Subjects are randomly assigned to one of two groups, the perceived stimulation group or the subliminal stimulation group. Some of these devices provide a stimulus that you can feel. Others provide a stimulus that is below conscious awareness. We are conducting this study to determine if one type of stimulation is more effective than the other.
1824841|NCT00768391|Biological|IMC-3G3|Intravenously, once every week for Cohorts 1 through 3 and once every other week for Cohorts 4 and 5. Starting dose will be 4mg/kg in Cohort 1, with dose doubling between cohorts. Dose escalation of 100% (2 x previous dose) Dose escalation increment reduced to 33% (1.33 x previous dose). Cohorts 4 and 5 will receive 15mg/kg and 20mg/kg, intravenously, once every other week.
1824842|NCT00768404|Drug|Topirmate and Phentermine|A single oral dose of the combination product VI-0521 (15 mg phentermine and 92 mg topiramate) will be administered with 240 mL of water at hour 0.
1824843|NCT00768417|Behavioral|10 chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 10 times before swallowing.
1824844|NCT00768417|Behavioral|25 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 25 times before swallowing.
1824845|NCT00768417|Behavioral|40 Chews|Participants were required to chew 55g grams of almonds per day for four days in 11, 5 gram portions. Almonds were to be chewed 40 times before swallowing.
1824846|NCT00768430|Drug|Ketamine|Single dose .5 mg/kg IV (in the vein) infused over 40 minutes
1824847|NCT00768430|Drug|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
1824848|NCT00768456|Drug|Ropivacaine 0.5 %|Local Infiltration with Ropivacaine 0.5 %
1824849|NCT00768456|Drug|Isotonic NaCl|Local Infiltration with NaCl
1958604|NCT01462292|Drug|GSK2402968 3mg/kg/week|Comparison of 2 doses of GSK2402968
1824851|NCT00768482|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants)
1824852|NCT00768482|Drug|Sublingual Buprenorphine|16 mg/day, QD
1824853|NCT00768508|Drug|Ondansetron 4 ug/kg b.i.d. + Cognitive Behavioral Therapy|Ondansetron 4 ug/kg b.i.d.for 12 weeks
1824854|NCT00768508|Drug|Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Naltrexone 50 mg/day for 12 weeks
1824855|NCT00768508|Drug|Ondansetron 4 ug/kg b.i.d.+ Naltrexone 50 mg/day + Cognitive Behavioral Therapy|Combination of ondansetron 4 ug/kg b.i.d. and naltrexone 50 mg/day for 12 weeks
1824856|NCT00768508|Other|Placebo + Cognitive Behavioral Therapy|Placebo comparator
1824857|NCT00768521|Drug|tolterodine tartrate|"Part I: tolterodine tartrate 4 mg capsule once a day (qd) for 7 days
Part IIa: tolterodine tartrate 4 mg capsule qd for 7 days
Part IIb: single dose tolterodine tartrate 4 mg capsule"
1824858|NCT00768521|Drug|Comparator: Placebo to tolterodine tartrate|"Part I: placebo to tolterodine tartrate 4 mg capsule once a day (qd) for 7 days
Part IIa: placebo to tolterodine tartrate 4 mg capsule qd for 7 days
Part IIb: single dose placebo to tolterodine tartrate 4 mg capsule"
1824859|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 80mg OD|Nifedipine (Adalat CR, BAYA1040) 80 milligram (mg) once daily (OD) in the morning
1824860|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 40mg BID|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) twice daily (BID). 40 mg in the morning and 40 mg in the evening
1824861|NCT00768560|Drug|Nifedipine (Adalat CR, BAYA1040) 40mg OD|Nifedipine (Adalat CR, BAYA1040) 40 milligram (mg) once daily (OD) in the morning
1824862|NCT00768573|Drug|sildenafil|Oral suspension of sildenafil.
1824863|NCT00768599|Drug|Econazole Nitrate Cream 1%|Topical cream, applied once daily for 4 weeks.
1824864|NCT00768599|Drug|Econazole Nitrate Foam 1%|Topical foam, applied once daily for 4 weeks.
1824865|NCT00768599|Drug|Vehicle Foam|Topical foam, applied once daily for 4 weeks.
1824866|NCT00768612|Drug|SCA-136 50mg/day|
1824867|NCT00768612|Drug|SCA-136 150 mg/day|
1824868|NCT00768612|Drug|SCA-136 300mg/day|
1824869|NCT00768612|Drug|Risperidone 4mg/day|
1824870|NCT00768638|Drug|Atorvastatin|Atorvastatin 10mg 1co id (10mg active) Placebo 40mg 1co id (40mg inactive)
1824871|NCT00768638|Drug|Atorvastatin|Atorvastatin 40mg 1co id (40mg active) Placebo 10mg 1co id (10mg inactive)
1824872|NCT00768651|Drug|Pantoprazole|Starting on Day 1, Pantoprazole 80 mg daily (40 mg every morning and 40 mg every evening) administered orally at the same time each day for a period of 6 months.
1824873|NCT00768651|Drug|Sitagliptin|Starting on Day 1, Sitagliptin 100mg once daily administered orally at the same time each day for a period of 6 months.
1824874|NCT00768664|Drug|PF-00299804|45 mg by continuous oral dosing
1824875|NCT00768677|Drug|topiramate|
1824876|NCT00768690|Drug|ABT-333|Capsule, or powder drug substance from the capsule powder mixed in an alternate vehicle. For additional information refer to arm description.
1824877|NCT00768690|Drug|ketoconazole|Tablet, see arms for intervention description
1824878|NCT00768690|Drug|placebo|Capsule or powder drug substance from the capsule powder mixed in an alternative vehicle. For additional information refer to arm description.
1824879|NCT00768703|Device|Percutaneous endoscopic fetal tracheal occlusion/unocclusion|Between 26-28 wks' gestation, percutaneous endoscopic placement of the tracheal balloon. Between 32-34 wks' gestation, percutaneous endoscopic removal of the balloon.
1824880|NCT00768716|Drug|Acetaminophen|2 x 500 mg by mouth once
1824881|NCT00768729|Drug|Sirolimus|Oral tablets or liquid taken every 12 hours. Dosage adjusted to attain target trough levels of 8-12 ng/mL. Participants who have maintained such levels at study entry on once daily dosage will be permitted to continue on once daily dosing.
1824882|NCT00768729|Drug|MMF or Azathioprine|600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
1824883|NCT00768742|Device|VizAblate Intrauterine Ultrasound-Guided RF Ablation|VizAblate enables a minimally invasive procedure to visualize, target and treat uterine fibroids using ultrasound visualization and RF energy.
1824884|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po
1824885|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused for 3 days before each cycle of concomitant chemotherapy
1824886|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
1824887|NCT00768755|Drug|axitinib|5mg BID po up to max 10mg BID po paused before each concomitant chemotherapy
1824888|NCT00768755|Drug|chemotherapy|Pemetrexed(500mg/m2)/Cisplatin(75mg/m2) x max 6 cycles
1824889|NCT00768768|Other|Electrokinetic Transungual System (ETS) - Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 3 mA-min as 0.3 mA for 10 min"
1824890|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 6 mA-min as 0.5 mA for 12 min"
1824891|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 6 mA-min as 0.3 mA for 20 min"
1824892|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 10 mA-min as 0.5 mA for 20 min"
1824893|NCT00768768|Other|ETS-Terbinafine Gel|"Iontophoresis in conjunction with a terbinafine gel
Drug Dose: ETS drug cartridge loaded with approximately 20 mg - 35 mg of terbinafine in the gel formulation, with the load depending on the size of the toenail to be treated.
Two different drug applicators to be tested on each subject
Single treatment on each toenail; one treatment with one drug applicator design, the second treatment with the alternative drug applicator design
Iontophoretic Dose: 15 mA-min as 0.5 mA for 30 min"
1824894|NCT00768781|Behavioral|Mindfulness-Based Stress Reduction|The rationale for treatment is that MBSR targets arousal, which is a prominent perpetuating factor of insomnia. Each session meets weekly for 120 minutes and consists of a therapist-led mindfulness meditation, followed by a discussion of the meditation and its application into the participant's everyday life. For homework, each participant is required to practice formal meditation at least 45 minutes a day, 6 days per week. Participants will be provided a tape, an mp3 file, or CD to aid in the participant's personal practice at home. Formal meditations that will be led and discussed include eating meditation, body scan, sitting meditation, Hatha Yoga, and walking meditation. In addition, informal mindfulness practices will be discussed.
1824895|NCT00768781|Behavioral|Mindfulness-Based Therapy for Insomnia|MBTI treatment includes the hypothesized active elements of both mindfulness meditation and behavior therapy for insomnia. The intervention includes 8 weekly sessions. Each session meets weekly for approximately 120 minutes. The general format of each session includes formal mindfulness meditation (quiet and movement meditations) and instructions for the behavioral intervention, with a focus on integrating the principles of mindfulness with these instructions. Each participant is required to practice formal meditation for at least 45 minutes a day, 6 days per week as homework. Participants are provided a tape, mp3 file, or CD to aid in the participant's personal practice at home.
1824896|NCT00768781|Behavioral|Wait-List + Behavioral Therapy for Insomnia|This delayed treatment condition consists of an 8-week monitoring period (sleep diaries, PSAS) and then BT. The BT treatment consists of 8 sessions of behavioral interventions for insomnia, with instructions targeting the nighttime symptoms of insomnia. The primary components of this treatment package are stimulus control, sleep restriction, and sleep hygiene education. In the BT condition, each weekly session lasts 120 minutes and consists of formal instructions for the behavioral interventions along with a time for discussion of the application of these instructions into each participant's unique circumstances.
1824897|NCT00768794|Dietary Supplement|Acidophilus|"Use of Acidophilus in the first part of the study, two participants will begin radiation therapy. When signs and symptoms of thrush are noted, such as smooth, creamy, white/yellow coating and/or patches on the tongue and inside of their mouth that are painful, subjects will begin taking acidophilus capsules twice each day until the last day of radiation therapy.
The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region."
1825011|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab at the time of surgery
1824898|NCT00768794|Dietary Supplement|Acidolphilus|The second part of the study is to determine if acidophilus is effective in preventing oral candidiasis (thrush) during radiation therapy to the head and neck region.
1824899|NCT00768807|Device|CPAP (continuous positive airway pressure)|Patients treated by CPAP for 06 months
1824900|NCT00768820|Drug|methylphenidate, fluoxetin, risperidone|first cognitive evaluation without methylphenidate,second cognitive evaluation with methylphenidate
1824901|NCT00768846|Device|Endeavor Resolute Stent|Zotarolimus-eluting Endeavor Resolute Stent
1824902|NCT00768846|Device|Xience V Stent|Everolimus-eluting Xience V Stent
1824903|NCT00768859|Drug|paclitaxel, trastuzumab and carboplatin|paclitaxel; 70 mg/m2 trastuzumab; 2 mg/kg (loading dose 4 mg/kg) carboplatin; AUC = 3
1824904|NCT00768885|Device|PureVision 1|Currently marketed PureVision soft contact lens.
1824905|NCT00768885|Device|PureVision 2|Alternate design soft contact lens.
1824906|NCT00768898|Other|2.5/5.0/10.0 ÂµL lissamine green|vital stain solution
1824907|NCT00768911|Drug|CT-322|"Intravenous solution, intravenous administration, starting dose level of 0.5 mg/kg/week
Dose levels: 0.5 mg/kg/week, 1.0 mg/kg/week, 2.0 mg/kg/week"
1824908|NCT00768911|Drug|Temozolomide|"75 mg/M2/day p.o. continuously 7 days per week during concurrent RT (max: 49 days)
150 mg/M2/day X 5 days; adjuvant cycle #1
200 mg/M2/day X 5 days; subsequent adjuvant cycles (# 2-12) if tolerability criteria met"
1824909|NCT00768911|Procedure|Radiation Therapy|RT will consist of fractionated focal irradiation administered using 2 Gy/fraction, QD x 5 days/week for 6 weeks, for a total dose of 60 Gy
1824910|NCT00768937|Drug|Sorafenib|All patients will receive Sorafenib (800 mg/day) p.o. beginning two weeks before the first TACE and every day thereafter until patient death or premature withdrawal from study.
1824911|NCT00768937|Procedure|Transarterial chemoembolisation (TACE)|TACE will be carried out with doxorubicin (75 - 50 - 25 mg/m2, depending on serum bilirubin levels ≤ 1.5, 1.5 - 3, 3 - 5 mg/dL) : lipiodol (1:1) in a total volume of 20 mL; after administration of doxorubicin:lipiodol, additional embolisation will be carried out with bead block-endospheres. TACE will be repeated every 4 weeks for 3 cycles; additional cycles will be offered if clinically indicated (but no PEI or RF-ablation should be carried out after inclusion into the study)
1824912|NCT00768950|Procedure|Capsule endoscopy examination|Examination of the small bowel with endoscopic videocapsule
1824913|NCT00768950|Procedure|Colonoscopy|Endoscopic examination of the large bowel and terminal ileum
1824914|NCT00760110|Device|blood pressure measurements based on HBP or CBP|To clarify which of HBP or CBP provides the stronger predictive power for the outcomes, the 400 patients were classified as with or without hypertension based on HBP and CBP measurements at baseline
1824915|NCT00760123|Other|Early Physical Therapy and Educational strategy|"Experimental group:
physical therapy including a manual lymph-drainage technique, progressive massage of the scar, and progressive active and action-assisted shoulder exercises started in conjunction with functional activities and proprioceptive neuromuscular facilitation without resistance and Educational strategy including instruction with printed materials about the lymphatic system, concepts of normal load versus overload, lymphedema source, the identification of possible precipitating factors,etc.
Other: control group: only the educational strategy"
1824916|NCT00760136|Procedure|Computed Tomography|CT imaging of bilateral knee
1824917|NCT00760149|Drug|Rifampicin in higher doses|Rifampicin 900 mg (study arm 2), and rifampicin 1200 mg (study arm 3)
1824918|NCT00760175|Biological|Vaxigrip (Aventis-Pasteur Canada)|The intramuscular dose (0.5 mL contains 15 micrograms antigen from each strain and the intradermal doses (2 x 0.1 mL)contain 6 micrograms antigen from each strain.
1824919|NCT00760188|Device|Cementless Oxford Partial Knee|Cementless Oxford Partial Knee Replacement
1824920|NCT00760214|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 40 mg, tablets, orally, once daily for up to 22 weeks.
1824921|NCT00760214|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg, tablets, orally, once daily for two weeks; then increased to 80 mg, tablets, orally, once daily for up to 22 weeks.
1824922|NCT00760214|Drug|Ramipril|Ramipril 2.5 mg, tablets, orally, once daily for two weeks; then increased to 10 mg, tablets, orally, once daily for up to 22 weeks.
1824923|NCT00760227|Other|Massage Therapy|Patient and parents will meet with a licensed massage therapist at the time of admission. During the session, the therapist will introduce them to the rationale of the massage intervention before moving on to provide the initial massage session. Each session will last approximately 1/2 hour. Massage sessions will be scheduled 3x/week from admission through week +3.
1824924|NCT00760227|Other|Humor Therapy|For this component will will utilize a humor cart, stocked with humorous video shorts, books, gags, props and games.
1824925|NCT00760227|Other|Relaxation Therapy|In the initial session held near the time of admission, parents will meet with the RA therapist, who will describe relaxation response and the benefits of a regular practice of relaxation techniques. They will be led through a modified progressive muscle relaxation induction, using breath awareness and muscle release, followed by guided imagery.
1824926|NCT00760266|Drug|Aliskiren|Aliskiren 150 mg for 1 week, Aliskiren 300 mg (with or without amlodipine)for 7 weeks
1824927|NCT00760266|Drug|Hydrochlorothiazide|Hydrochlorothiazide (HCTZ) 12.5 mg for week 1; Hydrochlorothiazide (HCTZ) 25 mg (with or without amlodipine)for 7 weeks
1824928|NCT00760279|Drug|Azithromycin|
1824929|NCT00760305|Behavioral|Pro self pain control programme|A 6 week psychoeducational programme that included three home visits and three phone calls. Patients were taught about pain medication and side effects and about incorrect information regarding cancer pain management
1824930|NCT00760318|Drug|Keppra|There will be flexible dose titration increasing by 250 mg per week for 12 weeks to a maximum of 3000 mg divided BID.
1824931|NCT00760344|Drug|SYR-472|SYR-472 3.125 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
1824932|NCT00760344|Drug|SYR-472|SYR-472 12.5 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
1824933|NCT00760344|Drug|SYR-472|SYR-472 50 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
1824934|NCT00760344|Drug|SYR-472|SYR-472 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
1824935|NCT00760344|Drug|Placebo|SYR-472 placebo-matching tablets, orally, once daily with lifestyle modification and/or metformin therapy for up to 12 weeks.
1824936|NCT00760344|Drug|Sitagliptin|Sitagliptin 100 mg, tablets, orally, once daily with lifestyle modification and/or metformin stable dose therapy for up to 12 weeks.
1824937|NCT00760370|Drug|Zoledronic Acid|4 mg intravenous (iv), one treatment
1824938|NCT00760383|Dietary Supplement|Essential amino acids|Subjects will ingest 20 grams of essential amino acids (EAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the EAA supplement 30 minutes after the end of each PT rehabilitation session.
1824939|NCT00760383|Dietary Supplement|Alanine|Subjects will ingest 20 grams of non-essential amino acid (NEAA) daily for 7 days prior to total knee arthroplasty (TKA) surgery and for 14 days after surgery daily. On the days they are seen by physical therapy (PT) they will ingest the NEAA supplement 30 minutes after the end of each PT rehabilitation session.
1824940|NCT00760396|Drug|VGX-1027|Subjects will
1824941|NCT00760422|Device|NIR|Thermometer
1824942|NCT00760435|Drug|Infliximab|5 mg/kg IV over 2 hours once
1824943|NCT00760435|Drug|Placebo|Placebo (same volume as active drug)
1824944|NCT00760448|Drug|insulin detemir|
1824945|NCT00760448|Drug|insulin NPH|
1824946|NCT00760461|Drug|Domperidone|10 mg 4 times daily 20 mg 4 times daily 30 mg 4 times daily
1824947|NCT00760474|Drug|Pregabalin, then placebo|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
1824948|NCT00760474|Drug|Placebo, then pregabalin|Placebo and pregabalin will be given orally twice daily in capsules at different times during the course of the study. The highest dose of pregabalin to be used in the study is 450 mg/day.
1824949|NCT00760487|Device|AcrySof Toric IOL|Implantation with the AcrySof Toric IOL for cataract replacement and multiple follow-up assessments
1824950|NCT00760500|Other|Nasopharyngeal Swab|Nasopharyngeal Swab
1824951|NCT00760513|Drug|OMACOR|4 grammes daily, oral capsule
1824952|NCT00760526|Device|Continuous glucose monitor|Daily use of a continuous glucose monitor
1824953|NCT00760526|Device|Home blood glucose monitor|Home monitoring 3 or more times a day
1824954|NCT00760539|Drug|Travoprost 0.004%/Timolol 0.5% BAC-free ophthalmic solution|
1824955|NCT00760539|Drug|Travoprost 0.004%/Timolol 0.5% ophthalmic solution|
1824956|NCT00760552|Other|High Intensity Intervention|High Intensity patients will be seen by the pharmacist at 3-6 month intervals, depending upon if patient is at goal BP. During these visits, the pharmacist will: 1) review barriers to BP control; 2) assess progress toward overcoming such barriers; 3) determine adherence; and 4) assess potential side effects. If the BP is at goal, the patient will be given encouragement and told to continue the regimen. If the BP is not at goal, the pharmacist will develop a new treatment strategy. If the treatment changes were in the plan negotiated with the physician, the PCP will simply be informed. If new changes are recommended, the pharmacist will develop a new treatment plan and review it with the PCP.
1824957|NCT00760552|Other|Low Intensity Intervention|Low intensity group will receive management by their PCP and a 3-part intervention that was effective in a recent VA study. This one-time intervention will occur 3 months after completion of the initial 6-month pharmacist intervention and will include: Provider education including an email message to re-evaluate the specific patient's BP regimen and a web link to the VA/JNC-7 hypertension guidelines. 1-time patient-specific computerized alert reminding the PCP of the goal BP, values of the patient's last 3 BP assessments, & possible options for medication changes if BP does not remain at goal. Patient education including a personalized letter with information on strategies to improve BP control, including medication adherence, Dietary Approaches to Stop Hypertension (DASH) diet/exercise. The letter will note that many patients require more than one medication and will provide a link to the VA patient education web library and American Heart Association (AHA) site.
1824958|NCT00760552|Other|All- 6 month pharmacist intervention|All patients will receive the initial 6-month pharmacist intervention. The intervention: 1) co-management of HTN by pharmacists can improve BP control; and 2) active follow-up is needed to reinforce progress and proactively identify and resolve problems. The intervention will include structured visits at baseline 1, 2, 4, and 6 months after baseline and telephone calls at 2 weeks and between the visits. At baseline, the pharmacist will review the computerized patient record system (CPRS) medical record and perform a structured interview, including: a detailed medication history of all prescription and non-prescription therapies; an assessment of patient knowledge of all meds, the purpose of each med, medication dosages and timing, and potential side effects; potential contraindications to specific medications; and expectations for future dosage changes and of the need for future monitoring potential barriers to BP control.
1824959|NCT00760565|Drug|RO4905417|3mg/kg iv every 28 days for 3 infusions
1824960|NCT00760565|Drug|RO4905417|20mg/kg iv every 28 days for 3 infusions
1824961|NCT00760565|Drug|RO4905417|7mg/kg iv every 28 days for 3 infusions
1824962|NCT00760565|Drug|placebo|3mg/kg iv every 28 days for 3 infusions
1824963|NCT00760565|Drug|placebo|7mg/kg iv every 28 days for 3 infusions
1824964|NCT00760565|Drug|placebo|20mg/kg iv every 28 days for 3 infusions
1824965|NCT00760578|Drug|Placebo|Once daily, oral
1824966|NCT00760578|Drug|Pioglitazone|Once daily, oral
1824967|NCT00760578|Drug|MSDC-0160 90 mg|Once daily, oral
1824968|NCT00760578|Drug|MSDC-0160 220 mg|Once daily, oral
1824969|NCT00760604|Procedure|Esophagectomy|Comparison of en-bloc vs. non-en bloc esophagectomy
1824970|NCT00760617|Biological|GSK Bio's influenza vaccine GSK2186877A|Intramuscular (IM) administration, 1 dose
1824971|NCT00760617|Biological|Fluarix|Intramuscular (IM) administration, 1 dose
1824972|NCT00760630|Device|FFR/CFR and IVUS|All patients with clinical indication for cardiac cath will have FFR and IVUS
1825012|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, twice daily, 96 weeks
1825013|NCT00768989|Drug|Raltegravir|Tablet, Oral, 400 mg, twice daily, 96 weeks
1825014|NCT00768989|Drug|Atazanavir|Capsules, Oral, 300 mg, once daily, 96 weeks
1825015|NCT00768989|Drug|Ritonavir|Capsules, Oral, 100 mg, once daily, 96 weeks
1825016|NCT00768989|Drug|Tenofovir/Emtricitabine|Tablet, Oral, 300-mg Tenofovir/200-mg Emtricitabine, once daily, 96 weeks
1824973|NCT00760669|Drug|Infliximab; observational study|This is an observational study. Participants with RA, AS and PA receiving induction intravenous infusions (a fluid or a medicine delivered into a vein by way of a needle) of infliximab will be observed. Participants with RA will receive infliximab 3 milligram per kilogram (mg/kg) as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks (maintenance) thereafter up to 30 weeks. Participants with AS and PA will receive 5 mg/kg infliximab as an intravenous infusion over 2-hour period followed by additional doses at 2 and 6 weeks up to 24-30 weeks and 30 weeks, respectively.
1824974|NCT00760669|Drug|Methotrexate; observational study|Participants with RA will receive methotrexate based on physician's clinical judgement.
1824975|NCT00760682|Procedure|Hyperbaric oxygen|30 preoperative and 10 postoperative HBO sessions 90 minutes each. Sequestrectomy is performed after 30 sessions.
1824976|NCT00760695|Drug|dronabinol|tablets, twice daily, for 4 weeks
1824977|NCT00760695|Drug|placebo|tablets, twice daily, for 4 weeks
1824978|NCT00760721|Behavioral|Educational Small Group Session|1 hour small group health-related discussion
1824979|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT at 1.5 ATA/60 minutes twice/day, five days/week for 40 or 80 treatments
1824980|NCT00760734|Drug|Low pressure hyperbaric oxygen therapy|HBOT: 1.5 ATA/60 minutes twice/day, 5 days/week for 40 or 80 treatments
1824981|NCT00760747|Drug|Atomoxetine|1.2 mg/kg/day up to 1.8 mg/kg/day, orally (PO)
1824982|NCT00760760|Drug|reesterified long-chain n-3 polyunsaturated fatty acids (EPA, DHA)|4g daily, 8 weeks
1824983|NCT00760760|Drug|control|equivalent amount of fat as butter
1824984|NCT00760773|Drug|Lacidophil (experimental high dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the high dose which will consist of 4 billion CFU (1 active sachet) PO BID (total daily dose = 8 billion CFU) x 5 days.
1824985|NCT00760773|Drug|Lacidophil (experimental standard dose)|Each sachet will contain a minimum of 4 billion CFU/sachet. The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated. Subjects in this arm will receive the standard dose which will consist of 4 billion CFU (1 active sachet) PO QAM (total daily dose = 4 billion CFU) plus 1 placebo sachet PO QHS x 5 days.
1824986|NCT00760773|Drug|Placebo|The total weight of all ingredients is 1 gm. All patients in this arm of the study will take 1 sachet twice daily for 5 days. Doses should be ideally separated by 12 hours (minimum of 8 hours) and taken within 30 minutes of food/drink. If the child vomits within 15 minutes of medication administration (initial or subsequent dose), the dose will be repeated.
1824987|NCT00760786|Drug|Intensive lipid lowering plus Omega3-fatty acid|Atorvastatin 40mg qd plus Omega3-fatty acid 2.0mg qd
1824988|NCT00760786|Drug|Moderate lipid lowering plus Omega3-fatty acid|atorvastatin 10mg qd plus Omega3-fatty acid 2.0mg qd
1824989|NCT00760786|Drug|Intensive lipid lowering plus placebo|atorvastatin 40mg qd
1824990|NCT00760786|Drug|Moderate lipid lowering plus placebo|atorvastatin 10mg qd
1824991|NCT00760799|Procedure|Discectomy with anular repair|Comparison of discectomy with and without repair to the anulus fibrosus of the intervertebral disc
1824992|NCT00760812|Behavioral|Early Social Interaction Project- PII|The PII is an intensive, individualized treatment that teaches parents how to support social communication skills in children with autism by embedding skills practice within everyday routines, activities, and places. Participants will have three 75-minute sessions weekly with study administrators for the first 7 months of the study. Participants will then have two sessions per week for the final 2 months of the study. Children will also practice socialization embedded in normal activities for 25 hours a week outside of study visits.
1824993|NCT00760812|Behavioral|Early Social Interaction Project- IES|The IES intervention provides access to a support group meeting twice monthly for children with autism and their parents. The support group provides information to families and a playgroup where parents may practice intervention strategies under the supervision of study officials knowledgeable about autism spectrum disorders.
1824994|NCT00760825|Biological|killed bivalent (O1 and O139)whole cell oral cholera vaccine|1.5 ml given twice orally, 14 days apart
1824995|NCT00760838|Drug|Azithromycin 250 mg|Azithromycin 250 mg three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
1824996|NCT00760838|Drug|Placebo|Placebo three times a week during treatment period (6 months); run-in period of 2 weeks; wash-out period of 4 weeks
1824997|NCT00760851|Other|probiotic strain Bb-12|10^9 CFU Bb-12 per 4 oz yogurt
1824998|NCT00760851|Other|no Bb-12|yogurt identical to intervention yogurt, only without Bb-12 added.
1824999|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 25 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
1825000|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 50 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
1825001|NCT00760864|Drug|TAK-715 and methotrexate|TAK-715 100 mg, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks.
1825002|NCT00760864|Drug|Methotrexate|TAK-715 placebo-matching, tablets, orally, twice daily and methotrexate stable dose for up to 6 weeks
1825003|NCT00760877|Drug|Nilotinib|Supplied in 200 mg capsules
1825004|NCT00760877|Drug|Imatinib|Supplied in 100 mg and 400 mg capsules
1825005|NCT00760890|Dietary Supplement|Fer-In-Sol (ferrous sulfate)|7.5 mg/day in the form of 0.3 ml once each day
1825006|NCT00760890|Dietary Supplement|Iron fortified cereal|1 jar each day of one of three wet pack cereals manufactured by the Gerber Company: Each jar provided 7 mg of ferrous sulfate.
1825007|NCT00760903|Other|Conventional MRI of the brain|
1825008|NCT00760903|Other|MR spectroscopy (MRS)|
1825009|NCT00760903|Other|MR Diffusion Tensor Imaging (DTI)|
1825010|NCT00768963|Drug|ranibizumab|0.5 mg subconjunctival ranibizumab 3 days prior to surgery
1825018|NCT00769015|Behavioral|BA-LVR|Low vision clinic-based optometry plus 6 in-home occupational therapy visits
1825019|NCT00769015|Behavioral|ST-LVR|Clinic-based low vision optometry plus 6 in-home sessions of Supportive Therapy
1825020|NCT00769028|Drug|Hyperimmune caprine serum|Subcutaneous injection of serum, 1ml twice weekly for 6 months
1825021|NCT00769028|Drug|Albumin|Subcutaneous injection of albumin, 1ml twice weekly for 6 months
1825022|NCT00769041|Drug|moxifloxacin|400mg
1825023|NCT00769041|Drug|avanafil|100mg single dose
1825024|NCT00769041|Drug|avanafil|800mg single dose
1825025|NCT00769041|Drug|sugar pill|single dose
1825026|NCT00769054|Drug|Ropivacaine|Local Infiltration Analgesia with 1 % Ropivacaine
1825027|NCT00769054|Drug|Isotonic NaCl|Local Infiltration with NaCl
1825028|NCT00769067|Drug|Erlotinib|Continuous oral dosing at 150 mg daily.
1825029|NCT00769067|Drug|PF-00299804|Continuous oral dosing at 45mg daily
1825030|NCT00769093|Drug|Ferumoxytol|2 mg/kg
1825031|NCT00769106|Biological|cytokine-induced killer cell (CIK) treatment|cytokine-induced killer cell treatment every two weeks, for 4 cycles
1825032|NCT00769119|Drug|AZD9668|2 x 30 mg, oral tablet, twice daily for 28 days
1825033|NCT00769119|Drug|Placebo|2 x Matched placebo, oral tablet, twice daily for 28 days
1825034|NCT00769132|Drug|Comparator: niacin + laropiprant|ER niacin 2 g/laropiprant 40 mg tablet once daily for 7 days
1825035|NCT00769132|Drug|Comparator: niacin|ER niacin 2 g tablet once daily for 7 days
1825036|NCT00769132|Drug|Comparator: laropiprant|laropiprant 40 mg once daily for 7 days
1825037|NCT00769132|Drug|Comparator: placebo|matching placebo tablets for each of the interventions once daily for 7 days
1825038|NCT00769145|Drug|Ranibizumab|0.5mg subconjunctival dose of ranibizumab 3 days prior to corneal transplantation and at the time of corneal transplantation (total 2 injections).
1825039|NCT00769158|Drug|Topiramate and Naltrexone|Topiramate 200 mg and Naltrexone 50 mg
1825040|NCT00769158|Other|Placebo|Placebo Comparator
1825041|NCT00769171|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin 400 mg every 24 h
1825042|NCT00769171|Drug|Ceftriaxone + Metronidazole|Ceftriaxone 2 g every 24 h and Metronidazole 500 mg every 12 h
1825043|NCT00769184|Drug|Corticosteroid|"One side of body:
clobetasol: 2 applications / day along with LCD application 2 applications/day"
1825044|NCT00769184|Other|Placebo|"One side of body:
Placebo Solution: 2 applications / day along with clobetasol 2 applications/day"
1825045|NCT00769184|Drug|LCD|"One side of body:
LCD Solution: 2 applications / day along with clobetasol 2 applications/day"
1825046|NCT00769210|Drug|Simvastatin|Simvastatin 40 mg tablet
1825047|NCT00769223|Other|medical chart review|
1825048|NCT00769223|Other|questionnaire administration|
1825049|NCT00769223|Procedure|quality-of-life assessment|
1825050|NCT00769223|Radiation|brachytherapy|
1825051|NCT00769223|Radiation|radiation therapy|
1825052|NCT00769236|Other|Blood sampling and biopsy|Biopsy and blood : Research for various antibodies
1825053|NCT00769236|Other|Biopsy and blood sampling|Biopsy and blood : research for various antibodies
1825054|NCT00769236|Other|Biopsy and blood sampling|Blood and biopsy : research for various antibodies
1825055|NCT00769249|Other|questionnaire administration|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
1825056|NCT00769249|Other|study of socioeconomic and demographic variables|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
1825057|NCT00769249|Procedure|psychosocial assessment and care|Patients and their caregivers complete three questionnaires that will take approximately 20 minutes either by mail or telephone. The questionnaires comprise of demographic and psychosocial correlates of posttraumatic growth including age, ethnicity, socioeconomic status, education, anxiety, relationship quality, coping style, social support, and cultural beliefs about caring for elders.
1825058|NCT00769262|Other|Conservative weaning|Infants will not be weaned from the isolette until their feeds are at full calorie goal (120 kcal/kg/day) and at least half of feeds are taken orally.
1825059|NCT00769262|Other|Aggressive Weaning|Infants will be weaned from the isolette based solely on their temperature without regard to feed status (current standard of care in our NICU)
1825060|NCT00769288|Drug|2'-F-ara-deoxyuridine|Given IV
1825061|NCT00769288|Other|positron emission tomography|Correlative studies
1825062|NCT00769288|Other|laboratory biomarker analysis|Correlative studies
1825063|NCT00769288|Other|pharmacological study|Correlative studies
1825064|NCT00769288|Other|pharmacogenomic studies|Correlative studies
1825065|NCT00769418|Drug|odanacatib|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.
Panel A: odanacatib tablets 2.5 mg qd for 14 days.
Panel B: odanacatib tablets 5 mg qd for 14 days.
Panel C: odanacatib tablets 10 mg qd for 14 days.
Panel D: odanacatib tablets 25 mg qd for 14 days.
Panel E: odanacatib tablets 0.5 mg qd for 21 days.
Panel F: odanacatib tablets 2.5 mg qd for 21 days.
Panel G: odanacatib tablets 10 mg qd for 21 days."
1825066|NCT00769418|Drug|Comparator: Placebo|"Panels A, B, C, and D will enroll males only; Panels E, F, and G will enroll females only.
Panel A: placebo to odanacatib tablets 2.5 mg qd for 14 days.
Panel B: placebo to odanacatib tablets 5 mg qd for 14 days.
Panel C: placebo to odanacatib tablets 10 mg qd for 14 days.
Panel D: placebo to odanacatib tablets 25 mg qd for 14 days.
Panel E: placebo to odanacatib tablets 0.5 mg qd for 21 days.
Panel F: placebo to odanacatib tablets 2.5 mg qd for 21 days.
Panel G: placebo to odanacatib tablets 10 mg qd for 21 days."
1825067|NCT00769431|Other|educational intervention|
1825068|NCT00769431|Other|study of socioeconomic and demographic variables|
1825069|NCT00769457|Device|Access Arm|Active OptiVol-System with CareAlert via CareLink
1825070|NCT00769470|Biological|trastuzumab|Given IV
1825073|NCT00769470|Drug|lapatinib ditosylate|Given orally
1825074|NCT00769483|Drug|MK-0646|Starting Dose Level: 5 mg/kg given intravenously over 60 minutes Days 1, 8, 15, 22 of 28 Day Cycle.
1825075|NCT00769483|Drug|Gemcitabine|1000 mg/m^2 given intravenously over 1-1/2 hours Days 1, 8, and 15 of each 28 Day Cycle.
1825076|NCT00769483|Drug|Erlotinib|100 mg by mouth daily.
1825077|NCT00769496|Drug|BAY 77-1931|Lanthanum Carbonate (BAY 77-1931)
1825078|NCT00769509|Other|energy expenditure in preterm fed with preterm formula|Assessment of energy expenditure by indirect calorimetry in preterm infant fed with preterm formula 24 hours before measurements.
1825079|NCT00769509|Other|assessment of energy expenditure|assessment of energy expenditure in preterm infant during fed with human milk with fortifier
1825080|NCT00769522|Biological|Rituximab|"cycle 1: 375 mg/m² i.v., day 0, q28d
cycle 2-6: 500 mg/m² i.v., day 1, q28d"
1825081|NCT00769522|Drug|Bendamustine|cycle 1-6: 90mg/m² i.v., day 1-2, q28d
1825082|NCT00769522|Drug|Cyclophosphamide|cycle 1-6: 250 mg/m² i.v., days 1-3, q28d
1825083|NCT00769522|Drug|Fludarabine|cycle 1-6: 25 mg/m² i.v., days 1-3, q28d
1825084|NCT00769535|Genetic|Polymorphisms of HSP70 and TNF promoter|To assess the relationship between clinical relevance and polymorphisms of HSP70 and tumor necrosis factor-alpha with PCR_RFLP
1825085|NCT00769548|Drug|flutamide|Drug used for TAS.
1825086|NCT00769548|Drug|goserelin acetate|Drug used for TAS.
1825087|NCT00769548|Radiation|low-LET photon therapy|radiation therapy
1825088|NCT00769561|Behavioral|Biofeedback-Based Cognitive Behavioral Treatment|The biofeedback-based cognitive behavioral intervention comprises 8 individual sessions, each containing both cognitive behavioral and biofeedback elements. Treatment elements are education about the disorder, biofeedback training aimed at improving proprioceptive awareness and reversing parafunctional habits, relaxation techniques, and stress management. Furthermore patients receive portable biofeedback devices for EMG-biofeedback training during day and nighttime in order to reverse diurnal and nocturnal bruxing habits.
1825089|NCT00769561|Device|Dental treatment with occlusal splint (OS)|Maxillary or mandibular occlusal splints are made of hard acrylic after taking impressions of the upper and lower dental arches, face bow registration and recording of centric relation. Splints are adjusted to provide even occlusal contact during jaw closing and chewing, and canine and incisor contact during protrusive movements of the jaw. Patients are instructed to use the splint each night and during day time for a period of 7 weeks. One week after initial insertion of the splint patients are requested to return for adjustment.
1825090|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
1825091|NCT00769574|Other|Biological analysis of biomarkers|Biological analysis of biomarkers
1825092|NCT00769587|Drug|thalidomide|
1958605|NCT01462292|Drug|GSK2402968 6 mg/kg/week|Comparison of 2 doses of GSK2402968
1958606|NCT01462292|Drug|Placebo to match GSK2402968 3 mg/kg/week|Matched placebo
1825095|NCT00769613|Biological|cytomegalovirus IE-1-specific cytotoxic T lymphocytes|
1825096|NCT00769613|Biological|cytomegalovirus pp65-specific cytotoxic T lymphocytes|
1825097|NCT00769613|Biological|therapeutic allogeneic lymphocytes|
1825098|NCT00769613|Genetic|polymerase chain reaction|
1825099|NCT00769613|Other|flow cytometry|
1825100|NCT00769613|Other|immunological diagnostic method|
1825101|NCT00769613|Other|laboratory biomarker analysis|
1825102|NCT00769626|Other|Usual Care|Patients in the usual care group will receive advice and education to remain active and anticipate a favorable prognosis. Patients will also receive medication from the primary care provider consistent with current evidence-based guidelines(acetaminophen or non-steroidal anti-inflammatories). Consistent with current practice guidelines, patients will be instructed to return to the primary care provider if they are not satisfied with their progress after 4 weeks.
1825103|NCT00769626|Other|Early Treatment|Patients in the early treatment group will receive the usual care intervention (advice and education, and medication consistent with current evidence-based guidelines). Patients will also be referred to physical therapy for 4 sessions over a 3-week period. A standardized protocol will be used in physical therapy including spinal manipulation and trunk strengthening exercises. Patients will be instructed to return to the primary care provider if they are not satisfied with their progress after completion of the 4 sessions.
1825104|NCT00769652|Behavioral|Medical nutrition therapy|Medical nutrition therapy (MNT) refers to intervention with a registered dietitian or nutrition professional. MNT is a cyclical process which includes nutrition assessment, intervention, follow-up, and reassessment. Patients will receive a total of three (3) visits with the dietitian over a six-week period with follow-up during weeks 2-3 and weeks 6-9 based on their treatment schedule.
1825105|NCT00769652|Behavioral|Standard Care|"Standard nutritional care includes the National Cancer Institute's booklet Eating Hints for cancer patients: before, during & after treatment."
1825106|NCT00769665|Other|Systane Ultra|Re-wetting ocular eye drop
1825107|NCT00769665|Other|Sensitive Eyes Rewetting Drops|Re-wetting ocular eye drop
1825108|NCT00769678|Device|Stimulation of the diaphragm|Stimulation of the diaphragm using an electrode
1825109|NCT00769704|Biological|Talimogene laherparepvec|Up to 4 mL of 10⁸ pfu/mL/per intratumoral injection
1825110|NCT00769704|Biological|GM-CSF|125 µg/m² subcutaneous injection
1825111|NCT00769717|Behavioral|Wellness-Centered (HUGS)|A health at every size intervention, the HUGS program was conceived and developed in 1987 by Linda Omichinski, Registered Dietitian. HUGS stands for Health focused, Understanding lifestyle, Group supported, and Self-esteem building. It is an integrated approach that promotes healthy eating, active living, and self acceptance regardless of weight. HUGS teaches strategies to recognize and respond to physiological signs of hunger and satiety to determine food intake. The manualized curriculum is accompanied by the books Tailoring Your Tastes and Staying Off of the Diet Roller Coaster which participants will receive in addition to a booklet of handouts. Kelly Bliss, a psychotherapist and fitness professional with 17 years experience in health-centered approaches for weight management, will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
1825148|NCT00770016|Drug|Levothyroxin|Dosage regulation will follow the local recommendations of treatment
1958607|NCT01462292|Drug|Placebo to match GSK2402968 6 mg/kg/week|Matched Placebo
1825112|NCT00769717|Behavioral|Weight-Centered (LEARN)|The LEARN Program for Weight Management is an evidence-based behavior modification approach to weight loss developed by Dr. Kelly Brownell, Ph.D. Psychologist. LEARN is an acronym that stands for Lifestyle, Exercise, Attitudes, Relationships, and Nutrition. This manualized curriculum shares many principals with the HUGS program in that both emphasize the importance of healthy lifestyle choices and gradual sustainable change. However, the LEARN program makes weight loss an explicit goal and focuses more on food intake levels based on external prescriptions and caloric restriction. Participants in the LEARN program will receive the LEARN Program for Weight Management manual and the LEARN Weight Stabilization and Maintenance Guide along with the LEARN Program CD set. Ann Wellock, a Registered Dietician from The Reading Hospital and Medical Center will deliver the intervention in 2 groups of 20 people that meet weekly for 6 months.
1825113|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of cognitive behavioral therapy delivered weekly over a period of 3 months.
1825114|NCT00769769|Behavioral|Psychotherapy|Participants will receive 12 sessions of telephone-based cognitive behavioral therapy delivered weekly over 3 months.
1825115|NCT00769782|Procedure|therapeutic conventional surgery|All patients undergo suegery to achieve macroscopic complete resection within 28 days after enrollment (including enrollment day). As long as tumor free margin is ensured, all resection margin distances and all surgical procedure are accepted. Surgical treatment in this study excludes the following, radiofrequency ablation (RFA) without resection of liver only or microwave coagulation therapy (MCT) only; for RFA or MCT is used as additional treatment under judgment of primary physician for new liver tumor which comfirmed during surgery in different parts of liver except portion scheduled for resection, RFA and MCT are included. After histological curative resection, patients are observed without treatment until comfirming recurrence. Patients with incomplete tumor removal are withdrawn from protcol treatment and receive imatinib treatment, 400 mg/day orally. For reccurrence is comfirmed, patients receive imatinib treatment, 400 mg/day orally.
1825116|NCT00769795|Drug|IMC-A12|IMC-A12 will be administered every 2 weeks for a total of 6 doses at 10 mg/kg per dose. The last dose of IMC-A12 will be at least 2 weeks prior to prostatectomy.
1825117|NCT00769795|Drug|Bicalutamide|Bicalutamide 50 mg daily orally for 12 weeks
1825118|NCT00769795|Drug|Goserelin|10.8 mg subcutaneous once
1825119|NCT00769821|Other|questionnaire administration|
1825120|NCT00769821|Procedure|assessment of therapy complications|
1825121|NCT00769821|Procedure|bioimpedance spectroscopy|
1825122|NCT00769821|Procedure|quality-of-life assessment|
1825123|NCT00769847|Procedure|Endoscopic strip craniectomy|Surgery
1825124|NCT00769860|Drug|Arimoclomol|Arimoclomol 100 mg TID for 4 months
1825125|NCT00769860|Other|Placebo|Placebo for 4 months
1825126|NCT00769873|Drug|Enoxaparin|Lovenox 40mg SC daily (30mg SC daily if creatinine clearance < 30) for 21 days
1825127|NCT00769886|Drug|Ketotifen/naphazoline|One drop of ketotifen/naphazoline in study eye at visit 3 and visit 4.
1825128|NCT00769886|Drug|Ketotifen|One drop of Ketotifen in study eye at visit 3 and visit 4.
1825129|NCT00769886|Drug|Naphazoline|One drop of naphazoline in study eye at vist 3 and visit 4.
1825130|NCT00769886|Drug|Vehicle|One drop of vehicle in study eye at visit 3 and visit 4.
1825131|NCT00769899|Drug|AZD7325|Capsule for oral, single dose
1825132|NCT00769899|Drug|Placebo|Placebo capsule for oral, single dose
1825133|NCT00769912|Drug|50% N2O- 50%O2 mixture|50% N2O- 50%O2 mixture administration
1825134|NCT00769912|Drug|Placebo (air)|Placebo administration during the intervention
1825135|NCT00769925|Behavioral|Cognitive Behavior Therapy-Primary Care|Children will receive cognitive behavioral therapy from a child anxiety specialist at their doctor's office (the primary care clinic). The children will learn skills to cope with fear and anxiety, and parents will learn how to support their children in using these new skills.
1825136|NCT00769925|Behavioral|Therapist-Assisted Bibliotherapy-Primary Care|Parents will receive educational workbooks and ongoing support over the phone from a child anxiety specialist to learn how to use cognitive behavioral therapy skills to manage their children's fears and worries.
1825137|NCT00769938|Device|PCI (percutaneous coronary intervention)|only patients scheduled for PCI can be included tough this intervention would also take place without this study. What we want to study is the difference in outcome after a little change in the antithrombotic treatment
1825138|NCT00769951|Other|medical chart review|Data will be obtained from patients medical records at baseline, 6 months, 1 year, and 3 years.
1825139|NCT00769951|Other|questionnaire administration|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care. The assessments include the Lawton's nine-item Instrumental Activities of Daily Living (IADL); the Katz's Activity of Daily Living (ADL); the Timed Up and Go Test; the Karnofsky Physician-Rated Performance Rating Scale (KPS); the number of falls in the past 6 months; the Mini Nutritional Assessment (MNA); the Body Mass Index; the percent of unintentional weight loss in the past 6 months; the Medical Outcomes Study (MOS) Social Support Subscale (emotional/information and tangible subscales); the MOS Social Activity Limitations Measures; the Charlson Comorbidity Index; the Cumulative Index Rating Scale Geriatrics (CIRS-G); the ACE-27; the Folstein's Mini-Mental State Examination (MMSE); the Geriatric Depression Scale (GDS); the Functional Pain Scale; and a list of medications.
1825140|NCT00769951|Procedure|cognitive assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
1825141|NCT00769951|Procedure|psychosocial assessment and care|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
1825142|NCT00769951|Procedure|quality-of-life assessment|Patients undergo a 1-hour comprehensive geriatric assessment at baseline and periodically during the study as part of routine care.
1825143|NCT00769964|Drug|VA111913 TS / placebo|
1825144|NCT00769990|Dietary Supplement|genistein|Genistein will be taken orally once daily as 500 mg capsules throughout the study (60 days).
1825145|NCT00769990|Radiation|radiation therapy|A course of palliative external beam radiation therapy -performed within 8 weeks prior to start of the study.
1825146|NCT00770003|Drug|AZD8848|nasal spray solution; 30 or 60 µg administered intranasally once weekly for one month
1825147|NCT00770003|Drug|Placebo|nasal spray solution. Once weekly intranasal administrations for one month.
1825149|NCT00770029|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
1825150|NCT00770029|Drug|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
1825151|NCT00770042|Drug|Ritonavir|Ritonavir 300 mg bid for 1 day (Day 2), 400 mg bid for 1 day (Day 3), 600 mg bid for 5 days (Day 4-8)
1825152|NCT00770042|Drug|Ketoconazole|Ketoconazole 400 mg qd for 5 days (Days 2-6)
1825153|NCT00770042|Drug|Erythomycin|Erythromycin 500 mg every 12 hours for 5 days (Days 2-6)
1825154|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 8
1825155|NCT00770042|Drug|Avanafil|Avanafil 50 mg on Days 1 and 6
1825156|NCT00770042|Drug|Avanafil|Avanafil 200mg Days 1 and 6
1825157|NCT00770055|Other|medical chart review|
1825158|NCT00770055|Other|questionnaire administration|
1825159|NCT00770055|Other|survey administration|
1825160|NCT00770055|Procedure|psychosocial assessment and care|
1825161|NCT00770081|Drug|vildagliptin|50mg qd
1825162|NCT00770081|Drug|sitagliptin|25mg qd
1997152|NCT02206035|Drug|Methotrexate|Methotrexate will be dosed at 15 mg/m2 Day +1 and 10mg/m2 Days +3, +6 and +11
1997153|NCT02206035|Drug|Tocilizumab|Tocilizumab will be administered intravenously at a dose of 8 mg/kg at Day -1
1825166|NCT00770107|Drug|Thiamine|Supplementation of thiamine (vitamin b1) 300 mg per day, once daily, for a duration of 4 weeks
1825167|NCT00770107|Drug|Placebo|Placebo, once daily, for a duration of 4 weeks
1825168|NCT00770120|Drug|everolimus|
1825169|NCT00770133|Drug|Ketotifen/naphazoline|One drop of ketotifen fumarate 0.025% and naphazoline HCl 0.05% ophthalmic solution at visit 3 and visit 4.
1825170|NCT00770133|Drug|Naphazoline|One drop of naphazoline HCl 0.05% ophthalmic solution at visits 3 and 4.
1825171|NCT00770133|Drug|Ketotifen|One drop of ketotifen fumarate 0.025% ophthalmic solution at visits 3 and 4.
1825172|NCT00770133|Drug|Vehicle|One drop of vehicle ophthalmic solution at visit 3 and visit 4.
1825173|NCT00770146|Drug|Mipomersen sodium|200 mg/mL
1825174|NCT00770146|Drug|Placebo|1 mL matching placebo (i.e., vehicle consisting of 9 mg of sodium chloride, 0.004 mg of riboflavin, filled to 1 mL with water).
1825175|NCT00770159|Drug|odanacatib|Panel A: MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: MK0822 tablets 100 mg once weekly for 6 weeks.
1825176|NCT00770159|Drug|Comparator: placebo to MK0822|Panel A: placebo to MK0822 tablets 25 mg once weekly for 3 weeks. Panel B: placebo to MK0822 tablets 50 mg once weekly for 3 weeks. Panel C: placebo to MK0822 tablets 100 mg once weekly for 3 weeks. Panel D: placebo to MK0822 tablets 5 mg once weekly for 3 weeks. Panel E: placebo to MK0822 tablets 100 mg once weekly for 6 weeks.
1825177|NCT00770172|Biological|filgrastim|Given subcutaneously
1825178|NCT00770185|Drug|ridaforolimus|oral ridaforolimus 40 mg days 1-5 each week (once daily for 5 consecutive days every week; cycle arbitrarily defined as a 4 week period)
1825179|NCT00770185|Genetic|gene expression analysis|
1825180|NCT00770185|Other|immunohistochemistry staining method|
1825181|NCT00770185|Other|laboratory biomarker analysis|
1825182|NCT00770211|Drug|IncobotulinumtoxinA (Xeomin) (20 Units)|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. The total dose of 20 Units IncobotulinumtoxinA (Xeomin) is reconstituted in a total injection volume of 0.5 mL that is to be injected to the five sites in equal aliquots of 0.1 mL.
1825183|NCT00770211|Drug|Placebo|The treatment will be administered only once at day 0 at five injection sites in the glabellar area. Volume of Placebo equivalent to IncobotulinumtoxinA (Xeomin).
1825184|NCT00770224|Biological|rituximab|
1825185|NCT00770224|Biological|tositumomab|
1825186|NCT00770224|Drug|cyclophosphamide|
1825187|NCT00770224|Drug|doxorubicin|
1825188|NCT00770224|Drug|prednisone|
1825189|NCT00770224|Drug|vincristine|
1825190|NCT00770224|Radiation|tositumomab|
1825191|NCT00770237|Behavioral|Smoking Cues|In the smoking cue condition, a pack of the participants preferred brand of cigarettes, a lighter, and an ashtray will be under the tray cover. In the neutral cue condition, a pack of unsharpened pencils, a pencil sharpener, and a small notepad will be under the cover. When instructed, the participant will lift the cover on the tray. In the smoking cue condition, participants will take one cigarette out of the pack, light it without puffing, hold it for 1 minute, extinguish the cigarette, and replace the cover on the tray.
1825192|NCT00770237|Behavioral|Neutral Cues|In the neutral cue condition, participants will take one pencil out of the pack, sharpen it, hold it for 1 minute as if to write on the notepad, and then replace the cover. Participants will complete the VAS during cue exposure and the TCQ-SF, VAS, and mood form immediately and 15 minutes after cue presentation; physiological measures will be recorded continuously.
1825193|NCT00770263|Drug|Erlotinib|
1825194|NCT00770263|Drug|Temsirolimus|
1825195|NCT00770289|Other|Cohort|Cohort (Patients diagnosed with MDD who are either changing treatment or have never received treatment).
1825196|NCT00770302|Drug|Saxagliptin|Oral tablet, once daily for 1 (single-dose) and 5 (multiple-dose) days
1825197|NCT00770315|Biological|Ambrosia artemisiifolia allergen extract (Amb a 1-U)|Rapidly dissolving tablet administered sublingually once daily, at a dose of 1.5, 6 or 12 units.
1825198|NCT00770315|Biological|Placebo|Placebo matching Ambrosia artemisiifolia allergen extract rapidly dissolving tablet, administered sublingually once daily
1997154|NCT02205541|Drug|Eculizumab|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28. According to the length of initial hospital stay, patients may have the remaining injections in the day ward of the recruiting center. Dosage of ECZ will be based on previous trials using ECZ in pediatric aHUS patients.
ECZ or placebo will be administrated intravenously as a 30-minute injection"
1825325|NCT00771017|Drug|bicalutamide|Given orally
1825204|NCT00770354|Drug|AS1402|A complete treatment cycle spans 28 days. Patients randomised to AS1402 will receive a 1-hour infusion of 9 mg/kg on day 1, 8, 15 and 22 of each cycle. Patients will receive letrozole (2.5 mg daily tablet).
1825205|NCT00770354|Drug|Letrozole|Daily 2.5 mg oral letrozole tablet
1825206|NCT00770367|Drug|Pioglitazone then Placebo|Subjects will take the pioglitazone 30mg tablet daily for 3 months. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take a placebo.
1825207|NCT00770367|Drug|Placebo then Pioglitazone|Subjects will take the placebo for the first 12 weeks of the study. This will be followed by a 4-week period during which subjects will not be taking either the study drug or placebo. During the final 12-week period the group will take the pioglitazone 30mg tablet daily for 3 months.
1825210|NCT00770393|Procedure|induction chemotherapy|Cisplatin was administered intravenously at a dose of 100 mg/m2 on day 1 and fluorouracil was administered at a dose of 1 000 mg/m2/day by continuous intravenous infusion on day 1 to 5 for 2 courses after 3 weeks. After induction chemotherapy patients underwent ears, nose and throat examination and computed tomography imaging. If a complete response (CR) or partial response (PR) of more than 80% is identified in the primary tumor, the patient was offered conventional radiotherapy as part of the protocol treatment. Radiotherapy was administered in 35 fractions of 2 Gy each over a 7 weeks period to the primary tumor (50 Gy) and the neck lymph nodes. The dose to the pathologically positive nodes was supplemented (20 Gy) at a total dose of 70 Gy. Doses and schedules of radiotherapy were identical in both treatment arms of the study.
1825211|NCT00770393|Procedure|Conventionnal chemotherapy|"Intravenous cisplatin at dose of 100 mg/m2 on days 1, 22 and 43 was administered concomitantly with conventional radiotherapy to the primary tumor and to the neck lymph nodes according to the pathological findings of the pre-treatment neck dissection at a total dose of 70 Gy.
- Surgery was recommended to all patients who had a response less than 80%, stable disease or progressive disease in the primary tumor. If surgery was not feasible, the treatment choice was left up to the investigator's discretion."
1825212|NCT00770406|Drug|botulinum toxin type A|100 or 200 units intravesically
1825213|NCT00770419|Other|medical chart review|
1825214|NCT00770419|Other|questionnaire administration|
1825215|NCT00770419|Procedure|psychosocial assessment and care|
1825216|NCT00770432|Drug|Polyethylene glycol 3350|Polyethylene glycol 3350 powder for solution. Single dose (17 grams in 4 to 8 ounces of beverage) for 7 days.
1825217|NCT00770432|Other|Placebo, maltodextrin 500 powder for solution|Maltodextrin 500 powder for solution, One single dose (one capful) in any 4 - 8 ounces beverage for 7 days.
1825218|NCT00770445|Drug|Pioglitazone and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin placebo-matching tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
1825219|NCT00770445|Drug|Pioglitazone and metformin and insulin|Pioglitazone 15 mg, tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
1825220|NCT00770445|Drug|Metformin and insulin|Pioglitazone placebo-matching tablets, orally, twice daily and metformin 850 mg, tablets, orally, twice daily and insulin glargine stable dose for up to 24 weeks.
1825221|NCT00770471|Drug|temozolomide|
1825222|NCT00770471|Drug|veliparib|
1825223|NCT00770471|Genetic|DNA methylation analysis|
1825224|NCT00770471|Genetic|gene expression analysis|
1825225|NCT00770471|Genetic|mutation analysis|
1825226|NCT00770471|Genetic|proteomic profiling|
1825227|NCT00770471|Other|high performance liquid chromatography|
1825228|NCT00770471|Other|immunoenzyme technique|
1825229|NCT00770471|Other|laboratory biomarker analysis|
1825230|NCT00770471|Other|mass spectrometry|
1825231|NCT00770471|Other|pharmacogenomic studies|
1825232|NCT00770471|Other|pharmacological study|
1825233|NCT00770471|Procedure|adjuvant therapy|
1825234|NCT00770471|Radiation|radiation therapy|
1825235|NCT00770484|Drug|Propranolol then Placebo|Propanolol 20 mg, given orally within 1 hour prior to exercising
1825236|NCT00770484|Drug|Placebo then Propranolol|Placebo, matching pill given orally within 1 hour prior to exercising
1825237|NCT00770497|Drug|Pioglitazone|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for two weeks; increased to:
Pioglitazone 30 mg, tablets, orally, once daily and ramipril placebo-matching tablets, orally, once daily for up to 10 weeks."
1825238|NCT00770497|Drug|Pioglitazone and ramipril|"Pioglitazone 15 mg, tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:
Pioglitazone 30 mg, tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
1825239|NCT00770497|Drug|Ramipril|"Pioglitazone placebo-matching tablets, orally, once daily and ramipril 2.5 mg, tablets, orally, once daily for two weeks; increased to:
Pioglitazone placebo-matching tablets, orally, once daily and ramipril 5 mg, tablets, orally, once daily for up to 10 weeks."
1825240|NCT00770510|Drug|Eszopiclone 1 mg|Eszopiclone 1 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
1825241|NCT00770510|Drug|Eszopiclone 2 mg|Eszopiclone 2 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
1825242|NCT00770510|Drug|Eszopiclone 3 mg|Eszopiclone 3 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
1825243|NCT00770510|Drug|Placebo|Placebo tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
1825244|NCT00770510|Drug|Zolpidem Tartrate 10 mg|Zolpidem Tartrate 10 mg tablet, taken orally at bed time for 2 consecutive nights. Each participant was assigned to one of 10 prespecified treatment sequence patterns. Each interval (five total intervals) of 2 consecutive nights was separated by a washout of approximately 5 days. A follow-up period consisted of 6 days.
1825245|NCT00770536|Drug|A1: AMG 386 10 mg/kg + Liposomal doxorubicin|Liposomal doxorubicin 50 mg/m2 IV Q4W in combination with AMG 386 10 mg/kg IV QW
1825246|NCT00770536|Drug|A3: AMG 386 15mg/kg + Liposomal doxorubicin|A3: AMG 386 15 mg/kg IV QW + Liposomal doxorubicin 50 mg/m2 IV Q4W
1825247|NCT00770536|Drug|B1: AMG 386 10 mg/kg + Topotecan|B1: AMG 386 10 mg/kg IV QW + Topotecan 4 mg/m2 IV days 1, 8, 15, of a 28 day dosing schedule
1825248|NCT00770536|Drug|B3: AMG 386 15mg/kg + Topotecan|AMG 386 15mg/kg IV QW + Topotecan 4mg/m2 IV days 1, 8, 15 of a 28 day dosing schedule
1825249|NCT00770562|Drug|rituximab|
1825250|NCT00770562|Drug|Dexamethasone|
1825251|NCT00770575|Drug|Pioglitazone and atorvastatin|"Pioglitazone 30 mg, capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increase to:
Pioglitazone 45 mg, capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
1825252|NCT00770575|Drug|Atorvastatin|"Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 20 mg, tablets, orally, once daily for 4 weeks; increased to
Pioglitazone placebo-matching capsules, orally, once daily and atorvastatin 40 mg, tablets, orally, once daily for up to 20 weeks."
1825253|NCT00770588|Drug|Gefitinib|Dose form: 250 mg/tablet; Route: oral; Frequency: 1 tablet per day; Duration: until to objective PD
1825254|NCT00770588|Drug|Placebo|To match Gefitinib
1825255|NCT00770601|Drug|Canakinumab|
1825256|NCT00770614|Drug|sodium bicarbonate solution|154 mEq/L in dextrose and H2O
1825257|NCT00770614|Drug|Isotonic saline|0.9% sodium chloride
1825258|NCT00770614|Drug|Placebo|Placebo
1825259|NCT00770627|Dietary Supplement|Omega 3 caps|Children between 6 and 8 years must take 2 caps/day Children between 9 and 11 years must take 3 caps/day Children between 12 and 15 years must take 4 caps /day
1825260|NCT00770640|Drug|Pioglitazone and insulin|Pioglitazone 30 mg, tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
1825261|NCT00770640|Drug|Insulin|Pioglitazone placebo-matching tablets, orally, once daily and variable insulin therapy for up to 24 weeks.
1825262|NCT00770653|Drug|Pioglitazone and Metformin|Pioglitazone 15 mg/metformin 850 mg combination tablets, orally, twice daily and glimepiride placebo-matching tablets, orally, once daily and metformin placebo-matching tablets, orally, twice daily for up to 24 weeks.
1825263|NCT00770653|Drug|Glimepiride and Metformin|Pioglitazone/metformin placebo-matching combination tablets, orally, twice daily and glimepiride 2 mg, tablets, orally, once daily and metformin 850 mg, tablets, orally, twice daily for up to 24 weeks.
1825264|NCT00770666|Drug|Nicotine patch, nicotine inhaler, bupropion|Patch - 21 mg - taper as able Inhaler - as needed Bupropion SR 150 mg daily
1825265|NCT00770666|Drug|Nicotine patch|21 mg daily for 6 weeks followed by 14 mg for 2 weeks and then 7 mg for 2 weeks
1825266|NCT00770679|Drug|lipitor|80 mg everyday (QD) for 3 weeks
1825267|NCT00770692|Drug|Eszopiclone 1 mg- Elderly|"Elderly participants: Eszopiclone 1 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.
Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
1825268|NCT00770692|Drug|Eszopiclone 2 mg- Elderly|"Elderly participants: Eszopiclone 2 mg tablet and 1 tablet placebo 1 mg daily by mouth at bedtime for 24 weeks.
Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
1825269|NCT00770692|Drug|Eszopiclone 3 mg- Non-elderly|"Non-elderly participants: Eszopiclone 3 mg tablet and 1 tablet of placebo 2 mg daily by mouth at bedtime for 24 weeks.
Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg placebo tablet additionally to maintain blind until the end of study treatment."
1825270|NCT00770692|Drug|Eszopiclone 2 mg- Non-elderly|"Non-elderly participants: Eszopiclone 2 mg tablet and 1 tablet of placebo 3 mg daily by mouth at bedtime for 24 weeks.
Dose escalation occurred after 4 weeks of treatment. Participants received 1 mg tablet additionally until the end of study treatment."
1825271|NCT00770705|Drug|Phenoxybenzamine|The drug will be administered in the operating room. After induction of anesthesia and the pIacement of appropriate cardiovascular monitoring lines, an initial loading dose of 0.25 mg/kg will be administered intravenously immediately prior to cardiopulmonary bypass.For up to 72 hours postoperatively, 0.25 mg/kg/day will be administered Based on published pharmacokinetic data these doses should block 90 -95% of alpha-peripheral receptors with a half life of 24 - 36 hours for regeneration.
1825272|NCT00770705|Other|Standard surgical approach|Historical controls
1825273|NCT00770718|Drug|Recombinant Activated Factor VII (rFVIIa)|Five patients who meet the selection criteria will be administered an intravenous dose of rFVIIa 1mg upon arrival. INR will be drawn at 20 minutes post-rFVIIa administration. If normalized (≤1.3), then repeat INR with be drawn every 2 hours thereafter for 6 hours total, and again at 24 hours after initial administration. If at any time, the INR is >1.3, then rFVIIa 1mg will be readministered and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. This may be repeated until a total dose of 80mcg/kg has been given.
1825274|NCT00770718|Drug|Prothrombin Complex Concentrate|5 patients will receive PCC based on ideal body weight. Each patient will receive 30 i.u./kg ideal body weight as is rounded to the nearest dispensed vial size. Vials are dispensed as 5mL (500 i.u.), 10mL (1000 i.u.), or 10mL (1500i.u.). INR will be drawn at 20 minutes post-administration and, if normalized (≤1.3), 2 hours post-administration and every 2 hours for 6 hours total. The INR will also be checked 24 hours post-administration. If at any time, the INR is >1.3, then PCC will be readministered at the same dose and the INR will again be checked 20 minutes after administration and every 2 hours for 6 hours total and again at 24 hours post-administration. A maximum total of 60 iu/kg can be administered.
1825326|NCT00771017|Drug|goserelin|Given intramuscularly
1825275|NCT00770718|Biological|Fresh Frozen Plasma|Five patients will receive transfusions of FFP to normalize INR. If the initial INR is between 2-4, then 2 units of FFP (Round 1) will be administered emergently. If the initial INR is >4, then 4 units of FFP will be administered (Round 1). The INR will be checked after each round of FFP infusion completed. Once INR ≤1.3, then the INR will be again checked every 2 hours after normalization for 6 hours total and then 24 hours post-initial infusion. If the INR should ever return to >1.3, then repeat infusions of FFP will begin as outlined above and the INR will be checked serially as defined above.
1825276|NCT00770731|Drug|Torisel (Temsirolimus)|Starting Dose 5 mg Intravenously over 30-60 minutes, Days 1, 8, and 15 of 21 Day Cycle
1825277|NCT00770731|Drug|Hycamtin (Topotecan)|Starting Dose 0.8 mg/m^2 Intravenously over 30-60 minutes on Days 1 and 8 of 21 Day Cycle
1825278|NCT00770731|Drug|Velcade (Bortezomib)|Starting Dose 0.3 mg/m^2 Intravenously over 1 minute on Days 1, 4, 8, and 11 of 21 Day Cycle
1825279|NCT00770744|Drug|Zicronapine|5-7mg/day; orally, encapsulated tablets, once daily
1825280|NCT00770744|Drug|Olanzapine|10-15mg/day; orally, encapsulated tablets, once daily
1825281|NCT00770757|Drug|CC-4047|
1825282|NCT00770770|Drug|Fluocinolone Acetonide|0.2 µg/day
1825283|NCT00770770|Drug|Fluocinolone Acetonide|0.5 µg/day
1825284|NCT00770783|Device|Thymatron|Right unilateral placement, 3x seizure threshold, 3 times per week for 4 weeks
1825285|NCT00770783|Device|Tonica MagPro MST|100% power, vertex placement, 3 times per week for 4 weeks
1825286|NCT00770796|Drug|Atorvastatin|80 mg die
1825287|NCT00770796|Drug|Placebo|
1825288|NCT00770809|Drug|Lapatinib Ditosylate|Given PO
1825289|NCT00770809|Biological|Trastuzumab|Given IV
1825290|NCT00770809|Drug|Paclitaxel|Given IV
1825291|NCT00770809|Other|Laboratory Biomarker Analysis|Correlative studies
1825292|NCT00770822|Device|HIFU (Sonablate® 500)|High Intensity Focused Ultrasound
1825293|NCT00770822|Device|Brachytherapy|Standard of care
1825294|NCT00770835|Drug|Pioglitazone and Metformin|Pioglitazone 30 mg, tablets, orally, once daily, metformin stable dose and lifestyle modification for up to 24 weeks.
1825295|NCT00770835|Drug|Glibenclamide and Metformin|Glibenclamide 10 mg, tablets, orally, once daily and metformin stable dose and lifestyle modification for up to 24 weeks.
1825296|NCT00770848|Drug|AMG 102|Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.
1825297|NCT00770848|Drug|AMG 102|Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.
1825298|NCT00770848|Drug|Mitoxantrone|Administered Q3W for a maximum of 12 cyles
1825299|NCT00770848|Drug|Placebo|Placebo
1825300|NCT00770848|Drug|Prednisone|5 mg orally BID
1825301|NCT00770861|Drug|Nebivolol|Nebivolol 5 mg, 5-mg Nebivolol nontrade tablets , oral administration Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
1825302|NCT00770861|Drug|Placebo|Matching placebo tablets, oral administration
1825303|NCT00770874|Drug|S-1 + Cisplatin (arm A)|S-1 will be administered orally, twice daily from Day 1 through Day 14 followed by a recovery period from Days 15 through Day 21. Initial dose of S-1 will be determined according to the patient's body surface area (80 to 120 mg/day). On Day 1, Cisplatin 50 mg/m2 will be administered intravenously (IV). This regimen is to be repeated every 3 weeks.
1825304|NCT00770874|Drug|Cisplatin (arm B)|Cisplatin 50 mg/m2 will be administered intravenously (IV) on Day 1, repeated every 3 weeks.
1825305|NCT00770887|Procedure|Self administration|Subjects will self administer injections of 104 mg of the subcutaneous formulation of depot medroxyprogesterone acetate (depo-subQ provera 104).
1825306|NCT00770900|Drug|montelukast sodium|"Asthmatic children and teenagers took montelukast daily for 12 weeks.
Children aged 2-5 years took 4mg tablet of montelukast
Children aged 6-15 years took 5mg tablet of montelukast
Children >15 years took 10mg tablet of montelukast"
1825307|NCT00770900|Drug|Comparator: placebo comparator|Asthmatic children and teenagers took Placebo tablet daily for 12 weeks.
1825308|NCT00770913|Drug|E3810|20 mg taken orally, once a day for 8 weeks.
1825309|NCT00770913|Drug|E3810|10 mg, taken orally, twice a day for 8 weeks.
1825310|NCT00770913|Drug|E3810|20 mg taken orally, twice a day for 8 weeks.
1825311|NCT00770926|Behavioral|Live Well, Be Well|Lifestyle change program using personal contact and telephone counseling
1825312|NCT00770939|Device|Vivostat PRF|Ulcer will be treated week 1,2,3,4,5 and 6 with Vivostat PRF
1825313|NCT00770952|Drug|Pioglitazone and Glimepiride|"Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 2 mg, tablets, orally once daily for two weeks; increased to:
Pioglitazone 30 mg, tablets, orally, once daily and Glimepiride 4 mg, tablets, orally, once daily for two weeks; increased to:
Pioglitazone 45 mg, tablets, orally, once daily and Glimepiride 4 mg, orally, once daily for up to 20 weeks."
1825314|NCT00770952|Drug|Glimepiride|"Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 4 mg, tablets, orally once daily for two weeks; increased to:
Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 5 mg, tablets, orally once daily for two weeks; increased to:
Pioglitazone placebo-matching tablets, orally, once daily and Glimepiride 6 mg, tablets, orally once daily for up to 20 weeks."
1825315|NCT00770965|Biological|AIN457|
1825316|NCT00770965|Biological|Placebo|
1825317|NCT00770978|Drug|ceftobiprole q12h|Ceftobiprole, 1G q12h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
1825318|NCT00770978|Drug|ceftobiprole q8h|Ceftobiprole, 1G q8h as 4 hour infusions, on Day 1 and Ceftobiprole, 1G as single 4 hour infusion on Day 2
1825319|NCT00770991|Drug|Black raspberry (BRB) Slurry|20 grams BRB Slurry
1825320|NCT00770991|Drug|Black Raspberry (BRB) Suppositories|Two, 730 mg BRB suppositories QHS
1825321|NCT00770991|Drug|Black Raspberry (BRB) Placebo Slurry|20 grams BRB placebo slurry
1825322|NCT00771004|Drug|Pioglitazone|Pioglitazone 30 mg, tablets, orally, once daily for one week; increased to Pioglitazone 45 mg, tablets, orally, once daily for up to two weeks.
1825323|NCT00771004|Drug|Placebo|Pioglitazone placebo-matching tablets, orally, once daily for up to three weeks.
1825324|NCT00771017|Biological|GVAX prostate cancer vaccine|Given intradermally
1825327|NCT00771017|Drug|leuprolide acetate|Given intramuscularly
1825328|NCT00771030|Drug|AMG 827|Five treatment dose levels in Part A with AMG 827 and one dose level in Part B with AMG 827
1825329|NCT00771030|Other|Placebo|Five treatment dose levels in Part A with placebo and one dose level in Part B with placebo
1825330|NCT00771043|Drug|TYSABRI and AVONEX|TYSABRI and AVONEX treatment per package insert.
1825331|NCT00771056|Drug|Hydroxychloroquine|400mg by mouth daily x 1 year
1825332|NCT00771095|Behavioral|podcasting|
1825333|NCT00771108|Behavioral|exercise|For 16 weeks subjects will exercise from 30-60 minutes five times a week.
1825334|NCT00771121|Drug|urea/lactic acid|new emulsion type
1825335|NCT00771121|Drug|Placebo|only emulsion base
1825336|NCT00771134|Drug|Lu AA39959|30mg/day; 15mg B.I.D. for 8 weeks
1825337|NCT00771134|Drug|Placebo|B.I.D. for 8 weeks
1825338|NCT00771134|Drug|Quetiapine|300mg/day for 8 weeks
1825339|NCT00771147|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients with diagnosis of advanced renal cell cancer and decision taken by the investigator to prescribe Nexavar®.
1825340|NCT00771160|Drug|montelukast sodium|Arm 1: montelukast tablet 5 mg, QD. Treatment period is 12-weeks. Arm 2: montelukast tablet 10 mg, QD. Treatment period is 12-weeks.
1825341|NCT00771173|Drug|phenazopyridine HCl|Phenazopyrdine HCl 200 mg q8h x 24
1825342|NCT00771173|Other|Placebo|Placebo tablet administered q8 hours for 24 hours postop.
1825343|NCT00771199|Drug|Transdermal Therapeutic System (TTS)-Fentanyl|Participants will receive 1 transdermal patch of TTS-fentanyl containing 12 micrograms per hour (mcg/h) for 28 days. Dose can be increased or decreased as per Investigator's discretion up to 100 mcg/h.
1825344|NCT00771212|Other|Observational pain control study|Observational pain control study
1825345|NCT00771225|Procedure|fascial repair|surgery to treat genital prolapse with fascia repair
1825346|NCT00771225|Procedure|mesh repair|surgery to genital prolapse with mesh
1825347|NCT00771238|Device|P500 Mattress|Study mattress
1825348|NCT00771251|Drug|CNTO 148|50 mg or 100 mg given as a subcutaneous (under the skin) injection once every 4 weeks up to Week 116.
1825349|NCT00771251|Drug|Placebo|Placebo identical in appearance to CNTO 148 given as a subcutaneous (under the skin) injection once every 4 weeks until week 12 and then CNTO148 50mg SC injections every 4 weeks from week 16 until week 116.
1825350|NCT00771264|Device|Urgent PC Neuromodulation System|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
1825351|NCT00771277|Behavioral|Support Teams|Use of volunteers organized into teams with a coordinator to provide services to TBI family
1825352|NCT00771290|Procedure|Air insufflation with standard endoscopy unit, CO2 insufflation for colonoscopy (special CO2 insufflation unit)|comparison of Air insufflation to CO2 insufflation during intraoperative endoscopy
1825353|NCT00771303|Other|Pregnant patients with suspected PE will undergo a strategy based on clinical probability assessment, D-dimer, lower limb vein ultrasonography and MSCT.|
1825354|NCT00771316|Drug|MK0826 (ertapenem)|A single dose of 1.0g IV infused over a 30 minute interval at hour 0
1825355|NCT00771316|Drug|Comparator: meropenem|500 mg IV infused over a 30 minute interval at hours 0, 8, and 16 for at least 4 days
1825356|NCT00771329|Drug|BIIB023|Single IV doses of BIIB023 in dose-escalating cohorts
1825357|NCT00771329|Other|Placebo (sterile normal saline)|Single IV dose of Placebo
1825358|NCT00771342|Drug|Nitric Oxide|1% gaseous nitric oxide, delivered for 40 minutes daily for 3 consecutive days
1825359|NCT00771342|Drug|Nitrogen|Nitrogen gas, delivered topically for 40 minutes daily for 3 consecutive days
1825360|NCT00771368|Drug|Nitric Oxide|1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
1825361|NCT00771381|Drug|18F-FAZA PET scan|Radioactive dose of 18F-FAZA: 110-600 MBq per injection. One pre-treatment injection of 18F-FAZA and PET scan will be permitted per patient.
1825362|NCT00771381|Drug|FluGlucoScan Injection (18F-FDB) PET scan|Radioactive dose of 100-700 MBq per injection. A single pre-treatment injection of FluGlucoScan Injection and PET scan will be permitted per patient.
1825363|NCT00771394|Drug|Tamsulosin hydrochloride|oral
1825364|NCT00771394|Drug|Solifenacin succinate|oral
1825365|NCT00771407|Device|Strattice Reconstructive Matrix|Strattice will be placed as a fascial inlay to support stoma sites
1825366|NCT00771407|Other|Standard ostomy creation|Ostomy will be created as routinely performed
1825367|NCT00771420|Drug|CAM-3001|A single patient shall be dosed with a dose of 0.01mg/kg of CAM-3001 followed no sooner than 24 hours later by a second patient at a dose of 0.03mg/kg.
1825368|NCT00771420|Drug|CAM-3001|Dosed at 0.1mg/kg.
1825369|NCT00771420|Drug|CAM-3001|Dosed at 0.3mg/kg
1825370|NCT00771420|Drug|CAM-3001|Dosed at 1.0 mg/kg.
1825371|NCT00771420|Drug|CAM-3001|Dosed at 3.0 mg/kg.
1825372|NCT00771420|Drug|CAM-3001|Dosed at 10 mg/kg.
1825373|NCT00771420|Other|Placebo|Active: Placebo 5:1 for arms 2-6
1825374|NCT00771433|Biological|filgrastim|Given subcutaneously
1825375|NCT00771446|Biological|ELAD plus standard of care treatment|ELAD is a liver assist system - Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
1825376|NCT00771446|Other|Standard of care treatment|Standard of care for acute liver failure patients including medications and treatments typically given to these patients (Pentoxifylline, corticosteroids, abdominal paracentesis, nutritional therapy, etc., if indicated)
1825377|NCT00771459|Drug|Ropivacaine 0.5 %|Local infiltration analgesia
1825378|NCT00771459|Drug|Isotonic NaCl|Local infiltration analgesia
1825379|NCT00771472|Drug|vorinostat|Parts I & II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
1825380|NCT00771485|Drug|FM-602|Study of Efficacy of Bowel Preparation Before Colonoscopy
1825381|NCT00771485|Drug|Marketed Bowel Cleanser|Marketed bowel cleanser
1825476|NCT00763906|Device|norepinephrine infused under computerized fuzzy logic control|
1825382|NCT00771498|Drug|Lopinavir|ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
1825383|NCT00771511|Drug|capsaicin|capsaicin cream 0.1% 10 ml applied to cervix
1825384|NCT00771511|Drug|Placebo|Only lidocaine gel will be appled to the cervix
1825385|NCT00771524|Drug|Ceftobiprole|Ceftobiprole, 500 mg single 2 hour infusion prior to hip replacement surgery
1825386|NCT00771537|Behavioral|Message Sidedness|There are 16 pairs of messages varying in sidedness. Arm 1 is a no message control condition regarding HIV testing + a no message control condition regarding trial participation. Arm 2 is control + a 1-sided message. Arm 3 is control + a trivial 2-sided message. Arm 4 is control + a major 2-sided message. Arm 5 is a 1-sided message + a control. Arm 6 is a 1-sided message + a 1-sided message. Arm 7 is a 1-sided message + a trivial 2-sided message. Arm 8 is a 1-sided message + a major2-sided message. Arm 9 is a trivial 2-sided message + a control. Arm 10 is a trivial 2-sided message + a 1-sided message. Arm 11 is a trivial 2-sided message + a trivial 2-sided message. Arm 12 is a trivial 2-sided message + a major 2-sided message. Arm 13 is a major 2-sided message + a control. Arm 14 is a major 2-sided message + a 1-sided message. Arm 15 is a major 2-sided message + a trivial 2-sided message. Arm 16 is a major 2-sided message + a major2-sided message.
1825387|NCT00771563|Drug|cisplatin + docetaxel|docetaxel 75 mg/m2 d1 and cisplatin 75mg/m2 d1 (q 3wks for 4 cycles)
1825388|NCT00771563|Drug|cisplatin + docetaxel + enoxaparin|cisplatin 75 mg/m2 d1 and docetaxel 75 mg/m2 d1 (q 3 wks for 4 cycles) + daily enoxaparin 1mg/kg/d sc
1825389|NCT00771589|Device|Active Knee Prosthesis|Motorized External Knee Prosthesis for above knee amputees.
1825390|NCT00771602|Drug|Rituximab|375 mg/m^2 by standard IV (intravenous) infusion on days 1, 8, 15, and 22 of weeks 1-4.
1825391|NCT00771602|Drug|Alemtuzumab|Dose escalation of 3, 10 and 30 mg subcutaneously (SQ) during week 1, followed by dose of 30 mg subcutaneously three times weekly (e.g. Monday-Wednesday - Friday) starting on week 2 for a total of 12 weeks (2-13).
1825392|NCT00771615|Biological|GSK A/turkey H5N1 Influenza vaccine|One dose administered intramuscularly (IM) in the deltoid region. Different formulations are tested.
1825393|NCT00771628|Device|Flex-It Stylet|Patients will be intubated using the GlideScope with an ETT fitted with a Flex-It stylet.
1825394|NCT00771628|Device|Standard malleable stylet|Patients will be intubated using the GlideScope with an ETT fitted with a standard malleable stylet.
1825395|NCT00771641|Procedure|conventional surgery|
1825396|NCT00771641|Radiation|low-LET cobalt-60 gamma ray therapy|
1825397|NCT00771641|Radiation|low-LET electron therapy|
1825398|NCT00771641|Radiation|low-LET photon therapy|
1825399|NCT00771641|Radiation|radiation therapy|
1825400|NCT00771654|Drug|Phentermine|Subjects will receive Phentermine 37.5mg everyday for one year
1825401|NCT00771654|Other|Placebo|daily for one year
1958611|NCT01456013|Device|RenalGuard Therapy|Induced Diuresis with matched replacement
1958612|NCT01456013|Drug|Standard Therapy|Standard of care for patients at risk of CIN
1958613|NCT01454739|Drug|rFVIIIFc|Administered as specified in the treatment arm.
1825412|NCT00771680|Drug|insulin detemir|Start dose and frequency at the discretion of the physician following clinical practice
1825413|NCT00771680|Drug|biphasic insulin aspart 30|Start dose and frequency at the discretion of the physician following clinical practice
1825414|NCT00771680|Drug|insulin aspart|Start dose and frequency at the discretion of the physician following clinical practice
1825415|NCT00771693|Drug|Insulin aspart (Novorapid®)|a cross-over study with subcutaneous injection of insulin aspart 0.1U/kg, 0.2u/kg or placebo, before the meal, on 3 different occasions.
1825416|NCT00771706|Drug|Proton Pump Inhibitor|The PPI arm will consist of a two week course of PPI at a dose 1mg/kg/dose twice daily (minimum dose: 7.5 mg BID; maximum dose: 30 mg BID)
1825417|NCT00771706|Drug|Placebo|To compare the cough reduction rate using either PPI or placebo in children with a chronic cough.
1825418|NCT00771719|Drug|Ceftobiprole|Ceftobiprole, 1 G q8h as 4 hour infusions for 2 days
1825419|NCT00771732|Device|light therapy|6 minute light therapy
1825420|NCT00771732|Device|light therapy|combination of wavelengths
1825421|NCT00771745|Drug|Thymoglobulin|Preloading Induction with Thymoglobulin® X 4 doses given day -4, day -2, day 0, and day 2 at 1.5 mg/kg/dose + corticosteroid taper + tacrolimus + MMF
1825422|NCT00771745|Drug|Thymoglobulin|Preloading Induction with Thymoglobulin® X 3 doses given day -4 (1.5mg/kg), day -2 (1.5mg/kg), and day 0 (3mg/kg) + corticosteroid taper + tacrolimus + MMF
1825423|NCT00771758|Drug|oxycodone IR|maximum daily dose 450 mg
1825424|NCT00771758|Drug|placebo|5 or 10 mg capsule every 4 - 6 hr as needed for up to 10 days
1825425|NCT00771758|Drug|tapentadol IR|50 or 75 mg capsule every 4 - 6 hr as needed for up to 10 days
1826112|NCT00774423|Drug|Riluzole|50 mg per day during 24 months
1825426|NCT00771771|Other|Early supported discharge with day unit rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in a day unit
1825427|NCT00771771|Other|Early supported discharge with home rehabilitation|Treatment by physiotherapist and occupational therapist up to 4 hours a day for up to 5 weeks in the patient's home
1825428|NCT00771797|Dietary Supplement|high dose flavanoids|flavanoid rich cocoa 2 times daily over 60 days
1825429|NCT00771797|Dietary Supplement|low dose flavanoids|treatment with flavanoid-low cocoa two times daily over 60 days
1825430|NCT00771810|Drug|TXA127|Once daily subcutaneous injection of 100 ug/kg
1825431|NCT00771810|Drug|TXA127|Once daily subcutaneous injection of 300 ug/kg
1825432|NCT00771810|Drug|Placebo|Once daily subcutaneous injection of placebo
1825433|NCT00771823|Drug|Maraviroc|Maraviroc 300 mg twice daily for the first 14 days of the study. Placebo twice daily for the last 14 days of the study
1825434|NCT00771823|Drug|Maraviroc|"Placebo twice daily for the first 14 days of the study.
Maraviroc 300 mg twice daily for the last 14 days of the study."
1825435|NCT00771849|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1825436|NCT00771849|Biological|Haemophilus Influenzae Type b (Hib) vaccine|0.5 mL, Intramuscular
1825437|NCT00771862|Procedure|perineural ropivicaine|Subjects will be randomized to one of two groups: ropivicaine 0.2% infusion for days 0-1 then infusion with normal saline (placebo) for days 1 through catheter removal (POD 4 or 5) or ropivicaine 0.4% infusion for day 0 through catheter removal (POD 4 or 5). The infusion rate will be set at 7-11 mL/h.
1825438|NCT00771875|Drug|Rabbit Antithymocyte Globulin (RATG)|All patients will receive Thymoglobulin dosed based on CD3 count. Patients will be redosed when the CD3 count is ≥ 25. Depending on rejection severity, Thymoglobulin will be given for a maximum of 7-14 days. CD3 levels will be monitored daily.
1825439|NCT00771875|Drug|Rituximab|Rituximab dose of 375 mg/ m2 on day 2. Patients will be premedicated with an antihistamine and acetaminophen prior to dosing per institution standard of care.
1825440|NCT00771875|Drug|Bortezomib|Patient will receive 1.3 mg/m2 via IV push over 3-5 seconds on days 2, 5, 9, and 12. Consolidation course of bortezomib will be dosed at 1.3 mg/m2 IVP X 4 doses administered on days 1, 4, 7 and 10.
1825441|NCT00771875|Drug|Acetaminophen|Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
1825442|NCT00771875|Drug|Antihistamine|Patients will be premedicated with an antihistamine prior to dosing per institution standard of care.
1825443|NCT00771875|Drug|Methylprednisolone|Methylprednisolone 250 mg with 1st dose of Thymoglobulin. Methylprednisolone 125 mg on treatment day 2 subsequent corticosteroids per institution standard of care; following treatment, corticosteroid therapy will resume at the pre-rejection dose.
1825444|NCT00771888|Drug|lanreotide|lanreotide
1825448|NCT00771914|Drug|Aspirin|Aspirin 81mg tablet
1825449|NCT00771914|Drug|Lovaza|Lovaza 4 grams
1825450|NCT00771914|Drug|Both Aspirin and Lovaza|Lovaza 4 grams plus aspirin 81 mg
1825451|NCT00771914|Other|Placebo|Capsule resembling fish oil and a tablet resembling aspirin
1825452|NCT00771927|Drug|Lacosamide|Vimpat was used as per site routine practices, and in-line with the marketing authorization.
1825453|NCT00771940|Drug|Ghrelin|Solvent, cont. infusion
1825454|NCT00771953|Drug|apricoxib|Oral apricoxib tablets will be provided as white or off-white film-coated tablets available in 100mg strength to be taken every day
1825455|NCT00771953|Drug|Placebo|Oral placebo tablets will be provided as white or off-white film-coated tablets to be taken every day
1825456|NCT00771953|Drug|Docetaxel or Pemetrexed|Docetaxel 75mg/m2 or Pemetrexed 500mg/m2 given as an IV infusion every 21 days. TheTreating physician will determine chemotherapy drug as per his usual practice.
1825457|NCT00763776|Device|clamp crushing technique|Liver transection during hepatectomy by clamp crushing technique
1825458|NCT00763776|Device|ultrasonic dissector|Liver transection during hepatectomy by the ultrasonic dissector
1825459|NCT00763789|Other|local anaesthesia and remifentanil sedation|
1825460|NCT00763789|Other|total intravenous anaesthesia|
1825461|NCT00763815|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
1825462|NCT00763815|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
1825463|NCT00763815|Device|Pen auto-injector|
1825464|NCT00763815|Drug|Pioglitazone|Dose to be kept stable.
1825465|NCT00763815|Drug|Metformin|Metformin, if given to be continued at stable dose (at least 1.5 gram per day) up to the end of treatment.
1825466|NCT00763828|Device|Life Recovery Systems ThermoSuit|Hypothermia induction (cooling to 32 to 34 degrees C core temperature) using the Life Recovery Systems ThermoSuit System (a device which cools patients using direct skin contact with cold water) followed by PCI (percutaneous coronary intervention) and maintenance of hypothermia for 3 hours following PCI.
1825467|NCT00763841|Device|Transcranial magnetic stimulation|Stimulation will be given daily at a particular site for three days a week
1825468|NCT00763841|Device|Sham|
1825469|NCT00763867|Drug|Placebo|
1825470|NCT00763867|Drug|Sildenafil|
1825473|NCT00763893|Drug|placebo|Cover key details of the intervention. Must be sufficiently detailed to distinguish between arms of a study (e.g., comparison of different dosages of drug) and/or among similar interventions (e.g., comparison of multiple implantable cardiac defibrillators). For example, interventions involving drugs may include dosage form, dosage, frequency and duration.
1825474|NCT00763893|Drug|Losartan|50 mg/day if < weight 50 kg 100 mg/day if weight > 50 kg
1825475|NCT00763906|Device|norepinephrine infused at the clinician's discretion|
1994415|NCT03011801|Behavioral|Interpersonal Therapy|reducing conflict in relationships, increasing social support in relationships, improving communication, reducing depressive symptoms
1994416|NCT03011801|Behavioral|Enhanced usual care|Treatment as Usual, including eclectic and supportive therapy, as well as psychiatric medication
1825477|NCT00763919|Behavioral|Psychoeducation module|The psychoeducation module will use psychological and medication education to address opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes toward drugs in general, lack of information about mood stabilizers, and stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments.
1825478|NCT00763919|Behavioral|Substance abuse module|The substance abuse module will address problematic substance abuse, particularly as it relates to medication adherence.
1825479|NCT00763919|Behavioral|Improved communication/rapport with provider module|The provider communication and rapport module will improve health care provider communication to address fear of side effects, concern regarding change in appearance, or side effect-related distress.
1825480|NCT00763919|Behavioral|Medication routines management module|The medication routines management module will develop strategies and behaviors that help create medication adherence routines for those who have difficulties with medication routines or experience outside opposition to medications.
1825481|NCT00763945|Other|data collection|The data of patients is collected from their hospital documentation The follow-up of all patients is done via phone calls in order to collect data about the outcome of each patient
1825482|NCT00763958|Drug|Placebo|Placebo to match buprenorphine administered for 3 months
1825483|NCT00763958|Drug|Buprenorphine|Buprenorphine provided for 3 months; dosing was as clinically indicated up to 32 mg daily.
1825484|NCT00763971|Drug|Lisdexamfetamine Dimesylate (LDX)|30, 50 or 70mg capsule once per day (Overencapsulated)
1825485|NCT00763971|Drug|Methylphenidate Hydrochloride|18, 36, or 54mg tablet one per day (Overencapsulated)
1825486|NCT00763971|Drug|Placebo|Placebo capsule once per day (Overencapsulated)
1825487|NCT00763984|Behavioral|Usual Care|This group will receive routine care, however, it is possible that that control condition participants will receive Pelvic Floor Muscle Training (PFMT) instruction from their health care providers. We will monitor control women's knowledge, adoption and maintaining of PFMT.
1825488|NCT00763984|Behavioral|Bladder Health class|Modeled on our intervention with older women, Bladder Health Class (BH Class) will include Pelvic floor muscle training (PFMT), defined by the International Continence Society as repetitive selective voluntary contraction and relaxation of specific pelvic floor muscles, and bladder training (BT), defined as a program of scheduled voiding with gradually progressive voiding intervals. The BT instructions will be modified for this pregnant group. We will monitor control women's knowledge, adoption and maintaining of PFMT and BT.
1825489|NCT00763997|Drug|dipyrone|Dipyrone is given in the operation room with 2,5 g intravenously, followed by an oral regime of 4x1g on the ward
1825490|NCT00763997|Drug|Ibuprofen|Ibuprofen is given orally 600mg in the Post Anesthesia Care Unit, followed by an oral regime of 800mg twice a day
1825491|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the Operation room, followed by an oral regime of 1g fourth a day
1825492|NCT00763997|Drug|Acetaminophen|Acetaminophen is given 1g intravenously in the operation room, followed by 1g orally fourth a day
1825493|NCT00763997|Drug|Parecoxib/Valdecoxib|40mg Parecoxib are given intravenously in the operation room, followed by 40mg of Valdecoxib orally twice a day
1825494|NCT00763997|Other|Blood samples|Blood samples for aggregometry are taken before induction of anesthesia, 1h after first drug intake, 4hs and 24hs after first intake
1825495|NCT00764010|Dietary Supplement|No dietary counseling and omega-3 capsules|Omega-3 2.4 g/day
1825496|NCT00764010|Dietary Supplement|Omega-3 capsules and dietary counseling|Omega-3 2.4 g/day and Mediterranean-like diet
1825497|NCT00764010|Dietary Supplement|Dietary counseling, placebo capsules for omega-3|Mediterranean-like diet
1825498|NCT00764036|Drug|artesunate|add-on therapy with daily single oral doses of 100, 150 or 200 mg of artesunate
1825499|NCT00764049|Device|Single pass albumin dialysis|6 hours sessions of albumin dialysis.
1825500|NCT00764062|Drug|Amoxicillin|Amoxicillin :drug
1825501|NCT00764075|Device|Beutel TM|application of BeutelTM
1825502|NCT00764075|Other|standard|standard procedure will be applied but no Beutel TM software
1825503|NCT00764075|Device|software Beutel TM|application of BeutelTM to patients data for determination of site of latest contraction
1825504|NCT00764101|Behavioral|Attentional Bias Modification|computerized training to reduce attentional bias in posttraumatic stress disorder
1825505|NCT00764114|Drug|antibiotic|6 or 12 weeks
1825506|NCT00764140|Biological|tumor growth factor concentration|spot urine or blood collection will be used to measure specific tumor growth factor
1825507|NCT00764153|Procedure|Bipolar hemiarthroplasty|Lateral approach. FWB.
1825508|NCT00764153|Procedure|Internal fixation|Fluoroscopic Control. Percutaneous. FWB. Two parallel screws (Olmed)
1825509|NCT00764166|Drug|Docetaxel + hormonal treatment (LH-RH agonist)|"Docetaxel will be administered:
To D1 of every cycle in the dose of 70 mg/m²,
Perfusion IV of 60 minutes diluted in 250 ml with physiological serum or with serum glucoside from a peripheral or central vein, Every 3 weeks during 6 cycles (except when unacceptable tolerance).
Triptorelin was given by injection for 4 times every 3 months Bicalutamide was given at the same time with LH-RH agonist for 3 weeks ; taken orally"
1825510|NCT00764166|Drug|Hormonal treatment (LH-RH agonist)|Triptorelin was given by injection for 4 times every 3 months. Bicalutamide given at the same time with LH-RH agonist for 3 weeks ; taken orally.
1825511|NCT00764179|Other|milk enriched in proteins (2.15 g/100ml)|"Neonates will drink the hyperproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
1825512|NCT00764179|Other|milk with normal protein concentration (1.45g/100ml)|"Neonates will drink the normoproteinic milk until they reach the 25th of Sempé and Pedron curve (milk to be taken at least until 40 weeks of amenorrhoea or at maximum until 4 months of corrected age)"
1825513|NCT00764192|Procedure|blood sample|blood sample before and after a single HD
1825514|NCT00764192|Procedure|Flow-mediated dilation (FMD) before and after a single HD|measuring of the flow-mediated dilation using high-resolution ultrasound
1825515|NCT00764218|Device|Positive airway pressure treatment|Positive airway pressure treatment as long as necessary
1825516|NCT00764218|Other|No positive airway pressure treatment|No treatment
1826143|NCT00774735|Drug|GSK1349572|30 mg in combination with darunavir/ritonavir
1825517|NCT00764231|Behavioral|Home-based exercise program|Subjects will be given a personalized 12-week exercise program consisting of cardiovascular, musculoskeletal and flexibility exercises by a certified exercise physiologist. They will receive fitness assessments at baseline, 6 weeks and 12 weeks.
1825518|NCT00764231|Behavioral|Wait list|Subjects will have a 12-week waiting period, during which time they will be asked not to change their exercise habits. These subjects will receive the same fitness assessments as the experimental group (baseline, 6 weeks, 12 weeks), but will not receive an exercise program during the wait-list period. Following the 12-week wait-list period, subjects will be given the same home-based exercise intervention as the experimental group.
1825519|NCT00764244|Procedure|Vitrectomy|Vitrectomy
1825520|NCT00764244|Drug|Intravitreal triamcinolone injections|Intravitreal triamcinolone injections
1825521|NCT00764244|Procedure|Laser photocoagulation|Laser photocoagulation
1825522|NCT00764257|Device|PREVELLE Shape|
1825523|NCT00764257|Device|Restylane|
1825524|NCT00764270|Dietary Supplement|R-alpha lipoic acid|300 mg R-alpha lipoic acid or placebo twice daily for 12 weeks, followed by a washout period of 12 weeks, followed by another treatment phase of the other treatment placebo or 300 mg R-alpha-lipoic acid for 12 weeks
1825525|NCT00764283|Device|Tegaderm dressing|Tegaderm dressing is used to secure the epidural catheter for postoperative analgesia
1825526|NCT00764283|Device|Epi-Fix dressing|Epi-Fix dressing is used to secure the epidural catheter for postoperative analgesia
1825527|NCT00764283|Device|Lockit-Plus|Lockit-Plus dressing is used to secure the epidural catheter for postoperative analgesia
1825528|NCT00764296|Other|no treatment|collection of samples of wound biofilm in Acute and Chronic Wounds
1825529|NCT00764296|Other|no treatment|collection of samples for the evaluation of Wound Biofilm in Acute and Chronic Wounds
1825530|NCT00764309|Drug|dasatinib|Tablets, Oral, 100 mg, once daily, 6 months
1825531|NCT00764322|Drug|tamoxifen citrate|Women found to be IM or PM will undergo increased tamoxifen to 40 mg/day (20 mg bid). Drug is given orally on a daily basis.
1825532|NCT00764322|Genetic|gene expression analysis|Genetic analysis of blood sample.
1825533|NCT00764322|Other|pharmacogenomic studies|Genetic analysis of blood sample.
1825534|NCT00764322|Other|questionnaire administration|Questionnaire called the survey of participants. Questionnaires is self administered on paper documents and given pre-study, and at 4 months
1825535|NCT00764322|Procedure|quality-of-life assessment|Self administration of a multiquestion questionnaire called the Functional Assessment of Cancer Therapy -Breast (FACT-B). Given pre-study, at 4 months and at 8-10 months.
1825536|NCT00764348|Other|no treatment|
1825537|NCT00764361|Drug|doxycycline|1.0% doxycycline gel applied topically to the wound once daily for 20 weeks
1825538|NCT00764361|Drug|placebo gel|placebo gel applied topically to the wound once daily for 20 weeks
1825539|NCT00764374|Drug|YM443|oral
1825540|NCT00764387|Drug|Gadovist® (Gadobutrol, BAY86-4875)|0,1 mmol/kg of body weight in the vein, single administration
1825541|NCT00764387|Drug|Dotarem|0,1 mmol/kg of body weight in the vein, single administration
1825542|NCT00764400|Behavioral|Word Retrieval Treatments for Aphasia|Speech therapy sessions take place 4 times per week for up to 90 minutes per session. Following a phase of baseline pre-testing, two phases of speech therapy will take place lasting up to 20 sessions per phase. Post-testing will take place immediately upon completion of the treatment phases and again at 1 month post study completion.
1825543|NCT00764413|Drug|methylprednisolone|1 gram intravenous a day for 3 days
1825544|NCT00764413|Drug|Sodium chlorid|Sodium chlorid 9mg/ml 500 ml per day in 3 days
1825545|NCT00764426|Drug|red wine, beer, ethanol|Alcoholic beverages equivalent to 30g of alcohol per day for men and 20g/d for women for 3 weeks
1825546|NCT00764426|Drug|de-alcoholised red wine, de-alcoholised beer, water|de-alcoholised red wine, de-alcoholised beer, water
1825547|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with Standard NRT user direction
1825548|NCT00764439|Drug|Nicotine replacement therapy|Nicotine replacement therapy with a Novel NRT user direction
1825549|NCT00764465|Drug|Maraviroc|300 mg BID
1825550|NCT00764465|Drug|Fosamprenavir|1400 mg BID, 700 mg BID or 1400 mg QD
1825551|NCT00764465|Drug|Ritonavir|100 mg BID, 100 mg QD
1825552|NCT00764478|Drug|Asenapine|asenapine tablet, 5 mg sublingually BID for 21 days
1825553|NCT00764478|Drug|Asenapine|asenapine tablet, 10 mg sublingually BID for 21 days
1825554|NCT00764478|Drug|Placebo|placebo sublingual tablet, administered BID for 21 days
1825555|NCT00764504|Device|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and no previous shoulder device implanted.
1825556|NCT00764504|Device|Reverse Shoulder Prosthesis|For subjects with rotator cuff arthropathy and a failed hemi or total shoulder implant.
1994417|NCT03011190|Behavioral|Emotional regulation|Educate people with difficulty in regulating their emotions and help them acquire skills to do so
1825561|NCT00764530|Device|Alumina/Alumina|CeramTec Acetabular Alumina Insert and CeramTec Alumina head used with Foundation Porous Coated Acetabular Shell
1825562|NCT00764530|Device|Standard|Foundation Porous Coated Acetabular Shell with Polyethylene Insert with the CeramTec Alumina head
1825563|NCT00764543|Device|24-hour ambulatory blood pressure monitor|Patients will go home with the 24-hour ambulatory blood pressure monitor to be returned at the clinic after 24 hours.
1825564|NCT00764556|Drug|Insulin|Intravenous insulin (actrapid) Subcutaneous insulin (aspart, glargine, detemir)
1825565|NCT00764569|Device|Fluorescence/Elastic Scattering Spectroscopy|Fluorescence/Elastic Scattering Spectroscopy Oral tissue measurement
1825566|NCT00764582|Drug|1.5% levofloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.
Group 1: 30 minutes prior to surgery
Group 2: 1 hour prior to surgery
Group 3: 2 hours prior to surgery
Group 4: 4 hours prior to surgery"
1825567|NCT00764582|Drug|0.5% moxifloxacin ophthalmic solution|"Topical application Instill 1 drop two times, 5 minutes apart. Time from last drop to surgery is determined by group.
Group 5: 30 minutes prior to surgery
Group 6: 1 hour prior to surgery
Group 7: 2 hours prior to surgery
Group 8: 4 hours prior to surgery"
1825568|NCT00764595|Drug|imatinib mesylate|Imatinib mesylate is administered as oral dose of 400 mg/d once daily after meal until 3 years after enrollment of the last patient.
1825569|NCT00764621|Procedure|Primovist MRI|Contrast-enhanced MRI with an i.v. application of Primovist in the approved dosage
1825570|NCT00764621|Procedure|Extracellular contrast media (ECCM) MRI|Contrast-enhanced MRI with an i.v. application of an approved extracellular contrast medium in the approved dosage
1825571|NCT00764621|Procedure|Contrast-enhanced CT|Contrast-enhanced 3 phase multidetector CT with an i.v. application of an approved iodinated contrast medium in the approved dosage
1825572|NCT00764634|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 28, and 182
1825573|NCT00764634|Biological|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 28 and 182
1825574|NCT00764634|Biological|Placebo (USP sterile saline for injection)|0.5 mL dose of placebo given by intramuscular injection at Days 0, 56 and 182
1825575|NCT00764634|Biological|rBV A/B-40 vaccine|0.5 mL dose of rBV A/B-40 vaccine given by intramuscular injection at Days 0, 56 and 182
1825576|NCT00764647|Behavioral|Education program for family caregivers of frail elders|Family caregiver participants in the educational program will receive an educational course presented by the investigator that focuses on the care of the frail elder and themselves. The course will involve four to five consecutive weekly sessions, each 2 1/2 to 3 hours long. The educational program will be offered biannually, spring and fall seasons.
1825577|NCT00764660|Drug|SCH 900435|tablets
1825578|NCT00764660|Drug|Placebo|tablets
1825579|NCT00764673|Device|3DKnee|Subjects with knee osteoarthritis and willing to participate in the study
1825580|NCT00764686|Other|Exercise and Education|One hydrotherapy class, one land-exercise class and one education session daily, for five days. Each exercise class and education session is one hour in duration.
1825581|NCT00764686|Other|Exercise and Education|Two hydrotherapy classes, one land-exercise class and one education session daily, for five days. Each exercise class and education are one hour in duration.
1994418|NCT03008252|Other|Lactose breath test|Lactose breath test in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
1825583|NCT00764712|Drug|insulin|Insulin was was administered according to each protocol rules/suggestions into a central venous line as a continuous infusion (Bath and eMPC protocols) or as a combination of a continuous infusion and boluses (Matias protocol). A standard concentration of 50 IU of insulin in 50 ml of 0.9% NaCl was used. In all patients, infusion of 10% glucose solution was initiated upon admission to ICU with glucose dose of 2.5 g/kg of ideal body weight (height in centimetres minus 100) per hour and lasted for 18 hours, when normal oral food intake was started. In ventilated patients, the glucose infusion lasted for 48 hours, and then standard enteral nutrition was initiated.
1825584|NCT00764725|Drug|conventional DMARD combination|MTX+SSZ+Plaquenil; can be changed to MTX+cyclosporin within protocol
1825585|NCT00764725|Biological|MTX plus anti-TNF|MTX + infliximab; can be changed to MTX + etanercept within protocol
1825586|NCT00764738|Device|OCT, Multifocal ERG, Microperimetry|"OCT performed monthly. Fluorescein Angiography performed at baseline, month 3, month 5, month 8 and month 12.
Microperimetry performed at baseline, month 3, month 5, month 8, and month 12 for monthly ranibizumab and at baseline, month 3, month 5 through month 12 for as needed ranibizumab.
Multifocal ERG done at the same monthly visits as the microperimetry."
1825587|NCT00764751|Drug|LEO 19123 Cream (calcipotriol plus LEO 80122)|Once daily application
1825588|NCT00764751|Drug|Dovonex® cream|Twice daily application
1825589|NCT00764751|Drug|Cream vehicle|Twice daily application
1825590|NCT00764764|Procedure|shoulder treatment|shoulder exercise, joint mobilization, home program, posture
1825591|NCT00764764|Procedure|Shoulder AND cervical treatment|Cervical and shoulder joint mobilization, exercise, posture, and home program
1825592|NCT00764777|Device|iliac stenting|Absolute Pro (Abbott Vascular) or Omnilink Elite (Abbott Vascular) stents
1825593|NCT00764790|Biological|Fluarix|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection. Two different doses are tested.
1825594|NCT00764790|Biological|Fluzone|One (Day 0) or two (Day 0 and Day 28) doses by intramuscular injection.
1825595|NCT00764803|Device|Encore 3DKnee™ system|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore 3DKnee™ system and willing to participate in the study.
1825596|NCT00764803|Device|Encore MJS™ Knee System|Subjects with rheumatoid arthritis, traumatic arthritis or osteoarthritis who were implanted with the Encore MJS™ Knee system and willing to participate in the study.
1825597|NCT00764816|Other|grain (soy) protein diet|The patient is to eat a grain (soy) protein diet for 7 days. The food is prepared by a registered dietitian.
1825598|NCT00764816|Other|casein (meat) protein diet|The patient is to eat a casein (meat) protein diet for 7 days. The food is prepared by a registered dietitian.
1825599|NCT00764842|Device|Encore CLP® Hip stem|Subjects with osteoarthritis, rheumatoid arthritis or avascular necrosis of the natural femoral head who have received the Encore CLP® Hip stem and are willing to participate in the study.
1825600|NCT00764855|Procedure|Automatic administration of propofol and opiates during routine clinical practice|"The clinical effect of administration of pharmaca can be measured in the changes of heartbeat, blood pressure, respiration and the changes of brain activity by registering EEG. These measurements are performed standard, to secure the safety of the patient.
The heartbeat and the EEG will be measured by non invasive adhesive electrodes on the skin of the patient.
The blood pressure will be measured by non invasive blood pressure cuff around the arm and the respiration parameters will be measured by non invasive spirometry, which are all standard available on a anesthesia device."
1825601|NCT00764868|Drug|Lisdexamfetamine Dimesylate (LDX)|optimal dose of 30, 50 or 70 mg once daily
1825602|NCT00764881|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658ID)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one encapsulated SH T00658ID for 28 days per cycle, for 6 treatment cycles: Days 1-2, 3.0 mg EV; Days 3-7, 2.0 mg EV+2.0 mg DNG; Days 8-24, 2.0 mg EV+3.0 mg DNG; Days 25-26, 1.0 mg EV; Days 27-28, placebo, encapsulated for blinding purpose
1825653|NCT00765206|Drug|Omeprazole/sodium bicarbonate|Single dose of omeprazole/sodium bicarbonate per day for either 1 or 7 days.
1825603|NCT00764881|Drug|Microgynon|Days 1 to 21: daily oral administration of one encapsulated Microgynon tablet; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Six 28-day treatment cycles.
1825604|NCT00764881|Drug|Placebo|Days 22 to 28: daily oral administration of one encapsulated placebo tablet. Six 28-day treatment cycles.
1825605|NCT00764894|Device|Foundation Knee|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis who received a primary Foundation Knee replacement and is willing to participate in the study.
1825606|NCT00764907|Drug|asparaginase|Given IV during reinduction
1825607|NCT00764907|Drug|cyclophosphamide|Given IV during reinduction
1825608|NCT00764907|Drug|cytarabine|Given IV during reinduction
1825609|NCT00764907|Drug|daunorubicin hydrochloride|Given IV during reinduction
1825610|NCT00764907|Drug|dexamethasone|Given IV or orally during reinduction
1825611|NCT00764907|Drug|doxorubicin hydrochloride|Given IV during reinduction
1825612|NCT00764907|Drug|etoposide|Given IV during reinduction
1825613|NCT00764907|Drug|ifosfamide|Given IV during reinduction
1825614|NCT00764907|Drug|leucovorin calcium|Given IV during reinduction
1825615|NCT00764907|Drug|mercaptopurine|Given orally during reinduction
1825616|NCT00764907|Drug|methotrexate|Given orally during reinduction
1825617|NCT00764907|Drug|prednisone|Given intrathecally during reinduction
1825618|NCT00764907|Drug|thioguanine|Given orally during reinduction
1825619|NCT00764907|Drug|vincristine sulfate|Given IV during reinduction
1825620|NCT00764907|Drug|vindesine|Given IV during reinduction
1825621|NCT00764920|Device|non-invasive imaging modalities for assessment of skin|skin imaging
1825622|NCT00764933|Behavioral|Structured information|Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.
1825623|NCT00764933|Other|Unspecific conversation|Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
1825624|NCT00764946|Drug|Comparator: raltegravir|400 mg tablets taken twice daily. Total treatment period is 48 weeks.
1825625|NCT00764959|Device|Encore Linear™ Hip System|Subjects with degenerative joint disease (DJD), osteoarthritis or rheumatoid arthritis, have received the hip system and are willing to participate in the study.
1825626|NCT00764972|Drug|Sorafenib and Vinorelbine|"vinorelbine, administered as a brief infusion twice every three weeks (on day 1 and 8 of 21-day cycles);
sorafenib, that you will take orally every day, at the dosage that your study doctor will prescribe."
1825627|NCT00764998|Biological|Fluviral|
1825628|NCT00765011|Drug|TPF, radiotherapy and cetuximab|3 cycles of: cisplatin: 75mg/m2, i.v., 1 hour, once daily docetaxel: 75 mg/m2, i.v., 1 hour, once daily 5-fluorouracilo: 750 mg/m2, i.v., 24 hours, 5 days Radiotherapy: 70Gy,divided into daily doses of 2 Gray (total days:35) Cetuximab: 400 mg/m2, i.v, 2 hours, 1 day Cetuximab: 250 mg/m2, i.v, 1 hour, 7 days
1825629|NCT00765011|Procedure|H&N surgery|Rescue surgery
1825630|NCT00765024|Drug|Ivermectin|single dose of 200 mcg/kg
1825631|NCT00765024|Drug|ivermectin|two single dose of 200mcg/kg in 2 weeks
1825632|NCT00765024|Drug|Albendazole|Albendazole 7 days
1825633|NCT00765037|Device|Encore Reverse Shoulder Prosthesis|rotator cuff deficiency and glenohumeral arthritis
1825634|NCT00765050|Biological|CD133+ cells transplant|intramuscular administration of CD133+ cells that have been mobilized from peripheral blood.
1825635|NCT00765063|Drug|Fragmin|Pre-filled syringes containing a single dose of 5000 IU Fragmin/ Dalteparin Sodium
1825636|NCT00765076|Biological|GSK Biologicals' influenza vaccine GSK2186877A|One intramuscular injection at Day 0
1825637|NCT00765076|Biological|GSK Biologicals' Fluarix|One intramuscular injection at Day 0
1825638|NCT00765089|Procedure|Isolation of pulmonary veins with Bipolar radiofrequency ablation|
1825639|NCT00765102|Drug|Bortezomib|"Bortezomib was administered at a dose of 1.0 mg/m^2 as an intravenous (IV) push over 3 to 5 seconds twice weekly for 2 consecutive weeks (Days 1, 4, 8 and 11) of each 28-day cycle. On days that bortezomib and romidepsin were administered together, bortezomib was administered prior to the romidepsin infusion.
Patients were treated to a maximum response plus two additional cycles or a maximum of eight cycles."
1825640|NCT00765102|Drug|Romidepsin|Romidepsin initially was administered at a dose of 10 mg/m^2 as a 1-hour intravenous (IV) infusion on Days 1, 8, and 15 of each 28-day cycle. Based on the occurrence of Grade 3 thrombocytopenia at this dose level, the dose was reduced by protocol amendment to 8 mg/m^2.
1825641|NCT00765115|Drug|LY450139|
1825642|NCT00765115|Drug|placebo|
1825643|NCT00765128|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
1825644|NCT00765128|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
1825645|NCT00765154|Drug|darunavir|two 400mg tablets (800mg) once daily
1825646|NCT00765154|Drug|ritonavir|one 100mg capsule once daily
1825647|NCT00765167|Drug|Fluoride|Brush half mouth twice daily for four days
1825648|NCT00765167|Drug|Triclosan|Brush half mouth daily for four days
1825649|NCT00765167|Drug|Chlorhexidine gluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days
1825650|NCT00765167|Drug|Fluoride|Brush half mouth daily for four days
1825651|NCT00765180|Device|TRE vs. NBI|TRE NBI
1825652|NCT00765193|Other|Inspection of covered areas|Clinicans performed a two-step examination for skin cancer, with clinical examination of individual lesions was aided by the use of dermoscopy, as needed. In the first step, physicians performed inspection of problem areas and uncovered areas only, and lesions suggestive of melanoma or non-melanoma skin cancer were noted. In the second step, TBSE was performed. Following both examinations, lesions suggestive of melanoma or non-melanoma skin cancer were excised or biopsied. Histopathologic diagnosis was recorded for each of the biopsied or excised lesions.
1825654|NCT00765206|Drug|omeprazole magnesium (20 mg equivalent)|Single dose of omeprazole magnesium per day for either 1 or 7 days.
1825655|NCT00765219|Behavioral|CBT|10-12 weekly sessions of CBT in person or over the telephone.
1825656|NCT00765219|Other|Usual Care|Treatment as usual provided by participants' physician(s)
1825657|NCT00765232|Drug|Ketorolac|90 mg ketorolac in 1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
1825658|NCT00765232|Drug|Placebo|1 L of normal saline infused at 40-120 mL/hr for 18.5-23 hours beginning 0.5 hours after the end of surgery.
1825659|NCT00765245|Drug|Lenalidomide|Orally once daily on days 1-21. Treatment repeats every 28 days for 12 courses in the absence of disease progression or unacceptable toxicity.
1825660|NCT00765245|Drug|Lenalidomide|Lenalidomide 20 mg daily, Days 1-21, followed by 7 days rest (28-day cycle). Cycles will be repeated every 28 days for a total of 12 cycles
1825661|NCT00765245|Drug|Rituximab|Rituximab 375 mg/m2 intravenously (IV) starting on Day 8, Cycle 1 of lenalidomide. Rituximab will be repeated on Day 8 of odd numbered cycles (Cycles 1, 3, 5, 7, 9, and 11) for a total of 6 doses from randomization.
1825662|NCT00765271|Drug|Abacavir|"Group 1 will be instructed to take • Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study
Group 2 will be instructed to take
• Abacavir 600 mg once daily (two 300 mg tablets once daily) as part of regular treatment throughout the whole study"
1825663|NCT00765271|Drug|Darunavir/ritonavir|"Group 1 will be instructed to take
• Three 300mg Darunavir tablets and one 100mg ritonavir tablet once a day for 14 days (on days 2 - 15)"
1825664|NCT00765271|Drug|Raltegravir|"Group 1 will be instructed to take • Two 200mg Raltegravir tablets twice daily for 14 days (on 16 - 29)
Group 2 will be instructed to take
• Two 200mg Raltegravir tablets twice daily for 14 days (on days 2-15)"
1825665|NCT00765297|Device|fall related movement (stumble) detector|movement pattern (gait,balance) of young subjects recovery of a stumble in young subjects
1825666|NCT00765297|Device|fall related movement characteristic (stumble) detector|age related gait changes influencing movement pattern different pattern to recover from a trip
1825667|NCT00765310|Dietary Supplement|R-alpha lipoic acid|600 mg in morning on empty stomach (two 300 mg capsules)
1825668|NCT00765310|Dietary Supplement|Placebo|two capsules once daily in morning on empty stomach
1825669|NCT00765323|Drug|Octreotide Implant|84 mg octreotide subcutaneous implant for 6 months
1825670|NCT00765323|Drug|Sandostatin LAR Depot|Injections of Sandostatin LAR (dose range ~10-40 mg every 28 days)
1825671|NCT00765336|Drug|minocycline extended release|1 mg/kg extended release minocycline HCL, once daily for 84 days.
1825672|NCT00765336|Drug|Placebo|placebo comparator for 1 mg/kg extended release minocycline HCL, once daily for 84 days.
1825673|NCT00765362|Device|Encore Mobile-Bearing Knee|Used for primary total knee replacement
1825674|NCT00765375|Drug|Botulinum Neurotoxin Type A|1.5-3 units of Botox/lesion
1825675|NCT00765375|Drug|Bacteriostatic saline|.1 cc bacteriostatic saline/lesion
1825676|NCT00765388|Device|SenSura Uro|The test product is a CE-marked non-sterile one-piece urostomy multi-chamber bag with the SenSura adhesive.
1825677|NCT00765388|Device|Hollister|The comparator product is CE-marked and non-sterile and produced for urostomy operated. It is a flat one-piece urostomy product, Hollister Moderma Flex Urostomy beige, Cut-to-Fit Bag, flat adhesive.
1825678|NCT00765414|Biological|Myozyme|30 mg/kg qow f and 40 mg/kg qow
1825679|NCT00765427|Drug|QLT091001|7-day repeated dose
1825680|NCT00765440|Dietary Supplement|therapeutic nutritional supplementation|Given orally
1825681|NCT00765440|Other|placebo|Given orally
1825682|NCT00765453|Other|Bone marrow derived progenitor cells or placebo infusion|Over-the-wire balloon catheter delivers infusion into coronary vessel using a stop-flow technique
1825683|NCT00765453|Other|Placebo infusion|Placebo infusion
1825684|NCT00765466|Drug|AVR118|daily doses of 4.0 mL AVR118 subcutaneously
1825685|NCT00765479|Dietary Supplement|soy protein isolate|Given orally
1825686|NCT00765479|Other|placebo|Given orally
1825687|NCT00765492|Drug|AZD8529|oral
1825688|NCT00765492|Drug|Placebo|oral
1825689|NCT00765505|Behavioral|Exercise Group|Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
1825690|NCT00765505|Behavioral|Health Education Group|Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
1825691|NCT00765518|Biological|Ixmyelocel-T|CRCs will be administered via direct injection into the heart muscle.
1825692|NCT00765518|Other|Standard of Care|
1825693|NCT00765531|Radiation|Radiological testing|Bone mineral density
1825694|NCT00765531|Genetic|Pediatric Urologic DNA and History Repository|"All Stone Forming Patients and their families will undergo one of three groups of testing:
Testing 1 - This testing form involves using a specimen from the Pediatric Urologic Blood, Tissue, Urine, Serum, and DNA Repository.
Testing 2 - Involves complete in-patient evaluation at UT Southwestern GCRC for patients with hypercalciuria and their families.
Testing 3 - Involves simple out-patient evaluation for patients with hypercalciuria and their family members."
1825695|NCT00765544|Device|Anklebot|The Ankle-Bot (Wheeler et al., 2004) is a stand-alone robot assisted device that is worn via a leather boot and knee brace (Fig.1). The Ankle-Bot can assist ankle movement throughout 3 planes. The percentage of force generated by the Ankle-Bot can be adjusted from no help, 0% assistance to 100% assistance. The device is low impedance and a subject can easily over come the forces generated by the Ankle-Bot. The Ankle-Bot will guide and assist the subject into ankle flexion, extension, inversion and eversion.
1825696|NCT00765544|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill .
1825697|NCT00765557|Drug|Miralax|Every subject will be given one bottle of the laxative/placebo, and depending on the patient's weight, will be instructed to take 1-3 tsps (.75 gm/kg) of the medication daily.
1825698|NCT00765570|Radiation|Spatially Fractioned Radiation Therapy|evaluate response to radiation therapy by a large bulky tumor influenced by adding a single dose of 15 Gy grid radiotherapy.
1825699|NCT00765570|Radiation|Treatment Group 1|one treatment of Grid therapy followed by 15 treatments with standard radiation
1825700|NCT00765570|Radiation|Standard radiation|15 Standard radiation treatments
1825701|NCT00765570|Radiation|Standard radiation|standard radiation treatment
1825703|NCT00765596|Other|Liquid diet for 3 days|The control group were given a 3 -day liquid diet similar to the RYGB post-op diet
1825704|NCT00765635|Drug|drops intilation (Taponoto ® )|four drops, unique doses
1825705|NCT00765635|Drug|drops intilation (Otocerum®)|four drops, unique doses
1825706|NCT00765635|Drug|drops intilation (Placebo)|Placebo
1825707|NCT00765648|Drug|nicardipine intravenous|nicardipine intravenous 5 mg/hour titrated every 5 minutes by 2.5 mg/hour until target systolic blood pressure range (TSBPR) is reached or maximum dose of 15 mg/hour is achieved.Following achievement of target systolic blood pressure range the infusion rate should be decreased to 3 mg/hour
1825708|NCT00765648|Drug|Labetalol|Labetalol: bolus therapy to start at 20 mg intravenous injection over 2 minutes, may repeat 20mg, 40mg or 80mg injections every 10 minutes until target systolic blood pressure range(TSBPR)is reached or a maximum of 300 mg is injected.
1825709|NCT00765661|Drug|Tacrolimus (Tacro™)|"The initial dose at 0.14 mg/kg (daily dose for African-American is 0.17 mg/kg), oral in the morning (before noon) within 12 hours after transplantation. Subsequent doses adjusted to maintain a target tacrolimus trough level of 7 - 20 ng/mL for (PK) phase of the study (through Study Day 14). Post PK maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
Other Names:
Tacrolimus modified-release"
1825710|NCT00765661|Drug|Prograf|"Prograf® capsules, twice daily: Starting total daily dose of 0.10 mg/kg administered in two equally divided doses, morning and evening, per product labeling. Subsequent doses adjusted to maintain a target whole blood tacrolimus trough level of 7 - 20 ng/mL for the remainder of the pharmacokinetic (PK) phase of the study (through Study Day 14). Post PK patient enter the maintenance phase of the study and remain on assigned study drug until Study Day 360. Dose of study drug was adjusted to maintain tacrolimus trough levels between 5 - 20 ng/mL from Day 15 until Day 90 and then between 5 - 15 ng/mL for the remainder of the study according to local standard of care.
Other name: tacrolimus"
1825711|NCT00765674|Drug|Aliskiren|150 and 300 mg tablets
1825712|NCT00765674|Drug|Amlodipine|5 and 10 mg capsules
1825713|NCT00765674|Drug|Hydrochlorothiazide (HCTZ)|12.5 and 25 mg capsules
1825714|NCT00765674|Drug|Placebo|tablet
1825715|NCT00765674|Drug|Placebo|capsules
1825716|NCT00765687|Drug|bisphosphates|any bisphosphate, repeated every 4 weeks for up to 24 months. Co-administration with Zometa: Calcium 500 mg + vitamin D 400-500 IU daily
1825717|NCT00765700|Drug|Topical Ketoprofen 10% Cream|Topical Administration
1825718|NCT00765700|Drug|Topical Placebo Cream|Topical Administration
1825719|NCT00765713|Device|Nasal continuous positive airway pressure|Nocturnal
1825720|NCT00765726|Biological|Moroctocog alfa(AF-CC)|Dosing is at the discretion of the investigator during the study
1825721|NCT00765726|Procedure|Blood draw for laboratory testing|Hematology and Chemistry panels, Factor VIII inhibitor and recovery studies
1825722|NCT00765739|Other|Neuromuscular electrical stimulation|neuromuscular electrical stimulation that produce 40% of the maximum voluntary contraction
1825723|NCT00765739|Other|voluntary strengthening exercise|contracting the quadriceps muscle voluntarily to produce 40% of maximum voluntary contraction
1825724|NCT00765765|Drug|hydroxychloroquine|Dose escalation from 200 mg po qd to 200 mg po bid.
1825725|NCT00765765|Drug|ixabepilone|Starting dose of 40 mg/m2 and can dose reduce to 32 mg/m2.
1958626|NCT01435772|Biological|BMN 701|GILT-tagged recombinant human GAA
1825728|NCT00765804|Drug|EGP-437 with EyeGate® II System|Transscleral iontophoretic delivery of EGP-437 (dexamethasone phosphate ophthalmic solution 40 mg/mL) delivered via EyeGate® II Drug Delivery System
1825729|NCT00765804|Drug|Sodium citrate buffer solution with EyeGate® II System|Transscleral iontophoretic delivery of sodium citrate buffer solution 100 mM delivered via EyeGate® II Drug Delivery System
1825730|NCT00765817|Drug|placebo|subcutaneous injection, twice a day
1825731|NCT00765817|Drug|exenatide|subcutaneous injection, twice a day, 10mcg
1825732|NCT00765830|Drug|vildagliptin|50mg qd
1825733|NCT00765830|Drug|Placebo|qd
1825734|NCT00765843|Device|orthoses|orthoses are provided for use in standardized shoes that all subjects receive
1825735|NCT00765856|Drug|Oxymorphone IR - Opioid|Opana IR 5mg tablet
1958627|NCT01435174|Drug|Ranolazine|A single dose of two oral ranolazine extended release 500 mg tablets
1958628|NCT01435174|Procedure|Pharmacokinetic Blood and Dialysate Sampling|Blood samples collected to assess ranolazine plasma and dialysate concentrations.
1825739|NCT00765882|Drug|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
1825740|NCT00765882|Drug|Linaclotide 145 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
1825741|NCT00765882|Drug|Placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
1825742|NCT00765895|Drug|Nortriptyline Hydrochloride|Nortriptyline; 10 mg, one capsule, po qhs (by mouth at bedtime each night) x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks, f06 visit, 50 mg, two capsules, po qhs x 3 weeks, f09 visit, 75 mg, three capsules, po qhs x 6 weeks, f15 visit: taper study drug by one capsule a week, off study drug for the last week
1825820|NCT00771979|Drug|AZD0530|of both the Phase II and Phase III AZD0530 125mg tablet variants (A and B) in a random order.
1825743|NCT00765895|Drug|Placebo (for nortriptyline)|Placebo (for nortriptyline), 10 mg, one capsule, po qhs x 3 weeks, f03 visit, 25 mg, one capsule, po qhs x 3 weeks;
1825744|NCT00765908|Device|Angioplasty balloon|90 second balloon inflation x 2
1825745|NCT00765908|Device|Angioplasty balloon|30 seconds or less balloon inflations x 2
1825746|NCT00765921|Drug|ranibizumab|Ranibizumab dose of 0.5mg or 1.0 mg will be administered intravitreally at the time of surgery for tumor localization and then bimonthly for 22 months (total of 12 injections).
1825747|NCT00765934|Drug|Rapydan|lidocaine / tetracaine 70/70 mg patch
1825748|NCT00765947|Drug|Aliskiren|Aliskiren 150 or 300 mg
1825749|NCT00765947|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 or 25 mg
1825750|NCT00765947|Drug|Amlodipine|Amlodipine 5 or 10 mg
1825753|NCT00765986|Other|18F-FAZA|Radioactive dose of 110-600 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) of RT, then 4 weeks, 90 days and 12 months post-RT and upon logo-regional progression or recurrence.
1825754|NCT00765986|Other|18F-Fluorodeoxyglucose (18F-FDG)|Radioactive dose of 100-710 MBq per injection. Up to a maximum of 6 injections per patient: pre-Tx, after 4 weeks (20 fractions) RT, then 4 weeks, 90 days, and 12 months post-RT, and upon loco-regional progression or recurrence.
1958629|NCT01435174|Procedure|QT Interval|Calculation of a QT interval will be performed throughout subject participation.
1825756|NCT00766012|Drug|AZD2066|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
1825757|NCT00766012|Drug|Placebo|Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
1825758|NCT00766025|Drug|Rosuvastatin Calcium|single oral dose on days 1, 4, 5, 6, 10-16, 17
1825759|NCT00766038|Drug|Recombinant human Growth Hormone|400 micrograms/day SC for 6 months. Dose adjusted based on serum IGF-1 measurements
1825760|NCT00766038|Drug|Placebo|SC injection daily
1825761|NCT00766051|Other|The intervention group: Neurophysiologically Based Occupational Therapy Intervention (NBOTI)|This study included a pre-feeding, feeding, and postural-respiratory protocol, given per the attending physician's order. The interventions were given daily when possible, and the infants FiO2 and heart rate, along with stress behaviors, were monitored prior to, during, and after the NBOTI. The intervention included parent education for feeding, handling, and interaction with their infant, along with nursing training during the feeding session. The occupational therapy investigator partnered with the parents and when the parents were not available, she partnered with the nursing staff.
1825762|NCT00766064|Drug|Paliperidone|"Paliperidone will be gradually increased to a final dose between 3 - 6 mg/day according to the following schedule:
Weeks 1 - 3: 3 mg daily, Weeks 4 - 5: flexible dosing according clinical situation, dose range between 3 mg - 6 mg daily*, Week 6: fixed dose,
*Criteria to increase the dose from 3 mg to 6 mg daily are 1] absence of any side effects, 2] patients not showing a sufficient response to 3 mg paliperidone can be increased to 6 mg daily. Response is defined as change in depression and anxiety ratings of at least 30% compared to baseline."
1825763|NCT00766090|Drug|GW685698X|Inhaled Corticosteroid
1825764|NCT00766103|Other|mild hypo- and hyperventilation|induction of mild hypo- and hypercarbia
1825765|NCT00766116|Drug|5-Azacitidine|A = given in cohorts of 3 starting with 2 doses of 5-azacitidine. The doses of 5-azacitidine will be escalated to 4 and then 6 doses if the dose escalation rules permit
1825766|NCT00766116|Drug|Gemtuzumab ozogamicin|M = Mylotarg given 2 times over 2 weeks
1825767|NCT00766129|Device|Taxus stent implantation|Patients will be treated with implantation of Taxus stent
1825768|NCT00766129|Device|Luc-Chopin stent|Patients will be treated will implantation of Luc-Chopin stent
1825769|NCT00766142|Biological|cetuximab|
1825770|NCT00766142|Drug|fluorouracil|
1825771|NCT00766142|Drug|leucovorin calcium|
1825772|NCT00766142|Drug|oxaliplatin|
1825773|NCT00766142|Procedure|adjuvant therapy|
1825774|NCT00766142|Procedure|therapeutic conventional surgery|
1825775|NCT00766155|Drug|capecitabine|Given orally
1825776|NCT00766155|Drug|oxaliplatin|Given IV
1825779|NCT00766181|Behavioral|Zingo TM (lidocaine hydrochloride monohydrate) powder intradermal injection system|0.5 mg lidocaine hydrochloride
1825780|NCT00766207|Other|Clinical decision support|multi-faceted decision support
1825781|NCT00766207|Other|stream-lined clinical alert|electronic notification that a medication is potentially teratogenic
1825782|NCT00766220|Drug|SIR-spheres Agent Administration|SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
1825783|NCT00766220|Drug|Cetuximab|"400 mg/m2 by vein over 2 hours once a week.
Cetuximab infusions will be continued weekly at a dose of 250 mg/m2 unless toxicity necessitates interruptions."
1825784|NCT00766220|Drug|Irinotecan|350 mg/m2 (or 300 mg/m2 in patients who are greater or equal to 70 years of age, or have an ECOG PS of 2 or have had prior pelvic and/or abdominal irradiation), by vein over 90 minutes, every three weeks.
1825785|NCT00766233|Other|Hyperthermal treatment|Hyperthermal treatment one or three times per week for 60 minutes
1825786|NCT00766246|Drug|bevacizumab|15 mg/kg administered in 21 day cycles on day 1 of each cycle for first-line and maintenance
1825787|NCT00766246|Drug|docetaxel|75 mg/m2 administered in 21-day cycles on day 1 of each cycle for first line treatment
1825788|NCT00766246|Drug|carboplatin|AUC=6 administered in 21-day cycles on day 1 of each cycle for first-line treatment
1825869|NCT00772291|Drug|placebo|placebo drug during 8 weeks
1825789|NCT00766272|Device|Lokomat|Body-weight will be supported using a harness, which suspends the subject above a motorized treadmill (Lokomat, Hocoma, Zurich, Switzerland). The system also incorporates a robot-driven gait orthotic, called the Lokomat, which will be secured to the subject's lower extremity and pelvis using adjustable cuffs and pads. The Lokomat uses computer-controlled motors to drive the hips and knees toward more normative kinematic patterns for gait.
1825790|NCT00766285|Biological|Trivalent inactivated influenza vaccine|Standard trivalent influenza vaccine consisting of 15 mcg per antigen (45 mcg total) by intramuscular deltoid injection.
1825791|NCT00766285|Biological|Trivalent Baculovirus-expressed Influenza HA vaccine|Influenza virus hemagglutinin proteins expressed in insect (SF+) cells under serum free conditions by recombinant baculovirus.
1825792|NCT00766298|Behavioral|Exercise|16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR
1825793|NCT00766298|Behavioral|Weight Loss|The reduction of kcal/day through implementation of low fat diet
1825794|NCT00766298|Behavioral|Exercise and weight loss|"Exercise: 16 week intervention; 6 exercise sessions weekly w 3 supervised exercise sessions weekly utilizing cycling or walking/jogging. Participants maintain exercise diaries: wks 1-4; 30 minutes at 60-70% MHR, wks 5-8; 40 minutes at 60-70% MHR, weeks 9-16; 40 minutes at 75% MHR.
Weight Loss: Reduction of kcal/day through implementation of a low fat diet."
1825795|NCT00766311|Other|Gross Motor Function|The Bruinicks-Osteretsky Test of Motor Proficiency Version 2 (BOT-2) will be used to measure participants' motor function. The test is norm- referenced and designed to test motor function in children and adolescents 4 -21 years of age. The motor composite score describes overall motor abilities and is comprised of fine motor control, manual coordination, body coordination, and strength and agility. We will use the total motor composite to describe overall motor function.
1825796|NCT00766311|Other|Knee extension strength|"Maximum isometric knee extension strength will be measured with the subject seated in an adjustable straight-back chair. The pelvis will be fixed by an adjustable strap and the knee flexed to 45 degrees. The participant will exert a maximal voluntary force until their contraction is broken."
1825797|NCT00766311|Other|Hand grip strength|Hand grip strength in kilograms will be measured using a Jamar hand held dynamometer (Sammons Preston Rolyan, Nottinghamshire, UK). Participants will be seated with the shoulder at 0-10 degrees and the elbow in 90 degrees of flexion. The forearm will be positioned in neutral. Each participant will complete three trials, and the average used for analysis.
1825798|NCT00766311|Other|Flexibility|Flexibility will be measured by having the participant perform the sit and reach test. A yardstick is placed on a firm flat surface and tape is placed across it at a right angle to the 15 inch mark. The participant sits with the yardstick between the legs with legs extended at right angles to the taped line on the floor. The heels of the feet touch the edge of the taped line and are 10-12 inches apart. The participant reaches forward with both hands as far as possible, keeping the hands parallel. The best value for three trials, in centimeters, at the most distant point of the fingertips is recorded.
1825799|NCT00766311|Other|Ankle range of motion|Ankle dorsiflexion active and passive range of motion will be measured with a goniometer. The goniometer is a reliable and valid measure of active and passive range of motion if the rater uses standard procedures
1825800|NCT00766311|Other|Aerobic capacity|Participants will complete the modified Cooper test where they walk in a corridor as fast as possible for six minutes. The distance is recorded in meters and can also be used to estimate peak V02
1825801|NCT00766311|Other|Body composition and vital signs|Height, body mass index, waist circumference, and blood pressure will be measured.
1825802|NCT00766324|Drug|PHA-739358|6-hr IV infusion weekly for 3 consecutive weeks in a 4-week cycle
1825803|NCT00766324|Drug|PHA-739358|24-hr IV infusion every 2 weeks in a 4-week cycle
1825807|NCT00766350|Drug|amitriptyline|initial dose 10 mg/day, target dose: 25 mg/day, maximum dose: 75 mg/day, dosage form: tablets, duration: 16 weeks
1825808|NCT00766350|Drug|quetiapine|initial dose: 50 mg/day, target dose: 100 mg/day, maximum dose: 300 mg/day, dosage form:extended release tablets , duration: 16 weeks
1825809|NCT00766363|Drug|EVP-6124 (0.1 mg/day)|EVP-6124 was administered as one 0.1 mg capsule per day for 28 days.
1825810|NCT00766363|Drug|EVP-6124 (0.3 mg/day)|EVP-6124 was administered as one 0.3 mg capsule every day for 28 days.
1825811|NCT00766363|Drug|EVP-6124 (1.0 mg/day)|EVP-6124 was administered as one 1.0 mg capsule every day for 28 days.
1825812|NCT00766363|Drug|Comparator: Placebo|Matching placebo was administered as one capsule per day for 28 days.
1825813|NCT00766363|Drug|Donepezil|Concomitant therapy with donepezil at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
1825814|NCT00766363|Drug|Rivastigmine|Concomitant therapy with rivastigmine at a stable dose, taken daily at the same time or immediately after the assigned EVP-6124 dose. Patients must have been taking concomitant therapy for at least 3 months prior to enrollment to be eligible for the study.
1825815|NCT00766376|Device|Erbium laser|Erbium laser treatment. Each subject will undergo up to 6 treatment sessions
1825816|NCT00766402|Drug|Tramadol /acetaminophen|Participants will receive a combination tablet of 37.5 milligram (mg) tramadol and 325 mg acetaminophen, orally twice daily up to 8 weeks.
1825817|NCT00766402|Drug|Diclofenac|Participants will receive 50 mg diclofenac tablet, orally twice daily up to 8 weeks.
1825818|NCT00771966|Procedure|Standard therapy|Standard therapy
1825819|NCT00771966|Procedure|Maximization of cardiac stroke volume with fluid infusion|Maximization of cardiac stroke volume with fluid infusion
1826301|NCT00776334|Drug|Fosinopril 40mg Tablets|
1958635|NCT01433445|Drug|panobinostat|Given 3 times a week, every other week in 28-day cycles.
1958636|NCT01433445|Drug|ruxolitinib|Given twice daily in 28-day cycles.
1825821|NCT00771979|Drug|AZD0530|Part II: Single doses of AZD0530 125mg oral solution and 2 out of 4 125mg tablet variants (C, D, E and F) in a random order.
1825822|NCT00771992|Procedure|Bronchoscopy|Bronchoscopy with segmental allergen challenge
1825823|NCT00772005|Drug|armodafinil|150 mg/day armodafinil
1825824|NCT00772005|Drug|placebo|placebo
1825825|NCT00772005|Drug|armodafinil|200 mg/day armodafinil
1825826|NCT00772005|Drug|armodafinil|250 mg/day armodafinil
1825827|NCT00772031|Drug|propranolol LA|Propranolol LA up to 240 mg/day
1825828|NCT00772031|Drug|topiramate|Topiramate is an effective, safe and generally well-tolerated drug used for treating chronic migraine. It is becoming the standard treatment among headache specialists.
1825829|NCT00772031|Drug|placebo|an inactive substance
1825830|NCT00772044|Device|Provent Professional Sleep Apnea Therapy Device|Application of active device (Provent)
1825831|NCT00772044|Device|Sham Device|Sham device will be applied
1825832|NCT00772057|Drug|Propranolol|Beta-blocker (propranolol) was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
1825833|NCT00772057|Drug|Placebo|Placebo tablets given two times daily.
1825834|NCT00772070|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
1825835|NCT00772070|Biological|A/C/Y/W-135, Meningococcal Polysaccharide Vaccine (Menomune®)|0.05 mL, Subcutaneous
1825836|NCT00772083|Behavioral|Educational brochure|This brochure will educate anemic blood donors regarding the possible causes of their anemia, and based on age will make recommendations for who should seek consultation with a physician.
1825837|NCT00772083|Behavioral|Standard pamphlet|The BloodCenter of Wisconsin's default action when a potential donor has been found to be anemic is to provide a standard pamphlet with very basic nutritional information.
1825838|NCT00772096|Drug|n-3 fatty acids|
1825839|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
1825840|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
1825841|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
1825842|NCT00772109|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
1825843|NCT00772122|Drug|G-CSF|daily sub-cutaneous administration of the recombinant G-CSF, at a dosage of 1 microgram (100000 IU)/kg/day from the 6th day after ovulation till the occurrence of menstruation or to the end of the 9th week of gestation.
1825844|NCT00772122|Drug|saline solution|daily sub-cutaneous administration of saline solution 0.2ml from the 6th day after the ovulation till to the recurrence of menstrual loss or to the end of the 9th week.
1825845|NCT00772135|Drug|sildenafil citrate|capsule of 50 mg , 90 minutes before exercise study
1825846|NCT00772148|Drug|LCP -Tacro|"LCP-Tacro tablets will be administered orally once daily in the morning starting at 0.07 - 0.11 mg/kg. The starting dose for African-American patients will be 0.09 - 0.13 mg/kg. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.
Other Names:Tacrolimus modified-release LCP-Tacro™ tablets (0.5 mg, 1 mg, 2 mg, 5 mg)"
1825847|NCT00772148|Drug|Prograf|"Oral Prograf capsules will be administered starting at 0.10 - 0.15 mg/kg per day in two equally divided morning and evening doses. Subsequent doses of each study drug will be adjusted to maintain target whole blood tacrolimus trough levels of 5 - 20 ng/mL.
Other name: tacrolimus Prograf® capsules (0.5 mg, 1 mg, 5 mg)"
1825848|NCT00772161|Drug|Methylphenidate|Comparison of two extended-release formulations of 20mg Methylphenidate in a cross-over design.
1825849|NCT00772174|Drug|Pioglitazone and Metformin|Pioglitazone 15 mg, tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone 15 mg, tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
1825850|NCT00772174|Drug|Metformin|Pioglitazone placebo-matching tablets, orally, two-times daily and metformin stable dose, orally, three-times daily for 4 weeks; then increased to pioglitazone placebo-matching tablets, orally, three-times daily and metformin stable dose, orally, three-times daily for up to 20 weeks.
1825851|NCT00772187|Drug|morphine|Single dose: 0.1-0.5 mg
1825852|NCT00772187|Drug|intrathecal analgesia (morphine)|0.1-0.5 mg of morphine
1825853|NCT00772187|Drug|general anesthesia (fentanyl)|general anesthesia alone
1825858|NCT00772213|Procedure|MIGTS treatment|treatment of multiple trauma patients in the MIGTS
1825859|NCT00772226|Device|music pillow|according to randomisation patients will receive with/without music.
1825860|NCT00772226|Device|pillow without music|According to randomisation patients will receive a pillow with/without music
1825861|NCT00772239|Device|Rotation thromboelastometry (ROTEM)|Coagulation measurement
1825862|NCT00772239|Procedure|Standard coagulation managment procedure|Standard coagulation managment procedure
1825863|NCT00772252|Other|liver support treatment|plasma exchange for liver support treatment
1825864|NCT00772265|Biological|Wosulin N|Total Dose per subject will be 0.4IU/Kg given Subcutaneously.
1825865|NCT00772265|Biological|Novolin N|Total dose per subject will be 0.4 IU/Kg given Subcutaneously.
1825866|NCT00772278|Procedure|carotid artery stenting|carotid artery angiography, angioplasty and stenting
1825867|NCT00772278|Procedure|carotid endarterectomy|open surgery including endarterectomy
1825868|NCT00772291|Drug|pregabalin|pregabalin 150-600mg/day during 8 weeks
1825870|NCT00772486|Biological|ISF35|Subjects participating in this study will receive a course of three infusions of 3x10^8 ISF35-transduced cells at periods of not less than 14 days apart followed by a standard regimen of three cycles of fludarabine, cyclophosphamide and rituximab (FCR) at monthly intervals.
1825871|NCT00772499|Drug|olmesartan medoxomil + hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
1825872|NCT00772499|Drug|atenolol+ hydrochlorothiazide + amlodipine + hydralazine if necessary to control blood pressure|Tablets and capsules for oral administration once or twice daily for up to 52 weeks
1825873|NCT00772512|Drug|PF-04802540|5 mg capsule, single dose
1825874|NCT00772512|Drug|PF-04802540|15 mg capsule, single dose
1825875|NCT00772512|Drug|Placebo|Placebo capsule, single dose
1825876|NCT00772525|Drug|Nerispirdine|"form: tablet
Route: oral"
1825877|NCT00772525|Drug|Placebo|"form: tablet
Route: oral"
1825878|NCT00772538|Drug|tiotropium 5mcg/day|Intervention = randomisation: Patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo
1825879|NCT00772538|Drug|placebo|Matching placebo
1825882|NCT00772564|Drug|Atorvastatin|Oral Atorvastatin
1825883|NCT00772577|Drug|Aliskiren Hydrochlorothiazide|Aliskiren HCTZ 150/12.5 mg: 1 week; Aliskiren HCTZ 300/25 mg: 7 weeks
1825884|NCT00772577|Drug|Ramipril|Ramipril 5mg: 1 week; Ramipril 10 mg: 7 weeks
1825885|NCT00772590|Drug|Raltegravir|Tablets, 400mg, twice daily
1825886|NCT00772590|Drug|Hyper-immune Bovine Colostrum|Tablet, 1800mg, twice daily
1825887|NCT00772590|Other|raltegravir placebo|One tablet, twice daily
1825888|NCT00772590|Other|Hyper-immune Bovine Colostrum placebo|Three tablets twice daily
1825889|NCT00772590|Drug|raltegravir and hyper-immune bovine colostrum|400mg twice daily raltegravir and 1800mg twice daily of hyper-immune bovine colostrum
1825890|NCT00772603|Drug|Placebo|Non-active tablet identical to study drug tablets
1825891|NCT00772603|Drug|2400mg SPN-804|tablets containing 600mg OXC XR, identical to non-active tablets
1825892|NCT00772603|Drug|1200mg SPN-804|two active tablets and two non-active tablets, all identical
1825893|NCT00772616|Drug|Remifentanil|closed-loop administration using bispectral index as the single input for the controller.
1825894|NCT00772616|Drug|Sufentanil|dosage according to usual criteria
1825895|NCT00772629|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1825896|NCT00772629|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1825897|NCT00772655|Drug|90Yttrium-Ibritumomab Tiuxetan (Zevalin®)+Rituximab|A single course of 90Y-Ibritumomab Tiuxetan (according to the standard procedure that includes Rituximab 250 mg/m2 plus 111In-Ibritumomab Tiuxetan for dosimetry on day one followed by Rituximab 250 mg/m2 and 90Y-Ibritumomab Tiuxetan 15 MBq/kg on day 8 or 9 [if platelets are below 150000/µl only 11 MBq/kg are administered).
1825898|NCT00772655|Drug|Rituximab|Consolidation/maintenance therapy with 4 weekly courses of Rituximab 375 mg/m2 followed by 4 bimonthly courses of Rituximab 375 mg/m2 for patients in clinical CR but with persistent Bcl-2-positivity 6 months after 90Y-Ibritumomab Tiuxetan.
1825899|NCT00772668|Drug|Rituximab|375 mg/m2 IV infusion at 50 mg/hr on Day 1 of every 21 days cycle for 8 cycles
1825900|NCT00772668|Drug|Bortezomib|1.6 mg/m2 IV push over 3-5 seconds on Days 1 and 8 of every 21 days cycle for 8 cycles
1825901|NCT00772668|Drug|Cyclophosphamide|750 mg/m2 IVPB over 30 minuntes on Day 1 of every 21 day cycle for 8 cycles
1825902|NCT00772668|Drug|Prednisone|100 mg PO daily on Days 1-5 of every 21 day cycle for 8 cycles
1825903|NCT00772681|Drug|docetaxel and cisplatin|3 cycles of docetaxel 75mg/m2 and 100mg/m2 cisplatin combination every 3 weeks
1825904|NCT00772694|Drug|sorafenib|tablets 200mg, 400mg bid continuously in 4-week cycles
1825905|NCT00772707|Device|Multi-Purpose Disinfecting Solution (OPTI-FREE RepleniSH)|OPTI‐FREE RepleniSH® used according to product labeled instructions for cleaning and disinfecting study contact lenses, 30 days.
1825906|NCT00772707|Device|Contact Lenses|Contact lenses per participant's habitual prescription removed nightly for cleaning and disinfecting.
1825907|NCT00772720|Drug|raltegravir|raltegravir 400 mg BID for 7 days
1825908|NCT00772720|Drug|Placebo|Placebo BID for 7 days
1825909|NCT00772759|Drug|AZD3199 Turbuhaler®|240, 720 and 2160 μ g, single and multiple (o.d. for 12 days)
1825910|NCT00772759|Drug|Placebo Turbuhaler®|single and multiple (o.d. for 12 days)
1825911|NCT00772772|Drug|Vitamin D3|2 single oral dose of Vitamin D3 30,000 international units and 8 weeks supply of Vitamin D3 (10,000 IU tablets, 3 pills to be taken by mouth as one dose weekly)
1825912|NCT00772785|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug. (4 implants 6-month duration)
1825913|NCT00772798|Drug|Paclitaxel, Carboplatin and Vorinostat|Intravenous paclitaxel (175 mg/m2) and carboplatin (AUC 5) and oral vorinostat 400 mg day 1-14 every three weeks.
1825914|NCT00772811|Drug|Flu-Mel|"Fludarabine and Melphalan will be infused intravenously over 30 minutes in D5W 100 mL.
Melphalan will be administered following the completion of Fludarabine infusion at day -2."
1825915|NCT00772824|Dietary Supplement|Glutamine|2g/kg body weight twice daily in divided doses for 5 days
1825916|NCT00772824|Dietary Supplement|IV Glutamine|50 ml of 20% glutamine IV before chemotherapy
1825917|NCT00772837|Drug|Omeprazole + Clarithromycin + Amoxycillin|Omeprazole 20mg BID for 1 week along with Clarithromycin 500mg BD and Amoxycillin 1g BD for 1 week
1825918|NCT00772837|Drug|Omeprazole + placebo antibiotics|omeprazole 20 mg bid for 1 week along with placebo antibiotics for 1 week
1826027|NCT00773747|Drug|placebo to vorinostat|Four placebo capsules taken orally, once daily, on Days 1-14 of each 21-day treatment cycle.
1958640|NCT01425723|Biological|rFIXFc|Administered as specified in the treatment arm.
1994419|NCT03008252|Other|DBPC cow's milk protein challenge|DBPC cow's milk protein challenge in NCWS patients with symptoms related to milk and/or milk derivates ingestion.
1994420|NCT03008616|Biological|Digoxin immune fab|Digoxin immune fab 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
1994421|NCT03008616|Other|Placebo|Normal saline, 30 minute IV infusion, every 6 hours x 4 days
1825919|NCT00772863|Drug|docetaxel and cisplatin|4 cycles Cisplatin 100 mg/m2 at every 3 weeks, after Cisplatin 4 cycles of docetaxel 100mg/m2 at every 3 weeks
1825920|NCT00772876|Drug|P1446A-05|P1446A-05 capsules will be given once daily for 28 days in each 28 day cycle for 4 such cycles. The starting dose, for first cohort will be 75 mg once daily. Subsequent cohorts of patients will receive higher doses till the recommended phase II dose is identified.
1825921|NCT00772889|Biological|Influenza vaccine GSK2186877A|One intramuscularly injection at Day 0
1825922|NCT00772889|Biological|GSK Biologicals' Fluarix™|One intramuscularly injection at Day 0
1825923|NCT00772902|Drug|Truvada + Kaletra|Truvada (emtricitabine 200 mg/tenofovir DF 300 mg)once daily for oral administration according to prescription information. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
1825924|NCT00772902|Drug|Kivexa + Kaletra|Continuing Kivexa (abacavir sulfate 600 mg/lamivudine 300 mg) once daily for oral administration according to prescription. As third agent, continuing Kaletra (lopinavir 200 mg/ritonavir 50 mg) for oral administration according to prescription.
1825925|NCT00772915|Drug|dexamethasone|"Dose: -40 mg once weekly (days 1, 8, 15, & 22) orally with food until progression.
If after 3 cycles, a partial response is not achieved on lenalidomide alone, dexamethasone 10 mg weekly will be added, and the weekly dexamethasone dose will be increased by 10 mg each cycle to a maximum of 40 mg weekly, as long as a partial response is not achieved. If a partial response is achieved at a dose of dexamethasone less than 40 mg weekly, patients will continue on that dose. If progression at any time, increase dexamethasone to 40 mg weekly. Patient will go off study only when progression is documented while receiving 40 mg/week of dexamethasone or the maximum tolerated dose of dexamethasone (if prior dose reductions have been implemented for toxicity). Increases in dexamethasone dose are to be made only at the initiation of a cycle.
If progression at any time while on lenalidomide alone (first 3 cycles), add dexamethasone 40 mg weekly."
1825926|NCT00772915|Drug|lenalidomide|"25mg once daily orally with food on days 1-21 of 28 day cycle until progression or to a maximum of 18 cycles.
Lenalidomide alone will be administered for the first 3 cycles, then in combination with dexamethasone as needed (described)."
1825927|NCT00772928|Biological|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
1825928|NCT00772928|Biological|Pentacel™: HCPDT-IPV//PRP-T Vaccine and Prevnar®|0.5 mL, Intramuscular
1825929|NCT00772941|Drug|Varenicline|"Champix Tablets 0.5mg or Champix Tablets 1mg, depending on the Investigator prescription.
Frequency and duration are according to Package Insert as follows.
The usual adult dosage for oral use is 0.5 mg of varenicline once daily after eating for days 1 to 3, 0.5 mg twice daily after eating in the morning and evening for days 4 to 7, and 1 mg twice daily after eating in the morning and evening on and after day 8. The drug should be administered to patients for 12 weeks."
1825930|NCT00772954|Biological|Vaccine diluent buffer|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
1825931|NCT00772954|Biological|Clostridium difficile toxoid vaccine (50 μg)|0.5 mL, Intramuscular at Day 0, Day 28 and Day 56, respectively.
1825932|NCT00772954|Biological|Clostridium difficile toxoid vaccine (100 μg)|0.5 mL, Intramuscular on Day 0, Day 28 and Day 56, respectively.
1825933|NCT00772967|Drug|Naproxen|Naproxen tablets 500 mg twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Twice daily on Day 2 and 500 mg once daily on Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
1825934|NCT00772967|Drug|Placebo|Placebo capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and 2 capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
1825935|NCT00772967|Drug|Ultracet|Ultracet (tramadol/acetaminophen) 37.5/325 mg/mg capsules twice daily on Day 1, a first dose at t = 0 hrs, and a second dose at t = 12 hrs. Three times daily on Day 2, and two 37.5/325 mg capsules on the morning of Day 3. Walking tests will be performed on Days 1 and 3 of the treatment period.
1825936|NCT00772980|Drug|Neramexane mesylate|Double-blind treatment period of 17 weeks up to 75 mg Neramexane mesylate per day, 12 weeks follow-up.
1825937|NCT00772980|Drug|Placebo|Double-blind treatment period of 17 weeks placebo, 12 weeks follow-up.
1825938|NCT00773019|Device|Refills (SynchroMed® II Programmable Drug Infusion Pump)|Refill information at 1, 6, and 12 months post-implant, as well as any additional refills required from implant through end of study. Amount removed from the pump (taken from syringe), Amount placed in the pump (from syringe),Pump predicted amount remaining in the pump.
1825939|NCT00773032|Drug|Sodium Oxybate|2.5g Sodium Oxybate administered during nap
1825940|NCT00773032|Drug|Zolpidem|5mg Zolpidem administered during nap
1825941|NCT00773032|Drug|placebo|Placebo administered during nap
1825942|NCT00773045|Other|A Pain training program and pain measurement|Comparing patients treated with and without analgesia and sedation protocol
1825945|NCT00773071|Device|SPECT/CT guided LM/SL|Pre-operatively, SLNs will be detected by low-dose SPECT/CT (99mTc-cystein rhenium colloids, 1cc/1mCi). Intra-operatively, a blue-dye (Patent Blue, 2cc) and a gamma-probe guidance will be used to detect the SLN nodes. All blue-stained and/or hot lymph nodes with a radioactivity greater than 10% of the hottest node will be considered as SLNs. Serial sections of SLNs will be analyzed by H-E staining. In cases of negative H-E, the SLNs will be further analyzed by immunochemistry (CKAE1/CKAE3, and high molecular weight Cytokeratin 34BE12). Non-SLNs will be analyzed as usual in routine by H-E.
1825946|NCT00773084|Drug|Aliskiren plus spironolactone vs. Lisinopril plus spironolactone|Subjects will be in the study for a total of 8 weeks. Subjects with stable diastolic HF on current ACEI therapy will be randomized into two treatment groups. The study group will receive Aliskiren plus spironolactone and the control group will receive Lisinopril plus spironolactone. These 2 groups will be further divided according to ethnicity: Mexican Americans and non-Hispanic whites. Sixty patients will be recruited, 30 per treatment group. Subjects will have a 2 week wash-out period. At the end of this period, blood will be collected and subjects will be asked to take the assigned medication once daily for 6 weeks. Subjects will be asked to return every 2 weeks at which time blood pressure, serum potassium and creatinine levels will be assessed. Their medications will be titrated depending on clinical tolerance and symptom control. At the end of 6 weeks of treatment blood markers will be drawn and differences will be analyzed.
1825947|NCT00773097|Biological|MUC1 - Poly ICLC|The vaccine will be administered on an outpatient basis in the Digestive Disorders Clinic. The total volume of each dose of vaccine MUC1+ POLY-ICLC will be approximately 250 microliters subcutaneously (SQ) in the upper thigh. The site of injection will remain the same thigh, to enhance the potential immune response.
1825948|NCT00773110|Drug|20% Human albumin solution|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), 20% Human serum albumin(300 mL), 0.9% sodium chloride solution (200 mL) and heparin (10,000 IU)
1825949|NCT00773110|Drug|Gelofusin|Priming of the cardiopulmonary bypass circuit with Hartmann's solution (1000 mL), Gelofusine (300 mL, 4% succinylated gelatin, a synthetic colloid) and heparin (10,000 IU)
1825950|NCT00773136|Drug|Bimatoprost Suspension|see prior
1825951|NCT00773149|Drug|Alemtuzumab (CAMPATH 1H) associated to G-CSF|"All patients receive Alemtuzumab in 3 successive phases:
Phase A: Test week: 3mg, then 10mg, then 30mg every other day for one week to test for tolerance.
Phase B: 30mg 3 times a week for 12 to 18 administrations until response or progression/failure has been documented.
Phase C: in patients in CR, maintenance with Alemtuzumab: 3 injections one week every 2 months."
1825952|NCT00773162|Drug|Seroquel|seroquel XR- oral extended release tablets, 50mg - 300mg, 16 weeks
1825953|NCT00773162|Drug|Sugar Pill|Sugar pill to match seroquel
1825954|NCT00773175|Drug|recombinant human hyaluronidase|150 Units in 1 mL
1825955|NCT00773188|Drug|bevacizumab [Avastin]|7.5mg/kg iv or 15mg/kg iv every 3 weeks
1825956|NCT00773188|Drug|cisplatin|75mg/m2 iv according to a standard chemotherapy treatment protocol
1825957|NCT00773188|Drug|vinorelbine|15mg/m2 iv according to a standard chemotherapy treatment protocol
1825958|NCT00773201|Drug|Sotalol 80 mg|healthy subjects will receive an unique dose of Sotalol and will have an effort test on ergonomic bicycle, an auditive stimulation and a taking of DNA
1825959|NCT00773214|Behavioral|Exercise|12-week supervised exercise programme (5 times /week at 75% maximal Heart Rate)
1825960|NCT00773227|Procedure|Autologous myoblasts transplantation and myotomy|Graft of autologous cell muscles (myoblasts) isolated from unaffected limb muscles into the pharyngeal muscles of patients diagnosed as suffering from OPMD and surgical procedure (myotomy)
1825961|NCT00773240|Drug|Grazax|1 tablet, 75,000 SQ-T, daily during the trial period
1825962|NCT00773240|Drug|placebo|1 placebo tablet, matching the active treatment, daily during the trial period
1825963|NCT00773253|Drug|Botulinum toxin A|All patients will be treated with Botox using both single-channel and multi-channel EMG mapping.
1825964|NCT00773279|Device|FlexTouch®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
1825965|NCT00773279|Device|FlexPen®|All subjects to receive insulin detemir treatment (and if relevant insulin aspart) with either a insulin pen PDS290 (FlexTouch®) or a Novo Nordisk marketed insulin pen (FlexPen®) for 12 weeks. After 12 weeks, all subjects will continue their insulin treatment with the other injection device.
1825966|NCT00773292|Drug|ciclosporin|Ciclosporin 2.5 - 5mg/kg/day in two equally divided doses. dose adjusted according to trough ciclosporin concentration
1825967|NCT00773318|Procedure|SPECT/CT guided LM/SL|Detection, localization, and removal of sentinel lymph node (s) from prostate cancer guided by an integrated SPECT/low-dose multislice CT
1825968|NCT00773331|Drug|epoetin beta|As prescribed
1825969|NCT00773331|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|120, 200 or 360 micrograms every 4 weeks
1825970|NCT00773344|Drug|Tanespimycin|"Solution, IV, Weekly two hour infusion, 4-cycles until disease progression or DLT
This is a one-arm study with 4 fixed doses of Tanespimycin (225mg/m2, 300mg/m2, 375mg/m2 and 400mg/m2)"
1825971|NCT00773357|Drug|guanfacine|3 mg/day, with 3-week lead-in medication period. The starting dose is 0.5 mg/day for days 1-3, followed by 1.5mg/day for days 4-7, followed by 2 mg/day for days 8-12, followed by 2.5 mg/day for days 13-15, followed by 3 mg/day from day 16 to remainder of study. 5-day taper at end of study.
1825972|NCT00773357|Drug|placebo|placebo
1825973|NCT00773357|Drug|Carvedilol|50 mg/day titrated to stead state. The starting dose is 12.5 mg/day for day 1, followed by 25 mg/day for days 2-3, followed by 50 mg from days 4 to the end of the study.
1825974|NCT00773370|Behavioral|APA-Stroke|Exercise program design specifically for individuals with residual hemiparetic gait deficits due to stroke. Exercises are progressive, beginning with a 5 minute walk at the beginning and end of each class and gradually progressing to a 15 minute walk at the beginning and end of each class. Exercises focus on walking and are designed to improve walking ability and balance. Program includes a homework component.
1825975|NCT00773370|Behavioral|Sittercise|Not stroke specific. This less vigorous exercise program consists of seated exercise focusing on stretching to improve general range of movement and weight exercises to strengthen the trunk, arms, and legs. There is no assigned exercise homework.
1825976|NCT00773383|Drug|RG1507|iv 9mg/kg weekly
1825977|NCT00773383|Drug|erlotinib [Tarceva]|150mg oral daily
1825978|NCT00773422|Drug|naltrexone|25 mg/day, with 1-week lead-in medication period. The starting dose is 0 mg/day for days 1-3, followed by 12.5mg/day for day 4, followed by 25mg/day for days 5-7, plus during the laboratory session (day 8).
1825979|NCT00773422|Drug|varenicline|2mg/day, with 1-week lead-in medication period. The starting dose is 0.5mg/day for days 1-2, followed by 0.5mg twice daily for days 3-5, followed by 1.0 mg twice daily for days 6-7, plus during the laboratory session (day 8).
1825980|NCT00773422|Drug|placebo|placebo
1825981|NCT00773435|Biological|Echinacea purpurea 100 mg/ml in liquid formulation|10 ml BID for 10 consecutive days at the start of 3 consecutive 30 day periods
1825982|NCT00773435|Other|placebo|10 ml PO BID for 10 consecutive days at the beginning of 3 consecutive 30 day periods
1825983|NCT00773448|Device|Comprehensive computed tomography of the abdomen/pelvis|Virtual colonoscopy and gastroscopy, a biphasic enhanced CT for hepatoma and renal cell carcinoma, parenchymal pancreatogram with minimum intensity projection (MinIP) reformation for pancreatic carcinoma, and finally uniphasic enhanced CT of distended bladder for bladder and ovarian carcinomas.
1825984|NCT00773448|Other|Limited Malignancy Screening|"1) A complete medical history and physical examination; 2) complete blood count; 3) liver function tests (AST, ALT, ALP, bilirubin, LDH); 4) renal function test (creatinine); 5) chest X-ray (if not performed in the past year)
In women, a pap smear/pelvic examination (if > 18 and < 70 years old and not performed during the past year),a mammogram (> 50 years old) will be performed if not conducted in last year. Similarly for men, prostate examination +/- PSA testing (>40 years old) will be performed if not conducted in the past year."
1825985|NCT00773461|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
1825986|NCT00773461|Drug|Placebo|iv every 4 weeks for 24 weeks
1825987|NCT00773474|Drug|Lonafarnib|All registered patients will be treated with Lonafarnib 200 mg PO BID daily on days 1-21 of every 21-day cycle until progression of disease, unacceptable toxicity, or investigator's discretion.
1825988|NCT00773487|Other|Bonchoscopy|Segmental instillation of allergen/Diesel particles; bronchoalveolar lavage
1825989|NCT00773500|Other|Electronic prescribing|Implementation of a commercially available electronic prescribing system with clinical decision support
1825990|NCT00773513|Drug|Darbepoetin Alfa|Darbepoetin alfa will be administered as per approved label.
1825991|NCT00773513|Drug|Epoetin Alfa|Epoetin alfa will be administered as per approved label.
1825992|NCT00773513|Drug|Epoetin Beta|Epoetin beta will be administered as per approved label.
1825993|NCT00773513|Drug|methoxy polyethylene glycol-epoetin beta|Participants who are currently not being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta administered at a starting dose of 0.6 mcg/kg body weight once every 2 weeks. Participants who are currently being treated with an ESA will receive methoxy polyethylene glycol-epoetin beta at a dose of 120, 200 or 360 mcg once monthly (based on ESA dose administered in Week -1)
1825994|NCT00773526|Drug|RO5126766|Administered orally daily for 28 days, at escalating doses (with a starting dose of 0.1mg) (Part 1). Optimal biological dose or maximum tolerated dose administered orally, daily (Part 2).
1825995|NCT00773539|Procedure|PVI using an open irrigated tip catheter|transseptal PVI using thermocooled ablation catheter (Biosense) with confirmation of conduction block
1825996|NCT00773539|Procedure|PVI using a closed irrigated tip catheter|transseptal PVI using the CHILLI II catheter from BOSTON with confirmation of conduction block
1825997|NCT00773539|Procedure|PVI using a cryoballoon|transseptal PVI using the cryoballoon from CRYOCATH
1825998|NCT00773552|Drug|solifenacin succinate|5mg PO Qday x 90 days
1825999|NCT00773552|Drug|placebo|1 tab PO Qday x 90 days
1826000|NCT00773565|Dietary Supplement|Optifast|Formula diet for twelve weeks combined with physical activity and behavioral therapy
1826001|NCT00773578|Device|Measurement of exhaled nitric oxide (eNO)|Chemiluminescence NO analyzer Measurement of lung function (spirometry)
1826002|NCT00773578|Device|Measurement of biomarkers of nasal inflammation|Nasal lavage
1826003|NCT00773591|Drug|NT 201, a Botulinum neurotoxin type A, free of complexing proteins|"NT 201: Solution for injection, one dose of 5 U will be administered. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge.
Placebo: Solution for injection, Dose n.a.; identical injected volume as active study medication. Route Injection into the soft palate 1 cm dorsal to the junction with the hard palate and 1 cm medial to the alveolar ridge."
1826004|NCT00773604|Device|Medtronic implantable deep brain stimulation (DBS) system|surgical placement of deep brain stimulation system for treatment of dystonia
1826005|NCT00773617|Behavioral|ICAT|ICAT is a new manual-based psychotherapy treatment for bulimia nervosa (BN) that focuses on emotions and bulimic behavior.
1826006|NCT00773617|Behavioral|CBT|CBT is a highly structured, manual-based psychotherapy that has been shown to be effective in the treatment of BN. CBT focuses on cognitions and bulimic behavior.
1826007|NCT00773630|Drug|Cilostazol|100 mg Cilostazol
1826009|NCT00773656|Other|Whole blood sample|70 ml per patient for collection of biological sample
1826010|NCT00773682|Other|local mud-pack therapy and balneotherapy|Patients will be treated with local mud-pack application on the hands for 20 minutes and thermal-mineral bath once a day for 15 days.
1826011|NCT00773695|Drug|Aromatase Inhibitor|Participants will receive aromatase inhibitor therapy, at a dose per investigator discretion, once daily for 24 weeks.
1826012|NCT00773695|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 15 mg/kg as IV infusion every 3 weeks (or 10 mg/kg every other week in participants receiving weekly paclitaxel), for 24 weeks.
1826013|NCT00773695|Drug|Epirubicine|Participants will receive epirubicine at a dose of 100 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
1826014|NCT00773695|Drug|5-Fluorouracil (5FU)|Participants will receive 5FU at a dose of 600 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
1826015|NCT00773695|Drug|Cyclophosphamide|Participants will receive cyclophosphamide at a dose of 600 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
1826016|NCT00773695|Drug|Paclitaxel|Participants will receive paclitaxel at a dose of 80 mg/m^2 as IV infusion every week for 12 weeks.
1826017|NCT00773695|Drug|Docetaxel|Participants will receive docetaxel at a dose of 100 mg/m^2 as IV infusion every 3 weeks for 12 weeks.
1826018|NCT00773708|Drug|raltegravir|intensify their therapy with Raltegravir(RAL):1 Protease inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL or 1 non-nucleoside reverse transcriptase inhibitor plus 2 nucleoside reverse transcriptase inhibitor plus RAL
1826019|NCT00773734|Drug|Apremilast 10mg|
1826020|NCT00773734|Drug|Apremilast 20mg|
1826021|NCT00773734|Drug|Apremilast 30 mg|
1826022|NCT00773734|Drug|Placebo|
1826023|NCT00773734|Drug|Apremilast 30mg|
1826024|NCT00773734|Drug|Apremilast 20mg|
1826025|NCT00773747|Drug|vorinostat|Four 100 mg capsules vorinostat taken orally, once daily, on Days 1-14 of each 21-day treatment cycle.
1826026|NCT00773747|Drug|bortezomib|1.3 mg/m2 of bortezomib by IV push, on Days 1, 4, 8, and 11 of each 21-day treatment cycle.
1826069|NCT00774150|Behavioral|Cognitive Behavioral Therapy|16 sessions of CBT
1826028|NCT00773760|Other|SNP genotyping|Coded blood specimens will be transported to the Department of Gene Technology TTÜ and genotyping analysis will be performed. Lymphocytes will be isolated from blood specimens using Ficol-Paq gradients, and genomic DNA isolated using a salting-out procedure. Variants of the MOR gene and other genes of interests will be performed by DNA sequence analysis of PCR-amplified DNA, using primers located in flanking intron sequence. All methods proposed are currently in operation in the respective facilities.
1826029|NCT00773773|Other|serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.|Patients referred for prostate biopsy as part of their routine care are to be recruited. Patients will undergo standard medical evaluation/care by undergoing a prostate biopsy because of an elevated PSA blood test and/or an abnormal digital rectal prostate examination. The protocol involves obtaining the research blood sample at the time of routine pre-biopsy blood draw. As such, an extra five (40 mL) tubes of blood will be drawn. The serum specimens obtained will be utilized for proteomic profiling comprising MALDI-TOF MS, and serum biomarker assays.
1826030|NCT00773786|Drug|Arformoterol (Brovana)|twice daily via nebulizer added to maintenance daily tiotropium
1826031|NCT00773786|Drug|Placebo|Placebo twice daily for 1 week (added to maintenance tiotropium)
1826032|NCT00773812|Drug|mecamylamine|The dosage is titrated at 6 weeks of .5mg, 2 weeks of 2.5 mg, and 6 weeks of 5.0 mg. One pill is taken once daily.
1826033|NCT00773812|Drug|placebo|One pill is taken once daily.
1826034|NCT00773838|Drug|vorinostat (HDAC inhibitor)|Four 100 mg vorinostat capsules once daily by mouth on days 1-14 of each 21 day treatment cycle. Up to 18 months of treatment.
1826035|NCT00773838|Drug|bortezomib|bortezomib 1.3 mg/m2 by IV on days 1, 4, 8, and 11 of each 21-day treatment cycle. Total treatment is up to 18 months.
1826036|NCT00773838|Drug|dexamethasone|Five 4 mg Dexamethasone tablets by mouth on days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day treatment cycle if disease progression is observed after 2 treatment cycles if no change to disease is observed after 4 treatment cycles .
1826037|NCT00773851|Procedure|mesh fixation by transfacial sutures|mesh fixation by transfacial sutures
1826038|NCT00773851|Procedure|mesh fixation by staples|mesh fixation by staples
1826039|NCT00773890|Drug|TRF-1101|once daily treatment with 300 mg orally for 12 weeks
1826040|NCT00773890|Drug|Placebo|Daily treatment with TRF-1101 vehicle for 12 weeks
1826041|NCT00773916|Drug|Methylphenidate|Dose increments according to clinical evaluation, starting with 0,3 mg/kg of weight/day
1826042|NCT00773929|Drug|TAK-593|"Tablets of TAK-593 investigational drug for oral administration, tablets in 2 strengths: 1 mg and 4 mg tablets.
Administration will initially be 4 mg, once a day and transition to 2 mg BID schedule dependant on safety"
1826043|NCT00773942|Behavioral|Basic medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview alone.
1826044|NCT00773942|Behavioral|Enhanced medication therapy management|Subjects in this arm will receive medication reconciliation and drug related problem assessment by a medication therapy management clinician utilizing patient interview and chart information.
1826045|NCT00773955|Drug|R-(-)-gossypol acetic acid|Given orally
1826046|NCT00773955|Other|pharmacological study|Correlative studies
1826047|NCT00773955|Other|laboratory biomarker analysis|Correlative studies
1826048|NCT00773968|Drug|Methoxy Polyethylene Glycol-Epoetin Beta|120, 200 or 360 micrograms every 4 weeks by subcutaneous injection.
1826049|NCT00773981|Procedure|Transrectal vacuum assisted drainage|Treatment with vacuum drainage (VD) is a new method primarily developed for wound therapy. The principle of the method is application of negative pressure on the wound surface with the help of a sponge that is connected to a pump. Sponge dressings should be changed 3 times pr week as long as vacuum therapy is used. If there has been no development of granulation tissue or no shrinking of the cavity in 3 weeks Vacuum therapy can be stopped. Maximum vacuum therapy is 8 weeks.
1826051|NCT00774007|Drug|mesalazine|
1826052|NCT00774007|Drug|placebo|
1826053|NCT00774020|Drug|Zoledronic acid|5mg, i.v. single dose
1826054|NCT00774033|Device|autologous epidermal cells harvesting kits|autologous epidermal cells harvesting kits used for the treatment of acute burn
1826055|NCT00774033|Procedure|classic skin grafts|classic skin grafts used for the treatment of acute burn
1826056|NCT00774046|Drug|Ara-C|"Induction: 3000mg/m2 IV infusion for day 1 and day 5
Mobilization: within 2 weeks of end of induction therapy - 2000mg/m2 as 2 hour IV infusion once every 12 hours for 3 days (6 doses total)"
1826057|NCT00774046|Drug|Mitoxantrone|Induction: 30mg/m2 after the end of HiDAC day 1 and day 5
1826058|NCT00774046|Drug|Etoposide|Mobilization: 30mg/kg over 6 doses given once every 12 hours for 3 days
1826060|NCT00774072|Drug|Tobramycin (Gernebcin®)|1 ml / day in each nostril
1826061|NCT00774085|Other|No intervention was given|Participants included patients treated with long-acting injectable risperidone (Risperdal Consta) in daily practice according to local label by the physicians
1826062|NCT00774098|Drug|dextrose 10% (D10W ®) infusion|Started at 8pm the day before surgery until the procedure begins
1826063|NCT00774098|Drug|hyperinsulinemic normoglycemic clamp|Started as the procedure begins, decreased at the end of the procedure and continued until 16 hours postoperatively
1826064|NCT00774098|Dietary Supplement|high calorie diet 35 kcal/kg|High Calorie meals start the day before the surgery and are given 5 hours apart. The last meal is given at 7 pm the day before surgery
1826065|NCT00774098|Drug|Intravenous normal saline (NS 0.9)|Intravenous normal saline (NS 0.9) started just before induction, and titrated to hemodynamic parameters and urine output
1826066|NCT00774111|Drug|GSK1349572|GSK1349572 50 mg in combination with Etravirine
1826070|NCT00774150|Behavioral|Client Centered Therapy|16 sessions of CCT
1994425|NCT03006809|Biological|Fecal Microbiota Transplantation (FMT), OpenBiome|Delivered by colonoscopy, enema or orally (as capsules)
1826071|NCT00774163|Biological|Lactobacillus reuteri|Lactobacillus reuteri (Lr): 108 (100 million) organisms of Lactobacillus reuteri per dose, given once daily for a five-day treatment period
1826072|NCT00774163|Other|Placebo|5 drops of the oil vehicle used in manufacturing the Lr suspension, given once daily for a five-day study period
1826073|NCT00774189|Drug|clarithromycin 250 mg tablets|
1826078|NCT00774241|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
1826079|NCT00774241|Drug|docetaxel|75mg/m2 every 3 weeks for 18 weeks
1826080|NCT00774267|Drug|BZA 20 mg/CE 0.45 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
1826081|NCT00774267|Drug|BZA 20 mg/CE 0.625 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as baxedoxifene/CE tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
1826082|NCT00774267|Drug|Raloxifene 60 mg|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as raloxifene tablets in capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
1826083|NCT00774267|Drug|Placebo|There was no drug taken during study 3115A1-4000. During the 3115A1-303 study the test article was supplied as placebo capsules. Subjects took one capsule orally, once daily at approximately the same time each day on a continuous regimen for 2 years or until early termination from the study.
1826084|NCT00774280|Drug|BuCy vs BuFlu|Arm 1:BuCy Arm 2:BuFlu
1826085|NCT00774293|Drug|placebo|5 placebo granules for Arnica 5 CH and 5 placebo granules for Bryonia 5 CH
1826086|NCT00774293|Drug|Arnica and Bryonia|Arnica 5CH granules, 5 per day plus Bryonia 5CH Granules, 5 per day for 5 days
1826087|NCT00774306|Drug|phenytoin|Phenytoin is a anti-seizure medication. Participants will receive phenytoin (PHT) at 5 mg/kg/day in 2 divided doses.
1826088|NCT00774306|Drug|valproate|Valproate is an anti-seizure medication. Participants will receive valproate (VPA) at 15 mg/kg/day in 3 divided doses.
1826089|NCT00774306|Drug|levetiracetam|Levetiracetam is an anti-seizure medication. Participants will receive levetiracetam (LEV) 1000-1500 mg/day in 2 divided doses.
1826090|NCT00774319|Radiation|conventional radiotherapy with 'high' dose cisplatin|"radiotherapy: 5 fractions/week, total treatment time 7 weeks. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions.
100 mg/m2 cisplatin iv on day 1, 22 and 43"
1826091|NCT00774319|Radiation|accelerated radiotherapy with 'low' dose cisplatin|Accelerated radiotherapy 6 fractions/week, total treatment time 6 weeks. During one of the weekdays two fractions will be delivered with an interval of at least 6h. Dose to gross tumor volume 70 Gy/35 fractions, dose to elective nodal areas 46 Gy/23 fractions cisplatin 40 mg/m2 iv on day 1,8,18,22,29,35
1826092|NCT00774332|Drug|CODOX-M|Cytoxan,Mesna,Adriamycin,Vincristine,Methotrexate,Leucovorin,Cytarabine
1826093|NCT00774345|Drug|Lenalidomide|Lenalidomide capsules given orally on days 1-28 of a 28 day cycle
1826094|NCT00774345|Drug|Placebo|Placebo capsules given orally on days 1 - 28 of a 28 day cycle
1826095|NCT00774358|Drug|Interleukin-2|We propose to subcutaneously administer 0.5 MU/m2 of IL-2 daily to WAS subjects for 5 days. Research treatment will be repeated 2 and 4 months later. Inter-patient dose escalation will be employed to 1 MU/m2 and/or 2 MU/m2 based on safety as the primary endpoint.
1826096|NCT00774371|Behavioral|Cognitive behavioral therapy CBT) for weight loss|The intervention program emphasizes regular physical activity, healthy eating, and psychological components within the structure of CBT for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity and strength training. A deficit of 500-1000 kcal/day is the recommended level of dietary modification to promote weight loss and maintenance. Group sessions are held weekly for 4 months, every other week for two months, and monthly sessions through 18 months. Data are collected at baseline, 6 months, and 18 months. Wait-list group subjects will receive general contact without specific reference to weight management topics through a 24-month period of data collection and will then be provided intervention materials in a seminar format.
1826097|NCT00774384|Biological|NZ MenB OMV vaccine (NZ98/254)|3 doses by intramuscular injection
1826098|NCT00774397|Drug|BI 201335 NA 240 mg QD / LI|240mg BI 201335 NA (Faldaprevir) once daily with a 3 days lead-in phase of PegIFN/RB, 24 weeks
1826099|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
1826100|NCT00774397|Drug|BI 201335 NA 120mg QD / LI|120mg BI 201335 NA (Faldaprevir) once daily, for 24 weeks
1826101|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
1826102|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
1826103|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
1826104|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
1826105|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
1826106|NCT00774397|Drug|BI 201335 NA 240 mg BID|240mg BI 201335 NA (Faldaprevir) twice, 24 weeks
1826107|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
1826108|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d),48 weeks
1826109|NCT00774397|Drug|BI 201335 NA 240 mg QD|240mg BI 201335 NA (Faldaprevir) once daily, 24 weeks
1826110|NCT00774397|Drug|PegIFN/RBV|PegIFN (180 µg/wk) and RBV (1000/1200mg/d), 24 or 48 weeks
1826113|NCT00774436|Procedure|focal cryotherapy|Those men meeting the re-staging biopsy criteria will subsequently be treated with focal cryotherapy. Clinical follow-up visits will be scheduled at 6 + 2 weeks, 3 + 1 months and 6 + 1 months after focal cryotherapy, at which time, a digital rectal examination and PSA test will be performed. Standard quality-of-life questionnaires, are completed by all patients treated by the Urology Service (whether on not they are treated on an IRB protocol).
1826114|NCT00774462|Drug|Rituximab|Rituximab 1000 mg intravenous, 2 times, 2 weeks apart and 1000 mg 6 months after the last injection
1826115|NCT00774475|Drug|comparison of different dosage of clopidogrel|clopidogrel 75 mg/day versus clopidogrel 150 mg/day
1826116|NCT00774475|Drug|doubled therapy|clopidogrel 150 mg/day
1826117|NCT00774488|Other|Glucose dependent insulinotropic polypeptide (GIP)|GIP-Infusions for 4 h in a postprandial concentration
1826118|NCT00774501|Procedure|image guidance with general anesthesia and suspended ventilation during treatment delivery|"All study patients will undergo marker implantation approximately 2 weeks prior to the PET-CT simulation and treatment planning. PET-CT is performed for treatment planning purposes. This part of the process is in routine clinical use at MSKCC.
Three cone beam imaging scans and an IV contrast injection just prior to the first cone beam scan will be added to the standard procedure. The use of these two techniques is investigational.
The treatment delivery will make use of general anesthesia and suspension of mechanical ventilation to render the patient apneic during both target localization and dose delivery. This will allow the dose to be delivered more precisely than the techniques currently in use, thus allowing the use of smaller treatment margins and reducing the high dose exposure of healthy liver tissue. These measures have not previously been used for treatment delivery."
1826119|NCT00774514|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of vasodilators Acetylcholine (5-20 mg/min), sodium nitroprusside (2-8 µg/min), bradykinin (100-1000 pmol/min) and verapamil (10-100 µg/min)
1826120|NCT00774527|Drug|Cyclophosphamide-fludarabine-anti thymocyte globulin|"Cyclophosphamide 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.
Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 5 consecutive days (days -6 to -2).
Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2."
1826121|NCT00774540|Drug|1 Ketorolac intraarticular|Ketorolac intraarticular 5 mg
1826122|NCT00774540|Drug|Placebo|Saline
1826123|NCT00774553|Drug|AZD1656|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
1826124|NCT00774553|Drug|Placebo|Dose titration of oral suspension to a tolerable dose given twice daily for 10 days.
1826127|NCT00774592|Behavioral|FOYC|FOYC is a face-to-face, eight-session, group behavioral intervention based on protection motivation theory and emphasizing skills and decision-making.
1826128|NCT00774592|Behavioral|Goal for it (GFI)|GFI is a one-session parent intervention consisting of a 20-minute video followed by a discussion regarding the process of setting and reaching goals.
1826129|NCT00774592|Behavioral|Wonderous Wetlands|Wonderous Wetlands is an eight-session, group intervention for youth. It includes field projects and discussions based on ways to save our environment.
1826130|NCT00774592|Behavioral|Caribbean Informed Parents and Children Together (CImPACT)|CImPACT is a parent intervention addressing parental monitoring and communication with youth. It consists of a 20-minute video, a condom practice, and role play simulating a parent-child discussion.
1826131|NCT00774592|Behavioral|Bahamian Focus on Older Youth (BFOOY)|10 session HIV prevention program
1826132|NCT00774592|Behavioral|Health and Family Life Curriculum (HFLE)|Standard Grade 10 curriculum
1826133|NCT00774605|Drug|Varenicline free base solution|A single application of a 4.8 mg varenicline solution will be applied to the upper back over a 24 hour period
1826134|NCT00774605|Drug|Varenicline free base patch|A single application of a nominal 1.2 mg dose of a varenicline transdermal delivery system (5 cm2 patch, 4.8 mg drug payload) will be applied to the upper back over a 24 hour period
1826135|NCT00774618|Device|Resection with or without plate fixation|Some enrolled subjects will undergo rib fracture surgery at OHSU. Devices used in the repair of rib fracture non-union could include RibLoc® or BioBridge ™. RibLoc® is a U-shaped permanent device that secures to the rib with screws locking from the front to the back of the metal plate (through the rib). BioBridge ™ is a resorbable, non-permanent device that stabilizes the ribs. Both devices are designed to stabilize the rib fracture non-union and promote healing of the non-union rib. For some patients, it may be determined that resection of the rib fracture non-union without an implanted device is the most appropriate treatment. The goal of surgical intervention is to improve the pain and disability associated with rib fracture non-union in appropriate patients.
1826136|NCT00774631|Procedure|Mild induced hypothermia (32-34°C)|"Mild Induced hypothermia:
Investigators are advised to use the cooling techniques as used in patients with cardiac arrest. Thus, the choice of cooling method will be left to investigators. Hypothermia will be induced by cold saline infusion as described in appendix 5 [6, 48]. Core temperature will be monitored by oesophageal probe and maintained between 32°C and 34°C during 48 hours and followed by strictly passive rewarming. During this phase of treatment, patients will receive deep sedation associated with neuromuscular blockers. Centers participating to the trial will have expertise in cooling methods."
1826137|NCT00774631|Procedure|local recommendations and guidelines|"Investigational procedure:
This study evaluates the impact of mild induced hypothermia (32-34°C) during 48 hours followed by passive rewarming according to recommendations described in appendix. All treatment will be according to local recommendations and guidelines of medical societies and literature. Physicians are advised to use these recommendations; however, the best treatment option for the individual patient should be used.
Controls will receive standard care and will be also be deeply sedated for 48 hours."
1826138|NCT00774644|Drug|Clarithromycin 500mg|
1826139|NCT00774683|Drug|Raltegravir (Isentress®)|400 mg p.o. BID x 7 days
1826140|NCT00774696|Drug|clarithromycin 500mg tablets|
1826141|NCT00774722|Drug|Metronidazole|10% ointment, three times daily for 14 days
1826142|NCT00774735|Drug|GSK1349572|30 mg given in combination with lopinavir/ritonavir
1826144|NCT00774748|Device|Insuflon|Indwelling subcutaneous catheter indicated for subcutaneous infusion of medication by injection. Maximum lifespan: 7 days or 75 injections.
1826145|NCT00774761|Drug|fluticasone propionate/formoterol fumarate|inhalation suspension
1826146|NCT00774761|Drug|fluticasone propionate|inhalation suspension
1826147|NCT00774761|Drug|formoterol fumarate|inhalation solution
1826148|NCT00774774|Device|control|"Non sterile surgical mask,high filtration AEROKYN,type 2 with eardrop"
1826149|NCT00774774|Device|Face mask|"Non sterile surgical mask, high filtration AEROKYN, type 2 with eardrop Masks will be worn at home by the patient over a period of 5 days following inclusion, whenever a member of the household will attend the same room or in other confined space (eg car), and changed after 3 hours of consecutive use or sooner if they are tor
Masks will not be worn:
during the night,
when the patient is alone in the room. Moreover, for all households, an incentive in nocturnal isolation of index-patient will be recommended"
1826150|NCT00774787|Drug|imiquimod 5% cream|1 packet (250 mg cream) 3 times per week for 4 weeks
1826151|NCT00774800|Drug|Humalog|
1826152|NCT00774800|Drug|Humulin-R|
1826153|NCT00774800|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
1826154|NCT00774800|Other|Liquid meal|
1826155|NCT00774813|Device|Nexalin 1.3mA Device|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)
Daily receipt of placebo antidepressant"
1826156|NCT00774813|Device|Nexalin 15mA device|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)
Daily receipt of a placebo antidepressant"
1826157|NCT00774813|Drug|placebo device and Citalopram|"3 treatment cycles (cycle is 5 daily treatments, followed by 2 days off)
Daily receipt of a a SSRI (Citalopram or similar)"
1826158|NCT00774826|Drug|R-CVP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1, Vincristina: 1,4 mg/mq day 1 Prednisone: 40 mg/mq day 1-5,
1826159|NCT00774826|Drug|R-CHOP|Rituximab: 375 mg/mq day 1 Ciclofosfamide: 750 mg/mq day 1 Doxorubicina: 50 mg/mq day 1 Vincristina: 1.4 mg/mq day 1 Prednisone: 100 mg/mq day 1-5
1826160|NCT00774826|Drug|R-FM|Rituximab: 375 mg/mq day 1, Fludarabina: 25 mg/mq day 1-3, Mitoxantrone: 10 mg/mq day 1,
1826161|NCT00774839|Behavioral|Patient Interview|The patient will participate in a semistructured interview conducted by a trained staff member and designed to last approximately 45 minutes. All interviews will take place at least 4 months into or up to 7 months after the end of the treatment, if possible and will be scheduled to occur at the time of the chemotherapy infusion, or at another time at the care facility when it is convenient for the patient. If the patient is not scheduled or chooses not to be at the care facility within a time frame that fits the study parameters, the patient may opt to be interviewed at another location, including the patient's home.
1826162|NCT00774852|Drug|abatacept|Intravenous infusion (500-1000 mg, dep on weight) at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
1826163|NCT00774852|Drug|cyclophosphamide|500 mg intravenous infusion every 2 weeks for 12 weeks
1826164|NCT00774852|Drug|azathioprine|2 mg/kg/day orally from weeks 12-28; continue until week 52 if only partial response observed at week 24
1826165|NCT00774852|Drug|prednisone|60 mg/day for 2 weeks, then taper to 10 mg/day by 12 weeks, then continue on stable dose
1826166|NCT00774852|Drug|abatacept placebo|Intravenous infusion at weeks 0, 2, and 4, then every 4 weeks until week 24; continue to week 48 only if partial response at 24 weeks
1826167|NCT00774852|Drug|azathioprine placebo|Oral capsule, daily from weeks 28 to 52, only if complete response observed at week 24
1826168|NCT00774865|Procedure|MIBI and CTA|Rest and Stress MIBI and CT Angiography
1826169|NCT00774878|Drug|AVE1642|AVE1642 is administered intravenously at the dose of 8 mg/kg.
1826170|NCT00774878|Drug|Fulvestrant|Fulvestrant is administered as a slow intramuscular injection (just before the AVE1642 infusion when given in combination).
1826171|NCT00774904|Drug|Losartan|Angiotensin II Type 1 Receptor Blockers
1826172|NCT00774917|Device|Numen|Numen Co-Cr coronary stent implant
1826173|NCT00774930|Drug|Lanreotide|deep s.c. injection, 120 mg, every 4 weeks (±3 days).
1826174|NCT00774930|Drug|Placebo|deep s.c. injection of placebo (0.9% saline solution) every 4 weeks (±3 days) for 16 weeks, then deep s.c. injection of lanreotide 120 mg, every 4 weeks (±3 days).
1826175|NCT00774943|Drug|AMG 557|A total of 4 cohorts will be administered multiple doses of drug or placebo subcutaneously. Dose escalation will take place by cohort.
1826176|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
1826177|NCT00774956|Procedure|Exercise training program|A 6 week shoulder exercise training program
1826178|NCT00774969|Drug|Metronidazole|Metronidazole 10% ointment three times a day 7 days
1826179|NCT00774982|Drug|Delayed Release 6 mercaptopurine|oral tablet, 1 x 40 mg Delayed Release 6MP tablet, single-dose
1826180|NCT00774982|Drug|6 Mercaptopurine|Oral Tablet, 2 x 50 mg 6MP Reference, single-dose
1826181|NCT00763932|Biological|Myozyme|10 mg/kg or 20 mg/kg qw OR 20 mg/kg or 40 mg/kg qow
1826182|NCT00769314|Drug|Acyclovir Lauriad|50 mg muco-adhesive buccal tablets, single application on the gum
1826183|NCT00769314|Drug|Placebo|50 mg muco-adhesive buccal tablets, single application on the gum
1826184|NCT00769327|Drug|imatinib mesylate|
1826185|NCT00769327|Drug|nilotinib|
1826186|NCT00769327|Genetic|cytogenetic analysis|
1826187|NCT00769327|Genetic|fluorescence in situ hybridization|
1826188|NCT00769327|Genetic|microarray analysis|
1826189|NCT00769327|Genetic|mutation analysis|
1826190|NCT00769327|Genetic|polymerase chain reaction|
1826191|NCT00769327|Genetic|polymorphism analysis|
1826192|NCT00769327|Other|laboratory biomarker analysis|
1826193|NCT00769353|Behavioral|Primary and Secondary Coping Enhancement Training|A cognitive behavioral therapy designed to help individuals cope with physical illness.
1826194|NCT00769353|Behavioral|Supportive Non-directive Therapy|A non-structured therapy designed to provide a supportive atmosphere in which individuals may discuss concerns and process events in their lives
1826195|NCT00769366|Behavioral|Psychotherapy|humanistic-existential psychotherapy conducted in individual and group meetings
1826196|NCT00769366|Drug|Medical therapy|Optimal medical therapy after Acute myocardial infarction
1958647|NCT01410409|Other|Neuromuscular training (NEMEX-TJR)|60min. of neuromuscular training two times a week for 3 months (12 weeks) using the neuromuscular training program called NEMEX-TJR.
1958648|NCT01410409|Drug|Paracetamol|1 g x 4/day
1958649|NCT01410409|Drug|Burana|400 mg x 3/day for three weeks
1958650|NCT01410409|Drug|Pantoprazol|20mg x 1/day for three weeks
1826204|NCT00769405|Drug|fluorouracil|Given IV
1826205|NCT00769405|Drug|leucovorin calcium|Given IV
1826206|NCT00769405|Drug|oxaliplatin|Given during surgery
1826207|NCT00769405|Procedure|hyperthermia treatment|Given intraperitoneally during surgery
1826208|NCT00774995|Biological|EngerixTM-B|Intramuscular injection, one dose.
1826209|NCT00775008|Behavioral|electronic health information|Participants will receive weight loss information via 1 of 2 different mediums.
1826210|NCT00775021|Device|etafilcon A|Contact Lens
1826211|NCT00775021|Device|nelfilcon A|Contact Lens
1826212|NCT00775034|Drug|Tisseel®|Mesh repair for open incisional hernia repair with fibrin sealant
1826213|NCT00775034|Procedure|Drainage|Mesh repair for open incisional hernia repair with drainage
1826214|NCT00775047|Other|Pharmacist-administered|women will receive their injections at a pharmacy by a clinical pharmacist
1826215|NCT00775047|Other|clinic-administered injections|women will return for their injections to the clinic where recruitment took place. They will receive one at 3 months and 6 months.
1826216|NCT00775073|Drug|Everolimus, Bevacizumab|Everolimus 5 mg tablet per day orally. Bevazicumab 5 mg per kg intravenous every 2 weeks.
1826217|NCT00775086|Drug|norelgestromin/ethinyl estradiol (NGMN/EE) transdermal contraceptive system.|
1826218|NCT00775099|Procedure|Forearm Vascular Study|Forearm venous occlusion plethysmography to measure forearm blood flow during intra-arterial infusion of the vasodilators Verapamil (10-100 µg/min), bradykinin (100-1000 pmol/min), sodium nitroprusside (2-8 µg/min) and Acetylcholine (5-20 mg/min).
1826219|NCT00775099|Procedure|Badimon Chamber|Ex-vivo assessment of thrombus formation using Badimon Chamber
1826220|NCT00775112|Device|pillow|use of pillow for lumbar punctures
1826221|NCT00775125|Drug|Telaprevir; Darunavir; Ritonavir; Fosamprenavir|
1826222|NCT00775138|Drug|Arikace 280 mg|Study subjects will receive Arikace™ 280 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
1826223|NCT00775138|Drug|Arikace 560 mg|Study subjects will receive Arikace™ 560 mg on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
1826224|NCT00775138|Drug|Matching Placebo|Study subjects will receive placebo on Days 1 through Day 28. Drug is administered once a day via a nebulizer.
1826225|NCT00775151|Drug|amlodipine 10 mg tablet|
1826226|NCT00775164|Drug|pioglitazone|15 mg per day for 4 weeks, then up-titrated to 30 mg per day for 12 weeks
1826227|NCT00775164|Drug|Metformin|Metformin XR; 1000 mg once daily
1826228|NCT00775177|Drug|Doxycycline monohydrate 100mg tablets|Bioequivalence Doxycycline monohydrate 100mg tablets fasting condition
1826229|NCT00775190|Drug|ortho tricyclen|brand name oral contraceptive
1826230|NCT00775190|Drug|Trinessa|generic oral contraceptive
1826231|NCT00775203|Drug|Trazodone Hydrochloride (HCl) Extended-Release Tablets|
1826232|NCT00775203|Drug|Placebo|
1826233|NCT00775216|Behavioral|"Behavioral counseling plus telephone helpline"|A trained behavioral counselor will place phone calls to Phase 2 intervention participants. These calls will be used to provide tailored physical activity advice and to extend our partnership with the Metro Nashville Parks and Recreation Department, directing participants to community centers close to their homes or workplaces where they can access a variety of physical activities (e.g., indoor pools, walking tracks, fitness centers, greenways, etc) using a newly developed electronic database. Following an orientation to the Metro Parks services which will be held at either Hadley Regional Park or Coleman Regional Park, participants will be directed to the Metro Parks facility most convenient to them.
1826234|NCT00775229|Drug|Naltrexone|pill, by mouth, 50mg-150mg/day for the duration of the study
1826235|NCT00775229|Drug|Placebo|pill, by mouth, daily
1826236|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different dosages of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Administered on a monthly basis during a six-month period.
1826237|NCT00775242|Drug|Estradiol and Progesterone|Injectable suspension of three different formulations of estradiol and progesterone a) 0.5 mg E/15 mg P; b) 1 mg E/20 mg P; c) 1 mg E/30 mg P. Each will be applied on a monthly basis during a six-month period
1826238|NCT00775255|Drug|clarithromycin 250 mg/5 mL powder for oral suspension|
1826239|NCT00775268|Procedure|Biopsy|Biopsy taken
1826240|NCT00775268|Radiation|Fluordeoxyglucose F 18|Undergo scans
1826241|NCT00775268|Other|[3'-deoxy-3'-[F-18] fluorothymidine|Undergo scans
1826242|NCT00775268|Procedure|computed tomography|Undergo scans
1826243|NCT00775268|Procedure|fine-needle aspiration|sample collected
1826244|NCT00775294|Drug|Maraviroc|Healthy male volunteers will take maraviroc 300 mg orally twice daily for 15 doses (8 days)
1826245|NCT00775307|Drug|PAZOPANIB|400 mg/day (24 weeks)
1826246|NCT00775307|Drug|Placebo|Placebo 400 mg/day (24 weeks)
1826247|NCT00775320|Procedure|FLT-PET scan|Imaging test
1826248|NCT00775905|Drug|amlodipine 10 mg tablet|
1826249|NCT00775918|Drug|Doxycycline monohydrate 100mg tablets|Bioequiavelnce Doxycycline monohydrate 100mg tablets fed conditions
1958651|NCT01410409|Behavioral|Dietary counseling|For participants with a BMI equal to or >25. The dietitian initiates a 3-month intervention that provides instruction and guidance in relation to diet and plans the number of visits according to the individual participant needs.
1958652|NCT01410409|Behavioral|Patient education|"The aim is to strengthen the participant's involvement in the treatment, so the participant will be in a position to handle, master and act reasonable in relation to their knee OA. This aspect of the intervention is based on principles from The Chronic Disease Self-Management Program, Lær at leve med kronisk sygdom (Learn to live with chronic illness) by The National Board of Health, Denmark and Artrosskolan Spenshult in Sweden."
1958653|NCT01410409|Procedure|TKR|Surgical treatment with insertion of total knee replacement following standard procedures.
1958654|NCT01410409|Other|Insoles|"The position of the knee is assessed using Single Leg Mini Squat. On the basis of this test it is decided which of two types of insoles (Formthotics System) the participant should have (neutral with a lateral wedge or neutral).
The participants will be advised to use the insoles in all shoes."
1826257|NCT00775944|Behavioral|Proactive telephone support|Pro-active telephone counselling allows for repeated, sequenced calls to be made by quitline counsellors to smokers and for counselling to be provided during accepted calls.
1826258|NCT00775944|Behavioral|Reactive (standard) telephone support|Reactive counselling usually involves the provision of evidence-based information to support quit attempts without any or with only very brief counselling to accompany it.
1826259|NCT00775944|Drug|Offer of voucher for cost-free Nicotine Replacement Therapy|Offer of voucher for cost-free Nicotine Replacement Therapy over the telephone
1826260|NCT00775957|Procedure|FLT-PET scan|imaging scan
1826261|NCT00775957|Procedure|FDG-PET scan|imaging scan
1826262|NCT00775970|Behavioral|walking activity|
1826263|NCT00775983|Device|laminaria|place device in cervix for dilation
1826264|NCT00775983|Device|Dilapan-S|Place in cervix for dilation.
1826265|NCT00775996|Drug|Clorazepate Dipotassium 15mg Tablets|
1826266|NCT00776009|Drug|Dex-Methylphenidate hydrochloride Extended Release (Focalin® XR)|10 mg and/or 20 mg capsules
1826267|NCT00776009|Drug|Placebo|Placebo Comparator
1826268|NCT00776022|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet fed conditions
1826269|NCT00776035|Procedure|PET (positron Emission Tomography)|this is a diagnostic scan that requires the injection of radioactive tracers into an IV placed in the arm.
1826270|NCT00776035|Procedure|Echocardiogram|an ultrasound of the heart
1826271|NCT00776035|Procedure|VO2 peak test|walking on a treadmill during which you will breath in and out through a tube
1826272|NCT00776035|Procedure|Body composition Study|a scan of your entire body measuring Body Mass Index, fat percentage etc...
1826273|NCT00776035|Radiation|15O water|radioactive tracer used to study blood flow during the PET scan
1826274|NCT00776035|Radiation|11C Acetate|radioactive tracer that helps study heart metabolism
1826275|NCT00776035|Radiation|11C Palmitate|radioactive tracer used to study fatty acid usage in the heart
1826276|NCT00776035|Radiation|11C Glucose|radioactive tracer usde to study glucose usage in the heart
1826277|NCT00776074|Drug|Leuprorelin (GF)|Leuprorelin (GF) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
1826278|NCT00776074|Drug|Leuprorelin (GC)|Leuprorelin (GC) 3.75 mg injection, subcutaneously, once every 4 weeks for up to 12 weeks.
1826279|NCT00776087|Device|Home Monitoring provided by Biotronik ICD and CRT-D devices|Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety
1826280|NCT00776087|Device|No Home Monitoring|Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).
1826281|NCT00776100|Other|clinical observation|Patients undergo observation for 6 weeks.
1826282|NCT00776100|Radiation|radiation therapy|Patients undergo radiotherapy 5 days a week for 6 weeks.
1826283|NCT00776113|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol fasting
1826284|NCT00776126|Device|Digital Breast Tomosynthesis Exam|Digital Breast Tomosynthesis Exam consisting of single view (MLO) of each breast will be performed.
1826285|NCT00776139|Drug|Cetirizine Hydrochloride 10 mg tablet|Bioequivalence Cetirizine Hydrochloride 10 mg tablet
1826286|NCT00776165|Biological|Recombinant Human GCSF (Shantha Biotechnics Limited)|Dose: 300 mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
1826287|NCT00776165|Biological|Neupogen|Dose: 300mcg/day administered subcutaneous/intravenous/continuous subcutaneous infusion for a minimum of 7 days and for a maximum of 14 days or till Neutrophil count of 10,000/mm3 is reached whichever is earlier
1826288|NCT00776191|Drug|Physioneal 35|Physioneal 35® for eight weeks, followed by Physioneal 40® for eight weeks
1826289|NCT00776191|Drug|Physioneal 40|Physioneal 40® for eight weeks followed by Physioneal 35® for eight weeks
1826290|NCT00776204|Device|JACTAX Drug eluting stent|Jactax stent placed in coronary artery
1826291|NCT00776204|Device|JACTAX LD drug eluting stent|JACTAX LD stent placed in coronary artery
1826292|NCT00776204|Device|Taxus Libertè|Taxus Libertè stent placed in coronary artery
1826293|NCT00776217|Drug|loratadine 10 mg orally disintegrating tablets|
1826294|NCT00776230|Biological|IC51|6 mcg im. at day 0 and day 28
1826295|NCT00776256|Dietary Supplement|beta-glucan and fructooligosaccharide|1g beta-glucan or 8 g fructooligosaccharide or combination per meal replacement bar given twice on day 1 and once on day 2
1826296|NCT00776269|Procedure|argon laser and radiofrequency|
1826297|NCT00776282|Drug|loratadine 10 mg orally disintegrating|
1826298|NCT00776295|Biological|Combined adenovirus vectored p53 tranfected dedritic cell vaccine and ex vivo expanded T-lymphocytes|Autologous Dendritic Cells Derived from Peripheral Blood Mononuclear Cells, Cultured with Granulocyte-Macrophage Colony-Stimulating Factor and Interleukin 4, Transfected with Adenovirus Vector (Ad5CMV-p53, Introgen Therapeutics) Expressing Wildtype p53 Gene; Combined with Autologous Expanded T Lymphocytes (CD3+, CD4+, and CD8+), Cultured with OKT3 (Orthoclone) and Anti-CD28 (Repligen) Coated Magnetic Beads
1826299|NCT00776321|Drug|Eprotirome|
1826300|NCT00776321|Drug|Placebo|
1826302|NCT00776347|Drug|Donepezil|Dosage: 3mg PO/day for the first 2 weeks and 5mg PO/day for the next 14 weeks Duration: 16 weeks
1826303|NCT00776347|Drug|Donepezil|
1826304|NCT00776360|Drug|oxytocin|80mIE/min as continuous infusion for 70 minutes
1826305|NCT00776360|Drug|oxytocin|80 mU/ min of oxytocin infusion for 70 min along with measuring the gastric emptying by ventricle scintigraphy
1826306|NCT00776373|Drug|Rapamycin + high dose etoposide and cytarabine|Rapamycin,by mouth, loading dose followed by a single daily dose for 8 days (dose level 1 = load of 9 mg followed by 3 mg daily doses, dose level 2 = 12 mg with daily doses of 4 mg; Etoposide 500 mg/m2/day IV and Cytarabine 2000 mg/m2/day IV every 24 hours for 4 days.
1826307|NCT00776399|Device|Lung radiofrequency ablation|A radiofrequency (RF) electrode is placed in the lung metastasis percutaneously. RF energy is applied to the tumor to induce coagulation necrosis.
1826308|NCT00776425|Drug|Epoetin beta|Epoetin beta subcutaneously or intravenously at a dose of 150 IU per kg of body weight thrice weekly or 30000 IU once weekly.
1826309|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.1 mL, Intradermal
1826310|NCT00776438|Biological|Inactivated, split-virion, influenza vaccine|0.5 mL, Intramuscular
1826311|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.1 mL, Intradermal
1826312|NCT00776438|Biological|Inactivated, split-virion influenza vaccine|0.5 mL, Intramuscular
1826313|NCT00776464|Device|Noveon laser|Two wavelenghts of light
1826314|NCT00776477|Drug|clopidogrel and aspirin|clopidogrel 75mg daily and aspirin 100mg daily
1826315|NCT00776477|Drug|aspirin|aspirin 100mg daily
1826316|NCT00776490|Drug|Glimepiride 1mg Tablets|
1826317|NCT00776503|Drug|VORINOSTAT|vorinostat; 400mg once daily; increasing duration (7-10-14 days)
1826318|NCT00776516|Drug|mirabegron|oral
1826319|NCT00776516|Drug|rifampin|oral
1826320|NCT00776529|Other|Sensorimotor training first, followed by strength exercises|nine sessions of one hour duration
1826321|NCT00776529|Other|Strength exercises and sensorimotor exercises alternated|nine sessions of one hour
1826322|NCT00776542|Drug|Minocycline 100mg Tablets|
1826323|NCT00776555|Drug|Lisdexamfetamine Dimesylate|Study is a two-period cross-over design where subjects will have 2 Screening visits, a Baseline visit, and then be enrolled into the study for 2 Periods. Each Period has 2-3 visits and lasts from 2-6 weeks. At each Period visit subjects will be given one of the two treatment arm drugs that have been solubilized and then have blood drawn for pharmacokinetic analysis and the Drug Rating Questionnaire administered. At the end of Period 1 subjects will be crossed-over to the alternative treatment drug for the Period 2. The Vyvanse™ capsule contents will emptied into water to make a solution and given to subjects to drink at the beginning of each Period visit.
1826324|NCT00776555|Drug|Racemic mixture of dextroamphetamine and lisdexamfetamine|Same visits as described for Vyvanse™. The ADDERALL XR® capsule contents will be crushed, solubilized with water, and given to subjects to drink prior to pharmacokinetic blood draws and DRQ-S administration over the course of two periods.
1826325|NCT00776568|Procedure|Extra-corporeal shockwave|Low intensity shock waves are applied as 300 shocks per visit for 09 visits. The treatment visit is carried at week 1, 5 and 9.
1826326|NCT00776568|Drug|Anti-hypertensive drugs|ACE inhibitors, Ca channel blockers, Beta blockers, Diuretics, Cholesterol lowering agents and/or other drugs used alone or in combination, as prescribed.
1826327|NCT00776581|Procedure|CSEA with PCA|Records regarding combined spinal-epidural analgesia with patient-controlled pump
1826328|NCT00776581|Procedure|CSEA with IBI|Records regarding combined spinal-epidural analgesia with intermittent bolus injection
1826329|NCT00776581|Procedure|EA with PCA|Records regarding epidural analgesia with patient-controlled pump
1826330|NCT00776581|Procedure|EA with IBI|Records regarding epidural analgesia with intermittent bolus injection
1826331|NCT00776594|Drug|Androgen Deprivation Therapy|leuprolide: 22.5mg given IM every 3 months for a total of 6 months or, goserelin acetate: 10.8mg given SC every 3 months for a total of 6 months
1826332|NCT00776594|Drug|bicalutamide|50mg orally daily for 6 months
1826333|NCT00776594|Drug|bevacizumab|15mg/ks given IV every three weeks for a total of 8 infusions over 6 months
1826334|NCT00776607|Drug|NovoMix 30|Insulin arm: Patients will be given advice on diet and exercise and life style and will be started on NovoMix 30, one dose of 6 U at the evening/main meal. Dose will be adjusted in increments of 2-6U depending on fasting glucose level When total dose equals 16 U patient will be started on 4 units with breakfast and continue with 16 units with evening meal. Breakfast and/or evening meal dose will be adjusted where necessary at increments of 2-6 U depending on fasting and/or pre-evening meal glucose level. Patient needs to keep a daily diary of insulin doses taken.
1826335|NCT00776607|Drug|Tablet treatment|Step 1: Lifestyle modification. If HbA1c at 7%+ or if on metformin/sulphonylurea go to step 2. Step 2: Glucophage. If HbA1c of 7%-7.5% give 500mg x 1 per day. If HbA1c 7.6%-8.0%, week 1 - 500mg x 1 day and then 500mg x 2 day. If HbA1c 8.0%+ then 500mg x 3 per day (Titrated). If HbA1c remains 7%+ give additional tablet until 2gms per day then progress to Step 3. Step 3: Rosiglitazone. HbA1c of 7%+ give 4 mg per day. If HbA1c remains 7%+ titrate to maximal dose 4 mg twice daily +/-Metformin. If HbA1c remains 7% + for an 3 months move to step 4. Before initiation of Rosiglitazone repeat medical history with special emphasis on cardiovascular disease, if patient has a history of CVD move to Step 4 (insulin). Any adverse events suggestive of heart disease move to step 4. Step 4: Insulin (oral agents will be stopped). Initiation of insulin will the same as for the insulin arm and will follow the protocol detailed in the Insulin arm.
1826336|NCT00776620|Drug|Glimepiride 1mg Tablets|
1826337|NCT00776633|Drug|aspirin|6 weeks triple therapy with aspirin, clopidogrel and oral anticoagulation
1826338|NCT00776633|Drug|clopidogrel|6 months triple therapy with aspirin, clopidogrel and oral anticoagulation
1826339|NCT00776633|Drug|oral anticoagulation|
1826340|NCT00776646|Drug|hydrochlorothiazide 50 mg tablet|
1826341|NCT00776659|Other|Aromasin|Non-Interventional study design.
1826342|NCT00776672|Drug|Fosinopril 40mg Tablets|
1826343|NCT00776685|Behavioral|Personality-targeted interventions|Motivational and cognitive behavioural interventions targeting four personality profiles. 2 90 minute group sessions with personality-matched peers facilitated by a trained teacher and co-facilitator
1826387|NCT00777062|Drug|Placebo|Placebo injection at the start of weeks 2 and 6.
1826344|NCT00776698|Drug|bevacizumab [Avastin]|7.5mg/kg every 3 weeks for 3 cycles (cohort 1) or 15mg/kg every 3 weeks for 3 cycles (cohort 2). Preferred dose every 3 weeks for 9 cycles (cohort 3).
1826345|NCT00776698|Drug|cisplatin|80mg/m2 iv every 3 weeks for 3 cycles
1826346|NCT00776698|Drug|etoposide|100mg/m2 iv for 3 consecutive days, every 3 weeks for 3 cycles
1826347|NCT00776711|Drug|Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005|
1826348|NCT00776711|Drug|VRC-AViDNA036-00-VP|
1826349|NCT00776724|Drug|Taxotere , Epirubicin|Taxotere 70 mg/m2 1hr iv infusion / Epirubicin 90 mg/m2 (TE) iv infusion on day 1.
1826350|NCT00776724|Drug|E-HDFL,EP,TE,N-HDFL,NP,T-HDFL,TP|"Tau+ topo II+ ERCC1+ : Epi 45mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.
Tau+ topo II+ ERCC1- : Epi 45mg/m2 iv/ Cis 35mg/m2 24 hrs iv infusion day 1 and 8.
Tau+ topo II- ERCC1+ : Vin 25mg/m2 iv / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.
Tau+ topo II- ERCC1- : Cis 35mg/m2 24 hrs infusion / Vin 25mg/m2 iv day 1 and 8.
Tau- topo II+ ERCC1+ : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.
Tau- topo II+ ERCC1- : Docetaxel 70 mg/m2 / Epirubicin 90 mg/m2 on day 1.
Tau- topo II- ERCC1+ : Tax 35mg/m2 1hr infusion / 5FU 2000mg/m2 + Lv 300mg/m2 24 hrs infusion, day 1 and 8.
Tau- topo II- ERCC1- : Tax 35mg/m2 1hr infusion / Cis 35mg/m2 24 hrs infusion day 1 and 8."
1826351|NCT00776750|Biological|trivalent split influenza vaccine|standard dose of 0.5 ml commercially available trivalent split influenza vaccine (Vaxigrip®, Aventis Pasteur MSD) by intramuscular injection
1826352|NCT00776763|Drug|Avastin intravitreal injection|1,25 mg of Bevacizumab (Avastin) will be intravitreally injected 4 weeks interval in the proliferative retinopathies groups (exudative age related macular degeneration and proliferative diabetic retinopathy)
1826353|NCT00776789|Other|skin to skin contact|Infants randomized to SSC group were placed prone over the mother's chest immediately after birth. Skin-to-skin contact was continued for the next two hours. breastfeeding at the time of discharge.
1826354|NCT00776789|Other|Control group|The infants who were allocated to the conventional care (control group) were kept by the mother's side and did not receive early SSC.
1826355|NCT00776802|Drug|GCS-100|GCS-100 80 mg/m2 IV (in the vein) on Study Days 1, 2, 3, 4, and 5 of a 21-day course. Three or up to six patients will be enrolled in each cohort until the maximum tolerated dose is reached. The dose levels: 1) 80 mg/m2; 2) 120 mg/m2; 3) 160 mg/m2
1826356|NCT00776802|Drug|Etoposide; Dexamethasone|Etoposide 100 mg/m2 on Study Days 3, 4 and 5; Dexamethasone 10 mg/m2 on Study Days 1, 2, 3, 4 and 5.
1826357|NCT00776828|Drug|cilostazol|Pletaal (Otsuka Pharm.) 100mg bid for six months
1826358|NCT00776841|Drug|Aramchol|1.Aramchol in 16 healthy male subjects at single doses ranging between 30 and 900 mg (Part A) and in 30 overweight, mildly hypercholesterolemic, otherwise healthy male subjects receiving multiple doses (Part B)
1826359|NCT00776841|Drug|Aramchol|Oral Aramchol at dose 30 mg to 900 mg
1826360|NCT00776841|Drug|Aramchol|Oral Aramchol at doses 30 mg to 900 mg single dose and 30 mg and high dose for 4 days
1826361|NCT00776854|Device|Noveon laser|870 and 930nm wavelengths
1826362|NCT00776867|Drug|perifosine|Open label, phase I study of oral perifosine in recurrent/progressive pediatric solid tumors. This will be a dose escalation study to determine the maximum tolerated dose (MTD) of perifosine alone in recurrent/progressive pediatric tumors. A standard 3+3 dose escalation design will be employed with 3-6 patients at each dose level. All patients will receive perifosine at a loading dose on the first day, followed by a maintenance dose to start on day two until progression each patient will be assigned to a dosing group based on one's body surface area (BSA).
1826363|NCT00776880|Other|ASA scale|ASA scale evaluation before operation
1826364|NCT00776880|Other|PPS scale|PPS scale evaluation before operation
1826365|NCT00776906|Device|Advance® 18PTX® Balloon Catheter|
1826366|NCT00776906|Device|Advance® 18LP Balloon Catheter|
1826367|NCT00776919|Drug|clindamycin / benzoyl peroxide gel|Once a day application to the face
1826368|NCT00776919|Drug|clindamycin gel|Once a day application to the face
1826369|NCT00776919|Drug|BPO gel|Once a day application to the face
1826370|NCT00776919|Drug|vehicle gel|Once a day application to the face
1826371|NCT00776958|Other|Questionnaire|Information Collection for Entry into Multicenter Registry: Survey 5-10 minutes. Participation lasts as long as patient agrees to continue having study information collected
1826372|NCT00776971|Other|Sugar-sweetened soft drink|500mL as a preload drink
1826373|NCT00776971|Other|Aspartame-sweetened soft drink|500mL as a preload drink
1826374|NCT00776971|Other|Semi-skimmed milk|500mL as a preload drink
1826375|NCT00776971|Other|Water|500mL as a preload drink
1826376|NCT00776984|Drug|tiotropium 5mcg/day|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
1826377|NCT00776984|Drug|placebo|Intervention = Randomisation: patient to receive double-blind treatment with either 5mcg/day tiotropium inhalation solution or placebo inhalation solution
1826378|NCT00776997|Device|Magnetic Sphincter Augmentation|The area of the lower esophageal sphincter (LES) is accessed using a standard laparoscopic approach. The tubular esophagus, in the area of the LES, is sized and the appropriately sized sphincter augmentation device is placed circumferentially around the esophagus in the area of the LES. After confirming proper placement, the ends of the device are secured. At this point, the implant procedure is complete, laparoscopic instruments are withdrawn and access points are closed.
1826379|NCT00777010|Other|Ketogenic diet|carbohydrate restricted diet
1826380|NCT00777010|Other|Healthy high carbohydrate diet|higher carbohydrate diet
1826381|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1200 mg|G-ER 1200 mg daily dosage given as two 600-mg tablets.
1826382|NCT00777023|Drug|Gabapentin Extended-Release (G-ER) 1800 mg|G-ER 1800 mg daily dosage given as one 600-mg tablet in the morning and two 600-mg tablets in the evening.
1826383|NCT00777023|Drug|Placebo|Matching placebo dosages of 1200 mg daily (two 600-mg tablets) and 1800 mg daily (one 600-mg tablet in the morning and two 600-mg tablets in the evening).
1826384|NCT00777036|Drug|Dasatinib|
1826385|NCT00777049|Drug|Panobinostat|Hard gelatine capsule - 5mg and 20mg
1826386|NCT00777062|Drug|VIVITROL (Naltrexone extended-release injectable suspension)|VIVITROL (Naltrexone extended-release injectable suspension), 380 mg injection at the start of weeks 2 and 6.
1826388|NCT00777075|Drug|L-arginine|
1826390|NCT00777088|Device|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach
1958661|NCT01406860|Drug|Droperidol|Droperidol 1.25 mg IV x 1, may repeat 0.625 mg if needed at 60 minutes
1826394|NCT00777114|Drug|bortezomib, tositumomab|"0.30mg/m2 bortezomib and 50cGy 131I-tositumomab,
0.30 mg/m2 bortezomib and 75 cGy 131I-tositumomab,
0.60 mg/m2 bortezomib and 75 cGy 131I-tositumomab,
0.90 mg/m2 bortezomib and 75 cGy 131I-tositumomab, and
1.2 mg/m2 bortezomib and 75 cGy 131I-tositumomab."
1826395|NCT00777127|Drug|Imiquimod|One course of treatment (COT) consisting of an overnight application of IMIQ (1 sachet for up to 50 cm2), applied 3 nights per week (e.g. Monday, Wednesday, Friday) for 4 weeks followed by a 4 weeks treatment pause. If necessary, this may be followed by a second COT.
1826396|NCT00777127|Drug|Diclofenac|Solaraze® is applied locally to the skin 2 times daily and smoothed into the skin gently. The amount needed depends on the size of the lesion. Normally 0.5 grams (the size of a pea) of the gel is used on a 25 cm2 lesion site. The duration of therapy is 12 weeks.
1826397|NCT00777140|Drug|Deferoxamine|"Intravenous deferoxamine: bolus 10mg/Kg (initiated during thrombolytic infusion, iv tPA), followed by intravenous perfusion of 20/40/60mg/Kg during 72h. It's a dose-finding study with 3 different doses of deferoxamine, with 20 patients (15 active:5 placebo) in each step.
Bolus + 72h perfusion of saline solution for the placebo group."
1826398|NCT00777153|Drug|Cediranib|30 mg/day, oral, until progression
1826399|NCT00777153|Drug|Cediranib|20 mg/day, oral, until progression
1826400|NCT00777153|Drug|Lomustine Chemotherapy|110 mg/m2 / Q6W, oral, until progression
1826401|NCT00777153|Drug|Placebo Cediranib|Oral, until progression
1826402|NCT00777166|Drug|oxytocin|oxytocin 5 units diluted with normal saline to a total volume of 10 mL
1826403|NCT00777166|Drug|oxytocin|oxytocin 10 units diluted with normal saline to at total volume of 10 mL.
1826404|NCT00777179|Drug|Vandetanib|Tablet, oral, daily
1826405|NCT00777179|Drug|Placebo|Placebo
1826406|NCT00777192|Behavioral|Questionnaires|20 Minute Questionnaires beginning Visit 1, to measure pain/other symptoms, mood, and quality of life
1826407|NCT00777205|Behavioral|Telephone-based peer support|Patients received a) a peer-support manual that outlines self-management and recovery principles and provides peer discussion topics and b) access to a specialized telephone platform that permits free calls to their partners, ready access to mental health staff for back-up and advice on being effective partners, and recorded tips on depression management. They were asked to call their peer partner at least once a week for 24 weeks.
1826408|NCT00777205|Behavioral|Enhanced Usual Care|Patients received their usual mental health care plus a copy of the Depression Helpbook by Wayne Katon and bi-weekly study mailings with depression management tips.
1826409|NCT00777218|Drug|propranolol|standard pediatric doses, based on body weight
1826410|NCT00777218|Drug|zonisamide|standard pediatric dosages, based on body weight
1826411|NCT00777218|Drug|topiramate|standard pediatric dosages, based on body weight
1826412|NCT00777231|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
1826413|NCT00777244|Drug|MITOTANE|mitotane will be administered at a starting dose of 1.5 g/day and increased in case of good gastrointestinal tolerance on day 2 to 3 g/day, on day 3 to 4.5 g/day, and on day 4 to 6 g/day. A dose of 6 g/day will be administered until first mitotane blood level is assessed. Further adjustment of dosage will be performed according to blood concentrations and tolerability.
1826414|NCT00777257|Biological|T dap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap)+ Placebo, Intramuscular; Day 28: 0.5 mL (Menactra®) Intramuscular
1826415|NCT00777257|Biological|Tdap + Meningococcal Polysaccharide Diphtheria Toxoid Conj.|Day 0: 0.5 mL (T dap) + 0.5 mL (Menactra®) Intramuscular; Day 28: Placebo 0.5 mL Intramuscular
1826416|NCT00777257|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conj. + T dap|Day 0: 0.5 mL (Menactra®)+0.5 mL Placebo, Intramuscular; Day 28: 0.5 mL (T dap) Intramuscular
1826417|NCT00777270|Procedure|repair of episiotomy or second degree tears|continuous suture technique with continuous non-locking suture in the vagina, perineum and subcutaneous tissue.
1826418|NCT00777270|Procedure|repair of episiotomy or second degree tears|interrupted technique with continuous locking suture of the vagina, interrupted sutures in the perineum muscle and interrupted transcutaneous suture
1826419|NCT00777296|Drug|Arikayce™|
1826420|NCT00777296|Drug|Placebo|
1826421|NCT00777309|Drug|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity or other discontinuation criterion is met
1826422|NCT00777309|Drug|Erlotinib|Erlotinib is a white, film coated tablet in strengths of 25, 100 and 150 mg administered once daily until disease progression, unacceptable toxicity or other discontinuation criterion is met.
1826423|NCT00777309|Drug|Placebo|The placebo is provided as a capsule
1826424|NCT00777322|Procedure|Excimer laser ablation, and collagen cross-linking|Surgery is performed with topical anaesthesia. The central corneal epithelium is removed. Excimer laser ablation is applied (typically 15−30 seconds). Residual bed thickness is checked with an ultrasonic pachymeter. Topical application of riboflavin 0.1% in dextran is commenced at 5 minute intervals. When an adequate saturation of the anterior chamber with riboflavin has been achieved, cross−linking treatment will proceed. Output from the UV light generating equipment is measured with a UV light meter and set at 3mW/cm². Thirty minutes of treatment is given, interrupted at five minute intervals by the application of more topical riboflavin drops. Finally the eye has a bandage soft contact lens placed, with preservative free topical antibiotic, steroid, and cycloplegic drop application.
1826425|NCT00777335|Drug|Panobinostat - LBH589|Solution for infusion - 25mg/5ml
1826426|NCT00777335|Drug|Panobinostat - LBH589|Hard gelatine capsules - 5mg and 20 mg
1826427|NCT00777348|Drug|Combination DSCG and Reproterol|1:
1826428|NCT00777361|Drug|AZD3480|Iv single dose, 4-hour infusion of 25 mg
1826429|NCT00777361|Drug|AZD3480|Oral solution single dose of 50 mg
1826430|NCT00777374|Drug|Patch|epicutaneous application of allergen patch
1826431|NCT00777374|Drug|Placebo patch|epicutanoeus application of a placebo patch
1826432|NCT00777387|Procedure|slow-freeze|Slow-freeze-rapid-thaw procedure of oocytes is characterized by prolonged exposure of the cell to cryoprotectants in a low metabolic state at very low temperatures
1826433|NCT00777387|Procedure|vitrification|Vitrification is the process by which water is prevented from forming ice due to the viscosity of a highly concentrated cryoprotectant cooled at an extremely rapid rate
1826434|NCT00777400|Drug|Efalizumab|1 mg/kg of efalizumab administered sub q once weekly
1826435|NCT00777413|Drug|Minocycline 100mg Tablets|
1826436|NCT00777439|Drug|Domperidone|10 mg of oral domperidone will be administered 4 times daily. This dose may be increased to 20 mg 4 times daily or 30 mg 4 times daily, depending on how the subject responds to the drug.
1826437|NCT00777478|Drug|capiri-sutent|A dose escalating study in a 3 + 3 design will be performed. At MTD dose 14 additional patients will be treated. First, the optimal dose of sunitinib in a continuous schedule will be determined, thereafter, further dose escalation of capecitabine and irinotecan will be investigated.
1826438|NCT00777491|Drug|cisplatin|Given IV
1826439|NCT00777491|Drug|fluorouracil|Given IV
1826440|NCT00777491|Drug|gemcitabine hydrochloride|Given IV
1826441|NCT00777491|Radiation|radiation therapy|Given once or twice daily
1826442|NCT00777504|Drug|usage oral angiogenesis inhibitor|see under 'study arms'
1826443|NCT00777504|Drug|stop oral angiogenesis inhibitor|see under 'study arms'
1826444|NCT00777517|Drug|Lipitor|A single dose of 10 mg Lipitor tablet
1826445|NCT00777517|Drug|Atorvastatin pediatric formulation|A single dose of 10 mg atorvastatin pediatric formulation
1826446|NCT00777530|Drug|Bosutinib (SKI-606)|
1826447|NCT00777543|Other|ferulic acid|Ferulic acid is naturally contained in wholegrain bread. Bran is the main source of ferulic acid while is low in white flour. Ferulic acid is mainly covalently bound to fiber and low bioaccessible. The bran is pretreated to increase the bioavailability of ferulic acid by increasing the free ferulic acid released from the food matrix.
1826448|NCT00777543|Dietary Supplement|Treated bran bread|This is a wholegrain bread enriched with bran that has been pretreated with food-grade enzymes and yeast fermentation
1826449|NCT00777543|Dietary Supplement|wholegrain bread|The control is the wholegrain bread enriched with bran that has not been pretreated
1826450|NCT00777556|Drug|DR-104|One 1.5 mg tablet of levonorgestrel for emergency contraception within 72 hours following unprotected sexual intercourse.
1826451|NCT00777569|Drug|Nicotine free cigarettes|Quest Step 2 contains 0.05 mg nicotine
1826452|NCT00777569|Drug|Extra-low nicotine cigarettes|Quest 2 cigarettes contains 0.3 mg nicotine
1826453|NCT00777569|Drug|Nicotine Lozenge|4 mg nicotine lozenge
1826454|NCT00777582|Drug|AZD2281|Oral single dose formulation
1826455|NCT00777595|Drug|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
1826456|NCT00777595|Drug|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
1826457|NCT00777595|Drug|Placebo|Inhaled solution, single dose of placebo
1826458|NCT00777595|Drug|Moxifloxacin|Tablet, oral, 400mg, single dose
1826459|NCT00777608|Drug|Comparator: Placebo 5mg (run in)|Matching placebo to donepezil - 5 mg capsules orally for 14 day run in prior to randomization.
1826460|NCT00777608|Drug|Donepezil 5 - 10 mg|"Donepezil 1 capsule (5 mg) orally, once daily for 14 days.
Donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
1826461|NCT00777608|Drug|Comparator: Placebo 5-10 mg|"Matching placebo to donepezil, 1 capsule (5 mg) orally, once daily for 14 days.
Matching placebo to donepezil 2 capsules (total 10 mg) once daily for 70 days (days 15-84)."
1826462|NCT00777608|Drug|Donepezil 10 mg|Donepezil 2 capsules (total 10 mg) orally, once daily for 24 weeks, from day 85 (optional).
1826463|NCT00777621|Other|Calorie Restriction|This group will undergo a 20% reduction in energy intake without any change in energy expenditure.
1826464|NCT00777621|Other|Exercise|This group will undergo a 20% increase in energy expenditure by exercising without any change in energy intake.
1826465|NCT00777621|Other|Calorie Restriction and Exercise|This group will undergo 10% reduction in energy intake and a 10% increase in energy expenditure via exercise.
1826466|NCT00777634|Other|No intervention.|There is no intervention used in this study. Cohort members are interviewed and blood pressure, weight, and laboratory specimens are obtained.
1826467|NCT00777647|Other|Sugar-sweetened soft drink|One litre a day for six months.
1826468|NCT00777647|Other|Aspartame-sweetened soft drink|One litre a day for six months.
1826469|NCT00777647|Other|Semi-skimmed milk|One litre a day for six months
1826470|NCT00777647|Other|Water|One litre a day for six months.
1826471|NCT00777673|Drug|Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim|"Eligible patients will receive:
nab-paclitaxel IV on days 1, 8, and 15. Treatment will be repeated every 28 days 28 days for 4 courses.
Carboplatin IV on day 1. Treatment will be repeated every 28 days for 4 courses.
Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 4 courses.
After completion of the above regimen, patients will receive:
Doxorubicin IV on day 1. Treatment will be repeated every 14 days for 4 courses.
Cyclophosphamide IV on day 1. Treatment will be repeated every 14 days for 4 courses.
Bevacizumab IV on day 1. Treatment will be repeated every 14 days for 2 courses.
Patients will then proceed with:
- Surgery including axillary staging
A minimum of 4 weeks post operatively, patient will receive:
- Bevacizumab IV on days 1 and 15. Treatment will be repeated every 28 days for 8 courses."
1826472|NCT00777686|Procedure|MRI/MRS Scan|MRI/MRS brain scan with intravenous contrast prior to chemotherapy, then repeated every 8 weeks.
1826473|NCT00777699|Drug|XL765 (SAR245409)|Gelatin capsules supplied in 5-mg, 10-mg, and 50-mg strengths; daily dosing
1826474|NCT00777699|Drug|erlotinib|Tablets supplied in 25-mg, 100-mg, and 150-mg strengths; daily dosing
1826475|NCT00777712|Other|Blood draw|Blood will be drawn from subjects once and VAC sponge will be collected (which is normally discarded material per standard of care).
1826476|NCT00777725|Device|FibroScan|Liver scan, similar to an ultrasound.
1826477|NCT00777738|Drug|BORTEZOMIB|"Bortezomib (Velcade(R)): 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days for 2 cycles (IV route, push).
For responding patients : up to 6 cycles
For non responding patient : Adjunction of dexamethasone (HD DXM) : 20 mg Days 1,D2, D 4,D 5, D8, D9 and D 11,D12 every 21 days"
1826543|NCT00778141|Drug|metformin HC1 750 mg extended-release tablets|
1826478|NCT00777764|Drug|Cohort I|"In sterile water for injection (SWFI), full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:1000, 1:100 and 1:10 were followed by 20 minutes of observation. For the skin prick test, participants were tested initially with positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.
For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.
Dilutions of omalizumab and its excipients were in SWFI."
1826479|NCT00777764|Drug|Cohort 2|"In a saline solution, full concentration and 1:1000, 1:100, 1:10 dilutions of 125 mg/mL of standard solution of omalizumab and its excipients. Skin prick test of each dilution concentration of 1:1000, 1:100, 1:10 and full concentration and Intradermal tests of each dilution concentration of 1:100,000 and 1:10,000 were followed by 20 minutes of observation.
For the skin prick test, participants were tested initially by positive control (histamine 6 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration. For the intradermal test, participants were tested initially with positive control (histamine 0.1 mg/mL) and negative control (saline), and with omalizumab and its excipients simultaneously from the lowest concentration.
Dilutions of omalizumab and its excipients were made in saline."
1826480|NCT00777777|Device|eSVS, saphenous vein supporting mesh|Surgical coronary artery bypass grafting to the right coronary artery and the circumflex coronary artery with saphenous vein grafts, one will be supported by the eSVS(TM).
1826481|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1826482|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1826483|NCT00777790|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1826484|NCT00777803|Drug|NT 201 (IncobotulinumtoxinA (Xeomin®/Bocouture®))|NT201, also known as IncobotulinumtoxinA (Xeomin®/Bocouture®), active ingredient: Clostridium botulinum neurotoxin type A free from complexing proteins, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
1826485|NCT00777803|Drug|OnabotulinumtoxinA (Vistabel®)|OnabotulinumtoxinA (Vistabel®), active ingredient: Clostridium botulinum neurotoxin type A, powder for solution for injection dose, 24 units; one injection session of solution, prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl). Of the 0.6 mL total injection volume, an aliquot of 0.15 mL was administered in the procerus muscle, aliquots of 0.125 mL were administered in the medial part of the both corrugator muscles and aliquots of 0.1 mL were administered in the middle part of both corrugator muscles.
1826486|NCT00777816|Drug|XOMA 052|A single dose of study drug on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
1826487|NCT00777816|Drug|Placebo|A single dose of placebo on Day 0, administered either as an intravenous (IV) infusion or as a subcutaneous (SC) injection.
1826488|NCT00777829|Drug|Low-dose sodium oxybate|Participants will receive one dose of 2.5 g before each nap.
1826489|NCT00777829|Drug|High-dose sodium oxybate|Participants will receive one dose of 3 g before each nap.
1826490|NCT00777829|Drug|Low-dose zolpidem|Participants will receive one dose of 5 mg before each nap.
1826491|NCT00777829|Drug|High-dose zolpidem|Participants will receive one dose of 10 mg before each nap.
1826492|NCT00777829|Drug|Placebo|Participants will receive a dose of placebo before each nap.
1826493|NCT00777842|Device|GTX™ Drug Eluting Coronary Stent System|Drug eluting stent
1826494|NCT00777855|Drug|warfarin plus rifampin|warfarin 7.5mg po x 1; rifampin 600mg IV x 1
1826495|NCT00777855|Drug|warfarin|warfarin 7.5mg po x 1
1826496|NCT00777868|Drug|Low Strength IDP-108|Topical application once a day for 9 months
1826497|NCT00777868|Drug|High Strength IDP-108|Topical application once a day for 9 months
1826498|NCT00777868|Drug|High Strength IDP-108 under occlusion|Topical application once a day for 9 months
1826499|NCT00777868|Drug|Vehicle|Topical application once a day for 9 months
1826500|NCT00777894|Radiation|3-dimensional conformal radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.
Phase I: Dose finding according to the following escalation table:
Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)
(3 patients) 27 x 2 Gy = 54 Gy
(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy
(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy
Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
1826501|NCT00777894|Radiation|intensity-modulated radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.
Phase I: Dose finding according to the following escalation table:
Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)
(3 patients) 27 x 2 Gy = 54 Gy
(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy
(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy
Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
1826544|NCT00778167|Biological|cixutumumab|Given IV
1826545|NCT00778167|Drug|erlotinib hydrochloride|Given PO
1826546|NCT00778167|Other|laboratory biomarker analysis|Correlative studies
1826547|NCT00778180|Drug|furosemide 80 mg tablets|
1826548|NCT00778193|Drug|Naproxen|1 tablet 500mg BID for 8 days
1826549|NCT00778193|Drug|Aspirin|1 tablet 81mg QD for 8 days
1826550|NCT00778193|Drug|Celecoxib|1 capsule 200mg QD for 8 days
1826502|NCT00777894|Radiation|stereotactic body radiation therapy|"Once daily RT sessions with 2 Gy, five days a week (on weekdays), will be performed.
Phase I: Dose finding according to the following escalation table:
Dose level Radiotherapy dose (1 x 2 Gy session/day, 5 sessions/week)
(3 patients) 27 x 2 Gy = 54 Gy
(3 patients) 29 x 2 Gy = 58 Gy, with optional field reduction after a dose of 54 Gy
(3 patients) 31 x 2 Gy = 62 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 33 x 2 Gy = 66 Gy, with optional field reduction after a dose of 54 Gy
(5 patients) 35 x 2 Gy = 70 Gy, with optional field reduction after a dose of 54 Gy
Phase II: The dose for phase II will be recommended according to the MTD determined in phase I, if the MTD is 62 Gy or higher. If the MTD is 58 Gy or lower, the phase II part of the trial will not be performed."
1826503|NCT00777907|Device|Pipeline Embolization Device (PED)|1 or more PEDs placed in the parent artery of the affected aneurysm via endovascular approach.
1826504|NCT00777907|Device|Coil embolization|Placement of bare platinum coils into the target aneurysm with balloon remodeling allowed.
1826506|NCT00777933|Drug|tacrolimus|
1826507|NCT00777933|Drug|cyclosporine|
1826508|NCT00777946|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet taken orally once a day with a glass of water.
1826509|NCT00777946|Drug|Aliskiren/Amlodipine 300/5 mg|Aliskiren/Amlodipine 300/5 mg tablet taken orally once a day with a glass of water.
1826510|NCT00777946|Drug|Aliskiren/Amlodipine 300/10 mg|Aliskiren/Amlodipine 300/10 mg taken orally once a day with a glass of water.
1826511|NCT00777946|Drug|Placebo to Aliskiren|Placebo to Aliskiren tablet taken orally once a day.
1826512|NCT00777946|Drug|Placebo to Aliskiren/Amlodipine|Placebo to Aliskiren/Amlodipine taken orally once a day.
1826513|NCT00777959|Drug|ridaforolimus (MK8669)|Three 10 mg tablets administered daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
1826514|NCT00777959|Drug|Comparator: Placebo|Three tablets of matching placebo to ridaforolimus administered daily for 5 consecutive days each week followed by 2 days without matching placebo and on 50 mg tablet of bicalutamide administered once daily for 7 days each week. Treatment will continue until disease progression.
1826515|NCT00777959|Drug|open-label ridaforolimus (MK8669)|Single dose of three 10 mg tablets ridaforolimus on Day 1, and 50 mg bicalutamide once daily starting on Day 2. On Day 8, patients will begin taking three 10 mg tablets of ridaforolimus daily for 5 consecutive days each week followed by 2 days without ridaforolimus and one 50 mg tablet of bicalutamide once daily for 7 days each week. Treatment will continue until disease progression.
1826516|NCT00777972|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
1826517|NCT00777985|Drug|bosentan|62.5 mg b.i.d for 4 weeks
1826518|NCT00777985|Device|nasal continuous positive airway pressure (CPAP)|Daily application throughout sleep for 4 weeks
1826519|NCT00777998|Procedure|Auto-Allo Tandem SCT and maintenance therapy with Thalidomide/ DLI|"*Multiple myeloma
-> Induction Therapy (max. 8 cycles)
-> Registration of patient, stem cell mobilization, start of donor search
-> Melphalan (200mg/qm) plus autologous PBSCT
-> 2 months later: Melphalan plus allogeneic PBSCT
-> day 120 after allogeneic PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)
-> day 180 after allogeneic PBSCT (if CsA discontinued): First DLI (1 x 10^6 (MRD) or 5 x 10^5 (MUD) CD3+ cells per kg BW)
-> day 250 after allogeneic PBSCT: second DLI (if no signs of GvHD: dose escalation by 0,5 Log)
-> Day 320 after allogeneic PBSCT: Third DLI (if no signs of GvHD: dose escalation by 0,5 Log)
-> Further DLI depending on MRD-measurement"
1826520|NCT00777998|Procedure|auto-auto Tandem stem cell transplantation and maintenance therapy with Thalidomide|"*Multiple myeloma
-> Induction Therapy (max. 8 cycles)
-> Registration of patient, stem cell mobilization, start of donor search
-> Melphalan (200mg/qm) plus autologous PBSCT
-> if no donor available (max 4 weeks after autologous PBSCT) or if patients declines allogeneic PBSCT): 2 months: Melphalan (200mg/qm) plus autologous PBSCT
-> day 120 after autologous PBSCT: Thalidomide, 100mg (max. 2 years or until progress or non-tolerable toxicity, respectively)"
1826521|NCT00778011|Drug|Ondansetron|dosage
1826522|NCT00778011|Drug|Ondansetron|4 mg
1826523|NCT00778011|Drug|Metoclopramide|10 mg IV
1826524|NCT00778024|Drug|fluoxetine HCL 40 mg capsules|
1826525|NCT00778037|Drug|Cyclobenzaprine hydrochloride 10 mg tablet|
1826526|NCT00778050|Drug|Amoxicillin 600mg|
1826527|NCT00778063|Drug|dexmedetomidine|2 mcg/kg intranasally 30 minutes prior to surgery
1826528|NCT00778063|Drug|saline|a volume of intranasal saline, calculated based on body weight, will be given 30 minutes prior to surgery
1826529|NCT00778076|Device|Hyaluronic acid|3 consecutive injections, each one week apart, of 20mg/2ml Hyaluronic acid.
1826530|NCT00778076|Device|Placebo (Saline injection)|3 consecutive injections, each one week apart, of 20mg/2ml of Placebo.
1826531|NCT00778089|Device|ArteFill® Skin Test|Subjects will receive the ArteFill® Skin Test at Visit 1, Day 0 on the volar forearm. After 30 days, if the test result is negative a second skin test will be administered on the contra volar forearm at Visit, 3, Day 30.
1826532|NCT00778102|Drug|5-FU|Bolus 400mg/m2, day 1 every 2 weeks
1826533|NCT00778102|Drug|5-FU|3200mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
1826534|NCT00778102|Drug|5-FU|2400mg/m2 46-hour continuous iv infusion, day 1 every 2 weeks
1826535|NCT00778102|Drug|Irinotecan|165mg/m2 1-hour iv infusion, day 1 every 2 weeks
1826536|NCT00778102|Drug|Leucovorin|400mg/m2 2-hour iv infusion, day 1 every 2 weeks
1826537|NCT00778102|Drug|Leucovorin|200mg/m2 2-hour iv infusion, day 1 every 2 weeks
1826538|NCT00778102|Drug|Oxaliplatin|85mg/m2 2-hour iv infusion, day 1 every 2 weeks
1826539|NCT00778102|Drug|bevacizumab [Avastin]|5mg/kg iv day 1 every 2 weeks
1826540|NCT00778115|Drug|Loperamide HCl 2 mg and simethicone 125 mg tablets|
1826541|NCT00778128|Drug|CP-4126|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose. Step 2: Oral CP-4126 day 1 and 15 + IV Gemcitabine 1000 mg/m2 day 8 in a 4 week schedule until complete response or disease worsening / progression
1826542|NCT00778128|Drug|Gemcitabine|Step 1: Dose escalation oral CP-4126 until maximum tolerated dose Step 2: Oral CP-4126 day 8 and 15 + IV Gemcitabine 1000 mg/m2 day 1 in a 4 week schedule until complete response or disease worsening / progression
1826551|NCT00778193|Drug|Clopidogrel|Day 0: 4 tablets QD for 1 day; Days 1-7: 1 tablet QD for 7 days
1826552|NCT00778193|Drug|Placebo|1 capsule BID for 8 days
1826553|NCT00778206|Drug|Kuvan|"After the baby is born, follow-up assessments will be requested for six months. If Kuvan is taken by the mother during and/or after pregnancy, blood samples will be requested from the mother and the baby.
If the mother is lactating and taking Kuvan, breast milk samples will be requested."
1826554|NCT00778219|Device|devices for tracheal intubation|tracheal intubation by laryngoscope or lightwand
1826555|NCT00778232|Drug|Gabapentin tablets 800 mg|
1826556|NCT00778245|Drug|cefprozil 500mg tablets|
1826557|NCT00778258|Biological|Baked Milk|At baseline, each subject will undergo sequential oral food challenges with the products that contain increasing amounts of milk protein that are baked: Stage 1 (muffin), Stage 2 (pizza), and Stage 3 (rice pudding) doses of baked milk to determine the extent to which they tolerate various baked milk proteins. Based on the outcomes of the baseline oral food challenges, subjects will be assigned to one of the 5 study arms.
1826558|NCT00778258|Biological|Non-baked Milk|Those subjects tolerant to rice pudding will undergo oral food challenge with non-baked milk.
1826559|NCT00778271|Drug|Gabapentin 400mg capsules|
1826560|NCT00778284|Drug|Amoxicillin 400mg + clovalunic acid 57.5mg chewable tablets|
1826561|NCT00778297|Biological|Vaccination with FluvalAB FL-K-004 trivalent flu vaccine|Treatment: 6 μg HA/strain/dos of FluvalAB FL-K-004 trivalent influenza vaccine will be administered once (at Day 0).
1826562|NCT00778297|Biological|Vaccination with FluvalAB trivalent influenza vaccine|Treatment: 15 μg HA/strain/dos of FluvalAB trivalent influenza vaccine will be administered once (at Day 0).
1826563|NCT00778310|Drug|methylphenidate-OROS|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of Concerta that are made to appear similar to placebo capsules. The subject will be administered their usual dose of Concerta the morning of the scan.
1826564|NCT00778310|Drug|Placebo|The collaborator (Ortho-McNiel Janssen Scientific Affairs, LLC) will provide capsules of placebo that are made to appear similar to Concerta capsules. The subject will be administered placebo the morning of the scan.
1826565|NCT00778323|Procedure|limb remote ischemic preconditioning (LRIPC)|LRIPC consists of three 5-min cycles of right upper limb ischemia induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mmHg,with an intervening 5 min reperfusion during which the cuff is deflated.
1826566|NCT00778349|Drug|Metformin solution 100 mg/mL|
1826567|NCT00778375|Drug|Clofarabine|20 mg/m^2 by vein as a 1- to 2-hour intravenous infusion daily for 5 days.
1826568|NCT00778375|Drug|Cytarabine|20 mg subcutaneously twice daily for 10 days, administered 3 to 6 hours following the start of the clofarabine infusions.
1826569|NCT00778375|Drug|Decitabine|20 mg/m^2 as a 1- to 2-hour infusion daily for 5 days.
1826570|NCT00778388|Biological|IC43|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
1826571|NCT00778388|Drug|Placebo|The study consists of a screening visit within 14 days before the administration of the investigational medicinal product (IMP), an experimental part of 180 days with seven outpatient visits on days 0, 3, 7, 14, 28, 90 and 180 and with vaccinations on days 0 and 7. IC43 vaccine will be administered intramuscularly during study visit 0 and 7 at three different doses, adjuvanted with Al(OH)3, or in one dose without Al(OH)3. Injection volumes will be 0.5 mL, 1 mL or 2 mL. Placebo will be administered intramuscularly at a dosage of 1 mL.
1826572|NCT00778401|Drug|Gabapentin tablets 800 mg|
1826573|NCT00772304|Drug|Olopatadine 0.6% / Azelastine 137 mcg|single dose; 2 sprays per nostril
1826574|NCT00772317|Device|High Intensity Focused Ultrasound|High Intensity Focused Ultrasound
1826575|NCT00772330|Device|Glaucoma Drainage Device|Insertion of MIDI Arrow subconjunctivally with a fornix-based incision after pretreatment of scleral surface with 0.4 mg/mL MMC and insertion of MIDI Arrow tube through sclera into anterior chamber of eye
1826576|NCT00772343|Biological|0.9% Normal Saline|0.5 mL, intramuscular on Days 0, 7, and 28
1826577|NCT00772343|Biological|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
1826578|NCT00772343|Biological|Clostridium difficile toxoid vaccine with adjuvant|0.5 mL, intramuscular on Days 0, 7, and 28
1826579|NCT00772343|Biological|Clostridium difficile toxoid vaccine|0.5 mL, intramuscular on Days 0, 7, and 28
1826580|NCT00772356|Device|Accu-Chek Spirit Insulin Pump|
1826581|NCT00772356|Device|Comparator insulin pump|
1826582|NCT00772382|Drug|MCI-196|3g to 15g/day (3 times a day), Tablet, 52 weeks of flexible dose
1826583|NCT00772395|Drug|Risedronate|35 mg given once weekly start on 2nd postoperative day for 26 weeks (6 months)
1826584|NCT00772395|Drug|Placebo|Placebo given once weekly start on 2nd postoperative day for 26 weeks (6 months)
1826585|NCT00772421|Device|There was no intervention.|There was no intervention. This study was designed as an in-clinic testing protocol to identify recruitment rhythms.
1826586|NCT00772447|Drug|Daptomycin|4mg/kg IV ; Q 24 hr (once every 24 hours)
1826587|NCT00772447|Drug|Vancomycin|"Vancomycin - 1g per 12 hrs, for 7-14 days
Or switch to
Vancomycin Followed by Semi-synthetic Penicillin-Cloxacillin:
- 1 g every 6 hours or 2 g every 8 hours"
1826588|NCT00772460|Device|Patient Warming with conductive / convective warming|Warming device set to maximum (43 °C)
1826589|NCT00772473|Other|subjects personal triptan|Subjects will treat 1 migraine attack with their usual triptan
1826590|NCT00778414|Drug|Amoxicillin-Clavulanic acid 600mg - 42.9 mg/ 5 mL oral suspension|
1826591|NCT00778427|Drug|metformin hydrochloride 1000 mg tablets|
1826592|NCT00778453|Other|Hospital-based mCIT|restraint of the unaffected arm and practice of the affected arm
1826593|NCT00778453|Other|Hospital-based BIT|bilateral symmetric, repetitive arm training
1826594|NCT00778453|Other|Hospital-based TR|hospital-based traditional rehabilitation : OT or PT or therapist-based training
1826595|NCT00778453|Other|Home-based mCIT|restraint of the unaffected arm and practices of the affected arm
1826596|NCT00778453|Other|Home-based BAT|bilateral symmetric, repetitive arm training
1826597|NCT00778453|Other|Home-based TR|home-based traditional rehabilitation:OT or PT or therapist-based training
1826598|NCT00778466|Drug|metformin hydrochloride 1000 mg tablets|
1826599|NCT00778479|Device|Sepraspray|Max. 10g of Sepraspray
1826600|NCT00778505|Drug|Propofol|closed-loop administration using bispectral index as the controller
1826601|NCT00778505|Drug|remifentanil|closed-loop administration using bispectral index as the controller
1826602|NCT00778505|Drug|Propofol|manual administration according bispectral index values
1826603|NCT00778505|Drug|Remifentanil|manual administration according bispectral index values
1826604|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.
1826605|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.
1826606|NCT00778518|Drug|ARX201|Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
1826607|NCT00778531|Device|ArteFill injectable implant|Treatment will be according to the approved labeling for ArteFill for the correction of nasolabial folds. The nasolabial fold is the line or fold that extends from approximately the inferior aspect of the ala of the nose to the commissure of the mouth on the right and left side of the face.
1826608|NCT00778544|Drug|amoxicillin-clavulanic acid 600 mg- 42.9 mg/ 5 mL oral suspension|
1826609|NCT00778557|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
1826610|NCT00778583|Drug|Nitrofurantoin 100 mg capsules|
1826611|NCT00778596|Drug|Prednisolone|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
1826612|NCT00778596|Drug|Placebo priming|Prednisolone priming for 4 weeks, then followed a telbivudine treatment for 2 years.
1826613|NCT00778609|Drug|EV/DNG (Qlaira, BAY86-5027)|Estradiol valerate (EV) and dienogest (DNG). Sequential 4-phasic regimen. Daily oral administration of one capsule SH T00658ID for 28 days per cycle for 6 treatment cycles no pill-free interval
1826614|NCT00778609|Drug|Encapsulated Microgynon + Placebo|Day 1 to 21; 0.03 mg ethinylestradiol (EE) + 0.15 mg levonorgestrel (LNG). Day 22 to 28 placebo
1826615|NCT00778622|Drug|Metformin XR|Tablets, Oral, 500mg tid, 1500 mg/day, 16 weeks
1826616|NCT00778648|Dietary Supplement|Juice Plus|"Juice Plus+® is a dietary supplement from concentrated fruits (apple, orange, pineapple,cranberry, cherry (acerola), papaya and peach) and vegetables (carrot, parsley, beet, broccoli, kale, cabbage, spinach, and tomato).
Subjects will take four capsules of Juice Plus+® daily."
1826617|NCT00778648|Dietary Supplement|Placebo|Four capsules of placebo daily.
1826618|NCT00778661|Drug|amoxicillin 400mg + clovalunic acid 57.5mg tablets|
1826619|NCT00778674|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
1826620|NCT00778700|Drug|INCB018424 Phosphate Cream|0.5% phosphate cream
1826621|NCT00778700|Drug|Placebo Cream|Cream with no active drug
1826622|NCT00778700|Drug|INCB018424 Phosphate Cream|1.0% phosphate cream
1826623|NCT00778700|Drug|INCB018424 Phosphate Cream|1.5% phosphate cream
1826624|NCT00778713|Drug|Fosinopril sodium and hydrochlorothiazide 20-12.5 mg tablets|
1826625|NCT00778726|Drug|Benazepril HCl/ Hydrochlorothiazide 20 mg/ 25 mg Tablets|
1826626|NCT00778739|Drug|CEFPROZIL FOR ORAL SUSPENSION USP 250 mg/ 5 mL|
1826627|NCT00778752|Drug|Revlimid (Lenalidomide)|"3 pat. will be enrolled on dose level 0. If no DLTs are observed during cycles 1+2 dose will be escalated to the next higher level in the 3 patients. If 1 of 3 pat. experiences DLT at the current dose, then up to 3 more pat. will be accrued at the same level. If none of these 3 additional pat. experience DLT dose will be escalated in subsequent patients. If 1 of these 3 patients experiences DLT, the next lower level will be declared to be MTD and the study will be filled up with patients at this dose level up to 25 pat. overall.
If 2 or more of 3 pat. or 3 or more of 6 pat. in the same cohort encounter DLT, the MTD has been exceeded and the previous lower dose level will be declared as MTD and the study will be filled up with patients at this level up to 25 pat. overall.
If DLT is observed in level 0, the next dose level will be -1 for the following cohort of 3 patients. If level 2 is well tolerated without DLT, this level will be claimed as recommended dose for further trials."
1826628|NCT00780520|Dietary Supplement|alanine-glutamine infusion|
1826629|NCT00780559|Behavioral|Tailored Diet and Physical Activity|Subjects will receive an individually tailored diet and physical activity enhancement program
1826630|NCT00780559|Behavioral|Standard of Care|Subjects will be told to reduce their baseline weight by 7% and exercise for 150 minutes/week. There is no tailored, directed program.
1826631|NCT00780572|Behavioral|ADE alert assistant|A note in CPRS alerting providers that patients are at risk for an adverse event based on prescription and lab value histories.
1826632|NCT00780585|Drug|SCH 900460|Subjects who participated in previous trials of Org 24448 (SCH 900460)
1826633|NCT00780598|Drug|Tosedostat|"In Part A, approximately 70 subjects will be randomized to one of 2 dose regimens of tosedostat which will be administered orally, once daily. The dose regimens of tosedostat will be:
120 mg for 6 months once daily, OR
240 mg (induction dose) once daily for 2 months, followed by 120 mg(maintenance dose) for 4 months
In Part B a further 130 subjects will receive the dose regimen of tosedostat identified in Part A as being appropriate, based on the interim analysis during Part A."
1826634|NCT00780624|Device|NIPPV|Ventilator is Bird VIP.
1826635|NCT00780624|Device|NIPPV|Ventilator(Bird VIP) is used for NIPPV device. Non-invasive NIPPV is used in the NIPPV group instead of nCPAP in the control group.
1826636|NCT00780624|Device|NIPPV|Ventilator (Bird VIP, USA) is used for provide of NIPPV in the NIPPV group instead of nCPAP in the control group. The duration of NIPPV is according to the baby's respiratory condition.
1826637|NCT00780637|Drug|Bradykinin|Patients receive 0, 10, 20, and 40 ng/100cc forearm volume/min of bradykinin intrabrachial.
1826638|NCT00780650|Drug|Atomoxetine|80 mg oral dose, once per day for 6 weeks
1826639|NCT00780650|Drug|Placebo|80 mg dose once per day for 6 weeks
1826640|NCT00780663|Drug|Quarfloxin|IV Quarfloxin 240 mg/m2 daily x5 days every 21 days
1826641|NCT00780676|Drug|Dasatinib|100 mg tablet by mouth daily
1826642|NCT00780676|Drug|AZD6244|75 mg by mouth twice daily.
1826683|NCT00781092|Other|Systane Ultra|Ophthalmic Solution, 1 gtt, three times daily to both eyes for 1 month post operative
1826643|NCT00780702|Drug|Airipiprazole|Participants receive aripiprazole (orally, up to 15 mg/day) plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
1826644|NCT00780702|Drug|Placebo|Participants receive identical capsules containing no active medication plus standard methadone maintenance (daily oral methadone and weekly individual counseling).
1958662|NCT01406860|Drug|Metoclopramide|Metoclopramide 20 mg IV infusion q30 minutes as needed with a maximum of 4 doses.
1958663|NCT01406860|Drug|Diphenhydramine|Diphenhydramine 25 mg IV injection x 1 given with the first dose of metoclopramide IV infusion and repeated x 1 given with the third metoclopramide IV infusion.
1994426|NCT03006809|Other|pretreatment antibiotics|5 day course (vancomycin PO 500mg bid, metronidazole PO 500mg bid, and neomycin PO 500mg bid) starting 6 days prior FMT
1826649|NCT00780728|Drug|Sildenafil|
1826650|NCT00780741|Procedure|Immediate Office Probing|Nasolacrimal duct probing in an office setting with topical anesthesia and restraint of the infant.
1826651|NCT00780741|Procedure|Deferred Facility Probing|Nasolacrimal duct probing performed under general anesthesia in a hospital outpatient surgery center or an ambulatory surgery center.
1826652|NCT00780754|Drug|dutasteride|0.5mg
1826653|NCT00780754|Procedure|prostate biopsy|prostate biopsy
1826654|NCT00780767|Device|ANGIOJET RHEOLYTIC THROMBECTOMY|The Angiojet catheter is a double lumen catheter percutaneously introduced via the common femoral vein into the main pulmonary trunk or the affected pulmonary artery respectively. One lumen serves to deliver high pressure saline jets into the thrombus and the other effluent lumen serves for clot removal utilizing a localized pressure region (Venturi effect) that attracts the thrombus for fragmentation into small particles. The fragmented debris are then pushed out through the evacuation line as a result of the retrograde high pressure saline jets, finally transporting them into a collection bag.
1826655|NCT00780780|Drug|Triamcinolone + Nepafenac|Triamcinolone intravitreal injection 0,1 ml (4mg) Nepafenac 1 drop, tid, during 6 months
1826656|NCT00780780|Drug|triamcinolone intravitreal injection|triamcinolone intravitreal injection
1826657|NCT00780793|Drug|progressive spacing of TNF-blocker injections|"Experimental arm
Progressive spacing of TNF-blocker injections according to the following algorithm :
if DAS28 ≤ 2.6 at trimestrial assessment: go for step N+1
if DAS28 > 2.6 and DAS28 change ≤ 0.6: continue at step N
if DAS28 > 2.6 and DAS28 change > 0.6 : return to step N-1 (relapse as defined by the European expert consensus).
Step 0 (inclusion) :
Adalimumab 40 mg / 14 days
Etanercept 50 mg / 7 days
Step 1 :
Adalimumab 40 mg / 21 days
Etanercept 50 mg / 10 days
Step 2 :
Adalimumab 40 mg / 28 days
Etanercept 50 mg / 14 days
Step 3 :
Adalimumab 40 mg / 42 days
Etanercept 50 mg / 21 days
Step 4 :
TNF-blocker stop"
1826658|NCT00780793|Drug|DMARD maintenance|DMARD maintenance
1826659|NCT00780806|Biological|meningococcal B rLP2086 vaccine candidate|vaccine, 0.5 mL, 3 doses, 0 - 2 - 6 to 9 months
1826660|NCT00780806|Procedure|Blood draw|Blood draw
1826661|NCT00780819|Device|PoleStar N20 intraoperative MRI|low field strength mobile intraoperative MRI system (0,15 Tesla) with local Faraday shielding (using the StarShield system)
1826662|NCT00780832|Behavioral|Dietary Caffeine reduction|Participants are counseled about reduction of dietary caffeine, given written information and a bladder control log.
1826663|NCT00780832|Drug|Anticholinergic medication|Detrol LA 4mg. orally, once daily for 30 days
1826664|NCT00780858|Drug|Ganirelix|Ganirelix 0.25mg s.c every 24 h starting stimulation day 6
1826665|NCT00780884|Device|acupuncture|16 sessions of acupuncture treatment, twice a week.
1826666|NCT00780910|Drug|MP-424|750 mg every 8 hours for 12 weeks
1826667|NCT00780910|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
1826668|NCT00780910|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
1826669|NCT00780923|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
1826670|NCT00780936|Procedure|femoral nerve block|
1826671|NCT00780949|Other|intestinal biopsies|intestinal biopsies during routine endoscopy
1994427|NCT03006536|Device|Li-ESWT|Participants will undergo 6 treatment sessions 2/week with 1 week pause with the Duolith® SD1 machine (Storz, Tägerwilen, Switzerland) according to the company's instructions
1826673|NCT00780975|Drug|Aplidin (plitidepsin)|Aplidin® administered at a starting dose of 5 mg/m2, as a 3-hours intravenous infusion, every 2 weeks.
1826674|NCT00780988|Biological|Autologous tumor cell + CpG vaccine|
1826675|NCT00780988|Procedure|Autologous hematopoietic and immune cell rescue (transplantation)|
1826676|NCT00781001|Drug|Cannabis|400mg placebo or active cannabis administered via the Volcano vaporizer 1x per study visit
1826677|NCT00781027|Procedure|Phacoemulsification|Comparison of longitudinal phacoemulsification and torsional phacoemulsification
1826678|NCT00781040|Other|Severe sepsis vs. non-severe sepsis|To compare these two groups
1826679|NCT00781053|Drug|P144 cream|P144 cream 0.03% will be used once a day during the whole extension period of 6 months. The patient will apply the cream by him/herself or with a help of a person uniformly in a 10% maximum affected surface until absorption
1826680|NCT00781066|Procedure|Controlled cord traction|"Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn), hold it in one hand.
Place the other hand just above the woman's pubic bone and stabilize the uterus by applying counter-pressure during controlled cord traction.
Keep slight tension on the cord and await a strong uterine contraction (2-3 minutes).
With the strong uterine contraction, encourage the mother to push and very gently pull downward on the cord to deliver the placenta. Continue to apply counter-pressure to the uterus.
If the placenta does not descend during 30-40 seconds of CCT, do not continue to pull on the cord:
Gently hold the cord and wait until the uterus is well contracted again;
With the next contraction, repeat CCT with counter-pressure."
1826681|NCT00781066|Procedure|No controlled cord traction|"Clamp the cord close to the perineum (once pulsation stops, or after three minutes in a healthy newborn).
No CCT will be used and no fundal pressure. The placenta will be delivered physiologically, and signs for placental separation will be awaited (gush of blood from the vagina, descent of the umbilical cord, and increase in the height of the uterus in the abdomen as the lower segment was distended).
After separation, delivery of the placenta will be aided only by maternal expulsive efforts and/or gravity."
1826682|NCT00781079|Behavioral|Consumer Provider|Adding a Consumer Provider to Intensive Case Management Teams (called MHICM in the VA)
1826684|NCT00781092|Other|Bausch and Lomb Sensitive Eyes|Ophthalmic Solution, 1 gtt, three times a day in both eyes for 1 month after LASIK
1826685|NCT00781105|Drug|Telbivudine|600 mg/day, oral tablets, once daily, 52 weeks
1826686|NCT00781118|Device|Guardian System|There is no intervention in this study. The device is a diagnostic only.
1826687|NCT00781131|Drug|Pregabalin|pregabalin 75 or 150 mg
1826688|NCT00781131|Drug|Placebo|lactulose placebo
1826689|NCT00781157|Drug|Phenylephrine bolus|"The initial dose of phenylephrine will be 100 mcg, a dose within the clinical range currently in use at our center. The subsequent dose is based upon the response of the preceding subject in the usual up-and-down method (UDM), which is outlined in the data analysis section of the protocol. The dosing changes will be in increments of 20 micrograms. A successful response to this dose will be entered into a spreadsheet, designed by our statistician, which will determine the subsequent dose based upon the UDM. If a failure is observed in the previous subject, the dose is stepped up in the next subject. If a success is observed the next subject is randomized with probability of 0.10 to the next lower dose and with probability 0.90 to the same dose."
1826690|NCT00781170|Procedure|allogeneic hematopoietic SCT|
1826691|NCT00781183|Other|pulmonary rehabilitation|6-weeks of in-patient pulmonary rehabilitation or 12-weeks of out-patient pulmonary rehabilitation
1826692|NCT00781196|Drug|folic acid|capsule 0.5 mg once a day
1826693|NCT00781196|Drug|placebo|capsule, once a day
1826694|NCT00781209|Procedure|Irradiation plus Stereotactic Radiosurgery|"Posterior Fossa Irradiation-total dose of 37.5 Gy in 2.5 Gy fractions administered via conformal beams.
Radiosurgical boost-total dose administered to each lesion will be titrated to the size of the metastatic focus as follows:
Maximum Tumor Diameter:<2.0 cm; Assigned Dose:24 Gy. Maximum Tumor Diameter:2.1-3.0 cm;Assigned Dose:18 Gy. Maximum Tumor Diameter:3.1-4.0 cm;Assigned Dose:15 Gy."
1826695|NCT00781248|Device|NG Shield|A device to reduce pain/discomfort related to nasogastric tube usage
1826696|NCT00781261|Drug|Zoledronic Acid|Subjects in the intervention group B will be given 5mg Zoledronic acid as a single injection.
1826697|NCT00781261|Drug|Placebo|Subjects in the control group will receive a placebo drug for a similar period
1826698|NCT00781274|Drug|MP-424|750 mg every 8 hours for 12 weeks
1826699|NCT00781274|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
1826700|NCT00781274|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
1826703|NCT00781300|Drug|Loteprednol Etabonate 0.5%|Patients in the Loteprednol Group received Loteprednol Etabonate 0.5% associated with Tobramycin 0.3% in separate eyedrops for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week
1826704|NCT00781300|Drug|Dexamethasone 0.1%|The patients in Dexamethasone Group received Dexamethasone 0.1% associated with Tobramycin 0.3% in a single eyedrop for four weeks: 6 times a day during the first postoperative week, 4 times a day during the second week, 3 times a day during the third week and twice-daily during the fourth week.
1826705|NCT00781326|Drug|Nimodipine|Nimodipine will be initiated at one, 30-mg tablet three times a day for 1 week, increased to 2 tablets three times a day for 1 week, and then increased to three tablets three times a day for the remaining 30 weeks of the study. Participants who cannot tolerate the maximum dose of 270 mg/day will be maintained at the highest tolerable dose.
1826706|NCT00781326|Drug|Placebo|Placebo will be given in doses matching those of nimodipine.
1826707|NCT00781339|Drug|sodium 2-(dichloroamino)-2-methylpropane-1-sulfonate monohydrate|0.1% NVC-422 in saline, up to 100 mL, Study Part 1 - once on Day 1 held in the bladder for 1 hour; Study Part 2 (Part 2a - 0.1% NVC-422, Part 2b - 0.2% NVC-422), once daily for 7 days, held in the bladder for 1 hour
1826708|NCT00781352|Drug|nitrous oxide|65% nitrous oxide administered during surgery
1826709|NCT00781352|Drug|nitrogen|Nitrogen administration during surgery
1826710|NCT00781365|Other|Telemonitors and pharmacy management|Patients in the intervention arm will receive home blood pressure monitors, and will have individual hypertension case management from a medication therapy management pharmacist.
1826711|NCT00781378|Drug|rt-PA|rt-PA 100 mg continuous intravenous infusion for 2 hours
1826712|NCT00781378|Drug|rt-PA|rt-PA 50 mg continuous intravenous infusion for 2 hours
1826713|NCT00781391|Drug|warfarin tablets|Warfarin tablets plus Edoxaban placebo tablets each taken once daily for 24 months
1826714|NCT00781391|Drug|Edoxaban tablets (high dose regimen-60mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
1826715|NCT00781391|Drug|Edoxaban tablets (low dose regimen-30mg)|Edoxaban tablets plus warfarin placebo tablets each taken once daily for 24 months
1826716|NCT00781391|Drug|placebo warfarin|placebo warfarin
1826717|NCT00781391|Drug|placebo edoxaban|placebo edoxaban
1826718|NCT00781404|Drug|Adenosine|Single dose of adenosine. Solution for infusion of 0.45 mg/mL. Enteral use.
1826719|NCT00781417|Dietary Supplement|Vitamin D|50,000 IU once a week for 12 weeks then every other week for 40 weeks
1826720|NCT00781417|Other|Placebo|Matching Placebo
1826721|NCT00781430|Drug|Neratinib (HKI-272)|Neratinib 40-mg oral tablets. SINGLE DOSE of 120-mg (3 x 40-mg tablets)
1826722|NCT00781443|Drug|lebrikizumab (MILR1444A)|Repeating subcutaneous injection
1826723|NCT00781443|Drug|placebo|Repeating subcutaneous injection
1826724|NCT00781456|Drug|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
1826725|NCT00781456|Drug|Placebo|1 tablet daily to match experimental arm
1826726|NCT00781482|Drug|eszopiclone, zolpidem, placebo|In random order, each subject will receive one study drug per visit over three visits. Visits will occur about 1 week apart. Each subject will eventually receive eszopiclone 3 mg., zolpidem 10 mg., and a placebo. PET scans will be done 1-2 hours after each dose.
1826728|NCT00781508|Drug|sildenafil|Changes in left ventricular filling pressure 1 hour after the administration of a single oral dose of sildenafil 50 mg.
1826729|NCT00781508|Other|Placebo|Changes in left ventricular filling pressure 1 hour after oral administration of placebo
1826730|NCT00781521|Drug|ofloxacin otic solution 0.3%|ofloxacin otic solution 0.3% instilled twice a day for seven days
1826731|NCT00781534|Dietary Supplement|Ginseng, ginsenoside Re or placebo|Each of the 3 arms will be compared to determine if there is any clinical difference in blood sugars between the 3 groups
1826732|NCT00781534|Dietary Supplement|Ginseng|
1826733|NCT00781534|Dietary Supplement|ginsenoside RE|active metabolite of ginseng
1826734|NCT00781534|Dietary Supplement|Placebo (sugar pill)|
1826735|NCT00781547|Drug|recombinant human growth hormone|The subjects will receive treatment with recombinant human GH (Genotropin®) or placebo administered by a daily s.c. injection before bedtime. The initial dose of GH will be 0.4 IU per day increased to 0.8 IU after 2 weeks and to 1.2 IU after 4 weeks of treatment. Thus, the target dose is 1.2 IU per day which resembles approximately 0.015 IU/kg/day. The GH dose will be reduced by half in the event of side-effects
1826736|NCT00781573|Drug|Clopidogrel|Clopidogrel, 75 mg QD, for one year
1826737|NCT00781586|Dietary Supplement|One-A-Day Weight S.A. (Multi-Vitamins, BAY94-9350)|One A Day Weight Smart Advanced 1 tablet at 1st visit
1826738|NCT00781586|Drug|Caffeine|Caffeine 100 mg 1 tablet at 1st visit
1826739|NCT00781586|Drug|Placebo|Placebo 1 tablet at 1st visit
1826740|NCT00781599|Drug|Chantix|Chantix 0.5 mg once daily on days 1-3, 0.5 mg twice daily on days 4-7, and 1 mg twice daily on day 8 through end of treatment at month 3
1826741|NCT00781599|Behavioral|Adherence Counseling|Induction Support counseling on days 8, 12, 20 and months 1 and 2. Adherence counseling based on the Information-Motivation-Behavioral Skills model of adherence behavioral change.
1826742|NCT00781599|Behavioral|Standard Counseling|Visit with counselor on Day 8 to develop a plan to quit smoking. Discuss strategies to quit, risks of continued smoking and discuss strategies for coping with withdrawal and craving.
1826748|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
1826749|NCT00781625|Dietary Supplement|UREX-cap-5|Size 3, white/white capsule, each containing 180 mg of a standardized, light beige fine powder consisting of freeze-dried cultures of: Lactobacillus rhamnosus, GR-1® (50%) Lactobacillus reuteri, RC-14® (50%) Ingredients Powder: Cultures, glucose anhydrate, potato starch, microcrystalline cellulose and magnesium stearate. Capsule: Gelatine, titanium dioxide Concentration Minimum of 5.4 billion (5.4 x 109) Colony Forming Units per capsule by end of bulk shelf life. Application For use as a dietary supplement. Packaging 20,000 capsules packaged in heat-sealed foil pouch.
1826750|NCT00781625|Dietary Supplement|Placebo Y cap G-3|Size 3, white/white capsule, each contaiing180 mg placebo blended powder. Daily oral and vaginal intake for a total duration of 6 months
1826751|NCT00781638|Device|Adacolumn®|The medical device Adacolumn® (CE-Mark Certificate G1 07 01 366 76013) is an adsorptive type extracorporeal apheresis column. It has been shown to effectively improve clinical and endoscopic signs and symptoms in UC in adults by removing granulocytes and monocytes and by changing the Cytokine production.
1826752|NCT00781664|Other|AN2718|AN2718 Cream SF Vehicle, Daily for up to 21 days
1826753|NCT00781664|Drug|AN2718|AN2718 Cream SF, 0.3%, Daily for up to 21 days
1826754|NCT00781664|Drug|AN2718|AN2718 Cream SF, 1%, Daily for up to 21 days
1826755|NCT00781664|Other|AN2718|AN2718 Gel Vehicle, Daily for up to 21 days
1826756|NCT00781664|Drug|AN2718|AN2718 Gel, 1.5%, Daily for up to 21 days
1826757|NCT00781664|Drug|AN2718|AN2718 Gel, 2.5%, Daily for up to 21 days
1826758|NCT00781664|Drug|AN2718|AN2718 Gel, 5%, Daily for up to 21 days
1826759|NCT00781664|Drug|AN2718|AN2718 Gel, 7.5%, Daily for up to 21 days
1826760|NCT00781664|Other|Sodium Lauryl Sulfate|Sodium Lauryl Sulfate, 0.5%, Daily for up to 21 days
1826761|NCT00781690|Device|Evodial hemodialysers and Evodia blood lines|Maximum 8 weeks treatment with Evodial dialysers with reduction of heparin dose
1826762|NCT00781703|Other|DIAMOND depression care model|Patients in activated clinic sites will receive the DIAMOND depression care model, including a care manager, frequent use of the PHQ9, treatment adjustment as indicated, psychiatric consultation, relapse prevention.
1826763|NCT00781716|Device|Drug eluting coronary stent system|Cypher Sirolimus-Eluting Coronary Stent System vs Endeavor Zotarolimus-Eluting Coronary Stent System
1826764|NCT00781729|Behavioral|Yoga, one hour class, 3 times per week, for 24 weeks|Yoga, one hour class, 3 times per week, for 24 weeks
1826765|NCT00781729|Behavioral|Luncheon Seminar Series, once per month, for 24 weeks|Luncheon Seminar Series, once per month, for 24 weeks
1826768|NCT00781755|Drug|varenicline|.5mg/day for 3 days then titrated to 1.0mg/day for 11 days. A total dosing regimen of 14 days.
1826950|NCT00775476|Drug|Placebo|2.4 g of placebo (sugar) twice daily
1994433|NCT03003442|Dietary Supplement|Supradyn® Energy 3RDA|Multivitamin/mineral containing co-Q10
1994434|NCT03003442|Dietary Supplement|Placebo|Placebo
1826769|NCT00781755|Behavioral|Adaptation of Motivational Interviewing|2 sessions of behavioral intervention designed to create ambivalence about quitting or plan for a quit attempt if the patient is ready.
1826770|NCT00781768|Drug|Standard PO ondansetron + dexamethasone|Dexamethasone 10 mg (dose blinded) in 50 ml D5W IVPB over 15 minutes daily + ondansetron 8mg PO q 8 hours - repeated qd of the preparative regimen and for 1 day after completion. A placebo capsule will be given daily on each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
1826771|NCT00781768|Drug|aprepitant (MK-869) + PO ondansetron + dexamethasone|Dexamethasone 7.5 mg (dose blinded) in 50 ml D5W IVPB over 15 min daily + ondansetron 8mg PO q 8 hours - repeated QD of the preparative regimen and for 1 day after completion. Aprepitant 125mg PO [blinded] will be given a minimum of 30 minutes prior to the preparative regimen on day 1. MK-Aprepitant 80mg PO [blinded] will be given will be given approximately 24 hours later starting on day 2 then each day of the preparative regimen plus 3 days after. Antiemetic therapy will start a minimum of 30 minutes prior to and continued for 24 hours after completion of the preparative regimen.
1826772|NCT00781781|Drug|Alemtuzumab|High risk: Total dose 100 mg in 5 doses of 20 mg, days -8 to -4 (inclusive) Low risk: Total dose 50 mg inn 5 dosing OF 10 mg, days -5 to -1 (inclusive).
1826773|NCT00781794|Drug|NSA-789 at 2 different doses|
1826774|NCT00781807|Other|multi-module rehabilitation program|"The multi-module rehabilitation program includes:
Nutrition management
Home-based ergometer training program
Psychosocial support"
1826775|NCT00781820|Drug|Bifonazole cream 1%|1 squeeze of Bifonazole cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
1826776|NCT00781820|Drug|Placebo cream|1 squeeze of Placebo cream sufficient to cover the infected nail bed(s) with a thin layer once daily for 28 days after nail ablation with urea paste
1826777|NCT00781833|Device|Radio Frequency Microstimulator|Implantable peripheral muscle microstimulator, delivering controlled pulsatile stimulation to femoral nerves for knee extension and peroneal nerves for dorsiflexion.
1826778|NCT00781846|Drug|ridaforolimus|oral tablets, daily for 5 days/week
1826779|NCT00781846|Drug|bevacizumab|IV infusion
1826780|NCT00781859|Drug|125 µg Ocriplasmin|125µg ocriplasmin intravitreal injection
1826781|NCT00781859|Drug|Placebo|Placebo intravitreal injection
1826782|NCT00781872|Biological|injection of autologous stem cells|60 milion cells intrathecally and 20 milion intravenously
1826783|NCT00781885|Drug|Beraprost sodium modified release|Tablets 60mcg
1958668|NCT01392443|Drug|Ruxolitinib|INC424 Tablet for oral use, provided in 5 mg bottles. The dosage strength is 5 mg/tablet INC424 phosphate (free base equivalent). Medication labels will be in the local language and comply with the legal requirements of each country. equivalent).
1826786|NCT00781911|Biological|IMC-A12 (cixutumumab)|Patients will receive intravenous (I.V.) IMC-A12 (cixutumumab) 10 mg/kg over 1 hour every 2 weeks. ). Treatment will continue until there is evidence of disease progression, intolerable toxicity, or other withdrawal criteria are met.
1826787|NCT00781911|Drug|depot octreotide|Patients must be receiving depot octreotide at the time of enrolling into the study.Patients on stable doses of depot octreotide will continue to receive the same dose and schedule of their last regimen.
1826788|NCT00781924|Procedure|biopsy|ultrasound guided biopsy of tumors.
1826791|NCT00781950|Dietary Supplement|Flaxseed|30 grams of milled flaxseed per day in food products or on its own.
1826792|NCT00781950|Dietary Supplement|Placebo|Wheat and Mixed Dietary Oils
1826793|NCT00781963|Behavioral|CBTI|Individual format
1826794|NCT00781963|Behavioral|CBTI|Group format
1826795|NCT00781963|Behavioral|Sleep education|Group format
1826796|NCT00781976|Drug|AZD7295|700mg per day maximum
1826797|NCT00781976|Drug|Placebo|matched placebo
1826798|NCT00782002|Biological|IMC-18F1|Cohorts 1-4 will receive IMC-18F1 intravenously for 4 weekly infusions, followed by a 2-week observation period. Cohort 5 will receive IMC-18F1 intravenously every other week for the first 6 weeks of therapy. Cohort 6 will receive IMC-18F1 every 3 weeks for the first 6 weeks for therapy. The starting dose in Cohort 1 will be 2mg/kg. The maximum dose of IMC-18F1 will not exceed 16mg/kg administered every week, 15mg/kg administered every other week, and 20mg/kg administered every 3 weeks. Dose escalation of 100% (2 x previous dose) if no dose limiting toxicities (DLTs) are observed in the first three patients within a cohort during the initial 6-week therapy period. Dose escalation increment will be reduced to 50% (1.5 x previous dose) following the occurrence of either grade 2 or higher AEs in 2 or more patients that are possibly, probably, or definitely-related to study medication or one DLT during the initial 6-week therapy period. No intrapatient dose escalation is allowed.
1826799|NCT00782015|Dietary Supplement|Almonds|3 oz. of almonds per day, supplied as 1 oz. snack packs to be consumed for 6 weeks.
1826800|NCT00782015|Dietary Supplement|Placebo Comparator:|NCEP Step 2 diet
1826801|NCT00782028|Other|Centering parenting/Group well child care|Intervention families will receive well child care in a group format for the first 12 month of the child's life.
1826802|NCT00782028|Other|Standard Care|
1826803|NCT00782041|Drug|Oxaliplatin|85 mg/m²
1826804|NCT00782041|Drug|5-FluoroUracil|2,000 mg/m²
1826805|NCT00782041|Drug|Folinic acid|20 mg/m²
1826806|NCT00782054|Other|Provase|NDC:60230-8573-0 Over the counter (OTC) moisturizer containing 2% dimethicone and a blend of endopeptidases. Use topically to affected area every 8 hours.
1826807|NCT00782054|Other|Control moisturizer|Over the counter (OTC) moisturizer containing 2% dimethicone. Use topically to affected area every 8 hours. Does NOT contain endopeptidases. Placebo intervention is identical to active intervention EXCEPT it does not contain endopeptidases.
1826808|NCT00782067|Drug|Midostaurin (PKC412)|Midostaurin was provided as 25 mg soft gelatin capsules for oral administration.
1826809|NCT00782080|Drug|Sedariston|St. John´s Wort (100 mg) Valerian Extract (50 mg)
1826810|NCT00782080|Drug|Placebo|Placebo
1826811|NCT00782093|Drug|volociximab|volociximab intravitreal injection
1826814|NCT00782145|Other|educational intervention|
1826815|NCT00782145|Other|informational intervention|
1826816|NCT00782145|Other|internet-based intervention|
1826817|NCT00782145|Other|questionnaire administration|
1826818|NCT00782145|Other|study of socioeconomic and demographic variables|
1826819|NCT00782145|Other|survey administration|
1826820|NCT00782145|Procedure|psychosocial assessment and care|
1826821|NCT00782145|Procedure|quality-of-life assessment|
1826822|NCT00782145|Procedure|standard follow-up care|
1826823|NCT00782171|Device|SLActive dental implant|"Straumann® SLActive implants will be placed. Implants in Arm 1 will be restored with a temporary restoration on the day of surgery.
Implants in Arm 2 will receive healing caps immediately after surgery and a provisional restoration will be placed between day 28 to day 34 post-surgery.
In both arms, the final restoration will be placed between 140 and 160 days (20 to 23 weeks) post-surgery."
1826824|NCT00782184|Drug|ezetimibe/simvastatin 10/40|ezetimibe/simvastatin 10/40 tablet once daily for 6 weeks.
1826825|NCT00782184|Drug|atorvastatin 40 mg|atorvastatin 40 mg tablet once daily for 6 weeks
1826826|NCT00782184|Drug|atorvastatin 20 mg|All participants will take atorvastatin 20 mg tablet once daily for the 5 week run-in period before randomization
1826827|NCT00782197|Device|PRGF Intraarticular injection|Three consecutive PRGF injections each one week apart.
1826828|NCT00782197|Device|Hyaluronic Acid Intraarticular injection|Three consecutive Hyaluronic acid (EUFLEXXA) injections, each one week apart.
1826829|NCT00782210|Drug|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
1826830|NCT00782210|Drug|Olodaterol (BI1744)|Comparison of low and high doses on efficacy and safety in COPD patients
1826831|NCT00782210|Drug|placebo|Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
1826832|NCT00782236|Device|Bone Graft Material|After screening and enrollment, subjects will undergo tooth extraction of a single tooth with placement of Straumann Bone Ceramic or Freeze Dried Allograft Bone (FDBA) with a resorbable collagen membrane (Bio-Gide) for preservation of the alveolar ridge following tooth extraction. Following 6 months of healing, a core of bone will be taken from the surgical site and a dental implant will be placed. The subjects will then be followed for 12 months following dental implant placement.
1826833|NCT00782249|Device|Vagus nerve stimulation paradigm #1|Vagus nerve stimulation parameters #1
1826834|NCT00782249|Device|Vagus nerve stimulation paradigm #2|Vagus nerve stimulation parameters #2
1826835|NCT00782249|Device|Vagus nerve stimulation paradigm #3|Vagus nerve stimulation parameters #3
1826836|NCT00782262|Dietary Supplement|KicStart™|KicStart™ is a nutritionally complete, but lower energy formulated liquid meal. Two sachets of KicStart™ (one for breakfast and one for lunch) provides 450 cal of energy per day, 0.8 grams per kilogram ideal body weight of high quality protein, and the recommended daily allowances (RDI) of minerals, vitamins, trace elements, omega 3 and 6 essential fatty acids. The Kicstart is supplemented with some salads, carbohydrate free vegetables and a small piece of meat fish or chicken each day in order to achieve a total energy intake of approximately 850 kcals/day.
1826839|NCT00782288|Drug|digitoxin|0.05mg tabs, once daily for 28 days
1826840|NCT00782288|Drug|digitoxin|0.1mg pills, once daily for 28 days.
1826841|NCT00782288|Other|placebo|pill taken once daily for 28 days
1826842|NCT00782301|Drug|maraviroc|maraviroc 150 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
1826843|NCT00782301|Drug|etravirine|etravirine 200 mg. p.o. b.i.d., darunavir 600 mg. p.o. b.i.d., ritonavir 100 mg. p.o. b.i.d., raltegravir 400 mg. p.o. b.i.d.
1826844|NCT00782327|Drug|Losartan|Daily maximal doses of Losartan will be 50mg for subjects under 50kg of weight and 100mg if the weight is over 50kg
1826845|NCT00782327|Drug|Placebo|Daily placebo capsule
1826846|NCT00782340|Drug|Placebo|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
1826847|NCT00782340|Drug|Droxidopa|100 mg, oral, three times per day 200 mg, oral, three times per day 300 mg, oral, three times per day 400 mg, oral, three times per day 500 mg, oral, three times per day 600 mg, oral, three times per day
1826848|NCT00782353|Drug|ANA598 200 mg bid or placebo|ANA598 200 mg bid or placebo
1826849|NCT00782353|Drug|ANA598 400 mg bid or placebo|ANA598 400 mg bid or placebo
1826850|NCT00782353|Drug|ANA598 800 mg bid or placebo|ANA598 800 mg bid or placebo
1826851|NCT00782366|Genetic|SNP analysis|The patients in the intervention group will obtain genetic risk assessments based on genome-wide association studies.
1826852|NCT00782379|Drug|busulfan|110 mg/m2 infused over 3 hours once daily on 4 consecutive days (Days -7, -6, -5, -4)
1826853|NCT00782379|Drug|cyclophosphamide|14.5 mg/kg infused over 1-2 hours once daily on 2 consecutive days (days -3,-2).
1826854|NCT00782379|Drug|fludarabine phosphate|30mg/m2 infused over 30 minutes once daily on three consecutive days (days -5, -4, -3)
1826855|NCT00782379|Drug|mycophenolate mofetil|15 mg/kg po three times a daily with a maximum dose of 3gm/day starting D+5. To be discontinued on Day +35 in the absence of clinically significant GVHD.
1826856|NCT00782379|Drug|tacrolimus|0.03 mg/kg/day infuse over 24 hours starting on day +5 (adjusted to maintain trough level of 5-15 ng/ml). Switch to oral (twice daily divided dose) on day +21 or when able to tolerate PO. Discontinue on day +180 in the absence of clinically significant GVHD.
1827048|NCT00783289|Biological|MEDI-563|25,50-mg MEDI-563 injections
1826857|NCT00782379|Procedure|allogeneic hematopoietic stem cell transplantation|Patients to received unmanipulated PBSCs on Day 0
1826858|NCT00782379|Procedure|peripheral blood stem cell transplantation|patients to receive unmanipulated PBSCs on day 0
1826859|NCT00782405|Drug|quetiapine|XR, 150-300mg
1826860|NCT00782405|Drug|mirtazapine|30-45 mg
1826861|NCT00782418|Drug|Comparator: exenatide|exenatide in two 5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 5mcg doses will be administered, followed by HCG or GGI.
1826862|NCT00782418|Drug|Comparator: exenatide|exenatide in two 1.5mcg subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 1.5mcg doses will be administered, followed by HCG or GGI.
1826863|NCT00782418|Drug|Comparator: Placebo|5% osmitrol in two 60 mcL subcutaneous doses 120 minutes apart, followed by either HGC or GGI. After a 14 day washout period two additional 60 mcL doses will be administered, followed by HCG or GGI.
1826864|NCT00782431|Biological|Vero cell derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
1826865|NCT00782431|Biological|Licensed egg-derived, trivalent seasonal influenza vaccine|Single intramuscular injection
1826866|NCT00782444|Procedure|Computer navigated knee replacement|Total knee replacement performed with the use of navigation system from Brainlab with the Profix total knee implant.
1826867|NCT00782444|Procedure|Conventional knee replacement|Conventional total knee replacement performed in a traditional way with the use of intramedullary rods, with the Profix implant.
1826868|NCT00782457|Procedure|RECTAL CANCER RESECTION|
1826869|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to stay on the prophylactic treatment (prospective)
1826870|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects electing to switch to on-demand treatment (prospective)
1826871|NCT00782470|Behavioral|Recombinant Factor VIII (Kogenate, BAY 14-2222)|Subjects remaining on-demand treatment (retrospective)
1826872|NCT00782483|Device|ThermoVision A20M Infrared Camera|FLIR Systems, Boston, MA. This is a non invasive passive thermal imaging device with less than minimal risk to subjects and staff.
1826873|NCT00782483|Device|ScleroPLUS|Sclerolaser, Candela Corp., Wayland, MA. This laser is approved by the food and drug administration (FDA) for treating PWS lesions and will be used as labeled.
1826874|NCT00782483|Device|3D Digital Camera|3dMD, Atlanta, GA. Approved by the food and drug administration (FDA) for imaging patients and will be used as labeled.
1826875|NCT00782496|Device|Education + new meter|Diabetes education and a new meter with basic features
1826876|NCT00782496|Device|Education + new meter + feature activation|Diabetes education and a new meter with advanced features
1826877|NCT00782509|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
1826878|NCT00782509|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
1826879|NCT00782509|Drug|Placebo|Olodaterol (BI 1744) placebo inhaled orally once daily from the Respimat inhaler
1826880|NCT00782522|Procedure|Eccentric training program|Eccentric training program
1826881|NCT00782522|Procedure|Traditional training program|Traditional training program
1826882|NCT00782535|Drug|CHF 4226 pMDI|Inhaled solution, single therapeutic dose
1826883|NCT00782535|Drug|CHF 4226 pMDI|Inhaled solution, single supratherapeutic dose
1826884|NCT00782535|Drug|Placebo|Inhaled solution, single dose of placebo
1826886|NCT00782561|Drug|FG-3019|FG-3019 5 mg/kg IV given over 2 hours every 2 weeks for 8 weeks
1826887|NCT00782574|Drug|AZD2281|Capsule Oral bid
1826888|NCT00782574|Drug|Cisplatin|IV every 3 weeks
1826889|NCT00782587|Drug|Chemophase|40 mg mitomycin with 800,000 U rHuPH20 total volume of 40 mL instilled
1826890|NCT00782600|Drug|suspension IR|50 mg IR suspension once daily for one day
1826891|NCT00782600|Drug|CR 1|50 mg shorter release CR once daily for one day
1826892|NCT00782600|Drug|CR 2|50 mg medium release CR once daily for one day
1826893|NCT00782600|Drug|CR 3|longer release SR formulation once daily for one day
1826894|NCT00782613|Drug|4,4-dimethyl-benziso-2H-selenazine|ALT-2074 in a 0.5% cream formulation
1826895|NCT00782613|Drug|Placebo|Placebo in a cream formulation
1826896|NCT00782626|Drug|everolimus|
1826897|NCT00782639|Drug|Iopamidol injection 76%|Iopamiro-370 (Iopamidol injection 76%) is provided in single dose bottles/vials, ready to use, aqueous, nonpyrogenic, colorless to pale yellow sterile solution
1826898|NCT00782639|Drug|iodixanol|Visipaque 320 (iodixanol) injection is provided in bottles/flexible containers, ready to use sterile, pyrogen-free colorless to pale yellow solution
1826899|NCT00782652|Drug|inhaled nitric oxide|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
1826900|NCT00782652|Drug|nitrogen gas|Continuous delivery at either 40 or 80 ppm for a duration of up to 14 days
1826901|NCT00782665|Procedure|Biopsy|1 centimeter x 1/2 centimeter piece cut from uterus
1826902|NCT00782691|Other|CT-FDG/PET scan of the head-and-neck region|CT-FDG/PET scan of the head-and-neck region
1826903|NCT00782717|Drug|Nepafenac ophthalmic suspension, 0.1% (NEVANAC)|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery.
1826904|NCT00782717|Other|Nepafenac ophthalmic suspension vehicle|1 drop TID beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
1826905|NCT00782717|Drug|Prednisolone acetate ophthalmic suspension (OMNIPRED)|One drop in the study eye 4 times daily (morning, late morning, late afternoon, and bedtime)for two weeks postsurgery.
1826951|NCT00775489|Drug|Nasal steroid Beclomethasone|Beclomethasone nasal steroids to be given to a very well controlled glaucoma patients to find if this normal dose will lead to increase in intraocular pressure up to 20% where the study will be stopped at this point.
1826952|NCT00775489|Drug|Saline|control group will receive normal saline inhaler
1826953|NCT00775502|Drug|BIW-8962|Intravenous administration of liquid dosage form. Doses 0.03, 0.10, 0.30, 1.0, 3.0, and 10 mg/kg. Frequency is once every two weeks. Duration is 6 months
1827049|NCT00783289|Other|Placebo|Placebo SC injections
1826906|NCT00782756|Other|radiotherapy (RT) in combination with temozolomide and bevacizumab|"Bevacizumab10 mg/kg IV once every two weeks on days 1 and 15 of every cycle (Cycle defined as 28 days). Temozolomide 75mg/m2 daily beginning on day 1 through completion of radiotherapy. Hypofractionated dose painting IMRT will start on day 1 and will be delivered on a Monday, Wednesday, Friday schedule for a total of 6 fractions.
Post RT therapy: Bevacizumab 10mg/kg IV every two weeks. Temozolomide 150-200mg/m2 daily for 5 consecutive days will be given on 28 day cycles.
Follow up: CBC weekly, comprehensive panel and urinalysis monthly, blood pressure every other week. Neurological/physical examination monthly. Gd-enhanced MRI with perfusion every 2 cycles. Neurocognitive testing (approximately 4months post RT, 1 year after diagnosis and then annually in long term survivors). Blood sample for correlative studies monthly."
1826907|NCT00782769|Drug|Oxybutinyn Vaginal Ring 4mg|
1826908|NCT00782769|Drug|Oxybutinyn Vaginal Ring 6mg|
1826910|NCT00782821|Drug|Rabbit Antithymocyte Globulin|rATG will be given 1.5mg/kg intravenous (IV) per dose.
1826911|NCT00782821|Drug|Velcade|Velcade will be given 1.3mg/m2 via intravenous push (IVP) per dose.
1826912|NCT00782821|Drug|Rituxan|Given via IV per group assignment.
1826913|NCT00782834|Drug|Nilotinib|400 mg orally twice daily until disease progression, intolerability or withdrawal of consent
1826914|NCT00782847|Behavioral|DiaNe consultation and support program|the DiaNe consultation and support program for clients with diabetic nephropathy consists of 4 sessions at 90-120 minutes conducted every week in a period of 4 weeks
1826915|NCT00782925|Other|educational program|Educational program will consist of 1, 2-hour, small-group (8-patient) session with a specialist physician in Physical and Rehablilitation Medecine. Workers will be given information about lower back pain, pain and psychosocial risk factors for persistent or recurrent back-related disability
1826916|NCT00782925|Other|exercise program|The exercise program will consist of 5, 90-minute, small-group (8-patient) sessions with a physical therapist. Healthcare workers will be taught exercises including warm-ups, floor exercises, and endurance training. Only one absence will be allowed, otherwise the worker will be considered as non-compliant.
1826917|NCT00782925|Other|Self-led exercises|Self-led exercises to perform as part of a daily exercise routine
1826918|NCT00782951|Drug|Org 28611|single IV dose of Org 28611 3 mcg/kg after dental impaction surgery
1826919|NCT00782951|Drug|morphine sulfate|single IV dose of morphine sulfate 0.12 mg/kg after dental impaction surgery
1826920|NCT00782951|Drug|Placebo|single IV dose of placebo after dental impaction surgery
1826921|NCT00782977|Other|Nasal oxygen therapy|Arm 1: Nasal cannulae with no oxygen flow. Arm 2: Nasal cannulae with oxygen flow at 5 L/min Arm 3: Nasal cannulae with oxygen flow at 10 L/min
1826922|NCT00782990|Procedure|Surgical treatment: TVT|
1826923|NCT00782990|Procedure|Surgical treatment: colposuspension|
1826924|NCT00783003|Drug|GSK233705 and GW642444|Inhaled Long acting muscarinic receptor antagonist (LAMA) and a inhaled Long acting Beta 2 agonist (LABA) both in development as treatment for Chronic Obstructive Pulmonary Disease, taken in combination.
1826925|NCT00783003|Drug|GW642444|Inhaled Long acting Beta 2 agonist (LABA)
1826926|NCT00783003|Drug|GSK233705|Inhaled Long acting muscarinic receptor antagonist (LAMA which is in development as a treatment for Chronic Obstructive Pulmonary Disease.
1826927|NCT00783003|Drug|Placebo|Matching placebo.
1826928|NCT00783016|Drug|Morphine|
1826929|NCT00775333|Procedure|Outcome after carpal tunnel release|Follow the outcome after standard carpal tunnel release in diabetic and non-diabetic patients
1826930|NCT00775359|Drug|Fenofibrate 160 mg tablets|
1826931|NCT00775372|Drug|Clarithromycin 250mg/5mL|
1826932|NCT00775385|Drug|Standard Chemotherapy|Pemetrexed Cisplatin Schedule : CDDP 75 mg/m² D1, pemetrexed 500 mg/m² D1 D1=D21, 4 cycles
1826933|NCT00775385|Drug|Customized Treatment|"Mutated EGFR : Erlotinib 150mg/day (1 year)
Wild-type EGFR or undetermined depends on ERCC1 status :
ERCC1 high : no treatment
ERCC1 low or undetermined : Pemetrexed Cisplatin, 4 cycles (63 days)"
1826934|NCT00775411|Drug|dexamethasone|700 µg dexamethasone intravitreal injection at Day 1 in the study eye.
1826935|NCT00775411|Biological|ranibizumab|Ranibizumab injection at Week 2 or 3 per specified criteria and starting at Week 4 at the investigator's discretion in the study eye.
1826936|NCT00775424|Biological|PENNVAX-B|PENNVAX-B is a cocktail of three expression plasmids. The plasmids include the genes which encode a synthetic HIV-1 envelope protein (pEY2E1-B), Gag (gagCAM02), and Pol (pK2C1). Each plasmid is manufactured to a concentration of 4.0 mg/mL and is formulated with bupivacaine (0.25%) as a facilitating agent for DNA uptake. All plasmids (2.0 mg each gag, pol, env) are premixed by the manufacturer in the same vial.
1826937|NCT00775424|Biological|GENEVAX IL-12-4532|GENEVAX IL-12-4532 This molecular adjuvant plasmid contains nucleotide sequences necessary for expression of the human IL-12 protein. IL-12 DNA is formulated at a concentration of 2.0 mg/mL with bupivacaine (0.25%).
1826938|NCT00775424|Biological|PLACEBO|PLACEBO
1826939|NCT00775424|Biological|IL-15 adjuvant|pIL15EAM is a plasmid that encodes human IL-15 and has been optimized to express 87 fold higher than native IL-15 DNA and 5.7 fold higher than an earlier generation optimized IL-15 DNA construct. This plasmid is formulated at a concentration of 4.0 mg/mL with bupivacaine (0.25%).
1826940|NCT00775437|Drug|Adalimumab|Adalimumab solution for injection for subcutaneous use.
1826941|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
1826942|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
1826943|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
1826944|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
1826945|NCT00775450|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
1826946|NCT00775463|Drug|treprostinil diethanolamine|oral sustained release tablet. Maximum tolerable dose not exceeding 16 mg twice daily (BID)
1826947|NCT00775463|Drug|placebo|
1826948|NCT00775476|Drug|N-acetylcysteine|Capsules of NAC, 1.2 g twice daily
1826949|NCT00775476|Drug|N-acetylcysteine|Capsules of NAC, 2.4 g twice daily
1826954|NCT00775515|Procedure|laparoscopic prostatectomy|laparoscopic prostatectomy
1826955|NCT00775528|Drug|Pancrelipase Delayed Release|3,000, 6,000 and 12,000 unit Lipase Capsules
1826956|NCT00775541|Dietary Supplement|Vitamin C|One IV infusion of 2 gm vitamin C
1826957|NCT00775554|Other|ultrasound guided hematoma block|pt. will receive ultrasound guided hematoma block
1826958|NCT00775554|Other|ultrasound guided hematoma block|ultrasound will be used to guide hematoma blocks
1826959|NCT00775567|Dietary Supplement|Fructose powder|30g in 250ml water twice a day
1826960|NCT00775580|Drug|Atenolol 100mg Tablets|
1826961|NCT00775593|Drug|clofarabine|"Patients will receive one course of low-dose Clofarabine in combination with Temsirolimus (CloTor regimen) for remission induction.
Induction therapy
- Clofarabine 20 mg/m2/day, administered by iv infusion over 1 hour on days 1 through 5"
1826962|NCT00775593|Drug|temsirolimus|"Those who achieve morphologic CR and morphologic CRi will receive maintenance treatment with Temsirolimus monthly for 12 months, or until relapse.
Those who achieve a PR will receive one additional course of CloTor and, if a CR/CRi is obtained, maintenance treatment with Temsirolimus as above.
Induction therapy:
- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1, 8 and 15.
Maintenance therapy:
- Temsirolimus 25 mg (flat dose) administered iv over 30 minutes on days 1 and 8 of each month for 12 months, or until relapse."
1826963|NCT00775606|Drug|Lopinavir 400 mg/ritonavir 100 mg|Lopinavir 400 mg/ritonavir 100 mg fixed dose combination BID + emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
1826964|NCT00775606|Drug|Efavirenz|Efavirenz 600 mg/emtricitabine 200 mg/tenofovir 300 mg fixed dose combination QD
1826965|NCT00775619|Drug|Carvedilol 12.5 mg tablets|bioequivalence Carvedilol 12.5 mg tablets fed conditions
1826966|NCT00775632|Drug|Alemtuzumab|A new GVHD prevention strategy will be tested against established GVHD prophylaxis in patients undergoing matched sibling donor transplant using peripheral blood stem cells.
1826967|NCT00775632|Drug|mycophenolate or cyclosporine and methotrexate|One of the two GVHD prophylaxis used at PMH-either cyclosporine and mycophenolate or cyclosporine and methotrexate
1826968|NCT00775645|Dietary Supplement|acetyl-L-carnitine hydrochloride|Given orally
1826969|NCT00775645|Other|placebo|Given orally
1826970|NCT00775658|Drug|olopatadine|olopatadine 0.2% opthalmic solution 1 drop into each eye at the same time each day
1826971|NCT00775658|Drug|placebo|placebo, normal saline opthalmic solution 1 drop into each eye at the same time each day
1826972|NCT00775671|Drug|placebo|Placebo pill by mouth daily for 21 days followed by either Nebivolol 5 mg by mouth daily or metoprolol ER 100mg by mouth daily for 12 weeks.
1826973|NCT00775671|Drug|Nebivolol|Nebivolol 5 mg by mouth daily for 12 weeks.
1826974|NCT00775671|Drug|Metoprolol|Metoprolol ER 100mg by mouth daily for 12 weeks.
1826978|NCT00775697|Drug|Montelukast|the arm will be treated with Montelukast 4 mg die for 4 weeks
1826979|NCT00775697|Drug|Montelukast|montelukast 4 mg day for 4 weeks
1826980|NCT00775710|Device|Nocturnal non-invasive ventilation|Prolongation of non-invasive ventilation during 3 nights.
1826981|NCT00775736|Drug|biphasic insulin aspart 30|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
1826982|NCT00775736|Drug|biphasic insulin aspart 50|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
1826983|NCT00775736|Drug|biphasic insulin aspart 70|Start dose and frequency and safety data collection at the discretion of the physician following clinical practice
1826984|NCT00775749|Drug|transdermal nicotine patch|The 7 mg transdermal nicotine patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
1826985|NCT00775749|Drug|placebo patch|The placebo patch will be applied to the right upper back prior to surgery. It will be covered with an opaque bandage to minimize inadvertent removal and conceal which patch has been placed.
1826986|NCT00775762|Drug|aspirin|Aspirin (75-100 mg)die for three months
1826987|NCT00775762|Drug|clopidogrel|Clopidogrel (75mg) die for three months
1826988|NCT00775762|Drug|clopidogrel plus aspirin|clopidogrel 75 mg die plus aspirin 75-100 mg for three months
1826989|NCT00775788|Procedure|Autologous Fat Grafting to Breasts|Fat injection of Fat to breasts
1826990|NCT00775801|Device|FLD|Artificial lumbar disc
1826991|NCT00775801|Device|Control|Artificial lumbar disc
1826992|NCT00775814|Drug|Candesartan and Hydrochlorothiazide|Candesartan 8 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for 2 weeks; increased to Candesartan 16 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
1826993|NCT00775814|Drug|Hydrochlorothiazide (HCT)|Candesartan placebo-matching tablets and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 24 weeks.
1826994|NCT00775827|Drug|fenofibrate 160 mg tablets|
1826995|NCT00775840|Drug|Candesartan|Candesartan up to 32 mg, tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
1826996|NCT00775840|Drug|Placebo|Candesartan matching-placebo tablets, orally, once daily and ongoing angiotensin-converting enzyme inhibitor/beta-blocker therapy for up to 24 weeks.
1826997|NCT00775866|Procedure|MRI-Guided Biopsy|Technical development and clinical testing of a novel technique for magnetic resonance imaging (MRI) guided prostate biopsy in a 1.5T horizontal bore scanner using a dedicated interventional table.
1826998|NCT00775879|Drug|Induction with Sevoflurane|
1826999|NCT00775892|Device|SeriACL Device ACL Reconstruction|Long-term Bioresorbable ACL Scaffold
1827000|NCT00783042|Drug|Rosuvastatin|40 mg, tablet, oral, once daily for 1 (double blind) +2 months (open).
1827001|NCT00783042|Drug|Placebo|Tablet, oral, once daily for 1 month (double blind)
1827002|NCT00783055|Other|Individually tailored programmes|Individualised intervention programmes based on individual wishes for daily activities
1827003|NCT00783068|Drug|GTS-21, [3-(2,4-dimethoxybenzylidene)-anabaseine dihydrochloride]|Subjects will receive GTS-21 or placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of GTS-21 or placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0)
1827004|NCT00783068|Drug|Placebo|Subjects will receive placebo 3 day before injection of LPS (150 mg tid) and a single oral dose of 150 mg of placebo the morning of LPS injection (07:00 AM). Subjects will then receive an oral dose of 150 mg placebo at 08:00 AM and another oral dose of 150 mg placebo at 1 hour before LPS administration (t=0).
1827005|NCT00783068|Drug|Lipopolysaccharide E. Coli 113:H 10:K negative|Subjects will be randomized to oral pre-treatment with GTS-21 (150 mg tid 3 days before LPS injection and an oral dose of 150 mg GTS-21 on the morning of the day of the experiment (07:00 AM). Subjects will then receive an oral dose of 150 mg GTS-21 or placebo at 08:00 AM and another oral dose of 150 mg GTS-21 or placebo at 1 hour before LPS administration (t=0). One hour after ingestion of the last dosage of the study drug, purified LPS prepared from E coli O:113 (2 ng/kg iv) will be injected intravenously.
1827006|NCT00783081|Drug|K-134|K-134 is given as low dose mid dose and high dose tablets for 26 Weeks.
1827007|NCT00783081|Drug|Cilostazol 100 mg BID|Cilostazol 100mg BID for 26 weeks.
1827008|NCT00783081|Drug|Placebo|Placebo BID for 26 weeks.
1827009|NCT00783094|Drug|Tadalafil 2.5 mg|oral, daily
1827010|NCT00783094|Drug|Tadalafil 5 mg|oral, daily
1827011|NCT00783094|Drug|Placebo|oral, daily
1827012|NCT00783107|Drug|Cyclosporine|Cyclosporine Inhalation Solution, Once Daily
1827013|NCT00783107|Drug|Placebo|
1827014|NCT00783120|Other|Repetitive transcranial magnetic stimulation|10 Hz rTMS of left dorsolateral prefrontal cortex (DLPFC) (15 sessions/3 weeks, 1000 stimuli per session, stimulation intensity 110 % related to the individual resting motor threshold); in total 15.000 stimuli.
1827015|NCT00783120|Other|Sham repetitive transcranial magnetic stimulation|placebo (sham)-rTMS of left DLPFC (15 sessions/3 weeks, 1000 stimuli per session; in total 15.000 stimuli
1827016|NCT00783133|Drug|Desloratadine 5 mg|Clarinex 5 mg daily x 7 days
1827017|NCT00783133|Drug|fexofenadine|Allegra 180 mg daily x 7 days
1827018|NCT00783146|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
1827019|NCT00783146|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
1827020|NCT00783146|Drug|placebo|placebo, once daily for 15 days
1827021|NCT00783159|Procedure|Power Training|Power training, Vitamin D substitution
1827022|NCT00783159|Procedure|Strength Training|Strength training, Vitamin D substitution
1827023|NCT00783159|Other|Control|Vitamin D substitution, Lifestyle consultation
1827024|NCT00783172|Drug|Gemcitabine|1000mg/m2, IV (in the vein) over 30 minutes after treatment with OGF; first cycle is consecutive seven weeks and one week off; subsequent cycles are three weeks on and one week off.
1827025|NCT00783172|Biological|Opioid Growth Factor (OGF)|Initial treatment is 150ug/kg (based on body weight of the patient) in a volume of 50ml sterile saline, IV (in the vein) over 45 minutes; subsequent treatments at dose of 250ug/kg
1827026|NCT00783185|Behavioral|Cannabis-Consumption-Reduction-Training|8 sessions within 4 weeks (twice a week, 45 minutes each) Cognitive behavioral therapy with focus on cannabis abuse
1827027|NCT00783185|Behavioral|Social competence Training|8 sessions within 4 weeks (twice a week, 45 minutes) training to develop and ameliorate social competences
1827028|NCT00783198|Biological|SCH 39641 6 Amb a 1-U|SCH 39641 6 Amb a 1-U sublingual tablets administered once daily
1827029|NCT00783198|Biological|SCH 39641 12 Amb a 1-U|SCH 39641 12 Amb a 1-U sublingual tablets administered once daily
1827030|NCT00783198|Biological|Placebo|matching placebo sublingual tablets administered once daily
1827031|NCT00783211|Drug|desloratadine|desloratadine, 5 mg oral tablets, once daily for 15 days
1827032|NCT00783211|Drug|fexofenadine|fexofenadine, 180 mg tablets, once daily for 15 days; for purposes of blinding, fexofenadine tablets were over encapsulated
1827033|NCT00783211|Drug|placebo|placebo, once daily for 15 days
1827034|NCT00783224|Drug|Placebo for MF|Placebo to mometasone furoate nasal spray, indistinguishable from mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
1827035|NCT00783224|Drug|Placebo for FP|Placebo to fluticasone nasal spray, indistinguishable from fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
1827036|NCT00783224|Drug|Mometasone|Mometasone furoate nasal spray. Patients in this arm take 2 sprays per nostril once a day for 2 weeks
1827037|NCT00783224|Drug|Fluticasone|Fluticasone propionate nasal spray. Patients in this arm take 2 sprays per nostril twice a day for 2 weeks
1827038|NCT00783237|Drug|Mometasone|Mometasone Furoate Nasal Spray, single dose of 200 mcg (2 sprays per nostril)
1827039|NCT00783237|Drug|Placebo|Placebo nasal spray, single dose of 2 sprays per nostril
1827040|NCT00783250|Drug|Salbutamol + Tiotropium|Salbutamol 400 micrograms + Tiotropium 18 micrograms
1827041|NCT00783250|Drug|Placebo + Tiotropium|Placebo via MDI + Tiotropium 18 micrograms
1827046|NCT00783276|Drug|SYN115|100 mg single dose
1827047|NCT00783276|Drug|PLACEBO|PLACEBO
1827050|NCT00783315|Behavioral|Call-Center Directed (CCD) Weight Loss Program|This program will be implemented by trained counselors of Healthways, Inc., and will use telephone, Web, and e-mail contacts to engage participants. There will be no in-person visits.
1827051|NCT00783315|Behavioral|In-Person Directed (IPD) Weight Loss Program|This program will be primarily implemented through in-person visits (including group sessions) with health counselors at Johns Hopkins University. Telephone, Web, and e-mail contacts will occasionally be used.
1827052|NCT00783315|Behavioral|Self-Directed Weight Loss Program|Participants will meet with study staff at the beginning of the study and will receive written information about weight loss.
1827053|NCT00783328|Drug|PF-00299804|Dosage form: 5 mg and 20 mg tablet Dosage: 15 mg, 30 mg and 45 mg, orally, once daily Number of Cycles: until progression or unacceptable toxicity develops.
1827054|NCT00783341|Drug|GAP-134|
1827055|NCT00783341|Drug|placebo|
1827056|NCT00783354|Drug|desloratadine|"Patients received desloratadine 5 mg daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (Placebo) in case of symptoms for 2 months."
1827057|NCT00783354|Drug|desloratadine|"Patients received Placebo daily, given as one tablet in the evening, and were asked to take one tablet of rescue medication (desloratadine 5 mg) in case of symptoms for 2 months."
1827058|NCT00783367|Drug|lenalidomide-low dose dexamethasone plus rituximab|Lenalidomide: 10mg capsules, orally, once daily for each 28 day cycle for the duration of the study; Dexamethasone: 8mg tablets, orally, once weekly on days 3, 10, 17, 24 of each 28 day cycle for the duration of the study; rituximab: 375mg/m2 IV (in the vein), once weekly on days 1, 8, 15, 22 during month 3 of therapy
1827059|NCT00783367|Drug|Lenalidomide + Rituximab|
1827060|NCT00785252|Device|Powered Intraosseous device (EZIO)|EZIO
1827061|NCT00785252|Device|standard central line|placement of a central line
1827062|NCT00785265|Behavioral|Group-Based (GB) Intervention|60-minute group session involving other study patients who have been assigned to this condition and their guests.
1827063|NCT00785265|Behavioral|Home-Based (HB) Intervention|60-minute educational intervention in their home, which will be delivered by an African American health educator.
1827064|NCT00785291|Drug|Paclitaxel|Given IV
1827065|NCT00785291|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1827066|NCT00785291|Drug|Ixabepilone|Given IV
1827067|NCT00785291|Biological|Bevacizumab|Given IV
1827068|NCT00785291|Other|Questionnaire Administration|Ancillary studies
1827069|NCT00785291|Other|Laboratory Biomarker Analysis|Correlative studies
1827070|NCT00785317|Drug|Angemin vs Activelle|1 mg of oral oestradiol (E2) in continuous combination with 2 mg of DRSP or 1 mg of oral E2 in continuous combination with 0.5 mg of NETA during six months.
1827071|NCT00785330|Drug|standard GVHD prophylaxis|Application of tacrolimus from day -1 with a goal of tacrolimus serum concentration of 10 ng / ml Aplication of mycophenolat mofetil from day +1 to day +28 in a dose of 2 x 1g per day
1827072|NCT00785330|Drug|rituximab|Patients receiving 375 mg/ m2 of rituximab at weeks 3, 4, 5, 6, 25, 26, 27, 28 after allogeneic stem cell transplantation in addition to standard GVHD prophylaxis (tacrolimus with aimed serum level of 10 ng / ml and mycophenolat mofetil 2 x 1 g p.o. day 1 to 28 after allogeneic SZT
1827073|NCT00785343|Device|Reo Go robotic arm trainer|Robotic training with the Reo Go is included with conventional treatment during daily OT sessions
1827074|NCT00785343|Procedure|Conventional Therapy|Occupational therapy that is the current standard of care
1827075|NCT00785356|Drug|Proellex 25 mg|Proellex 25 mg, 1 - 25 mg capsule and 1 placebo capsule daily for 3 months
1827076|NCT00785356|Drug|Proellex 50 mg|Proellex 50 mg, 2 - 25 mg capsules daily for 3 months
1827077|NCT00785356|Drug|Placebo|Placebo, 2 capsules daily for 3 months
1827078|NCT00785369|Device|Reflectance confocal microscopy|Reflectance confocal microscopy (VivaScope 1500)
1827079|NCT00785382|Drug|Placebo|Lactulose Placebo
1827080|NCT00785382|Drug|Pregabalin 150 mg|150 mg Q12H x 2 doses
1827081|NCT00785395|Drug|Oxytocin infusion|Up-down dosing determination
1827082|NCT00785408|Drug|AC2307|subcutaneous, twice daily, low dose
1827083|NCT00785408|Drug|placebo|subcutaneous, twice daily, low dose
1827084|NCT00785408|Drug|AC2307|subcutaneous, twice daily, middle dose
1827085|NCT00785408|Drug|placebo|subcutaneous, twice daily, middle dose
1827086|NCT00785408|Drug|AC2307|subcutaneous, twice daily, high dose
1827087|NCT00785408|Drug|placebo|subcutaneous, twice daily, high dose
1827088|NCT00785421|Drug|enoxaparin|Patients receive GFFC +/- LMWH (gemcitabine 1 g/m2 (30 min), cisplatin 30 mg/m2 (90 min), 5-fluorouracil 750 mg/m2 (24 h), folinic acid 200 mg/m2 (30 min), d1, 8; q3w +/- Enoxaparin 1mg/kg daily s.c.). Pts with KPS < 80 % and increased creatinin plasma levels (>1.3 mg/dl) receive the current standard therapy (gemcitabine 1 g/m2 (30 min), d1, 8, 15; q4w) +/- LMWM +/- Enoxaparin 1mg/kg daily s.c. After 12 weeks of initial chemotherapy all patients who have not progressed received the standard therapy (gemcitabine mono) +/- Enoxaparin 40mg/d s.c.
1827089|NCT00785421|Drug|chemotherapy with LMWH - enoxaparin|1-12 weeks: enoxaparin 1g/m², s.c. 12-PD or event: enoxaparin 0,4g s.c.
1827090|NCT00785421|Drug|only chemotherapy|observation, no treatment with LMWH
1827091|NCT00785434|Drug|escitalopram|Dose ranging up to 50mg
1827092|NCT00785447|Other|Mouth-to-mouth or mouth-to-nose breathing|Patients undergoing elective surgery under general anesthesia will be given mouth-to-mouth and mouth-to-nose breaths. The respiration process will be measured and recorded by the help of elastic bands put around the chest and abdomen. The efficiency of the breathing methods will be evaluated.
1827093|NCT00785460|Drug|Benfotiamine|
1827094|NCT00785473|Dietary Supplement|cholecalciferol|cholecalciferol capsules, 20,000 IU weekly for 2 years and calcium carbonate 500 mg daily
1827095|NCT00785473|Dietary Supplement|calcium carbonate|calcium carbonate 500 mg daily for 2 years
1827096|NCT00785486|Drug|Midazolam Alone|Midazolam 2 mg syrup was given orally after a fast of at least 10 hours.
1827150|NCT00785863|Drug|Parecoxib and remifentanil|Parecoxib IV and remifentanil infusion
1827194|NCT00786214|Other|Sham acupuncture|Patients will be given sham acupuncture treatment at dummy acupuncture points
1827195|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation D under fasted conditions (Reference)
1827097|NCT00785486|Drug|Qualaquin (quinine) alone steady state|Qualaquin (quinine) 324 mg capsules were given orally every 8 hours for 7 days ( 21 doses total). On day 9 after taking Qualaquin (quinine) for 5 days according to the stated regimen and fasting for at least 10 hours, all participants took their usual dose of Qualaquin (quinine). Blood was drawn at times sufficient to characterize the pharmacokinetics of quinine at steady state
1827098|NCT00785486|Drug|Midazolam and Qualaquin at steady state|On the morning of day 10 after taking Qualaquin (quinine) for 6 days according to the stated regimen (324 mg every 8 hours), all participants took their usual dose of Qualaquin (quinine) with an oral dose of midazolam 2 mg after a fast of at least 10 hours
1827099|NCT00785499|Behavioral|Milk Components and Metabolic syndrome|1 liter per day of the test drinks for 3 mo
1827100|NCT00785512|Drug|Nebivolol|Nebivolol 10 mg, 10-mg Nebivolol nontrade tablets , oral administration Nebivolol 20 mg, 20-mg Nebivolol nontrade tablets , oral administration Nebivolol 40 mg, two 20-mg Nebivolol nontrade tablets , oral administration
1827101|NCT00785512|Drug|Placebo|Matching placebo tablets, oral administration
1827102|NCT00785525|Drug|Filgrastim|PBSC donors will receive 10 µg/kg of filgrastim subcutaneously each day of a five day mobilization schedule.
1827103|NCT00785538|Biological|IMC-A12|"Cohort 1
3 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period."
1827104|NCT00785538|Biological|IMC-A12|"Cohort 2
6 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period."
1827105|NCT00785538|Biological|IMC-A12|"Cohort 3
10 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period."
1827106|NCT00785538|Biological|IMC-A12|"Cohort 4
15 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period."
1827107|NCT00785538|Biological|IMC-A12|"Cohort 5
21 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period."
1827108|NCT00785538|Biological|IMC-A12|"Cohort 6
27 mg/kg, I.V. once a week, for 4 weeks, followed by a 2 week observation period."
1827109|NCT00785551|Drug|quinine sulfate|2 x 324mg given in one dose to healthy subjects
1827110|NCT00785551|Drug|quinine sulfate|2 x 324mg given as one dose to subjects with mild renal impairment
1827111|NCT00785551|Drug|quinine sulfate|2 x 324mg given as one dose to subjects with moderate renal impairment
1827112|NCT00785577|Drug|Placebo|"LY545694 placebo BID po for 5 weeks
Pregabalin placebo capsules TID po for 6 weeks"
1827113|NCT00785577|Drug|Pregabalin|"Pregabalin TID po for 6 weeks: 50 mg TID po for Week 1, 100 mg TID po for Weeks 2 - 5, and 50 mg TID po taper for Week 6
LY545694 placebo BID po for 5 weeks"
1827114|NCT00785577|Drug|LY545694 21 mg|"LY545694 21 mg BID po for 1 week
Pregabalin placebo TID po for 6 weeks"
1827115|NCT00785577|Drug|LY545694 49 mg|"LY545694 escalated to 49 mg BID po for 1 week during Week 2.
Pregabalin placebo TID po for 6 weeks."
1827116|NCT00785577|Drug|LY545694 105 mg|"LY545694 105 mg BID po for 5 weeks
Pregabalin placebo TID po for 6 weeks"
1827117|NCT00785590|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
1827118|NCT00785603|Drug|Paroxetine|tablets of 20 mg paroxetine
1827119|NCT00785603|Drug|Paroxetin placebo|capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
1827120|NCT00785603|Drug|Tramadol|Capsules of 50 mg tramadol
1827121|NCT00785616|Other|MEMS cap monitoring|Electronic monitoring of medication adherence using MEMS caps
1827122|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time signature of each bottle opening.
1827123|NCT00785616|Other|MEMS cap monitoring|Adherence to antiretroviral medications will be measured using electronic bottle caps (MEMS caps) that record the time/date signature of each bottle opening.
1827124|NCT00785629|Drug|Calcium acetate|
1827125|NCT00785629|Drug|Lanthanum Carbonate|
1827126|NCT00785629|Drug|Sevelamer Carbonate|
1827127|NCT00785629|Drug|Placebo|
1827128|NCT00785642|Drug|Dermacyd PH_DETINLYN Tangerine Mix (Lactic Acid)|
1827129|NCT00785655|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
1827130|NCT00785668|Drug|AER 001|10 mg dry powder administered using a handheld device
1827131|NCT00785681|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
1827132|NCT00785694|Drug|hexaminolevulinate|Instillation of 50mL of 8mM Hexvix into the bladder through a catheter.
1827133|NCT00785720|Drug|Dermacyd PH_DETINBACK (Lactic Acid)|
1827134|NCT00785746|Other|Core|We have devised a series of core strength training exercises that can be easily and safely performed under the supervision of trained staff. The exercises will be individualized depending on the participants' ability and health conditions. The majority, but not all, of exercises will be performed on or with exercise balls of different sizes and shapes, round for more advanced persons and oval for more frail persons.
1827135|NCT00785759|Drug|AH110690 (18F) Injection|All subjects will receive an I.V. dose of [18F]AH110690 (less than 10 mg of total AH110690). The target activity of a single administration of [18F]AH110690 will be 185 MBq (equivalent to a dose of approximately 6 mSv).
1827136|NCT00785772|Drug|Gabapentin|100-200mg once a day
1827137|NCT00785772|Drug|Gabapentin|200-500mg once a day
1827138|NCT00785772|Drug|Gabapentin|400-1000mg (200-500 mg twice a day)
1827139|NCT00785785|Drug|Nilotinib (AMN107)|
1827140|NCT00785785|Drug|imatinib (STI571)|
1827141|NCT00785798|Drug|Vorinostat|200mg to 400 mg twice daily on days 1-7
1827142|NCT00785798|Drug|Pegylated Liposomal Doxorubicin (PLD), Doxil|IV 30mg/m2 on day 3 of a 21-day cycle
1827143|NCT00785811|Drug|L-arginine aspartate (Targifor)|3g of L-arginine taken orally in a single daily dose for 8 weeks
1827144|NCT00785811|Drug|Placebo L-arginine aspartate (Targifor)|Placebo of L-arginine taken orally in a single daily dose for 8 weeks
1827145|NCT00785837|Other|Aquatic Physical Therapy|The Physiotherapy was performed with gentle movements in eight shape, from left to right, in addition to movements of unbundling girdle, light and slow the trunk and extremities posture and body by flexing the organization Wrapping the body.
1827146|NCT00785850|Drug|Dermacyd PH_DETINBACK (Lactic Acid) Sweet Flower|
1827147|NCT00785863|Other|Placebo|Placebo IV before placebo infusion
1827148|NCT00785863|Drug|Remifentanil|placebo IV and remifentanil infusion
1827149|NCT00785863|Drug|Ketorolac and remifentanil|Ketorolac IV and remifentanil infusion
1827152|NCT00785889|Procedure|water infusion colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
1827153|NCT00785902|Device|AtriCure Bipolar System|
1827154|NCT00785915|Drug|AZD6765|single administration and once daily for 5 days
1827155|NCT00785915|Drug|Placebo|single administration and once daily for 5 days
1827156|NCT00785928|Biological|LY2127399|subcutaneously q 4 weeks
1827157|NCT00785928|Drug|Placebo|subcutaneously q 4 wks
1827158|NCT00785941|Biological|IMC-A12|"Cohort 1
6 mg/kg I.V., once every other week for 4 weeks"
1827159|NCT00785941|Biological|IMC-A12|"Cohort 2
10 mg/kg I.V., once every other week for 4 weeks"
1827160|NCT00785941|Biological|IMC-A12|"Cohort 3
15 mg/kg I.V., once every other week for 4 weeks"
1827161|NCT00785941|Biological|IMC-A12|"Cohort 4
21 mg/kg I.V., once every other week for 4 weeks"
1827162|NCT00785941|Biological|IMC-A12|"Cohort 5
27 mg/kg I.V., once every other week for 4 weeks"
1827163|NCT00785954|Drug|KAI-9803|STEMI Subjects will be randomly assigned to receive either KAI-9803 or Placebo
1827164|NCT00785967|Biological|Various vaccines|VAQTA: 1.0ml IM at weeks 24 & 48; Pneumovax 23: 0.5ml IM at screening; Td ADSORBED: 0.5ml IM at screening; phiX174 bacteriophage: 0.02ml/kg body weight IV at weeks 28, 32, 36, 40.
1827165|NCT00785980|Drug|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) administered on the morning of Day 1 after an overnight fast of at least 10 hours.
1827166|NCT00785980|Drug|Ciprofloxacin 500 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
1827167|NCT00785980|Drug|Quinine Sulfate Capsules 324 mg|A single dose of quinine sulfate (2 x 324 mg capsules) co-administered with a single dose of ciprofloxacin (1 x 500 mg tablet) in the morning on Day 11 after an overnight fast of at least 10 hours.
1827168|NCT00785993|Other|Vitrification of oocytes for IVF treatment|
1827169|NCT00785993|Other|Protocolary IVF treatment with fresh donor oocytes|
1827170|NCT00786006|Drug|FOLFIRI.3|FOLFIRI.3: Irinotecan 70 mg/m2 (over 60 min) on D1, LV 400 mg/m2 (over 2h) D1, 5-FU 2000 mg/m2 (over 46 hours) from D1, then irinotecan 70 mg/m2(over 60 min) at the end of the 5-FU infusion
1827171|NCT00786006|Drug|FOLFOX|FOLFOX: oxaliplatin 85 mg/m2 (over 120 min) on D1, LV 400 mg/m2 (over 2hour) on D1, 5-FU 400 mg/m2 IVP on D1, 5-FU 2,000 mg/m2 (over 46 hours)
1827172|NCT00786019|Behavioral|Exercise program|Three month exercise program located at the Anschutz Medical Campus at I-225 and Colfax. The program runs three times per week for about an hour each session. Gym is open Monday - Saturday during specific hours (morning, noon, evening).
1827173|NCT00786019|Drug|Ascorbic Acid (Vitamin C)|"During one exercise study visit, 0.06 g Vit C per kg fat-free mass per 100 ml of normal saline administered; Subjects will receive a bolus of 100mL Vit C solution given at 5ml/min over 20minutes followed by a drip-infusion given at 1.7ml/min."
1827174|NCT00786032|Device|BCI Device|A Brain Computer interface or BCI records brain signals and analyzes them to derive device commands. BCIs give their users communication and control channels that do not depend on peripheral nerves and muscles.
1827175|NCT00786045|Other|Home Cycling Program|Participants will be given a time and intensity graded program at an intensity that is comfortable and tolerable for the individual. The individual will be encouraged to augment, gradually, either the time of cycling per day or the work of cycling, always keeping within the limits of comfort and tolerability. Participants will also be given a target heart rate threshold to try and meet but not to exceed. This will be based their response to the stress test and will most likely be between 50% and 70% of maximum age-predicted heart rate. The aim is to build up to one-half hour of cycling per day. All bicycles will be equipped with electronic monitoring of speed, distance, and heart rate.
1827176|NCT00786058|Drug|OFF in experimental arm|OFF was given according to a six week cycle. FA (500 mg/m2 , 0.5h, i.v.) and 5-FU (2,600 mg/m2, 24-hour, i.v.) were administered on days 1, 8, 15, and 22. Oxaliplatin (85 mg/m2 , 2-4 h, i.v.) was administered directly before FA/ 5-FU on days 8 and 22.
1827177|NCT00786097|Drug|Dermacyd PH_DETINLYN (Lactic Acid)|
1827178|NCT00786110|Drug|Sorafenib|Treatment scheme consisted of oral Sorafenib 400 mg p.o. bid until disease progression.
1827179|NCT00786110|Drug|Paclitaxel|Intravenous Paclitaxel 60 mg/mq/weekly i.v., until disease progression.
1827182|NCT00786136|Drug|rosuvastatin|rosuvastatin
1827183|NCT00786149|Other|Varenicline plus Motivational Interviewing counseling|Motivational Interviewing; 8 weeks of counseling
1827184|NCT00786149|Other|Varenicline without counseling|Brief advice, one time during initial session
1827185|NCT00786162|Other|Internet-enabled automated self-management program|An internet platform to display blood pressure readings and provide subjects with automated messages and educational information about hypertension management.
1827186|NCT00786162|Other|BP cuff at workplace|Provided BP cuff for communal use at the worksite
1827187|NCT00786188|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive Brisdelle™ (paroxetine mesylate) Capsules 7.5 mg.
1827188|NCT00786188|Drug|Sugar pill|Subjects will receive a sugar pill.
1827189|NCT00786201|Drug|Placebo|Intravenous (IV) infusion every 4 weeks, from Week 0 through Week 48
1827190|NCT00786201|Drug|CNTO 888 1 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
1827191|NCT00786201|Drug|CNTO 888 5 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
1827192|NCT00786201|Drug|CNTO 888 15 mg/kg|IV infusion every 4 weeks, from Week 0 through Week 48
1827193|NCT00786214|Other|Acupuncture|Patients will be stimulated at specific acupuncture points as determined for treatment of the disease by certified acupuncturists
1827275|NCT00786929|Procedure|Catheter drainage|
1827196|NCT00786240|Drug|Fesoterodine|Single dose of 4 mg tablet in formulation E(1) under fasted conditions (Test)
1827197|NCT00786253|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil 10 mg on demand use
1827198|NCT00786253|Drug|Levitra (Vardenafil, BAY38-9456)|Vardenafil daily dosing 10 mg
1827199|NCT00786266|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
1827200|NCT00786266|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
1827201|NCT00786279|Other|ethanol|15 gm ethanol daily for 6 months
1827202|NCT00786279|Other|Ethanol-free beverage|0 grams ethanol daily for 6 months.
1827203|NCT00786292|Other|Assisted mechanical ventilation|Patients will be mechanically ventilated with noisy PSV and PSV in random sequence
1827204|NCT00786305|Drug|ceftazidime and amikacin|Nebulized ceftazidime 15 mg/kg/3h during 8 days and nebulized amikacin 25 mg/kg/day during 3 days
1827205|NCT00786305|Drug|ceftazidime and amikacin|Intravenous infusion of ceftazidime 30 mg/kg over 30 min followed by continuous infusion 90 mg/kg/day during 8 days and intravenous infusion of amikacin 15 mg/kg/day over 30 min during 3 days
1827206|NCT00786318|Drug|ziprasidone|ziprasidone 20mg IM
1827207|NCT00786318|Drug|Standard therapy|Haldol 5mg/ Ativan 2mg IM
1827208|NCT00786331|Drug|Pemetrexed|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 of a 21 days cycle
1827209|NCT00786331|Drug|Pemetrexed plus carboplatin|Pemetrexed 500 mg/m2 i.v. over approximately 10 minutes on day 1 and Carboplatin AUC 5 i.v. over approximately 30 minutes on day 1 (beginning approximately 30 minutes after the end of the pemetrexed infusion) of a 21 days cycle
1827210|NCT00786344|Behavioral|Lifestyle Redesign|"For a six-month period, each elder participated in weekly 2-hour sessions involving groups of size 8-10, and also received up to 10 hours of individualized treatment over this time period.
Modular treatment units included the following content areas: (1) Introduction to the Power of Activity; (2) Aging, Health, and Activity; (3) Transportation; (4) Safety; (5) Social Relationships; (6) Cultural Awareness; (7) Finances; and (8) Integrative Summary: Lifestyle Redesign Notebook. The methods of program delivery consisted of didactic presentation, peer exchange, direct experience, and personal exploration. Treatment materials were translated into Spanish and culturally adapted for approximately 15% of the subjects."
1827211|NCT00786357|Behavioral|NIOSH shiftwork booklet|weekly readings about coping with shiftwork
1827212|NCT00786357|Behavioral|Sleep Enhancement Training System|4 week program of readings and relaxation programs
1827213|NCT00786370|Drug|dexmedetomidine|Propofol or dexmedetomidine infusion will be started according to the randomized treatment allocation. The propofol group will receive a bolus of 2mg midazolam and 100mcg fentanyl and then continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved. The dexmedetomidine group will receive a bolus of dexmedetomidine 1mcg/kg for 10 minutes and then a continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
1827214|NCT00786370|Drug|Propofol|continuous propofol infusion at 50-100mcg/kg/min until a Ramsay score of 3 or Bis score of 60-80 is achieved
1827215|NCT00786370|Drug|Dexemedetomidine|continuous infusion of dexmedetomidine 0.2-0.7mcg/kg/hr until a Ramsay score of 3 or a Bis score of 60-80 are achieved.
1827216|NCT00786383|Biological|IMC-1121B|"Cohort 1
6 mg/kg I.V., once every other week for 4 weeks"
1827217|NCT00786383|Biological|1121B|"Cohort 2
8mg/kg I.V., once every other week for 4 weeks"
1827218|NCT00786383|Biological|1121B|"Cohort 3
10 mg/kg I.V., once every other week for 4 weeks"
1827219|NCT00786383|Biological|1121B|"Cohort 4
15 mg/kg I.V., once every 3 weeks for 6 weeks"
1827220|NCT00786383|Biological|1121B|"Cohort 5
20 mg/kg I.V., once every 3 weeks for 6 weeks"
1827221|NCT00786396|Behavioral|Directly administered antiretroviral therapy|Daily observation of subjects taking their HIV medications
1827223|NCT00786422|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Participants received 30 mg rivaroxaban bid (twice-daily) orally for the first 3 weeks followed by 20 mg rivaroxaban bid for the remainder of the 3-month treatment period.
1827224|NCT00786448|Drug|Darifenacin, Emselex (BAY79-4998)|Patients from routine practice
1827225|NCT00786461|Procedure|silver nitrate application to the Bartholin´s cyst|5 mm in diameter and 5 mm in length crystalloid silver nitrate stick is inserted into the cyst or abscess cavity.
1827226|NCT00786461|Procedure|silver nitrat stick|The silver nitrate treatment is performed under local anaesthesia on an outpatient basis. A simple vertical incision 1 cm in length is made in the vaginal mucosa and the underlying cyst or abscess wall. A crystalloid silver nitrate stick of 5 mm in diameter and 5 mm in length is inserted into the cyst or abscess cavity.
1827227|NCT00786474|Drug|Placebo|Normal saline solution, dosage determined by weight, self-administered by patient twice a day
1827228|NCT00786474|Drug|Dalteparin|Low molecular weight heparin (LMWH), dosage determined by weight, self-administered by patient twice a day
1827229|NCT00786487|Drug|20% lipid infusion|1.5 ml/min for 6 hours
1827230|NCT00786487|Drug|glycerol|glycerol infusion (2.25 g/100ml) will be administered at 1.5 ml/min,
1827231|NCT00786500|Dietary Supplement|Gynostemma pentaphyllum tea|3 grams twice daily, orally
1827232|NCT00786500|Dietary Supplement|Placebo tea|3 grams twice daily, orally
1827233|NCT00786513|Other|Conventional antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on conventional planktonic antimicrobial susceptibility testing results.
1827234|NCT00786513|Other|Biofilm antimicrobial susceptibility testing|Subjects in this arm will be prescribed 14 days of an intravenous 2 drug antibiotic combination based on biofilm antimicrobial susceptibility testing results.
1827235|NCT00786539|Device|Diffuse Optical Spectroscopy|mitochondria
1827236|NCT00786552|Drug|pemetrexed + paclitaxel|Pemetrexed 500 mg/m² i.v. over 10 minutes on day 8 Paclitaxel 90 mg/m² i.v. over 60 minutes on day1 and 8
1827237|NCT00786565|Device|Advanced Akreos Adapt in one operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
1827238|NCT00786565|Device|Akreos Adapt in fellow operated eye.|Cataract surgery to implant the assigned IOL according to randomized schedule.
1827276|NCT00786929|Drug|Conservative treatment|
1827239|NCT00786630|Behavioral|Strengths-based case management|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline.
1827240|NCT00786630|Behavioral|Case management plus facilitated treatment alliance|Clients will receive counseling and/or referrals for help with nine life domains (life skills, finances, leisure activities, relationships, living arrangements, occupation/education, health, mental health, recovery from substances, legal assistance) for a period of five months after baseline. They will also receive a facilitated treatment alliance, which consists of meetings with methadone counselors to aid in treatment entry.
1827241|NCT00786643|Drug|5-Fluorouracil|5-FU bolus was administered at 400mg/m^2 on day 1 and day 2 of each cycle. 5-FU at 600 mg/m^2 infusion was administered over 22 hours on day 1 and day 2 of each cycle.
1827242|NCT00786643|Drug|Leucovorin (LV)|Leucovorin 200mg/m^2 was administered over 2 hours on day 1 and day 2 of each cycle.
1827243|NCT00786643|Drug|Gamma-Interferon-1b (IFN-γ)|Gamma-Interferon 150 mcg/m^2 was administered by subcutaneous injection on day 1 of each cycle immediately before treatment with 5-FU and LV, and on day 3 of each cycle immediately after treatment with 5-FU and LV.
1827244|NCT00786643|Drug|Bevacizumab|Bevacizumab 5mg/kg was only added to the treatment regimen of patients in stratum 1 who demonstrated stable disease on imaging repeated prior to the 5th cycle of treatment. Bavacizumab was administered on day 4 of each cycle.
1827245|NCT00786669|Drug|Bevacizumab|Bevacizumab (IV) 15 mg/Kg on day 1 every 3 weeks for up to 6 cycles
1827246|NCT00786669|Drug|Temozolomide|100 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles. For patients under 0.5 m2 BSA, TEM = 3.3 mg/kg/day po on Days 1-5.
1827247|NCT00786669|Drug|Vincristine|1.5 mg/m2 on Day 1 (max dose 2 mg) administered as an IV bolus every 3 weeks for up to 6 cycles. For patients <0.5 m2 BSA, VCR dose = 0.05 mg/kg (maximum dose 2 mg).
1827248|NCT00786669|Drug|Irinotecan|90 mg/m2/day po on Days 1-5 every 3 weeks for up to 6 cycles
1827249|NCT00786669|Drug|Cefixime|8 mg/kg/day (max. daily dose 400 mg) of cefixime or 5 mg/kg/dose bid (max. daily dose 400 mg) of cefpodoxime starting Day -1 BEFORE chemotherapy and continuing EVERY DAY while on study, or for 2 days after last dose of chemotherapy if treatment stopped early for disease progression or toxicity
1827250|NCT00786682|Drug|docetaxel|
1827251|NCT00786682|Drug|hydroxychloroquine|
1827252|NCT00786695|Drug|esomeprazole|esomeprazole (40 mg o d) for 14 days
1827253|NCT00786695|Drug|Placebo|Identical looking Placebo, same regimen, for 14 days
1827254|NCT00786721|Device|Diffuse Optical Spectroscopy|muscle properties scanning
1827255|NCT00786734|Drug|Pitavastatin|4mg daily for 5-7 days before Percutaneous Coronary Intervention(PCI) and 4mg daily for 28 days after PCI
1827256|NCT00786734|Drug|Pitavastatin|4mg daily for 28 days after PCI
1827257|NCT00786747|Behavioral|Personally tailored computer program|The experimental computer program provides the user with information about colorectal cancer screening that is tailored to their self-efficacy, readiness, and perceived barriers to undergoing screening, in their preferred language (English or Spanish).
1827258|NCT00786747|Behavioral|Non-tailored control computer program|This program provides users with non-tailored information about colorectal cancer screening, in their preferred language (English or Spanish).
1827259|NCT00786760|Other|Cohort: 3000 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
1827260|NCT00786760|Other|Pilot study: 150 men examined every 6 months for 4 years.|Prospectively assess HPV infection in a large cohort of men in the US , Mexico, and Brazil representing countries of low and high risk.
1827261|NCT00786799|Dietary Supplement|Omega-3 Fatty Acids|"Omega-3's are administered in the form of an orange pudding made by Coromega
1 mg of omega-3 fatty acid 2 times per day"
1827262|NCT00786799|Dietary Supplement|Omega-3 Fatty Acids|"Omega-3 Fatty Acids in orange pudding form
1 packet two times per day"
1827263|NCT00786812|Drug|Nilotinib|
1827264|NCT00786825|Drug|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
1827265|NCT00786838|Drug|Trabectedin|Trabectedin will be administered as 1.3 mg/m2 3-hour intravenous infusion on Day 2.
1827266|NCT00786838|Drug|Placebo|Participants will receive 3-hour placebo intravenous infusion on Day 1.
1827267|NCT00786851|Drug|Lenalidomide and Dexametasone|Lenalidomide will be supplied as 5 mg and 25 mg capsules for oral administration.Dexamethasone (Soldesam 0.2%) will be supplied as 20 mg liquid for oral administration (1 bottle = 20 mg; daily dose = 2 bottles = 40 mg).
1827268|NCT00786864|Other|exercise programme|Specific low back pain exercise programme for children
1827269|NCT00786877|Other|Improved biomass cookstove with exterior ventilation|Improved cookstove design installed in house that is higher efficiency and is vented to the exterior.
1827270|NCT00786877|Other|Phase 2 intervention arm (LPG stove)|LPG two burner stove with a 12 month supply of LP gas.
1827271|NCT00786890|Other|observational, no intervention needed|observational, no intervention needed
1827272|NCT00786916|Drug|normal saline|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive saline placebo IV (Group A) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
1827273|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.25 mg/kg IV (Group B) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
1827274|NCT00786916|Drug|lidocaine|A blood pressure cuff is placed with its distal-most margin 10 cm proximal to the intravenous catheter insertion site and is inflated to 40 mmHg of pressure greater than the patient's pre-procedure systolic blood pressure. Subjects will receive lidocaine 0.5 mg/kg IV (Group C) prior to initiating propofol infusion. Five minutes after administration of the study agent, tourniquet pressure is released and propofol infusion will be immediately initiated.
1827277|NCT00786942|Procedure|high tibial osteotomy|addition of bone graft to fill the osteotomy gap
1827278|NCT00786942|Procedure|higi tibial osteotomy|the gap of the tibia is unfilled
1827279|NCT00786968|Drug|laronidase|1.74 mg intrathecally every 1-3 months for 1 year
1827280|NCT00786981|Other|Epidural steroid injection plus physical therapy|Patients in the ESI+PT Group will be treated additionally with a physical therapy program emphasizing lumbar flexion exercises, aerobic and strength/ conditioning exercises, and manual physical therapy as well as receiving up to 3 epidural steroid injection(s) and educational support using The Back Book.
1827281|NCT00786981|Other|Epidural steroid injection|Patients in the ESI Group will be treated with up to 3 epidural steroid injections, educational support, and general care by the treating physician.
1827282|NCT00786994|Drug|Oleogel-S10 100 mg/g|topical use once or twice daily
1827283|NCT00786994|Drug|Placebo (petroleum jelly)|topical use once or twice daily
1827284|NCT00787007|Drug|S-equol|capsule, oral, single dose
1827285|NCT00787007|Drug|Placebo|capsule, oral, single dose
1827286|NCT00787033|Drug|PF-04554878|Oral pills at increasing dose twice daily, 21 day cycle, continuous treatment schedule until progression of disease, unacceptable toxicity, or patient request. Some patients will undergo serial biopsy and/or FDG-PET imaging
1827289|NCT00787072|Drug|AZD8075|Single dose, the starting dose will be 7 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits.
1827290|NCT00787072|Drug|Placebo|Oral suspension
1827291|NCT00787098|Other|ETM protocol|ETM is 4 levels. Level 1, each receives repositioning from lateral to supine positions at even hours, totaling 60 minutes of activity/positioning over 24 hours. If tolerated, two periods of 20 minutes of supine position with a reverse trendelenberg position of 15-20 degrees will be used to promote orthostasis. Level 2 is turning every 2 hours, positioning in reverse trendelenberg at 15-25 degrees as tolerated, active resistance with ICU staff for 20 minutes daily for a total of 60-80 minutes of activity/positioning daily. At Level 3, 2 times 20 minutes of a sitting are added to active ROM and inbed turning (estimated 80-100 total minutes of activity daily). Sitting is in bed or with non-weightbearing assisted transfer to chair with backrest elevation at 75-90 degrees and legs in a dependent position. Level 3 interventions; minimal weight-bearing. Level 4, weight-bearing transfer to chair and ambulation are added to inbed turning.
1827292|NCT00787111|Drug|Fluoxetine (prozac)|Formulation: ODT
1827293|NCT00787137|Drug|PG102|A single intravenous infusion
1827294|NCT00787137|Drug|Placebo comparator|Phosphate-buffered saline
1827295|NCT00787150|Drug|Apixaban|Apixaban 5 mg tablet BID for 12 weeks
1827296|NCT00787150|Drug|Apixaban|Apixaban 2.5 mg tablet BID for 12 weeks
1827297|NCT00787150|Drug|Warfarin sodium|At each visit, the subject to take appropriate Warfarin tablet (on investigator's order) once a day every morning for 12 weeks
1827298|NCT00787163|Procedure|amnioinfusion|serial amnioinfusions aimed at restoring amniotic fluid volume
1827303|NCT00787189|Device|The Hearing Laser|Two 6-minute low level laser light applications to the head/neck/ears region, each one week apart.
1827304|NCT00787189|Device|Placebo Laser|inactive low level laser light therapy with no therapeutic output
1827305|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
1827306|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
1827307|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
1827308|NCT00787202|Drug|CP- 690 550|Administration via oral route twice daily for the duration of treatment
1827309|NCT00787202|Other|placebo|Administration via oral route twice daily for the duration of treatment
1827310|NCT00787215|Other|observational: no treatment involved|observational: no treatment involved
1827311|NCT00787254|Drug|Lansoprazole|Lansoprazole 15 mg, capsules, orally, once daily and gefarnate placebo-matching capsules, orally, twice daily for up to 6 to 24 months.
1827312|NCT00787254|Drug|Gefarnate|Gefarnate 50 mg, capsules, orally, twice daily and lansoprazole placebo-matching capsules, orally, once daily for up to 6 to 24 months.
1827313|NCT00787267|Drug|Dasatinib|70 mg PO twice daily until progression. Re-assess radiographically every 6 weeks.
1827314|NCT00787280|Behavioral|Low Carbohydrate Ketogenic Diet (LCKD)|participants will follow a low carbohydrate ketogenic diet for six weeks
1827315|NCT00787280|Behavioral|Low Fat Diet (LFD)|particpants will follow a low fat diet for six weeks
1827316|NCT00787293|Device|PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant|Percutaneous assessment from right or left subclavian vein, with PTMA implant in the coronary sinus, great cardiac vein, anterior interventricular vein.
1827317|NCT00787306|Behavioral|Active risk factor surveillance|Cardiovascualr risk status assessment followed by active surveillance and physician review where risk factor control is suboptimal
1827318|NCT00787319|Other|no intervention|Outpatients with age-related macular degeneration (AMD)
1827319|NCT00787332|Drug|Desirudin or Argatroban®|Desirudin 15mg SC Argatroban® IV dosing per Package Insert
1827320|NCT00787345|Other|simulation based training|simulation based training in aseptic techniques that included specified AT categories
1827321|NCT00787358|Drug|ZT-031|80 ul subcutaneous injection per day
1827322|NCT00787358|Other|placebo|80 ul daily subcutaneous injection of vehicle only
1827323|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.25 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
1827900|NCT00793572|Drug|Cyclosporine|Given IV
1827324|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 0.5 mcg/kg SC QW for 12 weeks
1827325|NCT00787371|Biological|PegIntron (peginterferon alfa-2b)|PegIntron 1.0 mcg/kg subcutaneously (SC) once a week (QW) for 12 weeks
1827326|NCT00787384|Drug|Imatinib|Patients received oral imatinib 100 mg/d; in case of unsatisfactory response (less than complete) Imatinib could be increased by 100 mg/die on a weekly basis and up to a maximum of 400 mg/die. Imatinib wsa discontinued after 12 total weeks of therapy.
1827327|NCT00787397|Behavioral|Cognitive Behavioral Therapy-Sleep|Cognitive Behavioral Therapy: 6 sessions of CBT
1827328|NCT00787410|Drug|ZD1839|250mg tablet, once daily, orally administered
1827329|NCT00787436|Drug|Thalidomide|Medical therapy has been used to decrease upper gastrointestinal bleeding in cirrhotics Non Selective beta blockers have been shown to effectively decrease the portal venous pressure
1827330|NCT00787462|Drug|Pregabalin|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
1827331|NCT00787462|Drug|Placebo|Available as 75 mg capsules. Subjects will begin Phase 1 treatment on either pregabalin (or placebo) 75mg BID (1 capsule BID) for one week then increasing to 150mg BID or placebo (2 capsules BID) for a further 7 weeks. During this period patients will be allowed to taper the drug to 225mg a day (75mg in am, 150mg in pm) or (75mg BID) if they develop significant adverse effects on the higher dose. After 8 weeks Phase 1 treatment subjects will taper study medication to 75mg BID or placebo (1 capsule BID) for 7 days and then continue taking placebo (1 capsule) for 7 additional days prior to the crossover. After the taper and washout, Phase 2 will begin using the alternate treatment and will follow the same dosing regime as Phase 1 for the remaining 10 weeks.
1827332|NCT00787475|Other|Community Health worker|Community Health workers with at least 4 home visits, 8 phone calls, and 10 group visits.
1827333|NCT00787488|Device|Hyperthermia|Every 3 weeks
1827334|NCT00787501|Drug|SSRI|SSRI: 25 patients will receive 14 weeks of an FDA approved selective serotonin reuptake inhibitor (SSRI), administered under the supervision of a staff psychiatrist. After an initial 30-45 minute session patients will be seen for 15-30 minute sessions for 16-20 sessions over 14 weeks. Medication will begin with 10mg escitalopram daily (or its equivalent), increased to 30 mg/day (or its equivalent) by week 6 if pt has not achieved a minimum level of response (i.e., CGI < 2) and tolerability is adequate. Nonresponse at week 10 (CGI < 2) will be cause for medication switch or augmentation.
1827335|NCT00787501|Behavioral|CBT|Cognitive Behavior Therapy: 40 patients will receive 16- 20 60 minute sessions of procedurally determined Cognitive Therapy (Beck, 1979) over 14 weeks. Patients will begin with 2 sessions per week which may be reduced to once per week in the latter part of the study period if the patient is responding to the therapy. Cognitive Therapy is designed to teach skills that help to reduce depressive severity. Each session will be videotaped and will include homework to be completed and brought to the following session.
1827336|NCT00787527|Drug|Zolinza (vorinostat)|Up to two 100 mg capsules of Vorinostat (dosage will vary from 100 mg orally (PO) twice daily (BID), 300 mg PO every evening and 200 mg PO BID with the starting dose at 300 mg PO every evening for the phase I trial) are to be administered orally twice daily (once in the morning and once in the evening, or if in the daily dosing cohort once in the evening) in repeated 21-day cycles consisting of 10 days dosing starting on days 5 through 14 followed by a 7-day rest period, during which no vorinostat will be administered.
1827337|NCT00787527|Drug|Cyclophosphamide|750 mg/m^2 by vein over 1 hour on Day 1 of 21 day cycle
1827338|NCT00787527|Drug|Doxorubicin|50 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
1827339|NCT00787527|Drug|Vincristine|1.4 mg/m^2 by vein over 15 minutes on Day 1 of 21 day cycle
1827340|NCT00787527|Drug|Prednisone|100 mg tablets by mouth once a day on Days 1-5 of 21 day cycle
1827341|NCT00787553|Drug|cefazolin|2.0 g, IV, 2 hours before surgery
1827342|NCT00787553|Drug|tinidazole|2.0 g orally, 12 hours before surgery
1827343|NCT00787553|Drug|cefazolin plus tinidazole|cefazolin, 2.0 g IV 2 hours before surgery plus tinidazole 2.0 g orally 12 hours before surgery
1827344|NCT00787566|Drug|Intranasal granisetron|0.5 mg, 1.0 mg or 2.0 mg dose of TRG prior to the administration of a highly-emetogenic chemotherapy regimen
1827345|NCT00787579|Device|Bifocal spectacles|+1.50D bifocal spectacles
1827346|NCT00787579|Device|Prismatic bifocal spectacles|+1.50D bifocal spectacles combined with 3Δ base-in prisms
1827347|NCT00787605|Drug|Amlodipine|Amlodipine 5 mg for 1 week followed by Amlodipine 10 mg for 7 weeks
1827348|NCT00787605|Drug|Hydrochlorothiazide (HCTZ)|Hydrochlorothiazide 12.5 mg for 1 week followed by Hydrochlorothiazide 25 mg for 7 weeks
1827349|NCT00787605|Drug|Aliskiren|Aliskiren 150 mg for 1 week followed by Aliskiren 300 mg for 7 weeks
1827350|NCT00787618|Drug|50 mg Proellex|Single dose
1827351|NCT00787644|Drug|Pioglitazone|Pioglitazone tablets; 30 mg/day for 2 weeks; then increased to 45 mg/day until week 12 (approximately 3 months)
1827352|NCT00787644|Drug|Placebo|Matching placebo (inert tablet)
1827353|NCT00787657|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients after first clinical events suggestive of MS (according to SMPC) and patients with RRMS within the first two years of diagnosis
1827354|NCT00787670|Other|Diabetes Support and Education|The subjects will attend three educational/social support sessions for 1 year after enrollment. The educational sessions include informational sessions on diet/nutrition and exercise. These sessions are informational and do not teach behavioral self-regulation skills.
1827355|NCT00787670|Procedure|gastric bypass surgery|gastric bypass surgery to induce weight loss in obese patients with type 2 diabetes
1827356|NCT00787670|Other|Tissue Control Group|During the abdominal surgery we would like to take 5 ml blood from the IV line and small pea-sized samples of the fat tissue just under the skin and around the stomach area. These samples will be stored so that we can compare these tissue with other patients.
1827901|NCT00793572|Drug|Cyclosporine|Given PO
1827357|NCT00787683|Device|Home-monitoring provided by LUMAX ICD device and CardioMessenger II|All study participants receive an ICD of the Biotronik lumax family. Only participants of the intervention group receive the CardioMessengerII to allow for transmission of regular home monitoring messages. All study participants will be followed for 12 to 24 months (depending on the time of recruitment). The intervention and comparison to be investigated is home-monitoring vs. no home-monitoring. The intervention involves a combination of in-clinic consultations and regular use of home-monitoring services. As part of the modified follow-up schedule of intervention patients compared to standard care, follow-up in-clinic consultations 3, 6, and 18 months after ICD implantation will be replaced by home-monitoring follow-up.
1827358|NCT00787696|Behavioral|Cognitive-behavioral HIV/STD risk reduction|18 60-minute group sessions plus 1 individual health and safety planning session
1827359|NCT00787709|Behavioral|Pathways|3-year, 30 lesson, School-based universal health promotion curriculum with parent component.
1827360|NCT00787722|Procedure|Hematopoietic stem cell transplantation|"Mobilization
G-CSF- guidelines, 5-10 mcg/kg/day will be started day +5 and continued until the absolute neutrophil counts reaches at least 1,000
Cytoxan dose of 2gm/m will be infused over two hours.
Mesna, given the dose of 2.0 gm/m, infusion to be given over 24 hours.
Transplant Conditioning Regimen
Cyclophosphamide 50 mg/kg/day will be given IV over 2 hours in 500 cc of normal saline.
r ATG 0.5 mg/kg given on day -5, then 1.0 mg/kg given on day -4, then 1.5 mg/kg given on days -3 through -1.
Rituxan ( Rituximab ) - The dose of 500 mg of Rituximab will be given on days -6 and on day + 1.
G-CSF - guidelines, 5-10 mcg/kg/day will be started day + 5 and continued until the absolute neutrophil counts reaches at least 1,000/μl."
1827361|NCT00787735|Behavioral|Counseling compliance|Rates of attendance to call counseling session over specific time points
1827362|NCT00778765|Drug|400 mg Gabapentin Capsules|
1827363|NCT00778778|Drug|cefprozil 500mg tablets|
1827364|NCT00778791|Drug|metformin HC1 750 mg extended-release tablets|
1827365|NCT00778804|Behavioral|telemedicine|Weekly transmission of health status (weight, activity, BP etc.) via the Internet with feeedback and reinforcement
1827366|NCT00778817|Biological|IMC-A12|Given IV
1827367|NCT00778817|Drug|mitotane|Given orally
1827368|NCT00778830|Drug|Cetuximab|Cetuximab will be administered intravenously at a dose of 500 milligram per square meter (mg/m^2) biweekly on Day 1 of 14 days treatment cycle until disease progression, occurrence of unacceptable toxicity, or withdrawal of consent.
1827369|NCT00778830|Drug|FOLFIRI|Irinotecan will be administered intravenously at a dose of 180 mg/m^2 along with folinic acid administration intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil will be administered intravenously at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal.
1827370|NCT00778830|Drug|FOLFOX|Oxaliplatin will be administered intravenously at a dose of 100 mg/m^2 along with folinic acid administration intravenously at a dose of 400 mg/m^2 (racemic) or 200 mg/m^2 (L-form) and 5-fluorouracil administration intravenously at a dose of 400 mg/m^2 bolus followed by a 46-hour continuous infusion of 2,400 mg/m^2 given biweekly until disease progression, death, or consent withdrawal.
1827371|NCT00778843|Dietary Supplement|Viusid|Viusid, three oral sachets daily during 24 weeks
1827372|NCT00778843|Other|Placebo|Placebo three oral sachets daily during 24 weeks
1827373|NCT00778856|Procedure|Hand transplantation|allotransplantation of deceased donor composite tissue (hand and forearm)
1827374|NCT00778869|Biological|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
1827375|NCT00778882|Drug|VM106|Autologous hematopoietic stem cells with MT-gp91 retroviral vector
1827376|NCT00778895|Biological|GSK Biologicals' influenza vaccine GSK1557482A|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
1827377|NCT00778895|Biological|Vaxigrip|one IM injection at Day 0 for primed subjects (defined as subjects who had a prior 2-dose priming influenza immunization) or two IM injections at Day 0 and approximately Day 28 for un-primed subjects (defined as subjects who have not previously received a complete 2-dose priming influenza immunization).
1827378|NCT00778908|Radiation|Late-course accelerated hyperfractionated IMRT|"IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease
IMRT delivery scheduling: (1) Six-week treatment: PTV1=60Gy/30fractions, PTV2=57Gy/30fractions,PTV3=54Gy/30fractions.(2) Concomitant boost to PTV1 as a second daily treatment for the last 10 treatments of the Six-week treatment: PTV1=12Gy/10fractions.(3) PTV3 will be treated with conventional radiotherapy technique separately."
1827379|NCT00778908|Drug|Concomitant cisplatin chemotherapy|cisplatin:40mg/m2 weekly infusion for 6 weeks
1827380|NCT00778908|Radiation|Conventionally fractionated IMRT|IMRT target definition: PTV1=Gloss tumor PTV; PTV2=High risk area containing subclinical disease; PTV3=Low risk area containing subclinical disease IMRT delivery scheduling: (1) Seven-week treatment: PTV1=70Gy/35fractions, PTV2=63Gy/35fractions,PTV3=55.8Gy/31fractions.(2) PTV3 will be treated with conventional radiotherapy technique separately.
1827381|NCT00778921|Drug|Amlodipine 10 mg|Amlodipine 10 mg
1827382|NCT00778921|Drug|Aliskiren 150|Aliskiren/Amlodipine 150/10 mg
1827383|NCT00778921|Drug|Amlodipine 300|Aliskiren/Amlodipine 300/10 mg
1827384|NCT00778934|Other|Intimate Health Gel|Intimate Health Gel
1827385|NCT00778947|Procedure|Harmonic Synergy Dissecting Hook (Harmonic Scalpel)|Harmonic Synergy Dissecting Hook (Harmonic Scalpel) uses ultrasound waves to coagulate and cut in surgery. It is available on the market, holds a CE mark and is coded as a Class IIb medical device.
1827386|NCT00778947|Procedure|Electrocautery Diathermy|Electrosurgery uses high temperatures (150-400oC) and causes obliterative coagulation. Diathermy is the use of high frequency electric current to produce heat. In surgery it is used to cut or destroy tissue and/or to produce coagulation. The electrical frequency produced in diathermy is in the range of 300kHz to 3MHz.
1827387|NCT00778960|Behavioral|Slow Breathing|The slowed breathing group will be trained on a breathing device, RESPeRATE, designed to reduce respiratory rate.They will practice with RESPeRATE once a week (for 6 weeks) in the laboratory with the research staff.
1827505|NCT00779792|Drug|vehicle ointment (paraffin oil/soft white paraffin)|0.5 mg vehicle ointment twice daily for 10 consecutive days
1827388|NCT00778960|Behavioral|Meditation|The Mindfulness Body Scan meditation will be used for the mindfulness meditation group.Participants will be trained once a week (for six weeks) in the laboratory by the research staff.
1827389|NCT00778960|Behavioral|Meditation and slow breathing|A structured Mindfulness breathing will be guided by the research staff during the lab trainings. The participant will sit upright and attempt to focus attention on his or her own breath as it passes the opening of the nostrils or on the rising and falling of the abdomen or chest. Whenever attention wanders from the breath, the participant will simply notice the distracting thought and then let it go as attention is returned to the breath. Training will be given once every week for 6 weeks.
1827390|NCT00778960|Behavioral|Sitting Quietly|"The SQ control group's intervention will include sitting quietly and listening to a neutral-content book on tape to serve as a time and attention control at each laboratory session. They will also be asked to sit quietly at home daily."
1827391|NCT00778973|Drug|sertraline 100 mg tablets|
1827392|NCT00778986|Device|heart failure remote patient monitoring system|remote monitoring of weight, blood pressure, ECG, and symptoms
1827393|NCT00778999|Drug|Marvelon|oral contraceptive 1 tablet daily for 14 to 21 days
1827394|NCT00779012|Biological|Infliximab|Remicade 5 mg/kg, given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks (maximum 9 infusions).
1827395|NCT00779025|Device|PD-F-5254|Female Personal Lubricant (MINE)
1827396|NCT00779025|Device|10855-096|Male Personal Lubricant (YOURS)
1827397|NCT00779038|Drug|Fentanyl ITS|40 mcg per 10 minutes of fentanyl dose up to a maximum of 240 mcg (6 doses each of 10 minutes duration) per hour but not more than a maximum of 3.2 milligram (80 doses) within a 24 hour period from an ITS. Total duration of treatment will be 72 hours.
1827398|NCT00779051|Drug|Zolpidem 10mg tablets|
1827399|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|10mg BID, Semi-sequential, dose escalation.
1827400|NCT00779064|Drug|Rivaroxaban (BAY59-7939)|20mg BID, Semi-sequential, dose escalation.
1827401|NCT00779090|Procedure|Alveolar recruitment manoeuvre|Increase airway pressure during pressure controlled ventilation up to peak-airway pressure of 40 cmH20 and PEEP of 15 cmH20.
1827402|NCT00779103|Drug|Histrelin Subcutaneous Implant|histrelin subcutaneous 50 mg implant
1827403|NCT00779116|Drug|Desloratadine|SCH 34117: desloratadine RediTabs, 1 tablet (2.5 mg), oral administration, single dose, single day
1827404|NCT00779116|Drug|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single dose, single day
1827405|NCT00779129|Drug|Pegylated Lyposomal Doxorubicin|Caelyx 35 mg/m2 intravenously, on Day 1, every 3 weeks, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
1827406|NCT00779129|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2, intravenously, on Day 1, every 6 weeks, during 6 cycles (concomitantly with Caelyx). Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
1827407|NCT00779142|Drug|Methotrexate intravenous 25mg/ml|Methotrexate intravenous 25mg/ml delivered once or twice (based on the therapeutic response) over a period of 2 months maximum. Total dosage 400ug in each dose. Statistical analysis would not be applicable in this small sample.
1827408|NCT00779155|Device|The Resonator|active magnetic field therapy
1827409|NCT00779155|Device|The Resonator control|inactive magnetic field therapy with placebo fields
1827410|NCT00779168|Drug|white button mushroom extract|For this dose escalation study 6 patients will be treated at each of the following dosages: 4 grams PO daily, 6 grams PO daily, 8 grams PO daily, 10 grams PO daily, 12 grams PO daily and 14 grams PO daily.
1827411|NCT00779168|Other|flow cytometry|Immune cell subset number will be evaluated by flow cytometry on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
1827412|NCT00779168|Other|immunologic technique|Testing will be performed on blood samples collected on days -14, -7, 1, 15, 29, 57, 85 from treatment and when coming off study.
1827413|NCT00779168|Other|laboratory biomarker analysis|Performed on blood samples collected pre-study (within 4 weeks of registration) and during weeks 3, 5, 9, 13, every 4 weeks beyond week 13 and at off study.
1827414|NCT00779168|Other|gas chromatography-mass spectrometry|Gas Chromatography-Mass Spectrometry (GC-MS) will be used to evaluate C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
1827415|NCT00779168|Other|pharmacological study|Evaluation of C-18 unsaturated fatty acids (CUFA) in blood samples collected on days -14, -7 prior to start of treatment. On day 1 of week 1 blood will be drawn at pre-dose, 0.25, 0.5, 0.75, 1, 2, 4, and 6 hours post-dose and subsequently on days 15, 29, 57 and 85 and when coming off study.
1827416|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a high total daily dose
1827417|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a mid level total daily dose
1827418|NCT00779181|Drug|ADX415|ADX415 taken three times a day to achieve a low total daily dose
1827419|NCT00779181|Drug|Placebo|Placebo taken three times a day
1827420|NCT00779194|Drug|Rapamycin|Rapamycin, is given to this group at a starting dose of 2 mg/day.
1827421|NCT00779207|Behavioral|weight loss and exercise|10% weight loss through diet and exercise plus multicomponent exercise training three times a week
1827422|NCT00779207|Behavioral|weight loss|10 percent weight loss through diet and behavioral modification
1827423|NCT00779220|Drug|placebo|Intravenous repeating dose
1827424|NCT00779220|Drug|methotrexate|Oral repeating dose
1827425|NCT00779220|Drug|ocrelizumabu 50mg|Intravenous repeating dose (50mg)
1827426|NCT00779220|Drug|ocrelizumabu 200mg|Intravenous repeating dose (200mg)
1827427|NCT00779220|Drug|ocrelizumab 500mg|Intravenous repeating dose (500mg)
1827428|NCT00779233|Drug|Zidovudine tablets 300 mg|
1827429|NCT00779246|Other|Nasal swabs for MRSA culture|Patients will have nasal swabs performed upon ICU admission, upon discharge, and every 2 weeks while they remain in the ICU.
1827506|NCT00779805|Drug|Pseudoephedrine hydrochloride 120 mg ER tablets|
1827507|NCT00779818|Device|Electrical acupuncture|Treatment by electrical acupuncture
1827430|NCT00779246|Drug|Chlorhexidine gluconate|CHG-impregnated cloths (2%) will be used to bathe patients at least daily during the duration of their medical ICU stay. Surveillance cultures will be obtained on admission, discharge and every 2 weeks while in the ICU, but results will be blinded until conclusion of the study.
1827431|NCT00779246|Other|Contact isolation|All patients will be placed in contact isolation until the results of their active surveillance cultures are negative; if positive, they will remain in isolation.
1827432|NCT00779259|Drug|Theophylline 300mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
1827433|NCT00779259|Drug|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
1827434|NCT00779259|Drug|Theophylline 300 mg|Single doses of theophylline 300 mg as an immediate-release oral solution 80mg/15ml concentration administered alone at 7 am on Day 1 after an overnight fast of at least 10 hours and along with quinine sulfate (2 x 324 mg capsules) at 7am on Day 12 after an overnight fast of at least 10 hours.
1827435|NCT00779259|Drug|Quinine 648 mg|648 mg quinine sulfate(2 x 324 mg capsules) initiated at 3pm on Day 5 and taken every 8 hours through Day 11 and co-administered with theophylline 300 mg as an immediate-release oral solution 80 mg/15 ml concentration at 7am on Day 12.
1827436|NCT00779285|Drug|Pegylated Liposomal Doxorubicin|Pegylated Liposomal Doxorubicin (Caelyx) IV, 50 mg/m2 once every 4 weeks for 6 cycles or until disease progression, whichever is earlier. Patients still receiving clinical benefit after a total of 6 cycles of Caelyx, may continue therapy at the discretion of the investigator.
1827437|NCT00779311|Drug|sorafenib|Sorafenib will be administered daily starting day 1 at 200mg QOD at Dose Level 1; 200mg/day at Dose Level 2; 200mg BID (5 days on/ 2 days off) at Dose Level 3; 200mg BID at Dose Level 4; and 400mg BID at Dose Level 5.
1827438|NCT00779311|Drug|bevacizumab|Bevacizumab will be administered as 5mg/kg IV on Day 1 of each treatment cycle.
1827439|NCT00779311|Drug|mFOLFOX6 regimen|The mFOLFOX6 regimen will be administered on Day 1 of each treatment cycle. This regimen consists of oxaliplatin 85 mg/m2 IV given over 2 hours, leucovorin 400 mg/m2 IV given over 2 hours, and fluorouracil 400 mg/m2 IV bolus, followed by fluorouracil 1200 mg/m2 per day for 2 days continuous infusion.
1827442|NCT00779337|Biological|Autologous AdE1- Latent Membrane Protein CTLs|Total dose 20-800 million CTL given in 4 equal doses (5-200 million CTL) given intravenously, at weekly intervals for the first cohort of 10 patients and twice a week for the second cohort of 10 patients.
1827443|NCT00779350|Drug|sertraline 100 mg tablets|
1827444|NCT00779363|Device|rechargeable TANTALUS II|Subjects will undergo an approximately two week baseline screening process. Eligible subjects will undergo device implantation. This will be followed by therapy initiation approximately one week after implantation. The device will then be activated to automatically deliver gastric contractility modulating (GCM) for 12 weeks of therapy. Stimulation will continue in for a safety monitoring period of 18 months following the therapy period.
1827445|NCT00779376|Drug|Zidovudine 300mg tablets|
1827446|NCT00779389|Drug|Erlotinib|Erlotinib 150mg will be taken once a day for 14-21days.
1827447|NCT00779389|Drug|Dasatinib + Placebo|Dasatinib (100 mg) once a day for 14-21 days.
1827448|NCT00779389|Drug|Erlotinib plus Dasatinib|Erlotinib (150 mg PO qD) plus Dasatinib (100 mg PO qD) 14-21 days
1827449|NCT00779389|Drug|Placebo|Placebo for 14-21 days.
1827450|NCT00779389|Drug|Erlotinib|Erlotinib 150 mg for 14-21 days.
1827453|NCT00779428|Drug|Tanespimycin|"Solution, IV
This is a one arm study with the dose, frequency, and duration assigned as per previous protocol (KOS-953, 17-AAG)"
1827454|NCT00779441|Drug|Zolpidem 10mg tablets|
1827455|NCT00779454|Drug|Gemcitabine, Oxaliplatin, Capecitabine,|Gemcitabin: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7
1827456|NCT00779454|Drug|Panitumumab, Gemcitabine, Oxaliplatin, Capecitabine|Gemcitabine: 1,000 mg/m2 day 1 Oxaliplatin: 60 mg/m2 day 1 Capecitabine: 1,000 mg/m2 x 2 daily days 1-7 Panitumumab: 6 mg/kg day 1
1827457|NCT00779467|Drug|Neostigmine|utilizing 3 different dosages of neostigmine and comparing it to the standard of fentanyl. Infusion runs via PCA throughout labor analgesia.
1827458|NCT00779467|Drug|Bupivacaine|
1827459|NCT00779467|Drug|fentanyl|fentanyl 2 mcg/ml
1827460|NCT00779480|Drug|KW-2449|KW-2449 50 mg capsules administered 3 or 4 times per day for 21-day cycles up to 6 cycles
1827461|NCT00779493|Dietary Supplement|curcumin|curcumin 900mg twice daily by mouth
1827462|NCT00779493|Dietary Supplement|placebo|placebo capsule to simulate 900mg curcumin capsule
1827463|NCT00779506|Drug|Quetiapine Fumarate XR|oral, once daily, flexible dose
1827464|NCT00779519|Drug|TTP435|
1827465|NCT00779519|Drug|Placebo|
1827466|NCT00779532|Drug|Moxifloxacin|Capsules containing 400 mg moxifloxacin, on Day 14 only
1827467|NCT00779532|Drug|NOMAC-E2 (Org 10486-0 + Org 2317)|Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.
1827468|NCT00779532|Drug|Moxifloxacin placebo|Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only
1827469|NCT00779532|Drug|NOMAC-E2 placebo|Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
1827470|NCT00779545|Drug|Placebo|One, two, or four sprays of placebo are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks.
1827471|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils in the morning, and one spray of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 100 mcg.
1827508|NCT00779818|Device|Laser|Treatment by laser
1827509|NCT00779831|Drug|120 mg Pseudoephedrine hydrochloride extended release tablets|
1827472|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and two sprays of placebo to the left and right at night for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
1827473|NCT00779545|Drug|Mometasone furoate|Four sprays of mometasone furoate 50 mcg are administered to the left and right nostrils in the morning, and four sprays of placebo to the left and right nostrils at night for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
1827474|NCT00779545|Drug|Mometasone furoate|One spray of mometasone furoate 50 mcg is administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 200 mcg.
1827475|NCT00779545|Drug|Mometasone furoate|Two sprays of mometasone furoate 50 mcg are administered to the left and right nostrils twice a day (in the morning and at night) for 2 weeks. The daily dose of mometasone furoate is 400 mcg.
1827476|NCT00779558|Drug|Heparin sulfate infusion at 10 units/kg/hour|Infusion of heparin to prevent central line thrombosis in infants after cardiac surgery
1827477|NCT00779558|Drug|Placebo infusion|Infusion of normal saline
1827478|NCT00779571|Behavioral|Crispbread|8 week low calorie diet
1827479|NCT00779584|Drug|MK-8776|IV infusion
1827480|NCT00779584|Drug|Gemcitabine|IV infusion
1827481|NCT00779597|Behavioral|SCION (Self care improvement through oncology nursing)-PAIN program|The intervention will be conducted by specially trained oncology nurses and will include the components of knowledge, skills training, and coaching to improve self care regarding pain management beginning with admission followed by booster session every third day and one follow up telephone counseling within 3 to 4 days after discharge from hospital.
1827482|NCT00779610|Procedure|Vibration with flexion|Vibration with forearm flexion (active contraction)
1827483|NCT00779610|Procedure|Vibration without flexion|Vibration without forearm flexion (passive)
1827484|NCT00779636|Drug|Desloratadine|Desloratadine 10 mg daily x 28 days
1827485|NCT00779636|Drug|Placebo|Placebo daily x 28 days
1827486|NCT00779649|Other|MoviPrep Kit|"Diet: At noon the day prior to the procedure, patients will begin a clear liquid diet. Patient will discontinue any ingestion by mouth 4 hours prior to the procedure.
Purgative: Starting at 6pm the evening before the procedure, patient will ingest 250 ml of MoviPrep® at 15 minute intervals until 1 liter is consumed. Following this, an additional 500 ml (approximately 16 oz) of clear liquids will be consumed. The next day, 6 hours before the procedure, the patient will repeat ingestion of one liter MoviPrep® over the course of an hour, again ingesting 250 ml at 15 minute intervals. Patient will then ingest an additional 500 ml (approximately 16 oz) of clear liquid following the MoviPrep® consumption."
1827487|NCT00779649|Other|HalfLytely and Bisacodyl Tablets Bowel Prep Kit|"Diet: Patients will refrain from solid food and have only clear liquids starting 8 am on the day before colonoscopy. In addition, patients will consume nothing by mouth, except clear liquids, from the time the preparation is completed until midnight. Patients will be instructed not to eat or drink anything from midnight until after the colonoscopy is completed.
Purgative: At noon on the day prior to colonoscopy patients will swallow (not chew or crush) 2 bisacodyl delayed release tablets (10 mg). Once the initial bowel movement has occurred (1 - 6 hours after taking the bisacodyl tablets), or if there has been no bowel movement, not more than 6 hours after ingestion of the bisacodyl tablets patients will then drink the reconstituted HalfLytely® solution over 1 hour and 20 minutes. Patients will drink one 8-oz glass every 10 minutes until the two liters is completed"
1827488|NCT00779675|Biological|Infliximab|Infliximab administered intravenously at a dose of 5 mg/kg body weight at Weeks 0, 2, 6 and then every 8 weeks (Weeks 14, 22, 30, 38, and 46 for the Treatment Period and Week 54, 62, 70, 78, 86, and 94 for the Extended Treatment Period) as per the product monograph (PM; Canada), summary of product characteristics (SPC; European Union), or local labeling (for all other countries).
1827489|NCT00779688|Device|Probe-based confocal laser endomicroscopy|ERCP with or without cholangiopancreatoscopy will be performed by the endoscopist as clinically indicated. If findings at ERCP and/or prior imaging studies and/or clinical assessment suggest possible malignancy and/or an indeterminate biliary or pancreatic pathology Cellvizio probe-based endomicroscopy will be performed during ERCP.
1827490|NCT00779701|Drug|Insulin|Insulin infusion titrated to patients blood glucose to maintain blood glucose between 80-110mg/dL
1827491|NCT00779714|Drug|DTIC (dacarbazine)|1000 mg/m2, d1 every 21 days
1827492|NCT00779714|Drug|paclitaxel + cisplatin|paclitaxel 200 mg/m2 cisplatin 50 mg/m2 d1 every 21 days
1827493|NCT00779714|Drug|treosulfan + cytarabine|treosulfan 2500 mg/m2, d2 cytarabine 100 mg/m2, d1-3 every 21 days
1827494|NCT00779727|Procedure|Placement of drainages|
1827495|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (100 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
1827496|NCT00779740|Drug|mometasone furoate|The dose will be 50 mcg as MF in one spray (50 µL) per nostril two times a day (morning and night) for 2 weeks. The daily dose of MF will be 200 mcg.
1827497|NCT00779753|Dietary Supplement|Amino Acid Solution with different amount of Lysine|The infants will be placed on a standard Primene solution for the first 24 hours of the study to obtain baseline values. During the second 24 hours they will receive an amino acid solution that has a different amount of lysine currently found in Primene, all lipid, CHO, minerals, vitamins and trace elements will remain unchanged. The Parenteral lysine will be studied at the following intake levels: 100, 110, 120, 130, 135, 140, 145, 150 , 155, 165, 170, 180, 200, 230, 245, 260mg/kg/d. The minimum energy intake will be 85-90 kcal/kg/day.
1827498|NCT00779766|Biological|HPV GSK 580299 vaccine|Subjects were planned to receive three doses of the study vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
1827499|NCT00779766|Biological|Placebo control|Subjects were planned to receive three doses of the placebo control administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
1827500|NCT00779779|Biological|Rotarix™|Two oral doses, with at least 4 weeks interval in-between
1827501|NCT00779792|Drug|clobetasol|0.5 mg Clobetasol propionate (0.5 mg/g) ointment applied twice daily for 10 consecutive days
1827502|NCT00779792|Drug|triamcinolone acetonide|0.5 mg ointment twice daily for 10 consecutive days
1827503|NCT00779792|Drug|tacrolimus|0.5 mg tacrolimus ointment(0.1%) twice daily for 10 consecutive days
1827504|NCT00779792|Drug|glycerol|0.5 mg glycerol ointment (20%) twice daily for 10 consecutive days
1827510|NCT00779844|Procedure|bariatric coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a close-loop system with the Bispectral Index as the single input for the controller
1827511|NCT00779844|Procedure|supra-umbilical coelioscopic surgical procedure|total intra-venous anesthesia (propofol and remifentanil) being delivered using a closed-loop system with the Bispectral Index as the single input for the controller
1827512|NCT00779857|Device|AtriCure LAA Exclusion System|Exclusion of the left atrial appendage using the AtriCure LAA Exclusion System
1827513|NCT00779870|Other|bronchoscopy|bronchoscopy under local anaesthetic and sedation to obtain endobronchial biopsies
1827514|NCT00779883|Biological|ISF35|Subjects participating in this study will receive a single dose of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells.
1827515|NCT00779896|Drug|Tazarotene|Topical 0.1 cream - apply to lesions on alternate days and at 2 week interval increase to once-daily application, if tolerated.
1827516|NCT00779909|Drug|vitamin D3|oral supplementation once per day for 12 weeks of different daily doses: 500 IU, 2500 IU, or 5000 IU after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
1827517|NCT00779909|Other|Placebo|oral supplementation once per day for 12 weeks of a sugar pill after abstaining from oral hygiene measures (brushing, flossing or antiseptic mouth rinses) for a period of 4 weeks to allow accumulation of plaque and development of experimental gingivitis.
1827518|NCT00779922|Drug|lenalidomide|
1827519|NCT00779935|Biological|Remicade|Remicade will be given at Weeks 0, 2, and 6 and then every 8 weeks up to Week 54.
1827520|NCT00779961|Procedure|Palatoplasty|Routine palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
1827521|NCT00779961|Procedure|Palatoplasty|Palatoplasty will be performed under the supervision of one of five surgeons within the Division of Plastic Surgery at Sick Kids
1827522|NCT00779974|Other|Evaluation|For this research study each enrolled subject will have a clinical exam, including range of motion (ROM), and strength testing. The lift off and belly compression tests will be performed. An ultrasound of the shoulder will be done to determine the integrity of the subscapularis tendon. An EMG will be done to determine functionality of the subscapularis.
1827523|NCT00779987|Drug|Autologous serum - Systane|20% autologous serum solution used four times a day for two weeks. Then 0.9% sodium chloride four times a day for one week. Finally, Systane (r) four times a day for two weeks.
1827524|NCT00779987|Drug|Systane - Autologous serum|Systane (r) four times a day for two weeks. Then 0.9% sodium chloride used four times a day for one weeks. Finally, 20% autologous serum solution four times a day for two week.
1827525|NCT00780000|Drug|Alvespimycin|Solution, IV, Alvespimycin 80 mg/m2, Weekly one hour infusion Days 1, 8, and 15, every 4 weeks thereafter until disease progression or DLT
1827526|NCT00780013|Drug|metformin hydrochloride liquid 500 mg per 5 mL|
1827527|NCT00780026|Procedure|insulin|bolus or infusion 80 to 110 mg/dl
1827528|NCT00780039|Drug|Pegylated Liposomal Doxorubicin|Subjects will receive Caleyx 30 mg/m2 intravenously on Day 1 of each 4-week cycle, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
1827529|NCT00780039|Drug|Carboplatin|Subjects will receive carboplatin dosed to target AUC of 5 mg/mL.min, intravenously, on Day 1 of each 4-week cycle, after the Caelyx infusion, during 6 cycles. Patients still achieving clinical benefit after a total of 6 cycles may continue therapy.
1827530|NCT00780052|Drug|c-myb AS ODN|Subjects will be admitted to the hospital to receive c-myb AS ODN as a 24-hour continuous intravenous infusion over 7 days. Dose level is increased with each new subject to determine if there is a MTD.
1827531|NCT00780078|Procedure|extubation|extubation failure in patients intubated orotracheally
1827532|NCT00780091|Other|classical monitoring strategy|intensive on-site monitoring, consistently with the pharmaceutical industry practices
1827533|NCT00780091|Other|optimized monitoring strategy|optimized on-site monitoring, depending on patient's risk
1827534|NCT00780104|Drug|Rapamycin, Mitoxantrone, Etoposide, Cytarabine|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
1827535|NCT00780104|Drug|Rapamycin + MEC|Rapamycin loading dose of 12 mg followed by a single daily dose for 8 days of 4 mg/day + MEC (Mitoxantrone 8 mg/m2/day IV, Etoposide 100 mg/m2/day IV and Cytarabine 1000 mg/m2 IV every 24 hours for 5 days. Starts after 4th dose of sirolimus.
1827536|NCT00780130|Other|No Intervention|male & female college students ages 20 to 50, asymptomatic normals
1827537|NCT00780143|Drug|Plitidepsin plus Cytarabine|Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
1827538|NCT00780169|Drug|sorafenib + FOLFIRI|"escalating doses of sorafenib and irinotecan
sorafenib starting dose 400 mg/day
irinotecan starting dose 80 mg/m2 on day 1"
1827539|NCT00780182|Drug|CMX001|CMX001 tablet fasted, CMX001 tablet fed, CMX001 solution fasted
1827540|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic euglycemic clamp (90 mg/dl)
1827541|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (70 mg/dl)
1827542|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (60 mg/dl)
1827543|NCT00780195|Procedure|glucose clamp|2 hour hyperinsulinemic hypoglycemic clamp (50 mg/dl)
1827544|NCT00780208|Drug|Daytrana (methylphenidate transdermal system)|Subjects will be provided with a 7-day supply of medication at each study visit. The dose will be flexible and will be titrated based on effect and tolerability. Unless a subject is experiencing side effects, the dose will be increased if a 25% reduction in ADHD symptoms as determined by the WRAADDS is not obtained. A proposed dosing schedule is as follows: Week 1: 12.5 cm2, Week 2: 18.75 cm2, Week 3: 25 cm2, Week 4: 37.5 cm2. The dose may be decreased as needed for tolerability.
1827545|NCT00780234|Procedure|fluorescence bronchoscopy|examination of the central airways with a bronchoscope. Both white light and fluorescent light will be used.
1827546|NCT00780234|Procedure|quantitative high resolution CT scan|High resolution CT scan of the chest
1827604|NCT00787891|Drug|rabeprazole|1.0 mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
1827547|NCT00780234|Drug|PIOGLITAZONE VS. PLACEBO 30 mg|"Patients will be randomized to receive either pioglitazone or placebo. Pioglitazone hydrochloride, a thiazolidinedione antidiabetic agent and a potent peroxisome proliferator-
activated receptor-gamma agonist. It is FDA approved for the treatment of Type II diabetes. It has been previously administered to non-diabetic subjects. The most common side effect of pioglitazone is fluid retention and modest weight gain. There is a potential risk that pioglitazone may cause an elevation in liver enzymes and more serious hepatotoxicity (rare). There is risk of edema and weight gain associated with pioglitazone therapy. 5% experienced peripheral edema in clinical trials. fluid retention may result in new onset heart failure or exacerbation of existing heart failure. Small risk of hypoglycemia, anemia, myalgia, bone fracture, headache, and macular retinal edema exists. There is insufficient information to confirm its safety in Pregnancy/Breastfeeding. Bladder cancer is more serious but rare."
1827548|NCT00780260|Behavioral|strengths-based case management|5 session individual strengths-based case management; peer-involvement v. no peer involvement
1827549|NCT00780273|Device|Ankylos Implants|ANKYLOS Implant System vs Certain PREVAIL Implant
1827550|NCT00780273|Device|Biomet 3i Prevail Implants|
1827551|NCT00780299|Device|hemodialysis with high permeability (HDHP)|HDHP (hemodialysis with high permeability) is a specific plasma epuration of inflammatory mediators
1827552|NCT00780299|Procedure|CVVH|hemofiltration intermittent dialysis
1827553|NCT00780312|Other|physiotherapy|50 patients in this group get the existing hospital treatment: A 10 minute instruction in mouth opening exercises by a nurse. Furthermore they receive in all 6-7 sessions of physiotherapy treatment for a 5-6 weeks period with sessions of approximately 45 minutes. 2 months after having completed radiotherapy treatment they receive a final physiotherapy treatment. The treatment consists of instruction in active and passive exercises for mouth opening, stretching exercises for the neck and shoulder region, tongue exercises, mimic exercises, self administered lymph drainage and softening of fibrotic tissue.
1827554|NCT00780325|Drug|CG100649 (2 mg)|CG100649 capsules: 2 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
1827555|NCT00780325|Drug|Celecoxib|Celecoxib (Celebrex®) capsules: 200 mg; single oral administration (Part 1 and 3)
1827556|NCT00780325|Drug|Placebo capsules|Placebo capsules: 198 mg silicified microcrystalline cellulose + 2 mg talc, multiple oral administrations (Part 1 and 3)
1827557|NCT00780325|Drug|Naproxen|Naproxen (Naprosyn®) tablets: 500 mg, single oral administration (Part 3)
1827558|NCT00780325|Drug|Acetazolamide|Acetazolamide (generic, immediate release) tablets: 250 mg, single oral administration (Part 3)
1827559|NCT00780325|Drug|CG100649 (8 mg)|CG100649 capsules: 8 mg, single oral administration (Part 1); CG100649 capsules: dose to be determined, single oral administration (the single CG100649 dose level used in Part 3 will be determined by part 1 and 2).
1827560|NCT00780338|Other|Assets Getting To Outcomes|Face to Face Training Assets Getting To Outcomes Manuals Technical Assistance
1827561|NCT00780351|Device|sustained low efficiency daily hemodiafiltration (SLEDD-f)|vancomycin 15mg/kg IV infusion on day 1 from 6PM to 8PM. Start SLEDD-f on day 2 from 9AM to 5PM.
1827562|NCT00780377|Drug|Bradykinin|Bradykinin 0, 0.2, 0.6, 2.0 ug/min intracoronary, for 5 minutes at each dose.
1827563|NCT00780390|Device|Spinal Cord Stimulator|SCS before and after implant
1827564|NCT00780390|Other|CRPS patients under treatment other than spinal cord stimulator|RSD CRPS Not currently using a spinal cord stimulator
1827565|NCT00780403|Drug|Desloratadine|desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day
1827566|NCT00780403|Drug|Zyrtec® (cetirizine)|Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
1827567|NCT00780416|Drug|MP-424|750 mg every 8 hours for 12 weeks
1827568|NCT00780416|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 24 weeks
1827569|NCT00780416|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 24 weeks
1827570|NCT00780416|Drug|Ribavirin|600 - 1000 mg/day based on body weight for 48 weeks
1827571|NCT00780416|Drug|Peginterferon Alfa-2b|1.5 mcg/kg/week for 48 weeks
1827572|NCT00780442|Drug|d-cycloserine|50 mg DCS or placebo
1827573|NCT00780455|Drug|Interferon beta-1b, FRP within 15 days after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program starting within 6 weeks after randomization
1827574|NCT00780455|Drug|Interferon beta-1b, FRP about 6 weeks after randomization|Treatment by Interferon beta-1b (Betaseron, BAY86-5046) for 3 month and beginning of the Functional Rehabilitation Program about 6 weeks after randomization.
1827575|NCT00780468|Behavioral|Existing diet plan|
1827576|NCT00780468|Behavioral|New diet plan|
1827577|NCT00780481|Drug|Bradykinin|Intrabrachial - 0, 10, 20, 40 ng/100cc/min over 5 minutes at each dose.
1827578|NCT00780494|Drug|bevacizumab|IV 15 mg/kg
1827579|NCT00780494|Drug|carboplatin|AUC 6, Intravenously Day 1 every 21 days
1827580|NCT00780494|Drug|capecitabine|850mg/m2, Orally twice daily days 1-14 every 21 days.
1827581|NCT00787761|Biological|anti-thymocyte globulin|"Anti-Thymocyte Globulin (ATG) is commercially available. The 1st vial contains 25 mg ATG, and the 2nd vial contains > 5 mL SWFI diluent. Ampuls must be refrigerated (2º C - 8º C). Do not freeze.
Reconstitute 25 mg vial with diluent provided by manufacturer. Roll vial gently to dissolve powder. Use contents of vial within 4 hours. Dilute dosage to a final concentration of 0.5 mg/mL in 0.9% sodium chloride injection or 5% dextrose injection. Gently invert admixture 1-2 times to mix. Use admixture solution immediately.
Infuse the 1st dose over at least 6 hours, and subsequent doses over at least 4 hours. Infuse through a 0.22 micron in-line filter. Premeds include acetaminophen 650 mg PO, diphenhydramine 25-50 mg PO/IV, and methyprednisolone 1mg/kg at the initiation and half-way through ATG administration."
1827599|NCT00787852|Drug|Group 2: Radiation, Paclitaxel, Carbo, Dasatinib days 1-38|"Group 2: Neoadjuvant Therapy for Potentially Resectable Stage III NSCLC SCHEMA DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-38 Paclitaxel 1 8 15 22 29 36 Surgery Carboplatin 1 8 15 22 29 36 Dasatinib & Maintenance Dasatinib RT: External radiotherapy 50.4 Gy, 1.8 Gy/fx for 28 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36
Dasatinib is to be taken 1x daily
50 mg daily 100 mg daily
70 mg daily 100 mg daily
100 mg daily 100 mg daily Maintenance x 2 years*"
1827582|NCT00787761|Drug|busulfan|"Commercially available in 60 mg/10 mL ampuls.
Dilute busulfan injection in 0.9% sodium chloride injection or dextrose 5% in water. The dilution volume should be 10 times the volume of busulfan injection, ensuring that the final concentration of busulfan is ≥ 0.5 mg/mL.
Store unopened ampuls at 2º C to 8º C. The diluted solution is stable for up to 8 hours at room temperature (25º C) but the infusion must also be completed within that 8-hour time frame. Dilution of busulfan injection in 0.9% sodium chloride is stable for up to 12 hours under refrigeration (2º C to 8º C) but the infusion must also be completed within that 12-hour time frame.
IV Bu should be administered via a central venous catheter as a 2-hour infusion every 6 hours for 2 consecutive days for a total of 8 doses."
1827583|NCT00787761|Drug|cyclophosphamide|"Cyclophosphamide is commercially available. Cyclophosphamide for injection is available in 2000 mg vials which are reconstituted with 100 ml sterile water for injection.
The concentration of the reconstituted product is 20 mg/ml. The calculated dose will be diluted further in 250-500 ml of Dextrose 5% in water.
Reconstituted solutions of lyophilized cyclophosphamide are chemically and physically stable for 24 hours at room temperature or for 6 days in the refrigerator. Specific temperatures are not provided by the manufacturer. Reconstitution of cyclophosphamide with bacteriostatic water containing benzyl alcohol preservative may result in decomposition.
Each dose will be infused over 1-2 hr (depending on the total volume)."
1827584|NCT00787761|Drug|fludarabine phosphate|"Fludarabine is commercially available as a white, lyophilized powder. Each vial contains 50 mg of fludarabine, 50 mg of mannitol and sodium hydroxide to adjust pH.
Intact vials should be stored under refrigeration. Reconstituted vials are stable for 16 days and solutions diluted in D5W or NS are stable for 48 hours at room temperature or under refrigeration.
Fludarabine should be reconstituted with 2 mL of Sterile Water for Injection, USP. Each mL of the resulting solution will contain 25 mg of fludarabine, 25 mg of mannitol, and sodium hydroxide to adjust the pH to 7-8.5. The product should be further diluted for intravenous administration in 5% Dextrose for Injection, USP or in 0.9% Sodium Chloride, USP.
Fludarabine will be administered as an IV infusion over 30 minutes."
1827585|NCT00787761|Drug|methotrexate|"Commercially available for injection in 2 mL (2.5 mg/mL), 2 mL, 4 mL, 8 mL, 10 mL (25 mg/mL) vials, or 20 mg, 25 mg, 50 mg, or 100 mg vials for reconstitution.
Vials requiring reconstitution should be reconstituted to a concentration of 25 mg/mL.
Intact vials should be stored at room temperature and protected from light. Once opened, solutions containing preservatives are stable for 4 weeks at room temperature and up to 3 months refrigerated.
Administer via slow IV push."
1827586|NCT00787761|Drug|tacrolimus|"Tacrolimus is commercially available as an injection (5 mg/mL; 1 mL ampuls) and as oral capsules (1 mg and 5 mg).
Tacrolimus injection must be diluted prior to IV infusion with 0.9% sodium chloride or 5% dextrose injection to a concentration of 4-20 μg/mL. Solutions should be prepared in non-PVC plastic or glass. Tacrolimus injection and diluted solutions of the drug should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit.
Oral therapy should be started as possible as per protocol and 8 to 12 hours after stopping intravenous therapy. Oral doses will be administered twice a day.
Store tacrolimus capsules and injection at controlled room temperature, 15-30º C (59-86º F)."
1827587|NCT00787761|Procedure|nonmyeloablative allogeneic HSCT|As demonstrated by groups in Houston, Jerusalem & Seattle, RICT has been used to treat hematologic & solid malignancies with related & unrelated donors. Although adequate comparisons of RICT versus ablative alloHCT remain to be reported, the studies of RICT so far suggest that TRM is generally less than would be expected for similar patients undergoing ablative alloHCT; incidence of acute & chronic GVHD is similar or less than ablative alloHCT; autologous hematopoietic recovery is more common than seen following ablative alloHCT if graft failure occurs; powerful GVT effects can be seen but are dependent on high levels of donor T-cell chimerism and RICT are less effective than ablative alloHCT in controlling aggressive malignancies
1827588|NCT00787774|Drug|resume raltegravir|resume raltegravir after 16 weeks of stopping
1827589|NCT00787787|Drug|sunitinib malate|Given PO
1827590|NCT00787787|Drug|capecitabine|Given PO
1827591|NCT00787800|Device|Dual Chamber ICD|Dual Chamber ICD: Atrial therapies and minimized ventricular pacing will be programmed on along with VT/VF detection and therapies with detection enhancements; remote monitoring set to alert for sustained atrial fibrillation Dual Chamber ICD Atrial prevention and termination therapies, Managed Ventricular Pacing (MVP)along with VT/VF detection and therapies for dual chamber device.
1827592|NCT00787800|Device|Single Chamber ICD|"Single Chamber: Optimally programmed VT/VF detection and therapies will be programmed on including use of detection enhancements.
VT/VF detection and therapies with discrimination criteria for single chamber device."
1827593|NCT00787813|Drug|N-Acetyl Cysteine|oral daily dose of 0.6 g of N-acetyl cysteine in effervescent form
1827594|NCT00787813|Drug|Placebo|
1992309|NCT03322358|Device|Home sleep aids|After a baseline period, participants in this condition will be provided with a set of home sleep aids (e.g. earplugs, eyeshades, a basic mattress, sheets, and pillow, etc) to take home with them if they wish. These sleep aids and their proper use are described to the participants and they are encouraged to use them if they find them helpful.
1827596|NCT00787839|Other|Glucose challenge test|At a first outpatient visit, at different times of the day and without a prior fast, subjects will have a 50 gram glucose drink followed by measurement of plasma and capillary glucose along with A1c one hour later. They will also fill out questionnaires. At a second outpatient visit, in the morning after fasting overnight, they will have a 75 gram oral glucose tolerance test.
1827597|NCT00787839|Other|Glucose tolerance test|Subjects found to have diabetes or prediabetes on the initial glucose tolerance test may be requested to have a repeat glucose tolerance test and A1c.
1827598|NCT00787852|Drug|Group 1: Radiation, Paclitaxel,Carbo, Dasatinib days 1-47|"Locally Advanced Stage III NSCLC DAY Radiation 1-5 8-12 15-19 22-26 29-33 36-40 43-47 Paclitaxel 1 8 15 22 29 36 43 Carboplatin 1 8 15 22 29 36 43 Dasatinib & Maintenance Dasatinib RT: External radiotherapy, 64.8 Gy, for 35 fx Paclitaxel: 50 mg/m2/week over 1 hour IV infusion days 1, 8, 15, 22, 29, 36, 43 Carboplatin: AUC = 2 IV infusion days 1, 8, 15, 22, 29, 36, 43
Dasatinib is to be taken 1x daily
50 mg daily 100 mg daily
70 mg daily 100 mg daily
100 mg daily 100 mg daily
Maintenance x 2 years*"
1827600|NCT00787878|Drug|somatropin|SGA previously treated with Norditropin®
1827601|NCT00787878|Drug|No treatment given|Untreated SGA
1827602|NCT00787878|Drug|No treatment given|AGA (Average gestational age)
1827603|NCT00787891|Drug|rabeprazole|0.5mg/kg once daily for 12 weeks plus option for F/u another 24 weeks
1827605|NCT00787917|Drug|Omalizumab|Omalizumab subcutaneous injections of 600 mg daily.
1827606|NCT00787917|Drug|Placebo|Placebo subcutaneous injections blinded to match experimental arm dosing regimen.
1827607|NCT00787917|Drug|Itraconazole|Itraconazole twice daily with a maximum daily dose of 400 mg.
1827608|NCT00787930|Drug|Valproic Acid|Tablets, 250mg-3000mg
1827609|NCT00787943|Drug|Topical benzoyl peroxide 10.0% cream - Formulation 1|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
1827610|NCT00787943|Drug|Topical benzoyl peroxide 10.0% cream - Formulation 2|Formulation 1 will be applied to the randomly-assigned single (left or right) side of the face twice daily.
1827611|NCT00787956|Behavioral|Internet Chronic Disease Self-Management Program (ICDSMP)|
1827612|NCT00787969|Biological|rituximab|Give IV
1827613|NCT00787969|Drug|cladribine|Give IV
1827614|NCT00787969|Drug|temsirolimus|Give IV
1827615|NCT00787969|Biological|Filgrastim|Give SC
1827616|NCT00787969|Biological|Pegfilgrastim|
1827617|NCT00787982|Device|MRI-Guided Laser Induced Thermal Therapy|LITT uses laser light to heat and destroy the affected tissue; this is sometimes referred to as tissue ablation. In LITT, small fiber-optic applicators are placed directly into the tumor and heating is performed from the inside out, which may lead to the destruction of the tumor
1827618|NCT00788008|Drug|inhalation anesthesia with isoflurane vs. TIVA with propofol|variable depending upon patient
1827619|NCT00788034|Drug|Lu AA21004|5 or 10 mg/day
1827620|NCT00788034|Drug|Placebo|Once daily
1827621|NCT00788047|Drug|Dextromethorphan|Dextromethorphan HCl 30 syrup single dose
1827622|NCT00788047|Drug|Dimebon + Dextromethorphan|Dimebon 20 mg tablets given three times daily for 14 days plus Dextromethorphan HCl 30 syrup single dose administered on Day 12
1827623|NCT00788060|Drug|Everolimus (RAD001)|5mg per day, continuously
1827624|NCT00788060|Drug|Sunitinib (Sutent)|37.5 mg per day, 14 days on, 7 day break
1827625|NCT00788073|Drug|STX209|Variable dose from 1 mg bid to 10 mg tid, Capsule, Oral, 4 weeks
1827626|NCT00788073|Drug|Placebo|variable dose (same flexible dose titration protocol), bid to tid, capsule, Oral, 4 weeks
1827627|NCT00788099|Drug|Plitidepsin and Sorafenib|Patients will receive i.v. plitidepsin over 1h on days 1, 8 and 15 every 4 weeks (d1, 8, 15 q4wk) and continuous oral sorafenib twice daily (bid) (a cycle is defined as an interval of 4 weeks).
1827628|NCT00788099|Drug|Gemcitabine and Plitidepsin|Patients will receive i.v. gemcitabine over 30 minutes followed 1 hour later by plitidepsin over 1 hour on d1, 8, 15 q4wk (a cycle is defined as an interval of 4 weeks).
1827629|NCT00791453|Behavioral|Education|Patients will receive literacy appropriate health information.
1827630|NCT00791466|Dietary Supplement|Placebo|Daily placebo supplementation from enrolment <14 wk of gestation until delivery
1827631|NCT00791466|Dietary Supplement|Iodine|Daily supplementation with 200 µg iodine from enrolment <14 wk of gestation until delivery
1827632|NCT00791479|Drug|LY2189265 and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
1827633|NCT00791479|Drug|Placebo solution and Lifestyle Measures|Subcutaneous injection once-weekly for up to 12 weeks
1827634|NCT00791492|Drug|Fx-1006A|Fx-1006A 20mg soft gelatin capsule administered orally once daily (at the same time each day) for 12 months.
1827635|NCT00791505|Drug|ciprofloxacin|1500 mg a day for 10 days
1827636|NCT00791505|Drug|trimethoprim-sulfamethoxazole|2000 mg a day for 10 days
1827637|NCT00791518|Drug|No intervention|No intervention
1827638|NCT00791531|Drug|Methotrexate|Oral methotrexate 5mg once daily for 5 consecutive days
1827639|NCT00791544|Drug|AVE1642|intravenous infusion
1827640|NCT00791544|Drug|sorafenib|oral intake
1827641|NCT00791544|Drug|erlotinib|oral intake
1827642|NCT00791557|Drug|Infliximab|IV drug given at weeks 1,2,14,22
1827643|NCT00791570|Biological|VEGFR1 and VEGFR2|Biological: VEGFR1 and VEGFR2 Patients will be vaccinated once a week for 12 weeks. On each vaccination day, VEGFR1 peptide (1mg) and VEGFR2 peptide (1mg) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
1827644|NCT00791596|Other|Ergonomic Intervention|The intervention used in this investigation was an ergonomic adjustment of the VDT workstation design
1827645|NCT00791622|Drug|Paliperidone ER|
1827646|NCT00791635|Behavioral|Questionnaires|11 Questionnaires
1827647|NCT00791648|Drug|atorvastatin|"Aim1 intervention: atorvastatin 80mg 1 day prior to open heart surgery and 40mg daily thereafter until hospital discharge.
Aim2 intervention: atorvastatin 80mg the day of cardiac surgery and 40mg on postop day 1."
1827648|NCT00791648|Drug|placebo|"Aim 1 control: placebo one day prior to cardiac surgery and daily thereafter until hospital discharge.
Aim 2 control: placebo the day of cardiac surgery and postop day 1."
1827649|NCT00791661|Drug|MK-1006|MK-1006 capsules in single oral doses beginning at 15 mg and rising to 45 mg in Panel A, beginning at 60 mg and rising to 80 mg and 60 mg fed state in Panel B, or beginning at 100 mg and rising to 170 mg in Panel C.
1827650|NCT00791661|Drug|Placebo|Matching placebo to MK-1006 in a single oral dose
1827651|NCT00791700|Drug|Maraviroc|Maraviroc will be administered twice daily either as a liquid or tablet formulation, depending on the age of the subject. The dosage administered will be dependent upon the subject's body surface area as well as the background therapy.
1827652|NCT00791713|Drug|Paliperidone ER|
1827653|NCT00791739|Drug|trazodone, pregabalin|"phase I (from baseline to week 12): trazodone, in a starting dose of 50 mg at bedtime subsequently adjusted according to drug's efficacy and tolerability
phase II (from week 12 to week 24): addition of pregabalin in a starting dose of 75 mg/day subsequently adjusted according to drug's efficacy and tolerability"
1827654|NCT00791752|Drug|AZD4017|ascending single doses (start dose 2 mg), oral suspension
1827655|NCT00791752|Drug|Placebo|Placebo
1827656|NCT00791765|Biological|Etanercept|Etanercept for subcutaneous injection.
1827657|NCT00791765|Biological|Placebo|Placebo for subcutaneous injection.
1827658|NCT00791778|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients in Sorafenib arm will receive 2 Sorafenib tablets (200 mg each) twice a day and in continuous administration.
1827659|NCT00791778|Drug|Placebo|Patients in Placebo arm will receive 2 matching placebo tablets twice a day and in continuous administration.
1827660|NCT00791791|Procedure|standardized pain stimulus|a tetanic stimulus (30s, 50 Hz, 60mA) applied as standardized pain stimulus
1827661|NCT00791804|Drug|AeroLEF|"Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)
for nebulized administration as required by the patient.
Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl."
1827662|NCT00791817|Drug|PG-760564|200 mg capsule, single dose,fasted when dosed, duration is 4 days
1827663|NCT00791817|Drug|PG-760564|200 mg capsule, single dose,high fat diet when dosed, duration is 4 days
1827664|NCT00791830|Drug|Irbesartan|Tablets, 300 mg * 1 daily, 1 year
1827665|NCT00791830|Drug|Placebo matching irbesartan 150 mg|Tablets, 300 mg * 1 daily, 1 year
1827666|NCT00791843|Drug|Growth hormone releasing hormone/ placebo|12 weeks of drug at max dose of 2mg/day administered in 4 pulses at 11pm, 1am, 3am, and 5am, followed by 6 weeks of washout period, then 12 weeks of placebo or vise versa- 12 weeks of placebo, 6 weeks washout, 12 weeks of drug.
1827667|NCT00791856|Drug|testosterone|28 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
1827668|NCT00791856|Drug|testosterone|14 cm2 testosterone patch, each patch is on for 4 days, 3 patches are used
1827669|NCT00791882|Behavioral|Social Skills Training|A program developed during 20 weeks according to adapted BELLACK 's manual (1997),including sessions in group one hour per week.
1827670|NCT00791895|Drug|biphasic insulin aspart 30|Treat-to-target dose titration scheme
1827671|NCT00791908|Procedure|Electrodessication|Treatment applied to a third of the torso at each study visit.
1827672|NCT00791908|Procedure|Pulsed dye laser (PDL)|Laser treatment applied to a third of the torso at each study visit.
1827673|NCT00791908|Procedure|potassium titanyl phosphate (KTP)|Laser treatment applied to a third of the torso at each study visit.
1827674|NCT00791921|Drug|CDP870|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2weeks until Week22 subcutaneously(SC)
1827675|NCT00791921|Drug|Placebo of CDP870|Placebo given every 2 weeks until Week22 (SC)
1827676|NCT00791934|Device|Stratus Microflow Ethmoid Spacer|The Spacer is inserted surgically into the ethmoid complex through the use of a sinus access system. Triamcinolone acetonide will be administered into the Spacer for this investigational study. The Spacer will be left in the ethmoid sinus for a period of 28 days. At the end of the implant period, the device is removed with standard instrumentation, during a follow-up office visit.
1827677|NCT00791947|Drug|CHOEP + G-CSF followed by BEAM|"CHOEP:
Cyclophosphamide: 750 mg/m2 i.v. day1 Hydroxydaunorubicin: 50 mg/m2 i.v. day1 Vincristine: 1.4 mg/m2 (max 2 mg) i.v. day 1 Etoposide: 100 mg/m2 i.v. day 1-3 Prednisone: 100 mg daily p.o. day 1-5
BEAM:
Carmustine: 300 mg/m2 i.v. day 1 Etoposide: 100 mg/m2 i.v. x2 daily day 2-5 Cytosine arabinoside: 200 mg/m2 i.v. x2 daily or 400 mg/m2 as continuous 24 hrs i.v. infusion, day 2-5 Melphalan: 140 mg/m2 i.v. day 6"
1827678|NCT00791960|Drug|Dimenhydrinate|single dose, 25mg, IV, diluted in 9.5mL normal saline.
1827679|NCT00791960|Other|Placebo|single dose, 10 mL normal saline, IV
1827680|NCT00791973|Drug|fluticasone furoate|2 puffs in each nostril once daily for 1 week
1827681|NCT00791973|Drug|Placebo|2 puffs in each nostril once daily for 1 week
1827682|NCT00791986|Device|ULB , LB|"ULB: The patients breath in slowly without resistance via the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks.
LB : The patients breath in slowly against resistance of 20 cmH2O provided by the water pressure threshold breathing (WPTB) device, 30 min/day, 7 days/week for 8 weeks."
1827683|NCT00791999|Drug|CDP870 400mg|400mg CDP870 given every 2 weeks until Week22 (SC)
1827684|NCT00791999|Drug|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week22 (SC)
1827685|NCT00791999|Drug|CDP870 100mg|200mg CDP870 given at Week0, 2, 4 and thereafter 100mg CDP870 given every 2 weeks until Week22 subcutaneously(SC)
1827686|NCT00791999|Drug|Placebo of CDP870|given every 2 weeks until Week22 (SC)
1827687|NCT00792012|Radiation|Hypofractionated Intensity-Modulated Radiation Therapy|All patients will receive one fraction of radiation therapy a day, 5 days a week, Monday through Friday. Radiation fraction size and number of fractions depend on dose fraction level the patient is assigned to.
1827688|NCT00792012|Drug|Temozolomide|Temozolomide will be administered orally, once a day starting on the first day of radiation, for 28 consecutive days during radiation, and after radiation for those patients completing radiation in less than 28 days.
1827689|NCT00792025|Drug|sunitinib malate|
1827690|NCT00792051|Biological|Inactivated influenza vaccine|0.5ml intramuscular single dose
1827691|NCT00792051|Biological|Saline|0.5ml intramuscular, one dose
1827692|NCT00792077|Drug|Lenalidomide|5 mg daily for 56 days.
1827693|NCT00792090|Other|Fermented milk|Formula used for non breastfed children or in complement of breastfeeding
1827694|NCT00792090|Other|Standard milk|Formula used for non breastfed children or in complement of breastfeeding
1827695|NCT00792103|Drug|NP101|NP101 study patch 4 hour application
1827696|NCT00792116|Behavioral|Gum Chewing|
1827697|NCT00792129|Device|The Atavi System|"The primary device in the Atavi system is the Flex Posture retractor and accessories such as dilators and an Expander Instrument.
The Atavi System includes instruments used to access the spine by dilation of the overlying tissues, as well as a retracting device that is used to maintain the access. Once the retractor is in place, the visualization components of the system may be used."
1827698|NCT00792142|Drug|bortezomib|Given IV
1827699|NCT00792142|Drug|dexamethasone|Given orally
1827700|NCT00792142|Drug|melphalan|Given IV
1827701|NCT00792142|Drug|thalidomide|Given orally
1827702|NCT00792142|Genetic|cytogenetic analysis|Performed on baseline and post transplant bone marrow specimens
1827703|NCT00792142|Genetic|fluorescence in situ hybridization|Performed on baseline and post transplant bone marrow specimens
1827704|NCT00792142|Other|laboratory biomarker analysis|Baseline, post transplant and prior to start of bortezomib, every 3 months post transplant for the first year, after 6 cycles of bortezomib, every year after transplant for 2-4 years.
1827705|NCT00792142|Other|questionnaire administration|Completed at baseline (within 6 weeks prior to enrollment) and at 2 months post transplant and once a month after that for the first year. For the second year the questionnaire will be completed every 3 months as long as on thalidomide for the duration of the study.
1827706|NCT00792142|Procedure|autologous hematopoietic stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
1827707|NCT00792142|Procedure|peripheral blood stem cell transplantation|Minimum dose of 2 X 10(6) CD34 + cells/kg day 0 after two days of treatment with Melphalan
1827708|NCT00792168|Drug|venlafaxine (Effexor)|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
1827709|NCT00792168|Other|placebo|venlafaxine 37.5 mg. or placebo will be prepared by the UCLA Pharmacy for the initial phase of the study. For the open-label phase of the study, subjects will receive the medication and dosage that is clinically indicated by the subject's primary physician in the community. After a one-week placebo lead-in, subjects will be randomly assigned to receive one capsule of either venlafaxine or placebo, with the dosage increase every two days until subjects receive four capsules daily (subjects will achieve a dose 150 mg. of venlafaxine after 7 days). The first dose will be administered in the morning, with subsequent capsules added on a b.i.d. schedule
1827710|NCT00792181|Drug|Midazolam|Midazolam 1 mg: 70 years or more and less than 70 kg Midazolam 2 mg: under 70 years and 70 kg or more
1827711|NCT00792181|Other|Course intervention - a professional development course for caregivers.|The nursing intervention involves a professional development course for caregivers. The course is expected to deepen the caregivers' knowledge about the encounter with patients as well as cardiovascular treatment.
1827712|NCT00792194|Other|Exercise training|"Subjects will be randomised in two groups:
a control group, where subjects are asked to continue their normal daily activities and physiotherapy regime.
a training group, where subjects are asked to exercise three times a week, whenever they want during the day."
1827713|NCT00792207|Other|Virtual Coach software|The intervention being tested, the Virtual Coach, is an automated empathic computer agent which will run on patient's home computer and engage the patient in dialogues to deliver personalized feedback, education and coaching based on physiological data.
1827714|NCT00792207|Other|Activity monitor and website|The control group will use an activity monitor and a website to track activity levels.
1827715|NCT00792220|Procedure|MSU|"In the Mobile Stroke Unit procedure: Conventional Emergency Medical Service together with the MSU will meet at the side, where the patient is found. The MSU is an ambulance, equipped with a neurologist and neuroradiologist and includes CT scanner and point of care laboratory unit. The patient's medical history and the physical examination will be directly performed by the neurologist. CT scan analysis will be performed by the neuroradiologist, while the neurologist will analyze the blood samples with the point of care laboratory unit. If the inclusion and exclusion criteria are fulfilled, the thrombolytic therapy will directly be started by the neurologist. A possible thrombolytic therapy will be performed under the current inclusion and exclusion criteria that are associated with the rt-PA drug approval in Europe. After performance of the acute therapy, the patient will be transported to the University Hospital of the Saarland."
1827716|NCT00792220|Procedure|OCCM|In the optimized conventional clinical management: After patient's medical history, physical examination and emergency treatment by the emergency physician, the patient will be transported to the University Hospital of the Saarland. The delivery of the patient will directly take place at the CT scanner. The neurologist will perform a second medical history, physical examination, while the blood will be drawn by the assisting nurse. CT scan will be performed, while the blood will be analyzed by point of care technique, placed close to the CT scanner. Additionally the blood will be sent in parallel to the hospital central laboratory for conventional laboratory analysis. Depending on the results, a thrombolytic therapy will be initiated directly at the CT. Thereafter, the patient will be transported to the hospital Stroke Unit.
1827717|NCT00792233|Other|Withdrawal of anti-TNF therapy|Anti-TNF therapy will be discontinued at the third visit in children who demonstrate persistent inactive disease for at least 6 months.
1827718|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
1827719|NCT00792246|Drug|voriconazole|Voriconazole formulation will be changed from oral to intravenous at the same dose the subject is currently receiving per standard of care.
1827720|NCT00792285|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition calls to health plan members to promote screening
1827721|NCT00792298|Drug|Suvorexant|oral tablet taken before bedtime
1827722|NCT00792298|Drug|Dose-matched Placebo to Suvorexant|Dose-matched placebo to suvorexant taken before bedtime (oral tablet)
1827723|NCT00792311|Procedure|Tsui test|The stimulator is set at frequency of 1Hz with 200ms pulse width and the current output ranging from 0 to 20 mA. The current output will be carefully increased from zero until motor activity is detected up to a maximum of 20 mA.
1827724|NCT00792324|Drug|Etravirine|Four 100mg tablets daily for 12-24 weeks
1827725|NCT00792324|Drug|Efavirenz|One 600mg tablet daily
1827726|NCT00792337|Drug|simvastatin|10 mg per oral once daily for 8 weeks
1827727|NCT00792337|Drug|B1-6-12|1 table per day for 8 weeks
1827728|NCT00792350|Drug|Sorafenib (Nexavar, BAY43-9006)|Treatment of Hepatocellular Carcinoma with Nexavar (HCC)
1827729|NCT00792363|Drug|Irinotecan|350 mg/m2 intravenously on day 1 every 3 weeks
1827730|NCT00792363|Drug|Panitumumab|9 mg/kg intravenously on day 1 every 3 weeks
1827731|NCT00792376|Drug|etoricoxib|etoricoxib (ETO) group (n=28) treated with etoricoxib 120 mg/day orally for 7 days
1827732|NCT00792376|Drug|diclofenac|diclofenac (DIC) group (n=28) received diclofenac 150 mg/day/7 days orally.
1827733|NCT00792389|Other|Warm humidified C02|Insufflation of warmed humidified gas during laparoscopic cholecystectomy
1827734|NCT00792389|Other|Cool dry C02|Insufflation of cool dry gas during laparoscopic cholecystectomy
1827735|NCT00792428|Device|Real Transcranial Direct Current Stimulation|A direct current runs between two electrode positions and affects the excitability of the underlying brain tissue
1827902|NCT00793572|Drug|Fludarabine Phosphate|Given IV
1827736|NCT00792428|Device|Sham Transcranial Direct Current Stimulation|A sham current runs between two electrode positions and might affect the underlying brain tissue.
1827737|NCT00792441|Device|intervention group|inspiratory muscle training at 50% of peak negative inspiratory muscle training (PNIP)will be performed with 6 breathe/set, 10 set/day, once a day for 28 days.
1827738|NCT00792454|Behavioral|exercise training|"Subjects will undergo renal rehabilitation in the form of guided exercises 2 times per week for 3 months. Subjects will be encouraged to walk for 1 hour on their own a third day of the week.Subjects will receive recommendations for cardiovascular, weight training and stretching exercises.
Cardiovascular and strength capabilities of all subjects will be evaluated at the initial session in order to prescribe the appropriate exercise regimen. An exercise physiologist will conduct these evaluations using the Perceived Level of Exertion Subjects will also receive education and practice in mindful meditation and a heart healthy diet.
Subjects will be encouraged to continue exercises, meditation, and healthy eating habits after the 3-month in-center program. Subjects will receive follow-up phone calls at 3-month intervals to encourage ongoing exercise, meditation, and healthy diet."
1827739|NCT00792467|Drug|ITF2357|ITF2357, supplied as hard gelatine capsules for oral administration at the strength of 50 mg each.
1827740|NCT00792480|Behavioral|Dietary and lifestyle counseling|"The intervention group will undergo a complete history and physical with attention to prepregnancy weight, current weight, height, and BMI. At the initial visit, they will meet with a registered dietician to receive a standardized counseling session, including information on pregnancy-specific dietary and lifestyle choices. The patient will be instructed to engage in moderate intensity exercise at least 3 times per week and preferably 5 times per week. They will also receive information on the appropriate weight gain during pregnancy using the IOM guidelines. Each subject will meet with the dietician only at the time of enrollment.
At each routine obstetric appointment, the participant's weight will be measured and charted on an IOM Gestational Weight Gain Grid in front of the participant. The healthcare provider will inform the participant if her weight gain was at the appropriate level and counsel her accordingly regarding increasing or decreasing her intake and exercise."
1827741|NCT00792493|Drug|ORM-12741|Alternating panel multiple dose escalation
1827742|NCT00792506|Drug|ITF2357|Treatment was to be administered on an inpatient basis from week 1 to week 13 and on an outpatient basis from week 14 to end of treatment. The patient had to be hospitalized on day 1 every week. The Investigator had to administer ITF 2357 in one single dose (two or three 200 mg capsules at one time) under his/her direct control.
1827743|NCT00792519|Behavioral|HIV support group|group support
1827744|NCT00792519|Behavioral|CBT|group cognitive behavioral treatment
1827745|NCT00792532|Procedure|interventional MRI for implantation of DBS electrodes|DBS implantation will be performed entirely within a Phillips 3T MRI scanner
1827746|NCT00792532|Device|DBS electrodes|Deep brain stimulation (DBS) electrodes
1827747|NCT00792558|Drug|BMS-817378|Capsule, Oral, Dose escalation to a MTD from a starting dose of 25 mg, once daily, until disease progression/subject discontinuation
1827748|NCT00792571|Drug|Beraprost Sodium Modified Release|
1827749|NCT00792584|Drug|etravirine|Patient receives etravirine/ placebo or efavirenz / placebo
1827750|NCT00792584|Drug|efavirenz|patient receives efavirenz / placebo or etravirine / placebo
1827751|NCT00792610|Biological|hepatitis B vaccine|Recombinant HBsAg, 20mcg/ml/vial (GSK) one vial IM at Day 0, Month 1, month 6 during follow-up, respectively.
1827752|NCT00792623|Biological|VarilrixTM|Subcutaneous injection, 2 doses, in the deltoid region of the non-dominant upper arm.
1827753|NCT00792636|Drug|sumatriptan and naproxen sodium combination tablet|sumatriptan 85mg and naproxen sodium 500mg
1827754|NCT00792636|Drug|sumatriptan tablet|sumatriptan 85mg
1827755|NCT00792636|Drug|naproxen sodium tablet|Naproxen sodium 500mg
1827756|NCT00792662|Drug|Methylphenidate|Subject will receive 5mg BID for the first two weeks then 10mg BID until week 16 of the study.
1827757|NCT00792662|Drug|Placebo|Standard inactive pill.
1827758|NCT00792675|Other|Aerobic and resistance exercise training|Exercise was performed 3 times per week. It consisted of 30 minutes of treadmill exercise at approximately 85% of heartrate max and 2 sets of 6 resistance weight lifting exercises resulting in volitional fatigue at 12 to 15 repetitions.
1827759|NCT00792688|Drug|GLYC-101 Gel (0.1%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
1827760|NCT00792688|Drug|GLYC-101 Gel (1.0%)|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
1827761|NCT00792688|Drug|GLYC-101 Placebo|Topical administration to the laser-ablated area on days 1 (day of laser ablation), 2, 3, 4, and 5.
1827762|NCT00792701|Drug|cisplatin|Given IV
1827763|NCT00792701|Drug|gemcitabine hydrochloride|Given IV
1827764|NCT00792714|Drug|Mannitol|400mg twice daily for 7 days
1827765|NCT00792727|Drug|ketoprofen Patch|2 topical patches applied once daily for 28 days
1827766|NCT00792727|Other|Placebo Patch|2 topical placebo patches applied once daily for 28 days
1827767|NCT00792740|Drug|ITF2357|ITF2357 will be supplied as hard gelatin capsules for oral administration at the dose strength of 50 mg.
1827768|NCT00792740|Drug|Placebo capsules|Placebo will be supplied as matching capsules for oral administration with the same outer appearance
1827769|NCT00792753|Device|Medtronic Endeavor Coronary Stent System|coronary stent implantation
1827770|NCT00792753|Device|DESyne BD Novolimus Stent System|coronary stent implantation
1827771|NCT00792753|Device|DESyne Novolimus Stent System|coronary stent implantation
1827772|NCT00792766|Drug|everolimus (RAD001)|Subjects will resume the dosing regimen that they were receiving at the completion of the initial RAD001 study.
1827773|NCT00792779|Drug|Propofol|Patients in the Propofol Group (PG) will be induced with target-controlled infusion (TCI) of propofol (Diprifusor, AstraZeneca) and remifentanil (Asena PK, Cardinal Health) at the target dose of 6.0 µg.ml-1 and 8.0 ηg.ml-1, respectively. The patients in the Sevoflurane Group (SG) will be induced with remifentanil TCI at target dose of 8.0 ηg.ml-1 and etomidate 0.5 mg.kg-1 in bolus.
1827774|NCT00792792|Device|Modulated Imaging|Modulated Imaging Spectroscopy
1827775|NCT00792805|Drug|Indacaterol 150 µg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
1827833|NCT00793000|Drug|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
1827776|NCT00792805|Drug|Indacaterol 300 μg|Indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
1827777|NCT00792805|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
1827778|NCT00792818|Drug|Curcuma domestica extracts|1,500 mg per day (oral)divided into 3 times for 28 days
1827779|NCT00792818|Drug|Ibuprofen|1,200 mg/days (oral) divided into 3 times for 28 days
1827780|NCT00792831|Drug|ITF2357|Histone-Deacetylase Inhibitor
1827781|NCT00792844|Dietary Supplement|Bio-K capsule formulation|Bio-K 1 capsule formulation daily for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
1827782|NCT00792844|Dietary Supplement|Bio-K drink|Bio-K 98 g of diary-free soy beverage formulation for the duration of antibiotic treatment and for 7 days after termination of antibiotics or until hospital discharge, whichever occurs first
1827783|NCT00792857|Drug|CTAP201 Injection|Comparison of different dose strengths of CTAP201 after single dose.
1827784|NCT00792857|Drug|Doxercalciferol|Comparison of different dose strengths of doxercalciferol after single dose.
1827785|NCT00792870|Behavioral|Evaluation of the Shape Up RI Campaign|The SURI Standard group will receive all of the Shape-Up RI program materials plus an organized directory of useful websites related to healthy eating, exercise, and weight control. The SURI enhanced group will receive the standard Shape-Up RI program materials plus access to 12 behavioral weight loss lessons.
1827786|NCT00792896|Behavioral|family conference|family conference
1992310|NCT03322358|Other|Sleep incentives|After a baseline period, participants in this condition will be provided with a small payment for each additional minute of sleep over their mean nighttime sleep in the baseline period.
1827789|NCT00792922|Drug|Azithromycin|Comparison of community coverage rate
1827790|NCT00792922|Drug|Azithromycin|Comparison of coverage levels at baseline treatment followed by annual treatment if prevalence of trachoma is >5%. In Niger, there will be a comparison of coverage levels in everyone versus in children ages twelve and under who are treated every 6-months.
1827791|NCT00792935|Drug|MK-0941|MK-0941 will be taken three times a day (TID), within 15 minutes before each meal. MK-0941 will be titrated to a maximally effective dose. The treatment period will be 6 weeks.
1827792|NCT00792935|Drug|Glimepiride|Glimepiride will be taken once a day (QD) in the morning, within 15 minutes before the breakfast meal. Glimepiride will be titrated to a maximally effective dose. The treatment period is 6 weeks.
1827793|NCT00792935|Drug|Metformin|The study will include an up to 4-week metformin dose titration/dose stabilization period. Once a participant has reached the maximum tolerated dose of metformin [(i.e., ≥1500 mg/day and ≤2550 mg/day (or ≤3000 mg/day, where the maximum dose of metformin per the local label is 3000 mg/day)], the participant should remain on the same metformin dose throughout the study.
1827794|NCT00792948|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic stem cell transplant
1827795|NCT00792948|Drug|Cyclophosphamide|Given IV
1827796|NCT00792948|Drug|Cytarabine|Given IT
1827797|NCT00792948|Drug|Dasatinib|Given PO
1827798|NCT00792948|Drug|Dexamethasone|Given IV or PO
1827799|NCT00792948|Drug|Doxorubicin Hydrochloride|Given IV
1827800|NCT00792948|Drug|Etoposide|Given IV
1827801|NCT00792948|Biological|Filgrastim|Given SC
1827802|NCT00792948|Other|Laboratory Biomarker Analysis|Correlative studies
1827803|NCT00792948|Drug|Leucovorin Calcium|Given IV
1827804|NCT00792948|Drug|Methotrexate|Given IV or IT
1827805|NCT00792948|Drug|Methylprednisolone|Given IV
1827806|NCT00792948|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic stem cell transplant
1827807|NCT00792948|Drug|Prednisone|Given PO
1827808|NCT00792948|Drug|Sirolimus|Given PO
1827809|NCT00792948|Drug|Tacrolimus|Given IV
1827810|NCT00792948|Radiation|Total-Body Irradiation|Undergo TBI
1827811|NCT00792948|Drug|Vincristine Sulfate|Given IV
1827812|NCT00792961|Device|Endomicroscopy|Rigid drop-in endomicroscope imaging probe
1827813|NCT00792974|Behavioral|A brief psycho-educational intervention|"A brief (3 single sessions) psycho-educational program with cognitive-behavioral and disease self-management techniques.
This study is an open pilot study (feasibility study) to develop a palliative psychological program for end-of-life fears in COPD, therefore all participants will be given the opportunity to receive treatment."
1827814|NCT00793000|Drug|PF-04287881|75 mg oral dose (prepared solution) given once
1827815|NCT00793000|Drug|Placebo|placebo to match 75 mg oral dose (prepared solution), given once
1827816|NCT00793000|Drug|PF-04287881|150 mg oral dose (prepared solution) given once
1827817|NCT00793000|Drug|Placebo|placebo to match 150 mg oral dose (prepared solution), given once
1827818|NCT00793000|Drug|PF-04287881|300 mg oral dose (prepared solution) given once
1827819|NCT00793000|Drug|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
1827820|NCT00793000|Drug|PF-04287881|750 mg oral dose (prepared solution) given once
1827821|NCT00793000|Drug|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
1827822|NCT00793000|Drug|PF-04287881|1000 mg oral dose (prepared solution) given once
1827823|NCT00793000|Drug|Placebo|placebo to match 1000 mg oral dose (prepared solution), given once
1827824|NCT00793000|Drug|PF-04287881|1250 mg oral dose (prepared solution) given once
1827825|NCT00793000|Drug|Placebo|placebo to match 1250 mg oral dose (prepared solution), given once
1827826|NCT00793000|Drug|PF-04287881|1500 mg oral dose (prepared solution) given once
1827827|NCT00793000|Drug|Placebo|placebo to match 1500 mg oral dose (prepared solution), given once
1827828|NCT00793000|Drug|PF-04287881|300 mg oral dose (prepared solution) given once
1827829|NCT00793000|Drug|Placebo|placebo to match 300 mg oral dose (prepared solution), given once
1827830|NCT00793000|Drug|PF-04287881|750 mg oral dose (prepared solution) given once
1827831|NCT00793000|Drug|Placebo|placebo to match 750 mg oral dose (prepared solution), given once
1827832|NCT00793000|Drug|PF-04287881|1000 mg based on safety and PK from previous cohorts; oral dose (prepared solution) given once
1827834|NCT00793013|Device|Volume-Cycled Assist-Control (AC) mode|"Patients ventilated with volume-cycled assist-control mode with PEEP and goal FIO2 < 40%
Rate of mandatory time-cycled, pressure controlled breaths,initially at 12 per breaths/min
Initial tidal volume set at 8mL/kg using predicted body weight (PBW) with a goal of 6mL/kg & setting positive end-expiratory pressure (PEEP) based on level of initial FiO2
Inspiratory to Expiratory ratio set at 1:1 to 1:3
If frequency of triggered breaths increased greater than 10 per min sedation will be increased. If needed,rate of mandatory breaths increased
Mgmt of PEEP will be conducted as per the ARDSnet Protocol
Oxygenation goal PaO2: PaO2-55-80 mm Hg O2 Sat: 88-95%
Tidal volume and respiratory rate adjusted to the desired pH and plateau pressures per ARDSnet protocol"
1827835|NCT00793013|Device|Airway Pressure Release Ventilation (APRV) mode|"Ventilation uses Drager Model X1
Spontaneous breathing allowed throughout ventilatory cycle at 2 airway pressure levels
Time periods for the high & low pressure levels can be set independently
Duration of the lower pressure level will be adjusted to allow expiratory flow to decay to 75% of total volume
Duration of higher pressure levels will be adjusted to produce 12 pressure shifts per min
Spontaneous frequency will be targeted for 6 to 18 breaths/per min
If spontaneous breathing is achieved,level of sedation will be decreased
If spontaneous respirations are >20 breaths/min, sedation will be increased
If spontaneous breathing frequency increased greater than 20/per min, sedation was increased and if needed the mechanical frequency increased"
1827836|NCT00793026|Drug|Dermacyd Breeze Pocket BR (Lactic Acid)|Dermacyd Breeze Pocket BR (Lactic Acid) during 21 consecutive days
1827837|NCT00793052|Drug|Etodalac, Etoricoxib and Dexamethasone|"Dexamethasone sodium phosphate 8 mg 1 hour before the extraction, 4 mg the day after the extraction and another 4 mg at second day to the extraction.
Etoricoxib 120 mg 1 hour before the extraction, 120 mg the day after the extraction and another 120 mg at second day to the extraction.
Etodalac 600 mg 1 hour before the extraction, 600 mg the day after the extraction and another 600 mg at second day to the extraction."
1827838|NCT00793065|Other|Electronic health record (EHR)|Computer-based system that allows physicians to access and manage patient records electronically.
1827839|NCT00793065|Other|Medical Home redesign|Implementation of NCQA Level III Medical Home
1827840|NCT00793091|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 120 days
1827841|NCT00793091|Drug|Placebo|4 drops applied daily for 120 days
1827842|NCT00793104|Procedure|Placement of allograft CR Plug in primary injury site|Core defect and implant allograft CR plug
1827843|NCT00793117|Procedure|packing|packing in middle meatus for duration of 5 day
1827844|NCT00793130|Dietary Supplement|Coltect|Two tablets twice daily (BID) during the 2 months of the study. Each tablet contains 500mg Curcumin, 250mg Green tea and 100mcg Selenomethionine.
1827845|NCT00793156|Drug|Nalfurafine HCl 2.5 µg|Daily dose of 2.5 µg
1827846|NCT00793156|Drug|Nalfurafine HCl 5.0 µg|Daily dose of 5.0 µg
1827847|NCT00793156|Other|Placebo|Placebo daily dose
1827848|NCT00793169|Procedure|Blood Draw|Serum levels were measured
1827849|NCT00793182|Drug|Ioversol 320 mgI/mL|125 mL of Ioversol administered in the vein
1827850|NCT00793182|Drug|Iodixanol 320 mgI/mL|125 mL of Iodixanol administered in the vein
1827851|NCT00793195|Drug|Intralipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
1827852|NCT00793195|Drug|SMOFlipid 20%|Dosing will be formulated according to a Nomogram for Parenteral Nutrition (PN) composition, which takes into account the percentage of the subject's caloric intake consumed parenterally. PN solution will be infused continuously over 12-24 hours by infusion pump, and the duration each day will depend on the enteral tolerance of the child. PN shall not be discontinued, unless the patient is taking 95% of calories enterally with good growth as evidence by appropriate weight gain. Subjects will receive the trial lipid for a total duration of 12 weeks or if they develop a serum conjugated bilirubin (sustained for 7 days) of 100 umol/l (6mg/dl) or full enteral tolerance prior to this end-point. Once the trial lipid is discontinued, in the event that PN is continued, subjects will return to the standard lipid preparation. A final follow-up data-point will be collected 4 weeks after the trial lipid is stopped.
1827853|NCT00793208|Biological|semi-allogeneic human fibroblasts (MRC-5) transfected with DNA|"Each vaccine consists of 1 x 10e7 DNA-transfected irradiated fibroblasts. A total of 4 weekly immunizations will be delivered to each patient. Each vaccine will be administered i.d. using a 1 mL syringe and a 25 gauge needle.
Subjects will have immunizations administered at 4 different sites for each vaccination as follows:
Site #1: Right arm Site #2: Left arm Site #3: Right thigh Site #4: Left thigh Approximately equal numbers of transfected fibroblasts will be administered at each site."
1827854|NCT00793221|Device|Implantation of sirolimus-eluting coronary stent|Implantation of sirolimus-eluting coronary stent after dilatation of the coronary occlusion
1827855|NCT00793221|Device|Implantation of everolimus-eluting coronary stent|Implantation of everolimus-eluting coronary stent after dilatation of the coronary occlusion
1827856|NCT00793234|Drug|TB-402|TB-402 administered as single bolus 18-24 post total knee replacement surgery.
1827857|NCT00793234|Drug|Enoxaparin|Enoxaparin 40mg/day sc injection for at least 10 days post-surgery
1827858|NCT00793247|Drug|PRU-PLA-PRU-PLA|
1827859|NCT00793247|Drug|PLA-PRU-PLA-PRU|
1827860|NCT00793247|Drug|PLA-PRU-PRU-PLA|
1827861|NCT00793247|Drug|PRU-PLA-PLA-PRU|
1827895|NCT00793546|Drug|Exemestane|25 mg - 1 tablet per day- once daily daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
1827896|NCT00793559|Drug|terlipressin|1 mg of terlipressin one time only
1827897|NCT00793559|Drug|terlipressin|1 mg of terlipressin in 50 cc of NS given at a drip of a total of 6 h
1827898|NCT00793572|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo transplantation
1827862|NCT00793260|Behavioral|Enhanced Support|"The Enhanced-Support Group program used lower risk thresholds for targeted outreach of individuals with chronic illness and for those likely to face discrete surgical interventions. Individuals at high financial risk but without one of the five chronic conditions were included in the Enhanced-Support Group.
The Enhanced-Support Group received up to five initial reach attempts while the Usual-Support Group received up to three attempts.
The Enhanced-Support Group used a 'tight loop' management structure including detailed, timely coach level feedback reports on efficiency and effectiveness."
1827863|NCT00793260|Behavioral|Usual-Support|Predictive models in the Usual-Support Group were aimed at identifying individuals through medical claims and administrative data (such as hospitalization notification). The output of the predictive models is a rank-ordered, or stratified, list of individuals who have support needs. These lists were then used to generate outbound mail, interactive voice response (IVR) calls or calls by health coaches.
1827864|NCT00793273|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug Levemir® in daily clinical practice
1827865|NCT00793286|Procedure|Mesh fixation by staples|Mesh fixation by staples
1827866|NCT00793286|Procedure|Mesh fixation by glue|Mesh fixation by glue
1827867|NCT00793299|Behavioral|Video Illness Narrative|video
1827868|NCT00793325|Drug|Somatropin|"Genotropin® 5.3mg, Genotropin®inj.12mg, Genotropin®MiniQuick s.c. inj.0.6mg・1.0mg・1.4mg, depending on the Investigator prescription.
Frequency and duration are according to Package Insert as follows.  Normally, the dosage is 0.021 mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. If efficacy is insufficient, the dose may be increased up to 0.47 mg/kg/week in 6-7 divided doses in a week by s.c. route."
1827869|NCT00793338|Drug|Sildenafil|Sildenafil 20mg three times a day for 3 months.
1827870|NCT00793351|Procedure|Reduced-intensity allogeneic hematopoietic stem cell transplantation|"Treatment Scheme
Enrollment - Pre-RIST treatment - RIST
4 cycles of conventional chemotherapy will be given prior to RIST.
Surgery will be done whenever possible prior to RIST.
Local radiotherapy will be applied whenever possible prior to RIST.
topotecan + cyclophosphamide) regimen will be used for pre-RIST conventional chemotherapy.
Cyclophosphamide/Fludarabine (CyFlu) regimen will be used as conditioning regimen for matched related or unrelated SCT. CyFlu-ATG regimen will be used as conditioning regimen for mismatched related SCT."
1827871|NCT00793364|Dietary Supplement|Stanol ester spread|Stanol ester spread 20 g every day
1827872|NCT00793364|Dietary Supplement|Placebo spread|Placebo spread 20 g every day
1827873|NCT00793364|Dietary Supplement|Mediterranean Diet|Mediterranean Diet every day
1827874|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen|Adriamycin will be given at a dose 50 mg/m2 and docetaxel at a dose of 75 mg/m2 every 14 days for four cycles.Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
1827875|NCT00793377|Drug|Adriamycin (Doxorubicin), Docetaxel, Tamoxifen, Cyclophosphamid|Adriamycin will be given at a dose of 60 mg/m2 and cyclophosphamide at a dose of 600 mg/m2 every 21 days for four cycles. Thereafter, docetaxel at a dose of 100 mg/m2 is given every 21 days for four cycles. Tamoxifen 20 mg is given once daily for five years to all patients, starting with the first day of chemotherapy.
1827876|NCT00793403|Other|As per routinary clinical care|As per routine clinical care
1827877|NCT00793416|Device|Shunt flow detection|Shunt flow detection based upon ShuntCheck results compared to radionuclide test results
1827878|NCT00793429|Drug|Prucalopride|
1827879|NCT00793429|Other|Placebo|
1827880|NCT00793442|Diagnostic Test|Blood Collection and Assays|The researchers will sample blood upon enrollment, at 6 and 24 hours after the baseline sampling. The researchers will measure 6 different endothelial related biomarkers compromising different components of endothelial permeability and hemostasis.
1827881|NCT00793455|Behavioral|Educational outreach|Participants will get a letter from their physician that explains that their records show the test has not been completed. The letter will be mailed along with an educational brochure and a DVD about colorectal cancer and colorectal cancer screening.
1827882|NCT00793468|Drug|GSK598809|GSK598809 once daily for 12 weeks
1827883|NCT00793468|Drug|Nicotine Replacement Transdermal Patch|All subjects will be treated during the 4 week open-label smoking cessation phase of the study. During Weeks 1-3, subjects will receive 21mg/day, and during Week 4, subjects will receive 14 mg/day. Those subjects who reached continuous abstinence on at least week 4 of the open-label phase will receive 7mg/day during Week 5 while taking GSK598809 or placebo.
1827884|NCT00793468|Drug|Placebo|Placebo once daily for 12 weeks
1827885|NCT00793481|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy non-invasively measure changes in the microvasculature
1827886|NCT00793494|Other|Probaclac|Bifidobacterium bifidum R0071, Bifidobacterium longum R0175, Lactobacillus helveticus R0052, Lactobacillus Delb. SSP bulgaricus R9001, Lactobacillus rhamnosus R0011, Lactococcus Lactis SSP. lactis R1058 et Streptococcus thermophilus (Probaclac™)
1827887|NCT00793494|Other|Placebo|Placebo composition matodextrin, gelatin, ascorbic acid, soya
1827888|NCT00793507|Other|Oral Health Care Early Intervention Project|The intervention group will receive routine preventive dental care, 2 to 4 times per year depending on risk of caries. The intervention group will also receive pre-scheduling, reminders, and care coordination by the dental hygienist. The control group will receive usual care, but will not receive pre-scheduling, reminders, or care coordination by the dental hygienist. In order to determine the incidence of early childhood caries at study enrollment, both intervention and control groups will receive a standardized oral examination with an assessment of caries presence and extent on the day of enrollment, at 12 months and at 24 months after enrollment. Both children in the control group and intervention group will be referred to a dentist if found to need restorative care.
1827889|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
1827890|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
1827891|NCT00793520|Drug|Placebo|Twice daily oral administration of placebo for 5 weeks.
1827892|NCT00793520|Drug|Milnacipran|Twice daily oral administration of Milnacipran for 5 weeks.
1827893|NCT00793546|Drug|Bosutinib|300 mg =(3x100mg) tablets once daily during the active phase of treatment until disease progression, unacceptable toxicity or withdrawal of consent occurs
1827894|NCT00793546|Drug|exemestane|25 mg tablet once daily
1827899|NCT00793572|Drug|Bortezomib|Given SC
1827903|NCT00793572|Other|Laboratory Biomarker Analysis|Correlative studies
1827904|NCT00793572|Drug|Melphalan|Given IV
1827905|NCT00793572|Drug|Mycophenolate Mofetil|Given PO
1827906|NCT00793572|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
1827907|NCT00793572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo transplantation
1827908|NCT00793572|Procedure|Syngeneic Bone Marrow Transplantation|Undergo transplantation
1827909|NCT00793572|Radiation|Total-Body Irradiation|Undergo radiotherapy
1827910|NCT00793585|Drug|allopurinol|Patients will receive the lifestyle modification and treatment of allopurinol (300 mg /d) and lifestyle modification for 4 weeks; when the UA level < 6mg/dl , the dosage changed to 200mg/d.
1827911|NCT00793585|Other|continue their usual therapy|Patients will receive lifestyle modification and continue their usual therapy.
1827912|NCT00793598|Drug|Placebo|Placebo Cohort 3A placebo once weekly for a total of 5 doses Cohort 4A placebo twice weekly for a total of nine doses Cohort 4B placebo once or twice weekly Cohort 4C placebo once or twice weekly
1827913|NCT00793598|Drug|CMX001|Cohort 3A 40mg CMX001 once weekly for a total of 5 doses Cohort 4A 100mg CMX001 twice weekly for a total of nine doses Cohort 4B 200mg CMX001 once or twice weekly Cohort 4C 300mg CMX001 once or twice weekly
1994025|NCT03085147|Drug|Olaparib|For PARRi-FL, imaging patients will first gargle a solution of PARRi-FL for 1 min, then spit out this solution and gargle with a cleaning solution (the solvent used for PARRi-FL) for 1 min. Then fluorescence imaging of the oral cavity and pharynx will be performed with an endoscope. The intensity and extent of the fluorescence signal will be recorded by one of the investigators for the tumor and adjacent normal mucosa.
1827916|NCT00793624|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
1827917|NCT00793624|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
1827918|NCT00793624|Drug|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
1827919|NCT00793624|Drug|Placebo|Placebo for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
1827920|NCT00793624|Drug|Placebo|Placebo for comparison Formoterolon safety and efficacy in COPD patients
1827921|NCT00793650|Drug|Bortezomib|Escalating doses of bortezomib 1.0, 1.3, or 1.6 mg/m2 in Arm A and Arm B.
1827922|NCT00793650|Drug|Melphalan|"All patients received melphalan (100 mg/m^2/day × 2; days
−3 and −2), for a total dose of 200 mg/m^2."
1827923|NCT00793650|Procedure|Autologous PBSC Transplant|Day 0 consists of the stem cell infusion.
1827924|NCT00793663|Drug|Xenon|Inhalational gas; maximum dose allowed: 70 % Xenon; the duration of the treatment will be defined through anesthesia-time.
1827925|NCT00793663|Drug|Sevoflurane|Inhalation gas; age adapted MAC-values; the duration of the treatment will be defined through anesthesia-time
1827926|NCT00793663|Drug|Dexamethasone|Intravenous use, 4 mg, single shot
1827927|NCT00793663|Drug|NaCl|Intravenous use; single shot
1827928|NCT00793663|Drug|Ondansetron|Intravenous use; 4 mg; single shot
1827929|NCT00793663|Drug|NaCl|Intravenous use; single shot
1827930|NCT00793676|Other|spirometry|
1827931|NCT00793676|Other|blood test|
1827932|NCT00793702|Biological|rdESAT-6 + rCFP-10|rdESAT-6 + rCFP-10 skin test administered intradermally by the mantoux injection technique
1827933|NCT00793715|Procedure|Decompressive laparotomy with temporary abdominal closure|Surgical intervention including midline incision with temporary abdominal closure and several planed staged relaparotomies
1827934|NCT00793715|Procedure|Percutaneous puncture with placement of abdominal catheter|Installation of abdominal catheter percutaneously via abdominal centesis 2cm bellow the umbilicus
1827935|NCT00793728|Procedure|Sleeve gastrectomy|Perform a gastrectomy guided by a 38F catheter and parallel to the small curvature of the stomach
1827936|NCT00793741|Drug|somatostatin|Somatostatin may be used to suppress endogenous insulin secretion
1827937|NCT00793754|Drug|Aspirin|100 mg / day for 8 weeks
1827938|NCT00793754|Drug|Atorvastatin|40 mg / day for 8 weeks
1827939|NCT00793754|Drug|Aspirin + Atorvastatin|Aspirin 100 mg / day + Atorvastatin 40 mg / day for 8 weeks
1827940|NCT00793767|Drug|erythropoietin|bolus of 400 IU/kg
1827941|NCT00793767|Drug|placebo (saline)|i.v
1827944|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
1827945|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
1827946|NCT00793793|Drug|BI201335|patient to receive rising doses of BI201335 solution qd +/- PegIFN/RBV fore 28 days
1827947|NCT00793793|Drug|BI201335|patient to receive 240mg solution BI201335 qd +/- PegIFN/RBV fore 28 days
1827948|NCT00793793|Drug|Placebo|
1827949|NCT00793806|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy measurements will be compared to a variety of laboratory parameters routinely measured in Chronic Inflammation and Oxidative Stress in Chronic Kidney Disease
1827950|NCT00793819|Drug|silodosin|α1-adrenergic antagonist
1827951|NCT00793832|Behavioral|supervised exercise|supervised exercise
1827952|NCT00793832|Behavioral|Diet advice|Diet Advice
1827953|NCT00793845|Drug|Cyclophosphamide|First HDCT
1827954|NCT00793845|Drug|Etoposide|First HDCT
1827955|NCT00793845|Drug|Carboplatin|First HDCT
1827956|NCT00793845|Drug|Thiotepa|Second HDCT
1827957|NCT00793845|Drug|Melphalan|Second HDCT
1827958|NCT00793845|Radiation|Total body irradiation|Second HDCT
1827959|NCT00793858|Drug|placebo, isotonic ciclesonide, hypotonic ciclesonide|200mcg/nostril
1827960|NCT00793871|Drug|Sunitinib Malate (SU011248)|Subjects will receive treatment with sunitinib in repeated 6-week cycles (4 weeks on, 2 weeks off), at a starting dose of 50 mg.
1827961|NCT00793897|Drug|BMS-754807|Tablets, Oral, escalating doses starting at 10 mg, continuous or intermittent, until disease progression, unacceptable toxicity or at the subject's request
1827962|NCT00793897|Drug|Paclitaxel|Vials, IV, 200 mg/m2, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
1827963|NCT00793897|Drug|Carboplatin|Vials, IV, 6 mg/mL.min, Day 1 of a 21-day cycle, until disease progression, unacceptable toxicity or at the subject's request
1827964|NCT00793910|Drug|Gabapentin|Gabapentin 300 mg taken by mouth thrice daily for 7 days
1827965|NCT00793910|Drug|placebo|placebo (sugar pill) taken by mouth thrice daily for 7 days
1827966|NCT00793923|Drug|ranibizumab and dexamethasone|Combination therapy (group 1): same day combination therapy with 0.05cc dose intravitreal dexamethasone injection (10mg/ml vial) and a single 0.5 mg intravitreal ranibizumab injection
1827967|NCT00793923|Drug|Ranibizumab|intravitreal injection of 0.5 mg ranibizumab
1827968|NCT00793962|Radiation|hypofractionation radiotherapy|radiotherapy of 43.5Gy/15f/3w to the chest wall and supraclavicular nodal region
1827969|NCT00793962|Radiation|conventional fractionation radiotherapy|50Gy/25/f/5w
1827970|NCT00793975|Biological|IMC-1121B|"Cohort 1
2 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
1827971|NCT00793975|Biological|1121B|"Cohort 2
4 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
1827972|NCT00793975|Biological|1121B|"Cohort 3
6 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
1827973|NCT00793975|Biological|1121B|"Cohort 4
8 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
1827974|NCT00793975|Biological|1121B|"Cohort 5
10 mg/kg I.V. once a week for 4 weeks, followed by a 2-week observation period."
1827975|NCT00793975|Biological|1121B|"Cohort 6
13 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
1827976|NCT00793975|Biological|1121B|"Cohort 7
16 mg/kg once a week for 4 weeks, followed by a 2-week observation period."
1827977|NCT00783380|Biological|Virosomal influenza vaccine|Influvacplus 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
1827978|NCT00783380|Biological|Subunit influenza vaccine|Influvac 2005/2006, Solvay Pharma AG, Bern, Switzerland Assigned to all 4 groups if immunocompromized patients
1827979|NCT00783393|Drug|Temozolomide|Temozolomide orally once daily for 5 consecutive days followed by a 23 day rest period to complete a 28 day treatment cycle. In Cycle 1, temozolomide will be administered at 150 mg/m2/day; in Cycle 2 and subsequent cycles, it will be administered at 100, 150, or 200 mg/m2, depending on hematology test results and adverse events observed.
1827980|NCT00783406|Drug|PF-00610355|dry powder inhaler, 1472 mcg, single dose
1827981|NCT00783406|Drug|PF-00610355|dry powder inhaler, 736 mcg, single dose
1827982|NCT00783406|Drug|PF-00610355|dry powder inhaler, 368 mcg, single dose
1827983|NCT00783406|Drug|Placebo|Placebo
1827984|NCT00783432|Drug|Astepro Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
1827985|NCT00783432|Drug|Astelin Nasal Spray (0.1% azelastine hydrochloride)|548 mcg (2 sprays per nostril) twice a day
1827986|NCT00783445|Behavioral|Community-Based Exercise Program (C-FIT)|Participants will do 1 hour of exercise two to three times each week in a community setting for 1 year, while being supervised by a personal coach.
1827987|NCT00783445|Behavioral|Self-Help Exercise Program (HOME)|After a fitness evaluation, participants will be given an exercise prescription and recommendations for home-based, self-mediated progressive exercise. Participants will be expected to do 1 hour of exercise two to three times each week for 1 year.
1827988|NCT00783458|Drug|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
1827989|NCT00783458|Drug|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
1827990|NCT00783471|Drug|Erlotinib, Docetaxel|Drug: Erlotinib 150 mg po daily, days 1-12 Drug: Docetaxel 75 mg/m2 IV over 30 min on day 15 Treatment will be repeated every 21 days
1827991|NCT00783471|Drug|Docetaxel, Erlotinib|Drug: Docetaxel 75 mg/m2 IV over 30 min on day 1 Drug: Erlotinib 150 mg po daily, days 4-15 Treatment will be repeated every 21 days
1827992|NCT00783484|Drug|PF-03716539|PF-03716539 10 mg oral solution, single dose
1827993|NCT00783484|Drug|PF-03716539|PF-03716539 25 mg oral solution, single dose
1827994|NCT00783484|Drug|PF-03716539|PF-03716539 3 mg oral solution, single dose
1827995|NCT00783484|Other|Placebo|Placebo for 3 mg, 10 mg and 25 mg of PF-03716539 (single dose)
1827996|NCT00783484|Drug|PF-03716539|PF-03716539 100 mg oral solution, single dose
1827997|NCT00783484|Drug|PF-03716539|PF-03716539 200 mg oral solution, single dose
1827998|NCT00783484|Drug|PF-03716539|PF-03716539 50 mg oral solution, single dose
1827999|NCT00783484|Other|Placebo|Placebo for 50 mg, 100 mg and 200 mg of PF-03716539 (single dose)
1828000|NCT00783484|Drug|Midazolam|Midazolam 1 mg IV, single dose
1828001|NCT00783484|Drug|Midazolam + PF-03716539 (100 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 100 mg oral solution, single dose
1828002|NCT00783484|Drug|Midazolam + PF-03716539 (50 mg)|Midazolam 1 mg IV, single dose plus PF-03716539 50 mg oral solution, single dose
1828003|NCT00783484|Drug|Darunavir|Darunavir 600 mg tablet twice daily for 9 days (Days 1-9)
1828004|NCT00783484|Drug|Darunavir + PF-03716539|Darunavir 600 mg tablet, single dose plus PF-03716539 50 mg oral solution, single dose (Day 10)
1828005|NCT00783484|Drug|Maraviroc|Maraviroc 150 mg tablet once daily for 6 days (Days 1-6)
1828006|NCT00783484|Drug|Maraviroc +PF-03716539|Maraviroc 150 mg tablet, single dose plus PF-03716539 100 mg oral solution, single dose (Day 7)
1828007|NCT00783484|Drug|Maraviroc|Maraviroc 225 mg tablet once daily for 6 days (Days 1-6)
1828008|NCT00783484|Drug|Maraviroc +PF-03716539|Maraviroc 225 mg tablet, single dose plus PF-03716539 200 mg oral solution, single dose (Day 7)
1828011|NCT00783523|Drug|Doxycycline or Placebo|Randomized to Doxycycline 100mg 2x/day or Placebo 2x/day for 1 or2-weeks pre-operatively.
1828012|NCT00783536|Drug|Etanercept + Methotrexate|
1828013|NCT00783536|Drug|DMARDS|
1828014|NCT00783549|Drug|an undetermined dose of GSK1292263|GSK investigational product or placebo
1828015|NCT00783549|Drug|ascending dose of GSK1292263|Ascending dose based on target exposures or placebo
1828016|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
1828458|NCT00803062|Other|Laboratory Biomarker Analysis|Correlative studies
1828017|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposures.
1828018|NCT00783549|Drug|ascending dose of GSK1292263|An ascending dose based on target exposure
1828019|NCT00783562|Other|Extension-oriented exercise program|The exercise program was composed of six graded sessions, two per week for three consecutive weeks. Sessions, each of one hour length, were conducted after the working hours in a wide room of the nursery school, gathering together all the teachers from each school. The exercises were selected in order to reinforce lumbar extension and to strengthen the primary stabilizers of the spine (transversus abdominis, oblique abdominal, multifidus, quadratus lumborum and erector spinae muscles)
1828020|NCT00783562|Other|Informative Brochure|The brochure showed the correct way to lift loads, and provided ergonomic suggestions to prevent musculoskeletal complaints, according to the Italian legislation
1828021|NCT00783588|Biological|ISF35|Subjects participating in this study will receive up to two doses of 1x10^8, 3x10^8, or 1x10^9 autologous Ad-ISF35-transduced CLL B cells, depending on the dose they received in the previous Phase I trial.
1828022|NCT00783601|Drug|Comparator: MK0524 + placebo|Two 150 mg MK0524 tablets + one placebo tablet in the matching image of montelukast 10 mg once daily for 3 weeks
1828023|NCT00783601|Drug|Comparator: MK0524 + montelukast|Two 150 mg MK0524 tablets and one 10 mg montelukast tablet once daily for 2 weeks
1828024|NCT00783601|Drug|Comparator: placebo + montelukast|Two placebo tablets in the matching image of MK0524 150 mg and one 10 mg tablet montelukast once daily for 2 weeks
1828025|NCT00783601|Drug|Comparator: Placebo|During the double-blind treatment periods, patients receive either two placebo tablets in the matching image of MK0524 150 mg or one placebo tablet in the matching image of montelukast 10 mg in a crossover manner. During the washout period before the crossover to the opposite treatment sequence, patients receive two placebo tablets in the matching image of MK0524 150 mg and one placebo tablet in the matching image of montelukast 10 mg once daily for two weeks.
1828026|NCT00783614|Drug|Aspirin 325mg|Patients randomized to Aspirin 325mg po daily versus placebo pill daily
1828027|NCT00783614|Drug|Antiretroviral therapy (ART)|Patients randomized to start ART immediately or defer use for 1 month
1828028|NCT00783627|Procedure|Angiography|Angiography done at the J1 visit
1828029|NCT00783640|Drug|Lactic Acid|Drug: Lactic Acid (Dermacyd Femina)
1828030|NCT00783653|Drug|Sunitinib|25 mg or 37,5 mg daily dose until DLT
1828031|NCT00783666|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
1828032|NCT00783679|Device|NICO device|"Measurement of cardiac output and simultaneous blood sampling.
The subjects' cardiac output will be measured by NICO device and also by thermodilution method. Simultaneously blood samples will be drawn from the pulmonary artery catheter and arterial line. The calculated and measured cardiac output values will be compared for accuracy."
1828033|NCT00783692|Drug|vedolizumab|Vedolizumab for intravenous infusion
1828034|NCT00783692|Other|Placebo|Placebo intravenous infusion
1828035|NCT00783705|Other|placebo|Given orally
1828036|NCT00783705|Drug|inositol|Given orally
1828037|NCT00783718|Drug|vedolizumab|Vedolizumab for intravenous infusion
1828038|NCT00783718|Other|Placebo|Placebo intravenous infusion
1828039|NCT00783731|Drug|Low dose midazolam|
1828040|NCT00783744|Drug|Insulin Glargine|In the morning to target FBG ≤ 100 mg/dl
1828041|NCT00783744|Drug|Glimepiride|Glimepiride 3 or 4 mg
1828042|NCT00783744|Drug|Metformin|At least 850 mg od
1828043|NCT00783744|Drug|Insulin monotherapy with premixed insulin NPH 30/70|Given before breakfast and before dinner, target of pre-prandial BG ≤ 100 mg/dl
1828044|NCT00783757|Device|Optical Imaging|TOBI scan performed before the participant starts cancer treatment and at the start of each treatment cycle
1828045|NCT00783796|Device|2.25 mm XIENCE V® Everolimus Eluting Coronary Stent System|Treatment of a maximum of two de novo native coronary artery lesions in small vessels.
1828046|NCT00783822|Other|RGCT|rapid genetic counseling and testing
1828047|NCT00783835|Drug|Long-Acting Methylphenidate|Long-Acting Methylphenidate within the range of 18, 36, 54 and 76 milligram will be orally administered once daily up to Day 56.
1828048|NCT00783861|Drug|Lactic Acid|Lactic Acid (Dermacyd Femina)
1828049|NCT00783887|Other|Blood sample|Blood sample of 5 ml
1828050|NCT00783900|Other|metoprolol, biatrial pacing|Prevention, atrial fibrillation, cardiac surgery, biatrial pacing, metoprolol
1828051|NCT00783913|Other|Visumotor Upper Extremity Training|Control
1828052|NCT00783913|Other|Anodal/Sham tDCS|Condition
1828053|NCT00783926|Biological|H5N1 Influenza Vaccine, Whole virion, Vero cell-derived, Inactivated Influenza Vaccine, non-adjuvanted (reverse genetic reassortant/H5N1 hemagglutinin antigen)|2 x 0.5 mL intramuscular injections 21 days apart (one of six different doses of hemagglutinin antigen without adjuvant)
1828054|NCT00783939|Drug|Lactic Acid|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)
1828055|NCT00783952|Device|Cerebral/Somatic Tissue Oximeter device|"Measurement of tissue oxygen saturation and simultaneous sampling for blood gas analysis.
Four sensors of the 'Cerebral/Somatic Tissue Oximeter' device will be placed on subject's both sides of the forehead, palm and calf area. Simultaneously, blood samples will be drawn from the pulmonary artery catheter and arterial line for blood gas analyses. The values obtained from the device measurements will be used in a new equation to calculate the mixed venous oxygen saturation. The calculated value will be compared to the real value from the blood gas analysis for accuracy."
1828056|NCT00783952|Device|Pulmonary artery catheter|Blood will be drawn form the pulmonary artery catheter for measurement of mixed venous oxygen saturation.
1828057|NCT00783965|Drug|tazarotene|Applied to the skin
1828058|NCT00783965|Other|placebo|Applied to the skin
1828059|NCT00783978|Other|whole blood sample|2 ml of whole blood for children 5 ml of whole blood for parents that will be used only if 1 mutation is found in children
1828060|NCT00784004|Other|Breathing Patterns|"All subjects will breathe in four different breathing patterns which are provided by specific masks. Patterns are as the following:
Breathing in through the nose only and out through the mouth only
Breathing in through the mouth only and out through the nose only
Breathing in and out through the nose only
Breathing in and out through the mouth only"
1828061|NCT00784017|Drug|asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
1828062|NCT00784017|Drug|recombinant asparaginase|5.000U /m²; IV; day 12, 15, 18, 21, 24, 27, 30, 33
1828063|NCT00784030|Other|Water|Participants will be first asked to drink 6 8-oz glasses of water over 2.5 hours on the first day, and then about 12 8-oz glasses of water over the course of the day for one week.
1828064|NCT00784043|Device|Cochlear Implant|Bilateral Implantation in children
1828065|NCT00784056|Drug|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)|Lactic Acid (Dermacyd PH_DETINLYN Tangerine Mix)
1828066|NCT00784069|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
1828067|NCT00784082|Drug|Hydroxycarbamide, Hydroxyurea (drug)|hydroxyurea 20-25 mg/kg/day since at least 3 months
1828068|NCT00784095|Other|Life completion and preparation|Subjects will discuss life review, issues of forgiveness and heritage and legacy.
1828069|NCT00784095|Other|Attention Control|Subjects will listen to a non-guided relaxation CD.
1828070|NCT00784108|Device|Modulated Imaging (MI)|Modulated Imaging measure effect of Photodynamic therapy treatment
1828071|NCT00784108|Other|Photodynamic therapy|Modulated Imaging measure effect of Photodynamic therapy treatment
1828072|NCT00784121|Drug|Lactic Acid|Lactic Acid (Dermacyd Breeze)
1828073|NCT00784134|Drug|Alteplase|1.0 mg of alteplase will be administered via the intraventricular catheter every 8 hours for up to 12 doses
1828074|NCT00784134|Other|Normal saline|1 ml of normal saline will be administered via the intraventricular catheter every 8 hours for up to 12 doses
1828075|NCT00784147|Drug|Ibalizumab|Ibalizumab 800 mg IV every 2 weeks
1828076|NCT00784147|Drug|Ibalizumab|Ibalizumab 2000 mg IV every 4 weeks
1828077|NCT00784160|Drug|Lactic Acid (Dermacyd PH_DETINBACK Tangerine Mix)|Lactic Acid
1828078|NCT00784186|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
1828079|NCT00784186|Drug|misoprostol|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
1828080|NCT00784186|Drug|placebo|placebo resembling mifepristone taken 24 hours before 800 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
1828081|NCT00784212|Drug|BGG492|
1828082|NCT00784212|Drug|BGG492|
1828083|NCT00784212|Drug|Placebo|
1828084|NCT00784225|Drug|selenium|200 mcg daily for 7-12 years
1828085|NCT00784225|Drug|vitamin E|400 IU daily by mouth for 7-12 years
1828086|NCT00784225|Drug|vitamin E placebo|daily for 7-12 years
1828087|NCT00784225|Drug|selenium placebo|daily for 7-12 years
1828088|NCT00784238|Drug|Paliperidone|Paliperidone ER oral tablet will be administered once daily at a starting dose of 6 milligram (mg) for 24 weeks, wherein dose range will be 3 to 12 mg per day.
1828089|NCT00784277|Drug|oxycodone CR|flexible dose tablets and capsules 2 x a day for 28 days (20-60mg/day)
1828090|NCT00784277|Drug|oxycodone IR|10mg for 14 days
1828091|NCT00784277|Drug|Tapentadol ER (CG5503)|flexible dose tablets and capsules 2 x a day for 28 days (100-500mg/day)
1828092|NCT00784277|Drug|Tapentadol IR (CG5503)|50mg for 14 days
1828093|NCT00784277|Drug|Tapentadol IR (CG5503)|75mg for 14 days
1828094|NCT00784277|Drug|placebo|1 capsule for 14 days
1828095|NCT00784277|Drug|placebo|Tablets and capsules 2 x a day for 28 days
1828096|NCT00784290|Drug|Orantinib (TSU-68)|200 or 400 mg bid day 1～day 28 cycle until progression or unacceptable toxicity develops
1828098|NCT00784316|Drug|metoprolol, amiodarone|to compare the effectiviness of intravenous administration of metoprolol and amiodarone in the prevention of atrial fibrillation after cardiac surgery
1828099|NCT00784329|Device|Optical Frequency Domain Imaging (OFDI) System|Optical Frequency Domain Imaging(OFDI)System. Additional biopsy obtained from regions of normal appearing tissue. Up to an additional 20 minutes to standard Bronchoscopy
1828100|NCT00784355|Procedure|Laparoscopic cholecystectomy|Surgery
1828101|NCT00784368|Drug|ITCZ Oral Solution|ITCZ syrup product containing ITCZ 10 mg per ml in dose range of 20 ml to 40 ml daily for 7 days up to 12 weeks
1828102|NCT00784368|Drug|ITCZ-IV|200 mg IV twice daily for 2 days and once daily for the next 1 to 12 days
1828103|NCT00784381|Device|computer-assisted counselling about target drugs|implementation in experimental units of a software coupled to electronic prescribing system . This software is operating in patients with creatinine clearance below 60 ml/mn. When a target drug is prescribed to such a patient, the software checks if the drug is contraindicated due to impaired renal function, and if not checks if the dose is appropriate relatively to creatinine clearance value
1828104|NCT00784394|Drug|diindolylmethane|Given PO
1828105|NCT00784394|Other|placebo|Given PO
1828106|NCT00784394|Other|pharmacological study|Correlative studies
1828107|NCT00784394|Other|laboratory biomarker analysis|Correlative studies
1828108|NCT00784394|Other|quality-of-life assessment|Ancillary studies
1828109|NCT00784407|Device|harmonic scalpel device utilized intraoperatively|harmonic scalpel device utilized intraoperatively (FOCUS in group A and HARMONIC ACE in group B patients)
1828110|NCT00784420|Drug|UK-453,061|UK-453,061 1000 mg once daily for 10 days
1828111|NCT00784420|Drug|UK-453,061|UK-453,061 1000 mg once daily for 10 days
1828112|NCT00784420|Drug|Raltegravir|Raltegravir 400 mg twice daily for 10 days
1828113|NCT00784420|Drug|Raltegravir|Raltegravir 400 mg twice daily for 10 days
1828114|NCT00784433|Dietary Supplement|alcohol|150 cc
1828115|NCT00784446|Drug|Oxaliplatin, Capecitabine, Bevacizumab, Imatinib|"Dose level I:
Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 100 mg/m2 Capecitabine days 1-14 bid: 800 mg/m2 Imatinib days 1-21: 300 mg
Repeat on day 22.
Dose level II:
Bevacizumab day 1: 7,5 mg/kg body weight Oxaliplatin day 1: 130 mg/m2 Capecitabine days 1-14 bid: 1000 mg/m2 Imatinib days 1-21: 300 mg
Repeat on day 22."
1828116|NCT00784459|Drug|abatacept|Treatment with abatacept, 10 mg/kg IV, for 5 doses.
1828117|NCT00784459|Drug|Placebo|Treatment with Placebo, IV
1828118|NCT00784472|Drug|oxycodone|intravenous according to patients weight, pn.
1828119|NCT00784472|Drug|morphine|intravenous administration according to patients weight, pn.
1828120|NCT00784485|Drug|Xolair injections|In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
1828121|NCT00784498|Drug|Ketamine/Midazolam|Intravenous bolus of midazolam 0.1mg/kg in titrated dose of 1 mg/min until spontaneous eye closure or up to 5mg (whichever comes first) followed by ketamine 0.5-1mg/kg (up to 100mg) in titrated dose of 10mg/30 seconds, to achieve the desired level of sedation
1828122|NCT00784498|Drug|Propofol|Intravenous bolus of propofol 0.5-1mg/kg in titrated dose of 10mg/30seconds (up to 100mg) to achieve the desired level of sedation
1828123|NCT00784511|Dietary Supplement|cholecalciferol|4000 IU/d
1828124|NCT00784511|Other|microcrystalline cellulose|1/d
1828127|NCT00784537|Drug|ABVD|"ABVD courses are scheduled every 28 days:
Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15
ABVD courses are scheduled every 28 days:
Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15
Randomization to Arm A (Observation)"
1828128|NCT00784537|Drug|ABVD and Radiotherapy|"ABVD courses are scheduled every 28 days:
Doxorubicin 25 mg/m2 i.v. day 1 and 15 Bleomycin 10 mg/m2 i.v. day 1 and 15 Vinblastine 6 mg/m2 i.v. day 1 and 15 Dacarbazine 375 mg/m2 i.v. day 1 and 15
Randomization to Arm B, Radiotherapy, in patients in CR, on the area of initial bulky disease (see above for the definition of nodal and/or mediastinal bulk)."
1828129|NCT00784550|Drug|Tiotropium Bromide|Long-acting muscarinic antagonist
1828130|NCT00784550|Drug|Fluticasone Propionate/Salmeterol|Inhaled corticosteroid plus long-acting bronchodilator
1828131|NCT00784563|Behavioral|Continuous training|The maximal heart rate (HRmax) in the exercise prescription was based on age[Goldberg, Elliot, and Kuehl1988] and reduced by 20% in participants who used beta-blockers.[Wonisch et al. 2003] The duration of exercise sessions (3x/week) was advanced from 15 to 45 minutes over the first 6 weeks. The goal for continuous training was to remain within 70-80% of HRmax throughout the session.
1828132|NCT00784563|Behavioral|Interval training|Interval trainees alternated every 3 minutes between slower (60-70% of HRmax) and faster (80-90% of HRmax) walking [Wisloff et al. 2007].
1828133|NCT00784589|Drug|General Corticotherapy|for patients with severe pemphigus : general corticotherapy Arm : 1.5mg/kg/d for 1 month, then 1.25mg/kg/d for 1 month, then 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 3 months, then 0.3 mg/kg/d for 3 months, then 0.2 mg/kg/d for 4 months, then 0.1 mg/kg/d for 4 months, for patients with moderated pemphigus : general corticotherapy Arm : 1mg/kg/d for 1 month, then 0.75mg/kg/d for 1 month, then 0.5mg/kg/d for 2 months, then 0.3 mg/kg/d for 2 months, then 0.2 mg/kg/d for 3 months, then 0.1 mg/kg/d for 3 months,
1828134|NCT00784589|Drug|Rituximab|for patients with severe pemphigus : rituximab Arm : 1mg/kg/d for 1 month, then 0.75 mg/kg/d for 1 month, then 0.5 mg/kg/d for 1 month, then 0.3 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month, then 0.1 mg/kg/d for 1 month for patients with moderated pemphigus : rituximab Arm : 0.5mg/kg/d for 1 month, then 0.30 mg/kg/d for 1 month, then 0.2 mg/kg/d for 1 month,
1828135|NCT00784615|Procedure|Blood samples, transvaginal ultrasound|Total testosterone, bioavailable testosterone, Free androgen index, Total cholesterol, LDL Cholesterol, HDL Cholesterol, Triglycerides, insulinemia, OGTT, HOMA index, Adiponectin, C Reactive Protein
1828136|NCT00784654|Drug|Lisdexamfetamine dimesylate (LDX)|LDX 30, 50, or 70mg capsule once per day (open-label and double-blind periods)
1828137|NCT00784654|Drug|Placebo|Placebo capsule once per day (double-blind period)
1828138|NCT00784667|Drug|Cetuximab|400mg/m2 intravenously week 1, then 250 mg/m2 weekly intravenously
1828139|NCT00784667|Drug|Erlotinib|100mg orally daily continuously
1828140|NCT00784680|Drug|Anastrozole|1mg, orally, once daily
1828141|NCT00784680|Drug|Tamoxifen|20mg, orally, once daily
1828142|NCT00784693|Biological|Tanezumab|15 mg IV single dose
1828143|NCT00784693|Drug|Placebo|Placebo IV single dose
1828144|NCT00784706|Other|EP|Participants were asked to wear glasses with a patch on the right lens to block the visual stimuli from the right side and force them to receive the stimuli from the left-side visual field.
1828145|NCT00784706|Other|CIT|The CIT addressed forced use of the affected UE and restricted the unaffected UE during training. Shaping skills were delivered while participants were forced to use their affected UE in the mass practice of functional tasks, such as drinking water and opening a jar. Participants wore a mitt on their unaffected hand and wrist for 6 hours/day during the 3-week training and reported their compliance in a daily log.
1828146|NCT00784706|Other|conventional therapy|Traditional occupational therapy matched in intensity and duration with the other groups. The training program included stretching and weight bearing of the affected UE, improving the range of motion of the affected UE, muscle strengthening, and the practice of tasks used for functional training might involve the unaffected UE to assist in the affected UE; for example, stabilizing a bottle while opening its lid or moving pegs into holes on a board.
1828147|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, low dose, dosed at least once/day, 8 weeks
1828148|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, medium dose, dosed at least once/day, 8 weeks
1828149|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, intermediate dose, dosed at least once/day, 8 weeks
1828150|NCT00784719|Drug|CP-690,550|Ophthalmic topical solution, high dose, dosed at least once/day, 8 weeks
1828151|NCT00784719|Drug|Cyclosporine|Ophthalmic topical solution, 0.05%, dosed at least once/day, 8 weeks
1828152|NCT00784719|Drug|CP-690,550 Vehicle|Ophthalmic topical solution, dosed at least once/day, 8 weeks
1828153|NCT00784732|Drug|QAV680|
1828154|NCT00784732|Drug|QAV680|
1828155|NCT00784732|Drug|Mometasone Furoate|
1828156|NCT00784745|Drug|Dexamethasone|2mg morning and night for 5 days.
1828159|NCT00784771|Behavioral|Hypnotherapeutic Olfactory Conditioning (HOC)|
1828160|NCT00784784|Biological|Fluviral|One dose
1828161|NCT00784784|Drug|Zanamivir|10 mg, OD, for duration of influenza season (10-23 weeks)
1828162|NCT00784797|Drug|mifepristone and misopristol|200 mg mifepristone and after 48 hours vaginal misopristol 800 mgr followed by oral misopristol 400 mgr every 3 hours for maxamum 5 doses
1828163|NCT00784797|Drug|mifepristone and oxytocin|200 mg mifepristone followed 48 hours with high dose oxytocin drip (9 unit per hour)
1828164|NCT00784810|Drug|Oxycodone/Naloxone|5/2.5, 10/5 and 20/10 mg oxycodone/naloxone combination, 12 hourly
1828165|NCT00784810|Drug|Codeine/Paracetamol|15/500 and 30/500 mg codeine/paracetamol tablets, 2 tablets 6 hourly
1828166|NCT00784823|Drug|Bortezomib|"Bortezomib is administered by rapid I.V. push (over 3-5 seconds) via a central or peripheral vein into a flowing saline line
Bortezomib will be administered any time on day -4 and 24 hrs after the start of the melphalan infusion on day -1
Dosing will be based on actual body weight Patient weight must be measured within seven days of the start of the treatment regimen"
1828167|NCT00784823|Drug|Melphalan|"Melphalan is administered by rapid intravenous infusion via a central or peripheral vein over one hour
Melphalan will be dissolved with 10 ml of diluent to a concentration of 5 mg/mL which is then immediately diluted in 0.9% normal saline to a concentration NOT exceeding 0.45 mg/mL prior to administration
The final dilution of melphalan is physically and chemically stable for 60 minutes and therefore will be administered within that time period
Melphalan will be given as a single dose (not split over 2 or more days)
Dosing will be based body surface area calculated using actual body weight"
1828168|NCT00784836|Drug|BG9418 (interferon beta 1-a)|
1828169|NCT00784849|Drug|Methylene blue|1 mC1
1828170|NCT00784862|Drug|Anastrozole|1mg, orally, once daily
1828171|NCT00784862|Drug|Tamoxifen|20mg, orally, once daily
1828172|NCT00784875|Drug|LY2624803|1 mg, oral capsule, once nightly before bedtime
1828173|NCT00784875|Drug|LY2624803|3 mg, oral capsule, once nightly before bedtime
1828174|NCT00784875|Drug|Placebo|matching placebo (capsule or tablet), once nightly before bedtime
1828175|NCT00784875|Drug|zolpidem|5 or 10 mg, oral tablet, once nightly before bedtime
1828176|NCT00784888|Other|Aromatase inhibitors|non-interventional study
1828177|NCT00784914|Drug|temsirolimus|Receive temsirolimus IV
1828178|NCT00784914|Other|pharmacological study|Plasma levels of temsirolimus and sirolimus will be evaluated in serial blood samples.
1828179|NCT00784914|Other|cytokine levels|Dialysate samples are collected at regular intervals during the 96 hours following placement of the catheter to measure changes in levels of cytokines, chemokines and growth factors
1828180|NCT00784927|Biological|rituximab|
1828181|NCT00784927|Drug|cyclophosphamide|
1828182|NCT00784927|Drug|dexamethasone|
1828183|NCT00784927|Drug|lenalidomide|
1828184|NCT00784940|Drug|Anastrozole|1mg, orally, once daily
1828185|NCT00784940|Drug|Tamoxifen|20mg, orally, once daily
1828186|NCT00784966|Drug|etanercept|Treatment option 'A'-Two weeks treatment with etanercept. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two weeks.
1828187|NCT00784966|Drug|etanercept|Etanercept will be given for a total of 2 months. The first dose of 50mg in normal saline will be given intravenously one hour before transplant. Then 25mg will be administered subcutaneously two times a week for two months.
1828188|NCT00784979|Drug|CMVIG|400mg/kg IV (60mg/kg/IV/hr initially, titrated up) once a week up to four weeks
1828189|NCT00784992|Procedure|Endonasal dacryocystorhinostomy|"The standard dacryocystorhinostomy operation performed in this centre uses silicone tubes to stent open the newly created ostium between the lacrimal sac and the nasal cavity. However many surgeons in other departments / countries around the world perform the surgery without tubes. No large well-conducted RCT has been published comparing success rates / complication rates for the two techniques. For this study the control group is the arm which receives tubes (our standard procedure) and the 'interventional' group is the arm not receiving tubes.
Details of the operative technique for endonasal DCR with tubes can be found in the following reference: Dolman PJ. Comparison of external dacryocystorhinostomy with nonlaser endonasal dacryocystorhinostomy. Ophthalmology. 2003 Jan;110(1):78-84. The group that will not receive tubes will undergo the same procedure except that the insertion of tubes will be omitted."
1828190|NCT00785018|Drug|C1-esterase inhibitor|C1-esterase inhibitor 100 U/kg infusion over 30 minutes.
1828191|NCT00785018|Drug|Endotoxin administration|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
1828192|NCT00785031|Other|internet based vascular risk factor intervention|The patient and a nurse practitioner create an internet dossier and the patient is instructed on how to use the internet dossier. The internet dossier is mainly meant for the patient: to improve knowledge of vascular risk factors, to give an overview of the actual status of the levels of his/her vascular risk factors and to give guidance and personal advice how to treat risk factors with medication and/or lifestyle.
1828193|NCT00785044|Drug|I-123 mIBG|This was an observational study. Participants were previously dosed in separate study.
1828194|NCT00785083|Drug|FTY720|
1828195|NCT00785083|Drug|Placebo|
1828196|NCT00785096|Other|Questionnaire|Questionnaire, complications, grading severity, visual analog scale
1828197|NCT00785109|Dietary Supplement|Vitamin K supplementation|Daily vitamin K supplementation per os (2 mg once a day)Experimental 1 Placebo Experimental 2
1828198|NCT00785122|Drug|Endoxana, Leukine, IMA910|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90
1828199|NCT00785122|Drug|Endoxana, Leukine, IMA910, Aldara|a single i.v. infusion of 300 mg/m2 Endoxana (Cyclophosphamide) and then 3 days later (visit 1) patients will start vaccination therapy with intradermal (i.d.) injections of 75µg GM-CSF followed by i.d. injections of 5.78 mg IMA90 followed by Aldara (Imiquimod)
1828235|NCT00794157|Drug|Placebo capsules|Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
1828200|NCT00785135|Device|Lenses containing prismatic correction|The patient will receive lenses containing prismatic correction for heterophoria, as well as correction for hyperopia, myopia and astigmatism as indicated during initial examination.
1828201|NCT00785135|Device|Lenses not containing prismatic correction|The patient will receive lenses containing correction for hyperopia, myopia and astigmatism as indicated during initial examination. The patient will not receive prismatic correction in these lenses.
1828202|NCT00785148|Drug|Dermacyd PH_DETINLYN Sweet Flower (Lactic Acid)|
1828203|NCT00785161|Device|Penumbra System|Mechanical Thrombectomy in acute stroke
1828207|NCT00785187|Device|exposure to UVB radiation|exposure to UVB radiation for limited time in order to establish subject's minimal erythema dose.
1828208|NCT00785200|Other|Chlorhexidine|Chlorhexidine-soaked disposable cloths will be distributed each Monday, Wednesday, and Friday to each enrolled detainee for a 6-month period.
1828209|NCT00785200|Other|Water|Water-soaked disposable wash cloths identical in appearance to the CHG cloths will be distributed to enrolled detainees on every Monday, Wednesday, and Friday for a 6-month period.
1828210|NCT00785213|Drug|Rosiglitazone 4 mg Tablets|Rosiglitazone 4 mg tablet administered as a single oral dose on the morning of Day 1.
1828211|NCT00785213|Drug|Rosiglitazone 4 mg Tablets|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
1828212|NCT00785213|Drug|Quinine Sulfate 324 mg Capsules|Co-administered single oral doses of rosiglitazone 4 mg (1 x 4 mg tablet) and quinine sulfate 648 mg (2 x 324 mg capsules) on the morning of Day 7.
1828213|NCT00785226|Drug|RDEA119|Total daily doses of RDEA119 from 10 mg/day to 100 mg/day
1828214|NCT00785226|Drug|Sorafenib|Total daily doses of sorafenib from 400 mg/day to 800 mg/day.
1828215|NCT00793988|Procedure|Vibration-assisted anaesthesia|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.
The vibration device and placebo will be operated by a single oculoplastics fellow. The vibrating device / placebo will be placed on the middle of the forehead 1 cm above the mid-brow point 1 second before the anaesthetic injection is commenced. It will be lifted off the skin every time the injection needle exits the skin and it will be replaced on the same point 1 second before the needle reenters the skin at a new injection site."
1828216|NCT00793988|Procedure|Switched-off vibrating device|The placebo consists of a switched-off vibrating device applied to the test site and a second identical switched-on vibrating device held close (but not touching) the first, which will therefore make the same sound. Care will be taken to ensure that the devices are out of the participants' view. The test and placebo will be randomly assigned to either the first or second eyelid; the right eyelid will be injected first in all patients, as is our routine practice.
1828217|NCT00794001|Behavioral|Data analysis and Feedback|Data analysis feedback: quarterly meetings with all stakeholders to present data and discuss potential areas of improvement.
1828218|NCT00794014|Procedure|Conservative strategy|"Main vessel stenting was performed.
Side branch ballooning and kissing ballooning were done if Thrombolysis In Myocardial Infarction (TIMI) flow <3 in the side branch after main vessel stenting in non-left main bifurcation (non-LM) subgroup, and diameter stenosis (DS) >75% in LM subgroup.
Side branch stenting was performed if TIMI flow <3 in the Side branch after ballooning in non-LM subgroup, and DS >50% or dissection in the Side branch after ballooning in LM subgroup."
1828219|NCT00794014|Procedure|Aggressive strategy|"Main vessel was performed.
Side branch ballooning and kissing ballooning were done if DS >75% in the side branch after main vessel stenting in non-LM subgroup, and DS >50% in LM subgroup.
Side branch stenting was performed if DS >50% in the side branch after ballooning in non-LM subgroup, and DS >30% or dissection in the side branch after ballooning in LM subgroup."
1828220|NCT00794027|Behavioral|Yoga Classes|8 weeks of yoga training that occurs 2 times per week. The patients will also perform yoga breathing at home 3 times per week.
1828221|NCT00794027|Behavioral|Yoga classes|Heart failure patients will undergo 8 weeks of yoga training 2 times per week and perform yoga breathing at home 3 times per week
1828224|NCT00794053|Procedure|detecting lymph node metastasis by staining|this started by collar incision, development of sub-platysmal skin flaps and separation of strap muscles in the midline. This was followed by exposure of the thyroid gland; identification of the thyroid tumour; injection of the dye into the tumour; waiting for the dye to reach the lymph nodes; identifying the stained node; labeling it as the sentinel node (SLN); performing total thyroidectomy and bilateral central neck dissection.
1828226|NCT00794079|Dietary Supplement|omega-3 fatty acids|4 grams per day for 8 weeks
1828227|NCT00794079|Dietary Supplement|corn oil|4 grams per day for 8 weeks
1828228|NCT00794092|Drug|Sinerem administration|Single dose
1828229|NCT00794118|Other|As per clinical practice|As per clinical practice
1828230|NCT00794131|Biological|GL-ONC1|a genetically-engineered vaccinia virus (encoding Renilla luciferase-Aequorea green fluorescent protein fusion, β-galactosidase, and β-glucuronidase )
1828231|NCT00794144|Drug|Olopatadine Hydrochloride Nasal Spray 0.6%|one spray in each nostril twice daily for 2 weeks
1828232|NCT00794144|Drug|Olopatadine Hydrochloride Nasal Spray Vehicle|one spray in each nostril twice daily for 2 weeks
1828233|NCT00794157|Drug|Indacaterol 150 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
1828234|NCT00794157|Drug|Indacaterol 300 μg capsules|Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
1828459|NCT00803062|Drug|Paclitaxel|Given IV
1828236|NCT00794170|Behavioral|Telephone and Print based intervention|Thiss intervention consisted of tailored phone calls and follow-up mailings.
1828237|NCT00794183|Device|CRT device settings|Comparision of A-V delay settings
1828238|NCT00794196|Behavioral|Pharmaceutical care program for antidepressant treatment|The pharmaceutical care program is a support program for patients starting and maintaining antidepressant treatment.
1828239|NCT00794209|Drug|i.v fentanyl, AeroLEF|"i.v fentanyl
5 mL of AeroLEF in Opti-Mist 750E continuous flow nebulizers (Maersk Medical Inc., (USA), McAllen, Texas)
5 mL, of AeroLEF in Misty-Neb continuous flow nebulizers (Allegiance Healthcare Corp., McGaw Park, Illinois)
5 mL of AeroLEF in PARI LC-Plus continuous flow nebulizers (PARI Respiratory Equipment Inc., London, Ontario)
3 mL, of AeroLEF in AeroEclipse breath-actuated nebulizers (Trudell Medical International, London, Ontario) - reference device."
1828241|NCT00794235|Drug|Sorafenib (Nexavar), Dacarbazine (DTIC)|"Sorafenib: 2x400 mg daily PO (2 tablets (200 mg each) each AM and PM). DAY 1-56.
DTIC: 1-hour IV infusion 1000mg/m2 DAY 14 and 42."
1828242|NCT00794248|Drug|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
1828243|NCT00794248|Drug|fexofenadine|Allegra 180 mg daily x 7 days
1828244|NCT00794261|Drug|Injection of Pegfilgrastim|Single subcutaneous administration of Pegfilgrastim (Neulasta® - Laboratory AMGEN) 6 mg at D5
1828245|NCT00794261|Drug|Injection of Filgrastim|Daily subcutaneous administration of Filgrastim (Neupogen® - Laboratory AMGEN) 5 µg/kg/day from D5 until recovery from aplasia (PNN > 0.5 G/L)
1828246|NCT00794274|Drug|CC-100004|After the screening period, subjects will receive CC-10004 20mg by mouth BID for 84 days. The 84-day duration of treatment is expected to provide adequate time to assess the short-term efficacy and safety of CC-10004 in a population of subjects with chronic cutaneous sarcoidosis.
1828247|NCT00794287|Other|Taking blood samples|No intervention is done. Only blood samples are taken.
1828248|NCT00794300|Device|second magnetic resonance imaging scan|
1828249|NCT00794313|Drug|Amantadine 300 mg|Amantadine, 300 mg, capsule, three times a day, two weeks
1828250|NCT00794313|Drug|Topiramate|Topiramate, 25 mg, capsule, two times a day, 1 week Sugar Pill, capsule, one time a day, 1 week Topiramate, 50 mg, capsule, three times a day, 1 week
1828251|NCT00794313|Drug|Sugar Pill|sugar pill, capsule, three times a day, 2 weeks
1828252|NCT00801632|Procedure|Kidney Transplantation|Surgical transplantation of donor kidney
1828253|NCT00801632|Procedure|Bone marrow transplantation|During kidney transplant, bone marrow cells donated by the same donor as the kidney are given through a plastic tube placed in a vein in the chest, underneath the collarbone
1828254|NCT00801632|Biological|MEDI-507|0.1 mg/kg on day -2; 0.6 mg/kg on days -1,0,1
1828255|NCT00801632|Drug|cyclophosphamide|60 mg/kg infusion on days -5, -4
1828256|NCT00801632|Biological|rituximab|375 mg/m^2 infusion on days -7, -2, 5, and 12
1828257|NCT00801632|Drug|Tacrolimus|0.05 mg/kg intravenously twice daily starting on day -1, adjusted to trough level of 10-15ng/ml, then tapered (if eligible) on days 1, 7, 14, 21, 28, 42, and 56
1828258|NCT00801632|Drug|corticosteroids|2 mg/kg prednisone on day 4, with an additional 500-mg pulse of methylprednisolone given on days 10, 11, and 12, and then tapered off by day 20
1828259|NCT00801632|Radiation|thymic irradiation|700 cGy of thymic irradiation administered in a single dose on day -1
1828260|NCT00801645|Behavioral|Exercise|The exercise groups engage in aerobic exercise training three 60-minute sessions per week for 12 weeks, in addition of school physical education. Training sessions consist of 30 minutes of aerobic exercise (walking, running, games, swimming), followed by strength training and stretching.
1828261|NCT00801658|Device|selective Laser Trabeculoplasty (SLT)|
1828262|NCT00801671|Procedure|cPAP|After reaching target level of BP patients will be randomized in active group (cPAP) and control group (sham-cPAP)
1828263|NCT00801684|Drug|Placebo|Supplied as an empty size-2 capsule and administered as a single dose via C2S inhaler.
1828264|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
1828265|NCT00801684|Drug|TrIP-2SS|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
1828266|NCT00801684|Drug|TrIP-2D|Trospium inhalation powder containing 400 mcg TrCl (trospium chloride), supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
1828267|NCT00801684|Drug|TrIP-2SS + Foradil|Trospium inhalation powder containing 100 mcg TrCl (trospium chloride), plus foradil (12 mcg formoterol fumarate) supplied as dry powder in size-2 capsules and administered as a single dose via C2S inhaler.
1828268|NCT00801697|Biological|DNA Vaccine|4 mg VRC-HIVDNA044-00-VP administered as 1 mL
1828269|NCT00801697|Biological|DNA Vaccine placebo|1 mL VRC-PBSPLA043-00-VP
1828270|NCT00801697|Biological|rAd35|VRC-HIVADV027-00-VP 1 x 10^10 PU administered as 1 mL
1828271|NCT00801697|Biological|rAd35 placebo|1 mL VRC-PBSPLA043-00-0VP
1828272|NCT00801697|Biological|rAd5|4 mg VRC-HIVADV038-00-VP administered as 1 mL
1828273|NCT00801697|Biological|rAd5 placebo|1 mL VRC-DILUENT013-DIL-VP
1828274|NCT00801710|Device|BridgePoint Medical System (CrossBoss Catheter, Stingray Catheter, Entera Guidewire)|"Revascularization of coronary artery chronic total occlusion.
Use of the BridgePoint Medical System to cross coronary CTOs prior to definitive revascularization treatment via angioplasty and/or stent implant"
1828275|NCT00801723|Drug|Budesonide MMX 6 mg Tablet|Budesonide MMX 6 mg Tablet once daily.
1828276|NCT00801723|Drug|Placebo Tablet|Placebo Tablet once daily.
1828277|NCT00801736|Drug|Cisplatin, Paclitaxel|"Cisplatin 75mg/m2, Day 1
Paclitaxel 175mg/m2, Day 1"
1828278|NCT00801749|Behavioral|sleep|
1828279|NCT00801762|Device|Fibered confocal microscope|
1828280|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
1828281|NCT00801788|Drug|Oxycodone hydrochloride|Extended release tablet
1828454|NCT00803023|Drug|Sodium Oxybate Oral Solution (6 grams)|6 grams per night taken in two equally divided doses
1828282|NCT00801801|Drug|Docetaxel + Sorafenib|Subjects will be treated with metronomic chemotherapy with low dose docetaxel weekly for 3 out of 4 weeks, and sorafenib will be administered continuously 400 mg bid on a 28 day cycle. Treatment with metronomic chemotherapy will be expressed as a 4-week cycle. Tumor response to treatment will be evaluated after every 8 weeks. Treatment with metronomic chemotherapy and sorafenib will continue for a total of 6 cycles unless there is evidence of disease progression, intolerable toxicity, or withdrawal of consent. Maintenance therapy with sorafenib will then continue until disease progression, intolerable toxicity or withdrawal of consent.
1828283|NCT00801814|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
1828284|NCT00801814|Dietary Supplement|PolyGlycopleX (PG)|5.0 grams of PGX
1828285|NCT00801814|Dietary Supplement|PolyGlycopleX|7.5 grams of PGX
1828286|NCT00801814|Dietary Supplement|Control|0g of PGX
1828287|NCT00801814|Dietary Supplement|Second Control|0g of PGX
1828288|NCT00801827|Drug|F-18 (fallypride)|Subjects undergoing bariatric surgery will have Positron Emission Tomography (PET)scans of their brains using the radioligand fallypride before and after the operation.
1828289|NCT00801853|Drug|Aerovant|Aerovant 1mg bid (dry powder)
1828290|NCT00801853|Drug|Aerovant|Aerovant 3mg bid (dry powder)
1828291|NCT00801853|Drug|Aerovant|Aerovant 10mg bid (dry powder)
1828292|NCT00801853|Other|placebo|placebo control (dry powder)
1828293|NCT00801866|Drug|Bevacizumab|Intravitreal administration
1828294|NCT00801866|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation
1828295|NCT00801879|Drug|Mupirocin calcium ointment, 2%|0.25 g in each nostril twice daily for 5 days (given monthly for up to 8 months)
1828296|NCT00801879|Drug|Placebo ointment|Placebo ointment 0.25g in each nostril twice daily for 5 days (repeated monthly for up to 8 months)
1828297|NCT00801892|Device|Continuous Positive Airway Pressure (CPAP)|Worn over nose to splint open the airway and prevent the subject from holding their breath (apneas).
1828298|NCT00801892|Device|Sham- Continuous Positive Airway Pressure (Sham-CPAP)|Worn over nose to splint open the airway and prevent the subject from holding their breath (apneas).
1828299|NCT00801905|Drug|Nepafenac|Topical nepafenac 0.1% is administrated every 6 hour 1 week before start pan-retinal photocoagulation and 4 weeks during all laser session performed biweekly, and 4 weeks after last laser sessión was completed.
1828300|NCT00801905|Other|Lubricant|Topical lubricating is administrated every 6 hours at fellow eye 1 week before start pan-retinal photocoagulation, 4 weeks during each laser session performed biweekly, and 4 weeks after last laser sessión was completed
1828301|NCT00801918|Drug|Denileukin Diftitox|Denileukin Diftitox: 18 mcg/kg/day: days 1-5 in cycles 1,2,3,4
1828302|NCT00801918|Drug|Denileukin diftitox, ifosfamide, cyclophosphamide, etoposide|Denileukin Diftitox: 18 mcg/kg/day days 1-2 in cycles 5 and 6 Ifosfamide: 3000mg/m²/IV/d X 3 days + Mesna 3000 mg/m2/d X 3 days Carboplatin: 635mg/m2/d X 1 day Etoposide: 100mg/m2/d X 3 days
1958707|NCT01350674|Procedure|EBUS-TBNA|endobronchial ultrasound transbronchial needle aspiration
1828309|NCT00801944|Drug|Solifenacin succinate|oral
1828310|NCT00801944|Drug|Placebo|oral
1828311|NCT00801957|Drug|tacrolimus ointment 0.03%|topical application
1828312|NCT00801957|Drug|hydrocortisone acetate ointment 1%|topical application
1828313|NCT00801957|Drug|hydrocortisone butyrate ointment 0.1%|topical application
1828314|NCT00801957|Biological|Meningitec|im injection
1828315|NCT00801957|Biological|AC VAX|im injection
1828316|NCT00801970|Behavioral|Psychological Treatment|15 weekly therapy sessions.
1828317|NCT00801970|Behavioral|Group Therapy|3 months of weekly group therapy sessions.
1828318|NCT00801983|Device|Alternative Keyboard|Subjects use either a typical or alternative keyboard
1828319|NCT00802009|Drug|Dexamethasone|Dexamethasone 8 milligrams (liquid) will be added to standard anesthetic solution administered during routine brachial plexus nerve blockade.
1828320|NCT00802009|Drug|Mepivicaine|Standard anesthetic solution administered during routine brachial plexus nerve blockade.
1828455|NCT00803049|Drug|Teriflunomide (HMR1726)|Tablet, oral administration QD.
1958712|NCT01343043|Biological|NY-ESO-1(c259)T Cells|Cytoreductive chemotherapy followed by infusion with NY-ESO-1(c259) transduced autologous T cells. Subjects will receive one infusion of NY-ESO-1 genetically engineered T cells on Day 0.
1958718|NCT01331239|Drug|LCI699|
1828321|NCT00802022|Device|spinal cord stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (50% of more pain reduction)a definite spinal cord system will be implanted.
1828322|NCT00802035|Drug|Baclofen IR|30 mg; single dose
1828323|NCT00802035|Drug|Baclofen ER|30 mg; single dose
1828324|NCT00802048|Drug|Local anesthetic (Ropivacaine)|Local anesthetic infusion
1828325|NCT00802048|Drug|Saline|Saline serum infusion
1828326|NCT00802061|Behavioral|Sleeping position in glaucoma patient|
1828327|NCT00802074|Drug|Raltegravir|400mg BID
1828328|NCT00802074|Drug|Fosamprenavir|1400mg BID, 700 mg BID or 1400 mg QD
1828329|NCT00802074|Drug|Ritonavir|100 mg BID or QD
1828330|NCT00802087|Drug|hydrocodone|Extended Release tablet
1828331|NCT00802087|Drug|hydrocodone & acetaminophen combination|Immediate Release tablet, hydrocodone and acetaminophen combination product
1828332|NCT00802100|Drug|Olanzapine|Daily tablets of 10 to 30 mg
1828333|NCT00802100|Drug|Perphenazine|Daily tablets of 8 to 24 mg
1828334|NCT00802100|Drug|Aripiprazole|Daily tablets of 10 to 30 mg
1828335|NCT00802100|Drug|Metformin|Daily tablets of 850 to 2550 mg
1828336|NCT00802100|Drug|Simvastatin|Daily tablets of 20 to 40 mg
1828337|NCT00802100|Drug|Benztropine|Daily tablets of 1 to 2 mg
1828340|NCT00802126|Drug|"Combination therapy IVB + rf-PDT"|low-fluence photodynamic therapy combined with intravitreal bevacizumab
1828341|NCT00802139|Drug|venoferrum(iron sucrose)|administer once weekly calculated quantity of Venoferrum® ampoules according to body weight and Hb level.
1828342|NCT00802139|Drug|Bolgre (Iron acetyl-transferase)|Twice daily administration with Bolgre® soln (one pouch per dosing which is equivalent to 40mg of iron) for 5 weeks
1828343|NCT00802152|Other|Home monitoring|The subject will take their blood pressure or glucose measurements 1-4 times per day, depending on patient condition. They will upload these measurements using the device to a secure website at least every other day. Data will be reviewed at least 2 times per week Monday through Friday by the clinic nursing staff. Data indicating problems, e.g., critical out of range values, will be communicated to the patient's primary care physician after review by the nurse. The physician will then determine what is needed for follow up action based on the patient's condition and data (e.g., telephone call to patient home, scheduling a clinic appointment, etc).
1828344|NCT00802165|Device|Electroacupuncture|Group is given a total of four electroacupuncture treatments to evaluate it's anesthetic effectiveness
1828345|NCT00802165|Device|Sham electroacupuncture|Sham electroacupuncture treatment gives comparison to the experimental group
1828346|NCT00802204|Radiation|PET scan|"Both lean and obese undergo a PET scan of the brain using the radioligand,fallypride [18F] at baseline. Obese subjects who complete caloric restriction will have repeat scan after diet.
Completed at baseline and post-VLCD"
1828347|NCT00802204|Procedure|Oral glucose tolerance test|Subjects will be required to drink a glucose solution; blood samples will be taken over a 5-hour time period Completed at baseline by both lean and obese and in obese post-VLCD
1828348|NCT00802204|Procedure|MRI|An MRI of the brain and abdomen will be performed prior to PET scan One time at baseline in both lean and obese
1828349|NCT00802204|Behavioral|Psychological scales to assess attitudes and behaviors related to eating and quality of life|A series of short psychological scales will be administered during the study. Completed at baseline
1828350|NCT00802204|Other|Caloric Restriction|Obese participants only complete a short-term (~10days) very low calorie diet
1828351|NCT00802217|Drug|Civamide|5 mg liquid filled softgel capsules
1828352|NCT00802217|Drug|Civamide|5 mg x 2 liquid softgel capsules
1828353|NCT00802230|Drug|Terbutaline Infusion|
1828354|NCT00802243|Drug|leflunomide|
1828355|NCT00802256|Procedure|pulpotomy|removal of caries and cronal pulp tissue and then restoring of tooth
1828356|NCT00802269|Procedure|Retinal laser photocoagulation|Retinal laser photocoagulation using a 532 nm laser
1828357|NCT00802282|Drug|psilocybin|dose manipulation as described in the protocol and to which volunteers are blinded
1828358|NCT00802282|Behavioral|Intensity of support for spiritual practice|Volunteers will be assigned to standard or high support, as described in the protocol
1828359|NCT00802282|Behavioral|Number of sessions|Volunteers will be assigned to either 2 or 3 sessions, as described in the protocol
1828360|NCT00802295|Drug|Gonadotrophins|Administration of standard ovarian stimulation protocol
1828361|NCT00802295|Drug|Low dosis Gonadotrophin|
1828362|NCT00802308|Drug|Morphine sulphate|Extended release tablet combined with alcohol or water
1828363|NCT00802321|Drug|Dutasteride|Subjects will receive a single dose of 2, 3 or 4 mg of dutasteride based on random assignment.
1828364|NCT00802334|Drug|generic lopinavir/ritonavir|"Screening visit
• Clinical and safety laboratory assessment. Viral load for patients on a PI-based regimen, if a VL results ≤ 3 months is not available
Baseline visit
• (Within 30 days after screening) Baseline clinical and laboratory assessment, patients who were on a Kaletra SGC formulation before baseline will undergo TDM. Start generic lopinavir/ritonavir tablets 200/50 in a 400/100mg bid dosage. Backbone will be chosen on the discretion of the study physician
Week 4
Steady state TDM lopinavir and ritonavir, at 10-12 hr after the last intake (Cmin)
Clinical, safety and laboratory assessment
Week 12: Clinical, safety and efficacy laboratory assessment Week 24: Clinical, safety and efficacy laboratory assessment Week 48: Clinical, safety and efficacy laboratory assessment"
1828365|NCT00802347|Drug|I5NP|"Single IV injection of I5NP
Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg
Part B: 10.0 mg/kg"
1828366|NCT00802347|Drug|Saline|"Single IV injection of saline
Part A: dose-escalation study; cohort 1 = 0.5 mg/kg; cohort 2 = 1.5 mg/kg; cohort 3 = 5.0 mg/kg; cohort 4 = 10.0 mg/kg
Part B: 10.0 mg/kg"
1828367|NCT00802360|Drug|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
1828368|NCT00802360|Drug|Progestrone vaginal insert|100 mg progesterone vaginal insert 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
1828369|NCT00802360|Drug|follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days until human chorionic gonadotropin (hCG) criteria are met.
1828370|NCT00802360|Drug|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
1828371|NCT00802360|Drug|Ganirelix|Ganirelix acetate 250 µg as a daily subcutaneous injection starting on day 6 and continuing until hCG criteria were met.
1828372|NCT00802373|Drug|Solifenacin succinate|oral
1828373|NCT00802373|Drug|Tolterodine|Oral
1828374|NCT00802399|Procedure|Partial Lacrimal Punctual Occlusion|Cauterization of the edge of all lacrimal punctum was carried out in all patients
1828375|NCT00802412|Drug|Topiramate|Topiramate will be titrated over 5 weeks to a maximum dosage of 200 mg according to the following schedule: 25mg daily for days 1-7, 50mg daily for days 8-14, 75mg daily for days 15-21, 100mg daily for days 22-28, 150mg daily for days 29-35, 200mg daily for days 36-42. Maximum dosage will be maintained for 6 weeks, followed by a one-week taper-off period (100mg daily for 4 days and 50mg daily for 3 days).
1828376|NCT00802412|Drug|Placebo|Placebo/study medication will be administered in opaque capsules in an identical fashion to maintain the double-blind study design.
1828377|NCT00802425|Drug|AM-111|single intratympanic injection
1828378|NCT00802425|Drug|placebo|single intratympanic injection
1828380|NCT00802451|Drug|Mesalamine|
1828383|NCT00802477|Procedure|Application of autologous blood products.|Autologous blood products (platelet rich and platelet poor plasma) produced by the PlasmaxTM Plus Plasma Concentration System will be applied to the surgical site.
1828384|NCT00802477|Procedure|Standard Modified Radical Mastectomy|Mastectomy per standard procedure without the application of autologous blood products.
1828385|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played twice a week, 1 hour per session for a period of ten weeks.
1828386|NCT00802490|Device|Brain-Computer Interface System|Newly-developed video games employing neurofeedback strategy to be played once for 1 hour.
1828387|NCT00802503|Dietary Supplement|SPN|SPN : in the treated group, SPN is started if at day 4 energy input by EN is < 60% of energy target in order to reach 100% of energy target by peripheral or central line.
1958727|NCT01314118|Drug|abiraterone acetate in combination with prednisone|Abiraterone acetate will be taken as 4 x 250 mg tablets by mouth (PO) once daily. Prednisone will be taken as 2 x 2.5 mg tablets PO once daily.
1958728|NCT01311024|Biological|PCV GSK1024850A|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
1828391|NCT00802529|Drug|Methylprednisolone|2 transtympanic injections at interval of two weeks.
1828392|NCT00802529|Drug|Gentamicin|2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
1828393|NCT00802555|Drug|ARQ 197|360 mg administered twice daily until disease progression, unacceptable toxicity, or other discontinuation criterion is met
1828394|NCT00802568|Biological|anti-thymocyte globulin|
1828395|NCT00802568|Drug|busulfan|
1828396|NCT00802568|Drug|fludarabine phosphate|
1828397|NCT00802568|Procedure|allogeneic bone marrow transplantation|
1828398|NCT00802568|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1828399|NCT00802581|Procedure|Circumferential spread of local anesthetic|The anesthetist will ensure, under ultrasound guidance, that local anesthetic (1 mL of 1% lidocaine) surrounds the sciatic nerve.
1828400|NCT00802581|Procedure|Non-circumferential spread of local anesthetic|"The anesthetist will perform a single shot injection of local anesthetic (1 mL of 1% lidocaine) near the sciatic nerve under ultrasound guidance, without ensuring circumferential spread around the nerve."
1828401|NCT00802594|Drug|DB289|A single 100 mg DB289 capsule will be taken by mouth twice a day, morning and evening. Drug is to be taken with a glass of water within 15 minutes of the completion of meal.
1828402|NCT00802620|Procedure|Conjunctival autograft versus conjunctival autograft treatment for recurrent pterygia|Amniotic membrane Conjunctival autograft Conjunctival autograft Recurrent pterygia
1828403|NCT00802633|Device|Stapling device during radical cystectomy|Hemostasis
1828404|NCT00802633|Device|Ligasure tissue sealing device|Efficacy of tissue sealing device during hemostasis
1828405|NCT00802646|Drug|saline|intrathecal preservative free normal saline, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested
1828406|NCT00802646|Drug|fentanyl/bupivacaine/epinephrine|intrathecal 0.125% fentanyl/bupivacaine/epinephrine, 8ml/hour, beginning after intrathecal sufentanyl until additional pain medication is requested The mother will then receive a new bag of fentanyl/bupivacaine/epinephrine.
1828407|NCT00802659|Radiation|Stereotactic radiotherapy|This study has 4 treatment groups: This will be determined based on what radiation treatment doses have been previously given to the patient on this study, how effective the dose has been with treatment patient's pain, and how many side effects participants before you have experienced.
1828408|NCT00802672|Drug|Ciclopirox Olamine Cream|topical cream
1828409|NCT00802672|Drug|Loprox Cream 0.77%|topical cream
1828410|NCT00802672|Drug|Placebo|topical cream
1828450|NCT00803010|Drug|Rapamycin (RAPA)|Rapamycin: initially as 9 mg oral loading dose on day -1. Thereafter, administered as an oral regimen of 4 mg daily.
1828451|NCT00803023|Drug|Sodium Oxybate|4.5 grams per night taken in two equally divided doses
1828452|NCT00803023|Drug|Sodium Oxybate & 6 Tablets|4.5 grams taken as a combination of liquid and 6 Placebo tablets in two equally divided doses per night
1828453|NCT00803023|Drug|Sodium Oxybate & 8 Tablets|6 grams taken as a combination of liquid and 8 Placebo tablets in two equally divided doses per night
1828456|NCT00803062|Biological|Bevacizumab|Given IV
1828411|NCT00802685|Drug|Early ibuprofen|"IBUPROFEN SCHEDULE: initial dose 10 mg/kg, then 2 doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Initial therapy is blinded. At PDA diagnosis, infants randomized to early treatment receive blinded ibuprofen. Infants randomized to late treatment receive blinded placebo. Hemodynamically significant PDA criteria: SIGNS OF PDA + pulmonary hemorrhage OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due to PDA) defined as at least two of the following: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV. Once hemodynamically significant PDA criteria met, if echo is positive, infants from both groups can receive open label ibuprofen."
1828412|NCT00802685|Other|Late ibuprofen expectant group (placebo)|"Drug: Late ibuprofen expectant group (placebo): DOSING SCHEDULE: At PDA diagnosis infants randomized to late ibuprofen expectant group will receive blinded placebo. If hemodynamically significant PDA develops, infants now receive open label ibuprofen at an initial dose of 10 mg/kg, then two doses 5 mg/kg each, after 24 and 48 h, slow IV infusion. Signs of a hemodynamically significant PDA include: SIGNS OF PDA + pulmonary hemorrhage ALONE OR SIGNS OF PDA +: Pulmonary edema, plus a large heart on CXR + one of the following: Hypotension, Respiratory failure (due PDA) defined as at least 2 of the following settings: Need for supplemental O2 > 50%; need IMV >40; need for PIP > 20; or need for HFOV."
1828413|NCT00802698|Device|Transcorneal electric stimulation|central artery occlusion
1828414|NCT00802698|Device|Transcorneal stimulation|new waveform
1828415|NCT00802698|Device|transcorneal electric stimulation|Novel waveform central artery occlusion
1828416|NCT00802711|Radiation|3-dimensional conformal radiation therapy|Given twice a day for 10 fractions
1828417|NCT00802711|Radiation|brachytherapy|Given twice a day for 10 fractions
1828418|NCT00802724|Behavioral|Classification-directed treatment|People in the Classification-directed treatment will be treated based on their direction-specific LBP classification. Treatment will consist of 3 primary components. The first component of treatment will be analysis and instruction in modification of the person's direction-specific alignment and movement strategies during symptomatic functional activities and activities in which the person uses similar strategies to those displayed with symptomatic functional activities. The second component is education about the principles of tissue injury and healing and the need to keep active. The third component is exercise prescription that consists of practice in performance of modified versions of the direction-specific impairment tests from the exam, with an emphasis on impairments that can be modified to eliminate symptoms.
1828419|NCT00802724|Behavioral|Non-specific treatment|People in the Non-specific treatment will be provided treatment that incorporates treatment commonly cited in the literature for people with chronic LBP. The first component of treatment will consist of training in functional activities based on biomechanical principles. The second component will include general education about low back pain. The third component is exercise prescription that is directed at improving the strength and flexibility of the trunk and limbs.
1828420|NCT00802737|Drug|Ofatumumab|Eight once weekly infusions (1 x 300 mg + 7 x 2000 mg), then 2000 mg once monthly for two years
1958729|NCT01311024|Biological|hepatitis B vaccine or hepatitis A vaccine|2 to 4 doses administered to the siblings in the cluster-randomized Finnish Invasive pneumococcal Disease Trial (ClinicalTrials.gov Identifier:NCT00861380)
1828422|NCT00802776|Procedure|Femtosecond laser assisted keratoplasty|
1828423|NCT00802776|Procedure|PKP|
1828424|NCT00802802|Drug|Efavirenz (EFV)|Participants will be administered oral EFV at a dose ranging from 50 mg to 800 mg once daily, based on weight and CYP 2B6 genotype. EFV capsules will be opened into a small amount of a compatible food or liquid vehicle; the smallest amount of food or liquid that will enable the child to swallow the capsule contents should be used (i.e., EFV should not be taken with a meal).
1828425|NCT00802802|Drug|Rifampin-containing anti-TB therapy|Treatment with rifampin-containing anti-TB treatment regimen. Treatment will last at least 24 weeks and up to 36 weeks.
1828426|NCT00802815|Drug|Etanercept|50 milligrams subcutaneously every week
1828427|NCT00802828|Drug|Famotidine Tablets, 40 mg|
1828428|NCT00802841|Drug|nilotinib|Supplied as 200 mg tablets
1828429|NCT00802841|Drug|imatinib|Supplied as 100 mg and 400 mg tablets
1828430|NCT00802867|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis (DAPTACEL®)|0.5 mL, Intramuscular
1828431|NCT00802880|Drug|Dacarbazine|
1828432|NCT00802893|Drug|6R-BH4|6R-BH4 5mg/kg or Placebo BID for four weeks and then 8 week dose-escalation period
1828433|NCT00802893|Other|Placebo|placebo given BID for entire length of study
1828434|NCT00802906|Device|subthreshold micropulselaser|on demand if leakage is persistent or recurs after initial treatment
1828435|NCT00802906|Drug|bevacizumab|1.5 mg initial intravitreal injection
1828438|NCT00802932|Device|Non-contrast Computed Tomography (CT) Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy, and during weeks 2, 4, 6.
1828439|NCT00802932|Device|Non-contrast CT Scans (Metallic Markers)|Non-contrast CT Scans prior to start of radiation therapy and on Day 5.
1828440|NCT00802945|Drug|NKTR-102|NKTR-102 given on a q14 day schedule
1828441|NCT00802945|Drug|NKTR-102|NKTR-102 given on a q21 day schedule
1828442|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Reference Product|Small amount applied and evaluated over the course of a day
1828443|NCT00802958|Drug|Halobetasol Propionate 0.05% Ointment-Test Product|Small amount applied and evaluated over the course of a day
1828444|NCT00802971|Dietary Supplement|FOS|Oligofructose (FOS, BioCare Ltd, Birmingham, England) powder will be distributed in sachets of 10 g. Two sachets are to be included in daily nutrition, preferentially 10 g diluted in water at breakfast and before supper.
1828445|NCT00802984|Device|Endovascular thoracic aortic aneurysm repair using TALENT TAA Stent Graft System|
1828446|NCT00802997|Device|Sinergy|radiofrequency denervation
1828447|NCT00802997|Device|Placebo sham|sham procedure
1828448|NCT00803010|Drug|Tacrolimus (TAC)|Tacrolimus: administered at 0.02 mg/kg/day (based on ideal body weight) continuous IV infusion or equivalent oral dosing starting on day -3.
1828449|NCT00803010|Drug|Methotrexate (MTX)|Methotrexate: administered on day 1 at dose of 15 mg/m^2, and a dose of 10 mg/m^2 on days 3, 6, and 11. Dose can be adjusted for reduced creatinine clearance.
1828457|NCT00803062|Drug|Cisplatin|Given IV
1828460|NCT00803062|Other|Quality-of-Life Assessment|Ancillary studies
1828461|NCT00803062|Other|Questionnaire Administration|Ancillary studies
1828462|NCT00803062|Drug|Topotecan Hydrochloride|Given IV
1828463|NCT00803075|Device|Endovascular Repair of Abdominal Aortic Aneurysms Using TALENT AAA Stent Graft System|
1828464|NCT00803088|Device|The Alair System|Treatment of airways with the Alair System
1828465|NCT00803101|Biological|Beriplex® P/N (Kcentra)|Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
1828466|NCT00803101|Biological|Fresh frozen plasma|Intravenous infusion, dosage depending on baseline INR and body weight
1828467|NCT00803114|Drug|Preservative-free epidural morphine|One time dose of preservative-free epidural morphine 2.5 mg given within one hour following vaginal delivery
1828468|NCT00803114|Drug|Placebo|5 ml of epidural preservative-free saline given within one hour following vaginal delivery
1828469|NCT00803127|Device|vs-sense|detection swab
1828470|NCT00803140|Procedure|Cautery vs Active Control Arm (Scalpel)|"Interventions: The cautery used will be the standard operating room monopolar cautery used at our institution. The cautery will be used on a cut setting of 20 with a blend setting of zero (pure cut). A standard protected needle tip cautery will be used.
A #15 blade carbon steel scalpel blade will be used on ½ of the incision; a cautery device with the above-mentioned settings will be used on the other ½ of the wound. The patient will be randomly assigned to receive the cautery incision on the left or right side. The same surgeon will make all of the skin incisions and perform the skin closures in order to provide as much standardization as possible.
The closure will be standardized."
1828471|NCT00803153|Procedure|Panretinal Photocoagulation [Pattern Scan Laser (PASCAL) system]|
1828472|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of three days
1828473|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test product 1|Small amount applied and evaluated over the course of three days
1828474|NCT00803166|Drug|Halobetasol Propionate 0.05% Cream-Test Product 2|Small amount applied and evaluated over the course of three days
1828475|NCT00803179|Drug|Nutropin AQ|Based on recommendations from the 2007 GH Deficiency Consensus Workshop on adult GH deficiency, the recommended initiation of treatment for adult males is 0.2mg/d and for women 0.4mg/d, with a titration upwards based on insulin-like growth factor (IGF-1) (product of GH stimulation at target tissues) levels and patient response. IGF-1 will be monitored at the 3,4,5 and 11 month intervals. For subjects under the age of 25 with an open epiphysis of the hand and/or wrist we will treat with the dose of 0.3mg/kg/week. Subjects will be on growth hormone for 8 months with a baseline visit prior to initiation of therapy and a 3 month follow-up visit after stopping therapy.
1828476|NCT00803192|Drug|Famotidine Tablets, 40 mg|
1828477|NCT00803205|Drug|Ataluren (PTC124)|Ataluren PO
1828478|NCT00803205|Drug|Placebo|Placebo PO
1828479|NCT00803218|Drug|Fluticasone Propionate 0.005% Ointment-Reference Product|Small amount applied and evaluated over the course of one day
1828480|NCT00803218|Drug|Fluticasone Propionate 0.005% Ointment-Test product|Small amount applied and evaluated over the course of one day
1828481|NCT00803244|Drug|300 IR|300 IR grass pollen allergen extract tablet starting 2 months before the grass pollen season and during the grass pollen season
1828482|NCT00803244|Drug|Placebo|Placebo sublingual tablet starting 2 months before the grass pollen season and during the grass pollen season
1828483|NCT00803257|Other|Lumbrical splint and Lumbrical exercises|Subjects receive one of four possible interventions - Dose and Frequency are the same for each
1828484|NCT00803270|Drug|Non-Surgical Intervention|Both oral urge incontinence medication and behavioral treatment
1828485|NCT00803270|Procedure|Surgical|Initial surgical (stress incontinence surgery) treatment approach.
1828486|NCT00803283|Drug|Hydromprphone Hydrochloride (HCl) OROS|Participants will receive hydromorphone HCl OROS 8 milligram (mg) every 24 hours, for 3 to 14 days of titration phase. Hydromorphone HCl OROS will be continued as per Investigator's discretion for next 14 days of maintenance phase.
1828487|NCT00803283|Drug|Morphine Sustain Release (SR)|Participants will receive morphine SR 8 mg every24 hours, for 3 to14 days of titration phase. Morphine SR will be continued as per Investigator's discretion for next 14 days of maintenance phase.
1828488|NCT00803296|Other|Oral glucose tolerance test (OGTT)|
1828489|NCT00803296|Other|Isoglycemic intravenous glucose infusion|
1828490|NCT00803309|Drug|pegylated interferon alpha-2b|1.5 µg/kg once weekly, syringe, 24 weeks
1828491|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 24 weeks
1828492|NCT00803309|Drug|pegylated Interferon alpha-2b|1.5 µg/kg once weekly, syringe, 12 weeks
1828493|NCT00803309|Drug|Ribavirin|800-1400 mg per os, daily, tablets, 12 weeks
1828494|NCT00803335|Drug|Vaginal conjugated estrogen cream 0.5gm|Women in this arm will apply 0.5gm vaginal estrogen cream nightly until surgery.
1828495|NCT00803335|Drug|Vaginal conjugated estrogen cream 1.0gm|Women in this arm will apply 1.0gm vaginal estrogen cream nightly until surgery.
1828496|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.2% ropivicaine at an infusion rate of 5mls/hr until 0600 on postoperative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.2% ropivicaine at an infusion rate of 5mls/hr with patient controlled boluses of 5ml available every 30 mins, until 0600 on the morning of postoperative day 2
1828497|NCT00803348|Drug|Bolus of 0.2% ropivicaine 20 mls followed by 0.1% ropivicaine at an infusion rate of 10mls/hr until 0600 on post-operative day 2|Initial bolus of 0.2% ropivicaine 20 mls into the femoral catheter followed by 0.1% ropivicaine at an infusion rate of 10mls/hr with patient controlled boluses of 10mls available every 30 mins, until 0600 on the morning of postoperative day 2
1828498|NCT00803348|Drug|Saline control|Bolus of 0.375% ropivicaine 30 mls followed by saline infusion until 0600 on postoperative day 2
1828499|NCT00803361|Drug|Duloxetine|60 to 120 mg, capsules, oral, once a day for 15 weeks
1828500|NCT00803361|Drug|Placebo|placebo capsules, oral, once a day for 15 weeks
1828501|NCT00803374|Drug|AntiCD137|Infusion, IV, 0.1 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
1828502|NCT00803374|Drug|AntiCD137|Infusion, IV, 0.3 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
1828503|NCT00803374|Drug|AntiCD137|Infusion, IV, 1.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
1828504|NCT00803374|Drug|AntiCD137|Infusion, IV, 3.0 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
1828505|NCT00803374|Drug|AntiCD137|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12 weeks, 12+ weeks depending on response
1828506|NCT00803374|Drug|Ipilimumab|Infusion, IV, 10 mg/kg, Q3 weeks for 12 weeks then Q12, 12+ weeks depending on response
1828507|NCT00803387|Drug|Travaprost without BAC (Travatan Z)|A double blind comparison was used to assess whether Xalatan or TrvatanZ affects the tear breakup times, corneal staining, and baseline tear secretion tests in patients that are already taking latanoprost regularly with complaints of dryness and irritation. Patients included in the study will be given two bottles, one labeled for their right eye and the other for their left eye. Each pair of bottles will be identical in appearance and randomized with either latanoprost or travoprost and each pair will be assigned a number to aid in future analysis of the final results. One Drop from both bottles will be dispensed in the respective eye once a day.
1828508|NCT00803400|Drug|Alprazolam|"The patients assigned to the pharmacological plan will receive 4 mg alprazolam daily for 12 weeks. Two weeks after the first interview they have their first baseline psychiatric control, where all the patients are tested.
Then, at the same visit, all the patients are indicated 4 mg of alprazolam. The dose is gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12."
1828509|NCT00803400|Drug|Alprazolam + Aerobic exercise|"The patients assigned to exercise have to pass an ergometric test to determine the functional capacity expressed in Metabolic Equivalents of Task (METs), and their maximum heart rates to standardize the future exercise indication.
Two weeks after the first interview they have their first baseline psychiatric control and at the same time they are indicated a 4 mg dose of alprazolam, gradually increased from 1 to 4 mg along the first week of treatment. The test is repeated during weeks 2, 4, 8 and 12.
At the same time they have to follow a protocolized aerobic exercise plan for this study 3 times a week for 12 weeks.
The type of selected exercise consists of a rapid walk (both in not inclined treadmill or natural courses) for 30 minutes divided in stages.
After each stage the patient has to control his own heart frequency that has to be maintained between 50 and 75% of their maximum not to turn to an anaerobic condition, according to the American Cardiological Association."
1828510|NCT00803413|Behavioral|Back School Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, and spine preventive care; 30 minutes of on-place supervised exercises for posture and spine flexibility (muscle stretching, relaxation, strengthening)
1828511|NCT00803413|Behavioral|Supervised Walking Intervention|Patients were submitted once a week for 5 consecutive weeks to sessions of 45 minutes including: 15-minute lectures about basics of physical activity, its advantages and benefits, barriers and facilitators, types and opportunities; 30 minutes of on-place supervised walking in group.
1828512|NCT00803413|Behavioral|Back School and Walking|Weekly sessions of 90 minutes including: 30-minute lectures about basics of spine's anatomy, ergonomics, techniques of lifting and transportation of weights and volumes, body posture in several daily tasks and situations, spine preventive care, and about physical activity, its advantages and benefits, barriers and facilitators, types and opportunities
1828513|NCT00803413|Behavioral|Control Group|Weekly sessions of 45 minutes including lectures about: stress control, healthy nutrition (2 lectures), sleep hygiene and injury prevention.; beside the 2-page folder content this group received no other information about LBP, BS or walking all along the follow-up.
1828514|NCT00803426|Procedure|Sciatic nerve blockade for ankle/foot surgery|Injection of local anesthetic near the nerve to achieve anesthesia.
1828515|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Reference Product|Small amount applied and evaluated over the course of two days
1828516|NCT00803439|Drug|Clobetasol Propionate 0.05% Foam-Test product|Small amount applied and evaluated over the course of two days
1958730|NCT01311648|Biological|Recombinant Factor VIII (BAY81-8973)|PTPs prophylaxis treatment 25-50 IU/kg at least 2x/week. PUPs 15 -50 IU/kg at least 1x/week.
1828520|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Reference Product|Small amount applied and evaluated over the course of two days
1828521|NCT00803465|Drug|Fluticasone Propionate 0.05% Cream-Test product|Small amount applied and evaluated over the course of two days
1828522|NCT00803478|Procedure|LASIK|
1828523|NCT00803491|Other|Problem based learning|Group sessions under supervision from a nurse. Each group including 8 subjects. 10 occasions during a period of one year.
1828524|NCT00803491|Other|Traditional rheumatology care.|Individually base.
1828525|NCT00803504|Procedure|ocular blood flow measurement|
1828526|NCT00803530|Drug|ATO + Ascorbic acid|"ATO will be diluted in 250 ml of normal saline solution at a dosage of 0.3 mg/Kg during the first week of therapy and at a dosage of 0.25 mg/Kg during the subsequent weeks (week 2 to 16), and administered intravenously over a 1-2 hour period.
The dose of ascorbic acid will be 1000 mg in 100 cc D5W or normal saline solution (NaCl 0.9 %) (protected from light and air) administered as an IV infusion over 15 to 30 minutes. The dosing solution is not to be mixed with any alkaline solution."
1828527|NCT00803543|Drug|Valacyclovir|500 mg tablets. Dosage two tablets (1000 mg)once daily for 24 weeks
1828528|NCT00803543|Drug|Placebo|Dosage: Two tablets once a day for 24 weeks
1828529|NCT00803556|Drug|Alvespimycin|Solution, IV, 60-100 mg/m2, weekly until disease progression or DLT
1828530|NCT00803556|Drug|Trastuzumab|Solution, IV, 2-4 mg/kg, weekly until disease progression or DLT
1828531|NCT00803556|Drug|Paclitaxel|Solution, IV, 60-90 mg/m2, weekly until disease progression or DLT
1828532|NCT00803569|Biological|ALVAC(2)-NY-ESO-1 (M)/TRICOM vaccine|
1828533|NCT00803569|Biological|sargramostim|
1828534|NCT00803582|Procedure|Traditional Chinese acupuncture|Acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions
1828535|NCT00803582|Procedure|Placebo acupuncture|Placebo acupuncture at two Hegu (LI4) and two Lieque (Lu7) points on the wrist, one Lianquan (CV23) and two Renying (St9) points on the neck and two Zhaohai (Ki6) for 12 30-minute sessions.
1828536|NCT00803595|Drug|CS-8958|CS-8958 powder 20 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
1828537|NCT00803595|Drug|CS-8958|CS-8958 powder 40 mg to be inhaled one time. Oseltamivir phosphate placebo capsules 2 times per day for 5 days
1828538|NCT00803595|Drug|oseltamivir phosphate|CS-8958 placebo powder to be inhaled one time. Oseltamivir phosphate oral capsules taken twice daily for 5 days.
1828539|NCT00803608|Device|TrueContour® Insole|Novel designed insole
1828540|NCT00803608|Device|Current standard of care insole|Current Medicare approved A5513 insole
1828541|NCT00803621|Other|Toxoplasma PCR assay|Toxoplasma PCR assay
1828542|NCT00803634|Drug|Clevidipine|Clevidipine was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative IV antihypertensive agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Patients who received an alternative antihypertensive agent along with the study drug were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered approximately 1 hour prior to the termination of clevidipine with study drug down-titrated or terminated in order to maintain the desired blood pressure level.
1828543|NCT00803634|Drug|Standard of Care IV antihypertensive|SOC IV antihypertensive agent will be administered for a minimum of 30 min and, if medically warranted, may continue beyond 96 hours at the investigator's discretion. As with clevidipine, the SOC agent was to be administered continuously as monotherapy during the first 30 minutes. Use of an alternative agent(s) was discouraged and was limited to where medically necessary to maintain patient safety. Higher dose titration rates were required to be attempted prior to making the decision to switch to or add on an alternative antihypertensive agent(s). Patients who received an alternative antihypertensive agent with SOC were allowed to continue in the study. If transition to an oral antihypertensive agent was required, it was to be administered per institutional practice.
1828544|NCT00803647|Biological|cetuximab|500 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles. Cetuximab dose will be escalated by 100 mg/m2 every 2 weeks to a maximum dose of 800 mg/m2 if, at the time of retreatment, skin rash is less than or equal to grade 1, diarrhea is grade 0 (defined as less than or equal to 3 stools per day over baseline), and the patient is not experiencing any other greater than or equal to grade 2 toxicity attributed to cetuximab.
1828545|NCT00803647|Drug|5-FU|3000 mg/m2 IV continuous infusion over 46 hours every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
1828546|NCT00803647|Drug|oxaliplatin|85 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
1828547|NCT00803647|Drug|leucovorin|400 mg/m2 IV every two weeks on days 1, 15, 29, and 43 of each 56 day cycle, for a total of 3 cycles.
1828548|NCT00803673|Drug|100mcg|100mcg '719
1828549|NCT00803673|Drug|500mcg|500mcg '719
1828550|NCT00803673|Drug|1000mcg|1000mcg '719
1828551|NCT00803673|Drug|Placebo|Placebo '719
1828552|NCT00803686|Drug|Oral rsCT tablet|On Study Day 1, subjects will be given their assigned treatment, based on one of two randomly ordered treatment sequences, at 10 PM (22:00). On Visit 3, subjects will return for administration of the second treatment with a minimum of 7 days washout interval between study drug administrations. On Visit 4, subjects will return for administration of third treatment of rsCT, either oral rsCT tablets or Fortical (rsCT) nasal spray. Interventions are described in Intervention Name, Other Names and in Intervention Description.
1828553|NCT00803686|Drug|Oral Placebo Tablet|Part 1, Double blind oral placebo tablet given once 4 hours after evening meal.
1828554|NCT00803686|Drug|Oral rsCT tablet|Part 2, Open-label, oral rsCT tablet given once 2 hours after the evening meal.
1828555|NCT00803686|Drug|Fortical (rsCT) nasal spray|Intervention: Open label, Fortical nasal spray given once 2 hours after the evening meal.
1828556|NCT00803699|Dietary Supplement|placebo|daily placebo capsules for 12 months
1828557|NCT00803699|Dietary Supplement|selenium as L-selenomethionine|daily capsules of 50, 100, or 200 micrograms of L-selenomethionine for 12 months
1828558|NCT00803712|Drug|Cinacalcet|Cinacalcet is a calcimimetic agent, which is synthesized as a hydrochloride salt.
1828559|NCT00803712|Drug|Vitamin D|Titration of active Vitamin D in accordance with treatment practice guidelines in order to treat Secondary Hyperparathyroidism.
1828560|NCT00803725|Drug|Mepivacaine without fentanyl|45 mg 1.5% mepivacaine injection for spinal anesthesia
1828561|NCT00803725|Drug|Mepivacaine with Fentanyl|10 micrograms fentanyl with 30 mg 1.5% mepivacaine injection for spinal anesthesia
1828562|NCT00803738|Drug|Terconazole Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
1828563|NCT00803738|Drug|Terazol Vaginal Suppository|Vaginal Suppository inserted intravaginally once daily before bedtime for 3 consecutive days
1828564|NCT00803751|Device|Truview EVO2 laryngoscope|will use the Truview laryngoscope instead of the traditional Macintosh laryngoscope
1828565|NCT00803751|Device|Macintosh laryngoscope|Intubation using the traditional Macintosh laryngoscope
1828566|NCT00803764|Drug|Naproxen Tablets, 500 mg|
1828567|NCT00803777|Device|Investigational Blood Glucose Monitoring System|Subjects with diabetes used a new blood glucose monitoring system with capillary blood. Certain results were compared to a laboratory glucose method.
1828568|NCT00803790|Drug|alendronate sodium+vitamin D combination|A single dose tablet of 70mg alendronate sodium+5600 IU vitamin D combination tablet in one treatment period of each sequence.
1828569|NCT00803790|Drug|Comparator: alendronate|A single dose tablet of 70mg alendronate in one treatment period of each sequence.
1828570|NCT00803790|Dietary Supplement|Comparator: Vitamin D|Two tablets of 2800 IU vitamin D, totaling 5600 IU, in one treatment period of each sequence.
1828571|NCT00803803|Drug|Pilocarpine Concentration|Varying concentration 0.5 to 8%
1828572|NCT00803803|Drug|Pilocarpine Frequency|1 to 4 times daily
1828573|NCT00803816|Drug|everolimus|everolimus 1.0 - 2.5mg oral daily dosage
1828574|NCT00803829|Other|Synbiotic (Synergy1/B. longum)|Probiotic Bifidobacterium longum Prebiotic Synergy 1
1828625|NCT00789191|Drug|sulphonylurea|Sulphonylurea (SU) dose and dosing frequency should initially remain unchanged. In case of hypoglycaemia SU dose may be reduced at the discretion of the investigator.
1828666|NCT00789464|Dietary Supplement|Lactobacillus reuteri DSM 17938|DSM 17938 drops (10^8 cfu/dose of 5 drops) + placebo elixir once daily for 1 year.
1828575|NCT00803842|Drug|doxycycline|Doxycycline (the study drug) will be provided to all subjects as 100 mg tablets. They will be allocated enough doxycycline to last them until their next scheduled visit. The doxycycline tablets should be taken orally (only) at a dosage of 100 mg every 12 hours. Administration of adequate amounts of fluid along with capsule and tablet forms of drugs in the tetracycline class is recommended to wash down the drugs and reduce the risk of esophageal irritation and ulceration. The doxycycline tablets should not be taken with foods that contain calcium. The absorption of doxycycline is reduced when taking bismuth subsalicylate. Duration of study period if 14 days
1828576|NCT00803855|Drug|AZD1446|oral, single dose
1828577|NCT00803868|Drug|varenicline|up to 1mg po bid for 9 weeks
1828578|NCT00803868|Drug|placebo|placebo matching study drug up to 1mg po bid
1828579|NCT00803881|Other|nasal lavage and sputum collection|non-invasive longitudinal assessment of pathogen colonization in both airway levels
1828580|NCT00803894|Drug|MK0752|Single dose MK0752 capsules, 1000 mg: there will be a 7-day washout period between treatments.
1828581|NCT00803894|Drug|Comparator: MK0752.|Single dose MK0752 capsules, 350 mg: there will be a 7-day washout period between treatments.
1828582|NCT00803894|Drug|Comparator: Placebo|Single dose placebo capsules: there will be a 7-day washout period between treatments.
1828583|NCT00803907|Drug|Imiquimod 5% cream|Imiquimod 5% cream (Aldara ®), once daily, 5 days per week for 8-16 weeks (average)
1828584|NCT00803933|Drug|DB289|Pafuramidine maleate (DB289), 100 mg BID orally
1828585|NCT00803933|Drug|Pentamidine|Pentamidine isethionate (Aventis) for injection (200 mg/vial), 4 mg/kg QD IM
1828586|NCT00803946|Drug|Ibuprofen Tablets, 800 mg|
1828587|NCT00803959|Other|Office evaluation|Office evaluation
1828588|NCT00803959|Other|UDS|Urodynamics
1828589|NCT00803972|Drug|rHuPH20|recombinant human hyaluronidase PH20
1828590|NCT00803985|Procedure|Retro-muscular versus on lay mesh|Operation for primary inguinal hernias i men
1828591|NCT00804011|Other|ATC|Automatic tube compensation
1828592|NCT00804011|Other|PSV|Pressure support ventilation
1828593|NCT00804024|Device|ClearWay™ RX Local Therapeutic Infusion Catheter|The ClearWay™ RX Local Therapeutic Infusion Catheter is a micro-porous PTFE balloon catheter designed for the localized infusion of various diagnostic and therapeutic agents into the coronary and peripheral vasculature.
1828594|NCT00804037|Procedure|Injection Snoreplasty|Injection of 0,5 ml of the sclerosing agent into the soft palate (3 points)
1828595|NCT00804050|Drug|infusion A: rEPO|rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.
1828596|NCT00804050|Drug|B Infusion rEPO combined with vitamins pills|rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
1828597|NCT00804063|Procedure|drawing blood sample|fasting blood sample
1828598|NCT00804076|Biological|NP2|Intradermal injection of NP2 at doses ranging from 10e7 to 10e9 pfu at the site of pain.
1828599|NCT00804089|Procedure|Traditional needle acupuncture|Traditional needle acupuncture using traditional meridian acupoints and Ashi (tender) points
1828600|NCT00804089|Procedure|Myofascial trigger point dry needling|Superficial dry needling of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
1828601|NCT00804089|Procedure|Myofascial trigger point acupressure|Blunt needle acupressure of myofascial trigger points found in the muscles related to low back pain, followed by their postisometric stretching
1828604|NCT00788970|Behavioral|Acupressure adjuvant therapy|Acupressure provided in 40-minute sessions, twice a week for 4 weeks. For placebo acupressure, different meridian points will be used.
1828605|NCT00788996|Behavioral|Brief intervention based in clinical practice guide|Minimal counseling at smoking parents with babies minor 1 year-old
1828606|NCT00789035|Drug|BI 10773|
1828607|NCT00789035|Drug|placebo|
1828608|NCT00789035|Drug|metformin|
1828609|NCT00789048|Other|radiograph|One radiograph with the patient lying on his contralateral side
1828610|NCT00789061|Drug|Proton pump inhibitor|One dosage/day/year
1828611|NCT00789074|Drug|Varenicline|Varenicline 1mg twice daily
1828612|NCT00789074|Drug|Placebo|Placebo 1mg BD
1828613|NCT00789087|Procedure|Videothoracoscopic talc poudrage (VT).|Videothoracoscopic talc poudrage
1828614|NCT00789087|Procedure|Talc slurry through a chest tube (DT).|Talc slurry through a chest tube
1828615|NCT00789113|Drug|Extended Release Lamotrigine|
1828616|NCT00789126|Drug|VX-509|
1828617|NCT00789139|Device|ICM Implantation|Sub cutaneous implantation of the ICM
1828618|NCT00789152|Drug|desloratadine|desloratadine 5 mg daily x 8 days
1828619|NCT00789152|Drug|levocetirizine|levocetirizine 5 mg daily x 8 days
1828620|NCT00789165|Drug|quinidine|quinidine at highest tolerated dose. Expected doses are hydroquinidine 600 - 900 mg daily.
1828621|NCT00789165|Drug|no therapy|No therapy; this is not a placebo-controlled trial
1828622|NCT00789191|Drug|insulin detemir|The detemir insulin dose is injected subcutaneously (under the skin) once daily in the evening and will be titrated (individually adjusted) weekly throughout the trial.
1828623|NCT00789191|Drug|sitagliptin|The sitagliptin dose is 100 mg/ day and should be kept stable throughout the trial. Frequency of sitagliptin is once daily.
1828624|NCT00789191|Drug|metformin|Metformin treatment with at least 1000 mg/ day. Dose and dosing frequency should remain unchanged throughout the trial.
1829184|NCT00809211|Genetic|mutation analysis|
1958734|NCT01299038|Drug|rosuvastatin|Taken orally once a day for 4 weeks
1958735|NCT01299610|Drug|GW870086 2.0%|White to slightly colored opaque cream
1828626|NCT00789204|Other|Global Postural Re-education|The treatment in Global Postural Re-education is a global approach that seeks to identify the biomechanical cause of the problem also in other parts of the body and involves actively the patient in the postural change. Using principles like causality, globality and individuality, the treatment consists of the use for one hour of progressive active stretching posture for specific muscular chain that are shortened. Every posture is maintained for 20 minutes with controlled breathing and the use of manual traction
1828627|NCT00789204|Other|Standard Exercise Training|The exercise programme included passive lumbar flexion, pelvic tilt, strengthening of flexor muscles, strengthening of extensor muscles, spine mobilization and stretching exercises.
1828628|NCT00789217|Procedure|Immediate skin test|Intradermal test with immediate reading
1828629|NCT00789230|Procedure|primary suture closure|primary suture closure of hernia
1828630|NCT00789230|Device|mesh enforced closure|mesh enforced closure of hernia
1828631|NCT00789243|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
1828632|NCT00789256|Drug|Melphalan|Melphalan: 2mg orally, once daily
1828633|NCT00789256|Drug|Bortezomib|Bortezomib: 1.0mg/M2 IV on days 1, 4, 8, 11
1828634|NCT00789256|Drug|Melphalan and bortezomib|
1828635|NCT00789269|Drug|rhubarb|14 days of rhubarb
1828636|NCT00789269|Drug|placebo|14 days of placebo
1828637|NCT00789282|Other|multidisciplinary approach|Provides an integrated, proactive approach to the management of patients with chronic diseases (ie: diabetes and sequelae) Wagner Model- care encompassed in 3 overlapping galaxies: wider community; the health care system; and the provider organization. There are 6 essential elements: community resources and policies; health care organization; patient self-management support; delivery system design; decision support; and clinical information systems.
1828638|NCT00789282|Other|multifactorial approach - for enhanced care group|optimized medical management support for development of enhanced patient self management skills organized proactive follow-up chronic disease management teams
1828639|NCT00789282|Other|reflects current patterns of care|"Continue under the care of their family physician and specialists with referral to diabetic assessment and treatment centers at the discretion of the patient and physician.
Normal manner of care: could attend diabetic self education classes and consultations regarding management of diabetes. Or, participate in other patient self management program of their choice."
1828640|NCT00789295|Other|Mediterranean diet and Low-Carbohydrates diet|The Mediterranean diet: relatively rich in Carbohydrate(52% of the total daily energy intake), rich in dietary fibre (28g/1000 kcal both of soluble and unsoluble types) and with a low glycemic index (51%) versus Low-carbohydrates diet : diet rich in MUFA (23%), relatively low in CHO (45%), low in dietary fibre (8g/1000 kcal) and with a relatively high glycemic index (87%)for 4 weeks
1828641|NCT00789308|Drug|Low Molecular Weight Sulfated Dextran (LMW-SD)|Inhibitor of IBMIR
1828642|NCT00789308|Drug|Heparin|Anticoagulation
1828643|NCT00789308|Drug|CellCept® (Mycophenolate mofetil) OR Rapamune® (Sirolimus)|Cell proliferation inhibitor
1828644|NCT00789308|Drug|Prograf® (Tacrolimus) OR Cyclosporine|Calcineurin inhibitor
1828645|NCT00789308|Drug|Thymoglobulin® (Anti-thymocyte Globulin) - at first transplant|
1828646|NCT00789308|Drug|Simulect® (Basiliximab) - at 2nd or 3rd transplant|Monoclonal IL-2 receptor blocker
1828647|NCT00789308|Drug|Klexane® (Enoxaparinsodium)|Anticoagulation Prophylaxis
1828648|NCT00789308|Drug|Trombyl® or Albyl-E® (Acetylsalicylicacid- ASA)|Anticoagulation Prophylaxis
1828649|NCT00789308|Drug|Enbrel® (Etanercept)|Anti-Inflammatory Therapy
1828650|NCT00789321|Drug|Comparator: amlodipine besylate|Two 5 mg tablets amlodipine daily for 6 weeks.
1828651|NCT00789321|Drug|Comparator: Placebo|Two 5 mg tablets placebo to amlodipine daily for 6 weeks
1958736|NCT01299610|Drug|GW870086 0.2%|White to slightly colored opaque cream
1958737|NCT01299610|Drug|FP 0.05%|White cream
1828654|NCT00789373|Drug|Pemetrexed|Induction therapy: 500 mg/m^2, intravenous (IV), on Day 1 of each 21-day cycle for 4 cycles
1828655|NCT00789373|Drug|Cisplatin|Induction therapy: Cisplatin: 75 mg/m^2, IV, on Day 1 of each 21-day cycle for 4 cycles
1828656|NCT00789373|Drug|Placebo|Maintenance therapy: Normal saline (0.9% sodium chloride) administered IV on Day 1 every 21-day cycle until progressive disease or treatment discontinuation
1828657|NCT00789373|Drug|Pemetrexed|Maintenance therapy: 500 mg/m^2, IV, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation.
1828658|NCT00789373|Other|Best Supportive Care|Best Supportive Care is treatment given with the intent to maximize quality of life. Best Supportive Care excludes any treatment in which the goal is to cure or slow the progression of the study disease. Patients will receive Best Supportive Care as judged by their treating physician. Those therapies considered acceptable include, but are not limited to, palliative radiation to extrathoracic structures, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral).
1828659|NCT00789386|Drug|Remifentanil|Remifentanil (Ultiva ®; Glaxo-Smith-Kline; Vienna, Austria) at an initial dose of 0.24 µg kg-1 min-1 will be applied iv during 60 minutes.
1828660|NCT00789386|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied iv as active placebo at a dose of 7.5 µg.kg-1.min-1 over 10 minutes to mimic typical central nervous side effects of remifentanil.
1828661|NCT00789399|Drug|Fondaparinux|Patients will receive a 2.5 mg dose of Fondaparinux subcutaneously for a total of 7 days post CABG
1828662|NCT00789399|Other|Placebo|subcutaneous equivolume isotonic saline
1828663|NCT00789425|Dietary Supplement|Standardized Extract of Olive Polyphenols|"Dietary supplement containing 250 mg of a standardized extract of olive polyphenols per day in 1 capsule.
A supplement with 1000 mg calcium per day will be supplied together with the active treatment."
1828664|NCT00789425|Dietary Supplement|Placebo|Placebo (starch). A supplement with 1000 mg calcium per day will be supplied together with the active treatment.
1828665|NCT00789451|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min). Venous blood sampling via cannula in antecubital fossa.
1958738|NCT01299610|Drug|Placebo|White to slightly colored opaque cream
1828667|NCT00789464|Drug|trimethoprim/sulfamethoxazole|Trimethoprim/sulfamethoxazole elixir (TMP/SMZ) (2 mg/kg), a standardized oral antibiotic prophylaxis, plus placebo capsule once daily for 1 year.
1828668|NCT00789477|Procedure|Laser Photocoagulation|laser every 16 weeks as needed
1828669|NCT00789477|Drug|Intravitreal Aflibercept Injection|
1828670|NCT00789490|Dietary Supplement|Daminaide 995 - SuppleFem Sprinkles|The study agent SuppleFem will be a preblend manufactured by Acatris in Oakville Ontario and will be repackaged into 1 gram aliquots in white plastic Tamper Seal Vials.1 ram to be taken with test meal
1828671|NCT00789490|Dietary Supplement|Materna|Materna is a pregnancy supplement available on the Canadian market and is manufactured by Wyeth. Dose is 1 tablet per day
1828672|NCT00789503|Dietary Supplement|Bread fortified with vitamin D3 and calcium|Bread fortified with vitamin D3 (5000 IU per bun) and calcium
1828673|NCT00789529|Device|Opti-Free® RepleniSH® MPDS|soft contact lens disinfecting solution
1828674|NCT00789529|Device|ReNu MultiPlus®|soft contact lens disinfecting solution
1828675|NCT00789542|Device|Intermittent Pneumatic compression|Thigh length sleeves applied to both legs from randomization to Day 30 (Day and night) whilst sitting and lying
1828676|NCT00789542|Other|Routine care|Routine care which might include: early mobilization, adequate hydration, aspirin if ischemic stroke and graduated compression stockings according to local protocols.
1828677|NCT00789555|Drug|Olopatadine hydrochloride 0.6% nasal spray (PATANASE)|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
1828678|NCT00789555|Other|Olopatadine nasal spray vehicle, pH 3.7|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
1828679|NCT00789555|Other|Olopatadine nasal spray vehicle, pH 7.0|Two sprays in each nostril twice a day (morning and evening) for up to 12 months
1828680|NCT00789568|Drug|sapropterin dihydrochloride|20 mg/kg and 100 mg/kg
1828681|NCT00789568|Drug|Moxifloxacin|Moxifloxacin is included as a positive control to demonstrate the assay sensitivity based on the expected increased QTc response.
1828682|NCT00789581|Drug|Doxorubicin|Doxorubicin 60 mg/m2
1828683|NCT00789581|Drug|Cyclophosphamide|Cyclophosphamide 600 mg/m2
1828684|NCT00789581|Drug|Ixabepilone (Ixempra)|Ixabepilone 40 mg/m2
1828685|NCT00789581|Drug|Paclitaxel (Taxol)|Paclitaxel 80 mg/m2
1828686|NCT00789594|Behavioral|laboratory monitoring alerts|laboratory monitoring alerts
1828687|NCT00789594|Behavioral|Result management module|Result management module
1828688|NCT00789607|Device|Transrectal APT Device or Transperineal Device will be used|Both are imaging probe devices that is inserted under local anesthetic, in the rectum using lubricant, positioning against the prostate gland, and attached to the table. This is done at baseline (Day 0) under local anesthetic with the patient in partial dorsal lithotomy position
1828689|NCT00789607|Device|TRUS probe|Patient is given local anesthetic transrectally to the prostate base and the probe is inserted with patient in the lateral decubitus position.
1828690|NCT00789620|Drug|lidocaine|1.5 mg/kg as Bolus intraoperative: 2 mg/kg/h postoperative: 1.3mg/kg/h during 24h
1828691|NCT00789620|Drug|placebo|Bolus 0.15 ml/kg NaCl 0.9% NaCl 0.2 ml/kg/h Perfusor NaCl 0.9% 0.13 ml/kg/h Perfusor
1828692|NCT00789633|Drug|masitinib (AB1010)|9 mg/kg/day
1828693|NCT00789633|Drug|placebo|matching placebo
1828694|NCT00789646|Procedure|Lidocaine/NSS|First injection: subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival NSS 0.4 ml. before antibiotic injection
1828695|NCT00789646|Procedure|NSS/Lidocaine|First injection: subconjunctival NSS 0.4 ml. before antibiotic injection Second injection (24 hours later): subconjunctival 2% lidocaine without adrenaline 0.4 ml. before antibiotic injection
1828696|NCT00789659|Other|Negative pressure dressing|A completely occlusive dressing that is attached to a device that allows a constant negative pressure of 125 mmHg to be generated.
1828697|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid (approximately 4.5 to 1 formulation)
1828698|NCT00789672|Device|patching|2 hours daily patching
1828699|NCT00789672|Drug|levodopa/carbidopa|Oral levodopa 0.51mg/kg tid with carbidopa 0.17 mg/kg tid (3 to 1 formulation)
1828700|NCT00789685|Drug|Interferon Beta|Interferon Beta administered intravenously daily for 6 days. Doses of 0.12 MIU, 1.2 MIU, 2.7 MIU or 6.0 MIU (dose escalation phase) or 2.7 MIU (dose expansion phase) were administered.
1828701|NCT00789698|Drug|Lurasidone HC1|Lurasidone 40-160 mg/day flexibly dosed.
1828702|NCT00789698|Drug|Quetiapine XR|Quetiapine XR 200-800 mg/day flexibly dosed.
1828703|NCT00789711|Drug|biphasic insulin aspart 30|Evaluation of the safety profile and effectiveness of biphasic insulin aspart 30 in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
1828704|NCT00789711|Drug|insulin detemir|Evaluation of the safety profile and effectiveness of insulin detemir in the treatment of diabetes mellitus under normal clinical practice conditions in the Philippines
1828705|NCT00789724|Drug|Anakinra|100 mg daily subcutaneous injection for 14 days
1828706|NCT00789724|Drug|Placebo|0.67 ml of NaCl 0.9% subcutaneously daily for 14 days
1828707|NCT00789737|Drug|Welchol|Welchol 625mg tablets
1828708|NCT00789737|Drug|Placebo|placebo
1828709|NCT00789750|Drug|Colesevelam|Colesevelam 625 mg tablets
1828710|NCT00789750|Drug|Placebo|Placebo tablets appearing to be colesevelam
1828711|NCT00789750|Drug|Pioglitazone|30 mg or 45 mg pioglitazone therapy
1828712|NCT00789763|Drug|Gemcitabine|300 mg/m2/one per week, i.v., during 5 weeks.
1828713|NCT00789763|Radiation|Radiotherapy|1.8 Gy/day 5 days per week during 5 weeks (total dose 45Gy)
1828714|NCT00789763|Drug|Sorafenib|200-800 mg/day p.o. during 5 weeks
1829185|NCT00809211|Genetic|polymerase chain reaction|
1828723|NCT00789802|Drug|transdermal estradiol|transdermal estradiol 0.1mg patch to be changed weekly for 12 weeks.
1828724|NCT00789802|Drug|naproxen|naproxen 500mg by mouth twice daily for the first 5 days of every 4 week period for a total of 12 weeks
1828725|NCT00789802|Drug|oral placebo|oral placebo to be taken by mouth twice daily for the first 5 days of a 4 week block for a total of 5 weeks
1828726|NCT00789815|Device|Bispectral index guide propofol infusion|"Induction:
Alfentanil: 5μg/kg slowly push. Propofol: 0.5-1.5mg/kg slowly push till BIS value 70.
Maintenance:
Propofol infusion (3~12 mg/kg/hour) to maintain BIS around 65~75. Alfentanil: 5μg/kg slowly push Q15min prn if severe cough."
1828727|NCT00789815|Drug|Clinical-judged midazolam administration|"Induction:
Alfentanil: 5μg/kg slowly push. Midazolam: 2 mg slowly push followed by increments of 2 mg/ 2min till OAA/S* 2~3.
Maintenance:
Midazolam: 2 mg/ 2min prn to keep OAA/S* 2~3 or if intolerance of procedure. Alfentanil as study arm.
*Observer's assessment of alertness/sedation (OAA/S):
Class 5: Responds readily to name spoken in normal tone.
Class 4: Lethargic response to name called in normal tone.
Class 3: Responds only to name called loudly.
Class 2: Responds only to shaking.
Class 1: No response to shaking."
1828728|NCT00789828|Drug|Everolimus|Everolimus was formulated as tablets of 1.0-mg strength and was blisterpacked under aluminum foil in units of 10 tablets.
1828729|NCT00789828|Drug|Placebo|Placebo was provided as a matching tablet and was blisterpacked under aluminum foil in units of 10.
1828730|NCT00789841|Device|Magnetic Tracking System (MTS) and radio-opaque markers|MTS: A small magnetic pill (6x15mm) is swallowed by the patient and the movement of this pill is registered by a sensor (coordinates x,y,z angles θ, φ) and depicted af graphs on a computer screen. For determination of GITT a capsule containing 10 radio-opaque markers is ingested every day for six days, on day seven an abdominal x-ray is performed.
1828731|NCT00789854|Drug|Quetiapine XR|300 mg once daily (od)
1828732|NCT00789854|Drug|Lithium carbonate|900 mg once daily (od)
1828733|NCT00789854|Drug|SSRI/Venlafaxine|SSRI - doses within label, Venlafaxine dose up to 225 mg/day
1828734|NCT00789867|Drug|pGM169/GL67A|Plasmid expressing the human CFTR gene complexed with cationic lipid 67 and helper lipids: 10 ml nebulised and 1 ml nasal administration (n=3) and 20 ml nebulised and 2 ml nasal (n=24)
1828735|NCT00789880|Drug|Vitamin D3|Administration of oral vitamin D3 at 4000IU
1828736|NCT00789880|Drug|Placebo|Administration of oral Vitamin D3 placebo
1828737|NCT00789893|Device|Vaginal Dilator|Participants will be instructed to use the dilators 3 times per week, regardless of frequency of sexual intercourse. At 5 time points, data will be collected to determine vaginal dilator size, grade vaginal stenosis & assess vaginal symptoms. 1)Baseline: patient self-assessment following consultation up until the end of the first week of radiation 2)Post-radiation: patient self-assessment one month ± 2 weeks follow-up from last day of radiation 3)Post-radiation: 3 month ± 4 weeks follow-up from initiation of dilator use 4)Post-radiation: 6 month ± 4 weeks follow-up from initiation of dilator use 5)Post-radiation: 12 months ± 4 weeks follow-up from initiation of dilator use. At the 1st & 2nd time points, the nurse will telephone the patient to retrieve her responses. The 1st phone call will occur between the time following consultation up until the end of the first week of radiation, & the 2nd will be one month ± 2 weeks from last day of radiation.
1828738|NCT00789919|Procedure|Delivery of infant|Vaginal delivery or cesarean section, whichever is indicated
1828739|NCT00789932|Behavioral|cognitive behavioral therapy|32 weeks of CBT, 1.5 hours weekly.
1828740|NCT00789932|Behavioral|Usual community care|16 weeks of community care, 16 weeks of CBT, 1.5 hours/week.
1828741|NCT00789945|Other|Control|Study Arm A will consist of patients with Type 1 diabetes who will continue their current intensive insulin therapy regimen with no additional interventions by the investigators. Their primary care providers will continue to manage their diabetes to obtain the best control as possible of their glucose, lipids, and blood pressure. Continuous Glucose Monitoring will be monitored. No timing of premeal insulin administration will be utilized in this arm.
1828742|NCT00789945|Other|Study Arm B|"Study Arm B will include participants with type 1 diabetes which will utilize Timing to adjust their pre-meal insulin dosages. Participants will continue taking their current insulin and will be placed on a continuous glucose monitor."
1828743|NCT00789958|Drug|capecitabine|"Adjuvant chemotherapy: 1500 mg/m^2/day, PO, Every 12 hrs on Days 1-14 of each cycle
Chemoradiotherapy: 1330 mg/m^2/day, PO, Every 12 hrs, 7 days per week beginning the first day of RT and finishing the last day of RT"
1828744|NCT00789958|Drug|gemcitabine hydrochloride|1000 mg/m^2, IV, Days 1 & 8 of each cycle
1828745|NCT00789958|Radiation|3-dimensional conformal radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 900 cGy during week 1 in 180 cGy fractions.
1828746|NCT00789958|Radiation|intensity-modulated radiation therapy|4,500 cGy over 5 weeks (5 days/week) in 180 cGy/fraction + 5,250 cGy in 210 cGy/fraction for a total of 25 fractions.
1828747|NCT00789971|Drug|triamcinolone acetonide|40 mg of triamcinolone acetonide given inferotemporally perioperatively during phacoemulsification
1828748|NCT00789971|Drug|Maxitriol|one month of topical G. Dexamethasone 0.1% with Neomycin sulphate 3500IU/g
1828749|NCT00789984|Device|noncontact specular microscopy|
1828750|NCT00789997|Drug|Prednisone|prednisone 40 mg daily for 10 days or placebo prednisone
1828751|NCT00789997|Drug|Etanercept|etanercept 50 mg subcutaneous given on the day of randomization and one week later or placebo subcutaneous injection
1828752|NCT00789997|Drug|levofloxacin|Levofloxacin 750 mg daily for 10 days.
1828753|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 1|Cohort 1: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
1828754|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 2|Cohort 2: Ipilimumab 10 mg/kg IV every 3 weeks x 4 doses(induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
1828755|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 3|Cohort 3: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 7.5 mg/kg IV every 3 weeks (continuous)
1828756|NCT00790010|Drug|Bevacizumab Plus Ipilimumab Cohort 4|Cohort 4: Ipilimumab 3 mg/kg IV every 3 weeks x 4 doses (induction), then every 3 months (maintenance); Bevacizumab 15 mg/kg IV every 3 weeks (continuous)
1828757|NCT00790023|Drug|80 mcg Ciclesonide|80 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
1828758|NCT00790023|Drug|160 mcg Ciclesonide|160 mcg Ciclesonide HFA Inhaler once daily (one actuation per nostril)
1828759|NCT00790023|Drug|Placebo|Placebo HFA Inhaler once daily (one actuation per nostril)
1828760|NCT00790036|Drug|Everolimus|Everolimus was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
1828761|NCT00790036|Drug|Everolimus Placebo|Everolimus placebo was formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
1828762|NCT00790049|Drug|ARRY-371797, p38 inhibitor; oral|single dose and multiple dose, escalating
1828763|NCT00790049|Drug|Placebo; oral|matching placebo
1828764|NCT00790062|Drug|Oxytocin|See arms
1828765|NCT00790075|Drug|risperidone|liquid risperidone was administered on a mg/kg basis to a child needing seclusion. 0.015mg/kg was the start dose. Dose was increased to 0.02mg/kg if duration of episode was >30 minutes.
1828766|NCT00790101|Drug|Risedronate|
1828767|NCT00790101|Drug|Raloxifene|
1828768|NCT00790101|Other|Placebo|
1828769|NCT00790114|Drug|AZD7325|Oral, day 1-12
1828770|NCT00790114|Drug|Midazolam|single dose, twice during treatment
1828771|NCT00790114|Drug|Caffeine|single dose, twice during treatment
1828772|NCT00790127|Drug|HQK-1001|HQK-1001 capsules (10, 20, 30 or 40 mg) administered once a day, orally, for 56 days
1828773|NCT00790127|Drug|Placebo|Matching placebo capsules administered once a day, orally, for 56 days
1828774|NCT00790140|Dietary Supplement|Prosure|This is an enteral tube feed with 125 kcals & 6.65g protein per 100mls. It contains Fat, Carbohydrate, and vitamins and minerals and is enriched with 2.2g Eicosapentaenoic Acid per 500mls of feed. Patients on this trial who are randomized to Prosure will receive the product orally for 5 days prior to surgery and for 21 days post surgery vis a feeding jejunostomy tube
1828775|NCT00790140|Dietary Supplement|Ensure Plus|This is a standard enteral tube feed with 150 kcals & 6.3 g protein per 100mls as well as carbohydrate, fat and vitamins and minerals. It does not have any active immunonutrients. Patients randomized to this arm will receive the product for 5 days pre op and 21 days post surgery via a feeding jejunostomy tube
1828776|NCT00790153|Drug|Insulin|Insulin infusion given during 3 hours at one occasion.
1828777|NCT00790153|Drug|AZD1656|Single dose oral suspension given at one occasion.
1828778|NCT00790166|Device|CPAP + ThermoSmart™ humidity|an absolute humidity (AH) of 28 mg/l +/- 2mg/l
1828779|NCT00790166|Device|CPAP + Conventional humidity|an absolute humidity (AH) of 18 mg/l +/- 2 mg/l
1828780|NCT00790166|Device|CPAP + No added humidity|ambient humidity
1828781|NCT00790179|Procedure|continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA|"0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.
Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA."
1828782|NCT00790192|Drug|Lurasidone|Lurasidone 80 mg tablets
1828783|NCT00790192|Drug|Lurasidone|Lurasidone 4 40 mg tablets
1828784|NCT00790192|Drug|Quetiapine XR|Quetiapine XR 600mg
1828785|NCT00790192|Drug|Placebo|Matching Placebo to Lurasidone or Quetiapine
1828786|NCT00790205|Drug|Sitagliptin|Sitagliptin, one 50 mg or one 100 mg tablet (dose dependant on renal function) orally, once daily.
1828787|NCT00790205|Drug|Placebo|Placebo tablet matching the 50 mg or 100 mg sitagliptin tablet, orally, once daily.
1828788|NCT00790218|Drug|CF102|CF102 capsules twice daily by mouth
1828789|NCT00790231|Device|urodynamic procedure|introduction of the urodynamic catheter into the bladder and assessment of the bladder function
1828790|NCT00790244|Drug|doxorubicin , ifosfamide|doxorubicin 60mg/m2+ifosfamide 6g/m2 every third week
1828791|NCT00790244|Drug|doxorubicin, ifosfamide|Doxorubicin and Ifosfamide given every three weeks, totally 6 courses.
1828792|NCT00790244|Drug|doxorubicin, ifosfamide|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 3 and four.
(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
1828793|NCT00790244|Drug|doxorubicin, ifosfamide|"<70y: 6 cycles with doxorubicin 60mg/m2+ifosfamide 6g/m2 of each 21day cycle and radiotherapy 36Gy (1.8Gy per fraction, two fractions daily) will be given between cycle 2 and 3.
(>=70y: doxorubicin 50mg/m2+ifosfamide 5g/m2)"
1828794|NCT00790257|Device|"Encapsulated human islets in a Monolayer Cellular Device"|"The product consists of isolated allogeneic human islets of Langerhans formulated in a serum-free transplant media. The islets will be encapsulated in an alginate-based Monolayer Cellular Device.
One device will be transplanted subcutaneously and corresponds to a patch of 1-3cm². One Device per patient. No Retransplantation."
1828795|NCT00790270|Drug|Cyclobenzaprine|5 mg orally every 8 hours as needed
1828796|NCT00790270|Drug|Ibuprofen|Ibuprofen 400 mg every 8 hours as needed
1828797|NCT00790270|Drug|Ibuprofen plus Cyclobenzaprine|Ibuprofen 400 mg plus cyclobenzaprine 5 mg every 8 hours as needed
1828798|NCT00790283|Device|PTCA with stent implantation|"Eligible patients will be randomly assigned to the implantation of one (or more) Numen or Vision/Mini Vision stent.
Each patient will undergo a 1-month follow-up and a clinical visit at 6 months from the procedure."
1828799|NCT00790296|Drug|Thyrotropin releasing hormone (TRH)|0.5mg and 1.5mg
1828800|NCT00790296|Drug|Placebo|Saline
1828801|NCT00790309|Procedure|Weight loss surgery|Weight loss surgery
1828802|NCT00790309|Procedure|Laparoscopic abdominal surgeries|laparoscopic abdominal surgeries
1828803|NCT00790322|Drug|SBG|Soluble beta-1,3/1,6-glucan is a solution for oral use
1828804|NCT00790322|Other|Placebo|Solution for oral use
1828805|NCT00790335|Drug|Recombinant tissue plasminogen activator (rt-PA)|Pharmacomechanical catheter-directed thrombolysis, consisting of intrathrombus administration of rt-PA using a catheter/device.
1828806|NCT00790374|Drug|BN83495 (Cohort 1)|20 mg daily BN83495 for 28 days
1828807|NCT00790374|Drug|BN83495 (Cohort 2)|40 mg daily BN83495 for 28 days
1828808|NCT00790374|Drug|BN83495 (Cohort 3)|60 mg daily BN83495 for 28 days
1828809|NCT00790387|Drug|Enoxaparin|Enoxaparin was administered at the commencement of PCI at a dose of 0.75 mg/kg
1828810|NCT00790387|Drug|Tirofiban|
1828811|NCT00790387|Drug|unfractionated heparin|
1828872|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
1828812|NCT00790400|Drug|Everolimus (RAD001)|Everolimus is used in 5 mg strength tablets, blister-packed under aluminum foil in units of ten tablets and dosed on a daily basis. 10mg daily dosing throughout the trial.
1828813|NCT00790400|Drug|Everolimus Placebo|Matching placebo was provided as a matching tablet and was also blister-packed under aluminum foil in units of ten.
1828814|NCT00790413|Drug|iodine I 131 metaiodobenzylguanidine|
1828815|NCT00790413|Drug|Fludarabine|
1828816|NCT00790413|Drug|Thiotepa|
1828817|NCT00790413|Procedure|T-cell depletion|
1828818|NCT00790413|Procedure|Haploidentical stem cell transplantation|
1828819|NCT00790413|Procedure|Donor Lymphocyte Infusion|
1828820|NCT00790413|Drug|Rituximab|
1828821|NCT00790413|Procedure|Co-transplantation of mesenchymal stem cells|
1828822|NCT00790426|Drug|TKI258|
1828823|NCT00790439|Drug|Low Molecular Weight Sulfated Dextran|Inhibitor of instant blood-mediated inflammatory reaction
1828824|NCT00790439|Drug|Heparin|Anticoagulant
1828825|NCT00790439|Drug|Mycophenolate Mofetil|Cell proliferation inhibitor, Transplantation (immunosuppressive)
1828826|NCT00790439|Drug|Sirolimus|Cell proliferation inhibitor, immunologic (immunosuppressive)
1828827|NCT00790439|Drug|Tacrolimus|Calcineurin inhibitor
1828828|NCT00790439|Drug|Cyclosporine|Calcineurin inhibitor, immunosuppressant
1828829|NCT00790439|Drug|Daclizumab|Monoclonal IL-2 receptor blocker
1828830|NCT00790439|Drug|Basiliximab|Monoclonal IL-2 receptor blocker
1828831|NCT00790439|Biological|Allogeneic Pancreatic Islet Cells|
1828832|NCT00790452|Drug|Aspirin|325 mg daily by mouth
1828833|NCT00790452|Drug|Placebo|Tablet daily by mouth
1828834|NCT00790465|Dietary Supplement|dark chocolate|21 g/d of dark chocolate for 2 weeks (7 g. before each meal). 7 grams of dark chocolate at day 1 during manometry.
1828835|NCT00790465|Dietary Supplement|placebo chocolate with crossover to dark chocolate|Placebo at day 1 during manometry, and than crossover to dark chocolate for 2 weeks treatment.
1828836|NCT00790478|Dietary Supplement|Melatonin|Study Pill (5 mg/d) taken once daily, preferably an hour before bedtime, for 12 weeks.
1828837|NCT00790478|Other|Placebo|Study Placebo taken once daily, preferably an hour before bedtime, for 12 weeks.
1828838|NCT00790491|Behavioral|guidance tool for providers for lifestyle changes|automated guidance tool for medical providers involved in patient encounters addressing lifestyle changes. Addresses dietary and physical activity. Seeks to reduce cardiac disease risk.
1828839|NCT00790517|Behavioral|Premier Lifestyle Intervention with DASH Diet|Comprehensive group lifestyle intervention focused on caloric restriction and increased moderate exercise using the DASH Diet. 6 months intensive intervention (weekly, group meetings) followed by 6 months of a less-intensive maintenance intervention (monthly group meetings with monthly telephone/e-mail consult)
1828842|NCT00790556|Drug|MK8245|MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
1828843|NCT00790556|Drug|Comparator: Placebo|MK8245 placebo capsules twice daily for 13 days. On Day 14, only the morning dose of study medication will be taken. There will be a 14 day washout period. Patients will then crossover to MK8245 50 mg capsules twice daily for 13 days. On Day 14, only the morning dose of study drug will be taken.
1828848|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 2 weeks.
1828849|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 4 weeks.
1828850|NCT00790595|Drug|SU011248|5 Subjects will receive 50.0 mg/d of the study drug for 1 week.
1828851|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 1 week.
1828852|NCT00790595|Drug|SU011248|5 Subjects will receive 37.5 mg/d of the study drug for 2 weeks.
1828853|NCT00790608|Drug|Nitric Oxide|Gaseous nitric oxide (1%), delivered for 30 minutes per day for 3 consecutive days
1828854|NCT00790647|Biological|filgrastim|16 mcg/kg daily beginning 3 days before stem cell collection through day before final stem cell collection
1828855|NCT00790647|Drug|bortezomib|1.0 mg/m2/dose D -6, D-3, D +1, D + 4
1828856|NCT00790647|Drug|melphalan|100 mg/m2/dose D -2, D -1
1828857|NCT00790647|Procedure|Stem Cell Infusion|infusion of previously collected autologous stem cells
1828858|NCT00790660|Drug|ASP1941|Oral
1828859|NCT00790660|Drug|Placebo|Oral
1828860|NCT00790673|Drug|CF 102|Oral capsules
1828861|NCT00790673|Drug|Placebo|Matching placebo capsules
1828862|NCT00790686|Procedure|Insertion of Memokath 051|Patients usually treated with double J stents will be included. The double J stent will be replaced by a MEMOKATH 051 stent under general anesthesia during a cystoscopy.
1994026|NCT03084679|Other|Stretching exercises|5-min stretching exercises will be performed in major muscle groups (legs, arms and trunk muscles)
1994027|NCT03084679|Other|Aerobic exercise in treadmill|30-40min of aerobic exercise in treadmill. The aerobic intensity will be established by heart rate levels that corresponded to anaerobic threshold up to 10% below the respiratory compensation point obtained in the cardiopulmonary exercise test. This intensity corresponded to 60-72% peak V̇o2. During the exercise sessions, when a training effect will be observed, as indicated by a decrease by 8 to 10% in heart rate, the treadmill velocity or inclination will be increased to return to the target heart rate levels.
1828865|NCT00790725|Other|Proportional Assist Ventilation|Proportional Assist Ventilation will be used to ventilate the patients.
1828866|NCT00790725|Other|Pressure Support Ventilation|Pressure Support ventilation will be used to ventilate the patients.
1828867|NCT00790738|Drug|Liothyronine (T3)|liothyronine (T3) up to 50 micrograms a day
1828868|NCT00790738|Drug|placebo|placebo
1828869|NCT00790751|Drug|placebo|30 minutes orally prior to initiation of sexual activity
1828870|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
1828871|NCT00790751|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
1994028|NCT03084679|Other|Local strengthening exercises|10 min of local strengthening exercises will be performed in major muscle groups (legs, arms and trunk muscles): three series of each exercise, 12-15 repetitions.
1828873|NCT00790764|Biological|MESENDO|For the cell product, proper aliquots of each cell type will be taken to fulfill the doses established for this protocol. The two aliquots will be mixed and resuspended to a final volume of 3 ml in the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin.
1828874|NCT00790764|Other|placebo|For placebo, 3 ml of the 'Final Suspension Medium' which consists of Dulbecco's Phosphate Buffered Saline (DPBS), containing 5% human serum albumin will be transferred to a 5 ml syringe
1828875|NCT00790777|Drug|Paliperidone ER|
1828876|NCT00790790|Drug|Placebo|LY545694 placebo BID po for 5 weeks
1828877|NCT00790790|Drug|LY545694 49 mg|LY545694 49 mg BID po for 5 weeks.
1828878|NCT00790790|Drug|LY545694 105 mg|LY545694 105 mg BID po for 5 weeks.
1828879|NCT00790803|Drug|Pegaptanib|Five patients will receive intravitreous injections of Macugen 0.3 mg every 6 weeks as needed for a total of no more than five.
1828880|NCT00790816|Drug|Lapatinib in combination with an anti-cancer agent|Lapatinib in combination with paclitaxel, letrozole, capecitabine, capecitabine/oxaliplatin, gemcitabine, docetaxel, trastuzumab, FOLFOX4, or FOLFIRI
1828881|NCT00790816|Drug|Lapatinib|Lapatinib monotherapy
1828882|NCT00790816|Drug|Lapatinib in combination with an anti-cancer agent as specified by parent protocol|Lapatinib in combination with an anti-cancer agent as specified by parent protocol
1828883|NCT00790829|Drug|transdermal nicotine patch|Generic seven-milligram nicotine patches for 24hours, placebo patch for 24 hours
1828884|NCT00790842|Drug|Group A=30-60 CrCl (mL/min)|Each Cycle=28 days. Lenalidomide by mouth days 1-21 and Dexamethasone 40 mg by mouth days 1, 8, 15 and 22. There is a 7 day rest (days 22-28) from lenalidomide. Continue until disease progression or unacceptable toxicity. Phase I will determine the dose of lenalidomide to be used in Phase II.
1828885|NCT00790842|Drug|Group B=CrCL<30 mL/min not on dialysis|Each Cycle=28 days. Lenalidomide by mouth days 1-21 and Dexamethasone 40 mg by mouth days 1, 8, 15 and 22. There is a 7 day rest (days 22-28) from lenalidomide. Continue until disease progression or unacceptable toxicity. Phase I will determine the dose of lenalidomide to be used in Phase II.
1828886|NCT00790842|Drug|Group C=CrCL<30 mL/min and on dialysis|"Each Cycle=28 days. Lenalidomide by mouth days 1-21 and Dexamethasone 40 mg by mouth days 1, 8, 15 and 22. There is a 7 day rest (days 22-28) from lenalidomide. Continue until disease progression or unacceptable toxicity. Phase I will determine the dose of lenalidomide to be used in Phase II.
Dialysis includes hemodialysis or peritoneal dialysis. When lenalidomide and/or dexamethasone treatment occurs on a dialysis day, lenalidomide and/or dexamethasone must be taken after dialysis."
1828887|NCT00790855|Drug|Bendamustine|Starting dose of 50 mg/m^2 through a needle or catheter in vein over 2 hours twice on Days 1-4 of every 4 week study cycle. A new study cycle may begin when blood cell counts have returned to an appropriate level or a new study cycle may begun earlier if disease gets worse or does not improve.
1828890|NCT00790881|Drug|Artemether/Lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
1828891|NCT00790881|Drug|Artemether/ lumefantrine|Coartem (fixed dose Artemether20mg /Lumefantrine 120mg) Dose: 4 tablets(80mg/480mg) twice daily for 3 days at 0,8,24,36,48 and 60 hours
1828892|NCT00790894|Drug|ixabepilone|Arm A: ixabepilone will be given at a dose of 40 mg/m2 as a 3-hour intravenous infusion on Day 1 in a 21 days cycle.
1828893|NCT00790894|Drug|ixabepilone|Arm B: ixabepilone will be given at a dose of 20 mg/m2 as a 3-hour intravenous infusion on Days 1, 8 and 15, then 1 week off in a 28-days cycle.
1828894|NCT00790907|Drug|fondaparinux background and standard dose UFH|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded standard dose UFH (based on planned glycoprotein [GP] IIb/IIIa inhibitor use: 60 units/kilogram (U/kg); no planned use: 85 U/kg and adjusted based on activated clotting time (ACT) [maximum two additional bolus doses]). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
1828895|NCT00790907|Drug|Fondaparinux background and low dose heparin|Open label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier. Participants indicated for PCI were randomized to receive adjunctive blinded low-dose UFH (50 U/kg), which was not adjusted for planned GPIIb/IIIa inhibitor use or ACT). Participants who presented in the catheterization laboratory and who were receiving commercially available fondaparinux prescribed for the initial treatment of UA/NSTEMI may have been considered for randomization.
1828896|NCT00790907|Drug|Open label fondaparinux|Open-label fondaparinux syringes pre-filled with 2.5 mg, administered s.c. once daily for up to 8 days or hospital discharge, whichever was earlier, for those participants not indicated for PCI and not randomized
1828897|NCT00790920|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 - 2 minutes on 1st day
1828898|NCT00790920|Drug|Placebo|IV, single bolus over 1 - 2 minutes on 1st day
1828899|NCT00790933|Drug|Vedolizumab|Vedolizumab intravenous infusion
1828900|NCT00790946|Drug|Valsartan|Valsartan 80 to 160 mg
1828903|NCT00790972|Drug|Sinofresh|two sprays in each nostril three times daily for one week
1828904|NCT00790972|Drug|Placebo|two sprays in each nostril three times daily for one week
1828905|NCT00790985|Dietary Supplement|flavocoxid|medical food
1828906|NCT00790985|Drug|Naproxen|antiinflammatory drug
1828907|NCT00790998|Drug|Moxidectin|Single dose of moxidectin 2 mg oral tablet x 4
1828908|NCT00790998|Drug|Ivermectin|Single dose of ivermectin 3 mg oral tablet x 2, 3 or 4
1828909|NCT00791011|Drug|AMG 655|AMG 655 is an investigational, fully human monoclonal agonist antibidy that selectively binds to Death Receptor-5 (DR-5).
1828910|NCT00791011|Other|Vorinostat|Vorinostat, a second generation polarplanar compound, binds to the catalytic domain of the histone deacetylases (HDAC).
1828911|NCT00791011|Other|Bortezomib|A dipeptide boronic acid analogue with antineoplastic activity.
1828912|NCT00791024|Drug|CRC-Pharma 001|50 mg
1828913|NCT00791024|Drug|lidocaine suspension|5.0 ml lidocaine suspension(20mg/ml) adm. 10 min. before oesophagogastroduodenoscopy.
1828914|NCT00791037|Biological|HER-2/neu peptide vaccine|Given ID
1828915|NCT00791037|Procedure|leukapheresis|Undergo leukapheresis
1828916|NCT00791037|Biological|ex vivo-expanded HER2-specific T cells|Given IV
1828917|NCT00791037|Drug|cyclophosphamide|Given IV
1828918|NCT00791037|Biological|sargramostim|Given ID
1828919|NCT00791037|Other|laboratory biomarker analysis|Correlative study
1828920|NCT00791050|Device|Allon Thermowrap. MTRE Advanced Technologies Ltd.|"Thermowrap set at 37 °C before induction of anesthesia and maintained until initiation of CPB; during CPB set to monitoring and set again to 37 °C from rewarming during CPB to end of surgery."
1828921|NCT00791063|Other|18F ML-10|Patients will undergo 2-3 brain PET/CT sessions; A pre-treatment session and 1-2 sessions post WBRT treatment. Each PET/CT session will be done following intravenous administration of 18F-ML-10, to assess tracer uptake by the tumor.
1828922|NCT00791076|Drug|Placebo|2pmol/kg-1/min-1 placebo infused continuously over 72 hours.
1828923|NCT00791076|Drug|Pancreatic Polypeptide (PP)|2pmol/kg-1/min-1 PP infused continuously over 72 hours.
1828924|NCT00791089|Drug|LOVAZA Omega 3-acid ethyl esters|Treatment with omega-3 fatty acids (4g/day) for 4 weeks before and 3 months after radiofrequency catheter ablation for AF.
1828925|NCT00791089|Drug|LOVAZA|(EPA+DHA 4 gram/day) for 4 weeks before and 3 months after the ablation procedure.
1828926|NCT00791089|Other|placebo|Control group will receive placebo before & after ablation.
1828927|NCT00791102|Drug|ASP-1001 nasal spray|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
1828928|NCT00791102|Drug|Placebo for ASP-1001|2 sprays (total 200 microliters) in each nostril 20 minutes before allergen challenge.
1828929|NCT00791115|Procedure|whole-mount sectioning of the prostate|A standard open retropubic radical prostatectomy will be performed. Whole fresh prostate is be embedded in gel and oriented in the anatomic position in a plastic cylinder using wood skewers. Standard pathology reports are generated from this tissue
1828930|NCT00791128|Device|GI Liner|Medical device placed endoscopically in the duodenum, nutritional counseling
1828931|NCT00791141|Drug|Cetuximab|Loading dose prior to chemoradiotherapy 400 mg/m², followed by every week infusion of 250 mg/m² during chemoradiotherapy. After chemoradiotherapy every 2 week infusions of 500 mg/m² over 6 months.
1828932|NCT00791154|Drug|AMG 479|AMG 479 is administered to subjects
1828933|NCT00791154|Drug|Etoposide|Etoposide is administered to subjects
1828934|NCT00791154|Drug|Placebo|Placebo is administered with Carboplatin and Etoposide
1828935|NCT00791154|Drug|AMG 102|AMG 102 is administered to subjects
1828936|NCT00791154|Drug|Carboplatin|Carboplatin is administered to some subjects in combination
1828937|NCT00791154|Drug|Cisplatin|Cisplatin is administered to some subjects in combination
1828938|NCT00791167|Drug|Paliperidone ER|
1828939|NCT00791193|Drug|Paliperidone ER|
1828940|NCT00791206|Procedure|Real preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 15 mmHg greater than systolic arterial pressure.
1828941|NCT00791206|Procedure|Sham preconditioning|Preconditioning will consist of four 5 minutes cycles of upper limb ischemia interspaced with 5 minutes of reperfusion, using a blood-pressure cuff inflated to a pressure 10mmHg with the same cycling protocol as the real preconditioning.
1828942|NCT00791219|Drug|SUBA-itraconazole|100 mg approximately 30 minutes prior to breakfast for 12 weeks of SUBA™-Itraconazole 50 mg capsules (HalcyGen Ltd)
1828943|NCT00791219|Drug|Itraconazole|200 mg taken with breakfast of SPORANOX® (itraconazole) 100 mg capsules (Janssen Pharma).
1828944|NCT00791219|Drug|Placebo|Two placebo capsules taken approximately 30 minutes prior to breakfast
1828945|NCT00791232|Drug|extended-release (ER) OROS paliperidone|
1828946|NCT00791245|Biological|Particulated Juvenile Cartilage Allograft|Particulated Juvenile Cartilage Allograft
1828947|NCT00791258|Drug|amlodipine and olmesartan medoxomil tablets|amlodipine and olmesartan medoxomil tablets administered orally, once daily for up to 20 weeks
1828948|NCT00791258|Drug|hydrochlorothiazide tablets|hydrochlorothiazide tablets may be administered orally, if necessary once daily, for up to 8 weeks
1828949|NCT00791271|Drug|Decitabine|Starting dose of 10mg/m^2 given daily via intravenous infusion on days 1-5 of 28 day cycle.
1828950|NCT00791271|Drug|Pegylated Interferon Alpha-2b|Starting dose of 3 µg/kg injection under the skin once a week on days 1, 8, 15, and 21 of 28 day cycle.
1828951|NCT00791284|Drug|Intermediate release (IR) Paliperidone|
1828952|NCT00791297|Drug|CDB-2914|Contraceptive Vaginal Rings delivering a daily dose of 1500 or 2500 μg of CDB-2914
1828953|NCT00791310|Drug|Flucis|FDG injected i.v
1828954|NCT00791323|Drug|Ketorolac 0.4%|One drop 4 times a day in the pre-operative eye beginning day 0 for 4 days
1828955|NCT00791323|Drug|Lubricating Eye Drop|One drop 4 times a day in the operative eye beginning one day prior to the peripheral iridotomy and continuing until the day of IOL implantation
1828956|NCT00791336|Drug|Nelfinavir|1250 mg twice daily starting for approximately 6.5 weeks.
1828957|NCT00791349|Drug|Immediate release (IR) Paliperidone|
1829013|NCT00808119|Drug|RTI-336 (CTDP 31862)|The RTI-336 drug product is formulated as hard, white, gelatin capsules. The dosage levels are 0.3, 1.0, and 3.0 mg (Cohort 1) and 6.0, 12.0, and 20.0 mg (Cohort 2). Subjects will receive a single dose of the study drug on study day 1.
1829064|NCT00808444|Biological|Infanrix hexa|Intramuscular injection, 3 doses in Malaysia and 2 doses in Singapore
1828958|NCT00791362|Other|National programme for accreditation and improvement of GP|The national programme for accreditation and improvement of general practice. This procedure consists of a package of activities, including audit, feedback, improvement plans, and follow-up. It is partly based on new theories on quality improvement, including the use of market forces and pressure for accountability. For the purpose of the study, the intervention group will be requested to focus their improvement plans in the first year on cardiovascular diseases. The control group is requested to focus their improvement plans in the first year on other domains and to provide cardiovascular care as usual.
1828959|NCT00791375|Behavioral|Physical activity intervention|Comparison of providing access to a targeted physical activity web-site v. providing information on cancer-related websites
1828960|NCT00791388|Drug|Placebo|oral capsule, 2x/day for 14 days
1828961|NCT00791388|Drug|PG-760564|oral capsule, 50 mg, 2x/day for 14 days
1828962|NCT00791388|Drug|PG-760564|oral capsule, 100mg, 2x/day for 14 days
1828963|NCT00791388|Drug|PG-760564|oral capsule, 200 mg, 2x/day for 14 days
1828964|NCT00791388|Drug|PG-760564|oral capsule, 400 mg, 2x/day for 14 days
1828965|NCT00791401|Drug|ER OROS Paliperidone|
1828966|NCT00791427|Drug|Ranibizumab|0.05 ml of ranibizumab injected into the eye monthly for one year
1828967|NCT00791440|Behavioral|Cognitive-Behavior Therapy|Weekly individual Cognitive-Behavior Therapy (CBT) to target hallucinations and delusions in addition to standard psychiatric treatment.
1828968|NCT00791440|Other|Standard Psychiatric Treatment|Standard psychiatric treatment.
1828970|NCT00804128|Procedure|contrast-enhanced magnetic resonance imaging|
1828971|NCT00804141|Drug|N-methylnaltrexone bromide (MOA-728)|48 week treatment with 12 mg MOA-728 administered subcutaneously at least once per week with a maximum frequency of once daily.
1828972|NCT00804154|Drug|(Resiniferatoxin)(RTX)|
1828973|NCT00804154|Drug|Intrathecal Resiniferatoxin|
1828974|NCT00804180|Behavioral|Self-Injection Anxiety Counseling|This 5-session group intervention involves: psychoeducation; physiological treatment of anxiety though the instruction and practice of relaxation techniques; cognitive restructuring for anxiety-reduction; practice physiological and cognitive treatments through in vivo injection procedures; and problem solving strategies to generalize treatment gains.
1828975|NCT00804193|Drug|Ciclopirox Olamine Topical Suspension|topical suspension
1828976|NCT00804193|Drug|Ciclopirox Topical Suspension 0.77%-Reference Product|topical suspension
1828977|NCT00804193|Drug|Ciclopirox Olamine Topical Suspension-Placebo|topical suspension
1828978|NCT00804206|Drug|bevacizumab|Intravitreal bevacizumab before panretinal photocoagulation
1828979|NCT00804206|Drug|bevacizumab|Intravitreal Bevacizumab after panretinal photocoagulation
1828980|NCT00804219|Biological|TBE vaccination and influenza vaccination|FSME-Immun, 0,5 ml, i.m., 1x Inflexal 0,5 ml, i.m., 1x
1828981|NCT00804232|Behavioral|childhood diabetes|the intervention compares three different regimes for children newly diagnosed with type 1 diabetes: (1) traditional hospital based care, (2) intensive psychological support to the family, and (3) home based family psychosocial support. A further aim is to identify families were the child runs the risk of decreased metabolic control and to give those families increased support.
1828982|NCT00804245|Procedure|needle biopsy|Biopsy of positive findings found on CT scan
1828983|NCT00804245|Drug|PET-CT scans supplemented with 11C-Choline tracer|Use of 11C-Choline tracer to enhance diagnostic utility of 11C-Choline tracer
1828984|NCT00804258|Drug|intraperitoneal chemotherapy|
1828985|NCT00804258|Other|educational intervention|
1828986|NCT00804258|Other|medical chart review|
1828987|NCT00804258|Other|questionnaire administration|
1828988|NCT00804258|Procedure|assessment of therapy complications|
1828989|NCT00804258|Procedure|end-of-life treatment/management|
1828990|NCT00804258|Procedure|psychosocial assessment and care|
1828991|NCT00804258|Procedure|quality-of-life assessment|
1828992|NCT00804271|Drug|memantine|memantine tablets, OD, 12 weeks
1828993|NCT00804284|Biological|DTaP-IPV/Hib|0.5 mL, Intramuscular
1828994|NCT00804284|Biological|Other DTap Vaccines|0.5 mL, Intramuscular
1828995|NCT00804297|Drug|Octreotide (drug)|
1828996|NCT00804310|Drug|ixabepilone|This intravenous treatment will be performed on an outpatient basis. Ixabepilone (15 - 20mg/m2) will be given weekly for 3 weeks, then one week off, every 28 days (4 weeks). The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
1828997|NCT00804310|Drug|lapatinib ditosylate|Lapatinib (1000-1500 mg) will be administered orally on a daily basis. The study doctor will decide how long to keep the participant on this treatment based on how the participant is tolerating the drug and how it is affecting the tumor.
1828998|NCT00804323|Procedure|Patter Scan Laser System (OptiMedica, Santa Clara, CA, USA)|Pattern Scan Laser trabeculoplasty
1828999|NCT00804336|Drug|SOM230|Given subcutaneously twice a day for four weeks then given intramuscularly once every four weeks thereafter
1829000|NCT00804336|Drug|RAD001|Given orally once a day
1829001|NCT00804349|Device|Autotitrating Positive Airway Pressure|Patients will be treated with Autotitrating Positive Airway Pressure therapy
1829002|NCT00804375|Drug|2PX|cutaneous solution to be applied twice daily for 84 days
1829003|NCT00804375|Drug|Placebo|cutaneous solution to be applied twice daily for 84 days
1829004|NCT00804388|Procedure|Total hip arthroplasty|32 mm versus 36 mm caput of ceramics Vitamin E stabilized polyethylene
1829005|NCT00804401|Drug|Naproxen Tablets, 500 mg|
1829006|NCT00804414|Drug|SBG|Solution for topical use
1829007|NCT00804414|Drug|Placebo Comparator|Solutin for topical use
1829008|NCT00804427|Dietary Supplement|Fish oil (90% triglycerides)|
1829009|NCT00804427|Dietary Supplement|Fish oil (60% triglycerides)|
1829010|NCT00804427|Dietary Supplement|Fish oil (ethyl esters)|
1829011|NCT00804427|Dietary Supplement|Soy oil|
1829012|NCT00804440|Drug|Ibuprofen Tablets, 800 mg|
1829063|NCT00808444|Biological|Pneumococcal conjugate vaccine GSK1024850A (different lots)|Intramuscular injection, 3 doses
1829014|NCT00808132|Drug|bazedoxifene 20 mg/ conjugated estrogens 0.45 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.45 mg (over-encapsulated), once a day for one year.
1829015|NCT00808132|Drug|bazedoxifene 20 mg/ conjugated estrogens 0.625 mg|One capsule, bazedoxifene 20 mg/conjugated estrogens 0.625 mg (over-encapsulated), once a day for one year.
1829016|NCT00808132|Drug|bazedoxifene 20 mg|One capsule, bazedoxifene 20 mg (over-encapsulated), once a day for one year.
1829017|NCT00808132|Drug|conjugated estrogens 0.45 mg/ medroxyprogesterone acetate 1.5 mg|One capsule, conjugated estrogens 0.45 mg and medroxyprogesterone 1.5 mg (over-encapsulated), once a day for one year.
1829018|NCT00808132|Drug|Placebo|One capsule, placebo (over-encapsulated), once a day for one year.
1829019|NCT00808145|Drug|Gemcitabine / Cisplatin / Sorafenib|All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
1829020|NCT00808171|Drug|Livopan|Inhalation of oxygen and nitrous oxide 50%
1829021|NCT00808171|Drug|Livopan|equimolar mixture of N2O/O2
1829022|NCT00808171|Drug|EMLA|Lidocaine-prilocain cream
1829023|NCT00808184|Drug|CPT-11, Raltegravir (Isentress®), Midazolam|
1829024|NCT00808197|Procedure|ocular blood flow measurement|Ocular blood flow will be determined by non-invasive methods, including laser Doppler flowmetry and laser interferometry
1829025|NCT00808210|Drug|infliximab|Intravenous repeating dose
1829026|NCT00808210|Drug|methotrexate|Oral or parenteral repeating dose
1829027|NCT00808210|Drug|methylprednisolone|Intravenous repeating dose
1829028|NCT00808210|Drug|ocrelizumab|Intravenous repeating dose
1829029|NCT00808210|Drug|sham|Intravenous repeating dose
1829030|NCT00808223|Biological|alefacept|IM injection
1829031|NCT00808236|Device|RhinoChill|Nasal catheters are placed and cooling is begun during the resuscitation attempt
1829032|NCT00808236|Other|Control|Advanced cardiac life support according to American Heart Association & European Resuscitation Council 2005 Guidelines
1829033|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
1829034|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
1829035|NCT00808249|Drug|AZD7325|2 tablets taken twice a day for 28 days
1829036|NCT00808249|Drug|Placebo|2 tablets taken twice a day for 28 days
1829037|NCT00808262|Biological|TNFa Kinoid|TNFa kinoid at days 0, 7, 28
1829038|NCT00808275|Dietary Supplement|Dietary calcium|Dairy and non-dairy calcium provided as a part of diet in the amounts of 500 mg/day and 1500 mg/day. Diet contained 70% of daily caloric requirements.
1829039|NCT00808288|Drug|PF-00610355|oral, inhaled, dry powder, 600ug, OD
1829040|NCT00808288|Drug|PF - 00610355|oral, inhaled, dry powder, 300ug, OD
1829041|NCT00808288|Drug|PF- 00610355|oral, inhaled, dry powder, 100ug, OD
1829042|NCT00808288|Drug|Placebo|oral, inhaled, dry powder, placebo, OD
1829043|NCT00808288|Drug|Salmeterol|salmeterol, 50ug, BID
1829044|NCT00808301|Other|Gluten-free products|Gluten-free bakery products containing oatmeal.
1829047|NCT00808327|Drug|Bupivacaine|A single, 15mg, intrathecal dose of bupivacaine.
1829048|NCT00808327|Drug|Bupivacaine, fentanyl|A single, 12 mg, intrathecal dose of bupivacaine, plus 15 micrograms of fentanyl
1829049|NCT00808340|Device|balafilcon A|multifocal contact lens
1829050|NCT00808340|Device|senofilcon A production|multifocal contact lens
1829051|NCT00808340|Device|senofilcon A test|multifocal contact lens
1829052|NCT00808366|Drug|Keratolytic/Antifungal|Intial treatment with RV4104A ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
1829053|NCT00808366|Drug|Keratolytic/Antifungal|Initial treatment with bifonazole-urea ointment for 3 weeks. Subsequent topical antifungal treatment with bifonazole cream for 8 weeks.
1829054|NCT00808379|Drug|Chemoradiation|Chemotherapy will begin on the first day of radiotherapy and continue until the completion of radiotherapy. Capecitabine will be administered orally daily 2000 mg/m2 in two divided doses (approximately 12 hours apart) for 2 weeks followed by a 1-week rest period given as 3 week cycles.
1829055|NCT00808379|Radiation|Additional Radiation boost to the primary tumor volume|15-20Gy
1829056|NCT00808392|Biological|Haemophilus influenzae type b vaccine|3 doses one month apart of Monovalent conjugated vaccine against Haemophilus influenzae type b vaccine
1829057|NCT00808392|Biological|Commercial Haemophilus influenzae type b vaccine|3 doses one month apart of Haemophilus influenzae type b vaccine.
1958750|NCT01278394|Drug|AN2690 Solution, 5.0%|Once daily application for 360 days
1829060|NCT00808418|Drug|Elesclomol Sodium|Chemotherapy agent
1829061|NCT00808418|Drug|Docetaxel|Chemotherapy agent
1829062|NCT00808431|Behavioral|Lifestyle counseling|3 month skills building program emphasizing parent training, behavior modification training, nutrition education, and physical activity promotion
1829065|NCT00808444|Biological|Infanrix-IPV/Hib|Intramuscular injection, only for Visit 2 in Singapore
1829066|NCT00808444|Biological|Rotarix|Oral, 2 doses
1829067|NCT00808470|Drug|beta-carotene, vitamins C and E, magnesium|"6 mint-flavored tablets per day, taken once daily
total daily dose label claim: micronutrient combination of 500 mg vitamin C (magnesium ascorbate), 315 mg magnesium (magnesium citrate, magnesium ascorbate, magnesium stearate), 267 mg vitamin E (d-α-tocopherol acetate), and 18 mg beta carotene."
1829068|NCT00808470|Other|Placebo|6 mint-flavored tablets per day, containing inactive substances including mannitol, peppermint flavor, sucralose, color prep, iron oxide yellow synthetic, stearic acid (vegetable grade), and silicon dioxide colloidal.
1829069|NCT00808483|Other|Walking skill training program|12 individualized training sessions containing functional exercises like walking, stair climbing, balance training and with supervision and guidance from a physiotherapist.
1829070|NCT00808496|Other|MRI|"Biannual disease progression monitoring with peripheral magnetic resonance imaging of the 2nd to 5th metacarpophalangeal joints of the worst-effected or dominant hand at baseline. Scored using the Xie-modified rheumatoid arthritis magnetic resonance imaging score (RAMRIS).
MRI intervention group also undergoes radiography imaging. Only protocol determined smallest detectable changes on MRI reported."
1829071|NCT00808496|Other|Radiography|"Biannual disease progression monitoring with radiography of both hands and wrists. Scored using the van der Heijde-modified Sharp score.
Radiography intervention group also undergoes MRI imaging. Only protocol determined smallest detectable changes on radiography reported."
1829072|NCT00808496|Other|Standard of Care|Diagnostic imaging results (MRI or radiography) reported upon requisition. Standard of Care intervention group undergoes both MRI and radiography imaging. Upon requisition of either MRI or radiography, radiology reports are delivered as per institutional standard of care
1829073|NCT00808509|Biological|adalimumab|40 mg every other week via subcutaneous injection
1829074|NCT00808509|Drug|methotrexate|At least 10 mg/week administered orally or subcutaneously
1829075|NCT00808522|Drug|hCG|recombinant hCG subcutaneous injections x 30 doses every other day lasting 60 days total.
1829076|NCT00808535|Procedure|Cardiac Perfusion MRI w Vasomotor Stress|All participants will undergo Cardiac Perfusion MRI with Vasomotor Stress. Vasomotor Stress will include both Cold Pressor Test and Adenosine Stress Test.
1829077|NCT00808548|Other|counseling, emotional support|
1829078|NCT00808548|Other|emotional support|emotional support during the interview
1829079|NCT00808548|Other|emotional support|emotional supporting during the interview
1829080|NCT00808561|Other|Group 1: Alternative Fistula|Performing other autogenous AV fistulas which include various options such as brachiocephalic AV fistula, basilic or brachial vein transpositions or a variety of other strategies to maintain a primary access. The advantage would be to maintain an autogenous all venous access with less risk of infection and thrombosis.
1829081|NCT00808561|Other|Group 2: Forearm AV Graft|a) ePTFE (polytetrafluoroethylene) bridge AV graft typically anastomosed in the proximal forearm to the radial or brachial artery and to an antecubital vein. The advantages include a quick maturation of 2-3 weeks, excellent flow rates and high technical success rates. Although secondary patency rates approach 80% at one year postoperatively, disadvantages include a more involved surgical procedure, a lower primary patency than a well functioning AV fistula, and higher revision and infection rates.4, 5
1829082|NCT00808574|Behavioral|Obstructive sleep apnea screening intervention|Brief, theory-based, online assessment of OSA risk followed by risk-tailed OSA presentation.
1829083|NCT00808600|Behavioral|resource-activating behavioural training programme|"Stepwise intervention based on the principles of resource-activating training (RAT) applied to the needs of patients in the process after lung transplantation.
Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Continued resource-activation and transfer by means of internet-based interventions (1 per 2 weeks) as well as personal interventions by trained nurses and a clinical psychologist during regular out-patient visits (approx. 4 times per year) over one year immediately following rehabilitation. Interventions focus on strengthening individual and interpersonal resources for well-being, psychoeducation, stress management and coping with illness. Phase 3: Termination and transfer, including a detailed medical report."
1829084|NCT00808600|Behavioral|Relaxation training|Phase 1: Build-up of therapeutic relationship through resource-activating training for patients after transplantation during rehabilitation in the rehabilitation centre Fallingbostel following inpatient treatment. Phase 2: Regular relaxation training after rehabilitation by self-guided relaxation compact disk and accompanying worksheets.
1829085|NCT00808600|Behavioral|Intensified anaerobic exercise training|Phase 1: Recruitment and initiation of intensified and individualised aerobic/anaerobic exercise training based on determination of aerobic/anaerobic threshold during rehabilitation in the rehabilitation centre Fallingbostel. During rehabilitation daily training sessions with a duration of 30 minutes each are performed under medical supervision. Phase 2: Home training on an IT-assisted ergometer 3.5 times a week with interval exercise intensity above the anaerobic threshold. Work load and heart rate are stored by an ergometer-chip, lung function analyses are performed and should be transferred via phone-based telemetry. Exercise training intensities will be adapted monthly, corresponding to training results. At regular 3 months visits to the outpatient clinic a medical examination is carried out. Moreover, according to the actual functional state of the patient estimated 3 monthly training work load will be adjusted. Phase 3: Termination, evaluation after a period of 12 months.
1829086|NCT00808600|Behavioral|Moderate aerobic exercise training|Phase 1: Recruitment and initiation of moderate aerobic exercise training based on 40 percent of maximal oxygen consumption in Watt during rehabilitation in the rehabilitation centre Fallingbostel. Phase 2: Moderate aerobic endurance training with the target intensity of 40 percent of the individual maximum exercise capacity will be performed 3.5 times a week with a duration of 30 minutes per session, work load will be adapted continuously according to the measures that are assessed during the repeated control examinations after periods of 3 months in the outpatient clinic of the pulmonary department of Hanover Medical School.
1829087|NCT00808613|Device|Optetrak PS|Optetrak Posterior Stabilized total knee replacement
1829088|NCT00808613|Device|Optetrak Hi-Flex|Optetrak Hi-Flex total knee replacement
1829133|NCT00808899|Drug|13-cis-retinoic acid|13-cis-retinoic acid
1829134|NCT00808912|Drug|sildenafil|sildenafil 50 mg ingested orally 1 hour prior to exercise testing
1829089|NCT00808626|Drug|99mTc-rBitistatin|Intravenous administration of a single dose (10 mCi, 0.1 ug/kg body weight) of 99mTc-rBitistatin, followed by collection of scintigraphic (planar and SPECT) images at 1 hour and 2-4 hours.
1829090|NCT00808639|Drug|Methotrexate|intravenously 30mg/m2 over 30 minutes
1829091|NCT00808639|Drug|Doxorubicin|intravenously 30mg/ms over 15 minutes
1829092|NCT00808639|Drug|vinblastine|intravenously 3mg/m2 over 30 minutes
1829093|NCT00808639|Drug|cisplatin|intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion
1829094|NCT00808639|Drug|Pegfilgrastim|Given subcutaneously 24 hours after last chemotherapy dose
1829095|NCT00808652|Other|Measurement of flow mediated dilation of brachial artery.|"Flow-mediated brachial artery reactivity will be measured and flow-mediated vasodilatation will be assessed with the subject's arm using a 15 MHz linear array ultrasound.
Study Phases:
Flow-mediated (endothelial-dependent) vasodilatation (FMD): Following a 2-minute baseline period, a longitudinal image of the artery will be obtained. A tourniquet placed around the forearm proximal to the target artery will be inflated to a pressure 50 mmHg higher than the subject's systolic blood pressure and held for 5 minutes. Cuff will be then deflated. A continuous scan will be performed at deflation, 60 and 90 seconds after cuff deflation, with frozen and Doppler measurements recorded at similar intervals to the baseline phase.
NTG-induced (non-endothelial-dependent) vasodilatation (NTG): After vessel recovery, sublingual 375 mg of isosorbide dinitrate spray will be administered, and scanning will be performed continuously for 5 minutes thereafter."
1829097|NCT00808678|Drug|ABT-143|once, see arm description for more information
1829098|NCT00808678|Drug|ABT-335|once, see arm description for more information
1829099|NCT00808678|Drug|rosuvastatin|once, see arm description for more detail
1829100|NCT00808691|Other|Critical care|Standard care for each group of patients
1829101|NCT00808704|Drug|recombinant human erythropoietin|r-hu-EPO were administered either 300 U/kg or 500 U/kg, subcutaneously the first time and then intravenously every other day for 2 weeks.
1829103|NCT00808730|Procedure|fiberoptic fibroscopy|Bronchial specimens will be obtained by fiberoptic bronchoscopy within 15 days after the enrolment
1829104|NCT00808743|Drug|Celecoxib|Celecoxib: 400mg twice daily, orally, 6 months
1829105|NCT00808743|Drug|Ursodeoxycholic acid|"Ursodeoxycholic acid: orally, 6 months, dosage based on body weight:
below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
1829106|NCT00808743|Drug|Placebo|"Placebo: orally, 6 months, dosage based on body weight:
below 50 kg: 1000mg, divided in two daily doses; 50-70 kg: 1500mg, divided in two daily doses; over 70 kg: 2000mg, divided in two daily doses"
1829107|NCT00808756|Dietary Supplement|Fermentable carbohydrates.|Infant formula enriched with fermentable carbohydrates.
1829108|NCT00808756|Other|Standard infant formula.|Standard infant formula.
1829109|NCT00808769|Drug|Zegerid®|capsule(20 mg omeprazole/sodium bicarbonate), single dose
1829110|NCT00808769|Drug|Prilosec OTC®|Omeprazole-magnesium 20.6 mg, tablet, single dose
1829111|NCT00808782|Device|Deep rTMS|Repetitive transcranial magnetic stimulation targeting the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks.
1829112|NCT00808782|Device|Sham rTMS|Sham (non-active) repetitive transcranial magnetic stimulation over the medial prefrontal cortices. 30 10s 5Hz rTMS trains per day, with a 20 gap between each (15 minutes total), each consecutive weekday for two weeks
1829113|NCT00808795|Drug|N-acetylcysteine|NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
1829114|NCT00808795|Drug|Placebo|Placebo of NAC is to be orally administered at the dose of 600mg twice a day, starting 24h before the procedure (two doses before and two doses after the procedure).
1829115|NCT00808808|Biological|Choice of TIV or FluMist with baseline advertisement|An intervention arm offering choice of TIV or FluMist with baseline advertisement, including advertisement to highlight the availability of FluMist
1829116|NCT00808808|Other|Choice of TIV or FluMist with enhanced advertisement and incentives|An intervention arm offering choice of TIV or FluMist with enhanced advertisement and additional incentives for receiving an influenza vaccination
1829117|NCT00808808|Biological|Control - Usual care offering TIV only with baseline advertisement|A control arm of usual care offering TIV with baseline advertisement
1829118|NCT00808834|Device|Lotrafilcon A contact lens|Investigational, silicone hydrogel, spherical, soft contact lens
1829119|NCT00808834|Device|Senofilcon A contact lens|Commercially marketed, silicone hydrogel, spherical, soft contact lens
1829120|NCT00808860|Dietary Supplement|GP group|Gliclazide MR 30mg once a day, orally Gynostemma pentaphyllum tea 3 grams twice daily, orally
1829121|NCT00808860|Dietary Supplement|Placebo group|Gliclazide MR 30mg once a day, orally Placebo tea 3 grams twice daily, orally
1829122|NCT00808873|Other|socio-educational intervention|brief mental health education and 6 follow-up visits
1829123|NCT00808899|Drug|Temsirolimus|Temsirolimus
1829124|NCT00808899|Drug|Irinotecan|Irinotecan
1829125|NCT00808899|Procedure|Surgical Resection of Primary Tumor|Surgical Resection of Primary Tumor
1829126|NCT00808899|Drug|Cyclophosphamide|Cyclophosphamide
1829127|NCT00808899|Drug|Doxorubicin|Doxorubicin
1829128|NCT00808899|Drug|Etoposide|Etoposide
1829129|NCT00808899|Drug|Cisplatin|Cisplatin
1829130|NCT00808899|Drug|Topotecan|Topotecan
1829131|NCT00808899|Procedure|PBSC|Peripheral Blood Stem Cell Harvest
1829132|NCT00808899|Radiation|Radiation Therapy|Radiation Therapy
1829135|NCT00808912|Other|placebo|matching placebo for sildenafil 50 mg to be ingested orally 1 hour prior to exercise testing.
1829136|NCT00808925|Other|exposure to heat|Dressed in shorts and tennis shoes the subjects will be exposed to exercise-heat stress for 12 consecutive days (excluding Saturday). Daily exposure will last 120 min, under the controlled environmental conditions of 40oC and 40% relative humidity. The exercise will consist of walking on a treadmill at a pace of 5km/h and 2% incline.
1829137|NCT00808938|Device|MST|Magnetic Seizure Therapy
1829138|NCT00808951|Drug|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
1829139|NCT00808951|Drug|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
1829140|NCT00808964|Drug|NU172|NU172 administered IV bolus followed by continuous infusion during CABG surgery
1829141|NCT00808977|Drug|Dersalazine sodium|Dersalazine sodium 2400 mg daily
1829142|NCT00808977|Drug|Mesalazine|Mesalazine 2400 mg daily
1829143|NCT00808977|Drug|Placebo|Placebo matching active and experimental treatments
1829144|NCT00808990|Dietary Supplement|BioFemale|BioFemale 6 months.
1829145|NCT00809016|Radiation|3-dimensional conformal radiation therapy|
1829146|NCT00809016|Radiation|fludeoxyglucose F 18|
1829147|NCT00809016|Radiation|intensity-modulated radiation therapy|
1829148|NCT00809029|Other|GIP (glucose dependent insulinotropic peptide) infusion|an intravenous infusion of GIP (glucose dependent insulinotropic peptide)or placebo will be administered at a rate of 2 pmol/kg/min and maintained for 240 minutes.
1829149|NCT00809042|Drug|hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day).
1829150|NCT00809042|Drug|L-carnitine and hydroxyurea|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day).
1829151|NCT00809042|Drug|hydroxyurea and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day.
1829152|NCT00809042|Drug|hydroxyurea,L-carnitine and magnesium chloride|Hydroxyurea (500 mg capsules) was administered in a single dose at a mean of 10/mg/kg/day (range8-12mg/kg/day). L-carnitine (Minoo, Iran, 250 mg tablets) was administered in divided doses (50mg/kg/day). Magnesium chloride powder ( tabib tajhiz nik, Iran) was formulated into suspension; each ml containing 1meq magnesium chloride. It was administered in divided doses at 0.6meq/kg/day
1829153|NCT00809055|Drug|Caffeine citrate|Caffeine to be administered as outlined to compare efficacy of different dosages.
1829154|NCT00809068|Drug|fenofibrate and tibolone|fenofibrate 160mg daily 8 weeks tibolone 2.5mg daily 23 weeks
1829155|NCT00809068|Drug|tibolone|tibolone 2.5 mg daily 23 weeks
1829156|NCT00809081|Procedure|Enteral Feeding and Total Parental Support|"Enteral Feeding : 20ml/hr on POD1
Velocity is progressively increased by 20ml/d until full nutritional goal (25Kcal/Kg)"
1829157|NCT00809094|Drug|N-acetylcysteine (NAC)|
1829158|NCT00809094|Drug|Placebo|
1829159|NCT00809107|Drug|HCG|5000IU
1829160|NCT00809120|Device|Neuromuscular Electrical stimulator (Cefar rehab 4 pro)|50Hz 30 min 7 sessions
1829161|NCT00809133|Drug|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
1829162|NCT00809133|Drug|Carboplatin|AUC6 given on day 1 of 21 day cycle
1829163|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
1829164|NCT00809133|Drug|Paclitaxel|Part A and B:80mg/m2 given on Day 1, 8 and 15 of 28 Day cycle.
1829165|NCT00809133|Drug|BIBW2992|MTD dose of part A
1829166|NCT00809133|Drug|Paclitaxel|175mg/m2 given on Day 1 of 21 Day cycle
1829167|NCT00809133|Drug|Carboplatin|AUC6 given on day 1 of 21 day cycle
1829168|NCT00809133|Drug|Bevacizumab|Escalating dose Cohorts - 5mg / kg, 7.5mg / kg and 10mg / kg given Day 1 and Day 15 of a 28 days cycle
1829169|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
1829170|NCT00809133|Drug|BIBW 2992|Escalating dose cohorts
1829171|NCT00809146|Drug|Intramuscular route of active treatment|IM administration by autoinjector of midazolam 5 mg for subjects under estimated weight of 40 kg or midazolam 10 mg for subjects with estimated weight of 40 kg or above, IV administration of matching volume of IV flush.
1829172|NCT00809146|Drug|Intravenous route of active treatment|IV administration of lorazepam 2 mg for subjects under estimated weight of 40 kg or midazolam 4 mg for subjects with estimated weight of 40 kg or above, IM administration by autoinjector of matching volume of saline.
1829173|NCT00809159|Biological|AIN457|AIN457A is a fully human recombinant IgG1 antibody that targets and neutralizes IL-17A.
1829174|NCT00809159|Drug|Placebo|Placebo to AIN457
1829175|NCT00809172|Drug|Ciclosporin|5 mg/kg/day per os during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
1829176|NCT00809172|Drug|Methotrexate|15 mg/week per os in one tablet during 8 weeks after the posology will be changed according to clinical response during the next 16 weeks
1829177|NCT00809185|Drug|everolimus|Patients will receive monotherapy with RAD001(everolimus)for 21 days within the 28 day cycle.
1829178|NCT00809185|Other|laboratory biomarker analysis|Laboratory correlates (cytotoxic t cell populations, S6K1 levels, GSTT-1 mutations, and the presence or absence of HLA-DR15) will be assessed to see if any of these correlates correspond to response.
1829179|NCT00809185|Procedure|Bone marrow aspirate/biopsy|Bone marrow aspirate and biopsy with cytogenetics should be obtained within 4 weeks prior to starting drug and at week 33. A bone marrow aspirate and biopsy should also be obtained for patients going off study prior to week 33 (including cytogenetics). The percentage of blasts on the aspirate should be used to determine the IPSS score.
1829180|NCT00809198|Other|Sodium Hyaluronate|
1829181|NCT00809198|Other|Carboxymethylcellulose sodium|
1829182|NCT00809211|Drug|nilotinib|
1829183|NCT00809211|Genetic|cytogenetic analysis|
1829186|NCT00809211|Other|pharmacological study|
1829187|NCT00809237|Drug|Gefitinib, Hydroxychloroquine|Gefitinib 250 mg om Hydroxychloroquine at maximally tolerated dose
1829188|NCT00809250|Biological|GM-K562/leukemia cell vaccine|Cultured cell line genetically changed to secrete GM-CSF mixed with irradiated leukemia cells obtained from the participant. A total of 6 vaccine will be given. Vaccines 1-3 will be given once a week. Vaccines 4-6 will be given every other week.
1829189|NCT00809263|Drug|homeopathic remedy|Homeopathic remedy 12C potency, 10 drops TID X 7 days
1829190|NCT00809276|Drug|Busulfan, Fludarabine, Cytoxan|"Busulfan once a day for 4 days
Fludarabine once a day for 4 days
Bone marrow transplant
Cytoxan two doses"
1829191|NCT00809289|Drug|esreboxetine|Once daily administration of 4mg esreboxetine for 3 days, followed by 8mg esreboxetine for 3 days, followed by 10mg esreboxetine for 3 days. Drug will be administered double-blind.
1829192|NCT00809289|Drug|placebo|Once daily administration of placebo for 9 days. Placebo will be administered double blind
1829193|NCT00809289|Drug|moxifloxacin|Once daily administration of placebo for 8 days followed by open label single oral dose of 400mg moxifloxacin on day 9
1829194|NCT00809302|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered BID for about 13 weeks
1829195|NCT00809315|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
1829196|NCT00809315|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
1829197|NCT00809328|Drug|Azithromycin|The intravenous formulation 500 mg is administered once daily for 2-5 days; followed by the oral formulation 500 mg will be given once daily to complete a 7 to 10-day course of therapy.
1829198|NCT00809341|Drug|R-CHOP, R-CHOEP, R-EPOCH|Based on the PET-CT scan results patients will complete standard chemotherapy consisting of R-CHOP (or equivalent anthracycline-containing regimen (e.g. R-CHOEP, R-EPOCH)
1829199|NCT00809341|Drug|R-ICE, Cyclophosphamide|Two cycles of R-ICE, followed by high dose cyclophosphamide and Rituximab
1829200|NCT00809354|Drug|NSAID|IV doses of placebo (to match tanezumab) every 8 weeks (through Week 48) plus oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
1829201|NCT00809354|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48) and oral placebo for NSAID BID from Weeks 2 through 56
1829202|NCT00809354|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 56) and oral placebo for NSAID BID from Weeks 2 through 56
1829203|NCT00809354|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 48)
1829204|NCT00809354|Drug|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
1829205|NCT00809354|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 48)
1829206|NCT00809354|Drug|NSAID|Oral naproxen 500 mg BID for 56 weeks or oral celecoxib 100 mg BID for 56 weeks
1829207|NCT00809367|Other|Collection of Leukemia Cells|Collection of leukemia cells either by 1) routine blood draw 2) bone marrow aspirate or 3) leukopheresis
1829208|NCT00809380|Behavioral|Parental presence|Patients in the study group will be accompanied by one of their parents for the whole procedure. Before this, a short explanation of the procedure, the patient's expected behavior during the procedure and what roles parents should play will be given to the parent by the research assistant. Parents will be seated close to the patient's head and will wear radiology proof gowns. If deemed necessary by the attending physician or if their behavior becomes unacceptable, parents can be asked to leave the procedure room at any given time. Parents will be allowed to leave the procedure room if they wish to at any time during the procedure.
1829209|NCT00809380|Behavioral|Control|One parent will stay with their child until he is in the procedure room and conscious sedation has begun. He will then be asked to leave the room and wait in an adjoining waiting room. The attending physician will invite the parent back in the room once the reduction is complete and the cast is done.
1829210|NCT00809393|Drug|tranexamic acid|10 mg/kg
1829211|NCT00809393|Drug|tranexamic acid|30 mg/kg
1829212|NCT00809419|Device|NeoVista Ophthalmic System|A single procedure with the NeoVista Ophthalmic System, with Lucentis (0.5mg) administered on an as needed basis for three years.
1829213|NCT00809432|Device|Face mask (Dust Respirator)|Subjects to wear a simple face mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask as much as possible when indoors and at all times when outdoors.
1829214|NCT00809432|Other|No Face mask|Subjects will not wear a face mask to reduce their personal exposure to air pollution
1829215|NCT00809445|Behavioral|On-site HIV rapid test and brief, prevention counseling|Participants will be offered an on-site oral fluid HIV rapid test with brief prevention counseling that addresses both risk reduction and motivation to be HIV tested based on an evidence-based counseling approach.
1829216|NCT00809445|Behavioral|On- site HIV rapid test & information|Participants will be offered an on-site oral fluid HIV rapid test with basic info.
1829217|NCT00809445|Behavioral|Referral for off-site HIV testing|Participants will be offered a referral list of HIV testing agencies in the community.
1829218|NCT00809458|Drug|Vitamin E|Patients will take one 400 IU tablet of vitamin E or a placebo daily. Patients will continue on this treatment from the time of randomization to the day before surgery or the brachytherapy procedure. This is expected to be between 4 to 6 weeks. The patient will continue with his regular medications. The vitamin E will be supplied by the clinical trial through the UNM CRTC pharmacy.
1829219|NCT00809471|Drug|placebo|30 minutes orally prior to initiation of sexual activity
1829220|NCT00809471|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
1829221|NCT00809471|Drug|avanafil|30 minutes orally prior to initiation of sexual activity
1829222|NCT00809497|Drug|Propionyl-L-carnitine Tablets|500mg tablets, oral administration of 2g daily
1829223|NCT00809510|Drug|ABT-089|20 mg ABT-089 taken once-daily for 6 months
1829224|NCT00809523|Device|Negative Ion Generator|Equivalent exposure to inactivated Negative Ion Generator
1829225|NCT00809523|Device|Light-emitting Photodiode light treatment device|Light-emitting Photodiode light treatment device, used for 30 min before 8 am
1829226|NCT00809536|Drug|Metformin|225 mg q12, oral PD 0332334 immediate release formulation on Days 1 through 5; Single, oral, 500 mg dose of metformin immediate release
1829227|NCT00809536|Drug|Metformin|Single, oral, 500 mg of metformin immediate release
1829228|NCT00809536|Drug|PD 0332334|500 mg q12, oral metformin immediate release administered on Days 1 through Day 6 Single, oral, 300 mg dose of PD 0332334 immediate release formulation administered on Day 3
1829229|NCT00809536|Drug|PD 0332334|Single, oral, 300 mg dose of PD 0332334 immediate release formulation
1829230|NCT00809549|Drug|Filgrastim|10 ug/kg sc once daily x 4 days. Repeated once, 6 weeks later.
1829231|NCT00809562|Drug|Placebo|po daily for 10 days
1829232|NCT00809562|Drug|RO4917523|orally daily for 10 days, cohorts receiving up to 5 different doses (according to safety and tolerability)
1829233|NCT00809575|Other|questionnaire administration|
1829234|NCT00809575|Other|fatigue assessment and management|
1829235|NCT00809575|Other|observation|
1829236|NCT00809575|Other|quality-of-life assessment|
1829237|NCT00809588|Biological|Autologous, lethally irradiated melanoma cells|Engineered to secrete human granulocyte-macrophage stimulating factor. Given on days 1, 8, 15, 29 and every two weeks after until the supply of vaccine has run out
1829238|NCT00809601|Device|Insertion of a specific type of ventilation tube through the tympanic membrane|"The ventilation tubes are tested using one type in one ear and another type as an active comparator in the other ear.
The investigators will test in total 4 different kinds of tubes. Four different combinations of tubes will be tested.
The first combination will test:
Shepard tube (double flanged, Fluoroplastic) vs Donaldson tube (double flanged, silicone)
The second combination will test:
Straight tube (single flanged, Fluoroplastic) vs Armstrong (single flanged, silicone)
The third combination will test:
Armstrong (single flanged, silicone) vs Donaldson tube (double flanged, silicone)
The fourth combination will test:
Straight tube (single flanged, Fluoroplastic) vs Shepard tube (double flanged, Fluoroplastic)"
1829239|NCT00809614|Biological|AIN457|The investigational drug, AIN457 50 mg lyophilizate vials was prepared by Novartis. Reconstitution of AIN457 with 1.2 mL SWFI produced a 47 mg/mL concentrate solution for infusion from which at least 1 mL was useable. The AIN457 concentrate was diluted in 5% glucose bags for infusion through a 0.2 micron in-line filter.
1829240|NCT00809614|Biological|Placebo|Matching placebo to AIN457
1829241|NCT00809627|Drug|Caffeine|Caffeine 500 mg IV
1829242|NCT00809627|Drug|saline|Normal saline
1829243|NCT00809640|Behavioral|Education (Back Comic-Book)|Through the Back Comic-Book the schoolchildren are taught prevention methods for low back pain.
1829244|NCT00809653|Device|No Face Mask|Subjects will not wear a face mask to reduce their personal air pollution exposure
1829245|NCT00809653|Device|Face Mask|Subjects will be asked to wear a simple face mask to reduce personal exposure to particulate air pollution. Subjects will be asked to wear the mask for 24 hours prior to the study day and the 24 hours of the study day. They will be instructed to wear the mask at all times when outdoors and as much as possible when indoors.
1829246|NCT00809666|Device|Automated blood pressure recording device Omron HEM 705CP|All subsequent blood pressure recordings done using the automated device
1829247|NCT00809679|Drug|T-62 Dose 1|Capsule dosage form 100 mg bid
1829248|NCT00809679|Drug|T-62 Dose 2|Capsule dosage form 200 mg bid
1829249|NCT00809679|Other|Placebo|Capsule dosage form placebo bid
1829250|NCT00809692|Procedure|validated techniques for histamine response|the prick test and iontophoresis technique (serial assessment of blood flow using validated Doppler technique)
1829251|NCT00809692|Procedure|new technique for histamine response|laser Dopper technique and genotyping
1829252|NCT00809705|Drug|Placebo|sc once weekly for 12 weeks
1829253|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20mg sc once weekly for 8 weeks
1829254|NCT00809705|Drug|taspoglutide|10mg sc once weekly for 12 weeks
1829255|NCT00809718|Drug|Raltegravir and rifapentine|"Period 1- Raltegravir 400 mg q12h by mouth for 4 days
Period 2- Rifapentine 900 mg taken by mouth once per week for 3 doses and raltegravir 400 mg q12h by mouth for 4 days
Period 3- Rifapentine 600 mg taken by mouth once daily for 5 of 7 days per week for 10 doses and raltegravir 400 mg q12h by mouth for 4 days"
1829256|NCT00809744|Drug|cholecalciferol|capsules, 20 000IU, twice a week, 6 months duration
1829257|NCT00809757|Drug|Levalbuterol|90 ug Levalbuterol (2 actuations)
1829258|NCT00809757|Drug|Levalbuterol UDV TID|0.31 ug Levalbuterol UDV TID
1829259|NCT00809757|Drug|Placebo|Placebo (2 actuations)
1829260|NCT00809770|Behavioral|Contingency Management|Opportunities to earn rewards are given three times a week for 12 weeks contingent on negative urine analyses indicating drug abstinence
1829261|NCT00809770|Behavioral|Non Contingent Control Condition|Opportunities to draw for rewards are provided three times a week for 12 weeks for providing urine analysis. Opportunities to earn rewards are not based on urine analysis results.
1829262|NCT00809783|Biological|tanezumab|Tanezumab 10 mg
1829263|NCT00809783|Biological|tanezumab|Tanezumab 5 mg
1829264|NCT00809783|Biological|tanezumab|Tanezumab 2.5 mg
1829265|NCT00809796|Drug|pentamidine|one dose of 4 mg/kg to two dose of 4 mg/kg with possibility of escalated to two dose of 6 mg/kg with or without standard chemotherapy.
1829266|NCT00809809|Drug|Zicam (Ionic zinc)|33mmol/l of ionic zinc
1829267|NCT00809809|Drug|placebo|placebo swab
1829268|NCT00809822|Drug|NPB-01|Intravenous immunoglobulin
1829269|NCT00809822|Drug|Placebo|Physiological saline
1829270|NCT00809835|Drug|Galantamine|Daily 8 mg galantamine capsule
1829271|NCT00809835|Behavioral|Computer Assisted Cognitive Behavioral Therapy (CBT)|CBT a psychotherapeutic approach that addresses dysfunctional emotions, maladaptive behaviors and cognitive processes and contents through a number of goal-oriented, explicit systematic procedures. The name refers to behavior therapy, cognitive therapy, and to therapy based upon a combination of basic behavioral and cognitive principles and research.
1829272|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.075%|AGN-210669 non-preserved ophthalmic solution, 0.075%. One drop in both eyes each morning once-daily for 2 weeks.
1829273|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.05%|AGN-210669 non-preserved ophthalmic solution, 0.05%. One drop in both eyes each morning once-daily for 2 weeks.
1829274|NCT00809848|Drug|AGN-210669 ophthalmic solution, 0.025%|AGN-210669 non-preserved ophthalmic solution, 0.025%. One drop in both eyes each morning once-daily for 2 weeks.
1829318|NCT00810147|Drug|BMS-708163|Capsules, Oral, 100 mg, once daily, 24 weeks
1829275|NCT00809848|Drug|bimatoprost ophthalmic solution 0.03%|Bimatoprost ophthalmic solution 0.03%. One drop in both eyes each morning once-daily for 2 weeks.
1829276|NCT00809848|Drug|AGN-210669 vehicle ophthalmic solution|AGN-210669 vehicle non-preserved ophthalmic solution. One drop in both eyes each morning once-daily for 2 weeks.
1829277|NCT00809861|Procedure|volar locking plating|open reduction and internal fixation
1829278|NCT00809861|Procedure|external immobilisation|closed reduction and external fixation
1829279|NCT00809874|Dietary Supplement|Casein|
1829280|NCT00809874|Dietary Supplement|Whey Isolate|
1829281|NCT00809874|Dietary Supplement|Whey Hydrolysate|
1829282|NCT00809874|Dietary Supplement|Alphalact-Albumin|
1829283|NCT00809887|Drug|Micafungin lock therapy|
1829284|NCT00809900|Dietary Supplement|Experimental|Administration of of 480 mL cranberry juice
1829285|NCT00809913|Drug|short treatment (ciprofloxacin)|7 days of antibiotic treatment for febrile urinary tract infection / acute pyelonephritis compared to standard treatment of 14 days
1829286|NCT00809926|Drug|Valsartan/aliskiren|Valsartan/aliskiren (160/150mg) for 2 weeks followed by forced titration to valsartan/aliskiren (320/300mg) for the remaining 6 weeks
1829287|NCT00809926|Drug|Valsartan|Valsartan (160mg) for 2 weeks followed by forced titration to Valsartan (320mg) for the remaining 6 weeks
1829288|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection of 250 mg until 34 weeks gestation
1829289|NCT00809939|Drug|natural progesterone|previous preterm delivery, treatment with daily vaginal progesterone 200 mg until 34 weeks gestation.
1829290|NCT00809939|Drug|17 alfa hydroxyprogesterone caproate|weekly injection, 250 mg until 34 weeks gestation
1829291|NCT00809939|Drug|vaginal progesterone|daily vaginal progesterone 200 mg until 34 weeks gestation.
1829292|NCT00809952|Procedure|recombinant FSH|
1829293|NCT00809965|Drug|Rivaroxaban 2.5 mg|One tablet twice daily
1829294|NCT00809965|Drug|Rivaroxaban 5 mg|One tablet twice daily
1829295|NCT00809965|Drug|Placebo|One placebo tablet twice daily
1829296|NCT00809965|Drug|Standard of care|
1829297|NCT00809991|Radiation|hypofractionation|This will be a Phase II study evaluating the effectiveness and toxicity of a regimen of 3.6 Gy per day to a total dose of 57.6 Gy (16 fractions). This choice of daily dose is based on the prior published experience showing safety and efficacy of hypofractionated regimens of 2.5 Gy, 2.7 Gy, and 3.0 Gy daily fractions. The total dose is calculated to be iso-effective for late effects to a conventionally fractionated total dose of 81 Gy, which has been shown to be effective and safe in a large prospective Phase II study. If the alpha/beta ratio for prostate is between 1.5-3.0, then this regimen should be at least as effective or more effective for tumor control than 81 Gy given in conventional fractions.
1829298|NCT00810004|Drug|Ferinject|Intravenous infusion of iron
1829299|NCT00810017|Drug|Etoposide|etoposide 100 mg/m2 daily for 3 days every three weeks for 6 cycles
1829300|NCT00810017|Drug|Trastuzumab|intravenous trastuzumab 8 mg/kg loading dose and then 6 mg/kg every three weeks and then single agent trastuzumab until progression of disease
1829301|NCT00810030|Drug|Ferric carboxymaltose|Dosage form: 5% w/v iron containing 50 mg iron per mL, as sterile solution of FERINJECT® in water for injection. In case of drip infusion FERINJECT® (10 to 20 ml) must be diluted only in sterile 0.9% sodium chloride (max 250 ml) FERINJECT® will be administered via i.v. drip infusion. Minimum administration time 15 minutes Dosage: 500 mg, 1000 mg, 1500 mg, according to patients' Hb and body weight
1829302|NCT00810030|Drug|Iron Sucrose|"VENOFER® will be administered via i.v. drip infusion, diluted only in sterile 0.9% sodium chloride solution as follows:
• 10 mL Venofer® (200 mg iron) in maximum 200 mL sterile 0.9% sodium chloride solution in at least 30 minutes.
The first 25 mL of solution should be infused as a test dose over a period of 15 minutes. If no adverse reactions occur, use infusion rate no more than 50 mL in 15 minutes.
The individual iron deficit will be calculated using the modified formula of Ganzoni.
If the patient's body mass index is >25, a normalised weight will be used for the calculation of iron deficit. Normalised weight = 25 x height [m] x height [m].
The calculated cumulative VENOFER® dose is to be rounded up or down to the nearest 200 mg.
Patients will receive one 200 mg VENOFER® infusion, twice a week, up to 11 times (max dosage 2200 mg), depending on their calculated iron deficit."
1829303|NCT00810043|Device|Kyphon® Curette|The Kyphon® Curette is intended to scrape and score bone in the spine. It may be used as an adjunctive device with Kyphon's family of standard access and fracture reduction instruments designed to treat compression fracture during balloon kyphoplasty procedures
1829304|NCT00810056|Other|Assessment|Cognitive, academic achievement, and mental health screening assessment and report.
1829305|NCT00810056|Behavioral|Fostering Healthy Futures (FHF)|Weekly therapeutic skill groups and mentoring over a 9-month period.
1829306|NCT00810069|Drug|Duloxetine Hydrochloride|Flexible dose of 60 or 120 mg daily
1829307|NCT00810069|Drug|Escitalopram|10 mg in both Early and Delayed Intervention. Flexible dose of 10 to 20 mg daily in Delayed Intervention.
1829308|NCT00810082|Device|ActiveStep|ActiveStep™ is a training simulator. The system uses a computer-controlled treadmill to recreate life-like dynamic balance challenges such as slipping and tripping in a safe, controlled environment.
1829309|NCT00810082|Other|Standard Physical Therapy for Fall Prevention|Standard physical therapy for fall prevention
1829310|NCT00810095|Device|MindFrame System|Thrombectomy Catheter designed to rapidly restore blood flow in patients experiencing an ischemic stroke
1829311|NCT00810108|Drug|lopinavir/ritonavir (Kaletra®) tablets|The subject will bring their own prescription of lopinavir/ritonavir. The patient will take a witnessed dose of lopinavir/ritonavir with an 6 ounce glass of cool water (if taken whole) or mixed in 4 ounces of Jell-O brand pudding (if crushed).
1829312|NCT00810121|Drug|ketoprofen 100 mg|100 mg b.i.d. for 5 days
1829313|NCT00810121|Drug|ketoprofen|150 mg b.i.d. for 5 days
1829314|NCT00810134|Procedure|Thrupass|Endovascular treatment (Thrupass) is performed as a femoropopliteal above knee endovascular recanalisation and Viabahn introduction with 6-7 mm Viabahn endo-prosthesis.
1829315|NCT00810134|Procedure|Bypass|Surgical procedure is performed as a femoropopliteal above knee by-pass with 6 mm non-coated PTFE-graft
1829316|NCT00810147|Drug|BMS-708163|Capsules, Oral, 25 mg, once daily, 24 weeks
1829317|NCT00810147|Drug|BMS-708163|Capsules, Oral, 50 mg, once daily, 24 weeks
1829319|NCT00810147|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 24 weeks
1829320|NCT00810147|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 24 weeks
1829321|NCT00810160|Dietary Supplement|ProlactPlus|Group 1 infants will be fed a concentration of Permeate mixed with formula. The ProlactPlus will be increased each week as follows: week 1 95:5 (formula:ProlactPlus), week 2 90:10, week 3 85:15, week 4 80:20, and week 5 75:25. Caloric content is roughly as follows: week 1 21 cal/oz, week 2 22 cal/oz, week 3 23 cal/oz, week 4 24 cal/oz, and week 5 25 cal/oz.
1829322|NCT00810160|Dietary Supplement|GOS galacto-oligosaccharides|Group 2 infants will have their formula supplemented with galacto-oligosaccharides (GOS) for each feeding as follows: week 1 0.25 g/dL, week 2 0.5 g/dL, week 3 1.0 g/dL, week 4 1.5 g/dL, and week 5 2.0 g/dL.
1829323|NCT00810160|Dietary Supplement|Bifidobacterium infantis|Group 3 infants will have their formula supplemented with B. infantis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
1829324|NCT00810160|Dietary Supplement|Bifidobacterium animalis|Group 4 infants will have their formula supplemented with B. animalis twice daily increasing the dose each week as follows: week 1 5x107, week 2 1.5x108, week 3 4.5x108, week 4 1.4x109, and week 5 4.2x109.
1829325|NCT00810173|Behavioral|phone call support|The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
1829326|NCT00810199|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg IV every 4 weeks.
1829327|NCT00810199|Drug|methotrexate|Approximately 15-17 mg methotrexate capsule orally once a week.
1829328|NCT00810199|Drug|placebo|Placebo matching methotrexate capsule taken orally once a week.
1829329|NCT00810212|Procedure|PLF with autograft|6 subjects
1829330|NCT00810212|Genetic|PLF with NeoFuse|6 subjects low dose
1829331|NCT00810212|Genetic|PLF with NeoFuse|6 subjects medium dose
1829332|NCT00810212|Genetic|PLF with NeoFuse|6 subjects high dose
1829333|NCT00810238|Biological|C-Cure|Intraventricular injection
1829334|NCT00810251|Device|MatrixRIB (FDA Approval # K081623)|MatrixRIB implants are comprised of anatomic rib plates and intramedullary rib splints for internal surgical stabilization of rib fractures.
1829335|NCT00810264|Device|CRT Therapy - LV Lead Registry|Collecting long-term safety and efficacy data on a market-released left ventricular lead.
1829336|NCT00810277|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
1829337|NCT00810290|Behavioral|lifestyle intervention|A group-based intervention including 13 group sessions complemented by three individual home visits was developed using principles of social learning theory and patient-centered counseling. The intervention was intended to increase awareness of diabetes prevention strategies, foster positive diabetes prevention attitudes (i.e., self-efficacy) and promote healthy lifestyle behaviors in the target Latino population using literacy-sensitive and culturally-tailored strategies and materials.
1829338|NCT00810303|Drug|Ezetrol (ezetimibe) multiple dose|administration of 1 tablet/day Ezetrol (10 mg ezetimibe) on study day 6-15 and a pharmakokinetic on study day 15 (0-24 h blood sampling, 0-24 h urine sampling and 5 d feces sampling (study day 11-15))
1829339|NCT00810303|Drug|Ezetrol (ezetimibe) multiple dose and Sustiva (efavirenz) single dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) on study day 16-20 and 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 16 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 16-20)
1829340|NCT00810303|Drug|Ezetrol (ezetimibe) and Sustiva (efavirenz) multiple dose|administration of 1 tablet/day Ezetrol(R) (10 mg ezetimibe) and 2 capsules/day Sustiva(R) (2x200 mg efavirenz) on study day 21-30 and with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) on study day 30 and feces sampling on study day 26-30)
1829341|NCT00810303|Drug|Sustiva (efavirenz) single dose|administration of 2 capsules Sustiva(R) (2x200 mg efavirenz) on study day 1 with a pharmakokinetic (0-120 h blood sampling, urine sampling (24 h intervals) and feces sampling on study days 1-5)
1829342|NCT00810316|Drug|Alprazolam|Administration of a single oral dose tablet of 1 mg of alprazolam immediate release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
1829343|NCT00810316|Drug|Alprazolam XR|Administration of a single oral dose tablet of 1 mg of alprazolam modified release on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
1829344|NCT00810316|Drug|Clonazepam|Administration of a single oral dose of two tablets of 0.5 mg of clonazepam on Day 1 morning, between 8-9 am with 250 ml of water in at least 10 hours of fasting conditions
1829345|NCT00810342|Behavioral|physical activity tailored|tailored telephone counseling, email feedback, and website resources over 12 months
1829346|NCT00810342|Behavioral|physical activity standard|standard print and website information on how to become more active
1829347|NCT00810355|Behavioral|Support Group|General support and problem solving for work activity
1829348|NCT00810355|Behavioral|Cognitive Behavior Therapy|Individual and group therapy focused on identifying and correcting maladaptive beliefs about work
1829349|NCT00810355|Behavioral|Cognitive Remediation|Computerized training to enhance cognitive functioning.
1829350|NCT00810368|Drug|Carnosine|500mg Carnosine x2 daily
1829351|NCT00810368|Drug|Placebo|Microcrystalline cellulose placebo tablets x2 daily
1829352|NCT00810381|Drug|Nitroglycerin|intravenous infusion; 0, 0.125, 0.25, 0.5, 1 and 2 µg/kg/min; 20 minutes per infusion step
1829353|NCT00810381|Drug|Isosorbide-Dinitrate|intravenous infusion; 0, 0.5, 1, 2, 4, and 6 µg/kg/min; 20 minutes per infusion step
1829354|NCT00810381|Drug|Sodium-nitroprusside|intravenous infusion; 0, 0.25, 0.5, 1, 2, and 4 µg/kg/min; 20 minutes per infusion step
1829355|NCT00810381|Drug|Physiologic saline solution (control substance)|intravenous infusion, infusion period 120 minutes
1829356|NCT00810394|Drug|Sorafenib|Patients will be registered and started on the standard recommended dose-schedule for sorafenib (400 mg tablet by mouth twice a day continuously). Dose reductions will be instituted in the event of grade 3 or higher hematologic or non-hematologic toxicity or for any toxicity that is considered by the patient or physician as intolerable.
1829394|NCT00788125|Genetic|western blotting|
1829395|NCT00788125|Other|immunohistochemistry staining method|
1829396|NCT00788125|Other|laboratory biomarker analysis|
1829397|NCT00788125|Procedure|therapeutic conventional surgery|
1829358|NCT00810433|Procedure|GO-LIF - Guided Oblique Lumbar Interbody Fusion|"All patients will undergo single-level instrumented interbody spinal fusion surgery with instrumentation.
Upon induction of general anesthesia, the patient will be positioned prone on a radiolucent operating table and prepared according to standard hospital procedure. An interbody fusion will be performed according to standard procedure and as indicated by the surgeon. The interbody fusion portion of the surgery will be carried out using any current technique - such as PLIF, TLIF, PLF, PLLF, XLIF or ALIF. The fusion strategy can be performed in an open or minimally invasive manner, as indicated. The interbody device will be inserted after the screws trajectory will be drilled and a 4.5mm Trajectory holder is in place. This will assure the surgeon that no collision will occur between the interbody and the screws.
Upon completion of the fusion stage of the surgery, SpineAssist will be used to introduce the GO-LIF screws for fixation of the spinal levels to be fused."
1829360|NCT00810472|Other|HLA Matching|HLA matching is exerted by selecting the donor with least-most additional HLA alleles. We will predict the waiting time for such a donor in order to assess eligibility for the trial [8]. In addition, we will dynamically adopt the degree of matching that is aimed at depending on the predicted time interval and actual waiting time: the first donors not exerting more than 7 mismatches at the triplet-amino-acid-residue-level (HLAMatchmaker method [6]) is accepted if the patient is waiting less than half of his predicted waiting time. The next available donor exerting a 2/6 match (or better) is assigned thereafter. The next graft will be assigned, regardless of HLA matching after 6 months.
1829361|NCT00810472|Procedure|Penetrating keratoplasty|Corneal transplantation.
1829362|NCT00810485|Drug|ADX10059|oral administration
1829363|NCT00810485|Drug|ADX10059|oral administration
1829364|NCT00810485|Drug|ADX10059|oral administration
1829365|NCT00810485|Drug|ADX10059 Matching Placebo|oral administration
1829366|NCT00810511|Device|Lotrafilcon A contact lens|Silicone hydrogel contact lens
1829367|NCT00810511|Device|Comfilcon A contact lens|Silicone hydrogel contact lens
1829368|NCT00810524|Drug|lamivudine|100mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
1829369|NCT00810524|Drug|Telbivudine|600mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
1829370|NCT00810524|Drug|Enticavir|0.5mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2 years.
1829371|NCT00810524|Drug|Adefovir Dipivoxil Tablets|10mg, P.O.,QD, duration: until HBeAg seroconversion for more than 2years.
1829372|NCT00810550|Other|Carotid ultrasound|Measurement of intima-media thickness
1829375|NCT00810576|Drug|Vorinostat|Dose of 200 mg by mouth twice daily on days 1-14 of each 21-day study.
1829376|NCT00810576|Drug|Bortezomib|Dose of 1.3 mg/m^2 by vein on days 1, 4, 8, and 11 of a 21 day cycle.
1829377|NCT00810589|Drug|Levemir|0,4 IE per kg bodyweight
1829378|NCT00810589|Drug|Humalog NPL Insulin|0,4 IE per kg bodyweight
1829379|NCT00810602|Procedure|reduced intensity, related donor stem cell transplant|"Fludarabine /Busulfan(FluBu2)regimen
Fludarabine: 40 mg/m2/day in 0.9 NS, administered IV on days -5 to day -2 pre-transplant for a total of 4 doses. Busulfan: 3.2 mg/kg in 0.9 NS administered IV on days -5 and -4 for a total of 2 doses. Total body irradiation 200 cGy delivered in a single fraction will be given on day 0 for patients receiving an HLA-mismatched transplant."
1829380|NCT00810602|Drug|tacrolimus (standard GVHD prophylaxis)|Tacrolimus will begin on day -3, IV or oral. Target trough level for tacrolimus is 8-12 ng/ml. In the absence of GVHD, tacrolimus tapering will begin on day +56 post transplant
1829381|NCT00810602|Drug|mycophenolate (standard GVHD prophylaxis)|Mycophenolate will begin on day 0 at 10 mg/kg/dose (up to 1 gram per dose) every 8 hours orally or intravenously and will continue until day 28.
1829382|NCT00810602|Drug|vorinostat|"Vorinostat given at a dose 100 mg PO BID starting day -10. If tolerated, vorinostat will be continued until day 100 post-transplant,whether or not acute GVHD develops.
Dose escalation/ de-escalation
Ten subjects treated at a dose of 100 mg PO BID. If dosing modifications are not required, during the pre-engraftment period in more than 4 patients, AND no more than two observed drug related toxicities CTC grade 4 or higher [probably or definitely related to the drug] then vorinostat dose will be escalated to 200 mg PO BID.
If dose escalation does not occur due to failure to meet the above criteria,then the study will enroll at the 100 mg PO BID dosing, subject to the protocol stopping rules.
If dose escalation occurs, subjects will be treated at 200 mg PO BID dosing level. If the probability of unacceptable toxicity exceeds the rules in protocol, then the dose of vorinostat will be de-escalated to 100 mg PO BID for the remainder of study."
1829383|NCT00788112|Drug|vorinostat|
1829384|NCT00788112|Genetic|protein expression analysis|
1829385|NCT00788112|Other|immunohistochemistry staining method|
1829386|NCT00788112|Other|laboratory biomarker analysis|
1829387|NCT00788112|Procedure|neoadjuvant therapy|
1829388|NCT00788112|Procedure|therapeutic conventional surgery|
1829389|NCT00788125|Drug|carboplatin|
1829390|NCT00788125|Drug|dasatinib|
1829391|NCT00788125|Drug|etoposide phosphate|
1829392|NCT00788125|Drug|ifosfamide|
1829393|NCT00788125|Genetic|microarray analysis|
1829398|NCT00788125|Radiation|radiation therapy|
1829399|NCT00788138|Dietary Supplement|Vitamin D3|250,000 IU of vitamin D3
1829400|NCT00788138|Dietary Supplement|Placebo|Matching Placebo
1829401|NCT00788151|Biological|Chimeric dengue serotype 1, 2, 3, and 4|0.5 mL, SC
1829402|NCT00788151|Biological|Pneumococcal polysaccharide vaccine|0.5 mL, SC
1829403|NCT00788164|Biological|TA-HPV|Given intramuscularly
1829404|NCT00788164|Biological|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|Given intramuscularly
1829405|NCT00788164|Drug|imiquimod|Given topically
1829406|NCT00788177|Drug|Pegaptanib (Macugen®)|Pegaptanib administered to the subretinal space (first dose) and to the vitreous cavity (following doses)
1829407|NCT00788190|Procedure|Distal Radius Fracture Reduction|Surgical Intervention to Reduce Distal Radius Fracture
1829408|NCT00788190|Other|Conservative Management|Conservative management of Distal Radius Fractures
1829409|NCT00788216|Other|Discussion & scoring of health states related to the treatment of cervical cancer|Subjects will be interviewed using the visual analog score and time trade off methods.
1829410|NCT00788229|Drug|AT01|eye drop for 12 weeks
1829411|NCT00788229|Drug|AT02|eye drop for 12 weeks
1829412|NCT00788229|Drug|AT03|eye drop for 12 weeks
1829413|NCT00788229|Drug|AT04|eye drop for 12 weeks
1829414|NCT00788242|Drug|Glucose-insulin-potassium|20 IU of insulin and 10 mM of KCl mixed with 50 ml of 40% Glucose. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
1829415|NCT00788242|Drug|Placebo|60 ml of isotonic saline. Administration of 0.8 ml/kg/h over 60 min before aortic cross-clamping
1829416|NCT00788255|Drug|Final exogenous oxytocin concentration=22.5 μU/mL|Citrated whole blood 1mL + 23μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
1829417|NCT00788255|Drug|Final exogenous oxytocin concentration=30.1μU/mL|Citrated whole blood 1mL + 31μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
1829418|NCT00788255|Drug|Final exogenous oxytocin concentration=32.9μU/mL|Citrated whole blood 1mL + 34μU oxytocin. After mixing by inversion 8-10 times, 360μL kaolin-activated blood of each study solution was pipetted into a plastic cup in a prewarmed Thromboelastograph® (37°C). Each sample was recalcified in a plastic cup with 10μL of CaCl2 6.45%, and TEG® analysis was commenced within 1 minute of reconstituted sample preparation.
1829419|NCT00788281|Procedure|laparoscopic surgery|surgery would be performed by laparoscope
1829420|NCT00788281|Procedure|open surgery|surgery would be performed by traditional surgery.
1829421|NCT00788294|Biological|tanezumab|Drug solution given intravenously only once at dose of 10 mg
1829422|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 5 mg.
1829423|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 10 mg.
1829424|NCT00788294|Biological|tanezumab|Drug solution given subcutaneously only once at dose of 19 mg.
1829425|NCT00788307|Biological|Ad5-CMV-NIS|
1829426|NCT00788307|Drug|liothyronine sodium|
1829427|NCT00788307|Genetic|reverse transcriptase-polymerase chain reaction|
1829428|NCT00788307|Other|laboratory biomarker analysis|
1829429|NCT00788307|Radiation|iodine I 131|
1829430|NCT00788320|Drug|Vitamin D3|Vitamin D3 50,000 IU three times a week for 8 weeks
1829431|NCT00788320|Drug|Placebo|Placebo three times a week for 8 weeks
1829432|NCT00788333|Drug|BMS-754807|Tablets, Oral, Dose escalation to MTD, then MTD to response/EOT, once daily, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
1829433|NCT00788333|Drug|trastuzumab (Herceptin®)|IV solution, IV, 4mg/kg Day 1 loading dose, 2mg/kg once weekly, Varies - treatment is continued to disease progression or MD/subject/Sponsor decision to stop
1829434|NCT00788346|Behavioral|Computerized alerts|Computerized Clinical Decision Support to clinician at the time of prescribing
1829435|NCT00788346|Behavioral|Alerts Plus Detailing|Computerized Clinical Decision Support to clinician at the time of prescribing PLUS one group academic detailing session
1829436|NCT00788372|Drug|Fentanyl|Fentanyl transdermal patch will be applied daily starting at a dose of 12.5 mcg/hr, and up to 52 weeks. Dose will be increased as per Investigator's discretion.
1829437|NCT00788385|Device|ShuntCheck test|
1829438|NCT00788398|Procedure|Saline Solution|Irrigation with Saline
1829439|NCT00788398|Procedure|Soap solution|Irrigation with Castile Soap Solution (80 ml per 3L bag of saline)
1829440|NCT00788398|Procedure|Gravity Flow Irrigation|Gravity flow irrigation will be standardized across participating centers as 3L bags of normal saline (alone or with soap solution) suspended 6-8 feet above floor level using an I.V. pole. Irrigation tubing (measuring 1/4 - 3/8 inch inner diameter) will be connected to the 3L bag and secured with a stopcock (or compressive device) until ready for use.
1829441|NCT00788398|Procedure|Low Pressure Irrigation|"Irrigation with the Stryker SurgiLav System. At the low pressure setting delivers 5.9 p.s.i. pressure. The high-flow irrigator tip will be held perpendicular to and 5cm above the wound.
Irrigation with the Zimmer PulsaVac. For low pressure delivery, the shower tip will be used at the low pressure setting which delivers a pressure of 5.8 p.s.i."
1829442|NCT00788398|Procedure|High Pressure|"Irrigation with the Stryker SurgiLav System. For the high pressure delivery, the multi-orifice tip will be used at the high setting which delivers a pressure of 30 p.s.i.
Irrigation with the Zimmer PulsaVac System: For the high pressure delivery the shower tip will be used at the high pressure setting which delivers a pressure of 23 p.s.i."
1829443|NCT00788424|Drug|AS101 Cream|4% AS101 Cream or Placebo cream, twice a day for 12 weeks
1829444|NCT00788463|Drug|Intranasal Beclomethasone aerosol|Beclomethasone aerosol intranasal, 100ug each nostril, twice daily for 6 months.
1829445|NCT00788463|Drug|Intranasal Beclomethasone spray|Beclomethasone spray intranasal, 100ug each nostril, twice daily for 6 months.
1829446|NCT00788476|Other|Survey|"Survey packets to adult (>18 years old) childhood cancer survivors who return to MDACC for follow-up appointments within the next 12-months and conduct a mailed survey with the remaining participants and their primary caregivers i.e. guardians of survivors who are currently under age 18."
1829450|NCT00788515|Drug|Volinanserin (M100907)|2 mg tablets QD
1829451|NCT00788515|Drug|Lormetazepam|1 mg tablets (overencapsulated) QD
1829452|NCT00788528|Drug|S-2367 (velneperit)|Tablet, 4 x 400 mg, taken once daily with morning meal, 54-weeks
1829453|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 6 mg/mL|Administered as an injection into an anterior juxtascleral depot
1829454|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 3.75 mg/mL|Administered as an injection into an anterior juxtascleral depot
1829455|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 96 mg/mL|Administered as an injection into an anterior juxtascleral depot
1829456|NCT00788541|Drug|Anecortave Acetate Sterile Suspension, 60 mg/ML|Administered as an injection into an anterior juxtascleral depot
1829457|NCT00788541|Other|Anecortave Acetate Vehicle|Administered as an injection into an anterior juxtascleral depot
1829458|NCT00788554|Procedure|Lichtenstein procedure|open surgical procedure for inguinal hernia correction
1829459|NCT00788554|Procedure|TEP|Total Exta Peritoneal procedure for inguinal hernia correction
1829460|NCT00788567|Drug|mycophenolate mofetil|1
1829461|NCT00788580|Drug|pazopanib hydrochloride|
1829462|NCT00788580|Drug|temsirolimus|
1829463|NCT00788580|Procedure|immunoenzyme technique|
1829464|NCT00788580|Procedure|laboratory biomarker analysis|
1829465|NCT00788580|Procedure|pharmacological study|
1829466|NCT00788593|Drug|Placebo|Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
1829467|NCT00788593|Drug|EUR-1008 (APT-1008) High Dose|EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
1829468|NCT00788593|Drug|EUR-1008 (APT-1008) Low Dose|EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
1829469|NCT00788606|Drug|bevacizumab, Rituximab|6 cycles of treatment. Bevacizumab at a dose of 15 mg/kg, diluted in normal saline will be administered as a intravenous infusion over 30 to 90 minutes on Day 1 of each cycle. Rituzimab 375 mg/m2 is given as a intravenous infusion after the administration of prednisolone and before the other cytotoxic drugs on Day 1 of each cycle.
1829470|NCT00788619|Procedure|Transfer of embryos on day 3 or day 5 after fertilization.|Subjects will be allocated at random to the two arms. Group 1 will have two embryos transferred on day 3 based on nitric oxide concentration. Group 2 will have two embryos transferred on day 5 based on morphologic criteria.
1829471|NCT00788619|Procedure|Day 5 transfer|Subjects will have embryo transfer on day 5 after fertilization. Selection of embryos to transfer will be based on morphologic criteria.
1829472|NCT00788632|Behavioral|Patient educational DVD and brochure|"Construct a tailored direct-to-patient intervention to educate and activate older women about osteoporosis testing and treatment and aimed at improving patient-provider communication and closing the loop between knowledge communication and action. The intervention will include risk assessment, will be delivered through culturally/ethnically tailored story-telling, and will be mailed-out as both a paper copy (Booklet) and an interactive DVD (allowing the patient to use the delivery mediums they are most comfortable with). A follow-up brochure will be sent as a booster."
1829473|NCT00788632|Behavioral|Physician web modules|Web based osteoporosis continuing medical education (CME) materials
1829474|NCT00788632|Behavioral|System|Create a practice redesign strategy to alert patients that they should receive a BMD test and provide them with direct patient access to schedule their own test
1829475|NCT00788645|Behavioral|COPD self care advice|Information leaflets on COPD and thermometers to monitor the ambient temperature in the bedroom and living room
1829476|NCT00788645|Behavioral|Poor weather forecast warning|Interactive automated telephone service to contact patients prior to anticipated periods of poor weather
1829477|NCT00788658|Behavioral|Diet modifications|Diet consultation
1829478|NCT00788658|Behavioral|Cognitive behavioral therapy|Cognitive behavioral therapy
1829479|NCT00788671|Device|Levonorgestrel IUD|Intrauterine placement during surgery
1829484|NCT00788710|Drug|etoricoxib (MK0663) 120 mg|120 mg of etoricoxib (MK0663) for a total of 5 days
1829485|NCT00788710|Drug|Comparator: Placebo|Placebo tablets once daily on Days 1-5. Total treatment is 5 days.
1829486|NCT00788710|Drug|etoricoxib (MK0663) 90 mg|90 mg of etoricoxib (MK0663) for a total of 5 days
1829533|NCT00794456|Drug|Valeriana|1 tablet PO twice a day
1829534|NCT00794469|Other|Water|Children will drink 10 cc/kg of cold water(4 degrees centigrade)
1829535|NCT00794482|Drug|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5 mL.
1829536|NCT00794495|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
1829487|NCT00788723|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) using paired-pulse technique at different interstimulus intervals (ISIs) allows the study of the excitatory and inhibitory system of human motor cortex non-invasively. Motor evoked potentials (MEP) will be recorded, and stored on a VikingSelect (Viasys Healthcare, USA). Two magnetic stimulators (Magstim 200, The Magstim Company Ltd, U.K.) connected through a Bistim and a Magstim figure-of-eight coil will be used for TMS.
1829488|NCT00788749|Drug|Prednisolone|tablets 25 mg/day
1829489|NCT00788749|Drug|Placebo|tablets once daily
1829490|NCT00788749|Other|fluticasone nasal drops|fluticasone nasal drops 800mcg/d
1829491|NCT00788749|Other|fluticasone nasal spray|fluticasone nasal spray 400 mcg/d
1829492|NCT00788775|Drug|Nilotinib|
1829493|NCT00788788|Drug|HELIOX|HELIOX is a mixture of Helium in Oxygen with a low density and the ability to reduce the work of breathing in subjects with airway obstruction. The fractions of Helium was altered in a different order depending on the arm of the study
1829494|NCT00788801|Drug|ABT-614|Baseline PET scan with radiotracer only, PET scan with radiotracer and ABT-614 Low Dose or ABT-614 High Dose
1829495|NCT00788814|Behavioral|Pathways|Strength-based curriculum addressing depression in women with with physical disabilities
1829496|NCT00788827|Biological|Autologous CD34+ stem cells|Up to 5 x 10 log 8 of autologous stem cells on a single occasion
1829497|NCT00788840|Drug|Insulatard|Insulatard insulin used as long-acting insulin for 16-week treatment phase of study.
1829498|NCT00788840|Drug|Detemir|Detemir insulin used as long-acting insulin in treatment phase of study.
1829499|NCT00788853|Other|No treatment given|No treatment is given
1829500|NCT00788866|Dietary Supplement|Pomegranate Juice|8 oz of pomegranate juice daily vs placebo juice identical in all respects except pomegranate
1829501|NCT00788866|Dietary Supplement|Placebo|Juice that matches the makeup of pomegranate in regards to sugar, vitamin C, etc. The only difference is that it lacks pomegranate juice.
1829502|NCT00788879|Behavioral|TSSC|The intervention community is exposed to the media messages of the TSSC campaign. Residents of this community also receive the lay health worker visits as well as benefit from the positive built environment changes.
1829503|NCT00788879|Behavioral|TSSC Randomized Behavioral Intervention for weight loss|"We will enroll up to 200 weight-loss challenge participants to receive text messages on personal mobile phones throughout the challenge. Consent and enrollment in the trial will take place at registration for the weight-loss community challenge in the language of their choice. Recruited participants will be randomly assigned to a group after consenting to the study and the timing and content of text messages will vary according to group assignment (Groups A - D).
Group A will receive weekly reminders for upcoming weigh-in events. Group B will receive the same weekly reminders but will also receive one-way messages every two weeks providing the participant motivational messages/topics and weight loss health tips. Group C will receive the same text messages as Group B but will also receive weekly prompts to self-monitor weight status. Group D will receive the same text messages as Group C plus daily prompts that will act as a guide for the participant to monitor behavior changes."
1829508|NCT00788918|Drug|Interferon and ribavirin|Interferon 180 microgram weekly s.c. and ribavirin (800/100/1200 mg daily) p.o.
1829509|NCT00788931|Drug|IV LBH589|
1829510|NCT00788931|Drug|Oral LBH589|
1829511|NCT00788931|Drug|trastuzumab|
1829512|NCT00788931|Drug|paclitaxel|
1829513|NCT00788944|Procedure|blood draw|Test Article was not provided to subjects for this study.
1829514|NCT00788957|Drug|Panitumumab|Panitumumab for intravenous infusion
1829515|NCT00788957|Drug|Ganitumab|Ganitumab for intravenous infusion
1829516|NCT00788957|Drug|Rilotumumab|Rilotumumab for intravenous infusion
1829517|NCT00788957|Drug|Placebo|Placebo intravenous infusion
1829518|NCT00794326|Drug|Solution for Peritoneal Dialysis|Treatment with one bag per day during 6 months
1829519|NCT00794339|Drug|64Cu-ATSM|
1829520|NCT00794339|Radiation|FDG|
1829521|NCT00794365|Drug|Varenicline|"There are two packs available for Varenicline (Champix™). The titration pack is prescribed initially to subjects with the recommended 1-week titration phase schedule as follows:
Days 1-3 0.5 mg once daily Days 4-7 0.5 mg twice daily Day 8 - End of treatment 1 mg twice daily
Following the titration period, Varenicline (Champix™) dosing is increased to 1mg twice daily for the remainder of the treatment period. Patient should set the target quit date to coincide with the start of 1 mg twice daily dosing. It should be taken after eating and with a full glass of water."
1829522|NCT00794378|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
1829523|NCT00794378|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
1829524|NCT00794391|Behavioral|Motivational interviewing|Motivational interviewing is a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller & Rollnick. 1993). This 45 minutes individual motivational intervention focuses on risky injection practices.
1829525|NCT00794391|Behavioral|Educational intervention|The educational intervention is a 45 minutes individual intervention based on a document written by the Québec ministry of health (Québec, Canada). The aim is to inform participants about safe injection practices and to show them how to use sterile injection equipment.
1829526|NCT00794417|Biological|Aflibercept|Administered in combination with the other two interventions via intravenous infusion.
1829527|NCT00794417|Biological|Pemetrexed|Administered in combination with the other two interventions via intravenous infusion.
1829528|NCT00794417|Biological|Cisplatin|Administered in combination with the other two interventions via intravenous infusion.
1829529|NCT00794430|Drug|V3381|100 mg capsules, titrated to a maximum of 400 mg bid for 13 weeks
1829530|NCT00794430|Drug|Placebo|Capsule, bid, for 13 weeks
1829531|NCT00794443|Drug|YM529 / ONO-5920|Oral
1829532|NCT00794456|Drug|Passiflora ; Crataegus and Salix|1 tablet PO twice a day
1829537|NCT00794495|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
1829538|NCT00794508|Biological|ADA gene transfer|Autologous CD34+ cells transduced with the retroviral vector MND-ADA, carrying the human ADA gene.
1829539|NCT00794547|Drug|Calcitriol|Escalating dose of Calcitriol will be infused IV over 1 hour every 21 days.
1829540|NCT00794547|Drug|Calcitriol|In this portion of the study, all patients will get the same dose of calcitriol (determined from the Phase I study) along with the standard chemotherapy
1829541|NCT00794560|Behavioral|patient education|"Possible, individualized interventions:
Improvement of patient's knowledge about medication, therapy and drug application by providing detailed written information material
Providing a complete equipment package for self-injection (disinfection patches, patches, plasters, waste disposal box for used syringes)
Patient training: oral instructions for self-injection (and application, if required), exercising the injection technique on a phantom
First self-injection under control of a specially trained pharmacist"
1829542|NCT00794573|Drug|varenicline|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
1829543|NCT00794573|Other|placebo|0.5 mg tablet once a day for the first three days, a 0.5 mg tablet twice a day for the following four days, and a 1.0 mg tablet twice a day for the remainder of the 12-week treatment.
1829544|NCT00794586|Drug|FTI, AZLI|Evaluation of 2 dosage combinations of fosfomycin and tobramycin inhaled twice daily for 28 days following 28 days of inhaled AZLI (Aztreonam Lysine for Inhalation)
1829545|NCT00794586|Drug|Placebo, AZLI|Volume-matched placebo inhaled twice daily for 28 days following 28 days of AZLI (Aztreonam Lysine for Inhalation).
1829546|NCT00794599|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
1829547|NCT00794599|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
1829548|NCT00794612|Drug|Dermacyd Femina Pocket BR (Lactic Acid)|Dermacyd Femina Pocket BR (Lactic Acid) during 21 consecutive days
1829549|NCT00794625|Drug|Valproate|Standard therapeutic doses of valproate, set according to valproic acid blood level, for 8 weeks
1829550|NCT00794625|Drug|Risperidone|Standard therapeutic doses of risperidone for 8 weeks
1829551|NCT00794625|Drug|Placebo|An inactive substance at identical dosing to active treatments for 8 weeks
1829552|NCT00794625|Drug|Stimulant medication|Stimulant medication standard in the care of ADHD, such as methylphenidate or dextroamphetamine
1829553|NCT00794625|Behavioral|Behavioral family counseling|Weekly behavioral counseling with a therapist
1829554|NCT00794664|Drug|Mipomersen|200 mg (1 mL), weekly subcutaneous injections for 26 weeks
1829555|NCT00794664|Drug|Placebo|1 mL weekly subcutaneous injections for 26 weeks
1829556|NCT00794677|Drug|ezetimibe|Blinded study medication (ezetimibe 10 mg or matching placebo in tablet form) will be taken orally once daily in the morning on rising. Single-blind ezetimibe placebo will be taken during the Run-In Period. Patients will be issued one bottle containing either active drug or placebo for each treatment period.
1829557|NCT00794690|Drug|Cimicifuga racemosa extract for the group|40 mg of Cimicifuga racemosa extract daily dor 12 months
1829558|NCT00794703|Drug|micafungin (Mycamine)|Intravenous
1829559|NCT00794703|Drug|itraconazole|oral
1829560|NCT00794716|Drug|NRL972|Single dose of 2 mg NRL972 administered intravenously. Total volume 5mL.
1829561|NCT00794755|Dietary Supplement|Vitamin K1 (Phytonadione)|Vitamin K1 tablets (100 micrograms per tablet) will be taken by patients randomized to the Vitamin K arm. Dosage is two tablets per day (200 micrograms per day) to be taken with warfarin for the 6 month study period.
1829562|NCT00794755|Dietary Supplement|Placebo|Lactose-based placebo tablets (identical in appearance to the Vitamin K1 tablets) will be taken by patients randomized to the placebo arm. Dosage is two tablets per day to be taken with warfarin for the 6 month study period.
1829563|NCT00794768|Drug|desloratadine 5 mg|Clarinex 5 mg daily x 7 days
1829564|NCT00794768|Drug|fexofenadine|Allegra 180 mg daily x 7 days
1829565|NCT00794781|Drug|E6201|E6201 Part A (Dose Escalation): Intravenous (IV) infusion administered over 30 minutes once weekly for 3 weeks (Days 1, 8, and 15). The first 3 to 6 subjects of the first cohort will receive 20 mg/m^2/week for a cycle of 3 weeks followed by a 1-week rest period. Subsequent dose escalations may increase at increments of 100% until two Grade 2 toxicities or 1 dose-limiting toxicity (DLT) are observed in a dose group. Thereafter, doses will be increased in increments of 50% or less until the maximum tolerated dose (MTD) is determined. Part B (MTD Expansion): After the MTD is determined in Part A, 15 additional subjects will continue to receive cycles at the MTD.
1829566|NCT00794794|Drug|Desloratadine (Clarinex)|Each subject received 5 mL of desloratadine syrup one time
1829567|NCT00794794|Drug|Cetirizine (Zyrtec)|Each subject received 5 mL of cetirizine syrup
1829568|NCT00794807|Drug|Alefacept|Alefacept=LFA-3/IgG1 fusion protein, once weekly, 15mg i.m.
1829569|NCT00794820|Drug|Fludarabine Phosphate|25 mg/m^2 by vein over 5-30 minutes daily for 3 days (days 2-4)
1829570|NCT00794820|Drug|Cyclophosphamide|250 mg/m^2 by vein over 60 minutes daily for 3 days (days 2-4)
1829571|NCT00794820|Drug|Rituximab|375 mg/m^2 by vein for dose 1 (given 1 day prior to chemotherapy) and then 500 mg/m^2 on days 2-3
1829572|NCT00794846|Drug|Desloratadine 5 mg (Clarinex)|Clarinex 5 mg daily x 7 days
1829573|NCT00794846|Drug|Cetirizine (Zyrtec)|Zyrtec 10 mg daily x 7 days
1829575|NCT00794872|Other|blood sampling|
1829576|NCT00794885|Drug|Enalapril/folic acid|Enalapril/folic acid, (10mg enalapril/0.8mg folic acid)/tablet, taken orally and once daily for a maximum of 5 years. Combination with other anti-hypertension drugs are allowed.
1829577|NCT00794885|Drug|Enalapril maleate|Enalapril, 10mg/tablet, taken orally once daily for a maximum of 5 consecutive years. Combination with other anti-hypertension drugs are allowed.
1829578|NCT00794898|Biological|Infliximab (Remicade)|Infliximab 3 mg/kg infusions at Weeks 0, 2, and 6. All patients will continue to receive the same dose of MTX they were receiving at entry throughout the subsequent treatment period.
1829579|NCT00794911|Behavioral|Quality of Life Therapy|8 weekly individual counseling sessions
1829580|NCT00794911|Behavioral|Supportive Therapy|8 weekly individual counseling sessions
1829581|NCT00794924|Dietary Supplement|VSL#3|one sachet per day, for 45 consecutive days
1829582|NCT00794924|Dietary Supplement|placebo|one sachet per day, for 45 consecutive days
1829583|NCT00794950|Drug|Sunitinib|"Patients are treated with a 6-week induction course of intravesical bacillus Calmette-Guerin (BCG) followed by a 2 week rest period and 4 week course of oral Sunitinib.
Patients will receive intravesical BCG (81 mg Theracys BCG in 50 ml normal saline) once weekly for 6 weeks within 6 weeks of bladder biopsy confirming high risk non-muscle invasive urothelial carcinoma. Two weeks after completion of BCG, patients will receive Sunitinib (50 mg daily) continuously for 28 days followed by a two week rest period. Patients will be reassessed with transurethral resection and urine cytology. Those with residual/recurrent disease will receive a second course identical to the initial protocol. Those with a complete response following initial or second treatment will be placed on maintenance BCG (3 week course every 6 months for 2 years). Those failing (progression, intolerance) initial/secondary treatments will be offered alternative therapy."
1829584|NCT00794963|Drug|Pravastatin, Fenofibrate, Metformin, Orlistat, irbesartan|The intervention in the 4 patients consisted in dietary recommendations, advice regarding increasing physical activity, and use of Orlistat 60 mg three times daily. No other drugs were prescribed.
1829585|NCT00794963|Other|As selected by community physician|As selected by community physician
1829586|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (low dose)|
1829587|NCT00794976|Drug|Dexamethasone Iontophoretic Patch (high dose)|
1829588|NCT00794976|Drug|Dexamethasone Passive Patch|
1829589|NCT00794976|Drug|Placebo Patch|
1829590|NCT00794989|Dietary Supplement|Ground Flaxseed|Given orally
1829591|NCT00794989|Other|No Intervention|Participants randomized to Arm 2 do not receive any intervention
1829592|NCT00795002|Drug|alvocidib|Given IV
1829593|NCT00795002|Drug|mitoxantrone hydrochloride|Given IV
1829594|NCT00795002|Drug|cytarabine|Given IV
1829595|NCT00795002|Other|pharmacological study|Correlative studies
1829596|NCT00795002|Other|laboratory biomarker analysis|Correlative studies
1829597|NCT00795015|Drug|insulin regular IV infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
1829598|NCT00795015|Drug|IV insulin infusion|IV insulin was administered by continuous infusion and the rate changed every hour according to the blood glucose level as determined by each of the protocols being compared
1829599|NCT00795028|Other|Standard Care for people after hip fracture|
1829600|NCT00795028|Other|Standard Care + exercise intervention|
1829601|NCT00795054|Other|Household financial data collection|Baseline financial survey pre-transplant, financial diary post-transplant every two weeks for 3 months, and financial questionnaire via phone survey at 6, 12, 18 and 24 months post-transplant.
1829602|NCT00795080|Procedure|Dynamic cervical MRI scans|Serial MRI examination with the neck in flexion and extension to document changes in the cord compression and cerebral spinal fluid (CSF)
1829603|NCT00795106|Drug|Capsaicin|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
1829604|NCT00795106|Drug|Placebo|Each group will undergo two 4-week treatment arms separated by a 4-week wash-out period. Participants will apply 1 hydrogel patch on both the right-sided and left-sided neck and shoulder girdle on the skin overlying a myofascial trigger point. No more than 2 patches will be used on each subject per treatment. During each 24-hour period, the patches will be placed on the skin for 12 hours and will be removed for 12 hours. Placebo hydrogel patches will be 2.5 cm in diameter with a breathable cloth backing. The experimental patches will be identical to placebo patches except will contain capsaicin 0.1% (500 mcg).
1829605|NCT00795119|Device|Near Infrared Spectroscopy (NIRS)|NIRS of the head is undertaken at the time of CT or MRI examination
1829606|NCT00795132|Drug|Busulfan|This drug is a bifunctional alkylating agent. Busulfan is highly toxic to noncycling or slowly-cycling cells. Pharmacokinetic studies of the IV formulation in pediatrics have shown that using a dose of 0.8mg/kg IV q6 hours most patients will achieve AUC levels between 800 and 1300 uM/min, representing steady state levels between 600-900ug/ml. The manufacturer recommends higher doses, 1.1mg/kg for children less than 12kg. Because this is a reduced intensity study and infants on the study will be very heavily pretreated we will use the lower dose of 0.8mg/kg q6 hours for a total of 8 doses for all patients.
1829607|NCT00795132|Drug|Anti-Thymocyte Globulin|"Thymoglobulin will be administered at a dose of 2.5 mg/kg recipient body weight intravenously on each of 4 successive mornings (Days -4, -3,-2,-1) for patients receiving unrelated grafts and at a dose of 2.5mg/kg as a single dose on d-1 for patients receiving related marrow grafts. ATG is infused over a minimum of 4 hours, but is generally better tolerated over 6-8 hours. Suggested premedications are acetaminophen (10 mg/kg/dose), diphenhydramine (1 mg/kg/dose), and methylprednisolone. The methylprednisolone should be given at a dose of
1mg/kg 30 minutes prior to the ATG, with another 1mg /kg four hours into the infusion (total 2mg/kg/d). Patients are observed continuously for possible allergic reactions throughout the infusion."
1829608|NCT00795132|Drug|Fludarabine|Administration and Dosage: Fludarabine will be administered at a dose of 30 mg/m2 in 100 ml of D5W intravenously over one hour on each of six consecutive days -10 through -5 for unrelated grafts or d-7 through d-2 for related grafts. Fludarabine is a fluorinated nucleotide analog of the antiviral agent vidarabine, 9-beta-D-arabinofuranosyladenine. Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. The half-life of 2-fluoro-ara-A is approximately 10 hours. The mean total plasma clearance is 8.9 L/hr/m2 and the mean volume of distribution is 98 L/m2. Approximately 23% is excreted unchanged. This metabolite appears to act by inhibiting DNA polymerase alpha, ribonucleotide reductase and DNA primase, thus inhibiting DNA synthesis.
1829657|NCT00795444|Drug|maraviroc|Maraviroc (INN), 300 mg tablets. A dose of 300 mg will be administered every 12 hours.
1829967|NCT00799292|Drug|Vasopressin|20cc of dilute vasopressin (20units in 50cc normal saline). At beginning of the procedure 5cc injected were injected at 2,4,8 and 10 o'clock on the cervix
1829609|NCT00795132|Drug|Cyclosporine|"Cyclosporine is a potent immunosuppressive agent that in animals prolongs survival of allogeneic transplants involving skin, kidney, liver, heart, pancreas, bone marrow, small intestine, and lung. The effectiveness of cyclosporine results from specific and reversible inhibition of immunocompetent lymphocytes in the G 0 - and G
1 -phase of the cell cycle. Administration and Dosage: Cyclosporin start on day -3 initially at a dose of 2.5mg/kg IV q12 hours or 3mg/kg/dose (neoral equivalent) PO q12 hours targeting suggested troughs of 250 to 350 ng/ml. Continuous infusion cyclosporin may be allowed per institutional preference. 3x daily dosing may be used for younger children to achieve therapeutic levels. PBMTC Protocol #ONC0313 19 Continuous infusion cyclosporin may be allowed per institutional preference."
1829610|NCT00795132|Drug|Mycophenolate mofetil|MMF is a potent, selective, uncompetitive, and reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH), and therefore inhibits the de novo pathway of guanosine nucleotide synthesis without incorporation into DNA. Administration and Dosage: Initial dosage will be IV or PO with switch to PO when tolerated. Starting doses will be 15 mg/kg/day bid (total dose 30mg/kg/d, IV same as PO dose) beginning day 0 with the first dose given approximately 4-6 hours after the stem cell infusion. This dose will stop on day +30 for patients receiving matched sibling BM/PBSC and UCB grafts, but will continue until day +40 and then taper at approximately 11%/wk over 8 weeks until patients are off at day +96.
1829611|NCT00795145|Drug|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
1829612|NCT00795145|Drug|Linezolid 900 mg|Intravenous, 900 mg linezolid, single dose
1829613|NCT00795145|Drug|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
1829614|NCT00795145|Drug|Placebo|Intravenous, Placebo control for blinding, Normal Saline, Single dose
1829615|NCT00795145|Drug|Linezolid 600 mg|Intravenous, 600 mg linezolid, single dose
1829616|NCT00795145|Drug|Linezolid 1200 mg|Intravenous, 1200 mg linezolid, single dose
1829617|NCT00795145|Drug|Moxifloxacin 400 mg|Oral, 400 mg moxifloxacin, single dose
1829618|NCT00795158|Drug|desloratadine|desloratadine 5 mg tablets; one tablet orally once a day for 28 days
1829619|NCT00795171|Drug|Docetaxel * Sunitinib|docetaxel 75mg/m2 day1 q 21d x 4 cycles, sunitinib 37.5mg/d day2 -day15 x 4 cycles
1829620|NCT00795171|Drug|Docetaxel|docetaxel 75mg/m2 day1 q 21d x 4 cycles
1829621|NCT00795171|Drug|Docetaxel|Docetaxel 75mg/m2 q21d for 4 cycles
1829622|NCT00795184|Device|Imaging procedures (NBI)|"Imaging procedures (pCLE) and (NBI) - All patients undergo both procedures back to back by two endoscopists, blinded to each other, in randomized order.
Procedure 1: Standard endoscopic procedure The patient receives white light endoscopy (WLE) examination. All visible lesions are noted and photographed. No biopsy is taken until both procedures are complete.
Procedure 2: NBI endoscopic procedure The patient receives a NBI endoscopy examination. All visible and NBI abnormal lesions are noted and photographed.
After both procedures are complete and all sites are unblinded to both endoscopists. pCLE with Cellvizio and physical biopsies are performed at all sites plus 4 quadrant sites."
1829623|NCT00795184|Device|HDWLE|
1829624|NCT00795184|Device|pCLE|
1829625|NCT00795210|Drug|Growth hormone|Recombinant Human Growth Hormone (Teva pharmaceuticals), with one arm receiving 6mcg/kg SC once daily for two weeks and the other arm receiving 2mg SC once daily for two weeks
1829626|NCT00795210|Drug|Growth Hormone Releasing Hormone|Tesamorelin (GHRH) 2mg SC QD x 2 weeks
1829627|NCT00795223|Drug|morphine and bupivacaine|0.3 mg morphine for spinal together with 0.5% bupivacaine for femoral nerve block
1829628|NCT00795223|Drug|spinal morphine and marcaine|0.3 mg spinal morphine together with 0.25% bupivacaine for femoral nerve block
1829629|NCT00795223|Drug|morphine and bupivacaine|0.2 mg morphine for spinal 0.5% bupivacaine for femoral nerve block
1829630|NCT00795223|Drug|morphine and bupivacaine|0.2 mg morphine for spinal together with 0.25% bupivacaine for femoral nerve block
1829632|NCT00795249|Behavioral|smoking cessation|After baseline examination, the group is asked to quit smoking for 2 weeks.
1829633|NCT00795262|Drug|Quinapril (Accupril) plus Alpha Lipoic Acid|Patients in Arm 2 (n=20) will receive quinapril 40 mg and Alpha Lipoic Acid (600 mg/day)for an 8-week treatment period (Treatment A).
1829634|NCT00795262|Drug|accupril, placebo|accupril 40 mg
1829635|NCT00795262|Drug|accupril, alpha lipoic acid|accupril (quinapril) 40 mg plus alpha lipoic acid 600 mg
1829637|NCT00795288|Drug|Simvastatin, 80 mg/day for 21 days|Active treatment group
1829638|NCT00795288|Drug|placebo|Control group
1829639|NCT00795301|Drug|Capecitabine, Cetuximab, Oxaliplatin|
1829640|NCT00795314|Drug|Fentanyl Citrate|Combined anesthesia with propofol (2-2.5mg/kg) and fentanyl (5 μg)
1829641|NCT00795314|Drug|Butorphanol Tartrate|Combined anesthesia with propofol (2-2.5 mg/kg) and butorphanol (1mg)
1829642|NCT00795327|Device|Sculptra (Poly-L-Lactic Acid Dermal Implant)|Drug Device study
1829643|NCT00795340|Drug|carboplatin|Given IV
1829644|NCT00795340|Drug|cediranib maleate|Given orally
1829645|NCT00795340|Drug|paclitaxel|Given IV
1829646|NCT00795340|Other|placebo|Given orally
1829647|NCT00795353|Drug|Amevive exposure|Commercial alefacept prescribed by Physician
1829648|NCT00795366|Drug|arginine vasopressin|Titrated to cerebral perfusion pressure greater than 60 mm Hg
1829649|NCT00795366|Drug|Standard catecholamine|Titrated catecholamine of attending physicians preference to cerebral perfusion pressure greater than 60 mm Hg.
1829650|NCT00795379|Behavioral|Interoceptive Exposure|Exposure to internal stimuli.
1829651|NCT00795392|Other|ASA scale|ASA scale evaluation before operation
1829652|NCT00795392|Other|Full-scale psychological assessment|Full-scale psychological evaluation before operation
1829653|NCT00795405|Behavioral|Exposure to sporting events|Exposure to sporting events
1829654|NCT00795405|Behavioral|No exposure to sporting events|No exposure to sporting events
1829655|NCT00795418|Biological|Placebo|Placebo comparator
1829656|NCT00795418|Biological|CAD106|
1829658|NCT00795457|Biological|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
1829659|NCT00795457|Biological|GAA/TT-peptide vaccine and poly-ICLC|Participants will be treated with subcutaneous injections of GAA/TT-vaccines on Weeks 0, 3, 6, 9, 12, 15, 18 and 21. I.m. poly-ICLC will be administered (20 mg/kg i.m.) on the day of, and on day 4 after each vaccine (e.g. if the vaccine is administered on Thursday, poly-ICLC will be administered on the day of vaccine and the following Monday). Each vaccine will be administered within 2 hours before or after the i.m. poly-ICLC administration.
1829660|NCT00795470|Drug|Antimicrobial|Appropriate antimicrobial based on urine culture results
1829661|NCT00795470|Device|Catheter change|Change urine catheter
1829662|NCT00795483|Drug|Zoledronic acid|Zoledronic Acid 5mg/year
1829663|NCT00795483|Behavioral|Lifestyle modifications|Lifestyle modifications
1829664|NCT00795483|Drug|Zoledronic acid|Zoledronic acid (5mg/2years)
1829665|NCT00795496|Procedure|Histamine provocation|A dosimetric histamine challenge test in which the provocative dose of inhaled histamine producing a decrease of 15% in FEV1 is measured.
1829666|NCT00795496|Procedure|Skin prick tests|Skin prick testing will be performed for: birch, timothy, mugwort, alder, pine, cat, dog, horse, house dust mite, Cladosporium herbarum.
1829667|NCT00795496|Procedure|Serum IgE blood testing|One blood test to measure total serum IgE
1829668|NCT00795496|Procedure|Mantoux-testing|Tuberculin (2 TU) s.c. on the forearm. The test is read after 72 hours.
1829669|NCT00795509|Drug|Tolterodine tartrate|"Detrusitol® Capsule 2mg and 4mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dosage for oral administration is 4 mg of tolterodine tartrate once daily. Occasionally dose reduction might be needed due to individual tolerability."
1829670|NCT00795522|Drug|Desloratadine|Subjects will receive DL 5 mg daily for 28 days. Each active DL tablet contains 5 mg of desloratadine
1829671|NCT00795548|Drug|5-Azacitidine|"5-Aza will be administered at doses of 100mg/m2 via subcutaneous injection over a period of 5 days. The total amount per treatment cycle, consisting of 5 days, is 500mg/m². Each treatment cycle is repeated every 28 days, with a treatment pause of 23 days between each 5-Aza cycle, to a total of 6 (optional 8 cycles) cycles.
DLI will be transfused on day +34 with a total count of CD3+ cells of DLI 1-5x10E6CD3+/kg bodyweight. In absence of GvHD DLI transfusion is repeated on day +90 with DLI 1-5x10E7CD3+/kg bodyweight and on day +142 with DLI 1-5x10E8CD3+/kg bodyweight. Additional DLI may be given."
1829672|NCT00795561|Procedure|Day care|Patients randomised to day care treatment of NVP will be instructed to present to the day services unit where they will receive a pre-agreed fluid and anti emetic regimen.
1829673|NCT00795561|Procedure|Inpatient|Patients randomised to inpatient management of NVP will be admitted to hospital where they will receive a pre-agreed fluid and anti emetic regimen.
1829674|NCT00795574|Drug|infliximab|Dosing is 5mgs/kg at weeks 0,2 and 6 to complete loading dose of drug and then every 8 weeks thereafter until end of treatment phase.
1829675|NCT00795574|Drug|Placebo Comparator|5mgs /kg given IV over a minimum of 2 hours at weeks 0,2 and 6 to complete loading dose and then every 8 weeks during maintenance treatment period.
1829676|NCT00795587|Drug|variation of mannitol dose|in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
1829677|NCT00795600|Drug|insulin detemir|Insulin detemir once daily plus insulin aspart at mealtime
1829678|NCT00795600|Drug|insulin NPH|Insulin NPH once daily plus insulin aspart at mealtime
1829679|NCT00795613|Drug|ESCALATED BEACOPP|Esc.BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 200 mg/m2/ev/die1°- 3° Doxorubicine35 mg/m2/ev/die 1° Cyclophosphamide1250 mg/m2/ev/die 1° Vincristine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/b.m./die 1°- 7° Prednison40 mg/m2/b.m./die 1°-14° G-CSF300mcg/die s/c from day 8 until PMN>1000/ul Recycle every 21 days Esc.R-BEACOPP as above plus Rituximab 375 mg/m2/ev/ die 1° Recycle every 21 days Baseline BEACOPP Bleomicine10 mg/m2/ev/die 8° VP-16 100 mg/m2/ev/die 1°-3° Doxorubicine25 mg/m2/ev/die 1° Cyclophosphamide650 mg/m2/ev/die 1° Vincrinstine1,4 mg/m2(max dose 2 mg)/ev/die 8° Procarbazine100 mg/m2/os/die 1°-7° Prednison40 mg/m2/os/die 1°-14° Recycle every 21 days Baseline R-BEACOPP as above plus Rituximab375 mg/m2/ev/ die 1° Recycle every 21 days
1829680|NCT00795613|Drug|CONVENTIONAL ABVD|ABVD(cycle repeats every 28 days) Doxorubicine25 mg/m2 iv days 1,15 Bleomicine10,000 units/m2 iv days 1,15 Vinblastine6 mg/m2 iv days 1,15 Dacarbazine375mg/m2 iv days 1,15 This will be given at full dose and on schedule,regardless of blood count.
1829681|NCT00795626|Behavioral|Systematic education in the reduction of the risk estimate to cardiovascular events|Systematic education during 4 assessment throughout one year
1829682|NCT00795639|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
1829683|NCT00795639|Drug|Placebo|Sitaxsentan Placebo = 1 tablet administered orally, once daily
1829684|NCT00795652|Behavioral|Distance Treatment for postpartum depression|Evidence-based, cognitive behavioural intervention for women with postpartum depression
1829685|NCT00795665|Drug|bevacizumab|Bevacizumab (10 mg/kg) will be given intravenously every other week starting one week before the first dose of BCNU. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
1829686|NCT00795665|Drug|carmustine|BCNU (200 mg/m2), will be given over 4 hours as a continuous intravenous infusion every 8 weeks. Treatment with both BCNU and bevacizumab for 6-months, after which the participant may continue to receive bevacizumab every 2 weeks for a maximum of one year and three additional cycles of BCNU.
1829687|NCT00795678|Drug|capecitabine|Capecitabine is an oral prodrug of 5 deoxy-5-fluorouridine (5DFRU) that is converted to 5-fluorouracil (5-FU). 5-FU is metabolized to 5-fluoro-2-deoxyuridine monophosphate (fDUMP) and 5-fluorouridine triphosphage (FUTP) which cause cell injury. Capecitabine is supplied in 150 mg (light peach colored) and 500 mg tablets (film coated)and will be administered pre-operatively.
1829688|NCT00795678|Drug|cyclophosphamide|Cyclophosphamide is biotransformed principally in the liver to active alkylating metabolites that cross-link tumor cell DNA. Cyclophosphamide is supplied in 100 mg, 200 mg, 500 mg and 1 gram and 2 gram vials as a white powder. The drug should be reconstituted with Sterile Water for Injection, USP, and may be diluted in either normal saline or D5W. Cyclophosphamide will be mixed in 250 mL of D5W and infused over 30 minutes prior to surgery.
1829689|NCT00795678|Drug|doxorubicin hydrochloride|Doxorubicin is an anthracycline anticancer agent which mediates tumoricidal effects by intercalating into double-stranded DNA and producing structural changes that disrupt DNA and RNA synthesis. Doxorubicin is supplied in 10, 20, and 50 mg single use vials, and 150 mg multidose vials as a red-orange, lyophilized power which has a storage stability of a least two years. The dose will be given 60mg/m2 over 15 minutes of time pre-operatively.
1829690|NCT00795678|Drug|gemcitabine hydrochloride|Gemcitabine is a fluorinated deoxynucleoside prodrug which disrupts DNA synthesis and induces apoptosis in a broad number of human tumors, including breast cancer. Gemcitabine is supplied as a lyophilized powder in sterile vials containing 200 mg of 1000 mg (1 gram) of gemcitabine as the hydrochloride salt (expressed as the free base) mannitol and sodium acetate. Dosage will be 1250mg/m2, IV pre-operatively over 30 minutes.
1829691|NCT00795678|Drug|lapatinib ditosylate|: Lapatinib ditosylate monohydrate tablets, 250 mg, are oval, biconvex, orange, film-coated tablets with one side of the tablet plain and other side of the tablet embossed with FG HLS. Lapatinib may also be supplied as oval, biconvex, tan tablets, with no markings. Lapatinib will be administered for at least 3 days pre-operatively at 1250mg.
1829692|NCT00795678|Drug|paclitaxel|Paclitaxel will be given as an intravenous infusion (80mg/m2) the morning of surgery as specified in the protocol, diluted in 0.9% Sodium Chloride Injection, USP, or 5% Dextrose Injection. Paclitaxel will be administered via an infusion control device (pump) using non-PVC tubing and connectors, such as the IV administration sets (polyethylene or polyolefin) which are used to infuse parenteral nitroglycerin.
1829693|NCT00795678|Drug|vinorelbine ditartrate|Vinorelbine (Navelbine®) is a unique semi-synthetic vinca alkaloid 3', 4-didehydro-4' deoxy-C'-norvincaleukoblastine (ditartrate) (IUPAC). The pyogen free, sterile parenteral dosage form is supplied in 10 mg/1 ml ampules/vials and 50 mg/5 ml vials. It will be administered at a dosage of 25mg/m2 IV over 10-30 minutes pre-operatively.
1829694|NCT00795678|Drug|Trastuzumab|Trastuzumab is a monoclonal immunoglobulin G1 kappa antibody which acts as a mediator of antibody-dependent cellular cytotoxicity (ADCC) agent through its high affinity, high specificity binding to extracellular domain of HER2 Receptor. Trastuzumab is supplied as a lyophilized, sterile powder containing 440 mg trastuzumab per vial under vacuum. Each carton contains one vial of 440 mg trastuzumab and one 30 ml vial of bacteriostatic water for injection, USP, 1.1% benzyl alcohol. This will be given the morning of surgery at 2mg/m2 IV over 90 minutes.
1829695|NCT00795691|Behavioral|low-carbohydrate diet|ketogenic low-carbohydrate diet in patients with type 2 diabetes
1829696|NCT00795691|Behavioral|low-fat diet|low-fat diet in patients with type 2 diabetes
1829697|NCT00795704|Drug|Mulberry Leaf Extract|Mulberry Leaf Extract 1000 mg by mouth three times daily for 3 months
1829698|NCT00795704|Drug|Placebo|Placebo 500 mg #2 capsules by mouth three times daily
1829699|NCT00795717|Drug|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 12 weeks.
1829700|NCT00795717|Drug|Placebo|2 capsules given twice daily
1829701|NCT00795730|Drug|NSA-789|
1829702|NCT00795730|Other|placebo|
1829703|NCT00795756|Drug|liposome-encapsulated cytarabine (DepoCyte)|DepoCyte 50 mg injected intrathecally x6-8 (6: B-lineage, 8: T-lineage) during induction/consolidation phases
1829704|NCT00795756|Drug|Triple intrathecal therapy (TIT)|Methotrexate 12,5 mg + Cytarabine 50 mg + Prednisolone 40 mg. injected intrathecally x12 during induction/consolidation therapy
1829705|NCT00795769|Drug|ondansetron|Given IV
1829706|NCT00795769|Other|survey administration|Correlative studies
1829707|NCT00795769|Procedure|management of therapy complications|Ondansetron IV
1829708|NCT00795782|Procedure|Prophylactic central lymph node dissection|prophylactic ipsilateral versus bilateral central lymph node dissection
1829709|NCT00795795|Procedure|Preimplantation Genetic Screening|Preimplantation Genetic Screening
1829710|NCT00795795|Procedure|IVF without PGS|IVF without PGS
1829711|NCT00795808|Drug|Metformin|500mg tds for 6 months
1829712|NCT00795808|Drug|Placebo|One tablet tds for 6 months
1829713|NCT00795808|Drug|Metformin + Clomiphene|500mg tds + Ovulatory dose for 6 months
1829714|NCT00795808|Drug|Metformin|500mg tds for 6 months
1829715|NCT00795808|Drug|Clomiphene|Ovulatory dose for 6 months
1829716|NCT00795821|Drug|LY2216684|Flexible Dosing: 6 mg, 9 mg, 12 mg and 18 mg (3 tablets) administered QD for up to 62 weeks
1829717|NCT00795821|Drug|Placebo|Dose: 3 tablets QD for 62 weeks
1829718|NCT00795834|Dietary Supplement|High polyphenol beverage|"Antioxidant capacity umol TE/L(ORAC): 19987 Polyphenolic Content(mcg/ml): 1445 Vitamin C (mg/100ml): 35.35 Calorie Content (Kcal/250ml):40.0
250ml twice daily for 1 month (56 doses)"
1829719|NCT00795834|Dietary Supplement|Placebo Beverage|"Antioxidant capacity umol TE/L(ORAC): negligible Polyphenolic Content(mcg/ml): negligible Vitamin C (mg/100ml): 0.00 Calorie Content (Kcal/250ml):40.0
250ml twice daily for 1 month (56 doses)"
1829720|NCT00795847|Drug|Preminent (losartan/hydrochlorothiazide combination drug)|Preminent 1T qd (Arm 1) or losartan 100 mg (Arm 2) was given for 3 months.
1829754|NCT00796133|Drug|NES/E2 gel|Lowest effective dose of 3 formulations of the NES/E2 gel to ensure ovulation suppression (P<10nmol/L) in 90-95% of the cycles. The high dose will deliver 4.5mg of NES; the medium dose will deliver 3mg of NES, and a low dose of 1.5mg of NES. Based on a 10% absorption rate, 450 µg/d, 300 µg/d and 150 µg/d will be absorbed respectively. The doses of Estradiol will also be tailored to the 3 formulations.
1829755|NCT00796159|Drug|Olmesartan medoxomil|olmesartan medoxomil 20 mg and HCTZ 12.5 mg
1830271|NCT00801450|Drug|Triamcinolone acetonide|40 mg
1829723|NCT00795886|Drug|RAPAMYCIN|Rapamycin (RAPA, RapamuneR) (sirolimus) is an immunosuppressive agent that was approved by the FDA in 1999. It is a macrocyclic lactone that is structurally similar to Tacrolimus (FK506) and binds to the same intracellular protein as FK506, FKBP1,2,3, but it has an entirely different mechanism of action and a different principal target protein. The target of the RAPA: FKBP complex is the mammalian target of rapamycin (mTOR). Unlike the calcineurin inhibitors cyclosporine (CSA) and - FK506, RAPA exerts its effects by inhibiting growth factor-driven transduction signals in the T-cell response to alloantigen, thus preventing proliferation among T and B lymphocytes3,4.
1829724|NCT00795899|Drug|Epirubicin / Cyclophosphamide in combination with Paclitaxel/Trastuzumab, followed by postoperative Trastuzumab|"Cycles 1-4 Epirubicin: 90 mg/m2, i.v. day 1 Cyclophosphamide: 600 mg/m2, i.v. day 1 Every 22d
Cycles 5-8 Paclitaxel: 175 mg/m2, i.v., 3h-infusion day 1 Trastuzumab: 8 mg/kg i.v. at day 0 of the 5th cycle and thereafter each 6 mg/kg i.v. day 1 in the cycles 6-8 Every 22d"
1829725|NCT00795912|Drug|Atorvastatin|atorvastatin titrated from 10-40 mg/day over 3 months and maintained at 40mg/day for a further 3 months
1829726|NCT00795925|Drug|propiverine hydrochloride|"coated tablets containing 5 mg
consecutive dose escalation of 5 mg, 10 mg or 15 mg propiverine b.i.d."
1829727|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
1829728|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
1829729|NCT00795938|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
1829730|NCT00795951|Biological|T.R.U.E. Test|48 hour application of 28 allergens and negative control
1829731|NCT00795964|Other|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 6 ml/kg predicted body weight
1829732|NCT00795964|Other|Randomized application of intraoperative tidal volume|intraoperative mechanical ventilation with 12 ml/kg predicted body weight
1829734|NCT00796003|Drug|JNJ-30979754 15 mg/m2|JNJ-30979754 (decitabine) 15 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1.
1829735|NCT00796003|Drug|JNJ-30979754 20 mg/m2|Phase I: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) Cycle 1. Phase II: JNJ-30979754 (decitabine) 20 mg/m2 will be administered once daily by 1-hour intravenous infusion from Day 1 to 5 of 4-Week (28-day) cycles until the decitabine was expected to be effective in participants.
1829736|NCT00796029|Drug|14C-paliperidone|
1829737|NCT00796042|Other|Usual care|Subjects will be encouraged to implement the standard wound care protocol that is consistent with the National (CAWC) and Provincial (RNAO) best practice guidelines for the treatment of pressures ulcers. This wound care program will be customized to subject's needs based on the results of the assessment performed by the wound care specialist. A registered dietitian will review blood values associated with nutritional status and make recommendations for dietary changes. Wherever possible, implementation of this wound care program will be coordinated with the subjects' current health care team and appropriate referrals to home care agencies or specialists will be initiated where needed. Subjects assigned to this group will continue their current level of activity (bed rest). Any equipment or services will be obtained through the usual provider agencies.
1829738|NCT00796042|Other|Pressure management and Mobility program|Subjects are provided with the same customized wound care program as the usual care group and a pressure management and mobility program that is customized to the individual's needs. This program is based on an in depth home assessment performed by a registered Occupational (OT) or Physical Therapist (PT). Pressure Management Program: A qualified OT or PT will examine the subject on all in-use surfaces and observe all transfers to identify sources of friction and shear, and any strength or balance deficits, identifying what equipment/services are required to manage pressure, improve mobility, and reduce friction and shear. Mobility Program: A qualified PT will assess strength, balance, range of motion, and functional independence with transfers and other ADLs and will develop a mobility program to optimize functional independence and improve strength and balance required for safe and effective transfers. Program to be implemented within one month of this evaluation.
1829739|NCT00796055|Drug|MEDI-547|Administered at a dose and schedule as determined by the subject's enrollment cohort as a 60 minute IV infusion as part of a 21-day treatment cycle.
1829747|NCT00796081|Drug|ER OROS paliperidone, paliperidone ER|
1829748|NCT00796094|Other|Ultrasound examination|Sonoelastrography is an ultrasound examination that can determine the elasticity of soft tissue. This examination takes approximately 10 minutes to complete.
1829749|NCT00796107|Drug|RG1507|16mg/kg iv every 3 weeks
1829750|NCT00796107|Drug|letrozole|2.5mg po daily
1829751|NCT00796120|Drug|Trabectedin|Trabectedin 1.5 milligram per square meter (mg/m^2) will be given as 24-hour continuous intravenous infusion every 3 weeks until disease progression.
1829752|NCT00796120|Drug|Doxorubicin|Doxorubicin 60 or 75 mg/m^2 will be given intravenously every 3 weeks until disease progression.
1829753|NCT00796120|Drug|Ifosfamide|Ifosfamide 6 to 9 g/m^2 will be given intravenously every 3 weeks until disease progression.
1958793|NCT01245712|Radiation|Accelerated Partial Breast Irradiation (APBI)|Two 3.4 Gy fractions administered per day, separated by at least 6 hours for a total of 34 Gy delivered in 10 fractions (5 - 6 days in a row).
1958794|NCT01245712|Behavioral|Questionnaires|Questionnaires completed about breast changes at baseline, end of treatment, and at each follow up visit for 10 years.
1829756|NCT00796172|Behavioral|Medication Adherence System (MAS)|Participants will receive individualized reports from the MAS and counseling from their doctors. The counseling will focus on adherence to blood pressure and cholesterol management medications.
1829757|NCT00796172|Behavioral|Usual Care|Participants will receive usual care from their doctors and written materials on CVD risk factors.
1829758|NCT00796185|Drug|Paliperidone ER|
1829759|NCT00796198|Drug|Xalatan+Cosopt|Xalatan ophthalmic solution one drop at 10pm + Cosopt ophthalmic solution one drop at 8am and one drop at 8 pm
1829760|NCT00796198|Drug|Xalatan|Xalatan ophthalmic solution one drop at 10pm
1829761|NCT00796211|Drug|CRx-197|CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
1829762|NCT00796211|Drug|CRx-197|CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
1829763|NCT00796211|Drug|Nortriptyline|0.1% nortriptyline HCl topical cream
1829764|NCT00796211|Drug|Calcipotriol|0.005% calcipotriol topical cream
1829765|NCT00796211|Other|Placebo|Vehicle of CRx-197 topical cream (placebo)
1829766|NCT00796224|Drug|60 mg/kg azithromycin ER|subjects taken 60 mg/kg azithromycin ER
1829767|NCT00796224|Drug|30 mg/kg azithromycin IR|subjects taken 30 mg/kg azithromycin IR (Immediate Release)
1829768|NCT00796237|Device|Whole body vibration therapy|In their regular physiotherapy sessions, the subjects in the experimental group will receive WBV (20-240Hz, 10-minute sessions, 1 session per day, 5 sessions per week). The vibration loading will be carried out using the Fit-Vibe System (Germany), which is a vibration platform that is capable of generating vertical vibration.
1829769|NCT00796237|Other|standing on the vibration platform but no vibration will be applied|The subjects in this group will perform the same exercises on the vibration platform as in the experimental group for the same duration, but no vibration will be given.
1829770|NCT00796250|Biological|Infliximab|Patients in this group were treated with azathioprine (AZA), infliximab, and placebo prednisolone. Infliximab was to be administered at a dose of 5 mg/kg at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
1829771|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
1829772|NCT00796250|Drug|Placebo Prednisolone|Patients in this group were treated with AZA, infliximab, and placebo prednisolone. Placebo prednisolone was to be administered by oral use.
1829773|NCT00796250|Drug|Prednisolone|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Prednisolone was to be administered by oral use, with the decreasing dose of 40 mg a day, 35 mg a day, 30 mg a day and 25 mg a day every week for each dosage, respectively; 20 mg a day for five weeks; 15 mg a day, 10 mg a day and 5 mg a day for one week for each dosage respectively, until discontinuation.
1829774|NCT00796250|Drug|AZA|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. All patients were treated with AZA, by oral use, with a 2 mgkg dose a day until the end of the study (30 weeks).
1829775|NCT00796250|Biological|Placebo Infliximab|Patients in this group were treated with AZA, prednisolone, and placebo infliximab. Placebo infliximab was to be administered at Visit 2 (Week 0), and at Weeks 2, 6, and 14 (total of four infusions). Infliximab infusions were administered by the investigators in the hospital during the patient's visit, usually in the morning.
1829776|NCT00796263|Drug|HAART|"2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily
Dolutegravir(DTG) 50 mg orally once daily"
1829777|NCT00796263|Drug|Mega-HAART|"2 nuceloside/nucleotide analog reverse-transcriptase inhibitor (NRTI) class medications or Kivexa (ABC300/3TC300) orally once daily
Dolutegravir(DTG) 50 mg orally once daily
Maraviroc (MVC) 600 mg orally twice daily"
1829778|NCT00796276|Drug|IR OROS paliperidone and ER OROS paliperidone|
1958795|NCT01245712|Device|Proton Therapy System|Proton beam design will take into account day-to-day variability in treatment set-up and organ motion.
1829785|NCT00796302|Drug|Methylphenidate HCl|"For children weighing less than 25 kg, the dose will be titrated at 18 mg for the first 7 days, 36 mg for the next 4 days, and, if needed, 54 mg for the next 4 days. For children weighing more than 25 kg, the dose will be titrated at 18 mg for the first 4 days, 36 mg for the next 3 days, 54 mg for the next 4 days, and 72 mg for the next 3 days.
Once the child's optimal dose is established, he or she will continue on that dose for the rest of the 21-week trial.
One pill is taken once daily."
1829786|NCT00796302|Drug|Risperidone|"For children weighing less than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 16, the child's dose may be increased to 2.0 mg a day. On Day 22, the child's dose may be increased to 2.5 mg a day.
For children weighing more than 45 kg, the dose will start at 0.5 mg at night. After 4 days, the child's dose may be increased to 1.0 mg a day. On Day 8, the child's dose may be increased to 1.5 mg a day. On Day 12, the child's dose may be increased to 2.0 mg a day. On Day 15, the child's dose may be increased to 2.5 mg a day. On Day 18, the child's dose may be increased to 3 mg a day. On Day 23, the child's dose may be increased to 3.5 mg a day."
1829839|NCT00796692|Drug|Nadroparin|LMWH is given with a weight adjusted dose of 86 international anti-factor Xa units of nadroparin (Fraxiparine) per kilogram of body weight(86 anti-factor Xa IU/kg) subcutaneously every 12 hours,which will be used at least 5-7 days.
1829787|NCT00796302|Behavioral|Parent Management Training (PMT)|PMT will include individual parent sessions held weekly for 9 weeks, with two booster sessions to be completed during the 3-month extension. Sessions will include development of problem-solving skills and behavior management strategies, practice activities, and role-playing with the behavioral therapist.
1829788|NCT00796302|Drug|Placebo|One pill will be taken once daily for the first 4 days and then twice daily until Week 21.
1829789|NCT00796315|Drug|Doxylamine Succinate USP|One dose of liquid, dosing range 3.125mg/7.5mL - 12.5mg/30mL
1829790|NCT00796328|Drug|Phenylephrine infusion|Up-down, biased coin design
1958805|NCT01226316|Drug|AZD5363|Patients will receive a single dose of AZD5363, administered orally, followed by a 3-7 day wash-out period. Patients will then commence with twice-daily dosing, administered orally, every day, to cessation of therapy.
1829794|NCT00796367|Drug|VI-0521|7.5 mg phentermine and 46 mg topiramate
1829795|NCT00796367|Drug|Placebo|placebo
1829796|NCT00796367|Drug|VI-0521|15 mg phentermine and 92 mg topiramate
1829797|NCT00796380|Drug|Xingnaojing|injection
1829798|NCT00796393|Dietary Supplement|Lactobacillus helveticus R0052, Bifidobacterium bifidum R0071, Bifidobacterium infantis R0033|1 pill per day for 12 weeks
1829799|NCT00796393|Dietary Supplement|Starch of potato|1 pill per day for 12 weeks
1829800|NCT00796419|Drug|5% human albumin|Intravenous administration of 250 milliliters (mL) 5% human albumin every 8 hours for 5 days
1829801|NCT00796419|Drug|6% hetastarch|Intravenous administration of 250mL 6% hetastarch every 8 hours for 5 days
1829802|NCT00796432|Drug|OROS paliperidone|
1994031|NCT03084003|Dietary Supplement|Almonds|
1829805|NCT00796458|Drug|docetaxel|Given IV
1829806|NCT00796458|Drug|releasing hormone agonist therapy|Patients receive luteinizing hormone-releasing hormone analogue therapy until disease progression.
1829807|NCT00796471|Drug|Paliperidone ER|
1829808|NCT00796484|Drug|XL888|Administered orally
1829809|NCT00796497|Drug|ondansetron|ondansetron hydrochloride (oral solution) dosage of 0.25 mg twice a day for 6 weeks followed by 0,5 mg twice a day for 6 weeks for a total observation period of 12 weeks.
1829810|NCT00796510|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily
1829811|NCT00796510|Drug|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
1829812|NCT00796523|Behavioral|Happiest Baby videotape|a videotape demonstrating the Happiest Baby on the Block technique for calming crying infants
1829813|NCT00796523|Behavioral|control videotape|a videotape with general newborn care instructions
1829814|NCT00796536|Behavioral|Group cognitive behavioral therapy|Each CBT session will last for 90 minutes and will teach participants specific skills to better cope with chronic pain. These skills will include breathing exercises, distraction, and relaxation techniques.
1829815|NCT00796536|Behavioral|Pain education|Patients will receive mailed educational materials to their homes on a weekly basis. Weekly materials will contain information about the nature of chronic back pain, treatment options, exercises and stretching techniques for maintaining strength and flexibility, and proper protection for a healthy back. Pain education is the standard of care for most outpatient clinics.
1829816|NCT00796549|Drug|BiBW 2992|BIBW 2992 in EGFR FISH positive NSCLC patients
1829817|NCT00796562|Drug|Busulfan|Patient will receive Busulfan injections, 4 times a day for 4 days with dilantin prophylaxis(in patients 10 years of age or older). Busulfan levels in the blood will be measured and dose adjusted, if needed.
1829818|NCT00796562|Drug|Cyclophosphamide|Patient will then receive Cy by IV once a day for 2 days.
1829819|NCT00796562|Radiation|Total body irradiation|Patients will receive TBI once a day for 4 days.
1829820|NCT00796575|Drug|CS-8080|CS-8080 1mg tablets, 3 tablets administered 1 times per day
1829821|NCT00796575|Drug|placebo tablets|placebo tablets matching active
1829822|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 2 tablets administered 1 times per day
1829823|NCT00796575|Drug|CS-8080|CS-8080 5 mg tablets, 4 tablets administered 1 times per day
1829824|NCT00796588|Other|remote preconditioning|Three periods of 10 minute occlusion of blood supply to leg using a pneumatic tourniquet
1829825|NCT00796601|Drug|Esreboxetine|Film coated tablets (2, 6, 8, 10 mg esreboxetine), once daily for 6 months
1829826|NCT00796601|Drug|Placebo|Film coated tablets (0 mg esreboxetine), once daily for 6 months
1829827|NCT00796614|Drug|tamsulosin hydrochloride|Oral
1829828|NCT00796614|Drug|Placebo|Oral
1829829|NCT00796627|Genetic|Healthy volunteers|Comparison of healthy volunteers to burn wounded volunteers
1829830|NCT00796627|Other|Burn volunteers|Comparison of burn wounded volunteers to healthy volunteers
1829831|NCT00796640|Drug|ER Paliperidone|
1829832|NCT00796653|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
1829833|NCT00796653|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on efficacy and safety in COPD patients
1829834|NCT00796653|Drug|Formoterol|Active comparator with Olodaterol (BI 1744) on safety and efficacy in COPD patients
1829835|NCT00796653|Drug|Placebo|Placebo devices for comparison with Olodaterol (BI 1744) on safety and efficacy in COPD patients
1829836|NCT00796666|Drug|Sitaxsentan|Sitaxsentan = 100 mg tablet administered orally, once daily Sildenafil placebo = 1 tablet administered orally, three times a day
1829837|NCT00796666|Drug|Sitaxsentan and Sildenafil|Sitaxsentan = 100 mg tablet administered orally, once daily plus Sildenafil = 20 mg tablet administered orally, three times a day
1829838|NCT00796679|Drug|paricalcitol|oral paricalcitol capsule 1 microgram once daily if iPTH <500pg/mL or 2 microgram once daily if iPTH >=500pg/mL. Thereafter, dose titration in 1 microgram decrement will be done based on safety reasons (that is, for low PTH or high calcium and phosphorus level). The duration of treatment will be for 1 year.
1829930|NCT00797368|Other|Home exercises|Home exercises
1830452|NCT00811993|Drug|erlotinib [Tarceva]|as prescribed
1994032|NCT03084003|Dietary Supplement|Graham crackers|
1829840|NCT00796692|Drug|Unfractionated heparin(UFH)|UFH is received with an initial bolus dose of 80 IU per kilogram, followed by a continuous intravenous infusion at an initial rate of 18 IU per kilogram per hour. The dose is subsequently adjusted so that the activated partial thromboplastin time (APTT) would be 1.5 to 2.5 times the control value in normal subjects. The tests are performed 4 hours after the start of treatment, whenever a sub-therapeutic APTT had been measured after a dose adjustment, and otherwise daily.UFH will be used at least 5-7 days.
1829841|NCT00796705|Drug|Adalimumab|40 mg injection of adalimumab administered subcutaneously
1829842|NCT00796705|Drug|Adalimumab placebo|1.0 ml .9% saline placebo administered subcutaneously
1829843|NCT00796705|Drug|Etanercept|50 mg dimeric fusion protein administered subcutaneously
1829844|NCT00796718|Radiation|Standard radiotherapy|Administered as prescribed according to normal clinical practice.
1829845|NCT00796718|Drug|Capecitabine [Xeloda]|825 milligrams per meter square (mg/m^2) orally twice daily for 5 weeks.
1829846|NCT00796731|Drug|SAR3419|administered by intravenous infusion
1829847|NCT00796744|Drug|NorLeu3-A(1-7) in a gel formulation|Gel will be applied to the wound once daily for four weeks (treatment period). Gel will have either no active ingredient (placebo), 0.03% or 0.01% active ingredient.
1829848|NCT00796757|Drug|bevacizumab [Avastin]|10mg/kg iv infusion every 2 weeks
1829849|NCT00796757|Drug|interferon alfa-2a|3 MIU sc t.i.w.
1829850|NCT00796770|Biological|Dendritic Cell Vaccine|"Biological/Vaccine: Experimental: Dendritic Cell Vaccine Patients will receive 4 doses of the vaccine at weeks 0, 4, 8 and 12. The vaccine will be injected subcutaneously, in 3 separate injection sites in the upper and lower extremities.
At week 24, patients will have HAART treatment interrupted. The HAART treatment will be resumed at week 48 or earlier at any time point if one of the following occur:
two consecutive measurements of CD4+ T cell count below 350x10e6 cells/L and/or 25% of total lymphocytes within at least a 2 weeks
an opportunistic infection
a CDC class C-defining event (defined in appendix 2)
a serious non-AIDS defining event.
Patients will have follow-up visits on weeks: 22, 24, 25, 26, 27, 28, 32, 36, 40, 44, and 48."
1829851|NCT00796783|Drug|Cushing's syndrome confirmation|
1829852|NCT00796796|Drug|Temsirolimus|
1829853|NCT00796796|Radiation|Radiation therapy|
1829854|NCT00796822|Drug|Pentoxifylline|400 mg three times a day for 8 weeks
1829855|NCT00796822|Drug|Placebo|One pill three times a day for 8 weeks
1829856|NCT00796835|Drug|ER OROS Paliperidone|
1829857|NCT00796848|Device|Navigator Continuous Glucose Monitor|
1994435|NCT03004027|Other|Self help leaflet|Self help leaflet entitled 'Building confidence in social situations: A guide for people living with a visible skin differences'
1829859|NCT00796874|Other|active surveillance|Correlative Study
1829860|NCT00796874|Other|imaging biomarker analysis|Correlative Study
1829861|NCT00796874|Procedure|biopsy|Tissue Removal
1829862|NCT00796874|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Radiolical Medical Imaging
1829863|NCT00796874|Procedure|magnetic resonance imaging|Radiolical Medical Imaging
1829864|NCT00796874|Procedure|magnetic resonance spectroscopic imaging|Radiolical Medical Imaging
1829865|NCT00796887|Drug|Extended-Release Niacin|500mg tablet once daily
1829866|NCT00796887|Drug|Extended-Release Niacin|1000mg tablet once daily
1829867|NCT00796887|Drug|Placebo|Placebo tablet once daily
1829868|NCT00796900|Drug|Dantrolene|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
1829869|NCT00796900|Drug|Placebo|Patients who satisfy the inclusion/exclusion criteria of the study and who are enrolled in this study will be randomized with computer-generated grouping to either one of two groups. One group of subjects will be given dantrolene for the first episode of fever. The other group will be given placebo. Dantrolene is supplied in 70-ml vials containing 20 mg dantrolene. Dantrolene will be given in the following dose: 5 mg/kg BW given intravenously over 30 minutes. As placebo NaCl 0,9% will be used.
1829870|NCT00796913|Other|Stop medication|Stop medication Stop medication + se supplement
1829871|NCT00796926|Drug|Systane Ultra eyedrops|Four times a day
1829872|NCT00796926|Drug|Refresh eye drops|Four times a day
1829873|NCT00796939|Device|Green light mask|Participants will receive approximately 10,000 lux from green light-emitting diodes.
1829874|NCT00796939|Device|Red Light Mask|Participants will receive approximately 0.5 lux from white light-emitting diodes covered by a red gel.
1829875|NCT00796952|Behavioral|focused attention sessions|"Patient management by the attending Radiation oncologist as usual. Patients assigned to this condition received focused attention sessions during the total course of their CRT treatment from a Speech Language Pathologist, consisting of weekly phone calls to monitor their swallowing outcome during the radiotherapy period."
1829876|NCT00796952|Behavioral|Valchuff|"Standardised sham or placebo swallowing therapy comprised a buccal extension maneuver (valchuff) and appropriate dietary modification, under the direction of the study speech pathologist, twice daily each week for the duration of the patient's total course of CRT treatment."
1829877|NCT00796952|Behavioral|Pharyngocise|Standardized high intensity behavioral swallowing therapy (Pharyngocise) comprised a battery of direct isometric / isotonic exercises and appropriate dietary modification, under the direction of the study speech pathologist, twice daily for the duration of the patient's total course of their CRT treatment (up to a maximum of 6 weeks)
1829878|NCT00796965|Drug|AZD7268|Solution/Capsule, Oral, once daily
1829879|NCT00796965|Drug|Placebo|
1829880|NCT00796978|Biological|trastuzumab|Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
1829881|NCT00796978|Other|laboratory biomarker analysis|Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).
1830453|NCT00811993|Drug|etoposide|as prescribed
1829882|NCT00796978|Procedure|adjuvant therapy|Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.
1829883|NCT00796978|Procedure|quality-of-life assessment|Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.
1829884|NCT00796991|Drug|Ipilimumab|Solution, intravenous, 10mg/kg, every 3 weeks in the induction phase, up to 4 doses in the induction phase, 48 weeks
1829885|NCT00796991|Drug|Carboplatin|Solution, intravenous, Area Under the Concentration Time Curve=6, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
1829886|NCT00796991|Drug|Paclitaxel|Solution, intravenous, 175 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
1829887|NCT00796991|Drug|Dacarbazine|Solution, intravenous, 850 mg/m2, every 3 weeks in the induction phase, up to 8 doses in the induction phase, 48 weeks
1829888|NCT00797017|Drug|fentanyl|Infection, starting with 12mcg/h (flexible dose)
1829889|NCT00797017|Drug|fentanyl|(CRPS) Complex Regional Pain Syndrome, starting with 12mcg/h (flexible dose)
1829890|NCT00797017|Drug|fentanyl|Bone Fracture, starting with 12mcg/h (flexible dose)
1829891|NCT00797017|Drug|fentanyl|(FBSS) Failed Back Surgery Syndrome, starting with 12mcg/h (flexible dose)
1829892|NCT00797017|Drug|fentanyl|Other Deformity, starting with 12mcg/h (flexible dose)
1829893|NCT00797017|Drug|fentanyl|(LDK) Lumbar Degenerative Kyphosis, starting with 12mcg/h (flexible dose)
1829894|NCT00797017|Drug|fentanyl|Degenerative Spine Disorder, starting with 12mcg/h (flexible dose)
1829895|NCT00797030|Drug|cyclosporine and sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethylcellulose 0.5% (one drop 4 times per day) and topical cyclosporine 0.05% (one drop twice a day) during six months
1829896|NCT00797030|Drug|sodium carboximethycellulose|Ten HIV-positive patients with dry eye received sodium carboximethycellulose (1 drop 4 times per day) during six months
1829897|NCT00797056|Drug|G-CSF|G-CSF 5 mcg/kg/day SQ daily for 10 days
1829898|NCT00797056|Drug|Placebo|Saline SQ daily for 10 days
1829899|NCT00797056|Drug|Aspirin|Aspirin 75 mg/day for 14 days
1829900|NCT00797056|Drug|Clopidogrel|Clopidogrel 75mg/day daily for 14 days
1829901|NCT00797069|Other|standard nutritional product (medical food)|once during crossover
1829902|NCT00797069|Other|nutritional product for diabetes (medical food)|once during crossover
1829903|NCT00797069|Other|diabetes specific experimental nutritional product (medical food)|once during crossover
1829904|NCT00797082|Device|MRI|MRI = Myocardial Perfusion Stress
1829905|NCT00797082|Device|MPS|MPS = Myocardial Perfusion Scintigraphy
1829906|NCT00797108|Drug|sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour, single loading dose and switch to oral PF-03709270 - 1000 mg twice a day
1829907|NCT00797108|Drug|Sulopenem and PF-03709270|Sulopenem - 600 mg infused over 1 hour twice daily for a minimum of 2 days and switch to oral PF-03709270 - 1000 mg twice a day
1829908|NCT00797108|Drug|Ceftriaxone and amoxicillin/clavulanate|IV ceftriaxone (2g) infused over 30 minutes QD (once daily) for minimum of 2 days Step down oral amoxicillin/clavulanate potassium suspension (400 mg/5 ml) BID (every 12 hours)
1829909|NCT00797121|Procedure|Preoperative biliary drainage|Percutaneous transhepatic biliary drainage(PTBD) is performed under the guidance of ultrasound. The duration may be around four weeks to make the total bilirubin of patients lower than 85μmol/L.
1829911|NCT00797186|Other|Intensive risk factor management|Aggressive medical and lifestyle therapy.
1829912|NCT00797212|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with blood taken from the palm and forearm. These blood glucose AST results are compared with results obtained by healthcare professionals (HCPs) from subject fingersticks.
1829913|NCT00797225|Drug|NBI-56418 sodium|NBI-56418 sodium, 150 mg or 250 mg
1829914|NCT00797225|Drug|Leuprorelin|Leuprorelin 3.75 mg
1829915|NCT00797225|Drug|placebo|Placebo tablet, placebo injection
1829916|NCT00797251|Procedure|Anatomical right posterior sectionectomy of the liver by IOUS-guided finger compression.|The technique consists in IOUS-guided finger compression of the right posterior portal pedicle at the level closest to the tumor but oncologically suitable. This method allows us to anatomically mark the area of resection with nor hilar plate nor IOUS-guided puncture of vessels, which are up to date the only two techniques available to perform anatomical right posterior sectionectomy - namely the removal of segment 6 and 7.
1829917|NCT00797264|Drug|Ketamine-Morphine|Ketamine bolus preoperative and syringe pump peroperative, and morphine postoperative (PCA)
1829918|NCT00797264|Drug|Morphine|Bolus preoperative of NaCl and syringe pump peroperative of NaCl, and morphine postoperative (PCA)
1829919|NCT00797264|Drug|Postoperative PCA of Ketamine and morphine|Bolus preoperative of NaCl and syringe pump peroperative of Ketamine, and morphine postoperative (PCA)
1829920|NCT00797277|Drug|IM olanzapine|10mg olanzapine IM
1829921|NCT00797277|Drug|IM haloperidol plus lorazepam|IM 5 mg haloperidol plus IM 2 mg lorazepam
1829922|NCT00797303|Drug|Bevacizumab|subconjunctival injection of 1.25 mg bevacizumab and had a follow-up of at least 2 months
1829923|NCT00797316|Drug|Aliskiren|Aliskiren 150 mg or 300 mg taken once daily in oral form
1829924|NCT00797316|Drug|Hydrochlorothiazide|Hydrochlorothiazide 12.5 mg or 25 mg taken once daily in oral form.
1829925|NCT00797329|Other|chart review|"cholesterol
cognitive profiles
violent behavior"
1829926|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the first cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
1829927|NCT00797342|Drug|PF-04629991|Oral; Sequential single dose escalation; three fourteen-day treatment periods per subject in the second cohort; randomized sequence of treatments (one placebo and two PF-04629991 doses)
1829928|NCT00797342|Drug|PF-04629991|Oral; sequential single dose escalation; three fourteen-day treatment periods per subject in the third cohort; randomized assignment to treatment (placebo or PF-04629991)
1829929|NCT00797368|Other|Manual Therapy and Exercise|Manual Therapy and Exercise
1829931|NCT00797394|Dietary Supplement|Combination of 2007RD01 and saw palmetto lipidic extract|Oral administration of one capsule containing a combination of 250 mg of 2007RD01 (a natural extract) and 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
1829932|NCT00797394|Dietary Supplement|Saw palmetto lipidic extract|Oral administration of one capsule of 160 mg of saw palmetto lipidic extract plus inactive fillers, twice a day between meals
1829933|NCT00797407|Dietary Supplement|Creatine|Creatine 5 gm orally twice a day for 5 days, followed by 5 gm once a day
1829934|NCT00797420|Drug|Fluconazole Loading Dose|Single Fluconazole loading dose 25 mg/kg
1829935|NCT00797420|Drug|Fluconazole Loading Dose & High Dose|Fluconazole loading dose 25 mg/kg, followed by fluconazole 12 mg/kg q24 hours for total of 5 days
1829936|NCT00797459|Device|Restylane and Restylane-L|This is a split face design and each subject received both Restylane and Restylane-L. Treatments were double blind, randomized, and successive.
1829937|NCT00797472|Drug|R-mabHD|An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
1829938|NCT00797472|Drug|ABVD|A combination of Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) will be given intravenously over a period of 3 hours every other week for 12 treatments.
1829939|NCT00797485|Biological|bevacizumab|Given IV
1829940|NCT00797485|Drug|capecitabine|Given orally
1829941|NCT00797485|Drug|fluorouracil|Given IV
1829942|NCT00797485|Drug|irinotecan hydrochloride|Given IV
1829943|NCT00797485|Drug|leucovorin calcium|Given IV
1829944|NCT00797498|Other|Xerostomia questionnaire|All of the tests, procedures and treatments may be considered standard of care for someone with this type of cancer, except for the Xerostomia Questionnaire.
1829945|NCT00797511|Biological|TdcP-IPV vaccine|0.5 mL, Intramuscular
1829946|NCT00797537|Procedure|Echography|Echography
1829947|NCT00797550|Biological|Bone Repair Cells (BRCs)|BRCs will be administered during spine fusion surgery
1829948|NCT00797550|Procedure|Autologous bone graft|
1829949|NCT00797563|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes use a new blood glucose monitoring system with capillary blood; healthcare professionals use the new blood glucose monitoring system with subject capillary and venous blood. All results are compared to a laboratory glucose method - Yellow Springs Instrument (YSI).
1829950|NCT00799136|Drug|R-EPOCH and cART|This is a prospective, single-arm, multi-centre, phase II trial of immuno-chemotherapy (rituximab and EPOCH) with mandatory combination antiretroviral therapy for initial treatment of AIDS-related lymphoma.
1829951|NCT00799149|Drug|Gabapentin, Etoricoxib, Sugar pill|Control (Sugar pill) or gabapentin (1200 mg) or etoricoxib (120 mg) administered 30-90 min before the patient entered the operating room with a sip of water. Subsequent doses of the oral study drugs were administered on the mornings (08H00) of the first, second, and third postoperative days. .
1829952|NCT00799162|Other|Psychophysical testing, questionnaires, and genetics|pre-operative psychophysical testing of endogenous pain modulation, pre-operative questionnaires, peri- and post-operative data collection, long term follow-up assessing chronic pain, SNP association analysis, and whole genome scanning association studies
1829953|NCT00799175|Drug|ropivacaine, ketorolac and epinephrine|In Group A, 400 mg ropivicaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation in the following way: Before inserting the components, 20-30 ml are injected into the posterior capsule and before closure of the wound the rest is injected into the capsule incision, the synovium, the ligament and the subcutaneous tissue. After 21 postoperative hours in Group A, 200 mg ropivicaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
1829954|NCT00799175|Drug|saline|In Group P (placebo) no injections were given intraoperatively. All patients had a tunnelled intra-articular multihole 20-G catheter placed at the end of the operation by the surgeon.After 21 postoperative hours 22 ml of saline was injected intraarticularly via the catheter.
1829955|NCT00799188|Drug|Everolimus|50% reduction of calcineurin inhibitors daily dose followed by further decrease or withdrawal. Everolimus will be introduced and tapered to a trough level of 6 to 10 microg/l.
1829956|NCT00799201|Drug|Naloxone and Docusate|Naloxone 6mg (15 mL) every 6 hours plus docusate sodium liquid 10 mL (100mg) every 12 hours
1829957|NCT00799214|Drug|Placebo|1 gram emollient cream to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
1829958|NCT00799214|Drug|Boric acid|Boric acid = 600 mg boric acid compounded in emollient cream (1 gram total) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
1829959|NCT00799214|Drug|Metronidazole|Metronidazole = 10 % intravaginal cream (Sanofi-Aventis Canada Inc Product DIN 01926861) (for a total of 37.5 mg metronidazole) to be inserted intravaginally qhs (once before bed) for 10 days or less if intolerable side effects occur.
1829960|NCT00799227|Drug|Dexamethasone|700 µg Dexamethasone Posterior Segment Drug Delivery System Applicator System at Day 1 in the study eye.
1829961|NCT00799240|Drug|Arm A: Pemetrexed Cisplatin|Pemetrexed: 500mg/m2 IV on day 1 and Cisplatin: 75 mg/m2 IV on day 1 every 21 days x 6 cycles.
1829962|NCT00799240|Drug|Arm B Pemetrexed, Cisplatin and MK-0646|Pemetrexed 500 mg/m2 IV on Day 1 and Cisplatin 75 mg/m2 IV on Day 1 every 21 days for 6 cycles in combination with MK-0646 will be given IV, 10 mg/KG, Days 1, 8 and 15 weekly.
1829965|NCT00799279|Behavioral|Smoking cessation training, support, and telephone follow-up|The CF group will receive the same smoking cessation training and practice support tools delivered to the PS group. In addition, patients in the FC group who are smokers and are willing to set a quit date within the next 30 days and who have set a quit date will be enrolled in an interactive voice response (IVR)-mediated telephone follow-up and counselling system. The IVR system will automatically contact patients via telephone 7 days before their TQD, and 5, 14, 30, and 60 days after their TQD to check the patients' smoking status, potential concerns, and their risk of relapse.
1829966|NCT00799279|Behavioral|smoking cessation intervention|Intervention practices will be provided with training in smoking cessation, and will be supported with integrating a waiting room screener for smoking and smoking consult form and patient quit plan into their practice routines.
1829968|NCT00799292|Other|No injection|Patients did not receive an injection of medication at cervix prior to beginning of procedure
1829969|NCT00799331|Drug|AZD5985|Oral suspension. Single oral doses of AZD5985 starting with 4 mg and subsequently with up to 3 dose escalations will be administered not exceeding AstraZeneca pre-defined upper exposure limits.
1829970|NCT00799331|Drug|placebo|Oral suspension.
1829971|NCT00799344|Device|Catania Stent|coronary stent implantation
1829972|NCT00799370|Procedure|Early weight bearing|Weight bearing performed immediately after surgery
1829973|NCT00799370|Procedure|Delayed weight bearing|Weight bearing performed 2 months after surgery
1829975|NCT00799396|Drug|Clopidogrel|300 mg on first day, then 75 mg per day for the next 6 days
1829976|NCT00799396|Drug|Aspirin|Single dose of 324 mg on the last day of clopidogrel treatment
1829977|NCT00799409|Drug|Placebo/ CONCERTA (methylphenidate HCl)|Placebo once daily on Lab School Day #1 and Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #2
1829978|NCT00799409|Drug|CONCERTA (methylphenidate HCl) / Placebo|Optimal Subject Dose (18 mg-54 mg) once daily during Lab School Day #1 and Placebo once daily on Lab School Day #2
1829979|NCT00799422|Device|Complete Easy Rub|Commercially marketed contact lens solution for contact lens care
1829980|NCT00799422|Device|ReNu MultiPlus|Commercially marketed contact lens solution for contact lens care
1829981|NCT00799422|Device|Clear Care|Commercially marketed contact lens solution for contact lens care
1829982|NCT00799422|Device|Contact lenses|Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
1829983|NCT00799435|Drug|Exenatide|5 μg of exenatide subcutaneously twice a day for 4 weeks, followed by 10 μg of exenatide subcutaneously twice a day for an additional 8 weeks
1829984|NCT00799448|Drug|repaglinide|
1829985|NCT00799448|Drug|biphasic human insulin 30|
1829986|NCT00799448|Drug|insulin NPH|
1829987|NCT00799461|Other|internet-based intervention|Delayed access to online educational information and resources for managing long term complications of hematopoietic cell transplantation
1829988|NCT00799461|Other|questionnaire administration|Completion of questions in an online format
1829989|NCT00799461|Procedure|psychosocial assessment and care|Assessment and care of psychosocial aspects
1829990|NCT00799461|Procedure|assessment of therapy complications|Evaluation of complications of treatment
1829991|NCT00799461|Procedure|management of therapy complications|Managing therapy complications
1829992|NCT00799461|Procedure|fatigue assessment and management|Assessing and managing fatigue
1829993|NCT00799461|Other|counseling intervention|Counseling provided via telephone
1829994|NCT00799487|Drug|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #1 with placebo on Day #2
1829995|NCT00799487|Drug|CONCERTA (methylphenidate HCl) or placebo|Optimal Subject Dose (18mg-54mg) once daily during Lab School Day #2 with placebo on Day #1
1829996|NCT00799500|Other|Screening|Weekly vaginal pH
1829997|NCT00799513|Drug|Lenalidomide|single-agent lenalidomide 25 mg once daily for 21 days out of 28, as maintenance treatment after the end of second-line chemotherapy until progression of disease.
1829998|NCT00799526|Procedure|Autologous Ex Vivo Conjunctival for Symblepharon Transplantation|Safety and efficacy of conjunctival ex vivo for reconstruction of the ocular surface.
1829999|NCT00799526|Procedure|Ex Vivo Conjunctival for Symblepharon Transplantation|The safety and efficacy of human conjunctival epithelial autologous cultivated ex vivo for reconstruction of the ocular surface with symblepharon.
1830000|NCT00799539|Drug|bortezomib|From cycles 1-4, 1.3mg/m^2 on days 1,4,8,11,22,25,29,and 32 of each 6-week cycle
1830001|NCT00799539|Drug|bortezomib|From cycles 5-9, 1.3mg/m^2 on days 1, 8, 22, and 29 of each 6-week cycle
1830002|NCT00799539|Drug|melphalan|9 mg/m^2 once daily on days 1-4 of each 6-week cycle
1830003|NCT00799539|Drug|prednisone|60 mg/m^2 once daily on days 1-4 of each 6-week cycle
1830004|NCT00799552|Drug|RX-10045|RX-10045 eye drop
1830005|NCT00799552|Drug|Placebo|Placebo eye drop
1830006|NCT00799565|Genetic|catch of blood|"4 tubes of blood are taken on subjects. Samples are sent in Pr Jeunemaître to extract DNA and stock it.
This DNA bank aims to search for susceptibility genes in MVP using a genome wide analysis and comparing results obtained in 1000 patients with MVP and 1000 non-MVP subjects"
1830007|NCT00799578|Drug|Cysteamine|Drug is in enteric-coated capsule form. The dosage will begin at 1g/m-squared body surface area with a maximum dose of 1000mg twice daily. Treatment period is 3-6 months.
1830008|NCT00799591|Other|Observational study so no intervention in the patient.|Observational study so no intervention in the patient.
1830009|NCT00799604|Drug|clevidipine|Clevidipine (0.5mg/mL in 20% lipid emulsion) was administered as an IV bolus (<5 sec) by rapid injection for Bolus 1 and for Bolus 2, if second bolus dose was administered, directly into a peripheral venous catheter followed by a normal saline flush (10mL).
1958806|NCT01226316|Drug|AZD5363|Patients will be given AZD5363 administered orally as a single dose, followed by a 3-7 day wash-out period. Patients will then receive AZD5363 twice daily on 6 or fewer days per weekly regimen, to cessation of therapy. Parts C,D: Oral AZD5363 twice daily, 4 days on treatment, 3 days off treatment, to cessation of therapy.
1830012|NCT00799630|Dietary Supplement|Carbohydrate drink|Maltodextrins, dextrose, fructose, amino acids (leucine, isoleucine, valine), natural flavors, sodium chloride, magnesium citrate, zinc, lactate, acid: malic acid, anti-caking agent: silicon dioxide; Curcumin (turmeric extract) , Thickener: xanthan gum, caffeine, vitamin C (Acerola extract), vitamin E - B1 - B2 - B3; piperine (black pepper extract).
1830013|NCT00799643|Drug|Salsalate|Salsalate 3.5 g/d orally, divided dosing
1830014|NCT00799643|Drug|Salsalate Placebo|
1830015|NCT00799656|Drug|ataciguat (HMR1766)|oral administration 200mg once daily for 28 days
1830016|NCT00799656|Drug|placebo|oral administration once daily for 28 days
1830017|NCT00799669|Behavioral|smoking cessation intervention|Standard quit-smoking counseling to help decrease their risk of cancer.
1830018|NCT00799669|Other|counseling intervention|Counseling focusing on decreasing risk of getting cancer by decreasing smoking and alcohol use.
1830019|NCT00799669|Other|preventive intervention|
1830020|NCT00799669|Other|questionnaire administration|
1830021|NCT00799682|Drug|Xalatan|0.005% 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
1830022|NCT00799682|Drug|Travatan Z|0.004%, 1 drop in each eye daily between 7:00 p.m. and 9:00 p.m.
1830023|NCT00799695|Behavioral|phone call contact|A sample of subjects who had not completed their annual diabetic screening exams were contacted by phone and offered appointments for eye exams
1830024|NCT00799708|Drug|Comparator: placebo|placebo capsule once daily for 7 days.
1830025|NCT00799708|Drug|Comparator: Estrace|Estrace 0.5 mg or 2 mg tablets once daily for 7 days.
1830026|NCT00799734|Drug|EXD|Interventions: Intake of prepacked Chinese herbal medicine therapy (EXD), one sachet of granules (15g extracted granules) twice a day and placebo therapy of 15g granules with similar colour and taste.
1830027|NCT00799747|Drug|AZD4017|ascending single doses (start dose 2 mg), oral suspension
1830028|NCT00799747|Drug|Placebo|placebo
1830029|NCT00799760|Drug|oseltamivir + zanamivir|oral oseltamivir 75mg twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 days
1830030|NCT00799760|Drug|oseltamivir + zanamivir's placebo|oral oseltamivir 75mg twice daily+ placebo inhaled by mouth twice daily during 5 day
1830031|NCT00799760|Drug|oseltamivir's placebo + zanamivir|oral placebo twice daily + zanamivir 10 mg inhaled by mouth twice daily during 5 day
1830032|NCT00799773|Drug|Rituximab|Dose of 375 mg/m2, given intravenously, repeated at 1-week intervals for a total of four doses
1830033|NCT00799773|Procedure|Plasma exchange|Target volume of 1.25 plasma volume replacement; fresh frozen plasma (FFP) is the required replacement fluid; provided daily until platelet counts are normal and signs of tissue damage have improved.
1830034|NCT00799773|Drug|Corticosteroids|1 mg/kg of prednisone (or equivalent) each day until plasma exchange is stopped
1830035|NCT00799786|Behavioral|Building Better Caregivers Online Workshop|
1830036|NCT00799799|Biological|NK cells|NK cells infusion after immunosuppressive chemotherapy
1830037|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v, swabstick (3 @ once).|3 swabsticks topically applied at the same time to intact skin
1830038|NCT00799812|Drug|CHG 2% w/v & IPA 70% v/v swab applied sequentially|Chlorhexidine gluconate 2% w/v and isopropyl alcohol 70% v/v; 3 swabsticks applied sequentially to intact skin.
1830039|NCT00799812|Drug|Aqueous CHG 4% w/v applied according to mfr's directions|Chlorhexidine gluconate 4% w/v in an aqueous base applied according to mfr's directions. Step 1) 5 ml of Hibiclens applied to a sterile gauze pad. Step 2) Product applied to treatment area on intact skin for 2 minutes. Area dried with sterile towel or sterile gauze. Steps 1 and 2 repeated.
1830040|NCT00799812|Other|Sterile swabstick with sterile water (3 @ once)|3 sterile swabsticks wetted with sterile water topically applied to intact skin at the same time.
1830041|NCT00799812|Other|Sterile swabstick with sterile water (one-at-a-time)|Sterile swabsticks wetted with sterile water topically applied to intact skin one-at-a-time.
1830042|NCT00799825|Biological|GSK Biological's HPV vaccine GSK580299 (Cervarix™)|All subjects will receive a 0.5 ml dose administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
1830043|NCT00799838|Drug|Ketoprofen|"Formulation: oral solution 20mg/mL
Route of administration: oral
Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
1830044|NCT00799838|Drug|Placebo (for Ketoprofen)|"Formulation: oral solution
Route of administration: oral
Dose regimen: 1 drop/Kg for children aged between 4 to 6 years old or 25 drops for children from 7 to 11 years old administered t.i.d"
1830045|NCT00799838|Drug|Amoxicillin|"Formulation: suspension 125mg/5 mL
Route of administration: oral
Dose regimen: 20-40mg/Kg/day administered t.i.d"
1830046|NCT00799851|Device|Variceal band ligation|
1830047|NCT00799851|Drug|cyanoacrylate injection|cyanoacrylate injection
1958807|NCT01226316|Drug|AZD5363|Optional additional schedule. Patients will be given AZD5363 administered orally. Regimen to be determined in response to emerging clinical findings.
1958808|NCT01226316|Drug|AZD5363|Patients will receive oral AZD5363 twice daily (4 days on 3 days off treatment)combined with background therapy of fulvestrant at licensed dose of 500mg intramuscularly on days 1,15,29 and once monthly thereafter.
1830054|NCT00799890|Drug|Sunphenon EGCG|200-800mg (1-4 capsules)
1830055|NCT00799890|Drug|Placebo|1-4 capsules
1830056|NCT00799903|Drug|Darapladib|Lp-PLA2 inhibitor administered in addition to standard therapy
1830057|NCT00799903|Drug|Placebo|Placebo administered in addition to standard therapy
1830058|NCT00799916|Drug|Resuscitation (Voluven)|Resuscitation aimed at venous oxygen saturation higher than 70%
1830059|NCT00799916|Drug|Resuscitation (Saline)|Resuscitation aimed at venous oxygen saturation higher than 70%
1830060|NCT00799929|Other|in vitro fertilization (IVF/ICSI)|
1830061|NCT00799942|Drug|Neramexane mesylate|open-label treatment of 36 months Neramexane mesylate up to 75 mg per day
1830062|NCT00799955|Procedure|Placebo block|100 micrograms of spinal morphine
1830063|NCT00799955|Procedure|Ultrasound-guided TAP block|1.5mg/kg of 0. 5% ropivacaine (to maximum dose of 20 mls = 100mg on each side) will be injected into the transversus abdominis plane, on each side
1830064|NCT00799968|Drug|Urokinase|UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours
1830065|NCT00799968|Drug|Urokinase|UK,20 000U/kg continuously intravenous infusion for 2 hours
1830454|NCT00811993|Drug|gemcitabine|as prescribed
1830066|NCT00800007|Drug|ANZ-521|3x10^7 cfu or 3x10^8 cfu ANZ-521 in 250 mL, IV over 2 hours, every 28 days for up to 3 doses.
1830067|NCT00800007|Drug|Placebo|250 mL normal saline, IV over 2 hours, every 28 days for up to 3 doses.
1830068|NCT00800033|Behavioral|Aerobic exercise training|Walking, jogging, rowing, cycling to be done 5 times per week for 45 minutes per session (3 supervised sessions, 2 sessions at home) for 5 months
1830069|NCT00800033|Dietary Supplement|pulse based diet|Two pulse-based meals per day (lentils, beans, chickpeas, or peas) for 2 months, followed by 1-month washout and then a normal diet for 2 months (order of diets is randomized)
1830070|NCT00800046|Device|AccuCinch® Ventriculoplasty System|Mitral valve repair due to functional disease
1830071|NCT00800059|Radiation|Total Marrow Irradiation|Total Marrow Irradiation delivered by chemotherapy delivered to cohorts of patients in a dose escalation. The initial cohort will receive 14 Gy. If tolerated subsequent cohorts will receive an additional 2 Gy until the maximum tolerated dose or 28 Gy is reached.
1830072|NCT00800072|Device|NOWOX|one experimental device assigned to each of the 10 patients including in the study for an experiemental session duration of 6 hours
1830073|NCT00800085|Drug|glucose 20%|maintain glycemia at 180 mg/dL till 150 min. after start glucose infusion: with a maintenance dose computed at 5- to 10-minute intervals
1830074|NCT00800098|Drug|herbal topical cream|
1830075|NCT00800111|Procedure|endothelial keratoplasty|Endothelial keratoplasty is surgical replacement of the corneal endothelial cell layer (the cell layer lining the inner surface of the cornea).
1830076|NCT00800124|Procedure|cemented Landos prosthesis vs. uncemented Landos prosthesis|randomization between the cemented and non-cemented prosthesis.
1830077|NCT00800137|Drug|low molecular weight heparin or unfractionated heparin|"For elective patients with greater than 5 days pre-implant; discontinue oral anti-coagulation (coumadin) 5 days before the procedure. Full therapeutic doses of subcutaneous LMWH 3 days before the procedure.
Patients with less than 5 days to implant can be given vitamin K (up to 2 mg) at the investigator discretion and start full therapeutic doses of either subcutaneous LMWH or IV Unfractionated Heparin (choice is at investigator's discretion) when INR is below the upper limit of the prescribed therapeutic range for the patient (usually greater than or equal to 2; 2.5 for some valve patients) and surgery to proceed when INR is less than 1.6.
Last dose given in the morning(ie. > 24 hours)of the day prior to the procedure.
Oral anti-coagulation (coumadin) will be resumed on the evening of the procedure.
Full dose LMWH or full dose IV heparin will be restarted 24 hours after surgery."
1830078|NCT00800137|Drug|Warfarin or coumadin|Continue on oral anti-coagulant (coumadin). INR on the day of surgery will be < 3.0
1830079|NCT00800150|Drug|fludarabine phosphate|
1830080|NCT00800150|Drug|melphalan|
1830081|NCT00800150|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1830082|NCT00800150|Radiation|intensity-modulated radiation therapy|
1830083|NCT00800150|Radiation|tomotherapy|
1830084|NCT00800150|Radiation|total marrow irradiation|
1830085|NCT00800150|Radiation|total nodal irradiation|
1830086|NCT00800163|Other|ED Activation/Immediate Transfer|ED Physician Activation and Immediate Transfer Protocol - see Circulation. 2007;116:67-76
1830087|NCT00800176|Drug|Placebo|po daily for 12 weeks
1830088|NCT00800176|Drug|RO4998452|2.5mg po daily for 12 weeks
1830089|NCT00800176|Drug|RO4998452|5mg po daily for 12 weeks
1830090|NCT00800176|Drug|RO4998452|10mg po daily for 12 weeks
1830091|NCT00800176|Drug|RO4998452|20mg po daily for 12 weeks
1830092|NCT00800176|Drug|RO4998452|40mg po daily for 12 weeks
1830093|NCT00800189|Radiation|Anterior electronic portal images (EPI)|EPI's are taken for the first three consecutive days of treatment to detect set-up errors.
1830094|NCT00800202|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
1830095|NCT00800202|Drug|carboplatin|AUC6 iv every 3 weeks for 6 cycles
1830096|NCT00800202|Drug|erlotinib [Tarceva]|150mg/day po
1830097|NCT00800202|Drug|paclitaxel|200mg/m2 iv every 3 weeks for 6 cycles
1830098|NCT00800215|Drug|iv SPM 927 and oral placebo tablet|60-minute infusion iv SPM 927 and oral placebo tablet
1830099|NCT00800215|Drug|oral SPM 927 tablet and iv placebo|60-minute infusion placebo and oral SPM 927 tablet
1830100|NCT00800215|Drug|iv SPM 927 and oral placebo tablet|30-minute infusion iv SPM 927 and oral placebo tablet
1830101|NCT00800215|Drug|oral SPM 927 tablet and iv placebo|30-minute infusion placebo and oral SPM 927 tablet
1830102|NCT00800254|Device|Neuromuscular Electrical Stimulation (NMES)|NMES 20 minutes twice a day for 6 weeks plus standard physical therapy
1830103|NCT00800254|Other|Standard Rehabilitation Protocol|Standard physical therapy for 8 weeks after surgery
1830104|NCT00800267|Drug|latanoprost 0.005%|placebo in the morning and latanoprost .005% in the evening
1830105|NCT00800267|Drug|fixed combination latanoprost-timolol|one drop in the morning and placebo in the evening
1830106|NCT00800267|Drug|timolol 0.5%|one drop in the morning and evening
1830107|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally
1830108|NCT00800280|Drug|PD 0332334|Single 300 mg dose of PD 0332334 immediate release capsules administered orally on Day 2.
1830109|NCT00800280|Drug|cimetidine|600 mg q 6 hours cimetidine immediate release formulation administered orally on Days 1 through 5.
1830110|NCT00800293|Drug|Betamethasone Dipropionate 0.05% Cream|Small amount applied and evaluated over the course of several hours
1830111|NCT00800306|Drug|Levosimendan|Intravenous administration of Levosimendan 0,2 µg•kg-1•min-1 for 24 hrs followed by the addition of 35 ppm of inhaled nitric oxide
1830112|NCT00800306|Drug|dobutamine|Intravenous administration of dobutamine 5 µg•kg-1•min-1 for 36 hrs. At the end of the first 24 hrs drug infusion, inhaled nitric oxide at the concentration of 35 ppm will be added for further 12 hrs.
1830113|NCT00800319|Drug|RDC-0313|Oral solution given in 5, 15, 25, 50, and 75 mg single doses
1830114|NCT00800319|Drug|Placebo|Volume matched placebo; oral solution; single dose
1830115|NCT00800332|Drug|CYT003-QbG10|subcutaneous injection
1830116|NCT00800332|Drug|Placebo|subcutaneous injection
1830117|NCT00800345|Drug|Oral Topotecan|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of topotecan administered by mouth.
1830118|NCT00800345|Drug|Pazopanib|Starting on Cycle 1 Day 1, each subject will receive the assigned dose of pazopanib administered by mouth.
1830119|NCT00800358|Drug|Paricalitol|oral paricalcitol variable daily dosing based on intact PTH level for 6 months
1830120|NCT00800358|Drug|Calcitriol|oral calcitriol variable daily dosing based on intact PTH level for 6 months
1830121|NCT00800371|Procedure|intra-articular steroid injection|Steroid injection into otherwise noncontrollable arthritis.
1830122|NCT00800384|Device|Implantable defibrillator|Implantable defibrillator to detect and terminate ventricular arrhythmias
1830123|NCT00800410|Behavioral|Community Health Worker (CHW) services|CHW services included access to an 11 week healthy lifestyle education curriculum, two home visits per month, two additional phone contacts per month, and accompanied participants to one clinic visit within the six month intervention period
1830124|NCT00800423|Drug|Brimonidine Tartrate 0.2%|"Brimonidine Tartrate 0.2% drops
1 drop twice a day for 1 month in the operated eye"
1830125|NCT00800423|Drug|Timolol maleate 0.5%|"timolol maleate 0.5% drops
1 drop twice a day for 1 month in the operated eye"
1830126|NCT00800436|Drug|Herceptin|Herceptin will be administered IV or SC at various dosages (depending upon the cohort to which the participant is assigned) on Day 1.
1830127|NCT00800462|Drug|Oxybutynin Cl|15 mg qd for 3 months
1830128|NCT00800462|Drug|Trospium Cl|20mg bid for 3 months
1830129|NCT00800462|Drug|Darifenacin Hydrogen Bromide (HBr)|15 mg qd for 3 months
1830130|NCT00800475|Drug|Gemfibrozil Tablets|
1830131|NCT00800501|Drug|sNN0029|Continuous ICV infusion at one of three dose levels
1830132|NCT00800501|Drug|Placebo|Continuous ICV infusion
1830133|NCT00800514|Drug|amantadine|amantadine twice daily
1830134|NCT00800514|Drug|amantadine|amantadine 100 mg twice daily
1830135|NCT00800527|Drug|Gabapentin|Gabapentin 800 mg one a day up to 30 day
1830136|NCT00800527|Drug|Diclofenac|Diclofenac 75 mg one a day up to 30 day
1830137|NCT00800540|Drug|Brinzolamide 10 mg/ml/Timolol 5 mg/ml eye drops suspension|Fixed combination ophthalmic suspension
1830138|NCT00800540|Drug|Brimonidine 20 mg/ml/Timolol 5 mg/ml eye drops solution|Fixed combination ophthalmic solution
1830139|NCT00800553|Drug|donepezil|5mg o.m. p.o. for approx. 2 weeks
1830140|NCT00800553|Drug|Placebo|5mg of placebo for approx. 2 weeks
1830141|NCT00800566|Drug|Oral Clofarabine|The starting dose will be 1 mg orally daily x 21 days every 4 weeks +/- 4 days.
1830142|NCT00800579|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
1830143|NCT00800579|Drug|Placebo|Inhaled volume-matched placebo in sterile saline
1830144|NCT00800592|Drug|sildenafil|10 mg sildenafil bolus
1830145|NCT00800605|Biological|Vero cell-derived, trivalent, seasonal influenza vaccine|Single intramuscular injection
1830146|NCT00800605|Biological|Placebo: Phosphate-buffered saline|Single intramuscular injection
1830147|NCT00800618|Drug|PF-02413873 100 mg QD|100 mg of PF-02413873 oral suspension once daily for 14 days
1830148|NCT00800618|Drug|PF-02413873 1500 mg QD|1500 mg of PF-02413873 oral suspension once daily for 14 days
1830149|NCT00800618|Drug|PF-02413873 20 mg QD|20 mg of PF-02413873 oral suspension once daily for 14 days
1830150|NCT00800618|Drug|PF-02413873 500 mg QD|500 mg of PF-02413873 oral suspension once daily for 14 days
1830151|NCT00800618|Drug|PF-02413873 Placebo|PF-0241383 Placebo once daily for 14 days
1830152|NCT00800644|Procedure|CT or MRI + Blood Test|"During routine visits, a magnetic resonance imaging (MRI) scan or a computed tomography (CT) scan.
Blood (about 1 tablespoon) will be drawn to test for bone turnover."
1830153|NCT00800657|Procedure|Pacing and Stem Cells Implantations.|Implantation of Cardiac Ressyncrhonization combined with the implantation of Stem Cells Hematopoietics.
1830154|NCT00800657|Procedure|Pacing and Stem Cells Implantation|Pacing and Stem Cells Implantation.
1830155|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^8 pfu of recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
1830156|NCT00800670|Biological|Ad5Ag85A|Single intra-muscular administration of 10^9 recombinant-deficient human adenoviral TB vaccine (Ad5Ag85A)
1830157|NCT00800683|Drug|BI 1356|BI 1356 dosed once daily
1830158|NCT00800683|Drug|placebo|placebo matching BI 1356 taken once daily
1830159|NCT00800696|Procedure|oral care|The study group will have their teeth brushed three times a day by the nursing staff by using a suction connected toothbrush, daily examination of the oropharynx by the nursing staff, and use of chlorhexidine varnish or another suitable antibacterial agent in the oropharynx
1830160|NCT00800709|Drug|Memantine|Initially memantine 5mg/day, titrated within the first month to a maintenance dose of 20mg/day
1830161|NCT00800722|Drug|Rapamycin Treatment of Port Wine Stain|Treatment of Port Wine Stain
1830162|NCT00800735|Drug|Pegylated-interferon alfa-2a|Pegylated-interferon alfa-2a was administered subcutaneously once weekly.
1830163|NCT00800735|Drug|Ribavirin|Participants received ribavirin with food, as the bioavailability of ribavirin is increased when taken with food. Ribavirin was administered as split doses, that is, 2 doses were given 12 hours apart, 1 in the morning and 1 in the evening. Participants received either 1000 or 1200 mg ribavirin per day according to body weight: 400 mg (2 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing < 75 kg or 600 mg (3 tablets) in the morning and 600 mg (3 tablets) in the evening for participants weighing ≥ 75 kg.
1830164|NCT00800748|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a was administered at a dose of 180 mcg SC weekly for 48 weeks to participants with genotype 1, 4, 5, 6 and to participants with HIV co-infection, or for 24 weeks to participants with genotype 2 and 3.
1830165|NCT00800748|Drug|Ribavirin|Ribavirin was administered at a dose of 1000-1200 mg PO daily for 48 weeks to participants with genotype 1, 4, 5, 6 or 800 mg PO daily for 24 weeks to participants with genotype 2 and 3.
1830166|NCT00800761|Drug|Deferoxamine and Deferiprone|comparison of two arms: the first one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die plus deferiprone tablets 75 mg/kg three times/die versus the second one treated with deferoxamine subcutaneous vials,40 mg/kg,12 hours/die
1830167|NCT00800761|Drug|Deferoxamine|deferoxamine vials,40 mg/kg,12 hours/die
1830272|NCT00801463|Drug|tripterygium wilfordii (TW)|Pre 30mg/d +TW 120 mg/d, po for 12 weeks
1830455|NCT00811993|Drug|irinotecan|as prescribed
1830168|NCT00800774|Procedure|LASIK|Nine eyes of nine patients (3 male and 6 female) with high anisometropia (>3.50 D), were included in this study. Minimum follow-up was 10 years. All patients were treated with the Chiron Technolas 217 excimer laser.
1830169|NCT00800787|Biological|Nabi-HB|"Hepatitis b Immune Globulin (Human)(Nabi-HB) 312 IU/L per dose administered subcutaneously.
Dosage will be according to each patients body weight, as follow:
< 75 kg: 500 IU weekly ( may be increase to 1,000 IU weekly if anti-HBs levels are <150 IU/ML > 75 Kg: 1,000 IU weekly"
1830170|NCT00800800|Drug|Rosuvastatin|40 mg, oral, single dose
1830171|NCT00800800|Drug|Placebo|oral, single dose
1830172|NCT00800813|Behavioral|Penile Exam, Peyronie's Plaque and Erectile function assessment|"At the baseline visit, the patient's co-morbidities, height, weight with calculation of body mass index will be documented.
After surgery, the patient will be instructed to keep a diary to record erectile function including how often they use a PDE-5 inhibitor or injection therapy and each time they get an erection and the level of rigidity. The diary is required to document PDE-5 inhibitor and injection therapy use and response in each sexual encounter, unlike the IIEF questionnaire, which addresses erectile function over a 4-week period. Accurate documentation is essential for erectile function assessment, as patient choice of erectile function medication may differ in each sexual encounter, and accordingly, the achieved rigidity level."
1830173|NCT00800826|Drug|dexmedetomidine|
1830174|NCT00800839|Drug|Busulfan|Starting dose of 32 mg/m^2 by vein over 3 hours each day. Test dose day -8 (inpatient) or test dose day -30 to day -8 (outpatient) and then, days -6,-5,-4, and -3.
1830175|NCT00800839|Drug|Fludarabine|Dose of 40 mg/m^2 by vein over 1 hour each day on Day -6 through Day -3 before receiving Busulfan.
1830176|NCT00800839|Drug|Cyclophosphamide|Dose of 50 mg/kg by vein over 3 hours on Days 3 and 4.
1830177|NCT00800865|Other|Biomarker sample collection before and after dosing with cytotoxic agent(s)|Participants will have blood and urine samples collected at Visit 1. After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at baseline, and at 24 and 48 hours post dosing with cytotoxic agent(s).
1830178|NCT00800865|Other|Biomarker sample collection before and after dosing with cytotoxic agent(s)|A second group of participants will have blood and urine samples collected at Visit 1 (there is no baseline). After allocation, punch skin biopsies, plucked hair samples, blood, and urine will be collected at at 24, 32 and 48 hours post dosing with cytotoxic agent(s).
1830179|NCT00800917|Drug|Temsirolimus|25 mg weekly IV
1830180|NCT00800917|Drug|Bevacizumab|10 mg/kg every 2 weeks
1830183|NCT00800943|Biological|Alemtuzumab (Campath-1H)|Campath is administered using escalating doses and alternating injection sites. The dose is escalated as tolerated using 3mg,10mg,and 30mg, administered subcutaneously (SC) (if tolerated). When escalation to 30 mg dose is tolerated, all subsequent doses are administered at 30 mg SC 3 times per week at alternating injection sites for up to 8 weeks
1830184|NCT00800956|Drug|[14C]-esreboxetine|Single oral dose of 6mg esreboxetine in solution containing approximately 100uCi [14C]-esreboxetine
1830185|NCT00800969|Procedure|FDG-PET-CT|Radiologic standard procedure
1830186|NCT00800982|Procedure|Narrow band (310-312 nm) ultraviolet light B phototherapy|Narrow band (310-312 nm) ultraviolet light B phototherapy 3 times a week during Weeks 12-24. NB-UVB therapy will be adjusted according to the clinical judgment of the University of California San Francisco Psoriasis Treatment Center phototherapy staff
1830187|NCT00800982|Drug|etanercept|Etanercept is given at the standard FDA approved dosage of 50 mg twice weekly x 3 months then 50 mg once weekly x 3 months.
1830188|NCT00800995|Dietary Supplement|SOD|
1830189|NCT00800995|Dietary Supplement|Sham|
1830190|NCT00801008|Behavioral|Exercise and relaxation intervention|Comparison of an exercise and relaxation intervention to a wait-list control condition
1830191|NCT00801021|Drug|Frio Mouth Rinse|Rinse with 15ml twice daily then expectorate
1830192|NCT00801034|Drug|Calcium|tablets, 1 tablet 2 times per day in 28 days
1830193|NCT00801034|Drug|Potassium|Tablets, 5 tablets 2 times per day for 28 days
1830194|NCT00801047|Drug|Bupivacaine epidural|Bupivacaine 0.1%, fentanyl 1 mic/kg
1830195|NCT00801047|Drug|Remifentanil|40-50 mic per 1-2 min via PCA
1830196|NCT00801060|Drug|Lumiliximab + FCR|Dose, schedule, and duration in the protocol
1830197|NCT00801060|Drug|FCR|Dosage, schedule, and duration in the protocol
1830198|NCT00801073|Procedure|Human Amniotic Membrane Transplantation|Human Amniotic Membrane Transplantation for The Treatment of Ocular Surface Disease
1830199|NCT00801086|Drug|7% (w/v) Tempol alcohol-based gel (MTS-01)|200mL gel applied daily prior to radiation dose and removed immediately thereafter.
1830200|NCT00801086|Drug|alcohol-based gel|200mL gel applied daily prior to radiation dose and removed immediately thereafter
1830201|NCT00801099|Drug|Amoxicillin/Clavulanic Acid|single shot dose of Amoxicillin/Clavulanic Acid approximately 30 min. preoperatively
1830202|NCT00801125|Drug|natalizumab|
1830203|NCT00801138|Drug|saline|2 ml 0.9% saline (placebo)
1830204|NCT00801138|Drug|Dexamethasone|dexamethasone 8 mg (2 ml)
1830205|NCT00801138|Drug|ropivacaine|30 ml 0.5% ropivacaine
1830206|NCT00801138|Drug|Bupivacaine|30 ml 0.5% bupivacaine
1830312|NCT00810758|Drug|PF-04878691 6mg|Oral solution, 6mg, twice weekly, 2 weeks
1830313|NCT00810758|Drug|PF-04878691 9mg|Oral solution, 9mg, twice weekly, 2 weeks
1830354|NCT00811395|Drug|Teriflunomide|"Film-coated tablet
Oral administration"
1958813|NCT01216280|Drug|placebo capsule|2 x 10 mg placebo capsules administered orally with water, b.i.d.
1958814|NCT01216280|Drug|10 mg Natura-alpha capsule and 10 mg placebo capsule|10 mg Natura-alpha capsule and 10 mg placebo capsule administered orally with water, b.i.d.
1958815|NCT01216280|Drug|2 x 10 mg Natura-alpha capsules|2 x 10mg Natura-alpha capsules administered orally with water, b.i.d.
1830207|NCT00801151|Drug|Zolinza (vorinostat), vinorelbine|"Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.
Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days).
Patients may receive a maximum of 6 cycles of study medication."
1830208|NCT00801164|Drug|Frio Mouth Rinse Placebo|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
1830209|NCT00801164|Drug|Frio Mouth Rinse|Prescription Mouth Rinse. Rinse with 15ml twice daily then expectorate.
1830210|NCT00801177|Biological|IMC-11F8|"Cohort 1
100 mg I.V."
1830211|NCT00801177|Biological|IMC-11F8|"Cohort 2
200 mg I.V."
1830212|NCT00801177|Biological|IMC-11F8|"Cohort 3
400 mg I.V."
1830213|NCT00801177|Biological|IMC-11F8 I.V.|"Cohort 4
600 mg I.V."
1830214|NCT00801177|Biological|IMC-11F8|"Cohort 5
800 mg I.V."
1830215|NCT00801177|Biological|IMC-11F8|"Cohort 6
1000 mg I.V."
1830216|NCT00801177|Biological|IMC-11F8|"Cohort 1
100 mg I.V."
1830217|NCT00801177|Biological|IMC-11F8|"Cohort 2
200 mg I.V."
1830218|NCT00801177|Biological|IMC-11F8|"Cohort 3
400 mg I.V."
1830219|NCT00801177|Biological|IMC-11F8|"Cohort 4
600 mg I.V."
1830220|NCT00801177|Biological|IMC-11F8|"Cohort 5
800 mg I.V."
1830221|NCT00801177|Biological|IMC-11F8|"Cohort 6
1000 mg I.V."
1830222|NCT00801190|Other|HES (130/0.4)|33 ml/kg i.v. during surgery
1830223|NCT00801190|Other|Ringer's Lactate|33 ml/kg i.v.
1830224|NCT00801203|Drug|IRCT|Up to two administrations of the IRCT during a single cough testing session
1830225|NCT00801216|Drug|High-dose sequential chemotherapy and autologous transplant|Two courses of methotrexate 3.5 g/mq day 1 and cytarabine 2 g/mq twice a day, for two days, Rituximab 375 mg/mq days 3 & 11 and Intrathecal liposomal cytarabine 50 mg day 6(Phase I) followed in case of response by cyclophosphamide 7 g/mq plus Rituximab 375 mg/mq and Intrathecal liposomal cytarabine 50 mg Leukapheresis A and cryopreservation (Phase II), Cytarabine 2 g/mq twice a day for 4 days, Rituximab 375 mg/m2 and Reinfusion of stem cells (Phase III), etoposide 2 g/mq, Intrathecal liposomal cytarabine 50 mg (Phase IV) and high-dose Thiotepa-BCNU supported by autologous stem cell transplant (Phase V), and whole-brain radiotherapy in patients who do not achieve a complete remission after chemotherapy (Phase VI)
1830226|NCT00801229|Drug|Vyvanse|Vyvanse 30, 50, or 70 mg daily
1830227|NCT00801229|Drug|Placebo|Placebo 30, 50, 70 mg daily
1830228|NCT00801242|Drug|Degarelix 240 mg / 80 mg|For each treatment cycle, a starting dose of 240 mg of degarelix was administered on Day 0 as two 120 mg subcutaneous (s.c.) injections in the abdominal region. Thereafter, 6 doses of 80 mg degarelix were administered 28 days apart via single s.c. injections.
1830229|NCT00801255|Drug|RO5024048|500mg po bid/100mg po q8h for 7 days
1830230|NCT00801255|Drug|danoprevir|500mg po bid/100mg po q8h for 14 days
1830231|NCT00801255|Drug|danoprevir|1000mg po bid/100mg po q8h for 14 days\n500mg po bid/200mg po q8h for 14 days
1830232|NCT00801255|Drug|danoprevir|1000mg po bid/200mg po q8h for 14 days
1830233|NCT00801255|Drug|danoprevir|1000mg/600mg po twice daily for 14 days
1830234|NCT00801255|Drug|danoprevir|1000mg/900mg po twice daily for 14 days
1830235|NCT00801268|Drug|tripterygium wilfordii|TW，60mg/d
1830236|NCT00801268|Drug|Emodin|100mg/d
1830237|NCT00801281|Drug|Rituximab|Rituximab 375 mg/m2 i.v. d. 1 q. 21 d.
1830238|NCT00801281|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m2 i.v. d. 1 q. 21 d.
1830239|NCT00801281|Drug|Doxorubicin|Doxorubicin 50 mg/m2 i.v. d. 1 q. 21 d.
1830240|NCT00801281|Drug|Vincristine|Vincristine 1.4 mg/m2 (max. 2 mg) i.v. d. 1 q. 21 d.
1830241|NCT00801281|Drug|Prednisone 1|Prednisone 100 mg p.o. d. 1-5 q. 21 d.
1830242|NCT00801281|Drug|Prednisone 2|Prednisone 40 mg/m2 p.o. d. 1-5 q. 21 d.
1830243|NCT00801294|Drug|BIBF 1120 and BIBW 2992|
1830244|NCT00801307|Device|spirometer|According to the randomisation order, the appropriate medical gas cylinder with the pressure regulator will be connected to a humidifier to avoid the inhalation of very dry gas; the humidifier will be connected to the breathing bag; the flow of the medical gas will be adjusted individually for each subject/patient by the valve of the pressure regulator.
1830245|NCT00801320|Procedure|Tumor collection|Tumor collected at the time of planned surgery
1830246|NCT00801346|Other|laboratory biomarker analysis|
1830247|NCT00801346|Other|metabolic assessment|
1830248|NCT00801346|Other|questionnaire administration|
1830249|NCT00801346|Procedure|assessment of therapy complications|
1830250|NCT00801346|Procedure|fatigue assessment and management|
1830251|NCT00801346|Procedure|quality-of-life assessment|
1830252|NCT00801359|Procedure|Phacoemulsification|
1830253|NCT00801359|Drug|BSSPlus solution|
1830254|NCT00801359|Drug|Lactated Ringer's solution|
1830255|NCT00801385|Drug|erlotinib hydrochloride|
1830256|NCT00801385|Drug|sorafenib tosylate|
1830257|NCT00801385|Genetic|DNA analysis|
1830258|NCT00801385|Genetic|mutation analysis|
1830259|NCT00801385|Genetic|polymerase chain reaction|
1830260|NCT00801385|Genetic|protein analysis|
1830261|NCT00801385|Genetic|protein expression analysis|
1830262|NCT00801385|Other|immunohistochemistry staining method|
1830263|NCT00801385|Other|laboratory biomarker analysis|
1830264|NCT00801398|Drug|Oxymorphone IR|Open-label, 2 part, ascending dose, single and multiple dose q4-6 hrs up to 48 hrs
1830265|NCT00801411|Drug|cyclophosphamide|Given IV
1830266|NCT00801411|Drug|docetaxel|Given IV
1830267|NCT00801411|Drug|doxorubicin hydrochloride|Given IV
1830268|NCT00801424|Device|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 36-37ºC, approx. 80-100% relative humidity) via a humidifier with a heated tube (Fisher&Paykel) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity
1830269|NCT00801437|Drug|Xalacom|Xalacom 1 drop into the affected eye daily
1830270|NCT00801450|Drug|Triamcinolone acetonide|4 mg
1830273|NCT00801476|Procedure|Pre-operative bilateral breast MRI|After the standard mammogram and ultrasound testing, the surgeon is asked which surgical procedure they feel is appropriate for the patient. A bilateral breast MRI is then performed prior to surgery. The surgeon is again asked which surgery they feel is appropriate based on the new information provided by the MRI. The study is trying to see if this pre-operative breast MRI helps define the tumour leading to a better first surgical decision.
1830274|NCT00801489|Drug|Fludarabine|30 mg/m^2 intravenously days 1, 2, 3, 4, and 5 (infusion time approximately 30 minutes). Post-Remission Therapy will consist of 3 days rather than 5 days.
1830275|NCT00801489|Drug|Cytarabine|2 g/m^2 intravenously over 4 hours daily days 1, 2, 3, 4, and 5; each infusion begins 3.5 hours after completion of that day's fludarabine infusion - Post-Remission Therapy will consist of 3 days rather than 5 days.
1830276|NCT00801489|Drug|G-CSF (Filgrastim, Neupogen)|5 mcg/kg body weight (rounded off to the nearest number) starting day-1 till recovery of absolute neutrophil count (ANC) to 1.0 x 109/L or above. (G-CSF will be started on day 2 for patients with presenting WBC count > 10 x 109/L. Post-Remission Therapy will consist of 4 days rather than 5 days.
1830277|NCT00801489|Drug|Idarubicin|6 mg/m2 by vein over 30 minutes to be given immediately after fludarabine administration on Days 3 and 4. Idarubicin will be administered as in induction cycle, in one post-remission cycle (from cycle 3-6). Idarubicin will be given immediately after fludarabine administration on Days 2 and 3.
1830278|NCT00801502|Dietary Supplement|Oily fish consumption|Two portions of salmon per week from week 20 of pregnancy until giving birth
1830279|NCT00801502|Other|Control|No change to habitual diet from week 20 of pregnancy until giving birth
1830280|NCT00801515|Drug|Maraviroc|150 mg twice per day
1830281|NCT00801528|Drug|Ropivacaine, Diclofenac, Water for injection|Ropivacaine 0.2 %, or diclofenac (300 mg/240 ml water for injection) or water for injection will be administered as a constant instillation rate set of 10 mL/hr for the subsequent 18 postoperative hours.
1830282|NCT00801567|Device|Magnetic resonance spectroscopy (MRS)|90-minute magnetic resonance scan.
1830283|NCT00801580|Drug|doxorubicin liposomal|"Cyclophosphamide
Mesna
Methotrexate
Doxorubicin liposomal
Vincristine
Dexamethasone
Rituximab
Cytarabine"
1830284|NCT00801593|Procedure|Steroid injection into the TMJs.|In case of otherwise noncontrollable TMJ involvement steroids are injected into arthritic TMJs under MRI guidance.
1830285|NCT00801606|Drug|Zinc|Zinc 20 mg/day
1830286|NCT00801606|Drug|Micronutrient without zinc|Multimineral 2 RDA
1830287|NCT00801606|Drug|Micronutrient with zinc|Multimineral 2 RDA and zinc 20 mg per day
1830288|NCT00801606|Drug|Placebo|Placebo
1830289|NCT00794638|Drug|SyB L-0501|The administration of SyB L-0501 90 mg/m2 or 120 mg/m2/day on Day 2 and Day 3 will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
1830290|NCT00794638|Drug|Rituximab|The administration of rituximab 375 mg/m2 on Day 1 of each cycle will be followed by 18 days of observation. In the absence of adverse events or progressive disease, treatment will be repeated up to a maximum of 6 cycles, where 1 cycle is the 21-day treatment period (3 days of administration and 18 days of observation).
1830292|NCT00810628|Behavioral|Cognitive Behavioral Therapy|Individual interviews and group discussion/training.
1830293|NCT00810641|Procedure|Gufoni maneuver|For Gufoni maneuver,16,18 the patient was quickly brought down to the side-lying position on the affected ear from the sitting position. After one minute in this position, the head of the patient was quickly turned 45O upward, so that the nose directed upward. Approximately 2 minutes later, the patient was returned to the upright position (Figure 2A).
1830294|NCT00810641|Procedure|Head-shaking maneuver|For head-shaking maneuver,15 patients were brought into a sitting position. After pitching the head forward by approximately 30O, we moved the head sideways in a sinusoidal fashion at an approximate rate of 3 Hz for 15 seconds.
1830295|NCT00810641|Procedure|sham maneuver|For the sham maneuver, patients quickly lied on the unaffected side, and returned to the sitting position after one minute.
1830296|NCT00810654|Dietary Supplement|Aspergillus niger prolyl endoprotease|160 PPU daily for 2 weeks
1830297|NCT00810654|Dietary Supplement|Placebo|Placebo
1830298|NCT00810667|Drug|Lu AE58054|twice daily oral dose (60 mg BID: total dose 120 mg/day)
1830299|NCT00810667|Drug|Placebo|twice daily oral dose
1830300|NCT00810680|Drug|Valproic acid|Tab. Valproic acid will be started at a dose of 10 mg per kg per day in two or three divided doses. If well tolerated the dose will be increased to a maximum of 20 mg per kg per day and continued for a period of 3 months. The drug will be continued for another 3 months for a maximum of 6 months in responding patients. The drug will be stopped in all those who develop intolerable side effects or develop disease progression during therapy.
1830301|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1mg tid - 2.5mg tid orally for 12 weeks
1830302|NCT00810693|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1.5mg tid orally for 12 weeks
1830303|NCT00810693|Drug|Placebo|Matching Placebo tid orally for 12 weeks
1830304|NCT00810706|Drug|exemestane|Patients randomised to receive exemestane (25 mg/day) for 5 years.
1830305|NCT00810719|Drug|Erlotinib|Erlotinib will be administered at 150 mg once daily by mouth on the following schedule: days 2-5, 9-12,16-26.
1830306|NCT00810719|Drug|gemcitabine|The dose for gemcitabine is 1,000 mg/m2 administered over 30 minutes as an intravenous infusion. The doses are administered weekly for 3 weeks (Days 1, 8 and 15) followed by one week of rest during which gemcitabine is not given. This 4 week period (28 days) constitutes a cycle.
1830307|NCT00810732|Drug|Sitaxsentan|Sitaxsentan sodium 100 mg orally administered once daily (double blind arm)
1830308|NCT00810732|Drug|Nifedipine|Nifedipine = 30 mg extended release tablets, orally administered once daily (open label arm)
1830309|NCT00810732|Drug|Placebo|Placebo for sitaxsentan, orally administered once daily (double blind arm)
1958821|NCT01204255|Drug|lorazepam|Given topically
1830311|NCT00810758|Drug|PF-04878691 3mg|Oral solution, 3mg, twice weekly, 2 weeks
1958822|NCT01204255|Drug|diphenhydramine hydrochloride|Given topically
1830314|NCT00810771|Behavioral|Standard Information|A computer based educational overview of CRC and CRC test options will be presented to the subject. The subject will be given a handout with a brief description of each of the screening options and will include the test that they have chosen as their preferred test. The subjects will be asked to take this handout to their upcoming clinic appointment and to discuss the screening options with their care provider.
1830315|NCT00810771|Behavioral|Preference-tailored Information|A preference elicitation exercise that will generate a list of the three top attributes for the subject and the CRC screening test most consistent with these attributes. Subjects will be provided with a handout to take to their clinic appointment as the Standard Information group does, but with the addition of a listing of their top attributes and the test most consistent with their top attributes.
1830316|NCT00810784|Behavioral|Education|(1) a risk-assessment tool completed at the time of a hospital admission, (2) structured educational sessions on VTE prevention, and (3) audit-feedback where institutional data was reviewed during the educational sessions. These sessions were given once to the clinical pharmacists and on three separate occasions to the medicine house officers.
1830317|NCT00810797|Drug|exemestane|Given orally
1830318|NCT00810797|Other|laboratory biomarker analysis|One year after completion of study treatment
1830319|NCT00810797|Procedure|quality-of-life assessment|One year after completion of study treatment
1830320|NCT00810797|Other|immunohistochemistry staining method|Correlative studies
1830324|NCT00810836|Drug|BG00012|oral
1830325|NCT00810836|Drug|BG00012|Oral
1830326|NCT00810836|Drug|placebo|oral placebo
1830327|NCT00810849|Drug|Prednisolone|Prednisolone and placebo will be supplied as 5 mg identical tablets and given at a dosage of 120 mg/day in the first week, followed by 90 mg/day in the second week, 60 mg/day in the third week, 30 mg/day in the fourth week, 15 mg/day in the fifth week, and 5 mg/day in the sixth week.
1830328|NCT00810849|Biological|Mycobacterium w immunotherapy|Patients enrolled in the Mycobacterium w experimental arm will receive 5 doses of 0.1 ml of the vaccine intradermally (on enrolment, at 2 weeks, 4 weeks, 6 weeks, and 3 months). Patients in the control arm of the Mycobacterium w comparison will receive a similar regime of placebo injections of normal saline in identically-packaged vials.
1830329|NCT00810862|Drug|pimecrolimus active cream|Pimecrolimus 1% cream apply to affected study area twice daily for 21 days
1830330|NCT00810862|Other|placebo base cream|apply to affected study area twice daily for 21 days
1958823|NCT01204255|Drug|haloperidol|Given topically
1958824|NCT01204255|Other|questionnaire administration|Ancillary studies
1830333|NCT00810901|Behavioral|Organ Donor|Subjects receive information about becoming a designated organ donor -via DVD, email, text messaging, website, and US mail.
1830334|NCT00810901|Behavioral|Alcohol Prevention|Use DVD, website, text messaging, email and US mail to educate teenagers about the consequences associated with purchasing and using alcohol.
1830335|NCT00810914|Drug|bupivicaine epidural|bupivicaine continuous epidural infusion
1830336|NCT00810914|Drug|bupivicaine epidural infusion patient epidural|bupivicaine
1830337|NCT00810914|Drug|bupivicaine|patient controlled anesthesia only
1830338|NCT00810927|Procedure|Suction cup application|he IOP will be raised by a 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
1830339|NCT00810927|Procedure|Laser Doppler flowmetry|Measurement of choroidal blood flow
1830340|NCT00810927|Procedure|Measurement of intraocular pressure|
1830341|NCT00810940|Drug|AbelaDrug200|IV 200 ml 28%drug in D5W every six hours, 10 min. duration, until ICP < 20 mmHg, then IV 100 ml same schedule for 24 hours
1830342|NCT00810940|Drug|mannitol|mannitol plus standard treatment
1830343|NCT00811291|Dietary Supplement|Vitamine-B and Folic Acid Complex, calcium|90 days of intake, will be given in drink (e.g. tea, milk, juice). Dosage within official recommendations for kindergarten kids
1830344|NCT00811291|Dietary Supplement|calcium|according to protocol
1958825|NCT01204255|Other|laboratory biomarker analysis|Correlative studies
1830347|NCT00811330|Drug|Atorvastatin 80 mg|Atorvastatin 80 mg PO every day for one year. The treatment will start 4 weeks before aortic valve replacement.
1830348|NCT00811343|Biological|QFTB-G and T-SPOT.TB tests|QFTB-G and T-SPOT.TB test before TST
1830349|NCT00811356|Drug|GSK932121; Rosiglitazone; Rosuvastatin|GSK932121 is the study drug that will be tested in all parts of this study as described above. Rosiglitazone and rosuvastatin will only be tested in the drug-drug interaction substudy.
1830350|NCT00811369|Drug|Fulvestrant + ZACTIMA|ZACTIMA 100 mg tablets. Dose = 1 tablet daily until disease progression or intolerance
1830351|NCT00811369|Drug|Fulvestrant + Placebo|ZACTIMA Placebo 100 mg tablets. Dose = 1 tablet daily for duration of study.
1830352|NCT00811382|Device|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, with Home Monitoring feature)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, where the physician receives relevant daily data from the implant via Home Monitoring
1830353|NCT00811382|Device|Home Monitoring (Cardiac resynchronization therapy and atrial fibrillation therapy, without Home Monitoring)|Cardiac resynchronization therapy and atrial fibrillation therapy according to medical guidelines, without daily data transmission from the implant via Home Monitoring (except for the safety data on device integrity)
1958830|NCT01197300|Drug|zoledronic acid|
1830355|NCT00811395|Drug|Placebo (for teriflunomide)|"Film-coated tablet
Oral administration"
1830356|NCT00811395|Drug|Interferon-β [IFN-β]|Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
1830357|NCT00811395|Drug|Glatiramer Acetate [GA]|Solution in prefilled syringe for subcutaneous injection
1830358|NCT00811408|Drug|carboplatin|
1830359|NCT00811408|Drug|cidofovir|
1830360|NCT00811408|Genetic|protein expression analysis|
1830361|NCT00811408|Other|laboratory biomarker analysis|
1830362|NCT00811408|Radiation|brachytherapy|
1830363|NCT00811408|Radiation|radiation therapy|
1830364|NCT00811421|Drug|Sulphadoxine-pyrimethamine|SP oral administration (500mg sulphadoxine and 25mg pyrimethamine) as IPTp at the 1st and 2nd Antenatal Clinic visit
1830365|NCT00811421|Drug|Mefloquine (full dose)|MQ oral administration (15 mg/Kg) on 1 day at the 1st and 2nd Antenatal Clinic visit as IPTp
1830366|NCT00811421|Drug|Mefloquine (split dose)|MQ oral administration (15 mg/kg) split dose over 2 days at the 1st and 2nd ANC visit as IPTp
1830367|NCT00811421|Drug|placebo|MQ-placebo oral administration at the 1st, 2nd and 3rd Antenatal Clinic visit as IPTp
1830368|NCT00811421|Drug|mefloquine|MQ oral administration (15 mg/Kg) at the 1st and 2nd Antenatal Clinic visit as IPTp
1830369|NCT00811434|Drug|Lactulose|1.5cc/kg/day po for three months
1830370|NCT00811434|Drug|placebo|1.5 ml sugar water/kg day for three months
1830371|NCT00811447|Drug|5-fluorouracil|600 mg/m²/day intravenous
1830372|NCT00811447|Drug|Cisplatin|60 mg/m² or 75 mg/m² intravenous
1830373|NCT00811447|Drug|Docetaxel|60 mg/m² intravenous
1830374|NCT00811460|Drug|Placebo|sc for 4 days
1830375|NCT00811460|Drug|taspoglutide|300micrograms/day sc for 2 days
1830376|NCT00811460|Drug|taspoglutide|800 micrograms/day sc for 2 days
1830377|NCT00811473|Drug|Quetiapine XR|Oral treatment with 150 up to 300 mg/day once daily in the evening
1830378|NCT00811473|Drug|Placebo|Oral treatment once daily in the evening
1830379|NCT00811486|Drug|Spironolactone and conivaptan|Tablet, 50 mg to 200 mg, daily, orally 20 mg intravenously one time over 30 minutes
1830380|NCT00811499|Drug|ARRY-371797, p38 inhibitor; oral|multiple dose, single schedule
1830381|NCT00811499|Drug|Placebo; oral|matching placebo
1830382|NCT00811499|Drug|Placebo; oral|multiple dose, single schedule
1830383|NCT00811525|Device|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|"The CPG mammary prosthesis is a silicone elastomer mammary device with a textured surface. The Siltex® (textured) shell consists of a smooth shell bonded to an additional layer of silicone that has a textured pattern imprinted into its surface. The Siltex® shell is textured to provide a disruptive surface for collagen interface. The CPG implant contains a gel that is a more cohesive silicone gel than that used in other Mentor gel implants. The gel is made from the same materials as Mentor's standard gel. The contour shape of the CPG is designed to provide inferior projection with reduced superior fullness. The CPG mammary prosthesis contains raised orientation marks on the anterior and posterior of the implant which may help the physician ensure proper placement. CPG was available in sizes 120 cc-775 cc and 5 styles with various projection and height options.
With approval of MemoryShape™ (CPG 321) Breast Implants, the study converted to a post approval study for this style."
1830384|NCT00811538|Procedure|Intravenous Thrombolysis|i.V. thrombolysis with rtPa
1830385|NCT00811538|Procedure|Intraarterial Thrombolysis|Endovascular treatment with i.a. Urokinase or i.a. rtPA or mechanical recanalization techniques
1830386|NCT00811551|Device|CRT-D (Intra-thoracic Impedance Monitoring)|Diagnostic Feature in CRT-D device that emits a sub-threshold pulse to measure resistance between two electrodes.
1830387|NCT00811564|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day
1830388|NCT00811564|Drug|latanoprost 0.005%|1 drop of study medication taken once daily
1830389|NCT00811577|Drug|Placebo|Patients in the Placebo-only arm were dosed intradermally with placebo (saline) in three trocar sites on Day 9 (plus/minus 2 days) and Day 21 (plus/minus 2 days) after arthroscopic shoulder surgery. In the AZX100-placebo arm, 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
1830390|NCT00811577|Drug|AZX100|AZX100 Drug Product 3 or 10 mg or placebo (saline) was administered intradermally at each of three trocar sites on each patient 9 ± 2 days and 21 ± 2 days after arthroscopic surgery. The three trocar sites (anterior, lateral, and posterior sides of the shoulder) were randomized to receive the same dose of study agent for both dose administrations.
1830391|NCT00811590|Drug|Everolimus|"Everolimus is a novel derivative of rapamycin. Everolimus has been in clinical development since 1996 as an immunosuppressant in solid organ transplantation. Since 2003, RAD001 is approved in Europe (trade name: Certican) via the Mutual Recognition Procedure (MRP) for the prevention of organ rejection in patients with renal and cardiac transplantation. Certican is also approved in Australia, South Africa, the Middle East, Central and South America, the Caribbean and some Asian countries.
Everolimus is being investigated as an anticancer agent based on its potential to act
directly on the tumor cells by inhibiting tumor cell growth and proliferation
indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell VEGF production and VEGF-induced proliferation of endothelial cells."
1830392|NCT00811603|Drug|Cefazolin (Timing of Antibiotic Prophylaxis)|Patients scheduled for a cesarean delivery will be randomly assigned to receive Cefazolin (antibiotic prophylaxis) either prior to skin incision or after the clamping of the umbilical cord
1830393|NCT00811616|Device|Supralimus-Core™|Sirolimus Eluting Cobalt Chromium based coronary stent system
1830394|NCT00811629|Other|sRAGE|The purpose of this observational prospective study is to determine wether sRAGE could be used in an ICU setting as a potential diagnostic and prognostic marker during ALI/ARDS, regardless of associated severe sepsis or septic shock
1830395|NCT00811642|Drug|Posaconazole|400mg BID oral suspension for 12 weeks
1830396|NCT00811655|Procedure|therapeutic conventional surgery|Surgery of a single brain metastasis.
1830397|NCT00811655|Radiation|stereotactic radiosurgery|Pre-operative single fraction SRS
1830398|NCT00811668|Device|CPAP before SOMNOVentCR|4 weeks CPAP treatment, 1 week wash out period, 4 weeks SOMNOventCR treatment
1830399|NCT00811668|Device|SOMNOventCR before CPAP|4 weeks SOMNOventCR treatment, 1 week wash out period, 4 weeks CPAP treatment
1830400|NCT00811681|Drug|pioglitazone|administered orally once a day after the first visit and for a total of 2 years. Initially, Pioglitazone will be started at 15mg /day. Dosage will then increase by 15mg /d/ week up to the maximal dose of 45mg /day
1830401|NCT00811681|Drug|Placebo|a placebo administered orally once a day after the first visit and for a total of 2 years.
1830402|NCT00811694|Other|ocular blood flow measurements|non-invasive haemodynamic measurements of retinal vessel diameters, laser Doppler flowmetry and laser Doppler velocimetry
1830403|NCT00811720|Drug|Placebo|as-needed use, tablets, orally, 6 months
1830404|NCT00811720|Drug|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
1830405|NCT00811733|Biological|Ofatumumab|Ofatumumab is a fully human antibody, targeting a unique epitope on the CD20 molecule expressed on human B cells.
1830406|NCT00811746|Drug|Rozerem (Ramelteon)|8 mg taken orally 30 minutes before a split-night PSG
1830407|NCT00811746|Drug|Lunesta (Eszopiclone)|3 mg taken orally 30 minutes before the start of a split-night PSG
1830408|NCT00811746|Other|Historical Controls|Chart review matched for demographics and comorbidities of the study drug groups.
1830409|NCT00811759|Drug|sorafenib tosylate|
1830410|NCT00811759|Drug|temozolomide|
1830411|NCT00811759|Genetic|gene expression analysis|
1830412|NCT00811759|Genetic|mutation analysis|
1830413|NCT00811759|Other|laboratory biomarker analysis|
1830414|NCT00811759|Other|pharmacological study|
1830415|NCT00811759|Procedure|biopsy|
1830416|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more bare metal stent(s)
1830417|NCT00811772|Device|Percutaneous coronary intervention (PCI)|Implantation of one or more drug eluting stent(s)
1830418|NCT00811785|Drug|Copper Histidine|A physiologically acceptable form of the trace metal copper.
1830419|NCT00811798|Biological|Cervarix|Subjects will receive three doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule.
1830420|NCT00811811|Behavioral|Behavioral neurocardiac training|6 training sessions scheduled over 8 weeks
1830421|NCT00811811|Behavioral|Autogenic relaxation training|6 training sessions scheduled over 8 weeks
1830422|NCT00811824|Behavioral|Physical activity and dietary change|6 months of combined resistance training and aerobic exercise (5 times per week x 30 minutes) plus 6-week nutrition counseling class
1830423|NCT00811837|Drug|Midazolam|Intravenous infusion
1830424|NCT00811837|Drug|Remifentanil|Intravenous infusion
1830425|NCT00811850|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
1830426|NCT00811850|Drug|fixed combination of dorzolamide hydrochloride timolol maleate ophthalmic solution|1 drop of study medication taken approximately 12 hours apart, dosed 2 times a day for a total of two weeks
1830427|NCT00811876|Other|Data Collection on Depo-Eligard exposure|Retrospective, Non-interventional
1830428|NCT00811889|Other|Placebo|Placebo
1830429|NCT00811889|Drug|Bardoxolone Methyl (RTA 402)|Oral, Once Daily
1830430|NCT00811902|Drug|Nerispirdine|tablet, oral administration
1830431|NCT00811902|Drug|placebo|tablet, oral administration
1830432|NCT00811915|Drug|Sirolimus|"Sirolimus introduction and tacrolimus withdrawal
Tacrolimus : 33 % decrease of daily dose with complete withdrawal at day 14. Sirolimus daily dose according to CYP3A5 genotype CYP3A5*1/*1 or *1/*3: 4 mg/d CYPY3A5*3/*3 : sirolimus 2 mg/j Adjusted to obtain a trough level between 6 and10 ng/ml"
1830435|NCT00811941|Drug|Placebo|as-needed use, tablets, orally, 52 weeks
1830436|NCT00811941|Drug|Nalmefene|18.06 mg as-needed use, tablets, orally, 52 weeks. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
1830437|NCT00811954|Drug|Emtricitabine/tenofovir disoproxil fumarate|200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
1830438|NCT00811954|Drug|Raltegravir|400 mg taken orally twice daily. An integrase inhibitor (INI).
1830439|NCT00811954|Drug|Darunavir|800 mg taken orally once daily. A protease inhibitor (PI).
1830440|NCT00811954|Drug|Ritonavir|100 mg taken orally once daily. A protease inhibitor (PI).
1830441|NCT00811954|Drug|Atazanavir|300 mg taken orally once daily. A protease inhibitor (PI).
1830442|NCT00811967|Biological|PegIntron (peginterferon alfa-2b; SCH 54031)|PegIntron administered at a dose of 1.5 ug/kg QW SC for up to 48 weeks
1830443|NCT00811967|Drug|Rebetol (ribavirin; SCH 18908)|Rebetol administered at a dose of 600, 800, or 1000 mg/day, orally, for up to 48 weeks.
1830444|NCT00811980|Drug|Linezolid or Vancomycin|Whole blood samples from healthy subjects will be incubated with MRSA bacterium or bacterial toxins in the presence and absence of either linezolid or vancomycin. Final concentrations will mimic physiologic conditions. Platelets and leukocytes will be isolated and assayed for the presence of absence of activation and pre-mRNA splicing.
1830445|NCT00811993|Drug|RG1507|Starting dose of >=3mg/kg iv escalating to a maximum dose of <=16mg/kg iv, depending on dosing schedule in each combination treatment arm
1830446|NCT00811993|Drug|RO1507|27mg/kg iv, monotherapy
1830447|NCT00811993|Drug|bevacizumab [Avastin]|as prescribed
1830448|NCT00811993|Drug|capecitabine [Xeloda]|as prescribed
1830449|NCT00811993|Drug|carboplatin|as prescribed
1830450|NCT00811993|Drug|cetuximab|as prescribed
1830451|NCT00811993|Drug|docetaxel|as prescribed
1830456|NCT00811993|Drug|mFOLFOX6|as prescribed
1830457|NCT00811993|Drug|paclitaxel|as prescribed
1830458|NCT00811993|Drug|pemetrexel|as prescribed
1830459|NCT00811993|Drug|sorafenib|as prescribed
1830460|NCT00811993|Drug|temozolomide|as prescribed
1830461|NCT00811993|Drug|trastuzumab [Herceptin]|as prescribed
1830462|NCT00812006|Drug|rizatriptan benzoate|rizatriptan 10 mg Orally Disintegrating Tablet (ODT) orally for a moderate or severe migraine attack
1830463|NCT00812006|Drug|Comparator: placebo|Placebo to rizatriptan 10 mg ODT orally for a moderate or severe migraine attack
1830476|NCT00812032|Drug|Aspirin|75 mg per day versus 75 mg twice daily and 320mg once daily
1830477|NCT00812032|Drug|aspirin|crossover study with three dosages: 75 mg once daily, 75 mg twice daily, 320 mg once daily.
1830478|NCT00812045|Drug|AZD1236|Oral tablet, 75 mg twice daily during 4 weeks
1830479|NCT00812045|Drug|Placebo|
1830480|NCT00812058|Drug|RG2417|1g bid dose escalates to 2g bid for weeks 2-8.
1830481|NCT00812058|Drug|Placebo|Similarly sized placebo pills to be taken in the same fashion as the RG2417 tablets.
1830482|NCT00812071|Biological|RiVax|vaccine
1830483|NCT00812097|Device|Mentor Siltex® Contour Profile Gel Mammary Prosthesis|The MENTOR® MemoryShape™ Breast Implant is a silicone elastomer mammary device with a textured surface.
1830484|NCT00812110|Drug|Influenzae vaccine|0.5 mL Deltoid Intramuscular Injection X 1
1830485|NCT00812123|Drug|Sirolimus|Loading dose 30 mg for three days, trough level of 10-20 ng/ml month 1-3, 8-15 ng/ml month 4 - 6
1830486|NCT00812123|Drug|Cyclosporine A|Loading dose of 300 mg for three days, trough levels 250-300 ng/ml months 1-3, 150-250 ng/ml months 4 to 6
1830487|NCT00812123|Drug|Prednisone|0.5 mg/kg, tapering every two weeks until 0.1 mg/kg
1830488|NCT00812123|Drug|Mycophenolate mofetil|2 x 1000mg, through level above 2ug/ml
1830489|NCT00812123|Procedure|Protocol biopsies|protocol kidney biopsies at month one and three
1830490|NCT00812136|Behavioral|Using Parent Mentors to Improve Asthma Care for Urban Minority Children|
1830491|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a high protein diet.
1830492|NCT00812162|Other|Energy Restriction|Energy restricted diet of 750 kcal less than subjects requirement with a lower protein diet.
1830493|NCT00812175|Drug|Sorafenib (Nexavar, BAY43-9006)|Systemic oral therapy according to product information
1830494|NCT00812188|Other|Medium Dose UVA-1|UVA-1 phototherapy treatment (60 J/cm2) three times per week for 12 weeks.
1830495|NCT00812188|Other|High Dose UVA-1|High dose (120 J/cm2)UVA-1 phototherapy three times per week for 12 weeks.
1830496|NCT00812201|Device|No intervention is used. Collection of signals only.|Device received per standard of care.
1830499|NCT00812227|Behavioral|Psychodynamic Psychotherapy|Screened and eligible patients will receive 16 individual sessions of psychodynamic psychotherapy, each lasting 45-50 minutes.
1830500|NCT00812240|Drug|masitinib (AB1010)|masitinib (AB1010) 7.5 mg/kg/day, per os
1830501|NCT00812240|Drug|imatinib|imatinib 400 mg or 600 mg per day, per os
1830502|NCT00812253|Drug|Intravenous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
1830503|NCT00812253|Drug|Subcutaneous insulin|Half of subjects will receive insulin through the intravenous route while the other half will receive 4 injections per day.
1830504|NCT00812266|Drug|topotecan + cisplatin|topotecan IV 2 mg/sqm d1-3 + cisplatin IV 50 mg/sqm d3 q3W
1830505|NCT00812266|Drug|Etoposide + carboplatin|Etoposide 120 mg/sqm IV d 1-3 + carboplatin AUC 5 d1 q3W
1830506|NCT00812279|Other|Distillation based smoking article (SMAR cigarette)|Subjects randomised to the SMAR arm will be trained by the site staff on the usage of SMAR and the corresponding lighter prior to smoking the first SMAR. Subjects will be allowed to smoke SMAR without any limit on consumption during the designated smoking times but have to request each SMAR from the site staff when they wish to smoke.
1830507|NCT00812279|Other|conventional cigarette|Subjects randomised to the CC arm will continue to smoke their preferred CC brand during the exposure period. Subjects will be allowed to smoke without any limit on consumption during the designated smoking times but will have to request each CC from the site staff when they wish to smoke.
1830508|NCT00812279|Other|smoking cessation|Subjects will not be allowed to smoke any cigarettes or to use any other nicotine/tobacco-containing products during the 5 days following randomisation.
1830509|NCT00812292|Drug|TMC278|
1830996|NCT00807339|Device|CyberKnife Robotic Radiosurgery System|
1830510|NCT00812305|Drug|SKY0402 300mg in healthy patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in healthy patients
1830511|NCT00812305|Drug|SKY0402 300mg in hepatically impaired patients|SKY0402, single administration of 300 mg via local infiltrations (subcutaneous) in hepatically impaired patients
1830512|NCT00812318|Drug|GSK1265744 10 mg oral solution|GSK1265744
1830513|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fasted
1830514|NCT00812318|Drug|GSK1265744 5 mg tablet|GSK1265744 5mg tablet, fed
1830515|NCT00812331|Drug|TMC435|From Day 1 to Day 7 all participants will take 200 mg TMC435350 as a single medication orally (by mouth) once daily.
1830516|NCT00812344|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
1830517|NCT00812344|Drug|Ketoconazole|tablets, orally, once daily for 3 days
1830518|NCT00812344|Drug|ketoconazole|dissolved tablets, dosing through the Loc-I-Gut catheter, single dose
1830519|NCT00812370|Drug|Bivalirudin|The initial bolus dose will be 0.125 mg/kg followed immediately by a continuous infusion of 0.125 mg/kg/hour.
1830520|NCT00812383|Device|RX ACCULINK™ Carotid Stent System; RX ACCUNET™ Embolic Protection System; PercuSurge GuardWire® 3-6 Temporary Occlusion and Aspiration System|Angiomax (bivalirudin) versus standard anticoagulation with heparin during carotid artery stenting with distal protection clinical endpoint evaluation
1830521|NCT00812396|Drug|Comparator: low dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 200 mg (0.8 mL) testosterone.
1830522|NCT00812396|Drug|Comparator: high dose testosterone|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 600 mg (2.4 mL) testosterone.
1830523|NCT00812396|Drug|Comparator: placebo|Subjects will receive two muscle biopsies, the first at baseline, and the second a week after a single intramuscular dose of 0.8 mL placebo saline solution.
1830524|NCT00812409|Dietary Supplement|Whey protein supplementation with exercise|Whey protein supplementation with resistance and aerobic exercise.
1830525|NCT00812409|Other|Non protein supplementation with exercise (control)|Non protein supplementation with resistance and aerobic exercise.
1830526|NCT00812422|Drug|Dexibuprofen|one dose of Dexibuprofen 2.5 or 5 mg/kg
1830527|NCT00812422|Drug|Dexibuprofen|one dose of Dexibuprofen 3.5 or 7 mg/kg
1830528|NCT00812422|Drug|Ibuprofen|one dose of Ibuprofen 5 or 10 mg/kg
1830529|NCT00812435|Drug|eptifibitide|Patients will be randomized to eptifibatide or no eptifibatide. If randomized to eptifibatide: 180 mcg/kg Bolus; 2 mcg/kg/min infusion immediately prior to primary PCI or at the time of PCI and for 18 - 24 hours following the PCI Second 180 mcg/kg Bolus 10 min after the first
1830530|NCT00812448|Dietary Supplement|tea catechin extracts|catechins are composed of tea catechin extracts available in grren tea supplements
1830531|NCT00812461|Drug|Placebo|as-needed use, tablets, orally, 6 months
1830532|NCT00812461|Drug|Nalmefene|18.06 mg, as-needed use, tablets, orally, 6 months. 18.06 mg nalmefene equals 20 mg nalmefene hydrochloride.
1830533|NCT00812487|Drug|Intravenous insulin|Patients will receive continuous insulin infusion through the vein.
1830534|NCT00812487|Drug|Subcutaneous insulin|4 injections of insulin/day
1830535|NCT00812500|Other|Lower Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a lower protein diet.
1830536|NCT00812500|Other|Medium Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a medium protein diet.
1830537|NCT00812500|Other|Higher Protein|Each subject completed an 18-day periods (trials) of strict dietary control of consuming a higher protein diet.
1830538|NCT00812513|Drug|R-Pdf/Gbb 0.01% gel|rhPDGF 0.01% gel is applied to the wound, then covered with dressing once daily for 3 months
1830539|NCT00812526|Procedure|Suction cup application|
1830540|NCT00812526|Procedure|Squatting|
1830541|NCT00812539|Other|"Subject/Provider Portal Diabetes Connected Health tool - Deluxe"|"Subjects enrolled into the Deluxeintervention will use a glucometer, a modem to upload the blood glucose readings to a secure, web-based portal (Diabetes Connected Health tool) where they can view detailed graphical representation of their blood glucose levels over time, educational material regarding diabetes management and receive personalized tips and feedback from their physicians (who will also have access to their subjects' information on the web portal and contact them by an embedded messaging system). Subjects with new high or low readings will be flagged. Providers can initiate messages to subjects regarding symptoms or medications. A medication summary and log of all readings uploaded with date/time will be displayed on the website as well as a graphical display of all uploaded glucose readings over time and will allow subjects to enter comments regarding each critical reading."
1830542|NCT00812539|Other|"Subject only Portal Diabetes Connected Health Tool Basic"|"Patients enrolled in the Diabetes Connect Basic intervention will use a glucometer, a modem which will upload the blood glucose readings to a secure, web-based portal (the Diabetes Connected Health tool) where they can view their readings in a less detailed/journal fashion. No detailed graphical representation of their blood glucose levels over time is available to this group, nor is any educational material regarding diabetes management. Their physicians will not have access to these subjects' information on the web portal and will not have the ability to contact them by an embedded messaging system."
1830543|NCT00812565|Drug|Placebo|Commercially available 0.9% isotonic sodium chloride solution.
1830544|NCT00812565|Biological|octagam 10%|octagam 10% was supplied as ready-to-use solutions of human immunoglobulin.
1830545|NCT00812578|Drug|Cholecalciferol|8 tablets equivalent to 280 micrograms for 2 weeks and 4 tablets equivalent to 140 micrograms for 10 weeks
1830546|NCT00812591|Procedure|OGTT and CLAMP|"Oral Glucose Tolerance Test (OGTT):
Oral glucose tolerance test combined with subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
Hyperinsulinemic euglycemic clamp (CLAMP):
Hyperinsulinemic euglycemic clamp with simultaneous subcutaneous insulin delivery and glucose sampling using microdialysis and microperfusion probe."
1830547|NCT00812604|Drug|Ping On Ointment|Ping On Ointment
1830548|NCT00812604|Drug|Vaseline|Placebo
1830549|NCT00812617|Dietary Supplement|Mineral water (Hita, Oita, Japan)|
1830550|NCT00812617|Dietary Supplement|Mineral water (Aso-gun, Kumamoto, Japan)|
1830551|NCT00812630|Drug|MENT or placebo|A dose of 1600µg/d of MENT will be delivered daily using a gel formulation containing 8.0 mg of MENT per 1.0 mL (delivering 800µg/d). Two mLs of gel will be applied daily for four weeks in the pilot study (by 6 men) and for 12 weeks in the main trial (by 62 men).
1830552|NCT00812643|Drug|AZD0837|Oral solution, dosing through the Loc-I-Gut catheter, single dose
1830553|NCT00812669|Biological|pegfilgrastim|
1830554|NCT00812669|Biological|rituximab|
1830555|NCT00812669|Drug|cyclophosphamide|
1830556|NCT00812669|Drug|fludarabine phosphate|
1830557|NCT00812669|Genetic|cytogenetic analysis|
1830558|NCT00812669|Genetic|fluorescence in situ hybridization|
1830559|NCT00812669|Genetic|gene expression analysis|
1830560|NCT00812669|Genetic|mutation analysis|
1830561|NCT00812669|Genetic|protein expression analysis|
1830562|NCT00812669|Other|flow cytometry|
1830563|NCT00812669|Other|laboratory biomarker analysis|
1830564|NCT00812682|Drug|Symbicort|
1830565|NCT00812695|Device|CPAP|Gold standard treatment for Obstructive sleep apnea
1830566|NCT00812708|Device|Surgery|Surgical implantation of Morcher iris device(s)
1830567|NCT00812721|Other|Preservative Free Saline|One drop will be instilled into each eye once
1830568|NCT00812721|Other|Optive|One drop will be instilled into each eye once
1830569|NCT00812721|Other|Refresh Moderate/Severe|One drop will be instilled into each eye once
1830570|NCT00812721|Other|Systane|One drop will be instilled into each eye once
1830571|NCT00812721|Other|Systane Ultra|One drop will be instilled into each eye once
1830572|NCT00812734|Procedure|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)|Blood sampling for genomics; harvesting of a sample of intercostal muscle for proteomics (thoracotomies only)
1830573|NCT00812747|Other|observation|
1830574|NCT00812760|Drug|levodopa|1 tablet of 200 mg levodopa plus 50 mg benserazide
1830576|NCT00812786|Drug|cyclosporine, tacrolimus, mycophenolate mofetil and everolimus (immunosuppressive drugs)|
1830577|NCT00812799|Drug|Oralgen|19.000 BU daily
1830578|NCT00812799|Other|placebo control|placebo control
1830579|NCT00812812|Drug|paroxetine 10mg tablet|1 or 2 tablet(s) once a day
1830580|NCT00812812|Drug|paroxetine 20mg tablet|1 tablet once a day
1830581|NCT00812812|Drug|matched placebo to paroxetine 10mg|2 tablets once a day
1830582|NCT00812812|Drug|matched placebo to paroxetine 20mg|1 tablet once a day
1830583|NCT00812825|Drug|PF-04171327|PF-0417327 will be provided as an oral solution administered at doses of 1, 3, 10 and 30 mg. If an additional cohort is required, the dose selected will not exceed 100 mg. Solution will be administered once daily for 14 days.
1830584|NCT00812825|Drug|Prednisolone|Oral doses of prednisolone (5, 10, and 20 mg) will be administered to the first three cohorts. The fourth cohort will receive between 1 and 20 mg to be determined after the third cohort completes dosing. If an additional cohort is required, the dose selected will not exceed 40 mg. Prednisolone tablets will be administered once daily for 14 days
1830585|NCT00812825|Drug|Placebo|Tablets similar in appearance to prednisolone will be administered once daily for 14 days.
1830586|NCT00812825|Drug|Placebo Solution|Placebo solution will be administered to those volunteers who are randomized to the placebo or prednisolone arms. This will be administered orally each day for 14 days.
1830587|NCT00812825|Drug|PF-04171327 Tablet|A single 10 mg dose of PF-04171327 tablet formulation will be administered orally to volunteers in Part 2 of this study.
1830588|NCT00812838|Drug|100 units of Botulinum Toxin Type A|Approximately 20 to 30 injections of 100 units of BOTOX® given with a 20 gage needle directly into the penile plaque
1830589|NCT00812838|Other|Preservative free normal saline|Approximately 20 to 30 injections of 10cc of preservative free normal saline given with a 20 gage needle directly into the penile plaque
1830590|NCT00812851|Drug|Dronabinol|
1830591|NCT00812864|Drug|Capecitabine|"Pharmacokinetic of its metabolites.
Capecitabine, 1250 mg/m2 twice a day"
1830592|NCT00812877|Drug|Mineral Trioxide Aggregate|Pulp capping agent, Mineral TrioxideAggregate
1830593|NCT00812877|Drug|Calcium Hydroxide|Pulp capping agent, Calcium Hydroxide
1830594|NCT00812890|Device|semi-quantitative pregnancy test|
1830595|NCT00812903|Behavioral|Exercise|Training exercises chosen with background in knowledge of intelligent training
1830596|NCT00812916|Procedure|RF ablation, using specialized CFAE software|RF ablation
1830597|NCT00812929|Drug|Placebo|The current study will include a placebo arm to allow for a valid evaluation of adverse events attributable to GSK2190915 versus those independent of GSK2190915.
1830598|NCT00812929|Drug|GSK2190915|This study will assess FEV1 at various intervals following exercise challenge in subjects who have been administered a single dose of 10 mg, 50 mg, 100 mg, or 200 mg GSK2190915, compared to a placebo control.
1830599|NCT00812942|Procedure|colonoscopy|colonoscopy screening
1830600|NCT00812942|Procedure|faecal test|faecal occult blood test for screening
1830601|NCT00812955|Drug|ABT-143|Once daily for 8 weeks
1830602|NCT00812955|Drug|simvastatin|Once daily for 8 weeks simvastatin capsules 40 mg
1830603|NCT00812968|Drug|Lenalidomide|Oral 10mg daily on Days 1-21 days every 28 days until disease progression/relapse or CC-5013 is permanently discontinued for any reason for up to 156 weeks (3 years).
1830604|NCT00812981|Biological|GSK1562902A|new-processed (NP), administered intramuscularly in the deltoid region of the non-dominant arm
1830605|NCT00812981|Biological|GSK1562902A|comparative-processed (CP), administered intramuscularly in the deltoid region of the non-dominant arm
1830606|NCT00812994|Drug|Escitalopram|SSRI antidepressant
1830607|NCT00812994|Drug|Placebo|
1830609|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 1 administered in equimolar doses
1830610|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 2 administered in equimolar doses
1831082|NCT00808002|Drug|Raltegravir|Raltegravir 400 mg every 12 hours
1830611|NCT00813020|Drug|semaglutide|Comparison of different formulations of the drug, semaglutide: Formulation 3 administered in equimolar doses
1830612|NCT00813033|Other|patient decision aid for endoscopy|patient decision aid will be administered at the point of decision making
1830613|NCT00813046|Biological|gpASIT+TM|oral administration of entero-coated capsules containing increasing doses of gpASIT+TM (25 to 1600µg), one dose per day for 4 days
1830614|NCT00813059|Drug|Intra-vitreal injection of bevacizumab (1.25mg/0.05ml)|Pars plana intra-vitreal injection of bevacizumab (1.25 mg/0.05 ml)
1830615|NCT00813072|Drug|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 day as a treatment cycle.
Number of Cycles: until progression or unacceptable toxicity develops."
1830616|NCT00813072|Drug|irinotecan|300 mg/m2, IV infusion on day 1 of each 21 day as a treatment cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1830617|NCT00813072|Drug|docetaxel|"75 mg/m2, IV infusion for 60 minutes on day 1 of each 21 day as a treatment cycle.
Number of Cycles: until progression or unacceptable toxicity develops."
1830618|NCT00813085|Other|Electronic disease management decision support|A Diabetes Tracker embedded in a Core Data Set (DT/CDS) supported by an automated telephone reminder system (ATRS)
1830619|NCT00813098|Drug|LX1031 High Dose|A high dose of LX1031; daily oral intake for 28 days
1830620|NCT00813098|Drug|LX1031 Low Dose|A low dose of LX1031; daily oral intake for 28 days.
1830621|NCT00813098|Drug|Placebo|Matching placebo dosing with daily oral intake
1830622|NCT00813111|Drug|SKY0402|600mg SKY0402 instilled into breast pocket during surgery
1830623|NCT00813111|Drug|Bupivacaine HCl|200mg Bupivacaine HCl instilled into breast pocket during surgery
1830624|NCT00813124|Drug|Fludarabine|40 mg/m^2 by vein over 60 minutes on Day -5 through Day -2.
1830625|NCT00813124|Drug|Busulfan|Busulfan administered at the dose calculated to achieve an area under curve (AUC) of 4000 µMol-min + 12% based on the pharmacokinetic studies (days -5, -4, -3, and -2).
1830626|NCT00813124|Drug|Thymoglobulin|2.5 mg/kg by vein over about 4-6 hours on Day -3 through Day -1.
1830627|NCT00813124|Drug|Azacitidine|Start cycles of 32 mg/m^2 daily as an injection under the skin once a day over 5 days in a row, starting about 5 weeks after the transplant. This may be repeated once a month for up to 4 months after the transplant.
1830628|NCT00813124|Procedure|Stem Cell Transplant|Stem cell infusion on day 0 administered by vein after collected from donor.
1830629|NCT00813137|Drug|Folfox4 plus recombinant human endostatin (Endostar)|Endostar 15mg iv drip D1~7, D15~21, Oxaliplatin 85mg/m2 iv drip D1,15, CF 200mg/m2 iv drip D1,2,15,16, 5-Fu 400mg/m2 iv D1,2,15,16, 5-Fu 600mg/m2 civ D1,2,15,16
1830630|NCT00813150|Drug|Dexamethasone|Type=exact number, number=20, unit=mg, form=tablet, route=oral. The patients will receive 20 mg of dexamethasone on days 1+2,4+5,8+9,11+12 for 21 days for 8 cycles.
1830631|NCT00813150|Drug|Bortezomib|Type=exact number, number=1.3, unit=mg, form=injection, route=intravenous. The patients will receive 1.3mg/m2 on days 1,4,8,11 for 21 days for 8 cycles.
1830632|NCT00813150|Drug|Cyclophosphamide|Type=exact number, number=50, unit=mg, form=tablet, route=oral. The patients will receive 50 mg of cyclophosphamide once daily continuously from cycle 1 to 8.
1830633|NCT00813163|Drug|PEP02|"120 mg/m2, IV infusion for 90 minutes on day 1 of each 21 days as a treatment cycle.
Number of Cycles: until progression or unacceptable toxicity develops."
1830636|NCT00813189|Device|GH treatment|GH treatment will be administered at a weekly dose of 0.46 mg/kg/ week, divided into seven daily subcutaneous injections. Subcutaneous injections should be given slowly, in the thigh. In order to prevent lipoatrophy, the injection site should be varied. The injection should be given at bedtime.
1830637|NCT00813202|Drug|Nesiritide|Nesiritide 0.01 mcg/kg/min intravenous (IV) infusion (with or without 2 mcg/kg bolus) for 24 to 168 hours (hrs)
1830638|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on saturated fat.
1830639|NCT00813215|Dietary Supplement|Meal challenge|Meal challenge with a test meal rich on monounsaturated fat
1830641|NCT00813241|Drug|celecoxib reference formulation|200 mg single oral dose of celecoxib tablets
1830642|NCT00813241|Drug|celecoxib test formulation A1|150 mg single oral dose of celecoxib A1 formulation tablets
1830643|NCT00813241|Drug|celecoxib test formulation B2|150 mg single oral dose of celecoxib B2 formulation tablets
1830644|NCT00813241|Drug|celecoxib test formulation C1|150 mg single oral dose of celecoxib Cl formulation tablets
1830645|NCT00813254|Behavioral|Questionnaire|Questionnaires 1 - 5 will be completed on Day 1 of study as a Baseline.
1830646|NCT00813267|Biological|mesenchymal stem cell infusion|
1830647|NCT00813267|Biological|bone marrow mononuclear cell infusion|
1830648|NCT00813293|Drug|Sorafenib|Short course of sorafenib given orally twice a day prior to RFA
1830649|NCT00813293|Procedure|radiofrequency ablation|all patients receive standard of care radiofrequency ablation
1830650|NCT00813306|Drug|AZD2066|13 mg oral solution, 1 single dose
1830651|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
1830652|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
1830653|NCT00813306|Drug|AZD2066|Dose to be decided after Part A, including dose A (active) and B (placebo). Oral solution, 1 single dose
1830654|NCT00813306|Drug|Placebo|Oral solution, 1 single dose
1830655|NCT00813319|Behavioral|Girls OnGuard|Using the Information-Motivation-Behavioral Skills Model (IMB) as a framework, Girls OnGuard is an interactive,culturally-appropriate, computer-delivered program design to enhance initial uptake of GARDASIL by addressing three major components: (1) information about GARDASIL; (2) motivation to obtain GARDASIL vaccination; and (3) behavioral skills to enhance self-efficacy of obtaining GARDASIL vaccination.
1830656|NCT00813332|Drug|Endostar(rh recombinant endostatin) plus Docetaxel|7.5mg/m2, IV( in the vein) on day1-14 of each 21-28 day cycle. Number of cycles: until progression or unacceptable toxicity develops.
1830657|NCT00813332|Drug|Placebo plus Docetaxel|Placebo plus Docetaxel
1830658|NCT00813345|Other|light therapy (1500 lux)|light therapy (1500 lux) for 90 minutes
1830659|NCT00813345|Other|standard light (100 LUX)|standard light (100 LUX) for 90 minutes
1830660|NCT00813358|Device|Zenith TX2® TAA Endovascular Graft|Endovascular treatment with the study device
1830661|NCT00813371|Device|Airway Pressure Release Ventilation|Airway Pressure Release Ventilation (APRV) also known as Bi-Vent or Bi-Level ventilation is a time-cycled, pressure-limited mode of ventilation that allows spontaneous respiration throughout the ventilator cycle.
1830662|NCT00813371|Device|ARDSnet protocol|ARDSnet protocol
1830663|NCT00813384|Drug|AMG 208|AMG 208 is a small molecule inhibitor of c-Met which is a well-characterized receptor tyrosine kinase expressed on the surface of epithelial cells. C-Met receptor signaling has been shown to play a key role in the survival of cancer cells. AMG 208 inhibits both ligand-dependent and ligand-independent c‑Met cellular growth regulation. Inhibition of c-Met signaling with AMG 208 provides a potential mechanism for blocking tumor growth and survival.
1830664|NCT00813397|Device|Sepraspray|Max. 10g of Sepraspray
1830665|NCT00813410|Procedure|Glucose measurement at the sc. insulin delivery site|Overnight fasting and oral glucose tolerance test (OGTT) combined with simultaneous subcutaneous insulin delivery and glucose sampling using a single microdialysis or microperfusion probe.
1830666|NCT00813423|Drug|Hydroxychloroquine|Given PO
1830667|NCT00813423|Other|Laboratory Biomarker Analysis|Correlative studies
1830668|NCT00813423|Other|Pharmacological Study|Correlative studies
1830669|NCT00813423|Drug|Sunitinib Malate|Given PO
1830670|NCT00813436|Drug|Oxytocin (also: syntocinon, pitocin)|24 IU for each subject (3 puffs in each nostril, 4 IU in each puff). each subject will receive a single administration, 40 minuets before task start time.
1830671|NCT00813436|Drug|Placebo|saline liquid, intranasally administered
1830672|NCT00813449|Drug|dacarbazine plus Endostar (Experimental group)|dacarbazine plus Endostar
1830673|NCT00813449|Drug|dacarbazine plus placebo (control group)|dacarbazine plus placebo
1830674|NCT00813475|Drug|Basal bolus insulin regimen (tight glucose control)|Basal bolus insulin regimen
1830675|NCT00813475|Drug|Basal bolus insulin regimen (standard control)|basal bolus insulin regimen
1830676|NCT00813488|Drug|Fentanyl Buccal Tablet|"FBT dose strengths = 200, 400, 600, or 800 mcg (1, 2, 3, or 4 tablets) taken prn (as needed) in the event of breakthrough pain.
The maximum dose of FBT permitted during the titration and double-blind periods in this study is 800 mcg (4 tablets).
For the subsequent 12-week open-label treatment period, patients will either continue with FBT treatment or begin treatment with an alternative short-acting opioid deemed appropriate for each patient by the clinician."
1830677|NCT00813488|Drug|Immediate release oxycodone|"Immediate release oxycodone dosage strength: 15, 30, 45, and 60 mg doses (1, 2, 3 or 4 capsules) to be taken prn (as needed) for breakthrough pain.
The maximum single dose would be 60 mg (4 capsules)."
1830678|NCT00813501|Biological|immunosuppressive therapy|
1830679|NCT00813501|Other|immunological diagnostic method|
1830680|NCT00813501|Procedure|allogeneic hematopoietic stem cell transplantation|
1830681|NCT00813514|Genetic|VEGF genotyping|blood sample for gene analysis
1830682|NCT00813527|Drug|Lapaquistat acetate and fenofibrate|Lapaquistat acetate 100 mg, tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
1830683|NCT00813527|Drug|Fenofibrate|Lapaquistat acetate placebo-matching tablets, orally, once daily and fenofibrate 145 mg, tablets, orally, once daily for up to 12 weeks.
1830684|NCT00813540|Behavioral|Exercise Training|The exercise group will perform supervised stationary cycle ergometer exercise 3 times per week for 12 weeks and be progressed from 15 to 45 minutes and 60% to 110% of the power output obtained at V02peak. Resistance training will be completed twice per week and will include exercises for all major muscle groups. The training will progress from 60% to 80% of 1RM over the course of the intervention.
1830685|NCT00813540|Other|Usual Care|Usual Care
1830686|NCT00813553|Dietary Supplement|placebo|daily
1830687|NCT00813553|Dietary Supplement|beta-alanine|daily
1830688|NCT00813553|Dietary Supplement|beta-alanine|daily
1830689|NCT00813566|Radiation|Multi-tracer PET exams of 18F-FDG, 18F-FLT, 11C-ACE, and 15O-H2O|"Baseline: prior to surgery or immediately after surgery and prior to any tumor-directed therapy;
After the initial (~6-8 weeks) chemoradiotherapy;
At the time of MRI-documented recurrence within 2 years (patients with a known primary brain tumor who have previously undergone treatment and have recurred will be eligible for study). The PET scanning will be implemented in two phases: Phase A (separate single-tracer scans with each tracer) will be completed with imaging over two consecutive days and Phase B (where two or more tracers will be imaged in a single scan using rapid multi-tracer PET techniques under development) in one or two imaging sessions according to the best method validated from the Phase A results. The exact order and timing of the multi-tracer exams will vary."
1830690|NCT00813592|Drug|SOM230B|SOM230 is an injectable somatostatin analogue. Like natural somatostatin and other somatostatin analogues (SRIFa), SOM230 exerts its pharmacological activity via binding to somatostatin receptors (sst). There are five known somatostatin receptors: sst 1, 2, 3, 4 and 5. Somatostatin receptors are expressed in different tissues under normal physiological conditions. Somatostatin analogues activate these receptors with different potencies (Schmid and Schoeffter 2004) and this activation results in a reduced cellular activity and inhibition of hormone secretion. Somatostatin receptors are strongly expressed in many solid tumors, especially in neuroendocrine tumors where hormones are excessively secreted e.g. acromegaly (Freda 2002), GEP/NET tumors (Oberg, et al 2004) and Cushing's disease.
1830691|NCT00813605|Other|FOLFIRI|"Day 1 of each Cycle
Combination Therapy of:
irinotecan 180 mg/m2 90-minute infusion leucovorin 400 mg/m2 2 hour infusion 5-FU 400 mg/m2 IV bolus 5-FU 2,400 mg/m2 46-48 hour infusion"
1830692|NCT00813605|Biological|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that selectively binds to Death Receptor-5 (DR-5)
1830693|NCT00813605|Other|Placebo|Inactive dummy agent (to maintain blind)
1830694|NCT00813605|Biological|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1
1830695|NCT00813618|Drug|MEDI-507|0.012 mg/kg given intravenously on Study Days 0, 3, 6 and 9
1830696|NCT00813618|Drug|MEDI-507|0.04 mg/kg given intravenously on Study Days 0, 3, 6 and 9
1830697|NCT00813618|Drug|MEDI-507|0.12 mg/kg given intravenously on Study Days 0, 3, 6 and 9
1830737|NCT00805649|Drug|triamcincolone|intravitreal injection of 8 mg triamcincolone
1831083|NCT00808002|Drug|Maraviroc|Maraviroc 300 mg every 12 hours
1830698|NCT00813631|Other|silver-releasing dressings|Experimental group are accepted primary dressing the AQUACEL Ag. control group are provided with the AQUACEL on the wound surface. Wound specialist or primary nurses undertaking wound care are informed by inclusion criteria that the treatment shall be adhered to during the two-week study period.All wounds are cleansed with sterile saline prior to assessment and dressing application.The sterile, non-woven sodium carboxymethylcellulose primary AQUACEL Ag with 1.2% ionic silver.Each secondary dressing is covered a sterile gauze.Dressings are changed between daily assessments when judged necessary.Patients attended the wound ward weekly for treatment evaluation. All participating clinics used the same wound management guidelines and data collection forms.
1830699|NCT00813657|Behavioral|Exercise|Women in the intervention group were enrolled in three sessions/week of individually supervised, resistance exercise training performed over the second and third trimester of pregnancy (in total 26 weeks, ~80 training sessions). Heart rate (HR) was carefully and individually controlled (≤80% of age-predicted maximum HR value, 220-age) through a heart rate monitor during the training sessions. In brief, each session consisted of 35-40 minutes of exercise divided in a light intensity (≤60% maximal heart rate) warm-up period (~8 minutes), followed by toning and very light resistance exercises (~20 minutes) and a light intensity cool-down (~8 minutes) period. Resistance exercises were performed with barbells (≤3kg per exercise) or low-to-medium resistance bands (Therabands).
1830700|NCT00813670|Drug|XPF-001|Single oral dose, or 6 days of repeated oral doses.
1830701|NCT00813683|Other|Acupuncture stimulation|"Acupuncture by stimulation of 67 Bladder point"
1830702|NCT00813683|Other|Acupuncture stimulation|"Acupuncture stimulation of 45 Stomach point (sham)"
1830703|NCT00813696|Drug|gemcitabine|1000 mg/m2 IV weekly for 7 weeks. Starting at week 9, gemcitabine 1000 mg/m2 on days 1, 8, and 15 every 4 weeks
1830704|NCT00813696|Drug|cisplatin|25 mg/m2 IV on days 1, 8, and 15 every 4 weeks
1830705|NCT00813709|Drug|RNF|Single dose of RNF will be administered subcutaneously three times weekly at least 48 hours apart at a starting dose of 8.8 microgram (mcg) for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
1830706|NCT00813709|Drug|RNF|Single dose of RNF will be administered subcutaneously once weekly at a starting dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
1830707|NCT00813709|Drug|RNF|Participants who were initially randomized in Study 27025 (REFLEX) to the placebo treatment group will be switched to single dose of RNF administered subcutaneously three times weekly at least 48 hours apart at a dose of 8.8 mcg for first 2 weeks followed by 22 mcg for next 2 weeks and finally 44 mcg until 60 months.
1830708|NCT00813709|Drug|Placebo|Single dose matching placebo will be administered subcutaneously twice weekly. Placebo is supplied as a transparent, sterile solution for injection in pre-filled syringes matching the RNF pre-filled syringes, each containing 0.5 milliliter (mL).
1830709|NCT00813722|Behavioral|phone call|patients received or not phone calls to give orientation abou treatment
1830710|NCT00813722|Drug|amlodipine (calcium chanel blocker) and losartan (at1 antagonist)|2,5 mg tid and 25 mg tid
1830711|NCT00813722|Drug|atenolol (beta blocker) and hydrochlorothiazide (diuretic)|25 mg tid and 12,5 mg tid
1830715|NCT00813748|Drug|Xolair|
1830716|NCT00813761|Device|O2Optix contact lens|control contact lens to be worn daily for approximately 7 months for entire length of study.
1830717|NCT00813761|Device|Proclear contact lens|control contact lens to be worn for entire length of study.
1830718|NCT00813761|Device|ReNu MultiPlus Multi-Purpose Solution|lens solution for overnight lens disinfection
1830719|NCT00813761|Device|Clear Care Cleaning and Disinfecting Solution|lens solution for overnight lens disinfection
1830720|NCT00805545|Drug|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
1830721|NCT00805545|Drug|Antibiotic|Cefazolin 1gm Intravenously and Azithromycin 500mg Intravenously
1830724|NCT00805584|Drug|desloratadine|Aerius (desloratadine) tablets; 5mg orally once a day in the morning for 15 days
1830725|NCT00805597|Radiation|radiation|radiotherapy of 50Gy/25f/5w to the chest wall and supraclavicular nodal region
1830726|NCT00805597|Radiation|no radiation|no radiotherapy
1830727|NCT00805610|Biological|Hepatocyte Transplantation|Briefly, prepared hepatocytes from a single donor will be transplanted into the liver via intraportal or intrasplenic routes.
1830728|NCT00805623|Dietary Supplement|sucrose|1 cc of sucrose 33.5% with or without pacifier
1830729|NCT00805636|Drug|2-(5-fluoro-pentyl)-2-methyl-malonic-acid ([18F]-ML-10)|[18F]-ML-10 will be radiolabeled at the PET Radioactive Drug Production (RDP) facility at or in close proximity to each clinical site, and will be administered as an intravenous bolus injection (in 3-10 ml sterile saline solution, containing no more than 10% ethanol by volume). The dose concentration selected for [18F]-ML-10 will be 7 MBq/Kg or 0.19 mCi/Kg. The radioactivity dosage of [18F]-ML-10 administered at each PET/CT session will be at least 300 MBq (8.1 mCi) and not more than 500 MBq (13.5 mCi).
1830730|NCT00805636|Radiation|Stereotactic Radio-Surgery (SRS) therapy|SRS will be administered according to the standard of care using a radiation dose of 14-24 Gy to each lesion.
1830731|NCT00805636|Procedure|Positron Emission Tomography|Each patient will undergo 2 PET/CT sessions, each following intravenous administration of [18F]-ML-10, to assess tracer uptake by the brain metastases treated by SRS. The PET/CT scan will be directed to the brain and will include one bed position. The PET/CT sessions will be performed at baseline, i.e., before the radiation treatment, and on the day after, within 24h after SRS treatment.
1830732|NCT00805649|Procedure|Low fluorescence Photodynamic therapy|42 J/cm2 for 72 sec
1830733|NCT00805649|Procedure|core pars plana vitrectomy|24 hours after photodynamic therapy, 1.5 mL core pars plana vitrectomy
1830734|NCT00805649|Drug|dexamethasone|intravitreal injection of 0.8 mg dexamethasone
1830735|NCT00805649|Drug|bevacizumab|intravitreal injection of 1.25 mg bevacizumab
1830736|NCT00805649|Procedure|core pars plana vitrectomy|0.4 mL core pars plana vitrectomy
1830738|NCT00805662|Drug|oxytocin, placebo|intranasal oxytocin during intrauterine insemination
1830739|NCT00805675|Drug|Telbivudine|600 mg monotherapy supplied in film-coated tablets.
1830740|NCT00805675|Drug|Tenofovir|Tenofovir disoproxil fumarate was supplied in 300 mg tablets
1830741|NCT00805675|Drug|Telbivudine plus tenofovir|Telbivudine 600 mg and Tenofovir 300 mg were purchased in commercial packs. Patients were instructed to take medication(s) orally every morning either with or without food.
1830742|NCT00805688|Behavioral|Questionnaires|Questionnaires including symptom review (MDSAI-GI) via personal or telephone interviews (interactive voice response telephone system - IVRS)
1830743|NCT00805688|Procedure|Blood Draws|Blood sample (3½ tbs.)to measure levels of cytokines (biomarkers in the blood) and DNA (the genetic material in cells) before treatment starts.
1830744|NCT00805688|Device|Pedometer|Worn daily to measure physical activity.
1830745|NCT00805701|Drug|avodart|0.5 avodart once daily for 13 weeks
1830746|NCT00805701|Drug|Placebo|placebo
1830747|NCT00805740|Drug|Active anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
1830748|NCT00805740|Drug|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
1830749|NCT00805753|Drug|ACTH|comparison of different dosages of drug
1830750|NCT00805766|Drug|TA-650|(1) Screening Period: 5 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours at week 0. If patients do not meet the Eligibility Criteria at week 8, they will be administered 5 mg/kg of TA-650 at week 8. (2) Increased Dose Period: 10 mg/kg of TA-650 will be intravenously infused over a period of more than 2 hours every 8 weeks for 32 weeks.
1830751|NCT00805779|Device|MagPro R30|Study treatments will be administered by a commercially available MagPro R30, with a cooled figure eight coil. The figure eight coil is placed directly over the posterior tibial nerve and the MagPro R30 will be activated. The coil will stimulate the posterior tibial nerve at 20 pulses per second for a 30 minute session.
1830752|NCT00805792|Drug|Donepezil|Study participants will be treated with donepezil orally at an initial dose of 5 mg daily for the first 4 weeks, then increased at their 30-day visit by 5 mg to a maximum dose of 10 mg daily, if tolerated. If the participant does not tolerate the 10 mg dose, they will remain on 5 mg through the course of the study.
1830753|NCT00805805|Drug|Tetrathiomolybdate|120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime, for one week to test gastric tolerance. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. Serum ceruloplasmin levels measured weekly will be used as a surrogate measure of copper status, with a target of 10-15 mg/dl (normal 20-40). When target Cp levels are reached, usually in 4-8 weeks, a maintenance dose of usually 40-80 mg of TM/day, divided half with a major meal, and half away from food at bedtime will be established (vary from 10 mg to 120 mg/day).
1830754|NCT00805805|Other|Placebo|Arm 2 will basically mirror Arm 1 with the patients receiving 120 mg/day, divided as 20 mg three times/day with meals and 60 mg away from food at bedtime the first week. Increased to 180 mg/day, divided as 40 mg three times/day with meals and 60 mg away from food at bedtime. With the dosage being reduced at about the same frequency as the patients receiving TM
1830755|NCT00805818|Drug|NNZ-2566|"Solution for intravenous infusion.
20 mg/kg intravenous bolus infusion over 10 minutes followed by a continuous intravenous infusion of 1, 3, or 6 mg/kg/h for a total of 72 consecutive hours."
1830756|NCT00805831|Device|HDH|sutureless vascular anastomosis
1830757|NCT00805857|Drug|Tipranavir|
1830758|NCT00805870|Drug|Lovaza (omega-3-acid ethyl esters)|Lovaza, 3 grams per day for 65 days
1830759|NCT00805870|Drug|Wheat Germ Oil|Wheat germ oil, 3 grams/day for 65 days
1830760|NCT00805883|Procedure|Focal Phothtermal Ablation|Under general anasthesia and in Lithotomy position 2-4 14 Fr laser fibers will be placed into the prostate using 3D US guidance.
1830761|NCT00805896|Drug|Songyou|4g/pack
1830762|NCT00805896|Drug|placebo|4g/pack
1830763|NCT00805909|Drug|NI-0401|5 daily infusions with escalating doses of NI-0401
1830764|NCT00805922|Other|No treatment given|Capillary or venous blood will be drawn for analysing HbA1c.
1830765|NCT00805935|Drug|Menotropin|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
1830766|NCT00805935|Drug|Progesterone vaginal insert|100 mg inserted vaginally 2 or 3 times daily (BID or TID) (start on the day after oocyte retrieval) until 10 weeks gestation or confirmation of negative pregnancy test.
1830767|NCT00805935|Drug|Follitropin beta|225 IU (up to 450 IU) by subcutaneous injection once per day for up to about 15 days.
1830768|NCT00805935|Drug|Progesterone in oil|50 mg by intramuscular injection once per day, starting on the day after oocyte retrieval until 10 weeks gestation or confirmation of negative pregnancy test.
1830769|NCT00805935|Drug|leuprolide acetate|Daily administration of 0.5mg of leuprolide acetate (depot formulations were not permitted) began on Day 21 following onset of menses, and then decreased to 0.25 mg when gonadotropin therapy was initiated.
1830771|NCT00805961|Radiation|Radiation therapy|Radiation therapy, 2.0 Gy daily, 5 days per week by single daily dose, to a total of 60 Gy over 6 weeks
1830772|NCT00805961|Drug|Temozolomide|Temozolomide 75mg/m2 by mouth daily, beginning day 1 of radiation therapy and continuing through the last day of radiation therapy
1830773|NCT00805961|Drug|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning day 1 of radiation therapy
1830774|NCT00805961|Drug|Bevacizumab|Bevacizumab 10mg/kg IV, every 2 weeks, beginning Week 11
1830775|NCT00805961|Drug|Everolimus|Everolimus 10mg by mouth daily, beginning Week 11
1830776|NCT00805974|Biological|Biological examinations (blood and urinary).|
1830777|NCT00806026|Drug|placebo and pregabalin|following 3 months placebo treatment, subjects are to be re-distributed to pregabalin 300 mg per day for 9 months. Both placebo and pregabalin are to be administered orally once a day, 1-3 hours before bedtime.
1830778|NCT00806026|Drug|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.25mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
1830822|NCT00806286|Drug|Paclitaxel|IV, 200mg/m2, once every three weeks for up to 18 weeks
1830779|NCT00806026|Drug|pramipexol|following 3 months placebo treatment, subjects are to be re-distributed to pramipexol 0.5mg per day for 9 months. Both placebo and pramipexol are to be administered orally once a day, 1-3 hours before bedtime.
1830780|NCT00806026|Drug|Pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
1830781|NCT00806026|Drug|pramipexol|pramipexol 0.25 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
1830782|NCT00806026|Drug|pramipexol|pramipexol 0.5 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 months
1830783|NCT00806039|Other|Early Renal Involvement|Renal Consultation
1830784|NCT00806065|Drug|ENMD-2076|Oral capsules, once daily in 28-day cycles
1830785|NCT00806078|Drug|quinine sulfate|2 x 324 mg capsules (648 mg)
1830786|NCT00806078|Drug|quinine sulfate|2 x 324 mg capsules (648 mg)
1830787|NCT00806104|Dietary Supplement|Fructo-oligosaccharides|Dietary supplementation for 4 weeks
1830788|NCT00806104|Dietary Supplement|Maltodextrins|Dietary supplementation for 4 weeks
1830789|NCT00806117|Radiation|Radiotherapy (RT)|"External irradiation 50Gy/5 weeks
Lateral: 2 cm lateral to the bony margin of the pelvis
Superior: Between L5 and S1
Inferior: 2 cm below the obturator foramen Intracavitary boost 30-35Gy/4 weeks(positive vaginal margins only)"
1830790|NCT00806117|Other|Concurrent chemoirradiation (CCRT)|Cisplatin 40mg/m2 every week during external irradiation
1830791|NCT00806117|Other|Sequence chemotherapy and radiotherapy (SCRT)|Paclitaxel 135~175mg/m2 over 3 hours Cisplatin 60~75mg/m2
1830792|NCT00806143|Device|repetitive transcranial stimulation (rTMS)|"Repetitive TMS will be administered using a MAGSTIM rapid magnetic stimulator (Magstim Company, Ltd., Whitland, U.K.) and a 70-mm figure-eight shaped coils.
In monolateral treatment in right DLPFC, three 140-second trains will be applied at 1 Hz and at 110% of RMT. There is a 30 seconds intertrain interval (total of 420 stimuli per session). In sequential treatment, the stimulation will be applied in the first to the right and then to the left dorsolateral prefrontal cortex. In right DLPFC will be applied three 140-second trains at 1 Hz and at 110% of RMT. There will be a 30 seconds intertrain interval (total of 420 stimuli per session). In left DLPFC will be applied twenty 5-second trains were applied at 10 Hz and at 100% of RMT. There will be a 25-second intertrain interval (total of 1000 stimuli per session). Patients will be treated from Monday to Friday, for a total of 15 days."
1830793|NCT00806143|Device|unilateral stimulation|Patients will be treated from Monday to Friday, for a total of 15 days in the same timeframe of the active group right sided low frequency stimulation
1830794|NCT00806156|Drug|NKTR-102|NKTR-102 given on a q14 day schedule
1830795|NCT00806156|Drug|NKTR-102|NKTR-102 given on a q21 day schedule
1830796|NCT00806169|Drug|triamcinolone and bevacizumab|
1830797|NCT00806195|Biological|MenACWY-CRM197|Four 0.5mL vaccinations of MenACWY-CRM197 conjugate vaccine was administered by intramuscular injection at 2, 4, 6 and 12 months of age.
1830798|NCT00806195|Biological|DTaP (Diptheria, Tetanus, Pertussis) Vaccine|Four vaccinations of DTaP (Diptheria, Tetanus, Pertussis) was administered at 2, 4, 6, and 15 months of age.
1830799|NCT00806195|Biological|Hib (Haemophilus influenza b) Vaccine|Four vaccinations of Hib (Haemophilus influenza b) vaccine was administered at 2, 4, 6 and 15 months of age.
1830800|NCT00806195|Biological|IPV (Inactivated Polio Vaccine) Vaccine|Three vaccinations of IPV (Inactivated Polio Vaccine) was administered at 2, 4, and 6 months of age.
1830801|NCT00806195|Biological|Pneumococcal conjugate Vaccine|Four vaccinations of Pneumococcal conjugate vaccine was administered at 2, 4, 6 and 12 months of age.
1830802|NCT00806195|Biological|MMR (Measles, Mumps, and Rubella) Vaccine|One vaccination of MMR (Measles, Mumps, and Rubella) was administered at 12 months of age.
1830803|NCT00806195|Biological|Varicella Vaccine|One vaccination of Varicella vaccine was administered at 12 months of age.
1830804|NCT00806195|Biological|Hepatitis A Virus|One vaccination of Hepatitis A Virus vaccine was administered at 12 months of age.
1830805|NCT00806208|Drug|MEDI-507|0.012 mg/kg MEDI 507 and Methylprednisolone
1830806|NCT00806208|Drug|MEDI-507|0.04 mg/kg MEDI 507 and Methylprednisolone
1830807|NCT00806208|Drug|MEDI-507|0.12 mg/kg MEDI 507 and Methylprednisolone
1830808|NCT00806208|Drug|MEDI-507|0.4 mg/kg MEDI 507 and Methylprednisolone
1830809|NCT00806208|Other|Placebo|Placebo IV (alternative) study days 0, 3,6, and 9
1830810|NCT00806221|Drug|emollient (Cetaphil cream)|Cetaphil cream applied daily from birth
1830811|NCT00806234|Drug|Aripiprazole or Perphenazine|Baseline second generation antipsychotic (SGA) treatment will be gradually decreased and discontinued over 8 weeks while treatment with aripiprazole or perphenazine will be increased to effective levels.
1830812|NCT00806234|Drug|Metformin|Metformin treatment will be added to current SGA treatment, with dosing based on participant weight and increased according to a preset titration schedule unless side effects interfere.
1830813|NCT00806234|Drug|Olanzapine, quetiapine, risperidone, ziprasidone, aripiprazole, asenapine, iloperidone, lurasidone, paliperidone, or olanzapine/fluoxetine|Current antipsychotic medication will be continued throughout the treatment period, with changes in dose only made as clinically indicated
1830814|NCT00806247|Drug|tapentadol HCl|
1830815|NCT00806260|Drug|VI-0521|Phentermine 3.75 mg and topiramate 23 mg daily for the 1st week; Phentermine 7.5 mg and topiramate 46 mg daily for the 2nd week; Phentermine 11.25 mg and topiramate 69 mg daily for the 3rd week; Phentermine 15 mg and topiramate 92 mg daily for the 4th week
1830816|NCT00806260|Drug|Placebo|Placebo daily for 4 weeks
1830817|NCT00806260|Other|Alcohol|
1830818|NCT00806260|Other|alcohol placebo|fruit juice
1830819|NCT00806273|Device|Vista Ultrasonic Bleach Bypass System|The ultrasonic needle will be activated by depressing the foot pedal which will begin the debridement process. Irrigants will be delivered constantly at the recommended rate via the syringe pump and the needle tip will be moved up and down with a 2mm amplitude for the entire 1 minute activation cycle, which will deliver a total of 3ml of irrigant. The ultrasonic unit will be turned off and the needle will be withdrawn from the canal.
1830820|NCT00806273|Device|Needle Irrigation|irrigation with 3ml 6% NaOCl is performed moving the needle from just short of binding to 2mm coronal in constant motion for 60 seconds and left untouched in a full canal for 60 seconds.
1830821|NCT00806286|Drug|CS7017 tablets|CS7017 tablets, strength 0.25mg, two tablets, two times daily for twenty-five to thirty months
1830823|NCT00806286|Drug|Carboplatin|IV, AUC of 6, once every three weeks for up to 18 weeks
1830824|NCT00806286|Drug|Placebo Tablets|Placebo tablets matching CS-7017 tablets
1830825|NCT00806299|Drug|Loperamide / Red Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without red grapefruit juice
1830826|NCT00806299|Drug|Loperamide/ White Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without white grapefruit juice
1830827|NCT00806299|Drug|Loperamide / Pink Grapefruit Juice|Fixed sequence of loperamide 4 mg with and without pink grapefruit juice
1830828|NCT00806338|Drug|Trodusquemine (MSI-1436)|A single dose of Trodusquemine (MSI-1436) will be administered every 72 hours on Days 0, 3, 6, 9, 12, 15, 18 and 21. Doses are 3mg/m2 in cohort 1, 6mg/m2 in cohort 2 and 10mg/m2 in cohort 3.
1830829|NCT00806338|Drug|Placebo|
1830832|NCT00806390|Drug|Metoprolol|Metroprolol tartrate titrated up
1830833|NCT00806403|Drug|reteplase 10+10 U|comparison to primary PCI
1830834|NCT00806403|Procedure|primary PCI|comparison to thrombolysis
1830835|NCT00806416|Drug|alendronate sodium (+) cholecalciferol|A single dose tablet of 70 mg alendronate/2800 IU (international unit) vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
1830836|NCT00806416|Drug|Comparator: alendronate|A single dose table of 70 mg alendronate in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
1830837|NCT00806416|Dietary Supplement|Comparator: cholecalciferol (Vitamin D)|A single dose tablet of 2800 IU vitamin D in one treatment period of each sequence. There will be a 12 day interval between each treatment period.
1830839|NCT00806442|Drug|Borage Seed Oil and Echium Seed Oil|2 g/day of borage seed oil and 7 g/day of echium seed oil to provide 1.6 g/day of GLA and 0.9 g/day of SDA.
1830840|NCT00806442|Dietary Supplement|Corn Oil|9 g/day of corn oil
1830841|NCT00806468|Drug|Desmotabs|Desmotabs encapsulated, 0,2 mg once daily for one week, 0,2 mg bid for one week
1830842|NCT00806481|Drug|Sevelamer carbonate|Treatment group: treatment with 1600mg tablets of sevelamer carbonate three times daily for 36 weeks
1830843|NCT00806481|Drug|Placebo|Treatment group: treatment with tablets of placebo three times daily for 36 weeks
1830844|NCT00806494|Drug|Fesoterodine|Fesoterodine 4mg for 4 weeks, escalating to fesoterodine 8mg if tolerated
1830845|NCT00806507|Procedure|Echocardiograms|Additional views performed in 5-10 minutes of regularly scheduled echocardiograms.
1830846|NCT00806507|Procedure|Blood Test|Measuring of hormones and metabolic proteins (such as sugars and acids).
1830847|NCT00806533|Drug|HES 130 / 0.42 (Venofundin 6%, Tetraspan 6%)|solution for intravenous infusion applied according to SmPC
1830848|NCT00806546|Drug|NP101|NP101 study patch four hour application
1830849|NCT00806559|Other|Re-designed room|In the redesigned room patients and clinicians are sitting at a single table in a different configuration compared to the usual clinical exam room, with the doctor at the computer and two chairs for the patient and family/friends.
1830850|NCT00806559|Other|Control room|This is the usual clinical room for a clinical visit, with physician at desk and chairs along the wall for patient/family.
1830851|NCT00806572|Drug|hOKT3gamma1(Ala-Ala)|3 cycles, six months apart, each consisting of 12 daily infusions with 455-1818ug/m2 hOKT3g1(Ala-Ala)
1830852|NCT00806585|Drug|MK-0736|
1830853|NCT00806585|Drug|Comparator: Placebo|
1830854|NCT00806585|Drug|Comparator: HCTZ|
1830855|NCT00806598|Drug|Thymoglobulin|"3.5 or 2.5 mg/kg/day IV for 5 days
Aplastic anemia patients receive 3.5 mg/kg/day for 5 days
MDS patients <55 years receive 3.5 mg/kg/day for 5 days
MDS patients >55 years receive 2.5 mg/kg/day for 5 days"
1830856|NCT00806598|Drug|Cyclosporine|5 mg/kg orally for 6 months; start after completing thymoglobulin.
1830857|NCT00806598|Drug|Methylprednisolone|1 mg/kg/day IV for 5 days, given before each dose of thymoglobulin.
1830858|NCT00806598|Drug|G-CSF|5 microgram/kg subcutaneously daily up to 3 months, start after thymoglobulin.
1830859|NCT00806611|Procedure|Alcohol Block|Operating surgeon by injecting 20 ml of either 50% ethanol or saline on each side of the aorta at the level of the celiac axis with a 20 or 22 gauge spinal needle
1830860|NCT00806624|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
1830861|NCT00806624|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 3 months
1830862|NCT00806624|Drug|Warfarin tablets|Warfarin tablets taken once daily for up to 3 months
1830865|NCT00806650|Genetic|gene expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
1830866|NCT00806650|Genetic|protein expression analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
1830951|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
1958851|NCT01184066|Behavioral|ACTS Intervention|ACTS (Attitudes, Communication, Treatment, Support) Intervention is a onetime intensive 45 minute intervention delivered by a black breast cancer survivor and utilizing video, graphics, teaching tools, and supportive testimony to encourage chemotherapy adherence.
1958852|NCT01184066|Behavioral|Usual Care|Usual Care will consist of standard therapy education by a registered nurse in the treatment center. Education and support from clinicians are offered as needed throughout the course of cancer treatment at all participating medical oncology clinics.
1958854|NCT01178944|Other|Laboratory Biomarker Analysis|Correlative studies
1830867|NCT00806650|Other|diagnostic laboratory biomarker analysis|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
1830868|NCT00806650|Other|immunoenzyme technique|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
1830869|NCT00806650|Other|immunohistochemistry staining method|Testing performed on blood draw taken prior to surgery or other treatment and on fresh or frozen primary or metastatic tissue samples
1830870|NCT00806663|Drug|sunitinib added to FOLFIRI|sunitinib 37 mg once daily (4 weeks on/2 weeks off)
1830871|NCT00806676|Drug|Gardasil® Vaccine (FDA-approved vaccination regimen)|Standard Gardasil® 3-dose regimen (0.5 mL/dose; doses at 0, 2 and 6 months) delivered to females with chronic kidney disease 9-21 years of age.
1830872|NCT00806689|Procedure|Cardiac rhythm monitor implantation|post surgical procedure implantation of insertable event recorder for long time heart rhythm surveillance afte ablation therapy
1830873|NCT00806689|Device|Reveal® XT 9525|During cardiac surgery after stand alone or concomitant ablation procedure, an insertable loop recorder will be implanted subcutaneously in left pectoral region. After surgery, patients will be monitored regularly in a quarterly basis by performing telemetry of the device in the outpatient clinic. Furthermore, home telemetry will be performed once a month for optimal heart rhythm observation.
1830874|NCT00806728|Drug|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of normal saline on Days 16, 23, 30, and 37.
1830875|NCT00806728|Drug|MEDI-507|0.12 mg/kg of MEDI-507 given every third day for 4 doses followed by doses of MEDI-507 on Days 16, 23, 30, and 37.
1830876|NCT00806741|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
1830877|NCT00806741|Drug|Phenylephrine|1μg/kg/min, infusion period 20 minutes
1830878|NCT00806741|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
1830879|NCT00806741|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim of the optic nerve head
1830880|NCT00806741|Device|Goldmann applanation tonometer|intraocular pressure measurements
1830881|NCT00806741|Other|squatting|Subjects will perform squatting for 6 minutes while blood flow is measured
1830882|NCT00806754|Drug|Ciclesonide nasal spray + placebo Azelastine|Ciclesonide nasal spray 50 mcg + Placebo Azelastine
1830883|NCT00806754|Drug|Ciclesonide nasal spray + Azelastine|Ciclesonide nasal spray 50 mcg + Azelastine 137 mcg
1830884|NCT00806767|Biological|therapeutic immune globulin|
1830885|NCT00806767|Drug|busulfan|
1830886|NCT00806767|Drug|fludarabine phosphate|
1830887|NCT00806767|Procedure|allogeneic hematopoietic stem cell transplantation|
1830888|NCT00806780|Procedure|on table cholangiography|x-ray imaging of common bile duct
1830889|NCT00806806|Drug|SKY0402|Local administration of SKY0402 followed by noxious stimulus
1830890|NCT00806806|Drug|Placebo|Local administration of Placebo followed by noxious stimuli
1830891|NCT00806819|Drug|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
1830892|NCT00806819|Drug|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
1830893|NCT00806819|Drug|pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
1830894|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
1830895|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
1830896|NCT00806819|Drug|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
1830897|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
1830898|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
1830899|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
1830900|NCT00806819|Drug|B12|1000 ug IM injection starting a week before first pemetrexed infusion and every 9 weeks thereafter until discontinuation of pemetrexed
1830901|NCT00806819|Drug|dexamethasone (or corticosteroid equivalent)|4 mg PO bid the day before, the day of and the day after each pemetrexed infusion
1830902|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
1830903|NCT00806819|Drug|placebo|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
1830904|NCT00806819|Drug|Folic Acid|400 ug once daily starting 1-2 weeks prior to the first dose of pemetrexed and continuing for at least 3 weeks after stopping pemetrexed.
1830905|NCT00806819|Drug|Nintedanib (BIBF1120)|starting dose of 200 mg bid taken daily except on the day of pemetrexed infusion . The dose can be reduced to 150 bid and then to 100 mg bid.
1830906|NCT00806819|Drug|Pemetrexed|500 mg/metre squared administered as an intravenous infusion over 10 minutes on Day 1 of each 21 day cycle.
1830907|NCT00806858|Device|NovoPen® 4|Insulin administration by means of a NovoPen® 4 pen device
1830908|NCT00806871|Drug|Methylprednisolone 40 mg|"Depo-medrol 40 mg , suspension, injection in the carpal tunnel, one time use
1 ml 40 mg Methylprednisolone + 1 ml 10mg Lidocaine + 1 ml saline"
1830909|NCT00806871|Drug|Methylprednisolone 80 mg|"Depo-medrol 80 mg , suspension, injection in the carpal tunnel, one time use.
2 ml 80mg Methylprednisolone + 1 ml 10mg Lidocaine"
1830910|NCT00806871|Drug|Sodium chloride|"Saline solution 0,9%, injection in the carpal tunnel, one time use
1 ml 10 mg Lidocaine + 2 ml saline"
1830952|NCT00807118|Drug|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fasted condition
1830953|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fasted condition
1831522|NCT00798304|Biological|meningococcal B rLP2086 vaccine|vaccination
1830911|NCT00806884|Other|Physiotherapy Musculoskeletal Treatment|Other: Physiotherapy Musculoskeletal Treatment Specific, gentle oscillatory mobilisations to the rib cage and thoracic spine of the subjects to improve joint alignment and mobility, and to reduce pain. Treatment of specific muscle dysfunction or tight muscle groups to further optimise muscle length and biomechanical relationships in the area , leading to improved efficiency of recruitment and improved power output. Postural education and awareness discussions to improve the subject's own joint alignment and ability in a functional manner. A short programme to reinforce the progress during the treatment sessions may be given.
1830912|NCT00806884|Other|Control group measurements|None other than control group measurements
1830913|NCT00806897|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
1830914|NCT00806910|Drug|Conivaptan|IV Vaprisol initially at 20 mg IV injection over 30 minutes, followed by a 20 mg IV infusion over the next 24 hours (i.e. 20 mg bolus, 20 mg continuous infusion approximately 24 hrs).
1830915|NCT00806910|Other|Placebo|Placebo (will be given at the same rate of Vaprisol given in the treatment arm)
1830916|NCT00806923|Drug|Cisplatin|80mg/m2 iv on day 1 of each 3 week cycle, for a maximum of 6 cycles
1830917|NCT00806923|Drug|Gemcitabine|1250mg/m2 on days 1 and 8 of each 3 week cycle for a maximum of 6 cycles
1830918|NCT00806923|Drug|Placebo|iv on day 1 of each 3 week cycle until disease progression
1830919|NCT00806923|Drug|bevacizumab [Avastin]|15mg/kg 1v on day 1 of each 3 week cycle until disease progression
1830920|NCT00806923|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of each 3 week cycle until disease progression
1830921|NCT00806936|Drug|human insulin|Any kind of human insulin administered at the discretion of the physician
1830922|NCT00806936|Drug|insulin analogue|Any kind of insulin analogue administered at the discretion of the physician
1958855|NCT01178944|Drug|Oxaliplatin|Given IV
1958856|NCT01178944|Drug|Pralatrexate|Given IV
1958857|NCT01177735|Drug|Pomalidomide|Only enough CC-4047 for 1 cycle of therapy may be provided to the patient each cycle. Participants will receive CC-4047 4 mg/day for 21 days, every 28 days. Treatment will continue until disease recurrence or untoward toxicity.
1830927|NCT00806975|Device|KwikPen® and FlexPen®|The treatment is changed to twice a day injection of the same unit of Novo Rapid 30 Mix injection FlexPen® or Humalog Mix 25 injection KwikPen®for 3 months, after which the final assessment is made.
1830928|NCT00806988|Procedure|Mitral Valve Repair|"Surgical techniques for mitral valve repair may need to be adjusted at the discretion of the surgeon, as based on intra-operative findings that may not be previously recognized in the pre-operative evaluation. The common elements for mitral annuloplasty planned as part of this study include the following:
All procedures will be performed with cardiopulmonary bypass (CPB) and with moderate hypothermia. Cannulation will be central with aortic cannulation for arterial inflow from the cardiopulmonary bypass circuit. Right atrial or bicaval (inferior and superior vena cava) drainage cannulas will be employed.
The heart will be arrested with cardioplegia.
A complete annular ring shall be placed unless specifically contraindicated by intra-operative findings. Additional repair of the mitral apparatus itself will be based on intra-operative findings."
1830929|NCT00806988|Procedure|CABG|CABG will be performed using standard surgical techniques. Conduit selection and harvesting methods will not be prescribed, except that utilization of the left internal mammary artery (LIMA) is recommended when a left anterior descending (LAD) graft is indicated. The technical details of bypass grafting will not be prescribed. Complete revascularization will be performed, within the judgment of the surgical investigator.
1830930|NCT00807001|Drug|IDX184|oral dose, active or placebo
1830931|NCT00807014|Drug|Duac Gel|Duac® Gel will be applied to the face once daily at night, for 12 weeks.
1830932|NCT00807014|Drug|Differin gel|Differin Gel will be applied to the face once daily at night, for 12 weeks.
1830933|NCT00807027|Drug|Activated T lymphocyte(Immuncell-LC)|"Efficacy/Effects: Removal of minimal residual cancer after removal of brain tumors and relapse prevention
Method of administration and quantity: Test Drug: Per 60kg of average adult body weight, administer 100mg that contains 109~2x1010 lymphocytes for one hour intravenously. (Duration of administration can be controlled based on patient conditions)"
1830934|NCT00807040|Procedure|Mitral Valve Repair with Annuloplasty|The annuloplasty ring will be chosen by the surgeon. The ring is sized to the anterior leaflet and intertrigonal distance. A semi-rigid or rigid annuloplasty ring will be used, and if tethering is present, a subvalvar procedure will be performed.
1830935|NCT00807040|Procedure|Mitral Valve Replacement|Mitral valve replacement will include complete preservation of the subvalvar apparatus. The technique of preservation, choice of prosthetic valve, and technique of suture placement will be dependent on the surgeon's preference. The prosthetic valve will be tested for paravalvular leaks by using the left ventricular saline infusion test.
1830936|NCT00807053|Drug|Ciclesonide HFA|75 mcg Ciclesonide HFA versus Placebo
1830937|NCT00807053|Drug|Ciclesonide HFA|150 mcg Ciclesonide HFA versus Placebo
1830938|NCT00807053|Drug|Ciclesonide HFA|300 mcg Ciclesonide HFA versus Placebo
1830939|NCT00807053|Drug|Placebo|Placebo
1830940|NCT00807066|Drug|Gefitinib|Gefitinib 250 mg/day
1830941|NCT00807066|Drug|Platinum|Platinum based chemotherapy with cycles every 21 days
1830942|NCT00807079|Drug|carboplatin|
1830943|NCT00807079|Drug|topotecan hydrochloride|
1830944|NCT00807092|Drug|biphasic insulin aspart 30|The initial doses for BIAsp 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 U/kg body weight and to be equally divided (1/2:1/2) between pre-breakfast and pre-dinner
1830945|NCT00807092|Drug|biphasic human insulin 30|The initial doses for BHI 30 twice-daily regimen will be recommended to start at a total daily dose of 0.3 IU/kg body weight and to be divided in the ratio of 2/3:1/3 between pre-breakfast and pre-dinner
1830946|NCT00807092|Drug|metformin|Metformin dose must remain the same as that used prior to the trial.
1830947|NCT00807105|Device|H-coil dTMS|treatment with deep TMS stimulation.
1830948|NCT00807118|Drug|Fesoterodine|Single dose of 2 x 4 mg tab in formulation F under fed condition
1830949|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation F under fed condition
1830950|NCT00807118|Drug|Fesoterodine|Single dose of 1 x 8 mg tab in formulation E(1) under fed condition
1830954|NCT00807131|Behavioral|Patient follow-up|Dader method, which was developed to provide pharmaceutical care, which consists of seven steps covering the evaluation of services, benefits of interventions, and identification of unexpected occurrences. Its objectives are to improve the patient quality of life.
1830955|NCT00807131|Behavioral|Counseling|The pharmacist proceeds the counseling when the patient comes to the pharmacy to take their medicines.
1830956|NCT00807131|Behavioral|Drug dispensing|The pharmacist gives the drugs to the patient with the minimum of information necessary to guarantee a safe and effective drug intake.
1830957|NCT00807131|Behavioral|pharmacy usual care|The patient receives no information about their medicines in the pharmacy, unless he asks for it.
1830958|NCT00807144|Drug|Tacrolimus (Kidney transplant maintenance immunosuppression)|Standard-release Tacrolimus 1 to 20mg daily in two divided doses to maintain trough drug levels 6-9ng/ml
1830959|NCT00807144|Drug|Kidney transplant maintenance immunosuppression|Prolonged-release Tacrolimus 1 to 20mg daily in a single am dose adjusted to trough drug levels 6-9ng/ml
1830960|NCT00807157|Dietary Supplement|PROBIOSTICK® during 30 days|Every morning subjects will consume a stick of PROBIOSTICK® during 30 days
1830961|NCT00807157|Dietary Supplement|Placebo during 30 days|Every morning subjects will consume a stick of placebo during 30 days
1830962|NCT00807170|Drug|ZD6474 (Vandetanib)|100 mg as a once daily oral dose, 21 days
1830963|NCT00807170|Radiation|Whole Brain Radiotherapy (WBRT)|
1830964|NCT00807170|Drug|ZD6474|200 mg as a once daily oral dose, 21 days
1830965|NCT00807170|Drug|ZD6474|300 mg as a once daily oral dose, 21 days
1830966|NCT00807183|Other|woodstove|installation of new EPA-certified woodstove
1830967|NCT00807183|Other|inactive air filter|air filter units without filter in place
1830968|NCT00807183|Other|Active air filter|air filter units correctly operating
1830969|NCT00807196|Drug|Rituximab|250mg/m2 day -21 and day -14 of preparative regimen
1830970|NCT00807196|Drug|90Y ibritumomab tiuxetan (Zevalin)|0.4 mCi/kg IV on day -14 of preparative regimen
1830971|NCT00807196|Drug|Cyclophosphamide|300mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
1830972|NCT00807196|Drug|Fludarabine|30mg/m2 IV daily for 5 days day -8 to day -4 of preparative regimen
1830973|NCT00807196|Other|Non myeloablative allogeneic stem cell transplantation|Blood stem cell infusion on day 0
1830974|NCT00807209|Drug|Low Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 75mg SKY0402 (25 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
1830975|NCT00807209|Drug|High Dose SKY0402|Bupivacaine, 15 mg/mL via epidural PLUS single total administration of 150 mg (50 mg to each of three segments) in 4 mL volume each for a total of 12 mL via nerve block (intercostal)
1830976|NCT00807209|Drug|Placebo|Bupivacaine, 15 mg/mL per epidural PLUS administration of 4 mL Placebo to each of three nerves for a total of 12 mL (intercostal)
1830977|NCT00807209|Drug|Fentanyl via PCA|Fentanyl via PCA
1830978|NCT00807209|Drug|Bupivacaine via epidural|Bupivacaine via epidural
1830979|NCT00807222|Drug|lisdexamfetamine dimesylate|Subjects will receive Vyvanse 30, 50, or 70 mg per day or placebo capsules orally for up to (a maximum of) seven (7) weeks.
1830980|NCT00807235|Drug|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 3 hours.
1830981|NCT00807235|Drug|Aerosolized lucinactant|Aerosolized lucinactant via nCPAP over 3 hours. Up to 3 retreatments will be allowed over a 48 hour period with each retreatment separated by at least 1 hour.
1830982|NCT00807248|Drug|Escitalopram placebo|Once daily before bedtime for 8 weeks
1830983|NCT00807248|Drug|Gaboxadol placebo|Once daily before bedtime for 8 weeks
1830984|NCT00807248|Drug|Escitalopram 20 mg|Once daily before bedtime for 8 weeks
1830985|NCT00807248|Drug|Gaboxadol 5 mg|Once daily before bedtime for 8 weeks
1830986|NCT00807248|Drug|Gaboxadol 10 mg|Once daily before bedtime for 8 weeks
1830987|NCT00807261|Drug|Gemcitabine and Docetaxel|"Drug and schedule
Gemcitabine 1000 mg/m2 IV over 10 mg/m2/min (D1, D8)
Docetaxel 35 mg/m2 IV (D1, D8) .. every 21 days
Dose modification
Treatment should be delayed if the ANC<1,500/ mm3, or if the platelet count <75,000/mm3 on the first day of the next cycle.
Gemcitabine & docetaxel are omitted on day 8, when ANC is less than 1000/mm3 or platelet count is less than 50,000/mm3; it is reduced by 25% if the ANC is between 1,000 and 1,500/mm3 or the platelet count is between 50,000 and 75,000/mm3 Study design Treatment should consist of at least 2 cycles unless rapid disease progression or unacceptable toxicities occur after one cycle of chemotherapy.
Patients with response or no change will receive 2 additional cycles."
1830988|NCT00807287|Procedure|Jejunal tube placement using the unguided frictional method|The self-advancing nasal jejunal feeding tube has small alternating cilia-like plastic flaps to help to advance it into the small bowel via peristalsis. The tube is placed in the stomach (50-60 cm mark). Then the tube is left in place for 1 hour to allow the patient's peristalsis to advance the tube by catching its small plastic tabs. Thereafter, the tube is manually advanced 10 cm every hour until the 100 cm mark of length is reached. To improve peristalsis, 10mg metoclopramide i.v. and 200mg erythromycin i.v. 15 minutes before the procedure are administered.
1830989|NCT00807287|Procedure|Jejunal tube placement using the endoscopic method|Jejunal feeding tubes are placed using endoscopy
1830990|NCT00807300|Radiation|CT-guided brachytherapy|catheter placed into the tumor by CT-guidance, radiation with iridium 192
1830991|NCT00807300|Procedure|transarterial chemoembolization|application of doxorubicin and cisplatin in lipiodol into the tumor-feeding artery
1830992|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg caplets|Oral, 2 caplets taken initially at investigator site followed by one caplet after each unformed stool, maximum 4 caplets in a 24 hour period for a maximum of 48 hours (per product label)
1830993|NCT00807326|Drug|Loperamide/simeticone 2 mg/125 mg chewable tablets|Oral, 2 chewable tablets taken initially at the site followed by one chewable tablet after each unformed stool, maximum 4 chewable tablets in a 24 hour period for a maximum of 48 hours (per product label)
1830994|NCT00807326|Drug|Probiotic Saccharomyces boulardii 250 mg capsules|Oral, 1 capsule twice a day, maximum 2 capsules in a 24 hour period for a maximum of 5 days (per product label)
1830995|NCT00807339|Radiation|Stereotactic radiation|Dose escalation three consecutive treatments
1830997|NCT00807365|Drug|GHRH|GHRH administered subcutaneously at 2.0 mg/kg/dose bolus each night at 11:00 Post Meridian (PM), 1:00 Ante Meridian (AM), 3:00 AM, & 5:00 AM for 6 months.
1830998|NCT00807378|Other|LUMBAR PUNCTURE|LUMBAR PUNCTURE FFOR CSF COLLECTION
1830999|NCT00807391|Procedure|TBCA, TBNA|One arm, in random order first transbronchial catheter aspiration and second transbronchial needle aspiration or vice verse, both techniques routinely used in the diagnosis of peripheral pulmonary lesions; the cytological specimens of TBCA and TBNA are in random order examined by two independent cytologists, all cytological specimens are afterwards examined by a third, supervising cytologist.
1831000|NCT00807404|Procedure|histopathologic examination|
1831001|NCT00807404|Procedure|optical coherence tomography|
1831002|NCT00807430|Device|Grindcare (Active)|Active treatment
1831003|NCT00807430|Device|Grindcare (Placebo - the device is not activated)|Placebo treatment
1831004|NCT00807443|Drug|Raltegravir|Raltegravir (INN), 400 mg tablets, developed and supplied by Merck Sharp & Dohme. A dose of 400 mg will be administered every 12 hours
1831005|NCT00807456|Device|ASTRA TECH Implant System, OsseoSpeed™|ASTRA TECH Implant System, OsseoSpeed™ Profile implants: Ø4.5, 5.0, 5.0S mm in lengths of 9, 11, 13, 15mm.
1831006|NCT00807495|Drug|MLN8237|MLN8237 will be administered orally at a dose of 50 mg twice daily for seven consecutive days followed by a 14-day rest period, in 21-day cycles until there is evidence of disease progression or unacceptable treatment-related toxicity
1831007|NCT00807508|Dietary Supplement|placebo|wheat meal capsules with each main meal
1831008|NCT00807508|Dietary Supplement|leucine|daily leucine capsules with each main meal
1831009|NCT00807521|Drug|Dexamethasone|Single high dose bolus of dexamethasone before surgery
1831010|NCT00807521|Drug|Placebo|Placebo for dexamethasone
1831011|NCT00807534|Drug|ipratropium bromide|ipratropium bromide nebulization
1831012|NCT00807534|Drug|placebo|placebo nebulization
1831013|NCT00807534|Behavioral|constant rate step test|nebulization of 500ug
1831014|NCT00807534|Behavioral|constant rate shuttle walk test|nebulization of 500ug
1831015|NCT00807547|Biological|Allergy vaccination (Alutard SQ)|Alutard SQ grasses and rye, 8 subcutaneous injections, updosing to 10.000 SQ-U, duration of treatment 50 days
1831016|NCT00807560|Behavioral|FBT-PO|The goal of FBT-PO is to resolve the eating disorder and return the patient to healthy psychosocial and physiological developmental trajectories through active family involvement across three treatment phases.
1831017|NCT00807560|Behavioral|NEC|Families assigned to NEC will receive a minimal nutrition and physical activity education curriculum across 16 sessions over 24 weeks.
1831018|NCT00807573|Drug|Paclitaxel|Day 1: Paclitaxel (90 mg/m^2 over 60 minutes) Day 15: Paclitaxel (90 mg/m^2 over 60 minutes)
1831019|NCT00807573|Drug|Pemetrexed|Day 1: Pemetrexed (500 mg/m^2 over 10 minutes) Day 15 Pemetrexed (500 mg/m2 over 10 minutes)
1831020|NCT00807573|Drug|Bevacizumab|Day 1:Bevacizumab (10 mg/kg over 20 minutes) Day 15: Bevacizumab (10 mg/kg over 20 minutes)
1831023|NCT00807599|Procedure|Stem cell transplant x 1 or x 2|"After 4 cycles of Ld, eligible patients will undergo stem cell mobilization and collection with standard-of-care cyclophosphamide and Neupogen (G-CSF) or with plerixafor G-CSF. Mobilization with cyclophosphamide is preferred, but plerixafor is also allowed. Ld will be held for at least 2 weeks prior to stem cell mobilization.
On the SCT arm, patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients, after one or two SCT, will receive maintenance L."
1831024|NCT00807599|Drug|lenalidomide and dexamethasone|Patients will then be randomized to continued Ld or high-dose melphalan with SCT. On the SCT arm patients not achieving VGPR by 3 months after the 1st SCT will undergo a 2nd SCT. All patients after one or two SCT, will receive maintenance L.
1831025|NCT00807612|Biological|AMG 479|AMG 479 at 12 mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 12 mg/kg IV monotherapy for up to 24 months from study day 1
1831026|NCT00807612|Biological|AMG 479|AMG 479 at 18mg/kg IV in combination with chemotherapy Day 1 of cycle 1 to 6 (except for subjects being evaluated by intensive PK who will be administered AMG 479 on Day 2 of cycle 1 and then day 1 of every cycle thereafter) followed by AMG 479 at 18 mg/kg IV monotherapy for up to 24 months from day 1
1831027|NCT00807612|Drug|Carboplatin|Carboplatin (AUC 6) IV infusion over 30 (± 10) minutes according to institutional guidelines Day 1 of Cycle 1 to 6
1831028|NCT00807612|Biological|AMG 479|AMG 479 IV in combination with chemotherapy on day 1 of every 3 week cycle for 4 to 6 cycles, followed by AMG 479 IV monotherapy for up to 24 months from study day 1. The AMG 479 dose to be used will be the final AMG 479 dose explored from Part 1
1831029|NCT00807612|Drug|Paclitaxel|Paclitaxel at 200 mg/m2 IV infusion over 3 hours (± 30 minutes) according to institutional guidelines Day 1 of Cycle 1 to 6
1831030|NCT00807625|Drug|Depo Provera|Depo Provera administered by injection at randomization visit and the 12-week study visit.
1831031|NCT00807625|Device|Copper T Intrauterine contraception device|IUCD inserted upon randomization to this study arm
1831032|NCT00807651|Procedure|AHSCT|All study participants given written informed consent will perform autologous hematopoietic stem cell transplantation(AHSCT) and be treated with immunosuppression.
1831033|NCT00807651|Drug|Insulin therapy|All study participants not accepted written informed consent will received insulin therapy with consistent or multiply subcutaneous injection.
1831036|NCT00807677|Drug|TAK-901|TAK-901 will be administered via IV infusion over a 3-hour period on Days 1,4,8,11,15,18,22, and 25 of each 28-day cycle.
1831037|NCT00807690|Drug|Tacrolimus ointment|Tacrolimus ointment 0.1%every night for at least 3 months, half body side
1831038|NCT00807703|Procedure|Select Stim|Select Stim: see summary
1831975|NCT00819052|Drug|Nevirapine XR|Nevirapine extended release
1831039|NCT00807716|Other|walking skill group|12 Individualized group training sessions with focus on functional exercises like walking and stair climbing including balance training under physiotherapy guidance, 12 times 70 minutes.
1831040|NCT00807716|Other|usual physiotherapy care|physiotherapy, mostly in non-weight bearing, 12 times 40 minutes
1831041|NCT00807729|Procedure|ERCP|Endoscopic Retrograde Cholangiopancreatography Patients randomized to ERCP/S + LC were scheduled to undergo the endoscopic procedure using fluoroscopy (OEC Diasonics 9400) in the endoscopy suite under moderate sedation (principally intravenous midazolam and meperidine) prior to the intended laparoscopy. Duodenal atony during ERCP was routinely achieved using intravenout glucagon. If choledocholithiasis was detected or suspected at the time of ERCP, a sphincterotomy was undertaken so that gallstones could be extracted using a balloon catheter or retrieval basket. Small bowel gas was aspirated endoscopically as much as possible at the conclusion of the ERCP. The laparoscopic cholecystectomy was subsequently performed as soon as technically feasible (i.e. following abdominal gas decompression) following the ERCP
1831042|NCT00807729|Procedure|LapCBDE|LC + LCBDE was performed in a routine fashion by one fulltime faculty member (SJR) with fellowship training in laparoscopy. Cholangiograms were obtained fluoroscopically using the same make and model fluoroscope (OEC Diasonics 9400) as used in ERCP by antegrade contrast flushing through the cystic duct. All fluoroscopy was performed by the principal author (SJR) in the presence of and concurrence with the ERCP endoscopist (JPC). When stones were detected or suspected by cholangiography, transcystic exploration was undertaken by balloon or basket with associated balloon dilation of the sphincter of Oddi A completion cholangiogram was obtained to confirm that all stones were removed. Once the LCBDE was completed, the cystic duct was ligated and the gallbladder removed.
1831043|NCT00807742|Drug|Nicotine Replacement Treatment (NRT)|Nicoderm CQ nicotine skin patch: 21mg patch for 4 weeks, then 14mg patch for 2 weeks and 7mg patch for 2 weeks. This is supplemental intervention provided to all.
1831044|NCT00807742|Behavioral|Brief Advice|Brief Advice (BA): Patients will receive four sessions of a manualized brief intervention based on NCI guidelines (Manley et al., 1991; Hollis et al., 1993) as modified for sobriety settings. This simple counseling has five components: (1) Assess smoking and initial interest in cessation; (2) Advise the patient to quit smoking; (3) Assist the patient in quitting; (4) Assess interest in quitting; and (5) Arrange booster sessions. This supplemental information is provided to all.
1831045|NCT00807755|Drug|Carboplatin|Intravenous (IV) on Day 1 of each 21-day cycle, as per dose escalation schedule (dose levels 1 and 2: dose levels 3 and 4). Number of cycles: 6 maximum.
1831046|NCT00807755|Drug|Etoposide|80mg/m2, Intravenous on Days 1, 2, 3 of a 21-day cycle (all dose levels). Number of cycles: 6 maximum.
1831047|NCT00807755|Drug|RAD001|Orally on Days 1-21 of a 21-day cycle, as per dose escalation schedule (dose level 1: 2.5 mg, dose level 2: 5 mg, dose level 3: 5.0 mg, and dose level 4: 10.0 mg). Number of cycles: unlimited (drug taken from Day 1 until progression of disease or unacceptable toxicity).
1831048|NCT00807768|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo pelvic radiation therapy
1831049|NCT00807768|Drug|Carboplatin|Given IV
1831050|NCT00807768|Radiation|Intensity-Modulated Radiation Therapy|Undergo pelvic radiation therapy
1831051|NCT00807768|Radiation|Internal Radiation Therapy|Undergo vaginal cuff brachytherapy
1831052|NCT00807768|Other|Laboratory Biomarker Analysis|Correlative studies
1831053|NCT00807768|Drug|Paclitaxel|Given IV
1831054|NCT00807768|Other|Quality-of-Life Assessment|Ancillary studies
1831055|NCT00807768|Other|Questionnaire Administration|Ancillary studies
1831056|NCT00807781|Biological|Mammaglobin-A DNA vaccine|
1831057|NCT00807794|Drug|MEDI-507|0.012 mg/kg dose given twice between 60 to 72 hours apart
1831058|NCT00807794|Drug|MEDI-507|0.06 mg/kg dose given twice between 60 to 72 hours apart
1831059|NCT00807794|Drug|MEDI-507|0.12 mg/kg dose given twice between 60 to 72 hours apart
1831060|NCT00807794|Drug|MEDI-507|0.24 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
1831061|NCT00807794|Drug|MEDI-507|0.50 mg/kg dose given twice between 60 to 72 hours apart (supplemental)
1831062|NCT00807807|Dietary Supplement|Folic Acid|100 mcg, 400 mcg, 1000 mcg, or 2000 mcg of folic acid once a day for 6 weeks
1831063|NCT00807807|Drug|Placebo Folic Acid|Placebo folic acid once a day for 6 weeks
1831064|NCT00807846|Drug|Celecoxib|Celecoxib 50 mg or 100 mg PO BID for 6 weeks
1831065|NCT00807846|Drug|Naproxen|Naproxen 7.5 mg/kg PO BID [maximum of 500 mg BID] for 6 weeks
1831066|NCT00807859|Drug|AMG 386 30 mg/kg, Paclitaxel and Trastuzumab|AMG 386 30 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
1831067|NCT00807859|Drug|AMG 386 30 mg/kg, Capecitabine and Lapatinib|AMG 386 30 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
1831068|NCT00807859|Drug|AMG 386 10 mgkg, Paclitaxel and Trastuzumab|AMG 386 10 mg/kg IV QW, paclitaxel 80 mg/m2 IV QW, trastuzumab: initial dose 8 mg/kg IV week 1, then 6 mg/kg IV Q3W
1831069|NCT00807859|Drug|AMG 386 10 mg/kg, Capecitabine and Lapatinib|AMG 386 10 mg/kg IV QW, capecitabine 2000 mg/m2 divided into 2 doses given PO Q12 hrs, days 1-14 every 21 days, lapatinib 1250 mg PO QD
1831070|NCT00807872|Biological|124I-labeled monoclonal antibody Mu 11-1F4|Single infusion of radiolabeled antibody: 2 mCi (1 mg)
1831071|NCT00807885|Drug|hylenex-facilitated subcutaneous Lactated Ringer's infusion|single subcutaneous 150 U dose of hylenex, followed by subcutaneous infusion of 1000 mL Lactated Ringer's solution
1831072|NCT00807911|Drug|Adjuvant FL|5-Fluorouracil 380 mg/m2, leucovorin 20 mg/m2 on D1-5 q 4 weeks X 4 cycles
1831073|NCT00807911|Drug|Adjuvant FOLFOX|oxaliplatin 85 mg/m2, leucovorin 200 mg/m2 on D1, 5-Fluorouracil bolus 400 mg/m2 on D1, 5-Fluorouracil continuous infusion 2400 mg/m2 for 46 hours q 2 weeks X 8 cycles
1831074|NCT00807937|Drug|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
1831075|NCT00807937|Drug|AZD7325|4 tablets and 1 capsule taken twice a day for 28 days
1831076|NCT00807937|Drug|Lorazepam|4 tablets and 1 capsule taken twice a day for 28 days
1831077|NCT00807937|Drug|Placebo|4 tablets and 1 capsule taken twice a day for 28 days
1831078|NCT00807950|Drug|Simvastatin|
1831079|NCT00807963|Drug|rHuPH20|recombinant human hyaluronidase PH20
1831080|NCT00807989|Drug|Carbamazepine|
1831081|NCT00807989|Drug|Lamotrigine/Valproate|
1831084|NCT00808002|Drug|Tenofovir/Emtricitabine|Tenofovir/Emtricitabine 300/200 mg every 24 hours
1831085|NCT00808015|Drug|varenicline|Champix will be prescribed as per usual practice and at the sole discretion of the physician
1831086|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
1831087|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
1831088|NCT00808028|Biological|meningococcal B rLP2086 vaccine.|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
1831089|NCT00808028|Other|normal saline (placebo)|vaccine, 0.5 mL, 0 - 2 - 6 to 9 months
1831090|NCT00808041|Device|Dedicated breast computed tomography imaging|Pre- and post-contrast enhancement acquisition of breast CT images of tumor-containing breast every two months.
1831091|NCT00808054|Drug|EMLA|0.5g topical EMLA
1831092|NCT00808067|Drug|dabigatran dose 1|dabigatran high dose twice daily
1831093|NCT00808067|Drug|dabigatran dose 2|dabigatran low dose twice daily
1831094|NCT00808080|Biological|AMLCTL|Ex-vivo expanded cytotoxic autologous AML-reactive T cells (CTL)
1831095|NCT00808093|Drug|GSK256073|GSK256073 100 mg study drug
1831096|NCT00813774|Biological|Certolizumab pegol|Lyophilized certolizumab pegol vial of 200mg for reconstitution of a solution with 1 mL water for injection, single dose of 400 mg given as two subcutaneous injections of 200mg
1831097|NCT00813774|Biological|Certolizumab pegol|Certolizumab pegol liquid formulation 200 mg/mL in 1 mL vial single dose of 400 mg given as two subcutaneous injections of 200mg
1831098|NCT00813774|Biological|Certolizumab pegol|200 mg/1 mL liquid certolizumab pegol solution in a pre-filled syringe, single dose of 400 mg given as two subcutaneous injections of 200mg
1831099|NCT00813800|Drug|Varenicline|Varenicline (Chantix®, Pfizer) is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4-7, and then to the maintenance dose of 1 mg twice daily for the 12 weeks of treatment.
1831100|NCT00813813|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
1831101|NCT00813826|Drug|SLC022|SLC022 150 mg capsule, 900mg daily dose
1831102|NCT00813826|Drug|Placebo|Placebo capsule, TID
1831103|NCT00813839|Other|daily weaning trails|daily SmartCare vs SBT until extubation criteria met
1831104|NCT00813852|Behavioral|exercise training, IMT|Each exercise session includes graded treadmill walking and resisted exercises. The graded treadmill walking exercise begins with a 5 minute warm-up period with the intensity of about 40% of maximal oxygen consumption (VO2max) follows by a 30 minutes training phase. The training intensity is set at about 70%-85% of VO2max and ends with a 5-minute cool-down period with the intensity of about 40% of VO2max. The resisted exercise program includes 20 minutes of weight training with rest after the first 5 minutes.
1831105|NCT00813865|Drug|AT2101|AT2101 oral capsules
1958858|NCT01176474|Biological|NY-ESO-1 157-165 (165V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.
Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.
Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity. Injections should be separated by at least 3 cm to avoid the formation of coalescent granulomas. All 4 peptides (total of 6 injections) will be administered in the same thigh and alternating thighs will be used for each subsequent treatment."
1958859|NCT01176474|Drug|Nivolumab|"Nivolumab (BMS-936558) is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1).
Nivolumab will be given at the following dosages: 1, 3, or 10 mg/kg.
Nivolumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
1831116|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week prior to PDT with verteporfin
1831117|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab one week after PDT with verteporfin
1831118|NCT00813891|Drug|Ranibizumab|Intraocular injection of 0.5mg of Ranibizumab with no accompanying PDT with verteporfin
1831119|NCT00813904|Biological|rThrombin, 1000 IU/mL|At least 1 application of reconstituted rThrombin, 1000 IU/mL, applied topically directly to the bleeding site, per product labeling.
1831120|NCT00813917|Drug|varenicline|12 weeks of varenicline 1 mg by mouth twice per day
1831121|NCT00813917|Drug|placebo|12 weeks of placebo (double blinded) by mouth twice per day
1831122|NCT00813930|Behavioral|INTERxVENT lifestyle modification program|It is a lifestyle behavior modification program which helps Type 2 diabetics manage diabetes better and reduce cardiovascular risk factors. The program involves up to 12 telephone mentor/coaching sessions with a certified health professional.
1831123|NCT00813943|Drug|Cilengitide (2-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously twice weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
1831124|NCT00813943|Drug|cilengitide (5-times weekly)|Cilengitide 2000 milligram (mg) will be administered intravenously 5-times weekly over 1 hour infusion from Weeks -1 to 77 or until occurrence of progressive disease, unacceptable toxicity, or withdrawal for any other reason. If considered beneficial in the opinion of the Investigator, continuation of cilengitide treatment will be optional in subjects without disease progression and after Week 77 since start of treatment.
1831174|NCT00814905|Drug|ampicillin gentamicin|one additional dose of antibiotics (ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV) following their vaginal delivery
1831523|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
1831125|NCT00813943|Drug|Temozolomide|Temozolomide (TMZ) 75 milligram per square meter [mg/m^2] will be administered intravenously once daily from Week 1 to 6. From Week 11 onwards, TMZ will be given as maintenance treatment at a dose of 150-200 mg/m^2 for consecutive 5 days every 4 weeks until Week 34 or until disease progression.
1831126|NCT00813943|Radiation|Radiotherapy|Radiation therapy (RTX) at a dose of 2 gray (Gy) per fraction will be given once daily, 5 days per week from Week 1 to 6, total dose 60 Gy.
1831127|NCT00813956|Drug|gemcitabine plus carboplatin plus BSI-201|iv, 3 week cycles
1831128|NCT00813969|Biological|Autologous mesenchymal stem cell transplantation|A single IV infusion of up to 2 million cells per kg based on the MSC numbers achieved after culture expansion
1831129|NCT00813982|Device|Lotrafilcon A Experimental Contact Lens|Experimental spherical, silicone hydrogel soft contact lens
1831130|NCT00813982|Device|Lotrafilcon A Commercial Contact Lens|Commercially marketed spherical, silicone hydrogel soft contact lens
1831131|NCT00813995|Drug|Comparator: Sitagliptin phosphate|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate 100 mg tablets once daily (q.d.) and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
1831132|NCT00813995|Drug|Comparator: Placebo|All participants will receive placebo tablets two weeks prior to treatment period. Participants will receive sitagliptin phosphate placebo tablets q.d. and continue on stable dose of metformin therapy (500 or 850 mg twice daily). Treatment period of 24 weeks.
1831133|NCT00814008|Drug|Insulin|Insulin Dosage form : intravenous infusion, infusion period 60 minutes Dosage: continuous dose of 0.5 mU/kg/min infused intravenously over 60 min; Insulin Lilly, Huminsulin, Lilly, Fegersheim, France
1831134|NCT00814008|Drug|Glucose|"Glucose:
Dosage form : intravenous infusion, infusion period 60 minutes per dose level Dosage: at a rate to maintain blood glucose level at 100mg ; 20mg/100ml Glucose"
1831135|NCT00814021|Drug|sunitinib malate|
1831136|NCT00814047|Drug|Yohimbine hydrochloride|
1831137|NCT00814060|Drug|neratinib|HKI-272
1831140|NCT00814086|Drug|Paclitaxel|Given IV or intraperitoneally
1831141|NCT00814086|Drug|Cisplatin|Given intraperitoneally
1831142|NCT00814099|Behavioral|Team approach to sedation management|"The team approach to sedation management includes the following:
Team education and consensus on the use of sedatives
Team identification of the patient's trajectory of illness and daily prescription of a sedation goal
A nurse-implemented goal-directed comfort algorithm that guides moment-to-moment titration of opioids and benzodiazepines
Team feedback on sedation management performance"
1831143|NCT00814099|Behavioral|Usual approach to sedation management|The pediatric ICU will continue its usual approach to sedation management.
1831144|NCT00814710|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
1831145|NCT00814710|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 3 doses
1831146|NCT00814710|Biological|Hiberix|Intramuscular injection, 3 doses
1831147|NCT00814710|Biological|Tritanrix-HepB|Intramuscular injection, 3 doses
1831148|NCT00814723|Drug|fluvastatin|80 mg MR, 12 weeks
1831149|NCT00814723|Drug|Fluvastatin plus ezetimibe|fluvastatin 80 mg MR plus ezetimibe 10 mg
1831150|NCT00814736|Drug|UK369,003|oral tablet, once a day
1831151|NCT00814736|Drug|sildenafil|single oral dose on day 14 or day 17
1831152|NCT00814736|Drug|sildenafil matching placebo|single oral dose on day 14 or day 17
1831153|NCT00814749|Procedure|midureteral sling|midureteral sling
1831154|NCT00814749|Other|surgical therapy or conservative|midureteral sling or conservative; medication, physiotherapy
1831155|NCT00814762|Biological|HIV Vaccine 732461|Two doses reconstituted adjuvanted vaccine, injected intramuscularly, at an interval of approximately one month.
1831156|NCT00814762|Biological|Placebo vaccine|Two doses of placebo, injected intramuscularly, at an interval of approximately one month
1831157|NCT00814775|Device|Fastrach Laryngeal Mask|Intubation of difficult airway using Fastrach Laryngeal Mask
1831158|NCT00814775|Device|CTrach Laryngeal Mask|CTrach Laryngeal Mask intubation
1831159|NCT00814788|Drug|Bicalutamide|50 mg oral tablet daily
1831160|NCT00814788|Drug|Everolimus|10 mg oral capsule daily
1831161|NCT00814801|Drug|Placebo|Form= tablet, route= oral use. Corresponding placebo tablets confirmed to be indistinguishable from the galantamine tablets will be administered for 24 weeks.
1831162|NCT00814801|Drug|Galantamine 16 mg/day|Type= exact number, number= 8, 16, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, and 16 mg galantamine daily for the remaining 20 weeks.
1831163|NCT00814801|Drug|Galantamine 24 mg/day|Type= exact number, number= 8, 16, 24, unit= mg/day, form= tablet, route= oral use. Patients will receive 8 mg galantamine daily for the first 4 weeks, then 16 mg galantamine daily for the following 4 weeks, and 24 mg galantamine daily for the remaining 16 weeks.
1831164|NCT00814840|Device|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with two intracardiac leads|Cardiac resynchronization with two intraventricular leads: one in the right ventricle and one in the left ventricle (via the coronary sinus)
1831165|NCT00814840|Device|Triple-site cardiac resynchronization|Cardiac resynchronization pacemaker (InSync Sentry or Concerto, Medtronic, Minneapolis, MN,USA) with three intraventricular leads: one in the right ventricle and two in the left ventricle (via the coronary sinus). Two left ventricular leads connected with Y-connector (Lead Adaptor 2827, Medtronic, Minneapolis, MN, USA)
1831167|NCT00814866|Drug|Adalimumab|Adalimumab 40 mg sub-cutaneously every two weeks
1831168|NCT00814879|Drug|Raltegravir|400 mg BID
1831169|NCT00814879|Drug|Atazanavir|300 mg BID
1831170|NCT00814879|Other|Standard treatment regimen|N(t)RTI(s) based backbone plus ritonavir boosted PI
1831171|NCT00814892|Biological|allogeneic tumor cell vaccine|Given intradermally
1831172|NCT00814892|Biological|therapeutic autologous dendritic cells|Given intradermally
1831173|NCT00814905|Drug|saline|A saline infusion after delivery (one dose)
1831175|NCT00814905|Drug|Ampicillin gentamicin clindamycin|one dose of ampicillin 2 grams IV, gentamicin 1.5 mg/kg IV, clindamycin 900 mg IV and then saline infusions instead of antibiotics until they are afebrile for 24 hours ( they will receive saline infusions instead of antibiotics)
1831176|NCT00814905|Drug|ampicillin gentamicin clindamycin|ampicillin 2 g IV every 6 hours, gentamicin 1.5mg/kg every 8 hours, and clindamycin 900 mg IV every 8 hours until the patient has been afebrile for 24 hours
1831177|NCT00814918|Drug|5-ALA with Blu-U Light|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to DUSA Blu-U light (417nm).
1831178|NCT00814918|Drug|5-ALA with Candela V-beam Pulse Dye Laser|20% 5-ALA Levulan Kerastick will be crushed and prepared for application after shaking for at least 3 minutes. Topical 5-ALA will be applied liberally on skin with extra pressure on lesions.Skin will be exposed to Candela V-beam Pulsed Dye Laser (595 nm).
1831179|NCT00814931|Drug|CXB722|900 mg CXB722 oral liquid suspension twice a day for 8 days
1831180|NCT00814931|Drug|Placebo|matching oral liquid suspension placebo twice a day for 8 days
1831185|NCT00814957|Drug|GSK618334|D3 receptor antagonist
1831186|NCT00814970|Device|Complete SE Vascular Stent System|Complete SE Vascular Stent System in the treatment of de novo and/or restenotic lesions or occlusions in the Superficial Femoral Artery (SFA) and/or the Proximal Popliteal Artery (PPA) in subjects with symptomatic Peripheral Artery Disease (PAD).
1831187|NCT00814983|Procedure|Naive T-cell Depleted Stem Cell Transplant|"The Isolex device from Baxter will be used to perform the cell selection procedure. After the CD34 selected stem cell graft has been collected, the CD34- flow-throughfraction will be depleted of CD45RA+ naive T-cells. To accomplish this, a second immunomagnetic bead selection process will be performed on the Isolex device, making use of a GMP-grade murine anti-human CE45RA antibody. This depleted fraction will comprise the donor lymphocyte inoculum given to the transplant recipient along with the stem cell component on day 0 of transplant."
1831188|NCT00814983|Procedure|Stem Cell Transplant No Manipulation|These patients will be transplanted with unmanipulated peripheral blood stem cells.
1831189|NCT00814983|Device|Isolex device from Baxter|
1831190|NCT00815009|Behavioral|Mod Fat/Low Processed Carb Diet and Moderate Exercise|Follow a moderate fat with low processed carbohydrate diet with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
1831191|NCT00815009|Behavioral|Low Fat Diet and Moderate Exercise|Follow a low fat diet along with moderate exercise at the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
1831192|NCT00815009|Behavioral|Moderate Exercise Only|No special dietary meal plan. Moderate exercise in the cardiac rehab clinic (2x/wk for 8 wks, 1x/wk for 8 wks, 1x/2wks for 8 wks)
1831193|NCT00815022|Drug|bupivacaine/fentanyl/morphine|Hyperbaric bupivacaine 12 mg, fentanyl 10 microg and morphine 200 microg
1831194|NCT00815035|Drug|Peanut OIT|Peanut flour that is orally ingested in a graded fashion.
1831195|NCT00815035|Drug|Placebo|Oat flour used as a placebo that is orally ingested a graded fashion
1831196|NCT00815048|Drug|Atropine/Remifentanil|"Atropine 20mcg/kg
Remifentanil 3mcg/kg"
1831197|NCT00815048|Drug|Fentanyl/Atropine/Succinylcholine|"Atropine 20mcg/kg
Fentanyl 2mcg/kg
Succinylcholine 2mg/kg"
1831198|NCT00815087|Device|Functional electrical stimulation|15 sessions of VitalStim® therapy, 60 minutes per session
1831199|NCT00815087|Behavioral|Exercise home program|Daily exercise training
1831200|NCT00815100|Drug|Ivabradine|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
1831201|NCT00815100|Drug|Placebo|Eligible patients will be randomized to 1 of the 2 treatment arms, namely, double-blind ivabradine, or placebo, after hospital admission (at 48 hours). The starting dose of ivabradine will be 5 mg (or matching placebo) twice daily in all patients. Patients receiving 5 mg twice daily (or matching placebo) 1 week after the inclusion with a resting HR of ≥60 beats per minute will receive the target dose of 7.5 mg twice daily (or matching placebo).
1831202|NCT00815126|Procedure|Lysine-ASA Nasal ProvocationTest|Lysine-ASA 80 µl (16 mg of aspirin) will be installed in both nostrils with pipette
1831203|NCT00815152|Behavioral|coping skills intervention training|The strategies will include ways to improve problem solving, communication skills, and managing activities.
1831204|NCT00815152|Behavioral|usual care|The ususal care at the Preston Robert Tisch Brain Tumor Center
1831205|NCT00815178|Behavioral|Inspiratory muscle training|For Inspiratory muscle training (IMT)patients carried out the IMT on a daily basis for eight weeks, with duration of 30 minutes and intensity corresponding to 30% of resting PImax, with a linear pressure resistance device (Threshold®). Weekly maximum inspiratory pressure (PImax) evaluations and workload adjustments were performed. Inspiratory load was adjusted on a weekly basis to maintain 30% of the subject's PImax. Training sessions were carried out at home for both groups and supervised once a week at the hospital.
1831206|NCT00815178|Behavioral|Inpiratory muscle training placebo|Inspiratory muscle training was carried out on the same basis as in the intervention group but with no inspiratory load.
1831207|NCT00815191|Device|a forced-air warming cover|A forced-air warming cover will be placed on the subject prior to surgery, remain on the subject during surgery and removed after surgery.
1831208|NCT00815191|Device|vital HEAT (vH2) Temperature Management System|The vital HEAT (vH2) Temperature Management System will be placed on the subjects arm prior to surgery. remain on the arm during surgery and removed after surgery.
1831209|NCT00815204|Procedure|MRI of the pituitary|Patients will undergo a T1 weighted MRI of the pituitary to measure pituitary volume
1831524|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
1831210|NCT00815204|Procedure|DEX/CRH test|Subjects will have blood drawn for baseline ACTH, cortisol, and other hormones and then undergo a DEX/CRH test. Will then measure ACTH and cortisol on test.
1831211|NCT00815217|Procedure|injection of lipoaspirate|Small volume lipoaspiration will be performed. This technique involves harvesting small amounts of fat by making a small incision in the donor site (usually the abdomen) and infiltrating 25-75cc of tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) into the adipose layer with a blunt infiltrator. The Coleman aspiration Cannulae, approximately 2-3 mm in diameter and 15 cm in length attached with a Luer-Lok suction syringe will be used to harvest up to 100 cc of fat. Gently pulling back on the syringe provides a small amount of negative pressure to allow for aspiration into the syringe.For the intervention wound, the adipose tissue will be implanted using the infiltration Cannulae (blunt end, 7 cm- COL-17) or the both approx. 1mm in diameter. The implantation will be in single tunnels radially around each wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
1831212|NCT00815217|Other|control|For the control wound, only the sterile injectable tumescence solution (1 liter of LR, 30 cc of 1% lidocaine, 1 ampule of 1:1,000,000 epinepherine) will be used. The solution will be injected in a similar fashion with single tunnels radially around the control wound spaced at 5-10 mm apart and approximately 3 - 5 cm in length.
1831213|NCT00815243|Procedure|Telemedicine consultation|Standard synchronous or asynchronous telemedicine consultations according recommendations and best practice models of ISfTeH
1831214|NCT00815243|Procedure|Treatment plan|Treatment plan include diagnostic tests (physical examination, laboratory tests, xray, CT, MRI), medications and surgical treatment (debridements, osteosynthesis, arthroplasty, ORIF etc)
1831215|NCT00815256|Procedure|Collagen Cross Linking with Riboflavin and UVA light|The patients randomized and allocated to this group are submitted to the treatment with riboflavin and ultraviolet -A light, if they do not match any of the exclusion criterion. The treatment is done as follows:after topical anesthesia, the epithelial tissue was removed in a 8.0mm diameter area of the central cornea, the 0,1% riboflavin solution were applied every 2 min, for 30 min followed by cornea irradiation with UVA light with a wavelength of 370 nm and an irradiance of 3 mW/cm2. During the irradiation, drops of the riboflavin solution were continuously applied onto the cornea every 5 min. After the procedure, a therapeutic contact lens and antibiotic eye ointment are applied onto the cornea for a week. We see the patient in the next day.
1831216|NCT00815269|Drug|Halothane|Induction: 2-4% halothane pluses 3-5 L/min oxygen Maintenance: different doses from 0.5% to 3% with 1-2 L/min oxygen
1831217|NCT00815269|Drug|Isoflurane|Induction: 2-5% isoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
1831218|NCT00815269|Drug|Sevoflurane|Induction: 3-8% sevoflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
1831219|NCT00815269|Drug|Desflurane|Induction: 2-8% desflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
1831220|NCT00815269|Drug|Enflurane|Induction: 2-5% enflurane pluses 3-5 L/min oxygen Maintenance: different doses from 1% to 4% with 1-2 L/min oxygen
1831221|NCT00815282|Drug|Human papilloma virus vaccine (cervarix)|vaccination at 0, 1 and 6 months
1831222|NCT00815295|Drug|Sorafenib|Phase 1 - Dose level 1 : Sorafenib will be given 200 mg twice daily oral, Phase 1 - Dose level 2 : Sorafenib will be given 400 mg twice daily oral, Phase 2 : Sorafenib will be given at the maximum tolerated dose from Phase 1
1831223|NCT00815295|Drug|Cetuximab|Cetuximab will be given at standard approved dose: 400 mg/m2 loading dose followed by 250 mg/m2 weekly.
1831224|NCT00815308|Drug|cetuximab (Erbitux)|Cetuximab,injection,loading dose400 mg/m^2,(Day1 in Week1) followed by 250 mg/m^2(Day1, every week for Weeks 2-8)
1831225|NCT00815308|Drug|Paclitaxel|Paclitaxel,injection,loading dose 45 mg/m^2,(Day1 in every week for Weeks 2-8)
1831226|NCT00815308|Drug|Cisplatin|Cisplatin,injection,loading dose 20 mg/m^2,(Day1 in every week for Weeks 2-8)
1831227|NCT00815308|Radiation|Radiation|Radiation, External beam therapy, total 59.4 Gy , 33 fractions, 1.8 Gy per fraction.(Day 1-Day 5 in every week 2-week 8).
1831228|NCT00815321|Biological|Autologous CIK cell infusion|4 CIK cells will be infused into patients at regular 3-weekly intervals for 4 infusions. The target cell dose per infusion is 1x10e10 CD3 cells. For patients with uncontrolled accelerated or blastic transformation undergoing chemotherapy, this will be given at the nadir of lymphopenia following chemotherapy. For other patients this will be given without interruption of the ongoing treatment with Imatinib or other kinase inhibitor.
1831229|NCT00815334|Procedure|Endoscopic subureteric injection|Endoscopic subureteric injection for the treatment of vesicoureteral reflux using variable materials (polydimethylsiloxane, collagen, and dextranomer/hyaluronic acid copolymer)
1831230|NCT00815347|Drug|bosentan|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
1831231|NCT00815347|Drug|placebo|Bosentan 62.5mg or placebo orally, twice a day for four weeks. After four weeks at this dose the subjects will have an increase to bosentan 125 mg or placebo orally twice daily for another four weeks. At week eight, subjects will crossover to bosentan or placebo depending upon their first randomization.
1831232|NCT00815360|Drug|intravitreal injection of ranibizumab|intravitreal injection of 0.5 mg ranibizumab
1831233|NCT00815360|Procedure|peripheral laser|ultra-widefield fluorescein angiography guided peripheral laser
1831234|NCT00815360|Drug|intravitreal injection of triamcinolone acetonide|intravitreal injection of 4.0 mg triamcinolone acetonide
1831235|NCT00815360|Procedure|macular laser|macular laser to areas of retinal thickening or leakage
1831236|NCT00815373|Drug|Dorzolamide+Timolol Maleate0.5%|Cosopt* b. i. d.
1831237|NCT00815373|Drug|Latanoprost+Timolol Maleate0.5%+Lytears|Xalacom* QHS
1831238|NCT00815386|Device|Percutaneous transvenous mitral annuloplasty|Catheterization procedure with anesthesia requiring subclavicular puncture, catheterization of the right atrium and coronary sinus vein, placement and optimization of the PTMA device with access hub remaining subcutaneous at the clavicle.
1831239|NCT00815399|Drug|Pioglitazone|15-45 mg/die
1831240|NCT00815399|Drug|Metformin|500-2000 mg/die
1831241|NCT00815412|Behavioral|Counseling in use of health care|
1831242|NCT00815412|Behavioral|Counseling in diet, exercise|
1831243|NCT00815412|Other|Control|
1831244|NCT00815438|Procedure|cholecystectomy.|Patients enrolled in the study will have a flexible transvaginal endoscopy used during laparoscopic cholecystectomy.
1831245|NCT00815451|Dietary Supplement|placebo|polyphenol-free dark chocolate 20g to be distributed throughout the day for 4 weeks
1831246|NCT00815451|Dietary Supplement|Acticoa polyphenol-rich dark chocolate|20g to be distributed throughout the day for 4 weeks
1831247|NCT00815464|Device|Liquid Acupuncture (Herb Acupoint Injection)|Each 4 weeks per one circle.The first 3 weeks for treatment practice(one per week)and the last week for test collection.
1831248|NCT00815477|Behavioral|Web-based lifestyle counseling messages|10 email messages based on readiness-to-change over a 4 month period
1831249|NCT00815477|Behavioral|Generic Information|Waitlist control plus educational material on lifestyle behavior and hyptertension
1831250|NCT00815490|Device|Desaturation|Reduction in blood oxygen saturation by sequential reduction in inspired gas composition. Steps are of 6 minutes duration with reduction in pulse oximeter oxygen saturation from 100 to 70%.
1831251|NCT00815503|Drug|Ropivacaine|Approved by the Danish Medicines Agency
1831252|NCT00815503|Drug|Placebo|Saline
1831253|NCT00815516|Drug|micafungin|Administered by intravenous infusion
1831254|NCT00815516|Drug|amphotericin B deoxycholate|Administered by intravenous infusion
1831255|NCT00815529|Device|Acupuncture, Pak-sham needle|25*40mm, from 10 to 15 per each person, with the death from 5 to 20 mm, for from 15 to 20 minutes.
1831256|NCT00815542|Device|double balloon catheter|cervical ripening using double balloon catheter
1831257|NCT00815542|Drug|prostaglandins E2|prostaglandins E2 - Intravaginal Propess for 24 hours
1831258|NCT00815555|Other|There is no intervention - this is an observational study|
1831259|NCT00815568|Drug|fludarabine phosphate, busulfan|Fludarabine ( 30mg/m2, iv, D-7~D-2) Busulfan (3.2mg/kg, iv, D-6~D-3) Total body irradiation (200cGy/day, D-2,-1)
1831260|NCT00815581|Device|photorefraction,cycloautorefraction,cycloretinoscopy|
1831261|NCT00815594|Drug|bevacizumab|0.05ml, 1.25mg
1831262|NCT00815607|Drug|INXN-1001|Capsules given once daily for 14 days for 3 treatment cycles.
1831263|NCT00815607|Biological|INXN-3001|Intratumoral injection
1831264|NCT00815633|Drug|Alefacept|15mg intramuscular injection weekly for 12 weeks
1831265|NCT00815646|Drug|Sildenafil|After measurement of the effect of cold water on cardiac output and pulmonary artery and wedge pressures, a single dose of sildenafil (50 mg) will be given orally, followed by similar hemodynamic measurements.
1831266|NCT00815659|Drug|rosuvastatin|medication start dose is 10mg. After 6 weeks of treatment will be force-titrated to 20mg.
1831267|NCT00815672|Behavioral|Exercise|Progressive walking and resistance exercise treatment
1831268|NCT00815685|Drug|Eicosapentaenoic Acid|Participants will receive Lovaza at a dose of 4 g for 6 weeks. Participants will be examined at six weeks for change in protein status as indicated by change in morphological (Height, weight, body mass index, body composition, lean body mass, body fat %), and biochemical (serum prealbumin) markers of protein status and immunological cytokines (Il-6, TNF- α) markers implicated in cancer cachexia. At baseline, 3 and 6 weeks, participants will undergo interviews and laboratory analysis for determining compliance and treatment-related toxicity.
1831269|NCT00815698|Procedure|suture|suture for mesh fixation
1831270|NCT00815698|Procedure|no suture|no suture for mesh fixation, because we use a self-adhesive mesh
1831271|NCT00815724|Behavioral|Distributed Asthma Learning Initiative (DALI) distance learning program|Participants will take part in two Webinar teleconferences, have access to an interactive Web site, and receive a CD-ROM of study materials and a toolkit.
1831272|NCT00815737|Drug|rhubarb|14 days of rhubarb
1831273|NCT00815737|Drug|Placebo|14 days of Placebo
1831274|NCT00815750|Other|Information Gathering|An information gathering phase leading to development of a new decision aid.
1831275|NCT00815750|Other|Decision Aid|To test the newly developed decision aid.
1831276|NCT00815763|Drug|ginsenoside-Rd|infusion ginsenoside-Rd 20 mg once a day and continued for 14 day
1831277|NCT00815763|Drug|placebo|infusion placebo once a day and continued for 14 day
1831278|NCT00815776|Device|Clayton Intra-aural Device (CID)|"The CID is a patented small, hollow, ear insert made of medical grade polymers that is custom-fit to each subject's ear. Each subject that is randomized to the CID study group will wear a pair of inserts, one in each ear. (For the purpose of this protocol, the pair of inserts will be referred to as the CID)."
1831279|NCT00815776|Device|Mouth Splint|Group 2 subjects will be assigned to the active control device, which is current standard of care therapy. The device is an intraoral flat-planed splint full coverage plastic (hard) orthotic that fits over the occlusal one-third surfaces of the dentition. The appliance is made by taking a standard wax bite registration and is made using the standard technique of taking alginate impressions of the subject's teeth, pouring dental laboratory stone into the impression and processing the acrylic appliance on the stone model. This appliance raises the plane of occlusion and provides complete contact with the opposing dentition.
1831280|NCT00815776|Other|Exercise Group|Subjects assigned to Group 3 will be asked to track daily compliance with the protocol-specific exercise plan in their 4 week diaries. The exercise plan will consist of the following instructions: subjects will be instructed to open their jaw as far as possible, without pain and hold the jaw in that position for 5 seconds. Subjects will then close their jaw and rest 10 seconds. The exercise should be repeated exactly ten times in a row, with a 10 second rest in between each stretch. Subjects will be advised to apply a warm compress to the jaw area after completing their exercises for 10 minutes.
1831281|NCT00815789|Behavioral|Tailored cardiovascular risk management (Nurse-administered )|A nurse-administered intervention, which includes a behavioral and a medication management component. The intervention consists of very brief monthly telephone calls and occurs over 12 months. Upon request, participants may also be mailed additional supportive educational material to supplement phone intervention. They will also receive a letter clarifying medications reviewed with them during the nurse-administered intervention.
1831282|NCT00815815|Behavioral|Structured Behavioral Treatment|Daily therapy sessions and a weight gain protocol involving set meals and exercise levels
1831283|NCT00815828|Other|Resistance exercises|Resistance exercises program consisting of 08 different exercises.
1831284|NCT00815841|Drug|METHYLPHENIDATE|15-20mg during one of the two sessions
1831285|NCT00815854|Dietary Supplement|Folic Acid|5 mg of folic acid taken daily for 3 months in an open label fashion
1831286|NCT00815854|Other|Placebo|Subjects may receive placebo (a sugar pill) for 4 months
1831287|NCT00815867|Drug|epoetin beta (NeoRecormon ®)|"comparison of administration of high dosage of epoetin vs no administration of epoetin
30000 UI: 4 injections"
1831288|NCT00815880|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
1831289|NCT00815893|Drug|dexmedetomidine|dexmedetomidine 1.0 mcg/kg infusion for 10minutes
1831290|NCT00815893|Drug|Normal Saline 0.9%|0.9% Normal Saline 0.25ml/kg infusion for 10minues
1831291|NCT00815893|Drug|propofol 1%|"Propofol: The initial target = 3 μg/ml. The TCI is adjusted by 0.5μg/ml according to patient comfort during the procedure.
The Orchestra® Base Primea(Fresenius, Brezins, France) offers a Target Controlled Infusion (TCI) target controlled infusion."
1831292|NCT00815906|Drug|SBI-087|IV, Single dose
1831293|NCT00815906|Drug|SBI-087|IV, Single dose
1831294|NCT00815906|Drug|SBI-087|SC, Single dose
1831295|NCT00815906|Drug|SBI-087|SC, Single dose
1831296|NCT00815919|Drug|bortezomib|Given intravenously at a dose of 1.3 mg/m^2 once a week for the first four weeks of a five week cycle for a total of 3 cycles
1831297|NCT00815919|Drug|Prednisone|Taken orally once a day at a dose of 0.5-1 mg/kg. Dose reduction may be initiated after 1 cycle of therapy. A suggested taper is 10-25% every 1-2 weeks.
1831298|NCT00815932|Device|TDCS/sham procedure on five consecutive days|The latency and amplitude of P300, subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined at before and 15 min and 120 min after the 1st and 5th tDCS/sham procedure, To receive tDCS/sham treatment, two electrodes will be placed on the patient´s skull (for details see section Methods) and the patient will rest for 5 min. After that, the patient will receive 20 minutes of 2 mA tDCS/sham. Subjective pain intensity, and pain thresholds for tactile and thermal stimuli will be determined before-, 15 min after and 120 min after each tDCS/Sham procedure. At the 1st and 5th tDCS/Sham session, the latency and amplitude of P300 will be determined before-, 15 min after and 120 min after the tDCS/sham procedure.
1831299|NCT00815945|Drug|PegLiposomal Doxorubicin|PegLiposomal Doxorubicin, intravenous, 40mg/m², every 28 days for up to 6 months
1831300|NCT00815945|Drug|Carboplatin|Carboplatin, intravenous, AUC 6, every 28 days for up to 6 months
1831301|NCT00815958|Procedure|Reaming with Synthes RIA (Reamer-Irrigator-Aspirator)|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the RIA group (Arm A), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines up until femoral reaming. These patients will receive reaming with RIA. The remainder of the surgery will also be done according to the standard of care. TEE and TCD data will be recorded throughout the surgery.
1831302|NCT00815958|Procedure|Reaming with conventional reamer|During knee replacement surgery, the study anesthesiologist will place probes for the transesophageal echocardiogram (TEE) and the transcranial Doppler ultrasound (TCD). In patients randomized to the control group (Arm B), surgery performed by the investigating orthopaedic surgeon will be done according to standard of care guidelines. These patients will receive reaming with the conventional method/reamer. TEE and TCD data will be recorded throughout the surgery.
1831303|NCT00815984|Procedure|measurements of lung function tests|Measurement of the concentration of FeNO , measurement of spirometry, plethysmography, exercise challenge test (ECT -spirometric), bronchial obstruction reversibility pharmacological test
1831304|NCT00815997|Device|TRI using a 4-Fr guiding catheter|TRI will be performed using a 4-Fr guiding catheter.
1831305|NCT00816010|Behavioral|telephone contact|for lifestyle and compliance counseling
1831306|NCT00816023|Drug|ecallantide|infusion administered IV over the duration of the surgical procedure
1831307|NCT00816023|Drug|placebo|"solution for IV infusion over the duration of the surgical
>> procedure"
1831308|NCT00816036|Behavioral|Smoking Cessation Guideline Implementation|"1. Enhanced academic detailing of staff nurses (face-to-face training, feedback on group performance, and periodic check-ins with both nurse managers and peer leaders); 2. Adaptation of the computerized information system (modified nursing admission database that includes pertinent questions about smoking, computerized quick orders for smoking cessation medications), 3) Patient self-management support (self-help materials, fax referral of motivated patients to state quit line), and 4) nursing peer leaders on each study unit."
1831309|NCT00816049|Drug|6MPindividualized|Oral 6-mercaptopurine with a starting dose of 25 mg/m2 and upward adjusted in steps of 25 mg/m2 (i.e. 50 or 75 mg/m2) if unacceptable bone-marrox toxicity is not encountered
1831310|NCT00816049|Drug|6MPfixed|Oral 6-mercaptopurine at a fixed dose of 25 mg/m2 treatment days 30-85
1831312|NCT00816075|Drug|distilled water|we plan to administer 200ml of distilled water after TUR of the tumor and block the catheter for 2 hours
1831313|NCT00816101|Other|Procellera™ Antimicrobial Dressing|Dressing indicated for partial and full-thickness wounds.
1831314|NCT00816101|Other|Mepilex® Border Lite|Self-adherent foam dressing
1831315|NCT00816101|Device|Adhesive Bandage|Adhesive bandage
1831317|NCT00816127|Drug|Desmopressin|intranasal desmopressin (300μg)
1831318|NCT00816127|Biological|blood transfusion|fresh frozen plasma 10ml/kg and/or 1 unit of single donor platelets
1831319|NCT00816140|Drug|Cravit based triple therapy|"Levofloxacin based triple therapy
LALa regimen: levofloxacin 750mg (levofloxacin500 1.5 tablets) once daily, amoxicillin 1000mg twice daily, lansoprazole 30mg twice daily for 7 days"
1831320|NCT00816140|Drug|Klaricid based triple therapy|"Clarithromycin based triple therapy
CALa regimen: clarithromycin 500mg twice daily, amoxicillin 1000mg twice daily, and lansoprazole 30mg twice daily for 7 days"
1831321|NCT00816153|Other|PVI-guided fluid management|Peroperative comparison of standard care with PVI-guided fluid management (optimization of the PVI value with fluid loading)
1831525|NCT00798317|Drug|Ocriplasmin 125µg|125µg of ocriplasmin intravitreal injection
1831322|NCT00816166|Device|Pharos Vitesse Neurovascular Stent System (Stent implantation) + Medical therapy (Aspirin and Clopidogrel)|Implantation of one or more balloon-expandable Pharos Vitesse stents to treat neurovascular ischemic lesions + Medical therapy [Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)]
1831323|NCT00816166|Drug|Aspirin and Clopidogrel (Medical therapy)|Medical therapy alone [Treatment with aspirin (81-325 mg daily for the duration of the study) and Clopidogrel (75 mg daily for first 3 months)]
1831324|NCT00816179|Procedure|Transgastric diagnostic endoscopic peritoneoscopy|Endoscopic abdominal exploration utilizing an endoscopically created gastrotomy.
1831325|NCT00816192|Procedure|Long-term electrical isolation of pulmonary veins|All AAD except amiodarone will be stopped five half-lives before the procedure. Our ablation protocol will require 3 catheters. A quadripolar stearable mapping catheter was inserted into the coronary sinus, a decapolar circular mapping catheter was placed at the antrum of the PV after transeptal puncture to help for electrical disconnection of all four PV with the randomized ablation catheter. After transseptal access, an intravenous bolus of heparin was administered and repeated 3 to 4 hours later. Atrial burst will then be used to induce AF. With the ablation catheter positioned proximal to Lasso catheter on the atrial aspect of PV ostium, isolation will be performed.
1831326|NCT00816205|Drug|Coated Nifedipine Suppositories|"Subjects will take rectally a total of 3 Coated Suppositories per study. 90 minutes after each coated suppository insertion this suppository will be removed and a amnometric study will be performed:
The first dose will contain 4 mg of Nifedipine and the manomentric measurement performed afterwards will be used to determine baseline anal pressures.
The second dose will contain 12 mg of Nifedipine. The third dose will contain 24 mg of Nifedipine."
1831327|NCT00816218|Drug|Pioglitazone|pioglitazone, 45 mg daily
1831328|NCT00816231|Behavioral|Tobacco|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving tobacco with brief summary at the end of the last session.
1831329|NCT00816231|Other|Alcoholic Beverage|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving and alcohol with brief summary at the end of the last session.
1831330|NCT00816231|Other|Placebo|Five research sessions. Session 1: Questionnaires, interviews, computer task, medical evaluation. Sessions 2 - 5: Lab Sessions involving placebo with brief summary at the end of the last session.
1831331|NCT00816244|Drug|Atorvastatin|Atorvastatin 80 mg daily for two weeks, ending at the day of operation for breast cancer.
1831332|NCT00816270|Procedure|Bilateral Upper eyelid blepharoplasty|Bilateral upper lid blepharoplasty was performed on each patient by the same experimented surgeon using a standard technique. One side (right or left upper eyelid) was randomly chosen for experimental closure with liquid bandage and the opposite eyelid served as the control being used a 6/0 nylon continuous sutures.
1831333|NCT00816283|Drug|dasatinib|50 mg orally 2 times per day or 140 mg orally one time per day
1831334|NCT00816283|Drug|vorinostat|100 mg orally 2 times per day
1831335|NCT00816283|Genetic|cytogenetic analysis|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
1831336|NCT00816283|Genetic|gene expression analysis|Bone marrow aspirate obtained pre-treatment, at first scheduled bone marrow assay and at relapse. Peripheral blood drawn pre-therapy, day +14 of first treatment cycle and at relapse.
1831337|NCT00816283|Genetic|mutation analysis|Performed at baseline and at every bone marrow analysis on peripheral blood
1831338|NCT00816283|Genetic|reverse transcriptase-polymerase chain reaction|Peripheral blood drawn prior to starting Vorinostat on Day 1 and on Day 14 of treatment
1831339|NCT00816283|Other|flow cytometry|Performed at the end of cycle two of treatment and every six cycles for patients with accelerated CML and every 3 cycles for patients with blast crisis or Ph+ ALL
1831340|NCT00816283|Other|laboratory biomarker analysis|Performed pre-treatment and day +14 of treatment
1831341|NCT00816296|Other|Blood Draw|2 tablespoons of blood will be drawn from participants at study entry, 3 months after study entry, and 6 months after study entry.
1831342|NCT00816296|Other|Stool collection|Stool will be collected from participants 3 times during the study -- at study entry, 3 months from study entry, and 6 months after study entry.
1831343|NCT00816296|Other|BodPod Measurement|Body composition will be measured using a BodPod at study entry, 3 months after study entry, and 6 months after study entry.
1831344|NCT00816296|Other|Liver Ultrasound|A liver ultrasound will be performed at study entry and 6 months after study entry.
1831345|NCT00816309|Device|Acapella Physiotherapy|twice daily- around 20 minutes
1831346|NCT00816322|Dietary Supplement|Omega-3 fatty acids|EPA 2.1 g/d+DHA 1.1 g/d
1831347|NCT00816322|Dietary Supplement|Placebo|high oleic oil
1831348|NCT00816335|Procedure|PET/CT scan|For all patients undergoing a preoperative PET/CT scan on the day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained on a Siemens Biograph 16 PET/CT scanner (Siemens, Knoxville, TN).
1831349|NCT00816335|Drug|18F-FDG Injection|Patients undergoing a preoperative PET/CT scan the day of surgery, are required to have fasted for at least 4 hours prior to the anticipated preoperative PET/CT scan. Patients participating in this pilot study (whether they have had their preoperative PET/CT scan prior to the day of surgery or whether they are having their preoperative PET/CT scan on the day of surgery) will receive a preoperative IV injection into a peripheral vein of 15 mCi of 18FFDG at time interval of approximately 60 to 180 minutes prior to anticipated time of surgery.
1831350|NCT00816335|Procedure|Preoperative 18F-FDG PET/CT Scan|Patients undergoing preoperative PET/CT scan day of surgery, at approximately 70 minutes post-injection of 18F-FDG, a diagnostic whole body PET/CT scan will be obtained. PET imaging will immediately be preceded by noncontrast transmission CT (for attenuation correction and anatomic correlation purposes) and will be obtained from the base of the skull to the mid thighs. Bed positions will be scanned for 3 minutes each, moving the patient through the scanner in a craniocaudal direction. Once the preoperative PET/CT scan is acquired, images will be reviewed by the nuclear medicine physician and the surgeon.
1831369|NCT00816413|Other|immunoenzyme technique|Peripheral blood for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
1831351|NCT00816335|Drug|18F-FDG for patients with Bladder Cancer|Elimination of 18F-FDG by the urinary system and accumulation in the bladder impacts the differentiation between residual 18F-FDG in the bladder and activity in tumor and adjacent lymph nodes. For patients with bladder cancer, the urinary catheter routinely placed in the operating room will be inserted in the Ambulatory Surgery Unit (ASU) by the urologist on-service or the urology research nurse. A 3-way Foley catheter will be placed for continuous bladder irrigation with Normal Saline (0.9%) initiated in ASU and will continue for the duration of the imaging procedure at a standard rate of 10cc/minute. The urology research nurse will transport the patient to and from the PET/CT area and monitor the continuous bladder irrigation during the imaging session.
1831352|NCT00816335|Procedure|Surgical Procedure|Previously determined operative procedure based on type of solid malignancy. Factors include extent and location of disease, physiologic status of patient intraoperatively, any technical considerations influenced by anatomic constraints, and a risk: benefit analysis of proposed procedure. The decision to proceed with resection on these factors, and will constantly re-evaluate during resection to ensure patient well-being, both short and long term, is foremost consideration. Evaluation of extent of disease during surgical exploration will include inspection and palpation of entire area being evaluated. Tissue that is highly suspicious for involvement with metastatic disease that alters the surgical decision making plan of resection will be biopsied or resected for histologic confirmation if feasible and safe. If patient is found to have resectable disease, deemed safe patient, surgeon will continue and proceed with definitive surgical resection with assistance of handheld gamma probe.
1831353|NCT00816335|Procedure|Specimen PET/CT Scan|Resected surgical specimen will be placed on top of paraffin block. Digital photos of the specimen will be obtained for visual correlation of specimen placement on paraffin block. Two bed position 10 minute specimen PET/CT scan will be performed on surgical specimen. If remnant tissue is available, a second image maybe acquired via MRI. Images will be processed and reviewed for quality and presence or absence of hypermetabolic foci and correlated with anatomical information provided by CT and MRI imaging that were originally noted in the preoperative clinical PET/CT scan. During the time when the excised surgical specimens are transported to radiology for specimen PET/CT scanning, additional evaluation of these ex-vivo specimens with other tumor detection devices may be undertaken. Specimen will then be transported back to the operating room in order to be sent to and processed by surgical pathology for standard pathologic evaluation.
1831354|NCT00816348|Drug|Omegaven|Omegaven® will be initiated at a dose of 0.5 gram/kg/day and is infused over 24 hours for 1-2 days, and then advanced to 1 gram/kg/day. Omegaven® will be infused intravenously through either a central or peripheral catheter alone or in conjunction with parenteral nutrition. Omegaven® will continue until weaned from PN. Monotherapy with Omegaven® can continue as an additional source of calories after the dextrose/protein portion of PN is discontinued. Omegaven may be restarted within seven days of discontinuing therapy. After seven days, and meeting inclusion criteria, Omegaven can resume at the initial dose of 0.5 grams/kg/day, advancing to 1 gm/kg/day.
1831355|NCT00816361|Drug|MEDI-573|Administered at a dose determined by the subject's enrollment cohort as an IV infusion as part of a 21 day treatment cycle.
1831356|NCT00816374|Other|Reading materials and discussions|"We will send 3 sets of materials via mail, containing information about melanoma prevention and detection, 1 set each month for 3 months. Materials published by:
The American Cancer Society
The American Academy of Dermatology
The Skin Cancer Foundation
The pamphlets contain information about ways to reduce risk for skin cancer including:
Sun protection practices
Risk factors for melanoma
Information about what melanoma looks like
How to do skin self-examinations
There will also be a telephone discussion with a health educator, discussing melanoma and other information contained in the pamphlets."
1831357|NCT00816374|Other|Reading materials and discussions|"We will send 3 separate pamphlets created specifically for participants. We will send 1 pamphlet each month for 3 months. The information in the pamphlets will be based on answers from the first survey. These pamphlets will contain information about:
Melanoma and skin cancer protection guidelines
The benefits of skin screening practices
Ways to protect yourself from the sun
In addition to these pamphlets, there will be a telephone discussion with a health educator to discuss melanoma and other information contained in the pamphlets."
1831358|NCT00816374|Other|Questionnaires|"Both groups will complete 3 surveys; at the beginning, 3 months later, 6 months after the second survey. Each survey will ask about:
knowledge of melanoma
current and past skin cancer screening practices
current and past sun protection practices
attitudes about skin cancer and sun protection
feelings about relative's melanoma diagnosis and treatment"
1831359|NCT00816387|Procedure|Fallopian tube sperm perfusion|Patients are treated with fallopian tube sperm perfusion
1831360|NCT00816387|Procedure|Intrauterine insemination using standard catheter|Patients are treated with standard intrauterine insemination
1831361|NCT00816400|Drug|MEDI-575|MEDI-575 as an IV infusion
1831362|NCT00816413|Drug|cyclosporine|2 mg/kg IV over 2 hours every 12 hours starting at 0700 on days -1, 0, and +1 (total of six doses).
1831363|NCT00816413|Drug|mycophenolate mofetil|15 mg/kg orally twice a day starting day 0 until day +27 then stopped without tapering in the absence of aGVHD then tapered over two months in the absence of aGVHD. Doses will be rounded to the nearest 250 mg.
1831364|NCT00816413|Drug|pentostatin|4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0).
1831365|NCT00816413|Genetic|cytogenetic analysis|At days +28 and +70 post-transplant, patients' blood will be evaluated for CD3 and overall WBC chimerism.
1831366|NCT00816413|Genetic|fluorescence in situ hybridization|Mixed chimerism is defined as the detection of 95% or less donor T cells (CD3+), expressed as a proportion of the total T cell and WBC population as measured by DNA.
1831367|NCT00816413|Genetic|protein analysis|Blood samples will be at baseline(day -11 or before) , days -8 and -1, prior to transplant on day 0, then weekly (days +7, +14, +21 and +28) post-transplant through day +28. Five ml's of blood will be drawn at each collection through a central line using heparinized vaccutainers. Samples will be spun down at 1200 g and plasma aspirated and stored in -80 oC until analyzed for the ELISA Assays being done for research purposes in this protocol.
1831368|NCT00816413|Other|flow cytometry|Peripheral blood Peripheral blood flow cytometry for immunophenotyping including Th/c1 and Th/c2 subsets, mitogens (PHA, PWM), NK and LAK function studies, DCs, apoptosis assay of tumor cells, and lymphocyte subsets (CD4, CD8, CD19, CD56
1831518|NCT00798291|Other|Ad lib diet/ placebo/ exercise|one packet with water two times a day; resistance training three times a week
1831370|NCT00816413|Other|laboratory biomarker analysis|Donor mononuclear cells from the stem cell product (SCP) obtained with apheresis will be analyzed for surface markers, including CD3, CD4, CD8, CD19, CD14, CD56, TCR+CD8+ cells, Th/c1 and Th/c2, Fas and FasL, and DCs, as well as for apoptosis
1831371|NCT00816413|Other|reduced-intensity transplant conditioning procedure|"Allopurinol 300 mg orally once daily x 10 days, to begin one day prior to treatment with Pentostatin (day -11 to day -2) .
Pentostatin 4 mg/m2/d IV over 30 minutes daily x 3 days, (days -10, -9, -8)to begin ten days prior to stem cell infusion (Day 0) .
Pre and Post Pentostatin Hydration: 1000ml Normal Saline IV over 2 hours pre each dose of Pentostatin and 1000ml Normal Saline IV over 4 hours post each dose of Pentostatin on days -10, -9, -8.
Pre Pentostatin Recommended Antiemetics: Ondansetron 32 mg IV over 30 minutes to be given 30 min. before each dose of Pentostatin on days -10, -9, -8. Alternative ondansetron equivalent or other ancillary antiemetics may be used at the discretion of the treating physician.
Pred Forte Eye Drops: two drops in each eye every 4 hours while awake x 7 days after starting Pentostatin (day -10 to day -4)."
1831372|NCT00816413|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Each patient will receive up to four IV infusions administered over 30 minutes of donor T cells at increasing cell doses given at intervals.
1831373|NCT00816413|Procedure|peripheral blood stem cell transplantation (PBSC)|PBSC are infused intravenously either by infusion or IV push on day 0 through a secure intravenous access (i.e. the double-lumen central catheter place pre transplant) according to institutional guidelines.
1831374|NCT00816413|Radiation|total-body irradiation|2.0 GY will be administered on day -1. Total-body irradiation (TBI) will consist of 2.0 GY at 8-12cGy/min via 6MV photons delivered AP/PA fields, without lung blocks or via lateral fields with lucite compensator along the head and neck region. TLD (thermal luminescent dosimetry) will be used to verify dose uniformity. It is anticipated that TBI will be given on day -1; however, the timing of TBI administration may be altered by factors beyond the control of the Principal Investigator because of the delivery of unrelated donor stem cells.
1831375|NCT00816426|Drug|Rifampicin|Rifampicin or rifampin (RIF) is a semi-synthetic compound derived from Amycolatopsis rifamycinica. It is mostly used in combination to treat TB, while other disease indications include brucellosis, leprosy, legionnaire's disease and problematic drug-resistant staphylococcal infections. RIF inhibits DNA-dependent RNA polymerase in bacterial cells by binding its beta-subunit, thus preventing transcription to RNA. Its MIC against replicating TB bacilli is 0.1 g/ml and its minimum bactericidal activity (MBC) is 0.5 g/mL. It is one of the rare anti-TB drugs with some activity against nonreplicating cells.
1831376|NCT00816426|Drug|Isoniazid|Isoniazid (INH) is a first-line antituberculous medication discovered in 1952 and used in the prevention (alone) and treatment (in combination) of tuberculosis. Isoniazid is a prodrug and must be activated by a bacterial catalase to inhibit the synthesis of mycolic acids in the mycobacterial cell wall. Consequently, INH is bactericidal to rapidly-dividing mycobacteria, with an MIC of 0.05 g/ml and an MBC of 1 g/ml, but is inactive if the mycobacterium is nonreplicating or slow-growing.
1831377|NCT00816426|Drug|Pyrazinamide|Pyrazinamide (PZA) is a synthetic derivative of nicotinamide requiring ctivation by the mycobacterial enzyme pyrazinamidase, only active under acidic conditions which are thought to be found within the phagolysosomal compartment of macrophages. The conversion product, pyrazinoic acid, inhibits fatty acid synthetase I, required by the bacterium to synthesize fatty acids, though this has been disputed. It has an MIC of 6 g/ml and is not cidal under in vitro conditions. Overall, its mechanism of action and reasons for good sterilizing activity in vivo are poorly understood. It is part of the 4-drug combination recommended by the WHO to treat drugsensitive tuberculosis and is also included in most econd-line regimens.
1831378|NCT00816426|Drug|Kanamycin|Kanamycin (KM) is an aminoglycoside antibiotic belonging to the same class of drugs as Streptomycin, one of the first drugs used to treat TB in the 50 s. It kills sensitive bacteria by binding to the 30S ribosomal subunit and interfering with protein synthesis. Its MIC and MBC against MTB are 2 and 6 g/mL, respectively, with a remarkably low MBC/MIC ratio. However, KM is only used to treat serious bacterial infections due to severe renal toxicity and ototoxicity. No interaction with the metabolism of other drugs has been reported. The drug is approved by the Korean Ministry of Food and Drug Safety (MFDS) but not the US FDA for use against pulmonary TB.
1831379|NCT00816426|Drug|Moxifloxacin|Moxifloxacin (MXF) is a synthetic fluoroquinolone antibiotic. It inhibits bacterial topoisomerase II (DNA gyrase) and topoisomerase IV, which are essential enzymes playing a crucial role in the replication and repair of bacterial DNA. Its MIC, MBC and intracellular activity against MTB are 0.5, 2 and 1 g/mL, respectively, with again a low MBC/MIC ratio.
1831380|NCT00816465|Dietary Supplement|Hoodia gordonii|PO administration of 1 Tab Hoodia gordoni extract per day.
1831381|NCT00816465|Other|Placebo|PO Placebo pill
1831382|NCT00816478|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
1831383|NCT00816491|Device|conventional white light colonoscopy|conventional white light colonoscopy
1831384|NCT00816491|Device|FICE (Fujinon Intelligent Chromoendoscopy)|chromoendoscopy
1831385|NCT00816504|Drug|Galactose|Oral galactose, 0.2 g/kg/dose twice daily for 28 days
1831386|NCT00816517|Biological|injection of botulinum toxin type A.|35 to 100 units injected around a skin lesion (plaque) one time.
1831387|NCT00816530|Device|Automated Breast Ultrasound (ABUS) as an adjunct to digital screening mammography|After density > 50% is confirmed by routine digital screening mammography, ABUS will be performed.
1831388|NCT00816543|Drug|DOCETAXEL|50 mg/m² IV as a 1 hour infusion on day 1 for each period of 3 weeks for 3 cycles.
1831389|NCT00816543|Drug|S-1|80mg/m² day 1-14 every 3 weeks for 3 cycles. The curative resection group will receive two oral doses of 40 mg/m²/day for 4 weeks, followed by 2 weeks rest, for 1 year.
1831390|NCT00816543|Drug|OXALIPLATIN|100 mg/m² on day 1 as a two-hour IV infusion for each period of 3 weeks for 3 cycles.
1831391|NCT00816556|Drug|Estriol|Estriol 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for 2 weeks and then twice weekly for 10 weeks.
1831392|NCT00816556|Drug|Estradiol valerate|Estradiol valerate 10 micrograms added to Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
1831393|NCT00816556|Drug|Vanicream Lite|Vanicream Lite 0.5 grams applied to vaginal introitus daily for two weeks and then twice weekly for 10 weeks
1831394|NCT00816569|Device|Orthokeratology contact lenses|Wearing Orthokeratology lens in one eye of a keratoconus patient
1831526|NCT00798317|Drug|Placebo|Intravitreal injection placebo.
1831395|NCT00816582|Procedure|Diagnostic Imaging: 18F-FDG PET/CT Scan - Baseline|A18F-FDG PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to identify the sites involved by the subject's cancer.
1831396|NCT00816582|Procedure|Diagnostic Imaging: 18F-FES PET/CT - Baseline|A 18F-FES PET/CT scan performed at baseline, prior to starting the fulvestrant treatment, to determine the hormone receptor content of the sites involved by the breast cancer.
1831397|NCT00816582|Procedure|Diagnostic Imaging: 18F-FES PET/CT - 3 month follow-up|A 18F-FES PET/CT scan performed after three (3) monthly injections of fulvestrant to determine whether estrogen uptake is blocked by fulvestrant.
1831398|NCT00816595|Biological|bevacizumab|Given IV
1831399|NCT00816595|Biological|pegfilgrastim|Given subcutaneously
1831400|NCT00816595|Biological|rituximab|Given IV
1831401|NCT00816595|Drug|cyclophosphamide|Given IV
1831402|NCT00816595|Drug|pentostatin|Given IV
1831403|NCT00816621|Behavioral|ABC for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the ability of children to regulate their attention, behavior, and physiology and to develop secure, organized attachments to their parents.
1831404|NCT00816621|Behavioral|DEF for Children Adopted Internationally|Participants will participate in 10 weekly in-home intervention sessions aimed at enhancing the intellectual and language development of children.
1831405|NCT00816634|Drug|Capecitabine plus cisplatin(XP) versus capecitabine plus paclitaxel(XT)|"3.2 Overview of Study Design This study is a prospective, randomized, phase II study comparing response rate between patients with XP chemotherapy versus XG chemotherapy for patients with metastatic squamous cell carcinoma.
Chemotherapy regimen (XP):
D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1 Cisplatin 75 mg/m2 + NS 150mL MIV over 1hr every 3 weeks
Chemotherapy regimen (XT):
D1- D14 Capecitabine 1000 mg/m2 bid p.o. D1, D8 Genexol (Paclitaxel) 80 mg/m2 + D5W 500mL MIV over 3hrs every 3 weeks"
1831406|NCT00816647|Procedure|Patellofemoral stabilizing surgery|Comparison of surgical techniques
1831409|NCT00816673|Drug|placebo Circadin|Placebo tabs of Prolonged release melatonin
1831410|NCT00816673|Drug|Circadin|prolonged release melatonin 2 mg taken daily 2 hours before bed-time for 3 weeks
1831411|NCT00816686|Biological|AGS-16M18|IV Infusion
1831412|NCT00816699|Other|preprint preoperative anesthetic risk information|preprint preoperative anesthetic risk information
1831413|NCT00816712|Drug|Comparator: Testosterone 300 mg, intramuscular injection|"Day 1 & 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.
Day 1 & 7 - Testosterone 300 mg, Intramuscular injection."
1831414|NCT00816712|Drug|Comparator: Testosterone 100 mg, Intramuscular injection|"Day 1 & 7- Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.
Day 1 & 7 - Testosterone 100 mg, Intramuscular injection."
1831415|NCT00816712|Drug|Comparator: Placebo given by Intramuscular Injection|"Day 1 & 7 - Infusion with radioactive tracer (dye), given over 12 hours, followed by two thigh muscle needle biopsies.
Day 1 & 7 - Placebo given as intramuscular injection."
1831416|NCT00816725|Behavioral|Mothers and babies Internet course and PPD informational brochure|An eight-lesson, self-help, Web-based program for the prevention of postpartum depression based on cognitive behavioral therapy, social-learning, and attachment theory. The PPD informational brochure is a four-page pamphlet that contains information about postpartum depression.
1831417|NCT00816751|Procedure|Paracervical block|The paracervical block was administered using 20 ml of buffered lidocaine and a 5/8 inch, 25-gauge needle. A small amount was injected at the tenaculum site, and the remainder equally distributed around the cervicovaginal junction at 3, 5, 7, and 9 o'clock. The depth was standardized at 5/8 inch by inserting the needle to the hub.
1831418|NCT00816751|Procedure|Intracervical|The intracervical block was administered using 20 ml of buffered lidocaine and a 1-1/2 inch, 20 gauge needle in order to overcome the increased resistance to injection caused by the cervical stroma. A small amount was injected at the tenaculum site, and the remainder into the cervical stroma at 12, 3, 6, and 9 o'clock, at a depth of 1-1/2 inch by inserting the needle to the hub.
1831419|NCT00816751|Drug|Buffered Lidocaine, vasopressin, sodium bicarbonate|The buffered lidocaine preparation for both block techniques consisted of 50 mL of 1% lidocaine, 5 units of vasopressin, and 5 mL 8% sodium bicarbonate.
1831420|NCT00816764|Biological|AGS-8M4|IV Infusion
1831421|NCT00816777|Procedure|Chemoembolization with irinotecan Bead|Intra arterial chemoembolization using Irinotecan Bead 100mg irinotecan per procedure in combination with irinotecan monotherapy 250mg/m2 alternating on a 3 weekly schedule
1831422|NCT00816777|Drug|Irinotecan|Irinotecan monotherapy: 250mg/m2 repeated every 3 weeks
1831423|NCT00816790|Drug|Piperacillin/Tazobactam|eGFR 20-40 mls/min: Piperacillin/Tazobactam 3.375g IV q6h x 24 hours eGFR < 20 mls/min: Piperacillin/Tazobactam 2.25g IV q6h x 24 hours
1831424|NCT00816790|Drug|Piperacillin/Tazobactam|Piperacillin/Tazobactam 4.5g IV q 6h x 24 hours
1831425|NCT00816803|Procedure|Autologous bone marrow transplant|
1831426|NCT00816803|Procedure|Physical therapy|
1831427|NCT00816816|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy: docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; and a continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.
concurrent chemotherapy:cisplatin 40 mg/m2 weekly."
1831428|NCT00816829|Drug|Placebo|Fenofibrate-matching placebo tablet
1831429|NCT00816829|Drug|Fenofibrate|145 mg NanoCrystal tablet
1831430|NCT00816855|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.
concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
1997155|NCT02205541|Drug|Placebo|"According to the patient body weight, there will be 3 to 5 injections at D0, D7, D14, D21 and D28.
ECZ or placebo will be administrated intravenously as a 30-minute injection"
1831432|NCT00816881|Device|flutter mucus clearance device|five minutes every session, four sessions per day
1831519|NCT00798291|Other|Ad lib diet; AN 777; exercise|one packet with water two times a day; resistance training three times a week
1831433|NCT00816894|Drug|D-serine|6 week fixed dose phase with D-serine 1500 mg/day to be increased starting from week two to 3000 mg/day followed by a 4 week flexible dose phase allowing for two 500 mg/day dose changes
1831434|NCT00816894|Drug|Olanzapine|6 week fixed dose phase with Olanzapine 15 mg/day to be increased starting from week two to 30 mg/day followed by a 4 week flexible dose phase allowing for two 5 mg/day dose changes.
1831435|NCT00816907|Drug|Metformin|500 mg to 1,000 mg taken twice daily for 16 weeks
1831436|NCT00816907|Drug|Placebo|1 to 2 placebo capsules taken twice daily for 16 weeks
1831437|NCT00816920|Other|Ultrasound examination of leg veins|Outpatients symptomatic for leg DVT follow the standard diagnostic procedure (ultrasound examination of proximal deep veins, pre-test clinical probability and D-dimer, and a second US after 5-7 days) to exclude proximal DVT; they also receive by another doctor a complete US examination of the deep leg veins to assess the presence of isolated calf DVT, the results of the latter examination are kept blind to the patient and to the treating doctor, and disclosed after three months
1831438|NCT00816933|Procedure|appendectomy|appendectomy according to the number of trocar
1831439|NCT00816946|Behavioral|Routine advice|Routine advice to mother and/or other key care provider by the local Lady Health Workers (LHWs)during her routine community visits.
1831440|NCT00816946|Behavioral|Enhanced education|"Enhanced Nutritional education/counseling to mothers on the following topics:
During Pregnancy: diet during pregnancy; antenatal care; iron tablets; colostrum Postpartum period: difficulties during lactation; diet during lactation; EBF; childhood vaccination; newborn care Complementary Feeding General Health: vitamin A; diarrhea management; iodine; hygiene for health; protection from malaria; ARI & protection against ARI"
1831441|NCT00816959|Drug|R-mabHDI and ABVD|"The subjects will receive R-mabHDI intravenously, separately for about 7 hours on days 1,8,15 and 22 (once a week) of every cycle. Each cycle is 4 weeks. R-mabHDI will be given for 2 cycles.
Also the subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles."
1831442|NCT00816959|Drug|ABVD|The subjects will receive the ABVD combination intravenously for about 1 hour on day 1 and 15 of every cycle (every 2 weeks). Each cycle is 4 weeks. ABVD will be given for 6 cycles.
1831443|NCT00816972|Drug|Desloratadine 2.5 mg|Desloratadine 2.5 mg BID
1831444|NCT00816972|Drug|Oxybutynin 2.5 mg|Oxybutynin 2.5 mg BID
1831445|NCT00816972|Drug|Placebo for Desloratadine 2.5 mg|Placebo BID
1831446|NCT00816972|Drug|Placebo for Oxybutynin 2.5 mg|Placebo BID
1831447|NCT00816985|Procedure|Liposuction|We plan to show the efficacy of liposuction as a treatment for lymphedema. Durability will be tested for equivalence, by comparing the 3-month and 12-month arm volumes.
1831448|NCT00816998|Procedure|Physical therapy|Physical therapy to instruct participant with exercises to assist in return to normal activities following the healing of their wrist fracture
1831449|NCT00816998|Procedure|Physical Therapy|Physical therapy to include exercises to help a participant improve the range of motion, grip and pinch strength following the fracture of their wrist
1831450|NCT00817011|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
1831451|NCT00817011|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
1831452|NCT00817024|Drug|Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules,|3# XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
1831453|NCT00817024|Drug|Sheng Mai Capsules Plus Placebo of Xuefu Zhuyu Capsules|3# SM capsules plus 3# placebo of XFZY capsules, po, Tid, for 4 weeks
1831454|NCT00817024|Drug|Placebo of Xuefu Zhuyu Capsules Plus Placebo of Sheng Mai Capsules|3# Placebo of XFZY capsules plus 3# placebo of SM capsules, po, Tid, for 4 weeks
1831455|NCT00817037|Drug|Sitaxsentan|Sitaxsentan 100mg once daily oral dosing for 6 weeks
1831456|NCT00817037|Drug|Nifedipine|Nifedipine 30mg once daily oral dosing for 6 weeks
1831457|NCT00817037|Drug|Placebo tablet|Placebo tablet once daily oral dosing for 6 weeks
1831458|NCT00817050|Drug|Mometasone Furoate Nasal Spray|One dose (2 sprays in each nostril) of Mometasone Furoate Nasal Spray
1831459|NCT00817050|Drug|fluticasone nasal spray|One dose (2 sprays in each nostril) of fluticasone nasal spray
1996144|NCT02555371|Biological|Mepolizumab 100mg|Mepolizumab is a fully humanised Immunoglobulin (IgG) antibody (IgG1, kappa) with human heavy and light chain frameworks. Mepolizumab will be provided as a lyophilised cake in sterile vials for individual use.
1831462|NCT00817076|Drug|desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
1831463|NCT00817089|Drug|naltrexone|phase 1: 30 or 50 mg of naltrexone prior to challenge session; phase 2: 50mg/day for 12 weeks
1831464|NCT00817089|Drug|placebo|placebo pills
1831465|NCT00817089|Other|alcohol|190 proof alcohol prepared to 11% volume mixed with fruit juice
1831466|NCT00817102|Procedure|FFR, IVUS, VH, or combination of the three|Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
1831467|NCT00817115|Device|Region-of-Interest Imaging (X-ray Fovea Imaging)|Use of an experimental fluoroscopy system fitted with a region-of-interest attenuator (fovea) to evaluate or treat lesions during cardiac interventional procedures.
1831468|NCT00817128|Procedure|PEPT|Pain Exposure Physical Therapy
1831469|NCT00817128|Procedure|CBO standard|Standard therapy as defined in CBO guideline 2006
1831470|NCT00817141|Other|Observational study, no intervention|Observation of the complications seen without urinary catheter (which is the habitual protocol in our institution)
1831471|NCT00817154|Behavioral|HOPES-I|The program progresses in three steps. First, participants receive a 10-week Basic Skills for Community Living course covering essential skills from each of the five modules to ensure that all participants establish basic competency in a core set of skills. Second, clinicians assess participants' functioning to identify skill areas that warrant additional improvement and engage participants in a shared decision making process to select skill areas to pursue in greater depth. Third, clinicians have weekly 60 minute sessions with participants in community settings for 7 months to provide training and to facilitate and support acquisition of core skills and rehabilitation goals.
1831520|NCT00798304|Biological|meningococcal B rLP2086 vaccine|vaccination
1831521|NCT00798304|Biological|Routine age appropriate childhood vaccines|vaccination
1831472|NCT00817167|Device|inReach bronchoscopy planning software|inReach planning software creates three-dimensional lung CT reconstruction, enabling rapid virtual endoscopic depiction of the airways that allows to plan bronchoscopy virtually.
1831473|NCT00817167|Device|Standard lung CT viewer|CT viewer, used for standard bronchoscopy
1831474|NCT00798031|Device|A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.|A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. The study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prosthesis.
1831475|NCT00798031|Device|Placement of dental implant|"Device: A minimum of two but up to three Astra Tech Dental Implant, Fixture Osseospeed will be placed in the posterior upper jaw of 20 eligible subjects.
A minimum of 2 but up to three dental implants will be placed in the posterior upper jaw of 20 subjects. The dental implants are produced by Astra Tech AB (Fixture Micro Thread OsseoSpeed TM Astra Tech AB. the study will include 15 clinic visits and interim analysis will occur at 6 months, 1, 2, and 3 years after loading of the temporary prothesis."
1831476|NCT00798031|Device|dental implant|Subjects will have a complete diagnostic work-up performed and assessment for eligibility in the study by both a Prosthodontist and Surgeon. Subjects will then have two and up to three dental implants placed in an out patient basis at the University of Iowa College of Dentistry
1831477|NCT00798044|Behavioral|Other: quality improvement feedback system|Surveys patients regarding treatment experiences.
1831478|NCT00798044|Behavioral|Patient Feedback|Weekly feedback reports provided to counselors
1831479|NCT00798070|Drug|dtEC→dtT|Individually tailored and two weekly dosed epirubicin (start dose 90mg/m2) + cyclophosphamide (start dose 600mg/m2) followed by a three weeks break followed by biweekly and tailored docetaxel (start dose 75mg/m2) given every second week. If toxicity measured by CTC-NCI criteria are grade 2 or less (except haematological toxicity) it will be possible to escalate doses
1831480|NCT00798070|Drug|FEC→T|Fixed dosed and three weekly epirubicin (100mg/m2), cyclophosphamide (500mg/m2) and 5-fluorouracil (500mg/m2), followed by fixed dosed and three weekly docetaxel (100mg/m2), no dose escalations.
1831481|NCT00798083|Drug|topical amitriptyline 2%, ketamine 1%, and lidocaine 5% in pluronic lecitine organogel(AKL in PLO gel)|Subjects will be taught to apply topical 2%amitriptyline, 1% ketamine and 5% lidocaine(AKL) in PLO gel to the sites of maximum neuropathic pain three times per day for up to 2 weeks after completion of radiotherapy.
1831482|NCT00798096|Drug|Fostamatinib Disodium|200 mg PO BID
1831483|NCT00798109|Behavioral|Motivational therapy|One hour of motivational therapy each weak during 4 weeks
1831484|NCT00798109|Behavioral|Usual care|Patients received at least six hour of usual therapy, as in the experimental group
1831485|NCT00798122|Procedure|Intravascular ultrasound|intravascular ultrasound
1831486|NCT00798122|Procedure|MRI|cardiac MRI
1831487|NCT00798135|Drug|itraconazole|oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
1831488|NCT00798148|Drug|131I-MIBG , Etoposide, Melphalan, Carboplatin, Autologous Peripheral Stem Cell Transplantation|131I-MIBG 12mci/kg CEM(Etoposide)=1200mg/m2 Melphalan=210mg/m2 Carboplatin=1500mg/m2 Autologous Peripheral Stem Cell Transplantation
1831489|NCT00798161|Drug|BI 1356|BI 1356 high dose tablet, once daily
1831490|NCT00798161|Drug|BI 1356 + metformin|BI 1356 low dose tablet + Metformin 500 mg tablet, twice daily
1831491|NCT00798161|Drug|Bi 1356 + metformin|BI 1356 low dose tablet + Metformin 1000 mg tablet, twice daily
1831492|NCT00798161|Drug|Metformin|Metformin 500 mg tablet, twice daily
1831493|NCT00798161|Drug|metformin|metformin 1000 mg tablet, twice daily
1831494|NCT00798161|Drug|matching placebo|matching placebo
1831495|NCT00798174|Device|Azygos vein coil|Addition of an azygos vein defibrillation coil instead of a standard SVC coil.
1831496|NCT00798187|Behavioral|Group Meetings|10 weekly group meetings lasting 2 hours.
1831497|NCT00798187|Behavioral|Questionnaire|Surveys
1831498|NCT00798200|Other|Exercise program|All exercise programs will include endurance and strength exercises.
1831499|NCT00798213|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21 day cycle until disease progression.
1831500|NCT00798213|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 9 mg/m2 IV on Day 1 and Day 15.
1831501|NCT00798226|Dietary Supplement|n-3 fatty acid|Oral intake of 4 capsules daily from week 24 og gestation to 1 week after delivery
1831502|NCT00798226|Dietary Supplement|olive oil|Oral intake of 4 capsules (1 g) daily from 26 weeks of gestation to 1 week after delivery
1831503|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micorgrams/cc BVF
1831504|NCT00798239|Other|Iliac crest autograft|autograft
1831505|NCT00798239|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|750 micrograms/cc BVF
1831506|NCT00798252|Drug|Capecitabine|Tablets, Oral, Dose escalation to a MTD from a starting dose of 850 mg/m², twice a day (BID) x 14d per cycle, until disease progression
1831507|NCT00798252|Drug|Doxorubicin|IV, Dose escalation to a MTD from a starting dose of 40 mg/m², Q3wks, until disease progression
1831508|NCT00798252|Drug|Ixabepilone|IV, Dose Escalation to a MTD from a starting dose of 32 mg/m², Q3wks, until disease progression
1831509|NCT00798252|Drug|Docetaxel|IV, Dose escalation to an MTD from a starting dose of 60 mg/m², Q3wks, Until disease progression
1831510|NCT00798252|Drug|Paclitaxel|IV, Dose escalation to an MTD from a starting dose of Paclitaxel 135 mg/m², Q3wks, Until disease progression
1831511|NCT00798252|Drug|Brivanib alaninate|Tablets, Oral, Dose escalation to a MTD from a starting dose of 400 mg, daily (QD), until disease progression
1831514|NCT00798278|Drug|Urokinase|Chest tube with intrapleural urokinase infusion for 3 days
1831515|NCT00798278|Procedure|Video-Assisted Thoracoscopic|Video-Assisted Thoracoscopic decortication
1831516|NCT00798291|Other|Ad lib diet and Control placebo|one packet with water two times a day
1831517|NCT00798291|Other|Ad lib diet and An 777|one packet with water two times a day
1831527|NCT00798343|Biological|Seasonal vaccine|Non-adjuvanted seasonal influenza vaccine (total dose 45ug)
1831528|NCT00798343|Biological|H5 vaccine|MF59-adjuvanted A/Vietnam/1194 H5N1 vaccine 7.5ug dose
1831529|NCT00798356|Other|Yoga training|Yoga training for 12 weeks
1831530|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1. The i.m. injection was recommended to be administered deeply into the gluteal muscle.
1831531|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
1831532|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
1831533|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
1831534|NCT00798369|Drug|Canakinumab|Randomized patients received one s.c. injection of canakinumab and placebo matching triamcinolone acetonide (0.9% sodium chloride) intramuscularly (i.m.) once, on Day 1.
1831535|NCT00798369|Drug|Triamcinolone acetonide|Randomized patients received triamcinolone acetonide 40 mg i.m. once and placebo matching canakinumab s.c. once, on Day 1.
1831536|NCT00798382|Other|soy protein formula|ad lib for 0-35 days of age
1831537|NCT00798382|Other|Commercially available soy formula|ad lib for 0-35 days of age
1831538|NCT00798382|Other|Soy formula experimental #2|ad lib for 0-35 days of age
1831539|NCT00798395|Drug|Org 50081|1.5 mg on day 1-7
1831540|NCT00798395|Drug|Org 50081|4.5 mg on Day 1-7
1831541|NCT00798395|Drug|Placebo|Once daily on Day 1-7
1831542|NCT00798395|Drug|zopiclone|Single dose of 7.5 mg
1831543|NCT00798408|Dietary Supplement|Fluid Supplement|The fluid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
1831544|NCT00798408|Dietary Supplement|Solid Supplement|The solid food items will contain 25% of each individual's total energy intake estimated from the gender-specific Harris Benedict equation*1.5 activity factor, volume, and amount and type of macronutrients
1831545|NCT00798434|Drug|Placebo|placebo administered orally in the morning or evening.
1831546|NCT00798434|Drug|Fesoterodine fumarate|Fesoterodine fumarate is an antimuscarinic drug recently approved by the European Medicines Evaluation Agency for treatment of symptoms of overactive bladder syndrome.
1831547|NCT00798447|Drug|MLF 541|22-24 h i.v. infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
1831548|NCT00798447|Drug|Lipofundin MCT|22-24 h iv.infusion, maximum 0.75 ml lipid emulsion per kg BW per hour
1831549|NCT00798460|Drug|adefovir|adefovir 10mg
1831550|NCT00798460|Drug|clevudine|clevudine 30mg
1831551|NCT00798460|Drug|lamivudine|lamivudine 100mg
1831552|NCT00798473|Drug|zoledronic acid|Zoledronic acid 0.066 mg/kg (maximum 4 mg) given as a single intravenous infusion over ten minutes
1831553|NCT00798473|Other|IV saline infusion|
1831554|NCT00798486|Device|A1C Test Kit|Subjects tested 3 times with A1C test kits. Two tests were performed by the subject and the third test was performed by a healthcare professional (HCP). All results were compared to results from a laboratory glucose analyzer (TOSOH).
1831555|NCT00798499|Other|Laboratory variables|1 visit
1831556|NCT00798512|Device|Carotid artery stenting|"The MO.MA is a cerebral protection catheter based on the proximal flow blockage concept which is achieved by endovascular clamping of Common Carotid Artery (CCA) and External Carotid Artery (ECA). The MO.MA proximal flow blockage cerebral protection device is indicated to be used in patients eligible for carotid angioplasty and/or the carotid bifurcation and is aimed to prevent brain embolism during the stenting procedure.
For the purpose of this study the Cristallo Ideale™ Carotid Stent System (Invatec S.R.L. Roncadelle, Italy) will be exclusively used. Cristallo Ideale™ consists of a carotid dedicated self-expanding stent pre-mounted on a rapid exchange delivery catheter. The stent platform is made of a Nitinol alloy and characterized by a hybrid design with closed cell in the central zone and open cell in both end zones (proximal and distal)."
1831557|NCT00798525|Drug|Argatroban|Argatra (Argatroban) will be diluted to 0.6 mg/ml and 0.5 µg/kg/min will be administered continuously in patients without liver disfunction. In patients with liver disfunction, defined by a bilirubin of > 4mg/dl, argatroban will be administered as a continuous infusion of 0,25 µg/kg/min with a final concentration of 0,3 mg/ml.
1831558|NCT00798525|Drug|Lepirudin|Refludan (Lepirudin) will be diluted to a final concentration of 0.1mg/ml and initiated as a continuous infusion of 5µg/kg/h in patients with continuous renal replacement therapy. In patients with moderate renal impairment (Creatinine ≥1,3 mg/dl) a final concentration 0,2 mg/ml of will be used to provide continuous infusion of 10 µg/kg/h. Patients without renal impairment (Creatinine < 1,3 mg/dl) will receive a continuous infusion of 50 µg/kg/h by a final concentration of 1 mg/ml of Lepirudin.
1831559|NCT00798538|Other|Services will be provided at one site|Provision of buprenorphine induction and management, substance abuse counseling and HIV care will be provided at one clinic: the Waterbury Hospital Infectious Disease Clinic..
1831560|NCT00798538|Other|Services remain dispersed; i.e., not centralized to one-location or provider.|Buprenorphine induction, substance abuse counseling, and HIV care will be provided at separate locations: the Community Health Care Van (CHCV), the Yale AIDS Program, and patients' own HIV providers, respectively.
1831561|NCT00798551|Behavioral|Risk counseling|cardiovascular risk counseling regarding elevated blood pressure
1831562|NCT00798577|Drug|Vigamox Ophthalmic Solution|Moxifloxacin 5mg/mL 3 times daily for 7 days
1831563|NCT00798577|Drug|BSS placebo|Balanced Saline Solution for 3 doses, then Moxifloxacin 5mg/mL 3 times daily for 7 days
1831564|NCT00798590|Drug|Glucagon-Like Peptide-1|5ng/kg-1/min-1 GLP-1 infused in 3 ml continuously over 72 hours.
1831565|NCT00798590|Drug|Saline|5ng/kg-1/min-1 placebo infused in 3 ml continuously over 72 hours.
1831566|NCT00798603|Biological|bevacizumab|
1831567|NCT00798603|Drug|carboplatin|
1831568|NCT00798603|Drug|pemetrexed disodium|
1831970|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM FLU-A low dose, Intramuscular
1831569|NCT00798616|Drug|prednisolone or methylprednisolone|either prednisolone 2mg/kg PO once daily or methylprednisolone 1.6mg/kg IV once daily (if IV access is present) for length of hospitalization, for a maximum of seven days
1831570|NCT00798616|Drug|placebo|oral or IV placebo
1831571|NCT00798629|Biological|Autologous dendritic cell-adenovirus CCL21 vaccine|Intradermal injections of adenovirus-CCL-21 transduced class I peptide-pulsed DC
1831572|NCT00798642|Behavioral|Hypnotherapy|8 weeks of gut-directed hypnotherapy
1831573|NCT00798642|Behavioral|Standard care|8 weeks of standard of care
1831574|NCT00798642|Behavioral|Mind Body Therapy|8 weeks of mind-body therapy
1831575|NCT00798655|Drug|Panitumumab|"Panitumumab, starting dose, 2.5mg/kg will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation and chemotherapy for 6 weeks; treatment takes about an hour.
The panitumumab dose will be calculated based on the subject's actual weekly body weight"
1831576|NCT00798655|Drug|Cisplatin|Cisplatin, 30 mg/m2 will be given as an intravenous infusion (IV) through a vein in your arm, once a week before radiation therapy and after panitumumab for 6 weeks; treatment takes about an hour
1831577|NCT00798655|Radiation|Radiation Therapy|"Radiation Therapy 60-66 Gy/200 cGy/daily, five days a week, Monday through Friday, except on weekends and holidays, for six weeks; treatments take about 20 minutes.
Radiation will be administered either prior to chemo treatment or after chemo treatment as long as radiation is given on the same day."
1831578|NCT00798668|Dietary Supplement|Liquid Supplements|Liquid supplement that provides 12.5% of the subjects total energy requirement.
1831579|NCT00798668|Dietary Supplement|Solid Supplement|Solid supplement that provides 12.5% of the subjects total energy requirement.
1831580|NCT00798681|Dietary Supplement|RTU TPN with olive oil as the primary lipid source|RTU will be provided as a 3 in 1 TPN ready-to-use TPN system in industrialized bags with 2.000 ml. The number of calories will be adjusted in accordance with patients' individual needs.
1831581|NCT00798681|Other|CNF Parenteral nutrition|CNF parenteral nutrition made with olive oil as the primary source of lipids
1831582|NCT00798681|Other|CNF parenteral nutrition|3 in 1 CNF parenteral nutrition made with LCT/MCT as the primary source of lipids
1996145|NCT02555371|Drug|Placebo|The placebo will be 0.9% sodium chloride solution and will be provided by the study site.
1831585|NCT00798707|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|25 mg tablet, once daily dosing for 8 weeks
1831586|NCT00798707|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|50 mg tablet, once daily dosing for 8 weeks
1831587|NCT00798707|Drug|placebo|Matching placebo tablets (25 or 50 mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
1831588|NCT00798720|Drug|vorinostat|400 mg by mouth once daily for days 1-14 of each 21 day cycle
1831589|NCT00798720|Drug|bortezomib|1.3 mg/m2 IV on days 1, 4, 8, 11 of each 21 day cycle
1831590|NCT00798746|Behavioral|Telephone Questionnaire|Ten questions regarding symptoms of reflux
1831591|NCT00798759|Drug|Travoprost ophthalmic solution 0.004% with SofZia® preservative system (TRAVATAN Z®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as travoprost.
1831592|NCT00798759|Drug|Latanoprost ophthalmic solution 0.005% (XALATAN®)|Ophthalmic solution for the treatment of open-angle glaucoma or ocular hypertension, one drop a day, dosed topically for 12 weeks (84 days). Referred to as latanoprost.
1831593|NCT00798772|Dietary Supplement|Micronutrients and antioxidants|8 capsules twice daily for two years
1831594|NCT00798772|Dietary Supplement|Multivitamins and minerals|8 capsules twice daily for two years
1831595|NCT00798785|Drug|ATG-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.
Tacrolimus levels for 2 years between 8-10 ng/ml.
At year 2: randomization:
group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant subcutaneous (total n=5) at the time of the first clinical implant in the liver."
1831596|NCT00798785|Drug|ATG-Rituximab-MMF-TAC|"ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.
Rituximab: the day before transplantation, day 5; 12 and 19 after implantation. Tacrolimus levels for 2 years between 8-10 ng/ml.
At year 2: randomization:
group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
1831597|NCT00798785|Drug|ATG-basilixumab-MMF-TAC|"First transplantation:
ATG-fresenium for max 6 consecutive days depending on CD3 count, starting the day before transplantation.
Second transplantation:
Basilixumab:
the day before the second transplantation followed by 4days after transplantation.
Tacrolimus levels for 2 years between 8-10 ng/ml.
At year 2: randomization:
group A: till 48 months: tacrolimus levels 8-10 ng/ml 48-60 months: tacrolimus levels 6-8 ng/ml group B: 24-36 months: 6-8 ng/ml 36-60 months: 4-6 ng/ml A subgroup of these patients will receive a sub clinical implant, subcutaneous at the time of the first clinical implant in the liver."
1831598|NCT00798785|Procedure|omentum|"Two clinical implants: first in omentum followed by a clinical implant in the liver:
In a group of 10 patients, a clinical implant in the omentum will be implanted. If random C-peptide levels >= 0.5 ng/ml are measured at 2 months post-transplantation, a second omental implant will be done. If no clinical relevant beta cell graft function is measured, two intraportal implants will be given as a compassionate use procedure. An interim analysis after 5 patients has to shown clinical relevant function at month 2 in 3 out of 5 patients before the subsequent 5 patients can be transplanted in the omentum."
1831599|NCT00798798|Device|Externally Implantable Tissue Expansion Device|Will Apply Externally Implantable Tissue Expansion Device for 2 Days
1831600|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|Surgery -> enroll Pre-RT chemotherapy (2 cycles: A1, B1) PBSC collection during first cycle (A1) (2nd look surgery if necessary) RT (Reduced dose CSI) Post-RT chemotherapy (4 cycles: A2, B2, A3, B3) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM)
1831635|NCT00798993|Drug|Cholecalciferol (25-Hydroxyvitamin D)|Cholecalciferol 2000U per day will be given for duration of study to all participants
1831601|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|Surgery pre-HDCT chemotherapy (6 cycles: A1, B1, A2, B2, A3, B3) PBSC collection during first cycle of chemotherapy (A1) (2nd look surgery if necessary) (if relapse or progression prior to HDCT, off study -> enroll S-083 protocol) HDCT1 (CTE) HDCT2 (CM) (RT if necessary) Observe
1831602|NCT00798811|Procedure|high-dose chemotherapy and autologous stem cell rescue|(Surgery if possible) Chemotherapy (4 cycles) PBSC collection during first cycle of chemotherapy during 4th cycle of chemotherapy (if BM involvement) (RT, if possible, after PBSC collection) (if less than PR prior to HDCT, off study) HDCT1 (CTE) HDCT2 (CM)
1831603|NCT00798824|Procedure|Indwelling nasogastric tube placement|The premature infant is fed with an indwelling nasogastric tube during feeding transition.
1831604|NCT00798824|Procedure|Intermittent orogastric tube placement|The premature infant is fed with an intermittently placed orogastric tube during feeding transition.
1831605|NCT00798824|Device|Nasogastric tube|Premature infants will be fed with a nasogastric tube in place and their feeding behaviors will be noted till discharge.
1831606|NCT00798824|Device|Oral gastric tube|Premature infants will be fed with intermittent orogastric tube placement and their feeding behaviors will be noted till discharge.
1831607|NCT00798837|Radiation|Intraprostatic maximal simultaneous boost|"Each patient will undergo a course of intensity modulated external beam radiation therapy (IMRT) using RapidArc for optimization and delivery.
Doses of radiotherapy are as follows:
The prescription dose will be 73.7 Gy in 28 fractions
A simultaneous intraprostatic boost will be given to as much of the CTV as possible without contravening OAR dose constraints."
1831608|NCT00798850|Procedure|Percutaneous Transluminal Angioplasty (PTA)|PTA will be performed by a consultant interventional radiologist with no deviation from the standard protocol at Hull & East Yorshire Yospitals NHS Trust.
1831609|NCT00798850|Procedure|Supervised Exercise Programme (SEP)|"SEP: Conducted 3 times per week for 12 weeks.The session will be supervised by a physiotherapist and conducted in the cardiac gym.
Each session begins with gentle warming up exercises followed by an exercise circuit of 6 stations(2 minutes each).
Station 1-Step-ups(20-cm high step,alternating leg after 10 step-ups)
Station 2-Exercise bicycles
Station 3-Knee extensions with weights(2kg beanbag)
Station 4-Heel raises
Station 5-Knee bends(Alternating legs after 10 bends)
Station 6-Rest station(2Kg Biceps curls) Gentle walk for 2minutes in between the stations to recover.For first 6weeks patients complete one full circuit, followed by on extra station/week, thus by 12weeks patients will complete 2 full circuits.Finally patients perform a series of gentle stretching and cooling down exercises.
This exercise programme was designed to comply with suggested guidelines based on a meta-analysis assessing the effectiveness of SEP for claudicants."
1831610|NCT00798850|Procedure|Combined Treatment|PTA will be performed according to routine protocol followed by enrollment of patient in SEP. SEP will commence in the week following PTA.
1831611|NCT00798863|Procedure|video assisted submandibular sialadenectomy|Step 1: A 15 to 20 mm skin incision is performed. The anterior part of the gland is then dissected off the mylohyoid muscle. The superficial part of the gland is dissected free. Now, the free superficial part of the gland is resected .Step 2: The scope is inserted into the wound to view the deeper part of the gland. The latter is dissected and removed after identifying the tendon of the digastric muscle, the hypoglossal nerve, the lingual nerve and the submandibular duct. The lingual nerve is released from its attachment to the gland. The submandibular duct is ligated using 3/0 vicryl. The deep part of the gland is extracted through the wound. Hemostasis is secured.
1831612|NCT00798876|Dietary Supplement|Fish Oil|Subjects will be asked to take 10 grams of fish oil per day for 4 weeks.
1831613|NCT00798876|Dietary Supplement|Vitamin E supplement|Subjects will be asked to take 800 International Units per day of Vitamin E for 4 weeks.
1831614|NCT00798876|Dietary Supplement|Western Diet|Subjects will be provided with a standard western diet, food and beverages, to consume during their 4 week participation in this study.
1831615|NCT00798876|Dietary Supplement|Low-Fat Diet|Subjects will be provided with a low-fat diet (food and beverages) for their 4 week participation in this study.
1831616|NCT00798876|Other|Medical Examination|Subjects will have a routine medical exam.
1831617|NCT00798876|Other|Dietary Interview|Subjects will meet with the study nutritionist and have their current diet evaluated. Subjects will also undergo a test (bioimpedance) to estimate their body fat, lean weight, and the rate at which their body burns fat.
1831618|NCT00798876|Other|Blood Draw|40 mL of blood will be drawn from subjects to measure PSA, fatty acids, insulin and various hormones.
1831619|NCT00798876|Procedure|Radical Prostatectomy|Subjects will undergo a radical prostatectomy as part of their standard of care.
1831620|NCT00798889|Drug|Sunitinib|Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
1831621|NCT00798902|Device|Prefix (AMPLEX) B2A Peptide Enhanced Ceramic Granules|150 micrograms/cc BVF
1831622|NCT00798902|Other|Iliac crest autograft|autograft
1831623|NCT00798915|Drug|Placebo|Intravenous infusion of 1% human albumin in normal saline
1831624|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
1831625|NCT00798915|Drug|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
1831626|NCT00798915|Drug|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
1831627|NCT00798941|Behavioral|mouth care|mouth spray, mouth swab, moisturizer
1831628|NCT00798941|Behavioral|pain intervention|music and massage
1831629|NCT00798954|Device|Sirolimus-eluting coronary stent (Cypher)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
1831630|NCT00798954|Device|Paclitaxel-eluting stent (TAXUS)|Drug eluting stents: Comparison Sirolimus with Paclitaxel eluting stents for treatment of coronary bifurcation lesions.
1831631|NCT00798967|Drug|teduglutide|0.05 mg/kg/day sc injection for 24 weeks
1831632|NCT00798967|Drug|placebo|Matching daily subcutaneous dose of placebo to teduglutide for 24 weeks
1831633|NCT00798980|Drug|Mirena (BAY86-5028)|Nulliparous Women
1831634|NCT00798993|Other|Structured Exercise program|30 minutes on an exercise bicycle during every dialysis
1831971|NCT00819013|Biological|Saline placebo|0.5 mL, Intramuscular
1831636|NCT00798993|Other|Usual exercise|Participants randomised to this arm at 3 months will continue on their usual exercise routine for the remaining 3 months
1831637|NCT00799006|Drug|Placebo|Subjects will be given placebo or PF-04620110
1831638|NCT00799006|Drug|PF-04620110|A single oral dose of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned and the period of the cross-over for that cohort. Initial planned doses are 0.3-30 mg but may be modified based on emerging PK and safety data.
1831639|NCT00799032|Device|PCI|coronary stent implantation
1831640|NCT00799045|Drug|Clopidogrel|Patients will be randomized either to aspirin (80 mg/day) or aspirin (80 mg/day) + clopidogrel (75 mg/day) for 3 months following ASD closure.
1831641|NCT00799058|Drug|dapivirine 4789|dapivirine gel 4789, 0.05%, 2.5g applied once daily
1831642|NCT00799058|Drug|dapivirine gel 4759|dapivirine gel 4759, 0.05%, 2.5g applied once daily
1831643|NCT00799058|Drug|Drug placebo|HEC-based universal placebo gel, 2.5g applied once daily
1831644|NCT00799071|Drug|posaconazole (PSZ)|Intake of PSZ oral suspension 40mg/ml twice daily with food. Starting dose is based on bodyweight. The dosage will be adjusted if the exposure is not adequate based on PSZ trough level on Day 10 and 20.
1831645|NCT00799084|Behavioral|Nurse|Receives 6 telephone calls over 8 weeks from an oncology nurse to assist with symptom management
1831646|NCT00799084|Behavioral|AVR|Receives 6 telephone calls over 8 weeks from an programmed automated telephone system to assist with symptom management
1831647|NCT00799110|Drug|GM-CSF|Injections given subcutaneously at the sight of vaccination on the day of the vaccination and for three days afterwards
1831648|NCT00799110|Biological|Dendritic Cell/Tumor Fusion Vaccine|Given subcutaneously once every three weeks for a total of three vaccines
1831649|NCT00799110|Drug|imiquimod|Cream applied to the skin at the injection sight 2 hours before injection and for 3 days following the injection
1831650|NCT00804453|Device|Cartridge blood set|Once a week
1831651|NCT00804453|Device|Standard blood line|Once a week
1831653|NCT00804479|Other|No intervention.|
1831654|NCT00804492|Behavioral|Multifaceted intervention|consulted, educated, referred or receive an exercise training for their fitness, strength and balance
1831655|NCT00804505|Device|SynergEyes Hybrid (petrafocon A hem-larafilcon A) Hybrid Contact Lens|Comparison to control hybrid lens with similar 'dose'minimum 8 hours daily use for up to 90 days.
1831656|NCT00804505|Device|SynergEyes Hybrid (paflufocon D hem-iberfilcon A) Contact Lens|Comparison to test lens: Daily use for minimum 8 hours up to 90 days.
1831657|NCT00804518|Other|Aerobic interval training|High intensity aerobic interval training consists of 10 minutes warm up at ~60% of maximal heart rate, 4x4 minutes intervals at 90-95 % of maximal heart rate corresponding to 85-90% of VO2max) walking/running uphill on a treadmill, with three minutes active pause between the exercise bouts at 60-70% maximal heart rate. The session is terminated with 3 minutes cool down. Total exercise time is 38 minutes.The training is supervised by an exercise physiologist and the subjects train 3 times per week for 12 weeks.
1831658|NCT00804531|Drug|Visipaque - Hydrocortancyl|Visipaque 320 mg I/ml - 1 ml intra-discal route Hydrocortancyl 25 mg/ml - 1 ml intra-discal route
1831659|NCT00804531|Drug|Placebo comparator|Visipaque - 320 mg I/ml - 1 ml in intra-discal route
1831660|NCT00804544|Device|SPECT/CT|SPECT/Low-Dose MultiSclice CT
1831661|NCT00804570|Drug|LY2196044|250 milligram (mg) (titrate via 1 week at 50 mg and 1 week at 125 mg), once daily, orally, 16 weeks
1831662|NCT00804570|Drug|placebo|once daily, orally, 16 weeks
1831663|NCT00804596|Device|Apollo Blood Glucose Monitoring System|Subjects with diabetes were rated for success in performing tasks with a new blood glucose monitoring system (BGMS). Also, subjects and healthcare professionals (HCPs) used the new blood glucose monitoring system with subject capillary blood. All blood glucose results were compared to a laboratory glucose method - Yellow Springs Instrument(YSI) Analyzer.
1958860|NCT01176474|Biological|gp100:280-288 (288V)|"The vaccine contains two peptides from two different proteins (peptides are pieces that make up proteins) called gpl00 and NY-ES0-1.
Route of Administration: When prepared as a vaccine emulsion with Montanide ISA 51 VG, the vaccine is given by deep subcutaneous injection.
Method of Administration: The 0.5 mg vaccine emulsion dose is administered as a 1 mL injection (0.5 mg/1 mL) as a deep subcutaneous injection in the anterior thigh of the same extremity."
1958861|NCT01176474|Drug|Montanide ISA 51 vegetable grade (VG)|"Route of Administration: Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
Method of Administration: Divide peptide vaccine emulsion dose volumes of greater than 1.5 mL into 2 or more injections. Administer injections typically into the anterior thigh deep subcutaneous tissue. Perform subsequent injections in rotating sites. Use a 20 or 21 gauge needle for deep subcutaneous injection of the peptide vaccine emulsion."
1831666|NCT00804622|Drug|telbivudine|daily oral administration,600mg,over 12 weeks
1831667|NCT00804622|Drug|tenofovir disproxil fumarate|daily oral administration,300mg,over 12 weeks
1831668|NCT00804622|Drug|telbivudine plus tenofovir disproxil fumarate|daily oral administration of telbivudine 600 mg and tenofovir disproxil fumarate 300 mg in combination given over 12 weeks
1831669|NCT00804648|Drug|Timolol Maleate in Sorbate|0.5%
1831670|NCT00804648|Drug|Timolol hemihydrate|0.5%
1831671|NCT00804648|Drug|Timolol maleate gel forming solution|0.5%
1831672|NCT00804661|Device|SENTEC device|Nocturnal recording SAO2 and PtcCO2 and wrist movements by means of actigraphy
1831673|NCT00804674|Drug|bupivacain|
1831674|NCT00804674|Drug|placebo|
1831675|NCT00804687|Other|Placebo|Single-dose of 1 milliliter (ml) placebo solution will be administered orally and/or placebo tablet orally in one of the treatment periods.
1831676|NCT00804687|Drug|JNJ-39220675|Single-dose of JNJ-39220675 will be administered as 1 ml of 10 milligram/milliliter solution orally in one of the treatment periods.
1831761|NCT00805259|Behavioral|Financial incentives|Financial incentives based on use of software designed to promote cognitive function
1958862|NCT01176474|Drug|Ipilimumab|"Ipilimumab will be given at the following dosage: 3 mg/kg.
Ipilimumab will be administered as an i.v. infusion, using a volumetric pump with a 0.2 micron in-line filter at the protocol-specified dose(s) and rate."
1831677|NCT00804687|Drug|Pseudoephedrine|Single-dose of 60 milligram pseudoephedrine tablet will be administered orally in one of the treatment periods.
1831678|NCT00804700|Behavioral|Active teaching in synchronous listening to music while exercising|Subjects will be instructed to exercise while listening to four audio tutorials that are stored on their MP-3 player. These tutorials guide the subject on how to synchronize his or her body movements to the beat of the music.
1831679|NCT00804713|Drug|BST|0.1 mcg/mL (1 dose) Battey skin test (BST) antigen administered using the Mantoux method.
1831680|NCT00804713|Drug|TST|Administer TB Skin test (TST)
1831681|NCT00804713|Other|QFT|Perform QFT TB test
1831682|NCT00804713|Other|T-spot|Perform T-Spot TB test
1831683|NCT00804726|Device|Akreos MI Five-O|Small incision cataract surgery with phacoemulsification cataract extraction and Akreos MI Five-O IOL surgical implantation
1831684|NCT00804739|Other|Mother-Infant Treatment Team|This is a treatment team approach that allows for outreach. The clinical team will be a nurse practitioner of psychiatry and a social worker. The nurse practitioner will provide either interpersonal psychotherapy, sertraline or both as indicated.
1831685|NCT00804752|Drug|Adding vitamin D|Adding 1000IU/Vitamin D daily
1831686|NCT00804752|Drug|Vitamin D|Addition of 1000IU/day Vitamin D
1831687|NCT00804765|Other|Therapeutic education|Intensive training individual and collective teaching
1831688|NCT00804765|Other|Follow-up|classical follow-up with two individual consultations
1831689|NCT00804791|Other|Systane Ultra Lubricant Eye Drops|artificial tears solution for lubricating the cornea
1831690|NCT00804791|Other|Unisol 4 Saline Solution|saline solution for irrigating the cornea
1831691|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
1831692|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
1831693|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
1831694|NCT00804804|Other|Sleep deprivation and multiple rest|To determine the evolution of the executive functions during a 40-hour extended wakefulness period or during a 40-hour multiple nap protocol in constant experimental conditions of confinement
1831695|NCT00804817|Behavioral|Control Group|Control: Care as usual, i.e. standard physical activity enhancement, oral mucositis prevention and treatment and mal nutrition prevention
1831696|NCT00804817|Behavioral|SCION-HSCT program|"Intervention: Patients receive SCION-HSCT program a multi-modular somatic-psycho-social care intervention. consisting of 3 modules: Activity Enhancement, Oral Mucositis Prevention and Mal-Nutrition Avoidance.
The intervention will be conducted by specially trained oncology nurses and will include components of knowledge, skills training, and coaching to improve self management. The intervention starts at admission followed by booster sessions during the period of hospitalization. Patients will be scheduled to an individualized physical activity program incl. endurance training on light level 60-80% of max heart rate. Additionally the patient will be counselled to follow a mouth care protocol based on self assessment of the mouth to prevent oral mucositis. Both interventions are accompanied by a systematic screening of the nutritional situation. All three interventions are aimed to improve patients' adherence to self management strategies of side effects."
1831697|NCT00804830|Drug|Bevacizumab|Avastin 15 mg/kg q3w and doxorubicin 20 mg q1w
1958863|NCT01176474|Procedure|Apheresis Procedure|"Some blood will be removed from the participant's veins and processed by a machine to remove a small portion of the white cells. The rest of the blood will be returned into their veins. This procedure is called apheresis. Apheresis is done to collect cells to allow the investigators to understand how their immune system is functioning before and after receiving nivolumab and vaccine. This will be done for research purposes only. The red cells and blood clotting cells will not be permanently removed during this procedure. White blood cells will need to be removed by apheresis before participants receive the study drug."
1831702|NCT00804856|Drug|BI 6727 (d1 and 15)|BI 6727 (d1 and 15 - one hour iv.v)
1831703|NCT00804856|Drug|BI 6727 (d1 and 15)|BI 6727 (d1 and 15 - one hour iv.v)
1831704|NCT00804856|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c.
1831705|NCT00804856|Drug|Cytarabine|Cytarabine 2 x 20 mg/d s.c.
1831706|NCT00804869|Device|PalmScan A2000 ultrasonography system (Micro Medical Devices, Calabasas, CA)|PalmScan biometric measurements
1831707|NCT00804869|Device|Standard A-mode ultrasound (Eye Cubed™, Ellex, Adelaide, Australia).|A-mode biometric measurements group
1831708|NCT00804895|Drug|ALTIM, cortivazol injections|ALTIM, cortivazol in greater occipital nerve injection separated by 2 or 3 days each.
1831709|NCT00804895|Drug|PROAMP, subcutaneous serum physiological saline|Three injections will be performed at the level of the greater occipital nerve with a suboccipital approach. Injection will be separated by two or three days each.
1831710|NCT00804895|Drug|Verapamil|standard prophylactic treatment
1831711|NCT00804908|Drug|temozolomide|temozolomide capsule administered orally once daily for 5 days every 28 days
1831712|NCT00804908|Drug|ABT-888|ABT-888 capsule administered orally twice daily for 7 days every 28 days
1831713|NCT00804908|Other|Placebo|Placebo for ABT-888 capsule administered orally twice daily for 7 days every 28 days
1831714|NCT00804921|Drug|bevacizumab|
1831715|NCT00804921|Procedure|anterior chamber paracentesis|
1831716|NCT00804921|Drug|acetazolamide|
1831717|NCT00804921|Drug|brimonidine|
1831718|NCT00804934|Drug|Lucentis|0.5mg Lucentis every four months
1831762|NCT00805272|Other|QTF-TB Gold and T-SPOT TB|evaluation of the theoric therapeutic impact of the use of IGRAS for diagnosis of LTBI in HIV-infected patients
1831719|NCT00804947|Drug|Intravenous busulfan and melphalan|BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
1831720|NCT00804960|Drug|Letrozole|1) Letrozole 5 mg starting on cycle day 2, which will be continued until the day of trigger. Recombinant FSH at doses 100-225 units, as determined by BMI, AFC, age, and ovarian reserve markers will be added on cycle day 4. The dose will be adjusted based on the response. An antagonist will be administered once the lead follicle reaches 14-mm in diameter or when estradiol level reaches 250 pg/mL. Oocyte maturation will be triggered by 20 iu of leuprolide acetate.
1831721|NCT00804960|Drug|Std IVF Protocol|2) Long protocol with luteal phase GnRHa suppression with gonadotropin dose at 200-450 IU. Oocyte maturation will be triggered by 250 micg of ovidrel.
1831722|NCT00804973|Drug|LY2590443|200mg as 4-50 mg capsules, oral, once
1831723|NCT00804973|Drug|Placebo injection|saline solution, injection, once
1831724|NCT00804973|Drug|Sumatriptan|6mg injection (0.5mL of 12mg/mL solution), once
1831725|NCT00804973|Drug|Placebo capsule|4 capsules, once
1831726|NCT00804986|Drug|LY2428757|Once weekly for 12 weeks as a subcutaneous injection.
1831727|NCT00804986|Drug|Placebo|1 of 5 volumes of placebo given once weekly for 12 weeks as a subcutaneous injection.
1831731|NCT00805012|Drug|docetaxel+CDDP|docetaxel+CDDP
1831732|NCT00805012|Drug|docetaxel+S-1|docetaxel+S-1
1831733|NCT00805025|Drug|AZLI|75 mg aztreonam for inhalation solution (AZLI), administered 3 times daily using the PARI Investigational eFlow® Nebulizer System (with a minimum of 4 hours between doses) following administration of a short-acting bronchodilator
1831734|NCT00805038|Behavioral|Transplant navigator|Navigator will provide help to patients in completing specific steps in transplant process.
1831735|NCT00805038|Behavioral|Usual care|Nephrologists and dialysis facilities will provide usual care regarding access to transplantation.
1831736|NCT00805064|Drug|triamcinolone and bevacizumab|
1831737|NCT00805077|Procedure|mechanical ventilation|mechanical ventilation with low tidal volume (5 ml/kg of ideal body weight) plus PEEP
1831738|NCT00805077|Other|tidal volume|tidal volume of 10 ml/kg of ideal body weight without PEEP
1831739|NCT00805090|Drug|Sporanox|200 mg
1831740|NCT00805090|Drug|Diclofenac Sodium|37.5 mg
1831741|NCT00805103|Radiation|Hypofractionated stereotactic radiotherapy|Patients will be initially administered 8 Gy RT (level). The dose at each level will be increase by 2 Gy up to level 4. If ≥ 2 of the patients in a dose cohort encounter a DLT, then that dose level will be declared the maximum administered dose. An additional 3 patients will then be entered at the previous dose level and provided no more than one patient experiences a DLT, that level will be declared the maximum tolerated dose (MTD). Up to 6 more patients can be treated at the given dose level while awaiting the results of 6 months of follow-up.
1831742|NCT00805116|Dietary Supplement|Whale blubber oil|15 ml/day for 4 months, divided on dosage morning and evening, orally.
1831743|NCT00805116|Dietary Supplement|Cod liver oil|15 ml/day for 4 months, divided on dosage morning and evening, taken orally
1831744|NCT00805129|Drug|Everolimus|Everolimus (RAD001) is a novel oral derivative of rapamycin. Everolimus will be administered orally as a once-daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take Everolimus in the morning, at the same time each day. Everolimus should be taken by the patient in a fasting state or with no more than a light fat-free meal.
1831745|NCT00805142|Drug|Tapentadol PR|Tapentadol PR tablets will be administered orally twice daily initiated at dose of 25 mg. Dose will be adjusted as per Investigator's discretion. Maximum dose limit is 500 mg per day. Total duration of treatment is 19 days.
1831746|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Reference Product|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
1831747|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test product 1|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
1831748|NCT00805155|Drug|Mometasone Furoate 0.1% Topical Lotion-Test Product 2|Small amount applied and evaluated over the course of two days. ChromaMeter used to measure response.
1831749|NCT00805168|Drug|Amikacin Inhalation Solution (BAY41-6551)|400 mg of aerosolized amikacin every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
1831750|NCT00805168|Drug|Aerosolized Placebo|Aerosolized placebo every 12 hours for 10 days to be administered using the Pulmonary Drug Delivery System (PDDS Clinical)
1831753|NCT00805207|Drug|Progesterone|Micronized progesterone, 100 mg/d vaginally, 14 days followed by 14 days of placebo. Repeat this cycle 3 times.
1831754|NCT00805207|Drug|testosterone|Testosterone gel 1250 ug/d, 21 days
1831755|NCT00805207|Drug|glucocorticoid|Dexamethasone 0.013 mg/kg fat-free mass daily, 21 days
1831756|NCT00805207|Device|continuous positive airway pressure|Breathe through the mask of a continuous positive airway pressure device every night when sleep, for 6 weeks
1831757|NCT00805207|Drug|Estrogens|Estrogen treatment (100 ug Estradiol daily) administered 14 days followed by 14 days without treatment. Repeat this cycle 3 times.
1831758|NCT00805220|Other|Nordic Walking|Walking training with and without poles will be twice a week. The sessions last 20 minutes each and consist of walking, stretching and mobility exercises. This will last 8 weeks in a total of 16 sessions. A therapist will closely monitor your exercises and modify them according to your needs and comfort
1831759|NCT00805233|Drug|combination ranibizumab + bromfenac|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months. Plus one drop of bromfenac in the study eye twice per day, each day, for 12 months.
1831760|NCT00805233|Drug|ranibizumab injection alone|ranibizumab injection in study eye each month for 4 months then as needed each month for 8 months
1831763|NCT00805285|Drug|Combination Oral Budesonide and Rectal Hydrocortisone|Budesonide 9 mg PO (oral) daily and hydrocortisone 100 mL PR (enema) for an 8-week period. The doses of each drug to be used in the pilot study are standard doses used in clinical practice. After 8-weeks, the budesonide will be tapered in the following manner: 1) budesonide 6 mg PO daily and hydrocortisone 100 ml PR every other day (EOD) for 3 weeks then 2) budesonide 3 mg PO daily and hydrocortisone 100 ml PR 2 x per week for 3 weeks then 3) discontinue budesonide.
1831764|NCT00805298|Drug|methylprednisolone|32 mg before surgery, 16 mg twice daily the day after surgery
1831765|NCT00805298|Drug|placebo|two tablets before surgery, one tablet twice daily on the day after surgery
1831766|NCT00805298|Drug|xyloplyin adrenalin|lidocaine local anaesthetic lidocaine 20 mg/ml, adrenalin 12,5 µg/ml maximum dosage 10 ml.
1831767|NCT00805298|Drug|marcain adrenalin|bupivacaine local anaesthetic bupivacaine 5 mg /ml, adrenaline 5 µg/ml maximum dosage 10 ml
1831768|NCT00805311|Procedure|Carotid Endarterectomy|CEA involves a neck incision and physical removal of the plaque from the inside of the artery
1831769|NCT00805311|Drug|atorvastatin, aspirin, losartan, amlodipine|aspirin 100 mg/day, atorvastatin 10 mg/day, losartan 50 mg/day, amlodipine 5 mg/day
1831770|NCT00805324|Drug|Desloratadine|desloratadine syrup; 5.0 mL once daily for 28 days
1831771|NCT00805337|Device|Intrabuccally-administered amplitude-modulated RFEM|Generation of amplitude-modulated electromagnetic fields: the device consists of a battery-driven radiofrequency (RF) electromagnetic field generator connected to a 1.5 meter long 50 Ohm coaxial cable, to the other end of which a spoon-shaped mouthpiece made of steel is connected with the inner conductor. The RF source of the device corresponds to a high-level amplitude-modulated class C amplifier operating at 27.12 MHz. The modulation frequency can be varied between 0.01 Hz and 150 kHz with a modulation depth of 85 ± 5%. The RF output is adjusted to 100 mW into a 50 Ohm load using a sinusoidal modulated test signal, which results in an emitting power identical to that of the device used in the treatment of insomnia (Pasche et al 1996, 19:327-336).
1831772|NCT00805350|Drug|Eplivanserin|one 5 mg tablet once a day
1831773|NCT00805350|Drug|Placebo|Placebo of Eplivanserin one tablet once a day
1831774|NCT00805376|Drug|DNX-2401|Surgical procedure precisely injects DNX-2401 through a catheter (small tube) into brain tumor.
1831775|NCT00805376|Procedure|Tumor Removal|Surgical Tumor Resection
1831776|NCT00805389|Biological|Engerix-B™|2 doses intramuscular injections
1831777|NCT00805389|Biological|Fendrix™|2 doses intramuscular injections
1831778|NCT00805389|Biological|GSK Biologicals' Hepatitis B vaccines (GSK223192A)|2 doses intramuscular injections 3 different formulations of (GSK223192A), each administered to 1 group
1831779|NCT00805389|Biological|HBsAg (Booster injection)|Single dose intramuscular injection
1831780|NCT00805402|Other|flow cytometry|flow cytometry
1831781|NCT00805415|Drug|EV/DNG (Qlaira, BAY86-5027, SH T00658K)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 2 and 3 mg
1831782|NCT00805415|Drug|EV/DNG (SH T00658L)|Estradiol valerate (EV) and dienogest (DNG) in a sequential 4-phasic regimen, EV 3, 2, and 1 mg and DNG 3 and 4 mg
1831785|NCT00805454|Drug|OPC-34712|Single oral dose, 0.5 to 25 mg
1831786|NCT00805467|Drug|Fostamatinib Disodium (R935788)|50 mg PO BID; 100 mg PO BID; 100 mg PO QD; 150 mg tablet PO QD
1831787|NCT00805480|Drug|AIN457|AIN457 was administered intravenously.
1831788|NCT00805480|Drug|Placebo|Matching placebo to AIN457 was administered intravenously.
1831789|NCT00805493|Drug|Riluzole|
1831790|NCT00805519|Drug|Glucosamine and chondroitin sulfate|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients, daily.
1831791|NCT00805519|Drug|glucosamine and chondroitin sulfate plus Prednisolone|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive Prednisolone 5 mg/day
1831792|NCT00805519|Drug|Glucosamine and Chondroitin sulfate plus Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive chloroquine 150 mg every two days.
1831793|NCT00805519|Drug|Glucosamine,Chondroitin sulfate,Prednisolone,Chloroquine|In this arm fixed dose glucosamine (400 mg) and chondroitin sulfate (500 mg)combination will be administrated to the patients as baseline therapy, daily. also,the patients will receive prednisolone 5 mg/day and chloroquine 150 mg every two days.
1831796|NCT00810953|Drug|Pentamidine|two dose of 6 mg/kg with or without standard chemotherapy.
1831797|NCT00810979|Drug|SLx-4090|tablet
1831798|NCT00810979|Drug|SLx-4090|tablet
1831799|NCT00810979|Other|Placebo|matching tablet
1831800|NCT00810979|Drug|Statin|Subjects were dosed with the statin prescribed specifically by their prescribing physician.
1831801|NCT00810992|Behavioral|Nutritional and behavioral program A|Recommendation for nutrition and behavior for patients with coronary artery disease according to the German Society of Nutritional Medicine and the International Task Force for the Prevention of Coronary Artery Disease
1831802|NCT00810992|Behavioral|Nutritional and behavioral program B|Recommendation for nutrition and behavior for patients with coronary artery disease according to the system of the Traditional Tibetan Medicine
1831844|NCT00817206|Drug|LCP-Tacro|LCP-Tacro tablets will be administered orally QD, at the same time in the morning to maintain trough levels at 5-15 ng/ML. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels. LCP-Tarco (tacrolimus) tablets provided in 0.5 mg, 1 mg, 2 mg, and 5 mg tablets.
1831803|NCT00811005|Radiation|8-methoxypsoralen or 5- methoxypsoralen|"Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.
Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
1831804|NCT00811005|Radiation|8-methoxypsoralen or 5methoxypsoralen|"PUVA treatment:
Intake of 8-methoxypsoralen in a dose of 0.6 mg/kg 1 hour before UVA irradiation or, in case of 8-methoxypsoralen intolerance, 5-methoxypsoralen in a dose of 1.2 mg/kg 2 hours before UVA irradiation.
Start of PUVA 2 weeks after initiation of acitretin or FAE treatment. Irradiation will be given three times per week over a maximum period of 12 weeks (36 exposures). PUVA exposure will be limited to the hands and feet."
1831805|NCT00811018|Drug|Sitaxsentan|Sitaxsentan 100 mg tablets once daily
1831806|NCT00811031|Drug|Taxotere|75 mg/m^2 Day 1 of every 21-day cycle by vein for 4 cycles prior to surgery.
1831807|NCT00811031|Drug|Prednisone|5 mg twice a day by mouth.
1831808|NCT00811057|Drug|1 Magnesium Sulfate|Participants randomized to this arm will receive a loading dose of 6gms intravenously followed by a maintenance dose of 2-4gm/hr, per physician discretion, until uterine quiescence is achieved. The Magnesium Sulfate dosage is then titrated down until discontinued per physician discretion.
1831809|NCT00811057|Drug|Nifedipine|Participants randomized to receive nifedipine will receive an initial 30mg loading dose, then 10 - 20mg q 4 - 6 hours as needed, per physician discretion, until uterine quiescence is achieved.
1831810|NCT00811057|Drug|Indomethacin|Participants randomized to receive indomethacin will receive an initial 100mg per rectum X1, may repeat x1, and then 25 - 50mg orally every 6 hours over 48 hours as needed per physician discretion until uterine quiescence has been achieved.
1831811|NCT00811070|Drug|SKI-606 (Bosutinib)|"Formulation: 100 mg Capsule for Part 1, 100 mg tablet for Part1 and Part 2.
SKI-606 (Bosutinib) will be taken by mouth with water and food as continuous once-daily dosing."
1831812|NCT00811083|Drug|DMSA - dimercaptosuccinic acid|dose of 10 mg/kg bodyweight 3 doses/day, for 3 days, followed by 11 days off
1831813|NCT00811096|Drug|Tinidazole|2gms, p.o. q.d. for 5 days
1831814|NCT00811096|Drug|chloroquine|
1831815|NCT00811109|Device|Standard Hemodialysis|Gold standard bicarbonate hemodialysis therapy with constant ultrafiltration rate and dialysis conductivity performed with Fresenius 4008S monitor (Fresenius Medical Care, France)
1831816|NCT00811109|Device|with Blood Volume Management (BVM®) only|Hemodialysis using Blood Volume on-line monitoring only. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® device (for blood volume monitor; Fresenius Medical Care, France)
1831817|NCT00811109|Device|with Blood Volume (BVM®) and Temperature (BTM®) on-line monitoring|Hemodialysis using Blood volume and Blood temperature on-line monitoring. Hemodialysis will be performed with Fresenius 4008S monitor (Fresenius Medical Care, France) equipped with BVM® and BTM® devices (for blood volume monitor and blood temperature management, respectively; Fresenius Medical Care, France)
1831818|NCT00811122|Radiation|11C-PIB PET Scan|Participants will receive an 11C-PIB PET scan of the brain.
1831819|NCT00811122|Radiation|FDG-PET Scan|Participants will receive an FDG-PET scan of the brain.
1831820|NCT00811135|Drug|bevacizumab [Avastin]|15mg/kg iv on day 2 of first 3-week cycle,and on day 1 of subsequent cycles
1831821|NCT00811135|Drug|capecitabine [Xeloda]|1000mg/m2 bid po on days 1-14 of each 3-week cycle
1831822|NCT00811135|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, followed by 6mg/kg iv maintenance dose on day 1 of subsequent cycles
1831824|NCT00811161|Device|Airgent|HA needle free injection, 3-4 treatments, 3-4 weeks apart
1831825|NCT00811174|Drug|Octagam 10%|300-600 mg/kg every 21 (+/- 3 days) to 28 days (+/- 3 days)
1831828|NCT00811200|Drug|ranibizumab|three initial monthly intra vitreal injections with 0.5 mg ranibizumab
1831829|NCT00811200|Drug|triamcinolone acetonide|at baseline one intra vitreal injection with 4.0 mg triamcinolone acetonide
1831830|NCT00811200|Other|sham|at baseline one sham-injection
1831831|NCT00811213|Device|SleepStyle 200 Auto Series with SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology enabled
1831832|NCT00811213|Device|SleepStyle 200 Auto Series with out SensAwake|Auto adjusting Continuous Postive Aiway Pressure (CPAP) Device with SensAwake technology disabled
1831834|NCT00811239|Drug|Bungarus multicinctus-candidus Antivenom|Five to ten ampoules of antivenom, depending on severity of muscle paralysis, were diluted with isotonic glucose solution to have total 50 ml and infused intravenously by electric pump during one hour. After a period of 6-8 hours, a second infusion was administered, under similar condition to the first, if no clinical improvement or adverse reaction had been noted. The patients also received supportive care such as intubation, ventilation...if necessary.
1831835|NCT00811239|Other|Supportive Care|Supportive Care only (endotracheal intubation, mechanical ventilation...)
1831836|NCT00811252|Drug|Placebo|capsules; daily; orally
1831837|NCT00811252|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets; daily; orally
1831838|NCT00811252|Drug|Duloxetine|encapsulated tablets; daily; orally
1831839|NCT00811265|Device|ExAblate MRgFUS for prostate cancer|Simulated use of ExAblate MRgFUS system
1831840|NCT00817180|Other|Positive Expiratory Pressure (PEP)|Physiotherapy technique for airway clearance
1831841|NCT00817180|Other|High Frequency Chest Wall Oscillation (HFCWO) using InCourage Vest System|Physiotherapy technique for airway clearance.
1831842|NCT00817193|Behavioral|Physical Activity|Physical Activity program
1831843|NCT00817193|Behavioral|Wellness|Wellness program
1831926|NCT00818701|Drug|low dose Nesiritide|Nesiritide infusion 0.005ug/kg/min
1831845|NCT00817206|Drug|Prograf|Oral prograf doses will be given BID (in the morning and evening), to maintain trough levels of 5- 15 ng/mL. Prograf capsules (tacrolimus) capsules, twice daily oral, provided in 0.5 mg, 1 mg, and 5 mg capsules.
1831846|NCT00817219|Drug|Calcipotriene plus betamethasone dipropionate ointment|Once daily application for 4 weeks
1831847|NCT00817232|Device|Microcurrent (Elexoma Medic)|monophasic frequency modulated square wave current applied for 99 minutes daily for 21 days
1831849|NCT00817258|Drug|cisplatin|Cisplatin 40mg/m2,weekly
1831850|NCT00817258|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|3D-CRT or IMRT
1831851|NCT00817271|Drug|AZD1656|Dose titration of oral suspension during 2 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose for another 6 days. On day 5 and 8 the dose will be given as a single dose
1831852|NCT00817271|Drug|Glucagon|1 mg injected 3 hr post AZD1656 morning dose on day 5 alt. day 8
1831853|NCT00817284|Drug|bevacizumab and Irinotecan and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15.
Irinotecan:
Irinotecan 125 mg/m2 is administered on days 1 and 15 to patients NOT receiving enzyme-inducing antiepileptic drugs (EIAED).
Irinotecan 340 mg/m2 is administered on days 1 and 15 to patients receiving EIAEDs.
During concomitant chemoradiotherapy, bevacizumab and irinotecan are given in the same doses and schedules as before and after chemoradiotherapy.
Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
1831854|NCT00817284|Drug|Bevacizumab and Temozolomide and radiotherapy|"Bevacizumab 10 mg/kg is administered on days 1 and 15. Temozolomide dosing before start concomitant chemoradiotherapy: 150 mg/m2/day on days 1-5 during the first 28 days treatment cycle, then 200 mg/m2/day on the subsequent cycles until radiotherapy.
Temozolomide administered concomitantly with the radiotherapy: Temozolomide 75 mg/m2/day for 7 days per week is administered on each day of radiotherapy.
After completed chemoradiotherapy, temozolomide is dosed and administered as it was prior to start chemoradiotherapy, i.e. temozolomide 200 mg/m2/day on days 1-5 out of a 28 days schedule, taking into consideration any previous dose-reductions already made.
Radiotherapy is delivered during 3rd and 4th cycle of chemotherapy and consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week (Monday to Friday) over a period of six weeks for a total dose of 60 Gy."
1831855|NCT00817297|Device|noninvasive ventilator|Experimental V60 Mask noninvasive Ventilator for treating patients with COPD, then Comparator Conventional Mask noninvasive Ventilator for treating patients with COPD in crossover study design
1831856|NCT00817323|Procedure|Dietary amino-acid depletion|See detailed description
1831857|NCT00817336|Drug|D Serine|60 mg/kg/day
1831858|NCT00817336|Drug|Placebo|oral
1831859|NCT00817362|Drug|IPI-504|IPI-504 IV infusion 300 mg/m2
1831860|NCT00817362|Drug|Trastuzumab|Trastuzumab IV infusion 8 mg/kg as the first dose of trastuzumab, followed by trastuzumab 6 mg/kg every 3 weeks. Subjects whose last dose of trastuzumab was <4 weeks prior to study entry will receive 6 mg/kg as the first dose of trastuzumab. For all additional cycles in Stage 1, trastuzumab will be administered with the first dose of IPI-504.
1831861|NCT00817375|Drug|SSRI treated group|Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
1831862|NCT00817375|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose
1831863|NCT00817388|Other|No intervention|No intervention
1831864|NCT00817401|Device|hypothermia|For the systemic hypothermia treatment (TS Med 200, Germany), the infants were nursed under an open unit, covered only by a diaper and a thin linen, loosing heat to the environment and to a cooling mat¬tress which was perfused by circulating liquid at a variable temperature. The rectal temperature was targeted at 33.5 °C (range of 33 to 34 °C) and was meant to be achieved within 60 min. The body temperature was checked every 10 min during induction hypothermia and every hour during the remaining period of cooling. The duration of hypothermia was 72 hrs. Rewarming was started by stopping the cooling system. The infant was meant to reach a 36.5°C rectal temperature in 6 hrs after stopping cooling to prevent rebound hyperthermia.
1831865|NCT00817414|Drug|Placebo|
1831866|NCT00817414|Drug|LCI699|
1831867|NCT00817427|Other|Controls Short sleep|Healthy control subject's bedtime will be decreased by 2 hours/night with acoustic sleep disruption
1831868|NCT00817427|Other|CKD- sleep extension|Sleep will be increased by 2 hours each night for 3 nights
1958882|NCT01161862|Device|Closed-loop blood glucose control with a bi-hormonal (insulin and glucagon) artificial pancreas|
1958883|NCT01161862|Device|Closed-loop blood glucose control with an insulin-only artificial pancreas|
1831871|NCT00817466|Drug|Racemic adrenaline|"For inhalation.
Dosing (as in previous study):
1) 0,1ml<5kg, 0,15ml 5-6,9kg, 0,20ml 7-9,9kg, 0,25ml >10kg of racemic adrenaline 20mg/ml diluted in 2ml NaCl 9mg/ml.3
Maximum 12 inhalations/24 hours. One bottle (10ml) per patient. The bottles will be marked with the name of the study and a randomisation number."
1831872|NCT00817466|Drug|Isotonic saline|2ml NaCl 9mg/ml.
1831873|NCT00817479|Drug|Dexamethasone|20 MG OF DEXAMETHASONE OR PLACEBO
1831874|NCT00817479|Drug|Placebo|Placebo saline
1831875|NCT00817505|Drug|AZD1656|Single dose oral tablet
1831876|NCT00817505|Drug|AZD1656|Single dose oral suspension
1831877|NCT00818415|Drug|Naproxen sodium ER (BAYH6689)|Extented release Naproxen sodium (660mg) administered once a day
1831878|NCT00818415|Drug|Commercial Naproxen (Aleve, BAYH6689)|Immediate release Commercial Aleve (220mg) administered in a two ( 440 mg) plus one (220mg) dosing regime, 660 mg daily
1831927|NCT00818701|Drug|nesiritide, Sildenafil|Nesiritide 0.005ug/kg/min Sildenafil 50 mg
1831972|NCT00819039|Drug|Aprepitant|Aprepitant administered orally or intraveously.
1831973|NCT00819039|Drug|Ondansetron|Ondansetron administered intravenously.
1831974|NCT00819052|Drug|Nevirapine XR|Nevirapine XR
1831883|NCT00818441|Drug|Dacomitinib (PF-00299804)|Dacomitinib (PF-00299804) at 45 mg daily or 30 mg daily by continuous oral dosing, to be escalated in tolerating patients to 45mg after at least 8 weeks of therapy (30 patients in Cohort A started at the lower dose).
1831884|NCT00818441|Drug|Dacomitinib (PF-00299804)|In Cohort B, patients getting Dacomitinib for first line therapy started at 30 mg, but those who had prior anti-cancer therapy started at 45 mg.
1831885|NCT00818454|Drug|Combivent CFC MDI|
1831886|NCT00818454|Drug|Albuterol HFA MDI|
1831887|NCT00818454|Drug|Respimat Combivent|
1831888|NCT00818467|Other|Tanning spray|using 3% DHA twice a week for the 1st week and then once a week for 4 weeks and receiving 40mJ UV-B phototherapy three times a week for four weeks
1831889|NCT00818467|Other|UVB|receiving 40mJ UV-B phototherapy three times a week for four weeks
1831890|NCT00818480|Drug|YM155|continuous infusion
1831891|NCT00818493|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, ascending flexible dose, every 4 to 6 hours
1831892|NCT00818493|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3mg/2mg or 6mg/4mg IR Capsule every 4 to 6 hours
1831893|NCT00818493|Drug|Percocet (oxycodone and acetaminophen)|One or two 5mg/325 mg tablets every 4 to 6 hours
1831894|NCT00818519|Drug|EE20/Drospirenone (YAZ, BAY86-5300)|20µg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
1831895|NCT00818519|Drug|Placebo|Inert tablet
1831896|NCT00818545|Drug|ER4017 (hydroxypropyltetrahydropyrantriol)|Cream, 10%, each day during 3 months
1831897|NCT00818545|Drug|placebo|
1831898|NCT00818558|Biological|ISET Methode|Sampling of blood - ISET Methode
1831899|NCT00818571|Drug|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 25 mg vildagliptin once daily
1831900|NCT00818571|Drug|Vildagliptin|Mild, moderate and severe renal impaired patients receiving 50 mg vildagliptin once daily
1831901|NCT00818571|Drug|Vildagliptin|Matching healthy volunteers receiving 25 mg vildagliptin once daily.
1831902|NCT00818571|Drug|Vildagliptin|Matching healthy volunteers receiving 50 mg vildagliptin once daily
1831903|NCT00818584|Drug|Micafungin|IV Administration
1831904|NCT00818597|Device|EISS|Two six hour-treatments with the EISS-Immune-cell bioreactor device within 72 hours post inclusion.
1831905|NCT00818610|Drug|Beta lactam (amoxicillin / clav. acid OR cefuroxime)|1.2 g 4x/d OR 1.5 g 3x/d IV
1831906|NCT00818610|Drug|Beta-lactam (amoxicillin / clav. acid OR cefuroxime) AND macrolide (clarithromycin)|1.2 g 4x/d OR 1.5 g 3x/d IV AND 0.5 g 2x/d IV/PO
1831907|NCT00818623|Drug|Degarelix|Degarelix (120 mg (20 mg/mL)) was given as a subcutaneous injection
1831908|NCT00818623|Drug|Degarelix|Degarelix (120 mg (40 mg/mL)) was given as a subcutaneous injection
1831909|NCT00818623|Drug|Degarelix|Degarelix (160 mg (40 mg/mL)) was given as a subcutaneous injection
1831910|NCT00818623|Drug|Degarelix|Degarelix (200 mg (40 mg/mL)) was given as a subcutaneous injection
1831911|NCT00818623|Drug|Degarelix|Degarelix (200 mg (60 mg/mL)) was given as a subcutaneous injection
1831912|NCT00818623|Drug|Degarelix|Degarelix (240 mg (40 mg/mL)) was given as a subcutaneous injection
1831913|NCT00818623|Drug|Degarelix|Degarelix (240 mg (60 mg/mL)) was given as a subcutaneous injection
1831914|NCT00818623|Drug|Degarelix|Degarelix (320 mg (60 mg/mL)) was given as a subcutaneous injection
1831915|NCT00818636|Behavioral|Expressive writing (in addition to group therapy as usual).|Participants in the expressive writing condition write about their feelings about an issue of their choosing three times, for at least 20 minutes each time, during a two week period.
1831916|NCT00818649|Drug|bortezomib|1.3mg/m^2 via peripheral subcutaneous administration on day 1, 4, 8, 11 of a 21 day cycle
1831917|NCT00818649|Drug|vorinostat|400 mg orally (po) every day on days 1-14 of a 21 day cycle
1831918|NCT00818662|Biological|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 400 mg/kg|400 mg/kg bodyweight every 2 weeks for 70 weeks
1831919|NCT00818662|Biological|Immune Globulin Intravenous (Human), 10% (IGIV, 10%) 200 mg/kg|200 mg/kg bodyweight every 2 weeks for 70 weeks
1831920|NCT00818662|Biological|Placebo solution: Human Albumin 0.25% - 4 mL/kg|Placebo solution: 0.25% human albumin solution infused at 4 mL/kg/2weeks for 70 weeks
1831921|NCT00818662|Biological|Placebo solution: Human Albumin 0.25% - 2 mL/kg|Placebo solution: 0.25% human albumin solution infused at 2 mL/kg/2weeks for 70 weeks
1831922|NCT00818675|Drug|Lead-In Ridaforolimus|Four 10mg tablets of ridaforolimus once daily for five consecutive days each week followed by 2 days days of treatment holiday, during the 8 week lead in treatment period.
1831923|NCT00818675|Drug|Comparator: Blinded Ridaforolimus|Four tablets of blinded ridaforolimus administered daily for 5 consecutive days each week followed by 2 days days of treatment holiday
1831924|NCT00818675|Drug|Comparator: Blinded Placebo|Four tablets of blinded placebo (to match ridaforolimus) administered daily for 5 consecutive days each week followed by 2 days of treatment holiday
1831925|NCT00818688|Procedure|compression ultrasonography at 3 months|A three-month follow-up prospective study was performed in the subgroup of patients with symptomatic ST but without deep-vein thrombosis on compression ultrasonography or documented symptomatic pulmonary embolism at inclusion, a group defined as patients with 'isolated ST'.
1831928|NCT00818714|Radiation|SBRT|"SBRT x 3 (start 6-9 weeks following standard ChemoRT; Time between SBRT Boost treatments: 40 hours to 8 days)
Dose Escalation Schema:
Cohort -3: 4 Gy x3 Cohort -2: 5 Gy x3 Cohort -1: 6 Gy x3 If de-escalation is required after initial cohort
Cohort 1: 7 Gy x 3 INITIAL COHORT Cohort 2: 8 Gy x 3 Cohort 3: 9 Gy x 3
Continue +1 Gy x 3 until reach MTD"
1831929|NCT00818740|Drug|ORM-12741|i.v., oral solution and oral capsule forms. Oral capsule given with and without food.
1831930|NCT00818753|Drug|dabigatran 110 mg|comparison of different dabigatran dosages with unfractionated heparin
1831931|NCT00818753|Drug|dabigatran 150 mg|comparison of different dabigatran dosages with unfractionated heparin
1831932|NCT00818753|Drug|unfractionated heparin|comparison of different dosages dabigatran with unfractionated heparin
1831933|NCT00818766|Drug|cefazolin or vancomycin|Cefazolin IV every eight hours post-operatively for 48 hours or until all chest tubes were removed, whichever occurred first. Participants under 80 kg received 1 gram of cefazolin and participants who were 80 kg or more received 2 grams of cefazolin. Participants who were penicillin-allergic received 1 gram of vancomycin every 12 hours for 48 hours or until all chest tubes were removed, whichever occurred first.
1831934|NCT00818766|Drug|Placebo|Participants received IV placebo for 48 hours post-operatively or until all chest tubes were removed, whichever occurred first.
1831937|NCT00818792|Device|Coronary stent|Comparison of bare-metal stent (Vision) and drug-eluting stent (Xience V)
1831938|NCT00818805|Drug|Olopatadine 0.1%|one drop in one eye
1831939|NCT00818805|Drug|Tranilast 0.5%|one drop in one eye
1831940|NCT00818805|Drug|Placebo (Olopatadine)|one drop in contralateral eye
1831941|NCT00818805|Drug|Placebo (Tranilast)|one drop in contralateral eye
1831942|NCT00818818|Drug|Meglumine antimoniate|5mg/kg/d of pentavalent antimony, IV, for 20 consecutive days
1831943|NCT00818831|Drug|QBI-139|QBI-139 is being administered once a week over a two hour infusion in escalating doses.
1831944|NCT00818844|Drug|Nepafenac 0.1%|NSAID
1831945|NCT00818844|Other|BSS|BSS
1831946|NCT00818857|Behavioral|Early Intervention|At the point of randomization the early group will receive increasingly intensive reminders to complete specific cancer screening tests.
1831947|NCT00818857|Behavioral|Delayed intervention|One year from the point of randomization patients will begin to receive increasingly intensive reminders to complete specific cancer screening tests.
1831948|NCT00818870|Drug|Omeprazole|20 mg capsule, orally, once daily (before breakfast) for 5 days.
1831949|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
1831950|NCT00818870|Drug|Vecam|1 capsule, orally, once daily at bedtime for 5 days.
1831951|NCT00818883|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablet, orally, once daily and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 10 weeks.
For participants who do not achieve target blood pressure by Week 6, the dose of chlorthalidone will be increased for the remaining 4 weeks of treatment."
1831952|NCT00818883|Drug|Azilsartan medoxomil and hydrochlorothiazide|"Azilsartan medoxomil 40 mg, tablets, orally, once daily and hydrochlorothiazide 12.5 mg, tablets, orally, once daily for up to 10 weeks.
For participants who do not achieve target blood pressure by Week 6, the dose of hydrochlorothiazide will be increased for the remaining 4 weeks of treatment."
1831953|NCT00818909|Other|Systane|Systane prescription
1831954|NCT00818935|Dietary Supplement|Low-Intermediate-Glycemic Index diets|
1831955|NCT00818935|Dietary Supplement|High GI diet|
1831956|NCT00818948|Drug|AMG 811|Part A of the study will enroll SLE without GN (non-renal) subjects into 3 cohorts (6 AMG 811: 2 placebo). All subjects will receive a dose of AMG 811 or placebo every 4 weeks beginning with day 1 (D1) for a total of 3 injections. Subjects will be followed through to study day 197, 5 months from the last dose of study medication. Part B of the study will enroll SLE subjects with GN into Cohorts 4, 5 and 6 (6 AMG 811: 2 placebo). Similar to Part A, subjects in Cohorts 4, 5 and 6 will be dosed every 4 weeks with AMG 811 or placebo for a total of 3 injections followed by a 5 month follow-up period. For Cohort 6, subjects will be followed by a 6 month follow-up period.
1831957|NCT00818961|Biological|alemtuzumab|43 mg subcutaneously over 3 days (3 mg on day -11, 10 mg on day -10, 30 mg on day -9)
1831958|NCT00818961|Biological|graft-versus-tumor induction therapy|curative potential of allogeneic transplant results from the immune anti-tumor effect of donor cells or GVT/GVL
1831959|NCT00818961|Biological|rituximab|in patients with Cd20+ malignancies: rituximab 375 mg/m*2 day -13. rituximab 1000 mg/m*2 on days, -6, +1, +8.
1831960|NCT00818961|Drug|busulfan|For patients with AML, CML, MDS, MPS and ALL only: IV or oral busulfan may be given IV busulfan: 130 mg/m2 over 3 hours once daily on days -6, -5, -4 and -3 Oral busulfan: taken every 6 hours x 15 doses beginning on day -7 at 6pm and continuing through day -3 at 6am. 1 mg/kg test dose will be given prior to day -7 and PK samples will be drawn to calculate AUC.
1831961|NCT00818961|Drug|cyclophosphamide|750 mg/m2 infused over 1 hour once daily on days -5, -4 and -3. Cyclophosphamide will be started approximately 4 hours after the start of Fludarabine
1831962|NCT00818961|Drug|fludarabine phosphate|For patients with CLL, NHL & HD: 30 mg/m2 infused over 30 minutes once daily on days -5, -4 and -3 For patients with AML, CML, MDS, MPS and ALL: 40 mg/m2 infused over 30 minutes once daily on days -6, -5, -4 and -3.
1831963|NCT00818961|Drug|methotrexate|5 mg/m2 administered on days +1, +3 and +6
1831964|NCT00818961|Drug|tacrolimus|0.03mg/kg/day infused over 24 hours starting on day -1 and switched to oral (twice daily divided dose) on day 14 or when able to tolerate PO
1831965|NCT00818961|Procedure|allogeneic bone marrow transplantation|Recipients will receive an allogeneic transplant on day 0 after receiving high-dose chemotherapy. This trial uses matched unrelated donor stem cells.
1831966|NCT00818987|Other|Open reduction internal fixation; reduction and immobilization|
1831967|NCT00819000|Drug|Glatiramer Acetate, IFN-beta 1a (IM), IFN-beta 1a (Subcutaneous), and IFN-beta 1b|MS therapies (listed above) used according to prescribers' instructions.
1831968|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 1, Intramuscular
1831969|NCT00819013|Biological|Influenza A Vaccine: ACAM FLU-A|0.5 mL ACAM-FLU-A low dose + Adjuvant 2, Intramuscular
1831976|NCT00819052|Drug|Nevirapine IR|Nevirapine Immediate Release
1831977|NCT00819065|Drug|Botulinum toxin type A from laboratory Lanzhou|Patients will receive botulinum toxin type A from laboratory Lanzhou either at time of allocation (arm BTA Lanzhou/Allergan) or three months later (arm BTA Allergan/Lanzhou), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of TBA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
1831978|NCT00819065|Drug|Botulinum toxin type A from laboratory Allergan|Patients will receive botulinum toxin type A from laboratory Allergan either at time of allocation (arm BTA Allergan / Lanzhou) or three months later (arm BTA Lanzhou /Allergan), so that all patients will receive both drugs in a crossover model. Application will be performed according to standard protocol and respecting parameters of the patients former sessions (if there were any), by a trained investigator, unaware of the kind of BTA in use. Standard dilution will be employed, within the usual dose and application spots (for patients already in treatment) or standard (for patients yet to start treatment). Identical dose will be used, with 2ml of saline solution 0,9% dilution for each 100units, thus, there will be no difference for the patient or investigator concerning the applicated volume.
1831979|NCT00819078|Drug|Bupropion|300 mg/d
1831980|NCT00819078|Drug|Placebo|no dosage
1831981|NCT00819091|Drug|BI 1356|5mg orally (po) tablet qd
1831982|NCT00819091|Drug|Placebo|Placebo matching BI 1356 5mg one tablet daily
1831983|NCT00819104|Drug|Metoprolol XL 50mg + Amlodipine 5mg|tablet,oral,OD,8 weeks
1831984|NCT00819104|Drug|Metoprolol XL 25 mg + Amlodipine 2.5mg|tablet,oral,OD,8 weeks
1831985|NCT00819104|Drug|Metoprolol XL 50mg|tablet,oral,OD,8 weeks
1831986|NCT00819104|Drug|Metoprolol XL 25 mg|tablet,oral,OD,8 weeks
1831987|NCT00819104|Drug|Amlodipine 5mg|tablet,oral,OD,8 weeks
1831988|NCT00819117|Device|Cardiac Resynchronization Therapy implant|Device implant with appropriate leads
1831989|NCT00819156|Drug|degarelix|Degarelix was given as subcutaneous injections.
1831990|NCT00819169|Biological|AMG 479|AMG 479 is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
1831991|NCT00819169|Biological|AMG 655|AMG 655 is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR 5.
1831992|NCT00819182|Behavioral|Paced respiration|Breathing exercise
1831993|NCT00819182|Behavioral|Sham comparator: fast shallow breathing|sham breathing exercise
1831994|NCT00819195|Drug|Glatiramer acetate|20 mg daily subcutaneous injection. Six-month duration.
1831995|NCT00819208|Behavioral|exercise intervention|3 phases Phase 1: Intensive intervention for 6 months Phase 2: Reduced intervention for months 6-12 Phase 3: Minimal intervention for months 12-36
1831996|NCT00819208|Other|counseling intervention|Achieving an increase in PA from baseline of ≥ 10 MET hours/week will require a significant amount of behavioural support. The intervention will comprise a 36-month individualized PA and behavioural support program with a PAC. This will include a personalized PA prescription which takes into account the baseline fitness test results, PA history, performance status and patient's personal PA preferences and any barriers to activity. Most patients are likely to choose a walking program however any PA of at least moderate intensity level is acceptable.
1831997|NCT00819208|Other|educational intervention|Once at the beginning of the program
1831998|NCT00819208|Other|laboratory biomarker analysis|Every 12 months
1831999|NCT00819208|Other|questionnaire administration|Every 6 months
1832000|NCT00819208|Other|study of socioeconomic and demographic variables|Every 6 months
1832001|NCT00819208|Procedure|fatigue assessment and management|Every 6 months
1832002|NCT00819208|Procedure|quality-of-life assessment|Every 6 months
1832003|NCT00819208|Other|Educational Intervention|For Arm 2 just once at beginning of program.
1832004|NCT00819208|Other|Fitness testing|Objective fitness testing for both arms
1832005|NCT00819221|Drug|AZD2281|capsules, oral, bd, 2 months
1832006|NCT00819221|Drug|liposomal doxorubicin|once every 4 weeks at 40mg/m2
1832007|NCT00819234|Drug|Placebo|placebo pramlintide and placebo metreleptin twice daily
1832008|NCT00819234|Drug|Pramlintide and Metreleptin|Subcutaneous injection, twice daily
1832009|NCT00819247|Drug|Degarelix|Given as a subcutaneous injection.
1832010|NCT00819260|Device|Harmonic Scalpel|harmonic scalpel used to reduce breast on this side
1832011|NCT00819260|Device|Electrocautery|Electrocautery used to reduce breast on this side
1832012|NCT00819286|Device|SternaLock Rigid Fixation System|patients will have their sternum closed by rigid fixation using SternaLock plates.
1832013|NCT00819286|Device|Wire (control)|patients will have their sternum closed using stainless steel wires.
1832014|NCT00819312|Drug|YAZ (SH T00186, BAY86-5300)|20ug ethinylestradiol, 3mg drospirenone, tablet, orally, opd
1832015|NCT00819325|Drug|pioglitazone|pioglitazone 30mg p.o. once a day for 6 months
1832016|NCT00819325|Drug|oral hypoglycemic agents|sulfonylurea or metformin
1832017|NCT00819338|Dietary Supplement|Efamax|5g daily as capsules for 3 months
1832018|NCT00819351|Drug|PEG Asparaginase at six weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at six weeks intervals (until the patient has received 33 weeks of therapy)
1832019|NCT00819351|Drug|PEG Asparaginase at two weeks interval|PEG-asparaginase (1.000 IU/m2/dose) given at two weeks intervals (until the patient has received 33 weeks of therapy)
1832020|NCT00819364|Behavioral|BCRI intervention program|"Phase 1: The parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.
Phase 2: BCRI model intervention.Parents and children will take part in a 24-halfday workshop to learn practical teaching skills in BCRI model. Then Home-based intervention using BCRI model for 11 months. At least 28 hours of BCRI intervention per week is acquired. Doctors or therapists will meet the parents and children once per month, each for 30 minutes, totally 10 times, to monitor and give advice on the interventions."
1832136|NCT00820105|Drug|ADX10059|Oral administration
1832021|NCT00819364|Behavioral|Standard community care|"Phase 1: the parents will receive a two-day lecture about autism to get the basic knowledge about autism intervention.
Phase 2:Any treatment and interventions available chosen by families for children with autism and ASD, for at least one and a half years.
Phase 3:One and a half years after enrollment, parents and children will be free to take part in the BCRI model intervention which is the same as Phase 2 for experimental group lasting for one year."
1832022|NCT00819377|Drug|Milrinone|inhaled milrinone 5 mg (as for the injectable solution)
1832023|NCT00819377|Drug|Normal saline|5 ml normal saline by inhalation over 15 min
1832026|NCT00819403|Drug|simvastatin|Subjects will receive 6 weeks of simvastatin 40 mg, after which atherothrombotic biomarker assessment will be studied.
1832027|NCT00819403|Drug|ezetimibe/simvastatin|Subjects will receive 6 weeks of ezetimibe/simvastatin 10/40 mg, after which atherothrombotic biomarker assessment will be studied.
1832030|NCT00819429|Dietary Supplement|Omega-3|1000mg of Omega-3 supplement will be given twice a day for a duration of 6 months. All supplements (including placebo) will be administered as two 500mg softgels twice daily, to be taken during breakfast and during the evening meal.
1832031|NCT00819429|Behavioral|Social Skills Training|1 hourly sessions over 12 weeks duration and 4 booster sessions at 3 weeks intervals. During these 16 sessions, children are taught empathy, pro-social skills, and a variety of positive coping techniques for problem-solving, emotional regulation, conflict resolution, and anger management via the use of practical strategies, materials, activities, role-play and games.
1832032|NCT00819429|Other|Standard Treatment (or TAU in Child Guidance Clinic)|Standard treatment is administered on a monthly basis to the parents of the child participants by the clinicians. Parents will be provided Parent Management Training where they will be taught behaviour and parenting techniques and may be referred to a parent support group. There is clinical pathway for the management of ADHD in our department which will be adhered to (i.e., Clinical Pathway for ADHD).
1832033|NCT00819442|Procedure|cardiobiopsy|5 samples will be taken from right ventricle by Cordis bioptome
1832034|NCT00819455|Behavioral|Experimental|Active Life style modification-motivation by I.T technology
1832035|NCT00819455|Behavioral|Control arm (usual care/standard care arm)|Life style modification only once
1832036|NCT00819468|Drug|teduglutide|20 mg dose of lypholized powder mixed with sterile water and injected subcutaneously into the abdomen.
1832037|NCT00819481|Device|3DKnee™ System|Total knee replacement joint for subjects with knee osteoarthritis and willing to participate in the study.
1832038|NCT00819494|Procedure|Skin tests with radiocontrast media|Skin prick tests and intradermal test will be performed in patients with a history of immediate reactions to iodinated radiocontrast media
1832039|NCT00819507|Drug|Fluocinonide|Fluocinonide 0.1% cream topical daily for two weeks
1832040|NCT00819520|Drug|ivermectin|Two single doses of oral ivermectin 400 mcg/kg (Days 1 and 8) plus 2 single applications of placebo lotion
1832041|NCT00819520|Drug|malathion|Two single applications of malathion 0.5% lotion (Days 1 and 8) plus 2 single doses of placebo tablets
1832042|NCT00819533|Device|sensor (ActiSight™ Needle Guidance System)|Patients will have their lung sample obtained under CT and ActiSight needle guidance system
1832043|NCT00819546|Drug|RAD001|Participants will receive RAD001 on day 1 at the dose specified then again on days 8-28 for the first cycle. For all subsequent cycles RAD001 will be taken once daily.
1832044|NCT00819546|Drug|PKC412|50mg orally twice a day on days 2-28 for the first cycle. For all subsequent cycles 50mg of PKC412 will be taken orally twice daily.
1832045|NCT00819559|Radiation|PCRT|Preoperative chemoradiotherapy
1832046|NCT00819572|Biological|DLX105, a single-chain (scFv) antibody fragment against TNF-alpha|Comparison of two different doses of intra-articular DLX105
1832047|NCT00819572|Drug|Placebo|
1832048|NCT00819585|Drug|Canakinumab 25 mg|25 mg subcutaneous injection once on day 1.
1832049|NCT00819585|Drug|Canakinumab 50 mg|50 mg subcutaneous injection once on day 1.
1832050|NCT00819585|Drug|Canakinumab 100 mg|100 mg subcutaneous injection once on day 1.
1832051|NCT00819585|Drug|Canakinumab 200 mg|200 mg subcutaneous injection once on day 1.
1832052|NCT00819585|Drug|Canakinumab 300 mg|300 mg subcutaneous injection once on day 1.
1832053|NCT00819585|Drug|Canakinumab repeated every 4 week (q4wk)|50 mg subcutaneous injection (s.c) once on day 1 and day 29 followed by 25 mg s.c. once on Days 57, and 85.
1832054|NCT00819585|Drug|Colchicine|0.5 mg capsule orally once daily for 16 weeks.
1832055|NCT00819585|Drug|Allopurinol|100- 300 mg orally once daily for 24 weeks.
1832056|NCT00819585|Drug|Placebo Matching Canakinumab|Subcutaneous injection.
1832057|NCT00819585|Drug|Placebo Matching Colchicine|Capsule orally once daily for 16 weeks.
1832058|NCT00819598|Procedure|BLOOD PRESSURE MEASURMENT|Blood pressures using Doppler and oscillometric methods will be obtained at each limb and on one toe from each foot.
1832059|NCT00819598|Procedure|BLOOD PRESSURE MEASUREMENT|Blood pressure measurements will be taken at each limb (arm and ankle) with Doppler and oscillometric based methods.
1832060|NCT00819611|Behavioral|Cogmed Working memory training|15 minutes of working memory training, 5 days a week for a period of 5 weeks
1832061|NCT00819611|Behavioral|Control version of Cogmed working memory training|15 minutes of 'sham' working memory training, 5 days a week for a period of 5 weeks
1832062|NCT00819624|Other|Interactive Voice Response System (IVRS)|Telephone based system
1832063|NCT00819624|Other|Personal Digital Assisstant (PDA)|Electronic Hand Held diary
1832064|NCT00819637|Drug|arformoterol (RR formoterol)|"Group 1 will receive nebulized arformoterol 15 ug every 20 minutes for 3 doses.
Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses."
1832065|NCT00819637|Drug|placebo|Group 2 will receive nebulized arformoterol 15 ug first dose and then placebo every 20 minutes for 2 doses.
1832066|NCT00819637|Drug|levalbuterol|Group 3 will receive nebulized levalbuterol 1.25 mg every 20 minutes for 3 doses.
1832067|NCT00819650|Drug|Licartin (generic name,[131I]metuximab injection)|Licartin, radioiodination of Metuximab with Na[131I],with radiochemical purity above 95% and specific activity between 173.25-288.75 MBq/ml.All patients in the treatment group received Licartin 3 times at an interval of 28 days beginning from the 4th week after liver resection
1832068|NCT00819676|Other|analysis of exhaled breath by biosensors|
1832069|NCT00819676|Other|measurement of exhaled nitric oxide|
1832070|NCT00819702|Other|Model Care|The Model Care provided training to pediatric health care providers to assess parental psychosocial risk factors to child maltreatment.
1832071|NCT00819728|Drug|Docetaxel|35mg/m2 IV each week for 4 weeks
1832072|NCT00819728|Drug|Irinotecan|50mg/m2 IV each week for 4 weeks
1832073|NCT00819741|Drug|repaglinide|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
1832074|NCT00819741|Drug|metformin|The dose was started from repaglinide 1 mg plus metformin 500 mg once daily. During the dose titration period, the dose could be titrated up to repaglinide 4 mg and metformin 500 mg three times daily, according to fasting glucose. the minimal dose was repaglinide 1 mg plus metformin 500 mg three times daily
1832075|NCT00819741|Drug|repaglinide|The dose was started from repaglinide 1 mg three times daily. During the dose titration period, the dose of repaglinide could be titrated up to 4 mg three times daily, according to fasting glucose.
1832076|NCT00819754|Drug|IXO regimen + bevacizumab|"Phase I study - identifies the safety of IXO with bevacizumab and recommended phase II dose
Phase II study - assesses efficacy and safety of IXO with bevacizumab"
1832077|NCT00819767|Drug|Aliskiren|Aliskiren was supplied in 150 mg tablets.
1832078|NCT00819767|Drug|Valsartan|Valsartan was supplied in 160 mg capsules.
1832079|NCT00819767|Drug|Placebo to aliskiren|Placebo to aliskiren was supplied in tablets matching aliskiren 150 mg.
1832080|NCT00819767|Drug|Placebo to valsartan|Placebo to valsartan was supplied in capsules matching valsartan 160 mg.
1832081|NCT00819780|Drug|Panitumumab|Panitumumab is a fully human immunoglobulin G (IgG)2 monoclonal antibody antagonist directed against human Epidermal Growth Factor receptor (EGFr).
1832082|NCT00819780|Drug|Bevacizumab|Bevacizumab is a humanized monoclonal IgG1 antibody that is directed against Vascular Endothelial Growth Factor (VEGF).
1832083|NCT00819780|Drug|mFOLFOX6|mFOLFOX6 regimen is a combination therapy of oxaliplatin (85 mg/m^2) administered as a 2-hour infusion on Day 1; leucovorin (400 mg/m^2) administered as a 2-hour infusion on Day 1; followed by a loading dose of 5-fluorouracil (5-FU; 400 mg/m^2) IV bolus administered over approximately 2 to 4 minutes on Day 1, then 5- FU (2400 mg/m^2) via ambulatory pump administered for a period of 46 to 48 hours.
1832084|NCT00819793|Device|CentriMag Ventricular Assist System|All eligible subjects will receive the CentriMag Ventricular Assist System. The system is comprised of a single-use centrifugal blood pump, a motor, a primary drive console, a back up drive console and cannulae. Blood from the failing heart is directed from the ventricle or the atrium to the inlet of the pump via an inlet cannula. Blood exits through the outlet port of the pump through the outlet cannula ultimately to the pulmonary or systemic circulation. The system can be used in either a right, left or biventricular configuration.
1832085|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and MHC class I peptides from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. The remaining 1.5 ml will be used for sterility testing. Each injection will be done in the vicinity of the nodal drainage of one extremity.
1832086|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I-restricted epitopes from NY-ESO-1 (NY-ESO-1 157-165V, NY-ESO-1 53-62 (MPS-190) and NY-ESO-1 94-102) and cyclophosphamide. The vaccine preparation is identical to arm A. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
1832087|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102) and three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) in three subcutaneous injections (i.e., 1mg of PF-3512676 at 15mg/ml and 50 μg of each peptide (2mg/ml) for each of the three injections + Montanide ISA 720 VG + saline). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml subcutaneous injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
1832088|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and three MHC class I epitopes (NY-ESO-1 157-165V, NY-ESO-1 53-62 and NY-ESO-1 94-102), three MHC class II epitopes (NY-ESO-1 87-111, NY-ESO-1 119-143 and NY-ESO-157-170) and cyclophosphamide. The vaccine preparation is identical to arm C. Low-dose cyclophosphamide (300mg/m2) IV will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
1832089|NCT00819806|Biological|Vaccine only|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injection (i.e. 3 mg of PF-3512676 or 300 μl of PF-3512676 at 10mg/ml, 300 μg or 900 μl of protein NY-ESO-1 at 0.35 mg/ml + Montanide ISA 720 VG). The final volume of immunization will be 4.5 ml administered as 3 separate 1.5 ml SC injections. Each injection will be done in the vicinity of the nodal drainage of one extremity. Each will consist of 1.5 ml of product.
1832090|NCT00819806|Biological|Vaccine + cyclophosphamide|PF-3512676, Montanide ISA 720 VG and the NY-ESO-1 protein in three subcutaneous injections and cyclophosphamide. The vaccine preparation is identical to arm E. Low-dose cyclophosphamide (300mg/m2) will be given IV, monthly, 3 days prior to the first, 3rd, 5th, 7th, 9th, and subsequent monthly immunizations.
1832091|NCT00819819|Dietary Supplement|Gluten|Purified gluten from exaploid wheat introduced per American Academy of Pediatric Recommendations. Three grams from 6-9 months and 5 grams from 9-12 months. The 3-5 grams represents the mean daily intake of gluten during the second half of the first year in infants of different countries.
1832137|NCT00820105|Drug|ADX10059 Matching Placebo|Oral administration
1832180|NCT00820417|Drug|Cetuximab/Gefitinib combination and/or monotherapy|
1832092|NCT00819819|Dietary Supplement|Gluten free diet|Non gluten containing starch added to diet. Three grams from 6-9 months and 5 grams from 9-12 months. After the age of 1 year all children will be allowed age appropriate unrestricted diet.
1832093|NCT00819832|Procedure|Kyphoplasty|A small fluid balloon will create a hole in the broken back bone where tumor is located. After balloon deflation and removal, hole is filled with medical cement.
1832094|NCT00819832|Procedure|Vertebroplasty|Medical cement will be injected into broken back bone.
1832095|NCT00819832|Device|Cavity SpineWand|Removes tissue (soft tissue, bone tissue, or both, but this will vary from person to person), including all or part of the cancerous tumors in the area of the broken back bone(s).
1832096|NCT00819845|Drug|carvedilol|carvedilol vs ramipril
1832097|NCT00819845|Drug|ramipril|carvedilol vs ramipril
1832098|NCT00819858|Dietary Supplement|RUTF (Plumpynut®)|Intervention group receives 500 kcal/day of RUTF for 2 weeks Control group receives no food supplement
1832099|NCT00819884|Drug|AZD1656|Oral suspension
1832100|NCT00819910|Drug|Rosiglitazone|Rosiglitazone 8mg daily for 12 weeks
1832101|NCT00819910|Drug|Placebo (Rosiglitazone)|Placebo (Rosiglitazone) 8mg daily for 12 weeks
1832102|NCT00819910|Drug|Placebo (Fenofibrate)|Placebo (Fenofibrate) 145 mg daily for 12 weeks
1832103|NCT00819910|Drug|Fenofibrate|Fenofibrate 145 mg daily for 12 weeks
1832106|NCT00819936|Procedure|forward walking|comparison forward walking vs backward walking in the physiotherapy after after abdominal surgery
1832107|NCT00819936|Procedure|backward walking|physiotherapy with use a backward walking type of physiotherapy
1832109|NCT00819962|Drug|Bupivacaine|Local anesthetic
1832110|NCT00819962|Other|TAP|
1832111|NCT00819975|Dietary Supplement|Casein|
1832112|NCT00819975|Dietary Supplement|Whey Isolate|
1832113|NCT00819975|Dietary Supplement|Whey Hydrolysate|
1832114|NCT00819975|Dietary Supplement|Alphalact-Albumin|
1958904|NCT01128621|Drug|GSK1292263|Tablet
1958905|NCT01128621|Drug|GSK1292263 matching placebo|Tablet
1832117|NCT00820001|Behavioral|Booster Treatment|Based on this collective evidence, booster treatment was designed to address three general goals: a) clarify key child and parent/family problems and family preferences regarding target problems, b) directly target and resolve these existing problems using the eight domains contained in the existing treatment protocol administered in the initial outcome study, and c) provide the family with clinical recommendations and information to promote the maintenance of skill developments in targeted domains or adaptive routines designed to prevent any further deterioration in clinical functioning. Thus, the clinician may provide a review of prior content or administer new material specifically for older adolescents, as needed, and will attempt to apply these skills to specific problematic situations identified by the family.
1832118|NCT00820001|Behavioral|No-Booster|All cases randomized to this condition will simply participate in all of the proposed routine assessments and will receive assessment feedback. Specifically, these families will be provided with a brief summary of the significant clinical findings obtained in their 36-month follow-up assessment (assessment feedback). Such an assessment was provided to clinicians in the original study in order to highlight specific areas in need of clinical attention based on a review of the normative data and clinical cutoffs available for each instrument. Selected information will be conveyed by phone to the participating parent/guardian in a straightforward manner followed by a discussion of some clinical recommendations designed to address these clinical problems. In addition, the parent/guardian will be provided with a listing of professionals who provide services appropriate for this age group and for children with similar problems.
1832119|NCT00820001|Other|No intervention|No intervention was administered with this arm. Saliva samples were collected 2 times in the lab and 2 times at home (once at bedtime, once at wake-up time) per initial voluntary saliva protocol at each timepoints to measure endocrine levels.
1832120|NCT00820001|Other|Treatment As Usual|All cases assigned to this arm simply participated in all of the proposed routine assessments.
1832121|NCT00820014|Drug|Placebo|Placebo control (vehicle) eye drops applied 4-times a day for 4 days before ocular surgery
1832122|NCT00820027|Drug|Etoricoxib 90 mg|One 90 mg tablet once daily
1832123|NCT00820027|Drug|Etoricoxib 120 mg|Two 60 mg tablets once daily
1832124|NCT00820027|Drug|Ibuprofen 600 mg|One tablet three times daily
1832125|NCT00820027|Drug|Matching Placebo for Etoricoxib 120 mg|Two tablets once daily
1832126|NCT00820027|Drug|Matching Placebo for Etoricoxib 90 mg|One tablet once daily
1832127|NCT00820027|Drug|Matching Placebo for Ibuprofen|One tablet three times daily
1832128|NCT00820053|Drug|epirubicin and lipiodol|using the technology of Seldinger,The drugs (30 mg epirubicin mixed with 5 ml lipiodol) are given via hepatica propria artery.
1832129|NCT00820079|Drug|ADX10059|oral administration
1832130|NCT00820079|Drug|ADX10059 Matching Placebo|oral administration
1832131|NCT00820092|Drug|Xerecept 1.0|24 hour infusion
1832132|NCT00820092|Drug|Xerecept 2.0|24 hour infusion
1832133|NCT00820092|Drug|Xerecept 3.0|24 hour infusion
1832134|NCT00820105|Drug|ADX10059|oral administration
1832135|NCT00820105|Drug|ADX10059|Oral administration
1958906|NCT01128621|Drug|Sitagliptin|Tablet
1958909|NCT01125293|Drug|Everolimus|Taken orally on a daily basis
1958910|NCT01125293|Drug|Rituximab|Given intravenously on days 1, 8, 15 and 22 of Cycle 1 and Cycle 4 only
1832138|NCT00820118|Drug|Structured treatment interruption|"The preferentially recommended treatment of the study is atazanavir boosted with ritonavir, associated with a fixed combination of abacavir and lamivudine or emtricitabine + tenofovir
Usual dosage recommended :
atazanavir : 300 mg/d
ritonavir : 100 mg/d
abacavir 600 mg and lamivudine 300 mg : once a day
tenofovir 245 mg and emtricitabine 200 mg : once a day"
1832139|NCT00820131|Procedure|selfgrip mesh|inguinal hernia repair using a selfgrip mesh
1832140|NCT00820131|Procedure|lightweight mesh with suture fixation|inguinal hernia repair using a lightweight mesh with suture fixation
1832141|NCT00820144|Biological|CTB by nasal way|
1832142|NCT00820144|Biological|absorption of CTB by oral way|absorption of CTB by oral way
1832143|NCT00820144|Biological|absorption of dukoral by oral way|absorption of dukoral by oral way
1832144|NCT00820144|Biological|absorption of CTB by sublingual way|absorption of CTB by sublingual way
1832145|NCT00820144|Biological|absorption of CTB by sublingual way|absorption of CTB by sublingual way
1958911|NCT01125293|Drug|Bortezomib|Given intravenously on days 1, 8 and 15 of every cycle
1832148|NCT00820170|Drug|Dasatinib and Paclitaxel|"A treatment cycle will consist of 28 days, according to the following schedule:
Dasatinib 120MG PO once daily, Weekly paclitaxel 80 mg/m2 given intravenously over 1 hour on day 1, 8, and 15 of a 28 day cycle.
The trial will initially test the combination of weekly paclitaxel and dasatinib given PO, once daily , continuously. In case of 2 dose-limiting toxicities (DLT) in the first cohort (0), the next cohort will test dasatinib given with a different schedule, 5 days on and 2 days off, omitting dasatinib the day prior and the day of administration of paclitaxel."
1832149|NCT00820183|Other|Quality Improvement plan for Hypertension Control|"Implementation of a plan of quality improvement addressed to health professionals in Primary Health Care Teams. It includes:
Specific training programme on how to diagnose hypertension , and measure blood pressure correctly To send feed back information to primary care health professionals about poorly controlled hypertensive patients An audit will be performed, every 6 months, to see the adhesion to the recommended clinical guidelines , and the information will be diffused among the participant primary health care professionals Each participant primary health care team will have a designated reference person, that will provide support on any doubts on the programme implementation"
1832150|NCT00820196|Drug|Nexagon®|
1832151|NCT00820196|Drug|Nexagon® vehicle|
1832152|NCT00820222|Drug|capecitabine|oral medication; daily dose divided into morning and evening dose and taken for 14 days of 21 day cycle
1832153|NCT00820222|Drug|lapatinib|oral medication; daily dose taken once a day
1832154|NCT00820222|Drug|trastuzumab|infusion therapy; loading dose of 8mg/kg, followed by 6mg/kg given every 3 weeks
1832155|NCT00820235|Device|OsseoSpeed™|OsseoSpeed™ implant
1832156|NCT00820235|Device|NobelSpeedy™ Replace®|NobelSpeedy™ Replace® implant
1832157|NCT00820235|Device|NanoTite™ Certain® PREVAIL®|NanoTite™ Certain® PREVAIL® implant
1832158|NCT00820248|Biological|panitumumab|Given IV
1832159|NCT00820248|Drug|cisplatin|Given IV
1832160|NCT00820248|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
1832161|NCT00820248|Radiation|accelerated radiation therapy|Patients undergo accelerated fractionation radiotherapy
1832162|NCT00820248|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy
1832164|NCT00820274|Procedure|amniotic membranes|The amniotic membrane is taken with a sterile crowbar then applied side foetal face against the ulcer and displayed in a homogeneous way
1832165|NCT00820287|Procedure|Biopsy of testicular tumor|testicular biopsies performed through open surgery
1832166|NCT00820300|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental doses of Latanoprost-PPDS for 4 months or until loss of efficacy.
1832167|NCT00820313|Behavioral|Dr. Dean Ornish Program for Reversing Heart Disease|"Exercise: At least 3 hours of aerobic exercise per week, 30 minutes per session. Additionally, patients are asked to perform a minimum of 2 strength training sessions per week.
Stress Management: Integrates stretching, relaxation, breathing techniques, meditation and guided imagery. Patients are asked to practice these techniques at least 1 hour per day.
Diet: Approximately 10% daily calories from fat, 15% protein and 75% complex carbohydrates (low-fat, whole foods, primarily plant-based).
Group Support: Weekly group support sessions provide social support to help patients adhere to and sustain the lifestyle-change program."
1832168|NCT00820326|Drug|Dolasetron|Patients will receive dolasetron at a dose of 12.5 mg / day for 4 days at J0, M1, M2 and M3
1832169|NCT00820326|Drug|Placebo|Patients will receive placebo everyday for 4 days at J0, M1, M2 and M3
1832170|NCT00820339|Procedure|Selective Hepatic Vascular Exclusion|Inflow occlusion with extraparenchymal control of major hepatic veins results in total liver isolation from the systemic circulation but without interruption of caval flow.
1832171|NCT00820339|Procedure|Pringle's Maneuver|Hepatic pedical clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
1832172|NCT00820352|Drug|bosentan|4 weeks of oral bosentan 62,5 mg b.i.d., followed by 8 weeks of 125 mg b.i.d.
1832173|NCT00820352|Drug|placebo|placebo twice a day for 12 weeks
1832174|NCT00820365|Drug|SC12267 (4SC-101)|Peroral administration of SC12267 (4SC-101) in patients with Inflammatory Bowel Disease over 12 weeks.
1832175|NCT00820378|Other|No special interventioin|Comprehensive transthoracic M-mode, 2-dimensional, and Doppler echocardiographic studies will be performed using commercially available equipment. The aortic dimensions were assessed at end-diastole at the different levels:
1832176|NCT00820391|Behavioral|KIDNET|Narrative Exposure Therapy for Children - a short term intervention for the treatment of trauma after war, organized violence, torture, abuse and other detrimental life events
1832177|NCT00820391|Behavioral|Meditation-Relaxation|a protocol of traditional/local meditation and relaxation exercises, such as breathing meditation, chanting, body relaxation
1832178|NCT00820404|Drug|BLI-489|
1832181|NCT00820430|Other|Magnetic Resonance Imaging|Subjects will undergo 4 sequential MRI evaluations of the target knee within a 4 week period to calculate precision error (ICC) in determination of cartilage morphometry (cartilage volume, mean thickness, and surface area), cartilage collagen (regional cartilage T2), and cartilage proteoglycan (regional cartilage T1rho).
1832182|NCT00820443|Device|Ceramic on metal prosthesis|Ceramic femoral head with a metal acetabular component
1832183|NCT00820456|Other|DCE-MRI|Participants will receive two (2) dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) prior to chemotherapy and one (1) DCE-MRI after the first cycle of chemotherapy. Participants will be followed for up to 2 years after the initiation of chemotherapy or until disease progression.
1832184|NCT00820469|Drug|Rituximab 375|rituximab 375 mg/m2 IV weekly, during 4 weeks
1832185|NCT00820469|Drug|rituximab 1000|rituximab 1000 mg IV, two infusions on day 1 and day 15
1832186|NCT00820482|Drug|Menopur®, Ferring|75 UI/day of Hp-hMG (Menopur®)
1832187|NCT00820482|Drug|rFSH (Gonal®,|75UI/day of rFSH (Gonal®, Serono) + 75UI/day of rLH (Luveris®, Serono)
1832188|NCT00820495|Behavioral|Web + Phone|Web + Phone
1832189|NCT00820495|Behavioral|Web Only|Web Only
1832190|NCT00820495|Behavioral|Phone Only|Phone Only
1832191|NCT00820495|Behavioral|Usual Care|Usual Care
1832192|NCT00820508|Drug|CHR-2845|Once daily oral ingestion of capsules (10, 40 or 80mg), dose depending on cohort, treatment cycle of 28 days
1832193|NCT00820521|Drug|active|
1832194|NCT00820521|Drug|placebo|
1832195|NCT00820534|Drug|Penciclovir|Penciclovir every 2 hours during waking hours for 96 hours
1832196|NCT00820534|Drug|Placebo|Placebo every 2 hous during waking hours for 96 hours
1832197|NCT00820547|Biological|bevacizumab|During neoadjuvant phase: 15 mg/kg, d1 q3w, 8 cycles During adjuvant phase:15 mg/kg, d1 q3w, 10 cycles
1832198|NCT00820547|Drug|cyclophosphamide|Neoadjuvant: 500 mg/m2 d1 q3w, 4 cycles
1832199|NCT00820547|Drug|docetaxel|Neoadjuvant: 100 mg/m2 q3w, 4 cycles
1832200|NCT00820547|Drug|epirubicin hydrochloride|Neoadjuvant: 100 mg/m2, d1 q3w, 4 cycles
1832201|NCT00820547|Drug|fluorouracil|Neoadjuvant: 500 mg/m2, d1 q3w, 4 cycles
1832202|NCT00820560|Drug|INCB007839|INCB007839 100 or 200 mg/dose as IR capsules
1832203|NCT00820573|Drug|Sitagliptin|tablet, 100 mg/day, 6 weeks
1832204|NCT00820573|Drug|Metformin|tablet, 1000 mg/ bid, 6 weeks
1832205|NCT00820573|Drug|Sitagliptin + Metformin|tablet, Sitagliptin (100mg/day) + tablet, Metformin (1000 mg/bid), 6 weeks
1832206|NCT00820573|Drug|Placebo|Placebo 6 weeks
1832207|NCT00820586|Procedure|Mononuclear bone marrow derived cells|Direct intramyocardial percutaneous delivery of autologous bone marrow-derived total mononuclear cells or selected CD34+ cells
1832208|NCT00820599|Device|Sapien XT™ transcatheter heart valve and delivery system|
1832209|NCT00820612|Drug|Indomethacin|100 mg PR once at the time of ERCP
1832210|NCT00820612|Other|Placebo suppositories|2 placebo suppositories at the time of ERCP
1832211|NCT00820625|Procedure|pulmonary vein isolation|common pulmonary vein isolation procedure
1832212|NCT00820625|Procedure|pulmonary vein isolation with additional ablation of fragmented potentials|common pulmonary vein isolation with additional but also common ablation of fragmented potentials
1832214|NCT00820651|Dietary Supplement|Diamel|Diamel, a nutritional supplement, 2 oral pills (660 mg), every 8 hours, daily, during 52 weeks
1832215|NCT00820651|Other|Placebo and lifestyle counseling|Hypocaloric diet of 1620 kcal daily (The dietary pattern will be distributed in carbohydrates 64%, fat 22% with <10% of saturated fatty acids and protein 14%, and exercise)
1832216|NCT00820664|Drug|Comparator: Estrace 0.5 mg|0.5 mg tablet taken once daily for 28 days
1832217|NCT00820664|Drug|Comparator: Estrace 2 mg|2 mg tablets taken once daily for 28 days.
1832218|NCT00820664|Drug|Comparator: Placebo|Placebo 0 mg capsule taken once daily for 28 days
1832219|NCT00820677|Behavioral|DVD/Video|One DVD or Video will be watched by all parents of newborns enrolled into the experimental group.
1832220|NCT00820690|Drug|doxorubicin|4 cycles AC: doxorubicin 60mg/m2
1832221|NCT00820690|Drug|cyclophosphamide|4 cycles AC: cyclophosphamide 600mg/m2
1832222|NCT00820690|Drug|paclitaxel|4 cycles T: paclitaxel 175mg/m2 after 4 AC
1832223|NCT00820690|Procedure|Surgery|"The surgery will be performed 30 days after the chemotherapy. The correlation between clinical, radiologic and pathologic response will be reported.
The oncoplastic surgery rate will be reported"
1832224|NCT00820703|Drug|Nexagon®|
1832225|NCT00820703|Drug|Nexagon® vehicle|
1832226|NCT00820716|Other|Exercise training|Comparison of two methods of exercise training: alternate load versus constant load realized at moderate or high intensities
1832227|NCT00820742|Drug|Macugen|Intravitreous injection of Pegaptanib Sodium 3.47 mg/mL solution every 6 weeks
1832228|NCT00820755|Drug|Cetuximab plus Platinum-based Doublet Chemotherapy|Single first dose of cetuximab 400 mg/m^2 infusion will be administered intravenously over 120 minutes (min) followed by cetuximab 250 mg/m^2 intravenous infusion over 60 min q1w with background platinum-based doublet chemotherapy up to maximum of 6 cycles, until progressive disease, unacceptable toxicity, or withdrawal of consent. Platinum based doublet chemotherapy will be administered as intravenous infusion as per study center included: vinorelbine 25 mg/m^2 on Day 1 (D1) and Day 8 (D8)+cisplatin 80 mg/m^2 on D1; or gemcitabine 1250 mg/m^2 on D1 and D8+cisplatin 75 mg/m^2 on D1; or gemcitabine 1000 mg/m^2 on D1 and D8+carboplatin at dose to reach area under curve (AUC)5 milligram*hour/milliliter (mg*hr/mL) on D1; or Docetaxel 75 mg/m^2 on D1+cisplatin 75 mg/m^2 on D1; or paclitaxel 175 mg/m^2 on D1+cisplatin 80 mg/m^2 on D1; or paclitaxel 200 mg/m^2 on D1+carboplatin at dose to reach AUC6 mg*hr/mL on D1, of each 3-week treatment cycle for a maximum of 6 cycles.
1832229|NCT00820755|Drug|Cetuximab 500 mg/m^2|Subjects who will be free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 500 mg/m^2 as intravenous infusion every 2 weeks, until progressive disease (PD), unacceptable toxicity, or withdrawal of consent.
1832286|NCT00797784|Drug|etanercept(Enbrel®)|etanercept(Enbrel®) 50mgs subcutaneous (SC) injections twice weekly for 20 weeks
1832287|NCT00797797|Drug|No Treatment Added|No added treatment
1832230|NCT00820755|Drug|Cetuximab 250 mg/m^2|Subjects who will free of disease progression at the end of combination therapy, will enter in the maintenance therapy period. In the maintenance period, subjects will be receive cetuximab 250 mg/m^2 as intravenous infusion weekly, until PD, unacceptable toxicity, or withdrawal of consent.
1832231|NCT00820768|Drug|ABI-010|17-AAG and ABI-007
1832232|NCT00820781|Procedure|Portacaval shunt|Subject taken to the operating room and undergoes portacaval shunt surgery
1832233|NCT00820781|Procedure|Sclerotherapy|Subject taken to Endoscopy Suite and undergoes endoscopic sclerotherapy
1832234|NCT00820794|Drug|Lithium|300 mg lithium, oral, once initially and then again at day 4 of PD 0332334 treatment
1832235|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
1832236|NCT00820794|Drug|Lithium|300 mg lithium, oral, at day 4 of PD 0332334 treatment and after 7 day washout
1832237|NCT00820794|Drug|PD 0332334|225 mg q12h PD 0332334, oral, 9 days treatment
1832238|NCT00820807|Other|Novel dietary fiber|oral consumption in beverage
1832239|NCT00820807|Other|Novel dietary fiber|oral consumption in beverage
1832240|NCT00820807|Other|Placebo|oral consumption in beverage
1832241|NCT00820820|Biological|ROUVAX|Measles vaccine (ROUVAX ®), Schwarz strain (>1000 DICC 50) in 0.5 ml of water for injection. One single subcutaneous injection.
1832242|NCT00820820|Biological|placebo|Vehicle (water for injection), 0.5 ml, once
1832243|NCT00820833|Other|standard infant formula|standard infant formula given from 3 to 12 months of age, as per standard requirement
1832244|NCT00820833|Other|Test formula|Test formula with different protein and calorie content than standard formula, given from 3 to 12 months of age. As per standard requirement.
1832245|NCT00820846|Biological|pGA2/JS7 DNA vaccine|1 mL of pGA2/JS7 DNA vaccine
1832246|NCT00820846|Biological|Placebo|1 mL of sodium chloride for injection
1832247|NCT00820846|Biological|MVA/HIV62 vaccine|1 mL of recombinant modified vaccinia Ankara/HIV clade B gag-pol-env (MVA/HIV62)
1832248|NCT00820859|Behavioral|TREA (Treatment Routes for Exploring Agitation)|Individualized non-pharmacological treatment plan for agitation
1832249|NCT00820859|Behavioral|Placebo Control Group|A presentation on the treatment of behavior problems in dementia given to the staff caregivers of the comparison group
1832250|NCT00820872|Biological|trastuzumab|
1832251|NCT00820872|Drug|carboplatin|
1832252|NCT00820872|Drug|docetaxel|
1832253|NCT00820872|Drug|lapatinib ditosylate|
1832254|NCT00820885|Drug|teduglutide|subcutaneous injection given once a day in the abdomen. Drug is lypholized powder.
1832255|NCT00820885|Drug|teduglutide|Once daily subcutaneous injection in the abdomen. Drug is lypholized powder reconstituted with sterile water
1832256|NCT00820885|Drug|tedguglutide|lypholized powder reconstituted with sterile water and injection subcutaneously once a day in the abdomen.
1832257|NCT00820898|Drug|Gemcitabine Hydrochloride|Given IV
1832258|NCT00820911|Drug|cyclosporine (reduced exposure) / everolimus|twice daily
1832259|NCT00820911|Drug|AEB071 300 mg b.i.d. / everolimus|twice daily
1832260|NCT00820911|Drug|AEB071 200 mg b.i.d. / everolimus|twice daily
1832262|NCT00797589|Drug|HES|20ml/kg as prime fluid
1832263|NCT00797589|Drug|Ringer lactate|
1832264|NCT00797615|Behavioral|Active intervention|12-week family-based weight gain intervention program focused on dietary intake and physical activity for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
1832265|NCT00797615|Behavioral|Alternative Intervention|12-week alternative intervention addressing self-esteem, for 8-10 year old Hispanic girls and their parents (N=30 girl-parent dyads).
1832266|NCT00797628|Behavioral|Decide2Quit|Patient intervention website that includes 1) interactive calculators to assess readiness to quit, symptoms and quit plan, 2) motivational content, and 3) links to other high quality information.
1832267|NCT00797628|Behavioral|Smoking Coach|"Control Patients will be referred by paper prescription to the control- Smoking Coach website."
1832268|NCT00797654|Behavioral|Information-motivation-behavior skills and cognitive processing therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors and reducing post-traumatic stress disorder (PTSD) symptoms.
1832269|NCT00797654|Behavioral|Pre and Post HIV-Test Counseling|Treatments are aimed at assessing and reducing behaviors that put participants at high risk of HIV infection.
1832270|NCT00797667|Drug|Telcagepant 140 mg|
1832271|NCT00797667|Drug|Telcagepant 280 mg|
1832272|NCT00797667|Drug|140 mg telcagepant placebo|
1832273|NCT00797667|Drug|280 mg telcagepant placebo|
1832274|NCT00797680|Other|72 hours hypothermia|72 hours mild hypothermia (33 +/1 1 degree Celsius)
1832275|NCT00797680|Other|24 hours hypothermia|24 hours mild hypothermia (33 +/1 1 degree Celsius)
1832276|NCT00797693|Drug|Misoprostol ( Cytotec) 200 microgram a tablet|In this study, two arms we put under study ... and to find how far a single drug, Misoprostol, is effective to have changes on the cervix.
1832277|NCT00797706|Drug|CHRONSEAL|Cream (1.4/2.8 g depending on ulcer size) topical administration, every 2nd day at 3 occasions
1832278|NCT00797719|Other|Pre-op RT +/- chemotherapy|Patients on the study will receive IMRT for approximately 1 week of 5 daily treatments. Short pre-operative hemithoracic RT is a new technique. 1 week post-RT, they will proceed with an extrapleural pneumonectomy. If the mediastinal lymph nodes that are removed during surgery are positive for tumour cells, 3 cycles of chemotherapy, consisting of raltitrexed and cisplatin, will be given 6-12 weeks post-surgery.
1832280|NCT00797745|Biological|peginterferon alfa 2b|1.5 mcg/kg subcutaneously weekly for up to 24 or 48 weeks
1832281|NCT00797745|Drug|ribavirin|ribavirin 600 to 1400 mg daily (weight-based dosing) by mouth twice daily for up to 24 or 48 weeks
1832282|NCT00797745|Drug|SCH 900518|SCH 900518 100 mg tablets taken as 200 mg PO QD, 100 mg PO BID, 400 mg PO QD, or 600 mg PO QD for 12 weeks.
1832283|NCT00797745|Drug|ritonavir|Ritonavir 100 mg capsules taken as 100 mg PO QD or 100 mg PO BID for 12 weeks.
1832284|NCT00797758|Other|Cord blood transplantation|Umbilical cord blood transplantation after reduced intensity conditioning
1832285|NCT00797771|Device|"Adi Insulin pump"|insulin delivery will be defined by the physician
1832288|NCT00797797|Drug|Milnacipran Added|Milnacipran 100 mg/d added
1832289|NCT00797810|Drug|Rituximab|
1832290|NCT00797823|Drug|Insulin, Asp(B28)-|Insulin dosing and frequency calculated by Fading Memory Proportional Derivative algorithm
1832291|NCT00797823|Drug|Glucagon|During incipient hypoglycemia, glucagon was given in an attempt to prevent overt hypoglycemia. Dosing and frequency was calculated by the Fading Memory Proportional Derivative algorithm
1832292|NCT00797823|Drug|Placebo|Saline solution 0.9%
1832293|NCT00797836|Procedure|Quantiferon Gold|"Interferon-gama release assay evaluating tuberculosis-specific T-lymphocytic response
Health Personnel Hospitals, General Occupational Diseases/*epidemiology/*statistics & numerical data Occupational Exposure/*statistics & numerical data
Tuberculosis/*diagnosis/*epidemiology/prevention & control Immunologic Tests/methods/*standards Disease Transmission, Horizontal/*statistics & numerical data Patient Isolation
Tuberculin Test/standards/*methods Immunoassay/methods/*standards T-Lymphocytes/immunology Interferon Type II/*blood/*analysis
*Reagent Kits, Diagnostic
Mass Screening/*methods Incidence Follow-Up Studies Comparative Study Sensitivity and Specificity Risk Assessment/*methods"
1832294|NCT00797849|Device|Farabloc Limb Cover|Wear prosthetics, sock or glove laminated with Farabloc
1832295|NCT00797849|Device|Sham Limb Cover|Wear prosthetics, sock or glove laminated with sham material
1832296|NCT00797862|Drug|Amlodipine|Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
1832297|NCT00797862|Drug|hydrochlorothiazide|Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
1832298|NCT00797862|Drug|Aliskiren|Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
1832299|NCT00797875|Procedure|PNF stretching|PNF stretching x 5 repetitions and continue 3 days
1832300|NCT00797875|Procedure|passive stretching|passive stretching x 5 repetitions continue 3 days
1832301|NCT00797888|Behavioral|telephonic|Between 4-8 phone calls each year for health behavior counseling to improve HbA1c
1832302|NCT00797901|Other|Collaborative Care|
1832303|NCT00797927|Drug|quetiapine|quetiapine (with equivalent dose to original antipsychotic agent) would replace the original antipsychotic agent for 28 days
1832304|NCT00797927|Other|no intervention|keep the original conventional antipsychotic agent for 28 days
1832305|NCT00797940|Drug|IL-4PE|Subjects will receive intratumoral infusion of PRX321 administered via convection-enhanced delivery (CED) at a concentration of 1.5 μg/mL and a total volume of 60 mL over 2 to 7 days.
1832307|NCT00797966|Drug|OPC-34712|Tablets, Oral, 1 - 4 mg OPC-34712 variable dose once daily, 14 weeks
1832308|NCT00797966|Drug|Placebo|Tablets, Oral, 1- 4 mg OPC-34712 once daily, 14 weeks
1832309|NCT00797966|Drug|ADT|Tablets, 10 - 225 mgs, dose once daily, 14 weeks
1832310|NCT00797979|Device|Skull Grip bone fixation|Skull Grip bone fixation
1832311|NCT00797979|Device|sutures|Standard skull bon flap fixation, sutures
1832312|NCT00797992|Drug|Injection|Intravitreal injection of 1.25 mg bevacizumab
1832313|NCT00798005|Drug|XRP0038 (NV1FGF)|
1832314|NCT00798018|Drug|2% lidocaine|lidocaine: 2%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
1832315|NCT00798018|Drug|placebo|Air injected into the cuff to seal the space between the trachea and the tube at minimal volume
1832316|NCT00798018|Drug|1% tetracaine|tetracaine: 1%, injected into the cuff to seal the space between the trachea and the tube at minimal volume
1832317|NCT00798018|Drug|N.S|0.9% Normal saline injected into the cuff to seal the space between the trachea and the tube at minimal volume
1832318|NCT00814125|Drug|Anastrozole (Arimidex)|1mg, orally, once daily
1832319|NCT00814125|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
1832320|NCT00814125|Drug|Nolvadex placebo|
1832321|NCT00814125|Drug|Arimidex placebo|
1832322|NCT00814138|Drug|Methotrexate|10 mg weekly for 2 weeks and then increase to 15mg for 2 weeks and then 20mg weekly until the end of the study
1832323|NCT00814138|Other|Placebo|Weekly
1832324|NCT00814151|Other|MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)|"In vitro diagnostic: The MicroPhage Intervention was to perform the MicroPhage diagnostic test to detect S. aureus in the blood culture sample and determine MSSA or MRSA status at 4 and 5 hours of test incubation. The Intervention results were not made available to the patient or their physician."
1832325|NCT00814164|Drug|clofarabine|IV
1832326|NCT00814164|Drug|daunorubicin hydrochloride|IV
1832327|NCT00814164|Genetic|cytogenetic analysis|Correlative study
1832328|NCT00814164|Genetic|protein expression analysis|Correlative Study
1832329|NCT00814164|Other|immunologic technique|Correlative Study
1832330|NCT00814164|Other|pharmacological study|Correlative Study
1832331|NCT00814177|Drug|warfarin|No change: Continue without any change in spite of prothrombin time outside the therapeutic range.
1832332|NCT00814177|Drug|warfarin|Change: Increase one dose in case prothrombin time is below the therapeutic range; delete or reduce one dose in case prothrombin time is above the therapeutic range.
1832333|NCT00814190|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
1832334|NCT00814216|Drug|QAV680|
1832335|NCT00814216|Drug|Matching placebo for QAV680|
1832336|NCT00814216|Drug|Fluticasone Propionate|
1832337|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 1.5microg|influenza H9N2 vaccine whole virus containing 1.5microg haemagglutinin by intramuscular injection
1832338|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intramuscular injection
1832339|NCT00814229|Biological|H9N2 whole virus vaccine vaccine, IM, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intramuscular injection
1832340|NCT00814229|Biological|H9N2 whole virus vaccine, IM, 45microg|influenza H9N2 vaccine whole virus containing 45microg haemagglutinin by intramuscular injection
1832341|NCT00814229|Biological|H9N2 whole virus vaccine, alum, IM, 1.5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 1.5microg haemagglutinin by intramuscular injection
1832342|NCT00814229|Biological|H9N2 whole virus, alum, IM, 5microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 5microg haemagglutinin by intramuscular injection
1832343|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 15 microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 15microg haemagglutinin by intramuscular injection
1832344|NCT00814229|Biological|H9N2 vaccine, whole virus, alum, IM, 45microg|influenza H9N2 vaccine whole virus adjuvanted with alum hydroxide containing 45microg haemagglutinin by intramuscular injection
1832345|NCT00814229|Biological|H9N2 virosome vaccine, IM, 1.5microg|influenza H9N2 vaccine virosomal containing 1.5microg haemagglutinin by intramuscular injection
1832346|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 5microg|influenza H9N2 vaccine virosome containing 5microg haemagglutinin by intramuscular injection
1832347|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 15microg|influenza H9N2 vaccine virosome containing 15microg haemagglutinin by intramuscular injection
1832348|NCT00814229|Biological|H9N2 virosomal vaccine, IM, 45microg|influenza H9N2 vaccine virosome containing 45microg haemagglutinin by intramuscular injection
1832349|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 5microg|influenza H9N2 vaccine whole virus containing 5microg haemagglutinin by intradermal injection
1832350|NCT00814229|Biological|H9N2 whole virus vaccine, ID, 15microg|influenza H9N2 vaccine whole virus containing 15microg haemagglutinin by intradermal injection
1832351|NCT00814242|Procedure|surgical resection|radical resection performed in patinets with HCC.
1832352|NCT00814242|Procedure|percutaneous radiationfrequency ablation|CT or Ultrasound-guided percutaneous radiofrequency ablation performed in patinets with HCC
1832353|NCT00814255|Drug|Adalimumab|Adalimumab 24 mg/m^2 (maximum dose 40 mg) sc q 14 days
1832354|NCT00814255|Drug|Lisinopril, losartan, and atorvastatin|Lisinopril PO 10-20 mg per day Losartan PO 25-50 mg per day Atorvastatin PO 10-20 mg per day
1832355|NCT00814255|Drug|galactose|galactose 0.2 g/kg/dose (maximum dose 15 g)po BID
1832356|NCT00814268|Drug|Clopidogrel|75mg tablet, oral administration once daily
1832357|NCT00814268|Drug|Clopidogrel placebo|Matching tablet, oral administration once daily
1832358|NCT00814268|Drug|Aspirin|100mg tablet, oral administration once daily
1832359|NCT00814281|Other|placebo|Placebo
1832360|NCT00814281|Drug|Montelukast|10 mg ingested orally 1 hour prior to exercise testing
1832361|NCT00814294|Drug|placebo|placebo capsule,0 units, QID for 18 weeks
1832362|NCT00814294|Drug|Oral HDV-I|Oral HDV-I Caps; 15 U; QID for 18 weeks.
1832363|NCT00814294|Drug|Oral HDV-Insulin|Oral HDV-I; Caps; 5 U; QID for 18 weeks.
1832364|NCT00814307|Drug|CP-690,550|5mg CP-690,550 BID PO for 6 months
1832365|NCT00814307|Drug|CP-690,550|10 mg CP-690,550 BID PO for 6 months
1832366|NCT00814307|Drug|Placebo|Placebo patients advance to 5mg CP-690,550 BID at Month 3 visit
1832367|NCT00814307|Drug|Placebo|Placebo patients advance to 10mg CP-690,550 BID at Month 3 visit
1832368|NCT00814320|Biological|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises subjects previously participating in Study 160601, who now only complete Study Epoch 2 (subcutaneous [SC] infusions) as bioavailability/exposure for intravenous (IV) treatment was already obtained in Study 160601.
Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
1832369|NCT00814320|Biological|Recombinant human hyaluronidase (rHuPH20)+ immune globulin intravenous (IGIV)|"Comprises all other subjects.
Study Epoch 1: IV infusion of IGIV, 10% (same dose and frequency as pre-study) to determine pharmacokinetics.
Study Epoch 2: Dose (calculated) of rHuPH20 followed by dose (calculated) of IGIV, 10% by SC infusion. Treatment intervals and doses are to be increased as defined, until treatment interval is the same as the pre-study treatment interval for IV treatment (ramp-up)."
1832370|NCT00814333|Drug|Thrombin-JMI|5,000 IU, to nasal mucosa via syringe spray applicator
1832371|NCT00814333|Drug|Merocel pack|8 cm pack, inserted within the affected side between the septum and inferior turbinate via bayonet forceps
1832372|NCT00814346|Drug|EGb761®|Four weeks for AD patients, 18 months for MC and CNE patients
1832373|NCT00814346|Drug|Placebo|Placebo 1 tablet BID
1832374|NCT00814359|Drug|Combination of Magic Mouthwash Plus Sucralfate|"Magic mouthwash will contain diphenhydramine powder 375mg, dexamethasone injection 2.8mg, and nystatin suspension 50ml (1000 units/ml) diluted to a total volume of 250ml with sterile water.
The concentration of the sucralfate suspension will be 1g/5ml.
Patients will be instructed to rinse first with 5ml of the magic mouthwash solution for 2 minutes then swallow, followed by rinsing with 5ml of the sucralfate suspension for 2 minutes before swallowing, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy."
1832375|NCT00814359|Drug|0.15% Benzydamine HCl|Patients will rinse with 15ml of 1.5mg/ml benzydamine HCl for 2 minutes then expectorate the solution, repeating this 4 times daily, starting on the day prior to the initiation of radiotherapy, and stopping 2 weeks after the completion of radiotherapy.
1832376|NCT00814372|Drug|MBX-102|capsule
1832377|NCT00814372|Drug|Placebo|matching placebo
1832378|NCT00814372|Drug|Actos|over-encapsulated to match MBX-102 and placebo
1832379|NCT00814372|Drug|Metformin|greater than or equal to 1500 mg/kg day
1832380|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
1832381|NCT00814385|Biological|Aflunov (Single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
1832382|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
1832383|NCT00814385|Biological|Aflunov (single prime, single boost)|Priming with single dose 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
1832384|NCT00814385|Biological|Aflunov (Double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
1832385|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 3.75microg at 52 weeks
1832386|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then non-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
1832387|NCT00814385|Biological|Aflunov (double prime, single boost)|Priming with two doses 7.5microg MF59-adjuvanted A/VN/1194/04 then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
1832388|NCT00814385|Biological|Aflunov (No prime, single boost)|No Priming then MF59-adjuvanted H5N1 vaccine containing 7.5microg at 52 weeks
1832389|NCT00814398|Procedure|Double Embryo Transfer (DET)|Two embryos are transferred during an IVF treatment
1832390|NCT00814398|Procedure|Single Embryo Transfer (SET)|A single embryo is transferred during an IVF treatment
1832391|NCT00814411|Behavioral|group family planning counseling|group family planning counseling for gynecological patients with unmet need
1832392|NCT00814411|Behavioral|Individual family planning counseling|Individual family planning counseling with gynecological patients - the current standard of care
1832393|NCT00814424|Device|monitored using currently marketed smart biteblock o2|oral nasal CO2 monitoring and oxygen delivery
1832394|NCT00814424|Device|monitored using investigational smart biteblock|monitored during ERCP procedure with nasal CO2 sampling and oral oxygen delivery at a flow rate up to 10 lit/min
1832395|NCT00814450|Device|Biopsy needle guidance system (ActiSight™)|The ActiSight system assists in guiding an aspiration or biopsy needle, to a designated point within the body by means of CT visualization.
1832396|NCT00814463|Behavioral|MMSE|Neurocognitive function via MMSE done every 3 months for length of study.
1832397|NCT00814463|Behavioral|QOL via FACT-Br|Quality of Life via FACT-BR every 3 months for length of study.
1832398|NCT00814463|Procedure|MRI|MRI done every 3 months for the length of the study.
1832399|NCT00814463|Radiation|Post-operative SRS|Single fraction SRS is currently a viable treatment option of intracranial metastatic lesions.
1832400|NCT00814476|Other|Medtronic CareLink therapy management system|At the first segment, the usage of the CareLink system will be accompanied by the diabetic team, through at least monthly contact via the internet initiated by the diabetic team. In the second phase of the study,during the following 4 months, there will be regular home use of the CareLink system, without support initiated by the diabetic team
1832401|NCT00814476|Other|regular home use and Medtronic CareLink Therapy Management|At the first 4 months patients will continue at their regular treatment and contacts initiated by the study team via internet/electronic mail will be made once a month. At the second segment of the study patients there will be home use of the CareLink System until the end of the study. No further contact will be initiated by the study team.
1832402|NCT00814489|Biological|GSK2231395A|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2. Two different formulations of this vaccine will be tested.
1832403|NCT00814489|Biological|Engerix-B|Two doses will be administered intramuscularly; one dose at Month 0 and the second dose a Month 2.
1832404|NCT00814502|Drug|Zolpidem CR|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
1832405|NCT00814502|Drug|Placebo|After a 48-hour period of baseline actigraphy and clinical measurements, study subjects were randomized to take either Zolpidem CR 6.25mg by mouth (1 pink tablet) or Placebo by mouth (also 1 pink tablet) for up to 3 weeks or the end of the subjects' hospital stay.
1832406|NCT00814515|Drug|NOVA22007 (Ciclosporin 0.1%)|Ciclosporin 0.1% Ophthalmic Emulsions
1832407|NCT00814515|Drug|NOVA22007|Vehicle
1832408|NCT00814528|Drug|5-ALA plus Blu-Light|20% 5-ALA ampoules will be crushed and prepared for application after shaking for 3 minutes. Topical ALA will be applied liberally on skin with extra pressure on lesions. Incubation of ALA will take place for 0-3 hours. Exposure to Blue U light source (417 nm) (DUSA), will be performed for Actinic Keratosis for 15 minutes. Application of combination light sources will be performed when lesions are traced with one pass of Pulsed dye laser (595 nm) (Candela) followed by exposure to Blue U light source for 5-8 minutes pending response.
1832409|NCT00814528|Drug|5-FU, Imiquimod or treatment with cryotherapy|Cryotherapy will be performed on lesions only every 2 week intervals. Application of Imiquimod will be done on the treated skin area 5 days weekly for 4-6 weeks. 5-FU will be once daily on the treated areas 4- 6 weeks. Responses will be monitored every 2 weeks.
1832410|NCT00814541|Drug|Bortezomib|
1832411|NCT00814541|Drug|Doxorubicin|
1832412|NCT00814541|Drug|Dexamethasone|
1832413|NCT00814554|Behavioral|Educational strategy|1.Educational strategy. The strategy is to implement health promotion actions aiming at developing personal skills to adopt healthy behaviors in the field of nutrition and physical activity in conformity with up-to-date recommendations and references. Each adolescent will be provided with about 50 education hours distributed in individual and collective activities in school (15 hours), interventions during courses (20 hours), and outdoors activities (15 hours).
1832414|NCT00814554|Behavioral|Screening strategy|2. Screening strategy. Screening includes measurement of BMI and plotting the growing chart with adolescents, measurement of eating troubles. Screening will be performed by the school medical and nurse team. At risk subjects will be defined according to precise criteria and will be referred to the GP and to obesity networks developed by Health Insurance system where they are provided with specific activities with dieticians, physical activity teachers and psychologists. Subjects with psychological difficulties will be referred for psychological care.
1832415|NCT00814554|Other|Environmental strategy|3. Environmental strategy. The strategy is to develop in schools favorable and supportive environments for healthy behaviors targeting the collective catering and physical activity offer and the establishment policy. Especially actions aim at increase fruits and vegetables availability, water consumption, physical activity inside the schools.
1832416|NCT00814567|Radiation|radiation therapy|Patients undergo standard whole breast, reduced whole breast, or standard partial breast radiotherapy
1832569|NCT00822419|Drug|non-drug cream|will be put on the skin
1832417|NCT00814580|Drug|Tapentadol IR|First dose: one 50 mg capsule (a re-dose of 50 mg is permitted as soon as one hour after the first dose on Day 1, if needed) Subsequent doses: one or two capsules (50 mg or 100 mg) every 4 to 6 hours as needed
1832418|NCT00814580|Drug|Oxycodone IR|First dose: one 5 mg capsule (a re-dose of 5 mg is permitted as soon as one hour after the first dose on Day 1, if needed Subsequent doses: one or two capsules (5 mg or 10 mg) every 4 to 6 hours as needed
1832419|NCT00814593|Biological|lymphokine-activated killer cells|Instilled into the tumor bed cavity
1832420|NCT00814593|Drug|polifeprosan 20 with carmustine implant|Intracranial placement
1832421|NCT00814606|Drug|Fluvastatin|Week 1: Fluvastatin 20mg daily Week 3: Fluvastatin 40mg daily Week 5: Fluvastatin 60mg daily Week 7: Fluvastatin 80 mg daily
1832422|NCT00814606|Drug|Peginterferon alfa2a|180 mcg/ml SQ injection once a week for 48 weeks (starting at week 9)
1832423|NCT00814606|Drug|ribavirin|1000-1200 mg daily orally in two divided doses for 48 weeks (starting at week 9)
1832424|NCT00814619|Biological|panitumumab|Given IV
1832425|NCT00814619|Drug|capecitabine|Given orally
1832426|NCT00814619|Procedure|therapeutic conventional surgery|Patients undergo surgical resection
1832427|NCT00814619|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
1832428|NCT00814632|Drug|CC-10004|CC-10004 20 mg. twice a day for 12 weeks
1832429|NCT00814645|Drug|Sodium Nitrite Inhalation Solution|a single dose of AIR001 Inhalation Solution administered by inhalation following nebulization
1832430|NCT00814645|Drug|Placebo and AIR001 Inhalation Solution (Expansion arm)|On Day 1, subjects will receive a single placebo-form dose of inhaled nebulized AIR001 Inhalation Solution (containing diluent and excipient solutions alone). On Day 2, the same subjects will receive a single administration of AIR001 Inhalation Solution at the minimum pharmacologically active and safe dose identified from dose levels 1-4. Subjects will be blinded to the treatment schema.
1832431|NCT00814658|Drug|Galantamine|Galantamine 8 mg/day for one month, followed by 4 weeks of galantamine 16 mg/day. If necessary and well tolerated, dosage of galantamine will be increased to 24 mg/day.
1832432|NCT00814658|Drug|Nimodipine|Nimodipine 30 mg 3 times a day (tid).
1832433|NCT00814658|Drug|Placebo|Matching placebo three times a day (tid).
1832434|NCT00814671|Drug|Rifapentine|rifapentine 450 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
1832435|NCT00814671|Drug|Rifapentine|rifapentine 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
1832436|NCT00814671|Drug|Rifampin|rifampin 600 mg + isoniazid + pyrazinamide + ethambutol once a day, seven days a week for 8 weeks
1832437|NCT00814697|Device|Repetitive Transcranial Magnetic Coil Stimulation (rTMS)|The first six patients were administered rTMS at 10Hz in 20 trains of 5 seconds with 20 second intervals between trains in each hemisphere. The total number of pulses for each session was set at 1000 pulses. The second six enrolled patients were administered rTMS at 15 Hz in 20 trains of 5 seconds with 25 second intervals between trains in each hemisphere.
1832438|NCT00820937|Procedure|Single photon emission computed tomography and Magnetic Resonance Imaging|
1832439|NCT00820950|Drug|INCB018424 phosphate cream|INCB018424 phosphate cream 0.5%
1832440|NCT00820950|Drug|Dovonex® calcipotriene 0.005%|Cream applied once or twice daily for up to 56 days.
1832441|NCT00820950|Drug|Diprolene® AF betamethasone dipropionate 0.05% cream.|Cream applied once or twice daily for up to 56 days
1832442|NCT00820950|Drug|Placebo cream|Cream applied once or twice daily for 56 days
1832443|NCT00820950|Drug|INCB018424 phosphate cream|INCB018424 phosphate cream 1.0%
1832444|NCT00820950|Drug|INCB018424 phosphate cream|INCB018424 phosphate cream 1.5%
1832445|NCT00820963|Drug|temozolomide|Given orally
1832446|NCT00820963|Radiation|hypofractionated radiation therapy|Patients undergo hypofractionated radiotherapy
1832447|NCT00820963|Radiation|radiation therapy|Patients undergo standard radiotherapy
1832448|NCT00820976|Drug|G-CSF|Filgrastim(5 µg/kg intravenously over 30 minutes ) was administered starting from day 8 until neutrophil recovery
1832449|NCT00820989|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
1832450|NCT00821002|Drug|Latanoprost|Comparison of punctal plug placement between upper and lower puncta
1832451|NCT00821015|Device|Pulmonary vein isolation with cryoballoon catheter|For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
1832452|NCT00821028|Drug|Paclitaxel|Paclitaxel will be administered intra-arterially through an irrigating catheter to treat a diseased segment of superficial femoral artery. Dosing will be based on ther lesion surface area, and will be calculated using the following formula: dose= 22/7 X diameter (mm) X length (mm) X 3 micrograms/mm^3
1832453|NCT00821041|Behavioral|Cognitive Behavioral Therapy|6 weeks of relaxation training, cognitive therapy, sleep restriction, stimulus control, sleep hygiene, psychoeducation, hypnotic tapering and mindfulness training
1832454|NCT00821054|Drug|Lapatinib|Treatment A: one dose of 1250mg lapatinib 1 hour before starting a low-fat breakfast; Treatment B: one dose of 1250mg lapatinib 1 hour after finishing a low fat breakfast; or Treatment C: one dose of 1250mg lapatinib 1 hour after finishing a high-fat breakfast.
1832455|NCT00821067|Dietary Supplement|D-ribose|A 6 gm/day (3 gm/bid) dose of D-ribose in water. Each subject will consume oral D-ribose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
1832456|NCT00821067|Dietary Supplement|Dextrose|A 6 gm/day (3 gm/bid) dose of dextrose in water. Each subject will consume oral dextrose, dissolved in 8 fl. oz of water (1 serving) twice daily, for 2 weeks.
1832457|NCT00821080|Drug|Sirolimus|Taken orally at different dose levels depending upon enrollment time period
1832458|NCT00821080|Drug|Vandetanib|Taken orally at different dose levels depending upon enrollment time period
1832459|NCT00821093|Drug|Indacaterol 150 µg|Indacaterol 150 μg was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
1832460|NCT00821093|Drug|Salmeterol 50 µg|Salmeterol 50 μg was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]).
1832461|NCT00821093|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder-filled capsules with a single-dose dry-powder inhaler (SDDPI).
1832462|NCT00821093|Drug|Placebo to salmeterol|Placebo to salmeterol was provided in the manufacturer's proprietary multi-dose dry-powder inhaler (MDDPI, [DISKUS]).
1832463|NCT00821106|Procedure|Right radial|diagnostic or interventional procedures performed through right transradial approach
1832464|NCT00821106|Procedure|left radial|diagnostic or interventional procedures performed through left transradial approach
1832465|NCT00821119|Device|nasal intermittent positive pressure ventilation|Nasal intermittent positive airway pressure will be compared are the nasal continuous positive pressure as an initial ventilatory mode in preterm infants with respiratory distress syndrome
1832466|NCT00821132|Other|Genetic study of ALS families|Collection and analysis of genetic material, medical and family histories from families with ALS
1832467|NCT00821145|Procedure|conventional surgery|AAA patients operated using a conventional incision
1832468|NCT00821145|Procedure|laparoscopic AAA resection|laparoscopic AAA resection
1832469|NCT00821145|Procedure|laparoscopic stapler anastomosis|laparoscopic AAA resection, proximal anastomosis performed with a stapler
1832470|NCT00821158|Drug|Antioxidant|Antioxidant iv bolus
1832471|NCT00821158|Other|Placebo|Placebo tablet and iv
1832472|NCT00821158|Drug|Anti-inflammatory drug|Anti-inflammatory tablet
1832473|NCT00821184|Drug|Vesicare (solifenacin)|5mg po qd
1832474|NCT00821184|Behavioral|Vesicare (solifenacin) plus behavioral modification|5 mg dose po once daily plus behavioral modification
1832475|NCT00821197|Procedure|long-limb gastric bypass|Laparoscopic long-limb gastric bypass (150 cm alimentary limb, 50 cm biliopancreatic limb)
1832476|NCT00821197|Procedure|distal gastric bypass|Laparoscopic distal gastric bypass (150 cm common channel, 50 cm biliopancreatic limb)
1832477|NCT00821210|Device|Sham CPAP|CPAP with pressure of 3cm H2O
1832478|NCT00821210|Device|CPAP of optimal pressure|CPAP of optimal pressure
1832482|NCT00821236|Device|Excimer Laser|WaveLight ALLEGRETTO WAVE™ wavefront guided or optimized excimer laser treatment
1832483|NCT00821236|Device|AMO/VISX CustomVue™|Excimer Laser
1832484|NCT00821236|Device|LADARVision 4000 excimer laser|Excimer Laser
1832485|NCT00821249|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
1832486|NCT00821249|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care; Part 3: standard of care.
1832487|NCT00821249|Drug|Dexamethasone, steroid; oral|Part 3: standard of care.
1832488|NCT00821262|Drug|sevoflurane|
1832489|NCT00821262|Drug|propofol|
1832490|NCT00821275|Procedure|Interventional radiological or surgical management|Uterine artery embolization will be done for the patients who enroll into UAE group and desire for future pregancy and reserving uterus.Myomectomy will be performed for the patients who enroll into SURGERY group and desire for future pregancy and reserving uterus.Hysterectomy will be done for the patients who enroll into SURGERY group and don't desire for reserving uterus and/or future pregnancy.
1832491|NCT00822003|Drug|Oral GLP-1|GLP-1 tablet (2mg)
1832492|NCT00822003|Drug|Placebo|Control tablet
1832493|NCT00822029|Drug|FOSAMAX|patient receiving one tablet (oral use) 70 mg Fosamax by week
1832494|NCT00822029|Other|PLACEBO|patient receiving one tablet (oral use) placebo by week
1832495|NCT00822042|Other|Samples and procedures|"Scanner, histomorphometry : at the inclusion and M3 visits
whole blood samples, cytoponction : at the inclusion and M3 visits"
1832496|NCT00822055|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
1832497|NCT00822055|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
1832498|NCT00822055|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
1832499|NCT00822055|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy|1 drop BID in each eye
1832500|NCT00822068|Device|anodal tDCS|anodal transcranial direct current stimulation
1832501|NCT00822068|Device|cathodal tDCS|cathodal transcranial direct current stimulation
1832502|NCT00822068|Device|sham stimulation|sham stimulation
1832503|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination|1 drop BID in each eye
1832504|NCT00822081|Drug|dorzolamide hcl 2%/ timolol maleate 0.5% fixed combination|1 drop BID in each eye
1832505|NCT00822081|Drug|brimonidine tartrate 0.2%/timolol maleate 0.5% fixed combination as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
1832506|NCT00822081|Drug|dorzolamide hcl 2%/timolol maleate 0.5% fixed combinatin as adjunctive to current prostaglandin therapy.|1 drop BID in each eye
1832507|NCT00822094|Drug|CPX-351|
1832508|NCT00822094|Drug|Intensive Salvage Therapy|
1832509|NCT00822107|Drug|Hydrochlorothiazide|50 mg one time
1992639|NCT03317652|Other|Hyperventilation|The subject is instructed to hyperventilate for 6 min to provoke a 0.7-1.2 kPa reduction in PaCO2, and the evaluation is repeated if the reduction in PaCO2 is not within this interval. The order of hyperventilation and 6% CO2 breathing is randomized.
1992640|NCT03317652|Other|6% CO2 breathing|The subject breathes a mixture of 6% CO2 (with 21% O2 and 73% N2) from a bag and a face mask for 6 minutes. The order of hyperventilation and 6% CO2 breathing is randomized.
1832522|NCT00822133|Drug|lidocaine|lidocaine 5%
1832523|NCT00822133|Drug|ketamine|ketamine cream
1832524|NCT00822133|Drug|non-active drug cream|will be put on the skin
1832525|NCT00822146|Device|CRT|classified
1832570|NCT00822458|Drug|vismodegib|Given orally
1832526|NCT00822159|Device|DensiProbe Hip|DensiProbe (CE marked) is a mechanical probe, which is used intra-operatively to assess mechanical stability of the trabecular bone in the proximal femur. It consists of a drill bit like tool and an electronic system for measuring the peak torque to break-away of trabecular bone in the femoral head. DensiProbe measurements are designed to be integrated in the DHS surgical procedure.
1832527|NCT00822172|Dietary Supplement|Levocarnitine tartrate|Capsule form, 1,002 mg (3 capsules) taken by mouth two times per day (morning and evening). L-carnitine will be taken from Day 0 to Day 180.
1832528|NCT00822172|Drug|cilostazol|"Background therapy beginning at 50mg (1 pill) taken by mouth two times per day for two to three weeks. Then 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for one to two weeks.
Randomized therapy will consist of 100 mg (1 pill) to be taken by mouth two times per day (morning and evening) for approximately 180 days."
1832529|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 5 mcg/kg
1832530|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 10 mcg/kg
1832531|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 20 mcg/kg
1832532|NCT00822185|Drug|vatreptacog alfa (activated)|One single dose is injected i.v. over 2 minutes to 6 subjects, 30 mcg/kg
1832533|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 5 mcg/kg
1832534|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 10 mcg/kg
1832535|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 20 mcg/kg
1832536|NCT00822185|Drug|placebo|Single dose is injected i.v. over 2 minutes to 2 subjects per dose level: 30 mcg/kg
1832537|NCT00822198|Device|plantar vibration|Subjects in the experimental component of the trial will be provided with a Juvent 1000-CS device in their home or workplace. The device will be placed in a convenient location where the device does not represent a trip hazard, and yet is readily accessible for use. The subjects will be instructed to use the device whenever it is convenient to do so, either by standing on the device, or by sitting with their feet on the device. Downloads of usage data will be obtained intermittently. Period interviews with the subjects will be conducted to ensure that the device is operating and that no problems are encountered with device usage.
1832538|NCT00822211|Drug|Vildagliptin 50 mg bid|
1832539|NCT00822211|Drug|Vildagliptin 50 mg qd|
1832540|NCT00822211|Drug|Placebo|
1832541|NCT00822224|Drug|MEOPA|inhalation of MEOPA during the painful care
1832542|NCT00822237|Biological|Varicella Virus Vaccine Live (2007 Process) (Oka/Merck)|VARIVAX (2007 process) in two 0.5 mL doses by injection ~6 weeks apart
1832543|NCT00822237|Biological|Comparator: Varicella Virus Vaccine Live (1999 Process) (Oka/Merck)|VARIVAX (1999 process) in two 0.5 mL doses by injection ~6 weeks apart
1832544|NCT00822237|Biological|Measles, Mumps, and Rubella Virus Vaccine Live (MMR)|M-M-R II in two 0.5 mL doses by injection ~6 weeks apart
1832545|NCT00822250|Other|analysis of pigmentation|cutting hair, skin description, skin biopsy for only 4 patients
1832546|NCT00822263|Drug|N-acetyl-cysteine (NAC)|Anti-oxidant in a pill format
1832547|NCT00822263|Drug|Placebo|Control for study
1832548|NCT00822302|Drug|Reconstituted High Density Lipoprotein|RecHDL (Lot Nos 05422-00006)is provided as a lyophilised powder and reconstituted with sterile water at 25 mg/ml. The infusion is made at 40 mg/kg over a period of 4 hours.
1832549|NCT00822302|Drug|Saline|Saline (0.9%) is provided as a sterile infusion bag and infused over a period of 4 hours, 24 hours prior to carotid endarterectomy
1832550|NCT00822315|Drug|efavirenz|tenofovir 245 mg / lamivudine 300 mg / efavirenz 600 mg
1832551|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 400 mg
1832552|NCT00822315|Drug|raltegravir|tenofovir 245 mg / lamivudine 300 mg / raltegravir 800 mg
1832553|NCT00822328|Dietary Supplement|Yakult®300|"Yakult®300 was given 100 ml once per day for four weeks.
Fermented or unfermented milk per 100 ml bottle per day for four week."
1832554|NCT00822328|Dietary Supplement|Lactobacillus casei strain Shirota|Lactobacillus casei strain Shirota
1832555|NCT00822341|Drug|TG-0054|0.1, 0.2, 0.4, 0.8, 1.6, and 3.2 mg/kg of TG-0054/placebo via 15 min IV infusion
1832556|NCT00822354|Drug|Tadalafil|Subjects will be randomized to receive either tadalafil for the first month followed by placebo or placebo for the first month and followed by tadalafil
1832557|NCT00822367|Dietary Supplement|Glucerna; Ensure; SlimFast|Each participant will consume all three nutritional supplements randomly assigned by computer program to drink one of the three products in one week intervals. Each product will contain 50 grams of carbohydrate but differs in volume, fat, protein, and fiber composition. BG will be tested by finger sticks before (fasting) and at 15, 30, 60, 90, 120, 150 and 180 minutes after drinking the supplement. The participants will have 8 finger stick blood sugar measurements over about 3 hours on each of the 3 testing days.
1832558|NCT00822380|Dietary Supplement|Iron|Daily 20mg of ferrous sulfate in liquid solution during 4 months
1832559|NCT00822380|Dietary Supplement|Multiple micronutrients supplement|Daily supplement with 10mg of iron plus several micronutrients following a formula designed to treat anemia in indigenous population in Mexico. During 4 months.
1832560|NCT00822380|Dietary Supplement|micronutrient fortified porridge powder|Daily powdered complementary food designed for a national program in Mexico with 10mg of iron plus several micronutrients during 4 months
1832561|NCT00822380|Dietary Supplement|Iron and ascorbic acid fortified water|A drink water product fortified with 6.7 mg ofiron, zinc and ascorbic acid. This product was asked to be used for drinking and for cooking for the child during 4 months.
1832562|NCT00822380|Dietary Supplement|Iron plus folic acid supplement|Daily liquid solution following the daily iron (12.5mg)and folic acid recommendation of UNICEF to treat anemia during 4 months
1832563|NCT00822393|Drug|Busulfan|4 x 0.8 mg/kg/d Intravenous Day -4 and -3
1832564|NCT00822393|Drug|Treosulfan|10 g/m2/d Intravenous Day -4, -3, -2
1832565|NCT00822406|Drug|homeopathic medicine|individualized homeopathic medicine
1832566|NCT00822406|Drug|placebo|placebo - 6 months
1832567|NCT00822419|Drug|lidocaine|lidocaine cream 5%
1832568|NCT00822419|Drug|ketamine|ketamine 5%
1832571|NCT00822458|Other|laboratory biomarker analysis|
1832572|NCT00822458|Other|pharmacological study|
1832573|NCT00822471|Behavioral|Diabetes Self-Management Education|"DSME intervention consisting of two interactive 2-1/2 hour classes taught by a diabetes educator focusing on the ABCs of diabetes and training in how to talk to your doctor."
1832574|NCT00822484|Biological|ILV-095|
1832575|NCT00822484|Other|Placebo|
1832576|NCT00822497|Behavioral|Music-Based Imagery (MBI)|MBI is form of music-assisted relaxation with imagery. This protocol is used at the patients' bedside before and after the debridement process.
1832577|NCT00822497|Behavioral|Music Alternate Engagement (MAE)|MAE consisted of a menu of music therapy interventions aimed at engaging the patients in music and diverting them away from the debridement process.
1832578|NCT00822510|Behavioral|Telephone Interpersonal Counseling|Telephone delivered 8 week education and counseling intervention based on interpersonal psychotherapy.
1832579|NCT00822510|Behavioral|Telephone delivered education only|Telephone delivered 8 week educational intervention on prostate cancer health, side effects, physical activity, diet, smoking cessation
1832580|NCT00822523|Drug|Botulinum Toxin, Type A|20 units, single dose, intramuscular in right EDB muscle
1832581|NCT00822523|Drug|Botulinum Toxin, Type A|2 units, single dose, intramuscular to right EDB muscle
1832582|NCT00822523|Drug|Saline|Single Dose, Intramuscular into right EDB muscle
1832583|NCT00822536|Drug|Aspirin and Clopidogrel|Aspirin <= 325 mg/j Clopidogrel = 75 mg /j
1832584|NCT00822536|Drug|Aspirin|Aspirin : <= 325 mg/j
1832585|NCT00822549|Drug|intravenous morphine titration|intravenous morphine titration
1832586|NCT00822562|Other|PRFA or PMCT|PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
1832587|NCT00822562|Procedure|surgery|only surgery
1832588|NCT00822575|Device|ZapperClick|The ZapperClick is a therapeutic device that employs the piezo-electricity principle to soothe itching and ease the swelling from mosquito and horsefly bites as well as jellyfish and nettle stings. It accomplishes this by discharging 13KV at 0.7mA for 10 microseconds over the area of the bite or sting each time it is activated.
1832589|NCT00822588|Device|Sangvia® System|Sangvia® Intra- and Post-op System
1832590|NCT00822601|Device|rTMS|Arm 1 (experimental) : rTMS, 4 weeks of stimulation with RMT frequency 1Hz, intensity 100% of RMT for 20 minutes (1500 pulses), 5 minutes of trains with 2 minutes of intra-train intervals to both SMA. Treatment will be given 5 times a week for 4 weeks.
1832591|NCT00822601|Device|Sham Comparator|sham rTMS (using a placebo coil), 4 weeks of stimulation, will mimic the active treatment mentioned above.
1832592|NCT00822614|Drug|Fentanyl TAIFUN|Inhalation of Fentanyl via TAIFUN inhaler
1832593|NCT00822614|Drug|Opioid|Current optimized BTP treatment
1832594|NCT00822627|Drug|Influenza Vaccination|0.5 mL Sanofi-Pasteur intramuscular influenza vaccination
1832595|NCT00822627|Behavioral|Education and referral|Patients are given information regarding the inactivated influenza vaccination and a list of community providers who provide influenza vaccination
1832596|NCT00822640|Device|Total Knee Arthroplasty|All patients receive the same posterior cruciate retaining implant but the tibial tray and bearing (B. Braun Aesculap Columbus CR and RP) by two experienced surgeons and will follow an identical rehabilitation regime.
1832597|NCT00822653|Device|Calf Muscle Pump Stimulation|Stimulation of the postural reflex arc to activate the soleus muscle during dialysis
1832598|NCT00822666|Drug|clopidogrel|comparison of two loading strategies of clopidogrel (300mg vs 900mg) in the two genetic profiles
1832599|NCT00822679|Drug|Eszopiclone|Subject receives Eszopiclone for 3 consecutive nights. 3 mg orally at bedtime for patients age 64 and under, and 2 mg QHS for patients age 65 and older.
1832600|NCT00822679|Other|Placebo|Subjects are given placebo for 3 consecutive nights
1832601|NCT00822692|Drug|Trim/ Sulfa DS|bactrim DS (800/160) two tablets PO BID x 7 days
1832602|NCT00822692|Drug|placebo|matched placebo 2 pills PO BID x 7 days
1832603|NCT00822705|Drug|Placebo tablet|Control arm
1832604|NCT00822731|Drug|Chemotherapy with or without radiotherapy|Treatment regimen will be determined by the sub-type of lymphoma
1832605|NCT00822744|Drug|SSR411298|"Form: capsule
Route: oral administration with food"
1832606|NCT00822744|Drug|Escitalopram|"Form: capsule (commercial escitalopram tablets were encapsulated within opaque capsules)
Route: oral administration with food"
1832607|NCT00822744|Drug|Placebo (for SSR411298)|"Form: capsule
Route: oral administration with food"
1832608|NCT00822757|Biological|Comparator: V710|Single dose V710 (60 Mcg/0.5 mL) by intramuscular injection.
1832609|NCT00822757|Biological|Comparator: placebo|Single dose of buffered saline placebo (0.5 mL) by intramuscular injection.
1832610|NCT00822770|Drug|Plerixafor|"Phase I: Starting dose of 0 (escalating doses 80, 160, 240 mcg/kg) given daily subcutaneously in abdomen for 4 doses.
Phase II: Maximum Tolerated Dose (MTD) as determined in Phase I"
1832611|NCT00822770|Drug|Filgrastim|Dose of 10 mcg/kg subcutaneous injection beginning on day -9 daily for 6 days.
1832612|NCT00822770|Drug|Fludarabine|Dose of 40 mg/m^2 beginning on Day -6 for four consecutive days.
1832613|NCT00822770|Drug|Busulfan|Dose of 130 mg/m^2 for four consecutive days, immediately after completion of Fludarabine.
1832614|NCT00822770|Procedure|Allogeneic blood stem cell transplant|Stem Cell Infusion (Bone marrow or PBPC)
1832615|NCT00822770|Drug|ATG (Thymoglobulin)|Dose(s) of 0.5 mg/kg on day -3; of 1.5 mg/kg on day -2; and of 2 mg/kg on day -1. Given only to patients with unrelated donors.
1832616|NCT00822783|Drug|Omalizumab|
1832617|NCT00822783|Drug|Placebo|
1832618|NCT00822796|Device|Thermogard™|Those who have a Thermogard™ central venous warming catheter placed prior to surgery
1832619|NCT00822796|Device|Standard central venous catheter|Those who have a standard central venous catheter placed prior to surgery
1832620|NCT00822809|Drug|Catumaxomab|"Catumaxomab will be infused 4 times within 11 days as follows:
10 µg on day 0, 20 µg on day 3, 50 µg on day 7, 150 µg on day 10"
1832621|NCT00822809|Drug|Prednisolone|25 mg premedication
1832622|NCT00822822|Behavioral|First Questionnaire|Complete questionnaire before completing health history
1832623|NCT00822822|Behavioral|Health History|Complete electronic health history
1832624|NCT00822822|Behavioral|Second Questionnaire|Complete questionnaire after completing electronic health history
1832625|NCT00822835|Biological|ILV-095|
1832626|NCT00822835|Biological|Placebo|
1832627|NCT00822848|Drug|epirubicin hydrochloride|I.V., days 1-3 of each cycle. Epirubicin to be omitted during cycle 2 (concomitant chemoradiation)
1832628|NCT00822848|Drug|ifosfamide|Over 90 minutes I.V., days 1-3 of each cycle. Administered with hydration and Mesna.
1832629|NCT00822848|Drug|sorafenib tosylate|P.O. daily beginning 2 weeks before first chemotherapy cycle, held 1 week before and after surgery.
1832630|NCT00822848|Other|immunoenzyme technique|
1832631|NCT00822848|Other|immunohistochemistry staining method|
1832632|NCT00822848|Other|laboratory biomarker analysis|
1832633|NCT00822848|Procedure|adjuvant therapy|Preoperative administration has been the preference at our institution.
1832634|NCT00822848|Procedure|neoadjuvant therapy|
1832635|NCT00822848|Procedure|therapeutic conventional surgery|Surgery should be planned for 2-4 weeks after the initiation of chemotherapy for cycle 3.
1832636|NCT00822848|Radiation|hypofractionated radiation therapy|28 Gy (350 centigray (cGy) x 8 fractions in 10 days) beginning at the start of cycle 2. *Boost: postoperative boost of 12 Gy (200 cGy x 6 fractions) for patients with positive surgical margins only.
1832637|NCT00822861|Drug|TPI ASM8|4 mg/mL, 1 mg BID for 4 days
1832638|NCT00822861|Drug|TPI ASM8|4 mg/mL, 2 mg BID for 4 days
1832639|NCT00822861|Drug|TPI ASM8|4 mg/mL, 4 mg BID for 4 days
1832640|NCT00822861|Drug|TPI ASM8|4 mg/mL, 8 mg OD for 4 days
1832641|NCT00822874|Procedure|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
1832642|NCT00822887|Drug|Vandetanib|Dose level 1:100 mg qd Dose level 2:200 mg qd Dose level 3:300 mg qd
1832643|NCT00822887|Radiation|Fractionated Stereotactic Radiotherapy|All patients will receive 36 Gy of radiation in three fractions, given in three consecutive days.
1832644|NCT00822900|Drug|Progesterone|Following a one hour loading dose of 0.714 mg/kg per infusion pump through a dedicated IV line, the study drug (progesterone or placebo) will be administered as a continuous intravenous infusion at 0.5 mg/kg/hr for 71 hours, then tapered over an additional 24 hours. To simplify the infusion protocol, a weight based dosing table will be used by the on-sight pharmacy to mix the correct dose for a 10 cc/hour continuous infusion over the 71 hour steady state period followed by three additional 8-hour decrements (7.5 cc/hr-5.0 cc/hr-2.5 cc/hr) to zero, for a total treatment duration of 96 hour. The progesterone/placebo will be combined with a 20% Intralipid mixture for infusion.
1832645|NCT00822900|Drug|Placebo|"Placebo stock solution is the ethanol diluent required for dissolving progesterone. The volume of placebo to be mixed with intralipid is based on the mg/kg/hr volume. Using an infusion pump through a dedicated IV line - a one hour loading dose of placebo plus intralipid is administered as a continuous intravenous infusion for 71 hours, then tapered over an additional 24 hours."
1832646|NCT00822913|Drug|Intravesical injection of Botulinum A toxin|One treatment, 200 U vials diluted in 20 ml normal saline
1832647|NCT00822926|Drug|Botulinum Toxin Type A|Patients receive a subcutaneous injection of Botulinum Toxin Type A into the scar tissue
1832648|NCT00822926|Drug|Saline|Subcutaneous injection of saline into scar tissue
1832649|NCT00822965|Other|Questionnaires|3 sets of questionnaires at the beginning of the study, at 2-months and at 4-months.
1832650|NCT00822965|Other|Phone Interviews|2 follow-up phone interviews.
1832651|NCT00822965|Behavioral|Educational Packet|Video or DVD of device information, updates, recalls, on-line resources and benefits of routine follow-up for device(s).
1832652|NCT00822978|Drug|ACHN-490 Injection vs placebo|Escalating doses beginning with test dose given once, followed by 4 mg/kg with a single dose then multiple dose. Dose escalation to continue up to 15 mg/kg as long as the treatment is deemed safe.
1832653|NCT00822991|Device|CE-US (Sonazoid™)|screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
1832654|NCT00822991|Device|B-mode US|screening by conventional B-mode US every 3-5 months
1832655|NCT00823004|Drug|letrozole|letrozole 5mg/day from day 3 to day 7 of menstrual cycle
1832656|NCT00823004|Drug|oral contraceptive (Marvelone)|oral contraceptive, first 21 days
1832657|NCT00823004|Drug|GnRH agonist (buserelin)|50 µg SC twice daily
1832658|NCT00823004|Drug|recombinant FSH or hMG|recombinant FSH or hMG 300-450 IU/day
1832659|NCT00823004|Drug|ganirelix acetate|GnRH antagonist (ganirelix acetate) when a leading follicle reaches a mean diameter of 14 mm, 0.25 mg per day (Antagon, Organon, West Orange, NJ)
1832660|NCT00823017|Other|Patient-preferred music|Music of patients' preference
1832661|NCT00823017|Other|Relaxation Music|Relaxation music compiled from results of first three stages of study
1832662|NCT00823017|Other|Standard Care Environment|Control, no interventions
1832663|NCT00823030|Procedure|Urodynamic study|A small catheter will be inserted into the bladder and water will slowly be instilled through the catheter and into your bladder. A series of measurements will then be taken to assess your bladder's capacity to hold liquid, the average and maximum urine flow rates, as well as bladder filling and leak point pressure readings.
1832664|NCT00823030|Drug|Lidocaine|20 cc of alkalinized lidocaine will be injected after the first UDS
1832665|NCT00823030|Other|Normal Saline|20 cc of normal saline will be injected into the bladder after the first UDS
1832666|NCT00823043|Drug|timolol hemihydrate|timolol hemihydrate 0.5% solution
1832667|NCT00823043|Drug|timolol maleate|timolol maleate in sorbate
1832668|NCT00823056|Dietary Supplement|probiotics|placebo
1832669|NCT00823056|Dietary Supplement|probiotics|0,53 ml MCT oil containing BB12 and TH4 in daily dosage in 9 months
1832670|NCT00823069|Device|Perlane and Perlane-L|This is a split face design and each subject received both Perlane-L and Perlane. Treatments were blinded, randomized, and successive.
1832671|NCT00823082|Drug|Antithrombin III|Single dose of antithrombin III sufficient to achieve a preoperative level of 120%
1832672|NCT00823095|Drug|Nitric Oxide|Topically applied gaseous nitric oxide at 8 to 10 parts per million, for 8 hours each night for 14 nights.
1832673|NCT00823108|Drug|GIK|12 hour infusion of GIK solution
1832674|NCT00823121|Procedure|freezing embryos by vitrification|vitrification by Cryotop method
1832675|NCT00823121|Procedure|fresh embryo transfers|fresh embryo transfers
1832676|NCT00823121|Drug|buserelin|Daily administration of 500 µg subcutaneous buserelin from day 21 of menstrual cycle; reduce to 250 µg daily when ovarian suppression is confirmed.
1832677|NCT00823121|Drug|recombinant FSH|gonadotropin stimulation with rFSH 150 IU/day from day 2 of menstrual cycle
1832678|NCT00823121|Drug|human chorionic gonadotropin (pregnyl)|hCG 10,000 IU is administered when at least 2 follicles reach a mean diameter of 18 mm.
1832680|NCT00823147|Behavioral|Pain Catastrophizing Induction|Participants will undergo a psychologist-guided 10-minute induction of negative cognitive focus on the theoretical future worsening of one's pain condition.Biological stress response will be measured via heart rate, blood pressure and serum cortisol.
1832681|NCT00823160|Procedure|Sternotomy|Sternotomy performed after finding blood in the pericardial sac
1832682|NCT00823160|Procedure|Subxyphoid window|Subxyphoid window performed after the finding of blood in the pericardial sac
1832683|NCT00823173|Biological|ESBA105|ESBA105 eye drops (10mg/mL), initially applied in hourly dosing intervals, followed by later dose tapering (prolongation of dosing intervals)
1832684|NCT00823186|Drug|Phyxol(Paclitaxel)|"Paclitaxel is 5ß,20-Epoxyl-1,2α,4,7,β 10 β,13 α-hexahydroxytax-11-en-9-one 4,10
-diacetae 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisocerine"
1832685|NCT00823199|Drug|Allopurinal|300mg once daily by mouth for four weeks
1832686|NCT00823212|Device|PROMUS Coronary Stent System|PROMUS is a device/drug combination product composed of two components, a device (coronary stent system including a cobalt chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating).
1832687|NCT00823212|Device|PROMUS Element Coronary Stent System|PROMUS Element is a device/drug combination product composed of two components, a device (coronary stent system including a platinum chromium stent platform) and a drug product (a formulation of everolimus contained in a polymer coating that is the same as on the PROMUS [XIENCE V] stent).
1832688|NCT00823212|Drug|Aspirin|Patients are required to take aspirin indefinitely after stent implant. It is recommended that aspirin 162-325 mg daily be given for at least 6 months after stent placement and that aspirin 75-162 mg daily be given indefinitely thereafter.
1832689|NCT00823212|Drug|Thienopyridine|Patients must be treated with one of the following thienopyridines for at least 6 months following the index procedure: clopidogrel 75 mg daily; or ticlopidine 250 mg twice daily; or prasugrel (outside the United States and if approved at the time of the procedure). If used, the prescribed dose should be in accordance with approved country-specific labeling. In patients not at high risk of bleeding, thienopyridine treatment should continue for at least 12 months after stent implant.
1832690|NCT00823225|Procedure|standard therapy|wound debridement, moist wound dressing
1832691|NCT00823225|Drug|Urokinase|"Daily infusion up to 21 applications, dose dependent on fibrinogen level:
> 2,5g/l 1 000 000 IU, < 2,5g/l 500 000 IU"
1832692|NCT00823238|Drug|ceftazidime and tobramycin|
1832693|NCT00823238|Drug|inhaled tobramycin|
1832694|NCT00823251|Device|IlluminOss device|The IlluminOss™ Bone Stabilization System is designed to deliver the device to the fracture site via the medullary canal of the bone using percutaneous techniques. Once the device is in place and has spanned the fracture site, the device is expanded and hardened to reduce and stabilize the fracture, to aid in the support and healing of the bone fracture by primary callous formation and remodeling.
1832695|NCT00823264|Drug|Activated Charcoal|50 grams by mouth every 4 hours until serum phenytoin level is less than 25.
1832696|NCT00823277|Other|Chronic care multidisciplinary intervention of childhood obesity|Overweight and obese Children, 5-20 Years old, followed by Paediatricians and other Health Personals (multidisciplinary team). Included at their first visit in the clinic (baseline)and follow-up after ~ 1 Year.
1832697|NCT00823290|Drug|Sorafenib + LBH589|Sorafenib standard regimen + oral LBH589
1832698|NCT00823303|Drug|Paricalcitol|1 mcg daily, adjusted to achieve 40-60% PTH suppression
1832699|NCT00823303|Drug|Calcitriol|0.25 mcg daily, adjusted to achieve 40-60% PTH suppression
1832700|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|1x1,000,000 hMSC/kg, IV after unrelated HSCT
1832701|NCT00823316|Biological|Human umbilical cord blood-derived mesenchymal stem cells|5x1,000,000 hMSC/kg, IV after unrelated HSCT
1832702|NCT00823329|Device|cardiac stress testing with an exercise machine|Standardized graded cardiac stress testing with an exercise machine will be performed according to the protocol of the American Heart Association
1832703|NCT00823342|Drug|CLEVUDINE + TENOFOVIR PLACEBO|30 MG
1832704|NCT00823342|Drug|CLEVUDINE IN ASSOCIATION TENOFOVIR|TENOFOVIR 300 mg qd in association with CLEVUDINE 30 mg qd
1832705|NCT00823342|Drug|TENOFOVIR + CLEVUDINE PLACEBO|TENOFOVIR 300 mg qd + CLEVUDINE Placebo
1832706|NCT00823355|Drug|forodesine hydrochloride|Cohort 1: 100mg / body (1 x 100mg tablet once daily)
1832707|NCT00823355|Drug|forodesine hydrochloride|Cohort 2: 200mg / body (2 x 100mg tablets once daily)
1832708|NCT00823355|Drug|forodesine hydrochloride|Cohort 3: 300mg / body (3 x 100mg tablets once daily)
1832709|NCT00823355|Drug|forodesine hydrochloride|Cohort 4: 400mg / body (4 x 100mg tablets once daily)
1832710|NCT00823368|Drug|STX209|
1832711|NCT00823381|Dietary Supplement|resveratrol|one pill of resveratrol (Resvida™) 75 mg once a day with breakfast
1832712|NCT00823381|Other|placebo|one placebo pill taken once a day with breakfast
1832713|NCT00823381|Behavioral|Calorie Restriction|supervised calorie restriction diet: 30% reduction in caloric intake
1832714|NCT00823394|Behavioral|Questionnaire|Completed privately via computer at Windsor Village Church, approximately 75 minutes. Repeated at Months 12 and 24.
1832715|NCT00823394|Other|Body Measurements|Waist, hip, height, and weight measured privately. Repeated at Months 12 and 24.
1832716|NCT00823394|Behavioral|Self-help Materials|Information on how to lower risk for developing cancer.
1832717|NCT00823407|Drug|MDA|subjects will receive a single oral dose of MDA 98mg/70kg body weight
1832992|NCT00824551|Other|Standard care|Patient will undergo standard care
1832718|NCT00823407|Drug|Placebo|Subjects will receive a single oral dose of placebo
1832719|NCT00823420|Procedure|prematuration culture|"The aneuploidy rate and the developmental potential of embryos obtained from PDE3 inhibitor-treated oocytes (a prolonged IVM (PMC)) in comparison to conventional IVM will be analysed. It is intended to assess the nuclear and cytogenetic constitution of the obtained embryos."
1832720|NCT00823433|Drug|oral penicillin V|2 grams of oral penicillin V given within 4 hours of delivery.
1832721|NCT00823446|Device|Revera Wound Care|Revalesio Part Number MDW0060
1832722|NCT00823446|Device|Normal Saline|Sodium Chloride for Irrigation
1992641|NCT03317652|Drug|Infusion of sodium nitroprusside|Using incremental intravenous infusion of sodium nitroprusside MAP is reduced by 20% (15%-25%) and then by 40% (35%-45%, MAP minimally at 50 mmHg).
1832724|NCT00823472|Drug|Mild stimulation|Fixed daily dose of 150 IU rFSH start cycle day 5 or day 2 depending on the Arm
1832725|NCT00823485|Procedure|fibrinolysis in situ|intraventricular injection of actilyse
1832726|NCT00823485|Procedure|drainage|drainage
1832727|NCT00823498|Behavioral|Focus Group|6 Focus Groups asked how living in public housing effects physical activity and feelings about neighborhood.
1832728|NCT00823498|Behavioral|Interview|Interview with a member of study staff at housing development site.
1832729|NCT00823498|Other|Photovoice Project|Activity allowing expression of thoughts and feelings about neighborhood through neighborhood pictures taken by youth and parent(s).
1832730|NCT00823524|Biological|donor natural killer cell infusion|give patients donor-derived NK cells 2 to 3 weeks after HLA-haploidentical hematopoietic cell transplantation
1832731|NCT00823537|Procedure|therapeutic electrical stimulation|
1832732|NCT00823550|Drug|Entecavir|entecavir 0.5 mg QD
1832733|NCT00823550|Drug|Lamivudine|lamivudine 100 mg QD
1832734|NCT00823563|Procedure|30 cc blood draw|
1832735|NCT00823563|Procedure|Intravascular ultrasound (IVUS)|
1832736|NCT00823563|Procedure|Coronary pressure/flow wire testing|
1832737|NCT00823563|Procedure|Coronary pressure/flow testing: Acetycholine challenge|
1832738|NCT00823563|Procedure|Procedure: Coronary pressure/flow testing: Nitroglycerin challenge|
1832739|NCT00823563|Procedure|Procedure: Procedure: Coronary pressure/flow testing: Adenosine challenge|
1832740|NCT00823576|Drug|Ropivacaine|Compare the evolution of the postoperative levels of pain until J2, in the scheduled lumbar surgery between 2 groups of patients, one receiving a single bolus of analgesic, one receiving a single bolus of analgesic and an infiltration of Ropivacaine during 48 hours.
1832741|NCT00823589|Other|Blood test and clinical test|Blood test and clinical test
1832742|NCT00823602|Drug|ganirelix|These patients started ovarian stimulation with 150 - 225 IU Gonal F on the second day of menstrual cycle with an S.C. injection once a day. Initiation of 0.25 mg Ganirelix took place on the 6th of the stimulation (fixed protocol) when HMG (Menogon, ferring, pharmacenticals , Germany ).
1832743|NCT00823602|Drug|suprefact|GnRH agonist, standard protocol
1832744|NCT00823615|Device|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
1832745|NCT00823615|Device|Senofilcon A multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
1832746|NCT00823628|Drug|contrast agent (iopromide)|coronary angiography using the allocated contrast agent
1832747|NCT00823628|Drug|contrast agent (iodixanol)|coronary angiography using the allocated contrast agent
1832748|NCT00823641|Drug|Infliximab|Infliximab 3mg/kg infused intravenously at weeks 0, 2 and 8 and then every 8 weeks until and including week 40 of the study
1832749|NCT00823654|Other|Blood draw and questionnaires|"At the start of the study: blood draw, questionnaire and menstrual calendar ↓ Start planned therapy (or observation/surveillance) for cancer treatment
↓
Tests in the middle of chemotherapy (if applicable):
Blood draw and collection of monthly menstrual calendars ↓
Tests when chemotherapy is over (if applicable):
Blood draw and collection of monthly menstrual calendars
↓
Tests every 4 months for about 1 year:
Blood draw, collection of monthly menstrual calendars, and questionnaire ↓
Tests every 6 months for about 1 year:
Blood draw, collection of monthly menstrual calendars, and questionnaire
↓
Yearly follow-up for about 2 years:
Blood draw collection of monthly menstrual calendars, and questionnaire"
1832750|NCT00823654|Other|Blood draw and questionnaires|"Study Schema for Unaffected High Risk Women with BRCA mutations Identify eligible premenopausal patients and obtain informed consent
↓ Register patients at Memorial Sloan-Kettering Cancer Center
↓ Baseline evaluation: Blood draw and baseline reproductive health and sexual questionnaires (Appendix A)/menstrual calendar (Appendix C)
↓ Annual follow-up x 4 years Blood draw and collection of monthly menstrual calendars/follow-up reproductive health and sexual health questionnaires"
1832751|NCT00823667|Other|educational intervention|Palliative care intervention at weeks 3,4,5 and 6 post study enrollment
1832752|NCT00823667|Other|medical chart review|Occurs at 1 year post study enrollment
1832753|NCT00823667|Other|questionnaire administration|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
1832754|NCT00823667|Procedure|end-of-life treatment/management|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
1832755|NCT00823667|Procedure|psychosocial assessment and care|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
1832756|NCT00823667|Procedure|quality-of-life assessment|Occurs at baseline, 6 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks post study enrollment
1832757|NCT00823680|Drug|Placebo|po bid for 4 weeks
1832758|NCT00823680|Drug|RO5027838|200mg po qd for 4 weeks
1832759|NCT00823680|Drug|RO5027838|50mg po bid for 4 weeks
1832760|NCT00823680|Drug|RO5093151|400mg po bid for 4 weeks
1832761|NCT00823680|Drug|RO5093151|10mg po bid for 4 weeks
1832762|NCT00823693|Drug|Bimosiamose Cream|
1832763|NCT00823693|Drug|Placebo Cream|
1832843|NCT00824239|Procedure|Intermittent sedation|Patients under intermittent sedation stay without any continuous sedation since intubation and/or admission but receive analgesics as needed and sedatives only when agitated (SAS of 5 or more).
1833040|NCT00826228|Drug|teriparatide|teriparatide 20ug daily sc for 6 months
1992642|NCT03317470|Other|Basic needs survey|-11 questions about food security, housing personal safety, neighborhood safety, childcare, and transportation
1832764|NCT00823719|Drug|ofatumumab + ICE|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 milligrams (mg); cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg
ICE regimen:
ifosfamide + mesna - 5 grams (g)/meters squared (m^2)/24 hours (hrs) continuous on day 2 of dosing cycle; carboplatin - AUC 5 (800 mg maximum) on day 2 of dosing cycle; etoposide - 100 mg/m^2 on days 1, 2 and 3 of dosing cycle."
1832765|NCT00823719|Drug|ofatumumab + DHAP|"3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg.
DHAP regimen:
dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m^2/24 hrs continuous on day 1 of dosing cycle; cytarabine - 2 g/m^2 q12 hrs (2 doses) on day 2 of dosing cycle."
1832766|NCT00823732|Other|educational intervention|Undergo individualized interdisciplinary palliative care intervention
1832767|NCT00823732|Other|medical chart review|Ancillary studies
1832768|NCT00823732|Other|questionnaire administration|Ancillary studies
1832769|NCT00823732|Procedure|end-of-life treatment/management|Undergo end-of-life treatment/management
1832770|NCT00823732|Procedure|psychosocial assessment and care|Undergo psychosocial assessment and care
1832771|NCT00823732|Procedure|quality-of-life assessment|Ancillary studies
1832772|NCT00823732|Procedure|management of therapy complications|Undergo management of therapy complications
1832773|NCT00823732|Procedure|assessment of therapy complications|Undergo assessment of therapy complications
1832774|NCT00823745|Drug|[14C]-PF-00868554|solution, single dose
1832775|NCT00823758|Behavioral|Focus Groups|6 to 8 participants per group.
1832776|NCT00823758|Behavioral|Personal Interviews|Conducted by phone and audiotaped.
1832777|NCT00823784|Procedure|Transanal doppler hemorrhoidal ligation|THD technique involves identification and ligation of the terminal hemorrhoid arteries (about 6) followed by mucopexy
1832778|NCT00823784|Procedure|stapled hemorrhoidopexy|Staple hemorrhoidopexy involves resection of a ring of low rectal mucosa an lifting the hemorrhoids up in the anal canal with a stapled suture
1832779|NCT00823797|Drug|Bendamustine Hydrochloride|Given IV
1832780|NCT00823797|Other|Quality-of-Life Assessment|Ancillary studies
1832781|NCT00823810|Other|PET/CT|18F-FDG PET/CT
1832782|NCT00823823|Other|Bivalved cast|Circumferential cast will be applied following closed reduction and then bivalved using a cast saw
1832783|NCT00823823|Other|Circumferential cast|Circumferential cast will be applied following closed reduction
1832784|NCT00823836|Drug|ropinirole PR/XR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.
The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).
Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.
Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.
Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
1832785|NCT00823836|Drug|ropinirole IR|"Double-blind non-inferiority verification phase (24 weeks) At the baseline visit (Week 0), subjects who completed screening period will be randomised (1:1) to double-blind treatment with either ropinirole PR-PR group or ropinirole IR-PR group.
The subjects'dose will be titrated according to the recommended schedule to achieve an optimal therapeutic response (ropinirolePR/XR2-15 mg/day ,ropinirolIR0.75-15 mg/day).
Double-blind PR/XR switching phase (8 weeks) Ropinirole IR-PR subjects will be switched overnight to a similar dose of ropinirole PR/XR, while the remaining ropinirole PR-PR group will continue on the same dosage.
Double blind long-term treatment phase (22 weeks) The same dose level at the end of PR/XR switching phase will be continued till week 54 under blind.
Down titration phase Subjects who complete Week 54 or withdrawn will be down titrated over a 1 to 4 weeks period."
1832786|NCT00823849|Drug|Cilostazol|From 50mg, Bid, PO after breakfast and dinner. After 1-week of administration, if no significant study drug related discomfort, the dose can increase to 100mg, Bid, PO. Otherwise, remain at the 50 mg level.
1832787|NCT00823849|Drug|Probucol|250 mg Bid, PO after breakfast and dinner.
1832788|NCT00823849|Drug|Cilostazol+Probucol|TBD
1832789|NCT00823849|Other|Control Group|Routine treatment
1832790|NCT00823862|Drug|SD-101|Intramuscular (IM)
1832791|NCT00823862|Drug|ribavirin|oral, 2 times per day, for 2 months
1832792|NCT00823875|Drug|Cilostazol group|Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
1832793|NCT00823875|Drug|Probucol group|Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner
1832794|NCT00823875|Drug|Cilostazol + Probucol group|"Cilostazol: At first, 50 mg (1 tablets) Bid, PO after breakfast and dinner. After administration of study drug for 1 week, and if patient has no significant discomfort, the drug dosage will increase to 100mg（2 tablets）Bid.
Probucol: 250 mg (1 tablet) Bid, PO after breakfast and dinner"
1832795|NCT00823875|Drug|control group|routine treatment
1832797|NCT00823901|Drug|Clindamycin Phosphate 1.2% And Tretinoin 0.025% Gel|Applied on entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
1832798|NCT00823901|Drug|Placebo gel|Applied placebo gel with no active medication to entire face (forehead, nose, cheeks, chin) once daily at night for 12 weeks
1832799|NCT00823940|Drug|GSK1362885|5 - 100mg of GSK1362885 or placebo
1832800|NCT00823940|Drug|GSK1362885|100 - 600mg or placebo
1832801|NCT00823940|Drug|Glucagon|0.5mg IV bolus
1832802|NCT00823940|Drug|Glucagon + GSK1362885|0.5mg Glucagon IV bolus + selected dose of GSK1362885
1832844|NCT00824239|Procedure|Daily interruption of sedation|Patients under daily interruption of sedation stay on continuous sedation with midazolam and fentanyl and are submitted to a daily interruption of sedation to a neurological evaluation until they reach a SAS of 4 or more, then continuous sedation is re-started in the half previous dosage.
1832803|NCT00823953|Drug|Momordica charantia|escalating doses of Momordica charantia administered in the form of capsules for the trial phase of three week.Dose level 1: capsules containing a total of 500 mg of freeze dried powder of Momordica charantia. Dose level 1: capsules containing a total of 1000 mg of freeze dried powder of Momordica charantia. Dose level 3: capsules containing a total of 1500mg of freeze dried powder of Momordica charantia.
1832804|NCT00823953|Other|starch powder|The placebo arm will be administered capsules containing a total of 500 mg of starch powder, at dose level 1; 1000 mg at dose level 2; 1500 mg at dose level 3.
1832805|NCT00823966|Drug|Rescriptor|"RESCRIPTOR® TABLETS 200mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dose is 400mg of Delavirdine Mesilate administered orally 3 times daily.This drug must always be administered in combination with other anti-HIV drugs."
1832806|NCT00823979|Drug|UK-453,061 Dose 1|UK 453,061 750 mg QD + one optimized NRTI + darunavir/ritonavir.
1832807|NCT00823979|Drug|UK-453,061 Dose 2|UK 453,061 1000 mg QD + one optimized NRTI + darunavir/ritonavir.
1832808|NCT00823979|Drug|Etravirine|Etravirine 200 mg BID + one optimized NRTI + darunavir/ritonavir.
1832809|NCT00823992|Drug|placebo|sc once weekly
1832810|NCT00823992|Drug|taspoglutide|10mg sc once weekly for 4 weeks, then 20mg sc once weekly
1832811|NCT00824005|Biological|Adult stem cells|Single procedure of intramyocardial electromechanical-guided injection of approximately 100 million bone marrow mononucleated cells (BM-MNCs), administered in 15 different injection sites
1832812|NCT00824005|Biological|Placebo|Single procedure of intramyocardial electromechanical-guided needle insertions and injection of 5% human serum albumin and saline in 15 different injection sites
1832813|NCT00824044|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT group will receive weekly 50-minute individual sessions over the course of 12 weeks conducted by experienced therapists who are trained in manual based CBT.
1832814|NCT00824044|Drug|Escitalopram|The medication group will receive open label treatment of escitalopram, 10-20 mg/day, flexible dose, for 12 weeks, and will be seen every two weeks by a study physician.
1832815|NCT00824044|Device|Quantitative electroencephalogram (QEEG)|The QEEG will be administered 5 times during the study (week 0, 1, 2, 8 and endpoint) allowing us to assess whether there are any correlations between QEEG patterns and changes in clinical functioning.
1832816|NCT00824057|Drug|AZD6280|oral
1832817|NCT00824057|Drug|Midazolam|oral
1832818|NCT00824057|Drug|Caffeine|oral
1832819|NCT00824070|Drug|Besifloxacin hydrochloride|Instill besifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
1832820|NCT00824070|Drug|moxifloxacin hydrochloride|Instill moxifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
1832821|NCT00824070|Drug|gatifloxacin|Instill gatifloxacin study medication in the study eye prior to making an incision for cataract extraction surgery.
1958922|NCT01076400|Drug|MK1775 + topotecan + cisplatin|Part 1: Dose escalation study. MK1775 capsules in sequentially rising dose levels twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
1832823|NCT00824109|Device|Second Generation Anti-Microbial bifurcated vascular graft (InterGard)|treatment of patients with aorto-iliac occlusion,stenosis, or aneurysm
1832824|NCT00824135|Drug|Clofarabine|"One dose intravenously every 24 hrs for five days total.
Dose level 1 Clofarabine 40 mg/m2/day intravenous Dose level 2 Clofarabine 45 mg/m2/day intravenous Dose Level 3 Clofarabine 50 mg/m2/day intravenous"
1832825|NCT00824135|Procedure|Stem Cell Transplantation, Hematopoietic|Haploidentical Hematopoietic Stem Cell Transplantation (two infusions, one on day 0 and the other on day +1)
1832826|NCT00824135|Other|OKT3|"Start at 0.0125 mg/kg intravenous once a day, taper dose down incrementally and discontinue after 17 days total
Muromonab-CD3"
1832827|NCT00824135|Drug|Thiotepa|5 mg/kg/day intravenous every 12 hours (2 doses total)
1832828|NCT00824135|Drug|Melphalan|60mg/m2 intravenous every 12 hours for 2 doses total.
1832829|NCT00824135|Drug|Mycophenolate mofetil|"Mycophenolate mofetil 600 mg/m2 intravenous two times a day
(continue for approximately 2 months or as clinically indicated)"
1832830|NCT00824135|Drug|Rituximab|375 mg/m2 intravenous for 1 dose total
1832831|NCT00824135|Other|G-CSF|G-CSF 5 mcg/kg/day subcutaneous or intravenous until ANC greater than 2.000/mm3 for 2 consecutive days and then as clinically indicated.
1832832|NCT00824148|Device|Guardian REAL-Time Continuous Glucose Monitoring System|One group will use the glucose monitoring system for 1 month
1832833|NCT00824148|Other|Conventional self-monitoring of plasma glucose|Finger prick blood glucose measurements
1832834|NCT00824161|Drug|TAS-109|"14-day continuous central intravenous infusion at a dose of 2.0 mg/m2/day followed by a 7-day rest period.
Number of cycles: until unacceptable toxicity or disease progression requires discontinuation."
1832835|NCT00824174|Behavioral|Questionnaire|1 questionnaire, about 15-20 minutes.
1832836|NCT00824187|Drug|EE20/DRSP(YAZ, BAY86-5300)|20 μg ethinylestradiol, 3mg drospirenone, tablet, orally, opd
1832837|NCT00824187|Drug|Placebo|Inert tablet
1832838|NCT00824200|Behavioral|Behavioral|Multicomponent Behavioral and Exercise Therapy (M-BET) - pelvic floor muscle exercises, urge suppression strategies, fluid strategies, sleep hygiene & non-pharmacological management of peripheral edema.
1832839|NCT00824200|Drug|tamsulosin (alpha-adrenergic antagonist medication)|0.4 mg given daily
1832840|NCT00824200|Drug|placebo|tamsulosin placebo
1832841|NCT00824200|Behavioral|placebo|placebo behavioral intervention
1832842|NCT00824226|Dietary Supplement|magnesium|magnesium 350 mg tablets once a day for 3 weeks
1832990|NCT00824538|Other|laboratory biomarker analysis|
1958923|NCT01076400|Drug|Comparator: MK1775 + topotecan + cisplatin|Part 2, Arm 1: MK1775 capsules at the dose determined in Part 1 twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
1996146|NCT02555059|Drug|Cipro (Ciprofloxacin, BAYQ3939)|Treatment parameters following the physician's decision based on the summary of product characteristics.
1832845|NCT00824252|Behavioral|Questionnaires & Study Visit|Individual Questionnaires (1 hour) and videotaped discussion during Study Visit (1 1/4 hours)
1832846|NCT00824265|Drug|OFC Infusion|Ofatumumab Cycle 1-Day 1 300mg, Cycle 1-Day 8 1000mg, then Cycles 2-6 Day 1 1000mg every 28 days, Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250 mg/m2 Days 1-3 every 28 days for 6 cycles
1832847|NCT00824265|Drug|FC infusion|Fludarabine 25mg/m2 Days 1-3 every 28 days for 6 cycles, Cyclophosphamide 250mg/m2 Days 1-3 every 28 days for 6 cycles
1832848|NCT00824291|Drug|desvenlafaxine succinate sustained release|50 mg/day oral tablet for 12 weeks
1832849|NCT00824291|Genetic|Genotyping|CYP2D6 genotyping at randomization
1832850|NCT00824317|Drug|methylphenidate|(15 mg daily), medium (25 mg daily) and high (40 mg daily)
1832851|NCT00824317|Drug|Placebo|
1832852|NCT00824330|Behavioral|Control Phase; Exercise Phase|After the completion of the control phase and at the start of the titration phase of the study, participants will be given pedometers and log books, then contacted on a regular basis to help insure compliance with the goal of walking 10,000 steps per day.
1832853|NCT00824343|Drug|P276-00|For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
1958924|NCT01076400|Drug|Comparator: Placebo to MK1775 + topotecan + cisplatin|Part 2, Arm 2: Placebo to MK1775 capsules twice daily for a total of nine doses on Days 1-5 of a 21-day cycle. Topotecan will be administered at a dosage of 0.75 mg/m^2 by intravenous (IV) infusion over 30 minutes on Days 1-3 . Cisplatin will be administered at a dosage of 50 mg/m^2 by IV infusion over 30 minutes on Day 1.
1832857|NCT00824369|Drug|No drug will be administered|No drug will be administered.
1832858|NCT00824382|Drug|BI 1744 CL 2 Âµg|2 puffs of 1 Âµg/actuation delivered by the RespimatÂ® inhaler
1832859|NCT00824382|Drug|BI 1744 CL 5 Âµg|2 puffs of 2.5 Âµg/actuation delivered by the RespimatÂ® inhaler
1832860|NCT00824382|Drug|BI 1744 CL 10 Âµg|2 puffs of 5 Âµg/actuation delivered by RespimatÂ®
1832861|NCT00824382|Drug|Placebo|2 puffs delivered by the RespimatÂ® inhaler
1832862|NCT00824408|Drug|pemetrexed|500 mg/m^2 i.v. on day 1 of 21 day cycle
1832863|NCT00824408|Drug|pemetrexed|500 mg/m^2 i.v. on day 1 of 21 day cycle
1832864|NCT00824408|Drug|BI 6727|BI 6727 i.v. on day 1 of a 21 day cycle
1832865|NCT00824421|Drug|UK-453, 061|UK-453,061 500 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
1832866|NCT00824421|Drug|UK-453, 061|UK-453,061 750 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 mg tablets PO QD.
1832867|NCT00824421|Drug|EFV +TVA|Efavirenz 600 mg tablets PO QD + Tenofovir DF 300 mg/Emtricitabine 200 tablets mg PO QD.
1832868|NCT00824434|Device|PROMUS Element™|Drug eluting coronary stent system
1832869|NCT00824447|Drug|Oralgen|allergen solution sublingually
1832870|NCT00824447|Other|placebo|placebo control
1832871|NCT00824460|Drug|1.25 g PA21 (250 mg iron)|Daily dose of 1.25 g PA21 (1 tablet/day) for 6 weeks. One PA21 tablet will be taken orally with the largest meal of the day.
1832872|NCT00824460|Drug|5.0 g PA21 (1,000 mg iron)|Daily dose of 5.0 g PA21 (4 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with the largest meal of the day, and one PA21 tablet will be taken orally with each of the two smaller main meals of the day (3 meals per day).
1832873|NCT00824460|Drug|7.5 g PA21 (1,500 mg iron)|Daily dose of 7.5 g PA21 (6 tablets/day) for 6 weeks. Two PA21 tablets will be taken orally with each of the three main meals of the day (3 meals per day).
1832874|NCT00824460|Drug|10.0 g PA21 (2,000 mg iron)|Daily dose of 10.0 g PA21 (8 tablets/day) for 6 weeks. Four PA21 tablets will be taken orally with the largest meal of the day, and two PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
1832875|NCT00824460|Drug|12.5 g PA21 (2,500 mg iron)|Daily dose of 12.5 g PA21 (10 tablets/day) for 6 weeks. Four tablets will be taken orally with the largest meal of the day, and three PA21 tablets will be taken orally with each of the two smaller main meals of the day (3 meals per day).
1832876|NCT00824460|Drug|Sevelamer hydrochloride|Daily dose of 4.8 g Sevelamer hydrochloride (6 tablets/day) for 6 weeks. Two Sevelamer tablets will be taken orally with each of the three main meals of the day (3 meals per day).
1832877|NCT00824473|Drug|Placebo|Placebo
1832878|NCT00824473|Drug|0.15% azelastine hydrochloride|0.15% azelastine hydrochloride 822 mcg
1832879|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses, with a starting dose of 1mg (Part 1) maximum tolerated dose administered po daily until disease progression(Part 2)
1832880|NCT00817518|Drug|RO4987655|Administered po daily for 28 days, at escalating doses , with a starting dose of 1mg (Part 1). Optimal biological dose administered po daily until disease progression (Part 2)
1832881|NCT00817531|Drug|Dasatinib|pill form, 100 mg daily
1832882|NCT00817544|Drug|ORM-12741|3 mg of ORM-12741 as a single dose. Contains 0.73 mg (2.5 MBq) 14C labelled ORM-12741
1832885|NCT00817583|Drug|docetaxel, cisplatin, fluorouracil|"neoadjuvant chemotherapy:docetaxel 75 mg/m2 on day 1; cisplatin 75 mg/m2 on day 1; continuous fluorouracil infusion at 500 mg/m2/d on days 1 through 5.
concurrent chemotherapy:cisplatin 40 mg/m2 weekly"
1832886|NCT00817583|Radiation|3D-CRT (three-dimensional conformal radiation therapy) or IMRT (intensity-modulated radiation therapy)|
1832887|NCT00817596|Device|Infusion Pump (Prometra)|Implantation of pump/catheter for infusion of morphine into the intrathecal space
1832888|NCT00817609|Drug|Angongniuhuang Pill|7 days of Angongniuhuang Pill
1832889|NCT00817609|Drug|placebo|7 days of placebo
1832890|NCT00817622|Dietary Supplement|EPA, Vitamin E|EPA pearls, 500 mg QID for 12 Weeks (2000 mg per day) Vitamin E pearls, 400 mg per day for 12 weeks
1832891|NCT00817635|Drug|LCI699|
1832892|NCT00817635|Drug|Placebo|
1832893|NCT00817635|Drug|Eplerenone|
1833041|NCT00826228|Other|weight-bearing|device assisted walking
1958925|NCT01074190|Drug|Group 1|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
1832896|NCT00817661|Dietary Supplement|Vitamin A|10000 IU Vitamin A or placebo per week
1832897|NCT00817661|Dietary Supplement|Placebo|10000 IU Vitamin A or placebo per week
1832898|NCT00817687|Drug|mycophenolate mofetil [CellCept]|As prescribed; + early biopsy
1832899|NCT00817687|Drug|mycophenolate mofetil [CellCept]|As prescribed; + standard treatment
1832900|NCT00817700|Other|Sleep restriction|Sleep restriction.
1832901|NCT00817713|Drug|Praziquantel, Ivermectin, Albendazole|"Standard HIV care plus triple anthelminthic treatment
Praziquantel 2400mg single dose
Ivermectin 12 mg, single dose
Albendazole 400mg, 2 doses in 1 day
All drugs given at baseline, after 6 months and after 12 months."
1832902|NCT00817739|Drug|Leuprorelin|Leuprorelin injection
1832903|NCT00817739|Drug|Flutamide|Flutamide tablets
1832904|NCT00817752|Dietary Supplement|Ashwagandha|Participants consume 3mL of Ashwagandha for 5 days. Blood work/immune cells (CD4 T-cells, CD8 T-cells, B-cells, NK cells, macrophages, IL-1, IL-6 and TNF-alpha) and psychological assessments (POMS and STAI Self-Evaluation) given at specified time intervals.
1832905|NCT00817765|Drug|Posaconazole|Posaconazole oral solution 40mg/mL; 400mg BID treatment for 10 days, including dose escalation
1832906|NCT00817765|Drug|Fosamprenavir|fosamprenavir tablet 700mg; 1 tablet BID for 10 days
1832907|NCT00817765|Drug|Ritonavir|Ritonavir 100mg capsule; 1 capsule BID for 10 days
1832908|NCT00817778|Drug|AZD1656|Subjects will be treated with tolerable dose twice daily for another 24 days.
1832909|NCT00817778|Drug|Placebo|Subjects will be treated with tolerable dose twice daily for another 24 days.
1832911|NCT00817804|Device|Use of the V60 Mask Ventilator|The V60 Mask Ventilator used to provide noninvasive ventilation. It is compared to the patient's conventional ventilator in a cross-over study. The ventilator settings can range from CPAP to Pressure Support ventilation with values of IPAP and EPAP to match the conventional ventilation on which the patient had been placed.
1832912|NCT00817817|Device|MF|One evening dose of dry powder inhaled MF 400 μg (Multidose device).
1832913|NCT00817817|Device|MF|One evening dose of dry powder inhaled 400 μg (400 μg capsules - Monodose).
1832914|NCT00817830|Drug|lodenafil carbonate|Patients will do a cardiopulmonary exercise test after placebo administration. Seven days later, a new cardiopulmonary test should be done using lodenafil carbonate, 80mg, orally.
1832915|NCT00817843|Drug|Simvastatin|6 weeks of treatment with simvastatin 80 mg
1832916|NCT00817843|Drug|Simvastatin/Ezetimibe|6 weeks of treatment with simvastatin 10 mg / ezetimibe 10 mg combination
1832917|NCT00817869|Other|New flooring|8.3mm thick vinyl floor covering with foam backing, manufactured by Tarkett and installed by Tyndale Flooring Ltd.
1832918|NCT00817882|Other|individually targeted vocational rehabilitation|"individually targeted vocational rehabilitation over 4 month period, maximum of 10 sessions, in addition to routine back pain rehabilitation.
Maximum of 25 participants with low back pain"
1832919|NCT00817882|Other|routine back pain rehabilitation|routine back pain rehabilitation Maximum of 25 patients with low back pain
1832920|NCT00817895|Drug|sustained released 5-FU and sustained released cisplatin|600mg sustained released 5-FU and 60mg sustained released cisplatin will be implanted into liver incisal margin after tumor is resected.
1832921|NCT00817895|Drug|sustained released 5-FU|600mg sustained released 5-FU will be implanted into liver incisal margin after tumor is resected.
1832922|NCT00817895|Procedure|TACE|All patients will accept TACE one month after tumor was resected.
1832923|NCT00817934|Drug|AB PREP|Potassium phosphate and Sodium Phosphate,(in the form of K-phos neutral 8 tablets.(Bisacodyl)6tablets. The third medication is (Metoclopramide).
1832924|NCT00817947|Device|High frequency chest wall oscillation|Airway clearance using high frequency chest wall oscillation ('The Vest')
1832925|NCT00817960|Drug|Methylphenidate|The effect of ritalin on postural stability of old adults (65 years old and over) will be measured using RCT study design
1832926|NCT00817973|Dietary Supplement|Casein|
1832927|NCT00817973|Dietary Supplement|Whey|
1832928|NCT00817973|Dietary Supplement|Cod|
1832929|NCT00817973|Dietary Supplement|Gluten|
1832930|NCT00817986|Drug|Arbaclofen placarbil, 20 mg|tablets
1832931|NCT00817986|Drug|Placebo|tablets
1832932|NCT00817986|Drug|Arbaclofen placarbil, 30 mg|tablets
1832933|NCT00817986|Drug|Arbaclofen placarbil, 40 mg|tablets
1832934|NCT00817999|Dietary Supplement|Grapefruit juice|Participants received grapefruit juice during 1 of the 2 periods.
1832935|NCT00817999|Drug|Clopidogrel 75 mg/day|
1832936|NCT00817999|Drug|Clopidogrel 300 mg|
1832937|NCT00818025|Behavioral|Pocket PATH (Personal Assistant for Tracking Health)|Participants in the intervention group will be trained to use a hand-held device with custom programs as a means of supporting, tracking, and interpreting discharge activities in addition to the standard paper-tracking methods.
1832938|NCT00818038|Drug|BG0002 (natalizumab)|Participants who are newly prescribed TYSABRI, but have not received their first infusion, will be invited to participate.
1832939|NCT00818051|Radiation|intensity-modulated radiation therapy|Given as 48, 53, or 56 Gy
1832940|NCT00818064|Drug|anti-IL-20|Single s.c. injection (per dose cohort)
1832941|NCT00818064|Drug|placebo|Single s.c. injection (per dose cohort)
1832942|NCT00818077|Other|Continuous Glucose Monitoring of Carbohydrate Intake|Subjects eat standard breakfast and lunch and keep food records.
1832943|NCT00818090|Drug|paclitaxel and cisplatin|paclitaxel and cisplatin every 3 weeks
1832944|NCT00818103|Drug|atorvastatin|Atorvastatin 40mg p.o. qn for 2 years
1832945|NCT00818103|Drug|β-interferon|β-interferon 50ug i.m. qod for 2 years
1832946|NCT00818103|Drug|EPO|EPO 10000U i.h. bid for 5 days
1832947|NCT00818116|Device|AcrySof ReSTOR Aspheric IOL|Bilateral implantation with the AcrySof ReSTOR Aspheric Intraocular Lens (IOL) for the replacement of cataract in the natural lens of the eye.
1832991|NCT00824551|Procedure|Hyperbaric Oxygen Therapy|2 sessions of HBOT ( HDMC 14)
1832948|NCT00818129|Drug|AZD7295|ascending single doses (start dose 90 mg), oral solution and then multiple ascending dose (tbd based on single dose results), oral solution
1832949|NCT00818129|Drug|Placebo|multiple ascending dose (tbd based on single dose results), oral solution
1832950|NCT00818142|Behavioral|ED/DM Support Group|The ED/DM Recovery Group focuses on assisting individuals with diabetes and an eating disorder - specifically the struggle of withholding insulin. The group utilizes strategies and tools that have been taught in other EDI programs, and also builds on the strengths of a group. The group is a means for learning and support as the individuals continue a regular schedule of school, work, and/or family life.
1832951|NCT00818155|Drug|desvenlafaxine succinate SR|desvenlafaxine succinate SR
1832952|NCT00818155|Other|Placebo|
1832953|NCT00818168|Biological|Infliximab|"Dosage and infusion intervals were employed in
accordance to the Summary of Product Characteristics (SmPC)"
1832954|NCT00818181|Drug|Biological: AL0206st|
1832955|NCT00818194|Drug|extended release tacrolimus|oral
1832956|NCT00818194|Drug|cyclosporine A microemulsion|oral
1832957|NCT00818207|Other|Full Smoking Cessation Treatment Coverage (100%)|This is a pragmatic study in which the intervention is a health policy (SCT reimbursement). Champix (varenicline), Zyban (bupropion) and NRTs (nicotine replacement therapies; patches, gums) are SCT eligible for reimbursement. Prescriptions will be issued as per the most recent version of the Product Monograph of the prescribed SCT or equivalent.
1832958|NCT00818207|Other|No Smoking Cessation Treatment Coverage (0%)|None of the subjects recruited in the study have access to SCT reimbursement in real-life. As such, subjects randomized to the control group represent lack of SCT coverage in real-life and are considered to receive standard of care for smoking cessation.
1832959|NCT00818220|Procedure|delayed umbilical cord clamping|at birth, the clamping of the umbilical cord will be delayed 30 to 45 seconds while the child is held lower than the placenta. At the end of the time, the cord is milked once and the cord is clamped. If the obstetrician feels he cannot delay the cord clamping, then the cord can be milked 2 to 3 times.
1832960|NCT00818220|Other|Immediate cord clamping|The umbilical cord is cut within 10 seconds after birth
1832961|NCT00818233|Device|Dynamic contour tonometry|Observe variability of measurements by dynamic contour tonometry
1832962|NCT00818246|Device|Sham light|
1832963|NCT00818246|Device|LumiPhase-R™, OPUSMED Inc. Montreal, Canada|660 nm wavelength delivered in a sequential pulsing mode
1832964|NCT00818259|Drug|Experimental: aprepitant|aprepitant powder for suspension, 125 mg/sachet, PO
1832965|NCT00818259|Drug|Experimental: fosaprepitant|fosaprepitant lyophilized powder for suspension, 115 mg/vial or 150 mg/vial, IV
1832966|NCT00818259|Drug|Comparator: ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
1832967|NCT00818259|Drug|Ondansetron|ondansetron solution for infusion, IV, administered per local standard of care
1832968|NCT00818259|Drug|Dexamethasone|dexamethasone solution for infusion, IV, administered per local standard of care
1832969|NCT00818272|Biological|Remicade (infliximab)|Participants with confirmed diagnosis of severe active Crohn's disease (CD) and participants suffering from fistulae who do not respond sufficiently to a complete and adequate therapy with a conventional treatment received infliximab administration as intravenous (IV) infusion over a period of two hours. Dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC): 5 mg/kg body weight at week 0 of infliximab therapy with additional infusions of 5 mg/kg at week 2 and week 6 after the initial dose, followed by infusions every 8 weeks (maintenance) or if signs and symptoms of the disease recur (readministration).
1832970|NCT00818285|Device|CDS for psychotropic drug management|Computerized decision support (CDS) for patients with available supplies of psychotropic medications. The decision support will consist of a screen displaying to the physician the patient's current risk of falling as well as what their risk could be lowered to with modifications to medications.
1832971|NCT00818298|Drug|ziprazidone|Up to and including the time of the third PET scan, subjects will be titrated to 60 mg BID of ziprazidone. Thereafter they will receive 20-80 mg BID of ziprazidone, according to clinical effectiveness and side effects.
1832972|NCT00818311|Device|LED GentleWaves®|primary spectral radiance with a dominant 590 nm wavelength (yellow visible light), irradiance power level of 4mW/cm2, Light pulsed with sequential period on/off for a total duration of 35 seconds per cycle.
1832973|NCT00818324|Drug|OPC-12759 Ophthalmic suspension|Instillation,4times/day,for 52weeks
1832974|NCT00818337|Drug|Aspirin|Aspirin 81mg and Aspirin 325mg, non-enteric coated, take one tablet by mouth daily
1832975|NCT00818350|Drug|SUNITINIB|50 MG ORAL, DAYS 1-28 FOLLOWED BY 2 WEEKS RESTING
1832976|NCT00818363|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER™-Bupivacaine/Once
1832977|NCT00818363|Drug|SABER™-Placebo|Injectable Solution; 5.0 mL SABER™-Placebo/Once
1832978|NCT00818376|Other|Dental prophylaxis|Two randomized quadrants will be cleaned with a prophylaxis to disrupt dental biofilm presence.
1832979|NCT00818389|Drug|Lithium Carbonate|Participants will receive capsules that contain 150 milligrams (mg) lithium carbonate. Participants will be randomized to lithium/riluzole or placebo/riluzole and treated for 52 weeks. Participants originally randomized to placebo who fail (progress) will crossover to lithium for the remainder of the trial.
1832980|NCT00818389|Drug|Riluzole|All participants enrolled in this study will be taking a stable dose of riluzole 50 milligrams (mg) by mouth (PO) twice per day (BID) for at least 30 days prior to screening.
1832981|NCT00818389|Drug|placebo|an inactive substance
1832982|NCT00824486|Behavioral|Injury prevention education (TIPP)|using TIPP materials
1832983|NCT00824486|Behavioral|Injury prevention education (safe home)|using safe home model
1832984|NCT00824499|Other|Complex regional intervention|"Components of the complex intervention:
Introduction of a program coordinator
Introduction of a self-management education program
Bottom up development of a interdisciplinary care protocol
Support program for the intiation of insulin therapy in primary care
Regional audit"
1832985|NCT00824512|Drug|EGb 761 120 mg|EGb 761® 120 mg bid, orally for 12 to 14 weeks
1832986|NCT00824512|Drug|Placebo|Placebo 1 tablet BID, orally for 12 to 14 weeks
1832987|NCT00824538|Drug|sunitinib malate|
1832988|NCT00824538|Other|flow cytometry|
1832989|NCT00824538|Other|immunohistochemistry staining method|
1832993|NCT00824564|Drug|Tranexamic Acid plus standard of care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + Standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
1832994|NCT00824564|Procedure|Standard of care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
1832995|NCT00824590|Drug|Dimebon|a single oral dose of 20 mg Dimebon
1832996|NCT00824590|Drug|Dimebon|a single oral dose of 20 mg Dimebon
1832997|NCT00824616|Drug|MK-0941|MK-0941 tablets 5 mg or 10 mg, taken 3 times daily, with increasing doses to maximally effective dose.
1832998|NCT00824616|Drug|Placebo|Placebo tablets, taken 3 times daily.
1832999|NCT00824616|Drug|Insulin|Insulin glargine (rDNA origin) injection solution for subcutaneous (SC) injection, taken once daily.
1833000|NCT00824629|Procedure|Afterloading embryo transfer procedure|Afterloading embryo transfer procedure
1833001|NCT00824629|Procedure|Direct embryo transfer procedure|Direct embryo transfer procedure
1833002|NCT00824642|Device|Transcutaneous electrical nerve stimulation (TENS)|Applied 45 minutes prior to exercise
1833003|NCT00824642|Device|placebo|placebo TENS applied prior to exercise
1833004|NCT00824655|Biological|13vPnC|13vPnC will be administered by intramuscular injection at approximately 5 and 12 months of age.
1833005|NCT00824655|Biological|13vPnC|13vPnC will be administered by intramuscular injection at approximately 12 months of age.
1833006|NCT00824668|Drug|biphasic insulin aspart 30|
1833007|NCT00824668|Drug|insulin glargine|
1833008|NCT00824668|Drug|insulin glulisine|
1833009|NCT00824681|Behavioral|Sound Of Family Together (S.O.F.T.) Music Program|Audio compact disk containing songs, music, special messages, poems from children of adults with major burns
1833010|NCT00824681|Other|Non-Therapy Related Activities (NTRA)|NTRA includes non-directed activities e.g. reading books/magazines, watching TV/movie in family lounge off the BICU, playing with toys, listening to music CDs/radio.
1833011|NCT00824694|Other|Targeted Self-Monitoring Of Blood Glucose (SMBG)|SMBG will alternate between 2 strategies: glucose profiling and target monitoring.
1833012|NCT00824694|Other|Provider Training|Focused on normalizing the most significant glucose abnormalities at any given time.
1833013|NCT00824694|Other|Patient Education|Focused on normalizing the most significant glucose abnormalities at any given time.
1833014|NCT00824707|Drug|Entecavir|Entecavir 0.5mg per day
1833015|NCT00824707|Drug|conventional therapy|conventional therapy including protecting the liver function, anti-tumor and so on
1833016|NCT00824720|Drug|High Dose Device|inserted for 14 days
1833017|NCT00824720|Drug|Low Dose Device|inserted for 14 days
1833018|NCT00824720|Device|Placebo Device|inserted for 14 days
1833019|NCT00824733|Drug|Trastuzumab|IV at 2 mg/kg over 30 minutes on day 1 of each weekly cycle. Patients who have not received trastuzumab for 4 weeks or more will receive a loading dose of 4 mg/kg over 90 minutes day 1 of the first cycle. The dose of trastuzumab will be based on the patient's actual weight at the start of each 4 week treatment cycle.
1833020|NCT00824733|Drug|PF03512676|Patients also receive PF03512676 subcutaneously on days 15 and 22 of course 1 and on days 1, 8, 15, and 22 of all subsequent courses.
1833021|NCT00824733|Other|Correlative Studies|Blood for performing the correlative studies will be drawn on week 1, 2, 6, 12 and 18.
1833022|NCT00824746|Drug|Gefitinib retreatment|phase II trial of Gefitinib retreatment for the advanced or metastatic (IIIb and IV) NSCLC patients who previously responded to gefitinib And progressive disease should be observed with at least one prior regimen following previous EGFR-TKI failure.
1833023|NCT00824759|Other|pure oxygen breathing versus air|one group will breath pure oxygen; the other will breath air
1833024|NCT00824785|Drug|epirubicin, oxaliplatin, capecitabine (EOX)|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 130mg/m(2) IV on day 1 with hydration capecitabine 1250mg/m(2)/day PO in two divided doses continuously from days 1-21
1833025|NCT00824785|Drug|EOX + panitumumab|epirubicin 50mg/m(2) IV on day 1 oxaliplatin 100mg/m(2) IV on day 1 with hydration capecitabine 1000mg/m(2)/day PO in two divided doses continuously from days 1-21 panitumumab -9 mg/kg every 21 days
1833026|NCT00824811|Drug|Cyclosporine Eye Drops (Restasis)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
1833027|NCT00824811|Drug|Lubricant Eye Drops (Refresh Endura™)|One drop twice a day (approximately 12 hours between instillations) for 84 consecutive days to both eyes.
1833028|NCT00824811|Drug|Fluorometholone Eye Drops (FML Forte®)|"Week 1: One drop four times a day to both eyes.
Week 2: One drop three times a day to both eyes.
Week 3: One drop twice a day to both eyes.
Week 4: One drop once a day to both eyes.
Wait at least 10 minutes after Restasis® or Refresh Endura™ instillation to instill FML Forte®."
1833029|NCT00824824|Drug|Dorzolamide 2%-timolol 0.5%|BID OU for 6 weeks
1833030|NCT00824824|Drug|Brimonidine 0.2%-0.5% timolol 0.5|BID OU for 6 weeks
1833031|NCT00826137|Dietary Supplement|Inulin and fructo-oligosaccharides.|Supplement during antibiotic treatment+14 days.
1833032|NCT00826137|Dietary Supplement|Placebo|Placebo is base powder of product with no oligosaccharides.
1958926|NCT01074190|Drug|Group 2|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
1833034|NCT00826163|Drug|Budesonide|Inhaled budesonide 400 mcg twice a day for 2 weeks
1833035|NCT00826176|Drug|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was to be administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could have been administered if necessary. At 1-2 PTC after the last administration of rocuronium, an IV single bolus dose of 4.0 mg/kg sugammadex was to be administered.
1833036|NCT00826202|Drug|D-serine|60 mg/kg/day
1833037|NCT00826202|Other|Placebo|Inert Placebo
1833038|NCT00826215|Device|electroacupuncture|Nine sections of 45 minutes electroacupuncture treatment in three weeks
1833039|NCT00826215|Device|Sham laser acupuncture|Sham laser acupuncture
1833042|NCT00826241|Drug|Temozolomide|Starting dose 125 mg/m2 daily by mouth on days 1-7 & 15-21 of a 28 day cycle.
1833043|NCT00826241|Drug|Lapatinib|Starting dose 1250 mg daily by mouth.
1833044|NCT00826254|Drug|Vitamin K|180 micrograms vitamin K daily
1833045|NCT00826254|Drug|Vitamin K|"2 capsules daily 180 micrograms vitamin K daily or placebo
1 year"
1833046|NCT00826267|Drug|lapatinib|lapatinib tablets 1500 mg daily
1833047|NCT00826267|Drug|BIBW 2992|BIBW 2992 high dose once daily (allowed dose reduction to medium or low once daily in case of AE)
1833048|NCT00826267|Drug|trastuzumab|trastuzumab 4mg/kg i.v. week 1, followed by 2mg/kg i.v. weekly
1833049|NCT00826280|Drug|regadenoson|IV
1833050|NCT00826280|Drug|overencapsulated caffeine|oral
1833051|NCT00826280|Radiation|technetium|IV
1833052|NCT00826280|Drug|placebo|oral
1833053|NCT00826293|Procedure|Stabilization belt|Patients receive true stabilization.
1833054|NCT00826293|Procedure|Stabilization belt|Patients receive sham stabilization.
1833055|NCT00826306|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on sunscreen. In the active comparison arm (control arm), the comparison intervention is written patient educational material on sunscreen.
1833056|NCT00826332|Procedure|transabdominal ultrasound|transabdominal ultrasound
1833057|NCT00826332|Procedure|transvaginal ultrasound|transvaginal ultrasound
1833058|NCT00826345|Other|Acupuncture / Moxibustion|"Acupuncture/Moxibustion points will be administered per point prescription.
- Active"
1833059|NCT00826345|Other|Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion - Not active
1833060|NCT00826358|Drug|ABT-143|Once, please see Arm Description for more details.
1833061|NCT00826358|Drug|ABT-335|Once, see Arm Description for more detail
1833062|NCT00826358|Drug|rosuvastatin|once, see Arm Description for more detail
1833063|NCT00826371|Drug|ranibizumab 0.5 mg|
1833064|NCT00826384|Procedure|balloon catheter|transcatheter arterial chemoembolization therapy with balloon catheter
1833065|NCT00826397|Procedure|Acupuncture|Each acupuncture session will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
1833066|NCT00826397|Procedure|Sham Acupuncture|The sham acupuncture session will consist of superficial needling at nonspecific body points, administered twice weekly for six weeks, and will last approximately 45 minutes and includes standardized body treatment with an emphasis on affected joints.
1833067|NCT00826410|Device|Redon drain|subcutaneous suction drain after laparotomy for two days
1833068|NCT00826449|Drug|Dasatinib|Starting dose of 70 mg by mouth daily for 21 day cycle.
1833069|NCT00826449|Drug|Erlotinib|150 mg by mouth daily every 21 day cycle.
1958927|NCT01074190|Drug|Group 3|A basal infusion rate for the PCEA will be set at 8 mL/h with patient administered boluses of 8 mL every 10 minutes and a one hour limit of 32 mL. Breakthrough pain in all groups will be managed using anesthesiologist administered boluses of bupivacaine 1.25 mg/mL without fentanyl.
1958928|NCT01070511|Drug|Tadalafil|Tadalafil will be administered orally on two consecutive days. The first dose—10 mg— will be administered the afternoon before the study. The second dose -20 mg—will be administered the morning of the study.
1833075|NCT00826475|Behavioral|Mindfulness Based Stress Reduction MBSR|Mindfulness Based Stress Reduction: 8 weeks behavioral structured group programme teaching mindfulness skills
1833076|NCT00826475|Behavioral|Psychoeducation|Psychoeducation on Migraine, Progressive Muscle Relaxation PMR, three group meetings within 8 weeks, daily home work
1833077|NCT00826488|Device|Digital Breast Tomosynthesis|Women with a positive screening mammogram called back for additional views will be asked to undergo an additional Digital Breast Tomosynthesis (3D mammogram) on the affected breast. Radiation dose is somewhat less than that of a screening mammogram.
1833078|NCT00826501|Procedure|Endoscopic cyst-gastrostomy|After passing a small camera into the stomach the pseudocyst will be punctured and drained into the stomach by stent placement.
1833079|NCT00826501|Procedure|Surgical cyst-gastrostomy|After making an incision in the abdomen the pseudocyst contents will be emptied and the pseudocyst will be sutured to the stomach.
1833080|NCT00826514|Drug|Tanezumab|Intravenous, 20 mg, single dose.
1833081|NCT00826514|Drug|Placebo|Intravenous placebo, single dose
1833082|NCT00826527|Drug|Solifenacin PO|Tab 5 mg Daily for 12 Weeks
1833083|NCT00826540|Drug|sorafenib tosylate|Given orally
1833084|NCT00826540|Biological|bevacizumab|Given IV
1833085|NCT00826553|Drug|Dexmedetomidine|Standard of care sedative. Dosage, frequency, and duration will be determined by the managing clinical team.
1833086|NCT00826553|Drug|GABA agonist|Patients sedated with GABA agonists (e.g. propofol, benzodiazepines) during mechanical ventilation will be enrolled. Patients randomized to the GABA agonist arm will continue the sedative that is active at enrollment. The specific drug as well as dosage, frequency, and duration will be determined and titrated by the managing clinical team.
1833087|NCT00826566|Dietary Supplement|Caffeine|2 times 250 mg caffeine per day
1833088|NCT00826566|Dietary Supplement|placebo|2 times 250 mg per day
1833089|NCT00826579|Procedure|Sentinel lymph node procedure|After careful mobilization of the affected colon segment, isosulfan blue 1% is injected in vivo into the subserosa circumferentially around the tumor. Lymph nodes in the mesentery staining blue within the first minutes are marked as SLN. The procedure is followed by a resection of the affected colon segment with standard lymphadenectomy.
1833090|NCT00826579|Procedure|Bone marrow aspiration|Prior to surgery, bone marrow is aspirated from both iliac crests. Bone marrow aspirates are analyzed for the presence of occult metastatic colon cancer cells.
1833091|NCT00826592|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on atopic dermatitis. In the active comparison arm (control arm), the comparison intervention is written patient educational material on atopic dermatitis.
1833092|NCT00826618|Drug|ranibizumab|This is an open-label, Phase I study of intravitreally administered 0.5mg ranibizumab in subjects with uveitic CME.
1833093|NCT00826631|Procedure|Fast food arm|Doubling of regular caloric intake based on fast food, no exercise allowed
1833094|NCT00826644|Drug|Belotecan/Cisplatin|Belotecan : 0.5mg/㎡/day for Day 1 to 4, Cisplatin : 60mg/㎡/day for Day 1.
1833095|NCT00826644|Drug|Etoposide/Cisplatin|Etoposide : 100mg/㎡/day for Day 1 to 3, Cisplatin : 60mg/㎡/day for Day 1. Repeat next cycle at Day 22.
1833096|NCT00826657|Dietary Supplement|Vitamin B12|500 microgram daily supplement of vitamin B12 1000 mg injection vitamin B12 given at the start of the study
1833097|NCT00826657|Dietary Supplement|placebo|placebo given as a daily supplement 1000 mg injection of vitamin B12 given at the end of the study
1833098|NCT00826670|Drug|Decolonization|"Colistin sulphate (50mg 4x/d PO) + Neomycin (250mg 4x/day PO) for 10 days
plus In the presence of urinary tract colonization choice of one of the following agents (according to susceptibility profile, creatinine clearance and individual contraindications) Nitrofurantoin (100mg 3x/day PO) or Norfloxacin (400mg 2x/day PO) for 5 days"
1833099|NCT00826670|Drug|Placebo (Decolonization)|Placebo
1833100|NCT00826683|Biological|Enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, Endothelial cell progenitor characterization by primary cell cultures|
1833101|NCT00826709|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC).
1833102|NCT00826722|Drug|Levetiracetam|1000 mg tablet
1833103|NCT00826735|Behavioral|Guided imagery|A relaxation focused guided imagery intervention was used through the remainder of pregnancy plus a physiologic guided imagery intervention was used during the third stage of labor.
1958929|NCT01070511|Drug|Placebo|A placebo pill will be administered orally on two consecutive days. The first pill will be administered the afternoon before the study. The second pill will be administered the morning of the study.
1833105|NCT00826761|Dietary Supplement|probiotic|One capsule per meal test (high dose or low dose)
1833106|NCT00826761|Dietary Supplement|placebo|1 capsuel every morning
1833107|NCT00826774|Behavioral|Usual Care|Participants in this group will receive usual medical care, provided by their own primary care providers (PCPs). PCPs also will provide participants recommendations for weight management at quarterly-scheduled visits.
1833108|NCT00826774|Behavioral|Brief Lifestyle Counseling|These participants, like those in the Usual Care group, will receive the same PCP visits, plus monthly brief counseling sessions with an auxiliary health care provider (e.g., a medical assistant), on-site or by phone.
1833109|NCT00826774|Behavioral|Enhanced Brief Lifestyle Counseling|These participants will receive the same intervention as those in the Brief Lifestyle Counseling condition, including quarterly PCP visits and monthly sessions with a medical assistant who will instruct them in lifestyle modification. These individuals also will select, in consultation with their PCP, the use of either meal replacements or weight loss medication, to facilitate the induction and maintenance of weight loss
1833110|NCT00826787|Drug|Levetiracetam|750 mg tablet
1833111|NCT00826800|Drug|FOLFOX and bevacizumab|The patient will receive six treatments, two weeks apart. On each treatment day you will get Oxaliplatin, 5-FU,Leucovorin. On the first four treatments you will also get Bevacizumab (Avastin). These drugs are given through a Mediport. They will be given in an outpatient chemotherapy unit. Each tx will take about 4 hours. A pump for the 5-FU is worn around your waist. This drug is given over 2 days. Part II: Colon Cancer Surgery is standard practice, and is not a research procedure.Part III: Post-operative Re-Evaluation and Recovery The doctor will decide on the type of chemotherapy based on how the patient responded to the first chemotherapy. The plan will be for the patient to get 6 more doses of FOLFOX, without any further bevacizumab, unless your doctor finds a reason to do otherwise.
1833112|NCT00826813|Device|Esophageal stent placement|The esophageal stent combined a self-expandable covered esophageal stent and 125I radioactive seeds. Sheathes were attached to the outer surface of the stent, containing 125I radioactive seeds of CIAE 6711. The seeds were loaded into the sheathes on the stent immediately before implantation of the stent. The numbers and dose of the radioactive stent seeds was determined by the treatment plan system based on the size of the individual tumor. To cover the entire lesion of the tumor by the sheaths containing 125I seeds, at least 2 cm exceeding the tumor margins was required. The distance between the two sheaths was 15mm. In the control group, conventional covered esophageal stents were used which provided by the same company as those attached with 125I seeds.
1833113|NCT00826826|Procedure|Catheter ablation|(Pulmonary vein isolation)
1833114|NCT00826826|Drug|Amiodarone|From the day of the catheter ablation procedure and 8 weeks forward.
1833115|NCT00826826|Drug|Placebo|From the day of the catheter ablation procedure and 8 weeks forward.
1833116|NCT00826839|Drug|Oral contraceptive pill and microdose lupron|Desogestrel/ethinyl estradiol tablets, 0.15 mg/0.03 mg, one tablet by mouth daily for 14 days Leuprolide acetate 40 µg by subcutaneous injection twice a day during ovarian stimulation (approximately 14 days)
1833117|NCT00826839|Drug|E2 patch/antagonist|"Estradiol transdermal system 0.1 mg/day (25 cm2 patch. Patch changed every other day x 3. Final patch left on for about 7 days. Total duration of therapy approximately 14 days.
Gonadotropin-releasing hormone antagonist 0.25 mg subcutaneously every other day for 3 total doses."
1833118|NCT00826852|Drug|docetaxel and carboplatin|weekly docetaxel 30mg/m2 and four weekly carboplatin AUC (Area under curve) 5
1833119|NCT00826865|Drug|Levetiracetam|750 mg tablet
1833120|NCT00826878|Drug|Tivozanib (AV-951)|"Subjects will receive 1.0 or 1.5 mg tivozanib (AV-951) once daily continuously beginning on Day 1 for 4 weeks. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks in the absence of disease progression or unacceptable toxicity.
Minimum of 8 weeks (2 consecutive dosing cycles), if tolerated."
1833189|NCT00827437|Other|Parent Interview|To include the PI, Nursing Research Specialist,Clinical Research Associate or Clinical Nurse Specialist
1833190|NCT00827450|Dietary Supplement|Ctl|Control, isocaloric diet; no coffee
1833191|NCT00827450|Dietary Supplement|High fructose diet; no coffee|Hypercaloric, high fructose diet; no coffee
1833192|NCT00827450|Dietary Supplement|fully torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
1833121|NCT00826891|Drug|Cisplatin Combined With Topotecan|"Patients must have specific minimum neutrophil and platelet counts before administration of Hycamtin. The dose of Hycamtin is 0.75 mg/m2 by intravenous infusion over 30 minutes daily on days 1, 2, and 3; followed by cisplatin 50 mg/m2 by intravenous infusion on day 1 repeated every 21 days (a 21-day course).
Dosage adjustments for subsequent courses of Hycamtin in combination with cisplatin are specific for each drug.
Dose levels for cisplatin Initial dose 0 = 50 mg/m2 Dose reduction level -1 = 37.5 mg/m2 Dose reduction level -2 = 25 mg/m2
Dose levels for topotecan Initial dose 0 = 0.75 mg/m2 Dose reduction level -1 = 0.60 mg/m2 Dose reduction level -2 = 0.45 mg/m2"
1833122|NCT00826930|Drug|Trans Sodium Crocetinate (TSC)|Single bolus intravenous administration in a superficial vein of the arm over a period of up to 2 minutes.
1833123|NCT00826943|Drug|Cetirizine|Cetirizine 10 mg tab daily x 7 days
1833124|NCT00826943|Drug|Levocetirizine|5 mg tab daily x 7 days
1833125|NCT00826943|Drug|Placebo|Placebo tablet daily x 7 days
1833126|NCT00826956|Procedure|one lung ventilation|measure the pulmonary blood flow in nondependent lung during 30min one lung ventilation
1833127|NCT00826969|Drug|Ciclesonide|320µg Ciclesonide versus Placebo
1833128|NCT00826969|Drug|Placebo|Placebo
1833129|NCT00826995|Other|Patient Educational Materials|In the experimental arm, the intervention is the video-based patient educational material on melanoma. In the active comparison arm (control arm), the comparison intervention is written patient educational material on melanoma.
1833130|NCT00827008|Drug|Neramexane mesylate|Up-titration treatment period of 5 weeks up to 75mg Neramexane mesylate oral per day followed by 49 weeks treatment maintenance
1833131|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|4000 IU/week I.V. Until the end of the trial
1833132|NCT00827021|Drug|Erythropoiesis Stimulating Agents (ESAs): epoetin alfa, beta or any other epoetin in equivalent dose.|18000 IU/week I.V. Until the end of the trial
1833133|NCT00827034|Drug|Warfarin|A: a single oral dose of warfarin 25 mg administered on Day 1 of the relevant dosing period, as tablets.
1833134|NCT00827034|Drug|Dimebon|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
1833135|NCT00827034|Drug|Warfarin|B is oral doses of Dimebon 10 mg TID on Days 1 7 and Dimebon 20 mg TID on Days 8 17, with co administration of a single oral dose of warfarin 25 mg on Day 12 of the relevant dosing period, both as tablets
1833136|NCT00827047|Procedure|Total hemihepatic vascular exclusion|A long vascular clamp is inserted along the midline of the anterior surface of the vena cava,proceed cranially up to the space between the right and the middle hepatic vein trunks. Two tapes are seized with the clamp passing between the anterior surface of the IVC and the liver parenchyma.One tape is use to pass around the hepatic parenchyma for occlusion of the bleeding from the remnant liver;the other is used to loop the right (or left )hepatic vein trunk and short hepatic vein,as well as inferior right hepatic vein,if present. Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection.Thus total hemihepatic vascular exclusion is achieved.
1833137|NCT00827047|Procedure|Hemihepatic vascular Clamping|Selectively interrupts the arterial and portal inflow to the part of the liver (right or left hemiliver)ipsilateral to the lesion that requires resection. Selective clamping can be achieved after carefully dissecting the right from the left hilar branches or after inserting a clamp between the right and left hilar branches without prior hilar dissection and looping the right or left portal structures with a tape.
1833138|NCT00827047|Procedure|Pringle's Maneuver|Hepatic pedicle clamping is performed by encircling the hepatoduodenal ligament with a tape and then applying a tourniquet or a vascular clamp until the pulse in the hepatic artery disappears distally.
1833139|NCT00827073|Drug|tetracaine 0.5%|betadine 5%
1833140|NCT00827073|Drug|Lidocaine 2% Jelly|Betadine 5%
1833141|NCT00827099|Biological|anti-thymocyte globulin|anti-thymocyte globulin
1833142|NCT00827099|Drug|fludarabine phosphate|fludarabine phosphate
1833143|NCT00827099|Drug|Melphalan|melphalan
1833144|NCT00827099|Drug|mycophenolate mofetil|mycophenolate mofetil
1833145|NCT00827099|Drug|tacrolimus|tacrolimus
1833146|NCT00827099|Procedure|umbilical cord blood transplantation|umbilical cord blood transplantation
1833147|NCT00827112|Drug|maraviroc|maraviroc (Selzentry, Celsentri) 150mg QD + atazanavir (Reyataz) /ritonavir (Norvir) (300/100mg) QD OR maraviroc (Selzentry, Celsentri) 150mg QD+ darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR maraviroc (Selzentry, Celsentri) 150mg QD+ lopinavir/ritonavir (Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
1833148|NCT00827112|Drug|maraviroc|emtricitabine/tenofovir (Truvada) 200/300mg QD + atazanavir (Reyataz) /ritonavir (Norvir) 300/100 mg QD OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + darunavir (Prezista)/ritonavir (Norvir) (800/100 mg) QD (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by darunavir (Prezista)/ritonavir (Norvir)) OR emtricitabine/tenofovir (Truvada) 200/300 mg QD + lopinavir/ritonavir(Kaletra, Aluvia) (400/100 mg) BID (if atazanavir (Reyataz) /ritonavir (Norvir) is replaced by lopinavir/ritonavir (Kaletra, Aluvia))
1833149|NCT00827125|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
1833150|NCT00827138|Drug|DCC-2036|150 mg BID tablets, continuous dosing of 28 day cycles
1833151|NCT00827151|Drug|Estrogen|Estrogen 100 mcg patch twice weekly with 10 days of oral progesterone monthly for 12 months versus no medication
1833152|NCT00827164|Behavioral|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
1833153|NCT00827164|Behavioral|Resistance Training|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patients will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks.
1833193|NCT00827450|Dietary Supplement|partially torrefied, caffeine-free coffee|Hypercaloric, high fructose diet + coffee
1833154|NCT00827177|Drug|Treatment with ARQ 197 in combination with sorafenib|"Patients will be treated with ARQ 197 and sorafenib at Dose Level 1 (ARQ 197 360 mg twice daily (bid) and sorafenib 200 mg bid). Patients with HCC will start treatment with ARQ 197 at 240 mg bid and sorafenib 200 mg bid. Enrollment of subsequent patient cohort will depend on the safety and tolerability of the combination treatment in the initial cohort.
If < 33% patients treated at Dose Level 1 experience dose-limiting toxicity(ies) (DLT) by the end of first treatment cycle (4 weeks), then next cohort of 6 patients will be enrolled and treated at Dose Level 2 (ARQ 197 360 mg bid and sorafenib 400 mg bid). If ≥ 33% patients treated at Dose Level 1 experience DLT(s) by the end of first treatment cycle, the next cohort of 6 patients will be enrolled and treated at Dose Level 0 (ARQ 197 240 mg bid and sorafenib 200 mg bid)."
1833155|NCT00827190|Drug|ILS-920|
1833156|NCT00827203|Drug|Elesclomol Sodium|Chemotherapy agent
1833157|NCT00827216|Drug|Placebo|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min.
1833158|NCT00827216|Drug|Erythromycin|For all patients, a standardised volume of 10 ml of the study drug (will be diluted in 90 ml NaCl 0.9% (total volume, 100 ml). Both, the study drug and the 90 ml NaCl bag will be prepared by the pharmacy. Using sterile syringes, the investigator will withdraw from this solution as many millilitres as necessary to obtain a volume that corresponds to 1 ml per kg bodyweight of the patient (i.e. for a 67 kg patient, 33 ml would be with withdrawn). Thus, the maximum volume that can be administered to a patient will be 100 ml (i.e. for a patient weighing ≥100 kg). Twenty minutes prior to the scheduled induction of anaesthesia, patients will receive their study drug solution as an intravenous infusion during 5 min. The regimen corresponds to 3 mg/kg of erythromycin.
1833159|NCT00827229|Device|Labor Monitor|
1833160|NCT00827242|Drug|Placebo|Following a 4-week placebo lead-in period, subjects received placebo tablet by mouth once daily over a 12-week period.
1833161|NCT00827242|Drug|tadalafil|Following a 4-week placebo lead-in period, subjects received tadalafil 5 mg tablet by mouth once daily over a 12-week period.
1833162|NCT00827255|Drug|Cyclosporine Ophthalmic Emulsion 0.05%|One drop two times a day approximately 12 hours apart
1833163|NCT00827268|Behavioral|One-on-one treatment of reading difficulties|Multimodal behavioral treatment focused on retraining sound to letter associations and skills in sounding out words when reading. Treatment has been pilot-tested in published papers since 1998.
1833164|NCT00827268|Radiation|Functional Magnetic Resonance Imaging (fMRI)|fMRI during reading pseudowords and during repeating pseudowords, as well as finger tapping (non-language task).
1833165|NCT00827281|Drug|D-cycloserine|Single dosage prior to sessions 3, 4 & 5
1833166|NCT00827281|Drug|Placebo|Single dosage prior to sessions 3, 4 & 5
1833167|NCT00827294|Behavioral|Mirror Therapy|The study is designed as a single group trial comparing pre- and post-treatment measures. Up to 40 subjects will be enrolled. Each subject will receive instruction in performing mirror therapy at home, either in person or by viewing a DVD. Subjects will be asked to practice mirror therapy 20-30 minutes daily. Prior to beginning treatment, subjects will complete standard questionnaires designed to measure phantom pain level, function, depressive symptoms, pain-related anxiety, catastrophizing, and sleep quality. Subjects will also be asked about current use of pain medications and demographic data will be collected. Subjects will complete the same questionnaires 1 month, 2 months, 3 months, and 6 months after beginning treatment. Subjects will also be asked to keep a daily diary to record the frequency of their home treatment sessions. Study staff will check in with the study subjects weekly for the first month after beginning treatment, and monthly thereafter.
1833168|NCT00827307|Drug|tamoxifen|In the monotherapy arm, patients receive once-daily oral dose of tamoxifen 20 mg.
1833169|NCT00827307|Drug|Goserelin|In the combination arm, patients receive ZOLADEX 3.6 mg by subcutaneous injection every 4 weeks along with once-daily oral dose of tamoxifen 20 mg
1833170|NCT00827320|Drug|Levetiracetam|1000 mg tablet
1833171|NCT00827333|Other|educational intervention|Family Caregiver Palliative Care Intervention at weeks 7, 8, 10, and 12 post study enrollment
1833172|NCT00827333|Other|questionnaire administration|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
1833173|NCT00827333|Procedure|end-of-life treatment/management|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
1833174|NCT00827333|Procedure|psychosocial assessment and care|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
1833175|NCT00827333|Procedure|quality-of-life assessment|Occurs at baseline, 7 weeks, 12 weeks, 18 weeks and 24 weeks post enrollment
1833176|NCT00827346|Drug|Clopidogrel|600 mg now
1833177|NCT00827346|Drug|Clopidogrel|600 mg now and 600 mg in 3 hours
1833178|NCT00827346|Drug|Clopidogrel|900 mg now
1833179|NCT00827346|Drug|Clopidogrel|600 mg now and 300 mg in 3 hours
1833180|NCT00827359|Drug|Everolimus|Tablet form taken orally once a day
1833181|NCT00827372|Drug|Pazopanib|Pazopanib will be administered at a starting dose of 800 mg orally once each day.
1833182|NCT00827398|Biological|MSC (hPPL)|Treatment with MSCs (hPPL) is indicated as soon as steroid refractory acute GVHD is diagnosed
1833183|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|modification of aspirin and clopidogrel/Prasugrel maintenance doses based on a biological assay
1833184|NCT00827411|Device|VerifyNow|point of care assay VerifyNow (ACCUMETRICS San Diego USA)
1833185|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|aspirin and clopidogrel/ Prasugrel maintenance doses (according to international guidelines)
1833186|NCT00827411|Drug|Aspirin and clopidogrel / Prasugrel|maintenance dose of clopidogrel / Prasugrel and aspirin
1833187|NCT00827411|Drug|Aspirin|Interruption of clopidogrel / Prasugrel after one year of follow-up
1833188|NCT00827424|Behavioral|Lifestyle counseling by applying a modified PACE protocol|Lifestyle counseling by applying a modified PACE protocol to obese Arab women
1833194|NCT00827450|Dietary Supplement|Partially torrefied, caffeinated coffee|Hypercaloric, high fructose diet + coffee
1833195|NCT00827463|Biological|dosage of the NFS and iron|a blood test will be made.
1833196|NCT00827476|Procedure|ovarian transplantation|ovarian xenotransplantation or in vitro culture
1833197|NCT00827489|Drug|HTC-867|
1833198|NCT00827489|Other|Placebo|
1833199|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fasted state
1833200|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as a powder in capsule formulation in the fed state
1833201|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fasted state
1833202|NCT00827515|Drug|PH797804|Single oral dose of 5mg PH797804 as an immediate release tablet formulation in the fed state
1833203|NCT00827528|Procedure|Traditional correction of anterior vaginal wall prolapse|"Traditional repair.
Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
1833204|NCT00827528|Procedure|Biologic Graft (SIS)|"Biologic graft (SIS - Small Intestine Submucosa) in correction of anterior vaginal wall prolapse.
Patients diagnosed with anterior vaginal wall prolapse will be submitted to surgical correction. They will be randomized to receive a traditional repair or a graft in surgery."
1833205|NCT00827541|Drug|Tigecycline|Tigecycline 50 or 100 mg intravenously. Therapy conducted according to the package leaflet of Tygacil and to international treatment guidelines. Tygacil will be dosed according to labeling. The administration and duration of the therapy will be determined by the treating physician to meet the patient individual needs for treatment.
1833206|NCT00827554|Drug|LMWH|Nadroparin Ca 4100 AXa iu twice daily lasted for 6 weeks
1833207|NCT00827554|Procedure|TACE|transarterial chemoembolization with lipiodol 1-1.5ml/cm tumor diametres，pharmorubicin 20mg，5-Fu 1g and Carboplatin 150mg。
1833208|NCT00827567|Drug|RAD 001|RAD 001-10 mg by mouth once everyday
1833209|NCT00827580|Drug|Eniluracil|
1833210|NCT00827580|Drug|Capecitabine|
1833211|NCT00827593|Behavioral|Standard behavioral weight loss treatment|Participants will receive 12 months of university-based behavioral weight loss treatment
1833212|NCT00827593|Behavioral|Weight Watchers|Participants will receive 12 months of Weight Watchers
1833213|NCT00827593|Behavioral|Combined Treatment|Participants will receive university-based behavioral weight loss treatment followed by Weight Watchers
1833214|NCT00827606|Drug|atorvastatin|Atorvastatin tablets or chewable tablets, 5, 10, 20, 40 mg strengths, once daily, for three years (an 80 mg maximum daily dose is delivered by taking two 40 mg strengths, once daily)
1833215|NCT00827619|Device|Zilver® Flex™ Vascular Stent|Stenting of the Above-the-Knee Femoropopliteal Artery
1833216|NCT00827632|Drug|Low dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.
Dose formula contains 20 ug of ethinyl estradiol (EE) and 100 ug of levonorgestrel (LN) per tablet."
1833217|NCT00827632|Drug|High dose formulation|"Participants are randomized to either Portia (levonorgestrel/ethinyl estradiol tablets, United States Pharmacopeia (USP)0.15 mg/0.03 mg or Lessina (levonorgestrel/ethinyl estradiol tablets, USP 0.1 mg/0.02 mg) for 3 months use.
Dose formula contains 30 ug of ethinyl estradiol (EE) and 150 ug of levonorgestrel (LN) per tablet."
1833219|NCT00827671|Drug|cetuximab|cetuximab initial dose 400 mg/m2 iv 1 week before start radiotherapy and subsequent weekly doses of 250 mg/m2 iv for the duration of the radiation treatment
1833220|NCT00827671|Radiation|radiotherapy to oesophageal tumour|45 Gy delivered in 25 fractions of 1.8 Gy 5d/wk
1833221|NCT00827684|Drug|Irinotecan|
1833222|NCT00827684|Drug|Temsirolimus|
1833223|NCT00827697|Other|Gen-Probe APTIMA Combo2 (AC2)|Laboratory Test
1833224|NCT00827710|Behavioral|point of care patient report cards|gives patient feedback on performance on glycemic, lipid, and blood pressure control relative to expert recommended goals
1833225|NCT00827710|Behavioral|Provider performance report card|Gives provider feedback on performance on their diabetes panel of patients and includes patient level data
1833226|NCT00827736|Procedure|Botox|injection of 10U of BT (Botox®; Allergan, Irvine, California, USA) in the IAS on each side of the anterior midline.
1833227|NCT00827736|Drug|ISDN ointment|application of ISDN 1% ointment 6 times a day
1833228|NCT00827736|Drug|Placebo|"Injection of placebo into internal anal sphincter (ISDN ointment arm)
Applied to the anoderm six times a day (Botox injection arm)"
1833229|NCT00827749|Device|respiratory plethysmography by inductance|contribution of respiratory plethysmography by inductance and informatic tool
1833230|NCT00827762|Drug|Kuvan|20/mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
1833231|NCT00827775|Drug|Carvedilol|Carvedilol 6.25 mg BID titrated weekly to maximum of 50 mg bid
1833232|NCT00827788|Drug|Iodixanol|Iso-osmolar contrast medium (Iodixanol) will be administered during PCI
1833233|NCT00827788|Drug|Iopromide|Low-osmolar contrast medium (Iopromide) will be administered during PCI
1833234|NCT00827801|Behavioral|MDASI-HF Questionnaire|M. D. Anderson Symptom Inventory - Heart Failure (MDASI-HF) questionnaire rating symptoms given in clinic Day 1, Weeks 4 & 8.
1833235|NCT00827814|Drug|Dutasteride|Dutasteride 0.5 mg od.
1833236|NCT00827827|Other|Exercise- Strength Training|3x per week lower-extremity ST lasting approximately 45 minutes to 1 hour.
1833237|NCT00827827|Other|Exercise- Stretching Control|3x per week upper and lower body stretching mixed with active and passive range of motion exercises
1833238|NCT00827840|Drug|Paliperidone ER|3mg to 12mg of Paliperidone ER once a day
1833239|NCT00827840|Drug|Risperidone|1 to 6 mg of risperidone once or twice a day
1833240|NCT00827853|Procedure|Conventional angioplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using conventional angioplasty balloon
1833241|NCT00827853|Procedure|cryoplasty balloon|Post-dilation of clinically indicated nitinol self-expanding stents in the SFA using cryoplasty balloon
1833444|NCT00828685|Procedure|CRPP|Closed reduction, percutaneous pinning
1833242|NCT00827866|Other|Counselor-Initiated Tobacco Quit Line|The proposed active intervention will be a the Counselor-Initiated QL which includes provision of 8 weeks of nicotine replacement therapy (NRT) and six scheduled telephone sessions of a behavioral intervention.
1833243|NCT00827866|Other|Self-Paced Tobacco Quit Line|The comparison condition will be the Self-Paced QL with provision of 2 weeks of NRT and encouraged obtainment of additional NRT. If participants in the Self-Paced condition make all six calls, they will receive the same behavioral intervention as in the Counselor-Initiated condition.
1833244|NCT00827879|Behavioral|Strength at Home Couples Group|A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.
1833245|NCT00827879|Behavioral|Supportive Group Therapy|A general support group designed to enhance support for healthy relationship building.
1833246|NCT00827892|Drug|Pioglitazone|Escalating doses for 3 days, then 30 mg orally daily for the duration of the study as determined by MRI
1833247|NCT00827892|Drug|Placebo Control|Lactose Capsule administered by mouth daily for the duration of the study as determined by MRI
1833248|NCT00827905|Device|RSpot Non-Contact Respiratory Rate Spot Check|The Kai Sensors RSpot 100 provides a measurement of respiratory rate at a single point in time. It uses a low-power radar to detect respiratory effort, and analyzes the respiratory effort signal to provide a respiratory rate.
1833249|NCT00827918|Drug|MK-8998|MK-8998 6 mg capsules twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 8 mg capsules twice daily. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
1833250|NCT00827918|Drug|Comparator: Olanzapine|Olanzapine 5 mg tablets twice daily with food on Days 1 through 7. On Day 8, dosage will be increased to 5 mg tablets in the morning and 10 mg tablets in the evening. Treatment period is 4 weeks. There will be a period of time when all participants will receive placebo.
1833251|NCT00827918|Drug|Comparator: Placebo|Placebo tablets matching olanzapine tablets and MK-8998 capsules
1833252|NCT00827931|Drug|Tranexamic acid + Standard of Care|Tranexamic acid given slowly intravenously (15 mg/kg body weight) 15 minutes before surgery followed by a second dose at three hour interval from first dose and third dose at three hour interval from the second + standard of care (Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss)
1833253|NCT00827931|Procedure|Standard of Care|Standard of care includes the routine surgical and anesthetic techniques being utilized to control blood loss
1833254|NCT00827944|Device|Parietex Progrip|"Surgical technique:
Self-gripping lightweight Polyester and Polylactic acid meshes providing a sutureless fixation."
1833255|NCT00827944|Device|Low weight polypropylene mesh|"Surgical technique:
Lichtenstein repair with lightweight polypropylene mesh (inferior to 70gr/m2) secured to the posterior inguinal wall with sutures"
1833256|NCT00827957|Device|Internal Cooling|The intravascular cooling system uses a single lumen (8.5 Fr,38 cm) central venous catheter inserted into the inferior vena cava via the left or right femoral vein. Normal saline is pumped through three balloons mounted on the catheter and returned to a central system in a closed loop. The saline flow within the balloons is in close contact with the patient's blood flow and serves as a heat exchange system. An automatic temperature control device adjusts the temperature of the circulating saline (4°C to 42°C) based on the patient's core temperature.
1833257|NCT00827957|Device|External Cooling|The gel-coated external cooling device consists of four water circulating gel coated energy transfer pads, and is placed on the patient's back, abdomen, and both thighs. Depending on the size used, the total surface area ranges between 0.60 and 0.77 m2. It is connected to an automatic thermostat controlling the temperature of the circulating water (4°C to 42°C) based on the patient's core temperature.
1833258|NCT00827970|Behavioral|Screening for urogenital Chlamydia trachomatis|Receeiving an invitation to be tested for urogenital Chlamydia trachomatis by use of a home-obtained and mailed sample.
1833259|NCT00827983|Drug|Progesterone|25 mg, s.c., once à day
1833260|NCT00827983|Drug|Progesterone|90 mg, vaginally, once à day
1833261|NCT00827996|Drug|adalimumab|Subjects will be given subcutaneous injections at weeks 0 (160mg), 2 (80mg), and then every other week (40mg) until week 12
1833268|NCT00828022|Biological|attenuated measles vaccine|4-week apart, two vaccines starting 4 weeks after last chemotherapy
1833269|NCT00828035|Procedure|laparoscopic surgery|comparison of two different laparoscopic surgeries : robot versus human
1833270|NCT00828061|Drug|Placebo|Single dose of 5 tablets matching placebo (5 x 0 mg) to prednisone. The washout between treatment periods will be approximately 4 weeks
1833271|NCT00828061|Drug|prednisone|Single dose of 5 tablets prednisone totaling 10 mg (3 x 0 mg + 2 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
1833272|NCT00828061|Drug|prednisone|Single dose of 5 tablets prednisone totaling 25 mg (5 x 5 mg). The washout between treatment periods will be approximately 4 weeks.
1833273|NCT00828074|Drug|sorafenib tosylate|Dose level 1 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 2 = 200 mg by mouth two times a day on days 1-28 of a 28 day cycle. Dose level 3 = 200 mg by mouth in the am and 400 mg by mouth in the pm on days 1-28 of a 28 day cycle. Dose level 4 = 400 mg by mouth two times a day on days 1-28 of a 28 day cycle.
1833274|NCT00828074|Drug|vinorelbine ditartrate|Dose level 1 = 20 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 2 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 3 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle. Dose level 4 = 25 mg/m2 IV weekly on days 1, 8, and 15 of a 28 day cycle.
1833275|NCT00828087|Drug|Everolimus Eluting Coronary Stent System|Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
1833276|NCT00828087|Device|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)|cobalt chromium balloon expandable stent ( non drug eluting stent Arm)implantation
1833445|NCT00828685|Procedure|ORIF|Open reduction, internal fixation
1833446|NCT00828698|Other|No intervention|
1833277|NCT00828100|Device|fluID Rapid Influenza Test|The fluID™ Rapid Influenza Test is an in vitro diagnostic assay designed to be used with a reader for the qualitative detection of influenza type A and type B nucleoprotein antigens, and the differentiation of influenza type A subtypes A/H1 and A/H3 antigens associated with the seasonal influenza H1N1 and H3N2, in nasal swabs, nasopharyngeal swabs and nasal wash/aspirate specimens. The test is intended as an aid in the rapid, qualitative diagnosis of influenza type A and type B viral infections in patients symptomatic with influenza-like illness. The fluID™ Rapid Influenza Test is intended for use by a healthcare professional in a laboratory or Point-of-Care (POC) setting.
1833278|NCT00828100|Device|BinaxNOW® Influenza A & B|The BinaxNOW Influenza A & B Test is an in vitro immunochromatographic assay for the qualitative detection of influenza A and B nucleoprotein antigens in nasopharyngeal (NP) swab and nasal wash/aspirate specimens. It is intended to aid in the rapid differential diagnosis of influenza A and B viral infections. Negative test results should be confirmed by culture.
1833279|NCT00828113|Drug|varenicline|Extension of 1 mg twice daily treatment to 52 weeks
1833280|NCT00828113|Drug|varenicline|Double-blind switch to placebo after 12 weeks of open-label therapy
1833281|NCT00828113|Behavioral|Individual smoking cessation counseling|Brief (<10 minutes) smoking cessation counseling delivered at clinic visits
1833282|NCT00828126|Procedure|PET-CT Scan|Positron emission tomography-computed tomography (PET-CT) scan performed within 30 days of contrast-enhanced CT.
1833283|NCT00828139|Biological|ziv-aflibercept|Given IV
1833284|NCT00828139|Drug|topotecan hydrochloride|Given IV
1833285|NCT00828152|Behavioral|Internet-delivered CBT.|12 weeks. Therapist contact through e-mail.
1833286|NCT00828152|Behavioral|On line discussion group|Placebo. On line discussion group.
1833287|NCT00828165|Drug|ARRY-300, MEK inhibitor; oral|single dose, escalating
1833288|NCT00828165|Drug|Placebo|matching placebo
1833289|NCT00828178|Drug|Omega-3|Omega-3-acid ethyl esters (Lovaza) 3 gram once a day for 12 weeks
1833290|NCT00828178|Device|flow-mediated dilation of the brachial artery|flow-mediated dilation of the brachial artery measurement at baseline and after 12 weeks
1833291|NCT00828178|Other|corn starch|3 capsules qd for 12weeks
1833292|NCT00828191|Drug|Progesterone|25 mg, once a day, SC
1833293|NCT00828191|Drug|Progesterone|100 mg, twice a day, vaginally
1833294|NCT00828204|Device|single-use autoinjector with a prefilled liquid Avonex syringe|
1833295|NCT00828204|Device|Avonex prefilled syringe via manual IM injection|
1833296|NCT00828204|Drug|BG9418 (interferon beta-1a)|
1833297|NCT00828217|Other|adapted physical activity|one session of adapted physical activity per day (30 minutes each session), during the whole stay at the hospital
1833298|NCT00828230|Drug|budesonide|One application of 2mg budesonide once daily for 8 weeks
1833299|NCT00828230|Drug|Placebo foam|One application of placebo foam once daily for 8 weeks
1833300|NCT00828243|Drug|Nutrient|We administer stable isotopically labeled precursors of surfactant phospholipids (palmitate and acetate) and of surfactant-associated proteins (leucine) to infants with neonatal respiratory distress syndrome. We measure with mass spectrometry incorporation of stable isotopically labeled precursors into tracheal aspirates to estimate surfactant phospholipid and protein kinetics.
1833301|NCT00828256|Procedure|arthroscopy of shoulder|arthroscopic repair of chronic rotator cuff tears
1833302|NCT00828269|Procedure|Comparator: Fine needle aspiration biopsy|"Visit 1: Screening Visit 2 (7-14 days from screening): Core needle biopsy and fine needle aspiration biopsy - liver.
Visit 3:(7 days from visit 2): Fine needle aspiration biopsy - liver. Visit 4: (14 days from Visit 3): follow-up visit"
1833303|NCT00828282|Drug|Simvastatin|Treatment will be administered on an outpatient basis. Subjects will be given 7.5 mg/kg twice daily of Simvastatin for 7 days on a 21-day cycle with a goal of 6 cycles.
1833304|NCT00828295|Drug|palonosetron|palonosetron IV 1 mcg/kg
1833305|NCT00828295|Drug|palonosetron|palonosetron 3mcg/kg IV
1833306|NCT00828308|Drug|Ixabepilone|Ixabepilone, 16 mg/m2 or 20mg/m2, weekly x 3, in 4 week cycles, x 4 cycles.
1833307|NCT00828308|Procedure|Prostatectomy|
1833308|NCT00828321|Drug|Ramipril 10 mg capsule|1 x 10 mg
1833309|NCT00828321|Drug|Altace® 10 mg capsule|1 x 10 mg
1833310|NCT00828347|Drug|1.0 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 1.0 μg/day in patients whose iPTH level was controlled to < 150 pg/mL by initial maxacalcitol therapy.
1833311|NCT00828347|Drug|0.25 μg/day Alfacalcidol|We compared the efficacy of two protocols for maintenance therapy, which were oral administration of alfacalcidol at a dose of 0.25 μg/day in patients whose iPTH level was controlled to < 150 pg/mL by initial maxacalcitol therapy.
1833312|NCT00828373|Drug|Placebo|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the Placebo group this will be physiologic saline. The infusion will be stopped after complete recovery from the neuromuscular block.
1833313|NCT00828373|Drug|Lidocaine|Immediately before induction, patients will receive 0.15 ml kg-1 of the study drug as an intravenous bolus followed, after tracheal intubation, by a continuous intravenous infusion of 0.2 ml kg-1 h-1. In the lidocaine Arm this regimen corresponds to 1.5 mg kg-1 lidocaine bolus injection and 2 mg kg-1 h-1 lidocaine continuous infusion. The infusion will be stopped after complete recovery from the neuromuscular block.
1833314|NCT00828386|Procedure|Induction chemotherapy + concurrent radiochemotherapy vs. concurrent radiochemotherapy|Induction chemotherapy (Docetaxel, Cisplatin and 5-Fluorouracil) + concurrent radiochemotherapy
1833315|NCT00828399|Dietary Supplement|Glutamine|Oral glutamine 30g/day
1833316|NCT00828399|Dietary Supplement|Whole protein|Oral whole protein 30 g/day
1833317|NCT00828412|Device|EpiCeram Skin Barrier Emulsion|topical cream, twice daily, 6 weeks
1833318|NCT00828412|Drug|Desonide Cream 0.05%|topical cream, twice daily, 6 weeks
1833319|NCT00828438|Drug|Lorcaserin 10mg|
1833701|NCT00835432|Device|Biogide|controls
1833321|NCT00828464|Drug|clobetasol propionate|Clobetasol propionate. The study product will be applied topically twice a day (morning and evening) for 14 days of treatment.
1833322|NCT00828477|Drug|Xibrom|Xibrom: two times a day for seven days in the first eye.
1833323|NCT00828477|Drug|Nevanac|Nevanac: three times a day for seven days in the second eye.
1833324|NCT00828490|Behavioral|provider feedback|The provider-level intervention includes a targeted review of trigger-flagged beneficiaries' drug utilization history and an information packet sent to providers which includes patient-specific pharmacy and medical claims history, patient specific recommendations, and provider comparative profiling.
1833325|NCT00828490|Behavioral|patient intervention|The patient intervention arm includes the provider-level intervention mentioned above in addition to Medication Therapy Management Services (MTMS), a program that provides patients one-on-one therapy counseling administered by community pharmacists who have completed an MTMS certificate program.
1833326|NCT00828490|Behavioral|Process-level|The process-level intervention includes the provider-level intervention plus in-clinic evidence-based quality improvement workshops with opportunity for CME credit
1833327|NCT00828503|Drug|Certican (everolimus) + valganciclovir|"Oral MED 1: Certican® initial dose: 1,5-3 mg day target trough level: 3-8 ng/mL (first levels will be performed after 3 days and then adjusted until - according to the judgement of the clinical investigator - a stable degree of immunosuppression is reached; thereafter Certican® trough levels will be performed at the scheduled appointments)
MED 2: Valganciclovir (or ganciclovir) will be administered in addition to Certican (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)"
1833328|NCT00828503|Drug|Valganciclovir|Valganciclovir (or ganciclovir) will be administered alone (valganciclovir: 450 mg twice daily, ganciclovir 5 mg/kg i.v. twice daily)
1833329|NCT00828516|Other|Acupuncture and moxibustion|Acupuncture is a form of traditional east Asian medicine that uses needles inserted superficially under the skin to stimulate sites on the body known as acupuncture points. Traditional practice encompasses moxibustion, the application of heat (usually from the smouldering herb artemisia vulgaris or mugwort) to stimulate the points by warming them.
1833330|NCT00828529|Drug|TMC207|
1833331|NCT00828542|Drug|etonogestrel implant|Etonogestrel-releasing subdermal implant (Implanon) inserted during the immediate postpartum period (from 24 to 48 hours postpartum)
1833332|NCT00828542|Drug|depot medroxyprogesterone acetate|150 mg medroxyprogesterone administered I.M. every three months starting 6 weeks after delivery
1833333|NCT00828555|Other|Vaccination Program|Design & implement a program for Ob/Gyns to vaccinate women against human papillomavirus, influenza, & pertussis
1833334|NCT00828568|Drug|Imiquimod 5% manufactured by Taro|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
1833335|NCT00828568|Drug|Aldara - Imiquimod 5%|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
1833336|NCT00828568|Drug|Imiquimod Vehicle manufactured by Taro|Treatment applied as a thin layer to target area once daily, 2 days each week, for 16 weeks
1833337|NCT00828581|Drug|lorcaserin|
1833338|NCT00828594|Drug|RAD001|
1833339|NCT00828594|Drug|RAD001, sorafenib|
1833340|NCT00821288|Behavioral|Survivorship Intervention|"Survivorship Consultation is a one hour consultation in a survivorship clinic. The consultation will be performed by a nurse practitioner under the supervision of a medical oncologist. The consultation will result in a detailed written document outlining the individuals Survivorship Prescription including treatment summary, surveillance recommendations, risk for late-effects, cancer screening recommendations, genetic risk, and life style recommendations. This written document will be provided to the patient and her treating physician. In addition, referrals will be made to appropriate adjunct services as needed (e.g. psychologist, nutritionist, social worker)."
1833341|NCT00821288|Behavioral|Facing Forward|Facing Forward: Life after Cancer Treatment is a guide for people who were treated for cancer published by the NCI. It is a 24-page manual that summarized many key issues of interest to cancer survivors during the re-entry phase, and contains sections on medical care after treatment, symptoms after treatment, feelings after treatment, social relationships after cancer treatment, and dealing with practical matters such as insurance and employment. The manual is available in English and Spanish. This will be given at the time of registration and the table of contents will be reviewed with the patient.
1833342|NCT00821301|Drug|Fluphenazine HCl|Fluphenazine HCl will be administered intravenously. To quickly reach and maintain the target bone marrow concentration for 18 hours, the study drug will be administered using 3 bolus injections (0, 6, and 12 hours). Fluphenazine will be dose-escalated according to a modified Fibonacci scheme, terminating in 40% increments. Treatments will be administered on days 1 and 8 of every 21 day cycle.
1833343|NCT00821327|Drug|Gemcitabine, Cisplatin, Sunitinib|"Patients will receive gemcitabine 800 mg/m2 IV (Days 1 and 8), cisplatin 60 mg/m2 IV (Day 1), and sunitinib 37.5 mg PO daily (Days 1-14) of each 21-day cycle.
2. One cycle of treatment is defined as 21 days (3 weeks). Restaging studies will be performed after every 3 cycles of therapy.
3. Successive cycles will be initiated every 3 weeks, and will be continued through 6 cycles unless a patient shows evidence of disease progression or intolerable toxicity."
1833344|NCT00821340|Genetic|rAAV2-hRPE65|Uniocular subretinal injections; relative doses: Cohort 1 - basic (lowest) viral dose; Cohort 2 - higher (1.5 times basic) viral dose; Cohort 3 - patients 8-17 years of age will receive basic viral dose; patients 18 years of age and over will receive higher dose;
1833345|NCT00821353|Procedure|RF catheter ablation|RF catheter ablation
1833346|NCT00821353|Drug|Antiarrhythmic drugs|One of AA drugs (preferably Amiodarone) and cardioversion in cases of chronic AF
1833347|NCT00821366|Behavioral|ARV peer adherence support (PAS)|Adherence support provided during twice weekly visits to the patient by an experienced ART patients who received basic training in ARV peer adherence support
1833348|NCT00821366|Dietary Supplement|Nutritional support|Weekly delivery by peer adherence supporter (PAS) of two 400g cans of meatballs and spaghetti in tomato sauce
1833349|NCT00821366|Drug|ARV treatment|Households including ARV patients who receive the ARV treatment and associated support provided as part of government's ARV treatment programme
1833350|NCT00821392|Drug|Febuxostat|
1833351|NCT00821418|Device|PulseHaler treatment|treatment is for two weeks, 3 times per day
1833352|NCT00821418|Device|CPAP treatment (through a deactivated version of PulsHaler)|treatment is for two weeks, 3 times per day
1833353|NCT00821431|Device|Compression Device|"Subjects randomized to the compression device regime were instructed to wear the compression device for all wakings hours for 12 weeks. The device was applied at the following pressures:
Foot 40 mmHg, ankle 40 mmHg, mid-calf 30 mmHg, upper cuff 20 mmHg.
Subjects were instructed to wear the Intermittent Pneumatic Compression for 2 hours per day."
1833354|NCT00821431|Device|Profore|Subjects randomised to the 4-layer compression bandage regime, Profore, were to wear the bandage system for 24 hours a day and bandage applications/dressing changes were to be performed by a trained health care professional. Four different sizes of Profore were available and size selection was based on measurement of the ankle circumference of the subject on the index leg. Profore was to be used according to the instructions provided by the manufacturer described in their package insert.
1833355|NCT00821444|Drug|ziprasidone|40 mg capsule, single dose x 3
1833356|NCT00821444|Drug|B16 Fasted|40 mg tablet, single dose X 3
1833357|NCT00821444|Drug|B16 Fed|40 mg tablet, single dose X 3
1833358|NCT00821457|Drug|Juvista|250ng
1833359|NCT00821457|Drug|Placebo|Powder for solution for injection
1833360|NCT00821457|Drug|Juvista|500ng
1833361|NCT00821470|Procedure|core decompression|core decompression procedure only
1833362|NCT00821470|Procedure|Bone marrow implantation into the necrotic lesion|
1833363|NCT00821483|Drug|Frovatriptan|2.5mg, qd
1833364|NCT00821496|Drug|ethinyl estradiol, norethindrone, VI-0521|Oral contraceptive
1833365|NCT00821509|Behavioral|Hand washing|Instructions for proper coughing and sneezing, and for reduced hand shaking, frequent hand washing in office and at home
1833366|NCT00821509|Behavioral|Disinfectant rubbing|Instructions for proper coughing and sneezing, and for reduced hand shaking; frequent rubbing of hands with alcohol containing disinfectant in office and at home
1833367|NCT00821522|Procedure|Remote Ischemic Preconditioning|Three 5-minute intervals of leg ischemia induced by tourniquet inflation, prior to initiation of cardiopulmonary bypass.
1833368|NCT00821535|Drug|maraviroc (Selzentry, Celsentri)|12 subjects will receive a single dose of 300 mg maraviroc (two 150 mg maraviroc commercial tablets) under fasting conditions.
1833369|NCT00821548|Procedure|electrostimulation|Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients
1833370|NCT00821561|Drug|Nexagon®|
1833371|NCT00821561|Drug|Nexagon® vehicle|
1833372|NCT00821574|Drug|Fluvastatin|Fluvastatin: daily 80 mg, oral
1833373|NCT00821574|Drug|Valsartan|Valsartan: daily 160 mg, oral
1833374|NCT00821574|Drug|Hydrochlorothiazide|Hydrochlorothiazide: daily 12.5mg, oral
1833375|NCT00821587|Drug|Cyclosporine|Patients randomized to CsA had TAC discontinued and were treated with CsA at a dose of 2.0-4.0 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 150-200 ng/ml.
1833376|NCT00821587|Drug|Tacrolimus|Patients receiving TAC were treated with a dose of 0.08-0.12 mg/kg/day orally in two divided doses with target trough whole blood concentrations of 10-15 ng/ml for the first month post-transplant followed by 5-10 ng/ml thereafter. Immunosuppression was typically tapered to monotherapy (TAC alone) within 4-6 months of transplantation.
1833377|NCT00821600|Drug|risperidone IR and LAI formulation|1 mg risperidone IR single injection, followed after 7 to 14 days with 75mg risperidone 4-week-LAI single injection
1833378|NCT00821626|Device|BD Directigen EZ Flu A+B|Naso-pharyngeal swab and rapid flu test
1833379|NCT00821626|Other|Control|No rapid flu test
1833380|NCT00821639|Behavioral|Counseling, educational pamphlet and a sticker|Infants exposed to secondhand smoke will be recruited and randomized based on parents to receive or not receive counseling, an educational pamphlet and a sticker on SHS.
1833383|NCT00821665|Dietary Supplement|Sucrose consumption|Sucrose
1833384|NCT00821665|Dietary Supplement|water consumption|water
1833385|NCT00821678|Other|Telemedicine Outreach for PTSD|The intervention involves an off-site PTSD care team (tele-psychiatrist, tele-psychologist, tele-pharmacist, and tele-nurse care manager) and uses telemedicine technologies (telephone, interactive video and electronically shared medical records). A dedicated nurse telephone care manager educates/activates patients, identifies preferences, overcomes treatment barriers, monitors symptoms, side-effects and adherence, identifies psychiatric comorbidities, and encourages patient self-management. Tele-pharmacists provide medication management by phone. Tele-psychologists provide Cognitive Processing Therapy via interactive video. Tele-psychiatrists supervise the off-site care team as well as conduct consultations and provide medication management via interactive video.
1833386|NCT00821691|Drug|Amantadin|Amantadin caps
1833387|NCT00821691|Drug|Placebo|Placebo caps
1833388|NCT00821717|Drug|Ferinject ® (Ferric carboxymaltose)|"Ferinject® will be administered in doses of 200 mg (4 mL) weekly up to iron repletion (correction phase of variable duration depending on individual iron deficit). The calculated dose will be rounded to the next 100 mg iron, i.e. the final dose may be 100 mg iron depending on the individual iron deficit.
After the correction phase, Ferinject® will be given monthly in doses of 200 mg until the 24th week (maintenance phase)."
1833389|NCT00821717|Drug|Normal saline (0.9%)|During the correction phase, patients will receive the number of normal saline injections (4 mL weekly) corresponding to the calculated total iron dose needed according to the individual iron deficit. During the maintenance phase, placebo patients will receive 4 mL normal saline monthly.
1833390|NCT00821743|Device|Deep brain stimulation electrode|The DBS electrodes (model 3389, Medtronic) will be stereotactically implanted bilaterally in the PPN, according to the technique usually used for STN-DBS, and connected to the subcutaneously implanted stimulator (Kinetra, Medtronic).
1833391|NCT00821756|Behavioral|OPAC (Outreach, Problem solving, Adherence, Continuity)|Assertive outreach immediately after the suicide attempt with about 8 home visits plus contact by telephone, phone messages, e-mails. Duration of intervention 6 months.
1833392|NCT00821782|Drug|Levofloxacin; Azithromycin|
1833393|NCT00821795|Drug|NPH/Regular 70/30 mix|injectable solution, subcutaneous,0.3-0.5 units/kg/day divided into twice per day dosage, 16 weeks duration
1833394|NCT00821795|Drug|insulin aspart protamine/insulin aspart 70/30 mix|injectable solution, subcutaneous, 0.3-0.5 units/kg/day divided into twice per day dosage, for 16 weeks
1833395|NCT00821808|Device|Compression Device|"The compression device will be worn for 8 hours each day on one leg. The device will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:
Immediately following device application
1 hour
4 hours
8 hours"
1833396|NCT00821808|Device|Profore®|"Profore® will be worn for 8 hours each day on opposite leg. Profore® will be applied by the same clinician every morning.Interface pressure measurements will be made in both the sitting and standing position at three locations on the leg at the following time intervals:
Immediately following device application
1 hour
4 hours
8 hours"
1833397|NCT00821821|Drug|MCI-186|"Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion
Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion"
1833398|NCT00821821|Drug|Placebo|"Cohort1:circa 1000mg / 72-hour infusion matching placebo
Cohort2:circa 2000mg / 72-hour infusion matching placebo"
1833399|NCT00821834|Drug|clopidogrel (SR25990)|"Form: tablets
Route: oral"
1833400|NCT00821834|Drug|ticlopidine|"Form: tablets
Route: oral"
1833401|NCT00821834|Drug|Placebo|"Form: tablets
Route: oral"
1833402|NCT00821847|Other|DEXA scan|DEXA scan
1833403|NCT00821860|Other|talc|Talc pleurodesis
1833404|NCT00821860|Procedure|therapeutic thoracoscopy|Talc pleurodesis via thoracoscopy
1833405|NCT00821860|Procedure|therapeutic videothoracoscopy|Video-assisted thoracoscopic pleurectomy
1833406|NCT00821873|Other|CR Plug|CR Plug will be placed in the harvest site
1833407|NCT00821886|Drug|Ixabepilone|Ixabepilone 40mg/m2 IV infusion over 3 hours on day 1 of cycles 1-6 (all treatment cycles are 21 days in length)
1833408|NCT00821886|Drug|Trastuzumab|Trastuzumab 8mg/kg IV over 90 minutes for the first infusion (Cycle 1, Day 1) with a 60 minute post-infusion observation period. Subsequent infusions (Day 1 of Cycles 2-6 with all cycles being 21 days in length) 6mg/kg over 30 minutes if the previous dose was well tolerated; peri-operative trastuzumab 6mg/kg IV every 3-4 weeks; post-operative trastuzumab 6mg/kg IV day 1 every 3 weeks until week 52
1833409|NCT00821886|Drug|Carboplatin|Carboplatin AUC=6 IV per institutional guidelines on Day 1 of Cycles 1-6 (all treatment cycles are 21 days in length)
1833410|NCT00821899|Biological|administration of autologous bone marrow blood|administration of autologous bone marrow blood through magna pancreatic artery after femoral catheterization once during 12-month study period
1833411|NCT00821912|Drug|Docetaxel|30 mg/m2, administered as a 30 min. i.v. infusion on cycle day 1, 8 and 15 or cycle day 1 and 8 in an alternating 3 weekly schedule
1833412|NCT00821912|Drug|Capecitabine|1650 mg/m2 /day orally b.i.d., day 1-14 every 3 weeks.
1833413|NCT00821925|Procedure|bone densitometry|All patients do a bone densitometry after the inclusion.
1833414|NCT00821938|Procedure|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Responder-arm, will be permanently paced bi-ventricularly
1833415|NCT00821938|Procedure|LV dp/dt pressure measurement|Assessment of response to bi-ventricular pacing. Non-esponder-arm, will be treated with standard ICD-treatment
1833416|NCT00821951|Drug|Vorinostat|200 mg, 300 mg, 400 mg, once per RT fraction
1833417|NCT00821951|Radiation|Radiotherapy|Standard fractionation of 3.0 Gy per day over 2 weeks, to a total dose of 30 Gy, will be utilized for all patients. All patients will be treated one time per day, 5 days per week unless interruption is clinically indicated.
1833418|NCT00821964|Drug|imiquimod|Given topically
1833419|NCT00821964|Drug|Abraxane|Given IV
1833420|NCT00821964|Other|laboratory biomarker analysis|Correlative studies
1833421|NCT00821964|Genetic|RNA analysis|Correlative studies
1833422|NCT00821964|Other|immunoenzyme technique|Correlative studies
1833423|NCT00821977|Drug|Vildagliptin|
1833424|NCT00821977|Drug|Vildagliptin|
1833425|NCT00821977|Drug|Placebo|
1833426|NCT00821990|Drug|Chemotherapy|The administration of chemotherapy regimen (docetaxel or irinotecan) will be determined at the discretion of investigator, and depends on the patient's previous chemotherapy.
1833427|NCT00821990|Other|Best supportive care|It includes nutritional support, analgesics, antibiotics, antiemetics, transfusions, or any other symptomatic therapy (with the exception of cytotoxic chemotherapy) and/or assistance of a psychological support. Localized radiotherapy to alleviate symptoms such as pain is allowed provided that the total dose delivered is in a palliative range.
1833428|NCT00828620|Other|Imaging study|PET-CT
1833429|NCT00828646|Drug|BMS-708163|Capsules, Oral, 50 mg, once daily, 14 days
1833430|NCT00828646|Drug|BMS-708163|Capsules, Oral, 100 mg/day, once daily, 14 days
1833431|NCT00828646|Drug|BMS-708163|Capsules, Oral, 75 or 100 mg/day, once daily, 14 days
1833432|NCT00828646|Drug|Placebo|Capsules, Oral, once daily, 14 days
1833433|NCT00828659|Drug|Placebo|
1833434|NCT00828659|Drug|Active Comparator #1|
1833435|NCT00828659|Drug|Active Comparator #2|
1833436|NCT00828659|Drug|Active Comparator #3|
1833437|NCT00828659|Drug|Lorcaserin Dose #1|
1833438|NCT00828659|Drug|Lorcaserin Dose #2|
1833439|NCT00828659|Drug|Lorcaserin Dose #3|
1833440|NCT00828672|Drug|Oxaliplatin|Administered on days 15,22,29,36 en 43; 50 mg/m2
1833441|NCT00828672|Drug|Bevacizumab|Administered on days 1,15,29 and 43 ; 5mg/kg
1833442|NCT00828672|Drug|Capecitabine|825 mg/m2 ; 25 days - 5days per week, concurrent with radiotherapy
1833443|NCT00828672|Radiation|radiotherapy|Total dose 45Gy
1833447|NCT00828711|Drug|MVI 100|Dose reservoir of 100 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 100 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
1833448|NCT00828711|Drug|MVI 150|Dose reservoir of 150 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 150 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
1833449|NCT00828711|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
1833450|NCT00828724|Drug|Lorcaserin 10mg|
1833451|NCT00828737|Drug|Gadobutrol (Gadovist, BAY86-4875)|Gadovist in approved indications at approved dosages
1833452|NCT00828750|Drug|Eltrombopag oral tablets|Eltrombopag oral tablets once daily
1833453|NCT00828763|Drug|[14c}-GSK1349572|HIV-Integrase inhibitor labelled with a carbon 14 marker
1833454|NCT00828776|Biological|Heparin sodic - Cristália|5000UI/mL
1833455|NCT00828776|Biological|heparin - Liquemine (Roche)|5000UI/mL
1833456|NCT00828789|Drug|Efavirenz; Tenofovir disoproxil fumarate; Telaprevir|
1833457|NCT00828802|Drug|Lenalidomide, Decitabine|Decitabine 20mg/m2 over one hour IV for 5 days, with cycles repeated every 28 days. Lenalidomide given orally on Days 1-21 followed by 7 days of rest at various dose escalated cohorts (5 mg, 10mg, 15mg, 20 mg, 25 mg)
1833458|NCT00828815|Drug|TMC125|
1833459|NCT00828828|Biological|Influenza Vaccine|One 0.5 ml dose of influenza vaccine injected intramuscular.
1833460|NCT00828841|Drug|Cetuximab|Cetuximab will be administered at a loading dose of 400 mg/m2 on Day 1, Cycle 1 and at a dose of 250 mg/m2 weekly during chemotherapy. During the maintenance period, cetuximab will be dosed at 500 mg/m2 every two weeks.
1833461|NCT00828841|Drug|Paclitaxel|Paclitaxel 200 mg/m2 Day 1 every 21 days
1833462|NCT00828841|Drug|Carboplatin|Carboplatin AUC 6 Day 1 every 21 days
1833463|NCT00828841|Drug|Gemcitabine|Gemcitabine 1,000 mg/m2 Days 1 and 8 every 21 days
1833464|NCT00828841|Drug|Cisplatin|Cisplatin 75 mg/m2 Day I every 21 days
1833465|NCT00828854|Drug|entinostat (SNDX-275)|5 mg PO every week
1833466|NCT00828867|Drug|100 mg GSK investigational drug|
1833467|NCT00828867|Drug|200 mg GSK investigational drug|
1833468|NCT00828867|Drug|400 mg GSK investigational drug|
1833469|NCT00828867|Drug|800 mg GSK investigational drug|
1833470|NCT00828867|Drug|2000 mg GSK investigational drug|
1833471|NCT00828867|Drug|1500 mg GSK investigational drug|
1833472|NCT00828867|Drug|800mg fed GSK investigational drug|
1833473|NCT00828867|Drug|3000mg GSK investigational drug|
1833474|NCT00828867|Drug|4000mg GSK investigational drug|
1833475|NCT00828880|Device|DRX9000|DRX9000 - non-invasive spinal decompression. Treatments 28 min 5 x/wk x 2wks, 3x/wk x 2 wks, 2x/wk x 2 wks for a total of 20 treatments in a 6-week period
1833476|NCT00828893|Device|navigation station|navigation station for gestures (carried out under CT) guidance
1833477|NCT00828906|Drug|DuoTrav|DuoTrav Eye Drops
1833478|NCT00828919|Drug|axitinib|BID oral tablets. dose of AG 013736 will be the same as they were taking in the previous trial
1833479|NCT00828932|Drug|Lorcaserin|
1833480|NCT00833742|Behavioral|Intensive Short-term Dynamic Psychotherapy|A brief psychotherapy format
1833481|NCT00833755|Drug|Ketamine|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
1833482|NCT00833755|Drug|Placebos|To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
1833483|NCT00833768|Drug|Sevelamer carbonate|800mg tablets to be taken orally with meals three times per day
1833484|NCT00833768|Drug|Placebo for sevelamer carbonate|Placebo tablets to be taken orally with meals three times per day
1833485|NCT00833781|Biological|mRNA-transfected autologous dendritic cells|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
1833486|NCT00833781|Biological|autologous dendritic cells with no mRNA transfection|Injections will be administered intradermally at weeks 0, 2, 6 and 10.
1833487|NCT00833794|Drug|Tramadol Once a day|
1833488|NCT00833794|Drug|Placebo|
1833489|NCT00833807|Drug|Nab-Paclitaxel (Abraxane)|"Day 1 of Cycles 1-6, Starting Dose of 130 mg/m2 received through arterial catheter over 30 minutes. Cycle is 21 Days.
Day 1 of Cycle 7+, Dose received through catheter in vein over 30 minutes. Cycle is 21 Days."
1833490|NCT00833820|Procedure|Real rTMS of the brain|Repetitive transcranial magnetic stimulation will be performed using a focal coil held over motor cortex on each hemisphere. Stimulation protocol used will be the cTBS in which three pulses of stimulation are given at 50 Hz, repeated every 200 ms for a total of 300 pulses delivered over the right motor cortex. The stimulus intensity will be set at 80% of Action Motor Threshold.
1833491|NCT00833820|Procedure|Sham rTMS of the brain|Sham repetitive transcranial magnetic stimulation will be performed using the same stimulator connected to the placebo butterfly coil MCF-P-B-65 which has no stimulating effect on the cortex but produces similar auditory and tactile sensations as the active coil. The site of stimulation and the number of stimuli will be identical to those used for the active magnetic rTMS.
1833492|NCT00833833|Drug|Pomalidomide|1 mg, 2 mg, and 5 mg capsules for oral administration packaged in bottles containing a 21-day supply
1833493|NCT00833833|Drug|Dexamethasone|oral dexamethasone
1833494|NCT00833833|Drug|Aspirin|As prophylactic anti-thrombotic treatment, all participants were given aspirin 81-100 mg daily (commercial supply) unless contraindicated. If aspirin was contraindicated, participants were given another form of anti-thrombotic therapy according to hospital guidelines or physician preference.
1833497|NCT00833872|Drug|LEO 22811|First-in-man
1833498|NCT00833872|Drug|placebo solution|
1833499|NCT00833885|Device|Masks|Wearing of surgical masks
1833500|NCT00833885|Device|Masks & hand hygiene|Wearing of surgical masks and intensified hand washing
1833501|NCT00833885|Other|Control|General information about virus transmission in households and basic means to prevent it
1833502|NCT00833898|Device|Paced respiration as part of PEPRR|The FDA approved RESPeRATE™ is the size of a portable compact disk (CD) player with a visual display, an elastic belt-type respiratory sensor, and a set of headphones. During a relaxation session, the device analyzes respiratory pattern of the subject and creates a melody of pleasant tones selected by the subject (one for inhalation and one for exhalation). The subjects can observe a cartoon figure on the screen of the device that indicates their inhalation and exhalation. The subject synchronizes their breathing to these tones as the exhalation tone is gradually increased in duration with a target of less than 10 breaths/minute. Subjects were encouraged to use RESPeRATE 3-5 times a week for 20 minutes.
1833503|NCT00833898|Behavioral|PEPRR|PEPRR consist of 8 sessions, each lasting approximately 60min. The first 4 sessions are weekly, followed by biweekly mtgs for the remaining 4 sessions. Sessions begin the week that the patient receives the transfusion of donor cells. Session 1-4 are conducted at the hospital where the patients receive their transplant. Once discharged from the hospital, sessions will be conducted at the outpatient BMT clinic to coincide with patients' post-transplant visits. Sessions are devoted to a separate topic with the goal of assisting the caregiver in development & application of various stress-mgmt techniques such as effective problem-solving, identifying & challenging cognitive distortions, relaxation techniques, coping skills training, effective use of social support & goal setting.
1833504|NCT00833911|Drug|Tramadol Once A Day|
1833505|NCT00833924|Device|Zenith(R) Low Profile AAA Endovascular Graft|The Zenith(R) Low Profile AAA Endovascular Graft and ancillary components are indicated for the endovascular treatment of patients with abdominal aortic, aorto-iliac, or iliac aneurysms having morphology suitable for endovascular repair.
1833506|NCT00833937|Drug|Zolpidem 10 mg tablets|1 x 10 mg
1833507|NCT00833937|Drug|AMBIEN® 10 mg tablets|1 x 10 mg
1833508|NCT00833950|Device|Phase Out treatment in pure tone tinnitus patients|Phase Out treatment: 30 min 3x/w during 6 weeks
1833509|NCT00833963|Drug|Trastuzumab|Participants will receive trastuzumab as determined by their treating physicians' standards of care.
1833510|NCT00833963|Drug|Pertuzumab|Participants will receive pertuzumab as determined by their treating physicians' standards of care.
1833511|NCT00833963|Drug|Ado-Trastuzumab Emtansine|Participants will receive ado-trastuzumab emtansine as determined by their treating physicians' standards of care.
1833512|NCT00833976|Drug|Lovaza|4 grams per day
1958939|NCT01029691|Device|Positive Airway Pressure|Women will use positive airway pressure until delivery
1833515|NCT00834002|Biological|injection of antigen-loaded cultured dendritic cells|intradermal injection of WT1-RNA-electroporated autologous dendritic cell vaccine (therapeutic cell vaccine)
1833516|NCT00834015|Other|Outcome of lumbar spinal fusion patients and significance of postoperative exercise therapy: A randomized controlled trial|combined strength and aerobic training group
1833517|NCT00834041|Drug|Aliskiren 3.125 mini-tablets|Oral mini-tablets (3.125 mg) of aliskiren once each morning
1833518|NCT00834054|Procedure|Double-lung transplantation|Double-lung transplanted patients
1833519|NCT00834067|Drug|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
1833520|NCT00834067|Drug|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
1833521|NCT00834080|Drug|Medisorb naltrexone 380 mg|Intramuscular (IM) injection administered once every 4 weeks for up to 2 years
1833525|NCT00834119|Drug|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day for 28 days
1833526|NCT00834119|Drug|Mometasone furoate|Mometasone furoate 200 mcg (2 puffs in each nostril) once a day plus an oral antihistamine added at Day 28 (Visit 2) at the discretion of the physician
1833527|NCT00834132|Drug|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fed
1833528|NCT00834132|Drug|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fed
1833529|NCT00834145|Device|A mechanical compression pump|Patients in the experimental arm will receive a NormaTec pump which will be used twice daily during hospitalization and once daily on an ambulatory basis. A cuff is placed over the leg and a pneumatic system automatically compresses the leg according to predefined parameters of pressure, time etc.
1833530|NCT00834158|Procedure|TACE|1 time
1833531|NCT00834158|Procedure|PVE|1 time
1833532|NCT00834171|Drug|Loteprednol etabonate ophthalmic suspension 0.5%|Apply one to two drops of Loteprednol etabonate ophthalmic suspension 0.5% into the conjunctival sac as prescribed by your physician
1833533|NCT00834171|Drug|Loteprednol etabonate (0.5%) and tobramycin (0.3%).|Apply one or two drops of Loteprednol etabonate (0.5%) and tobramycin (0.3%) into the conjunctival sac as prescribed by your physician.
1833534|NCT00834184|Drug|nikkomycin Z|"Multiple rising doses. Doses packaged on a unit dose basis in 250 mg capsules. Subjects take 1-3 capsules per dosing block for 14 days unless ADE or study withdrawal. Dose escalation unless a dose-limiting adverse effect is noted. Subjects assigned to BID dosing will receive 28 doses and subjects assigned to TID dosing will receive 42 doses.
250 mg BID (n=6) vs Placebo capsule BID (n=2), 500 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg BID (n=6) vs Placebo capsule BID (n=2), 750 mg TID (n=6) vs Placebo capsule TID (n=2) At least 4 subjects complete lower dose before randomization includes next higher dose, thus there are 4 arms for active intervention and corresponding placebos."
1833535|NCT00834197|Drug|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose non-fasting
1833536|NCT00834197|Drug|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose non-fasting
1833537|NCT00834210|Drug|Dapsone|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
1833538|NCT00834210|Drug|Tazarotene|Tazarotene Cream 0.1%, 1 pea-size amount QD x 12 weeks
1833539|NCT00834223|Device|Aquashunt|A shunt which is implanted into the suprachoroidal space.
1833540|NCT00834236|Other|normal subject|biomarker in gastric juice, i.e., alpha 1-antitrypsin, CEA
1833541|NCT00834236|Other|gastric cancer|biomarker in gastric juice, e.g., alpha 1-antitrypsin
1833542|NCT00834249|Drug|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
1833543|NCT00834249|Drug|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
1833544|NCT00834262|Drug|biphasic insulin aspart 30|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1833545|NCT00834262|Drug|biphasic insulin aspart 50|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1833546|NCT00834262|Drug|biphasic insulin aspart 70|Dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1833547|NCT00834275|Drug|Cefadroxil 500 mg Capsules|1 x 500 mg
1833548|NCT00834275|Drug|DURICEF® capsules 500 mg|1 x 500 mg
1833549|NCT00834288|Drug|Tramadol HCl|1x200 mg Tramadol HCl OAD tablet daily
1833550|NCT00834288|Drug|Tramadol HCl|1x50 mg Tramadol HCl IR (Ultram®) tablet 6-hourly
1833551|NCT00834301|Dietary Supplement|Oral Multivitamin|Oral Multivitamin
1833552|NCT00834314|Procedure|Vacuum-Pack-technique for temporary abdominal closure|"Negative-pressure-wound-therapy applying a method described by Brock, Barker et al 1995: Temporary Closure of Open Abdominal Wounds - the Vacuum Pack (see citations)."
1833553|NCT00834314|Procedure|Abdominal-dressing-technique for temporary abdominal closure|Negative-pressure-wound-therapy for temporary abdominal closure applying a device of KCI International (V.A.C.® Abdominal Dressing System). see: http://www.kci-medical.com/kci/corporate/kcitherapies/vactherapy/dressings/abdominal/#
1833554|NCT00834327|Drug|aplindore MR tablets or Placebo|aplindore MR tablets administered QD for about 4 weeks
1833555|NCT00834340|Drug|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose fasting
1833556|NCT00834340|Drug|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose fasting
1833557|NCT00834353|Drug|ATT|
1833558|NCT00834366|Drug|Tramadol HCl|Single oral administration in fasting conditions of 1x200mg Tramadol HCl 200 mg Film-coated Tablet or Tramadol HCl 200 mg Uncoated Tablets based on randomization schedule.
1833559|NCT00834379|Drug|pravastatin sodium|40 mg Tablet
1833560|NCT00834379|Drug|Pravachol®|40 mg tablet
1833561|NCT00834392|Behavioral|Exercise|Walking exercise
1833562|NCT00834405|Drug|ARAVA® 20 mg tablets|1 x 20 mg, single-dose non-fasting
1833563|NCT00834405|Drug|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose non-fasting
1833564|NCT00834418|Drug|Leflunomide 20 mg Tablets|1 x 20 mg, single-dose fasting
1833565|NCT00834418|Drug|ARAVA™ 20 mg Tablets|1 x 20 mg, single-dose fasting
1833566|NCT00834431|Drug|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
1833567|NCT00834431|Drug|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
1833568|NCT00834444|Drug|Famciclovir 500 mg Tablets|1 x 500 mg, single-dose fasting
1833569|NCT00834444|Drug|Famvir® 500 mg Tablets|1 x 500 mg, single-dose fasting
1833570|NCT00834457|Drug|abacavir/3TC/zidovudine|continued use of oral co-formulated abacavir 300mg/3TC 150mg/zidovudine 300mg for 96 weeks
1833571|NCT00834457|Drug|abacavir /3TC plus ritonavir boosted lopinavir|fixed dose abacavir 600mg/3TC 300mg one tablet po QD for 96 weeks plus fixed dose ritonavir 33.3mg/lopinavir 133.3mg four tablets po QD for 96 weeks
1833572|NCT00834470|Drug|Atropine|Ketamine 2mg/kg IV + Atropine 0.01mg/kg or Same volume of Normal saline
1833573|NCT00834483|Device|Knotless suture for wound closure|Angiotech Quill SRS
1833574|NCT00834483|Device|Layered traditional wound closure (monocryl)|Layered traditional wound closure (monocryl)
1833575|NCT00834496|Procedure|Liver biopsy|percutaneous liver biopsy
1833576|NCT00834509|Device|CPAP|Use CPAP for 4-6 weeks as clinically prescribed.
1833577|NCT00834522|Drug|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose non-fasting
1833578|NCT00834522|Drug|Kytril® 1 mg tablets|2 x 1 mg, single dose non-fasting
1833579|NCT00834535|Drug|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose non-fasting
1833580|NCT00834535|Drug|OMNICEF® Capsule 300 mg|1 x 300 mg, single-dose non-fasting
1833581|NCT00834548|Procedure|Whole body magnetic resonance angiography (WB-MRA)|WB-MRA will be performed once in each patient.
1833582|NCT00834561|Drug|Lamotrigine|200 mg Tablet
1833583|NCT00834561|Drug|Lamictal®|200 mg Tablet
1833584|NCT00834574|Drug|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
1833585|NCT00834574|Drug|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single dose fasting
1833586|NCT00834587|Drug|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose non-fasting
1833587|NCT00834587|Drug|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose non-fasting
1992679|NCT03315702|Other|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
1833590|NCT00834613|Drug|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fed
1833591|NCT00834613|Drug|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fed
1833592|NCT00834626|Procedure|Ileal Interposition with Sleeve Gastrectomy|Transposition of a segment of Ileum proximally coupled with limited /complete sleeve gastrectomy.
1833593|NCT00834639|Drug|divalproex sodium|delayed-release 500 mg tablet
1833594|NCT00834639|Drug|Depakote®|delayed-release 500 mg tablet
1992682|NCT03315260|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Ra-223 is a radiopharmaceutical with an indication to treat Castration Resistant Prostate Cancer (approved indication in Japan)
1833597|NCT00834665|Biological|Telomerase (hTERT vaccine + pneumococcal conjugate vaccine (PCV))|One vaccination prior to autologous transplant and 3 vaccination after autologous transplant.
1833598|NCT00834665|Biological|PCV vaccine|Receipt of PCV vaccine and GM-CSF injections prior to autologous transplant and post transplant
1833599|NCT00834678|Drug|bendamustine|100 or 120 mg/m2 IV on days 1 and 2
1833600|NCT00834678|Drug|erlotinib|100 or 150 mg po on days 5 - 21 of each 28 day cycle
1833601|NCT00834678|Drug|Maintenance erlotinib|150 mg po daily (days 1 - 28 of 28 day cycle)
1833602|NCT00834704|Drug|PEGPH20|PEGylated recombinant human hyaluronidase
1833603|NCT00834717|Drug|Granisetron hydrochloride 1 mg tablets|2 x 1 mg, single dose fasting
1833604|NCT00834717|Drug|Kytril® 1 mg tablets|2 x 1 mg, single dose fasting
1833605|NCT00834730|Drug|N2O gas vs ketamine|Ketamine : 2mg/kg IV N2O : 50%-70% N2O gas
1833606|NCT00834743|Drug|Glucophage® XR 750 mg Tablets|1 x 750 mg, single-dose fasting
1833607|NCT00834743|Drug|Metformin ER 750 mg Tablets|1 x 750 mg, single-dose fasting
1833608|NCT00834756|Drug|Azithromycin 600 mg Tablet|1 x 600mg, single-dose fasting
1833609|NCT00834756|Drug|Zithromax® 600 mg Tablet|1 x 600mg, single-dose fasting
1996345|NCT02497638|Drug|Placebo (corresponding to metformin)|One month of one placebo tablet (corresponding to metformin) once daily, followed by one placebo tablet twice daily until progression.
1833611|NCT00834795|Drug|Carvedilol 25 mg tablets|1 x 25 mg
1833612|NCT00834795|Drug|COREG® 25 mg tablets|1 x 25 mg
1833613|NCT00834808|Drug|Tramadol HCl|One single oral administration of Tramadol HCl 100 mg, 200 mg or 300 mg as per randomization schedule.
1833614|NCT00834821|Behavioral|Parent Focused Training (PFT)|PFT will involve parenting skills training supplemented with a phone session between a therapist and teacher to cover ADHD, inattentive type. This intervention will include ten 90-minute parent group training sessions and up to five individual sessions with the study therapist.
1833615|NCT00834821|Behavioral|Child Life and Attention Skills (CLAS) Program|CLAS will involve parenting skills training adapted for ADHD, inattentive type; child life skills training; and teacher consultation. This intervention will include ten 90-minute parent group training sessions; ten 90-minute child group training sessions; up to five individual family sessions with the study therapist; and up to six 30-minute sessions with the teacher, parent, and therapist.
1833616|NCT00834834|Drug|Fluoxetine|Starting dose of 20 mg daily will increase over 4 weeks, depending on tolerability, up to 40 mg daily. Treatment will last 6 months.
1833617|NCT00834834|Behavioral|DBT|One 60-minute individual therapy session and one 90-minute group therapy session every week. Treatment will last 6 months.
1833618|NCT00834834|Drug|Citalopram|Dose set by study psychiatrist, up to 60 mg daily. Treatment will last 6 months.
1833619|NCT00834847|Drug|pravastatin|40 mg tablet
1833620|NCT00834847|Drug|Pravachol®|40 mg Tablet
1833622|NCT00834873|Drug|Carvedilol 25 mg tablets|1 x 25 mg
1833623|NCT00834873|Drug|COREG® 25 mg tablets|1 x 25 mg
1833624|NCT00834886|Dietary Supplement|Melatonin|Capsules, 3 mg, once every night
1833625|NCT00834886|Other|Bright light|Bright light therapy 10.000 lux by Miljølys AS
1833626|NCT00834886|Other|Placebo red light|Red light 400 lux as placebo light
1833627|NCT00834886|Other|Placebo capsule|Capsules containing 3 mng rice flour, once every night
1833628|NCT00834899|Drug|Eptifibatide|Patients randomized to eptifibatide will receive two 180 mcg/kg boluses of eptifibatide 10 minutes apart (i.e., a double bolus), followed by a continuous infusion at 2 mcg/kg/min for 6 hours.
1833629|NCT00834899|Drug|Placebo|Patients randomized to the placebo arm will receive a saline solution delivered at a volume and rate identical to that of the active drug.
1833630|NCT00834912|Drug|Tramadol hydrochloride|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
1833631|NCT00834912|Drug|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Confab Laboratories), fed condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
1833632|NCT00834912|Drug|Tramadol HCl|1x300mg Tramadol Hydrochloride (HCl) tablet (Trillium Healthcare) fasting condition. Taken for one treatment period only, then subjects switched treatment at each period as per randomization schedule. Results are presented per treatment group overall.
1833633|NCT00834925|Drug|low dose diltiazem|Low dose diltiazem: 0.15mg/kg over 2 minutes Standard dose diltiazem: 0.25mg/kg over 2 minutes
1833634|NCT00834938|Other|No intervention|No intervention
1833635|NCT00834951|Radiation|Low dose total body irradiation|Low dose total body irradiation is given 3 weeks after the end of chemo-immunetherapy in the form of 4 daily fractions 0.2 Gy per fraction to be repeated after 2 weeks of rest
1833636|NCT00834964|Drug|Venlafaxine 25 mg Tablets|1 x 25 mg, single-dose fasting
1833637|NCT00834964|Drug|Effexor® 25 mg Tablets|1 x 25 mg, single-dose fasting
1833638|NCT00834977|Drug|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
1833639|NCT00834977|Drug|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
1833640|NCT00834990|Drug|divalproex sodium|delayed-release 500 mg tablet
1833641|NCT00834990|Drug|Depakote®|delayed-release 500 mg tablet
1833642|NCT00835003|Procedure|Elective caesarean section|Procedure performed at 38 weeks and 3 days of gestation (+/- 2 days)
1833643|NCT00835003|Procedure|Elective caesarean section|Procedure performed at 39 weeks and 3 days of gestation (+/- 2 days)
1833644|NCT00835016|Behavioral|Early psychosocial stimulation (LTP)|Learning through Play (LTP) groups will be conducted weekly for the first eight sessions and two fortnightly sessions. Parenting issues will be discussed with the mothers and play activities will be demonstrated with the children using LTP and home made materials.
1833840|NCT00825071|Drug|Ondansetron|4 mg, intravenously
1833841|NCT00825071|Drug|normal saline|2 ml, intravenously
1833645|NCT00835029|Drug|Clotrimazole varnish|Each patient will receive 14 syringes (with no needle, equivalent to 50 mg of Clotrimazole in each one) . The varnish will be applied on a dried denture at the inner side by means of a soft brush and left to dry for 60 sec for 14 days.
1833646|NCT00835029|Drug|Clotrimazole troches|The troche group will be asked to dissolve it in the mouth according to the manufacture instructions five times a day after removal of the denture, for 14 days.
1833647|NCT00835042|Drug|Moexipril HCl/hydrochlorothiazide 15/25 mg tablets|1 x 15/25 mg
1833648|NCT00835042|Drug|UNIRETIC® 15/25 mg tablets|1 x 15/25 mg
1833649|NCT00835068|Other|No intervention|As it is a non interventional study, patient receives his usual treatment (BeneFIX) as determined by the physician
1833650|NCT00835081|Drug|Cefadroxil 500 mg Capsules|1 x 500 mg
1833651|NCT00835081|Drug|DURICEF® capsules 500 mg|1 x 500 mg
1833652|NCT00835094|Device|Mometasone furoate|MF-DPI 400 mcg once daily in the morning for 12 weeks
1833653|NCT00835094|Device|Mometasone furoate|MF-DPI 400 mcg once daily in the evening for 12 weeks
1833654|NCT00835107|Drug|ziprasidone hydrochloride|oral capsules, from 40-80 mg BID, for one month with the option to continue the medication after the study has been completed
1833655|NCT00835107|Drug|placebo|placebo comparator, oral capsules, BID, for one month
1833656|NCT00835120|Drug|Pioglitazone|An open-label 12-week trial of pioglitazone monotherapy. The investigators will titrate pioglitazone to the maximum tolerable dose up to 45mg per day.
1833657|NCT00835133|Other|biologic sample preservation procedure|one blood sample or saliva sample collection
1833658|NCT00835133|Other|medical chart review|confirmation of cancer diagnosis
1833659|NCT00835133|Other|survey administration|at baseline enrollment and 12 months post-enrollment
1833660|NCT00835146|Drug|Ribavirin 200 mg tablets|1 x 200 mg, single-dose fasting
1833661|NCT00835146|Drug|COPEGUS™|1 x 200 mg, single-dose fasting
1833662|NCT00835159|Drug|Rivastigmine Patch|Rivastigmine Patch 4.6 mg/24 hours: 5 cm2 size containing 9 mg rivastigmine applied to upper back preoperatively for a period of 24 hours
1833663|NCT00835159|Other|Placebo Patch|A 2x2 gauze and a Tegaderm dressing applied to upper back within 3 hours of surgery for a period of 24 hours.
1833664|NCT00835172|Drug|Glimepiride 4 mg Tablets|1 x 4 mg, single-dose non-fasting
1833665|NCT00835172|Drug|AMARYL® 4 mg Tablets|1 x 4 mg, single-dose non-fasting
1833666|NCT00835185|Biological|IMC-11F8 (necitumumab)|IMC-11F8 800 milligrams (mg) intravenous (IV) infusion over 50 minutes on Day 1
1833667|NCT00835185|Drug|Oxaliplatin|Oxaliplatin 85 milligrams per meter square (mg/m²) IV infusion over 2 hours on Day 1
1833668|NCT00835185|Drug|Folinic acid (FA)|FA 400 mg/m² IV infusion bolus injection
1833669|NCT00835185|Drug|5-FU|5-FU 400 mg/m² as a bolus followed by 2400 mg/m² IV continuous infusion over 46 hours
1833670|NCT00835198|Drug|Dapsone; Tretinoin|Dapsone topical gel 5%, 1 pea-size amount BID x 12 weeks and Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
1833671|NCT00835198|Drug|Tretinoin|Tretinoin gel 0.025%, 1 pea-size amount QD x 12 weeks
1833672|NCT00835211|Drug|Desmopressin Acetate 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
1833673|NCT00835211|Drug|DDAVP® 0.2 mg Tablets|4 x 0.2 mg, single-dose fasting
1833674|NCT00835224|Drug|L-NAME|A non-selective inhibitor of nitric oxide synthase and placebo. It has been used experimentally to induce hypertension.
1833675|NCT00835224|Drug|Midodrine|To treat low blood pressure.
1833676|NCT00835224|Drug|Placebo|A pill with an inactive substance that looks like the study drug.
1833677|NCT00835237|Biological|Boostrix®|Intramuscular, single dose.
1833678|NCT00835237|Biological|Decavac™|Intramuscular, single dose.
1833679|NCT00835250|Procedure|Transvaginal hybrid NOTES cholecystectomy|Cholecystectomy performed by using a combination of working tools inserted through the entry port for the minilaparoscopy and the videogastroscope, inserted into peritoneal cavity by transvaginal approach. The gallbladder is removed transvaginally through the videogastroscope.
1833680|NCT00835250|Procedure|Cholecystectomy|Extirpation of the gallbladder by a surgical procedure
1833681|NCT00835263|Drug|Lamotrigine|200 mg Tablet
1833682|NCT00835263|Drug|Lamictal®|200 mg Tablet
1833683|NCT00835276|Drug|Fexofenadine 180 mg tablets|1 x 180 mg
1833684|NCT00835276|Drug|ALLEGRA® 180 mg tablets|1 x 180 mg
1833685|NCT00835289|Dietary Supplement|n-3 polyunsaturated fatty acids|Omax3[TM] (Cenestra Health [TM]) is a 1 g softgel capsule containing 94.5% omega-3 fatty acids. Each serving size is a 1 gram capsule, which contains 690 mg of eicosapentanoic acid (EPA) and 182 mg of docosahexanoic acid (DHA). Inactive ingredients include: Vitamin E/Tocopherol 2294 ppm (in a carrier of partially hydrogenated vegetable oils including soybean oil), gelatin, glycerol, and purified water (components of the capsule shell). The study participants will be randomized to 3 softgel capsules a day for 6 months.
1833686|NCT00835289|Other|Placebo|3 capsules of matching corn oil placebo
1833687|NCT00835302|Procedure|Cervicothoracic manipulation|Thrust and non-thrust manipulation to the cervical and thoracic spine
1833690|NCT00835354|Drug|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
1833691|NCT00835354|Drug|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
1833692|NCT00835367|Drug|Amlodipine-benazepril 10 mg-20 mg capsules|1 x 10-20 mg
1833693|NCT00835367|Drug|Lotrel® 10 mg-20 mg capsule|1 x 10-20 mg
1833694|NCT00835380|Biological|Hepatitis A Vaccine, Purified Inactivated (VAQTA™)|Subjects will be given a 25-U/0.5 mL intramuscular injections of VAQTA™ at Day 1 and Month 6.
1996346|NCT02497638|Drug|Placebo (corresponding to atorvastatin)|One placebo tablet (corresponding to atorvastatin) once daily until progression.
1996347|NCT02496975|Drug|Cyclosporine A|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
1833697|NCT00835406|Drug|Alendronate Sodium Tablets 70mg|1 x 70mg, single dose fasting
1833698|NCT00835406|Drug|Fosamax® Tablets 70mg|1 x 70 mg, single dose fasting
1833699|NCT00835419|Drug|P276-00|P276-00 -small molecule Cdk 4-D1, Cdk1-B and Cdk9-T inhibitor
1833700|NCT00835432|Device|Ossix|Test group
1996348|NCT02496975|Other|Placebo|Participants will receive 2.5mg/kg load then 5mg/kg qd continuous infusion x 3 days (72hours)
1833703|NCT00835471|Drug|erlotinib plus docetaxel or pemetrexed|"non-squamous carcinoma: pemetrexed 500 mg/m2 on Day 1 plus erlotinib 150 mg/day days 2-16, every 21 days. Pemetrexed will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression.
squamous carcinoma: Docetaxel 75mg/m2 on Day 1 plus erlotinib 150mg/day days 2-16, every 21 days. Docetaxel will be given for a maximum of 4 cycles. Thereafter erlotinib will be continued continuously until disease progression."
1833704|NCT00835471|Drug|erlotinib|erlotinib 150 mg/day continuously until disease progression
1833705|NCT00835484|Drug|Cefdinir Capsules 300 mg|1 x 300 mg, single-dose fasting
1833706|NCT00835484|Drug|OMNICEF® 300 mg|1 x 300 mg, single-dose fasting
1833707|NCT00835497|Drug|5 mg/500 mg Glipizide Metformin Hydrochloride Tablets|1 x 5 mg/500 mg, single-dose fasting
1833708|NCT00835497|Drug|5 mg/500 mg METAGLIP™ Tablets|1 x 5 mg/500 mg, single-dose fasting
1833709|NCT00835510|Drug|Butenafine cream 1% manufactured by Taro|Treatment applied to affected area twice daily for 7 days
1833710|NCT00835510|Drug|Lotrimin Ultra (butenafine) 1%|Treatment applied to affected area twice daily for 7 days
1833711|NCT00835510|Drug|Butenafine Vehicle manufactured by Taro|Treatment applied to affected area twice daily for 7 days
1833712|NCT00835536|Drug|Ribavirin 200 mg tablets|1 x 200 mg, single-dose non-fasting
1833713|NCT00835536|Drug|COPEGUS™ 200 mg Tablets|1 x 200 mg, single-dose non-fasting
1833714|NCT00835549|Drug|Cefdinir for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
1833715|NCT00835549|Drug|OMNICEF® for oral suspension 250 mg/5mL|1 x 250 mg/5mL, single-dose non-fasting
1833716|NCT00835562|Procedure|Non-surgical management|Non-surgical management (physiotherapy and self-training)
1833717|NCT00835562|Procedure|Osteosynthesis|Osteosynthesis with angle-stable plate followed by physiotherapy and self-training
1833718|NCT00835562|Procedure|Hemiarthroplasty|Primary modular hemiarthroplasty followed by physiotherapy and self-training
1833719|NCT00835575|Drug|Mirtazapine 15 mg (Orally Disintegrating) Tablets|1 x 15 mg, single-dose fasting
1833720|NCT00835575|Drug|REMERON SolTab® 15 mg Orally Disintegrating Tablets|1 x 15 mg, single-dose fasting
1833721|NCT00835588|Drug|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
1833722|NCT00835588|Drug|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
1833723|NCT00835614|Drug|Cefprozil for oral suspension 250 mg/5 mL|1 x 250 mg/5 mL, single-dose fasting
1833724|NCT00835614|Drug|CEFZIL® for Oral Suspension 250 mg/5mL|1 x 250 mg/5 mL, single-dose fasting
1833725|NCT00835627|Drug|sertraline|flexible dose sertraline
1833726|NCT00835627|Behavioral|CBT-ip|cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: 12 individual 1 hour therapy sessions
1833727|NCT00835627|Other|Combined (sertraline + CBT-ip)|flexible dose sertraline and cognitive behavioral therapy-informed psychotherapy for nonepileptic seizures: flexible dose sertraline and 12, individual 1 hour therapy sessions
1833728|NCT00835627|Other|Standard Care|community care, treatment as usual: routine follow up with existing providers
1833729|NCT00835640|Drug|Fexofenadine 180 mg tablets|1 x 180 mg
1833730|NCT00835640|Drug|ALLEGRA® 180 mg tablets|1 x 180 mg
1833731|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
1833732|NCT00835653|Procedure|median nerve block|median nerve block performed under echographic guidance
1833733|NCT00835666|Drug|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
1833734|NCT00835666|Drug|PROSCAR®|1 x 5 mg, single dose fasting
1833735|NCT00835679|Biological|cetuximab|Given IV
1833736|NCT00835679|Drug|dasatinib|Given orally
1833737|NCT00835679|Procedure|therapeutic conventional surgery|Undergo surgery
1833738|NCT00835679|Other|laboratory biomarker analysis|Correlative studies
1833739|NCT00835692|Drug|Clarithromycin|500 mg Tablet
1833740|NCT00835692|Drug|Biaxin®|500 mg Tablet
1833741|NCT00835705|Drug|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
1833742|NCT00835705|Drug|Augmentin®|400 mg-57 mg chewable tablet
1833743|NCT00835718|Drug|Comparator: MK0594 5 mg/day|MK0594 5 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 15 mg MK0594 will be administered.
1833744|NCT00835718|Drug|Comparator: MK0594 1 mg/day|MK0594 1 mg tablets taken orally once daily for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
1833745|NCT00835718|Drug|Comparator: MK0594 1 mg/week|MK0594 1 mg tablets taken orally once every 7 days for 12 weeks. At the randomization visit, a loading dose of 3 mg MK0594 will be administered.
1833746|NCT00835718|Drug|Comparator: Placebo to MK0594|Matching placebo to MK0594 tablets taken orally once daily for 12 weeks.
1833749|NCT00835744|Drug|clomiphene citrate|ovulation induction
1833750|NCT00835744|Drug|gonadotropins|ovulation induction
1833751|NCT00835770|Drug|dimethyl fumarate|BG00012 capsules
1833752|NCT00835770|Drug|Placebo|Capsules taken to maintain the blind in the 240 mg BID treatment group.
1833753|NCT00835796|Drug|Finasteride 5 mg tablets|1 x 5 mg, single dose fasting
1833754|NCT00835796|Drug|PROSCAR® 5mg tablets|1 x 5 mg, single dose fasting
1833801|NCT00836134|Procedure|rectus sheath block|ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision
1833755|NCT00835822|Drug|Venocur Triplex®|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
1833756|NCT00835822|Drug|placebo|Administered by oral route, two coated tablets per day, after the meals (breakfast and dinner), with some liquid, but not with alcoholic beverages.
1833757|NCT00835835|Other|Body-weight supported treadmill training +/- Lokomat assistance|walking
1833758|NCT00835835|Other|Usual Care - no active intervention|No treatment used for comparison
1833759|NCT00835848|Drug|Exenatide|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 25 μg Byetta (Lilly, Exenatide) and 0.1% human albumine are added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
1833760|NCT00835848|Drug|Saline|Following arrival at the catheter laboratory informed consent is obtained and the patient randomised to placebo or exenatid treatment. 0.1% human albumine is added to 250 ml isotonic NaCl. Infusion is started immediately at 72ml/hour for 15 min, followed by 26ml/hour to be contoinued for 6 hours.
1833761|NCT00835861|Drug|Metformin|Women randomized to the Experimental arm will receive standard diet and glucose self-monitoring education. They will be initiated on Metformin 500 BID if they were medication naïve, or will be continued on their current dosage of Metformin if they were taking it prior to pregnancy. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to a maximum of 2250mg/day to achieve target glycemic control. If glycemic control can not be achieved with Metformin as a single agent insulin will be added.
1833762|NCT00835861|Drug|Insulin|Women randomized to the Insulin group will receive standard diet and glycemic monitoring education. They will be initiated on weight based Regular and NPH insulin at a total dosage of 0.7units/kg in the first trimester or 0.8units/kg in the second trimester divided as 2/3 of the total dosage (with 2/3 given as NPH and 1/3 given as Regular) administered before breakfast and 1/3 of the total dosage (with 1/2 given as NPH and 1/2 given as Regular)administered with dinner. At each clinic visit fasting and one hour post prandial glucose values will be reviewed, and dosage will be titrated to achieve optimal glycemic control with fasting values <90 and one hour post prandial values <130.
1833763|NCT00835874|Drug|Probiotics|Lactobacillus acidophilus, b.lactis capsule. Once daily.2X 10 by the power of 10 bacteria per dose.
1833764|NCT00835887|Dietary Supplement|low and high dose flavanoids|treatment with flavanoid-rich or flavanoid-low cacao twice daily
1833765|NCT00835900|Drug|varenicline|variable dosing schedule
1833766|NCT00835900|Drug|placebo|placebo
1833767|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
1833768|NCT00835926|Biological|Influenza virus vaccine|0.5 mL, Intramuscular
1833769|NCT00835939|Drug|25% Dextrose and 1% Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
1833770|NCT00835939|Drug|Lidocaine|Up to 3 injections provided to neovessels outside of the tendon
1833771|NCT00835939|Procedure|sclerotherapy|
1833772|NCT00835952|Drug|ATX-101|ATX-101 single doses
1833776|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label) + axitinib dose titration (blinded)
1833777|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label) + placebo dose titration (blinded)
1833778|NCT00835978|Drug|axitinib|axitinib 5mg BID (open-label)
1833779|NCT00835991|Drug|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
1833780|NCT00835991|Drug|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fed
1833781|NCT00836004|Drug|Clindamycin 300 mg capsule|1 x 300 mg
1833782|NCT00836004|Drug|Cleocin HCl 300 mg capsules|1 x 300 mg
1833783|NCT00836017|Other|No Intervention|No intervention was administered as part of the study.
1833784|NCT00836030|Other|No treatment given|No treatment given
1833785|NCT00836043|Drug|Alemtuzumab (MabCampath)|Intravenous therapy according to product information.
1833786|NCT00836056|Drug|Clindamycin 300 mg capsule|1 x 300 mg
1833787|NCT00836056|Drug|Cleocin HCl 300 mg capsules|1 x 300 mg
1833788|NCT00836069|Drug|PD 0332334|Experimental study drug for generalized anxiety disorder, oral tablet, twice daily
1833789|NCT00836069|Drug|Paroxetine|FDA Approved medication for generalized anxiety disorder, oral tablet
1833790|NCT00836069|Other|Placebo|inactive substance, oral tablet, once per day
1833791|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 0.5mg given once daily for 14 days.
1833792|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 1mg given once daily for 14 days.
1833793|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 4mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 4mg will be administered once daily for 14 days.
1833794|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
1833795|NCT00836082|Drug|PF-04457845, FAAH inhibitor|Oral solution of 8mg will be administered as a single dose 7-14 days prior to the multiple dosing phase where 8mg will be administered once daily for 14 days.
1833796|NCT00836082|Drug|PF-04457845, FAAH inhibitor|A randomized food treatment will be administered 7-14 days prior to and on day 1 of the multiple dosing phase
1833797|NCT00836095|Device|Supreme Laryngeal mask airway|Supreme Laryngeal mask airway is a new, single use laryngeal mask airway variant
1833798|NCT00836095|Device|Proseal laryngeal mask airway|Proseal is a multiple use, variant of the laryngeal mask airway
1833799|NCT00836108|Behavioral|breathing strategy|Subjects will practice a rhythmic overhead arm exercise, during which they will be taught to inspire when they elevate their arms or they will be taught to expire when they elevate their arms or, a third group, will practice a rhythmic overhead arm exercise, during which they will not be provided with any instruction regarding a specific breathing pattern. The arm exercise practiced by all groups will be identical.
1833800|NCT00836121|Procedure|right thoracotomy|complete surgical resection
1833839|NCT00825071|Drug|Dexamethasone|8 mg, Intravenous
1833802|NCT00836134|Procedure|local anesthetic infiltration|Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
1833803|NCT00836147|Drug|Avotermin (Juvista)|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
1833804|NCT00836147|Drug|Placebo|20 patients undergoing surgical revision of bilateral ear lobe keloids. Injecting intradermally 250ng/100µL/linear cm of the wound margin to one ear lobe and placebo into the other wound margin immediately after surgery and then 24hrs after wound closure.
1833805|NCT00836173|Drug|RICE|RICE treatment: Rituximab by intravenous infusion over 6-8 hours on day 1, Eptoposide by intravenous infusion over 2 hours on day 3-5, a 1-hour infusion of Carboplatin on day 4 and a 24-hour infusion of Ifosfamide on day 4, each cycle is 14 days (2 weeks). Patients will receive 3 cycles of RICE treatment.
1833806|NCT00836173|Drug|GaRD Treatment|After RICE treatment, patients will have gallium nitrate IV through a vein continuously over a 7 day period. Patients will also receive rituximab by intravenous infusion over a 3-6 hour period on day 1 of each cycle. Dexamethasone will be given as pills to be taken for 4 days in a row on the first 4 days of each cycle. The length of each cycle is 21 days (3 weeks). All patients will have 2 cycles of GaRD.
1833807|NCT00836186|Radiation|radiation therapy|Patients will receive whole breast radiation therapy at a dose of 180-200 cGy per fraction for 23-27 fractions to a total dose of 4600 - 4860 cGy. Additional radiation to the lumpectomy bed (Boost) is at the discretion of the treating physician. The total dose to the tumor bed cannot exceed 6600cGy. Treatments will be given Monday through Friday.
1833808|NCT00836199|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
1833809|NCT00836199|Biological|Placebo vaccine|Placebo vaccine given 6 times over 6 months
1833810|NCT00824837|Other|Larger pore haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
1833811|NCT00824837|Other|Standard haemodialysis membrane|Patients receive haemodialysis sessions 3 times a week. They are randomized to start with either treatment A (experimental arm) or treatment B (active comparator arm) and continue for 2 weeks, followed by a 1-week washout period. The patients then cross-over and receive the other treatment (either B or A) for 2 weeks.
1833812|NCT00824850|Biological|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
1833813|NCT00824850|Biological|13-valent Pneumococcal Conjugate Vaccine|single injection, single dose, single site, 0.5 mL per dose.
1833815|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
1833816|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
1833817|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
1833818|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
1833819|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
1833820|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
1833821|NCT00824889|Other|Biopsy and sample of blood|Biopsy and sample of blood
1833822|NCT00824902|Procedure|Tissue Elastography Imaging|Using special elastography software, probe pressed gently against prostate during routine ultrasound before prostate surgery, 10-15 minutes process.
1833823|NCT00824928|Procedure|Cryoablation / Cryotherapy|Salvage Cryoablation of the prostate
1833824|NCT00824954|Procedure|ECP (performed on Themos UVAR-XTS or external UVA irradiator after cell collection by apheresis)|ECP (performed on Thermos UVAR-XTS or external UVA irradiator after cell collection by apheresis)
1833825|NCT00824967|Other|Training and valuation of the treating personnel|Training and valuation of the treating personnel
1833826|NCT00824980|Drug|IP10.C8|IP10.C8 Gel 1%
1833827|NCT00824993|Drug|Ibandronate|Infusion of 3 mg by vein over 15 to 30 seconds for 4 doses at 3-6 weeks after transplant, and at Months 3, 6, and 9 after the transplant.
1833828|NCT00824993|Drug|Vitamin Supplements|"Calcium 500 mg by mouth everyday for 12 months
Vitamin D 400 units by mouth 2 times a day for 12 months"
1833829|NCT00825006|Device|Triple site pacing mode|"The experimental Triple site pacing mode includes pacing with Cardiac resynchronization therapy device using two leads; one in the right ventricle (RV) and one in the left ventricle (LV) but stimulates three sites: LV tip, RV tip and RV ring (instead of the usual two sites: LV tip and RV ring.
Patients with evidence of improved LV dyssinchrony parameters during the triple pacing mode (anodal stimulation) will be programmed to anodal stimulation for 3 months."
1833830|NCT00825019|Drug|amibegron (SR58611A)|oral administration of 2x 700 mg/day in 12h intervals
1833831|NCT00825019|Drug|placebo|oral administration in 12h intervals
1833832|NCT00825019|Drug|paroxetine|oral administration of 20 mg/day
1833833|NCT00825032|Procedure|comprehensive PR|Inpatient comprehensive PR program that lasted lasted 3 weeks and included a minimum of 15 daily sessions of specific training for lower extremities, education, nutritional intervention, psychosocial intervention. It complied with the recommendation of the ATS/ERS.
1833834|NCT00825032|Procedure|UEET|Experimental program consisting of 15 additional daily sessions of unsupported UEET.
1833835|NCT00825045|Drug|risperidone|Following the baseline clinical and cognitive assessments, risperidone will be initiated at 0.5-1.0 mg/day and subsequently increased by 0.25 - 1.0 mg on a weekly basis with the target of clinical stabilization (i.e. 20 or more % reduction in the total BPRS score) until a maximum dose of 4.0 mg/day is reached. To achieve this, a weekly assessment with BPRS will be performed. Physicians-of-record will be closely liaised with investigators. Dosage modification will be performed following this dosing schedule, however, this can be changed by treating physicians to meet clinical necessity. For example, in case psychotic symptoms are not controlled by this dosing schedule, facilitated dose increment will be allowed.
1833836|NCT00825058|Drug|amibegron (SR58611A)|oral administration 2 X 350mg/day at 12 hours intervals
1833837|NCT00825058|Drug|placebo|oral administration 12 hours intervals
1833838|NCT00825058|Drug|paroxetine|oral 20 mg/day
1833842|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
1833843|NCT00825084|Drug|Dimebon|dose escalation of single oral doses of 5, 10 and 20 mg
1833844|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
1833845|NCT00825084|Drug|Dimebon|10 mg TID of Dimebon for 7 days followed by 20 mg TID of Dimebon for 7 days
1833846|NCT00825097|Procedure|Selective tibial neurotomy|Selective tibial neurotomy is a neurosurgical intervention consisting in partially and selectively cutting the motor nerve branches destinated to the spastic muscles.
1833847|NCT00825097|Drug|Botulinum toxin injection|Botulinum toxin type A
1833848|NCT00825123|Drug|Ivabradine|Ivabradine 10 mg once
1833849|NCT00825123|Drug|Metoprolol|Metoprolol 50 mg once
1833850|NCT00825123|Drug|Placebo|Lactose powder
1833851|NCT00825136|Behavioral|relaxation|Participants were asked to log in the system to keep the muscle relaxation program every day and complete some self-rating scales on browser every week.
1833852|NCT00825136|Behavioral|biofeedback (finger temperature biofeedback)|Participants were asked to log in the system to keep the muscle relaxation program plus finger temperature biofeedback every day and complete some self-rating scales on browser every week.
1833853|NCT00825149|Drug|Bendamustine|Bendamustine will be administered as per schedule specified in the respective arm.
1833854|NCT00825149|Drug|Cyclophosphamide|Cyclophosphamide will be administered as per schedule specified in the respective arm.
1833855|NCT00825149|Drug|Doxorubicin|Doxorubicin will be administered as per schedule specified in the respective arm.
1833856|NCT00825149|Drug|Fludarabine|Fludarabine will be administered as per schedule specified in the respective arm.
1833857|NCT00825149|Drug|Obinutuzumab|Obinutuzumab will be administered as per schedule specified in the respective arm.
1833858|NCT00825149|Drug|Prednisone|Prednisone will be administered as per schedule specified in the respective arm.
1833859|NCT00825149|Drug|Vincristine|Vincristine will be administered as per schedule specified in the respective arm.
1833860|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.25mL)
1833861|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single or two-vaccination regimen (0.5mL)
1833862|NCT00825162|Biological|CSL Limited Influenza Virus Vaccine|Single vaccination regimen (0.5mL)
1833863|NCT00825175|Behavioral|Treadmill Training|Parents hold their infants on an infant treadmill for 8 minutes a day, 5 days a week. The treadmill speed is set at 0.2 m/s.
1833864|NCT00825175|Device|Supramalleolar Orthoses|In addition to treadmill training the infants receive Supramalleolar orthoses. They wear the orthoses for 8 hours a day, 5 days a week.
1833865|NCT00825188|Drug|eplerenone, amlodipine|Eplerenone 25mm qd versus amlodipine 5mg qd x 4weeks the Eplerenone 50mg qd versus amlodipine 10mg qd x 4weeks
1833866|NCT00825188|Drug|eplerenone|Eplerenone 25-50mg daily x 8 weeks
1833867|NCT00825188|Drug|eplerenone|eplerenone 25- 50 mg daily for 8 weeks
1833868|NCT00825188|Drug|amlodipine|amlodipine 5-10mg daily for 8 weeks
1833869|NCT00825201|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IP
1833870|NCT00825201|Other|liquid chromatography|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
1833871|NCT00825201|Other|mass spectrometry|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
1833872|NCT00825201|Other|pharmacological study|Plasma and peritoneal fluid samples will be collected prior to nab-paclitaxel, at completion of nab-paclitaxel infusion and at hours 1, 2, 4, 6, 8, 12, 24 and 48 following completion of infusion.
1833873|NCT00825201|Other|laboratory biomarker analysis|Correlative studies
1833874|NCT00825214|Device|Zapperclick|Device deliveres small piezoelectrical discharge to bite site (forearm)
1833875|NCT00825214|Device|Inactivated zapperclick device|placebo
1833876|NCT00825227|Drug|Armodafinil 150 mg/day|"150 mg/day armodafinil
concurrent with one cycle of taxane chemotherapy alone or in combination with other agents
patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
1833877|NCT00825227|Drug|Placebo,|"placebo
concurrent with one cycle of taxane chemotherapy alone or in combination with other agents
patients may then continue receiving armodafinil treatment after the double-blind treatment period by entering a 24-week open-label extension period, with continuing taxane chemotherapy alone, or in combination with other agents"
1833878|NCT00825240|Behavioral|One-time Questionnaire + Recorded Qualitative Interview|One-time questionnaire + recorded qualitative interview, approximately 45 minutes total.
1833879|NCT00825253|Drug|biphasic insulin aspart 30|
1833880|NCT00825253|Drug|biphasic human insulin 30|
1833881|NCT00825266|Drug|bosentan|Bosentan 62.5 mg BID for 4 weeks, then 125mg BID for duration of study.
1833882|NCT00825266|Drug|Pioglitazone|Pioglitazone 15 mg a day for 4 weeks then Pioglitazone 30 mg a day for the duration fo the study.
1833883|NCT00825279|Device|Bare Metal Stent|Stainless steel stent
1833884|NCT00825279|Device|Drug Eluting Stent|stent coated with the biodegradable polymer matrix hemoparin and paclitaxel
1833885|NCT00825292|Procedure|Polp removal and identification|Identify polyp during colonoscopy then remove polyp
1833886|NCT00825292|Procedure|colon polyp removal|identify and remove polyp
1833887|NCT00825292|Procedure|ETMI colonoscope (ETMI scope is a FDA approved device)|ETMI colonoscope used to identify colon polyps as compared to HD white light colonoscope identifying colon polyps.
1833888|NCT00825305|Biological|Abbreviated Zagreb 2-1-1 schedule|Subjects received the abbreviated Zagreb 2-1-1 schedule in a safety-lead-in phase.
1833889|NCT00825305|Biological|Standard Essen 1-1-1-1-1 schedule|Subjects received the standard Essen regimen.
1833890|NCT00825318|Procedure|Ultrafiltration|Frequency of ultrafiltration is increased from the conventional 3 times a week to 6 times a week.
1833891|NCT00825344|Drug|Etanercept|50 mg subcutaenous preoperatively
1833892|NCT00825344|Drug|Saline|Given subcutaneously preoperatively
1833893|NCT00825370|Drug|Hydromorphone|1 mg IV hydromorphone followed by an optional 1mg IV hydromorphone 15 minutes later
1833894|NCT00825370|Drug|IV opioid|Any IV opioid in the dose chosen by the treating physician. May include hydromorphone as well.
1833895|NCT00825383|Other|High Fiber and Moderate Fiber Diets|Dietary
1833896|NCT00825396|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 150 days
1833897|NCT00825422|Drug|Ropivacaine / Placebo|Wound infiltration with local anesthesics/placebo through a parietal paravertebral catheter
1833898|NCT00825435|Procedure|Coronary CT Angiogram|Coronary CT Angiogram
1833899|NCT00825448|Procedure|Hospitalization for a week|Patient in hospital a week before the date of surgery for the treatment of their addiction to alcohol (alcohol weaning)
1833900|NCT00825474|Other|operation;TACE plus PEI|Under normal rules, the operation group open abdomen to perform operation through subtotal incision while the patient has been general anesthesia with trachea cannula. The operation range on hepatic tissue of un-tumor tissue around tumor should maintain at least 1cm. As for the micro-create treatment combination group, taking TACE all through arteria cruralies super-elect arteria hepatica and injecting MITO、FUDR、iodipin. By B transonogram guiding to nyxis liver biopsy,and perform per cutem absolute alcohol injection treatment.
1833901|NCT00825487|Drug|ARQ 621|Treatment will be initiated at a dose level of 10 mg/m^2 IV infusion for an hour once weekly in 4-week (28 day) consecutive and continuous cycles. ARQ 621 should be infused IV over two hours at doses 200 mg/m^2 and higher (cohort 8 and above).
1833902|NCT00825500|Drug|Inhaled Placebo|Inhaled Staccato placebo (0 mg)
1833903|NCT00825500|Drug|Inhaled Loxapine 1.25 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
1833904|NCT00825500|Drug|Inhaled Loxapine 2.5 mg|Inhaled Staccato Loxapine 1.25 mg, single dose
1833905|NCT00825513|Device|Akreos Toric IOL|Lens implant following cataract surgery
1833906|NCT00825513|Device|Akreos Advanced Optics Aspheric Intraocular Lens (Akreos AO)|Lens implant following cataract surgery
1833907|NCT00825526|Behavioral|Mindfulness Based Stress Reduction (MBSR) Therapy|The objectives of MBSR therapy are to 1) understand their personal response to stress and 2) develop techniques to change the way these patients respond and cope with stress
1833908|NCT00825539|Drug|AQW051|
1833909|NCT00825539|Drug|Placebo|
1833910|NCT00825552|Drug|Risperidone|0,5-4 mg/day for 8 weeks (twice a day)
1833911|NCT00825565|Drug|Alwextin cream|Alwextin cream contains active ingredient, allantoin 3%. Use 1 application daily for 3 month duration.
1833912|NCT00825578|Device|Intra-bronchial valve (Spiration IBV)|Device: Intra-bronchial valve (Spiration IBV) The IBV is comprised of a Nitnol frame and a polymer membrane, which is held against the airway mucosa by six elastic struts and will expand and contract with airway movement during breathing. The valve is designed to conform to the size and shape of the airways. The frame has 5 flexible anchors that gently secure to the mucosal wall at a controlled depth. Valves are available in 5, 6 and 7mm diameters appropriate for different airways. During a minimally invasive procedure, a catheter is passed through a bronchoscope (a flexible tube passed into the airways through the mouth) to deploy the umbrella-shaped valves into the airways. Only flexible bronchoscopy equipment is required. The valves are designed to be removed if indicated.
1833913|NCT00825591|Dietary Supplement|Melatonin|Oral administration before bed. We will test two doses (0.5 or 3.0 mg/m2. 6 week duration.)
1833914|NCT00825591|Dietary Supplement|Placebo Comparator|Oral administration before bed. 6 week duration.
1833915|NCT00825604|Procedure|Percutaneous coronary angioplasty (PCI)|optimized medical treatment, physical training and smoking cessation with complimentary treatment with coronary angioplasty (PCI):
1833916|NCT00825617|Drug|Hormone replacement therapy|Women with TS were treated with oral hormone substitution consisting of 2 mg 17β-estradiol/day for days 1-12, 2 mg 17β-estradiol/day and 1 mg norethisterone acetate/day for days 13-22 and 1 mg 17β-estradiol/day for days 23-28 (Trisekvens, Novo Nordisk A/S, Bagsværd, Denmark)
1833917|NCT00825630|Drug|Lansoprazole (Lanton)|Oral administration of Lanzoprazole for 14 days in 25 patients with H.pylori infection
1833918|NCT00825630|Drug|Omeprezole (Losec)|Oral administration of Omeprazole for 14 days in 25 patients with H.pylori infection
1833919|NCT00825630|Drug|Pantoprazole(Controloc)|Oral administration of Pantoprazole for 14 days in 25 patients with H.pylori infection
1833920|NCT00825630|Drug|Esomeprazole (Nexium)|Oral administration of Esomeprazole for 14 days in 25 patients with H.pylori infection
1833921|NCT00825643|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of a normal clinical evaluation
1833923|NCT00825669|Drug|TACE|TACE: The chemotherapeutic drugs and 2 to 10 ml lipiodol are given via hepatica propria artery. The chemotherapeutic drugs include 5-Fu 1500 mg, epirubicin 30 mg, cisplatin 30 mg.
1833924|NCT00825669|Procedure|Laser ablation|Laser ablation is given to the PVTT.
1833925|NCT00825682|Other|Reflexology treatment.|Reflexology treatments (45 min. each) will be initiated at the beginning of radiation therapy, once a week, for 10 weeks.The treatment includes manual pressure on specific points of foot soles and massage of the calf area, adapted individually to each patient.
1833926|NCT00825695|Dietary Supplement|cocoa|two servings of cocoa daily for one month
1833927|NCT00825708|Device|rTMS|42 2 sec trains of 20HZ rTMS in 100% MT
1833928|NCT00825708|Device|shamTMS|sham TMS session
1833929|NCT00825721|Drug|LiquiTears|4 drops applied daily for 360 days
1833930|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
1833931|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
1833932|NCT00825721|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 360 days
1833933|NCT00825734|Drug|Sorafenib|Dose Level 1 - Sorafenib PO BID (200mg) Dose Level -1 - Sorafenib PO BID (200mg) Dose Level 1a - Sorafenib PO BID (400mg)
1833934|NCT00825734|Drug|Ixabepilone|Dose Level 1 - Ixabepilone IV every 21 days (40mg/m^2) Dose Level -1 - Ixabepilone IV every 21 days (32mg/m^2) Dose Level 1a - Ixabepilone IV every 21 days (32mg/m^2)
1833935|NCT00825747|Device|SeeLens AF intra-ocular lens|the SeeLens AF is an acrylic hydrophilic C shaped haptics intra-ocular lens, designed for implantation in the lenticular capsular bag or the sulcus during cataract surgery.
1833936|NCT00825760|Drug|Topical PPA904 gel and light|
1833937|NCT00825760|Drug|Topical placebo gel plus light|
1833938|NCT00825773|Device|Percutaneous Transluminal Coronary Angioplasty|Patients will be randomly assigned (2:1) to one of two treatment arms (the Excel DES or the Cypher DES). Randomization will be stratified by study site and number of vessels intended to be treated by the site investigator. Randomization will be accomplished through use of envelope randomization at the sites using the pre-assigned envelope randomization system. The study patient is considered enrolled upon randomization.
1833939|NCT00825786|Drug|Ropivacaine|ropivacaine (15 ml).
1833940|NCT00825786|Drug|Mepivacaine|One syringe will contain mepivacaine (15 ml)
1833941|NCT00825812|Drug|Sugammadex|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium intravenous (IV) could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 2.0 mg/kg sugammadex was administered.
1833942|NCT00825812|Drug|neostigmine|After induction of anesthesia an intubation dose of 0.6 mg/kg rocuronium was administered. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary. At reappearance of T2 after the last administration of rocuronium, an IV single bolus dose of 50 µg/kg neostigmine (combined with 10-20 μg.kg-1 atropine, in a ratio ranging from 2.5:1 to 5:1) was administered.
1833943|NCT00825825|Drug|Escitalopram|One week of escitalopram taken orally at 10 mg followed by one week at 20 mg daily.
1833944|NCT00825825|Drug|Citalopram|One week of citalopram taken orally at 20 mg followed by one week at 40 mg daily.
1833945|NCT00825825|Drug|Placebo|Two weeks of placebo taken orally.
1833946|NCT00825838|Dietary Supplement|Chronic consumption of chili pepper extract|6mg chili pepper extract per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
1833947|NCT00825838|Dietary Supplement|Chronic consumption of matching placebo|0mg chili pepper extract (matching placebo) per day in two divided doses (before the morning meal and before the evening meal) up to 12 weeks.
1833948|NCT00825851|Drug|Transdermal nicotine patch|15mg/16h + 10mg/16h to be used 24h
1833949|NCT00825851|Drug|Placebo patch|
1833950|NCT00825851|Behavioral|Smoking cessation|
1833951|NCT00825851|Behavioral|Continuous smoking|subjects smoke 20 cigarettes per day
1833952|NCT00825864|Drug|diclofenac drops|one drop 4 times a day for 3 months
1833953|NCT00825864|Drug|dexamethasone sodium phosphate 0.1% eye drops|for first week after the operation : one drop 6 times a day. Then tapering by reducing one drop for a week
1833954|NCT00825903|Behavioral|Exercise|Exercise 3 times each week for a total of 12 weeks. Each session is 50 min. in length.
1833955|NCT00825916|Drug|AZX100 Drug Product|Subjects were administered AZX100 3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
1833956|NCT00825916|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
1833957|NCT00825916|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
1833958|NCT00825942|Drug|C-KAD Ophthalmic Solution|4 drops applied daily for 180 days
1833962|NCT00825981|Other|screening coagulation abnormalities|if specific coagulation abnormalities are observed which increase patient's risk of bleeding, appropriate treatment will start
1833963|NCT00825994|Drug|Omega-3 Fatty Acids|2 g omega-3 fatty acids (docosahexaenoic acid [DHA] + eicosapentaenoic acid [EPA]), PO [by mouth], qd [every day]
1833964|NCT00826020|Drug|Omegaven™|10% Omegaven™, 50 or 100 mL bottle; 1gram/kg/day and is infused over 12-24 hours.
1833965|NCT00826046|Drug|Prochymal®|Patients will be treated with Prochymal twice per week at a dose of 2 x 106 hMSC/kg (actual body weight) for each of 4 consecutive weeks. Infusions will be administered at least 3 days apart.
1833966|NCT00826059|Device|The Ischemic Stroke System|SPG stimulation and standard of care
1833967|NCT00826059|Device|Sham control|Sham stimulation and standard of care
1833968|NCT00826085|Drug|ThermoDox in combination with Microwave Hyperthermia (heat)|"ThermoDox is a 30 minute intravenous infusion followed by hyperthermia within 60 minutes of infusion completion.
Hyperthermia is a therapy used to heat tumors for 60 minutes. Using heat energy, the tumor is heated to a certain temperature. The heat can damage cancer cells at levels that are usually safe for normal cells and can be used to attack cancer in four major ways: 1) heat damages or weakens the cells of the tumor; 2) heat increase blood flow through the weakened tumor; 3) increased blood flow raises oxygen levels in tumors; and 4) when the body senses fever it can stimulate the nature immune system.
All patients will receive up to six ThermoDox/hyperthermia treatments at 21-day intervals."
1833969|NCT00826098|Biological|Platelet Rich Plasma|Addition of PRP to total knee replacement procedure
1833970|NCT00826111|Drug|Eszopiclone|Subjects receive 10 mg escitalopram daily for four weeks and 10 or 20 mg for an additional six weeks. Subjects also receive 3 mg eszopiclone.
1833971|NCT00826111|Drug|Placebo|Subjects receive 10 mg of escitalopram daily for four weeks followed by 10 or 20 mg for an additional six weeks. Subjects also receive placebo for eszopiclone.
1833972|NCT00826124|Procedure|Epidural steroid injection|Injection based solely on history and physical exam
1833973|NCT00826124|Procedure|Epidural steroid injection|Two epidural steroid injections two weeks apart based on history, physical exam and MRI
1833974|NCT00826124|Procedure|Magnetic Resonance Imaging (MRI)|Imaging of lumbar spine
1834010|NCT00836498|Biological|Comparator: Placebo|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
1834176|NCT00838084|Drug|LY2811376|Oral capsules
1833975|NCT00836212|Drug|Reducing dose of Lopinavir|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
1833976|NCT00836212|Drug|Reducing dose of efavirenz|Patients with blood levels measured 2 times at 2 weeks intervals in the upper quartile (>percentile 75) of concentrations reported under standard therapy (i.e. EFV 600 mg q.d. or LPV/r 400 or 533 mg bid) will have their dose reduced by approximately one third, with the aim to bring their concentration in the 25-75% percentile range.
1833977|NCT00836225|Drug|ISIS 388626|"4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg
Placebo: 0.9% sterile saline"
1833978|NCT00836238|Behavioral|Interview|Physical Function and Symptom Assessment Interviews
1833979|NCT00836238|Other|Physical Function Tests|3 physical function tests.
1833980|NCT00836251|Dietary Supplement|H218O and 2H2O, administered as a mixed cocktail|0.195 g of H218O and 0.117 g of 2H2O per kg of estimated total body water (TBW), administered as a mixed cocktail
1833981|NCT00836277|Drug|Panitumumab|9mg/kg IV Day 1 Cycle = 21 days
1833982|NCT00836277|Drug|Irinotecan|125mg/m2 IV Day 1 and Day 8
1833983|NCT00836290|Behavioral|Pre-Release (Group 1)|Participants in the pre-release intervention group will receive four sessions in the four-week period prior to release and will receive a comprehensive booster session four weeks after release.
1833984|NCT00836290|Behavioral|Post-release (Group 2)|Participants in the post-release intervention group will receive one comprehensive introductory session four weeks before release and four sessions during the four-week period after release.
1833985|NCT00836303|Behavioral|Colorecatal Cancer Screening Activation|Research assistants showed intervention patients a colorectal cancer educational video in Spanish on a portable personal digital video display device while the patients were waiting for their visit. The 11-minute video was developed by the National Alliance for Hispanic Health and was accompanied by a brochure with key information from the video {http://www.hispanichealth.org/publication/}. Intervention patients were also given a one-page reminder to hand to their physicians notifying them 1) of their patients' eligibility for colorectal cancer screening, and 2) of their patients' receipt of CRC educational material.
1833986|NCT00836316|Drug|levobupivacaine|intraperitoneal administration of levobupivacaine on pain after laparoscopic cholecystectomy
1833987|NCT00836329|Behavioral|Intensive Glucose Management|Participants in the intensive glucose management group will undergo strict management of their blood glucose levels with a target whole blood glucose level of 100-140 mg/dL preoperatively, intraoperatively, and postoperatively in the intensive care unit (ICU). Once meals are started, targets for glycemia management will be (a) fasting: 80-140 mg/dL, (b) postprandial: 140-180 mg/dL. Prior to hospital discharge, participants will receive an in-depth diabetes education session. After hospital discharge, participants will attend monthly study visits for 6 months so that study researchers can monitor their glycemia management.
1833988|NCT00836329|Behavioral|Traditional Glucose Management:|Participants will receive traditional management of blood glucose levels while in the hospital. They may receive insulin several times a day, based on the results of glucose monitoring.
1833989|NCT00836355|Drug|Enoxaparin|2 (or 3) intravenous doses, the first on study entry, the last 24 hours later
1833990|NCT00836355|Drug|Minocycline|200 mg orally once daily for 5 days
1833991|NCT00836368|Dietary Supplement|gamma-tocopherol|oral doses 1,200 mg of gamma tocopherol (2 capsules of the gamma tocopherol enriched vitamin E preparation)
1833992|NCT00836381|Drug|Tolterodine extended-release (ER) 4mg|Tolterodine extended-release (ER) 4mg once daily for 12 weeks
1833993|NCT00836381|Drug|Placebo|Identical Placebo once daily
1833994|NCT00836394|Device|Galileo (whole body vibration (WBV) therapy)|6 minutes of training on 5 days a week for 3 months
1833995|NCT00836407|Drug|Ipilimumab|Ipilimumab (10mg/kg) will be administered intravenously at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
1833996|NCT00836407|Biological|Pancreatic Cancer Vaccine|The Pancreatic Cancer Vaccine (5E8 cells) will be administered intradermally at weeks 1, 4, 7 and 10. Subjects will also be offered maintenance phase dosing every 12 weeks.
1833997|NCT00836420|Procedure|no intervention|the value of the clinical use of microdialysis monitoring of the brain
1833998|NCT00836433|Behavioral|CONNECT educational intervention|The CONNECT educational intervention is a training program for staff to improve communication with a more dense network of co-workers, in order to improve resident problem-solving. Includes in class sessions, group and individual mapping exercises, self-monitoring of interactions, and individual staff coaching.
1833999|NCT00836433|Behavioral|FALLS educational intervention|FALLS is a traditional falls quality improvement education program including online modules, audit and feedback, and academic detailing sessions
1834000|NCT00836446|Other|physical activity|physical activity routines 5 times a weeks for 12 weeks.
1834001|NCT00836459|Behavioral|Mini Booster|Two telephone-based physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
1834002|NCT00836459|Behavioral|Full Booster|Two face-to-face physical activity consultations, delivered in a motivational interviewing style, at one month and two months from randomisation
1834003|NCT00836472|Drug|Glyburide/Metformin 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
1834004|NCT00836472|Drug|Glucovance® 5 mg/500 mg Tablets|1 x 5 mg/500 mg, single-dose fasting
1834005|NCT00836485|Drug|Ketotifen 4.0% Patch|This investigational drug is a transdermal patch indicated to treat allergic conjunctivitis. Application is intended for overnight wear between 8-10 hours.
1834006|NCT00836485|Drug|Placebo|The control is a placebo patch that contains only the inactive ingredients of ketotifen.
1834007|NCT00836485|Drug|Olopatadine 0.2%|1 gtt/eye on two separate occasions
1834008|NCT00836485|Drug|Artificial tears|1 gtt/eye on two separate occasions
1834009|NCT00836498|Biological|Comparator: RotaTeq|Three 2.0 mL oral doses of RotaTeq. Vaccination 1 administered on Day 1, Vaccination 2 administered 28-42 days after Vaccination 1, and Vaccination 3 administered 28-42 days after Vaccination 2.
1834011|NCT00836498|Biological|Comparator: RotaTeq + Placebo|One 2.0 mL oral dose of RotaTeq and two 2.0 mL oral doses of placebo over an approximately 3-5 month treatment period
1834012|NCT00836524|Procedure|ultrasound|4 ultrasound examinations during pregnancy and every time a blood sample is colletted. blood sample from the mother and the umbilical cord is collected as well
1834013|NCT00836537|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fed
1834014|NCT00836537|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fed
1834015|NCT00836550|Behavioral|Video|The participants saw a 6 minute video
1834016|NCT00836550|Behavioral|in-person HIV pre-test counseling|
1834017|NCT00836641|Biological|prevenar|7-valent pneumococcal conjugate vaccine
1834018|NCT00836641|Biological|pneumovax|23 valent pneumococcal polysaccharide vaccine
1834019|NCT00836654|Biological|Catumaxomab (Removab)|Puncture free survival
1834020|NCT00836654|Procedure|paracentesis|
1834021|NCT00836667|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
1834022|NCT00836667|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
1834023|NCT00836680|Device|Colorectal Stent|"Diagnosis of an internal rectal prolapse:
The device will be introduced and placed into the patient via a proctoscopic procedure. After that the doctor can measure and determine the internal rectal prolapse. After the diagnosis results have been received, the device will be removed from the patient via proctoscopic examination. The whole procedure will take approx. 5 minutes.
An additional X-ray examination procedure with the use of contrast media will be made for the determination of a pelvic floor ptosis and for the determination of an internal hernia into the Douglas pouch."
1834024|NCT00836693|Drug|tadalafil|5 milligrams (mg) administered orally once a day for 12 weeks
1834025|NCT00836693|Drug|placebo|tablet administered orally once a day for 12 weeks.
1834026|NCT00836706|Drug|clarithromycin|500 mg Tablet
1834027|NCT00836706|Drug|BIAXIN®|500 mg Tablet
1834028|NCT00836719|Drug|Polyphenon E|Polyphenon E capsules containing 200 mg of Epigallocachin-galleate. Two capsules twice a day.
1834029|NCT00836732|Procedure|harvest of a small bone marrow sample|harvest of a small bone marrow sample during open chest surgery
1834030|NCT00836745|Other|Non Interventional|Sutent capsule, once daily administered per the locally approved product information.
1958951|NCT01010763|Device|Total Hip Arthroplasty|Degenerated hip is replaced with implantable devices, which include femoral stem, acetabular cup, femoral head and acetabular liner(control group only).
1834032|NCT00836771|Dietary Supplement|Infant Formula|
1834033|NCT00836784|Other|old toothbrush|All children will receive new tooth brush 3 months before starting the study, at the end of 3 month the worn tooth brushes will be returned and the surface area within the outline will be determine using NIH (national institutes of health) image software.
1834034|NCT00836784|Other|New tooth brush|"The tooth brush which will be use in this study is Jordan. A new Jordan toothbrush will be give to all children, and in new tooth brush group they will use these toothbrushes."
1958953|NCT01007071|Drug|Human Growth hormone - nutropin|
1834037|NCT00836823|Drug|Alfuzosin|Alfuzosin 10mg once daily for 12 months
1834038|NCT00836836|Other|Modified Atkins diet|"Modified Atkins Diet administration
Carbohydrates intake will be restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)
Fats (e.g. cream, butter, oils, ghee) encouraged.
Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.
Clear carbohydrate-fluids not restricted.
Calcium and multivitamin supplementation will be provided."
1834039|NCT00836849|Drug|Zoloft® 100 mg Tablets|1 x 100 mg, single-dose fed
1834040|NCT00836849|Drug|Sertraline hydrochloride 100 mg Tablets|1 x 100 mg, single-dose fed
1834041|NCT00836862|Other|Biologic specimens|Banking of serum, DNA and tissue
1834042|NCT00836875|Drug|Voriconazole|"All subjects will receive voriconazole for a minimum of 6 weeks and a maximum of 12 weeks. All subjects must receive intravenous (IV) voriconazole for the first week of therapy.
Group 1: Subjects 2 to 11 years old and subjects 12 to 14 years old with low body weight (<50 kg) will receive 9 mg/kg IV every 12 hours (q12h) on day 1, then 8 mg/kg IV q12h starting day 2. If there is a significant clinical improvement after the first week of IV therapy, subjects may be switched to the step-down oral regimen (9 mg/kg PO q12h with a maximum dose of 350 mg PO q12h) at the discretion of the investigator.
Group 2: Subjects 12 to 17 years old (excluding 12-14-year-olds weighing <50 kg) will receive 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h starting day 2. Similar to Group 1, subjects may be switched to the step-down oral regimen (200 mg PO q12h) at the discretion of the investigator. Oral voriconazole can be administered as tablet or oral suspension."
1834043|NCT00836888|Biological|ONO-4538|1mg/kg, 3mg/kg, 10mg/kg and 20mg/kg ONO-4538 infusion cohorts
1834044|NCT00836901|Drug|amoxicillin-clavulanic acid|400 mg-57 mg chewable tablet
1834045|NCT00836901|Drug|Augmentin®|400 mg-57 mg chewable tablet
1834046|NCT00836914|Drug|CAL-101|CAL-101 100mg capsules administered orally twice a day (BID) for 7 days
1834047|NCT00836914|Drug|Placebo|Placebo capsules administered orally BID for 7 days
1834049|NCT00836940|Drug|GRC 8200|Capsules, 25 to 100mg, once/ twice a day, 12 weeks
1834050|NCT00836953|Biological|Influenza virus vaccine (Pediatric formulation)|0.25 mL, Intramuscular
1834051|NCT00837018|Other|physical exercise program|45 min, 3times a week
1834052|NCT00837031|Drug|Lenalidomide|The starting dose of lenalidomide for the lead-in portion will be 25 mg orally daily on Days 1-21, followed by a 7-day rest period (28-day cycle). If the 25-mg dose of lenalidomide is found to be intolerable or unsafe (i.e., if more than one of the 6 patients experience a DLT), then the dose will be reduced to 20 mg orally daily, and 6 additional patients will be treated. All patients will receive lenalidomide at the confirmed tolerable dose (either 25 mg or 20 mg given orally daily on Days 1-21 of a 28-day cycle) until disease progression. If the 20-mg daily dose is found to be intolerable or unsafe, enrollment will be put on hold.
1834053|NCT00837031|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV will be administered on Days 1, 8, and 15 for a 28-day cycle.
1834054|NCT00837044|Drug|Treximet|Treximet
1834055|NCT00837044|Drug|Migraine rescue medication of choice|Migraine rescue medication of choice
1834056|NCT00837057|Procedure|crrt|early CRRT (35 ml/kg/h)& acute kidney injury or failure or nearly anuria more than 2hr or late conventional dialysis indication
1834057|NCT00837070|Procedure|Percutaneous zygapophyseal cyst rupture|Patients will be treated by introducing a 20G spinal needle in the inferior joint recess of the zygapophyseal joint.1 ml of celestone-chronodose,1 ml of Marcain 5 mg/ml and 1-3 ml of contrast media:Omnipaque 240 will be injected until the cyst ruptures.
1834058|NCT00837096|Device|V.A.C. Therapy|Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.
1834059|NCT00837096|Device|Moist wound therapy (MWT)|Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
1834060|NCT00837109|Behavioral|Veteran Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
1834061|NCT00837109|Behavioral|Treatment-as-usual|Treatment-as-usual in the Trauma Recovery Program (that does not specifically target PTSD symptoms)
1834062|NCT00837135|Other|Screening|"A. SCREENING
Consent
Disease Evaluation (CT Scan/MRI; EGC/EUS; Laparoscopy)
Physical Exam, History, Blood Tests
Skin Test (for allergy to saccaromyces cerevisiae) yeast.
Collection of Blood for research
B. CHEMOTHERAPY AND RADIATION (as determined by Doctor)
C. ENROLLMENT INTO ACTIVE PART OF STUDY
Consent
Chemotherapy
GI-4000 Vaccine #1 + Prevnar + Activated T Cells
GI-4000 Vaccine #2
Disease Evaluation (CT Scan/MRI). If disease has spread, subject is taken off study. If disease is stable, subject go on to ARM A or ARM B."
1834063|NCT00837135|Biological|GI-4000 Vaccine|"Chemotherapy and Radiation
GI-4000 Vaccine #3
GI-4000 Vaccine #4"
1834064|NCT00837135|Biological|GI-4000 Vaccine + Activated T Cells|"Apheresis #2
Chemoradiation
Activated T Cells + GI-4000 Vaccine #3
GI-4000 Vaccine #4"
1834065|NCT00837135|Biological|Surgical Evaluation after Vaccine #4|"SURGICAL EVALUATION (to determine disease status) A. For those who have complete removal of tumor. These subjects will continue to receive Chemotherapy AND GI-4000 Vaccination Monthly during Chemotherapy. Disease evaluation every 3-6 months (CT Scan/MR.
B. For those sucjects who cannot have surgery or who have not had complete removal of tumor. These subjects will continue to have GI-4000 Vaccinations Monthly as long as there is no disease progression. Disease evaluation every 3-6 months (CT Scan/MR."
1834066|NCT00837148|Drug|Sorafenib and Dacarbazine|"Treatment will be administered on an outpatient basis. Sorafenib is supplied as 200-mg tablets. The starting dose of sorafenib will be 400 mg PO twice daily (every 12 hours) continuously. There is no planned treatment interruption between cycles.
All patients will receive dacarbazine as an open-label dose of 850 mg/m2 by IV infusion over 60 minutes, starting on Week 1 and repeated every 3 weeks until disease progression or intolerance."
1834067|NCT00837161|Device|Philips MR guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis
1834068|NCT00837174|Drug|Vorinostat in combination with Bortezomib|Patients will be treated with oral vorinostat on days 1 through 14 followed by a 7-day rest period, for a 21-day treatment cycle for up to 6 cycles in the absence of disease progression or unacceptable toxicity. The patients will receive once-daily oral vorinostat (400 mg) with bortezomib 1.3 mg/m2 as an IV push on days 1, 4, 8, 11.
1834069|NCT00837187|Drug|Intravenous dexmedetomidine|100 ug
1834070|NCT00837187|Drug|Intranasal dexmedetomidine|100 ug
1834071|NCT00837200|Drug|Oncaspar, Doxil, Decadron|Once enrolled, patients will receive a cycle (28 days) of Oncaspar (2500 IU/m2 IV on days 1, 15; Doxil 20 mg/m2 IV days 1,15; and Decadron 20 mg PO days 1, 8, 15, 22. Continue until disease progression or unacceptable side effects.
1834072|NCT00837213|Drug|Benzoyl peroxide with clindamycin|Benzoyl peroxide wash - Clindamycin foam
1834073|NCT00837213|Drug|Benzoyl peroxide with clindamycin and doxycycline|Benzoyl peroxide wash - Clindamycin foam - Doxycycline capsules
1834074|NCT00837239|Drug|Gemcitabine|1,000 mg/m2 once a week for 3 weeks then 1 week off (28 Day Cycle).
1834075|NCT00837239|Drug|HuaChanSu|20 mL/m2 for total 500 mL given as a 2 hour infusion, 5 days a week for 3 weeks then one week off (28 Day Cycle).
1834076|NCT00837239|Drug|Placebo|500 ml saline only administered as a 2 hour infusion by central line.
1834077|NCT00837252|Drug|Finasteride|Participants received 5mg of oral finasteride daily for three months.
1834078|NCT00837265|Biological|Neugranin|Neugranin (Recombinant Human Albumin-Human Granulocyte Colony Stimulating Factor)at two dose levels or comparator (pegfilgrastim 6 mg) administered approximately 24 hours following chemotherapy for 4 treatment cycles
1834079|NCT00837265|Drug|Pegfilgrastim|6mg
1834080|NCT00837265|Drug|Chemotherapy|study treatment was administered 24 hours after initiation of chemotherapy
1834081|NCT00837291|Drug|CF101|CF101 tablets 1 mg BID
1834082|NCT00837291|Drug|Placebo|Placebo tablets BID
1834083|NCT00837304|Device|PillCam Colon Capsule|PillCam Colon Capsule: The PillCam Colon capsule has two cameras that enable the device to take video images from both ends. It is 31.11 mm in size and takes pictures at a rate of 4 frames per second. The delay mode allows recording of images from the esophagus and the stomach for 5 minutes before the capsule switches into sleep mode for 2 hours to save energy.
1834084|NCT00837304|Procedure|Standard Colonoscopy|Standard Colonoscopy: Pts. undergo colonoscopy with a video colonoscope (CF H180 AI; Olympus, Tokyo, Japan).
1834085|NCT00837317|Dietary Supplement|Olive Oil, SF, SF+DMP, SF+phenols|All the volunteer subjects will be administered four breakfast meals that have been prepared with four different types of oil, each of which will have been subjected to a standardised frying. The meals will be administered according to a cross-randomized Latin squares design
1834086|NCT00837330|Drug|ranibizumab 0.5 or 0.3 mg/0.05 cc|ranibizumab 0.5 or 0.3 mg/0.05 cc administered intraocularly on a monthly basis for 3 months, followed by monthly examination with the option of further ranibizumab treatment or other therapies at the discretion of the treating physician
1834126|NCT00837759|Biological|Diamyd|
1834127|NCT00837759|Drug|GAD65 (Diamyd)|
1834128|NCT00837772|Device|Standard cutting guide for TKA|Use of the usual cutting guide for surgical replacement of a diseased knee
1834088|NCT00837356|Drug|Advate®|Subjects will receive Advate® at a dose of 50 IU/kg body weight in the first session
1834089|NCT00837356|Drug|turoctocog alfa|After a washout period of 4 days, subjects will subsequently receive turoctocog alfa (recombinant factor VIII (N8)) at a dose of 50 IU/kg body weight in the second session
1834090|NCT00837369|Drug|Regadenoson|400ug IV bolus injection, single dosage
1834091|NCT00837382|Behavioral|MEDVAMC Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting
1834092|NCT00837382|Behavioral|Telepsychiatry Nightmare Treatment|Veteran Nightmare Treatment Using Imagery Rescripting Through Videoconferencing
1834095|NCT00837447|Device|Total knee replacement with NexGen CR knee prosthesis|comparison of functional outcome in patients receiving either NexGen posterior cruciate-retaining or a high-flexion posterior cruciate-retaining total knee prosthesis
1834096|NCT00837447|Device|Total knee replacement(TKR) with Nexgen CR-flex|TKR using Nexgen CR-flex implant
1834097|NCT00837460|Other|rehabilitation|4 weeks of bilateral followed or preceded by 4 weeks of unilateral similar prehension oriented repeated rehabilitation tasks. About 45 minutes 3 times a week, the subject is coached by a physiotherapist to enhance his prehension habilities.
1834098|NCT00837473|Device|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures|Plexur-P used as a Bone Void Filler in Iliac Crest Harvesting Procedures
1834099|NCT00837486|Device|Reclaim™ DBS System|
1834100|NCT00837499|Behavioral|Questionnaire|Interview and survey during visit or by phone, 30 - 40 minutes.
1834101|NCT00837512|Device|Microneedle|Microneedle used to deliver insulin at a depth less than 900 micrometers
1834102|NCT00837512|Device|Subcutaneous insulin catheter|Subcutaneous insulin catheter used to deliver insulin at a depth of 9 mm (9000 micrometers)
1834103|NCT00837525|Procedure|nasal valve implant|Injectable implantation of a biodegradable material for support of the Nasal valve.
1834104|NCT00837551|Drug|WBI-1001|Doses of 0,0.5% and 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with one week follow-up.
1834105|NCT00837564|Other|CBASP psychotherapy|specific psychotherapy for chronic depression
1834106|NCT00837564|Drug|Escitalopram|Escitalopram 10-20 mg once daily for the treatment of depression in combination with clinical management
1834107|NCT00837577|Drug|Comparator: Placebo|Placebo to sitagliptin once daily for 12 weeks (double-blind period)
1834108|NCT00837577|Drug|Sitagliptin|"Sitagliptin/Sitagliptin arm only: Sitagliptin 50 mg once daily orally before breakfast for 12 weeks (double-blind period).
Both arms: Sitagliptin 50 mg once daily orally before breakfast for 40 weeks (open-label period). The dose of sitagliptin was increased up to 100 mg for participants who had an inadequate response to sitagliptin 50mg after treatment Week 20."
1834109|NCT00837577|Drug|Voglibose|"All participants received a stable dose of voglibose, in
accordance with the package insert, throughout the study."
1834113|NCT00837603|Behavioral|Training|Controlled home ergometer training
1834114|NCT00837616|Drug|17 B estradiol orally|Group A will be given estrogen by mouth daily(0.5 mg or 1mg or 2 mg of 17B Estradiol. Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
1834115|NCT00837616|Drug|17 B estradiol|Group B will be given estrogen via a patch applied to the skin twice a week (0.375mg or 0.05mg or 0.075mg) Doses will vary depending on the blood levels of estrogen starting with the lower doses and adjusting these doses up as needed to keep the levels in the normal range. The estrogen will be taken for 21 days. In order to have a menstrual cycle progesterone will be given for 7 days, starting from day 14 through day 21 of each cycle. Then both medications are stopped on day 21 for a total of 7 days. Labs will be obtained at baseline, 1,2,3,6,9 and 12 months. Dual-energy X-ray absorptiometry (DXA) scan and calorimetry will be done at baseline and at 6 and 12 month.
1834116|NCT00837642|Dietary Supplement|Vitamin C and E|
1834117|NCT00837655|Drug|Sevelamer|sevelamer tablets, 800 mg (Renagel(r), Genzyme Inc). The initial daily dose of sevelamer will be 2400 mg (800 mg x 3). After the first week of treatment the dose will be increased to 4800 mg. If treatment with sevelamer is well tolerated and if a phosphate concentration of <1.8 mmol/l is not obtained, the dose may be increased further. The maximum daily dose of sevelamer will be 9600 mg. If a patient experiences side effects, the dose of sevelamer will be reduced to the highest acceptable dose, and, if a phosphate concentration of <1.8 mmol/l is not obtained, the treatment will be supplemented with calcium carbonate in a dose tolerated by the patient.
1834118|NCT00837655|Drug|Calcium carbonate|Calcium carbonate tablets, 250 mg (Kalcidon, Abigo AB). Calcium carbonate will be prescribed at the dose given prior to the washout period. The dose will be adjusted weekly to obtain a serum phosphate concentration <1.8 mmol/l.
1834119|NCT00837707|Drug|aripiprazole|Flexible dose: 5-30 mg/day
1834120|NCT00837733|Procedure|Endometrial biopsy|Endometrial biopsy was done at luteal phase on the day 21-26 of spontaneous menstrual cycles, when GnRH agonist uses begun. Endometrial samples were taken by a biopsy catheter
1834121|NCT00837733|Procedure|Endometrial Biopsy|Biopsy catheter
1834122|NCT00837746|Drug|risedronate|risedronate tablet, 5 mg daily or 35 mg once weekly for 5 years
1834123|NCT00837759|Drug|Insulin|
1834124|NCT00837759|Drug|Lansoprazole|
1834125|NCT00837759|Drug|Sitagliptin|
1992686|NCT03315507|Drug|PB1046 Subcutaneous Injection|Eight weekly doses of PB1046.
1992687|NCT03314662|Biological|MF59-adjuvanted Quadrivalent Subunit Inactivated Egg-derived Influenza Vaccine (aQIV)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for quadrivalent vaccines.
1834129|NCT00837772|Device|Otismed MRI generated cutting guide for TKA|Use of the customized MRI generated cutting guide for surgical replacement of a diseased knee
1834130|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally three times a day
1834131|NCT00837785|Drug|BG00012|240 mg (two 120 mg capsules) orally twice a day
1834132|NCT00837798|Device|CRM Device|Pacemaker, ICD, or CRT device
1834133|NCT00837811|Biological|LY2127399|60 mg (with potential for dose escalation to 120 mg) subcutaneously every 4 weeks for 48 weeks
1834134|NCT00837824|Biological|Fabrazyme (agalsidase beta)|1.0 mg/kg every 2 weeks
1834135|NCT00837824|Biological|Fabrazyme (agalsidase beta)|3.0 mg/kg every 2 weeks
1834136|NCT00837837|Drug|Chlorpheniramine|
1834137|NCT00837850|Device|Bone cement 1|Bone cement SmartSet® HV
1834138|NCT00837850|Device|Bone cement 2|Bone cement Palacos R
1834139|NCT00837863|Drug|Somatropin|ALTU-238 0.3 mg/kg daily
1834140|NCT00837863|Drug|Somatropin|ALTU-238 0.6 mg/kg daily
1834141|NCT00837863|Drug|Somatropin|ALTU-238 0.9 mg/kg daily
1834142|NCT00837863|Drug|Somatropin|Nutropin AQ 0.043 mg/kg daily
1834143|NCT00837876|Drug|Sorafenib|400 mg taken by mouth 1 time per day.
1834144|NCT00837876|Drug|Erlotinb|150 mg taken by mouth 1 time per day.
1834145|NCT00837889|Drug|diuretics, inotropica|
1834146|NCT00837902|Drug|Atenolol (β-blocker)|25 mg tablet
1834147|NCT00837915|Drug|Loratadine 10mg /Pseudoephedrine Sulfate 240 mg Extended-Release Tablets|
1834148|NCT00837928|Drug|bendamustine|40 mg/m2 will be administered IV on days 1,2,and 3 prior to surgery.on each day of SRT.
1834149|NCT00837928|Other|laboratory biomarker analysis|samples will be obtained on day 1 or 2 only from patients undergoing surgery on day 3 (i.e. PK samples will not be collected from patients who begin SRT on day 1).
1834150|NCT00837928|Procedure|Surgical Resection of Brain Metastases|Surgical Resection of Brain Metastases Day 3 (immediately after Bendamustine)
1834151|NCT00837928|Radiation|Stereotactic body radiation therapy|Starting at least 4 weeks after surgery (Day 1 if no surgery ); 30 Gy in 5 daily fractions(Mon-Fri)
1834152|NCT00837941|Drug|Comparator: A: Pregabalin|1 Pregabalin 300 mg capsule
1834153|NCT00837941|Drug|Comparator: B: Duloxetine|1 Duloxetine hydrochloride 60 mg capsule
1834154|NCT00837941|Drug|Comparator: C: Diphenhydramine hydrochloride|1 Diphenhydramine hydrochloride 25mg capsule
1834155|NCT00837954|Device|Lyostypt® AND Surgicel®|"The investigational products are the hemostats Lyostypt® and Surgicel® (=Tabotamp® ). Lyostypt® will be provided in the size 5cm x 8cm, Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.
Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII.
Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
1834156|NCT00837954|Device|Lyostypt®|"The investigational product is the hemostat Lyostypt®. Lyostypt® will be provided in the size 5cm x 8cm. The devices will be cut into half.
Lyostypt® is an absorbable wet-stable collagen compress made of collagen fibrils of bovine origin. Collagen leads to thrombocyte adhesion and to activation of coagulation factor XII."
1834157|NCT00837954|Procedure|Surgicel®|"The investigational product is the hemostat Surgicel® (=Tabotamp® ). Surgicel® will be provided in the size 5cm x 7,5cm. The devices will be cut into half.
Surgicel® absorbable Haemostat is a sterile absorbable knitted fabric prepared by the controlled oxidation of regenerated cellulose. After Surgicel® has been saturated with blood, it swells into a brownish or black gelatinous mass which aids in the formation of a clot, thereby serving as a haemostatic adjunct in the control of local haemorrhage."
1834158|NCT00837967|Drug|Symbicort Turbuhaler|160/4.5μg for 3 days
1834159|NCT00837967|Drug|Terbutaline Turbuhaler|0.4 mg for 3 days
1834163|NCT00838019|Procedure|Intrabone administration of umbilical cord blood|Single administration
1834166|NCT00838045|Device|The Bausch & Lomb Akreos TL IOL (MI60) posterior chamber IOL|Surgery to implant the Bausch & Lomb Akreos TL Intraocular Lens will be performed using standard microsurgical techniques following cataract surgery.
1834167|NCT00838058|Drug|CE-224,535|one 250mg tablet, once in the morning in fasted state
1834168|NCT00838058|Drug|CE-224,535|2x250 mg tablets, once in the morning, in fasted state
1834169|NCT00838058|Drug|CE-224,535|4x250mg tablets, once in the morning, in fasted state
1834170|NCT00838058|Drug|CE-224,535|2x250mg tab, once in the morning, after being fed a high fat meal
1834171|NCT00838058|Drug|CE-224,535|4x125 mg tabs, once in the morning, in the fasted state. This arm will only occur as part of Part 2, if needed, pending results of Part 1.
1834172|NCT00838058|Drug|CE-224,535|4x125 mg IR once in the morning after being fed a high fat meal
1834173|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 tabs once in the morning in the fasted state
1834174|NCT00838058|Drug|CE 224,535|2x250 mg controlled release formulation 5 once in the morning after being fed a high fat meal
1834175|NCT00838071|Drug|Specific intravenous anti-hepatitis B immunoglobulin|Monthly doses of 5000 IU administered intravenously during 6 consecutive months
1834177|NCT00838084|Drug|Placebo|Oral capsules
1834178|NCT00838110|Drug|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 26
1834179|NCT00838110|Drug|Placebo|10 mg TID for week 1 followed by 20 mg TID through Week 26
1834180|NCT00838110|Drug|Dimebon|10 mg TID for week 1 followed by 20 mg TID through Week 12
1834181|NCT00838110|Drug|Placebo|20 mg matched Placebo (Cohort 2) 10 mg TID for week 1 followed by 20 mg TID through Week 12
1834182|NCT00838136|Drug|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
1834183|NCT00838136|Drug|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fed
1834184|NCT00838149|Dietary Supplement|Glutamine|"Glutamine group :
Glutamine would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble commercial preparation containing 10 gm of pure L- Glutamine in the crystalline form. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
1834185|NCT00838149|Dietary Supplement|Whey protein|"Whey protein group:
Whey protein would be supplemented (0.5gm/Kg ideal body weight) in the form of a water soluble whey protein concentrate containing 70 % protein. The patient in this group would be counseled to meet the remaining protein requirement (i.e1g/Kg/wt) by usual diet. This intervention would be made over a period of two months."
1834186|NCT00838162|Drug|TMC310911 75 mg twice daily|TMC310911 75 mg twice daily orally (by mouth) on Days 1 to 14.
1834187|NCT00838162|Drug|TMC310911 150 mg twice daily|TMC310911 150 mg twice daily orally (by mouth) on Days 1 to 14
1834188|NCT00838162|Drug|TMC310911 300 mg twice daily|TMC310911 300 mg twice daily orally (by mouth) on Days 1 to 14
1834189|NCT00838162|Drug|TMC310911 300 mg once daily|TMC310911 300 mg once daily orally (by mouth) on Days 1 to 14
1834190|NCT00838162|Drug|Ritonavir 100 mg twice daily|Ritonavir 100 mg twice daily orally (by mouth) on Days 1 to 14
1834191|NCT00838162|Drug|Ritonavir 100 mg once daily|Ritonavir 100 mg once daily orally (by mouth) on Days 1 to 14
1834193|NCT00838188|Other|Way of Feeding - Breast feeding vs. Bottle feeding|Each infant was evaluated twice, once after breastfeeding and once after bottle feeding of breast. Computer-generated random numbers in sealed opaque envelopes to assign the breast/bottle sequence
1834194|NCT00838201|Drug|Denosumab|60 mg SC of Denosumab will be administered on study day 1, month 6, month 12, and month 18
1834195|NCT00838214|Drug|budesonide|3mg capsule, 3x per day for 6 months
1834196|NCT00838214|Drug|prednisone|5mg tablet, 40mg starting dose per day, titration to 10mg per day within 3 months
1834197|NCT00838227|Drug|modafinil|Modafinil up to 400 mg daily will be added to a stable antipsychotic regimen
1834198|NCT00838240|Drug|clofarabine|Given IV
1834199|NCT00838240|Drug|cytarabine|Given IV
1834200|NCT00838240|Drug|idarubicin|Given IV
1834201|NCT00838253|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
1834202|NCT00838253|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
1834203|NCT00838253|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
1834204|NCT00838253|Drug|Placebo|Placebo continuous i.v. infusion for 24 hours
1834205|NCT00838266|Drug|mouthrinse (Grape Seed Extract + nicomethanol fluorhydrate)|Antiplaque mouthrinse containing active component three times a day, during 1 minute, for 4 days
1834206|NCT00838266|Other|mouthrinse containing non-active component|Antiplaque mouthrinse containing non-active component three times a day, during 1 minute, for 4 days
1834207|NCT00838279|Drug|Lamotrigine 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
1834208|NCT00838279|Drug|Lamictal® 25 mg Chewable Tablets|2 x 25 mg, single-dose fasting
1834209|NCT00838292|Dietary Supplement|fortified blended flour - Insta Foundation Plus (with whey protein concentrate)|300 grams/day for 6 months
1834210|NCT00838292|Other|nutrition counseling|
1834211|NCT00838305|Drug|MDMA and citalopram|MDMA 1.5 mg/kg and citalopram 20 mg
1834212|NCT00838305|Drug|Placebo|drug: placebo subjects also get citalopram and placebo in a 2x2 crossover design
1834213|NCT00838318|Behavioral|Interview|Audiotaped Phone Interview/Survey, 30 - 45 minutes.
1834214|NCT00838331|Biological|Fresh blood|For fresh transfusions, a whole blood unit will be drawn from volunteers, processed, and then reinfused on the same day during the study. For impaired and repaired transfusions, the volunteers will be brought to the blood bank to donate; then, after processing and the appropriate length of storage (eg, 28 days), they will return for the FBF studies. Since recipients of fresh transfusions are relatively anemic after donation and before reinfusion, recipients of impaired/repaired transfusions should also be mildly anemic for the study. Thus, they will donate another whole blood unit prior to beginning the study course, they will be transfused with their stored unit during the study, and then the autologous unit collected at the beginning of the day will be reinfused at the end of the day after the study is complete.
1834215|NCT00838331|Biological|Aged blood|"In a separate aim, the FMD assay will be used to investigate NO-mediated vasodilation in patients with CVD who are receiving transfusions. Over 60% of blood orders for cardiology patients at Emory are for 2 units or more. Therefore, when a 2-unit order is placed on a consented patient, they will be issued both fresh (< 7 days) and impaired (> 28 days) compatible units from inventory. Prior to starting transfusions, the patient will be randomized to either receive the fresh or the older unit first. All RBC units will be ACD/AS1. Units will also be leukoreduced and/or irradiated, if either of those modifications were found to impair NO bioavailability in prior studies. If washing or rejuvenation were found to be successful in significantly repairing NO bioavailability in previous aims, some patients may also receive impaired and repaired (> 28 days; washed or rejuvenated) RBC transfusions."
1834216|NCT00838344|Other|Medication Adherence Program (MAP)|Telephone follow-up call to individuals with diabetes (Type 2) who have missed a prescription refill by 6 or more days. Call includes assessment of refill need, discussion of diabetes care progress and any medication adherence barriers with intervention to resolve barriers.
1834217|NCT00838357|Drug|Generic = Plerixafor|240µg/kg administered as an SC injection 10 to 11 hours prior to initiation of apheresis. Daily administration for 1 up to 5 consecutive days
1834387|NCT00829374|Drug|Dimebon|20 mg orally three times daily
1834218|NCT00838370|Drug|Capecitabine, 5-fluorouracil|"Patients to treat with capecitabine/5-FU will be screened prior to start of therapy for DPYD*2A. Patients heterozygous or homozygous mutant for DPYD*2A receive dose reductions of capecitabine/5-FU of at least 50% in the first two courses. In case this dose is tolerated well, doses will be increased.
In addition, the pharmacokinetics of capecitabine/5-FU and their metabolites will be assessed in these patients."
1834219|NCT00838383|Drug|sitaxsentan (Thelin)|sitaxsentan (1.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
1834220|NCT00838383|Drug|sitaxsentan (Thelin)|sitaxsentan (2.0 mg/kg) will begin immediately following cross-clamp release and 12 hours post-CPB.
1834221|NCT00838383|Drug|Placebo|Placebo will begin immediately following cross-clamp release and 12 hours post-CPB.
1834222|NCT00838396|Drug|XP19986 CR|
1834223|NCT00838396|Drug|Placebo for XP19986 CR|
1834224|NCT00838435|Drug|sapropterin dihydrochloride|A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
1834225|NCT00838448|Behavioral|Exercise|Exercise performed on a treadmill for 20-30 minutes
1834226|NCT00838461|Drug|HSD-016|
1834227|NCT00838461|Drug|placebo|
1834228|NCT00838474|Other|music|Each infant was randomized to receive music therapy or no music over 2 consecutive days
1834229|NCT00838487|Other|condroflex and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
1834230|NCT00838487|Other|sugar pill and exercise|1 sachet oral once a day by 12 Weeks / therapeutic exercise 3 times a week
1834231|NCT00838500|Drug|Immediate spa treatment|1st year, soon after randomization: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
1834232|NCT00838500|Drug|Late spa treatment|2nd year, soon after 12 months visit: Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts(walk in a specially pool, whirlpool bath with automatic air and water massages cycles, massaging shower...)
1834233|NCT00838513|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
1834234|NCT00838526|Drug|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
1834235|NCT00838526|Drug|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
1834243|NCT00838578|Biological|KRN330|KRN330 will be dosed at 0.5 mg/kg weekly until disease progression.
1834244|NCT00838578|Drug|Irinotecan|Irinotecan will be dosed at 180 mg/m2 biweekly until disease progression.
1834245|NCT00838591|Drug|MN-221|Dose: intravenous 1-hour infusion of MN-221 (total dose 1200 μg) or matching placebo.
1834246|NCT00838591|Drug|Placebo|
1834247|NCT00838630|Drug|Cilostazol 100 mg tablets|1 x 100 mg
1834248|NCT00838630|Drug|Pletal® 100 mg tablets|1 x 100 mg
1834249|NCT00838656|Drug|carboplatin|Given IV in one of two schedules
1834250|NCT00838656|Drug|gemcitabine hydrochloride|Given IV in one of two schedules
1834251|NCT00838656|Drug|paclitaxel|Given IV in one of two schedules
1834252|NCT00838669|Drug|Extended release OROS paliperidone|
1834253|NCT00838682|Drug|omeprazole sodium IV|Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
1834254|NCT00838682|Drug|Rabeprazole|Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.
1834255|NCT00838695|Drug|phenylephrine and nitroglycerin|Intravenous phenylephrine at low doses (approximately 10 doses ranging from 0-5000 ng/min) Intravenous nitroglycerin at low doses (approximately 10 doses ranging from 0.05-100 ng/min)
1834256|NCT00838708|Drug|SRD174 Cream|topical SRD174 Cream
1834257|NCT00838708|Other|vehicle cream|topical vehicle cream
1834258|NCT00838721|Other|laser trabeculoplasty|Deliver laser energy to the trabecular meshwork using the Pascal Laser System
1834259|NCT00838760|Drug|TMC558445; TMC310911; Darunavir; Placebo|
1834260|NCT00838773|Behavioral|YMSM|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
1834261|NCT00838773|Behavioral|YHA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
1834262|NCT00838773|Behavioral|ROMA|Leaders of networks in the experimental condition will participate in a 9-session intervention training program that will inspire and assist leaders to communicate HIV prevention risk reduction messages with their immediate friends. The first five sessions will focus on HIV risk predictors including HIV/AIDS knowledge, safer sex peer norms, condom attitudes, condom use intentions, and self-efficacy in remaining safe. The remaining four sessions will reinforce the leaders for continuing their HIV prevention communications and remind them of the topics during the main sessions.
1834263|NCT00838799|Drug|RGH-896|45 mg TID, capsules, 14 weeks.
1834264|NCT00838799|Drug|RGH-896|30 mg TID, capsules, 14 weeks.
1834265|NCT00838799|Drug|RGH-896|15 mg TID, capsules, 14 weeks.
1834266|NCT00838799|Drug|pregabalin|100 mg, TID, capsules, 14 weeks.
1834267|NCT00838799|Drug|placebo|TID, capsules, 14 weeks.
1834268|NCT00838812|Drug|application of the topic gel|Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
1834269|NCT00838825|Other|introduction of the chronic care model|The care management team is organized according to the chronic care model for health care delivery. They are supported by an information registry for diabetes, receive instruction in self-management, have redesigned their work flow to include delegation of functions to care managers who follow specific guidelines and protocols for managing diabetes
1834270|NCT00838838|Drug|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients > 18yrs in medical practices fulfilling all criteria for documentation.
1834271|NCT00838851|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 20,000 EU Clinical Center Reference Endotoxin (CCRE)
1834272|NCT00838864|Drug|ceftrioxone|500 mg iv q12h for 3 days
1834273|NCT00838864|Drug|ceftrioxone|500 mg q12h for 7 days
1834274|NCT00838877|Drug|radioligand [18F]AZD4694|single dose of iv. admin. 1-2 times per subject
1834275|NCT00838877|Drug|radioligand [11C]AZD2184|single dose of iv admin. 1 time per subject
1834276|NCT00838890|Drug|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, QD x 14 days until MTD is achieved, 14 days per 28 day cycle/QD, 12 months
1834277|NCT00838890|Drug|Cdc7-inhibitor (BMS-863233)|Tablets, Oral, MTD of Cdc7-inhibitor (A) Arm, QD x 7 days until MTD achieved, 7 days per 21 day cycle/QD, 12 months
1834278|NCT00838903|Biological|albiglutide|albiglutide
1834279|NCT00838903|Drug|sitagliptin|sitagliptin
1834280|NCT00838903|Drug|glimepiride|Glimepiride
1834281|NCT00838903|Drug|metformin|Metformin
1834282|NCT00838903|Biological|placebo albiglutide|placebo to match albiglutide
1834283|NCT00838903|Drug|placebo sitagliptin|placebo to match sitagliptin
1834284|NCT00838903|Drug|placebo glimepiride|placebo to match glimepiride
1834285|NCT00838916|Biological|albiglutide|albiglutide weekly injection
1834286|NCT00838916|Drug|insulin glargine|insulin glargine
1834287|NCT00838929|Drug|Vorinostat|"All doses given for 3 weeks
Dose level -2 - 50 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level -1 - 100 mg PO qd (to be used in de-escalation if toxicity occurs) Dose level I - 200 mg PO qd (initial starting dose) Dose level II - 300 mg PO qd Dose level III - 400 mg PO qd"
1834288|NCT00838929|Radiation|Radiation Therapy|Patients will take Vorinostat daily during radiation therapy, they will be recommended to swallow the capsule 60-90 minutes prior to estimate time of radiation.
1834289|NCT00838942|Behavioral|Questionaries|MMS (Mini Mental Status), ADAS-cog Alzheimer Disease Assessment Scale for cognitive functions, NPI (Neuropsychiatric Inventory) for behavior troubles, IADL (Instrumental Activities of Daily) for autonomy evaluation, GDS (Geriatric Depression Scale) or Cornell Scale (Cornell Scale for Depression in Dementia) for mood troubles.
1834290|NCT00838955|Drug|Temsirolimus|Temsirolimus 25 mg IV infusion on Days 1, 8, 15, and 22 of a 28 day cycle
1834291|NCT00838968|Drug|interferon-alpha|interferon-alpha is intramuscularly or subcutaneously injected at 3,000,000-5,000,000 U three times a week for 18 months
1834292|NCT00838981|Drug|Modafinil|Modafinil is started at 200mg on the first day of week 1 (treatment phase) and increased to 400mg by the end of that week. Subjects will continue to receive 400mg/day for the remainder of the study.
1834293|NCT00838981|Drug|Sugar Pill|placebo, sugar pill will mirror active drug
1834294|NCT00838981|Behavioral|Contingency Management|Subjects in the CM conditions will earn vouchers for providing cocaine-free urine specimens. Subjects will be informed of the urine test results when available and, for subjects in the CM condition, receive a voucher at that time if the sample is negative. Subjects in the CM condition earn a minimum of $3 for each urine sample they submit that is negative for cocaine. Voucher amounts will escalate by $1 per consecutive clean urine sample submitted up to a maximum of $15 per clean sample.
1834295|NCT00838981|Drug|Methadone|Subjects will be started on 30 mg of methadone and the dose will be increased as tolerated to reach 60 mg at the end of the first 1-2 weeks of the induction phase. Methadone dosing will bestabilized. During methadone maintenance (weeks 1-11 of treatment phase), subjects continue to receive their maintenance doses of methadone plus modafinil or placebo.
1834296|NCT00838981|Behavioral|cognitive behavioral treatment|All subjects will receive a manual-guided CBT treatment over the course of their 16-week participation. This manual-guided therapy promotes abstinence through a functional analysis of high-risk situations and coping skills training.
1834297|NCT00838981|Behavioral|Voucher Control|Subjects in the Yoked-Control condition (YC) will be paired with a CM subject. Subjects in the YC condition will be informed that they will receive vouchers according to an unpredictable schedule, and that they cannot control when they will receive these vouchers or how much they will be worth.
1834298|NCT00838994|Other|Acupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
1834299|NCT00839007|Drug|CD-NP|Infusion of CD-NP at one of up to 6 doses or placebo
1834300|NCT00839020|Procedure|Navigated TKA with a minimally invasive approach|Navigated total knee arthroplasty with a minimally invasive approach
1834301|NCT00839020|Procedure|Navigated TKA with a conventional approach|A navigated total knee arthroplasty is performed using the Orthopilot navigation system. A conventional approach is performed
1834388|NCT00829374|Drug|Placebo comparator|Placebo orally three times daily
1834433|NCT00829725|Device|screws-internal fixation|3-4-screws-internal fixation
1834302|NCT00839033|Device|mechanical insufflation - exsufflation|Patients will receive MI-E treatment with the following settings: insufflation pressure of at least +30 cm H2O and an exsufflation pressure ≥ -30 cm H2O. There will be at least 6 hyperinflation/exsufflation sequences per session of chest physiotherapy. There will be at least two daily sessions done routinely by the respiratory therapist at 8 hour intervals.
1834303|NCT00839033|Device|Standard respiratory physiotherapy|Traditional chest physiotherapy without mechanical insufflation-exsufflation
1834304|NCT00839046|Behavioral|Community Health Worker Intervention|The Community Health Worker (CHW) intervention consists of visits by CHWS to help families reduce children's exposure to common asthma triggers (allergens and irritants) in the indoor environment. The content of the CHW visits and the materials distributed will follow NHLBI Expert Panel Report 2 recommendations. Each household will receive 6 visits over a 12-month period in which the CHW will provide education on environmental triggers (e.g., reduction of dust mites, cockroaches, cat and dog dander, and environmental tobacco smoke); materials including vacuum cleaners with HEPA filters, mattress and pillow covers, and cleaning supplies; social support to the caregivers; and, if indicated, referrals to other services.
1834305|NCT00839046|Other|Air Filter|Fifty households will receive an Air Filter, in addition to receiving the standard community health worker intervention. These households will receive a HEPA room AF (Whirlpool 510 or equivalent), a relatively high capacity unit that can be quietly operated. Similar to other studies the filter will be placed in the room where the child sleeps. The HEPA AF will be installed at the beginning of the intervention period.
1834306|NCT00839046|Other|Air Filter and Air Conditioner|Fifty households will receive the air filter and the air conditioner, in addition to receiving the standard community health worker intervention. The air filter will be installed at the beginning of the intervention, after baseline measurement. In the spring of the year (2009), a small window AC unit (Whirlpool Designer Style ACQ058MM or equivalent) will also be installed in the room where the child sleeps.
1834307|NCT00839059|Drug|lenalidomide|"Dose escalation:
Level 0 to level 5, starting with level 1 = 25mg lenalidomide per os daily, Cohorts of 3 patients (to be expanded up to 6 if 1 DLT is observed among the first 3 patients) will be sequentially allotted to progressively higher dose levels of lenalidomide on the basis of the presence and severity of lenalidomide related toxicity encountered in the first cycle or lenalidomide related serious adverse reactions.
Duration of the first cycle: 56days, each following cycle will last 28 days"
1834308|NCT00839072|Drug|Trazodone HCl|100 mg immediate-release tablet, dosing q8h
1834309|NCT00839072|Drug|Trazodone HCl|300 mg extended-release caplet, single dose
1834310|NCT00839085|Drug|GSE|grape seed extract (100 mg/6h), PO
1834311|NCT00839085|Drug|Vit C (Ascorbic Acid)|Vit C 25 mg/ kg
1834312|NCT00839098|Other|Instruction Group: Power seat function usage instruction- verbal and written instruction|Subjects assigned to the Intervention Group will be assigned to an Intervention Group Clinician. The Intervention Group Clinicians will provide the same training as the Control Group Clinicians, with the addition of discussing the Veteran's activity and seating function usage data, reviewing and providing a study pamphlet and compact disk as a reference guide on use of power seat functions.
1834313|NCT00839098|Other|Instruction and Virtual Coach Group: Power seat function usage instruction- verbal, written, and virtual coach|Subjects assigned to the Instruction & Virtual Coach Group will be assigned to an Intervention Group Clinician and will receive the same training and instructional materials as the Instruction Group. Subjects will also be instructed in use of the virtual coach system, which will be active during the in-home usage periods to provide personalized feedback. As the Virtual Coach is a dynamic intelligent system, it will adjust its coaching to the needs of the individual. For example, if the person is compliant, the Virtual Coach will give positive feedback and then gradually transition to operating quietly in the background. If a person is not fully compliant, it will alter feedback modes (e.g., verbal cues, auditory tones, visual cues) and timing to attempt to increase compliance.
1834314|NCT00839111|Drug|sorafenib|Sorafenib 400mg twice daily from d3 to d14,d17-28
1834315|NCT00839111|Drug|FOLFIRI|Irinotecan 180 mg/m2,CF 400mg/m2 5Fu 400mg/m2 bolus, followed by 2.4g/m2 continuously intravenous infusion for 46 hours, days 1 and 15, every 4 weeks per cycle
1834316|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation challenge with 20,000 EU CCRE
1834317|NCT00839124|Biological|Clinical Center Reference Endotoxin (CCRE)|inhalation of 20,000 EU CCRE
1834318|NCT00828945|Device|Lipid Self Test|Self test for lipid levels, twice during study period
1834319|NCT00828958|Drug|Risperidone long-acting injectable|
1834320|NCT00828971|Drug|Avelox (Moxifloxacin, BAY12-8039)|Sequential IV/PO moxifloxacin 400/400 mg every 24 hours, for 7 to 21 days.
1834321|NCT00828971|Drug|Amoxicilline/clavulanic|IV Amoxicilline/clavulanic acid 2000/200 mg TID followed by PO amoxicilline/clavulanate 875/125 mg TID for a total of 7 to 21 days
1834322|NCT00828984|Drug|macrogol 3350-based oral osmotic laxative|Given PO
1834323|NCT00828984|Other|Placebo|Given PO
1834324|NCT00828984|Other|Laboratory Biomarker Analysis|Correlative studies
1834325|NCT00828997|Biological|Prevenar vaccination|vaccination with Prevenar vaccine in patients with arthritis
1834326|NCT00829010|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as 3 or 4 doses
1834327|NCT00829010|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
1834328|NCT00829010|Biological|measles|Intramuscular injection, 2 doses
1834329|NCT00829010|Biological|Rotarix|Oral, 2 doses
1834330|NCT00829010|Biological|Local OPV|Oral 4 doses. Given at any time during the study, routinely given concurrently with DTPw-HBV/Hib vaccine
1834331|NCT00829023|Other|chlorhexidine gluconate and isopropyl alcohol, iodophor and isopropyl alcohol, povidone-iodine scrub and paint|surgical skin preparation solutions
1834332|NCT00829036|Device|Wayfinding Prototype|A Wayfinding Prototype is used by subjects to determine any advantages over current standard of rehabilitation.
1834333|NCT00829049|Drug|Tazarotene Cream 0.1%|1 pea-size amount, QD x 16 weeks
1834334|NCT00829049|Drug|Adapalene|1 pea-size amount, QD x 16 weeks
1834389|NCT00829387|Behavioral|CBT plus standard pharmaceutical care (CBT/SC)|Ten sessions of individual treatment delivered by a doctoral level psychologist.
1834480|NCT00830076|Drug|Comparator: placebo sitagliptin|Placebo to sitagliptin 100 mg in the morning on Days 1 and 2. There will be a 7-day washout between treatment periods.
1834335|NCT00829062|Device|Continuous glucose glucose sensor- physician ordered|Charts will be reviewed to identify recipients of Missouri Medicaid who receive daily injections to manage their diabetes. Children who have submitted an application for the Medtronic MiniMed insulin pump will be identified by the PI and Medtronic Diabetes. They will be asked to wear a 72 hour continuous glucose monitor. The children who wear the sensor will be asked to keep a daily logbook of their blood sugars, activities, food intake, and insulin doses during this 72 hour period. The families of the children will be provided with a pre-addressed FedEx envelope for them to return the digital recorder and daily logbooks to the PI. The results of the glucose sensor will be downloaded by the PI. The families will be contacted by the PI with the results and treatment recommendations.
1834336|NCT00829075|Drug|r-FSH|
1834337|NCT00829075|Drug|HP-hMG|
1834338|NCT00829075|Drug|r-FSH plus HP-hMG|
1834339|NCT00829088|Drug|AZD2066|1 dose oral solution
1834340|NCT00829114|Drug|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
1834341|NCT00829114|Drug|ETHINYL ESTRADIOL AND LEVOGESTREL|30 MCG OF ETHINYL ESTRADIOL AND 150 MCG LEVOGESTREL
1834342|NCT00829127|Drug|AZD8075|single dose, oral suspension, on Day 1. Repeated dosing will commence on Day 3 once daily for 14 days. The planned starting dose will be 35 mg with up to 2 dose escalations not exceeding AstraZeneca pre-defined upper exposure limits or the exposure obtained so far in the SAD study.
1834343|NCT00829127|Drug|Placebo|Oral suspension
1834344|NCT00829140|Drug|Placebo|
1834345|NCT00829140|Drug|Lorcaserin 10mg BID|
1834346|NCT00829153|Device|U Clip|Interuppted nitional clips
1834347|NCT00829153|Procedure|Conventional prolene anastomosis|Continuous prolene anastomosis
1834348|NCT00829166|Drug|Trastuzumab emtansine|Trastuzumab emtansine 3.6 mg/kg IV infusion over 30-90 minutes on Day 1 of each 21-day treatment cycle.
1834349|NCT00829166|Drug|Lapatinib|Lapatinib 1250 mg (five 250 mg tablets) orally once daily during each 21-day cycle.
1834350|NCT00829166|Drug|Capecitabine|Capecitabine 1000 mg/m^2 orally twice daily on Days 1-14 of each 21-day treatment cycle.
1834351|NCT00829179|Drug|RhuMab-E25|three subcutaneous injections spaced 1 month apart; dose based on subject weight and baseline IgE level.
1834352|NCT00829192|Drug|Afamelanotide (CUV1647)|16 mg subcutaneous implant administered every 60 days
1834353|NCT00829192|Drug|Placebo|Placebo subcutaneous implant administered every 60 days
1834354|NCT00829205|Biological|filgrastim|
1834355|NCT00829205|Biological|rituximab|
1834356|NCT00829205|Dietary Supplement|Se-methyl-seleno-L-cysteine|
1834357|NCT00829205|Drug|carboplatin|
1834358|NCT00829205|Drug|etoposide|
1834359|NCT00829205|Drug|ifosfamide|
1834360|NCT00829205|Other|laboratory biomarker analysis|
1834361|NCT00829205|Other|pharmacological study|
1834362|NCT00829218|Other|Glutamate additive-free diet|All subjects will follow a diet for one month where all foods containing the additive glutamate have been removed. At the end of the one month diet, subjects who have responded positively to the diet will go onto the challenge arms of the study, where they will be randomized to receive placebo (mixed juice alone) for three days on one week, and 5 grams of glutamate in the mixed juice for three days on the other week.
1834363|NCT00829218|Other|Placebo diet|Juice with nothing added.
1834364|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Mildly Hepatic Impaired Subjects
1834365|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Moderately Hepatic Impaired Subjects
1834366|NCT00829231|Drug|Sorafenib (Nexavar, BAY43-9006)|Healthy Subjects
1834367|NCT00829244|Drug|GONAL f® prefilled pen|GONAL f® doses starting at minimum of 112.5 IU per day and a maximum of 450 IU per day for 1 cycle only
1834368|NCT00829244|Drug|GONAL f® prefilled pen|GONAL f® standard treatment arm (150 IU of GONAL f® per day) up to Day 5 of stimulation after which the dose can be adjusted based upon the subject's ovarian response and according to the center's standard practice.
1834369|NCT00829257|Drug|HFA-BDP|HFA-BDP (Qvar) 100ug 2puff b.i.d
1834370|NCT00829257|Drug|Fluticasone|Fluticasone propionate Accuhaler 250ug b.i.d.
1834371|NCT00829257|Drug|Seretide|Fluticasone/Salmeterol (Seretide) 500/50ug, 1 puff b.i.d
1834372|NCT00829283|Behavioral|Behavioral Weight Loss|weekly individual sessions for 6 months
1834373|NCT00829283|Behavioral|Behavioral Weight Loss + Guided self-help Cognitive-behavioral Therapy|weekly BWL sessions for 4 weeks and 6-8 CBT sessions for 5 months
1834374|NCT00829283|Drug|Placebo|One pill daily
1834375|NCT00829283|Drug|Sibutramine/Orlistat|Sibutramine 15 mg daily or Orlistat 120mg TID
1834376|NCT00829296|Drug|nebivolol|Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached
1834377|NCT00829296|Drug|Metoprolol|Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached
1834378|NCT00829309|Drug|Pravastatin|80 mg Tablet
1834379|NCT00829309|Drug|Pravastatin|80 mg Tablets
1834380|NCT00829322|Drug|Modafinil|Modafinil 100mg once daily for 14 days, increasing to 200mg once daily for a further 14 days
1834381|NCT00829322|Drug|Placebo|One capsule daily for 14 days, increasing to two capsules daily for 14 days
1834382|NCT00829335|Procedure|IOUS-GUIDED INTRAHEPATIC VESSEL COMPRESSION|Using the IOUS, the tumor and the level targeted for compression are identified. Than, under the IOUS guidance, the surgeon compresses bilaterally the liver at the targeted position resulting in the compression of the portal pedicle feeding the tumor previously identified. This maneuver is constantly monitored in real-time just using the same microconvex probe, and it is maintained until the surface of the targeted liver area begins to discolor, at that time the first assistant marks the discolored area with the electrocautery, and the compression is released. Once the area is demarcated, liver dissection is started under intermittent Pringle's maneuver.
1834383|NCT00829348|Other|No intervention|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge - control group
1834384|NCT00829348|Behavioral|Short Message Service (SMS)|60 patients post ACS receiving the study medication + doctor/pharmacist explanation at discharge + daily SMS reminder service (8 PM) - study group
1834385|NCT00829361|Other|Telemedicine|Two way site independent audio/video telemedicine system with DICOM.
1834386|NCT00829374|Drug|Dimebon|5 mg orally three times daily
1834390|NCT00829387|Behavioral|Diabetic Education plus standard pharmaceutical care (ED/SC)|Ten individual sessions of diabetes educations delivered by a doctoral level psychologist under the supervision of a certified diabetes educator.
1834391|NCT00829400|Behavioral|Cognitive Remediation|Brain Fitness, Insight, and Aristotle Cognitive Remediation Software Suites Targeting 100 hours of training
1834392|NCT00829400|Behavioral|Nintendo Brain Age|Brain Age 2 Software Nintendo DS Portable for home or office use Targeting 100 hours of training
1834394|NCT00829426|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
1834395|NCT00829426|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose fasting
1834396|NCT00829439|Drug|Levodopa/Carbidopa (4:1)|"Dosages are based on levodopa.
Each cohort of 3 subjects will be placed on an increasing dose of levodopa (2, 5, 10, and 15 mg/kg/day) for 1 week, provided subjects in the preceding cohort tolerated the lower dose.
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
1834397|NCT00829452|Drug|Ramipril 10 mg capsule|1 x 10 mg
1834398|NCT00829452|Drug|Altace® 10 mg capsule|1 x 10 mg
1834399|NCT00829465|Drug|Licartin|Licartin
1834400|NCT00829465|Procedure|Transcatheter arterial chemoembolization|TACE
1834401|NCT00829478|Behavioral|Decision Aid for Atrial Fibrillation|Single contact educational session
1834402|NCT00829478|Other|Usual Care|Usual Care
1834403|NCT00829491|Behavioral|CVD risk reduction program|Participants will be selected through review of the DH administrative databases or by referral from their primary care provider. After completion of the forms, the navigator and client will discuss potential CVD risk reduction activities and programs available through this program for the client to participate in. Potential activities will include self-monitoring using self-help tools,healthy nutrition and exercise activities, community-based exercise programs using the recreation centers in the community, and referral to the Colorado Quitline for smoking cessation activities. Follow-up questionnaires will be completed at 6 and 12 months after enrollment to assess changes in levels of exercise, dietary patterns, and beliefs and attitudes about behavioral change.
1834404|NCT00829504|Drug|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg
1834405|NCT00829504|Drug|Requip® 0.25 mg Tablets|1 x 0.25 mg
1834406|NCT00829517|Other|computer-assisted provision of hormonal contraception|a computer program available at a kiosk will offer women information about and a prescription for hormonal contraception that they can ask their clinician to sign.
1834407|NCT00829517|Other|STI module|computer module available at a kiosk that will encourage women to be screened for chlamydia
1834408|NCT00829530|Drug|Ramipril 10 mg capsule|1 x 10 mg
1834409|NCT00829530|Drug|Altace® 10 mg capsule|1 x 10 mg
1958978|NCT00984165|Procedure|Single fraction radiation|8-Gy fraction of radiation
1834411|NCT00829556|Device|Integuseal|
1834412|NCT00829569|Dietary Supplement|Intralipid +/- Omegaven|"Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.
Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.
Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil)."
1834413|NCT00829582|Drug|"ETI-204, Anthim"|single intravenous infusion of 120, 240 or 360 mg of ETI-204
1834414|NCT00829582|Other|placebo|single intravenous infusion
1834415|NCT00829595|Biological|23-valent polysaccharide pneumococcal vaccine (Pneumovax TM)|0.5mL intramuscular, one time
1834416|NCT00829608|Biological|Human Papillomavirus Vaccine|0.5 mL of quadrivalent HPV vaccine will be given intramuscularly at three separate intervals. Dose 2 is given 2 weeks after dose 1 and dose 3 is given 4 weeks after dose 1 for a total of 3 doses over 2 months.
1834417|NCT00829621|Other|75 mmHg suction|Incisional Vacuum Assisted Closure (IVAC) Device, set to 75 mmHg suction throughout the duration of the IVAC use.
1834418|NCT00829621|Other|125 mmHg|Incisional Vacuum Assisted Closure (IVAC) Device, set to 125 mmHg suction throughout the duration of the IVAC use.
1834419|NCT00829634|Drug|l-methamphetamine|5mg of l-methamphetamine per day throughout the 2 week study
1834420|NCT00829634|Drug|d-methamphetamine|15mg on Study Day 9, 30mg on Study Day 11, 45mg on Study Day 13
1834421|NCT00829647|Drug|dasatinib and lenalidomide|dasatinib will be started at 70mg/day po and lenalidomide will be started at 2.5mg/day po
1834422|NCT00829660|Drug|Acarbose|The participants were given one tablet (50mg) of acarbose per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day (50mg twice a day i.e. 100mg/day) and then three tablets/day (50mg three times a day i.e. 150mg/day) thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 150mg/day).
1834423|NCT00829660|Drug|Matching Placebo|The participants were given one tablet of matching placebo per day, taken with a meal during their first week (7 days). During the second week, the dose was increased to two tablets/day and then three tablets/day thereafter. The maximum tolerated dose is being taken for the duration of the trial (maximum dose is 3 tablets/day).
1834424|NCT00829673|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
1834425|NCT00829673|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
1834426|NCT00829686|Drug|Septra|(800/125) PO BID X 7 days
1834427|NCT00829699|Procedure|euinsulinemic euglycemic glucose clamp|euinsulinemic euglycemic glucose clamp with lipid infusion 48 ml/hr for 4 hours
1834428|NCT00829699|Procedure|euinsulinemic hyperglycemic glucose clamp|euinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
1834429|NCT00829699|Procedure|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
1834430|NCT00829699|Procedure|Hyperinsulinemic hyperglycemic glucose clamp|Hyperinsulinemic hyperglycemic glucose clamp with lipid infusion at 48 ml/hr for 4 hours
1834431|NCT00829712|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
1834432|NCT00829712|Drug|Dexmethylphenidate Hydrochloride|10 mg Tablet
1834434|NCT00829725|Device|TARGON FN|"The Targon FN implant consists of a small side plate with six locking screw ports. The two distal holes are used to fix the plate to the lateral cortex of the femur with angle stable 4.5 mm cortical screws. The proximal holes allow the implementation of up to four TeleScrews which cross the fracture site. These 6.5 mm screws are dynamic and allow therewith the collapse of the fracture at the femoral neck. The sliding during the collapse occurs within these screws so that a protrusion of the screws in the lateral soft tissue is prevented"
1834435|NCT00829738|Drug|Pantoprazole|This was an observational study. Therefore, the physician decided about dosage according to individual needs (20 or 40 mg pantoprazole).
1958979|NCT00984165|Biological|Donor Lymphocyte Infusion (DLI)|Unmanipulated Donor Lymphocyte Infusion
1958980|NCT00984165|Procedure|Apheresis|Donors will undergo a 5-liter apheresis procedure on a CS-3000 or equivalent machine.
1834438|NCT00829764|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
1834439|NCT00829764|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
1834440|NCT00829777|Drug|6β-Naltrexol escalating doses from 0.05-0.5 mg IV|"Drug: Naloxone 0.1 mg IV/5 minutes to all subjects to determine tolerability to precipitated withdrawal during screening. Those that tolerate withdrawal proceed to Stage 1:
Drug: Lactulose 10 gm orally plus 3 IV infusions 30 minutes apart of Naloxone 0.1 mg IV and 2 placebo given randomly to all subjects. If tolerated, proceed to 5 additional medication dosing sessions with all subjects receiving oral Lactulose 10 GM plus IV escalating 6β-Naltrexol 0.05 mg, 0.15 mg, 0.5 mg with a randomized placebo."
1834441|NCT00829790|Drug|Doxycycline Monohydrate|25 mg 5mL oral dose
1834442|NCT00829790|Drug|Doxycycline Monohydrate|25 mg 5 mL dose
1834443|NCT00829803|Device|SNAP monitor; Bispectral Index Monitor (BIS Monitor)|Intended to monitor the state of the brain by data acquisition of EEG signals.
1834444|NCT00829816|Drug|Dimebon|
1834445|NCT00829816|Drug|Placebo|
1834446|NCT00829829|Other|Placebo|Placebo loading dose followed by placebo injections (2 mL) qw for 16 weeks.
1834447|NCT00829829|Drug|Rilonacept 80 mg|Rilonacept 160 mg loading dose followed by Rilonacept 80 mg/2 mL injections qw for 16 weeks.
1834448|NCT00829829|Drug|Rilonacept 160 mg|Rilonacept 320 mg loading dose followed by Rilonacept 160 mg/2 mL injections qw for 16 weeks.
1834449|NCT00829842|Other|oral hygiene|oral hygiene with 0.12% chlorexidine
1834450|NCT00829842|Other|placebo|oral hygiene placebo
1834451|NCT00829868|Drug|Zaleplon 10 mg Capsules|1 x 10 mg
1834452|NCT00829868|Drug|SONATA® 10 mg capsules|1 x 10 mg
1834453|NCT00829881|Drug|Betahistine Hydrochloride|A single betahistine hydrochloride capsule, increasing in dose from 50 mg, to 100 mg, to 200 mg, over 3 weeks
1834454|NCT00829881|Drug|Placebo Capsule|A single placebo capsule
1834455|NCT00829894|Drug|Risperidone|1 mg Tablet
1834456|NCT00829894|Drug|Risperidone|1 mg Tablet
1834457|NCT00829907|Drug|ORM-12741|Single dose as a capsule, oral administration
1834458|NCT00829933|Drug|DU-176b tablets|DU-176b tablets taken once daily for up to 12 weeks
1834459|NCT00829933|Drug|Warfarin potassium tablets|Warfarin potassium tablets taken once daily for up to 12 weeks
1834460|NCT00829946|Behavioral|Physical activity|Participants in the intervention group were enrolled in two training sessions per week for 12 weeks. The core portion of the training session consisted of 11 strength exercises engaging the major muscle groups, i.e. bench press, shoulder press, leg extension, leg press, leg curl, abdominal crunch, low back extension, arm curl, elbow extension, seated row and lateral pull-down. For each exercise, the participants performed one set of 8-15 repetitions (total of ~ 20s duration) with resting periods of 1-2 min between exercises. The load was gradually increased as the strength of each child improved, i.e. from 20-30% of 6 repetition maximum (6RM) at the start of the program to 50-60% of 6RM at the end. Participants also performed isometric contractions of large muscle groups (6 sets of 3 repetitions each, 20-30s duration per repetition) with their own body weight (for lower body exercises) or barbells (1-3kg) for upper body.
1834461|NCT00829959|Behavioral|Questionnaire|1 - 2 questionnaires, lasting 10-15 minutes.
1834462|NCT00829985|Biological|Glycerinated German Cockroach Allergenic Extract|Concentrated (1:20 w/v) daily doses of glycerinated German cockroach allergenic extract placed under the tongue to dissolve. The extract is also administered during the preliminary dosing visits in up to five escalating doses or until the maximum study dose (420 microliters, 1:20 w/v) is achieved.
1834463|NCT00829985|Biological|Placebo|Daily doses of cockroach allergenic extract placebo placed under the tongue to dissolve
1834464|NCT00829998|Drug|Zaleplon 10 mg Capsules|1 x 10 mg, single-dose fasting
1834465|NCT00829998|Drug|Sonata® 10 mg Capsules|1 x 10 mg, single-dose fasting
1834466|NCT00830011|Behavioral|cognitive behavioral therapy|Ten sessions of manualized CBT delivered by a PhD level psychologist
1834467|NCT00830011|Other|standard medical care|any care recommended by physician for treatment of diabetic neuropathy including medication.
1834468|NCT00830024|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
1834469|NCT00830024|Drug|Alprazolam Extended-Release 3 mg Tablets|1 x 3 mg, single dose non-fasting
1834470|NCT00830037|Drug|IV Iron|IV iron sucrose 200 mg over 2 hours baseline visit, week 2, week 4, week 6 and week 8 for a total of 1000mg total dose. Further cycles of iv iron may be used based on periodic monitoring of iron stores.
1834471|NCT00830037|Drug|Ferrous Sulfate|Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
1834472|NCT00830050|Drug|Naproxen|500 mg BID 7 days
1834473|NCT00830050|Drug|Placebo|BID 7 days
1834474|NCT00830063|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
1834475|NCT00830063|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
1834476|NCT00830063|Drug|naproxen|naproxen 1000 mg daily for 16 weeks
1834477|NCT00830063|Other|placebo|placebo to match tanezumab and naproxen dosing
1834478|NCT00830076|Drug|sitagliptin phosphate|Sitagliptin 100 mg tablet on Day 1 and Day 2 in the morning. There will be a 7-day washout between treatment periods.
1834479|NCT00830076|Drug|metformin hydrochloride|Metformin 500 mg tablet in the morning and evening on Day 1 and two 500 mg tablets of metformin (total dose 1000 mg) on Day 2 in the morning. There will be a 7-day washout between treatment periods.
1834481|NCT00830076|Drug|Comparator: placebo metformin|Placebo to metformin 500 mg tablet in the morning and evening on Day 1 and two placebo to metformin 500 mg tablets (1000 mg total dose) in the morning of Day 2. There will be a 7-day wash out between treatment periods.
1834482|NCT00830089|Drug|Levobupivicaine 0.25%|40mls of 0.25% L-bupivicaine will be injected into the transversus abdominis plane (TAP) under ultrasound guidance - 20mls on either side of the abdomen.
1834483|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol 12 ug)
Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI
Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)
Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
1834484|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation)
Period 2 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)
Period 3 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)
Period 4 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)"
1834485|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)
Period 2 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)
Period 3 Treatment Regimen F: Placebo (Two actuations of placebo HFA pMDI)
Period 4 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)"
1834486|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)
Period 2 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)
Period 3 Treatment Regimen A: FlutiForm 100/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 50/5 ug/actuation)
Period 4 Treatment Regimen B: FlutiForm 250/10 ug (Two actuations of fluticasone/formoterol HFA pMDI 125/5 ug/actuation)"
1834487|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)
Period 2 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA pMDI 125 ug/actuation)
Period 3 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)
Period 4 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI)"
1834488|NCT00830102|Drug|fluticasone propionate, formoterol fumarate|"Period 1 Treatment Regimen F: Placebo (Two actuations of Placebo HFA pMDI
Period 2 Treatment Regimen E: Foradil Aerolizer 12 ug (One inhalation of formoterol DPI 12 ug)
Period 3 Treatment Regimen D: Flixotide Evohaler 250 ug (Two actuations of fluticasone HFA MDI 125 ug)
Period 4 Treatment Regimen C: Flixotide Evohaler 250 ug + Foradil Aerolizer 12 ug (Two actuations of fluticasone HFA pMDI 125ug/actuation and one inhalation of formoterol DPI 12ug/inhalation)"
1834489|NCT00830115|Drug|Pantoprazole|Observational, non-interventional study (NIS). The physician decided about dosage according to individual needs (20 or 40 mg pantoprazole, once daily).
1834490|NCT00830128|Drug|pregabalin (Lyrica)|Dosage: 300-450 mg/day (150-225 mg twice daily), oral administration, Treatment duration: 52 weeks
1834491|NCT00830154|Drug|pagoclone|0.30 mg BID, 0.60 mg BID
1834492|NCT00830154|Other|placebo|placebo
1834493|NCT00830167|Drug|Placebo|Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
1834494|NCT00830167|Drug|Pregabalin|Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)
1834495|NCT00830180|Biological|Anti-NGF AB|Solution for injection, 10 mg, one injection/8 weeks
1834496|NCT00830193|Drug|N-acetylcysteine|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo in 100 cc D5W (pre-CT dose) or 2.5 g of NAC or placebo in 50 cc D5W (post-CT doses).
1834497|NCT00830193|Drug|D5W Placebo|Medication packages were prepared and dispensed by pharmacy and included three premixed and prepackaged minibags containing either 5 g of NAC or placebo (D5W) in 100 cc D5W (pre-CT dose) or 2.5 g NAC or placebo in 50 cc D5W (post-CT doses).
1834498|NCT00830206|Other|Azithromycin|Oral Suspension
1834499|NCT00830206|Drug|Zithromax®|Oral Suspension
1834500|NCT00830219|Drug|Ropinirole HCl 0.25 mg Tablets|1 x 0.25 mg, single dose fed
1834501|NCT00830219|Drug|Requip® 0.25 mg Tablets|1 x 0.25 mg, single dose fed
1834502|NCT00830232|Device|closed-cell stent|"Patients enrolled in this study arm underwent for carotid stenting using closed stent cell. The graft used in this groups was the Xact closed-cell stent. This type of device is rigid device with dense conposition of the nitinol rigns.
Carotid stenting was used on standard fashion using filters as embolic protection device."
1834503|NCT00830232|Device|Open-cell stent|"Patients enrolled in this study arm underwent for carotid stenting using open stent cell stents. This type of stent is a tube shaped graft composed of flexible nitinol rings. The device used in this group was the Acculinx open-cell stent.
Stenting procedure eas performed on standard fashion.Filters were used as embolic protection device."
1834504|NCT00830245|Drug|Erlotinib|Erlotinib 150mg/day
1834505|NCT00830258|Drug|Pravastatin sodium 80 mg tablets|1 x 80 mg
1834506|NCT00830258|Drug|Pravachol® 80 mg tablets|1 x 80 mg
1834507|NCT00830271|Device|Vicryl plus and Monocryl plus|closure of skin and subcutaneous tissues
1834508|NCT00830271|Device|wound closure with Vicryl and Monocryl|wound closure skin and subcutaneous tissues
1834509|NCT00830284|Procedure|Recruitment maneuver|"Three types of maneuvers will be performed.
6cc/kg tidal volumes at an appropiate rate on current prescribed PEEP level.
6cc/Kg tidal volumes at an appropiate rate following a 40 cmH2O for 40 seconds maneuver returning to a pflex plus 2 cmH2O PEEP level.
PEEP titration starting a 15 cmH2O and increasing in 5 cmH2O increases until the PaO2+PaCO2 is 400 or higher."
1834510|NCT00830297|Drug|Insulatard (long-acting insulin)|In group No.1 (study arm 1 (=A)), patients will be treated with long-acting insulin (Insulatard) as soon as the glucose-level before supper surpasses 140 mg/dl. The normoglycemic goal in this group will be from 110 to 120 mg/dl.
1834879|NCT00833664|Drug|Lamisil® 250 mg Tablets|1 x 250 mg
1834511|NCT00830297|Drug|Conventional|In group No.2 (study arm 2 (=B)), patients will be treated conventionally according to the decisions taken by the physicians on the ward. The following suggestions will be brought to the attention of the ward in order to standardize the treatment of the patients in study arm B: 1. Treatment in this group should be initiated if the fasting glucose level surpasses the renal glucose threshold, i.e. 180 mg/dl. 2. As the proposed life-style modifications for the treatment of NODAT1 are not feasible during this very early post-transplant phase, the basis of the conventional therapy will be proposed to be sulfonyl urea drugs (i.e. Gliclazide - Diamicron®, 30 mg, not more than twice daily). 3. Short-acting insulin will be strongly recommended to be used for corrections of capillary blood glucose levels above 250 mg/dl.
1834512|NCT00830310|Behavioral|Psychoeducation module|"Individuals will be assigned the psychoeducation module if they are identified as having opposition to prophylaxis, denial of illness severity or therapeutic effectiveness, negative attitudes towards drugs in general, or lack of information about mood stabilizers operationalized as a score of 1 or higher on any of these AMSQ subscales. Additionally, those individuals who are non-adherent/sub-optimally adherent because of stigma or embarrassment over medications or in relation to the use of complementary or alternative treatments will be assigned to participate in the psychoeducation module (ROMI stigma item or complementary/alternative treatment supplemental item)."
1834513|NCT00830310|Behavioral|Substance use module|Individuals will be assigned the substance use module if they endorse the ROMI substance use item or if substance use is identified as problematic on the clinician assessment.
1834514|NCT00830310|Behavioral|Improved communication/rapport with provider module|"Individuals will be assigned the provider communication/rapport module if they are identified as having fear of side effects operationalized as a score of 1 or higher on these AMSQ items. Additionally, those individuals who are non-adherent/suboptimally adherent because of concern regarding change in appearance appearing medicated or who experience side-effect-related distress as identified by the ROMI will be assigned the provider communication module."
1834515|NCT00830310|Behavioral|Medication routines management module|"Individuals will be assigned the medication routines management module if they are identified as having difficulties with medication routines operationalized as a score of 1 or higher on this AMSQ sub-scale, or if they are identified as experiencing outside opposition to medications by the ROMI."
1834516|NCT00830323|Drug|oseltamivir + zanamivir|oseltamivir (75mg bd for 5 days, oral) zanamivir (5mg bd for 5 days, inhaled by mouth)
1834517|NCT00830323|Drug|oseltamivir+ amantadine|oseltamivir (75mg bd for 5 days, oral) + amantadine (100mg bd for 5 days, oral)
1834518|NCT00830323|Drug|oseltamivir|oseltamivir (75mg bd for 5 days, oral)
1834519|NCT00830336|Drug|Azithromycin|Oral Suspension
1834520|NCT00830336|Drug|Zithromax®|Oral Suspension
1834521|NCT00830349|Drug|Risperidone|1 mg Tablet
1834522|NCT00830349|Drug|Risperidone|1 mg Tablets
1834523|NCT00830362|Drug|Propranolol|40 mg administered once
1834524|NCT00830362|Drug|Placebo|administered once
1834525|NCT00830375|Drug|Memantine|10-30mg, by mouth, daily
1834526|NCT00830388|Drug|Ketoconazole 2% Foam|Ketoconazole 2% Foam, twice daily application to affected areas for 4 weeks.
1834527|NCT00830401|Procedure|Treatment of predefined abnormality by hysteroscopic surgery|"Polyp resection with Hysteroscopic scissors or Versapoint
Resection of myoma with Resectoscope Storz or Versapoint
Septum resection with Resectoscope Storz or Versapoint
Resection of adhesions with Hysteroscopic scissors or Versapoint"
1834528|NCT00830401|Drug|Ofloxacinum/Doxycycline|Treatment of endometrial inflammation: Ofloxacinum 400mg/day or Doxycyline 2x100mg on day one, followed by 100mg/day during 8 days.
1834529|NCT00830414|Drug|medroxyprogesterone acetate|IM Injection
1834530|NCT00830414|Drug|medroxyprogesterone acetate|IM injection
1834531|NCT00830427|Drug|PF-00610355|100 mcg, QD, dry powder inhaler
1834532|NCT00830427|Drug|PF - 00610355|600 mcg, QD, dry powder inhaler
1834533|NCT00830427|Other|Placebo|QD, dry powder inhaler
1834534|NCT00830427|Drug|PF - 00610355|300 mcg, QD, dry powder inhaler
1834535|NCT00830440|Device|EndoBarrier Device|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp and EndoBarrier Device for 12 weeks
1834536|NCT00830440|Behavioral|Diet & Lifestyle Counseling|NIH derived dietary, exercise and behavior modification 2005 guidelines. https://health.gov/dietaryguidelines/2005.asp
1834537|NCT00830453|Procedure|Hyperbaric oxygen therapy (HBO2)|60 daily hyperbaric oxygen sessions 1.5 atmospheres absolute, 100% oxygen 60 minutes per session, from door closing to door opening
1834538|NCT00830466|Drug|Laser and rapamycin versus laser alone|Laser and rapamycin versus laser alone
1834539|NCT00830479|Procedure|Anti-reflux surgery|Open ureteroneocystostomy for correction of vesicoureteral reflux
1834540|NCT00830479|Procedure|Endoscopic injection|Endoscopic injection of dextranomer/hyaluronic acid gel (Deflux) for correction of vesicoureteral reflux
1834541|NCT00830492|Drug|clomiphene citrate|100 mg from cycle day 3 through 7
1834542|NCT00830492|Procedure|Ultrasound|cycle day 8
1834543|NCT00830492|Drug|GnRH antagonist|Daily, started with dominant follicle greater than 14 mm (Ganirelix , Organon, Netherlands).
1834544|NCT00830492|Drug|gonadotopin (HMG)|75 IU human menopausal gonadotropin (Menogon, ferring, pharmacenticals , Germany)
1834545|NCT00830492|Drug|buserelin|Buserelin (suprefact, Aventis, Frankfurt, Germany) 500µg subcutaneously (S.C.) everyday for menstrual cycle 21, until the baseline evaluation, which takes place in the first few days of menstruation. If baseline levels of estradiol (<50 pg/ml ) had been achieved, then the dose of buserelin would be reduced to 250µg.
1834546|NCT00830492|Drug|rFSH|150-225 IU recombinant FSH (r_FSH) (Gonal F, Serono, Aubnne, Switzerland) S.C.
1834591|NCT00830765|Drug|Placebo|2cc of placebo liquid formulated by pharmacy personnel at the University of Mississippi Medical Center injected IM weekly until 34 weeks' gestation has been reached or delivery, whichever occurs first.
1834592|NCT00830778|Procedure|Pancreaticojejunostomy|Pancreaticojejunostomy (PJ) reconstruction/anastomosis
1834593|NCT00830778|Procedure|Pancreaticogastrostomy|Pancreaticogastrostomy (PG) reconstruction/anastomosis
1834549|NCT00830518|Drug|MLN8237|"MLN8237 will be administered orally (PO) at a dose of 50 mg twice daily (BID) for seven consecutive days followed by a 14-day rest period, in 21-day cycles. Dose reductions will be implemented in the setting of drug-related toxicities.
The first dose of MLN8237 on Cycle 1, Day 1 will be administered in the study clinic. Patients will continue to receive repeated cycles of MLN8237 treatment for up to 12 months, or until there is evidence of disease progression or unacceptable treatment-related toxicity. Treatment with MLN8237 may be continued beyond 12 months if it is determined that a patient would clearly derive benefit from continued therapy."
1834552|NCT00830544|Drug|Neoadjuvant chemotherapy|Docetaxel 75 mg/m2, day 1 Epirubicin 80 mg/m2, day 1 Cyclophosphamide 500 mg/m2, day 1 Navelbine 25 mg/M2 in 250 cc NS over 60 min on day 1 and day 8 Bevacizumab 5 mg/kg in 100 cc NS over 90 min day 1 and day 8 Capecitabine 825 mg/M2 p.o. bid from day 1-14. Trastuzumab
1834553|NCT00830544|Drug|Chemotherapy|Neoadjuvant chemotherapy
1834554|NCT00830544|Drug|Neoadjuvant chemotherapy|Experimental chemotherapy regimen
1834555|NCT00830557|Other|medical chart review|baseline, 12 month and 36 months
1834556|NCT00830557|Other|survey administration|baseline, 6 month, 12 month
1834557|NCT00830557|Other|biospecimen collection|baseline
1834558|NCT00830570|Other|CYP 2C9 and VKORC1 Testing for Warfarin|Test patients for their warfarin sensitivity and provide this information to their physician authorizing the test.
1834559|NCT00830583|Procedure|blood test|There is only a blood test at the beginning.
1834560|NCT00830596|Other|HVLA-SM|High velocity, low amplitude lumbo-pelvic manipulation
1834561|NCT00830596|Other|LVVA-SM|Low velocity, variable amplitude lumbo-pelvic manipulation
1834562|NCT00830596|Other|Sham Intervention|2 weeks of light effleurage and a sham mechanically-assisted chiropractic treatment followed by 4 weeks active care with full spine spinal manipulation
1834563|NCT00830609|Drug|Peginterferon alfa 2 A|Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 800 mg/day po (Control Group) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epoetin β (450 IU/kg/week) SC over 4 weeks (Arm B1) Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day po plus Epo beta 450 UI over four weeks (Arm B1) If RNA-HCV positive at week 4, Peginterferon alfa 2 A 180 mcg/week SC plus Ribavirin 1,600 mg/day plus Epo beta 450 UI to keep Hb>12 g/dL if required over 20 additional weeks (Arm B2)
1834564|NCT00830609|Drug|Peginterferon alfa 2 A, ribavirin + Epo Beta|Ribavirin 1,600 mg/day plus peginterferon alfa 2A 180 mcg/week plus Epo beta 450 IU/Kg/day to maintain Hb>12g/dl over 4 or 24 weeks
1834565|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 24 weeks
1834566|NCT00830609|Drug|ribavirin|ribavirin 800 mg/day for 24 weeks
1834567|NCT00830609|Drug|Peginterferon alfa 2|Peginterferon alfa 2 a 180 mcg/week for 4 weeks and then peginterferon alfa 2A for 20 weeks
1834568|NCT00830609|Drug|ribavirin|RBV 1600 mg/day 4 weeks and then ribavirin 800 mg/day 20 weeks
1834569|NCT00830622|Other|Cell Phone Intervention|Participant receives weekly SMS text messages from the health care provider.
1834570|NCT00830635|Other|educational intervention|
1834571|NCT00830635|Other|informational intervention|
1834572|NCT00830635|Other|internet-based intervention|
1834573|NCT00830635|Other|questionnaire administration|
1834574|NCT00830635|Other|study of socioeconomic and demographic variables|
1834575|NCT00830635|Other|survey administration|
1834576|NCT00830635|Procedure|psychosocial assessment and care|
1834577|NCT00830635|Procedure|quality-of-life assessment|
1834578|NCT00830648|Biological|Live Attenuated Varicella Virus Vaccine|0.5 mL, Subcutaneous
1834579|NCT00830661|Procedure|Ligation of intersphincteric fistula track procedure|Subjects randomized to this arm will receive the ligation of the intersphincteric fistula track (LIFT) procedure. This procedure will be performed as per standard operating procedure.
1834580|NCT00830661|Procedure|anal fistula plug|placement of the porcine anal fistula plug as per the instructions for use in product packaging
1834581|NCT00830674|Drug|Placebo|single dose IV or SC administration
1834582|NCT00830674|Drug|KRN23|Single IV administration on day 1: 0.003, 0.01, 0.03, 0.1 and 0.3 mg/kg and Single SC administration on day 1: 0.1, 0.3, 0.6 and 1.0 mg/kg
1834583|NCT00830687|Device|TARGON FN|The Targon FN implant consists of a small side plate with six locking screw ports
1834584|NCT00830700|Other|CATMH intervention|This intervention is comprised of 6-tandem-sessions of pharmacotherapy and a behavioral intervention conducted over 4-5 months. The telepsychiatrist makes prescribing decisions during the intervention following consensus guidelines for ADHD treatment. The telepsychiatrist also provides education about how neurobiological deficits of ADHD relate to observed behavioral learning and difficulties. After the 6th session, the PCP resumes care of the patient. The behavioral intervention component is delivered by therapists at each participating clinic. The therapists are trained and supervised remotely by a telepsychologist . The 6-session behavioral intervention consists of approaches to managing children's behaviors and coordination with schools and other community agencies to advocate for the child.
1834585|NCT00830713|Procedure|Melanocyte-keratinocyte transplantation procedure (MKTP)|skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
1834586|NCT00830726|Drug|Pharmacologic and mechanical heart failure treatment|Optimised, standard, evidence based heart failure therapy including the use of biventricular pacing.
1834587|NCT00830726|Procedure|Aortic valve replacement|Standard aortic valve replacement as per standard criteria in the department of thoracic surgery.
1834588|NCT00830726|Procedure|Revascularisation in Acute Coronary Syndrome|Standard percutaneous or surgical revascularisation in ACS.
1834589|NCT00830726|Procedure|Revascularisation in chronic stable angina pectoris|Standard percutaneous or surgical revascularisation
1834590|NCT00830765|Drug|Progesterone (OHP17)|100mg of OHP17 or comparable amount of placebo administered by IM injection weekly until either 34 weeks' gestation or delivery has been achieved, whichever occurs first.
1835003|NCT00841815|Drug|Norvasc®|10 mg Tablet
1834594|NCT00831194|Behavioral|Personalized diet plan and PDA self reporting.|Participants will be given personalized diet plan with a 0.5- 1 lb weight loss/week, based on each person's goals. He/she will also be prompted by a pre programmed PDA to enter dietary lapses and stress inducing events. Saliva samples will be collected as per the study plan.
1834595|NCT00831233|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
1834596|NCT00831233|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
1834597|NCT00831233|Drug|Bicalutamide|On Day 0, three days before the first dose of goserelin on Day 3, patients began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
1834598|NCT00831246|Other|chewing gum - Extra Winterfresh|Patients are given standard post-op care with clear liquid diet as tolerated plus chewing gum q8 for 30minute chewing intervals.
1834599|NCT00831246|Other|Standard Post-Op Care|Patients are given standard post-op care with clear liquid diet as tolerated.
1834600|NCT00831272|Drug|naltrexone|50mg/day
1834601|NCT00831272|Drug|Placebo|Placebo
1834602|NCT00831285|Dietary Supplement|food product|food product given at one of six visits
1834603|NCT00831298|Other|Analysis of sleep disturbance|Behavioral Questionnaire Sleep Recordings Genetic analysis
1834604|NCT00831311|Biological|DTaP-IPV-HB-PRP~T|0.5 mL, Intramuscular
1834605|NCT00831311|Biological|DTaP-IPV//PRP~T combined vaccine & Recombinant hep B vaccine|0.5 mL, Intramuscular (right and left thighs, respectively)
1834606|NCT00831337|Dietary Supplement|VSL3|2 times daily 450 billion live bacteria (in each saschet)
1834608|NCT00831363|Procedure|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
1834609|NCT00831363|Procedure|standard approach total hip arthroplasty|standard Hardinge approach/traditional transgluteal approach
1834610|NCT00831376|Drug|levosalbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
1834611|NCT00831376|Drug|racemic salbutamol|Patients will be asked to take two puffs four times a day for 2 weeks
1834612|NCT00831376|Drug|placebo|Patients will be asked to take two puffs four times a day for 2 weeks
1834613|NCT00831389|Device|Closed Loop|Insulin pump controlled by closed loop unit and algorithm
1834614|NCT00831402|Dietary Supplement|Oligobs Maxiode|The 50 women will be follow up with a supplémentation iodized by vitamins of pregnancy strengthened in iodin everything in the course of the pregnancy and during the 3 months post partum (Oligobs Maxiode, 150 mcg / of iodizes, is 2cp a day)
1834615|NCT00831402|Dietary Supplement|controll group|50 women will be studied in the absence of iodized supplémentation(natural history of function thyroïdienne in the course of the pregnancy and in the post partum)
1834616|NCT00831415|Drug|desvenlafaxine succinate sustained release tablets|25-mg or 50-mg DVS SR tablets taken orally, once daily, at the same time each day. 100 mg dose will be supplied as 2 tablets of 50-mg tablet.
1834617|NCT00831428|Other|no intervention|this is a screening study, not an interventional study
1834618|NCT00831441|Drug|Apixaban|Tablets, Oral, 5 mg, twice daily, until study end
1834619|NCT00831441|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, until study end
1834620|NCT00831467|Biological|CV9103|Over a period of 23 weeks 5 vaccinations with CV9103 will be administered.
1834621|NCT00831480|Drug|everolimus|everolimus 10 mg PO once daily for 3-5 weeks followed by removal of the kidney. Everolimus will begin again between 2 to 4 weeks after surgery.
1834622|NCT00831493|Radiation|Chemoradiation (Radiation Therapy)|Dose of 50.4 Gy in 1.8 Gy fractions in 28 fractions, Monday to Friday, Weeks 1 to 6.
1834623|NCT00831493|Drug|Vorinostat|Starting Dose of 200 mg orally once daily, Monday to Friday, Weeks 1 to 6.
1834624|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) plus placebo three times daily (TID), 8 hours apart for 14 days.
1834625|NCT00831506|Drug|digoxin|digoxin once daily (0.125 mg QD) for 14 days.
1834626|NCT00831506|Drug|dimebon|Dimebon three times a day, 8 hours apart for 14 days (10 mg TID on Days 1-7 and 20 mg TID on Days 8-14).
1834627|NCT00831532|Drug|Dimebon|Dimebon 5mg in healthy controls
1834628|NCT00831532|Drug|Dimebon|Dimebon 5mg in mild hepatic impairment patients
1834629|NCT00831532|Drug|Dimebon|Dimebon 5mg in moderate hepatic impairment patients
1834630|NCT00831532|Drug|Dimebon|Dimebon 5mg in Severe Hepatic Impairment
1834631|NCT00831545|Drug|Temozolomide|150 mg/m2 given once a day for 7 consecutive days (Days 1 through 7) repeated every other week until disease progression or toxicity or for a maximum of one year. After amendment, schedule was modified: a second rest week was added after the second wash-out week (Days 1 through 7, 15 through 21 every 35).
1834632|NCT00831597|Drug|bendamustine|120 mg/m2 IV, Days 1, 2 of Cycles 1-6
1834633|NCT00831597|Drug|rituximab|375 mg/m2 IV, Day 1 of Cycles 1-6
1834634|NCT00831610|Procedure|Bariatric surgery (Roux-en-Y Gastric Bypass) + Post-bariatric abdominoplasty.|Surgical removal of the exceeding skin and adiposity of the abdominal wall by one midline vertical fuse and one supra-pubic horizontal fuse. Skin suture without flap undermining and with low tension.
1834635|NCT00831610|Procedure|Roux-en-Y gastric bypass (bariatric surgery) + Post-bariatric abdominoplasty (without flap undermining)|Bariatric surgery Plastic surgery Abdominoplasty
1834636|NCT00831623|Radiation|Proton Radiation|3 Cobalt Gray Equivalent (CGE) /Day to isocenter, one treatment per day, 5 days per week for 20 treatments (=60 CGE to isocenter/20 fractions)
1834637|NCT00831623|Radiation|Proton|As above
1834638|NCT00831636|Drug|CP-4055|D1-5 and D8(+2)-12(+2) q4w
1834639|NCT00831636|Drug|CP-4055|IV administration day 1-5 and day 8-12 in a 4 week schedule
1834640|NCT00831649|Drug|natalizumab|
1834641|NCT00831662|Drug|Diquafosol tetrasodium ophthalmic solution, 2%|One to two drops in each eye QID for 6 weeks
1834642|NCT00831662|Drug|Placebo|One to two drops in each eye QID for 6 weeks
1834643|NCT00831675|Biological|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
1834644|NCT00831675|Biological|Influenza Vaccine 2004-2005 Paediatric Formulation|0.25 mL (Day 0 and Day 28), Intramuscular
1834645|NCT00831688|Device|Meniett(C) device by MedTronic|pulsed pressure application, up to 12 cm H20 column, 3 times daily for 5 minutes, generated by Meniett device and conducted to middle ear cavity via tympanostomy tube
1834646|NCT00831688|Device|placebo treatment|device seemingly identical to active device, manufactured by Medtronic. 3 times daily for 5 minutes.Produces similar sound effect, but without pulsed pressure elevation.
1834647|NCT00831701|Drug|Tamsulosin|0.4 mg Tamsulosin once daily for 21 days
1834648|NCT00831701|Drug|Placebo|One placebo pill per day for 21 days or until stone expulsion
1834649|NCT00831714|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for VTE prophylaxis with Rivaroxaban has been made
1834650|NCT00831714|Drug|Standard care treatment for VTE prophylaxis|Female and male patients, who are at least 18 years of age and will undergo elective hip or knee arthroplasty, after the decision for a pharmacologic VTE prophylaxis treatment other than rivaroxaban has been made
1834651|NCT00831727|Behavioral|Expressive Writing|Participants will write about their experienced trauma for 20 minutes on each of three consecutive days using techniques associated with expressive writing
1834652|NCT00831727|Behavioral|Control|Participants will write as factually as possible about an assigned trivial topic for 20 minutes on each of three consecutive days
1834653|NCT00831740|Other|Speech and Language Therapy (SLT)|Participants randomised into the treatment arm will receive early SLT of up to three sessions per week for a maximum duration of 16 weeks. The SLT intervention has been developed by a team of expert Speech and Language Therapists according to 'Best Practice Standards'. The intervention procedure is manualised to allow replicability by other Speech Therapy Departments if it is shown to be effective.
1834654|NCT00831740|Other|Attention Control|Those in the attention control arm of the trial will receive similar levels of contact as those in the SLT arm. However contact will be with an ACT NoW Visitor who has no specific knowledge about communication therapy. They will provide empathy and spend time with the patient, without any input from Speech and Language Therapists.
1834655|NCT00831753|Biological|DTaP IPV HB PRP~T vaccine|0.5 mL, Intramuscular
1834656|NCT00831753|Biological|DTaP-HB-IPV and Haemophilus influenzae type b|0.5 mL, Intramuscular
1834657|NCT00831766|Drug|Idarubicin|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
1834658|NCT00831766|Drug|Cytarabine|Intravenous infusion of Idarubicin as outlined in Phase I and Phase II Treatment Arms.
1834659|NCT00831766|Drug|Lenalidomide (Revlimid®)|Lenalidomide as outlined in Phase I and Phase II Treatment Arms.
1834660|NCT00831779|Drug|Dapagliflozin|Tablets, Oral, 5 mg, once daily, 12 weeks
1834661|NCT00831779|Drug|Placebo|Tablets, Oral, 0 mg, Once daily, 12 weeks
1834662|NCT00831792|Drug|TK1258|4 capsules (100 mg/capsules) of TKI 258 by mouth once daily (total of 400 mg of TKI258 per day).
1834663|NCT00831831|Behavioral|Safety planning|See detailed description
1834664|NCT00831844|Biological|cixutumumab|Given IV: Week 1 day 1, 9 mg/kg/dose over 1 hour. Week 2 Day 8, 9 mg/kg/dose over 1 hour. Week 3 Day 15, 9 mg/kg/dose over 1 hour. Week 4 Day 22, 9 mg/kg/dose over 1 hour.
1834665|NCT00831844|Other|laboratory biomarker analysis|Correlative studies
1834666|NCT00831857|Other|89Zr-Bevacizumab PET-scan|At baseline, after two weeks of treatment and after 6 weeks of treatment.
1834667|NCT00831883|Behavioral|Partner-Specific IMB-based HIV risk reduction intervention|5 session partner-specific HIV risk reduction group intervention based on the Information-Motivation-Behavioral Skills model.
1834668|NCT00831883|Behavioral|Healthy Lifestyle|5 session psychoeducational group, designed to provide equivalent time and attention, that focuses on the importance of maintaining a good diet, exercise, and developing health skills.
1834669|NCT00831896|Biological|TAK-701|"Either 2, 5, 10, or 20 mg/kg IV. Cycle 1: single dose at 2x the dose assignment; Cycle 2 and beyond: dose once every two weeks
Dosing continues until disease progression, unacceptable toxicity related to TAK-701, or maximum of 12 cycles, unless determined that patient would benefit from continued therapy."
1834670|NCT00831922|Drug|masitinib (AB1010)|3 mg/kg/day
1834671|NCT00831922|Drug|masitinib (AB1010)|6 mg/kg/day
1834672|NCT00831948|Genetic|mitochondrial DNA mutations diagnosis|Identification of large-scale mutations of POLG gene by QMPSF in patients with mitochondrial DNA instability.
1834673|NCT00831961|Procedure|Conjunctival and nasopharyngeal bacteria cultures|Conjunctival and nasopharyngeal bacteria cultures
1834674|NCT00831974|Drug|masitinib (AB1010)|3 mg/kg/day
1834675|NCT00831974|Drug|masitinib (AB1010)|6 mg/kg/day
1834676|NCT00831987|Biological|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
1834677|NCT00831987|Biological|Fluzone®: Influenza virus vaccine 2004-2005 formulation|0.5 mL, Intramuscular
1834678|NCT00832000|Drug|Mexiletine|200 mg three times a day; in pill form
1834679|NCT00832000|Drug|Placebo|Placebo three times a day; in pill form
1834680|NCT00832013|Drug|Propofol|See detailed description
1834681|NCT00832013|Drug|Propofol|See detailed description
1834682|NCT00832026|Device|Trans Nasal Insuflation (TNI) [nasal canula]|"Trans Nasal Insuflation, or TNI, uses air at flow rates delivered through a small nasal canula to reduce the severity and frequency of sleep apnea events.
By using TNI we hope to increase the amount of air that the patient can breathe during periods of obstructive sleep disordered breathing."
1834683|NCT00832039|Drug|sodium-selenite|An intravenous bolus of 1000 µg followed by a continuous intravenous infusion of 1000 µg/day until patient is discharged from the ICU but not more than 21 applications à 24 hours.
1834684|NCT00832039|Drug|Placebo|An intravenous bolus of placebo followed by a continuous intravenous infusion with placebo until patient is discharged from the ICU but not more than 21 applications à 24 hours.
1834805|NCT00833053|Drug|Infliximab and methotrexate|Infliximab 5 mg/kg body weight intravenous infusion (given every 8 weeks) plus methotrexate 7.5 mg orally (once weekly)
1834806|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 25µg of gpASIT+TM
1834685|NCT00832039|Procedure|Procalcitonin guided therapy|"Causal therapy of sepsis is guided by applying the following algorithm:
Day 4: PCT drop from baseline >=50%: no change in causal therapy; PCT drop from baseline <50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control.
Day 7, 10, 14: PCT <=1.0 ng/ml: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement >=50%: finish antimicrobial therapy; PCT >1.0 ng/ml and PCT drop from last PCT measurement <50%: change or optimize antimicrobial therapy, new intervention (i.e. surgery, diagnostics) recommended for source control."
1834686|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 5 mg q12 hours for 7 days.
1834687|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 15 mg q12 hours for 7 days.
1834688|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
1834689|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 7 days. Actual dose may be adjusted based on pharmacokinetic and other data from prior dose cohorts.
1834690|NCT00832052|Drug|PF-04447943|Planned oral dose is PF-04447943, 35 mg q12 hours for 14 days. Actual dose may be adjusted downward based on pharmacokinetic and other data from prior dose cohorts.
1834691|NCT00832078|Device|SpeediCath Compact Male|CH 12 hydrophilic coated intermitten compact catheter
1834692|NCT00832078|Device|Speedicath|CH 12 hydrophilic coated intermittent coated catheter
1834693|NCT00832091|Drug|Thymosin Beta 4|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There were three concentrations of gel used for topical administration to the active groups: 0.01% weight/weight (w/w), 0.03% w/w, and 0.1% w/w thymosin beta 4 gel applied once daily for up to 84 days
1834694|NCT00832091|Drug|Placebo|There were 3 groups of patients with venous stasis (VS) ulcers. Each group included 18 patients receiving active drug and 6 receiving placebo. There was one concentration of placebo gel for topical administration to the placebo group. The concentration was 0.0% weight/weight (w/w) thymosin beta 4 gel applied once daily for up to 84 days
1834695|NCT00832117|Drug|Ixabepilone|Escalation: Solution, intravenous (IV), 32-40 mg/m2, every 3 weeks, approximately 6 months
1834696|NCT00832117|Drug|Cisplatin|Escalation: Solution, IV, 60-100 mg/m2, every 3 weeks, approximately 6 months
1834697|NCT00832117|Drug|Ixabepilone|Expansion: Solution, IV, 32 mg/m2, every 3 weeks, approximately 6 months
1834698|NCT00832117|Drug|Cisplatin|Expansion: Solution, IV, 60-80 mg/m2, every 3 weeks, approximately 6 months
1834699|NCT00832130|Device|Manual Mini System|In-office device treatment for meibomian gland dysfunction by a physician
1834700|NCT00832130|Device|iHeat Portable Warm Compress Therapy|At-home daily warm compress therapy
1834701|NCT00832143|Behavioral|Referral Card with one-to-one counseling|A Referral Card (Neonatal Well-Being Card) along with one-to-one counseling to mothers within 48 hours of institutional delivery
1834702|NCT00832156|Biological|Cultured autologous keratinocytes|The experimental wound site will be covered with cultured keratinocytes on a collagen/elastin carrier after the application of a meshed split skin autograft. The control wound site will be covered with a meshed split skin autograft alone.
1834703|NCT00832169|Drug|AZD1386|1 dose of oral solution
1834704|NCT00832182|Drug|insulin aspart|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
1834705|NCT00832182|Drug|insulin NPH|Insulin aspart at breakfast, lunch and dinner time. Neutral protamine Hagedorn insulin at breakfast, lunch, dinner and bedtime. Injections were optional but at least one injection per day
1834706|NCT00832195|Device|Motion Controlling Running Shoe|Running shoe with thermoplastic mid-foot shank stiffener, denser durometer foam on medial aspect of mid-sole, reinforced heel counter, wider sole-plate, and lateral foam crash-pad.
1834707|NCT00832195|Device|Neutral Running Shoe|Standard running shoe with single density mid-sole foam.
1834708|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|21.0 mg/kg total dose. Given iv as 3mg/kg/day on days 1,2,3,4,5, and 14 and 21
1834709|NCT00832208|Drug|Liposomal amphotericin B (Ambisome)|liposomal amphotericin b given intravenously as single dose at 7.5 mg/kg increasing to 10, 12.5 and 15.0mg/kg depending on results of interim analyses.
1834710|NCT00832221|Drug|SEROQUEL XR (quetiapine)|repeated dose of oral tablets, 8 times per subject
1834711|NCT00832221|Drug|SEROQUEL IR (quetiapine)|repeated dose of oral tablets, 4 times per subject
1834712|NCT00832221|Drug|radioligand [11C]raclopride|single dose of iv admin, 5 times per subject
1834713|NCT00832234|Drug|Bortezomib, Dexamethasone, Rituximab|The combination of bortezomib, dexamethasone and rituximab will be administered in five treatment cycles. Bortezomib will be administered as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle one. On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each cycle. Only on cycles 2 and 5, following the administration of bortezomib, dexamethasone 40mg IV and rituximab 375mg/m2 IV will be administered. A total of 8 infusions of rituximab will be administered. The administration of bortezomib before rituximab may abrogate the IgM flare phenomenon that occurs frequently after the first course of rituximab.
1834714|NCT00832247|Genetic|Autologous bone marrow mononuclear cells infusion|At least 100.000.000 autologous BMMC will be infused in a peripheral vein once suspended in albumine during 10 minutes
1834715|NCT00832273|Device|ELAD®|liver assist system
1834716|NCT00832286|Drug|Ciprofloxacin|Licensed medication, dose: 500 mg every 12 hours for 3 days.
1834717|NCT00832299|Drug|FOLFOX|6 cycles of neo-adjuvant mFOLFOX6
1834718|NCT00832299|Procedure|total mesorectal excision (TME)|TME will be done 4-6 weeks after 6 cycles of neo-adjuvant FOLFOX.
1834719|NCT00832312|Other|ozone-oxygen mixture|10 cc of an ozone-oxygen mixture with ozone concentration 10000 mcg/L (10 mcg/ml)
1834720|NCT00832312|Other|placebo (saline)|Injection of 1cc of saline into the knee joint
1834721|NCT00832325|Behavioral|interview|The doctor and/or one of her trained research study staff will ask the patient about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take (approximately 1-1 ½ hours)to complete. Interviews will be audiotaped and transcribed by a professional transcription service.
1834807|NCT00833066|Biological|Placebo|placebo entero-coated capsules
1834722|NCT00832325|Behavioral|Focus groups|The patient will participate with 6-8 other adolescent/young adult cancer survivors. The doctor and/or her trained research study staff will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life. It should take about one-and-a-half hour to complete. Focus groups will be audio taped and transcribed by a professional transcription service.
1834723|NCT00832325|Behavioral|Questionnaire|The patient will be asked to participate in three 60-90 minute telephone interviews conducted by the doctor and/or her trained research study staff scheduled at the patient's convenience, the second interview approximately 6-8 months after the first and the last interview approximately 12-16 months after the first. The questionnaire will ask about their experience as an adolescent/young adult cancer survivor, their health and quality of life.
1834724|NCT00832338|Drug|Docetaxel with Cytoxan|Docetaxel 75 mg/m² plus cytoxan 600 mg/m² every 3 weeks for 6 cycles.
1834725|NCT00832338|Drug|Dexamethasone|Dexamethasone 4 mg BID PO for 3 consecutive days starting 12-24 hours prior to each dose of docetaxel.
1834726|NCT00832351|Procedure|Mobilisation|Mobilisation
1834727|NCT00832364|Drug|Acitretin (also called U0279)|Capsules containing 25 mg U0279 taken once a day.
1834728|NCT00832364|Drug|Placebo|Placebo capsules
1834729|NCT00832364|Biological|Etanercept|Injectable Biologic
1834730|NCT00832377|Drug|timolol/dorzolamide combination|Timolol/Dorzolamide, 1 drop, twice daily, for 12 weeks
1834731|NCT00832390|Drug|sitagliptin phosphate|Patients will receive sitagliptin with metformin for 24 weeks, given as oral tablets
1834732|NCT00832403|Other|implants of polytetrafluoroethylene in tha nasal fossa|surgical implants of polytetrafluoroethylene in the nasal fossa
1834733|NCT00832416|Drug|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
1834734|NCT00832416|Drug|Placebo|One Placebo tablet daily.
1834735|NCT00832429|Procedure|Lymphatic Mapping|SPECT/CT scan following Tc99m-Sulfur colloid injection into eyelid tumor(s) making lymph nodes visible on imaging scan.
1834736|NCT00832429|Procedure|SLN Mapping/Biopsy|SLN mapping and biopsy done in OR under general anesthesia. Injection of Tc99m-Sulfur colloid again around eyelid tumor(s) or removed tumor site(s). Lymph nodes visible from injection removed and tested for signs of metastatic disease.
1834737|NCT00832442|Drug|Beta blocker|as determined by individual study
1834738|NCT00832442|Other|Placebo|in addition to usual care
1834739|NCT00832455|Drug|montelukast sodium|Montelukast 4-5 mg for 12 weeks, oral tablet
1834740|NCT00832468|Other|ear acupressure|The ear acupressure that is used involved a 0.3 cm-sized magnetic pellet on a 1 cm size sticky patch (Ching-Ming Co., Taiwan), which was placed on the bilateral ear Shenmen points; each of the points were pressed once a second for one minute (60 times) before sleep every night. The time period of the treatment course was four weeks.
1834741|NCT00832468|Other|sham ear acupressure|The sham ear acupressure that was used involved a 1 cm size sticky patch placed on the bilateral ear Shenmen points. There was no magnetic pellet attached to the sticker and no need to press it.
1834744|NCT00832494|Drug|DMXAA in combination with carboplatin and paclitaxel|Administered every 21 days
1834745|NCT00832507|Drug|Cicletanine|Cicletanine capsules 150 mg or 300 mg administered orally once or twice daily
1834746|NCT00832507|Drug|Cicletanine Placebo|Placebo to match cicletanine administered orally once daily, followed by active cicletanine in the blinded extension period
1834748|NCT00832546|Drug|Placebo|
1834749|NCT00832546|Drug|Oral NGX426 (Powder in solution)|
1834750|NCT00832559|Biological|Coxsackievirus A21|1, 3 or 6 doses of CAVATAK (10^9 TCID50) at 48 hour intervals.
1834751|NCT00832572|Drug|Ranolazine|Ranolazine ER tablet administered orally for 6 weeks (500 mg twice a day for 3 weeks, followed by either 500 mg or 1000 mg twice a day for 3 weeks).
1834752|NCT00832572|Drug|Placebo|Placebo to match ranolazine administered twice a day for 6 weeks
1834753|NCT00832585|Drug|Alefacept|Alefacept 15mg IM every week for 12 weeks
1834754|NCT00832598|Radiation|[18F]FACBC PET and [18F]FLT PET imaging|[18F]FACBC PET and [18F]FLT PET imaging on 30 patients with gliomas scheduled for treatment with pathway inhibitor agents such as receptor tyrosine kinase inhibitors, antibodies (e.g., bevacizumab), VEGF-Trap, etc. Patients with measurable disease on MRI will undergo PET imaging at baseline (prior-to) and after approximately 1 month of treatment.
1834755|NCT00832611|Device|Arteriovenous Fistula (ROX AC1)|The percutaneous creation of an arteriovenous fistula.
1834756|NCT00832624|Drug|sitagliptin|Sitagliptin, 100 mg, 1 Tablet, once a day, for 18 weeks
1834760|NCT00832650|Drug|fesoterodine fumarate|8 mg OD for 14 days
1834761|NCT00832650|Drug|placebo|OD for 14 days
1834762|NCT00832650|Drug|solifenacin|10 mg OD for 14 days
1834763|NCT00832663|Drug|NSAID|Effect of NSAID ingestion on muscle regeneration
1834764|NCT00832663|Drug|placebo|receive placebo
1834765|NCT00832689|Drug|Irinotecan and Gemcitabine|
1834766|NCT00832702|Procedure|Cardiac MRI|CMRI provides unique clinical utilities including excellent soft tissue characterization and contrast, three-dimensionality, quantitation of blood flow, and overall superior temporal and spatial resolution to image vascular and myocardial abnormalities.
1834767|NCT00832715|Procedure|EBUS-TBNA|Tissue sample collected bronchoscope using needle aspirate of lung lymph gland, procedure takes 1 hour.
1834768|NCT00832728|Other|Standard of Care|Standard hospital protocol for the treatment of acute liver failure
1834769|NCT00832728|Device|ELAD®|ELAD therapy
1834770|NCT00832754|Device|RDT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
1834771|NCT00832754|Other|Clinical Judgement as basis for treatment of malaria with ACT|Study children attending RDT+ACT HCs with a febrile illness will be tested with an RDT to confirm malaria and treated with ACT only if they have a positive test for malaria parasite. However if there are signs suggestive of other co-morbidities they will be treated with appropriate medicines in addition to AS+AQ.
1958990|NCT00977457|Genetic|DNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
1958991|NCT00977457|Genetic|DNA methylation analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
1834774|NCT00832780|Radiation|Stereotactic Body Radiation|A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days. Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours. Dose will be prescribed to the isodose line which covers at least 90% of the planning target volume. Dose homogeneity +/- 5%.
1834775|NCT00832806|Behavioral|Extended IVR (integrated voice response technology)|See detailed description
1834776|NCT00832806|Drug|Varenicline (Champix)|See detailed description
1834777|NCT00832806|Behavioral|IVR treatment|See detailed description
1834778|NCT00832819|Drug|E7080|Drug: E7080 will be administered orally starting at a dose of 6 mg twice daily during the 7-day run-in period and for 3 weeks (Cycle 1).
1834779|NCT00832819|Drug|E7080|Maximum tolerated dose determined in the Dose-Escalation Cohort will be administered to the Expansion Cohort. After E7080 is taken on Day 1, paclitaxel (200 mg/m2) will be administered intravenously (IV), followed by IV carboplatin (AUC 6.0 min/mg/mL).
1834780|NCT00832819|Drug|Paclitaxel|Paclitaxel (200 mg/m2) will be administered intravenously (IV) on Day 1 after administration of E7080.
1834781|NCT00832819|Drug|Carboplatin|Carboplatin (AUC 6.0 min/mg/mL) will be administered IV on Day 1 after administration of E7080 and Paclitaxel.
1834782|NCT00832832|Other|Eyelid closure|Eyelid will be closed after eye drop instillation
1834783|NCT00832832|Other|No intervention will be assigned|No intervention will be assigned to this arm
1834784|NCT00832845|Behavioral|CBSST plus treatment as usual|Patients will receive CBSST in addition to their regular treatment for 24 weeks.
1834785|NCT00832845|Behavioral|Treatment as usual (TAU)|Patients will receive their regular treatment for 24 weeks without CBSST. TAU consists of the standard care that patients receive, including routine visits and contacts with their physicians and clinicians. However, in addition to the standard of care, subjects receiving TAU will have 24 weekly 60-minute non-structured meetings, including half-hour lunch break, to control for non-specific factors associated with group therapy.
1834786|NCT00832871|Drug|Mifepristone|Mifepristone 200 mg will be administered orally
1834787|NCT00832884|Drug|Lacosamide|0.7 mg/kg (up to maximum of 50 mg) x 5 subjects x 30 minutes
1834788|NCT00832884|Drug|Lacosamide|1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 30 minutes
1834789|NCT00832884|Drug|Lacosamide|2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 30 minutes
1834790|NCT00832884|Drug|Lacosamide|2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 30 minutes
1834791|NCT00832884|Drug|Lacosamide|0.7 mg/kg (up to a maximum of 50 mg) x 5 subjects x 15 minutes
1834792|NCT00832884|Drug|Lacosamide|1.4 mg/kg (up to a maximum of 100 mg) x 5 subjects x 15 minutes
1834793|NCT00832884|Drug|Lacosamide|2.1 mg/kg (up to a maximum of 150 mg) x 5 subjects x 15 minutes
1834794|NCT00832884|Drug|Lacosamide|2.9 mg/kg (up to a maximum of 200 mg) x 5 subjects x 15 minutes
1834795|NCT00832897|Procedure|Corneal collagen crosslinking|"The patients will be submitted to corneal collagen crosslinking, that consists:
Instillation of riboflavin eyedrop in the cornea for thirty minutes, and after, the patient will stay under the Crosslinking equipment, for more thirty minutes, also receiving riboflavin eyedrop."
1834796|NCT00832923|Behavioral|PEPAC|"The proposed enhancement of the IMPACT DC intervention will consist of three key components: (1) an enhanced IMPACT DC Asthma Clinic visit; (2) short-term case management to increase the rate of primary care follow-up visits in the first month after the IMPACT DC Asthma Clinic visit; and (3) training in an asthma care toolkit to improve communication around asthma care with the child's primary care provider."
1834797|NCT00832962|Genetic|Genotyping|Whole blood sample
1834798|NCT00832962|Other|Usual prophylaxis|Prophylactic anti-RhD
1834799|NCT00832988|Other|VentricularAutoCaptureTM & ACapTM Confirm|The testing algorithms allow the device to display threshold measurements at time of device interrogation. These will be evaluated against manual testing results.
1834800|NCT00833001|Device|GYNECARE PROLIFT+M* Pelvic Floor Repair System|Pre-shaped mesh implants made of GYNECARE GYNEMESH M composite mesh, comprised of absorbable polyglecaprone 25 monofilament fiber and nonabsorbable polypropylene monofilament fiber
1834801|NCT00833014|Device|Dynamic Annuloplasty Ring (with option to adjust off-pump)|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant.
1834802|NCT00833027|Drug|sitagliptin phosphate|Sitagliptin 100 mg/day - tablet for 24 weeks
1834803|NCT00833040|Drug|Sublingual sufentanil NanoTabs™ and placebo NanoTabs™|During the Titration Phase, patients titrated to the dose of sufentanil that provided adequate pain relief without intolerable side effects. Dosages were 20, 30, 40, 60 and 80 mcg. During the Double Blind Phase, patients were randomized to one of six sequences and took 7 doses of sufentanil (dosage determined in the titration phase, and 3 doses of placebo.
1834804|NCT00833053|Drug|Infliximab|Infliximab 5 mg/kg body weight intravenous infusion given every 6 weeks
1834878|NCT00833664|Drug|Terbinafine HCl 250mg tablets|1 x 250 mg
1834808|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 100µg of gpASIT+TM
1834809|NCT00833066|Biological|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM
1834810|NCT00833079|Drug|Tacrolimus 0.1% manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
1834811|NCT00833079|Drug|Protopic - Tacrolimus 0.1%|Treatment applied as a thin layer to target area twice daily for 14 days
1834812|NCT00833079|Drug|Tacrolimus Vehicle manufactured by Taro|Treatment applied as a thin layer to target area twice daily for 14 days
1834813|NCT00833092|Dietary Supplement|Sugar Pill|Sugar pill supplementation for 9 weeks
1834814|NCT00833092|Dietary Supplement|magnesium|300 milligrams daily for 8 weeks
1958992|NCT00977457|Genetic|RNA analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
1834816|NCT00833118|Procedure|Jaw thrust maneuver (Intubation)|Visualization of Larygnoscopic anatomy during intubation
1834817|NCT00833131|Radiation|Short course of radiotherapy|5 x 5 Gy and afer one week interval consolidating chemotherapy of 3 courses of FOLFOX4
1834818|NCT00833131|Radiation|Radiochemotherapy|28 x 1,8 Gy with simultaneous neoadjuvant chemotherapy: two courses of 5-Fu 325 mg/m2/day i.v. bolus and LV 20 mg/m2/day i.v.-bolus over 5 days given during 1-5 and 29-33 days of radiation. Oxaliplatin is given 50 mg/m2 once a week 5 times during 1, 8, 15, 22 and 29 days of radiation.
1834819|NCT00833157|Drug|glucosamine sulphate|Subjects are administered glucosamine-sulphate tablets of 500 mg * 3 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks.
1834820|NCT00833157|Drug|ibuprofen|Subjects are administered 600 mg * 2 daily, while they are performing a strength-training program with both legs (*3 weekly) for 12 weeks
1834821|NCT00833157|Drug|placebo|Subjects are administered placebo tablets, while they are performing a strength-training program (*3 weekly) with both legs for 12 weeks
1834822|NCT00833183|Drug|MAL|80 mg/g cream one administration with incubation for 90 minutes
1834823|NCT00833209|Procedure|PET (withdrawal)|3 (18F)FDG-PET (before withdrawal, 3 months, 1 year), 2 MRI (before withdrawal, 1 year), will take the Iowa Gambling Task Test(before withdrawal) and will answer questionnaires measuring psychological dimensions (before withdrawal, 3 months, 1 year)
1834824|NCT00833209|Procedure|Imaging|2 MRI (inclusion, 1 year) ; Iowa Gambling Task Test(inclusion) and questionnaires (inclusion)
1834825|NCT00833209|Procedure|Imaging|1 MRI ; Iowa Gambling Task test and questionnaires.
1834826|NCT00833235|Other|Artificial Tears|Artificial tears (any brand) may be used to treat dry eye symptoms.
1834827|NCT00833248|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
1834828|NCT00833248|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 3. The second and third doses of goserelin were administered on Days 31 and 59, respectively.
1834829|NCT00833248|Drug|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 14 days after the first dose of goserelin.
1834830|NCT00833261|Drug|cetuximab|cetuximab
1834831|NCT00833261|Drug|cisplatin|cisplatin
1834832|NCT00833261|Radiation|intensity-modulated radiation therapy|IMRT
1834833|NCT00833274|Behavioral|computerized test|Using a computerized test, each patient is asked to press a button (mouse of the computer) each time the screen of the computer becomes completely white.
1834834|NCT00833300|Drug|Haloperidol|"2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.
Reassess in 24 hours.
Delirium absent - Continue dose for 24 hours then discontinue.
Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.
Reassess in 24 hours.
Delirium absent - Continue dose for 24 hours then discontinue.
Delirium present - Discontinue current drug therapy and select one of:
Quetiapine up to 100 mg/day
Risperidone up to 6 mg/day
Loxapine up to 50 mg/day
Methotrimeprazine up to 75 mg/day
Reassess in 24 hours.
Delirium absent - Continue for 24 hours then discontinue.
Delirium present - Treatment at discretion of attending physician."
1834835|NCT00833300|Drug|Olanzapine|"2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.
Reassess in 24 hours.
Delirium absent - Continue dose for 24 hours then discontinue.
Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.
Reassess in 24 hours.
Delirium absent - Continue dose for 24 hours then discontinue.
Delirium present - Discontinue current drug therapy and select one of:
Quetiapine up to 100 mg/day
Risperidone up to 6 mg/day
Loxapine up to 50 mg/day
Methotrimeprazine up to 75 mg/day
Reassess in 24 hours.
Delirium absent - Continue for 24 hours then discontinue.
Delirium present - Treatment at discretion of attending physician."
1834836|NCT00833313|Other|Atrial biopsy|Biopsy of right atrial free wall
1834837|NCT00833326|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
1834838|NCT00833326|Drug|Docetaxel, mitotic inhibitor; intravenous|multiple dose, single schedule
1834839|NCT00833326|Drug|Prophylactic growth factors; subcutaneous|standard of care
1834840|NCT00833339|Drug|mifepristone|600 mg/day x 1 week
1834841|NCT00833339|Drug|placebo|placebo
1834842|NCT00833352|Device|CRT-D Therapy|Implant of a defibrillator with cardiac resynchronization therapy to detect and terminate ventricular arrhythmias and resynchronize ventricles.
1834843|NCT00833365|Drug|Ibuprofen|Ibuprofen 10 mg/kg/dose for one dose, then repeated 24 hrs later at 5 mg/kg/dose and repeated 24 hrs later at 5 mg/kg/dose
1834844|NCT00833365|Drug|Ibuprofen|Initial dose of ibuprofen is 10 mg/kg and then repeated every 24 hours times two with doses of 5 mg/kg
1834845|NCT00833378|Drug|Eltrombopag|Eltrombopag 100 mg single oral dose
1834846|NCT00833378|Drug|Lopinavir/Ritonavir|Lopinavir/Ritonavir 400/100 mg oral dose given twice a day for 14 days
1834847|NCT00833378|Drug|Eltrombopag and Lopinavir/Ritonavir|Elrombopag 100 mg single oral dose and Lopinavir/Ritonavir 400/100 mg oral dose given in the AM and PM
1958993|NCT00977457|Genetic|gene expression analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
1834848|NCT00833391|Drug|open label|This is an open-label, randomized, single-dose, five-period, crossover study. All subjects will receive GSK1838262.
1834849|NCT00833404|Drug|Nicotine transdermal patch|8-week nicotine patch regimen (21mg/day during week 1-4, 14mg/day during week 5-6, and 7mg/day during week 7-8).
1834850|NCT00833417|Drug|Vismodegib 150 mg|Vismodegib 150 mg was provided in hard gelatin capsules.
1834851|NCT00833443|Drug|Bupropion|Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
1834852|NCT00833469|Drug|Escitalopram|Once daily by mouth
1834853|NCT00833482|Drug|Voriconazole|Treatment A: Participants with functional CYP2C19 alleles (EM) received oral tablets of voriconazole, 400 mg, twice daily (BID), on Day 1, then 200 mg BID on Days 2 and 3. Voriconazole dose was given at least 1 hour after a light meal. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
1834854|NCT00833482|Drug|Atazanavir|Treatment B in EM participants: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Treatment B in participants who were poor metabolizers of CYP2C19 (PMs): PM participants received oral tablets of atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30.
1834855|NCT00833482|Drug|Ritonavir|"Treatment B: EM participants received atazanavir/ritonavir, 300/100 mg once daily (QD), on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal.
Treatment C: EM participants received atazanavir/ritonavir, 300/100 mg QD, plus voriconazole, 400 mg BID on Day 21 then 200 mg BID on Days 22-30. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal, and 1 hour before voriconazole morning dose.Treatment E: PM participants received atazanavir/ritonavir, 300/100 mg QD plus voriconazole, 100 mg BID, on Day 21, then 50 mg BID on Days 22-30. Treatment B in PM participants: PM participants received atazanavir/ritonavir, 300/100 mg QD, on Days 11 through 20. Atazanavir/ritonavir dose was administered in the morning within 5 minutes of completing a light meal."
1834856|NCT00833495|Drug|Prednisolone Acetate 0.12% (Pred Mild®)|Indicated for the treatment of mild to moderate noninfectious allergic and inflammatory disorders of the lid, conjunctiva, cornea, and sclera (including chemical and thermal burns). Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary.
1834857|NCT00833495|Drug|FOV1101-00|This investigational drug is a low dose cyclosporine (also known as cyclosporine A; CsA) formulation for topical ocular administration. FOV1101-00 is presented as a solution for topical ophthalmic administration in two strengths, concentration 1 or concentration 2 w/v cyclosporine in citrate buffered aqueous vehicle. Application is intended as four times per day.
1834858|NCT00833495|Drug|Prednisolone Acetate 1% (Pred Forte®)|PRED FORTE® is indicated for the treatment of steroid-responsive inflammation of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the globe. Instill one to two drops into the conjunctival sac two to four times daily. During the initial 24 to 48 hours, the dosing frequency may be increased if necessary. Care should be taken not to discontinue therapy prematurely.
1834859|NCT00833495|Drug|Placebo|The vehicle is an eye drop that contains only the inactive ingredients of FOV1101-00.
1834860|NCT00833508|Other|Cardiopulmonary exercise testing|Cardiopulmonary exercise testing involves cycling on an exercise bicycle whilst oxygen consumption and carbon dioxide generation are measured from expired gases. This is used to calculate patient fitness from their peak oxygen consumption and their anaerobic threshold.
1834861|NCT00833521|Drug|Zolpidem 10 mg tablets|1 x 10 mg
1834862|NCT00833521|Drug|AMBIEN® 10 mg tablets|1 x 10 mg
1834863|NCT00833534|Biological|rituximab|Given IV
1834864|NCT00833534|Drug|lenalidomide|Given orally
1834865|NCT00833547|Drug|eszopiclone|3 mg of eszopiclone at bedtime on two consecutive nights
1834866|NCT00833547|Drug|placebo|Placebo capsules looking identical to eszopiclone at bedtime on two consecutive nights
1834867|NCT00833560|Drug|Cyclophosphamide|In Part 1, cyclophosphamide with dose ranging from 900 to 1500 mg will be administered intravenously on Day 1 of each 21 day cycle for 3 cycles to determine optimal dose. In Part 2, optimal dose determined in Part 1 will be administered on Day 1 of each 21 day cycle for 3 cycles.
1834868|NCT00833560|Drug|Bortezomib|Bortezomib 1.3 mg/m2 will be administered intravenously on Days 1,4,8, and 11 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
1834869|NCT00833560|Drug|Dexamethasone|Participants will receive dexamethasone 40 mg orally or intravenously on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21 day cycle for 3 cycles in both parts (Part 1 and Part 2).
1834870|NCT00833586|Drug|Terbinafine HCl 250mg tablets|1 x 250 mg
1834871|NCT00833586|Drug|Lamisil® 250 mg Tablets|1 x 250 mg
1834872|NCT00833599|Drug|NIRFLI with ICG|We conduct Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic trafficking in subjects. We seek to use the resulting phenotypes acquired in normal and diseased patients to correlate to mutations of specific genes reported to be associated with lymphatic development.
1834873|NCT00833612|Device|Counterpulsation with IAB|IABC pre-reperfusion PCI
1834874|NCT00833625|Procedure|PET/CT (FDG PET/CT)|PET/CT scan with fluorodeoxyglucose (FDG) solution by vein, scan done 10-14 days after beginning chemotherapy and radiation (chemoradiation).
1834875|NCT00833625|Other|Biomarker Testings|Tissue obtained at MDACC during previous biopsy and at time of post chemoradiation surgery will be used for biomarker analysis.
1834876|NCT00833638|Drug|Placebo|One tablet orally daily
1834877|NCT00833638|Drug|Tadalafil|Orally once daily
1834880|NCT00833677|Behavioral|Chinese Coping Skills Training|Six-week group behavioral intervention: Chinese Coping Skills Training
1834881|NCT00833690|Drug|Placebo|500 mg of inactive substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing adjusted algorithmically to parallel that in the inosine arms
1834882|NCT00833690|Drug|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a mildly elevated serum urate range of 6.1 - 7.0 mg/dL
1834883|NCT00833690|Drug|inosine|500 mg of active substance per capsule; 1 to 6 capsules per day (in up to 3 divided doses) for 2 years; dosing titrated to a moderately elevated serum urate range of 7.1 - 8.0 mg/dL
1834884|NCT00833703|Drug|Clopidogrel|"Form: reconstituted solution using Clopidogrel powder
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight"
1834885|NCT00833703|Drug|placebo|"Form: reconstituted solution using matching placebo powder
Route: oral or enteric
Frequency: once daily
Dose: daily dose adjusted for weight"
1834886|NCT00833716|Drug|semaglutide|10 mg/mL of semaglutide solution for s.c. injection, single dose
1834887|NCT00833729|Drug|etanercept|50 mg twice weekly (BIW) for 12 wks followed by a dose reduction to 50mg once weekly (OW) for an additional 12 weeks.
1834888|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
1834889|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
1834890|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|30 mg bid main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
1834891|NCT00839163|Drug|Xarelto (Rivaroxaban, BAY59-7939)|40 mg od main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84).
1834892|NCT00839163|Drug|Enoxaparin/Vitamin K-Antagonist|Enoxaparin/Vitamin K-Antagonist main treatment period of 21 days followed by an extended period of trial therapy until week 12 (Day 84). Enoxaparin was to be administered 1mg/kg bid sc for about 5-7 days. It was to be discontinued when INR was within the therapeutic range 2-3 for 2 consecutive days
1834893|NCT00839176|Drug|RX-10100|Extended-release tablet, 5~15mg, twice day (morning & evening) at least 30 min before meal, 8 weeks
1834894|NCT00839189|Biological|Clinical Center Reference Endotoxin (CCRE)|Inhalation of 10,000 EU CCRE
1834895|NCT00839202|Other|FVIII immuno-assay|There is no intervention. This is a study of the differences in assays.
1834896|NCT00839228|Drug|Perhexiline|100mg o bd for 3 months
1834897|NCT00839228|Drug|Placebo|Placebo one tablet bd for 3 months
1834898|NCT00839241|Device|Bellovac ABT|Bellovac ABT (autologous blood)
1834899|NCT00839241|Procedure|Allogenic Blood Transfusion|"Transfusion of allogenic (bank) blood."
1958994|NCT00977457|Genetic|polymerase chain reaction|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
1958995|NCT00977457|Other|diagnostic laboratory biomarker analysis|Performed on Post-massage urine (PMU) and/or expressed prostatic secretions (EPS) samples obtained at the time of surgery
1958996|NCT00977457|Procedure|therapeutic conventional surgery|
1834903|NCT00839280|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
1834904|NCT00839280|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
1834905|NCT00839293|Drug|ABT-335|Once, see arm description for more information
1834906|NCT00839306|Drug|Rabeprazole ER|50 mg capsule, taken orally, once daily for 26 weeks.
1834907|NCT00839306|Drug|Ranitidine|150 mg capsule, taken orally, twice daily for 26 weeks.
1834908|NCT00839319|Drug|Acyline|300 ug/kg subcutaneous injections on Day 1.
1834909|NCT00839319|Other|placebo hCG (no active ingredient)|placebo hCG
1834910|NCT00839319|Drug|hCG (human chorionic gonadotropin)|15 IU subcutaneous injection every other day for 10 days (5 doses)
1834911|NCT00839319|Drug|hCG (human chorionic gonadotropin)|60 IU subcutaneous injection
1834912|NCT00839319|Drug|hCG (human chorionic gonadotropin)|125 IU subcutaneous injection
1834913|NCT00839319|Drug|Testosterone gel|75 mg testosterone gel applied transdermally for 10 days
1834914|NCT00839332|Drug|LY2603618|70-300 mg/m2 intravenous administered once per week for 3 weeks followed by 1 week of rest, repeating every 28 days for a minimum of 2 cycles and until disease progression
1834915|NCT00839332|Drug|Gemcitabine|1000 mg/m2 intravenous administered once per week for 3 weeks followed by 1 week of rest, repeating every 28 days for a minimum of 2 cycles continuing until disease progression
1834916|NCT00839345|Drug|clopidogrel|The intervention will involve the change of dosage or change of drug. The traditional maintenance dose of clopidogrel is 75 mg per day. We will test in non-responders to this classical dose higher doses up to 225mg per day. In patients,who will not respond to this 3times higher dose,clopidogrel will be replaced by ticlopidine.
1834917|NCT00839358|Drug|albumin|albumine 40 g every 15 days
1834918|NCT00839358|Drug|Midodrine|Midodrine 5mg/8 hs, can be increase up to 8mg/8hs if there is a lack of increase in at least 10mmHg in mean arterial pressure after 15 days of treatment.
1834919|NCT00839358|Drug|Placebo|saline solution
1834920|NCT00839371|Drug|Propofol|i.v. propofol titration until adequate depth of sedation
1834921|NCT00839371|Drug|Midazolam|i.v. midazolam titration until adequate depth of sedation
1834922|NCT00839384|Device|Advisa IPG|Implantable Pulse Generator will be implanted
1834958|NCT00841503|Other|buckwheat, rice crackers, glucose, sugar substitute|crackers contain equal amounts of available carbohydrates; 50 mls of oral solution for both glucose and Splenda
1834959|NCT00841516|Other|Placebo|Placebo was given the same way as a subcutaneous (just under the skin) injection.
1834960|NCT00841516|Biological|rBet v1-FV|Placebo was given the same way as a subcutaneous (just under the skin) injection.
1834961|NCT00841529|Device|Medtronic LAA Occlusion Device|Placement of the occlusion band on the LAA
1834962|NCT00841542|Drug|Amlodipine Besylate|10 mg Tablet
1834923|NCT00839397|Drug|Paroxetine|"Subjects will take the treatment phase medication once daily after an evening meal. All subjects will be maintained at Dose Level II (20 mg/day) for the first 2 weeks. If a sufficient clinical response (1. Very much improved or 2. Much improved based on the CGI Global Improvement) is achieved, the subject will continue on the same dose level. When the clinical response is not sufficient but the investigational product is well tolerated, the dose will be increased to Dose Level III (30 mg/day) and then to Dose Level IV (40 mg/day) at intervals of at least 2 weeks until a sufficient response is reached. Once a sufficient response is obtained, the treatment will be continued at that dose. The treatment phase will last for a total of 52 weeks. In those patients receiving Dose Level III or IV, dosage reductions to the next lowest level (Dose Level II or III) consequent to an adverse event are permitted.
Dosage adjustment will be made at the discretion of the PI or Sub-PI"
1834924|NCT00839423|Drug|Placebo|capsules, daily, orally
1834925|NCT00839423|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
1834926|NCT00839423|Drug|Venlafaxine XL|capsules, daily, orally
1834927|NCT00839436|Drug|CYT107|
1834928|NCT00839449|Drug|Eicosapentaenoic acid ethyl ester|Orally administered 900 mg eicosapentaenoic acid ethyl ester three times a day (2700 mg ⁄ day) from the surgery next day to 30 days after the onset of SAH.
1834929|NCT00839462|Drug|Dexpanthenol foam spray, new formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
1834930|NCT00839462|Drug|Dexpanthenol foam spray, old formulation|2 applications of 2 micro liter/square centimeter on a 4X4 cm area corresponding to 32 micro liter
1834931|NCT00841269|Drug|Uridine|Uridine 500 mg by mouth twice per day for 6 weeks
1834932|NCT00841282|Procedure|Colonoscopy for colorectal cancer screening|
1834933|NCT00841282|Procedure|Water Infusion Colonoscopy|water infusion in lieu of air insufflation for screening colonoscopy
1834934|NCT00841282|Procedure|Air insufflation colonoscopy|Conventional colonoscopy with air insufflation
1834935|NCT00841295|Drug|Parenteral L-carnitine supplementation|Parenteral carnitine supplementation (9 ± 1 mg/kg/d), from day 4, until than enteral nutrition provides sufficient carnitine source.
1834936|NCT00841295|Drug|Parenteral supplementation with sterile water|Parenteral supplementation with an equivalent volume of sterile water
1834938|NCT00841321|Drug|Ginkgo biloba|120 mg orally twice a day for 12 weeks
1834939|NCT00841321|Drug|Placebo|One capsule orally twice a day for 12 weeks
1834940|NCT00841334|Behavioral|ACTION|Overweight/obese adolescents enrolled in ACTION will meet with SBHC providers over a 6 month period in one school year. SBHC providers will use Motivational Enhancement Therapy to motivate overweight/obese adolescents to adopt strategies for improving nutrition and physical activity.
1834941|NCT00841334|Behavioral|Usual care|Overweight/obese adolescents in the second arm will receive a well child check with usual anticipatory guidance.
1834942|NCT00841347|Behavioral|habitual sleep length period + extended sleep length period|On obese group, realisation of an habitual sleep length period followed by an extended sleep length period
1834943|NCT00841347|Behavioral|extended sleep length period + habitual sleep length period|On obese group, realisation of an extended sleep length period followed by an habitual sleep length period
1834944|NCT00841360|Other|Index Recruiter|Participants agree to recruit at least two female friends from their friendship network to undergo HIV screening.
1834945|NCT00841360|Other|Friendship Network Member|Participants are recruited by Index Recruiters to enroll in study and receive HIV screening and complete a questionnaire either on Facilitators of HIV Screening or Barriers to HIV Screening.
1834946|NCT00841373|Procedure|Panretinal Photocoagulation|Panretinal Photocoagulation treatment
1834947|NCT00841373|Procedure|Panretinal Photocoagulation and intravitreal injection of ranibizumab|Panretinal photocoagulation and ranibizumab
1834948|NCT00841386|Drug|Riboflavin-5-phosphate|Riboflavin 0.1% (10 mg riboflavin-5-phosphate in 10 ml dextran T-500 20% solution, supplied in a sterile, single dose container) will be applied to the cornea every 2-3 minutes for 15 minutes prior to starting UV irradiation. The UV irradiation will be given in six 5 minute intervals. Additional riboflavin will be administered following each 5 minute UV treatment.
1834949|NCT00841386|Drug|Sham cross-linking|Topical anesthesia (lidocaine jelly 2%) will be used. Differing from the treatment group, no epithelium will be debrided, but instead, this step will be skipped and 2% methylcellulose solution with 1% sodium fluorescein will be applied to the cornea every 5 minutes for 15 minutes, and then every 5 minutes during the sham UV treatment. The patient will be placed under the UV device, and the aiming beam applied.
1834951|NCT00841412|Behavioral|Immediate Intervention Group|Unit staff received weekly training and feedback for 12-weeks to improve daily nutritional care processes.
1834952|NCT00841412|Behavioral|Delayed Intervention Group|Research staff monitored this group under usual care conditions, then these units crossed over into intervention.
1834953|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
1834954|NCT00841438|Drug|Clotinab|Clotinab: IV bolus 0.25 mg per Kg and a 12-hour IV infusion 0.125 μg per kg
1834955|NCT00841451|Drug|Lovaza (Fish Oils)|Double blinded placebo controlled
1834956|NCT00841477|Biological|hepatitis B vaccine 3 dose schedule (0,1,2 month)|hepatitis B (HB) vaccine: Engerix-B (GlaxoSmithKline) (20 µg/dose) accelerated HB vaccine schedule (0,1,2 month),vs, standard HB vaccine schedule (0,1,6 m)
1834957|NCT00841477|Behavioral|HBV Vaccination Self-Efficacy Intervention|HB Vaccination Intervention consists of 4 sessions - Sessions 1, 2: at screening and enrollment after intake, vs regular risk reduction education Sessions 3, 4: coincide with the vaccination schedule ions 4 before 3rd dose
1834963|NCT00841542|Drug|Norvasc®|10 mg Tablet
1835115|NCT00842673|Drug|ST101|180 mg; administered once/day
1834964|NCT00841555|Drug|temozolomide|"Chemotherapy will be given for 5 weeks; it will start 1 week before Radiotherapy, will continue for the 3 weeks of Radiotherapy, and will continue for 1 week post-Radiotherapy.
Dose Level 1: 50 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 2: 65 mg/m2 x first 4 weeks/75 mg/m2 x last 1 weeks of treatment Dose Level 3: 75 mg/m2 over the entire 5 weeks of treatment"
1834965|NCT00841555|Radiation|Hypofractionated radiation therapy|Patients will undergo HIMRT
1834966|NCT00841555|Radiation|Intensity-modulated radiation therapy|Patients undergo HIMRT
1834968|NCT00841581|Drug|Ranibizumab|Ranibizumab 0.5 mgs. (0.05 mls.) intravitreally for 6 months then as needed prn for 6 months.
1834969|NCT00841594|Drug|nitroglycerin 0.9 % (MXQ-503)|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
1834970|NCT00841594|Drug|Nitroglycerin ointment 2%, USP|MQX-503, topical cream for nitroglycerin 0.9% vs Nitroglycerin ointment 2%, USP.
1834971|NCT00841607|Procedure|pancreaticojejunostomy vs pancreaticogastrostomy|
1834972|NCT00841620|Procedure|Haemorrhoidectomy a.m. Milligan|Surgery
1834973|NCT00841620|Procedure|Stapled anopexy|Surgery
1834974|NCT00841633|Drug|Induced hypertension with norepinephrine|Hypertension will be induced with norepinephrine. Administration of norepinephrine results in vasoconstriction, leading to an increase in blood pressure. The normal blood pressure of the patient will be calculated as the average MAP of the day before the start of the study. To achieve the intended hypertension (30 mmHg above the normal MAP for patients allocated to index group 2) in most cases a dose of 100-300 ng/kg/minute must be administered. Norepinephrine will be started on a dose of 100 ng/kg/minute, after which the dosing will be adjusted to achieve the desired blood pressure level. The maximum dose to be used in the study is 1000 ng/kg/minute. Norepinephrine is administered through the central venous catheter.
1834975|NCT00841646|Biological|Monovalent inactivated influenza vaccine|2 doses of monovalent inactivated influenza vaccine with adjuvant
1834976|NCT00841659|Drug|Paroxetine HCl|40 mg Film-Coated Tablet
1834977|NCT00841659|Drug|Paxil®|40 mg Film-Coated Tablet
1834978|NCT00841672|Drug|Aliskiren/amlodipine 300/10 mg tablet|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
1834979|NCT00841672|Drug|Amlodipine 10 mg capsule|Each dose was taken by mouth with water at approximately 8:00 in the morning with or without food, except on the morning of the next office/clinic visit, when the medication was taken at the site after the visit procedures were completed. In order to adequately blind the study, patients were required to take a total of two tablets and one capsule of study medication per day throughout the study.
1834980|NCT00841685|Device|Goldlock|Insertion of Goldlock marker
1834981|NCT00841685|Device|Visicoil smallest size|Insertion of Visicoil, smallest size, marker
1834982|NCT00841685|Device|Visicoil larger size|Insertion of Visicoil, larger size, marker
1834983|NCT00841685|Device|Bard goldmarker smallest size|Insertion of Bard goldmarker, smallest size
1834984|NCT00841685|Device|Bard goldmarker larger size|Insertion of Bard goldmarker, larger size
1834985|NCT00841698|Drug|Paroxetine HCl|40 mg Film-Coated Tablet
1834986|NCT00841698|Drug|Paxil®|40 mg Film-Coated Tablet
1834987|NCT00841711|Behavioral|Intensive Case Management|Transitions involves the integration of evidence-based interventions, intensive case management that incorporates outreach elements similar to assertive community treatment (ACT). Intensive case management goes beyond the tenets of case management and incorporates community outreach. This model of case management has its roots in assertive community treatment (ACT) and has demonstrated a 37% greater reduction in homelessness and a 26% greater improvement in psychiatric symptom severity compared with standard case management treatments. As such, intensive case management is likely to result in important outcomes for the target population, is evidence-based and has been validated in prison-release programs.
1834988|NCT00841724|Drug|Fludarabine, Busulfan, Thymoglobuline|
1834989|NCT00841737|Other|Psychoeducational group|The intervention group receive weekly a psychoeducational group during 12 weeks run by 2 nurses. The program have a structures contend.
1834990|NCT00841737|Other|Control Group|In the control group the depression is treated as usual with the conventional treatment.
1834991|NCT00841750|Procedure|Do not leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, an air leak proof will take place and if no air leak is noted, the surgical incisions for thoracoscopy ports will be closed without leaving a chest tube inserted in the pleural cavity of the patient.
1834992|NCT00841750|Procedure|Do leave a chest tube in the pleural cavity.|At the end of a VATS wedge resection, a chest tube will be inserted in the pleural cavity of the patient through the inferior surgical incision for thoracoscopy port; the rest of the incisions will be closed.
1834993|NCT00841763|Biological|Placebo|One dose of 0.5 ml IM injection of isotonic saline solution was administered in the deltoid muscle.
1834994|NCT00841763|Biological|Trivalent influenza virus vaccine (TIV)|A single IM injection of a 0.5 ml dose of non-adjuvanted trivalent influenza virus vaccine administered in the deltoid muscle, preferably of the non-dominant arm.
1834995|NCT00841763|Biological|Adjuvanted monovalent influenza virus vaccine (aH5N1)|Two intramuscular (IM) injections of a 0.5 ml dose administered three weeks apart in the deltoid muscle.
1834996|NCT00841763|Biological|Adjuvanted trivalent influenza vaccine (aTIV)|Two IM injections of a 0.5 ml dose of adjuvanted trivalent influenza virus vaccine administered three weeks apart, in the deltoid muscle.
1834997|NCT00841776|Drug|Duac|Clindamycon and benzoyl peroxide topical gel once a day for 12 weeks
1834998|NCT00841776|Drug|Ziana gel|Clindamycin and tretinoin gel once a day for 12 weeks.
1834999|NCT00841789|Drug|Etanercept|etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
1835000|NCT00841789|Drug|Placebo|Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
1835001|NCT00841802|Drug|Prednisone|Prednisone 30mg once daily x 5 days
1835002|NCT00841815|Drug|Amlodipine Besylate|10 mg Tablet
1958999|NCT00957723|Device|Triathlon® CR Total Knee System|The purpose is to evaluate the Triathlon® CR Total Knee System.
1959000|NCT00955396|Drug|GSK1014802|Tablets
1835006|NCT00841854|Drug|pantoprazole|pantoprazole 40mg bid
1835007|NCT00841854|Drug|bismuth|bismuth 300mg qid
1835008|NCT00841854|Drug|metronidazole|metronidazole 500mg tid
1835009|NCT00841854|Drug|tetracycline|tetracycline 500mg qid
1835010|NCT00841867|Procedure|All subjects will undergo a 120 minute Oral Glucose Tolerance Test at study visit 2.|All subjects will ingest a 75 g glucose solution (Glucola brand) and have blood drawn at 7 timepoints over 120 minutes.
1835011|NCT00841880|Drug|Ramipril + Felodipine|Ramipril 5mg + Felodipine 5mg once a day
1835012|NCT00841880|Drug|Ramipril|10 mg once a day
1835013|NCT00841880|Drug|Ramipril|5mg once a day
1835014|NCT00841893|Dietary Supplement|Mustard (dijon)|The specific spice added to a brunch meal
1835015|NCT00841893|Dietary Supplement|Placebo|Placebo added to a brunch meal
1835016|NCT00841906|Device|Alice PDx with only written instructions|Participants will be asked to follow the Alice PDx user instructions to apply basic leads and sensors and undergo a sleep study in their home. Participants will receive little or no instruction concerning the set up of the Alice PDx device. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
1835017|NCT00841906|Device|Alice PDx with written and verbal instructions|Participants will be provided instruction by a trained sleep professional on the set up of the Alice PDx device. They will then be asked to follow the instructions for the Alice PDx device, if necessary, and undergo a sleep study in their home. After the Alice PDx home study has proven successful, participants will return to the sleep center to undergo a second sleep study, the Lab Night, in which simultaneous monitoring with the Alice PDx and Alice 5 will be performed.
1959001|NCT00955396|Drug|Placebo|Tablets
1959002|NCT00950170|Procedure|Laboratory Tests|Blood draws to determine the level of factor VIII activity before and after dosing at appropriate visits, and blood draws to determine levels of factor VIII inhibitor (antibody to factor VIII).
1835021|NCT00841932|Procedure|Fractional Flow Reserve|Fractional Flow Reserve performed without anticoagulation
1835022|NCT00841945|Drug|rituximab|RITUXIMAB 375 MG/M² IV DAY 1 or each course
1835023|NCT00841945|Drug|doxorubicin|doxorubicin 50 mg / m² iv day 1 of each course
1835024|NCT00841945|Drug|vincristine|VINCRISTINE 1?4 MG/M² IV ON DAY 1
1835025|NCT00841945|Drug|prednisone|Prednisone 40 mg/m² DAy 1 to day 5
1835026|NCT00841945|Procedure|radiotherapy|radiotherapy : total dose = 40 GY (5 fractions by week)
1835027|NCT00841958|Procedure|Autologous bone marrow mononuclear stem cells or peripheral blood stem cells|Cells concentration is 150х106 cells/ml (2ml) with CD34+ cells=2.5±1.44%
1835028|NCT00841971|Drug|Anidulafungin|200 mg IV loading dose followed by 100 mg qd for 21 days
1835029|NCT00841971|Drug|Fluconazole|400 mg IV for 21 days
1835030|NCT00842023|Drug|Nesiritide|Bolus 2 mcg/kg followed by 0.01 mcg/kg/min
1835031|NCT00842023|Drug|Nitroglycerin|5-10 mcg/min titrating per protocol based on blood pressure
1835032|NCT00842036|Behavioral|Community Reinforcement and Family Training|Community Reinforcement and Family Training (CRAFT) is an intervention designed for the concerned significant other (CSO) of a drug or alcohol using loved one. The CRAFT intervention consists of approximately 12 sessions lasting 45-60 minutes. The goal of the CRAFT intervention is to train the CSO in new ways to interact with the person of concern (PC). There are four components that the CSO is trained on which include awareness training, community reinforcement training, treatment entry training, and CSO mood enhancement.
1835033|NCT00842036|Behavioral|Treatment Entry Training|Treatment Entry Training (TEnT) is a component of the Community Reinforcement and Family Training intervention and it is currently under investigation to determine if it is sufficient to produce the primary and most consistent outcome of CRAFT- treatment entry of the drug user. The intervention will consist of a minimum of 4 sessions and a maximum of 6 sessions that are each 45-60 minutes long. TEnT will include awareness training, safety training, and the Treatment Entry Training component of CRAFT.
1835034|NCT00842036|Behavioral|12- step Al/Nar- Anon Facilitation|The underlying philosophy of the 12- step approach for concerned significant others (CSO) is that the CSO is powerless to control the drinker/drug user and must detach, focusing instead on accepting the situation and on strengthening his or her mental health. Eight content areas are discussed with the CSO over the course of the intervention. There will be a minimum of 8 sessions and a maximum of 12 sessions that are each 45-60 minutes long.
1835116|NCT00842673|Drug|Placebo|placebo to match ST101 tablets
1959011|NCT00943722|Biological|V503|Multivalent HPV L1 VLP vaccine, 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6. Vaccine dose administered is obtained from manufacturing Lots 1, 2, or 3.
1835035|NCT00842049|Device|Lumbar Drain (Medtronic lumbar drainage system)|Insertion of lumbar drain to drain cerebrospinal fluid
1835036|NCT00842049|Other|No lumbar drain|No lumbar drain
1835037|NCT00842062|Device|MyoScience Tissue Remodeling Device|Percutaneous treatment with the MyoScience device
1835038|NCT00842075|Drug|pramlintide|subcutaneous injection (15 mcg initial dose)prior to meals
1835039|NCT00842088|Drug|Placebo|Matching placebo capsule. Administered orally once a day on dosing days.
1835040|NCT00842088|Drug|HQK-1001|HQK-1001 capsules. 10 mg/kg, 20 mg/kg or 30 mg/kg administered once a day on dosing days.
1835041|NCT00842101|Device|Quick Pressure Monitor|The monitor measures actively the actual pressure inside the compartment affected.
1835042|NCT00842114|Biological|R+CVP+IFN|Immunochemotherapy
1835043|NCT00842127|Drug|OROS-methylphenidate (Concerta)|dose: 18mg, 27mg, 36mg, 45mg, 54mg/day, po duration: 8 weeks
1835044|NCT00842140|Drug|oral contraceptive|oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate)once a day for 12 months
1835045|NCT00842140|Drug|Oral contraceptive plus spironolactone|The patient will receive an oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 100 mg spironolactone. One pill each once a day for twelve months.
1835046|NCT00842140|Drug|Oral contraceptive plus metformin|Oral contraceptive (0,03mg ethynylestradiol and 2mg chlormadinone acetate) plus 850 mg of metformin
1835049|NCT00842166|Other|BLOOD DRAW|specific interview, sequential blood collection to allow virus isolation, molecular and serological diagnostics in patients
1835050|NCT00842192|Drug|insulin detemir|Insulin detemir for s.c. injection, once daily, in addition to current OAD treatment. Dose to be determined by physician.
1835051|NCT00842205|Drug|pegylated interferon|peg-IFN alfa 2a 180ug s.c. QW or peg-IFN alfa 2b 1.5 ug/kg s.c. QW
1835052|NCT00842205|Drug|Ribavarin|ribavirin 1000-1200mg p.o. daily 48weeks or ribavirin 100-1200mg p.o. daily 48 weeks
1835053|NCT00842231|Other|Visual performance measures|Collection of visual performance measures in subjects with low levels of astigmatism.
1835054|NCT00842244|Drug|axitinib|Twice daily oral dose of axitinib continuously depending upon side effects observed. Starting dose is 5mg twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
1835055|NCT00842244|Drug|capecitabine|Given orally twice daily for 14 days followed by 7 days of drug free period. Starting dose is 1000mg/m^2 twice daily. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed.
1835056|NCT00842244|Drug|cisplatin|Given through a vein on Day 1 of every 21 days. Each 21 day cycle is repeated until progression of disease or unacceptable toxicity is observed. The starting dose is 80 mg/m^2 on day 1.
1835057|NCT00842257|Drug|panitumumab|Panitumumab is administered intravenously (IV) by an infusion pump through a peripheral line or indwelling catheter using a 0.2 or 0.22-micron in-line filter infusion set-up over 1 hour 15 minutes. The starting panitumumab dose is 6 mg/kg administered every 14 days for as long as patients are on study without evidence of disease progression or demonstrating intolerance to treatment. The total dose may be rounded up or down by no greater than 10 mg. The panitumumab dose will be calculated based on the subject's actual body weight at each visit. Panitumumab will be diluted in a minimum of 100 mL of pyrogen-free 0.9% sodium chloride solution (normal saline solution, supplied by the site). The maximum concentration of the diluted solution to be infused should not exceed 10 mg/mL.
1835058|NCT00842270|Drug|AB1010|3 mg/kg/day
1835059|NCT00842270|Drug|AB1010|4,5 mg/kg/day
1835060|NCT00842270|Drug|AB1010|6 mg/kg/day
1835061|NCT00842270|Drug|placebo|matching placebo to AB1010 dosages
1835062|NCT00842283|Other|skin tissue sample|skin tissue sample
1835064|NCT00842309|Drug|d-cycloserine|100mg of d-cycloserine in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
1835065|NCT00842309|Drug|Placebo|Placebo in pill form administered 1 hour before behavior therapy sessions once a week for 8 weeks.
1835066|NCT00842322|Behavioral|high fluid intake|fluid intake of 4 litres per day
1835067|NCT00842322|Behavioral|normal fluid intake|Fluid intake of 2 litres per day
1835068|NCT00842335|Drug|JI-101|JI-101, 50 mg capsules, will be administered daily for up to 112 days (four 28-day cycles); treatment may be extended if, in the opinion of the investigator, a patient has tolerated the treatment and appears to be benefitting from receiving study medication
1835069|NCT00842348|Drug|lanreotide (Autogel formulation)|Autogel 120 mg
1835070|NCT00842361|Drug|insulin degludec/insulin aspart|The insulin NN5401 (insulin degludec/insulin aspart) injected subcutaneously immediately before breakfast and dinner.
1835071|NCT00842361|Drug|biphasic insulin aspart 30|The insulin (biphasic insulin aspart 30) injected subcutaneously immediately before breakfast and dinner.
1835072|NCT00842400|Drug|Metformin, VI-0521, Sitagliptan, Probenecid|"This trial is an open-label, non-randomized, one-sequence crossover study.
metformin 500 mg tablet twice daily on Days 1 to 5 and on Days 30 to 34
sitagliptan 100 mg tablet once daily on Days 6 to 10 and on Days 35 to 39
VI-0521 (phentermine/topiramate) capsule once daily each morning at 3.75/23 mg for 2 days (Days 11-12), 7.5/46 mg for 3 days (Days 13-15), 11.25/69 mg for 3 days (Days 16-18) and 15/92 mg for 21 days (Days 19-39)
2 g (four 500 mg) probenecid tablets on Day 29."
1835073|NCT00842426|Behavioral|Self-management program (SM)|"Participants will attend a group orientation where the study nutritionist will provide an overview of the self-management lifestyle intervention program. Participants will receive instructions on how to use HeartHubTM, the American Heart Association's patient portal for information, tools, resources about cardiovascular risk assessment, goal setting, action planning, and self-monitoring.
During the remainder of the 15-month intervention, participants will receive reminders on a regular basis to use the patient portal to assist in their ongoing self-management."
1835117|NCT00842686|Drug|bevacizumab, capecitabine|bevacizumab 5mg/kg days -15,1,15,29 capecitabine 1250 mg/square m/day during radiotherapy radiotherapy 50,4 Gy (1,8 Gy per fraction)
1835118|NCT00842712|Drug|Cilengitide|Cilengitide (Cil) will be administered at a dose of 1000 milligram (mg) as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
1835074|NCT00842426|Behavioral|Care management program (CM)|"In addition to participating in the activities described above, with the exception of the orientation session, participants in the Care Management Program will attend 12 weekly weight management classes during the initial 3 months. Classes will be co-led by a dietician and exercise specialist and will include a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by individual action-planning and goal-setting.
During the remainder of the 15-month intervention, participants will continue to monitor their body weight, caloric intake, physical activity, and other data according to their care plan. In addition, study interventionist will follow up with participants regularly, via secure messaging or by phone, to provide ongoing counseling and support."
1835075|NCT00842439|Behavioral|CBI|Participants will have have one hour sessions, once a week for 12 weeks, where they will meet with an interventionist to go over cognitive-behavioral skills.
1835076|NCT00842439|Dietary Supplement|NUT|Participants will be asked to take omega-3 supplements, calcium tablets, and multivitamins every day for 12 weeks.
1835077|NCT00842452|Drug|topotecan hydrochloride|Patients receive oral topotecan hydrochloride on days 1, 8, and 15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
1835078|NCT00842452|Other|pharmacological study|Patients treated at the maximum tolerated dose undergo blood sample collection periodically on day 1 of course 1 for pharmacokinetic studies.
1835079|NCT00842465|Biological|blood collection for hormonal status analysis|for hormonal status analysis
1835080|NCT00842465|Procedure|breast Biopsy or surgery|breast Biopsy or surgery
1835081|NCT00842465|Genetic|blood collection|blood collection for prlR gene sequencing
1835082|NCT00842465|Other|ultrasonography (pelvis and breast), bone mineral density|ultrasonography (pelvis and breast), bone mineral density
1835083|NCT00842478|Procedure|Toothbrushing|
1835084|NCT00842491|Drug|endostar, cisplatin, capecitabine|"Product 1: endostar
Dosing schedule: 15mg daily dose, d1-14
Mode of administration: intravenously"
1835085|NCT00842491|Drug|capecitabine|"Product 2: capecitabine
Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
Mode of administration: orally"
1835086|NCT00842491|Drug|cisplatin|"Product 3: cisplatin
Dosing schedule: 80mg/m2, day 1 of every 3 weeks
Mode of administration: intravenously"
1835087|NCT00842504|Drug|Micafungin|3 mg/kg IV once over 1 hour
1835088|NCT00842517|Behavioral|Contingency Management|
1835089|NCT00842530|Biological|Chimeric tetravalent dengue (serotype 1, 2, 3, 4)|0.5 mL, Subcutaneous
1835090|NCT00842530|Biological|Inactivated Rabies virus vaccine|0.5 mL, Subcutaneous
1835091|NCT00842543|Dietary Supplement|Fruit and Vegetable Juice Concentrate (FVJC)|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
1835092|NCT00842543|Dietary Supplement|Placebo|Take FVJC or placebo twice a day for 6 months while receiving dietary and physical activity counseling from a Registered Dietician.
1835093|NCT00842556|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
1835094|NCT00842556|Drug|Glimepiride|Tablets, Oral, 4 mg, Single Dose
1835095|NCT00842556|Drug|Sitagliptin|Tablets, Oral, 100 mg, Single Dose
1835096|NCT00842582|Drug|Azacitidine|Azacitidine 20 milligrams per meter squared subcutaneous once daily for 7 days.
1835097|NCT00842582|Drug|Azacitidine|Azacitidine 40 milligrams per meter squared subcutaneous once daily for 7 days.
1835098|NCT00842582|Drug|Azacitidine|Azacitidine 75 milligrams per meter squared subcutaneous once daily for 7 days.
1835099|NCT00842595|Drug|rituximab|6 courses every 28 days
1835100|NCT00842595|Drug|vinorelbine|6 courses every 28 days
1835101|NCT00842595|Drug|ifosfamide|6 courses every 28 days
1835102|NCT00842595|Drug|Mitoxantrone|6 courses every 28 days
1835103|NCT00842595|Drug|Prednisone|6 courses every 28 days
1835104|NCT00842608|Behavioral|Reduced exposure to anticholinergics|"Using the computerized support, physicians will be notified if they attempt to prescribe a patient a medication with anticholinergic properties and will be given a safe alternative to the drug.
Patients who are in the non-haldol arm will have their medical records manually reviewed by the study pharmacist as the computerized support is not set to differentiate between patients who can & cannot receive Haldol"
1835105|NCT00842608|Procedure|Reduced exposure to benzodiazepines|Tapering exposure to benzodiazepines by 50% over the first 48 hours after mechanical ventilation, complete stop by discharge; no benzodiazepine orders for patients not requiring mechanical ventilation
1835106|NCT00842608|Drug|Haloperidol|0.5 to 1 mg haloperidol every 8 hours via oral or parenteral route for a total of seven days or until discharge from the hospital
1835107|NCT00842608|Procedure|Usual care|May include use of typical and atypical neuroleptics, benzodiazepines, and other sedatives to manage the symptoms of delirium
1835108|NCT00842621|Procedure|Clinical Evaluations|All clinical evaluations should be performed greater than 30 days from illness or hospitalization. Participants will have weight, height, body mass index (BMI), heart rate, respiratory rate, blood pressure (systolic and diastolic) and pulse oximetry recorded while at rest on room air by clinical staff. Cardiac examination will be performed by echocardiogram.
1835109|NCT00842621|Other|Laboratory Studies|"Blood for:
Complete Blood Count with Differential, Reticulocyte Count, Micronuclei enumeration, α-globin genotype, G6PD activity, genotype, SNP array,
Serum for:
Soluble VCAM-1, ICAM-1, Soluble CD40L, Arginase, Endothelin-1, Prothrombin Fragment 1+2, IL-6, -8, -10, Soluble E-selectin, NOx, Haptoglobin, Tumor necrosis factor alpha
Plasma for:
Chemistry 18, Cystatin-C, Ferritin, Lactate Dehydrogenase, C-reactive protein, Erythropoietin, NT-proBNP, Haptoglobin, Von Willibrand Factor Antigen, D-dimer, Factor VIII Assay, Quantitative amino acids, Free hemoglobin, Tumor necrosis factor- α, Thrombin-Antithrombin complex, endothelin-1
Urine for:
Urinalysis, Urine spot protein, creatinine, Microalbumin, Urine hemosiderin, Urine hepcidin"
1835110|NCT00842634|Biological|ZFN modified T cells|A single infusion of 5-10 billion ZFN Modified CD4+ T Cells
1835111|NCT00842634|Other|Structured Treatment Interruption|Stop Taking HAART Medication for up to 12 weeks (4 weeks after infusion to 16 weeks after infusion)
1835112|NCT00842660|Drug|Gemzar (gemcitabine)|Gemzar(gemcitabine) Hcl has 2'deoxy-2,2'-difluorouridine monohydrochloride
1835113|NCT00842673|Drug|ST101|30 mg; administered once/day
1835114|NCT00842673|Drug|ST101|90 mg; administered once/day
1835119|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1 and 4.
1835120|NCT00842712|Drug|Cetuximab|Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) as intravenous infusion over 2 hours on Day 1.
1835121|NCT00842712|Drug|Cisplatin|Cisplatin (Cis) will be administered at a dose of 75 mg/m^2 as intravenous infusion on Day 1.
1835122|NCT00842712|Drug|Cisplatin|Cis will be administered at a dose of 80 mg/m^2 as intravenous infusion on Day 1.
1835123|NCT00842712|Drug|Gemcitabine|Gemcitabine (Gem) will be administered at a dose of 1250 mg/m^2 as intravenous infusion on Days 1 and 8.
1835124|NCT00842712|Drug|Vinorelbine|Vinorelbine (Vin) will be administered at a dose of 25 mg/m^2 as intravenous infusion on Days 1 and 8.
1835125|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion once weekly over 1 hour on Days 1, 8 and 15 of each 3-week cycle until progressive disease, death, unacceptable toxicity, or consent withdrawal.
1835126|NCT00842712|Drug|Cilengitide|Cil will be administered at a dose of 2000 mg as intravenous infusion twice weekly over 1 hour on Days 1, 4, 8, 11, 15, and 18 of each 3-week cycle followed by once weekly administration after end of chemotherapy until progressive disease, death, unacceptable toxicity, or consent withdrawal.
1835127|NCT00842712|Drug|Cetuximab|Cetuximab will be administered at a dose of 400 mg/m^2 as intravenous infusion over 2 hours on Day 1 of Cycle 1 followed by 250 mg/m^2 intravenous infusion over 1 hour once weekly on Days 8 and 15 of Cycle 1 and Days 1, 8, and 15 of all subsequent cycles until progressive disease, death, unacceptable toxicity, or consent withdrawal.
1835128|NCT00842712|Drug|Chemotherapy|Cis 80 mg/m^2 intravenous infusion on Day 1 + Vin 25 mg/m^2 or Cis 75 mg/m^2 intravenous infusion on Day 1 + Gem 1250 mg/m^2 intravenous infusion on Days 1 and 8 of each 3-week cycle will be administered along with Cil and cetuximab as per Investigator's discretion up to a maximum of 6 cycles.
1835129|NCT00842738|Behavioral|Mindfulness meditation|Mindfulness meditation
1835130|NCT00842738|Other|No meditation|Health care services as usual
1835131|NCT00842738|Other|Controls|No intervention
1835132|NCT00842751|Drug|First Intervention (7 days)|Acyline 300mcg/kg subcutaneous (days 1, 15 & 29) + testosterone undecanoate 200 mg, twice daily orally + finasteride placebo
1835133|NCT00842751|Other|First Washout (7 days)|Washout of 7 days between each of the 3 treatment arms
1835134|NCT00842751|Drug|Second Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 0.5mg twice daily, orally
1835135|NCT00842751|Drug|Third Intervention (7 days)|Acyline 300mcg/kg subcutaneous + testosterone undecanoate 200 mg, twice daily orally + finasteride 1mg twice daily, orally
1835136|NCT00842751|Other|Second wash-out period|Washout of 7 days between each of the 3 treatment arms
1835137|NCT00842764|Device|eyelid|eyelid
1835138|NCT00842777|Behavioral|Parent manualized group treatment|"Parent manualized group treatment in childhood obesity; 10 manualized group treatment over a 6 months period.
Ten sessions will be conducted with the following content: 1) Expectancies and goal setting,; 2) Taking to the child about overweight; 3) Daily physical activity; 4) Everyday meals and nutrition; 5) Mastery and motivation; 6) Guidance and limit setting; 7) Who should join the team? The role of siblings and the social network; 8) Parents' history of eating and physical activity; 9) Self-concept and body image; and 10) Vacations and parties.
Thereafter booster-meetings every third month over 1,5 years, in all 2 years treatment"
1835139|NCT00842777|Behavioral|Parent self-help groups|Professionals initiate and organize the self-help groups initially and attend the two first meetings. Their role will be to organize group and facilitate group rules governing group behaviors to be formed. The sharing of experiences, feelings, and thoughts concerning being a parent to an overweight child is encouraged, in addition to sharing tips and advices concerning managing their child's behavior. The groups will not receive any teaching or counseling concerning eating and physical activity.
1835140|NCT00842803|Drug|Albumin infusion (25% albumin)|Patients in this arm will receive albumin infusions 3 times a day for the first 7 days post-operative
1835141|NCT00842816|Drug|ST101|10 mg; administered once/day
1835142|NCT00842816|Drug|ST101|60 mg; administered once/day
1835143|NCT00842816|Drug|ST101|120 mg; administered once/day
1835144|NCT00842816|Drug|Placebo|placebo tablets to match ST101 tablets
1835145|NCT00842829|Drug|Fentanyl Buccal Tablet (FBT)|FBTs were self-administered by participants via the oral mucosa. During the open-label dose titration period, participants used 1 to 4 tablets of the 100 mcg or 200 mcg strength to individually titrate upwards to an effective dose through the range of available strengths (i.e. 100, 200, 400, 600, or 800 mcg). For the open-label treatment and continuation periods, single dose tablets at the effective dose identified during the titration period were used. The maximum dose allowed per breakthrough pain (BTP) episode was 800 mcg. On any single day, participants were not to use FBT for more than 4 BTP episodes.
1835146|NCT00842842|Procedure|tack fixation of mesh|tack fixation of mesh
1835147|NCT00842842|Procedure|glue fixation of mesh|glue fixation of mesh
1835148|NCT00842881|Device|Healingstone navel belt|6~8hours/day for 3months
1835149|NCT00842894|Drug|insulin detemir|Safety and effectiveness data collection in connection with the use of the drug.
1835150|NCT00842894|Drug|biphasic insulin aspart 30|Safety and effectiveness data collection in connection with the use of the drug in daily clinical practice.
1835153|NCT00842920|Drug|Simvastatin|60 mg once daily
1835154|NCT00842920|Drug|Placebo|one tablet once daily
1835155|NCT00842933|Drug|Corticosteroid|Cessation of corticosteroids 24 hours after cessation of vasopressors
1835156|NCT00842933|Drug|Corticosteroid|Administer daily for 7 days after diagnosis of acute adrenal insufficiency during septic shock
1835200|NCT00843362|Drug|Dinoprostone vaginal pessary|10 mg controlled-release dinoprostone pessary applied for 24 hours
1835201|NCT00843362|Drug|Dinoprostone vaginal gel|2 mg vaginal dinoprostone gel, two daily doses with a 6 hours interval
1835157|NCT00842946|Behavioral|Exposure w/ Acceptance-Based Rationale|"Treatment focuses on the ineffectiveness of participants' past attempts to control or reduce their anxiety in public speaking situations. Acceptance of one's private experiences (thoughts, feelings, sensations) will be introduced. Willingness to experience unwanted thoughts and feelings while simultaneously engaging in valued activities, especially those related to public speaking, is stressed. Techniques designed to foster psychological acceptance are practiced prior to and during exposure exercises, as well as assigned for homework between sessions."
1835158|NCT00842946|Behavioral|Exposure w/ Habituation-Based Rationale|Exposure to feared public speaking situations are accompanied by explanations of behavioral principles, including classical/operant conditioning and habituation. The process of associating public speaking situations with unwanted feelings of anxiety will be discussed, as well as negative reinforcement of escape and avoidance behaviors. The underlying principle of habituation is reviewed. When engaging in exposure exercises (both in session and assigned homework exercises), participants will be encouraged to remain in the feared speaking situation until their subjective ratings of anxiety decrease.
1959019|NCT00926848|Behavioral|Partners Together in Health (PaTH) Intervention|Both partners actively participate in comprehensive CR and the usual care group where only the patient participates in CR and the partner is invited to attend the educational sessions with the patient. The CR activities that patients in both groups and partners in the intervention group will be provided with will be the same and are based on the clinical practice guidelines of the core components of CR. These components are: prescribed exercise, education about cardiac risk factor modification, and counseling about self-efficacy strategies that may be effective in assisting with initial lifestyle changes and in preventing and managing relapse. All patients and partners in CR will be provided with a comprehensive, individualized, multidisciplinary risk factor modification program focused on all of the person's risk factors for coronary heart disease.
1835161|NCT00842985|Drug|drug condition|Dronabinol (15mg) or Modafinil (400mg) or Dronabinol + Modafanil or placebo
1835162|NCT00842998|Drug|Trastuzumab or Lapatinib|Trastuzumab: loading dose 8 mg/kg iv in 90 min.followed by weekly doses of 2 mg/kg Lapatinib: 1500 mg/die orally
1835163|NCT00843011|Drug|Orvepitant|Orvepitant 60 mg, single dose. 2 different formulation. Formulation 2 is administered with and without food.
1835164|NCT00843024|Drug|Sumatriptan and Naproxen Sodium|Sumatriptan succinate and naproxen sodium
1835165|NCT00843024|Drug|Placebo|Placebo to match
1835166|NCT00843037|Drug|Sunitinib|50 mg oral dose daily for 4 weeks, 2 week rest period (repeating 6 week cycles)
1835167|NCT00843050|Drug|P276-00|P276-00: All patients will receive P276-00 185 mg/m2/day as intravenous infusion over 30 minutes in 200 ml of 5% dextrose from day 1 to day 5 in each 21 days cycle for minimum 6 and maximum 12 cycles or until there is progression of disease or unacceptable toxicity
1835168|NCT00843063|Drug|pantoprazole vs famotidine|pantoprazole 20 mg om and matching placebo nocte vs. famotidine 40 mg om and nocte
1835169|NCT00843089|Other|Education|Educational session with pharmacist, nutritionist, and cardiac rehabilitation nurse
1835170|NCT00843115|Other|donepezil|Routine clinical practice of prescribing donepezil as per the Canadian label. No drug was supplied as part of this study
1835171|NCT00843128|Device|robot-assisted gait training (RAGT)|20 patients will be treated with RAGT, 12 sessions over three weeks.
1835172|NCT00843128|Device|conventional walking training (CWT)|The control group will be treated by CWT, 12 sessions in three weeks.
1835173|NCT00843141|Behavioral|cognitive computerized training|cognitive computerized training utilizing executive attention tasks
1835174|NCT00843141|Behavioral|simple cognitive computerized training|simple computerized cognitive program utilising simple reaction time tasks that do not challenge executive attention
1835175|NCT00843154|Drug|Candesartan and standard chronic heart disease therapy|Candesartan 4mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for two weeks; then Candesartan increased up to 32mg, tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
1835176|NCT00843154|Drug|Standard chronic heart disease therapy|Candesartan placebo-matching tablets, orally, once daily and stable dose therapy for chronic heart disease for up to 48 weeks.
1835177|NCT00843167|Dietary Supplement|broccoli sprout extract|Given orally
1835178|NCT00843167|Other|placebo|Given orally
1835179|NCT00843180|Other|massage|one to three massages per week by massage practitioner additional massages by resident parent who is being taught to massage her/his child
1835183|NCT00843219|Procedure|PET/CT Scan|PET/CT scan performed with elastic belt around lower chest/upper abdomen to track breathing motion.
1835184|NCT00843245|Other|No intervention|No intervention
1835185|NCT00843258|Device|Abduction treatment|Abduction treatment with a Frejka's pillow for 6 weeks
1835186|NCT00843284|Drug|Pregabalin|Capsules, 150 - 600 mg/day, 2-3 times/day, 8 weeks
1835187|NCT00843297|Device|Coolgard|invasive Cooling via femoral ICY-catheter
1835188|NCT00843297|Device|ArcticSun|Noninvasive surface-cooling by saline-cooled thermo-vest
1835189|NCT00843297|Other|Conventional treatment|Intensive care-treatment without cooling
1835190|NCT00843310|Drug|Lenalidomide (Revlimid)|
1835191|NCT00843310|Drug|Melphalan|
1835192|NCT00843310|Drug|Dexamethasone|
1835193|NCT00843323|Other|Methylaminolevulinate - photodynamic therapy|Methylaminolevulinate cream 16% applied for 3 hours under occlusion on the face and then illuminated with red LED device
1835194|NCT00843336|Behavioral|Electronic hormonal fertility monitoring|Use of an electronic hormonal fertility monitor that provides three levels of fertility; low, high, and peak. Monitor is based upon urinary levels of E3G (estrogen) and LH. Monitor readings are placed in an electronic charting system on the Internet.
1835195|NCT00843336|Behavioral|Self-monitoring|Self-monitoring of externally observed cervical mucus to determine level of fertility.
1835196|NCT00843349|Drug|Lanthanum Carbonate|Phosphorus binder
1835197|NCT00843349|Other|900 mg Phosphate Diet|Amount of phosphorus consumption in a day kept below 900 mg.
1835198|NCT00843349|Drug|LC Placebo|Placebo for Lanthanum Carbonate
1835199|NCT00843349|Other|Ad Libitum Diet|Patients continued to eat their usual diet.
1836582|NCT00854685|Drug|Placebo|Placebo s.c. - fortnightly
1835204|NCT00843427|Behavioral|CIAT|Patients are to receive constraint-induced aphasia therapy for 2 weeks at 4 hours per day. Detailed description of this intervention is in Szaflarski et al., 2015 Medical Science Monitor.
1835205|NCT00843440|Drug|Bevacizumab|5 mg / kg every 14 days with a total of 6 injections.A two-phase Gehan method will be used with a first phase designed to eliminate a non effective treatment quickly and a second phase allowing assessment of efficacy.
1835206|NCT00843453|Other|blood collection|blood collection
1835207|NCT00843453|Drug|treatment (cyanocobalamin nasal spray)|cyanocobalamin nasal spray -- 500 mcg q week for eight weeks
1835208|NCT00843466|Other|Mild, moisturizing hand cleanser|"Hand cleanser ingredient list:
Ammonium Lauryl Sulfate, Ammonium Laureth Sulfate, Cocamide MEA, PEG-5 Cocamide Cocamidopropyl Betaine Sodium Lauroyl Sarcosinate Glycerin Petrolatum Soybean Oil Sodium Hydroxypropyl Starch Phosphate Lauric Acid Lauryl Alcohol PEG-14M Guar hydroxypropyl trimonium chloride DMDM Hydantoin; Iodopropynyl Butylcarbamate Etidronic Acid Tetrasodium EDTA Titanium Dioxide Fragrance Sodium Hydroxide Water"
1835209|NCT00843492|Drug|Fondaparinux sodium|After randomization (Day 1), subjects will receive subcutaneously once daily fondaparinux 2.5 mg [0.5mL] (1.5 mg [0.3mL] in patients with creatinine clearance between 30 and 50 mL/min) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
1835210|NCT00843492|Drug|Nadroparin|After randomization (Day 1), subjects will receive subcutaneously once daily nadroparin 2850 anti-Xa IU (0.3 mL) for at least 21 Days, up to complete mobilization, corresponding to cast or brace removal. The maximal duration of treatment is 45 days.
1835211|NCT00843505|Behavioral|Telemedicine Smoking Cessation Program|Participants will receive four sessions of telemedicine smoking cessation counseling over an 8-week period. The telemedicine sessions will be delivered by two-way Webcams mounted on desktop computers in the doctors' offices.
1835212|NCT00843505|Behavioral|Telephone Quitline Smoking Cessation Program|Participants will receive four sessions of smoking cessation counseling delivered by telephone in their homes over an 8-week period.
1996369|NCT02493764|Drug|Piperacillin|Piperacillin 4000 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
1835215|NCT00843531|Drug|RAD001|5 mg/day PO (oral)
1835216|NCT00843531|Drug|erlotinib|100 mg/day (oral)
1835217|NCT00843544|Behavioral|Integrative Medicine|"Participants assigned to the treatment group will begin in groups of ten. The treatment protocol will consist of six 1-2 hour sessions over a six-week period as follows:
Subjects will attend a two-session class on healthy eating focused on reducing inflammation-promoting foods in the diet. All subjects will also be started on fish oil and vitamin C supplements, as well as on a supplement called Kaprex, which is an extract from hops and rosemary with anti-inflammatory action. Supplements willl be provided free of charge. Subjects will be provided with a take home supply to begin using.
Subjects will attend two classes at CCHH in yoga breathing techniques and will then be provided with a CD for home study and practice
Subjects will attend two guided journaling sessions at CCHH in which subjects will be asked to write for a 30-minute period about the most traumatic or stressful life experience to date."
1835218|NCT00843570|Drug|Nafarelin acetate, Oestradiol Valerate, Progesterone|Nafarelin acetate, Nasal spray, 400 mcg b.d., 4 weeks Oestradiol Valerate, tablet, 2mg o.d day 1-5, 2mg b.d. day 6-9, 2mg t.d.s day 10-13 (step-up protocol), 2mg q.d.s (if pregnancy confirmed, 4-10 weeks Progesterone, pessary, 200mg b.d. and t.d.s. (if pregnancy confirmed), 2-10 weeks
1835219|NCT00843596|Procedure|cardiac surgery requiring ECC|the vacuum device is left on the 2 wounds (caused by the ECC cannulas) for 15 min (possible a second time of 15 min : 30 min max.)
1835220|NCT00843609|Device|Navigator continuous glucose monitor (Freestyle Navigator®)|Continuous use of the Free Style Navigator for monitoring of glycemia in patients with type 1 diabetes with HbA1c below 7.5 %
1835221|NCT00843622|Drug|Low-nitrosamine smokefree tobacco product for oral use|Smokeless tobacco in paper sachets containing 1.0 or 0.5 g of the product. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
1835222|NCT00843622|Other|Non-tobacco, non-nicotine placebo product|Placebo product in paper sachets containing 1.0 or 0.5 g. Product made of cocoa bean fibers and oat fibers. Usage ad libitum. Recommended dosages: 10-24 sachets per day (1.0 g sachets). Among participants who typically smoke >15-20 cigarettes per day and/or has a Fagerström score of 7 or higher, the recommended maximum number of sachets per day is 30. For participants who use small sachets (0.5 g) the recommended daily use is double compared that of 1.0 g sachets.
1835223|NCT00843635|Drug|Tadalafil|Given orally
1835224|NCT00843635|Other|Placebo|Given orally
1835225|NCT00843661|Drug|ezetimibe|10 mg ezetimibe/day
1835226|NCT00843661|Drug|fenofibrate|200 mg fenofibrate/day
1835227|NCT00843661|Drug|pravastatin|40 mg pravastatin/day
1835228|NCT00843687|Drug|Risperidone long-acting injectable|
1835229|NCT00843700|Behavioral|Interpersonal Psychotherapy-Trauma in Community Settings|Interpersonal Psychotherapy-Trauma in Community Settings (IPT-TCS) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of depressed patients with trauma histories seen in community settings.
1835230|NCT00843700|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a community mental health center.
1835231|NCT00843713|Drug|raltegravir|For patients assigned to the raltegravir group, subjects will receive raltegravir 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
1835232|NCT00843713|Drug|Placebo|For the patient assigned to the placebo group, subjects will take a matching placebo pill 400mg to be taken by mouth twice daily for 24 weeks in addition to taking their current HIV medication
1835233|NCT00843726|Radiation|stereotactic body radiation therapy|Patients undergo 1 or 3 high-dose fractions
1835234|NCT00843739|Device|EMST - Active Treatment|Hand held device used for strengthening expiratory muscles
1835235|NCT00843739|Device|sham EMST|Four week sham device training program
1835273|NCT00831025|Biological|Placebo|Placebo for subcutaneous monthly administration
1835274|NCT00831038|Procedure|Infant Pulmonary Function Tests|Tests will be performed on study patients within 1 week of study enrollment and again 6 months later.
1835236|NCT00843765|Other|acupuncture, massage and basic TCM treatment|"During hospitalization:Patients accept TCM rehabilitation and basic treatment including WM basic treatment and Chinese medicine injection,decoction,herb soak treatment and health education.
After discharge from hospital: In the TCM group,add prescriptions according to two conditions:a. patients using A injection (one Chinese herb injection admitted by SFDA) will take A' capsule (one Chinese herb capsule admitted by SFDA) for 6 months;b.patients using B injection (ditto) will take B' capsule (ditto) for 6 months.Both of them will accept TCM health education.In the WM group, patients are suggested with targeted rehabilitation programs according to different causes."
1835237|NCT00843765|Other|rehabilitation and WM basic treatment|"there two steps:
during hospitalization: patients accept modern rehabilitation and basic treatment of life supporting and medicine using and health education
After discharge: make rehabilitation plans for patients including management of anticoagulant drugs, blood pressure, blood lipid and blood glucose, health education, and some suggestions for resisting alcohol ,smoking and reasonable diet"
1835238|NCT00843778|Biological|Certolizumab Pegol|"200 mg every two weeks
Certolizuimab Pegol 200 mg every two weeks Subjects who flared at Week 48 or Week 52 of feeder study C87076 [NCT00674362], will receive respectively once 400 mg Certolizumab Pegol or three times 400 mg Certolizumab Pegol at two weeks interval as part of an induction phase in the C87080 study. Thereafter the subject enters the C87080 study and will be further treated with 200 mg Certolizumab Pegol every two weeks."
1835239|NCT00830791|Drug|MK-0941 20 mg|Two 10-mg tablets of MK-0941 administered as a single oral dose.
1835240|NCT00830791|Drug|MK-0941 5 mg|MK-0941 administered as one single 5-mg tablet.
1835241|NCT00830804|Drug|Raltegravir|400 mg tablet taken orally twice daily
1835242|NCT00830804|Drug|Darunavir/Ritonavir|800 mg Darunavir/100 mg Ritonavir tablet taken orally once daily
1835243|NCT00830830|Drug|Hyalgan (sodium hyaluronate)|
1835244|NCT00830843|Drug|Propofol|Propofol(3-4 mg/kg/ora)administrated for 2 hours.
1835245|NCT00830843|Drug|Isoflurane|Isoflurane inhalatorial administration for 2 hours at 0.8-1.0% Minimum Alveolar Concentration
1835246|NCT00830856|Drug|Fluconazole|Fluconazole 800mg po qday
1835247|NCT00830856|Drug|Fixed dose - Stavudine, lamivudine and Nevirapine|Initiation within 72 hours of diagnosis of Cryptococcal meningitis.
1835248|NCT00830856|Drug|Fixed dose - Stavudine, Lamivudine, Nevirapine|Delayed initiation of ART defined as 10 weeks after initiation of high dose fluconazole therapy.
1835249|NCT00830869|Drug|IXAZOMIB|"All patients will receive IXAZOMIB IV injection on Days 1, 4, 8, and 11 of each treatment cycle followed by a rest period of 10 days.
The first stage of the study will be initiated at a starting dose of 0.125 mg/m2
Subsequent doses will increase until a maximum tolerated dose (MTD) is established."
1835250|NCT00830882|Drug|levosalbutamol|2 puffs four times a day for 2 weeks
1835251|NCT00830882|Drug|racemic salbutamol|2 puffs four times a day for 2 weeks
1835252|NCT00830882|Drug|placebo|2 puffs four times a day for 2 weeks
1835253|NCT00830895|Drug|RAD001|RAD001 10mg/day
1835254|NCT00830908|Device|HairMax LaserComb|LaserComb to be used 3 times weekly on non-consecutive days, according to User Manual instructions. Use is preferably following a shower, prior to using any styling products on the hair or scalp. Hair may be wet or dry during treatment.
1835255|NCT00830921|Device|Transcranial Magnetic Stimulation|Transcranial magnetic stimulation (TMS) is a non-invasive method for altering brain activity in vivo.
1835256|NCT00830934|Procedure|Individual care|The first treatment group (individual care group) will involve 3 sessions held weekly. Each session will last approximately 45 minutes.
1835257|NCT00830934|Procedure|group care|The second treatment group (group care group) will be assigned to weekly group exercise classes, focusing on core stability and strengthening exercises. Classes will last one hour and will be conducted for 4 weeks. In both treatment groups pain scores will be followed up for 1 week post last treatment.
1835258|NCT00830947|Device|OrthoAccel Device|The OA device provides a light vibration at 0.25 Newtons and 30 Hz frequency for 20 minutes daily.
1835259|NCT00830947|Device|Sham Device|Inactive sham device that is held in the mouth for 20 minutes.
1835260|NCT00830960|Drug|Prasugrel|Oral, daily, 90 days
1835261|NCT00830960|Drug|Clopidogrel|Oral, daily, 90 days
1835262|NCT00830973|Other|Poor Metabolism Status Follow Up Therapy Considerations|If the patient's CYP2D6 metabolism status is 'poor' then specialist pharmacist will discuss drug therapy alternatives to tamoxifen.
1835263|NCT00830973|Other|CYP2D6 Inhibiting Drugs|If the patient after having a CYP2D6 test has any drugs that inhibit tamoxifen metabolism then specialist pharmacist will contact the physician for alternative drug therapies.
1835264|NCT00830986|Device|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using Conventional Intramedullary Instrumentation
1835265|NCT00830986|Device|Total Knee Arthroplasty Implant (Scorpio®)|Implantation of a Total Knee Arthroplasty using a Computer Assisted Software, without Intramedullary Instrumentation
1835266|NCT00830999|Behavioral|Positive energy balance|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands.
1835267|NCT00830999|Behavioral|Energy balance with exercise|Subjects will consume over a 24 hour period 33% more calories than they require to meet their energy demands but will perform 2 hours of exercise that will be sufficient to burn off the excess calories consumed resulting in subjects being in net energy balance.
1835268|NCT00830999|Behavioral|Negative energy balance|Subjects will consume over a 24 h period only 66% of the calories required to meet their energy demands such that they will be in a net negative calorie balance in this trial.
1835269|NCT00830999|Behavioral|Negative energy balance with exercise|Subjects will consume over a 24 hour period the same amount of calories as ingested in the isocaloric trial but will also perform 2 hours of exercise that will be sufficient to burn off a third of the calories they consumed during this day resulting in subjects being in net negative energy balance in this trial
1835270|NCT00830999|Behavioral|Energy balance|Subjects will consume over a 24 hour period a sufficient amount of calories to meet their energy needs.
1835271|NCT00831012|Biological|rDEN3delta30/31‐7164|A live attenuated, recombinant DEN3 candidate vaccine virus
1835272|NCT00831025|Biological|Immunotherapy with modified extract of Olea europaea pollen|Subcutaneous immunotherapy with modified extract of Olea europaea. A subcutaneous monthly treatment.
1835275|NCT00831051|Drug|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 12mg/8mg IR Capsule q6h
1835276|NCT00831051|Drug|Morphine sulfate|One morphine sulfate 12mg IR capsule q6h
1835277|NCT00831051|Drug|Oxycodone HCl|One oxycodone HCl 8mg IR Capsule q6h
1835278|NCT00831051|Drug|Q8003|One Q8003 (morphine sulfate and oxycodone HCl) 6mg/4mg IR Capsule q6h
1835279|NCT00831051|Drug|Morphine sulfate|Two morphine sulfate 3mg IR capsules q6h
1835280|NCT00831051|Drug|Oxycodone HCl 4mg|Two oxycodone HCl 2mg IR Capsules q6h
1835281|NCT00831064|Procedure|colonoscopy bowel prep|PEG, bisacodyl, NaP, PSMC and Mg-citrate
1835282|NCT00831077|Drug|ORM-14540|i.v.
1835283|NCT00831077|Drug|ORM-12741|i.v.
1835284|NCT00831103|Drug|EPB-348|Treated over seven days
1835285|NCT00831103|Drug|Valacyclovir|Treated over seven days
1835286|NCT00831116|Device|Intravascular Near Infrared Spectroscopy|Intravascular imaging with a catheter based spectroscopy system.
1835287|NCT00831129|Drug|Rosiglitazone|4 mg daily
1835288|NCT00831129|Drug|Placebo Rosiglitazone|1 tab daily
1835289|NCT00831129|Drug|Simvastatin|40 mg daily
1835290|NCT00831155|Drug|Nicotine Patches, Denicotinized Cigarettes|Both groups will receive standard Nicotine Replacement Therapy after the quit date. The Extinction Based group will receive Nicotine patches and denicotinized cigarettes before their quit date
1835291|NCT00831168|Behavioral|Effects of Active Dissemination|No medical intervention involved. It is purely information based.
1835300|NCT00836576|Drug|Benazepril HCl 40 mg Tablets|1 x 40 mg, single-dose fasting
1835301|NCT00836576|Drug|Lotensin® 40 mg Tablets|1 x 40 mg, single-dose fasting
1835302|NCT00836589|Device|ICD Therapy - ICD Lead Registry|Collecting long-term safety and efficacy data on a family of market-released ICD leads.
1835303|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 1 mg, Once daily, 7 days
1835304|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, 2 mg, Once daily, 7 days
1835305|NCT00836602|Drug|BMS-779788|Oral Solution, Oral, <= 4 mg, Once daily, 7 days
1835306|NCT00836602|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 7 days
1835307|NCT00836628|Drug|Busulfan|
1835308|NCT00843791|Drug|placebo|treatment with placebo for 3 months
1835309|NCT00843791|Drug|pioglitazone|treatment with 30mg daily for two weeks then 45mg every day with pioglitazone for three months
1835310|NCT00843817|Drug|Pulmozyme|Pulmozyme® 2.5mg by inhalation
1835311|NCT00843830|Radiation|tumoral irradiation|On day 1 of the study treatment, patients will begin tumoral irradiation, which will be given daily for 4 days in 6Gy fractions (days 1 through 4)
1835312|NCT00843830|Biological|Dendritic cell vaccination|Three intra-tumoral injections of 1 ml cell suspensions of KLH (keyhole limpet hemocyanin)- pulsed DC (dendritic cells) will be delivered percutaneously under ultrasound into a selected hepatic metastasis in the outpatient setting.
1835313|NCT00843843|Device|Bright light box|Bright light of about 5000 lux, administered while sitting at a desk.
1835314|NCT00843856|Drug|tacrolimus|tacrolimus 2mgs bd adjusted to obtain levels of 5-12ng/ml
1835315|NCT00843856|Drug|tacrolimus and mycophenolate mofetil|tacrolimus 2mg bd adjusted to achieve levels of 5-12ng/L mycophenolate mofetil 500mgs bd adjusted to achieve levels of 1.5-3mg/L
1835319|NCT00843895|Biological|pneumococcal conjugate vaccine(prevenar)|to see the vaccine impact on pneumococcal diseases
1835320|NCT00843908|Device|Tension Free Vaginal Tape|Tension Free Vaginal Tape inserted in the conventional manner in a theatre environment
1835321|NCT00843908|Device|Miniarc|The Miniarc suburethral sling will be inserted in the conventional manner in a theatre environment under general anaesthesia
1835322|NCT00843921|Drug|N-carbamylglutamate|100 mg/kg/day or 2.2 g/M2/day in 3-4 divided doses for 3 days
1835323|NCT00843934|Drug|epirubicin|Arm E: Suspension is prepared before arterial infusion as follows: Epirubicin is dissolved with water-soluble, non-ionized contrast medium then mixed with Lipiodol by pumping. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of EPI and Lipiodol are 60mg/m2 and 0.3mL/Kg, respectively.
1835324|NCT00843934|Drug|Cisplatin|Arm C: Suspension is prepared before arterial infusion as follows: Cisplatin (Water soluble CDDP: IA CALL) is mixed with Lipiodol. Then this suspension is administered by catheter as quick as possible, and gelatin is infused for arterial embolization. Maximum dose of Cisplatin and Lipiodol are 65mg/m2 and 0.3mL/Kg, respectively.
1835325|NCT00843947|Procedure|Reduced Intensity Stem Cell Transplantation|Reduced Intensity Stem Cell Transplantation
1835326|NCT00843960|Behavioral|behavioral adaptation and symptom management|behavioral adaptation and symptom management
1835327|NCT00843973|Procedure|iliac crest bone graft|iliac crest bone graft procedure
1835328|NCT00843973|Procedure|Reamer Irrigator Aspirator|Reamer Irrigator Aspirator (RIA) Procedure
1835329|NCT00843986|Drug|conivaptan|Premix bag
1835330|NCT00843986|Drug|placebo|Premix bag
1835331|NCT00844012|Drug|Continuous OC (clormadinone acetate plus ethinil-estradiol - Belara®, Grunenthal, Milan, Italy)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a continuous regimen.
1835332|NCT00844012|Drug|Cyclic OC (clormadinone acetate plus ethinil-estradiol)|Low-dose monophasic OC containing 2.0 mg clormadinone acetate plus 0.03 mg ethinil-estradiol (Belara®, Grunenthal, Milan, Italy) will be administered with a cyclic regimen.
1835333|NCT00844025|Behavioral|Pharmacist intervention|Medication review, medication reconciliation, and pharmacotherapy recommendation.
1837621|NCT00859989|Other|educational intervention|
1835334|NCT00844051|Biological|School-based influenza vaccination program|School-based influenza vaccination program
1835335|NCT00844064|Drug|AP 12009|"Initial scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.
Modified scheme: AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (4 days), every other week, up to 10 cycles"
1835336|NCT00844090|Drug|methylphenidate or placebo|treat apathy to improve diabetes self care behaviors thereby improving glycemic control
1835337|NCT00844103|Drug|AZD8566|10ml oral solution administered once a day over 10 days. Specific dose will be selected by the safety review committee
1835338|NCT00844103|Drug|Placebo|10ml oral solution administered once a day over 10 days.
1835339|NCT00844116|Device|spirometry|Conventional and telematic spirometry
1835340|NCT00845897|Drug|Botulinum Toxin|200 units of botulinum toxin, and 300 units of botulinum toxin. Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
1835341|NCT00845897|Drug|Saline|Placebo (saline) (3cc). Injection are given at one session. 2 injections into the medial gastrocnemius, 2 injections into the lateral gastrocnemius, and 2 injections into the soleus
1835342|NCT00845910|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of every 3 week cycle
1835343|NCT00845910|Drug|capecitabine [Xeloda]|900mg/m2 po on days 1-14 of every 3 week cycle
1835344|NCT00845910|Drug|docetaxel|60mg/m2 iv on day 1 of every 3 week cycle
1835345|NCT00845923|Drug|Civamide Patch|Patch containing Civamide (zucapsaicin) 0.015%, containing 0.210 mg Civamide per patch, applied once a day for four weeks.
1835346|NCT00845936|Drug|Metformin|Metformin 850 mg bid
1835347|NCT00845962|Drug|chloroprocaine|spinal administration of chloroprocaine 2%, 40 mg (2 mL)
1835348|NCT00845962|Drug|bupivacaine|spinal administration of bupivacaine 0,75% 7,5 mg (1 mL)
1835349|NCT00845975|Device|Erchonia Hearing Lasers #1 & #2|"Two treatments with Erchonia Hearing Laser #1 administered by the investigator at the test site, each treatment seven days apart.
Seven treatments with the Erchonia Hearing Laser #2 administered by the subject at home, one time each day for seven consecutive days, the first administration on the same day as the first administration with the Erchonia Hearing Laser #1 at the test site."
1835350|NCT00845975|Device|Placebo Lasers|The same test site and at-home treatment administration protocols are followed, but the laser devices do not emit any therapeutic light.
1835351|NCT00845988|Drug|aripiprazole|dosage form : po recommended dosage : more than 10mg/day duration : 28 weeks
1835352|NCT00846001|Procedure|Coronary artery bypass grafting|Standard coronary surgry according guidelines
1835353|NCT00846001|Device|Epicardial implantation of cardiac resynchronization therapy device|During the cardiac surgery, the CABG+CRT arm patients will be implanted with epicardial leads to the right atrium, right and left ventricles. Left ventricle leads will be fixed to the posterolateral wall provided that there is no scar or fat tissue (behind and 2-3 cm apical than obtuse marginal artery). Right atrial and right ventricular leads will be fixed in a traditional way. Then the leads will be guided into a preformed pocket (left subclavian region) and connected with the CRT device.
1835354|NCT00846014|Drug|Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the drug aformoterol will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
1835355|NCT00846027|Drug|Bevacizumab|Bevacizumab was supplied as a sterile liquid in glass vials.
1835356|NCT00846027|Drug|Paclitaxel|Paclitaxel was supplied as a sterile liquid in glass vials.
1835357|NCT00846027|Drug|Gemcitabine|Gemcitabine was supplied as a sterile liquid in glass vials.
1835359|NCT00846066|Other|Hands on training|Hands on training by a pediatric dentist on preventive oral health
1835360|NCT00846066|Other|Web based training|Web based training alone
1835361|NCT00846079|Device|Regadenoson (Lexiscan) [muti-detector computed tomography]|Regadenason, typical dosing
1835362|NCT00846092|Device|Warp 10 LED Device|Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months
1835363|NCT00846092|Device|Near-infrared light (NIR)|"Subjects will be exposed to light emitted from LED's at wavelengths of 670 nm (+/-15nm) with a minimum exposure of 4 J/cm2 (4.0 - 7.68J/cm2). This is accomplished by applying the 50 mW/cm2 (50 - 80 mw/cm2) LED-generated light to the study eye.
Treatments involve application of the LED-generated light for 80 seconds, twice daily."
1835364|NCT00846105|Other|Rapid MRSA PCR test for screening carriers|In the rapid test intervention arm, all patients admitted to study wards will be sampled within 24 h after admission. To ensure comparison of like with like, sample taking will include: (1) a swab from the anterior nares for PCR testing according to the test manufacturer's instructions; (2) the swab of anterior nares, and swabs from throat, perineum and of any wounds, bladder catheter or intravenous catheter exit site will be processed by conventional testing.
1835365|NCT00846118|Drug|Pitavastatin|1-4mg/day
1835366|NCT00846131|Drug|Sorafenib|Randomized to Y-90 ± Sorafenib
1835367|NCT00846131|Drug|Yttrium-90 (Y-90)|Patients undergo radioembolization with Yttrium 90 microspheres by hepatic artery infusion
1835368|NCT00846144|Dietary Supplement|copper sulfate|copper sulfate 3mg/d for a period of 6 months
1835369|NCT00846157|Biological|NKM injection|NKCell about 100mg IV for 6times in each chemotherapy period.
1835370|NCT00846170|Drug|co-biotic|give probiotic 2 t/day
1835371|NCT00846170|Drug|placebo 2T/day|cross over of patients from study arm to placebo arm
1835372|NCT00846183|Procedure|local injury|In one group, on the day of oocyte retrieval, local injury to endometrium with a Novak curet to anterior and posterior wall of endometrium are performed
1835373|NCT00846196|Drug|risedronate DR (Phase III clinical supply)|Reference - (Phase III clinical supply) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
1835374|NCT00846196|Drug|risedronate 35 mg DR (Commercial Tablet)|Test - (Commercial tablets) one 35 mg DR tablet administered as a single oral dose after an overnight (10-hour) fast, followed by a 4-hour fast
1835375|NCT00846209|Other|Enhanced drug labeling|use of clear concise text and icons on drug warning labels
1835376|NCT00846222|Procedure|Hypothermia|Mild therapeutic hypothermia, 33-34 celsius, for 12 hours
1835377|NCT00846235|Other|Aqualan L, Aqualan Plus, Aqualan L + glycerol ad 20%|moisturising cream twice daily three weeks
1835378|NCT00846248|Dietary Supplement|Chromium|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
1835379|NCT00846248|Dietary Supplement|placebo|We will enroll non-obese, non-diabetic subjects with insulin resistance in a 16 week treatment program with 500 μg of chromium picolinate twice daily. Insulin action will be determined by insulin clamp and OGTT using deuterated glucose both before and after treatment. Subjects will be compared to a placebo-treated group.
1835380|NCT00846261|Device|Use it to treatment bone nonunion (Ilzarov)|Detect the variation of limb lengthening
1835381|NCT00846274|Biological|SK Antithrombin III|
1835382|NCT00846287|Drug|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. The first three bags will be administered with a break between each of five to ten minutes. Then the intervention (drug or placebo) will be administered and an hour will pass. Then three additional bags will be administered, again with five to ten minutes between each bag.
1835383|NCT00846287|Drug|Placebo|Subject will inhale a placebo (nebulized saline) with no drug.
1835384|NCT00846287|Drug|Aformoterol|Subjects will receive the drug arformoterol prior to scanning
1835385|NCT00846300|Behavioral|Physician counseling for health behavior change|Physician counseling for health behavior change, compared to a no-counseling comparison group
1835386|NCT00846313|Other|Individual dietary counseling.|Dietary advice based on individual requirement and symptom burden. Dietary intervention may be dietary advice, energy rich foods and drinks, oral nutritional supplements, appetite stimulation with Megestrol Acetate, enteral or parenteral nutrition.
1835387|NCT00846326|Drug|oxymetazoline-fluticasone propionate|Oxymetazoline 0.05% w/v Fluticasone propionate 0.05% w/w 2 squirts in each nostril twice daily
1835388|NCT00846326|Drug|Oxymetazoline|oxymetazoline 0.05% w/v and placebo nasal spray 2 squirts in each nostril twice daily
1835389|NCT00846339|Drug|Bupropion|bupropion
1835390|NCT00846352|Procedure|Variation in the time for performing bronchoscopy|The study will compare outcomes amongst patients assigned to receive early bronchoscopy (within 36 hours of enrollment)versus those in whom bronchoscopy is delayed (5 days after enrollment).
1835391|NCT00846365|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
1835392|NCT00846365|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks."
1835393|NCT00846365|Drug|Olmesartan medoxomil-hydrochlorothiazide|"Olmesartan medoxomil 20 mg/hydrochlorothiazide 12.5 mg, tablets, orally, and Azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for 8 weeks.
If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to olmesartan medoxomil 40 mg/hydrochlorothiazide 25 mg, tablets, orally, once daily for the remaining 4 weeks."
1835394|NCT00846378|Procedure|Post conditioning|after 30 seconds of re-established coronary flow following the therapeutic balloon dilatation and deflation, the same balloon will be re-inflated for 30 seconds and then again deflated for 30 seconds. This procedure of balloon inflation/deflation will be performed a total of 3 to 4 times.
1835395|NCT00846378|Procedure|Usual Care for STEMI|Usual care for treatment of TIMI 0 to TIMI 1 flow in occluded infarct related artery. Usual care includes reperfusion of the artery per operator discretion, i.e. primary stenting, thrombectomy, balloon inflation/deflation without timed intervals.
1835396|NCT00846391|Drug|MK8245 5 mg (twice a day) b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.
Patients randomized to the 5 mg b.i.d. treatment group took 2 capsules of MK8245 2.5 mg in the morning and 2 capsules of MK8245 2.5 mg in the evening."
1835397|NCT00846391|Drug|MK8245 50 mg b.i.d.|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.
Patients randomized to the 50 mg b.i.d. treatment group took 2 capsules of MK8245 25 mg in the morning and 2 capsules of MK8245 25 mg in the evening."
1835398|NCT00846391|Drug|Placebo|"All patients will receive placebo capsules 2 weeks prior to treatment period to be taken twice daily.
Patients randomized to the placebo treatment group took 2 capsules of placebo matching MK8245 capsules in the morning and 2 placebo capsules matching MK8245 capsules in the evening."
1835399|NCT00846430|Drug|Peg-Interferon alpha-2b|age and weight dependant
1835400|NCT00846430|Drug|Celecoxib (Celebrex)|age and weight dependant
1835401|NCT00846430|Drug|Temozolomide (temodar)|age and weight dependant
1835402|NCT00846430|Drug|Vincristine Sulfate (Oncovin)|age and weight dependant
1835403|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:400 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
1835404|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:66 Gy in 33 fractions
1835405|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:70 Gy in 35 fractions
1835529|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression.
1835406|NCT00846443|Other|Concurrent Pemetrexed, Cisplatin and Radiotherapy|pemetrexed:500 mg/m2, IV, day 1 and day 22; cisplatin: 25 mg/m2, IV, days 1-3 and 22-24; radiotherapy:74 Gy in 37 fractions
1835407|NCT00846456|Biological|Dendritic cell vaccine with mRNA from tumor stem cells|Intradermal injection of transfected dendritic cells
1835408|NCT00846469|Procedure|CCTA (coronary computed tomography angiography)|A CCTA (coronary computed tomography angiography) scan is a CT scan of the blood vessels of the heart. This CCTA (Coronary Computed Tomography Angiography)will be performed and a contrast medication will be injected through an IV line to help make the CT pictures more clear. Medication may or may not be given to control your heart rate during the scan. After the scan is completed it will be read. Your emergency room physician will use the CT results to determine your treatment.
1835409|NCT00846469|Other|Control section|Normal emergency room treatment for symptoms of chest pain.
1835410|NCT00846482|Drug|Oxaliplatin|Oxaliplatin will be administered once every 2 or 3 weeks
1835411|NCT00846495|Drug|topiramate|topiramate 25mg 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 1 tab in PM x 1 week topiramate 25mg 1 tab in AM / 2 tabs in PM x 1 week topiramate 25mg 2 tabs in AM / 2 tabs in PM x 5 weeks
1835412|NCT00846495|Drug|frovatriptan|frovatriptan 5mg tab during premonitory phase of migraine
1835413|NCT00846508|Drug|Cisplatin|Cisplatin is available commercially as a sterile lyophilized white power in single-dose amber vials containing 10 mg or 50 mg of cisplatin for administration by IV infusion. Every effort should be made to obtain and record the lot numbers of the batches of cisplatin used. Unopened vials of cisplatin are stable for the shelf-life indicated on the package when stored in accordance with the manufacturers' instructions.
1835414|NCT00846521|Drug|Acarbose|At baseline, subjects underwent an OGTT and 72 hr of out-patient continuous glucose monitoring. They were treated with acarbose (50 mg with meals three times daily) for 6 weeks and repeat 72 hr CGMS profiles were obtained at the end of the study.
1835415|NCT00846547|Drug|Arbaclofen|variable dose from 1mg bid to 10 mg tid, oral capsule, 8 week treatment period
1835416|NCT00846573|Drug|Hyperpolarized Helium-3|Patients will be required to breath in individual 1 liter bags of gas while in an MRI to produce lung images. These bags of gas are each made up of 333mL of Helium-3 gas and 667mL of Nitrogen. Three bags will be administered to acquire three different scans.
1835417|NCT00846586|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
1835418|NCT00846586|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together the manufacture's proprietary inhalation device (HandiHaler®).
1835419|NCT00846586|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
1835422|NCT00846612|Drug|Doxil|1 cycle: 3 weeks; 30 mg/m^2, IV, every cycle
1835423|NCT00846612|Drug|Bevacizumab (Avastin)|1 cycle: every 3 weeks; 15 mg/kg, IV, beginning on cycle 2 and every cycle 20-24 hours following Doxil administration
1835424|NCT00846625|Drug|triamcinolone|Intravitreal injection (4 mg/0.1 ml)
1835425|NCT00846625|Drug|ranibizumab|Intravitreal injection, 0.5 mg
1835426|NCT00846638|Behavioral|Brief Intervention|Diagnostic assessment followed by a single session Brief Intervention with 3, 6, and 12 month follow-up
1835427|NCT00846638|Behavioral|Diagnostic assessment|Single session diagnostic assessment with 12 month followup
1835431|NCT00846664|Procedure|Logan Short Arc Banding|Group 1 wil perform short arc banding twice a week for four weeks and have diagnostic ultrasound of multifidus measured before and after intervention
1835432|NCT00846677|Dietary Supplement|Vitamin D, cholecalciferol|Oral Quick Dissolve Strip, 400 IU once per day for 21 days
1835433|NCT00846677|Dietary Supplement|Vitamin D, cholecalciferol|Oral Syrup, 400IU per day for 21 days
1835436|NCT00846703|Drug|6-mercaptopurine, Methotrexate|"6-mercaptopurine p.o. qd
Methotrexate p.o. qw"
1835437|NCT00846703|Drug|6-mercaptopurine, Methotrexate, Vincristine, Dexamethasone|"(1)6-mercaptopurine p.o. qd x 7w Methotrexate p.o. qd x 7w
(2)Vincristine qw x 1w Dexamethasone p.o. qd x 7d
Go to (1) and (2)"
1835438|NCT00846716|Drug|Pioglitazone add on to SU or biguanide|As an initial dosing, 15mg/day of pioglitazone is administered to the patients for 2 years, who are taking SU or biguanide.
1835439|NCT00846716|Drug|SU or Biguanide|As an initial dose,a common dose of SU or biguanide is administered to the patients for 2 years.
1835440|NCT00846729|Procedure|CT angiogram of the remaining kidney.|
1835441|NCT00846729|Procedure|Kidney Function study using Iothalamate & PAH as clearance markers|
1835444|NCT00846755|Drug|Levothyroxine, Propylthiouracile|Drugs were titrated to render euthyroid pregnant patients with thyroid disease
1835445|NCT00846768|Drug|BI 1744 CL|
1835446|NCT00846781|Drug|Denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
1835447|NCT00846833|Biological|Haploidentical NK cell|"Collection of PBMCs by leukapheresis
CD3+ depletion of apheresis product using CliniMACS®"
1835448|NCT00846846|Device|Endeavor® Zotarolimus Eluting Coronary Stent System|Endeavor® Zotarolimus Eluting Coronary Stent System in a patient population requiring stent implantation
1835449|NCT00846859|Drug|varenicline (Champix/Chantix)|14 weeks of per oral tablet treatment in an escalating dosing regimen (0.5 mg - 1.0 mg/day; 1 - 2 tablets/day).
1835450|NCT00846859|Drug|placebo for varenicline|14 weeks of per oral tablet treatment in an escalating dosing regimen (1 - 2 tablets/day)
1835451|NCT00846872|Drug|GHRP-3 low dose|0.1 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
1835452|NCT00846872|Drug|GHRP-3 high dose|0.5 µg/kg/hr will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
1835453|NCT00846872|Drug|Saline|5% mannitol will be infused subcutaneously in a continuous manner using the Omnipod at the rate of 28 µl/hr
1835454|NCT00846885|Drug|Sumatriptan Succinate|100 mg Tablet
1835455|NCT00846885|Drug|Imitrex®|100 mg Tablet
1835456|NCT00846898|Dietary Supplement|cinnamon 2g per day for 12 weeks|Subjects in intervention group will receive cinnamon capsules for 12 weeks period. The 2 g dose of cinnamon will be spread over the day as 500 mg (1 capsule) after breakfast, 1000 mg (2 capsules) after lunch and 500 mg (1 capsule) after dinner. The subjects will be instructed to take the capsules immediately after the meals.
1835457|NCT00846911|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients with acute exacerbation of chronic bronchitis for whom the physician decided to prescribe moxifloxacin
1835458|NCT00846924|Device|a 30-day ambulatory cardiac event monitor|Patients will be fitted with dry electrode belt (including cardiac event monitor)and instructed to wear the device for as many hours(waking and sleeping) each day as possible, for a total of 30 days.
1835459|NCT00846924|Device|24-hour Holter|Repeat standard 24-hour Holter Monitor
1835460|NCT00846937|Dietary Supplement|Plant stanolester and fatty acid|Plant stanol ester 2gr/day and fatty acid in a beverage compared to plant stanol ester 2gr /day and placebo
1835461|NCT00846950|Drug|dexchlorpheniramine, lorazepam|
1835462|NCT00846963|Drug|Ursodiol|"Ursodiol is given by mouth, three times a day from second value of elevated conjugated bilirubin (>33mmol/L) to the resolution of cholestasis (conjugated bilirubin <34mmol/L) If Nil per os, 3,3mg/kg/dose is given. If Nil per os is required (e.g. pre-surgery, or necrotizing enterocolitis), none is given.
If enteral feeding is under 100mL/kg/day, 6,7 mg/kg/day is given. If enteral feeding exceeds 100mL/kg/day, 10 mg/kg/day is given."
1835463|NCT00846963|Drug|placebo|Placebo given in the same amount that ursodiol would be given, depending on enteral feeding and weight. It is also given three times a day, until cholestasis resolution.
1835464|NCT00846976|Drug|Bicalutamide|200mg daily
1835465|NCT00846989|Drug|RKI983A|RKI983 0.05 % twice daily
1835466|NCT00846989|Drug|RKI983A|RKI983 0.1 % twice daily
1835467|NCT00846989|Drug|Latanoprost|Latanoprost 0.005 % once a day
1835468|NCT00847002|Device|Standard Wound Care|Standard wound care treatment will include gentle wound ulcer cleansing with saline solution at each visit, maintaining moisture balance in the wound and periwound with appropriate dressings (e.g Acticoat, Aquacel Ag, or Mepilex Ag foam dressings), reminding subjects of the importance of proper nutrition, leg elevation at rest and activity, including frequent ambulation and ankle range of motion exercises through the day. The FarrowWrap Classic device is applied over the dressing to achieve suitable compression pressures as an important component of the standard treatment.
1835469|NCT00847002|Device|Flexitouch System with Standard Wound Care|In addition to standard wound care, patients who have been randomized to this group will be provided a home Flexitouch unit. They will be given instructions to use it on a twice daily basis. They will be instructed to remove the FarrowWrap during the time they are using Flexitouch. The Flexitouch System works by applying dynamic low-pressure compression to the trunk and affected limbs using gentle, rhythmic massage action.
1835470|NCT00847015|Drug|Sunitinib|Sunitinib will be administered at a dose of 25mg orally once daily for 2 consecutive weeks followed by a 1 week rest period.
1835471|NCT00847015|Drug|Gemcitabine|Gemcitabine 1,000 mg/m^2
1835472|NCT00847015|Drug|cisplatin|cisplatin 35 mg/m^2 will be administered intravenously on days 1 and 8.
1835473|NCT00847028|Other|glucose 10%|2 minutes prior to the venipuncture, a 10% glucose concentration was administered orally
1835474|NCT00847028|Other|20% glucose|2 minutes prior to the venipuncture, a 20% glucose concentration was administered orally
1835475|NCT00847028|Other|glucose 30%|2 minutes prior to the venipuncture, a 30% glucose concentration was administered orally
1835476|NCT00847028|Other|sterile water|2 minutes prior to the venipuncture, sterile water was administered orally
1835477|NCT00847054|Drug|MORAb-004 (monoclonal antibody to TEM1)|Intravenous administration
1835478|NCT00847067|Procedure|Paravertebral block|3ml 1% Ropivacaine at each level T1 - T5
1835479|NCT00847067|Procedure|Sham injections|Sham injections with Normal Saline
1835480|NCT00847080|Drug|Sitagliptin phosphate|Sitagliptin phosphate 100 mg per day per 2 weeks
1835481|NCT00847080|Drug|Placebo|Placebo 1 tablet per day per 2 weeks
1835482|NCT00847093|Drug|LMX4|One inch every six hours
1835483|NCT00847093|Drug|LMX4 Placebo|One inch every six hours
1835484|NCT00847106|Drug|Daclizumab|
1835485|NCT00847106|Biological|Dendritic cells|
1835486|NCT00847119|Biological|Bevacizumab|Bevacizumab 4 cycles each 15 days, the first 10 mg/kg and the rest of cycles with 5 mg/kg.
1835487|NCT00847119|Drug|capecitabine (Xeloda)|Capecitabine 900 mg/m2 two times a day concomitant during radiotherapy period
1835488|NCT00847119|Radiation|Rectal Radiotherapy|Radiotherapy in rectum 45 Gy starting on Bevacizumab 2nd cycle during 5 weeks, 1.8 Gy per day, 5 days at week.
1835489|NCT00847132|Behavioral|Collaborative Care Treatment|Depression education, treatment recommendations, coordination of care
1835490|NCT00847132|Behavioral|Usual Care Treatment|Treatment as usual, providers are notified of diagnoses
1835491|NCT00847145|Biological|1a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and routine vaccine at study month 12.
1835492|NCT00847145|Biological|1b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine at study month 12 and routine vaccine at study month 13.
1835493|NCT00847145|Biological|2a - Routine and rMenB+OMV NZ vaccines|One dose of routine vaccine at study month 12 and two doses of rMenB vaccine at study months 13 and 15.
1835494|NCT00847145|Biological|2b - rMenB+OMV NZ and routine vaccines|Two doses of rMenB vaccine at study months 12 and 14 and one dose of routine vaccine at study month 12.
1835495|NCT00847145|Biological|3a - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
1835496|NCT00847145|Biological|3b - 1 dose of rMenB+OMV NZ plus routine infant vaccinations|One dose of rMenB vaccine at study month 12 and one dose of routine vaccine study month 13.
1835497|NCT00847145|Biological|4a- rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
1835498|NCT00847145|Biological|4b - rMenB+OMV NZ and routine vaccines|One dose of rMenB vaccine and one dose of routine vaccine at study month 12.
1835499|NCT00847158|Procedure|phacoemulsification alone|phacoemulsification alone
1835500|NCT00847158|Device|iStent Trabecular Micro-Bypass Stent|phacoemulsification and implantation of the iStent® trabecular micro-bypass stent
1835501|NCT00847171|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|"Day 0 : Allogeneic GM-CSF-secreting Breast Cancer Vaccine administered as:
12 intradermal injections of a divided total dose of 5 x108 cells."
1835502|NCT00847171|Biological|trastuzumab|"Patient HAS received prior Trastuzumab within the last two weeks, give Trastuzumab 2 mg/kg weekly on Day -1 for 5 weeks.
Patient has NOT received Trastuzumab within the last two weeks, give On Cycle 1, Day -1 ONLY, Loading dose 4 mg/kg"
1835503|NCT00847171|Drug|cyclophosphamide|Cyclophosphamide 200mg/m2 IV in NS 100ml over 30 minutes on Day -1 ONLY. Note: there are no dose modifications for Cyclophosphamide.
1835504|NCT00847171|Other|flow cytometry|Samples will be analyzed by flow cytometry using Cell Quest software
1835505|NCT00847171|Other|immunoenzyme technique|
1835506|NCT00847171|Other|immunohistochemistry staining method|Measuring Immune Priming In Vivo By Vaccine Site Biopsies
1835507|NCT00847171|Other|laboratory biomarker analysis|
1835508|NCT00847171|Other|pharmacological study|
1835509|NCT00847171|Procedure|biopsy|skin biopsy to be performed on day 3 and day 7 for cycle 1 and 3 only
1835512|NCT00847197|Drug|MK1903|Three 50 mg capsules MK1903 by mouth every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
1835513|NCT00847197|Drug|Comparator: Placebo|Three 50 mg capsules placebo to MK1903 every 8 hours for 4 weeks. All participants will receive placebo for a 2 week run-in period.
1835514|NCT00847210|Drug|Dexlansoprazole MR|Dexlansoprazole MR 30 mg, capsules, orally, once daily for up to 7 days.
1835515|NCT00847210|Drug|Dexlansoprazole MR|Dexlansoprazole MR 60 mg, capsules, orally, once daily for up to 7 days.
1835516|NCT00847223|Drug|ZARNESTRA (Tipifarnib)|
1835517|NCT00847249|Drug|AZD9164|Each subject will receive a single-dose starting dose 4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
1835518|NCT00847249|Drug|Placebo|Each subject will receive a single-dose.
1835519|NCT00847262|Drug|Temisartan|Temisartan, initial dose: 40 mg per day, Max dose: 160 mg per day
1835520|NCT00847262|Drug|Amlodipine|Amlodipine, initial dose: 5 mg per day, Max dose: 10 mg per day
1835521|NCT00847275|Other|Exclusive nephrology follow-up|"250 patients will be included and randomized in the exclusive nephrology follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. In addition to their nephrology consultations, patients will benefit from a geriatric evaluation with MMS, GDS and ADL scoring."
1835522|NCT00847275|Other|Geriatric follow-up|"250 patients will be included and randomized in geriatric follow-up arm will continue their usual nephrology follow-up with consultations every 6 months during 3 years for dialysis patients or with consultations every 6 months before dialysis, 3 months after starting dialysis and every 6 months for a total duration of 3 years for non-dialysis patients. Patients randomized in the geriatric follow-up arm will also have more complete tests to evaluate cognitive functions (memory, language and movements), psychological functions (depression and anxiety) and dependency in activities of daily living. Other tests will allow evaluate vision, audition, mobility and nutritional status."
1835523|NCT00847288|Other|Monthly Review Arm|Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
1835524|NCT00847288|Other|Quarterly Review Arm|Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.
1835525|NCT00847314|Drug|Testosterone Undeconate (Nebido-R, BAY86-5037)|Male patients > 35yrs in medical practices fulfilling all criteria for documentation.
1835526|NCT00847327|Behavioral|Parental Support|The intervention utilizes cognitive behavioral strategies. Session 1 uses relaxation and cognitive reframing and explores parents' responses to the challenges of parenting a child with diabetes. Session 2 focuses on the emotional impact of having a child with diabetes and utilizes problem solving techniques. Session 3 focuses on child behavior and strategies for effective parenting. To facilitate support and community, Session 4 is a group session via conference call to discuss issues related to social support. Session 5 focuses on the impact diabetes has on the family and parents are taught cognitive reframing to help with managing diabetes. Parents are invited to participate in an Internet bulletin board moderated by trial personnel.
1835527|NCT00847327|Behavioral|Diabetes Education|The education comparison group also participates in 5 sessions across 9 weeks. This group provides educational and resource support that is specific to managing diabetes in young children. Education topics include blood glucose monitoring, nutrition, and physical activity. Print materials are provided to participants and intervention sessions focus on talking points raised in these reading materials.
1959040|NCT00892736|Other|Laboratory Biomarker Analysis|Correlative studies
1835641|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
1959041|NCT00892736|Other|Pharmacological Study|Correlative studies
1959042|NCT00892736|Drug|Veliparib|Given PO
1959043|NCT00887458|Drug|Itraconazole 200 mg|Itraconazole, 200 mg, by mouth, once daily (200 mg total daily dose)
1959044|NCT00887458|Drug|Itraconazole 300mg|Itraconazole, 300 mg, by mouth, twice daily (600 mg total daily dose)
1835530|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression
1835531|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression
1835532|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression
1835533|NCT00847366|Drug|Perifosine|All patients should continue therapy on their current regimen until disease progression
1835534|NCT00847379|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (20 mg/kg with breakfast, 20 mg/kg with lunch, and 40 mg/kg with dinner) for up to 96 weeks.
1835535|NCT00847392|Procedure|Ultrasound prior to bladder catheterization|Bedside ultrasound to estimated volume of urine in bladder
1835536|NCT00847405|Drug|Sumatriptan Succinate|100 mg Tablets
1835537|NCT00847405|Drug|Imitrex®|100 mg Tablet
1835538|NCT00847418|Drug|esketamine hydrochloride|
1835539|NCT00847444|Drug|Drug-based intervention|Randomization A AA: 3 cycles of 5-Fluorouracil 500 mg/m² i.v. body surface area and Epirubicine 100 mg/m² i.v. and Cyclophosphamide 500 mg/m² i.v., (FEC100), each administered on day 1, repeated on day 22, subsequently followed by 3 cycles of Docetaxel 100 mg/m² body surface area i.v. (D), administered on day 1, repeated on day 22 AB: 6 cycles of Docetaxel 75 mg/m² and Cyclophosphamide 600 mg/m² i.v. body surface area i.v. (DC), administered on day 1, repeated on day 22
1835540|NCT00847444|Behavioral|Lifestyle-based Intervention|"All Patients with a Body Mass Index (BMI) of 24 - 40 kg/m² at the time of enrollment will be subsequently randomized as follows:
Second randomization B BA: Lifestyle intervention program to reduce body weight comprising individual weight loss, diet and physical activity goals in the framework of a 2-year standardized and structured telephone and mail-based intervention."
1835541|NCT00847457|Behavioral|Aerobic exercise|Aerobic exercises completed three to four times per week for 20 to 30 minutes per session
1835542|NCT00847457|Behavioral|Stretching|Easy to moderate stretching routines completed three times per week, with a new set of routines given each week
1835543|NCT00847483|Drug|latanoprost 0.005% ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
1835544|NCT00847483|Drug|Travoprost 004% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
1835545|NCT00847483|Drug|Bimatoprost .03% sterile ophthalmic solution|One drop in the evening in the affected eye(s) at 8:00pm
1835546|NCT00847496|Device|AWBAT|One-time application of dressing over partial-thickness burns
1835547|NCT00847496|Device|Biobrane|One-time application over partial-thickness burns
1835548|NCT00847509|Drug|[F-18]FLT|The individual doses of [F-18]FLT contain a maximum of 10 mCi. The single IP dose is administered to the study subject approximately 30 to 60 minutes prior to the start of PET imaging.
1835550|NCT00847535|Biological|autologous muscle cell injection|Injection of autologous muscle cells
1835551|NCT00847548|Behavioral|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse.
1835552|NCT00847548|Behavioral|CBT addressing partner violence|This treatment is comprised of 16 sessions of cognitive behavioral therapy addressing partner violence.
1835553|NCT00847561|Behavioral|Family-based CBT|Eight, 1-hour weekly sessions with a trained clinician.
1835554|NCT00847561|Behavioral|Information Monitoring|Packet providing information on strategies for coping with anxiety
1835555|NCT00847574|Behavioral|Moderate-fat|35% of calories from fat
1835556|NCT00847574|Behavioral|Lower-fat|20% of calories from fat
1835557|NCT00847587|Drug|Etonogestrel contraceptive implant|Implant insertion postpartum prior to hospital discharge
1835558|NCT00847587|Drug|Etonogestrel contraceptive implant|Standard insertion at 4-8 weeks postpartum
1835559|NCT00847600|Dietary Supplement|Pregnenolone|50 mg, caps.
1835560|NCT00847600|Dietary Supplement|Placebo|caps
1835561|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
1835562|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
1835563|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
1835564|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
1835565|NCT00847613|Drug|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
1835566|NCT00847613|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily through the end of the study during the double-blind, active-extension period.
1835567|NCT00847613|Drug|Placebo|Oral placebo tablets administered BID daily for 6 months (nonresponders advance to second intervention at 3 months) during the double-blind, placebo-controlled period.
1835568|NCT00847613|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily through the end of the study during the double-blind, active-extension period.
1835569|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
1835570|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 20 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
1835571|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
1835572|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
1835573|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
1835574|NCT00847626|Drug|Azilsartan medoxomil and chlorthalidone|Azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
1835575|NCT00847626|Drug|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 12.5 mg combination tablets, orally, once daily for up to 8 weeks
1835576|NCT00847626|Drug|Chlorthalidone|Azilsartan medoxomil placebo and chlorthalidone 25 mg combination tablets, orally, once daily for up to 8 weeks
1835577|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 20 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
1835578|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 40 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
1835579|NCT00847626|Drug|Azilsartan medoxomil|Azilsartan medoxomil 80 mg and chlorthalidone placebo combination tablets, orally, once daily for up to 8 weeks
1835580|NCT00847639|Drug|lenalidomide|"Lenalidomide maintenance therapy will start within 60 to 90 days after allogeneic HCT at a starting dose of 10mg PO once daily.
Dose escalation and de-escalation are performed depending on tolerability of lenalidomide.
The dose range is 5mg every other day and 5 to 25 mg daily from days 1-21 followed by 7 days of rest for 12 cycles (each cycle 28 days)."
1835581|NCT00847665|Other|repositioning|Turning every 4 or 2 hours
1835582|NCT00847678|Biological|Efungumab (Mycograb)|
1835583|NCT00847678|Biological|placebo|
1835584|NCT00847678|Biological|Amphotericin B|
1835585|NCT00847678|Biological|5 flucytosine|
1835586|NCT00847704|Device|Assisted movement and enhanced sensation|Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
1835587|NCT00847717|Procedure|Selective neck dissection|Level IIb preserving neck dissection
1835588|NCT00847717|Procedure|Conventional Neck dissection|Conventional neck dissection (MRND type III or Supraomohyoid)
1835589|NCT00847730|Device|V.A.C. Negative Pressure Wound Therapy System|This is a non-invasive wound treatment system that uses controlled, localized negative pressure to create an enviroment that promotes wound healing in chronic and acute wounds
1835590|NCT00847743|Dietary Supplement|Tart Cherry Juice|8 fl.oz. twice per day
1835591|NCT00847756|Other|questionnaire|Identification of risk factors
1835592|NCT00847756|Procedure|blood sample|venal puncture, 5ml. A blood sample will be taken at the day of surgery and after 2-3 months.
1835593|NCT00847756|Procedure|collection of middle ear fluid|During routine surgery middle ear fluids are collected per patient.
1835594|NCT00847756|Procedure|nasopharyngeal swab|A nasopharyngeal swab is taken at the end of the surgical procedure and after 2-3 months.
1835595|NCT00847769|Other|High velocity, low amplitude stretch|This group (n=9) will receive talocrural traction manipulation. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
1835596|NCT00847769|Other|Slow, mobilization stretch|This group (n=9) will receive talocrural traction mobilization. With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating investigator's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
1835597|NCT00847769|Other|Passive Positioning|This group (n=9) will receive the manual therapy control intervention. This will consist of the same patient and clinician preparation for the mobilization/manipulation techniques. However, a single standardized treating investigator will simply maintain passive ankle positioning for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force characteristic of the intervention received by the other 2 comparison groups.
1835598|NCT00847782|Procedure|Blood draw|1 day
1835599|NCT00847795|Drug|Avotermin|Intradermal administration
1835600|NCT00847795|Drug|Placebo|Placebo
1835601|NCT00847808|Drug|Dexlansoprazole MR QD|Dexlansoprazole MR 30 mg, capsules and dexlansoprazole MR placebo-matching capsules, orally, each once daily for up to 6 weeks.
1835602|NCT00847821|Drug|Bazedoxifene 10 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
1835603|NCT00847821|Drug|Bazedoxifene 20 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
1835604|NCT00847821|Drug|Bazedoxifene 40 mg/CE 0.625 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
1835605|NCT00847821|Drug|Bazedoxifene 10 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
1835642|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
1835643|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
1835644|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
1835606|NCT00847821|Drug|Bazedoxifene 20 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
1835607|NCT00847821|Drug|Bazedoxifene 40 mg/CE 0.45 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as bazedoxifene/CE tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
1835608|NCT00847821|Drug|Raloxifene 60 mg|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as raloxifene tablets in capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
1835609|NCT00847821|Drug|Placebo|No dose taken during this study; however, this intervention was taken while study 3115A1-303 was ongoing. In the 3115A1-303 study, test article was supplied as placebo capsules. The dosage was one capsule orally, once daily, at approximately the same time each day on a continuous regiment for 2 years, or until early discontinuation from the study.
1835610|NCT00847834|Drug|Irbesartan 150mg / Hydrochlorothiazide 12.5mg|Once a day
1835611|NCT00847834|Drug|Irbesartan 150mg|Once a day
1835612|NCT00847847|Procedure|Anconeus Muscle biopsy|Anconeus muscle specimens will be surgically removed. The biopsy will be performed under regional anaesthesia and will require an about 5 cm incision of the skin and muscle fascia from the lateral condyle to over the ridge of the proximal ulna, 3 or 4 cm distal to the tip of the olecranon. A triangular muscle flap will be removed, and then the fascia and skin will be closed with running dissolving suture.
1835613|NCT00847860|Drug|Cilostazol|Cilostazol 100 mg bid for 12 months
1835614|NCT00847860|Drug|Aspirin|Aspirin 100 mg qd for 12 months
1835615|NCT00847873|Behavioral|substance abuse/domestic violence treatment|This intervention is comprised of 16 sessions of cognitive behavioral therapy. 8 sessions are addressing partner violence and 8 sessions are addressing substance abuse
1835616|NCT00847873|Behavioral|Cognitive behavioral therapy addressing substance abuse|This intervention is comprised of 16 sessions of cognitive behavioral therapy addressing substance abuse.
1835617|NCT00847886|Drug|LX3305|Daily oral intake of LX3305 for 14 days.
1835618|NCT00847886|Drug|LX3305 Placebo|Matching placebo dosing with daily oral intake for 14 days.
1835619|NCT00847886|Drug|Methotrexate|Once weekly stable-dose methotrexate.
1835620|NCT00847899|Drug|AR9281|AR9281 taken in BID dosing regimen for 28 days
1835621|NCT00847899|Drug|AR9281|AR9281 taken in TID dosing regimen for 28 days
1835622|NCT00847899|Drug|Placebo|Placebo taken in BID dosing regimen for 28 days
1835623|NCT00847899|Drug|Placebo|Placebo taken in TID dosing regimen for 28 days
1835626|NCT00847925|Drug|Avotermin (RN1001)|100ul/linear cm of wound. Dosed before surgery and 24h later
1835627|NCT00847938|Drug|neostigmine|0.04 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
1835628|NCT00847938|Drug|neostigmine|0.02 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
1835629|NCT00847938|Drug|neostigmine|0.01 mg/kg IV bolus, injection when the of train of four is > or = to 40 %
1835630|NCT00847951|Procedure|3D Ultrasound Imaging|Ultrasound scanning with power Doppler is used to determine the fractional blood volume of the kidneys in pre-mature and/or very low birth weight babies. This is a measure of perfusion and an indication of how well the kidneys are working.
1835631|NCT00847964|Device|Algisyl-LVR|method of left ventricular restoration in patients with dilated cardiomyopathy
1835632|NCT00847977|Drug|use of a non balced fluid and of a macromolecular fluid|Physiological serum: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Heafusine: boli 10 ml/kg on 20 minutes
1835633|NCT00847977|Drug|use of balanced crystalloids fluid and macromolecular fluid|Isofundine: basic flow 30 ml/kg/j during 48 hoursand boli wished by physicians 20 ml/kg on 20 minutes Tetraspan: boli 10 ml/kg on 20 minutes
1835634|NCT00847990|Other|Maternal blood screening test for fetal aneuploidy|One blood draw of 20 to 30 mL
1835635|NCT00848003|Drug|Bifidobacterium animalis subsp. lactis strain BB-12|Bifidobacterium animalis subsp. lactis (B. lactis) strain BB-12 (BB-12) probiotic supplemented yogurt, 4 ounces taken orally for 10 days
1835636|NCT00848003|Drug|Placebo|Strawberry flavored yogurt
1835637|NCT00848016|Drug|R-(-)-gossypol acetic acid|Participants take 20mg oral R-(-)-gossypol acetic acid once daily on days 1-21. Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity.
1835638|NCT00848029|Biological|Monovalent inactivated influenza vaccine|Two doses of monovalent inactivated influenza adjuvanted vaccine
1835639|NCT00848042|Device|AuroLase Therapy|Infusion of AuroShell particles followed by laser illumination for photothermal ablation of target lesions
1835640|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
1835645|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
1835646|NCT00848055|Drug|AbGn168 intravenous infusion|single dose intravenous infusion
1835647|NCT00848055|Drug|AbGn168 subcutaneous injection|single dose subcutaneous injection
1835648|NCT00848068|Other|FID 114657|artificial tears
1835649|NCT00848068|Other|OPTIVE Lubricant Eye Drops|artificial tears
1835650|NCT00848081|Drug|Tadalafil|5 mg taken by mouth once daily for 12 weeks
1835651|NCT00848081|Drug|Placebo|By mouth once daily for 12 weeks
1835652|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 46 Gy in 2 Gy per fractions for arm I . Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 62 Gy for arm I.
1835653|NCT00848094|Radiation|3DCRT/IMRT|The starting radiation doses were the total tumor doses of 40 Gy in 2 Gy per fractions for arm II. Escalation was achieved by increasing the tumor dose of each cohort in increments of 4.0 Gy. Subsequent cohorts received higher doses up to a chosen maximum of 52 Gy for arm II.
1835654|NCT00848107|Drug|treprostinil diethanolamine|sustained release tablet; BID dosing; up to 16 mg BID
1835655|NCT00848120|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 24 weeks
1835656|NCT00848133|Procedure|mini-midvastus surgical approach for total knee arthroplasty|
1835657|NCT00848133|Procedure|mini-subvastus surgical approach for total knee arthroplasty|
1835658|NCT00848146|Procedure|Endoscopically assisted Laparoscopic Cholecystectomy Surgery|Using endoscopic instruments a small incision will be made in the gastric wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The gallbladder will be removed through the stomach and out of the mouth. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the gastrotomy.
1835659|NCT00848172|Drug|Octanoic Acid|4mg/kg
1835660|NCT00848172|Drug|Placebo|identical capsules
1835661|NCT00848211|Other|Placebo|Subcutaneous injection on Day 0, Day 28, and Day 84
1835662|NCT00848211|Biological|TUTI-16 (0.03mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
1835663|NCT00848211|Biological|TUTI-16 (0.1mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
1835664|NCT00848211|Biological|TUTI-16 (0.6mg)|Subcutaneous injection on Day 0, Day 28, and Day 84
1835665|NCT00848224|Behavioral|systems-based and pharmacist-mediated program|Patients in the SI were seen by a study pharmacists prior to discharge to establish a relationship with the patient, explain the pharmacist's role in the study, provide education about all discharge medications and a medication card listing all medications and their manner of use, and set the framework for the follow-up telephone calls. Patients received pharmacist-delivered adherence counseling telephone contacts that took place at two weeks following discharge, and at months 1, 3, 6, and 9 oriented towards assisting patients to remain adherent to prescribed lipid-lowering and other medications, and also towards ensuring that all patients were either documented to be at the LDL-C goal, or were assisted to reach the goal by facilitating the scheduling of repeat lipid measurement as needed and providing information, guidelines and prompts to the patient's physician or nurse practitioner.
1835666|NCT00848237|Device|Radiofrequency Ablation (HALO Ablation Systems)|Subjects undergo ablation procedures (circumferential or focal) plus standard anti-secretory drug therapy (proton pump inhibitor, PPI). All Patients undergo endoscopy with biopsy in a Physician prescribed surveillance pattern after a negative biopsy.
1835667|NCT00848250|Drug|Angiotensin Converting Enzyme Inhibitor|Patients randomized to this group will continue their current dose of ACE inhibitors until surgery
1835668|NCT00848250|Other|No ACE Inhibitor|Patients randomized to this group will stop their ACE inhibitors 48 hours before surgery
1835669|NCT00848263|Procedure|Volar plate|Treatment with a volar plate (DVR) inserted through a volar incision of 8-10 cm over the distal radius (Henry's approach).
1835670|NCT00848263|Procedure|Dorsal nail plate|Treatment with a dorsal nail plate (DNP) inserted through a 3-4 cm dorsal incision.
1835671|NCT00848289|Behavioral|Interviews|Data collected by personal interview for Epidemiology and Nutrition Questionnaires, with personal and follow-up telephone interviews.
1835672|NCT00848302|Drug|L-arginine|30 patients will receive either 50, 100 or 500mg L-arginine supplementation infused via a end-hole catheter
1835673|NCT00848315|Behavioral|Cognitive Behavioral Intervention|The intervention emphasizes patients' ethnic preferences and traditions (e.g., adapting ethnic recipes to meet dietary goals) and the use of available community resources (e.g., available areas for exercise), and is delivered utilizing strategies and materials appropriate for low-literate/illiterate patients.
1835674|NCT00848328|Biological|Rituximab|Injection for Intravenous Use, 375 mg/m2/wk x 4 weeks, to begin Cycle 1, Day 15.
1835675|NCT00848328|Drug|Lenalidomide|Supplied as 5mg capsules; Dosage: 20 mg daily, days 1-21 of a 28 day cycle, to begin Day 1 of cycle 1 and continue until disease progression.
1835676|NCT00848341|Device|GUIDANT ICD SYSTEM|
1835677|NCT00848354|Biological|Phase 1: Etanercept|Phase 1: prefilled syringe 50mg/ml, administered once weekly for study weeks 0 - 24
1835678|NCT00848354|Drug|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg, dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
1835679|NCT00848354|Drug|Phase 2: Optional ETN, SSZ, HCQ, MTX|"Phase 2: All therapies are optional and may include any combination of the following: ETN, SSZ, HCQ, MTX Phase 2: Optional ETN: prefilled syringe 50mg/ml, dose variable after study week 24 to week 128.
Phase 2: Optional SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations after study week 24 to week 128.
Phase 2: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations after study week 24 to week 128.
Phase 2: MTX: oral tablet, 2.5mg dose variable after week 24 to week 128."
1835680|NCT00848354|Drug|Phase 1: Methotrexate|Phase 1: oral tablet, 2.5mg dose variable from 7.5mg to 25mg, once weekly for study weeks 0 - 24.
1835681|NCT00848354|Drug|Phase 1: Conventiaonal DMARD|Phase 1: SSZ: oral tablet, 0.5gm, dose variable per approved local label recommendations. OR Phase 1: HCQ: oral tablet, 200mg, dose variable per approved local label recommendations.
1835783|NCT00840333|Drug|MP-376 (Levofloxacin solution for Inhalation)|DOSE BASED ON PATIENTS WEIGHT
1835682|NCT00848367|Behavioral|Group Psychodynamic Interpersonal Psychotherapy|This intervention will consist of 16 weekly 90 minute sessions of Group Psychodynamic Interpersonal Psychotherapy (GPIP). GPIP was developed and empirically tested in a randomized controlled trial (RCT) at our Centre. GPIP will be preceded by an individual pre-group preparation session conducted by a psychologist trained in GPIP to orient the patient to the therapy. Patients are given a rationale for the treatment.
1835683|NCT00839488|Drug|pantoprazole 40 mg iv|pnatoprazole 40 mg iv qd
1835684|NCT00839488|Drug|famotidine 20 mg iv|famotidine 20 mg q12h
1835685|NCT00839501|Dietary Supplement|Potassium|40 mEq twice daily in pill form during the first 3-day inpatient visit, followed by 40 mEq twice daily in liquid form during the first 18-week treatment period, as is randomly scheduled, and continued during the second 18-week treatment period as long as there are no limiting side effects
1835686|NCT00839501|Drug|Acetazolamide|250 mg twice daily, orally, during the second 3-day inpatient visit and during the second 18-week treatment period, as is randomly scheduled
1835687|NCT00839527|Drug|placebo to match albiglutide|albiglutide matching placebo weekly subcutaneous injection
1835688|NCT00839527|Biological|albiglutide|albiglutide weekly subcutaneous injection
1835689|NCT00839527|Drug|metformin|metformin
1835690|NCT00839527|Drug|glimepiride|glimepiride
1835691|NCT00839527|Drug|pioglitazone|pioglitazone
1835692|NCT00839527|Drug|placebo to match pioglitazone|pioglitazone matching placebo
1835693|NCT00839540|Drug|micafungin|100 mg qd by slow IV infusion for 24 h
1835694|NCT00839540|Drug|Micafungin|200 mg qd by slow IV infusion for 24 h
1835695|NCT00839540|Drug|Caspofungin|70 mg LD followed by 50 mg qd by slow IV infusion for 24 h
1835696|NCT00839553|Procedure|Intrapleural Minocycline application|
1835697|NCT00839566|Procedure|Ablation|AV-node ablation
1835698|NCT00839566|Other|Rate Control|Rate control by drug
1835699|NCT00839579|Other|1x4 min interval|Aerobic interval training
1835700|NCT00839592|Other|Electroacupuncture|Acupuncture at bilateral Ear Shenmen, Sishencong EX-HN1, Anmian, and unilateral Yintang EX-HN3 and Baihui GV20. The needles will be left for 30 min and then removed. Acupuncture treatment will consist of three sessions per week for 3 consecutive weeks.
1835701|NCT00839605|Drug|Dexmedetomidine|loading dose:0.3mcg/kg. Infusion of 0.3mcg/kg/hr
1835702|NCT00839631|Drug|EC D-3263 HCl|EC D-3263 HCl, capsules, 50 mg. Oral administration. Dose escalation cohorts (cycle one: single dose on Day 1, daily doses on day 8-28; subsequent cycles: 1 week drug holiday followed by 3 weeks of daily dosing). Expansion Cohort: daily dosing for 28 days followed by a single 7 day drug holiday (Cycle 1), continuing thereafter with daily dosing.
1835703|NCT00839644|Device|High frequency chest wall oscillation|Therapy prescribed twce daily for twenty minute sessions. High frequency chest wall oscillation (HFCWO) applies sharp compression pulses via an air-pulse generator and inflatable vest. HFCWO generates transient increases in airflow at low lung volumes, cough-like shear forces, and alterations in the consistency of secretions.
1835704|NCT00839644|Device|Oscillatory Positive Expiratory Pressure|Therapy was prescribed twice daily for 20 minute sessions and included airway vibration, oscillating PEP, and forced expiratory technique (FET) with coughing.
1835705|NCT00839644|Other|PD&P: Postural drainage and percussion|Each of the six positions are to be clapped or vibrated for 4 minutes. After each position the patient is to do three forced expiratory techniques (FET) and cough, continue with FET and coughing until all mobilized mucus has been cleared.
1835706|NCT00839657|Behavioral|Genotype-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical and genetic information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical and genetic information.
1835707|NCT00839657|Behavioral|Clinical-guided dosing algorithm for warfarin|Initial dosing of warfarin for the first 3-4 days of treatment will be determined by an algorithm that uses clinical information. Following this initiation dose of warfarin, a second dose adjustment will be made after 3 and/or 4 doses of warfarin using a dose revision algorithm that incorporates the clinical information.
1835708|NCT00839670|Other|Light constraint induced therapy|90 minutes of motor training with a physical or occupational therapist and 270 minutes of self-rehabilitation, 5 days/week/2 weeks.
1835709|NCT00839670|Other|Standard constraint induced therapy|360 minutes of motor training with a physical or occupational therapist, 5 days/week/2 weeks
1835710|NCT00839683|Drug|simvastatin|Tablets, Oral, 20 mg, Single Dose
1835711|NCT00839683|Drug|Dapagliflozin|Tablets, Oral, 20 mg, Single Dose
1835712|NCT00839683|Drug|simvastatin|Oral, 40 mg, Single Dose
1835713|NCT00839683|Drug|valsartan|Tablets, Oral, 320 mg, Single Dose
1835714|NCT00839709|Procedure|blood sampling|peripheral blood draw
1835715|NCT00839722|Procedure|embolization|fertility after embolization
1835716|NCT00839761|Dietary Supplement|iron fortified rice|
1835717|NCT00839761|Dietary Supplement|iron drops|
1835718|NCT00839774|Other|Whole yellow pea flour|Whole pea flour was administered at 50 g/day.
1835719|NCT00839774|Other|Fractionated pea flour|Fractionated pea flour was administered according to the level of fiber in whole pea flour treatment. 12 g/day
1835720|NCT00839774|Other|White wheat flour|White wheat flour will be administered at 50 g/day
1835721|NCT00839787|Drug|Morphine Sulfate|Morphine Sulfate group: If weight is <50 Kg; Morphine 0.1mg/kg IV to a maximum of 10mg can be given; if weight ≥ 50 Kg a maximum of 10mg can be given
1835722|NCT00839800|Drug|Symbicort Turbuhaler|160/4.5 µg
1835723|NCT00839800|Drug|Terbutaline Turbuhaler|0.4 mg
1835725|NCT00839826|Drug|Rivaroxaban (BAY59-7939)|2,5 mg bid,5 mg bid,10mg bid, 20 mg bid, 20 mg tid, 30 mg bid, dose escalation trial
1835726|NCT00839826|Drug|Enoxaparin|40 mg bid
1835727|NCT00839839|Procedure|Oocyte Vitrification|All oocytes retrieved will be vitrified (rapidly frozen) after egg retrieval. The oocytes will then be warmed on the same day and fertilized per standard IVF-ICSI. Resulting embryos will be transferred back to the patient as per protocol.
1836583|NCT00854698|Other|exercise training|subjects are asked to exercise 20 or 30 minutes.
1835728|NCT00839852|Drug|Cariprazine|Patients who meet eligibility criteria will receive open-label cariprazine.
1835729|NCT00839865|Drug|herb ointment|a kind of ointment made from herb
1835730|NCT00839878|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
1835731|NCT00839891|Drug|VI-0521|PHEN/TPM 7.5/46 mg (a potential therapeutic dose) PHEN/TPM 22.5/138 mg (a supra-therapeutic dose)
1835732|NCT00839904|Behavioral|exercise|two supervised, 60-minute weekly exercise sessions + instructions to perform additional physical activities throughout the day
1835733|NCT00839917|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)|Single administration of 0.5 mL subcutaneous injection
1835734|NCT00839917|Biological|M-M-R™ II and Varivax™|Single administration of 0.5 mL subcutaneous injection
1835735|NCT00839930|Drug|Cilostazol 50 mg Tablets|1 x 50 mg, single-dose fasting
1835736|NCT00839930|Drug|Pletal®|1 x 50 mg, single-dose tablet
1835737|NCT00839943|Other|ozone, 0.4 ppm|2 hour ozone exposure, 0.40 ppm
1835738|NCT00839956|Drug|Bortezomib|Given IV
1835739|NCT00839956|Drug|Vorinostat|Given PO
1835740|NCT00839969|Procedure|Cystoscopy|Saline cystoscopy under general anaesthesia
1835741|NCT00839969|Procedure|Cystoscopy and urethral dilatation|Saline cystoscopy and urethral dilatation (using Hegar dilators) under general anaesthesia
1835742|NCT00839982|Drug|clofarabine|Given PO
1835743|NCT00839982|Drug|cytarabine|Given SC
1835744|NCT00840008|Other|Educational intervention|As per detailed protocol.
1835745|NCT00840034|Drug|LY2216684|Starting dose is 6 mg, then titrate up to 9 mg, 12 mg, or 18 mg (3 tablets) administered PO QD for up to 12 weeks
1835746|NCT00840034|Drug|Placebo|3 tablets PO QD for up to 12 weeks
1835747|NCT00840047|Drug|Methionine|Intravenous injection
1835748|NCT00840060|Behavioral|AMALS|Addressing multiple aspects of language simultaneously
1835749|NCT00840060|Behavioral|DTA|Discrete Trial Approach
1835750|NCT00840073|Drug|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fed
1835751|NCT00840073|Drug|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fed
1835752|NCT00840086|Drug|turoctocog alfa|Subjects will receive bleeding preventive treatment (home treatment with self-injection i.v.) with turoctocog alfa at a dose of 20-40 IU/kg body weight every second day or 20-50 IU/kg body weight three times per week at the investigator's discretion.
1835753|NCT00840099|Drug|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fed
1835754|NCT00840099|Drug|Augmentin ES-600™ 600 mg/42.9 mg/5 mL Suspension|1 x 600 mg/42.9 mg/5 mL, single-dose fed
1835755|NCT00840112|Dietary Supplement|Vitamin E supplement|400 IU (268 mg) capsules of will be provided for the subjects. Subjects will be instructed to take one capsule with meals 2 times per day.
1835756|NCT00840125|Drug|erlotinib|150mg tablet daily
1835757|NCT00840125|Drug|docetaxel|30 mg/m2 days 1,8 of 22 days cycles, up to 6 cycles
1835758|NCT00840138|Procedure|Surgical reconstruction|"Hepaticojejunostomy
End-to-end anastomosis
Duct suture over T-tube"
1835759|NCT00840151|Behavioral|contingency management|Participants randomized to a contingency management treatment condition can earn the chance to win prizes for attending substance abuse treatment.
1835760|NCT00840177|Drug|cytarabine|
1835761|NCT00840177|Drug|idarubicin|
1835762|NCT00840177|Drug|pravastatin sodium|
1835763|NCT00840190|Drug|P1446A-05|P1446A-05 available as 25mg,50mg,100mg capsule. Subjects will be enrolled at at different dose levels of P1446A-05 to be taken once a day for 14 days followed by 7 days rest.This constitutes one cycle of P1446A-05. Four such cycles will be administered.
1835764|NCT00840203|Drug|Rowasa® 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
1835765|NCT00840203|Drug|Mesalamine 4 gm/60 mL Rectal Enema|1 x 4 gm/60 mL, single-dose
1835766|NCT00840216|Drug|Clarithromycin ER 500 mg tablets|1 x 500 mg
1835767|NCT00840216|Drug|BIAXIN® XL 500 mg tablets|1 x 500 mg
1835768|NCT00840229|Drug|Triamcinolone hexacetonide|20 mg
1835769|NCT00840229|Drug|Triamcinolone hexacetonide|1 ml (20 mg) + 6 ml Lidocaine 10 mg/ml
1835770|NCT00840242|Drug|Nicotine gum|8-12 pieces per day, maximum 24 daily
1835771|NCT00840242|Drug|Placebo gum|8-12 pieces per day, maximum 24 daily
1835772|NCT00840242|Drug|Nicotine inhaler|6-12 cartridges per day, maximum 12 daily
1835773|NCT00840242|Drug|Placebo inhaler|6-12 cartridges per day, maximum 12 daily
1835774|NCT00840255|Behavioral|BBTI-MV|Twenty participants will be randomized to BBTI-MV. As previously described, the intervention will be delivered over 4 consecutive weeks, which include individual face-to-face visits on Weeks 1 and 3, and telephone appointments on Weeks 2 and 4. Interventions will be delivered at Western Psychiatric Institutes and Clinic. If possible, (according to space availability), the face-to-face sessions may also be conducted at the VAPHS clinics or at Reserve and Veterans Centers locally and regionally to strengthen our relations with local care and services providers and centers, and to facilitate future collaborative efforts. The duration of the first treatment visit is 45-minutes, and the follow-up visit on Week 3 will last no more than 30 minutes. Brief (<20 minutes) telephone sessions will be conducted on Weeks 2 and 4.
1835775|NCT00840255|Other|Information Control|Participants will receive two brochures from the American Academy on Sleep Medicine of Sleep Hygiene and on Insomnia. The therapists will read the content of the 2 brochures with participants, and discuss how the information provide relates to individual participants' sleep experiences. No recommendations for altering sleep schedules will be made by the assigned therapist. Participants will be instructed to read these two brochures over the course of the following week, and to consider how the information provided in the brochures related to their own sleep patterns
1835776|NCT00840268|Drug|Hydroxypropyl Guar Galactomannan (HPGG) 0.25% ophthalmic gel|
1835777|NCT00840268|Drug|Hydroxypropyl Guar Galactomannan Vehicle|Inactive ingredients used as a placebo comparator
1835778|NCT00840281|Drug|Cefzil® 500 mg tablets|1 x 500 mg, single-dose fasting
1835779|NCT00840281|Drug|Cefprozil 500 mg Tablets|1 x 500 mg, single-dose fasting
1835780|NCT00840294|Drug|Ciprofloxacin|
1835781|NCT00840320|Drug|1278863|15mg, 25mg, 50mg, 150mg
1835782|NCT00840320|Drug|Placebo|matching placebo
1835784|NCT00840346|Drug|panobinostat|20 mg, 30 mg, 40 mg in combination with idarubicin and cytarabine, according to the classical 3+3 schedule.
1835785|NCT00840359|Procedure|Photodynamic therapy|Application of Metvix 16% cream followed by exposure to daylight for 2.5 hours
1835786|NCT00840359|Procedure|Cryotherapy|Cryotherapy for 2 times 20 sec
1835787|NCT00840372|Procedure|Buttonhole cannulation with semi-blunt needles|Use of semi-blunt needles, compared to blunt needles, at every dialysis session
1835788|NCT00840385|Drug|FAD|Fludarabine 40mg/m2 po.d1-3; Adriamycin 50mg/m2 i.v.d1; Dexamethasone 20mg/d po.d1-5.
1835789|NCT00840398|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fed
1835790|NCT00840398|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fed
1835791|NCT00840411|Drug|Clarithromycin ER 500 mg tablets|1 x 500 mg
1835792|NCT00840411|Drug|BIAXIN® XL 500 mg tablets|1 x 500 mg
1835793|NCT00840450|Drug|Gleevec/Paclitaxel|"One treatment cycle:
Gleevec: 300 mg twice a day orally for 4 consecutive days, then off for 3 days, every 7 days for 28 days.
Paclitaxel: 80 mg/m^2/week intravenously, 3 weeks on, one week off, every 28 days.
After 3 treatment cycles, decision made to continue or not with the combination based on tolerance and lack of progression."
1835794|NCT00840463|Drug|Ambrisentan|Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).
1835795|NCT00840463|Other|Placebo|Sugar pill
1835796|NCT00840476|Drug|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fasting
1835797|NCT00840476|Drug|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fasting
1835798|NCT00840489|Drug|Ribavirin|Ribavirin 1000-1200 mg qd for 24 weeks
1835799|NCT00840489|Drug|Colchicine|Colchicine 0.5 mg bd for 24 weeks
1835800|NCT00840528|Other|ozone|0.4 ppm ozone for 2 hours
1835801|NCT00840554|Other|Clinic-based physical therapy program.|All patients will receive a routine clinic-based physical therapy program. This program may include supervised aerobic conditioning, strengthening exercise, balance retraining, functional activity training, therapeutic exercise, and manual therapy.
1835802|NCT00840554|Other|Home exercise program.|In addition to the clinic-based physical therapy program, patients will perform home exercises. Home exercise will include a walking and strengthening program 5 days per week. The home exercise routine will be recorded in an exercise diary.
1835803|NCT00840567|Procedure|Skin biopsy|
1835804|NCT00840567|Procedure|Blood draw & sample|
1835805|NCT00840580|Drug|Moxifloxacin 0.5% ophthalmic solution (Vigamox)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
1835806|NCT00840580|Drug|Levofloxacin 0.5% ophthalmic solution (Cravit)|One drop 4 times a day in study eye for one week prior to surgery, followed by one drop 4 times a day for two weeks beginning Day 1 post surgery.
1835807|NCT00840593|Procedure|Non-surgical group|The non-surgical treatment consisted of immobilisation of the injured AC-joint in a Kenny-Howard-type splint for four weeks. The patient was encouraged in mobilisation of the elbow several times per day and the mobilisation of the shoulder with pendulum type movements were initiated four weeks after the injury. Active mobilisation of the shoulder was allowed six weeks after the injury.
1835808|NCT00840593|Procedure|Surgical group|The surgical treatment was accomplished within two days after the injury, and it consisted of an open reduction and fixation of the AC joint with two smooth Kirschner wires (2 mm in diameter) across the AC-joint. The K-wires were bent at the proximal ends, with suturing of the superior AC ligament. The position of Kirschner wires was confirmed during the operation using C-arm transillumination. The articular disc of AC joint was removed if it was damaged. Postoperative care consisted of immobilisation of the AC joint in a sling, (Polysling, body band) for four weeks and the mobilisation of the shoulder started four to six weeks later in a similar manner as in the non-operative group.
1835809|NCT00840606|Drug|BUSPAR® 30 mg Tablet|1 x 30 mg, single-dose fasting
1835810|NCT00840606|Drug|Buspirone Hydrochloride 30 mg Tablet|1 x 30 mg, single-dose fasting
1835811|NCT00840632|Drug|Trandolapril 4 mg Tablets|1 x 4 mg, single-dose fasting
1835812|NCT00840632|Drug|Mavik® 4 mg Tablets|1 x 4 mg, single-dose fasting
1835813|NCT00840645|Drug|YM178|Oral
1835814|NCT00840658|Behavioral|Interactive injection and sexual risk intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of both, a) unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared; and b) unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
1835815|NCT00840658|Behavioral|Interactive Sexual Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe sex and condom use with clients, and associated risks (e.g., HIV (Human Immuno-deficiency Virus), STIs (Sexually Transmitted Infections), pregnancy).
1835816|NCT00840658|Behavioral|Interactive Injection Risk Intervention|This is a one-on-one intervention that incorporates elements of motivational interviewing (MI) and principles of Social Cognitive Theory (SCT) and Theory of Reasoned Action (TRA) to address the context of unsafe injection sharing and the extent to which syringes and other injection paraphernalia is shared.
1835817|NCT00840671|Drug|Cerebrolysin|Cerebrolysin, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
1835818|NCT00840671|Drug|0.9% Saline Solution|0.9% Saline Solution, 30 ml/day as intravenous infusion, first infusion after completion of thrombolytic therapy. Daily infusion for 10 consecutive days.
1835819|NCT00840684|Drug|amsacrine|
1835820|NCT00840684|Drug|busulfan|
1835821|NCT00840684|Drug|cytarabine|
1835822|NCT00840684|Drug|daunorubicin hydrochloride|
1835823|NCT00840684|Drug|laromustine|
1835824|NCT00840684|Drug|melphalan|
1835825|NCT00840684|Drug|mitoxantrone hydrochloride|
1835826|NCT00840684|Procedure|allogeneic hematopoietic stem cell transplantation|
1835827|NCT00840684|Procedure|autologous hematopoietic stem cell transplantation|
1837622|NCT00859989|Other|immunoenzyme technique|
1835828|NCT00840697|Behavioral|Exercises and work related rehabilitation|Treatment in groups, twice a week for 3 weeks. The treatment includes exercises, cognitive intervention and work related rehabilitation. The exercises include fitness, strength and stretching
1835829|NCT00840697|Behavioral|Brief intervention|1 consultation at the physiotherapist, which give advice Summary talk with the physician about activity and work when having neck- and low back pain
1835830|NCT00840697|Behavioral|multidisciplinary exercise group|10 days during 3 weeks. Treatment in groups, exercise and cognitive treatment
1835831|NCT00840736|Procedure|Laparoscopic adjustable gastric banding|Laparoscopic adjustable gastric banding
1835832|NCT00840736|Procedure|vertical banded gastroplasty|vertical banded gastroplasty
1992688|NCT03314662|Biological|Licensed MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine (aTIV-1)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines.
1996370|NCT02493764|Drug|Tazobactam|Tazobactam 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
1835835|NCT00840762|Other|VircoType HIV-1 genotypic interpretation|VircoType HIV-1 genotypic interpretation
1835836|NCT00840762|Other|Local Expert Review of HIV Genotypic resistance testing|Local Expert Review of HIV Genotypic resistance testing
1835837|NCT00840775|Device|Catheterization, stent deployment|Standard catheterization procedure including Bare Metal Stent deployment.
1835838|NCT00840788|Procedure|octyl-2-cyanoacrylate adhesive glue|use of octyl-2-cyanoacrylate adhesive glue for perineal skin repair after episiotomy
1835839|NCT00840788|Procedure|Subcuticular suture of perineal skin|Use of continuous subcuticular suture with rapidly absorbable polyglactin 910 for closure of the perineal skin in episiotomy repair
1835840|NCT00840801|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive three vaccinations with FSME-IMMUN 0.25ml Junior on days 0, 28 and 360
1835841|NCT00840801|Biological|Tick-Borne Encephalitis (TBE) Vaccine (Inactivated)|Subjects receive two vaccinations with Encepur 0.25ml Children on days 0 and 28 and a third vaccination with FSME-IMMUN 0.25ml Junior on day 360.
1835842|NCT00840827|Drug|lenalidomide|Lenalidomide 10mg po daily
1835843|NCT00840827|Drug|cyclosporine A|CSA 250mg orally twice daily
1835844|NCT00840840|Drug|600 mg Amoxicillin/42.9 mg Clavulanate Postassium /5 mL|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
1835845|NCT00840840|Drug|Augmentin ES-600™|1 x 600 mg/42.9 mg/5 mL, single-dose fasting
1835846|NCT00840853|Genetic|CD19CAR/virus specific T cells|CD19CAR/virus specific T cells will be thawed and given by intravenous injection from day +30 post transplant.
1835847|NCT00840866|Drug|cefprozil|500 mg Tablet
1835848|NCT00840866|Drug|Cefzil®|500 mg Tablet
1835849|NCT00840879|Drug|Meloxicam 15 mg Tablets|1 x 15 mg, single-dose fed
1835850|NCT00840879|Drug|Mobic® 15 mg Tablets|1 x 15 mg, single-dose fed
1835851|NCT00840892|Other|INTERdisciplinary COMmunity-based COPD management (INTERCOM)|The INTERCOM program consisted of exercise training, education, nutritional therapy and smoking cessation support offered by local physiotherapists and dieticians in the proximity of the patient's home and by respiratory nurses in the hospital. The program was divided in a 4-month intensive intervention phase, followed by a 20-month maintenance phase.
1835852|NCT00840918|Drug|Lidocaine|Intravenous Lidocaine Group - Lidocaine administered intravenously throughout surgery and during the 24 hours following surgery.
1835853|NCT00840918|Other|Placebo|Placebo is administered intravenously throughout surgery and during the 24 hours following surgery
1835854|NCT00840931|Drug|lenalidomide|Patients will take 10 mg capsules of lenalidomide per day for 21 days followed by 7 days of rest. This 28 day period is considered 1 cycle. Patients will receive 4 treatment cycles with 28 days in each cycle.
1835855|NCT00840931|Biological|bystander vaccine|In addition to lenalidomide, during each 28 day cycle patients will also receive GM.CD40L bystander vaccination injections in 2-week intervals on days 8 and 22 for a total of 8 immunizations during the 4 cycle treatment period.
1835856|NCT00840944|Drug|somatropin|somatropin 0.050 mg/kg/day
1835857|NCT00840944|Drug|triptorelin|triptorelin 3.75 mg each month
1835858|NCT00840957|Biological|infliximab|chimeric monoclonal antibody to Tumor Necrosis Factor-alpha
1835859|NCT00840983|Procedure|delayed cord clamping|cord clamping was delayed for 30 to 45 seconds and infant was held lower than the level of the placenta
1835860|NCT00840996|Drug|Lidocaine|perioperative intravenous lidocaine (2 mg/kg/h) with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
1835861|NCT00840996|Drug|placebo|perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
1835862|NCT00841022|Other|Information with comics|Information of children with comic leaflet
1835863|NCT00841035|Drug|erlotinib|Preoperative dosing of 150 mg oral erlotinib for 7 days before surgery. followed by erlotinib 100 mg daily 6 month/6 chemotherapy cycles. Gemcitabine 1000 m2 weekly after surgery for 6 cycles.
1835864|NCT00841048|Drug|AZD4017|ascending multiple doses(start dose 75mg od), oral suspension
1835865|NCT00841048|Drug|Placebo|
1835866|NCT00841061|Dietary Supplement|electrolytic iron|1/4 a cup of cereal fortified with electrolytic iron per day between the ages of 112 days and 280 days of age
1835867|NCT00841061|Dietary Supplement|ferrous fumarate|1/4 cup of cereal fortified with ferrous fumarate to be fed per day between ages of 112 days and 280 days of age
1835868|NCT00841074|Drug|chlorhexidine|0.12% chlorhexidine mouthwash spray, ~1.3 ml, twice a day.
1835869|NCT00841074|Drug|Placebo mouthwash|Placebo mouthwash spray application of ~1.3 ml twice a day.
1835870|NCT00841087|Drug|insulin degludec|The insulin NN1250 (insulin degludec) injected subcutaneously at bedtime
1835871|NCT00841087|Drug|insulin detemir|Injection subcutaneously at bedtime
1835872|NCT00841087|Drug|insulin aspart|Injection subcutaneously immediately before each meal.
1835873|NCT00841100|Drug|Kuvan|20mg/kg/d, once daily
1835874|NCT00841113|Drug|Abarelix|100 mg by Intramuscular injection on days; 1, 15 and 29 and monthly thereafter
1837623|NCT00859989|Other|laboratory biomarker analysis|
1835875|NCT00841113|Drug|Goserelin plus Bicalutamide|Goserelin - 3.6 mg by monthly subcutaneous injection Biaclutamide 50 mg orally daily for first three months
1835876|NCT00841126|Drug|Magnesium iron hydroxycarbonate|500 mg tablets, administered orally: initial dosage 500 or 1000 mg (total daily dose 1500 or 3000 mg) depending on serum phosphate concentration, titrated to a maximum DAILY dose of 9000 mg). The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 3000 mg.
1835877|NCT00841126|Drug|Lanthanum carbonate|750 mg chewable tablets, administered orally: initial dosage 750 mg up to 3-times daily (total daily dose 2250 mg), titrated to a maximum SINGLE dose of 1500 mg (DAILY dose 3750 mg). The total daily dose should be divided and taken with meals.
1835878|NCT00841126|Drug|Placebo|0 mg (500 mg-size) tablets, administered orally: The total daily dose should be divided and taken with meals. Any SINGLE dose should not exceed 6 tablets.
1835879|NCT00841139|Drug|Perhexiline|100mg o bd
1835880|NCT00841139|Drug|Placebo|1 tablet bd
1835881|NCT00841152|Device|Bioactive glass|Surgical implantation
1835882|NCT00841152|Device|Beta-tricalcium phosphate (ChronOs)|Surgical implantation
1835883|NCT00841152|Procedure|Autograft|Surgical transplantation from iliac crest
1835884|NCT00841152|Procedure|Allograft (frozen femoral head)|Surgical transplantation
1835887|NCT00841178|Procedure|Surgery|Saphenopopliteal junction ligation, stripping of the Short Saphenous vein where possible, perforator ligation and ambulatory phlebectomy, where necessary.
1835888|NCT00841178|Procedure|EVLT|EVLT of the Short saphenous vein with perforator ligation and / or ambulatory phlebectomy as required.
1835889|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 2.8 milligram per kilogram (mg/kg) will be administered as 1-hour intravenous infusion (a fluid or a medicine delivered into a vein by way of a needle) on Day 1, Day 28, Day 42 and Day 56
1835890|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 5.5 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 42 and Day 56
1835891|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 11 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
1835892|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion on Day 1, Day 28, Day 49 and Day 70
1835893|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days
1835894|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with ovarian cancer.
1835895|NCT00841191|Drug|CNTO 328; Anti-interleukin-6 monoclonal antibody|Siltuximab 15 mg/kg will be administered as 1-hour intravenous infusion once every 21 days for up to a total of 231 days to participants with tumors harboring Kirsten rat sarcoma viral oncogene homolog (KRAS) mutations or pancreatic cancer, or non-small cell lung cancer (NSCLC), colorectal cancer (CRC), or head and neck (H&N) cancer that were refractory or resistant to anti-epidermal growth factor receptor (EGFR) therapy
1835896|NCT00841204|Drug|sulindac|Given orally
1835897|NCT00841204|Other|placebo|Inactive agent
1835898|NCT00841204|Other|laboratory biomarker analysis|Correlative studies
1835899|NCT00841217|Drug|GW501516|2.5mg/day
1835900|NCT00841217|Drug|placebo pill|
1835901|NCT00841230|Drug|Deanxit|Deanxit 1x/day
1835902|NCT00841230|Drug|Lactose placebo|Lactose used as placebo
1835903|NCT00841243|Dietary Supplement|Nutrison (Nutricia)|During 48 weeks of treatment, the patient will receive at T=0, 2, 4, 8, 12, 18, 24, 36, 48 weeks dietary advise combined with daily nutritional support in the form of a nutritional supplement drink at bedtime.
1835904|NCT00841256|Biological|Grass pollen allergens in a water/glycerol solution|In total up to 4 drops (dose for maintenance therapy) are administered under the tongue.
1835905|NCT00841256|Drug|Placebo|Placebo was given in the same way as the sublingual active treatment. Symptomatic standard treatment, i.e. antihistamines and glucocorticoids as well as alphamimetics is allowed during grass pollen season.
1835909|NCT00848419|Drug|Epidural administration of bolus|
1835910|NCT00848432|Drug|risperidone|Patients with schizophrenia who were clinically stabilized following an acute episode were randomly assigned to a 'maintenance group' (optimal therapeutic doses continued for at least 1 year), a 4-week group (optimal therapeutic doses continued for 4 weeks followed by a 50% dose reduction that was maintained for at least 11 months) or a 26-week group (optimal therapeutic doses continued for 26 weeks followed by a 50% dose reduction for at least another 6 months)
1835911|NCT00848445|Device|Guidant Pulsar Max II or Insignia Plus DR|market approved pacemaker. programmed per protocol
1835912|NCT00848445|Device|Atrial pacing preference turned on or off|programing changes in the device
1835913|NCT00848458|Other|Iontophoresis|iontophoresis with 15% azelaic acid gel twice weekly
1835914|NCT00848458|Other|Azelaic acid cream|topical treatment with 20% azelaic acid cream twice daily
1835915|NCT00848471|Device|Quark RMR|Quark RMR calorimeter (Cosmed)
1835916|NCT00848471|Device|Deltatrac II|Deltatrac II (GE health Care Clinical Systems)
1835917|NCT00848484|Drug|MK5757|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 25 mg capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 MK5757 50 mg capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days
1835918|NCT00848484|Drug|Comparator: Placebo|This is a 2 period, cross-over study. In each of the two treatment periods, each patient will receive the following: Days 1 and 28 MK5757 one placebo capsules three times a day (tid). Days 2 through 14 and Days 29 through 42 two MK5757 placebo capsules tid. Study drug is taken 3 times daily. Each treatment period is 14 days.
1835919|NCT00848497|Drug|Testim®|Testim® 5 g of gel (one tube) containing 50 mg of testosterone once daily. This was the dose given to the patient which he started.
1835920|NCT00848497|Other|Placebo Testim®|Placebo Testim® 5 g of gel (one tube)
1835921|NCT00848497|Drug|Viagra®|Viagra 25mg was the dose given to the patient which he started.
1835922|NCT00848510|Biological|EMD 525797|Abituzumab will be administered as an intravenous infusion for an hour at a dose of 250 milligram (mg) to 1500 mg at Weeks 1, 3 and 5. In case of clinical benefit (stable disease [SD], complete response [CR], or partial response [PR]) that will be assessed by the Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) during initial 6 Weeks, subjects will be allowed to continue treatment at the start of Week 7 at the given dose (250 mg or 500 mg or 1000 mg or 1500 mg) every second week until intolerance to treatment, withdrawal of consent, or the subject is no longer benefiting from treatment in the opinion of the Investigator.
1835923|NCT00848523|Drug|Panobinostat|30 mg, three times a week, patients will continue with treatment until they experience unacceptable toxicity that precludes further treatment, disease progression, and/or at the discretion of the investigator.
1835924|NCT00848536|Drug|Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
1835925|NCT00848536|Drug|Travoprost 0.004% (BAK-preserved) Eye Drops, Solution|One drop once daily in the evening for 3 months
1835926|NCT00848549|Drug|Zonisamide|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 500 mg; the minimum daily dose allowable is 200 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events, respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 100 mg per week.
1835927|NCT00848549|Drug|Carbamazepine|Subjects will start on the same dose that was achieved at the end of study E2090-E044-310. Maximum daily dose allowable is 1200 mg; the minimum daily dose allowable is 400 mg. During the study, subjects will be titrated up or down depending on seizure-free status or intolerability/adverse events respectively. Should a dose outside of the maximum be required the subject will be with drawn and gradually down titrated by 200 mg per week.
1835928|NCT00848562|Drug|Nicorandil|Oral administration of nicorandil (15 mg/day)
1835929|NCT00848575|Device|Flexible Endoscope|
1835930|NCT00848601|Drug|SGI-1776|Starting dose 100 mg (total daily dose) administer as 50 mg every 12 hours for 14 days of a 21-day cycle, dose escalation in successive cohorts until progression or toxicity develops
1835931|NCT00848627|Other|Specimen and questionnaires only|Specimen and questionnaires only
1835932|NCT00848640|Drug|Sorafenib|400 mg twice daily
1835933|NCT00848653|Device|CRT device|market approved CRT device
1835934|NCT00848666|Drug|Topical therapy|One time immersion of the feet in a liquid containing water, alcohol, vinegar, benzoic acid and salicylic acid for a total of 30 minutes.
1835935|NCT00848679|Drug|Epidural lidocaine|Epidural 2% lidocaine, administered in 5mL incremental boluses. Looking at dose-response effect.
1835936|NCT00848679|Drug|Epidural lidocaine 2%|5 x 5ml boluses of either epidural lidocaine 2% or epidural saline
1835937|NCT00848692|Drug|Rituximab|Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart
1835938|NCT00848692|Drug|Saline (NaCl 0,9 %) (placebo)|Two infusions of saline (NaCl 0,9 %) given two weeks apart
1835939|NCT00848705|Behavioral|YourWay Internet Intervention|The intervention is an 11 week program that teaches problem solving of barriers to self-management.
1835940|NCT00848718|Drug|MK-2206 combined with carboplatin + paclitaxel|MK-2206 given by mouth on days 1, 3, 5, and 7 of the 21 day cycle (30 mg, 45 mg, or 60 mg) OR MK-2206 given by mouth on Day 1 of the 21 day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg). On Day 1 of each 21 Day cycle, carboplatin + paclitaxel is given intravenously.
1835941|NCT00848718|Drug|MK-2206 combined with docetaxel|MK-2206 given by mouth on days 1, 3, 5, and 7 of the 21 day cycle (either 45 mg or 60 mg) (this dosing schedule is no longer enrolling). MK-2206 given by mouth on Day 1 of the 21 day cycle (60 mg, 90 mg, 135 mg, 200 mg , or 250 mg). On day 1 of each 21 day cycle, docetaxel is given intravenously. In this treatment arm, an oral corticosteroid is to be taken by mouth every day.
1835942|NCT00848718|Drug|MK-2206 combined with erlotinib|MK-2206 given by mouth every other day (30 mg, 45 mg or 60 mg) OR MK-2206 given by mouth on Days 1, 8, and 15 of the 21 day cycle (90 mg, 135 mg, or 200 mg). In addition, erlotinib is given daily by mouth in a continuous 21 day cycle for the duration of the study.
1835943|NCT00848913|Other|Rehabilitation with strength training|Basic mobility and exercise therapy following a guideline with 12 specific exercises, progressed individually, and supplemented with progressive knee-extension strength training (10RM) of the fractured limb using ankle weight cuffs, daily during hospital stay.
1835944|NCT00848913|Other|Rehabilitation without strength training|Basic mobility and exercise therapy without strength training following a guideline with 12 specific exercises, progressed individually.
1835945|NCT00848926|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by intravenous infusion
1835946|NCT00848939|Drug|treprostinil diethanolamine|Cohort 1: Single 1 mg treprostinil diethanolamine sustained release tablet dose
1835947|NCT00848939|Drug|treprostinil diethanolamine|Cohort 2: treprostinil diethanolamine sustained release doses will be escalated up to a target dose of 4 mg BID
1835948|NCT00848952|Other|3 imaging techniques are done|all patients have : MRI, CTscanner, enhanced contrast ultrasound
1835949|NCT00848965|Drug|Fluticasone propionate|Corticosteriod, with anti-inflammatory effects
1835950|NCT00848965|Drug|Placebo|Placebo comparator
1835951|NCT00848978|Behavioral|8-week aerobic and strength training program|Participants allocated in the intervention group will be enrolled in three weekly non-consecutive training sessions for 8 weeks. Each session will last for about 45-50 min. The exercise program will consist of muscular strength and aerobic exercises. Each session will start and end with a low intensity ~5-7 min warm-up and cool-down period respectively, consisting mainly of stretching exercises involving all major muscle groups.
1837624|NCT00859989|Other|questionnaire administration|
1835952|NCT00848991|Drug|Precedex|Subjects randomized to the comparison group will receive a standardized general anesthetic. Anesthesia will be induced with propofol 1.5 ? 2.5 mg/kg, rocuronium 0.6 mg/kg, and sufentanil 0.1 ? 1mcg/kg. Anesthesia will be maintained with an infusion with propofol 25 -200 mcg/kg/min, sufentanil 0.0025 - 0.03 mcg/kg/min, and zemuron as needed. For the Precedex group the drug will be infused at 0.3-0.7 mcg/kg/hr. Blood pressure will be maintained within 10% of baseline prior to opening of the dura, subsequently to be maintained between a systolic of 100 ? 130 mmHg. Hypertension will be managed with standardized amounts of labetalol and nicardipine. Morphine will be titrated as needed to a maximum of 0.05mcg/kg at the conclusion of case. Hemodynamic data and emergence evaluations will be collected in the operating room, pre-induction until the end of anesthesia and discharge from the operating room. There will be no further follow up.
1835953|NCT00848991|Drug|Propofol|evaulation of propofol for emergence from anesthesia
1835954|NCT00849004|Other|silicone gel|silicone gel
1835955|NCT00849004|Other|silicone sheet|silicone sheet
1835956|NCT00849004|Other|paper tape|paper tape
1835957|NCT00849017|Biological|albiglutide|albiglutide weekly injection
1835958|NCT00849017|Biological|albiglutide uptitration|albiglutide uptitration at week 12
1835959|NCT00849017|Biological|placebo|matching albiglutide placebo weekly injection
1835960|NCT00849030|Drug|Anastozole (Arimidex)|1mg, orally, once daily
1835961|NCT00849030|Drug|Tamoxifen (Nolvadex)|20mg, orally, once daily
1835962|NCT00849030|Drug|Anastozole (Arimidex) placebo|1mg, orally, once daily
1835963|NCT00849030|Drug|Tamoxifen (Nolvadex) placebo|20mg, orally, once daily
1835964|NCT00849056|Biological|albiglutide|albiglutide weekly subcutaneous injection
1835965|NCT00849056|Drug|placebo|placebo weekly subcutaneous injection
1835968|NCT00849082|Drug|cyproterone acetate|
1835969|NCT00849082|Drug|goserelin acetate|
1835970|NCT00849082|Radiation|radiation therapy|
1835971|NCT00849095|Drug|budesonide/formoterol combination (PRN)|budesonide/formoterol combination 160/4.5 mcg 1 inhalation used as needed for a period of 52 weeks
1835972|NCT00849095|Drug|budesonide/formoterol combination|budesonide/formoterol 160/4.5 mcg 1 inhalation bid
1835973|NCT00849095|Drug|placebo|bid inhaled placebo
1835974|NCT00849095|Drug|terbutaline|as needed terbutaline 500 mcg for a period of 52 weeks
1835975|NCT00849108|Drug|BMS747158|"dosages at rest and at stress were not to exceed a total of 14 mCi.
Cohort 1: Patients received either 2 or 3 IV bolus injections of BMS747158: 1 at rest and 1 or 2 during stress, over a 1-day or 2-day period.
Cohort 2: Patients to recieve IV bolus injections of BMS747158:
For the Pharmacologic (Adenosine) Stress:
Doses at rest were to range between 2.9 and 3.4 mCi.
Doses under stress were to be a factor of 2.0 to 2.4 greater than the rest dose, resulting in a range of stress doses between 5.8 and 8.2 mCi.
For the Exercise Stress:
Doses at rest were to range between 1.7 and 2.0 mCi.
Doses under stress were to be a factor of 3.0 to 3.6 greater than the rest dose, resulting in a range between 5.1 and 7.2 mCi."
1835976|NCT00849121|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for 6 total doses, followed by pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. every 3 months until radiographic disease progression
1835977|NCT00849121|Biological|pTVG-HP with rhGM-CSF|pTVG-HP (100 µg) with rhGM-CSF (200 µg) administered i.d. biweekly for a minimum of 6 total doses, and continuing biweekly until evidence of T-cell immune response, and then following a booster schedule as defined by evidence of T-cell immune response.
1835978|NCT00849134|Drug|GSK1482160 or placebo|GSK1482160 is a P2X7 receptor antagonist
1835979|NCT00849147|Biological|Haploidentical Bone Marrow Transplantation|"The transplant preparative regimen is listed below. The - sign is the number of days before the transplant.
Fludarabine: 30 mg/m2 intravenously (IV) on Days -6, -5, -4, -3, and -2
Cyclophosphamide (Cy): 14.5 mg/kg IV on Days -6 and -5
Total body irradiation (TBI): 200 centigray (cGy) on Day -1
Day 0 is the day of the infusion of non-T-cell depleted bone marrow. The bone marrow will be obtained from haploidentical related donor."
1835980|NCT00849147|Biological|GVHD prophylaxis|"The GVHD prophylaxis regimen will consist of the following:
Cy: 50 mg/kg IV on Days 3 and 4
Tacrolimus: (IV or orally) beginning on Day 5 with dose adjusted to maintain a level of 5 to 15 mg/mL
Mycophenolate mofetil (MMF): 15 mg/kg orally three times a day (TID) beginning on Day 5; maximum dose will be 1 g orally TID
Granulocyte-colony stimulating factor (G-CSF) 5 mcg/kg/day beginning on Day 5 until absolute neutrophil count (ANC) is greater than or equal to 1,000/mm^3 for 3 consecutive days"
1835981|NCT00849160|Drug|darunavir|darunavir/r 800/100 mg once daily by oral route, 48 weeks of treatment
1835982|NCT00849186|Drug|sunitinib malate|oral
1835983|NCT00849186|Procedure|neoadjuvant therapy|IV
1835984|NCT00849186|Procedure|therapeutic conventional surgery|Surgery
1835985|NCT00849212|Drug|E2007|The dose of E2007 will start from 2 mg and will be increased by 2 mg every week up to 12 mg (the maximum dose). The dose will be adjusted during 6 weeks (i.e., titration period). Subsequently, the dose will be fixed and maintained during 4 weeks (Maintenance period). Patients must visit study site at Weeks -4, 1, 2, 3, 4, 5, 6, 8, 10 and 14 to confirm.
1835986|NCT00849238|Drug|mycophenolate mofetil|
1835987|NCT00849251|Drug|cyclophosphamide|Given IV or PO
1835988|NCT00849251|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
1835989|NCT00849251|Drug|bortezomib|Given IV
1835990|NCT00849251|Drug|dexamethasone|Given IV or PO
1835991|NCT00849264|Drug|chemotherapy with endostar|15mg/d×14d
1835992|NCT00849264|Drug|treatment with CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d
1835993|NCT00849264|Drug|treatment with endostar, CBP and 5-FU|CBP 300mg/d×2d，5-FU 1000mg/d×5d ，Endostar 15mg/d×14d
1835994|NCT00849277|Drug|Lactobacillus casei Shirota|
1835995|NCT00849290|Biological|APC8015F|APC8015F is an autologous active cellular immunotherapy product designed to stimulate an immune response against prostate cancer. APC8015F consists of autologous peripheral blood mononuclear cells (PBMCs), including antigen presenting cells (APCs), that have been activated in vitro with a recombinant fusion protein.
1836108|NCT00850252|Device|Lifeline|Surgical arteriovenous fistula formation with the use of Lifeline blood vessel
1835996|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts within 10 days since stroke onset.
1835997|NCT00849303|Other|gait-oriented rehabilitation|Patients practise walking every workday for 60 min (actual 30min) either on a treadmill or on a gait trainer for four weeks, and receive also other physiotherapy 60 min daily.Patients starts five weeks after stroke onset.
1835998|NCT00849316|Drug|insulin aspart|Safety and effectiveness data collection in connection with the use of the drug NovoRapid™ in patients with coexisting diabetes and chronic kidney disease in daily clinical practice.
1835999|NCT00849329|Drug|lapatinib|1250mg lapatinib
1836000|NCT00849329|Drug|lapatinib plus esomeprazole|1250mg lapatinib plus esomeprazole 40mg
1836001|NCT00849342|Drug|insulin detemir|Safety and effectiveness (weight and HbA1c) data collection in connection with the use of the drug Levemir® in daily clinical practice.
1836002|NCT00849355|Drug|RCOMP-14 + rituximab|"Pretreatment: vincristine 1mg at day -6 and Methylprednisolone 100 mg from -6 to day 0.
Treatment: rituximab 375m/m2 + ciclophosphamide 750 mg/m2 + Vincristine 1.4 mg/m2 + Doxorrubicine 50 mg/m2 at day 1 and every 14d. Prednisone 100 mg/d from day 1 to 5 and every 14 d."
1836003|NCT00849368|Drug|Azathioprine / Allopurinol|"Both drugs are applied orally. A pre-specified dose escalation regimen will be chosen.
Azathioprine: Imurek (R) 50 mg and 25 mg tablets
Allopurinol: Mephanol (R) 100 mg tablets"
1836004|NCT00849381|Biological|GSK580299, GSK Biological's HPV vaccine|All subjects will receive 3 doses administered as an intramuscular injection, according to a 0, 1, 6-month schedule.
1836005|NCT00849446|Device|Activity monitor (SenseWear Pro armband)|Activity monitoring during specific physical activities such as walking at different speeds
1836006|NCT00849459|Biological|adenovirus-mediated human interleukin-12|"The purified ADV-hIL12 is suspended in formulation buffer (10mM Tris, pH 7.5/
1mM MgCl2/ 150mM NaCl/ 10% glycerol) and aliquoted into 1ml cryovials. The filled vials are stored at or below -60 degC."
1836007|NCT00849472|Drug|doxorubicin + cyclophosphamide|4 cycles of doxorubicin + cyclophosphamide followed by 4 cycles of paclitaxel + pazopanib.
1836008|NCT00849472|Drug|paclitaxel + pazopanib|4 cycles of paclitaxel + pazopanib
1836009|NCT00849472|Procedure|surgery|neoadjuvant surgery for breast cancer
1836010|NCT00849472|Drug|pazopanib monotherapy|6 months of treatment with pazopanib monotherapy
1836011|NCT00849485|Drug|Levetiracetam|750 mg Tablet
1836012|NCT00849485|Drug|Keppra®|750 mg Tablet
1836013|NCT00849511|Drug|melatonin|Circadin (melatonin) 2 mg ret. TAB vesp. for 8 weeks
1836014|NCT00849524|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
1836015|NCT00849537|Drug|Triamcinolone|Injection of intravitreal Triamcinolone
1836016|NCT00849550|Drug|capecitabine/oxaliplatin/bevacizumab/RAD001 (XELOX-A-Ev)|bevacizumab IV, capecitabine oral, oxaliplatin IV, RAD001 oral
1836017|NCT00849563|Other|Standardized Risk Assessment|patients interested in genetic testing will be randomly assigned to either get testing for type 2 diabetes or not. All arms with receive standardized risk asessements. This study is evaluating behavior after receipt of genetic risk information and different types of counseling.
1836018|NCT00849576|Drug|Regular Human Insulin|0.10 U/Kg- 15 minutes before ingestion of a standardized liquid meal.
1836019|NCT00849576|Drug|Insulin Lispro|90% of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal.
1836020|NCT00849576|Drug|Insulin VIAject™ (75%)|75 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
1836021|NCT00849576|Drug|Insulin VIAject™ (90%)|90 % of Regular Human Insulin dose administer immediately before ingestion of a standardized liquid meal
1836022|NCT00849589|Behavioral|Computerized screening and brief physician advice|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors
1836023|NCT00849589|Behavioral|Computerized SBA with technological extenders|Participants complete screening for alcohol use and other health risk behaviors on the computer, receive some related health information on the computer, and meet with a primary care provider for a short discussion of health risk behaviors. In addition, the provider sends them a brief email or text message at 4 months and 9 months after study entry to reinforce the brief advice.
1836024|NCT00849602|Drug|Placebo|Placebo bid for three days
1836025|NCT00849602|Drug|Chloroquine|Chloroquine bid for three days
1836026|NCT00849615|Drug|Docetaxel|50mg/m2 qd15
1836027|NCT00849615|Drug|5-Fluorouracil|2600mg/m2 qd15
1836028|NCT00849615|Drug|Oxaliplatin|85mg/m2 qd15
1836029|NCT00849615|Drug|folinic acid|200mg/m2 qd15
1836030|NCT00849654|Drug|PCI-32765|"In the dose-escalation cohorts, PCI-32765 will be administered in 1.25, 2.5, 5.0, 8.3, 12.5, and 17.5 mg/kg/d dose orally once per day for 28 days followed by a 7-day rest period to determine the MTD. If MTD is not reached, dosing levels may be increased beyond 17.5mg/kg/d by 33% increments.
In the continuous dosing cohorts, PCI-32765 will be administered in 8.3 mg/kg/day and 560 mg/day (fixed dose) dose orally once per day for 35 days."
1836031|NCT00849667|Drug|MORAb-003 (farletuzumab)|MORAb-003 1.25 mg/kg infusions will take place weekly during combination therapy and then as single agent maintenance until progression.
1836032|NCT00849667|Drug|MORAb-003 (farletuzumab)|MORAb-003 2.5mg/kg infusions will take place weekly during combination therapy and then as single agent maintenance until progression.
1836033|NCT00849667|Drug|0.9% Saline|0.9% infusions will take place weekly during combination therapy and then as single agent maintenance until progression.
1836034|NCT00849680|Other|Comparator: Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine|Placebo to the MRKAd5 HIV-1 gag/pol/nef vaccine.
1836035|NCT00849680|Biological|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)|Monovalent MRKAd5 HIV-1 gag vaccine (1x10^9 vp/dose)
1836036|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^6 vp/dose)
1836109|NCT00850265|Device|Volumatic spacer|A spacer is a plastic device to inhaler medication
1836037|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^7 vp/dose)
1836038|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^8 vp/dose)
1836039|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^9 vp/dose)
1836040|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (3x10^10 vp/dose)
1836041|NCT00849680|Biological|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)|Trivalent MRKAd5 HIV-1 gag/pol/nef vaccine (1x10^11 vp/dose)
1836042|NCT00849680|Biological|Comparator: Placebo to MRKAd5 HIV-1 gag vaccine|Placebo to the MRKAd5 HIV-1 gag vaccine.
1836043|NCT00849693|Drug|Placebo|Capsules identical in appearance, color, taste, and smell to study drug, orally, once daily for 10 weeks (acute treatment phase)
1836044|NCT00849693|Drug|fluoxetine|20 milligram (mg) orally, once daily for 10 weeks (acute treatment phase) and 20-40 mg orally, once daily for additional 6 months (extension phase)
1836045|NCT00849693|Drug|duloxetine|60 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
1836046|NCT00849693|Drug|duloxetine|30 mg orally, once daily for 10 weeks (acute treatment phase) and 60-120 mg orally, once daily for additional 6 months (extension phase)
1836047|NCT00849706|Other|Study participants will work their regular shifts, and tested after night shifts.No shifts will be added because of the study.|Night shifts in our medical center are working 8 hours from 23:00 to 7:00 the following day for nurses, and working overnight (24h) for doctors.
1836048|NCT00849719|Drug|a combination of PCA MO and continuous infusion of MO|Patients in this arm will recieve a combination of PCA MO (10 ug/kg/bolus, by request) and continuous infusion of MO (10 ug/kg/h), when visual analog scale (VAS) exeeds 5/10 boluses will be self-administered by the patient. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
1836049|NCT00849719|Drug|PCA MO only|When visual analog scale [VAS] exeeds 5/10, and after the PACU drug-blinded attending physician had established that the patient is coherent and cooperative, a PCA system will be connected to the patient's IV line. The physician will start device, and deliver the first bolus. The subsequent drug boluses will be self-administered by the patient. Group 2 will be administered with only boluses of 1.5 mg/bolus of MO, by request. Rescue diclofenac 75 mg IM will be allowed once to help prompt start analgesia instead of opioid titration, and 6h later. No hourly dose limit will be set for the protocols.
1836050|NCT00849732|Biological|V520|Intentionally Blank
1836051|NCT00849732|Biological|Comparator: V520 (1x10^9 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^9 vp/d given at Day 1, Week 4, and Week 26
1836052|NCT00849732|Biological|Comparator: V520 (1x10^10 vp/d)|1.0 mL intramuscular injection of MRKAd5 HIV-1 gag vaccine at 1x10^10 vp/d given at Day 1, Week 4, and Week 26
1836053|NCT00849732|Biological|Comparator: Placebo|Placebo to MRKAd5 HIV-1 gag vaccine 1.0 mL intramuscular injection given at Day 1, Week 4, and Week 26
1836054|NCT00849745|Procedure|Nonmyeloablative allogeneic stem cell transplant|Prior to receiving Campath-1H, patients will be premedicated with Benadryl 50 mg IV or PO, and acetaminophen 650 mg orally. Hydrocortisone 100 mg IV is given on the first day of Campath. The preparative regimen will begin on day -5 and consist of 4 days of daily fludarabine at 30 mg/m2/d infused over 30 minutes, cyclophosphamide 500 mg/m2/d infused over 1 hour, 5 days of Campath-1H at 20 mg/d in 250 ml of D5 normal saline or normal saline infused over 3 hours. The mixed dosage of chemotherapy may be rounded off to within +/- 5% of the calculated dose, and doses of fludarabine and cyclophosphamide will be based on adjusted ideal body weight. IV hydration and diuretics will be used to maintain adequate urine output during and after administration of cyclophosphamide.
1836055|NCT00849797|Drug|Oxcarbazepine|600 mg Tablet
1836056|NCT00849797|Drug|Trileptal®|600 mg Tablet
1836057|NCT00849810|Drug|Metoprolol|Metoprolol tablets 25-200 mg daily times four weeks. Nebivolol daily for 4-5 weeks
1836058|NCT00849810|Drug|Nebivolol|5 - 20 mg daily, at a stable dose for 4 to 5 weeks
1836059|NCT00849823|Behavioral|Male Sexual Health Program|"An attention equivalent control condition entailing a 60-minute one-to-one session that will didactically teach teens about several aspects of male sexual health. The content and objectives are related only to knowledge acquisition. In addition to this program, teens randomized to the control condition will receive standard-of-care services from the clinic. This involves the provision of free condoms (one size fits all condoms) and a brief (nurse-delivered) counseling message to practice safer sex."
1836060|NCT00849823|Behavioral|Focus on the Future Program|A 60-minute, theory-guided program designed to increase the quality and frequency of teens' condom use within the context of making safer choices regarding partners and sexual behaviors. The program is explicitly designed to increase the quality and frequency of teen's condom use.
1836061|NCT00849862|Drug|Levetiracetam|750 mg Tablet
1836062|NCT00849862|Drug|Keppra®|750 mg Tablet
1836063|NCT00849875|Biological|Immunotherapeutic GSK2132231A|Intramuscular administration
1836064|NCT00849875|Drug|Dacarbazine|Intravenous administration Chemotherapy
1836065|NCT00849888|Biological|Serum Free Thymus Transplantation with Immunosuppression|Cyclosporine pre-transplant (trough 180-220ng/ml) until naive T cells develop. Subjects >4,000/cumm T cells, pre-transplant methylprednisolone or prednisolone 1-2mg/kg/day. All subjects pre-transplant days -5,-4,-3: 3 doses 2mg/kg rabbit anti-thymocyte globulin. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects, FBS cultured thymus is transplanted in 1 leg & serum free (SF) in other. After first 2 subjects >10% naïve T cells, 3rd receives only SF thymus. After 3rd subject >10%naive T cells, 4th subject transplanted. Thymus dose 4-18 grams/m2 body surface area. Thymus biopsy 8-12 weeks post-transplant. Skin biopsy at time of transplant & thymus biopsy. Followed by immune evaluations.
1836105|NCT00850226|Behavioral|ACT|Acceptance-and-Commitment Therapy Intervention: Subjects receiving the ACT strategies will be taught to defuse from their anxiety (or recognize that their thoughts are just thoughts). They will be taught to accept their anxiety and to learn to live with anxiety. Subjects will be told that while they cannot control the occurrence of their thoughts, they can control whether or not they choose to view them as separate from the self versus part of the self.
1836066|NCT00849888|Other|Serum Free Thymus Transplantation without immunosuppression|Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Transplant under general anesthesia into quadriceps. First 2 subjects: FBS cultured thymus transplanted in 1 leg & serum free cultured thymus in other leg. After first 2 subjects have thymopoiesis in serum-free biopsy, >10% naïve T cells, 3rd subject receives only serum free cultured thymus. After 3rd subject >10% naive T cells, 4th subject receives transplant of only serum free cultured thymus. Dose 4-18grams/m2 body surface area. At time of transplant, skin biopsy. Allograft biopsy & skin biopsy done 8 to 12 weeks post-transplant. (Graft biopsy not done if subject medically unstable.) Post-transplant, subjects followed by immune evaluations, using blood samples, for two years.
1836067|NCT00849901|Drug|duloxetine|30-120 mg, PO, QD, for up to 38 weeks
1836068|NCT00849901|Drug|Placebo|Capsules identical in appearance, color, taste and smell to study drug, orally (PO), once daily (QD). Dose: placebo, 6 capsules, QD for 10 weeks
1836069|NCT00849901|Drug|fluoxetine|10-40 milligram (mg), PO, QD, for up to 38 weeks
1836070|NCT00849940|Device|CAS NIRS FORE-SIGHT oximeter|Comparison of non-invasive tissue oxygen saturation with blood sample-derived (calculated) tissue oxygen saturation.
1836071|NCT00849966|Drug|Celebrex suspension|"Patients will be randomized to receive celecoxib suspension 6 mg/kg one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of celecoxib (3 mg/kg) to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.
All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
1836072|NCT00849966|Drug|Placebo|"Patients will be randomized to receive placebo by mouth one hour prior to their scheduled surgery. In addition the patient will receive seven weight-based doses of the placebo to be administered every 10-12 hours while the child is awake; the first dose being administered the evening of surgery.
All participants will receive undergo and post surgery anesthetic treatment according to the usual standards of practice at CHEO."
1836073|NCT00849979|Behavioral|Questionnaire|Day 1 MDASI-GI Questionnaire
1836074|NCT00849979|Other|Interview|Open-ended, audiotaped interviews
1836075|NCT00849992|Drug|Imiquimod 5%|Imiquimod 5% cream used three days a week for 4 weeks
1836076|NCT00849992|Procedure|Photodynamic therapy|Photodynamic therapy involves applying Metvix cream to the affected area followed by illumination. It will be done twice during the study at a 2 week interval.
1836077|NCT00850005|Biological|Intravenous immunoglobulin|2 g/kg divided over five days
1836078|NCT00850005|Biological|Normal Saline|Same volume as experimental arm
1836079|NCT00850018|Procedure|Monthly blood transfusion regimen|Participants will receive blood transfusions at 3- to 4-week intervals for 6 months for the treatment of SCD-related anemia; the total number of transfusions that participants will receive will vary between six and eight.
1836080|NCT00850018|Behavioral|Usual care|Participants will receive usual care for the treatment of SCD.
1836081|NCT00850031|Device|AcuFocus Corneal Inlay|Inlay implanted in cornea for improvement of near vision
1836082|NCT00850044|Drug|ABT-450|capsules,QD, one dose, see Arm Descriptions for more information
1836083|NCT00850044|Drug|ritonavir|capsules, QD, one dose, escalating doses, see Arm Descriptions for more information
1836084|NCT00850044|Drug|placebo for ABT-450|capsules, QD, one dose
1836085|NCT00850044|Drug|Placebo for ritonavir|capsules, QD, one dose
1836086|NCT00850057|Biological|Intranodal injection of Ad-ISF35|Ad-ISF35, a replication-defective recombinant type V adenovirus encoding a recombinant humanized CD154 homolog (ISF35).
1836087|NCT00850070|Drug|sapropterin|Patients will receive sapropterin 20 mg per kilogram per day for 16 weeks
1836088|NCT00850070|Drug|Placebo|Patients will receive a placebo identical in form and dosage to the active drug daily for 16 weeks.
1836089|NCT00850096|Other|Placebo for Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two placebo sprays administered three times daily just prior to meals for 6 weeks.
1836090|NCT00850096|Drug|Nasulin|Basal insulin (glargine) administered as a 1x daily injection in the morning and two (50 IU) or four (100 IU) sprays of Nasulin (intranasal insulin spray 1%) administered three times daily just prior to meals for 6 weeks.
1836091|NCT00850122|Drug|cefazolin|"Cefazolin dosing - administered for 48 hours Dosage
≤28 days of age 25 mg/kg IV q12 29-120 days of age 25 mg/kg IV q8"
1836092|NCT00850135|Device|The Seven Continuous Glucose Monitoring System|Between 24-28 weeks of gestation, the recommended period of glucola testing, a soft sensor for continuous glucose monitoring system (CGMS) will be inserted superficially under the skin. The patient will be instructed on how to wear and care for the device. She will wear the CGMS for 7 days, then return to the clinic for removal of the device, and downloading of the data. Finger stick blood glucoses will be checked by the patient 2 times daily during the 7 days of wearing the CGMS.
1836093|NCT00850148|Procedure|Anwar|Anwar surgical method
1836094|NCT00850148|Procedure|Melles|Melles surgical method
1836095|NCT00850161|Drug|aspart|Meal-time insulin. Administered subcutaneously based on routine clinical therapy.
1836096|NCT00850161|Drug|Nasulin™|100 IU(2 puffs in each nostril)
1836097|NCT00850174|Drug|Oxcarbazepine|600 mg Tablet
1836098|NCT00850174|Drug|Trileptal®|600 mg Tablet
1836099|NCT00850187|Biological|Bone marrow derived mesenchymal stem cells|Bone Marrow Aspiration A total volume of 300 ml bone marrow will be aspirated from the iliac crest and are cultured for mesenchymal stem cells
1836100|NCT00850200|Radiation|Proton Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
1836101|NCT00850200|Radiation|Conventional Photon Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
1836102|NCT00850200|Radiation|Intensity Modulated Radiation Plan|Between 21-39.6 Gy/CGE to the PTV
1836103|NCT00850213|Device|Endeavor Resolute Stent|Single implantation
1836104|NCT00850226|Behavioral|CT|Cognitive Therapy Intervention: Subjects receiving the CT strategies will be taught to restructure their negative thoughts to make them more positive, based on the concept that thoughts are linked to their problems with test anxiety because beliefs can cause strong powerful emotions and behaviors. Subjects will be taught not to blame their environments for emotional and behavioral responses, and they will be shown how to change their beliefs in order to affect their emotions and their behaviors.
1836106|NCT00850239|Drug|dutogliptin|400 mg
1836107|NCT00850239|Drug|placebo|
1836110|NCT00850278|Other|FLT-PET imaging|Prior to surgical resection, patient will undergo [11C]MET PET imaging, [18F]FLT PET imaging, MRI, and spectroscopy imaging.
1836111|NCT00850304|Drug|Cytosar|Cytosar 20 mg /q12h/ sc/10d/q28d for 2 cycle
1836112|NCT00850304|Drug|Arsenic trioxide|Arsenic trioxide 10mg/infusion2h/iv/DW5% d1-d5,d7-d11
1836113|NCT00850330|Other|on line software to detect DI early on|Patients hospital records will be reviewed on the day of admission to assess all their indication using on line software to early detect drug interactions.
1836114|NCT00850343|Drug|Certolizumab pegol|Subcutaneous (SC) injection
1836115|NCT00850369|Other|RBC transfusion|Study subjects will receive monthly transfusions with 2 units of red blood cells
1836116|NCT00850382|Drug|Dasatinib|"Induction cycle(s):
Dasatinib 100 mg QD on days 8-21.
Consolidation Cycles 1, 2, 3, 4:
Patients will receive dasatinib 100 mg QD on days 6-28.
Maintenance therapy:
Patients completing consolidation therapy will continue to receive single agent dasatinib 100 mg QD for one year (or until relapse)."
1836117|NCT00850382|Drug|daunorubicin|"Induction cycle(s):
Daunorubicin 60 mg/m2/day administered on days 1 through 3"
1836118|NCT00850382|Drug|Cytarabine|"Induction cycle(s):
Cytarabine 200 mg/m2/day administered by continuous IV infusion daily for 7 days (days 1 through 7).
Consolidation cycles 1, 2, 3, 4:
Consolidation therapy consists of high-dose cytarabine 3 g/m2 (>60 years: 1 g/m2) q12h, d 1, 3, 5, administered intravenously over three hours."
1836119|NCT00850395|Drug|maraviroc|No intervention; any procedure at the discretion of the treating physician, in line with the SmPC
1836120|NCT00850408|Procedure|Repetitive Transcranial Magnetic Stimulation|For real rTMS,1200 pulses will be delivered at a frequency of 1Hz, with an intensity equal to the 115% of the motor threshold as established at baseline. For Sham rTMS, procedures will be identical to those used for real rTMS with the exception that a placebo coil will be used, which provides acoustic and sensory stimulation like the real coil but does not stimulate neural tissue. 20-minute Real and Sham stimulation sessions will be administered bi-weekly for a period of 4 weeks
1836121|NCT00850421|Drug|Botulinum Toxin Type A|100 Units - Dilution: 25U/ml (4:1 BOTOX/preservative free saline)
1836122|NCT00850447|Other|Cognitive Remediation Therapy|Cognitive Remediation Therapy (CRT) is a standardized intervention that involves performing cognitive exercises to improve attention, processing speed, and memory through practice. Participants will have one 60-minute CRT session each week for ten weeks. The CRT to be used in the proposed study is CogPack (version 6.0 Marker Software, Mannheim Germany). CogPack demonstrates flexibility in terms of developing a targeted intervention plan based on the levels of baseline cognitive impairment. There are approximately 6 different exercises presented in each training session, with the starting level of difficulty individualized on the basis of baseline neuropsychological performance.
1836123|NCT00850447|Other|Videogame|Participants will play the videogame Tetris once each week for 30 minutes. Tetris is a video puzzle game that involves manipulating falling shapes. The object of the game is to manipulate these shapes, by moving them sideways or rotating them, to create a horizontal line of blocks without gaps. As the game progresses, the shapes fall faster.
1836124|NCT00850460|Drug|Statins|Subjects will be randomized to continue their statin dosage or placebo for 8 weeks. They will stay on the same dosage as prescribed by their physician. Usual dosage for atorvastatin 10-80 mg/tab once daily by mouth; simvastatin 20-80 mg/tab once daily by mouth; pravastatin 10-80 mg/tab once daily by mouth; rosuvastatin 5-20 mg/tab once daily by mouth.
1836125|NCT00850460|Drug|Placebo|Placebo pills will consist of lactose and will be given one capsule once daily
1836126|NCT00850473|Radiation|Positron Emission Tomography|image scan. approximately 1 hour
1836127|NCT00850473|Radiation|18F-2-fluoro-2-deoxy-D-glucose fluorodeoxyglucose|maximum of 10mCi of 18F-FDG will be injected for imaging purposes
1836128|NCT00850473|Radiation|Computed Tomography|image scan
1836129|NCT00850473|Drug|CT Contrast Dye|used for obtaining images. weight based dose
1836130|NCT00850486|Device|Exercise test with HyperQ technology|High frequency components of the QRS complex within the ECG signal are analyzed off-line to provide an indication of ischemia induced depolarization abnormalities
1836131|NCT00850499|Drug|fludarabine|fludarabine 40mg/m2/day orally on Days 1 to 5 of every 35-day cycle
1836132|NCT00850499|Drug|rituximab|rituximab 375mg/m2 on Day 1 of every 35-day cycle
1836133|NCT00850499|Drug|VELCADE|1.6 mg/m2 intravenously (IV) on Days 1, 8, 15, and 22 of every 35-day cycle
1836134|NCT00850512|Drug|CHOP21-R|Four months for CHOP21-R and two treatment days one week apart
1836135|NCT00850512|Drug|Zevalin|12-week safety period for Zevalin
1836136|NCT00850538|Radiation|MRI|1.5T MRI exam of signal knee with knee coil (estimated time: 35 minutes)
1836137|NCT00850538|Procedure|Primary Total Knee Replacement|Fluid, bone, and meniscus specimens obtained from total joint replacement will be collected.
1836138|NCT00850551|Other|Early Intervention|Twice a week home spirometry and symptom assessment
1836139|NCT00850564|Drug|Growth Hormone Releasing Hormone (Tesamorelin)|Tesamorelin 2mg subcutaneous daily x 2 weeks
1836140|NCT00850577|Drug|Paclitaxel|Solution, IV, 200 mg/m2, Q21days, 6 cycles
1836141|NCT00850577|Drug|Carboplatin|Solution, IV, AUC=6, Q21days, 6 cycles
1836142|NCT00850577|Drug|CT-322|Solution, IV, 2 mg/kg, Q7days, Until PD
1836143|NCT00850577|Drug|Bevacizumab|Solution, IV, 15 mg/kg, Q21days, Until PD
1836144|NCT00850577|Drug|Bevacizumab placebo (ie saline solution)|Solution, IV, 0 mg/kg, On days 8 and 15 of a 3-weekly cycle, Until PD
1836145|NCT00850590|Drug|NRL001|Four single doses of NRL001 or placebo. NRL001 is administered at lower (5, 7.5 and 10 mg) or higher (10, 12.5 and 15 mg) doses in a slow release rectal suppository weighing either 1 g or 2 g.
1836146|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.5 mL, Subcutaneous
1836147|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Subcutaneous
1836148|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.05 mL, Intradermal
1836149|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.1 mL, Intradermal
1836150|NCT00850603|Biological|Meningococcal Polysaccharide Groups A\C\Y\W-135 Combined|0.15 mL, Intradermal
1836151|NCT00850616|Biological|V526|0.5 mL intramuscular injections of MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4 and Week 26.
1836152|NCT00850616|Biological|Comparator: Placebo to V526|0.5 mL intramuscular injections of placebo to MRKAd5+6 trigene vaccine (V526) in a 3-dose regimen on Day 1, Week 4, and Week 26.
1836153|NCT00850629|Behavioral|multimodal lifestyle intervention|After an initial weight loss, the weight regain will be measured during multimodal lifestyle intervention in children, adolescents and adults
1836154|NCT00850629|Behavioral|placebo|no intervention, only follow up
1836157|NCT00850668|Biological|E. Coli-Encapsulated, Recombinant Modified Peanut Proteins Ara h 1, Ara h 2, and Ara h 3|Up to 7 mL solution administered rectally
1836158|NCT00850681|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
1836159|NCT00850720|Other|Blood draws|Samples of blood to be drawn before surgery, and nine hours after surgery.
1836160|NCT00850746|Drug|YM443|Oral
1836161|NCT00850746|Drug|Placebo|Oral
1836162|NCT00850746|Drug|Moxifloxacin|Oral
1836163|NCT00850759|Device|virtual pedestrian environment|a computer-driven virtual pedestrian environment
1836164|NCT00850759|Device|computer and video|various computer-based and video-based programs such as Otto the Auto and WalkSafe
1836165|NCT00850759|Behavioral|streetside training|one-on-one training by an adult with the child at streetside locations, to teach children street-crossing skills
1836166|NCT00850772|Dietary Supplement|Early post-operative enteral feeding|During primary surgical treatment an enteral feeding tube will be inserted through the patient's nose into their small bowel. Enteral feeding will commence 4 hours following return to ward from surgery. Feeding will start at a rate of 40 ml/hr for the first 24 hours, and then increased to goal weight. Goal will be calculated by 125 kiloJoules/kilogram adjusted body weight.
1836167|NCT00850785|Biological|DRibble vaccine|Docetaxel 75 mg/m2 will be administered in the several days after leukapheresis. Intradermal (ID) vaccine injections of DRibbles made from at least 5 million and up to 20 million cell equivalents per vaccination will begin 14 days after the first docetaxel. Each DRibble vaccine will be followed by the 6-day infusion of GM-CSF via the CADD-MS 3 pump (50 micrograms/24 hrs).
1836168|NCT00850798|Drug|Intensive glycemic control|Intensive glycemic control
1836169|NCT00850798|Drug|Conservative glycemic control|OADs and insulin
1836170|NCT00850811|Drug|PEP005 (ingenol mebutate) Gel|PEP005 (ingenol mebutate) Gel, 0.01%
1836171|NCT00850824|Behavioral|Community Health Worker home visits|Community health workers will educate diabetes patients and families about need for regular medical care, taking medications, increasing exercise patterns, improving diet, keeping medical referral exams for specialty.
1836172|NCT00850837|Drug|Acidform Lubricant|5 g application of acid buffered gel (pH = 3.5)
1836173|NCT00850837|Drug|HEC gel|5 g application of hydroxyethylcellulose gel
1836174|NCT00850850|Drug|physostigmine|1 mg of physostigmine time 0 min. If the condition persisted after 15 min. the same amount of active drug would be administered once again.
1836175|NCT00850850|Drug|Isotonic sodium chloride solution|Patients who have difficulties in awakening from the general anaesthesia and do not suffer from excess nausea or vomiting will be randomised to receive 1 ml of isotonic sodium chloride solution (placebo) time 0 min. If the condition persisted after 15 min. the same amount of non-active drug would be administered once again.
1836176|NCT00850889|Device|Hyaluronic acid gel (24 mg/mL) with 0.3% lidocaine|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
1836177|NCT00850889|Device|A gel of hyaluronic acid (concentration of 20 mg/mL)|Day 0, maximum total volume (dosage) allowed for each NLF is 1.6 mL
1836178|NCT00850902|Other|High Humidity (HH)|High Humidity Level
1836179|NCT00850902|Other|Moderate Humidity|Moderate Humidity Level
1836180|NCT00850915|Other|community IPT|"In the intervention group, the household contacts of enrolled TB/HIV co-infected patient are visited at home by community health workers. Those contacts providing informed consent and considered fit (assessed by simple questionnaire) are assumed not to have active TB and are eligible for IPT. They are offered isoniazid at 300mg (5 mg per Kg for children) once daily for 6 months, regardless of their HIV-status.
In the control group, in line with routine care, eligible index cases are requested to send their contacts to the clinic for evaluation. Contacts presenting to the clinic will be screened for TB and receive IPT, if under 5 years and when active TB is ruled out as per the current national guidelines.
All contacts (both intervention and control group) are followed up monthly to assess occurrence of symptoms suggestive of TB."
1836181|NCT00850941|Behavioral|Questionnaire|Information collection.
1836182|NCT00850954|Behavioral|Printed Materials|"Pamphlets:
Specific materials for non-smokers and motivated/not motivated smokers."
1836183|NCT00850954|Behavioral|Fotonovelas|Illustrated storybooks.
1836184|NCT00850993|Drug|stannsoporfin|single IM injection of 1.5, 3.0, or 4.5 mg/kg
1836185|NCT00850993|Other|Saline|Normal saline (0.9%) solution
1836186|NCT00851006|Drug|Creatine Monohydrate|Creapure brand of creatine monohydrate
1836187|NCT00851019|Behavioral|DDR|"Ad libitum attendance to engage in Dance Dance Revolution (DDR) Exergaming, for a 3-month period"
1836188|NCT00851019|Behavioral|Treadmill|Ad libitum attendance to engage in treadmill exercise, for a 3-month period
1836189|NCT00851032|Other|Molecular Profiling Analyses|Molecular profiling analyses from advanced cancer participants' stored tissue bank samples.
1836190|NCT00851045|Drug|Irinotecan|Solution, IV, 180 mg/m2, Q14 days, Until PD
1836191|NCT00851045|Drug|5-Fluorouracil (bolus)|Solution, IV, 400 mg/m2, Q14 days, Until PD
1836192|NCT00851045|Drug|5-Fluorouracil (infusional)|Solution, IV, 2400 mg/m2, Q14 days, Until PD
1836193|NCT00851045|Drug|Leucovorin calcium|Solution, IV, 400 mg/m2, Q14 days, Until PD
1836194|NCT00851045|Drug|CT-322|Solution, IV, 2 mg/kg, Q7 days, Until PD
1836195|NCT00851045|Drug|Bevacizumab|Solutions, IV, 5 mg/kg, Q14 days, Until PD
1836196|NCT00851045|Drug|Bevacizumab Placebo (saline solution)|Solution, IV, 0 mg/kg, On day 8 of a 2-week cycle, Until PD
1836197|NCT00851058|Behavioral|Brief group counseling|Four group counseling sessions and six hours of direct observations of the emergency and trauma services in a busy urban hospital.
1836198|NCT00851058|Behavioral|Community Counseling|Four session of group counseling and six hours of guided observation of the emergency and trauma services at a busy urban hospital
1836199|NCT00851058|Behavioral|Prototypic community service|Two educational session on road safety and 16 hours of volunteering in a local not for profit community service.
1836200|NCT00851058|Behavioral|Prototypic community service|Four hours education about road safety and 16 hours volunteering at a local not for profit community service
1836201|NCT00851071|Behavioral|Cognitive Behavioral Therapy|Three 45 minute CBT sessions scheduled over a 3 month period.
1836202|NCT00851084|Drug|aflibercept|administration: IV infusion
1836203|NCT00851084|Drug|oxaliplatin|administration: IV infusion
1836204|NCT00851084|Drug|5-FU|administration: IV infusion
1836205|NCT00851084|Drug|Folinic Acid|administration: IV infusion
1836206|NCT00851110|Procedure|stem cell reinfusion|hematopoietic stem cell reinfusion
1836207|NCT00851110|Drug|Chemotherapy|High-dose chemotherapy consisting of cyclophosphamide, thiotepa and carboplatin
1836208|NCT00851123|Behavioral|Modified Constraint-Induced Movement therapy|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing the affected arm. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own. A restraining mitt has to be worn 5 hours a day.
1836209|NCT00851123|Behavioral|Task-specific bimanual training|Four hours of treatment a week for four weeks by a physiotherapist or an occupational therapist emphasizing bimanual tasks. Patients will receive an individually tailored home training program and are supposed to train 2-3 hours daily on their own.
1836210|NCT00851136|Drug|bevacizumab|Intravenous repeating dose
1836211|NCT00851136|Drug|FOLFOX|Intravenous repeating dose
1836212|NCT00851136|Drug|PRO95780|Intravenous repeating dose
1836214|NCT00851162|Biological|Trinity multipotent stem cells|Enough to fill voids which vary in size
1836215|NCT00851162|Biological|Demineralized bone matrix(DBM)|Enough DBM to fill a bone void defect
1836216|NCT00851175|Drug|rosuvastatin|7 day treatment with rosuvastatin 1dd 20mg
1836217|NCT00851175|Drug|caffeine|intra-arterial (brachial artery of non dominant arm) administration of caffeine(90 ug/min/100ml forearm volume)for approximately 60 minutes
1836218|NCT00851188|Behavioral|Internet CBT self-help|Internet based Cognitive behavioral self-help method for insomnia
1836219|NCT00851188|Behavioral|CBT self-help booklet|Cognitive behavioral self-help method for insomnia via booklet
1836220|NCT00851188|Other|Waiting list|Waiting list
1836222|NCT00851214|Device|NexfinHD Monitor|Finger cuff device (NexfinHD Monitor, BMEYE, Amsterdam) that can measure hemodynamics on a beat to beat basis and that can be easily applied to acutely ill individuals.
1836223|NCT00851227|Drug|conivaptan hydrochloride|intravenous
1836224|NCT00851240|Drug|BTT-1023|intravenous
1836225|NCT00851240|Drug|Placebo|Intravenous
1959064|NCT00855010|Drug|pioglitazone|pioglitazone 45 mg daily
1836227|NCT00851266|Biological|V512|"Subjects received 1 of 8 formulations of the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6:
1) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 2) 0.5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 3) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 4) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 5) 5 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX; 6) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 20 mcg IMX; 7) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 60 mcg IMX; 8) 20 mcg each of A/M2 and B/HA0 peptides with 225 mcg MAA and 100 mcg IMX;"
1836228|NCT00851266|Biological|Comparator: Placebo to V512|Subjects received placebo to the BIPCV/IMX vaccine (V512) in a 3-dose regimen of 0.5 mL injections at Day 1, Month 2, and Month 6.
1836229|NCT00851279|Device|Magnetic irrigated ablation catheter|Magnetic irrigated catheter to be used with the magnetic navigation system
1836230|NCT00851292|Device|TRUS probe|end-firing and side-firing vary in the angle in which they sample the prostate
1836231|NCT00851305|Device|Endomicroscope (Pentax, Tokyo, Japan)|A Pentax EC3870K endomicroscope which can produce conventional white light endoscopic images and confocal images at the same time with a optical slice thickness of 7 μm, a lateral resolution of 0.7 μm, a scanning depth of 0 to 250 μm, a pixel density of 1024×512 pixels (at an image acquisition rate of 1.6 frames/second)，and a field of view of 475 μm×475 μm.
1836232|NCT00851305|Device|Gastroscopes (Pentax, Tokyo, Japan)|Conventional white light gastroscopes (Pentax EG-2940 gastroscopes)
1836233|NCT00851318|Drug|Certolizumab pegol|Subcutaneous (SC) injection
1836234|NCT00851318|Drug|Methotrexate|Methotrexate dose between 6 to 8 mg/week.
1836235|NCT00851331|Genetic|genome analyzes (genetic defects and pathophysiological mechanisms )|
1959065|NCT00855010|Drug|placebo|one daily
1996371|NCT02493764|Drug|Linezolid|Linezolid 600 mg administered open-label by IV every 12 hours for up to 14 days
1996372|NCT02492711|Biological|Margetuximab|15 mg/kg via IV (intravenous) infusion over 120 minutes on day 1 of each 21 day cycle, until progression or unacceptable toxicity develops.
1836241|NCT00851357|Drug|Nicotine Patch|Subjects are randomized into 1 of 3 conditions: active, placebo or usual care. Usual care subjects are not mailed patches; however, we facilitate their use by providing a certificate that can be used by the State Medicaid program and some insurance companies to obtain free patches. For those mailed patches directly, we will mail 8 weeks of patches. Dosage depends on the number of cigarettes per day (cpd). Light smokers (6-10 cpd) will receive 6 weeks of 14 mg and 2 weeks of 7 mg patches. Heavy smokers (11+ cpd) will receive 4 weeks of 21 mg, 2 weeks of 14 mg and 2 weeks of 7 mg patches. Placebo patches will have no nicotine, but will be packaged to mimic the active patches.
1836396|NCT00845195|Drug|Olopatadine HCl Nasal Spray, 0.6%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
1836242|NCT00851357|Behavioral|Telephone Counseling|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.
Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Telephone counseling includes a comprehensive pre-quit session (to include motivation, planning, and setting of a quit date and discussion of nicotine patch use) plus up to 5 proactive follow-up calls. Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling."
1836243|NCT00851357|Drug|Placebo|Placebo nicotine patch
1836244|NCT00851357|Other|Self-Help Materials|"Subjects call the Helpline and are screened for services. Eligible clients who give consent will be randomly assigned to a group.
Subjects will be randomized into one of 2 behavioral conditions: telephone counseling or self-help materials. Reading materials and written consent will be mailed to all study subjects the next business day."
1836245|NCT00851370|Drug|Omalizumab (Xolair)|Bi-weekly
1836246|NCT00851370|Drug|Placebo|Bi-Weekly
1836247|NCT00851383|Biological|Ad35-GRIN/ENV|This is a dose-escalation trial. Each group will receive the Ad35-GRIN/ENV vaccine at different dosage levels.
1836248|NCT00851383|Biological|Ad35-GRIN|This is a dose-escalation trial. Group D will receive the Ad35-GRIN vaccine.
1836249|NCT00851409|Drug|Recombinant Human C1 Inhibitor|"50 IU/kg rhC1INH, IV injection over 4 to 5 minutes, once weekly over an 8-week treatment period."
1836250|NCT00851435|Biological|KBPA-101|1.2 mg/kg KBPA-101 i.v. infusion, 3 single doses, every third day
1836251|NCT00851448|Dietary Supplement|oral nutritional supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
1836252|NCT00851461|Drug|Goserelin|Goserelin 10.8 mg SC every 3 months
1836253|NCT00851461|Procedure|Electrophysiologic study|Nerve conduction study Electromyogram
1836254|NCT00851461|Procedure|tissue biopsy|skin and muscle biopsy before and after treatment every year
1836255|NCT00844142|Drug|Etanercept 25mg|patients will receive etanercept 25mg twice weekly
1836256|NCT00844142|Drug|Sulfasalazine|in this arm patients will receive sulfasalazine 2000- 3000mg per os daily
1836257|NCT00844155|Drug|Oseltamivir 75 mg|The primary objective of this study is to demonstrate that the pharmacokinetics of oseltamivir, when given enterally to critically ill patients, in the standard treatment dose of 75 mg or double that dose, 150 mg, will yield a plasma concentration - versus - Time Area under the curve (AUC) similar to that observed in adults with influenza treated successfully with a dose of 75 mg, that the disposition characteristics are dose proportionate and are not altered by the concomitant administration of enteral feedings.
1836258|NCT00844168|Drug|sorafenib tosylate|Given orally
1836259|NCT00844168|Other|laboratory biomarker analysis|Correlative studies
1836260|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
1836261|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all responders of both arms week 7-12
1836262|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
1836263|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (responder for 2 weeks)
1836264|NCT00844194|Drug|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
1836265|NCT00844194|Drug|Duloxetine 90 mg QD|given to non-responders of both arms from day of notice that 120 mg is not tolerated to week 12 as 60 mg+30 mg Duloxetine QD
1836266|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
1836267|NCT00844194|Drug|Duloxetine 60 mg QD|given to (1) all patients week 2-6; (2) all non-responders of both arms for first week of taper down
1836268|NCT00844194|Drug|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
1836269|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
1836270|NCT00844194|Drug|Duloxetine 30 mg QD|given to (1) all patients for one week as taper in; (2) all patients for taper down (non-responder for the second week of taper down)
1836271|NCT00844194|Drug|Duloxetine 120 mg QD|given to non-responders of both arms from week 7-12 as 2x60 mg Duloxetine QD, if tolerated
1836272|NCT00844207|Drug|Fixed combination of Azithromycin and Chloroquine|Pfizer will provide the study medications, fixed combination azithromycin/chloroquine tablets (250 mg/155 mg, base), The study treatment is single dose.
1836273|NCT00844207|Drug|Azithromycin and Chloroquine|Pfizer will provide Zithromax (500 mg) and Aralen (500 mg containing 300 mg chloroquine base). The study treatment is single dose.
1836274|NCT00844220|Procedure|CT/MR|CT/MRI-directed clinical management strategy
1836275|NCT00844220|Procedure|Catheterization|Standard clinical management directed by conventional coronary angiography
1836276|NCT00844233|Device|Irinotecan Bead|Irinotecan eluting bead
1836277|NCT00844246|Other|Developmental screening using ASQ and MCHAT|In the SRS intervention arm subjects will complete developmental screening tools with a school readiness specialist at their 9, 18, 24 and 30 month well child visits and then complete their well child visit with their primary care clinician to discuss the results.
1836278|NCT00844246|Other|Developmental screening using ASQ and MCHAT|Subjects who are randomized to PCP arm will be screened for developmental delays by their Primary Care Clinician at their 9, 18, 24 and 30 month well child visits. The corresponding screening tools may be mailed to the study participants 2 weeks before the scheduled well child visits. Those who do not complete the screening tools or those who did not receive them in the mail will then complete the questionnaire in the office prior to seeing their doctor or with their doctor. The PCP will then score the screening tool and interpret the test results. Developmental counseling and/or anticipatory guidance will be provided, as per usual care. EI referral will be completed, at the discretion of the provider with the approval of the caregiver , if the subject fails the developmental screen or the caregivers raise a specific concern about the child's development.
1836397|NCT00845195|Drug|Azelastine HCl Nasal Spray, 0.1%|2 sprays/nostril, twice daily (in addition to Fluticasone Propionate Nasal Spray 50 mcg 2 sprays/nostril once daily) for 14 +/- 3 days
1836279|NCT00844272|Behavioral|Psychoeducation|"Group-therapeutic intervention with 12 sessions plus 5 update sessions with 24-week therapy duration and/or 12 sessions plus 10 update sessions with 48-week therapy duration Module I: Create understanding, resources, problems and solutions Module II: Information on hepatitis C infection Module III: Information on treatment Module IV: Specific information on depression and withdrawal symptoms under interferon The meetings take a minimum of 60 min. time, should be once weekly. The group size should lie between 6 and 12 participants.
The group leaders are trained in performance of the psycho-education."
1836280|NCT00844285|Drug|Cimzia|The associated drug description is a total of two 200 mg subcutaneous injections of Cimzia to total 400 mg.
1836281|NCT00844298|Drug|Nilotinib+mVPD|"Induction:
Daunorubicin 90 mg/m2/day by continuous iv infusion (d1-3)
Vincristine 2 mg iv push (d1, 8, 15, 22)
Prednisolone 60 mg/m2/day po (d1-28)
Nilotinib 400mg bid/d (d8-)
Consolidation A (cycle1)
Daunorubicin 45 mg/m2/day by continuous iv (d1, 2)
Vincristine 2 mg iv (d1, 8)
Prednisolone 60 mg/m2/day po (d1-14)
Nilotinib 400mg bid/d
Consolidation B (cycles 2&4)
Cytarabine 2,000 mg/m2/day iv over 2 hours (d1-4)
Etoposide 150 mg/m2/day iv over 3 hours (d1-4)
Nilotinib 400mg bid/d
Consolidation C (cycles 3&5)
Methotrexate 220 mg/m2 iv bolus, then 60mg/m2/h for 36 hours (d1-2, 15-16)
Leucovorin followed immediately by 50 mg/m2 iv every 6hrs for three doses,
Nilotinib 400mg bid/d
Maintenance
◦Nilotinib 400mg bid/d (during 2 years, for patients without alloHCT)
Consider alloHCT"
1836282|NCT00844311|Drug|rFSH|150 iu/day of rFSH
1836283|NCT00844311|Drug|human chorionic gonadotropin|50 iu/day of hCG from stimulation day 1
1836284|NCT00844311|Drug|human chorionic gonadotropin|100 iu/day of hCG from stimulation day 1
1836285|NCT00844311|Drug|human chorionic gonadotropin|150 iu/day of hCG from stimulation day 1
1836286|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1 mg/mLDose: 32 mg, single dose
1836287|NCT00844324|Drug|Candesartan cilexetil|Formulation:Oral suspensionStrength:1.6 mg/mLDose: 32 mg, single dose
1836288|NCT00844337|Drug|Gentamicin & Amoxicillin x 7days|"Injectable gentamicin once daily and oral amoxicillin twice daily for seven days.
The dose for gentamicin is 4 - 5 mg/kg/24 hours. The dose for amoxicillin is 90-115 mg/kg/day."
1836289|NCT00844337|Drug|Penicillin & gentamicin x 2 d + Amoxicillin X 5 d|Injectable penicillin and gentamicin once daily for two days followed by oral amoxicillin twice daily for five days. The dose for penicillin is 40,000 - 50,000 U/kg/24 hours, the dose for gentamicin is 4 - 5 mg/kg/24 hours, and the dose for amoxicillin is 90-115 mg/kg/day.
1836290|NCT00844337|Drug|Standard reference therapy|Injectable procaine-benzyl penicillin and gentamicin once daily each for seven days. The penicillin dose is 40,000 - 50,000 U/kg/24 hours, and the gentamicin dose is 4 - 5 mg/kg/24 hours.
1836291|NCT00844350|Drug|letrozole , oxytocin,hCG,clomiphene citrate|
1836292|NCT00844363|Procedure|NB-UVB|UVB light will be administered to the entire body except for the genitals in men and eyelids, which will be shielded.NB-UVB dosing is increased by 5-20% increments in exposure time, depending on response of the patient.
1836293|NCT00844376|Drug|Atorvastatin suspension|A single dose of 80 mg Atorvastatin suspension
1836294|NCT00844376|Drug|Lipitor|A single dose of 80 mg Lipitor tablet
1836295|NCT00844389|Device|Near to infrared light retinal stimulation|Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
1836296|NCT00844389|Device|Green light stimulation|Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
1836297|NCT00844402|Drug|Atorvastatin|oral, 10 mg, daily, 48 weeks
1836298|NCT00844415|Drug|dabigatran etexilate|2.14 mg/kg BID to a max 150 mg BID
1836299|NCT00844428|Drug|eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
1836300|NCT00844441|Other|medical chart review|
1836301|NCT00844441|Other|questionnaire administration|
1836302|NCT00844441|Procedure|quality-of-life assessment|
1836303|NCT00844454|Procedure|multi-pronged ethanol ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then inject ethanol to destroy the whole tumor tissue.
1836304|NCT00844454|Procedure|radiofrequency ablation|Under ultrasound guidance, insert an applicator into the tumor percutaneously and then deliver radiofrequency energy to destroy the whole tumor tissue.
1836305|NCT00844467|Biological|serotypes and resistance|screening patients with invasive pneumococci
1836306|NCT00844480|Drug|zoledronic acid|zoledronic acid, 5mg, iv
1836307|NCT00844480|Drug|placebo|iv
1836308|NCT00844493|Biological|E coli strain H10407 and buffer|7 or 8 logs of the bacteria with bicarbonate buffer
1836309|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 8 logs with CeraVacx buffer
1836310|NCT00844493|Biological|E coli strain H10407 and buffer|Bacteria in a dose of 7 logs and CeraVacx buffer
1836311|NCT00844493|Biological|E coli H10407 and buffer|Bacteria in a dose of 8 logs with bicarbonate buffer
1836312|NCT00844506|Drug|P53-SLP vaccine|The P53-SLP vaccine is a vaccine consisting of a total of 10 long (30 amino acids on average length) peptides, covering the p53 protein sequence from amino acid 70 to 251, combined with Montanide ISA51 an adjuvant with a sustained dendritic cell activating ability. Patients will be immunised subcutaneously with the peptide vaccine four times with a three week interval (300μg/peptide).
1836313|NCT00844506|Drug|Cyclophosphamide|Two days prior to each peptide vaccination, patients will receive 300mg/m2 cyclophosphamide i.v.
1836314|NCT00844519|Drug|Maraviroc|For subjects assigned to the maraviroc group, they will receive maraviroc at 300mg by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications. For subjects on ritonavir, the dose will be reduced to 150mg by mouth twice daily for 24 weeks.
1836315|NCT00844519|Drug|placebo|For subjects assigned to the placebo group, they will receive a matching placebo pill 300mg to be taken by mouth twice daily for 24 weeks in addition to taking their current anti-HIV medications.
1836398|NCT00845208|Behavioral|Network Support|12 Weekly sessions intended to help patients change their social networks to be more supportive of abstinence
1836316|NCT00844532|Device|Absolute Pro™ Peripheral Self-Expanding Stent System|Absolute Pro™ Peripheral Self-Expanding Stent System: Devices include both Absolute Pro™ and Absolute Pro™ LL Peripheral Self-Expanding Stent Systems. It is indicated for the treatment of a maximum of two bilateral de novo or restenotic atherosclerotic lesions in the native common iliac artery and/or native external iliac artery (one lesion per side).
1836317|NCT00844545|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange
1836318|NCT00844558|Other|Gait Training|Gait training with a physical therapist 2/week for the first 3 months followed by 1/week for the following 3 months
1836319|NCT00844558|Other|Control|There is no intervention associated with this arm of the study
1836320|NCT00844571|Other|E-learning program|Participants are committed to accomplish the program in approximately 2 hours. Additionally to these mandatory hours, they were able to access the e-learning program at any time and place.
1836321|NCT00844584|Procedure|epicardial radiofrequency ablation|epicardial radiofrequency ablation to treat atrial fibrillation under totally thoracoscope
1836322|NCT00844597|Drug|AVI-4658 for Injection|AVI-4658 for Injection, is packaged as 100 mg/mL in phosphate buffered saline with 1 mL per vial. Study dosages will be infused over a 1 hour period with Normal saline in 6 dose cohorts.
1836323|NCT00844623|Genetic|TK99UN|escalated dosis from 2x10e10 to 2x10e12 viral particles injected intratumorally
1836324|NCT00844636|Device|Sharp needle|
1836325|NCT00844636|Device|Blunt needles|
1836326|NCT00844649|Drug|Albumin-bound paclitaxel (ABI-007)|ABI-007 125 mg/m^2 administered by intravenous infusion
1836327|NCT00844649|Drug|Gemcitabine|Gemcitabine, 1000 mg/m2 administered weekly for 7 weeks, Day 1 through Day 43 followed by a week of rest (Cycle 1), followed by cycles of weekly administration for 3 weeks, Days 1, 8, and 15 followed by a week of rest (Cycle 2 onward).
1836328|NCT00844662|Drug|Fermagate|Film coated tablet 500mg
1836329|NCT00844662|Drug|Sevelamer hydrochloride|Tablet 800mg
1836330|NCT00844675|Drug|rabeprazole|The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
1836331|NCT00844675|Drug|placebo|The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
1836332|NCT00844688|Drug|sorafenib|"Patients will be treated with 400 mg oral sorafenib twice a day on a continuous basis. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:
Progression of disease.
The patient is unlikely to benefit from further treatment as
Judged by the Investigator.
Intolerable toxicity of the drugs.
Withdrawal of consent for any reason."
1836333|NCT00844688|Drug|Gemcitabine|"Patients will be treated with Gemcitabine 1000mg/m2 administered on day 1 & 8 of a 4 week cycle. Patients in this protocol may continue to be treated with this combination for a minimum of 4 cycles until any of the following criteria for protocol discontinuation is reached:
Progression of disease. The patient is unlikely to benefit from further treatment as
Judged by the Investigator.
Intolerable toxicity of the drugs. Withdrawal of consent for any reason."
1836334|NCT00844714|Drug|Rituxan|1000mg rituxan by intravenous infusion will be given on day 1 and day 15 of the study
1836335|NCT00844727|Drug|Rofecoxib|
1836336|NCT00844727|Drug|placebo|placebo pills
1836337|NCT00844740|Drug|Cinacalcet|Stable patients with XLH already treated with Phosphate and calcitriol will add Cinacalcet to their treatment regimen. Sequential monitoring of blood nand urine biochemical variables will follow, based on which adjustments to the doses of the 3 medications will be done.
1836338|NCT00844753|Drug|atomoxetine|atomoxetine
1836339|NCT00844753|Drug|Placebo|Placebo + parent management treatment
1836340|NCT00844753|Behavioral|Parent Management Training|
1836341|NCT00844779|Procedure|Bariatric surgery|Gastric bypass.
1836342|NCT00844779|Procedure|cholecystectomy or benign liver tumor removal|cholecystectomy or benign liver tumor removal
1836345|NCT00844805|Drug|Infliximab|
1836346|NCT00844805|Drug|Placebo|
1836347|NCT00844805|Drug|Naproxen|
1836348|NCT00844818|Behavioral|Telephone Quitline Enrollment|The intervention included a brief motivational interview (MI), enrollment in the proactive state quitline, and follow-up faxes to the pediatric, OB, and PCP providers with tailored treatment messages.
1836349|NCT00844831|Drug|Lubiprostone|24 mcg bid for 28 days
1836350|NCT00844844|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
1836351|NCT00844857|Drug|Olanzapine Fluoxetine Combination (OFC)|OFC doses are capsules of 3 milligrams (mg) olanzapine and 25 mg fluoxetine (3/25), 6/25, 12/25, 6/50, or 12/50 mg to be taken orally once daily in the evening for 8 weeks.
1836352|NCT00844857|Drug|Placebo|Orally, once daily in the evening for 8 weeks.
1836353|NCT00844870|Behavioral|stabilization training|training of arm function with the trunk stabilized
1836354|NCT00844870|Behavioral|auditory training group|response to an auditory signal
1836355|NCT00844883|Drug|sorafenib|sorafenib: given 400 mg twice per day for as long as it is beneficial
1836356|NCT00844883|Procedure|LC Bead-TACE|"LC Beads loaded with doxorubicin
Doxorubicin loaded LC Beads: given intra-arterially into the liver, up to fours times in a 6 month period"
1836399|NCT00845221|Drug|Imatinib mesylate 100 mg (Glivec)|260 mg/m2/day tablets
1836357|NCT00844896|Behavioral|DEF-only|"The DEF protocol is from the National Child Traumatic Stress Network (NCTSN). DEF provides a sequential methodology for clinicians to assess medically traumatized children and their families and to plan specific interventions for them.
In the present study, the DEF intervention is both a generalized approach taught to all Shriners Hospitals for Children (SHC)- Boston clinical staff, and for those participants of the present study, consists of an optional meeting with a member of the SHC Psychiatry Department. During this meeting, parents will have the chance to review any areas of pain, anxiety, or support that came up during their interviews or any other areas of concern about their child or his/her hospitalization that they wish to raise."
1836358|NCT00844896|Behavioral|DEF + COPE|"All enrolled participants will be offered the chance to meet with a psychiatric clinician for the DEF component of the intervention.
For those assigned to receive COPE (Creating Opportunities for Parent Empowerment), parents will receive one of two versions of the materials: one for children less than one year old, and one for children ages 1-5 years. The COPE program was adapted for children with burns and developed to target major stressors that parents experience when their children are hospitalized, such as the loss of parental control. COPE also contains a behavioral component to help parents to carry out the recommendations provided to them. Each of these versions of the COPE program is essentially self-administered to parents via audio tapes and activity workbooks."
1836359|NCT00844909|Drug|CNTO 136|
1836360|NCT00844922|Drug|SCH 900636|"Org 34517 300 mg on Day 1, 600 mg on Day 2, then 900 mg daily starting from Day 3. Subjects in this arm were also to continue the usual treatment for psychotic major depression."
1836361|NCT00844922|Drug|Placebo|Placebo
1836362|NCT00844961|Behavioral|Internet delivered cognitive behavior therapy|10 weeks of internet delivered cognitive behavior therapy targeted at reducing experience of IBS symptoms and improving quality of life. Patients are offered guidance via email by a therapist.
1836363|NCT00844974|Other|Prevalence|Mood and cognitive assessments
1836364|NCT00845000|Drug|SCH 420814 10 mg|one 10-mg capsule, orally, at hour 0 of treatment period
1836365|NCT00845000|Drug|SCH 420814 100 mg|single oral dose of four SCH 420814 25-mg capsules at hour 0 of treatment period
1836366|NCT00845000|Drug|Placebo|Placebo capsule, oral, at hour 0 of treatment period
1836367|NCT00845000|Drug|Levodopa|levodopa intravenous (IV) infusion (1 mg/kg body weight) was beginning 1 hour after study drug administration and continued for 2 hours
1836368|NCT00845000|Drug|Carbidopa|one 25-mg table, orally, at hours 0, 2 and 4 of each treatment period
1836369|NCT00845026|Drug|LY2140023|80mg, oral tablets,twice daily: 40 mg in the morning, 40 mg in the evening, for 24 weeks. The dose may be adjusted to a minimum of 40mg or a maximum of 160mg.
1836370|NCT00845026|Drug|aripiprazole|10mg, oral tablets, once a day in the evening for three days. Followed by a dose increase to 20mg, 2-10mg oral tablets,once a day in the evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10mg or a maximum of 30mg (3-10mg oral tablets).
1836371|NCT00845026|Drug|olanzapine|10mg dose (2-5mg oral tablets) once every evening, for 3 days. Followed by an increase to 15mg (3-5mg oral tablets) once every evening, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 10mg or a maximum of 20mg (4-5mg oral tablets).
1836372|NCT00845026|Drug|risperidone|2mg dose, 2-1mg oral tablets, given once or twice a day for 3 days. Followed by an increase to 4mg (4-1mg tablets), given once or twice a day, for 23 weeks and 4 days. The dose may be adjusted to a minimum of 2mg/day or a maximum of 6mg/day (6-1mg tablets).
1836373|NCT00845039|Biological|Cetuximab|Cetuximab 500 mg/m2 every 14 days until disease progression or patient intolerance
1836374|NCT00845039|Drug|Irinotecan|180 mg/m2 every 14 days until disease progression or patient intolerance
1836375|NCT00845039|Biological|IMC-A12 (cixutumumab)|IMC-A12 10mg/kg every 14 days until disease progression or patient intolerance
1836376|NCT00845065|Drug|Boceprevir|800 mg, using SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
1836377|NCT00845065|Other|Placebo|800 mg, using placebo matching SCH 503034 200-mg capsules, three times a day (TID) orally (PO) for 48 weeks
1836378|NCT00845065|Biological|Peginterferon alfa-2a|Peginterferon alfa-2a, pre-filled syringes, given 180 μg/week subcutaneously (SC) for 48 weeks
1836379|NCT00845065|Drug|Ribavirin|"Ribavirin 200-mg capsules, weight-based dosing
<75 kg, 1000 mg/day orally (PO), divided twice daily (BID)
>=75 kg, 1200 mg/day PO, divided BID
for 48 weeks"
1836380|NCT00845091|Behavioral|Exercise|moderate-intensity, low-impact, supervised, aerobic exercise
1836381|NCT00845091|Behavioral|Heart Healthy Education|Educational topics related to heart health (e.g., nutrition, smoking, sleep)
1836382|NCT00845104|Drug|fludarabine phosphate|Given IV
1836383|NCT00845104|Biological|rituximab|Given IV
1836384|NCT00845104|Biological|bevacizumab|Given IV
1836385|NCT00845104|Other|laboratory biomarker analysis|Correlative studies
1836386|NCT00845104|Other|flow cytometry|Correlative studies
1836387|NCT00845104|Genetic|polymerase chain reaction|Correlative studies
1836388|NCT00845104|Genetic|fluorescence in situ hybridization|Correlative studies
1836389|NCT00845117|Procedure|Cultivated limbal stem cell graft transplantation|A limbal biopsy taken from the contralateral good eye in cases of unilateral disease or from a living related or cadaveric donor in cases of bilateral disease. The limbal stem cells from the biopsy are cultivated until a sheet of cells measuring approximately 12mm in diameter is obtained. This is then ready for transplantation onto the diseased eye.
1836390|NCT00845130|Biological|ascorbic acid (Vitamin C)|ascorbic acid IV 1 g/kg
1836391|NCT00845156|Dietary Supplement|Alpha Lipoic Acid|Two 400 mg tablets of Alpha Lipic Acid are taken 3 times daily
1836392|NCT00845169|Procedure|Forearm vascular study|Forearm venous occlusion plethysmography to measure forearm blood flow during intrabrachial infusion of nitric oxide synthase inhibitors L-NMMA (2-8 µg/min), S-methionyl-L-citrulline (25-200 nmol/min) and 1400W (100-1000 nmol/min) and positive control norepinephrine (60-540 pmol/min)
1837625|NCT00859989|Other|study of socioeconomic and demographic variables|
1836400|NCT00845234|Behavioral|Intervention|Intervention consisted of a brief, educational CBT intervention and included the following domain areas: ICD knowledge and post-discharge care, understanding shock, stress management, family and relationships, device recall, and survivorship. The intervention was provided at baseline (0 weeks). Intervention was led by investigator and lasted 15 minutes in duration.
1836401|NCT00845247|Other|Nurse case management|Intervention group patients are offered the support of a nurse case manager throughout their course of treatment.
1836402|NCT00845260|Behavioral|Internet-based cognitive behavior therapy (CBT).|Self-help program and guidance by psychologist via e-mail during 10 weeks.
1836403|NCT00845260|Behavioral|Group CBT|Group cognitive behavior therapy (CBT) during 10 weeks.
1836404|NCT00845273|Drug|Pegaptanib sodium|"Macugen Intravitreous Injection Kit 0.3mg depending on the Investigator prescription.
Frequency and duration are according to Package Insert as follows. Pegaptanib sodium is administered intravitreously once every 6 weeks at a dose level of 0.3 mg (on an oligonucleotide of pegaptanib basis )."
1836405|NCT00845286|Behavioral|Munich Marathon|42,195 km marathon run
1836406|NCT00845299|Drug|Latanoprost punctal plug|Control of IOP compared to baseline for the experimental dose of Latanoprost punctal plug for 6 weeks or until loss of efficacy.
1836407|NCT00845299|Drug|artificial tears preserved with Benzalkonium Chloride|
1836408|NCT00845325|Behavioral|Group One|They will begin exercises on the day after surgery and perform them three times daily for two weeks. The patients will have no restrictions concerning activity or return to work.
1836409|NCT00845325|Behavioral|Control Group Two|The patients will be restricted from using that hand during its implementation. One week following surgery the splint will be removed and the patient will be instructed to begin activity without restriction.
1836410|NCT00845338|Drug|Darifenacin (BAY79-4998)|Darifenacin 7,5mg tablets once daily for 14 days, darifenacin 7,5mg or 15mg once daily for 14 consecutive days
1836411|NCT00845351|Drug|Bexarotene|bexarotene at 300 mg/m2/day
1836412|NCT00845364|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
1836413|NCT00845364|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
1836414|NCT00845377|Behavioral|Comprehensive psychosocial support for depressed elderly|The model includes a psychiatric nurse as a care manager, a multiprofessional team with a physiotherapist, psychologist and psychiatrist. Each participant receives individually tailored services such as therapeutic groups, conversation groups, physical exercise, music therapy, art therapy and nutritional counseling
1836415|NCT00845429|Biological|Influenza virus vaccine - cell based (2007-2008 Formulation)|0.5 mL, Intramuscular
1836416|NCT00845429|Biological|Influenza virus vaccine - cell-based (2007-2008 Formulation)|1.0 mL, Intramuscular
1836417|NCT00845429|Biological|Influenza virus vaccine (2007-2008 Formulation)|0.5 mL, Intramuscular
1836418|NCT00845442|Device|pacemaker|Placement of pacemaker over the chest wall to stimulate the larynx in the neck via a tunneled electrode
1836419|NCT00845481|Drug|Daivobet® ointment|Once daily application 6 days a week for 3 weeks
1836420|NCT00845481|Drug|Betnovat® ointment|Once daily application 6 days a week for 3 weeks
1836421|NCT00845481|Drug|Diprosalic ointment|Once daily application 6 days a week for 3 weeks
1836422|NCT00845481|Drug|Dermovat ointment|Once daily application 6 days a week for 3 weeks
1836423|NCT00845481|Drug|Elocon ointment|Once daily application 6 days a week for 3 weeks
1836424|NCT00845481|Drug|Daivobet® ointment vehicle|Once daily application 6 days a week for 3 weeks
1836425|NCT00845494|Behavioral|cognitive behavioral intervention|The intervention will consist of an hour of cognitive behavioral education. The first 15 minutes spent discussing cases examples of medication errors. The next 15 minutes will include identifying old rules or assumptions nurses have about medication history obtainment. The next 15 minutes will be utilized reviewing a medication tool to be used, and the last 15 minutes will be discussing techniques to help nurse obtain information from elderly patients.
1836426|NCT00845507|Drug|Exenatide|The dosage of study medication will be 5 mcg injection of exenatide twice daily for 28 days. On day 28 the dosage may be increased, as tolerated, to 10 mcg twice daily.
1836427|NCT00845533|Drug|Dihydroartemisinin-Piperaquine|
1836428|NCT00845546|Drug|10 mg Loratadine/240 mg Pseudoephedrine Sulfate Extended-Release Tablets|
1836429|NCT00845559|Drug|Exenatide|Subjects randomized to treatment will receive a four month supply of exenatide and will be taught how to administer subcutaneous injections with their exenatide pen and instructed on the following dosing schedule: exenatide - 5 μg twice a day for 7 days, followed by exenatide 10 μg twice a day for the remainder of the four month supply.
1836430|NCT00845572|Behavioral|Consta Club|Biweekly group for patients receiving Risperdal Consta injections. Each 45 minute group includes socialization time, goal-setting, illness and medication education, and refreshments.
1836431|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
1836432|NCT00845585|Device|Below Knee Arterial Reconstruction|Patency, Reinterventions, Amputations, mortality
1836433|NCT00845598|Drug|Azelastine , fluticasone|"Azelastine Hydrochloride BP 0.10% w/v AND Fluticasone propionate BP 0.0357% w/v as combination
1 squirt in each nostril twice daily"
1836434|NCT00845598|Drug|Fluticasone propionate|Fluticasone propionate 0.05% w/w 2 squirts in each nostril (50 μg per squirt)
1836435|NCT00845611|Biological|peptide vaccine|peptides emulsified with Montanide ISA51
1836436|NCT00845637|Drug|Eggplant extract|Dry eggplant extract in two 450mg capsules, twice a day (before the main meals) for fourteen days.
1836437|NCT00845637|Drug|Placebo|Placebo in two 450mg capsules, twice a day (before the main meals) for fourteen days.
1836438|NCT00845650|Biological|Anthrax Immune Globulin Intravenous (AIGIV)|Three cohorts evaluating three dosage levels of AIGIV containing 3.5, 7.0, or 14.0 mg/kg anti-PA IgG as a single intravenous infusion.
1836439|NCT00845650|Biological|Gamunex|Three cohorts evaluating three dosage levels containing Gamunex 90, 180, or 360 mg/kg total IgG as a single intravenous infusion.
1836440|NCT00845663|Drug|Certolizumab pegol|Auto-injection device (test) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
1836534|NCT00854308|Drug|Erlotinib HCl|Erlotinib 150 mg oral dose once daily.
1836441|NCT00845663|Drug|Certolizumab pegol|Pre-filled syringe (reference) containing 1 mL of certolizumab pegol liquid formulation, 200 mg/mL; 2 injections
1836442|NCT00845676|Drug|Pegylated interferon alfa-2a + Ribavirin|Pegylated interferon alfa-2a 180 mcg subcutaneous injection once weekly for 24 weeks Ribavirin 1000-1200mg daily, dosed according to body weight and divided twice daily, for 12-24 weeks
1836443|NCT00845689|Drug|placebo|NaCl 0,9 %
1836444|NCT00845689|Drug|adenosine|intravenous infusion of adenosine 0, 2 %
1836445|NCT00845689|Drug|adenosine|intravenous infusion of adenosine 0,2 %
1836446|NCT00845689|Procedure|Liver resection|Liver resection with Pringle maneuver
1836447|NCT00845702|Drug|Gadoterate meglumine (Dotarem)|Each subject will receive one injection of Dotarem 0.2 ml/kg
1836448|NCT00845702|Other|Time of Flight Magnetic Resonance Angiography|Each subject will undergo a TOF MRA
1836449|NCT00845715|Other|Early motion|Early referral to physical therapy for range of motion (2 days post)
1836450|NCT00845715|Other|Standard motion|Standard referral to physical therapy for range of motion (4 weeks post)
1836451|NCT00845728|Drug|Indacaterol 150 µg|Indacaterol 150 µg o.d. delivered via SDDPI
1836452|NCT00845728|Drug|Tiotropium|Tiotropium 18 µg o.d. delivered via handihaler®
1836453|NCT00845754|Drug|ketorolac|15mg IV every6 hours for 4doses
1836454|NCT00845754|Drug|saline|15mg IV every 6hrs for 4 doses
1836455|NCT00845767|Procedure|Forearm Vascular Study|"Forearm venous occlusion plethysmography during intraarterial infusion of L-NMMA (2-8 µmol/min) followed by co-infusion of sodium nitroprusside (90-900 ng/min) as a nitric oxide clamp. Forearm blood flow then measured during the clamp in response to infused vasodilators acetylcholine (5-20 mg/min), bradykinin (100-1000 pmol/min), verapamil (10-100 µg/min) and sodium nitroprusside (2-8 µg/min)."
1836456|NCT00845780|Drug|withdrawal or continuation of amiodarone therapy|withdrawal or continuation of amiodarone therapy after at least 6 months sinus rhythm maintenance on amiodarone therapy
1836457|NCT00845793|Behavioral|Nutritional guidance|The guidance will be performed using the food tray during the hospitalization and will consist of meeting the nutritionist and receiving brochures along with the meal tray focusing on constituents and elements of the diet. The served meals will consist of elements recommended for patients with T2DM (such as whole grains, low fat dairy products and canola oil).
1836458|NCT00845806|Other|MRI|All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
1836459|NCT00845819|Drug|rhEGF + povidone iodine, chlorhexidine, & nystatin|"Topical application of 50 µg/mL rhEGF solution twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%) & nystatin (5,000IU/mL) three times a day.
Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.
For each application of rhEGF, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
1836460|NCT00845819|Drug|Placebo + povidone iodine, chlorhexidine, & nystatin|"Topical application of placebo drug twice daily + oral gargling with povidone iodine (1%), chlorhexidine (0.5%), and nystatin (5,000IU/mL) three times a day.
Application of drugs begins with start of intensive chemotherapy and ends at the time of recovery from neutropenia (ANC>1000/µL for 3 days) or disappearance of oral mucositis.
For each application of placebo drug, spray total 6 times at palate, oropharynx, both buccal mucosa, tongue, and gingiva."
1836461|NCT00845832|Drug|Placebo|iv on days 1 and 15 (Parts 1 and 2)
1836462|NCT00845832|Drug|rituximab [MabThera/Rituxan]|0.5g iv on days 1 and 15 (Parts 1 and 2)
1836463|NCT00845832|Drug|tocilizumab [RoActemra/Actemra]|2mg/kg-8mg/kg iv in Part 1 and selected dose in Part 2, on weeks 4, 8 and 12---Arm 1\n8mg/kg iv on weeks 4,8 and 12 (Parts 1 and 2)--- Arm 2
1836464|NCT00845845|Drug|Omega-3-acid ethyl esters (Lovaza)|4 milligrams daily omega-3-acid ethyl esters (Lovaza) with dietary counseling for 24 weeks.
1836465|NCT00845845|Drug|Placebo|Daily placebo with dietary counseling for 24 weeks.
1836466|NCT00845858|Drug|metoclopramide|30 minutes before meals and at bedtime for 4 weeks
1836467|NCT00845858|Drug|Placebo|30 minutes before meals and at bedtime
1836468|NCT00845871|Drug|deferasirox:|deferasirox 20mg/kg/day unless on a higher dose at time of study entry. Crushed or dissolved tablets taken once daily with either breakfast,dinner or no meal for 4 months.
1836469|NCT00845884|Drug|Docetaxel, Cisplatin, Capecitabine, Bevacizumab|"Docetaxel 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.
Cisplatin 30-35 mg/m2 IV, on Days 1 and 8, Q:21 days.
Capecitabine 1,600 mg/m2/d PO, divided into two daily doses, on Days 1-14, Q:21 days.
Bevacizumab 7.5 mg/kg IV, on Day 1, Q:21 days."
1836470|NCT00851487|Drug|Amoxicillin|Oral Amoxicillin 15 mg/kg/dose 8 hourly
1836471|NCT00851487|Drug|Placebo|The placebo was similar in colour, consistency and volume as oral amoxicillin
1836472|NCT00851500|Drug|K-604|K-604 is given for 26 weeks
1836473|NCT00851500|Other|Placebo|placebo tablets are given for 26 weeks
1836474|NCT00851513|Drug|Lidocaine|local anesthetics
1836475|NCT00851513|Drug|Depmedrol|local steroids
1836476|NCT00851513|Other|physiological serum|important volumes of physiological serum
1836477|NCT00851539|Behavioral|Video|Behavioral Intervention Video
1836478|NCT00851552|Biological|rituximab|Given IV
1836479|NCT00851552|Drug|bortezomib|Given IV
1836480|NCT00851552|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
1836481|NCT00851552|Genetic|gene expression analysis|Correlative Study
1836482|NCT00851552|Genetic|polymerase chain reaction|Correlative Study
1836483|NCT00851552|Genetic|polymorphism analysis|Correlative Study
1836484|NCT00851552|Genetic|proteomic profiling|Correlative Study
1836485|NCT00851552|Other|flow cytometry|Correlative Study
1836486|NCT00851552|Other|laboratory biomarker analysis|Correlative Study
1836487|NCT00851565|Procedure|Measurement of serum infliximab and anti-infliximab antibodies|"In the intervention group treatment of patients with Crohn's disease with secondary loss of response to infliximab is based on serum infliximab and anti-infliximab Ab levels according to following algorithm:
Low s-infliximab in the presence of anti-infliximab Ab: Adalimumab 80 mg s.c. followed by 40 mg every 2 weeks.
Low s-infliximab without anti-infliximab Ab: Infliximab 10 mg/kg i.v. every 8 weeks.
High s-infliximab without anti-infliximab Ab: Stop infliximab treatment. Review history. Steroids or surgery.
High s-infliximab in the presence of anti-infliximab Ab: Same as number 3."
1836488|NCT00851565|Procedure|Treatment according to current standards without knowledge of serum infliximab and anti-infliximab Ab status|In the control group patients with Crohn's disease with secondary loss of response to infliximab is treated according to current standard of care which is to increase dose of infliximab to 5 mg/kg every 4 weeks without knowledge of serum infliximab levels and anti-infliximab Ab status.
1836489|NCT00851578|Device|WATCHMAN|WATCHMAN LAA Closure Device
1836490|NCT00851591|Drug|fenugreek|3 capsules 3 times per day with a full glass of water each dose for 7 days
1836491|NCT00851591|Drug|Placebo (Psyllium)|3 capsules 3 times a day with a full glass of water each dose for 7 days
1836492|NCT00851617|Device|Threshold® IMT|The IMT group was trained using the threshold IMT device with a 40% MIP load. Each training session consisted of 5 sets with 10 breaths, twice a day
1836493|NCT00851630|Drug|Fixed dose combination zidovudine/lamivudine/abacavir|All subjects will receive fixed dose combination zidovudine(300 mg) / lamivudine (150 mg) / abacavir (300 mg) by mouth twice daily. Medications will be provided as long as deemed beneficial by the site investigator and study subject for up to two years. Toxicity substitutions are allowed per protocol.
1836494|NCT00851643|Biological|Octavalent HPV with 15 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
1836495|NCT00851643|Biological|Octavalent HPV with 30 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
1836496|NCT00851643|Biological|Octavalent HPV with 60 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
1836497|NCT00851643|Biological|Octavalent HPV with 120 mcg IMX / AAHS|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
1836498|NCT00851643|Biological|Comparator: Quadrivalent HPV Vaccine (qHPV), (GARDASIL™)|0.5-mL intramuscular injection administered at Day 1, Month 2 and Month 6
1836499|NCT00851669|Behavioral|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD)|Interpersonal Psychotherapy for Co-occurring Alcohol Dependence and Major Depression (IPT-ADMD) is Interpersonal Psychotherapy with modifications specifically designed for the treatment of patients with co-occurring alcohol dependence and major depression
1836500|NCT00851669|Behavioral|Treatment as Usual|Individual psychotherapy following usual care practice in a chemical dependency treatment program.
1836501|NCT00851682|Device|MRI scan|Each patient will undergo one, contrast-enhanced MRI scan prior to his planned, standard of care procedure, either radical prostatectomy or brachytherapy, depending on the study arm. Patients will be randomized to be imaged with either a phased array body coil or an endorectal coil.
1836502|NCT00851708|Drug|N-acetylcysteine|600 mg bid orally from day 1 to 7 postoperative
1836503|NCT00851721|Biological|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|85 ± 15 U/kg of FEIBA NF every other day during the 12-month prophylactic period
1836504|NCT00851721|Biological|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|FEIBA NF dose and dosing interval as prescribed by the treating physician
1836505|NCT00851734|Drug|voclosporin ophthalmic solution|0.02%, 0.2% t.i.d. or b.i.d.
1836508|NCT00851760|Procedure|Consecutive surgery|Consecutive surgery for epiretinal macular membrane and cataract extraction
1836509|NCT00851760|Procedure|Combined surgery|Combined surgery for epiretinal macular membrane and cataract extraction
1836510|NCT00851773|Drug|semaglutide|0.1 mg once weekly, s.c. injection
1836511|NCT00851773|Drug|semaglutide|0.2 mg once weekly, s.c. injection
1836512|NCT00851773|Drug|semaglutide|0.4 mg once weekly, s.c. injection
1836513|NCT00851773|Drug|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
1836514|NCT00851773|Drug|semaglutide|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, 1.2 mg once weekly for 6 weeks, s.c. injection
1836515|NCT00851773|Drug|placebo|0.1 mg once weekly, s.c. injection
1836516|NCT00851773|Drug|placebo|0.2 mg once weekly, s.c. injection
1836517|NCT00851773|Drug|placebo|0.4 mg once weekly, s.c. injection
1836518|NCT00851773|Drug|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 7 weeks, s.c. injection
1836519|NCT00851773|Drug|placebo|0.4 mg once weekly for 1 week, 0.8 mg once weekly for 1 week, followed by 1.2 mg once weekly injections for 6 weeks, s.c. injection
1836520|NCT00851786|Biological|ZOSTAVAX|Subcutaneous injection of 0.65 mL of ZOSTAVAX at Day 0 and Week 6
1836521|NCT00851786|Biological|Placebo|Subcutaneous injection of 0.65 mL of placebo at Day 0 and Week 6
1836522|NCT00851799|Drug|Emtricitabine/tenofovir disoproxil fumarate|"200 mg emtricitabine/300 mg tenofovir disoproxil fumarate taken orally daily. A combination drug of two nucleoside reverse transcriptase inhibitors (NRTIs).
Other Name: TDF/FTC"
1836523|NCT00851799|Drug|Ritonavir|"100 mg taken orally once daily. A protease inhibitor (PI).
Other Name: RTV"
1836524|NCT00851799|Drug|Atazanavir|"300 mg taken orally once daily. A protease inhibitor (PI).
Other Name: ATV"
1836525|NCT00851799|Drug|Raltegravir|"400 mg taken orally twice daily. An integrase inhibitor (INI).
Other Name: RAL"
1836526|NCT00851799|Drug|Darunavir|"100 mg taken orally once daily. A protease inhibitor (PI).
Other Name: RTV"
1836527|NCT00851812|Behavioral|Exercise|Standard care monitoring
1836528|NCT00851812|Behavioral|Progressive walking and resistance exercise treatment|Home-based exercise : Progressive walking and resistance program
1836529|NCT00854256|Procedure|Canaloplasty|Canaloplasty surgery
1836530|NCT00854256|Procedure|Trabeculectomy with mitomycin C|Trabeculectomy with mitomycin C surgery
1836531|NCT00854269|Procedure|surgery|cervical biopsy or specimen of hysterectomy
1836532|NCT00854282|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
1836533|NCT00854295|Device|NexGen LPS-Flex Mobile Bearing Knee|Total Knee Replacement
1997160|NCT02204618|Device|cochlear implantation|
1836535|NCT00854308|Drug|MetMAb|MetMab (a monovalent antagonist antibody to the receptor MET) 15 mg/kg in 250 CC 0.9% saline intravenous infusion every 3 weeks.
1836536|NCT00854308|Drug|placebo (0.9 % saline)|Placebo Intravenous infusion every 3 weeks.
1836537|NCT00854321|Drug|rituximab|rituximab two 1000 mg intravenous infusions separated by two weeks
1836538|NCT00854321|Drug|rituximab, observational study amon patients with active RA|two 1000 mg intravenous infusions separated by 2 weeks
1836539|NCT00854360|Drug|Beclomethasone dipropionate HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
1836540|NCT00854360|Drug|Placebo|HFA Vehicle Aerosol
1836541|NCT00854373|Drug|Bravelle(follicle stimulating hormone)|One dose of 6 amps of Bravelle given at the same time as HCG ovulation trigger.
1836542|NCT00854373|Other|Saline ( placebo)|1 cc of Normal Saline (placebo) given at the same time as HCG ovulation trigger.
1836543|NCT00854386|Drug|liberal fluid administration|patients in the liberal group (LG) will receive 8 ml/kg•hr of ringer lactate (RL) solution
1836544|NCT00854386|Drug|restrictive fluid administration|Patients in the restrictive group (RG) will receive 2 ml/kg•hr of Ringer Lactate (RL) solution throughout the intraoperative period
1836545|NCT00854399|Procedure|Staging surgery or debulking surgery|Staging surgery or debulking surgery
1836546|NCT00854412|Other|Weight loss|Very low-calorie diet (VLCD) of 800 kcal/day for 8 weeks
1836547|NCT00854425|Drug|L-asparaginase|L-asparaginase 600mg/m2 days 1-7 repeated every 3 weeks for a total of 6 cycles
1836548|NCT00854438|Other|Multidisciplinary drug reviews by pharmacist and physician|Reduction of anticholinergic drug effects by pharmacist review
1836549|NCT00854451|Drug|omeprazole plus amoxicillin|
1836550|NCT00854451|Drug|omeprazole plus amoxicillin|
1836551|NCT00854451|Drug|omeprazole plus amoxicillin|
1836552|NCT00854451|Drug|omeprazole plus amoxicillin|
1836553|NCT00854477|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily for 14 days every 3 weeks. Number of cycles: 8 cycles unless there is evidence of disease progression, or unacceptable toxicity
1836554|NCT00854503|Drug|Simvastatin|20 mg/day in one oral administration
1836555|NCT00854503|Drug|Rosuvastatin|20 mg/day in one oral administration.
1836556|NCT00854516|Procedure|A new treatment approach is to have an effective working pressure combined with a low resting pressure.|"Procedure Schedule: The total duration for study participation will be 14 days (8 visits).
Subject eligibility will be determined at the initiation visit. All eligible subjects will receive the compression device on the study leg and will return to the clinical center at day 1, 2, 3, 4, 7, 10 and 14 to assess safety. At each clinical visit (except visit day 14) the compression device will be reapplied. The study participation ends after 14 days."
1836557|NCT00854529|Drug|Bevacizumab|sub-conjunctival injection of 1.25mg Bevacizumab
1836558|NCT00854542|Behavioral|Telepsychiatry-based Culturally Sensitive Collaborative Treatment|T-CSCT: Patients in Group A will receive T-CSCT, which consists of Telepsychiatry-based Culturally Sensitive Psychiatry Assessment using the Engagement Interview Protocol (EIP) plus Care Management.
1836559|NCT00854555|Other|Locomotor training with robot|60 days locomotor training during 6 months period in out-patient setting. Minimum 60 min training up to 3 times per week. Control group receives conventional training/treatment.
1836560|NCT00854555|Other|Locomotor training with manual assistance|60 days training during 6 months period on in-patient setting. Training 2 times per day total 120 minutes. Control group receives conventional training/treatment.
1836561|NCT00854568|Drug|CEOP regimen|cyclophosphamide 750mg/m2 IV day 1 epirubicin 70mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
1836562|NCT00854568|Drug|CHOP regimen|cyclophosphamide 750mg/m2 IV day 1 doxorubicin 50mg/m2 IV day 1 vincristine 1.4mg/m2 IV day1 (maximum: 2mg) prednisone 50mg PO days 1~5 twice per day Or combined with rituximab 375mg/m2 IV day 0
1836563|NCT00854581|Biological|PEG-interferon alfa-2b|PEG-IFN-alfa2b 1.5 ug/kg SQ weekly.
1836564|NCT00854581|Biological|Interferon alfa-2b|Days 3 - 14: Interferon Alpha-2b 5 10 million units IV twice daily.
1836565|NCT00854581|Drug|Valproic Acid|Patients will be started on one capsule (250 mg) with water twice daily.
1836566|NCT00854581|Drug|Zidovudine|Days 1-2: (0-48 hours) Zidovudine (AZT) 1.5 grams intravenously (IV) twice daily. Days 3-14: Zidovudine (AZT) 1.5 grams IV twice daily and Interferon Alpha-2b 5 10 million units IV twice daily. Subsequent doses dependent on patient response.
1836567|NCT00854581|Genetic|Molecular Evaluation/Analysis of Malignant Clones of ATLL|Blood Sample - Baseline/Pre-Treatment, months 3 and 6, End of Month 12, Disease Progession
1836568|NCT00854581|Genetic|NF-kB Inhibition|Blood Sample - Baseline/Pre-Treatment, Induction,
1836569|NCT00854594|Behavioral|Role modeling in Shared medical appointments to Promote Establishing Collaborative Teams (ReSPECT)|The intervention is designed to educate the clinicians at intervention CBOCs by modeling interprofessional team practices during SMAs for diabetes mellitus (DM) patients from each CBOC primary care provider's (PCP) patient panel. We hypothesize that this education at intervention CBOCs will improve interprofessional practices and overall quality care delivered to veterans.
1836570|NCT00854607|Other|No Intervention|Blood samples will be collected for 12 weeks to evaluate levels of fungal biomarkers.
1836571|NCT00854620|Drug|Sorafenib|Sorafenib administered in escalating 28-days cycles (400, 600 and 800 mg BID)
1836572|NCT00854633|Drug|Talactoferrin|Enteral, 150 mg/kg twice per day
1836573|NCT00854633|Drug|Placebo|Oral, twice per day
1836574|NCT00854646|Drug|ON 01910.Na|The drug is a sterile, concentrated 75mg/mL solution in polyethylene glycol 400, in labeled, sealed glass vials. The Concentrate must be diluted with aqueous infusion solutions (0.9% NaCl, USP and Water for Injection, USP according to instructions) immediately prior to intravenous administration.
1836575|NCT00854659|Drug|ABT-102|BID tablets, 7 days of treatment
1836576|NCT00854659|Drug|Placebo|BID tablets, 7 days of treatment
1836577|NCT00854685|Drug|ART621|3.0mg/kg s.c. - weekly
1836578|NCT00854685|Drug|ART621|3.0mg/kg s.c. - fortnightly
1836579|NCT00854685|Drug|ART621|1.5mg/kg s.c. - weekly
1836580|NCT00854685|Drug|ART621|1.5mg/kg s.c. - fortnightly
1836581|NCT00854685|Drug|Placebo|Placebo s.c. - weekly
1836584|NCT00854698|Other|subjects are asked to exercise during 20 or 30 minutes|subjects are asked to exercise during 20 or 30 minutes
1836585|NCT00854711|Procedure|inhaled nitric oxide|80 PPM
1836586|NCT00854724|Drug|Puerarin, Placebo|400 mg, three times a day for 7 days
1836587|NCT00854737|Dietary Supplement|cytidine|cytidine (2g po daily for 4 months)
1836588|NCT00854737|Dietary Supplement|omega-3 fatty acids|omega-3 fatty acids (4g po daily for 4 months)
1836589|NCT00854737|Drug|placebo|sugar pill
1959070|NCT00846651|Other|Colloid administration|The patients received 0.5 L colloid solution (hydroxyethylstarch 6%) or 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
1959071|NCT00846651|Other|Crystalloid administration|The patients received 1.5 L Ringer lactate prior to spinal anesthesia for cesarean section.
1959072|NCT00846651|Drug|phenylephrine infusion|A phenylephrine infusion will be started immediately after performing the spinal anesthesia and continued until time of uterine incision.
1836594|NCT00854763|Drug|olmesartan|olmesartan
1836595|NCT00854776|Drug|lansoprazole|30 mg once daily
1836596|NCT00854776|Drug|aluminum hydroxide 334 mg and Mg hydroxide 166 mg|1 tablet once daily
1836598|NCT00854802|Drug|Debio 025|Debio 025 supplied in soft gel capsules
1836599|NCT00854802|Drug|Peg-IFNα2a|Peg-IFNα2a supplied in pre-filled syringes
1836600|NCT00854802|Drug|Ribavirin|Ribavirin supplied in tablets
1836601|NCT00854802|Drug|Debio 025 placebo|Debio 025 placebo supplied in soft gel capsules
1836602|NCT00854815|Procedure|Irrigation|Irrigation of the area with at least 500ml NS using the power suction/irrigator
1836603|NCT00854815|Procedure|No Irrigation|Suction only using suction/irrigator
1836604|NCT00854828|Procedure|Surgical intervention|Surgical intervention as appropriate for adults with symptomatic lumbar scoliosis
1836605|NCT00854828|Other|Non-operative intervention|Non operative intervention as appropriate for treatment of adults with symptomatic lumbar scoliosis such as: injections, medications, physical therapy, etc.
1836606|NCT00854841|Drug|Dasatinib and Imatinib|"Dasatinib Dasatinib will be administered orally at a dose of 100 mg QD. During the first month, subjects will be instructed to take dasatinib in the morning.
Imatinib Imatinib will be administered orally at a dose of 600 mg once daily (QD). Each 600 mg dose should be administered with a meal and taken with a large glass of water. If a scheduled dose is missed for more than 12 hours or dosing is interrupted for toxicity or for any other reason, these doses should be omitted."
1836607|NCT00854854|Biological|TKCell|"TKCell 150ml IV for 7times after each FOLFOX-4 regimen :
From the second cycle of FOLFOX4(start Day1),TKCell is administered in Day3 and Day8.In the third cycle of FOLFOX4(Day1),TKCell is administered in Day3 and Day8.In the fourth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the fifth cycle of FOLFOX4(Day1),TKCell is administered in Day8.In the sixth cycle of FOLFOX4(Day1),TKCell is administered in Day8"
1836608|NCT00854867|Drug|Whole Brain Radio Therapy (WBRT) with sequential Depocyte|
1836609|NCT00854867|Drug|Whole brain radiotherapy (WBRT) with concomitant Depocyte|
1836610|NCT00854880|Drug|PDC339|
1836611|NCT00854880|Drug|Placebo|
1836612|NCT00854893|Device|transcranial direct current stimulation|1 mV for 20 min (verum conditions: anodal and cathodal)or 30 seconds (placebo condition: sham) during language learning , active electrode over primary motor cortex of language dominant hemisphere, reference electrode over contralateral supraorbital area
1836613|NCT00854919|Drug|atypical antipsychotic drug|For SSRI-refractory group, either atypical antipsychotic such as mean doses of RIS (3.1±1.9mg/day), of OLZ (5.1±3.2mg/day), and of QET (60.0±37.3mg/day) was added on ongoing SSRI(Paroxetine, Fluvoxamine).
1836614|NCT00854919|Behavioral|exposure response prevention|After at least 12 weeks from treatment initiation, cognitive-behavioral therapy (CBT) using exposure and response prevention was added with psychoeducational interventions and behavioral analysis.
1836615|NCT00854932|Other|Procalcitonin-guided decision making|In the PCT group, if infection is considered to be unlikely or possible, antibiotic therapy is discontinued when two consecutive PDT values are within the normal range.
1836616|NCT00854945|Drug|ON 01910.Na|1800 mg/day as a 24-hour continuous intravenous infusion administered three times a week every 2 weeks
1836617|NCT00854971|Biological|TKCell|Biological/Vaccine: TKCell
1836618|NCT00854984|Behavioral|Living Life to the Full|A nurse-supported, self-help, cognitive behavioural therapy with web, video and booklet formats.
1836621|NCT00855036|Other|Attenuated bedrest|Patients are allowed to ambulate the morning after admission and then can be discharged when eating well and pain is controlled on oral pain medication regardless of hematuria
1836622|NCT00855049|Drug|Acetaminophen|Intranasal acetaminophen administration
1836623|NCT00855049|Drug|Acetaminophen|Oral acetaminophen administration
1836624|NCT00855062|Drug|minocycline|100 mg capsule every 12 hours by mouth
1836625|NCT00855062|Drug|minocycline placebo capsule|1 capsule every 12 hours by mouth
1836626|NCT00855075|Device|Cerebral State Monitor|A cerebral state monitor will provide a cerebral state index for mechanically ventilated intensive care patients. Recorded cerebral state indexes will be correlated with clinical assessments of sedation using the Richmond Agitation-Sedation Scale.
1836627|NCT00855088|Drug|darunavir|Healthy male volunteers will take darunavir 600 mg orally twice daily for 15 doses (8 days)
1836628|NCT00855088|Drug|Ritonavir|Healthy male volunteers will take ritonavir 100 mg orally twice daily for 15 doses (8 days)
1836629|NCT00855088|Drug|Etravirine|Healthy male volunteers will take etravirine 200 mg orally twice daily for 15 doses (8 days)
1836630|NCT00855101|Drug|voriconazole|6 mg/kg IV q12h on Day 1, and 4 mg/kg IV q12h on Days 2-7, then switch to 200 mg oral tablet q12h on Days 8-14.
1836631|NCT00855114|Drug|everolimus|5 mg/day x 7 days by mouth
1836632|NCT00855114|Procedure|therapeutic conventional surgery|Definitive excision of breast cancer tissue
1837626|NCT00859989|Procedure|evaluation of cancer risk factors|
1836634|NCT00855153|Other|VR (Virtual reality)|VR stimulation of combat scenarios utilized as the exposure therapy tool.
1836635|NCT00855153|Drug|D-Cycloserine|50 mg DCS 30 min prior to individual 90 min session with graded VR exposure treatment
1836636|NCT00855166|Drug|Dapagliflozin|Tablet oral 10 mg total daily dose once daily 102 weeks
1836637|NCT00855166|Drug|Metformin|Tablet oral 1500 - 2500 mg total daily dose 1-3 times a day104 weeks
1836638|NCT00855166|Drug|Sitagliptin|Tablet oral 100 mg total daily dose once daily rescue medication
1836639|NCT00855166|Drug|Placebo|Matching placebo for dapagliflozin, tablet, oral, once daily, 102 weeks
1836640|NCT00855179|Drug|Red vine leaf extract (AS 195)|Antistax film-coated tablet 360 mg
1836641|NCT00855179|Drug|Placebo|Placebo tablets identical to those containing Anstistax 360 mg
1836642|NCT00855192|Behavioral|mindful meditation|interpersonal and psycho-educational
1836643|NCT00855192|Behavioral|interpersonal therapy|psycho-educational
1836645|NCT00855218|Drug|Sorafenib (Nexavar, BAY43-9006)|800 mg sorafenib (4 tablets) will be taken daily (400mg b.i.d. [twice daily], 2 tablets). Transarterial Chemoembolization (TACE) using DC Bead
1836646|NCT00855218|Drug|Placebo|4 tablets of placebo will be taken daily (2 tablets b.i.d). TACE using DC Bead
1836647|NCT00855244|Other|Diagnostic exams|Growth hormone stimulation testing, oral glucose tolerance test, hyperinsulinemic euglycemic clamp
1836648|NCT00855257|Drug|Acid Nicotinique|
1836649|NCT00855257|Drug|Placebo|
1836650|NCT00855270|Drug|Placebo|IV saline will be used as placebo for control
1836651|NCT00855270|Drug|Hydrocortisone|A single dose 90-150mg of Intra Venous Hydrocortisone. 90mg will be administrated to participants weighing 45-59kg. 100mg will be administrated to participants weighing 60-69kg. 120mg will be administrated to participants weighing 70-89kg. 140mg will be administrated to participants weighing 90-99kg. 150mg will be administrated to participants weighing 100-120kg.
1836652|NCT00855283|Drug|IN NEO|20 mg Neostigmine via intranasal and sublingual administration
1836653|NCT00855283|Drug|IN NEO|40 mg Neostigmine via intranasal administration
1836654|NCT00855283|Drug|IN NEO|60 mg Neostigmine via intranasal administration
1836655|NCT00855283|Drug|IN NEO + IN Glycopyrrolate|Intranasal or sublingual Neostigmine (at effective dose: 20, 40, or 60 mg) + 4-12 mg intranasal or sublingual Glycopyyrolate
1836656|NCT00855283|Drug|IV Visit|2mg NEO and .4mg GLY given intravenously to see if the subject responds to the intervention. If they respond, then they will proceed to the IN portion of the study.
1836657|NCT00855309|Drug|acyclovir sodium|Given IV
1836658|NCT00855322|Other|Gym exercise group intervention|Gym based circuit class
1836659|NCT00855322|Other|Hydrotherapy group exercise intervention|Hydrotherapy group exercise class
1836660|NCT00855322|Other|Control group|No intervention
1836661|NCT00855335|Drug|Darunavir|TMC114 (darunavir) two 300 mg or one 600 mg tablet twice daily up to 12 weeks postpartum in Group 1. TMC114 (darunavir) 800mg tablet once daily up to 12 weeks postpartum in Group 2.
1836662|NCT00855335|Drug|Ritonavir|100 mg tablet twice daily up to 12 weeks postpartum.
1836663|NCT00855335|Drug|Etravirine|Two 200 mg tablets twice daily up to 12 weeks postpartum.
1836664|NCT00855335|Drug|Rilpivirine|One 25 mg tablet once daily up to 12 weeks postpartum.
1836665|NCT00855335|Drug|Darunavir/Cobicistat (FDC)|Fixed dose combination (FDC) tablet of TMC114 (darunavir) 800 mg and cobicistat 150 mg once daily up to 12 weeks postpartum.
1836666|NCT00855348|Other|All eligible subjects will provide blood for SEPT9 biomarker testing|A single blood sample per participant selected according to analysis plan is tested for evidence of methylation of a specific DNA sequence, SEPT9.
1836667|NCT00855361|Drug|Rabeprazole sodium|One single daily dose of rabeprazole sodium 1 mg as a microgranule formulation for up to 28 consecutive days (Part 1), and one single daily dose of rabeprazole sodium 2 or 3 mg as a microgranule formulation for up to 28 consecutive days (Part 2). The study drug will be administered through a nasogastric or orogastric tube.
1836668|NCT00855387|Other|No additional intervention than the intended major surgery in pancreas, liver, colorectal, gastric bypass and small bowel|No additional intervention than the intended major surgery (liver, bile duct, pancreas, colorectal, gastric bypass and small bowel resections) comparing with costs
1836669|NCT00855400|Procedure|Laminectomy and bone marrow stem cells transplantation|T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation
1836670|NCT00855400|Procedure|Autologous bone marrow cells collection|Autologous bone marrow cells collection under sedation. Sixty mL are obtained and processed through a ficoll gradient.
1836672|NCT00855439|Drug|Exenatide|Exenatide is given according to current FDA prescribing guidelines. Exenatide and other diabetes medications will be titrated in order to achieve optimal blood glucose levels
1836673|NCT00855439|Drug|Glargine|Subjects will take 1 daily injection of insulin glargine in manner consistent with current prescribing guidelines. Glargine and other diabetes medications will be adjusted to achieve optimal levels of blood sugar control
1836674|NCT00855452|Procedure|one - three cycles of cell therapy during 4-6 weeks (3-5x10^7 cells/kg will be given through IV systemically|Patients will be eligible to participate in a treatment program based on systemic administration of mismatched lymphocytes activated in vitro with rIL-2(LAK) followed by rIL-2 inoculation in vivo
1836675|NCT00855465|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid orally for 16 weeks.
1836676|NCT00855465|Drug|Placebo|Matching Placebo tid orally for 16 weeks
1959079|NCT00833989|Drug|GSK249320|I.V. infusion
1836678|NCT00855491|Procedure|Phaco|AcrySof Single-Piece IOL
1836679|NCT00855517|Drug|Latanoprost-PPDS|Control of IOP compared to baseline for the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
1836680|NCT00855530|Drug|amibegron (SR58611A)|oral administration of 300 mg twice daily
1959080|NCT00833989|Drug|PLACEBO|Placebo
1997280|NCT02149823|Drug|Syntocinon 40 Intranasal Units (IU)|
1997281|NCT02149823|Drug|Intranasal Placebo|
1836681|NCT00855556|Genetic|blood draw|"The blood collection is designed to obtain blood samples as a source of DNA for genotyping and to establish a plasma and serum storage repository for future assays. GCRC nurses will perform all blood draws associated with this study. The following procedures are designed to standardize sample collection:
Blood will be collected with the participant in the seated position with the reclining position reserved for those with a history of fainting during blood collection.
Participants will be instructed to drink plenty of water (e.g., at least 8 large glasses of water) prior to the clinic visit as this facilitates easier collection.
No fasting, activity or medication restrictions are required prior to or following blood collection.
Blood collection will follow completion of the questionnaires. They will be performed by a nurse or technician with documented class time and experience in phlebotomy. Technician certification will occur prior to blood collection."
1836682|NCT00855569|Device|Stasilon|Stasilon and gauze will be applied to donor site. Dressings will be collected and evaluated for amount of shed blood.
1836683|NCT00855582|Drug|Tadalafil|tablet once daily by mouth for 12 weeks.
1836684|NCT00855582|Drug|Placebo|Matching 2.5 or 5 mg placebo tablet once daily by mouth for 12 weeks.
1836685|NCT00855595|Drug|Azelaic acid (Finacea, BAY39-6251)|Participants received topical azelaic acid gel 15% twice daily for 12 weeks
1836686|NCT00855595|Drug|Metronidazole (Metrogel)|Participants received topical metronidazole 1% gel once daily for 12 weeks
1836687|NCT00855595|Drug|Doxycycline (Oracea)|Participants received systemic doxycycline 40 mg once daily for 12 week
1836688|NCT00855608|Drug|adalimumab|intravitreal adalimumab injection 0.03 ml in volume (1.5mg) one dose to one eye
1836689|NCT00855621|Procedure|Deep brain stimulation of the subthalamic nucleus|Chronic bilateral deep brain stimulation in the nucleus subthalamicus is performed using the most effective of four electrode contacts identified during testing of stimulation settings. Stimulation settings will be variable and adjusted according to the symptoms of each individual patient. Stimulation parameters will be recorded at each individual examination. Dopaminergic and other necessary medication will be given according to the need of each patient.
1836690|NCT00855634|Procedure|Resection of metastases|resection of the primary tumor, followed by resection of the liver metastasis/metastases
1836691|NCT00855634|Procedure|Resection of infiltrated veins|resection of the primary tumor with resection of the portal vein (and/or superior mesenteric vein/splenic
1836692|NCT00855647|Procedure|Hypo-fractionated Radiotherapy|
1836693|NCT00855660|Drug|Riociguat (Adempas, BAY63-2521) immediate release tablet of 2.5 mg|Riociguat administered in a dose of 2.5 mg (single tablet), thrice daily, over 14 days.
1836694|NCT00855660|Drug|Placebo|Placebo administered as a single tablet, thrice daily, over 14 days.
1836695|NCT00855673|Device|Intermittent Mechanical Compression|FM220 device
1836696|NCT00855673|Drug|Control|Standard medical treatment
1836697|NCT00855686|Drug|Memantine|20mg once daily oral dose
1836698|NCT00855686|Drug|Placebo|Daily oral dose
1836699|NCT00855699|Drug|Acamprosate|Acamprosate 333mg tablets, two tablets three times a day for duration of alcohol detox.
1836700|NCT00855712|Device|Organ Care System|The Organ Care System (OCS) is a portable organ perfusion and monitoring system intended to preserve a donated heart in a near normal physiologic beating state during transport for eventual transplantation into a recipient. The OCS maintains organ viability by providing a controlled environment that simulates near-normal physiological conditions, continuously perfusing the donated heart with warm, oxygenated blood, supplemented with the Solution Set. The blood is collected from the donor and continuously circulated to the organ in a closed circuit along with the Solution. The OCS preserves and monitors the organ's perfusion and metabolic state after explantation from a donor and connection to the device, during transportation to the recipient site, and until disconnection from the device.
1836701|NCT00855712|Device|Cold Cardioplegia Solution|This is the standard of care solutions used to arrest and preserve the donated heart during transport until arrival at recipient hospital
1836702|NCT00855725|Other|fMRI|Subjects will undergo MRI scanning to gather data about cognetive functions.
1836703|NCT00855725|Other|Hamilton Depression Rating Scale|Investigator will evalute the subject during a one on one interview for depression using the Hamilton Depression Rating Scale.
1836704|NCT00855725|Other|Beck's Depressive Inventory|Subjects will complete self assessment to evaluate their level of depression.
1836705|NCT00855725|Other|Interictal Dysphoric Disorder Inventory (IDDI)|Subject will complete self assessment to determine if there have been any changes in mood, emotions and or feelings from time to time.
1836706|NCT00855738|Drug|Gabapentin, Lamotrigine, Levetiracetam, Pregabalin, Oxcarbacepine, Tiagabine, Topiramate, Zonisamide|"Gabapentin: up to 3.600 mg/d
Lamotrigine: up to 400 mg/d
Levetiracetam: up to 3.000 mg/d
Pregabalin: up to 600 mg/d
Oxcarbazepine: up to 2.400 mg/d
Tiagabine: up to 30 mg/d
Topiramate: up to 400 mg/d
Zonisamide: up to 500 mg/d"
1836707|NCT00855764|Drug|Paclitaxel|Solution, IV, 100 mg/m2, weekly for 6 of 7 weeks, until evidence of disease progression or unacceptable side effects became apparent
1836708|NCT00855777|Drug|etoricoxib|etoricoxib 120 mg/day for 3 days
1836709|NCT00855777|Drug|ibuprofen|ibuprofen 1,800 mg/day for 3 days
1836710|NCT00855790|Other|evaluate the effectiveness of the RJ4 biopsy forcep versus the RJ3 biopsy forcep|Use of either the RJ3 or RJ4 biopsy forcep for colon polypectomy. will evaluate the effectiveness of removal of polyps less than 6 mm.
1836711|NCT00855803|Radiation|radiation|Given in 1 or 5 fractions
1836712|NCT00855816|Behavioral|Breathing training|relaxation training
1836713|NCT00855829|Device|Miniature Actilady device active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).
The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.
Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
1836714|NCT00855829|Device|Miniature Actilady device not active|"Devices: Targeted pressure waves are created by two kind of methods ActiLady).
The effect of the waves used will be examined by the use of a silicon tube or polyvinyl chloride (PVC) tube which is inserted into the vaginal cavity. The other end of the tube will be connected to an off the shelf pressure waves generator and controller.
Self manufactured device inserted into the vaginal cavity and creating subsound pressure waves."
1836715|NCT00855842|Device|osmotic dilator insertion|osmotic dilators are placed in the cervix to cause cervical dilation
1836716|NCT00855855|Biological|DTaP-IPV/Hib|0.5 mL, Intramuscular
1836717|NCT00855868|Drug|florbetapir F 18|370 MBq (10 mCi), intravenous (IV) injection, single dose
1836718|NCT00855868|Drug|[11C]-PIB|555 MBq (15 mCi), IV injection, single dose [11C]-PIB
1836719|NCT00855881|Drug|tegafur-uracil|tegafur-uracil 1 cap, bid for 1 year
1836720|NCT00855894|Drug|Pertuzumab|After a single administration of a loading dose of 840 mg IV, patients received a maintenance dose of 420 mg IV every 3 weeks (q3w).
1836721|NCT00855894|Drug|Erlotinib|Patients received 150 mg orally once a day which was reduced to 100 mg orally once a day in a protocol amendment dated 19 May 2010.
1836722|NCT00855907|Other|clinical evaluation|"Patients will fill up a questionnaire regarding their disease, demographic data, other co-morbidities and medications and risk factors for metabolic syndrome.
Each patient will undergo blood examinations in order to assess inflammation, and metabolic status. Fatty liver will be assessed by liver ultra-sonography."
1836723|NCT00855920|Drug|Rilonacept|Two subcutaneous injections of Rilonacept 160 mg (for a total of 320 mg) on Day 1 (Baseline).
1836724|NCT00855920|Drug|Indomethacin|Indomethacin orally TID for 12 days (Indomethacin 50 mg for first 3 days and then, Indomethacin 25 mg for next 9 days).
1836725|NCT00855920|Other|Placebo (for Indomethacin)|Placebo (for Indomethacin) orally TID for 12 days.
1836726|NCT00855920|Other|Placebo (for Rilonacept)|Two subcutaneous injections of Placebo (for Rilonacept) on Day 1 (Baseline).
1836727|NCT00855933|Device|Experimental Floss|Experimental Glide® floss with cetylpyridinium chloride (~13% dry weight CPC)
1836728|NCT00855959|Drug|Budesonide|Inhalation powder, inhalation, twice daily, 4 weeks followed by Suspension for nebulisation, inhalation, once or twice daily, 6 weeks
1836729|NCT00855959|Drug|Pulmicort Turbuhaler|Pulmicort Turbuhaler 200 µg, Dry powder inhaler, budesonide 200 µg/dose, 112 doses/Turbuhaler
1836730|NCT00855972|Drug|Low Dose Naltrexone|
1836731|NCT00855985|Procedure|type of anastomosis after pancreaticoduodenectomy|pancreaticojejunostomy (arm 1) versus pancreaticogastrostomy (arm 2)for reconstruction of the pancreatic remnant after pancreaticoduodenectomy
1836732|NCT00856024|Biological|Peginterferon alfa-2b|PegIntron 80 μg, PegIntron 100 μg, or PegIntron 120 μg. The duration of the complete treatment and the doses of pegylated interferon alfa 2b should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
1836733|NCT00856024|Drug|Ribavirin|Ribavirin 250 mg. The duration of the complete treatment and the doses of ribavirin should have been prescribed according to local guidelines, and according to the investigating physician's orientation.
1836734|NCT00856037|Drug|Doxorubicin Hydrochloride|Given IV
1836735|NCT00856037|Other|Laboratory Biomarker Analysis|Correlative studies
1836736|NCT00856037|Other|Quality-of-Life Assessment|Ancillary studies
1836737|NCT00856037|Drug|Topotecan Hydrochloride|Given PO
1836738|NCT00856050|Drug|letrozole|Taken orally once a day continuously
1836739|NCT00856063|Drug|atomoxetine (or placebo)|Each child will be randomized to receive either ATMX or placebo in the 1st crossover phase followed by the alternative drug condition in the 2nd crossover phase. The study drug (ATMX or placebo) will be administered BID and will be titrated blindly based on clinical response and tolerability. ATMX will be initiated at 0.5 mg/kg/day for 3 days. Based on clinical response, ATMX dose will be titrated to 0.8 mg/kg/day during week 1, 1.4 mg/kg/day during week 2, and a maximum of 1.8 mg/kg/day during week 3, unless serious untoward effects intervene.
1836740|NCT00856089|Drug|Retapamulin|Retapamulin ointment, 1%, apply a thin layer, BID for 5 days
1836741|NCT00856102|Behavioral|Exercise|Home-base walking program
1836742|NCT00856102|Behavioral|Control|Usual care
1836743|NCT00856115|Other|medical chart review|Patient charts are reviewed to obtain medical data.
1836744|NCT00856115|Other|questionnaire administration|Patients undergo a 45-60 minute interview to obtain information on variations in symptom perception, assessment, and patient-physician communication process. Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity), information of close confidants (i.e., relationship, family history of cancer, and caregiver/decision-making status), and physician characteristics. Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
1836745|NCT00856115|Other|study of socioeconomic and demographic variables|Patients are assessed by sociodemographic characteristics (i.e, education, gender, age, insurance status, employment status, income, race/ethnicity, and religiosity).
1836746|NCT00856115|Other|survey administration|Patients are also assessed by the Trust in the Health Care System, DMPQ, RCS, Brief COPE scale, Lukwago Religiosity scale, and RAND Social Support Survey questionnaires.
1836747|NCT00856141|Device|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
1836748|NCT00856141|Device|phacoemulsifcation|A sensor (Blumenthal cannula) connected to a transducer, a signal amplifier, an IOP recording device, and a display unit
1836749|NCT00856154|Biological|Peptides on autologous Dendritic Cells|"10 Peptides Pulsed onto 10e7 autologous macrophage-derived maturated dendritic cells administered s.c. week 0, 2, 4, 8.
Gag150 RLLNAWVKV
Gag433 FLGKIWPV
Env 67 NIWATHACV
Pol606 KLGKAGYVV
Vpu66 ALVEMGHHV
Vif101 GLADQLIHL
Vif23 SLVKHHMYV
Gag298 KRWIILGLNKIVRMY
gp41 VWGIKQLQARVLAVERYLKD
Padre AKXVAAWTLKAAA"
1836750|NCT00856167|Drug|TCM|whole system Traditional Chinese Medicine, including acupuncture, herbs, tuina, lifestyle counseling
1836751|NCT00856167|Behavioral|Self-care for TMD|a 5-session 8 hour intervention targeting TMD knowledge, stretching and exercises, stress reduction, lifestyle modification
1836752|NCT00856180|Drug|Bevacizumab|
1836753|NCT00856180|Drug|Cyclophosphamide|
1836754|NCT00856193|Drug|Placebo|Matching placebo capsules were supplied for inhalation once daily with Concept 1 device.
1836755|NCT00856193|Drug|NVA237|NVA237 50 μg capsules were supplied for inhalation once daily with Concept 1 device.
1836756|NCT00856206|Biological|Rilonacept|Rilonacept 160 mg subcutaneous injection once a week
1836757|NCT00856206|Other|Placebo|Placebo subcutaneous injection once a week
1836758|NCT00856219|Dietary Supplement|Enteral Continuous|Continuous Tube Feeding for 72 hours
1836759|NCT00856219|Dietary Supplement|Enteral Intermittent|Intermittent Tube Feedings
1836760|NCT00856219|Dietary Supplement|Parenteral Continuous|Parenteral Continuously for 72 hours
1836761|NCT00856232|Biological|Medical Air|Compressed medical air
1836762|NCT00856232|Biological|Oxygen|Medical Oxygen
1836763|NCT00856245|Drug|Rituximab|375 MG/M2 (milligram per meter squared) given IV (intravenously) weekly x 4-8 doses.
1836764|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses were suspensions of drug candidate. Doses were administered once daily for 10 consecutive days.
1836765|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
1836766|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
1836767|NCT00856258|Drug|PF 03882845 and Placebo|The constituted dosage form for all doses will be suspensions of drug candidate. Doses will be once daily for 10 consecutive days.
1836768|NCT00856271|Drug|olmesartan medoxomil|oral tablets, once daily for 8 weeks
1836769|NCT00856271|Drug|losartan potassium|capsules, once daily for 8 weeks
1836773|NCT00856297|Biological|MenACWY-CRM conjugate vaccine|
1836774|NCT00856297|Biological|Licensed comparator|
1836775|NCT00856310|Biological|REGN475 (SAR164877)|Subcutaneous administration REGN475 (SAR164877)
1836776|NCT00856323|Drug|Truvada|At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
1836777|NCT00856323|Behavioral|CM|Participants will submit a urine sample every Monday, Wednesday, and Friday for 8 weeks (a total of 24 urine samples). Samples will be tested for methamphetamine metabolites.
1836778|NCT00856336|Drug|DMXAA|DMXAA, given intravenously over 20 minutes. Patients were to each undergo six doses of treatment at weekly intervals, receiving each of six doses (300, 600, 1200, 1800, 2400 and 3000 mg/m2)
1836779|NCT00856349|Behavioral|Therapy Programming Report (TPR)|Center-specific therapy programming reports (TPRs) illustrating physician usage of shock reduction programming are provided to each center approximately 9-12 months after their first enrollment and monthly thereafter throughout the study.
1836780|NCT00856362|Drug|Moxidectin|
1836781|NCT00856362|Drug|Midazolam|
1836782|NCT00856375|Drug|NKTR-102|IV every 3 weeks
1836783|NCT00856375|Drug|irinotecan|IV every 3 weeks
1836784|NCT00856388|Drug|fludarabine phosphate|Given IV
1836785|NCT00856388|Drug|melphalan|Given IV
1836786|NCT00856388|Radiation|total-body irradiation|Undergo total-body irradiation
1836787|NCT00856388|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic stem cell transplantation
1836788|NCT00856388|Biological|anti-thymocyte globulin|Given IV
1836789|NCT00856401|Drug|PTH1-84 in parent study|daily injection of rhPTH(1-84); 25, 50 75, or 100mcg in parent study. In ADD-ON study, there is no intervention, only testing.
1836790|NCT00856414|Biological|botulinum toxin Type A|20U, up to two injections administered intramuscularly into the glabella (2 in each side of the corrugators and 1 in the procerus)
1836791|NCT00856427|Radiation|radiation therapy treatment planning/simulation|Undergo implantation of radio-opaque markers
1836792|NCT00856427|Procedure|implanted fiducial-based imaging|Undergo implantation of radio-opaque markers
1836793|NCT00856440|Drug|Fleets Oral Sodium Phosphate Solution (OSPS)|Osmotic preparation for colonoscopy
1836794|NCT00856440|Drug|Colyte|Lavage preparation for colonoscopy
1836795|NCT00856440|Drug|Dual (OSPS & Colyte)|Combined, two-day preparation utilizing both preparations
1836796|NCT00856453|Behavioral|Home yoga practice|training for and tracking of patient's practice of yoga at home
1836797|NCT00856453|Behavioral|yoga classes|organized out of home classes for yoga
1836798|NCT00856479|Device|Infuse Bone Morphogenic Protein (BMP) 2|"Infuse is a synthetic bone morphogenic protein which means it has the ability to help your bone to form and heal if inserted in the fracture site. Infuse may be the first commercially available product approved by Health Canada to accelerate the healing of long bone non-unions requiring surgical intervention."
1836799|NCT00856479|Procedure|iliac crest autograft|A piece of the patients iliac crest bone is take and mixed with bone from a bone bank to supplement the bone loss in the fracture
1836800|NCT00856492|Biological|bevacizumab|Given IV
1836801|NCT00856492|Biological|pegfilgrastim|Given subcutaneously
1836802|NCT00856492|Drug|cyclophosphamide|Given IV
1836803|NCT00856492|Drug|doxorubicin hydrochloride|Given IV
1836804|NCT00856492|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV
1836805|NCT00856505|Drug|Everolimus and mycophenolate sodium|Everolimus tablets, 1.5mg/day bid, dosage adjusted to plasma levels Mycophenolate sodium, 720mg/day bid Duration: Mycophenolate tapering starts at day 56 after stem cell transplantation Everolimus tapering starts at day 100 after stem cell transplantation if no GvHD evident
1836806|NCT00856518|Device|EMST|Pressure threshold device (Expiratory Muscle Strength Trainer) targeted at increase muscle force generation of expiratory and submental muscles.
1836807|NCT00856518|Device|Sham|The same device just like the EMST but does not provide a load on the target muscle group
1836808|NCT00856544|Drug|CP-690,550|Film coated tablet, 5 mg PO BID, 1 year
1836809|NCT00856544|Drug|CP-690,550|Film coated tablet, 10 mg PO BID, 1 year
1836810|NCT00856544|Drug|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
1836811|NCT00856544|Drug|Placebo|Film coated tablet, 1 tablet PO BID, 3-6 months
1836812|NCT00856557|Behavioral|Seminar and Practicum|A 4 hour seminar and practicum for internal medicine residents designed to provide a systematic approach to identifying contextual factors essential to planning patient care.
1836813|NCT00856570|Drug|warfarin|Oral
1836814|NCT00856570|Drug|YM178|Oral
1837627|NCT00859989|Procedure|support group therapy|
1836815|NCT00856583|Drug|Sertindole|Sertindole was supplied as 4, 12, 16, and 20 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national Summary of Product Characteristics (SPC) for sertindole; in countries where sertindole was not marketed, the European Union (EU) SPC applied (all national and EU SPCs were essentially identical). Recommended dose range: 12 to 20 mg/day. The investigators were instructed to contact H. Lundbeck A/S if they deemed it necessary to increase the dose of sertindole to 24 mg/day, which was allowed in exceptional cases
1836816|NCT00856583|Drug|Risperidone|Risperidone was supplied as 1, 2, 3, and 4 mg tablets. The start and maintenance dosages as well as dose titration were set by the investigator, in accordance with the national SPC for risperidone. Recommended dose range: 2 to 8 mg/day
1836817|NCT00856596|Drug|Sertaconazole nitrate cream 2%|Once a day topical cream
1997285|NCT02147964|Drug|Testosterone 1% Gel|Testosterone 1% gel 5g daily for 4 months [all subjects]
1836822|NCT00856622|Drug|i. Fixed combination of latanoprost 0.005% and timolol 0.5%|one drop in the morning and placebo in the evening
1836823|NCT00856622|Drug|timolol 0.5% ophthalmic solution|one drop in the morning and evening
1836824|NCT00856622|Drug|latanoprost 0.005% ophthalmic solution|placebo in the morning and latanoprost .005% in the evening
1836825|NCT00856635|Drug|Glatiramer Acetate|20 mg injected daily subcutaneously
1836826|NCT00856635|Drug|placebo|injected daily subcutaneously
1836827|NCT00856648|Device|SmartPill ingestion and monitoring|The SmartPill device will be ingested and remotely monitored until it is excreted in a normal bowel movement.
1836828|NCT00856661|Drug|Desmoteplase|90 μg/kg bodyweight, IV, single bolus over 1 to 2 minutes on 1st day
1836829|NCT00856661|Drug|Placebo|IV, single bolus over 1 to 2 minutes on 1st day
1836830|NCT00856674|Biological|OPL-CCL2-LPM|"CCL2-LPM
intravenous 0.001 mg/kg, 0.01 mg/kg, 0.05 mg/kg, 0.1 mg/kg, 0.5 mg/kg, 1 mg/kg
2 doses one week apart"
1836831|NCT00856687|Drug|PF-03893787|Oral, two doses 12 hours apart
1836832|NCT00856687|Drug|Placebo|Oral, two doses 12 hours apart
1836833|NCT00856687|Drug|Montelukast|Oral, two doses 12 hours apart
1836834|NCT00856700|Drug|GLP-1 infusion|Participants will receive intraarterial infusion of GLP-1 (20 pmol/ml solution) for 100 min.
1836835|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
1836836|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
1836837|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
1836838|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
1836839|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
1836840|NCT00856713|Drug|NRL972|Single intravenous dose of 2 mg NRL972
1836841|NCT00856726|Drug|1-34 parathyroid infusion|1-34 parathyroid infusion at 0.055 mcg/kg/hr for 6 hours
1836842|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 after pre-treatment with 600 mg p.o. rifampicin once daily from the evening of Day D-7 until the evening of Day D-1
1836843|NCT00856752|Drug|NRL972|Reference test: Single intravenous administration of 2 mg NRL972
1836844|NCT00856752|Drug|NRL972|Single intravenous administration of 2 mg NRL972 injection after pre-treatment with 100 mg cyclosporine on the evening of Day D-1 and on the morning of Day D01 one hour before administration of NRL972
1836845|NCT00848731|Drug|nitric oxide|nitric oxide gas is delivered by facemask
1997286|NCT02147964|Drug|Acyline|Acyline 300 ug/kg SQ injections every 2-weeks for 4 months [all subjects]
1997287|NCT02147964|Drug|Dutasteride|Dutasteride 2.5 mg (day 1) followed by 0.5 mg daily for 4 months
1997288|NCT02147964|Drug|Ketoconazole|ketoconazole 400 mg PO daily for 4 months
1836849|NCT00848770|Drug|Esmolol, Sodium Nitroprussiate (NPS) or Norepinephrine (NOR)|"Esmolol(2,5g /10ml + SG5% 240ml = 10mg/ml). Start with a bolus of 500mcg/kg in 1 min (ou 0,5mg/kg)and maintain the dose of 50mcg/kg/min (or 0,05mg/kg/min). Increase de infusion in 25mcg/kg/min after each 5 min until the randomized SAP or if the heart beat is lower than 60. The maximum dose is 200ug/kg/min (ou 0,2 mg/kg/min). If the randomized SAP do not reach the goal pressure with the maximum dose of esmolol, start a infusion of sodium nitroprussiate (NPS).
NPS (50mg + SG5% 250ml= 200mcg/ml). No bolus. Start the infusion with 0,2 mcg/kg/min and maintain 0,5 a 5mcg/kg/min. Increase de dose each 15 min to a maximum of 10mcg/kg/min.
NOR: (8mg/8ml + SG5% 242ml=32mcg/ml)No bolus. Start 1 to 5 mcg/min to a maximum dose of 20mcg/min."
1836850|NCT00848770|Drug|Esmolol, NPS or NOR|We use one of the three drug to manipulate the systolic arterial pressure
1836851|NCT00848770|Drug|manipulation of SAP|Esmolol or NPS or NOR
1836852|NCT00848783|Drug|Irinotecan|
1836853|NCT00848783|Drug|Cisplatin|
1836854|NCT00848783|Procedure|Surgery|
1836855|NCT00848783|Drug|Floxuridine|
1836856|NCT00848783|Drug|Capecitabine|
1836857|NCT00848796|Drug|Heparin Leo and Hepalean|Dosage based on Heparin does response curve obtained from the Medtronic HMS plus
1836858|NCT00848809|Procedure|Blood sample|9 blood samples will be sent to the laboratory for the subjects in the SLED cohort
1836859|NCT00848809|Procedure|Blood sample|10 blood samples will be collected and sent to the laboratory for the subjects in the intermittent hemodialysis cohort.
1836860|NCT00848835|Device|defibrillation lead (ENDOTAK EZ and RELIANCE)|defibrillation lead
1836861|NCT00848848|Biological|Trivalent Influenza Vaccine|1 dose of Trivalent Influenza Vaccine
1836862|NCT00848848|Biological|Trivalent Influenza Vaccine + high A|1 dose of Trivalent Influenza Vaccine with high A content
1836863|NCT00848848|Biological|Trivalent Influenza Vaccine + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ¼ dose adjuvant
1836864|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ¼ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ¼ dose adjuvant
1997289|NCT02147964|Drug|HCG|HCG 60 IU injection Subcutaneously, every other day for 4 months
1997290|NCT02147964|Drug|placebo dutasteride|placebo oral dutasteride PO daily for 4 months
1997291|NCT02147964|Drug|placebo ketoconazole|placebo ketoconazole daily for 4 months
1997292|NCT02146378|Drug|Vyndaqel|20mg/day
1997293|NCT02145949|Drug|Essential Amino Acids (EAA)|Twice daily ingestion of 20 or 23 grams of EAA for 7 days leading up to surgery and continuing for 6 weeks after surgery [surgery = primary total knee arthroplasty]
1836865|NCT00848848|Biological|Trivalent Influenza Vaccine + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine plus ½ dose adjuvant
1836866|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + ½ dose adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus ½ dose adjuvant
1836867|NCT00848848|Biological|Trivalent Influenza Vaccine + adjuvant|1 dose of Trivalent Influenza Vaccine plus adjuvant
1836868|NCT00848848|Biological|Trivalent Influenza Vaccine + high A + adjuvant|1 dose of Trivalent Influenza Vaccine with high A plus adjuvant
1836869|NCT00848848|Biological|Trivalent Influenza Vaccine intradermal dose|1 dose of Trivalent Influenza Vaccine intradermal dose
1836870|NCT00848848|Biological|Trivalent Influenza Vaccine + high A intradermal dose|1 intradermal dose of Trivalent Influenza Vaccine + high A
1836871|NCT00848861|Drug|propofol (sedation for outpatient colonoscopy)|
1836872|NCT00848861|Drug|midazolam plus meperidine (sedation for outpatient colonoscopy)|
1836873|NCT00848874|Behavioral|PVGS|Student use of SymTrend PVGS daily then tapering off for 14 weeks in conjunction to ratings by a coach.
1836874|NCT00848887|Biological|Adjuvanted and un-adjuvanted influenza vaccines|16 different formulations of trivalent influenza vaccine and 1 marketed influenza vaccine comparator.
1836875|NCT00848900|Behavioral|Outdoor activity|Adding 1 hour outdoor time into school curricula
1836876|NCT00856765|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
1836877|NCT00856765|Device|Bare metal stent|Bare metal stent
1836878|NCT00856765|Device|Drug eluting stent|Paclitaxel eluting stent
1836879|NCT00856778|Device|Virtue® Male Incontinence Sling|The VIRTUE® male sling is a Class II, implantable, sub-urethral, permanent, non-absorbable support sling indicated for the surgical treatment of male SUI resulting from intrinsic sphincter deficiency. The sling is manufactured from polypropylene and is sold for single use only.
1836880|NCT00856791|Drug|ON 01910.Na|
1836881|NCT00856804|Drug|thalidomide|Open-label pilot study analyzing the impact of adding thalidomide (200 mg/d)to SOC on 12 weeks virological response in patients with chronic hepatitis C and interferon resistance.
1836882|NCT00856817|Drug|L-arginine + heme arginate|L-arginine first, heme arginate second three day treatment
1836883|NCT00856817|Drug|Heme arginate + L-arginine|Heme arginate first, L-arginine second three day treatment
1836884|NCT00856830|Drug|Novel Drug Combination|"This novel drug combination includes: Bendamustine, Irinotecan, and Etoposide/Carboplatin. Subjects will be treated with irinotecan (150 mg/m2) infusion on Day 1 followed by infusion of bendamustine on Days 1 and 2 at increasing dose levels using a 3+3 design (starting dose of 80-mg/m2/d with 20 mg/mg/d incremental increase to max 120 mg/m2/d) (Regimen A). This will be repeated every 3 weeks for a total of 3 cycles. Restaging for response will be performed prior to the next regimen.
All subjects will then be given carboplatin (AUC 6) on day 1 and etoposide (100 mg/m2) on days 1, 2 and 3 (Regimen B). They will receive 3 cycles of this regimen every 3 weeks prior to restaging.
At the end (3 weeks after) of the sixth total round of chemotherapy, subjects will be re-evaluated for response, and will be followed-up for recurrent disease every 8 weeks."
1836885|NCT00856843|Drug|BLI800|Solution for oral administration prior to colonoscopy
1836886|NCT00856843|Drug|Polyethylene glycol 3350 based bowel preparation|Solution for oral administration prior to colonoscopy
1836888|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
1836889|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
1836890|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
1836891|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
1836892|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
1836893|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
1836894|NCT00856869|Drug|NRL972|Single 2 mg intravenous injection administered once after an overnight fast and once after a standard meal
1836895|NCT00856882|Dietary Supplement|soy protein|
1836896|NCT00856882|Dietary Supplement|isoflavones|
1836897|NCT00856882|Dietary Supplement|milk protein|
1836898|NCT00856908|Drug|AZD1656|Tolerable dose given twice daily
1836899|NCT00856908|Drug|Placebo|Tolerable dose given twice daily
1836900|NCT00856934|Biological|Autologous Platelet Rich Plasma|Platelet Rich Plasma isolated from patient blood sprayed onto wound bed along with 10% Calcium Chloride solution in a 10 to 1 proportion.
1836901|NCT00856934|Biological|Keratinocyte suspension|Autologous keratinocytes isolated from skin biopsy suspended in platelet rich plasma before spraying.
1836902|NCT00856934|Other|Standard dressings|Three layers of paraffin gauze, topped with standard dry bandages and an elastic bandage.
1836903|NCT00856947|Dietary Supplement|Cholecalciferol D3|2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
1836904|NCT00856947|Other|Placebo tablet|2 tablets containing no active substance
1836905|NCT00856960|Drug|Aliskiren|Single dose of four 150 mg tablets (600 mg total) Aliskiren in one of three study periods. There will be at least 10 days between each study period.
1836906|NCT00856960|Drug|Aliskiren|Single dose of one 150 mg tablet of Aliskiren in one of three study periods. There will be at least 10 days between each study period.
1836907|NCT00856960|Drug|Comparator: Losartan|Single dose of one 100 mg tablet Losartan in one of three study periods. There will be at least 10 days between each study period.
1836908|NCT00856960|Drug|Comparator: Placebo to Aliskiren|Three or four tablets placebo to Aliskiren 150 mg in one of three study periods. There will be at least 10 days between each study period.
1836909|NCT00856960|Drug|Comparator: Placebo to Losartan|Single dose of placebo to Losartan 100 mg in one of three study periods. There will be at least 10 days between each study period.
1836910|NCT00856973|Drug|eszopiclone|1 mg eszopiclone for 6-11 years, 2 mg for 12-17 years
1838246|NCT00866060|Drug|Placebo donepezil|Placebo donepezil
1836911|NCT00856973|Drug|eszopiclone|2 mg eszopiclone for 6-11 years, 3 mg eszopiclone for 12-17 years
1836912|NCT00856973|Drug|Placebo|1 tablet per day for 12 weeks
1836913|NCT00856986|Drug|liraglutide|Liraglutide 1.8 mg/day for subcutaneous (under the skin) injection.
1836914|NCT00856986|Drug|insulin detemir|Insulin detemir subcutaneous (under the skin) injection once daily. Dose will be titrated (individually adjusted) based on fasting self-measured plasma glucose levels according to a pre-specified algorithm
1836915|NCT00856986|Drug|metformin|Metformin tablets, at least 1500 mg/day
1836916|NCT00856999|Drug|Botox|Botox Cosmetic will be delivered in standard doses of 4 units per injection site over a total of 5 sites, thus treating the procerus and corrugator superciliaris muscle groups
1836917|NCT00857025|Biological|beta-glucan MM-10-001|Dose escalation with six patients treated at each of the following oral dosages: 2.5, 5.0, 7.5, 10, 15, 20, 30, 40, 50, and 80 mg/day
1836918|NCT00857025|Other|flow cytometry|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and every 4 weeks until the end of study treatment.
1836919|NCT00857025|Other|laboratory biomarker analysis|Performed on blood samples collected within 14 days prior to study treatment and at week 1, week 5, week 9, week 13 and at the end of study treatment.
1836920|NCT00857025|Other|questionnaire administration|Assessment pre-study and week 5, week 9, week 13 and at off study.
1836921|NCT00857038|Drug|Doxycycline|Doxycycline tablets, 100mg daily
1836922|NCT00857038|Drug|Placebo|Placebo tablets 100mg
1836923|NCT00857051|Other|Hotline Service|A 24 hour hotline to answer questions about baby care or mother self-care. Hotline will be answered by a midwife and answers will be based on algorithms.
1836924|NCT00857051|Other|Film|A DVD addressing common stressors in the early postpartum.
1836925|NCT00857077|Drug|Sulfadoxine-pyrimethamine|
1836926|NCT00857077|Drug|Placebo|
1836927|NCT00857090|Drug|OMS201|"Stage 1: OMS201 irrigation solution at 3X the base concentration during surgery
Stage 2: OMS201 irrigation solution up to 10X the base concentration during surgery"
1836928|NCT00857090|Drug|Vehicle|Stages 1-2: Vehicle irrigation solution during surgery
1836929|NCT00857194|Procedure|2 hour Oral Glucose Tolerance Test|Fasting baseline blood samples will be drawn for analysis of insulin and glucose. A 75-gram glucose solution will be administered and subjects remain sedentary for 2 hours. After 2 hours, blood is drawn to analyze post-load insulin and glucose levels.
1836930|NCT00857194|Procedure|Fat Meal Test|A fasting blood draw is performed for analysis of lipids, insulin, and glucose. Subjects ingest a high fat meal (milkshake made from heavy whipping cream and premium ice cream) within 15 minutes. Postprandial blood draws at 2, 4, and 6 hours are made for analysis of lipids, insulin, and glucose.
1836931|NCT00857207|Behavioral|Goal Management Training|Enhanced Goal Management Training is a 10-week group therapy that teaches strategies to improve an individual's ability to complete everyday tasks.
1836934|NCT00857233|Drug|Memantine|20 mg oral tablets once daily
1836935|NCT00857246|Drug|Cetuximab|
1836936|NCT00857246|Drug|Irinotecan|
1836937|NCT00857246|Drug|Cisplatin|
1836938|NCT00857246|Procedure|Surgery|
1836939|NCT00857246|Drug|5-FU|
1836940|NCT00857246|Radiation|Radiation|
1836941|NCT00857259|Drug|Everolimus|5 mg oral tablet
1836942|NCT00857259|Drug|Ranibizumab|0.5 mg administered by intravitreal injection
1836943|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl - reformulation|multi dose formulation (tablet/solution) for oral administration prior to colonoscopy
1836944|NCT00857272|Drug|PEG electrolyte lavage solution + bisacodyl|multi dose preparation (tablet/solution) for oral administration prior to colonoscopy
1836945|NCT00857285|Drug|olmesartan medoxomil|olmesartan medoxomil oral tablets, once daily for up to 12 weeks
1836946|NCT00857285|Drug|losartan potassium|losartan oral tablets, once daily for up to 12 weeks
1836947|NCT00857298|Behavioral|Dietary Intervention|The nutrition curriculum will involve weekly group and individual sessions. The initial calorie goal will be ~750 kcal below the resting energy equivalent, and adjusted as needed to achieve weight loss targets.
1836948|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
1836949|NCT00857311|Biological|Comparator: Placebo|1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26
1836950|NCT00857311|Biological|Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed|0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only
1836951|NCT00857311|Biological|MRKAd5 HIV-1 gag vaccine (V520)|3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
1836952|NCT00857324|Drug|Vorinostat|"Patients will start induction treatment with a standard dose of MP and escalating doses of Vorinostat:
Melphalan 0.18 mg/Kg for 4 days; Prednisone 1.5 mg/Kg for 4 days. Each cycle will be repeated every 28 days for a total of 6 courses
In the first part of the study, the standard oral MP will be combined with escalating doses of Vorinostat.
Level -1 Vorinostat = 100 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4
Level 0 Vorinostat = 200 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4
Level +1 Vorinostat = 300 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4
Level +2 Vorinostat = 400 mg daily on days 1-21 Melphalan = 0.18 mg/kg on days 1 - 4 Prednisone = 1.5 mg/kg on days 1 - 4"
1836953|NCT00857376|Dietary Supplement|Alpha lipoic acid at 3 doses compared to placebo|This is a randomized study comparing the antioxidant effects of 3 doses of alpha lipoic acid (total of 600 mg daily, 1200 mg daily and 1800 mg daily) compared to placebo. These doses will be taken as 2 pills 3 times a day for 8 to 10 weeks.
1836954|NCT00857389|Drug|Thiotepa|5 mg/kg through a central venous catheter (CVC) over 2 hours on Day -8.
1836955|NCT00857389|Drug|Clofarabine|40 mg/m^2 through a central venous catheter (CVC) over 1 hour daily on 4 consecutive days (Days -6 through -3).
1837006|NCT00857623|Drug|AZD2066|Capsule, once daily, 12 mg AZD2066 day 1-4 and 18 mg AZD2066 day 5-28.
1836956|NCT00857389|Drug|Busulfan|"Test dose of 0.5 mg/kg through a central venous catheter (CVC)over 30 minutes on Day -7.
High dose 5,000 µMol-min through a central venous catheter (CVC) over 3 hours on Days -5, -4, and -3."
1836957|NCT00857389|Procedure|Allogeneic Stem Cell Transplantation|Infusion of stem cells through through a central venous catheter (CVC) On Day 0.
1836958|NCT00857389|Drug|Thymoglobulin (ATG)|1.25 mg/kg by vein on Day -4 and 1.75 mg/kg on Day -3.
1836959|NCT00857389|Drug|G-CSF (Filgrastim)|5 µg/kg Injection under the skin once a day, starting 1 week after transplant, until blood cell levels return to normal.
1836960|NCT00857389|Drug|Tacrolimus|Starting dose of 0.015 mg/kg (ideal body weight) as a 24 hour continuous infusion daily, to be changed to oral dosing when tolerated. Tacrolimus is to be tapered as indicated after transplant day 90, if no GVHD is present. Tacrolimus is adjusted trough level of 5-15 ng/mL.
1836961|NCT00857389|Drug|Methotrexate|5 mg/m2 by vein on Days 1, 3 and 6 and Day +11 post transplant. The Day 11 methotrexate dose may be held as indicated if mucositis is present.
1836962|NCT00857389|Drug|Cyclophosphamide|Post haploidentical stem cell transplant participants: 50 mg/kg by vein on Days + 3 and + 4.
1836963|NCT00857389|Drug|Mesna|Post haploidentical stem cell transplant participants: 10 mg/kg by vein just prior to the first dose of cyclophosphamide, repeated every 4 hours for a total of ten (10) doses.
1836964|NCT00857402|Dietary Supplement|Peanuts|30g of peanuts daily for 4 weeks (directly observed). This dose of peanuts is equivalent to 1 gram of arginine.
1836965|NCT00857402|Dietary Supplement|Daboqolo|30g of Daboqolo per os daily for 4 weeks (given supervised). 30g of Daboqolo is equivalent to 0.1 g of arginine.
1836966|NCT00857415|Drug|florbetapir F 18|Single i.v. bolus injection of 370MBq (10 mCi) followed by saline flush, 50 minutes prior to imaging, 10 minute image duration
1836967|NCT00857428|Drug|oxymorphone|Tablets
1836968|NCT00857428|Drug|Oxymorphone|40 mg tablets
1836969|NCT00857441|Device|Drug eluting balloon|Percutaneous transluminal coronary balloon angioplasty catheter eluting paclitaxel
1836970|NCT00857441|Device|Liberté|Bare metal stent
1836971|NCT00857441|Device|PTCA balloon catheter|Percutaneous transluminal coronary angioplasty catheter
1836972|NCT00857441|Device|Taxus|Paclitaxel eluting stent
1836973|NCT00857454|Drug|Testosterone MD-Lotion|30 mg to 120 mg administered topically once daily for 60 days
1836974|NCT00857467|Drug|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 1 g rectal suppository, with a 7-day washout period between dosing.
1836975|NCT00857467|Drug|NRL001|Subjects receive single doses of 5 mg NRL001, 10 mg NRL001 and placebo in a 2 g rectal suppository, with a 7-day washout period between dosing.
1836976|NCT00857480|Drug|NRL972|Single intravenous administration of 2 mg NRL972
1836977|NCT00857480|Drug|NRL972|Pre-treatment and co-treatment with 1 g Cloxacillin t.i.d. for three days from the morning of D-3 until the morning of Day D01 0:30 hour before the intravenous administration of NRL972.
1836978|NCT00857480|Drug|NRL972|Three week pre-treatment with daily doses of 500 mg b.i.d ursodeoxycholic acid from the morning of D-20 until the evening of Day D-1
1836979|NCT00857493|Biological|IMVAMUNE|Two s.c. vaccinations with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50 / dose
1836980|NCT00857493|Biological|IMVAMUNE|One s.c. vaccination with placebo (0.5 ml saline), followed by a second s.c. vaccination with 0.5 ml IMVAMUNE® vaccine containing 1 x 10E8 TCID50
1836981|NCT00857506|Drug|florbetapir F 18|370 Mega Becquerel (10 mCi)
1836982|NCT00857519|Drug|Melphalan, Carboplatin|Intra-arterial chemotherapy.
1836983|NCT00857532|Drug|florbetapir F 18|10 millicurie (mCi) (370 MBq) florbetapir F 18 Injection
1836984|NCT00857545|Other|Laboratory Biomarker Analysis|Correlative studies
1836985|NCT00857545|Biological|Polyvalent Antigen-KLH Conjugate Vaccine|Given SC
1836986|NCT00857545|Biological|Saponin-based Immunoadjuvant OBI-821|Given SC
1836987|NCT00857558|Drug|saxagliptin|orally administration at 1 mg once a day for 12 weeks
1836988|NCT00857558|Drug|saxagliptin|orally administration at 2.5 mg once a day for 12 weeks
1836989|NCT00857558|Drug|saxagliptin|orally administration at 5 mg once a day for 12 weeks
1836990|NCT00857558|Drug|placebo|orally administration once a day for 12 weeks
1836991|NCT00857571|Drug|150 mg Suspension|Single oral dose of 150 mg of PF-02413873 suspension
1836992|NCT00857571|Drug|30 mg Suspension|Single oral dose of 30 mg of PF-02413873 suspension
1836993|NCT00857571|Drug|400 mg Suspension|Single oral dose of 400 mg of PF-02413873 suspension
1836994|NCT00857571|Drug|5 mg Suspension|Single oral dose of 5 mg of PF-02413873 suspension
1836995|NCT00857571|Drug|750 mg Suspension|Single oral dose of 750 mg of PF-02413873 suspension
1836996|NCT00857571|Drug|150 mg Tablet|Single oral dose of 150 mg of PF-02413873 tablets
1836997|NCT00857571|Drug|30 mg Tablet|Single oral dose of 30 mg of PF-02413873 tablets
1836998|NCT00857571|Drug|400 mg Tablet|Single oral dose of 400 mg of PF-02413873 tablets
1836999|NCT00857571|Drug|5 mg Tablet|Single oral dose of 5 mg of PF-02413873 tablets
1837000|NCT00857571|Drug|750 mg Tablet|Single oral dose of 750 mg of PF-02413873 tablets
1837001|NCT00857584|Drug|Extended release quetiapine (quetiapine XR)|"Flexible dose from 300 to 600 mg/d (combination of tablets of 50mg, 200mg and 300mg) oral, daily, 8 weeks length.
Quetiapine XR was initiated at 50 mg/day and titrated to 100 mg on day 2, 200 mg on day 3, 300 mg on day 4, and flexible doses of 300 to 600 mg/d from day 5 to the end of the study."
1837002|NCT00857584|Drug|Sertraline|"Flexible dose from 50 to 200 mg/d (combination of tablets of 50mg and 100mg) oral, daily, 8 weeks length.
Sertraline titration: 50 mg on day 1-3, 100 mg on day 4, and flexible doses of 50 to 200 mg/d from day 5 to the end of the study."
1837003|NCT00857584|Drug|adequate mood stabilizer|An adequate mood stabilizer treatment with lithium or valproate(defined as a serum concentration of 0.5-1.2 mEq/L or 50-100 microg/ml, respectively).
1994034|NCT03082989|Device|fractional flow reserve performed|assessing fractional flow reserve to drive revascularization
1837007|NCT00857623|Drug|Placebo|Capsule, once daily
1837008|NCT00857636|Behavioral|Health literacy, health message|The intervention will consist of three main components: (1) 2-hour in-class health literacy-focused education; (2) tailored telephone counseling; and (3) healthcare system navigation assistance tailored to the woman's specific barriers.
1837009|NCT00857649|Drug|Memantine|20 mg Oral Tablets Once Daily
1837010|NCT00857649|Drug|Placebo|Oral Tablets Once Daily
1837011|NCT00857662|Device|Onyx|Embolization
1837012|NCT00857662|Device|TRUFILL|Embolization
1837013|NCT00857675|Drug|AAAA|Adefovir Dipivoxil (12 weeks) + open lable Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260weeks)
1837014|NCT00857675|Drug|AAPA|Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + placebo (12 weeks) + open label-Adefovir Dipivoxil (52-260 weeks)
1837015|NCT00857675|Drug|PAAA|Placebo (12 weeks) + Open label Adefovir Dipivoxil (28 weeks) + Adefovir Dipivoxil (12 weeks) + Open label Adefovir Dipivoxil (52-260 weeks)
1837016|NCT00857688|Drug|Bismu-Jet|Bismuth sodium tartrate, neomycin sulfate, procain hydrocloride
1837017|NCT00857688|Other|Placebo|Placebo: Menthol, saccharin sodium, propylene glycol, sodium hydroxide, glycerol, ethyl alcohol, water
1837018|NCT00857701|Device|Knee Extension Dynasplint|Dynamic Splinting utilizes the protocols of Low-Load, Prolonged-Duration Stretch (LLPS) with calibrated, adjustable tension to increase the Total End Range Time (TERT) to reduce contracture. The Knee Extension Dynasplint for the Experimental group will have tension chambers delivering therapeutic treatment from the device.
1837019|NCT00857714|Drug|lapatinib|1500 mg lapatinib for 14-21 days
1959085|NCT00825955|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
1837022|NCT00857740|Behavioral|Education|Education about the neurophysiology of pain
1837023|NCT00857753|Drug|Fentanyl patch 25 ug/nr Sandoz|
1837024|NCT00857753|Drug|Duragesic|
1837025|NCT00857766|Drug|ADVAIR DISKUS™ 250/50mcg|ADVAIR DISKUS™ 250/50mcg is indicated for the twice-daily maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema. ADVAIR DISKUS™ 250/50mcg is also indicated to reduce exacerbations of COPD in patients with a history of exacerbations.
1837026|NCT00857766|Other|Placebo|COPD subjects-Placebo DISKUS
1837027|NCT00857779|Biological|subcutaneous immunotherapy|7 injections
1837028|NCT00857792|Drug|regadenoson|Subjects will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus).
1837029|NCT00857805|Procedure|Transarterial Chemoembolization|Application of carboplatin, doxorubicin in ethiodol into the artery for one or more sessions.
1837030|NCT00857805|Radiation|Proton Beam Radiotherapy|Fifteen consecutive sessions
1837031|NCT00857818|Drug|Aripiprazole|Aripiprazole administered orally as tablets, 5 mg once daily (QD) in Week 1; 10 mg QD in Week 2. Flexible dosing allowed after Week 2, adjusted in 5-mg increments every 7 days within a range of 10 to 30 mg daily, for 16 weeks
1837032|NCT00857818|Drug|Oanzapine, risperidone, or quetiapine|Oanzapine, risperidone, or quetiapine administered orally as tablets at prior dosage for 16 weeks
1837033|NCT00857831|Dietary Supplement|Vitamin D and Calcium|2000 IU/day Vitamin D3 (cholecalciferol) and 1.3 g/day calcium carbonate will be taken for 15-20 weeks.
1837037|NCT00857870|Drug|Metformin|"Metformin is administered as coated tablet. Initial dose is 500 mg twice a day (morning and evening) during or after the meal. The first administration takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c.
Initial dose of 500 mg bid was increased after 4 weeks (visit 2) to 850 mg bid when the patient tolerated the initial dose. If the side effects were not tolerable, the initial dose was decreased to 500 mg once a day and where appropriate increased at a later visit.
After 8 weeks (visit 3) metformin dose was increased to 1000 mg bid when tolerated. If dose is not tolerated, it was decreased to the next lower dose."
1837038|NCT00857870|Drug|Insulin glargine|Insulin glargine is given subcutaneously with an insulin-pen (SoloStar®). The dose was titrated to reach a fasting plasma glucose value of <5.6 mmol/l. Insulin glargine was given once a day in the evening before going to bed (bed-time injection). The first insulin injection takes place on the evening of visit 1c. The duration of the therapy is 36 weeks until visit 8c. All patients were trained in handling and storage of the insulin-pen.
1837039|NCT00857883|Drug|GSK1521498 or placebo|GSK1521498 is a mu-opioid receptor inverse agonist
1837040|NCT00857896|Drug|Fesoterodine|4 mg once daily for Weeks 1-4 and 8 mg once daily for Weeks 5-8
1837041|NCT00857909|Drug|Amiloride|1 tablet twice a day
1837042|NCT00857909|Drug|Spironolactone|1 tablet twice a day
1837043|NCT00857909|Drug|Placebo|Placebo
1837044|NCT00857909|Drug|Placebo and spironolactone|5mg twice daily
1837045|NCT00857909|Drug|Spironolactone|25mg twice daily
1837046|NCT00857922|Other|tissue and data repository|Tissue and data will be maintained in a repository for study from consenting subjects.
1837047|NCT00857935|Drug|NatrOVA Creme Rinse - 1%|NatrOVA Creme Rinse, one or two, 10-minute topical treatments (7 days apart)
1837048|NCT00857935|Drug|NIX Creme Rinse - 1% permethrin|NIX Creme Rinse: one or two, 10-minute topical treatments (7 days apart)
1837049|NCT00857948|Drug|ivermectin treatment conditioner|Application followed by thorough rinsing of the hair and scalp with water.
1837050|NCT00857948|Drug|Placebo, vehicle control|Application followed by thorough rinsing of the hair and scalp with water.
1837051|NCT00857961|Drug|Testosterone MD-Lotion|Administered Topically
1837092|NCT00858364|Drug|darbepoetin alfa 500 mcg Q3W|darbepoetin alfa 500 mcg (Q3W)
1837093|NCT00858364|Drug|placebo|Placebo
1837094|NCT00858377|Drug|Arm 1- Dose Escalation|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
1837052|NCT00857974|Other|Physical Activity|The intervention is an individualized, structured, moderate intensity home-based physical activity program. During the first 12 weeks the program will focus on lower extremity strengthening, and thereafter incorporate cardiovascular activity. The target duration of activity is 150 minutes per week, i.e., 20-30 min on most days of the week. However, the program is adjusted based on each participant's progression, initial level of physical fitness and will be modified in response to illness, injury, or physical symptoms.
1837053|NCT00857987|Drug|EMS Expectorant|Guaifenesin - 100mg, Etafedrine hydrochloride 20mg, Succinate doxilamine 6mg.
1837054|NCT00857987|Other|Placebo|Vehicle
1837055|NCT00858000|Other|Retrospective analysis of already archived samples|RNA extracted from tissue samples already archived
1837056|NCT00858013|Drug|Nateglinide|Nateglinide 90~120mg three times a day
1837057|NCT00858013|Drug|Glimepiride|Glimepiride 1~2mg once a day
1837058|NCT00858026|Other|Breastmilk|Exclusively breastfed babies
1837059|NCT00858026|Other|Standard milk|Weaning babies fed with the standard formula
1837060|NCT00858026|Other|Fermented milk|Weaning babies fed with the fermented formula
1837061|NCT00858052|Device|Saline-filled breast implant [IDEAL IMPLANT (R)]|Breast augmentation
1837062|NCT00858065|Behavioral|Strengthening Families Program (SFP)|Prevention program with 7 weekly group sessions for parent and child.
1837063|NCT00858065|Behavioral|Family Matters|Prevention program with 4 booklets for families to do at home with their child.
1837064|NCT00858104|Procedure|Percutaneous Laser Ablation|Single session with standardized approach: Two fibers, up to 2 laser emissions; nodule volume up to 10 ml are treated by 800 Joules /ml and above 10 ml by 600 Joules/ml.The treatment is performed under local anesthesia and with diazepam sedation.
1837065|NCT00858117|Biological|Alemtuzumab|Alemtuzumab administered subcutaneously 30mg per day, 3 days per week for 18 weeks
1837066|NCT00858117|Biological|Rituximab|Rituximab administered intravenously at 375mg/m2 every 2 weeks for 18 weeks
1959086|NCT00825955|Other|Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
1837068|NCT00858143|Other|Non Interventional Observation|Post marketing surveillance study = prospective, non-interventional observation of the use of Somavert®
1837069|NCT00858156|Drug|BG9928|Oral 75 mg single dose
1837070|NCT00858182|Drug|PD solution for nocturnal exchanges|Instillation of a PD solution containing xylitol (1.5%), L-carnitine (0.1%) and glucose (0.5%) for the nocturnal exchange in CAPD treated patients. PD solutions are instilled for 4 weeks.
1837071|NCT00858182|Drug|PD solution for diurnal exchanges|Instillation of a PD solution containing xylitol (0.6%), L-carnitine (0.1%) and glucose (0.5%) for the diurnal exchanges in CAPD treated patients. PD solutions are instilled for 4 weeks.
1837072|NCT00858195|Drug|Indomethacin 75mg Extended-Release Capsules, Sandoz|
1837073|NCT00858195|Drug|Indocin 75mg SR Capsules|
1837074|NCT00858208|Drug|pegaptanib sodium|pegaptanib sodium intravitreal injection every 6 weeks for 2 years
1837075|NCT00858234|Drug|vorinostat|MK0683 (400 mg) Oral, once daily treated for Day 1 through 14 of a 21 day cycle
1837076|NCT00858234|Drug|bortezomib|bortezomib (1.3 mg/m2 ) intravenous push on Day 1, 4, 8 and 11 of a 21 day cycle
1837077|NCT00858247|Dietary Supplement|Vitamin D3|One arm would receive vitamin D3 at a dose of 400 IU by mouth once daily for 12 weeks and the other arm would receive vitamin D3 as a single oral daily dose of 2000 IU for 12 weeks.
1837078|NCT00858260|Genetic|blood sample|Searching for Klotho variants in DNA
1837079|NCT00858273|Dietary Supplement|Antioxidant supplement|1 capsule daily with dinner
1837080|NCT00858273|Other|Diabetes treatment|Intensification of diabetes treatment regimen, including education and counseling, home blood glucose monitoring, multiple daily insulin injections (MDI), diet plan, and frequent phone contact with a certified diabetes educator
1837081|NCT00858273|Drug|Regular Insulin|Regular Insulin, IV, to maintain blood glucose in normoglycemic range (70-140) during metabolic study
1959087|NCT00825955|Procedure|Best Supportive Care|Trans-Arterial Chemo-Embolization (TACE) Therapy
1837083|NCT00858299|Drug|valsartan|160 mg oral once in a day for initial 8 weeks and 320 mg, oral, once in a day for subsequent 16 weeks
1837084|NCT00858312|Other|high dairy diet|12 week energy restriction with 3-4 servings of dairy foods/day.
1837085|NCT00858312|Other|Low Dairy|less than 1 serving of dairy foods per day.
1837086|NCT00858325|Drug|Daptomycin|4mg/kg and 6 mg/kg dissolved in 0.9% sodium chloride for injection, administered intravenously over 30 minutes.
1837087|NCT00858338|Procedure|Potentially curative surgery|"Surgery:
Week 1: Potentially curative surgery. If the tumor successfully resected (microscopically disease-free margins, Ro, with regional lymphadenectomy for proper staging), the ip catheter in place.
Weeks 2-4: Recovery. Then continue to adjuvant IP chemotherapy."
1837088|NCT00858338|Drug|Floxuridine (IP)|"Adjuvant IP Chemotherapy:
week 1: ip Floxuridine 3 gm/day, days 1,2,3. week 2: 1 week without treatment. week 3: ip Floxuridine 3 gm/day protocol days 15,16,17. week 4: 1 week without treatment. Then continue to chemoradiation therapy."
1837089|NCT00858338|Procedure|Adjuvant Chemoradiation therapy|"Adjuvant Chemoradiation therapy:
week 1: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; weeks 2-4: recovery; weeks 5-9: radiation, 150 cGy x 5 fractions/week x 5 weeks; week 5: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-4; week 9: 5-FU 400 mg/m2 + LV 20 mg/m2 each day on days 1-3; week 14: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days; week 19: 5-FU 425 mg/m2/day x 5 days + Leucovorin (LV) 20 mg/m2/day x 5days."
1837090|NCT00858351|Behavioral|Thermal Biofeedback Assisted Relaxation|6 sessions, 25 minutes in duration of relaxation and imagery training while temperature of hands and feet are recorded.
1837091|NCT00858351|Behavioral|Discussion with therapist|6 sessions, 25 minutes each, discussing topics with a therapist.
1838247|NCT00866060|Drug|Placebo memantine|Placebo memantine
1837095|NCT00858377|Drug|Arm 1- Dose Expansion|AMG 900 is a small molecule inhibitor of aurora kinases A, B and C. AMG 900 will be administered daily for 4 days every 2 weeks (i.e., 4 consecutive days of dosing followed by 10 consecutive days off treatment).
1837096|NCT00858390|Dietary Supplement|enteral feeding with Oxepa® and Glutasolve®|enteral feeding with Oxepa® and RESOURCE® GLUTASOLVE®
1837097|NCT00858403|Drug|Dasatinib|Take tablets of Dasatinib by mouth once a day.
1837098|NCT00858416|Device|"Kineticure System followed by sham"|20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion) during the first 4 weeks followed by 2 weeks wash out and 4 weeks of sham device
1837099|NCT00858416|Device|"sham followed by Kineticure System"|sham device during the first 4 weeks then 2 weeks wash out period followed by 4 weeks for 20 minutes sessions with knee brace (integrated heating pad, a vibration unit and a foot pedal that delivers continuous passive motion)
1837100|NCT00858429|Drug|capecitabine|1000 mg/m2 twice daily, for 14 consecutive days followed by a 7 day treatment free rest period for cycles 1, 2 and 3.
1837101|NCT00858429|Radiation|yttrium Y 90 glass microspheres|The amount of radioactivity required to deliver the desired dose to the liver is calculated using a formula. The dose depends on the cohort upon which the patient is enrolled. Y90 is administered during Cycle #2 on days 1-7.
1837102|NCT00858442|Procedure|With PRP|Release of burn contractures and skin graft on the affected limb, a rigorous haemostasis. The surgeon must distribute the activated PRP evenly, forming a very fine clot over it. Immediately the split skin graft must be applied, duly fenestrated. The grafted zone will be measured in it's longest width and length, taking a standardized photograph. On the 5th day the nurse will evaluate the graft's conditions. The evaluation will be done following a previously established follow-up protocol. Measurements of width & length of graft and standardized photo taken at the initiation of the compressive system. Measurement of graft's width & length and standardized photo at the end of the compressive system according protocol. Statistical analysis.
1837103|NCT00858455|Drug|GSK1349572 and MaaloxAdvanced Maximum Strength|A single dose of GSK1349572 co-administered with a single dose of 20 mL of Maalox Advanced Maximum Strength
1837104|NCT00858455|Drug|GSK1349572 and Maalox Advanced Maximum Strength|A single dose of GSK1349572 administered 2 hours prior to administration of a single dose of 20 mL of Maalox Advanced Maximum Strength
1837105|NCT00858455|Drug|GSK1349572 and One A Day|A single dose of GSK1349572 50 mg co-administered with a single dose of a One A Day Maximum multivitamin
1837106|NCT00858455|Drug|GSK1349572|A single dose of GSK1349572
1837107|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
1837108|NCT00858468|Biological|Influenza virus vaccine (2004-2005 Formulation)|0.25 mL, Intramuscular
1837109|NCT00858481|Drug|Spinosad Creme Rinse - Vehicle Control|One or two, 10-minute topical applications (7 days apart)
1837110|NCT00858481|Drug|Spinosad Creme Rinse|0.5% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
1837111|NCT00858481|Drug|Spinosad Creme Rinse|1.0% Spinosad Creme Rinse: one or two, 10-minute topical applications (7 days apart)
1837112|NCT00858481|Drug|Spinosad Creme Rinse|2.0% Spinosad Creme Rinse - one or two, 10-minute topical applications (7 days apart)
1837114|NCT00858507|Behavioral|RN Brief Intervention|RN administered personal health assessment along with a brief intervention for behavior change administered to homeless veterans in the community
1837115|NCT00858507|Behavioral|Social Worker Outreach|Social worker will encounter homeless veteran in the community and encourage to come to the VA for care
1837116|NCT00858533|Behavioral|Health at Work workplace health advice and support|The intervention group will receive additional support from a H@W Workplace Health Advisor who will deliver an intervention aimed at sickness absence prevention or sustained return to work, depending on individual circumstances. The intervention will be standardized as far as possible to show types of activity undertaken with participants, their GP, line managers, human resources departments and trade union representatives.
1837117|NCT00858546|Device|Repetitive transcranial stimulation|Repetitive transcranial stimulation
1837118|NCT00858559|Device|Implantable cardioverter defibrillator with Home Monitoring function|Implantable cardioverter defibrillators can send data from its diagnostic and therapy memory via wireless Home Monitoring on a daily basis to an internet based platform, securely accessed by the attending physician
1837119|NCT00858559|Device|Standard implantable cardioverter defibrillator|Implantable cardioverter defibrillators used as standard devices without Home Monitoring
1837120|NCT00858572|Drug|STA-9090 (ganetespib)|Chemotherapy agent
1837121|NCT00858611|Drug|VRC-FLUDNA047-00-VP|
1837122|NCT00858611|Drug|Flulaval (Registered) Seasonal Influenza Vaccine|
1837123|NCT00858624|Drug|ketamine|Administration of low dose intravenous ketamine. Dose: 0.075mg/kg over 10 minutes followed by 0.005mg/kg/min over 20 minutes. Given as single infusion.
1837124|NCT00858637|Drug|MCI-196|Tablets of 3 g to 12 g/day (3 times a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
1837125|NCT00858637|Drug|Placebo of Simvastatin|Tablets once a day, for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
1837126|NCT00858637|Drug|Simvastatin|Tablets of 10 mg to 40 mg/day (once a day) with dose escalation design during 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
1837127|NCT00858637|Drug|Placebo of MCI-196|Tablets 3 times a day for 16 weeks of Active Comparison Phase, and 4 weeks of fixed dose during Withdrawal Phase (Week 16 to Week 20)
1837128|NCT00858650|Other|Standard of Care|Standard of care may or may not include use of testosterone replacement therapy
1837163|NCT00858923|Device|Energex HemoModulator|To use ultraviolet light to reduce HIV virus in the patient's blood
1837164|NCT00858936|Drug|IK-1001|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
1837165|NCT00858936|Drug|Normal Saline|6 escalating dose levels of 0.2, 0.5, 0.75, 1.0, 1.25, and 1.5 mg/kg/hr infusion for 6 hours
1837402|NCT00853034|Dietary Supplement|FOS-IN|"prebiotic fructo-oligosaccharide enriched inulin
intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
1837129|NCT00858663|Radiation|intensity modulated radiation therapy|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.
Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.
Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
1837130|NCT00858663|Drug|RAD001 (everolimus) + Cisplatin|"All patients will receive standard treatment with definitive radiation therapy (IMRT, intensity modulated radiation therapy), administered as one fraction per day (Monday through Friday) over approximately 33 fractions. Patients with resected tumors will be treated to a maximum dose of 66 Gy. Patients with unresected tumors will be treated to a maximum dose of 70 Gy.
Patients will receive daily RAD0001 it will be administered orally or via percutaneous gastrostomy tube (PEG) once daily according to the dose escalation scheme plus cisplatin intravenously once per week (Days 1, 8, 15, 22, 29, 36) according to the dose escalation scheme.
Approximately 3 - 4 months after completion of chemoradiation, radiologic response assessment will be performed. This will include cross-sectional imaging of the primary tumor (with CT scan and/or MRI) as well as a whole body FDG-PET (fluorodeoxyglucose positron emission tomography) scan."
1837131|NCT00858676|Drug|acarbose|50mg acarbose 3 times a day PO. duration: one year
1837132|NCT00858689|Drug|Minocycline|50-100 mg PO BID for 8 weeks with an option for a 1 year extension.
1837135|NCT00858715|Drug|aspirin|100 mg aspirin
1837136|NCT00858715|Drug|clopidogrel|75 mg (Arm 1) and 150 mg (Arm 2)
1837137|NCT00858728|Behavioral|5 portions|Subjects randomised to the intervention group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 5 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
1837138|NCT00858728|Behavioral|2 portions|Subjects randomised to the control group will be provided with a selection of fruit and vegetables once a week (from a local supermarket) and will be asked to consume 2 portions of fruit and vegetables per day. For the purposes of this study, a portion will be as defined by the Food Standards Agency, i.e. an 80 g serving (one apple, orange or banana, or 3 heaped tablespoons of vegetables).
1837139|NCT00858741|Radiation|single fraction|8 Gy x 1 fraction to 8 Gy total dose in single dose.
1837140|NCT00858741|Radiation|multiple fractions|3.0 Gy x 10 fractions to 30.0 Gy total dose in two weeks.
1837141|NCT00858754|Drug|methylnaltrexone|
1837142|NCT00858754|Drug|placebo|
1837143|NCT00858767|Dietary Supplement|menaquinone-7 from casein capsules|90 µg menaquinone-7 daily during 8 weeks
1837144|NCT00858767|Dietary Supplement|menaquinone-7 from arabic gum capsules|90 µg menaquinone-7 daily during 8 weeks
1837145|NCT00858767|Dietary Supplement|menaquinone-7 from linseed oil capsules|90 µg menaquinone-7 daily during 8 weeks
1837146|NCT00858780|Drug|Etanercept|50 mg etanercept once weekly + methotrexate
1837147|NCT00858780|Drug|Etanercept|25mg etanercept once weekly + methotrexate
1837148|NCT00858780|Drug|Placebo|Placebo comparator once weekly + methotrexate
1837149|NCT00858793|Procedure|PBSC-M87o, Gene (M87o)-modified, CD34+ peripheral blood progenitor cells (PBSC)|Patient stem cells will be mobilized with induction chemotherapy (R)-ICE and G-CSF. If sufficient cells can be mobilized, patients will be treated with high-dose chemotherapy and a transplant of autologous CD34+ cells transduced with an antiviral vector (M87o). If autologous CD34+ yield is insufficient, allogeneic gene-modified cells will be given, if a compatible donor is available. To minimize risk of transplant failure, a second unmodified CD34+ cell transplant will be given one week after the first transplant.
1837150|NCT00858806|Drug|Imatinib|"Intermittent Imatinib administration.
1 week on / 1 week off for the 1st month(weeks 1-4)
2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)
1 month on / 1 month off from the 4th month thereafter (weeks 13 on)"
1837151|NCT00858832|Drug|Methergine|Scheduled methergine 0.2 mg PO every 6hrs for duration of postpartum stay
1837152|NCT00858845|Drug|Clonidine Patch|A clonidine patch (0.1 mg/week) will be worn for 3 months.
1837153|NCT00858858|Drug|Ursodeoxycholic Acid|8 weeks of oral UDCA treatment 10 mg/kg qd
1837154|NCT00858871|Drug|Brivanib|Tablets, Oral, 800 mg, Once Daily, Until disease progression or unacceptable toxicity
1837155|NCT00858871|Drug|Placebo|Capsules, Oral, twice Daily, Until disease progression or unacceptable toxicity
1837156|NCT00858871|Drug|Sorafenib|Capsules, Oral, 800 mg, twice daily, Until disease progression or unacceptable toxicity
1837157|NCT00858871|Drug|Placebo|Tablets, Oral, Once Daily, Until disease progression or unacceptable toxicity
1837158|NCT00858884|Other|Clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain|All participating subjects (patients with and without neuropsychiatric SLE and healthy controls) will undergo clinical and laboratory evaluations, transesophageal echocardiography, carotid duplex, transcranial duplex, and magnetic resonance of the brain
1837159|NCT00858897|Other|Cysteine isotope infusion at normoglycemia vs hyperglycemia|L-[3,3-2H2]cysteine
1837160|NCT00858897|Drug|Regular Insulin|Regular insulin, IV, as needed to maintain blood glucose in near-normoglycemic range (80-140 mg/dL) or hyperglycemic range (200-250 mg/mL) during metabolic studies
1837161|NCT00858910|Other|Motor imagery (MI) training|MI training encloses the internal rehearsal of a known motor skill without any overt motor output.
1837162|NCT00858910|Other|Control intervention|"The control intervention encloses relaxation and breathing exercises, and information about:
the disease (stroke),
therapy options,
self-help groups and their offers for support,
helping aids for independent living at home."
1838370|NCT00866853|Drug|TMC435|
1837166|NCT00858962|Drug|Raltegravir|400 mg of raltegravir orally twice daily together with normally prescribed stable dose of buprenorphine for a minimum of 4 days and up to 14 days.
1837167|NCT00858975|Procedure|cryotherapy|Placing 4-6 cryotherapy probes into the renal tumors and conducting two cycles of freezing and thawing
1837168|NCT00858988|Drug|Rifaximin|
1837169|NCT00859001|Drug|FM+R|Fludarabine-Mitoxantrone-Rituximab
1837170|NCT00859001|Drug|Zevalin (Ibritumomab Tiuxetan)|
1837171|NCT00859014|Biological|Autologous Bone Marrow Mononuclear Cells|Harvest of bone marrow from ischemic stroke patients, isolation of bone marrow mono-nuclear cells, and peripheral IV infusion of autologous bone marrow mono-nuclear cells
1837172|NCT00859027|Drug|risedronate|35 mg/week by mouth
1837173|NCT00859027|Drug|placebo|One tablet by mouth every week as directed
1837175|NCT00859053|Drug|BMS-790052|Capsules, Oral, 30 mg, single dose, one day
1837176|NCT00859079|Drug|GLP-1|Patients received GLP-1 intravenously at a dose of 1.2 pmol/kg/min for at maximum 8 hours.
1837177|NCT00859079|Drug|Human regular insulin intravenously|Human regular insulin intravenously according to the Munich-registry.
1837178|NCT00859092|Dietary Supplement|Simply Thick|Simply Thick® added to each bottle of formula or beast milk to create nectar or honey consistency
1837179|NCT00859105|Drug|Imiquimod 5%: manufactured by Apotex|Treatment applied as a thin layer to target area once a day, 2 days each week, 16 weeks
1837180|NCT00859105|Drug|Adara 5% Cream US|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
1837181|NCT00859105|Drug|Adara 5% Cream Canada|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks.
1837182|NCT00859105|Drug|Imiquimod Vehicle|Treatment applied as a thin layer to target area once a day, 2 days each week, for 16 weeks
1837183|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only)
1837184|NCT00859118|Drug|AG-013736|Axitinib 5 mg PO BID x ~2 weeks (12-14 days), followed by 1 week drug break (for cycle 1 only). After Scan#3 obtained, patients will commence with Axitinib 5 mg PO BID continuously without breaks, repeated in 3 week cycles.
1837185|NCT00859131|Drug|Rabbit Antithymocyte globulin|1.5 mg/kg IV pre-op, day 1, day 2, day 3, day 4
1837186|NCT00859131|Drug|Daclizumab|1.0 mg/kg pre-op and 1.0 mg/kg on Day 7
1837187|NCT00859144|Behavioral|Be Proud! Be Responsible!|This intervention consists of highly structured modules that involve group discussions, videos, games, brainstorming, experiential exercises, and skill building activities. The program encourages participants to be proud of themselves and their community, to behave responsibly for themselves and their community, and to consider their goals for the future and how risk behaviors may interfere with the attainment of their goals.
1837188|NCT00859144|Behavioral|Becoming A Responsible Teen (BART)|This program consists of highly structured modules administered using intervention manuals in community-based settings. Each intervention session involves group discussion, videos, games, presentations, demonstrations, role plays, and practice. Youth learn problem solving, decision-making, communication, condom negotiation and use skills, and behavioral self-management. Youth also meet with HIV infected peers to promote risk recognition and improve their perception of vulnerability.
1837189|NCT00859144|Behavioral|Reducing the Risk|This program consists of instruction on developing social skills to reduce sexual risk-taking behavior and role plays to practice and model skills. Additional activities-such as teaching decision making and assertive communication skills, offering encouragement to obtain relevant health information from stores and clinics, and asking parents about their views on abstinence and birth control-support the premise that students should avoid unprotected intercourse, either by remaining abstinent or using contraceptives.
1837190|NCT00859157|Procedure|therapeutic conventional surgery|Patients undergo tumescent or standard mastectomy
1837191|NCT00859170|Device|Accordion device|an antiretropulsion device
1837192|NCT00859183|Drug|Sirolimus|cumulative loading dose of 8 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
1837193|NCT00859183|Drug|Sirolimus|cumulative loading dose of 24 mg of oral sirolimus two days prior to and the day of repeat intervention followed by maintenance therapy of 2 mg/day for 7 days
1837194|NCT00859183|Drug|Placebo|Placebo oral
1837195|NCT00859196|Drug|Dexpanthenol (BAY81-2996)|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
1837196|NCT00859196|Drug|Placebo|Test product and the respective placebo will be applied to previously wounded test areas and the surrounding skin (approx. 3 cm2). After a certain time the second skin biopsy will be taken from the treated test areas. The skin biopsies will be analysed via micro array.
1837197|NCT00859222|Drug|LBH589|
1837198|NCT00859222|Drug|bevacizumab|
1837199|NCT00859235|Drug|Chlorhexidine gluconate 0.2%|Mouth wash prior to procedure
1837200|NCT00859235|Other|Plain water|Mouth wash prior to procedure
1837201|NCT00859261|Procedure|Experimental 3D Breast Ultrasound imaging|Subjects will be seated and have the indicated breast positioned in the 3D breast ultrasound imaging device. An ultrasound gel will be applied to the breast by the technician. The breast will be gently compressed between the ultrasound plates to facilitate the 3D (dimensional)breast imaging. This imaging session will take approximately 30 minutes to complete.
1837202|NCT00859261|Procedure|Experimental Photoacoustic Imaging|Subjects will be placed in a seated position for the photoacoustic tomography(PAT) imaging. The subjects will be given a laser protective mask to wear. Each subject will be instructed how to wear this mask(goggles) to protect their eyes during the imaging session. Pulse monitor leads may be placed on their chest to allow the computer to record the images of blood flow in the breast. The breast will be placed on the laser device platform and positioned so that the laser beam is appropriately directed to the targeted area of the breast. During the imaging the temperature of the skin under laser light, will be checked often with a thermometer to make sure that the skin is not getting too hot. This laser based imaging scan will take approximately 10 minutes to complete.
1837203|NCT00859274|Drug|budesonide|Budesonide is given via inhalation utilising a dry powder inhaler called Easyhaler. The dosage is 400 ug twice daily. The duration of the study is 12 weeks but very probably the patients continue the usage of this drug as a part of their routine clinical management.
1837204|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
1837205|NCT00859300|Genetic|Blood sample|Blood sample Determination of genetic background
1837206|NCT00859313|Drug|Sufentanil NanoTab PCA System/15 mcg|15 mcg Sufentanil NanoTab taken sublingually q 20 minutes as needed for pain for 12 hours
1837207|NCT00859339|Drug|Gemcitabine|Gemcitabine ( 1000 mg/m2) IV days 1 and 8
1837208|NCT00859339|Drug|Cisplatin|Cisplatin (70 mg/m2) IV day 1
1837209|NCT00859339|Drug|Sunitinib Malate|Sunitinib malate (37.5 mg) oral daily for days 1-14
1837210|NCT00859339|Procedure|Radical Cystectomy|Radical cystectomy performed no sooner than 2 weeks but within 6 weeks of the last dose of sunitinib malate.
1837211|NCT00859352|Drug|AZD1981|oral tablets during 14 consecutive days.
1837212|NCT00859352|Drug|Midazolam|Each subject will receive two single doses of 7.5 mg midazolam given as oral solution. The Midazolam dose will be given on Day 1 and on day 16.
1837213|NCT00859365|Procedure|Real Acupuncture|Real acupuncture treatment in real acupuncture points
1837214|NCT00859365|Procedure|Placebo Acupuncture|empty plastic acupuncture guide-tube located on the patients back in a non visable area and connected to a visible electric stimulator
1837215|NCT00859365|Procedure|No intervention|Patients lay down for a period of 35 minutes without any treatment o intervention
1837216|NCT00859378|Device|Cemented semiendoprosthesis|Application of a cemented semiendoprosthesis (Basis, Smith & Nephew)
1837217|NCT00859378|Device|non-cemented|Patients are treated with a non-cemented semiendoprosthesis (Biomet Taperloc, Biomet Inc.)
1837218|NCT00859404|Drug|oglemilast|Tablet oglemilast or placebo once a day, for 12 weeks
1837219|NCT00859417|Procedure|Traditional surgery|Traditional surgical method without prosthesis (correction of the anterior prolapse through vaginal tract with the use of autologous tissue).
1837220|NCT00859417|Device|Perigee® prosthesis|Surgical method with Perigee® prosthesis
1837221|NCT00859430|Drug|Levetiracetam|1000 mg Tablet
1837222|NCT00859430|Drug|Keppra®|1000 mg Tablet
1837223|NCT00859456|Drug|Sunitinib|Taken daily PO for a 42 day cycle. This cycle is repeated at least twice.
1837224|NCT00859469|Drug|Oxaliplatin/Gemcitabine|Gemcitabine 1000mg/m2 IV infusion for 90 minutes followed by oxaliplatin 100 mg/m2 IV infusion for 2 hours repeated for 14 days up to 6 cycles
1837225|NCT00859495|Drug|Doxorubicin and cisplatin (intrapleural) + cisplatin and pemetrexed (systemic)|Thoracoscopy to implant two intrapleural catheters followed by intrapleural chemotherapy with doxorubicin and cisplatin (weeks 1, 2, 4, 5, 7, and 8). Systemic chemotherapy treatments with cisplatin and pemetrexed during weeks 3, 6, and 9. Intrapleural radiotherapy with P-32 will be given 3 weeks after last dose of chemotherapy and 11 to 12 weeks after initial thoracoscopy.
1837226|NCT00859508|Device|SyntheCel|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
1837227|NCT00859508|Device|Other FDA cleared dura replacements|Patients will be clinically followed post-surgery until hospital discharge or within ten (10) days of the procedure and at one (1) month, three (3) months and six (6) months. The data up to and including the 6 month follow-up visit will be used in demonstrating the performance of SyntheCelTM Dura Replacement.
1837228|NCT00859521|Drug|Levetiracetam|1000 mg Tablet
1837229|NCT00859521|Drug|Keppra®|1000 mg Tablet
1837230|NCT00859534|Drug|afamelanotide|16mg afamelanotide, one dose for the duration of the clincial trial
1837231|NCT00859547|Biological|rThrombin, 1000 IU/mL|rThrombin,1000 IU/mL, 1000 IU/mL, applied topically to the bleeding site during a single surgery procedure on Day 1.
1837234|NCT00859586|Device|Miltenyi Magnetic cell sorter for CD3|Receipts will receive 1 x 10 to eighth power CD3 cells/kg of familial haploidentical positively selected cluster of differentiation 34 (CD34)+ stem cells from the same DLI donor.
1837235|NCT00859599|Device|Monochromatic phototherapy, Biolight®|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
1837236|NCT00859599|Device|Monochromatic phototherapy|Monochromatic phototherapy (Biolight®) will be given locally, additional to standard care, three times weekly during the first four weeks and twice weekly the following sixteen weeks or until the ulcer is completely healed, according to a pre-determined treatment plan.
1837237|NCT00859625|Procedure|nurse observation during colonoscope withdrawal|nurse observation during colonoscope withdrawal
1837238|NCT00859638|Behavioral|Physiotherapy|group self-management classes
1837239|NCT00859638|Behavioral|Occupational Therapy|group self-management classes
1837240|NCT00859638|Behavioral|Capacity Building|workshops and case reviews with primary health care team members
1837241|NCT00859651|Drug|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.
Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
1837242|NCT00859651|Drug|Placebo capsule|Matching placebo capsules
1837243|NCT00859664|Other|Genotyping of Cytochrome P450|Genotyping of Cytochrome P450
1837244|NCT00859703|Drug|Risedronate|35mg oral risedronate once per week for 24 months
1837245|NCT00859703|Drug|Placebo|Placebo 35 mg once a week for 24 months
1837246|NCT00851838|Drug|L-Carnitine|Instillation of glucose-based (1.5 or 2.5 w/v) PD solution containing L-carnitine during the nocturnal exchange in APD treated patients. L-Carnitine (0.1% w/v) is present only in the first 5 Liter APD bag. PD solutions are instilled for 5 days.
1837403|NCT00853034|Dietary Supplement|AXOS|"arabinoxylan-oligosaccharides (AXOS)
intake period: 2 weeks, 1.25 or 2.50g every morning and evening"
1837247|NCT00851864|Drug|Tinzaparin|"LMWH (tinzaparin-Innohep, Leo Pharma A/S) 175 anti-factor Xa units per kilogram of body weight sub-cutaneously once daily.
Treatment will be done for the duration of the pregnancy."
1837248|NCT00851877|Biological|cetuximab|cetuximab infusion
1837249|NCT00851877|Drug|cisplatin|cisplatin
1837250|NCT00851877|Drug|paclitaxel albumin-stabilized nanoparticle formulation|paclitaxel albumin-stabilized nanoparticle formulation
1837251|NCT00851877|Radiation|3-dimensional conformal radiation therapy|3-dimensional conformal radiation therapy
1837252|NCT00851877|Radiation|intensity-modulated radiation therapy|intensity-modulated radiation therapy
1837253|NCT00851890|Drug|ABT-333|50 mg capsules
1837254|NCT00851890|Other|Placebo for ABT-333|Capsule
1837255|NCT00851890|Drug|Pegylated interferon|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
1837256|NCT00851890|Drug|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
1837257|NCT00851903|Drug|Insulin Glargine|Subcutaneous injection. 100 Units/mL solution for injection in a prefilled SoloStar® pen (3 mL).
1837258|NCT00851903|Drug|Sitagliptin|Oral administration. 100mg film-coated tablets.
1837259|NCT00851903|Drug|Metformin|Patients continued with metformin as usual oral anti-diabetic treatment.
1837260|NCT00851916|Radiation|CyberKnife Radiosurgery|CyberKnife Radiosurgery
1837261|NCT00851929|Drug|Ambrisentan|ambrisentan 5 mg/day for month month, then 10 mg/day for 3 additional months
1837262|NCT00851942|Drug|Synacthen (Tetracosactrin)|IV injection of 250 micrograms of Synacthen in 1ml
1837263|NCT00851968|Procedure|Pringle's Maneuver|The entire hilar pedicle was encircled with a rubber tape to perform a Pringle maneuver with a tourniquet.
1837264|NCT00851968|Procedure|Hemihepatic vascular Clamping|The portal vein,hepatic artery ,and biliary duct were dissected in the hilum by opening the peritoneal fascia. Either the right or left portal pedicle was isolated and encircled with a tourniquet or clamped with Shatinsky clamp. Separate clamping of accessory left hepatic artery was performed when present in controlling the left hemihepatic portal traid.
1837265|NCT00851968|Procedure|Portal vein occlusion|The proper hepatic artery was dissected first from the duodenohepatic ligament, portal pedicle was blocked with a rubber encircled through the posterior wall of proper hepatic artery and the bottom of duodenohepatic ligament.When aberrant hepatic arteries emerging from the superior mesenteric artery are found in duodenohepatic ligament ,they should be dissected and kept unobstructed.
1837266|NCT00851981|Other|Placebo|TID
1837267|NCT00851981|Dietary Supplement|SAMe|300 mg TID
1837268|NCT00852007|Biological|DC-Tn-MUC1: autologous dendritic cells expressing Tn-MUC1|1.2 x 10e7 dendritic cells per dose. One dose delivered intradermally (i.d.) and into a node (i.n.). Two weeks after this,two injections i.d. 2 weeks apart. Optional booster injections at 6 (i.d. and i.n.) and and 12 months (i.d.).
1837269|NCT00852020|Dietary Supplement|oral nutrition supplement, food for special medical purposes|2 servings of 200-300 ml per day, treatment period: 16 weeks
1837270|NCT00852033|Behavioral|Brief Motivational Intervention (BMI)|Students met with trained interventionists. The initial BMI took place during the fall semester of the freshmen year for approximately 45 minutes. Individualized feedback was used to guide the BMI sessions. The feedback data were gathered through an online survey completed within two weeks of the scheduled appointment to ensure the use of proximal feedback reflecting current drinking. Feedback was tailored so that drinkers received information on their personal drinking patterns, heavy episodic drinking, and alcohol-related consequences, and abstainers received feedback on their perceived barriers for maintaining abstinence, the safety and health benefits of their choice not to drink, and their experience with second-hand effects of alcohol use. In the spring of the freshmen year, students received a BMI 'booster' session. Individualized feedback was created from the original online survey and the 10 month follow-up assessment.
1837271|NCT00852033|Behavioral|Parent Based Intervention plus booster|The PBI is a handbook-based intervention modified from Turrisi and colleagues (2001). It was designed to raise parental awareness of alcohol abuse and consequences among college students and increase parental effort to address this issue with their teen.
1837272|NCT00852033|Behavioral|Combined brief motivational intervention and parent based intervention plus boosters for both interventions|A combination of Intervention 1 and 2.
1837273|NCT00852033|Other|Assessment only|No intervention, assessment only.
1837274|NCT00852046|Drug|Dexmedetomidine|IV solution, 0.2 mcg/kg/hr or 0.6 mcg/kg/hr for a max of 5 days
1837275|NCT00852059|Drug|Immediate release methylphenidate (Medikinet®)|Treatment: methylphenidate in the morning and 3-4 h later (twice daily), immediate release
1837276|NCT00852059|Drug|Extended release methylphenidate (Medikinet retard®)|Treatment: methylphenidate applied with breakfast(once daily), extended release
1837277|NCT00852072|Procedure|Mechanical Lithotripsy|Ability to clear the CBD of all stones using mechanical lithotripsy within 20 minutes following sphincterotomy.
1837278|NCT00852072|Procedure|Balloon Sphincteroplasty|Ability to clear the bile duct of all stones within 20 minutes in one ERCP session using balloon sphincteroplasty.
1837279|NCT00852085|Behavioral|Enhanced community service|Two educational sessions and volunteering at a local community service site
1837280|NCT00852085|Behavioral|Group MI|Four group counseling sessions and two directed observational visits to an emergency department
1837281|NCT00852098|Procedure|Lap Nissen fundoplication with division of short gastric vessels|Dividing short gastric vessels
1837282|NCT00852098|Procedure|Laparoscopic Nissen fundoplication without division of short gastric vessels|non-dividing short gastric vessels
1837283|NCT00852124|Biological|VSL#3|VSL#3 2 times daily
1837284|NCT00852124|Biological|VSL#3 or placebo|1 packet 2 x daily of placebo
1837285|NCT00852137|Drug|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel 0.05% once daily for 2 consecutive days
1837286|NCT00852137|Drug|Vehicle Gel|Vehicle Gel once daily for 2 consecutive days
1837287|NCT00852163|Drug|Clofarabine with Busulfan|Clofarabine 40 mg/m2 IV QD × 5 days Busulfan (Busulfex™) 3.2 mg/kg IV QD × 2 days
1837288|NCT00852189|Drug|EC0489, Injection|PART A: Dose escalation from a starting dose of 1.0 mg/m2 IV bolus on Monday, Wednesday, and Friday Weeks 1 and 3 of a 4-week cycle to the Maximum Tolerated Dose (MTD)
1837289|NCT00852189|Drug|EC20|20-25 mCi 99mTc-EC20 administered IV bolus 1-2 hours prior to imaging and at end of study for subjects who received 1 cycle or more of EC0489.
1837290|NCT00852189|Drug|EC0489, Injection|PART B: Once PART A MTD is determined, PART B will begin. Dose escalation from a starting dose of 4.2 mg/m2 IV bolus once weekly in a 4-week cycle to the Maximum Tolerated Dose (MTD).
1837291|NCT00852202|Drug|cariprazine|Drug: cariprazine (0.25 - 0.75 mg/day)
1837292|NCT00852202|Drug|cariprazine|Drug: cariprazine (1.5 - 3.0 mg/day)
1837293|NCT00852202|Drug|placebo|placebo capsules, oral administration, once daily dosing
1837294|NCT00852215|Device|Taxus stent|Stenting with Paclitaxel-eluting coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
1837295|NCT00852215|Device|Vision stent|Stenting with VISION coronary stent system for coronary lesions with > 50% diameter stenosis with ischemic symptoms or positive functional study, or > 70% diameter stenosis without ischemic symptoms or positive functional study
1837296|NCT00852228|Drug|IV cetuximab|Cetuximab is administered every two weeks at the dose of 500 mg/m² over 2h30 (150 minutes).
1837297|NCT00852228|Drug|HAI chronomodulated chemotherapy|"Irinotecan (180 mg/m²) on day 2 as a 6 hour infusion, starting at 2:00, with a peak at 5:00
Oxaliplatin (85 mg/m²) in split daily doses for 3 days, starting on day 2. Daily sinusoidal infusion duration will last from 10:15 to 21:45, with peak delivery rate at 16:00.
5-Fluorouracil (2800 mg/m²) in split daily doses for 3 days, alternating with oxaliplatin infusions, starting on day 2. Daily sinusoidal infusions will last from 22:15 to 9:45 , with peak delivery at 4:00.
Treatments will be repeated every 2 weeks."
1837298|NCT00852228|Drug|HAI conventional chemotherapy|"Irinotecan (180 mg/m²) on day 1 as a one hour infusion, then
Oxaliplatin (85 mg/m²) on day 1 as a two hour infusion, then
5-Fluorouracil (2800 mg/m²) as a 48 h infusion starting on day 2, after completion of oxaliplatin delivery.
Treatments will be repeated every 2 weeks."
1837300|NCT00852267|Other|High Carbohydrate, High Saturated Fat Diet|50% Carbohydrate; 12% Protein; 38% Fat (15% Saturated Fat; 15% Monounsaturated Fat)
1837301|NCT00852267|Other|Low Carbohydrate, High Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (15% Saturated Fat; 14% Monounsaturated Fat)
1837302|NCT00852267|Other|Low Carbohydrate, Low Saturated Fat Diet|31% Carbohydrate; 31% Protein; 38% Fat (8% Saturated Fat; 21% Monounsaturated Fat)
1837304|NCT00852293|Other|A blood test|A blood test of about 5ml of blood will be taken to determine Chitinase 3 like-1 protein levels.
1837305|NCT00852306|Procedure|oocyte freezing|retrieved oocytes from the donor will be split in half and frozen by both existing egg freezing methods: slow freezing and vitrification. The recipients will then be randomized as to which group of eggs will be thawed out for their first attempt at achieving a pregnancy.
1837306|NCT00852319|Behavioral|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
1837307|NCT00852319|Behavioral|Interpregnancy Care|The intervention package includes: 1) Creation of an individualized interpregnancy care plan based on assessments of risks for subsequent poor pregnancy outcomes; 2) Basic dental care and provision of primary health care services for 24 months; 3) Assistance in achieving a woman's desire for subsequent pregnancies and her need for optimum child spacing (ideally at least 18 months); 4) Provision of appropriate social services and community outreach in each woman's community.
1837308|NCT00852332|Dietary Supplement|Curcumin|
1837309|NCT00852332|Drug|Taxotere|
1837310|NCT00852345|Drug|clofazamine|clofazamine 50mg po qday (duration varies according to physician)
1837311|NCT00852358|Drug|laronidase|For the treatment group, intrathecal rhIDU injections will consist of 3 cc of Aldurazyme® (laronidase) (approximately 1.74 mg) diluted with 6 cc of Elliotts B® solution for a total injection of 9 cc. The diluted enzyme will be administered via a lumbar puncture (IT) on day 0 after baseline assessments. IT injections will be repeated on days 30, 60, and 90. The subsequent doses will be administered at 3-month intervals for a total of 10 doses during the two-year period. Control patients will not receive treatment, lumbar puncture, or placebo, but will undergo all other study procedures and assessments during year one. Control patients will then enter a treatment phase consisting of four IT doses at 3-month intervals.
1837312|NCT00852371|Drug|sulfadoxine-pyrimethamine|25 mg/kg po once on day 0
1837313|NCT00852371|Drug|amodiaquine + sulfadoxine-pyrimethamine|Amodiaquine: 10 mg/kg po daily for 3 days (on days 0, 1, 2) SP: 25 mg/kg po once on day 0
1837314|NCT00852371|Drug|dihydroartemisinin-piperaquine|2.1/17.1 mg/kg daily for three days (on days 0, 1, 2)
1837315|NCT00852371|Drug|placebo|dosed as for amodiaquine (10mg/kg po daily on days 1, 2)
1837316|NCT00852384|Procedure|NIPPV and IRM|"non invasive positive pressure support ventilation (NIPPV group)
alveolar recruitment maneuver (IRM group)"
1837317|NCT00852397|Drug|Apixaban|Apixaban 2.5 mg tablet BID for 24 weeks
1837318|NCT00852397|Drug|Apixaban|Apixaban 5.0 mg tablet BID for 24 weeks
1837319|NCT00852397|Other|Placebo|Placebo tablet for 24 weeks
1837320|NCT00852410|Drug|1% lidocaine with 1:100,000 adrenaline|high dose
1837321|NCT00852410|Drug|1% lidocaine with 1:200,000 adrenaline|1% lidocaine with 1:200,000 adrenaline
1837322|NCT00852423|Drug|Dihydroartemisinin-piperaquine|DHA-PQ tablets are green film coated intended for oral use and contain 20/160mg or 40/320mg of dihydroartemisinin (DHA) and piperaquine phosphate (PQ) respectively. In this trial the 40/320mg for adults will be used. Developed by Sigma Tau in partnership with Medicines for Malaria Venture.
1837358|NCT00852709|Drug|Cyclophosphamide|Single-agent cyclophosphamide will be administered by 2-hour IVI on Day 0 of cycle 1. On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
1959098|NCT00799266|Drug|Zoledronic acid|intravenous infusion
1959099|NCT00799266|Drug|Placebo|intravenous infusion
1837323|NCT00852423|Drug|Artesunate-mefloquine|MQAS will be provided as a fixed-dose ACT. There are 2 strengths (AS25+MQ55mg and AS100+MQ220mg) and dosing regimen is calculated according to 12 mg/kg AS and 24mg/kgMQ total dose over three days. Pregnant women will receive 2 tablets/day for 3 days. It is developed by Farmanguinhos with the Drugs for Neglected Diseases Initiative. To be noted: if the FDCs will not get the WHO pre-qualification before the start of recruitment, the separate AS and MQ will be used
1837324|NCT00852423|Drug|Artesunate-amodiaquine|AQAS, developed by teh DNDi with Sanofi-Aventis and manufactured by Sanofi-Aventis, has been pre-qualified by the WHO in 2008 and is available in several African countries, including those involved in this trial. AQ-AS tablets are round, yellow on one side and white-slightly yellow on the other, with a breaking bar, AS engraved on one side and either 25, 50 or 100 on the other side. Tablets to be used in this trial are those 100mg/270mg AS/AQ, containing 100 mg of artesunate, 352.640 mg of amodiaquine hydrochloride corresponding to 270mg of amodiaquine base.
1837325|NCT00852423|Drug|Artemether-lumefantrine|AL (tablets containing a FDC of 20 mg of artemether and 120 mg of lumefantrine) is manufactured by Novartis and has been extensively used in Africa for the treatment of uncomplicated malaria. AL was registered in Switzerland in 1999, has since received marketing authorisation in several endemic and non-endemic countries and it is WHO pre-qualified.
1837326|NCT00852436|Drug|pregabalin|Pregabalin capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
1837327|NCT00852436|Drug|placebo|Placebo capsules in 75 mg,dosing increment from 150, 300, to 600mg/day at weekly intervals,administered orally one (or two, or four) capsule(s), twice daily. Fixed schedule of dosing increment from 150, 300, to 600mg/day at weekly intervals, until the highest tolerated dose has been reached. A single downward dose titration will be allowed depending on tolerability, after which the patient will remain on this dosage for the rest of the study.
1837328|NCT00852449|Other|restrictive and liberal fluid therapy|In both group, when hypovolemia is suspected (peak aortic velocity variation > 13%): fluid bolus (hydroxyethyl starch 130/0.4/6%) according to a predefined algorithm designed to maintain peak aortic velocity < 13% and no further increases in SV
1837329|NCT00852462|Behavioral|SAMI|Patients and Health care providers use Symptom Assessment and Management Intervention: patient report symptoms by answering validated questionnaires in a secure online program. The system generates a report for providers that displays symptoms and customized suggestions for their clinical management.
1837330|NCT00852475|Dietary Supplement|MUFA MOVE! (Monounsaturated fatty enriched diet)|MUFA MOVE!diet and exercise program
1837331|NCT00852475|Dietary Supplement|PUFA MOVE! (Polyunsaturated fatty acid enriched diet)|PUFA MOVE! diet and exercise program
1837332|NCT00852488|Procedure|Placement of transthoracic catheter|Placement of transthoracic catheter into the inferior vena cava
1837333|NCT00852501|Other|To perform RT-PCR on the tissue obtained during surgery|The performance of surgery is the standard of care in the management of non-functioning pituitary macroadenomas. The tissue obtained during surgery is routinely sent for histopathological examination. A piece of the tissue will undergo receptor characterisation via RT-PCR.
1837334|NCT00852514|Device|Bioelectrical impedance-guide dry weight reduction|for optimal determination of fluid status, monthly BIA was performed to monitor fluid status and avoid dehydration
1837335|NCT00852540|Drug|Retpamulin Ointment, 1%|Topical retapamulin (SB-275833) ointment, 1% (w/w), and placebo ointment, will be provided as approximately 10 grams of an off-white smooth ointment in collapsible aluminum tubes with reverse-taper puncture-tip caps. Retapamulin or placebo ointment will be applied twice daily for 5 days.
1837336|NCT00852540|Drug|Linezolid|Adult and adolescent (=>12 years of age) subjects will receive one 600mg linezolid tablet (overencapsulated), or one placebo capsule, twice daily for 10 days. Pediatric subjects aged 5-11 years will receive 10mg/kg body weight of a 100mg/5mL oral linezolid suspension, or placebo suspension, twice daily for 10 days. Pediatric subjects <5 years of age will receive 10mg/kg of a 100mg/5mL oral linezolid suspension, or placebo suspension, three times daily for 10 days.
1837337|NCT00852566|Drug|Imatinib|Per oral imatinib 400mg once daily (continuous medication)
1837338|NCT00852566|Drug|Dasatinib|Per oral dasatinib 100mg once daily (continuous medication)
1837339|NCT00852579|Drug|Azithromycin|Daily dose 250mg
1837340|NCT00852579|Drug|Placebo|Placebo
1837341|NCT00852592|Device|7000lux broad-spectrum light|dosage - 15-60minutes NOON-2PM daily
1837342|NCT00852592|Device|50lux dim red light|dosage: 15-60minutes NOON-2PM daily
1837343|NCT00852605|Other|Intermittent Non-Invasive Ventilation|
1837344|NCT00852631|Drug|Quetiapine fumarate (Seroquel)|600mg Extended release tablet, oral, once daily
1837349|NCT00852657|Procedure|Tendon repair with acromioplasty|Open or mini-open tendon repair in combination with an acromioplasty and eventually a tenodesis of the long head of the biceps
1837350|NCT00852657|Procedure|Physiotherapy|According to a rehabilitation program which was established prior to study start.
1837351|NCT00852670|Drug|ACT-128800|ACT-128800 administered orally once daily
1837352|NCT00852670|Drug|Placebo|Matching placebo capsules administered orally once daily
1837353|NCT00852683|Drug|Pregabalin|75 mg twice a day
1837354|NCT00852683|Drug|Placebo|75 mg twice a day
1837355|NCT00852696|Drug|Solifenacin|Solifenacin is used to treat overactive bladder. It works by relaxing the bladder muscles to prevent urgent, frequent, or uncontrolled urination. Take orally once daily for 9 weeks.
1837356|NCT00852696|Other|Placebo|Take orally once daily for 9 weeks.
1837357|NCT00852709|Drug|Clofarabine|On Days 1, 2, and 3 and Days 8, 9, and 10 clofarabine will be administered by IVI 2 hours before each dose of cyclophosphamide
1837401|NCT00853021|Biological|bevacizumab|Bevacizumab will be administered on day -14, then on day 1 and every 2 weeks thereafter (days 1, 15, 29, and 42) in a continuous manner.
1837359|NCT00852722|Other|Low fat study diet|The low fat study diet is a very low-saturated-fat, plant food based diet. It will be approximately 10% fat, 14% protein and 76% carbohydrate.The diet is is starched based and also contains fresh or frozen fruits and vegetables and there is no animal meat used, including no use of fish. This diet is very low in saturated fats and enriched in unsaturated fats. Subjects do not take dietary supplements.
1837360|NCT00852735|Dietary Supplement|Rapeseed Oil (prevention of cardiovascular diseases)|to assess the effect of optimized oil (enriched with micronutriments) on the prevention on cardiovascular diseases
1837361|NCT00852761|Drug|Olux-E Foam|Olux-E (clobetasol propionate 0.05%) foam. Starting at baseline, subjects were to apply twice daily Olux-E foam to the affected elbows and/or knees up to day 15.
1837362|NCT00852761|Drug|Clobex lotion|Clobetasol propionate 0.05% lotion. Starting at baseline, subjects were to apply twice daily Clobex lotion to the affected elbows and/or knees up to day 15
1837363|NCT00852787|Drug|Digoxin immune fab|Intravenously one time
1837364|NCT00852787|Drug|Placebo|Intravenously one time
1837365|NCT00852800|Drug|Albumin|1.5 g/kg IV on day 1 and 1 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
1837366|NCT00852800|Drug|Albumin|1 g/kg IV on day 1 and 0.5 g/kg IV on day 3 with saline solution to complete total volume of 1000 ml on day 1 and 500 ml on day 3. Infusion in 4 hours.
1837367|NCT00852813|Dietary Supplement|arabinoxylan-oligosaccharides (AXOS)|intake period: 3 weeks, 10 g/day
1837368|NCT00852826|Procedure|Standard axillary lymphadenectomy|Standard axillary lymphadenectomy
1837369|NCT00852826|Procedure|Collagen sponge coated with human coagulation factors|Three patches of collagen sponge coated with human coagulation factors (TachoSil®, Nycomed Pharma, AS) were perpendicularly placed at the end of lymphadenectomy on the axillary neurovascular bundle, thoracodorsal pedicle, and costal wall, covering the axillary walls
1837370|NCT00852839|Drug|Placebo|The placebo formulation will be identical to the oromucosal formulation of 552-02 except for 552-02 content.
1837371|NCT00852839|Drug|552-02|The oromucosal formulation of 552-02 contains 552-02 (25 μg/mL), surfactant, flavoring agents, a humectant, and preservatives. The placebo formulation will be identical except for 552-02 content.
1837372|NCT00852852|Behavioral|Electronic Self-Report Assessment - Cancer (ESRA-C)|The Electronic Self-Report Assessment-Cancer (ESRA-C) is a program allowing patients to report symptoms and quality of life issues and learn information about how to deal with these experiences.
1837373|NCT00852865|Drug|Lactobacillus farciminis|1 capsule per day. Each capsule containing 4*109 CFU
1837374|NCT00852865|Drug|Placebo|1 capsule per day
1837375|NCT00852878|Behavioral|Biofeedback|Biofeedback will teach resonant frequency breathing for 6-8 sessions
1837376|NCT00852878|Behavioral|Behavioral Protocol|Behavioral protocol will teach a variety of pain management techniques such as relaxation, distraction, and coping statements over 6-8 sessions
1837377|NCT00852917|Drug|Tramadol Once A Day|One Tramadol Once A Day tablet at randomized dose daily.
1837378|NCT00852917|Drug|Placebo|One Placebo tablet daily.
1837379|NCT00852930|Procedure|laser and MLD combined|The intervention is therapist administered laser and mld treatment combined
1837380|NCT00852930|Procedure|laser alone|The intervention is therapist administered laser
1837381|NCT00852930|Procedure|manual lymphatic drainage|The intervention is therapist administered manual lymphatic drainage
1837382|NCT00852956|Drug|Betahistine|"The study will be comprised of three treatment periods for a total of 4 weeks treatment duration:
Period I 1 week (Days 1-7) administration of betahistine 48 mg three times daily (144 mg/day total) or matching placebo Period II 1 week (Days 8-14) titration of olanzapine once daily (from 2.5 mg up to 10 mg) and continuation of betahistine or matching placebo administration (three times daily as in Period I) Period III 2 weeks (Days 15-28) of co-administration of betahistine or matching placebo (three times daily; as in Periods II and III) and olanzapine once daily (7.5 or 10 mg, as tolerated)
On Day 1, after a 7-day screening period, eligible subjects will be randomized to one of the two treatment groups in a 1:1 ratio:
Betahistine 48 mg TID; 08:00, 13:00 and 18:00 (144 mg/day total) Matching placebo TID; 08:00, 13:00 and 18:00"
1837383|NCT00852969|Drug|Niacin|1000 mg tablets once per day
1837384|NCT00852969|Drug|Active Placebo|100 mg Niacin tablets once per day
1837385|NCT00852982|Behavioral|Exercise|Nordic walking, with walking poles, five hours per week during four months
1837386|NCT00852995|Biological|HP802-247|One dose of HP802-247 consists of 260 microliters (uL) containing keratinocytes and fibroblasts totaling 0.5 x 10-6 power or 5.0 x 10-6 power cells per mL, plus fibrin.
1837387|NCT00852995|Biological|Placebo (Vehicle)|"Placebo (Vehicle) consisting of:
Component 1 - acellular fibrinogen solution; Component 2 - acellular thrombin solution"
1837388|NCT00853008|Drug|Vincristine|Vincristine (VCR): 1.5 mg/m2 (max 2 mg) IV d 1, 8, 15, 22 in induction VCR 2 mg, IV, d 1,8 in consolidation (cycle 1, 2)
1837389|NCT00853008|Drug|Daunorubicin|Daunorubicin (DNR): 60 mg/m2 IV d 1, 8, 15, 22
1837390|NCT00853008|Drug|Prednisone|Prednisone (PDN): 60 mg/m2/d IV or PO, d 1-28
1837391|NCT00853008|Drug|Mitoxantrone|Mitoxantrone:12 mg/m2, IV d 15-17 in induction 12 mg/m2, IV,d 5 in cycle 2 consolidation
1837392|NCT00853008|Drug|Cytosine Arabinoside|ARA-C 2,000 mg/m2/12h IV, d18,19 (4 doses) in induction
1837393|NCT00853008|Drug|Dexamethasone|Dexamethasone 20 mg/m2,IV, d 1-5,10 mg/m2,IV, d 6 and 5 mg/m2,IV, d 7 in Consolidation (3 cycles)
1837394|NCT00853008|Drug|Methotrexate (MTX)|Methotrexate (MTX)3 g/m2,IV, d1 (24h)in consolidation, cycles 1 and 2 MTX (15 mg/m2/wk, IM)in maintenance MTX 15 mg, IT
1837395|NCT00853008|Drug|Cytarabine|Cytarabine 2g/m2/12h, IV d5 in cycle 1 consolidation Cytarabine 2g/m2/12h, IV d 1,2 in cycle 3 consolidation Cytarabine 30 mg, intrathecal
1837396|NCT00853008|Drug|ASP|ASP 25,000 IU/m2, IV, d5 in consolidation (cycle 1, 2, 3)
1837397|NCT00853008|Drug|Mercaptopurine|Mercaptopurine 100 mg/m2, PO, d 1-5 in consolidation
1837398|NCT00853008|Drug|Teniposide|Teniposide 150 mg/m2, IV d 3,4 in consolidation cycle 3
1837399|NCT00853008|Drug|Hydrocortisone|Hydrocortisone 20 mg, IT d 1, 28, 49, 77, 105, 175, 203, 231, 259,287, 311 intrathecal
1837400|NCT00853021|Biological|aldesleukin|SQ Aldesleukin (Days 1-5) Monday through Friday for six weeks followed by a two-week break.
1959107|NCT00795860|Behavioral|Weight loss - diet only|Subjects adhere to a reduced calorie diet until they lose exactly 12% of their initial body weight. After they achieve this weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
1959108|NCT00795860|Behavioral|Weight loss plus exercise|Subjects adhere to a reduced calorie diet and perform 4 session of endurance exercise training per week until they lose exactly 12% of their initial body weight. Exercise training consists of stationary bicycle exercise. the exercise duration and intensity ramp up over the first few weeks of training until subjects exercise 45 min per session at an intensity of 85% of their maximal heart rate. 3 of the 4 exercise session each week are supervised by an Exercise physiologist. After they achieve the 12% weight loss goal, they are placed on a weight-maintaining diet for 3-4 weeks before follow-up experiments are performed. Subjects meet weekly with a research dietitian throughout their weigh-loss and weight maintenance program.
1837413|NCT00853073|Drug|bevacizumab|1.0mg (0.04 cc of 25 mg/ml subconjunctival bevacizumab following bleb needling procedure
1837414|NCT00853073|Other|balanced salt solution|0.04 cc of balanced salt solution injected to the bleb following bleb needling procedure
1837415|NCT00853086|Drug|activated recombinant human factor VII|Safety data collection in connection with the use of the drug NovoSeven® in daily clinical practice
1837416|NCT00853099|Biological|adalimumab|
1837417|NCT00853099|Drug|placebo|
1837427|NCT00853138|Behavioral|cognitive-behavioral therapy|"In addition to standard medical care, the children and parents in the family CBT condition will also receive education about chronic pain, pain behaviors and operant strategies as well as training in coping skills using an interactive, engaging format on the Internet.
The Internet site will consist of three main sections: child treatment modules, parent treatment modules, and diary tracking. All users will complete 8 treatment modules (one per week) over the 8-week treatment period. Each module will require approximately 30-40 minutes to complete. There is separate specific content of the intervention for child users and for parent users.
Assignments are incorporated into each module for the participant to work on during the treatment week."
1837428|NCT00853151|Drug|LY2428757|14 mg subcutaneous injection 1 time a week for 5 weeks
1837429|NCT00853151|Drug|TT223|subcutaneous injection once a day for 4 weeks
1837430|NCT00853151|Drug|Placebo for LY2428757|subcutaneous injection 1 time a week for 5 weeks
1837431|NCT00853151|Drug|Placebo for TT223|subcutaneous injection once a day for 4 weeks
1837432|NCT00853164|Behavioral|walking exercise|Subjects will be given an exercise prescription for walking 3 times a week for eight weeks
1837433|NCT00853164|Behavioral|weight training|participants will be given a weight training prescription to do 3 times a week for eight weeks.
1837434|NCT00853164|Behavioral|Usual Care|Subjects in this arm will continue with their usual care and not start any exercise program for eight weeks.
1837435|NCT00853177|Procedure|MEOPA inhalation|N2O of 50% and 50% O2
1837436|NCT00853177|Procedure|xylocaine|Ampoule-bottle of 20 ml
1837437|NCT00853190|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose with food
1837438|NCT00853190|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose with food
1837439|NCT00853203|Behavioral|Interviews|Open-ended Interviews, audiotaped, lasting 30 minutes to 1 hour.
1837440|NCT00853203|Behavioral|Questionnaires|Written survey taking about 1 hour.
1837441|NCT00853203|Other|Electronically Activated Recorder (EAR)|Recording system (a digital tape-recorder and small external microphone) programmed to record for 30 seconds every 12 minutes, repeating over two consecutive days of wearing.
1837442|NCT00853203|Behavioral|Group Meetings|12 Audiotaped Group Meetings over 4 months: 9 weekly meetings, 2 semi-monthly (twice a month) meetings, and a final meeting in month 4. Each meeting will last 1 hour.
1837443|NCT00853203|Behavioral|Written Materials|Written educational materials plus community resource information.
1837444|NCT00853216|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose fasting
1837445|NCT00853216|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose fasting
1837446|NCT00853229|Drug|pregabalin|pregabalin 150mg twice daily for 4 weeks
1837447|NCT00853242|Drug|Placebo|
1837448|NCT00853242|Drug|Genz-644470|
1837449|NCT00853242|Drug|Sevelamer carbonate|
1837450|NCT00853255|Biological|Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)|Vaccine administered by nasal spray
1837451|NCT00853268|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose with food
1837452|NCT00853268|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose with food
1837453|NCT00853281|Other|Hammocks with LLIN|Locally-made hammocks covered with long lasting insecticidal nel (LLIN)
1837454|NCT00853281|Other|Standard vector control measures|Insectice-treated net
1837455|NCT00853294|Drug|Chlorpheniramine polistirex equivalent to 8 mg of chlorpheniramine maleate and hydrocodone polistirex equivalent to 10 mg of hydrocodone bitartrate capsule|Chlorpheniramine polistirex/hydrocodone polistirex extended release capsule, single dose fasting
1837502|NCT00853658|Drug|Enalapril|Enalapril 10 mg film-coated tablet and administered orally.
1837456|NCT00853294|Drug|5 mL chlorpheniramine (8 mg/5 mL)/hydrocodone (10 mg/5 mL) extended release oral suspension|Tussionex® Pennkinetic® Extended Release Oral Suspension, single dose fasting
1837457|NCT00853307|Drug|MLN8237|MLN8237 will be given by mouth in a dosage of 50 mg twice a day for 7 Days (Days 1-7) of each 21-day treatment cycle.
1837458|NCT00853320|Drug|Oxycodone hydrochloride tablet 15 mg|Oxycodone hydrochloride tablet 15 mg, single dose fasting
1837459|NCT00853320|Drug|Roxicodone™ tablet 15 mg|Roxicodone™ tablet 15 mg, single dose fasting
1837460|NCT00853333|Drug|dexmedetomidine|
1837461|NCT00853333|Drug|midazolam|
1837462|NCT00853333|Drug|propofol|
1837463|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
1837464|NCT00853346|Behavioral|Cognitive Behavioral Therapy|12 weeks of Cognitive Behavioral Therapy designed for adults with Parkinson's Disease and comorbid Depression
1837465|NCT00853372|Drug|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of RCC and will be administered to all subjects.
1837466|NCT00853372|Drug|AMG386|10 mg/kg IV QW AMG 386 will be administered until a subject develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
1837467|NCT00853372|Drug|Sunitinib|Sunitinib will be administered 50 mg QD and is considered to be the background therapy as it is licensed for treatment of RCC and will be administered to all subjects.
1837468|NCT00853372|Drug|AMG 386|15 mg/kg IV QW AMG 386 will be administered until a subject develops disease progression, clinical progression, unacceptable toxicity, withdraws consent, or death.
1837469|NCT00853385|Drug|CP 690,550|tablets 5 mg BID PO plus q2 week placebo SC injections for 12 months
1837470|NCT00853385|Drug|CP-690,550|tablets 10 mg BID PO plus q2 week placebo SC injections for 12 months
1837471|NCT00853385|Other|Placebo|placebo tablets BID PO advance to 5mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
1837472|NCT00853385|Other|Placebo|tablets BID PO advance tablets to10mg CP 690,550 BID at Month 3 or 6 visit plus q2 week placebo SC injections for 12 months
1837473|NCT00853385|Biological|Biologic TNFi|placebo tablets BID PO plus adalimumab 40 mg q2 week SC injections for 12 months
1837474|NCT00853398|Procedure|surgical technique|
1837475|NCT00853411|Drug|prednisone|Druing asthma exacerbation, subjects will be dosed to prednisone.
1837476|NCT00853424|Procedure|islet cell transplant|Human pancreases are retrieved from multiorgan donors and processed with intraductal collagenase perfusion, continuous digestion, and density gradient purification with impure tissue fractions cultured in vitro and then repurified to retrieve additional islets. Islets are implanted by ultrasound guided percutaneous portal embolization, to provide more than 12, 000 islet equivalents (IE) per kilogram of body weight (infusions from 1-3 donors per patient) Immunosuppression consists of antithymocyte globulin, basiliximab, mycophenolate mofetil and tacrolimus as described (Warnock et al Arch Surg 2005;140:735).
1837477|NCT00853424|Other|Medical therapy|subjects receive all recommended medical treatment for diabetes and diabetic eye disease
1837478|NCT00853450|Drug|AZD6482|Single intravenous infusion during a maximum of 5 hours
1837479|NCT00853450|Drug|Clopidogrel|Oral doses given once daily during 7 days. 300 mg on day 1 and 75 mg on day 2 to 7.
1837480|NCT00853450|Drug|ASA|75 mg orally once daily during 7 days in each treatment arm
1837481|NCT00853463|Behavioral|Alert|The responsible physician will be notified that: 1) his or her patient is at high risk for VTE and 2) VTE prophylaxis should be considered in the Discharge orders
1837482|NCT00853489|Device|recombinant bone morphogenetic protein 2|Patients will receive 1.50 mg/ml -12 mg of rhBMP-2 soaked on a absorbable collagen sponge (rhBMP-2/ACS) as an adjuvant to a freeze-dried cancellous allograft
1837483|NCT00853489|Procedure|Autogenous iliac crest bone graft|Patients will undergo autogenous iliac crest bone graft surgery per the surgeon's usual practice.
1837484|NCT00853502|Drug|testosterone cypionate|dose dependent on pubertal stage, intramuscular injection once every 3 weeks for 12 months
1837485|NCT00853515|Other|Goal-directed fluid resuscitation|Targeted, weight-based fluid resuscitation
1837486|NCT00853528|Other|questionnaire administration|prior to radiosurgery, at radiosurgery completion, and then at subsequent follow-ups (3, 6, 9, 12, 18, and 24 months after treatment
1837487|NCT00853528|Procedure|diffusion tensor imaging|prior to initiating CyberKnife radiosurgery, at 6 weeks after CyberKnife therapy, and at 6 months after CyberKnife therapy
1837488|NCT00853528|Procedure|functional magnetic resonance imaging|prior to CyberKnife, at 6 weeks, and 3 months after CyberKnife?, every 3 months for the first year, and every 6 months thereafter
1837489|NCT00853528|Radiation|hypo-fractionated SRS|two to three consecutive daily sessions within one week for 3 cohorts- Cohort 1 = 21 Gy; Cohort 2 = 24 Gy; Cohort 3 = 27 Gy
1837490|NCT00853528|Radiation|single-fraction SRS|two to three consecutive daily sessions within one week for 3 cohorts- for 3 cohorts- Cohort 1 = 16 Gy; Cohort 2 = 18 Gy; Cohort 3 = 20 Gy
1837491|NCT00853554|Drug|Hydromorphone Hydrochloride tablet 8 mg|Hydromorphone Hydrochloride tablet 8 mg, single dose fasting
1837492|NCT00853554|Drug|Dilaudid® tablet 8 mg|Dilaudid® tablet 8 mg, single dose fasting
1837493|NCT00853567|Drug|Proellex|25 mg oral daily dose vs. 50 mg oral daily dose vs. placebo
1837494|NCT00853567|Other|placebo|Placebo
1837497|NCT00853593|Device|Pacing Lead|implant and follow-up of study device
1837498|NCT00853606|Drug|avanafil|All subjects will initially be assigned to treatment with avanafil 100 mg. Subjects who are unable to tolerate treatment with 100 mg may undergo dose reduction to 50 mg. Subjects who tolerate avanafil 100 mg but who desire increased efficacy may request a dose increase to 200 mg.
1837499|NCT00853619|Other|Service based decision support intervention|Delivering CDS via services
1837500|NCT00853632|Device|CEP MAGNA MITRAL PERICARDIAL BIOPROSTHESES|Mitral valve replacement
1837501|NCT00853645|Device|Subcutaneous Implantable Defibrillator (S-ICD) System|
1837503|NCT00853658|Drug|Aliskiren|Aliskiren 150 mg titrated to 300 mg film-coated tablet and administered orally.
1837505|NCT00853684|Drug|OXCE|Oxaliplatin 130 mg/m2 iv drip D1, Capecitabine 1000 mg/m2 bid d1-14. Every three weeks.
1837506|NCT00853684|Drug|Endostar|Endostar 7.5 mg/m2 iv drip D1-14. Every 3 weeks.
1837507|NCT00853697|Other|testosterone (AndroGel®) with the 5α-reductase inhibitor dutasteride|"Patients will be treated with dutasteride 3.5 mg once daily (oral administration). To avoid rapid conversion of testosterone to DHT in case 5α-reductase is not adequately inhibited during the first few days of concurrent treatment with dutasteride and testosterone, daily dutasteride treatment will be initiated 7 days prior to testosterone initiation.
Patients will receive AndroGel® at the dose of 15 g (3 times the standard replacement dose for hypogonadism) once daily (topical administration), starting on Day 8 and continuing for 12 weeks (or until disease progression or withdrawal from the study)."
1837508|NCT00853710|Other|PSA assay|rapid prostate specific antigen assay.
1837509|NCT00853723|Drug|Parathyroid hormone related protein (1-36)|PTHrP (1-36) 400 micrograms / day administered subcutaneously for 3 months
1837510|NCT00853723|Drug|Parathyroid hormone related protein(1-36)|PTHrP(1-36)600 micrograms subcutaneously administered daily for 3 months
1837511|NCT00853723|Drug|Parathyroid hormone (1-34)|PTH(1-34)20 micrograms subcutaneously administered daily for 3 months
1837512|NCT00853736|Drug|Roxicodone™ tablet 30 mg|Roxicodone™ tablet 30 mg, single dose with food
1837513|NCT00853736|Drug|Oxycodone hydrochloride tablet 30 mg|Oxycodone hydrochloride tablet 30 mg, single dose with food
1837514|NCT00853749|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL intramuscular injection
1837515|NCT00853749|Procedure|Blood draw|Collection of 10 mL of blood
1837516|NCT00853762|Drug|Atacicept 25 mg|Subjects who received atacicept 25 milligram (mg) subcutaneously (SC) as loading dose twice weekly for first 4 weeks, followed by atacicept 25 mg SC for 32 weeks, in 28063 study will continue with atacicept 25 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
1837517|NCT00853762|Drug|Atacicept 75 mg|Subjects who received atacicept 75 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 75 mg SC for 32 weeks, in 28063 study will continued with atacicept 75 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
1837518|NCT00853762|Drug|Atacicept 150 mg|Subjects who received atacicept 150 mg SC as loading dose twice weekly for first 4 weeks, followed by atacicept 150 mg SC for 32 weeks, in 28063 study will continue with atacicept 150 mg SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
1837519|NCT00853762|Drug|Atacicept 150 mg|Subjects who received placebo SC twice weekly for first 4 weeks, followed by placebo SC for 32 weeks, in 28063 study will continue with atacicept 150 mg (without loading dose) SC once weekly up to 5 years or up to early termination of treatment or early termination of the study.
1837520|NCT00853775|Other|No intervention, observational study|
1837521|NCT00853801|Behavioral|Lifestyle intervention and provider feedback|"Patients receive lifestyle education and counseling after each visit with their primary care provider. Lifestyle modification goals are set and progress monitored. Frequency is dependent on frequency of visits with primary care provider which can range from one month to nine months.
Primary care providers of the intervention patients receive one education session at the commencement of the study covering the diagnosis and treatment of metabolic syndrome and pre-diabetes. Feedback on provider performance as assessed by provider documentation of diagnosis and treatment recommendations compared to patient outcomes is given every six months."
1837522|NCT00853814|Behavioral|Access to sedentary behaviors|Access to sedentary behaviors: Reduced access - reduce access to sedentary behaviors by 50% using TV Allowance technology. Usual access - monitoring only, no change in access to sedentary behaviors. Access to neighborhood parks: High access - large amount of park land very near to the child's home. Low access - little to no park land near the child's home.
1837523|NCT00853827|Drug|Placebo|Placebo
1837524|NCT00853827|Drug|Aliskiren|300 mg
1837525|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
1837526|NCT00853840|Drug|Vardenafil|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Vardenafil 20 mg.
1837527|NCT00853840|Drug|Maraviroc|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
1837528|NCT00853840|Drug|Placebo|Maraviroc 300 mg twice daily for 3 - 4 days plus a single oral dose of Placebo.
1837529|NCT00853853|Device|EnSeal Device|Hemorrhoidectomy using the EnSeal Device, which is an instrument cuts and seals with heat energy leaving a sutureless wound, which heals with security against bleeding.
1837530|NCT00853853|Procedure|Ferguson Hemorrhoidectomy technique|The closed Ferguson hemorrhoidectomy technique is a gold standard operation that has been in existence for 50 years. This operation is done under general or intravenous sedation, and the operating surgeon uses a special clamp to go across the hemorrhoidal complex followed by excision of the hemorrhoid. Sutures that dissolve (such as 3.0 vicryl) are then placed at the root of the hemorrhoid, securely tied, and then run about the clamp. The clamp is removed and then the suture tightened, then the suture line is reinforced. This can be done from 1-3 hemorrhoidal groups at a single time.
1837531|NCT00853866|Drug|reboxetine|single dose of 4mg reboxetine 80 minutes before assessment of Jebsen Taylor test
1837532|NCT00853866|Drug|Placebo|placebo, 80 min before assessment of Jebsen Taylor test
1837533|NCT00853866|Device|tDCS verum|20 minutes of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
1837534|NCT00853866|Device|tDCS sham|30 seconds of 1 mV transcranial direct current stimulation with 5x5 cm electrodes with active electrode over the primary motor representation of the stroke hemisphere and reference electrode over the contralateral supraorbital area Application during assessment of Jebsen Taylor test
1837619|NCT00859989|Behavioral|telephone-based intervention|
1959119|NCT00787059|Drug|Ad5.hAC6|Intracoronary delivery of test substance in 3:1 randomization (Ad5.hAC6 : placebo) with dose escalation, starting at 3.2 x 10^9 vp to 10^12 vp in 5 dose groups
1959120|NCT00787059|Drug|Sucrose (3%)|
1837535|NCT00853879|Dietary Supplement|Folic Acid, Vitamin B6, Vitamin B12|"Intervention #1. A combination of the following vitamin supplements: 2.5mg of folate, 25mg of vitamin B6 and 2mg of vitamin B12. This combination will be described as triple therapy with folate."
1837536|NCT00853879|Dietary Supplement|B6, B12, L-methylfolate|Intervention #2. A combination of the following vitamin supplements: 2.8mg of L-methylfolate, 25 mg of vitamin B6 and 2mg of vitamin B12.
1837537|NCT00853879|Dietary Supplement|B6, B12, Placebo|"Intervention #3. A combination of the following vitamin supplements: 25mg of vitamin B6 and 2mg of vitamin B12 without supplementary folate or L-methylfolate. This combination will be described as triple therapy with placebo"
1837538|NCT00853892|Drug|Controlled-Release Oxycodone Hydrochloride 40 mg tablet|Controlled-Release Oxycodone Hydrochloride 40 mg, single dose fasting
1837539|NCT00853892|Drug|OxyContin® 40 mg tablet|OxyContin® 40 mg tablet, single dose fasting
1837540|NCT00853905|Drug|Triesence|At the end of standard glaucoma surgery after the anterior chamber is reformed with balanced salt solution or viscoelastic to adequate intraocular pressure; 0.2cc of Triesence will be delivered into the anterior chamber through the previously created paracentesis wound
1837541|NCT00853905|Drug|balanced salt solution BSS|standard technique for glaucoma surgery . At the end of the case anterior chamber will be reformed with balanced salt solution to adequate intraocular pressure.
1837542|NCT00853918|Other|$20 cash|$20 cash incentive mailed with survey
1837543|NCT00853918|Other|$50 cash|$50 cash incentive mailed with survey
1837544|NCT00853918|Other|$50 check|$50 check incentive mailed with survey
1837545|NCT00853918|Other|$100 check|$100 check incentive mailed with survey
1837546|NCT00853931|Drug|Panitumumab|Panitumumab 6 mg/kg will be administered by intravenous infusion every 2 weeks (Q2W), +/- 3 days, (eg, week 1, 3, 5 [i.e. Cycles 1, 2, 3, etc.]) until disease progression or intolerance panitumumab as determined by the investigator.
1837548|NCT00853957|Drug|Aliskiren/Amlodipine|Aliskiren/Amlodipine 150 mg/5 mg titrated to 300 mg/10 mg
1837549|NCT00853957|Drug|Amlodipine|Amlodipine 5 mg titrated to 10mg
1837550|NCT00853970|Drug|Bromfenac Ophthalmic Solution|sterile ophthalmic solution
1837551|NCT00853970|Drug|Placebo Comparator|sterile ophthalmic solution
1837552|NCT00853983|Drug|[14C] AZD0530|Solution, Oral, once
1837553|NCT00853996|Drug|acolbifene hydrochloride|Given orally
1837554|NCT00854009|Drug|BLI-489|
1837555|NCT00854009|Drug|Placebo|
1837556|NCT00854035|Drug|MK-0431/ONO-5435|Double-blind period (16 wk); 50 mg QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50mg QD to 100mg QD
1837557|NCT00854035|Drug|MK-0431/ONO-5435|Double-blind period (16 wk); placebo QD. The double-blind period will be followed by a 36 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
1837558|NCT00854061|Drug|T-Pred|sterile ophthalmic solution
1837559|NCT00854061|Drug|Pred Forte|sterile ophthalmic solution
1837560|NCT00854074|Device|ElectroCore RMS-1100 Resolution Motility System™|An electrical neurostimulation signal will be applied to the spine
1837561|NCT00854087|Drug|Fuzheng Huayu|The subjects will be taking 2 tablets three times a day for 48 weeks.
1837562|NCT00854087|Drug|Placebo|The subjects will be taking 2 tablets three times a day for 48 weeks.
1837563|NCT00854100|Drug|Antidepressant + placebo|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + Placebo Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
1837564|NCT00854100|Drug|Antidepressant + cariprazine (0.1-0.3 mg/day)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (0.1-0.3 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
1837565|NCT00854100|Drug|Antidepressant + cariprazine (1-2 mg/d)|Drug: Antidepressant (citalopram, duloxetine, escitalopram, sertraline, or venlafaxine XR) + cariprazine (1-2 mg/d) Oral, once daily for 8 weeks following an 8 week Prospective Treatment (Baseline) Period.
1837566|NCT00854113|Drug|EGT0001474|Oral ascending doses given daily as capsules for up to 14 days
1837567|NCT00854113|Drug|Placebo|Placebo to match EGT0001474
1837568|NCT00854126|Drug|GDC-0980|Escalating repeating dose
1837569|NCT00854139|Drug|Cyclophosphamide, anti-thymocyte globulin|"Cyclophosphamide 60 mg/kg IV on Day -5, -4 Anti-thymocyte globulin 20 mg/kg IV on Day -1, Day +1, +3, +5
Cyclosporine starting on Day -1 at 5 mg/kg daily I.V. and reduced to 3 mg/kg on Day +4, and adjusted to provide a trough whole blood concentration of 250-400 ng/mL. The route of administration will be changed to oral as soon as the patient is able to tolerate oral medications"
1837570|NCT00854139|Procedure|Kidney transplant|On Day 0 the renal transplant is performed according to standard surgical techniques, preferably using an iliac fossa, extraperitoneal approach
1837571|NCT00854139|Radiation|Thymic irradiation|Thymic irradiation 7 Gy on Day -1
1837572|NCT00854139|Procedure|Bone marrow transplant from a related donor|• Donor bone marrow (> 2 x 108 nucleated cells/kg of recipient body weight) is prepared for infusion according to the standard procedure at the medical center. A total of 15,000 Units of heparin is mixed with the marrow, which is infused at a rate of 300-500 cc/hr. The infusion begins in the operating room as soon as the vascular anastomosis of the renal allograft has been completed. Protamine, 25 mg, is administered I.V. after completion of the first half of the bone marrow infusion. If a partial thromboplastin time measured after completion of the marrow infusion is > 60 seconds, the protamine treatment shall be repeated
1837573|NCT00854152|Drug|GDC-0980|Escalating repeating dose
1837574|NCT00854178|Drug|Comparison of two anesthetic drugs|Isoflurane 1,0 minimum alveolar concentration Propofol 2mg/kg and 4ug/ml
1837575|NCT00854191|Device|simulator training|4 half-day of simulator ERCP practice as endoscopist and/or assistant followed by usual training
1837576|NCT00854204|Drug|TMC114; TMC41629|
1837577|NCT00854217|Procedure|acute normovolemic hemodilution|
1837578|NCT00854230|Drug|Naltrexone|Naltrexone dose 25-100mg
1837579|NCT00859716|Biological|ACE393|ACE393 250 micrograms as intra muscular injection at day 0 and day 21
1837620|NCT00859989|Other|counseling intervention|
1837580|NCT00859716|Biological|Placebo vaccine|Placebo 500 micrograms Alhydrogel as intra muscular injection at day 0 and day 21
1837581|NCT00859729|Biological|pVAXrcPSAv53l (DNA encoding rhesus PSA)|5 doses, 4 weeks apart
1837582|NCT00859729|Device|DERMA VAX™ intradermal DNA delivery system|in vivo electroporation is applied after each DNA injection
1837583|NCT00859742|Procedure|EBUS-TBNA, integrated PET/CT|EBUS-TBNA and integrated PET/CT will be performed for patients with non-small cell lung cancer after induction therapy. PET/CT will be performed before EBUS-TBNA. Negative findings of EBUS-TBNA will be evaluated by surgery.
1837584|NCT00859755|Drug|ARRY-403, glucokinase activator; oral|single dose, escalating
1837585|NCT00859755|Drug|Placebo; oral|matching placebo
1837586|NCT00859768|Other|Questionnaire administration|The patient receives the SIPP at two different time points during their RT period. The first time point is before the first consultation with the radiotherapist (before starting RT) and the second time point is before the last consultation with the radiotherapist at the end of the RT period. At both time points, the SIPP is handed over to the radiotherapist at the start of the consultation. The radiotherapist screens the scores of the SIPP to get an overview of potential psychosocial problems and patient's needs of psychosocial care.
1837587|NCT00859781|Drug|177Lu-J591|177Lu-J591 70 mCi/m2 on day 29 (+/- 2 days) of treatment
1837588|NCT00859781|Drug|Ketoconazole|Ketoconazole at a dose of 400 mg (two 200 mg tabs) to be taken orally (preferably on an empty stomach) three times per day (total daily dose of 1200 mg)
1837589|NCT00859781|Drug|Hydrocortisone|Hydrocortisone at a dose of 20 mg orally each morning, 10 mg orally each evening (total daily dose of 30 mg)
1837590|NCT00859781|Drug|111In-J591|111In-J591 at a dose of 5 mCi on day 29 (+/- 2 days) of treatment
1837591|NCT00859794|Other|fMRI|Subjects will undergo MRI scanning to gather data about cognitive functions.
1837592|NCT00859794|Other|Releasing Data|Subjects in the study will be asked to release data about their surgery, and electrostimulation to the research team for analysis.
1837593|NCT00859794|Other|Neuropsychological Testing|Subjects will have a neuropsych evaluation as part of their standard of care for surgery. The research team is asking the subject to release their neuropsych evaluations for analysis.
1837594|NCT00859794|Other|Additional electrode implantation|Subjects normally will have anywhere from 100-200 electrodes implanted as part of their surgery. As part of the study, we would implant 1-2 electrodes that are able to record from smaller, more specific parts of the brain to better understand how your brain is wired.
1837595|NCT00859794|Other|Brain stimulation|Subjects may be asked to undergo additional electrical brain stimulation (in addition to what is required for clinical purposes) to map brain function and epileptogenic areas. This may include extended stimulation mapping, low frequency stimulation (CCEPs), and transcranial stimulation.
1837596|NCT00859807|Drug|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
1837597|NCT00859807|Drug|Flavoquine®, Camoquin® Suspension|Treatment A 15.3 mL (50 mg/5 mL) AQ suspension single dose. Treatment B (1 x 200 mg tablet Flavoquine® (Sanofi Aventis) single dose.
1837598|NCT00859833|Drug|Adenosine|Myocardial perfusion reserve measured with quantitative MRI during adenosine infusion (0.14 mg/kg/min x 6 minutes).
1837599|NCT00859833|Drug|Regadenoson|Myocardial perfusion reserve measured during regadenoson (0.4 mg/5 ml) bolus administration using quantitative perfusion MRI.
1837600|NCT00859846|Procedure|Arterial line placement|"The following measures will be collected and compared.
Time (in seconds) required for successful placement of the arterial line. This is the time elapsed between either palpation or placement of ultrasound probe on the patient's wrist and the successful demonstration of arterial waveform on the anesthesia monitor.
number of attempts, defined as forward advancements of needle, required to cannulate the artery.
number of separate skin punctures.
number of arteries into which entry is attempted."
1837601|NCT00859859|Device|Vagus Nerve Stimulation|"Vagus nerve stimulation for 5 minutes with an oscillatory device (Brookstone) used in previous experimental animal studies for stimulating the vagus nerve on the neck by carotid massage. The oscillatory part of this pen-like device is approximately 0,5 cm2.
Basic lab tests (metabolic panel and CBC with differential) and monocyte cytokine synthesis and other inflammatory markers will be analyzed."
1837602|NCT00859872|Drug|risperidone oral solution|risperidone oral solution (2-6mg/d) combination clonazepam (4-8mg/d) oral
1837603|NCT00859872|Drug|haloperidol|haloperidol IM injection (5-20mg/d)
1959121|NCT00783510|Biological|adalimumab|As prescribed by treating physician
1959122|NCT00783510|Drug|Methotrexate|As prescribed by treating physician
1837606|NCT00859898|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 24 weeks
1837607|NCT00859898|Drug|Metformin XR|Tablets, Oral, up to 2000 mg, once daily, 24 weeks
1837608|NCT00859898|Drug|Metformin XR|Tablets, Oral, 500 mg up to 2000 mg, once daily 24 weeks
1837609|NCT00859898|Drug|dapagliflozin matching Placebo|Tablets
1837610|NCT00859898|Drug|metformin HCl Modified Release matching Placebo|Tablets
1837611|NCT00859911|Dietary Supplement|Multiple micronutrients|A tablet on three days a week containing: Vitamin A 1500 µg, Vitamin D 15 µg, Thiamine Mononitrate 1.22 mg, Riboflavin 1.7 mg, Ascorbic Acid 60 mg, Niacin amide 20 mg, Pyridoxine hydrochloride 2 mg, Folic Acid 400 µg, Calcium pantothenate 10.8 mg, Cyanocoblamin 6 µg, Vitamin E 18 IU, ferrous sulphate 19 mg, potassium iodide 145 µg, Potassium sulphate 11 mg, Manganese sulphate 0.38 mg, copper sulphate 0.509 mg, zinc sulphate 15 mg
1837612|NCT00859937|Drug|dasatinib|Given orally
1837613|NCT00859937|Other|laboratory biomarker analysis|Correlative studies
1837614|NCT00859950|Device|Continuous Positive Airway Pressure (CPAP)|Continuous positive airway pressure (CPAP) is a method of respiratory ventilation which is accepted as the gold standard to treat Obstructive Sleep Apnea (OSA). Subjects found to have OSA after the Nocturnal Polysomnography (NPSG) will be trained in the use of CPAP and will be instructed to use CPAP every night for 30 nights. These subjects will then return for a post-treatment blood draw.
1994035|NCT03082989|Other|fractional flow reserve not performed|description of the main reasons leading the operator to not use fractional flow reserve to drive the coronary revascularization
1994036|NCT03082742|Drug|Hydrochlorothiazide|
1837617|NCT00859989|Behavioral|behavioral dietary intervention|
1837618|NCT00859989|Behavioral|exercise intervention|
1837628|NCT00860015|Drug|Alimta/Gemcitabine|500 mg/m2 Alimta via IV for 10 minutes, followed by 1000 mg/m2 Gemcitabine via IV for 90 minutes for 14 days. This cycle is repeated for 4 cycles
1837629|NCT00860028|Drug|Varenicline|
1837630|NCT00860041|Behavioral|pain questionnaires|
1837631|NCT00860054|Dietary Supplement|Different amount of phytosterols are added into diets|Diets with 59, 400, or 2000 mg of phytosterols daily for 4 weeks were given to each subject, in random order.
1837632|NCT00860067|Biological|Q/LAIV (MEDI3250)|0.2 mL dose at Day 0
1837633|NCT00860067|Biological|FluMist/B/Yamagata|0.2 mL dose at Day 0
1837634|NCT00860067|Biological|FluMist/B/Victoria|0.2 mL dose at Day 0
1837635|NCT00860457|Drug|Rituximab|375 mg/m2 IV infusion Day 1 of each 28-day cycle for maximum of 6 cycles
1837636|NCT00860457|Drug|Fludarabine|25 mg/m2 IV Days 1-5 of each 28-day cycle for maximum of 6 cycles
1837637|NCT00860457|Drug|Lenalidomide|5-10 mg PO daily on Days 1-21 of each 28-day cycle for a maximum of 6 cycles
1837638|NCT00860470|Dietary Supplement|Iron (27 mg) - folic acid (600 ug)|"Supplement serves as the Control (providing the current standard of care during pregnancy). Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
1837639|NCT00860470|Dietary Supplement|Multiple micronutrient|"Containing 15 micronutrients all at an RDA including: vitamin A (770 ug retinol equivalents, vitamin D (5 ug), vitamin E (15 mg), folic acid (600 ug), thiamin (1.4 mg), riboflavin (1.4 mg), niacin (18 mg), vitamin B-12 (2.6 mg), vitamin B-6 (1.9 mg), vitamin C (85 mg), iron (27 mg), zinc (12 mg), iodine (220 ug), copper (1000 ug), selenium (60 ug).
Mothers instructed to take 1 tablet per day, from the 1st trimester through 12 weeks post-partum."
1837640|NCT00860483|Other|observational|PET Scan
1837641|NCT00860496|Drug|CP- 690,550 and Tacrolimus|10 mg, single dose of CP-690,550 on Day 1 5 mg, every 12 hours of Tacrolimus on Days 1-8 10 mg, single dose of CP-690,550 on Day 8
1837642|NCT00860496|Drug|CP- 690,550 and Cyclosporine|10 mg, single dose of CP-690,550 on Day 1 200 mg, every 12 hours of Cyclosporine on Days 1-6 10 mg, single dose of CP-690,550 on Day 6
1837643|NCT00860509|Other|Low Phytosterol and High Phytosterol Diets|Diets with 600 or 100 mg of daily phytosterols for 4 weeks were given to each subject, in random order
1837644|NCT00860522|Drug|JVRS-100|Level 1: 0.5 µg/Kg D1,8,15; Level 2: 1.0 µg/Kg D1,8,15; Level 3:2.0 µg/Kg 1,15; Level 4: 2.0 µg/Kg D1,8,15; Level 5: 4.0 µg/Kg D1,15
1837645|NCT00860522|Drug|JVRS-100|Change to Stage 2 with starting dose of 4.0 µg/Kg D1,8,15 if no toxicity level by Level 5.
1837646|NCT00860535|Other|Comparator: Biomarker evaluation|"Patients on standard of care treatment will have blood drawn to evaluate biomarker changes in response to treatment with BCR-ABL inhibitors over a ~3.5 month period.
Part I will enroll patients who are beginning treatment with imatinib (recommended dose 400 mg every day [qd]), dasatinib (recommended dose 70 mg twice a day [bid]), or nilotinib (recommended dose 400 mg bid).
Part II will enroll patients who are changing from imatinib therapy to either dasatinib or nilotinib. A decision to initiate Part II will be made based on analysis of the results of Part I."
1837647|NCT00860548|Drug|currently available therapy in the community|Participants will receive telephone calls every 3 months for approximately 44 months for the purpose of outcome surveys
1837648|NCT00860574|Drug|treosulfan|Given IV
1837649|NCT00860574|Drug|fludarabine phosphate|Given IV
1837650|NCT00860574|Radiation|total-body irradiation|Low dose starting at 2Gy
1837651|NCT00860574|Procedure|peripheral blood stem cell transplantation|Given IV per institutional standard practice
1837652|NCT00860574|Drug|tacrolimus|Given IV or PO
1837653|NCT00860574|Procedure|allogeneic bone marrow transplantation|Given IV per institutional standard practice
1837654|NCT00860574|Procedure|allogeneic hematopoietic stem cell transplantation|Given IV per institutional standard practice
1837655|NCT00860574|Drug|methotrexate|Given IV
1837656|NCT00860600|Drug|PG2|500mg/vial, iv infusion, 3 ~ 5 times/week, 2.5 ~ 3.5 hr/time
1837657|NCT00860613|Other|medical nutrition therapy program|the dietary guidelines were based on the Nutrition Practice guidelines for gestational diabetes developed by the American Dietetic Association. Dietary strategies were based on carbohydrate counting and/or restriction of high glycemic index foods. Even carbohydrate distribution throughout the day was emphasized.
1837658|NCT00860626|Drug|interferon α plus nucleoside analogue|Standard dose of interferon is used for 12 weeks. On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. And lamivudine is added for 3 months. After nucleoside analogue is added for 3 months, HBV DNA is tested again. If negative, stop nucleoside analogue and use interferon alone for another 6 months or longer. If HBV DNA is still positive, change to another nucleoside analogue or add another nucleoside analogue.
1837659|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is still detectable (>1000 copies/ml), or HBeAg is still positive. But no nucleoside analogue is added.
1837660|NCT00860626|Drug|interferon α|Standard dose of interferon is used for 12 weeks.On 12th week of treatment, HBV DNA is undetectable, or HBeAg is negative. And interferon is continued alone for another 9 months.
1837661|NCT00860639|Drug|gemtuzumab ozogamycin|gemtuzumab ozogamycin = 6mg/m² during the induction course (Day 4) gemtuzumab ozogamycin = 6mg/m² during the first intensive consolidation course (Day 4)
1837662|NCT00860652|Radiation|Adjuvant Radiotherapy|Adjuvant RT (ART) commenced within 4 months of Radical Prostatectomy. 64Gy in 32 fractions to the prostate bed.
1837663|NCT00860652|Radiation|Early Salvage Radiotherapy|Active surveillance with early Salvage RT (SRT). SRT - 64Gy in 32 fractions to the prostate bed. RT should commence no later than 4 months following the first PSA measurement ≥ 0.2ng/mL.
1837664|NCT00860678|Other|Physical activity|
1837665|NCT00860678|Other|no Intervention|
1837666|NCT00860691|Procedure|Therapeutic conventional colorectal surgery|Patients with colorectal cancer undergo open laparotomy and colorectal resection
1837667|NCT00860691|Procedure|Therapeutic laparoscopic colorectal surgery|Patients with colorectal cancer undergo laparoscopic colorectal resection
1837698|NCT00860925|Drug|ASA Placebo|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA placebo tablets. After the first dose, patients will ingest 1 placebo tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take placebo orally will receive it rectally.
1994037|NCT03082742|Drug|Furosemide|
1837668|NCT00860691|Other|Peripheral blood sampling and performing: ELISA test of sFas, sFasL, IL - 17 and Bursttest|Informed consent will be obtained.Blood samples will be obtained at one time point. .Samples will be processed to serum, using a refrigerated centrifuge, then stored at -80C until analysis. Peripheral blood samples for measurement of oxidative burst in neutrophils will be collected into heparinised blood tube.Serum concentrations of sFas will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fas MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA). Serum concentrations of sFasL will be quantitative determinated by a sandwich enzyme immunoassay technique (ELISA) using specific anti-Fasl MoAbs, Human sFas Immunoassay (Code: DFS00; QUANTIKINE R&D Systems Inc, Minneapolis, USA).Respiratory burst neutrophil production will be determined quantitatively by flow cytometry using a commercial kit Bursttest Kit (Cat. No: 10-0200; ORPEGEN Pharma, Germany)
1837669|NCT00860704|Other|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
1837670|NCT00860704|Other|fluidotherapy with ringer-lactate|a bolus of 250ml ringer-lactate is administered, if there is fluid demand monitored by the Esophageal Doppler
1837671|NCT00860717|Procedure|Routine treatment|Subjects from the Control Group received routine treatment, including daily simple dressings with sterile gauze after wound cleaning with a 0.9% physiologic solution, use of 1% hydrophilic silver sulfadiazine cream (Prati Donaduzzi Laboratory, Toledo, Brazil) and orientation about the use of adapted footwear, self-care and the prevention of disabilities. Surgical debridement was done whenever indicated by nursing or orthopedic services from UREMC.
1837672|NCT00860717|Radiation|Low level laser therapy (LLLT)|"The LLLT equipment was an indium-gallium-aluminnium-phosphide (InGaAlP) semiconductor laser with a maximum output power of 40 mW, continuous radiation emission of visible red light with 660 nm wavelength (+/- 10 nm) and a spot area of 0.04 cm². The energy density used was 4 J per point in the wound edges and 2 J/cm² in the wound bed with a power density of 1 W/cm2.
Wound beds were irradiated using a scanning technique with no direct contact."
1837673|NCT00860730|Device|Aortic valve replacement with Perceval aortic heart valve|Replacement of diseased or malfunctioning native aortic valve via traditional surgery (open chest) with the Perceval S prosthesis
1837675|NCT00860756|Other|Relaxation CD|A music CD specifically created for this study to promote effective sleep while deployed. It includes sleep instructions tailored to the military deployment environment. The CD includes a voice directed meditation component that helps focus the listener on relaxation in preparation for sleep. The second track is specifically designed music to promote slow breathing and induce sleep.
1837676|NCT00860769|Behavioral|ASHA LIFE|6-session education groups discussing HIV prevention, anti-retroviral therapy (ART), coping enhancement, nutrition, parenting and life skills
1837677|NCT00860769|Behavioral|USUAL Care|3 session educational group focusing on HIV prevention, anti-retroviral therapy and parenting
1837678|NCT00860782|Behavioral|Parent Educational Support|Parents will attend 45-minute educational sessions that will focus on providing them with information regarding SCD and how they can best help their child perform better in school.
1837679|NCT00860795|Biological|Echinacea purpurea|Echinacea purpurea 100 mg/ml, 25 ml daily in 2 divided doses for 10 days
1837680|NCT00860795|Drug|placebo|placebo 25 ml daily in 2 divided doses for 10 days
1837681|NCT00860808|Drug|AM-101|Triple intratympanic injection (one on each day 1, 2, and 3)
1837682|NCT00860821|Drug|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
1837683|NCT00860821|Drug|AZD8309|oral solution 30 mg/g, dose: 300mg bid for 3 days
1837684|NCT00860834|Behavioral|Asthma Coaching Program|Parents will have access to an asthma coach for 12 months. Telephone calls between parents and coaches will occur anywhere from once a week to once a month.
1837685|NCT00860834|Behavioral|Usual Care|Children of parents enrolled in the study will receive the normal asthma care that their pediatricians usually provide.
1837686|NCT00860847|Dietary Supplement|Aged garlic extract and Coenzyme Q10|AGE (1200 mg) and CoQ10 (120 mg)
1837687|NCT00860860|Drug|TF2|TF2: 75-300 mg
1837688|NCT00860860|Drug|IMP-288 labeled with In111 and Lu177|IMP-288: 100 microgram
1837689|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate + Glucosamine Sulfate (Oral powder)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
1837690|NCT00860873|Dietary Supplement|EMS Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg Glucosamine Sulfate 1500mg
1837691|NCT00860873|Dietary Supplement|Zodiac: Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (Oral powder)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
1837692|NCT00860873|Dietary Supplement|Zodiac Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg (hard capsules)|Chondroitin Sulfate 1200mg + Glucosamine Sulfate 1500mg
1837693|NCT00860899|Drug|clonidine, levobupivacaine|One hour prior to skin incision, on epidural catheter, patients received 5 µg/kg of clonidine [Catapres®, Boehringer Ingelheim, Germany], 7 mL of 0.25% levobupivacaine [Chirocaine®, Abbott S.p.A., Italy] or 7 mL of saline.The study was designed to compare clonidine and levobupivacaine, and than both with the control group, in order to asses their analgesic and immunomodulation efficacy.
1837694|NCT00860912|Procedure|Collagen Matrix|surgical/reinforcing material
1837695|NCT00860925|Drug|active clonidine|Prior to surgery (goal 2-4 hours) patients will ingest 1 tablet of clonidine (0.2 mg) and will have a transdermal clonidine patch (0.2 mg/day) applied. The patch will be removed at 72 hours after surgery.
1837696|NCT00860925|Drug|active ASA|Prior to surgery (goal 2-4 hours) patients will ingest 2 ASA tablets (81 mg per tablet). After the first dose, patients will ingest 1 tablet daily for 7 or 30 days according to the stratum they are allocated to. Patients who are not able to take ASA orally will receive it rectally.
1837697|NCT00860925|Drug|Clonidine Placebo|Prior to surgery (goal 2-4 hours) patients will take oral clonidine placebo and will have a transdermal placebo patch applied. The patch will be removed at 72 hours after surgery.
1994038|NCT03082521|Behavioral|Improving the antibiotic prescribing quality|The goal is to improve the antibiotic prescribing quality of GPs in a GPC by setting up a participatory action research. The interventions will be co-designed with the GPs.
1837700|NCT00860951|Device|Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
1837701|NCT00860964|Drug|Placebo|Placebo, calcium 900mg/d, VitD200iu/d and exercise
1837702|NCT00860964|Drug|estradiol valerate|estradiol valerate 1mg/d,medroxyprogesterone 6mg/d for 10 days,calcium 900mg/d, VitD200iu/d and exercise
1837703|NCT00860977|Drug|valacyclovir|oral valacyclovir 500mg twice daily
1837704|NCT00860977|Drug|Placebo|Odourless placebo tablet identical to valacyclovir in appearance and taste, to be taken twice daily
1837705|NCT00860990|Other|Completion of GI quality of life survey|Subjects are asked to complete a survey related to bowel care and its effects on various variables related to quality of life.
1837706|NCT00861003|Device|Medication Event Monitoring System (MEMS)|MEMS is a medication vial cap that electronically records the date and time of bottle opening.
1837707|NCT00861016|Drug|metoprolol succinate prolonged-release tablet and felodipine|a regimen that starts with metoprolol succinate prolonged-release tablet 47.5mg once daily, orally and allows for dose escalation to 95mg once daily, orally at 4 weeks if not controlled; at week 8 allows for the addition of felodipine sustained release tablet 5mg once daily, orally
1837708|NCT00861029|Drug|Pazopanib|Subjects treated with pazopanib
1837709|NCT00861029|Other|Placebo for pazopanib|Control for comparison with pazopanib
1837710|NCT00861029|Drug|Moxifloxacin|Comparator for pazopanib
1837711|NCT00861029|Other|Placebo for moxifloxacin|Placebo for moxifloxacin
1837712|NCT00861042|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 400mg/day, intake in the morning and in the evening; duration of intake depending on individual trial participation
1837713|NCT00861068|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage up to 600mg/day, intake in the morning and in the evening, intake for 11 weeks
1837714|NCT00861068|Other|Placebo|Placebo tablets two times a day for 10 weeks
1837715|NCT00861081|Behavioral|Care Management|Over a period of one year, subjects will participate in two regular stroke clinics, three group clinics, obtain self-management tools, and will receive a series of four scheduled telephone calls by nurse practitioners to review information delivered during the group clinics and help with care coordination. Usual care will also be available.
1837716|NCT00861081|Behavioral|Written Materials|Educational materials about stroke that will be distributed during the group clinic session will be mailed to these subjects. These materials have been developed by the American Heart Association. Usual care will also be available.
1837717|NCT00861094|Drug|cisplatin|
1837718|NCT00861094|Drug|5-FU|
1837719|NCT00861094|Drug|oxaliplatin|
1837720|NCT00861094|Radiation|radiation therapy|
1837721|NCT00861094|Drug|Folinic Acid|
1994075|NCT03073070|Drug|biotin labeled RBCs|Autologous red blood cells are biotin labeled and transfused to the subjects. Survival of these red blood cells is tracked through examination of blood samples until no biotin-labeled red blood cells is detectable.
1837726|NCT00861120|Drug|Pegylated liposomal doxorubicin|40 mg/m2 on day 1 of a 28 days cycle
1837727|NCT00861120|Drug|Panitumumab|6 mg/kg on days 1 and 15 of a 28 days cycle
1837728|NCT00861133|Device|Sleuth AT Implantable ECG Monitoring System|The study device provides monitoring only. It cannot provide intervention or treatment.
1837729|NCT00861146|Behavioral|behavioral counseling plus contingency management|Individual counseling sessions with voucher rewards for smoking abstinence, transdermal nicotine patch and nicotine gum
1837730|NCT00861172|Procedure|3T MR scanner|"The follow-up will be scheduled for one year; it will consist in a weekly MR examination during the first two months, and subsequently on the 6th and the 12th months.
We will perform for each MRI exploration an intravenous injection of contrast agents: gadobutrol (gadovist 1,0 mmol/ml) which is a stable agent with a cyclic structure. This agent is few responsible for NFS, given their low capacity to liberate gadolinium GD3+ in tissues.
The same imaging protocol will be performed for each MR examination. Evaluation of creatinemia will be used before inclusion and during the 1st, 3rd, 5th, 7th, 9th, and the 10th MRI examination. Thus we will take advantage of catheter to perform the creatinemia blood test and to reduce the discomfort produced by the injection."
1837731|NCT00861185|Drug|senicapoc|Loading Dose: 80 mg twice daily x 3 days Maintenance Dose: 40 mg daily for remainder of the treatment period (total 4 weeks)
1837732|NCT00861185|Drug|Placebo|Placebo looks identical to active study medication and will be dosed according to the same dosing regimen
1837733|NCT00861198|Other|ERCP as per medical indication|ERCP as per medical indication
1837734|NCT00861211|Drug|senicapoc|Loading Dose: 80 mg twice daily x 3 days followed by Maintenance Dose: 40 mg daily x 11 days
1837735|NCT00861211|Drug|Placebo|Placebo comparator
1837736|NCT00861224|Other|No Intervention for Observational Study|No intervention was used on this protocol, as this was an observational study.
1837737|NCT00861237|Drug|Nux vomica (active comparator)|Patients receive Nux vomica in a homeopathic potentiation
1837738|NCT00861237|Drug|Placebo (placebo comparator)|Patients receive Placebo looking similar to active drug
1837739|NCT00861250|Drug|bortezomib + dexamethasone|Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
1837740|NCT00861263|Device|overtube use during enteroscopy|use of overtube for the regular scheduled enteroscopy
1837741|NCT00861276|Drug|Nasal Spray Nicotine Substitute (Experimental)|During the first month, subjects in the intervention group received instruction from the physician to use NNS regularly (at least 2 puffs/hour, for an average of 1 mg nicotine/hour when awake).
1837787|NCT00861601|Drug|eltrombopag 25 mg tablet|eltrombopag 25 mg tablet once a day
1837742|NCT00861276|Drug|Nasal Spray Nicotine Substitute (ad libitum)|In the control group, participants were instructed to use NNS as needed to suppress withdrawal symptoms when cravings appeared.
1837743|NCT00861302|Behavioral|Mind-body emotional awareness program|This intervention, developed and offered by Dr. Howard Schubiner of St. John Providence Health System, consists of a single individual session with him, followed by four, classroom group sessions. The intervention includes expressive writing, mindfulness, and other techniques designed to enhance awareness and acceptance of the emotional factors underlying the chronic pain problem.
1837744|NCT00861315|Drug|Nebulized amikacin|Amikacin is nebulized at a dose of 60 mg/Kg (6 first patients of the arm), 80 mg/Kg (6 subsequent patients) or 100 mg/Kg (last 6 patients of the arm)
1837745|NCT00861315|Drug|Intravenous amikacin|20 mg/Kg amikacin are administred intravenousely once a day during three days.
1837746|NCT00861315|Drug|Placebo nebulization|0.9% saline solution is nebulized once a day during three days
1837747|NCT00861315|Drug|Placebo infusion|0.9% saline is administered intravenousely once a day during three days
1837748|NCT00861328|Drug|ON 01910.Na and irinotecan|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety evaluation.
The suggested starting dose of Irinotecan is 180 mg/m2 administered by intravenous (IV) infusion over 90 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
1837749|NCT00861328|Drug|ON 01910.Na and oxaliplatin|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher dose levels after safety review of the combination regimen in the previous cohort.
The suggested starting dose of Oxaliplatin is 85 mg/m2 administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Reductions in the starting doses according to recommendations of current approved prescribing information may be considered after review of patients' medical histories and potential tolerances to treatment with the chemotherapy agent."
1837750|NCT00861341|Drug|Aspirin|81 mg
1837751|NCT00861341|Drug|Pioglitazone|30mg Pioglitazone x1
1837752|NCT00861354|Device|Microlife blood pressure monitor with AF detection (Microlife AFIB MLU3MQ1)|Monitoring heart rhythm daily for 30 days using the blood pressure monitor and the ECG recorder.
1837753|NCT00861367|Drug|transurethral surgery with or without aspirin|aspirin 100mg once a day, transurethral surgery with or without aspirin
1959125|NCT00781612|Drug|Docetaxel|Docetaxel will be administered as per local prescribing information.
1959126|NCT00781612|Drug|Paclitaxel|Paclitaxel will be administered as per local prescribing information.
1837757|NCT00861393|Behavioral|CBT|12 Session CBT group
1837758|NCT00861393|Behavioral|Waitlist CBT|Participants in the waitlist will receive CBT when first group has completed CBT and been tested.
1837759|NCT00861406|Drug|Pegylated Interferon-Alfa 2b (PEG Intron)|"Group 1:
6 mcg/kg by injection under skin once weekly for 4 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 20 weeks.
Group 2:
6 mcg/kg by injection under skin once weekly for 8 weeks, followed by Maintenance Phase of 3 mcg/kg weekly for 16 weeks.
Group 3:
6 mcg/kg by injection under skin once weekly for 12 weeks followed by Maintenance Phase of 3 mcg/kg weekly for 12 weeks."
1837760|NCT00861406|Drug|GP-100 Peptide Vaccine|Injection under skin once every 3 weeks (Weeks 1, 4, 7, 10, 13, 16, 19, and 22), for a total of 8 injections.
1837761|NCT00861419|Drug|Sorafenib|Sorafenib 400 mg PO (BID)
1837762|NCT00861419|Drug|AMG 706|AMG 706 125 mg PO (QD)
1837763|NCT00861419|Drug|AMG 706|AMG 706 75 mg PO (QD)
1837764|NCT00861419|Drug|AMG 386|AMG 386 10 mg/kg IV (QW)
1837765|NCT00861419|Drug|Sunitinib|Sunitinib 50 mg PO (QD)
1837766|NCT00861419|Drug|Bevacizumab|Bevacizumab 15mg/kg IV Q3W
1837767|NCT00861419|Drug|AMG 386|AMG 386 3 mg/kg IV (QW)
1837768|NCT00861432|Other|additive homeopathic treatment|These patients receive additive homeopathic treatment
1837769|NCT00861445|Drug|SPM927/Lacosamide|SPM927 (film-coated tablets, 25/50/100mg per tablet), dosage 400mg/day, intake in the morning and in the evening, intake for 10 weeks
1837770|NCT00861445|Other|Placebo|Placebo tablets two times a day for 10 weeks
1837771|NCT00861458|Drug|Pharmacokinetics|Single dose of 750 mg PF-00868554 as a solution and tablets.
1837772|NCT00861471|Drug|Docetaxel|"One treatment cycle is defined as 21 days.
Docetaxel: 70 mg/m^2 (60 mg/m^2 was tested in Phase I as well), Intravenous, every 21 days."
1837773|NCT00861471|Drug|Imatinib Mesylate|"One treatment cycle is defined as 21 days.
Imatinib Mesylate: 24-36 hours after Docetaxel, 600 mg (400 mg was tested in Phase I as well), orally, daily x 14 days."
1837774|NCT00861484|Drug|GSK958108|Coated Tablets 1 mg
1837775|NCT00861484|Drug|Placebo|Coated tablets
1837776|NCT00861497|Drug|Bifeprunox|Flexible dosage: 20, 30, or 40 mg/day
1837777|NCT00861510|Drug|ON01910 Na|
1837778|NCT00861523|Drug|thiamine & promethazine|thiamine 100 mg IV promethazine 25 mg IV
1837779|NCT00861536|Drug|ATG Fresenius|Day 0: 9 mg/kg bw bolus Days 1-4: 3 mg/kg bw/d
1837780|NCT00861536|Drug|Thymoglobuline Genzyme|Day 0-3: 1.5 mg/kg bw/d
1837781|NCT00861549|Drug|Phencynonate hydrochloride|2mg/tablet
1837782|NCT00861562|Drug|Imescard water smartweed composed pills|01 pill at every 8 hours for 5 days.
1837783|NCT00861562|Drug|Placebo|01 pill at every 8 hours for 5 days, with the exact same appearance as the other intervention.
1837784|NCT00861588|Drug|isoflavones (Soylife 25)|40mg of soy isoflavones capsule (once daily)
1837785|NCT00861588|Drug|placebo|starch placebo
1837786|NCT00861601|Drug|eltrombopag 12.5 milligrams (mg) tablet|eltrombopag 12.5 mg tablet once a day
1837788|NCT00861614|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, Up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
1837789|NCT00861614|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase, up to 24 weeks in Induction, 48+ weeks in the Maintenance Phase, or until Treatment Stopping Criteria are met, withdrawal of consent, lost to follow-up, death, study closure
1837790|NCT00861627|Biological|REOLYSIN®|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
1837791|NCT00861627|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
1837792|NCT00861627|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of 21 day cycle
1837793|NCT00861640|Drug|Intravenous Omeprazole|Intravenous Omeprazole 1amp qd (every day)
1837794|NCT00861640|Drug|Oral Rabeprazole|Oral Rabeprazole 1 bid
1837795|NCT00861666|Behavioral|Forgiveness-Based Writing|"Participants will be asked to complete self-report measures during the initial session, will be given writing instructions and will complete the first writing task on-site. The first writing task will focus on describing an offense in which someone hurt or angered the participant, and about which the participant is still hurt and angry.
Eleven additional writing tasks will be completed at home, three per week for a month. Writing assignments will include topics such as describing thoughts and feelings about the offense, identifying possible motives or mitigating circumstances, identifying benefits of the offense itself, identifying times when one has offended others and how one felt afterwards, identifying benefits of letting go of the offense, and writing a letter to the offender.
Participants will return each written assignment to the study staff. All participants will be tracked closely by the study coordinator and receive a reminder phone call on the day of each writing task."
1837796|NCT00861679|Procedure|Transplantation with Stem Cells from Umbilical Cord|"According to results from published experiences in children following suggestions are given:
Number of Cells:
Number of nucleated cells infused exceed 2,5x10*7/kg recipient BW or
Number of nucleated cells collected exceed 3x10*7/kg BW
Number of CD34+ cells infused exceed 2x10*5/kg Recipient BW
GVHD-prophylaxis:
• MSD: CSA 3 mg/kg as described in the protocol + Prednisolone 1 mg/kg (day O to day 15, then tapering until day 28)
• UD: as above + additional immunosuppression according to local protocols; ATG might increase risk of infectious complication and might be replaced by other drugs according to local protocols.
HLA-matching for unrelated CB: a matched UB is defined by 6/6 HLA matches (A, B antigenic medium resolution and DRB1 allelic) and allocate to the transplantation group MD. Less than 6/6 HLA matches allocate the patient to the MMD group.
If many choices available ABO- major incompatibility should be avoided."
1837797|NCT00861692|Drug|argatroban|
1837798|NCT00861705|Biological|Bevacizumab|Given IV
1837799|NCT00861705|Drug|Carboplatin|Given IV
1837800|NCT00861705|Drug|Cyclophosphamide|Given IV
1837801|NCT00861705|Drug|Doxorubicin Hydrochloride|Given IV
1837802|NCT00861705|Other|Laboratory Biomarker Analysis|Correlative studies
1837803|NCT00861705|Drug|Paclitaxel|Given IV
1837804|NCT00861718|Drug|AZD7268|Capsule, Oral, QD
1837805|NCT00861718|Drug|AZD7268|Capsule, Oral, BID
1837806|NCT00861718|Drug|Placebo|Capsule, Oral BID
1837807|NCT00861731|Drug|simvastatin|simvasatin therapy alone at the dose of 40 mg/day
1837808|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/20 mg/day
1837809|NCT00861731|Drug|EZE/simvastatin|EZE/simvastatin combined therapy at the dose of 10/40 mg/day
1837810|NCT00861744|Biological|GSK Biological's investigational vaccine 209762|Subcutaneous injection, one dose
1837811|NCT00861744|Biological|M-M-R® II (Merck and Co)|Subcutaneous injection, one dose
1837812|NCT00861744|Biological|Varivax®|Subcutaneous injection, one dose
1837813|NCT00861744|Biological|Havrix®|Intramuscular injection, one dose
1837814|NCT00861744|Biological|Prevnar®|Intramuscular injection, one dose
1837815|NCT00861757|Drug|Tadalafil|by mouth (PO), once daily (QD) (30 min after meal) for 12 weeks
1837816|NCT00861757|Drug|Placebo|PO, QD (30 min after meal) for 12 weeks
1837817|NCT00861757|Drug|Tamsulosin|PO, QD (30 min after meal) for 12 weeks
1837818|NCT00861770|Other|Ultrafiltration|Ultrafiltration based on standard of care.
1837819|NCT00861770|Other|Ultrafiltration using BVM|Ultrafiltration will be guided by blood volume measurement results.
1837820|NCT00861783|Drug|irinotecan and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.
Irinotecan 180 mg/m2 will initially be administered by IV infusion over 90 minutes q2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labelling."
1837821|NCT00861783|Drug|oxaliplatin and ON 01910.Na|"ON 01910.Na will be administered by IV infusion over 24 hours once per week in a 6-week cycle (6 doses per cycle). The dose of ON 01910.Na will start at 250 mg/m2 and will proceed to higher levels based on safety of the combination regimen in the previous cohort.
Oxaliplatin 85 mg/m2 will initially be administered by IV infusion over 120 minutes every 2 weeks of a 6-week cycle (3 doses per cycle). Dose modifications due to toxicity will be instituted according to approved labeling."
1837822|NCT00861796|Drug|CYR-101|Experimental arm
1837823|NCT00861796|Drug|Placebo|Placebo comparator
1959127|NCT00781612|Drug|Pertuzumab|Pertuzumab will be administered intravenously at a dose of 420 milligrams (mg) no more frequently than every 3 weeks (Q3W) (or as directed in the parent study protocol if less than Q3W).
1837828|NCT00861822|Other|Advanced red blood cell transfusion|"Sixty anemic (Hg 100-120 g/L) adult patients undergoing cardiac surgery with CPB will be randomized to the 'advance RBC transfusion' (ART) group or the standard-of-care RBC transfusion' (SRT) group (1:1 ratio).
In the ART group, subjects will receive 1-2 units of stored RBCs 1-2 days before surgery to reach a target Hb of 130-140 g/L. Each unit of blood will be transfused over 2 hours under medical supervision, with appropriate monitoring and management of fluid status to ensure patients are not over-hydrate"
1837829|NCT00861835|Other|ROSE|rapid on-site evaluation by cytopathology
1837830|NCT00861861|Drug|Pitavastatin|comparison of two drugs in increasing HDL-C and adiponectin
1837831|NCT00861861|Drug|Atorvastatin|comparison of two drugs in increasing HDL-C and adiponectin
1837832|NCT00861874|Drug|Decitabine|20 mg/m2 IV, Days 1-5
1837833|NCT00861874|Drug|Rapamycin|Dose level 1 = 2mg/daily, Dose level 2 = 4mg/daily, Dose level 3 = 6mg/daily. Oral, Days 6-26
1837834|NCT00861887|Drug|Standard Vancomycin|Vancomycin treatment 125 mg po every 6 hours x 2 weeks
1837835|NCT00861887|Drug|Extended Vancomycin|Vancomycin 125 mg every 6 hours x 2 weeks
1837836|NCT00861913|Other|Laboratory Biomarker Analysis|Correlative studies
1837837|NCT00861913|Drug|Pazopanib Hydrochloride|Given orally
1837838|NCT00861913|Other|Pharmacological Study|Correlative studies
1837839|NCT00861926|Drug|Ventolin|Ventolin : salbutamol sulfate 100µg
1837840|NCT00861926|Drug|beclometasone /formoterol|BDP 100µg/FF 6µg, 1 inhalation bid
1837841|NCT00861939|Drug|Bupropion HCI 300 mg Extended-Release Tablets EON|
1837842|NCT00861939|Drug|WELLBUTRIN XL 300 mg Extended-Release Tablets GlaxoSmithKline|
1837843|NCT00861952|Other|Neuragen|2-3 drops applied topically 2-3 times per day as needed over a 3 month period
1837844|NCT00861952|Other|Mineral oil|Ad lib use of mineral (scent and color matched to Neuragen) applied topically 2-3 times per day in 2-3 drops per application
1837845|NCT00861965|Biological|AlloStim-8|intravenous infusion of mis-matched AlloStim-8
1837846|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 7
1837847|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 14
1837848|NCT00861965|Biological|AlloStim-8|intravenous infusion of AlloStim-8 on day 21
1837849|NCT00861978|Drug|St. John's Wort extract|Coated tablets (batch no. 02080277) containing 300 mg of St. John's Wort extract LI 160 (drug-extract ratio 3-6:1; extraction solvent: 80% Methanol in water; batch no. 02019073) administered orally twice daily (morning and evening) with some liquid for 8 weeks
1837850|NCT00861978|Drug|Placebo|Coated placebo tablets (batch no. 01010177) that were identical in shape, size, taste and color were administered orally twice daily (morning and evening) with some liquid for 8 weeks.
1837851|NCT00861991|Behavioral|Perspective taking instruction|Students were asked to take the perspective of their standardized patients during clinical skills examinations
1837852|NCT00862004|Procedure|VATS|video-assisted thoracoscopic surgery (VATS) major pulmonary resection with systematic node dissection (SND) for clinical stage IIIA non-small cell lung cancer
1837853|NCT00862017|Dietary Supplement|MSg supplementation|
1837854|NCT00862017|Dietary Supplement|NaCl supplementation|
1837855|NCT00862030|Procedure|CT- simulation scan|Patients who are receiving standard palliative radiotherapy planned under x-rays will also undergo 1 CT-simulation scan which they would otherwise not require. The planning x-rays and CT scan will then be compared dosimetrically
1837856|NCT00862043|Drug|Sildenafil Citrate|40 mg t.i.d.
1837857|NCT00862043|Drug|Placebo|Placebo t.i.d.
1837858|NCT00862056|Procedure|Cardiac CT|All participants will undergo a coronary artery CT angiogram with contrast.
1837859|NCT00862082|Drug|PR104 550 mg/m^2 + sorafenib|550 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
1837860|NCT00862082|Drug|PR104 770 mg/m^2 + sorafenib|770 mg/m^2 PR104 IV on day 1 of each 28 day cycle + 400 mg sorafenib PO twice daily. Number of Cycles: until progression or unacceptable toxicity develops.
1837861|NCT00862095|Drug|Placebo|Every month for 3 months
1837862|NCT00862095|Drug|Propranolol|target does 80 mg per day for 3 months
1837863|NCT00862095|Drug|Amitriptyline|Target does of 50 mg per day for 3 months
1837864|NCT00862095|Drug|Topiramate|Target dose 100 mg a day for 3 months
1837865|NCT00862108|Drug|Methylphenidate|mg/kg dose: 0.7~1.2mg/kg PO daily morning intake 8 weeks
1837866|NCT00862121|Drug|Pentasa|6 g/day orally, 2 g in the morning and 4 g in the evening
1837867|NCT00862121|Drug|Placebo|6 g/day orally, 2 g in the morning and 4 g in the evening
1837868|NCT00862134|Drug|PR104|770 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
1837869|NCT00862134|Drug|docetaxel|75 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
1837870|NCT00862134|Drug|docetaxel|60 mg/m^2, IV, every 21 days. Number of Cycles: until progression or unacceptable toxicity develops.
1837871|NCT00862134|Drug|Granulocyte colony-stimulating factor|Subjects randomized to PR104/docetaxel will receive prophylactic G-CSF per package insert administration recommendations. Number of Cycles: until progression or unacceptable toxicity develops.
1837872|NCT00862147|Behavioral|ICDP|Parent training group
1837873|NCT00862147|Behavioral|Treatment as usual|Parent and/or child focused interventions
1837874|NCT00862160|Device|ROCsafeTM|using minimized perfusion circuit while CABG
1837875|NCT00862186|Behavioral|'Fatigue Facts & Fixes'|"'Fatigue Facts & Fixes' is an evidence based educational resource for adolescents with cancer. It is a bright colored laminated 8.5x11 double sided page. One side features information on cancer-related fatigue: Why am I so tired? (description of cancer-related fatigue); What causes fatigue? (contributing factors - environmental, personal/behavioral, cultural/family/other, and treatment-related); and What can help me to not be so tired? (alleviating factors - environmental, personal/behavioral, cultural/family/other, and treatment-related). The other side is a 'Do Not Disturb' sign with a pillow graphic which adolescents can use in the hospital or at home when they need some quiet time and which may also serve to attract their interest to the resource."
1837876|NCT00862212|Behavioral|Brief Alcohol Intervention|At the Week 6 visit, all subjects who are randomized to the Experimental Group will receive the experimental brief alcohol intervention. The intervention will be in addition to a standard 20-minute physician visit, for a maximum of 30 minutes. The physician will use the Updated NIAAA Clinician's Guide to ask about drinking and will draw the connection between social anxiety and drinking and how they relate to each other. Subjects will be asked to consider making changes in their drinking and if they agree, a goal will be set and progress toward that goal will be monitored at subsequent visits.
1837957|NCT00862797|Other|pressure measurement during swallowing|measurement of endotracheal tube cuff pressure during swallowing while recovering from anaesthesia
1837877|NCT00862225|Drug|Placebo|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
1837878|NCT00862225|Drug|Desloratadin|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
1837879|NCT00862225|Drug|IG-RD-001 / Ze 339|Following a 3-way crossover treatment design (IG-RD-001 (Ze 339), desloratadine, placebo), a controlled, unilateral, nasal allergen provocation (grasses) will be carried out on 18 study participants. The time-dependent development of the nasal obstruction, measured via rhinomanometry before and after the allergen provocation, will be the effect parameter.
1837880|NCT00862238|Behavioral|Art Messaging|4-session educational group which utilizes art, photography, film, painting to portray a message to reduce drug use, and prevent hepatitis A, B, & C
1837881|NCT00862238|Other|Health Promotion|4 session education which offers basic information about the prevention of hepatitis A, B, & C
1837882|NCT00862251|Drug|ezetimibe (+) simvastatin|ezetimibe/simvastatin 10/20 mg tablets, taken once daily for six weeks.
1837883|NCT00862251|Drug|simvastatin 40 mg or atorvastatin 20 mg|simvastatin 40 mg or atorvastatin 20 mg tablets, taken once daily for six weeks.
1837884|NCT00862251|Drug|Rosuvastatin|rosuvastatin 10 mg tablets, taken once daily for six weeks.
1837885|NCT00862251|Drug|atorvastatin 10 mg or simvastatin 20 mg|All patients will take atorvastatin 10 mg tablets OR simvastatin 20 mg tablets, taken once daily in a 6-week screening/stabilization period prior to randomization.
1837886|NCT00862264|Drug|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI|Fixed combination Beclomethasone Dipropionate/Formoterol HFA 134a-pMDI
1837887|NCT00862277|Biological|Menactra®|0.5 mL, Intramuscular (from a previous study)
1837888|NCT00862277|Biological|Menomune®|0.5 mL, Intramuscular (from a previous study)
1837889|NCT00862303|Biological|DC-CIK|Patients receive autologous dendritic cells (DC) loaded with autologous tumor lysate (DC vaccine) by endermic injection and infusion of CIK cells.
1837890|NCT00862303|Drug|IL-2/IFN-α|Patients receive treatment of IL-2 or IFN-α.
1837891|NCT00862316|Device|Oxford Unicompartmental Knee|Knee Arthroplasty
1837892|NCT00862329|Dietary Supplement|Casein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of casein
1837893|NCT00862329|Dietary Supplement|Milk soluble protein-enriched diet|Subjects consume for 9 days a supplement of 30g/d of milk soluble protein
1837894|NCT00862329|Dietary Supplement|Casein and milk soluble proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of a mix of casein and milk soluble protein
1837895|NCT00862329|Dietary Supplement|Soy proteins-enriched diet|Subjects consume for 9 days a supplement of 30g/d of soy protein
1837896|NCT00862342|Drug|Bevacizumab (Avastin)|Bevacizumab plus chemotherapy (chemotherapy will be chosen by physician's decision)
1837897|NCT00862355|Drug|SPARC147609|IV infusion
1837898|NCT00862355|Drug|Reference147609|IV infusion
1837899|NCT00862368|Behavioral|PAM|Visit 1 included asthma education (or child wellness for healthy children), expired air carbon monoxide feedback, Motivational Interviewing, and techniques to accelerate the participants readiness to quit. Visit 2 included a follow up on the child's asthma (PAM and PAM-Enhanced only), assessing the smoker's motivation to quit, feedback on CO readings and air sampler results (smoke exposure to the child), risks of smoking, and benefits of quitting. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
1837900|NCT00862368|Behavioral|PAM-Enhanced/Asthma Counseling Phone Calls|PAM-Enhanced/Asthma counseling calls were made over the 4 months following in-home counseling and focused on: 1) checking in on the child's asthma, 2) motivating quit attempts, and 3) preventing relapse among quitters. The final phone call (#6) included feedback on the 2nd set of air samplers placed in the home and with the child after phone call 5. Only the PAM-Enhanced/Asthma condition received this 2nd round of ETS feedback. A printed feedback report was provided to participants. If still smoking, counseling focused on ETS reduction and motivation to change. If quit, counseling focused on reinforcement of successful behavior change and motivation to stay quit. Motivational Interviewing techniques were used. Free nicotine patch tx was given if they were ready to quit within 30 days.
1837901|NCT00862368|Behavioral|Follow-Up Phone Calls - Child Wellness Topic|Over the 4 months following in-home counseling visits, subjects in the PAM-Asthma and PAM-Healthy conditions received 6 phone calls that included an asthma check-in (PAM-Asthma only) and discussion of a child wellness topic. Counselors employed Motivational Interviewing techniques. Free nicotine patch tx was given if they were ready to quit within 30 days.
1837902|NCT00862381|Drug|Hydrocortisone|hemisuccinate d'hydrocortisone, 200mg per 24 hours, 48 hours of treatment
1837903|NCT00862381|Drug|Placebo|NaCl 0.9%
1837904|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol Next DPI 100/6 µg (daily dose : 200/12 µg)
1837905|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 200/12 µg)
1837906|NCT00862394|Drug|BDP/Formoterol Next DPI|BDP/Formoterol 100/6 µg (daily dose : 400/24 µg)
1837907|NCT00862394|Drug|Foster|BDP/Formoterol HFA pMDI 100/6 µg (daily dose : 400/24 µg)
1837908|NCT00862420|Drug|clopidogrel (SR25990)|oral administration (tablets)
1837909|NCT00862420|Drug|ticlopidine|oral administration (tablets)
1837910|NCT00862433|Dietary Supplement|Vitamin E|
1837911|NCT00862433|Dietary Supplement|Vitamin C|
1837912|NCT00862446|Drug|Omegaven|1 gram/kg/day daily until on feeds
1837913|NCT00862459|Drug|Gadobutrol~0.03 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.03 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
1837914|NCT00862459|Drug|Gadobutrol~0.1 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.1 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
1837958|NCT00862810|Biological|Received HPV vaccine first|
1837915|NCT00862459|Drug|Gadobutrol~0.3 mmol/kg BW (Gadavist, Gadovist, BAY86-4875)|Participant received one dose of 0.3 mmol/kg BW of Gadobutrol. Gadobutrol was administered via a power injector at a rate of 5 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
1837916|NCT00862459|Drug|OptiMARK~0.1 mmol/kg BW|Participant received one dose of 0.1 mmol/kg BW of OptiMARK. OptiMARK was administered via a power injector at a rate of 2 mL/s followed by a 20 mL 0.9% saline flush at the same rate.
1837917|NCT00862472|Drug|DuoTrav APS|DuoTrav APS QD AM
1837918|NCT00862472|Drug|DuoTrav|DuoTrav QD AM
1837919|NCT00862498|Other|Written Disclosure|Five sessions, each spaced 1 week apart, during which participants are asked to write about their motor vehicle accident for 30 minutes. The first session of the intervention also involves a description of common reactions to a motor vehicle accident and the rationale for this treatment.
1837920|NCT00862511|Device|Coated Total Knee Arthroplasty|Implantation of a coated Total Knee Arthroplasty
1837921|NCT00862511|Device|Standard Total Knee Arthroplasty|Implantation of a Standard Total Knee Arthroplasty
1837922|NCT00862524|Drug|ARRY-334543, EGFR/ErbB2 inhibitor; oral|multiple dose, escalating
1837923|NCT00862524|Drug|Gemcitabine, nucleoside analogue; intravenous|multiple dose, single schedule
1837924|NCT00862537|Device|Resonator Device|active pico-tesla magnetic fields treatment for Parkinson's disease individuals
1837925|NCT00862550|Other|Acupuncture|20 Minute Acupuncture Sessions Before Radiation Therapy Treatment, 3 Days Per Week for 7 Weeks.
1837926|NCT00862563|Drug|Topiramate|Topiramate will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses 300 mg topiramate.
1837927|NCT00862563|Drug|Zonisamide|Zonisamide will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 400 mg of zonisamide.
1837928|NCT00862563|Drug|Levetiracetam|Levetiracetam will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14. Subjects will be dose titrated as tolerated to a target doses of 2000 mg levetiracetam capsules.
1837929|NCT00862563|Drug|Sugar Pill|Matched placebo will be administered orally twice daily beginning on Day 1, Week 1 and continue through Day 7, Week 14.
1837930|NCT00862589|Other|GLP-1 infusion|physiological effect of GLP-1
1837931|NCT00862602|Behavioral|Stepping Up to Health|Internet-mediated pedometer-based intervention with gradually increasing goals and feedback on step counts. Also includes educational content targeted at women who have had gestational diabetes about exercise, diet & nutrition and prevention.
1837932|NCT00862615|Other|Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.|"Measurement of muscle protein synthesis using stable isotopes and muscle biopsies.
Isotopes are :
(13C)bicarbonate (0.09 mg/kg fat-free mass) and L(1-13C)leucine (1.3 mg/kg fat-free mass) (intravenous way) L-(5,5,5 2H3) leucine(0.09 µmoles/(kg de fat-free mass.min) (oral way)"
1837933|NCT00862628|Drug|Rebamipide|100mg tid, 4 or 8 weeks
1837934|NCT00862641|Drug|Regadenoson|IV
1837935|NCT00862641|Drug|Placebo|IV
1837936|NCT00862654|Drug|clobetasol propionate shampoo (4/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo & ketoconazole shampoo
1837937|NCT00862654|Drug|clobetasol propionate shampoo (2/week) - ketoconazole shampoo (2/week)|Association: clobetasol propionate shampoo & ketoconazole shampoo
1837938|NCT00862654|Drug|clobetasol propionate shampoo (2/week)|Monotherapy with clobetasol propionate shampoo
1837939|NCT00862654|Drug|ketoconazole shampoo (2/week)|Monotherpay ketoconazole shampoo (2/week)
1837940|NCT00862667|Drug|Treatment A|PF-00241939 300ug using Inhaler A
1837941|NCT00862667|Drug|Treatment B|PF-00241939 300ug using Inhaler B
1837942|NCT00862667|Drug|Treatment C|PF-00241939 300ug using Inhaler C
1837943|NCT00862680|Procedure|PET/CT Scan|Routine PET/CT scan with small plastic box (weighing less than 1 oz) placed on abdominal area to track breathing motion.
1837944|NCT00862693|Drug|Calcitriol|0.5ug/Biw
1837945|NCT00862706|Drug|Telbivudine/LDT600A|Oral once daily
1837946|NCT00862719|Drug|Sitagliptin|600 mg sitagliptin taken orally per the schedule listed in each of the three separate arms.
1837947|NCT00862732|Behavioral|Cognitive behavioural therapy|Will receive a series of sessions of cognitive behaviour therapy. Delivery of CBT will be by three therapists; PI and two other Medical Officers. Each session will last for 30- 45 minutes and they will be delivered at the participant's residence (or at an alternative place of participant's choice) at two weeks intervals. They will be followed-up for three months from the cessation of CBT sessions.
1837948|NCT00862732|Other|Treatment as usual|Will be referred to the MO(MH). They also will be followed-up for an equal length of time period as of the participants in the intervention group.
1837949|NCT00862745|Drug|Fesoterodine|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
1837950|NCT00862745|Drug|Matching Placebo|Participants will be instructed to take one tablet of blinded study medication once a day, orally, for 12 weeks. They will start with a 4 mg dose of study medication and will have the option of doubling that dose after 2 or 4 weeks if they wish. At the end of the 12 week blinded trial, participants will be offered open-label fesoterodine (Toviaz™), for 9 months beginning at 4 mg with participant directed dose adjustment.
1837951|NCT00862758|Drug|Tocilizumab|8 mg/kg would be administered IV every 2 weeks for six weeks.
1837952|NCT00862784|Biological|IMC-1121B (ramucirumab)|8 milligrams/kilogram (mg/kg) IMC-1121B (ramucirumab) infusions every 2 weeks
1837953|NCT00862784|Drug|Oxaliplatin|85 milligrams/square meter (mg/m²) intravenous infusion over 2 hours on Day 1
1837954|NCT00862784|Drug|Folinic acid|400 mg/m² intravenous infusion over 2 hours on Day 1
1837955|NCT00862784|Drug|5-FU|400 mg/m² intravenous bolus injection over 2-4 minutes, immediately following folinic acid infusion
1837956|NCT00862784|Drug|5-FU|2400 mg/m² intravenous continuous infusion over 46 hours immediately following bolus 5-FU on Days 1 and 2
1837959|NCT00862810|Biological|Received concomitant vaccines first|
1837960|NCT00862823|Drug|tenofovir, emtricitabine and efavirenz fixed dose tablet|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
1837961|NCT00862823|Drug|tenofovir, emtricitabine and efavirenz tablet added to solution|Atripla contains 300mg of tenofovir, 200mg of emtricitabine and 600mg of efavirenz
1837962|NCT00862836|Drug|Vandetanib|100mg doses orally, once daily
1837963|NCT00862849|Drug|Insulin Lispro|
1837964|NCT00862849|Drug|Regular Human Insulin|
1837965|NCT00862849|Drug|rHuPH20|
1837966|NCT00862875|Drug|Detemir or Glargine|Initial dose of 10 units of insulin at bedtime. The insulin dose will be increase by 1 unit per day until fasting plasma glucose (FPG) levels are 5.0 mmol/L.
1837967|NCT00862888|Drug|PF-00446687|Single 200mg dose as an oral solution
1837968|NCT00862888|Drug|Placebo|Placebo for oral solution
1837969|NCT00862888|Drug|Placebo|Placebo for tablet
1837970|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
1837971|NCT00862888|Drug|PF-00446687|Single 125 mg dose as an oral solution
1837972|NCT00862888|Drug|PF-00446687|Single 175 mg dose as an oral solution
1837973|NCT00862888|Drug|PF-00446687|Single 20 mg dose as an oral solution
1837974|NCT00862888|Drug|Placebo|Placebo for oral solution
1837975|NCT00862888|Drug|Placebo|Placebo for tablet
1837976|NCT00862888|Drug|Sildenafil|Single oral dose 100 mg tablet
1837977|NCT00862901|Device|CLIPT patch|A Diomed laser will deliver 630nm (red spectrum) light through a Fiber optic Patch. The Fiber Optic Patch will be compatible with the laser, delivering light to a designated region on the patient's skin. Patients will receive a single intravenous injection of Photofrin (0.8mg/kg body weight) 36 - 48 hours prior to the CLIPT procedure. PDT will be delivered over 24 hours for the dose of each arm. Patients will be enrolled in sequential cohorts of six, at increasing laser intensity until the maximum tolerated dose is reached.
1837978|NCT00862927|Other|Breath Sample|Breathe into machine measuring carbon monoxide.
1837979|NCT00862927|Other|Saliva Sample|Chew cotton ball for 30 seconds for cotinine measurement.
1837980|NCT00862927|Behavioral|Questionnaire|6 surveys, taking approximately 30 minutes total.
1837981|NCT00862927|Behavioral|View Virtual Reality Scenes|Use virtual reality helmet and hand-held controller to answer questions about 4 viewing scenes while wearing physiological measurement skin sensors, approximately 6 minutes.
1837982|NCT00862940|Drug|Memantine|10 mg tablets twice daily
1837983|NCT00862940|Drug|Placebo|Tablets twice daily
1837984|NCT00862953|Dietary Supplement|Normal protein energy-restricted|Normal protein diet energy restricted
1837985|NCT00862953|Dietary Supplement|High protein energy-restricted|High protein diet, with either low or normal carbohydrate content
1837986|NCT00862966|Other|citrate|comparison of different catheter lock solutions
1837987|NCT00862966|Other|heparin|comparison of different lock solutions
1837988|NCT00857103|Behavioral|CHOICE|Use of Choice support system as preparation for patient consultations
1837989|NCT00857116|Drug|Albendazole|Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
1837990|NCT00857116|Drug|Placebo|Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
1837991|NCT00857129|Procedure|Normal Unit|low-risk patients randomised to Normal Unit
1837992|NCT00857129|Procedure|Special birth unit|Low-risk women are randomised to the Special birth unit. Organised to take care of women with extended need for surveillance before, under and after birth.
1837993|NCT00857142|Drug|oxymorphone hydrochloride|
1837994|NCT00857142|Drug|Opana|
1837995|NCT00857155|Other|Clopidogrel withdraw prior to CABG|Patients on clopidogrel are stratified into time-based platelet function recovery groups as determined by point of care methods and based on these groups clopidogrel is withdrawn at a pre-specified timepoint before surgery.
1837996|NCT00857168|Drug|Testosterone MD-Lotion|
1837997|NCT00862979|Drug|Sandimmun Optoral / Tac + RAD001|RAD001 / CNI group
1837998|NCT00862979|Drug|MPA + RAD001|RAD001 / MPA group
1837999|NCT00862992|Drug|Cariprazine low dose|
1838000|NCT00862992|Drug|Cariprazine medium dose|
1838001|NCT00862992|Drug|Cariprazine high dose|
1838002|NCT00863005|Drug|K201|Cream
1838003|NCT00863005|Drug|K201|
1838004|NCT00863031|Behavioral|problem-solving therapy|Three sessions of problem-solving therapy at week 1, 3 and 5.
1838005|NCT00863031|Behavioral|Video-viewing|Three sessions of viewing health educational videos.
1838006|NCT00863044|Procedure|Apnea|Ventilation will be stopped for the duration of the anastomosis as it's done currently. At all other times during the surgery, the ventilatory parameters will be adjusted to maintain a PaCO2 between 40 and 45 mmHg.
1838007|NCT00863044|Procedure|High frequency ventilation|The patients will be ventilated using a tidal volume of 1.5 ml per Kg and a respiratory rate of 100 per minute for as long as the surgeon needs to perform the distal anastomosis of the coronaries.
1838008|NCT00863057|Drug|Duloxetine|During each treatment period, participants will take duloxetine in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
1838009|NCT00863057|Drug|Duloxetine placebo|During each treatment period, participants will take duloxetine placebo in the following doses. On Days 1 to 5, participants will take one 30-mg capsule orally, once daily. On Days 6 to 28, participants will take two 30-mg capsules orally, once daily. During days 29 to 31 dosage will be reduced to one capsule daily and then discontinued on Day 32.
1838010|NCT00863057|Drug|Methadone|During each treatment period, participants will take methadone in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
1838085|NCT00864916|Drug|Pentoxifylline|Participants will receive 400 mg of pentoxifylline three times per day for 48 weeks.
1838011|NCT00863057|Drug|Methadone placebo|During each treatment period, participants will take methadone placebo in the following doses. On Days 1 to 5, participants will take one 5-mg capsule orally, twice daily. On Days 6 to 10, participants will take one 5-mg capsule orally, three times daily. On Days 11 to 28, participants will take two 5-mg capsules orally, three times daily. On Days 29 to 31, dosage will be one 5-mg capsule orally, three times daily. On Days 32 to 34, dosage will be decreased to one 5-mg capsule, twice daily and ultimately discontinued on Day 35.
1838012|NCT00863083|Behavioral|Multifamily weight management intervention|8 week multifamily group weight management intervention incorporating behavioral health, nutrition, and activity disciplines.
1838013|NCT00863096|Biological|Gardasil|HPV vaccine
1838014|NCT00863109|Biological|Peginterferon alfa-2b (PEG)|Pegylated interferon alfa-2b was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
1838015|NCT00863109|Drug|Ribavirin (RBV)|Ribavirin was administered in accordance with the dosage and pattern prescribed by each participant's physician (standard clinical practice).
1838017|NCT00863135|Device|CPAP|continuous positive airways pressure
1838018|NCT00863135|Device|Control|Patients are 3 months without any change in their treatment, and are in the waiting list to come into the CPAP procedure after that time
1838019|NCT00863148|Drug|Clofarabine in combination with IV busulfan and ATG|A conservative approach has been used for the determination of the dose due to the high risk studied population, e.g., decrease to 30 mg m²/day for a 4-day course of clofarabine. Clofarabine will be started at Day -8 to allow improvement of liver function tests, if any, by time of allo-HSCT. Clofarabine (C) 30 mg/m²/day for 4 days (day -8 to day-5). Busilvex (B): 3.2 mg/kg/day for 2 days (day -4 and day-3)Thymoglobuline (T): 2.5 mg/Kg/day for 2 days (day -2 and day-1). Graft (G) at day 0 GVHD prophylaxis: Cyclosporine 3 mg/kg/day starting day-1. Genzyme provided supplies of clofarabine for all patients included in the study.
1838020|NCT00863161|Drug|AZD3355|capsule, oral, single dose
1838021|NCT00863174|Drug|SPARC147709|SPARC147709 injection
1838022|NCT00863174|Drug|Reference147709|Reference147709 injection
1838023|NCT00863187|Biological|rituximab|b cell depletion
1838024|NCT00863200|Behavioral|Telephone Intervention|Symptom information will be collected using an automated telephone system, approximately 5 minutes per week.
1838025|NCT00863200|Behavioral|Questionnaires & Interviews|3 questionnaires and one-on-one interviews during 3 regularly scheduled clinic visits.
1838026|NCT00863213|Procedure|Atrial fibrillation ablation|"Atrial fibrillation ablation with radiofrequency, guided by 3D navigation map. Either 4mm or cooled tip-catheters will be used.
It will include, at least, pulmonary veins isolation; all other radiofrequency lines, including roof and mitral isthmus line, and complex fractioned electrograms ablation will be performed according to each Hospital protocol. Radiofrequency lines block will be tested."
1838027|NCT00863213|Drug|Antiarrhythmic drug|Usual drug therapy for atrial fibrillation. In patients with structural heart disease, amiodarone is recommended, while flecainide plus diltiazem or beta-blockers are encouraged in patients without structural heart diseases.
1838028|NCT00863226|Device|Resonator Device|Application of Magnetic Fields Using the Resonator Device
1838029|NCT00863239|Drug|ribavirin|Co-administered in all arms: oral ribavirin, 200 mg capsules. Subjects with body weight < 65 kg: 800 mg/day; Subjects with body weight 65-85 kg: 1000 mg/day; Subjects with body weight > 85 kg: 1200 mg/day.
1838030|NCT00863239|Drug|Locteron™ (controlled-release interferon alpha 2b)|investigational controlled-release recombinant interferon alpha 2b formulated in 1500/77/23 PolyActive microspheres as a lyophilized powder, reconstituted with carboxymethyl cellulose immediately before subcutaneous injection every other week as part of the treatment of chronic hepatitis C
1838031|NCT00863239|Drug|PEG-Intron™|commercially available pegylated interferon alpha 2b injected subcutaneously weekly in a dose of 1.5 ug/kg as part of the treatment of chronic hepatitis C
1838032|NCT00863252|Drug|mycophenolate mofetil|Orally at 0.75 g bd to 1 g bd for 6 months
1838033|NCT00863252|Drug|angiotensin blockade|Continuation of angiotensin blockade
1838034|NCT00863265|Drug|Phytosterol-Deficient Diet, Ezetimibe 10 mg, Phytosterol Esters Containing 2000 mg Phytosterols|Subjects will undergo three diet periods of 21 days each. Food will be supplied by a metabolic kitchen and will consist of a phytosterol-deficient baseline diet. Subjects will also receive either no active treatment, ezetimibe, or ezetimibe plus phytosterols.
1838035|NCT00863278|Procedure|pulsed dye laser treatment|On one side of the face according to Arm placement.
1838036|NCT00863278|Drug|Kligman's Trio|The combination of hydroquinone, retinoic acid and steroids combined in topical daily application.
1838037|NCT00863291|Drug|buprenorphine|buprenorphine (range = 0.2-1.6 mg/day, starting dose = 0.2 mg/day, N = 20)
1838038|NCT00863291|Drug|placebo|Placebo in a manner similar to the active comparator
1838039|NCT00863304|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
1838040|NCT00863304|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
1838041|NCT00863304|Drug|naproxen|naproxen 1000 mg daily for 16 weeks
1838042|NCT00863304|Other|placebo|placebo to match tanezumab and naproxen dosing
1838043|NCT00864591|Procedure|SPECT Imaging|Myocardial SPECT imaging will be performed 10-12 minutes after the stress injection of Tl-201, at 4 hours, and at 18-24 hours in patients with non-reversible or partially reversible defect on 4-hour imaging. Images will be obtained with a rotating single- or dual-head gamma camera equipped with low-energy high resolution collimators. Energy windows of 20% and 10% will be centered on the 70 KeV and 167 KeV peaks of Tl-201, respectively. Thirty images will be obtained (40 seconds each for the stress and 4-hour redistribution imaging, and 60 seconds each for the 18-24-hour imaging) over 180° extending from the 45° right anterior oblique to the 45° left posterior oblique projections.Localization of the disease in the left anterior descending artery (LAD), left circumflex (Cx) and right coronary artery (RCA) will be performed using a quantitative analysis software.
1838086|NCT00864916|Drug|Placebo|Participants will receive placebo three times per day for 48 weeks.
1838125|NCT00865189|Radiation|Preoperative Radiotherapy|Radiotherapy will be delivered in fraction of 1.8 gray per day (Gy/day), 5 days a week for 5 weeks, i.e., a total dose of 45 Gy will be administered in 25 fractions over a period of 33 days.
1838371|NCT00866866|Drug|N-Acetyl Cysteine|600 mg PO BID
1838044|NCT00864591|Procedure|Stress Adenosine CMR|"CMR will be performed using a 3-T scanner and a dedicated eight-element cardiac phased-array coil Cine CMR will be performed using steady state free precession in the short-axis, two chamber, three chamber and four-chamber, 8 mm thick, separated by 0-mm gaps.
Adenosine perfusion CMR: Adenosine will be administered intravenously at 140 µg/kg/min over 6 min. Four minutes into the infusion (or earlier if angina is provoked), a bolus (0.1 mmol/kg at 5 ml/s) of Gadolinium DTPA will be administered. Patients will be instructed to hold their breath. Stress perfusion images will be acquired in the short axis plane (parameters and planning will be similar for stress and rest perfusion evaluation). The patients will be monitored by vector ECG, noninvasive sphygmomanometry, pulse oximetry and capnography."
1838045|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fed conditions
1838046|NCT00864604|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fed conditions
1838047|NCT00864617|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under non-fasting conditions
1838048|NCT00864617|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under non-fasting conditions
1838049|NCT00864630|Behavioral|Computer-based problem solving therapy|Computer program developed by Dr. James Cartriene at Beth Israel Deaconess Hospital, Boston, MA.
1838050|NCT00864643|Drug|Lapaquistat acetate and atorvastatin|Lapaquistat acetate 100 mg, tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
1838051|NCT00864643|Drug|Atorvastatin|Lapaquistat acetate placebo-matching tablets, orally, once daily and atorvastatin 10 mg or 20 mg, tablets, orally, once daily for up to 6 weeks.
1838052|NCT00864669|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
1838053|NCT00864669|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
1838054|NCT00864682|Drug|Saline|3.3 mL normal saline
1838055|NCT00864682|Drug|Lidocaine / propofol admixture|lidocaine 50 mg plus propofol 50 mg intravenous (iv)
1838056|NCT00864682|Drug|lidocaine pretreatment|lidocaine 50 mg iv under tourniquet-control
1838057|NCT00864695|Other|Supportive care|protocol designed to evaluate one or more interventions where the primary intent is to maximize comfort, minimize side effects or mitigate against a decline in the subject's health or function. In general, supportive care interventions are not intended to cure a disease.
1838058|NCT00864708|Device|radio frequency-controlled (RF) Microstimulator (RFM) Gait System|Fully Implanted FES system to assist patient with gait component practice
1959128|NCT00781612|Drug|Trastuzumab|Trastuzumab will be administered as per local prescribing information.
1838060|NCT00864734|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
1838061|NCT00864734|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
1838062|NCT00864747|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under non-fasting conditions
1838063|NCT00864747|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products non-under fasting conditions
1838064|NCT00864760|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
1838065|NCT00864760|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
1995585|NCT02715856|Behavioral|Electronic Questionnaires|At the end of each follow-up visit, participant completes an electronic questionnaire about their quality of life. At the end of the study, participant completes a survey regarding the study and use of the mobile device.
1838067|NCT00864786|Drug|PF03635659|Inhaled doses of 200 mcgQD
1838068|NCT00864786|Drug|PF03635659|Inhaled doses of 600 mcg QD
1838069|NCT00864786|Drug|PF03635659|Inhaled doses of 1000 mcg QD
1838070|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
1838071|NCT00864786|Drug|PF03635659|Inhaled dose to be decided based on all available data from previous cohorts. It will run if maximum tolerated dose is not identified from previous cohorts or if a lower dose is required to be investigated.
1838072|NCT00864799|Drug|Misoprostol|Comparison of 3 routes of administration of misoprostol for termination of pregnancy 14-24 weeks
1838073|NCT00864812|Drug|tiotropium with fluticasone propionate/salmeterol (FSC)|COPD patients treated with tiotropium with fluticasone propionate/salmeterol (FSC)
1838074|NCT00864812|Drug|tiotropium|COPD patients treated with tiotropium
1838075|NCT00864825|Drug|Allopurinol|Allopurinol 1 capsule 300 mg, or placebo, bid (twice a day) for 42 days.
1838076|NCT00864838|Drug|Acetazolamide|250 mg 1 hour before intravitreal injection
1838077|NCT00864838|Drug|Brimonidine tartarate|1 drop 1 hour before intravitreal injection
1838078|NCT00864838|Procedure|Anterior chamber paracentesis|Immediately after bevacizumab injection
1838079|NCT00864851|Biological|Replagal|Intravenous (IV) infusion for 12 months
1838080|NCT00864864|Drug|Sunitinib|Taken orally on days 1-7 prior to surgery and then starting again on Day 22 for 4 weeks followed by a 2 week rest period
1838081|NCT00864877|Device|biodegradable fixation system (Inion OTPS FreedomPlateTM)|
1838082|NCT00864890|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
1838083|NCT00864890|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fed conditions
1838084|NCT00864916|Drug|Combination antiretroviral therapy (cART)|Participants will receive the appropriate cART medications, as prescribed by their primary HIV doctor for 48 weeks. (cART medications may be prescribed beyond the length of this study.)
1838087|NCT00864942|Drug|bendamustine and lenalidomide|Lenalidomide is given daily orally for one week followed by bendamustine HCL 90 mg/m2 IV over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
1838088|NCT00864942|Drug|BL-NHL|Bendamustine HCL 90 mg/m2 given intravenously over 30 to 60 minutes on days 1 and 2 in combination with lenalidomide, given orally, in dose-escalating cohorts. After a maximum of 6 cycles of combination therapy with bendamustine and lenalidomide, lenalidomide monotherapy is continued for an additional 6 cycles as tolerated or until disease progression.
1838089|NCT00864942|Drug|BLR-CLL|Lenalidomide is given orally for 7 days followed by rituximab 375 mg/m2 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
1838090|NCT00864942|Drug|BLR-NHL|Rituximab 375 mg/m2 is given on day 1 on day 1 in addition to bendamustine 90 mg/m2 intravenously over 30-60 minutes on days 1 and 2 and lenalidomide orally daily every 28 days for a total of 6 cycles. After 6 cycles of bendamustine, lenalidomide and rituximab, lenalidomide monotherapy is administered as continued therapy for an additional 6 cycles as tolerated or until disease progression.
1838091|NCT00864955|Radiation|UVA and UVB irradiation|"4 cutaneous biopsies for Ex-vivo irradiation
Determination of the minimal erythemic dose of UVA and UVB for each volunteer"
1838092|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|A: Experimental Subjects received Actavis Elizabeth LLC formulated products under fasting conditions
1838093|NCT00864968|Drug|Nabumetone 750 mg tablets, single dose|B: Active comparator Subjects received Teva formulated products under fasting conditions
1838094|NCT00864981|Drug|Bupropion HCI ER Tablets, 150 mg; EON Labs Inc.|
1838095|NCT00864981|Drug|WELLBUTRIN SR (Bupropion HCI) Sustained-Release Tablets, 150 mg; GlaxoSmithKline|
1838096|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir)|NRTI sparing
1838097|NCT00865007|Drug|Monotherapy (Lopinavir/ritonavir) + ABC/3TC|NRTI sparing regimen
1838098|NCT00865020|Drug|Aliskiren|Aliskiren 150 mg tablets taken orally daily. 1 tablet for the first two weeks followed by 2 tablets for 10 weeks.
1838099|NCT00865020|Drug|Telmisartan|Telmisartan 40 mg capsules taken orally daily. 1 capsule the first 2 weeks followed by 2 capsules for 10 weeks.
1838100|NCT00865020|Drug|Placebo to Aliskiren|Placebo to Aliskiren tablets taken orally daily. 1 Tablet for the first 2 weeks and 2 tablets during the no treatment (withdrawal) week.
1838101|NCT00865020|Drug|Placebo to Telmisartan|Placebo to Telmisartan capsule taken orally daily. 1 capsule for the first 2 weeks and 2 capsules during the no treatment (withdrawal) week.
1838102|NCT00865033|Drug|Metformin HCL Tablets, 1000 mg Sandoz|
1838103|NCT00865033|Drug|Glucophage 1000 mg|
1838104|NCT00865046|Other|Periosteal stimulation|Four acupuncture needles are placed around the knee to the level of the periosteum and two needles are placed pretibially in the soft tissue. All needles are stimulated with 100 Hz current. The stimulation of the needles in the soft tissue is discontinued after one minute.
1838105|NCT00865046|Other|Control-Periosteal Stimulation|Acupuncture needles are placed as per the PST intervention, but only the soft tissue needles receive electrical stimulation for one minute.
1838106|NCT00865059|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
1838107|NCT00865059|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
1838108|NCT00865072|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
1838109|NCT00865072|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
1838110|NCT00865085|Drug|Citalopram HBr 40 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
1838111|NCT00865085|Drug|CelexaTM 40 mg tablets, single dose|B: Active comparator Subjects received Forest Labs formulated products under fasting conditions
1838112|NCT00865098|Drug|Cetuximab|Patients receive Cetuximab at an initial dose of 400 mg/m^2 of Cetuximab to be infused 6 or 7 days before starting radiotherapy, followed by subsequent weekly infusions at a dose of 250 mg/m^2 of Cetuximab and RT (72.0 Gy total in 42 fractions) for the next 6 weeks of the treatment course. Subjects will receive Cetuximab until radiographically documented progressive disease or unacceptable toxicity occurs or consent is withdrawn. If RT is delayed, administration of Cetuximab every 7 days is continued. If RT is discontinued for any reason, treatment with Cetuximab monotherapy every 7 days is continued.
1838113|NCT00865111|Drug|Bupropion 150 mg Extended-Released Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
1838114|NCT00865111|Drug|Wellbutrin SR® 150 mg Sustained-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
1838115|NCT00865124|Drug|Spironolactone|25 mg capsule daily for 6 months
1838116|NCT00865124|Drug|Hydrochlorothiazide + potassium|hydrochlorothiazide (HCTZ) + potassium, 12.5 mg/10 milliequivalents (mEq) capsule daily
1838117|NCT00865124|Other|Placebo|Placebo capsule daily
1838118|NCT00865137|Drug|Tacrolimus, modified release|Oral
1838119|NCT00865176|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
1838120|NCT00865176|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
1838121|NCT00865189|Drug|Bevacizumab|Bevacizumab will be administered at the fixed dose of 5 milligrams per kilogram (mg/kg) as an IV infusion over 30 to 90 minutes.
1838122|NCT00865189|Drug|Oxaliplatin|Oxaliplatin will be administered at a dose of 85 milligrams per square meter (mg/m^2) as a 2-hour IV infusion.
1838123|NCT00865189|Drug|Folinic Acid|Folinic acid will be administered at a dose of 200 mg/m^2 as a 2-hour infusion.
1838124|NCT00865189|Drug|5-fluorouracil|5-fluorouracil will be administered at a dose of 400 mg/m^2 as an IV bolus, then at a dose of 600 mg/m^2 as a continuous infusion for 22 hours in Phase 1, and will be administered at a dose of 225 mg/m^2 as a 24-hour infusion, 5 days a week, for 5 weeks in Phase 2.
1838126|NCT00865189|Procedure|Surgery|Radical rectal excision based on the TME technique.
1838127|NCT00865202|Drug|L-tryptophan supplementation|L-tryptophan 1 gram enterally TID for a maximum of nine doses or to be discontinued at the time of discharge from the ICU (whichever occurs first)
1838128|NCT00865202|Drug|placebo|Similar appearing placebo administered post-operatively (1 enterally TID) for a total of nine doses or discharge from ICU (whichever occurs first)
1838129|NCT00865215|Drug|Propranolol Hydrochloride Extended Release Capsules 160 mg|A: Experimental Subjects received Actavis formulated products under fasting conditions
1838130|NCT00865215|Drug|INDERAL® LA 160 mg Capsules, single dose|B: Active comparator Subjects received Wyeth Pharmaceuticals formulated products under fasting conditions
1838131|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 100 mg, tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
1838132|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate 100 mg, tablets, orally, once daily in the evening for up to six weeks.
1838133|NCT00865228|Drug|Lapaquistat acetate|Lapaquistat acetate 50 mg, tablets, orally, once daily in the morning and Lapaquistat acetate 50 mg, tablets, orally, once daily in the evening for up to six weeks.
1838134|NCT00865228|Drug|Placebo|Lapaquistat acetate placebo-matching tablets, orally, once daily in the morning and Lapaquistat acetate placebo-matching tablets, orally, once daily in the evening for up to six weeks.
1838135|NCT00865241|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
1838136|NCT00865241|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
1838137|NCT00865254|Behavioral|Standard Treatment|Brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
1838138|NCT00865254|Behavioral|Traditional Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (50% of draws are prizes). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
1838139|NCT00865254|Behavioral|Early Enhanced Contingency Management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking. Prize draws result in incentives on an intermittent schedule (100% of draws are prizes in week 1; 33% are prizes in weeks 2-4). Participants are also provided with brief counseling for smoking cessation followed by continued brief supportive sessions and frequent monitoring of smoking cessation efforts.
1838140|NCT00865267|Drug|Ultravate® 0.05% ointment, single exposure|A: Experimental Subjects received Bristol-Myers Squibb Company formulated products
1838141|NCT00865280|Drug|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
1838142|NCT00865280|Drug|linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600 mg IV infusion solution; For gram negative treatment: Moxifloxacin 400 mg tablets and pre-mixed 400mg IV infusion solution
1838143|NCT00865306|Behavioral|"Being Brave: A Program for Coping with Anxiety for Young Children and Their Parents."|"This is a cognitive-behavioral intervention modeled loosely after Kendall's Coping Cat, which includes 7 parent-only sessions and 8-13 child-only sessions. It focuses on helping parents learn strategies for coaching their child in coping with anxiety, and on teaching the child coping skills and carrying out exposure exercises in session and in parent-child homework assignments."
1838144|NCT00865319|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG to be injected
1838145|NCT00865319|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20mCi)
1838146|NCT00865345|Device|MMT-7003 subcutaneous glucose sensor|All subjects will use the glucose sensor, randomized to participate in a 12-hour frequent (15-minute) blood glucose sampling period on one of six days of sensor wear. Blood samples will be analyzed using a laboratory standard (YSI) for comparison to the glucose sensor to evaluate accuracy.
1838147|NCT00865358|Behavioral|Yoga Group|Reproducible standardized 12 week series of hatha yoga classes specifically developed for patients with chronic low back pain and little or no experience with yoga
1838148|NCT00865371|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fed conditions
1838149|NCT00865371|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
1838150|NCT00865384|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
1838151|NCT00865384|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under non-fasting conditions
1838152|NCT00865397|Drug|insulin detemir|Effectiveness data collection in connection with the use of the drug Levemir® in daily clinical practice.
1838153|NCT00865410|Drug|Abrika Bupropion 150 mg Extended-Released Tablet|A: Experimental Subjects received Abrika formulated products under fasting conditions
1838154|NCT00865410|Drug|Wellbutrin SR® 150 mg Extended-Release Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
1838155|NCT00865423|Drug|Gabapentin 800 mg Tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
1838156|NCT00865423|Drug|NEURONTIN® 800 mg Tablets, single dose|B: Active comparator Subjects received Parke-Davis formulated products under fasting conditions
1838157|NCT00865436|Drug|Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg|A: Experimental Subjects received Alpharma formulated products under fasting conditions
1838158|NCT00865436|Drug|CLUCOVANCE® 5 mg/500 mg Tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
1838159|NCT00865449|Drug|spironolactone|25 mg daily of spironolactone given for 6 months in the peritoneal dialysis patients
1838160|NCT00865449|Drug|Placebo|Placebo, given daily for 6 months to Peritoneal Dialysis Patients
1838161|NCT00865462|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fed conditions
1838162|NCT00865462|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fed conditions
1838163|NCT00865475|Drug|AZT+3TC+ABV (Trizivir)|Patients on treatment with TZV and viral suppression will be randomized to keep on TZV vs switching to LPV/r monotherapy
1838164|NCT00865475|Drug|Switching to LPV/r monotherapy (Kaletra)|Patients on AZT+3TC+ABV with viral suppression will be randomized to keep on vs switching to LPV/r
1838165|NCT00865488|Biological|ADHEXIL|Adhesions prevention
1838166|NCT00865501|Drug|spironolactone|25mg per oral once daily
1838167|NCT00865501|Drug|placebo|placebo
1838168|NCT00865514|Drug|Dichloroacetate|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
1838169|NCT00865514|Genetic|Genotyping|Subjects will have 5 mls of blood drawn for genotyping
1838170|NCT00865514|Other|Leucine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
1838171|NCT00865514|Other|tyrosine|Healthy men and women with different haplotypes will receive an infusion of leucine and tyrosine. The following day they begin a 5 day course of dichloroacetate (DCA)at a dose of 2.5mcg/kg/day. On day 6 they return and receive another infusion of leucine and tyrosine. After a 30 day washout period the subject returns and again receives an infusion of leucine and tyrosine. Then on day 2 they begin a dose of DCA at 25mg/kg for 5 days and then return for the final infusion of leucine and tyrosine.
1838172|NCT00865527|Other|Fecal occult blood test|FOBT
1838173|NCT00865527|Procedure|Virtual colonoscopy|computed tomographic colonography
1838174|NCT00865527|Procedure|Optical colonoscopy|optical (conventional / endoscopic) colonoscopy
1838175|NCT00865540|Drug|prednisolone acetate 1%|1 drop every 8h two days before surgery
1838176|NCT00865540|Drug|ketorolac tromethamine 0.4%|1 drop every 8h two days before surgery
1838177|NCT00865540|Drug|nepafenac 0.1%|1 drop every 8h two days before surgery
1838178|NCT00865540|Drug|methylcellulose 0.5%|1 drop every 8h two days before surgery
1838179|NCT00865553|Behavioral|computer-assisted smoking cessation intervention|
1838180|NCT00865553|Other|cancer prevention|
1838181|NCT00865553|Other|educational intervention|
1838182|NCT00865553|Other|survey administration|
1838183|NCT00865566|Biological|DNA plasmid vaccine|4-mg injection administered as 1 mL intramuscularly (IM) via Biojector® in either deltoid
1838184|NCT00865566|Biological|Recombinant adenoviral serotype 5 (rAD5) vector vaccine|1 x 10^10 particle units (PU) administered as 1mL IM by needle and syringe in either deltoid
1838185|NCT00865566|Biological|DNA vaccine placebo|1 mL IM via Biojector® in either deltoid
1838186|NCT00865566|Biological|HIV-1 recombinant adenovirus vaccine placebo|1 mL administered IM by needle and syringe in either deltoid
1838187|NCT00865579|Drug|Safinamide|"The Investigational Medicinal Product will be provided by the Sponsor in the form of tablets at dosage strengths of safinamide 50 mg (small - 7 mm) or safinamide 100 mg (large - 9 mm).
Trial Medication is to be taken once daily, in the morning."
1838188|NCT00865592|Drug|dutogliptin|dutogliptin 400 mg, once daily tablet
1838189|NCT00865605|Drug|Halobetasol Propionate 0.05% Ointment, single exposure|A: Other Subjects received Alpharma/Purepac USHP formulated products
1838190|NCT00865605|Drug|Ultravate® 0.05% ointment, single exposure|Subjects received Bristol-Myers Squibb Company formulated products
1838191|NCT00865618|Drug|Eplerenone 50 mg Tablets Sandoz Inc., USA|
1838192|NCT00865618|Drug|Inspra 50 mg Tablets GD Searle LLC, USA|
1838193|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under fasting conditions
1838194|NCT00865631|Drug|NEURONTIN® 400 mg capsules, single dose (2 capsules)|B: Active comparator Subjects received Parke-Davis formulated products under non-fasting conditions
1838195|NCT00865631|Drug|Gabapentin 800 mg tablets, single dose (1 tablet)|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
1838196|NCT00865644|Drug|Imiquimod 5% Cream|Applied topically to three tumors 5 times per week for a full 6 weeks
1838197|NCT00865657|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
1838198|NCT00865657|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under non-fasting conditions
1838199|NCT00865670|Drug|Azithromycin Monohydrate 600 mg Tablets|
1838200|NCT00865670|Drug|Zithromax (azithromycin dihydrate) 600 mg Tablets|
1838201|NCT00865683|Dietary Supplement|DHA Supplements|Participants will receive 800 mg of DHA each day for approximately 3 months (until they give birth).
1838202|NCT00865683|Dietary Supplement|Placebo Supplements|Participants will receive placebo supplements each day for approximately 3 months (until they give birth).
1838203|NCT00865696|Drug|Mirtazapine 15 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
1838204|NCT00865696|Drug|REMERON® 15 mg tablets, single dose|B: Active comparator Subjects received Organon Inc. formulated products under fasting conditions
1838243|NCT00866047|Drug|brentuximab vedotin|1.8 mg/kg every 3 weeks by IV infusion
1838244|NCT00866060|Drug|Memantine|20mg memantine
1838245|NCT00866060|Drug|Donepezil|10mg donepezil
1838205|NCT00865709|Drug|Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral Sorafenib 400 mg twice daily (BID) continuously and intravenous (IV) mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease (PD)
1838206|NCT00865709|Drug|Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)|Subjects will receive oral matching placebo 2 tablets BID continuously and IV mFOLFOX6 (5-FU 400 mg/m^2 bolus and 2400 mg/m^2 for 46-48 hrs; levo-leucovorin 200 mg/m^2; 85 mg/m^2 oxaliplatin) every 14 days until progressive disease
1838207|NCT00865722|Procedure|Remote Postconditioning|Lower limb compression using a cuff inflated to 200 mmHg for 5 ' followed by 5' of reperfusion fo three times during 30'
1838208|NCT00865748|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
1838209|NCT00865748|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
1838210|NCT00865761|Drug|Alprazolam 3 mg Extended Release Tablets, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
1838211|NCT00865761|Drug|XANAX XR® 3 mg tablets, single dose|B: Active comparator Subjects received Pharmacia & Upjohn Company formulated products under fasting conditions
1838212|NCT00865774|Behavioral|Quantity Frequency Model|The quantitative intervention involves emphasis on tracking and measuring the number of drinks on a weekly basis.
1838213|NCT00865774|Behavioral|Targets Subjective Drunkenness|Explores factors leading to drunkenness and alternative coping strategies for healthier function.
1838214|NCT00865813|Procedure|Punch Biopsy|"Instillation of anesthetic eye drops.
Asepsis
Placement of surgical cloths and drapes
Infiltration of the involved region with anesthetic solution plus adrenalin in1:200.00 dilution.
Trephination of the most typical area of the lesion with a punch (2mm in diameter) of stainless steel by applying gentle pressure and twisting the trephine until its introduction into the suspicious lesions
Removal of the excised tissue with the aid of an insulin needle or conjuntival forceps, the base then bein cut with an number 11 surgical blade"
1838215|NCT00865826|Other|Standardized diagnostic evaluation|Participants will undergo a diagnostic evaluation for TB at study entry
1838216|NCT00865839|Drug|Metformin HCl 500 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
1838217|NCT00865839|Drug|CLUCOPHAGE® XR 500 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under fasting conditions
1838218|NCT00865852|Drug|Metformin HCl 750 mg Extender Release tablets, single dose|A: Experimental Subjects received Purepac formulated products under non-fasting conditions
1838219|NCT00865852|Drug|GLUCOPHAGE® XR 750 mg tablets, single dose|B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
1838220|NCT00865865|Procedure|Computer aided total knee arthroplasty|Use of computer aided surgery to balance soft tissue tension in total knee arthroplasty
1838221|NCT00865865|Procedure|Conventional total knee arthroplasty|Conventional method of total knee arthroplasty
1838222|NCT00865878|Drug|Aminolevulinic Acid|20% aminolevulinic acid HCL (ALA) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) ALA-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
1838223|NCT00865878|Other|Vehicle|Vehicle ingredients only (VEH) applied topically for 90 +/- 30 minutes prior to treatment with 10 j/cm2 blue light. Up to nine (9) VEH-PDT treatments will be given: The initial four (4) treatments will be given at 4-5 week intervals, with the remaining five (5) treatments given every 6 +/-1 weeks.
1838224|NCT00865891|Drug|Nifedipine Extended Release tablets 60 mg, single dose|A: Experimental Subjects received Abrica Pharmaceuticals LLLP formulated products under fasting conditions
1838225|NCT00865891|Drug|ADALAT® CC Extended Release Tablets 60 mg|B: Active comparator Subjects received Bayer Pharmaceuticals Corporation, Bayer HealthCare formulated products under fasting conditions
1838226|NCT00865904|Drug|VX-809|Capsules
1838227|NCT00865904|Drug|Placebo|Placebo matched to VX-809 capsules.
1838228|NCT00865917|Drug|beta-blocker (Metoprolol)|Metoprolol 95 mg once per day
1838229|NCT00865917|Drug|I(f)-blocker (ivabradine)|ivabradine 7.5 mg once per day
1838230|NCT00865917|Drug|Placebo|matching appearance
1838231|NCT00865943|Drug|Citalopram HBr eq. 10 mg tablets, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
1838232|NCT00865943|Drug|CELEXATM 10 mg tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc. marketed products under fasting conditions
1838233|NCT00865956|Behavioral|Contingency Management|Rite Aid vouchers (stepped value) for reinforcement of adherence to primary care
1838234|NCT00865956|Other|Case management|Nurse case manager assigned to participant
1838235|NCT00865969|Drug|PXD101|Belinostat (PXD101) 1000 mg/m²administered as a 30 minute IV infusion on days 1-5 of every 3-week cycle
1838236|NCT00865982|Drug|Docetaxel, Cisplatin, Capecitabine|"3 preoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks
followed by resection
and 3 postoperative cycles with Docetaxel 75 mg/m² d1 Cisplatin 60 mg/m² d1 Capecitabine 1875 mg/m²/day d1-14 repeated every 3 weeks."
1838237|NCT00865995|Procedure|Tracheal Lavage|Tracheal Lavage will be performed on the control population patients and the tracheal fluid obtained from this procedure will be used as the research sample.
1838238|NCT00866008|Drug|Ovarian stimulation|"Conventional regimen with a daily dose of 225 IU recombinant FSH and GnRH agonist long protocol co-treatment
Mild ovarian stimulation regimen using the endogenous FSH production by starting treatment on day 5 of the menstrual cycle with 150 IU / d recFSH with GnRH antagonist co treatment starting on day 6. As soon as two follicles reach 12 mm, treatment is continued with 200 IU / d rec hCG."
1838239|NCT00866021|Drug|Lopinavir/ritonavir|NRTI sparing-regimen
1838240|NCT00866021|Drug|Lopinavir/ritonavir with two nucleoside analogs|LPV/r plus 2NRTIs + PEG-INF + RBV
1838241|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Fixed start of a daily dose of 0.25mg Cetrotide on cycle day 2
1838242|NCT00866034|Drug|Cetrotide (Ovarian stimulation)|Late fixed start of a daily dose of 0.25mg Cetrotide on cycle day 6.
1838248|NCT00866073|Drug|Decitabine 15 mg/m2 i.v.|Decitabine at 15 mg/m2 i.v. x 3 hours, three times daily on three consecutive days
1838249|NCT00866086|Other|questionnaire administration|
1838250|NCT00866086|Procedure|computed tomography|
1838251|NCT00866086|Radiation|radiation therapy treatment planning/simulation|
1838252|NCT00866099|Other|Educational Dementia training|"Tailored learning activities on dementia, over a three-month period and will be given an electronic training manual (based on Microsoft packages) which they can run in the background during and after consultations with people with known or suspected dementia syndrome and face-to- face individualised workshop sessions.
Tailoring of the education programme is carried out in a three step process: 1) an educational needs analysis is carried our using a standard checklist to identify aspects of dementia care which the practice perceives as problematic for them; 2) a prescription for education is then written to address shortcomings; 3) the best forms of learning are then identified."
1838253|NCT00866112|Other|Educational session to promote physical activity|Educational session, goal setting, self monitoring of daily engagement in physical activity
1838254|NCT00866112|Other|Minimal contact|Self guided education manual about adopting physical activity, self monitor daily engagement in physical activity
1838255|NCT00866138|Drug|masitinib (AB1010)|masitinib 9 mg/kg/day per os
1838256|NCT00866164|Device|Prometra Programmable Pump|Implantation of Prometra Pump for delivery of intrathecal morphine for the treatment of chronic intractable pain
1838257|NCT00866177|Other|Laboratory Biomarker Analysis|Correlative studies
1838258|NCT00866177|Drug|Selumetinib|Given orally
1838259|NCT00866190|Drug|SQ109|SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
1838260|NCT00866190|Drug|Placebo|Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
1838261|NCT00866203|Drug|HDS vs ProMECE/CytaBOM|
1838262|NCT00866216|Drug|Azithromycin Monohydrate 600mg Tablets Geneva Pharmaceuticals|
1838263|NCT00866216|Drug|Zithromax (Azithromycin Dihydrate) 600mg Tablets Pfizer Inc.|
1838264|NCT00866229|Drug|Rosuvastatin|10 mg per day for 12 weeks
1838265|NCT00866229|Drug|Simvastatin|20 mg per day
1838266|NCT00866242|Biological|CVD 1208S, Challenge strain of wild-type Shigella flexneri 2a|The challenge strain consists of freshly harvested Shigella flexneri 2a strain 2457T diluted in phosphate buffered saline to reach the desired inoculum Form: liquid Dose 10 to the 3rd power CFU in 1.0 ml Route: oral.
1838267|NCT00866255|Device|endotracheal tube pressure measurement probe|The endotracheal tube pressure measurement probe is inserted into the endotracheal tube prior to intubation for measurement of tracheal pressure at the tip of the endotracheal tube.
1838268|NCT00866268|Device|low pressure suction drainage|In the experimental group the drainage catheter was connected to a modified DRENOFAST® system. This system consisted of a sterile plastic bottle with a holding capacity of 600 mL of fluid and a negative pressure of 700mmHg. It was hermetically closed and had two connections. The DRENOFAST® modification consisted of establishing an open connection between the bottle and a wall vacuum source (normally used to administer oxygen) placed next to the patient's bed. The 50 mmHg constant negative pressure of the bottle was maintained by the wall vacuum source and verified by flow meter. Duration: Drains were removed after bleeding had ceased (48-72h).
1838269|NCT00866268|Device|High pressure suction drainage|In order to mask the type of intervention from the patient and the investigators, both drainage systems had two drain catheters. One catheter allowed the blood to flow from the wound to the bottle. The second catheter connected the bottle to the vacuum source. In the experimental arm the second catheter was open, while in the control group it was closed. So that the system used could not be distinguished, the connection of the second catheter to the bottle was covered with opaque adhesive tape.Drains were removed after bleeding had ceased.
1838270|NCT00866281|Drug|midostaurin|Midostaurin 25 mg/mL oral solution was provided in bottles of 50 mL, administered with water. The pediatric starting dose of midostaurin was set at 30 mg/m2 bid and was not to exceed 60 mg/m2 bid.
1838271|NCT00866294|Drug|paroxetine IR 10mg tablet|1 or 2 tablets once a day
1838272|NCT00866294|Drug|paroxetine IR 20mg tablet|1 tablet once a day
1838273|NCT00866294|Drug|matched placebo to paroxetine IR 10mg or 20mg|1 or 2 tablets once a day
1838274|NCT00866294|Drug|Paroxetine CR 12.5mg tablet|1 or 2 tablets once a day
1838275|NCT00866294|Drug|Paroxetine CR 25mg tablet|1 or 2 tablets once a day
1838276|NCT00866294|Drug|matched placebo to paroxetine CR 12.5mg or 25mg|1 or 2 tablets once a day
1838277|NCT00866307|Drug|pegaspargase|Given IV
1838278|NCT00866307|Drug|cytarabine|Given IT and IV or SC
1838279|NCT00866307|Drug|vincristine sulfate|Given IV
1838280|NCT00866307|Drug|doxorubicin hydrochloride|Given IV
1838281|NCT00866307|Drug|cyclophosphamide|Given IV
1838282|NCT00866307|Drug|prednisone|Given IV or PO
1838283|NCT00866307|Drug|dexamethasone|Given IV
1838284|NCT00866307|Drug|methotrexate|Given IT and PO
1838285|NCT00866307|Drug|daunorubicin hydrochloride|Given IV
1838286|NCT00866307|Drug|mercaptopurine|Given PO
1838287|NCT00866307|Drug|thioguanine|Given PO
1838288|NCT00866307|Radiation|prophylactic cranial irradiation|Undergo radiation
1838289|NCT00866307|Other|laboratory biomarker analysis|Correlative studies
1838290|NCT00866320|Drug|sorafenib tosylate|Sorafenib (BAY 43-9006) is an oral multi-kinase inhibitor targeting both tumor cells and the tumor vasculature. Patients with metastatic RCC meeting eligibility criteria will receive 400 mg BID of sorafenib in a single-arm phase II study. Treatment will be administered on an outpatient basis.
1838291|NCT00866333|Drug|entinostat (SNDX-275)|entinostat, oral, once weekly for 3 weeks followed by a 1-week break in a 4-week cycle
1838292|NCT00866346|Biological|PR1-primed lymphocyte (PR1-CTL) Infusion|"Two infusions of PR1-specific T lymphocytes (donor immune cells) 60 days apart.
Starting infusion dose 1 x 106 nucleated cells/kg."
1838372|NCT00866866|Drug|Placebo|1 tab PO BID
1995586|NCT02715856|Behavioral|Mobile Device Training|At a clinic visit before surgery, participant taught how to take photos of their surgical wounds and make videos using a mobile device.
1838295|NCT00866385|Drug|AZD8566|Single 6 mg oral solution dose
1838296|NCT00866385|Drug|AZD8566 IV carbon labelled|Single 10 mcg intravenous carbon-14 microtracer dose
1838297|NCT00866411|Procedure|cranial electrotherapy stimulation (CES) with Alpha-Stim|three weeks of the cranial electrotherapy stimulation (CES) treatment (15 sessions of 60 minute treatments)
1838298|NCT00866411|Procedure|placebo|three weeks of placebo treatment via a double-blinded procedure so that neither the Soldier nor the study investigators will know whether the Soldier is receiving the actual treatment or placebo
1838299|NCT00866424|Procedure|Hyperbaric oxygen, Mock hyperbaric chamber|"Hyperbaric oxygen treatment for 10 days in treatment groups and mock hyperbaric chamber treatment for 10 days in control groups.
Hyperbaric oxygen treatment: While in the hyperbaric chamber the subjects breathe 100% oxygen saturation with mask at 2.0bars.
Mock hyperbaric chamber treatment: The subjects breathe air freely in the imitation environment chamber at 1.0bars."
1838300|NCT00866437|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.
Hormones:
Progesterone 1mmol/L
Estradiol 1mmol/L
Estrone 3mmol/L
Estriol 3mmol/l
Controls:
Saline (NaCl) 0.9%
Ethyl Oleate with 10% Benzyl Alcohol
Histamine phosphate 1mg/ml (epicutaneous- prick test)"
1838301|NCT00866437|Drug|Skin test panel|"Hormones:
Progesterone 1mmol/L
Estradiol 1 mmol/L
Estrone 3 mmol/L
Estriol 3mmol/l
Controls:
Saline (NaCl) 0.9%
Ethyl Oleate with 10% Benzyl Alcohol
Histamine phosphate 1mg/ml (epicutaneous- prick test)"
1838302|NCT00866450|Dietary Supplement|Western style diet (high fat and low in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
1838303|NCT00866450|Dietary Supplement|Prudent-style diet (low fat and high in calcium)|Subjects will be randomized to begin on either a WD or a PD for 30 + 3 days. Once that dietary intervention is complete, subjects will have a four (4) week wash-out period and then will be placed on the other dietary intervention for 30 + 3 days
1838304|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Oral Tablet With Water
1838305|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet With Water
1838306|NCT00866463|Drug|Sildenafil|Single Dose of 50 mg Sildenafil Experimental Tablet Without Water
1838307|NCT00866476|Biological|CVD 1208S, a Shigella flexneri 2a live, oral vaccine|CVD 1208S consists of freshly harvested ∆guaBA, ∆sen, ∆set S. flexneri 2a strain 2457T suspended in phosphate buffered saline to reach the desired inoculum Form: liquid Dose: 10 to the 9th power CFU in 1.0 ml Route: oral.
1838308|NCT00866476|Other|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
1838309|NCT00866489|Procedure|remote preconditioning|Remote ischemic preconditioning consist of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff is deflated.
1838310|NCT00866502|Drug|sNN0031|Continuous ICV infusion for two weeks
1838311|NCT00866502|Drug|Placebo|Continous ICV infusion
1838312|NCT00866515|Drug|Ketoconazole + GW642444M|Ketoconazole 400mg OD days 1-6, GW642444M 25ug single dose on D5
1838313|NCT00866515|Drug|Placebo + GW642444M|Placebo to match D1-6 + GW642444M 25ug single dose on D5
1838314|NCT00866528|Drug|pazopanib|oral pazopanib once daily (Phase I starting dose 800 mg)
1838315|NCT00866528|Drug|paclitaxel|paclitaxel IV once every 3 weeks (Phase I starting dose 135 mg/m2).
1838316|NCT00866541|Device|artificial increased resistance (flow proportional pressure support)|respiratory resistance is increased by interpose of an artificial resistance tool in the in- and expiratory airways of the mechanical respirator
1838317|NCT00866554|Drug|administration of a LHRH agonist and Bicalutamide|3-month treatment with an LHRH agonist chosen by the treating radiation oncologist and Bicalutamide 50 mg daily for the first month of treatment with the LHRH agonist.
1838318|NCT00866554|Drug|administration of Bicalutamide, Dutasteride and Tamoxifen|"Dutasteride given at dose of 0.5 mg daily starting three months prior to day of implant procedure and continued for 3 months up until procedure.
Bicalutamide: given at a dose of 50 mg daily for 3 the same 3 month period as dutasteride
Tamoxifen: given at dose of 10 mg daily for 3 months that dutasteride and bicalutamide are administered."
1838319|NCT00866580|Biological|GSK's candidate influenza vaccine 1562902A|Intramuscular dose on Day 0 and Day 21
1838320|NCT00866580|Biological|FluarixTM|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
1838321|NCT00866580|Biological|Placebo|Intramuscular dose on Day 42 or on Day -30, according to the vaccination schedule
1838322|NCT00866593|Drug|Generic Escitalopram|10mg/d or 20mg/d
1838323|NCT00866593|Drug|Innovator Escitalopram|10mg/d or 20mg/d
1838324|NCT00866606|Biological|Benefix|BeneFIX for on-demand treatment of bleeding episodes were according to investigator prescription. FIX recovery was assessed by determining the FIX activity (FIX:C) levels in individual subjects. BeneFIX dosage for recovery assessments: single 75 IU/kg (±5 IU/kg) IV bolus infusion.
1838629|NCT00868504|Other|no intervention|no intervention
1959129|NCT00781612|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as intravenous (IV) infusion. Participants on weekly dosing schedule of trastuzumab emtansine in parent study, may switch to Q3W schedule as per the clinical judgment of the investigator. The starting dose of Q3W schedule must not exceed 3.6 milligrams per kilograms (mg/kg).
1838330|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in a group setting for 11 sessions, for 1 to 1.5 hours/session.
1838331|NCT00866632|Behavioral|Cognitive Behavioural Therapy|Cognitive behavioural therapy to be delivered in one-on-one via the telephone across 11 sessions, for 1 to 1.5 hours/session.
1838332|NCT00866645|Drug|Intramuscular Haloperidol|1ml：5mg/ampoul the recommended dose is 10 mg per day administered. Doses of 10 mg may be administered 5mg bid with an interval longer than 4 hours for 3 days.
1838333|NCT00866645|Drug|Intramuscular Levosulpiride|2ml：50mg/ampoul the recommended dose is 100 mg per day administered. Doses of 100 mg may be administered 50mg bid with an interval longer than 4 hours for 3 days.
1838334|NCT00866658|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
1838335|NCT00866658|Drug|Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
1838336|NCT00866658|Device|Pen auto-injector|
1838337|NCT00866658|Drug|Sulfonylurea|Sulfonylurea if given, to be continued at a stable dose.
1838338|NCT00866658|Drug|Basal Insulin|To be continued at a stable dose.
1838339|NCT00866671|Drug|nelarabine|Nelarabine is a prodrug of 9-β-D-arabinofuranosylguanine (ara-G), a deoxyguanosine analogue.
1838340|NCT00866684|Drug|Sirolimus|Dosage form: coated tablet; Dosage: 4-8 micrograms/litre; Route of administration: oral use; Frequency: one tablet per day; Duration: 24 month
1838341|NCT00866684|Drug|Azathioprine|Dosage form: Coated tablet; dosage: 1-4 milligrams/kilogram; Frequency: daily; Duration: 24 month
1838342|NCT00866684|Drug|Mycophenolate|Dosage form: Tablet; dosage: 2 gram; Frequency: daily; Duration: 24 month
1838343|NCT00866684|Drug|Ciclosporin|Dosage form: Capsule; Dosage: 50-80 micrograms/litre; Frequency: daily; Duration: 24 month
1838344|NCT00866684|Drug|Tacrolimus|Dosage form: Capsule; dosage: 3-5 micrograms/litre; Frequency: daily; Duration: 24 month
1838345|NCT00866697|Drug|Pazopanib|Pazopanib 800 mg daily for 104 weeks (24 months)
1838346|NCT00866697|Drug|Placebo|Matching placebo 800 mg daily, for 104 weeks (24 months).
1838347|NCT00866710|Other|Exercise-based behavioral therapy|Participants will be taught pelvic floor muscle exercises as well as urge suppression strategies to overcome the urge to void. In the first 20 participants, computer-assisted biofeedback will also be utilized to help participants identify the pelvic floor muscles and contract and relax these muscles while keeping the abdominal muscles relaxed
1838348|NCT00866723|Drug|bevacizumab|
1838349|NCT00866736|Drug|dasatinib|100mg QD
1838350|NCT00866749|Drug|Daunorubicin|Starting Dose 25 mg/m^2 by vein weekly
1838351|NCT00866749|Drug|Vincristine|Starting Dose 2 mg by vein weekly
1838352|NCT00866749|Drug|PEG-asparaginase|Starting Dose 2000 International units/m2 by vein in week 1
1838353|NCT00866749|Drug|Intrathecal Methotrexate|Starting Dose 12 mg on week 2 and week 5 injected into spinal fluid
1838354|NCT00866749|Drug|Cyclophosphamide|Starting Dose 1g/m2 by vein in weeks 1 and 5
1838355|NCT00866749|Drug|Cytarabine|75 mg/m2 subcutaneous or by vein for four consecutive days on days 1-4 and days 8-11 of both months
1838356|NCT00866749|Drug|Mercaptopurine|Starting Dose 60 mg/m2 by mouth on days 1-14 of each month
1838357|NCT00866749|Drug|Methotrexate|"Starting Dose at 100 mg/m2 by vein and escalating by 50 mg/m2/dose every 10
+/- 2 days for 5 doses to toxicity (e.g myelosuppression or mucositis grade 3"
1838358|NCT00866749|Drug|Doxorubicin|25 mg/m2 by vein in weeks 1, 2 and 3
1838359|NCT00866749|Drug|Thioguanine|60 mg/m2 by mouth daily for two weeks
1838360|NCT00866762|Drug|HDAC inhibitor (MK-0683)|400 mg once daily for 6 months
1838361|NCT00866775|Drug|Eslicarbazepine acetate|1600 mg QD
1838362|NCT00866775|Drug|Eslicarbazepine acetate|1200 mg QD
1838363|NCT00866788|Drug|omalizumab|Administered by subcutaneous injection
1838364|NCT00866788|Drug|placebo|Participants received a single subcutaneous placebo injection on Day 0 of the study.
1838365|NCT00866788|Drug|H1 antihistamines|Patients received one of the following: Cetirizine 10 mg once per day (QD), Levocetirizine dihydrochloride 5 mg QD, Fexofenadine 60 mg twice per day or 180 mg QD, Loratadine 10 mg QD or Desloratadine 5 mg QD
1838366|NCT00866788|Drug|Diphenhydramine|Diphenhydramine was provided and used on an as-needed basis (25 mg per dose)
1838367|NCT00866814|Device|Bard Ventrio Hernia Patch|The Ventrio Hernia Patch is a self-expanding, non-absorbable, sterile prosthesis for use in the reconstruction of soft tissue deficiencies, such as for the repair of hernias.
1838368|NCT00866827|Other|Protocols for Treatment|Determine protocols for treatment of airway vascular malformation and to evaluate results from treatment of these lesions.
1995587|NCT02715570|Drug|PC945 - single doses|Safety and tolerability of single doses
1995588|NCT02715570|Drug|Placebo - single doses|Safety and tolerability of single doses
1995589|NCT02715570|Drug|PC945 - repeat doses|Safety and tolerability of repeat doses
1995590|NCT02715570|Drug|Placebo - repeat doses|Safety and tolerability of repeat doses
1995596|NCT02713945|Drug|Simvastatin|Experimental drug administrated orally
1995597|NCT02713945|Drug|Placebo|Treatment for the control group
1995598|NCT02714062|Drug|Placebo|Placebo, po once daily
1838373|NCT00866879|Drug|Sirolimus|Sirolimus will initially be given at a dose of 2-4 mg orally (PO) daily. The dose will be modified to achieve 24 hours trough concentrations of 6-10 ng/ml by high-performance liquid chromatography (HPLC) assay. This medication will be given in an open label fashion. The first dose of sirolimus will be given at the time of randomization to those patients assigned to have tacrolimus switched to sirolimus.
1838374|NCT00866879|Other|Demographic Data, Medical History, and Donor Data|Age at transplant, sex, race, cause of end-stage renal disease, medical history, donor age, cadaveric vs. living kidney transplant, histocompatibility/cross match data, viral serology, history of acute rejection and delayed graft function, use of induction therapy and immunosuppressants, use of Angiotensin Converting Enzyme Inhibitor (ACEI) and/or Angiotensin Receptor Blockers (ARB) level of renal allograft function-estimated GFR (e-GFR(12) using Modification of Diet in Renal Disease (MDRD) formula, proteinuria.
1838375|NCT00866879|Procedure|Blood Draws for Control Group|Subjects maintaining standard of care drug treatment of TAC and MMF will have monthly labs in addition to the baseline pre-randomization labs, at 6, 12, and 24 Months post-randomization. Peripheral blood leukocytes will be obtained.
1838376|NCT00866879|Procedure|Blood Draws for Experimental Group|This group will have monthly labs taken but will also have weekly labs during the period of conversion to monitor renal function and bone marrow function. In addition to the baseline pre-randomization labs, and labs collected at 6, 12, and 24 Months post-randomization, peripheral blood leukocytes will be obtained.
1838377|NCT00866879|Procedure|Donor Blood Draws|Peripheral blood leukocytes from living donors obtained at the time of randomization. These donor leukocytes will be used as stimulator cells to study the functional activity of the recipient's lymphocytes function.
1838378|NCT00866879|Other|Donor Information|Donor age, cadaveric vs. living donor, and histocompatibility and cross match to recipient
1838379|NCT00866879|Procedure|Kidney Biopsy|Kidney biopsy at 24 Months to compare to the standard of care biopsy taken at 12 Months. This information will help evaluate renal allograft pathology and renal allograft tissue gene expression profiles of the two groups. Renal allograft biopsies will be stored in RNA later (preservative) to further extend knowledge on the effect of calcineurin-inhibitors (CI) free immunosuppression on gene expression profiles.
1838380|NCT00866892|Procedure|Irrigation|irrigation
1838381|NCT00866892|Procedure|No irrigation|no irrigation
1838382|NCT00866905|Drug|Ixabepilone|40 mg/m2 IV infusion over 3 hours on day 1 of a 21 day cycle for 6 cycles
1838383|NCT00866905|Drug|Cyclophosphamide|600 mg/m2 IV infusion per institutional guidelines on day 1 of a 21 day cycle for 6 cycles
1838384|NCT00866918|Drug|arsenic trioxide|Given IV
1838385|NCT00866918|Drug|mitoxantrone hydrochloride|Given IV
1838386|NCT00866918|Other|diagnostic laboratory biomarker analysis|Correlative studies
1838387|NCT00866918|Drug|idarubicin|Given IV
1838388|NCT00866918|Drug|tretinoin|Given orally
1838389|NCT00866918|Drug|cytarabine|Given IT or IV
1838390|NCT00866918|Drug|mercaptopurine tablet|Given orally
1838391|NCT00866918|Drug|methotrexate|Given orally
1838392|NCT00866944|Drug|Adecatumumab|Adecatumumab,6-9mg/kg, every 14 days, 24 cycles
1838393|NCT00866944|Drug|Adecatumumab and FOLFOX|FOLFOX 4, every 14 days, 12 cycles followed by Adecatumumab, 6-9mg/kg, every 14 days, 12 cycles
1838394|NCT00866944|Drug|FOLFOX 4|FOLFOX 4, every 14 days, 12 cycles
1838395|NCT00866957|Procedure|Blood draw|A two-time blood draw: one prior to cancer treatment, the second after cancer treatment. Total amount of blood approximately 8 teaspoons (40mL).
1838396|NCT00866970|Biological|ALD518|ALD518 80 mg on Day 1, Week 8 and Week 16
1838397|NCT00866970|Biological|ALD518|ALD518 160 mg IV on Day 1, Week 8 and Week 16
1838398|NCT00866970|Biological|ALD518|ALD518 360 mg IV on Day 1, Week 8, and Week 16
1838399|NCT00866970|Biological|Infusion of 0.9% Saline without ALD518|Infusion of 0.9% Saline without addition of ALD518
1838400|NCT00866983|Drug|sildenafil (Revatio) 20 mg TID|To provide access to sildenafil for patients completing the A1481244 study, resides in Brazilian States where Revatio™ is not supplied by Health Secretary and are judged by the Investigator to derive clinical benefit from continued treatment with sildenafil. It will be supplied until the patient gets access to Sildenafil through Brazilian State Health Secretary from where the patient resides.
1838401|NCT00866996|Drug|Methylphenidate extended-release; Atomoxetine|
1838402|NCT00867009|Drug|Pemetrexed|Induction therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles Maintenance therapy: 500 mg/m², intravenous, on Day 1 of each 21-day cycle until progressive disease or treatment discontinuation
1838403|NCT00867009|Drug|Cisplatin|Induction therapy: 75 mg/m², intravenous, on Day 1 of each 21-day cycle for 4 to 6 cycles
1838404|NCT00867009|Drug|Cetuximab|"Induction therapy: Loading dose of 400 mg/m², intravenous, on Day 1 of cycle 1, then 250 mg/m², intravenous, weekly for 4 to 6 cycles, 21 day cycles
Maintenance therapy: 250 mg/m², intravenous, weekly until progressive disease or treatment discontinuation"
1838405|NCT00867035|Drug|Chlorine dioxide and scraper|20ml of mouthwash used for 30sec as adjunct to tongue scraper twice a day
1838406|NCT00867035|Drug|Chlorhexidine gluconate and scraper|The intervention was accomplished by subject after instructions by investigator: twice a day the scraper was used for 4 strokes then 20ml 0.12% chlorhexidine gluconate rinse for 30sec, for one week.
1838407|NCT00867048|Drug|All licensed antiretroviral medications|In both arms, participants may be prescribed any licensed antiretroviral medication, in accordance with national treatment guidelines. The nature of the intervention is the timing of when to begin treatment with these medications, as described in the two treatment arms.
1838408|NCT00867061|Drug|ON 01910.Na Concentrate|5-day continuous intravenous dosing of ON 01910.Na given every 2 weeks (1 cycle) at a dose of 800 mg/m2/day or 1500mg/m2/day for up to 24 cycles.
1838409|NCT00867087|Drug|inotuzumab ozogamicin (CMC-544)|1.8 mg/m2 every 21 days by intravenous infusion, 3 to 6 doses
1838410|NCT00867087|Drug|rituximab|375 mg/m2 two days before cycle 1 by intravenous infusion; 375 mg/m2 every 21 days by intravenous infusion, 3 to 6 doses
1838411|NCT00860080|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. The substance is formulated in a viscous solution of sodium hyaluronate. 10, 20, and 40 mg PXL01 will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
1839542|NCT00875836|Drug|Buspirone|Flexible dose, up to 60 mg daily
1838412|NCT00860080|Drug|Placebo|Placebo is prepared by dilution of sodium hyaluronate using 0.9% sodium chloride solution. The concentration of sodium hyaluronate is 15 mg/ml after dilution. Placebo will be administered as an abdominal subcutaneous injection of 0.5, 1, and 2 ml respectively.
1838413|NCT00860093|Other|placebo|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
1838414|NCT00860093|Drug|MPC-5971|After SWL treatment subjects will be randomized to receive either MPC-5971 or placebo. Two tablets of MPC-5971 or placebo will be taken orally twice a day (bid). This will give a daily dosage equal to 40 mEq of potassium, 20 mEq of magnesium and 60 mEq of citrate. MPC-5971 or placebo will be taken bid for 90 days beginning immediately after SWL treatment.
1838415|NCT00860106|Other|ED, DDimers and phone follow up|ED score, DDimers level and phone questionnary
1838416|NCT00860119|Drug|alprazolam sublingual tablet|1 mg alprazolam sublingual tablet, given as a single dose to each subject
1838417|NCT00860119|Drug|alprazolam oral tablet|1 mg alprazolam immediate release oral tablet, given as a single dose to each subject
1838418|NCT00860145|Procedure|radiosurgery|The stereotaxic frame will be secured to the skull with four pins. Patients will be taken to the MRI unit and receive a stereotaxic MRI. MRI data will be transferred to the Gamma Knife computer. Each patient will receive radiation to the mesial temporal lobe during a single treatment session. The amygdala and anterior 2cm of the hippocampus as well as the immediately adjacent parahippocampal gyrus will be included in the radiosurgical target. Patients will receive 24Gy to the 50% isodose line using an unlimited number of isocenters. The brainstem and optic nerve plus chiasm will receive less than 10 Gy and 8 Gy, respectively. After treatment, the stereotaxic frame will be removed from the patient's head.
1838419|NCT00860145|Procedure|temporal lobectomy|The temporal lobectomy will be performed under general anesthesia. The superior temporal gyrus will be resected to a minimal degree (typically between 1 and 2cm) and the middle and inferior temporal gyri will be resected to approximately 3cm.The minimum amount of lateral temporal cortex required to perform an aggressive resection of medial temporal structures will be performed. The temporal portion of the amygdala and the anterior two to three cm of the hippocampus will be resected. In addition, nearby entorhinal cortex will be removed.
1838420|NCT00860158|Drug|Dasatinib|Dasatinib 100 mg administered once daily per oral route for 28 consecutive days
1838421|NCT00860158|Drug|Leuprolide Acetate (LHRH Analogue)|Leuprolide acetate 7.5 mg administered subcutaneously on day 1 every 28 days (+ 7 days).
1838422|NCT00860158|Procedure|Radical Prostatectomy|Radical prostatectomy should be performed no sooner than 8 hours but preferably within 24 hours of the last administered dasatinib dose.
1959138|NCT00752102|Drug|Calcitriol (Rocaltrol®)|Subjects taking calcitriol will be started at 0.25 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then calcitriol will be increased to 0.5 mcg 3x/week.
1838426|NCT00860197|Dietary Supplement|Fully torrefied coffee|Fully torrefied coffee
1838427|NCT00860197|Dietary Supplement|Partially torrefied coffee|Partially torrefied coffee
1838428|NCT00860210|Device|Neurostep™ System|The Neurostep™ System is a neurostimulation investigational medical device. The entire system is designed to be implanted into the subject's leg via a surgical procedure, during which electrodes are attached to the peripheral nerves responsible for sensing and stimulating the proper muscles that lift the foot during normal walking.
1838429|NCT00860223|Drug|Digoxin|
1838430|NCT00860223|Drug|Neratinib|HKI-272
1838431|NCT00860236|Other|Psycoeducation/counseling|2 days of education on mechanisms of illness and coping strategies
1838432|NCT00860236|Behavioral|Cognitive behavioural therapy|4 days intensive training in understanding and behavioural changes
1838433|NCT00860249|Behavioral|Letter Only|Prior to a scheduled upcoming appointment, participants will get a letter signed by their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening.
1838434|NCT00860249|Behavioral|Letter and Educational DVD|Participants will get a letter from their physician that provides brief information about colorectal cancer (CRC) and notes the importance of CRC screening. It will be accompanied by an educational DVD about the screening. The participants will receive this prior to a scheduled upcoming appointment with their physician.
1838435|NCT00860262|Drug|amlodipine|amlodipine 5mg for the first 2w then force titration to Amlodipine 10mg for remaining 6 w
1838436|NCT00860262|Drug|telmisartan|telmisartan 80mg for the 8w, no titration required
1838437|NCT00860262|Drug|telmisartan and amlodipine|telmisartan 80 and amlodipine 5mg for the first 2 weeks, then force titrated to telmisartan 80mg and amlodipine 10mg for the remaining 6w
1838438|NCT00860275|Drug|BMS-708163|Capsule, Oral, 50 mg, once, Day 1
1838439|NCT00860275|Drug|BMS-708163 + Ketoconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day Day 12 (Ketoconazole) - Tablet, Oral, 400 mg, daily, 1 day
1838440|NCT00860275|Drug|Ketoconazole|Tablet, Oral, 400 mg, daily, 16 days
1838441|NCT00860275|Drug|Fluconazole|Tablet, Oral, 1 day 400 mg then 3 days 200 mg
1838442|NCT00860275|Drug|BMS-708163 + Fluconazole|(BMS-708163) - Capsule, Oral, 50 mg, daily, 1 day (Day 12) (Fluconazole) - Tablet, Oral, 200 mg, daily, 13 days
1838443|NCT00860288|Drug|Vildagliptin|
1838444|NCT00860288|Drug|Metformin|
1838445|NCT00860288|Drug|Placebo|
1838446|NCT00860288|Drug|Sitagliptin|
1838447|NCT00860301|Other|Acupuncture|Infants come to the clinic twice a week for three weeks. Parents meet a nurse and hand the infant to her. The nurse brings the infant to a room where another nurse is alone with the infant for five minutes. Infants in the acupuncture group get acupuncture. One needle is inserted 1-3 mm in the point LI4 on one of the infants hands for one to three seconds and then withdrawn.
1838448|NCT00860314|Procedure|external electrical cardioversion (with antero-posterior electrode position)|external biphasic electrical cardioversion with step-up-protocol of 50-75-100-150-200 Joules if necessary with antero-posterior electrode position until restoration of normal sinus rhythm
1838503|NCT00867308|Drug|Lenalidomide|Lenalidomide 50 mg PO daily on days 1 - 28 out of a 42 day cycle for 4 cycles.
1838504|NCT00867321|Biological|bevacizumab|Given IV
1838449|NCT00860314|Procedure|external electrical cardioversion (with antero-lateral electrode position)|external biphasic electrical cardioversion with step-up protocol of 50-75-100-150-200 Joules if necessary with antero-lateral electrode position until restoration of normal sinus rhythm
1838450|NCT00860340|Drug|Spironolactone|100 mg tablet of Spironolactone (Aldactone) by mouth with half a glass of water.
1838451|NCT00860353|Drug|AZD2551|Single dose of oral solution.
1838452|NCT00860353|Drug|Placebo|Single dose of oral solution
1838453|NCT00860366|Drug|Uric Acid|1 gram dissolved in a vehicle containing 500 ml of 0'1% Lithium Carbonate and 5% Mannitol, IV (in the vein), single dose.
1838454|NCT00860366|Other|Vehicle|Single intravenous infusion of a 500 ml vehicle containing 0'1% Lithium Carbonate and 5% Mannitol.
1838455|NCT00860379|Drug|Selenium1|2 ug/kg
1838456|NCT00860379|Drug|Selenium2|4 ug/kg
1838457|NCT00860379|Drug|Placebo|IV saline as placebo
1838458|NCT00860392|Drug|Stable isotope tracer (13-C(4)-BHB)|A stable isotope tracer (13-C(4)-BHB), a commercially available lipid emulsion, and heparin will be administered intravenously. Ketone body concentrations will be measured before beginning the infusion, at approx. 135 minutes, and at approx. 255 minutes.
1838459|NCT00860405|Drug|HES 130/0.4 (6%) in sodium chloride (Voluven®, solution for infusion), Human serum albumin (HSA 50g/L)|Study medication will be given as part of the priming of the ECC and for plasma volume replacement after start of ECC up to the maximum dosage of 50 mL/kg body weight/day.
1838460|NCT00860405|Drug|Human serum albumin (HSA 50g/L)|Human serum albumin (HSA 50g/L)
1838461|NCT00860418|Behavioral|Pediatric Asthma Alert (PAAL)|Asthma nurse conducts 2 home visits and accompanies the child to primary care provider visit after ED visits
1838462|NCT00860418|Behavioral|Standard asthma education|Standard asthma education during 2 home visits.
1838463|NCT00860431|Drug|AST-120|6g/day (3 times a day)
1838464|NCT00860444|Behavioral|Basic Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting.
1838465|NCT00860444|Behavioral|Comprehensive Educational and Counseling Program|Participants will receive one session of brief patient-centered physician counseling, along with educational handouts and nurse-assisted guidance with goal-setting. They will also receive 12 months of telephone counseling and a monthly newsletter.
1959139|NCT00752102|Drug|Paricalcitol|Subjects taking paricalcitol will be started at 2 mcg 3x/week and titrated up during the next visit according to PTH levels. If at the 12 week visit, PTH is still not at goal, then paricalcitol will be increased to 4 mcg 3x/week.
1838467|NCT00867113|Drug|imatinib mesylate|imatinib mesylate 400 mg once per day by mouth for 5 years.
1838468|NCT00867126|Drug|pioglitazone hydrochloride|
1838469|NCT00867126|Other|laboratory biomarker analysis|
1838470|NCT00867126|Other|questionnaire administration|
1838471|NCT00867126|Procedure|quality-of-life assessment|
1838472|NCT00867139|Drug|TCAD|TCAD (amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
1838473|NCT00867139|Drug|Zanamivir or Oseltamivir|Zanamivir or Oseltamivir
1838474|NCT00867139|Other|Open label treatment with TCAD|TCAD(amantadine hydrocholoride, ribavirin and oseltamivir phosphate)
1838475|NCT00867152|Drug|Darunavir|Darunavir 600 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Darunavir is approved by the FDA as an HIV medication in the protease inhibitor class.
1838476|NCT00867152|Drug|Etravirine|Etravirine 200 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Etravirine is approved by the FDA as an HIV medication in the non-nucleoside reuptake inhibitor class.
1838477|NCT00867152|Drug|Ritonavir|Ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
1838478|NCT00867152|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonavir 100 mg every 12 hours for 14 days in Periods 2 and 3. Period 3 may not be done. Lopinavir/Ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class.
1838479|NCT00867152|Drug|GSK1349572|GSK1349572 50 q24h for 5 days in Period 1 and for 14 days in Period 2. GSK1349572 20 mg q12h for 14 days in Period 3 if Period 3 is done. GSK1349572 is an investigational (not approved by the FDA) HIV medication in the integrase inhibitor class.
1838480|NCT00867165|Drug|ezetimibe|oral tablets: ezetimibe 10 mg once daily for 12 weeks
1838481|NCT00867165|Drug|Placebo|oral tablets: placebo to match ezetimibe 10 mg; administered once daily during the 5-week, single-blind, placebo run-in and diet stabilization period and 12-week double-blind treatment period
1838482|NCT00867178|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo conformal radiation therapy
1838483|NCT00867178|Drug|Carboplatin|Given IV
1838484|NCT00867178|Drug|Cisplatin|Given IV
1838485|NCT00867178|Drug|Cyclophosphamide|Given IV
1838486|NCT00867178|Drug|Etoposide Phosphate|Given IV
1838487|NCT00867178|Drug|Isotretinoin|Given PO
1838488|NCT00867178|Other|Laboratory Biomarker Analysis|Correlative studies
1838489|NCT00867178|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
1838490|NCT00867178|Drug|Thiotepa|Given IV
1838491|NCT00867178|Drug|Vincristine Sulfate|Given IV
1838492|NCT00867178|Drug|Vorinostat|Given PO
1838493|NCT00867191|Drug|Placebo|Placebo, 1 tablet daily, per os., 15 days
1838494|NCT00867191|Drug|Desloratadine|Desloratadine, one 5 mg tablet daily, per os, 15 days
1838495|NCT00867204|Procedure|ERCP|Patients with clinical indication for ERCP were invited to participate in the Study
1838498|NCT00867230|Drug|FTS|Starting dose of 100 mg twice a day by mouth, Days 1 through 21 of a 28-day cycle.
1838499|NCT00867282|Drug|Treatment A|PF-00241939 750ug using inhaler A
1838500|NCT00867282|Drug|Treatment B|PF-00241939 750ug using inhaler B
1838501|NCT00867295|Drug|cefazolin Sodium|cefazolin Sodium 1g i.v. before operation
1838502|NCT00867295|Drug|placebo|placebo
1838505|NCT00867321|Drug|sorafenib tosylate|Given orally
1838508|NCT00867347|Procedure|therapeutic conventional surgery|Patients undergo radical cystectomy
1838509|NCT00867347|Radiation|radiation therapy|Patients undergo radiotherapy
1838510|NCT00867360|Drug|Mifepristone (RU-486)|
1838511|NCT00867360|Drug|Placebo|Placebo medication
1838512|NCT00867373|Behavioral|Education Intervention|The intervention is a short educational handout regarding BMI and the effect of parental weight status on children.
1838513|NCT00867399|Drug|ABT-126|See arm for details
1838514|NCT00867425|Behavioral|Virtual Lifestyle Management|"The VLM online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program (1). VLM will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs.
Participants will be encouraged to complete 16 online, weekly lessons. The VLM curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives. The VLM lifestyle coaching team will review these entries weekly, and provide support, feedback about progress, tips on how to problem-solve around lifestyle barriers, and guidance on how to use the Keeping Track functions of VLM (e.g. keeping track of weight, fat intake, calories or physical activity)."
1838515|NCT00867516|Biological|ALD518|Two doses of ALD518, each given in an infusion of normal saline, IV over 1 hour, at Weeks 1 and 8
1838516|NCT00867516|Biological|Infusion without ALD518`|250 cc Normal saline IV over one hour Weeks 1 and 8.
1838517|NCT00867529|Biological|rituximab|Given IV
1838518|NCT00867529|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
1838519|NCT00867529|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative allogeneic peripheral blood/hematopoietic stem cell transplantation
1838520|NCT00867529|Other|pharmacological study|Correlative studies
1838521|NCT00867529|Other|laboratory biomarker analysis|Correlative studies
1838522|NCT00867542|Other|no intervention|no intervention
1838523|NCT00867555|Dietary Supplement|Effect of the green tea extract TEAVIGO, high in EGCG, on postprandial fat oxidation|green tea extract TEAVIGO, high in EGCG
1838524|NCT00867568|Drug|TPI 287|Three patients will be enrolled to receive single agent TPI 287 IV administered on Days 1, 8 and 15 of the first and second 28-day cycle. The starting dose of 90 mg/m2 (Dose Level 1) is 75% of the established adult MTD for this schedule in adults, which is 125 mg/m2. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
1838525|NCT00867594|Drug|ORMD 0801|1 capsule ORMD 0801 3 times a day, before each meal
1838526|NCT00867607|Drug|MRX-6|b.i.d treatment for 21 days
1838527|NCT00867607|Drug|Steroid|b.i.d. 21 days
1838528|NCT00867659|Drug|Cetrotide acetate|cetrotide acetate is a GnRH antagonist. The dose is 3 mg once on the day of oocyte retrieval.
1838529|NCT00867672|Drug|Decitabine|i.v. Decitabine 20 mg/m² over 1h, 5 days (total dose 100 mg/m²), repeated every 4 weeks
1838530|NCT00867672|Drug|VPA|VPA starting on day 6 of first cycle continuously throughout all treatment cycles
1838531|NCT00867672|Drug|ATRA|ATRA (45 mg/m² p.o.) from day 6 to day 28 of each treatment cycle
1838532|NCT00867685|Drug|AZD2624|Single dose of 40 mg AZD2624 liquid suspension, PO
1838533|NCT00867685|Drug|AZD2624|Single dose of 40 mg AZD 2624 (2x20mg tablets), PO
1838534|NCT00867698|Drug|AST-120|AST-120
1838535|NCT00867724|Device|Aer-O-Scope Colonoscopy|Screening Colonoscopy
1838536|NCT00867737|Drug|Advair HFA MDI 115/21|Two puffs from MDI twice daily for 4 weeks
1838537|NCT00867737|Drug|Symbicort 160/4.5 pMDI|"Symbicort 160/4.5 pMDI
Two puffs from MDI twice daily for 4 weeks"
1838538|NCT00867750|Device|Radioembolisation (SIR-Spheres® microspheres)|Yttrium-90 SIR-Spheres microspheres
1838539|NCT00867750|Drug|Transarterial Chemoembolisation|TACE with embolising agent Embospheres (150-300 μm or 300-500 μm diameter) with 50 mg of chemotherapeutic agent epirubicin admixed with 5 ml lipiodol.
1838540|NCT00867763|Procedure|In vitro maturation and in vitro fertilization|No gonadotropin, eggs harvested early
1838541|NCT00867763|Procedure|Low doses of gonadotropin stimulation.|Gonadotropin followed by conventional IVF
1838542|NCT00867776|Behavioral|AAHC Exercise Program Support Group|6-week community-based, culturally tailored support group program, focusing on exercise and healthy lifestyle habits. Groups will also include basic psychoeducation about depression and depression care. Groups will have up to 20 participants and will meet weekly for 2 hours. By the end of the program, participants will be encouraged to create a personalized action plan focusing on exercise and other healthy lifestyle choices.
1838543|NCT00867789|Drug|Trimethoprim-sulfamethoxazole|10mg/kg/day (based on trimethoprim component), divided twice daily for ten days (maximum dose: 160mg (TMP component) per dose)
1838544|NCT00867789|Drug|Sugar pill|10mg/kg/day divided twice daily for ten days. Placebo liquid will contain simple syrup, lactose powder, grape flavor, and food coloring. Placebo capsules will contain lactose powder.
1838545|NCT00867802|Behavioral|Mindfulness-Based Stress Reduction program|Mindfulness- Based Stress Reduction comprising of 8 classes and a one-day retreat, taught over a period of 6 weeks. Intervention also includes practice at home for 20-30 minutes.
1959147|NCT00739752|Behavioral|Non-Framed-Offered|Subjects received information only and are offered the vaccine.
1959148|NCT00739752|Behavioral|Non-Framed-Recommended|Subjects receive information only and are recommended the vaccine.
1959149|NCT00739752|Behavioral|Gain-Framed-Offered|Subjects receive gain-framed messages and are offered the vaccine.
1959150|NCT00739752|Behavioral|Gain-Framed-Recommended|Subjects receive gain-framed messages and are recommended the vaccine.
1959151|NCT00739752|Behavioral|Loss-Framed-Offered|Subjects receive loss-framed messages and are offered the vaccine.
1959152|NCT00739752|Behavioral|Loss-Framed-Recommended|Subjects receive loss-framed messages and are recommended the vaccine.
1838547|NCT00867828|Dietary Supplement|Neptune Krill Oil|Softgels 1g QD. Each softgel of Neptune Krill Oil will provide approximately 150 mg EPA and 100 mg DHA.
1838548|NCT00867828|Dietary Supplement|Fish Oil|Softgels 1g QD. Each softgel of Fish Oil will provide approximately 150 mg EPA and 100 mg DHA.
1838549|NCT00867828|Dietary Supplement|Placebo (soy oil)|Softgels 1g QD. The soy oil placebo will provide neither EPA nor DHA.
1838550|NCT00867841|Procedure|nasopharyngeal swab|PCR of NP swab for Mycoplasma, Chlamydophila, pneumococcus, pneumococcus macrolide resistance genes.
1838551|NCT00867854|Other|Blood draw|This sub-study does not involve additional treatment of any ATN 061 or ATN 071 study subjects. The only intervention involved is the requirement for whole blood collection (40 ml and 60 ml) to be drawn at the same time as four ATN 061 study visits (36, 48, 56, and 80 weeks) for subjects co-enrolled into ATN 061. When these time points coincide with ATN 061 Central Laboratory samples, the 60 ml blood sample will not be collected. For subjects co-enrolled into ATN 071, there are also two samples of whole blood collection (40 ml and 60 ml) required to be drawn at four time points but at weeks 36, 48, 56, and 80 after the initiation of HAART.
1838552|NCT00867867|Drug|Ferrous fumarate|9.3 mg once per day, 6 days per week, for 9 months
1838553|NCT00867867|Drug|Ferric pyrophosphate|9.3 mg once per day, 6 days per week, for 9 months
1838554|NCT00867867|Drug|Placebo|9.3 mg once per day, 6 days per week, for 9 months
1838555|NCT00867880|Drug|IVIb|800mg IVIb diluted in 200mL NS will be given IV (in the vein) concurrently with an oral placebo on Day 1 and 200ml Normal Saline will be given IV (in the vein)concurrently with 800mg oral ibuprofen on Day 8
1838556|NCT00867906|Biological|Cat-PAD|Cat-PAD dose 1x8 administrations 2 weeks apart
1838557|NCT00867906|Biological|Placebo|Placebo comparator, 1x8 administrations 2 weeks apart
1838558|NCT00867919|Behavioral|Behavioral Family Treatment|"11 to 15 sessions of a cognitive behavioral family therapy that will be developed during the course of this study and will address the following:
parent-adolescent conflict
adolescent development
support and closeness
behavioral activation
response to adolescent negative affect
relapse prevention
suicide prevention, if necessary"
1838559|NCT00867919|Other|Community-based treatment as usual|Treatment as usual, which will most likely consist of 8 to 10 sessions of community-based depression treatment
1838560|NCT00867932|Drug|Eculizumab|
1838561|NCT00867958|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
1838562|NCT00867971|Other|Measuring intraoccular pressure|Measurement of intraoccular pressure by tonometry
1838563|NCT00867984|Other|Torsion optimized|Torsion optimized VV timing plus AV optimization (VTI)
1838564|NCT00867984|Other|Usual Care|AV optimization (VTI) only
1838565|NCT00867997|Other|Chemoactive (remineralizing, neuroactive) dentifrice treatment|Chemoactive (remineralizing, neuroactive) dentifrice treatment
1838566|NCT00867997|Other|Clearfil S3 Bond; Clearfil Liner Bond 2 Protect Liner F|Self-etch DBA followed by a hydrophobic resin layer
1838567|NCT00867997|Other|Clearfil S3 Bond; Premise Flowable resin-based composite|Restoration with a dentin bonding agent (DBA) and flowable resin-based composite
1838568|NCT00868010|Drug|donepezil|5 mg or 10 mg, titrated per drug insert. Participants may remain in the study at 5 mg if unable to tolerate 10 mg.
1838569|NCT00868010|Drug|placebo|Participants will receive a placebo pill for 12 weeks if randomized to this treatment.
1838570|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
1838571|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 400/24 µg)
1838572|NCT00868023|Drug|CHF 1535 Next DPI|CHF 1535 DPI : BDP/Formoterol : 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg)
1838573|NCT00868023|Drug|Foster BDP/Formoterol|BDP/Formoterol 100/6 µg (daily dose : BDP/Formoterol : 100/6 µg
1838574|NCT00868023|Drug|Placebo|Placebo
1838576|NCT00868062|Other|Succinylated gelatine, 40g/L, (Gelofusine - B Braun)|1 litre infusion following induction of anaesthesia
1838577|NCT00868075|Procedure|Chest physiotherapy|Twice daily for 8 weeks
1838578|NCT00868075|Procedure|Chest Physiotherapy + Exercise Program|Twice daily chest physiotherapy and Three times weekly exercise program (two sessions supervised)for 8 weeks
1838579|NCT00868088|Procedure|PDT prior to Mohs surgery|"Day 1: Screening and consent for this study. If eligible, a scouting biopsy will be obtained at 1 cm from the clinical border of the SCC for confirmation of AC.
7-14 Days after consultation: PDT to all subjects in the study. If during treatment a subject requests to discontinue due to pain the treatment will be terminated.
3-5 weeks after consultation: return for assessment. At this visit, the assigned treatment may be repeated if the treatment site is adequately healed. Re-treatment will only occur if there is persistent actinic damage.
6-8 weeks after consultation: Mohs surgery will be performed as per routine. Following tumor removal a scouting biopsy will be taken at a site 1 cm from the wound site created by SCC removal. The current waiting time for non-urgent surgery is 8 weeks. Standard care is not being altered for subjects in the study, other then their receiving the PDT intervention.
Photographs may be taken at each subject visit."
1838580|NCT00868101|Procedure|Remote ischemic preconditioning|Remote ischemic preconditioning was induced by four 5-minutes cycles of lower limb ischemia and reperfusion using a blood pressure cuff
1838581|NCT00868114|Biological|KLH-pulsed autologous dendritic cell vaccine|5 X10e7 KLH-pulsed autologous dendritic cell vaccine once weekly times three weeks
1838582|NCT00868127|Drug|Lapaquistat acetate|"Participants from 01-04-TL-475-008 Monotherapy Study:
Lapaquistat acetate 100 mg, tablets, orally, once daily for up to 48 weeks."
1838627|NCT00868491|Radiation|radiotherapy|Three-dimensional conformal radiotherapy planning and delivery (35x2 Gy/day over 7 weeks - weeks 14 - 20 of the study protocol
1838628|NCT00868491|Drug|cetuximab, cisplatin|"cetuximab 400 mg/m2 I.V. week 13, cetuximab 250 mg/m2 I.V. weeks 14-20
cisplatin 30 mg/m2 I.V. weeks 14-20 (concomitantly with radiothrapy)"
1838583|NCT00868127|Drug|Lapaquistat acetate and additional lipid-lowering therapy|"Participants from 01-04-TL-475-009 Atorvastatin Add-on Study:
Lapaquistat acetate 100 mg, tablets, orally, once daily and current Atorvastatin therapy for up to 4 weeks.
Then, Lapaquistat 100 mg, tablets, orally, once daily and dose adjustment of Atorvastatin OR additional companion lipid-lowering therapy as needed for target LDL-C for up to 42 weeks."
1838586|NCT00868153|Drug|Levonorgestrel IUS (Mirena , BAY86-5028)|One group
1838589|NCT00868179|Drug|Pradax|Pradax (dabigatran etexilate) is a prodrug that when converted to the active from in the liver and plasma it becomes a reversible, competitive direct thrombin inhibitor. Thrombin catalyses the conversion of soluble fibrinogen into soluble fibrin, the final step in the coagulation cascade. Pradax competitively blocks the active site of both free and clot-bound thrombin, preventing the development of a thrombus. they will take 110 mg 1-4 hours post op. and 220mg daily until 10 days post op.
1838590|NCT00868192|Drug|Pemetrexed|
1838591|NCT00868192|Drug|Bevacizumab|
1838592|NCT00868205|Dietary Supplement|Coffee consumption|3 or 5 cups of coffee daily for eight weeks
1838593|NCT00868218|Biological|Influenza vaccine|"Influenza virus strain:
avian influenza Influenza A/Vietnam/1194/2004 NIBRG-14"
1838594|NCT00868231|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 15 days.
1838595|NCT00868231|Drug|Tiotropium 18 μg once-daily|Tiotropium 18 μg once-daily via inhalation by Handihaler® dry powder inhaler: 1 puff in the morning for 15 days.
1838596|NCT00868231|Drug|Placebo|Inhaled placebo: 1 puff in the morning (placebo to tiotropium) or in the morning and evening (placebo to aclidnium) for 15 days.
1838597|NCT00868283|Drug|Cerebrolysin|30 ml study drug will be given once daily by intravenous infusion for 10 consecutive days.
1838598|NCT00868283|Drug|0.9% Saline Solution|30 ml will be given once daily by intravenous infusion for 10 consecutive days.
1838599|NCT00868296|Drug|pantoprazole|
1838600|NCT00868309|Biological|Anavip|Anavip, 10 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 4 vials every 6 hrs
1838601|NCT00868309|Biological|CroFab|CroFab, 5 vials Intravenous (IV) every 2 hours until initial control has been achieved; then 3 maintenance doses of 2 vials every 6 hrs
1838602|NCT00868335|Device|Activ C disc prosthesis|cervical disc prosthesis
1838603|NCT00868335|Procedure|Anterior cervical discectomy|Removal of protruding cervical disc through an anterior approach
1838604|NCT00868348|Drug|Ketorolac|30 mg (1 ml) infiltration combined with Intraarticular bolus injection of 120 mg (4 ml) ketorolac
1838605|NCT00868348|Drug|Saline|1 ml infiltration 4 ml intraarticular bolus injection of placebo
1838606|NCT00868361|Drug|Talampanel (non-radiolabeled), [14C] Talampanel|50 mg capsule single dose
1838607|NCT00868374|Drug|Quetiapine XR|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
1838608|NCT00868374|Drug|Placebo|Days 1-14 - 50 mg/day; Days 14-21 - 100mg/day; Day 21-End of Study - 150mg/day
1838609|NCT00868387|Other|energy-restricted, CHO-restricted diet|carbohydrate content of the diet < 40% Frequency: daily Duration: 12 months
1838610|NCT00868387|Other|energy-restricted, CHO-rich diet|carbohydrate content of diet > 55% Frequency: daily Duration: 12 months
1838611|NCT00868400|Dietary Supplement|commercially available high-carbohydrate beverage|800 ml before the day of surgery, and additional 400 ml two hours prior to surgery
1838612|NCT00868400|Dietary Supplement|flavored water|will be given in doses equal to those of high-carbohydrate beverage
1838613|NCT00868413|Drug|ABT-263|ABT-263 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
1838614|NCT00868413|Drug|FCR|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle; Fludarabine will be given by intravenous infusion for 3 days out of each 28 day cycle; and Cyclophosphamide will be given by intravenous infusion for 3 days out of each 28 day cycle
1838615|NCT00868413|Drug|BR|Rituximab will be given by intravenous infusion for 2 days out of each 28 day cycle and Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle
1838616|NCT00868426|Drug|Budesonide/Formoterol Batch 1|Single, inhaled dose
1838617|NCT00868426|Drug|Budesonide/Formoterol Batch 2|Single, inhaled dose
1838618|NCT00868426|Drug|Budesonide/Formoterol Batch 1 and charcoal|Single, inhaled dose
1838619|NCT00868439|Drug|patiromer|Active investigational drug
1838620|NCT00868439|Drug|placebo|placebo
1838621|NCT00868452|Drug|lurasidone + (lithium or divalproex)|lurasidone 20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7.
1838622|NCT00868452|Drug|Placebo + (lithium or divalproex)|20 mg/day for Days 1-2-3, 40 mg/day for Days 4-5-6, and 60 mg/day on Day 7
1838623|NCT00868465|Drug|Artemether-Lumefantrine|Treatment with artemether-lumefantrine (AL; Coartem; Novartis Pharma), administered as half a tablet (20 mg of artemether and 120 mg of lumefantrine) per 5 kg of body weight in a 6-dose regimen (at enrolment and 8, 20, 32, 44, and 56 h [+/-90 min] after the initiation of treatment). AL is currently the first line treatment in Tanzania
1838624|NCT00868465|Drug|Dihydroartemisinin-piperaquine|Dihydroartemisinin-piperaquine (DP; Artekin; Duocotexin, Holley Pharm, 40 mg dihydroartemisinin/320 mg piperaquine tablets), with a dihydroartemisinin dose of 2.5 mg per kilogram and a piperaquine phosphate dose of 20 mg per kilogram daily for 3 days. DH is registered in Tanzania as Artekin and has been tested extensively in Asia and recently in clinical trials in Uganda and Rwanda
1838625|NCT00868478|Drug|Milatuzumab|Milatuzumab will be given at a starting dose of 120 mg/m2, and then if no response or significant toxicity is seen after a total of 12 weeks, the dose will be gradually increased, by 120 mg/ m2 every four weeks, for a total of another 12 weeks.
1838626|NCT00868491|Drug|docetaxel, cisplatin, 5-fluorouracil|docetaxel 75 mg/m2 I.V. day 1, cisplatin 75 mg/m2 I.V. day 1, 5-fluorouracil 750 mg/m2 I.V. continuous infusion days 1-5 repeated every 21 days for 4 cycles
1959164|NCT00725764|Drug|GSK1363089 (foretinib)|Multitargeted tyrosine kinase inhibitor
1838630|NCT00868517|Other|True group auricular acupuncture|Received true group auricular acupuncture
1838631|NCT00868517|Other|Sham group auricular acupuncture|Received sham auricular acupuncture.
1838632|NCT00868517|Other|Wait-List Control Group|Received conventional care only. Eligible to receive true group auricular acupuncture once study period completed.
1838633|NCT00868530|Biological|Xyntha|Xyntha for on-demand treatment of bleeding episodes were according to investigator prescription during the 6 months observation period. The recovery assessed by determining the Factor VIII (FVIII) concentration (FVIII:C) levels in individual subjects at the initial and final visits. The dose of Xyntha for recovery assessments is: single 50 IU/kg (±5 IU/kg) IV bolus infusion. All Xyntha administrations occurred in the clinic (hospital).
1838634|NCT00868543|Procedure|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 150cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
1838635|NCT00868543|Procedure|laparoscopic gastric Roux-en-Y gastric bypass|The fundus is separated by linear cutter. The intestine is opened approximately 75 cm from the ligament of Treitz and approached to the stomach. The gastrojejunostomy is performed in antecolic position The jejunum has to be in an antimesenteric position. After removing the endocutter, the anastomotic incision is closed with a continuous suture. The distance between the gastrojejunostomy and jejunojejunostomy was measured on the antimesenteric border with the bowel on a stretch. The jejunojejunostomy is performed in 250cm distance from gastrojejunostomy. The anastomosis is made by a posterior staple line and an anterior suture line. Preparation of a small window for the endocutter branches into the jejunal mesenterium 2-3 cm proximal to the gastrojejunostomy and above the entero-intestinal anastomosis.
1838636|NCT00868569|Procedure|TACE + folfox 4|"tace: oxaliplatin 100mg + fudr 1g + mmc 10mg + iodine 2ml
folfox4"
1838637|NCT00868569|Procedure|TAC + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg
folfox4"
1838638|NCT00868582|Other|PET scanning in cancer|Collection of institutional practice PET imaging data
1838639|NCT00868595|Biological|BPX-101|Vaccine
1838640|NCT00868595|Drug|AP1903|Activating agent, infusion
1995599|NCT02714062|Drug|VI-0521 Mid Dose|phentermine 7.5 mg and topiramate 46 mg, po once daily
1838642|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
1838643|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1 Cycles are repeated every three weeks.
1838644|NCT00868634|Drug|capecitabine|1000 mg/m2 twice daily, oral, days 1-14. Cycles are repeated every three weeks.
1838645|NCT00868634|Drug|bevacizumab|15 mg/kg i.v., day 1. Cycles are repeated every three weeks.
1838646|NCT00868634|Drug|vinorelbine|25 mg/m2 i.v., days 1+8. Cycles are repeated every three weeks.
1838647|NCT00868647|Procedure|Radiofrequency ablation (RFA)|Radiofrequency tumor ablation (RFA) is an imaging guided percutaneous or intra-operative procedure that uses a probe on the end of a sharp needle that is inserted directly into the tumor. The tumor is ablated by heating the probe (using electrical current alternating at radio frequency) which raises the temperature of the tumor potentially causing irreversible cell death.
1838648|NCT00868660|Drug|ZP1848|sc. bolus
1838649|NCT00868673|Dietary Supplement|low fructose|"patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done."
1838650|NCT00868673|Dietary Supplement|Normal fructose arm|patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
1838651|NCT00868686|Device|Volar aluminum splint|Alumafoam strip with padding removed, placed on the VOLAR aspect of the digit spanning the middle and distal phalanges only.
1838652|NCT00868686|Device|Dorsal aluminum splint|Alumafoam strip with padding removed, placed on the DORSAL aspect of the digit spanning the middle and distal phalanges only.
1838653|NCT00868686|Device|Custom thermoplastic|Customized thermoplastic splint with circumferential contact proximal to the joint and volar contact distal to the joint. This is a similar design to the original Stack splint, except that it is custom molded.
1838654|NCT00868699|Drug|lurasidone|lurasidone 20 mg/day for Days 1-2, 40 mg/day for Days 3-4, 60 mg/day for Days 5-6 and 80 mg/day on Day 7 and 80-120 mg/day
1838655|NCT00868699|Drug|lurasidone|lurasidone 20 mg/day for Days 1-7
1838656|NCT00868699|Drug|Placebo|Placebo Comparator
1838657|NCT00868725|Other|no intervention, observation only|Oral cavity will be imaged by a thermal camera.
1838658|NCT00868738|Dietary Supplement|Vitamin D|Subjects will be provided supplemental vitamin D3 (1000 IU) or placebo, given once daily (based on the stratification noted above). Vitamin D/placebo will be provided using a softgel or liquid. Subjects will be instructed to take the supplement daily for 8 weeks.
1838785|NCT00869596|Drug|Comparator: Lipopolysaccharide (LPS)|20,000 EU LPS by inhalation 1 hour postdose of fluticasone or placebo in each of three treatment periods
1838912|NCT00863772|Biological|tanezumab|10 mg dose Intravenously every 8 weeks for duration of study
1838659|NCT00868751|Biological|tocilizumab|"Initial therapy: Tocilizumab dosed by body weight (8mg/kg based on body weight ≥ 30kg) given by intravenous infusion every two weeks for 12 weeks.
Extension of therapy: Continuation of treatment with tocilizumab at 8mg/kg by body weight given by intravenous infusion every 2 weeks based upon achievement of Primary Objective by week 12, OR continuation of treatment with escalation of tocilizumab dose to 12mg/kg by body weight, given by intravenous infusion every two weeks, for failure to achieve ACR JIA30 at 12 weeks or ACR JIA50 response at any time after week 16."
1838660|NCT00868764|Drug|granisetron|3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days
1838661|NCT00868777|Procedure|Sinus grafting using allogenic bone|Surgical bone grafting procedure oriented to provide enough bone volume in atrophic posterior maxillary segments, when placement of endosteal implants is planned in order to restore missing teeth.
1838662|NCT00868790|Drug|MK-3577|MK-3577 oral tablets totaling 6 mg in the evening (PM), 10 mg in the morning (AM), or 25 mg twice daily (BID) depending upon randomization, administered during a 4 week treatment period.
1838663|NCT00868790|Drug|Placebo to MK-3577|Dose-matched placebo tablets to MK-3577 administered during a 4 week treatment period
1838664|NCT00868790|Drug|Metformin|Two 500 mg tablets of metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
1838665|NCT00868790|Drug|Placebo to Metformin|Two placebo tablets to metformin were administered twice daily (2000 mg total daily dose) to domiciled participants during a 4 week treatment period.
1838666|NCT00868816|Drug|12 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200 mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 12 cycles
1838667|NCT00868816|Drug|8 cycles of oxaliplatine based adjuvant chemotherapy|oxaliplatine 85 mg/㎡ d1, lv 200mg/㎡ d1, 5-fu 1300 mg/㎡ ivgtt maintain for 48hr, every 3 weeks/cycle, 8 cycles
1838668|NCT00868829|Device|Firebird2|For the patient participated, only Firebird2 Stent will be implanted.
1838669|NCT00868855|Drug|Bradykinin|Bradykinin, 0.2 ug - 2ug/minute, one time intracoronary infusion over 6 minutes. Drug (bradykinin) will be infused into the left main coronary artery via diagnostic catheter (JL4) at an escalating rate of 0.2, 0.6, 2 g/ml (1ml/min). A 5F Multipurpose catheter will be advanced to coronary sinus for blood sampling.
1995600|NCT02714062|Drug|VI-0521 Top Dose|phentermine 15 mg and topiramate 92 mg, po once daily
1838674|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast and taking one Caltrate® 600+D tablet
1838675|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard dinner
1838676|NCT00868907|Drug|35 mg risedronate DR tablet|35 mg risedronate DR oral tablet administered within 5 minutes after completing a standard breakfast
1838677|NCT00868920|Other|patient control of pump|Patient controls sedation pump during colonoscopy.
1838678|NCT00868920|Other|anesthesiologist controlled sedation|Anesthesiologist will control the sedation pump during colonoscopy.
1838679|NCT00868933|Other|Low glycemic index dietary intervention program|The intervention group involves dietary advice and monitoring. No drug or invasive procedure is involved.
1838680|NCT00868933|Other|simple lifestyle advice|The control group receives lifestyle advice from a clinician, and the clinical care is not inferior to current practice.
1838681|NCT00868946|Drug|Virazole (Ribavirin)|"Duration of Subject Participation:7-day course of treatment with follow-up 28 - 60 days after first dose of IV ribavirin Route of Administration and Regimen:The drug is administered IV in a volume of 50-100 mL of normal saline to be infused over 30-40 minutes.
Ribavirin Loading dose, 33 mg/kg (maximum dose: 2.64 g), followed by a dose of 16 mg/kg (maximum dose: 1.28 g) every 6 hours for the first 4 days (15 doses), and 8 mg/kg (maximum dose: 0.64 g) every 8 hours for the subsequent 3 days (9 doses)."
1838682|NCT00868959|Drug|lurasidone|Lurasidone 20-120 mg/d Flexibly Dosed - 24 weeks
1838683|NCT00868972|Procedure|Percutaneous renal stenting intervention|Percutaneous renal stenting intervention
1838684|NCT00868972|Device|Distal embolic protection|Distal embolic protection device (filter wire ex; Cordis Endovascular, USA).
1838685|NCT00868985|Drug|PEG 3350 plus electrolytes|Each patient was treated with PEG 3350 with electrolytes for 10 days at a dose of either one, two or three sachets per day.
1838686|NCT00868985|Drug|PEG 3350 without electrolytes|Each patient was treated with PEG 3350 for 10 days at a dose of either one, two or three sachets per day.
1838687|NCT00868998|Drug|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
1838688|NCT00869011|Other|Endurance exercise|Endurance exercise, 3 times weekly for 35-45 minutes, 12 weeks.
1838689|NCT00869024|Biological|Intramyocardial Delivery of Bone Marrow Derived Mononuclear Cells|Ten separate injections will be delivered into the LV free wall (20 X 106 cells / 400 micro lit).
1838690|NCT00869037|Drug|Periarticular Injection|A 20 ml bolus of saline will be given through the sham femoral nerve block catheter. Periarticular infiltration solution containing 400 mg Ropivicaine, 30 mg Ketorolac, 5 mg Epidural Grade Morphine, and 0.6 ml of 1:1000 Epinephrine will be made up to a volume of 100 ml with saline. Intra-op, 20 ml will be injected into the posterior capsule; 40 ml in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 40 ml in the skin and subcutaneous tissues. The sham catheter will be connected to a saline infusion running at 15 ml/hr until the morning of post-operative day 2.
1838691|NCT00869037|Drug|CFNB + Posterior Capsular Injection|A 20 ml bolus of 0.2% Ropivacaine will be given via a femoral nerve catheter. Periarticular infiltration will be performed intra-op. 20 ml of 1% Ropivacaine in the posterior capsule; 20 ml of normal saline in the quadriceps mechanism, retinacular tissues, medial and lateral collateral ligaments; 20 ml of normal saline for the skin and subcutaneous tissues. Postoperatively, the femoral catheter will be infused with 0.15% Ropivacaine running at 15 ml/hour until the morning of post-operative day 2
1838913|NCT00863772|Other|Placebo|Placebo, Intravenously, every 8 weeks for duration of study
1838692|NCT00869050|Drug|Capecitabine|"Capecitabine 1500 mg/m2/day (PO divided BID) with a maximum daily dose of 2500mg Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles
After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
1838693|NCT00869050|Drug|Temozolomide|"Temozolomide 150-200 mg/m2/day (PO divided BID).
Two week treatment regimen followed by two weeks off treatment, repeated for 12 cycles
After patients have completed 12 cycles with no signs of progression of disease, radiologic evaluation (CT or MRI) will be done after three cycles. This will result in two 28 day cycles and one 35 day cycle."
1838694|NCT00869063|Drug|Diclofenac Sodium Patch|Topical 1% diclofenac sodium patch, applied once daily for 7 days
1838695|NCT00869063|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active drug arm except for diclofenac sodium; applied once daily for 7 days
1838696|NCT00869076|Other|Pharmacist Management|Pharmacist Managed the patient's diabetes in collaboration with their primary care physician
1838697|NCT00869076|Other|Usual care|Patient was managed by their primary care physician as usual
1838698|NCT00869089|Drug|CC-10004|30mg,oral medication, BID, for 24 weeks (60mg total DAILY)
1838699|NCT00869102|Drug|GLP-1|intravenous, 124,5 pmol/kg body weight
1838700|NCT00869115|Drug|Istaroxime|Istaroxime 0.5 μg/kg/min (30 μg/kg/h) continuous i.v. infusion for 24 hours
1838701|NCT00869115|Drug|Istaroxime|Istaroxime 1.0 μg/kg/min (60 μg/kg/h) continuous i.v. infusion for 24 hours
1838702|NCT00869115|Drug|Istaroxime|Istaroxime 1.5 μg/kg/min (90 μg/kg/h) continuous i.v. infusion for 24 hours
1838703|NCT00869115|Drug|Istaroxime|Placebo continuous i.v. infusion for 24 hours
1838704|NCT00869128|Drug|Circadin|2 mg prolonged-release melatonin
1838705|NCT00869128|Drug|Placebo|
1838706|NCT00869141|Drug|glaucoma medications (Timolol, Brimonidine, Dorzolamide, Brinzolamide)|Subjects may receive glaucoma medications after Ahmed valve implantation
1838707|NCT00869154|Behavioral|primary care follow up|Multidisciplinary examination, good advice from rehabilitation specialists and follow up by the family doctor.
1838708|NCT00869154|Behavioral|Multidisciplinary follow up|Multidisciplinary examination and follow up by rehabilitation specialists, a multidisciplinary team following an individual rehabilitation programs.
1838709|NCT00869167|Drug|Ramelteon|melatonin agonist
1838710|NCT00869180|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
1838711|NCT00869180|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
1838712|NCT00869193|Dietary Supplement|Grape seed extract|Subjects will daily consume one capsule with grape seed extract for 8 weeks.
1838713|NCT00869193|Dietary Supplement|Microcrystalline cellulose (placebo)|Subjects will daily consume one capsule with microcrystalline cellulose for 8 weeks.
1838715|NCT00869219|Drug|Nevanac|1 drop of NEVANAC at random eye
1838716|NCT00869219|Drug|Acular LS|One drop of Acular LS
1996373|NCT02492711|Biological|Trastuzumab|8 mg/kg via IV (intravenous) infusion for the first dose and 6 mg/kg for all subsequent doses via IV infusion over 30-90 minutes on day 1 of each 21 day cycle, until progression or unacceptable toxicity develops.
1996374|NCT02492711|Drug|Capecitabine|1000 mg/m2 BID for 14 days in a 21-day cycle
1996375|NCT02492711|Drug|Eribulin|1.4 mg/m2 on days 1 and 8 of a 21-day cycle
1996376|NCT02492711|Drug|Gemcitabine|1000 mg/m2 on days 1 and 8 of a 21-day cycle
1996377|NCT02492711|Drug|Vinorelbine|25-30 mg/m2 on days 1 and 8 of a 21-day cycle
1838725|NCT00869245|Other|OU - Cardiac MRI|During ED evaluation, patients are randomized to cardiac MRI or conventional care testing.
1838726|NCT00869245|Other|OU - Conventional Care Testing|Patients in the conventional testing arm will undergo testing as determined by their treating physician.
1838727|NCT00869258|Drug|Gemcitabine, docetaxel, and capecitabine|Day 1-14: Capecitabine 1500 mg/m2/day (+/- 2days) Day 4 and 11: Gemcitabine 750 mg/m2/day (+/- 2days) Day 4 and 11: Docetaxel 30 mg/m2/day (+/- 2 days) Two week treatment regimen is followed by one week off, repeated for a total of 3 cycles
1838728|NCT00869258|Radiation|Radiation therapy with gemzar|Starting on week 12 +/- 5 days radiation therapy will be given in the standard manner over 5 weeks with daily radiation fractions Monday through Friday. Once a week gemcitabine will be given IV over 30 minutes at 250-300 mg/m2
1838729|NCT00869271|Procedure|tac + folfox4|"tac: oxaliplatin 100mg + fudr 1g + mmc 10mg
folfox4
Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle. After 3 cycles, patients will received transhepatic arterial chemotherapy(TAC) using oxaliplatin, fudr and mmc. Then begin folfox4 again."
1838730|NCT00869271|Procedure|Folfox4|"folfox4
Folfox4 chemotherapy was done within 28 days after primary surgery. Per 3 weeks, patients will receive one cycle"
1838731|NCT00869284|Drug|CEEP regimen|cyclophosphamide 1200 mg/m² intravenously on day 1 (d1), epirubicin 100 mg/m² intravenously on d1, vindesine 3 mg/m² intravenously on d1 and prednisone 80 mg/m² orally or intravenously on d1-5, with two weeks intervals
1838732|NCT00869284|Procedure|Tandem high-dose therapy (HDT) followed by autologous peripheral blood stem cell (PBSC)|"The conditioning regimen of the first HDT was mitoxantrone 45 mg/m² intravenously on d1 + cytarabine 1000 mg/m² by a 3-hour infusion every 12 hours from d1-4.
The conditioning regimen of the second HDT started d30 to d45 after the first stem cell infusion, and consisted of 1200 cGy total body irradiation (TBI) in 6 twice daily 200 cGy fractionated doses with a 800 cGy pulmonary shielding, followed by CBV: carmustine 300 mg/m² intravenously on d4, etoposide 200 mg/m² intravenously on d5-8 and cyclophosphamide 1500 mg/m² intravenously on d5-8."
1838733|NCT00869297|Other|Goal Directed Fluid Administration|Intravenous Fluid will be given if SVV exceeds 13%
1838734|NCT00869297|Other|Control|Fluids titrated at discretion of anesthesiologist.
1838735|NCT00869310|Drug|aprepitant + dexamethasone|Dexamethasone 8 mg orally: 24 hours after chemotherapy (day 2) and then at 8 am on days 3-4 plus Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3.
1838786|NCT00869596|Drug|Comparator: albuterol|Albuterol two 100 mcg inhalations by metered dose inhaler prior to sputum induction at screening, twice during each of the three treatment periods, and at the post-study follow up visit.
1838736|NCT00869310|Drug|metoclopramide + dexamethasone|dexamethasone 8 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on days 3-4 plus Metoclopramide 20 mg orally 4 times a day: 24 hours after chemotherapy and then at 4 pm, 7 pm, 10 pm on day 2 then at 7 am, 12 am, 5 pm, 10 pm on days 3-4.
1838737|NCT00869323|Biological|rituximab|375 mg/m^2 intravenously on Days 1,8, 15 and 22
1838738|NCT00869323|Drug|bortezomib|1.3 mg/m^2 intravenous bolus days 1, 8, 15 and 22
1838739|NCT00869336|Drug|Luliconazole Cream 1% - 2 wks|Topical cream applied daily for 2 weeks
1838740|NCT00869336|Drug|Placebo Comparator -2 wks|Placebo cream applied daily for 2 weeks
1838741|NCT00869336|Drug|Luliconazole Cream 1% - 4 wks|Topical cream applied daily for 4 weeks
1838742|NCT00869336|Drug|Placebo Comparator - 4 wks|Placebo cream applied daily for 4 weeks
1838743|NCT00869349|Behavioral|IFS|"The program will begin with a half day orientation to meet the trained professional coaches and other patients enrolled in the program. Following the orientation there will be group meetings of 8-10 RA patients every other week for twelve weeks with one of the trained coaches. In the weeks patients do not meet with the group, patients will have individual coaching sessions. The group meetings will last approximately 90 minutes and the individual meetings will last 50 minutes. A maintenance program will follow with bimonthly coaching sessions and a group meeting once a month over the next six months.
Three, six and nine months after the beginning of the program, patients will return to the hospital to complete the same research questionnaire and physical examination they received at baseline."
1838744|NCT00869349|Other|Education|The intervention for the controls includes an initial meeting with a health professional. Once a month for 9 months, patients will received educational material and a follow-up phone call to ask if the patient received the information and to answer any questions about the material.
1838745|NCT00869362|Other|Diabetes management team|MD evaluation followed by NP education and and medication titration
1838746|NCT00869375|Device|Endovascular peripheral intervention|Clearway Balloon: percutaneous transluminal angioplasty with simultaneous in situ thrombolysis using the Clearway balloon AngioJet Rheolytic Thrombectomy System: percutaneous transluminal angioplasty with simultaneous mechanical thrombectomy using the Angiojet
1838747|NCT00869388|Biological|rBBX-01|
1838748|NCT00869401|Drug|dasatinib|Given orally
1838749|NCT00869401|Drug|temozolomide|Given orally
1838750|NCT00869401|Other|placebo|Given orally
1838751|NCT00869401|Radiation|radiation therapy|Radiation therapy is performed as 30 fractions of 200 cGy for a total of 6000 cGy.
1838752|NCT00869414|Drug|Evening only administration of insulin glargine|Evening only administration of insulin glargine, with normal saline injection administered in the morning.
1838753|NCT00869414|Drug|Morning only administration of insulin glargine|Morning only administration of insulin glargine, with normal saline injection administered at night.
1838754|NCT00869414|Drug|split dose insulin glargine|split dose of insulin glargine, half administered in the morning, half administered in evening
1838755|NCT00869427|Drug|vitamin C|vitamin C 1g bid for 1 year
1838756|NCT00869440|Drug|CNS 7056|Administered as a single intravenous injection by a syringe driver over 1 minute
1838757|NCT00869440|Drug|Midazolam|Administered as a single intravenous injection by a syringe driver over 1 minute
1838758|NCT00869453|Other|test meal|Mixed meal containing bread, butter, beef
1838759|NCT00869453|Other|glucose|administration of a glucose meal
1838760|NCT00869453|Other|fat|administration of a lipid meal
1838761|NCT00869453|Other|protein|administration of a protein meal
1838762|NCT00869453|Other|control|no meal
1838763|NCT00869466|Behavioral|behavioral dietary intervention|
1838764|NCT00869466|Behavioral|exercise intervention|
1838765|NCT00869466|Other|counseling intervention|
1838766|NCT00869466|Other|educational intervention|
1838767|NCT00869466|Other|laboratory biomarker analysis|
1838768|NCT00869466|Other|questionnaire administration|
1838769|NCT00869466|Procedure|quality-of-life assessment|
1838770|NCT00869466|Procedure|support group therapy|
1838771|NCT00869492|Drug|benzoyl peroxide|benzoyl peroxide %5 solution once dailly
1838772|NCT00869492|Drug|nadifloxacine|Nadifloxacine 1% cream twice dailly
1838773|NCT00869518|Drug|rifabutin plus trimethoprim sulfamethoxazole|rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
1838774|NCT00869518|Drug|placebo plus trimethoprim-sulfamethoxazole|placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days
1838775|NCT00869531|Other|wholegrain|wholegrain wheat vs. refined wheat products
1838776|NCT00869531|Other|refined wheat|refined wheat products
1838777|NCT00869557|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR once daily (QD) + placebo to match Atripla once daily prior to bedtime (QHS)
1838778|NCT00869557|Drug|Atripla|Atripla (EFV 150 mg/FTC 200mg/TDF 300 mg) STR QHS + placebo to match Stribild QD
1838779|NCT00869570|Drug|capecitabine|Phase II: 2 x 825 mg/m2 per day (during 5 weeks)
1838780|NCT00869570|Drug|sorafenib tosylate|Phase II: 1 x 400 mg per day (during 5 weeks)
1838781|NCT00869570|Radiation|radiation therapy|Phase II: 1.8 Gy per day in 25 fractions (during 5 weeks)
1838782|NCT00869583|Behavioral|Physical Activity Program|Participants will receive counseling from a community health educator that will focus on the importance of increasing physical activity. Participants will be encouraged to engage in moderate physical activity (3.0 to 6.0 metabolic equivalents [METS]) for 30 minutes on 5 or more days per week. Participants will be encouraged to start their physical activity program slowly and to gradually increase both frequency and intensity to meet the study goal (e.g., beginning with three sessions per week for 15 minutes and building up to five sessions per week for 30 minutes by Week 12). They will receive educational materials and telephone calls or visits from health educators on a monthly basis for 6 months.
1838783|NCT00869596|Drug|fluticasone propionate|Single dose of fluticasone 440 mcg (2 x 220 mcg) or 1980 mcg (9 x 220 mcg) by metered dose inhaler in two of three treatment periods
1838784|NCT00869596|Drug|Comparator: Placebo to fluticasone|Single dose of placebo to fluticasone (9 x 0 mcg) by metered dose inhaler in one of three treatment periods
1839543|NCT00875836|Drug|Placebo|Flexible dose, up to 60 mg daily
1838787|NCT00869609|Behavioral|GLB Traditional Maintenance (TM)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. Participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
1838788|NCT00869609|Behavioral|GLB-Carb-focused Maintenance (CF)|After completion of the GLB 12 core sessions, participants will be randomly assigned to either Group Lifestyle Balance (GLB) program traditional maintenance or GLB Carb-focused maintenance. GLB-CF participants will attend monthly maintenance sessions to assist them in maintaining the healthy lifestyle they have adopted during the 12 Core sessions. In addition, they will receive information on healthy carbohydrate intake and hunger management.
1838789|NCT00869622|Drug|Risedronate|35 mgs/week + calcium and vit d
1838790|NCT00869622|Drug|Placebo + Calcium and Vitamin D|sugar pill + calcium 1200mgs/day and vitamin d at least 800IU
1838791|NCT00869635|Drug|S-1 Chemotherapy|S-1 chemotherapy before intolerable complication or definite tumor progression Based on the body surface area, <1.25m2: 80mg/day, 1.25~1.5m2: 100mg/day, ≧1.5m2: 120mg/day Given orally twice daily for 14days, followed by 7 days without treatment
1838792|NCT00869635|Procedure|Photodynamic therapy|PDT with Photofrin® 2mg/kg i.v. 48hrs before laser activation
1838793|NCT00869635|Procedure|Systemic chemotherapy except S-1|Variable systemic chemotherapy except S-1
1838794|NCT00869648|Procedure|Extension|After anaesthesia induction the head is placed in extension
1838795|NCT00869648|Procedure|Neutral head position|After anaesthesia induction the head is placed in neutral position
1838796|NCT00869648|Procedure|Anaesthesiologist's position|after anaesthesia induction the head is placed in a position deemed optimal by the anaesthesiologist
1838797|NCT00869661|Drug|Copegus|1000/1200mg po daily for 24 or 48 weeks
1838798|NCT00869661|Drug|Copegus|1000/1200mg po daily for 48 weeks
1838799|NCT00869661|Drug|Pegasys|180 micrograms sc weekly for 24 or 48 weeks
1838800|NCT00869661|Drug|Pegasys|180 micrograms sc weekly for 48 weeks
1838801|NCT00869661|Drug|RO5024048|1000mg bid for 24 weeks
1838802|NCT00869661|Drug|RO5024048|500mg bid for 12 weeks
1838803|NCT00869661|Drug|RO5024048|1000mg bid for 8 weeks
1838804|NCT00869661|Drug|RO5024048|1000mg bid for 12 weeks
1838805|NCT00869674|Procedure|GeneSearch™ Breast Lymph Node (BLN) Assay|"Each of the sentinal lymph node will be divided in half according to cutting scheme.
Half of the sentinal lymph node will be tested using rountine pathological method as normal practice, half of the node will have GeneSearch BLN testing."
1838806|NCT00869687|Device|Poly-L-Lactic Acid Injection|0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
1838807|NCT00869700|Drug|Artemether/Lumefantrine|"80mg artemether/480mg lumefantrine
Trade name: Coartem
Indication: for management of non-severe malaria"
1959167|NCT00715520|Other|Transcranial Magnetic Stimulation (TMS)|Each TMS training session will begin with a baseline measurement lasting about 30 minutes in which brief magnetic pulses will be generated by the single—pulse and paired pulse TMS stimulator and the responses are recorded with surface EMG electrodes. Participants will be instructed to move their wrist for up to ½ hour. After these measures, rTMS will be applied to the scalp during training. Stimulation will occur at a low rate of different frequencies and different times with respect to the training movement depending on the experimental condition. In the last phase of the session post—training measurements will be done using single TMS pulses. TMS pulses and intensity with be given in random order.
1838809|NCT00869726|Drug|dirucotide|500mg, intravenous, dosed once every six months for 18 months
1838810|NCT00869726|Drug|Placebo|intravenous, once every six months for 18 months
1838811|NCT00869739|Behavioral|telephone-based intervention|
1838812|NCT00869739|Other|educational intervention|
1838813|NCT00869739|Other|partner-assisted coping skills training|
1838814|NCT00869739|Other|questionnaire administration|
1838815|NCT00869739|Procedure|psychosocial assessment and care|
1838816|NCT00869739|Procedure|quality-of-life assessment|
1838817|NCT00869752|Biological|anti-IGF-1R recombinant monoclonal antibody MK-0646|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
1838818|NCT00869752|Drug|cisplatin|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
1838819|NCT00869752|Drug|etoposide|MK-0646 should be given 1st followed within 30-60 minutes by cisplatin and then etoposide for cycles which include both MK-0646 and chemotherapy. Cycles are 21 days
1838820|NCT00869765|Drug|D-Cycloserine|100 mg D-cycloserine once every weekday taken 2 hours before tDCS session.
1838821|NCT00869765|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm, 35 cm2) covered by sponges soaked in saline will be used, held in place by a head band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
1838822|NCT00869778|Biological|εPA-44|subcutaneously injection of εPA-44 at week 0, 4, 8, 12, 20, 28.
1838823|NCT00869778|Other|Placebo|subcutaneously injection of Placebo at week 0, 4, 8, 12, 20, 28.
1838824|NCT00869791|Drug|IPX066|experimental drug product: extended-release carbidopa-levodopa capsules
1838825|NCT00869791|Drug|IR CD-LD|active comparator: immediate-release carbidopa-levodopa capsules
1838826|NCT00869804|Behavioral|Aerobic/ Resistance Exercise Intervention|The intervention will consist of a tailored home-based program of both aerobic (walking, using pedometer) and strength training exercises for upper and lower extremities using resistance power bands.
1838827|NCT00869804|Behavioral|Attention control|
1838828|NCT00869830|Other|biofeedback therapy|biofeedback therapy was applied using the surface electromyography (EMG) method with a perianal sensor (Perry, Elan, SRS Medical Systems, Redmond, WA, USA) and biofeedback PC equipment (Orion, Platinum, SRS Medical Systems, Inc., Redmond, WA, USA).
1838829|NCT00869843|Procedure|RF Ablation|
1838911|NCT00863772|Biological|tanezumab|5 mg dose Intravenously every 8 weeks for duration of study
1838830|NCT00869856|Drug|HX575 solution for s.c. administration|Containing different strengths of epoetin alfa (1 to 10 KIU), s.c. injection, 1x per week (qw) or 1x every two weeks (q2w), injection into abdomen or upper thigh
1838831|NCT00869869|Drug|melatonin|2.5 mg melatonin, by mouth, 1 per day, for 3-4 weeks
1838832|NCT00869869|Drug|placebo|placebo
1838833|NCT00869882|Procedure|Circumferential arthrodesis|"Patients are carefully positioned in the proned position and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs which can be performed at surgeon's demand during the whole surgery time.
The preceding procedure is performed. In case of foraminal stenosis, decompression is performed at the same time as discal approach via the narrowest foramen.
In addition to this, before preparation of bed for bone grafting, nerve roots are retracted and the disc nucleus is removed entirely, then endplate decortication is performed. The disc space is distracted. The most anterior part of the disc space is packed with cancellous bone. A cage packed with bone is inserted into the anterior portion of the interspace. According to cage location, bone graft could be inserted in the posterior portion of the interspace. Cage placement is radiologically checked.
The end of the procedure is the same as for GPLI."
1838834|NCT00869882|Procedure|Posterolateral fusion with instrumentation|"Patients are carefully positioned in pronation and submitted to a posterior surgical approach under general anaesthesia. Surgical levels are viewed laterally by mean of intraoperative radiographs performed at surgeon's demand during the whole surgery time.
Pedicle screw instrumentation is performed, followed by posterior neural decompression depending on the type of stenosis:
Central stenosis: decompression is performed including medial facectomy, laminectomy;
Foraminal stenosis: foraminotomy is performed, while preserving a graft bed as large as possible;
Pure foraminal stenosis: spinal duct is not opened. Local bone is harvested from the lamina and the spinous process and carefully fragmented for autologous graft.
Subperiosteal dissection is performed between the transverse processes and lateral aspects of the facet joints.
Two rods are placed and locked on screws in maximum compression to optimize segmental lordosis.
Bone autograft is placed into this bed."
1838835|NCT00869895|Drug|E7050|Oral dosing starting at 100 mg once daily. After the MTD of once daily dosing has been determined, subsequent cohorts will be treated with a divided dosing schedule either twice or three times daily. The starting dose for this schedule will be an appropriate level below the MTD for once daily dosing.
1838836|NCT00869908|Drug|insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1838837|NCT00869908|Drug|insulin detemir|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1838838|NCT00869908|Drug|biphasic insulin aspart|Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1838839|NCT00869934|Other|Cognitive-Behavior Therapy|Sleep restriction, stimulus control, cognitive therapy
1838840|NCT00869934|Other|Behavior Therapy|Sleep restriction and stimulus control
1838841|NCT00869934|Other|Cognitive Therapy|Cognitive restructuring therapy
1838842|NCT00869947|Device|Powered ankle-foot prosthesis|The powered ankle-foot prosthesis is comprised of a series-elastic actuator (SEA) and an elastic leaf spring. This technology has been previously developed for robotic and human rehabilitation applications. The SEA allows for precise force control of the ankle joint, thus mimicking the spring-like behavior of the human ankle, as well as providing adequate energy for forward progression of the body. From the early stance period to the mid-stance period of walking, the SEA will be controlled so that the ankle joint behaves like a spring. During the late stance period, the SEA will be employed to power the forward movement of the body. The elastic leaf spring will provide shock absorption during foot strike, energy storage during early stance, and energy return during late stance.
1838843|NCT00869947|Other|No device|
1838844|NCT00869960|Drug|tenofovir|tenofovir 300 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle)
1838845|NCT00869960|Drug|emtricitabine|emtricitabine 200 mg on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
1838846|NCT00869960|Drug|atazanavir|atazanavir 300mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
1838847|NCT00869960|Drug|ritonavir|ritonavir 100 mg one dose on 2 separate visits: within 5 days after Day 1 of Follicular phase and then within a 4 day window of the leutal phase (day 14 of the menstrual cycle).
1838848|NCT00869973|Drug|Aprepitant|Aprepitant 80 mg orally: 24 hours after chemotherapy on day 2 and then at 8 am on day 3
1838849|NCT00869973|Drug|dexamethasone|dexamethasone 4 mg orally: 24 hours after chemotherapy and at 8 pm on day 2, then at 8 am and 8 pm on day 3
1838850|NCT00869986|Drug|dirucotide|500mg, intravenous, every 6 months for 15 months
1838851|NCT00869986|Drug|placebo|intravenous, once every six months for 15 months
1838852|NCT00863317|Drug|montelukast sodium|4mg granules daily for 14 days
1838853|NCT00863317|Other|sucrose|table sugar as placebo daily for 14 days
1838854|NCT00863330|Biological|Tumor Infiltrating Lymphocytes (TIL)|Tumor harvest process tumor infiltrating lymphocytes. Non myeloblative chemotherapy consisting of cyclophosphamide and fludarabine. Infusion of TIL cells followed by high dose IL-2.
1838855|NCT00863343|Biological|Public Health Notification|For any H5 positive results, notification of the result to the site's local public health authorities.
1838856|NCT00863356|Device|2009-I-Epistaxis-1|Trial of a Novel Chitosan Hemostatic Sealant in the Management of Complicated Epistaxis, 48 hour removal, 1 week follow-up.
1838857|NCT00863369|Biological|rituximab|Given IV
1838858|NCT00863369|Drug|bortezomib|Given IV
1838859|NCT00863369|Drug|gemcitabine hydrochloride|Given IV
1838860|NCT00863369|Other|questionnaire administration|Ancillary studies
1838861|NCT00863382|Device|Standard Event Monitor|Standard Event Monitor
1838862|NCT00863382|Device|Sleuth Monitor|Implantable Sleuth Recorder
1838863|NCT00863395|Procedure|skin biopsy|Lidocaine 1% c Epinephrine for local anesthesia
1838864|NCT00863434|Drug|clofarabine|Given IV
1838865|NCT00863434|Drug|cytarabine|Given IV
1838866|NCT00863434|Biological|filgrastim|Given SC
1838867|NCT00863460|Radiation|cranial radiotherapy|40 Gy
1838868|NCT00863460|Drug|intensive chemotherapy and hematopoietic stem cell rescue|intensive chemotherapy and hematopoietic stem cell rescue
1838869|NCT00863460|Drug|MTX based chemotherapy|R-MBVP 2 cycles day1 and day28 followed by R-Aracytine 2 cycles days58&59 and days79&80
1838870|NCT00863473|Procedure|Surgical treatment with LCP|
1838871|NCT00863499|Drug|Short Acting Methylphenidate|Dosage: 5 mg twice daily (before breakfast and lunch) with gradual increments of 5 to 10 mg weekly. Daily dosage above 60 mg is not recommended.
1838872|NCT00863499|Drug|Long Acting Methylphenidate|Dosage: 9 to 20 mg once daily in the morning (with or without food) with gradual increments of 9 to 20 mg weekly. Daily dosage above 60 mg is not recommended.
1838873|NCT00863512|Drug|cisplatin|Given IV
1838874|NCT00863512|Drug|docetaxel|Given IV
1838875|NCT00863512|Drug|gemcitabine hydrochloride|Given IV
1838876|NCT00863512|Drug|pemetrexed disodium|Given IV
1838877|NCT00863512|Drug|vinorelbine tartrate|Given IV
1838878|NCT00863512|Procedure|standard follow-up care|Standard care
1838879|NCT00863525|Drug|odanacatib|A single oral dose of 100 mg odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
1838880|NCT00863525|Drug|Comparator: Placebo|A single oral dose of Placebo to odanacatib administered with a light meal in one treatment period and without a meal in the other treatment period. There will be 10 days between treatment periods.
1838881|NCT00863538|Drug|KPS-0373|
1838882|NCT00863551|Drug|Trospium Chloride|Extended release, 60 mg, oral daily
1838883|NCT00863564|Dietary Supplement|Caseine|
1838884|NCT00863564|Dietary Supplement|Cod|
1838885|NCT00863564|Dietary Supplement|Gluten|
1838886|NCT00863564|Dietary Supplement|Whey Isolate|
1838887|NCT00863577|Drug|Oral bemiparin|Bemiparin tablets and bemiparin tablets into hard gelatine capsules
1838888|NCT00863590|Drug|odanacatib|[Intervention Name: odanacatib (Panel A)] Panel A: Odanacatib tablets will be administered to male subjects in rising single doses of 2, 10, 50, 200, or 400 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
1838889|NCT00863590|Drug|Comparator: odanacatib (Panel B)|Panel B: Odanacatib tablets will be administered to male subjects in rising single doses of 5, 25 (fasting), 100, 25 (fed), or 600 mg over 5 treatment periods. Each subject will receive placebo to odanacatib in one or two of the 5 treatment periods. There will be at least 7 days between each treatment period.
1838890|NCT00863590|Drug|Comparator: odanacatib (Panel C)|Panel C: Odanacatib tablets will be administered to female subjects in rising single doses of 50 or 100 mg over 2 treatment periods. Half of the subjects will receive placebo to odanacatib in one of the 2 treatment periods. There will be at least 7 days between each treatment period.
1838891|NCT00863590|Drug|Comparator: odanacatib (Panel D)|Panel D: Odanacatib tablets or placebo to odancatib will be administered to male subjects in rising single doses of 100, 200, or 300 mg following a high-fat breakfast over 3 treatment periods. Three of twelve subjects will receive placebo to odanacatib in all 3 treatment periods. There will be at least 10 days between each treatment period.
1838892|NCT00863603|Other|oxygen|5 Liter/minute by nasal cannula for 6 wks
1838893|NCT00863616|Device|HFCWO - SmartVest|SmartVest with vest administered for 20min at 11-13Hz
1838894|NCT00863629|Drug|Insulin|In the CGC group, continuous insulin infusion was started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion was tapered slowed down and eventually stopped. In the IGC group, insulin infusion was started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. After the start of insulin infusion protocol a glycemic control was provided every hour in order to obtain three consecutive values that were within the goal range. Plasma glucose levels were checked every two hours in both CGC and IGT patients throughout the study period. The infusion lasted until stable glycemic goal (ICG group: 80-140 mg/dl; CGC group: 180-200 mg/dl) at least for 24 h. Subcutaneous insulin was initiated at the cessation of the infusion. Insulin was given as short-acting insulin before meals and intermediate long-acting insulin in the evening, in both group.
1838895|NCT00863642|Procedure|Laparoscopic cholecystectomy within 48 hours of admission|Patients are taken to the operating room for laparoscopic cholecystectomy within 48 hours of admission
1838896|NCT00863642|Procedure|Laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values|Patients are taken to the operating room for laparoscopic cholecystectomy after resolution of abdominal pain and laboratory values
1838897|NCT00863655|Drug|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
1838898|NCT00863655|Drug|Exemestane|Exemestane 25 mg orally daily.
1838899|NCT00863655|Drug|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) were administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
1838900|NCT00863668|Drug|Efavirenz + Tenofovir DF/Emtricitabine|600mg QD for 52 weeks + 300mg/200mg QD for 52 weeks
1838901|NCT00863668|Drug|Raltegravir + Tenofovir DF/Emtricitabine|400mg BID for 52 weeks + 300mg/200mg QD for 52 weeks
1838902|NCT00863668|Procedure|Colonoscopy with biopsies|Day 0, Day 2, Day 7, Day 14, Week 52
1838903|NCT00863668|Procedure|Inguinal Lymph Node Excision|Day 0, Day 2, Day 7, Day 14, Week 52
1838905|NCT00863707|Drug|Regadenoson|IV
1838906|NCT00863707|Drug|Placebo|IV
1838907|NCT00863733|Drug|DMXAA|Administered as a 20 minute IV infusion, once every three weeks at doses ranging from 6 mg/m2 to 4900 mg/m2
1838908|NCT00863746|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
1838909|NCT00863746|Drug|Placebo|Placebo - 2 tablets twice daily (BID)
1838910|NCT00863759|Procedure|implantation of intraocular lens (IOL)|"implantation of intraocular lens during cataract surgery.
Arm 1: implantation of aspheric IOL Akreos AO in right eye and an spheric IOL Akreos Fit in left eye.
Arm 2: implantation of aspheric IOL Akreos AO in left eye and an spheric IOL Akreos Fit in right eye."
1838914|NCT00863785|Drug|Corticoids plus N Acetyl Cysteine|40 mg/d prednisolone N Acetyl Cysteine infusion 150mg/kg in 30 minutes then 50 mg/kg in 4 h then 100mg/kg in 16 h and finally 100mg/d2 to d5
1838915|NCT00863798|Drug|Desvenlafaxine Succinate Sustained-Release 10mg|10 mg tablet, once daily dosing for 8 weeks
1838916|NCT00863798|Drug|Desvenlafaxine Succinate Sustained-Release 50 mg|50 mg tablet, once daily dosing for 8 weeks
1838917|NCT00863798|Drug|placebo|Matching placebo tablets (10 or 50mg). Daily dosing for 10 +/- 4 days during a placebo lead-in period, and then 8 weeks during the double-blind period.
1838918|NCT00863837|Drug|terlipressin (vasoconstrictor)|Ligation plus terlipressin 1mg q6h
1838919|NCT00863837|Drug|pantoloc (proton pump inhibitor)|Pantoloc infusion (1 vial q.d.); Using pantoloc to reduce rebleed after EVL
1838920|NCT00863850|Drug|bendamustine|Bendamustine 120 mg/m2 on Days 1 and 2 every 28 days (one cycle) for up to 6 cycles. Radiolabeled [14C] bendamustine will be given on day 1 of cycle 1 only.
1838921|NCT00863863|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under non-fasting conditions
1838922|NCT00863863|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under non-fasting conditions
1838923|NCT00863889|Drug|Depomedrol injection|1 cc of Depomedrol 80
1838924|NCT00863889|Drug|Lidocaine, Marcaine|4 cc of each local anesthetic
1838925|NCT00863902|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
1838926|NCT00863902|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fed conditions
1838927|NCT00863915|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products sprinkled on one tablespoonful of applesauce
1838928|NCT00863915|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products sprinkled on one tablespoonful of applesauce
1996378|NCT02491164|Other|BAC TWO|BAC TWO administration
1838930|NCT00863941|Drug|Abrika Bupropion 150 mg XL Tablet, single dose|A: Experimental Subjects received Abrika formulated products under fasting conditions
1838931|NCT00863941|Drug|Wellbutrin XL® 150 mg Tablet, single dose|B: Active comparator Subjects received GlaxoSmithKline formulated products under fasting conditions
1838932|NCT00863954|Device|Resonator Device|comparison of different parameter settings of electromagnetic fields using the Resonator Device
1838933|NCT00863980|Drug|Micardis (Telmisartan)|40-80 mg/day oral administration
1838934|NCT00863980|Drug|Blopress (Candesartan)|8-12 mg/day oral administration
1838935|NCT00864006|Drug|Divalproex Sodium|
1838936|NCT00864006|Drug|Depakote DR Tablets|
1838937|NCT00864019|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under non-fasting conditions
1838938|NCT00864019|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under non-fasting conditions
1838939|NCT00864032|Drug|Sorafenib|400mg twice daily
1838940|NCT00864045|Drug|Sertindole|Sertindole flexible doses per os, 12, 16 or 20mg/day according to response and tolerability, initially up-titrated from 4mg/day to target dose 16mg/day within the first 16 days
1838941|NCT00864045|Drug|Olanzapine|Olanzapine flexible doses per os, 10, 15 or 20mg/day according to response and tolerability, initially up-titrated from 10mg/day to target dose 15mg/day within the first 16 days
1838942|NCT00864058|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Actavis formulated products under fasting conditions
1838943|NCT00864058|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
1838944|NCT00864071|Drug|Griseofulvin 125 mg/5 mL Suspension, single dose|A: Experimental Subjects received Alpharma formulated products under fasting conditions
1838945|NCT00864071|Drug|Grifulvin V® 125 mg/5 mL Suspension, single dose|B: Active comparator Subjects received Ortho Neutrogena formulated products under fasting conditions
1838946|NCT00864084|Other|Pulmonary rehabilitation|Pulmonary rehabilitation involves the prescription of customized exercise programs and education on disease management.
1838947|NCT00864097|Biological|tanezumab|IV tanezumab 10 mg every 8 weeks (through Week 16)
1838948|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
1838949|NCT00864097|Biological|tanezumab|IV tanezumab 5 mg every 8 weeks (through Week 16)
1838950|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
1838951|NCT00864097|Biological|tanezumab|IV tanezumab 2.5 mg every 8 weeks (through Week 16)
1838952|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
1838953|NCT00864097|Drug|diclofenac|Oral diclofenac SR 75 mg BID for 32 weeks
1838954|NCT00864097|Other|IV placebo|IV placebo to match tanezumab every 8 weeks (through Week 16)
1838955|NCT00864110|Radiation|Radiolabeled (99Tc) EC-DG (ethylenedicysteine-deoxyglucose)|one injection of Technetium ethylenedicysteine-deoxyglucose to yield a target activity of 20 mCi (range 20-30 mCi) to be given by slow IV push (over 3-5 minutes) 1mg of EC-DG will be injected
1838956|NCT00864110|Radiation|Technetium 99m ethylenedicysteine-deoxyglucose|99mTc EC-DG injection, single dose, slow IV push over 3-5 minutes, yielding a target activity of 20 mCi (range 20-30 mCi)
1838957|NCT00864110|Radiation|18 F fluorodeoxyglucose|single injection of 18F FDG (range 10-20 mCi)
1838958|NCT00864123|Behavioral|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks that is based on the protocol used in POTS (2004). Sessions 1-4 will be held twice weekly; thereafter sessions will be held on a weekly basis. This evidence-based E/RP intervention (POTS, 2004) includes psychoeducation, cognitive training, and exposure and response prevention. By design, this manual provides sufficient flexibility to accommodate the child's developmental needs and address maladaptive parent-child interactions (e.g., accommodation).
1839038|NCT00870038|Device|Percutaneous coronary intervention: Uncoated balloon + Genous stent|Predilatation with uncoated balloon, the stenting with Genous stent.
1839039|NCT00870038|Device|Percutaneous coronary intervention: Drug eluting stent (Taxus stent)|Predilatation with uncoated balloon, the placement of a Taxus stent.
1838959|NCT00864123|Drug|D-cycloserine|D-cycloserine (Seromycin, 250 mg; Eli Lilly and Co, Indianapolis, Indiana) will be capsulated into 25mg with identical placebo capsules. Children weighing between 25-45kg will be given a dosage of 25mg (approximately 0.56-1.0 mg/kg/day). Children weighing between 46-80kg will be given a dosage of 50mg (approximately 0.63-1.08mg/kg/day). DCS or placebo will be given by parents 1 hour prior to psychotherapy sessions (before sessions 4-10 only) based on past success in patients with acrophobia (Ressler et al., 2004) and DCS absorption rates.
1838960|NCT00864123|Drug|Placebo pill|This intervention involves taking a placebo pill(s) that matches the d-cycloserine capsules in size, shape, weight, and taste. Placebo contains an no active medication.
1838961|NCT00864136|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
1838962|NCT00864136|Drug|Conventional medical treatment|Women using combined oral contraceptives, oral/injectable progestogens, non-steroidal anti-inflammatory drug
1838963|NCT00864136|Drug|Conventional medical treatment|Women using anti-fibrinolytic agent for treatment of menorrhagia
1838964|NCT00864149|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fed conditions
1838965|NCT00864149|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fed conditions
1838966|NCT00864162|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fed conditions
1838967|NCT00864162|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fed conditions
1838968|NCT00864175|Drug|INCB007839 and trastuzumab|100 mg BID
1838969|NCT00864175|Drug|INCB007839 and trastuzumab|200 mg BID
1838970|NCT00864175|Drug|INCB007839 and trastuzumab|300 mg BID
1838971|NCT00864175|Drug|INCB007839 and Docetaxel|300 mg BID
1838972|NCT00864188|Dietary Supplement|no bacterial strains|Glucono-Delta-Lactone acidified milk containing no bacterial strains
1838973|NCT00864188|Dietary Supplement|One probiotic strain - Lactobacillus paracasei NCC2461|Glucono-Delta-Lactone acidified or fermented milk containing one probiotic strain.
1838974|NCT00864188|Dietary Supplement|Two standard yogurt fermenting bacterial strains - Streptococcus thermophilus and Lactobacillus delbrueckii subsp. bulgaricus|Fermented milk containing two standard yogurt bacterial strains.
1838975|NCT00864188|Dietary Supplement|Vit B2, B3, C and E, Beta Carotene and Oil|Fermented milk containing nutritional supplements
1838976|NCT00864201|Drug|bosentan|bosentan 62mg bid x 4 weeks, followed by bosentan 125mg bid x 20 weeks
1838977|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
1838978|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 2.5 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
1838979|NCT00864214|Drug|bioidentical hormone (Biest)|Estrogen is the Biest 3.0 mg bioidentical cream; the placebo is the transdermal patch; the progesterone is compounded progesterone-100 mg
1838980|NCT00864214|Drug|bioidentical hormone (Vivelle-Dot)|Estrogen is the Vivelle-Dot patch 0.05 mg; the placebo is the transdermal cream; the progesterone is micronized progesterone-100 mg
1838983|NCT00864240|Drug|Clobex TM (Clobetasol) 0.05% Lotion, single exposure|Subjects received Galderma Laboratories, L.P. formulated products
1838984|NCT00864253|Drug|ABI-007|Patients who receive ABI-007 will be dosed intravenously over approximately 30 minutes without steroid pre-medication and without G-CSF prophylaxis (unless modified as described below). ABI-007 150 mg/m2 will be administered on Days 1, 8, and 15 every 4 weeks.
1838985|NCT00864253|Drug|Dacarbazine|Patients who receive dacarbazine will be dosed intravenously at 1000 mg/m2 on Day 1 with steroid and antiemetic pre-medication. Treatment will be repeated every 21 days.
1838986|NCT00864266|Drug|Chemotherapy|Standard cisplatin-based chemotherapy in agreement with the ELCWP guidelines (available on the website www.elcwp.org)
1838987|NCT00864279|Drug|Cetirizine Hydrochloride 10 mg tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fast conditions
1838988|NCT00864279|Drug|Zyrtec® 10 mg tablets, single dose|B: Active comparator Subjects received Pfizer Inc. formulated products under fast conditions
1838989|NCT00864305|Drug|Gabapentin 400 mg capsules|A: Experimental Subjects received Purepac formulated products under fed conditions
1838990|NCT00864305|Drug|NEURONTIN® 400 mg capsules|B: Active comparator Subjects received Parke-Davis's marketed product
1838991|NCT00864305|Drug|Gabapentin 400 mg capsules, single dose|C: Experimental Subjects received Purepac formulated products under fasting conditions
1838992|NCT00864318|Drug|Paclitaxel|200mg/m2 for 3 hours at Cycle 1 day 1 and Cycle 2 day 1 with 14 days between cycles
1838993|NCT00864318|Drug|Ifosfamide|2g/m²/day in 1 liter of G5 for 3 hours at Cycle 1 and Cycle 2 from day 2 to day 4 with 14 days between cycles
1838994|NCT00864318|Drug|Carboplatine|"From cycle 3 to cycle 5 :
Carboplatine is administered with AUC = 24 mg/mL x min from Day 1 to Day 3. Day 3 Carboplatine dose is calculated taking into account real creatinine clearance defined at day 1 for each patient"
1838995|NCT00864318|Drug|Etoposide|From Cycle 3 to cycle 5, 400mg/m2/day from day 1 to day 3
1839040|NCT00870051|Device|Endurant Stent Graft|Endurant Stent Graft implantation
1839544|NCT00875849|Biological|cetuximab|
1838996|NCT00864318|Procedure|cytapheresis + transfusion of autologous peripheral blood stem cells|"Cytapheresis occured between day 11 and day 13 of the 2 first cycle (Taxol® +Holoxan®). Cytapheresis total objective is 9X106 CD34+/kg of patient weight.
At cycle 3, 4 and 5 at day 5 : Re-injection of stem cells (1/3 with minimum 2.106 CD34/kg) 48 hours after chemotherapy end"
1838997|NCT00864331|Radiation|radiation|39 Gy in 13 daily fractions of 3 Gy
1838998|NCT00864331|Other|Chemotherapy and radiotherapy|Chemotherapy followed by low dose palliative radiotherapy
1838999|NCT00864331|Drug|Chemotherapy|Chemotherapy given alone
1839000|NCT00864331|Other|Palliative radiotherapy and chemotherapy|Low dose palliative radiotherapy followed by chemotherapy
1839001|NCT00864344|Drug|Sertraline HCl 100 mg tablets, single dose|A: Experimental SSubjects received Purepac formulated products under fasting conditions
1839002|NCT00864344|Drug|Zoloft® 100 mg tablets, single dose|B: Active comparator Subjects received Pfizer formulated products under fasting conditions
1839003|NCT00864357|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under non-fasting conditions
1839004|NCT00864357|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under non-fasting conditions
1839005|NCT00864383|Drug|Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin|"Moxifloxacin 400 mg Rifampicin < 45 kg 450 mg > 45 kg 600 mg Isoniazid 300 mg Pyrazinamide < 40 kg 25 mg/kg rounded to nearest 500 mg* 40-55 kg 1000 mg > 55 kg - 75 kg 1500 mg > 75 kg 2000 mg Ethambutol < 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg > 55 kg - 75 kg 1200 mg > 75 kg 1600 mg *For pyrazinamide dosing in patients < 40 kg, 1000 mg used instead of 500 mg
All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm."
1839006|NCT00864396|Drug|Prevacid|30mg of Lansoprazole twice daily (or placebo)for eight weeks.
1839007|NCT00864409|Drug|ropivacaine 0,2%|Local wound infiltrtation with 170 mL ropivacaine 2 mg/mL
1839008|NCT00864409|Drug|saline.9%|Wound infiltration with 170 mL sterile saline
1839009|NCT00864422|Behavioral|Skilled motor training|This involves training subjects to independently and cognitively activate the deep abdominal muscles, transversus abdominis, with minimal or no activity in other trunk muscles. The contraction is held for 10 seconds and subjects complete three blocks of ten contractions, twice per day for two weeks. This training protocol is commonly used clinically for people with chronic back pain.
1839010|NCT00864422|Behavioral|Walking exercise|The control intervention involves walking exercises for ten minutes, twice per day. Subjects are advised to walk at their own pace with no instructions on activation of specific trunk muscles. The exercise is performed over two weeks.
1839011|NCT00864435|Drug|Carvedilol 12.5 mg Tablets, single dose|A: Experimental Subjects received Shasun Chemicals and Drugs Ltd. formulated products under fasting conditions
1839012|NCT00864435|Drug|Coreg® 12.5 mg Tablets , single dose|B: Active comparator Subjects received GlaxoSmithKline, USA formulated products under fasting conditions
1839013|NCT00864448|Drug|Ramipril10 mg Capsules, single dose|A: Experimental Subjects received Purepac formulated products under fasting conditions
1839014|NCT00864448|Drug|Atlace® 10 mg capsules, single dose|B: Active comparator Subjects received Monarch Pharmaceuticals Inc. formulated products under fasting conditions
1839015|NCT00864474|Drug|CELSENTRI® Tablets|"CELSENTRI ® Tablets 150mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage is 300 mg twice daily. Maraviroc must be used in combination with other anti-HIV drugs. The dosage may be adjusted according to co-administered medical products. Maraviroc can be taken with or without food."
1839016|NCT00864487|Drug|Neratinib|HKI-272
1839017|NCT00864500|Drug|Clobetasol Propionate 0.05% lotion, single exposure|A: Experimental Subjects received Alpharma USPD, Inc formulated products
1839018|NCT00864500|Drug|Clobex TM 0.05% Lotion, single exposure|B:Active Comparator Subjects received Galderma Laboratories, L.P. formulated products
1839019|NCT00864513|Drug|pemetrexed|pemetrexed 500 mg/m2 IV day 1 of each 21 day cycle until disease progression or unacceptable toxicity for a maximum of 8 cycles
1839020|NCT00864526|Drug|Oxycodone HCl 5 mg / Ibuprofen 400 mg tablets, single dose|A: Experimental SSubjects received Actavis formulated products under fasting conditions
1839021|NCT00864526|Drug|COMBONOX® tablets, single dose|B: Active comparator Subjects received Forest Pharmaceuticals, Inc formulated products under fasting conditions
1839022|NCT00864539|Dietary Supplement|fortified milk|daily intake of milk fortified with 100 IU vitamin D and 500 mg calcium/200 ml package for 10 weeks
1839023|NCT00864539|Dietary Supplement|plain milk|daily intake of 200 ml plain milk
1839024|NCT00864539|Dietary Supplement|fortified orange juice|daily intake of orange juice fortified with 100 IU vitamin D and 500 mg calcium/250 ml package
1839025|NCT00864539|Dietary Supplement|plain orange juice|daily intake of 250 ml plain orange juice
1839026|NCT00864539|Dietary Supplement|calcium-vitamin D supplement|daily calcium-vitamin D supplement (500 mg calcium + 200 IU vitamin D)
1839027|NCT00864539|Dietary Supplement|Placebo|daily placebo
1839028|NCT00864552|Drug|Kogenate (BAY14-2222)|Patients with severe haemophilia A (<2% FVIII:C baseline level) treated with Kogenate Bayer as their only source of recombinant FVIII
1839029|NCT00864565|Drug|Fentanyl 25 μg/h transdermal system, single application|A: Experimental Subjects received Corium International, Inc formulated products
1839030|NCT00864565|Drug|Duragesic 25 μg/h transdermal system single application|B: Active comparator Subjects received Jassen Pharmaceutica Products, L.P. formulated products
1839031|NCT00869999|Drug|Everolimus|Taken orally once daily in the morning
1839032|NCT00869999|Drug|rituximab|Given intravenously on Days 1, 8, 15, and 22 of Cycle 1 then on Day 1 of cycles 2-6
1839033|NCT00870012|Drug|Lepicol probiotic & prebiotic formula|NAFLD patients treated with Lepicol probiotic and prebiotic formula for 24 weeks.
1839034|NCT00870012|Other|Simple lifestyle advice|NAFLD patients treated with lifestyle advice.
1839035|NCT00870025|Biological|human chorionic gonadotropin|200 IU, sc, every 5 days, 4 doses
1839036|NCT00870025|Biological|placebo|diluent, every 5 days, s.c., 4 doses
1839037|NCT00870038|Device|Percutaneous coronary intervention: Paclitaxel eluting balloon (Elutax) + Genous stent|Predilatation with paclitaxel-eluting balloon, then stenting of the lesion with Genous stent
1839041|NCT00870064|Procedure|Formal Operative Treatment|Children randomized to the OR arm will be taken to the OR within 24 hours for irrigation and debridement and appropriate bone management.
1839042|NCT00870064|Procedure|Emergency Department Treatment|Children in the ED arm will have a washout in the emergency room under conscious sedation, a closed reduction and home antibiotics.
1839043|NCT00870077|Dietary Supplement|ProWHEY 94 CFM, SponserR|3 times 20g per day
1839044|NCT00870103|Drug|Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops|1 drop every 6 hours into the study eye
1839045|NCT00870116|Radiation|SBRT by cyberknife|treatment = 2x15 Gy during 2 weeks
1839046|NCT00870116|Radiation|SBRT by linear accelerator|treatment = 2x15 Gy during 2 weeks
1839047|NCT00870116|Radiation|Conformational radiotherapy|treatment = 5x2 Gy during 7 weeks (free breathing or breath holding)
1839048|NCT00870129|Procedure|MRI and advanced MRI sequences|This is a nonrandomized study in which each patient will receive the standard clinical care (in the form of surgery, radiation therapy and/or chemotherapy), as per the treating physician. Surgical resection will be performed at the discretion of the treating Neurooncologist and/or Neurooncology Tumor Board. Advanced brain MRIs with the 2 (or, in some cases, 3) special sequences will be obtained at the time of the clinically scheduled contrast MRIs, which are usually obtained immediately prior to and 1 months±3 weeks after radiation therapy if the patient requires radiation therapy for his/her tumor. The advanced brain MRI may also be obtained before surgery for suspected or confirmed gliomas, as per the standard of care, in some patients who may or may not require radiation therapy.
1839049|NCT00870142|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fasting conditions
1839050|NCT00870142|Drug|Norvasc® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fasting conditions
1839051|NCT00870155|Drug|dirucotide|500mg, intravenous, every 6mos until regulatory approval, denial or sponsor termination
1839052|NCT00870168|Drug|chemotherapy|
1839053|NCT00870168|Genetic|gene expression analysis|
1839054|NCT00870168|Other|laboratory biomarker analysis|
1839055|NCT00870168|Procedure|breast biopsy|
1839056|NCT00870181|Biological|ADV-TK/GCV|gene therapy
1839057|NCT00870181|Procedure|Surgery|
1839058|NCT00870181|Drug|systemic chemotherapy|
1839059|NCT00870194|Drug|exenatide and sitagliptin|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; sitagliptin-100mg tablet orally once a day
1839060|NCT00870194|Drug|exenatide and placebo|exenatide-subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (16 weeks), twice a day; placebo-tablet orally once a day
1839061|NCT00870207|Behavioral|Tu Salud Si Cuenta Worksite Intervention|The intervention will consist of providing TSSC newsletters to employees of the worksite. Additionally, informational sessions about physical activity and healthful food choice (consistent with the TSSC messages) during work hours will be implemented. Social support groups for the behavior changes will be established thru colleague networks. Individualized behavior change plans will be designed for enrolled participants. Additionally, environmental changes including a well equipped exercise facility on site and access to healthful foods in vending machines and work groups providing fruit and vegetable access in kitchen area will be implemented.
1839062|NCT00870220|Drug|Norditropin, Menostar 14mcg patch, Vivelle dot 25mcg patch|GH will be maintained at 0.05mg/kg/d, adjusted every 3 months. Estradiol 14mcg patch will be applied for 10 days/month for the first 6 months in Group 2. Estradiol 25mcg patch will be applied for 10 days/month for the second 6 months in Group 2, and for the first 6 months in Group 3. Estradiol 25mcg patch will be applied for 3 weeks per month for the second 6 months in Group 3.
1839063|NCT00870233|Behavioral|online platform WEBCORE|Enrollees will be sent weekly email reminders to login to WEBCORE from home. Participants will be expected to complete the questionnaire once pre-operatively and then weekly starting 7 days after surgery until the 6-week post-operative period has ended.
1839064|NCT00870259|Dietary Supplement|Optifast VLCD|Meal replacement, three times daily for 8 weeks
1839065|NCT00870272|Drug|Misoprostol|400mcg misoprostol taken sublingually or buccally
1839066|NCT00870285|Radiation|UVB 311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
1839067|NCT00870298|Drug|Trimethoprim/Sulfamethoxazole and Warfarin|
1839068|NCT00870311|Drug|Lithium Carbonate|300mg PO, three times daily with dose titrated to obtain a therapeutic plasma level of 0.8 to 1.2meq/L) over the first week of treatment. Total duration is a minimum of 3 weeks. Medication is dispensed in the form of blinded research capsules.
1839069|NCT00870324|Device|OptiSense Lead|"The OptiSense™ Model 1699 lead is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in the right atrium. The tip-to-ring spacing in the OptiSense lead is 1.1mm and narrow-spaced compared to the Tendril lead."
1839070|NCT00870324|Device|Tendril Lead|"The Tendril® is a bipolar, steroid-eluting, silicone-insulated, active fixation implantable lead, designed for long-term pacing and sensing in either the atrium or the ventricle. The tip-to-ring spacing in the Tendril is wide spaced compared to the OptiSense lead."
1839071|NCT00870337|Drug|everolimus|
1839072|NCT00870467|Biological|Double-blind adalimumab|Double-blind adalimumab 40 mg administered subcutaneously (SC) every other week (eow)
1839073|NCT00870467|Drug|Double-blind Placebo|Double-blind adalimumab-matching placebo administered subcutaneously (SC)every other week (eow)
1839074|NCT00870467|Biological|Open-label Adalimumab|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) after completion of the first 26 weeks in the study
1839075|NCT00870467|Biological|Open-labelAdalimumabRescue|Open-label adalimumab 40 mg administered subcutaneously (SC) every other week (eow) as rescue treatment to complete the first 26 weeks in the study- dependent on participant eligibility (increase in disease activity), applies to Weeks 12 to 26
1839076|NCT00870480|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fasting conditions
1839077|NCT00870480|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fasting conditions
1839078|NCT00870493|Drug|Aliskiren|Aliskiren 300 mg daily oral
1839079|NCT00870493|Drug|Placebo|starch tablet, 300 mg/day
1839080|NCT00870506|Behavioral|video|5-minute video compared (intervention) to no video and no other intervention (control)
1839081|NCT00870519|Drug|I-123-MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
1839082|NCT00870519|Drug|123-I MNI-168|Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
1839083|NCT00870532|Drug|oral vinorelbine|The patients will be divided into 3 cohorts (15 patients per cohort), each cohort receiving a fixed metronomic (thrice a week) dose of oral vinorelbine at 60 mg/week, 90 mg/week, and 120 mg/week respectively. We should arrive at 3 different MTDs from the 3 cohorts.
1839084|NCT00870532|Drug|sorafenib|Each patient within each cohort will receive a starting dose of sorafenib at 200 mg bid for 4 weeks. In the absence of dose-limiting toxicities, the dose of sorafenib will be escalated to 400 mg bid for another 4 weeks, 600 mg bid for 4 weeks and then finally 800 mg bid. We should arrive at 3 different MTDs from the 3 cohorts.
1839085|NCT00870545|Behavioral|Telephone support groups|There was one intervention. Participants were enrolled in one of 14 telephone groups (each with a trained Group Leader and 6 participants) will focus on education, training in and practice of coping skills and cognitive restructuring (identifying and re-shaping negative and destructive thoughts), and support through 12 hour-long structured sessions. The content, modeled on Soldier BATTLEMIND, targets readjustment concepts based on the letters of BATTLEMIND, including Bonds, Adding and subtracting family roles, Taking control, Talking it out, Loyalty and commitment, Emotional balance, Mental health and readiness, Independence and interdependence, Navigating the system, Denial of self and a concluding session entitled Moving forward.
1839086|NCT00870558|Drug|ethiodized oil|Given as an intra-arterial infusion
1839087|NCT00870558|Radiation|iodine I 131 ethiodized oil|Given as an intra-arterial infusion
1839088|NCT00870571|Drug|AMLODIPINE (as BESILATE) TABLETS 10 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
1839089|NCT00870571|Drug|NorvasC® 10 mg Tablets|B: Active comparator Subjects received Pfizer Labs Division of Pfizer Inc. formulated products under fed conditions
1839090|NCT00870584|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of omalizumab for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
1839091|NCT00870584|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use, 5 mL vial. The vial was designed to deliver 150 mg (1.2 mL) of placebo for subcutaneous (s.c.) administration after reconstitution with 1.4 mL sterile water for injection. Doses of more than 150 mg were divided among multiple injection sites to limit injections to not more than 150 mg per site.
1839092|NCT00870597|Procedure|Multifocal IOL implantation + Vitrectomy|25-gauge transconjuntival sutureless vitrectomy (TSV)
1839093|NCT00870597|Procedure|Multifocal IOL implantation - Vitrectomy|Multifocal IOL implantation without transconjunctival vitrectomy
1839094|NCT00870610|Procedure|retrograde jugular venous cannulation|Retrograde cannulation of jugular vein and intermittent sampling of venous blood from cerebral circulation before, during and after hypothermia.
1839095|NCT00870636|Drug|Bevacizumab (Avastin)|Dosage of 0.75mg/0.03ml intravitreal injectable, one time only.
1839096|NCT00870649|Biological|Bilhvax vaccine (Sh28GST)|Four vaccine sc administrations over a year associated with chemotherapy (PZQ)
1839097|NCT00870649|Biological|placebo|Four placebo sc administrations over a year associated with chemotherapy (PZQ)
1839098|NCT00870662|Device|AFS System|AFS System with patient specific flow rate
1839099|NCT00870688|Drug|sodium valproate|valproate sustained release minitablets, once daily.
1839100|NCT00870701|Radiation|Radiotherapy|50 grays in 25 fractions of 2 Gys or 50.4 grays in 28 fractions of 1.8 grays
1839101|NCT00870701|Other|absence of radiotherapy|absence of radiotherapy
1839102|NCT00870714|Drug|Docetaxel|Docetaxel 55mg/m2 to be given IV as a one-hour infusion to be repeated every 21 days for four treatment cycles.
1839103|NCT00870714|Drug|Ketoconazole|Ketoconazole 400mg P.O. BID daily to start on day 2 following the first docetaxel treatment. In patients who experience no grade 2 or higher toxicity, the ketoconazole dose will be increased to 400mg TID on day 2 following cycle #2 of docetaxel. This will be continued daily until completion of study treatment.
1959168|NCT00715520|Drug|Carbidopa-Levodopa|"Participants will receive one oral dose of carbidopa-levodopa 25mg one hour prior to measuring wrist extension movements.
The order in which Carbidopa-Levodopa is given will be randomized per participant."
1839106|NCT00870740|Biological|BIIB019 (Daclizumab High Yield Process)|SC injection
1839107|NCT00870740|Drug|Placebo|Placebo SC injection
1839108|NCT00870753|Behavioral|Yoga|90 min hatha yoga 2 times per week for 12 weeks.
1839109|NCT00870766|Procedure|Abdominal contrast-enhanced CT scanning|Contrast-enhanced (iohexol 350 mgI/ml, 100 ml IV) CT scanning
1839110|NCT00870779|Drug|5-aminolevulinic acid|20mg/kg 3 hours prior to surgery
1839111|NCT00870792|Behavioral|Adherence report|During the intervention phase, the data collected at the study visit were summarized in a 3-page report that was given to the provider before each intervention visit. The report included data on self-reported adherence, MEMS adherence, reminder use, beliefs about ART, reasons for missed doses, alcohol and drug use, and depression.
1839112|NCT00870805|Procedure|bilateral ultrabrief ECT|Bilateral ECT at 3-4 times seizure threshold with an ultrabrief pulse (0.3ms)
1839113|NCT00870805|Procedure|bilateral standard ECT|Bilateral ECT with at 1.5 times seizure threshold with a standard pulse (1.0ms)
1839114|NCT00870805|Procedure|right-unilateral ultrabrief ECT|Right-unilateral ECT at 6 times seizure threshold with an ultrabrief pulse (0.3ms)
1839115|NCT00870805|Procedure|right-unilateral standard ECT|Right-unilateral ECT with at 5 times seizure threshold with a standard pulse (1.0ms)
1839116|NCT00870818|Drug|Teplizumab|No additional drug or placebo will be administered in this study. Blood will be drawn every 6 months after the last visit of the Protege Study for 3 years. Blood will be collected for chemistry, hematology, thyroid function, immunology, serology, autoantibodies, and metabolic function.
1839205|NCT00871377|Drug|Low Dose Fish Oil|n-3 fatty acids, 2160 mg EPA + DHA
1839117|NCT00870831|Other|OGTT (Oral Glucose Tolerance Test)|Subjects would consume 75grams of sugar (Dextrose, 10 oz) and blood samples taken at specified time points to measure glucose, insulin and C-peptide
1839118|NCT00870844|Drug|Lu AA24493 (CEPO)|0.5 to 50.0 mcg/kg body weight, IV, within 0 to 48 hrs from symptom onset
1839119|NCT00870844|Drug|Placebo|Vials with solution for IV infusion
1839120|NCT00870870|Drug|Gemcitabine|"1000 mg/m2 on Days 1 and 8 of each cycle
(First 6 cycles [18 weeks])"
1839121|NCT00870870|Drug|Cisplatin|"75 mg/m2 , day 1 of each cycle
(First 6 cycles [18 weeks])"
1839122|NCT00870870|Biological|IMC-A12 (cixutumumab)|"6 mg/kg I.V. infusion, administered once per week (on Days 1, 8, and 15 of each cycle)
(First 6 cycles [18 weeks])"
1839123|NCT00870870|Biological|Cetuximab|"400 mg/m2 I.V. infusion, administered on Day 1 of Cycle 1, 250 mg/m2 once per week thereafter
(First 6 cycles [18 weeks])"
1839124|NCT00870870|Biological|IMC-A12 (cixutumumab)|"10 mg/kg I.V. infusion, administered once every 2 weeks
[Maintenance period]"
1839125|NCT00870870|Biological|Cetuximab|"500 mg/m2 I.V. infusion, administered once every 2 weeks
[Maintenance period]"
1839126|NCT00870870|Drug|Carboplatin|"AUC = 5, day 1 of each cycle
(First 6 cycles [18 weeks])
*Carboplatin will be replaced by Cisplatin"
1839127|NCT00870883|Drug|N-acetylcysteine and deferoxamine|N-acetylcysteine bolus dose of 50mg/kg/4h, by a manutention of 100mg/kg/day during 2 days and deferoxamine single dose of 1g administered 15mg/kg/h.
1839128|NCT00870896|Drug|Tiotropium|Each subject will then receive Spiriva 18 ug/day for a total of 4 weeks. Each subject will be instructed by the PI on the proper use of the Spiriva inhaler and demonstrate the ability to properly perform the inhalation technique prior to leaving the laboratory. The patient will receive their first dose in the laboratory under the direct supervision of one of the investigators. In addition, subjects will be requested to take their Spiriva inhalation treatment the same time each day.
1839129|NCT00870909|Procedure|active tDCS|Intensity 2 mA during 20 minutes, 2 times per day
1839130|NCT00870909|Procedure|sham tDCS|sham condition as delivered by the stimulator
1839131|NCT00870922|Procedure|Active release techniques|Participants will receive ART and have Therabite (mouth opening) and pain (VAS) measured before and after ART
1839132|NCT00870935|Procedure|Balloon catheter|Hysterosalpingography is performed using intrauterine balloon catheter
1839133|NCT00870935|Procedure|Cervical vacuum cup|Hysterosalpingography is performed using cervical vacuum cup
1839134|NCT00870948|Drug|ABT-874|See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
1839135|NCT00870961|Dietary Supplement|cholecalciferol|Given orally
1839136|NCT00870961|Other|placebo|Given orally
1839137|NCT00870974|Drug|[18F]FPEB|Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not >10% of 5 mCi limit) of [18F]F-PEB
1959169|NCT00715520|Drug|Methylphenidate|"Participants will receive one oral dose of methylphenidate 40mg 2 hours prior to measuring wrist extension movements.
The order in which Methylphenidate is given will be randomized per participant."
1839140|NCT00871000|Biological|Boostrix Polio™ 711866|Single dose, intramuscular administration.
1839141|NCT00871000|Biological|Priorix Tetra TM 208136|Single dose, subcutaneously.
1839142|NCT00871000|Biological|Tetravac TM|Single dose, intramuscular administration.
1839143|NCT00871013|Drug|Melphalan|"Given by vein, Day 3
First Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4
Second Inter-Therapy Treatment Bortezomib (Velcade) By vein Days 1 and 4
Second Transplant Bortezomib (Velcade) By vein Day -5 and Day -2
Year 1 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 28 days
Years 2 & 3 Maintenance Velcade (bortezomib) By vein Days 1, 8, 15, 22(weekly) Every 56 days"
1839144|NCT00871013|Drug|Velcade|Given by vein, Days 1, 5, 8, 11
1839145|NCT00871013|Drug|Thalidomide|Given by mouth at bedtime, Days 5-8
1839146|NCT00871013|Drug|Dexamethasone|Given by mouth, once per day Days 5-8
1839147|NCT00871013|Drug|Cisplatin|Given by vein, Days 5-8 continuous infusion
1839148|NCT00871013|Drug|Adriamycin|Given by vein, days 5-8 continuous infusion
1839149|NCT00871013|Drug|Cyclophosphamide|Given by vein days 5-8 continuous infusion
1839150|NCT00871013|Drug|Etoposide|Given by vein days 5-8 continuous infusion
1839151|NCT00871026|Procedure|orthodontic treatment with customized archwires|orthodontic treatment with customized archwires
1839152|NCT00871026|Procedure|orthodontic treatment with prefabricated archwires|orthodontic treatment with prefabricated archwires
1839153|NCT00871039|Drug|Propofol|Patients to be sedated for up to 72 hours with study drug propofol
1839154|NCT00871039|Drug|Midazolam|Patients to be sedated for up to 72 hours with study drug midazolam
1839155|NCT00871052|Drug|Calcipotriol-containing cream|Topical treatment twice a day for 7 days
1839156|NCT00871065|Drug|Sildenafil citrate|20 mg tablet orally every 8 hours until Day 14 post-hemorrhage
1839157|NCT00871078|Device|Optical Coherence Tomography (OCT)|Macular and retinal nerve fiber layer OCT (Stratus OCT, Carl Zeiss Meditec, Dublin, CA) will be performed both in patients and controls
1839158|NCT00871078|Device|Frequency Doubling Technology (FDT) perimeter|24-2 FDT Threshold (Humphrey Matrix, Carl Zeiss Meditec, Dublin CA; Welch-Allyn, Skaneateles, NY) will be performed both in patients and controls.
1839159|NCT00871091|Procedure|orthodontic treatment with customized archwires|customized arch wires depending on the amount of needed tooth movement
1839160|NCT00871091|Procedure|orthodontic treatment with prefabricated archwires|prefabricated archwires depending of the needed movement of the teeth
1839161|NCT00871091|Procedure|orthodontic tx w/ conventional archwires+manual adjustments|conventional archwires modified by manual adjustment, depending of needed correction
1839162|NCT00871104|Drug|Fosfomycin and imipenem|IV Fosfomycin 2 gr./6 hours and IV Imipenem 1 gr./6 hours adjusted acoording to renal function during 4-8 weeks
1839163|NCT00871104|Drug|Vancomycin|IV Vancomycin 30 mg/kg twice a day with valley leves higher than 15 mcg/kg
1839164|NCT00871117|Biological|GSK Biologicals'Kinrix®|One dose as intramuscular injection at visit 1
1839165|NCT00871117|Biological|Merck and Company's MMRII|One dose as subcutaneous injection at visit 1
1839166|NCT00871117|Biological|Merck and Company's Varivax|One dose as subcutaneous injection at visit 1 or at visit 2
1839167|NCT00871130|Procedure|Bariatric surgery|gastric banding, gastric bypass or vertical gastroplasty either open or laparoscopic or a combination of any
1839168|NCT00871143|Behavioral|CBT specific for BDD|This consisted of 12 wks of 1 hr sessions (1 per week).The consisted of engagement in a developmental understanding of the problem and setting up an alternative view of the problem. Imagery rescripting followed for past aversive memories that were associated with the onset (e.g. bullying). The behaviours were aimed at either (1) threat detection and monitoring or (2) preventing feared consequences by avoidance or (3) attempts to undo the appearance concerns. The therapist aimed to help individuals identify their beliefs about processes, conduct behavioural experiments that tested out their expectations and to gradually drop the safety-seeking behaviours and test out their fears.
1839169|NCT00871143|Behavioral|Non specific CBT|Anxiety Management treatment was provided once a week for 12 weeks, with each session lasting 1 hr. AM was planned to entail a therapeutic alliance, support and homework similar to the CBT group. The rationale provided was that when triggered, the person would experience a threat and negative thoughts about their appearance. This, in turn, would lead to physical symptoms of anxiety and magnify the perceived threat. The treatment consisted of (1) practising progressive muscle relaxation and breathing daily, (2) identifying triggers and physical symptoms associated with appearance-related anxiety and (3) utilising brief muscle relaxation and breathing techniques in trigger situations.
1839170|NCT00871156|Drug|Chloroquine, Tafenoquine|Chloroquine and Tafenoquine
1839171|NCT00871156|Drug|Placebo|Placebo
1839172|NCT00871169|Drug|Irinotecan, oxaliplatin, and cetuximab|"Irinotecan at 90 mg/m2 intravenously every two weeks (administered over 60 minutes) + Oxaliplatin at 60 mg/m2 intravenously every two weeks(administered over 60 minutes) + Cetuximab at 250 mg/m2 intravenously every two weeks (administered over 90 minutes).
The treatment interval (one cycle) is every 14 days."
1839173|NCT00871182|Drug|Inhaled PT001|single dose, inhaled
1839174|NCT00871182|Drug|Inhaled Placebo|single dose, inhaled
1839175|NCT00871182|Drug|Tiotropium Handihaler|single dose, tiotropium 18 mcg administered via the Handihaler
1839176|NCT00871208|Drug|Altabax (R)|Retapamulin 1% ointment is to be applied to lesional atopic dermatitis twice-daily in addition to a topical corticosteroid (Locoid lipocream (R))
1839177|NCT00871208|Drug|Vehicle and Locoid lipocream (R)|The vehicle base of retapamulin ointment will be applied twice-daily to active lesions of atopic dermatitis in addition to locoid lipocream (R)
1839178|NCT00871234|Drug|Etravirine|Two one-hundred mg tablets orally twice daily for four weeks
1839179|NCT00871247|Drug|Finasteride 5 mg Tablet, single dose|A: Experimental Subjects received Intas Pharmaceuticals Ltd, India formulated products under fed conditions
1839180|NCT00871247|Drug|Proscar® 5 mg Tablet, single dose|B: Active comparator Subjects received Merck Sharp and Dohme, U.S.A formulated products under fed conditions
1839181|NCT00871260|Drug|regadenoson|Subjects in open label group will be given a single dose of regadenoson (0.4 mg, i.e. 5 ml i.v. bolus) as contrast.
1839182|NCT00871273|Drug|capecitabine|film-coated tablet 1250 mg/m2 twice daily 14 days for 14 days. Number of cycles: 3 cycles pre-operatively and 3 cycles post-operatively unless there is evidence of disease progression on chemotherapy
1839183|NCT00871286|Procedure|Pre-treatment Sinus CT Scan|Pre-treatment Sinus CT Scan
1839184|NCT00871286|Procedure|Post-treatment Sinus CT Scan|Post-treatment Sinus CT Scan
1839185|NCT00871299|Behavioral|Mindfulness Based Cognitive Therapy|"Mindfulness-Based Cognitive Therapy (MBCT) is a group treatment that integrates mindfulness meditation training with some CBT concepts and was specifically developed as a relapse prevention intervention for MDD. The program teaches skills that allow patients to disengage from habitual (automatic) dysfunctional cognitive routines, in particular depression-related ruminative thought patterns, as a way to reduce future risk of relapse and recurrence of depression."
1839186|NCT00871299|Behavioral|Health Enhancement Program and medication management|The Health Enhancement Program (HEP)was developed at the University of Wisconsin, Madison and is modeled after traditional activity and nutrition programs used in weight management- cardiac rehab and diabetes prevention programs. The program is designed to increase overall health and well-being by focusing on four health domains that impact health and are interventions regularly practiced at integrative medicine. These include: (I) Music Therapy (2) Nutrition (3) physical activity including, walking and stretching and (4) Functional movement.
1839187|NCT00871312|Device|Topical wound oxygen therapy|90 minutes 4 days per week Active Topical Oxygen Therapy
1839188|NCT00871312|Device|Topical wound oxygen Placebo|90 mins per day 4 days per week Placebo Therapy
1839189|NCT00871325|Drug|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
1839190|NCT00871325|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
1839191|NCT00871325|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is a granule. Subject will take a daily dose divided three times a day for 5 days.
1839192|NCT00871338|Biological|GSK2197870A|3 doses given at 2, 3 and 4 months of age
1839193|NCT00871338|Biological|Prevenar™|3 co-administered doses, intramuscular into right thigh
1839194|NCT00871338|Biological|Menitorix™|1 booster dose at 12 months of age
1839195|NCT00871338|Biological|Pediacel™|3 doses given at 2, 3 and 4 months of age
1839196|NCT00871338|Biological|Menjugate™|2 doses given at 3 and 4 months of age
1839197|NCT00871351|Drug|Ezetimibe|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
1839198|NCT00871351|Drug|Atorvastatin|1 tablet of 10 mg daily for 12 weeks (Weeks 5-16)
1839199|NCT00871351|Drug|Atorvastatin|2 tablets of 10 mg daily for 12 weeks (Weeks 5-16)
1839200|NCT00871351|Drug|Rosuvastatin|1 tablet of 2.5 mg daily for 12 weeks (Weeks 5-16)
1839201|NCT00871364|Drug|VENLAFAXINE TABLETS 50 mg , single dose|A: Experimental Subjects received EMCURE PHARMACEUTICALS LTD. formulated products under fed conditions
1839202|NCT00871364|Drug|Effexor® Tablets equivalent to 50 mg venlafaxine|B: Active comparator Subjects received Wyeth Pharmaceuticals Inc. formulated products under fed conditions
1839203|NCT00871377|Drug|Placebo|corn oil (n-6 fatty acids)
1839204|NCT00871377|Drug|High Dose Fish Oil|n-3 fatty acids, 1060 mg EPA + DHA
1839545|NCT00875849|Drug|cisplatin|
1839206|NCT00871403|Drug|pazopanib and pemetrexed|oral pazopanib 600 mg once daily and pemetrexed intravenous (IV) 500mg/m^2 once every 3 weeks, then pazopanib 800 mg once daily
1839207|NCT00871403|Drug|pemetrexed and cisplatin|pemetrexed IV 500 mg/m^2 and cisplatin IV 75 mg/m^2 once every 3 weeks
1839208|NCT00871416|Device|NovoFine® needle 6 mm|
1839209|NCT00871416|Device|NovoFine® needle 12 mm|
1839210|NCT00871429|Other|Lindi skin care products|"Subjects will then be instructed to apply all three products daily for 1 month.
The products include: Lindi Skin soothing balm (product A), Lindi Skin face serum (product B, and Lindi Skin face wash (product C)."
1839211|NCT00871442|Other|No Basal Infusion|Group 1: Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
1839212|NCT00871442|Other|Basal infusion|Group 2 Basal Infusion: 0 ml/hr; Bolus 10 ml q 30min prn (10ml demand dose with 30min lockout)
1839213|NCT00871442|Drug|PCEA solution (bupivacaine and fentanyl)|PCEA solution: Bupivacaine 0.0625% with fentanyl 2 mcg/ml
1839214|NCT00871455|Drug|Baclofen|Subjects will receive 20 mg baclofen for 8 weeks, followed by 40 mg baclofen for 8 weeks.
1996379|NCT02491164|Device|FE and Cellvizio viewer software|Fibre based endomicroscopy to visualise fluorescent signal emitted by optical agents.
1839217|NCT00871481|Biological|ipilimumab|Given IV
1839218|NCT00871481|Drug|cyclophosphamide|Given IV
1839219|NCT00871481|Procedure|biopsy|Optional correlative studies
1839220|NCT00871481|Biological|aldesleukin|Given SC
1839221|NCT00871481|Other|immunohistochemistry staining method|Correlative studies
1839222|NCT00871481|Genetic|polymerase chain reaction|Correlative studies
1839223|NCT00871481|Other|immunoenzyme technique|Correlative studies
1839224|NCT00871481|Biological|therapeutic cytotoxic T lymphocytes|Given IV
1839225|NCT00871494|Drug|Azithromycin|The patients will receive 500 mg intravenous azithromycin QD for 1 to 2 days. The period of administration of intravenous dosing is judged by investigators according to patient status. Following intravenous administration, the patients will be received the 250 mg oral azithromycin (tablet formulation) QD to complete a total of 7 days therapy.
1839226|NCT00871507|Drug|JNJ-38431055 Dose 1|Liquid suspension/solution of JNJ-38431055 administered as a single dose
1839227|NCT00871507|Drug|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose.
1839228|NCT00871507|Drug|Placebo|Placebo suspension/solution and Placebo capsule administered as single doses
1839229|NCT00871507|Drug|JNJ-38431055 Dose 2|Liquid suspension/solution of JNJ-38431055 administered as a single dose
1839230|NCT00871520|Other|no specific interventions|There are no specific interventions in this observational study
1839231|NCT00871533|Drug|IFNα2b|IV injection at 20 million IU/m2. IFNα2b IV injection will be performed every day between day -14 and day -9 (5 infusions) and also every day between day -7 and day -2 (5 infusions) for a total of 10 infusions.
1839232|NCT00871533|Drug|IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary, at 10 million IU/m2. IFNα2b Injection will be performed every other day between day -14 and day -9 (3 injections) and also every other day between day -7 and day -2 (3 injections) for a total of 6 injections.
1839233|NCT00871533|Drug|PEG- IFNα2b|SC injection at 6mcg/kg will be performed systemically (at site that is not regional): first injection at day -14, second injection at day -7, for a total of 2 injections.
1839234|NCT00871533|Drug|PEG- IFNα2b|SC injections peri-lesionally (PL) in the vicinity of the primary at 3ug/kg: first injection at day -14, second injection at day -7, for a total of 2 injections.
1839235|NCT00871546|Drug|SCH 727965|SCH 727965 50 mg/m2 IV on Day 1 of each 21-day cycle until disease progression.
1839236|NCT00871546|Drug|Bortezomib|Bortezomib 1.3 mg/m2 IV on Days 1, 4, 8, and 11 of each 21-day cycle until disease progression.
1839237|NCT00871546|Biological|Alemtuzumab|Alemtuzumab dose-titrated to the goal maintenance dose of 30 mg/day IV or SC three times a week on alternate days for a total of 12 weeks.
1839238|NCT00871559|Drug|REGN421(SAR153192)|
1839239|NCT00871572|Drug|LY2409021|4 capsules by mouth taken once daily for 12 weeks
1839240|NCT00871572|Drug|Placebo|4 capsules by mouth once daily for 12 weeks
1839241|NCT00871598|Drug|BTT1023|intravenous, three infusions over three weeks
1839242|NCT00871598|Drug|Placebo|intravenous, three infusions over three weeks
1839243|NCT00871598|Drug|BTT1023|Test challenge
1839244|NCT00871624|Drug|Dexmedetomidine|Dexmedetomidine will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
1839245|NCT00871624|Drug|Placebo|Placebo infusion will be started at a rate of 0.2mcg/kg/hr and titrated by 0.1 mcg/kg/hr every 30 minutes to a maximum of 0.7 mcg/kg/hr to maintain a Riker-SAS 3-4.
1839246|NCT00871650|Other|Sleep data recording|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
1839247|NCT00871650|Other|PET scan - waking|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
1839248|NCT00871650|Other|PET scan - REM Sleep|After completing the screening procedures, eligible participants will sleep in the laboratory for three consecutive nights of EEG sleep studies, one waking [18F]-FDG PET scan, and one REM sleep PET scan according to published methods.
1839249|NCT00871663|Drug|SCH 727965|Dose escalation of SCH 727965 IV administered in 28-day cycles, on Days 1, 8, and 15 of each 28-day cycle.
1839250|NCT00871676|Behavioral|Lifestyle modification|16 weekly followed by 8 monthly group behavioral weight loss sessions.
1839251|NCT00871676|Behavioral|Lifestyle modification plus gum|16 weekly followed by 8 monthly group behavioral weight loss sessions. Subjects were also given gum along with instructions for times and occasions to chew with the aim of facilitating weight loss and appetite control.
1839252|NCT00871689|Biological|aldesleukin|IL-2 will be administered (9 million units; 5 million units if weight is less than 45 kg) every other day beginning on day +3 for a total of 6 doses and again on day +60 every other day for 6 doses.
1839474|NCT00873119|Drug|carboplatin, paclitaxel|
1839253|NCT00871689|Drug|cyclophosphamide|60 mg/kg over 1 hour intravenously (IV) on days -7 and -6.
1839254|NCT00871689|Drug|fludarabine phosphate|25 mg/m^2 intravenously (IV) over 1 hour on days -7 through -5.
1839255|NCT00871689|Procedure|umbilical cord blood transplantation|On day 0, transplantation will occur with double T-cell depleted (TCD) umbilical cord blood (UCB) units
1839256|NCT00871689|Radiation|total-body irradiation|administered on days -5 through -2; 330 cGy daily
1839257|NCT00871702|Genetic|CD34-TK75 transduced donor lymphocytes|
1839258|NCT00871702|Radiation|Sub Study - 18 FHBG PET/CT Scans|Three 18 FHBG PET/CT Scans will be performed first one at pre-DLI infusion, second 14 days post-DLI infusion and third 30 days post-DLI infusion - patients #3 - #8
1839259|NCT00871715|Behavioral|Accelerated Skill Acquisition Program (ASAP)|A 30-hour dose is administered over 1-hour visits at a frequency of 3x/week for a 10-week duration. A 2-hour orientation/evaluation session precedes the first visit.
1839260|NCT00871715|Behavioral|Dose-Equivalent Usual & Customary Care - DEUCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting, adjusted for dose, but otherwise administered in accordance with usual and customary practices. This is a 30-hour dose equivalency group, administered over 1-hour visits at a frequency of 3x/week for a 10-week duration.
1839261|NCT00871715|Behavioral|Usual and Customary Care - UCC|Usual and customary arm therapy administered early post-acutely in the outpatient setting. This is an observation only group and treatment dose will be administered in accordance with usual and customary practices.
1839262|NCT00871728|Drug|Itraconazole|Itraconazole (ICZ) capsule will be administered in 3 cycles (Week 1, Week 5 and Week 9) and each cycle will consist of taking 2 capsules of 100 milligram (mg) each, orally twice daily, continuously for 1 week and then not taking medication for next 3 weeks. Total duration of treatment will be 49 weeks.
1839263|NCT00871741|Biological|GSK2202083A vaccine|Intramuscular, three doses
1839264|NCT00871741|Biological|Infanrix hexa|Intramuscular, three doses
1839265|NCT00871741|Biological|Menjugate|Intramuscular, two doses
1839266|NCT00871767|Drug|AZD5672|40 mg tablet (Test formulation)
1839267|NCT00871767|Drug|AZD5672|40 mg tablet (Reference formulation)
1839268|NCT00871767|Drug|AZD5672|100 mg tablet (Test formulation)
1839269|NCT00871767|Drug|AZD5672|100 mg (2 x 50 mg tablet (Reference Formulation)
1839270|NCT00871780|Drug|BG00002 (natalizumab)|
1839271|NCT00871793|Other|Occupational therapy|Participants in this arm will receive six sessions of occupational therapy in a 5 week period.
1839272|NCT00871806|Drug|Commercial tablet with water|40 mg tablet, given once to each subject
1839273|NCT00871806|Drug|ODT #1 without water|40 mg tablet given once to each subject
1839274|NCT00871806|Drug|ODT #2 without water|40 mg tablet given once to each subject
1839275|NCT00871806|Drug|ODT #1 with water|40 mg tablet given once to each subject
1839276|NCT00871806|Drug|ODT #2 with water|40 mg tablet given once to each subject
1839277|NCT00871819|Device|Precision Spinal Cord Stimulation (SCS)|Various SCS device programming parameters
1839280|NCT00871858|Drug|anastrozole|Given orally
1839281|NCT00871858|Drug|fulvestrant|Given intramuscularly
1839282|NCT00871871|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 50 mg (two 25 mg capsules) once daily for 4 weeks per treatment period.
1839283|NCT00871871|Drug|Comparator: Placebo to HCTZ|Placebo to HCTZ two 0 mg capsules once daily for 4 weeks per treatment period
1839284|NCT00871871|Drug|Isosorbide mononitrate (ISMN)|ISMN 60 mg extended release capsule once daily for 4 weeks per treatment period
1839285|NCT00871871|Drug|Comparator: Placebo to ISMN|Placebo to ISMN 0 mg capsule once daily for 4 weeks per treatment period
1839286|NCT00871884|Behavioral|Psychoeducation|Education about the common prognostic considerations, normal symptoms experienced and etiology of symptoms following mild head injury. Includes some basic suggestions surrounding methods to diminish the impact of symptoms on one's life.
1839287|NCT00871884|Behavioral|Relaxation Training|Includes Progressive Muscle Relaxation, Guided Visualization, and various other relaxation techniques to induce deep relaxation.
1839288|NCT00871884|Behavioral|Interoceptive Exposure|Includes a variety of exercises used to elicit somatic sensations which may be feared by the participant, in an attempt to extinguish or lessen the fear reaction to these sensations.
1839296|NCT00871923|Drug|Tarceva (Erlotinib hydrochloride)|150 mg by mouth every day beginning Day 1.
1839297|NCT00871923|Radiation|Radiation Therapy|Whole Brain Radiation Therapy (WBRT) for total dose of 3500cGy in 14 daily fractions beginning after Day 6.
1839298|NCT00871936|Drug|SLx-4090|SLx-4090
1839299|NCT00871936|Other|Placebo|matching tablets
1839300|NCT00871936|Drug|Metformin|
1839301|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
1839302|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
1839303|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
1839304|NCT00871949|Drug|PNU-100480|300 mg oral suspension given once
1839305|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
1839306|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
1839307|NCT00871949|Drug|PNU-100480|100 mg oral suspension given once
1839308|NCT00871949|Drug|PNU-100480|35 mg oral suspension given once
1839309|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
1839310|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
1839311|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
1839312|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
1839313|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
1839314|NCT00871949|Drug|PNU-100480|1500 mg oral suspension given once
1839315|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
1839316|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
1839317|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
1839318|NCT00871949|Drug|PNU-100480|1000 mg oral suspension given once
1839319|NCT00871949|Drug|PNU-100480|600 mg oral suspension given once
1839320|NCT00871949|Drug|PNU-100480|Fed conditions, 600 mg oral suspension given once
1839321|NCT00871949|Drug|Placebo|placebo to match oral suspension given once
1839322|NCT00871962|Other|OXYGEN SUPPLEMENTATION|Patients treated by LTOT, with or without clinically fulfilled criteria for LTOT, with PaO2<55mmHg or less at rest or during sleeping or less during exercise, if supplemental oxygen is demonstrated to improve the exercise-associated hypoxia. Patients with PaO2 56-59mmHg if they also have dependent edema, pulmonary hypertension or hematocrit higher than 56%
1839323|NCT00871975|Device|Urodynamics + TETRA - NIRS|Urodynamics will be performed as per standard of care for patients enrolled, whereby one catheter is inserted into the bladder and one in the rectum to analyze bladder filling, storage and voiding conditions via pressures measured and urine flow rates detected by a uroflowmeter. Tetra-NIRS will be concurrently performed where Tetra-NIRS unit uses near infrared light at 3 different wavelengths to measure changes in haemoglobin and cytochrome. A patch is applied externally to measure these changes in the detrusor muscle of the human bladder wall. This process is similar to what is used for cerebral and muscle oxygenation monitoring (e.g., pulse oximetry). Previous clinical feasibility studies have identified a correlation between the changes in haemoglobin and cytochrome and the pressure values obtained during urodynamics procedures.
1839324|NCT00872001|Drug|Acadesine|Acadesine 42 mg/kg diluted in normal saline to a total of 500 mL, delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 0.1 mg/kg/min (translating into 1.2 mL/min for a 500 mL solution). In addition, a 5 µg/mL cardioplegia solution of acadesine will be administered, and acadesine will be added to the priming solution (5 µg/mL) in the heart lung machine during CPB.
1839325|NCT00872001|Drug|Normal Saline|Normal saline, 500 mL delivered as an IV infusion over approximately 7 hours commencing within approximately 30 minutes before induction of anesthesia at a rate of 1.2 mL/min for a 500 mL solution. In addition, standard cardioplegia solution with added normal saline will be administered, and placebo (normal saline) will also be added to the heart lung machine priming solution.
1839326|NCT00872014|Drug|AMG 386|Two doses of AMG 386 (15 mg/kg) IV QW will be studied
1839327|NCT00872014|Drug|AMG 386|Two doses of AMG 386 (10 mg/kg) IV QW will be studied
1839328|NCT00872014|Drug|Sorafenib|Sorafenib 400 mg PO BID orally twice daily in an every 4 week dosing schedule for 15mg/kg cohort & 10mg/kg cohort
1839329|NCT00872027|Drug|Escitalopram|10 mg of escitalopram administered enterally with the option for dose escalation to 20 mg after 3 to 5 weeks if the medical condition is stable and no liver disease presents
1839330|NCT00872027|Drug|Placebo|Placebo pills for 8 weeks
1839331|NCT00872040|Other|Ultrasound assessment of pelvic floor|Sample of women will undergo ultrasound examination of their pelvic floor before and after delivery. The assessment will be performed by transperineal probe.
1959170|NCT00715520|Drug|Amphetamine Sulfate|"Participants will receive one oral dose of amphetamine sulfate 10mg 2 hours prior to measuring wrist extension movements.
The order in which Amphetamine Sulfate is given will be randomized per participant."
1959171|NCT00715520|Drug|Placebo|"Participants will receive one oral tablet of placebo 2 hours prior to measuring wrist extension movements.
The order in which Placebo is given will be randomized per participant."
1839334|NCT00872066|Device|SmartSet® HV bone cement|A high viscosity bone cement for use in total hip replacement (without gentamicin)
1839335|NCT00872066|Device|SmartSet® GHV bone cement|A high viscosity bone cement for use in total hip replacement (with gentamicin)
1839336|NCT00872079|Device|Genomics|Model predictive control is a computer based algorithm that can be applied to drug dosing. This computer tool uses a model of how a patient will respond to a drug dose based on demographic and historical dosing information to predict a new drug response. A drug dose controller applies all possible doses to the response model and selects the one dose that best meets the stated goals of the drug therapy. In the case of warfarin, we will calculate an international normalized ratio (INR) value within a specific target range.
1839337|NCT00872092|Other|Stable-isotope labeled lactose ureide breath test|2 g 13C-labeled lactose ureide orally
1839338|NCT00872105|Procedure|Non-operative Treatment|Standard protocol for conservative treatment will consist of the implementation of a sling, for clavicular support and patient comfort. Pendulum or gentle Range of Motion (ROM) shoulder exercises may be implemented at any time as dictated by the attending surgeon.
1839339|NCT00872105|Procedure|Operative Treatment|"The operating surgeon will determine the positioning of the patient for surgery. ORIF of the distal clavicle fracture will be carried out as follows:
Anatomic reduction of the fracture Definitive fixation with a contoured clavicle plate and screws; a AO hook plate; a 3.5 LCDC, reconstruction, or compression plate is acceptable; a 1/3 tubular plate is not acceptable Use of bone graft is optional (iliac crest bone autograft)"
1839340|NCT00872118|Behavioral|Brief Intervention for Socially Anxious Drinkers (BISAD)|integrated alcohol and social anxiety individual intervention
1959172|NCT00715520|Other|Sham Transcranial Magnetic Stimulation (TMS)|Sham TMS pulses will be randomly administered during TMS sessions.
1839341|NCT00872118|Behavioral|Enhanced Alcohol Skills Building and Education Program|alcohol-focused group intervention
1839342|NCT00872131|Drug|Sertraline|Oral sertraline will begin at 50 mg per day, then increase to 75 mg per day on Day 8, then increase to 100 mg per day on Day 15. The dose may be increased to 150 mg per day on Week 8, based on clinical response and medication toleration.
1839343|NCT00872144|Drug|Sativex|Sativex (or placebo) will be dispensed identical 5.5 ml containers. Participants will be instructed to start with a dose of 1 spray trans-mucosally at 1800 hrs. If there are no limiting adverse effects such as sedation or dizziness, participants will be instructed to increase the dose to 2 sprays- one in the morning and the other in the early evening on day two. Participants may increase the dose by 1-2 sprays per day to a maximum dose of 12 sprays per day given 3 sprays 4 times per day. In the initial titration phase participants will be instructed to space each dose actuation 15 minutes apart until accustomed to the preparation. Participants will titrate the dose to a level where they obtain an analgesic effect without limiting side effects.
1839344|NCT00872157|Drug|BMTP-11|Starting Dose of 6 mg/m2 by vein over 2 hours on Days 1, 8, 15, and 22.
1839345|NCT00872170|Drug|Sildenafil|"Participants will receive sildenafil for 12 weeks with the following therapy:
50 mg of oral sildenafil three times a day (TID) increased to 100 mg TID as tolerated in adults and children greater than 50 kg; 1 mg/kg sildenafil TID without dose escalation in children less than 50 kg"
1839346|NCT00872196|Drug|ABT-072|Blood samples are being taken from subjects previously treated with ABT-072.
1839347|NCT00872209|Drug|0.3% Ciprofloxacin Ear Drops|4 gtt BID for 7 days.
1839348|NCT00872209|Drug|0.3% Ciprofloxacin Foam Otic Cipro|1 application, BID for 7 days
1839349|NCT00872222|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
1839350|NCT00872235|Drug|fixed-dose combination of quinapril 20 mg and hydrochlorothiazide 25 mg tablets|
1839351|NCT00872248|Procedure|Spinal anesthesia|Procedures of spinal anesthesia with bupivacaine 0.5%, 10-15mg
1839352|NCT00872248|Procedure|Epidural anesthesia|Procedures of epidural anesthesia with ropivacaine 0.75%, 75-120mg
1839353|NCT00872274|Drug|sumatriptan 100mg|
1839354|NCT00872287|Procedure|Laparoscopic Cholecystectomy|Four ports classic laparoscopic cholecystectomy
1839355|NCT00872287|Procedure|SILS|Single transumbilical incision laparoscopic cholecystectomy
1839356|NCT00872300|Drug|PHA-739358|Weekly IV infusion for 3 consecutive weeks in a 4-week cycle
1839357|NCT00872326|Procedure|Autologous Bone Marrow Mononuclear Cells|Infusion > 80 millions mononuclear cells. Intraarterial administration at popliteal artery level. Infusion during 3 minutes with antegrade blockage of arterial flow.
1839358|NCT00872352|Procedure|EMG|Nerve conduction study will be consisted of sequential evaluation of the motor nerves: median, ulnar, peroneal and tibial; and the sensory nerves: median, ulnar, superficial peroneal and sural nerves using a standardized protocol
1839359|NCT00872365|Behavioral|Regular aerobic physical exercise|Walking (10 minutes), aerobic exercise (30 minutes), stretching (10 minutes) and relaxation exercise (10 minutes). Exercise will be performed at three sessions per week. All sessions will be supervised by a physical therapist and a physical educator.
1839360|NCT00872365|Dietary Supplement|Micronutrients|Zinc 30mg, Magnesium 400mg, Beta-carotene 9 mg, Tocopherol 30mg, vitamin C 200mg y Niacin 100mg.
1839361|NCT00872365|Other|Activities of daily living + placebo|"Basic activities of daily living (bathing, dressing, eating, walking) without counseling by a physical therapist and prenatal care.
Placebo Comparator: Equivalent to placebo (maltodextrin)."
1839362|NCT00872378|Drug|Exenatide|Exenatide titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
1839363|NCT00872378|Drug|Placebo|Placebo titrated up to 20mcg BID. (4 weeks at 5mcg BID; 4 weeks at 10mcg BID; 4 weeks at 15mcg BID; 37 weeks at 20mcg BID).
1839364|NCT00872391|Radiation|Hypofractionated linear accelerator radiotherapy|10 fractions of stereotactic linear accelerator radiotherapy with 6 Gy per fraction at the 80% isodose for the planning target volume.
1839365|NCT00872404|Drug|CP-751,871|20mg/kg/3 weeks
1839366|NCT00872417|Drug|first line ARV (3TC+NVP+D4T or 3TC+NVP+AZT)|use the generic regimens: 3TC+NVP+D4T or 3TC+NVP+AZT to initiate the ARV therapy, after 6 months, half of the group 3TC+NVP+D4T patients switch to the the treatment of 3TC+NVP+AZT
1839367|NCT00872417|Drug|second line ARV therapy (3TC+TDF+LPV/RTV)|Use 3TC+TDF+LPV/RTV to treat those drug resistance patients, to explore the efficiency and safety of the second line ARV available in China
1839368|NCT00872430|Other|Placebo|In order to produce similar taste and color, 7 drops of caramel color and 10 drops of orange essence were mixed into 1.6 liters of boiling water. The patients received 150 ml of placebo 3 times a day for 5 days.
1839369|NCT00872430|Other|Klein Laxative Tea|The laxative tea was prepared using 1 gram of grinded plant into 150 ml of water, left under infusion by 5 minutes. Patients received 150 ml of tea 3 times a day for 5 days.
1839370|NCT00872443|Other|Data collection|"Collection of characteristics of interauricular septum, characteristics of the CVA, and headache history.
Collection of anamnesis data, surgical past history, especially at the moment of the implement of prothesis, collection of dtat of transthoracic echography, transcranial echodoppler, holter ECG, cerebral MRI."
1839371|NCT00872469|Drug|Tranexamic acid|1-2 grams by intravenous injection
1839372|NCT00872469|Drug|Placebo [Saline]|Matched to active comparator
1839373|NCT00872482|Drug|nimotuzumab|Nimotuzumab (200 mg fixed dose) will be administered by the intravenous route weekly during WBRT and following WBRT Radiotherapy will consist of 30 Gy, in 10 fractions of 3 Gy/day.
1839374|NCT00872521|Drug|PAD induction|"Open Label Treatment:
Four 21-day Treatment Cycles Bortezomib 1.3 mg/m2 i.v. (D1, 4, 8 & 11), Doxorubicin 20 mg/m2 i.v. (D1 & 4), Dexamethasone 20 mg p.o. (D1, 2, 4, 5, 8 , 9, 11 & 12)"
1839375|NCT00872534|Drug|acetylsalicylic acid|325mg once a day for 7 days
1839376|NCT00872547|Device|DePuy ASR™ Hip System|Resurfacing system
1839377|NCT00872547|Device|DePuy ASR™ XL Head / ASR™ Acetabular Cup System|Large Metal-on-Metal Total Hip Replacement
1839378|NCT00872560|Device|NovoFine® needle 6 mm|
1839379|NCT00872560|Device|NovoFine® needle 8 mm|
1839380|NCT00872573|Device|C-Stem™ AMT Femoral Component (standard and high off-set variants)|A polished triple tapered cemented femoral component for use in total hip replacement
1839381|NCT00872586|Drug|olmesartan medoxomil + hydrochlorothiazide|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 20mg oral tablets + hydrochlorothiazide 12.5 mg oral tablets, once daily for up to 8 weeks
1839382|NCT00872586|Drug|olmesartan medoxomil|olmesartan medoxomil 20mg oral tablets, once daily for 4 weeks then olmesartan medoxomil 40mg oral tablets, once daily for up to 8 weeks
1839383|NCT00872599|Drug|fenofibrate|Subjects will be randomized to receive either fenofibrate 160 mg/day or matching placebo for five days by mouth.
1839384|NCT00872599|Drug|Placebo|Subjects will be randomized to receive placebo or fenofibrate for five days by mouth
1839385|NCT00872612|Procedure|EUS-FNA/EBUS-TBNA + BAL|"EUS-FNA = Endoscopic Ultrasound guided fine needle aspiration of mediastinal lymph nodes.
EBUS-TBNA = Endobronchial Ultrasound guided transbronchial needle aspiration of mediastinal and hilar lymph nodes.
BAL = bronchoalveolar lavage"
1839386|NCT00872612|Procedure|EBB + TBLB + BAL|EBB = Endobronchial biopsy TBLB = Transbronchial biopsy BAL = Bronchoalveolar lavage
1839387|NCT00872625|Drug|cyclophosphamide|
1839388|NCT00872625|Drug|docetaxel|
1839389|NCT00872625|Drug|epirubicin hydrochloride|
1839390|NCT00872625|Drug|fluorouracil|
1839391|NCT00872625|Procedure|neoadjuvant therapy|
1839392|NCT00872625|Procedure|therapeutic conventional surgery|
1839393|NCT00872625|Radiation|hypofractionated radiation therapy|
1839394|NCT00872625|Radiation|image-guided radiation therapy|
1839395|NCT00872625|Radiation|radiation therapy|
1839396|NCT00872625|Radiation|stereotactic radiosurgery|
1839397|NCT00872638|Procedure|Eversion|Surgical incisions will be closed in such a manner so as to evert the wound edges.
1839398|NCT00872638|Procedure|Approximation|Surgical incisions will be closed in such a manner so that wound edges are approximated exactly, i.e. without eversion.
1839399|NCT00872651|Drug|Travoprost 0.004%/Timolol 0.5%|Travoprost 0.004%/Timolol 0.5%
1839400|NCT00872651|Drug|Latanoprost 0.005% / Timolol 0.5%|Latanoprost 0.005% / Timolol 0.5%
1839401|NCT00872664|Dietary Supplement|carotenoids|beta-carotene, lycopene, lutein
1839402|NCT00872677|Behavioral|Diet|Talk to study dietitian (eight in person or by phone) weekly for the first 3 months, every other week for the next 3 months and monthly thereafter.
1839403|NCT00872677|Other|Spiritual counseling|Spiritual counselor weekly in months 6-9, every other week in months 9-12 and monthly thereafter.
1839404|NCT00872716|Drug|Quetiapine XR|100 mg single-dose Quetiapine XR
1839405|NCT00872716|Other|Placebo|Placebo
1839406|NCT00872729|Drug|Cystagon®|"Reference Product: Cystagon® (Cysteamine Bitartrate) Capsules, 150 mg/50 mg.
Duration of Treatment and Dose: Reference Period up to four doses Q6H."
1839407|NCT00872729|Drug|RP103|"Test Product: RP103 (Cysteamine Bitartrate) Delayed-release Capsules, 75 mg.
Duration of treatment and Dose: Single dose of Test Product at dose equivalent to Reference Product."
1839408|NCT00872742|Behavioral|Acceptance enhanced behavior therapy (AEBT)|Ten 1-hour sessions over 12 weeks, enhancing awareness of hair-pulling behavior and teaching strategies to deal with hair pulling
1839409|NCT00872742|Behavioral|Psychoeducation and supportive therapy (PST)|Ten 1-hour sessions over 12 weeks, teaching the participant about hair pulling and discussing how hair pulling affects those who do it
1839410|NCT00872755|Procedure|Nissen|Laparoscopic Nissen Fundoplication
1839411|NCT00872755|Procedure|Gastropexy|posterior gastropexy
1839412|NCT00872781|Drug|fixed dose combination of Quinapril HCl 20 mg and Hydrochlorothiazide 25 mg tablets|
1839413|NCT00872794|Device|DePuy ASR™ Hip System|A metal-on-metal bearing surface replacement system for use in resurfacing hip arthroplasty.
1839414|NCT00872807|Behavioral|Lifestyle counseling in groups|"The activity school in Finnmark. Lifestyle counseling (physical activity and dietary modification) in groups both at the hospital and in their own municipality.
They meet a multidisciplinary team, receive organized physical activity in the municipality and are invited to a 3 days camp after 4-6 months."
1839415|NCT00872807|Behavioral|Individual intervention|Conventional lifestyle counseling individually by single health professionals, both in hospital and in municipality.
1839416|NCT00872820|Behavioral|Acceptance- and commitment-based behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; strategies for dealing with anxiety will include mindfulness and acceptance of negative feelings
1839417|NCT00872820|Behavioral|Cognitive behavioral therapy|12 weekly treatment sessions conducted individually with a therapist; methods for dealing with anxiety will include cognitive and breathing strategies
1839418|NCT00872846|Device|BALANCE System intestinal electrical stimulator|The BALANCE System stimulates the duodenum in a specialized way to strengthen the natural contractions and mimic the sensation of fullness (satiety). The patient is expected to feel full after eating smaller amounts of food than normal. In addition, duodenal stimulation has been shown to induce favorable changes in postprandial glucose levels, glucose tolerance testing and insulin levels.
1839419|NCT00872859|Procedure|Implantation of Dermal Matrix substitute|Dermal Matrix implanted in post mastectomy pts at time of mastectomy.
1839420|NCT00872872|Drug|AZT/3TC 2 weeks after delivery|AZT/3TC 300/150mg will be given every 12 hours for 1 week after NVP discontinuation in arm 1 and for 2 weeks after NVP discontinuation in arm 2.
1839421|NCT00872885|Drug|GRT6005|liquid formulation, 200 to 600 µg, single dose, one day
1839422|NCT00872885|Drug|Morphine|60 mg
1839423|NCT00872885|Drug|Placebo|single dosage
1839424|NCT00872898|Drug|Memantine - Extended Release (ER)|Memantine - 3mg and 6mg capsules, dose ranging 3 - 18 mg/day in 4 weight groups, administered orally.
1839425|NCT00872898|Drug|Placebo|Placebo capsules, once daily, oral administration.
1839426|NCT00872911|Dietary Supplement|Amino acids|mixed pure crystalline amino acids for human use (Ajinomoto), 15 g/d
1839427|NCT00872911|Drug|Exercise|progressive exercise training
1839428|NCT00872924|Drug|sumatriptan 100mg|
1839429|NCT00872950|Drug|3,4-DIAMINOPYRIDINE|Treatment will begin with a low dose and will be increased as clinically needed as tolerated. The upper limit will be a total of 100mg/day.
1839430|NCT00872950|Drug|3,4-Diaminopyridine|
1839431|NCT00872963|Biological|RTS,S/AS01E|0.5MLS of RTS,S/AS01E at 0,1,2 monthly schedule 0.5mls Rabies vaccine at 0,1,2 monthly schedule
1839432|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #1: Dasatinib - Tablets/Oral Solution, at assigned dose level, once daily (QD)
1839433|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, 50 mg, then at 80 mg, at 80 mg, and at 100 mg, once daily (QD), at assigned ascending dose, for 28 day cycles for a maximum of six cycles
Bendamustine, injection, IV injection, 50 mg/m²/Day 1 and Day 2, then at 50 mg/m², at 70 mg/m², at 70 mg/m², at assigned ascending dose, once daily 30 minute IV infusion Day 1 and Day 2 for a maximum of six cycles"
1839434|NCT00872976|Drug|Dasatinib|One Week Initial Treatment for Cohort #2: Dasatinib - Tablets/Oral Solution, at 100 mg, once daily (QD)
1839435|NCT00872976|Drug|Combination of Bendamustine + Dasatinib|"Dasatinib, Tablets/Oral Solution, Oral, at 100 mg, once daily (QD), for 28 day cycles for maximum of six cycles
Bendamustine, injection, IV injection, 100 mg/m²/Day 1 and Day 2, once daily 30 minute IV infusion Day 1 and Day 2 for maximum of six cycles"
1839436|NCT00867438|Procedure|Sigmoidoscopy|
1839437|NCT00867451|Behavioral|Sleep Intervention|A structured sleep protocol is taught to parents, use of a white noise generator
1839438|NCT00867451|Drug|Melatonin|Body Weight <40mg will be given 3mg at bedtime for two weeks Body Weight >40mg will be given 6 mg at bedtime for two weeks
1839439|NCT00867477|Procedure|Breathing Test|Exhale into NO breath analyzer for 10 seconds, repeated 3 times (before radiation therapy starts, after completing radiation therapy, and after scheduled PET scan).
1839440|NCT00867477|Behavioral|Respiratory Symptoms Questionnaire|3 page questionnaire about breathing and any symptoms experienced, at each of 2 NO breathing tests.
1839441|NCT00867477|Procedure|Pet Scan|Between 40 and 50 days after the end of the radiation therapy. Ten (10) participants will receive a second PET scan within 2-7 days after the first PET scan in order to check reproducibility.
1839442|NCT00867490|Drug|Candesartan+HCTZ - Phase 1|4 weeks treatment with candesartan 32 mg (two 16 mg tablets) plus hydrochlorothiazide 25 mg (two 12.5 mg tablets) taken orally with water in the morning between 7 and 10 am.
1839443|NCT00867490|Drug|Aliskiren+HCTZ - Phase 2|Patients with uncontrolled mean sitting diastolic blood pressure (msDBP ≥ 90 mm Hg) at the end of Phase 1 were treated for 4 weeks with aliskiren 300 mg plus hydrochlorothiazide 25 mg in a single tablet taken orally with water in the morning between 7 and 10 am.
1839444|NCT00867490|Drug|Aliskiren+HCTZ+amlodipine - Phase 3|The first 60 patients with uncontrolled mean sitting systolic or diastolic blood pressure (msDBP ≥ 90 mm Hg and/or msSBP ≥ 140 mm Hg) at the end of Phase 2 were offered 4 weeks treatment with aliskiren 300 mg plus HCTZ 25 mg in a single tablet plus an amlodipine 5 mg tablet taken orally with water in the morning between 7 and 10 am.
1839445|NCT00867503|Drug|Bendamustine HCL|bendamustine HCL 90 mg/m2 intravenously on days 1(± 1 day) and 2 (± 1 day) every 28 days. If no grade ≥3 hematologic adverse event appears the dose will be escalated to 120 mg/m2 on days 1(± 1 day) and 2 (± 1 day) every 28 days at cycle 2.
1839446|NCT00872989|Drug|docetaxel|Given IV
1839447|NCT00872989|Drug|vandetanib|Given orally
1839448|NCT00873002|Drug|panobinostat|Dose escalation: 7.5 mg/m2 day 1 and day 8 of 21 days cycle 10 mg/m2 day 1 and day 8 of 21 days cycle 15 mg/m2 day 1 and day 8 of 21 days cycle 20 mg/m2 day 1 and day 8 of 21 days cycle 30 mg/m2 day 1 and day 8 of 21 days cycle
1839449|NCT00873002|Drug|sorafenib tosylate|400 mg PO BID
1839450|NCT00873015|Drug|Sodium nitrite|14 day continuous infusion of one of 3 escalating doses of sodium nitrite: 32 nmol/min/kg, 48 nmol/min/kg, or 64 nmol/min/kg
1839451|NCT00873015|Drug|Saline|14 day continuous infusion of a vehicle control infusion
1839452|NCT00873028|Other|In Hospital Cardiopulmonary Rehabilitation|The program consisted of bronchial hygiene characterized by detachment and removal of secretions and respiratory exercises which were applied in the respiratory muscles in order to strengthen and increase the resistance. Patients were instructed to maintain diaphragmatic breathing, at a rate of 12 to 18 breaths per minute during EPAP mask use, and the expiratory pressure was increased progressively in the following fashion: 3-8 cm H2O during 3-12 minutes. Also, they performed flexion/extension of hip and knee, active free exercises for upper limbs, ambulation exercise and ascent/descend of stairs
1839453|NCT00873041|Drug|deferasirox|Supplied as 125 mg, 250 mg and 500 mg tablets.
1839454|NCT00873041|Drug|placebo|Supplied as matching 125 mg, 250 mg and 500 mg tablets.
1839455|NCT00873067|Procedure|Additional Complex Fractionated Electrograms ablation|Atrial fibrillation ablation with pulmonary vein ablation and roof line. In addition, complex fractionated atrial electrograms ablation will be performed, lasting at most 30 minutes.
1839456|NCT00873067|Procedure|Standard atrial fibrillation ablation procedure|Standard procedure for persistent atrial fibrillation including circumferential pulmonary vein ablation and roof line, both being tested. No other lines or lesions will be performed.
1839457|NCT00873093|Drug|L-asparaginase|Given IM 6000 IU/m2/dose Days 2 and 9
1839458|NCT00873093|Drug|doxorubicin hydrochloride|Given IV 60 mg/m2/dose on Day 1
1839459|NCT00873093|Drug|therapeutic hydrocortisone|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22
1839460|NCT00873093|Drug|vincristine sulfate|Given IV 1.5 mg/m2 (max 2 mg) on Days 1, 8, 15 and 22
1839461|NCT00873093|Drug|cytarabine|Given IT or IV 3,000 mg/m2/dose on Days 1, 2, 8 and 9
1839462|NCT00873093|Drug|prednisone|Given PO or IV 40 mg/m2/day on Days 1-28
1839463|NCT00873093|Drug|bortezomib|Given IV 1.3 mg/m2/dose Block 1: Days 1, 4, 8 and 11 Block 2: Days 1, 4 and 8
1839464|NCT00873093|Drug|pegaspargase|Given IM or IV (over 2 hours) 2500 IU/m2/dose on days 2, 8,15 and 22
1839465|NCT00873093|Drug|methotrexate|Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22
1839466|NCT00873093|Drug|etoposide phosphate|Given IV 100 mg/m2/dose on Days 1-5
1839467|NCT00873093|Drug|cyclophosphamide|Given IV 440 mg/m2/dose on Days 1-5
1839468|NCT00873093|Biological|filgrastim|Given IV or SC 5 micrograms/kg/dose Only on Day 6
1839469|NCT00873093|Drug|leucovorin calcium|Given PO or IV 15mg/m2/dose q6h x 3 doses
1839470|NCT00873093|Other|laboratory biomarker analysis|Correlative studies
1839471|NCT00873093|Drug|High Dose MTX|IV 5000 mg/m2/dose Block 2: Day 22
1839472|NCT00873106|Device|Optical coherence tomography|Stratus OCT: fast radial lines 3D OCT-1000: radial 2048 and 3D OCT Cirrus HD OCT: 3D OCT
1839473|NCT00873119|Drug|belinostat, carboplatin, paclitaxel|
1839475|NCT00873145|Procedure|HMRS|Modular prosthetic replacement of the humerus and elbow.
1839476|NCT00873158|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
1839477|NCT00873184|Behavioral|Massage Therapy|The setting for massage intervention will take place at The Duke Center for Living (DCL). . The massage therapists at the DCL work closely with physicians to design appropriate interventions for patients who are receiving treatment at DUMC, including cancer patients. All DCL therapists have completed more than 600 hours of training, are nationally certified and hold a North Carolina license to practice massage. These types include Swedish, deep muscle, myofascial release, trigger point, acupressure, Bowen Technique, sports massage and chair massage.
1839478|NCT00873197|Drug|granisetron|"Sancuso® 3.1 mg/24 hours; transdermal. One patch applied to healthy intact skin on the upper outer arm and worn for 7 days (168 hours) followed by a second patch applied to the opposite arm at 168 hours for a further 7 days (168 to 336 hours).
Kytril® (granisetron hydrochloride) 1 mg/mL; IV; 0.01 mg/kg (maximum 1 mg) administered over 30 seconds immediately following patch application on Day 1 only."
1839479|NCT00873210|Drug|Sutent|50 mg per day for 4 consecutive weeks, followed by 2 weeks treatment pause
1839480|NCT00873223|Drug|liraglutide|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
1839481|NCT00873223|Drug|insulin detemir|Subjects will self-inject liraglutide subcutaneously daily during the trial and three euglycemic clamps will be performed: one without liraglutide (insulin detemir alone), the second with only liraglutide treatment and the third with liraglutide and insulin detemir administration
1839482|NCT00873236|Biological|bevacizumab|Given IV
1839483|NCT00873236|Biological|recombinant interferon alpha-2a|Given SC
1839484|NCT00873262|Drug|Skin test panel and desensitization kit|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.
Hormones:
Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L
Controls:
Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)
Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the appropriate hormone at the same concentration as it was used in the skin test as follows:
Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml
Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml
Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
1839485|NCT00873262|Drug|Skin test panel and solvent|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.
Hormones:
Progesterone 1mmol/L; Estradiol 1mmol/L; Estrone 3mmol/L; Estriol 3mmol/L
Controls:
Saline (NaCl) 0.9%; Ethyl Oleate with 10% Benzyl Alcohol; Histamine phosphate 1mg/ml (epicutaneous- prick test)
Patients with positive skin test to at least one sex hormone will be injected with an increasing volume of the solvent as follows:
Week 4th of the study (luteal phase of 2nd menstrual cycle) - 0.04 ml
Week 8th of the study (luteal phase of 3rd menstrual cycle) - 0.08 ml
Week 12th of the study (luteal phase of 4th menstrual cycle) - 0.16 ml"
1839486|NCT00873275|Biological|bevacizumab|5mg/kg IV day 1 and 15 of each 28 day course of treatment
1839487|NCT00873275|Drug|FOLFOX regimen|Leucovorin, 5-FU and Oxaliplatin
1839488|NCT00873275|Drug|fluorouracil|400 mg/m2 IV bolus immediately following leucovorin on days 1 and 15 of a 28 day course of treatment. Then 2.4 gm/m2 IV continuous infusion over 46 hours immediately following bolus dose on days 1 and 2 and 15 and 16 of a 28 day course of treatment
1839489|NCT00873275|Drug|leucovorin calcium|400 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
1839490|NCT00873275|Drug|oxaliplatin|85 mg/m2 IV infusion over 2 hours on days 1 and 15 of a 28 day course of treatment.
1839491|NCT00873275|Drug|ursodiol|Dose escalation in cohorts (3 patients/cohort) from an initial dose of 125 mg PO BID through 625 mgs PO BID beginning on Day -6 from infusion of bevacizumab and FOLFOX continuing for the duration of the treatment.
1839492|NCT00873275|Genetic|RNA analysis|Analysis on discard tissues
1839493|NCT00873275|Genetic|gene expression analysis|Determined in normal and malignant tissues in patients who undergo surgical resection after treatment on this trial
1839494|NCT00873275|Genetic|polymerase chain reaction|Analysis on discard tissues
1839495|NCT00873275|Genetic|western blotting|Determined on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
1839496|NCT00873275|Other|immunohistochemistry staining method|Performed on tumor blocks from the primary and the metastases from the patients on study
1839497|NCT00873275|Other|laboratory biomarker analysis|Performed on blood collected at Day -6, Day 0 and Day 7 (1 week after the first cycle of chemotherapy) from treatment and at the end of treatment
1839498|NCT00873275|Other|pharmacological study|Day 0, day 7 before treatment, 1/2 hour after the start of treatment, 1, 2, 3, 4, and 8 hours after the start of treatment.
1839499|NCT00873275|Procedure|positron emission tomography (PET)|Patients will undergo PET scan imaging as part of their original staging or at baseline. If the PET scan was more than 2 weeks prior to Day 0 from study treatment, there will be a PET scan at Day 0. In any case there will be a PET scan when the patient completes treatment.
1996404|NCT02487771|Drug|Placebo Capsule|600 mg of Soybean Oil and Corn Oil, which does not contain any DHA
1839502|NCT00873301|Procedure|vestibulectomy|Evaluation of the outcome of vestibulectomy which is the treatment of vulvar vestibulitis
1839503|NCT00873314|Behavioral|Bed rest|The woman assigned to the bed rest group, will be instructed to keep in bed for the study period of four days and will be allowed to go to the toilet
1839504|NCT00873314|Behavioral|Activity restriction|Women assigned to activity restriction group will do the restriction of activities during four days.During the activity restriction phase the women will be allowed to ambulate at home, work at home (home office), child care, household tasks, meal preparation or any forceless activities.
1839505|NCT00875524|Biological|Chimeric dengue serotypes (1, 2, 3, 4).|0.5 mL, Subcutaneous
1839506|NCT00875524|Biological|Meningococcal Polysaccharide A+C; NaCl; Typhoid Vi polysaccharide|Each at 0.5 mL, Subcutaneous, respectively
1839507|NCT00875537|Other|Capsaicin oral gel 0.025%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
1839508|NCT00875537|Other|Capsaicin oral gel 0.01%|Application 3 times daily for 14 days on the tongue, followed by 14 days wash-out
1839509|NCT00875550|Drug|Dexmedetomidine|Study drug titrated up or down to maintain target UMSS range.
1839510|NCT00875550|Drug|Midazolam|Rescue medication for sedation according to UMSS scores
1839511|NCT00875550|Drug|Fentanyl|Rescue medication for pain based on UMSS scores
1839512|NCT00875550|Drug|Morphine|Rescue medication for pain based on UMSS scores.
1839513|NCT00875563|Device|Zenith(R) Fenestrated AAA Endovascular Graft|The Zenith(R) Fenestrated AAA Endovascular Graft with the H&L-B One-Shot™ Introduction System is indicated for the endovascular treatment of patients with abdominal aortic or aortoiliac aneurysms having morphology suitable for endovascular repair
1839514|NCT00875602|Device|EverOn (EarlySense) contactless monitoring device|Hospitalized patients on the study unit are monitored by a contactless device
1839515|NCT00875615|Drug|Carboplatin|Carboplatin AUC =6 at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
1839516|NCT00875615|Drug|Cisplatin|Cisplatin 60 m/m² via percutaneous intrahepatic (IA) artery infusion at the investigator's discretion. Treatment is given every 6 weeks for up to 12 Cycles.
1839517|NCT00875615|Drug|Sorafenib|Sorafenib 400 mg po bid daily starting on Day 1 (± up to 3 days) continuously.
1839518|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 100 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
1839519|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Oral solution Dosage: PF-00868554 300 mg or placebo under fasting conditions Frequency: BID (twice daily) Duration: 14 days
1839520|NCT00875628|Drug|PF-00868554 or Placebo|Dosage Form: Tablet Dosage: PF-00868554 600 mg or placebo under fed conditions Frequency: BID (twice daily) Duration: 14 days
1839523|NCT00875667|Drug|Lenalidomide|"For patients with a creatinine clearance of ≥60 mL/min: 25mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity.
For patients who have a moderate renal insufficiency (creatinine clearance is ≥30 mL/min but <60mL/min: 10mg daily x 21 days of a 28 day cycle (Cycles 1 and 2). After Cycle 2, if the patient remains free of Grade 3 or Grade 4 toxicity, the dose will be increased to 15mg daily x 21 days of a 28 day cycle until disease progression or unacceptable toxicity."
1839524|NCT00875667|Drug|Investigators choice single agent|Investigators choice single agent - Chlorambucil, Rituximab, Cytarabine, Gemcitabine, or Fludarabine
1839525|NCT00875680|Device|autoPPC|To test the efficacy of autoPPC machines on residual sleep-related events during a one night autotitration polysomnography.
1839526|NCT00875693|Drug|CPX-351|CPX-351 is a liposomal formulation of a fixed combination of the antineoplastic drugs cytarabine and daunorubicin. The two drugs are present inside the liposome in a 5:1 molar ratio.
1839527|NCT00875706|Behavioral|Educational Intervention|The intervention consists of two (2) different types of training, both to be delivered through a train-the-trainer approach. The first of these is coaching-supervision training for nurse managers and other supervisory personnel in the CLC units. The second component is a one-day training for DCWs on communication and managing problem behaviors associated with dementia. These two trainings build on validated training models that have been developed by PHINational, but will be adapted and customized to include VA-developed clinical content on the management of problem behaviors associated with dementia.
1839528|NCT00875719|Device|Oxygen concentrators versus constant flow axygen|Each patient performed 2 walking tests, and received oxygen supplementation from a portable concentrator or a liquid oxygen source, in a random order.
1839529|NCT00875719|Device|oxygen concentrator|comparison walk distance and saturation with continuous oxygen compared to intermittent oxygen
1839530|NCT00875732|Device|Bi Ventricular Pacing|
1839531|NCT00875732|Device|Right Ventricular Pacing|
1839532|NCT00875745|Drug|Sorafenib-Vorinostat|Patients will be entered in successive cohorts. The first cohort will receive Sorafenib at 400 mg bid (800 mg daily) and Vorinostat at 100 mg bid (200 mg daily).
1839533|NCT00875758|Procedure|Removal of CSF through ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile + 2 standard deviations. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
1839534|NCT00875758|Procedure|Removal of CSF through a ventricular access device|Ventricular access devices (VADs) are surgically implanted when cranial ultrasound measures reach treatment group-specific criteria. For the standard-threshold arm, VADs will be implanted when the age-adjusted ventricular index shows the ventricles to be at the 97th percentile. Cerebrospinal fluid is then removed from the VADs 1-3 times daily as required to maintain ventricles within these parameters.
1839535|NCT00875771|Drug|Capecitabine+Irinotecan+Bevacizumab|"Capecitabine: 1000 mg/m2, bid, oral, days 2-8. Every 2 weeks
Irinotecan: 175 mg/m2, iv infusion 90 minutes, day 1, every 2 weeks
Bevacizumab: 5 mg/kg day 1, every 2 Weeks
Treatment will be given until disease progression or unacceptable toxicity."
1839536|NCT00875784|Drug|TREXIMA™|sumatriptan succinate / naproxen sodium tablet
1839537|NCT00875784|Drug|IMITREX® (4mg)|sumatriptan succinate injection (4mg) administered using the IMITREX STATdose System®
1839538|NCT00875784|Drug|IMITREX® (6mg)|sumatriptan succinate injection (6mg) administered using the IMITREX STATdose System®
1839539|NCT00875784|Drug|IMITREX Tablet 100mg|IMITREX 100mg tablet followed 2 hours later by a second IMITREX 100mg tablet
1839540|NCT00875797|Dietary Supplement|parenteral glutamine|Dipeptiven, Fresenius Kabi, Graz, Austria was given intravenously through central venous line in a dose up to 30 g per day
1839541|NCT00875797|Dietary Supplement|enteral glutamine|Alitraq, Abbott Laboratories, B.W. Zwolle, the Netherlands was given via nasogastric tube as continuous infusion of enteral diet, dose up to 30 g per day
1839546|NCT00875849|Radiation|radiation therapy|
1839547|NCT00875862|Procedure|Interscalene catheter with Ropivicaine or normal saline|Patients will be randomized to one of two groups: 0.2% Ropiviciane or normal saline in the infusion pump, following a shoulder manipulation for adhesive capsulitis. The patients will be followed by doctors and study staff to assess pain, range-of-motion and quality-of-life.
1839548|NCT00875875|Drug|Rifaximin|Rifaximin 200 mg TID for 3 days OR Rifaximin 600 mg Daily for 3 days
1839549|NCT00875888|Device|continuous venovenous hemodialysis|dialysate flow rate 35 ml/h/kg. Blood flow rate should be aimed at 200 ml/min, but not less than 150 ml/min. Bicarbonate- or lactate-buffered solutions will be used as dialysis fluids. Study dialyzers will be changed routinely every 24 h or earlier if the filter is obstructed by clotting.
1839550|NCT00875901|Radiation|Peripherally located lung tumor|12 cobalt gray equivalent per fraction for 4 fractions, 2-3 treatments per week (every other day), over 2 weeks for a total of 48 cobalt gray equivalent (Fractions at lest 40 hours apart)
1839551|NCT00875901|Radiation|Centrally located lung tumor|6 cobalt gray equivalent per fraction for 10 fractions, 5 treatments per week over 2-3 weeks for a total of 60 cobalt gray equivalent (no more than one fraction per calendar day)
1839552|NCT00875914|Procedure|RF-ablation|4mm-tip catheter manually guided vs magneticallly navigated
1839553|NCT00875927|Other|no scraping microcapsules|1, 4 grams isomalt candy containing no scraping microcapsules
1839554|NCT00875927|Other|scraping microcapsules containing inert TCP microcapsules|1, 4 grams isomalt candy containing 2% inert TCP scraping microcapsules
1839555|NCT00875927|Other|scraping microcapsules containing Propolis|1, 4 grams, isomalt candy containing 2% Propolis scraping microcapsules
1839556|NCT00875927|Other|scraping microcapsules containing and Zinc|1, 4 grams, isomalt candy containing 2% Zinc scraping microcapsules
1839557|NCT00875927|Other|scraping microcapsules containing Propolis and Zinc|1, 4 grams, isomalt candy containing 2% Propolis and Zinc scraping microcapsules
1839558|NCT00875940|Other|Diagnostic imaging procedures.|
1839559|NCT00875953|Procedure|standard neck dissection|standard surgical technique
1839560|NCT00875953|Procedure|Harmonic Scalpel Dissection|harmonic scalpel used for neck dissection after flaps are raised.
1839561|NCT00875966|Drug|Azithromycin for Oral Suspension 200mg/5mL Eon Pharma, LLC|
1839562|NCT00875966|Drug|Zithromax (azithromycin for oral suspension) 200mg/5mL Pfizer|Subjects randomized to Zithromax received a single oral dose of Zithromax 600mg (15mL), administered with 240mL of water under fed conditions
1839563|NCT00875979|Drug|Trastuzumab emtansine [Kadcyla] 3.0 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
1839564|NCT00875979|Drug|Trastuzumab emtansine [Kadcyla] 3.6 mg/kg|Trastuzumab emtansine was provided as a single-use lyophilized formulation.
1839565|NCT00875979|Drug|Pertuzumab 420 mg|Pertuzumab was provided as a single-use formulation.
1839566|NCT00875992|Device|ETN with ASLS|Angle stable locking of ETN using ASLS
1839567|NCT00875992|Device|ETN locked with conventional locking bolts|Conventional surgical procedure
1839568|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 80%
1839569|NCT00876005|Other|Oxygen by mask|Postoperatively, an aerosol face mask is used to deliver oxygen at 30%
1839570|NCT00876018|Other|Nutritional supplement|Fortified nutritional powder
1839571|NCT00876018|Other|Placebo|Un-fortified nutritional powder
1839573|NCT00876044|Drug|aflibercept (AVE0005)|Intravenous route
1839574|NCT00876044|Drug|placebo|Intravenous route
1839575|NCT00876057|Procedure|Total abdominal hysterectomy|Total abdominal hysterectomy
1839576|NCT00876057|Procedure|Subtotal abdominal hysterectomy|Subtotal abdominal hysterectomy
1839577|NCT00876083|Drug|Ultravist (Iopromide, BAY86-4877)|Patients with indication for an X-ray examination and for whom the radiologist has decided to use the contrast medium Ultravist.
1839578|NCT00876096|Other|Catch of blood then PCR|To optimize the technology of extraction of nucleic acids of origin fongique by collaborating with the laboratories of Parasitologie and Mycology of the TEACHING HOSPITAL of Rennes and Toulouse.
1839579|NCT00876109|Drug|GDC-0941|GDC-0941 will be administered in escalating oral doses QD or BID in Groups A and B, respectively. In Group C, the dose/regimen will be determined on the basis of data from Groups A and B. The overall starting dose will be 15 mg administered in the first cohort enrolled in Group A.
1839580|NCT00876122|Drug|GDC-0941|Escalating oral dose
1839581|NCT00876135|Drug|Ventolin|Ventolin or Placebo will be given before the 4 field tests (2 with ventolin in prevention and 2 with placebo in prevention) and 2 eucapnic voluntary hyperpnoea tests (one preceded by Ventolin and one preceded by Placebo).
1839582|NCT00876161|Drug|DAS181|DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 5 mg, 10 mg and 20 mg.
1839583|NCT00876161|Drug|Lactose|
1839584|NCT00876174|Procedure|Blood sampling of peripheral blood mononuclear cells|Group 1, (Patients): PMBC (20 ml blood) to be drawn at baseline, weeks 4 and 12 during antiviral therapy and 24 weeks following the end of antiviral therapy
1839585|NCT00876174|Procedure|Blood draw, 20ml peripheral blood mononuclear cells|One time blood draw of 20 ml
1839586|NCT00876187|Biological|Tanezumab 20 mg IV|2 IV administrations of tanezumab 20 mg at an 8 week interval
1839587|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
1839588|NCT00876187|Biological|Tanezumab 10 mg IV|2 IV administrations of tanezumab 10 mg at an 8 week interval
1839589|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
1839590|NCT00876187|Biological|Tanezumab 5 mg IV|2 IV administrations of tanezumab 5 mg at an 8 week interval
1839591|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
1839592|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
1839593|NCT00876187|Drug|Naproxen|Oral naproxen 500 mg twice a day for 16 weeks
1839594|NCT00876187|Biological|Placebo for tanezumab|2 IV administrations of placebo for tanezumab at an 8 week interval
1839911|NCT00882024|Drug|Placebo|Placebo tablets, bid, 12 weeks
1839595|NCT00876187|Drug|Placebo for naproxen|Oral placebo for naproxen twice a day for 16 weeks
1839596|NCT00876200|Drug|Minoxidil|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
1839597|NCT00876200|Drug|Placebo|"Normotension: 0.2mg/kg/day for children under 12 and 5mg/day for children aged 12 or more.
Hypertension: 0.2mg/kg/day, increasing up to a maximal dosage of 1 mg/kg) for children under 12. 5mg/day, increasing as needed of 0.1 mg/kg/day (up to a maximal dosage of 40 mg/day) for children aged 12 or more."
1839598|NCT00876226|Drug|Citalopram|"Citalopram pharmacokinetics will be studies in subjects with short bowel syndrome.
Citalopram 20mg orally will be given to the subjects and on the seventh day blood will be drawn at hours 0,1,2,3,4,6,8,12,16 and 24 hours post-dose."
1839599|NCT00876252|Biological|IC43|
1839600|NCT00876252|Drug|Placebo|NaCl
1839601|NCT00876265|Device|Belotero|Belotero, injectable hyaluronic acid gel device, implanted into the nasolabial fold in the Treatment Phase of the study (multiple injections of 0.1 to 0.2 mL, up to a maximum of 3 mL over 2 treatment sessions). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered.
1839602|NCT00876265|Device|Zyplast|Zyplast Collagen Implant, an injectable dermal collagen device, implanted into the nasolabial fold in the Treatment Phase of the study (average injection of 1.0 mL). Dose was based on the severity of the wrinkle, with a maximum dose to achieve 100% correction to be administered. Zyplast was obtained by each site from commercially available supplies.
1839603|NCT00876278|Device|*AT.Smart 46LC|Primary implantation of *AT.Smart 46 LC into the eye's capsular bag for the visual correction of aphakia in persons in whom the cataractous lens has been removed by phacoemulsification extracapsular cataract extraction. The IOL is intended to be placed only in an intact capsular bag. When implanted, the *AT.Smart 46LC replaces the natural lens of the eye and functions as a refracting medium in the correction of aphakia.
1839604|NCT00876291|Dietary Supplement|Lactobacillus GG (probiotic )|LGG capsules: each cp containing 3 × 109 colony forming units, CFU
1839605|NCT00876291|Dietary Supplement|Placebo|placebo which consisted of capsules identical in taste and appearance to the active study product except for the absence of freeze-dried LGG (and cryoprotectants)
1839606|NCT00876304|Drug|PF-04802540|Multiple ascending doses for 10 days; planned doses include capsules totaling 5 mg and 20 mg every 12 hours, with additional doses determined based on accumulating data
1839607|NCT00876304|Drug|Placebo|Placebo capsules every 12 hours for 10 days
1839608|NCT00876317|Drug|Etoricoxib 60 mg|Etoricoxib 60 mg per oz per day for 14 days
1839609|NCT00876317|Drug|Etoricoxib 90 mg|Etoricoxib 90 mg per oz for 14 days
1839610|NCT00876330|Other|Clinical Decision Support for Hypertension|Clinical decision support alerts for antihypertensive therapy
1839611|NCT00876330|Other|Automated Telephone Outreach for Antihypertensive Therapy|Automated Telephone Outreach to patients for antihypertensive medication therapy.
1839612|NCT00876330|Other|Clinical Decision Support for Lipid-lowering Therapy|Clinical Decision Support alerts for Lipid-lowering medication therapy.
1839613|NCT00876330|Other|Automated Telephone Outreach for Lipid-lowering Therapy|Automated telephone outreach to patients for Lipid-lowering medication therapy.
1839614|NCT00876343|Drug|Aripiprazole (Fixed dose)|administered orally once daily, 3 mg daily, 6 weeks
1839615|NCT00876343|Drug|Aripiprazole (Titrated dose)|administered orally once daily, 3 to 15 mg daily, 6 weeks
1839616|NCT00876343|Drug|Placebo|administered orally once daily, 6 weeks
1839617|NCT00876356|Dietary Supplement|Conjugated Linoleic Acid (CLA)|CLA 4.5g/day in three divided doses p.o. for 12 weeks
1839618|NCT00876356|Dietary Supplement|Olive oil|Olive oil 4.5g/day x 12 weeks
1839619|NCT00876395|Drug|Everolimus|
1839620|NCT00876395|Drug|Placebo|
1839621|NCT00876421|Drug|Placebo|Placebo / 12 weeks
1839622|NCT00876421|Drug|Tolterodine|4mg / 12 weeks
1839623|NCT00876421|Drug|ONO-8539|low dose / 12 weeks
1839624|NCT00876421|Drug|ONO-8539|medium dose / 12 weeks
1839625|NCT00876421|Drug|ONO-8539|higher dose / 12 weeks
1839626|NCT00876434|Drug|Sirolimus|
1839627|NCT00876447|Biological|Botulinum Toxin Type A 300U|Botulinum toxin Type A 300U injections into the detrusor > 12 weeks as needed for up to 3 years.
1839628|NCT00876447|Biological|Botulinum Toxin Type A 200U|Botulinum toxin Type A 200U injections into the detrusor > 12 weeks as needed for up to 3 years.
1839629|NCT00876460|Drug|BIBF 1120 M + docetaxel M|BIBF 1120 Medium dose bid + docetaxel 60 mg/m2
1839630|NCT00876460|Drug|BIBF 1120 M + docetaxel H|BIBF 1120 Medium dose bid + docetaxel 75mg/m2
1839631|NCT00876460|Drug|BIBF 1120 H + docetaxel H|BIBF 1120 HIgh dose bid + docetaxel 75 mg/m2
1839632|NCT00876460|Drug|BIBF 1120 L + docetaxel M|BIBF 1120 Low dose bid + docetaxel 60 mg/m2
1839633|NCT00876460|Drug|BIBF 1120 H + docetaxel M|BIBF 1120 HIgh dose bid + docetaxel 60 mg/m2
1839634|NCT00876473|Procedure|CPAP system|"Evaluating the effects of different CPAP systems on respiratory mechanics, respiratory effort and gas-exchange
CPAP systems:
Continuous high-flow CPAP with fixed value PEEP valve
Continuous high-flow CPAP with Boussignac valve
Demand flow CPAP supplied by ventilator"
1839635|NCT00876486|Drug|Genexol-PM®|Genexol-PM® 260mg/m2, intravenous infusion over 3 hours, every 3 weeks
1839636|NCT00876486|Drug|Genexol®|Genexol® 175mg/m2, intravenous infusion over 3 hours, every 3 weeks
1839637|NCT00876499|Behavioral|Questionnaire|A total of 8 questionnaires regarding fatigue taking approximately 30 minutes each, given before radiation therapy, weekly during, and after completion.
1839638|NCT00876525|Device|Freedom SOLO|The Freedom SOLO heart valve prosthesis is a stentless bioprosthesis manufactured with bovine pericardium.
1839639|NCT00876538|Drug|Olesoxime (TRO19622)|2 capsules of TRO19622 (330 mg) once day with the noon meal
1839640|NCT00876538|Drug|Placebo Control|Placebo Control 2 capsules once day with the noon meal
1839677|NCT00876876|Drug|Lixivaptan|Capsules containing 25, or 50 mg doses of oral lixivaptan to be administered BID or QD Lixivaptan will be administered for 12 weeks in the Open-Label Period which will be followed by a 4 week Randomized, Placebo-Controlled period.
1840241|NCT00873600|Other|medical chart review|
1839641|NCT00876551|Procedure|Endoscopic vacuum assisted closure|"Endoscopic debridement of wound using a regular biopsy forceps.
Introduction via the nose and oral exteriorization of a silicone duodenal tube (Freka Tube, 15 Ch, Fresenius Kabi, Bad Homburg v.d. H. Germany)
Fixation of a polyurethane foam (sponge, pore size 400-600 µm, KCI, Wiesbaden Germany) to the tip of the duodenal tube with a mersilene suture (0,35mm, Johnson & Johnson, St-Stevens-Woluwe, Belgium).
Trimming of the sponge to the specific wound size.
Endoscopic placement of the sponge in the intrathoracic leak with a grasping forceps (Olympus, Germany)
Application of continuous suction of 125mmHg using vacuum pump (KCI, Wiesbaden Germany).
Sponge exchange twice a week until wound grounds are clean and closed"
1839642|NCT00876564|Other|Trauma patients|
1839643|NCT00876577|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin injection with/without sequential tablet treatment according to the local product information
1839644|NCT00876603|Procedure|ACDF|Anterior cervical decompression and fusion
1839645|NCT00876603|Procedure|Cervical laminoplasty|Cervical laminoplasty
1839646|NCT00876616|Drug|Tacrolimus+Mycophenolate mofetil|FK506 4mg/d,MMF 1.0g/d
1839647|NCT00876616|Drug|Cyclophosphamide|CTX 0.75g/m2 BSA
1839648|NCT00876629|Device|Pneumatic Driver|"Ten healthy volunteers will undergo MR Elastography using a pneumatic driver connected to a commercially available speaker and the stiffness of the left kidney will be measured.
The examination will be repeated on the same volunteers at least one month later and the same stiffness measurements will be performed."
1839649|NCT00876642|Drug|Aloe vera gel|The aloe vera gel which was commercially available, contained water, aloe vera, D-panthenol, triethanolamine, carbomer 934P, hyaluronic acid, potassium sorbate, diazolidinyl urea, methylparaben, and propylparaben.
1839650|NCT00876655|Drug|TR-701 di-sodium phosphate salt|One 200 mg capsule of TR-701 di-sodium phosphate salt (equivalent to 150 mg TR-700)
1839651|NCT00876655|Drug|TR-701 free acid phosphate|One 182 mg capsule of TR-701 free acid phosphate (equivalent to 150 mg TR-700)
1839652|NCT00876681|Procedure|Popliteal catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: Popliteal-sciatic catheter placed via ultrasound-guidance or placed via electrical stimulation. All patients will be given 40ml of 1.5% mepivicaine prior to surgery and then given a pain pump after surgery containing 0.2% ropivacaine. The patients pain scores will be assessed just prior to surgery and the day following surgery. The time of catheter placement and numbness the patient is experiencing in their foot and toes is also assessed and recorded by research staff.
1839653|NCT00876694|Drug|Indacaterol 300 µg|Indacaterol 300 µg once daily (od) via SDDPI
1839654|NCT00876694|Drug|Salmeterol 50 µg|Salmeterol 50 µg twice daily (bid) via Diskus®
1839655|NCT00876707|Device|Tecnis implant|Implant of diffractive multifocal IOL Tecnis
1839656|NCT00876707|Device|ReSTOR implant|Implant of multifocal IOL ReSTOR
1839657|NCT00876707|Device|ReZoom implant|Implant of multifocal IOL ReZoom
1839658|NCT00876720|Device|rTMS - Intervention 1|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 20Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
1839659|NCT00876720|Device|rTMS - Intervention 2|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
1839660|NCT00876746|Procedure|Supraclavicular vs. Infraclavicular ropivicaine infusion|Patients will be randomized to one of two groups: nerve blocks in the supraclavicular location or the infraclavicular location. Following surgery the patient will be called by study staff to assess pain scores, sleep disturbances, infusion side effects, feeling in fingers and other study outcomes.
1839661|NCT00876759|Radiation|whole brain radiotherapy|WBRT in 10 fractions to a total dose of 30Gy
1839662|NCT00876759|Radiation|whole brain radiotherapy with simultaneous boost|Total dose: 10 fractions: whole brain total dose: 30Gy, metastases: total dose 50Gy
1839663|NCT00876772|Drug|Olanzapine|Randomized, placebo-controlled, parallel group trial to evaluate the effectiveness and tolerability of an oral dose of 10 mg Olanzapine in combination with Riluzole for the treatment of Loss of Appetite in patients with amyotrophic lateral sclerosis (ALS)
1839664|NCT00876785|Other|Rye bread breakfast|A randomised, within-subject comparison design was used. Appetite (hunger, satiety and desire to eat) was rated regularly from just before breakfast at 08:00 until 16:00. Amount, type and timing of food and drink intake during the study period were standardised.
1839665|NCT00876785|Other|wheat bread based breakfast|Reference wheat bread breakfast
1839666|NCT00876798|Drug|Lixivaptan|Capsules, 25mg lixivaptan or matching placebo once daily. Study medication can be titrated up to 50mg or 100mg once daily. Acceptable dosages are once daily administration of 25mg, 50mg, or 100mg as a single dose.
1839667|NCT00876798|Drug|Placebo|Capsule. Subjects will be randomized (3:1) on an outpatient basis to 25 mg lixivaptan or matching placebo, once daily.
1839668|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries daily for four weeks, followed by a four week period of non-treatment.
1839669|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of two-cups frozen red raspberries for an additional two weeks, followed by four weeks of non-treatment.
1839670|NCT00876811|Dietary Supplement|individually quick frozen red raspberries|Consumption of one-cup frozen red raspberries for two weeks, then consumption of four-cups frozen red raspberries for an addition two weeks, followed by four weeks of non-treatment.
1839671|NCT00876824|Drug|Amphotericin B Lipid emulsion|Amphotericin B lipid emulsion (Amphomul) 15 mg/kg on day 1 in group A for treatment of Visceral Leishmaniasis
1839672|NCT00876824|Drug|Liposomal Amphotericin B|Liposomal Amphotericin B in visceral leishmaniasis - 15 mg/kg on day 1 in group B
1839673|NCT00876850|Drug|PTK 0796|PTK 0796 100mg for injection; PTK 0796 tablet 150mg
1839674|NCT00876850|Drug|Linezolid|For gram positive treatment: Linezolid 600 mg tablets and pre-mixed 600mg IV infusion solution; For gram negative treatment: Moxifloxacin 400mg tablets and pre-mixed 400mg IV infusion solution
1839675|NCT00876863|Genetic|CERE-110: Adeno-Associated Virus Delivery of NGF|CERE-110 2.0 X 10^11 vg
1839676|NCT00876863|Procedure|Placebo Surgery|Placebo Surgery
1839678|NCT00876889|Drug|Riluzole|50mg PO (by mouth) every 12 hours starting within 12 hours of injury and continuing for 14 days (28 doses).
1839679|NCT00876902|Drug|recombinant P-selectin glycoprotein ligand Ig fusion protein|The active study drug dose includes both a 1 mg/kg IV infusion for the recipient and a 20 mg [approximately 0.27 mg/kg] as an ex vivo flush. The doses will be administered via 2 separate infusions of study agent: one 20 mg dose into the portal vein of the liver prior to implantation as an ex vivo flush with Viaspan®; and the second infusion of 1 mg/kg intravenously into the recipient, when technically feasible, prior to the hepatic artery anastomosis. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of study agent at the end of the transplant surgery.
1839680|NCT00876902|Drug|Viaspan® and saline|Placebo of a volume equivalent to active study drug will be prepared for administration to the control group to help maintain the blind. Those patients that experience an intraoperative blood loss of >10 units, will receive an additional 1 mg/kg IV infusion of placebo equivalent at the end of the transplant surgery.
1839681|NCT00876915|Drug|dalteparin injection|Potency is described in international anti-Xa units (IU). One unit (anti-Xa) of dalteparin sodium, average molecular weight 5,000, corresponds to the activity of one unit of the 1st International Standard for Low Molecular Weight Heparin (LMWH)with respect to inhibition of coagulation Factor Xa in plasma utilizing the chromogenic peptide substrate S-2765 (N-alpha-Benzyloxycarbonyl-D-arginyl-glycyl-arginine-pNA.2HCl).
1839682|NCT00876928|Drug|vitamin D|liquid vitamin D3 dissolved in medium chain triglyceride once a week
1839683|NCT00876928|Drug|placebo|medium chain triglyceride given once per week
1839684|NCT00876941|Behavioral|Standard Brief Intervention|"Intervention: Structured, brief negotiated interview.
Intervention preparation and content: Preparation: review of ASSIST results; Content: The intervention involves 4 major parts: 1) establishing rapport and asking the subject for permission to raise the topic of drug use; 2) exploring the pros and cons of use; 3) providing feedback and assessing readiness to change; and 4) advising and negotiating a plan.
Counselor: Health Promotion Advocate, High School graduate or GED minimum Training specific to the brief intervention: Didactic and experiential; competency demonstrated by observation and/or video recordings which are content scored using a standardized form.
Contacts, Duration: One, 10-15 minutes.
Communication content delivered to primary care physician: Results of screening and BI.
Supervision: Weekly 1-hour meeting with supervisor to discuss job performance and discuss cases; biannual shadowing by supervisor."
1839685|NCT00876941|Behavioral|Enhanced Brief Intervention|"Intervention: Less structured, motivational interview.
Intervention preparation and content: Preparation: review of ASSIST, drug consequences (SIP-D), risk behaviors, CIDI Short Form, and medical record for discussion; Content: Motivational interviewing discussing above.
Counselor: Master's level/Doctoral student.
Training specific to the brief intervention: Didactic and experiential, followed by additional work towards, and confirmation of, proficiency using audio recordings coded for motivational interviewing content.
Contacts, Duration: One plus offer of one optional booster contact, each 30-45 minutes; 2nd by telephone or in person depending on subject's preference; availability of counselor for further readiness discussions.
Communication content delivered to primary care physician: Results of screening, BI, and plan including follow-up.
Supervision: Weekly 1.5-hour meeting with supervisor with review of coded audio recordings."
1839686|NCT00876941|Behavioral|Control: Information and Feedback|Subjects randomized to the control group will not receive a BI at enrollment. But, all study subjects will receive screening and its results as part of the informed consent process (that they are at least at risk for drug use health hazards) along with a written list of resources available, including local options.
1839687|NCT00876954|Procedure|Normothermia|Warming without increase in core temperature
1839688|NCT00876954|Procedure|Hyperthermia|Core hyperthermia (39 °C) for 2,5 hours
1839689|NCT00876967|Device|metallic single use blade|metallic single use blade
1839690|NCT00876967|Device|plastic single use blade|plastic single use blade
1839691|NCT00876967|Device|metallic reusable blade|metallic reusable blade
1839692|NCT00876980|Device|nasal Continuous Positive Airway Pressure|A standard treatment for OSA. A portable machine delivers positive pressure through a mask to the upper airway during sleep at night.
1959173|NCT00715520|Other|Transcranial Magnetic Stimulation (TMS) Training|TMS surface electromyographic activity will be recorded with surface electrodes mounted on the skin overlaying a forearm muscle. Single pulses of TMS at increasing intensity will be delivered to measure motor cortex excitability. Peak acceleration and TMS evoked responses in the muscle will be measured prior to the training, after completion of the training and again one hour after completion of the training.
1839696|NCT00877006|Drug|bendamustine|
1839697|NCT00877006|Drug|rituximab|
1839698|NCT00877006|Drug|vincristine|
1839699|NCT00877006|Drug|prednisone|
1839700|NCT00877006|Drug|cyclophosphamide|
1839701|NCT00877006|Drug|doxorubicin|
1839702|NCT00877019|Device|Sonicare elite medium brush head|
1839703|NCT00877019|Device|Sonicare elite mini brushhead|
1839704|NCT00877019|Device|GABA Elmex sensitive extra soft toothbrush|
1839705|NCT00877019|Device|ADA reference toothbrush|
1839706|NCT00877032|Biological|RN6G|intravenous, single dose, dose ranging from 0.3mg/kg up to a maximum of 40 mg/kg.
1839707|NCT00877032|Biological|Placebo|intravenous, single dose with experimental dose.
1839708|NCT00877058|Behavioral|preventive home visit|
1839709|NCT00877058|Behavioral|senior meetings|
1839710|NCT00877071|Drug|LC Bead loaded with doxorubicin|LC Bead is a new product specifically designed for TACE. LC Bead microspheres will be loaded with between 50-100mg of doxorubicin for each of several TACE procedures. The bead will utilize embolic induced ischemia as well as local chemotherapy in an effort to downstage unresectable HCC to liver transplantation
1839711|NCT00877084|Other|Resistance training|Resistance training: series of 3x8 repetitions will be performed for the quadriceps muscle at 70% of the 1 Repetition Maximum determined as the weight the patient can lift once over the full range of motion. The weight can be applied using free weights or using a classical multi-gym device or a quadriceps chair.
1959177|NCT00703664|Drug|Bortezomib|Given IV
1839712|NCT00877084|Other|Usual care|usual care according to clinical pathway for COPD, No training
1839713|NCT00877097|Drug|Klodronate and Kliogest|
1839714|NCT00877097|Procedure|Placebo+ Kliogest|
1839715|NCT00877097|Drug|Bonefos|
1839716|NCT00877110|Drug|cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8|Patients will receive combination chemotherapy with intravenous (IV) cyclophosphamide 70mg/kg/day (for patients with body weight<70kg) or 2100mg/m2/day (for patients with body weight ≥70kg) for two days, IV vincristine 0.067mg/kg or 2mg/m2/day (lower of the two doses to be chosen; maximum 2mg) for one day, and IV topotecan 2.4 mg/m2/day for 3 days during their first cycle. If receiving a second and/or third cycle, the only chemotherapy patients will receive is cyclophosphamide at 50 mg/kg/day for 2 days. On Day 0, patients will receive a single dose of allogeneic NK cells isolated from a HLA-haploidentical related donor. On day +3, the patient will start daily infusion of 3F8 for 5 days. The treatment schedule may require minor adjustment by ±1 day as clinically indicated (e.g. due to PDH closure for holidays or due to inclement weather).
1839717|NCT00877123|Drug|Oral vitamin D 100,000 IU|Oral vitamin D 100,000 IU once a month for three consecutive months.
1839718|NCT00877123|Drug|Placebo|similar placebo once a month for three consecutive months
1839719|NCT00877136|Device|TheraSphere®|TheraSphere® consists of insoluble glass microspheres where yttrium-90 is an integral constituent of the glass. TheraSphere® is delivered into the liver tumor through a catheter placed into the hepatic artery. This artery provides the main blood supply to the tumor in the liver. TheraSphere® being unable to traverse the tumor vasculature is embolized within the tumor and exerts a local beta radiation radiotherapeutic effect with relatively limited concurrent injury to surrounding normal tissue.
1839720|NCT00877149|Drug|telbivudine/LDT600|
1839721|NCT00877162|Behavioral|Controlled crying and routines|Behavioural (teaching and support)
1839722|NCT00877175|Drug|1% tropicamide and 2.5% phenylephrine|For the eyes receiving lower conjunctival fornix packing (study group), one small piece of the cotton wool soaked with one drop of 2.5% phenylephrine and one drop of 1% tropicamide was packed in the lower conjunctival fornix. For the eyes receiving the instillation (control group), 2.5% phenylephrine and 1% tropicamide were alternately instilled every 5 minutes for two doses each.
1839723|NCT00877188|Other|exercise|supervised combined aerobic and progressive resistance training for 12 weeks
1839724|NCT00877201|Drug|CDR2|
1839725|NCT00877214|Drug|Rituximab|Follicular Lymphomas: induction therapy with bendamustine + rituximab. If CR or PR: Maintenance therapy with rituximab every 2 months for 4 years Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years
1839726|NCT00877214|Drug|Rituximab / observation|Follicular Lymphomas:induction therapy with bendamustine + rituximab If CR or PR: Maintenance therapy with rituximab every 2 months for 2 years (standard) Immunocytomas, marginal zone and mantle cell lymphomas: induction therapy with bendamustine + rituximab If CR or PR: observation (standard)
1839727|NCT00877227|Drug|5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv)|Folinic acid was given for two weeks as 5-formyltetrahydrofolate (10 mg/ml) (Pharmachemie bv). This solution was administered either intravenously (first week) or orally. To lower homocysteine in adults 5 mg/day folic acid is frequently used. Using an average bodyweight of 70 kg for adults we calculated a daily dose of 70 microgram/kg/day for our newborns.
1839728|NCT00877240|Behavioral|Behavioral intervention-to determine the effectiveness of a general intervention on healthy living habits of IDF staff|the program consists of 3 times a week of physical activity, nutrition advice, weight lodd program, stress workshop and smoking cessation workshop
1839729|NCT00877253|Drug|Genexol-PM 220mg/㎡, Carboplatin 5AUC|Genexol-PM 220mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
1839730|NCT00877253|Drug|Genexol-PM 260mg/㎡, Carboplatin 5AUC|Genexol-PM 260mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
1839731|NCT00877253|Drug|Genexol-PM 300mg/㎡, Carboplatin 5AUC|Genexol-PM 300mg/m2 by IV infusion over 3 hours on day 1 of every 21 day cycle. Carboplatin, AUC 5 given by IV infusion over 30-60 minutes on day 1 of every 21 day cycle.
1839732|NCT00877266|Procedure|perineural mepivicaine catheter placed via ultrasound or electrical stimulation|Patients will be randomized to one of two groups: catheter placement via ultrasound or nerve stimulation. Placement of the catheter will be timed by research staff and discomfort level asked after placement of catheter. If the catheter is not placed by the randomized method within 15 minutes, the practitioner my switch to the alternate method. Patients will be called the morning after surgery by research staff to assess discomfort levels.
1839733|NCT00877279|Device|CosmoDerm1|CosmoDerm1 is a single use syringe, injected into the mid dermal layer.
1839734|NCT00877279|Device|Belotero Soft|Dermal Filler
1839735|NCT00877305|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to 200 mmHg (at least a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line).
1839736|NCT00877305|Other|Control|Sham intervention with four 5-min cycles of inflation of the blood pressure cuff at 20 mmHg and 5 min deflation without any upper leg ischaemia.
1839737|NCT00877318|Device|SCAD information system|Cardiac rehabilitation at home by telemedicine
1839738|NCT00877331|Behavioral|Brief intervention using motivational interviewing|One brief, in-person motivational interviewing session (30-45 minutes) in conjunction with the medical appointment. Plus one brief follow-up phone call one week later.
1839739|NCT00877344|Device|LNG-IUC or Copper T380|Immediate timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
1839740|NCT00877344|Device|LNG-IUC or Copper T380|Interval Timing of insertion for a LNG-IUC OR Copper 380mg T-shaped IUD after an abortion for a gestational age between 12 weeks zero days and 23 weeks 6 days. Immediate insertions occur during the visit for the abortion immediately after the abortion is complete, interval insertions will be scheduled for not earlier than two weeks and not later than four weeks after the abortion.
1839741|NCT00877357|Biological|Shan 5|Diphtheria, tetanus, whole cell pertussis, recombinant hepatitis B and Hib tetanus toxoid conjugate pentavalent liquid combination vaccine
1839742|NCT00877370|Drug|ertapenem|One gram ertapenem will be infused intravenously in subjects receiving continuous hemodialysis (CVVHD). Pharmacokinetic sampling in this study will occur with the first dose of ertapenem. While on CVVHD, enrolled subjects will receive ertapenem 1 g intravenously administered over 30 minutes. Two blood samples (5 mL each) will be collected from the arterial (pre-diafilter) port of the CVVHD tubing at time 0 (baseline), ½ hour (end of infusion), 1, 1½, 2, 3, 6, 12, and 24 hours. Effluent (5 mL) will also be collected at these predefined time points from the effluent port of the CVVHD tubing. If ertapenem is discontinued after the first dose then additional samples will be collected at 36 and 48 hours, otherwise ertapenem will be administered as soon as the 24 hour sample is obtained.
1839743|NCT00877383|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
1839744|NCT00877383|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with the manufacturer's proprietary inhalation device (HandiHaler®).
1839745|NCT00877383|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
1839746|NCT00877396|Biological|Influenza vaccination|Influenza vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose (0.5 mL) 4 weeks later.
1839747|NCT00877396|Biological|Hepatitis A Vaccine|Hepatitis vaccination- 0.5 mL. Children under 9 who have never received a influenza vaccine will receive a 2nd dose ( saline- 0.5 mL) 4 weeks later.
1839748|NCT00877409|Drug|Benzoyl Peroxide 5% and Sulphur 2%|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
1839749|NCT00877409|Drug|Vehicle of Acnase|The product will be applied topically forming a thin layer, 1 time a day (at night) throughout the area affected by lesions.
1839750|NCT00877422|Dietary Supplement|Vitamin D3|Group A and Group C are followed without drugs and Group B is followed with vitamin D3.
1839751|NCT00877435|Behavioral|Cognitive behavioral therapy (CBT)|
1839752|NCT00877448|Biological|Adjuvanted Multimeric-001 250 Mcg|
1839753|NCT00877448|Biological|Multimeric-001 250 Mcg|
1839754|NCT00877448|Biological|Phosphate Buffered saline|
1839755|NCT00877448|Biological|Adjuvanted PBS|
1839756|NCT00877448|Biological|Adjuvanted Multimeric-001 500 Mcg|
1839757|NCT00877448|Biological|Multimeric-001 500 Mcg|
1839758|NCT00877448|Biological|Multimeric-001 125 Mcg|
1839759|NCT00877474|Drug|PM01183|Vials containing 0.2 mg of PM01183 as powder for concentrate for solution for infusion
1839760|NCT00877487|Drug|SPD489 (Lisdexamfetamine dimesylate)|1 capsule (either 30, 50, or 70mg strength) per day for 6 weeks.
1839761|NCT00877487|Drug|Placebo|1 capsule (identical to drug capsules) per day for 4 weeks during the double blind period.
1839762|NCT00877500|Drug|Ixabepilone|40 mg/m^2 by vein over 3 hours on Day 1 of each 21-day study cycle for up to 6 cycles.
1839763|NCT00877513|Behavioral|Smoking cessation|Smoking cessation program over 8 weeks, consisting of cognitive behavioral counseling every 2 weeks along with adjunctive use of bupropion
1839764|NCT00877526|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
1839765|NCT00877539|Drug|PF-03526299|Inhaled, two doses 4 hours apart
1839766|NCT00877539|Drug|Placebo|Inhaled, two doses 4 hours apart
1839767|NCT00877539|Drug|Fluticasone propionate|Inhaled
1839768|NCT00877578|Dietary Supplement|Nutri-Energie ®, Aliscience society|Nutri-Energie ® is a new cake of high caloric density and palatability, enriched in different specific pharmaco nutrients.
1839769|NCT00877578|Dietary Supplement|Clinutren 1.5 ®, Nestlé Clinical Nutrition|Clinutren 1.5 ®, isocaloric commercially available supplement, twice a day for 4 weeks, in addition to an enriched diet
1839770|NCT00877591|Drug|Fosamprenavir/Ritonavir|1400/200 mg once daily for 15 days total
1839771|NCT00877591|Drug|Darunavir/Ritonavir|800/100 mg once daily for 15 days total
1839772|NCT00877591|Drug|Rifampin|600 mg once daily for 15 days total
1839773|NCT00877591|Drug|Rifabutin|300 mg once daily for 15 days total
1839774|NCT00877591|Drug|Buprenorphine|"FOSAMPRENAVIR/RITONAVIR Dosing information: 1400 mg fosamprenavir + 200 mg ritonavir once daily for 15 days
DARUNAVIR/RITONAVIR Dosing information: 800 mg darunavir + 100 mg ritonavir once daily for 15 days
RIFAMPIN Dosing information: 600 mg once daily in the morning for 15 days
RIFABUTIN Dosing information: 300 mg once daily in the morning for 15 days"
1839775|NCT00877604|Drug|tauroursodeoxycholic acid (TUDCA)|Oral route at the dose of 1 g b.i.d. (2 g daily) for 1 year
1839776|NCT00877604|Drug|Placebo|identical placebo by oral route at the same dosing schedule
1839777|NCT00877617|Behavioral|QOL Questionnaire|Mailed survey.
1839778|NCT00877643|Other|Upstream therapy|Aldosterone receptor antagonists and statins, dietary restrictions, counseling, and cardiac rehabilitation.
1839779|NCT00877643|Other|Conventional rhythm control|Usual care for atrial fibrillation and heart failure according to the present guidelines
1839780|NCT00877656|Biological|HuMax-CD4|Active treatment
1839781|NCT00877669|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
1839782|NCT00877669|Procedure|Holmium Laser Enucleation of the Prostate|HoLEP using 100W Ho:YAG laser
1839783|NCT00877682|Procedure|Cryoablation|Under general anesthetic using ultrasonic guidance, freezing (cryoablation) portion of prostate.
1839784|NCT00877695|Behavioral|Entre Culturas: Navigating Culture, Identity, and HIV Risk|A pilot test of a culturally and developmentally tailored MEI to reduce risky sex (unprotected anal sex and multiple partners) among young Hispanic men who have sex with men (YHMSM) to be delivered face-to-face (FtF) and through the Internet using a real-time implementation approach. A tailored MEI for two delivery modalities, and a health education control (HEALTH) comparable in time and number of sessions. We will test the MEI's acceptability and feasibility, obtain effect size estimates of the intervention's strength to reduce risky sex, and determine if it is ready for efficacy testing.
1839869|NCT00878176|Procedure|First stage tined lead procedure|bilateral first stage tined lead placement
1839785|NCT00877721|Device|Self Mobility Improvement in the eLderly by using the SMILING system|The effect of treatment with the SMILING system on postural stability and gait of elderly individuals will be measured using RCT cross over study design
1839786|NCT00877734|Drug|baclofen|10 mg Baclofen administered tid for 11 weeks
1839787|NCT00877734|Drug|placebo|Placebo administered tid for 11 weeks
1839788|NCT00877734|Behavioral|BRENDA counseling|
1839789|NCT00877760|Drug|pegylated interferon a-2a|180 μg, once per week s.c. for 24 weeks
1839790|NCT00877760|Drug|Entecavir|0.5 mg once daily per os, either 72 weeks or 96 weeks
1839791|NCT00877773|Drug|Temsirolimus|25 mg by vein over 60 minutes on Days 1, 8, 15, and 22 of each 4-week study cycle.
1839792|NCT00877786|Behavioral|Cognitive Behavioral Group Therapy|Cognitive behavioral therapy (CBT) is a form of psychotherapy that addresses the links between thoughts, emotions and behaviors.
1839793|NCT00877799|Drug|CR845|CR845 (0.024 mg/kg) administered the day after surgery (Day 1)
1839794|NCT00877799|Drug|CR845|CR845 (0.008 mg/kg) administered the day after surgery (Day 1)
1839795|NCT00877799|Drug|CR845|CR845 (0.040 mg/kg) administered immediately after surgery (Day 0)
1839796|NCT00877799|Drug|Placebo|Matched placebo administered the day after surgery (Day 1)
1839797|NCT00877799|Drug|Placebo|Matched placebo administered immediately after surgery (Day 0)
1839798|NCT00877812|Dietary Supplement|Arm 1 glycine and leucine|Arm 1 glycine and leucine: A subset of 14 participants out of the total enrolled participants with an adequate nutritional status will undergo the tracer infusion of glycine and leucine amino acids protocol while an adequate vitamin pyridoxine, B6 status. After the first infusion each participant will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by a repeat of fasting blood sampling and tracer infusion protocol.
1839799|NCT00877812|Dietary Supplement|Arm 2 Intervention of Serine and methionine infusion|Arm 2 Intervention of Serine and methionine infusion: A subset of 14 participants out of the total enrolled participants. Received an adequate nutritional status will undergo the tracer infusion of methionine and serine amino acids protocol while in adequate vitamin pyridoxine, B6 status. After the first infusion each subject will then begin a diet low in vitamin B6 (<0.5 mg/d) for 4 weeks to achieve marginal B6 status followed by repeat of fasting blood sampling and tracer infusion protocol.
1839800|NCT00877825|Procedure|dairy food control diet and high- and low- isoflavone soyfood diets|
1839801|NCT00877838|Drug|NXN-188|NXN-188 600 mg (3 gelatin capsules each containing 200 mg) when experiencing migraine aura.
1839802|NCT00877838|Drug|Placebo|Gelatin capsules resembling the ones containing the active substance
1839803|NCT00877851|Behavioral|CD-ROM|The intervention group will receive an initial training session which will include a demonstration of the layout and main features of the CD−ROM and some instructions on how to navigate around the different sections of the CD−ROM. As a minimum level of use, participants will be asked to use the self−monitoring and goal setting aspects of the CD−ROM on at least a weekly basis.
1839804|NCT00877864|Behavioral|High volume combined aerobic/resistance exercise|High volume combined aerobic/resistance exercise
1839805|NCT00877864|Behavioral|Low volume combined aerobic/resistance exercise|Low volume combined aerobic/resistance exercise
1839806|NCT00877864|Behavioral|High volume combined A/R exercise, printouts, pedometers|High volume combined aerobic/resistance exercise, printouts, pedometers
1839807|NCT00877864|Behavioral|Low volume combined A/R exercise, printouts, pedometers|Low volume combined aerobic/resistance exercise, printouts, pedometers
1839808|NCT00877864|Behavioral|Printed PA information, pedometers and step log group|Printed PA information, pedometers and step log group
1839809|NCT00877864|Behavioral|Control|No exercise program provided by the study
1839810|NCT00877877|Procedure|Blood sampling|Blood samples were to be collected at Months 60, 72, 84, 96, 108 and 120
1839811|NCT00877890|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week
1839812|NCT00877890|Drug|exenatide twice daily|subcutaneous injection; 5mcg (4 weeks) and 10mcg (20 weeks); twice a day
1839813|NCT00877903|Drug|Prochymal®|Intravenous infusion of ex vivo cultured adult human mesenchymal stem cells
1839814|NCT00877903|Drug|Placebo|Intravenous infusion of excipients of Prochymal®
1839815|NCT00877929|Drug|Telmisartan 80|Telmisartan 80 mg
1839816|NCT00877929|Drug|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
1839817|NCT00877929|Drug|Amlodipine 10|Amlodipine 5 for two weeks, then forced titration to Amlodipine 10
1839818|NCT00877955|Drug|alprazolam sublingual tablet commercial|0.5 mg sublingual tablet, single dose
1839819|NCT00877955|Drug|alprazolam sublingual tablet test|0.5 mg tablet, single dose
1839820|NCT00877968|Dietary Supplement|Whole wheat banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 62.8 g Available CHO: 51.7 g"
1839821|NCT00877968|Dietary Supplement|Whole pea flour banana bread|"Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 67.8 g Available CHO: 52.0 g"
1839822|NCT00877968|Dietary Supplement|Whole wheat biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 79.8 g Available CHO: 53.1 g"
1839823|NCT00877968|Dietary Supplement|Whole pea flour biscotti|"Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 86 g Available CHO: 51.7 g"
1839824|NCT00877968|Dietary Supplement|Whole wheat pasta|"Dose was portioned so that subjects received 50 g available carbohydrate
Portion (Dry): 70 g Available CHO: 51.1 g"
1839825|NCT00877968|Dietary Supplement|Whole pea pasta|"Dose was portioned so that subjects received 50 g available carbohydrate Pea pasta is 30% whole pea pasta, 70 white wheat durum
Portion (Dry pasta) : 90 g Available CHO: 53.1 g"
1839826|NCT00877968|Dietary Supplement|White bread|"Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 100 g Available CHO: 50 g"
1839827|NCT00877968|Dietary Supplement|Boiled yellow peas|"Dose was portioned so that subjects received 50 g available carbohydrate
Portion: 100 g (dry) --> 250 g cooked Available CHO: 52.8 g"
1839828|NCT00877981|Procedure|Minimal invasive Parathyroid surgery|
1959178|NCT00703664|Other|Laboratory Biomarker Analysis|Correlative studies
1959179|NCT00703664|Drug|Vorinostat|Given PO
1839829|NCT00877994|Behavioral|Nurture Support Group Therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists.
1839830|NCT00877994|Behavioral|Group therapy|Participants will be randomly assigned (like the flip of a coin) to either receive the curriculum immediately (immediate group) or at a later time point approximately 16 weeks later (delayed group). Both groups will receive 16, 90 minute long group sessions delivered over 4 months. Groups will include 4-8 mothers and one or two co-therapists. The curriculum will focus on increasing positive healthy eating patterns in children of mothers who have had disordered eating and body image struggles.
1839831|NCT00870350|Biological|Td5ap|Intramuscular injection of 0.5 mL Td5ap (COVAXiS) on day 1.
1839832|NCT00870350|Biological|Td1aP|Intramuscular injection of 0.5 mL Td1aP (diTekiBooster) on day 1.
1839833|NCT00870363|Drug|maraviroc in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food taken in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
1839834|NCT00870363|Drug|maraviroc plus raltegravir in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor)|maraviroc 300mg 1 tablet taken twice a day without regard to food PLUS raltegravir 400mg 1 tablet taken twice a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
1839835|NCT00870363|Drug|efavirenz [or other NNRTI (non-nucleoside reverse transcriptase inhibitor)]|efavirenz 600mg 1 capsule is taken once a day without regard to food in combination with 2 NRTIs (dual nucleoside reverse transcriptase inhibitor) pre-determined with primary care physician
1839836|NCT00870376|Other|biomarkers|To define a biomarker or combination of overactive bladder syndrome
1839837|NCT00870402|Drug|Spironolactone|25 mg per day for 9 months
1839838|NCT00870402|Drug|Placebo|Placebo 1 tablet per day for nine months
1839839|NCT00870415|Procedure|quality-of-life assessment|
1839840|NCT00870415|Procedure|therapeutic conventional surgery|
1839841|NCT00870441|Drug|ASP2151|Oral
1839842|NCT00870441|Drug|Valacyclovir|Oral
1839843|NCT00870441|Drug|Placebo|Oral
1839844|NCT00870454|Drug|Pregabalin 300 mg/d|75 mg/d twice daily for Week 1, followed by 150 mg twice daily for the remainder
1839845|NCT00870454|Drug|Carisbamate 800 mg/d|200 mg/d twice daily, titrated up to 400 mg twice daily, as tolerated, by Week 3
1839846|NCT00870454|Drug|Carisbamate 1,200 mg/d|200 mg/d twice daily, titrated up to 600 mg twice daily, as tolerated, by Week 3
1839847|NCT00870454|Drug|Placebo|Placebo capsules twice daily
1839848|NCT00878007|Drug|Intermittent screening and treatment for malaria|All children will be screened for malaria using rapid diagnostic tests (RDTs) once a term (thrice yearly). Children (with or without clinical malaria symptoms) found to be RDT-positive will be treated with artemether-lumefantrine according to national guidelines. Screening and treatment will be administered by district public health staff once a school term, observed by the evaluation research team.
1839849|NCT00878007|Behavioral|Teacher training on literacy instruction|Education intervention designed to improved early grade literacy instruction, focusing on phonological awareness & vocabulary and relationship between letters and sounds in a systematic and explicit fashion. Specific interventions will include training on (i) how to monitor students' progress in large classes (ii) developing and using instructional materials for reading (iii) lesson planning for explicit teaching of letter-sound relationships (iv) instructional techniques for large classes.
1839850|NCT00878007|Other|IST plus literacy instruction programme|Schools will receive both IST and the literacy instruction programme
1839851|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose, 1 day
1839852|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, 1 day
1839853|NCT00878020|Drug|BMS-830216|Capsules, Oral, Single Dose on Day 1, Period 1 and Day 1, Period 2, 2 days
1839854|NCT00878020|Drug|Placebo|Capsules, Oral, 0mg, Single Dose, on Day 1, Period 1 and Day 1, Period 2, 2 days
1839855|NCT00878046|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
1839856|NCT00878072|Drug|Famciclovir|Famciclovir 1500 mg (3 x 500 mg tablets) oral as a single dose.
1839857|NCT00878085|Device|Robot Therapy Device|3x a week for 4 weeks
1839858|NCT00878085|Behavioral|Occupational Therapy|3x a week for 4 weeks
1839859|NCT00878111|Drug|NGR-hTNF|"First cohort: iv q3W 60 mcg/sqm over 120 min*
Second cohort: iv q3W 80 mcg/sqm over 120 min*
Third cohort: iv q3W 100 mcg/sqm over 120 min*
Fourth cohort: iv q3W 125 mcg/sqm over 120 min*
Fifth cohort: iv q3W 150 mcg/sqm over 120 min*
Sixth cohort: iv q3W 175 mcg/sqm over 120 min*
Seventh cohort: iv q3W 200 mcg/sqm over 120 min*
Eighth cohort: iv q3W 225 mcg/sqm over 120 min*
Ninth cohort: iv q3w 250 mcg/sqm over 120 min*
Tenth cohort: iv q3w 275 mcg/sqm over 120 min*
Eleventh cohort: iv q3w 300 mcg/sqm over 120 min*
Twelfth cohort: iv q3w 325 mcg/sqm over 120 min*
* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period."
1839860|NCT00878124|Dietary Supplement|Coenzyme Q10 co treatment|CoenzymeQ10 300mg twice a day continuously. Ceased when patient conceives or at the end of the study.
1839861|NCT00878124|Other|Placebo Caps|3 caps twice a day continuously until pregnant or at the end of the study.
1839862|NCT00878137|Device|INR by point-of-care instruments and venopuncture|Three fingersticks will be performed and from each one drop of capillary or venous whole blood collected from a fingerstick performed by the primary investigator to measure PT/INR using the CoaguChekXSTM (10 microliters), ProTimeTM (27 microliters), the investigational ProTime, and INRatioTM 15 microliters) point-of-care instruments and one i.v. blood draw (20 mL of blood) will be performed by a phlebotomist.
1839863|NCT00878150|Behavioral|In-person Cognitive Behavioral Therapy|12 sessions of CBT delivered in-person over 16 weeks
1839864|NCT00878150|Behavioral|Telephone Cognitive Behavioral Therapy|12 sessions of telephone-based CBT over 16 weeks
1839873|NCT00878228|Drug|Ondansetron|The study group will receive 4 mg of IV ondansetron perioperatively and also postoperative oral ondansetron tablets (8 mg each day for two days). The tablets will be concealed in generic capsules prepared by the pharmacy at the Hospital for Special Surgery to make the ondansetron tablets indistinguishable from the placebos.
1839874|NCT00878228|Drug|Placebo|The control group will receive IV ondansetron intraoperatively and then oral placebo tablets (for 2 days). These placebo tablets will contain lactose and be indistinguishable from the study medication.
1839875|NCT00878241|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
1839876|NCT00878254|Biological|G-CSF|Granulocyte-colony stimulating factor (G-CSF) 480 mcg subcutaneously (SQ) starting on Day 13 of Cycles 1 and 3; and Day 7 of Cycles 2 and 4, per study protocol.
1839877|NCT00878254|Drug|Rituximab|Rituximab 375 mg/m^2 intravenously (IV) on Day 1 for 4 Cycles, per study protocol. For study participants achieving complete remission, during maintenance therapy every 6 months for up to three years, per study protocol.
1839878|NCT00878254|Drug|Cyclophosphamide|Cyclophosphamide 800 mg/m^2 IV on Day 1 and 200 mg/m^2 IV on Days 2 through 5 of Cycles 1 and 3, per study protocol.
1839879|NCT00878254|Drug|Cytarabine|Cytarabine 2 grams/m^2 IV on Days 1 and 2 of Cycles 2 and 4, per study protocol.
1839880|NCT00878254|Drug|Doxorubicin|Doxorubicin 45 mg/m^2 IV bolus Day 1 of Cycles 1 and 3, per study protocol.
1839881|NCT00878254|Drug|Etoposide|Etoposide 60 mg/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
1839882|NCT00878254|Drug|Ifosfamide|Ifosfamide 1.5 grams/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
1839883|NCT00878254|Drug|Leucovorin|Leucovorin: 100 mg/m^2 IV beginning 36 (+/-4) hours after start of Methotrexate infusion, and then 10 mg/m^2 at 6 hour (+/- 30 min) intervals until Methotrexate level is < 0.1 µmol/L during Cycles 1 and 3 per study protocol.
1839884|NCT00878254|Drug|Mesna|Mesna 360 mg/m^2 IV on Days 1 through 5 of Cycles 2 and 4, per study protocol.
1839885|NCT00878254|Drug|Methotrexate|Methotrexate 1,200 mg/m^2 in 250 mL D5W IV over 1 hour, followed by Methotrexate 3,000 mg/m^2 in 1,000 mL D5W by continuous infusion over 23 (+/-2) hours on Day 10 of Cycles 1 and 3, per study protocol.
1839886|NCT00878254|Drug|Vincristine|Vincristine 1.5 mg/m^2 IV push (maximum of 2 mg) on Days 1 and 8 of Cycles 1 and 3, per study protocol.
1839887|NCT00878267|Behavioral|Interview|3 step process including person to person meeting and questionnaires taking about 30 minutes.
1839888|NCT00878293|Drug|GRT6005|liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days
1839889|NCT00878293|Drug|MS Continus®|60 mg, capsule, once daily
1839890|NCT00878293|Drug|Placebo|liquid formulation and capsule, once daily
1839891|NCT00878306|Drug|Disulfiram|62.5 mg daily x3 days, then 250 mg daily x3 days
1839892|NCT00878306|Drug|Disulfiram + Efavirenz|Efavirenz 600 mg daily x10 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
1839893|NCT00878306|Drug|Disulfiram + Atazanavir|Atazanavir 400 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
1839894|NCT00878306|Drug|Disulfiram + Ritonavir|Ritonavir 200 mg daily x8 days, then in addition with 62.5 mg daily x3 days, then Disulfiram 250 mg daily x3 days
1839895|NCT00878319|Procedure|Open reduction and internal fixation (ORIF)|Antero-latero or posterior surgical approach using a 3.5 mm or 4.5 mm dynamic compression plate (DCP) or 4.5 mm broad DCP.
1839896|NCT00878319|Other|Non-surgical|Sugartong splint followed by transition to functional co-aptation brace
1839897|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
1839898|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
1839899|NCT00881907|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection and cell proliferation.
1839900|NCT00881920|Biological|Kappa CD28 T cells|"T cells will be given in a lymphopenic environment. Patients will receive T-cell products transduced with CAR-Kappa, with or without lymphodepleting chemotherapy (Cy/Flu) prior to T cell infusion as outlined below:
Patients who are not lymphopenic may receive 3 daily doses of cyclophosphamide (500mg/m2/day) together with fludarabine (30mg/m2) to induce lymphopenia, finishing at least 24 hours before T cell infusion.
Patients with lymphopenia due to current drug therapy may be infused at any time starting at least 24 hours after finishing their current cycle of chemotherapy.
ASCT recipients (relapsed/refractory intermediate grade lymphoma) may be infused 14-60 days after the date of transplant.
Group 1: Day 0 2x10^7 cells/m^2 CAR-Kappa
Group 2: Day 0 1x10^8 cells/m^2 CAR-Kappa
Group 3: Day 0 2x10^8 cells/m^2 CAR-Kappa"
1839901|NCT00881933|Other|Cyclophosphosphamide, TBI|fludarabine (30 mg/m2 once daily i.v. on days -7, -6, -5, -4, -3, & -2) (if body weight < 10 kg or if age < 1 year: 1.33 mg/kg) cyclophosphamide (60 mg/kg once daily i.v. on days -9, & -8) total body irradiation (3G on days -1)
1839902|NCT00881946|Drug|GSK21110183|Starting Dose = 25mg once daily with dose escalation until unacceptable toxicity develops
1839903|NCT00881959|Device|Puros® Dermis versus Alloderm®|Puros Dermis and Alloderm (both Allograft Tissue Matrix)
1839904|NCT00881972|Behavioral|Exercise|walking/running/cycling
1839905|NCT00881985|Device|continuous positive airway pressure|Use CPAP whenever sleep
1839906|NCT00881998|Procedure|Minimally Invasive Total Hip Arthroplasty|
1839907|NCT00881998|Procedure|Conventional Total Hip Arthroplasty|
1839908|NCT00882011|Other|Latest generation chemotherapies for T-LBL + transplant|"Standard doses of one of the following chemotherapies:
Holzer
LSA2-L2 modified
Stanford regimen
Hyper CVAD
Sequential treatments analogous to the ones above mentioned (e.g.: GIMEMA LAL094, others)
Intensive chemotherapy, ALL-type, MRD oriented (NILG-TLL Clinical Trial)
Autologous transplant or allogeneic transplant or mini-allogeneic transplant"
1839909|NCT00882024|Drug|Tranilast|150 mg tranilast tablets, bid, 12 weeks
1839910|NCT00882024|Drug|Tranilast|75 mg tablets, bid, 12 weeks
1959182|NCT00695305|Drug|rilapladib|250 mg oral dose once daily
1959183|NCT00695305|Drug|placebo|placebo
1959184|NCT00695305|Other|18F Fluorodeoxylucose (FDG)-PET|FDG-PET
1959185|NCT00692770|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg twice daily (BID)
1839915|NCT00882063|Drug|P276-00|Subjects will be enrolled at different dose levels of P276-00 to determine maximum tolerated dose of P276-00.Starting dose level of P276-00 is 50 mg/m2/day to be administered intravenously in 200 ml of 5% dextrose (D5W) over a period of 30 min from day 1 to day 5 every 21 days. This constitutes one cycle of P276-00. Six such cycles will be administered to subjects.
1959186|NCT00692770|Drug|Placebo|Placebo 2 tablets twice daily (BID)
1839918|NCT00882089|Device|Contura catheter|Radiation therapy is delivered to a total dose of 34 Gy in 10 fractions bid over 5-7 days. Each day, the high dose rate iridium-192 brachytherapy treatments are separated by 6 hours. Each radiation treatment takes 15-30 minutes.
1839919|NCT00882102|Drug|Decitabine|Decitabine 20 mg/m^2 IV over 1-1/2 hours daily for 5 days.
1839920|NCT00882102|Drug|Gemtuzumab ozogamicin|Gemtuzumab ozogamicin 3 mg/m^2 IV on day 5.
1839922|NCT00882141|Behavioral|Diet modification|Weight loss sessions are held by a registered dietitian for 1 hour once a week for 6-9 months; recommended caloric intake to elicit a weight loss of approximately 0.2-0.4 kg per week
1839923|NCT00882141|Behavioral|Aerobic exercise|Treadmills and other aerobic exercise equipment 3 times a week for 6-9 months, beginning at low levels of VO2max and progressing in duration and intensity to more than 75% VO2max for 45 minutes
1839924|NCT00882154|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
1839925|NCT00882154|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
1839926|NCT00882167|Other|CineMRI|CineMRI scan of the abdomen at 1.5 Tesla.
1839927|NCT00882180|Drug|ALN-VSP02|IV infusion administered every two weeks
1839928|NCT00882193|Drug|Betaine|Betaine 20 gm/day in 2 divided doses for 48 weeks
1839929|NCT00882193|Drug|Peginterferon alpha 2a|Peginterferon alpha 2a 180mcg/0.5ml by subcutaneous injection weekly for 48 weeks
1839930|NCT00882193|Drug|Ribavirin|Ribavirin 200mg - weight based, 1000 - 1200 mg/day for body weight < or > 75mg in 2 divided doses
1839931|NCT00882206|Drug|cytarabine|"At baseline when peripheral blood draw and bone marrow aspirate performed.
*Intrathecal Cytarabine administered dependent upon age - ranging from 30 mg to 70 mg."
1839932|NCT00882206|Drug|decitabine|Days 1-4, 15 mg/m^2 intravenously (IV) over 1 hour
1839933|NCT00882206|Drug|doxorubicin hydrochloride|Day 5, 60 mg/m^2 intravenously (IV) over 15 minutes
1839934|NCT00882206|Drug|imatinib mesylate|340 mg/m2 by mouth every day (rounded to the nearest 100 mg) for age <18 years and 400 mg orally every day for >18 years on Days 5-33.
1839935|NCT00882206|Drug|methotrexate|**Intrathecal Methotrexate administered dependent upon age - ranging from 8 mg to 15 mg.
1839936|NCT00882206|Drug|pegaspargase|2,500 IU/m2 IM or IV q week (days 6, 12, 19, 26)
1839937|NCT00882206|Drug|prednisone|40mg/m2/day divided BID (days 5 - 33)
1839938|NCT00882206|Drug|vincristine sulfate|1.5mg/m2 (max 2 mg) iv push q week (days 5, 12, 19, 26)
1839939|NCT00882206|Drug|vorinostat|Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
1839940|NCT00882219|Device|Xience V®|Placement of a Xience V® stent within a restenosed bare metal stent.
1839941|NCT00882232|Device|Cross-linked hyaluronan gel|"Single, transperitoneal injection of 9 mL cross-linked hyaluronan gel into anterior perirectal fat under anesthesia. The gel is injected prior to the start of radiotherapy and is absorbed by the body over several months. It increases the seapartion between the prostate and rectum by 1/3 to 2/3 at the start of radiotherapy."
1839942|NCT00882245|Other|Vehicle ointment|Topical vehicle cream
1839943|NCT00882245|Drug|Ointment|SRD441 Ointment
1839944|NCT00882258|Drug|12.5 mg Proellex|12.5 mg Proellex administered orally daily
1839945|NCT00882258|Drug|25 mg Proellex|25 mg Proellex administered orally daily
1839946|NCT00882258|Drug|Placebo|Administered orally daily
1839947|NCT00882271|Other|Acupuncture|Ten Acupuncture treatments within six weeks
1839948|NCT00882297|Procedure|Echoguided vein puncture|Puncture with echographic visualization of vein in transversal and longitudinal way.
1839949|NCT00882310|Drug|Gemcitabine|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
1839950|NCT00882310|Drug|Docetaxel|Days 4 and 11: gemcitabine 600 mg/m2 over 60 mins intravenous (IV) followed by docetaxel 30 mg/m2 over 60 mins IV
1839951|NCT00882310|Drug|Capecitabine|Day 1-14: capecitabine at 1000 mg/m2/day divided into 2 doses given two times a day (BID) by mouth (PO) Maximum dose 2000mg/day divided into BID dosing
1839952|NCT00882323|Drug|Cyclophosphamide, Fludarabine, Thymoglobulin|"cyclophosphamide (60 mg/kg once daily i.v. on days -8, -7)
fludarabine (40 mg/m2 once daily i.v. on days -6, -5, -4, -3, -2)
thymoglobulin (2.5 mg/kg once daily i.v. on days -4, -3, -2)"
1839953|NCT00882362|Drug|OPC-14597 (Aripiprazole)|administered orally once daily, 3 to 15 mg daily, 52 weeks
1840242|NCT00873600|Other|questionnaire administration|
1959193|NCT00657553|Drug|Bortezomib|Year 1:1.0 mg/m2. IV. Days 1, 4, 8, 11 every 4 weeks Year 2: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 8 weeks Year 3: 1.0 mg/m2. IV. Days 1, 4, 8, 11 every 12 weeks
1959196|NCT00653432|Device|MONOVISC|Intra-articular injection
1839954|NCT00882375|Drug|Nicotine|Nicotine administered using novel NRT user instructions
1839955|NCT00882375|Drug|Placebo|Placebo administered using novel NRT user instructions
1839956|NCT00882388|Drug|aspirin|aspirin 100 mg qd for 7 days
1839957|NCT00882388|Drug|celecoxib|celecoxib 200 mg bid * 7 days
1839958|NCT00882388|Drug|aspirin + celecoxib|aspirin 100 mg qd + celecoxib 200 mg bid for 7 days
1839959|NCT00882388|Drug|aspirin + clopidogrel|asprin 100 mg qd + clopidogrel 75 mg qd for 7 days
1839960|NCT00882388|Drug|aspirin + clopidogrel + celecoxib|aspirin 100 mg qd + clopidogrel 75 mg qd + celecoxib 200 mg bid
1839961|NCT00882401|Drug|Ergocalciferol (Vitamin D)|ergocalciferol: 50,000 IU per week for 1 month followed by 50,000 IU per month for 5 months.
1839962|NCT00882401|Drug|Placebo|Matching placebo at same dose schedule as ergocalciferol
1839963|NCT00882414|Drug|FERINJECT® (Ferric carboxymaltose)|FERINJECT® will be administered i.v. into a peripheral vein in the arm. 500 mg FERINJECT® will be diluted to a total volume of 100mL in 0.9% saline for infusion and administered over 15 minutes duration.
1839964|NCT00882414|Drug|Placebo|Placebo will be administered i.v. into a peripheral vein in the arm. A total volume of 100mL 0.9% saline will be administered over 15 minutes duration.
1839965|NCT00882427|Other|enhanced model predictive control algorithm (eMPC)|eMPC (software on a bedside computer) advised insulin titration to establish tight glycaemic control
1839966|NCT00882440|Drug|losartan potassium|losartan oral capsule (10, 25, 50, 100 or 150 mg) once daily for 8 weeks
1839967|NCT00882440|Drug|Placebo|Placebo capsule to losartan
1839968|NCT00882440|Drug|Enalapril|Enalapril 20 mg oral tablet taken once daily for 8 weeks
1839969|NCT00882453|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Intravenous therapy according to product information
1839970|NCT00882466|Drug|human recombinant erythropoietin|intravenous bolus injection of EPO (50unit/kg)
1839973|NCT00882505|Dietary Supplement|vitamin D|Subject will receive vitamin d supplements
1839974|NCT00882505|Other|Placebo|Subject will receive a placebo.
1839975|NCT00882518|Drug|Quetiapine Fumarate (SEROQUEL) Extended-Release (XR)|200 mg or 300 mg, oral, single dose
1839976|NCT00882518|Drug|Chlorpromazine|50 mg, oral, double dose
1839977|NCT00882531|Drug|isotretinoin|0.25 mg/kg, 1 per day, 4 month of treatment
1839978|NCT00882531|Drug|placebo|
1839981|NCT00882570|Drug|Cefdinir 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
1839982|NCT00882570|Drug|Omnicef 250 mg/5 ml Oral Suspension of Cefdinir (Abbot Laboratories, USA)|
1839983|NCT00882583|Drug|Cetuximab|single agent cetuximab loading dose of 400mg/m2 on day1, cetuximab maintenance dose 250mg/m2 on day 8
1839984|NCT00882583|Drug|Dasatinib|Oral Dasatinib Days 8 through 64.
1839985|NCT00882583|Drug|Cisplatin|Q 3 weeks (Days 15, 36 and 57): +/- 3 Days
1839986|NCT00882583|Radiation|Radiation Therapy|Standard Radiation Therapy.
1839987|NCT00882596|Device|Accelerated partial breast irradiation|A total radiation dose of 34 Gy is delivered in 10 fractions bid over 5-7 days with 6 hours between the radiation treatments each day. Each radiation treatment takes 15-30 minutes. There is no radioactivity left behind in the patient.
1839988|NCT00882609|Device|Bone Scan: F18-Fluoride PET/CT or TC-MDP|Each patient will be randomized into one of two groups with one group receiving Sodium Fluoride F18 Injection and the other receiving the control agent, 99mTc-MDPSodium Fluoride F18 Injection Dosing and Administration. The dose will be tailored for the specific patient for whom the dose was ordered. The dose of Sodium Fluoride F18 Injection administered will range from 5-10 mCi/patient.Each patient randomized to the control group will be administered 99mTc-MDP as a single intravenous bolus dose. The administered radioactivity will be determined based on the sites routine clinical practice for conventional bone imaging.
1839989|NCT00882622|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 15 mm Hg greater than the systolic arterial pressure measured via the arterial line.
1839990|NCT00882622|Procedure|Control/sham procedure|Sham placement of the blood pressure cuff around the upper limb without inflation.
1839991|NCT00882635|Drug|enoxaparin|"Enoxaparin 0.5 mg/kg IV bolus (Regardless of whether the investigator has chosen to initiate concomitant GP IIb/IIIa antagonist; provision for additional IV enoxaparin to be administered if elapsed time to PCI exceeds 2 hours (from original IV dose) - enoxaparin 0.25 mg/kg IV will be administered At the discretion of the treating physician, if sustained anticoagulation is required then enoxaparin subcutaneously will be administered - enoxaparin 1.0 mg/kg SQ q 12 hours.
Maintenance dose adjustment for renal insufficiency - creatinine clearance < 30 ml/min, sc enoxaparin should be administered at 1.0 mg / kg / q24 hours. No adjustment of IV dose is required in case of renal insufficiency"
1839992|NCT00882635|Drug|Unfractionated heparin|Unfractionated heparin 70 u/kg IV bolus (consistent with ASSENT 4 PCI) Baseline ACT will be draw at time of sheath insertion - With use of GP IIb/IIIa antagonist additional UFH will be administered to achieve an ACT of ≥200 - 250 seconds If IIb/IIIa is not utilized - additional UFH will be administered to achieve an ACT of ≥250-350 seconds At the discretion of the treating physician if sustained anticoagulation is required:UFH infusion 12/u/kg/hr IV infusion to commence
1839993|NCT00882661|Device|SECURE-C Cervical Artificial Disc|Treatment of symptomatic cervical disc disease with the SECURE-C Cervical Artificial Disc
1839994|NCT00882661|Device|ASSURE Cervical plate and an allograft interbody spacer|Treatment of symptomatic cervical disc disease utilizing an instrumented anterior discectomy and interbody fusion
1839995|NCT00882674|Drug|RG1507|16mg/kg, 9mg/kg, 3mg/kg or 1mg/kg iv on Day 1 in one of 4 cohorts of patients
1839996|NCT00882687|Drug|Lifitegrast|Ophthalmic Solution
1839997|NCT00882687|Other|Placebo|Ophthalmic Solution
1839998|NCT00882700|Drug|Cefdinir 300 mg Capsule (Sandoz, Austria)|
1839999|NCT00882700|Drug|Omnicef Cefdinir 300 mg Capsule (Abbott Laboratories, USA)|
1840000|NCT00882713|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Subcutaneous injection every 4 weeks (starting dose of 120, 200 or 360 micrograms, based on previous ESA therapy)
1840001|NCT00882726|Drug|CNTO 3649 IV (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (1, 3, 10, 30, 100 or 300 microgram per kilogram, subject to change) as a 2-hour IV infusion.
1840002|NCT00882726|Drug|CNTO 3649 SC (Healthy participants)|Healthy participants will each receive a single dose of CNTO 3649 (10, 30, 100 or 300 microgram per kilogram, subject to change) as a SC injection.
1840003|NCT00882726|Drug|CNTO 3649 SC (Diabetic patients)|Diabetic patients will receive multiple doses of CNTO 3649 (30, 100 or 300 microgram per kilogram, subject to change) as subcutaneous injections once weekly for 4 consecutive weeks.
1840004|NCT00882726|Drug|Placebo|Participants within each dosing group who are randomized to placebo will receive a corresponding IV infusion or SC injection of placebo.
1840005|NCT00882739|Drug|Clopidogrel 300 mg|Patients will receive a 300 mg clopidogrel loading dose in the cath-lab setting
1840006|NCT00882739|Drug|Clopidogrel 600 mg|Patients will receive a 600 mg clopidogrel loading dose at first medical contact
1840007|NCT00882739|Drug|Clopidogrel 900 mg|Patients will receive a 900 mg clopidogrel loading dose at first medical contact
1840008|NCT00882752|Procedure|molecular analysis|bowel disease
1840009|NCT00882765|Dietary Supplement|genistein|Given orally
1840010|NCT00882778|Drug|eptacog alfa (activated)|Retrospective data collection of the use of activated recombinant human factor VII as prophylaxis in haemophilia patients with inhibitors
1840011|NCT00882804|Drug|Hemin infusion|Hemin (Panhematin®, Ovation Pharmaceuticals, Deerfield, IL) will be administered through a large-caliber peripheral vein at a dose of 1.25 mL/kg and at a rate of 60 mL/hour. To enhance stability, Panhematin® will be diluted in ~ 132 mL of 25% albumin to obtain a hemin concentration of 2.4 mg/mL.
1840012|NCT00882804|Drug|placebo infusion|25 % albumin will be administered through a large-caliber peripheral vein at a dose at a rate of 60 mL/hour.
1840013|NCT00882817|Other|Pulmonary Rehabilitation|The intervention group will perform a 6 month pulmonary rehabilitation program which consists of training, patient education, nutrition counseling and psychosocial support. They will be evaluated with some tests for the study.
1840014|NCT00882830|Procedure|EMS|EMS sessions on both lower extremities (quadriceps and peroneus longus) simultaneously.
1840015|NCT00882856|Drug|Bisoprolol|"Bisoprolol Vitabalnas 10 mg once daily"
1840016|NCT00882856|Drug|Placebo|placebo
1840017|NCT00882869|Drug|AEG35156 antisense IV infusion|Dose escalation (100, 200 and 300 mg/day) over 2 hr infusion, once weekly over 21 days (Day 1, 8, 15)
1840018|NCT00882869|Drug|Sorafenib|Sorafenib will be administered at 400 mg BID every day
1840019|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
1840020|NCT00882882|Drug|Metformin HCL 500 mg Extended-Release Tablets, Geneva PTC|
1840021|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
1840022|NCT00882882|Drug|GLUCOPHAGE XR 500 mg ER Tablets Bristol-Myers Squibb|
1840023|NCT00882895|Procedure|Stem cell infusion|
1840024|NCT00882895|Procedure|TLI|
1840025|NCT00882895|Drug|Anti-thymocyte globulin|
1840026|NCT00882895|Drug|Solumedrol|
1840027|NCT00882895|Drug|Tacrolimus|
1840028|NCT00882895|Drug|Mycophenolate mofetil|
1840029|NCT00882908|Drug|TMC435|TMC435 will be administered as one or two 75 mg capsules orally, once daily, for 12 or 24 weeks.
1840030|NCT00882908|Drug|Ribavirin (R)|Ribavirin (R) will be administered as 200 mg tablets (5 to 6 tablets) orally, twice daily, for 48 weeks.
1840031|NCT00882908|Drug|PegIFNα-2a (P)|PegIFNα-2a (P) 180 micrograms will be administered as a subcutaneous (under the skin) injection, once weekly for 48 weeks.
1840032|NCT00882908|Drug|Placebo|Placebo capsules identical in appearance to TMC435 capsule will be administered orally, once daily, for 48 weeks.
1840033|NCT00882921|Biological|Idursulfase|Patients received idursulfase as prescribed by their physician following locally approved prescribing information. Patients will not be provided idursulfase by Shire Human Genetic Therapies, Inc. or the HOS.
1840034|NCT00882934|Other|Induction to efficient treatment|Informative letters.
1840035|NCT00882934|Other|Doubt to the efficacy of treatment|Informative letters.
1840036|NCT00882934|Other|Induction to ineffective treatment|Informative letters
1840037|NCT00882947|Drug|Ventavis (Iloprost, BAYQ6256)|Iloprost solution for inhalation, BAYQ6256, Synthetic Prostacyclin analog
1840038|NCT00882960|Drug|intravenous fentanyl|An IV will be established and used to deliver Fentanyl at 50 micrograms to patients who meet pre-hospital protocol for pain management. Examples of this may be burn patients, fractures, trauma.
1840039|NCT00882960|Drug|intra-nasal fentanyl|a mucosal atomization device will be used to deliver 50 mcg of Fentanyl to patients who have been identified at requiring pre-hospital pain management
1840040|NCT00882973|Drug|Genexol-PM|Cremophor EL-free polymeric micelle of paclitaxel
1840041|NCT00882999|Drug|LY2127399|Injection: 6 doses, one every 4 weeks or every 12 weeks for 24 weeks.
1840042|NCT00882999|Drug|Placebo|Injection: Every 4 weeks in the placebo arm for 24 weeks. Every 4 weeks in the LY arms for 24 weeks (except week 12 and week 24).
1840043|NCT00883012|Biological|Trivalent sub-unit influenza vaccine|"Composition per 0.5 ml dose:
Active substance:
Split Influenza virus*, inactivated Strains for 2009 Southern hemisphere A/Brisbane/59/2007- like (H1N1) 15 micrograms**, A/Brisbane/10/2007 (H3N2) - like strain (A/Brisbane/10/2007 (IVR-147) 15 micrograms**, B/Florida/4/2006 - like strain (B/Brisbane/3/2007)15 micrograms** Two doses, one month apart"
1840044|NCT00883012|Biological|Saline, 0.5ml|Saline IMI, 0.5ml. Two doses one month apart
1840045|NCT00883038|Other|diabetic diet following the DNSG guidelines|The DNSG diet consists of 15-20% protein, ≤7% saturated fat, 60-70% carbohydrate and monounsaturated fats, cholesterol ≤200 mg/day, fiber content 20-30g/day.
1840046|NCT00883038|Other|low-fat vegetarian diet|The low-fat vegetarian diet (~10% of energy from fat, 15% protein, and 75% carbohydrate, fiber content 40-50 g/day) consists of vegetables, fruits, grains, legumes and small amounts of nuts. Participants will be asked to avoid animal products and added fats and to favor low-glycemic index foods, such as beans and green vegetables.
1840243|NCT00873600|Procedure|adjuvant therapy|
1840047|NCT00883051|Drug|COL-144|Oral application of one dose of either COL-144 50 mg, COL-144 100 mg, COL-144 200 mg, COL-144 400 mg or placebo as the first treatment for a new migraine attack providing that any aura symptoms have resolved and the headache is either moderate or severe and has been so for less than 4 hours.
1840048|NCT00883051|Drug|Placebo|Placebo
1840049|NCT00883064|Drug|Lisinopril 40 mg Tablet (EON Labs Manufacturing Inc, USA)|
1840050|NCT00883064|Drug|Lisinopril 40 mg Tablet (Zestril) (Zeneca, USA)|
1840051|NCT00883090|Biological|FXIII Concentrate (Human)|Subjects will receive approximately 40 U/kg of FXIII every 28 days for 3 doses administered as a bolus intravenous (IV) injection at approximately 250 U/minute.
1840052|NCT00883103|Drug|2% Lidocaine jelly|2% Lidocaine jelly will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
1840053|NCT00883103|Drug|Plain aqueous gel|Plain aqueous gel will be applied onto the catheter and then the cotton swab during evaluation of postvoid residual and the Q-tip test.
1840054|NCT00883116|Drug|Ixabepilone|
1840055|NCT00883116|Drug|Doxorubicin|
1840056|NCT00883116|Drug|Paclitaxel|
1840057|NCT00883129|Drug|Mycophenolate mofetil|24 months of oral mycophenolate mofetil, up to a maximal dose of 1.5 grams twice daily as tolerated
1840058|NCT00883129|Drug|Cyclophosphamide|12 months of oral cyclophosphamide, up to a maximal dose of 2 mg/kg daily as tolerated
1840059|NCT00883129|Drug|Placebo|12 months of placebo will be delivered to participants in the Cyclophosphamide arm during the second year in order to maintain the blind with the Mycophenolate arm, which receives drug for the entire 2 years.
1840060|NCT00883155|Drug|Bupropion HCl 100 mg Tablets (Invamed Inc.)|
1840061|NCT00883155|Drug|Wellbutrin 100 mg Tablets (Glaxo Wellcome)|
1840062|NCT00883168|Drug|Placebo|Placebo
1840063|NCT00883168|Drug|azelastineHcl|azelastine hydrochloride 548 mg
1840064|NCT00883168|Drug|fluticasone propionate|fluticasone propionate 200 mcg
1840065|NCT00883168|Drug|azelastine Hcl/fluticasone propionate|azelastine hydrochloride 548 mcg/fluticasone propionate 200 mcg
1840066|NCT00883194|Drug|PRF-108|Ropivacaine
1840067|NCT00883194|Drug|Placebo|PRF-108 Placebo
1840068|NCT00883194|Drug|Ropivacaine|Solution
1840069|NCT00883194|Drug|PRF-110|
1840070|NCT00883207|Behavioral|Psychotherapy|Narrative and dialogical approach for couples
1840071|NCT00883220|Behavioral|Self-management of urinary catheter|Awareness, self-monitoring, and self-management of urine flow are taught. Focus is on attaining adequate and consistent levels of fluid intake and preventing catheter dislodgement.
1840072|NCT00883233|Drug|Adapalene BPO Gel standard daily overnight application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel standard daily overnight application for 12 week
1840073|NCT00883233|Drug|Adapalene-BPO 3-hour daily application before bedtime|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel 3-hour daily application before bedtime for first 4 weeks and then standard overnight daily application for the following 8 weeks
1840074|NCT00883233|Drug|Adapalene-BPO Gel every other day application|Adapalene 0.1% /Benzoyl Peroxide 2.5% Gel every other day application for the first 4 weeks and then standard overnight daily application for the following 8 weeks
1840075|NCT00883233|Drug|Adapalene-BPO Gel standard+Cetaphil® Moisturizing Lotion|Adapalene 0.1% / Benzoyl Peroxide 2.5% Gel standard daily overnight application with Cetaphil® Moisturizing Lotion application at wake-up time for the first 4 weeks and then standard daily overnight application for the following 8 weeks
1840076|NCT00883246|Device|SilverHawk Peripheral Plaque Excision System|Removal of atherosclerotic plaque from artery walls.
1840077|NCT00883259|Drug|Metformin|850 mg twice daily
1840078|NCT00883259|Other|Placebo|Microcristallyne cellulose 1 table twice daily
1840079|NCT00883272|Dietary Supplement|DT56a (Femarelle) [Se-cure pharmaceuticals, Dalton, Israel]|a unique enzymatic isolate of the active complex in Tofu
1840081|NCT00883311|Device|BRT-FC-83C|BRT-FC-83C is a topical cream to treat atopic dermatitis. It is applied topically, twice a day, to the atopic dermatitis skin lesion for six weeks.
1840082|NCT00883337|Drug|Interferon β-1a|"Sterile preservative-free solution packaged in graduated pre-filled syringes
Subcutaneous injection
Ascending doses from 8.8 to 44 mcg according to local standard for Rebif®"
1840083|NCT00883337|Drug|Teriflunomide|"Film-coated tablet
Oral administration"
1840084|NCT00883350|Behavioral|RIDE e-health application|The RIDE e-Health application utilizes the latest technology to obtain near real-time food intake, body weight, and exercise data from participants living in their natural environment. The application also provides personalized and timely feedback and treatment recommendations based on participants' data. The application relies on the Remote Food Photography Method (Martin, 2009), which was developed by our research team, to collect freeliving food intake data that is transmitted to the researchers in near realtime using a camera and Bluetooth-enabled cell phone. A scale is used to collect daily body weight data from participants and these data are automatically transmitted to the researchers via the same cell phone. The e-Health application collects exercise data from participants and these data are delivered to the researchers via the internet; personalized feedback and treatment recommendations are sent to the participant every 1 to 3 days via the cell phone.
1840085|NCT00883363|Procedure|Precondition|Precondition on a arm in four intervals at start of surgery for ruptured aortic aneurysm
1840086|NCT00883389|Device|Medical Alert Bracelet|Medical Alert Bracelet alerting health care providers to consider the patient's chronic kidney disease condition when planning care. It also provides a link to a website about safe kidney care (safekidneycare.org)
1840087|NCT00883402|Procedure|CEA, CAS|Carotid Artery Stenting (CAS) Carotid endarterectomy (CEA)
1840088|NCT00883415|Drug|Darbepoetin alfa|Subjects will undergo anemia management with darbepoetin after baseline assessment of MGU and will continue for six months with repeat assessment of MGU at completion of protocol
1840089|NCT00883428|Other|Set of questionnaires|A set of questionnaires to determine the existence of low back and pelvic pain during the pregnancy, and to identify possible risk factors.
1840195|NCT00884312|Drug|Carfilzomib|IV push on Days 1, 2, 15, and 16 of a 28 day cycle (e.g., every other week)
1840090|NCT00883441|Other|Insecticide treated curtains and insecticide treated covers|The study is comparing the introduction of two new vector control tools (insecticide treated curtains and insecticide treated covers) through two different distribution strategies. These tools are curently not in use in the routine programmes of the concerned countries.
1840091|NCT00883467|Procedure|preconditioning|3 times of five minutes ischemia, produced by cuff inflation to a suprasystolic pressure positioned on the thigh
1840092|NCT00883467|Procedure|no preconditioning|no preconditioning
1840093|NCT00883480|Drug|Docetaxel|Docetaxel 75 mg/day 1 x 4 cycles
1840094|NCT00883480|Drug|Docetaxel-Cisplatin|Docetaxel-Cisplatin 75 mg/day 1 x 4 cycles
1840095|NCT00883480|Drug|Gemcitabine-Cisplatin|"Cisplatin 75 mg/ day 1 x 4 cycles
Gemcitabine 1250 mg/ day 1 and 8 x 4 cycles"
1840096|NCT00883480|Drug|Erlotinib|Erlotinib 150 mg/day x 21 days
1840097|NCT00883493|Drug|Quetiapine fumarate XR|Quetiapine XR (extended release) will be administered once daily at bedtime in oral tablet form, Day 1: 50 mg, Day 2: 100 mg, Day 3: 200 mg, Day 4 onwards: 300 mg.
1840098|NCT00883493|Drug|Lithium carbonate|Twice daily from Day 1 to Day 56. From Day 1 to Day 7, the total daily dose of lithium could be increased gradually within the dose range 300 mg/day to 1800 mg/day. From Day 8 to Day 56, the total daily dose could be adjusted from 600 to 1800 mg/day
1840099|NCT00883506|Drug|Lisinopril 40 mg Tablet (Zestril) under fed conditions.|
1840100|NCT00883506|Drug|Lisinopril 40 mg Tablet under fasting conditions.|
1840101|NCT00883506|Drug|Lisinopril 40 mg Tablet under fed conditions.|
1840102|NCT00883519|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|12 psychotherapy sessions delivered over 16 weeks
1840103|NCT00883519|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents and Parents|12 psychotherapy sessions delivered over 16 weeks
1840104|NCT00883532|Drug|budesonide|budesonide, 0.25 mg/Kg/dose every 8 hours until the infant requires FIO2 < 30% or is extubated
1840105|NCT00883532|Drug|surfactant and air (placebo)|receive surfactant and air as control through endotracheal route
1840106|NCT00883545|Other|Woman endoscopist|This group will receive an invitation to schedule a screening colonoscopy with a woman endoscopist.
1840107|NCT00883545|Other|Usual care|This group will receive an invitation to schedule a screening colonoscopy with any available endoscopist.
1840108|NCT00883558|Drug|Insulin Lispro|
1840109|NCT00883558|Drug|regular human insulin|
1840110|NCT00883558|Drug|recombinant human hyaluronidase PH20|
1840111|NCT00883558|Drug|Insulin glargine|
1840112|NCT00883571|Procedure|house advancement flap group|A house flap of healthy tissue was incised to the depth of ischiorectal fat. The flap consisted of skin and subcutaneous tissue. The flap was sufficiently mobilized without undermining its fatty base containing perforating blood vessels. The flap should be loose and easily advanced into the anal canal. When the ''base'' of this house-shaped flap was advanced into the anal canal defect, it was fixed to the top of the excised area with 3/0 Vicryl sutures.
1840113|NCT00883571|Procedure|Rhomboid flap GROUP|A rhomboid flap was incised in ischeorectal fossa and was mobilized without undermining of its fatty base into the anal canal so that the tip of rhomboid flap is sutured to the top of stricured area using vicryl 3/0.
1840114|NCT00883571|Procedure|Y-V anoplasty GROUP|Y-V anoplastyis performed by making a v shaped incision in the perianal skin posteriorly starting from the lower end of the wound resultant from excision of scared area. A V-shaped flap is then dissected with preservation fatty base .The V flap is then advanced into the anal canal so that its tip is sutured to the top of structured area using vicryel 3/0.
1840115|NCT00883584|Drug|IMD-1041|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
1840116|NCT00883584|Drug|Placebo|Capsule 4 x 100mg BID (30 minutes after breakfast/dinner) 12 weeks
1840117|NCT00883623|Drug|Lenalidomide|Up to 6 cycles of oral L-Mel-Dex, every 28 days Revlimid® 10 mg daily for 21 days, (add on therapy), Melphalan 0.15 mg/kg/day day 1-4, Dexamethasone 20 mg day 1-4
1840118|NCT00883636|Other|Cardiovascular Assessment|Measure of BNP, and Pro-BNP Complete 2 Dimensional Echocardiogram with Doppler evaluation including determination of, Left Ventricular mass, Ejection fraction, Midwall fractional shortening, velocity of early and late diastolic transmitral flow, and measurement of E/A ratio, Ratio of end-systolic wall stress to rate corrected velocity of circumferential fiber shortening.
1840119|NCT00883636|Other|Renal Assessment|Complete a metabolic panel, CMP. Calculation of glomerular filtration rate, GFR, measure of urinary total protein, albumin and creatinine excretion in a first morning urine sample, 24 hour blood pressure monitoring,
1840120|NCT00883636|Other|Genetic Evaluation|All patients will undergo genetic screening for all known podocyte gene mutations.
1840121|NCT00883649|Dietary Supplement|Hydroeye|2 Capsules BID
1840122|NCT00883649|Other|Inactive Capsule|2 Capsules BID
1840123|NCT00883662|Drug|Levonorgestrel (Mirena, BAY86-5028)|Patients older than 18 years with previously taken decision of their gynecologist to insert Mirena according to registered indications
1840124|NCT00883675|Drug|Docetaxel-Carboplatin|Docetaxel: 75 mg/m2 over 1 hour every 3 weeks for 3 doses Carboplatin AUC 5.5 over 0.5 to 1 hour every 3 weeks for 3 doses
1840127|NCT00883714|Other|Supervised exercise|The patients will carry out a daily exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The patients will be supervised by medical personnel.
1840128|NCT00883714|Other|Exercise Instruction|The patients will receive instructions about exercise and will have access to a bike ergometer to work out. However, they will not receive daily supervision or participate in a structured exercise program.
1840129|NCT00883727|Drug|Stem cell|IV infusion of stem cells
1840130|NCT00883727|Drug|Plasmalyte A|IV infusion
1840131|NCT00883740|Drug|Pregabalin|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks titrated to 300-450 mg/day
1840132|NCT00883740|Drug|Placebo|Capsule, flexible dosing double-blind. Treatment duration is approximately 4 weeks
1840133|NCT00883753|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg IV (maximum dose not exceeding 800 mg in a single infusion) every 4 weeks.
1840134|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with a long agonist protocol|"Day 1 of 1st menstruation: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5
Day 18-24 of cycle: Leuprorelin (Procrin ®) 0.1 s.c. for 14-21 days
Day 1 of 2nd menstruation (=Day 1 COH cycle): Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm
Day 2of COH cycle: rFSH (Gonal F ®) 150 IU/day for 4 days; Leuprorelin (Procrin ®) 0.1 s.c. (and following days)
Day 7 of COH (and following): Measure FSH, LH, E2, Pg + Ultrasound
Day before HCG: stop rFSH
Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)
Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C
Day 7 after pick-up: ultrasound, patient evaluation.
Day 14 after pick-up: HCG in blood
Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive
(OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
1840135|NCT00883766|Other|Controlled ovarian hyperstimulation for IVF with an antagonist protocol|"Day 1 of pre COH-cycle: OC for 18-21 days (Microdiol ®) + Metformin (Dianben ®) 850 x 2/day if: BMI>30, HOMA >3.8, G/I ratio <4.5
Day 3 of free-pill interval: Hormonal profile (FSH, LH, E2, Pg, T, SHBG), Ultrasonography to exclude cyst >10 mm
Day 5 of free-pill interval (=Day 1 COH cycle): Cetrorelix acetate (Cetrotide®) 0.25 mg s.c. + rFSH (Gonal F ®) 150 IU/day (and following days)
Day 3-4-10 of COH cycle: measure FSH, LH, E2, Pg + ECO
Day before HCG: stop rFSH + cetrorelix
Day HCG: measure FSH, LH, E2, Pg, administer 250 mcg Choriogonadotropin-alfa ( Ovitrelle®)
Day of pick-up: Follicular fluid from 1st follicle to be centrifuged and stored at -20°C
Day 7 after pick-up: ultrasound, patient evaluation.
Day 14 after pick-up: HCG in blood
Day 28 after pick-up: Ultrasound to visualize heart beat if pregnancy test positive (OC= oral contraceptive; COH= Controlled Ovarian Hyperstimulation)"
1840136|NCT00883779|Drug|Placebo|po on days 15-28 of each 4 week cycle until disease progression
1840137|NCT00883779|Drug|Platinum chemotherapy (cisplatin or carboplatin)|cisplatin --75mg/m2 oon day 1 of each 4 week cycle for 6 cycles or carboplatin--5xAUC on day 1 of each 4 week cycle for 6 cycles
1840138|NCT00883779|Drug|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle until disease progression
1840139|NCT00883779|Drug|gemcitabine|1250mg/m2 iv on days 1 and 8 of each 4 week cycle for 6 cycles
1840140|NCT00883792|Procedure|Colonoscopy|Once-only colonoscopy screening
1840141|NCT00883805|Biological|Blood draw|Subjects will give blood for analysis of metal ion concentrations
1840142|NCT00883805|Radiation|X-Ray of Hip|Subject will have x-ray of hip to assessment of osteolysis
1840143|NCT00883818|Drug|azithromycin, doxycycline|"azithromycin 1g once for women with positive cultures at baseline
doxycycline 100 mg twice daily for 7 days for women with persistent infection after treatment of azithromycin 1g"
1840144|NCT00883831|Procedure|Individualized manual acupuncture|Acupuncture treatment will be provided according to traditional korean medicine (TKM) theory which focuses on patient's individual symptoms and conditions. 10-12 needles will be inserted into acupuncture point on the body except one arm where arteriovenous fistula is located for hemodialysis access. Needle retention time will be 30 minutes with intermittent manual stimulation to elicit de-qi sensation. Biweekly treatment will be conducted at non-dialysis access day or before hemodialysis at dialysis-access day for 6 weeks.
1840145|NCT00883844|Drug|Nucleos(t)ide analogue treatment with a peginterferon add-on strategy|peginterferon 1.5 microgram/kg once a week Treatment with one of the approved nucleos(t)ide analogues
1840146|NCT00883844|Drug|Nucleos(t)ide analogue treatment|Treatment with one of the approved nucleos(t)ide analogues
1840147|NCT00883870|Drug|mesenchymal stem cells|Intramuscular injection
1840148|NCT00883870|Drug|Plasmalyte A|Intramuscular injection
1840149|NCT00883883|Drug|Cefdinir 250 mg/5 ml Suspension (Sandoz, Austria)|
1840150|NCT00883883|Drug|Omnicef Cefdinir 250 mg/5 ml Suspension (Abbott Laboratories, USA)|
1840151|NCT00883896|Other|Placebo|Part 1: Placebo SC administration every 2 weeks X 10 weeks.
1840152|NCT00883896|Drug|ILV-094|Part 1: ILV-094 100 mg SC every 4 weeks (alternating ILV-094 100 mg and placebo every 2 weeks) X 10 weeks.
1840153|NCT00883896|Drug|ILV-094|Part 1: ILV-094 100 mg SC every 2 weeks X 10 weeks.
1840154|NCT00883896|Other|Placebo|Part 2: Placebo SC administration every 2 weeks X 10 weeks
1840155|NCT00883896|Drug|ILV-094|Part 2: ILV-094 200 mg SC every 2 weeks X 10 weeks
1840156|NCT00883909|Drug|dutasteride|A follow-up study in adult male subjects who have received investigational product
1840157|NCT00883935|Drug|GSK1349572|GSK1349572 30 mg once a day for 5 days in Period 1 and 14 days in Period 2
1840158|NCT00883935|Drug|Atazanavir 300 mg|Atazanavir 300 mg once per day for 14 days in Period 2
1840159|NCT00883935|Drug|Atazanavir 400 mg|Atazanavir 400 mg once a day for 14 days in Period 2
1840160|NCT00883935|Drug|Ritonavir|Ritonavir 100 mg once a day for 14 days in Period 2
1840161|NCT00883948|Behavioral|Minimal (Trophic) Feeding|Upon admission to the ICU, enteral feeds will be started at 10 cc per hour and continued at this rate for 144 hours. After 144 hours of trophic enteral feeds, the feeding rate will be advanced to full-calorie rates, which will continue for the duration of mechanical ventilation up to Day 28.
1840162|NCT00883948|Behavioral|Full Feeding|Upon admission to the ICU, a full-calorie feeding rate will be determined, which will be calculated to deliver 25 to 35 kcal/kg predicted body weight (PBW) each day. Enteral feeds will be initiated at 25 cc per hour. The feeding rate will be increased by 25 cc per hour every 6 hours until goal rate is achieved, which will be administered for the duration of mechanical ventilation up to Day 28.
1840163|NCT00883961|Other|Supervised exercise|The patients will carry out a daily endurance exercise program consisting of walking on a treadmill for 30 minutes at an intensity of about 80% of the maximum heart rate under supervision from study personnel.
1840164|NCT00883974|Behavioral|Sensitivity Training|"The parent sensitivity training program was delivered in NICU (9 sessions) with a home-booster session. Therapists worked with parents following a manualized protocol. Targets of intervention included: recognizing signs of infant stress, shut-down mechanisms, alert-available behavior, motor behaviors, facial expressions,posture/muscle tone; graded stimulation; how to optimize interactions; touch, movement and massage; kangaroo care (nesting infants skin-to-skin against their mother); vocal, visual and multi-sensory stimulation; normalizing parental feelings; challenging dysfunctional thinking, and diary keeping."
1840165|NCT00884000|Drug|Genotropin|
1840166|NCT00884000|Drug|Zomacton|
1840238|NCT00873587|Procedure|Chest tube pull on inspiration|Pull chest tube on Inspiration
1840167|NCT00884026|Device|AIx measurement with a Sphygmacor TM|All subjects will have their AIx measured prior to surgery. After 30 subjects are recruited, they will be split into 2 groups. Group 1 will be those subjects who developed hypotension, and Group 2 will be those subjects who did not develop hypotension. We will then look at the preoperative measured AIx to determine whether there is a baseline difference between the two groups. A threshold value of the AIx with the best sensitivity and specificity for prediction of hypotension will then be determined.
1840168|NCT00884026|Device|AIx measurement with a Sphygmacor TM|The second part of the study will then use the threshold AIx value found from the subjects who developed hypotension from the first 30 subjects to prospectively predict hypotension after spinal anesthesia in another 60 subjects
1840169|NCT00884039|Drug|anecortave acetate|anterior juxtascleral depot of 15 mg anecortave acetate
1840170|NCT00884039|Drug|30 mg anecortave acetate|anterior juxtascleral depot of 30mg anecortave acetate
1840173|NCT00884065|Other|Diacutaneous Fibrolysis|The implementation of the technique consists of three consecutive stages: The first stage involves manual palpation, which is carried out by the hand that is not holding the hook, with the objective to find the area to be treated; the second, or instrumental palpation stage, is carried out by introducing the spatula of the hook together with the index finger of the palpatory hand to locate with precision the adherent connective fibers or fibrous corpuscles; the third, or fibrolysis stage, is the actual treatment. Here, a brief supplementary traction is carried out with the hook.
1840174|NCT00884065|Other|Diacutaneous Fibrolysis (placebo)|The placebo was designed for this study and the stages of manual and instrumental palpation occur strictly at a superficial level. In the third stage, instead of fibrolysis a pinch of skin is hold with the thumb of the palpatory hand and the tip of the spatula, so that the patient feels the hook distinctly but without any action taking place on the deep tissular planes.
1840175|NCT00884078|Other|Culturally adapted manualized problem solving training|The areas covered by the manual include an evaluation of the self-harm attempt, crisis skills, problem solving, and basic cognitive techniques to manage emotions and negative thinking and relapse prevention strategies. The treatment will be structured around patient's current problems with the relevant sections of the manual helping the patient to deal with specific problems leading to the self-harm act. Between the sessions the manual can be used for homework tasks by the patient. We will be able to linguistically match the therapist and the participant in three most common languages spoken and understood in South Asian population i.e. Urdu, Hindi and Punjabi.
1840176|NCT00884104|Drug|Solifenacin|Oral
1840177|NCT00884117|Drug|Oseltamivir|Participants may receive treatment at the discretion of the investigator according to local practice standards, and there is no protocol-specified intervention. However, analyses will be presented separately for participants treated with oseltamivir during the course of the study.
1840178|NCT00884130|Procedure|laparoscopic colorectal resection|
1840179|NCT00884130|Procedure|open colorectal resection|
1840180|NCT00884169|Drug|M518101|Proper quantity twice a day
1840181|NCT00884169|Drug|placebo|Proper quantity twice a day
1840182|NCT00884182|Biological|A/H5N1 Inactivated, Split Virion Pandemic Influenza Vaccine|0.5 mL, Intramuscular
1840183|NCT00884195|Behavioral|Gratitude Journaling|Participants will be asked to write down 5 things every day for which they are grateful.
1840184|NCT00884195|Behavioral|Neutral Journaling|Participants will be asked to write down 5 things every day that they noticed about being involved in a weight loss program.
1840185|NCT00884221|Drug|Highly purified menotrophin|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.
NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
1840186|NCT00884221|Drug|Recombinant FSH|"The gonadotrophin starting dose was 150 IU daily for the first 5 days. From stimulation day 6 and onwards, dosing could be adjusted according to individual participant response. The dose adjustment could be by 75 IU per adjustment and could not be done more frequently than every 4 days. The maximum allowed gonadotrophin dose was 375 IU daily and participants could be treated with gonadotrophin for a maximum of 20 days.
NOTE: The gonadotrophins (highly purified menotrophin and the active comparator recombinant FSH) were administered in an identical fashion."
1840187|NCT00884234|Other|Vehicle Control|Two sequential doses of RT001 or Vehicle Control at Baseline (Day 0) and Week 2
1840188|NCT00884234|Drug|RT001 (Botulinum Toxin Type A Topical Gel)|Two sequential doses of RT001 or Vehicle Control at Baseline (Day 0) and Week 2
1840189|NCT00884260|Drug|Levonorgestrel IUS (LCS, BAY86-5028)|In Vitro release rate: 12µg LNG/24h
1840190|NCT00884273|Drug|Degarelix|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The second and third doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections on Days 28 and 56, respectively.
1840191|NCT00884273|Drug|Goserelin|Goserelin implants (3.6 mg) were inserted s.c. into the abdominal wall every 28 days. The first dose was administered on Day 0. The second and third doses of goserelin were administered on Days 28 and 56, respectively.
1840192|NCT00884273|Drug|Bicalutamide|On Day 0, participants began once-daily per-oral (p.o.) treatment with bicalutamide (50 mg) as anti-androgen flare protection; this treatment continued for 28 days after the first dose of goserelin.
1840193|NCT00884286|Drug|Aplidin®|Aplidin® will be administered at a starting dose of 3.2 mg/m2, as a 1-hour intravenous infusion, on days 1, 8 and 15, every 28 days cycle.
1840194|NCT00884299|Dietary Supplement|Diet rich in antioxidants|Dietary intervention based on diet with increased consumption of foods containing antioxidants such as fresh fruits, fruit juices and vegetables. Patients are advised by a physician and a specialist nurse during regular scheduled outpatient clinic visits to increase fresh fruit /fruit juices/vegetable consumption of at least one portion per day compared to baseline and to maintain this regime throughout the study period.
1840239|NCT00873587|Procedure|Expiration|Pull chest tube on Expiration
1840196|NCT00884325|Drug|Levocetirizine dihydrochloride (Xyzal)|One tablet 5 mg taken orally at night for 28 days
1840197|NCT00884325|Drug|placebo|One tablet taken orally at night for 28 days
1840198|NCT00884338|Other|Endurance exercise|The patients will carry out an endurance exercise program consisting of walking on a treadmill for 30 to 40 minutes at a speed corresponding to 80% of the maximum heart rate
1840199|NCT00884338|Other|Counseling|Counseling about exercise and behavioural techniques to reduce fatigue
1840200|NCT00884364|Other|Aerobic exercise|The patients will carry out an aerobic exercise program consisting of walking on a treadmill for 30 minutes at an intensity of 80% of the maximum heart rate. The training will be carried out three times a week.
1840201|NCT00884364|Behavioral|Fatigue counseling|The patients will receive a counseling regarding the causes of fatigue, how to cope with this symptom, and general recommendations about exercise. However, they will not participate at a structured exercise program.
1840202|NCT00884377|Drug|Sodium stibogluconate (Pentostam)|intravenous 20 mg/kg/day for 10 days
1840203|NCT00884377|Device|ThermoMed|ThermoMed heat treatment device, one treatment
1840204|NCT00884390|Drug|moroctocog alfa (AF-CC) (ReFacto AF)|Providing moroctocog alfa (AF-CC) as test article for use during this study.
1840205|NCT00884390|Procedure|Laboratory tests|Laboratory samples are collected during study visits, in order to collect safety and efficacy data related to the administration of test article.
1840206|NCT00873327|Drug|piperacillin-tazobactam|"6 doses intravenously at the following doses:
Infants <32 weeks gestation at birth < 14 days PNA 100 mg/kg Q8 ≥ 14 weeks PNA 100 mg/kg Q6
Infants ≥32 weeks gestation at birth < 14 days PNA 100 mg/kg Q6
≥ 14 days PNA 100 mg/kg Q6"
1840207|NCT00873340|Drug|Interferon-1beta (Betaseron, BAY86-5046)|Patients with a first demyelinating event suggestive of MS, as well as patients with remittent recurrent MS (RRMS), secondary progressive MS (SPMS) and primary progressive MS (PPMS) will be observed.
1959208|NCT00625846|Other|Laboratory Biomarker Analysis|Correlative studies
1959209|NCT00625846|Drug|Pazopanib Hydrochloride|Given PO
1840216|NCT00873379|Dietary Supplement|melatonin|one half of a 1 mg tablet of GNC rapid dissolving Melatonin, NPN (natural product number) 80001380, available over the counter in Canada
1840217|NCT00873379|Dietary Supplement|placebo|half a white placebo tablet
1840218|NCT00873392|Drug|Transdermal nicotine|Steps of 5 mg until 20 mg Then steps of 10 mg until the dose of 90mg or the maximal tolerated dose One stable dose phase, (90 mg or maximal tolerated dose) during 28 weeks
1840219|NCT00873392|Other|Usual drug treatment of Parkinson's disease|Usual drug treatment of Parkinson's disease
1840222|NCT00873418|Behavioral|Coping skills training|16 weekly telephone session using to teach heart failure patients self-management skills and how to cope more effectively with psychological distress associated with heart failure.
1840223|NCT00873431|Biological|IC47|solution/suspension for i.m. injection dosage: 30/150 mcg frequency: 3 times at Day 0, Day 42 and Day 84
1840224|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with ceramic liner for use in total hip replacement
1840225|NCT00873444|Device|Pinnacle™ Acetabular System|A cementless acetabular cup with metal liner for use in total hip replacement
1840226|NCT00873457|Drug|perifosine|Perifosine 50 mg will be taken orally twice a day for a maximum of six 28-day cycles
1840227|NCT00873470|Procedure|esophagal stimulation|ECG (rest) esophagal stimulation (rest and during effort)
1840228|NCT00873483|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|0.55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 3 cycles
1840229|NCT00873496|Drug|Hydroxychloroquine|
1840230|NCT00873509|Drug|Buspirone|Buspirone liquid, 2.5 mg in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
1840231|NCT00873509|Drug|Buspirone|Buspirone liquid, 5.0 mg in 1 ml , once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
1840232|NCT00873509|Drug|Placebo|Placebo liquid, in 1 ml, once per day in the evening for the first week of administration and thereafter twice a day 12 hours apart for the entire study
1840233|NCT00873535|Drug|Varenicline|This group (N=40) will receive Varenicline (0.5mg once daily for days 1-3, 0.5mg twice daily for days 4-7 followed by 1mg twice daily for days 8-14). The group will consist of heavy smokers and heavy drinkers (N=20) and heavy smokers and social drinkers (N=20).
1840234|NCT00873535|Drug|Placebo|This group (n=40) will receive matching placebo capsules in the identical dosing regimen described for the Varenicline arm. The group will consist of heavy smokers who are heavy drinkers (n=20) and heavy smokers who are social drinkers (n=20).
1840235|NCT00873548|Device|PFNA-Asia|"The operation is performed under regional or general anesthesia and involves the following main steps:
Positioning of the patient
Definition of the CCD-angle
Fracture reduction
Determination of the nail diameter
Incision
Insertion of the device"
1840236|NCT00873561|Drug|NBI-6024|0.1, 0.5 or 1 mg NBI-6024 First 3 doses every 2 weeks. Remaining doses given monthly. Total duration of dosing 24 months. Placebo controlled.
1840237|NCT00873574|Biological|Blood samples and buccal swabs|Peripheral blood samples (35 ml) and buccal swabs
1840240|NCT00873600|Drug|chemotherapy|
1959220|NCT00616200|Other|Very low carbohydrate diet|4 weeks on strictly controlled low carbohydrate diet
1959221|NCT00612924|Device|Anaconda Stent Graft System|Endovascular device
1959222|NCT00612924|Device|Anaconda ONE-LOK Stent Graft System|Endovascular device
1840244|NCT00873600|Procedure|assessment of therapy complications|
1840245|NCT00873600|Procedure|cognitive assessment|
1840246|NCT00873600|Procedure|psychosocial assessment and care|
1840247|NCT00873600|Procedure|quality-of-life assessment|
1840248|NCT00873613|Procedure|Use of Non-dilated retinal photography|Kowa Non-Myd alpha-D Non-dilated fundus camera will be used to obtain photographs.
1840249|NCT00873626|Drug|levofloxacin, ciprofloxacin and ofloxacin (fluoroquinolones)|Levofloxacin 500mg : 1/j Ofloxacin : 200mgX2/j Ciprofloxacin 500mg X2/j
1840250|NCT00873639|Drug|insulin aspart|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
1840251|NCT00873639|Drug|insulin detemir|Effectiveness and safety data collection in connection with the use of the drug NovoRapid® and Levemir® in routine clinical practice
1840252|NCT00873652|Biological|Engerix B®, a recombinant hepatitis B vaccine|Single 0.5 ml dose intramuscularly into the deltoid muscle
1840253|NCT00873665|Other|aerobic exercise|To determine the effects of supervised aerobic exercise training versus usual care on incidence of ED among men undergoing radical prostatectomy for clinically localized prostate cancer.
1840254|NCT00873665|Other|wait-list control|To determine the effects of aerobic exercise training versus wait-list control on changes in patient symptoms (i.e., erectile function score, sexual functioning, urinary incontinence, and QOL) and the number of men receiving phosphodiesterases type-5 (PDE-5) inhibitor therapy as well as therapy dose.
1840255|NCT00873678|Biological|Whole blood sample|Whole blood sample (10 ml)
1840256|NCT00873691|Device|ICD|Intervention isn an ICD. Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
1840257|NCT00873704|Other|supplemental postoperative oxygen|
1840258|NCT00873717|Other|Dentary|cleaning-up of oral cavity, with trimestrial dental and oral check-up with counseling for appropriate care (if needed).
1840259|NCT00873717|Other|Nutrition|control of the administration of dietary prescriptions, incitement to eat.
1840260|NCT00873717|Other|Dentary + Nutrition|"trimestrial follow-up of patients and counseling for appropriate care (if needed), in order to restore a minimum masticatory function, associated with particular focus on the realization of daily oral wash.
associated with control of the administration of dietary prescriptions, incitement to eat."
1840261|NCT00873730|Drug|etanercept|Etanercept 50 mg twice a week (BIW) for 12 weeks
1840262|NCT00873730|Drug|etanercept/placebo|Etanercept 50 mg once a week (QW) and placebo once a week for 12 weeks
1840263|NCT00873756|Drug|FOLFOX regimen|Intravenous repeating dose
1840264|NCT00873756|Drug|bevacizumab|Intravenous repeating dose
1840265|NCT00873756|Drug|dulanermin|Intravenous repeating dose
1840266|NCT00873769|Drug|Inhaled Loxapine 10 mg|Staccato Loxapine 10 mg, single dose
1840267|NCT00873782|Other|Retrograde high pressure transvenous perfusion with normal saline|Dose escalation of saline volume, infusion rate, and tourniquet pressure, as determined in a stepwise manner and by careful monitoring
1840269|NCT00873808|Drug|clodronate disodium|
1840270|NCT00873808|Drug|demeclocycline hydrochloride|
1840271|NCT00873808|Drug|ibandronate sodium|
1840272|NCT00873808|Drug|tetracycline hydrochloride|
1840273|NCT00873808|Drug|zoledronic acid|
1840274|NCT00873808|Other|laboratory biomarker analysis|
1840275|NCT00873808|Procedure|adjuvant therapy|
1840276|NCT00873808|Procedure|computed tomography|
1840277|NCT00873808|Procedure|dual x-ray absorptiometry|
1840278|NCT00873821|Drug|MK-0941|Part 1 (in house): MK-0941 twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. The starting dose on Day 1 was 10 mg tablets twice daily and titrated to a maximum dose of 60 mg twice daily through Day 9. The Day 9 dose was maintained throughout Day 13. Part 2 (at home): participants continued treatment for an additional 14 days with MK-0941 60 mg tablets (or maximum dose achieved in Part 1) twice daily, before meals with 240 mL of water.
1840279|NCT00873821|Drug|Comparator: Placebo|Part 1 (in house): placebo twice daily on Days 1 through 13 before breakfast and dinner with 240 mL water. Part 2 (at home): participants continued treatment for an additional 14 days with placebo twice daily, before meals with 240 mL of water.
1840280|NCT00873834|Drug|fluoxetine|"Treatment with fluoxetine in an oral solution will be given at 0.25mg/kg day during 2 weeks and at 0.4mg/kg day during 16 weeks.
A progressive decreased of dosage on a period of 4 weeks to 0.25mg/kg/day (2 weeks) and 0.10mg/kg/day(2 weeks) will be realized"
1840281|NCT00873834|Drug|placebo|Placebo comparator. The packaging of study drug and placebo will be performed according to applicable regulatory requirements in the same packaging. An oral solution will be administrated.
1840282|NCT00873860|Other|Placebo|Placebo matched to CAT-354 subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
1840283|NCT00873860|Biological|CAT-354 150 mg|CAT-354 150 milligram (mg) subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
1840284|NCT00873860|Biological|CAT-354 300 mg|CAT-354 300 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
1840285|NCT00873860|Biological|CAT-354 600 mg|CAT-354 600 mg subcutaneous injection once every 2 weeks on Day 1, 15, 29, 43, 57, 71, and 85.
1840286|NCT00873886|Drug|Oseltamivir (Tamiflu)|"The following procedures will be performed on two occasions: once at least three days prior to the scheduled pregnancy termination procedure and again about eight weeks after the termination procedure.
A) Subject will take 75 mg of oseltamivir pill by mouth
B) Multiple blood draws (1 teaspoon each) over the next 48 hours after taking oseltamivir. Urine samples also will be collected."
1840287|NCT00873886|Procedure|Blood Draws|Two blood draws (1 teaspoon each) will be performed: once during third trimester of pregnancy and again about eight weeks after delivery.
1840318|NCT00874146|Genetic|Fluorescent in-situ hybridization (FISH)|Dual color FISH test to assess ratio of HER2/neu amplification
1840319|NCT00874159|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
1996409|NCT02487394|Other|Asthma, Smokers and Non-Smokers|Comparing protein expressions between the two groups.
1840288|NCT00873899|Device|The Medtronic CareLink system (Minneapolis, MN, USA).|The Medtronic CareLink system(Minneapolis, MN, USA)includes a patient monitor plugged into a standard analog telephone connection, and a lightweight wand to communicate with the implanted device. Interrogation of the device and transmission of the data occur when the patient places the wand over the implanted device. The system uses radio frequency telemetry for wireless automatic communication. This allows for data transmission without patient intervention and enables automatic transmissions at pre-specified routine intervals as well as alert-based downloads.The system can transmit data in case of programmable conditions on diagnostic variables, arrhythmias, delivered ICD therapies, battery/lead issues, and alert the physician via phone or e-mail. The patient's information is sent to a secure Network server via the telephone connection and clinical staff can review device information.Available data are equivalent to that which can be retrieved at an in-office visit.
1840289|NCT00873912|Biological|Monovalent influenza virus vaccine|Monovalent vaccine was supplied in intranasal sprayers containing a total volume of 0.5 mL of sucrose-phosphate buffer, egg allantoic fluid, and approximately 10^7 FFU (fluorescent focus units) of the cold-adapted, attenuated, 6:2 reassortant influenza strain B/Brisbane/60/2008 (Victoria lineage).
1840290|NCT00873912|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer.
1840291|NCT00873925|Biological|Autologous UCB|Umbilical Cord Blood stem cells CAN be collected and frozen immediately after birth in private and public cord blood banks. If a child with recent onset T1D has their OWN cord blood in storage they may qualify for this study. The cells would be released to the University of Florida where we would perform a single IV infusion of the cells once they have been thawed and washed. Depending on how the cells are stored, it may be possible to keep some portion of the cells in storage for future use.
1840292|NCT00873925|Dietary Supplement|Omega 3 FA|Omega 3 Fatty Acids commonly found in fish oil may play an important role in preserving beta cell function via their anti-inflammatory actions. Those subjects randomized to treatment will take a daily supplement supplied as a capsule that can either be swallowed whole or opened so the contents can be mixed with food.
1840293|NCT00873925|Dietary Supplement|Vitamin D|Vitamin D is important for calcium absorption and bone health but may also play an important role in promoting healthy immune responses. Subjects randomized to intervention will take vitamin D supplied as a liquid in a dropper (1 drop per day added to food) for 1 year.
1840294|NCT00873951|Other|Intestinal and metabolic exploration|Subjects are studied for 8h following the ingestion of a standard meal containing 15% of energy as protein. Intestinal, blood and urine are collected at regular intervals.
1840295|NCT00873951|Dietary Supplement|15N-labelled intact casein|standard mixed meal containing 15% of energy as 15N-labelled intact casein
1840296|NCT00873951|Dietary Supplement|15N-labelled hydrolyzed casein|standard mixed meal containing 15% of energy as 15N-labelled hydrolyzed casein
1840297|NCT00873951|Dietary Supplement|mixture of AA|standard mixed meal containing 15% of energy as a mixture of AA mimicking the composition of casein but devoid in serine
1840298|NCT00873977|Device|CPAP (REMstar (Respironics))|Pressure-relief CPAP treatment may reduce the sensation of breathing against high pressure without causing the upper airways to collapse and improve adherence.
1840299|NCT00873990|Other|Total etch bonding agent (5th generation)|"Selected teeth would receive prophylaxis with pumice using prophylaxis brushes for 20 seconds. The teeth will be isolated with cotton rolls before application of bonding agent. The tooth selected for etch and rinse bonding system (two step bonding agent) will be treated with 37% phosphoric acid (Total Etch Ivoclar Vivadent) for 15 seconds followed by rinsing for 30 seconds and then drying with air syringe till frosty white appearance is achieved.
Adper Single Bond 2 (3M ESPE) will be applied to occlusal fissure using applicator brushes followed by curing for 10 seconds. Clinpro(3M ESPE) fissure sealant will be applied to pits and fissures and then light cured for 20 seconds."
1840300|NCT00873990|Other|Self etch (7th generation ) bonding agent|For teeth selected for application of self etching bonding agent (Adper Easy Bond 3 M), the bonding agent will be applied to occlusal surface with microbrushes and will be left undisturbed for 20 seconds followed by air drying for 5 seconds and then will be light cured for 10 seconds. Fissure sealant (Clinpro 3M ESPE) will be applied in a similar manner as for etch and rinse group and light cured.
1840301|NCT00874003|Drug|mirtazapine|oral tablet, 30 mg daily
1840302|NCT00874003|Drug|placebo|oral tablet, 1 daily
1840303|NCT00874016|Device|Airtraq|Intubation using Airtraq
1840304|NCT00874016|Device|Direct Laryngoscopy|Intubation using direct laryngoscopy
1840305|NCT00874029|Device|Halt Procedure|The Halt 2000 Electrosurgical Radiofrequency Ablation System is indicated for use in percutaneous, laparoscopic and intraoperative, coagulation and ablation of soft tissue.
1840306|NCT00874042|Drug|Treatment with ARQ 197 in combination with gemcitabine|"Enrollment of an initial cohort of 3 or 6 patients will follow the traditional 3 + 3 dose escalation scheme. These patients will be treated with ARQ 197 and gemcitabine. ARQ 197 will be administered by mouth BID continuously. Gemcitabine will be administered by intravenous infusion over 30 minutes once weekly for 3 consecutive weeks followed by a week of rest."
1840307|NCT00874068|Other|InFat™ based infant formula|high sn-2 palmitic acid oil based infant formula
1840308|NCT00874068|Other|Standard vegetable oil based infant formula|standard vegetable oil based infant formula
1840309|NCT00874094|Biological|Platelet rich fibrin matrix|0-2 cc of autologous platelet rich fibrin matrix injected intra and subdermally to effect nasolabial fold.
1840310|NCT00874107|Biological|Imprime PGG® Injection|4 mg/kg, i.v. over 2 hr, weekly until progression or discontinuation
1840311|NCT00874107|Biological|Bevacizumab|15 mg/kg, i.v., over 90 minutes, on Day 1 only of each 3-week treatment cycle
1840312|NCT00874107|Drug|Paclitaxel|200 mg/m2, i.v. over 3 hr, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles.
1840313|NCT00874107|Drug|Carboplatin|AUC of 6 mg./mL · min based on the Calvert formula; i.v. over 30 min, on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
1992689|NCT03314662|Biological|MF59-adjuvanted Trivalent Subunit Inactivated Egg-derived Influenza Vaccine Containing the Alternate B Strain (aTIV-2)|The strain composition is that recommended by the World Health Organization for the 2017-2018 Northern Hemisphere influenza season (WHO, 2017) for trivalent vaccines except the B strain present in this vaccine is the second/alternate B strain recommended for inclusion in quadrivalent vaccines (ie, Alternate B strain).
1840320|NCT00874172|Drug|Rapid optimized analgesic strategy|"Oral treatment :
1 gr Acetaminophen 20 mg of nefopam delivered on a lump sugar Nitrous oxide inhalation with initial output of 9 L/min subsequently Intravenous morphine bolus of 3 mg Nitrous oxide interruption after 5 minutes of the initial morphine bolus"
1840321|NCT00874172|Drug|current analgesic strategy|"paracetamol 1 g per os nasal oxygen therapy
1 amp of morphine 10 mg / 10 cc of glucose 5 %, by repeated bolus administration"
1840323|NCT00874211|Procedure|assessment of therapy complications|By dental and medical assessments.
1840324|NCT00874224|Procedure|laparoscopic left lateral hepatic sectionectomy|laparoscopic left lateral hepatic sectionectomy
1840325|NCT00874224|Procedure|open left lateral hepatic sectionectomy|open left lateral hepatic sectionectomy
1992691|NCT03313908|Procedure|detection of the tumor lesion|non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
1992692|NCT03313791|Dietary Supplement|Whey protein concentrate|see arm description
1992693|NCT03313791|Dietary Supplement|Yoghurt|see arm description
1840329|NCT00874250|Device|GORE CTAG Device|Endovascular aortic stent-graft
1840330|NCT00874276|Drug|Dichloroacetate (DCA)|Dichloroacetate 2.5.ug/kg will be administered for five days in the clinical research center. On day 5 with the dose of DCA a pharmacokinetics test will be performed for 24 hours. 30 days later the individuals will return to the clinic and receive Dichloroacetate 25mg/kg (clinical dose) for five days. On day 1 and day 5 Pharmacokinetics will be performed to determine the relationship between DCA metabolism and haplotype.
1840331|NCT00874276|Genetic|Genetic Marker on Chromosome 14q24.3|Individuals were genotyped at the beginning of the study and their haplotypes were defined. The study is looking at individuals with genetic markers on Chromosome 14q24.3 to determine if there will be a difference in how the DCA will be metabolized.
1840332|NCT00874289|Other|NGAL kit|Kit to test NGAL levels in heart failure patients
1840333|NCT00874302|Drug|Proellex|One 25mg capsule taken orally once every day.
1840334|NCT00874302|Drug|Proellex|Two 25mg capsules Proellex (50mg) taken orally once every day
1840335|NCT00874315|Other|anti-thymocyte globulin|2.5 mg/kg/day for 4 doses on day -3, -2 , -1 and day +2.
1840336|NCT00874315|Drug|busulfan|0.8 mg/kg/dose for total of 8 doses.
1840337|NCT00874315|Drug|cyclosporine|1.5 mg/kg/dose every 12 hours.
1840338|NCT00874315|Drug|fludarabine phosphate|30 mg/m2/day for 5 days.
1840339|NCT00874315|Drug|mycophenolate mofetil|15 mg/kg/dose every 8 hours
1840340|NCT00874315|Drug|tacrolimus|0.03 mg/kg/day as continuous infusion or 12 hour divided doses
1840341|NCT00874315|Procedure|allogeneic hematopoietic stem cell transplantation|Donor stem cell transplantation from HLA matched sibling donor or an unrelated donor.
1840342|NCT00874328|Drug|Irinotecan|Irinotecan iv D1 q 3 weeks until maximum 6 cycles
1840343|NCT00874328|Drug|Cisplatin|cisplatin 60mg/m2 iv D1 q 3weeks until maximum 6 cycles
1840344|NCT00874328|Drug|TS-1 (S-1)|TS-1 po D1~D14 q 3 weeks until maximum 6 cycles
1840345|NCT00874341|Other|Fruit and vegetable intervention|Dose-response effect of fruit and vegetable intake (1-2 vs 4 vs 7 portions per day for 12 weeks)
1840346|NCT00874354|Drug|Intracoronary Transplantation of Bone Marrow Stem Cells|Intracoronary application of autologous bone marrow-derived mononuclear cells in infarct artery 3 - 14 days after PCI for acute myocardial infarction.
1840347|NCT00874380|Other|Increasing total fiber intake in patient's diet|Second counsel patients biweekly about their compliance with a high fiber diet, target being 25 to 30 gm of fiber a day.Follow them for a period of 2 years and assess if their is any significant decrease in their cardiovascular events and profile, in addition to assessing the effect of high fiber on kalemia.
1840348|NCT00874393|Drug|Dopamine|Dopamine
1840349|NCT00874393|Drug|Hydrocortisone|Hydrocortisone
1840350|NCT00874393|Drug|Infusion Placebo|Dextrose (D5W)
1840351|NCT00874393|Drug|Syringe Placebo|Normal saline
1840352|NCT00874406|Drug|tac + folfox4|tac: oxaliplatin 100mg + fudr 1g + mmc 10mg 7 days later： operation within 28 days after operation: folfox4
1840353|NCT00874406|Drug|folfox4|folfox4 will be done within 28 days after liver resection
1840354|NCT00874419|Drug|erlotinib|erlotinib 150 mg oral, once a day
1840355|NCT00874419|Drug|gemcitabine/carboplatin|gemcitabine 1000mg/m2 on d1,8 with carboplatin AUC=5 on d1 intravenously, every 3 weeks, up to 4 cycles
1840356|NCT00874432|Drug|angiotensin converting enzyme inhibitor|Active comparator in chronic kidney disease and age matched control will take 1x40mg per day Placebo comparator in chronic kidney disease and age matched control will take 1 placebo pill per day
1840357|NCT00874432|Drug|lisinopril|1 x 40 mg per day
1840358|NCT00874445|Device|ICD/ CRT-D|Patients in experimental group will have their ICDs programmed to Tuned waveform and those in the control group will have their ICDs programmed to Fixed Tilt waveform.
1840359|NCT00874458|Procedure|magnetic resonance imaging|
1840360|NCT00874458|Procedure|radiomammography|
1840361|NCT00874458|Procedure|ultrasound imaging|
1840362|NCT00874484|Drug|Clexane (enoxaparin)|One arm receives enoxoparin, second arm receives saline
1840363|NCT00874497|Drug|tetomilast|Oral tetomilast 25 mg once daily for 2 weeks followed by 50 mg once daily for 2 years.
1840364|NCT00874497|Drug|placebo|Placebo for 104 weeks (2 years)
1840365|NCT00874510|Behavioral|Mandatory Naps|As above, interns on extended duty overnight call shifts will be required to transfer cell phones and cross-coverage responsibilities to night float residents for a 5 hour period each night they are on call. For Year 2, interns will nap in shifts, instead of concurrently, with the first nap shift between 12am-3am and the second shift between 3am-6am
1840366|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks then atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks
1840367|NCT00874523|Drug|atazanavir plus raltegravir|atazanavir 300 mg + ritonavir 100 mg + raltegravir 800 mg once daily for 4 weeks then atazanavir 300 mg + raltegravir 400 mg twice daily for 4 weeks
1840368|NCT00874536|Dietary Supplement|omega-3 fatty acid alpha-linolenic acid (ALA)|3 grams of ALA-containing plant oil
1840369|NCT00874536|Dietary Supplement|Placebo|
1840370|NCT00874549|Biological|Menomune®: A, C, Y, W-135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
1840371|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1840372|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL. Intramuscular
1840373|NCT00874549|Biological|Menactra®: Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1840374|NCT00874562|Drug|Corticosteroid|Initial dose of corticosteroid given intravenously. After the first dose, corticosteroid will be taken orally every 8 hours for the duration of the five-day period
1840375|NCT00874562|Drug|Rapamycin|Taken orally mixed with water or orange juice
1840376|NCT00874575|Dietary Supplement|Placebo|
1840377|NCT00874575|Dietary Supplement|Vitamin D|
1840378|NCT00874575|Dietary Supplement|Beta-hydroxy-Beta-methylbutyrate|
1840379|NCT00874575|Drug|Beta-hydroxy-Beta-methylbutyrate and Vitamin D|
1840380|NCT00874588|Biological|HLA-A*2402restricted URLC10, CDCA1, VEGFR1 and VEGFR2|Escalating doses of every peptide will be administered by subcutaneous injection on days 1,8,15 and 22 of each 28-day treatment cycles. Planned doses of peptides are 1.0mg and 3.0mg.
1840381|NCT00874601|Drug|Diovan® (valsartan)|"The valsartan will be initially given 80 mg of Diovan® (valsartan) per oral once daily in the morning on day 1, and flexibly will be adjusted to a dose of 80 -320 mg per day during next 6 days if more than 30% of SBPs measured at least 4 times in a day will not get the target level of SBPs.
In those patients not achieving target level of blood pressure (more than 15% reduction of initial blood pressure or below 145 mmHg of systolic blood pressure), an additional antihypertensive drugs (diuretics, beta blockers) can be given despite of Valsartan 320 mg. If the BP is considered to be low enough, dose of valsartan can be decreased to 40 mg per day. If the administration of valsartan is judged to be inappropriate by duty doctor due to any reasons, it can be stopped and the reasons will be recorded."
1840382|NCT00874614|Radiation|Ultratrace® Iobenguane I131|Each subject will be administered 3 mCi to 6 mCi Ultratrace® Iobenguane I 131, referred to as the Imaging Dose, to confirm that subject meets radiological entry criteria and to establish dosimetry. All subjects meeting entry criteria will then receive the investigational product referred to as the Therapeutic Dose (500 mCi or 8 mCi/kg if the subject weighs 62.5 kg or less) of Ultratrace Iobenguane I 131, followed by imaging at 7 days post infusion or upon discharge from isolation. The Therapeutic Doses will be adjusted equally if warranted by results of the dosimetry evaluation. At least 3 months later, subjects will receive the second Therapeutic Dose.
1840383|NCT00874627|Other|Milk|sublingual administration of milk
1840384|NCT00874627|Other|Milk|placebo
1840385|NCT00874640|Biological|Gadobutrol (Gadovist, BAY86-4875)|Patients with indication for a MRT or MR-Angiography and for whom the radiologist has decided to use the contrast medium gadobutrol
1840386|NCT00874653|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for intrauterine treatment of menorrhagia
1840387|NCT00874666|Other|crushed garlic clove|1 gram crushed garlic in gelatin capsules, one dose once every 2-16 weeks
1840388|NCT00874666|Dietary Supplement|garlic powder tablet|tablets, dose to contain 1 gram of garlic powder, consume one dose once every two weeks for up to 52 weeks
1840389|NCT00874679|Drug|Levitra (Vardenafil, BAY38-9456)|Patients with diagnosis of erectile dysfunction who get vardenafil in routine treatment
1840390|NCT00874692|Other|BMS and sterilisation programme|BMS with reduced hot water temperature and sterilisation programme
1840391|NCT00874718|Behavioral|educational program|6-week educational program for prevention of occupational musculoskeletal diseases.
1840392|NCT00874718|Behavioral|General education|Non-specific educational program for general health.
1840393|NCT00874731|Drug|Ridaforolimus 100 mg|Part 1: A single oral dose of 100 mg ridaforolimus (10 x 10 mg tablets) was given on Day 2.
1840394|NCT00874731|Drug|Ridaforolimus 40 mg|Part 2 (optional): Ridaforolimus 40 mg (4 x 10 mg tablets) was received on a regimen of daily oral doses for 5 consecutive days followed by 2 days off-drug.
1840395|NCT00874731|Drug|Placebo|A single oral dose of placebo (10 x placebo tablets) was given on Day 1.
1840396|NCT00874744|Drug|Bevacizumab|1.25mg bevacizumab (0.05ml)
1840397|NCT00874744|Drug|Triamcinolone acetonide|4.0 mg Triamcinolone acetonide injection
1840398|NCT00874770|Drug|Daclatasvir|Tablets, oral, 3 mg, Daily, 48 weeks
1840399|NCT00874770|Drug|Daclatasvir|Tablets, oral, 10 mg, Daily, 48 weeks
1840400|NCT00874770|Drug|Daclatasvir|Tablets, oral, 60 mg, Daily, 48 weeks
1840401|NCT00874770|Drug|Placebo|Tablet, oral, 0 mg, Daily 48 weeks
1840402|NCT00874770|Drug|Peginterferon alpha-2a|Syringe, subcutaneous, 180 µg, Weekly, 48 weeks
1840403|NCT00874770|Drug|ribavirin|Tablet, oral, 1000 or 1200 mg, based on weight, Daily, 48 weeks
1840404|NCT00874796|Drug|GS-9450|Taken as one capsule by mouth once daily
1840405|NCT00874796|Drug|Placebo|Taken as one placebo capsule (matching in appearance to GS-9450 capsules) by mouth once daily
1840406|NCT00874809|Device|CGMS with an insulin pump using rapid acting insulin|To determine basal changes subject will wear a CGMS with an insulin pump infusing rapid acting insulin
1840407|NCT00874835|Device|EndoSaver™ Corneal Endothelium Delivery Instrument|Efficacy of device to maintain function and integrity of corneal endothelial cells during insertion into the eye during keratoplasty.
1840408|NCT00874848|Biological|Imprime PGG Injection|4 mg/kg i.v. over 2 hrs, weekly, in three week cycles
1840409|NCT00874848|Biological|Cetuximab|initial loading dose of 400 mg/m^2 over 120 min and subsequent doses at 250 mg/m^2 over 60 min, weekly on Days 1, 8 and 15 of each 3-week treatment cycle
1840410|NCT00874848|Drug|Paclitaxel|200 mg/m^2 i.v. over 3 hr on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
1840411|NCT00874848|Drug|Carboplatin|dose equal to an AUC of 6 mg/mL · min based on the Calvert formula; i.v. over 30 min on Day 2 of each 3-week treatment cycle for the first 4 to 6 treatment cycles
1840464|NCT00875251|Device|body composition|Measurements of body composition using 2 differents devices: Bioimpedance measurements will be made with the RJL System (Quantum BIA 101Q equipment) air-displacement plethysmography in the PEA POD System (Life Measurement).
1992694|NCT03313791|Dietary Supplement|50%whey-50% casein (Standard)|see arm description
1992695|NCT03313791|Dietary Supplement|50%whey-50% casein (Alternative)|see arm description
1992696|NCT03313791|Dietary Supplement|Micellar Casein Isolate- WPH|see arm description
1840412|NCT00874861|Biological|Peptide vaccine + Poly-ICLC|"Subcutaneously in right or left upper arms with intact draining axillary nodes. Each will be injected to the same location in the same arm as the previous vaccine was administered. In case of no intact axillary lymph nodes as draining nodes, vaccines will be administered in the upper thigh on the same side with intact inguinal lymph nodes.
Vaccine will be administered on weeks 0,3,6,9,12,15,18 and 21. Poly-ICLC First course(20 mg/kg i.m., up to 1640 µg/injection) will be administered on an outpatient basis in the Clinical & Translational Research Center (CTRC)the day of the first GAA/TT-vaccine and on day 4 after the vaccine. For each of the repeated vaccinations (on Weeks 3,6,9,12,15,18 and 21) poly-ICLC will be administered on day of the vaccine and on day 4 after the vaccine."
1840413|NCT00874874|Drug|sorafenib tosylate|
1840414|NCT00874887|Drug|moxifloxacin 0.5% HCI ophthalmic solution|1 drop in study eye three times a day for 14 days
1840415|NCT00874887|Drug|gatifloxacin ophthalmic solution 0.3%|1 drop in study eye four times a day for 14 days
1840416|NCT00874900|Other|Educational game|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to the game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department."
1840417|NCT00874900|Other|Educational game + motivational interview|"Quest for the Code is an educational asthma computer game. Participants randomized to this intervention will have access to this game for a minimum of one hour while receiving treatment in the Seattle Children's Emergency Department (ED).Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques."
1840418|NCT00874900|Other|Motivational interview|Participant randomized to this group will receive standard care for the treatment of their asthma, including an education asthma booklet developed by Seattle Children's. Before leaving the ED, participants in this group will have a brief asthma goal setting activity using motivational interview techniques.
1840419|NCT00874913|Device|measurement of ocular blood flow|measurement of ocular blood flow with a laser Doppler flowmeter
1840420|NCT00874926|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Haemophilia A patients
1840421|NCT00874939|Drug|MK-0249 7.5 mg|4 tablets (1 x 0.5 mg + 2 x 1 mg + 1 x 5 mg) totaling 7.5 mg, single oral dose during each crossover period
1840422|NCT00874939|Drug|MK-0249 25 mg|5 x 5 mg tablets totaling 25 mg, single oral dose during each crossover period
1840423|NCT00874939|Drug|Donepezil 5mg|One 5 mg tablet, single oral dose during each crossover period
1840424|NCT00874939|Drug|Placebo to MK-0249|Five tablets, single oral dose during each crossover period
1840425|NCT00874939|Drug|Placebo to Donepezil|One over-encapsulated capsule, single oral dose during each crossover period
1840426|NCT00874965|Device|Electrostimulation|50Hz; 0.4 ms; 30 min; 5 times / week
1840427|NCT00874965|Device|Sham stimulation|30 min; 5 times / week
1840428|NCT00874978|Drug|lenalidomide|Oral lenalidomide 10mg (two 5mg capsules) daily on days 1-21 every 28 days for up to 6 cycles.
1840429|NCT00875004|Biological|epoetin beta|
1840430|NCT00875004|Drug|systemic chemotherapy|
1840431|NCT00875004|Procedure|quality-of-life assessment|
1840432|NCT00875017|Drug|Lanthanum Carbonate|1 x 1000mg tablet
1840433|NCT00875017|Drug|Sevelamer|3 x 800mg tablets
1840434|NCT00875030|Drug|artesunate sachets|single dose 50 mg (2 X 25 mg) artesunate sachets
1840435|NCT00875030|Drug|Arsuamoon|single dose 50 mg arsuamoon tablet
1840436|NCT00875056|Drug|vorinostat|MK0683 (200 mg capsule) Oral, twice daily (400 mg/day) for Day 1 through 14 of a 21 day cycle
1840437|NCT00875069|Other|Ethanol|Dialysis catheter lock performed after renal replacement therapy session. Lock is instilling ethanol (or placebo) in each catheter lumen for 2 minutes before being withdrawn.
1840438|NCT00875082|Drug|Montelukast|Montelukast, chewing tablets 5mg, once daily, 8 weeks
1840439|NCT00875082|Drug|placebo|placebo chewing tablets once daily, plus inhaled short acting beta2 agonist as needed, 8 weeks
1840440|NCT00875108|Drug|VIAject™|Subcutaneous injection 25 IU/mL
1840441|NCT00875134|Other|Verbal prompt|Patient hears a voice recording
1840442|NCT00875134|Other|Skin Stimulus|Patient receives either a skin stimulus
1840443|NCT00875147|Drug|bevacizumab|Neoadjuvant chemotherapy with bevacizumab
1840444|NCT00875160|Drug|AT2101|225mg (nine 25mg capsules total dose) to be taken by mouth every day for 9 days (Study Days 1, 3-10)
1840445|NCT00875173|Drug|Selenium|selenium as a drug according to Brazilian regulation laws
1840446|NCT00875173|Drug|Placebo (for Selenium)|Placebo with similar flavor, smell and colour.
1840447|NCT00875186|Other|aerobic endurance training|participants exercises 2 times weekly for 1 hour (aerobic endurance training)
1840448|NCT00875186|Other|aerobic endurance training|participants exercised 1 time weekly for 1 hour (aerobic endurance training)
1840449|NCT00875199|Behavioral|contingency management|Prize-based contingency management for weight loss
1840450|NCT00875199|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling session with research staff
1840451|NCT00875212|Drug|calcium glycerophosphate|use of a dentifrice containing CaGP (0.13%) and no fluoride
1840452|NCT00875212|Drug|no active ingredient|dentifrice without calcium glycerophosphate and no fluoride
1840453|NCT00875212|Drug|fluoride|use of a dentifrice containing fluoride (1500ppm) only
1840454|NCT00875212|Drug|CAGP + fluoride|calcium glycerophosphate and fluoride dentifrice
1840455|NCT00875225|Behavioral|DVD|Control group will receive usual care DVD from health professionals
1840456|NCT00875225|Behavioral|Intervention DVD|Intervention group will receive intervention DVD with patient stories and information from health care professionals
1840457|NCT00875238|Biological|trastuzumab|
1840458|NCT00875238|Drug|doxorubicin hydrochloride|
1840459|NCT00875238|Genetic|polymorphism analysis|
1840460|NCT00875238|Other|laboratory biomarker analysis|
1840461|NCT00875238|Other|questionnaire administration|
1840462|NCT00875238|Procedure|assessment of therapy complications|
1840463|NCT00875238|Procedure|magnetic resonance imaging|
1992697|NCT03313791|Dietary Supplement|Micellar Casein Isolate - Na-caseinate|see arm description
1992698|NCT03313791|Dietary Supplement|Micellar Casein Isolate|see arm description
1840465|NCT00875264|Drug|CEP-11981 (kinase inhibitor)|Patients will be treated with oral CEP-11981 once daily for 28 days, followed by a treatment-free period of 14 days. This 42-day (6-week) period will constitute 1 cycle. The starting dose for the study will be 3 mg/m2. Dose escalation from this starting dose follows a modified Fibonacci sequence.
1840466|NCT00875277|Drug|LEO 29102 cream and combination products|Once daily application 6 days a week for 4 weeks
1840467|NCT00875290|Device|Real-time glucose sensor|Children assigned to this intervention will use a real-time sensor continuously
1840468|NCT00875303|Behavioral|Play Nicely program|The intervention was the Play Nicely program, a multimedia educational program. Permission to demonstrate the program to multiple viewers was obtained from the copyright holder. English speaking caregivers viewed the 2nd English language edition and Spanish speaking caregivers viewed the Spanish edition. In the program, there are 16 options (20 options in the Spanish version) to respond to the hypothetical situation of witnessing a young child have hurtful behavior toward another child. Caregivers in the intervention group were instructed to view 4 of the interactive options of their choosing. On average, it takes 1 minute to view one option. Parents in the control group received routine primary care with their pediatrician.
1840469|NCT00875303|Behavioral|Control|Routine primary care.
1840470|NCT00875316|Drug|Cogane™ (PYM50028)|Orally active neurotrophic factor inducer
1840471|NCT00875342|Drug|DCS|1. Cognitive behavioral treatment with exposure therapy plus D-Cycloserine (100 mg on days of therapy session (approximately 9 times)
1840472|NCT00875342|Other|Placebo|2. Cognitive behavioral treatment with exposure therapy plus a placebo(sugar pill) (Placebo given on days of therapy session (9 times)
1840473|NCT00875355|Drug|temozolomide|Given orally
1840474|NCT00875355|Radiation|radiation therapy|Patients undergo radiotherapy
1840475|NCT00875368|Drug|maraviroc|maraviroc dose dependent on co-medication
1840476|NCT00875368|Drug|Placebo|Placebo drug
1840477|NCT00875394|Drug|sitagliptin phosphate|sitagliptin 100 mg Once a day (QD) for 24 weeks
1840478|NCT00875394|Drug|Comparator: metformin|metformin 850 mg Twice a day (BID) for 24 weeks
1840479|NCT00875394|Drug|Comparator: metformin|metformin 500 mg Three times a day (TID) to 850 mg Twice a day (BID), for 24 weeks
1840480|NCT00875394|Drug|Comparator: Antidiabetic Standard of Care|Patient can take any oral antidiabetic drug (other than metformin)
1840481|NCT00875407|Other|Scintigraphy in 123I-IBZM|
1840482|NCT00875420|Drug|RAD1901|10 mg Oral once a day for 28 days.
1840483|NCT00875420|Drug|RAD1901|25 mg Oral once a day for 28 days
1840484|NCT00875420|Drug|RAD1901|50 mg Oral once a day for 28 days.
1840485|NCT00875420|Drug|RAD1901|100 mg Oral once a day for 28 days
1840486|NCT00875420|Drug|Placebo|Placebo Oral once a day for 28 days
1840487|NCT00875433|Drug|BIBW 2992|patients to receive continuous oral daily dosing of BIBW 2992
1840488|NCT00875446|Drug|PLACEBO|Placebo
1840489|NCT00875446|Drug|GSK1223249|I.V Infusion
1840490|NCT00875459|Drug|VIAject™|Subcutaneous injection 25 IU/mL
1840491|NCT00875485|Procedure|Blood sampling|Blood sampling at Years 11, 12, 13, 14, 15 and at the time of challenge dose administration and one month after challenge dose administration.
1840492|NCT00875485|Biological|Additional challenge dose|If a subject became seronegative for anti-HAV antibodies (< 15 mIU/mL) or if anti-HBs antibody concentrations decreased below 10 mIU/mL during the long-term follow-up, immune memory against the antigen was evaluated by administering a challenge dose of the appropriate antigen (vaccine) 6 to 12 months after the Year 15 follow-up time-point.
1840493|NCT00875498|Procedure|active iTBS|"Intermittent Theta Burst Stimulation (iTBS) over Left dorsolateral prefrontal cortex.
80% MT, 20 sessions of 6 minutes, 2 per day"
1840494|NCT00875498|Procedure|sham iTBS|iTBS placebo (placebo coil)
1840495|NCT00884416|Drug|Sorafenib dose escalation|Sorafenib dose escalation scheme: 3 first patients: 200 mg/d, if dose limiting toxicities (DLT) not reached: 3 patients at 200 mg BID, if no DLT reached: 3 patients at 400 mg bid
1840496|NCT00884429|Procedure|Chest physiotherapy - Conventional|Percussion Postural Drainage and thorax compression
1840497|NCT00884429|Procedure|Chest physiotherapy - actual techniques|Slow prolonged expiration and clearance rhinopharynx retrograde
1840498|NCT00884429|Procedure|3-Airway suction|Airway suction
1840499|NCT00884442|Drug|Nifedipine (Gen-nifedipine extended release, previously referred to as Gen-Nifedipine XL)|60 mg nifedipine
1840500|NCT00884442|Drug|Nifedipine (Bayer Healthcare AG manufactured as Adalat® XL®, Adalat® LA, Adalat® Crono, Adalat® OROS)|60 mg nifedipine
1840501|NCT00884481|Other|Natalizumab|Participants treated with Tysabri
1840502|NCT00884494|Drug|Ghrelin infusion to assess effects on insulin sensitivity|
1840503|NCT00884507|Drug|Placebo|po daily for 24 weeks
1840504|NCT00884507|Drug|RO5313534|1mg po daily for 24 weeks
1840505|NCT00884507|Drug|RO5313534|5mg po daily for 24 weeks
1840506|NCT00884507|Drug|RO5313534|15mg po daily for 24 weeks
1840507|NCT00884520|Drug|[F-18] VM4-037|"The individual doses of [F-18]VM4-037 contain a maximum of 20 mCi for normal volunteers and 10 mCi for cancer subjects.
The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
1840508|NCT00884533|Drug|Rosi XR|Rosi XR
1840509|NCT00884533|Other|Placebo|Placebo
1840510|NCT00884533|Drug|Moxifloxacin|400mg single dose
1840511|NCT00884546|Drug|BMS-833923|Capsule, Oral, Once daily, 6 months
1840512|NCT00884546|Drug|Lenalidomide|Capsule, Oral, Once daily, 6 months
1840513|NCT00884546|Drug|Dexamethasone|Capsule, Oral, Once a week, 6 months
1840514|NCT00884546|Drug|Bortezomib|Powder, IV, On days 1, 4, 8, 11, 6 months
1840515|NCT00884559|Other|instruction|Debriefing
1840516|NCT00884585|Drug|Cyclosporine Vehicle|Placebo (cyclosporine vehicle) administered 4 times a day to the qualified eye(s) for 3 months.
1840517|NCT00884585|Drug|Cyclosporine 0.010%|Cyclosporine ophthalmic solution 0.010% administered 4 times a day to the qualified eye(s) for up to 12 months; at Month 9 the dose may be adjusted to 2 times a day.
1840518|NCT00884598|Drug|cilengitide|
1840519|NCT00884598|Other|pharmacological study|
1840520|NCT00884598|Radiation|radiation therapy|
1840524|NCT00884663|Drug|Candesartan|Candesartan cilexitil tablets, 16 mg once daily
1840525|NCT00884663|Drug|propranolol|Propranolol hydrochloride capsules 160 mg once daily, slow release formulation
1840526|NCT00884663|Drug|placebo|placebo tablets and capsules
1840527|NCT00884676|Drug|Ixabepilone|"Administered intravenously. Dosage assigned by Phase I center as determined by dose-escalation schedule:
Schedule A: Weekly for 3 weeks each cycle (Days 1, 8 and 15)
Schedule B: Day 1 of each 3-week cycle."
1840528|NCT00884676|Drug|Sunitinib|For both Schedules A and B, daily, orally, starting on Day 8 of Cycle 1
1840529|NCT00884715|Drug|Octreotide|short acting octreotide
1840530|NCT00884741|Radiation|Radiation therapy pre-randomization|The first 3 weeks of the full 6 weeks of RT treatment: One treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks. The radiation therapy can be intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3DRT).
1840531|NCT00884741|Biological|Bevacizumab|Each dose will be will be via IV, 10 mg/kg of actual body weight. Post-Randomization during concomitant RT: Days 1 and 15 of each 28-day cycle, at the beginning of the 4th week of radiation. Post-Radiation: At the beginning of the second week after completion of radiation. Then concurrently (same day) as the initiation of the first cycle of the post-radiation TMZ.
1840532|NCT00884741|Drug|Placebo|Each dose will be will be via IV, 10 mg/kg of actual body weight. Post-Randomization during concomitant RT: Days 1 and 15 of each 28-day cycle, at the beginning of the 4th week of radiation. Post-Radiation: At the beginning of the second week after completion of radiation. Then concurrently (same day) as the initiation of the first cycle of the post-radiation TMZ.
1840533|NCT00884741|Drug|Temozolomide pre-randomization|Concurrent with RT: First 3 weeks of TMZ is administered continuously from day 1 of RT at a daily oral dose of 75 mg/m2.
1840534|NCT00884741|Drug|Temozolomide post-randomization|Concurrent with RT: TMZ continues to be administered continuously for last 3 weeks of RT to the last day of RT at a daily oral dose of 75 mg/m2 for a maximum of 49 days from start of RT. Post-Radiation: TMZ is administered orally once per day for 5 consecutive days (days 1-5) of a 28-day cycle. The starting dose for the first cycle will be 150 mg/m2/day, with a single dose escalation to 200 mg/m2/day in subsequent cycles if no treatment-related adverse events > grade 2 are noted. At the completion of 6 cycles, patients may receive up to an additional 6 cycles of treatment (therefore, a maximum of 12 cycles).
1840535|NCT00884741|Radiation|Radiation therapy post-randomization|The last 3 weeks of the full 6 weeks of RT treatment: One treatment of 2 Gy will be given daily 5 days per week for a total of 60 Gy over 6 weeks. The radiation therapy can be intensity-modulated radiation therapy (IMRT) or 3-dimensional conformal radiation therapy (3DRT).
1840536|NCT00884832|Drug|Clonidine|Subjects randomized to Clonidine will take 0.1 mg of the medication orally twice a day for a total of 4 weeks.
1840537|NCT00884832|Drug|Placebo|Subjects randomized to the placebo group will also take 0.1 mg of matching placebo pills orally twice a day for a total of 4 weeks.
1840538|NCT00884845|Drug|PM02734 and erlotinib|PM02734 drug product (DP) 1 mg/vial is a powder for concentrate for solution for infusion
1840539|NCT00884845|Drug|Erlotinib|Erlotinib is provided as 25 mg, 100 mg and 150 mg white film-coated tablets
1840540|NCT00884858|Drug|Maraviroc|Maraviroc is administered BID according to the other drugs within HAART; dosage ranges from 150 mg to 600 mg bid.
1840541|NCT00884871|Procedure|LapBand|Prospective observation study of 100 obese women undergoing laparoscopic gastric banding to determine impact of weight loss on pelvic floor disorders
1840542|NCT00884884|Drug|Double Placebo|1 capsule daily
1840543|NCT00884884|Drug|Aripiprazole 15, placebo|15 mg Aripiprazole daily plus placebo daily
1840544|NCT00884884|Drug|Aripiprazole 7.5, Placebo|Aripiprazole 7.5 mg daily plus Placebo daily
1840545|NCT00884884|Drug|Topiramate 100, Placebo|Topiramate 100 mg daily plus Placebo daily
1840546|NCT00884884|Drug|Topiramate 200, Placebo|Topiramate 200 mg daily plus Placebo daily
1840547|NCT00884884|Drug|Topiramate 100, Aripiprazole 15|Topiramate 100 mg daily plus Aripiprazole 15mg daily
1840548|NCT00884884|Drug|Topiramate 100, Aripiprazole 7.5|Topiramate 100 mg daily plus Aripiprazole 7.5mg daily
1840549|NCT00884884|Drug|Topiramate 100, Aripiprazole 15mg|Topiramate 100 mg daily plus Aripiprazole 15mg daily
1840550|NCT00884884|Drug|Topiramate 200, Aripiprazole 7.5mg|Topiramate 200 mg daily plus Aripiprazole 7.5mg daily
1840551|NCT00884884|Drug|Topiramate 200, Aripiprazole 15|Topiramate 200mg daily plus Aripiprazole 15mg daily
1840552|NCT00884897|Drug|Oxytocin|Oxytocin given as 20 IU BID
1840553|NCT00884897|Drug|Placebo|Placebo given as 20 IU BID
1840554|NCT00884910|Device|Provox Vega voice prosthesis 22.5 Fr|The patients' current Provox2 voice prosthesis will be removed and the new Provox Vega voice prosthesis will be inserted.
1840555|NCT00884949|Drug|BMN 110|"Subjects will receive a weekly 4- to 5-hour intravenous infusion of BMN 110 in 3 consecutive 12-week dosing intervals, using the following regimen:
Weeks 1-12: 0.1 mg/kg/week
Weeks 13-24: 1.0 mg/kg/week
Weeks 25-36: 2.0 mg/kg/week
Subjects who complete the 36-week Dose-Escalation Period will have the option to continue drug treatment for an additional 36 to 48 weeks. Subjects continuing on treatment after the Dose-Escalation period will receive weekly 4- to 5-hour intravenous infusions of BMN 110 at a dose of 1.0 mg/kg/week."
1840556|NCT00884962|Device|Polymeric Lung Volume Reduction System (PLVR)|20ml (each) of polymer will be injected into 2, 3 or 4 subsegments during the first treatment. Eligible patients may have 20ml (each) of polymer will be injected into 2 or 3 subsegments during the second treatment.
1840557|NCT00884988|Drug|Lymphomyosot|20 drops X3/day, until discharge
1840558|NCT00884988|Drug|Placebo remedy|20 drops X3/day, until discharge
1840559|NCT00885001|Procedure|Short Arc Banding|Lumbar extension on the ATM II from back project. Rehabilitation exercise intervention.
1840560|NCT00885014|Behavioral|CBT|Telephone cognitive-behavioral therapy
1840561|NCT00885014|Behavioral|EAP|Employees Assistance Program
1840562|NCT00885053|Dietary Supplement|fish oil|Capsules. Approximately 1000 mg n-3 PUFA daily. One day + 6 weeks
1840563|NCT00885053|Dietary Supplement|olive oil|Capsules. Approximately 1 g olive oil daily. One day + 6 weeks
1840564|NCT00885066|Drug|capecitabine|
1840565|NCT00885066|Drug|erlotinib hydrochloride|
1840566|NCT00885066|Drug|gemcitabine hydrochloride|
1840567|NCT00885079|Drug|OPC-12759 Ophthalmic suspension|OPC-12759 Ophthalmic suspension 2%
1840568|NCT00885079|Drug|Hyalein Mini Ophthalmic solution|Hyalein Mini Ophthalmic solution 0.1%
1840569|NCT00885092|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses.
1840570|NCT00885092|Device|RepleniSH Multi-Purpose Disinfecting Solution (MPDS) (OPTI-FREE® RepleniSH®)|Commercially marketed solution intended for use as a cleaning, conditioning, rinsing, disinfecting, and storage solution for all silicone hydrogel and soft (hydrophilic) contact lenses.
1840571|NCT00885092|Device|Senofilcon A contact lens (ACUVUE® Oasys™)|Commercially marketed silicone hydrogel contact lens for daily wear use
1840572|NCT00885092|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
1840573|NCT00885105|Biological|Influenza Virus Vaccine|0.25 mL, Intramuscular
1840574|NCT00885105|Biological|Influenza Virus Vaccine|0.25 mL, Intramuscular
1840575|NCT00885118|Drug|Placebo (middle dose)|Placebo tablets once a day
1840576|NCT00885118|Drug|Placebo|Placebo tablets once a day
1840577|NCT00885118|Drug|BI 10773|BI 10773 middle dose tablets once a day
1840578|NCT00885118|Drug|BI 10773|BI 10773 high dose tablets once a day
1840579|NCT00885118|Drug|BI 10773|BI 10773 middle dose tablets once a day
1840580|NCT00885118|Drug|Placebo (high dose)|Placebo tablets once a day
1840581|NCT00885118|Drug|BI 10773|BI 10773 low dose tablets once a day
1840582|NCT00885118|Drug|Placebo (low dose)|Placebo tablets once a day
1840583|NCT00885144|Dietary Supplement|Nutributter|"Test dose of standard supplementary lipid based nutrient supplement (LNS). 15 grams of Nutributter will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation."
1840584|NCT00885144|Dietary Supplement|LNS-20gM|Test dose of modified LNS-20gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
1840585|NCT00885144|Dietary Supplement|LNS-20gNoM|Test dose of modified LNS-20gNoM (milk free) supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-20gNoM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
1840586|NCT00885144|Dietary Supplement|LNS-10gM|Test dose of modified LNS-10gM supplementary lipid based nutrient supplement (LNS). 15 grams of LNS-10gM will be mixed with 30 g of maize porridge and fed to the child over a maximum of 15 minute period, under direct observation.
1840587|NCT00885157|Biological|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.1 mL, intradermal
1840588|NCT00885157|Biological|Inactivated types 1, 2, and 3 poliovirus, D antigens|0.5 mL, Intramuscular
1840589|NCT00885170|Drug|Odanacatib|Odanacatib 50 mg tablets once weekly for 24 months
1840590|NCT00885170|Drug|Placebo|Placebo to odanacatib 50 mg tablets once weekly for 24 months
1840591|NCT00885170|Dietary Supplement|Vitamin D3|Vitamin D3, two 2800 IU tablets, taken once weekly for 24 months
1840592|NCT00885170|Dietary Supplement|Calcium|Participants will receive calcium carbonate supplements as needed to ensure a daily calcium intake of 1200 mg.
1840593|NCT00885183|Procedure|Acupuncture therapy|12 acupuncture treatment sessions for a period of 16 weeks
1840594|NCT00885196|Drug|Placebo|
1840595|NCT00885196|Drug|AEB071|
1840596|NCT00885222|Device|DBS parameters setting|DBS parameters will be set to increase the DBS affected volume to include both the cognitive and limbic territories in addition to the dorso-lateral motor territories of the STN. This novel approach to parameter selection is directed to achieve improvement in cognitive and limbic as well as motor domains of PD. The patients will therefore be assessed for cognitive, limbic and motor state at multiple time points; there will be a baseline assessment prior to starting treatment (prior to DBS surgery and/or prior to parameters changes); thereafter assessments will follow the stimulation parameter changes; thereafter follow-up assessments at 6 - 12 months. Stimulation parameters will be changed every 2 weeks or earlier if an urgent clinical state emerges. Patients with depression will be monitored for antidepressant effects of stimulation changes. Patients without depression will be monitored for evidence of treatment emergent depression.
1840597|NCT00885274|Drug|Pico-Salax|Both doses of Pico-Salax taken the evening prior to colonoscopy
1840598|NCT00885274|Drug|Split Dose Pico-Salax|One dose of Pico-Salax taken the evening prior to colonoscopy and the other the morning of the procedure.
1840599|NCT00885287|Drug|Artemether-lumefantrine (AL)|Standard treatment-dose of artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria according to national treatment guidelines
1840600|NCT00885300|Drug|cloxacillin|cloxacillin 100mg/ml as catheter lock at the end of hemodialysis
1840601|NCT00885300|Drug|heparin|heparin 1000iu/ml as catheter lock at the end of hemodialysis
1840602|NCT00885313|Drug|DHA250|DHA 250 mg/kg/d
1840603|NCT00885313|Drug|DHA500|DHA 500 mg/kg/d
1840604|NCT00885313|Drug|PLACEBO|placebo
1840605|NCT00885313|Behavioral|Lifestyle intervention|lifestyle intervention [including hypocaloric diet (25-30 cal/kg/d) or isocaloric diet (40-45 cal/kg/d) and physical activity], for 12 months.
1840606|NCT00885326|Drug|Bevacizumab|Every course will be 28 days. Bevacizumab 10 mg/kg/dose , will be administered intravenously every 14 days beginning on day 0 of the second course.
1840607|NCT00885326|Drug|cyclophosphamide|Cyclophosphamide will be administered as an intravenous (IV) bolus according to the protocol assigned dose level followed by daily oral dosing (25mg/m2/day) without interruption (unless toxicity supervenes).
1840608|NCT00885326|Drug|zoledronic acid|Administered on day 0 of course 1 and day 1 of course 2 and all subsequent courses in a dose of 4mg/m2 (max 4 mg per dose). On days when zoledronic acid (ZA) and cyclophosphamide (CTX) are given together, CTX should be given first.
1840609|NCT00885352|Drug|Sitagliptin|Sitagliptin 100 mg tablet orally once daily for 26 weeks.
1840610|NCT00885352|Drug|Comparator: Placebo|Placebo to sitagliptin 100 mg tablet orally once daily for 26 weeks.
1840641|NCT00885599|Drug|placebo mouthwash|colored water mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
1840611|NCT00885352|Drug|Pioglitazone|Participants taking 30 mg or more pioglitazone oral tablet(s) daily at screening in combination with metformin will enter a 4-week dose-stable period followed by a 2-week single-blind run-in and a 26-week treatment period. Participants taking 4 mg or more rosiglitazone oral tablet(s) daily at screening in combination with metformin were to be switched to a corresponding dose of pioglitazone prior to starting a 4-week dose-stable period. Participants who are taking less than 30 mg/day or no pioglitazone at screening will be titrated to a stable dose of at least 30 mg pioglitazone once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with pioglitazone will be up to 42 weeks.
1840612|NCT00885352|Drug|Metformin|Participants taking 1500 mg or more metformin oral tablet(s) and at least 30 mg pioglitazone or 4 mg rosiglitazone daily at screening will enter a 4-week dose-stable period followed by a 2-week single-blind placebo run-in, and a 26-week treatment period. Participants who are taking less than 1500 mg/day metformin at screening will be titrated to a stable dose of at least 1500 mg metformin once daily over a maximum of 4 weeks followed by a dose-stable period of 10 weeks, a 2-week single-blind placebo run-in, and a 26-week treatment period. Total treatment with metformin will be up to 42 weeks.
1840613|NCT00885352|Drug|Glipizide|Participants not meeting specific glycemic controls during the 26-week treatment period will use glipizide oral tablets as rescue therapy. In countries where glipizide is not available, participants will receive a sulfonylurea marketed in that country.
1840614|NCT00885365|Drug|tobramycin / Bramitob|300mg/4ml solution, via a nebuliser, over a 4-week treatment in a twice-daily regimen
1840615|NCT00885365|Drug|tobramycin / TOBI|300mg/5ml solution administered via nebuliser, over a 4-week treatment in a twice-daily regimen
1840616|NCT00885378|Drug|Saxagliptin plus metformin IR|Tablets, Oral, 2.5 mg, Twice daily, 12 weeks
1840617|NCT00885378|Drug|Placebo plus metformin IR|Tablets, Oral, Placebo, Twice daily, 12 weeks
1840618|NCT00885404|Drug|Lower chloride fluids (Hartmann's solution and Plasmalyte®)|Intravenous fluids used during the 6 month intervention period (after). Amount of fluids to be used is based on clinicians' discretion.
1840619|NCT00885417|Drug|Cravit-based sequential therapy|Eligible patients will be treated with (esomeprazole 40mg bid +amoxicillin 1gm bid) for 5 days, followed by (esomeprazole 40mg bid + levofloxacin 250mg bid + metronidazole 500mg bid ) for another 5 days
1840620|NCT00885430|Drug|Pico-Salax|Two sachets of Pico-Salax given 5 hours apart
1840621|NCT00885443|Drug|Propofol|Patients will be anesthetised according to standard induction protocols with propofol/remifentanil intravenously. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
1840622|NCT00885443|Drug|sevoflurane|Patients will be anesthetised according to standard induction protocols with sevoflurane by inhalation. A laryngeal mask airway (LMA) will be placed by the anesthesiologist, as is usual practice for these cases. A standard dose of fentanyl (1 mcg.kg-1 IV, MAX dose 25 mcg) for postoperative pain and ondansetron (0.1 mg.kg-1 IV, MAX dose 2.5 mg) for PONV prophylaxis will be given to both groups. Dexamethasone will NOT be permitted as an additional antiemetic.
1840623|NCT00885456|Behavioral|PREVENT program|12-week program of aerobic/strengthening exercises and education designed to induce physiological and behavioral changes deemed necessary to reduce vascular risk
1840624|NCT00885456|Behavioral|Usual Care|Three or more out-patient visits to the neurovascular clinic for assessment, counseling and referral to appropriate health care professionals.
1840625|NCT00885482|Drug|Lamiduvine (Epivir)|Epivir 300 mg
1840626|NCT00885482|Drug|Atazanavir (Reyataz)|Reyataz 300 mg
1840627|NCT00885482|Drug|Ritonavir (Norvir)|Norvir 100 mg
1992699|NCT03313791|Dietary Supplement|UHT milk|see arm description
1992700|NCT03313791|Dietary Supplement|Recombined milk|see arm description
1840630|NCT00885508|Drug|Lenalidomide|"Induction treatment Lenalidomide 10 mg once daily PO during 3 weeks . in combination with classical 7+3 chemotherapy.
Consolidation treatment 6 monthly courses of : Lenalidomide 10 mg/ d during the first 2 weeks in combination with classical 5+1 consolidation chemotherapy
Maintenance treatment Lenalidomide 10 mg/d 2 weeks every month until relapse
In absence of toxicity, 20 additionnal patients will be included with lenalidomide dose of 25mg/J, then 20 other additionnals patients with Lenalidomide 50mg/J"
1840631|NCT00885521|Other|Exercise|8 week, twice weekly exercise program with endurance and upper and lower limb strength training
1840632|NCT00885534|Drug|Cisplatin, Vinblastine, Temozolomide|"Patients will receive CVT chemotherapy which consists of the following:
Cisplatin 25 mg/m2 given intravenously on days 2-5 Vinblastine 1.5 mg/m2 given as an intravenous push on days 2-5 Temozolomide 150 mg/m2 given orally on days 1-5. In patients who cannot receive temozolomide, dacarbazine can be used instead. Dacarbazine will be given at 800 mg/m2 IV on day 1."
1840633|NCT00885547|Drug|tripterygium wilfordii (TW)|90 mg/d for 6 months
1840634|NCT00885573|Device|Measurement of pharyngeal sensitivity (SENSITEST)|Measurement of pharyngeal sensitivity using the SENSITEST the morning following the nocturnal polysomnographic recording to diagnose sleep disordered breathing.
1840635|NCT00885586|Device|Sham-laser acupuncture|Laser irradiation is faked, approaching a non-functioning laser pen.
1840636|NCT00885586|Drug|gabapentine|Patients in this arm are treated individually with gabapentine 900 mg/d - 3600 mg/d, according to the recommended scheme given by the manufacturer
1840637|NCT00885586|Procedure|Acupuncture|The needle acupuncture technique used in this trial is performed according the traditional way (TCM) using expendable needles.
1840638|NCT00885599|Drug|Herbal API|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
1840639|NCT00885599|Drug|Cepacol|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
1840640|NCT00885599|Drug|Listerine Antiseptic Mouth Rinse|mouthwash;rinse full strength for 30 seconds with 20 ml (2/3 fl. Ounce or 4 teaspoonfuls) morning and night.
1992701|NCT03313791|Dietary Supplement|Recombined 50%whey milk|see arm description
1992702|NCT03313791|Dietary Supplement|Ca-caseinate|see arm description
1992703|NCT03313791|Dietary Supplement|Milk protein isolate|see arm description
1840642|NCT00885625|Biological|7-valent pneumococcal conjugated vaccine|7-valent pneumococcal conjugated vaccine is given twice with 4 weeks apart
1840643|NCT00885638|Drug|Sitagliptin|100 mg sitagliptin before ingestion of macronutrient
1840644|NCT00885638|Drug|placebo|A placebo tablet is given before ingestion of macronutrients
1840647|NCT00885664|Drug|Truvada (tenofovir/emitricitabine)|Tenofovir/emitricitabine fixed dose combination once daily
1840648|NCT00885664|Drug|Kaletra (lopinavir/ritonavir)|Lopinavir/ritonavir 400/100 mg twice daily
1840649|NCT00885677|Device|Medtronic CareLink® Network|"Continuous monitoring via a disease remote management system.
Patients of the Study group will receive a remote monitor and their device will be programmed to have wireless telemetry, Care Alerts, and the ability to transmit over the Medtronic CareLink® network. Clinical and device conditions will be then monitored continuously and alarms for the physician will be generated if a set of pre-defined potentially harming conditions should occur."
1840650|NCT00885690|Drug|Sertindole|Sertindole 16-24 mg once daily
1840651|NCT00885690|Drug|Olanzapine|Olanzapine 10-20 mg
1840652|NCT00885703|Drug|Fluconazole|Dosages will be 1200 mg, 1600 mg, or 2000 mg for Stage 1, Arm A. MTD determined in Stage 1 (1600 mg or 2000 mg) will be given to participants in Stage 2, Arm C. Participants in both stages of the study will receive lower doses of fluconazole (a minimum daily dose of 200 mg) in Steps 2, 3, and 4 than in Step 1.
1840653|NCT00885703|Drug|Amphotericin B|Ampho B given intravenously for approximately 2 weeks at a dosage of 0.7 to 1.0 mg/kg, dependent on a participant's weight
1840654|NCT00885716|Behavioral|patient training in shared decision making|
1840655|NCT00885716|Behavioral|cognitive training|
1840656|NCT00885729|Procedure|stem cells|Stem cells or chondrocytes under a commercial available membrane
1840657|NCT00885729|Procedure|Chondrocytes|Implantation of chondrocytes
1840658|NCT00885729|Other|Rehabilitation program|Strength exercises, neuromuscular exercises
1840659|NCT00885742|Biological|FXIII Concentrate (Human)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.
Subjects enrolled in this study who did not complete the pharmacokinetic study (Factor XIII Study BI71023_2002 [NCT00883090]) will initially receive FXIII Concentrate (Human) at a dose of 40 U/kg by intravenous (IV) infusion."
1840660|NCT00885755|Drug|Standard taxane therapy|As prescribed
1840661|NCT00885755|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3-week cycle (only in patients who have progressed)
1840662|NCT00885755|Drug|trastuzumab [Herceptin]|8mg/kg iv loading dose on day 1 of first 3-week cycle, and 6mg/kg iv on day 1 of each subsequent cycle
1840663|NCT00885768|Procedure|angiography|all patients undergoing coronary angiography with VISIPAQUE and if they had coronary stenosis then renal artery angiography will be done. the dose of contrast will be chosen according to renal function and clinical conditions which will be varied from 75 to 300 ml.
1840664|NCT00885781|Drug|lipid emulsion for TPN|1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
1840665|NCT00885794|Drug|Ranibizumab|3 intravitreal injection every 5 weeks
1840666|NCT00885820|Drug|Tacrolimus|Oral
1840667|NCT00885820|Drug|MMF|Oral
1840668|NCT00885820|Drug|Corticosteroids (Prednisone)|Oral
1840669|NCT00885833|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, -6 for cord blood and on days -4, -3, -2 for bone marrow or mobilized peripheral blood)
1840670|NCT00885846|Other|Qigong therapy|For 12 weeks, subjects in Qigong therapy group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
1840671|NCT00885846|Other|Progressive resistance training|For 12 weeks, subjects in the PRT group are to follow a disciplined regular practice, 3 times a week for about 30 minutes, including once a week with a certified instructor to lead and check the correctness of their practice.
1840672|NCT00885859|Device|TENStemeco Schwa Medico [Transcutaneous Electrical Nerve Stimulation (TENS)]|Patients are instructed how to use the TENS device during the two weeks at home.Self-adhesive reusable electrodes are used to deliver the electrical stimulation. The frequency is 100 Hz, pulse duration 250 μ sec. Stimulus intensity is strong but not unpleasant. The TENS electrodes are attached proximally and distally around the maximum pain point/area. Patients use TENS 4 times daily (30 minutes each time).
1840673|NCT00885872|Drug|Rosuvastatin (Crestor)|at visit 2 each eligible subject will be allocated to rosuvastatin. study medication wil be taken orally with water once daily, as directed by the study physician. subjects who meet the criteria at visit 3, dosage of rosuvastatin will be titrated.
1840674|NCT00885885|Drug|Panitumumab+FOLFOX-4|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.
A cycle of panitumumab is defined as 14 days.
FOLFOX 4 chemotherapy will be administered on day 1 of each 14-day treatment cycle:
Oxaliplatin 85mg/m2 as a 120 minute infusion on day 1 of each cycle
Folinic acid 200mg/m2 as a 120 minute infusion on days 1 and 2
A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on days 1 and 2
5-FU at 600mg/m2 as a continuous infusion of 22 hour infusion on days 1 and 2"
1840675|NCT00885885|Drug|Panitumumab+FOLFIRI|"Panitumumab will be administered as a 60-minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. If the first infusion of panitumumab is well tolerated (without any serious infusion related reactions) all subsequent infusions may be administered over 30 minutes ± 10 minutes.
A cycle of panitumumab is defined as 14 days.
FOLFIRI chemotherapy will be administered on day 1 of each 14-day treatment cycle:
Irinotecan 180 mg/m2 will be administered over 90 minutes ± 15 minutes on day 1 of each cycle
Folinic acid 400 mg/m2 will be administered over 2 hours ± 15 minutes during the irinotecan infusion but without mixing
A bolus (2 to 4 minutes) of 5-FU at 400mg/m2 on day 1
5-FU at 2400 mg/m2 continuous intravenous infusion over 46-hour ± 2-hour on day 1 of each cycle."
1841043|NCT00880139|Procedure|Ophthalmic examination and fundus photography|7 + 1 standard fields
1840676|NCT00885898|Procedure|Non-invasive-ventilation|increased oxygen fraction, continuous positive pressure ventilation, if necessary pressure support ventilation or even intermittent positive pressure ventilation
1840677|NCT00885898|Procedure|conventional treatment|oxygen, diuretics, bronchodilators, positive inotropic drugs
1840678|NCT00885924|Drug|Desmopressin|Desmopressin 0.3 microgram/kg as an intravenous infusion given during 20 min.
1840679|NCT00885924|Drug|Placebo|NaCl 0.9%
1840680|NCT00885937|Drug|Dexpanthenol (Sinecort, BAY81-2996)|1 squeeze of Sinecort cream sufficient to cover the area of the application chamber, (=50 mikro liter)
1840681|NCT00885937|Drug|Positive control, Na-laurylsulfat-solution|50 mikro liter of 0.5 % Sodium-laurylsulfate-solution
1840682|NCT00885937|Device|Untreated skin under application chamber|Application of treatment chamber as in arm 1 and arm 2 on untreated skin
1840683|NCT00885963|Drug|sapacitabine|twice daily by mouth for 7 days or once daily by mouth for 5 days/week x 2 weeks every 21 days
1840684|NCT00885989|Drug|SLV338|5 - 1000 mg IV
1840685|NCT00885989|Drug|Placebo|Placebo
1840686|NCT00886002|Drug|Fentanyl; Buprenorphine; Naloxone|
1840687|NCT00886015|Device|TT Clamp|trichiasis surgery performed with TT clamp
1840688|NCT00886015|Procedure|Standard BLTR Technique|bilamellar tarsal rotation procedure in trichiasis surgery
1840689|NCT00886028|Drug|Liposomal doxorubicin|"Liposomal doxorubicin 60 mg/m2 every 4 weeks for 6 cycles.
Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
1840690|NCT00886028|Drug|Cisplatin|"Cisplatin 80 mg/m2 every 4 weeks for 6 cycles.
Thirty patients with epithelial, sarcomatoid or biphasic histological confirmed diagnosis of MPM from the Instituto Nacional de Cancerología and the Instituto Nacional de Enfermedades Respiratorias were included to receive LD 60mg/m2 plus cisplatin 80 mg/m2 every 4 weeks for 6 cycles."
1840691|NCT00886041|Procedure|laparoscopy|subjected to laparoscopy
1840692|NCT00886041|Other|ovarian stimulation|ovarian stimulation and timed intercourse for 3 cycles followed by ovarian stimulation and intrauterine insemination for another 3 cycles
1840693|NCT00886067|Drug|AZD1446|Solution, oral, single dose
1840694|NCT00886067|Radiation|2-[18F]-F-A85380|iv, single dose
1840695|NCT00886080|Procedure|Pulmonary vein isolation using microwave energy|The surgical ablation procedure is the first step during surgery and is performed before institution of cardiopulmonary bypass allowing off-pump beating heart ablation. The off-pump beating heart ablation procedure is performed according to a specific box lesion surrounding the pulmonary veins, using microwave energy. Afterwards cardiac surgery is performed as usual in both treatment arms.
1840696|NCT00886093|Drug|PF-04447943|35 mg tablet of PF-04447943 taken in the fed state in Period 1 followed a week later by administration of the same tablet and dose taken in the fasted state in Period 2
1840697|NCT00886093|Drug|PF-04447943|35 mg tablet of PF-04447943 taken in the fasted state in Period 1 followed a week later by administration of the same tablet and dose in the fed state in Period 2.
1840698|NCT00886106|Drug|Remifentanil|Remifentanil (Ultiva®; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to circa 0.7 µg kg-1 min-1
1840699|NCT00886106|Drug|Midazolam|Midazolam (Dormicum®; Roche; Vienna, Austria) will be applied intravenously as active placebo at a dose of 15 µg kg-1 min-1 over 5 minutes to mimic typical central nervous side effects of remifentanil
1840700|NCT00886119|Device|Lotrafilcon B multifocal contact lens|Silicone hydrogel, soft, multifocal contact lens for daily wear use
1840701|NCT00886119|Device|Omafilcon A multifocal contact lens|Hydrogel, soft, multifocal contact lens for daily wear use
1840702|NCT00886132|Drug|Sunitinib|37.5 mg taken orally, daily every 28-day cycles
1840703|NCT00886145|Device|Vibration: Right Leg and No Vibration: Left Leg.|"Vibration- right leg: The subjects will undergo a mechanical vibration intervention (Juvent Vibrating plate) in the seated position, with a load of 50lbs will be added to the right leg by using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month.
No Vibration-left leg: At each vibration training session, the left leg will serve as a control with a load of 50lbs added to the left leg using an extra wide strap equipped with bungee cords, 5 sessions a week, and each session lasting 20 minutes for a total of 6 month."
1840704|NCT00886171|Behavioral|Social Skills Training|Social skills group will consist of one session (60 minutes) per week for 8 weeks
1840705|NCT00886171|Behavioral|Physical Activity Training|Physical activity groups consist of one session (60 minutes) per week for 8 weeks
1840706|NCT00886184|Procedure|Hypothermia.|Induction of pre hospital therapeutic hypothermia.
1840707|NCT00886184|Procedure|No early hypothermia|Induction of therapeutic hypothermia only once arrived at hospital.
1840708|NCT00886210|Procedure|intra abdominal drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group A nelton catheter (no 20) inserted at the end of operation.
1840709|NCT00886210|Procedure|LC without drain|Under general anesthesia, and same antibiotics (3rd generation cephalosporin). Surgery was performed using conventional four ports umbilical port, port below xiphoid and two ports below right costal margin. Pneumoperitonum at pressure 12 mmHg. In group no drain at the end of operation.
1840710|NCT00886223|Procedure|laparoscopic robot-assisted sacropexy|Repair of vaginal vault prolapse with laparoscopic sacropexy assisted by robotic surgical system (da Vinci®-System)
1840711|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Gabapentin 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
1840789|NCT00886769|Drug|Placebo|Placebo was provided in individual 6 mL glass vials each containing 150 mg placebo powder matching canakinumab as a lyophilized cake. Each reconstitued vial provided 150mg of placebo per 1 mL.
1840712|NCT00886236|Drug|Placebo|Placebo 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
1840713|NCT00886236|Drug|Gabapentin|Gabapentin 1200 mg (24 cc) by mouth 1 hour prior to surgery AND Placebo 300 mg (6cc) by mouth x 6 doses after surgery (0800PM the evening of surgery, 0800AM postoperative day 1, 0200PM postoperative day 1, 0800PM postoperative day 1, 0800AM postoperative day 2, 1200PM postoperative day 2)
1840714|NCT00886249|Device|Acrysof IQ|Intraocular lens
1840715|NCT00886249|Device|Acrysof Natural IOL|Intraocular Lens
1840716|NCT00886262|Drug|Vasopressin|Patients randomly assigned to the experimental arm of the study will receive vasopressin 0.5U/hr IV (20 U vasopressin in 250mL of 0.9% NaCL to infuse at a rate of 6.25mL/hr) via internal jugular catheter. Vasopressin infusion is started at the time of incision and is stopped at the time abdominal closure is completed
1840717|NCT00886262|Drug|Normal saline placebo|Patients randomly assigned to the placebo arm of the study will receive placebo (0.9% NaCl to infuse at a rate of 6.25 mL/hr) via internal jugular catheter
1840718|NCT00886275|Drug|Dexmedetomidine|The loading dose of dexmedetomidine is 0.5 mcg/kg over 10 minutes as needed. Then, continuous infusion of 0.2-0.7 mcg/kg/h dexmedetomidine is used to maintain RASS between 0 to -3.
1840719|NCT00886275|Drug|Midazolam|The loading dose of midazolam is 0.05 mg/kg over 10 minutes as needed. Then, continuous infusion of 20-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
1840720|NCT00886275|Drug|Dexmedetomidine, Midazolam|The loading doses are dexmedetomidine 0.25 mcg/kg and 0.025 mg/kg of midazolam over 10 minutes. Then, continuous infusion of 0.1-0.7 mcg/kg/h dexmedetomidine and 10-300 mcg/kg/h midazolam is used to maintain RASS between 0 to -3.
1840721|NCT00886301|Procedure|liver biopsy|liver biopsy
1840722|NCT00886314|Drug|midazolam|Children in this group will be premedicated with oral midazolam syrup (0.3 mg.kg) at least 15 minutes before the surgical procedure and one of the parents will be present throughout the anesthesia induction process.
1840723|NCT00886314|Other|clown doctor|Children will interact with clowns before entering the operating room and will stay with them and one of the parents throughout the anesthesia induction process.
1840724|NCT00886327|Procedure|Colonic capsule endoscopy|
1840725|NCT00886340|Behavioral|Enhanced standard care|One appointment with nurse practitioner (20 minutes) One appointment with nutritionist (45 minutes)
1840726|NCT00886340|Behavioral|Lifestyle counseling|Enhanced standard care Six appointments with nurse practitioner (20 minutes)
1840727|NCT00886353|Biological|APN01|APN01, a physiological formulation of recombinant human Angiotensin Converting Enzyme 2 administrated i.v.
1840728|NCT00886353|Other|Placebo|Physiological saline administrated i.v.
1840729|NCT00886366|Drug|AZD6714|Oral single doses a-h suspension
1840730|NCT00886366|Drug|Placebo|Oral single doses suspension
1840731|NCT00886366|Drug|AZD6714|Oral single doses a-d suspension
1840732|NCT00886366|Drug|AZD6714|Oral single doses d and g suspension
1840733|NCT00886379|Dietary Supplement|Mongolian milk without vitamin D|710ml per day for 49 days
1840734|NCT00886379|Dietary Supplement|Mongolian milk with vitamin D|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
1840735|NCT00886379|Dietary Supplement|UHT milk|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
1840736|NCT00886379|Dietary Supplement|Milk Substitute|710ml per day for 49 days. A total of 13,700 IU of vitamin D over the intervention period.
1840737|NCT00886379|Dietary Supplement|Seasonal D supplement|Deliver dosage of 13,700 IU vitamin D over 7 days
1840738|NCT00886379|Dietary Supplement|Daily D supplement|Deliver dosage of 13,700 IU vitamin D in vitamin capsules over 49 days.
1840739|NCT00886405|Drug|Transdermal nitroglycerin|Transdermal nitroglycerin (25mg/day) during 5 days (2 days before and 3 days after chemotherapy) at the beginning of each chemotherapy cycle for a total of 4 cycles
1840740|NCT00886418|Drug|muscle relaxant|muscle relaxant administration throughout anesthesia
1840741|NCT00886418|Drug|normal saline|no muscle relaxant throughout anesthesia (normal saline infused as a placebo)
1840742|NCT00886431|Other|embryo vitrification|Ultra rapid cooling of embryos by immersion in liquid nitrogen. The formation of potentially damaging ice crystals is prevented by briefly incubating the embryos in high concentrations of a mix of cryoprotectants.
1840743|NCT00886444|Drug|Ferucarbotran (Resovist)|single time intravenous bolus injection of a contrast agent
1840744|NCT00886457|Drug|Decitabine and Pegylated Interferon-Alfa 2B|Patients will receive decitabine 3.7 mg/m2/day i.v. over 1 hour daily in 10 doses over 2 weeks elapsed time (Monday-Friday) every 28 days plus fixed dose of PEG-Intron (0, 0.5, 1.5, 3 or 6 mcg/kg PEG-Intron) weekly by subcutaneous injection in 28-day cycles .
1840745|NCT00886470|Biological|ACCS (Amnion-derived Cytokine Suspension)|ACCS is a clear liquid containing more than 200 proteins, cytokines, and growth factors in solution. Patients will be treated for 21 days unless both wounds have healed prior to 21 days, at which time a punch biopsy of the epithelialized area of each wound will be performed. A study evaluation visit for assessment of the biopsy site will occur on day 28 or within 7 days of the punch biopsies, whichever occurs first. Six months after the punch biopsy, the patient will return to the burn center for a final examination and photographs of the study wounds.
1840746|NCT00886483|Device|Active Neurofeedback|A comparison of active neurofeedback to sham neurofeedback and of two treatment schedules: twice weekly vs. three times a week, with the same amount of total treatment over 40 sessions, varying only in frequency.
1840747|NCT00886483|Device|Sham neurofeedback|Active neurofeedback vs. sham neurofeedback for 40 treatments, either twice or three times per week.
1840748|NCT00886496|Biological|recombinant human mannose-binding lectin|
1840749|NCT00886509|Biological|pegfilgrastim|s.c. administration of pegylated G-CSF over 6 months
1840750|NCT00886509|Other|Placebo|Placebo control Arm 1: Collateral promotion; PCI after 6 months
1840790|NCT00886782|Drug|Cdc7-inhibitor|Capsules, Oral, QD x 14 days until MTD is reached, 14d per 28 day cycle/QD 12 months
1840791|NCT00886795|Drug|abatacept (Orencia ®)|4 doses of abatacept administered intravenously at baseline, 2 weeks, 4 week, and 8 weeks.
1840792|NCT00886808|Drug|iCo-007 Intravitreal Injection|single dose iCo-007 Intravitreal Injection
1840751|NCT00886522|Procedure|Intrabone cord blood infusion|"Myeloablative conditioning regimen (MAC):
i.v. Busulfan 12.8 mg/kg, Cyclophosphamide 120 mg/kg, ATG-Fresenius 30 mg/kg
Reduced intensity conditioning regimen (RIC):
Tiothepa 10 mg/kg, Fludarabine 100 mg/kg, Cyclophosphamide 100 mg/kg, ATG-Fresenius 30 mg/kg
GVHD prophylaxis:
Cyclosporine 1 mg/kg since day -7 to +120, Mycophenolate 15 mg kg x 2 since day +1 to +27"
1840752|NCT00886548|Procedure|Ultrasound performed|Nurse-driven ultrasound performed
1840753|NCT00886561|Behavioral|HIV risk reduction intervention|Education intervention designed to reduce HIV risk behaviors and enhance HIV prevention behaviors among female sex workers in Armenia
1840754|NCT00886574|Drug|Cilostazol|Cilostazol 200 mg (50 mg 2T twice per day)
1840755|NCT00886574|Drug|Aspirin|100 mg once a day
1840756|NCT00886587|Device|F# 11054-010|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
1840757|NCT00886587|Device|F# 10495-053|Apply 3 times daily (or as needed) on all body areas, including the affected areas of the body and face throughout duration of study. Massage gently into skin.
1840758|NCT00886600|Drug|losartan potassium|losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
1840759|NCT00886600|Drug|Comparator: placebo|placebo capsules to losartan potassium (50 or 100 mg) administered orally once daily (q.d.)or twice daily (b.i.d) for four weeks
1840760|NCT00886600|Drug|hydrochlorothiazide (HCTZ)|open-label hydrochlorothiazide (HCTZ) 12.5 mg (for patients with Sitting Diastolic Blood Pressure (SiDBP) ≥85 mm Hg after 4 weeks of losartan monotherapy (Combination Therapy Period)) orally once daily (q.d.) for 2 weeks
1840761|NCT00886613|Biological|V212|Two doses of 0.65 mL V212 subcutaneous injection administered at Day 1 and Day 31
1840762|NCT00886613|Biological|Comparator: Zostavax™|Two doses of 0.65 mL Zostavax™ subcutaneous injection administered at Day 1 and Day 31
1840763|NCT00886613|Biological|Comparator: Placebo|Two doses of 0.65 mL subcutaneous injection of placebo administered at Day 1 and Day 31
1840764|NCT00886613|Other|VZV Skin Test|Three intradermal injections of the 0.1 ml varicella antigen (VZV Skin Test reagent) were administered, once at baseline before the first vaccination, a second time before the second vaccination, and a third time approximately 14 days after the second vaccination.
1840765|NCT00886613|Other|Saline|One intradermal injection of the 0.1 ml saline was administered at the time of the baseline VZV skin test prior to the first vaccination. Saline and VZV skin test reagents were administered on opposite arms.
1840766|NCT00886626|Drug|Exenatide|Exenatide, subcutaneous injection, 10 mcg, twice per day
1840767|NCT00886639|Other|6MWT with oxygen|2 liter per minute as continuous-flow
1840768|NCT00886639|Other|6MWT with medical air|2 liters as continuous-flow
1840769|NCT00886652|Other|Aerobic exercise program|Three weekly sessions, with an interval of one day between each, lasting 60 minutes each, and divided into three separate stages: - A 10-minute warm-up (stretching and low intensity aerobic exercises such as slow, gradual walking); - 40 minutes of aerobic exercise on an electric treadmill, with the work intensity maintained at a 60% to 80% of the maximum heart rate; - 10 minutes of winding down and relaxation (stretching exercises, low energy expenditure aerobics and relaxation techniques).
1840770|NCT00886665|Drug|placebo|placebo, 4 g, powder, oral, 3 times a day
1840771|NCT00886665|Drug|JWHGWT|JWHGWT, 4 g, powder, oral, 3 times a day
1840772|NCT00886678|Drug|pemetrexed|500 mg/m2, IV, q 21 days x 2 cycles
1840773|NCT00886678|Drug|carboplatin|AUC=5,IV,q 21 days x 2 cycles
1840774|NCT00886678|Radiation|thoracic radiation|66 Gy over 33 fractions
1840775|NCT00886691|Biological|bevacizumab|Given IV
1840776|NCT00886691|Drug|everolimus|Given orally
1840777|NCT00886691|Other|placebo|Given orally
1840778|NCT00886704|Dietary Supplement|500 mg eicosapentaenoic (EPA) plus docosahexaenoic acids (DHA)|"Composition of active convenience drink (smartfish): 200 ml drink, enriched with 940 mg omega-3 fatty acids, of which 200 mg are EPA, 300 mg DHA and 100 mg DPA, slightly carbonized..
Energy content 486 kJ (116 kcal), protein 0.6 g, Carbohydrates 22 g, total fat 4 g, of which 0.6 g saturated fatty acids, 1.8 g monounsaturates, 1.4 g polyunsaturates. Vitamin D 0.85 ug.
Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil."
1840779|NCT00886704|Dietary Supplement|Control convenience drink|Control convenience drink: as above, containing about 1 g Omega-6 fatty acids from e.g. corn oil.
1840780|NCT00886717|Drug|carboplatin|
1840781|NCT00886717|Drug|paclitaxel-loaded polymeric micelle|
1840782|NCT00886730|Behavioral|Simple Card|"Participants will receive a simple 3x5 card with the name of the website and the following description. www.psychobabble.com (or new name). A website to help individuals with depression recover."
1840783|NCT00886730|Behavioral|Patient Centered Brochure|"Participants will receive an 8x11 handout that provides a more complete description of the depression website. The handout will be based on a patient perspective with samples of Internet postings from users. This card will emphasize peer-to-peer support and not mention health care organizations or health care provider endorsements. The information will address potential barriers to use: user will not be identified, posting will not take that much time, information from peers can be checked for accuracy with other peers and providers, and helping patient learn how to tell their usual health care providers about their activities on the Internet site. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks. They will still be part of the study even if they will not provide their email."
1840784|NCT00886730|Behavioral|Physician's endorsement|Participants will include the same card in experimental group 2 with the addition of a personal endorsement by the patient's health care provider in the form of a standardized letter signed by the physician. Participants will be asked to provide their email so a reminder about the Internet depression site can be emailed to them at 1 week and 2 weeks.
1840785|NCT00886743|Drug|oprelvekin|injection, 50 mg/kg, once daily
1840786|NCT00886756|Drug|AZD8529|Oral
1840787|NCT00886756|Drug|Placebo|Oral
1840788|NCT00886769|Drug|Canakinumab|Canakinumab was supplied in individual 6 mL glass vials each containing 150 mg canakinumab powder as a lyophilized cake. Each reconstituted vial provided 150mg of canakinumab per 1 mL.
1840793|NCT00886821|Biological|CVX-096|Subcutaneous administration of CVX-096 with doses ranging from 0.1 mg up to a maximum of 36 mg
1840794|NCT00886834|Drug|Misoprostol|400 micrograms inserted vaginally or buccally, per the participants desire prior to the IUD insertion.
1840795|NCT00886834|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
1840796|NCT00886847|Procedure|Lymph Node Needle Tissue Collections|Total of two lymph nodes sampled per patient. Four biopsies will be taken from each lymph node. Two with suction (FNA) and two without suction (FNC).
1840797|NCT00886860|Drug|misoprostol|misoprostol 50 micrograms oral every 4 hours until cervical dilatation 3 cm
1840798|NCT00886860|Drug|misoprostol|misoprostol 20 micrograms oral every hours until cervical dilatation 3 cm
1840799|NCT00886873|Drug|Mifepristone|
1840800|NCT00886886|Drug|MDMA|125 mg, single dose
1840801|NCT00886886|Drug|Reboxetine, 8 mg|two doses 12h and 2h before MDMA
1840802|NCT00886886|Drug|Placebo|capsules identical to MDMA or Reboxetine
1840803|NCT00886899|Device|Recanalization of a coronary chronic total occlusion|Crossing a CTO to allow definitive treatment via balloon angioplasty and/or stent placement
1840804|NCT00886912|Other|hypoxia|training in simulated altitude in a hypoxic chamber (normobaric hypoxia)
1840805|NCT00886912|Other|normoxia|training under normoxic conditions
1840806|NCT00886925|Drug|Albumin|Albumin 20%. Day 0: 400-600 ml. Day 2: 200-400 ml.
1840807|NCT00886925|Drug|Sodium chloride 0.9%|Day 0: 400-600 ml. Day 2: 200-400 ml.
1840808|NCT00886938|Device|Repetitive Transcranial Magnetic Stimulation (rTMS), pilot study|Repetitive transcranial magnetic stimulation, pilot study
1840809|NCT00886951|Drug|I123MNI388/I123MNI390|Subjects will be dosed by intravenous injection up to 5 mCi and not to exceed 5.5 (not >10% of 5 mCi limit) 123-I MNI-388 or 123-I MNI-390.
1840810|NCT00886964|Biological|Intradermal HBV 1 course|"Dosage: 2 microgram (mcg), 0.1 ml per dose
Location: left deltoid area x 1 injection
Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
1840811|NCT00886964|Biological|Intramuscular HBV I course|"Dosage: 2 microgram (mcg), 0.1 ml per dose
Location: left deltoid area x 1 injection
Common reactions: local pain, low grade fever, small hyperpigmented induration (granulomatous reaction) which may last up to 6-12 months"
1840812|NCT00886977|Drug|YAM80|Oral administration, 2 to 6 mg, once a day.
1840813|NCT00886990|Drug|ritonavir-boosted PI-based second line treatments|single PI boosted by low dose ritonavir
1840814|NCT00886990|Drug|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir|two PIs boosted by low dose ritonavir or one PI plus full dose ritonavir
1840815|NCT00887003|Drug|Bupivacaine|Low Volume, Low Dose (5cc, 5mg plain Bupivacaine)
1840816|NCT00887003|Drug|Bupivacaine|Low Volume, High Dose (5cc, 10mg plain Bupivacaine)
1840817|NCT00887003|Drug|Bupivacaine|High Volume, Low Dose (10cc, 5mg plain Bupivacaine)
1840818|NCT00887003|Drug|Bupivacaine|High Volume, High Dose (10cc, 10mg plain Bupivacaine)
1840819|NCT00887003|Drug|Depo-Medrol|80mg Depo-Medrol
1840820|NCT00887029|Drug|DuoTrav (travoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
1840821|NCT00887029|Drug|Xalacom (latanoprost-timolol ophthalmic drops)|topical ophthalmic drops instilled 1 drop daily
1840822|NCT00887042|Drug|Fludarabine, Busulfan, Thymoglobulin|fludarabine (40 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4 & -3) busulfan (0.8 mg/kg every 6 hours i.v. on days -6, -5, -4, & -3) thymoglobulin (2.5 mg/kg once daily i.v. on days -8, -7, & -6)
1840823|NCT00887055|Device|CRT device|
1840824|NCT00887068|Drug|Azacitidine|32 mg/m^2 given through a needle under the skin for five consecutive days of each 28 day cycle and the maximum treatment will be 12 cycles.
1840825|NCT00887081|Drug|PEG-IFN alpha2a or PEG-IFN alpha2b and Ribavirin|PEG-IFN alpha2a 180 mcg weekly or PEG-IFN alpha2b 1.5 mcg/kg of body weight weekly plus ribavirin 800-1200 mg daily according to body weight.
1840826|NCT00887094|Behavioral|Acute aerobic exercise|Aerobic exercise (on a cycle ergometer, for 50 min)
1840827|NCT00887094|Behavioral|Acute aerobic-resistance exercise|Aerobic-resistance exercise (on a cycle ergometer plus strength training, for 50 min in total)
1840828|NCT00887107|Drug|Sorafenib (nexavar)|6 months therapy with Sorafenib 800 mg/day
1840829|NCT00887120|Drug|Lopinavir/ritonavir standard dose According to WHO simplified dosing table|"BW 6-7.9 kg: 1.5 mL oral q 12 hr
BW 8.0-16.9 kg: 2.0 ml oral q 12 hr
BW 17.0-19.9 kg: 2.5 ml oral q 12 hr
BW 20.0 - 24.9 kg: 3.0 ml oral q 12 hr
BW 25.0 - 29.9 kg: 3.5 ml oral q 12 hr
BW 30.0-34.9 kg: 4.0 ml oral q 12 hr
BW > 35 kg: 5.0 ml oral q 12 hr
Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
1840830|NCT00887120|Drug|Lopinavir/ritonavir low dose ( 70% of WHO recommended dosing table)|"BW 6-7.9 kg: 1.0 mL oral q 12 hr
BW 8.0-16.9 kg: 1.5 ml oral q 12 hr
BW 17.0-19.9 kg: 1.8 ml oral q 12 hr
BW 20.0 - 24.9 kg: 2.0 ml oral q 12 hr
BW 25.0 - 29.9 kg: 2.5 ml oral q 12 hr
BW 30.0-34.9 kg: 3.0 ml oral q 12 hr
BW > 35 kg: 3.5 ml oral q 12 h
Dose of Zidovudine (AZT) is 180-240 mg/m2 per dose every 12 hours Dose of Lamivudine (3TC) is 4 mg/kg every 12 hours Dose of Lopinavir/ritonavir (LPV/r)"
1840831|NCT00887146|Drug|concomitant temozolomide (TMZ)|75 mg/m^2, orally daily
1840832|NCT00887146|Radiation|radiotherapy|
1840833|NCT00887146|Drug|procarbazine|Days 8-21: 60 mg/m^2 orally
1840834|NCT00887146|Drug|adjuvant temozolomide (TMZ)|150 or 200 mg/m^2 orally
1840835|NCT00887146|Drug|CCNU|Day 1: 110 mg/m^2 orally
1840836|NCT00887146|Drug|vincristine|Days 8 and 29: 1.4 mg/m^2 IV
1840837|NCT00887159|Drug|Cisplatin|Given IV
1840838|NCT00887159|Biological|Cixutumumab|Given IV
1840839|NCT00887159|Drug|Etoposide|Given IV
1840840|NCT00887159|Other|Laboratory Biomarker Analysis|Correlative studies
1840841|NCT00887159|Drug|Vismodegib|Given PO
1840871|NCT00878384|Procedure|Catheter Ablation for Persistent Atrial Fibrillation|Radiofrequency catheter ablation, which may include pulmonary vein isolation, atrial substrate modification, and/or linear ablation.
1840872|NCT00878397|Device|School-based delivery of long lasting insecticide nets|Free distribution of long lasting insecticide nets to school children and their younger siblings
1840993|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
1841094|NCT00880490|Drug|Inhaled placebo|single dose, inhaled
1840842|NCT00887172|Drug|Jing Fang Bai Du san|The Jing Fang Bai Du san can relieve external symptoms and effectively clear up the pathogenic cold. It contains 13 herbs including, Radix Angelicae Pubescentis, Radix Peucedani, Radix Ginseng, Smilacis Glabrae Rhizoma, Rhizoma Chuanxiong, Fructus Aurantii, Radix Platycodi, GlycyrrhizaeRadix, Herba Schizonepetae, Fructus Arctii, MenthaeFolium, Radix Saposhnikoviae, Rhizoma et Radix Notopterygii.The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
1840843|NCT00887172|Drug|Placebo|The sachets of the CHM formulae and placebo were identical in appearance except for the randomization numbers. The placebo contains Maltose-dextrine granules that are identical in weight, appearance, flavour and texture as the CHM granules. Both the Chinese medicine practitioner who assessed the subjects and the subjects were blinded to the nature of the treatment. The pharmaceutical supplier kept the medication and placebo codes, which were broken at the end of the study after completion of all the assessment and data analyses.
1840844|NCT00887172|Drug|Ying Qiao san|The Ying Qiao san can relieve external symptoms and effectively clear up the pathogenic heat. It contains 10 herbs: Fructus Forsythiae, LoniceraeFlos, Radix Platycodi, MenthaeFolium, GlycyrrhizaeRadix, Herba Schizonepetae, Sojae Semen praeparatum, Fructus Arctii, PhragmitisRhizoma and LophatheriHerba. The CHM preparations were manufactured and supplied by Pura Pharm International (H.K.) Ltd., in the form of concentrated granules which follows the GMP standard. None of the herbs in these two formulas are included in the Toxic Chinese Herbal Medicine List of the Chinese Medicine Ordinance Schedule 1 or being a controlled substance, animal product, or endangered species.
1840845|NCT00887185|Other|Simulator training for temporal bone surgery|Subjects in experimental arm are asked to spend 2 weeks practicing temporal bone surgical procedures using a computer simulation.
1840846|NCT00887198|Drug|Abiraterone acetate|1000 mg per day (4 x 250-mg tablets) taken orally.
1840847|NCT00887198|Drug|Placebo|4 placebo tablets per day taken orally.
1840848|NCT00887198|Drug|Prednisone|5 mg tablet orally twice daily.
1840849|NCT00887211|Device|stent|ProStent rapamycin-eluting stent system manufactured by Tianjian Medical Technology (Suzhou) Co., Ltd.
1840850|NCT00887211|Device|stent|Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd.
1840851|NCT00887224|Drug|Desvenlafaxine succinate sustained release 50 mg|50 mg tablet, once daily. 5 months open-label duration for all enrolled subjects; additional 6 months double-blind duration for randomized subjects assigned to this arm.
1840852|NCT00887224|Drug|Desvenlafaxine succinate sustained release 25 mg|25 mg tablet for taper, once daily for 1 week
1840853|NCT00887224|Drug|Placebo|Matching placebo tablet, once daily. 6 months double-blind duration for randomized subjects assigned to placebo.
1840854|NCT00887237|Device|CRT with triple site ventricular stimulation|CRT with triple site ventricular stimulation (2 RV leads and 1 LV lead)
1840855|NCT00887237|Device|Conventional cardiac resynchronization|Conventional cardiac resynchronization
1840856|NCT00887250|Drug|losartan potassium|50 mg Losartan (MK0954) tablet taken once daily for 12 weeks.
1840857|NCT00887250|Drug|Comparator: losartan|50 mg tablet of Losartan (MK0954) taken once daily for 6 weeks, Non-responders will then have the dose up titrated to 100 mg for remaining 6 weeks.
1840858|NCT00887250|Drug|Comparator: Placebo|Placebo to Losartan
1840859|NCT00887263|Drug|Budesonide|3 mg TID
1840860|NCT00887263|Drug|Placebo|0 mg TID
1840861|NCT00887276|Drug|Moxifloxacin|"intravenous infusion: at least 3 days until to the drug switch (oral use),3 times daily (all 8 hours)
20 ml physiologic saline solution (placebo)(over 30 min) + Moxifloxacin infusion solution(400 mg/250ml) over 60 minutes
20 ml physiologic saline solution (placebo) (over 30 min)
20 ml physiologic saline solution (placebo) (over 30 min)
following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):
1 capsule Moxifloxacin (400 mg) + 1 capsule Placebo
2 capsules Placebo
2 capsules Placebo
Total time of the therapy:at least 7 days, but at most 10 days"
1840862|NCT00887276|Drug|Ampicillin;Amoxicillin|"intravenous infusion:at least 3 days until to the drug switch (oral use), 3 times daily (all 8 hours)
2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min) + 250 ml physiologic saline solution (placebo) (over 60 min)
2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)
2 g Ampicillin dissolved in 20 ml aqua (i.v. over 30 min)
following oral therapy(possible at the earliest day 4): 3 times daily (all 8 hours):
2 capsules Amoxicillin (0,5 g)
2 capsules Amoxicillin (0,5 g)
2 capsules Amoxicillin (0,5 g)
Total time of the therapy: at least 7 days, but at most 10 days"
1840863|NCT00887315|Drug|Docetaxel and cisplatin|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV repeated every 21 days for 2 additional cycles. For patients randomized to group 1, the chemotherapy is identical to that administered for the first 2 cycles
1840864|NCT00887315|Radiation|Docetaxel and cisplatin Plus Hypofractionated Radiotherapy|Docetaxel 75 mg/m2 and cisplatin 75 mg/m2 IV for 2 cycles along with hypofractionated radiotherapy to all known sites of disease
1840865|NCT00878345|Drug|dexmedetomidine sedation protocol|Arm 1 will undergo sedation with dexmedetomidine, using 2 mcg/kg load IV over 10 minutes followed by an IV infusion of 1 mcg/kg/hr. May use versed 0.5 mg/kg IV x 1 for incomplete sedation, followed by increase of dexmedetomidine infusion to 1.5 mcg/kg/hr. Infusion will run throughout non-painful procedure (most likely MRI).
1840866|NCT00878345|Drug|pentobarbital sedation protocol|"Pentobarbital Sedation Protocol IV: 2.5 mg/kg, followed by 1.25 mg/kg as needed x2. Maintenance: May give additional 1.25 mg/kg IV x 2 if needed. Max total dose of 200 mg pentobarbital throughout sedation.
May give midazolam 0.05 mg/kg IV x 1 PRN agitation for rescue sedation."
1840867|NCT00878358|Other|Hydrotherapy|
1840868|NCT00878358|Other|Physiotherapy|
1996410|NCT02487394|Other|COPD, Smokers and Non-Smokers|We will validate the prdictive value of the proteomic signatures for therapeutic responses.
1840870|NCT00878384|Drug|Medication to control ventricular rate in AF|Standard pharmacologic rate control. Current therapy will be adjusted to achieve rate-control targets of <80bpm and <110bpm on exercise (6 minute walk). Where necessary, additional medication will be given as per standard practice (digoxin or beta-blocker). Typical does: Digoxin 62.5-250mcg o.d. ; Bisoprolol 1.25-20mg o.d.; Carvedilol 3.125-50mg b.d. ; Nebivolol 1.25-10mg o.d.
1841042|NCT00880139|Device|Blue field entoptic technique (Blue field stimulator, BFS-2050)|performed once
1840873|NCT00878423|Drug|AT13387|Two dosing schedules will be evaluated; twice or once weekly dosing, on three weeks out of four. The starting dose for the once weekly schedule was 10mg/m2/dose, given as one hour intravenous (IV) infusions on Days 1, 4, 8, 11, 15 and 18 of a twenty-eight day cycle. The starting dose for the twice weekly schedule, given as one hour intravenous (IV) infusions on Days 1, 8 and 15 of a twenty-eight day cycle, will be 150mg/m2/dose
1840874|NCT00878423|Drug|AT13387|Intravenous infusion over one hour on days 1, 4, 8, 11, 15 and 18, every four weeks or intravenous infusion over one hour on days 1, 8 and 15, every four weeks . Treatment may be continued indefinitively in the presence of clinical benefit
1959224|NCT00598195|Drug|Ketamine|subject will then receive an intravenous bolus dose of ketamine 2 mg/kg as a rapid intravenous bolus, over less than two minutes just prior to CPB. In the non-CPB patients, ketamine will be administered just prior to the skin incision. All doses will be rounded to the nearest tenth of a milligram. Timed blood samples will be collected at standardized times after the completion of the ketamine infusion and samples will be obtained from an indwelling arterial line. Each blood sample for pharmacokinetic analysis will be 1 mL.
1840877|NCT00878449|Drug|ABT-263|150mg of ABT-263 is taken daily for 3 out of 21 days. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
1840878|NCT00878449|Drug|etoposide/cisplatin|etoposide = 100 mg/m2 Days 1-3 of each Cycle; Max duration 6 cycles. cisplatin = 75 mg/m2 Day 1 of each Cycle; Max duration 6 cycles
1840879|NCT00878462|Drug|Asenapine WHITE raspberry flavor (Treatment A)|Asenapine (Org 5222), 5 mg white raspberry flavored as fast dissolving tablets
1840880|NCT00878462|Drug|Asenapine RED raspberry flavor (Treatment B)|Asenapine (Org 5222), 5 mg red raspberry flavored as fast dissolving tablets
1840881|NCT00878462|Drug|Asenapine WHITE UNFLAVORED (Treatment C)|Asenapine (Org 5222), 5 mg WHITE UNflavored as fast dissolving tablets
1840882|NCT00878501|Drug|AZD1386|oral, during 4 weeks
1840883|NCT00878501|Drug|AZD1386|oral, during 4 weeks
1840884|NCT00878501|Drug|Placebo|Oral, during 4 weeks
1840885|NCT00878514|Drug|Alprazolam|Alprazolam 1 mg tablet
1840886|NCT00878514|Drug|Xanax|Xanax 1 mg tablet
1840888|NCT00878540|Drug|mirtazapine|30 mg mirtazapine once daily for 7 days
1840889|NCT00878553|Drug|placebo|tablet at bedtime
1840890|NCT00878553|Drug|SKP-1041 (experimental formulation of zaleplon)|tablet at bedtime
1840891|NCT00878566|Other|Enhanced pharmacist care|The primary intervention will be enhanced pharmacist care. Pharmacists will assess patients with regards to cardiovascular risk reduction including reviewing BP control, treatment goals and determining lifestyle modifications for the patient to undertake to help manage their BP. The pharmacist will also review the patient's current hypertensive therapy regimen and decide on the options for improvement of BP control (lifestyle modification, increase dose, additional BP medications), and implementation of these strategies.
1840892|NCT00878566|Other|Usual Care|Patients randomized to usual care will receive a wallet card for BP readings, pamphlet on BP and usual pharmacist and physician care. Patients will be seen at 12 weeks for interim BP measurement only. Both groups of patients will be seen at 24 weeks for BP measurement.
1840893|NCT00878579|Device|PDS System|Percutaneous Dynamic Stabilization System
1840894|NCT00878579|Device|Fusion|Transforaminal Interbody Fusion (TLIF) with Autograft and Pedicle Screws
1840896|NCT00878605|Drug|Cyclo-Z|Cyclo-Z is a cyclic dipeptide Cyclo (his-pro) plus zinc that may lower blood glucose
1840897|NCT00878605|Drug|Placebo|Placebo control
1840898|NCT00878618|Drug|AZD0837|Extended-release tablets, test formulation. 2 tablets given in the morning for 6 days
1840899|NCT00878618|Drug|AZD0837|Extended-release tablets, reference formulation. 2 tablets given in the morning for 6 days
1840900|NCT00878631|Drug|hypertonic saline mixed with dextran|a single dose 250 ml of 7.5% hypertonic saline in 6% dextran 70 is given within 4 hours from the time of the accident
1840901|NCT00878631|Drug|Normal Saline|250 ccs of normal saline infused within 4 hours of the accident
1840902|NCT00878644|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32 to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36 to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
1840903|NCT00878644|Other|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
1840904|NCT00878657|Drug|gemcitabine hydrochloride|Pre-Chemoradiation (Induction) Chemotherapy Gemcitabine will be given weekly for seven doses at a dose of 1000 mg/m2/wk (Days 1, 8, 15, 22, 29, 36, 43) unless toxicity develops. Chemoradiation gemcitabine will be given 400 mg/m2, infused over 30 minutes, within 120 minutes before radiotherapy. Post-chemoradiation chemotherapy, patients will receive two cycles of gemcitabine. A cycle will be defined as three weeks of gemcitabine at 1000 mg/m2/d, once weekly, followed by a one-week rest.
1840905|NCT00878657|Radiation|intensity-modulated radiation therapy|"Dose escalation levels (cohorts) for this study:
Dose Level 1: GTV plus drainage areas 45 Gy, Boost GTV 50.4 Gy Dose Level 2: GTV plus drainage areas 45 Gy, Boost GTV 54.0 Gy Dose Level 3: GTV plus drainage areas 45 Gy, Boost GTV 59.4 Gy Dose Level 4: GTV plus drainage areas 45 Gy, Boost GTV 64.8 Gy Dose Level 5: GTV plus drainage areas 45 Gy, Boost GTV 70.2 Gy"
1840906|NCT00878670|Drug|EPOGAM 1000|One capsule of EPOGAM 1000 contains 932-1073 mg Oenothera seminis oleum, equivalent to 80 mg gamma-linolic acid. Children (2-12 years) take 2 capsules in the morning and evening, whereas persons over 12 years take 3 capsules in the morning and evening. The duration of the treatment is 12 weeks.
1840907|NCT00878683|Device|silicone catheter boot|silicone device using Dermabond
1840952|NCT00879489|Biological|Dendritic Cell Vaccination|Autologous dendritic cells will be pulsed with human recombinant oncofetal antigen (OFP/iLRP). The vaccine will be injected intradermally.
1841180|NCT00881244|Drug|AS1411|I.v. 4-7 days, 1-40 mg/kg/day
1840908|NCT00878696|Procedure|TMS transcranial magnetic stimulation|"200 pulses of tonic TMS (see Graph 1) were administered with an intensity at 50% of the maximal TMS device output (50%DO).
The frequency of the tonic pulses was randomly chosen between 1Hz, 5Hz, 10Hz or 20Hz.
Burst stimulation was delivered at a burst frequency of 5, 10 or 20Hz. Each burst consisted of 3, 5 or 10 pulses. The individual pulse rate within a burst was 50 or 100Hz."
1840911|NCT00878722|Drug|PXD101|
1840912|NCT00878722|Drug|idarubicin|
1840913|NCT00878735|Behavioral|Zen meditation|Zen meditation retreat (7 days: 5 days from 5:30 to 9:30 plus one day for adaptation and the departure day). The program starts everyday at 5:30 and finish at 9:30. In silence, the volunteers perform seating and walking meditation, stretching exercises, eating and all tasks in mindfulness.
1840914|NCT00878748|Drug|Effexor XR|
1840915|NCT00878748|Other|Effexor XR discontinue|
1840916|NCT00878761|Biological|STX-100|SC, single dose followed by multiple dose
1840917|NCT00878774|Biological|ToleroMune Ragweed|ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
1840918|NCT00878774|Biological|Placebo|Placebo comparator, 1x4 administrations 2 weeks apart
1840920|NCT00878800|Drug|PXD101|Administered in combination with doxorubicin (BelDox)
1840921|NCT00878800|Drug|Doxorubicin|Administered in combination with PXD101 (BelDox)
1840922|NCT00878813|Procedure|Sampling of 15ml blood|On admission, 2 x 7.5ml blood tubes will be drawn during the first routine blood sampling
1840923|NCT00878813|Procedure|Blood-Sampling|On day 1 after intra-arterial thrombolysis, 2 x 7.5ml blood tubes on the following routine blood-sampling will be drawn.
1840924|NCT00878826|Drug|Enoxaparin|"Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.
Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation."
1840925|NCT00878839|Device|Toric|AcrySof Toric IOL
1840928|NCT00878865|Drug|Alprazolam|1 mg tablet one oral dose
1840929|NCT00878865|Drug|Alprazolam|1 mg tablet
1840930|NCT00878878|Drug|Optison (Perflutren Protein-Type A Microspheres Injectable Suspension)|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.
Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
1840931|NCT00878878|Drug|Dextrose|"Arm A: Single intravenous (IV) injection of 0.5 mL Optison followed by single IV injection of 0.5 mL 5% dextrose.
Arm B: Single IV injection of 0.5 mL 5% dextrose followed by single IV injection of 0.5 mL Optison."
1840932|NCT00878891|Device|Continuous glucose monitoring for immediate correction of abnormal glycemia|Prevention of hyper and hypo glycemia
1840933|NCT00878904|Drug|epirubicin hydrochloride|
1840934|NCT00878904|Drug|panobinostat|
1840935|NCT00878904|Genetic|gene expression analysis|
1840936|NCT00878904|Genetic|protein expression analysis|
1840937|NCT00878904|Genetic|western blotting|
1840938|NCT00878904|Other|immunologic technique|
1840939|NCT00878904|Other|laboratory biomarker analysis|
1840940|NCT00878904|Other|pharmacological study|
1840941|NCT00879398|Drug|Toviaz treatment|4 mg starting then can be followed by 8 mg
1840942|NCT00879411|Drug|Micardis|
1840943|NCT00879424|Dietary Supplement|cholecalciferol (vitamin D)|"1000 IU once daily x 1 month
Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
1840944|NCT00879424|Dietary Supplement|Placebo|"1000 IU once daily x 1 month
Experimental group will receive Ddrops (Toronto, Canada). Placebo group will receive placebo drops."
1840945|NCT00879437|Drug|Valproic acid|"Daily (pre-XRT, During XRT, Post-XRT and Maintenance Therapy) Started at 15 mg/kg/day divided into three doses a day as soon as patients have recovered from surgery but no later than the first day of XRT.
Dosage will be adjusted in increments of 5 mg/kg/day every 3-5 days to achieve and maintain trough concentrations between 85 and 115 mcg/ml"
1840946|NCT00879437|Drug|Bevacizumab|All patients will receive bevacizumab (10mg/kg iv) during the maintenance phase every two weeks for a maximum duration of therapy of 24 months.
1840947|NCT00879437|Radiation|Radiation therapy|Radiation therapy will start within 30 days of the definitive surgical procedure. Primary brain malignant gliomas will receive a total dose of between 54.0 and 59.4 Gy in 30-33 fractions over 6-7 weeks. Total dose will be 54.0 Gy for completely resected tumors and brainstem gliomas. the total dose will be 59.4 if the tumor is located in the brain but not the brainstem, and the tumor was incompletely resected. Primary spinal cord malignant gliomas will receive a total dose of between 50.4-54 Gy in 28-30 fractions over 5-6 weeks.
1840948|NCT00879450|Other|Booklet|booklet given to parents for home exercises
1840949|NCT00879463|Procedure|Brain tissue oxygen saturation monitoring|Brain tissue oxygen saturation monitoring with infrared spectrophotoscopy
1840950|NCT00879463|Procedure|Transfusion according to the anesthesiologist's judgement|Transfusion if hemoglobin is between 5.5-7 mg/dl
1840951|NCT00879476|Drug|Ramipril 10mg capsules|
1840992|NCT00879788|Drug|Ramipril 10mg capsules|
1840953|NCT00879528|Other|Patients with negative PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.
After the end of salvage therapy, consolidation depends on the outcome of PET:
PET negative: These patients will follow a standard treatment that includes high-dose chemotherapy with reinfusion of autologous peripheral stem cells."
1840954|NCT00879528|Other|Patients with positive PET after salvage therapy|"All patients included in the study will treat with a salvage scheme according to each center.
After the end of salvage therapy, consolidation depends on the outcome of PET
PET positive, the consolidation therapy consists of 2 phases:
phase1:common to all consists in a series of high-dose chemotherapy with Melphalan 200 mg/sqm, followed by reinfusion of autologous peripheral stem cells
phase2:depends on the availability of a compatible donor. If there is a donor, the patient will continue with an allogeneic transplant preceded by a reduced intensity conditioning.
If there is not a donor, the patient will continue with a second round of high-dose chemotherapy with BEAM with reinfusion of autologous peripheral stem cells."
1840955|NCT00879541|Biological|Biostate® [SP]|Single bolus intravenous dose of 50 IU/kg
1840956|NCT00879541|Biological|Biostate® [SP]|The dose is dependent on the reason for use and may consist of repeated bolus doses as required to manage haemophilia condition.
1840957|NCT00879541|Biological|Biostate® [RP]|Single bolus intravenous dose of 50 IU/kg.
1840958|NCT00879554|Biological|CVX-045|Weekly, intravenous dose
1840959|NCT00879593|Device|PtcCO2|Nocturnal assessment will be performed during the initial polysomnography (and at 6 months) with a combined PtcCO2/pulse oxymetry TOSCA500 Radiometer monitoring evaluating different physiological parameters.
1840960|NCT00879606|Drug|ALT-836|In the first part of this study, recombinant chimeric anti-tissue factor antibody ALT-836 was administered as a single dose (0.06 mg/Kg) via intravenous infusion over 15 minutes. In the second part of this study, up to four doses (0.06 mg/Kg) of ALT-836 will be administered via intravenous infusion over 15 minutes.
1840961|NCT00879606|Drug|Placebo|In the first part of this study, a single dose of Placebo was administered via intravenous infusion over 15 minutes. In the second part of this study, up to four doses of Placebo will be administered via intravenous infusion over 15 minutes.
1840962|NCT00879619|Drug|sunitinib malate|Given PO
1840963|NCT00879619|Drug|docetaxel|Given IV
1840964|NCT00879619|Drug|prednisone|Given PO
1840965|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide administered intravenously at 1.5 mg/kg/hr for 3 hours
1840966|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
1840967|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.5 mg/kg/hr for 3 hours
1840968|NCT00879645|Drug|Sodium Sulfide|Sodium sulfide intravenously at 1.0 mg/kg/hr for 3 hours
1840969|NCT00879658|Drug|BAF312|
1840970|NCT00879658|Drug|Placebo|
1840971|NCT00879671|Dietary Supplement|lutamax (leutein)|leutein 20 mg for 3 months, then lutein 10 mg
1840972|NCT00879671|Dietary Supplement|placebo|Placebo capsules identical in taste and appearance
1840973|NCT00879684|Biological|CVX-060|Weekly, intravenous dose
1840974|NCT00879697|Behavioral|Walking Training|The Walking Training program was performed using a treadmill. In each session, patients performed fifteen 2-min bouts of exercise followed by a 2-min rest interval, as previously described. Walking speed was set in order to induce perceived exertion of 11 to 13 and claudication pain in the last 30 seconds of each exercise bout.
1840975|NCT00879697|Behavioral|Strength Training|The strength training program consisted of 8 exercises (leg press, crunches, unilateral knee extension, seated row, unilateral knee flexion, seated bench press, calf raises on leg press, and seated back extension). In each exercise, subjects performed 3 sets of 10 repetitions with a 2-min interval between sets and exercises.
1840976|NCT00879710|Drug|simvastatin or ezetimibe|Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
1840977|NCT00879723|Dietary Supplement|Vitamin and Mineral supplementation|"IV - 2x per day given 2 - 12 hours apart. A.M. solution - Infuvite multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. solution - Cuperic Chloride 9mg (provides Copper 3.36mg) and Vitamin C 500mg. Each fluid solution will run for 4 hours.
Enteral (oral) 2 x per day given 2 - 12 hours apart. A.M. dose - multivitamin with minerals, Selenium 200mcg, Zinc 30mg, Vitamin B1 100mg and Vitamin C 500mg. P.M. dose - Copper 4mg and Vitamin C 500mg."
1840978|NCT00879736|Behavioral|THT PACE Training|Patient training
1840979|NCT00879736|Behavioral|THT PACE Training|Patient training
1840980|NCT00879736|Other|placebo|
1840981|NCT00879749|Biological|9 micrograms Nexvax2|9 micrograms, weekly intra-dermal injection, 3 week duration
1840982|NCT00879749|Biological|30 micrograms Nexvax2|30 micrograms, weekly intra-dermal injection, 3 week duration
1840983|NCT00879749|Biological|90 micrograms Nexvax2|90 micrograms, weekly intra-dermal injection, 3 week duration
1840984|NCT00879749|Biological|60 micrograms Nexvax2|60 micrograms, weekly intra-dermal injection, 3 week duration
1840985|NCT00879749|Biological|Up to 900 micrograms Nexvax2|Up to 900 micrograms, weekly intra-dermal injection, 3 week duration
1840986|NCT00879749|Other|Placebo|100 microlitres 0.9% sterile sodium chloride for injection
1840987|NCT00879762|Biological|IMVAMUNE® High Dose|IMVAMUNE® Vaccinia Vaccine, undiluted, delivered by subcutaneous route on Day 0 at high dose 5×10^8 TCID50 (5×10^8 TCID50 per 1.0 mL dose - administered as 2 x 0.5 mL.
1840988|NCT00879762|Drug|Placebo|0.5 mL injection of saline placebo administered with vaccine on Day 0 (Group B) or single saline placebo dose (single 0.5 mL injection) on Day 28 (Group A).
1840989|NCT00879762|Biological|IMVAMUNE® Standard Dose|IMVAMUNE® Vaccinia Vaccine delivered by subcutaneous (SC) route on Day 0 and 28 at standard dose (diluted with saline by study pharmacist to (1×10^8 tissue culture infectious dose 50 [TCID50] per 0.5 mL dose)
1840990|NCT00879775|Drug|Caffeine|Intravenous injection of caffeine 200mg with 100ml of normal saline over 1 hour, once a day, for two days.
1840991|NCT00879775|Drug|Normal saline|Intravenous injections of 100ml of normal saline over 1 hour, once a day, for two days
1840994|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
1840995|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
1840996|NCT00879814|Biological|rLP2086 vaccine or control|intra-muscular vaccine (solution), 0.5 mL, 3 doses, schedule: 0, 2, 6 months
1840997|NCT00879827|Biological|Pediarix TM, Infanrix penta TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
1840998|NCT00879827|Biological|Hiberix TM|The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
1840999|NCT00879853|Behavioral|Interpersonal Therapy|
1841000|NCT00879866|Biological|EMD 521873|After local irradiation (5 x 4 Gy) given over 5 consecutive days and 2 treatment free days cohorts of 3-6 subjects will receive EMD 521873 (as a 1h-infusion) on 3 consecutive days in 3-week cycles at dose levels of 0.15, 0.30, and 0.45 mg/kg, respectively.
1841001|NCT00879879|Drug|losartan|50 mg losartan taken daily by mouth in capsule form for 1 year
1841002|NCT00879892|Drug|xenon|Gas, 24 hour inhalation, en tidal target concentration 40%
1841003|NCT00879892|Other|Hypothermia|24 hour, target core temperature 33
1841004|NCT00879905|Drug|HSP990|
1841005|NCT00879918|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
1841006|NCT00879931|Drug|Methylprednisolone|Methylprednisolone
1841007|NCT00879931|Drug|Placebo|Placebo (NaCl 0.9%)
1841008|NCT00879944|Other|Blood pressure|Blood pressure will be measured once while patient is seated
1841009|NCT00879944|Other|Height|Height will be measured in centimeters at the time of enrollment
1841010|NCT00879944|Other|Weight|Weight will be measured in kilograms at enrollment
1841011|NCT00879944|Other|BMI|Body Mass Index (BMI) will be calculated from a subject's height and weight
1841012|NCT00879944|Other|Waist Circumference|Waist circumference will be measured midway between the lowest rib and the superior border of the iliac crest with an inelastic measuring tape at the end of normal expiration to the nearest 0.1cm
1841013|NCT00879957|Drug|heparin|Heparin will be added to PICC infusions at a dose of 0.5 units heparin per milliliter of intravenous fluid/parenteral nutrition.
1841014|NCT00879957|Drug|No heparin|In the no heparin group, the subjects will not receive heparin as an additive to their PICC infusions.
1841015|NCT00879970|Drug|pioglitazone|Pioglitazone30 mg and 45 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
1841016|NCT00879970|Drug|rosiglitazone|Rosiglitazone 4 mg and 8 mg tablets are over-encapsulated with Swedish orange size DB-AA capsule shell.
1841017|NCT00879970|Drug|placebo|Placebo to match is Swedish orange size DB-AA capsule filled with white to off-white non-active powder blend.
1841018|NCT00879970|Dietary Supplement|Vitamin D|Vitamin D factor intervention
1841019|NCT00879970|Dietary Supplement|Placebo|Vitamin D factor intervention
1841020|NCT00879983|Drug|azithromycin (Zithromax)|"a single dose of azithromycin ER 2g
3-day regimen of azithromycin tablet 500mg"
1841021|NCT00879983|Drug|azithromycin (Zithromax)|"3-day regimen of azithromycin tablet 500mg
a single dose of azithromycin ER 2g"
1841022|NCT00879996|Drug|Methadone|Oral, 10-60 mg per day, 2-4 times per day, 6 months
1841023|NCT00879996|Drug|Buprenorphine/naloxone|Sub-lingual, 4-16 mg per day, divided 2-4 times/day, 6 months
1841024|NCT00880009|Drug|Bosutinib|400mg (4x100)mg tablets once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
1841025|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
1841026|NCT00880009|Drug|Letrozole|2.5 mg - one tablet per day- once daily during the active phase of treatment until Disease Progression, unacceptable toxicity or withdraw of consents occurs
1841027|NCT00880022|Device|Flexitouch System|pneumatic compression ( 10 to 30 treatments depending on group assignment)
1841028|NCT00880035|Device|MP3 music program listening|3 days with two 1 hour periods of headset music listening (1 day on, 1 day wash-out, 1 day off)
1841031|NCT00880061|Drug|IL13-PE38QQR|
1841032|NCT00880074|Radiation|PET Scan|3 Positron Emission Tomography (PET) scans performed 60-90 minutes after intravenous injection of FLT: 1) within 2 weeks before day 1 of chemotherapy treatment; 2) day 6-7 of chemotherapy treatment; and,3) at end of chemotherapy treatment, day 19-20.
1841033|NCT00880074|Drug|FLT|FLT solution is administered through a peripheral intravenous catheter approximately 60 minutes before the PET scan. Dosage of FLT in the range between 1 and 10 mCi.
1841034|NCT00880087|Procedure|Therapeutic Hypothermia|Participants who are assigned to receive therapeutic hypothermia will be cooled to a target temperature of 33º C plus or minus 1º C (32° to 34º C). This temperature will be maintained for 48 hours (2 days) and then participants will be warmed to a target temperature of 36.75º C plus or minus 0.75º C (36° to 37.5º C). This temperature will be maintained until 120 hours (5 days) after the cardiac arrest.
1841035|NCT00880087|Procedure|Therapeutic Normothermia|Participants who are assigned to receive therapeutic normothermia will have their temperature maintained at 36.75º C plus or minus 0.75º C (36° to 37.5º C) for 120 hours (5 days) after the cardiac arrest.
1841036|NCT00880100|Drug|Ultrase® MT12|Ultrase® MT12 capsules will be given orally daily based on investigator's discretion to a maximum dose of 2,500 lipase units per kilogram (kg) body weight per meal or snack for 19 to 24 days during the treatment phase. Total maximum dose not to exceed 10,000 lipase units/kg/day.
1841037|NCT00880113|Procedure|Non-contrast CT, CT-perfusion and CT-angiography|Included patients will undergo one additional combined CT-scan (NCCT, CTP and CTA) on day 3 (+/- 2 days).
1841038|NCT00880126|Behavioral|Community Development Teams|CDTs bring together counties who are implementing a new practice
1841039|NCT00880139|Procedure|Blood sampling|Determination of cytokine plasma levels (ELISA)
1841040|NCT00880139|Procedure|Noninvasive measurement of systemic hemodynamics|performed once
1841041|NCT00880139|Procedure|Visual acuity assessment|ETDRS charts
1841044|NCT00880139|Device|Retinal Vessel Analyzer (DVA)|Assessment of retinal vessel reactivity to stimulation with flickering light
1841045|NCT00880139|Device|High resolution optical coherence tomography (OCT)|performed once
1841046|NCT00880152|Behavioral|Mindfulness-based stress reduction|An 8-week course in mindfulness training
1841047|NCT00880165|Device|Continuous positive airway pressure apparatus|Veterans randomized to both arms who are diagnosed with obstructive sleep apnea will be started on treatment with continuous positive airway pressure.
1841048|NCT00880178|Drug|Simvastatin and Extended-Release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
1841049|NCT00880178|Drug|Simvastatin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
1841050|NCT00880191|Drug|dexamethasone|Given orally
1841051|NCT00880191|Drug|gabapentin|Given orally
1841052|NCT00880191|Other|placebo|Given orally
1841053|NCT00880204|Behavioral|ESS-EMCH training|"The trainings of the ESS-EMCH programme are based on two well-tried and tested structured training methodologies of Advanced Pediatric Life Support (APLS) and Management of Obstetric Emergencies and Trauma (MOET)."
1841054|NCT00880217|Drug|Atomoxetine 80 mg/d|40-mg capsule for 3 days, followed by 80-mg capsule once daily for 39 days
1841055|NCT00880217|Drug|Placebo|Placebo capsule once daily for 42 days
1841056|NCT00880217|Drug|OROS methylphenidate HCl 54 mg/d|36-mg capsule for 3 days, followed by 54-mg capsule once daily for 39 days
1841057|NCT00880217|Drug|JNJ-31001074 3 mg/d|3-mg capsule once daily for 42 days
1841058|NCT00880217|Drug|JNJ-31001074 1 mg/d|1-mg capsule once daily for 42 days
1841059|NCT00880217|Drug|JNJ-31001074 10 mg/d|10-mg capsule once daily for 42 days
1841060|NCT00880230|Device|Scuba Iliac Stent System|The Scuba™ Stent System consists of a balloon-expandable stent and an over the wire (OTW) delivery system.
1841061|NCT00880243|Drug|GM-CSF|"Randomization 1: GM-CSF (5micogram/Kg/d) versus no GM-CSF during induction chemotherapy and all consolidation courses.
Randomiization 2: Consolidation high dose AraC versus consolidation EMA"
1841062|NCT00880256|Behavioral|mindfulness-based stress reduction|An 8-week course in mindfulness training
1841063|NCT00880269|Drug|Panobinostat/LBH589|
1841064|NCT00880282|Biological|cixutumumab|Given IV
1841065|NCT00880282|Drug|temsirolimus|Given IV
1841066|NCT00880282|Other|pharmacological study|Correlative studies
1841067|NCT00880282|Other|laboratory biomarker analysis|Correlative studies
1841068|NCT00880295|Procedure|endoscopic carpal tunnel release|endoscopic surgery, which is standard of care for carpal tunnel release
1841069|NCT00880295|Procedure|open carpal tunnel release|open surgery, which is standard of care for carpal tunnel release
1841070|NCT00880308|Drug|LDE225|
1841071|NCT00880321|Drug|GSK2118436|Dose escalation with GSK2118436 may proceed until either a maximum tolerated dose is established, or the toxicokinetic safety limit is reached.
1841072|NCT00880321|Drug|GSK2118436|Part 2 will use the recommended Part 2 dose of GSK2118436 identified during Part 1 of the study. Biologically active doses will be identified by measurement of pharmacodynamic markers in tumor tissue and blood across a range of doses and these doses may be explored in Part 2.
1841073|NCT00880321|Drug|Midazolam|Midazolam will be administered alone and with GSK2118436 in a sub-set of subjects in Part 2 to study the effect of GSK2118436 on CYP3A using midazolam as a probe.
1841074|NCT00880334|Drug|Docetaxel|Given intravenously on Day 1 of each 21-day cycle
1841075|NCT00880334|Drug|vandetanib|taken orally once a day, every day
1841076|NCT00880334|Drug|Placebo|Taken orally once a day every day
1841077|NCT00880347|Device|Blood sampling|Venous blood sampling in PaxGene tubes intended to collect blood RNA that will be then analyzed using SpliceArray (tm) technology for transcriptomic profile. sAPPalpha levels will be also dosed. Clinical data to be collected in parallel (medical history, concomitant treatment, MMSE,clinical examination,...)
1841078|NCT00880360|Drug|Ontak|Patients will be treated with Ontak at 12 µg/kg monthly as long as they meet response criteria.
1841079|NCT00880373|Drug|Ibuprofen|Oral ibuprofen 800 mg three times daily for a total of 2400 mg per day for 4 days
1841080|NCT00880373|Drug|Placebo|Matching placebo three times daily for 4 days
1841081|NCT00880373|Drug|Diamorphine or Morphine|Diamorphine or Morphine by PCA
1841082|NCT00880386|Drug|Losartan|50 mg Losartan will be taken daily by subjects for 24 weeks
1841083|NCT00880399|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
1841084|NCT00880399|Other|placebo|inactive placebo to match orvepitant 30 and 60 mg dosage forms
1841085|NCT00880412|Drug|EHT 0202 etazolate|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
1841086|NCT00880412|Drug|Placebo|In each arm, 2 capsules of study treatment (capsules of EHT0202 40mg and/or placebo) are taken twice a day during breakfast and dinner over a 3-month treatment period. There is non treatment adjustment.
1841087|NCT00880464|Biological|Autologous, Lethally Irradiated Breast Cancer Cells|Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out
1841088|NCT00880477|Biological|DTPa-HBV-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
1841089|NCT00880477|Biological|DTPa-IPV/Hib vaccine|Vaccination according to a 3-dose schedule at at 1 ½, 3 ½ and 6 months of age with booster at 15-18 months of age.
1841090|NCT00880477|Biological|EngerixTM-B|The vaccine was administered according to a 2-dose schedule at 1½ and 6 months of age with booster at 15-18 months of age.
1841091|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
1841092|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
1841093|NCT00880490|Drug|Inhaled PT005|single dose, inhaled
1841095|NCT00880490|Drug|Formoterol Fumarate 12 mcg (Foradil Aerolizer)|single dose, Formoterol Fumarate 12 mcg administered via the Aerolizer
1841096|NCT00880529|Device|ON-Q bupivicaine administration|continuous subcutaneous bupivicaine drip
1841097|NCT00880529|Drug|IV opioid administration|Patient controlled analgesia with IV narcotics
1841098|NCT00880542|Drug|sorafenib|Patients with sarcoma who have resectable disease will be treated with neoadjuvant sorafenib and ifosfamide. PET/CT will be used to assess the metabolic and radiographic response to therapy.
1841099|NCT00880542|Drug|Ifosfamide|Patients with sarcoma who have resectable disease will be treated with neoadjuvant ifosfamide and sorafenib. PET/CT will be used to assess the metabolic and radiographic response to therapy.
1841100|NCT00880568|Drug|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Day 1 of each 21-day cycle
1841101|NCT00880568|Drug|MK-1496|MK-1496 (20 to 120 mg), orally, administered on Days 1 and 3 each week for 3 weeks (Days 1, 3, 8, 10, 15 and 17) of each 28-day cycle
1841102|NCT00880581|Drug|PF-3512676|18 mg injection
1841103|NCT00880581|Radiation|Local radiotherapy|2 gray (2 Gy) on each of Days 1 and 2
1841104|NCT00880594|Drug|Desipramine|"Desipramine 25 mg/day administered in the evening. Dosing may be increased dependent upon side-effects and clinical response to a maximum of 100 mg/day. Absent significant side-effects, all patients are increased at the one week visit to 50 mg/day at bedtime if they have not achieved a report of Adequate relief. Thereafter, up to week 4, the daily desipramine dose may be increased weekly by 25 mg up to the 100 mg/d maximum."
1841106|NCT00880620|Drug|Placebo|Placebo
1841107|NCT00880620|Drug|IPX066 95 mg LD|IPX066 capsule containing 95 mg LD/23.75 mg CD
1841108|NCT00880620|Drug|IPX066 145 mg LD|IPX066 capsule containing 145 mg LD/36.25 mg CD
1841109|NCT00880620|Drug|IPX066 195 mg LD|IPX066 capsule containing 195 mg LD/48.75 mg CD
1841110|NCT00880620|Drug|IPX066 245 mg LD|IPX066 capsule containing 245 mg LD/61.25 mg CD
1841111|NCT00880646|Dietary Supplement|Oolong tea containing L-arabinose and indigestible dextrin|
1841112|NCT00880646|Dietary Supplement|Oolong tea (Placebo)|
1841113|NCT00880659|Behavioral|Soap|Promotion of handwashing with soap
1841115|NCT00880685|Drug|Memantine|10-30mg, daily for 8 weeks
1841118|NCT00880724|Device|IBV Valve|Placement of IBV Valve in the airways of treatment subjects. Bronchoscopic procedure in control group.
1841119|NCT00880750|Drug|Lanthanum carbonate Granule Formulation|3x's per day for 3 days, 1 dose in the am for day 4. (A single dose equals 1000mg of lanthanum carbonate granule formulation. Dose is administered immediately after each meal.)
1841120|NCT00880750|Drug|Lanthanum carbonate Chewable Tablets (Fosrenol)|3x's per day for 3 days, 1 dose on day 4. (A single dose equals a 1000mg tablet of lanthanum carbonate. Dose is administered immediately after each meal.)
1841121|NCT00880763|Drug|Vaniprevir|Vaniprevir oral capsule administered twice daily (200, 600 or 1200 mg/day) for 28 days
1841122|NCT00880763|Drug|Pegylated Interferon (peg-IFN)|Open-label peg-IFN alfa-2a subcutaneous injection (sourced locally) administered weekly, 180 micrograms, for 6 weeks
1841123|NCT00880763|Drug|Ribavirin|Open-label ribavirin (sourced locally) administered orally twice daily, 600 to 1000 mg/day, for 6 weeks
1841124|NCT00880763|Drug|Comparator: Placebo|Placebo to vaniprevir oral capsule twice daily for 28 days
1841125|NCT00880789|Biological|CMV/AdV specific T cells|CTL Dose Given from Day +30 post SCT (stem cell transplant). For the trial, two patients are allocated in each cohort and are followed for 30 days post IV injection of transduced T-cells for evaluation of DLTs. A maximum 18 patients will be accrued into each group. The final MTD will be the dose with probability closest to the target toxicity rate at these termination points. The trial continues until a minimum of 12 patients have been treated. The trial will stop when the maximum 18 patients have been treated, or when six patients have been treated at the current MTD. We therefore expect to enroll between 12-18 patients into this trial.
1841126|NCT00880815|Drug|Bendamustine|Starting dose of 70 mg/m^2 by vein over 1 hour on Day -5 through Day -3.
1841127|NCT00880815|Drug|Rituximab|Dose of 375 mg/m^2 by vein over 5-7 hours on Day -13 and 1000 mg/m^2 on Day -6, Day +1 and Day +8 (1 time each week for four weeks).
1841128|NCT00880815|Drug|Fludarabine|30 mg/m^2 on Day -5 to Day -3.
1841129|NCT00880815|Procedure|Stem Cell Transplant (SCT)|Infusion of donor blood stem cells by vein over 30-45 minutes on Day 0.
1841130|NCT00880828|Other|FIR cervical collar with Acetaminophen|FIR cervical collar with Acetaminophen QID/PRN for 4 weeks
1841131|NCT00880828|Other|Conservative cervical collar with Acetaminophen|Conservative cervical collar with Acetaminophen QID/PRN for 4 weeks
1841132|NCT00880828|Drug|Acetaminophen only|Acetaminophen QID/PRN for 4 weeks
1841133|NCT00880841|Drug|Buprenorphine / Naloxone|oral formulation of buprenorphine / naloxone
1841134|NCT00880854|Drug|BCG and CP-675,206|"Dose level -1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 3 mg/kg I.V. week 3, week 15
Dose level 1: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 6 mg/kg I.V. week 3, week 15
Dose level 2: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 10 mg/kg IV week 3, week 15
Dose level 3: BCG 81 mg intravesical weekly x 6 beginning on week 1, and weekly x 3 beginning at week 15 CP-675,206 15 mg/kg IV week 3, week 15"
1841181|NCT00881257|Device|GRST Peripheral Catheter System|Treatment to dilate stenoses and reduce plaque in treated vessels
1841182|NCT00881270|Drug|LACTIC ACID(ND)|Dermacyd Infantile (LACTIC ACID)
1841365|NCT00888758|Device|biolimus A9|200 patients with STEMI will be treated using Biomatrix stent.
1841135|NCT00880867|Drug|Poly-ICLC|An accessible site of disease (lymph node, cutaneous, subcutaneous, etc.) will be selected by the principal investigator. Patients will then receive two doses of low dose irradiation (2 Gy per day) to that single site on days 1 and 2. Intratumorally or peritumorally Poly-ICLC will be dosed on days 3 and 4 by the physician during weeks 1, 2, 3, 4, and 8.
1841136|NCT00880880|Other|e-PAQ-PF|Participants will fill out the e-PAQ-PF prior to their clinic visit. The e-PAQ-PF has 4 dimensions (urinary, bowel, vaginal, sexual) and asks about symptoms severity, bother of symptoms, and impact on quality of life. A copy of the results will be given to their clinician and the participant.
1841137|NCT00880893|Biological|CYD Dengue vaccine|0.5 mL, Subcutaneous on Day 0, Months 6 and 12
1841138|NCT00880893|Biological|NaCl + influenza virus or hepatitis A vaccine|0.5 mL, Subcutaneous (Intramuscular - Hepatitis A)
1841139|NCT00880906|Procedure|Esophageal dilation|The esophagus is stretched during the upper endoscopy using Maloney dilators or balloon dilatation.
1841140|NCT00880906|Drug|Steroid and Proton Pump Inhibitor Therapy|
1841141|NCT00880919|Drug|quetiapine extended-release|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
1841142|NCT00880919|Drug|Placebo|Seroquel XR 150mg/day vs Seroquel XR 300mg/day vs Placebo
1841143|NCT00880932|Behavioral|Electronic Alert|
1841144|NCT00880958|Dietary Supplement|Mixture of various probiotics and fermentation products|
1841145|NCT00880958|Dietary Supplement|Placebo|
1841146|NCT00880971|Radiation|3D conform radiotherapy|3D conform radiotherapy, 2 Gy per fraction, total 25 fractions (50Gy).
1841147|NCT00880984|Device|Compression Anastomosis Ring: CAR™ 27|Creation of anastomosis in colorectal surgeries using CAR™ 27
1841150|NCT00881010|Behavioral|Telephone Intervention|Automated Telephone Interactive Voice Response (IVR) system taking approximately 5 minutes, 2 times week for 10 weeks, to rate pain and symptoms.
1841151|NCT00881010|Behavioral|Questionnaires|Surveys approximately 1 hour each at 2 regularly scheduled clinic visits to rate pain and symptoms. Regardless of group, all symptoms are to be reported.
1841152|NCT00881023|Procedure|Microfracture|The microfracture procedure is a standard method for treatment of cartilage damage in which the surgeon will clean the site of your cartilage damage and then will make several small holes in your bone to stimulate your bone marrow with the intention to repair the damaged area with new cartilage tissue
1841153|NCT00881023|Device|Cartilage Autograft Implantation System|A surgical treatment of damaged knee cartilage using the subject's own healthy cartilage obtained from a non-weight or low weight-bearing region
1841154|NCT00881049|Drug|Imatinib (Gleevec)|Imatinib will be given for enrolled patients to investigate efficacy and safety
1841155|NCT00881062|Drug|Proellex|A single oral dose administered after at least a 10 hour fast
1841156|NCT00881075|Drug|SeeMore(TM)|single dose intravenous injectable
1841157|NCT00881088|Drug|Nadroparin|nadroparin 0,3 cc once daily during immobilization period
1841158|NCT00881088|Drug|Fondaparinux|Fondaparinux 2,5 mg daily during immobilization period
1841159|NCT00881101|Drug|Liposomal paclitaxel|All Patients will receive liposomal paclitaxel (starting at a dose of 190mg/m2,3h,ivgtt,at d1)each cycle for 1 cycle.
1841160|NCT00881114|Drug|Cisplatin|Intensity modulated radiation therapy with concurrent chemotherapy. Cisplatin will be administered at a dose of 100 mg/m2 during weeks 1, 4, and 7 of radiation therapy. Post treatment neck dissection will be performed if clinically indicated.
1841161|NCT00881114|Drug|Cetuximab|Intensity modulated Radiation Therapy with concurrent chemotherapy. Cetuximab will be administered beginning at a dose of 400 mg/m2 the week before radiation commences, then at a dose of 250 mg/m2 weekly during weeks 1 to 7. Post treatment neck dissection will be performed if clinically indicated.
1841162|NCT00881127|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg (Sandoz, USA)|
1841163|NCT00881127|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
1841164|NCT00881140|Drug|mifepristone vaginal tablets|Daily use of 10 mg administrated per vagina for 3 months
1841165|NCT00881153|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz GmbH)|
1841166|NCT00881153|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb)|
1841167|NCT00881166|Drug|MP-470 + topotecan|Topotecan 1.5 mg/m2 IV infusion over 30 minutes on Days 1-5
1841168|NCT00881166|Drug|MP-470 + docetaxel|Docetaxel 75 mg/m2 IV infusion over 1 hour on Day 1
1841169|NCT00881166|Drug|MP-470 + erlotinib|150 mg PO once daily at least 1 hour before or 2 hours after eating
1841170|NCT00881166|Drug|MP-470 + paclitaxel/carboplatin|Paclitaxel 200 mg/m2 IV infusion over 3 hours followed by carboplatin IV infusion over 1 hour to a target AUC of 6 mg∙min/mL on Day 1
1841171|NCT00881166|Drug|MP-470 + carboplatin/etoposide|Carboplatin IV infustion over 1 hour to target AUC of 5 mg min/mL on Day 1 followed by etoposide 100mg/m2 IV infustion over 2 hours on Days 1-3
1841172|NCT00881179|Drug|Clarithromycin 250 mg Tablets (Geneva Pharmaceuticals, USA)|
1841173|NCT00881179|Drug|Biaxin (Clarithromycin) 250 mg Tablets (Abbott Laboratories, Inc, USA)|
1841174|NCT00881192|Procedure|IABP|preoperative IABP placement
1841175|NCT00881205|Drug|Rivastigmine transdermal patch|Transdermalapplication of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. All patches are round, beige in color.
1841176|NCT00881205|Drug|Placebo|Transdermal application of one 5 cm² patch, followed by an increase to the target dose of 10 cm² patch size. Matching the size, shape and color of rivastigmine patches.
1841177|NCT00881218|Drug|Regadenoson|Regadenoson 400 micrograms will be administered IV bolus via an antecubital cannula.
1841178|NCT00881231|Drug|Cilostazol 50 mg Tablets (Eon Pharma, LLC, USA)|
1841179|NCT00881231|Drug|Pletal (Cilostazol) 50 mg Tablets (Otsuka Pharma Co, Ltd., USA)|
1841183|NCT00881296|Drug|gemcitabine and carboplatin|Gemcitabine 1000mg/m2, DIV on day 1 and 15 of each 28 day cycle. Carboplatin AUC=3, DIV on day 1 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles.
1841184|NCT00881296|Drug|Gemcitabine|Gemcitabine 1000mg/m2, DIV on day 1, 8 and 15 of each 28 day cycle. Number of cycles: until progression or unacceptable toxicity develops, up to 6 cycles
1841185|NCT00881309|Drug|Tripterygium|TW 90mg/d
1841186|NCT00881322|Dietary Supplement|BC-130 (Gas Defense)|"Product Dosing:
Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)
Gas Defense Serving Size: 1 tablet Active Ingredients: B. Coagulans, Enzyme Blend (Cellulase - Trichoderma longibrachiatum, Cellulase - Aspergillus niger, Hemicellulase, Alpha Galactosidase, Invertase) Inactive Ingredients: vegetable capsule, Magnesium Stearate, Silicon Dioxide, Maltodextrin Contains: Wheat, Fish."
1841187|NCT00881322|Dietary Supplement|Placebo|"Product Dosing:
Take one capsule daily, at approximately the same time of day, without regard to food (may be taken with or without food)
Placebo - matched in size and color to the active product Inactive Ingredients: microcrystalline cellulose, FD&C yellow #5 Lake, FD&C blue #1 Lake, FD&C red #46 Lake and vegetable capsule"
1841188|NCT00881335|Device|flutter mucus clearance device|five minutes every sessions, three sessions per day
1841189|NCT00881348|Drug|LACTIC ACID(ND)|Dermacyd infantile (Lactic Acid)
1841190|NCT00881361|Drug|systemic chemotherapy|
1841191|NCT00881361|Procedure|axillary lymph node dissection|
1841192|NCT00881361|Procedure|neoadjuvant therapy|
1841193|NCT00881361|Procedure|sentinel lymph node biopsy|
1841194|NCT00881361|Procedure|therapeutic conventional surgery|
1841195|NCT00881361|Procedure|ultrasound imaging|
1841196|NCT00881374|Drug|LACTIC ACID(ND)|Dermacyd Infantile (Lactic Acid)
1841197|NCT00881387|Biological|rituximab|Given IV
1841198|NCT00881387|Drug|gemcitabine hydrochloride|Given IV
1841199|NCT00881387|Drug|vinorelbine ditartrate|Given IV
1841200|NCT00881400|Drug|Cefprozil 250 mg/5 ml Oral Suspension (Sandoz, Austria)|
1841201|NCT00881400|Drug|Cefzil (Cefprozil) 250 mg/5 ml Oral Suspension (Bristol-Myers Squibb, USA)|
1841202|NCT00881413|Drug|Esomeprazole|Intravenous esomeprazole (Nexium®, AstraZeneca, Sodertalje, Sweden) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral esomeprazole 40 mg (Nexium®, AstraZeneca, Sodertalje, Sweden) for 2 months
1841203|NCT00881413|Drug|Pantoprazole|After successful endoscopy, intravenous pantoprazole (Pantoloc®, Nycomed GMBH, Konstanz, Germany) is administered with 80mg bolus and 8mg/hr infusion for 72 hours. After 3 days, patients receive oral pantoprazole 40 mg (Pantoloc®, Nycomed GMBH, Oranienburg, Germany) for 2 months
1841204|NCT00881426|Drug|Cefprozil 500 mg Tablets (Sandoz GmbH)|
1841205|NCT00881426|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb)|
1841206|NCT00881439|Drug|Aliskiren|Oral, 300 mg, once daily, 6 months
1841207|NCT00881439|Drug|Placebo|Matching Placebo once daily, 6 months
1841208|NCT00881452|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
1841209|NCT00881452|Drug|Placebo|Single unit dose powder of non-active substance administered 3 times per day for 90 days
1841210|NCT00881465|Behavioral|Cognitive-behavioral therapy|Cognitive-Behavioral Therapy. The psychotherapy protocol will include 14 90-minute sessions of videophone administered CBT over 12 weeks.
1841211|NCT00881465|Behavioral|Wait-list control|Waitlist Control. The participant and his/her parents will be instructed to not obtain treatment outside of the protocol or make medication changes/additions. This will be assessed through interview at the Post-Waitlist assessment.
1841212|NCT00881478|Other|Nutrition counseling + portion control tool|Nutrition counseling with registered dietician in addition to teaching about how use of a portion control tool
1841213|NCT00881478|Other|Nutrition counseling|Nutrition counseling with registered dietician
1841214|NCT00881491|Drug|Double Antibiotic Paste|ciprofloxacin and metronidazole powder mixed at a 1:1 ratio used as a intracanal medicament for disinfection.
1841215|NCT00881491|Drug|Triple Antibiotic Paste|ciprofloxacin, metronidazole & minocycline mixed to a 1:1:1 powder used as a intracanal medicament for disinfection.
1841216|NCT00881491|Drug|Mineral Trioxide Aggregate|standard material providing an apical barrier
1841217|NCT00881504|Drug|"Bevacizumab in combination with modified FOLFOX6."|Oxaliplatin 85 mg/m2 IV on Day 1 5-FU: 400 mg/m2 IV bolus on Day 1, followed by 2400 mg/M2 over 46 hours Leucovorin: 400 mg IV Day 1 Bevacizumab: 10 mg/kg IV on Day 1 Repeat cycles every 2 weeks until death, disease progression, unacceptable toxicity, patient refusal, or treatment delay > 4 weeks
1841218|NCT00881517|Drug|HCMV-specific hyperimmune globulin (Cytotect®)|100U (2.0ml)/Kg i.v. every 4 weeks up to 38 weeks' gestation or HCMV-positive amniocentesis or pregnancy termination.
1841219|NCT00881517|Drug|Isotonic solution of sodium chloride (placebo)|2.0ml/Kg i.v. every 4 weeks until 38 weeks'gestation or HCMV-positive amniocentesis or pregnancy termination
1841220|NCT00881530|Drug|BI 10773|BI 10773 high dose once daily
1841221|NCT00881530|Drug|Metformin|open label comparator
1841222|NCT00881530|Drug|BI 10773|BI 10773 low dose once daily
1841223|NCT00881530|Drug|Sitagliptin|open label comparator
1841224|NCT00881543|Drug|Dipeptidyl Peptidase IV inhibitors|Dosage 100 mg each day, once a day, 2 months
1841225|NCT00881556|Drug|Reduced Intensity Transplant conditioning|"Palifermin (Kepivance®) 60 mcg/kg/day for 6 days
Fludarabine 30 mg/m2 IV x 1 for 6 days
Busulfan 4 mg/kg/day IV divided BID for 4 days
Lorazepam 0.02-0.05 mg/kg for 5 days
Alemtuzumab 20 mg/m2 IV for 5 days
Tacrolimus 0.03mg/kg/24 hours as continuous infusion for 4 days"
1841226|NCT00881569|Drug|CS-7017|CS-7017 tablets twice daily at strength 0.25mg
1841227|NCT00881582|Drug|Pegylated interferon alfa-2a plus ribavarin|PEG-interferon alfa-2a and ribavirin. Pegylated interferon alfa-2a - standard dose; plus ribavirin - standard dose (determined by creatinine clearance); for 24 to 48 weeks (genotypes 1 & 4: 48 weeks; genotypes 2 & 3: 24 weeks)
1841267|NCT00887328|Drug|Placebo|placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
1841268|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; first infusion 1h duration, subsequent infusions 31 minutes duration
1841228|NCT00881595|Drug|Chemoradiotherapy Temozolomide|Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks.Temozolomide: 75 mg/m2 five days per week during radiotherapy for 5 weeks. Temozolomide should be taken orally 1 hour before each session of radiotherapy during weekdays (Monday through Friday). The dose will be determined using the body surface area (BSA) calculated at the beginning of the concurrent treatment. The BSA will be calculated from the height obtained at the pretreatment visit and the weight obtained before the first day of treatment. The concurrent treatment will last until the end of radiotherapy.
1841229|NCT00881595|Radiation|Proton therapy|50 cobalt gray equivalent(CGE), 25 daily fractions, 5 weeks (2 CGE/fx)
1841230|NCT00881595|Procedure|Proton Chemoradiotherapy followed by surgery|Proton Chemoradiotherapy followed by surgery. Resection of tumor at 4-6 weeks post-treatment.
1841231|NCT00881608|Drug|Placebo|Placebo, 1 capsule daily for five days
1841232|NCT00881608|Drug|Proellex|Proellex, one 3, 6, 12 or 25 mg capsule daily for five days
1841233|NCT00881621|Drug|Lapatinib and Capecitabine|Lapatinib 1250-mg PO daily one hour before or after meals Capecitabine 1000 mg/m2 PO twice daily on days 1-14 of 21-day cycle for a total of 8 cycles
1841234|NCT00881634|Drug|Cetirizine HCl/Pseudoephedrine HCl 5 mg/120 mg Tablets (Sandoz, USA)|
1841235|NCT00881634|Drug|Zyrtec-D 12 Hour 5 mg/120 mg Extended Release Tablets (Pfizer, USA)|
1841236|NCT00881647|Other|Cognitive Behavioral Treatment for Insomnia (CBT-I)|CBT-I includes strategies and instructions targeted toward improving the quality of sleep and resolving problems falling and staying asleep
1841237|NCT00881660|Device|Goldballoon Detachable Balloon and delivery microcatheter|"Between 27+0/7 - 29+ 6/7 weeks gestation for severe CDH and can be as early as 22+0/7 weeks gestational age for those deemed as extremely severe cases of CDH, placement of the Goldvalve detachable balloon. Balloon retrieval will be planned for between 32+0/7 and 34+6/7 weeks or no longer than 10 weeks after balloon placement at the discretion of the FETO center."
1841238|NCT00881673|Drug|AL38583 Ophthalmic Solution|Topical ophthalmic
1841239|NCT00881673|Drug|Maxidex|Topical ophthalmic
1841240|NCT00881673|Drug|Vehicle|AL38583 Vehicle
1841241|NCT00881686|Drug|adenosine|1.5mg/Kg adenosine will be administered intravenously before surgery
1841242|NCT00881699|Behavioral|HIV Prevention Intervention - Project PRISSMA - HIV I have my eye on you|Eight weekly 2-hour HIV risk reduction intervention sessions, with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about HIV risk behaviors and safer sex options; (2) increase identification of personal risk of HIV and enhance the motivation to engage in safer sex behaviors; and (3) enhance skills to achieve safer sex, particularly negotiating safer sex, using condoms, and communicating within a relationship.
1841243|NCT00881699|Behavioral|Health Promotion Intervention|Eight weekly 2-hour health promotion intervention sessions with three weekly 2-hour booster sessions completed 6 months after the initial intervention. Specific goals of the intervention are to (1) increase information about health issues specific to psychiatric patients, (2) increase identification of personal health risks and enhance motivation to engage in healthier behaviors, and (3) enhance skills to achieve healthier behaviors.
1841244|NCT00881712|Radiation|PET positive nodal disease measuring 15 mm or greater|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 74 cobalt gray equivalent with concomitant weekly chemotherapy.
1841245|NCT00881712|Radiation|PET positive nodal disease measuring less than 15 mm|Proton radiation at 2 cobalt gray equivalent per fraction to a total of 60 cobalt gray equivalent with concomitant weekly chemotherapy.
1841246|NCT00881712|Radiation|Patients considered resectable|Proton radiation at 2 cobalt gray per fraction. Re-evaluation performed between days 18-22 of treatment. If considered resectable after re-evaluation, radiotherapy will discontinue after a total of 50 cobalt gray equivalent and surgery will be performed.
1841247|NCT00881725|Drug|Metformin|500mg tablets t.i.d. for 4-12 weeks prior to Radical Prostatectomy
1841248|NCT00881738|Drug|Clarithromycin 250 mg Tablets (Geneva, USA)|
1841249|NCT00881738|Drug|Biaxin 250 mg Tablets (Abbott Laboratories, Inc, USA)|
1841250|NCT00881751|Biological|bevacizumab|Given IV
1841251|NCT00881751|Drug|erlotinib hydrochloride|Given orally
1841252|NCT00881751|Drug|sorafenib tosylate|Given orally
1841253|NCT00881764|Procedure|Inguinal hernia surgery|Non-experimental procedure
1841254|NCT00881764|Procedure|General anesthesia|Non-experimental procedure/treatment
1841255|NCT00881777|Procedure|Radiofrequency heating of the myocardial infarct scar|Radiofrequency energy is applied to the epicardial surface of the heart using an external generator and a hand-held probe to heat myocardial infarction scar.
1841256|NCT00881777|Procedure|Coronary Artery Bypass Grafting (CABG) surgery|A standard surgical procedure performed to relieve angina and reduce the risk of death from coronary artery disease. Arteries or veins from elsewhere in the body are grafted to the coronary arteries to bypass atherosclerotic narrowings and improve the blood supply to the coronary circulation supplying the myocardium.
1841257|NCT00881790|Other|Fluoride varnish|the topical application of fluoride varnish to all surfaces of exposed teeth
1841258|NCT00881816|Drug|Liposomal paclitaxel plus capecitabine|All Patients will receive liposomal paclitaxel (with a dose of 60mg/m2,3h,ivgtt,at d1,8,15) and capecitabine (with a dose of 1600mg/m2,bid,po.,at d1-14),each cycle for 4 cycles.
1841259|NCT00881829|Device|Pulse Oximeter, Blood Pressure, Respiratory Rate, Respiratory Gasses, Temperature|Measurement of physiological parameters.
1841260|NCT00881842|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
1841261|NCT00881855|Drug|Cefprozil 500 mg Tablets (Sandoz, GmbH)|
1841262|NCT00881855|Drug|Cefzil (Cefprozil) 500 mg Tablets (Bristol-Myers Squibb, USA)|
1841263|NCT00881868|Drug|clobetasol propionate spray 0.05%|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
1841264|NCT00881868|Drug|Vehicle spray|Apply enough product to cover affected areas topically twice daily at least 8 hours apart
1841265|NCT00881894|Drug|Rotigotine transdermal patch|Rotigotine 4.5mg/10cm^2 patch applied for 24 hours
1841266|NCT00887328|Drug|Tissue Plasminogen Activator (Alteplase)|0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
1841364|NCT00888745|Drug|PRO283698|Intravenous and subcutaneous ascending dose
1841269|NCT00887341|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 infusions; each infusion 1h duration
1841270|NCT00887354|Drug|Teriparatide|Administered subcutaneously
1841271|NCT00887354|Drug|Risedronate|Administered orally
1841272|NCT00887354|Drug|Placebo|"Weekly: Administered orally
Daily: Administered subcutaneously"
1841273|NCT00887354|Dietary Supplement|Calcium|Approximately 500 to 1000 mg/day administered orally throughout study.
1841274|NCT00887354|Dietary Supplement|Vitamin D|Approximately 800 International Units per day (IU/day) administered orally throughout study.
1841275|NCT00887367|Drug|GSK598809|Two 175 mg doses of GSK598809 will be given.
1841276|NCT00887367|Other|Ethanol|A constant ethanol level of 0.6 g·L-1 for five hours will be given to the subjects intravenously. This level shows significant CNS effects, without causing too many inadvertent events. Furthermore this level is considered safe as it is just above the legal driving limit in the Netherlands (i.e. 0.5 g·L-1) and these levels are routinely achieved during social drinking. Moreover, this level leaves enough room for CNS-impairment without compromising safety, in case of a (supra-) addictive drug-alcohol interaction.
1841277|NCT00887380|Drug|Pre-radiotherapy commencement of anastrozole|Anastrozole: 1mg per day will be prescribed for 12 weeks. Commencing within 1 week of randomisation, to be administered from a min of 1 week before and a max of 4 weeks before commencement of radiotherapy and continued throughout radiotherapy. After 12 weeks administration of anastrozole according to trial regimen, anastrozole can be continued at the treating clinician's discretion and in accordance with the preference selected at the time of randomisation and stratification. The alternative options to long-term anastrozole are tamoxifen or cessation of anti-oestrogen therapy.
1841278|NCT00887380|Radiation|Radiotherapy|Radiotherapy must commence within 1 month of randomisation. Radiotherapy planning and treatment is as per the protocol.
1841279|NCT00887380|Drug|Post radiotherapy commencement of anastrozole|Anastrozole 1mg per day will be prescribed for 12 weeks after radiotherapy is completed. Anastrozole should commence within 1 week of the last fraction of radiotherapy and be continued for a total of 12 weeks. After 12 weeks administration according to the trial regimen, any subsequent hormone therapy is as for the concurrent arm.
1841280|NCT00887393|Other|low carbohydrate diet|1000 to 1200 kcalorie low carbohydrate diet (< 15% of total kcaloric intake)
1841281|NCT00887393|Other|low-fat diet|1000 to 1200 kcalorie low-fat diet (30% fat, 60% carbohydrates of total kcaloric intake)
1841282|NCT00887406|Drug|GSK961081 15mcg SD|Single dose delivered via solution for nebulisation
1841283|NCT00887406|Drug|GSK961081 3mcg SD|single dose delivered via nebulsier
1841284|NCT00887406|Drug|GSK961081 50mcg SD|single dose delivered via solution for nebulisation
1841285|NCT00887406|Drug|Placebo SD|single dose via nebuliser
1841286|NCT00887406|Drug|GSK961081 100mcg SD|single dose delivered via solution for nebulisation
1841287|NCT00887406|Drug|GSK961081 200mcg SD|single dose via nebuliser
1841288|NCT00887406|Drug|GSK961081 300mcg SD|single dose via nebuliser
1841289|NCT00887406|Drug|GSK961081 100mcg RD|repeat dose via nebuliser
1841290|NCT00887406|Drug|GSK961081 300mcg RD|repeat dose vai nebuliser
1841291|NCT00887406|Drug|Placebo RD|repeat dose via nebuliser
1841292|NCT00887419|Behavioral|Coping Skills Training|Patients meet individually with therapist for 6 sessions to learn coping skills for stress management, behavioral activation, and communication.
1841293|NCT00887419|Behavioral|Education|Patients meet individually with a health educator for 6 sessions in a presentation/discussion format to receive basic information on the etiology and treatment of chronic pain.
1841300|NCT00887445|Drug|SLV341|5 - 1000mg once daily
1841301|NCT00887445|Drug|placebo|
1841304|NCT00887471|Procedure|PITA or T&A|PITA - Microdebrider-assisted Partial Intracapsular Tonsillectomy and Adenoidectomy T&A - Bove Electrocautery Complete Tonsillectomy and Adenoidectomy
1841305|NCT00887484|Drug|BENZOYL PEROXIDE/ CLINDAMYCIN|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
1841306|NCT00887484|Drug|BENZOYL PEROXIDE/ ADAPALENE|Commencing at baseline, subjects will apply once daily both treatment arm #1 and treatment arm #2 in a bilateral split-face fashion (allocation to left and right side randomly assigned) for an initial 2 weeks. At 2 weeks, subjects will apply benzoyl peroxide/clindamycin gel to the entire face for an additional 6 weeks.
1841307|NCT00887497|Procedure|Angioembolization|Angioembolization
1841310|NCT00887523|Behavioral|radiation in prone position|radiation in prone position
1841311|NCT00887523|Behavioral|radiation in supine position|radiation in supine position
1841312|NCT00887536|Drug|bevacizumab|bevacizumab 15 mg/kg IV every 21 days for 6 cycles followed by bevacizumab 15 mg/kg IV every 21 days until 1 year following the first dose of bevacizumab
1841313|NCT00887536|Drug|docetaxel|docetaxel 75 mg/m2 IV every 21 days for 6 cycles
1841314|NCT00887536|Drug|doxorubicin|doxorubicin 50 mg/m2 IV every 21 days for 6 cycles
1841315|NCT00887536|Drug|cyclophosphamide|"Group 1: cyclophosphamide 500 mg/m2 IV every 21 days for 6 cycles
Group 2 and 3: cyclophosphamide 600 mg/m2 IV every 21 days for 6 cycles"
1841316|NCT00887536|Drug|pegfilgrastim|pegfilgrastim 6 mg subcutaneous (SC) Day 2 every 21 days for 6 cycles [filgrastim (Neupogen®) 5 mcg/kg Days 2-10 may be given in lieu of pegfilgrastim (Neulasta®), but pegfilgrastim is preferred.]
1841317|NCT00887549|Drug|pemetrexed|Induction Therapy: 500 milligrams per square meter (mg/m^2), intravenous, day 1 of each 21 day cycle for the first 4 cycles; Maintenance Therapy: 500 milligrams per square meter (mg/m^2), intravenous, day 1 of each 21 day cycle until progression or unacceptable toxicity occurs
1841318|NCT00887549|Drug|cisplatin|Induction Therapy: 75 mg/m^2, intravenous, day 1 of each 21 day cycle for the first 4 cycles
1841319|NCT00887562|Drug|Idebenone|900 mg/day for 1 month
1841320|NCT00887562|Drug|Idebenone|2250 mg/day for 1 month
1841321|NCT00887562|Other|Placebo|Placebo - No idebenone
1841322|NCT00887575|Drug|Paclitaxel|IV infusion per institutional guidelines on Days 1, 8 and 15 of a 28 day cycle as follows depending on dose level (DL): DL1- 70 mg/m2, DL2- 80 mg/m2, DL3- 80mg/m2, DL4- 80mg/m2, DL-1- 70mg/m2, DL-2- 60mg/m2
1841323|NCT00887575|Drug|Carboplatin|IV infusion per institutional guidelines Day 1 of a 28 day cycle as follows depending on dose level (DL): DL1- AUC=5, DL2- AUC=5, DL3- AUC=6, DL4- AUC=6, DL-1- AUC=4, DL-2- AUC=4
1841324|NCT00887575|Drug|Sunitinib|By mouth (PO) once daily on days 1-21 of a 28 day cycle as follows depending on dose level (DL): DL1- 25mg, DL2-25mg, DL3- 25mg, DL4- 37.5mg, DL-1- 25mg, DL-2- 25mg. Maintenance therapy of 25mg daily
1841325|NCT00887588|Drug|LCZ696|50 mg, 100 mg and 200 mg tablets
1841326|NCT00887588|Drug|Valsartan|40 mg, 80 mg and 160 mg tablets
1841327|NCT00887588|Drug|Placebo|matching placebo to LCZ696 and Valsartan
1841328|NCT00887601|Drug|MK3134|Single dose 25 mg (5 x 5 mg) MK3134 capsules in one of the four treatment periods.
1841329|NCT00887601|Drug|Comparator: Placebo|Placebo capsules only in one of the four treatment periods.
1841330|NCT00887601|Drug|Donepezil|Single dose 5 mg donepezil capsules in two of the four treatment periods.
1841331|NCT00887601|Drug|MK3134|Single doses of 1 mg, 5 mg, or 25 mg MK3134 capsules in the assigned treatment periods
1841332|NCT00887614|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
1841333|NCT00887627|Drug|conivaptan hydrochloride|intravenous
1841334|NCT00887640|Drug|Temsirolimus|dosage form: IV dosage, frequency and duration: 25mg weekly until clinical progression
1841335|NCT00887640|Drug|Diphenhydramine|Dosage form: IV or PO Dosage, frequency and duration: 25-50mg, 30 minutes prior to Temsirolimus infusion
1841336|NCT00887653|Drug|raltegravir|This will be a single arm study where subjects will be given the option to switch from their current regimen to raltegravir at 400mg twice daily.
1841337|NCT00888550|Procedure|Post-Op Splinting|Splint will applied post-operatively and will remain on for two weeks
1841338|NCT00888550|Procedure|No Splinting|Patient will be discharged post-operatively without a splint on their lower leg.
1841339|NCT00888602|Dietary Supplement|3.4 g psyllium|3.4 g psyllium served with meal
1841340|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium served with a meal
1841341|NCT00888602|Dietary Supplement|6.8 g psyllium|6.8 g psyllium
1841342|NCT00888602|Other|Meal|meal
1841343|NCT00888615|Drug|Elesclomol Sodium|Given IV
1841344|NCT00888615|Drug|Paclitaxel|Given IV
1841347|NCT00888641|Procedure|Hypothermia|Surround kidney in ice slush for 10 minutes after arterial clamping
1841348|NCT00888654|Drug|B-Dim|B-DIM 225 mg orally twice daily x 14-72 days (based on scheduling of surgery)
1841349|NCT00888654|Procedure|Radical Prosatectomy|
1841350|NCT00888667|Other|Pacing interventions|10 seconds recording of atrial paced rhythm at 100 ppm in sitting 10 seconds recording of atrial paced rhythm at 150 ppm in supine 10 seconds recording of atrial paced rhythm at 150 ppm in sitting
1841351|NCT00888680|Drug|BGC20-1531|BGC20-1531 administered orally
1841352|NCT00888680|Drug|Lactose|Placebo administered orally
1841353|NCT00888693|Drug|ABT-288|See Arm Description for details.
1841354|NCT00888693|Drug|Placebo|See Arm Description for details.
1841355|NCT00888706|Behavioral|Control Condition|The group participated in the usual nursing home activities and routines.
1841356|NCT00888706|Behavioral|Individualized Social Activities (ISA)|The group received individualized social activities one hour daily, during usual brief daytime napping episodes, between 9 am to 5 pm in brief 15-30 minute intervals five days a week.
1841357|NCT00888706|Behavioral|Physical Resistance Training and Walking (PRT/walking)|The group participated in high intensity PRT to the hip and arm extensors (three sets of eight repetitions per muscle per group, approximately 40 minutes) plus 10 minutes of warm-up and 10 minutes of cool-down on Monday, Wednesday and Friday afternoons for one hour (between 2-5pm). On Tuesdays and Thursdays, participants walked with a research assistant for as long as the participant could walk for up to 60 minutes.
1841358|NCT00888706|Behavioral|Combined ISA/PRT/walking|The group had one hour of ISA in the morning or afternoon and one hour of PRT/walking in the afternoon from 2-5pm five days a week. This group received interventions for 2 hours per day.
1841359|NCT00888719|Drug|CWP-0403 100mg|100mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
1841360|NCT00888719|Drug|placebo|"Tablet not containing CWP-0403 and indistinguishable from CWP-0403 50mg, 100mg tablets.
Twice a day, 1 tablet at a time for 12 weeks"
1841361|NCT00888719|Drug|CWP-0403 50mg|50mg/tablet, Twice a day, 1 tablet at a time for 12 weeks
1841362|NCT00888732|Drug|Insulin Aspart, BIAsp 70, BIAsp50, Human Insulin|0.2 U/IU/kg subcutaneous injection, single dose
1841363|NCT00888745|Drug|placebo|Intravenous and subcutaneous ascending dose
1841366|NCT00888758|Device|everolimus|200 patients with STEMI will be treated with PROMUS DES.
1841367|NCT00888784|Procedure|Endoscopic Cyanoacrylate injection|Endoscopic Cyanoacrylate injection in gastric varix
1841368|NCT00888784|Drug|beta-blocker (propranolol)|Propranolol was started at a dose of 20 mg twice daily. The principle of incremental dosing was used to achieve the target heart rate for propranolol. The dose was increased every alternate day to achieve a target heart rate of 55/min or to the maximal dose to 360 mg/day if the medication was well tolerated and the systolic blood pressure was >90 mm Hg. On the occurrence of intolerable adverse effects, systolic blood pressure <90 mm Hg or pulse rate <55/min, the dose of the medication was decreased step-wise, and eventually stopped if these adverse events persisted. Reintroduction of the medication was attempted if cessation of the medication did not result in improvement of the reported side-effect.
1841369|NCT00888797|Drug|Propranolol and Etodolac|Both study medications will be given orally for an intervention phase of 20 days as follows: 5 days prior to surgery, on the day of surgery, and 14 days postoperatively. Etodolac:800 mg PO bid for the entire intervention period,Propranolol:20 mg PO bid for 5 preoperative days, 80 mg PO bid on the day of surgery, 40 mg PO bid for the first postoperative week, 20 mg PO bid for the second postoperative week.
1841370|NCT00888810|Drug|TOPOTECAN|IV administration on Day 1, day 8 and day 15, at the dose level of 3.2 mg/m² for 6 cycles of 28 days(up to 8 cycles)
1841371|NCT00888810|Drug|LAPATINIB|Daily oral administration during all the study. 1250 mg/day
1841372|NCT00888823|Radiation|Stereotactic Radiotherapy|Stereotactic Radiotherapy
1841373|NCT00888836|Procedure|Gastric bypass|Gastric bypass (GBP): A subcardial gastric pouch with a 30±10 ml capacity will be created on a naso-gastric 36F calibrating tube by sectioning the stomach with a linear stapler 3-4 cm horizontally on the lesser curve, 4 cm distal to the e-g junction, and then vertically until attainment of the angle of Hiss. After identification of the Treitz ligament, the jejunum will be transected at 100 cm from the ligament of Treitz and the two stumps will be closed. The distal stump will be anastomosed to the distal end of the gastric pouch. The preferred gastro-jejunal anastomosis is the totally hand-sewn one, but it can be performed using any other the technique the surgeon is more familiar with. Finally, the proximal stump of the transacted bowel will be joined end-to-side to the jejunum 150 cm distal to the gastroenterostomy.
1841374|NCT00888836|Procedure|Bilio-pancreatic diversion|Biliopancreatic diversion (BPD): A distal two-third gastrectomy will be carried out aiming at leaving an about 400 ml gastric remnant. The gastrointestinal continuity will be re-established by sectioning the small bowel 300 cm proximal to the ileocecal valve, closing the intestinal stumps, and joining the proximal one end-to-side to the distal ileum at 50 cm from the ligament of Treitz. The distal stump of the transacted bowel will be anastomosed to the left corner of the gastric stump, preferably in a totally hand-sewn fashion.
1841375|NCT00888836|Behavioral|anti-diabetic drugs and behavioral suggestions|Medical therapies (oral hypoglycemic agents and insulin) are optimized on an individual basis. Lifestyle modification programs, including reduced energy and fat (<30% total fat and <10% saturated fat, high fibre content) intake and increased physical exercise (suggested at least 30 minutes of brisk walking every day possibly associated with a moderate intensity aerobic activity twice a week), are tailor made by an experienced diabetologist assisted by a dietitian. After the two years, the patients in control group will be offered the choice to undergo one of the two surgical procedures.
1841376|NCT00888849|Procedure|Advant 55 Linear Cutter/Stapler|Advant 55 Linear Cutter/Stapler
1841377|NCT00888849|Procedure|Suturing|Suturing
1841378|NCT00888862|Drug|Desvenlafaxine Succinate|Desvenlafaxine Succinate, 50-100mg/day for 8 weeks
1841379|NCT00888875|Device|i-gel|insertion after induction of anaesthesia. Afterwards, intubation over the device fiberoptically
1841380|NCT00888875|Device|ILMA|Insertion after Induction. Insertion of tracheal tube over device
1841381|NCT00888888|Procedure|Right hemicolectomy with or without primary anastomosis|During open classic appendectomy (McBurney incision) the surgeon decided to convert to midline extended laparotomy to perform a right hemicolectomy
1841384|NCT00888914|Drug|RT001|RT001
1841385|NCT00888914|Drug|RT001|RT001
1841386|NCT00888914|Drug|RT001|RT001
1841387|NCT00888914|Drug|RT001|RT001
1841388|NCT00888914|Other|Vehicle Comparator|Vehicle Comparator
1841389|NCT00888927|Biological|KW-0761|The starting dose will be 0.1 mg/kg administered i.v. once every week for four weeks, followed by a 2-week observation period in the first treatment course. Succeeding dose levels will include 0.3 and 1 mg/kg. If a subject has demonstrated an overall CR, may continue on study for up to an additional four infusions beyond CR on an every other week infusion schedule. If a subject experiences a PR or SD, the subject may continue therapy on an every other week infusion schedule until disease progression occurs or other withdrawal criteria are met.
1841390|NCT00888940|Drug|Ecallantide|2.25 mg/L pump prime, 0.13 mg/kg loading dose, 2.25 mg/L constant infusion
1841391|NCT00888940|Drug|Cyklokapron(R)|1000-mg loading dose followed by a continuous infusion of 400 mg/hr with an additional 500 mg added to the pump prime
1841392|NCT00888953|Other|Fall risk assessment|Assessment of presence of risk factors (previous falls, self efficacy, balance and gait disorders, weakness, daily living impairment, limb pain, foot problems, dizziness, cognitive impairment, vision impairment, depression, urinary incontinence, heart disease, polimedication and consumption of neuroleptics and psychotropic medication)
1841393|NCT00888953|Other|Tailored intervention|Induction of an intervention for each identified risk factor. If is possible the intervention will be directed towards the treatment of the underlying cause.
1841394|NCT00888979|Drug|Nicotrol Inhaler|10 mg of nicotine per one inhaler cartridge. Inhaler use will substitute the usual smoking pattern
1841395|NCT00888992|Behavioral|Quitline Service + 10 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 10 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be two calls per a week for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
1841396|NCT00888992|Behavioral|Quitline service + 20 automated monitoring calls|This group will receive the usual care provided in Alere Wellbeing's Quit For Life® program. The program includes 5 telephone counseling calls. In addition, participants receive 20 automated telephone monitoring calls to help them stay off cigarettes. The automated call schedule will be one automated call a day for 2 weeks, then once a week for 6 weeks. Participants whose answers indicate that they may be having trouble quitting smoking will be automatically connected to a Quit Coach for individualized relapse prevention counseling.
1841398|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 560 mg/m2 (18.6 mg/kg for children £36 months old). .
1841399|NCT00889018|Drug|carboplatin|Table. 1: Chemotherapy protocol Vincristine Etoposide Carboplatin Day1 + + + Day2 ---- + ---- This regimen is repeated once a month for 6 months.Dose:Vincristine: 1.5 mg/m2 (0.05 mg/kg for children £36 months old and maximum dose 2 mg).Etoposide: 150 mg/m2 (5 mg/kg for children £36 months old).Carboplatin: 750 mg/m2 (25 mg/kg for children £36 months old).
1841400|NCT00889031|Other|No Intervention|Patients with Chronic Lymphocytic Leukemia (CLL)
1841401|NCT00889044|Drug|clopidogrel by chewing|600 mg clopidogrel by chewing
1841402|NCT00889044|Drug|Placebo|Placebo p.o
1841403|NCT00889057|Drug|sorafenib|400 mg bid until progression or inacceptable toxicity
1841404|NCT00889096|Drug|propranolol|Oral administration of 80 mg propranolol (1 gelatine capsules; content: 2 tablets of Obsidan® 40 mg Tablets) or placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
1841405|NCT00889096|Drug|placebo|Oral administration of placebo (1 gelatine capsules; content: 1 tablet placebo; microcrystalline cellulose, magnesium stearate, cellulose powder, lactose monohydrate) according to randomization list with 240 ml tap water.
1841406|NCT00889109|Other|Three dimensional unrestricted arm movements|The subjects will carry out three dimensional unrestricted arm movements. The subjects' movements will be recorded by optoelectronic infrared cameras and software. Assessment of smoothness parameters of subjects' movements will allow discriminating between subjects with intact or impaired proprioception.
1841407|NCT00889122|Behavioral|Exergame (DDR)|Use of an active videogame vs. pedometers given to entire families to promote physical activity.
1841408|NCT00889135|Drug|droxidopa|Droxidopa (L-DOPS) comes in capsule form, 100 mg or 200 mg strength and is usually administered 2 - 3 times per day. It would be taken indefinitely to improve symptoms of orthostatic hypotension
1841409|NCT00889148|Drug|Gabapentin|600mg gabapentin given 2 hrs preoperatively and 200mg three times a day after surgery for 3 days
1841410|NCT00889148|Other|Placebo|Half the patients will be randomized to placebo
1841411|NCT00889161|Drug|Curcumin|Initial dosage of 500mg twice a day for 3 weeks. Using the forced dose titration design, dose will be titrated up to 1g twice a day at Week 3 for a total of three weeks and then titrated again to 2g twice a day at Week 6 for three weeks.
1841412|NCT00889187|Radiation|Neoadjuvant Short-Course Photon Radiation|
1841413|NCT00889187|Drug|Capecitabine|
1841414|NCT00889200|Drug|eszopiclone|6 weeks standard oral therapy
1841415|NCT00889213|Procedure|Falciform patch and fibrin glue application|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament. Those patients randomized to autologous falciform patch will have the falciform membrane harvested. The falciform patch will be laid over the suture line of the resected pancreatic stump and secured to the pancreatic capsule utilizing #4-0 PDS suture placed at 12, 3, 6, and 9 o'clock positions. Fibrin glue (Vitagel) will be utilized to fill the potential space within this membranous capsule. Fibrin glue will be prepared as per standard instructions. Drains will be placed in the splenic bed and/or adjacent to the stump of the pancreas for postoperative fluid evacuation.
1841416|NCT00889213|Procedure|standard pancreatic closure|Following standard surgical exploration, the pancreatic gland will be mobilized appropriately to the level of transaction in the pancreatic neck, body or tail. The gland may be divided by stapling device, electrocautery or sharp division. Suture material will be at the discretion of the surgeon but may include absorbable or non-absorbable braided on mono-filament.
1841417|NCT00889226|Drug|Pitavastatin|Drug: Pitavastatin 2mg daily for 8wks after initial visit. After assessment of LDL-C <100mg/dL at 8wks → Dose adjustment Yes → 2mg daily for second 8wks No → 4mg daily for second 8wks
1841418|NCT00889226|Drug|Atorvastatin|Drug: Atorvastatin 10mg daily for 8wks after initial visit. After assessment of LDL-C <100mg/dL at 8wks → Dose adjustment Yes → 10mg daily for second 8wks No → 20mg daily for second 8wks
1841419|NCT00889239|Other|lithia-disilicate-based crown|all-ceramic crown
1841420|NCT00889252|Device|contact lens with ketotifen|K-Lens (generic name not established) and Ketotifen combination drug-device product
1841421|NCT00889252|Device|contact lens|Placebo contact lens
1841422|NCT00889265|Device|CopiOs Pericardium Membrane|CopiOs Pericardium, Puros Cancellous
1841423|NCT00889304|Device|Position HTO system|open wedge high tibial osteotomy
1841424|NCT00889317|Device|fmri (functional magnetic resonance imaging)|functional image acquisition (75mn) anatomical image acquisition (15mn)
1841425|NCT00889330|Drug|alcaftadine|0.25% Ophthalmic Solution, one drop in each eye at each of two visits.
1841426|NCT00889330|Drug|Placebo|Vehicle without active, one drop in each eye at each of two visits.
1841427|NCT00889343|Drug|Sorafenib|2x200 mg filmcoated tablets BID on day 2-12 of a 14-days cycle, oral
1841428|NCT00889343|Drug|Placebo|2 filmcoated tablets BID, day 2-12 of a 14-days cycle, oral
1841429|NCT00889343|Drug|Oxaliplatin or Irinotecan|Oxaliplatin 100 mg/m2 intravenous infusion on day 1 of 14-days cycle, Irinotecan 180 mg/m2 intravenous infusion on day 1 of 14-days cycle
1841430|NCT00889343|Drug|Leucovorin|400 mg/m2 intravenous infusion on day 1 of a 14-days cycle
1841431|NCT00889343|Drug|5-Fluorouracil|400 mg/m2 intravenous bolus infusion on day 1, 2400 mg/m2 46 hour intravenous infusion on day 1 to 2 of a 14-days cycle
1841432|NCT00889356|Drug|Clindamycin 100mg and Ketoconazole 400mg|1 vaginal capsule once a day at night
1841433|NCT00889356|Drug|Tetracycline 100mg and Amphotericin B 50mg|One full applicator, once a day at night
1841434|NCT00889369|Drug|Duloxetine|Duloxetine, flexible dose, 60-120mg/per day for 8 weeks, following a 2-week placebo lead-in phase to determine study eligibility
1841435|NCT00889382|Drug|OSI-906|Administered orally
1841436|NCT00889382|Drug|Paclitaxel|Administered intravenously
1841437|NCT00889395|Behavioral|MISC training for primary caregivers|Caregivers of children in the intervention arm will undergo a year long training in MISC
1841438|NCT00889408|Biological|DT2219ARL|anti-CD19/CD22 bispecific ligand-directed toxin DT2219ARL
1841439|NCT00889421|Drug|Apremilast|oral dose of 30 mg BID for 6 months
1841440|NCT00889434|Dietary Supplement|ECGC|1 cycle will comprise 28 days of continuous daily treatment with EGCG given once/day(total 375 mg) /day in the morning with food followed by a 14 day wash out period without drug.
1841441|NCT00889434|Dietary Supplement|Tocotrienol|One cycle will comprise 28 days of continuous daily treatment with Tocotrienol given 2 times/6 soft gel capsules (total 600 mg) /day (BID) in the morning and in the evening with food followed by a 14 day wash out period without drug.
1841442|NCT00889434|Dietary Supplement|EGCG + Tocotrienol|combination of both arms 375 mg EGCG + 600mg/day Tocotrienol
1841443|NCT00889460|Biological|rBet v 1|Two tablets (1 placebo + 1 rBet v 1 or 2 rBet v 1) were administered every day over 2 weeks with a 2-day break for the week-end. Administered doses ranged from 12.5 to 100 µg rBet v 1.
1841444|NCT00889460|Biological|Placebo|Two matching placebo tablets were administered every day over 2 weeks with a 2-day break for the week-end.
1841445|NCT00889473|Drug|Larazotide acetate|gelatin capsule
1841446|NCT00889473|Drug|Placebo|gelatin capsule
1841447|NCT00889473|Dietary Supplement|Gluten 900 mg|gelatin capsule
1841448|NCT00889486|Drug|TZP-102|
1841449|NCT00889486|Drug|Placebo|
1841450|NCT00889499|Drug|Tropisetron 2 mg|Antagonist of the 5HT3 receptor.
1841451|NCT00889499|Drug|Tropisetron 5mg|Antagonist of the 5HT3 receptor.
1841452|NCT00889499|Drug|Placebo|NHCL 0,9%
1841453|NCT00889512|Drug|Luveris fixed dose|Luveris 75IU daily throughout ovarian stimulation
1841454|NCT00889512|Drug|Luveris increasing dose|Luveris 75IU until estradiol level reaches 250 pg/ml then increasing to 75IU BID for two days, then TID until hCG
1841455|NCT00889525|Drug|Cabergoline|Dose 1 mg/week in divided doses, increased by 1 mg/week every month, to the maximum of 5 mg/week. If response is seen than the dose at which response is seen is continued until the end of the study.
1841456|NCT00889538|Drug|placebo|50 mL of 1/2 normal saline IV
1841457|NCT00889538|Drug|glutathione|glutathione 600 mg IV
1841458|NCT00889538|Drug|glutathione, vit C and NAC|Glutathione 600 mg IV Vitamin C 2000 mg IV N-acetylcysteine 20 mg/kg IV (max dose = 600 mg) Mix above three in 1/2 NS for a total volume of 50 mL
1841459|NCT00889564|Device|HeRO Vascular Access Device|Long-term subcutaneous vascular access device for hemodialysis
1841460|NCT00889590|Drug|Zoledronic acid|4 mg, monthly for 3 months followed by a 3-monthly schedule for up to one year after surgery
1841461|NCT00889603|Drug|Aricept® Evess|"5 mg film-coated orodispersible tablets, 10 mg film-coated orodispersible tablets.
Treatment may be started with 5 mg donepezil/ day (once-a-day dosing) and after four weeks can be titrated to 10 mg/day (once-a-day dosing)."
1841462|NCT00889616|Drug|BSAM2/Alhydrogel + CPG 7909|
1841463|NCT00889629|Drug|Doxercalciferol|1 mcg qd then uptitrated as specified in protocol
1841464|NCT00889629|Drug|placebo|placebo of doxercalciferol
1841467|NCT00889655|Drug|Golytely (polyethylene glycol)|4 L of golytely, in split dosing. If the patient has a morning colonoscopy, they will take 2 L of golytely over 2 hours the morning prior to their procedure and repeat this at 6 pm the night prior to their procedure.
1841468|NCT00889655|Drug|MiraLax (polyethylene glycol 3350)|238 gm of MiraLax mixed in 64 oz of Gatorade, to be consumed in split dosing the day prior to scheduled colonoscopy.
1841469|NCT00889668|Device|GlucoTrack|comparison of different glucose monitoring devices
1841470|NCT00889681|Device|Arctic Front Cardiac Cryoablation System|The CryoCath Arctic Front® Cardiac CryoAblation Catheter System, including the Freezor MAX Cardiac Cryoablation Catheter, is indicated for the treatment of patients with paroxysmal atrial fibrillation to reduce the likelihood of subsequent detectable atrial fibrillation.
1841471|NCT00889694|Drug|Tripterygium|Tripterygium: 2 capsules per time, 3 times per day for 12 weeks.
1841472|NCT00889694|Drug|Sulfasalazine|Sulfasalazine: 0.75 gram per time, 2 times per day for 12 weeks.
1841473|NCT00889694|Drug|placebo|Placebo: 2 capsules per time, 3 times per day for 12 weeks.
1841474|NCT00889707|Drug|PRX302|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
1841475|NCT00889707|Drug|Placebo|PRX302 will be administered at a volume equivalent to 20% of the prostate volume and at a fixed concentration. Treatment will be administered through 1 injection into the transition zone of each lobe of the prostate. A minimum of 2 deposits will be made in the transition zone into each of the right and left lobes of the prostate, with a minimum of 1.0 mL per deposit.
1841476|NCT00889720|Drug|Varenicline|Varenicline film coated tablets - escalating dose with maximum dose of 1mg bd
1841477|NCT00889733|Drug|Intraperitoneal (IP) Cisplatin|For patients who have had neoadjuvant chemotherapy followed by optimal debulking surgery they go on to receive combined IP Cisplatin and IV Paclitaxel.
1841516|NCT00890149|Drug|Ondansetron + BASICS Plus|Ondansetron (4ug/kg bid), Brief Alcohol Screening and Intervention for College Students
1841517|NCT00890149|Drug|Placebo + BASICS Plus|Placebo bid, Brief Alcohol Screening and Intervention for College Students
1841478|NCT00889785|Behavioral|Comprehensive intervention (disease management program)|The intervention will include participation in a comprehensive disease management program that includes: (1) application of treatment algorithms, (2) phone assessment from a diabetes nurse practitioner and dietician to assess barriers and promote problem solving, treatment adherence and management, and (3) a behavioral Internet-administered self-management problem solving component.
1841479|NCT00889785|Behavioral|Usual Care|Will receive usual care and monthly phone calls as an active control.
1841480|NCT00889811|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min lower limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis )
1841481|NCT00889824|Device|balance prosthesis|vibrotactile stimulation
1841482|NCT00889837|Drug|Inhaled Loxapine|Staccato Loxapine, 10 mg x 2 doses, 10 hours apart
1841483|NCT00889837|Drug|Inhaled Placebo|Staccato Placebo, inhalations x 2 , 10 hours apart
1841484|NCT00889850|Drug|40 mg Esomeprazole Mepha (Mepha Ltd., Switzerland)|40 mg esomeprazole, single dose administration under fasted and fed condition
1841485|NCT00889850|Drug|INexium 40 mg MUPS tablets (AstraZeneca, France)|40 mg esomeprazole, oral single dose administration under fasted and fed condition
1841486|NCT00889863|Drug|canakinumab|Canakinumab 4 mg/kg dose subcutaneous injection supplied as 6 mL glass vials each containing 150 mg canakinumab as a lyophilized cake.
1841487|NCT00889863|Drug|placebo|Placebo powder matching canakinumab supplied as 6 mL glass vials containing a lyophilized cake for subcutaneous injection every 4 weeks in Part II.
1841488|NCT00889876|Drug|Metformin group|2000 mg/day for one year
1841489|NCT00889876|Behavioral|Exercise|3 times/week with a personal coach for one year. Endurance training.
1841490|NCT00889889|Biological|Cell-Derived Trivalent Subunit Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
1841491|NCT00889889|Biological|Placebo|Placebo
1841492|NCT00889915|Drug|Methylphenidate transdermal system|Not specified in protocol; determined by local standard of care.
1841493|NCT00889915|Drug|Lisdexamfetamine dimesylate|Not specified in protocol; determined by local standard of care.
1841494|NCT00889915|Drug|Osmotic-release oral system methylphenidate (OROS MPH)|Not specified in protocol; determined by local standard of care.
1841495|NCT00889915|Drug|Mixed amphetamine salts extended release|Not specified in protocol; determined by local standard of care.
1841496|NCT00889928|Device|NOTES GEN 1 Toolbox|"Articulating Hook Knife
Articulating Snare
Articulating Needle Knife
Articulating Graspers
Articulating Biopsy Forceps
Steerable Flex Trocar with Rotary Access Needle
Flexible Bipolar Hemostasis Forceps
Flexible Maryland Dissector"
1841497|NCT00889941|Procedure|LASIK|laser-assisted in situ keratomileusis
1841498|NCT00889954|Biological|TGFBeta resistant HER2/EBV-CTLs|"Each patient will receive one injection of the TGFBeta resistant HER2/EBV-specific CTLs. Each pt will be followed for 6 weeks after the CTL infusion for evaluation of dose limiting toxicity (DLT).
Patients may receive up to six additional doses of the T cells at 6 to 12 weeks intervals."
1841499|NCT00889967|Drug|Ciprofloxacin for Inhalation|100 mg once daily by inhalation for 28 days
1841500|NCT00889967|Drug|Ciprofloxacin for Inhalation|150 mg once daily by inhalation for 28 days
1841501|NCT00889967|Drug|Placebo|Placebo once daily by inhalation for 28 days
1841502|NCT00889980|Other|Biospecimen banking|SLN and one non-SLN (8mm and larger in longest dimension). fourteen 10cc tubes or a total of 140mL of blood will be collected from subjects weighing over 102.6 pounds. If the subject weighs less than 102.6 pounds, the amount of blood drawn will be based on exact body weight. The amount of blood drawn will be no more than 3mL/kg of body weight.
1841503|NCT00889993|Dietary Supplement|Mixed Fiber Supplement|Breakfast Muffin containing 0g, 4g, 8g, and 12g of mixed fiber (total fiber amount as listed).
1841504|NCT00890006|Procedure|Advanced imaging for radiotherapy planning and guidance|Integration of MRI in the treatment planning process / Integration of daily cone-beam computed tomography (CBCT)
1841505|NCT00890019|Biological|AdCh63 ME-TRAP|"A:Intradermal injection 1x10^8 vp at day 0
A:Intradermal injection 1x10^9 vp at day 0
A:Intradermal injection 1x10^10 vp at day 0
A:Intradermal injection 5x10^10 vp at day 0
5:Intramuscular injection 1x10^10 vp at day 0
6A:Intramuscular injection 5x10^10 vp at day 0
7A: Intramuscular injection 2x10^11 vp at day 0"
1841506|NCT00890019|Biological|AdCh63 ME-TRAP; MVA ME-TRAP|"B: AdCh63 ME-TRAP intradermally at dose of 1x10^8 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
B: AdCh63 ME-TRAP intradermally at dose of 1x10^9 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
B: AdCh63 ME-TRAP intradermally at dose of 1x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
B: AdCh63 ME-TRAP intradermally at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
6B: AdCh63 ME-TRAP intramuscularly at dose of 5x10^10 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)
7B and 7C: AdCh63 ME-TRAP intramuscularly at dose of 2x10^11 vp at day 0; MVA ME-TRAP intradermally at dose of 2x10^8 pfu at day 56 (+/- 7 days)"
1841507|NCT00890032|Biological|BTSC mRNA-loaded DCs|An escalating total dose of BTSC mRNA-loaded DCs (2x10^6, 5x10^6, and 2x10^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
1841508|NCT00890045|Device|HeRO Vascular Access Device|HeRO Vascular Access Device
1841509|NCT00890045|Device|Conventional ePTFE hemodialysis graft|Conventional ePTFE hemodialysis graft
1841510|NCT00890071|Other|Fluid administration|500 ml of synthetic colloid (Voluven®, hydroxyethylstarch 6%; Fresenius, Bad Homburg, Germany) infused over 30 minutes
1841511|NCT00890084|Drug|Telmisartan or Telmisartan + Hydrochlorothiazide (HCTZ)|Telmisartan 40mg or 80mg +/- HCTZ 12.5mg or 25mg
1841512|NCT00890097|Drug|AL-8309B Ophthalmic Solution|
1841513|NCT00890097|Drug|AL-8309B Vehicle|Inactive ingredients used as placebo comparator
1841514|NCT00890110|Biological|Autologous renal cell vaccine based on DNP modified cells|Primary or metastatic tumor resected in an Israeli hospital will be used to derive autologous cell lines used for vaccinations following DNP modifications in combination with the regular Sunitinib treatments. Immunological and clinical followup of the patients will be performed
1841515|NCT00890123|Dietary Supplement|Omegaven-IV FO|Will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
1841521|NCT00890175|Drug|Inhaled loxapine @ 0 & 10 h|10 mg, 2 doses, 10 hours apart
1841522|NCT00890175|Drug|Inhaled placebo @ 2 & 10 hours|placebo, 2 doses, 10 hours apart
1841523|NCT00890188|Drug|THALIDOMIDE and UFUR|T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
1841524|NCT00890201|Procedure|Gallbladder bile sampling and intraoperative cholangiography|"Interventions were exactly similar for both groups, and that is how it was intended to be:
Gallbladder bile sampling: Sample 5 cc of gallbladder bile after the cystic duct has been clipped or ligated.
Intraoperative cholangiography: Perform cholangiography before the cholecystectomy is finished"
1841525|NCT00890214|Drug|prostacyclin|prostacyclin was infused as CRRT circuit anticoagulant into the arterial-line of the circuit at 4 ng/Kg/min
1841526|NCT00890214|Drug|heparin|was prepared using our standard protocol: 2 ml of an already-stored solution containing 5000 IU/ml of UFH were diluted in 20 ml of saline obtaining a final concentration of 500 IU/ml, and infused pre-filter at 6 IU/Kg/h, according to the post-filter activated clotting time measured hourly, and adjusted to obtain a value between 180 and 200 sec.
1841527|NCT00890227|Procedure|Traditional technique|All level open instrumented posterior spinal fusions
1841528|NCT00890227|Procedure|Minimally invasive technique|Open surgery for all the levels except the proximal segment (most proximal instrumented level) where minimally invasive technique will be used.
1841529|NCT00890240|Drug|JNJ-31001074|
1841530|NCT00890253|Drug|Basiliximab (Simulect)|20 mg basiliximab (Simulect) iv on day 0 and 4 after OLT
1841531|NCT00890253|Drug|Myfortic|1080 mg q12 EC-MPS (Myfortic) po starting within 24h after OLT
1841532|NCT00890253|Drug|everolimus|1 mg q12 everolimus (Certican) po starting on 10th post-operative day
1841533|NCT00890253|Drug|Prednisolone|Prednisolone 1mg per kg body weight starting within 24 hours after transplantation. Then q24 but with reduction by 5 mg every 48 hours until maintenance dose of 7.5 mg
1841534|NCT00890266|Procedure|Collagen cross-linking with hypotonic riboflavin|Topical anaesthesia, corneal epithelial debridement, application of hypotonic riboflavin 0.1% solution (20 minutes), application of UV light (30 minutes).
1841535|NCT00890279|Drug|Cilnidipine|Cilnidipine up to 20 mg
1841536|NCT00890279|Drug|Imidapril|Imidapril up to 10 mg per day
1841537|NCT00890292|Drug|JNJ-31001074|
1841538|NCT00890305|Drug|CT-011|
1841539|NCT00890305|Drug|FOLFOX|"FOLFOX-4: each cycle consists of the following: oxaliplatin 85 mg/m2 on Day 1, leucovorin 200 mg/m2/day on Day 1 and Day 2 followed by 5-FU 400 mg/m2 bolus and a 22 hour infusion of 5-FU 600 mg/m2 for two consecutive days.
mFOLFOX-6: each cycle consists of the following: oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 on Day 1, followed by 5-FU 400 mg/m2 bolus, followed by 5-FU 1200 mg/m2/day for two consecutive days (total 2,400 mg/m2 over 46-48 hours)."
1841540|NCT00890318|Drug|ABT-072|Powder contents from capsules mixed in an alternative vehicle, for additional information refer to Arm Description.
1841541|NCT00890318|Other|ketoconazole|Tablet, see Arm Description for intervention information.
1841542|NCT00890318|Drug|Placebo|Capsule or powder drug substance from the capsule mixed in an alternative vehicle, for additional information refer to Arm Description.
1841543|NCT00890331|Behavioral|TeamWork CS Sessions|The intervention focuses on an authoritative parenting approach that emphasizes continued parental involvement in daily disease care. Dyadic coping skills of communication, problem solving, conflict resolution, along with attitude and behavior change are highlighted. Families meet with a study interventionist in conjunction with four consecutive medical appointments.
1841544|NCT00890331|Behavioral|Diabetes Education|Diabetes Education The education comparison group meets with an educational interventionist in conjunction with four consecutive medical appointments. This group focuses on diabetes educational and resource support for parents and their youth with type 1 diabetes.
1841545|NCT00890370|Procedure|Airway clearance technique|
1841546|NCT00890383|Drug|tetrastarch (Voluven)|Goals directed volume therapy for severe trauma resuscitation
1841547|NCT00890409|Device|Cooling cap (YJW608-04B)|A semiconductor water circulation cooling device (YJW608-04B, Henyang Radio Manufactory, Hunan, China) was used to conduct head cooling. The hypothermia group was fitted with a cooling cap around the head for 72 hours. The temperature of the cap could be adjusted between 5 to 20 degree C and was automatically regulated by a servo-controlled temperature probe placed in the nasopharynx to maintain the nasopharyngeal temperature at (34±0.2)degree C. All infants were nursed under a servo-controlled radiant warmer and the rectal temperature was maintained at 34.5 to 35 degree C. Head cooling was started within 6 hours after birth for 72 hours followed by spontaneous re-warming and the average time to reach the target temperature was 2 hours.
1841548|NCT00890422|Biological|FSME vaccination (FSME-Immun)|intra muscular 0.5 ml
1841549|NCT00890435|Other|questionnaire administration|
1841550|NCT00890435|Procedure|psychosocial assessment and care|
1841551|NCT00890448|Other|Pharmacogenomic whole blood sampling|10 mL, whole blood, one sample on Visit 2
1841552|NCT00890461|Radiation|CT scan of the chest without contrast|Patients consenting to participate in the study may also undergo a baseline CT scan of the cest without contrast to allow for the geometrical characterization of their intracardiac electrodes from the ICD system in relation to the position of the 12-lead surface ECG electrodes which would be applied to the chest prior to the CT scan. This scan involves a small amount of radiation, a dose of approximately 1 rem. For comparison, radiation workers are permitted, by federal regulation, a maximum annual radiation exposure of 20 rems to the most sensitive organs of their body.
1841553|NCT00890474|Procedure|Moxibustion of the BL67 acupoint|Moxibustion sessions every day (every other day in hospital, self-administration at home the other day) during a maximum of 14 days. Stopped if cephalic version.
1841554|NCT00890487|Other|hyaluronic acid pill|pill, 220 mg, once a day, three months
1841555|NCT00890500|Drug|Fludarabine|30mg/m2/day IV x 6 days
1841556|NCT00890500|Drug|Melphalan|100 mg/m2/day IV x 1 day
1841557|NCT00890500|Drug|Antithymocyte Globulin|1mg/kg/day x 4 days
1841558|NCT00890500|Drug|Sirolimus|GVHD Prophylaxis: Target range 3-12 ng/ml
1841559|NCT00890500|Drug|Tacrolimus|GVHD Prophylaxis: Target range 5-10 ng/ml
1841679|NCT00879229|Drug|Ambrisentan|Ambrisentan (5 mg or 10 mg tablet) administered orally once daily.
1841680|NCT00879229|Drug|Placebo|Placebo to match ambrisentan administered orally once daily.
1841560|NCT00890526|Other|Sound Therapy (Tinnitus Retraining Therapy)|The conventional sound therapy will be achieved with commercially available noise generators. Our clinic uses General Hearing Instruments (OHI) model Tranquil devices as noise sources for TRT. These flexible devices offer an adjustable volume control, with a frequency response extending from ~500 to 8000 Hz. Matched devices will be fitted binaurally and adjusted to each individual ear to achieve audibility of the noise sources (assessed by slight threshold shifts. typically 10- 15 dB, across the audiometric frequency range above 500 Hz). The sound pressure level output and frequency response of each noise source will be measured and documented using both real ear and standard electroacoustic methodologies. Each subject will be carefully instructed as to care of the instruments and correct volume setting. The bilateral noise generators will be used chronically during the intervention period except during sleep.
1841561|NCT00890526|Other|Counseling (Tinnitus Retraining Therapy)|The directive counseling to be used will include an in-depth participatory discussion with the patient to review audiometric and functional test results, along with the anatomy and physiology of the auditory system. A minimum of two hours will be scheduled to impart this information to the patients so that they will have a clear understanding of the disorder based upon the most current scientific data. The counseling will be focused on educating the patient, neutralizing their negative emotional association with the hyperacusis, and discussing their treatment.
1841562|NCT00890526|Other|No Counseling|Patients who are enrolled in Arms 3 and 4 of this study will not be offered directive counseling, but will be fitted with either conventional or placebo noise generators for their sound therapy components. These patients will be told only that their treatment for hyperacusis uses sound therapy. Otherwise, in the instrument fitting appointment (either for the conventional instrument or the placebo device), these patients will receive the same instruction in the care and use of sound generators as those patients enrolled in Treatment Arms 1 and 2 of the clinical trial.
1841563|NCT00890526|Other|Placebo Sound Therapy|The placebo sound therapy will use factory-modified GHI Tranquil noise generators, which will appear identical to the conventional Tranquil devices. The placebo Tranquil devices will have a control sensor installed to detect insertion of the device in the ear canal. When the sensor detects the insertion of the placebo device into the ear canal it will trigger gradual decay of the sound output from the placebo device, The time constant of the decaying noise output will be sufficiently long to allow the clinician time to set the volume of each binaural set of devices and to instruct the patient in their use before any noticeable sound attenuation occurs.
1841564|NCT00890539|Drug|Methacholine challenge|Clinical and research test used in asthma
1841565|NCT00890552|Drug|Lenalidomide|"Lenalidomide is a a derivative of thalidomide.
Orally-administered lenalidomide 10 mg will be taken daily on days 1 to 21 of 28-day cycle."
1841566|NCT00890552|Drug|Melphalan|"Melphalan is a phenylalanine derivative of mechlorethamine.
Orally-administered melphalan 0.18 mg/kg will be taken on days 1 to 4 of a 28-day cycle"
1841567|NCT00890552|Drug|Dexamethasone|"Dexamethasone is an anti-inflammatory and immunosuppressant steroid medication.
Orally-administered dexamethasone 40 mg orally once weekly of a 28-day cycle"
1841568|NCT00890565|Drug|granisetron|Treatment A: Sancuso® patch (3.1mg/24 hours) on Day 1 and IV placebo (0.9% saline) on Day 3 Treatment B: Granisetron IV 10 mcg/kg over 30 seconds on Day 1 and placebo patch on Day 3 Treatment C: Placebo patch on Day 1 and IV placebo on Day 3 Treatment D: 400 mg oral moxifloxacin on Day 1 and placebo patch on Day 3
1841569|NCT00890578|Procedure|adhesive to suture|surgical closure
1841570|NCT00890591|Drug|olmesartan medoxomil + hydrochlorothiazide, if necessary + amlodipine, if necessary|olmesartan medoxomil tablets,or olmesartan medoxomil/hydrochlorothiazide tablets, if necessary + amlodipine tablets, if necessary. All interventions are once-daily for 4 to 9 weeks
1841571|NCT00890604|Drug|Acetaminophen|APAP 650mg q4h prn; RTC dosing
1841572|NCT00890604|Other|Usual Care|Care per attending physician discretion for fever management
1841573|NCT00890604|Drug|Ibuprofen|Ibuprofen 600mg q6h
1841574|NCT00890604|Other|Physical Cooling Measures|Fan, Ice Packs
1841575|NCT00890604|Device|Cooling Blanket|Water Circulating Cooling Blanket
1841576|NCT00890604|Device|Hydrogel Cooling Pads|Application to torso and extremities
1841577|NCT00890617|Procedure|Cryotherapy (PTC)|CT-guided PTC with the intent to eradicate the entire tumor(s).
1841578|NCT00890617|Drug|Prednisone|"Prednisone taken:
20mg BID on the day of the cryotherapy procedure 20mg BID on the day after the procedure 20mg BID two days after the procedure 20mg AM and 10mg PM three days after the procedure 10mg AM and 10mg PM four days after the procedure 10mg five days after the procedure 5mg six days after the procedure"
1841579|NCT00890630|Procedure|Intracervical Balloon Catheter|Intracervical insertion of an 80cc Double-Balloon Catheter.
1841580|NCT00890630|Drug|Oxytocin|IV Oxytocin infusion, dose dependent on patient response. Start at 2mIU/min, increasing every 30 minutes by 2mIU/min, to max 24mIU/min.
1841581|NCT00890643|Drug|prazosin hydrochloride|prazosin 1-20 mg/day in divided doses
1841582|NCT00890643|Drug|placebo|placebo
1841583|NCT00890656|Drug|Cyclophosphamide (CTX)|300 mg/m^2 by vein (IV) over 3 hours every 12 hours for 6 doses days 1, 2, 3 of
1841584|NCT00890656|Drug|Vincristine|2 mg by vein (IV) weekly for 3: Days 1, 8, 15
1841585|NCT00890656|Drug|Doxorubicin|50 mg/m^2 by vein (IV) over 24 hours
1841586|NCT00890656|Drug|Decadron|80 mg by vein (IV) or by mouth (P.O.) daily days 1-4 and 15-18
1841587|NCT00890656|Drug|G-CSF|10 mcg/kg/day (rounded) by vein (IV) or under the skin (subcutaneously) within 72 ± 48 hours
1841588|NCT00890656|Drug|Methotrexate (MTX)|200 mg/m2 by vein (IV) over 2 hours followed by 800 mg/m2 over 22 hours on day 1
1841589|NCT00890656|Drug|Ara-C|3 gm/m^2 by vein (IV) over 2 hours every 12 hours for 4 doses on days 2 and 3.
1841590|NCT00890656|Drug|Pegaspargase|2,500 units/m2 by vein (IV) on day 1 of odd courses and day 5 of even courses
1841591|NCT00890669|Other|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):
treadmill training with additional body load (A1),
control condition (conventional physical therapy group) (B). and
treadmill training with additional body load again (A2).
Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
1841592|NCT00890682|Drug|SKY0402|Local infiltration of 8cc SKY0402
1841593|NCT00890682|Drug|Placebo|Local infiltration of 8cc Placebo
1841594|NCT00890695|Dietary Supplement|Ready to use supplementary food (RUSF)|It is a strategy of detection of moderate malnutrition and providing advice and short term provision of a standard formulation of ready to use supplementary food (RUSF) for 4 weeks with appropriate counseling on its use.The amount supplied will be based on the child's weight; 100kcal per kg per day which is equivalent to 25g RUSF per kg per day.
1841595|NCT00890708|Drug|Voriconazole (therapeutic drug monitoring)|dosage adjustment according to trough level of voriconazole in plasma
1841596|NCT00890721|Drug|SKY0402|During the operation, 30cc of SKY0402 are injected into the wound.
1841597|NCT00890721|Drug|Placebo|During the hemorrhoidectomy, 30cc Placebo injected into the wound.
1841598|NCT00890734|Drug|CYT003-QbG10|subcutaneous injection
1841599|NCT00890734|Drug|Placebo|subcutaneous injection
1841600|NCT00890747|Drug|sunitinib malate|Given PO
1841601|NCT00890747|Other|pharmacological study|Correlative studies
1841602|NCT00890747|Other|laboratory biomarker analysis|Correlative studies
1841603|NCT00890760|Biological|AdCh63 ME-TRAP|5 x 10*10 vp IM
1841604|NCT00890760|Biological|MVA ME-TRAP|2 x 10*8 pfu ID
1841605|NCT00890760|Other|Sporozoite challenge|Infected mosquito bite
1841606|NCT00890760|Biological|Mixture of AdCh63 ME-TRAP and MVA ME-TRAP intramuscularly|AdCh63 ME-TRAP 5 x 10*10 vp MVA ME-TRAP 2 x 10*8 pfu
1841607|NCT00890786|Drug|Temozolomide|"High Grade Glioma Temozolomide during radiotherapy: 90mg/m2/day PO daily (for patients ≤ 18 years of age); 75mg/m2/day PO daily (for patients ≥ 19 years of age); must begin by Day 5 of radiotherapy for a total of 42 days consecutively.
High Grade Glioma Temozolomide during maintenance chemotherapy: 150mg/m2/day PO on Days 1-5."
1841608|NCT00890786|Drug|Bevacizumab|"High Grade Glioma Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Day 22 (± 2 days)and Day 36 (± 2 days) of radiotherapy.
High Grade Glioma Bevacizumab during maintenance chemotherapy:10 mg/kg as a 90 minute infusion on Day 1 (+ 2 days)and Day 15 (± 2 days) of each course.
Diffuse Intrinsic Pontine Gliomas Bevacizumab during radiotherapy: 10 mg/kg as a 90 minute infusion on Days 1 (+ 2 days),15, 29, and 43(±2 days for all 3 doses) of radiotherapy.
Diffuse Intrinsic Pontine Gliomas Bevacizumab during maintenance chemotherapy: 10 mg/kg as a 90 minute infusion on Day 1 (+2 days)and 15 (±2 days)."
1841609|NCT00890786|Drug|Irinotecan|"High Grade Glioma Irinotecan during maintenance chemotherapy:125 mg/m2/day IV over 90 minutes on Days 1 (+ 2 days)and 15 (±2 days) of each course, given no sooner than one hour after temozolomide on Day 1.
Diffuse Intrinsic Pontine Gliomas Irinotecan maintenance chemotherapy: 125 mg/m2/day IV on Day 1 (+2 days)and Day 15 (±2 days)."
1992706|NCT03312920|Device|tDCS|Active tDCS or Sham tDCS
1992707|NCT03311685|Device|vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after surgery in a 3 month interval.
1841615|NCT00890838|Dietary Supplement|Omegaven-IV FO|will receive IV Omega 3 fatty acids (Omegaven®) for 3 pre operative days
1841616|NCT00890851|Procedure|Transurethral Needle Ablation (TUNA)|Transurethral needle ablation of benign prostatic hyperplasia by radio frequencies
1841617|NCT00890864|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
1841618|NCT00890877|Drug|OC000459 or placebo|Pills, active and/or placebo given twice daily for 17 weeks
1841619|NCT00890890|Drug|Avagacestat|Capsules, Oral, 50 mg, once daily, 104 - 220 Weeks
1841620|NCT00890890|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 104 - 220 Weeks
1841621|NCT00890916|Device|FIRSTHAND System|Implanted neuroprosthesis with myoelectric control and electrical stimulation of multiple channels.
1841622|NCT00890929|Drug|Lenalidomide|5 mg, 10 mg, 25 mg, and/or 50 mg of lenalidomide administered PO from day 8 to Day 28 of each cycle
1841623|NCT00890929|Drug|Azacitidine|75 mg/m2 Azacitidine administered intravenously (IV) or subcutaneously (SC) for days 1 to 7 of each cycle
1841624|NCT00890942|Drug|naloxone|naloxone 0.4mg.(1 ml) intramuscular
1841625|NCT00890942|Drug|normal saline|normal saline 1 ml IM
1841626|NCT00890955|Drug|Amrubicin|"Dose Level -1: 20mg/m2
Dose Level 1: 25mg/m2
Dose Level 2: 30mg/m2
Dose Level 3: 35mg/m2
Dose Level 4: 40mg/m2
Amrubicin will be given as a slow IV push or infusion over approximately 5 minutes once daily for 3 consecutive days starting on day 1 of each 21 day cycle."
1841627|NCT00890955|Drug|Cyclophosphamide|Cyclophosphamide will be given at a fixed dose as 500mg/m2 IV infusion over 30-60 minutes on day 1 of each 21 day cycle (following amrubicin).
1841628|NCT00890968|Drug|Triamcinolone Acetonide (TAC) DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
1841629|NCT00890968|Drug|Placebo DuraPeel|topical gel; once daily (nightly); total duration: 4 weeks
1841630|NCT00890981|Procedure|high-resolution peripheral quantitative computed tomography (HR-pQCT)|Bone densitometry and microarchitecture assessments of the distal radius and the distal tibia by HR-pQCT on Day 1.
1841631|NCT00890981|Procedure|Dual energy X-ray absorptiometry (DXA)|Bone densitometry assessments of the forearm by DXA on day 1.
1841632|NCT00890981|Biological|Denosumab|Denosumab 60 mg subcutaneously every 6 months in the previous study
1841633|NCT00890981|Drug|Placebo|Placebo to denosumab subcutaneously every 6 months in the previous study
1841634|NCT00891007|Biological|MVA-mBN85B|Low Dose arm, 1x 10E7 TCID50
1841635|NCT00891007|Biological|MVA-mBN85B|Normal Dose arm, 1x 10E8 TCID50
1841636|NCT00891007|Biological|Rouvax|Standard measles vaccine, approved in South Africa
1841637|NCT00891020|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous every 4 weeks for 24 weeks
1841638|NCT00891020|Drug|tocilizumab [RoActemra/Actemra]|4 mg/kg every 4 weeks for 24 weeks
1841639|NCT00891020|Drug|Nonbiologic DMARDs of investigator's choice|Nonbiologic disease-modifying antirheumatic drugs (DMARDs) As prescribed
1841640|NCT00878917|Drug|Dorzolamide 2 % eye drops solution|1 drop into eye(s) three times a day for the duration of each treatment phase
1841641|NCT00878943|Drug|Sildenafil citrate|20 mg tablet to be taken thrice daily for 1 year
1841681|NCT00879242|Drug|Deferasirox|Dispersible tables of 125, 250 and 500 mg at the dose of 30 mg/kg/day, oral administration.
1841986|NCT00893269|Drug|eszopiclone|Oral capsule at dose recommended for adults
1841642|NCT00878956|Drug|Sodium Bicarbonate|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium bicarbonate at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
1841643|NCT00878956|Drug|Sodium Chloride|In all patients body weight adjusted dose of study medication will be achieved by infusion of sodium chloride at a dose of 0.5 mmol/kg body weight (=bolus) diluted in 250 mL over 1 hour immediately after the induction of anesthesia, prior to the first surgical incision followed by continuous intravenous infusion of 0.2 mmol/kg/hr (=maintenance) diluted in 1000 mL 23 hours (total dose of 5 mmol/kg over 24 hours).
1841644|NCT00878969|Drug|valsartan (ARB)|
1841645|NCT00878969|Drug|ramipril (ACE inhibitor)|
1841646|NCT00878969|Drug|Placebo|
1841649|NCT00879008|Drug|Moxifloxacin (Avelox, BAY12-8039)|Patients from the normal praxis routine, treated with Moxifloxacin according to the local product information
1841650|NCT00879021|Drug|Lyrica|study participants will start will be on 150mg of Pregabalin or placebo capsules by mouth , twice a day.They will be on drug approx. 49 weeks and followed for another 49 weeks after stopping the medication.
1841651|NCT00879021|Drug|matching placebo|150 mg by mouth ,twice a day for 49 weeks
1841652|NCT00879034|Drug|Lonafarnib|Lonafarnib capsules are to be orally administered twice per day approximately every 12 hours. Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Dose levels are 150, 115, 90 and 70 mg/m2. Patients experiencing significant drug related grade 3 or 4 toxicity and not responding to therapy interruption or supportive care measures will be dose reduced by one dose level.
1841653|NCT00879034|Drug|Zoledronic Acid|Zoledronic acid will be administered intravenously at week one of this treatment trial. Week one administration will consist of one infusion over a 30 minute period, 0.0125 mg/kg body weight.
1841654|NCT00879034|Drug|Pravastatin|Pravastatin will begin at 5 mg by mouth once daily for children weighing less than 10 kg, and 10 mg by mouth once daily for children weighing 10 kg or greater.
1841655|NCT00879047|Drug|Alcohol|Consumed orally as liquid mixed with a juice beverage, 1 g/kg formula, administered once at baseline and again at either 2 or 3 weeks
1841656|NCT00879047|Drug|Alcohol placebo|Liquid alcohol spritzed on top of juice beverage immediately prior to administration in order to give smell of alcohol, administered once at baseline and again at either 2 or 3 weeks
1841657|NCT00879060|Drug|spironolactone|spironolactone 50mg daily
1841658|NCT00879073|Drug|Bendamustine|Approximately 15-24 study patients will be enrolled in this Phase I trial. Study patients will receive a weekly dose of IV bendamustine with whole brain radiation therapy for 3 weeks and then receive a fourth dose of IV bendamustine one week after completion of whole brain radiation therapy. The first dose of IV bendamustine will be given when whole brain radiation is initiated.
1841661|NCT00879099|Drug|Paroxetine|Paroxetine 20 mg once a day during two treatment periods. One treatment period lasts for 3 days.
1841662|NCT00879099|Drug|Placebo|Gelatine capsule once a day during two treatment periods. One treatment period lasts for 3 days.
1841663|NCT00879099|Drug|timolol maleate|Oftan Timolol 0,5 % eye drop. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
1841664|NCT00879099|Drug|timolol maleate|Timosan 0,1 % eye gel. One drop into both eyes on day 3 after taking paroxetine or placebo capsules for three days.
1841665|NCT00879112|Drug|MB07811|Oral
1841666|NCT00879112|Drug|Placebo|Oral
1841667|NCT00879138|Drug|VA106483|
1841668|NCT00879151|Behavioral|Cognitive Behavioral Therapy for Adolescents|The therapist will work with the adolescent to understand triggers to binge eating and purging, such as thoughts, feelings, and interpersonal difficulties. Also, establishing regular eating patterns and eliminating medically harmful behaviors associated with the eating disorder is a primary goal.
1841669|NCT00879151|Behavioral|Supportive Psychotherapy|SPT focuses on having the patient build a relationship with the therapist and explore their unique individual needs within the context of their life and the experience of having an eating disorder.
1841670|NCT00879151|Behavioral|Family Based Therapy for Bulimia Nervosa|FBT helps parents to take an active role in guiding their child through eating disorder treatment. In this therapy, the parents are supported in helping their child stop bingeing, purging and engaging in other harmful weight-control behaviors. The way in which the eating disorder has impacted the family and the adolescent's development is also explored.
1841671|NCT00879164|Drug|bupivacaine hydrochloride|
1841672|NCT00879164|Other|questionnaire administration|
1841673|NCT00879177|Drug|Varenicline|Varenicline: 1 tab 0.5mg once a day for 3 days; 1 tab 0.5mg twice a day for 4 days; followed by 1 tab 1mg twice a day for 11 weeks.
1841674|NCT00879177|Behavioral|behavioral therapy|confirmed negative smoking status at different time points
1841675|NCT00879190|Drug|Unasyn|Unasyn 3 grams intravenously every 6 hours, plus intravenous normal saline placebo dose every 8 hours until 24 hours post delivery.
1841676|NCT00879190|Drug|Ampicillin/gentamicin|Gentamicin 1.5mg/kg intravenously every 8 hours plus ampicillin 2 grams intravenously every 6 hours until 24 hours post delivery.
1841677|NCT00879216|Drug|VA106483|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
1841678|NCT00879216|Drug|Placebo|4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
1841682|NCT00879255|Behavioral|Cognitive Processing Therapy Group Videoteleconference|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, through videoteleconference.
1841683|NCT00879255|Behavioral|Cognitive Processing Therapy Group In-Person|Cognitive Processing Group Therapy is delivered to male combat veterans who have been diagnosed with PTSD, in-person, rather than through videoteleconference.
1841684|NCT00879268|Device|Vasosol Organ Perfusion Solution and Medtronic Portable Bypass System|Utilization of Vasosol with Medtronic System for Machine Preservation of the Liver for Liver Transplantation
1841685|NCT00879281|Behavioral|Action plan|"Individualized written Action Plan to enhance self-management and early detection of an exacerbation."
1841686|NCT00879294|Device|Motion sickness wristband|No drugs are involved.
1841687|NCT00879294|Dietary Supplement|Chewing Gum|Patients will be asked to chew gum for 20 minutes, four times daily.
1841688|NCT00879307|Drug|quetiapine|Use of quetiapine for 16 weeks in acute mania and depression
1841689|NCT00879333|Drug|Everolimus|Everolimus was formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
1841690|NCT00879333|Drug|Everolimus placebo|Placebo was formulated to be indistinguishable from the everolimus tablets, also formulated as tablets of 5 mg strength. In both treatment arms, the study drug was given by continuous oral daily dosing of 10 mg (2 tablets x 5 mg) each morning.
1841691|NCT00879333|Drug|Best Supportive Care (BSC)|Best supportive care is defined as care in accordance with the local practice of an individual institution or center, specifically excluding anti-cancer treatments.
1841692|NCT00879346|Drug|AZD8931|160mg oral single dose (4 x 40mg tablets)
1841693|NCT00879359|Drug|carboplatin, paclitaxel, and bevacizumab|All patients enrolled will receive carboplatin AUC 5 plus paclitaxel 175 mg/m2 (135 mg/m2 if prior radiation to greater than 25% of bone marrow) plus bevacizumab 15 mg/kg every 3 weeks.
1841694|NCT00879372|Drug|tianeptine|tianeptine 12,5mg TID
1841695|NCT00879372|Drug|Placebo|Placebo 12.5 mg TID
1841696|NCT00879385|Drug|Dacogen™ (decitabine)|"Dacogen™ (decitabine) is a FDA approved drug (NDA - 021790) for the treatment of myelodysplastic syndromes (MDS) including previously treated and untreated, de novo and secondary MDS (refractory anemia, refractory anemia with ringed sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia).
Decitabine will be given on this study at 45 mg/m2 IV over 2 hrs"
1841697|NCT00879385|Drug|Vectibix® (panitumumab)|"Vectibix® (panitumumab) is a FDA approved drug (BLA-125147) indicated as a single agent for the treatment of EGFR-expressing metastatic colorectal carcinoma with disease progression on or following fluoropyrimidine, oxaliplatin, and irinotecan chemotherapy regimens. Approval is based on progression-free survival; no data demonstrate an improvement in disease-related symptoms or increased survival.
DRUG DESCRIPTION Vectibix® (panitumumab) is a recombinant, human IgG2 kappa monoclonal antibody that binds specifically to the human epidermal growth factor receptor (EGFR). Panitumumab has an approximate molecular weight of 147 kDa. Panitumumab is produced in genetically engineered mammalian (Chinese Hamster Ovary) cells.
Panitumumab will be given on this study at 6 mg/kg, IV over 1 hr"
1841698|NCT00884754|Device|GlideScope rigid stylet|Patients will be intubated either with a rigid stylet meant to be used with the GlideScope, or with a standard malleable stylet used with other modalities of intubation.
1841699|NCT00884767|Drug|FOLFOX regimen|
1841700|NCT00884767|Drug|fluorouracil|
1841701|NCT00884767|Drug|leucovorin calcium|
1841702|NCT00884767|Drug|oxaliplatin|
1841703|NCT00884767|Genetic|gene expression analysis|
1841704|NCT00884767|Genetic|protein expression analysis|
1841705|NCT00884767|Genetic|proteomic profiling|
1841706|NCT00884767|Other|laboratory biomarker analysis|
1841707|NCT00884767|Other|pharmacogenomic studies|
1841708|NCT00884793|Drug|raltegravir|The baseline ART regimen will be intensified with raltegravir 400mg orally (PO) twice daily (BID) (all participants) +/- a study NNRTI or protease inhibitor (PI) (at the option of the participant and the study clinical team).
1841709|NCT00884793|Drug|Study NNRTI|Subjects who are not already on an NNRTI and who are suitable candidates will have the option of adding a study NNRTI (either efavirenz or etravirine).
1841710|NCT00884793|Drug|Study PI|Subjects who are not on a PI and who are suitable candidates will have the option of adding a study PI. PIs used as study drugs will include atazanavir (+/- ritonavir), fosamprenavir (+/-ritonavir), lopinavir/ritonavir, and darunavir/ritonavir.
1841711|NCT00884806|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, conditioning, disinfecting, and storage solution for silicone hydrogel (SiH) contact lenses
1841712|NCT00884806|Device|Etafilcon A contact lens (ACUVUE® 2™)|Commercially marketed hydrogel contact lens for daily wear use
1841713|NCT00884806|Device|Senofilcon A contact lens (ACUVUE® OASYS™)|Commercially marketed silicone hydrogel contact lens for daily wear use
1841714|NCT00884806|Device|Lotrafilcon B contact lens (O2 OPTIX®)|Commercially marketed silicone hydrogel contact lens for daily wear use
1841715|NCT00884806|Device|Balafilcon A contact lens (PureVision®)|Commercially marketed silicone hydrogel contact lens for daily wear use
1841716|NCT00884819|Drug|Fenofibrate|fenofibrate 200 mg daily for 6-months
1841717|NCT00884819|Other|Placebo|Placebo match for 6 months
1841718|NCT00891033|Drug|Bortezomib (Velcade)|During the study Bortezomib will be administered intravenously as a 3-5 second bolus IV injection, at a dose of 1.0 mg/m2 on days 1, 4, 8, and 11 of each 21-day treatment cycle.
1841719|NCT00891033|Drug|Panobinostat|During the study, panobinostat IV will be administered intravenously as once daily on (day 1 and 8 of the 21 day cycle 2 and beyond). Patients enrolled on first group will receive 5 mg/m2 panobinostat IV, second group 10 mg/m2 panobinostat IV, third group 15 mg/m2 panobinostat IV and the fourth group 20 mg/m2 panobinostat IV. Each infusion of panobinostat will be administered over 30 minutes.
1841720|NCT00891046|Drug|Canakinumab|Canakinumab
1841721|NCT00891072|Drug|R-(-)-gossypol acetic acid|Given orally
1841722|NCT00891072|Drug|paclitaxel|Given IV
1841723|NCT00891072|Drug|carboplatin|Given IV
1841724|NCT00891072|Other|pharmacological study|Correlative studies
1841725|NCT00891098|Behavioral|Imaginal exposure|7 individual sessions of imaginal exposure of trauma memories according to the prolonged exposure treatment manual
1841726|NCT00891098|Behavioral|Imagery rescripting|7 individual sessions of imagery rescripting of trauma memories according to the imagery rescripting and reprocessing therapy manual
1841727|NCT00891111|Behavioral|Direct Payment|$25 gift card given upon completion of Health Risk Assessment
1841728|NCT00891111|Behavioral|Regret Lottery|Entered into a lottery upon completion of Health Risk Assessment
1841729|NCT00891137|Biological|human myeloid progenitor cells|Single intravenous injection/infusion
1841730|NCT00891150|Drug|Oxytocin|"Pre-mixed, oxytocin solutions with either 20U/500ml, 30U/500ml or 40U/500ml of Lactated Ringer's solution will be available in the pharmacy department. The bags will be identical in appearance. Each bag will be labeled with a study identification number, from which the pharmacy could determine the administered dose. Subjects as well as the medical providers will be blinded to the assignment of the solution used.
Immediately after delivery of the infant, the study solution will be infused over 30 minutes using a continuous infusion pump (666 mU/min versus 999 mU/min versus 1332mU/min)."
1841733|NCT00891176|Biological|MenitorixTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
1841734|NCT00891176|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
1841735|NCT00891176|Biological|PrevenarTM|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study.
1841736|NCT00891176|Biological|MeningitecTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
1841737|NCT00891176|Biological|NeisVac-CTM|Intramuscular injection into the thigh as primary vaccination at 2 and 4 months of age and as booster dose at 11-18 months of age. No vaccine was administered during this long-term follow up study
1841738|NCT00891176|Biological|InfanrixTM hexa|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
1841739|NCT00891176|Biological|InfanrixTM penta|Intramuscular injection into the thigh as primary vaccination at 2, 4 and 6 months of age (all countries) and as booster dose at 11-18 months of age (Germany and Poland). No vaccine was administered during this long-term follow up study
1841740|NCT00891176|Biological|InfanrixTM IPV/Hib|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
1841741|NCT00891176|Biological|InfanrixTM IPV|Intramuscular injection into the thigh as booster dose at 11-18 months of age (Spain). No vaccine was administered during this long-term follow up study
1841742|NCT00891202|Drug|Eliglustat tartrate|PAP: Eliglustat tartrate (ET) capsule 50 mg orally on Day 1 followed by ET 50 mg capsule twice daily (BID) from Day 2 to Week 4, then either ET 50 mg capsule BID (participants with Genz-99067 [active moiety of ET in plasma] trough plasma concentration >=5 ng/mL) or ET 100 mg capsule BID (participants with Genz-99067 trough plasma concentration <5 ng/mL), up to Week 39. PK assessment at Week 2 used for dose adjustment after Week 4. LTTP: Participants of the eliglustat arm in PAP who completed PAP were included in LTTP and received ET capsule 50 mg BID orally from Day 1 (post Week 39) until Week 43 followed by ET 50 mg or 100 mg capsule BID up to Week 47, then ET 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration <5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 & Week 45, respectively.
1841743|NCT00891202|Drug|Placebo|PAP: Matching placebo capsule once daily on Day 1 followed by matching placebo capsule BID from Day 2 through Week 39. LTTP: Participants of the placebo arm in PAP who completed PAP were included in LTTP and received eliglustat tartrate from Day 1 (post Week 39) up to Week 312. Day 1 (post Week 39) was considered as baseline for LTTP. On Day 1, participants received eliglustat tartrate capsule 50 mg BID orally until Week 43 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 47, then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 312. Dose adjustments at Week 43 and Week 47 were based on Genz-99067 trough plasma concentrations (if trough plasma concentration <5 ng/mL: next higher dose administered; if >=5 ng/mL: same dose continued) at Week 41 & Week 45, respectively.
1841748|NCT00891241|Drug|LMI 1195-101|Single dose, bolus IV injection of LMI 1195
1841749|NCT00891254|Device|Implant of a prosthetic mesh|A prosthetic mesh will be implanted either intraperitoneally or in the on-lay (supra-fascial) position depending on the arm of the study
1841750|NCT00891267|Drug|Olmesartan medoxomil tablets low dose|Olmesartan medoxomil tablets low dose, taken once daily for 6 weeks
1841751|NCT00891267|Drug|Olmesartan medoxomil tablets high dose|Olmesartan medoxomil tablets high dose, taken once daily for 6 weeks
1841752|NCT00891267|Drug|Amlodipine|Amlodipine tablets taken once daily for 6 weeks
1841783|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
1841753|NCT00891280|Drug|CX-4945 oral formulation|CX-4945 Capsules, Oral, Dose escalation study, Dose schedule: twice daily or four times daily for 21 consecutive days every 28 days.
1841754|NCT00891293|Drug|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters)|Open-label Antara (fenofibrate) + open-label Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
1841755|NCT00891306|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
1841756|NCT00891306|Drug|mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
1841757|NCT00891306|Drug|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
1841758|NCT00891306|Drug|methylprednisolone|single intravenous bolus of methylprednisolone (1 mg/kg bodyweight)
1841760|NCT00891332|Drug|S-1 plus LV (The combination therapy of S-1 and Leucovorin)|S-1 40-60 mg bid day 1～day 7 LV 25 mg bid day 1～day 7
1841761|NCT00891345|Biological|ALECSAT|Autologous activated CTL and NK-cells injected as a single intravenous injection.
1841762|NCT00891358|Behavioral|Prevention Empowerment Intervention for Young Women|"Using three intervention sites, focus groups will guide the development of the intervention's framework and content areas. An initial list of content areas and potential activities for presentation to the focus groups will be developed by the protocol team by reviewing existing HIV prevention interventions that have been implemented with adolescents and young adults, as well as interventions that have targeted HIV+ populations.
The three focus groups will be convened (1 per selected ATN site) with young women living with HIV to solicit information on their intervention needs."
1841763|NCT00891371|Drug|lanreotide (Autogel formulation)|Autogel 120mg
1841764|NCT00891579|Drug|Pemetrexed (Alimta)|treatment of single pemetrexed with vitamin supplement until discontinued conditions are met
1841765|NCT00891579|Drug|Gefitinib (IRESSA)|treatment of Gefitinib will be applied until discontinued conditions are met
1841766|NCT00891592|Biological|Ex Vivo CD3/CD28 costimulated Umbilical Cord Blood T cells|"Single infusion of Cord Blood Cells AND Single Infusion of ex vivo CD3/CD28 costimulated Umbilical Cord Blood T cells.
Table 6: Dose escalation (Dose level CD3+ cell dose)
1xE5 cells/kg
2xE6 cells/kg
3xE7 cells/kg
4xE8 cells/kg"
1841767|NCT00891592|Other|Observation Arm|Single infusion of Cord Blood Cells
1841768|NCT00891605|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-3 out of each 21 day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
1841769|NCT00891605|Drug|paclitaxel|"175 mg/m2 over 3 hours of paclitaxel will be given by intravenous infusion on Day 1 of each 21 day cycle.
Note - The dose and schedule is subject to change based on the toxicities observed."
1841770|NCT00891618|Other|Acupuncture|3 acupuncture sessions per week for 4 weeks (Weeks 1-4), 1 week off (Week 5), then 2 per week for 4 more weeks (Weeks 6-10), total of 20 sessions. Each session lasts 20-30 minutes.
1841771|NCT00891631|Behavioral|iSBIRT|Participants will receive the internet/intranet based screening, brief intervention, and referral to treatment program.
1841772|NCT00891631|Behavioral|iSBIRT/TE|Participants will receive the internet/intranet screening, brief intervention, and referral to treatment system along with technological extenders
1841773|NCT00891644|Other|Case Management|"Clinical personnel at each AMTU site may work with other personnel from organizations authorized to have access to personal health information to identify clients identified as HIV positive within the past 6 - 18 months.
Initial contact will be made by persons at source organizations who are authorized to have access to personal health information. Persons so authorized will explain the nature of the research study and request permission from the client for subsequent contact by research personnel from the AMTU site. If permission for contact is received, research personnel at each site will attempt calls as specified by the potential participant or at random times (before 12:00 pm; between 12:00 - 4:00 pm; and between 4:00 - 10:00 pm) for no more than 10 attempts."
1841774|NCT00891644|Other|Snowball sampling|"Snowball sampling assumes that social networks of HIV sero-positive persons in treatment may overlap with those of HIV sero-positive persons not in treatment.
When a site is assigned to identify HIV positive adolescents not in care by snowball sampling, all HIV positive persons in care at the site will be invited to refer other adolescents known to them as HIV positive, but not in care, for possible participation in the study.
Printed information containing a brief description of the research in English and in Spanish and contact information of site study personnel will be provided to in-care adolescents at the site for distribution to those known HIV positive adolescents who are not in care."
1841775|NCT00891644|Other|Referral Lists|AMTU staff will develop lists of potential participants at their sites who have had an initial HIV-related health care visit but not received additional visits within the 12 mos prior the list (or before protocol screening) or have completed initial and follow up visits but dropped out of care for 12 or more mos. Back-up lists will be made of potential participants who have gone 9-12 mos and 6-9 mos without a visit. Clinical staff at each AMTU may work with staff from other organizations authorized to access personal health information to find potential participants. 1st contact will be made by persons at source organizations who are authorized to access personal health information. Authorized staff will explain the study and ask permission for contact by research staff at the AMTU site. If so, research staff will attempt calls as specified by the potential participant or at random (before 12 pm; between 12-4 pm; and between 4-10 pm) for no more than 10 attempts.
1841776|NCT00891657|Device|SprayShield™|Anti-adhesion barrier
1841777|NCT00891670|Drug|cilostazol|100mg twice daily for at least 1 month
1841778|NCT00891670|Drug|clopidogrel|"75mg once daily (triple group arm)
150mg once daily (high maintenance dose group arm)"
1841779|NCT00891670|Drug|aspirin|aspirin 100mg
1841780|NCT00891683|Drug|AEG33773 oral dosing|AEG33773 capsules: subjects will receive a daily dose of either 100 mg, 200 mg, or 400 mg AEG33773. Placebo capsules: subjects will receive a daily dose of placebo (matching test product). Capsules will be taken by mouth, over 28 consecutive days
1841781|NCT00891696|Drug|Rapamycin|Single 16-mg oral dose
1841782|NCT00891696|Other|Amino acid supplementation|Nutritional drink containing essential amino acids
1841784|NCT00891696|Drug|Sodium nitroprusside|Variable rate for 3 hours
1841785|NCT00891696|Device|Blood flow restriction cuff|Blood flow restriction for 5 minutes after the second biopsy
1841786|NCT00891696|Other|Low-intensity resistance exercise|Leg extension exercises on a Cybex leg extension machine
1841787|NCT00891709|Drug|LEO 29102|First-in-man. Healthy volunteers
1841788|NCT00891722|Other|biologic sample preservation procedure|
1841789|NCT00891722|Other|laboratory biomarker analysis|
1841790|NCT00891722|Other|questionnaire administration|
1841791|NCT00891735|Drug|Ranibizumab|Sterile solution for intravitreal injection.
1841792|NCT00891748|Genetic|AdCD40L|Adenovirus vector serotype 5, E1/E3 deletion with human CD40L gene driven by RSV promoter
1841793|NCT00891761|Drug|Dexamethasone|16 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
1841794|NCT00891761|Drug|Dexamethasone|20 mg administered orally within 75 minutes prior to the initiation of cisplatin on Day 1, followed by 8 mg doses twice daily (bid) at approximately 12+/-4 hour intervals on days 2, 3, and 4, starting at approximately the same time of day as the Day 1 dose was administered.
1841795|NCT00891761|Drug|IV casopitant (placebo)|IV casopitant (placebo) administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study day 1.
1841796|NCT00891761|Drug|IV casopitant (active)|Single-dose 90 mg IV casopitant administered within 75 minutes prior to the start of cisplatin-based highly emetogenic chemotherapy on study Day 1.
1841797|NCT00891761|Drug|Ondansetron|32mg IV ondansetron administered over not less than 15 minutes, with administration started and completed within the 75 minutes prior to the initiation of cisplatin therapy on study Day 1.
1841798|NCT00891774|Device|EVOLENCE®|Single injection of material into the mid-dermis of the wrinkle - Second 'touch-up' injection is permitted approximately 14-Days later if needed to achieve satisfactory results
1841799|NCT00891787|Dietary Supplement|Probiotic Supplement|
1841800|NCT00891800|Device|Brachytherapy|SIR-Sphere contains radiation of Y-90.
1841801|NCT00891800|Device|SIR-Sphere|Brachytherapy Radiation seeds
1841802|NCT00891813|Drug|Zemplar (paricalcitol)|Zemplar (paricalcitol) dose will be calculated mcg=PARATHYROID HORMONE level/100; this will be provided 3 times per week. Dose will be adjusted by 2-4 mcg every 4 weeks according to the parathyroid hormone level.
1841803|NCT00891826|Dietary Supplement|Omega-3 fatty acids (EPAX 6015 TG)|The study drug is a food supplement called EPAX 6015 TG. One capsule of EPAX 6015 TG contains 530 mg of EPA (eicosapentaenoic acid) and 150 mg of DHA (docosahexaenoic acid), provided as triglycerides. For the entire study period (12 weeks) patients will receive 4 capsules of EPAX 6015 TG per day.
1841804|NCT00891826|Dietary Supplement|Corn oil|The corn oil capsules look exactly the same as the capsules containing omega-3 fatty acids. For the entire study period patients will receive 4 capsules of corn oil per day.
1959279|NCT00547378|Device|InterStim|
1959280|NCT00547378|Drug|Standard Medical Therapy|Oxybutynin 2.5mg, 5mg Oxybutynin extended release 5 mg, 10mg, 15mg Oxybutynin transdermal 3.9mg Solifenacin 5mg, 10mg Tolterodine 1mg, 2mg Tolterodine extended release 2mg, 4mg Trospium 20mg Darifenacin extended release 7.5mg, 15mg fesoterodine Fumarate 4mg, 8mg
1959281|NCT00545844|Drug|montelukast sodium|montelukast sodium, 10 mg, one tablet once a day for 8 weeks as add on therapy to usual current asthma controller treatment
1841809|NCT00891904|Biological|cetuximab|Given IV
1841810|NCT00891904|Radiation|stereotactic body radiation therapy|Undergoing Radiotherapy
1841811|NCT00891917|Drug|Ubiquinol-10 Syrup|10 mg/kg/day in 2 divided doses for 3 months or Placebo Syrup for 3 months
1841812|NCT00891930|Biological|Panitumumab|Panitumumab 6 mg/kg administered via IV infusion over 60 minutes
1841813|NCT00891930|Biological|Ganitumab|AMG 479 12 mg/kg adminstered by IV infusion over 60 minutes
1841814|NCT00891930|Drug|Irinotecan|Irinotecan starting dose of 180 mg/m² adminstered via IV infusion
1841815|NCT00891943|Other|Structured lifestyle support|The intervention group will meet with a research nurse on 14 occasions over the 1 year research study, for structured lifestyle support, including dietary, physical activity and behavioral advice. They will also receive a pedometer.
1841816|NCT00891982|Drug|CTGel/ BPO Wash|"Benzoyl Peroxide (BPO) wash will be used once daily in the morning for 28 days
Clindamycin and Tretinoin (CT) gel will be used once daily in the evening for 28 days."
1841817|NCT00891982|Drug|Soap Free Cleanser and CTGel|"Soap Free Cleanser will be used once daily in the morning for 28 days
Clindamycin and Tretinoin gel will be used once daily in the evening for 28 days."
1841818|NCT00891995|Device|Closed loop|Closed loop therapy for up to 4 to 6 days
1841819|NCT00891995|Device|Home glucose monitoring|Standard diabetes management using a home glucose meter.
1841820|NCT00891995|Device|Insulin pump|Insulin pump use for 2 years
1841821|NCT00891995|Device|Continuous glucose monitor|Continuous glucose monitor use for 2 years
1841822|NCT00892008|Drug|Pregabalin|Pregabalin 75-150 mg BID for at least 2 weeks.
1841823|NCT00892021|Drug|NSA-789|
1841824|NCT00892021|Drug|Placebo|
1841825|NCT00892047|Drug|venlafaxine XR plus aripiprazole|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
1841826|NCT00892047|Drug|venlafaxine plus placebo|Dosage varies. Subject remains on antidepressant throughout the 36 week study. Will be randomized to aripiprazole or placebo for up to 24 weeks.
1841827|NCT00892073|Drug|Diazoxide|Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
1841828|NCT00892073|Drug|Metformin|Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.
1841829|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given weekly
1841830|NCT00892099|Drug|Ergocalciferol|50,000 IU tablet given monthly
1841831|NCT00892099|Other|Placebo|Placebo equivalent of ergocalciferol, given weekly as one tablet
1841832|NCT00892112|Drug|Intravenous Immunoglobulins|2 gr/kg body weight of intravenous immunoglobulin product Nanogam® administered as 0.5 gr/kg IV over a period of 6 hours on each of 4 consecutive days
1841833|NCT00892112|Drug|plasma volume expander|10 ml/kg BW will be administrated on four consecutive days.
1841834|NCT00892125|Drug|paliperidone ER; Carbamazepine|
1841835|NCT00892138|Behavioral|Mindfulness training|7 week course modeled on MBSR according to Kabat-Zinn
1841836|NCT00892151|Device|GLUCOFACTS® Deluxe|Diabetes Data Management Software
1841837|NCT00892164|Device|harmonic scalpel device (FOCUS)|hemostatic device utilized intraoperatively
1841838|NCT00892164|Device|electrothermal bipolar vessel sealing system (LIGASURE PRECISE)|hemostatic device utilized intraoperatively
1841839|NCT00892177|Biological|bevacizumab|Given intravenously
1841840|NCT00892177|Drug|dasatinib|Given orally
1841841|NCT00892177|Other|placebo|Given orally
1841842|NCT00892190|Drug|dasatinib (SPRYCEL)|DL0 - 50 mg every 24 hours DL1 (START)- 70 mg every 24 hours DL2 - 100 mg every 24 hours DL3 - 140 mg every 24 hours
1841843|NCT00892190|Drug|all trans retinoic acid (VESANOID)|22.5mg/m2 every 12 hours
1841844|NCT00892203|Drug|BGG492|
1841845|NCT00892203|Drug|Sumatriptan|
1841846|NCT00892203|Drug|Placebo|
1841847|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay.
1841848|NCT00892216|Device|Acupressure (BioBand)|Band will remain on from 20 minutes before surgery until the end of the hospital stay. The same band will be placed and turned so the beads face the corresponding point on the dorsal surface of the upper limb area.
1841849|NCT00892229|Drug|Misoprostol (given buccally)|400 microgram misoprostol given buccally three hours before dilation and curettage (PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
1841850|NCT00892229|Drug|Misoprostol (given vaginally)|400 microgram misoprostol (MISOPROSTOL - PHARMACIA CORPORATION - Istanbul, serial number 022-00, a tablet contains 200 micrograms)
1841851|NCT00892242|Drug|Zoledronic acid|
1841852|NCT00892255|Device|Microwave Ablation|Tumor tissue from the liver is inter-operatively treated with the microwave ablation device to measure the destruction of tissue.
1841853|NCT00892268|Procedure|acupuncture therapy|Undergo acupuncture
1841854|NCT00892268|Procedure|pain therapy|Receive standard care
1841855|NCT00892281|Drug|doxycycline (Oracea®) 40 mg modified release as monotherapy|Take once daily in the morning
1841856|NCT00892281|Drug|doxycycline (Oracea®) 40 mg modified release as add-on therapy|Take once daily in the morning
1841857|NCT00892307|Radiation|Dual Source Multidetector CT (DSCT) w/ Adenosine enhancement|Somatom Definition Dual Source CT Scanner Stress/Rest Image scan using weight based CT contrast dye
1841858|NCT00892320|Drug|ER OROS paliperidone|
1841859|NCT00892346|Procedure|Single ASCT with Thalidomide maintenance|"Single ASCT with Thalidomide maintenance:
Single Autologous Stem Cell Transplantation: conditioning with Melphalan 200mg/m2 (iv)
Thalidomide maintenance: starting from D60 after transplantation at 100-200mg daily (Oral)"
1841860|NCT00892359|Drug|Anidulafungin|treatment for 3 days, 200 mg intravenously on the first treatment day and 100 mg on the 2 following treatment days each.
1841861|NCT00892385|Drug|methoxyamine|Methoxyamine IV over 1 hour every 28 days. Methoxyamine IV administration will follow, within 5 minutes, initial administration of TMZ on day 1.
1841862|NCT00892385|Drug|temozolomide|Patients receive oral temozolomide once daily on days 1-5. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
1841863|NCT00892385|Genetic|DNA analysis|Blood sampling during cycles 1 and 2 depending upon the PK data from initial subjects. Samples are analyzed for DNA strand break determination by comet assay.
1841864|NCT00892385|Other|laboratory biomarker analysis|Blood sampling during cycles 1 and 2 depending upon the PK data from initial subjects. Samples are analyzed for apurinic/apyrimidinic sites.
1841865|NCT00892385|Other|pharmacological study|Blood sampling during cycles 1 and 2 depending upon the PK data from initial subjects. Samples are analyzed for methoxyamine and temozolomide pharmacokinetics.
1841866|NCT00892398|Drug|ranibizumab|Two ranibizumab subconjunctival injections (0.5 mg ∕ 0.05 mL). The first injection at the end of the surgery (intraoperative) and the second two weeks post-operatively.
1841867|NCT00892398|Procedure|standard care|standard post-operative care after trabeculectomy with mitomycin C
1841868|NCT00892424|Drug|Sorafenib|Sorafenib doses will be 200mg twice daily orally for 28 days in level I, 400 mg in the morning and 200mg in the evening in level II, and 400mg twice daily orally for 28 days in level III . Radiotherapy will be started at day 8, patients will receive a total of 6 fractions over 2 weeks. Patients will be assessed weekly during treatment, 1 month post-tx, then at 3-month intervals for up to a year after tx, and then followed-up at 6-month intervals up to 3 years.
1841869|NCT00892437|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
1841870|NCT00892437|Drug|RTV|Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
1841871|NCT00892437|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
1841872|NCT00892437|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
1841873|NCT00892437|Drug|COBI placebo|Placebo to match COBI administered orally once daily
1841874|NCT00892437|Drug|RTV placebo|Placebo to match RTV administered orally once daily
1841875|NCT00892450|Drug|Oxybutynin and darifenacin|Participants with overactive bladder will take each medication for 4 weeks.
1841876|NCT00892463|Drug|Quetiapine (Seroquel) XR|50mg/day - first 2 weeks 150mg/day - remaining 4 weeks min dose: 50mg/day max dose: 300mg/day
1841928|NCT00892788|Behavioral|contingency management|Prize-based contingency management for weight loss
1841877|NCT00892476|Dietary Supplement|Calcium Supplementation|"Ca-gluconate powder (molar weight 430.4 g) will be measured with household measuring spoons and added to the feeding mixtures as follows:
Amount of feeding Actual Weight < 1000 g Actual Weight < 1000 g
25 ml ¼ tsp 1/8 tsp
50 ml ½ tsp ¼ tsp
100 ml 1 tsp ½ tsp
200 ml 2 tsp 1 tsp"
1841878|NCT00892476|Other|Standard of Care|Infants are feed breast milk with fortifier or 24 cal/oz formula per standard of care
1841879|NCT00892489|Drug|ER OROS Paliperidone|
1841880|NCT00892502|Drug|Bismuth tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
1841881|NCT00892502|Drug|Placebo tablets|1000 mg x 2 for five days prior to chemotherapy/radiotherapy 500 mg x 2 for ten days during and after chemotherapy/radiotherapy
1841882|NCT00892515|Behavioral|exercise intervention|
1841883|NCT00892515|Other|counseling intervention|
1841884|NCT00892515|Other|gas chromatography|
1841885|NCT00892515|Other|immunoenzyme technique|
1841886|NCT00892515|Other|immunologic technique|
1841887|NCT00892515|Other|laboratory biomarker analysis|
1841888|NCT00892515|Other|mass spectrometry|
1841889|NCT00892515|Other|physiologic testing|
1841890|NCT00892515|Other|questionnaire administration|
1841891|NCT00892515|Other|survey administration|
1841892|NCT00892515|Procedure|dual x-ray absorptometry|
1841893|NCT00892515|Procedure|magnetic resonance imaging|
1841894|NCT00892515|Procedure|study of high risk factors|
1841895|NCT00892541|Drug|ER OROS paliperidone|
1841896|NCT00892554|Dietary Supplement|Docosahexaenoic Acid|Capsules providing 10 mg DHA/kg body weight/day taken once daily
1841897|NCT00892554|Dietary Supplement|Corn/soy oil|Capsules taken once daily
1841898|NCT00892567|Biological|9 Peptides from Her-2/neu, CEA, & CTA|Each vaccination will be administered on days 1, 8, 15, 36, 43, and 50. All participants will receive 9 class I MHC-restricted synthetic peptides and a class II MHC-restricted tetanus helper peptide administered in Montanide ISA-51. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
1841899|NCT00892580|Drug|STX209|collection of serum for DNA to elucidate a potential biomarker for patients with ASD
1841900|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
1841901|NCT00892593|Device|Fecal Immunochemical Testing|Fecal Immunochemical Testing is a stool test specific for human hemoglobin.
1841902|NCT00892606|Drug|Methadone|Patients will receive 0.2 mg/kg of methadone IV immediately after intubation
1841903|NCT00892606|Drug|Morphine|Patients will receive 0.2 mg/kg of morphine IV immediately after intubation
1841904|NCT00892619|Procedure|using ILM forceps alone|Using ILM forceps to initiate and complete ILM peel
1841905|NCT00892619|Procedure|Breaking and peeling with end-grasping forceps|Using an instrument to create a break in the ILM followed by peeling of the membrane with end-grasping forceps
1841906|NCT00892632|Procedure|ERCP and Confocal imaging|A major new advancement in cancer imaging is the development of a probe-based confocal endomicroscopy (pCLE) system capable of cellular and sub-cellular imaging of the biliary tree.
1841907|NCT00892658|Drug|Sorafenib|Patients will receive sorafenib alone (following the dose escalation scheme) for one week, followed by 2 weeks of concurrent administration of sorafenib with conformal radiation therapy (6 fractions over two weeks). Sorafenib administration will continue for four weeks following completion of radiation. At three months following radiation, when liver toxicity is assessed, full dose sorafenib (400mg PO BID) will then be initiated and continued until disease progression or serious toxicity occurs, to a maximum time of 12 months.
1841908|NCT00892671|Other|Simulation|simulation of airway management and vascular access
1959285|NCT00542438|Behavioral|Physical Activity Recall|Hand-held computers will be used to record information for 7 days about physical activity. Assessments will be completed either 3 times a day or once a day.
1841911|NCT00892697|Drug|Telaprevir|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
1841912|NCT00892697|Drug|Peginterferon alfa-2a|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
1841913|NCT00892697|Drug|Ribavirin|Fifteen subjects will receive the same treatment: 12 weeks of telaprevir (750 mg q8h) with Peg-IFN- alfa-2a (Pegasys(R)) (180 mcg SQ qwk) and RBV (1200 mg per day if >75 kg or 1000mg per day if < 75 kg).
1841914|NCT00892710|Drug|Pemetrexed|500 mg/m2 IV given over 10 minutes every 21 days
1841915|NCT00892710|Drug|Bevacizumab|15 mg/kg IV every 21 days
1841916|NCT00892710|Drug|Carboplatin|AUC=5 IV every 21 days
1841917|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 0.3 mg per linear centimeter (low dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
1841918|NCT00892723|Drug|Placebo|Subjects were administered placebo (0.9% saline) per linear centimeter intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
1841919|NCT00892723|Drug|AZX100 Drug Product|Subjects were administered AZX100 10 mg per linear centimeter (high dose) intradermally at the site of the keloid scar removal. The first dose was given 19-23 days following surgery, and the second dose was given 40-44 days following surgery.
1841923|NCT00892749|Drug|ASP1585|oral
1841924|NCT00892762|Drug|Travoprost APS 40 micrograms/ml eye drop solution|non-BAK (benzalkonium chloride) medication
1841925|NCT00892762|Drug|Latanoprost 50 micrograms/ml eye drop solution|BAK-preserved medication
1841929|NCT00892788|Behavioral|weight loss manual-guided individual therapy sessions|once weekly counseling sessions with research staff
1841930|NCT00892801|Drug|RAD001|Taken by mouth once a day, for 15 days, one day prior to initiation of whole brain radiation therapy at 5 or 10 mg/day during the phase I component. One of these doses will be selected as the maximum tolerable dose and will be selected for the phase II component
1841931|NCT00892801|Radiation|whole-brain radiation therapy|Standard whole brain radiation therapy (WBRT) 30 Gy will be given in ten fractions.
1841932|NCT00892814|Radiation|Partial breast irradiation|40 Gy/15 fractions, 3 weeks
1841933|NCT00892814|Radiation|Whole breast irradiation|40 Gy/15 fractions, 3 weeks
1841934|NCT00892827|Drug|Rituximab (Mabthera) , FFP (Fresh Frozen Plasma)|Rituximab (375 mg/m2) with FFP will be given every two weeks
1841935|NCT00892840|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg to 4 mg, Once daily, 14 days
1841936|NCT00892840|Drug|Placebo|Oral Solution, Oral, 0 mg, Once daily, 14 days
1841937|NCT00892853|Procedure|CT of the bones|A CT scan will be performed on one arm and one leg for the purpose of acquiring images for this research study.
1841938|NCT00892866|Other|Cytology Specimen Collection Procedure|Correlative studies
1841939|NCT00892866|Other|Laboratory Biomarker Analysis|Correlative studies
1841940|NCT00892879|Device|Laparoscopic cholecystectomy surgery|Single port laparoscopic cholecystectomy surgery versus a standard four port device.
1841941|NCT00892892|Drug|Rilmenidine|1 mg Rilmenidine per day versus
1841942|NCT00892892|Drug|Nitrendipine|20 mg Nitrendipine per day
1841943|NCT00892918|Drug|Moxifloxacin ophthalmic solution 0.5% ; Gatifloxacin ophthalmic solution 0.3%|Each drug will be given 4 times a day, 1 drop each time to the operated eye, for 21 days.
1841944|NCT00892931|Drug|Azixa|3.3 mg/m2 of Azixa administered by intravenous infusion over 2 hours once weekly for 3 consecutive weeks every 4 weeks (1 cycle = 4 weeks)
1841945|NCT00892944|Drug|AZD2516|Fractionated single oral dose
1841946|NCT00892957|Biological|Fibrin Sealant, Vapor Heated, Solvent/Detergent-treated with 500 IU/ml thrombin and synthetic aprotinin (FS VH S/D 500 s-apr)|The actual dose of FS VH S/D 500 s-apr will depend on the length of the suture line and the intensity of bleeding (but shall not exceed 4 mL FS VH S/D 500 s-apr).
1841947|NCT00892957|Other|Surgical gauze pads|Manual compression with surgical gauze pads
1841948|NCT00892970|Drug|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
1841949|NCT00892970|Drug|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 12 days
1841950|NCT00892983|Behavioral|FAB|Standard well child care plus 8 extra parent contacts for augmented education and support around breast feeding, food and activity with 1 before birth and then at 1-2 weeks, 3-4, 6, 12, 15, 18, and 21 months post-partum.
1841951|NCT00892983|Behavioral|Sleep|"Standard well child care plus 5 extra contacts focussed on Sleep with 1 before birth (anticipatory guidance), sleep problem prevention starting at 3 weeks and then sleep problem intervention starting at 6 months or if problems emerge upto 2 years of age. Main prevention advice focussed on placing baby to sleep awake, maximising night-day differences and use of sleep place in parents bedroom for first 6 months. Intervention after 6 months uses preferentially a technique called parental presence, and if this does not fit family a technique called camping out and finally, if neither of the first two fit family, controlled crying."
1841952|NCT00892996|Drug|dexamethasone|Metoclopramide 10 mg and dexamethasone 5 mg intravenous
1841953|NCT00892996|Drug|dexamethasone 5 mg|Ondansetron 8 mg and dexamethasone 5 mg IV
1841954|NCT00893009|Drug|Theophylline|100 mg twice a day
1841955|NCT00893009|Drug|Placebo|Placebo
1841956|NCT00893048|Drug|Prednisone|Prednisone, 60 mg, one time at time of diagnosis
1841957|NCT00893048|Drug|Placebo Oral Tablet|Placebo
1841958|NCT00893061|Drug|anastrozole|Given orally
1841959|NCT00893061|Drug|exemestane|Given orally
1841960|NCT00893061|Drug|letrozole|Given orally
1841961|NCT00893061|Drug|tamoxifen citrate|Given orally
1841962|NCT00893074|Drug|Dronabinol 30mg/day|10mg dronabinol administered 3x/day for 5 days
1841963|NCT00893074|Drug|Dronabinol 60mg/day|20mg dronabinol administered 3x/day for 5 days
1841964|NCT00893074|Drug|Dronabinol 120mg/day|40mg dronabinol administered 3x/day for 5 days
1841965|NCT00893074|Drug|Placebo|placebo dronabinol administered 3x/day for 5 days
1841966|NCT00893087|Device|Triggering mode of the ventilator|10 min of each triggering mode
1841967|NCT00893087|Device|Triggering method of the ventilator|Flow triggering
1841968|NCT00893087|Device|Triggering method of the ventilator|Pressure triggering
1841969|NCT00893087|Device|Triggering method of the ventilator|NAVA triggering
1841970|NCT00893100|Drug|Diltiazem|2%,3 times daily
1841971|NCT00893113|Drug|Placebo|Alfuzosin-matched One tablet once daily
1841972|NCT00893113|Drug|Alfuzosin|10 mg once daily
1841973|NCT00893126|Procedure|CCTA Scan (Coronary CT Angiogram)|CCTA scan will be performed to study and evaluate the prevalence and severity of coronary artery disease (CAD).
1841974|NCT00893139|Drug|AL-38583 ophthalmic solution 0.05%|
1841975|NCT00893139|Drug|AL-38583 ophthalmic solution 0.10%|
1841976|NCT00893139|Drug|AL-38583 vehicle|Inactive ingredients used as a placebo comparator
1841977|NCT00893165|Behavioral|moderate physical activity|bed mounted cycles for physical activity for 30 min during each hemodialysis session
1841978|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|250 mcg
1841979|NCT00893217|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|500 mcg
1841980|NCT00893230|Dietary Supplement|probiotic L sakei KCTC 10755BP|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
1841981|NCT00893230|Dietary Supplement|microcrystalline cellulose (placebo)|freeze-dried, 50,0000,0000 colony-forming units, twice daily, for 12 weeks
1841982|NCT00893256|Drug|Risperidone|Risperidone: tablet; oral; 4-6 mg/day; once daily; 12 weeks
1841983|NCT00893256|Drug|risperidone|Risperidone: tablet; 4-8 mg/day; once daily; 12 weeks
1841984|NCT00893256|Drug|Citalopram|Citalopram: tablet; oral; 20 mg/day; once daily; 12 weeks
1841985|NCT00893256|Drug|Placebo|Placebo: once daily
1841987|NCT00893269|Drug|Placebo|Participants receive placebo prior to sleep
1841988|NCT00893269|Drug|ramelteon|ramelteon
1841989|NCT00893269|Drug|zolpidem|zolpidem
1841990|NCT00893282|Device|BackStop|BackStop in a gel plug that potentially prevents retropulsion during intracorporeal lithotripsy.
1841991|NCT00893282|Device|Intracorporeal lithotripsy without the use of an anti-retropulsion device|
1841992|NCT00893295|Other|informational intervention|
1841993|NCT00893295|Other|medical chart review|
1841994|NCT00893295|Other|screening questionnaire administration|
1841995|NCT00893295|Other|study of socioeconomic and demographic variables|
1841996|NCT00893295|Procedure|barium enema injection|
1841997|NCT00893295|Procedure|colon imaging study|
1841998|NCT00893295|Procedure|screening colonoscopy|
1841999|NCT00893295|Procedure|sigmoidoscopy|
1842000|NCT00893321|Procedure|Inferior Oblique Muscle Recession and Myectomy|
1842001|NCT00893347|Behavioral|Treatment as usual|Single session with early intervention coordinator for assessment, education about mild traumatic brain injury, and recommendations for symptom management.
1842002|NCT00893347|Behavioral|Cognitive-behavioural therapy|6-session manualized cognitive-behavioural therapy protocol designed to prevent persistent post-concussion syndrome
1842003|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 12.5 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
1842004|NCT00893360|Biological|Autologous stem cell infusion|Subjects will receive 25 million of autologous (grown from your own heart muscle specimen) cardiosphere-derived stem cells via intracoronary delivery.
1842005|NCT00893373|Drug|sorafenib|Standard AML chemotherapy plus sorafenib 400 mg BID
1842006|NCT00893373|Drug|placebo|Standard AML chemotherapy plus placebo
1842007|NCT00893386|Procedure|LV Lead Extraction|Removal of a LV lead using any tools & techniques.
1842008|NCT00893399|Drug|Gemtuzumab Ozogamicin (Mylotarg)|"Induction Cycle 1, 2: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after etoposide IVI. No dose reduction is foreseen in elderly (> 60 yrs) patients.
Consolidation 1: GO 3mg/m² by intravenous infusion (IVI) on day 1 (total dose 3 mg/m2). Start after first dose of high-dose cytarabine. No dose reduction is foreseen in elderly (> 60 yrs) patients.
For all patients experiencing prolonged thrombocytopenia CTC-Grade 3/4 during the first or second induction therapy, which occurs for more than day 35 after start of the cycle, the further cycles of therapy will be administered without Gemtuzumab ozogamicin.
Consolidation 2, 3: no GO"
1842009|NCT00893399|Drug|standard chemotherapy|Idarubicin, Etoposide, Cytarabine, ATRA, Pegfilgrastim
1842010|NCT00893412|Drug|Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)|1 tablet of 50 mg Fast-release Orodispersible Tramadol Tablet (Tradonal odis®)
1842011|NCT00893412|Procedure|Hysterosalpingography (HSG)|One HSG using a metal canula or balloon catheter, 30 minutes after tablet
1842012|NCT00893412|Drug|Placebo|
1842013|NCT00893425|Drug|ramipril|
1842016|NCT00893451|Drug|cholecalciferol (TillVal-D)|In a randomized, two-way cross-over design participants will take vitamin D3 or placebo twice daily during treatment periods of 10 weeks separated by a washout period of 6 weeks.
1842017|NCT00893451|Drug|Placebo|Placebo orally twice daily
1842018|NCT00893464|Drug|IXAZOMIB|Patients will be administered IXAZOMIB by IV on Days 1, 8, and 15 of a 28-day cycle. The first stage of the study will be initiated at a starting dose of 0.125 mg/m2. Subsequent doses will increase until a maximum tolerated dose (MTD) is established.
1842019|NCT00893477|Biological|rituximab|
1842020|NCT00893477|Biological|sargramostim|
1842021|NCT00893477|Genetic|gene expression analysis|
1842022|NCT00893477|Genetic|gene rearrangement analysis|
1842023|NCT00893477|Genetic|polymerase chain reaction|
1842024|NCT00893477|Genetic|polymorphism analysis|
1842025|NCT00893477|Other|laboratory biomarker analysis|
1842026|NCT00893490|Device|Ahmed Glaucoma Valve (AGV)|AGV implantation
1842027|NCT00893490|Drug|Mitomycin C (MMC)|3 minute MMC application
1842028|NCT00893490|Procedure|amniotic membrane coverage|single layer coverage of amniotic membrane
1842029|NCT00893503|Procedure|colonoscopy|Patients will provide stool and urine samples and will be scheduled to undergo a colonoscopy. The colonoscopy will be done per standard of care - no study specific procedural requirements imposed.
1842030|NCT00893516|Biological|CHOP + CD4|
1842031|NCT00893516|Drug|CHOP|
1842032|NCT00893529|Dietary Supplement|lemonade with sugar|250 milliliters of lemonade with sugar daily for 18 months
1842033|NCT00893529|Dietary Supplement|lemonade low in sugar|250 milliliters of lemonade low in sugar daily for 18 months
1842034|NCT00893542|Drug|Mycophenolate Mofetil|mycophenolate mofetil 250 mg capsule
1842035|NCT00893555|Drug|voriconazole|TDM (through level of 2-5mg/L).
1842036|NCT00893555|Drug|voriconazole (dosing according to the SPC)|No serum concentrations are determined
1842037|NCT00893568|Other|resonance magnetic imaging (fMRI),|a cerebral study will be performed at the neuroanatomic and functional levels by resonance magnetic imaging (fMRI) realized in three times (before, one week and six months after treatment)
1842038|NCT00893581|Drug|Quetiapine & Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
1842075|NCT00893867|Drug|DP-b99|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
1842076|NCT00893867|Drug|Placebo|1mg/kg/day over 4 consecutive days given intravenously and initiated up to 9 hours following acute stroke onset.
1842077|NCT00893880|Drug|1% gaseous Nitric Oxide blended in Oxygen|1% gaseous nitric oxide blended in oxygen applied for 30-60 minutes over 1-2 consecutive days.
1842039|NCT00893581|Drug|Lithium and Placebo|Bipolar adolescents will be initiated on 100 mg per day of quetiapine (or placebo) and 30 mg/kg (maximum starting dose of 600 mg twice daily) of lithium carbonate (or placebo), depending on randomization assignment. Patients will be given placebo for the medication to which they were not assigned. Quetiapine will be adjusted based on tolerability and response to a target dose of 400-600 mg and lithium will be adjusted to a target dose based on achieving a serum level of 1.0-1.2 mEq/L.
1842040|NCT00893581|Other|Healthy Controls|Healthy control (patients given placebo -- sugar pill intended to mimic drug)
1842041|NCT00893594|Drug|sumatriptan with naprosyn|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
1842042|NCT00893594|Drug|placebo|Subjects will be randomized before treatment. Subjects will take one sumatriptan 85mg/naprosyn 500mg tablets (Treximet) or placebo at onset of a migraine aura. Dose to be repeated at 2 hours if no effect in preventing onset of migraine pain.
1842043|NCT00893607|Drug|NRL001|10mg NRL001 was administered as a slow release suppository
1842044|NCT00893620|Device|Zenith(R) Connection Endovascular Covered Stent with the Zenith® Branch Endovascular Graft-Iliac Bifurcation and Zenith Flex(R) AAA Endovascular Graft|These devices will be used in patients with an unsuitable distal sealing site for the standard Zenith(R) iliac leg component proximal to the common iliac bifurcation to maintain internal iliac artery patency with endovascular aneurysm repair.
1842045|NCT00893646|Behavioral|weight loss counseling|individual monthly lifestyle counseling, face-to-face (6 times, each 45 min) and by telephone (7 times, each 30 min), on how to decrease energy intake and change eating habits to improve quality of dietary fat and carbohydrate, how to increase daily walking steps; and how to improve sleep quality (sleep hygienic tips)
1842046|NCT00893659|Dietary Supplement|wheat bread with beta-glucan|3 g beta-glucan in approximately 200 g of wheat bread per day for 3 months
1842047|NCT00893659|Dietary Supplement|wheat bread without beta-glucan|Approximately 200 g of wheat bread (without beta-glucan supplementation) per day for 3 months
1842048|NCT00893685|Device|Wireless monitors for disease specific clinical parameters.|Homes of participants will be equipped with wireless monitors for blood pressure, blood oxygen, blood glucose, peak expiratory flow, electrocardiogram, body weight. All vital parameters are monitored on a continuous, at least daily basis and obtained values are transmitted to a monitoring centre. Abnormal values are classified for their health risk and health alarms and/or intervention of health professionals is triggered.
1842049|NCT00893698|Procedure|bilateral allotransplantation|bilateral allotransplantation of upper limbs
1842050|NCT00893711|Other|Lactobacillus reuteri DSM 17938|Lactobacillus reuteri is administered at a dose of 1.000.000.000 colony forming units (CFU) in V drops/day for 21 days
1842051|NCT00893711|Other|Placebo|Placebo is administered in V drops once a day for 21 days. Placebo is inactive, similar to the studied treatment with the same package, taste, characteristics of colour and consistency.
1842052|NCT00893711|Dietary Supplement|L.reuteri + Vit D|
1842053|NCT00893711|Dietary Supplement|Vit D placebo|
1959286|NCT00542438|Behavioral|Environmental Assessments|Hand-held computer programs will be used to collect information about the community. Some factors will be assessed only once (e.g., availability of facilities) while other information will be collected over the course of 7 days (e.g., perceptions of neighborhood safety).
1959288|NCT00534209|Biological|Allogeneic B7.1/HLA-A1|Dose: At least 4x10^7 irradiated HLA/B7.1 transfected AD100 cells Given intradermally
1842057|NCT00893737|Drug|sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)|Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
1842058|NCT00893750|Behavioral|NET Truth Education|Individual Narrative Exposure and Truth Education in Groups
1842059|NCT00893750|Behavioral|Conflict Resolution and Social Competence Skills|Conflict Resolution and Social Competence Skills in Groups
1842060|NCT00893750|Behavioral|Traditional Ways of Coping|Methods Collected by Local Teachers to Help Vulnerable Children and Youths in Northern Uganda
1842061|NCT00893763|Procedure|Pre-intubation CHX|Oral application of 5 ml CHX gluconate 0.12% solution pre-intubation, and 5 ml CHX gluconate 0.12% solution twice a day following intubation.
1842062|NCT00893763|Procedure|Control|No pre-intubation intervention, 5 ml CHX gluconate 0.12% solution twice a day following intubation
1842064|NCT00893789|Drug|Armodafinil|Armodafinil 50 mg/day
1842065|NCT00893789|Drug|Armodafinil|Armodafinil 150 mg/day
1842066|NCT00893789|Drug|Armodafinil|Armodafinil 250 mg/day
1842067|NCT00893789|Other|Placebo|Placebo
1842068|NCT00893802|Other|Scaling and root planning|Intervention will consist of supra and subgingival scaling and root planning performed by a single trained periodontist using Gracey curettes (Hu-Friedy, Chicago, USA) without local or general anesthesia during the second trimester of gestation, followed by professional prophylaxis and oral hygiene instruction. Treatment will be performed only once during study.
1842069|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets and caplets, take with liquid before bedtime
1842070|NCT00893841|Drug|quetiapine (Seroquel) XR|tablets, take with liquid before bedtime
1842071|NCT00893841|Drug|placebo|placebo
1842072|NCT00893841|Drug|pramipexole dihydrochloride|tablets and caplets, take with liquid before bedtime
1842073|NCT00893854|Drug|Diclophenac|
1842074|NCT00893854|Drug|Triamcinolone|
1959289|NCT00534209|Other|Placebo|Given intradermally
1959290|NCT00532675|Drug|LBH589|
1842078|NCT00893906|Biological|seasonal trivalent inactivated influenza vaccine|vaccine to be used according to marketed dosage and frequency
1842079|NCT00893906|Biological|inactivated polio vaccine|vaccine to be used according to marketed dosage and frequency
1842080|NCT00893919|Drug|mycophenolate mofetil|mycophenolate mofetil 250 mg capsule
1842081|NCT00893945|Drug|DC/AAT|Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
1842082|NCT00893945|Drug|DC/AAT-Flu|Intradermal injection of Autologous dendritic cell vaccine (DC/AAT-Flu) after co-culture with flu-infected AAT
1842083|NCT00893945|Drug|DC/KLH|Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
1842084|NCT00893958|Drug|Mycophenolate Mofetil|Prophylaxis of Organ Rejection
1842085|NCT00893971|Drug|PT001|Inhaled PT001, single dose
1842086|NCT00893971|Drug|PT005|Inhaled PT005, single dose
1842087|NCT00893971|Drug|PT003|Inhaled PT003, single dose
1842088|NCT00893971|Drug|PT001 + PT005|Inhaled PT001 + PT005, single dose
1842089|NCT00893984|Drug|Nebivolol|Bystolic (Nebivolol), 5 mg per day for 30 days, titrated up to 10 mg at 2 weeks if necessary for blood pressure control.
1842090|NCT00893997|Biological|PR-1 vaccine|0.5 mg injections under the skin once every 3 weeks for a total of 4 vaccinations.
1842091|NCT00894010|Drug|carbamazepine 400mg|
1842092|NCT00894010|Drug|levetiracetam 1000mg|
1842093|NCT00894023|Drug|Intracoronary bolus wtih ClearWay™RX catheter|Intracoronary bolus with Clearway catheter
1842094|NCT00894023|Drug|IV abciximab|IV abciximab + infusion
1842095|NCT00894049|Drug|reduced intensity conditionings|comparison of non myeloablative (Flu-TBI) and reduced intensity (FLU-BU-ATG)
1842096|NCT00894062|Device|Zotarolimus eluting stent (Endeavor resoulte - ZES resolute)|Zotarolimus eluting stent (ZES)
1842097|NCT00894062|Device|Everolimus eluting stent (Xience - EES)|Everolimus eluting stent (EES)
1842098|NCT00894075|Biological|ENB-0040|1mg/kg subcutaneous injection thrice weekly for 6 months
1842099|NCT00894088|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
1842100|NCT00894101|Drug|[F-18] FLT|10 mCi [F-18] FLT and 10 mCi [F-18] FDG will be used for PET imaging.
1842101|NCT00894114|Biological|V520|MRKAd5 HIV-1 gag vaccine, a single dose 1.0 mL intramuscular injection
1842102|NCT00894114|Biological|Comparator: ALVAC-HIV vaccine|A single dose 0.1 intramuscular injection
1842103|NCT00894127|Device|CyPath|CyPath diagnostic assay for the early detection of lung cancer using sputum
1842104|NCT00887679|Drug|Escitalopram|10-20 mg/day oral of Escitalopram for 6-weeks. Escitalopram flexible dose (10-20 mg/day). A forced escalation schedule of escitalopram was used to titrate it to the maximum tolerated dose. Drug was discontinued at the end of the study.
1842105|NCT00887692|Behavioral|prone and supine position|patients will be treated alternating daily between prone and supine position for breast radiotherapy.
1842106|NCT00887705|Behavioral|ADL training|The control group gets the standard rehabilitation programme which includes one hour ADL- training. The experimental group also gets the standard rehabilitation program, but instead of one hour they get an additional five hours ADL- training.
1842107|NCT00887718|Biological|PET Scan|18F-Fluorodeoxyglucose (FDG) injection
1842108|NCT00887744|Device|Aperius® Percutaneous Interspinous Spacer|Implantation of the Aperius® device
1842109|NCT00887757|Drug|ABT-263|"150mg of ABT-263 is taken orally once daily on Days 1-3 and Days 8-10 out of each 21 day cycle.
325 mg of ABT-263 is taken orally once daily on days 1-3, 8-10, 15-17 out of each 28 day cycle.
This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study."
1842110|NCT00887757|Drug|gemcitabine|Gemcitabine 1000 mg/m2 will be given by intravenous infusion on Day 1 and Day 8 of each 21 day cycle. Gemcitabine 1000 mg/m2 will be given by intravenous infusion on days 1, 8 and 15 of each 28 day cycle.
1842111|NCT00887770|Drug|AZD5672|12 x 50mg tablet, oral, single dose
1842112|NCT00887770|Drug|Moxifloxacin|1 x 400mg capsule, oral, single dose
1842113|NCT00887770|Drug|placebo|12 x matched to AZD5672 50 mg tablet
1842114|NCT00887770|Drug|AZD5672|3 x 50mg tablet, oral. single dose
1842115|NCT00887770|Drug|placebo|9 x matched to AZD5672 50mg tablet
1842116|NCT00887770|Drug|placebo|1 x matched to Moxifloxacin capsule
1842120|NCT00887809|Drug|gemcitabine|
1842121|NCT00887809|Drug|docetaxel|
1842122|NCT00887809|Drug|bevacizumab|
1842123|NCT00887822|Drug|Bevacizumab|7.5 mg/kg IV infusion on Day 1 of every 3-week cycle
1842124|NCT00887822|Drug|Placebo|Placebo matched to bevacizumab on Day 1 of every 3-week cycle
1842125|NCT00887822|Drug|Capecitabine|1000 mg/m^2 orally twice daily on Days 1-14 of every 3-week cycle
1842126|NCT00887822|Drug|Cisplatin|80 mg/m^2 IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles
1842127|NCT00887835|Device|PERPOS™ PLS|To stabilize the spine as an aid to fusion through bilateral immobilization of the facet joints.
1842128|NCT00887848|Other|Lokomat training|15 sessions of Lokomat training within 5 weeks (3 trainings/week)
1842129|NCT00887861|Drug|Investigational new drug, company code: BGG492|
1842130|NCT00887861|Drug|Placebo|
1842131|NCT00887874|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study.
1842132|NCT00887900|Procedure|Deep anterior lamellar keratoplasty (DALK)|Deep anterior lamellar keratoplasty (DALK) using the big-bubble technique.
1842133|NCT00887900|Procedure|Penetrated keratoplasty|Regular corneal transplant using the penetrated keratoplasty technique
1842134|NCT00887913|Device|Fractional RF treatment with Matrix RF applicator|3 treatments, single pass, 2-50J
1842247|NCT00896207|Drug|Akt inhibitor SR13668|Given orally as a single dose
1842250|NCT00896246|Drug|Moviprep®|Two litres of solution administered orally as a divided dose
1842366|NCT00896857|Other|immunoenzyme technique|
1842135|NCT00887926|Biological|IMC-EB10|Cohort 1 will receive IMC-EB10 intravenously for 3 weekly infusions, followed by a 1-week observation period. The starting dose in Cohort 1 will be 5 mg/kg. After all patients in Cohort 1 complete the first cycle of therapy, dose escalation for subsequent cohorts will proceed as follows: Cohort 2 - 10 mg/kg, Cohort 3 - 20 mg/kg, Cohort 4 - 30 mg/kg. Patients who experience a dose limiting toxicity (DLT) will not receive further IMC-EB10 treatment, but will continue to be followed on the protocol. Patients may continue to receive IMC-EB10 therapy, in the absence of treatment failure, treatment intolerance, or other withdrawal criteria for additional 28-day cycles at the same dose that they initially received. Dosing for cycle 2 and beyond will be administered on Days 1, 8, 15, and 22 of a 28-day treatment cycle
1842136|NCT00887952|Procedure|Partial removal of carious dentine|All procedures will be carrying out under local anesthesia and rubber dam. The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to test group: cavity floor covered with calcium hydroxide cement; restoration using amalgam or steel crown following their usual clinical procedures based on the instructions of the manufacturer
1842137|NCT00887952|Procedure|Stepwise excavation|The treatment will be performed as follow: access to the lesion using rotator instruments (if necessary); fully removal of carious tissue from the cavity walls according to hardness criteria by rotator instruments and/or hand excavator; removal of the necrotic carious tissue (soft and disorganized carious tissue) from the cavity floor by hand excavator (to avoid pulp exposure); cleaning with distilled water and drying with sterile filter paper; group randomization. If the tooth is assigned to SE: indirect pulp capping with calcium hydroxide cement; temporary filling with IRM; cavity re-opening after 60 days, removal of the remaining soft carious tissue and filling following the same procedures described to test group.
1842138|NCT00887965|Drug|Previous denosumab|Participants who had previously received denosumab received a transiliac crest bone biopsy performed following standard labeling procedures with tetracycline or tetracycline derivative.
1842139|NCT00887978|Drug|UT-15C SR|treprostinil diolamine sustained release tablets
1842140|NCT00887978|Drug|Placebo|
1842141|NCT00888004|Drug|AFQ056|
1842142|NCT00888004|Drug|Placebo|
1842143|NCT00888030|Other|there are no interventions currently listed for this study|
1842144|NCT00888043|Drug|CNTO 95 and avastin|"STAGE 1 (Dose escalation) Cohort # subjects CNTO 95 Bevacizumab
2 3-6 2.5 mg/kg IV Q3 weeks 7.5 mg/kg IV Q3 weeks
1 3-6 2.5 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks
3-6 5 mg/kg IV Q3weeks 15 mg/kg IV Q3 weeks
3-6 10 mg/kg IV Q3 weeks 15 mg/kg IV Q3 weeks STAGE 2 (Biomarker) Cohort # subjects CNTO 95 Bevacizumab
20 Recommended Phase II Dose Recommended Phase II Dose"
1842145|NCT00888056|Procedure|Bilateral chronic electrical stimulation of the hypothalamus/fornix|Clinical, neuro-psychological, biological and imaging assessment will be performed 3 and one month before and 3, 6, 12 and 24 months after surgery. Bilateral electrodes (Medtronic 3389) will be implanted, under local anesthesia, by MR-guided frame-based stereotaxy, in the hypothalamic part of the fornix, before its entry in the mamillary body (well defined on T2 weighted sequences). Intra-operative stimulation will be used to search adverse effects or acute effects. Electrodes will be connected to the generator (Kinetra, Medtronic) under general anesthesia. Chronic high-frequency stimulation will be delivered immediately after surgery.
1842146|NCT00888069|Drug|CTAP101 Capsules|Single dose oral administration
1842147|NCT00888069|Drug|CTAP101 Injection|single IV injection
1842148|NCT00888082|Drug|Goserelin acetate|3.6 mg depot injectable preparation
1842149|NCT00888095|Procedure|deep brain stimulation|electrode implantation in either STN or cZI
1842150|NCT00888108|Drug|ABT-263|150 mg of ABT-263 is taken orally once daily on Days 1-5 or Days 1-3 of each 21 day cycle. 150 mg of ABT-263 on Days 1-3, 8-10 and 15-17 of each 28-day cycle. This is a dose escalation study, therefore the dose of ABT-263 will change throughout the study.
1842151|NCT00888108|Drug|Docetaxel|75 mg/m2 will be given by intravenous infusion on day 1 of each 21 -day cycle. 30 mg/m2 will be given by intravenous infusion on day 1, 8, 15 of each 28 -day cycle.
1842152|NCT00888134|Drug|Selumetinib|Given PO
1842153|NCT00888147|Dietary Supplement|Fiber containing tube feeding formula|This group will be prescribed adequate calories, protein and fluid using a formula that contains fiber.
1842156|NCT00888186|Drug|levodopa/carbidopa|intestinal gel, for continuous daytime infusion
1842157|NCT00888199|Device|Experimental prosthetic foot (K3 Promoter)|Experimental prosthetic foot
1842158|NCT00888212|Procedure|Bronchoscopy|Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
1842159|NCT00888225|Procedure|Eccentric exercise|Eccentric exercise treatment performed at home with three sets of 15 repetitions daily
1842160|NCT00888225|Procedure|Concentric exercise|Concentric exercise treatment at home with three sets of 15 repetitions daily
1842161|NCT00888238|Drug|sitagliptin|Single oral dose of sitagliptin 100 mg (2 x 50 mg) tablets followed by the hyperglycemic clamp procedure and meal tolerance test.
1842162|NCT00888238|Drug|Comparator: Placebo|Single oral dose of 2 tablets placebo to sitagliptin followed by the hyperglycemic clamp procedure and meal tolerance test.
1842163|NCT00888251|Other|Comprehensive weight management program|Full meal replacement, behaviorial modification, medical monitoring, exercise.
1842164|NCT00888290|Drug|Sodium bicarbonate|Sodium bicarbonate at 3 different doses or placebo. The different doses tested will be: 0.3 mEq/kg of ideal body weight, 0.6 mEq/kg of ideal body weight and 1 mEq/kg pf ideal body weight
1842165|NCT00888303|Drug|Dexamethasone|20 minutes before total or partial thyroidectomy for benign disease a single dose of intravenous 8 mg/2mL of dexamethasone is administered
1842166|NCT00888303|Drug|saline solution|20 minutes before total or partial thyroidectomy for benign disease 100 mg of saline solutions are administered intravenous
1842167|NCT00888303|Procedure|Thyroidectomy, total or partial|Surgical standard intervention
1842288|NCT00896467|Procedure|quality-of-life assessment|
1842168|NCT00888316|Procedure|magnetic resonance imaging|"MRI of the liver will be performed within 30 days prior to HSCT (day 0) and can be done during receipt of conditioning regimen chemotherapy and/or radiation therapy. MRI will also be performed in selected patients at 1 year post-HSCT. This MRI will be done within ± 30 days of their 1-year post-transplant followup date.
The R2 MRI is a specific MRI technique and cannot be used for the purpose of general diagnostic imaging. In our study, this modality is being used specifically for the estimation of LIC."
1842169|NCT00888316|Procedure|Serum ferritin|Blood samples will be taken pre-transplant, 3, 6, 9 and 12 months post-transplant
1842170|NCT00888329|Drug|Aprepitant|40 mg administered orally with a sip of water prior to anesthesia induction.
1842171|NCT00888329|Drug|Placebo|Placebo
1842172|NCT00888342|Drug|supplementary oxygen|Supplementary oxygen 2 L/min if SpO2 < 90%. If SpO2 < 90 % the oxygen dose is titrated until SpO2 reads 88-92%. For patients on LTOT the oxygen dose is doubled for intervention.
1842173|NCT00888342|Drug|zopiclone|5 mg sedative given approximately 1 hour before sleep
1842174|NCT00888342|Other|alcohol|5 mg alcohol/kg body-weight approximately 1 hour before sleep
1842175|NCT00888355|Drug|losartan potassium|losartan tablet (MK0954) 25 or 50 mg q.a.m. or 25 mg b.i.d., for 12 weeks
1842176|NCT00888355|Drug|Comparator: placebo|placebo to losartan tablet q.a.m. , for 12 weeks
1842177|NCT00888368|Procedure|Transpatellar Approach|The transpateller approach for the injection of the dye will be used.
1842178|NCT00888368|Procedure|Suprapatellar|The suprapatellar approach will be used for the injection of the dye.
1842179|NCT00888381|Biological|Inactivated Influenza Vaccine (2009 / 2010 formulation)|A single 0.5mL intramuscular injection into the deltoid region of the arm on Day 0.
1842180|NCT00888394|Procedure|chiropody|basic procedure of chiropody in podiatry
1842181|NCT00888394|Procedure|basic orthesis|individual basic orthesis of foot
1842182|NCT00888394|Procedure|advantage orthesis|advantage orthesis of foot with special material and design
1842183|NCT00888394|Procedure|chiropody and advantage orthesis|chiropody and advantage orthesis of foot
1842184|NCT00888407|Behavioral|HBV Screening - Small group educational session|Small group HBV focused discussion with HBV screening resources.
1842185|NCT00888407|Behavioral|Nutrition - Small group educational session|Small group session with diet & nutrition focused, topic related resources provided.
1842186|NCT00888420|Other|Performance Improvement Measures|PDSA (Plan, Do, Study, Act) performance improvement measures
1842187|NCT00888433|Device|Renal Denervation (Symplicity® Renal Denervation System)|Catheter-based renal denervation
1842188|NCT00888446|Biological|tgAAC09|
1842189|NCT00888446|Biological|tgAAC09|
1842190|NCT00888446|Biological|tgAAC09|
1842191|NCT00888446|Other|Formulation buffer|Sterile isotonic buffered salt solution
1842192|NCT00888459|Drug|nicotine replacement therapy|4 mg nicotine lozenges, ad lib, for 12 weeks.
1842193|NCT00888459|Drug|placebo NRT|Placebo nicotine lozenges
1842194|NCT00888472|Procedure|Leukocytapheresis|5000 ml, the blood volume per body, treated once. Twice at an interval of 6 days.
1842195|NCT00888485|Behavioral|Behavioral interventional program|Cognitive behavioral therapy intervention adapted to coronary disease patients performed in 20 group sessions during one year.
1842196|NCT00888498|Other|Passive Positioning|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface, which is similar to the positioning used for the active comparator groups. The treating investigator will maintain passive positioning of the ankle for the duration of 1 deep inhalation and exhalation by the subject rather than induce an iatrogenic force.
1842197|NCT00888498|Other|High-Velocity, Low-Amplitude Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. A thrust will be delivered parallel to the long axis of the subject's lower leg after the treating therapist induces passive ankle dorsiflexion to end range.
1842198|NCT00888498|Other|Slow, Mobilization Stretch|With the subject in a seated position on a treatment table and the lower extremity of interest stabilized to the table with a belt, a single standardized treating investigator will grasp the foot of interested with the thenar eminences on the foot's plantar surface. Traction will be delivered to the talocrural joint at the treating therapist's second perception of tissue resistance in 3 bouts of 30-second holds, separated by 10 seconds of rest.
1842201|NCT00888524|Procedure|GP in Physio|manual therapy, educational advice of health promotion and physical exercises therapy based in a individual assessment
1842202|NCT00888524|Procedure|GP in Physio plus DWR|GP in Physio plus a supplementation of DWR training in high intensive aerobic threshold
1842203|NCT00888537|Other|AMI Choice Decision Aid|The decision aid describes the risk of dying in the first six months following a heart attack without and with taking a bundle of medications to help the heart heal.
1842204|NCT00888537|Other|Usual Care|Patients and clinicians in this arm will discuss medications to help the heart heal after a heart attack in their usual manner.
1842205|NCT00894140|Device|DePuy Silent™ Hip femoral prosthesis|A short cementless, femoral component for use in total hip arthroplasty
1842206|NCT00894153|Drug|chemotherapy plus p53|chemotherapy plus p53
1842207|NCT00894153|Drug|chemotherapy|chemotherapy
1842208|NCT00894153|Radiation|radiotherapy|radiotherapy
1842209|NCT00894166|Drug|Nicotine Patches|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
1842248|NCT00896233|Procedure|MRE|"Part 1: Participants will have a screening visit, followed ~1 month later by two imaging visits over ~14 days. Each imaging visit will consist of two liver MRE scans.
Part 2: Participants will have a screening visit, followed ~1
month later by one imaging visit. The imaging visit will consist
of two liver MRE scans."
1842249|NCT00896246|Drug|Klean-Prep®|Four litres of solution administered orally as a divided dose.
1842210|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches)nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
1842211|NCT00894166|Drug|Nicotine patches, then varenicline (Pre-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first week (# of daily patches based on baseline carbon monoxide level); starting with week 2: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
1842212|NCT00894166|Drug|Nicotine patches, then nicotine patches (Pre-Quit)|21mg (1 patch) or 42mg (2 patches)nicotine patches for first five weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
1842213|NCT00894166|Drug|Nicotine patches, then bupropion & nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 150mg of bupropion once daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for first 3 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg (1 patch) or 42mg (2 patches) nicotine patches for 3 weeks and 4 days (# of daily patches based on baseline carbon monoxide level); 150mg of bupropion twice daily and 21mg nicotine patch for 4 weeks; 150mg of bupropion twice daily and 14mg nicotine patch for 2 weeks and 150mg of bupropion twice daily and 7mg nicotine patch for 2 weeks.
1842214|NCT00894166|Drug|Nicotine patches, then varenicline (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first three weeks (# of daily patches based on baseline carbon monoxide level); starting with week 4: 0.5mg of varenicline once daily for first 3 days; 0.5mg of varenicline twice daily for the next 4 days; and 1mg of varenicline twice daily for the remainder of the study (11 weeks)
1842215|NCT00894166|Drug|Nicotine patches, then nicotine patches (Post-Quit)|21mg (1 patch) or 42mg (2 patches) nicotine patches for first seven weeks (# of daily patches based on baseline carbon monoxide level); 21mg nicotine patch for 4 weeks; 14mg nicotine patch for 2 weeks and 7mg nicotine patch for 2 weeks.
1842216|NCT00894192|Device|Izon Wavefront-guided lenses|Subjects will use prescribed eyeglasses for one week. Their visual functioning will be tested at the end of the week.
1842217|NCT00894192|Device|Conventional lenses|We will test the subjects with these lenses after they have worn them for one week. Same procedures will be followed as with the other lenses.
1842218|NCT00894205|Behavioral|strengthening exercise program|"A low intensity strengthening exercise program based on the Tufts University Strong Bones program. Utilizes small free weights and chair exercises. Participants attend community based class 2-3x/wk for 4 wks."
1842219|NCT00894218|Procedure|Arthroplasty|Hip or knee arthroplasty
1842220|NCT00894231|Drug|levocetirizine (Xyzal)|5mg po QD
1842221|NCT00894231|Drug|placebo|sugar tablet
1842222|NCT00894244|Device|Radiofrequency device|One treatment pass on one arm. 2-5 treatment passes on the other
1842223|NCT00894270|Procedure|Sterile air injection|Injection of 20 microlitres using Novofine 5mm needle of sterile air into either abdomen or thigh using either a pinched or unpinched skin fold and either a vertical or angled approach.
1842224|NCT00894270|Procedure|Placebo injection|Injection of either 20, 40 or 60 IU of placebo media into either abdomen or thigh using either a vertical or angled Novofine 5 mm needle. Leakage of fluid will be blotted and then weighed to establish fluid loss.
1842225|NCT00894270|Device|Novofine needle|Novofine 5mm needle
1842226|NCT00894283|Drug|Enoxaparin|Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.
1842227|NCT00894283|Drug|Fondaparinux|Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.
1842228|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 10.0 mg, single injection
1842229|NCT00894322|Drug|exenatide once weekly|subcutaneous injection, 2.0 mg, once a week for 12 weeks
1842230|NCT00894322|Other|Placebo|subcutaneous injection, volume equivalent to Cohort 2 experimental intervention, once a week for 12 weeks
1842231|NCT00894361|Procedure|TKA surgery with the rotating platform mobile-bearing knee design|Depuy Sigma RP rotating platform design
1842232|NCT00894361|Procedure|TKA surgery with the all-polyethylene tibia knee design|Depuy Sigma fixed-bearing design with all-polyethylene tibia
1842233|NCT00894374|Drug|Artesunate (Test)|Oral tablet, single dose, 1 x 100 mg
1842234|NCT00894374|Drug|Artesunate (Comparator)|Oral tablet, single dose, 2 x 50 mg
1842235|NCT00894387|Drug|Aliskiren|Aliskiren 150 mg and Aliskiren 300 mg
1842236|NCT00894387|Drug|Placebo|Placebo
1842237|NCT00894400|Procedure|catheter ablation|catheter ablation using radiofrequency energy
1842238|NCT00894413|Drug|Tadalafil|20 mg once daily for 10 - 14 days
1842239|NCT00894413|Other|Placebo Pill|Placebo
1842240|NCT00894439|Drug|BLI-489/Piperacillin|
1842241|NCT00894439|Drug|BLI-489|
1842242|NCT00894439|Drug|Piperacillin|
1842243|NCT00894465|Drug|midazolam|Children are randomized to receive oral midazolam .5 mg/kg prior to undergoing VCUG
1842244|NCT00894465|Drug|placebo|Children are randomized to receive a placebo prior to undergoing VCUG
1842245|NCT00896194|Behavioral|Standard Behavioral Treatment|SBT consists of group counseling sessions where participants learn about healthy eating and physical activity. Participants are also given standard calorie goals, fat gram goals, and physical activity goals (minutes).
1842246|NCT00896194|Behavioral|Modified Standard Behavioral Intervention + Self-Efficacy|This group receives identical group intervention sessions. The goals (calories, fat grams, and physical activity minutes) are tailored to the individual's progress. Participants meet regularly with an interventionist for one-on-one lifestyle counseling.
1842251|NCT00896259|Other|home based exercise and education program|Individual assessment with physiotherapist with educational information, exercise instruction and prescription provided. Instructed to perform home exercises and walking for 12 weeks. Will be individually tailored to participants, bi-monthly phone calls will be used to monitor and facilitate exercise and walking progression .
1842252|NCT00896285|Other|Large bore chest drain + NSAID based analgesic regimen|Chest tube greater than 14 French size and ibuprofen.
1842253|NCT00896285|Other|Small bore chest drain + NSAID based analgesic regimen|Chest tube less than or equal to 14 French size and ibuprofen.
1842254|NCT00896285|Other|Large bore chest drain + opiate based analgesic regimen|Chest tube greater than 14 French size and morphine.
1842255|NCT00896285|Other|Small bore chest drain + opiate based analgesic regimen|Chest tube less than or equal to 14 French size and morphine.
1842256|NCT00896298|Drug|Leptin|Leptin injected subcutaneously twice a day, to be administered at 100% of the estimated replacement dose during the first month, which is a dosage of 0.03mg/kg for female children, 0.04mg/kg for adult females, and0.02 mg/kg for all males, and then at 200% subsequently, or placebo.
1842257|NCT00896298|Drug|Placebo|Sugar pill
1842258|NCT00896311|Drug|IV Nitroglycerin|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
1842259|NCT00896311|Drug|Normal saline|IV injection, initial dose of 1ml, with further doses of 1-3mL, up to a recommended maximum of 10mL
1842260|NCT00896324|Behavioral|Cognitive Rehabilitation|Cognitive rehabilitation exercises: 30 minutes per day, 5 days per week for 6 weeks.
1842261|NCT00896324|Behavioral|Neurofeedback Training (randomized)|Neurofeedback training: 2-3, 30 min training sessions.
1842262|NCT00896324|Behavioral|Neuropsychological testing and MRI assessments|Neurofeedback training: 2-3, 30 min training sessions.
1842263|NCT00896337|Device|Epic™ Nitinol Stent System|The Epic™ Nitinol Stent System is comprised of two components: the implantable nitinol endoprosthesis and the stent delivery system.
1842264|NCT00896337|Drug|Anti-platelet therapy|Investigators must prescribe concomitant anti-platelet medication consistent with current clinical practice. Anti-platelet therapy should be administered preprocedure and continued throughout participation in the trial.
1842265|NCT00896337|Drug|Anti-coagulation therapy|Anti-coagulation therapy must be administered during the procedure consistent with current clinical practice.
1842266|NCT00896350|Drug|chemotherapy|
1842267|NCT00896350|Other|diagnostic laboratory biomarker analysis|
1842268|NCT00896350|Other|tissue oxygen measurement|
1842269|NCT00896350|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
1842270|NCT00896350|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1842271|NCT00896350|Procedure|magnetic resonance spectroscopic imaging|
1842272|NCT00896350|Radiation|radiation therapy|
1959302|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
1842275|NCT00896376|Biological|trastuzumab|
1842276|NCT00896376|Other|laboratory biomarker analysis|
1842277|NCT00896376|Other|pharmacological study|
1842278|NCT00896389|Procedure|Salt loading|"We will perform salt loading intervention, a routinely prescribed diagnostic test to determine if patients have hypoaldosteronism, on 120 subjects. After overnight fasting, subjects will arrive at the Amish Research clinics. After taking height, weight, BP, and body temperature (intervention will not proceed if fever is detected), the patient will be in supine position, have IV line inserted and fitted for an automatic BP monitor. BP will be taken every 5 minutes until the last 3 SBP (systolic blood pressure) readings are within 3 mmHg. Once the BP has equilibrated 2 L of 0.9% NaCl (sodium chloride) saline will be intravenously infused over 4 hours. BP will be taken every 15 minutes during this procedure and for 2 hours after the intervention. Blood and urine samples will be collected from all subjects pre- and post-infusion."
1842279|NCT00896389|Drug|Hydrochlorothiazide (HCTZ)|We will perform short-term HCTZ intervention on the same 120 subjects.The subjects will arrive to the ARC after overnight fasting (day 1), have their height, weight, and BP measured. Subjects are given seven 12.5 mg HCTZ tablets and instructed to take 1 tablet daily for one week. The subjects will return to ARC on day 8 and have height, weight, and BP measured again. Blood and urine will be collected on both day 1 and day 8. After a minimum 6-week wash-out period, the subjects will come back to the ARC and repeat the 7-day diuretics intervention, taking 25 mg of HCTZ instead. Subjects with plasma potassium levels below 3.6 mmol/L on day 8 of 12.5 mg HCTZ will be given a daily supplement of 16 milliequivalents of potassium to prevent harmful loss of potassium while taking HCTZ.
1842280|NCT00896402|Drug|Skin antisepsis with chlorhexidine|Chlorhexidine swabs will be used to antiseptically clean the skin, then cultures of the skin and femoral nerve block catheters will be analyzed via standard microbiological techniques
1842281|NCT00896402|Drug|povidone-iodine|Povidone-iodine swabs will be used to antiseptically clean the skin; then cultures of the skin and femoral nerve catheters will be performed by standard microbiologic techniques
1842282|NCT00896428|Drug|Methoxyverapamil (gallopamil)|200 mg/day (1 tablet 100 mg morning and evening) for 12 months.
1842283|NCT00896428|Drug|Placebo.|1 tablet morning and evening for 12 months
1959303|NCT00494442|Drug|KU-0059436 (AZD2281)(PARP inhibitor)|oral
1842285|NCT00896454|Drug|denosumab|120 mg subcutaneously (SC) every 4 weeks with a loading dose of 120 mg SC on study days 8 and 15.
1842286|NCT00896467|Other|questionnaire administration|
1842287|NCT00896467|Procedure|psychosocial assessment and care|
1959310|NCT00432965|Device|Moist Wound Therapy|Moist Wound Therapy (Standard of Care)
1842290|NCT00896493|Drug|anti-thymocyte globulin|1.5 mg/kg x 5 days, IV
1842291|NCT00896493|Drug|cyclosporine|5 mg/kg PO or IV
1842292|NCT00896519|Biological|rituximab|
1842293|NCT00896519|Biological|sargramostim|
1842294|NCT00896519|Drug|cyclophosphamide|
1842295|NCT00896519|Drug|doxorubicin hydrochloride|
1842296|NCT00896519|Drug|prednisone|
1842297|NCT00896519|Drug|vincristine sulfate|
1842298|NCT00896519|Genetic|gene expression analysis|
1842299|NCT00896519|Genetic|gene rearrangement analysis|
1842300|NCT00896519|Genetic|polymerase chain reaction|
1842301|NCT00896519|Other|R-CHOP regimen|
1842302|NCT00896519|Other|laboratory biomarker analysis|
1842303|NCT00896532|Drug|Placebo to Romosozumab|Administered by subcutaneous injection QM or Q3M.
1842304|NCT00896532|Drug|Alendronate|Administered orally once a week
1842305|NCT00896532|Drug|Teriparatide|Teriparatide 20 μg administered by subcutaneous injection once a day
1842306|NCT00896532|Drug|Romosozumab|Administered by subcutaneous injection
1842307|NCT00896532|Drug|Denosumab|Denosumab 60 mg administered by subcutaneous injection Q6M
1842308|NCT00896532|Drug|Placebo to Denosumab|Administered by subcutaneous injection Q6M
1842309|NCT00896532|Drug|Zoledronic acid|Zoledronic acid 5 mg administered intravenously
1842310|NCT00896545|Behavioral|5-keys counseling|5-session small group intervention
1842311|NCT00896545|Behavioral|Lifestyle counseling|5-session small group behavioral intervention
1842312|NCT00896558|Drug|GSK1322322/placebo|GSK1322322/placebo escalating doses from 500mg to 1500mg
1842313|NCT00896558|Drug|GSK1322322/placebo and midazolam|GSK1322322/placebo and 5mg midazolam
1842314|NCT00896571|Drug|Ethinylestradiol/Gestogene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
1842315|NCT00896597|Drug|NRL972|2 mg NRL972 in 5 mL solution for injection administered as a 15-second intravenous injection on each of four occasions.
1842316|NCT00896623|Genetic|mutation analysis|
1842317|NCT00896623|Genetic|polymorphism analysis|
1842318|NCT00896623|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|
1842319|NCT00896636|Procedure|Random fine need aspiration (rFNA)|Deep infiltration into the tissue of each breast with up to a 21 gauge needle attached to a syringe with about 4-5 passes at each location (up to 8-10 passes per breast) under local anesthesia (lidocaine).
1842320|NCT00896636|Other|Mammogram|Standard mammography of both breasts to obtain images for breast density measurement.
1842321|NCT00896649|Other|questionnaire administration|Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.
1842322|NCT00896649|Procedure|digital mammography|standard screening mammogram
1842323|NCT00896649|Procedure|positron emission mammography|one-time positron emission mammography to compare recall rates with that of standard mammogram
1842324|NCT00896662|Other|immunologic technique|immunologic technique
1842325|NCT00896662|Other|laboratory biomarker analysis|laboratory biomarker analysis
1842326|NCT00896662|Other|pharmacological study|pharmacological study
1842327|NCT00896675|Other|proteomic profiles|blood samples analysis
1842328|NCT00896675|Other|proteomic profiles|blood samples analysis
1842329|NCT00896688|Procedure|cervical medial branch blocks using the Quincke spinal needle|#25 gauge 1 and 1/2 inch long needle and #25 gauge 10cm long Quincke spinal needle will be used for placement.
1842330|NCT00896701|Other|flow cytometry|
1842331|NCT00896701|Other|immunologic technique|
1842332|NCT00896701|Other|laboratory biomarker analysis|
1842333|NCT00896714|Device|Closed loop anesthesia|Propofol and Remifentanil are administered automatically using a closed-loop system
1842334|NCT00896727|Genetic|gene expression analysis|
1842335|NCT00896727|Genetic|protein expression analysis|
1842336|NCT00896727|Other|fluorescent antibody technique|
1842337|NCT00896727|Other|laboratory biomarker analysis|
1842338|NCT00896740|Genetic|microarray analysis|
1842339|NCT00896740|Procedure|biopsy|
1842340|NCT00896766|Genetic|loss of heterozygosity analysis|
1842341|NCT00896766|Genetic|microarray analysis|
1842342|NCT00896766|Genetic|polymorphism analysis|
1842343|NCT00896766|Genetic|tumor replication error analysis|
1842344|NCT00896779|Drug|ranibizumab|"Group 1 - 0.5mg intravitreal injection every month for 3 months then as needed for 12 months
Group 2 -0.5mg intravitreal injection every month for 6 months then as needed for 12 months"
1842345|NCT00896792|Other|counseling intervention|
1842346|NCT00896792|Other|questionnaire administration|
1842347|NCT00896792|Other|survey administration|
1842348|NCT00896792|Procedure|end-of-life treatment/management|
1842349|NCT00896792|Procedure|psychosocial assessment and care|
1842350|NCT00896818|Genetic|DNA analysis|
1842351|NCT00896818|Genetic|genetic linkage analysis|
1842352|NCT00896818|Genetic|loss of heterozygosity analysis|
1842353|NCT00896818|Genetic|polymorphism analysis|
1842354|NCT00896818|Other|laboratory biomarker analysis|
1842355|NCT00896818|Other|medical chart review|
1842356|NCT00896818|Other|questionnaire administration|
1842357|NCT00896831|Drug|L-ornithine-L-aspartate|L-ornithine-L-aspartate: 5 g (1 sachet) three times per day for 60 days
1842358|NCT00896831|Drug|placebo|Placebo: 5 g (1 sachet) three times per day for 60 days
1842359|NCT00896844|Behavioral|emotional disclosure|writing about emotional events from the past
1842360|NCT00896844|Behavioral|placebo writing|writing about how they spent their time the previous day
1842361|NCT00896857|Genetic|RNA analysis|
1842362|NCT00896857|Genetic|polymerase chain reaction|
1842363|NCT00896857|Genetic|protein expression analysis|
1842364|NCT00896857|Genetic|reverse transcriptase-polymerase chain reaction|
1842365|NCT00896857|Genetic|western blotting|
1842367|NCT00896857|Other|immunohistochemistry staining method|
1842368|NCT00896857|Other|laboratory biomarker analysis|
1842369|NCT00896857|Procedure|breast duct lavage|
1842370|NCT00896883|Device|Middle Turbinate Implant|Middle Turbinate Implant placement at time of surgery and follow ups.
1842371|NCT00896896|Other|immunologic technique|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
1842372|NCT00896896|Other|laboratory biomarker analysis|Sera from head and neck cancer or colorectal cancer patients who were treated with cetuximab will be obtained from Tumor Tissue Repository
1842373|NCT00896909|Genetic|gene expression analysis|
1842374|NCT00896909|Genetic|mutation analysis|
1842375|NCT00896909|Genetic|polymerase chain reaction|
1842376|NCT00896909|Other|diagnostic laboratory biomarker analysis|
1842377|NCT00896922|Genetic|microarray analysis|
1842378|NCT00896922|Other|immunohistochemistry staining method|
1842379|NCT00896922|Other|laboratory biomarker analysis|
1842380|NCT00896935|Other|biologic sample preservation procedure|biologic sample preservation procedure
1842381|NCT00896948|Genetic|Southern blotting|
1842382|NCT00896948|Genetic|TdT-mediated dUTP nick end labeling assay|
1842383|NCT00896948|Genetic|gene expression analysis|
1842384|NCT00896948|Genetic|protein expression analysis|
1842385|NCT00896948|Other|flow cytometry|
1842386|NCT00896948|Other|fluorescent antibody technique|
1842387|NCT00896948|Other|immunoenzyme technique|
1842388|NCT00896948|Other|immunohistochemistry staining method|
1842389|NCT00896948|Other|immunologic technique|
1842390|NCT00896961|Drug|EF5|
1842391|NCT00896961|Other|diagnostic laboratory biomarker analysis|
1842392|NCT00896961|Other|pharmacological study|
1842393|NCT00896974|Other|Laboratory Biomarker Analysis|Correlative studies
1842394|NCT00896974|Other|Pharmacological Study|Correlative studies
1842395|NCT00896974|Drug|Retinoid 9cUAB30|Given orally
1842396|NCT00896987|Drug|lamotrigine (Lamictal)|lamotrigine: titration for 8 weeks (25 mg~200 mg per 2 weeks) and maintenance for 40 weeks (200 mg)
1842397|NCT00896987|Drug|Carbamazepine (Tegretol)|Carbamazepine: titration for 8 weeks (100 mg~600 mg) and maintenance for 40 weeks (600 mg)
1842398|NCT00897026|Drug|cyclophosphamide|
1842399|NCT00897026|Drug|doxorubicin hydrochloride|
1842400|NCT00897026|Drug|paclitaxel|
1842401|NCT00897026|Genetic|fluorescence in situ hybridization|
1842402|NCT00897026|Other|immunohistochemistry staining method|
1842403|NCT00897039|Other|flow cytometry|
1842404|NCT00897039|Other|immunohistochemistry staining method|
1842405|NCT00897052|Genetic|microarray analysis|Assay RNA obtained from archived formalin fixed paraffin embedded tissue samples
1842406|NCT00897052|Other|laboratory biomarker analysis|The gene expression data will be linked to the clinical information in order to generate profile of recurrence and survival as a biomarker.
1842407|NCT00897065|Genetic|microarray analysis|
1842408|NCT00897065|Genetic|polymerase chain reaction|
1842409|NCT00897065|Genetic|protein expression analysis|
1842410|NCT00897065|Other|diagnostic laboratory biomarker analysis|
1842411|NCT00897065|Other|fluorescent antibody technique|
1842412|NCT00897065|Other|immunohistochemistry staining method|
1842413|NCT00897065|Other|immunologic technique|
1842414|NCT00897078|Other|laboratory biomarker analysis|Not specified
1842415|NCT00897078|Other|medical chart review|not specified
1842416|NCT00897078|Other|metabolic assessment|not specified
1842417|NCT00897078|Other|questionnaire administration|will be obtained at a single clinic visit
1842418|NCT00897078|Procedure|assessment of therapy complications|not specified
1842419|NCT00897091|Genetic|comparative genomic hybridization|
1842420|NCT00897091|Genetic|microarray analysis|
1842421|NCT00897091|Genetic|reverse transcriptase-polymerase chain reaction|
1842422|NCT00897091|Other|diagnostic laboratory biomarker analysis|
1842423|NCT00897104|Drug|rizatriptan benzoate (MK0462)|single dose 5 mg rizatriptan p.o.
1842424|NCT00897104|Drug|Comparator: sumatriptan|single dose 50 mg sumatriptan p.o.
1842425|NCT00897104|Drug|Comparator: Placebo|Placebo to rizatriptan or sumatriptan, single dose placebo tablet taken orally
1842426|NCT00897117|Genetic|gene expression analysis|Blood and lung tissue collection
1842427|NCT00897117|Genetic|microarray analysis|Blood and lung tissue collection
1842428|NCT00897117|Genetic|protein expression analysis|Blood and lung tissue collection
1842429|NCT00897117|Other|biologic sample preservation procedure|Blood and lung tissue collection
1842430|NCT00897117|Other|laboratory biomarker analysis|Blood and lung tissue collection
1842431|NCT00897117|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Blood and lung tissue collection
1842432|NCT00897130|Drug|Azacytidine|Azacitidine will be given at a dose of 75mg/sqm subcutaneous daily for 5 consecutive days every 28 days (every month) for a total of 8 courses. 5-Aza dosages will be adjusted
1842433|NCT00897143|Genetic|microarray analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
1842434|NCT00897143|Genetic|mutation analysis|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
1842435|NCT00897143|Other|flow cytometry|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
1842436|NCT00897143|Other|immunologic technique|analyzed using an immunomagnetic bead enrichment assay to isolate cells of epithelial origin
1842437|NCT00897169|Other|Oral Glucose Tolerance Test (OGTT)|A 5-hour oral glucose tolerance test (OGTT) is performed at visit 2
1842438|NCT00897169|Other|Euglycaemic hyperinsulinaemic clamp|A 4-hour euglycaemic, hyperinsulinaemic clamp is performed at visit 3
1842439|NCT00897182|Genetic|microarray analysis|
1842440|NCT00897182|Genetic|polymerase chain reaction|
1842441|NCT00897208|Other|high performance liquid chromatography|
1842442|NCT00897208|Other|laboratory biomarker analysis|
1842443|NCT00897208|Other|mass spectrometry|
1842444|NCT00897208|Other|medical chart review|
1842445|NCT00897208|Procedure|evaluation of cancer risk factors|
1842446|NCT00897221|Drug|Deferiprone oral solution 100mg/mL|Deferiprone oral solution (20 mg/kg/day)
1842447|NCT00897221|Drug|Deferiprone oral solution 100 mg/mL|Deferiprone oral solution(40mg/kg/day)
1842448|NCT00897234|Other|Mass Spectrometry|Levels of Cathepsin D (CD) and fatty acid synthase (FAS) will be measured using isobaric tag labeling coupled with mass spectrometry. RNA concentration will be measured using spectrophometer and purity will be analyzed.
1842449|NCT00897247|Genetic|microarray analysis|
1842450|NCT00897247|Genetic|protein expression analysis|
1842451|NCT00897247|Genetic|proteomic profiling|
1842452|NCT00897247|Other|laboratory biomarker analysis|
1842453|NCT00897260|Drug|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|"To determine the time to and rate of hematologic engraftment following unrelated umbilical cord blood transplantation in adults with one or two cord blood units using total body irradiation and fludarabine as the transplant conditioning regimen and cyclosporine/MMF as graft-versus-host disease prophylaxis.
DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
Fludarabine 40mg/m2 10:00am (After TBI) over 60 minutes x x x x Umbilical cord blood infusion (minimum of 24hrs after Flu infusion) x
Fludarabine dose adjustment:
70ml/min: decrease dose by Creatinine Clearance 20% Fludarabine dosing will be based on the 40% adjusted ideal body weight.
UCB Infusion"
1842454|NCT00897260|Radiation|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|DRUG/DOSE DAYS -9 -8, -7 -6 -5 -4 -3 -2 -1 Total Body Irradiation 150 cGy per treatment (1350cGy total) 2x 2x 2x 2x 1x
1842455|NCT00897260|Procedure|Umbilical Cord Blood Transplantation as Treatment of Adult Patients with Hematologic Disorders|
1842456|NCT00897273|Genetic|comparative genomic hybridization|
1842457|NCT00897273|Genetic|gene expression analysis|
1842458|NCT00897273|Other|study of socioeconomic and demographic variables|
1842459|NCT00897273|Procedure|evaluation of cancer risk factors|
1842460|NCT00897273|Procedure|study of high risk factors|
1842461|NCT00897299|Genetic|microarray analysis|
1842462|NCT00897299|Genetic|protein expression analysis|
1842463|NCT00897299|Other|immunohistochemistry staining method|
1842464|NCT00897299|Other|laboratory biomarker analysis|
1842465|NCT00897312|Biological|infliximab|Not specified
1842466|NCT00897312|Biological|pegylated interferon alfa|not specified
1842467|NCT00897312|Biological|ticilimumab|not specified
1842468|NCT00897312|Drug|ribavirin|not specified
1842469|NCT00897312|Other|high performance liquid chromatography|not specified
1842470|NCT00897312|Other|laboratory biomarker analysis|not specified
1842473|NCT00897338|Other|flow cytometry|laboratory analysis
1842474|NCT00897338|Other|fluorescence activated cell sorting|laboratory analysis
1842475|NCT00897338|Other|immunohistochemistry staining method|laboratory analysis
1842476|NCT00897338|Other|immunologic technique|laboratory analysis
1842477|NCT00897338|Other|biomarker analysis|laboratory analysis
1842478|NCT00897351|Genetic|mutation analysis|
1842479|NCT00897351|Genetic|polymorphism analysis|
1842480|NCT00897351|Genetic|protein expression analysis|
1842481|NCT00897351|Other|immunohistochemistry staining method|
1842482|NCT00897351|Other|laboratory biomarker analysis|
1842483|NCT00897377|Radiation|Radiation therapy|
1842484|NCT00897377|Drug|Temozolomide|
1842485|NCT00897390|Drug|Saxagliptin|Tablet, Oral, 2.5 mg, Once Daily, 1 week
1842486|NCT00897390|Drug|Metformin IR (glucophage)|Tablets, Oral, 1000 mg, Once Daily, 1 week
1842487|NCT00897390|Drug|Saxagliptin + Metformin IR (FDC)|Tablet, Oral, Saxagliptin 2.5 mg + metformin IR 1000 mg, Once Daily, 1 Week
1842488|NCT00897403|Other|biologic sample preservation procedure|
1842489|NCT00897403|Procedure|diagnostic colonoscopy|
1842490|NCT00897416|Other|laboratory biomarker analysis|
1842491|NCT00897429|Procedure|laboratory biomarker analysis|Correlative studies
1842492|NCT00897442|Other|Laboratory Biomarker Analysis|Correlative studies
1842493|NCT00897455|Genetic|DNA analysis|
1842494|NCT00897455|Genetic|mutation analysis|
1842495|NCT00897455|Genetic|polymorphism analysis|
1842496|NCT00897455|Other|laboratory biomarker analysis|
1842497|NCT00897455|Procedure|evaluation of cancer risk factors|
1842498|NCT00897468|Other|laboratory biomarker analysis|Tissue samples will either be collected at the time of medically indicated surgical procedures or through research core biopsies. A sample of urine will also be obtained. Blood will be collected via venipuncture and lymphocytes (mononuclear cells) separated and processed as a source of normal DNA and normal cells.
1842499|NCT00897468|Other|medical chart review|patient chart review will occur in conjunction with patient data collection for final analyses.
1842500|NCT00897481|Genetic|gene expression analysis|
1842501|NCT00897481|Genetic|mutation analysis|
1842502|NCT00897481|Other|diagnostic laboratory biomarker analysis|
1842503|NCT00897481|Other|immunohistochemistry staining method|
1842504|NCT00897481|Procedure|sentinel lymph node biopsy|
1842505|NCT00897494|Genetic|protein expression analysis|Venous blood collection
1842506|NCT00897494|Other|laboratory biomarker analysis|Venous blood collection
1842507|NCT00897494|Other|mass spectrometry|Venous blood collection
1842508|NCT00897494|Other|surface-enhanced laser desorption/ionization-time of flight mass spectrometry|Venous blood collection
1842509|NCT00897507|Genetic|polymorphism analysis|
1842510|NCT00897520|Biological|recombinant interferon alfa|
1842511|NCT00897520|Genetic|proteomic profiling|
1842512|NCT00897520|Other|immunoenzyme technique|
1842513|NCT00897520|Other|laboratory biomarker analysis|
1842514|NCT00897533|Genetic|gene mapping|
1842515|NCT00897533|Genetic|polymorphism analysis|
1842516|NCT00897533|Other|diagnostic laboratory biomarker analysis|
1842517|NCT00897533|Other|immunohistochemistry staining method|
1842518|NCT00897546|Other|laboratory biomarker analysis|
1842519|NCT00897559|Genetic|gene expression analysis|
1842520|NCT00897559|Genetic|mutation analysis|
1842521|NCT00897559|Genetic|polymorphism analysis|
1842522|NCT00897559|Genetic|protein analysis|
1842523|NCT00897559|Other|flow cytometry|
1842524|NCT00897559|Other|laboratory biomarker analysis|
1842525|NCT00897611|Procedure|DNA methylation analysis|
1842526|NCT00897611|Procedure|polymerase chain reaction|
1842527|NCT00897611|Procedure|computed tomography|
1842528|NCT00897611|Procedure|magnetic resonance imaging|
1842529|NCT00897624|Genetic|gene expression analysis|
1842530|NCT00897624|Genetic|reverse transcriptase-polymerase chain reaction|
1842531|NCT00897624|Other|laboratory biomarker analysis|
1842532|NCT00897637|Other|laboratory biomarker analysis|Correlative studies
1842533|NCT00897650|Genetic|DNA/RNA sequencing and expression levels|Lung tumor tissue will be collected.
1842534|NCT00897650|Genetic|Protein expression analysis|Lung tumor tissue will be collected.
1842535|NCT00897650|Procedure|Lung tumor biopsy|Tissue will be collected by percutaneous fine needle aspiration, a percutaneous core biopsy, or during a medically indicated procedure during which lung tumor tissue will be removed
1842536|NCT00897650|Procedure|Blood sample|Patients will be asked for a venous blood sample
1842537|NCT00897663|Genetic|gene expression analysis|
1842538|NCT00897663|Genetic|microarray analysis|
1842539|NCT00897663|Genetic|protein expression analysis|
1842540|NCT00897663|Other|diagnostic laboratory biomarker analysis|
1842541|NCT00897663|Other|immunohistochemistry staining method|
1842542|NCT00897676|Drug|Exendin-(9-39)|100-500pmol/kg/min
1842543|NCT00897676|Drug|placebo|placebo (0.9% NaCl)
1842544|NCT00897702|Other|Blood draw|A single 10ml tube of blood will also be obtained for a comparison of patient's normal DNA for genomic analyses either at the time of the procedure or at a followup appointment if feasible.
1842545|NCT00897702|Other|immunoenzyme technique|
1842546|NCT00897702|Procedure|biopsy|
1842547|NCT00897702|Procedure|histopathologic examination|
1842548|NCT00897715|Drug|Rilonacept|160 mg of rilonacept administered subcutaneously once a week for 12 weeks
1842549|NCT00897715|Drug|Placebo|160 mg of placebo administered subcutaneously once a week for 12 weeks
1842550|NCT00897728|Other|laboratory biomarker analysis|
1842551|NCT00897741|Genetic|microarray analysis|
1842552|NCT00897741|Other|laboratory biomarker analysis|
1842553|NCT00897754|Genetic|gene expression analysis|
1842554|NCT00897754|Genetic|protein expression analysis|
1842555|NCT00897754|Genetic|reverse transcriptase-polymerase chain reaction|
1842556|NCT00897754|Other|immunoenzyme technique|
1842557|NCT00897754|Other|immunohistochemistry staining method|
1842558|NCT00897754|Other|immunologic technique|
1842559|NCT00897767|Other|biologic sample preservation procedure|
1842560|NCT00897780|Behavioral|Biofeedback with virtual reality|Participant will use biofeedback technique in combination with virtual reality technique
1842561|NCT00897793|Procedure|venipuncture|Venipuncture for blood samples. Samples will be tested for TGF-beta.
1842562|NCT00897793|Radiation|radiation therapy|Radiation treatments vary according to type of cancer and by patient per doctors' recommendation
1842563|NCT00897806|Genetic|Microarray analysis|
1842564|NCT00897806|Other|Laboratory biomarker analysis|
1842565|NCT00897819|Genetic|DNA methylation analysis|
1842566|NCT00897819|Genetic|loss of heterozygosity analysis|
1842567|NCT00897819|Genetic|microsatellite instability analysis|
1842568|NCT00897819|Other|laboratory biomarker analysis|
1842569|NCT00897832|Other|laboratory biomarker analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), it will be determined if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival.
1842570|NCT00897845|Genetic|RNA analysis|
1842571|NCT00897845|Genetic|microarray analysis|
1842572|NCT00897845|Other|immunohistochemistry staining method|
1842573|NCT00897845|Other|laboratory biomarker analysis|
1842574|NCT00897871|Drug|carboplatin|
1842575|NCT00897871|Drug|cyclophosphamide|
1842576|NCT00897871|Drug|etoposide phosphate|
1842577|NCT00897871|Genetic|gene expression analysis|
1842578|NCT00897871|Genetic|polymorphism analysis|
1842579|NCT00897871|Other|pharmacological study|
1842580|NCT00897884|Drug|Metformin|500 mg tablet, taken 3 times a day for 2-3 weeks
1842581|NCT00897897|Device|Philips MRI-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
1842582|NCT00897910|Other|flow cytometry|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
1842583|NCT00897910|Other|immunoenzyme technique|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
1842584|NCT00897910|Other|laboratory biomarker analysis|Collection of PBMCs over a period of 9-12 months, and the laboratory component will be performed over another year.
1842585|NCT00897923|Procedure|radionuclide imaging|
1842586|NCT00897923|Radiation|indium In 111-labeled autologous peripheral blood mononuclear cells|
1842587|NCT00897923|Radiation|indium In 111-labeled autologous polymorphonuclear leukocytes|
1842588|NCT00897936|Genetic|DNA methylation analysis|
1842589|NCT00897936|Genetic|comparative genomic hybridization|
1842590|NCT00897936|Genetic|fluorescence in situ hybridization|
1842591|NCT00897936|Genetic|microarray analysis|
1842592|NCT00897936|Genetic|polymerase chain reaction|
1842593|NCT00897936|Other|diagnostic laboratory biomarker analysis|
1842594|NCT00897936|Other|immunologic technique|
1842595|NCT00897949|Drug|rizatriptan benzoate (MK0462)|Single dose administration of 5 or 10 mg oral tablet of rizatriptan, taken immediately upon development of acute/severe migraine headache.
1842596|NCT00897949|Drug|Comparator: placebo|Placebo to rizatriptan
1842597|NCT00897962|Other|Healthy Controls|One blood draw (2 teaspoons)
1842598|NCT00897962|Other|Metastatic Breast Cancer|Blood samples will be drawn every 3 months, for up to 18 months.
1842599|NCT00897962|Other|Non-cancer medical illness|One blood draw (2 teaspoons)
1842604|NCT00897988|Genetic|gene expression analysis|
1842605|NCT00897988|Genetic|mutation analysis|
1842606|NCT00897988|Genetic|polyacrylamide gel electrophoresis|
1842607|NCT00897988|Genetic|polymerase chain reaction|
1842608|NCT00897988|Genetic|protein expression analysis|
1842609|NCT00897988|Genetic|reverse transcriptase-polymerase chain reaction|
1842610|NCT00897988|Other|flow cytometry|
1842611|NCT00897988|Other|immunoenzyme technique|
1842612|NCT00897988|Other|immunologic technique|
1842613|NCT00897988|Other|laboratory biomarker analysis|
1842614|NCT00897988|Other|pharmacological study|
1842615|NCT00898014|Genetic|fluorescence in situ hybridization|
1842616|NCT00898014|Other|immunologic technique|
1842617|NCT00898014|Other|laboratory biomarker analysis|
1842618|NCT00898027|Other|laboratory biomarker analysis|laboratory biomarker analysis
1842619|NCT00898040|Genetic|polymorphism analysis|
1842620|NCT00898053|Other|laboratory biomarker analysis|Correlative studies
1842621|NCT00898066|Genetic|cytogenetic analysis|marrow and peripheral blood
1842622|NCT00898066|Genetic|fluorescence in situ hybridization|marrow and peripheral blood
1842623|NCT00898079|Other|cytology specimen collection procedure|Correlative studies
1842624|NCT00898092|Genetic|microarray analysis|
1842625|NCT00898092|Genetic|molecular genetic technique|
1842626|NCT00898092|Genetic|mutation analysis|
1842627|NCT00898092|Genetic|polymerase chain reaction|
1842628|NCT00898092|Genetic|reverse transcriptase-polymerase chain reaction|
1842629|NCT00898092|Other|diagnostic laboratory biomarker analysis|
1842630|NCT00898118|Genetic|polymerase chain reaction|
1842631|NCT00898118|Other|flow cytometry|
1842632|NCT00898118|Other|laboratory biomarker analysis|
1842633|NCT00898118|Procedure|allogeneic hematopoietic stem cell transplantation|
1842634|NCT00898144|Other|Papanicolaou test|
1842635|NCT00898144|Other|laboratory biomarker analysis|
1842636|NCT00898157|Other|laboratory biomarker analysis|
1842637|NCT00898170|Procedure|myoma removal|surgical removal of myoma by hysterectomy
1842638|NCT00898183|Genetic|gene expression analysis|
1842639|NCT00898183|Genetic|polymorphism analysis|
1842640|NCT00898209|Genetic|protein expression analysis|Blood and exhaled breath condensate will be collected.
1842641|NCT00898209|Genetic|proteomic profiling|Blood and exhaled breath condensate will be collected.
1842642|NCT00898209|Other|biologic sample preservation procedure|Blood and exhaled breath condensate will be collected.
1842643|NCT00898209|Other|laboratory biomarker analysis|Blood and exhaled breath condensate will be collected.
1842644|NCT00898209|Other|matrix-asst laser desorption/ionization time flight mass spectrometry|Blood and exhaled breath condensate will be collected.
1842645|NCT00898209|Other|questionnaire administration|Questionnaire will be completed.
1842646|NCT00898222|Drug|aspirin|81 mg orally daily for two weeks
1842647|NCT00898235|Genetic|clonality analysis|analyze clonality
1842648|NCT00898235|Genetic|polymerase chain reaction|analyze polymerase chain reaction
1842649|NCT00898235|Genetic|protein analysis|analyze protein
1842650|NCT00898235|Other|biologic sample preservation procedure|preserve biologic samples
1842651|NCT00898235|Other|laboratory biomarker analysis|analyze laboratory biomarkers
1842652|NCT00898235|Procedure|fluorescence spectroscopy|perform fluorescence spectroscopy on specimens
1842653|NCT00898235|Procedure|quality-of-life assessment|assess quality of life at each follow-up for life
1842654|NCT00898261|Genetic|microarray analysis|
1842655|NCT00898261|Genetic|reverse transcriptase-polymerase chain reaction|
1842656|NCT00898261|Other|flow cytometry|
1842657|NCT00898274|Other|immunoenzyme technique|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
1842658|NCT00898274|Other|laboratory biomarker analysis|Participants undergo blood sample collection. Samples are used to measure levels of antioxidant enzymes (i.e., glutathione, glutathione peroxidase, glutathione reductase, superoxide dismutase, and reduced glutathione) and biomarkers of oxidative stress and DNA damage in leukocytes (i.e., thiobarbituric acid reactive substances [TBARS] and 8-hydroxydeoxyguanosine). Samples are analyzed via antioxidant enzyme assay, TBARS assay, and enzyme-linked immunosorbent assay.
1842720|NCT00898508|Other|fluorescent antibody technique|
1842659|NCT00898287|Drug|P276-00|Subjects will be enrolled at different levels of P276-00 dosage as follows:- Level 1 - 100mg/ m 2/day x 5 q 3 weeks Level 2 - 140 mg/ m2/day x 5 q 3 weeks Level 3 - 185 mg/ m2 /day x 5 q 3 weeks P276-00 will be administered as intravenous infusion in 200 ml of 5% dextrose over 30min from days 1 to 5 per 21 day cycle. Six such cycles will be administered unless there is progression of disease or unacceptable toxicity.
1842660|NCT00898287|Drug|Gemcitabine|Gemcitabine will be administered as an intravenous infusion at dose of 1000mg/m 2 over 30 mins every week for 7 weeks followed by a gap of one week and then 3 weekly doses every 4 weeks. This treatment will be continued for six P276-00 cycles of 3 weeks each unless there is progression of disease or unacceptable toxicity.
1842661|NCT00898300|Other|biologic sample preservation procedure|
1842662|NCT00898300|Procedure|biopsy|
1842663|NCT00898313|Genetic|comparative genomic hybridization|Collection of sputum, blood, urine, and a small amount of lung tissue.
1842664|NCT00898313|Genetic|gene expression microarray analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
1842665|NCT00898313|Genetic|proteomic profiling analysis|Collection of sputum, blood, urine, and a small amount of lung tissue.
1842666|NCT00898313|Other|biologic sample preservation procedure|Collection of sputum, blood, urine, and a small amount of lung tissue.
1842667|NCT00898313|Procedure|nasal brushing|Using a brush, superficial cells are removed from the nose.
1842668|NCT00898313|Procedure|Blood draw|Venous blood will be collected
1842669|NCT00898313|Procedure|Urine collection|Subjects will be asked to provide a urine specimen.
1842670|NCT00898313|Procedure|sputum sample|Prior to their bronchoscopy, subjects will be asked for a sputum specimen. This is a collection of mucous that you cough up.
1842671|NCT00898313|Procedure|fluorescence bronchoscopy with airway biopsy|A flexible tube attached to a fluorescent light source will be inserted into the subject's mouth or nose to reach the airway. Samples of the lining of the airway will be taken, as well as bronchial secretions and epithelial cell from brushings of the lining of the airway.
1842672|NCT00898313|Procedure|fine needle aspiration of the lung|A small needle is inserted into the lung to collect tissue. This procedure will only be performed if the patient's physician orders it.
1842673|NCT00898313|Procedure|thoracentesis|A small needle is inserted into the patient's lung cavity and a small amount of fluid is collected. This procedure will only be performed if the patient's physician orders it.
1842674|NCT00898326|Other|biopsy|Conduct prostatic needle biopsy at 36-39 months-after brachy therapy. Basic method is by transectal ultra-sound-guided systematic biopsy,; systematic sextant biopsy which involves samples from both seminal vesicles is adopted as much as possible.
1842675|NCT00898352|Procedure|regional lymph node dissection|
1842676|NCT00898352|Radiation|radiation therapy|
1842677|NCT00898365|Other|laboratory biomarker analysis|Correlative studies
1842678|NCT00898365|Other|cytology specimen collection procedure|Correlative studies
1842679|NCT00898378|Genetic|gene expression analysis|gene expression analysis
1842680|NCT00898378|Genetic|polymerase chain reaction|polymerase chain reaction
1842681|NCT00898378|Genetic|polymorphism analysis|polymorphism analysis
1842682|NCT00898378|Genetic|protein expression analysis|protein expression analysis
1842683|NCT00898378|Genetic|proteomic profiling|proteomic profiling
1842684|NCT00898378|Other|gas chromatography|gas chromatography
1842685|NCT00898378|Other|laboratory biomarker analysis|laboratory biomarker analysis
1842686|NCT00898378|Other|liquid chromatography|liquid chromatography
1842687|NCT00898378|Other|mass spectrometry|mass spectrometry
1842688|NCT00898378|Other|questionnaire administration|questionnaire administration
1842689|NCT00898391|Other|laboratory biomarker analysis|Correlative studies
1842690|NCT00898391|Genetic|polymerase chain reaction|Correlative studies
1842691|NCT00898391|Genetic|polyacrylamide gel electrophoresis|Correlative studies
1842692|NCT00898391|Genetic|DNA analysis|Correlative studies
1842693|NCT00898404|Other|laboratory biomarker analysis|Correlative studies
1842694|NCT00898417|Biological|bevacizumab|
1842695|NCT00898417|Drug|carboplatin|
1842696|NCT00898417|Drug|paclitaxel|
1842697|NCT00898417|Genetic|proteomic profiling|
1842698|NCT00898417|Other|laboratory biomarker analysis|
1842699|NCT00898417|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
1842700|NCT00898430|Genetic|DNA Microarray analysis|Tumors will be assayed on Affymetrix Human Genome U133 GeneChip
1842701|NCT00898430|Genetic|MALDI-TOF mass spectrometry|Supervised analysis techniques will be employed to identify patterns of protein peaks useful for treatment response and survival prediction. Hierarchical clustering analyses will be used to visualize data.
1842702|NCT00898430|Genetic|DNA microarray and MALDI-TOF mass spectrometry|Tumors from the specific Aim 1/2 and from preliminary data, previously analyzed, will be examined for HPV 16 infection.
1842703|NCT00898443|Other|Epidural anesthetic|Use of the existing continuous labor epidural for surgical anesthetic for postpartum tubal ligation
1842704|NCT00898443|Other|Spinal anesthetic|This group was assigned to receive spinal anesthetic for postpartum tubal ligation.
1842705|NCT00898456|Genetic|gene expression analysis|
1842706|NCT00898456|Genetic|molecular genetic technique|
1842707|NCT00898456|Genetic|polymorphism analysis|
1842708|NCT00898456|Genetic|protein expression analysis|
1842709|NCT00898456|Other|diagnostic laboratory biomarker analysis|
1842710|NCT00898469|Genetic|polymorphism analysis|
1842711|NCT00898482|Other|This is a non-intervention study for all groups.|This is a non-intervention study.
1842712|NCT00898482|Other|study of socioeconomic and demographic variables|Non-intervention study.
1842713|NCT00898495|Genetic|loss of heterozygosity analysis|
1842714|NCT00898495|Genetic|polymerase chain reaction|
1842715|NCT00898495|Genetic|polymorphism analysis|
1842716|NCT00898508|Genetic|gene expression analysis|
1842717|NCT00898508|Genetic|mutation analysis|
1842718|NCT00898508|Genetic|proteomic profiling|
1842719|NCT00898508|Genetic|reverse transcriptase-polymerase chain reaction|
1842721|NCT00898508|Other|immunohistochemistry staining method|
1842722|NCT00898508|Other|laboratory biomarker analysis|
1842723|NCT00898508|Other|liquid chromatography|
1842724|NCT00898508|Other|mass spectrometry|
1842725|NCT00898508|Other|medical chart review|
1842726|NCT00898508|Procedure|quality-of-life assessment|
1842727|NCT00898521|Drug|DGD|"DGD is a mixture of lyophilized enzymes derived from purified Bromelain from pineapple stem.
Two grams or 5 grams of Debrase powder are dissolved in 20 grams or 50 grams of Gel Vehicle to obtain DGD. DGD is applied to the burn wound at a dose of 2g Debrase/20g Gel per 100 cm2 of skin or 5g Debrase/50g Gel per 250 cm2 for a duration of four hours. In an average human adult, 100 cm2 represents approximately 1% of Total Body Surface Area (TBSA).
Please note that for individuals of exceptional size (e.g. children), it is important to calculate the dosage based on the 100 cm2 measurement.
The Debrase powder and the Gel Vehicle are to be mixed at the patient bedside for a maximum of 15 min prior to use.
DGD should not be applied to more than 15% TBSA in one session. If the wound area to be treated is more than 15% TBSA, DGD should be applied in two or more separate sessions.
DGD should not be applied more than twice to the same burn wound area."
1842728|NCT00898534|Device|Bayer DCA2000+ Hemoglobin A1c analyzer|Point-of-care hemoglobin A1c measurement of blood obtained by fingerstick
1842729|NCT00898547|Other|immunoenzyme technique|
1842730|NCT00898547|Other|laboratory biomarker analysis|
1842731|NCT00898560|Drug|eslicarbazepine acetate and Microginon®|"eslicarbazepine acetate: once-daily oral dose of 800 mg on days 1- 15 of treatment period.
Microginon®: single oral dose on day 14 of treatment period"
1842732|NCT00898560|Drug|Microginon®|Single oral dose of Microginon® (30ug ethinyloestradiol and 150ug levonorgestrel)
1842733|NCT00898573|Drug|lapatinib ditosylate|
1842734|NCT00898573|Genetic|fluorescence in situ hybridization|
1842735|NCT00898573|Genetic|gene expression analysis|
1842736|NCT00898573|Genetic|mutation analysis|
1842737|NCT00898573|Genetic|polymerase chain reaction|
1842738|NCT00898573|Genetic|reverse transcriptase-polymerase chain reaction|
1842739|NCT00898573|Other|cell sorting|
1842740|NCT00898573|Other|immunohistochemistry staining method|
1842741|NCT00898573|Other|laboratory biomarker analysis|
1842742|NCT00898599|Dietary Supplement|Prebiotic|Inulin type fructooligosaccharides
1842743|NCT00898599|Dietary Supplement|Placebo|Maltodextrin as placebo
1842744|NCT00898638|Other|biologic sample preservation procedure|
1842745|NCT00898638|Other|medical chart review|
1842746|NCT00898664|Genetic|cytogenetic analysis|not specified
1842747|NCT00898664|Genetic|gene expression analysis|Not specified
1842748|NCT00898664|Genetic|mutation analysis|Not specified
1842749|NCT00898664|Genetic|polymerase chain reaction|not specified
1842750|NCT00898664|Other|immunohistochemistry staining method|not specified
1842751|NCT00898664|Other|laboratory biomarker analysis|not specified
1842752|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 5mg rizatriptan (by Mouth) p.o.
1842753|NCT00898677|Drug|rizatriptan benzoate|single dose administration of 10 mg rizatriptan p.o.
1842754|NCT00898677|Drug|Comparator: sumatriptan|single dose administration of sumatriptan 100 p.o.
1842755|NCT00898677|Drug|Comparator: Placebo|placebo to rizatriptan
1842756|NCT00898690|Genetic|cytogenetic analysis|
1842757|NCT00898690|Genetic|gene expression analysis|
1842758|NCT00898690|Genetic|microarray analysis|
1842759|NCT00898690|Genetic|mutation analysis|
1842760|NCT00898690|Genetic|reverse transcriptase-polymerase chain reaction|
1842761|NCT00898690|Other|immunohistochemistry staining method|
1842762|NCT00898703|Other|flow cytometry|
1842763|NCT00898703|Other|immunoenzyme technique|
1842764|NCT00898703|Other|laboratory biomarker analysis|
1842765|NCT00898716|Drug|BMS-754807|Tablets, Oral, 20 mg, 30 mg, 50 mg, 70 mg, 100 mg, 130 mg, 160 mg, 200 mg once daily, 3-5 months, depending on response
1842766|NCT00898742|Genetic|DNA and tissue microarray analysis|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
1842767|NCT00898742|Genetic|reverse transcriptase-polymerase chain reaction|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
1842768|NCT00898742|Other|mass spectrometry|The lab has a candidate gene expression signature for the prediction of the cetuximab response. It may be possible to identify patients who will respond to cetuximab based on the patterns of gene and protein expression.
1842769|NCT00898755|Genetic|DNA analysis|
1842770|NCT00898755|Genetic|reverse transcriptase-polymerase chain reaction|
1842771|NCT00898755|Other|biologic sample preservation procedure|
1842772|NCT00898755|Other|flow cytometry|
1842773|NCT00898755|Other|laboratory biomarker analysis|
1842774|NCT00898768|Procedure|Capsule endoscopy|Capsule endoscopy at baseline and after 2 years
1842775|NCT00898794|Biological|bevacizumab|
1842776|NCT00898794|Other|coagulation study|
1842777|NCT00898794|Other|laboratory biomarker analysis|
1842778|NCT00898794|Other|platelet aggregation test|
1842779|NCT00898807|Drug|citalopram|target dose 30mg daily for 9 weeks
1842780|NCT00898807|Drug|placebo|daily for 9 weeks
1842781|NCT00898820|Genetic|gene expression analysis|
1842782|NCT00898820|Genetic|polymorphism analysis|
1842783|NCT00898820|Genetic|protein expression analysis|
1842784|NCT00898833|Other|laboratory biomarker analysis|
1842785|NCT00898846|Drug|UFT adjuvant chemotherapy|UFT is given at a dose of 500-600 mg/day as tegafur in 2 divided doses after meals for 5 days, followed by a 2-day rest. This one-week cycle is repeated for one year.
1842786|NCT00898872|Other|cryopreservation|
1842788|NCT00898898|Other|diagnostic laboratory biomarker analysis|Correlative studies
1842789|NCT00898911|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
1842790|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm: 25 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression.
1842791|NCT00891384|Drug|Lenalidomide|Patients will receive maintenance therapy according to their assigned treatment arm:5 mg daily for 21 days every 28 days. During the treatment period patients will be seen every 4 weeks until disease progression is documented. All patients who have to discontinue the study drug will be followed until disease progression
1842792|NCT00891397|Drug|Pregabalin|Dose of 150mg/day divided in two doses. Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.
1842793|NCT00891397|Other|Placebo|Sugar pill
1842794|NCT00891423|Drug|Meropenem short infusion|
1842795|NCT00891423|Drug|Meropenem extended infusion|
1842796|NCT00891436|Drug|Fluticasone furoate nasal spray|2 sprays each nostril every morning for 2 weeks
1842797|NCT00891436|Drug|Placebo nasal spray|2 sprays each nostril every morning for 2 weeks
1842798|NCT00891462|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 12 weeks of treatment
1842799|NCT00891462|Drug|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 12 weeks of treatment
1842800|NCT00891462|Drug|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks of treatment
1842801|NCT00891475|Procedure|Radiofrequency ablation; Interferon-alpha|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive following immunotherapy with Interferon-alpha 9 MIU subcutaneously three times per week, 3 weeks on, 3 weeks off till progression. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off till progression. Evaluation for response will be after second cycle.
1842802|NCT00891475|Procedure|Radiofrequency ablation; Sunitinib maleate|Patients undergo ablation by radiofrequency energy under CT-guidance. RFA continues until the entire tumor is treated. Treatment ceases when the entire lesion has undergone necrosis or the zone of necrosis or significant heat deposition approaches vital neurovascular structures. 38 patients will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
1842803|NCT00891475|Drug|Sunitinib maleate|38 patients with unresected primary tumor will receive sunitinib maleate 50 mg orally once day, 28 days on, 14 days off, till progression. Evaluation for response will be after second cycle.
1842804|NCT00891501|Procedure|Bone Marrow Aspiration|Autologous bone marrow is aspirated from the iliac crest (hip bone) of the patient using a 21-gauge bone marrow aspiration needle under complete aseptic conditions and proper anaesthesia
1842805|NCT00891501|Procedure|Bone marrow mesenchymal stem cell implantation|The culture expanded mesenchymal stem cell pellet will be implanted into the osteochondral knee defect via open surgery or arthroscopically under complete sterile aseptic conditions and proper anaesthesia. The defect will be covered with an autologous periosteal flap from the proximal tibia and then sealed with human fibrin glue to seal the defect and retain the cell pellet in place
1842806|NCT00891514|Behavioral|Aerobic Exercise|Treadmill training- begins at 15 minutes total duration at 40-50% maximal heart rate reserve 3 times per week, increasing to 60-70% maximal heart rate reserve for 45-60 minutes for 6 months
1842807|NCT00891514|Behavioral|Stretching|Stretching, balance exercises, and components of conventional physical therapy-- begins at 15 minutes and progresses to 45 minutes for 6 months
1842808|NCT00891527|Drug|Bevacizumab (Avastin) and Imatinib Mesylate (Gleevec)|"Imatinib Mesylate Orange to grayish orange, opaque, 100mg capsules dissolved in 50-100mls of mineral water or apple juice. Given at 340mg/m2 once daily, preferably with a meal.
Bevacizumab Clear to slightly opalescent liquid. Given at 10mg/kg once every 2 weeks IV. The calculated dose should be placed in an IV bag and diluted with 0.9% sodium chloride to obtain a final volume of 25-100mls. The vials contain no antibacterial preservatives. Once diluted, must be administered within 8 hrs. Initially administered over 90 mins. If no adverse reactions occur, 2nd dose administered over 60 mins. If still no adverse reactions, subsequent doses administered over 30 mins. If infusion-related adverse reactions occur, further infusions administered over the shortest period that was well tolerated."
1842809|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.5%
1842810|NCT00891540|Drug|Ropivacaine|Ropivacaine 0.2%
1842811|NCT00891540|Drug|placebo|Isotonic NaCl
1842812|NCT00891553|Procedure|DXA|CR9112792 is a follow-up study of CR9108963, in which the effects of ronacaleret (100mg, 200mg, 300mg, 400mg) on bone mineral density (BMD), safety and tolerability were evaluated in comparison with placebo and 2 active comparators, alendronate and teriparatide. In this study we will follow-up subjects between 6 and 12 months after they discontinued treatment with placebo or ronacaleret (200mg, 300mg, 400mg) to evaluate the potential for mineralization of bone following cessation of ronacaleret therapy, evaluating lumbar spine and hip BMD by DXA. There is no administration of drug in this study.
1842813|NCT00891566|Procedure|Immobilization|compared the healing status for 8 weeks of immobilization with the conventional 4 weeks of immobilization after rotator cuff repair
1842814|NCT00898924|Genetic|molecular diagnostic method|
1842815|NCT00898924|Genetic|mutation analysis|
1842816|NCT00898937|Genetic|microarray analysis|tumor specimen will be assessed by microarray analysis
1842817|NCT00898937|Procedure|breast biopsy|A breast biopsy will be done to obtain a tumor specimen
1842818|NCT00898950|Drug|Aspirin|Aspirin 75mgs/day orally for 2 weeks.
1842819|NCT00898950|Drug|Aspirin|300mgs/day orally for 2 weeks
1842820|NCT00898950|Drug|Aspirin|aspirin 900mgs QID orally for 2 weeks
1842821|NCT00898950|Other|placebo tablet|placebo tablet with lactose and excipients.
1842822|NCT00898963|Genetic|gene expression analysis|
1842823|NCT00898963|Genetic|microarray analysis|
1842824|NCT00898963|Genetic|polymorphism analysis|
1842825|NCT00898963|Other|diagnostic laboratory biomarker analysis|
1842826|NCT00898963|Other|immunohistochemistry staining method|
1842827|NCT00898963|Other|immunologic technique|
1842828|NCT00898976|Other|immunohistochemistry staining method|
1842829|NCT00898976|Other|laboratory biomarker analysis|
1842830|NCT00899002|Genetic|comparative genomic hybridization|Not specified
1842831|NCT00899002|Genetic|molecular genetic technique|Not specified
1842832|NCT00899002|Genetic|mutation analysis|Not specified
1842833|NCT00899002|Genetic|polymerase chain reaction|Not noted
1842834|NCT00899002|Genetic|proteomic profiling|not specified
1842835|NCT00899002|Other|immunohistochemistry staining method|not noted
1842836|NCT00899002|Other|laboratory biomarker analysis|not noted
1842837|NCT00899002|Other|mass spectrometry|not noted
1842838|NCT00899002|Other|medical chart review|not noted
1842839|NCT00899015|Other|pharmacological study|
1842840|NCT00899028|Genetic|comparative genomic hybridization|
1842841|NCT00899028|Genetic|fluorescence in situ hybridization|
1842842|NCT00899028|Genetic|gene expression analysis|
1842843|NCT00899028|Genetic|microarray analysis|
1842844|NCT00899028|Genetic|protein expression analysis|
1842845|NCT00899028|Other|immunohistochemistry staining method|
1842846|NCT00899028|Other|laboratory biomarker analysis|
1842847|NCT00899028|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
1842848|NCT00899028|Other|medical chart review|
1842849|NCT00899028|Procedure|diagnostic bronchoscopy|
1842850|NCT00899041|Procedure|Total Knee Arthroplasty (TKA)|28 subjects will receive the standard Sigma FB knee prosthesis. 28 subjects will receive the high flexion Sigma RP-F knee prosthesis.
1842851|NCT00899054|Drug|P276-00|P276-00 will be administered at different dose levels: level 1: 100 mg/m2/day dose level 2: 140 mg/m2/day dose level 3: 185 mg/m2/day to be given from day 1 to day 5 every 21 days for 2 cycle. P276-00 will be administered as intravenous infusion in 200 ml 5% Dextrose over 30 min from days 1 to 5 per 21 day cycle for two cycles.
1842852|NCT00899054|Radiation|External beam radiotherapy (EBRT)|All subjects will receive external beam radiotherapy (EBRT)by using standard conventional fractionation i.e. 2 Gy per day for 5 days a week for a total radiation dose of 60 Gy over 6 weeks followed by upto 10 additional Gy if required.
1842853|NCT00899080|Genetic|gene expression analysis|
1842854|NCT00899080|Genetic|reverse transcriptase-polymerase chain reaction|
1842855|NCT00899080|Other|immunoenzyme technique|
1842856|NCT00899080|Other|laboratory biomarker analysis|
1842857|NCT00899080|Other|platelet aggregation test|
1842858|NCT00899093|Other|Cytology Specimen Collection Procedure|Correlative studies
1842859|NCT00899093|Other|Laboratory Biomarker Analysis|Correlative studies
1842860|NCT00899119|Procedure|leukapheresis|
1842861|NCT00899132|Genetic|in situ hybridization|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
1842862|NCT00899132|Genetic|protein expression analysis|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
1842863|NCT00899132|Other|immunologic technique|Tumor tissue samples from paraffin-embedded tissue blocks are analyzed for TAB3 transcript and protein expression using in situ hybridization and immunostaining with TAB3 cRNA probe and antibody. Antibodies against the proteins involved in the NFkB signaling pathway (e.g., p65, TAK1, MyD88, and Akt) are used in the immunostaining assays.
1842864|NCT00899145|Other|Laboratory Biomarker Analysis|Correlative studies
1842865|NCT00899158|Other|immunologic technique|
1842866|NCT00899158|Other|laboratory biomarker analysis|
1842867|NCT00899158|Procedure|biopsy|
1842868|NCT00899171|Genetic|DNA analysis|
1842869|NCT00899171|Genetic|DNA methylation analysis|
1842870|NCT00899171|Genetic|RNA analysis|
1842871|NCT00899171|Genetic|gene expression analysis|
1842872|NCT00899171|Genetic|reverse transcriptase-polymerase chain reaction|
1842873|NCT00899171|Other|laboratory biomarker analysis|
1842874|NCT00899184|Genetic|polymorphism analysis|
1842875|NCT00899184|Other|laboratory biomarker analysis|
1842876|NCT00899197|Drug|tamoxifen citrate|
1842877|NCT00899197|Genetic|gene expression analysis|
1842878|NCT00899197|Genetic|protein expression analysis|
1842879|NCT00899197|Other|immunoenzyme technique|
1842880|NCT00899197|Other|laboratory biomarker analysis|
1842881|NCT00899210|Other|laboratory biomarker analysis|
1842882|NCT00899210|Procedure|cryosurgery|
1842883|NCT00899210|Procedure|radiofrequency ablation|
1842884|NCT00899210|Procedure|therapeutic conventional surgery|
1842885|NCT00899223|Other|biologic sample preservation procedure|
1842886|NCT00899262|Other|immunohistochemistry staining method|
1842887|NCT00899262|Other|laboratory biomarker analysis|
1842888|NCT00899262|Other|sputum cytology|
1842889|NCT00899262|Procedure|Fourier transform infrared spectroscopy|
1842890|NCT00899262|Procedure|diagnostic bronchoscopy|
1842892|NCT00899288|Procedure|spectroscopy|Nails will be chemically characterized using Raman spectroscopy.
1842893|NCT00899301|Other|biologic sample preservation procedure|Tissue, urine and blood collection.
1842894|NCT00899353|Dietary Supplement|Omega 3 Fatty Acid|Omega 3 supplementation will be initiated at three 1250 mg capsules daily for the first month. If dose is well tolerated, it will be increased to six 1250 mg capsules daily for 30 days, and finally to nine 1250 mg capsules daily. Treatment period is 12 months.
1842895|NCT00899366|Genetic|microarray analysis|
1842896|NCT00899366|Genetic|mutation analysis|
1842897|NCT00899366|Other|immunologic technique|
1842898|NCT00899379|Drug|rizatriptan benzoate|Rizatriptan 10 mg p.o. at onset of moderate to severe migraine headache
1842899|NCT00899379|Drug|Comparator: Placebo|Placebo to Rizatriptan, Oral Tablet
1842900|NCT00899392|Other|Emmi Pediatric Upper Endoscopy Patient Education Module|Emmi Pediatric Upper Endoscopy Patient Education Module as designed by EMMI SOLUTIONS, LLC
1842901|NCT00899418|Genetic|gene expression analysis|
1842902|NCT00899418|Genetic|polymerase chain reaction|
1842903|NCT00899418|Genetic|polymorphism analysis|
1842904|NCT00899418|Other|immunohistochemistry staining method|
1842905|NCT00899431|Drug|Lenalidomide|Starting dose 5 mg by mouth every other day; increase to 5 mg/d daily in 4-5 weeks for 6 - 12 months
1842906|NCT00899431|Drug|Fludarabine|30 mg/m^2 intravenously daily on days -5, -4, -3.
1842907|NCT00899431|Drug|Rituximab|375 mg/m2 intravenously on day -13, and 1000 mg/m^2 on days -6, +1 and +8.
1842908|NCT00899431|Drug|Thymoglobulin|1.0 mg/kg intravenously over 4 hours (day -2 and -1).
1842909|NCT00899431|Procedure|Stem Cell Transplantation|On Day 0, donor blood stem cells collected will be transplanted over 30-45 minutes.
1842910|NCT00899431|Drug|Bendamustine|130 mg/m2/day by vein daily on day -5, -4, -3 (following Fludarabine).
1842911|NCT00899431|Drug|Allopurinol|300 mg by mouth daily beginning at the start of lenalidomide therapy and continuing for 3 months.
1842912|NCT00899457|Genetic|proteomic profiling|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
1842913|NCT00899457|Other|biologic sample preservation procedure|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
1842914|NCT00899457|Other|laboratory biomarker analysis|Collection of tissue, blood, urine, mouth cells, spit, nasal airway cells and breath
1842915|NCT00899457|Procedure|bronchoscopy|Collection of breath condensate.
1842916|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fasted|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fasted conditions
1842917|NCT00899470|Drug|Saxagliptin/Metformin, Fasting|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fasting conditions
1842918|NCT00899470|Drug|Co-administration of Saxagliptin and Metformin IR, Fed|Participants received oral co-administration of a 2.5 mg tablet of saxagliptin and a 500 mg tablet of metformin immediate release (IR) under fed conditions
1842919|NCT00899470|Drug|Saxagliptin/Metformin, Fed|Participants received a single oral dose of a fixed dose combination (FDC) tablet of 2.5 mg saxagliptin/500 mg metformin IR under fed conditions
1842920|NCT00899483|Drug|Glucose potassium insulin solution|Enhanced glycaemic control in diabetics with glucose-potassium-insulin solution
1842921|NCT00899496|Other|immunological diagnostic method|
1842922|NCT00899496|Other|physiologic testing|
1842923|NCT00899509|Other|laboratory biomarker analysis|correlative studies
1842924|NCT00899522|Other|biologic sample preservation procedure|Once the pathologist has taken the material needed to establish diagnosis of cancer, the anonymized snap-frozen and fresh samples will be either shipped to our laboratory for analysis or will be picked up by a member of the principal investigator's lab team. Samples will be stored indefinitely.
1842925|NCT00899522|Procedure|biopsy|Once the pathologist has taken the material needed to establish diagnosis of cancer, 1-10 grams of the remaining tissue should be placed in phosphate buffered saline and shipped to the Bagby Lab.
1842926|NCT00899535|Genetic|DNA analysis|
1842927|NCT00899535|Genetic|RNA analysis|
1842928|NCT00899535|Genetic|microarray analysis|
1842929|NCT00899535|Genetic|mutation analysis|
1842930|NCT00899535|Genetic|polymorphism analysis|
1842931|NCT00899548|Genetic|DNA methylation analysis|laboratory analysis
1842932|NCT00899548|Genetic|microarray analysis|laboratory analysis
1842933|NCT00899548|Genetic|polymerase chain reaction|laboratory analysis
1842934|NCT00899548|Other|laboratory biomarker analysis|laboratory analysis
1842935|NCT00899574|Drug|Imiquimod|"Each treatment cycle consists of 8 weeks.
Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.
Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease."
1842936|NCT00899587|Drug|enalapril|enalapril 5 mg every night
1842937|NCT00899587|Other|oxygen|oxygen 10 lit/min 1 hour twice a day at the first month, once a day at the second month and every other day at the third month
1842938|NCT00899587|Drug|placebo|
1842939|NCT00899600|Drug|Ketamine|Peripheral provision of 0.5mg/kg of ketamine on induction followed by a 10mcg/kg/min infusion until surgical wound closure
1842940|NCT00899600|Other|Normal saline|Normal saline at same rate as the previously described ketamine infusion (10mcg/kg/min), same amount of ketamine/placebo syringe on induction (0.5mg/kg).
1842941|NCT00899613|Other|laboratory biomarker analysis|
1842942|NCT00899613|Procedure|study of high risk factors|
1842943|NCT00899626|Genetic|protein analysis|
1842944|NCT00899626|Genetic|proteomic profiling|
1842945|NCT00899626|Other|biologic sample preservation procedure|
1842946|NCT00899626|Other|laboratory biomarker analysis|
1842947|NCT00899626|Other|medical chart review|
1842948|NCT00899626|Procedure|diagnostic colonoscopy|
1842949|NCT00899626|Procedure|diagnostic endoscopic procedure|
1842950|NCT00899626|Procedure|diagnostic endoscopic surgery|
1842951|NCT00899626|Procedure|diagnostic surgical procedure|
1842952|NCT00899626|Procedure|endoscopic surgery|
1842953|NCT00899626|Procedure|screening colonoscopy|
1842954|NCT00899652|Genetic|Southern blotting|
1842955|NCT00899652|Genetic|chromosomal translocation analysis|
1842956|NCT00899652|Genetic|cytogenetic analysis|
1842957|NCT00899652|Genetic|gene rearrangement analysis|
1842958|NCT00899652|Genetic|mutation analysis|
1842959|NCT00899665|Genetic|fluorescence in situ hybridization|
1842960|NCT00899665|Genetic|microarray analysis|
1842961|NCT00899665|Genetic|molecular diagnostic method|
1842962|NCT00899665|Other|immunohistochemistry staining method|
1842963|NCT00899665|Other|laboratory biomarker analysis|
1842964|NCT00899665|Procedure|biopsy|
1842965|NCT00899665|Procedure|immunoscintigraphy|
1842966|NCT00899678|Drug|Certolizumab Pegol|"400 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg"
1842967|NCT00899678|Drug|Certolizumab Pegol|"200 mg administered subcutaneously at once every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
*prior to this dosing regimen, subjects will undergo an induction of Certolizumab Pegol administered subcutaneously every 2 weeks (total 3 injections) at of either 400 mg for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg"
1842968|NCT00899691|Genetic|protein expression analysis|
1842969|NCT00899704|Genetic|microarray analysis|
1842970|NCT00899704|Genetic|allele-specific oligonucleotide real-time quantitative polymerase chain reaction|
1842971|NCT00899704|Other|diagnostic laboratory biomarker analysis|
1842972|NCT00899717|Procedure|Occlusal adjustment|modification of occlusal surfaces
1842973|NCT00899717|Procedure|Placebo occlusal adjustment|Simulated modification of occlusal surfaces
1842974|NCT00899743|Genetic|polyacrylamide gel electrophoresis|polyacrylamide gel electrophoresis
1842975|NCT00899743|Genetic|western blotting|western blotting
1842976|NCT00899743|Other|immunologic technique|immunologic technique
1842977|NCT00899743|Other|laboratory biomarker analysis|laboratory biomarker analysis
1842978|NCT00899756|Genetic|molecular diagnostic method|
1842979|NCT00899756|Genetic|mutation analysis|
1842980|NCT00899769|Genetic|protein expression analysis|
1842981|NCT00899769|Genetic|proteomic profiling|
1842982|NCT00899769|Other|immunoenzyme technique|
1842983|NCT00899769|Other|laboratory biomarker analysis|
1842984|NCT00899769|Other|liquid chromatography|
1842985|NCT00899769|Other|mass spectrometry|
1842986|NCT00899782|Other|cytology specimen collection procedure|correlative studies
1842987|NCT00899795|Genetic|cytogenetic analysis|
1842988|NCT00899795|Genetic|fluorescence in situ hybridization|
1842989|NCT00899795|Other|flow cytometry|
1842990|NCT00899795|Procedure|biopsy|
1842991|NCT00899821|Biological|aldesleukin|
1842992|NCT00899821|Biological|recombinant interleukin-12|
1842993|NCT00899821|Biological|sargramostim|
1842994|NCT00899821|Other|immunologic technique|
1842995|NCT00899821|Procedure|biopsy|
1843007|NCT00899873|Genetic|cytogenetic analysis|
1843008|NCT00899873|Other|flow cytometry|
1843009|NCT00899873|Other|fluorescence activated cell sorting|
1843010|NCT00899873|Other|immunoenzyme technique|
1843011|NCT00899873|Other|laboratory biomarker analysis|
1843012|NCT00899899|Genetic|microarray analysis|
1843013|NCT00899899|Genetic|reverse transcriptase-polymerase chain reaction|
1843014|NCT00899899|Other|laboratory biomarker analysis|
1843015|NCT00899912|Genetic|microarray analysis|
1843016|NCT00899912|Other|diagnostic laboratory biomarker analysis|
1843017|NCT00899951|Drug|fentanyl citrate|
1843018|NCT00899951|Other|pharmacological study|
1843019|NCT00899964|Behavioral|Physical activity|6-month physical activity intervention (endurance activities) delivered by internet with tailored training schedules
1843020|NCT00899977|Drug|Placebo|Matching placebo
1843021|NCT00899977|Drug|TC-5214|
1843022|NCT00899990|Other|laboratory biomarker analysis|Correlative studies
1843023|NCT00900003|Genetic|protein analysis|Using material that is already being acquired as a component of clinical care (only that which is excess after routine clinical care), we will determine if pre-treatment markers can be used to correlate with clinical outcomes of survival and recurrence. Examples of such markers include studying if the integrity of DNA repair pathway in pancreatic cancers, analyzed by Rad51 and phosphorylated DNA-PK foci formation, correlates with tumor response to radiotherapy, chemotherapy, and overall survival. The markers targeted are proteins secreted by cancer cells and/or cancer associated cells.
1843024|NCT00900003|Other|laboratory biomarker analysis|A method of extracting and identifying secreted cytokines and growth factors from tissues of the quantity of typical biopsy tissues has been developed.The purpose of this study is to determine if this method of biomarker discovery can now be applied to pancreatic cancer population.
1843025|NCT00900016|Genetic|protein expression analysis|
1843026|NCT00900016|Genetic|western blotting|
1843027|NCT00900016|Other|immunohistochemistry staining method|
1843028|NCT00900016|Other|immunologic technique|
1843029|NCT00900016|Other|laboratory biomarker analysis|
1843030|NCT00900029|Biological|No HP802 Treatment|
1843031|NCT00900029|Other|No HP802 Vehicle Treatment|
1843032|NCT00900042|Genetic|DNA ploidy analysis|
1843033|NCT00900042|Genetic|DNA stability analysis|
1843034|NCT00900042|Genetic|chromosomal translocation analysis|
1843035|NCT00900042|Genetic|cytogenetic analysis|
1843037|NCT00900042|Other|laboratory biomarker analysis|
1843038|NCT00900055|Genetic|microarray analysis|
1843039|NCT00900055|Genetic|polyacrylamide gel electrophoresis|
1843040|NCT00900055|Genetic|polymerase chain reaction|
1843041|NCT00900055|Genetic|protein expression analysis|
1843042|NCT00900055|Genetic|reverse transcriptase-polymerase chain reaction|
1843043|NCT00900055|Genetic|western blotting|
1843044|NCT00900055|Other|chromatography|
1843045|NCT00900055|Other|high performance liquid chromatography|
1843046|NCT00900055|Other|immunoenzyme technique|
1843047|NCT00900068|Other|immunoenzyme technique|
1843048|NCT00900068|Other|laboratory biomarker analysis|
1843049|NCT00900068|Other|medical chart review|
1843050|NCT00900081|Other|immunohistochemistry staining method|
1843051|NCT00900081|Other|laboratory biomarker analysis|
1843052|NCT00900081|Other|medical chart review|
1843053|NCT00900094|Genetic|fluorescence in situ hybridization|
1843054|NCT00900094|Genetic|polymerase chain reaction|
1843055|NCT00900094|Genetic|protein expression analysis|
1843056|NCT00900094|Other|immunohistochemistry staining method|
1843057|NCT00900094|Other|laboratory biomarker analysis|
1843058|NCT00900094|Other|mass spectrometry|
1843059|NCT00900107|Procedure|Exercise|
1843060|NCT00900133|Other|immunoenzyme technique|Serum samples are evaluated by enzyme-linked immunosorbent assay for tumor marker expression.
1843061|NCT00900133|Other|laboratory biomarker analysis|Blood draw following diagnosis of breast cancer to assess levels of circulating tumor markers, calgranulin A and calgranulin B.
1843062|NCT00900146|Drug|Canakinumab|Canakinumab lyophilized cake (25 mg and 150 mg in individual 6 mL glass vials ) was reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
1843063|NCT00900146|Drug|Metformin|Before randomization, in drug naïve patients at a dose of 1000 mg with the evening meal or 500 mg b.i.d. (twice daily) with two main meals. At the randomization visit, patients were prescribed with no less than 1,000mg/day.
1843064|NCT00900146|Drug|Placebo|Placebo lyophilized cake will be reconstituted and then used to dilute the 25mg or 150mg solutions to make 5mg, 15mg and 50mg injections.
1843065|NCT00900159|Drug|eszopiclone|3mg eszopiclone prior to daytime sleep for 3 days (at home) and 1 day (in lab)
1843066|NCT00900159|Drug|matching placebo|matching placebo prior to daytime sleep for 3 days (at home) and 1 day (in lab)
1843067|NCT00900172|Biological|bevacizumab|
1843068|NCT00900172|Drug|carboplatin|
1843069|NCT00900172|Drug|paclitaxel|
1843070|NCT00900172|Genetic|gene expression analysis|
1843071|NCT00900172|Genetic|polymerase chain reaction|
1843072|NCT00900172|Genetic|polymorphism analysis|
1843073|NCT00900172|Other|laboratory biomarker analysis|
1843074|NCT00900185|Genetic|mutation analysis|
1843075|NCT00900185|Genetic|polymerase chain reaction|
1843076|NCT00900185|Genetic|polymorphism analysis|
1843077|NCT00900198|Procedure|Biopsy|Tissue samples will be collected for research purposes from non-surgical procedures, such percutaneous biopsies for the sole purpose of obtaining specimens or biological fluids for the protocol.
1843078|NCT00900211|Genetic|microarray analysis|
1843079|NCT00900211|Genetic|molecular diagnostic method|
1843080|NCT00900211|Other|biologic sample preservation procedure|
1843081|NCT00900224|Genetic|DNA analysis|
1843082|NCT00900224|Genetic|DNA methylation analysis|
1843083|NCT00900224|Genetic|gene expression analysis|
1843084|NCT00900224|Genetic|mutation analysis|
1843085|NCT00900224|Genetic|polymerase chain reaction|
1843086|NCT00900224|Genetic|reverse transcriptase-polymerase chain reaction|
1843087|NCT00900224|Other|high performance liquid chromatography|
1843088|NCT00900224|Other|laboratory biomarker analysis|
1843089|NCT00900237|Drug|Eslicarbazepine acetate|Oral administration 600 mg QD morning from Day 1-3 and 1200 mg from Day 4-9
1843090|NCT00900237|Drug|Oxcarbazepine|Oxcarbazepine 300 mg BID from Day 1-3 (morning and evening) and oxcarbazepine 600mg BID from Day 4-9 (morning and evening, only morning dose on Day 9)
1843091|NCT00900250|Other|Cytology Specimen Collection Procedure|Correlative studies
1843092|NCT00900263|Genetic|cytogenetic analysis|
1843093|NCT00900263|Genetic|microarray analysis|
1843094|NCT00900263|Other|biologic sample preservation procedure|
1843095|NCT00900263|Other|laboratory biomarker analysis|
1843096|NCT00900276|Other|immunologic technique|
1843097|NCT00900276|Other|laboratory biomarker analysis|
1843098|NCT00900276|Other|mass spectrometry|
1843099|NCT00900289|Genetic|DNA methylation analysis|
1843100|NCT00900289|Genetic|microarray analysis|
1843101|NCT00900289|Genetic|polymerase chain reaction|
1843102|NCT00900289|Other|immunohistochemistry staining method|
1843103|NCT00900289|Other|laboratory biomarker analysis|
1843104|NCT00900302|Genetic|protein expression analysis|The first ten cases will be reviewed to assess the spectrum of OX-40 expression and to devise a semiquantitative scoring system. Each slide will be scanned in its entirety and then scored according to representative views with the greatest expression of immunostaining. Two independent viewers, who will be blinded to clinical data and outcome at the time of scoring, will review all slides. Scores from these independent readings will be compared, and differences were resolved upon mutual review of given cases. We will estimate the distribution of OX-40 IHC score by tumor type and tumor stage. OX-40 IHC score will be correlated with the IHC scores of other markers using Spearman's correlation coefficient. Kruskal-Wallis test will be used to test whether OX-40 IHC score is comparable between tumor type and tumor stage
1843213|NCT00900887|Drug|Polietilenglicol 400, propilenglicol|"ocular presentation Polietilenglicol 400 (4 mg), propilenglicol (3 mg), HP guar (1.9 mg)/1 ml
dosage: one drop (0.2 mg polietinglicol 400, 0.15 mg propilenglicol, 0.095 mg HP guar) 3 times a day during one week"
1843214|NCT00900900|Dietary Supplement|dehydroepiandrosterone (DHEA)|one-time 400mg oral dose of DHEA
1843105|NCT00900302|Other|immunohistochemistry staining method|5-micron sections will be cut, mounted on capillary gap slides and dried in a 60°C oven. The slides will then be then deparaffinized in xylene baths and gradually hydrated in graded alcohol. For epitope retrieval, the slides are placed in baths of 0.5 M Tris buffer at pH 10 and subjected to microwave irradiation for at least 19 minutes. The slides will be cooled and washed with deionized water and 0.05% TWEEN. They are then placed in a blocking solution of 0.3% bovine serum albumin, drained, and placed in wells of their primary antibody in a humidity chamber at room temperature overnight. Primary mouse antihuman antibodies will include anti-OX-40, anti-CD4, and anti-HLA class II. Anti-rat CD45 will be used as a negative control for each section. The slides will then be then washed and placed in their appropriate biotinylated anti-mouse secondary antibody for 24 minutes. Endogenous peroxidase in the samples is blocked using a solution of 3% hydrogen peroxide.
1843106|NCT00900302|Other|laboratory biomarker analysis|Lymphocytes will be collected from fresh tissue and peripheral blood (PBLs) for use in marker analysis and in vitro assays of immune function. Tissues will be dissociated to obtain lymphocytes
1843107|NCT00900302|Procedure|biopsy|De-identified tissue samples will be obtained from the OHSU Pathology Department. Tissues will consist of paraffin blocks collected either prospectively for previous cases, or fresh tissue collected prospectively for patients enrolled in the study. For either case, tissue will be collected only after tissue necessary for the adequate rendering of the pathologic diagnosis has been collected by the pathology Department. Thus, the collection of tissue will not compromise patient diagnosis/care.
1843108|NCT00900328|Other|laboratory biomarker analysis|Correlative Studies
1843109|NCT00900341|Genetic|DNA analysis|
1843110|NCT00900341|Genetic|gene expression analysis|
1843111|NCT00900341|Genetic|protein expression analysis|
1843112|NCT00900341|Genetic|reverse transcriptase-polymerase chain reaction|
1843113|NCT00900341|Genetic|western blotting|
1843114|NCT00900341|Other|immunohistochemistry staining method|
1843115|NCT00900341|Other|laboratory biomarker analysis|
1843116|NCT00900354|Genetic|molecular genetic technique|
1843117|NCT00900354|Other|mass spectrometry|
1843118|NCT00900354|Other|pharmacological study|
1843119|NCT00900367|Other|high performance liquid chromatography|
1843120|NCT00900367|Other|laboratory biomarker analysis|
1843121|NCT00900367|Procedure|spectroscopy|
1843122|NCT00900380|Other|flow cytometry|
1843123|NCT00900380|Other|immunological diagnostic method|
1843124|NCT00900380|Other|laboratory biomarker analysis|
1843125|NCT00900406|Genetic|gene expression analysis|blood collection
1843126|NCT00900406|Genetic|microarray analysis|Blood collection
1843127|NCT00900406|Genetic|polymorphism analysis|Blood collection
1843128|NCT00900406|Genetic|proteomic profiling|Blood collection
1843129|NCT00900406|Other|flow cytometry|Blood collection
1843130|NCT00900406|Other|immunologic technique|Blood collection
1843131|NCT00900406|Other|laboratory biomarker analysis|Blood collection
1843132|NCT00900406|Procedure|biopsy|Blood collection
1843133|NCT00900419|Other|immunohistochemistry staining method|Laboratory test
1843134|NCT00900419|Other|laboratory biomarker analysis|Laboratory Test
1843135|NCT00900419|Other|sputum cytology|Laboratory Test
1843136|NCT00900419|Procedure|biopsy|Laboratory Test
1843137|NCT00900432|Other|immunoenzyme technique|
1843138|NCT00900432|Other|laboratory biomarker analysis|
1843139|NCT00900445|Drug|daunorubicin hydrochloride|Given IV
1843140|NCT00900445|Drug|prednisolone|Given orally
1843141|NCT00900445|Drug|prednisone|Given orally
1843142|NCT00900445|Drug|vincristine sulfate|Given IV
1843143|NCT00900445|Other|pharmacological study|Correlative studies
1843144|NCT00900458|Behavioral|Aerobic Exercise training|aerobic exercise training (cycling)
1843145|NCT00900471|Other|biologic sample preservation procedure|
1843146|NCT00900471|Other|medical chart review|
1843147|NCT00900484|Other|biologic sample preservation procedure|
1843148|NCT00900484|Other|immunohistochemistry staining method|
1843149|NCT00900484|Other|laboratory biomarker analysis|
1843151|NCT00900510|Procedure|Incision and drainage|
1843152|NCT00900510|Drug|Trimethoprim/Sulfamethoxazole (Bactrim)|Trimethoprim/Sulfamethoxazole, oral
1843153|NCT00900510|Drug|Placebo|
1843154|NCT00900523|Genetic|protein expression analysis|protein expression analysis
1843155|NCT00900523|Other|immunohistochemistry|immunohistochemical staining of tumor tissue to measure COX-1 and COX-2 levels
1843156|NCT00900536|Genetic|mutation analysis|
1843157|NCT00900536|Genetic|polymorphism analysis|
1843158|NCT00900536|Genetic|protein expression analysis|
1843159|NCT00900536|Other|immunohistochemistry staining method|
1843160|NCT00900536|Other|laboratory biomarker analysis|
1843161|NCT00900549|Device|CRT on|12 months
1843162|NCT00900549|Device|CRT off|12-month
1843163|NCT00900562|Drug|Zalypsis ( PM00104)|Zalypsis (PM00104) (2.5 mg/vial) is provided as a powder for concentrate for solution for infusion
1843164|NCT00900575|Device|Optical Spectroscopy Bench-Top System|This device is a bench-top optical spectrometer
1843165|NCT00900575|Device|Portable Optical Spectrometer|This device is a portable optical spectrometer
1843166|NCT00900575|Device|Transvaginal colposcope|
1843167|NCT00900588|Biological|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
1843215|NCT00900900|Dietary Supplement|pregnenolone|one-time 400mg oral dose of pregnenolone
1843216|NCT00900900|Drug|Placebo|one-time dose oral dose
1843217|NCT00900913|Drug|ropivacaine (Naropin)|intravenous infusion 1 mg/kg bw
1843250|NCT00901303|Drug|ABVD chemotherapy|Adriamycin 25 mg/m2 bleomycin 10 units/m2 vinblastine 6 mg/m2 dacarbazine 375 mg/m on Days 1 and 15 of each 28 day cycle
1843504|NCT00895687|Drug|Erlotinib Hydrochloride|Beginning dose of 150 mg taken by mouth daily for 21-day cycle.
1843169|NCT00900614|Drug|APR-246|Intravenous infusion. Dose escalating. Dosing will be conducted with three patients at each dose level.
1843170|NCT00900627|Drug|AZD8931|Tablet Oral bid
1843171|NCT00900627|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off (repeated cycles)
1843172|NCT00900627|Drug|Placebo|Oral bid (twice daily)
1843173|NCT00900640|Procedure|ERCP as medically indicated by subjects referring physician|Determine the incidence of adverse reactions to CM administered during ERCP in patients with prior reaction to IV CM administration and/or shellfish allergy.
1843174|NCT00900653|Drug|Gynoflor E (low dose estriol with lactobacillus)|The medication, in the form of one vaginal tablet, is administered in the evenings for 18 days
1843175|NCT00900666|Drug|placebo|A total of 2 cc sterile normal saline: will be injected in 0.5 cc aliquots into 4 different injectate sites within the rectus femoris (with EMG guidance) of the involved limb.
1843176|NCT00900666|Drug|botulinum toxin A (BTX-A)|200 Units BTX-A reconstituted with 2 cc sterile normal saline in 100:1 ratio. Teflon-coated EMG guidance for confirmation of injection into the Rectus femoris muscle in addition to utilizing standardized injection landmarks, the solution will be injected in 0.5 cc aliquots into 4 different injectate sites within the muscle.
1843177|NCT00900679|Behavioral|telephone-based intervention|
1843178|NCT00900679|Other|counseling intervention|
1843179|NCT00900679|Other|educational intervention|
1843180|NCT00900679|Other|medical chart review|
1843181|NCT00900679|Other|questionnaire administration|
1843182|NCT00900679|Procedure|psychosocial assessment and care|
1843183|NCT00900679|Procedure|quality-of-life assessment|
1843184|NCT00900692|Device|Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
1843185|NCT00900718|Device|Straumann Bone Ceramic|Bone augmentation, after tooth extraction, with Straumann Bone Ceramic (synthetic bone graft material) in combination with resorbable collagen membrane Bio-Gide.
1843186|NCT00900718|Device|Bio-Oss|Bone augmentation, after tooth extraction, with Bio-Oss (bovine-derived xenograft)in combination with resorbable collagen membrane Bio-Gide.
1843187|NCT00900731|Drug|Indacaterol 150 μg|Indacaterol 150 μg was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
1843188|NCT00900731|Drug|Tiotropium 18 μg|Tiotropium 18 μg was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
1843189|NCT00900731|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
1843190|NCT00900731|Drug|Placebo to tiotropium|Placebo to tiotropium was provided in powder filled capsules with the manufacturer's proprietary inhalation device (HandiHaler®).
1843191|NCT00900744|Drug|Tamoxifen|20 mg daily
1843192|NCT00900757|Drug|Palonosetron (PALO)|Eligible patients should receive a planned total dose of 54-60 GY of radiation and 75 mg/m2 of daily temozolomide for a total of six weeks of treatment. For each week of radiation patients will receive a single 0.25 mg intravenous dose of palonosetron 30 minutes before each week of radiation fraction. This schedule will be repeated for each week of radiation for a total of 6 weeks.
1843193|NCT00900783|Drug|valacyclovir|1 gram, three times a day for seven days
1843194|NCT00900783|Drug|FV-100|400 mg, once daily, for seven days
1843195|NCT00900783|Drug|FV-100|200 mg, once daily, for seven days
1843196|NCT00900783|Drug|Valacyclovir placebo|three times a day, for seven days
1843197|NCT00900783|Drug|FV-100 placebo|once daily, for seven days
1843198|NCT00900796|Other|Treatment switching|If the patients do not response to first AntiTNF treatment, Investigator can switch to another anti TNF.Spanish Guidelines will be provided to the investigators, which recommend stopping biologics if there is an inadequate response after 16w of therapy and switch to another biologic. Responsive patients to the first anti-TNF who continue with this first anti-TNF adjusting dose treatment according to the Spanish guidelines or investigator criteria. The doses for each Anti TNF will be done following specific SmPc and under Investiagtor criteria
1843199|NCT00900809|Biological|Neukoplast™ (NK-92)|The Neukoplast™ (NK-92) cells will be administered intravenously over 60 minutes. The starting dose of Neukoplast™ (NK-92) cells will be 1 x 10e9 ZRx-101 cells/m2 (The 3 dose levels are: 1 x 10e9 cells/m2, 3 x 10e9 cells/m2 and 5 x 10e9 cells/m2). The second infusion will only be administered after 24 hours if no unacceptable or dose limiting toxicities side effects due to the infusion of Neukoplast™ were encountered after the first infusion.
1843200|NCT00900822|Device|Straumann Bone Ceramic|Granules applied once during surgery
1843201|NCT00900822|Device|BioOss|Granules that are applied once during surgery
1843202|NCT00900835|Other|educational intervention|
1843203|NCT00900835|Other|questionnaire administration|
1843204|NCT00900835|Other|study of socioeconomic and demographic variables|
1843205|NCT00900835|Procedure|assessment of therapy complications|
1843206|NCT00900835|Procedure|fatigue assessment and management|
1843207|NCT00900835|Procedure|quality-of-life assessment|
1843208|NCT00900835|Procedure|standard follow-up care|
1843209|NCT00900874|Drug|salbutamol|two puffs (100 microgram each of salbutamol) by MDI and spacer
1843210|NCT00900874|Drug|Formoterol|Formoterol 2 puffs (6 µg /puff) by MDI and spacer
1843211|NCT00900887|Drug|Ketorolac|ophthalmic presentation 5 mg/ml dosage one drop (0.25 mg) in the treated eye 3 times a day during one week
1843212|NCT00900887|Drug|Nepafenac|topic presentation 1 mg/ml dosage one drop (0.05 mg) in the treated eye 3 times a day during one week
1959336|NCT00392353|Drug|Azacitidine|Given SC
1959337|NCT00392353|Other|Laboratory Biomarker Analysis|Correlative studies
1959338|NCT00392353|Other|Pharmacological Study|Correlative studies
1843218|NCT00900939|Behavioral|Low-fat, vegan diet|Participants in the intervention group will be asked to follow a low-fat, vegan diet for the full 16 weeks of the study. They will also be guided to favor foods with a low glycemic index. The diet consists of whole grains, vegetables, legumes, and fruits, with no restriction on energy intake. Animal products, added oils, and added sugars will be excluded.
1843219|NCT00900939|Behavioral|Control|Participants assigned to the control group will be instructed to follow their usual diets for the full 16 weeks of the study.
1843220|NCT00900952|Other|Clinical record review|
1843221|NCT00900965|Device|Electroacupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|A specially designed copper needle (0.22 x 4 mm), which can be used safely in MRI suite, will be inserted through a plaster over the respective acupoints, under which a plastic ring will be positioned, connected with electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair) through wires with stimulation frequency of 150 Hz, lasting for 30 minutes.
1843222|NCT00900965|Device|Sham acupuncture treatment (electrical stimulation machine (EY-3308 Model, G6805-2 Mayfair))|Needle will be positioned at 2 cm away from the true respective acupoints, with a blunted, telescopic placebo needle. The same electric stimulation will be the same as real acupuncture treatment.
1843223|NCT00900978|Biological|7 valent pneumococcal conjugate vaccine (7v-PCV) - Prevenar|The 7v-PCV will be given to children below 2 years of age. Nasopharyngeal swabs will be taken from the children before vaccination and after finishing the vaccination. The vaccine will be given in a 2+1 scheme.
1843224|NCT00900991|Biological|split-virion pandemic influenza vaccine (H5N1 strain NIBRG-14)|
1843225|NCT00901017|Device|Straumann BoneCeramic|Bone augmentation procedure performed with Bone Ceramic
1843226|NCT00901017|Device|Bio-Oss|Bone Augmentation procedure performed with Bio Oss
1843227|NCT00901030|Procedure|Blood drawn|Blood samples will be taken once in the preoperative clinic and once again at the end of the surgery in the post anesthetic care unit to do the TEG and PMA tests.
1843228|NCT00901043|Dietary Supplement|Walnut supplementation|Eight weeks of walnut supplementation
1843229|NCT00901043|Dietary Supplement|Ad lib diet|Eight weeks without walnut supplementation
1843230|NCT00901056|Device|Extracorporeal Shockwave Therapy|Energy Density - 0.02 - 0.15 mJ/mm2
1843231|NCT00901069|Drug|Azacitidine with rituximab, vincristine, and cyclophosphamide|Azacitidine cycle days 1-5 Cyclophosphamide cycle days 6-9 Vincristine cycle day 8 Rituximab cycle day 8 Rituximab is only for those patients with CD20+ lymphoma. Azacitidine 25 mg/m2^ Azacitidine 50 mg/m2^ Azacitidine 75 mg/m2^ Azacitidine 100 mg/m2^
1843232|NCT00901082|Behavioral|Relaxation and information session|Relaxation and information session before the medial branch block
1843233|NCT00901095|Behavioral|Lifestyle intervention|Participants will attend a 15 weekly class sessions during the first 4 months. Classes will be co-lead by a dietician and exercise specialist and will involve a private weigh-in, a group discussion, a presentation of a lifestyle topic, 30 minutes of supervised moderate physical activity, followed by action-planning and goal-setting. During the next 2 months, participants will meet with a dietician on an individual basis for a private weigh-in, personal discussion and problem solving, review of self-monitoring records, and action-planning. The last 6 months will consist of applying and maintaining what has been learned in previous class sessions. Self-monitoring records, questions and problems will be discussed with interventions at least once every 2 months or more frequently if needed.
1843234|NCT00901108|Procedure|Trabectome-IOL|"Trabectome removes an arc of trabecular meshwork and inner wall of Schlemm's canal to enhance aqueous outflow through natural drainage pathways.
Trabectome will be done first, followed by cataract surgery because Trabectome requires a clear view through the cornea using a goniolens, and this view may be compromised after cataract surgery."
1843235|NCT00901108|Procedure|Trab-IOL|"Trabeculectomy bypasses the normal aqueous outflow channels of the eye and creates an external filtration pathway (called a filtering bleb) for aqueous to drain and be reabsorbed back into the circulation. Mitomycin C is an agent used during this procedure to decrease scar formation around the new passage.
Cataract surgery will be done first, followed by Trabeculectomy with Mitomycin C."
1843236|NCT00901121|Device|Straumann BoneCeramic|Straumann BoneCeramic (500-1000 microns, 0.5g)
1843237|NCT00901121|Device|Bio-Oss|Bio-Oss spongiosa granules, size of particle 0.25-1 mm
1843238|NCT00901147|Drug|panobinostat and bortezomib|oral panobinostat 30 mg 3 times per week AND intravenous bortezomib 1.3mg/m2 on days 1,4,8,11 per cycle
1843239|NCT00901160|Procedure|blood test|Blood will be taken from patients shortly after surgery in the recovery room in order to perform Thromboelastography® and Platelet Mapping Assay™ tests.
1843240|NCT00901186|Drug|RFB002|0.5 mg
1843241|NCT00901186|Procedure|Laser photocoagulation|
1843242|NCT00901199|Drug|Combo Chelation with Deferasirox (Exjade) and Desferal (DFO)|All subjects will be given Exjade 7 days per week 20-30mg/kg and Deferoxamine 3-7 days per week 50mg/kg. Days per week are dependent on how much iron overload subject has.
1843243|NCT00901212|Device|Device programming|6-month period
1843244|NCT00901225|Drug|G-CSF plus Plerixafor|"On Day 5 of G-CSF mobilization,
if the patient's peripheral CD34+ cell count is < 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected.
if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is < 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected."
1843245|NCT00901238|Procedure|Intra-arterial Chemotherapy|selective catheterization of the ophthalmic artery and injection of melphalan and topotecan
1843246|NCT00901277|Behavioral|web intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors. This is a web-based intervention.
1843247|NCT00901277|Behavioral|nurse intervention|A multi-behavioral, comprehensive approach is proposed addressing up to 13 health behaviors focused on improving subject management of CVD and related health behaviors given by the nurse via phone.
1843248|NCT00901290|Drug|monophasic oral contraceptive|mg, oral dose
1843249|NCT00901290|Drug|AZD7325|mg, oral dose
1843251|NCT00901316|Procedure|Routine Measures Group|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using separate culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. All patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding routine measures."
1843252|NCT00901316|Procedure|Bleach Bath Group (Bleach plus routine measures)|"Cultures will be obtained from the anterior nares of the nose, the throat and the groin using culturette swabs. S. aureus isolates will be identified and antibiotic susceptibility determined. Isolates will subsequently undergo testing for susceptibility to methicillin to determine if the isolate is an MSSA or MRSA strain. Patients and parents will be instructed orally and provided written instructions about routine measures employed for the prevention of S. aureus skin infections. Patients will be given further oral and written instructions regarding clorox baths. Please see supplemental material from the publication Randomized Trial of Bleach Baths plus Routine Hygienic Measures vs Routine Hygienic Measures Alone for Prevention of Recurrent Infections Clinical Infectious Diseases 2014;58:679-682 for the details regarding instructions for bleach baths."
1843253|NCT00901329|Device|NexGen Gender Fixed Bearing Knee prosthesis|new female prosthesis
1843254|NCT00901329|Device|NexGen LPS-Flex Fixed Bearing Knee prosthesis|standard knee prosthesis
1843255|NCT00901342|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF)
1843256|NCT00901368|Drug|FOSTER|CHF1535 (beclometasone dipropionate 100 µg plus formoterol 6 µg) pMDI aerosol via HFA-134a propellant 2 inhalations b.i.d. (daily dose 400 µg + 24µg)
1843257|NCT00901368|Drug|Seretide|Fluticasone 250 µg + salmeterol 50 µg DPI (Seretide® Diskus®) 1 inhalation b.i.d. (daily dose 500+100 µg)
1843258|NCT00901381|Drug|Filgrastim|10 µg/kg subcutaneously once daily x 5 days
1843259|NCT00901394|Drug|B12-Folic Acid, nitrous oxide|"IV vitamin B12 (cyanocobalamin) 1 mg, single administration over 30 min.
IV folic acid, 5 mg, single administration over 30 min.
Both diluted in 250 ml normal saline."
1843260|NCT00901394|Drug|Nitrous oxide (NO) and placebo|60% nitrous oxide anesthesia plus saline
1843261|NCT00901394|Other|Placebo|Saline
1843262|NCT00901394|Other|oxygen nitrogen|60% air and oxygen mix.
1843263|NCT00901407|Drug|lamotrigine|lamotrigine augmentation 25 to 100 mg tablets, 25 to 200 mg bid,10 weeks
1843264|NCT00901407|Drug|placebo|placebo: 1-2 tablets bid; 10 weeks
1843265|NCT00901407|Drug|paroxetine|open label paroxetine 10 to 50 mg, at bedtime for 18 weeks (8 weeks prior to randomization and 10 weeks after)
1843266|NCT00901420|Procedure|Urodynamics Test|90 Minute videotaped bladder function procedure involving pressure-monitoring catheters in bladder and rectum.
1843267|NCT00901420|Behavioral|Questionnaire|Survey of urinary function and quality-of-life (regarding daily living after surgical treatment for prostate cancer), taking 30 minutes to complete.
1843268|NCT00901433|Device|Personal WheezoMeter|pulmonary sounds analyzer
1843269|NCT00901446|Device|Intravascular ultrasound and spectroscopy|Intracoronary imaging with a catheter based ultrasound transducer and near infrared spectroscopy tip that is pulled back at an automated rate of 0.5 millimeters per second.
1843270|NCT00901459|Device|Active rTMS Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
1843271|NCT00901459|Device|rTMS Location Control Condition|Low frequency rTMS (90% Motor Threshold at 1 HZ) will be administered over the motor cortex (MC) during the presentation of smoking and control cues.
1843272|NCT00901459|Device|rTMS Frequency Control Condition|High frequency rTMS (90% Motor Threshold at 10 HZ) will be administered over the superior frontal gyrus (SFG) during the presentation of smoking and control cues.
1843273|NCT00901485|Device|AutoVPAP|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation and back up respiratory rate determined by learn function. Nocturnal use for one month in patient's home.
1843274|NCT00901485|Device|VPAPIIIST-A|Standard non-invasive ventilator with pressure and respiratory rate settings determined by healthcare professional. Nocturnal use for one month in the patient's home.
1843275|NCT00901498|Drug|BMS-708163|Oral, 25 mg Hard Gelatin Capsule, Size #2, 150 mg, Once per period of 3, 7 days between dosings. Will be compared with any 2 comparators.
1843276|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 1, 150 mg, Once per period of 3, 7 days between dosings
1843277|NCT00901498|Drug|BMS-708163|Oral, 50 mg Hard Gelatin Capsule, Size #0, 150 mg, Once per period of 3, 7 days between dosings
1843278|NCT00901498|Drug|BMS-708163|Oral, 75 mg Soft Gelatin Capsule, 150 mg, Once per period of 3, 7 days between dosings
1843279|NCT00901498|Drug|BMS-708163|Oral, 75 mg Tablet Formulation 2, 150 mg, Once per period of 3, 7 days between dosings
1843280|NCT00901511|Drug|GM-CSF [Leukine (Sargramostim)]|"Acute treatment: the PAP subjects will receive inhaled rGM-CSF (Sargramostim, Leukine) at the dose of 250 mcg/24 hours. The acute treatment will be accomplished in 12 weeks, for 7 consecutive days every second week (thus, 6 weeks on and 6 weeks off). For those PAP patients receiving the GM-CSF for the first time (1st and 2nd level treated groups), the treatment will be performed by 1 week run-in, after discharge from the ICU, in the Respiratory Disease Department (during this period PAP patients usually receive e.v. corticosteroids, and oral antibiotics). After the run-in period, the patient is discharged and inhalation treatment will continue at home.
Maintenance treatment: 17 weeks after the WLL (4 weeks after the completion of the acute treatment), the PAP patient will start the maintenance treatment. He/she will receive inhaled GM-CSF at the dose of 250 mcg/daily for 2 consecutive days every 14 days (2 days on and 12 days off) for a period of 6 month"
1843281|NCT00901511|Procedure|WLL|Whole lung lavage
1843282|NCT00901524|Drug|Peg-interféron alpha 2a + ribavirin|Pilot study, multicenter, open label
1843406|NCT00894959|Biological|Heparin sodium APP|Heparin sodium APP 5.000 USP
1843584|NCT00901979|Drug|LCQ908A|
1843283|NCT00901537|Drug|Azacitidine and Cisplatin|We plan to give azacitidine daily as subcutaneous injection at escalated doses (37, 60, 75, 85, 100 and 110 mg/m2) for 5 days from day 1 to day 5, and give cisplatin 75 mg/m2 as intravenous injection on day 8, every 4 weeks as a cycle.
1843284|NCT00901550|Drug|Methotrexate|All participants received oral Methotrexate(MTX), starting at 7.5 mg/week. In patients with persistent tender or swollen joints, the dose was escalated in a graduated manner (2.5 mg/week every 1-2 weeks) to 15 mg/week by week 4 or 20 mg/week by week 8
1843285|NCT00901550|Drug|Infliximab|Patients in combination group receive infliximab 3mg/kg at weeks 0, 2, and 6 and every 8 week thereafter.
1843286|NCT00901563|Drug|Rotigaptide|Prior to 20 mins of ischaemia induced by a blood pressure cuff inflated to 200 mmHg around the upper non-dominant arm, rotigaptide will be infused for 30mins. During the ischaemic period no drug will be infused but the infusion will be restarted once the blood pressure cuff has been deflated and blood flow returns to the limb.
1843287|NCT00901563|Other|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of substance P (2,4,8 pmol/min) or Acetylcholine (5, 10 , 20 micromol/min) . Venous blood sampling via cannula in antecubital fossa.
1843288|NCT00901576|Drug|SPD503|SPD503 (guanfacine hydrochloride) extended-release 4 mg orally administered tablets
1843289|NCT00901576|Drug|Concerta|CONCERTA (methylphenidate HCl) extended-release 36 mg orally administered tablets.
1843290|NCT00901576|Drug|SPD503 + Concerta|SPD503 4 mg + CONCERTA 36 mg orally administered tablets (taken together).
1843291|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily containing 2.2 g marine n-3 polyunsaturated fatty acids in total
1843292|NCT00901589|Dietary Supplement|thistle oil|four capsules a day
1843293|NCT00901589|Dietary Supplement|marine n-3 polyunsaturated fatty acids|Four capsules daily, 2.2 g marine n-3 PUFAs in total
1843294|NCT00901589|Dietary Supplement|Thistle oil|Four capsules daily
1843295|NCT00901615|Drug|Lenalidomide and R-CHOP|Lenalidomide dose administered orally during 14 days in combination with 6 courses of fixed doses of R-CHOP 21.
1843296|NCT00901628|Drug|ropivacaine|300mg (0.75%, 40cc) intraoperative periarticular injection
1843297|NCT00901628|Drug|morphine sulfate|10mg intraoperative periarticular injection
1843298|NCT00901628|Drug|ketorolac|30 mg intraoperative periarticular injection
1843299|NCT00901628|Drug|epinephrine|300 microgram (1:1000) intraoperative periarticular injection
1843300|NCT00901628|Drug|cefuroxime|750mg intraoperative periarticular injection
1843301|NCT00901641|Device|CogniFit Personal Coach®|The program provides individually tailored cognitive training based on the results of a baseline evaluation (the Neuropsychological Examination - CogniFit Personal Coach®).7 The program assigns scores to 17 cognitive abilities that are subsequently trained by means of 21 different tasks.
1843302|NCT00901654|Biological|ACE527 vaccine|"First cohort: Two doses, each of 3x10^9 cfu of each strain (9x10^9 cfu total per dose) administered on Days 0 and Day 21 (out-patient).
Second cohort: Two doses, each of 3x10^10 cfu of each strain (9x10^10 cfu total per dose) administered on Days 0 and Day 21"
1843303|NCT00901654|Biological|Placebo vaccine|First and second cohort: The placebo vaccine will be administered at Days 0 and Days 21.
1843304|NCT00901693|Drug|AL-46383A Ophthalmic Solution|
1843305|NCT00901693|Drug|AL-46383A Ophthalmic Solution Vehicle|
1843306|NCT00901706|Other|Comprehensive Geriatric Assessment and APS Usual Care|Comprehensive Geriatric Assessment coupled with APS usual care which collectively will consist standardized cognitive, functional, affective, social, and legal interventions.
1843307|NCT00901706|Other|APS usual care|APS usual care consists of social, medical, and legal assistance.
1843308|NCT00901719|Drug|Apelin|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial apelin infusions at 0.3, 1.0 and 3.0 nanomol/ml.
1843309|NCT00901719|Drug|Acetylcholine|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 5, 10 and 20 microg/min
1843310|NCT00901719|Drug|Sodium nitroprusside|Using the technique of venous occlusive plethysmography subjects will receive three intrabrachial acetylcholine infusions at 1, 2 and 4 microg/min
1843311|NCT00901719|Drug|Systemic apelin infusion|Following plethysmography patients will receive systemic infusion of (Pry)Apelin-13 (30, 100 and 300 nmol/min) for 5 mins cardiac output, blood pressure, heart rate and systemic vascular resistance will be measured at 5-min intervals.
1843312|NCT00901732|Device|Caphosol|Oral Mouth Rinse
1843313|NCT00901745|Drug|Angiotensin II|Infusion of up to 30picmol/ml angiotensin II will be infused and respondent vasoconstriction assessed.
1843314|NCT00901745|Drug|Noradrenaline infusion|Infusion of up to 480 picomol/ml of noradrenaline will be infused.
1843315|NCT00901758|Drug|IV Nitroglycerin|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL.
1843316|NCT00901758|Drug|Normal saline|IV injection, initial does of 1mL, with further doses of 1-3mL, up to a recommended maximum of 10mL
1843317|NCT00901771|Device|Provent|This is a non-randomized, single-arm, case series study. All subjects will receive Provent device.
1843318|NCT00901784|Drug|Topiramate|25mg Tablets
1843319|NCT00901797|Procedure|Arthroscopic Bankart repair|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
1843320|NCT00901797|Procedure|ABR+ARIC|Seated in a beach chair position, arm fixed with a skin traction device (Spider shoulder Immobilizer or 3kg traction), arthroscopy through a posterior portal, anterior portal used for inspection and instrumentation, labral lesion released using a suture liberator, full radius and VAPER. Preparation of the glenoid with rasp up and down. Insertion of anchors as necessary into the glenoid and ligation of labral lesion with the sutures. Through additional anterior superior portal a suture is passed inferior and adjacent to the SSP and through the superior portion of the Sub Scapularis tendon while the arm in 30 degree of external rotation. Tightening the suture on top of the capsule underneath the deltoid. Wound closure with ethilon 4/0 suture, striped dressing, velpeau arm sling.
1959339|NCT00392353|Drug|Vorinostat|Given PO
1843323|NCT00901823|Drug|Diazoxide choline|A single dose low dose DCCR then re-randomized to either multiple dose low dose DCCR or high dose DCCR
1843324|NCT00901823|Drug|Diazoxide choline high dose|A single dose high dose DCCR then re-randomized to either low or high multiple doses of DCCR
1843325|NCT00901836|Radiation|Preoperative proton therapy|28 daily fractions of 1.8 cobalt gray equivalent(CGE)/fx for total of 50.4 CGE over 5.5 weeks.
1843326|NCT00901836|Procedure|Surgery|Standard of care surgery will be performed 4-6 weeks after completion of radiation.
1843327|NCT00901849|Drug|Tarceva and Rapamycin|Tarceva will be administered once a day for 28 days without interruption. THen Rapamycin will be administered, orally twice daily, in combination with the Tarceva for the remainder of the study.
1843328|NCT00901862|Device|Pulsed magnetic fields (Quantum MH-2MR bracelet)|Pulsed magnetic fields
1843329|NCT00901862|Device|Sham pulsed magnetic fields (Quantum MH-2MR bracelet)|Hybrid circuits crucial for the generation of the electromagnetic field had been removed.
1843330|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|Sublingual tablets
1843331|NCT00901875|Drug|Buprenorphine + naloxone (Suboxone)|
1843332|NCT00901888|Drug|Apelin infusion|Infusion of up to 10picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
1843333|NCT00901888|Drug|Sodium nitroprusside infusion|Infusion of up to 150-600picmol/min will be administered intra-arterially to induce vasoconstriction. Thereafter infusions of apelin (0.1, 1.0, 3.0nmol/min) will be given for 6mins each. During the same study, sodium nitroprusside will given (1.0, 2.0, 4.0 microg/min) for 6mins.
1843334|NCT00901901|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg twice daily + matching erlotinib placebo daily
1843335|NCT00901901|Drug|Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva|Sorafenib 400 mg twice daily + erlotinib 150 mg daily
1843336|NCT00901914|Biological|Placebo|One sublingual tablet of matching placebo daily during approximately 5.5 months
1843337|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 12.5 µg daily during approximately 5.5 months
1843338|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 25 µg daily during approximately 5.5 months
1843339|NCT00901914|Biological|rBet v 1|One sublingual tablet containing rBet v 1 at a dosage of 50 µg daily during approximately 5.5 months
1843340|NCT00894478|Procedure|Diffusion Tensor Imaging (DTI)|"MR and DTI: MRI and DTI will be done using 3.0T Philips MR scanner (Philips Medical Systems, Best, The Netherlands) using an eight channel head coil. DTI and axial 3D T1 will be performed on patients and controls.
DTI will be performed using single shot diffusion-weighted echo planar imaging, b=1000s/mm2 and 15 noncollinear directions (TR/TE=10,000/60 ms, slice thickness=2mm, field of view=22cm, matrix=112x112, NEX=2)
Axial 3D T1 (TR/TE=4.9/2.3 ms, slice thickness=1 mm, field of view = 24 cm, matrix=220x220, NEX=1) Patients will have additional sequences (axial and coronal T2, proton density and FLAIR) as part of their clinical scan"
1843341|NCT00894478|Procedure|Magnetoencephalography|MEG will be performed using a whole-head Omega 151-channel gradiometer system (VSM MedTech, Port Coquitalam, BC, Canada). At least 15 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 625Hz, a bandpass filter of 10 to 70 Hz and a notch filter of 60 Hz.
1843342|NCT00894504|Drug|Panitumumab|6 mg/kg IV on Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
1843343|NCT00894504|Drug|Carboplatin|AUC=2.5 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
1843344|NCT00894504|Drug|Gemcitabine|1500 mg/m2 IV, Day 1 of each 2-week treatment cycle for 3 cycles (6 weeks)
1843345|NCT00894517|Biological|Botulinum Toxin Type A|OnabotulinumtoxinA (botulinum toxin Type A) 200U injected into the prostate on Day 1.
1843346|NCT00894517|Drug|Placebo (saline)|Saline injected into the prostate on Day 1.
1843347|NCT00894530|Drug|Azithromycin ophthalmic solution, 1%|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
1843348|NCT00894530|Drug|Placebo|One drop in each eye twice a day for the first two days; then one drop in each eye once a day for 26 days
1843349|NCT00894543|Drug|Escitalopram|10 mg (1 pill) escitalopram daily for the first four weeks. Dose increased to 20 mg (2 pills) escitalopram daily if relief from hot flashes has not occurred during the first four weeks of the daily 10 mg dose.
1843350|NCT00894543|Other|Placebo|Inactive pill (1 pill or 2 pills) daily for the 8-11 weeks of the trial.
1843351|NCT00894556|Drug|rizatriptan|Single dose of 10 mg orally disintegrating tablet at onset of migraine attack
1843352|NCT00894556|Drug|Comparator: Placebo|Placebo to Rizatriptan
1843353|NCT00894556|Drug|Comparator: Sumatriptan|single dose of generic sumatriptan 100 mg at onset of migraine attack
1843354|NCT00894569|Drug|paclitaxel/carboplatin|6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.
1843355|NCT00894569|Drug|cetuximab|cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
1843356|NCT00894582|Procedure|Components separation hernia repair|Components separation is one method currently employed for repair of massive ventral hernias. In this study we simply measured the volume of patients' abdomen (who were already undergoing this surgery) as well as their pulmonary function both pre and postoperatively.
1843357|NCT00894595|Behavioral|Knäkontroll, SISU Idrottsböcker©, Sweden, 2005|The preventive program (Knäkontroll, SISU Idrottsböcker©, Sweden, 2005) consists of six exercises focusing on knee control and core stability and is performed during the warm-up at two training sessions per week throughout the 2009 competitive season.
1843467|NCT00895362|Drug|Erlotinib|Starting dose 100 mg by mouth 1 time every day for 28-day cycle (Pediatric starting dose 50 mg).
1959344|NCT00379145|Drug|trabectedin|
1959345|NCT00376090|Biological|MVA-CMDR|10^7 PFU IM, 1.0 mL
1959346|NCT00376090|Biological|Placebo|1.0 mL IM
1843360|NCT00894621|Drug|Norepinephrine|Solution administration contend titrated norepinephrine in doses of 0,1 to 0,4 mc/kg/min. Initiated solution 24 hours after beginning mechanical ventilation. Use of the solution during 72 hours.
1843361|NCT00894621|Drug|Placebo|
1843362|NCT00894634|Drug|Brompheniramine maleate|
1843363|NCT00894647|Drug|imiquimod cream|Imiquimod 3.75% cream (250 mg/packet) up to 2 packets applied daily Two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
1843364|NCT00894647|Drug|placebo cream|cream applied once daily for two 2-week treatment periods (Cycle 1 and Cycle 2) separated by a 2-week no-treatment period
1843365|NCT00894660|Drug|Amodiaquine (Test)|Oral tablet, single dose, 1 X 300 MG
1843366|NCT00894660|Drug|Amodiaquine (Comparator)|Oral tablet, single dose, 2 X 150 MG
1843367|NCT00894673|Biological|Heparin sodium Hipolabor|Heparin sodium Hipolabor 5.000 UI/mL
1843368|NCT00894673|Biological|Heparin sodium APP|Heparin sodium APP 5.000 USP
1843369|NCT00894686|Biological|FSME-IMMUN 0.25 mL Junior (1.2 µg TBE antigen/0.25 mL) or FSME-IMMUN 0.5 mL (2.4µg TBE antigen/0.5 mL)|Dosage form: solution/suspension; injectable. Dosage frequency: once. Mode of administration: intramuscular.
1843370|NCT00894699|Drug|Sublingual Sufentanil/Triazolam NanoTab™ (ARX-F03)|Single dose of sublingual Sufentanil 15 mcg/Triazolam 200 mcg NanoTab™
1843371|NCT00894699|Drug|Placebo NanoTab™|Single dose of sublingual placebo NanoTab™
1843372|NCT00894712|Other|Sulforaphane-containing broccoli sprout extracts (active agent)|Topical application, prepared with acetone, 280 nml daily, 3 times a week.
1843373|NCT00894712|Device|Vehicle (inactive control)|Subjects will have measurements of skin erythema using a device called a chromometer
1843374|NCT00894725|Procedure|laparoscopic left colonic resection|laparoscopic colonic resection
1843375|NCT00894725|Procedure|open left colonic resection|conventional open colonic resection
1843376|NCT00894738|Procedure|Testing (MRS, US, DEXA)|Magnetic Resonance Spectroscopy (MRS) of the liver to determine hepatic triglyceride content; ultrasound (US) of the carotid artery to determine intima-media thickness; dual energy X-ray absorptiometry (DEXA) to determine body composition; fasting lipids, fasting insulin, C-reactive protein, liver enzymes and fibrinogen levels.
1843377|NCT00894751|Drug|dexmedetomidine|dexmedetomidine general anesthesia for MRI
1843378|NCT00894751|Drug|propofol|propofol general anesthesia for MRI
1843379|NCT00894777|Other|Clinical record review|
1843380|NCT00894790|Drug|Celecoxib|celecoxib 200 mg BID (twice a day) with a loading dose of 400 mg
1843381|NCT00894790|Drug|oral Diclofenac|diclofenac 75 mg tablet BID (twice a day)
1843382|NCT00894803|Drug|Eptifibatide|IV Eptifibatide is an approved drug by the Food and Drug Administration as a treatment for blood clots causing heart attack and chest pain.Eptifibatide inhibits platelet aggregation by blocking activated platelets from binding fibrinogen.
1843383|NCT00894803|Drug|rt-PA|Intravenous recombinant tissue plasminogen activator (rt-PA) is the only approved acute stroke therapy.
1843386|NCT00894829|Biological|heparin sodium - Eurofarma|Heparin sodium 5.000 UI - Eurofarma
1843387|NCT00894829|Biological|heparin sodium - APP|Heparin sodium APP 5.000 USP
1843388|NCT00894842|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 days, followed by Pregnenolone 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Pregnenolone 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
1843389|NCT00894842|Drug|Placebo|Placebo 50 mg BID x 14 days, followed by Placebo 300 mg per day for 14 days (200 mg qAM and 100 mg qPM), followed by Placebo 500 mg per day for the remainder of the 8-week trial (300 mg qAM and 200 mg qPM)
1843390|NCT00894855|Behavioral|education about sun protection|This comprehensive education program included a visit with a health educator, on the education van, who gave education about sun safety.
1843391|NCT00894855|Behavioral|biometric feedback|Participants received biometric feedback using a Dermascan Analyzer and Ultra Violet (UV) Reflectance Photography. The Dermascan Analyzer is an educational tool that enhances visibility of skin texture, markings or lesions and is commonly used in health fairs and at schools all over the country. The analyzer highlights the sun damage on the participants skin as dark purple blotches, which the participants are able to see in the mirror placed inside the analyzer. Ultra Violet (UV) Reflectance Photography provides participants with a visual image of their skin damage that can be taken with them.
1843392|NCT00894855|Other|dermatologist skin exam|Full body skin exam.
1843393|NCT00894868|Drug|vildagliptin|
1843394|NCT00894868|Drug|placebo of vildagliptin|
1843395|NCT00894881|Procedure|Gut cleaning as a preparation to colonoscopy [resting energy expenditure (REE)]|resting energy expenditure (REE).
1843396|NCT00894894|Drug|MP-470|escalating daily doses of amuvatinib
1843397|NCT00894894|Drug|amuvatinib (MP-470)|escalating doses of daily amuvatinib
1843398|NCT00894907|Other|PiCCO-parameter-guided volume resuscitation|"Insertion of an arterial PiCCO catheter. Resuscitation using crystalloids and/or colloids with the following goals:
ITBI: 850-1000 ml/sqm, if ELWI <=12*ml/kg; ITBI 750-850 ml/sqm, if ELWI >12*ml/kg and/or PaO2:FiO2 <200 (*ELWI<=12ml/kg, if MAP>65mmHg without catecholamines; ELWI<=14ml/kg, if catecholamines required for MAP>65mmHg); SVV<10% (only in controlled ventilation and sinus rhythm); MAP>65mmHg (MAP: Mean Arterial Pressure); IAPP >60mmHg (IAPP: Intra-abdominal Perfusion Pressure)"
1843399|NCT00894907|Other|Control-group|"Haemodynamic management without ITBI and ELWI using any other haemodynamic monitoring tool, with the exception of the PiCCO-system.
Main haemodynamic goals: CVP 8-12 mmHg; MAP >65mmHg;IAPP >60mmHg"
1843400|NCT00894920|Dietary Supplement|biotin|capsule approximately 30 mcg daily 21 days
1843401|NCT00894920|Dietary Supplement|biotin|capsule 300 mcg daily 21 days
1843402|NCT00894933|Device|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
1843403|NCT00894946|Procedure|Lipiodol + IVF|IVF preceded by lipiodol
1843404|NCT00894946|Procedure|IVF|IVF alone
1843405|NCT00894959|Biological|Heparin sodium Blausiegel 1|Heparin sodium Blausiegel 1 5.000 UI
1843585|NCT00901979|Drug|LCQ908A|
1843407|NCT00894972|Other|Rehabilitation following lumbar disc surgery (discectomy)|Exercise: walking, range of motion, and general trunk strengthening with or without specific trunk muscle motor control exercises.
1843408|NCT00894985|Biological|heparin sodium - blausiegel|heparin sodium 5.000UI
1843409|NCT00894985|Biological|heparin sodium - APP|heparin sodium 5.000 USP - APP
1843410|NCT00894998|Biological|heparin sodium - Cristália|Heparin sodium 5000UI - Cristália
1843411|NCT00894998|Biological|Heparin sodium APP|Heparin Sodium 5.000 USP - APP
1843412|NCT00895011|Drug|Placebo|One dose 30 minutes prior to initiation of sexual activity
1843413|NCT00895011|Drug|Avanafil|One dose 30 minutes prior to initiation of sexual activity
1843414|NCT00895011|Drug|Avanafil|One dose 30 minutes prior to initiation of sexual activity
1843415|NCT00895024|Behavioral|Phone Interview/Questionnaire|35-minute questionnaire over the phone.
1959347|NCT00376090|Biological|MVA-CMDR|10^6 PFU ID, 0.1 mL
1843417|NCT00895050|Other|Review of clinical records|
1843418|NCT00895063|Behavioral|Vocal Exercise|This project will examine whether or not exercise performed immediately following botulinum toxin injection affects the clinical benefit received from the injection. This is a cross-over study and subjects will be randomly assigned to a group where they will speak continually for one hour or remain silent for one hour following injection. Data on the effectiveness of the exercise will be collected just before each injection and at 2 weeks, 6 weeks, and 3 months following injection.
1843419|NCT00895076|Drug|dexamethasone|iontophoretic patch and injection
1843420|NCT00895089|Drug|Moxifloxacin (Avelox)|moxifloxacin 400 mg IV qd for 14 days, followed by moxifloxacin 400 mg po qd for another 1 week
1843421|NCT00895089|Drug|ceftriaxone|ceftriaxone 2 gm IV q 12 h for 14 days, followed by cephalexin 1 gm PO q 6 h for 1 week
1843422|NCT00895102|Drug|ABT-333 Tablet|See Arm Description for more information.
1843423|NCT00895102|Drug|Placebo|See Arm Description for more information.
1843424|NCT00895102|Drug|ABT-333 Capsule|See arm description for more information
1843425|NCT00895115|Dietary Supplement|vitamin E|Given once daily
1843426|NCT00895115|Procedure|sham intervention|No supplementation
1843427|NCT00895128|Drug|Erlotinib Hydrochloride|Starting dose of 100 mg taken by mouth 1 time a day every day for 28 day cycle or 50 mg for pediatric patients.
1843428|NCT00895128|Drug|Dasatinib|Starting dose of 50 mg by mouth 1 or 2 times a day every day for 28 day cycle.
1843429|NCT00895141|Dietary Supplement|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat diet (40%E) with 8%E saturated fat
1843430|NCT00895141|Dietary Supplement|Saturated Fat Diet|Moderate carbohydrate (35%E), moderate protein (25%E), high fat (40%E) diet with 20%E saturated fat
1959348|NCT00376090|Biological|Placebo|0.1 mL ID
1959349|NCT00376090|Biological|MVA-CMDR|10^8 PFU IM, 1.0 mL
1843433|NCT00895167|Dietary Supplement|curcumin|one oral dose of 12 caplets = 12 g curcumin
1843434|NCT00895180|Biological|olaratumab|Given IV
1843435|NCT00895180|Biological|ramucirumab|Given IV
1843436|NCT00895193|Other|Apple pectin|Apple pectin 2000mg
1843437|NCT00895193|Drug|Aspirin 325 mg|Aspirin 325 mg
1843438|NCT00895193|Other|Placebo|Placebo
1843439|NCT00895206|Drug|individual adapted immunosuppression|individual adapted immunosuppression
1843440|NCT00895206|Drug|golden standard therapy|golden standard therapy
1843441|NCT00895219|Other|Breathing re-training|Breathing re-training
1843442|NCT00895219|Other|Breathing re-training and musculoskeletal techniques|Breathing re-training and musculoskeletal physiotherapy techniques including mobilisation techniques to normalise muscle and joint restrictions, doming of the diaphragm to enhance contraction and relaxation, and rib raising to free restriction in rib cage motion.
1843443|NCT00895232|Drug|Cohort I|
1843444|NCT00895232|Drug|Cohort II|
1843445|NCT00895232|Drug|Cohort III|
1843446|NCT00895245|Drug|fosaprepitant dimeglumine|Given IV
1843447|NCT00895245|Drug|cisplatin|Given IV
1843448|NCT00895245|Drug|palonosetron hydrochloride|Given IV
1843449|NCT00895245|Drug|dexamethasone|Given IV and orally
1843450|NCT00895245|Other|Functional Living Index-Emesis Questionnaire|Ancillary studies
1843451|NCT00895245|Behavioral|Emesis Diary|Ancillary studies
1843452|NCT00895245|Radiation|Radiotherapy|Undergo radiotherapy
1843453|NCT00895258|Behavioral|Individual placement and support plus cognitive training (IPS-CT)|One IPS plus one CT session each week for 12 weeks
1843454|NCT00895258|Behavioral|Individual placement and support plus enhanced support (IPS-ES)|One IPS plus one ES session each week for 12 weeks
1843455|NCT00895284|Procedure|Robotic hysterectomy|Robotic hysterectomy.
1843456|NCT00895284|Procedure|Standard Hysterectomy|Standard hysterectomy.
1843457|NCT00895297|Drug|Dasatinib (Sprycel)|100mg of Dasatinib will be administered as tablets, by mouth, once a day (or twice in some cases depending on the stage of the disease) consistently either in the morning or evening for 12 months. Dose of Dasatinib will be modified according to the patients response.
1843458|NCT00895310|Drug|Ketoconazole|Ketoconazole is taken three times a day by mouth.
1843459|NCT00895310|Drug|Hydrocortisone|Hydrocortisone is taken by mouth 20 mg every morning and 10 mg every evening.
1843460|NCT00895323|Other|enzyme-linked immunosorbent assay|
1843461|NCT00895323|Other|pharmacological study|
1843462|NCT00895323|Procedure|whole-body scintigraphy|
1843463|NCT00895323|Radiation|iodine I 131-labeled anti-CEA/anti-HSG bispecific monoclonal antibody TF2|
1843464|NCT00895336|Biological|Lactobacillus GG|1 capsule taken twice daily for a minimum of 28 days to a maximum of 35 days.
1843465|NCT00895349|Procedure|CT Abdomen and Pelvis scan + whole body PET-CT scan|Pre-treatment scan
1843466|NCT00895349|Procedure|CT Abdomen and Pelvis scan|Pre-treatment scan
1843586|NCT00901979|Drug|LCQ908A|
1959350|NCT00376090|Biological|MVA-CMDR|10^7 PFD ID, 0.1 mL
1843468|NCT00895362|Drug|Cetuximab|Loading dose of 200 mg/m^2 (maintenance 125 mg/m^2) by vein 1 day every week of 28-day cycle, on Days 1, 8, 15 and 22. First dose given over 2 hours and over 1 hour each subsequent time.
1843469|NCT00895388|Behavioral|Structured Rehabilitation program|Questionnaire send by post at 3, 6, 12, 18 and 24 months after operation
1843470|NCT00895401|Dietary Supplement|Nepro with Carb Steady|Nepro with Carb Steady is a commercially available renal specific oral nutritional supplement designed to meet the nutrient needs of dialysis patients. The supplement is 8 oz and provides 425 kcal and 19 grams of protein.
1843471|NCT00895401|Other|Standard of Care|Standard of Care for malnourished maintenance hemodialysis patients
1843474|NCT00895453|Drug|itraconazole|6-months maintenance regimen with monthly single-day itraconazole 200mg twice daily (bid)
1843475|NCT00895453|Drug|lactobacillus gasseri|Lactobacillus vaginal tablets monthly given through 6 days
1843476|NCT00895453|Drug|classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)|CH treatment was provided by a licensed CH practitioner. Specifically, a personal history was taken and an individualised treatment scheme was prescribed. The most often used homeopathic remedies were carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, and sepia M. Potencies of homeopathic remedies ranged from C 30 to C 1000.
1843477|NCT00895466|Biological|PEP-223/CoVaccine HT|
1843478|NCT00895479|Procedure|Graft placement surgery plus Trinam therapy|"Trinam arm: graft placement surgery plus 1ml perivascular administration of Trinam vector.
Control arm: graft placement surgery"
1843479|NCT00895505|Drug|Phenprocoumon|Phenprocoumon 3 mg, tablet, INR adjusted
1843480|NCT00895505|Drug|Warfarin-Natrium|Warfarin-Natrium 5 mg, tablet, INR adjusted
1843481|NCT00895518|Behavioral|Prolonged Exposure (PE) Therapy|Three PE sessions lasting 1 hour each, delivered 1 week apart
1843482|NCT00895531|Drug|Depodur|7.5 mg Depodur via the epidural catheter
1843483|NCT00895531|Procedure|sciatic nerve block|The sciatic nerve will be identified at the subgluteal level with ultrasound. A point 3 cm lateral and 4 cm caudad will be marked. Patients will be placed in the lateral position. A 18 G Tuohy needle will be inserted at a 45° angle until a peroneal or tibial twitch is obtained at 1.5 mA. Once the current can be reduced to obtain a twitch less than 0.5 mA, a catheter will be inserted and placed perineurally. If placed preoperatively, the catheter will be flushed with normal saline or 5% dextrose and will not be dosed until after surgery. After the patient is in the PACU and the surgeons have verified the sciatic nerve function, the sciatic catheter will be dosed with 35 mL 0.25% ropivacaine.
1843484|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose B (Indonesia strain) for booster vaccination (Day 360)
1843485|NCT00895544|Biological|Influenza vaccine (whole virion, Vero cell derived)|Dose A (Vietnam strain) for priming vaccination (Day 0) - Dose A (Indonesia strain) for booster vaccination (Day 360)
1843486|NCT00895557|Drug|chantix|.5 mg once a day 1 to 3, .5 mg twice a day on days 4 to 7, 1 mg from day 8 to end of treatment
1843487|NCT00895570|Drug|modafinil|During each day of the 7-day sleep restriction phase of the study modafinil was administered (200 mg tablet at 0600, and a second dose of 100 mg tablet at 1300).
1843488|NCT00895570|Drug|placebo|During each day of the 7-day sleep restriction phase of the study a sugar pill was administered.
1843489|NCT00895583|Drug|Tacrolimus|During the screening phase, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is from transplantation until randomization (from 90 to 150 days).
1843490|NCT00895583|Drug|Sirolimus|Following randomization, sirolimus is provided by the Sponsor in 1 and 2 mg oral tablets. Sirolimus is dosed once daily to achieve a target trough level of 7 to 15 ng/mL in the 1st year post-transplant and 5 - 15 ng/mL in the 2nd year post-transplant. Duration of treatment is from randomization through 2 years post-transplant (19 to 21 months).
1843491|NCT00895583|Drug|Tacrolimus|During the study, tacrolimus is provided by the investigator (not the Sponsor) and is dosed to achieve a target trough level determined by the investigator. Therefore, the dosage form, dosage, and frequency are determined by the investigator. Duration of treatment is 2 years post-transplant.
1843492|NCT00895596|Drug|LB80380|Total treatment period: 12 weeks, followed by 24 weeks of treatment with adefovir dipivoxil 10mg
1843493|NCT00895609|Drug|Sugammadex, Neostigmine, Saline|"Single intravenous injection of either:
Sugammadex 0.0625 mg/kg (Sgx 0.0625) Sugammadex 0.125 mg/kg (Sgx 0.125) Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 1.0 mg/kg (Sgx 1.0) Neostigmine 5 mg/kg (Neo 5) Neostigmine 8 mg/kg (Neo 8) Neostigmine 15 mg/kg (Neo 15) Neostigmine 25 mg/kg (Neo 25) Neostigmine 40 mg/kg (Neo 40) Saline 0.9% (Saline)"
1843494|NCT00895622|Other|clinical observation|Patients undergo observation.
1843495|NCT00895622|Radiation|3-dimensional conformal radiation therapy|Patients undergo 3-dimensional conformal radiation therapy once daily 5 days a week for 6 weeks
1843496|NCT00895622|Radiation|intensity-modulated radiation therapy (IMRT)|Patients undergo IMRT once daily 5 days a week for 6 weeks
1843497|NCT00895635|Behavioral|Treadmill Exercise Training|60-minute sessions of supervised treadmill exercise training three times a week for 12 weeks
1843498|NCT00895635|Behavioral|Arm Ergometry Exercise Training|60-minute sessions of supervised aerobic arm exercise training using an arm ergometer three times a week for 12 weeks
1843499|NCT00895635|Behavioral|Usual Care|Usual care for PAD
1843500|NCT00895648|Drug|Pemetrexed|500 mg/m² iv infusion every 3 weeks for 3 cycles
1843501|NCT00895648|Drug|Cisplatin|75 mg/m² iv infusion every 3 weeks for 3 cycles
1843502|NCT00895661|Drug|rituximab|Increased dose (750 mg/m2) intravenously for 4 weekly doses followed by maintenance dosing once every three months for up to 2 years. Maintenance dose is standard (375 mg/m2).
1843503|NCT00895674|Drug|Nexavar (Sorafenib, BAY43-9006)|Patients with a diagnosis of advanced RCC
1843505|NCT00895687|Drug|Bortezomib|Beginning dose of 1. mg/m^2 by vein over about 1-5 minutes on Days 1, 4, 8, and 11 of each 21-day cycle.
1843507|NCT00895713|Drug|intramuscular hepatitis B virus immune globulin|Biweekly intramuscular doses of 2000 IU administered during 6 consecutive months
1843508|NCT00895726|Drug|APD209|Oral tablets twice per day for 56 days
1843509|NCT00895739|Biological|alemtuzumab|
1843510|NCT00895739|Drug|cyclosporine|
1843511|NCT00895752|Drug|Riluzole|Six week open-label treatment with riluzole, maximum dose of 50 mg twice a day.
1843512|NCT00895778|Other|Neuromuscular blockade with rocuronium and reversal with sugammadex|
1843513|NCT00895791|Device|AXXESS Biolimus A9-eluting bifurcation stent|implantation of stent
1843514|NCT00895791|Device|culotte stenting (Xience V)|implantation of stent
1843515|NCT00895804|Drug|MDMA|capsule, 1.6 mg/kg body weight, single dose
1843516|NCT00895804|Drug|Pindolol|capsule of 20mg pindolol, single dose 1h before MDMA
1843517|NCT00895817|Drug|Swallowed fluticasone|440 µg twice daily for 8 weeks
1843518|NCT00895817|Drug|Esomeprazole|40 mg once daily for 8 weeks
1843519|NCT00895830|Drug|APD405|IV
1843520|NCT00895830|Drug|Placebo|IV
1843521|NCT00895843|Drug|Brufen retard|Single dose 2 x 800mg tablets 2 hours prior to surgery
1843522|NCT00895843|Drug|ibuprofen|Single dose ibuprofen 2 x 200mg tablets 2 hours prior to surgery
1843523|NCT00895843|Drug|Bupivacaine|Up to 10ml of Bupivacaine 0.5% with 1:200,000 Adrenaline given prior to surgical incision as inferior alveolar nerve block and long buccal nerve infiltration.
1843524|NCT00895856|Other|Evaluation of the functional capacity|An evaluation (questionnaire) was performed by the Katz Index of individuals in this group, including personal issues (sex and age) and different levels of functional independence for the elderly in their basic activities of daily living (ABVD's) such as: bathe, dress, use the bathroom for withdrawals, transfers perform, has control of the sphincters and the food itself. Subject themselves, if capable of responding to the issues of consistency index, did. The answers were given to the auxiliary nurse responsible for care to residents.
1843525|NCT00895882|Drug|vaniprevir (MK7009)|vaniprevir 300 mg soft gel capsules twice daily.
1843526|NCT00895882|Drug|Comparator: vaniprevir (MK7009)|vaniprevir 600 mg soft gel capsules twice daily.
1843527|NCT00895882|Drug|Comparator: Pegylated Interferon (peg-IFN) alfa-2a|Peg-IFN 180 mcg/0.5 mL subcutaneous injection once weekly
1843528|NCT00895882|Drug|Comparator: Ribavirin|Ribavirin, at a total daily dose of 1000 mg or 1200 mg based on patient weight, will be administered twice daily.
1843529|NCT00895882|Drug|Comparator: Placebo to vaniprevir|Placebo to vaniprevir soft gel capsules twice daily.
1843530|NCT00895895|Drug|Placebo|Capsules SAM-531 placebo and 5 mg tablet encapsulated Donepezil placebo capsules, once a day during 24 weeks.
1843531|NCT00895895|Drug|SAM-531 1.5 mg|Capsules SAM-531 1.5 mg, once a day during 52 weeks.
1843532|NCT00895895|Drug|SAM-531 3.0 mg|Capsules SAM-531 3.0 mg, once a day during 52 weeks.
1843533|NCT00895895|Drug|SAM-531 5.0 mg|Capsules SAM-531 5.0 mg, once a day during 24 weeks or 52 weeks.
1843534|NCT00895895|Drug|Donepezil|Encapsulated Donepezil 5 mg tablets, once a day during 52 weeks. After Day 42, the dose can up titrated up to 10 mg of Donepezil.
1843535|NCT00895908|Behavioral|Friendship Group|Social skills training for 30 sessions, held twice per week over 4 to 5 months
1843536|NCT00895908|Behavioral|Academic tutoring|Tutoring to support emergent literacy skills, held 1 to 2 times per week over 4 months
1843539|NCT00895934|Drug|vorinostat|Given orally
1843540|NCT00895934|Drug|gemtuzumab ozogamicin|Given intravenously (IV)
1843541|NCT00895934|Drug|azacitidine|Given IV or subcutaneously (SC)
1843542|NCT00895947|Drug|interferon-alpha|a lozenge for oral dissolution containing 150 international units of human interferon-alpha taken once daily for 16 weeks
1843543|NCT00895947|Other|placebo|placebo lozenges for oral dissolution taken once daily for 16 weeks
1843544|NCT00895960|Drug|Dasatinib|Starting dose of 150 mg/day administered by mouth daily on Days 1 to 28 of every 28 day cycle, beginning on the first day of RT.
1843545|NCT00895960|Radiation|RT (Radiotherapy)|As a part of standard of care, receive 60 Gy radiation therapy Monday-Friday for a total of 30 radiation treatments (about 6 weeks).
1843546|NCT00895960|Drug|TMZ (Temozolomide)|75 mg/m^2 capsules daily by mouth for up to a maximum of 7 weeks beginning first day of RT until RT end followed by 4 weeks off then 150 mg/m^2 daily on Days 1-5 of each 28 day study cycle and 200 mg/m^2 daily of subsequent cycles.
1843547|NCT00895973|Other|Stirrups delivery vs bed delivery|Position of legs at time of vaginal delivery (bed vs stirrups)
1843548|NCT00895986|Behavioral|Conversation Maps Diabetes Education|The Conversation Maps program is a set of innovative, interactive diabetes education tools developed by the Healthy Interactions, Inc (Healthy I) and endorsed by the American Diabetes Association. It consists of four conversation maps covering: 1) Diabetes Overview, 2) Diabetes and Healthy Eating, 3) Blood Glucose and Monitoring, and 4) The Natural Course of Diabetes (a fifth map covering gestational diabetes will not be used in this study), and a program manual to help educators successfully implement the program.
1843549|NCT00895986|Behavioral|Heart Healthy Living Diabetes Education|The Joslin Clinic offers a series of two 120-minute classes specifically for people with diabetes that address dyslipidemia and blood pressure problems. A registered nurse and/or a registered dietitian teach the classes, which have a formal written curriculum, including PowerPoint slides.
1843550|NCT00895999|Behavioral|Interpersonal Therapy for Pain (IPT-P)|IPT-P focuses on improving relationships as a way to improve depression and pain. The patient and therapist work together to improve communication and enhance relationships and social support. Patients choose a problem focus and goal related to both their pain and depression. Up to 8 IPT-P sessions are provided regardless of ability to pay.
1843587|NCT00901979|Drug|LCQ908A|
1843588|NCT00901979|Drug|Placebo|
1843589|NCT00901979|Drug|Sitagliptin|
1843590|NCT00901979|Drug|metformin|
1843551|NCT00895999|Behavioral|Enhanced Support and Connection to Counseling|Research staff connect patients with the Strong Family Therapy Services, Women's Behavioral Health Service, or other appropriate mental health care and reduce potential barriers from making it to the initial appointment. This support includes navigating insurance issues, addressing issues of childcare and transportation, helping to schedule the initial appointment, reminder calls, and follow-up after the scheduled intake. Research staff will also check-in monthly to see if the patients require any additional support to remain in mental health treatment. Up to 8 therapy sessions are covered regardless of ability to pay.
1843552|NCT00896012|Procedure|Kidney Biopsy|Skin over the kidney will be cleansed and disinfected. The skin and deeper tissue will be numbed with novocaine like solution. A special needle will be inserted guided by ultrasound into the kidney for an instant to withdraw the small specimen.
1843553|NCT00896012|Drug|Rapamune (sirolimus/rapamycin)|Rapamune will be given at a dose of 5mg/day for two days beginning at the initiation of tacrolimus reduction. Thereafter, Rapamune will be given at a dose of 3 mg/day. The dose of Rapamune will be titrated to achieve a blood level (by HPLC) between 5 and 10 for the duration of the study.
1843554|NCT00896012|Drug|Tacrolimus|Patients in this group will continue to receive tacrolimus at reduced doses. Doses will be titrated to achieve tacrolimus trough blood levels between 4 and 6. Myfortic at doses of 720 mg BID and steroids will be continued for the duration of the study (12 months).
1843555|NCT00896025|Drug|N-acetylcysteine|"Patients will be included in the trial from the onset of any hepatic coma grade and will receive NAC for the following 72 hrs.
NAC Solutions: The N-acetylcysteine will be added to 5% dextrose in defined concentrations according to the sequence of four specific doses required for the study.
i.Solution A: 150 mg/kg bodyweight in 250 ml 5% dextrose over one hour
ii.Solution B: 50 mg/kg in 500 ml 5% dextrose over four hours
iii.Solution C: 125 mg/kg in 1000 ml 5% dextrose over 19 hours
iv.Solution D: 150 mg/kg in 1000 ml 5% dextrose per 24 hours
v.Solution E: 150 mg/kg in 1000 ml 5% dextrose per 24 hours"
1843556|NCT00896038|Drug|Aprepitant|Aprepitant is a neurokinin 1 receptor antagonist shown to have anti-stress actions in preclinical studies, and antidepressant efficacy in human clinical trials
1843557|NCT00896038|Drug|Placebo|Non-active placebo
1843558|NCT00896051|Drug|Atazanavir (ATV) 300 mg|Atazanavir (ATV) 300 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 300 mg by mouth following a meal each morning on Substudy Days -1 to 7.
1843559|NCT00896051|Drug|Atazanavir (ATV) 400 mg|Atazanavir (ATV) 400 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take ATV 400 mg by mouth following a meal each morning on Substudy Days -1 to 7.
1843560|NCT00896051|Drug|Ritonavir (rtv) 100 mg|Ritonavir (rtv) 100 mg taken by mouth following a meal each morning for 2 weeks during the Pre-Treatment Period and for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take rtv 100 mg by mouth following a meal each morning on Substudy Days -1 to 7.
1843561|NCT00896051|Drug|Nucleo(side)/(tide) reverse transcriptase inhibitors (NRTIs)|2 investigator-selected NRTIs taken as specified in the individual product labels for 2 weeks during the Pre-Treatment Period followed by 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) taken as specified in the individual product label for 48 weeks during the Treatment Period. If participating in the optional substudy, participants will take 1 investigator-selected NRTI (of the 2 NRTIs in the Pre-Treatment Phase) mg taken as specified in the individual product label during the Substudy.
1843562|NCT00896051|Drug|Etravirine (ETR) 200 mg|Etravirine (ETR) 200 mg taken twice daily as two 100-mg tablets following a meal (morning and evening) for at least the first two weeks of the 48-week Treatment Period. If participating in the optional substudy, participants will take ETR 200 mg twice daily as two 100-mg tablets following a meal each morning and evening on Substudy Days -1 to 7.
1843563|NCT00896051|Drug|Tenofovir disoproxil fumarate (TDF) 300 mg|Tenofovir disoproxil fumarate (TDF) 300 mg taken by mouth following a meal each morning on Substudy Days 1 to 7.
1843564|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 1)|One dose will be administered intramuscularly at Study Day 0.
1843565|NCT00896064|Biological|Pneumococcal vaccine GSK2189242A (formulation 2)|One dose will be administered intramuscularly at Study Day 0.
1843566|NCT00896077|Drug|Lisofylline|Lisofylline via i.v. administration vs Lisofylline vs s.c. administration
1843567|NCT00896129|Other|HRQOL Survey Packet|Questionnaires
1843568|NCT00896155|Drug|Tamoxifen|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
1843569|NCT00896155|Radiation|Radiotherapy|260 patients of breast cancer will be accrued into the study. After inclusion in the study, all the patients will be randomized into two arms. ARM 1 will receive Tamoxifen 20 Mg once daily given concurrently with radiotherapy while in ARM-2 radiotherapy followed by tamoxifen 20 mg once daily sequentially.
1843570|NCT00896168|Drug|Infliximab|Infliximab 3 mg per kg intravenous infusion at Week 0, 2, 6, 14 and 22.
1843571|NCT00896168|Drug|Methotrexate|MTX stable dose (7.5 to 20 mg/week equal to the dose used before participation in the study) for 22 weeks.
1843572|NCT00896181|Drug|docetaxel|Given IV
1843573|NCT00896181|Drug|cisplatin|Given IV
1843574|NCT00896181|Drug|carboplatin|Given IV
1843575|NCT00896181|Drug|fluorouracil|Given IV
1843576|NCT00896181|Radiation|3-dimensional conformal radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
1843577|NCT00896181|Radiation|intensity-modulated radiation therapy|Undergo 3-dimensional conformal or intensity-modulated radiotherapy
1843578|NCT00901927|Drug|Bendamustine|Starting dose 90 mg/m^2 by vein over 30-60 minutes on Days 1 and 2 of each cycle.
1843579|NCT00901927|Drug|Mitoxantrone|10 mg/m^2 by vein over 15 minutes on Day 2 of each cycle.
1843580|NCT00901927|Drug|Rituximab|375 mg/m^2 by vein over several hours on Day 1 of each cycle.
1843581|NCT00901940|Biological|Meningococcal (Groups A, C, Y and W-135) Conjugate|2 x 0.5 mL dose
1843582|NCT00901940|Biological|Meningococcal polysaccharide A, C, Y and W135 and Menveo|1 x 0.5 mL dose of ACWY Vax, 1 x 0.5 mL dose of Menveo
1843583|NCT00901979|Drug|LCQ908A|
1843591|NCT00901992|Behavioral|MEDIAS 2 ICT|MEDIAS 2 ICT is a newly developed education program for the initiation of intensive conventional insulin therapy in type 2 diabetic patients (10 lessons of group sessions for 4-8 participants)
1843592|NCT00901992|Behavioral|Current ICT program (ACC-ICT)|This program is conducted in 10 lessons in a group setting (4-8 participants)
1843594|NCT00902031|Drug|Docusate Sodium, Sennoside|"Docusate sodium: given in capsule form (100 mg/capsule), at a dosage of 200 mg, taken twice daily for 10 days.
Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days."
1843595|NCT00902031|Drug|Sennoside + Placebo|"Sennoside: will be given in tablet form (8.6 mg), 1-3 tablets taken 1-3 times daily for 10 days.
Placebo: will be taken in capsule form, similar in size, shape, and color to docusate, taken twice daily for 10 days"
1843596|NCT00902044|Genetic|Autologous HER2-specific T cells|Each patient will receive one intravenous injection of autologous HER2-specific T cells at one of the dose levels. If the patient has stable disease or a reduction in the size of the tumor they can receive additional doses of HER2-specific T cells at 6 to 12 weeks intervals-each of which will consist of the same cell number as their HER2-specific T-cell injection. For the first two subsequent HER2-specific T-cell infusions, patients will be able to receive additional lymphodepleting chemotherapy according to their dose levels.
1843597|NCT00902044|Drug|Fludarabine|"Fludarabine will be administered for 5 days prior to the T cells
The dose:
>10 kg: 25 mg/m2/day;
<10 kg: 1 mg/kg/day IV over 30 minutes"
1843598|NCT00902044|Drug|Cyclophosphamide|"Cyclophosphamide will be administered for 2 days and then fludarabine will be given for the next 5 days and then the T cells will be administered
Cyclophosphamide Dose:
30 mg/kg/day IV over 1 hour (with Mesna and IV hydration)
Fludarabine Dose:
>10 kg: 25 mg/m2/day; <10 kg: 1 mg/kg/day IV over 30 minutes"
1843599|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 1.5mcg
1843600|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 3mcg
1843601|NCT00902057|Drug|desmopressin|single desmopressin subcutaneous injection, 15mcg
1843602|NCT00902057|Drug|placebo|saline subcutaneous
1843603|NCT00902070|Drug|Rocuronium|Normally, for adults, 0.6 mg/kg of rocuronium bromide is intravenously administered to support endotracheal intubation. If additional administration is necessary, 0.1 - 0.2 mg/kg is intravenously administered. In the case of continuous infusion, infusion is initiated at a rate of 7 μg/kg/min. Dosage should be adjusted based on the age or symptom. The upper limit of this drug for the intubation is 0.9 mg/kg.
1843604|NCT00902083|Drug|p53 gene with surgery|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
1843605|NCT00902083|Procedure|surgery|remove tumor surgery
1843606|NCT00902083|Drug|p53 with chemotherapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times Chemotherapy: standard chemotherapy
1843607|NCT00902083|Drug|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
1843608|NCT00902109|Device|Perimetry|different perimetric devices, different perimetric grids: Octopus: New Scotoma-Oriented Perimetry (SCOPE) Using a New Fast German Adaptive Threshold Estimation (GATE) HFA: 30-2, Sita (Swedish Interactive Thresholding Algorithm) full threshold
1843609|NCT00902109|Device|Confocal Scanning Laser Tomography|HRT examinations for the clinical evaluation of the optic disc.
1843610|NCT00902109|Device|Optical Coherence Tomography (OCT)|imaging of the retinal nerve fiber layer
1843611|NCT00902122|Drug|rAd-p53 gene|pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 5 times
1843612|NCT00902122|Procedure|surgery|removal of thyroid tumor
1843613|NCT00902122|Drug|p53 gene therapy|p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
1843614|NCT00902122|Radiation|p53 gene therapy with radioactive iodine|p53 gene therapy with concurrent radioactive iodine pre-surgery p53 gene treatment: 10exp12 virus particles per 3 days for 10 times
1843615|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant together with a reminder
1843616|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon) and Personal Digital Assistant without a reminder
1843617|NCT00902135|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Interferon beta-1b (Betaferon)
1843618|NCT00902148|Device|Polylactic Acid Sheet|SurgiWrapTM bioresorbable sheet will be secured directly below the abdominal incision.
1843619|NCT00902161|Drug|MK0893|Single dose of MK0893 1000 mg (ten 100 mg tablets)
1843620|NCT00902161|Drug|MK0893-matched Placebo|Single dose of placebo to MK0893 (ten tablets)
1843621|NCT00902161|Drug|Propranolol Hydrochloride (HCL)|Propranolol tablets titrated up to 80 mg three times daily over a four week period. Total treatment was approximately 7 weeks.
1843622|NCT00902174|Drug|imatinib mesylate|Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
1843623|NCT00902174|Drug|Placebo|Placebo to imatinib 100 mg film coated tablets
1843624|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
1843625|NCT00902187|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 4 mg
1843626|NCT00902200|Drug|AR-12286|See arms
1843627|NCT00902200|Drug|AR-12286 vehicle|See arms
1843628|NCT00902213|Behavioral|Physical Therapy|Each patient in this group will have physical therapy performed. The intervention will be tested for its effect on: 1) physical function outcomes (muscle strength, range of motion, endurance, gross motor skills), bone density and bone mineral content (end of therapy only); and 2) HRQL.
1843629|NCT00902213|Behavioral|Support|Visits with an Advanced Practice Nurse to support sustained motivation.
1843630|NCT00902226|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
1843728|NCT00903214|Procedure|therapeutic conventional surgery|
1959369|NCT00316732|Procedure|IPSS Questionnaire|
1843634|NCT00902265|Drug|desmopressin|desmopressin (Nocturin®) 0.1 mg tablet per day for 12 weeks
1843635|NCT00902629|Procedure|Early surgery|Intervention group contains patients randomized to receive surgery for their epiretinal fibrosis, at an earlier point than what the common clinical practice is now.
1843636|NCT00902642|Behavioral|an eight day university training course designed to integrating psychosocial factors in clinical practice on a patient level|an eight day university training course on psychosocial factors for physical therapists
1843637|NCT00902655|Drug|Desmopressin|Desmopressin 0.1,0.2 or 0.4 mg once daily for 3-weeks of dose titration phase and 4-weeks of treatment phase
1843638|NCT00902668|Drug|lovastatin|
1843639|NCT00902668|Other|questionnaire administration|
1843640|NCT00902668|Procedure|adjuvant therapy|
1843641|NCT00902668|Radiation|accelerated partial breast irradiation|
1843642|NCT00902668|Radiation|external beam radiation therapy|
1843643|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
1843644|NCT00902681|Drug|Fesoterodine|A fesoterodine extended-release tablet (ER) formulation once daily administration of 8 mg
1843645|NCT00902694|Behavioral|ACHIEVE Intervention|Group and individual weight loss counseling and group physical activity classes for 18 months
1843646|NCT00902694|Other|Control|group health classes quarterly with topics not related to weight
1843647|NCT00902707|Drug|Mucinex 1200mg|Compared to Placebo
1843648|NCT00902707|Drug|Placebo|Compare to active Mucinex
1843649|NCT00902720|Other|Tissue sample storage|The tissue sample is frozen and held at -140 degrees at the in vitro fertilization lab at the Center for Health and Healing at OHSU.
1843650|NCT00902733|Other|medical chart review|
1843651|NCT00902733|Other|questionnaire administration|
1843652|NCT00902733|Procedure|fatigue assessment and management|
1843653|NCT00902733|Procedure|psychosocial assessment and care|
1843654|NCT00902733|Procedure|quality-of-life assessment|
1843655|NCT00902746|Drug|NPC-01|"This study consist of the following steps.
Step 1(Norethisterone 0.6mg, Ethinyl Estradiol 0.035mg):From first study medication to 3th menstrual cycles.
Step 2(Norethisterone 1mg, Ethinyl Estradiol 0.035mg):
After interim analysis of the results of step 1, in the case of the efficacy results meet prespecified criterion, same dose level will be continued to 13th menstrual cycles including step 1. If the results do not meet prespecified criterion, the dose will be increased to Norethisterone 1mg, Ethinyl Estradiol 0.035mg and be continued newly until 13th menstrual cycle from this point."
1843656|NCT00902759|Other|Walking Program|"Brisk walking is defined as faster than the slow walk, but not to exhaustion and not a running pace. Participants will be instructed to walk at home, at a gym or in a shopping mall for as far as possible on a level surface, wearing appropriate footwear as described in the walking booklet. (Patients may continue to walking longer if they desire and are symptom free). Participants should stop or slow down if they experience any discomfort (such as uncomfortable shortness of breath, chest pain, or body pain). The goal is to eventually walk for 90-120 minutes per week in three to four sessions. Participants will not be asked to take their pulse or to record their perceived exertion in order to simplify the program."
1843657|NCT00902772|Drug|Lorazepam|mg, oral dose
1843658|NCT00902772|Drug|AZD7325|mg, oral dose
1843659|NCT00902772|Drug|Placebo|
1843660|NCT00902785|Other|no drug|observational no drug
1843661|NCT00902798|Behavioral|Cognitive Enhancement Therapy|An 18-month comprehensive, small group approach for the remediation of cognitive deficits in neurodevelopmental disorders consisting of individual sessions and 45 group training sessions in social cognition that are integrated with approximately 60 hours of computer assisted training in attention, memory, and problem solving skills.
1843662|NCT00902798|Behavioral|Enriched Supportive Therapy|An 18-month intervention that uses individual supportive therapy to help adults learn about autism spectrum disorder, manage their emotions and stress, improve their social skills, and cope with everyday problems. Participants will learn about the impact of stress on their lives, and how to identify their own early cues of distress and apply effective coping strategies.
1843663|NCT00902811|Drug|AM(FDC)|Artesunate-mefloquine fixed dose combination (artesunate 25mg/mefloquine hydrochloride 55mg, or artesunate 100mg/mefloquine hydrochloride 220mg), according to age-group.
1843664|NCT00902811|Drug|AM(LT)|Artesunate (Arsumax®, Sanofi) 50 mg tabs given at 4 mg/Kg/day on day 0, day 1 and day 2 (total 12 mg/Kg) PLUS Mefloquine 250 mg base tabs given at 25 mg/Kg on day 0. Treatment is given in three equally divided daily doses to the nearest quarter tablet.
1843665|NCT00902811|Drug|AL|Coartem®: artemether 20 mg - lumefantrine 120 mg co-formulated tabs (Coartem®, Novartis) given as six twice-daily doses over three days, according to weight-groups. The second dose should be taken 6 to 10 hours after the first dose, given at inclusion. Patients will be advised to take some fatty food (or encouraged to give breast feeding) before each dose is taken. Fatty food or milk will not be provided by the researchers.
1843666|NCT00902811|Drug|DP|40 mg dihydroartemisinin/320 mg piperaquine tablets and Dihydropiperaquine 20mg/ Piperaquine 160 mg tablets),. Treatment is given according to age groups. In the age group <6yrs of age, a subdivision according to weight is made
1843667|NCT00902811|Drug|AA(FDC)|Artesunate-amodiaquine fixed dose combination (FDC) (Artesunate Amodiaquine Winthrop® Sanofi Aventis); Artesunate 25mg/amodiaquine 67.5mg; Artesunate 50mg/amodiaquine 135mg ; Artesunate 100mg/amodiaquine 270mg
1843668|NCT00902824|Biological|ADVAX|Receive 4mg ADVAX at Months 0, 1, and 2 (Biojector), and receive boost of 5x10^7 pfu TBC-M4 (IM)
1843669|NCT00902824|Biological|TBC-M4|Receive 5x10^7 pfu TBC-M4 (IM) at Months 0, 1, and 6.
1843670|NCT00902824|Other|Placebo|"Group A (n=4) will receive the ADVAX placebo (formulation buffer) via Biojector.
Group B (n=4) will receive the TBC-M4 placebo (formulation buffer) via IM."
1843671|NCT00902837|Drug|Oxycodone naloxone prolonged release tablets (OXN)|
1843672|NCT00902837|Drug|oxycodone prolonged release tablet|
1843673|NCT00902837|Drug|oxycodone naloxone tablet|
1959370|NCT00316732|Procedure|EQ-5D Questionnaire|
1843674|NCT00902850|Device|SofLens Daily Disposable|Lenses to be worn for 8-16 hours
1843675|NCT00902850|Device|Marketed 1 Day Contact Lens|Lenses to be worn for 8-16 hours
1843676|NCT00902863|Behavioral|YOGA|Patients with chronic pain will undergo a six week course of YOGA
1843677|NCT00902876|Device|Mucograft|Collagen Matrix for soft tissue regeneration
1843678|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPI (lower caudal two contacts), 4 weeks wash-out, 6 weeks stimulation GPE (upper cranial two contacts)
1843679|NCT00902889|Procedure|Stimulation|6 weeks stimulation with GPE (upper cranial two contacts), 4 weeks wash-out, 6 weeks stimulation with GPI (lower caudal two contacts)
1843680|NCT00902915|Drug|lenalidomide plus dexamethasone|peroral application; lenalidomide dosage according to severity grade of renal failure.
1843681|NCT00902928|Drug|YM150|oral
1843682|NCT00902928|Drug|enoxaparin|SC injection
1843683|NCT00902941|Drug|Azilect 1mg|1 mg daily orally for 120 days
1843684|NCT00902941|Drug|Placebo|1 mg daily orally for 120 days
1843685|NCT00902954|Drug|anastrozole|anastrozole 1 mg qd
1843686|NCT00902954|Drug|letrozole|letrozole 2.5 mg qd
1843687|NCT00902954|Drug|exemestane|exemestane 25 mg qd
1843688|NCT00902967|Drug|Atorvastatin|Atorvastatin 10 mg, once a day dosing at night after meals
1843689|NCT00902967|Drug|Placebo|Placebo tablets of similar shape size and color given once a day at night time after meals
1843690|NCT00902980|Other|Chart Review|Chart review of patients / graft outcome in renal transplant recipients
1843691|NCT00902993|Drug|AZD1446|Solution, oral single and multiple dose
1843692|NCT00902993|Drug|Placebo|Placebo
1843693|NCT00903006|Drug|Fulvestrant|Starting dose of 500 mg through a needle into muscle on Days 1 and 15 of Cycle 1 and on Day 1 of Cycles 2 and beyond. On Day 1 of Cycle 1, injections into 2 different muscles, all other times one injection.
1843694|NCT00903006|Drug|MK-0646|Group 3 or Group 4, receive starting dose of 5 mg/kg by vein on Days 1, 18, 15, and 22 of every cycle.
1843695|NCT00903006|Drug|Dasatinib|Group 2 or Group 4, starting dose of 70 mg (capsules) by mouth daily.
1843696|NCT00903019|Behavioral|Tele-Problem-Solving Therapy|Six sessions of tele-PST
1843697|NCT00903019|Behavioral|In-Person PST|Six sessions of in person PST
1843698|NCT00903019|Behavioral|Attention control|Six weekly telephone calls
1843699|NCT00903032|Behavioral|Intervention|The multi-faceted patient centered intervention will adapt elements of prior successfully adherence interventions and include the following core components: collaborative care (between pharmacists, primary care providers, and cardiologists), patient education (tailored to patient needs and provided on a regular ongoing basis), tailoring of medication regimens (i.e., simplification of dosing, use of pill boxes, synchronization of refill dates), and tele-monitoring via IVR technology as well as patient-specific aides based on identified needs.
1843700|NCT00903032|Behavioral|Usual care|Usual care following ACS hospital discharge.
1843701|NCT00903045|Drug|Propiverine hydrochloride|Propiverine hydrochloride 20mg twice a day
1843702|NCT00903045|Drug|Placebo|Identical placebo twice a day
1843703|NCT00903071|Behavioral|Real PPL|See above arm description
1843704|NCT00903071|Behavioral|Sim PPL|See above arm description
1843705|NCT00903084|Drug|Tenofovir Disoproxil Fumarate|300-mg tablet
1843706|NCT00903110|Drug|Increlex®|Increlex® (mecasermin [rDNA origin] injection), 10 mg/ml solution for injection, 20-120mcg/kg BID or 0,02 to 0,12 mg/kg BID, as prescribed by physician
1843707|NCT00903136|Other|questionnaire administration|
1843708|NCT00903136|Procedure|comparison of screening methods|
1843709|NCT00903136|Procedure|diagnostic endoscopic procedure|
1843710|NCT00903136|Procedure|esophagogastroduodenoscopy|
1843711|NCT00903136|Procedure|tethered capsule endoscopy|
1843712|NCT00903162|Drug|leuprolide|Given intramuscularly beginning on day 1 and then either 7.5 mg every month or 22.5 mg every 3 months for two years
1843713|NCT00903162|Drug|letrozole|Taken orally once a day 6-8 weeks after initial leuprolide administration
1843714|NCT00903162|Drug|zoledronic acid|If desired, given intravenously every 6 months for a total of 4 injections (optional)
1843715|NCT00903175|Drug|everolimus|Everolimus was administered orally at 10 mg/day. Everolimus is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 10 tablets.
1843716|NCT00903175|Drug|sunitinib|Sunitinib was administered orally 50 mg daily, on a schedule of 4 weeks on/2 weeks off. Sunitinib was supplied as hard gelatin capsules of 12.5 mg, 25 mg, or 50 mg strength according to local practice.
1843717|NCT00903188|Drug|cyclosporine|"Cyclosporine (Group 1):
basiliximab dose: 1x20 mg IV on Day 0 and 1x20 mg IV on Day 4
Cyclosporine: 8 mg/kg PO given before surgery, followed by 2x4 mg/kg/d. C-0h levels: month 1: 150-250 ng/ml; month 2: 100-200 ng/ml; month 3: withdrawal steroids: 100-150 ng/ml.
C-2h levels: month 1: 900-1100 ng/ml; month 2: 800-1000 ng/ml; month 3: withdrawal steroids: maintain level of 750 ng/ml
Enteric-coated mycophenolate(MPA):720mg PO pre-operatively followed by 1.44 g/day.
Steroids: pre-operatively: 250mg methylprednisolone IV; day 1:125mg IV.
Methylprednisolone:day 2-30:PO 12mg/d; day 31-60:tapered to 8mg/d ,day 61-90 :4mg/d; Month 3:stop"
1843718|NCT00903188|Drug|Everolimus|"Everolimus (Group 2):
Basiliximab dose: idem as in group 1
Cyclosporine: first three months idem group 1; month 3: decreased dose by 50%, simultaneously initiate everolimus at a starting dose of 0.75 mg bid.
Once the everolimus blood levels range 6 - 12 ng/ml, cyclosporine will be stopped.
Enteric-coated mycophenolate (MPA) dosing idem as group 1.
Everolimus starting dose: 0.75 mg bid, trough levels: 6-12 ng/ml.
Steroid dosing: idem group 1, but maintained at 4 mg methylprednisolone after day 60."
1843722|NCT00903214|Drug|riluzole|100 mg orally twice a day, tablets self-administered, administered from day -14 to day 0 (scheduled surgery and preserve tissue for biormarker analysis)
1843723|NCT00903214|Genetic|polymorphism analysis|Pre-treatment, day -15 but may be done any time after enrollment but before surgery.
1843724|NCT00903214|Procedure|axillary lymph node biopsy|
1843725|NCT00903214|Procedure|digital image analysis|
1843726|NCT00903214|Procedure|needle biopsy|
1843727|NCT00903214|Procedure|sentinel lymph node biopsy|
1843729|NCT00903227|Drug|Fluticasone Evohaler pMDI|One puff of inhaled Fluticasone Evohaler pMDI 50 µg twice a day (Total FP dose 100 µg)
1843730|NCT00903227|Drug|Placebo|1 puff of inhaled Placebo twice a day
1843731|NCT00903227|Drug|Fluticasone Evohaler|One puff of inhaled Fluticasone Evohaler 250µg twice a day (Total daily FP dose 500µg)
1843732|NCT00903227|Drug|Placebo intranasal spray|placebo intranasal spray 2 squirts each nostril once a day
1843733|NCT00903227|Drug|fluticasone propionate (Flixonase®)|intranasal fluticasone propionate (Flixonase®) 50ug 2 squirts
1843734|NCT00903253|Drug|LNK-754|
1843735|NCT00903266|Behavioral|Melodic Intonation Therapy|MIT emphasizes the prosody of speech through the use of slow, pitched vocalization (singing).
1843736|NCT00903266|Behavioral|Speech-Repetition-Therapy|Speech-Reception-Therapy is an equally intensive, alternative verbal treatment method developed for this study.
1843737|NCT00903279|Drug|Placebo|Placebo will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
1843738|NCT00903279|Drug|Altabax (retapamulin)|Retapamulin 1% ointment will be administered intranasally an amount approximating 0.25 ml will be applied to each nasal vestibule by sterile cotton applicator in the evening prior to surgery and immediately on call on the day of surgery.
1843739|NCT00903292|Drug|erlotinib (Tarceva)|chemotherapy with erlotinib
1843740|NCT00903292|Drug|pemetrexed (Alimta)|Chemotherapy with pemetrexed
1843741|NCT00903305|Other|medical chart review|
1843742|NCT00903305|Other|questionnaire administration|
1843743|NCT00903305|Procedure|fatigue assessment and management|
1843744|NCT00903305|Procedure|psychosocial assessment and care|
1843745|NCT00903305|Procedure|quality-of-life assessment|
1843746|NCT00903318|Behavioral|Questionnaire|Questionnaire about family's characteristics taking about 30-35 minutes to complete.
1843747|NCT00903331|Drug|ACT-064992 (macitentan)|ACT-064992 (macitentan) tablet, 10 mg, once daily
1843748|NCT00903331|Drug|Placebo|matching placebo, once daily
1843749|NCT00903344|Drug|Vitamin D3|4000IU vitamin D3 tablet taken daily
1843750|NCT00903344|Dietary Supplement|Multivitamin|Multivitamin containing 400IU vitamin D in tablet taken daily
1843751|NCT00903357|Drug|Montelukast first, then placebo|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
1843752|NCT00903357|Drug|Placebo first, then Montelukast|"Patients in Montelukast first, then placebo will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks. And after 2 weeks wash-out period, they will receive chewable ascorbic acid placebo for 8 weeks. Patients in Placebo first, then Montelukast are received chewable ascorbic acid placebo for 8 weeks. And after 2 weeks wash-out period, they will receive 4 mg of montelukast under the age of 6 years (5 mg of montelukast at 6 years) once daily for 8 weeks."
1843753|NCT00903370|Procedure|MVS|All participants will have their left atrial appendage excised or excluded. For mitral regurgitation, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, and for most cases of mitral stenosis, a valve replacement will be performed.
1843754|NCT00903370|Device|Ablation|For participants treated by pulmonary vein isolation, two separate encircling lesions will be made around the left and right pulmonary veins. For participants treated with biatrial maze lesion set, the left atrial lesions will include, the two encircling lesions, as well as connecting lesions between to the pulmonary veins, from the pulmonary veins to the mitral valve annulus, and from the pulmonary veins to the left atrial appendage. The right pulmonary veins will be isolated first. Isolation will be confirmed by pacing the pulmonary veins at the previously identified threshold for capture. If no atrial capture is noted, it will be inferred that the right pulmonary veins were isolated. If atrial capture is noted, additional ablations on the atrial cuff will be performed until isolation is confirmed. This will be repeated on the left pulmonary veins.
1843755|NCT00903383|Drug|LX3305 low dose|A low dose of LX3305; daily oral intake for 12 weeks
1843756|NCT00903383|Drug|LX3305 mid dose|A mid dose of LX3305; daily oral intake for 12 weeks
1843757|NCT00903383|Drug|LX3305 high dose|A high dose of LX3305; daily oral intake for 12 weeks
1843758|NCT00903383|Drug|Placebo|Matching placebo dosing with daily oral intake for 12 weeks
1843759|NCT00903396|Drug|palonosetron hydrochloride|Given IV
1843760|NCT00903396|Other|placebo|Given IV
1843762|NCT00903422|Drug|eltrombopag olamine|thrombopoietin receptor agonist
1843763|NCT00903422|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
1843764|NCT00903435|Other|Quantitative Sensory Testing and Stimulus|No therapeutic intervention will be given. Quantitative Sensory Testing, thermal/mechanical/ischemic stimulus will be performed.
1843765|NCT00903448|Drug|Prilosec OTC (omeprazole-magnesium)|Prilosec OTC (omeprazole-magnesium 20.6 mg) tablet to be taken with a glass of water prior to breakfast
1843766|NCT00903448|Drug|Prevacid|Prevacid (15 mg lansoprazole) capsule to be taken with a glass of water prior to breakfast
1843767|NCT00903461|Biological|EGFR Antisense DNA|"Intratumoral EGFR AS injections weekly x 7 weeks (or less if there is no identifiable tumor), starting 2 weeks prior to radiation. The first EGFR AS injection must be given after cetuximab is administered. Subsequent EGFR AS injections can be given before or after cetuximab is administered. Injections will be in the primary and/or lymph nodes. One site will be injected per weekly session. If it is necessary the antisense injection can be scheduled within 1 business day of the original schedule date and then resume the original schedule
EGFR AS will be administered by direct intratumoral injection using direct visualization, endoscopy, or imaging-guidance (ultrasound) as clinically determined. The same lesion (primary tumor or lymph node) will be injected during treatment."
1843768|NCT00903474|Other|questionnaire administration|
1843769|NCT00903474|Other|study of socioeconomic and demographic variables|
1843770|NCT00903474|Procedure|CAM exercise therapy|
1843771|NCT00903474|Procedure|psychosocial assessment and care|
1843772|NCT00903474|Procedure|quality-of-life assessment|
1843773|NCT00903474|Procedure|stress management therapy|
1843774|NCT00903500|Behavioral|Daily physical activity, pedometer and counseling|Individual counseling session, telephone counseling (7 calls), given by a psychologist and a pedometer, based on cognitive behavioral therapy, the Diabetes Prevention Program, the first Step Program and Motivational Interviewing
1843775|NCT00903500|Behavioral|Usual care|Usual care
1843776|NCT00903539|Device|SecurAcath Securement System|Subcutaneous catheter securement system
1843777|NCT00903552|Biological|Influenza VLP Vaccine|
1843778|NCT00903552|Biological|Placebo|phosphate-buffered saline (PBS)
1843779|NCT00903591|Other|questionaire, blood or saliva sample|Take part in an approximately 45 minute telephone interview, with questions about detailed treatment (chemotherapy, hormonal therapy, radiation therapy (RT)) for all study participants. Their medical records will be reviewed to get further details about treatment of their breast cancer. They donate either a 35 ml blood sample (about 3 tablespoons) or a saliva sample. Blood Sample: if patient consents to give a blood sample, following the interview, they will be contacted by our staff phlebotomist (a person trained to draw blood). A scheduled appointment to draw a blood sample from you at your home. At the time of the blood draw, the phlebotomist will collect approximately 2 and 1/3 tablespoons of blood. Saliva Sample: if they choose not to give a blood sample, but consent to give a saliva sample instead, a saliva kit will be sent to there home. Once they provide the sample in the kit, they will be asked to mail back the sample in the pre-labeled kit that was sent to them.
1843780|NCT00903604|Drug|AP214|Three 10-minutes infusions of sequential ascending dosages of AP214
1843781|NCT00903604|Drug|Placebo|Three 10-minutes infusions of isotonic saline solution
1843782|NCT00903617|Drug|GSK256073|5 mg for 8 weeks
1843783|NCT00903617|Drug|GSK256073|50 mg for 8 weeks
1843784|NCT00903617|Drug|GSK256073|150 mg for 8 weeks
1843785|NCT00903617|Drug|Placebo|placebo for 8 weeks
1843786|NCT00903617|Drug|Niaspan|1500 mg for 8 weeks
1843787|NCT00903617|Drug|GSK256073|x mg for 8 weeks based from data from Part A
1843788|NCT00903617|Drug|GSK256073|optional dose based on data from Part A
1843789|NCT00903630|Drug|Lenalidomide|administered by mouth at the assigned dose daily for each 28 day cycle
1843790|NCT00903630|Drug|liposomal doxorubicin|administered at a fixed dose of 40 mg/m^2 intravenously (IV) on day 1 of each 28 day cycle
1843791|NCT00903643|Other|Physical examination|Physical examination and multiple questionnaires will be administered
1843792|NCT00903656|Drug|doxorubicinhydrochloride, Lapatinib|Lapatinib 1250mg/d p.o. Caelyx 40 mg/m² i.v. q4w for a maximum of 6 cycles
1843793|NCT00903682|Drug|etravirine (ETR, TMC125)|400mg once daily (4x100mg tablet) + 2 NRTI + 1 EFV placebo tablet for 48 weeks
1843794|NCT00903682|Drug|efavirenz (EFV)|600mg once daily (1x600mg tablet) + 2 NRTIs + 4 ETR placebo tablets for 48 weeks
1843795|NCT00903695|Drug|Memory XL|An over-the-counter vitamin nutriceutical patented by Univ. of Mass. that contains folic acid 400 mg, Vit. B12 6 ug, alpha-tocopherol 30 IU, S-adenosyl methionine (SAM) 400 mg, N-acetyl cysteine (NAC) 600 mg, & acetyl-L-carnitine (ALCAR) 500 mg; 2 pills per day for 12 months
1843796|NCT00903695|Drug|placebo|placebo comparator
1843797|NCT00903708|Drug|LY2275796|100 mg administered by vein as a loading dose daily over 3 days, and then as a maintenance dose weekly thereafter.
1843798|NCT00903721|Drug|mometasone furoate|"Metered-dose spray type suspension containing 50 μg mometasone furoate per spray. 2 sprays per nostril twice daily (total daily dose 200 μg)
Duration: up to 6 months"
1843799|NCT00903734|Drug|Erlotinib Hydrochloride (Tarceva)|Dose of 150 mg daily by mouth.
1843800|NCT00903747|Drug|prucalopride|2-10 mg prucalopride
1843801|NCT00903747|Drug|moxifloxacin|400 mg moxifloxacin (Group 2a)
1843802|NCT00903747|Drug|placebo|placebo (Group 2b)
1843805|NCT00903773|Drug|telaprevir|
1843807|NCT00903799|Device|Implantation of ENTERRA therapy|Gastric electrical stimulation using Enterra Therapy
1843808|NCT00903812|Other|No intervention|No intervention as observational study
1843809|NCT00903825|Procedure|Ultrasound guided injection of femoral local anesthetic (lidocaine)|Injection of lidocaine (< 10 mls of lidocaine, 1%w/v) before femoral artery puncture with free-hand duplex ultrasound guidance.
1843810|NCT00903825|Procedure|Injection of femoral local anesthetic (lidocaine) with manual palpation|Injection of lidocaine before femoral artery catheterization with manual palpation.
1843811|NCT00903838|Drug|pardoprunox|1.5 to 12 mg/day
1843812|NCT00903838|Drug|pramipexole|0.75-4.5 mg/day
1843813|NCT00903851|Drug|Lidoderm|Patients participated in an 8-week treatment period; patients at one site were to continue treatment for the entire 8 weeks while patients at two sites were to terminate treatment after 3 weeks. Commercially available Lidoderm® (lidocaine patch 5%) was provided to each patient with up to four patches applied topically 18 hours on, 6 hours off per day to the area of maximal peripheral neuropathic pain.
1843814|NCT00903877|Drug|T3|Patients receive T3 in a dose of 25mcg and 50mcg
1843815|NCT00903890|Other|Survey|Survey asking questions regarding the subjects cardiac and general health.
1843816|NCT00903929|Drug|Eltrombopag|dose escalation
1843817|NCT00903942|Radiation|radiation therapy|1) PTV = CTV (GTV + 1.5-cm margins and the most adjacent nodal regions) + 0.5 cm margins to 5,040 cGy in 180 cGy daily fractions; and (2) Cone Down PTV = GTV +1.5 cm margins to 6,480 cGy.
1843860|NCT00904241|Other|cytology specimen collection procedure|Correlative studies
1844112|NCT00907933|Drug|SB-705498|0.5mg intranasal SB-705498
1843818|NCT00903942|Drug|Paclitaxel Protein-Bound, and CARBOPLATIN|Induction Chemotherapy Abraxane(260 mg/m2) / Carboplatin (AUC of 6) x one cycle Concurrent Chemotherapy(with radiation)--for first 3 pts--20 mg/m2 Abraxane, 3 times per week then for next group of 3 pts--30 mg/m2 Abraxane twice a week
1843819|NCT00903955|Other|7% hypertonic saline|Administered via jet nebulizer to subjects in specific aim 3
1843820|NCT00903968|Drug|Plerixafor|
1843821|NCT00903968|Drug|bortezomib|
1843822|NCT00903968|Drug|Dexamethasone|
1843823|NCT00903981|Drug|Avanafil|2 tablets(Avanafil 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
1843824|NCT00903981|Drug|Avanafil|2 Tablets(Avanafil 200mg tablet + Placebo 100mg tablet), 30 minutes before sexual intercourse
1843825|NCT00903981|Drug|Placebo|2 Tablets(Placebo 100mg tablet + Placebo 200mg tablet), 30 minutes before sexual intercourse
1843826|NCT00903994|Drug|Ketoprofen Topical Patch 20%|Ketoprofen is a pressure-sensitive adhesive material containing 20% Ketoprofen which is applied to a polyester textile and covered with a foil release liner.for the treatment of mild to moderate acute pain associated with Tendonitis or Bursitis of the shoulder, elbow or knee
1843827|NCT00904007|Other|Interactive Spaced Education (ISE) --- online education|"ISE is a novel educational methodology based on the spacing effect, the psychological finding that repeated presentations of educational material over spaced intervals increase learning efficiency and improve knowledge retention. ISE is delivered using periodic emails that contain clinical case scenarios and multiple-choice questions."
1843828|NCT00904020|Drug|Lidoderm|Patients participated in a 2-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain.
1843829|NCT00904033|Drug|calcitriol|Will receive pill once a week
1843830|NCT00904033|Behavioral|Exercise|Progressive walking and resistance band training
1843831|NCT00904033|Dietary Supplement|Multivitamin|One daily multivitamin
1843832|NCT00904046|Drug|Pioglitazone|30 mg orally daily for 6 months
1843833|NCT00904046|Drug|Placebo|Placebo taken orally once a day for 6 months.
1843834|NCT00904059|Drug|BMS-650032|Capsules, Oral, 600 mg, Q12h, Days 1-7
1843835|NCT00904059|Drug|BMS-790052|Capsules, Oral, 60 mg, Q24h, Days 1-7
1843836|NCT00904059|Drug|BMS-650032|Capsules, Oral, 200 mg, Q12h, Days 8-21
1843837|NCT00904059|Drug|BMS-790052|Capsules, Oral, 30 mg, Q24h, Days 8-21
1843838|NCT00904085|Drug|Oxymorphone IR|5 mg
1843839|NCT00904098|Drug|Frovatriptan|"This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:
A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)
An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period."
1843840|NCT00904098|Drug|Usual Care|Current treatment used to treat all migraine headaches
1843841|NCT00904111|Drug|Lidoderm®|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
1843842|NCT00904111|Drug|Placebo Topical Patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
1843843|NCT00904124|Dietary Supplement|cellulose, alginate, guar gum|6 different food products are developed with different dosages of dietary fiber. Regular flour is replaced by dietary fiber, dosages are described in the 'arms'section.
1843844|NCT00904137|Procedure|Cast|
1843845|NCT00904137|Procedure|Splint|
1843846|NCT00904137|Procedure|Tape|
1843847|NCT00904176|Drug|Dapagliflozin|Tablets, Oral, 20 mg, followed by 10 mg, Single Dose
1843848|NCT00904176|Drug|Warfarin|Tablets, Oral, 25 mg, Single Dose
1843849|NCT00904176|Drug|Digoxin|Tablets, Oral, 0.25, Single Dose
1843850|NCT00904189|Radiation|Standard of care given for treatment of cancer|Subjects receiving a known dose of radiation during Total Body Irradiation.
1843851|NCT00904202|Drug|Placebo Capsules + Placebo Patch|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
1843852|NCT00904202|Drug|Placebo capsules + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
1843853|NCT00904202|Drug|Gabapentin + Placebo|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
1843854|NCT00904202|Drug|Gabapentin + Lidoderm®|Patients participated in a 5-week treatment period. Eligible patients were randomized into one of four treatment groups: placebo capsules + placebo patch (Placebo Group), placebo capsules + Lidoderm patch (Lidocaine Group), Gabapentin capsules 1800 mg/day + placebo patch (Gabapentin Group), or Gabapentin capsules 1800 mg/day + Lidoderm patch (Combination Group).
1843855|NCT00904202|Drug|Gabapentin 300 mg capsules 1800 mg/day + placebo patch|Gabapentin 300 mg capsules 1800 mg/day + placebo patch
1843856|NCT00904202|Drug|Gabapentin 1800 mg/day + Lidoderm patch|
1843857|NCT00904215|Drug|telmisartan/telmisartan + HCTZ (Hydrochlorothiazide)|
1843858|NCT00904228|Other|Plastic Lined Stockinette hat|hat made of unbleached 100% cotton stockinette that is lined with plastic (standard food sandwich bag)
1843859|NCT00904241|Other|laboratory biomarker analysis|Correlative studies
1843861|NCT00904254|Radiation|EP 1645/Solution For Injection, 99mTC|(Fab-fragment of Anti-human CD4,technetium-99m)
1843862|NCT00904280|Drug|Oxymorphone ER|Open label
1843863|NCT00904293|Other|Genotype-guided dose determination|Patients in both arms will be treated with warfarin. Those in the experimental group will have initial doses determined using an algorithm (from www.warfarindosing.org) incorporating genetic and clinical factors. Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
1843864|NCT00904293|Other|Non-genotype guided warfarin dosing|Those in the control group will have doses determined using the same algorithm, but without including the genetic factors.
1843865|NCT00904306|Dietary Supplement|Sugar Pill|placebo oral tablet taken once per day
1843866|NCT00904306|Dietary Supplement|chromium picolinate|1000 ug/day chromium picolinate for 6 months
1843867|NCT00904306|Dietary Supplement|chromium picolinate|600 ug/day chromium picolinate
1843868|NCT00904319|Other|Aquatic Power Training|Aquatic power training program with an exercise specialist 2/week for 6 weeks.
1843869|NCT00904345|Drug|Cetuximab|Patients will receive a single dose of cetuximab 400 mg/m (Day 0). On day 7 (+/- 1 day), a repeat biopsy will be performed. Radiation concurrent with weekly cetuximab 250 mg/m.
1843870|NCT00904345|Radiation|50-60 Gy and 70 Gy|Within approximately 4 days (after single dose of Cetuximab), definitive radiation will begin (70 Gy in 35 fractions to the gross tumor, 50-60 Gy to subclinical target volumes) concurrent with weekly cetuximab 250 mg/m.
1843871|NCT00904358|Diagnostic Test|cross sectional area|
1843872|NCT00904397|Drug|Lidoderm®|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
1843873|NCT00904397|Drug|Celecoxib|Patients participated in a 14-day washout period followed by a 12-week active treatment period. Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or celecoxib 200 mg.
1843874|NCT00904410|Other|FDG-PET|370 MBq of FDG one hour before imaging acquisition PET just before neo-adjuvant chemotherapy and just before the second cycle
1843875|NCT00904423|Drug|Vitamin D|up to 2400 mg; oral tablet
1843876|NCT00904436|Drug|ipratropium (Atrovent)|Bronchodilator Treatment: Subjects will inhale 1 unit dose vial of aerosolized ipratropium (500 mcg of ipratropium (Atrovent) mixed in 2.5 ml of saline).
1843877|NCT00904449|Drug|Oxymorphone ER|10mg, 20mg, and 40mg PO
1843878|NCT00904462|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
1843879|NCT00904462|Drug|Placebo patch|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine 5% patch or matching placebo patch.
1843880|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
1843881|NCT00904475|Drug|Lidoderm®|Eligible patients were randomized equally to one of two groups: lidocaine patch 5% or matching placebo patch. During the 6-week treatment period, patients used up to three patches daily applied q24h.
1843882|NCT00904488|Drug|Intravenous Bolus Furosemide and Oral Metolazone|Addition of oral metolazone 5 mg daily to continued intravenous bolus furosemide
1843883|NCT00904488|Drug|Intravenous Continuous Infusion Furosemide|Transition from intravenous bolus to continuous infusion furosemide
1843884|NCT00904501|Procedure|Bone marrow harvest|Implantation of placebo
1843885|NCT00904501|Procedure|Bone marrow harvest|Implantation of bone marrow - mononuclear cells
1843886|NCT00904514|Genetic|gene expression analysis|
1843887|NCT00904514|Genetic|microarray analysis|
1843888|NCT00904514|Genetic|mutation analysis|
1843889|NCT00904514|Genetic|polymerase chain reaction|
1843890|NCT00904514|Other|flow cytometry|
1843891|NCT00904514|Other|immunoenzyme technique|
1843892|NCT00904514|Other|laboratory biomarker analysis|
1843893|NCT00904527|Behavioral|relaxation (Schultz)|Patients have relaxation consultations during 2 months
1843894|NCT00904540|Drug|Lidoderm®|Patients participated in a 6-week treatment period. Commercially available Lidoderm (lidocaine patch 5%) was provided to patients with up to four patches applied topically once daily (q24h) to the area of maximal peripheral pain. Patients were stratified into the following groups at enrollment: acute (<6 weeks) LBP, subacute (6 weeks to <3 months) LBP, short-term chronic (3 months to 12 months, inclusive) LBP, and long-term chronic (>12 months LBP)
1843895|NCT00904553|Radiation|Novalis Shaped Beam Surgery|Treatment using Novalis SRS
1843896|NCT00904592|Drug|Qi ming granula|Qi ming granula Usage:4.5g，po，tid. duration:12 months/ arise Endpoint Event
1843897|NCT00904592|Drug|Placebo Comparator|"Control group: Basic therapy ＆ placebo
Therapy for DM: To control blood glucose, blood pressure, and serum lipid through drug, dietary management , exercise and education.
placebo,Usage: 4.5g，po，tid"
1843898|NCT00904605|Drug|Lidoderm|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h
1843899|NCT00904605|Drug|Celecoxib|Eligible patients were randomly allocated to receive one of two treatments for 12 weeks: lidocaine patch 5% or celecoxib 200 mg daily. Lidocaine patch 5% (Lidoderm®, Endo Pharmaceuticals Inc.), 1⅓ patches applied topically to each affected knee every 24 hours (q24h)
1843900|NCT00904618|Procedure|TVT-SECUR - 'Hammock' technique|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
1843901|NCT00904618|Procedure|TVT-SECUR - 'U-Method'|The surgery was done under local anesthesia by one high-volume surgeon. The 'Hammock' technique, similar to the transobturator tape dissection, was used in the first 23 cases and the 'U-Method', similar to the retropubic tape dissection, in the last 25 cases. Interim analysis performed after 23 cases led us to change the technique to the 'U-Method'.
1843941|NCT00904917|Behavioral|Psychoeducation|Two 1-hour sessions focusing on psychoeducation about depression and its impact on children and the family.
1843902|NCT00904618|Drug|Local anesthesia (30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%).|Local anesthesia consisted of 30 to 40 ml of a mixture of 35 ml of lidocaine 2% and 5 ml of bicarbonate 3%. Sedation was used in association with local anesthesia, including 1 mg of lorazepam sublingual as well as a combination of 0.5 to 2 mg intravenous (IV) of midazolam and 50 to 200 ug IV of fentanyl. Postoperative analgesia consisted of a prescription of 30 tablets of morphine 5 mg.
1843903|NCT00904631|Device|Eraser device+ salicylic acid (5%)|Subjects will be treated with the Eraser device, using salicylic acid (5%) as washing fluid. The skin will be examined by a physician and the tattoo area will be photographed. The Eraser device will be used to remove the tattoo from the entire tattoo area (up to 30 minutes in a single session). An absorbent bandage will be put on the treated area for one-hour post treatment. After Care Treatment, based on a Dermatologist's consultation, will be performed on a case-by-case basis (for example, use of antibiotic ointments in case of infection).
1843904|NCT00904644|Drug|Raltegravir|Raltegravir standard dosage of 400mg tablets every 12 hours together with an optimized backbone antiretroviral drug regimen
1843905|NCT00904657|Drug|sunitinib (Sutent)|50 mg capsule Sutent, one application a day for five days
1843906|NCT00904670|Drug|Quillivant Oral Suspension XR|Oral Suspension 25mg/5mL; 20-60 mg/day
1843907|NCT00904670|Drug|Placebo|Matching Placebo Oral Suspension 25mg/5mL; 20-60 mg/day
1843908|NCT00904670|Drug|Placebo|Matching placebo was a solution that was identical in taste and appearance to the Active drug that was used in this study.
1843909|NCT00904683|Drug|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
1843910|NCT00904683|Drug|Placebo|intravenously (IV) every 4 weeks for 80 weeks
1843911|NCT00904709|Drug|tranexamic acid|After The starting dose of tranexamic acid will be 500 mg twice daily beginning the first day of menstrual flow for a total of 6 days per menstrual cycle. If after 2 days there is still menorrhagia without significant side effects the will be increased. The women will be assessed again at day 4 and 9 and dose escalation will continue until they have reached the optimal dose.The dose of tranexamic acid will be increased as follows: 1000 mg twice daily, 1000 mg three times daily, 1500 mg/1000 mg/1000 mg, 1000 mg four times daily, 1500 mg three times daily, and 1500 mg four times daily (maximum dose).Each patient will be followed for a minimum of one menstrual cycle and a maximum of 3 cycles.
1843912|NCT00904722|Drug|CT-011|Administered intravenously at a dose of 3.0 mg/kg on days 1, 29 (+/- 7 days), 57 (+/- 7 days), and 85 (+/- 7 days).
1843913|NCT00904722|Drug|Rituximab|Administered intravenously at the standard dose of 375 mg/m^2 weekly for 4 weeks on days 17 (+/- 1 day), 24 (+/- 1 day), 31 (+/- 1 day), and 38 (+/- 1 day).
1843914|NCT00904735|Drug|hydroxyurea|Given orally
1843915|NCT00904735|Drug|imatinib mesylate|Given orally
1843916|NCT00904748|Drug|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose without water
1843917|NCT00904748|Drug|sildenafil citrate 100 mg CT|sildenafil citrate 100 mg CT, single dose with water
1843918|NCT00904748|Drug|Viagra®|sildenafil citrate 100 mg film-coated tablet (Viagra®), single dose
1843919|NCT00904761|Other|exercise training|The exercise group took supervised aerobic training twice per week at hospital and thrice per week at home for eight weeks at the intensity of 60-70% VO2peak
1843920|NCT00904787|Drug|ENMD-2076|capsule, dose escalation, taken orally, daily in 28 day cycles
1843921|NCT00904800|Drug|AZD0837|tablet, oral, once daily, 1+5 days
1843922|NCT00904800|Drug|Placebo|Placebo
1843923|NCT00904813|Radiation|Preoperative radiotherapy|5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
1843924|NCT00904813|Radiation|Preoperative radiotherapy|5 times 5 Gray during five consecutive days, preferably Monday - Friday, with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
1843925|NCT00904813|Radiation|Preoperative radiotherapy|2 Gy in 25 fractions during 5 weeks, total dose 50 Gy with a four-field box technique, including the primary tumour and the primary and secondary lymph nodes in the pelvis.
1843926|NCT00904826|Drug|Eculizumab|"The patient will receive eculizumab at a dose of 600mg intravenously (an infusion given into the vein) each week for 4 weeks, then 900mg intravenously at the fifth week, then 900mg every 2 weeks for 48 weeks.
The first infusion will be given at Mayo Clinic site; subsequent infusions will be administered in the subject's home by a company which will send a nurse to administer the infusion. Subjects will receive therapy for a total of 12 months."
1843927|NCT00904839|Drug|BIBF 1120|BIBF 1120 100 and 150 mg capsules
1843928|NCT00904839|Drug|BIBF 1120|BIBF 1120 100 and 150 mg capsules
1843929|NCT00904839|Drug|mFolfox|standard i.v chemotherapy
1843930|NCT00904839|Drug|Bevacizumab|100 mg/Kg solution , IV infusion
1843931|NCT00904839|Drug|mFolfox 6|IV standard chemotherapy
1843932|NCT00904839|Drug|bevacizumab|100 mg/4 ml solution
1843933|NCT00904852|Drug|Tandutinib, bevacizumab, and temozolomide|All patients will have completed treatment with concurrent radiation therapy and temozolomide. Patients will be entered into different dosing groups of tandutinib. Patients will receive up to 6 cycles of treatment with oral temozolomide at 150 mg/m2 daily for the first 5 days of a 28 day cycle, oral tandutinib at escalating doses 250, 375, 500, or 625 mg twice daily on days 1 to 28, and intravenous bevacizumab at 10 mg/kg on days 1 and 15 of each cycle
1843934|NCT00904865|Procedure|SPA cholecystectomy|SPA cholecystectomy
1843935|NCT00904865|Procedure|Laparoscopic cholecystectomy|Laparoscopic cholecystectomy
1843936|NCT00904891|Behavioral|Cognitive-behavioral group|Six sessions of cognitive-behavioral depression prevention group intervention
1843937|NCT00904891|Behavioral|Cognitive-behavioral bibliotherapy|"Cognitive-behavioral bibliotherapy, delivered from the book Feeling Good"
1843938|NCT00904904|Drug|Indomethacin ophthalmic solution|Indomethacin 0.1% eye drops administered pre-cataract surgery and for 4 weeks post-cataract surgery
1843939|NCT00904904|Drug|Ketorolac Ophthalmic Solution|Ketorolac 0.5% eye drops administered pre-cataract surgery and 4 weeks post-cataract surgery
1843940|NCT00904917|Behavioral|Prevention Intervention Project|Eight 1-hour sessions focused on psychoeducation, coping with stress, and cognitive-behavioral strategies. The sessions were tailored as required to meet the clinical and cultural needs of each family; other family members, such as fathers, spouses, and grandparents, were invited to participate in the intervention.
1843942|NCT00904930|Device|Wire Composite Splint (Dentaflex 0.45 mm)|Wire-Composite-Splint: Dentaflex 0.45 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow (IvoclarVivadent, Schaadn, Liechtenstein) to the teeth
1843943|NCT00904930|Device|Wire Composite Splint (Denture Strengtheners)|Wire-Composite-Splint: Denture Strengtheners 0.8x1.8 mm (Dentaurum, Pforzheim, Germany) attached with Tetric flow to the teeth
1843944|NCT00904943|Drug|Topiramate Capsules, 25 mg|2 x 25 mg Capsules
1843945|NCT00904943|Drug|Topamax® Capsules, 25 mg|2 x 25 mg Capsules
1959386|NCT00270855|Procedure|Arm Crank Ergometry|Use of an upper body cycle to perform exercise.
1843948|NCT00904982|Behavioral|Financial Incentive and Med-eMonitor|"Financial Incentives: Study participants are entered into a daily lottery. It includes a chance to win either $10 or $100 on any given day throughout the participant's duration in the study (6 months). Participants are assigned a number and each day a computer randomly draws a winning number. Participants whose number is drawn can only collect money if they have taken the medication correctly.
Med-eMonitor: The Med-eMonitor is a device used to measure medication compliance. The device has 5 drawers in which the participants' medication is placed. When a drawer opens, a message displays on the monitor, and asks the participant if he/she is taking his/her medication for the day. The device registers their answers and sends the compliance information via the participants' telephone line nightly to a central study server."
1843949|NCT00904982|Device|2Med-eMonitor|Med-eMonitor is a device that subjects will be given that will monitor an individual's warfarin adherence.
1843950|NCT00904995|Drug|Voriconazole|Starting dose of 400 mg by mouth twice a day for first day, followed by 200 mg by mouth twice a day thereafter.
1843951|NCT00904995|Drug|Voriconazole|6 mg/kg by vein for first dose, followed by 200 mg by mouth twice a day thereafter.
1843952|NCT00905008|Procedure|transluminal percutaneous coronary intervention|All interventions were done according to current practice guidelines. The operator was responsible for the decision to choose a specific treatment strategy. Angiographic success was defined as residual stenosis <30% by visual analysis in the presence of TIMI 3 flow grade. The patients were prescribed aspirin plus clopidogrel 75 mg per day, after a loading dose of 300 mg or 600 mg, before or during the index coronary intervention. After procedure, all patients were advised to maintain lifelong use of aspirin. The use of clopidogrel (75 mg per day) was always adapted according to guideline recommendations. Heparin was infused throughout the procedure to maintain an activated clotting time of at least 250 sec. The administration of platelet glycoprotein IIb/IIIa receptor blocker was encouraged, unless in existing contraindications.
1843953|NCT00905008|Device|Drug-Eluting and Bare-Metal stents|Sirolimus-eluting stents (Cypher®), Paclitaxel-eluting stents (Taxus®) Zotarolimus-eluting stents (Endeavor®) and uncoated (bare-metal) stents
1843954|NCT00905021|Drug|Exemestane|Exemestane 25 mg by mouth every day.
1843955|NCT00905021|Drug|Sutent|Sunitinib 37.5 mg by mouth every day.
1843956|NCT00905034|Drug|Methotrexate|200 mg/m^2 by vein on days 1 and 15.
1843957|NCT00905034|Drug|Vincristine|1.4 mg/m^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
1843958|NCT00905034|Drug|PEG-l-asparaginase|2500 International units/m^2 by vein on days 2 and 16
1843959|NCT00905034|Drug|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and 15-18.
1843960|NCT00905034|Drug|Rituximab|Rituximab 375 mg/m^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
1843961|NCT00905047|Drug|XELODA|"XELODA, 2500 mg/m²/bid, with approximatively an interval of 12 hours, 30 minutes after breakfast and dinner - during 14 days.
Cycle treatment duration : 21 days"
1843962|NCT00905047|Drug|TEGAFUR URACIL - FOLINIC ACID|"Tegafur 300 mg/m2/tid with folinic acid 75 mg/tid during 28 days.
Duration of treatment cycle : 35 days."
1843963|NCT00905060|Biological|HSPPC-96|"Patients will receive 4 weekly injections of HSPPC-96 followed by a 5th vaccine injection on the same day of the start of maintenance temozolomide administered 2 weeks (+ 4 days) following vaccine administration #4 on the same day of the start of maintenance temozolomide (Day 36). Monthly vaccine injections will then begin on day 21 (+/- 7 days) of the first 28 day temozolomide cycle (Day 56 of the study)3 weeks following vaccine administration #5 and will continue every 28 days until depletion of vaccine or progression.
Immune monitoring will be completed pre-operatively, intra-operatively, 48-hours post-surgery, prior to vaccine administration #1, at prior to vaccine administration #5 and at weeks 09, 13, 37 and 53.
The total volume of each vaccine or place provided is 0.47 mL. The total volume that should be administered is 0.4 mL (0.07 mL overage)."
1843964|NCT00905073|Drug|cyclosporin and methotrexate|cyclosporin 7.5 mg/kg/day for 6 weeks and then 4 mg/kg/day for one year and methotrexate 5 mg/kg/day for one year. After 6 weeks, cyclosporin doses will adjusted to maintain blood cyclo levels to 100-200 ng/ml.
1843965|NCT00905086|Other|questionnaire administration|Two weeks before completing planned radiotherapy, patients undergo assessment of stress appraisal and other factors predictive of post-radiotherapy psychosocial adjustment. At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
1843966|NCT00905086|Procedure|cognitive assessment|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
1843967|NCT00905086|Procedure|psychosocial assessment and care|Patients complete psychosocial assessments, including measures of patient perceptions of their illness (i.e., cognitive appraisal) and of the factors influencing their perceptions (i.e., uncertainty by the Mishel Uncertainty in Illness Scale-Community Form; symptom distress by the Memorial Symptom Assessment Scale Short Form; and comorbidity by the Charlson Comorbidity Index).
1959387|NCT00270855|Procedure|FES Cycle Ergometer|Use of an FES cycle ergometer to perform exercise
1843968|NCT00905086|Procedure|quality-of-life assessment|At 1 month after completion of radiotherapy, patients undergo repeat assessment of stress appraisal and psychosocial adjustment.
1843969|NCT00905112|Other|Manual Therapy|Receives manual therapy, stabilization exercise and patient education
1843970|NCT00905112|Other|Standard OB Care|Receive standard obstetrical care
1843971|NCT00905125|Biological|Fluzone®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluzone® does not contain thimerosal.
1843972|NCT00905125|Biological|Fluarix®|Single 0.5 mL injection of the 2008-2009 seasonal inactivated trivalent influenza vaccine administered intramuscularly in the deltoid. Fluarix® contains less than 1 microgram (trace or a very small amount) thimerosal per shot.
1843973|NCT00905138|Drug|GLPG0259|single ascending doses, oral solution
1843974|NCT00905138|Drug|placebo|single dose, oral solution
1843975|NCT00905138|Drug|GLPG0259|multiple dose, oral solution, 5 days
1843976|NCT00905138|Drug|placebo|oral solution, 5 days
1843977|NCT00905164|Drug|Topiramate Capsules, 25 mg|Topiramate Capsules, 2 x 25 mg
1843978|NCT00905164|Drug|Topamax® Capsules, 25 mg|Topamax® Capsules, 2 x 25 mg
1843979|NCT00899327|Genetic|DNA methylation analysis|
1843980|NCT00899327|Genetic|RNA analysis|
1843981|NCT00899327|Genetic|cytogenetic analysis|
1843982|NCT00899327|Genetic|gene expression analysis|
1843983|NCT00899327|Genetic|mutation analysis|
1843984|NCT00899327|Genetic|polymerase chain reaction|
1843985|NCT00899327|Genetic|protein expression analysis|
1843986|NCT00899327|Other|laboratory biomarker analysis|
1843987|NCT00899340|Genetic|gene expression analysis|profiles of HPV(+) and (-) HNSCCs
1843988|NCT00899340|Genetic|microarray analysis|microarray analysis
1843989|NCT00899340|Genetic|protein expression analysis|protein expression analysis
1843990|NCT00899340|Other|immunohistochemistry staining method|immunohistochemistry staining method
1843991|NCT00899340|Other|laboratory biomarker analysis|laboratory biomarker analysis
1843992|NCT00905190|Drug|Ondansetron|24 mg one time
1843993|NCT00905203|Other|exercise|exercise training
1843994|NCT00905216|Drug|heparin sodium - Bergamo|5.000 UI/mL
1843995|NCT00905216|Drug|heparin sodium - APP|5.000 USP
1843996|NCT00905229|Drug|Phytonadione|2.5 mg po
1843997|NCT00905229|Drug|Phytonadione|0.5 mg IV
1843998|NCT00905242|Drug|GI medication|Patients on daily dosing were asked to discontinue their GI medication at baseline. Patients on twice daily dosing were asked to reduce GI medication to once a day at baseline and asked to discontinue GI medication at day 30.
1843999|NCT00905255|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1844000|NCT00905255|Device|Pen auto-injector|
1844001|NCT00905268|Drug|idebenone|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
1844002|NCT00905268|Drug|Placebo|12 months of 1 of 3 treatments arms of oral idebenone or placebo.Treatment taken 3 times daily with meals.
1844003|NCT00905281|Other|Action Group|"On inclusion, a visit will be organized between the patient and at least 2 members of the DISSPO staff. It will allow an evaluation of supportive care needs and the proposition of a personalized care plan.
Then, a consultation between the referring oncologist and the DISSPO will be organized once a month, so that the personalized care plan could be adapted if necessary."
1844004|NCT00905281|Other|Standard care|No specific intervention
1844005|NCT00905294|Other|Blood draws|Observational: blood draws only
1844006|NCT00905307|Drug|OPC-34712|oral, once daily
1844007|NCT00905307|Drug|Placebo|Placebo
1844008|NCT00905307|Drug|Aripiprazole|oral, once daily
1844009|NCT00905320|Procedure|Metallic Fasteners and Sutures|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners and sutures.
1844010|NCT00905320|Procedure|Metallic Fasteners Alone|Subjects will undergo hernia repair with mesh fixation. Fixation involves using metallic fasteners alone.
1844011|NCT00905333|Drug|Candesartan (test)|16 mg oral tablet, single dose
1844012|NCT00905333|Drug|Felodipine (test)|5 mg oral extended release tablet, single dose
1844013|NCT00905333|Drug|Candesartan Cilexetil|16 mg oral tablet, single dose
1844014|NCT00905333|Drug|Felodipine|5 mg oral extended release tablet, single dose
1844015|NCT00905346|Drug|Topiramate 25 mg Capsules|Topiramate Capsules 2 x 25 mg
1844016|NCT00905346|Drug|Topamax® 25 mg Capsules|Topamax® Capsule 2 x 25 mg
1844017|NCT00905346|Other|Applesauce|Applesauce
1844018|NCT00905359|Procedure|Aperius™ PercLID™ System|Aperius™ PercLID™ System: implantation with the Interspinous Process Device Aperius.
1844019|NCT00905359|Procedure|Standalone Decompressive Surgery|Lumbar decompressive surgery without instrumentation or fusion
1844020|NCT00905372|Drug|LY2062430|400 mg intravenously (IV) every 4 weeks for 80 weeks
1844021|NCT00905372|Drug|Placebo|intravenously (IV) every 4 weeks for 80 weeks
1844022|NCT00905385|Biological|NTHi Strain 2019|Nontypeable Haemophilus influenzae (NTHi) strain 2019 StrR Number 1 is an antibiotic susceptible clinical strain that has a point mutation in the rRNA that renders the isolate resistant to streptomycin. This agent will be introduced by nasal droplets.
1844023|NCT00905398|Drug|Nilotinib|400mg, Oral, Bid, Daily for three years
1844024|NCT00905411|Behavioral|PacDASH intervention|"Effect of the PacDASH intervention on nutrition and physical activity behavior of children.
15 months study."
1844025|NCT00905424|Drug|Antidepressant + SPD489 (lisdexamfetamine dimesylate)|Escitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
1844026|NCT00905424|Drug|Antidepressant + placebo|Escitalopram oxalate (antidepressant) 20 mg/day oral + placebo oral once daily for 6 weeks
1844027|NCT00905437|Drug|Placebo|Placebo as an adjunct to standard of care
1844028|NCT00905437|Drug|Pregabalin|75 mg BD for 14 days
1844029|NCT00905450|Drug|BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug concentrations and dose schedules.
1844030|NCT00905450|Drug|Vehicle for BOL-303242-X|Medication instilled into the study eye, subjects randomized to various drug dose schedules.
1844031|NCT00905463|Procedure|Lung transplantation|Lung transplantation
1844032|NCT00905489|Drug|Nevirapine Immediate Release (IR)|200 mg Tablet or 50 mg / 5 ml oral suspension
1844033|NCT00905489|Drug|Nevirapine Extended Release (XR)|200 mg, 300 mg or 400 mg Tablet formulation
1844034|NCT00905502|Drug|Lactated Ringer's solution|Patients in the RG received 4 ml/kg•hr of Lactated Ringer's solution (RL) throughout the intra-operative period
1844035|NCT00905502|Drug|Lactated Ringer's solution|patients in the LG received 10 ml/kg•hr of RL solution intraoperatively
1844036|NCT00907309|Behavioral|iMET|Participants will receive the iMET intervention
1844037|NCT00907309|Behavioral|iMET/TE|Participants will receive the iMET intervention and also receive TEs (Technological Extenders)
1844038|NCT00907322|Drug|Dimebon|Oral tablet; 20 mg Dimebon, single dose
1844039|NCT00907322|Drug|Dimebon|Oral tablet; 40 mg Dimebon, single dose
1844040|NCT00907322|Drug|Dimebon|Oral tablet; 60 mg Dimebon, single dose
1844041|NCT00907322|Drug|Dimebon|Oral tablet; placebo, single dose
1844042|NCT00907335|Drug|Retin-A Micro 0.04% facial acne treatment|Retin-A Micro 0.04% facial acne treatment used once daily
1844043|NCT00907335|Drug|Vehicle control|Color-matched facial gel vehicle control used once daily
1844044|NCT00907348|Drug|LR-CHOP21|"FIRST DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 5 mg/day D1-D14
SECOND DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1;Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 10 mg/day D1-D14
THIRD DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 15 mg/day D1-D14
FOURTH DOSE LEVEL: Rituximab 375 mg/sqm D 0 or 1; Cyclophosphamide 750 mg/sqm iv D1; Doxorubicin 50 mg/sqm iv D1; Vincristine 1.4 mg/sqm iv D1; Prednisone 40 mg/sqm orally D1, D2, D3, D4, D5; Revlimid 20 mg/day D1-D14 Repeated every 21 days"
1844045|NCT00907361|Device|MRI with pacemaker or ICD|The aim of the present protocol is to prospectively determine the adverse event rate of non-thoracic MRI for patients with implanted cardiac devices by collecting pre- and post-MRI device interrogations in a multi-center registry.
1844046|NCT00907374|Drug|benazepril|benazepril 10 mg orally once daily
1844047|NCT00907374|Drug|benazepril|40-80 mg benazepril plus 25-100 mg losartan orally once or twice daily
1844048|NCT00907387|Drug|RT001|Dose A RT001
1844049|NCT00907387|Drug|RT001|Dose B RT001
1844050|NCT00907387|Other|Placebo|Dose C Placebo
1844051|NCT00907400|Drug|PN400|oral tablet
1844052|NCT00907400|Drug|Naproxen|oral tablet
1844053|NCT00907413|Procedure|ERCP and Photodynamic Therapy|Photodynamic Therapy is a new therapeutic approach that specifically targets neoplastic cells. This therapy has been used in other tumors as a local treatment and involves the intravenous administration of a photosensitizing agent followed by activation of the agent by illumination with non-thermal light of a specific wavelength, resulting in cell death from direct cytotoxicity and ischemic necrosis. Cytotoxicity is directly proportional to tissue oxygenation.
1844054|NCT00907413|Procedure|ERCP only|Endoscopic retrograde cholangiopancreatography and stenting.
1844055|NCT00907426|Drug|Bimatoprost 0.03% solution|Once daily, one drop of Bimatoprost 0.03% solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
1844056|NCT00907426|Drug|Vehicle solution|Once daily, one drop of vehicle solution using a single-use per eye applicator will be applied to the upper eyelid margin (where the eyelashes meet the skin).
1844057|NCT00907452|Drug|melphalan-prednisone-thalidomide|
1844058|NCT00907452|Drug|lenalidomide-dexamethasone|
1844059|NCT00907478|Biological|romiplostim|Romiplostim administered by subcutaneous injection
1844060|NCT00907491|Device|pulmonary sounds analyzer|Cough counting device based on the WIM Technology
1844061|NCT00907504|Drug|CP-751,871|CP-751,871 20mg/kg every 3 weeks
1844062|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
1844063|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
1844064|NCT00907504|Drug|Cisplatin|Cisplatin 80 mg/m2 every 3 weeks
1844065|NCT00907504|Drug|Gemcitabine|Gemcitabine 1,250 mg/m2 Day1+8 of evey 3 week-cycle
1844066|NCT00907517|Drug|MK-8776|IV infusion
1844067|NCT00907517|Drug|Cytarabine|IV infusion
1844068|NCT00907530|Drug|MULTIHANCE:|MULTIHANCE ® 0.5 M,0.1 mmol/kg
1844069|NCT00907530|Drug|GADOVIST|GADOVIST ® 1.0 M,0.1 mmol/kg
1844070|NCT00907543|Other|Preoperative treatment of chemotherapy and radiation|Cisplatin + 5FU with concurrent radiation followed by surgery
1844071|NCT00907543|Other|Postoperative treatment of chemotherapy and radiation|Surgery followed by cisplatin + 5FU + epirubicin as indicated by pathological stage with extended beam radiation
1844072|NCT00907569|Radiation|Hypofractionated Chest Radiotherapy|Hypofractionated chest radiotherapy regimen of 58 Gy delivered in 25 fractions in 5 weeks.
1844073|NCT00907582|Procedure|autologous hematopoietic cell transplantation|"Autologous hematopoietic cell transplantation and condition with the following:
idarubicin 15mg/m2•d day -11 and -10; busulfan 0.8mg/kg•q6h day -6 to -3."
1844074|NCT00907595|Drug|Ramelteon|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
1844075|NCT00907595|Drug|Placebo|After 2 weeks of baseline sleep study, subjects will be randomized to take either Ramelteon or Placebo for 4 weeks.
1844076|NCT00907608|Drug|Darbepoetin alfa|Starting dose of 20 microgram per week, to be titrated over a 3-month period until target hemoglobin level is reached (female: 11 g/dL and male: 12 g/dL). Route of administration is subcutaneous injection.
1844077|NCT00907621|Procedure|Acupuncture with Seirin 020x15 mm sterile acupuncture needle|Bilateral insertion of a Seirin 020x15mm sterile acupuncture needle to a depth of 12mm for 30 seconds during 3 consecutive working days at the WHO designated acupuncture point St36.
1844078|NCT00907660|Behavioral|Weight loss counseling|Monitoring of weight; review of food and physical activity records; counseling to reduce calorie intake by 500-1000 calories per day
1844079|NCT00907660|Dietary Supplement|Portion-Controlled Foods|"Consumption of shakes, meal bars, and prepared entrees for 2 out of 3 meals per day during the 14 weeks of the study. Full dose patients are provided with both meals by the study; half dose patients are provided with one out of two meals by the study."
1844080|NCT00907673|Device|Automatic Fluid Shunt System|Fully implantable peritoneal catheter, bladder catheter, and pump
1844081|NCT00907699|Genetic|DNA analysis|DNA is extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways.
1844082|NCT00907699|Genetic|RNA analysis|RNA is extracted from tumor samples. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
1844083|NCT00907699|Genetic|fluorescence in situ hybridization|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
1844084|NCT00907699|Genetic|gene expression analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
1844085|NCT00907699|Genetic|mutation analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
1844086|NCT00907699|Genetic|polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
1844087|NCT00907699|Genetic|reverse transcriptase-polymerase chain reaction|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
1844088|NCT00907699|Other|laboratory biomarker analysis|DNA and RNA are extracted from tumor samples. Genomic DNA is analyzed using real-time PCR/ reverse transcriptase PCR analysis and/or FISH analysis in order to study resistance mechanisms such as secondary EGFR mutations and the c-MET and PI3K pathways. RNA is analyzed using TaqMan quantitative PCR in order to determine the copy number of EGFR expressed in these tissues. Peripheral blood samples are used to isolate peripheral blood mononuclear cells positive for epithelial cell adhesion molecule (EpCAM).
1844089|NCT00907712|Other|cardiac echo examination|cardiac echo examination - before and after the surgery
1844090|NCT00907725|Other|serum BhCG follow-up|Subjects in this arm will receive medical abortion follow-up using BhCG blood draw
1844091|NCT00907725|Other|ultrasonographic follow-up|Subjects in this arm will receive medical abortion follow-up by ultrasound
1844092|NCT00907738|Drug|vorinostat|All patients will receive vorinostat at the same dose and schedule as they received in the base protocol until disease progression or unacceptable toxicity.
1844093|NCT00907751|Drug|rituximab|Patients will be treated according to the recommendations of the Reference Centre for the management of thrombotic microangiopathies. Infusions of rituximab (375 mg/m2) will be added to this treatment at day 1, 4 and 15, immediately after plasma exchange sessions.
1844094|NCT00907764|Drug|regadenoson|400 ug, IV
1844095|NCT00907777|Biological|Pneumococcal conjugate vaccine GSK 1024850A|One dose of vaccine will be injected intramuscularly into the deltoid.
1844096|NCT00907777|Biological|Pneumococcal conjugate vaccine Prevenar™ (Wyeth Lederle's)|One dose of vaccine will be injected intramuscularly into the deltoid.
1844097|NCT00907790|Behavioral|Usual Care (Control Group)|
1844098|NCT00907790|Behavioral|Comprehensive Self-Management (CSM)|Comprehensive Self-Management includes 8 sessions that cover education, diet, relaxation training, and cognitive behavioral strategies as they related to symptoms of IBS
1844099|NCT00907803|Drug|ST-246 400 mg|Capsules, 400 mg daily for 14 days
1844100|NCT00907803|Drug|ST-246 600 mg|Capsules, 600 mg daily for 14 days
1844101|NCT00907803|Drug|Placebo|Capsules, once daily for 14 days
1844102|NCT00907829|Drug|lidocaine|comparison of the effect of the drug to help improve finger function
1844103|NCT00907829|Device|muscle stimulator|comparison of the effect of stimulated muscle(s) on finger function
1844104|NCT00907842|Device|Parietex Parastomal Mesh|mesh placed intraperitoneally around the stoma
1844105|NCT00907868|Radiation|partial breast irradiation|Patients undergo radiation tumor bed boost
1844106|NCT00907868|Radiation|whole breast irradiation|Patients undergo whole breast irradiation
1844107|NCT00907881|Drug|Sulfonylurea|The dose and frequency of administration of study drug (sulfonylurea) was decided by the investigator according to the individual need of each participant.
1844108|NCT00907894|Drug|LDT600 (Telbivudine)|LDT600 (Telbivudine)
1844109|NCT00907907|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil Tablet 500 mg
1844110|NCT00907907|Drug|CellCept® Tablets|CellCept® Tablets, 500 mg
1844111|NCT00907920|Other|laboratory biomarker analysis|Correlative studies
1844113|NCT00907933|Drug|SB-705498|1.5mg intranasal SB-705498
1844114|NCT00907933|Drug|SB-705498|3mg intranasal SB-705498
1844115|NCT00907933|Drug|SB-705498|6mg intranasal SB-705498
1844116|NCT00907933|Drug|SB-705498|12mg intranasal SB-705498
1844117|NCT00907933|Drug|Placebo|Placebo '498
1844118|NCT00907933|Drug|SB-705498|6mg intranasal SB-705498 for 14 days bid
1844119|NCT00907933|Drug|SB-705498|12mg intranasal SB-705498 14 days bid
1844120|NCT00907933|Drug|Placebo|Placebo
1844121|NCT00907946|Procedure|NT at the surgery|A bladder urine culture will be obtained prior to surgery and appropriate antibiotic treatment will be initiated if necessary. The nephrostomy tract will be placed at the time of surgery under fluoroscopic guidance. All patients will receive empiric intravenous peri-operative antibiotics at induction. Renal pelvis urine and stone will be collected for culture and post-operative treatment will be initiated if necessary.
1844122|NCT00907946|Procedure|NT 1 day before PCNL|"A bladder urine culture will be obtained prior to nephrostomy tube placement and antibiotic treatment will be initiated if necessary. A nephrostomy tube will be placed at least one day prior to surgery in the Vascular Interventional Radiology (VIR) suite under fluoroscopic or ultrasound guidance. The type of imaging will be determined by the radiologist at the time of procedure and documented. A renal pelvis urine culture will be obtained at the time of nephrostomy tube placement. If the culture is positive, the patients will be treated with appropriate antibiotics for at least one week prior to PCNL. If the culture is negative, the patient will be stratified into 2 groups:
Hydronephrosis present and/or stone greater than 2cm empiric antibiotics will be initiated.
If neither of the above criteria (a.) are met, and the urine culture is negative, no antibiotics will be administered except peri-operatively according to standard protocol."
1844123|NCT00907959|Drug|BZL101|Oral BZL101 20 grams/day (10 grams BID).
1844124|NCT00907972|Dietary Supplement|Vitamin D3|Vitamin D3
1844125|NCT00907972|Other|Placebo|Placebo
1844126|NCT00907985|Drug|Placebo|Single dose of placebo will be provided.
1844127|NCT00907985|Drug|Vofopitant|Vofopitant (GR205171) will be provided as 5 milligram single dose capsule administered orally. It will be available as swedish orange, size 0 capsules.
1844128|NCT00907985|Drug|Lamotrigine|Lamotrigine will be provided as 25 milligrams or 100 milligrams single dose dispersible tablet administered orally.
1844129|NCT00907998|Drug|APL180|
1844130|NCT00907998|Drug|APL180|
1844131|NCT00907998|Drug|Placebo|
1844132|NCT00908011|Drug|Ezetimibe|10mg/day ezetimibe in addition to ongoing rosuvastatin treatment (10mg/day)- tablet, orally, 10mg/day for 12 weeks
1844133|NCT00908011|Drug|Rosuvastatin (standard care)|Increased dose of rosuvastatin to 20mg/day
1844134|NCT00908024|Drug|BMS-754807|Tablets, Oral, doses vary during dose escalation, once daily, varies - treatment is continued to disease progression or MD/subject/sponsor decision
1844135|NCT00908024|Drug|cetuximab (Erbitux®)|IV infusion, IV, 400 mg/m² loading dose, then 250 mg/m², weekly, varies - treatment is continued to disease progression or MD/subject/sponsor decision
1844136|NCT00908037|Drug|eltrombopag|thrombopoietin receptor agonist
1844137|NCT00908037|Drug|Placebo|placebo for comparison
1844139|NCT00908063|Drug|Oxycyte|A single dose of one of three dosage levels (dose escalating design), given by intravenous infusion at the rate of 15 mL/min (total duration expected to be between 5 and 20 minutes).
1844140|NCT00908063|Drug|Normal Saline|Normal saline will be administered as one of three volume doses based on cohort assignment (1.0 mL/min; 2.0 mL/min; 3.0 mL/min). The infusion will be administered at a rate of 15mL/min and will begin within 12 hours of injury.
1844141|NCT00908076|Drug|LUBIPROSTONE|Subjects will be randomized into placebo and study groups. Half of the study group (N=39) will be given lubiprostone (24 mcg) twice daily; the other half will receive matching placebo twice daily.
1844142|NCT00908089|Drug|Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and infliximab 3 mg/kg during first 6 months
1844143|NCT00908089|Drug|Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo|methotrexate 10-25 mg/week, sulfasalazine 1-2 g/day, hydroxychloroquine 35 mg/kg/week, prednisolone 7.5 mg/day, and placebo infusion during first 6 months
1844144|NCT00908102|Other|Moderate|A two level active intervention with a control group was executed for patients suffering from non-acute, moderate LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
1844145|NCT00908102|Other|Mild|A one level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Patients were selected by using a self-administered postal questionnaire.
1844146|NCT00908102|Other|Mild vs. NC|A two level intervention with long-term effectiveness and cost-effectiveness was executed for patients suffering from non-acute mild level LBP in occupational health. Intervention arms were compared to NC - no intervention group.
1844147|NCT00908102|Other|Moderate vs. NC|A three level intervention with two control groups was executed for patients suffering from non-acute, moderate LBP in occupational health. RCT intervention groups were compared to NC group - i.e. no intervention.
1844148|NCT00908115|Biological|GSK Biologicals' Infanrix™|Primary and booster vaccination according to vaccination schedule. Intramuscular injection
1844149|NCT00908128|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg Tablet
1844150|NCT00908128|Drug|CellCept®|CellCept® Tablets, 500 mg
1844151|NCT00908141|Biological|sargramostim|Given subcutaneously on varying schedule
1959400|NCT00218920|Behavioral|Strength training|a strength training regime of 4 series with 5 repetitions each, at approximately 90% of 1 repetition maximum (RM), in a leg press apparatus to develop maximal strength mainly from neural adaptation with minimal weight gain due to muscular hypertrophy.
1844154|NCT00908167|Drug|Sorafenib|Please see detailed description.
1844155|NCT00908167|Drug|Cytarabine|Please see Detailed Description.
1844156|NCT00908167|Drug|Clofarabine|Please see Detailed Description.
1844157|NCT00908180|Biological|alemtuzumab|
1844158|NCT00908180|Biological|donor lymphocytes|
1844159|NCT00908180|Drug|carmustine|
1844160|NCT00908180|Drug|cyclosporine|
1844161|NCT00908180|Drug|cytarabine|
1844162|NCT00908180|Drug|etoposide|
1844163|NCT00908180|Drug|melphalan|
1844164|NCT00908180|Procedure|allogeneic hematopoietic stem cell transplantation|
1844165|NCT00908193|Device|Laparoscopic DA VINCI Robot Assisted coelioscopy|Patients with abdominal wall hernia will be treated by robot-assisted coelioscopy for the poses of abdominal plate
1844166|NCT00908193|Procedure|conventional coelioscopy|Patients with abdominal wall hernia will be treated by conventional coelioscopy for the poses of abdominal plate
1844167|NCT00908206|Drug|GSK598809|Subjects will receive a single 175 mg oral dose of GSK598809.
1844168|NCT00908219|Drug|Bevacizumab|Bevacizumab is given as an IV infusion of 15 mg/kg every three weeks for 12 weeks.
1844169|NCT00908232|Drug|Cyclophosphamide|500 mg, p.o daily, days 1, 8 and 15 for cycles 5 to 8 cycles
1844170|NCT00908232|Drug|Bortezomib|1.3 mg/m2 IV bolus on Day 1, 4, 8, 11 for cycles 1 to 8
1844171|NCT00908232|Drug|Dexamethasone|20 mg orally daily, on Days 1, 2, 4, 5, 8, 9, 11, 12 for cycles 1 to 8
1844172|NCT00908232|Drug|Lenalidomide|10 mg orally daily, days 1-14 for cycles 5 to 8
1844173|NCT00908245|Procedure|Control|Surgery without preconditioning surgery
1844174|NCT00908245|Procedure|Preconditioning ischemia|Surgery with a preconditioning ischemia
1844175|NCT00908271|Drug|Dapagliflozin|Tablet and IV solution, Oral and IV, 10 mg po and 100 µg IV, Single oral dose followed by a single IV dose (IV dose administered at 1h after oral dose), 1 day
1844176|NCT00908284|Behavioral|Exercise Program|Participants will exercise in the study exercise laboratory for 1 hour on 2 nonconsecutive days a week for 12 weeks. The program will consist of a warm-up with flexibility exercises, aerobic conditioning, a muscular circuit, and a cool-down period with flexibility training.
1844177|NCT00908284|Behavioral|Control Group|Participants will attend group sessions once a week for 12 weeks to watch videos, including some exercise videos, and play games that do not require physical activity.
1844178|NCT00908297|Dietary Supplement|Coenzyme Q10|"By mouth (wafer) once daily for duration of study (8 weeks).
Dose escalation:
300 mg for two weeks
600 mg for two weeks
1200 mg for two weeks
1800 mg for final two weeks"
1844179|NCT00908310|Drug|Omniscan|OMNISCAN will be administered intravenously at the medical discretion of the prescribing physician.
1844180|NCT00908323|Biological|JS7 DNA vaccine|
1844181|NCT00908323|Biological|MVA/HIV62 vaccine|
1844182|NCT00908336|Drug|Docetaxel and Erlotinib|Docetaxel (Taxotere®) 75 mg/m2 iv first day of each 21-day cycle. Erlotinib (Tarceva®) 150 mg po days 2-16 of each 21-day cycle. Total: 4 cycles in the absence of disease progression
1844183|NCT00908336|Drug|Erlotinib|150 mg/day po daily
1844184|NCT00908349|Drug|Oxcarbazepine XR|Open Label Study
1844185|NCT00908362|Drug|fluticasone|Participants inhale fluticasone (250 µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
1844186|NCT00908362|Drug|fluticasone/salmeterol|Participants inhale fluticasone/salmeterol (250/50µg) via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
1844187|NCT00908362|Drug|placebo|Participants inhale placebo twice daily via discus. Before and after this therapy, a bronchoalveolar lavage is performed.
1844188|NCT00908375|Drug|Pregabalin|One pregabalin 75mg capsule will be prescribed twice daily for the first week of the study (150mg/day). For the subsequent 2 weeks, the dose will be increased to 2 pregabalin capsules twice a day (300mg/day). The total duration of the treatment will be 3 weeks.
1844189|NCT00908375|Drug|Sugar Pill|One sugar pill will be prescribed twice daily for the first week of the study. For the subsequent 2 weeks, 2 placebo(sugar pills) capsules twice a day. The total duration of the treatment will be 3 weeks.
1844191|NCT00908401|Other|Breastmilk|Breastmilk: 0.2 ml
1844192|NCT00908401|Other|Oral Sucrose|oral sucrose: 0.2 ml one time 1 minute before the painful procedure with a pacifier
1844193|NCT00908414|Drug|TMC589337 40 mg|Participants will receive TMC589337 40 mg in Session Ia of Panel 1.
1844194|NCT00908414|Drug|TMC589337 100 mg|Participants will receive TMC589337 100 mg in Session IIa of Panel 1.
1844195|NCT00908414|Drug|TMC589337 200 mg|Participants will receive TMC589337 200 mg in Session IIIa of Panel 1.
1844196|NCT00908414|Drug|TMC589337 400 mg|Participants will receive TMC589337 400 mg in Session IVa of Panel 1.
1844197|NCT00908414|Drug|TMC589354 40 mg|Participants will receive TMC589354 40 mg in Session Ib of Panel 2.
1844198|NCT00908414|Drug|TMC589354 100 mg|Participants will receive TMC589354 100 mg in Session IIb of Panel 2.
1844199|NCT00908414|Drug|TMC589354 200 mg|Participants will receive TMC589354 200 mg in Session IIIb of Panel 2.
1844200|NCT00908414|Drug|TMC589354 400 mg|Participants will receive TMC589354 400 mg in Session IVb of Panel 2.
1844201|NCT00908414|Drug|TMC589337 AA mg|Participants will receive TMC589337 AA mg on Days 1 to 7 in Session Va of Panel 3.
1844202|NCT00908414|Drug|TMC589354 BB mg|Participants will receive TMC589354 BB mg on Days 1 to 7 in Session Vb of Panel 4.
1844203|NCT00908414|Drug|TMC589337 CC mg|Participants will receive TMC589337 CC mg on Days 1 to 7 in Session VIa of Panel 5.
1844204|NCT00908414|Drug|TMC589354 DD mg|Participants will receive TMC589354 DD mg on Days 1 to 7 in Session VIb of Panel 6.
1844205|NCT00908414|Drug|TMC589337 EE mg|Participants will receive TMC589337 EE mg on Days 1 to 7 in Session VII of Panel 7.
1844206|NCT00908414|Drug|TMC589354 YY mg|Participants will receive TMC589354 YY mg on Days 1 to 7 in Session VII of Panel 7.
1844207|NCT00908414|Drug|TMC310911 300 mg|Participants will receive TMC310911 300 mg in Panel 3, 4, 5, 6 and 7.
1844208|NCT00908414|Drug|TMC310911 600 mg|Participants will receive TMC310911 600 mg in Panel 7.
1844209|NCT00908414|Drug|Placebo|Participants will receive matching placebo to TMC589337 or TMC589354 in Panel 1 and 2.
1844210|NCT00908427|Procedure|photoselective vaporization prostatectomy (PVP)|PVP using 80 W KTP laser with a Greenlight system (GreenLight PVTM, Laserscope®, San Jose, CA)
1844211|NCT00908427|Procedure|Transurethral resection of the prostate|Standard transurethral resection of the prostate using electrocautery loop
1844212|NCT00908440|Behavioral|Decision Aid|25 page booklet informing patients about PTSD symptoms and treatment options
1844213|NCT00908453|Drug|fosphenytoin|15mg/kg, 18mg/kg or 22.5mg/kg of loading doses of fosphenytoin
1959401|NCT00218920|Behavioral|continuous moderate-intensity aerobic training|The moderate-intensity group walked continuously for 47 min at 60-70% of maximum heart rate (HRmax) to ensure that the training protocols were isocaloric.
1959402|NCT00218920|Behavioral|high-intensity interval aerobic training|High-intensity training consisted of a 10 min warm-up period at 50-60% of HRmax [maximal HR (heart rate)], followed by 4×4-min intervals at 85-95% of HRmax with 3 min active breaks in between the intervals, consisting of walking or jogging at 50-60% of HRmax. The exercise session was terminated by a 5 min cool-down period.
1844216|NCT00908479|Behavioral|Leg Exercise Program|Participants will engage in an extra 45-60 minutes per day of self-managed lower extremity homework exercises focused on improving strength, balance and walking ability.
1844217|NCT00908479|Behavioral|Leg Management group|Therapist provides educational information about leg pain, recovery, bone density, and fall risk.
1959403|NCT00218296|Drug|Usual Care Group|Nicotine replacement therapy
1959404|NCT00218296|Other|Reduction Group|Subject selects preferred method for reduction.
1844220|NCT00908505|Procedure|physiotherapy|physiotherapy either by biphasic cuirass ventilator or physiotherapist
1844221|NCT00908531|Drug|letrozole (Femara)|tablet 2.5 mg daily
1844222|NCT00908544|Other|PHI-patients|Treatment initiation with multi drug class (MDC) HAART. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
1844223|NCT00908544|Other|CHI-patients|Treatment intensification of PI-based HAART with Maraviroc and Raltegravir. 2 NRTI + 1 PI/r + Maraviroc + Raltegravir
1844224|NCT00908557|Other|readability improvement and good practice redaction|improvement using Flesch readability index and good practice in redaction of informed consent documents.
1844225|NCT00908557|Other|Control|information based on the classic informed consent document
1844226|NCT00908570|Drug|estriol|4 ml vaginal cream (1.0 mg estriol/1 ml cream), 3 days/week for approximately 2 months.
1844227|NCT00908570|Drug|Placebo|Placebo cream
1844228|NCT00908583|Drug|plasmapheresis|Patients will receive plasmapheresis 1.5 x plasma volume prior to each Bortezomib dose. Plasma volume replacement will be per physician discretion.
1844229|NCT00908583|Drug|Bortezomib|Patients will receive bortezomib as described in protocol
1844230|NCT00908583|Drug|Rituximab|Patients will receive rituximab as described in protocol
1844231|NCT00908583|Drug|Methylprednisolone|Each bortezomib dose will be preceded by intravenous methylprednisolone (100mg for first two doses and 50mg for following doses).
1844232|NCT00908596|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Primovist/Eovist in approved indications at approved dosages
1844233|NCT00908622|Procedure|Percutaneous autologous myoblast implantation|Endocavity implantation of autologous myoblasts
1844234|NCT00908622|Procedure|Cardiac revascularization|Cardiac revascularization
1844235|NCT00908648|Procedure|Narrow Band Imaging|Narrow Band Imaging
1844236|NCT00908661|Device|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh|Lightweight polipropilene and poliglecaprone 25 and oxidized cellulose mesh
1844237|NCT00908674|Drug|Cyproterone acetate (Androcur)|"The study drug will be administered either as monotherapy or in combination with other interventions (surgical castration or LHRH analogue treatment).
Daily dosage as monotherapy: 200-300 mg cyproterone acetate. Daily dosage following surgical castration: 100-200 mg cyproterone acetate. Daily dosage in combination with an LHRH-analogue: 100-200 mg cyproterone acetate.
Administration period: 12 months."
1844238|NCT00908687|Biological|A/H5N1|A/H5N1 Low Dose
1844239|NCT00908687|Biological|A/H5N1|A/H5N1 High Dose
1844240|NCT00908687|Biological|LT Adjuvant Patch|LT Adjuvant Patch Low Dose
1844241|NCT00908687|Biological|LT Adjuvant Patch|LT Adjuvant Patch High Dose
1844242|NCT00908700|Procedure|Surgical occlusion of the left atrial appendage|Study intervention: Within the trial, occlusion must be performed using either amputation and closure (cut and sew) or stapler device.
1844243|NCT00908700|Procedure|Best medical practice|Best medical practice for atrial fibrillation related stroke prevention as per guidelines.
1844244|NCT00908713|Drug|methylprednisolone|methylprednisolone 0.5 mg/kg body weight every 12 h for 5 days
1844245|NCT00908713|Drug|Placebo|Sodium chloride 0.9% 10 mL every 12 h for 5 days
1844246|NCT00908726|Drug|propofol|Each subject received both propofol formulations in a crossover fashion separated by a 7-day washout period, and the order of the drug administration was randomized. Subjects received both propofol formulations (Lipid emulsion propofol: Diprivan® and Microemulsion propofol: AquafolTM) during 60 min. The infusion rate was assigned according to a nonblinded, randomized design to 1.5, 3, 6, or 12 mg/kg/hr.
1844247|NCT00908739|Genetic|gene expression analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
1844248|NCT00908739|Other|immunohistochemistry staining method|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
1844249|NCT00908739|Other|laboratory biomarker analysis|immunohistochemistry for levels of expression of five different factors related to aggressive tumor behavior (i.e., VEGF expression, E-cadherin regulation, matrix metalloproteinase 2 and 9 activity, and carbonic anhydrase 9 activity)
1844253|NCT00908765|Behavioral|Exercise|"High aerobic intensity treadmill walking. 4 by 4 minutes interval training on a graded treadmill at a heart rate corresponding to 85-95% of maximal heart rate. 3 times per week for 10 weeks.
Moderate continuous intensity treadmill walking on a graded treadmill at a heart rate corresponding to 60-70 of maximal heart rate, 3 times per week for 10 weeks"
1844254|NCT00908778|Drug|Vitreosolve|intravitreal injection
1844255|NCT00908778|Drug|Vitreosolve|intravitreal injection
1844257|NCT00908804|Procedure|open appendectomy|
1844258|NCT00908804|Procedure|laparoscopic appendectomy|
1959411|NCT00189540|Genetic|HGF plasmid|Intramuscular injections into the index leg on days 0, 14, and 28
1959412|NCT00189540|Genetic|Placebo|Intramuscular injections into the index leg on days 0, 14, and 28
1844262|NCT00908843|Other|Intravenous hydration with bicarbonate|Intravenous hydration with bicarbonate 1/6 M intravenous infusion (3ml/Kg/h) one hour before the administration of intravenous contrast
1844263|NCT00908843|Other|Oral hydration with Sodium solution|Oral hydration with Sodium solution (Casen solution of rehydration) in the 4 hours before of the intravenous contrast administration (75 ml/10 kg as equivalent to 0,25 g of sodium chloride /10 kg).
1844264|NCT00908856|Biological|autologous bone marrow mononuclear cell transfusion|a single intravenous transfusion approximately 2 days after bone marrow aspiration, and 4 days after stroke onset; the full amount of autologous mononuclear cells derived from 30 cc of bone marrow
1844265|NCT00908856|Biological|marrow stromal cells|a single intravenous transfusion approximately 21 days after bone marrow aspiration, and 23 days after stroke onset; the full amount of marrow stromal cells cultured over 21 days from 30 cc of bone marrow (expected to be approximately 1,000,000 cells/kg body weight)
1844266|NCT00908856|Drug|placebo|a single intravenous transfusion of saline, approximately 2-21 days after bone marrow aspiration, and 4-23 days after stroke onset; the full amount of mononuclear cells derived from 30 cc of bone marrow
1844267|NCT00908869|Drug|Vinorelbine, Cyclophosphamide and Interferon alpha 2b|"Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.
Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.
Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.
Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week ."
1844268|NCT00908882|Behavioral|Motivation Interviewing Counseling|Stage-based smoking cessation information written in the spirit of motivational interviewing in addition to weekly telephonic motivational interviewing counseling sessions
1844269|NCT00908895|Procedure|Radio-radial fixator|Using the Distal Radius Fixator from Synthes. A single splint for 5 days.
1844270|NCT00908895|Procedure|Percutaneous pinning|Insert two K-wires in the distal radius, one in the fracture line dorsally and one from the styloid. A cast for 6 weeks.
1844271|NCT00908908|Drug|eribulin|Cycle 1 day 1: radio-labeled dose of 2 mg radioactive eribulin, followed by 1.4 mg/m^2 of non-radio-labeled eribulin thereafter on days 1 and 8 every 21 days.
1844272|NCT00908921|Drug|GLIMEPIRIDE|Dosage of 1mg, 2mg and 4mg of AMARYL (Glimepiride)
1844273|NCT00908934|Drug|AZD9056 formulation Phase III 50 mg (T)|Given as 50 mg tablet (T)
1844274|NCT00908934|Drug|AZD9056 formulation Phase IIb 50 mg (R)|Given as 50 mg tablet (R)
1844275|NCT00908934|Drug|AZD9056 formulation Phase III 200 mg (T)|Given as 400 mg (2 x 200 mg tablet (T))
1844276|NCT00908934|Drug|AZD9056 formulation Phase IIb 200mg (R)|Given as 400 mg (2 x 200 mg tablet (R))
1844277|NCT00908947|Device|PTA followed by placement of LifeStent® Vascular Stent|PTA followed by placement of LifeStent® Vascular Stent
1844278|NCT00908960|Drug|Enoxaparin|Given subcutaneously daily for 2 months
1844279|NCT00908986|Drug|Rituximab|375mg/m2 q week x 4; repeated in 6 months
1844280|NCT00909012|Dietary Supplement|high oleic sunflower oil|placebo, which does not provide DHA
1844281|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 35 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
1844282|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
1844283|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 140 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
1844284|NCT00909012|Dietary Supplement|microalgal oil|the supplement provides 225 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
1844285|NCT00909025|Drug|Claudiximab|"Patients receive Claudiximab as intravenous infusion over 2 hours on day 1. Cohorts of 3-6 patients receive escalating doses of Claudiximab until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which no dose-limiting toxicity (DLT) is diagnosed in 3 patients or no more than 1 out of 6 patients exhibits a DLT.
After completion of study treatment, patients are followed for 4 weeks."
1844286|NCT00909051|Drug|Acarbose (Glucobay, BAYG5421)|Patients with diabetes type 2 newly treated with Glucobay
1844287|NCT00909064|Drug|Fondaparinux Sodium (Arixtra)|2.5 mg once per day to begin 6-8 hours after surgery and continued for 10 days.
1844288|NCT00909077|Drug|Dexamethasone|Dexamethasone tablets: 40 mg/day for four days
1992709|NCT03312387|Other|Exercise|Aerobic exercise performed 3/d per week during intervention
1992710|NCT03312387|Dietary Supplement|Essential Amino Acids|Mixture of 10g of essential amino acids ingested throughout intervention
1992711|NCT03312387|Dietary Supplement|Placebo|10g of maltodextrin ingested throughout intervention
1844289|NCT00909077|Drug|Dexamethasone and Rituximab|Dexamethasone tablets: 40 mgs/day for four days Rituximab iv 375 mg/m^2 weekly, a total of four times. Administered on day 2 (i.e. the patient has been treated with Dexamethasone for one day)
1844290|NCT00909090|Dietary Supplement|lutein and zeaxanthin supplements|12 mg taken daily for one year
1844291|NCT00909090|Drug|Placebo|Placebo
1844292|NCT00909116|Procedure|Stapled Transanal Rectal Resection with Contour Transtar|Transanal Stapling procedure - Stapled Transanal Rectal Resection
1844293|NCT00909129|Drug|pegylated interferon-alpha (Pegasys)|Pegylated interferon-alpha 2a 180 micrograms s.c. weekly
1844294|NCT00909129|Drug|ribavirin (COPEGUS)|ribavirin bid 800-1200 mg depending on HCV genotype and body weight
1844295|NCT00909142|Drug|Bonefos (Clodronate, BAY94-8393)|Patients in regular clinical practice receiving Bonefos according to local drug information
1844296|NCT00909155|Drug|Venlafaxine ERT|Titrated to a minimum dose of 75mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 37.5 mg; Days 7-14: 75 mg; Days 15-180: 75-300mg based on clinician assessment. Titration rate is a maximum of 75mg/7d.
1844297|NCT00909155|Drug|Fluoxetine|Titrated to a minimum dose of 20mg. Further titration based on clinician assessment at followup visits. Intervention to continue through completion of study (180 days). Initial titration: Days 1-7: 20mg; Days 7-14: 20mg; Days 15-180: 20-80mg based on clinician assessment. Titration rate is a maximum of 20mg/7d
1844298|NCT00909168|Drug|FLAIMy - Fluda, Ida, Ara-C, Mylotarg|"FLUDARABINE: 25 mg/m2/day, 250 FS in 30', start h 9 - 1, 2, 3, 4, 5
ARABINOSYL-CYTOSINE (Cytarabine): 2 g/m2/day, 500 FS in 3 h, start h 13 - 1, 2, 3, 4, 5
IDARUBICIN: 10 mg/m2/day, 100 FS in 1 h, start h 16 - 1, 3, 5
GEMTUZUMAB OZOGAMICIN (Mylotarg): 5 mg, single dose 500 FS in 4 h - 6"
1844299|NCT00909181|Drug|Oxybutynin|"Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.
Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
1844300|NCT00909181|Drug|Placebo|"Placebo Gel Oxybutynin Gel. Transdermal gel was applied once-daily (in the morning) during 12 weeks of treatment.
Evaluation: reduction of incontinent episodes (baseline vs 12 weeks); comparison 56 resp. 84 mg vs placebo"
1844301|NCT00909194|Behavioral|Psychoeducational Seminar and Relaxation Technique|Psychoeducational seminar on Juvenile Primary Fibromyalgia (pain management, diet, exercise and sleep hygiene) followed by a total body relaxation technique
1844302|NCT00909207|Behavioral|Interview|Review list of 25 cancer symptoms, 20-30 minute audio-taped personal interview and 15-20 minute questionnaire.
1844304|NCT00909233|Drug|Vardenafil, (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
1844305|NCT00909259|Device|Phrenic stimulation device|In Stage 1, a stimulation lead will be introduced via standard access methods and positioned to provide stimulation. A second lead may also be placed for sensing purposes. The proximal portions of the implanted lead(s) will remain externalized such that stimulation and observation can be made using external stimulation and recording equipment. Study subjects will be observed and stimulation will be performed for up to 2 nights of sleep in a clinically supported environment. In Stage 2, a stimulation device and lead will be permanently implanted.
1844306|NCT00909272|Procedure|Lumbar medial branch block|The ultrasound probe will be placed perpendicular to skin along the midline of lumbar spinous process on longitudinal view first to count the lumbar level. The midpoint of each lumbar level will be marked on the longitudinal view and then will be rotated ninety degrees counter clockwise to axial view to locate the facet joint and the transverse process of lumbar spine. A #22 gauge 10cm long Quincke spinal needle will be inserted to the target area using in plane approach on the axial view. Then the probe will be rotated ninety degrees clockwise to longitudinal view to ensure needle tip is placed on the cephalad aspect of the transverse process. It will then be immediately confirmed by C-arm fluoroscopy on oblique view.
1844307|NCT00909272|Procedure|Ultrasound landmarks|The target point is the superior medial aspect of transverse process of lumbar spine from L3 to S1. A #22 gauge 10cm long Quincke spinal needle will be use for needle placement. Needle placement will be visualized with ultrasound. Practice on cadavers with 3 different operators and see if results are reproducible. Verify with fluoroscopy.
1844308|NCT00909285|Device|TMS stimulation|TMS stimulation and cognitive training
1844309|NCT00909285|Device|Sham comparator|Sham comparator
1844310|NCT00909285|Behavioral|Cognitive training|TMS stimulation and cognitive training
1844311|NCT00909298|Drug|TTP889|300 mg
1844312|NCT00909298|Drug|Placebo|Placebo
1844313|NCT00909311|Drug|ABT-450|capsules, QD, 1 dose in each cross-over period
1844314|NCT00909311|Drug|ritonavir|capsule, QD, 1 dose in each cross-over period
1844315|NCT00909324|Drug|Pre-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting 5 days prior to LASIK surgery and continuing through 1 month after LASIK surgery.
1844316|NCT00909324|Drug|Post-LASIK 0.3% hypromellose|Patients self-administered GenTeal eye drops qid (quarter in die, 4 times a day) starting on the day of LASIK surgery and continuing through 1 month after surgery.
1844317|NCT00909337|Drug|Bosentan|2x62.5mg for 4 weeks, then 2x125mg
1844318|NCT00909363|Drug|Promacta (eltrombopag)|Patients will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP.
1844319|NCT00909363|Drug|Eltrombopag/promacta|Patients will start on 1 mg/kg of eltrombopag daily and be seen weekly for 12 weeks. Dose adjustment will be based on the weekly monitoring of the platelet count as utilized in ongoing studies in ITP.
1844320|NCT00909389|Drug|Vytorin (R) (Ezetimibe + Simvastatin)|Vytorin (R) (Ezetimibe + Simvastatin) 1 tablet once daily to be taken by mouth in the evening for 28 days
1844321|NCT00909402|Drug|BMS-833923|Capsule, Oral, Starting dose 30 mg, Once daily, continuous until discontinuation from study
1844322|NCT00909402|Drug|Cisplatin|Vial, intravenous (IV), 80 mg/m² IV, Once every 21 days, 1 day per cycle until discontinuation from study
1844323|NCT00909402|Drug|Capecitabine|Tablets, Oral, 1000 mg/m², twice a day (BID), 14 days per cycle, until discontinuation from study
1844324|NCT00909428|Drug|Solifenacin Succinate|Participants take 10mg daily solifenacin succinate for 30 days
1844325|NCT00909441|Procedure|Sentinel Lymph Node Biopsy|Sentinel node biopsy is a technique in which a radioactive isotope is injected in the breast, with or without blue dye. These substances will then migrate and concentrate in the first nodes in the axilla that drain the breast: The sentinel nodes. These nodes (usually one to four nodes) are then evaluated for the presence of cancer cells.
1844326|NCT00909454|Dietary Supplement|2000 IU Vitamin D3 daily supplement|2000 IU vitamin D3 supplement to be taken once daily over 4 months
1844327|NCT00909454|Dietary Supplement|400 IU Vitamin D3 supplement|400 IU Vitamin D3 supplement to be taken daily over 4 months
1844328|NCT00909467|Other|echocardiography, right heart catheterisation|at each patient an echocardiography will be performed at rest and during exercise. For the evaluation of exercise capacity, cardiopulmonary exercise testing and six-minute walk is performed. Right heart catheterisation is recommended to those with suspected pulmonary hypertension.
1844329|NCT00909480|Drug|insulin detemir|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.
S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
1844330|NCT00909480|Drug|insulin glargine|"Treat-to-target (individually adjusted dose) titration according to titration algorithm.
S.c. (under the skin) injection once daily as an add-on to subjects' stable pre-trial metformin dose (at least 1500 mg/day). Any other use of OAD will be discontinued"
1844331|NCT00909493|Other|Network Access|Primary Care Physicians in this treatment group will have access to a pain specialist at the Pain Management Unit.
1844332|NCT00909506|Drug|Placebo|"Control: Receive placebo pill once every evening on 1~2 weeks.
Receive placebo pill in every morning and evening on 3~24 weeks (twice a day)."
1844333|NCT00909506|Drug|Metformin|"Metformin 500 mg/d: Receive oral metformin 500 mg dose once daily on 1~2 weeks.
Receive placebo pill in every morning and oral metformin 500 mg in every evening on 3~24 weeks."
1844334|NCT00909506|Drug|Metformin|"Metformin 1000 mg/d : Receive oral metformin 500 mg dose once daily on 1~2 weeks. (Dose-escalate)
Receive oral metformin 500 mg in every morning and evening on 3~24 weeks (metformin 500 mg * twice a day = 1000 mg per day)."
1844335|NCT00909519|Drug|naproxcinod|naproxcinod 750 mg bid
1844336|NCT00909519|Drug|Naproxen|Naproxen 500 mg bid
1844337|NCT00909519|Drug|placebo|placebo
1844338|NCT00909519|Drug|furosemide|furosemide
1844339|NCT00909532|Drug|Ivacaftor|150-mg tablets given orally q12h for up to 48 weeks
1844340|NCT00909532|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
1844341|NCT00909545|Drug|Isradipine CR 5mg|5mg dose: 1 Dynacirc CR 5mg tablet, 3 tablets placebo once daily
1844342|NCT00909545|Drug|Isradipine CR 10mg|10mg dose: 2 Dynacirc CR 5mg tablets, 2 tablets placebo once daily
1844343|NCT00909545|Drug|Isradipine CR 20mg|20mg dose: 4 Dynacirc CR 5mg tablets once daily
1844344|NCT00909545|Drug|Placebo|4 Placebo to Match (PTM) tablets once daily
1844345|NCT00909558|Biological|Autologous Natural Killer / Natural Killer T Cell Immunotherapy|"The study drug is derived from ex vivo expansion of each subject's own white blood cells and is therefore autologous.
The current study proposes a 3-course treatment of doses administered at one week intervals with monitoring at each administration plus 2 weeks after the last dose. The total study time (apheresis through last follow-up) is estimated at 15 weeks."
1844346|NCT00909571|Drug|FK506E (modified release tacrolimus)|oral
1844347|NCT00909571|Drug|Prograf (tacrolimus)|injection
1844348|NCT00909584|Drug|Ezatiostat Hydrochloride|Starting Dose 2000 mg orally per day in two divided doses with dose to increase or decrease to achieve target median ANC (Range 1,500-10,000 cells/uL)
1844349|NCT00909597|Drug|pioglitazone|30mg po once daily for 4 weeks, followed by 45mg once daily
1844350|NCT00909597|Drug|taspoglutide|10mg sc once weekly
1844351|NCT00909597|Drug|taspoglutide|10mg sc once weekly for 4 weeks, followed by 20 mg sc once weekly
1844352|NCT00909610|Drug|Ursodiol|Ursodiol Tablets, 500 mg
1844353|NCT00909610|Drug|Urso Forte™|Urso Forte™ Tablets, 500 mg
1844354|NCT00909636|Drug|ABT-333|See arm description for more information
1844355|NCT00909636|Drug|Placebo|See arm description for more information
1844356|NCT00909649|Procedure|fibrin glue in breast surgery|fibrin glue 8 ml in the bed after modified radical mastectomy in fibrin treated group
1844357|NCT00909662|Procedure|assessment of therapy complications|"Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen
Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS
Borg 15-Category Scale"
1844358|NCT00909662|Procedure|cognitive assessment|Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
1844359|NCT00909662|Procedure|fatigue assessment and management|"Questionnaires: Brief Fatigue Inventory, Brief Mental Fatigue and BDI FastScreen
Cognitive Task (2 timed 2-minute tests) with Concomitant EEG
Physical Task (Sustained Elbow Flexion) with Concomitant EEG and EMG plus TMS
Borg 15-Category Scale"
1844360|NCT00909688|Drug|BLI-489|
1844361|NCT00909688|Drug|placebo|
1844362|NCT00909701|Dietary Supplement|PreOP Booster|1 serving of 400 ml per study arm
1844363|NCT00909701|Dietary Supplement|PreOP (Nutricia Clinical Care, Trowbridge, UK)|1 serving of 400 ml per study arm
1844364|NCT00909714|Device|DC-Stimulator to apply tDCS|Anodal tDCS (20 minutes) stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
1844365|NCT00909714|Device|DC-Stimulator to apply Sham tDCS|Sham stimulation will be applied once a day in combination with standardized upper extremity rehabilitative training
1844366|NCT00909727|Drug|Ivacaftor|150-mg tablet given orally q12h for up to 48 weeks
1844367|NCT00909727|Drug|Placebo|Tablet given orally q12h for up to 48 weeks
1844368|NCT00909740|Drug|MEGF0444A|Intravenous escalating dose
1844369|NCT00909753|Drug|Ursodiol|Ursodiol Tablets, 500 mg
1844370|NCT00909753|Drug|Urso Forte™|Urso Forte™ Tablets, 500 mg
1844371|NCT00909766|Drug|BMS-830216|Capsules, Oral, 30 mg, once daily, 28 days
1844372|NCT00909766|Drug|BMS-830216|Capsules, Oral, 100 mg, once daily, 28 days
1844373|NCT00909766|Drug|BMS-830216|Capsules, oral, 300 mg, once daily, 28 days
1844374|NCT00909766|Drug|BMS-830216|Capsules, oral, 600 mg, once daily 28 days
1844375|NCT00909766|Drug|BMS-830216|Capsules, oral, 1200 mg, once daily, 28 days
1844376|NCT00909766|Drug|BMS-830216|Capsules, Oral, to be determined, once daily, 28 days
1844377|NCT00909766|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
1844378|NCT00909779|Drug|Arformoterol|Arformoterol Tartrate Inhalation Solution 15 mcg twice daily (BID) for a duration of one year
1844379|NCT00909779|Drug|Placebo|Placebo inhalation solution, twice daily (BID) for a duration of one year.
1844380|NCT00909792|Device|Lotrafilcon B|Silicone hydrogel, soft, multifocal contact lens
1844381|NCT00909792|Device|Senofilcon A|Silicone hydrogel, soft, multifocal contact lens
1844382|NCT00909805|Device|cutaneous suture (Surjet)|cutaneous surjet suture
1844383|NCT00909805|Device|2-octyl-cyanoacrylate (Dermabond® glue)|the cutaneous suture is made with glue only
1844384|NCT00909818|Radiation|standard fractionated radiotherapy|standard fractionated radiotherapy 50 Gy/25 fractions
1844385|NCT00909818|Radiation|hypofractionated radiotherapy|hypofractionated radiotherapy 40 Gy/15 fractions
1844386|NCT00909831|Drug|hydroxychloroquine|
1844387|NCT00909831|Drug|temsirolimus|
1844388|NCT00909831|Other|electron microscopy|
1844389|NCT00909831|Other|high performance liquid chromatography|
1844390|NCT00909831|Other|immunologic technique|
1844391|NCT00909831|Other|laboratory biomarker analysis|
1844392|NCT00909831|Other|mass spectrometry|
1844393|NCT00909831|Other|pharmacological study|
1844394|NCT00909831|Procedure|autophagy inhibition therapy|
1844395|NCT00909844|Drug|Triptorelin (I.N.N.)|Decapeptyl® SR 11.25mg
1992716|NCT03310320|Drug|AZD0284 oral solution 2.5 mg/mL|AZD0284 oral solution 2.5 mg/mL, 100 mg twice daily for for 4 weeks
1992717|NCT03310320|Drug|Placebo|Placebo for AZD0284 oral solution, twice daily for 4 weeks
1844401|NCT00902291|Biological|AGS-1C4D4|IV infusion
1844402|NCT00902291|Biological|Gemcitabine|IV infusion
1844403|NCT00902304|Drug|Valsartan and hydrochlorothiazide (HCTZ) - monotherapy|Monotherapy arm - if monotherapy valsartan 320mg per day orally was not sufficient, then could add HCTZ up to 25 mg per day orally
1844404|NCT00902304|Drug|Valsartan and amlodipine|From valsartan 80mg/amlodipine 5mg per day to valsartan 160mg/amlodipine 10mg per day orally
1844405|NCT00902304|Drug|Usual care|As directed by investigator
1844406|NCT00902304|Drug|Valsartan|Valsartan 160mg per day to 320mg per day orally
1844407|NCT00902304|Drug|Valsartan and hydrochlorothiazide (HCTZ) - combination arm|Combination arm - from valsartan 80mg/hydrochlorothiazide 12.5mg per day to valsartan 160mg/hydrochlorothiazide 25mg per day orally
1844408|NCT00902317|Procedure|Cryoplasty (PolarCath peripheral balloon catheter)|Cryoplasty involves advancing the balloon catheter to the site of the lesion and delivering liquid nitrous oxide into the balloon, where it expands into gas and inflates the balloon.
1844409|NCT00902317|Procedure|Laser Angioplasty (Spectranetics)|The basic concept of laser angioplasty is to apply light energy directly to the arterial plaque, thereby altering the plaque in some helpful way, without damaging the surrounding artery.
1844410|NCT00902317|Procedure|SilverHawk Atherectomy|Once the catheter is connected to the cutter driver, by retracting the positioning lever this simultaneously turns on the motor and caused the distal portion of the cutter housing to deflect, forcing the device against the target lesion.
1844411|NCT00902317|Device|Viabahn Endograft|The Gore-Viabahn should be positioned across the target lesion using the radiopaque hub and tip markers on the catheter. These markers identify the proximal and distal ends of the device, respectively.
1844412|NCT00902317|Procedure|"Angioplasty/Stent (Guidant Absolute stent)"|A Stent is a metal scaffold that is also delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood flow. The stent remains implanted in the blood vessel, and after a few weeks, the inner lining of the blood vessel will grow over the stent surface.
1844413|NCT00902330|Procedure|energy-based therapy|Given once a day for 18 weeks
1844414|NCT00902330|Procedure|sham intervention|Given once a day for 18 weeks
1844415|NCT00902343|Procedure|nomogram-based selection for acute normovolemic hemodilution|Will use the nomogram to determine whether or not the patient needs ANH during surgery. The nomogram assigns a point value to certain pre-op factors to determine whether or not the patient will need an ANH. Preoperative factors that will be used are platelet count, planned amount of liver to be removed, hemoglobin level, if the surgeon needs to operate on any organ outside of the liver to remove the tumor, and the patients health overall.
1844416|NCT00902343|Procedure|standard selection for ANH based on a planned resection of 3 or more segments|Will use the planned amount of liver to be removed to determine whether or not the patient needs an ANH during surgery.
1844417|NCT00902356|Drug|AMG 167|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
1844418|NCT00902356|Drug|Placebo|Subjects will be randomized to receive 1 of 5 doses of AMG 167 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 167 in fixed doses of 21 mg, 70, 210, 350, or 700 mg SC (under the skin), or 70 mg or 350 mg IV (in the vein), while men will receive doses of 70 mg or 350 mg SC or IV.
1844419|NCT00902369|Drug|AK106-001616|Part1: Dose escalation Part2: Dose expansion
1844420|NCT00902369|Drug|Placebo|
1844421|NCT00902369|Drug|Active comparator|
1844422|NCT00902395|Drug|Midazolam|Oral midazolam 1.0 mg/kg (maximum 20 mg)
1844423|NCT00902395|Behavioral|Protective stabilization|Children will receive a protective stabilization (physical restrain) with sheet fixed with tapes.
1844424|NCT00902395|Drug|Midazolam, ketamine|Combined oral midazolam (0.5 mg/kg) and ketamine (3 mg/kg) (MK)
1844425|NCT00902408|Dietary Supplement|Lutein enriched eggs|1 year of daily enriched lutein eggs or placebo
1844426|NCT00902421|Drug|Selective serotonin reuptake inhibitors|escitalopram 10mg once daily for 3 months
1844427|NCT00902421|Drug|Antimuscarinics|Antimuscarinics for 3 months
1844428|NCT00902460|Drug|midazolam; CP-690,550 + midazolam|Period 1 : 2 mg midazolam oral syrup alone Period 2: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID
1844429|NCT00902460|Drug|CP-690,550 + midazolam; midazolam|Period 1: 2 mg midazolam oral syrup plus 30 mg CP-690,550 after 6 days of CP-690,550 at 30 mg BID Period 2: 2 mg midazolam oral syrup alone
1844430|NCT00902473|Drug|Topiramate|25mg tablets
1844431|NCT00902486|Drug|INCB028050|4 mg capsules QD
1844432|NCT00902486|Drug|INCB028050|7 mg capsules QD
1844433|NCT00902486|Drug|INCB028050|10 mg capsule QD
1844434|NCT00902486|Drug|Placebo|Placebo matching INCB028050 QD
1844435|NCT00902512|Drug|Treatment A|Viagra® 100 mg tablet, administered with water single dose
1844436|NCT00902512|Drug|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
1844437|NCT00902512|Drug|Treatment B|Sildenafil 100 mg CT administered with water single dose
1844438|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
1844439|NCT00902512|Drug|Treatment C|Sildenafil 100 mg CT administered without water single dose
1844440|NCT00902512|Other|Blood samples for the analysis of sildenafil in plasma|Blood samples for the analysis of sildenafil in plasma
1844441|NCT00902525|Drug|90Y-Ibritumomab Tiuxetan|All patients receive 2 courses of age-adjusted R-miniDHAP followed by two doses of 90Y-Ibritumomab Tiuxetan
1844442|NCT00902538|Drug|Olmesartan medoxomil 40 mg - Amlodipine 10 mg|Oral tablets containing Olmesartan medoxomil-Amlodipine 40-10 mg, given once daily
1844443|NCT00902538|Drug|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
1844444|NCT00902538|Drug|Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
1844445|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
1844446|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
1844447|NCT00902538|Drug|OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg|Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
1844448|NCT00902564|Drug|Escitalopram|Flexible-dosed (5 to 20 mg Oral Tablets Daily)
1844452|NCT00902590|Other|saliva sample and questionaire|"Urothelial Cancer Registry- Patients will complete a family history and urothelial cancer risk questionnaire, and will provide a buccal sample for germline DNA. If the cases have previously completed athe the Urothelial Baseline Questionnaire, in an MSKCC urology clinic they will not need to complete the urothelial cancer risk questionnaire."
1844453|NCT00902590|Other|saliva sample, questionaire|Urothelial Cancer Registry- These participants will be requested to complete the risk factor questionnaire and to provide a saliva sample for DNA extraction.
1844454|NCT00902603|Drug|Commercial Ventavis® (iloprost)|Commercial Ventavis® (iloprost) administered via portable nebulizer (I-neb® AAD® system using the power disc-6)
1844455|NCT00902616|Dietary Supplement|L-arginine|3gm TDS for three months
1844456|NCT00902616|Dietary Supplement|Placebo Lactose powder|3gm TDS for 3 months
1844457|NCT00909857|Drug|Estradiol valerate, Dienogest (Natazia, Qlaira, BAY86-5027)|Daily oral administration of one tablet SH T00658ID for 28 days per cycle in the respective treatment period; no tablet-free interval
1844458|NCT00909857|Drug|Ethinyl estradiol, Levonorgestrel (Miranova)|Daily oral administration of one tablet for 28 days per cycle in the respective treatment period; no tablet-free interval
1844459|NCT00909857|Drug|Placebo Match to SH T00658ID|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
1844460|NCT00909857|Drug|Placebo Match to SH D593B|Daily oral administration of one tablet placebo for 28 days without tablet-free interval for 3 treatment cycles.
1994234|NCT03047993|Drug|CB-839|"Phase 1b: CB-839 administered at Starting Dose Level 600 mg twice a day continuously.
Phase II Starting Dose Level is RPSD from Phase 1b."
1844463|NCT00909883|Drug|Botulinum Toxin: Xeomin|45 patients with an Idiopathic Parkinson's disease and a foot dystonia. Double blind, randomized study
1844464|NCT00909883|Drug|Placebo|Placebo injection
1844465|NCT00909909|Radiation|External beam boost|3-dimensional conformal radiation therapy and intensity modulated radiation therapy
1844466|NCT00909909|Radiation|whole breast irradiation|accelerated, hypofractionated whole breast irradiation
1844467|NCT00909935|Drug|Dexmedetomidine|Initial 2 mcg/kg bolus administered over 10 minutes to achieve the Ramsey sedation score of 4 followed by an infusion of 1.5 mcg/kg/hr, which will run until patient is transferred to recovery area. Up to a further two boluses of 2 mcg/kg may be given to maintain an RSS of 4.
1844468|NCT00909948|Other|Fludarabine and total body irradiation|The patients in the second cohort will receive fludarabine 30 mg/m2/day on days -4 to -2 and 200 cGy TBI on day 0.
1844469|NCT00909948|Radiation|Total body irradiation|Patients will receive 200 cGy TBI on day 0,4-6 hours prior to HCT.
1844470|NCT00909961|Drug|Zoledronic acid|
1844517|NCT00910377|Behavioral|counseling sessions|The intervention groups received counseling sessions about breastfeeding and complementary feeding at maternity ward and at home with 7,15,30,60 and 120 days.
1844471|NCT00909974|Dietary Supplement|UNIMMAP - multiple micronutrients|"Daily supplementation of one UNIMMAP tablet
multiple micronutrient supplements (MMN): UNIMMAP: vitamin A 800µg, vitamin E 10 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 18 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 400 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
1844472|NCT00909974|Dietary Supplement|Food supplement enriched with multiple micronutrients|"One dose of 72g per day during whole pregnancy
Recipe of food supplement: 33% peanut butter, 32% soy flour, 15% vegetable oil, 20% sugar, UNIMMAP in powdered form Nutritional composition (per dose of 72g) Energy 1.56 MJ, protein 14.7 g, vitamin A 881 µg, vitamin E 13 mg, vitamin D 5 µg, vitamin B1 1.4 mg, vitamin B2 1.4 mg, niacin 21 mg, vitamin B6 1.9 mg, vitamin B12 2.6 µg, folic acid 461 µg, vitamin C 70 mg, iron 30 mg, zinc 15 mg, copper 2 mg, selenium 65 µg, and iodine 150 µg"
1844473|NCT00909987|Drug|Capecitabine|PO 1000 mg/m2 bid during day 1 to 15 for 3 cycles (every cycle has 3 weeks)
1844474|NCT00909987|Drug|Oxaliplatin|IV 130 mg/m2 during day 1 for 3 cycles (every cycle has 3 weeks)
1844475|NCT00909987|Drug|Bevacizumab|IV 7.5 mg/Kg during 30 minutes day 1 during 4 cycles (every cycle has 3 weeks)
1844476|NCT00909987|Radiation|Radiotherapy|Total dose 50.4 Gy administered during 28 days (1.8 Gy/day in 5 weeks).
1844477|NCT00909987|Drug|Capecitabine during all Radiotherapy period|825 mg/m2 bid
1844478|NCT00909987|Procedure|Total Mesorectal Excision (TME)|4 weeks from the last chemotherapy dose. In those patients who receive radiation TME wil be performed six weeks after
1844479|NCT00910000|Drug|Vorinostat|
1844480|NCT00910000|Drug|Carboplatin|
1844481|NCT00910000|Drug|Gemcitabine|
1844482|NCT00910013|Drug|Ropivacaine|0.5% intra-articular ropivacaïne (20cc)
1844483|NCT00910026|Procedure|low tidal volume ventilation|6 ml/kg tidal volume ventilation
1844484|NCT00910026|Procedure|high tidal volume ventilation|12 ml/kg tidal volume ventilation
1844485|NCT00910039|Drug|sunitinib malate|Treatment will be administered on an outpatient basis. Patients will receive sunitinib 37.5mg once daily in the morning without regard to meals in repeated 6-week cycles comprising daily therapy for 4 weeks followed by a 2-week rest period. Patients who tolerate this dose may increase the dose to 50 mg once daily.
1844486|NCT00910039|Other|cognitive assessment|The memory test has six alternate forms. The other tests measure motor and information processing speed and are relatively resistant to the effects of practice. The total time for test administration, including the QOL and symptom measures, is 40 minutes.The difference between the pre-treatment baseline and follow-up assessment scores will be determined by the reliable change (RC) index. This index is derived from the standard error of measurement (SEM) for each test in the battery: 1 (deterioration), 2 (no change), or and 3 (improved).
1844487|NCT00910052|Device|Tisseelä fibrin sealant|Fibrin sealant applied intraoperatively
1844488|NCT00910065|Drug|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 500 mg IV|Single IV dose of aspirin at a dose of 500 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
1844489|NCT00910065|Drug|D,L-lysine acetylsalicylate (Aspirin, BAY81-8781) 250 mg IV|Single IV dose of aspirin at a dose of 250 mg as bolus infusion injection in approximately 30 seconds through the vein on Day 1.
1844490|NCT00910065|Drug|Acetylsalicylic acid (Aspirin, BAYe4465) 300 mg Tablet|Single oral dose of aspirin tablet at a dose of 300 mg on Day 1.
1844491|NCT00910091|Drug|BN83495|BN83495 will be administered as a 40 mg tablet once a day orally
1844492|NCT00910091|Drug|Megestrol Acetate (MA)|MA will be administered orally as 160mg daily
1844493|NCT00910104|Drug|Omegaven®|10% Omegaven® 1g/kg/day, IV (in the vein) until the patient no longer requires parenteral nutrition or until participation in the study is terminated
1844494|NCT00910117|Drug|nimotuzumab|nimotuzumab 400 mg d1
1844495|NCT00910117|Drug|PF regimen (cisplatin and 5-FU)|cisplatin 75 mg/m2 d1 and 5-FU 750 mg/m2/d CIV d1-5
1844496|NCT00910143|Procedure|conventional rectal surgery|type of rectal surgery before the introduction of TME
1844497|NCT00910143|Procedure|total mesorectal excision|total mesorectal excision
1844498|NCT00910156|Device|Airtraq laryngoscope|Airtraq intubation
1844499|NCT00910156|Device|Glidescope laryngoscope|glidescope intubation
1844500|NCT00910156|Device|Macintosh laryngoscope|Macintosh intubation
1844501|NCT00910169|Other|inpatient treatment|Hospitalisation modalities are described but are naturalistic
1844502|NCT00910182|Procedure|splenorrhaphy|surgical treatment of splenic injuries after blunt abdominal trauma.
1844503|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 3000 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
1844504|NCT00910234|Drug|recombinant human erythropoietin (rhEpo)|rhEpo is administered 100 U/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
1844505|NCT00910234|Drug|Normal saline|normal saline is administered 0.5/kg, iv at 3 to 6 hours after birth, and at 24 hours interval for another 2 doses.
1844506|NCT00910247|Drug|Eslicarbazepine acetate|800 to 2400 mg once daily (QD)
1844507|NCT00910260|Procedure|Blood analysis|Serum 25-hydroxyvitamin D, calcium, parathormone, phosphate, C-reactive protein and albumin levels will be measured at every visit: day 0, day 7 and day 84.
1844508|NCT00910273|Drug|etanercept|etanercept 50 mg/week
1844509|NCT00910286|Other|Pulmonary Ventilator|The aim of the present study was to compare two different cycling off modes in PSV, a fixed and other automatic, about ventilatory mechanic variables, breathing comfort and patient-ventilator asynchrony patterns
1844510|NCT00910299|Drug|Prasugrel|One time 60 milligram (mg) oral loading dose and 10 mg once daily oral maintenance dose up to 6 months.
1844511|NCT00910299|Drug|Clopidogrel|75 mg oral daily maintenance dose up to 6 months.
1844512|NCT00910312|Device|Ice-Sense|Ice-Sense Cryoprobe
1844513|NCT00910325|Procedure|Laparoscopic-assisted transvaginal cholecystectomy|Trans-vaginal Cholecystectomy with Laparoscopic Assistance
1844514|NCT00910338|Device|PFMT with Extracorporeal Biofeedback|"Pelvic Floor Muscle Training with Extracorporeal Biofeedback Device for 12 weeks
Twice a week for the first 4 weeks
Once a week for the next 8 weeks"
1844515|NCT00910351|Drug|Ciprofloxacin (Cipro, BAYQ3939)|25 mg inhaled Ciprofloxacin
1844516|NCT00910364|Other|Exercise|Exercise
1845205|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
1844518|NCT00910390|Other|Slow freezing|Embryos at different developmental stages will be frozen using a solution that contains propanediol and sucrose, individually placed in high security straws, cooled with a programmator and stored in liquid nitrogen.
1844519|NCT00910390|Other|VIT-Irvine|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
1844520|NCT00910390|Other|Vit-Vitrolife|Embryos at different developmental stages will be frozen using the vitrification solution according to the manufacturer's instructions, individually placed in high security vitrification devices and plunged directly in liquid nitrogen for storing.
1844521|NCT00910403|Procedure|LASIK|Excimer Laser Ablation using LASIK
1844522|NCT00910416|Drug|propofol, remifentanil, atracurium|propofol, remifentanil, atracurium dosages are adapted according to clinician's judgment
1844523|NCT00910416|Drug|propofol, remifentanil, atracurium, sevoflurane|dosages are adapted according to clinician's judgment
1844524|NCT00910416|Device|EEG monitoring|simultaneous monitoring with Bis and Neurosense
1844525|NCT00910429|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521 - 1 mg tid - 2,5 mg tid orally until end of study
1844526|NCT00910442|Dietary Supplement|Glutathione precursors|HIV+ patients were assigned to 7 day diets containing either NAC or Gln
1844527|NCT00910455|Drug|SRX246|single oral dose of SRX246 capsule
1844528|NCT00910455|Drug|Placebo|Single oral dose of placebo capsule
1844529|NCT00910468|Procedure|Robot-assisted Laparoscopic myomectomy|Robot-assisted Laparoscopic myomectomy
1844530|NCT00910481|Device|Intra-Aortic Balloon Pump|Elective IABP insertion before PCI
1844531|NCT00910494|Radiation|Photon Radiosurgery System IORT|
1844532|NCT00910494|Radiation|Photon Radiosurgery System IORT|
1844533|NCT00910507|Behavioral|Exercise counseling|Each participant in the experimental group receives 2 months of exercise counseling from the same physical therapist as described in previous research. In short, during each exercise counseling session, the physical therapist addresses the benefits of exercise for people with type 2 diabetes, advises each participant to adhere to the prescribed exercise program, and assists each participant by reviewing the prescribed exercise program. Exercise counseling is tailored to the stage of exercise behavior as described in previous literature. The experimental group is also provided access to a fitness center.
1844534|NCT00910507|Behavioral|Supervised exercise training|Participants who are randomly allocated to the comparison group receive a 2-month supervised exercise program. Each participant in the comparison group receives the same prescribed exercise program as the experimental group and is supervised during each exercise training session by a trained co-investigator in a controlled exercise laboratory setting.
1844535|NCT00910520|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
1844536|NCT00910520|Drug|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
1844537|NCT00910533|Drug|ceftriaxone|ceftriaxone 2 g od i.v. for 14 days
1844538|NCT00910546|Device|visicoil gold marker 0.7 x 20 mm|CT - guided implantation into lung tumors
1844539|NCT00910572|Device|Yttrium-90 microspheres (Therasphere MDS Nordion)|Y-90 is incorporated into very tiny glass beads (microspheres: Therasphere MDS Nordion) and is injected into the liver tumor through the hepatic arteries, which are responsible for the feeding of the neoplastic liver tissue. Since the microspheres are unable to pass through the micro-vasculature of the liver parenchyma and tumor they are trapped at those sites and exert a local radio-therapeutic effect.
1844540|NCT00910585|Behavioral|Coaching, providing social support|Active telephone and in person coaching
1844541|NCT00910598|Drug|glatiramer acetate|20 mg daily s.c. for 1 year
1994235|NCT03047993|Drug|Azacitidine|Phase 1b and II: Azacitidine 75 mg/m2 by vein or as an injection under the skin about 1 hour after taking CB-839 on Days 1-7 of every 28 day cycle.
1844543|NCT00910624|Drug|Boceprevir|Boceprevir, 200-mg capsules, 800 mg three times a day (TID) orally (PO)
1844544|NCT00910624|Biological|Peginterferon alfa-2b (SCH 54031)|Peginterferon alfa-2b 1.5 µg/kg/week subcutaneously (SC)
1844545|NCT00910624|Drug|Ribavirin (SCH 18908)|Ribavirin weight-based dosing (WBD) 600 mg/day to 1400 mg/day PO divided twice daily (BID).
1844546|NCT00910637|Drug|Gestodene/EE Patch (BAY86-5016)|55 mg ethinyl estradiol & 2.1 mg gestodene, 21 days for 13 cycles
1844547|NCT00910650|Biological|F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells|After chemotherapy, patients receive up to 1 x 10(9) MART-1 F5 TCR transgenic T cells infused i.v., 1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally, and low dose IL-2 500,000 IU/m2 s.c. twice daily for 14 days.
1844548|NCT00910650|Drug|non-myeloablative conditioning chemotherapy|Patients receive non-myeloablative conditioning chemotherapy with Cyclophosphamide 60 mg/kg/day x 2 days and Fludarabine 25 mg/m2/day i.v. over 30 minutes for 4 days
1844549|NCT00910663|Drug|Mycophenolate Mofetil|250 mg Capsule
1844550|NCT00910663|Drug|CellCept®|250 mg Capsule
1844551|NCT00910676|Drug|Diprosone|"Start of treatment: as soon as the EGF-R inhibitors treatment begins
Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening
Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.
Period of treatment: 8 weeks"
1844552|NCT00910689|Drug|Propranolol or nadolol|Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated. If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second medication (nadolol). Participants initially receive a single 40 mg capsule of nadolol and increased to 2 capsules (80 mg) as tolerated. At week 12 dose stabilized at highest tolerated level. In evaluation phase, an increase to 4 capsules of long acting propranolol hydrochloride (240 mg) or 3 capsules of nadolol (120 mg) permitted.
1844553|NCT00910689|Drug|Placebo control|Placebo
1844824|NCT00912652|Behavioral|Health Education Control|Health education control group will receive 16 session of health education related to diet and exercise over a two-year period.
1844554|NCT00910689|Behavioral|Behavioral Migraine Management (BMM)|"Session 1: Overview of the pathophysiology of migraine; introduce muscle stretching, deep breathing, PMR, imagery; Session 2: Development trigger management strategy; Use early warning signs as a cue to use behavioral migraine management and acute medication; Session 3:(a) continue with basic migraine management skills if these skills have not been mastered;(b) introduce cognitive-behavioral stress-management, if stress is a salient migraine trigger;(c) introduce thermal biofeedback (hand warming) training with a portable home thermal biofeedback device, if stress is not a notable migraine trigger. Session 4: Review problems using various behavioral migraine management skills; Prepare written migraine management plan; Relapse prevention addressed"
1844555|NCT00910689|Drug|Optimal Acute Therapy|This acute therapy protocol emphasized treatment with a 5-HT1B/D-agonist or triptan. Nonsteroidal anti-inflammatory (NSAID; ibuprofen) and anti-emetic (metoclopramide) medication could be added as needed. The choice of triptans (rizatriptan®, sumatriptan®), the route(s) of triptan administration (oral, nasal spray, subcutaneous injection), and the addition of a NSAID, or anti-emetic were tailored to participant preference, treatment history and acute therapy response. Individualized handouts and a phone call (week 3) of the OAT Run-in were used to help participants evaluate and optimize their acute therapy.
1844556|NCT00910702|Device|foldable capsular vitreous body(FCVB)|the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB) after PPV
1844557|NCT00910715|Drug|doxycycline|doxycycline 100 mg bid, 10 days
1844558|NCT00910715|Drug|doxycycline|doxycycline 100 mg bid, 15 days
1844559|NCT00910715|Drug|placebo|control subjects without a history of Lyme borreliosis
1844560|NCT00910728|Drug|AZD1480|Oral capsule 2.5 mg, 10 mg and 40 mg
1844561|NCT00910741|Drug|Nanoplatin (NC-6004) and Gemcitabine|
1844562|NCT00910754|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg (4 x 250 mg tablets) administered orally once daily.
1844563|NCT00910754|Drug|Prednisone|Prednisone 5 mg tablets administered orally twice daily.
1844564|NCT00910767|Device|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
1844565|NCT00910767|Device|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
1844566|NCT00910780|Drug|Aripiprazole|via oral tablets, everyday
1844567|NCT00910780|Drug|Zyprexa|via oral tablets, taken once daily
1844568|NCT00910780|Drug|Risperdal|via oral tablets, taken once daily
1844569|NCT00910793|Drug|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
1844570|NCT00910806|Drug|TMC207; nevirapine|
1844571|NCT00910832|Drug|Eductyl suppository|one suppository every morning during 21 days
1844572|NCT00910832|Drug|Placebo suppository|placebo suppository every morning during 21 days
1844573|NCT00910845|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (botulinum toxin Type A) 100 U injected into the detrusor at Day 1, followed by a repeat injection of onabotulinumtoxinA 100 U after a minimum of 12 weeks (if applicable). Or, if placebo is administered at Day 1, onabotulinumtoxinA 100 U injected after a minimum of 12 weeks (if applicable).
1844574|NCT00910845|Drug|normal saline|Normal saline (placebo) injected into the detrusor at Day 1.
1844575|NCT00910858|Drug|Lenalidomide|Lenalidomide 5-mg capsules for oral administration
1844576|NCT00910858|Drug|Recombinant human erythropoietin|Recombinant human erythropoietin (rhu-EPO) subcutaneous injection of 40,000 units.
1844577|NCT00910871|Drug|TMC207|TMC207 400mg once daily for 2 weeks then 200mg three times a week for 22 weeks.
1844578|NCT00910871|Drug|Background Regimen (BR) for MDR-TB|Background Regimen (BR) of antibacterial drugs used in the treatment of TB according to national TB program and selected at the baseline visit as specified in the protocol for up to 96 weeks.
1844579|NCT00910884|Other|laboratory biomarker analysis|No supplements are given
1844580|NCT00910884|Procedure|therapeutic dietary intervention|Given orally daily for 12 months
1844581|NCT00910897|Drug|Velcade-Dexamethasone|
1844582|NCT00910897|Drug|Velcade-Thalidomide-Dexamethasone|
1844583|NCT00910910|Drug|Lenalidomide|"For patients with normal renal function (defined as CrCl ≥ 60 mL/min), 5 mg once daily on Days 1 through 28 of the first 28-day cycle, 10 mg once daily on Days 1 through 28 starting at the second cycle, 15 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first.
For patients with moderate renal impairment (defined as CrCl ≥ 30 to < 60 mL/min), 2.5 mg once daily on Days 1 through 28 of the first 28-day cycle, 5 mg once daily on Days 1 through 28 starting at the second cycle, 7.5 mg once daily starting at the third cycle and for the remainder of the study until PD or unacceptable toxicity, whichever occurs first."
1844584|NCT00910910|Drug|Chlorambucil|Patients assigned to the chlorambucil arm will receive oral chlorambucil tablets at 0.8 mg/kg on Days 1 and 15 of each 28-day cycle for a total duration of 12 months (approximately 13 cycles).
1844585|NCT00910923|Drug|JNJ-38431055|
1844586|NCT00910936|Behavioral|Exercise|12 weeks endurance training, 3 times weekly for 35 minutes
1994289|NCT03035474|Other|Direct Engagement|Health system engagement to improve local QI programs
1844590|NCT00910975|Drug|Peg-interferon-alfa2a (Pegasys)|Peg-interferon-alfa2a 180 µg per week
1844591|NCT00910975|Drug|Ribavirin (Copegus)|Ribavirin 1000 or 1200 mg per day depending on if body weight is below or above 75 kg
1844592|NCT00910988|Drug|Olanzapine|
1844593|NCT00910988|Drug|Ziprasidone|
1844594|NCT00911001|Behavioral|No Drug|Patients in daily life clinical treatment receiving pharmacological agents to prevent VTE.
1844595|NCT00911014|Other|Questionnaire|From September 2005 to January 2006, 58 women who underwent surgery for vesicovaginal fistula at the National Hospital Fistula Center in Niamey, Niger were interviewed post-operatively using a questionnaire developed to investigate demographic, social, economic, and cultural factors that may affect formation of fistula. Also included in this questionnaire was evaluation of access to health care as well as patient understanding of counseling regarding their surgery and post-operative instructions, in particular information about future fertility and fistula development.
1845206|NCT00916058|Drug|Bendamustine|30 mg/m2 given on day 2 of melphalan
1844596|NCT00911027|Drug|Contrast-enhanced ultrasound guided biopsy|"One to two bolus (each 2.4mL) of SonoVue per patient in the optimization part
One to four bolus (each 2.4mL) of SonoVue per patient in the main part"
1844597|NCT00911027|Procedure|ultrasound guided systematic biopsy|Current practice of ultrasound guided systematic biopsy
1844598|NCT00911053|Drug|Melatonin|Melatonin will be administered under FDA IND #26,318, doses between 0.025 mg and 20 mg.
1844599|NCT00911053|Behavioral|Regular Sleep Schedule|Subjects will maintain a regular sleep schedule of their choosing.
1844600|NCT00911053|Behavioral|Light|Subjects will be exposed to light.
1844601|NCT00911066|Drug|MLN4924|"MLN4924 intravenous (IV) on a 21-day cycle on one of the following schedules:
Days 1, 3, and 5, followed by a rest period of 16 days (Schedule A)
Days 1, 4, 8, and 11, followed by a rest period of 10 days (Schedule B)
Continuous weekly dosing on Days 1, 8, and 15 (Schedule C)
Days 1, 4, 11, 15 for Cycle 1 only; Days 1, 4, 8, 11 for all subsequent cycles (Schedule D)
Dosing on Days 1, 3, and 5 in patients with high-grade MDS or AML (Schedule E)"
1844602|NCT00911066|Drug|Azacitidine|Azacitidine will be administered (IV or subcutaneous (SC)) on Days 8 to 12 and Days 15 and 16 in Cycle 1, and on Days 1 to 5 and Days 8 to 9 (Schedule D)
1844603|NCT00911079|Procedure|Hyperthermia|Single course of Catheter-based Ultrasound Hyperthermia (within approximately 2 hours of a Standard-of-care High Dose Rate (HDR) Brachytherapy)
1844604|NCT00911079|Radiation|HDR brachytherapy|Completion of standard-of-care high dose rate (HDR) Brachytherapy treatments (radiation fractions) using Session #1 catheter implants
1844605|NCT00911092|Procedure|Blood sampling|Before any study treatment, 14 days after radiotherapy, 15 weeks after radiotherapy
1844606|NCT00911092|Radiation|Radiation|Week 1 to week 5-6 1.8-2 Gys/fraction, 5 days a week for a total of 5 to 6 weeks
1844607|NCT00911092|Drug|Chemotherapy (Fluorouracil and Cisplatin)|"At weeks 1, 5, 8 and 11
Day 1 to day 4: Fluorouracil 1 gr/m²/day
Day 1 or 2: Cisplatin 75 mg/m²"
1844608|NCT00911118|Radiation|Hypofractionated, image-guided, intensity-modulated external beam radiation|A standard dose escalation design is utilized, with the initial treatment assigned as 6.5 Gy/fraction for five fractions to a total dose of 32.5 Gy. For any given dose tier, an initial cohort of 30 patients will be treated. However to adjust for potentially inevaluable patients who dropout prior to a full toxicity collection to assess potential DLTs enrollment of up to five additional patients per cohort can occur, per PI's discretion. Dose escalation will proceed if < 10% of the 30 patients treated per tier exhibit any dose limiting toxicity (DLT) once the entire tier cohort has a minimum follow-up of 3 months and half the tier cohort has a minimum follow-up of 6 months. Dose escalation to the next tier will occur by increasing the dose per fraction by 0.5 Gy while keeping the fraction number constant at 5, leading to a total dose increase of 2.5 Gy per dose tier.
1844609|NCT00911131|Device|Capsule endoscopy (PillCam ESO)|The capsule endoscope is placed in the mouth and the patient is asked to swallow it with 100cc of water with simethicone in the supine position. Recording is done for 2 minute in this position and then the head is elevated to 30 degrees for 2 minutes and then 60 degrees for 1 minute. After 1 minute, the patient sips 10cc of water and after 15 seconds, they sit upright and sip water again. They can then walk and resume normal activity for 15 minutes.
1844610|NCT00911131|Procedure|EGD|Patients will undergo conventional EGD under conscious sedation for routine screening of esophageal varices.
1844611|NCT00911131|Device|Capsule endoscopy (PillCam ESO) with abdominal binder|An abdominal binder with and inflatable girdle is wrapped around the stomach prior to swallowing the capsule endoscope. The girdle is inflated to 10mmHg for 10 minutes. The capsule is swallowed by the patient and the routine method for the procedure is performed.
1844612|NCT00911144|Biological|GSK Biologicals' Synflorix™ (Pneumococcal vaccine GSK1024850A)|Intramuscular injection, administered as a single dose
1844613|NCT00911144|Biological|Wyeth-Lederle's Prevenar™|Intramuscular injection, administered as a single dose
1844614|NCT00911144|Biological|GSK Biologicals' Hiberix™|Intramuscular injection, administered as a single dose
1844615|NCT00911157|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (< 50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
1844616|NCT00911157|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
1844617|NCT00911170|Drug|Pegfilgrastim|Administered as a single 6 mg subcutaneous injection using a pre-filled syringe. There will be no dosage adjustments for investigational product.
1844618|NCT00911170|Drug|Placebo|Administered as a single subcutaneous injection using a pre-filled syringe.
1844619|NCT00911170|Biological|Bevacizumab|5 mg/kg by intravenous (IV) infusion on day 1 of each 14-day cycle.
1844620|NCT00911170|Drug|Standard Chemotherapy|"Each participant received one of the following chemotherapy regimens at the discretion of treating physician:
FOLFOX: Oxaliplatin, leucovorin, and 5-fluorouracil; FOLFIRI: Irinotecan, leucovorin and 5-flurouracil."
1844621|NCT00911183|Biological|filgrastim|Given subcutaneously
1844622|NCT00911183|Biological|pegfilgrastim|Given subcutaneously
1844623|NCT00911183|Biological|rituximab|Given IV
1844624|NCT00911183|Drug|cyclophosphamide|Given IV
1844625|NCT00911183|Drug|liposome-encapsulated doxorubicin citrate|Given IV
1844626|NCT00911183|Drug|prednisone|Given orally
1844627|NCT00911183|Drug|vincristine sulfate|Given IV
1844628|NCT00911196|Other|Retrospective analysis of already archived samples|Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
1844629|NCT00911209|Behavioral|Dietitian counselling|Once a week for 14 weeks then 1 monthly visit. Visits last 40-50 minutes
1844630|NCT00911222|Other|non-interventional|non-interventional
1844631|NCT00911235|Drug|Fesoterodine|Single 8 mg oral dose of fesoterodine
1844632|NCT00911235|Drug|fesoterodine plus fluconazole|On Day 1, fluconazole (200 mg oral dose) will be given 1 hour before and approximately 11 hour following a single 8 mg oral dose of fesoterodine (fesoterodine SD). Fluconazole will also be administered 200 mg BID on the Day 2 (ie, at approximately 24 and 36 hours following the fesoterodine SD treatment given on Day 1)
1844633|NCT00911248|Drug|PTC299|PTC299 will be administered orally at 100 mg/dose twice per day for up to 1 year or until tumor progression
1844634|NCT00911261|Drug|Oxymorphone Extended Release|"Study Medication: Oxymorphone ER 5 mg, 10 mg, 20 mg, and 40 mg tablets
Rescue Medication: Oxymorphone IR 5 mg and 10 mg tablets
Treatment will consist of up to 12 months of dosing with Oxymorphone ER."
1844635|NCT00911274|Drug|Mycophenolate Mofetil|250 mg Capsule
1844636|NCT00911274|Drug|CellCept®|250 mg Capsule
1844637|NCT00911287|Drug|Oxymorphone extended release|Study Medication: Oxymorphone ER 5 mg, 10 mg, and 20 mg tablets. Rescue Medication: Oxymorphone IR 5 mg tablets. Treatment will consist of up to 6 months of dosing with oxymorphone ER.
1844638|NCT00911300|Drug|fondaparinux|Comparison of different drugs
1844639|NCT00911300|Drug|unfractionated heparin|Comparison of different drugs
1844640|NCT00911300|Drug|Vitamin-K-Antagonist|Comparison of different drugs
1844641|NCT00911313|Drug|Letrozole tablets (Femara; Novartis Pharma, Switzerland)|2.5 mg letrozole daily from day 3 of the menses for 5 days
1844642|NCT00911313|Drug|metformin HCl (Cidophage®; CID,Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks
1844643|NCT00911313|Drug|CC (Clomid®; Global Napi Pharmaceuticals, Cairo, Egypt)|150 mg CC for 5 days starting from day 3 of menstruation
1844644|NCT00911326|Drug|Lymphoseek|Single injection of 50 micrograms Lymphoseek radiolabeled with either 0.5 mCi (for same day surgery) or 2.0 mCi (for next day surgery) of Tc 99m
1844645|NCT00911339|Drug|Atorvastatin|Atorvastatin 10 mg associated with stent genous
1844646|NCT00911339|Drug|Atorvastatin|Atorvastatin 80 mg associated with stent genous
1844647|NCT00911352|Device|Frozen gel glove (Elasto-Gel Mitten)|Gel glove is frozen for > 3 hours at -5 to -30°C prior to use. Each patient wears a triple glove set (surgical glove overlaid with cotton glove, overlaid with gel glove) on their intervention hand. Gloves are worn for duration of infusion (15 mins pre, 60 minutes intratreatment and 15 mins post) to ensure the patients' peripheries are vasoconstricted on commencement of the infusion and for enough time afterwards to ensure circulating drug does not reach the target area. Because of the duration of the infusion, more than one gel glove will be used successively (for 45 minutes each) to maintain a consistently low temperature on the hand and nails.
1844648|NCT00911365|Biological|autologous mesenchymal stem cells|"4*107 stem cell (100ml) Intra arterial infusion/ one time, then 4*107 stem cell(100ml)Intravenous infusion 3 times/monthly
-> Total four times"
1844649|NCT00911365|Biological|normal saline|saline
1844650|NCT00911378|Procedure|Pressure support ventilation|These patients are weaned by gradual reduction of pressure support and extubated when they tolerate a pressure support of 7 cm of water for one hour.
1844651|NCT00911378|Procedure|Spontaneous breathing trials|These patients are weaned by giving a T piece trial with 8 cm of water pressure support and extubated when they tolerate it for one hour.
1844652|NCT00911391|Device|Oesophageal Doppler|Non-invasive measurement of doppler-derived cardiovascular variables (CO, aortic flow rate). Used safely over 800, 000 times
1844653|NCT00911391|Procedure|Intraoperative fluid restriction|Current best practice of avoiding fluid overload by intraoperative fluid restriction
1844654|NCT00911404|Behavioral|Low CHO|"Diet with 40% total calories from carbohydrates. In the Low-CHO arm, 15% of calories from carbohydrates will be substituted by monounsaturated fat."
1844655|NCT00911404|Dietary Supplement|High CHO diet|Diet with 55% total calories from carbohydrates.
1844656|NCT00911417|Device|Pathway Jetstream Atherectomy System|The Pathway Jetstream System is a commercially available rotating, aspirating, expandable catheter for active removal of plaque and blood clots in peripheral arteries of the lower limbs.
1844657|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 1.6 mg|Dacarbazine 800 mg/m2 IV on day 1;Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 1.6 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
1844658|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
1844659|NCT00911443|Biological|Dacarbazine + Interferon alpha + Thymosin-alpha-1 6.4 mg|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 Thymosin-alpha-1 6.4 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
1844660|NCT00911443|Biological|Dacarbazine + Thymosin-alpha-1 3.2 mg|Dacarbazine 800 mg/m2 IV on day 1; Thymosin-alpha-1 3.2 mg SC from day 8 to 11 and from day 15 to 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
1844661|NCT00911443|Drug|Dacarbazine + Interferon alpha|Dacarbazine 800 mg/m2 IV on day 1; Interferon alpha 3MIU SC on day 11 and 18 of each 28 day cycle up to 6 cycles or until progression or unacceptable toxicity develops.
1844662|NCT00911456|Procedure|Image-Guided Radiation Therapy using 3D Ultrasound Guided-Therapy|Subjects will have 3 x 3DUS during radiation therapy
1844663|NCT00911456|Procedure|Ultrasound Guided Imaging|"Subjects will undergo a CT scan and an US of your breast for the planning of radiation therapy after a breast conserving operation.
About 1 week after the start of radiation treatment subjects will have a second CT and US. During this visit subjects will have one CT and three US's. These US's will be performed by 3 different radiation therapists. Part of the current study is to compare the similarity of the 3 US pictures taken by different individuals."
1844664|NCT00911456|Procedure|3 DUS|3 DUS
1844665|NCT00911469|Drug|AS902330|3, 10, 30, 100 or 300 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30, 100, 300 µg or highest tolerated dose intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
1844666|NCT00911469|Drug|Placebo|Placebo or, 3, 10, 30, 100 or 300 µg intra-articular injection per subject in SAD cohorts and placebo or, 10, 30, 100, 300 µg or highest tolerated dose of AS902330 intra-articular injection per week for three weeks per subject in MAD cohorts.
1844667|NCT00911495|Drug|GMI-1070|Intravenous GMI-1070 given as two doses over the course of one day
1844668|NCT00911508|Device|Left atrial ablation|"St. Jude: Livewire TC™ , Therapy™ Dual / Thermocouple, Safire,Therapy Cool Path
Biosense Webster: NAVI-STAR, NAVI-STAR/NAVI-STAR DS, Celsius Braided/Long Tip, NAVI-STAR™ and Celsius™ ThermoCool, NAVI-STAR® RMT, Celsius® RMT, ThermoCool® SF
Medtronic CryoCath LP: Freezor®/Freezor MAX®, Artic Front®, Cardiac Ablation System
Bard: Stinger
Boston Scientific: Blazer II RF/XP, Blazer RPM, Chilli II Cooled, SteeroCath"
1844669|NCT00911508|Drug|Rate or Rhythm Control Therapy|"Rate control: Metoprolol 50-100mg, Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg, Carvedilol 6.25-25mg, Diltiazem 180-240mg, Verapamil 180-240mg, Digoxin 0.125-0.25mg
Rhythm control: Propafenone 450-625mg, Flecainide 200-300mg, Sotalol 240-320mg, Dofetilide 500-1000mcg, Amiodarone 200-400mg, Quinidine 600-900mg, Dronedarone 800mg"
1844670|NCT00911521|Drug|human papillomavirus vaccination (Gardasil)|3 doses of the human papillomavirus vaccines to be given at baseline, month 2 and month 6
1844671|NCT00911534|Drug|rabeprazole sodium|One rabeprazole extended release (ER) 50 mg capsule daily; rescue medication will be provided to subjects to take as needed.
1844672|NCT00911534|Drug|Placebo|One rabeprazole placebo capsule daily; rescue medication will be provided to subjects to take as needed.
1844673|NCT00911547|Drug|montelukast sodium|10 mg tablet taken once daily at bedtime for 16 weeks
1844674|NCT00911547|Drug|beclomethasone|200 ug inhaled, taken twice daily for 16 weeks
1844675|NCT00911547|Drug|Placebo inhaler|placebo inhaler taken twice daily for 16 weeks
1844676|NCT00911547|Drug|placebo tablet|placebo tablet taken once daily at bedtime for 16 weeks
1844677|NCT00911560|Biological|adjuvant OPT-821 in a vaccine containing two antigens (GD2L and GD3L) covalently linked to KLH|Patients receive a total of 7 subcutaneous injections, at weeks 1, 2, 3, 8, 20, 32, and 52. Minor schedule adjustments are permitted, as needed, provided that there is a minimum of 6 days between injections. Induction of antibody response against the target antigens will be assessed. A fixed dose of oral β-glucan (40 mg/kg/day) is started at week 6 or 7(to allow time for generation of antibodies), and continued as approximately 2 weeks on, 2 weeks off, up to 1 cycle after the last vaccination. Neutrophils will be tested for glucan effects on cytotoxicity. Antineuroblastoma activity will be monitored using standard radiographic and bone marrow studies, as well as RT-PCR for measurement of minimal residual disease in blood and bone marrow. The treatment schedule may require minor adjustment as clinically indicated or due to unforeseen circumstance (e.g., due to PDH closure for holidays or due to inclement weather).
1844678|NCT00911573|Drug|Tigecycline|50 mg IV every 12 hours up to 14 days
1844679|NCT00911573|Drug|Clindamycin (or Vancomycin if needed)|For clindamycin 10mg/kg (not to exceed 900mg) IV every 8 hours up to 14 days. For vancomycin 15mg/kg (not to exceed 2g/day and adjusted as needed for renal impairment) IV every 8 hours
1844680|NCT00911586|Drug|Testosterone undecanoate|Oral testosterone undecanoate, twice daily for one month.
1844681|NCT00911599|Device|A Class BFH|A Class BFH versus Metal on Poly
1844682|NCT00911599|Device|Metal on Polyethylene|A Class BFH versus Metal on Poly
1844683|NCT00911612|Drug|Colesevelam|Welchol (Colesevelam HCL) 1.875 gram twice daily for 12-14 days
1844684|NCT00911612|Drug|Placebo|Inert capsule matching the study drug, given twice daily
1844685|NCT00911625|Drug|0.5 units/kg daily insulin|Participants randomized to receive this intervention will receive a standard-dose of 0.5 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
1844686|NCT00911625|Drug|0.25 units/kg daily insulin|Participants randomized to receive this intervention will receive an experimental dose of 0.25 units/kg daily insulin. Half of this dose will be given as glargine and the other half will be given as glulisine.
1844687|NCT00911638|Behavioral|Patient decision aid|"Patients will receive i) Patient education:usual take home education brochure from recruiting hospital ii)a video/DVD PtDA for either hip (Treatment choices for hip osteoarthritis) or knee (Treatment choices for knee osteoarthritis) © Health Dialog 2005.
iii) a personal decision form:an interactive form used by patients after the DVD to elicit their knowledge, values, preferred option, and perceptions of the decision making process.
iv) Referred onward to the surgeon with their preferences for surgery using a standardized report of their clinical findings plus decisional data (knowledge, values, preference)."
1844688|NCT00911638|Behavioral|Usual care|"Patients will receive i) the usual take-home educational brochure available at the recruiting hospital describing preparation for surgery after the decision is made, recovery after surgery, and discharge plans.
ii) Referral onward to surgeon with a standardized report of clinical findings only"
1844689|NCT00911651|Drug|Salbutamol|400 µg inhalation once
1844690|NCT00911651|Drug|ipratropium bromide|80 µg inhalation once
1844691|NCT00911664|Dietary Supplement|Vitamin D|Weekly dose of 5600 IU (800 IU per day)
1844692|NCT00911664|Drug|No supplementation|Control
1844693|NCT00911664|Dietary Supplement|Vitamin D|Weekly dose of 11,200 IU (1600 IU per day)
1844694|NCT00911716|Biological|bevacizumab|
1844695|NCT00911716|Drug|cyclophosphamide|
1844696|NCT00911716|Drug|docetaxel|
1844697|NCT00911716|Procedure|adjuvant therapy|
1844698|NCT00911742|Drug|Tramadol Contramid OAD|1 Tramadol Contramid OAD 200 mg tablet as a single dose
1844699|NCT00911742|Drug|Zytram|1 Zytram 200 mg tablet as a single dose
1844700|NCT00911755|Procedure|Endotracheal Intubation|This study is comparing 2 currently accepted methods of endotracheal intubation: laryngoscopy and videolaryngoscopy
1844701|NCT00911755|Procedure|Endotracheal Intubation|
1844702|NCT00911768|Dietary Supplement|Korean Red Ginseng Powder Capsule|Generic name: Korean Red Ginseng Powder Capsule Original herb name: Panax ginseng Form and contents: Capsule with powder of steamed root of 6-year Panax ginseng Dosage and frequency: 6 g per day (twice a day), Oral administration Administration duration: 56 days in the study
1844703|NCT00911768|Dietary Supplement|Corn-starch powder with ginseng flavor|"There is no specific name because this intervention is placebo. This placebo has the same form, color and flavor as Korean Red Ginseng Powder Capsule.
The dosage form, dosage, frequency and duration is also same as experimental intervention (Korean Red Ginseng Powder Capsule).
Main contents: corn-starch with Panax ginseng flavor"
1844704|NCT00911781|Other|No intervention|We are only asking for photographs from parents.
1844705|NCT00911794|Other|Disclosure Writing (Written Disclosure Therapy)|Patients write about a stressful life experience
1844706|NCT00911794|Other|Neutral (Sham) Writing|Patients write about neutral subjects
1844707|NCT00911807|Drug|Cerebrolysin + donepezil|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.
Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
1844708|NCT00911807|Drug|Cerebrolysin + placebo|"Cerebrolysin (10 ml) was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.
Placebo for donepezil was given PO once daily during the whole study duration (28 weeks)."
1844709|NCT00911807|Drug|Donepezil + placebo|"Placebo for Cerebrolysin was given as IV infusion on five days per week for four consecutive weeks (week 1-4) with repetition of this treatment course (week 13-16) after a two-months treatment free interval, accounting for a total of 40 infusions.
Donepezil was given PO once daily during the whole study duration (28 weeks). After four weeks the daily dosage was increased from 5 mg to 10 mg."
1992718|NCT03311126|Drug|Bendamustine|Bendamustine is a chemotherapeutic agent that has dual functional properties of both an alkylating agent and a nitrogen mustard. Through these unique cytostatic properties, bendamustine is able to inhibit DNA transcription, replication, and repair. Bendamustine is approved in the U.S. for treatment of CLL and for indolent B cell NHLs progressing during or within 6 months of rituximab or a rituximab - containing regimen.
1844714|NCT00911846|Other|interview|interview using questionnaires
1844715|NCT00911859|Drug|Siltuximab11 mg/kg|Participants will receive siltuximab 11 mg/kg as a 1-hour intravenous infusion every 3 weeks in Part 1.
1844716|NCT00911859|Drug|Siltuximab 8.3 mg/kg or 11 mg/kg|Participants will receive siltuximab 8.3 mg/kg or 11 mg/kg as a 1-hour intravenous infusion every 3 weeks for 9 cycles of treatment in Part 2, Arm A and in maintenance period.
1844717|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert in Part 1.
1844718|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection for 9 cycles of the treatment period in Part 2. It will be administered twice weekly for first 4 cycles (on Days 1, 4, 8, 11, 22, 25, 29, and 32, followed by a 10-day rest period) and once weekly for next 5 cycles (on Days 1, 8, 22, and 29, followed by a 13-day rest period)
1844719|NCT00911859|Drug|Melphalan|Participants will take melphalan 9 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
1844720|NCT00911859|Drug|Melphalan|Participants will receive melphalan according to currently approved package inserts. Melphalan 9 mg/m2 will be administered orally for 9 cycles of treatment period in Part 2, Arm A.
1844721|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 will be administered orally on Days 1 to 4, followed by a 38-day rest period in Part 1.
1844722|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 orally for 9 cycles of treatment period in Part 2, Arm A.
1844723|NCT00911859|Drug|Velcade (bortezomib)|Participants will receive Velcade 1.3 mg/m2 as an intravenous bolus injection according to the current approved package insert.
1844724|NCT00911859|Drug|Melphalan|Participants will take melphalan 9 mg/m2 orally according to currently approved package insert.
1844725|NCT00911859|Drug|Prednisone|Participants will take prednisone 60 mg/m2 orally according to the package insert.
1844726|NCT00911872|Device|collagen (EVOLENCE)|injectable collagen
1844727|NCT00911885|Behavioral|Dietary Intervention|The efficacy of the two dietary change interventions will be compared in a randomized controlled trial, with 120 patients per group. The two approaches are 1) the American Heart Association (AHA) Dietary Guidelines; and 2) a simple dietary change condition that focuses on increasing fiber. Patients in both conditions will receive intensive dietary instruction for 3 months, followed by a 9 month maintenance phase. Both conditions will receive dietary instructions via individual and group sessions led by registered dietitians.
1844728|NCT00911898|Drug|MM-111|For Phase 1: Dose-escalation cohorts, drug is administered weekly via IV
1844729|NCT00911911|Procedure|Blood sampling|Taken at different times : inclusion, at the cycle 4 and at the cycle 6 during the neoadjuvant chemotherapy
1844730|NCT00911911|Procedure|BIOPSY|Biopsy at the moment of inclusion, before neoadjuvant chemotherapy
1844731|NCT00911911|Procedure|SURGERY|Surgery after neoadjuvant chemotherapy
1844732|NCT00911924|Device|iStent|Glaukos iStent, medication
1844733|NCT00911937|Drug|Fesoterodine|Fesoterodine 4mg and 8 mg tablets taken daily.
1844734|NCT00911937|Drug|Placebo|Placebo sham 4mg and 8 mg tables taken daily.
1844735|NCT00911963|Drug|VCH-222 or matching placebo|capsule, oral, 4 doses once daily or twice daily, 3 days
1844736|NCT00911963|Drug|VCH-222 or matching placebo|capsule, oral, 400 mg twice daily or 750 mg twice daily, 12 weeks
1844737|NCT00911963|Biological|peginterferon alfa-2a|subcutaneous injection, 180 μg, once weekly, 48 weeks
1844738|NCT00911963|Drug|ribavirin|tablet, oral, 1000-1200 mg daily based on body weight, 48 weeks
1844739|NCT00911976|Device|Xience V coronary stent|The Xience V stent will be implanted in aortocoronary saphenous vein bypass graft lesions
1844740|NCT00911989|Device|NOTES toolbox|Using SFT for endoscope access during Transvaginal Sleeve Gastrectomy procedure. Visualization will occur through endoscope
1844741|NCT00912002|Drug|MK-0941|A single dose of 40 mg of [14C]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
1844742|NCT00912015|Drug|Tramadol OAD|
1844743|NCT00912015|Drug|Tramadol OAD|
1844744|NCT00912015|Drug|Tramadol OAD|
1844745|NCT00912015|Drug|Tramadol OAD 100mg|
1844746|NCT00912028|Device|senofilcon A|contact lens
1844747|NCT00912028|Device|lotrafilcon B|contact lens
1844748|NCT00912028|Device|balafilcon A|contact lens
1844749|NCT00912028|Device|methafilcon A|contact lens
1844750|NCT00912028|Device|vifilcon A|contact lens
1844751|NCT00912041|Device|Placement of the BrainGate2 sensor(s) into the motor-related cortex|One or two 4x4 mm BrainGate2 sensor(s) are placed into the motor-related cortex, connected to a percutaneous pedestal. Neural recordings are made at least weekly for a year or more.
1844752|NCT00912054|Drug|DuoTrav APS|travoprost APS 40 micrograms/ml / timolol 5 mg/ml, Eye Drops, Solution, once daily
1844753|NCT00912054|Drug|Xalacom|XALACOM® (latanoprost 50 micrograms/ml / timolol 5 mg/ml) Eye Drops, Solution
1844754|NCT00912080|Genetic|genomic signature|genomic signature analysis
1844755|NCT00912093|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
1844756|NCT00912093|Drug|Placebo|Single subcutaneous injection of matching placebo
1844757|NCT00912106|Other|Synovial fluid composition and lubrication analysis|Before HA injection, synovial fluid must be drawn to increase treatment effectiveness. The drawn synovial fluid was then analyzed in the lab. There was no influence for patients enrolled because the drawn synovial fluid would usually be discarded.
1844758|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group C (high dose) will receive a loading dose of EACA of 100 mg/kg over ten minutes followed by a continuous EACA infusion at 40 mg/kg/hr, which will be continued until the end of surgery.
1844759|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group A (low dose) will receive a loading dose of EACA of 25 mg/kg over ten minutes followed by a continuous EACA infusion at 10 mg/kg/hr, which will be continued until the end of surgery
1844760|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group B (intermediate dose) will receive a loading dose of EACA of 50 mg/kg over ten minutes followed by a continuous EACA infusion at 20 mg/kg/hr, which will be continued until the end of surgery
1844761|NCT00912119|Drug|Epsilon-Aminocaproic Acid|Group D (extra low dose) will receive a loading dose of EACA of 12.5 mg/kg over ten minutes followed by a continuous EACA infusion at 5 mg/kg/hr, which will be continued until the end of surgery
1844762|NCT00912145|Drug|Alprazolam Tablets, 2 mg (Geneva Pharmaceuticals, Inc.)|
1844763|NCT00912158|Other|standard therapy (ST)|standard medical therapy
1844764|NCT00912158|Device|CPAP|Non-invasive mechanical ventilation (CPAP)
1844765|NCT00912158|Device|BIPAP|Non-invasive mechanical ventilation (BIPAP)
1844766|NCT00912171|Drug|budesonide (Aircort 50 nasal spray)|50 mcg per nostril once daily for cycles of 21 days with a break of 7 days for 6 months
1844767|NCT00912171|Drug|montelukast (Singulair)|Daily administration in 4 mg chewable tablet for children younger than 6 years or in 5 mg tablet for children 6 years and older
1844768|NCT00912184|Device|Standard polyamide high flux membrane|Standard haemofiltration; CVVH; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hr, anticoagulation as clinically indicated, bicarbonate buffered replacement fluid
1844769|NCT00912184|Device|High cut-off (super high flux) polyamide membrane|CVVH with standard haemofiltration settings; blood flow 200 ml/min, ultrafiltrate 25 ml/kg/hour, anticoagulation as clinically indicated, bicarbonate-buffered replacement fluid
1844770|NCT00912197|Dietary Supplement|Oligofructose|Participants will be asked to consume 30g of oligofructose daily for six weeks after a 2-week run-in.
1844771|NCT00912197|Dietary Supplement|Placebo|Participants will be asked to consume 3 doses (a total of 30g dietary fibres) of the placebo product daily for six weeks after a 2-week run-in
1844772|NCT00912210|Dietary Supplement|Whey protein isolate|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50g/day (two 25 g doses taken at breakfast and afternoon snack mixed with food or beverage)
1844773|NCT00912210|Dietary Supplement|Maltodextrin powder supplement|Loss of 10% baseline weight over 6 months, with whey protein isolate supplemented at 50 g / day (two 25 g doses at breakfast and afternoon snack mixed with food or beverage)
1844775|NCT00912249|Behavioral|Horticulture Therapy|We will design courses of Horticultural therapy to provide to the Patients in Day Care Unit
1844776|NCT00912262|Drug|Capsaicin Topical Liquid|
1844777|NCT00912275|Drug|lapatinib plus oral vinorelbine|Lapatinib -dose level -I, I, II, III 1000mg po daily;dose level IV:1250mg po daily; Oral vinorelbine at the dose level reached on days 1, and 8 of a 21 days cycle. Dose level -I:30mg/m2,I:40mg/m2,II:50mg/m2,III:60mg/m2,IV:60mg/m2,V:80mg/m2
1844778|NCT00912288|Drug|Dimebon 20 mg po TID|Dimebon 10 mg po TID for 1 week followed by Dimebon 20 mg TID for 25 weeks
1844779|NCT00912288|Drug|Placebo po TID|Placebo (matched to Dimebon) po for 26 weeks
1844780|NCT00912301|Drug|Sodium chenodeoxycholate (NaCDC)|500 or 1000 milligrams NaCDC per day each for a period of 4 days
1844781|NCT00912301|Other|Placebo|Placebo capsules with identical appearance to the study drug were prepared by the Mayo Clinic research pharmacy.
1844782|NCT00912314|Procedure|PTNS|Monthly PTNS after 12 weeks of weekly PTNS
1844783|NCT00912327|Biological|Imprime PGG|Imprime PGG, 4 mg/kg, i.v. over 2 hr, weekly in 6 week cycles and Cetuximab, initial dose will be 400 mg/m2 via i.v., and subsequent doses will be 250 mg/m2 via i.v., weekly in 6 week cycles
1844784|NCT00912340|Drug|Everolimus|
1844785|NCT00912340|Biological|Trastuzumab|
1844786|NCT00912353|Drug|AZD7268|Single Oral
1844787|NCT00912353|Drug|Placebo|Single Oral
1844788|NCT00912366|Procedure|Lobectomy|Assessment of VATS versus open surgery.
1844789|NCT00912379|Biological|hemoglobin determination|laboratory and non invasive hemoglobin determinations
1844790|NCT00912392|Drug|Endostar|Endostar® 7.5mg/m2 on day 1 to day 14
1844791|NCT00912392|Drug|Etoposide-Carboplatin|Etoposide 60 mg/m2 on day 1 to day 5 and carboplatin AUC 5 on day 1.
1844792|NCT00912405|Device|Steroid-Eluting Sinexus Intranasal Splint|Intranasal drug-coated splint placed after functional endoscopic surgery (FESS)
1844793|NCT00912418|Biological|autologous tumor cells plus GM-CSF-in Adjuvant|"Autologous tumor cells plus 225 ug GM-CSF in-adjuvant: The autologous tumor cells will be administered intradermally. Subjects will be vaccinated over at least a 6 week period (at weeks 0, 1, 2, 4, 5, 6), with responders vaccinated every 4 weeks thereafter for a maximum of 9 vaccinations (up to week 18). Systemic low-dose interleukin-2 will also be administered daily for 6 weeks following the second vaccination at week 1.
Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 vaccinations in a different site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods."
1844794|NCT00912431|Drug|ABT-126|ABT-126 administered on Day 1 of Period 1
1844795|NCT00912431|Drug|Placebo|Placebo for ABT-126 administered on Day 1 of Period 2
1845207|NCT00916058|Drug|Melphalan|70 mg/m2 given 2 and 3 days prior to autologous cell transplant
1844796|NCT00912444|Drug|Docetaxel, Anthracycline (Doxorubicin or Epirubicin), Cyclophosphamide|Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 every 3 weeks for six cycles
1844797|NCT00912444|Drug|Docetaxel, cyclophosphamide|Docetaxel 75mg/m2, cyclophosphamide 600mg/m2 every 3 weeks for six cycles
1844798|NCT00912457|Drug|donepezil|donepezil 5 mg/day for 14 days followed by donepezil 10 mg/day for 14 days
1844799|NCT00912457|Drug|placebo|placebo 1 p/day for 28 days
1844800|NCT00912470|Procedure|ocular blood flow measurement|"Retinal blood flow (with scanning laser Doppler flowmetry, laser Doppler velocimetry + retinal vessel analyzer) each measurement once on the study eye
Choroidal blood flow (with laser Doppler flowmetry, laser interferometry, pneumotonometry)
Frequency distribution of alleles of genetic markers for NOS3, more precisely eNOS -786CC polymorphism and of ET-1 (EDN1), and the receptors ETA (EDNRA), more precisely EDN1/+138/ex1 del/ins, EDN1/K198N, EDNRA/C+1222T, EDNRA/C+70G polymorphisms"
1844801|NCT00912483|Biological|heparin sodium - Blausiegel|Heparin sodium - 5.000UI/0.25mL, twice a day for 7 days and 2 hours before the surgery
1844802|NCT00912483|Biological|Heparin sodium - APP|Heparin sodium - 5.000USP/mL, twice a day for 7 days and 2 hours before the surgery
1844803|NCT00912496|Biological|MF-59|Doses of A/Anhui/05 vaccine (A) will be administered with or without MF59 adjuvant.
1844804|NCT00912496|Biological|A/Anhui/05|Monovalent inactivated surface antigen influenza A/H5N1 (modified Hemagglutinin and Neuraminidase of A/Anhui/01/2005) vaccine supplied in 5mL multi-dose vials with thimerosal [0.01%(w/v)] as a preservative. Each dose level includes both unadjuvanted and MF59C.1 adjuvanted formulations: 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) with MF59C.1, and 7.5, 15, 30, or 60 micrograms (mcg) of H5 Hemagglutinin per milliliter (mL) without MF59C.1 adjuvant.
1844805|NCT00912496|Drug|Placebo|Sterile normal saline for injection (0.9% Sodium Chloride Injection, USP Preservative-Free).
1844808|NCT00912522|Device|TMS|TRANSCRANIAL MAGNETIC STIMULATION
1844809|NCT00912535|Drug|Quetiapine extended release tablet|Quetiapine extended release tablet of 50-300mg/day
1844810|NCT00912535|Drug|Placebo|Placebo orally, as adjunct to the same antidepressant at the same dose.
1844811|NCT00912548|Drug|goserelin|"Zoladex™ administration:
Zoladex™ depot is available as a sterile disposable syringe. The depot is administered subcutaneously under the abdominal skin under sterile conditions. If necessary the injection site may be pre-treated with a local anaesthetic.
Sequence of administration Zoladex depot:
The substance is administered for 24 months (2 years) at 28-day intervals (a period of 34 days between 2 administrations must not be exceeded).
Dosage:
Each depot contains 3.6mg Zoladex. The substance Zoladex is contained in a while cylindrical rodlet .
Storage instructions for Zoladex™ Zoladex™ is kept a room temperature."
1844812|NCT00912548|Drug|tamoxifen|"Dose and period of Tamoxifen therapy:
Tamoxifen is administered in tablet form. Each day 2 X 10 mg or 1 X 20 mg Tamoxifen are taken in the form of the respective tablet.
Storage instructions for Tamoxifen Tamoxifen is stored at room temperature away from light."
1844813|NCT00912561|Behavioral|Intense aerobic exercise|3 Units (of at least 30 minutes) of intense aerobic exercise per week for 8 weeks
1844818|NCT00912587|Drug|ghrelin|0.1 microgram/kg/min, intravenous for 60 minutes
1844819|NCT00912600|Other|Intensive Care Unit admission|Intensive Care Unit admission
1844820|NCT00912613|Other|ICU Diary|ICU Diary containing daily information of patients condition and treatment with appropriate photographs
1844821|NCT00912626|Behavioral|One week follow up assessment results|FU-1 feedback group will receive child behavior assessment results and interpretation,and a brief intervention to encourage support options.
1844822|NCT00912639|Drug|Paclitaxel loaded Polymeric micelle|Genexol-PM at a dose of 300mg/m2 was diluted in 500 ml of 5% dextrose solution or normal saline and infused i.v. for 3 h on day 1.Treatment was repeated every 3 weeks until either disease progression or intolerance. A minimum of 6 cycles was recommended.
1844823|NCT00912652|Behavioral|lifestyle intervention|Three doses of lifestyle intervention will be compared to an education control condition.
1959429|NCT00151411|Drug|Metformin|Medication was initiated in a step-up fashion every five days, from one tablet per day to four (500 mg per tablet).
1959430|NCT00151411|Drug|Placebo|Placebo
1959431|NCT00151411|Behavioral|Lifestyle Intervention|A combined intervention of diet and exercise was employed with the goal of achieving an average weight loss of at least 7% of initial body weight over six months with a prescription of 150 min/week of exercise combined with a low-calorie diet.
1844825|NCT00912665|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
1844826|NCT00912665|Device|Goldmann applanation tonometer|intraocular pressure measurements
1844827|NCT00912665|Other|squatting|Subjects will perform squatting for 6 minutes while either blood flow or intraocular pressure measurements
1844828|NCT00912665|Device|Suction cup|Experimental stepwise increase of intraocular pressure while either optic nerve head blood flow or intraocular pressure measurements
1844829|NCT00912678|Drug|MMF (Cellcept) and Steroids|Prograf was withdrawn completely after randomization, MMF and steroids were given.
1844830|NCT00912678|Drug|Tacrolimus (Prograf)|After randomization CellCept was withdrawn completely, low-dose tacrolimus was given.
1844831|NCT00912691|Drug|CM-AT|Single unit dose powder of active substance (CM-AT) administered 3 times per day for 90 days
1844832|NCT00905515|Drug|cyclosporine|Maintain on cyclosporine at target trough level of 50-250 ng/mL.
1844833|NCT00905515|Drug|Prograf (Tacrolimus)|Convert to Prograf at target trough levels of 3.0-5.9 ng/mL (Arm 2) or target trough levels of 6.0-8.9 ng/mL (Arm 3).
1844834|NCT00905528|Drug|Telmisartan 80 mg/d|
1844835|NCT00905528|Drug|Ramipril 10 mg/d|
1844836|NCT00905541|Drug|simvastatin|40 mg/day
1844837|NCT00905541|Drug|simvastatin|80 mg simvastatin acute-on-chronic
1844838|NCT00905554|Procedure|warm water irrigation|warm water irrigation during insertion phase of colonoscopy
1844839|NCT00905554|Procedure|air insufflation|air insufflation during the insertion phase of colonoscopy
1844840|NCT00905567|Drug|Topiramate 2 x 25 mg tablet|
1844841|NCT00905567|Drug|Topamax® Tablet 2 x 25 mg|
1844842|NCT00905580|Drug|Pregabalin|Pregabalin 150 mg orally
1844843|NCT00905580|Drug|Vitamin Complex (placebo)|Vitamin Complex 150 mg orally
1844844|NCT00905593|Drug|Nilotinib|
1844845|NCT00905606|Drug|Topiramate Tablets|
1844846|NCT00905606|Drug|Topamax® Tablets|
1844847|NCT00905632|Drug|BI 207127 middle dose +SOC|BI 207127 middle dose tid + SOC
1844848|NCT00905632|Drug|BI 207127 high dose+SOC|BI 207127 high dose tid +SOC
1844849|NCT00905632|Drug|Placebo + SOC|Placebo tid +SOC
1844850|NCT00905632|Drug|BI 207127 low dose + SOC|BI 207127 low dose tid + SOC
1844851|NCT00905645|Device|Silimed Gel-Filled Mammary Implant|
1844852|NCT00905658|Dietary Supplement|therapeutic nutritional supplementation|Patients receive systematic nutritional supplementation
1844853|NCT00905658|Procedure|standard follow-up care|Patients undergo standard monitoring
1844854|NCT00905671|Device|LipiScan Coronary Imaging Catheter|Intravascular near infrared spectroscopic imaging of the coronary artery with a fiberoptic catheter.
1844855|NCT00905684|Drug|EE30/DRSP (Yasmin, BAY86-5131)|Patients under regular daily life treatment receiving Yasmin according to local drug information
1844856|NCT00905684|Drug|Any other OC|Patients under regular daily life treatment receiving any other OC according to local drug information
1844857|NCT00905697|Procedure|Living donor lung transplantation|Living donor lung transplantation
1844858|NCT00905710|Procedure|Chromoendoscopy|Chromoendoscopy: spraying of the mucosa of the right colon with indigo-carmine
1992719|NCT03311126|Drug|Obinutuzumab|Obinutuzumab is a glycoengineered, humanized, type II anti-CD20 mAb.
1844862|NCT00905736|Procedure|Microcurrent treatment (controlled current)|primarily monophasic waveform of average amplitude 40 microamps, 1 hr daily for 3 weeks
1844863|NCT00905736|Procedure|Micocurrent treatment (controlled voltage)|Microcurrent delivered for 6 hours daily for 3 weeks
1844864|NCT00905762|Drug|Gatifloxacin|Gatifloxacin 0.3% one drop instilled into study eye at visit 2.
1844865|NCT00905762|Drug|Moxifloxacin|Moxifloxacin 0.5% one drop instilled into study eye at visit 2.
1844866|NCT00905762|Drug|Besifloxacin|Besifloxacin 0.6% one drop instilled into study eye at visit 2.
1844867|NCT00905788|Procedure|prevention of embryo expulsion|The prevention of embryo expulsion will be carried out after embryo transfer
1844868|NCT00905801|Other|CT Perfusion|Subjects will be examined with a CTP Imaging protocol which comprises repeated CT-scans of the tumor over a period of 50 seconds following the injection of a 30cc bolus of an FDA-approved low osmolar, iodinated CT contrast agent using a 64 row-multidetector row CT unit (LightSpeed VCT, GE Healthcare, Milwaukee, WI). One scan will be acquired every 3 seconds over a 50s period at 100 kV, and 100mA tube current. With this method, a 4cm long segment of the tumor can be analyzed, and 32 images of a slice thickness of 1.25 mm reconstructed simultaneously. Images will be evaluated using standard CT blood flow software (Perfusion 2, AW, GE Health Care, Milwaukee, WI).
1844869|NCT00905814|Drug|AG-013736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
1844870|NCT00905814|Drug|AG-103736|single oral dose of film coated immediate release tablet (one 5-mg tablet for Treatment A and five 1-mg tablets for Treatment B)
1844871|NCT00905827|Behavioral|CAMS|Collaborative assessment management in suicidality
1844872|NCT00905840|Device|Titanium Zircon implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.
The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
1844873|NCT00905840|Device|Titanium Grade IV implant|"The implant surgery is performed under local anesthesia following standard surgical techniques. The surgeon will be supported by one or two assistants.
The bone will be excavated and prepared for the placement of the implant. After the implant was placed by using a hand ratched or motor drive device, a healing abutment will be inserted to ensure a transmucosal healing."
1844874|NCT00905853|Procedure|Catheter Ablation|Intracardiac electrode catheters are placed via central vasculature to identify myocardial scar, and surviving conduction channels within the scar which form the substrate for ventricular tachycardia. Radiofrequency energy is applied to these sites, interrupting the VT circuits.
1844917|NCT00906282|Drug|Pemetrexed|500 mg/m2 IV over 10 minutes on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
1845341|NCT00917111|Drug|Inactive Placebo Gas|Placebo
1844875|NCT00905853|Drug|Escalated Antiarrhythmic Therapy|"Patients who have 'failed' antiarrhythmic therapy (except amiodarone) will be prescribed: Amiodarone 400 mg twice daily for 2 weeks, followed by 400 mg/day for 4 weeks, followed by 200 mg/day thereafter.
Patients who 'failed' amiodarone (less than 300mg/day) will be prescribed: Amiodarone 400 mg three times a day for 2 weeks, followed by 400 mg/day for 1 week and 300 mg/day thereafter.
Patients who 'failed' amiodarone (greater or equal to 300mg/day) will be prescribed: Amiodarone at the current dose with the addition of mexiletine 400 to 800 mg/day"
1844876|NCT00905866|Other|PAS and SF-36 questionnaires|Patients who agree to participate in this study will be asked to fill out a translated PAS questionnaire and a Taiwan version of SF-36 before and after surgery
1844877|NCT00905879|Drug|Gadobutrol (Gadovist, BAY86-4875)|Patients who will need to undergo contrast enhanced MRI with gadobutrol (Gadovist)
1844878|NCT00905892|Dietary Supplement|Hyperlipidic overfeeding|100g per day of cheese + 40g per day of almonds + 20g per day of butter
1844879|NCT00905905|Drug|Simvastatin|Simvastatin 40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
1844880|NCT00905905|Drug|Ezetimibe-Simvastatin|Ezetimibe-Simvastatin 10-40 mg/day during the first 7 days and then 20 mg/day for 3 more weeks until the evaluation of flow-mediated brachial artery dilation
1844881|NCT00905918|Dietary Supplement|vitamin E|Given orally
1844882|NCT00905918|Other|laboratory biomarker analysis|All patients undergo biomarker analyses
1844883|NCT00905931|Drug|Lycopene|30 mg oral, daily, for 21 days
1844884|NCT00905931|Drug|placebo|starch
1844885|NCT00905944|Other|Endurance exercise|The patients carry out an exercise program (walking on a treadmill) three times weekly for 12 weeks at a speed corresponding with an intensity of 70% of VO2max.
1844886|NCT00905957|Procedure|TAP block|TAP block using 20 ml of a local anaesthetic agent will be used in the treatment group
1844887|NCT00905957|Procedure|TAP block with placebo|TAP block using a placebo after induction of anaesthesia
1844888|NCT00905983|Drug|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
1844889|NCT00905996|Procedure|Endoscopic cyanoacrylate injection|Endoscopic cyanoacrylate injection in gastric varix
1844890|NCT00905996|Drug|Beta-blocker (propranolol)|
1844891|NCT00906022|Device|Astron Pulsar Stent|Stenting with Astron Pulsar
1844892|NCT00906022|Device|PTA alone|Balloon angioplasty alone
1844893|NCT00906035|Drug|Dipyridamole 200mg and Aspirin 25mg bid:|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
1844894|NCT00906035|Drug|Dipyridamole 200 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
1844895|NCT00906035|Drug|Aspirin 25 mg bid|All subjects will receive their randomly assigned study medication to be taken each morning and evening approximately 8am and 8 pm for the 180 day duration of the study.
1844896|NCT00906048|Drug|Levofloxacin (HR355) and Rifampicin Therapy|"Film-coated scored tablet measured at 500 mg of levofloxacin and capsule at 300 mg of rifampicin per os once a day
Weight < 70 kg: 1 tablet of levofloxacin and 2 capsules of rifampicin Weight > 70 kg: 1 tablet of levofloxacin and 3 capsules of rifampicin"
1844897|NCT00906061|Drug|Gemcitabine and Docetaxel|Docetaxel 50 mg/m2, IV, and Gemcitabine 2000 mg/m2, IV, on day 1 and 14 of each 28 day cycle. Number of Cycles: 6
1844898|NCT00906074|Procedure|Elective or emergency abdominal surgery|Clinical record review.
1844899|NCT00906074|Procedure|Elective or emergency abdominal surgery|Clinical record review
1844900|NCT00906087|Drug|Cosopt (combination eyedrop of dorzolamide and timolol)|One drop in each eye every twelve hours for six weeks
1844901|NCT00906113|Drug|Intra-arterial injection of melphalan|Injection of 5 milligrams of melphalan into the ophthalmic artery once every 3 weeks for a total of 6 courses
1844902|NCT00906113|Drug|Injection of melphalan into the ophthalmic artery|Injection of 5 milligrams of melphalan into the ophthalmic artery in an eye affected by retinoblastoma
1844903|NCT00906126|Drug|Misoprostol|Oral misoprostol
1992721|NCT03310853|Dietary Supplement|Probiotic|Dosing regimen of one capsule daily for a maximum of 18 weeks
1992722|NCT03310853|Other|Placebo|Dosing regimen of one capsule daily for a maximum of 18 weeks
1844907|NCT00906165|Device|Straumann® Bone Level SLActive Implant (4.1mm diameter)|Straumann® Bone Level Implants will be placed in healed alveolar ridge (at least 8 weeks post extraction). Implants in Arm 1 will be immediately provisionalized. Implants in Arm 2 will not be immediately provisionalized. Implants in both Arms will be loaded at 16 weeks (final prosthetic reconstruction will be performed according to the standard procedure for single crown restoration)
1844908|NCT00906178|Behavioral|CyberSenga|Internet-based HIV prevention program
1844909|NCT00906191|Drug|SAM-531|
1844910|NCT00906204|Biological|Single-dose rabbit Anti-thymocyte Globulin induction|6 mg of rATG administered in a single dose on the day of kidney transplantation
1844911|NCT00906204|Biological|Divided-dose rabbit Anti-thymocyte Globulin induction|6 mg/kg total rabbit Anti-thymocyte Globulin dose administered as 1.5 mg/kg doses on 4 sequential days, beginning on the day of kidney transplantation.
1844912|NCT00906243|Biological|CV9103|CV9103 encodes for 4 prostate specific antigens.
1844913|NCT00906256|Drug|AZD7295|Capsules 260mg, 455mg, 650mg (single doses), 650mg q12h, 650mg q8h.
1844914|NCT00906256|Drug|Placebo|Placebo
1844915|NCT00906269|Drug|Sildenafil therapy plus post-NSRRP HBO2T|Sildenafil (Viagra) 50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP hyperbaric oxygen therapy (90 minutes of 100% oxygen at 2.2ATA (equivalent to the pressure exerted at a depth of approximately 40 feet below sea level). There will be 5 or 10 treatments. The full treatment cycle will be completed within 2 weeks.
1844916|NCT00906269|Drug|Sildenafil therapy plus sham post-NSRRP HBO2T|Sildenafil (Viagra)50 mg - PO QHS for 12 months beginning the first evening they return home from surgical hospital stay PLUS Post-NSRRP sham hyperbaric oxygen therapy - 90 minutes at 2.2ATA but instead of 100% oxygen, they will receive air administered via the oxygen hoods, as if they were being administered oxygen. Participants in this group will receive 5 or 10 sham treatment sessions. Full treatment cycle will be completed within 2 weeks.
1844918|NCT00906282|Drug|Carboplatin|AUC 6.0 IV on Day 1 of every 3-week treatment cycle for a total of 4 cycles (12 weeks).
1844919|NCT00906295|Other|Allowed drop in hemoglobin to 4.5-5.5 mmol/L|Transfusion with red blood cells to hemoglobin between 4.5-5.5 mmol/L (Transfusion threshold of 4.5 mmol/L)
1844920|NCT00906295|Other|Allowed drop in hemoglobin to level between 5.6-6.5 mmol/L|Transfusion with red blood cells to between hemoglobin 5.6-6.5 mmol/L (Transfusion threshold of 5.5 mmol/L)
1844921|NCT00906308|Drug|MF101 5 g/day|PO (orally) 5 g/day (administered twice a day, BID) for up to 12 weeks
1844922|NCT00906308|Drug|Placebo|PO (orally) matched placebo (administered twice a day, BID) for up to 12 weeks
1844923|NCT00906308|Drug|MF101 10 g/day|PO (orally) 10 g/day (administered twice a day, BID) for up to 12 weeks
1844924|NCT00906321|Behavioral|Web-Based Decision Support|
1844925|NCT00906334|Drug|ON 01910.Na|The original dosing regimen was 800 mg/m^2 ON 01910.Na.
1844926|NCT00906334|Drug|ON 01910.Na|Per Amendment 3 to the Protocol, the dosing regimen was changed to 1800 mg ON 01910.Na. Patients enrolled at the original dosing regimen could choose to remain in the original regimen or switch to the new regimen.
1844927|NCT00906347|Drug|Misoprostol|75 micrograms orally every 4 hours for up to 2 doses.
1844928|NCT00906347|Drug|Oxytocin|Intravenous oxytocin will be administered per the established Labor and Delivery protocol at Parkland Memorial Hospital
1844929|NCT00906360|Drug|sunitinib malate|Given orally or by percutaneous gastrostomy tube
1844930|NCT00906360|Other|pharmacological study|Correlative studies
1844931|NCT00906360|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
1844932|NCT00906360|Biological|cetuximab|Given IV
1844933|NCT00906373|Biological|IMC-A12 (cixutumumab)|intravenous infusions 10 mg/kg on day 1 of each 3 week cycle
1844934|NCT00906373|Biological|IMC-A12 (cixutumumab)|intravenous infusions 20 mg/kg on day 1 of each 3 week cycle
1844935|NCT00906373|Drug|sorafenib|400 mg twice per day orally
1844936|NCT00906386|Drug|Varenicline|oral, 1 mg twice daily, 12 weeks
1844937|NCT00906386|Drug|placebo|oral, 1 mg twice daily, 12 weeks
1844938|NCT00906399|Drug|BIIB017 (peginterferon beta-1a)|Supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 µg dose), self-administered by subcutaneous injection.
1844939|NCT00906399|Drug|Placebo|Matched placebo provided in pre-filled syringes, to deliver 0.5 mL self-administered by subcutaneous injection.
1844940|NCT00906425|Device|Straumann Bone Level Implant|Straumann Bone Level Implant, SLActive surface, diameter 4.1, length 8, 10, 12, and 14 mm
1844941|NCT00906438|Dietary Supplement|2006-RD-05|300 mg daily, once a day for 28 consecutive days
1844942|NCT00906438|Dietary Supplement|Placebo|Capsule similar in shape, weight and color from active, once a day for 28 consecutive days
1844943|NCT00906451|Drug|Simvastatin|Simvastatin
1844944|NCT00906477|Procedure|Modified CI therapy|10 treatment days 3 hours a day: Shaping exercises 2 hours. Task practice 0,5 hours. Behavioral therapy (Transfer package) 0,5 hour. Encouragement to wear a restraining mitt on the least affected arm for all safe activities.
1844945|NCT00906490|Device|Intravenous Blood Glucose monitoring system|Insertion of blood glucose monitoring sensor into peripheral vascular IV line.
1844946|NCT00906503|Drug|dexamethasone|Four 4 mg dexamethasone tablets by mouth after food 40, 28, 16 and 4 hrs before the scan
1844947|NCT00906503|Procedure|PET/Computed Tomography (CT)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
1844948|NCT00906503|Radiation|fludeoxyglucose (18F)|Radioactive tracer (18F-FDG), approx. 1 ml (1/5 of a tsp.); Scanned for about 15 minutes for imaging the lungs
1844949|NCT00906516|Drug|Neuradiab in combination with Bevacizumab (Avastin)|"Patients will be treated following surgical removal of recurrent glioblastoma with a single intracavitary dose of Neuradiab® delivering 44 Gy±10% to the ridge of the surgically created resection cavity followed by therapy with Bevacizumab (Avastin) at a minimum of 30 days after Neuradiab administration.
Treatment with Bevacizumab will consist of 10mg/kg iv on days 1 and 15 every 28 days. Other chemotherapies (in addition to Avastin) will be permitted based on most current clinical practice and clinical evaluation of the patient."
1844950|NCT00906529|Drug|Levemir (Detemir) and Novolog (Aspart) Insulin|Will use individualized doses of levemir (detemir) and novolog (aspart) insulin to reach blood glucose goal
1844951|NCT00906555|Procedure|modification of hemodialysis parameters on dialysis machine|Modification of hemodialysis parameters such as dialysis time, blood flow rate and dialysate flow rate to reach a Kt/V ≥ 1.7.
1844952|NCT00906581|Behavioral|Computer-based Problem-Solving Treatment|6 sessions of problem-solving treatment delivered via computer
1844953|NCT00906594|Drug|latanoprost|
1844954|NCT00906620|Other|QPR: question, persuade and refer (SEYLE)|"The QPR prevention program will be used in two modules, one for school staff and one for parents. According to the US Surgeon General's National Strategy for Suicide Prevention (2001), key gatekeepers are people who regularly come into contact with individuals or families in distress and gatekeeper training has been identified as one of a number of promising prevention strategies."
1844955|NCT00906646|Dietary Supplement|Metabolic therapy|Coenzyme Q10 - 100 mg tds Magnesium orotate - 400 mg tds Lipoic acid - 100 mg tds Omega-3 fatty acids - 300 mg (in 1 g fish oils) tds Selenium - 200 µg
1844956|NCT00906646|Dietary Supplement|Placebo|Placebo tablets
1844957|NCT00906672|Device|INTEGRA®|A plaque of dermal substitute Integra® is adjusted to the size of the wound and sutured. A negative pressure bandage is placed on the wound. 7 to 11 days post surgery, the Integra® silicone layer is removed and the neoderm is covered with a skin graft.
1844958|NCT00906672|Procedure|Flap technique|A flap is a part of skin, cutaneous tissue or muscle that is taken from an healthy area of the body and put on the damaged area for coverage.
1844959|NCT00906685|Drug|bevacizumab|Intravitreal injection of 1.25 mg bevacizumab
1844960|NCT00906685|Drug|Sham bevacizumab injection|Sham intravitreal injection
1844961|NCT00906698|Drug|BIBW 2992 low (20mg) dosage|Patients will receive 20mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
1844962|NCT00906698|Drug|BIBW 2992 medium (40mg) dosage|Patients will receive 40mg dosage per day of BIBW 2992 plus standard dosage of vinorelbine.
1844963|NCT00906698|Drug|BIBW 2992 high (50mg) dosage|Patients will receive 50mg dosage of BIBW 2992 plus standard dosage of vinorelbine.
1844964|NCT00906698|Drug|Vinorelbine per os 60 mg/m²|Patients will receive 60 mg/m² Vinorelbine per os at J1 J8 and J15
1844965|NCT00906698|Drug|Vinorelbine per os 80 mg/m²|Patients will receive 80 mg/m² Vinorelbine per os at J22
1844966|NCT00906698|Drug|Vinorelbine i.v. 25 mg/m²|Patients will receive 25 mg/m² of Vinorelbine i.v.
1844967|NCT00906724|Procedure|Aerobic exercise|"A graded exercise stress test (GXT) will be done under cardiologist supervision.
Subjects will undergo three month of supervised aerobic exercise."
1844970|NCT00906750|Biological|FluMist|FluMist is a live attenuated intranasal influenza vaccine
1844971|NCT00906750|Biological|Inactivated influenza vaccine|Inactivated influenza vaccine
1844972|NCT00906763|Dietary Supplement|Chocolate|A single oral application of 200 grams of chocolate (85% cocoa for arm #1; 0% cocoa for arm #2).
1844973|NCT00906776|Device|Emdogain PLUS|Emdogain treatment followed by Straumann Bone Ceramic application during periodontal surgery
1844974|NCT00906776|Device|Autogenous bone|Autogenous bone application during periodontal surgery
1844975|NCT00906789|Behavioral|Software|This is an observer performance study. Radiologists will interpret chest radiographs without and then with the Riverain software, both SoftView (TM) OnGuard (TM) CADe Software with be tested
1844976|NCT00906802|Procedure|R-Y reconstruction|The reconstruction was performed by R-Y anastomosis.
1844977|NCT00906828|Drug|levodopa/carbidopa|intestinal gel, continuous infusion (daytime or 24-hour)
1844978|NCT00906828|Drug|entacapone|Tablet, 200 mg, given twice during the study at t=0h and t=5hrs
1844979|NCT00906828|Drug|tolcapone|Tablet, 100 mg, given twice during study, at t=0h and t=5hrs.
1844980|NCT00906841|Drug|90Y-DOTA-hLL2|Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)
1844981|NCT00906867|Other|Methacholine challenge testing|Nebulized methacholine administered at the following doses: 0,1 mg/0,4 mg/0,8 mg/1,6 mg
1844982|NCT00906867|Procedure|Rhino-laryngoscopy|Topical anesthesia (Xylocain Pump spray) followed by transnasal fiberoptic laryngoscopy with a flexible fiberoptic laryngoscope.
1844983|NCT00906880|Drug|Nifurtimox-Eflronithine Combination Treatment (NECT)|co-administration of nifurtimox (10 days, 15 mg/kg/day, p.o. TID) and eflornithine (7 days, 400 mg/kg/day, i.v. BID)
1844984|NCT00906893|Procedure|18F]-FMISO PET-CT|pretherapy([18F]-FMISO) positon emission tomography-computed tomography. Different acquisition protocols will be tested and a wild panel of quantification parameters issued from published studies and original ones developed by our team enable to describe [18F]-FMISO uptake will be used.
1844985|NCT00906906|Device|Doppler probes|Probes to be placed on CPB tubing to measure blood flow
1844986|NCT00906919|Behavioral|Regular diabetes patient education|Professionally-led diabetes patient education delivered by health professionals over a two day period
1844987|NCT00906919|Behavioral|Augmented diabetes patient education|Professionally-led diabetes patient education led by nurse and dietitian over a two day period augmented by participation in the Stanford Chronic Disease Self-Management Program. This program takes place for 2 1/2 hours per week for six consecutive weeks.
1844988|NCT00906945|Drug|G-CSF|
1844989|NCT00906945|Drug|Plerixafor|
1844990|NCT00906945|Drug|Mitoxantrone|
1844991|NCT00906945|Drug|Etoposide|
1844992|NCT00906945|Drug|Cytarabine|
1844993|NCT00906971|Other|diaphragmatic breathing, isometric training of the abdominal muscles and abdominal massage|Exercises will be conducted by one physiotherapist. A one-minute rest period will be observed between each series. Isometric training of the abdominal muscles: This will consist of a contraction of the upper abdomen muscle and diaphragm and the simultaneous relaxation of the lower abdomen. Training will be carried out in two manners: with the patient lying in a left lateral decubitus position with the hip and knee flexed at 90º and sitting. Breathing exercises: With the patient in a seated position, with one hand placed on the abdomen and the other on the thorax, and will be instructed to breath in slowly,. Two series will be completed, with ten repetitions. Abdominal massage: The physiotherapist will perform slow circular clockwise movements, along the line of the colon, with a regular tennis ball, remaining on each point for one minute, beginning with the ascending colon moving in the direction of the sigmoid colon.
1844994|NCT00906984|Device|TheraSphere|Given IV
1844995|NCT00906997|Procedure|Immunochemical fecal occult blood test|Biennial, without diet restriction, 1 stool sample. Positive cut-off level: 75 ng/ml.
1844996|NCT00906997|Procedure|Colonoscopy|Every 10 years, with sedation.
1844997|NCT00907036|Biological|alemtuzumab|
1844998|NCT00907036|Biological|donor lymphocytes|
1844999|NCT00907036|Drug|cyclosporine|
1845000|NCT00907036|Drug|fludarabine phosphate|
1845001|NCT00907036|Drug|melphalan|
1845002|NCT00907036|Procedure|allogeneic hematopoietic stem cell transplantation|
1845003|NCT00907062|Dietary Supplement|Ginkgo biloba|60 mg Ginkgo biloba per capsule, standardized to 15 mg ginkgofavonglycosides per pill
1845004|NCT00907075|Behavioral|NES With Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement, with an energy deficit of approximately 500 kilocalories.
1845005|NCT00907075|Behavioral|NES Without Energy Restriction|The NES will be administered based upon the individual's calculated daily energy requirement.
1845006|NCT00907088|Other|Healthy milk intake|In addition to the standard nutrition counselling, the intervention group will receive specific information regarding healthy milk intake (2 cups per day, maximum 16 ounces) and the potential negative health effects of prolonged bottle use and excessive milk intake including anemia, iron depletion, and dental carries.
1845007|NCT00907088|Other|Standard nutrition counselling|Parents of children will receive nutrition counselling via trained study personnel, including recommendations for iron containing food choices and timing of cow's milk introduction. This group will also receive a colourful nutrition book.
1845008|NCT00907101|Drug|Adapalene 0.1%/Benzoyl Peroxide 2.5% Gel (Epiduo® Gel)|Apply once daily
1845201|NCT00916045|Drug|Fludarabine|
1845009|NCT00907114|Drug|Ketorolac tromethamine|Presentation 5 mg/ml; Dosage: one drop (0.25 mg) four times a day during one week after panphotocoagulation
1845010|NCT00907114|Drug|Polivynilic alcohol|Presentation: alcohol polivinilico 14 mg/ml; Dosage: one drop (0.7 mg alcohol polivinilico) four times a day during one week after panphotocoagulation
1845011|NCT00907127|Behavioral|Exercise and Diet (Metabolic Fitness Program)|6 month program of diet and exercise training and support.
1845012|NCT00907140|Procedure|Positron Emission Tomography|FDG PET/CT imaging is performed at baseline, after 2 and 4 weeks of radiation therapy and approximately 3 months after chemoradiation is completed
1959433|NCT00130728|Drug|bevacizumab|intravenous infusion of bevacizumab at a dose of 15 mg/kg on the first day of each 3-week cycle
1845015|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1,4, 8, 11, 15, 18, of 28 day cycle in cancer patients.
1845016|NCT00907166|Drug|CPI-613|IV infusion of CPI-613 given on Days 1, 4, 8, 11, 15, 18, of 28 day cycle in patients with pancreatic carcinoma.
1845017|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
1845018|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in cancer patients.
1845019|NCT00907166|Drug|Gemcitabine|IV infusion of 1000 mg/m^2 of Gemcitabine given on Days 1, 8, and 15 of a 28 day cycle in patients with pancreatic carcinoma.
1845020|NCT00907179|Drug|LBH 589|"LBH589 three-times-a-week (doses will be at least 2 days apart, e.g. Monday, Wednesday, Friday), until disease progression or intolerable toxicities LBH589 will start the week prior to the first pemetrexed cycle and PD studies will be performed (week -1).
Dose level: 1 LBH589: 10 mg Pemetrexed: 500 mg/m2
Dose level: 2 LBH589: 15 mg Pemetrexed: 500 mg/m2
Dose level: 3 LBH589: 20 mg Pemetrexed: 500 mg/m2
Dose level: 4 LBH589: 30 mg Pemetrexed: 500 mg/m2"
1845021|NCT00907179|Drug|Pemetrexed|Pemetrexed 500mg/m2 IV, day 1, every 21 days, on the first day of the week LBH589 is given.
1845022|NCT00907192|Behavioral|Personal Interview|Interview questions about use of pain drugs and other knowledge and/or attitudes about them. Take about 5-10 minutes to complete.
1845023|NCT00907192|Behavioral|Questionnaire|5 short questionnaires about use of pain drugs, attitudes about the pain drugs and their use, and concerns about use of these pain drugs. Take about 10-15 minutes to complete.
1845024|NCT00907205|Drug|SF1126|Dose Escalating with 3+ patients in each cohort
1845026|NCT00907257|Drug|benzoyl peroxide wash|5% benzoyl peroxide wash
1845027|NCT00907257|Drug|Tretinoin gel|0.04% tretinoin gel
1845028|NCT00907270|Dietary Supplement|Cholecalciferol|Cholecalciferol: 4,000 IU/day and 400 IU/day
1845029|NCT00907283|Drug|Deferiprone|15 mg/Kg/twice for 1 year
1845030|NCT00907296|Drug|AMG 785 210mg|210mg AMG 785, subcutaneous (under the skin) injection
1845031|NCT00907296|Drug|AMG 785 70mg|70mg AMG 785, subcutaneous (under the skin) injection
1845032|NCT00907296|Drug|AMG 785 140 mg|140mg AMG 785, subcutaneous (under the skin) injection
1845033|NCT00907296|Drug|Placebo|Placebo, subcutaneous (under the skin) injection
1845034|NCT00912743|Drug|olaparib|400 mg po bid continuously
1845035|NCT00912756|Drug|cilostazol|200 mg/day BID
1845036|NCT00912782|Drug|Vitamin D3|Vitamin D3 200,000 IU once a week for 3 weeks
1845037|NCT00912782|Drug|Placebo|Placebo one time per week for 3 weeks
1845038|NCT00912795|Behavioral|SMS Turkey|"6-week smoking cessation program delivered via daily text messages
SMS Turkey: 6-week smoking cessation program delivered via text messaging. SMS Turkey content is guided by the Cognitive Behavioral Therapy (CBT) theory.
Content was tailored based on participant's stage in quitting (i.e., pre-quit, quit day, early-quit, late-quit, relapse). Based on the typical relapse trajectory, content paths were created for participants based on whether or not they were smoking 2 days after quit day; and again at 7 days after quit day.
Depending on the participant's content path, the total number of messages received ranged from 91 (for those assigned to the encouragement arm) to 146 (for those who relapsed and then were assigned to the late quit messages)."
1845039|NCT00912808|Drug|Donepezil|donepezil, 5 mg, capsule, once a day, 3 weeks
1845040|NCT00912808|Drug|Sugar Pill (placebo)|sugar pill, one capsule, once a day, 3 weeks
1845041|NCT00912821|Drug|6 L dialysate|6 L peritoneal dialysis solution
1845042|NCT00912821|Drug|8 L dialysate|8 L peritoneal dialysis solution
1845043|NCT00912860|Drug|Interferon beta-1a|serum free Avonex given IM once a week
1845044|NCT00912873|Drug|ropivicaine (Psoas compartment block)|Patients will be randomized to one of two groups: ropivicaine 0.1% infusion or ropivicaine 0.4% infusion. The infusion rate will be set at 12mL/hour and 3mL/hour respectively and the outcome measures will be assessed by physical therapy using the described methods.
1845045|NCT00912899|Drug|Noscapine HCl|Escalating doses given twice per day
1845046|NCT00912912|Drug|Sunitinib Malate|50 mg capsules once a day (by mouth) for 4 weeks in a row in a 6 week cycle.
1845047|NCT00912925|Biological|rhIDU (recombinant human-Alpha-L-Iduronidase)|Patients in the active treatment group received Aldurazyme intravenously at a dose of 100 units/kg (approximately 0.58mg/kg) administered intravenously over approximately 4 hours once weekly for 26 weeks.
1845048|NCT00912925|Biological|Placebo|Patients in the Placebo-control group were administered a solution of 100mM sodium phosphate , 150mM sodium chloride, and 0.001% polysorbate-80, adjusted to a pH of 5.8 administered intravenously over a time period of approximately 4 hours once weekly for 26 weeks.
1845202|NCT00916045|Drug|Melphalan|
1845203|NCT00916045|Drug|Thymoglobulin|
1845049|NCT00912938|Drug|zoledronic acid|Intravenous zoledronic acid 4mg over a minimum of 15 minutes in at least 100mls of calcium free infusion solution (0.9% sodium chloride or 5% glucose solution) every 4 weeks.
1845050|NCT00912964|Drug|Mirabegron|Mirabegron tablets
1845051|NCT00912964|Drug|Placebo|Matching mirabegron placebo tablets.
1959434|NCT00130728|Drug|erlotinib HCl|oral erlotinib HCl 150 mg/day orally
1845054|NCT00913003|Drug|Lidocaine|Lidocaine bolus infusion 1.5 mg/kg IV using participants IBW(Ideal Body Weight) Lidocaine infusion after bolus and continuing until 1 hour after skin closure 33.3 mcg/kg/mn IV (IBW)
1845055|NCT00913003|Drug|Placebo|Placebo (normal saline) bolus similar to the lidocaine infusion minus active drug
1845056|NCT00913029|Device|iStent|iStent
1845057|NCT00913029|Drug|latanoprost/timolol|Combination latanoprost/timolol
1845058|NCT00913042|Other|sample blood|"Early culture
Bacterial DNA tests in blood"
1845059|NCT00913055|Drug|octreotide acetate|subcutaneous implant
1845060|NCT00915135|Drug|Ramelteon and Placebo (25 possible combinations total)|"Randomized sequence over two consecutive nights for a total of five treatment periods to include the following:
Ramelteon 4 mg, tablets, orally over two nights
Ramelteon 8 mg, tablets, orally over two nights
Ramelteon 16 mg, tablets, orally over two nights
Ramelteon 32 mg, tablets, orally over two nights
Ramelteon placebo-matching tablets, orally over two nights"
1845061|NCT00915148|Other|Ultrasound examination|Trans-abdominal and trans-perineal 3D ultrasound examination
1845062|NCT00915174|Drug|Neramexane|25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days
1845063|NCT00915187|Drug|CCS/C|Adjuvant to influenza vaccine
1845064|NCT00915187|Biological|Influenza Vaccine|Influenza vaccine
1845065|NCT00915200|Dietary Supplement|N-acetylcysteine|600 mg orally twice daily for three months
1845066|NCT00915200|Dietary Supplement|silibin|480 mg orally twice daily for three months
1845067|NCT00915200|Dietary Supplement|high-dose silibin|960 mg orally twice daily for three months
1845068|NCT00915200|Dietary Supplement|N-acetylcysteine placebo|excipient orally twice daily for three months
1845069|NCT00915200|Dietary Supplement|silibin placebo|excipient orally twice daily for three months
1845070|NCT00915226|Procedure|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
1845071|NCT00915226|Procedure|Squatting|Squatting
1845072|NCT00915239|Drug|Pantoprazole|40 mg pantoprazole once daily for 28 days
1845073|NCT00915239|Drug|Placebo|identical placebo once daily for 28 days
1845074|NCT00915252|Drug|azacitidine|"Starting dose has been determined during run-in dose finding part of the study. Starting dose of the interventional drug is 75 mg/m²/d. Application form:
During induction therapy phase: i.v. on days -5--1 before standard chemotherapy for 1 or 2 cycles, During consolidation therapy: s.c. on days -5--1 before standard chemotherapy (2 cycles).
During maintenance therapy: s.c. on days 1-5 on a 28day cycle till maximum one year after start of first induction therapy."
1845075|NCT00915252|Drug|standard chemotherapy (7+3 scheme): Daunorubicin, Cytarabine|"Induction therapy:
Daunorubicin 60mg/m²/d i.v.on days 3,4,5 AraC 100mg/m²/d i.v. on days 1-7
Consolidation therapy:
AraC 1g/m² twice a day on day 1,3,5"
1845076|NCT00915265|Other|Multilobed catheter (group CPA)|- CPA group: continuous preperitoneal administration of 0.2% ropivacaine using a multilobed catheter positioned between the previously closed parietal peritoneum and the underside of the transversalis fascia
1845077|NCT00915265|Other|Multilobed catheter (group EA)|EA group : thoracic epidural infusion of 0.2 % ropivacaine
1845078|NCT00915278|Drug|PF-04605412|PF-04605412 will be administered as 2 hr IV infusion every 4 or 2 weeks. Start dose is 7.5 mg. Multiple doses are foreseen. Treatment will continue until intolerable toxicity, progression of disease or patient's refusal
1845079|NCT00915291|Other|Web-based educational modules|Interactive case-based modules that includes video vignettes of clinical interactions between hypothetical patients interacting with physicians
1845080|NCT00915304|Behavioral|The EBMeDS reminders|"Phase I: EBMeDS reminders specific to the visiting or caring patient and his/her clinical problem are generated when the practitioner uses the electronic patient record. During visits of intervention group patients the EBMeDS reminders will be shown on screen to the practitioner.
Phase II: As phase I and in addition, results of the Virtual Health Check (VHC) of all the intervention group patients will be shown to the practitioners.Phase II will be fulfilled in Autumn 2010 and follow-up time will be about 3 months."
1845081|NCT00915330|Procedure|Rapid on-site cytopathologic evaluation (ROSE)|ROSE: examination in the endoscopy suite, by a pathologist, during the bronchoscopic procedure, of samples obtained with transbronchial needle aspiration.
1845082|NCT00915330|Procedure|TBNA|transbronchial needle aspiration
1845083|NCT00915343|Drug|hydrocortisone (modified release), oral tablet 20 and 5 mg|The modified release hydrocortisone tablet was administered orally o.d. at 8 AM in the fasting state. The dose was the same as patients have had before entering the trial
1845084|NCT00915343|Drug|Hydrocortisone, oral tablet, 10 mg|The reference drug was administered orally thrice daily (at 8 AM, 12 AM and 4 PM). The morning dose was administered in the fasting state. The total daily dose was the same as in the experimental treatment arm.
1845085|NCT00915356|Drug|AZD1305|Intravenous (iv) single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
1845086|NCT00915356|Drug|Placebo|iv single infusion given intravenously until successful conversion of Atrial Fibrillation (AF) to Sinus Rhythm (SR) occur or for a maximum of 30 minutes
1845087|NCT00915369|Drug|Nanoxel (Paclitaxel Nanoparticle formulation )|Nanoxel (Nanoparticle Paclitaxel) at 4 different dose levels of 220, 260, 310 and 375 mg/m2. Each patient will recieve upto 6 cycles.
1845088|NCT00915382|Drug|S-1 and cisplatin|"S-1: 80 mg/m2/day po on Days 1-14
cisplatin: 60 mg/m2 iv on Day 1"
1845089|NCT00915382|Drug|S-1 and cisplatin|"S-1: 80 mg/day with BSA less than 1.25 m2, 100 mg/day with BSA more than 1.25 m2 and less than 1.5 m2, 120 mg/day with BSA more than 1.5 m2 on Days 1-21 and
cisplatin: 60 mg/m2 iv on Day 1 or 8"
1845090|NCT00915408|Drug|Lenalidomide|Oral lenalidomide 25mg daily on Days 1-21 every 28 days cycles for up to 9 cycles. From Cycle 10 Lenalidomide 25mg orally on days 1-21, every 28 days.
1845204|NCT00916045|Drug|Ciclosporin|
1845091|NCT00915408|Drug|Dexamethasone|Dexamethasone 20mgs orally, daily on Days 1-4 and 8-11 repeated every 28 day cycles for up to 9 cycles.
1845092|NCT00915408|Drug|Cyclophosphamide|Oral Cyclophosphamide will be added to the regime starting on days 1 and 8. The dose of Cyclophosphamide will be escalated in cohorts rising in 100mg increments from 300 to 700mgs days 1,and 8 every 28 day cycles for up to 9 cycles.
1959435|NCT00130728|Drug|placebo|intravenous infusion of placebo at a dose of 15 mg/kg on the first day of each 3-week cycle
1845094|NCT00915434|Drug|JNJ-31001074|
1845095|NCT00915460|Drug|Interferon beta-1a (Avonex)|dosage and frequency as per Biogen Idec protocol
1845096|NCT00915473|Drug|bupivicaine|2.5 mL 0.5% bupivicaine
1845097|NCT00915473|Drug|normal saline|2.75 mL normal saline
1845098|NCT00915473|Drug|methylprednisolone|0.5 mL 20 mg methylprednisolone
1845099|NCT00915473|Drug|lidocaine|0.25 mL 1% lidocaine
1845100|NCT00915486|Procedure|Good Standard of Care (GSoC)|Procedural treatment twice per week
1845101|NCT00915486|Biological|Vehicle|Topical fibrin as an adjunct to GSoC twice per week
1845102|NCT00915486|Biological|I-020201|Topical treatment with 3 different concentrations as an adjunct to GSoC twice per week
1845103|NCT00915499|Device|VPAP Adapt SV|Comparison of ASV and CPAP modes
1845104|NCT00915512|Drug|Paliperidone extended-release (ER)|Paliperidone ER tablets will be administered orally once daily as flexible dose ranging from 3 to 12 milligram (mg) per day for 12 months. The recommended dose will be 6 mg once daily.
1845105|NCT00915525|Biological|botulinum toxin Type A|Botulinum toxin Type A 100U or 150U injected into the detrusor, after protocol specified criteria are met, and no more frequently than every 12 weeks.
1959436|NCT00113919|Drug|Busulfan|Dexamethasone 40 mg PO 1-4 Thalidomide 200 mg PO 1-6 Cisplatin* 10 mg/m, Continuous infusion 1-4 Adriamycin** 10 mg/m2, Continuous infusion 1-4 Cyclophosphamide 400 mg/2, Continuous infusion 1-4 Etoposide 40 mg/m2, Continuous infusion 1-4 All doses will be based on calculated body weight (actual weight + ideal body weight ÷ 2) and height, and not to exceed a BSA of 2.0 m2 The daily dose of cyclophosphamide, etoposide, and cisplatin will be mixed in a 1L bag of NS to be UAMS infused over 24 hours. Adriamycin will be mixed in at least 50cc D5W to be infused over 24 hours
1845108|NCT00915551|Drug|PEP005 (Ingenol Mebutate) gel, 0.015%|once daily for 3 consecutive days
1845109|NCT00915551|Drug|Vehicle Gel|once daily for 3 consecutive days
1845110|NCT00915564|Drug|TMC435|Participants will receive 150 mg dose of TMC435 orally (by mouth) once daily for 7 days of treatment (from Day 1 to Day 7).
1845111|NCT00915564|Other|Methadone|Participants will receive supervised individualized methadone dose (dose of methadone will be adjusted for each participant between a range of 30 and 150 mg daily [extremes included]) from Day -14 untill Day 8. Participants will continue to receive individualized methadone during follow up of 30 to 32 days.
1845112|NCT00915577|Drug|Interferon beta-1a|30mcg, IM once-a-week
1845113|NCT00915577|Device|Single-use autoinjector|Single-use autoinjector with Avonex 30mcg pre-filled syringe
1845114|NCT00915590|Drug|Placebo|Custom eye drop eye three times a day in both eyes for a period of 6 weeks
1845115|NCT00915590|Drug|IL-1Ra|5% custom made topical IL-1Ra 3 times a day in both eyes for a period of 6 weeks
1845116|NCT00915603|Drug|Everolimus|Everolimus 10mg PO daily continuously for all 28 days of a cycle
1845117|NCT00915603|Drug|Bevacizumab|Bevacizumab 10mg/kg IV Days 1 and 15 of 28 day cycle
1845118|NCT00915603|Drug|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
1845119|NCT00915603|Drug|Placebo|Placebo PO daily continuously for all 28 days of a cycle
1845120|NCT00915603|Drug|Bevacizumab|Bevacizumab 10mg/kg IV days 1 and 15 of 28 day cycle
1845121|NCT00915603|Drug|Paclitaxel|Paclitaxel 90mg/m2 1-hour IV infusion Days 1, 8 and 15 of 28 day cycle. Patients will receive standard pre-medication before each paclitaxel treatment to prevent a hypersensitivity reaction.
1845122|NCT00915616|Drug|Melatonin|
1845123|NCT00915629|Dietary Supplement|Lactibiane candisis 5M|2 gelules per day for 2 months then 1 gelule per day for 4 months
1845124|NCT00915655|Drug|darunavir|Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks
1845125|NCT00915655|Drug|ritonavir|Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks
1845126|NCT00915655|Drug|zidovudine|NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
1845127|NCT00915655|Drug|lamivudine|NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
1845128|NCT00915655|Drug|abacavir|NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and < 18 years in a particular country
1845129|NCT00915668|Drug|JNJ-31001074|
1845131|NCT00915694|Drug|nelfinavir mesylate|
1845132|NCT00915694|Drug|temozolomide|
1845133|NCT00915694|Procedure|adjuvant therapy|
1845134|NCT00915694|Radiation|radiation therapy|
1845135|NCT00915707|Other|Baseline|Subjects are allowed time in bed for sleep as their usual time at home.
1845136|NCT00915707|Other|Sleep restriction|Subjects sleep is reduced to 4.5 hours in bed for 4 nights.
1845137|NCT00915707|Other|Reduced Sleep Quality|Subjects sleep quality is reduced for 4 nights.
1845138|NCT00915733|Drug|cilostazol|100 mg twice daily for at least 1 month
1845139|NCT00915733|Drug|clopidogrel (Plavix)|150 mg once daily (high maintenance dose group arm), 75 mg once daily (triple group arm)
1845140|NCT00915733|Genetic|CYP2C19|CYP2C19 polymorphism study: Two CYP2C19 polymorphisms, CYP2C19*2 (rs4244285, c. 681G>A, p.P227P), and CYP2C19*3 (rs4986893, c. 636G>A, p. W212X), are investigated using the ABI SNaPshot reaction and the ABI 3100 automated genetic analyzer.
1845141|NCT00915733|Drug|aspirin (Acetylsalicylic acid)|aspirin 100 mg qd
1845142|NCT00915746|Drug|JNJ-31001074; ketoconazole|
1845143|NCT00915759|Device|ProKera|ProKera placed in non-dominant eye after PRK
1845144|NCT00915759|Device|Bandage contact lens|Bandage contact lens placed in dominant eye, the current standard after PRK
1845145|NCT00915772|Drug|Linagliptin + metformin|Linagliptin tablet low dose + metformin tablet 500 mg bid
1845146|NCT00915772|Drug|Linagliptin+metformin|Linagliptin low dose tablet + metformin 1000 mg tablet bid
1845147|NCT00915772|Drug|Metformin|Metformin 1000 mg tablet bid
1845148|NCT00915785|Drug|5 azacytidine|Patients will receive azacytidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment.
1845149|NCT00915798|Behavioral|Cigarette smoking|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking a cigarette.
1845150|NCT00915798|Behavioral|Abstinence|Participants had an fMRI scan during an experimental task consisting of mathematical problems after smoking abstinence.
1845151|NCT00915811|Drug|Fludarabine|Fludarabine 30mg/m2 intravenously daily on days -9 to -5 inclusive of stem cell infusion.
1845152|NCT00915811|Drug|Busulphan|Busulphan 0.8mg/kg intravenously 6 hourly on days -4 and -3 of stem cell infusion.
1845153|NCT00915811|Drug|Thymoglobuline (Anti-thymocyte globulin [rabbit]) - Genzyme|Thymoglobuline will be given intravenously over a minimum of 6 hours for the first two doses and 4 hours for the subsequent doses. Acute side effects of ATG appear to be reduced if a very low dose is given for the first injection. Thymoglobuline 0.5mg/kg iv on day -4, 1.5mg/kg/day on day -3; and 2mg/kg/day iv on day -2 to -1 inclusive.
1845154|NCT00915811|Procedure|Haematopoietic stem cell infusion|The source of stem cells will be PBSC wherever possible. Patients whose donors decline or are unable to donate PBSC will be transplanted with marrow cells.
1845155|NCT00915824|Other|STOPP/START criteria|Application of STOPP/START criteria to the patient's prescription and diagnostic information with subsequent written recommendation on pharmaceutical care to the patient's medical team
1845156|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; slow release formulation approximately 1-3 mcg/day
1845157|NCT00915837|Drug|triamcinolone acetonide|Helical intravitreal triamcinolone implant- 925 mcg drug; fast release formulation approximately 3-5 mcg/day
1845158|NCT00915850|Drug|DCF|docetaxel, Cisplatin and 5-FU
1845159|NCT00915863|Procedure|Billroth-II-type reconstruction|surgical procedure
1845160|NCT00915863|Procedure|Isolated Roux-en-Y type reconstruction|surgical procedure
1845161|NCT00915876|Drug|Paricalcitol|paricalcitol 1 mcg QD x 8 weeks
1845162|NCT00915876|Drug|Placebo|Placebo for Paricalcitol 1 mcg QD x 8 weeks
1845163|NCT00915889|Behavioral|telephone-based intervention|Either 6 or 8 telephone educational sessions
1845164|NCT00915889|Other|counseling intervention|counseling and communications studies
1845165|NCT00915889|Other|questionnaire administration|Ancillary studies
1845166|NCT00915889|Other|study of socioeconomic and demographic variables|Ancillary Studies
1845167|NCT00915889|Procedure|psychosocial assessment and care|6 weeks or 8 weeks of psychoeducational telephone sessions
1845168|NCT00915902|Drug|Omega-3-acid ethyl esters|Omega-3-acid ethyl esters (Lovaza), two 1-gram capsules taken twice daily for 8 weeks
1845169|NCT00915902|Drug|Placebo|Placebo (corn oil), two 1-gram capsules taken twice daily for 8 weeks
1845170|NCT00915915|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+2.1mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
1845171|NCT00915915|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|Transdermal patch: 0.55mg Ethinylestradiol (EE+1.05mg GSD)Gestodene; 3x7 days patch- wearing phase and a patch-free interval of 7 days (1 pre-treatment cycle, 3 treatment cycles), 1 Follow - up cycle)
1845172|NCT00915928|Drug|Perindopril|2,5 mg daily for 3 months
1845173|NCT00915928|Drug|Placebo|
1845174|NCT00915954|Other|oral glucose tolerance test|Participants will have their blood drawn for a baseline value and then will be asked to drink a beverage with 75 grams of sugar. Blood will then be drawn every 30 minutes for 2 hours.
1845175|NCT00915954|Other|Subcutaneous administration of recombinant human IGF-1|Participants will receive a subcutaneous injection of recombinant human IGF-1 followed by a series of blood draws.
1845176|NCT00915967|Drug|Vancomycin|Subjects randomized to the vancomycin group will receive an injection (up to 10 mL) of 5 mg/mL vancomycin administered directly into the wound with a blunt needle following watertight fascial closure.
1845177|NCT00915967|Drug|Placebo (Saline Solution)|Subjects randomized to the saline group will receive an injection (up to 10 mL) of saline solution directly into the wound following watertight fascial closure.
1845178|NCT00915980|Procedure|gastric bypass surgery and testing|The patients will be tested with OGTT and meal testing before and after undergoing gastric bypass surgery.
1845179|NCT00915993|Drug|sunitinib malate|
1845180|NCT00915993|Genetic|mutation analysis|
1845181|NCT00915993|Other|immunohistochemistry staining method|
1845182|NCT00915993|Other|laboratory biomarker analysis|
1845183|NCT00915993|Other|pharmacological study|
1845184|NCT00915993|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1845185|NCT00916006|Drug|PEP005 Gel|0.015%, three day treatment
1845186|NCT00916006|Drug|Vehicle gel|Vehicle gel, three day treatment
1845187|NCT00916019|Other|exercise training|60 min of low-intensity exercise, 5 days/week, 12 weeks
1845188|NCT00916032|Biological|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|Participants will receive 3000 IU Advate using one 3000 IU potency vial dissolved in 5 mL diluent followed by two 1500 IU potency vials dissolved in 5 mL diluent each (administered in 10 mL diluent in total) or the alternate sequence
1845189|NCT00916045|Drug|Thiotepa|
1845190|NCT00916045|Drug|Fludarabine|
1845191|NCT00916045|Drug|Intravenous busulphan|
1845192|NCT00916045|Drug|Thymoglobulin|
1845193|NCT00916045|Drug|Ciclosporin|
1845194|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
1845195|NCT00916045|Drug|Fludarabine|
1845196|NCT00916045|Drug|Cyclophosphamide|
1845197|NCT00916045|Radiation|Radiotherapy|
1845198|NCT00916045|Drug|Thymoglobulin|
1845199|NCT00916045|Drug|Ciclosporin|
1845200|NCT00916045|Drug|Mycophenolate mofetil (MMF)|
1845208|NCT00916058|Drug|Bendamustine|60 mg/m2 given on the 2nd day of melphalan
1845209|NCT00916058|Drug|Bendamustine|90 mg/m2 given on the 2nd day of melphalan
1845210|NCT00916058|Drug|Bendamustine|60 mg/m2 given on the 1st and 2nd day of melphalan
1845211|NCT00916058|Drug|Bendamustine|90 mg/m2 given on the 1st day of melphalan and 60 mg/m2 given on the 2nd day of melphalan
1845212|NCT00916084|Device|Fixed Tongue Appliance|A functional appliance used for maxillary protraction. It has two bands on first molars, expansion screw and long palatal plate in the canine area which cages the tongue and transfers the force of the tongue during physiological activity to the upper arch.
1845213|NCT00916084|Device|Fixed Face Mask|An extra-oral appliance used for treatment of maxillary deficiency in growing patients. It takes anchorage from the chin and forehead, has a fixed intra-oral appliance with an expansion screw and hooks for elastics that exert a force of 300 gr. It should be used 14 hours a day.
1845214|NCT00916097|Drug|DOCETAXEL(XRP6976)|docetaxel 75mg/m2 by intravenous infusion over 60 minutes on Day 1 of a 3-week cycle
1845215|NCT00916110|Drug|ATN-103|1.5 mg solution, single subcutaneous injection
1845216|NCT00916110|Drug|ATN-103|4 mg solution, single subcutaneous injection
1845217|NCT00916110|Drug|ATN-103|10 mg solution, single subcutaneous injection
1845218|NCT00916110|Drug|ATN-103|25 mg solution, single subcutaneous injection
1845219|NCT00916110|Drug|ATN-103|25 mg solution, single intravenous injection
1845220|NCT00916110|Drug|ATN-103|50 mg solution, single subcutaneous injection
1845221|NCT00916110|Drug|ATN-103|100 mg solution, single subcutaneous injection
1845222|NCT00916110|Drug|ATN-103|200 mg solution, single subcutaneous injection
1845223|NCT00916110|Drug|ATN-103|200 mg solution, single intravenous injection
1845224|NCT00916123|Drug|Docetaxel|75 mg/m2 by intravenous infusion over one hour on day 1 of a 21 day cycle.
1845225|NCT00916123|Drug|Prednisone|10 mg per day starting on cycle 1, day 1
1845226|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 20 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
1845227|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 25 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
1845228|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 30 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
1845229|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 35 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
1845230|NCT00916123|Drug|177Lu-J591|Two infusions of 177Lu-DOTA-J591 at 40 mCi/dose will be given. The first infusion will be administered 2-3 days prior to docetaxel cycle 3. The second infusion will be administered two weeks later, i.e., day 13-15 of cycle 3.
1845231|NCT00916136|Procedure|Femoral Traction|Femoral Traction is a temporary intervention to realign the broken bone and help relieve pressure and muscle spasms until operative fixation.
1959437|NCT00105560|Radiation|radiation therapy|Radiation therapy with proton beam to standard doses
1959440|NCT00083915|Drug|Cisplatin|20mg/m2 continuous infusion days -3 and -2.
1959441|NCT00083915|Drug|Cyclophosphamide|800 mg/m2 continuous infusion days -3 and -2.
1959442|NCT00083915|Drug|Adriamycin|20mg/m2 continuous infusion -3 and -2.
1959443|NCT00083915|Drug|Etoposide|80mg/m2 continuous infusion -3 and -2.
1959444|NCT00083915|Drug|Melphalan|200 mg/m2 IV over <20 minutes on -1 on Arm 1. 50mg/m2 IV over 20 minutes days -3 and -2 on Arm 2.
1845240|NCT00916188|Dietary Supplement|Black Tea Extract|Amount/dose depends on Arm assignment.
1845241|NCT00916201|Drug|URB597|10 mg / d for 5 days, orally
1845242|NCT00916201|Drug|intranasal Insulin|160 IU / d for 5 days, intranasal
1845243|NCT00916201|Drug|Cannabidiol CR|320 mg / d for 5 days, orally
1959445|NCT00083915|Drug|Thalidomide|200mg PO Continuing to Day +5, then hold until platelets >50 thousand (K).
1959446|NCT00083915|Drug|Dexamethasone|40 mg po days 1 - 4 (4 days)
1959454|NCT00005792|Drug|etoposide phosphate|Etoposide phosphate 1363 mg/m^2/day IV over 4 hours (total dose 2726 mg/m^2, or 2400 mg/m^2 etoposide equivalents), beginning 24 hours after the completion of the last infusion of topotecan Days -4, -3
1959455|NCT00005792|Drug|melphalan|Melphalan 50 mg/m^2/day IV over 30 minutes (total dose 150 mg/m^2), followed immediately by topotecan. Days -7, -6, -5
1959456|NCT00005792|Drug|topotecan|Topotecan 3.3 mg/m^2/day (starting total dose = 10 mg/m^2 for level 2) IV over 30 minutes. No topotecan will be administered on the first dose level Days -7, -6, -5
1959457|NCT00005792|Procedure|Autologous Stem Cell Rescue|reinfusion of stem cells, Day 0
1845244|NCT00916214|Other|Pharmaceutical care program|The pharmaceutical care program consists of 2 elements, that includes individualized medication education and regular follow up
1845245|NCT00916227|Drug|ARRY-614, p38/Tie2 inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
1845246|NCT00916240|Behavioral|Multisystemic Therapy|Treatment will consist of a home- and community-based intensive intervention. Psychological treatment sessions will be provided in participants' homes, at a time designated by the participant and will last about 1 hour.
1845247|NCT00916240|Behavioral|Home-based, Non-Directive Family Support|Treatment will consist of Rogerian, client-centered, non-directive counseling. Participants will receive weekly home-based, supportive family counseling, with sessions lasting about 45 minutes.
1845248|NCT00916253|Drug|Modafinil|"Modafinil is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):
during 3 days at home
during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day and 2 driving sessions (one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under treatment (Modafinil)."
1845249|NCT00916253|Drug|Placebo|"Placebo is taken by narcoleptics or hypersomniacs during 5 successive days, twice a day (at the breakfast and at the lunch):
during 3 days at home
during the period of 2 nights and 2 successive days of hospitalization in order to realise a Maintenance of Wakefulness Test the first day, and 2 driving sessions ( one simulated driving during the morning and one real driving during the afternoon) of 2 hours each the day after, under Placebo."
1845250|NCT00916266|Procedure|Stem cell transplantation|Transplantations with autologous bone marrow mononuclear stem cells by selective posterior cerebral artery angiography
1845251|NCT00916279|Device|Lutonix Paclitaxel-Coated Balloon|PTCA
1845252|NCT00916292|Drug|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. Low dose: FGF-1, 0.3 mg per square centimeter.
1845253|NCT00916292|Drug|FGF-1 141|Each subject will receive two, 3 mm squared punch skin biopsies, one biopsy will receive the study drug, and the second biopsy will remain untreated as a control. High dose: FGF-1, 3.0 mg per square centimeter.
1845254|NCT00916305|Other|Modified Audio video|An audio video modified to mimic noise induced hearing loss after one night at a loud club
1845255|NCT00916305|Other|Unmodified audio video|An audio video with unaltered music
1845256|NCT00916318|Behavioral|Obesity-Children|"(A) internet based information and communication tool Sundabarn.se(B) psychologist directed seminars with different themes, giving parents tools to implement necessary changes in family-patterns and life style, combined with A, (C) occupational therapist directed group-treatment intended to help parents alter their daily life patterns and, combined with A, (D) control group."
1845259|NCT00916344|Device|EVIA Pacemaker|patient has standard indication for pacemaker therapy
1845260|NCT00916357|Drug|Humalog|
1845261|NCT00916357|Drug|Humulin-R|
1845262|NCT00916357|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
1845263|NCT00916370|Device|Core size Xience Prime|Core size includes a range of stent sizes.
1845264|NCT00916370|Device|Xience Prime Long Lesion (LL)|Long lesion stent sizes include a range of sizes.
1845265|NCT00916383|Drug|350 mg Donepezil Transdermal Patch|Active and placebo patches will be applied to opposite sides for 7 days.
1845266|NCT00916383|Drug|Placebo Patch|Active and placebo patches will be applied to opposite sides for 7 days.
1845267|NCT00916396|Drug|Dehydroepiandrosterone|100 mg of DHEA a day (50 mg twice a day) for six weeks
1845268|NCT00916396|Drug|placebo|100 mg of Placebo a day (50 mg twice a day) for six weeks
1845269|NCT00916409|Device|NovoTTF-100A device|patients will be treated continuously with the NovoTTF-100A device, in addition to Temozolomide. NovoTTF-100A treatment will consist of wearing four electrically insulated electrode arrays on the head. The treatment enables the patient to maintain regular daily routine.
1845270|NCT00916409|Drug|Temozolomide|"maintenance Temozolomide will be administered according to the approved dosing scheme as follows: Maintenance Phase Cycle 1: Four weeks after completing the Temozolomide + Radiotherapy phase, Temozolomide is administered for an additional 6 cycles of maintenance treatment. Dosage in Cycle 1 (maintenance) is 150 mg/m2 once daily for 5 days followed by 23 days without treatment.
Cycles 2-6: At the start of Cycle 2, the dose is escalated to 200 mg/m2, if the CTC non-hematologic toxicity for Cycle 1 is Grade ≤2 (except for alopecia, nausea and vomiting), absolute neutrophil count (ANC) is ≥ 1.5 x 109/L, and the platelet count is ≥ 100 x 109/L. The dose remains at 200 mg/m2 per day for the first 5 days of each subsequent cycle except if toxicity occurs. If the dose was not escalated at Cycle 2, escalation should not be done in subsequent cycles."
1845271|NCT00916422|Biological|Allergen extract (Phleum pratense)|Subcutaneous immunotherapy with modified extract of Phleum pratense. A subcutaneous monthly treatment.
1845272|NCT00916422|Biological|Placebo|Subcutaneous monthly treatment
1845273|NCT00916448|Drug|Atazanavir|capsules of 150 mg, 2 capsules, twice daily on 4 consecutive days
1845274|NCT00916448|Drug|E. coli endotoxin|2 ng/kg E. coli reference endotoxin 11:H 10:K negative intravenously
1845275|NCT00916461|Drug|Minocycline|Minocycline + treatment as usual. 50 mg twice daily increasing to 200 mgs per day, increments of 50 mgs every 2 weeks.
1845276|NCT00916461|Drug|Placebo|Placebo + treatment as usual.
1845277|NCT00916474|Drug|telaprevir|
1845279|NCT00916500|Drug|CONCURRENT CHEMORADIATION (CISPLATIN)|Cisplatin IV 75mg/m2 Every 3 Week For 3 Cycles; External Pelvic Radiation 40Gy; Brachytherapy Up To 85-90 Gy To Point A
1845383|NCT00917501|Drug|Placebo|Placebo given twice a day which will be compared to Omega 3
1845384|NCT00917527|Drug|Atorvastatin|Atorvastatin 40mg/D for 6 weeks to improve endothelial dysfunction
1845385|NCT00917553|Drug|doxycycline monohydrate|50 mg
1845386|NCT00917553|Drug|Placebo|Cellulose Placebo Capsule
1845387|NCT00917566|Device|Airtraq|intubation with airtraq
1845280|NCT00916526|Procedure|bronchial provocation test with mannitol|"Bronchial provocation test with mannitol: Aridol is supplied in kit form containing sufficient capsules to complete one complete challenge, and the inhalation device.
Apply nose clip and subject should be directed to breathe through the mouth
Insert 0 mg capsule into inhalation device. Puncture capsule by depressing buttons on side of device slowly, and once only (a second puncture may fragment the capsules)
The patient should exhale completely, before inhaling from device in a controlled rapid deep inspiration
At the end of deep inspiration, start 60 second timer, subject should hold breath for 5 seconds and exhale through mouth before removal of nose clip
At the end of 60 seconds, measure the FEV1 in duplicate (this becomes baseline FEV1)
Insert 5 mg capsule into inhalation device, and proceed as above
Repeat steps 1 - 4 following the dose steps in the table below until the patient has a positive response or 635 mg has been administered."
1845281|NCT00916539|Device|Cast that immobilizes the thumb|Cast that immobilizes the thumb
1845282|NCT00916539|Device|Cast that does not immobilize the thumb|Cast that does not immobilize the thumb
1845283|NCT00916552|Drug|Erythropoietin|40.000 IU/ml epoetin alfa is administered as intravenous infusions over 15 min weekly for 8 weeks.
1845284|NCT00916578|Radiation|Radiation Therapy|50-57 Gy per faction once or twice a day, 5 days a week, for about 5 -7 weeks, about 15-30 minutes each time.
1845285|NCT00916578|Drug|Capecitabine|During 5-7 weeks of radiation therapy, 825 mg/m2 (pills) by mouth, 2 times a day, about 12 hours apart, 30 minutes after eating food and about 2 hours before radiation therapy.
1845286|NCT00916604|Drug|AZD1656|Three increasing dose-steps with oral suspension, 8 days treatment
1845287|NCT00916604|Drug|Placebo|Placebo oral suspension, 8 days treatment
1845288|NCT00916617|Drug|bapineuzumab|5 mg/week subcutaneous bapineuzumab
1845289|NCT00916630|Drug|pemetrexed|Given intravenously over a 10 to 20 minute period once every 14 days.
1845290|NCT00916643|Device|HELP Secura (apheresis treatment)|Process is described in Arm (above).
1845291|NCT00916656|Biological|Fibrinogen Concentrate, Human (FCH)|"Intravenous (IV) infusion to reach the peak target levels of 100 mg/dL with an accepted lower limit of 80 mg/dL on at least 3 subsequent days for minor bleeding episodes and 150 mg/dL with an accepted lower limit of 130 mg/dL on at least 7 subsequent days for major bleeding episodes.
If a subject's fibrinogen level is not known on Day 1, at the time treatment is initiated for the acute bleed (e.g., because they did not have a screening visit), the starting dose is to be 70 mg/kg b.w. Otherwise, the dose will be calculated individually."
1845292|NCT00916656|Biological|Cryoprecipitate|Patients that received on-demand treatment with Cryoprecipitate for a classified bleeding event (minor or major) with a documented hemostatic efficacy assessment.
1845293|NCT00916669|Drug|Etoposide|Etoposide given as an infusion on day 1, day 2 and day 3 of a three-week cycle for a total of 6 cycles
1845294|NCT00916669|Drug|Cisplatin|Given as an infusion on day 1 of a three-week cycle for a total of 6 cycles
1845295|NCT00916669|Drug|enoxaparin sodium|Given as a subcutaneous injection in the abdomen daily during chemotherapy treatment and then continuing daily for 1 year. Dose will vary.
1845296|NCT00916695|Device|Xience V Everolimus Eluting Coronary Stent System. Abbott Laboratories. Abbott Park, Illinois, U.S.A.|"Complex PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), and subsequent implanting of the stent in the main vessel, the side branch is approached by implanting a new stent as T technique.
Simple PCI strategy for bifurcation: After optional pre-dilation of one or both vessels (main and side branch), a stent is deployed at main vessel. Side branch is approached by using provisional T stenting technique."
1845297|NCT00916708|Procedure|Intensive/Low-Risk follow up (IA G1; IA G2)|"- First 2 years of FU since the end of primary treatment: clinical visit* every 4 months; Pap tests; chest, abdomen, pelvis CT every 12 months
- Since the third to the fifth year of FU: clinical visit* every 6 months; Pap test every 12 months
* clinical visit with gynecological exploration"
1845298|NCT00916708|Procedure|Intensive/High-Risk follow up (≥ IA G3)|"- First 3 years of FU since the end of primary treatment: clinical visit*, Ca125, trans-vaginal and abdominal ultrasound every 4 months (except in conjunction with TC); Pap smear, abdomen, pelvis CT every 12 months
- In the fourth and fifth years of FU: clinical visit*, Ca125, trans-vaginal and abdominal ultrasound every 6 months (except in conjunction with TC) Pap smear; chest, abdomen, pelvis CT every 12 months
* clinical visit with gynecological exploration"
1845299|NCT00916708|Procedure|Minimalist/Low-Risk follow up (IA G1; IA G2)|"- First 5 years of FU since the end of primary treatment: clinical visit* every 6 months.
* clinical visit with gynecological exploration"
1845300|NCT00916708|Procedure|Minimalist/High-Risk follow up (≥ IA G3)|"- First 2 years of FU since the end of primary treatment: clinical visit* every 4 months; chest, abdomen, pelvis CT every 12 months
- Since the third to the fifth year of surveillance: clinical visit* every 6 months.
* clinical visit with gynecological exploration"
1845301|NCT00916721|Drug|Propranolol|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
1845302|NCT00916721|Drug|Placebo|Visit 2 (first smoking-related memory reactivation session) the subject will be given 0.67 mg/kg (minimum 40 mg; maximum 80 mg) of short-acting propranolol (or placebo) rounded to the nearest 10 mg. Ninety minutes after this dose, if subject has tolerated the short-acting dose well, and if systolic blood pressure has not fallen by 10 mmHg or more to below 100 mmHg, the subject will be given oral long-acting propranolol 1 mg/kg (minimum 60 mg; maximum 120 mg) or placebo rounded to the nearest 20 mg. . If the subject tolerates the combination dose well, during treatment phase (from visit 7 to 12), both the short- and long-acting doses will be given together immediately prior to memory reactivation.
1845303|NCT00916734|Procedure|MDT (McKenzie Method)|Subjects who perform exercises in their direction of preference.
1845304|NCT00916734|Procedure|Spinal thrust manipulation|Subjects who receive spinal thrust manipulation as an intervention.
1845388|NCT00917566|Device|Macintoch|use Macintoch laryngoscope for intubation
1846305|NCT00925535|Drug|Rifabutin|300 mg once daily for 10 days
1845305|NCT00916747|Drug|Lonafarnib, Zoledronic Acid, and Pravastatin|"Lonafarnib: Lonafarnib dosing will begin at 150 mg/m2 by mouth twice daily. Lonafarnib will be orally administered without planned breaks, approximately every 12 hours, for a period of 24 months. For patients unable to swallow capsules, the capsules can be opened and dissolved into Ora Blend SF or Ora-Plus.
Zoledronic Acid: Zoledronic acid will be administered intravenously at week one, and months 6, 12, 18 and 24 of this treatment trial. Treatment will consist of one infusion over a 30 minute period.
Pravastatin: Pravastatin will be orally administered once daily without planned breaks, approximately every 24 hours, for a period of 24 months. The drug may be taken with meals. For patients unable to swallow pills, pills can be crushed into food. Pravastatin will be dosed according to the patient weight. Patients less than 10 kg will receive 5 mg pravastatin orally, once daily. Patients weighing 10 kg or greater will receive 10 mg pravastatin daily."
1845306|NCT00916760|Biological|Depigoid Parietaria judaica 1000DPP/ml|Subcutaneous monthly treatment
1845307|NCT00916760|Biological|Placebo|Subcutaneous monthly treatment
1845308|NCT00916773|Device|continuous positive airway pressure (CPAP)|CPAP of optimal pressure used during sleep for 3 months
1845309|NCT00916799|Device|Use of Telehealth equipment (Viterian V-100)|Patient will daily enter answers to questions generated from a home telehealth monitor
1845310|NCT00916825|Behavioral|"rehabilitation programme getting better together"|Mothers and their children (age 0-16) take part in a 3-week, family-oriented oncological rehabilitation programme which consists of medical, psychological and psychooncological treatments for mothers and children.
1845311|NCT00916877|Radiation|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation
1845312|NCT00916890|Drug|Morphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral sustained-release morphine will be randomly assigned to a patient.
1845313|NCT00916890|Drug|Oxycodone|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dose of oral extended-release oxycodone will be randomly assigned to a patient.
1845314|NCT00916890|Drug|Fentanyl|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal fentanyl will be randomly assigned to a patient.
1845315|NCT00916890|Drug|Buprenorphine|After a titration phase with fast-release oral morphine, once the optimal dosage (no side effects and less than two rescue doses per day) is reached, an equipotent dosage of transdermal buprenorphine will be randomly assigned to a patient.
1845316|NCT00916916|Other|Blood draw|A blood draw will occur to take 10cc of blood to measure lanreotide levels.
1845317|NCT00916929|Device|Impedance Monitoring Feature|Algorithm in cardiac device that measures intra-thoracic impedance from the implanted leads
1845318|NCT00916942|Drug|capsaicin 8%|High concentration capsaicin 8% dermal patch applied for one hour
1845319|NCT00916942|Drug|Lidocaine (2.5%)/Prilocaine (2.5%) Cream|Pre-treatment for NGX-4010
1845320|NCT00916955|Other|Observation|Observe development of syndrome over time
1845321|NCT00916968|Device|Standard CR-Flex total knee|total knee implant used for joint replacement surgery of the knee
1845322|NCT00916968|Device|Gender specific CR-Flex|TKA by Gender specific Nexgen CR-Flex
1845323|NCT00916981|Procedure|percutaneous autologous preosteoblast cells implantation|percutaneously injection of preosteoblast into the nonunion under radioscopic control
1845324|NCT00916994|Device|SpaceGuard Balloon|Positioning of the balloon into the subacromial space between the humerus head and the acromion
1845325|NCT00917020|Drug|Nasal CO2|As-Needed during the 14 day Treatment Period
1845326|NCT00917020|Drug|Inactive Placebo Gas|Placebo
1845327|NCT00917033|Device|GlideScope|Orotracheal intubation
1845328|NCT00917033|Device|Macintosh direct laryngoscope|Orotracheal intubation
1845329|NCT00917046|Behavioral|high-intensity interval training|3 weekly sessions of high-intensity interval training in 12 weeks
1845330|NCT00917046|Behavioral|Moderate continuous training|3 weekly sessions of moderate continuous training for 12 weeks
1845331|NCT00917046|Behavioral|Recommendation of regular moderate exercise|Recommendation of regular exercise at moderate intensity at individual choice. In addition patients will meet for treadmill walking in order to motivate for post intervention testing
1845332|NCT00917059|Drug|Escitalopram|Fixed dose of 10 mg per day
1845333|NCT00917059|Drug|Bupropion XL|Fixed dose of 150 mg per day
1845334|NCT00917072|Behavioral|Didactic|Group #1: will have a focused, interactive power point lecture on the background, content and guidelines for a good handoff (focus on a standardized electronic hand-off tool). They will have an exercise to complete
1845335|NCT00917072|Behavioral|Didactic+Simulation|Group #2: will undergo the same power point lecture ( as in Group #1) with an additional intervention focused not only on the hand-off tool, but on a standardized hand-off process using an OSCE exercise (objective structured clinical exam). This group will be trained about the effective implementation of the hand-off tool. They will be taught how to standardize the hand-off process and will be given an opportunity to practice with their peers in the HFH simulation center
1845336|NCT00917072|Behavioral|Control|The control group received no formal handoff training other than an introduction to handoffs for all interns during orientation at the start of the academic year along with expected ward based experiential training from senior residents throughout the intern year.
1845337|NCT00917085|Behavioral|Skin-to-Skin contact|Infants in the Skin-to-Skin group also had standard care provided by hospital staff. In addition, the researchers facilitated skin-to-skin contact by placing diaper-clad infants prone between their mothers' breasts as soon as possible after birth. Thereafter the infants and their mothers experienced skin-to-skin contact as often as possible and for as long as possible each time throughout the protocol.
1845338|NCT00917098|Behavioral|Behavior Therapy|Eight weekly sessions during Phase 1 and four sessions every other week during Phase 2; participants will work on implementing habit reversal techniques with psychoeducation, cognitive restructuring, and relaxation, if necessary
1845339|NCT00917098|Behavioral|Supportive Counseling|Eight weekly sessions during Phase 1 of psychoeducation, support, and emotion management related to trichotillomania and other stressors
1845340|NCT00917111|Drug|Nasal CO2|Four times a day for 14 days
1845342|NCT00917124|Device|INVOS|"Monitoring cerebral oxygenation (rSO2) with INVOS. When rSO2 decline occur it can be responded with simple interventions to prevent a brain injury including: repositioning of the head or perfusion cannulae to avoid mechanical obstruction of cerebral blood flow, increasing arterial carbon dioxide tension within normal referent values, increasing oxygen inspiration concentration to maintain adequate tissue oxygen saturation, increasing arterial blood pressure, pump flow rate and cardiac index, temperature decreasing and increasing of anesthetic depth to reduce cerebral oxygen consumption and blood transfusion if hematocrit decreases below 22%.
None of the interventions are outside the range of good clinical practice."
1845343|NCT00917137|Procedure|TBNA + transbronchial lung biopsy + bronchial washing|
1845344|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 12.5mg OPC-6535, once daily for 24months
1845345|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 25mg OPC-6535, once daily for 24months
1845346|NCT00917150|Drug|tetomilast (OPC-6535)|oral administration of 50 mg OPC-6535, once daily for 24months
1845347|NCT00917150|Drug|placebo|oral administration of placebo, once daily for 24months
1845348|NCT00917163|Device|Supralimus(R) Sirolimus-Eluting Coronary Stent System|Drug eluting stent implantation in the treatment of coronary artery disease.
1845349|NCT00917163|Device|Xience V™ Everolimus Eluting Coronary Stent|Drug eluting stent implantation in the treatment of coronary artery disease
1845350|NCT00917176|Device|Occipital nerve stimulation|
1845351|NCT00917189|Behavioral|Challenging Our Minds Program|A computerized cognitive intervention that provides training in attention, memory, and executive function
1845352|NCT00917202|Drug|Methylenblue|
1845353|NCT00917215|Device|Disposable stainless steel acupuncture (0.2mmx4mm)|"For active acupuncture group, needles were inserted into nine acupoints (CV22 and bilateral LU5, ST40, BL13, EXB1)with De-qi three times a week for 4 weeks.
For sham acupuncture group, Nine non-acupoints corresponded with each active acupoint were treated with minimal penetration into skin three times a week for 4 weeks."
1845354|NCT00917228|Device|recordings with device equipped|
1845355|NCT00917228|Device|Control|Recording without device equipped
1845356|NCT00917241|Drug|MMI combined with IID|MMI titration regimen for 18 months,initial dosage of MMI was 20 mg/d,which combined with IID for 3 months.Dexamethasone was injected into the two side of thyroid, the dose of dexamethasone was 5 mg by every side, twice a week. The treatment strategy was changed to once a week at the second month and twice a month at the third month, the dose of dexamethasone was the same as the first month.
1845357|NCT00917241|Drug|MMI|MMI treatment with titration regimen for 18 months, initial dosage was 20 mg/d.
1845358|NCT00917254|Drug|YM150|oral
1845359|NCT00917254|Drug|Placebo|oral
1845360|NCT00917254|Drug|Enoxaparin|injection
1845361|NCT00917267|Drug|exenatide once weekly|2.0mg subcutaneous injection, once a week
1845362|NCT00917267|Drug|exenatide twice daily|5mcg subcutaneous injection twice a day (4 weeks), 10mcg subcutaneous injection twice a day (22 weeks)
1845363|NCT00917293|Drug|Pyridoxal 5'-Phosphate|Pyridoxal 5'-Phosphate 500mgs po bid for 12 weeks.
1845364|NCT00917293|Drug|Placebo|Placebo 2 pills, po bid for 12 weeks.
1845365|NCT00917306|Drug|PEP005 Gel|0.05% two day treatment
1845366|NCT00917319|Other|Bundling Infection Control Interventions|identify risk factors for developing HAIs, receive general infection control measures as well as infection control measures appropriate for the identified risk factor (s)
1845367|NCT00917332|Behavioral|"relaxation (breathing and muscles) and guided imagery (safe place)"|intervention group: daily practice of relaxation and guided imagery CD, for a rew weeks, until childbirth.
1845368|NCT00917345|Drug|captopril test|The blood samplings were obtained one hour after the administration of 50 mg of captopril.The testing is performed in the morning on a seated ambulatory patient
1845369|NCT00917358|Drug|Pegylated interferon alfa-2a|Pegylated interferon alfa-2a 135 ug/week for 24 weeks
1845370|NCT00917384|Biological|ramucirumab|Administered via intravenous infusion every 2 weeks at a dose of 8 mg/kg
1845371|NCT00917384|Drug|Placebo|Placebo comparator for ramucirumab 8 mg/kg as intravenous infusion every 2 weeks
1845372|NCT00917384|Other|Best Supportive Care (BSC)|BSC as determined appropriate by the investigator(s). BSC may include but are not limited to antiemetic agents, opiate and nonopiate analgesic agents, appetite stimulants, and granulocyte and erythroid growth factors.
1845373|NCT00917397|Drug|Sertraline|varies
1845374|NCT00917397|Behavioral|trauma-focused cognitive behavioural therapy|once a week
1845375|NCT00917410|Behavioral|SMS support|"The intervention consisted of sequences of SMS messages sent to the intervention group, each containing 2 or 3 monitoring questions and one reminder to take the preventive medication. The SMS sequence was as follows.
Remember to take your preventive asthma medication (sent at 8.00 am).
Were you awakened during the night due to your asthma? Answer YES or NO.
How many times have you taken your asthma attack medication during the last 24 hours? Answer a number.
What was your peak flow this morning? Answer a number (optional, depending on the participant's use of a spirometer prior to the study)."
1845376|NCT00917436|Drug|Thiocolchicoside|
1845377|NCT00917449|Drug|L-arginine|Oral L-arginine (3.2 gr bid)for 18 months
1845378|NCT00917449|Drug|Placebo|Oral Placebo BID for 18 months
1845379|NCT00917462|Drug|Sorafenib, administered orally|Sorafenib 400 mg twice daily administered continuously. Patients will continue on treatment until progression of disease. Each cycle consists of 28 days. The cycle start date will coincide with the physician visit date. Because of the potential need for physician visit scheduling to vary (due to both physician and patient issues), to avoid violation of, and deviation from, the protocol, these visits may vary by up to one to fourteen (1-14) days. A study diary will be completed by patients to ensure compliance with the study drug.
1845380|NCT00917462|Procedure|CT/MRI|A CT (computerized tomography) or MRI (magnetic resonance imaging) scan of the chest and abdomen will be obtained at baseline, after the first four weeks of therapy, at eight weeks, and then every eight weeks there afterwith a scheduling window of up to one to fourteen (1-14) days. The same imaging modality performed at baseline (CT or MRI) will be repeated at subsequent imaging.
1845381|NCT00917488|Other|Standardization of allergenic extract (Gly. domesticus)|Allergenic extract for cutaneous prick-test
1845382|NCT00917501|Drug|OMega 3|Individual omega-3 capsules contain 400 mg EPA and 200 mg DHA taken twice a day
1845389|NCT00917579|Drug|Atorvastatin|A single 10 mg dose of marketed 10 mg atorvastatin tablets
1845390|NCT00917579|Drug|Atorvastatin|A single 10 mg dose of new formulation of 10 mg atorvastatin
1845391|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid 1 gr every 8 hours 48 hours followed by oral amoxicillin plus clavulanic acid 1 gr every 8 hours for 10 days
1845392|NCT00917592|Drug|amoxicillin plus clavulanic acid|intravenous amoxicillin plus clavulanic acid for 7 days followed by oral antibiotic for 5 days
1845393|NCT00917605|Other|Robot-assisted therapy|Patients will receive an intervention for 20 training sessions (1.5 hours/day, 5 days/week for 4 consecutive weeks). The Robot-assisted arm trainer, Bi-Manu-Track (Reha-Stim Co., Berlin, Germany), will be used in this project. The Bi-Manu-Track enables the symmetrical practice of 2 movement patterns: forearm pronation-supination and wrist flexion-extension (Hesse et al., 2003; Hesse et al., 2005). Each movement has three computer-controlled modes: (1) passive-passive, with both arms being moved by the machine with speed and range of motion individually adjustable; (2) active-passive, with the nonaffected arm driving the affected arm in a mirror-like fashion; and (3) active-active, with both arms actively moving against resistance. Mode 3 is an active mode as in 2, but the paretic arm had to overcome an individually set, initially isometric resistance to allow the bilateral movement. The speed of movement, the amount of resistance, and the range of movement can be adjusted individually.
1845394|NCT00910195|Device|CPAP treatment with subsequent Bi-Level-APAP treatment|CPAP treatment during the first night and then Bi-level-APAP treatment during second night
1845395|NCT00910195|Device|Bi-Level-APAP treatment with subsequent CPAP treatment|Bi-level-APAP treatment during the first night and then CPAP treatment during the second night
1845396|NCT00910208|Device|Patient-controlled analgesia|Intravenous morphine delivered via Curlin painsmart PCA device
1845397|NCT00910208|Drug|morphine|Intravenous morphine
1845398|NCT00910221|Drug|Atorvastatin|Atorvastatin tablet
1845399|NCT00910221|Drug|Placebo|Placebo tablet
1845402|NCT00917631|Procedure|Co-bedding (caring for twins in the same incubator)|"Twin infants will be placed together in a Incubator or crib lying side-by-side. Twins will be diaper clad and nested together in boundaries consistent with neonatal care practices. All infants will have cardio-respiratory monitoring while co-bedding.
Infants in the co-bedding group be co-bedded for no less than 24 hours prior to heelstick to allow for stabilization following transfer. The heelstick being studied will occur no greater than 10 days following initiation of co-bedding. Duration of co-bedding will be recorded and controlled for in the analysis if necessary.
Monitoring and video-tape recording will take approximately 20-30 minutes per participant - a baseline period (5-10 minutes prior to heel stick), warming (3 minutes), heel stick (2-5 minutes), and recovery phase (approximately 10 minutes)."
1845403|NCT00917644|Drug|Atorvastatin|A single 80 mg dose of marketed 80 mg atorvastatin tablets
1845404|NCT00917644|Genetic|Atorvastatin|A single dose of new formulation of 80 mg atorvastatin tablets
1845405|NCT00917657|Procedure|Photorefractive keratectomy|
1845406|NCT00917696|Procedure|Comparator: Iontophoresis and Laser Doppler with ATP|Iontophoresis treatments with 10 mM ATP (adenosine triphosphate) solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
1845407|NCT00917696|Procedure|Comparator: Iontophoresis and Laser Doppler with Saline|Iontophoresis treatments with 20 mM saline solution and a current of 0.8 or 1.2 mA. Iontophoresis treatments will last 4 minutes. Laser doppler will be used during the iontophoresis treatments to measure dermal blood flow.
1845408|NCT00917709|Other|Imaging with IBVM|in vivo molecular imaging of presynaptic molecular target of cholinergic systems with [123I]-iodobenzovesamicol
1845409|NCT00917709|Other|Imaging with DATSCAN|in vivo molecular imaging of presynaptic molecular target of dopaminergic systems (DAT) with DATSCAN
1845410|NCT00917709|Behavioral|neuropsychological evaluation|neuropsychological evaluation using neuropsychological tests
1845411|NCT00917735|Drug|Green tea extract supplement|Two green tea extract capsules twice daily after breakfast and dinner for one year
1845412|NCT00917735|Other|Placebo|Two placebo capsules twice daily after breakfast and dinner for one year
1845413|NCT00917748|Drug|DOCETAXEL(XRP6976) + MODAFINIL|arm 1: best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily arm 2: best supportive care (docetaxel chemotherapy) plus placebo of modafinil 200mg mane daily
1845414|NCT00917748|Drug|Modafinil|best supportive care (docetaxel chemotherapy) plus modafinil 200mg mane daily
1845415|NCT00917748|Drug|Placebo of Modafinil|Best supportive care (docetaxel chemotherapy) + placebo capsules one daily-mane (before noon)
1845416|NCT00917761|Drug|Entecavir and peginterferon (Pegasys) (52 weeks)|Entecavir 0.5 mg/day po at week 1-4 Peginterferon alfa-2a 180 ug/week sc at week 5-52
1845417|NCT00917761|Drug|Peginterferon (Pegasys) (96 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-96
1845418|NCT00917761|Drug|Peginterferon (Pegasys) (48 weeks)|Peginterferon alfa-2a 180 ug/week sc at week 1-48
1845419|NCT00917774|Device|Standard LPS flex TKA|TKA by Standard LPS flex TKA
1845420|NCT00917774|Device|Gender specific LPS -Flex TKA|Total knee design created specific for female patients
1845421|NCT00917813|Drug|KD-247|Cohort 1 - 4 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 2 - 8 mg/kg KD-247 IV on Days 1, 8, and 15; Cohort 3 - 16 mg/kg KD-247 IV on Days 1, 8, and 15
1845422|NCT00917813|Drug|Physiological saline|Cohort 1 - Physiological saline IV on Days 1, 8, and 15; Cohort 2 - Physiological saline IV on Days 1, 8, and 15; Cohort 3 - Physiological saline IV on Days 1, 8, and 15
1845423|NCT00917826|Drug|Arginine Butyrate|1,000 mg/kg/day administered IV over 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
1845424|NCT00917826|Drug|Ganciclovir|5 mg/kg administered IV over 1 hour (Days 1-5 of each 21 day cycle)
1845425|NCT00917826|Drug|Valganciclovir|900 mg BID for 16 days (Days 6-21 of each 21 day cycle)
1845426|NCT00917839|Drug|lamotrigine|100 mg, once daily, 12 months
1845427|NCT00917852|Device|Gore Conformable TAG Thoracic Endoprosthesis|Endovascular stent graft
1845535|NCT00921063|Drug|PD 0332334|100 mg capsule, BID for 4 weeks
1845428|NCT00917865|Drug|anti [18F]FACBC|Anti[18F]FACBC (10mci) will be given intravenously over 1-2 minutes prior to obtaining PET-CT images At 4 minutes, 10 consecutive/4minutes images will be obtained of the pelvis to include the prostate.
1845429|NCT00917878|Dietary Supplement|Milk|500 mL low-fat milk added to high-fat meal
1845430|NCT00917878|Dietary Supplement|Protein|Milk protein in 500 mL water added to high-fat meal
1845431|NCT00917878|Dietary Supplement|Calcium|Milk calcium in 500 mL water added to high-fat meal
1845432|NCT00917878|Dietary Supplement|Control|Lactose in 500 mL water added to high-fat meal
1845433|NCT00917891|Drug|dapivirine|"dosage form: vaginal gel
dosage: 1.25mg dapivirine/day
frequency: once daily
duration: 6 weeks"
1845434|NCT00917891|Drug|placebo|"dosage form: vaginal gel
frequency: once daily
duration: 6 weeks"
1845435|NCT00917904|Drug|dapivirine|"dosage form: vaginal gel
dosage: 1.25mg dapivirine/day
frequency: once daily
duration: 6 weeks"
1845436|NCT00917904|Drug|placebo|"dosage form: vaginal gel
frequency: once daily
duration: 6 weeks"
1845437|NCT00917917|Behavioral|Type of physical activity (resistance, endurance)|"To determine which type of physical activity is the best to reduce metabolic syndrome parameters especially abdominal circumference.
Group 1 will perform mostly resistance activities, group 2 mostly endurance activities, and Group 3 performing both activities at low level, serves as a control group for physical activities."
1845438|NCT00917917|Behavioral|Restrictive diet|All subjects will have the same restrictive diet (500- 700 kcal/d).
1845439|NCT00917930|Behavioral|physical training|intensive cardiac rehabilitation program
1845440|NCT00917943|Behavioral|Tailored Counseling Intervention Arm|Study staff contact women when they are between 28 and 34 weeks pregnant, confirm their non-smoking status, and make an appointment to explain the study further, obtain written informed consent, conduct the risk assessment, and collect baseline data. Bio-behavioral and pregnancy-specific factors are used to triage women in the treatment arm to one of four levels of stepped-care that includes one in-person counseling session and at least one telephone session during pregnancy and from 6 to 11 telephone sessions over the first 9-months postpartum.
1845444|NCT00920465|Drug|mifegyne and cytotec|One day dosage versus two days dosage
1845445|NCT00920478|Other|Musculoskeletal Ultrasound|Gray scale and power doppler - to identify the presence of synovitis
1845446|NCT00920478|Other|28 Joint Disease Activity Score|Clinical assessment of synovitis - composite score incorporating 28 tender joint count, 28 swollen joint count, erythrocyte sedimentation rate and patient global VAS
1845447|NCT00920491|Biological|biomarker-enhanced disposition decision with proADM|To compare the outcome of standard of care with an approach combining the standardized course and biomarker levels (biomarker-enhanced disposition decision with proADM) for the disposition of patients with non-specific complaints presenting to the emergency department (ED), in order to evaluate safety.
1845448|NCT00920504|Behavioral|German PRO-SELF(c) Plus Pain Control Program (PCP)|Educational intervention directed at patients and their family caregivers to reduce cancer pain and related symptoms
1845449|NCT00920504|Other|Standard Care|Patients in the standard care group will receive routine care provided by their treating physicians without any further care concerning the PRO-SELF© PCP. Patients in the standard care group will be seen by a research nurse in their homes at weeks 1, 2, 4, 6, 8 and 10 and telephone interviews will be conducted at weeks 3, 5, 7 and 9 but the focus of the visits and phone calls will be data collection only.
1845450|NCT00920517|Biological|rDEN2/4delta30(ME) vaccine|10^3 PFU dose
1845451|NCT00920517|Biological|Placebo|placebo for rDEN2/4delta30(ME) vaccine
1845452|NCT00920543|Drug|Placebo|Twice daily dosing
1845453|NCT00920543|Drug|FP 100mcg|Twice daily dosing
1845454|NCT00920543|Drug|FP 500mcg|Twice daily dosing
1845455|NCT00920543|Drug|FP 250mcg|Twice daily dosing
1845456|NCT00920543|Drug|FSC 100/50mcg|Twice daily dosing
1845457|NCT00920543|Drug|FSC 250/50mcg|Twice daily dosing
1845458|NCT00920543|Drug|FSC 500/50mcg|Twice daily dosing
1845461|NCT00920582|Drug|Teplizumab (MGA031)|IV dosing daily for 14 days times 2 courses
1845462|NCT00920582|Drug|Placebo|IV dosing daily for 14 days times 2 courses
1845463|NCT00920595|Drug|CEP-9722|Starting dose of CEP-9722 is 150 mg/day (total dose). The study consists of a 14-day cycle of CEP-9722 alone, and at least one 28-day cycle of CEP-9722 plus temozolomide (150 mg/m2/day on Days 1-5). Patients who are receiving clinical benefit may receive subsequent cycles of study drug treatment.
1845464|NCT00920608|Drug|AZD9056|Tablets for oral use. 400 mg once daily for 7 days
1845465|NCT00920608|Drug|Methotrexate|Tablet for oral use.7.5 to 20 mg single dose administration at visit 2 and 3.
1845466|NCT00920621|Dietary Supplement|Vitamin D 3 cholecalciferol|Dosage form oral Dosage 4000IU Vitamin D 3 cholecalciferol
1845467|NCT00920621|Dietary Supplement|Vitamin D3|4000 IU of vitamin D3 administered orally once a day during pregnancy
1845468|NCT00920634|Drug|Follitropin beta|For subcutaneous or intramuscular injection, the usual dosage is 50 IU of follitropin beta (recombinant) once daily for 7 days. The dosage should be adjusted subsequently while monitoring the development of follicles (dose increase by 25 IU every 7 days if the response of the ovaries is poor) and, after confirming presence of follicles of 18 mm or larger in mean diameter by the ultrasonic tomography, ovulation is induced by the administration of a human chorionic gonadotropin preparation.
1845469|NCT00920647|Other|Control|3 dose cohorts were planned. Within each dose cohort, patients will be randomized to 1 of 2 treatment options: treatment with study drug or no treatment with 4 treated patients per dose group and a total of 4 untreated patients (1-2 untreated patients will be assigned in each dose cohort). They will not undergo surgical placement of an Intrathecal Drug Delivery Device (IDDD), and will not receive Idursulfase-IT.
1845470|NCT00920647|Drug|Idursulfase IT (1 mg)|The original design of the study was to test the dose levels of 10, 30 and 100 mg. This was based on a calculation of a minimally effective dose around 10 mg, with subsequent dose levels being chosen as increasing half-log steps. During the conduct of the study; however, it became clear that the 10 mg dose elicited a strong Pharmacodynamic response, as measured by a dramatic and sustained drop in the CSF GAG levels. This indicated the need to explore a lower level as a minimally effective dose level, leading to the introduction of the 1 mg group. Enrollment of patients in this dose cohort will commence after the last patient has been enrolled in 30 mg dose cohort. 4 patients will be undergo surgical placement of an IDDD and receive 1 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
1845471|NCT00920647|Drug|Idursulfase IT (10 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 10 mg idursulfase-IT as an intrathecal (IT) injection via an IDDD once per month (ie, every 28 days) for 6 month.
1845472|NCT00920647|Drug|Idursulfase IT (30 mg)|Patients will be enrolled in 10 mg dose cohort and 30 mg dose cohort in a sequential, escalating fashion. 4 patients will undergo surgical placement of an IDDD and receive 30 mg idursulfase-IT as an IT injection via an IDDD once per month (ie, every 28 days) for 6 month.
1845473|NCT00920660|Drug|Placebo|Matching placebo is supplied containing microcrystalline cellulose (Avicel PH 105). Placebo will be administered as eight matched capsules.
1845474|NCT00920660|Drug|0.25g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.25g SRT2104 treatment visit will be administered as one SRT2104 capsule with 7 placebo capsules. Dosing will take place during one of the 6 treatment visits.
1845475|NCT00920660|Drug|Prednisolone|During the last treatment period, subjects will receive 30 mg open-label prednisolone.
1845476|NCT00920660|Drug|0.5g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 0.5g SRT2104 treatment visit will be administered as two SRT2104 capsules with 6 placebo capsules. Dosing will take place during one of the 6 treatment visits.
1845477|NCT00920660|Drug|1g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 1g SRT2104 treatment visit will be administered as four SRT2104 capsules with four placebo capsules. Dosing will take place during one of the 6 treatment visits.
1845478|NCT00920660|Drug|2g SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg. The 2g SRT2104 treatment visit will be administered as eight SRT2104 capsules. Dosing will take place during one of the 6 treatment visits.
1845479|NCT00920673|Procedure|MRI|MRI during 35 to 65 minutes
1845480|NCT00920686|Drug|NXN-188|NXN-188 hard gelatin capsules, 600 mg administered as three 200 mg capsules
1845481|NCT00920686|Drug|placebo|administered as 3 placebo hard gelatin capsules
1845482|NCT00920686|Drug|sumatriptan succinate|administered in a hard gelatin capsule with 2 capsules of placebo
1845483|NCT00920699|Drug|CoQ10|Capsules containing 300 mg of CoQ10 or matching placebo taken orally twice a day. All participant will start on a dosage of 600 mg/day in divided doses, increasing weekly by 600 mg/day to a maximum dosage of 2400 mg/day at week 4. Dosage should be stable from week 4 until week 20.
1845484|NCT00920712|Drug|Weiqi decotion|Decoction ,two times a day
1845485|NCT00920725|Drug|Insulin (Aspart Insulin [Novolog], Regular Insulin)|"Aspart Insulin 0.2units/sq q 2 hours
Regular Insulin 0.1units/kg/hr intravenous
Aspart Insulin 0.1 units/kg/hr intravenous"
1845486|NCT00920738|Other|metabolic assessment|Physical examination, medical history, blood pressure, anthropometrics, laboratory studies and other procedures (body composition, bone density, growth hormone, vascular, functional mobility, body fat assessments, etc).
1845487|NCT00920738|Other|questionnaire administration|Dietary habits will be evaluated using the Youth/ Adolescent Questionnaire (YAQ)and the Modifiable Activity Questionnaire for Adolescents (MAQA) will be used to assess participation in leisure time and competitive activities during the past year will be administered on Day 2.
1845488|NCT00920751|Procedure|Water infusion|Water infusion in lieu of air insufflation during colonoscope insertion
1845489|NCT00920751|Procedure|Air insufflation|Conventional air insufflation colonoscopy
1845490|NCT00920764|Drug|Placebo for Atrasentan 0.2 mg/mL solution|10 mL oral solution, daily, 8 weeks
1845491|NCT00920764|Drug|0.25 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
1845492|NCT00920764|Drug|0.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
1845493|NCT00920764|Drug|1.75 mg Atrasentan QD|10 mL oral solution, daily, 8 weeks
1845494|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 16 weeks
1845495|NCT00920777|Behavioral|CBT|Individual Cognitive Behavior Therapy during 8 weeks
1845496|NCT00920777|Behavioral|Control group|Waiting 16 weeks and receiving 8 weeks individual CBT after waiting period.
1845497|NCT00920790|Biological|KW-0761|KW-0761 is administered weekly for 8 weeks as an intravenous infusion of 2 hours at a dose of 1.0 mg/kg.
1845498|NCT00920803|Drug|Placebo|Placebo will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. Placebo must be used immediately following mixing. Placebo will be administered orally, once daily for 14 days.
1845499|NCT00920803|Drug|SRT501|SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. The final drug product must be used immediately following mixing. SRT501 will be administered orally, once daily for 14 days.
1845500|NCT00920816|Drug|Axitinib (AG-013736)|axitinib will be given at a starting dose of 5 mg BID with continuous dosing
1845501|NCT00920816|Drug|Sorafenib|sorafenib will be given at a dose of 400 mg BID continuous dosing
1845502|NCT00920829|Drug|Drug|Naltrexone 25 or 50 mg per tiration schedule
1845503|NCT00920829|Drug|Placebo|placebo
1845504|NCT00920855|Drug|bendamustine|"Bendamustine was administered to 3 cohorts of patients at escalating doses of 50 (cohort 1), 70 (cohort 2) and 90 mg/m^2/dose (cohort 3). Doses were administered by intravenous (iv) infusion once daily on days 1 and 4 of each 28-day cycle. Each iv was administered over 60 minutes and followed the injection of bortezomib.
Bortezomib will be administered to patients at a dose of 1.0 mg/m2/dose as an iv push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered to patients on days 1, 4, 8 and 11 of the 28-day cycle."
1845536|NCT00921063|Drug|placebo|0 mg capsule, BID for 4 weeks
1845505|NCT00920855|Drug|bortezomib|Bortezomib was administered at a dose of 1.0 mg/m^2/dose as an intravenous (iv) push over 3 to 5 seconds followed by a standard saline flush or through a running iv line. Doses are to be administered on days 1, 4, 8 and 11 of each 28-day cycle.
1845506|NCT00920868|Drug|dasatinib|dasatinib at 50 mg PO BID)
1845507|NCT00920868|Drug|bevacizumab|7.5 mg/kg IV day 1
1845508|NCT00920868|Drug|Oxaliplatin|130 mg/m2 IV day 1
1845509|NCT00920868|Drug|Capecitabine|850 mg/m2 PO BID on days 1-14
1845510|NCT00920881|Device|FreeStyle Navigator Continuous Glucose Monitoring System|Subjects wore 2 Navigator sensors for approximately 122 hours. Subjects and clinical staff were masked to continuous glucose data. During the time the subjects wore the continuous sensor, they were instructed to continue with their current diabetes management plan. Subjects stayed at the clinic for approximately 50 hours during the study period. While in the clinic, venous blood samples were collected every 15 minutes to determine whole blood reference glucose concentrations using the Yellow Springs Instrument. Subjects were also asked to obtain up to 50 FreeStyle finger blood glucose measurements using the system in the Navigator receiver for comparative analysis and system calibration. This was not a treatment study.
1845511|NCT00920894|Dietary Supplement|plant stanol ester|the effect of plant stanol esters on plasma lipids
1845512|NCT00920907|Biological|Ipilimumab|Solution, Intravenous, 10 mg/kg, Every 3 weeks (up to 4 doses) in induction phase, every 12 weeks in maintenance phase, 48 weeks
1845513|NCT00920920|Radiation|3D MRI-guided Brachytherapy|MRI-based 3D-4D brachytherapy in locally advanced cervical cancer
1845514|NCT00920933|Biological|AIN457|
1845515|NCT00920933|Other|Placebo|
1845516|NCT00920933|Drug|prednisolone|
1845517|NCT00920946|Drug|Dimebon|20 mg Dimebon orally TID
1845518|NCT00920946|Other|Placebo|Orally TID
1845519|NCT00920959|Drug|FP 100mcg|Once-daily dosing
1845520|NCT00920959|Drug|FSC 100/50mcg|Once-daily dosing
1845521|NCT00920959|Drug|Placebo|Once-daily dosing
1845522|NCT00920972|Drug|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|"Day -22 Campath-1H 3 mg IV or SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on Day 0...
GVHD Prophylaxis:
Starting day -3: Tacrolimus or cyclosporine... Days +1, +3, +6: Methotrexate"
1845523|NCT00920972|Drug|Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan|"Day -50 to -21 Hydroxyurea 30mg/kg PO… Day -22 Campath-1H 3 mg IV or SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -4 Thiotepa 8mg/kg IV… Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
GVHD Prophylaxis Options:
Regimen 1= Starting day -3: Tacrolimus or cyclosporine... Days +1, +3, +6: Methotrexate.... Starting on day +7: Prednisone...
OR Regimen 2 = Starting day -3: tacrolimus or cyclosporine Starting day -3: mycophenolate mofetil"
1845524|NCT00920972|Drug|Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan|"Day -50 to -21 Hydroxyurea 30mg/kg PO… Day -22 Campath-1H 3 mg IVor SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -4 Thiotepa 8mg/kg IV… Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
GVHD Prophylaxis Regimen:
Children < 6 years of age, BM recipients:
Regimen 1 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Starting day +7: prednisone...
Children >/=6 years, BM recipients:
Regimen 3 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Days -1, +5, +14, +28: abatacept...
UCB recipients:
Regimen 1 (described above) OR Regimen 2 = Starting day -3: tacro or CsA... Starting day -3: MMF"
1845525|NCT00920972|Drug|Transplant conditioning regimen of hydroxyurea, campath, fludarabine, thiotepa, & melphalan|"Day -50 to -21 Hydroxyurea 30mg/kg PO… Day -22 Campath-1H 3 mg IV or SQ... Day -21 Campath-1H 10 mg IV or SQ... Day -20 Campath-1H 15 mg IV or SQ... Day -19 Campath-1H 20 mg IV or SQ... Day -8 Fludarabine 30mg/m2 IV... Day -7 Fludarabine 30mg/m2 IV... Day -6 Fludarabine 30mg/m2 IV... Day -5 Fludarabine 30mg/m2 IV... Day -4 Fludarabine 30mg/m2 IV... Day -4 Thiotepa 8mg/kg IV… Day -3 Melphalan 140 mg/m2 IV... (dose modifications for patients <10 kgs) Procedure/Surgery: Hematopoietic stem cell infusion on day 0...
GVHD Prophylaxis Regimen:
Children < 6 years of age, BM recipients:
Regimen 1 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Starting day +7: prednisone...
Children >/=6 years, BM recipients:
Regimen 3 = Starting day -3: tacro or CsA... Days +1, +3, +6: MTX... Days -1, +5, +14, +28: abatacept...
UCB recipients:
Regimen 1 (described above) OR Regimen 2 = Starting day -3: tacro or CsA... Starting day -3: MMF"
1845526|NCT00920985|Drug|Gestodene/EE (FC Patch Low, BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 7 cycles and placebo tablets matching the conditions of the treatment of Arm 2
1845527|NCT00920985|Drug|Oral contraceptive (equivalent to the active treatment tablets of Levlite), 21-day blister SH D00593A|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 7 cycles and placebo patches matching the conditions of the treatment of Arm 1
1845528|NCT00920998|Drug|Z-338|oral
1845529|NCT00921024|Drug|CXA-101|intravenous
1845530|NCT00921024|Drug|Ceftazidime|intravenous
1845531|NCT00921037|Procedure|Erbium-YAG laser vaporization|spot size 2-5 mm diameter, applying about 1,2 -2 J at a frequency of 6-12 Hz
1845532|NCT00921050|Drug|levothyroxine sodium|Daily intake (fasting) levothyroxine bimonthly adjusted; to keep TSH between 0.5 to 2.5 mUI/L range. Start with 12.5mcg an investigator other than the caregiver will review the TSH measurements to adjust levothyroxine dose that will contain the coded bottle with the pils given to patient.
1845533|NCT00921050|Drug|excipient without levothyroxine (placebo)|Daily intake (fasting) a pill. bimonthly adjusted; an investigator other than the caregiver will review the TSH measurements and pretend to adjust dose contained in the coded bottle with the pills given to patient.
1845534|NCT00921063|Drug|PD 0332334|250 mg capsule, BID for 4 weeks
1845537|NCT00921063|Drug|Alprazolam extended release|1 mg capsule, BID for 4 weeks
1845538|NCT00921076|Behavioral|Gait Analysis|A computerized motion analysis system to observe the effect of ankle arthroplasty versus ankle arthrodesis on the kinematic behaviour of the foot and ankle during gait.
1959470|NCT00054353|Drug|fludarabine phosphate|Given IV
1845543|NCT00921115|Drug|Fulvestrant|Fulvestrant IM on day 14 and on day 28 followed by day 28 of all subsequent cycles thereafter. Treatment will be continued for a total of 4 cycles.
1845544|NCT00921115|Drug|Anastrazole|Anastrazole, 1mg by mouth every day of all 28 day cycles and continued for a total of 4 cycles
1845545|NCT00921128|Drug|Muscimol|
1845546|NCT00921154|Drug|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods with a 14 day wash-out period. Doses will be administered after an overnight fast.
1845547|NCT00921167|Drug|Bevacizumab/Irinotecan|Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs [EIAEDs] or 340mg/m2 for patients on EIAEDs) every 2 weeks
1845548|NCT00921180|Drug|Entecavir and peginterferon alfa-2a|Entecavir (Baraclude) 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
1845549|NCT00921180|Drug|Placebo and peginterferon|Placebo 0.5 mg/day po at week 1-4 Peginterferon alfa-2a (Pegasys) 180 ug/week sc at week 5-52
1845550|NCT00921193|Device|Radiation Therapy Positioning System (RTPS)|
1845551|NCT00921206|Biological|VAX102|1 ug i.m. compared to 2 ug s.c.
1845552|NCT00921219|Drug|ivermectin|Each subject will receive single doses of (i) 22.5 ml ivermectin oral solution (22.5 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
1845553|NCT00921232|Behavioral|Questionnaires|"During a consultation:
3 questionnaires (HADS, FRI, CRA)
and a form for the sociodemographic data"
1845554|NCT00921245|Drug|Darifenacin (Emselex, BAY79-4998)|Patients in daily clinical treatment receiving Emselex according to local drug information
1845555|NCT00921258|Procedure|prostate biopsy|"patient of control group will have :
1 prostate biopsy 3 months after diagnostic biopsy
1 prostate biopsy each year during 2 years
1 prostate biopsy each 2 years during 8 years"
1845556|NCT00921271|Device|Monitoring of StO2|Monitoring of lower limb anterior compartment StO2, taking measurements on an hourly basis for the duration of the study protocol.
1845557|NCT00921284|Drug|NaCl 9/00|Same volume as in the dexmedetomidine group
1845558|NCT00921284|Drug|dexmedetomidine|1 mcg/kg administered in 10 minutes followed by a continuous infusion of 0,5 mcg/kg/hr
1845559|NCT00921297|Procedure|Immediate Cataract Surgery|Cataract surgery, as part of standard of care, will be performed on 1/2 of the group under investigation.
1845560|NCT00921310|Drug|Pemetrexed|
1845561|NCT00921310|Drug|Temsirolimus|
1845562|NCT00921323|Behavioral|Goal-setting group|This intervention group will be advised to increase their daily steps by at least 20% gradually over 3 months
1845563|NCT00921336|Drug|KW-2450|Dose escalation may proceed once >= 3 subjects have completed the Day 29 blood sample to evaluate glucose. The safety of each dose level will be established prior to enrollment of subjects in the next dose level. Dose escalation will proceed sequentially with accelerated escalation. Once the criteria for completing the accelerated titration are reached, dose escalation will follow a modified Fibonacci schedule. Up to 6 subjects will be enrolled at each dose level. Enrollment will proceed until the maximum tolerated dose (MTD) has been established or the highest dose level (800 mg/day) has been reached. The Sponsor will enroll up to 12 additional subjects, in an expanded safety cohort.
1845564|NCT00921349|Procedure|Ligation of varices|all varices are ligated until obliteration
1845565|NCT00921349|Drug|Nadolol|Nadolol (beta-blocker)
1845566|NCT00921375|Drug|TULY|TULY (rasburicase) 0.20 mg/kg body weight intravenously for 4 days
1845569|NCT00921401|Behavioral|Asthma Feedback|All participants will log in to the study Web site at least once a month and before all doctor visits. They will answer a series of questions and receive individualized feedback about the types of questions they should ask their doctor.
1845570|NCT00921414|Drug|Rituximab|2 months after ASCT maintenance treatment with Rituximab 500mg/m² IV every 2 months during 3 years
1845571|NCT00921414|Other|Watch and wait|No treatment patient follow-up every 2 months during 3 years
1845572|NCT00921427|Behavioral|Vision Restoration Therapy (VRT)|30 min, twice a day, 3 days a week, 12 weeks
1845573|NCT00921427|Device|Transcranial direct current stimulation (tDCS)|2 mA/min, 30 min, twice a day, 3 days a week for 12 weeks
1845574|NCT00921492|Device|Low-frequency electro-acupuncture (EA)|2 Hz EA during 30 minutes, twice a week, 14 weeks.
1845575|NCT00921492|Other|Meeting a therapist - attention control|Meeting a therapist, twice a week during 30 minutes in order to control for the increased amount of attention.
1845576|NCT00921505|Drug|Ibuprofen|Tablet ibuprofen 400 mg oral single dose (1 tablet)
1845577|NCT00921505|Drug|Ibuprofen|Tablets (2 x 600 mg) oral single dose (2 tablets)
1845578|NCT00921505|Drug|Paracetamol (acetaminophen) 1000 mg|Tablets (2 x 500 mg) oral single dose (2 tablets)
1845579|NCT00921505|Drug|Paracetamol + ibuprofen|Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
1845743|NCT00913081|Dietary Supplement|Quercetin|Quercetin 500, 1000, or 2000 mg PO one time
1959471|NCT00054353|Drug|melphalan|Given IV
1959472|NCT00054353|Radiation|total-body irradiation|Undergo TBI
1959473|NCT00054353|Drug|mycophenolate mofetil|Given PO
1959474|NCT00054353|Drug|cyclosporine|Given PO
1845580|NCT00921518|Drug|0.9% Sodium Chloride (Placebo)|0.9% Sodium Chloride (placebo) will infuse at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
1845581|NCT00921518|Drug|Sodium Bicarbonate|Group two will receive sodium bicarbonate 150mEq in 850ml of a 5% dextrose solution at 3 ml/kg/hr for one hour pre-operatively until the patient is started on cardiopulmonary bypass. Then the infusion will be reduced to 1 ml/kg/hr throughout cardiopulmonary bypass and for six hours following cardiopulmonary bypass.
1845582|NCT00921531|Drug|Thalidomide|"Thalidomide is used for adjuvant therapy for TACE
Thalidomide will be given at the dose of 200 mg/day in beginning, with dose escalation of 100 mg/day each week, until to the dosage of 400 mg/day."
1845583|NCT00921531|Drug|TACE|TACE (5-FU 1.0 g, OXP 150mg, MMC 10 mg, lipiodol 5-30 ml) will be performed every two months (defined as a course) until no radiological evidence of survival of tumor (based on contrast MRI) or 6 courses.
1845584|NCT00921544|Other|Sucrose|0.2 ml sucrose 24% given by mouth using a syringe and pacifier
1845585|NCT00921544|Other|Sterile water|Sterile water administered 2 mins prior to eye exam
1845586|NCT00921557|Drug|Alendronate|Oral tablet taken once weekly: 70 mg if participant greater than 30 kg or 35 mg if participant less than or equal to 30 kg
1845587|NCT00921557|Drug|Placebo|Oral tablet taken once weekly
1845588|NCT00921557|Dietary Supplement|Calcium carbonate/vitamin D|Tablet taken once or twice daily: calcium carbonate (600 mg) and vitamin D (400 IU) once daily for participants with 25-OH-vitamin D levels greater than or equal to 20 ng/mL or twice daily for those with 25-OH-vitamin D levels less than 20 ng/mL
1845589|NCT00921570|Drug|Amlodipine|calcium channel blocker (Amlodipine 10 mg) during 12 weeks
1845590|NCT00921570|Drug|Valsartan|AII receptor blocker inhibitor (Valsartan 160 mg) during 12 weeks
1845591|NCT00921583|Device|Long-term examination|Follow-up dental implants 20 year in function
1845592|NCT00921596|Procedure|cardiac operation with totally endoscopic method|Cardiac operations are performed with three keyholes in the right chest wall. Video images are obtained by digital thoracoscope through one hole. Intracardiac lesions are accessed with surgical instruments and repaired through the other two holes. Cardiopulmonary bypass is set up with femoral cannulations. Moderate system hypothermic is applied for the operation. Cardiac arrest is achieved with ascending aorta clamp and cardioplegia solution delivery through aortic root cannulation. After the intracardiac lesions are repaired, aortic clamp is removed, and the heart is reperfused to restore its spontaneous rhythm. After the patients are rewarmed to normal temperature, CPB is discontinued. Femoral cannulations are removed, and surgical wounds are closed.
1845593|NCT00921609|Other|OGTT|An OGTT is a test that lowers growth hormone in the body to very low levels for a short time in order to see how low the growth hormone levels are in your blood.
1845594|NCT00921622|Dietary Supplement|Vitamin D|1000 IU twice daily for up to 10 days
1845595|NCT00921622|Dietary Supplement|Vitamin C|500 mg twice daily for up to 10 days
1845596|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 120 g/L
1845597|NCT00921635|Procedure|Blood transfusion|Blood transfusion to maintain hemoglobin level above 100 g/L
1845598|NCT00921661|Drug|AVE0005 (aflibercept)|IV infusion
1845599|NCT00921674|Drug|ivermectin|Each subject will receive single doses of (i) 30 ml ivermectin oral solution (30 mg) and (ii) 10 x 3 mg tablets of ivermectin (30 mg) in 2 separate dosing periods. Doses will be administered 20 minutes after a standard breakfast.
1845600|NCT00921687|Behavioral|Education only|The education will consist of a lecture and distribution of a CKD reference card.
1845601|NCT00921687|Behavioral|Multifactorial intervention|Providers in the intervention group will receive a lecture on CKD, a CKD reference card, academic detailing (residents only), and access to the CKD registry.
1845602|NCT00921700|Drug|Ibuprofen + Paracetamol|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg in gelatine capsules
1845603|NCT00921700|Drug|Ibuprofen + Paracetamol + Codeine|Single oral dose of ibuprofen 400 mg combined with paracetamol (acetaminophen) 1000 mg and codeine 60 mg in gelatine capsules
1845604|NCT00921700|Drug|Paracetamol + Codeine|Single oral dose of paracetamol (acetaminophen) 1000 mg combined with codeine 60 mg in gelatine capsules
1845605|NCT00921700|Drug|Placebo|Single oral dose of lactose as placebo in gelatine capsules
1959475|NCT00054353|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
1845608|NCT00921726|Drug|Zanamivir|Continuous (800 mg in Regimen A, 3600 mg in Regimen C) and intermittent (3600 mg in Regimen D) infusion
1845609|NCT00921726|Drug|Oseltamivir|150 mg oral tablets taken five times over 3 days in Regimens A, B, C, and D
1845610|NCT00921739|Radiation|Esophageal sparing IMRT|6 fractions/week of 2Gy each for 29 fx (58 Gy), 31 fx (62 Gy), 33 fx (66 Gy), 35 fx (70 Gy), or 37 fx (74 Gy).
1845611|NCT00921765|Drug|Saline|Saline single bolus dose followed by saline single bolus dose iv
1845612|NCT00921765|Drug|Saline + Ketamine|Single bolus dose of saline followed by ketamine 0.2 mg/kg bw
1845613|NCT00921765|Drug|Naloxone + Placebo|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of saline
1845614|NCT00921765|Drug|Naloxone + Ketamine|Single bolus dose of naloxone 0.2 mg/kg bw followed by single bolus dose of ketamine 0.2 mg/kg bw
1845615|NCT00921778|Device|Lapcone|Use of Lapcone during LSH
1845616|NCT00921778|Procedure|laparoscopic supracervical hysterectomy|laparoscopic supracervical hysterectomy
1845617|NCT00921791|Device|HBPM|Automatic oscillometric device for home blood pressure measurement and usual care.
1845618|NCT00921791|Device|HBPM and Pharmaceutical care|Automatic oscillometric device for blood pressure measurement at home and consultations with the pharmacists
1845619|NCT00921791|Behavioral|Pharmaceutical care|consultations with the pharmacists
1845620|NCT00921791|Other|Usual care|Consultation with the physician.
1845621|NCT00921804|Drug|AZD 8529|40mg oral daily capsule administered as a single dose in the morning for 28 days
1845622|NCT00921804|Drug|Risperidone|4mg (2mg on Day 1) oral daily capsule administered as a single dose in the evening for 28 days
1845744|NCT00913081|Dietary Supplement|Placebo|Placebo PO one time
1845623|NCT00921804|Drug|Placebo to match AZD8529|Placebo to match AZD8529 administered as a daily capsule in the morning for 28 days during the treatment period and also during the 3-7 day washout or run-in period
1845624|NCT00921804|Drug|Placebo to match risperidone|Placebo to match risperidone administered as a daily capsule in the evening for 28 days during the treatment period and also during the 3-7 day washout or run-in period
1845625|NCT00921830|Drug|ibuprofen|Each subject will receive single doses of (i) ibuprofen 50 mg suppository (ii) ibuprofen 200 mg suppository and (iii) ibuprofen 200 mg tablet in 3 separate dosing periods. Doses will be administered after an overnight fast.
1845626|NCT00921843|Drug|Methadone|Subjects will receive methadone as their intraoperative opioid.
1845627|NCT00921856|Other|Intracoronary acetylcholine provocation test|Intracoronary provocation of coronary spasm with acetylcholine in augmented dosages of 2 µg, 20 µg, 100 µg and 200 µg non-selectively in the LCA as well as 80 µg in the RCA. During the procedure, a 12 channel ECG will be recorded.
1845628|NCT00921869|Drug|E7050|The starting dose of E7050 will be 50 mg given orally, twice-daily, in patients with advanced tumors that have progressed following effective therapy.
1845629|NCT00921882|Procedure|Oral glucose tolerance test|Subjects will have the Oral glucose tolerance test 48 hours post-partum and the same test 8 weeks post-partum.
1845630|NCT00921895|Device|RPS Adeno Detector IV|One time test with the RPS Adeno Detector IV
1845631|NCT00921908|Other|2 mBq radioactive technetium diluted in 20 mL saline|
1845632|NCT00921921|Drug|HFA-BDP|HFA-BDP 100 mcg bid for 3 weeks, then 400 mcg bid for 3 weeks
1845633|NCT00921921|Drug|Placebo|1 puff bid for 3 weeks, then 1 puff bid for 3 weeks
1845634|NCT00921947|Biological|VAX102|Universal M2e influenza vaccine
1845635|NCT00921960|Other|Intervention Care|Intervention Care is defined as a collaborative cardiovascular management between primary care and specialist hospital based services. This will involve natriuretic peptide guided evaluation of LVD and follow-up as appropriate - for example including echocardiographic assessment of left ventricular systolic dysfunction and appropriate pharmacotherapy.
1845636|NCT00921973|Biological|VAX102|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
1845637|NCT00921973|Biological|Placebo|All subjects receive TIV, one half of the subjects are randomized to receive VAX102 1 ug and one half are randomized to receive placebo
1845638|NCT00922012|Device|Electromagnetic Stimulation Therapy|Electromagnetic Stimulation Therapy for 24 weeks
1845639|NCT00922038|Behavioral|Cash reward|Enrollees testing negative for treatable sexually transmitted infections will receive cash rewards.
1845640|NCT00922051|Device|Transcutaneous electrical nerve stimulation (TENS)|
1845641|NCT00922051|Device|Transcutaneous electrical nerve stimulation (TENS)|Placebo
1845642|NCT00922064|Procedure|ECT|ECT series consisting of 6 to 14 ECTs
1845643|NCT00922077|Behavioral|standard physical therapy program with emphasis on dynamic balance exercises|
1845644|NCT00922103|Procedure|Ileal Neo Rectal Anastomosis|Comparison of the Ileal Neo Rectal Anastomosis to the Ileal Pouch Anal Anastomosis in patients treated for medical refractory Ulcerative Colitis
1845645|NCT00922103|Procedure|Ileal Pouch Anal Anastomosis|Comparison of the Ileal Pouch Anal Anastomosis to the Ileal Neo Rectal Anastomosis in patients treated for medical refractory Ulcerative Colitis
1845646|NCT00922116|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every month (starting dose of 100, 120, 150 or 200 micrograms based on previous ESA therapy)
1845647|NCT00922129|Drug|Sirolimus (Rapamune)|Started at 5 mg (Target levels 6-10mg/mL), Daily, PO, 24 months
1845648|NCT00922129|Drug|Cyclosporin (Neoral) or Tacrolimus (Prograf)|"Cyclosporin: 3-4 mg/kg, BID, PO, 24 months
Tacrolimus: 0-.038-0.045 mg/kg, BID, PO, 24 months"
1845649|NCT00922155|Device|guide sheath|The guide sheath (GS) was originally the balloon covered sheath (MAJ-643R, external diameter 2.6mm) of the EBUS probe. The two ends of the balloon covered sheath were cut and trimmed. The EBUS probe was covered with guide sheath and then inserted through the working channel to the targeted bronchus.
1845650|NCT00922181|Device|Microwave ablation|Liver tumors are destructed/ablated using single-probe microwave energy device
1845651|NCT00922181|Device|Radiofrequency ablation|Liver tumors are destructed/ablated using radiofrequency energy device
1845652|NCT00922194|Drug|Extended Release Metformin|0.5g twice a day to 2g twice a day for at least 12 months or more
1845653|NCT00922207|Drug|Adefovir|From week -4 to week 2
1845654|NCT00922207|Drug|Entecavir|From week -4 to week 2
1845655|NCT00922207|Drug|Placebo|From week -4 to week 2
1845656|NCT00922207|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc weekly, from week 1-48
1845657|NCT00922220|Other|stationary bike|Participants rode a stationary bike for five minutes
1845658|NCT00922220|Other|lumbar extension exercise|Participants performed four sets of fifteen lumbar extension exercises over fifteen minutes
1845659|NCT00922220|Other|spinal manipulative therapy|participants received spinal manipulative therapy to the low back
1845660|NCT00922233|Drug|levonorgestrel|oral contraceptive pills
1845661|NCT00922246|Device|custom-made insoles (Thermo+Camel, cost for the military 20,50 euros)|The custom made insoles (Thermo+Camel, cost for the military 20,50 euros) were fabricated from firm-density polyethylene and the hard plastic shell was a three-quarter length.
1845662|NCT00922259|Biological|Influenza A H7N7 vaccine|Participants will be administered two doses of the candidate vaccine at a dosage of approximately 10^7.5 50% tissue culture infectious dose (TCID50), in the form of nasal spray. The doses will be administered 28-62 days apart.
1845663|NCT00922272|Drug|SPD489 (lisdexamfetamine dimesylate)|oral, 20, 30, 40, 50, 60, or 70 mg once daily
1845664|NCT00922272|Drug|Placebo matching SPD489 (lisdexamfetamine dimesylate)|oral, once daily
1845665|NCT00922285|Other|psychosocial support for caregiver|6 weekly 60 minute sessions
1845666|NCT00922285|Other|questionnaire administration|Evaluated at baseline, week 1 and week 6 of art therapy
1845667|NCT00922285|Procedure|quality-of-life assessment|Evaluated at baseline, week 1 and week 6 of art therapy
1845668|NCT00922285|Procedure|stress management therapy|6 weekly 60 minute sessions
1845669|NCT00922311|Drug|Aliskiren|Titrate from 150 mg daily to 300 mg daily
1845797|NCT00913484|Drug|Placebo|Placebo daily
1845670|NCT00922324|Drug|STP206 or vehicle control|STP206 or vehicle administered as either a single dose or as a daily dose for 7 consecutive days
1845671|NCT00922337|Device|MGuard Coronary Stent system|MGuard Coronary Stent system implanted within a PCI
1845672|NCT00922350|Other|HELIOX|The nebulization was conducted in the same way that heliox + posture group, except the attitude of trunk, where the patients in this group did the Nebulizer with the trunk upright.
1845673|NCT00922350|Other|OXYGEN|The NEBULIZATION was performed the same way as the heliox group, except for torso posture, where the patients in this group with the trunk upright Nebulizer Oxygen for cars have A NEBULIZATION.
1845674|NCT00922350|Other|HELIOX+POSTURE|"Patients underwent two carried by heliox nebulization associated with fenoterol (2.5 mg) and ipratropium bromide (0.25 mg). We used three ml of saline solution at 0.9%. For nebulization with heliox or oxygen, was used a system of distribution not invasive, semi-closed in a mask that is non toxic connected to a piece Y with a nebulizer in a follow and a bag of tank with a capacity for 2.5 L in the other connected with a valve action. This system was used so that there was a dilution gas. The proportion of 80:20 heliox was used (80% helium: 20% oxygen). To postural change in groups and heliox Oxygen + posture + posture, oriented to the participants to maintain an angle of inclination of the trunk and elbows supported on the thighs, measured from the anterior axillary line and lateral epicondyle of the femur, between 50th and 60th ."
1845675|NCT00922350|Other|OXYGEN + POSTURE|The NEBULIZATION was conducted in the same way that heliox + posture GROUP, however the patients in this group have the Oxygen for Carr A NEBULIZATION
1845676|NCT00922363|Biological|50 µg Ag85B-ESAT-6 alone|0.5 mL solution for injection x 2 (2 months interval)
1845677|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 125/25 µg CAF01|0,5 mL suspension for injection x 2 (2 months interval)
1845678|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 313/63 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
1845679|NCT00922363|Biological|50 µg Ag85B-ESAT-6 + 625/125 µg CAF01|0.5 mL suspension for injection x 2 (2 months interval)
1845680|NCT00922376|Device|Mobile phone telehealth application: Think Positive (T+)|T+ consists of the Glucometer paired with a cradle that transmits via Bluetooth blood glucose results to a mobile phone. Data is stored and sent to a secure website. The website can be accessed by the patient as well as by health care providers (HCP). HCP can discuss data on the phone and make recommendations via text messages to patients. Visual feedback (graphs and statistics) illustrating recent blood sugar levels patterns is automatically and immediately sent to the patient when data is transferred from the T+ phone.
1845681|NCT00922389|Procedure|will receive G-CSF and peripheral blood derived mononuclear cells|Multiple intra muscular implantation of mononuclear stem cells derived from peripheral blood after G-CSF (granulocyte colony-stimulating factor)mobilization in either of two individual dose ranges which would be given to equal number of subjects.
1845682|NCT00922389|Drug|G-CSF|5 micrograms/kg/day for 4 days by subcutaneous route
1845683|NCT00922389|Drug|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
1845684|NCT00922402|Procedure|Intensive insulin infusion|"The intensive control of glycemia is obtained with a shared in-hospital insulin infusion protocol, supported by the use of a continuous glucose monitoring system (Medtronic Guardian REAL Time). Any sudden variation of glycemia levels and/or alarms, as indicated by the device, has to be confirmed with a finger-stick before any therapy modification.
In-hospital management is subdivided in a 2-day intensive and a 3-day post-intensive phase."
1845685|NCT00922441|Drug|Fimasartan 60 mg group|Fimasartan 60 mg
1845686|NCT00922441|Drug|Fimasartan 120 mg group|Fimasartan 120 mg
1845687|NCT00922441|Drug|Reference (Valsartan 80 mg) group|Reference (Valsartan 80 mg)
1845688|NCT00922454|Procedure|Endovascular Repair of the abdominal aorta|"Patients will undergo or have undergone endovascular aneurysm repair which is minimally invasive approach using endoluminal placement of a stent graft.
EVAR, CTA imaging, 1, 6 12 months post treatment."
1845689|NCT00922454|Device|Cook Zenith Stent-Graft|Cook Zenith AAA Endovascular Graft
1845690|NCT00922454|Device|Talent Stent-Graft|Talent AAA Abdominal Stent Graft System
1845691|NCT00922467|Drug|NaCl 9/00|Same volume as in the esmolol group
1845692|NCT00922467|Drug|Esmolol|1 mg/kg administrated over 10 minutes followed by an infusion of 0,2 mg/kg/hr during all the anesthetic period
1845693|NCT00922480|Drug|Fimasartan|Fimasartan 60 ~ 120mg/po take one tablets once a day
1845694|NCT00922480|Drug|Losartan (Control)|Losartan 50 mg ~ 100 mg/po, take one tablets once a day
1845695|NCT00922493|Other|inspiratory muscle training|"Protocol of inspiratory muscle training using threshold IMT®: After the MIP was measured, inspiratory muscle training was initiated. The Threshold-IMT® device of a linear pressure load produces a resistance to inspiration through the use of a flow-independent one-way valve. During expiration there is no resistance because the unidirectional valve opens, while during inspiration the valve closes, becoming hard due to the resistance of the spring. The suggested protocol was: initial load of 30% of the M24, increasing daily by 10%, with training for five minutes, twice a day, seven times a week in the period from the beginning of the weaning from the MV until the extubation of the patient.
An essential factor was the use of supplemental oxygen (O2) as needed by the patient. The patients were in DD with fowler 45º."
1845696|NCT00922506|Drug|doxazosin plus tolterodine SR|doxazosin plus tolterodine SR(2 mg, qd)for 12 weeks or (4 mg, qd) for 12 weeks
1845697|NCT00922519|Other|18F-Sodium Fluoride (Na18F)|200-400 MBq/injection, up to 4 doses of Na18F will be permitted per patient as part of acceptable disease assessment.
1845698|NCT00922532|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm through an INOvent delivery system for up to 14 days.
1845699|NCT00922532|Drug|Placebo|Nitrogen gas will be administered in the same manor as the experimental drug
1845700|NCT00922545|Other|Implementation of Clinical Practice Guidelines (GPC) and Health Education Program|Intervention: The program includes giving clinical results to the health care workers(doctor and nurse), from the medical records and interview. A training course (20h)that deals with aspects related to GPC, motivational interview and health education (tobacco, inhalers, alimentation, exercise and physiotherapy).
1959476|NCT00054353|Procedure|peripheral blood stem cell transplantation|Undergo reduced-intensity allogeneic PBSCT
1845897|NCT00914160|Drug|Diclofenac Sodium 50 mg Tablets Under Fasting Conditions (Geneva Pharmaceuticals, Inc)|
1845702|NCT00922571|Procedure|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
1845703|NCT00922571|Device|FS Laser System|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery. The intervention consists of the both surgery and the use of the device.
1845704|NCT00922584|Drug|sorafenib (Nexavar)|oral sorafenib 400 mg, twice daily, until disease progression or unacceptable toxicity
1845705|NCT00922597|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients undergoing surgery and receiving continuous infusion with Kogenate Bayer according to local drug information.
1845706|NCT00922610|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|sc every 2 weeks at a starting dose of 0.6micrograms/kg;subsequently every 4 weeks
1845707|NCT00922623|Device|Belotero®|Hyaluronic acid dermal filler, Belotero®, single use syringe, injected into mid to deep dermal layer
1845708|NCT00922636|Drug|LY2216684|Taken in tablet form QD po.
1845709|NCT00922636|Drug|Methylphenidate|Extended-release methylphenidate 18 mg/day to 54 mg/day, based on weight, QD po as a capsule for the 8-week double-blind treatment phase.
1845710|NCT00922636|Drug|Placebo (tablet)|Placebo given as a tablet for LY2216684 blind QD po for the 8-week double-blind treatment phase, followed by 2 weeks in the taper phase.
1845711|NCT00922636|Drug|Placebo (capsule)|Placebo given as a capsule for methylphenidate blind QD po for the 8-week double-blind treatment phase followed by 2 weeks in the taper phase.
1845712|NCT00922649|Device|Insulin Pump therapy|Initiation of Insulin pump therapy in patients on >2 OAs (Cohort A), basal insulin ± OAs (Cohort B), or basal-bolus insulin ± OAs (Cohort C.
1845713|NCT00922675|Procedure|Postconditioning|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting. In the postconditioning group 4 additional balloon inflations separated by 1 minute reperfusion are given, starting after 1 minute of reperfusion.
1845714|NCT00922675|Procedure|Control intervention|After opening of IRA and establishment of TIMI-flow grade 2 or 3, the control group continues the procedure with stenting.
1845715|NCT00922688|Drug|Dipeptide Alanyl-Glutamine|Intravenous supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
1845716|NCT00922688|Drug|Placebo|Intravenous and enteral supplementation of placebo is started 24 hours prior to surgery and continued 24 hours postoperatively.
1845717|NCT00922688|Drug|Dipeptide Alanyl-Glutamine|Enteral supplementation of the dipeptide alanyl-glutamine is started 24 hours prior to surgery (dosage glutamine: 0,5 g/kg/day, and continued 24 hours postoperatively.
1845718|NCT00922701|Drug|L-carnitine|Instillation of glucose-based (1.5% weight/volume) peritoneal dialysis solution containing L-carnitine (0.25% weight/volume) for the nocturnal exchange. Patients were treated with the experimental peritoneal dialysis solution for 5 days.
1845719|NCT00922714|Drug|Glutamine|Intravenous glutamine supplementation (0.285 g/kg body weight/24 h)
1845720|NCT00922714|Drug|saline (placebo)|NaCl 0.9 g/L
1845721|NCT00922727|Biological|L. reuteri|The oil drops contains 10^8 CFU (colony forming units). As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops. The dose given is within the release limit which is greater than 2 x 10^8 CFU/ 5 drops and less than 8 x 10^8 CFU/ 5 drops.
1845722|NCT00922727|Biological|Sunflower Oil|As suggested by the manufacturer in the Certificate of Analysis the daily dose given to each patient will be 5 x 10^8 CFU/ 5 drops.
1845723|NCT00922740|Drug|VA106483|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
1845724|NCT00922740|Drug|Placebo|Placebo on Day 1, 1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
1845725|NCT00922753|Other|VS|Spontaneous breathing of 100% oxygen in a facemask for 3 minutes
1845726|NCT00922753|Other|AI-4/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 4 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes
1845727|NCT00922753|Other|AI-6/PEEP-4|Spontaneous breathing of 100% oxygen in a facemask with application of an inspiratory pressure of 6 cm H2O and a positive end-expiratory pressure of 4 cm H2O, for 3 minutes.
1845728|NCT00922766|Drug|Dalteparin|Patients prescribed dalteparin for non-ST segment elevated acute coronary syndromes in nursing home patients who will be treated conservatively (without corornary intervention [PCI] or coronary artery bypass graft [CABG] within 48 hours).
1845729|NCT00922779|Drug|peginterferon alfa-2a [Pegasys]|180micrograms sc weekly for 12-48 weeks
1845730|NCT00922779|Drug|ribavirin|800mg, or 1000-1200mg, po daily (dependent on HCV genotype and body weight)
1845731|NCT00922792|Drug|activated recombinant human factor VII, long acting|Single dose of 0,2 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration
1845732|NCT00922792|Drug|activated recombinant human factor VII, long acting|Multiple doses of 100 mg/kg LA-rFVIIa injected i.v. (intravenous) of 2 minutes duration every 48 hours
1845733|NCT00922805|Dietary Supplement|guar gum|guar gum (20 g/l of formula) for one week
1845734|NCT00922844|Drug|Sevoflurane and isoflurane|Patients will be randomized to a 10 minute treatment with isoflurane, followed by a wash-out period, followed by a 10 minute treatment with sevoflurane, or the other way round.
1845735|NCT00922857|Procedure|Respiratory rehabilitation|The training begins 5 days after the initial assessment. It consists of 3 weekly sessions for 8 consecutive weeks, including the following activities interspersed with periods of rest, according to the needs of patients
1845736|NCT00922870|Device|Cascade|Cascade treatment over 48h
1845737|NCT00922870|Other|Standard treatment|Standard therapy
1845740|NCT00922896|Drug|Gemcitabine, Cisplatin, Erlotinib (Tarceva)|"Erlotinib 100 mg po q d daily AND
Gemcitabine 1000 mg/m² with 250 mL of normal saline intravenously infusion over 30 mins on Day 1, 8
Cisplatin 25 mg/m2 with 150 mL of normal saline intravenously infusion over 60 mins on D1,8
Every 3 weeks"
1845741|NCT00913068|Procedure|Transverse Abdominal Plan (TAP)|An injectable anesthetic is introduced to a specific anatomic area where the sensory neurons supplying the operative field.
1845742|NCT00913068|Procedure|standard post op pain control|opiates
1845745|NCT00913107|Drug|Lamictal®|"The regime of prescription for Lamictal® during the clinical trials was as follows:
50 mg twice daily for 10days, followed by,
100 mg twice daily for the next 10days, followed by,
100 mg thrice daily for the next10 days, followed by,
100 mg four times daily for the final 10 days."
1845746|NCT00913107|Drug|Tegretol®|"The regime of prescription for Tegretol® during the clinical trials was as follows:
150 mg twice daily for 10days, followed by,
200 mg thrice daily for the next 10days, followed by,
300 mg thrice daily for the next 10 days, followed by,
300 mg four times daily for the final 10 days."
1845747|NCT00913120|Drug|YM150|oral
1845748|NCT00913120|Drug|Placebo|oral
1845749|NCT00913120|Drug|Enoxaparin|injection
1845750|NCT00913133|Drug|Desirudin|Desirudin SC 15mg q12h
1845751|NCT00913159|Procedure|Extracorporeal Shock Wave Lithotripsy (ESWL)|Using electric shock wave to treat urolithiasis
1845752|NCT00913172|Other|Treatment|Directly observed treatment (DOT) by health extension workers (HEWs)
1845753|NCT00913185|Drug|Acne Free, Proactiv|
1845754|NCT00913198|Drug|IV CP-4126|1250 mg/m2/d, IV (in the vein) on day 1, 8 and 15 of each 4 week cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1845755|NCT00913211|Device|rTMS|600 pulses of 6 hz priming rTMS at 90% of threshold followed by 600 pulses of low-frequency rTMS at 90% of threshold.
1845756|NCT00913211|Procedure|Motor learning training|one hour of repeated finger tracking movements toward a changing target.
1845757|NCT00913211|Procedure|rTMS and Tracking|Combination of rTMS and finger tracking
1845758|NCT00913211|Device|Sham rTMS|Sham treatment of rTMS
1845759|NCT00913224|Drug|Diclofenac Sodium 50 mg Tablets (Geneva Pharmaceuticals, Inc)|
1845760|NCT00913224|Drug|Voltaren 50 mg Tablets (Geigy Pharmaceuticals)|
1845761|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Cord Laboratories)|
1845762|NCT00913237|Drug|Desipramine Hydrochloride 50 mg Tablets (Merrell Dow Pharmaceuticals, Inc)|
1845763|NCT00913250|Drug|Serum containing Avonex|60mcg IM dose of serum containing Avonex on Day 1, followed by 60mcg IM dose of serum free Avonex on Day 15
1845764|NCT00913250|Drug|Serum Free Avonex|60mcg IM dose of serum free Avonex on Day 1, followed by 60mcg IM dose of serum containing Avonex on Day 15.
1845765|NCT00913263|Drug|2-hydroxyflutamide (2-HOF) [Liproca Depot]|Ready made paste including 600 mg 2-HOF for injection as a single dose
1845766|NCT00913263|Drug|2-Hydroxyflutamide|The Product consists of two sterile components, one aqueous liquid and a dry powder, containing the active drug 2-Hydroxyflutamide (2-HOF. The two components were mixed under aceptic conditions to a paste prior to administration.
1845767|NCT00913276|Drug|Propofol|
1845768|NCT00913276|Drug|Sevoflurane|
1845769|NCT00913289|Biological|adipose tissue derived stromal cells|dosage
1845770|NCT00913302|Behavioral|Cardiovascular Training|cardiovascular training, 3 times/week for 30-60 minutes, over 12 weeks
1845771|NCT00913315|Drug|tolterodine|4 mg of tolterodine ER
1845772|NCT00913315|Drug|tamsulosin|0.4 mg of tamsulosin once a day for 8 weeks
1845773|NCT00913315|Drug|placebo|placebo once a day for 8 weeks
1845774|NCT00913328|Drug|Montelukast (Singulair)|10 mg tablet once daily
1845775|NCT00913328|Drug|Placebo|Oral placebo once daily
1845776|NCT00913341|Drug|Alprazolam Tablets, 1 mg (Geneva Pharmaceuticals)|
1845777|NCT00913341|Drug|Alprazolam Tablets, 1 mg (The Upjohn Company)|
1845778|NCT00913354|Device|Acupuncture (Carbo®)|The acupuncture points were chosen according to traditional Chinese medicine and included DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
1845779|NCT00913354|Device|Placebo acupuncture (Strietberger®)|"The acupuncture points were the same as in the true acupuncture group, namely DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.
Sham acupuncture needles used were the validated Strietberger® placebo-needle from the company, Asia Med. The needle is not fixed inside the copper handle and its tip is blunt. When the needle touches the skin it moves inside the handle and appears to be shortened. A pricking sensation is felt by the patient, simulating the puncturing of the skin. Developed by dr. Konrad Streitberger."
1845780|NCT00913367|Drug|glimepiride + insulin glargine (Amaryl + Lantus)|"Amaryl® 4 mg at breakfast + Lantus® at dinner
The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
1845781|NCT00913367|Drug|glimepiride/metformin fixed combination+insulin glargine (AmarylM + Lantus)|"Amaryl® M 1/500 mg at breakfast + Amaryl® M 1/500 mg at dinner + Lantus® at dinner
The initial dose of Lantus® is 0.2IU/kg at baseline. Lantus® titration will be made by patients every 3 days based on the mean value of previous 3 fasting SMBG level before breakfast"
1845782|NCT00913380|Radiation|Diagnostic CT|2 mSv in an average patient (Low-dose (1/4 to 1/5 of standard-dose))
1845783|NCT00913380|Radiation|Diagnostic CT|8 mSv in an average patient (Standard-dose CT)
1959477|NCT00054353|Other|laboratory biomarker analysis|Correlative studies
1845787|NCT00913406|Other|Lutein fortification|
1845788|NCT00913406|Other|Standard formula|
1845789|NCT00913419|Drug|Cyclobenzaprine HCl Tablets 10 mg, Cord Laboratories|
1845790|NCT00913419|Drug|Cyclobenzaprine HCl Tablets 10 mg, Merck Sharp & Dohme|
1845791|NCT00913432|Drug|masitinib|3 mg/kg/day oral route
1845792|NCT00913432|Drug|masitinib|masitinib 6 mg/kg/day oral route
1845793|NCT00913445|Procedure|appendicectomy|Wound healing after absorbable and nonabsorbable stitches are compared
1845794|NCT00913458|Drug|etanercept|
1845795|NCT00913471|Other|blood samples|"Chronic patients - a one time blood sample (12 mL) and questionnaire; 10 subjects will donate a 3-5mm skin tissue sample.
Longitudinal Patients - 5 blood samples (12 mL each, totaling 60 mL at the following time points: within 48 hours, one week, one month, 6 months and 18 months post injury to coincide with standard visits) and questionnaire. 10 subjects will donate a 3-5mm skin sample.
Healthy, pain free volunteers - a one time blood sample (12 mL), vital signs per standard CRU protocol and questionnaire confirming they are healthy."
1845796|NCT00913484|Drug|Disulfiram|Disulfiram 250 mg per day
1845798|NCT00913497|Drug|insulin glulisine|Insulin glulisine (Apidra®) Sanofi-Aventis; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days
1845799|NCT00913497|Drug|insulin aspart|Insulin aspart (NovoLog®) Novo Nordisk; U100 (100 units/mL) 10 mL vials Prescribed dosage to be given subcutaneously at breakfast for a total of ten days.
1845800|NCT00913510|Device|CIC using LoFric Primo|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, and start of CIC using LoFric Primo catheters, i.e. Drug + Device.
1845801|NCT00913510|Drug|Anticholinergic medication|Anticholinergic medication according to clinical practice and investigator´s judgement, either started at screening visit or continued from before study start, i.e. Drug.
1845802|NCT00913523|Device|Experimental - Tampon with GML|Regular and Super Tampon with Glycerol Monolaurate (GML) added to the cover
1845803|NCT00913523|Device|Sham Control - Tampons without GML|There is no intervention associated with these arms - they are sham controls.
1845804|NCT00913536|Other|Using Cone beam CT in patients with Bladder Cancer|Using cone beam CT scanner will help to increase the accuracy of your radiotherapy treatment. The cone beam CT scanner is a part of the radiotherapy treatment unit.
1845805|NCT00913549|Drug|Clemastine Fumarate Tablets, 2.68 mg (Cord Laboratories)|
1845806|NCT00913549|Drug|Tavist Tablets, 2.68 mg (Sandoz Pharmaceutical Corp.)|
1845807|NCT00913562|Drug|Rosuvastatin|one tablet rosuvastatin 10 mg per day for 12 weeks
1845808|NCT00913562|Drug|Placebo|one tablet a day for 12 weeks
1845809|NCT00913575|Other|preoperative neuromuscular training|The neuromuscular training group will receive a minimum of 8 and a maximum of 24 training sessions; as well as 4 sessions of the Knee OA School.
1845810|NCT00913575|Behavioral|knee OA School|The education group will only receive 4 sessions of the Knee OA School.
1845811|NCT00913588|Drug|Fluoxetine HCl 20 mg Capsules Under Fasting Conditions (Geneva Pharmaceutical, Inc.)|
1845812|NCT00913588|Drug|Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Geneva Pharmaceutical, Inc.)|
1845813|NCT00913588|Drug|Prozac Fluoxetine HCl 20 mg Capsules Under Fed Conditions (Dista)|
1845814|NCT00913601|Device|Medtronic INTERSIM II - 3058|Medtronic INTERSIM II - 3058 Impuls Generator
1845815|NCT00913614|Drug|Eplivanserin (SR46349)|Oral administration
1845820|NCT00913653|Drug|LCZ696|
1845821|NCT00913666|Drug|Interferon beta-1a (Avonex)|30 mcg by intramuscular injection once a week
1845822|NCT00913679|Procedure|Surgical approach (ReCap Hip Resurfacing System)|two different surgical approaches in hip resurfacing arthroplasty
1845823|NCT00913692|Drug|Glutamine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
1845824|NCT00913692|Drug|Glycine|Subjects were randomized to take one of the study agents, 15 gm by mouth twice daily for 5 months. After a 2 week washout period, subjects began the other agent at 15 gm by mouth twice daily for 5 months.
1845825|NCT00913705|Drug|Neoadjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21-day intervals. Prior to surgery.
1845826|NCT00913705|Drug|Adjuvant chemotherapy (taxol and carboplatin)|Taxol: 200mg/m2 infusion over 3 hours; Carboplatin: AUC= 6 at the end of the Taxol infusion. Administration of 3 cycles at 21 days interval. Post-surgery
1845827|NCT00913705|Procedure|Surgery|Surgery
1845828|NCT00913718|Drug|Fluoxetine Hydrochloride 20 mg Capsules (Geneva Pharmaceutical, Inc.)|
1845829|NCT00913718|Drug|Prozac Fluoxetine Hydrochloride 20 mg Capsules (Dista)|
1845830|NCT00913744|Drug|Ocriplasmin|ocriplasmin intravitreal injection (125 µg)
1845831|NCT00913744|Drug|Sham injection|Sham injection
1845832|NCT00913770|Behavioral|Brief Negotiation Interview (BNI)|Brief Negotiation Interview (BNI) is a manual-guided therapy that is designed to be feasible in the ED setting. The purpose of the BNI is to assist patients in recognizing and changing their drug use and HIV risk behaviors. It combines techniques based on motivational interviewing and a stage-model of change. The main goal of the interview is to decrease the subject's ambivalence about signing up for a formal drug treatment program.
1845833|NCT00913770|Drug|Buprenorphine Initiation|
1845834|NCT00913783|Drug|Clomipramine Hydrochloride 25 mg Capsules (Geneva Pharmaceuticals)|
1845835|NCT00913783|Drug|Anafranil Clomipramine Hydrochloride 25 mg Capsules (Basel)|
1845836|NCT00913796|Drug|Potassium citrate|2.41 gram of citrate b.i.d. for 12 months. Dosage to be adjusted according to serum potassium concentration.
1845837|NCT00913796|Drug|Potassium chloride|370 mg potassium t.i.d. for 12 months. Dosage to be adjusted according to serum postassium concentration.
1845838|NCT00913809|Drug|Desipramine HCL 100 mg Tablets Cord Laboratories|
1845839|NCT00913809|Drug|Norpramin 100 mg Tablets Merrell Dow Pharmaceuticals, Inc|
1845840|NCT00913822|Drug|Desipramine Hydrochloride 100 mg Tablets (Cord Laboratories)|
1845841|NCT00913822|Drug|Norpramin 100 mg Tablets (Merrell Dow Pharmaceuticals, Inc.)|
1845842|NCT00913835|Biological|Olaratumab|20 milligrams per kilogram (mg/kg) administered by intervenous (IV) infusion every 2 weeks (14 days). Treatment will continue until there is evidence of progressive disease (PD) or development of unacceptable toxicity
1845843|NCT00913835|Drug|liposomal doxorubicin|40 milligrams per square meter (mg/m²) administered according to the manufacture's instructions every 4 weeks (28 days). Treatment will continue until there is evidence of PD or development of unacceptable toxicity
1845844|NCT00913848|Drug|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
1845845|NCT00913848|Drug|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
1845846|NCT00913861|Behavioral|hypnosis|Hypnosis: induction of hypnosis by visual fixation and recollection of a pleasant memory, suggestion of relaxation, of self-control and post-hypnotic suggestion for bowel relaxation.
1845847|NCT00913861|Drug|standard sedation|Standard sedation: fentanyl 2x0,5 microg/kg at beginning of procedure and propofol PCS: 20mg bolus than 10mg/bolus, lock-out = 0.
1845848|NCT00913861|Behavioral|Structured attention|Structured attention: verbal and nonverbal communication; attentive listening; provision of the perception of control; encouragement; use of emotionally neutral descriptors, focus on a sensations.
1845849|NCT00913874|Drug|Divalproex Sodium 500 mg DR Tablets (Sandoz Inc., USA)|
1845850|NCT00913874|Drug|Depakote 500 mg DR Tablets (Abbott Laboratories, USA)|
1845851|NCT00913887|Drug|Diclofenac Sodium 75 mg Tablets Under Fasting Conditions (Geneva Pharmaceutical)|
1845852|NCT00913887|Drug|Diclofenac Sodium 75 mg Tablets Under Fed Conditions (Geneva Pharmaceutical)|
1845853|NCT00913887|Drug|Voltaren 75 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
1845854|NCT00913900|Biological|autologous CD133+ cells|Intramuscular injection
1845855|NCT00913913|Biological|DC vaccine|DC Vaccine therapy 10E7 intranodally every cycle
1845856|NCT00913913|Drug|Bevacizumab|Bevacizumab 10mg/kg iv every 2 weeks
1845857|NCT00913913|Biological|IL-2|IL-2 18 MiU/m2 CI 5 days
1845858|NCT00913913|Biological|IFN|IFN 6 MiU subc TIW
1845859|NCT00913926|Drug|E2/LNG oral (Wellnara, BAY86-5029)|Patients in daily life treatment receiving Wellnara according to local drug information.
1845860|NCT00913939|Procedure|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive two fractions (treatments) of brachytherapy over 14 days (+/- 7 days).
1845861|NCT00913939|Procedure|MRI Guided Needles to deliver HDR Brachytherapy|Patients in this arm will receive 2 fractions (treatments) of brachytherapy before the start of RT, and 4-5 weeks towards the end of EBRT.
1845862|NCT00913952|Drug|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fasting Conditions|
1845863|NCT00913952|Drug|Geneva 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
1845864|NCT00913952|Drug|Basel (Anafranil) 25 mg Clomipramine Hydrochloride Capsules Under Fed Conditions|
1845865|NCT00913965|Drug|Atenolol Tablets 100 mg (Cord Laboratories)|
1845866|NCT00913965|Drug|Atenolol Tablets 100 mg (Stuart Pharmaceutical)|
1845867|NCT00913978|Other|Warming pre operatively|The first group will have the warming devices started in the pre operative area. You will receive warm blankets and a full body warm air blanket called the Bair Paws. This device is non experimental and is FDA approved and used within the hospital to keep patients warm. You will have an intravenous catheter (IV is a small plastic flexible hollow tubing) placed by the pre operative care staff. You will then receive warmed IV solution (salt water).
1845868|NCT00913978|Other|Warming in OR|The second group will receive the warming devices and warmed IV fluids once they are in the operating room.
1845869|NCT00913991|Behavioral|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
1845870|NCT00913991|Behavioral|Stress Management Training|Weekly 60-minute session with a trainer for 8 consecutive weeks. Daily home practice of approximately 20 minutes per day via CD.
1845871|NCT00914004|Drug|Desipramine HCl 50 mg Tablets Cord Laboratories|
1845872|NCT00914004|Drug|Norpramin 50 mg Tablets Merrell Dow Pharmaceuticals, Inc|
1845873|NCT00914017|Drug|Atorvastatin|Atorvastatin, 40 mg daily for 1 year
1845874|NCT00914017|Drug|Placebo|sugar pill daily for 1 year
1845875|NCT00914030|Other|Neuropsychological evaluation|Study one: global/local processing, with a neutral prime (stimulus influencing the processing of the subsequent stimulus)Study two: global/ local processing with a prime whose elements are collinear.Study three: global/local processing with a prime whose elements are not collinear
1845876|NCT00914043|Genetic|gene expression analysis|
1845877|NCT00914043|Genetic|microarray analysis|
1845878|NCT00914043|Genetic|polymerase chain reaction|
1845879|NCT00914043|Genetic|polymorphism analysis|
1845880|NCT00914043|Genetic|reverse transcriptase-polymerase chain reaction|
1845881|NCT00914043|Other|biologic sample preservation procedure|
1845882|NCT00914043|Other|enzyme-linked immunosorbent assay|
1845883|NCT00914043|Other|laboratory biomarker analysis|
1845884|NCT00914043|Procedure|fatigue assessment and management|
1845885|NCT00914056|Drug|lactulose|withdrawal of lactulose
1845886|NCT00914069|Device|RIVS vascular access|Access to peripheral vasculature
1845887|NCT00914069|Device|Conventional vascular access|Vascular access using conventional venous access device
1845888|NCT00914082|Behavioral|Self hypnosis|3 antenatal classes of 1 hour. 3 audio compact discs for reenforcement. 1 audio compact discs for support at birth
1845889|NCT00914095|Drug|methylphenidate|10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
1845890|NCT00914095|Drug|placebo|tablets of placebo 3 times a day
1845891|NCT00914108|Behavioral|Newborn Individualized Developmental Care|The developmental care model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists observed each infant's behavior throughout hospitalization and to 2 weeks corrected age and formulated descriptive neurobehavioral reports with suggestions to structure caregiving procedures adapted to the infant's sleep/wake cycle and in support of the infant's well-regulated behavioral balance. Parents were supported to care for their infant, encouraged to nurse and hold their infant skin-to-skin, and to cradle them during stressful procedures.
1845892|NCT00914121|Drug|SKI-606|
1845893|NCT00914121|Drug|Placebo|
1845894|NCT00914121|Drug|Moxifloxacin|
1845895|NCT00914134|Drug|Levodopa infusion|Naso-duodenal infusion line is inserted in fluoroscopy control. Levodopa infusion is then tested approximately 5 days. If patient responds favorably to the treatment, PEG-infusion line is inserted in gastroscopy control and patient is followed in hospital for 2 to 4 days to ensure stability of the infusion line. The dosage is individually adjusted, starting dose is estimated from earlier oral levodopa dose.
1845896|NCT00914147|Procedure|pulmonary function testing|After signing consent, patients will undergo a complete spirometry test, lung volumes and diffusing capacity (DLCO) measurement utilizing the single-breath breath holding technique, according to the ATS/ERS consensus and standardization.
1845898|NCT00914160|Drug|Diclofenac Sodium 50 mg Tablets Under Fed Conditions (Geneva Pharmaceuticals, Inc)|
1845899|NCT00914160|Drug|Voltaren 50 mg Tablets Under Fed Conditions (Geigy Pharmaceuticals)|
1845900|NCT00914173|Device|Scanlaf Circulator and water bath|Cold Pressor Test
1845901|NCT00914173|Device|Medoc TSA 2000|Thermal stimuli pain
1845902|NCT00914186|Drug|TS022|Lotion
1845903|NCT00914186|Drug|Vehicle|Lotion
1845904|NCT00914199|Procedure|Percutaneous coronary intervention (PCI)|Implantation of coronary stent in bifurcation lesion.
1845905|NCT00914212|Drug|Placebo|Single dose placebo to sibutramine in two of three treatment periods.
1845906|NCT00914212|Drug|Comparator: sibutramine|Single dose sibutramine 30 mg (2 x 15 mg) in one of three treatment periods.
1845907|NCT00914225|Other|Bednets and Water Purification|Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
1845908|NCT00914238|Behavioral|2 years OPUS treatment|2 years OPUS and transfer to standard treatment.
1845909|NCT00914238|Behavioral|OPUS 5 years|
1845910|NCT00914251|Drug|Hesperidin|Administration of oral Hesperidin, 500 mg/daily
1845911|NCT00914251|Drug|Placebo|Administration of oral Placebo, 500 mg/daily
1845912|NCT00914264|Device|continuous positive airway pressure|CPAP with adequate pressure for 1 day, 3 & 12 months
1845913|NCT00914277|Drug|SAR407899|Oral administration
1845914|NCT00914277|Drug|Placebo|Oral administration
1845915|NCT00914277|Drug|Sildenafil|Oral administration
1845916|NCT00914290|Drug|IPX056|IPX056 ER capsule containing 10 mg baclofen
1845917|NCT00914290|Drug|Baclofen IR|Encapsulated baclofen tablet 5 mg per capsule
1845918|NCT00914290|Drug|Placebo IPX056|Placebo capsule for IPX056
1845919|NCT00914290|Drug|Placebo IR|Placebo encapsulated baclofen placebo tablet
1845920|NCT00914303|Drug|AZD3241|Oral Tablet, Repeated Administration
1845921|NCT00914303|Drug|Placebo Tablet|Oral Tablet. Repeated Administration
1845922|NCT00914316|Drug|Ranolazine|Ranolazine, 1000 mg, capsule, twice daily, by mouth.
1845923|NCT00914316|Drug|Placebo|twice daily
1845924|NCT00914329|Drug|Gelsemium Sempervirens|5CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
1845925|NCT00914329|Drug|Gelsemium Sempervirens|15CH, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
1845926|NCT00914329|Drug|Placebo|placebo, one dose of globules morning and evening during 2 days plus one dose the morning of the day of the stress-test.
1845927|NCT00914355|Radiation|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver.You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment.Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
1845928|NCT00914368|Drug|Clopidogrel|Patients not already on clopidogrel treatment a loading dose of clopidogrel 600 mg followed by a maintenance dose of 75 mg once daily will be administered.
1845929|NCT00914381|Behavioral|Behavioral therapy|
1845930|NCT00914394|Drug|NG-monomethyl-L-arginine (L-NMMA)|bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
1845931|NCT00914394|Drug|Phenylephrine|1µg/kg/min, infusion period 20 minutes
1845932|NCT00914394|Drug|Physiological saline solution (as placebo)|infusion period 20 minutes
1845933|NCT00914394|Device|Laser Doppler Flowmetry|Measurements will be performed at the neuroretinal rim to assess ONH blood flow.
1845934|NCT00914394|Device|Goldmann applanation tonometer|intraocular pressure measurements
1845935|NCT00914394|Device|Suction cup|Experimental stepwise increase of intraocular pressure while measurement of optic nerve head blood flow.
1845936|NCT00914407|Drug|Oxygen|100% Oxygen inhalation for 30 minutes
1845937|NCT00914420|Device|Intrepide Trapidil eluting stent|"The INTREPIDE coronary stent system consists of a balloon expandable stent coated with two layers of Trapidil and parylene. The Trapidil eluting stent is pre-mounted on a Nimbus PCTA balloon and is intended for use in the treatment of CAD.
The controlled release of Trapidil is achieved through the parylene barrier, locally delivering the drug to the target lesion, inhibiting smooth muscle cell proliferation and hence neointimal hyperplasia."
1845938|NCT00914420|Device|Taxus drug eluting stent|Paclitaxel Drug eluting stent manufactured by Boston Scientific
1845939|NCT00914433|Drug|TPI 1100|1 dose only increasing dose
1845940|NCT00914446|Procedure|hepatic biopsies|hepatic biopsies
1845941|NCT00914459|Biological|Moroctocog alfa ( AF-CC)|Dosing is at the discretion of the Investigator
1845942|NCT00914459|Procedure|Laboratory tests|Factor VIII PK samples, Hematology, Chemistry and Coagulation testing, FactorVIII Inhibitor and Anti Factor VIII antibody
1845943|NCT00914472|Biological|heparin sodium - APP|Heparin 5000 IU / mL
1845944|NCT00914472|Biological|Heparin sodium - Hipolabor|Heparin 5000 IU / mL
1845945|NCT00914485|Behavioral|Provider Communication Skills Training|"Consists of 4 separate 1-hour sessions, 1 per best act, in which physicians view 3 video-recorded performances of each act performed by trained actors of varied race/ethnicity."
1845946|NCT00914498|Drug|Local, pre-incisional injection of 20 ml 1% xylocaine|Local, pre-incisional injection of 20 ml 1% xylocaine
1845947|NCT00914511|Drug|avanafil 200mg|single dose tablet of 200mg avanafil
1845948|NCT00914511|Drug|avanafil 200mg|single tablet dose of 200mg avanafil
1845949|NCT00914524|Drug|olmesartan medoxomil|olmesartan medoxomil tablets, once daily
1845950|NCT00914550|Other|Procalcitonin level, caregiver informed|Procalcitonin levels will be measured and known by investigator, only 1/2 of the patients' caregivers will know the results of serial Procalcitonin levels. We will analyze the rate of antibiotic discontinuation for the two arms
1845951|NCT00914563|Device|LIDCO Lithium Dilution Cardiac Output|Lithium Dilution Cardiac Output (LIDCO) Plus permits through analysis of the arterial blood pressure trace to acquire items about CO, SVR and DO2.
1845952|NCT00914563|Other|Standard Care|We will compare the standard monitored and volume resuscitated group of patients with the LIDCO monitored group. The control group will be composed of the patients supervised in a standard way, volume resuscitated according to the Brooke or Parkland formulas.
1845953|NCT00914576|Drug|Vitamin and mineral supplement|1 capsule/day in the morning for 14 days, containing: Lutein 12mg, Vitamin C 300mg, Zinc 10mg, Ginko Biloba 10mg, Flavonoids 25mg, Fish oil 300mg
1845954|NCT00914576|Drug|Vitamin and mineral supplement|1 capsule/day in the evening for 14 days, containing: Zeaxanthin 5mg, Vitamin E 60mg, Copper 1mg, Selene 20µg, Ginko Biloba 10mg, Flavonoids 25mg, Alpha Lipon acid: 150mg
1845955|NCT00914576|Drug|Placebo|2 capsules/day for 14 days
1845956|NCT00914576|Drug|100% Oxygen|breathing of 100% O2 for 30 minutes on both study days
1845957|NCT00914576|Drug|Escherichia coli Endotoxin|Escherichia coli Endotoxin (LPS, US Standard Reference Endotoxin, dose: 2 ng/kg bodyweight (corresponding to 20 IU/kg), i.v. bolus on both study days.
1845958|NCT00914589|Drug|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
1845959|NCT00914589|Drug|catridecacog|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
1845960|NCT00914589|Drug|placebo|Single dose via slow intravenous (i.v.) push at a rate not exceeding two mL per minute
1845961|NCT00914602|Drug|XP21279|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
1845962|NCT00914602|Drug|Sinemet®|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
1845963|NCT00914602|Drug|Lodosyn®|After screening all subjects will be placed on a fixed dosing Sinemet® time regimen for approximately 14 days. Upon completion of Sinemet® treatment eligible subjects will be placed on a fixed dosing time regimen of XP21279 (with Lodosyn®).
1845964|NCT00914615|Radiation|Stereotactic Body Radiation|Radiation therapy will be delivered on six occasions, over two weeks. Each treatment will take approximately 30 minutes to deliver (up to an hour including all imaging and set-up procedures). You may be asked to swallow 250 cc of oral contrast before each radiation therapy treatment. Pepto Bismol (a liquid that coats the stomach and is used to treat heartburn) and/or water may be combined with the contrast to improve the quality of the stomach's image.
1845965|NCT00914628|Genetic|HSV-Tk|Infusion of genetically modified lymphocytes 1x10^7 c/kg: first at +21-+49 days after HSCT; in absence of immune reconstitution and GvHD further infusions up to 4 will be administered on monthly basis.
1845966|NCT00914628|Other|T-cell depleted or T-cell replete strategies|Haploidentical HCT with the infusion of CD34+ cells plus a fixed dose of T cells (1 x 10^4/Kg) or unmanipulated haploidentical stem cell transplantation followed by high-dose cyclophosphamide as part of GvHD prophylaxis
1845967|NCT00914641|Drug|Apixaban IR|immediate release tablet, 10 mg, single dose
1845968|NCT00914641|Drug|Apixaban MR1|modified release tablet 1, 10 mg, single dose
1845969|NCT00914641|Drug|Apixaban MR2|modified release tablet 2, 10 mg, single dose
1845970|NCT00914641|Drug|Apixaban MR3|modified release tablet 3, 10 mg, single dose
1845971|NCT00914654|Drug|inhaled formoterol|Inhalation of 18 microgram formoterol as one dose. Oxis Turbohaler 9 microg/dose, MA no. 30072.
1845972|NCT00914667|Drug|warfarin|Single Dose Warfarin 25 mg on Day 1
1845973|NCT00914667|Drug|Warfarin plus Fesoterodine|Fesoterodine 8 mg ER tablets QD for 9 Days and Single Dose Warfarin 25 mg on Day 3
1845974|NCT00914680|Procedure|magnetic seizure therapy|antidepressant treatment with MST
1845975|NCT00914693|Drug|Ethinylestradiol/Gestodene (BAY86-5016)|7-day patch containing 0.55 mg ethinylestradiol (EE) and 2.1 mg gestodene (GSD) in a 21-day regimen
1845976|NCT00914706|Other|P-PROMPT|P-PROMPT is a web-based chronic disease management system. The system will help to ensure that all patients have up-to-date laboratory monitoring and visits as recommended by the Canadian Diabetes Association Guidelines.
1845977|NCT00914719|Behavioral|Information only|
1845978|NCT00914719|Behavioral|Sexual risk reduction intervention|
1845979|NCT00914719|Behavioral|sexual risk reduction + alcohol risk reduction component|
1845980|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered by subcutaneous (SC) route at 1x10^8 TCID50 per 0.5 mL dose on Days 0 and 28.
1845981|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine liquid formulation delivered at lower dose [2x10^7 tissue culture infectious dose 50 (TCID50) per 0.1 mL dose] by intradermal (ID) route on Days 0 and 28.
1845982|NCT00914732|Biological|MVA Smallpox Vaccine|Vaccinia vaccine lyophilized formulation delivered by subcutaneous (SC) route at 1x10^8 TCID50 per 0.5 mL dose on Days 0 and 28.
1845983|NCT00914745|Drug|Ointment|Each time about 1.5 cm ointment have to be applied on the upper lip and 1.5 cm on the lower lip, twice daily for prophylaxis for e period of 6 month.
1845984|NCT00914771|Biological|H5N1 pandemic Influenza vaccine 3.75µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 3.75µg H5N1 antigen
1845985|NCT00914771|Biological|H5N1 pandemic Influenza vaccine 7.5µg|2 doses of monovalent MF59-adjuvanted H5N1 pandemic vaccine containing 7.5µg H5N1 antigen
1845986|NCT00914797|Drug|inhaled and oral terbutaline|"Inhalation of 2 mg terbutaline as powder as a single dosage. Oral terbutaline 10 mg as a single dosage.
Inhaled: Bricanyl Turbohaler 0.5 mg/dose, MA no. 41076.
Oral: Tablet Bricanyl Retard 5 mg, MA no. 10954."
1845987|NCT00914810|Dietary Supplement|Vitamin D (cholecalciferol)|2000 I.U. daily for 6 weeks
1845988|NCT00914810|Dietary Supplement|Placebo|Placebo (sugar pill) daily for 6 weeks
1845989|NCT00914823|Drug|kisspeptin 112-121|one or more intravenous doses of kisspeptin 112-121, and/or short infusion (up to 12 hours) of kisspeptin 112-121
1845990|NCT00914823|Drug|GnRH|One or more intravenous doses of GnRH
1845991|NCT00914836|Drug|Betamethasone Sodium Phosphate|1cc:2cc
1845992|NCT00914836|Drug|1 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
1845993|NCT00914836|Drug|2 cc - Betamethasone Sodium Phosphate|Betamethasone Sodium Phosphate
1845994|NCT00914849|Drug|AMD3100|
1845995|NCT00914849|Procedure|Leukopheresis|
1845996|NCT00914849|Procedure|Stem cell transplant|
1845997|NCT00914862|Drug|Ramelteon|Ramelteon tablets, orally for one day only.
1845998|NCT00914888|Drug|Tigecycline|"Subject with cIAI:
Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12 hours, metronidazole placebo IV will be administered every 8 hours. In addition, at the discretion of the investigator, an aminoglycoside placebo IV may also be administered."
1845999|NCT00914888|Drug|Tigecycline|"Subject with CAP:
IV therapy period: Dosing information for subjects 8 to 11 years old is currently under investigation and will be determined later. Subjects 12 to 17 years old will receive tigecycline 50 mg IV every 12h. At the discretion of the investigator oral clarithromycin placebo may be given every 12h.
Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
1846000|NCT00914888|Drug|cIAI: Ceftriaxone with metronidazole, plus if applicable aminoglycoside|"Subject with cIAI:
Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12 hours, metronidazole 10 mg/kg (maximum of 1 g/dose) IV will be administered every 8 hours.
In addition, at the discretion of the investigator, an aminoglycoside IV (adjusted dose if necessary) may also be given."
1846001|NCT00914888|Drug|CAP: Ceftriaxone, plus if applicable oral clarithromycin|"Subject with CAP:
IV therapy period: Subjects will receive ceftriaxone 35 mg/kg (maximum of 1 g/dose) IV every 12h. At the discretion of the investigator, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old).
Oral therapy period: If oral switch criteria are met, on or after Day 4 amoxicillin/clavulanate may be prescribed (40 mg/kg per day divided into 3 equal doses, maximum of 500 mg/dose to subjects weighing less than 40 kg and 500 mg every 8h to subjects weighing 40 kg or greater). In addition, if oral clarithromycin or placebo had been given during the IV period, oral clarithromycin may be given every 12h (7.5 mg/kg, maximum dose 500 mg for subjects 8 to 11 years old, 500 mg for subjects 12 to 17 years old)."
1846002|NCT00914901|Drug|inhaled salmeterol|Inhalation of 100 micrograms salmeterol in one dose.
1846003|NCT00914914|Drug|p28|p28 will be dissolved in normal saline and infused intravenously into the patient over 15-30 minutes.
1846004|NCT00914927|Drug|E5501|E5501 First Dose 80 mg followed by 10 mg a day for up to 6 additional days
1846005|NCT00914927|Drug|E5501|E5501 First Dose 80mg followed by 20 mg a day for 3 days and then Placebo for 3 additional days
1846006|NCT00914927|Drug|Placebo|Placebo or inactive substance once a day for up to 7 days
1846007|NCT00914940|Drug|Fludarabine Phosphate|Fludarabine will be administered in a dose of 25 mg/m2/day IV over approximately 30 minutes for 5 consecutive days (day -6 to -2). The total dose of fludarabine will be 125 mg/m2.
1846008|NCT00914940|Drug|Tacrolimus|"Tacrolimus will be administered beginning on day -1 at a dose of 0.03 mg/kg/day by continuous IV infusion.
For the first cohort of 35 patients, if there is no evidence of grade II-IV acute GVHD on or prior to day 50, tacrolimus should then be tapered at the rate of approximately 5% of the day 50 dose each week for liquid, and 20% of the day 50 dose per month for capsules.
In the second cohort of 25 patients if there is no evidence of grade II GVHD on or prior to day 30, tacrolimus should then be tapered at the rate of approximately 8% of the day 30 dose each week for liquid, and 33% of the day 30 dose per month for capsules."
1846009|NCT00914940|Drug|Thiotepa|Thiotepa will be administered in a dose of 5 mg/kg/day (adjusted body weight) IV over approximately 4 hours for 2 consecutive days (day -6 and day -5).
1846010|NCT00914940|Radiation|Total-Body Irradiation (TBI)|TBI will be given as 165 cGy fractions twice per day x 4 days - total dose 1320cGy (days -10 to -7).
1846011|NCT00914940|Other|Magnetic Affinity Cell Sorting|Device
1846012|NCT00914940|Procedure|Peripheral Blood Stem Cell Transplantation|Patient will undergo a PBSC transplantation
1846013|NCT00914940|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients who are considered appropriate candidates for allogeneic hematopoietic stem cell transplantation
1846014|NCT00914940|Biological|T Cell-Depleted Hematopoietic Stem Cell Transplantation|Patients who are eligible will receive a T Cell-Depleted Hematopoietic Stem Cell Transplantation
1846015|NCT00914953|Drug|oxytocin (Pitocin)|40 IU OT intranasally (IN) once-daily for 10 consecutive days
1846016|NCT00914966|Biological|C1 inhibitor (human) [C1 INH]|
1846017|NCT00914979|Device|AngioSculpt|The AngioSculpt Scoring Balloon Catheter is a standard balloon dilatation catheter with a scoring balloon near the distal tip
1846018|NCT00914992|Procedure|Suction cup application|The IOP will be raised by an 11 mm diameter, standardized suction cup placed on the temporal sclera with the anterior edge at least 1 mm from the limbus.
1846019|NCT00914992|Other|Squatting|Squatting
1846020|NCT00915005|Radiation|Photon Therapy|Group 1: 74 Gy 37 radiation treatments, given 5 days a week for about 7 1/2 weeks. Each daily treatment should take about 20-30 minutes to complete.
1846021|NCT00915005|Radiation|Proton Therapy|"Group 2: 74 Gy in 2 CGE per fraction given 5 days a week for about 7 1/2 weeks.
Group 3: 66 Gy with conventional fractionation given 5 days a week for about 6-7 1/2 weeks.
Each daily treatment should take about 20-30 minutes to complete."
1846022|NCT00915005|Drug|Paclitaxel|50 mg/m2 by vein 1 time each week for 7 weeks.
1846023|NCT00915005|Drug|Carboplatin|AUC 2 by vein 1 time each week for 7 weeks.
1846267|NCT00925106|Drug|Test formulation D2|Single dose 150 mg celecoxib as formulation D2
1846028|NCT00915057|Drug|NRL972|Single dose of NRL972 administered at baseline, at 3-monthly intervals during treatment for up to 12 months (or the end of treatment) and at 3 and 6 months after the end of treatment.
1846029|NCT00915070|Drug|BQ-123|60 mcg/min, infusion period: 60 min
1846030|NCT00915070|Drug|Physiological saline solution|infusion period 60 minutes
1846031|NCT00915070|Device|Laser Doppler Flowmetry|blood flow measurements at the temporal neuroretinal rim to assess optic nerve head blood flow
1846032|NCT00915070|Device|Goldmann Applanation Tonometer|intraocular pressure measurements
1846033|NCT00915070|Other|squatting|subjects will perform squatting for 6 minutes while blood flow measurements
1846034|NCT00915083|Drug|Amrubicin|40mg/m^2 5 minute IV infusion for 3 consecutive days (21 day cycle)
1846035|NCT00915122|Radiation|Dose Escalated IMRT|Patients will receive external beam RT 55.1Gy in 29 once daily fractions to pelvic lymph nodes/prostate/seminal vesicles followed by 24.7Gy in 13 once daily fractions to the prostate/seminal vesicles using intensity modulated radiation therapy.
1846036|NCT00922909|Behavioral|Simon task|Reaction time task
1846037|NCT00922935|Device|Cresco|Cresco components loading 10 days post surgery
1846038|NCT00922935|Device|Cresco|Cresco loading at 6-8 weeks post surgery
1846039|NCT00922935|Device|Straumann components|Straumann components loading 6-8 weeks post surgery
1846040|NCT00922948|Procedure|Cryoablation|Cryoneedles and one temperature probe are inserted under endoscopic and sonographic guidance.
1846041|NCT00922948|Procedure|Radiofrequency ablation|Thermal injury is the predominant mechanism of action of RFA. A high-frequency alternating current emitted from the exposed noninsulated portion of the electrode generates frictional heat, agitating ions in the tissue surrounding the tip of the needle.
1846042|NCT00922961|Biological|Blood sample|Blood sample taken for the analysis of the rate of CD8 T-Lymphocyte Apoptosis
1846043|NCT00922961|Procedure|Clinical exam|Assessment of the esthetic score, and the late cutaneous side effect by 2 physicians
1846044|NCT00922974|Radiation|external beam radiation therapy|Patients undergo 1 standard-dose external beam radiotherapy treatment.
1846045|NCT00922974|Radiation|image-guided radiation therapy|Patients undergo 1 high-dose image-guided radiosurgery treatment.
1846046|NCT00922974|Radiation|radiosurgery|Patients undergo 1 high-dose image-guided radiosurgery treatment.
1846047|NCT00922974|Radiation|stereotactic body radiation therapy|Patients undergo 1 high-dose image-guided SBRT treatment.
1846048|NCT00922987|Drug|Lyrica (pregabalin)|The daily dose may range from 150mg to 600mg, administered as two single doses. The treatment should be started with 150mg daily dose (2x75mg). Depending on response and tolerability after 7 days may the dose be increased to 300mg/day (2x150mg) and after further 7 days to maximum dose 600mg/day (2x300mg)
1846049|NCT00923000|Drug|Nalbuphine|Nalbuphine 10mg with oral administration
1846050|NCT00923000|Drug|Morphine|Morphine 10mg with oral administration
1846051|NCT00923000|Drug|Morphine with Long dan xie gan tang|Morphine 10mg with oral administration
1846052|NCT00923000|Drug|Nalbuphine with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g tid with oral administration
1846053|NCT00923000|Drug|Nubian with Long dan xie gan tang|Nalbuphine 10mg with Long dan xie gan tang 3g with oral administration
1959490|NCT00001379|Biological|Interferon|For LYG Grade 1 and 2: Interferon starting at 7.5 million Units subQ 3 times a week and increasing on the following schedule: 10 million U; 15 million U; 20 million U; 25 million U; and increased in 5 million U increments, as tolerated. Patients continue taking interferon for 1 year beyond CR.
1846058|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide + placebo|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
1846059|NCT00923091|Drug|Olmesartan medoxomil + amlodipine + hydrochlorothiazide + placebo|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
1846060|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
1846061|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. One hydrochlorothiazide 12.5 mg tablet + one hydrochlorothiazide 12.5 mg placebo tablet taken once per day.
1846062|NCT00923091|Drug|olmesartan medoxomil + amlodipine + hydroclororthiazide|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day. Two hydrochlorothiazide 12.5 mg tablets taken once per day.
1846063|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 20 mg + amlodipine 5 mg combination oral tablet taken once per day
1846064|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 5 mg combination oral tablet taken once per day.
1846065|NCT00923091|Drug|olmesartan medoxomil + amlodipine|One olmesartan medoxomil 40 mg + amlodipine 10 mg combination oral tablet taken once per day.
1846066|NCT00923117|Drug|Sutent (sunitinib)|Oral dose 37.5 mg daily on a continuous 4 week cycle
1846067|NCT00923130|Drug|Bevacizumab|Bevacizumab will be administered intravenously every 3 weeks on an outpatient basis with the exception of admissions for the purpose of facilitating research studies. The dose of bevacizumab to be given is 15 mg/kg.
1959491|NCT00001379|Drug|Rituxan and EPOCH|For LYG Grade 3: EPOCH-R (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituxan) every 3 weeks for 6 cycles.
1959492|NCT00001596|Drug|Pirfenidone|Treatment with pirfenidone 801 mg (3 pills of 267 mg each), three times daily.
1959493|NCT00001596|Drug|Placebo|Placebo (3 pills), three times daily.
1846068|NCT00923130|Drug|Ixabepilone|Ixabepilone will be given on days 1, 2, 3, 4, and 5 of each three week cycle as a one hour intravenous infusion. The dose will be 6 mg/m(2)/day on five successive days.
1846069|NCT00923156|Drug|aliskiren|Aliskiren 150 mg once daily up titrated to 300 mg once daily after 1 week of treatment following a clinical safety patient assessment at the study site
1846070|NCT00923156|Drug|ramipril|2.5 mg , 5.0 mg or 10 mg once daily
1846071|NCT00923156|Drug|Placebo to aliskiren|matching placebo to aliskiren in double blind phase
1846072|NCT00923156|Drug|Placebo to ramipril|Matching placebo to ramipril capsule in double blind phase
1846073|NCT00923169|Drug|Anti-Transforming Growth Factor-beta (GC 1008)|
1846074|NCT00923182|Drug|alemtuzumab|
1846075|NCT00923195|Drug|MART-1: 26-35(27L) Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).
One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
1846076|NCT00923195|Drug|Montanide ISA 51 VG|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).
One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
1846077|NCT00923195|Drug|gp100:154-162 Peptide|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).
One mg of either the gp100:154-162 or the MART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14."
1846078|NCT00923195|Procedure|Radiation|2Gy of TBI twice on day -2 and once on day -1 (total dose 6 Gy) at a rate of 0.07 Gy/minute
1846079|NCT00923195|Drug|Aldesleukin|Within 24 hours of cell infusion administration of aldesleukin will be initiated as 720,000 IU/kg/dose IV over 15 minutes every 8 hours for up to 5 days (maximum 15 doses).
1846080|NCT00923195|Drug|Fludarabine|Day -6 to -2: Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days
1846081|NCT00923195|Drug|Cyclophosphamide|Day -6 to -5: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with mesna15 mg/kg/day over 1 hr X 2 days.
1846082|NCT00923195|Genetic|Anti-gp 100:154 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).
One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
1846083|NCT00923195|Genetic|Anti-MART-1 F5 TCR PBL|"Day 0:Autologous transduced CD8+PBL (anti-gp100:154 TCR PBL and anti-MART-1 F5 TCR PBL) infusion will be administered intravenously over 20 to 30 minutes (minimum 5 x 10e8 and up to a maximum of 2 x 10e11 of each transduced lymphocyte population).
One mg of either the gp100:154-162 or theMART-1:26-35(27) emulsified in IFA by deep subcutaneous injection into each thigh to be administered prior to cell infusion and on days 7 and 14"
1846084|NCT00923234|Drug|Azacitidine|75 mg/m² SC days 1-5 every 28 days for a maximum of 8 cycles
1846085|NCT00923234|Drug|Lenalidomide|10 - 25 mg PO days 6-19 every 28 days for a maximum of 8 cycles
1846086|NCT00923247|Drug|Bortezomib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & 11 every 28 days in adults
1846087|NCT00923247|Drug|Vandetanib|This study is designed to assess the safety, tolerance and activity of daily oral vandetanib and bortezomib on days 1, 4, 8 & 11 every 28 days in adults
1846088|NCT00923260|Procedure|Laparoscopic Roux-en-Y Gastric Bypass|Laparoscopic Roux-en-Y Gastric Bypass was performed according to the following standards: Gastric pouch was constructed using the lesser curvature of the stomach. A 45mm stapler was initially fired horizontally 2 to 3 cm below the gastroesophageal junction and then 2 o 3 additional fires towards the angle of His and against a 32 French intragastric tube completed the vertical transection. Lengths of the biliopancreatic and alimentary limbs were approximately 50, and 150 cm respectively. An antecolic and antegastric gastrojejunostomy, 1.0 to 1.5 cm in size was hand sewn and the jejuno-jejunostomy was completed in a latero-lateral fashion using one fire of 45 mm lineal stapler with hand sewn closure of the common enterotomy.
1846089|NCT00923260|Procedure|Omentectomy|After laparoscopic gastric bypass, the greater omentum was divided in the middle from the free edge to the colonic margin using ultrasonic energy. Attachments between the omentum and the transverse colon were dissected. The omentum was detached from the stomach transecting the vessels between the right gastroepiploic vessels and the greater curvature of the stomach. Once the omentum was freed from the stomach, the duodenum and the lower pole of the spleen, it was extracted from the abdominal cavity in a sterile plastic bag.
1846090|NCT00923806|Biological|PG13-CEA_TCR (Anti-CEA TCR PBL)|
1846091|NCT00923806|Drug|Aldesleukin|720,000 IU/kg intravenous over 15 minutes every 8 hours for up to 5 days
1846092|NCT00923819|Procedure|Laparoscopic gastric bypass|Patients are referred to Morbid Obesity Center from other hospitals in Norway. The procedure will take place at the Hospital of Vestfold.
1846093|NCT00923819|Behavioral|Standard conservative treatment|The participants are included for 2 years follow-up with visits to a multidisciplinary team every 3rd month, either at the Morbid Obesity Center or a similar center in Norway.
1846094|NCT00923845|Drug|Pentostatin|Pentostatin: 2- 4mg/m^2(CrCL based dosing) intravenous (IV) on days 1, 8, and 15
1846095|NCT00923845|Drug|Sirolimus|Sirolimus: 4 mg by mouth (PO) on days -3 to +7 post-transplant (No Sirolimus administered after day 7 post-stem cell transplant (SCT))
1846096|NCT00923845|Drug|Cyclophosphamide|Cyclosporine: 2 mg/kg every 12 hours PO or IV starting on day -4 of hematopoietic stem cell transplant (HSCT)
1846097|NCT00923845|Procedure|Allogeneic Hematopoietic Stem Cell Transplant (HSCT)|Allogeneic Hematopoietic Stem Cell Transplant
1846098|NCT00923845|Procedure|Th2 rapa cells|Th2 rapa cell Transplantation
1846099|NCT00923845|Procedure|Donor Lymphocyte Harvest|Apheresis
1846100|NCT00923845|Procedure|Induction Therapy|Pentostatin and cyclophosphamide (PC) conditioning regimen.
1846101|NCT00923845|Procedure|GVHD prophylaxis|Short course of sirolimus plus maintenance therapy with sirolimus A.
1846102|NCT00923845|Procedure|Donor Hematopoietic Stem Cell Harvest|Following lymphocyte harvest, donors for recipients will undergo stem cell mobilization and harvest.
1846103|NCT00923871|Procedure|Cone Beam CT|Patients will also have a CBCT scan when they are having their first IMRT treatment.
1846104|NCT00923897|Radiation|Palliative RT|Prior to receiving radiation treatment, it is recommended that you take medications to reduce the chance of nausea related to therapy. The treatment will take approximately 30 minutes.
1846105|NCT00923910|Drug|WT1 Peptide-Pulsed Dendritic Cells|
1846106|NCT00923910|Drug|Donor Lymphocytes|Lymphocytes from donors (related or unrelated) collected via lymphapheresis.
1846107|NCT00923910|Drug|IL-4|water-soluble protein; this study will use GMCSF (granulocyte macrophage colony stimulating factor)/IL-4 generated monocyte derived dendritic cells
1846108|NCT00923910|Drug|KLH|Neoantigen known to induce helper responses; will be used concurrently as a vaccine adjuvant and control antigen.
1846109|NCT00923910|Drug|WT1 Peptides|dendritic cell vaccine
1846110|NCT00923910|Drug|Endotoxin|Purified lipopolysaccharide prepared from E.Coli 0:113
1846111|NCT00923910|Drug|Diphenhydramine|Pre-medication
1846112|NCT00923910|Drug|Acetaminophen|Pre-medication
1846113|NCT00923923|Behavioral|stress|compare levels of stress
1846114|NCT00923936|Drug|Liposomal Doxorubicin|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles.
1846115|NCT00923936|Drug|Bevacizumab|Induction phase dose: Intravenous (IV) bevacizumab 15 mg/kg once, followed 7 days later by liposomal doxorubicin mg/m^2 and bevacizumab every 3 weeks for six cycles. Maintenance phase dose: IV bevacizumab every 3 weeks for 11 cycles.
1846116|NCT00923949|Drug|Pioglitazone|45 mg tablet daily by mouth for six weeks
1846117|NCT00923962|Drug|Glucagon like peptide-1|0,1 pmol/kg/min
1846118|NCT00923962|Drug|Adenosine|20-40 microgram/minute
1846119|NCT00923975|Device|DIDGET World Web Community Reports|During the study subjects performed specific tasks, such as uploading meter results to a secure website and displaying reports.
1846120|NCT00923988|Other|secondhand smoke exposure|Participants will be exposed to secondhand smoke for one hour. As a measure of secondhand smoke exposition, room carbon monoxide concentration will be continuously measured using an Ambient Carbon Monoxide Monitor APMA-360 and kept constant between 4.5-6.0 ppm. Levels in this magnitude are typically seen in smoking areas of restaurants and bars.
1846121|NCT00924001|Drug|DMF5 Melanoma Reactive TIL|given intravenously over 20-30 minutes (between 1 x 10^9 and 1 x 10^11 lymphocytes) after expansion in interleukin-2 and OKT-3
1846122|NCT00924001|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenously
1846123|NCT00924001|Drug|Fludarabine|25 mg/m^2/day intravenously x 5 days
1846124|NCT00924001|Drug|Aldesleukin|720,000 IU/kg/dose intravenously every 8 hours for up to 15 doses
1846125|NCT00924014|Drug|Conivaptan|Conivaptan 20 mg IV bolus followed by a 4 hour infusion at 1.2 mg/hr
1846126|NCT00924014|Drug|Furosemide|Furosemide will be given IV at the subjects usual oral dose up to 80 mg. If the dose is 80 mg or more only 1/2 the dose will be given IV.
1846127|NCT00924014|Drug|Conivaptan and furosemide|Furosemide bolus first; conivaptan 20 mg IV bolus/infusion at 1.2 mg/hour for a total of 4 hours
1846129|NCT00924040|Drug|BL22 (CAT-3888)|30 micrograms/kg intravenous over 30 minutes every other day (QOD) on days 1, 3, 5, of a 4 week cycle (at least 26 days) for a maximum of 16 cycles or until they become ineligible.
1846130|NCT00924053|Drug|EGT0001474|Cohort 1: single dose of 25 mg EGT0001474 given as an oral capsule; Cohort 2: single dose of 75 mg EGT0001474 given as 3 oral capsules; Cohort 3: single dose of 150 mg EGT0001474 given as 6 oral capsules.
1846131|NCT00924053|Drug|Placebo|Placebo capsules to match EGT0001474
1846132|NCT00924066|Drug|Ixempra (Ixabepilone (BMS-247550) )|Participants received Ixabepilone 6mg/m^2 for a total of 30mg/m^2 inpatient or outpatient intravenously over an hour on the first five days of each 21 day cycle.
1846133|NCT00924079|Drug|nalbuphine|oral dosage form, 66 mg, single dose
1846134|NCT00924092|Biological|GI-6207 [Recombinant Saccharomyces Cerevisia|
1846135|NCT00924092|Drug|(Yeast CEA Vaccine)(GI-6207[Recombinant Sarrcharomyces Cerevusua-CEA (610D)])|
1846136|NCT00924105|Drug|CYT013-IL1bQb|s.c. injection
1846137|NCT00924105|Drug|Placebo|s.c. injection
1846138|NCT00924118|Drug|Sodium Nitrite|Subjects assigned to sodium nitrite will receive an initial infusion of 6 nmol/min/kg for 48 hours. After the first six subjects have been enrolled (3 active drug, 3 control) and if there are no dose limiting toxicities, additional cohorts of six subjects each will be randomized to escalating doses of sodium nitrite versus control for a total of 30 subjects.
1846139|NCT00924157|Dietary Supplement|IPP|Protein hydrolysate rich in lacto-tripeptide (IPP) up to 5 to 15 mg/day
1846140|NCT00924157|Other|Placebo|Matching placebo capsules
1846141|NCT00924170|Drug|LMB-2|Begin with 30 mcg/Kg intravenous (IV) on days 3, 5 and 7. Escalate to 40 mcg/Kg if dose limiting toxicity (DLT) in 0/3 or 1/6 at 30 mcg/Kg. Continue at 40 mcg/Kg if 0-1 of 6 have DLT at 40 mcg/Kg.
1846142|NCT00924170|Drug|Fludarabine|"Days 1-3:
Patients 1-7, 10-14, and >18:25mg/m^2/day Patients 8 - 9:30 mg/m^2/day Patients 15- 17:20 mg/m^2/day"
1846143|NCT00924170|Drug|Cyclophosphamide|"Days 1-3:
Patients 1-7, 10 -14, and >18:250 mg/m^2/day Patients 8 - 9:300 mg/m^2/day Patients 15-17:200 mg/m^2/day"
1846144|NCT00924183|Other|Treatment-as-usual|
1846145|NCT00924209|Drug|Gemcitabine|1250 mg/m^2 dose for two doses on days 1 and 8
1846146|NCT00924209|Drug|Cisplatin|80 mg/m^2 on day 1
1846147|NCT00924209|Drug|Bevacizumab|7.5 mg/m^2 on day 1 every 21 days for first two cycles only
1846148|NCT00924209|Procedure|Surgery|thoracotomy with lobectomy/pneumonectomy and mediastinal lymph node dissection 4-6 weeks post completion of last cycle of cisplatin
1846149|NCT00924209|Drug|Etoposide|100 mg/m^2 intravenous per day for consecutive 3 days on days 1 to 3 every 3 weeks for 4 cycles.
1846150|NCT00924222|Drug|Sevoflurane|Sedation with sevoflurane
1846151|NCT00924222|Drug|Propofol|Sedation on intensive care unit with propofol
1846152|NCT00924248|Drug|Gadoxetic acid disodium (Primovist, BAY86-4873)|Patients in daily life clinical practice treatment receiving Primovist according to indication on the label.
1846153|NCT00924261|Other|Hip Stretch|Hip flexor stretch daily for 3 min x 10 weeks
1846154|NCT00924261|Other|Shoulder Stretch|Shoulder Adduction stretch - 3 minutes, daily, for 10 weeks
1846155|NCT00924274|Dietary Supplement|rapeseed oil|rapeseed oil in amounts between 14 and 27 g
1846156|NCT00924274|Dietary Supplement|sunflower oil|sunflower oil
1846157|NCT00924287|Drug|in vitro tumor reactive, chimeric T cell receptor (CAR ) gene-transduced PBL plus IV aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
1846158|NCT00924287|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenously (IV) in 250 ml 5% dextrose in water (D5W) with mesna 15 mg/kg/day x 2 days over 1 hour
1846159|NCT00924287|Drug|Fludarabine|25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
1846160|NCT00924287|Drug|Mesna|3 mg/kg/hour intravenously diluted in a suitable diluent over 23 hours after each cyclophosphamide dose.
1846161|NCT00924313|Drug|(C-11 Acetate)|11C-acetate positron emission tomography (PET)/computed tomography (CT)for 30 minutes, intravenous bolus injection
1846165|NCT00924339|Dietary Supplement|soy protein diet|Intervention-Group (n = 15): Fat- modified dietary regime and a minimum amount of soy protein: 0,25 g/ kg BW/d
1846166|NCT00924339|Dietary Supplement|rapeseed oil|Control-Group (n = 15): Diet reduced in SFA, modified in fatty acid pattern. Only rapeseed oil should to be used for preparation of the meals (baking, frying, in salad, and as spread.
1846167|NCT00924352|Drug|Dasatinib|Dasatinib tablets will be administered continuously starting on Day 1, Cycle 1 once daily (QD).Dose Level 2;140 mg QD,Dose Level 1;100 mg QD,Dose Level 0 (Starting Dose);100 mg QD,Dose Level − 1;100 mg QD,Dose Level − 2;70 mg QD.
1846168|NCT00924352|Drug|Ixabepilone|Ixabepilone, for injection 15 mg supplied with diluent for ixabepilone, 8 mL. Dose Level 2;20 mg/m2,Dose Level 1;20 mg/m2,Dose Level 0 (Starting Dose);16 mg/m2,Dose Level − 1;12 mg/m2,Dose Level − 2;12 mg/m2.
1846169|NCT00924391|Dietary Supplement|phytosterol enhanced soy based beverage|
1846170|NCT00924391|Dietary Supplement|1% milk|
1846171|NCT00924404|Drug|Xylitol|5% solution for sinus rinse
1846172|NCT00924404|Drug|Saline|saline for sinus rinse
1846173|NCT00924417|Behavioral|Routine Care|Parent given placebo intervention that entails brief information about what is routine care for intravenous line placement in the emergency department
1846174|NCT00924417|Behavioral|Distraction|"Parent given brief information about the cognitive behavioral technique known as distraction. Parent and child then given 3 distraction toys/tools to assist with peripheral intravenous line placement."
1846175|NCT00924430|Drug|Simvastatin- SLV337 SD beta- SLV337 SD alpha - SLV337 MD beta- SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 beta capsule, single dose of 1400 mg SLV337 alpha capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
1846176|NCT00924430|Drug|Simvastatin - SLV337 SD alpha - SLV337 SD beta - SLV337 MD beta - SLV337 SD beta+ Simvastatin|Single dose of 40 mg simvastatin tablet, single dose of 1400 mg SLV337 alpha capsule, single dose of 1400 mg SLV337 beta capsule, multiple dose over 12 days of 1400 mg/day SLV337 beta capsule including a single dose of 40 mg simvastatin tablet before the last dosing day
1846177|NCT00924443|Drug|clofarabine|
1846178|NCT00924456|Behavioral|Transcendental Meditation program|a natural effortless mental technique
1846179|NCT00924469|Drug|Abiraterone|Abiraterone acetate tablets will be administered orally at a total dose of 1000 milligram (mg) per day at least 1 hour before a meal or 2 hours after a meal for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
1846180|NCT00924469|Drug|Leuprolide|Leuprolide acetate will be administered at a dose of 22.5 mg (dose adjusted as per Investigator's discretion) as intramuscular injection (injection of a substance into a muscle) once every 12 weeks in Group 1 and Group 2.
1846181|NCT00924469|Drug|Prednisone|Prednisone tablets will be administered orally as 5 mg once daily for 24 weeks in Group 1 and from Week 13 to Week 24 for Group 2.
1846182|NCT00924482|Device|Placed ECOM endotracheal cardiac output monitor in patients undergoing cardiac surgery|Measure cardiac output during perioperative period and compare to pulmonary artery thermodilution cardiac output measurements.
1846183|NCT00924495|Device|transcranial magnetic stimulation|rTMS therapy daily for two weeks, five times per week each lasting for half an hour
1846184|NCT00924508|Device|hydrogel patch|occlusion of eczema with a hydrogel patch composed of an adhesive, thin, flexible, hydrogel layer on an impermeable urethane surface.
1846185|NCT00924508|Drug|Triamcinolone (TAC) 0.1% cream|Triamcinolone Acetonide (triamcinolone acetonide cream) is a topical corticosteroid used as anti-inflammatory and antipruritic agent. Each gram of TAC Cream USP, 0.1% contains 1 mg Triamcinolone Acetonide (triamcinolone acetonide cream) in a cream base consisting of cetyl alcohol, glyceryl monostearate, cetyl esters wax, isopropyl palmitate, polysorbate-60, polysorbate-80, propylene glycol and purified water.
1846186|NCT00924521|Dietary Supplement|Whole grain diet|Participants in this group will receive 6-9 servings of whole grain daily to replace the refined grains typically included in the average American diet. Number of servings will depend upon calorie assignment.
1846187|NCT00924521|Dietary Supplement|Refined grain|Participants in this group will receive only refined grains as typically consumed in the average American diet.
1846188|NCT00924534|Drug|Placebo|Placebo
1846189|NCT00924534|Drug|SLV337|SLV337 400 mg/day
1846190|NCT00924534|Drug|SLV337|SLV337 800 mg/day
1846191|NCT00924534|Drug|SLV337|SLV337 1400 mg/day
1846192|NCT00924547|Dietary Supplement|Docosahexanoic Acid Supplement|"The active treatment will consist of Martek's chewable DHA capsules containing 200mg in each capsule. The treatment will be provided as approximately 25mg/kg/day and 35mg/kg/day.
These dosages will be divided BID-TID and will be given for 4 weeks."
1846193|NCT00924547|Dietary Supplement|Placebo|Placebo identical to active treatment.
1846194|NCT00924560|Drug|91-day Levonorgestrel Oral Contraceptive|"Levonorgestrel/ethinyl estradiol 0.15/0.03 mg and ethinyl estradiol 0.01 mg tablet.
Take 1 tablet daily"
1846195|NCT00924560|Drug|28-day Levonorgestrel Oral Contraceptive|Levonorgestrel/ethinyl estradiol 0.10/0.02 mg tablet and placebo. Take 1 tablet daily
1846196|NCT00924573|Drug|Metformin|oral administration
1846197|NCT00924573|Drug|placebo|oral administration
1846198|NCT00924573|Drug|Glimepiride (HOE490)|oral administration
1846199|NCT00924586|Drug|ONO-1101|Placebo for one minute IV
1846200|NCT00924586|Drug|ONO-1101|0.125 mg/kg for one minute IV
1846201|NCT00924599|Behavioral|Prevention of recurrent gestational diabetes through weight loss and exercise (English & Spanish)|Intervention groups will attend weekly sessions focused on healthy weight loss, healthy eating, exercise.
1846202|NCT00924599|Behavioral|Lifestyle education (English & Spanish)|The lifestyle education group will focus on learning about healthy eating, and healthy activity. This group will also learn stress reduction techniques as well as new ways of increasing activity. Group will meet one time per month for 3 months, then once a month until conception.
1846203|NCT00924612|Drug|Oral testosterone undecanoate (containing 300 mg of T)|Single dose administered orally, 30 minutes after the initiation of protocol-defined breakfast or while fasting, in each of the 5 arms.
1846204|NCT00924625|Other|Neuromuscular electrical stimulation|Strength of the quadriceps muscles will be tested at the beginning of each session. During administration of the NMES participant will sit with the knees bent at 70 degrees. The force sensing pad will be secured to the ankle joint. Two electrodes will be placed on the thigh muscle; one near the hip and the other near the knee joint. The intensity of NMES will be increased gradually according with tolerance. During each treatment 15 electrically elicited muscle contractions will be administered to each thigh. Each contraction will last 14 sec followed by 1min rest.
1846205|NCT00924625|Other|Volitional exercises|The training will include bilateral exercises using resistance equipment (Leg Extension and Leg Press machines). Each resistance exercise will have: (a) dynamic muscle action at moderate repetition velocity (1-2 s concentric, 1-2 s eccentric, 2-3 s interval); (b) 3 sets of 8 repetitions with a load corresponding to 80% of one repetition maximum(1-RM); (c) 2-min rest period between sets and exercises.
1846206|NCT00924638|Device|Reveal® XT Insertable Cardiac Monitor|The Insertable Cardiac Monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. ECG data are stored when the device detects a cardiac arrhythmia.
1846207|NCT00924651|Behavioral|exercise|home based walking and progressive resistance training exercise
1846208|NCT00924664|Biological|Tanezumab 20 mg|Tanezumab 20 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
1846209|NCT00924664|Biological|Tanezumab 10 mg|Tanezumab 10 mg administered IV every 8 weeks for 3 administrations followed by SC administration every 8 weeks for 4 administrations over a period of 64 weeks
1846212|NCT00924690|Other|Behavioral Messages|Participants will read 10 behavioral messages about colon cancer screening and physical activity.
1846213|NCT00924690|Other|Generic Messages|Individuals will read 10 generic messages about colon cancer screening and physical activity.
1846214|NCT00924703|Drug|rAvPAL-PEG|The doses are planned to be in the same range as those tested in PAL-002 or PAL-004 and then modified either by increasing or decreasing the dose, adhering to an upper limit up to 5.0 mg/kg per week or 375 mg/week, considering each subject's individual responses related to safety and efficacy.
1846217|NCT00924742|Drug|Tapimycin (piperacillin 4 g + tazobactam 0.5g)|One intravenous infusion (piperacillin 4 g + tazobactam 0.5 g powder for injection) over 30 minutes/single dosing
1846219|NCT00924768|Biological|20K EU CCRE|Inhalation of CCRE
1846220|NCT00924781|Drug|MK2578 1mcg for every 600 Units (U) of Epogen® (epoetin alfa) received per week at Baseline|MK2578 was to be administered intravenously (IV). Participants in Cohort 1 were to receive 1 mcg of MK2578 for every 600 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to every week (QW) or once every 4 weeks (QM) dosing schedules within each cohort.
1846221|NCT00924781|Drug|MK2578 1 mcg for every 350 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 2 were to receive 1 mcg of MK2578 for every 350 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
1846222|NCT00924781|Drug|MK2578 1 mcg for every 200 U of Epogen (epoetin alfa) received per week at Baseline|MK2578 was to be administered IV. Participants in Cohort 3 were to receive 1 mcg of MK2578 for every 200 U of Epogen (epoetin alfa) received per week at Baseline. Participants were to be randomized to QW or QM dosing schedules within each cohort.
1846223|NCT00924794|Procedure|Cancer Registry of Norway (database)|Review of database to identify women with primary conization presenting with high grade lesions/ microinvasive cervical carcinomas. Recurrent cones with high grade lesions/ microinvasive cervical carcinomas or invasive cervical cancer will be identified for all women with primary cones.
1846304|NCT00925535|Drug|Lersivirine|1000 mg once daily for 10 days
1846224|NCT00924807|Drug|Leuprolide acetate, Bicalutamide, Sorafenib|Leuprolide acetate - depot, Bicalutamide 50 mg, Sorafenib 400mg
1846226|NCT00924833|Drug|placebo|placebo tablet BID
1846227|NCT00924833|Drug|Carvedilol|Carvedilol 25 mg tablets. One tablet twice daily.
1846228|NCT00924833|Drug|Nebivolol|nebivolol 5 mg tablets. One nebivolol tablet daily. One placebo tablet daily.
1846229|NCT00924846|Procedure|High frequency oscillatory ventilation|Mechanical ventilation as high frequency oscillatory ventilation for 8h periods
1846230|NCT00924859|Other|ELISA Test|assess the overall accuracy of D-dimer values and FXIII activation peptide (FXIII-AP), using a newly developed ELISA test
1846231|NCT00924872|Other|wheelchair skills training|Five 30-minute training sessions, at a target frequency of 3-5 sessions per week, aimed at improving their power wheelchair skills.
1846232|NCT00924885|Device|Swemed Follicle Aspiration Set Reduced Single Lumen|Thin tip to penetrate the tissue
1846233|NCT00924885|Device|Swemed Follicle Aspiration Set Single Lumen (1.4 mm)|Standard (1.4 mm) needle to penetrate the tissue
1846234|NCT00924898|Drug|efavirenz, emtricitabine, and tenofovir|Once daily ART with emtricitabine, tenofovir DF and efavirenz
1846235|NCT00924911|Drug|GSK1322322|Four different formulations of 1000mg of GSK1322322
1846236|NCT00924911|Drug|GSK1322322|GSK1322322 1000mg
1846237|NCT00924924|Behavioral|Act Healthy!|Six-week class of 50 minute sessions of self-management training for health behaviors
1846238|NCT00924924|Behavioral|Delayed treatment control|Delayed self-management training group - begins following completion of the experimental group training
1846241|NCT00924950|Drug|Taclonex Ointment and Hydrogel Patch|Each patient will have bilateral symmetrical psoriatic plaques. One plaque will be treated with Taclonex Ointment daily along with Hydrogel Patch daily. All treatment will be for 4 weeks.
1846242|NCT00924950|Drug|Taclonex Ointment|Taclonex ointment daily for one psoriatic plaque.
1846243|NCT00924963|Device|J-Tip jet injector|0.2ml 1%buffered lidocaine delivered by jet injector
1846244|NCT00924963|Device|Jet injection saline|0.2ml saline delivered via J-Tip jet injection
1846245|NCT00924963|Drug|lidocaine cream|4% lidocaine cream applied for 30 minutes to the skin
1846246|NCT00924976|Behavioral|Steps for Achieving Financial Empowerment (SAFE)|The SAFE is a brief, 5-component intervention that aims to facilitate a cooperative consumer-payee relationship, increase accurate knowledge about representative payeeship, promote collaborative money management and effective budgeting, and prepare mutually developed plans for carrying out the payeeship in the future.
1846247|NCT00924989|Drug|OSI-906|Administered orally
1846248|NCT00924989|Other|Placebo|Matching placebo administered orally
1846250|NCT00925015|Biological|Dalotuzumab 10 mg/kg|Dalotuzumab at 10 mg/kg was intravenously administered once weekly
1846251|NCT00925015|Biological|Cetuximab|Following pre-treatment with a histamine-receptor antagonist, Cetuximab was administered with an initial intravenous infusion of 400 mg/m^2, followed by subsequent once weekly intravenous infusions of 250 mg/m^2
1846252|NCT00925015|Drug|Irinotecan|Irinotecan was administered with an intravenous infusion of 150 mg/m^2, once every other week for 42 days
1846253|NCT00925015|Biological|Dalotuzumab 15/7.5 mg/kg|Dalotuzumab was intravenously administered, with the first infusion of 15 mg/kg, followed by subsequent infusions of 7.5 mg/kg
1846254|NCT00925028|Drug|Warfarin|Patients of group A will have the task of managing their own warfarin therapy using the provided nomograms. In the second office visit patients will be told to which group they were randomized and if they are in group A they will then be instructed on how to use the warfarin adjustment nomograms provided. After four months the groups will switch to the alternate management strategy. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
1846255|NCT00925028|Drug|Warfarin|Patients of group B will continue to be managed by their physician. This time those in group B will be instructed on how to use the nomograms during an office visit. Patients in both groups will use warfarin tablets of two dosage strengths, 1 mg and 5 mg. All INR testing will be done at the community laboratory and results will be made available to the patient for dosage adjustment, as well as the physician. The physician's office will be available for appointments and phone calls from study subjects to discuss and support the process at any time.
1846256|NCT00925054|Drug|rAvPAL-PEG|In Part 1, the planned starting dose levels are those tested in PAL-001 (0.001, 0.003, 0.01, 0.03, and 0.1 mg/kg), provided no dose-limiting toxicity was observed in PAL-001. After each subject completes Part 1, the subject's rAvPAL-PEG dosing will continue in Part 2. In Part 2, each subject's dose will be adjusted to attain a target blood Phe concentration with target levels between 120-600 micromol/L and a minimum blood Phe concentration decrease of 30% from baseline.
1846257|NCT00925067|Procedure|laparoscopic (TEP) inguinal hernia repair|laparoscopic inguinal hernia repair with a standard heavyweight Marlex (control group) prosthesis or new generation lightweight VyproII and TiMesh prostheses (study group)
1846258|NCT00925067|Device|lightweight TiMesh|
1846259|NCT00925067|Device|lightweight VyproII|
1846260|NCT00925067|Device|Heavyweight Marlex|
1846261|NCT00925080|Device|IVBG|Venous blood glucose measurement every 7.5 minutes for 72-hours
1846262|NCT00925093|Drug|Vancomycin|Vancomycin is administered intravenously and subsequently measured in cerebrospinal fluid sample
1846263|NCT00925093|Drug|Teicoplanin|Teicoplanin is administered intravenously and subsequently measured in cerebrospinal fluid sample
1846264|NCT00925093|Drug|Linezolid|Linezolid is administered intravenously and subsequently measured in cerebrospinal fluid sample
1846265|NCT00925106|Drug|Celebrex capsule|Single dose 200 mg commercial Celebrex capsule
1846266|NCT00925106|Drug|Test formulation D1|Single dose 150 mg celecoxib as formulation D1
1846268|NCT00925106|Drug|Test formulation D3|Single dose 150 mg celecoxib as formulation D3
1846270|NCT00925132|Drug|Temozolomide, Decitabine, Panobinostat|"Temozolomide - given each cycle.
Decitabine - 6 cohorts with dose escalation.
Panobinostat - 6 cohorts with dose escalation."
1846271|NCT00925145|Procedure|Single Incision Laparoscopic Appendectomy|
1846272|NCT00925158|Procedure|Dissector Assisted Malar Elevation|Malar dissector - Surgical instrument for video endoscopic rhytidoplasty.
1846273|NCT00925171|Behavioral|Pulmonary Intervention|Maintenance programme of 2 hours duration, every 3 months. During the first hour patients will describe the extent to which they have been able to continue with their exercises at home on an individual basis and ways of enhancing adherence to this training will be discussed. Positive re-enforcement will be provided. Patients with suspected depression or social isolation will be referred to their GP for additional management. Patients will be advised on dyspnoea management strategies, especially controlled breathing combined with supervised activity exertion on activities relevant to their daily living. This will be followed by 1 hour of supervised strength and endurance training including walking, cycling, standing from sitting, arm exercises using dumbbells and step-ups. Patients will receive a written report on their progress by their physician and copied to their GP. This will be in addition to the standard advice given to the control group.
1846274|NCT00925197|Other|INR self-testing program|
1846275|NCT00925210|Procedure|Sequential pEBUS - ENB|"Subject will undergo bronchoscopy with peripheral endobronchial ultrasonography to identify the peripheral lung nodule. If the lesion is identified with pEBUS, samples will be collected.
If the lesion is not found by pEBUS, the electromagnetic navigation system will be deployed and directed to the lesion of interest, once again using pEBUS to confirm final location before samples are collected."
1846276|NCT00925262|Behavioral|Cognitive Processing Therapy|an adaptation of cognitive behavioral therapy used to address mental health effects of trauma exposure
1846277|NCT00925262|Behavioral|Behavioral Activation|form of counseling intervention to promote positive behaviors and reduce negative behaviors as a means of reducing depression symptomatology and severity
1846278|NCT00925262|Behavioral|nonspecific counseling|nonspecific counseling interventions useful for a broad range of mental health and psychosocial problems.
1846279|NCT00925275|Drug|I-131-CLR1404|Single intravenous injection of 10 millicuries of I-131-CLR1404 given on Day 0
1846280|NCT00925288|Biological|Gardasil|Dosage Form: 0.5 ml intramuscular injection Dosage: Gardasil 0.5ml suspension Frequency: 3 doses
1846281|NCT00925301|Drug|migalastat hydrochloride|oral capsule every other day
1846282|NCT00925301|Drug|Placebo|oral capsule every other day
1846283|NCT00925314|Biological|CB-10-01 (Transgenic Lymphocyte Immunization)|1 Primary Infusion and 2 Booster Infusions
1846284|NCT00925327|Other|Corneal collagen cross-linking with riboflavin/UVA light|Corneal collagen cross-linking with riboflavin/UVA light
1846285|NCT00925340|Behavioral|Family Check Up|The Family Check-Up provides a thorough assessment of individual family strengths and weaknesses and utilizes principles of motivational interviewing to encourage families to change.
1846286|NCT00925340|Behavioral|Psychoeducation|Psychoeducation regarding teen alcohol and drug use in general, along with ways parents can help their children stay safe from using alcohol or drugs.
1846287|NCT00925353|Drug|4% lidocaine gel|1 ounce 4% lidocaine gel on skin of breasts and chest wall for 1 hour under occlusion, then removed with warm water
1846288|NCT00925366|Other|Imaging Procedure|CT Arthroscopy of the Shoulder - MR Arthroscopy of the Shoulder - MR of the shoulder
1846289|NCT00925392|Drug|Doripenem|Intravenous 500 mg every (q) 8 hours for 3 doses
1846290|NCT00925392|Drug|Doripenem|Intravenous 1000 mg q 8 hours for 3 doses
1846291|NCT00925405|Procedure|Breast MRI|Magnetic resonance imaging (MRI) scans of the breasts once per year
1846292|NCT00925405|Procedure|Mammogram|Breast x-ray used to detect breast cancer and look for abnormalities in the breast.
1846293|NCT00925418|Procedure|Frozen Glove|Using frozen glove during chemotherapy with Taxotere®
1846294|NCT00925431|Behavioral|Lifestyle Modification|16 hours of motivational, lifestyle management session, 8 hours nutritional education.
1846295|NCT00925431|Behavioral|Supportive education|16 hours general fibromyalgia education, 8 hours of nutritional education
1846296|NCT00925444|Device|FOREseal|a pair of alginate sleeves for linear cutting staplers used in lung surgery
1846297|NCT00925444|Device|Stapling|Stapling alon or associated with sealants
1846298|NCT00925457|Other|No Intervention|Neither current domperidone nor current PPI
1846299|NCT00925457|Drug|Current Domperidone|Current domperidone at any dose, regardless of proton pump inhibitor status
1846300|NCT00925457|Drug|Current proton pump inhibitor (PPI)|Current PPI and not current dapoxetine
1846301|NCT00925483|Procedure|dialysis|different dialysis schedules for each arm
1846302|NCT00925509|Procedure|Therapeutic assessment -Radio-surgical guidance.|"The first steps of the procedure include the production of a radiosurgical guide and the preparation of a mask in order to allow precise, non invasive repositioning of the guide.
Secondarily, the patient undergoes a CT-scan with the mask on and the radiosurgical guide in place. This provisional scan is used for preimplantation evaluation and drilling of the guide hole.
Under general anaesthesia, the mask is placed on the patient and the guide is fixed to the mask. A hole is drilled with a burr in the mandible through the hole in the guide. Implants are placed and the guide and mask are removed.
A second, post-implantation CT-scan is planned 3 months after implantation. Comparison of pre- and post-implantation CT-scans allows to evaluate the precision of the placement."
1846303|NCT00925522|Device|Therapy Cool Path Duo Cardiac Ablation System|"Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.
1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode."
1846306|NCT00925535|Drug|Lersivirine|1000 mg once daily for 10 days
1846307|NCT00925535|Drug|Rifabutin|300 mg once daily for 10 days
1846308|NCT00925548|Biological|Tecemotide (L-BLP25) and Hormonal Treatment|"Investigational Arm:
Pretreatment (Single Dose) 300 mg/m^2 of intravenous cyclophosphamide in investigational arm to a maximum of 600 milligrams (mg).
Primary treatment phase:
Hormonal treatment plus 8 consecutive weekly subcutaneous vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)* (Week 1 to 8).
Maintenance treatment phase:
Hormonal treatment plus vaccinations with tecemotide (L-BLP25) 1000 micrograms (actual delivered dose was 930 micrograms)* at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD).
*calculated as mass of lipopeptide (antigen)"
1846309|NCT00925548|Biological|Placebo of tecemotide (L-BLP25) and Hormonal Treatment|"Control Arm:
Pretreatment (Single Dose) NaCl 9 g/L infusion as a substitute for cyclophosphamide.
Primary treatment phase:
Hormonal therapy plus 8 consecutive weekly subcutaneous placebo doses (Week 1 to 8).
Maintenance treatment phase:
Hormonal therapy plus placebo doses at six-week intervals beginning at Week 14 and continued until Progressive Disease (PD)."
1846310|NCT00925548|Drug|cyclophosphamide|300 mg/m^2 (to a maximum of 600 mg) of intravenous cyclophosphamide.
1846311|NCT00925548|Drug|sodium chloride (NaCl)|NaCl 9 g/L infusion
1846312|NCT00925574|Drug|CNTO 1959; Placebo|
1846313|NCT00925587|Drug|darbepoetin alfa|Drug administered either Q2W or QM using a prefilled syringe. Allowable doses of: 10, 20, 30, 40, 50, 60, 80, 100, 130, 150, 200, 300, 400 or 600 mcg.
1846314|NCT00925600|Biological|Denosumab|Prefilled syringe for subcutaneous (SC) injection administered at a dose of 60 mg
1846315|NCT00925600|Biological|Placebo|Prefilled syringe for subcutaneous (SC) injection
1846316|NCT00925613|Device|LMA Proseal|"Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then the LMA proseal is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
If failure to insert Proseal occurs, a second attempt is made after deepening anesthesia with propofol 1mg/kg and remifentanil 0.5ug/kg IV. If failure occurs again, the patient is intubated with a tracheal tube."
1846317|NCT00925613|Device|Tracheal tube|Once surgery is completed, the patient is transferred onto a gurney. Train of four is checked. Patient is ventilated with 100% oxygen. Remifentanil 0.5 ug/ml IV is administered. 30 seconds to 1 minute later, secretions are suctioned. Depth of anesthesia is ensured by deflating, inflating, then deflating the tracheal balloon of the DLT and checking for absence of movement, swallowing, or coughing. The DLT is removed, then a tracheal tube (size 7 for women, size 8 for men) is inserted. Respiratory and hemodynamics parameters are noted. Tolerance of the exchange (presence of cough, movement, laryngospasm, desaturation) is noted. Inhalational gas is stopped. Reversal agent is administered if appropriate. Spontaneous breathing is titrated for <12 with boluses of fentanyl 25ug or sufentanil 2.5ug q 5mins.
1846318|NCT00925626|Procedure|Sub-Vastus arthrotomy|Sub-vastus arthrotomy
1846319|NCT00925626|Procedure|Mid - Vastus arthrotomy|Mid-vastus arthrotomy
1846320|NCT00925639|Drug|Isoflavone|150 mg of concentrated extract of soy containing 60 mg of isoflavone comprising 40 mg of genistein, 14,55 mg of daidizein, 3,02 mg of daidzine, 1,14 mg of glicitine, 0,91 mg genistine and 0,38 mg of glicetein.
1846321|NCT00925639|Drug|Placebo|Starch pill
1846322|NCT00925652|Drug|Bevacizumab|Given intravenously once every 3 weeks for approximately 6 months, then every 6 weeks for additional 1.5 years.
1846323|NCT00925652|Drug|Cyclophosphamide|Taken orally once a day for approximately 6 months.
1846324|NCT00925652|Drug|Methotrexate|One pill orally twice a day on days 1 and 2 of each week for approximately 6 months.
1846325|NCT00925652|Behavioral|Diet Intervention|Series of 13 telephone calls over the course of one-year with a dedicated and trained counselor
1846326|NCT00925652|Behavioral|Diet and Exercise Intervention|Counseling targeted toward increasing physical activity and a series of 13 telephone calls over the course of one-year with a dedicated and trained counselor.
1846327|NCT00925665|Device|Glidescope|Patients are to be intubated using the Glidescope technique
1846328|NCT00925665|Device|Macintosh laryngoscope|Patients are to be intubated using direct laryngoscopy with a Macintosh laryngoscope
1846329|NCT00925678|Drug|DSP-3025|
1846330|NCT00925678|Drug|Placebo|
1846331|NCT00925691|Device|RV lead|The RV lead is implanted at the apex or at the interventricular septum
1846332|NCT00925704|Drug|Calcitriol|Calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
1846333|NCT00925704|Drug|Lanthanum carbonate + Calcitriol|Lanthanum carbonate (1000 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
1846334|NCT00925704|Drug|Sevelamer carbonate + Calcitriol|Sevelamer carbonate (2400 mg three times daily with meals for one day) + calcitriol (1.0 microgram) single dose at lunch administered on Day 1 of the study period.
1846335|NCT00925730|Drug|Pimecrolimus|
1846336|NCT00925743|Drug|cabazitaxel (XRP6258)|"administered by IV infusion
in addition to cisplatin treatment"
1846337|NCT00925756|Drug|Maraviroc|Maraviroc will be given dose-adjusted to background HIV treatment
1846338|NCT00925769|Drug|bevacizumab [Avastin]|Escalating doses of 5/10mg/kg q2w
1846339|NCT00925769|Drug|capecitabine [Xeloda]|Escalating doses of 500/650/750/900mg/m2 bid
1846340|NCT00925769|Drug|erlotinib [Tarceva]|Escalating doses of 100/150mg daily
1846341|NCT00925782|Drug|Melphalan HCL for Injection (Propylene Glycol-Free)/Alkeran for Injection|Patients will be randomized to receive 100 mg/m2 of Melphalan HCL for Injection (Propylene Glycol-Free) on Day -3 and Alkeran for Injection on Day -2 prior to ASCT.
1846342|NCT00925782|Drug|Alkeran for Injection/Melphalan HCL for Injection (Propylene Glycol-Free)|Patients will be randomized to receive 100 mg/m2 of Alkeran for Injection on Day -3 and Melphalan HCL for Injection (Propylene Glycol-Free)on Day -2 prior to ASCT.
1846669|NCT00920088|Drug|GSK2248761|NNRTI under investigation
1846345|NCT00925808|Behavioral|Questionnaires|Survey tools and VTE Symptom Follow-up Questionnaire
1846346|NCT00925821|Procedure|allogeneic stem cell transplant versus second autologous transplantation|Transplantation of stem cells from a MRD or MUD, respectively after dose-reduced conditioning versus autologous stem cell graft after preparation with melphalan 200 mg/m²
1846347|NCT00925821|Drug|RAD|After enrollment, patients are to receive four cycles of RAD induction treatment: a combination of lenalidomide (Revlimid), adriamycin, and dexamethasone.
1846348|NCT00925834|Behavioral|Verbal suggestions|Verbal suggestions of a vasodilatory effect on cardiac vessels
1846349|NCT00925847|Drug|lithium|lithium LP 400mg daily po (doses were adjusted during the study to maintain targeted blood levels.)
1846350|NCT00925860|Procedure|non positive pressure mechanical ventilatory support|
1846351|NCT00925873|Drug|Active comparator (no fludarabine)|"Ara-C (100 mg/m2/d by continuous IV infusion 7 days), idarubicin (8 mg/m2/d (IV) for 5 days), GM-CSF a dose of 5 mg/kg/d on day 1. (Novartis Laboratory, Rueil-Malmaison, France).
The consolidation course: intermediate-dose Ara-C (1g/m2 g 3-hour infusion twice a day 1 through 3) and idarubicin (10 mg/m2 on days 4 through 5). In the allocated arm
Maintenance therapy for one year with 6-thioguanine (100 mg/m2/d orally on days 1 through 4 every week, Ara-C (60 mg/m2 SC on day 5 weekly) interrupted every 3 months with a reinduction course including CCNU (40 mg orally on day 1), mitoguazone (350 mg/m2 on day 1) and Ara-C (40 mg/m2 sc twice daily day 1 to 5)"
1846352|NCT00925873|Drug|Experimental (fludarabine)|"The same regimen with addition of fludarabine in every treatment sequence
Induction course: Fludarabine (20 mg/m2/d, IV for 30 minutes) was started in the assigned group on day 2 and continued until the end of cytarabine treatment on day 7.
Consolidation course: In the allocated arm, fludarabine (20 mg/m2/d, IV) was administered on days 2 through 3, 4 hours prior to cytarabine infusion.
Reinduction courses: Ara-C associated in the allocated group with fludarabine (20 mg/m2/d, IV) on days 1 through 2."
1846353|NCT00925886|Procedure|Acrysof Toric one-piece intraocular lens|Cataract Surgery with a intraocular lens implantation
1846354|NCT00925899|Drug|Melatonin|20 mg melatonin orally every evening about 1 hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of melatonin followed by one week of placebo, or the other way around), the participant may receive melatonin for 6 weeks.
1846355|NCT00925899|Drug|Placebo|Placebo tablet orally every evening about one hour before bedtime for one week. After having participated in the cross-over part of the trial (one week of placebo followed by one week of melatonin, or the other way around), the participant may receive melatonin for 6 weeks.
1846356|NCT00925912|Procedure|spinal block|0.5% bupivacaine 1.5-2 ml injected to subarachnoidal space
1846357|NCT00925912|Procedure|Perianal block|0.25% bupivacaine injected at perianal region
1846358|NCT00925925|Other|Cord blood collection for analysis|Cord blood will be collected from the placentas at delivery for analysis
1846359|NCT00925938|Drug|misoprostol|One vaginal insert containing 100, 200, 400, 800, 1200, 1600 mcg misoprostol administered intravaginally one time and remain in place for 18 - 24 hours prior to the hysteroscopy procedure. An adaptive design will be used to determine whether to escalate or reduce the dose, starting with MVPI 400 mcg.
1846360|NCT00925938|Drug|placebo|placebo
1846361|NCT00925951|Device|Wet Cupping|Wet cupping (Seongho trade & company, Korea) will be practiced at two selected points (among the 6 acupoints, left or right BL23, BL24, BL25)
1846362|NCT00925951|Drug|Acetaminophen|Acetaminophen 500 mg tablets will be offered to both of the wet cupping group and waiting group for relieving severe pain.
1846363|NCT00925977|Drug|insulin Glargine + Insulin Apidra|12 wees treatment with Insulin Glargine + Insulin Apidra
1846364|NCT00925977|Drug|Insulin NPH + Insulin Apidra: Active Comparator|Insulin NPH + Insulin Apidra: Active Comparator
1846365|NCT00925990|Drug|ribavirin|200 mg capsules, either 1000 or 1200 mg taken twice daily for up to 24 weeks
1846366|NCT00925990|Drug|CTS-1027|5 and 10 mg tablets, 15 mg taken twice daily, for up to 24 weeks
1846367|NCT00925990|Drug|Placebo for ribavirin|Capsules identical to ribavirin in appearance containing inactive ingredients
1846370|NCT00926016|Drug|Pioglitazone (Actos)|pioglitazone 45 mg a day
1846371|NCT00926029|Drug|Fluoride|Brush twice daily
1846372|NCT00926029|Drug|Triclosan, fluoride|Brush twice daily
1846373|NCT00926029|Other|Metal salt|Brush twice daily
1846374|NCT00926055|Drug|Ezetrol (Ezetimibe)|Ezetrol - 10 mg once daily for 3 months
1846375|NCT00926055|Drug|Vytorin (Ezetimibe + Simvastatin)|Vytorin - 10/20 mg once daily for 3 months
1846376|NCT00926068|Drug|HO/03/03 10µg|
1846377|NCT00926068|Drug|Placebo|
1846378|NCT00926081|Behavioral|Supervised exercise training|A standardized supervised exercise training program
1846379|NCT00926107|Drug|Temsirolimus|Temsirolimus 25mg weekly until clinical progression
1846380|NCT00926120|Dietary Supplement|Mogroside sweetener (PureLo)|Mogroside sweetener administered at a dosage level of 5g every 6 hours for 14 days
1846381|NCT00926133|Other|OGTT|Oral glucose tolerance test (diagnostic procedure) eary after an acute STEMI and at three months follow-up.
1846382|NCT00926146|Behavioral|NCMIT|Nurse Case Management Plus Contingency Management and Tracking (NCCMT) Program includes 20 minute case management, delivered by the NCCMT nurse and a separate 45 minute culturally competent specialized education, delivered by the two assigned nurses and research assistants weekly over 8 weeks. Participants of this group will also receive the HBV vaccine subsequently at one month and four months after baseline and incentives for three-weekly urine samples.
1846431|NCT00918216|Genetic|fluorescence in situ hybridization|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
1992723|NCT03310450|Other|160kms cycling|main exposure is long distance cycling touring (TdB) consists of two groups; 160kms and 100kms
1992724|NCT03309917|Other|MAP set at 80-85 mmHg for 5 min|MAP is set at 80-85 mmHg for 5 min using infusion of noradrenaline or nitroglycerin.
1992725|NCT03309917|Other|MAP set at 70-75 mmHg for 5 min|MAP is set at 70-75 mmHg for 5 min using infusion of noradrenaline or nitroglycerin.
1992726|NCT03309917|Other|MAP set at 60-65 mmHg for 5 min|MAP is set at 60-65 mmHg for 5 min using infusion of noradrenaline or nitroglycerin.
1846383|NCT00926146|Behavioral|SCMIT|Standard with Contingency Management and Tracking (SCMT) Program. Participants in the SCMT group will interact three times a week over the four-month intervention period with the research nurse and research assistant and will be offered: 1) a brief HBV/HCV education program; 2) receipt of the vaccine subsequently at one month and four months after baseline; and 3) voucher incentives for three-weekly urine samples. The SCMT participants will not receive the specialized education sessions nor the case management delivered weekly over the first 8 weeks sessions.
1846384|NCT00926185|Drug|Lifitegrast|Ophthalmic Solution
1846385|NCT00926185|Drug|Placebo|Ophthalmic Solution
1846386|NCT00926211|Device|ARTAS™ System|Hair harvest using a computer-assisted system
1846387|NCT00926211|Procedure|Manual Hair Harvest|Hair harvesting via the manual technique
1846388|NCT00926224|Device|FibroScan M and XL probes|Each patient undergo two liver stiffness measurements with the FibroScan: once with the M probe and once with the XL probe
1846389|NCT00926237|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) - ACTIVE|Active rTMS will be targeted according to the following decision tree: 1) to auditory cortex in the superior temporal gyrus opposite the ear with loudest tinnitus; 2) to the same region in the left temporal lobe. Active stimulation will be delivered at 110% of motor threshold (MT) at a frequency of 1 or 10 Hz for a total of 1800 magnetic pulses per session (and a total of 4 sessions per week of active rTMS therapy).
1846390|NCT00926237|Device|Repetitive Transcranial Magnetic Stimulation (rTMS) - SHAM|Sham rTMS will be targeted using a commercially available sham coil and delivered to the same site within the temporal lobe as active rTMS and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.
1846391|NCT00926250|Dietary Supplement|Oral PS-IPC supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
1846392|NCT00926250|Dietary Supplement|Placebo supplement|Each subject in this study will be provided the PS-IPC dietary supplement or placebo to consume three times per day for the 12-week duration of the intervention. The placebo supplement will consist of an iso-caloric supplement designed to match the PS-IPC supplement in volume, color, consistency, and palatability.
1846393|NCT00926263|Biological|CP-751,871|single dose, 1-hr IV infusion
1846394|NCT00926263|Biological|CP-751,871|single dose, 1-hr IV infusion
1846395|NCT00926263|Biological|CP-751,871, moxifloxacin, saline|Two doses at 20 mg/kg each on two consecutive days, each administered via 1-hr IV infusion
1846396|NCT00926276|Procedure|Fundoplication|Fundoplication
1846397|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
1846398|NCT00926289|Drug|Telmisartan|Telmisartan 80mg
1846399|NCT00926289|Drug|Hydrochlorothiazide|Hydrochlorothiazide25mg
1846400|NCT00926302|Drug|Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)|Levetiracetam 500mg/tablet Oral once
1846401|NCT00926302|Drug|Keppra (Levetiracetam - USB SA Pharma Sector)|Levetiracetam 500mg/tablet oral once
1846402|NCT00917982|Other|vision therapy|
1846403|NCT00917995|Device|Polypropylene Mesh, density 25-40g/square meter|colostomy with a prophylactic hernia mesh
1846404|NCT00918008|Genetic|Blood draw|The research intervention is the blood sample only collected prior to surgery. Analyses of the data will be made by correlating the gene profile expression with the pathologic finding at surgery and the clinical status of the patients 2 years after surgery.
1846405|NCT00918021|Drug|olanzapine|normal dosage of olanzapine (the same dosage as on hospital ward)
1846406|NCT00918021|Drug|placebo|placebo
1846407|NCT00918034|Drug|talaporfin sodium|LS11 (talaporfin sodium) dose of 1mg/kg will be administered intravenously by slow push (3-5 minutes)
1846408|NCT00918034|Device|Transurethral illumination with light emitting diodes|A light dose of 100 Joules per centimeter (J/cm) will be delivered at 20 mW/cm to each patient for a treatment duration of 1 hour 23 minutes
1846409|NCT00918034|Procedure|Placement|Placement of device in prostate urethra
1846410|NCT00918047|Drug|SPN-804O|Open Label study
1846412|NCT00918086|Dietary Supplement|Vitamin D pill|Oral tablet taken for 16 weeks
1846413|NCT00918086|Dietary Supplement|Placebo|An inactive pill that looks and tastes like the Vitamin D pill
1846414|NCT00918099|Procedure|Avaulta mesh|Insertion of a mesh vs conventional repair
1846415|NCT00918099|Procedure|Anterior repair|Conventional repair
1846416|NCT00918138|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 4 weeks
1846417|NCT00918138|Drug|Metformin XR|Tablets, Oral, 1500 mg, once daily, 4 weeks
1846418|NCT00918138|Drug|Placebo matching Metformin XR|Tablets, Oral, 0 mg, once daily, 4 weeks
1846419|NCT00918138|Drug|Metformin XR|Tablets, Oral, 500 mg, once daily, 4 weeks
1846420|NCT00918138|Drug|Placebo matching Saxagliptin|Tablets, Oral, 0 mg, once daily, 4 weeks
1846421|NCT00918151|Other|No treatment given|Subject will only fill out a questionaire when entering the observational study
1846422|NCT00918164|Drug|PF-04457845|Single dose, 8 mg as oral tablet and solution formulation
1846423|NCT00918177|Drug|AP09004|
1846424|NCT00918177|Drug|Carbidopa/Levodopa, immediate release|
1846425|NCT00918190|Drug|Placebo|Saline
1846426|NCT00918190|Drug|Ondansetron, Dexamethasone|Use of ondansetron and dexamethasone as combined antiemetics
1846427|NCT00918190|Drug|Midazolam, dexamethasone|use of midazolam and dexamethasone as combined antiemetic
1846428|NCT00918203|Biological|Olaratumab|15 mg/kg of olaratumab on Days 1 and 8 of each 21-day cycle, administered intravenously (IV) at 25 milligram/minute (mg/min), with a minimum infusion time of 30 minutes.
1846429|NCT00918203|Drug|Paclitaxel|200 mg/m2 is then administered IV over 3 hours
1846430|NCT00918203|Drug|Carboplatin|AUC=6 administered IV over 30 minutes on Day 1 of each 3-week cycle for a maximum of six cycles. Once the maximum of 6 cycles of carboplatin are reached the participant may continue on olaratumab maintenance for up to 12 months.
1846665|NCT00920088|Drug|lopinavir/ritonavir|LPV/RTV 400/100mg
1846432|NCT00918216|Other|immunohistochemistry staining method|Additional histochemical, immunohistochemical, and fluorescence in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
1846433|NCT00918216|Other|medical chart review|Patients' medical charts are reviewed to obtain clinical information
1846434|NCT00918216|Procedure|fluorescence spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
1846435|NCT00918216|Procedure|histopathologic examination|Hematoxylin and eosin stained sections of the tissue samples are examined by light microscopy for histopathological analysis.
1846436|NCT00918216|Procedure|light-scattering spectroscopy|The freshly excised breast tissue samples are analyzed ex vivo by fluorescence, reflectance, and/or Raman spectroscopy.
1846437|NCT00918229|Device|BioProtect biodegradable balloon implant|biodegradable balloon implant to extend the distance between prostate and anterior rectal wall
1846438|NCT00918229|Procedure|Balloon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
1846439|NCT00918255|Biological|adalimumab|Subcutaneous injection using prefilled syringe containing adalimumab 40 mg in 0.8 milliliters
1846440|NCT00918255|Drug|Placebo|Subcutaneous injection using prefilled syringe containing 0.8 milliliters
1846441|NCT00918268|Biological|Influenza vaccine|One 0.5mL dose of Inactivated, Influenza Vaccine using the strain composition 2009/2010
1846442|NCT00918281|Drug|Fluciclatide Injection|Fluciclatide Injection (AH111585 (18F) Injection)
1846443|NCT00918294|Device|QuickOpt|The QuickOpt algorithm will suggest values for programming AV, PV and VV delay.
1846444|NCT00918307|Drug|Varenicline|Day 1 to day 3 : 0.5 mg daily ; Day 4 to day 7 : 0.5 mg twice daily ; Day 8 to week 12 : 2 x 0.5 mg twice daily
1846445|NCT00918307|Drug|Placebo|Day 1 to day 3 : 1 pill daily ; Day 4 to day 7 : 2 pills daily ; Day 8 to week 12 : 2 pills twice daily
1846446|NCT00918320|Drug|Temozolomide/Hycamtin (Topotecan)|"Temozolomide: bottles containing 5 capsules of 5, 20, 100 and 250 mg
Hycamtin (Topotecan): a lyophilisate for infusion in vials containing 4 mg
Patients receive during 5 days (Day 1 to Day 5):
Temozolomide 150 mg/m2/day per os, dose will be adjusted to the closest 5 mg, followed one hour later by Hycamtin(Topotecan) 0.75 mg/m2/day as an intravenous infusion over 30 minutes"
1846447|NCT00918333|Drug|panobinostat|Given PO
1846448|NCT00918333|Drug|everolimus|Given PO
1846449|NCT00918333|Other|laboratory biomarker analysis|Correlative studies
1846450|NCT00918333|Other|pharmacological study|Correlative studies
1846451|NCT00918346|Drug|Tafluprost 0.0015%|Eye drops, 0.015 mg/ml, once daily to affected eye(s)
1846452|NCT00918385|Drug|Nilutamide|Nilutamide 150mg orally each day for 28 days per cycle. After first progression, Nilutamide 150mg orally each day in combination with Dasatinib 100mg orally each day for 28 days per cycle.
1846453|NCT00918385|Drug|Dasatinib|Dasatinib 100mg orally daily x 28 days per cycle. After first progression, Dasatinib 100mg orally each day in combination with Nilutamide 150mg orally each day for 28 days per cycle.
1846454|NCT00918398|Drug|AZD1981|100 mg iv infusion, single dose, 4 hours infusion
1846455|NCT00918398|Drug|AZD1981|514 mg oral solution, single dose
1846456|NCT00918398|Drug|AZD1981|500 mg oral tablet A (optimal dissolution) give as 2x250 mg tablets, single dose
1846457|NCT00918398|Drug|AZD1981|500 mg oral tablet B (slower dissolution) give as 2x250 mg tablets, single dose
1846458|NCT00918411|Drug|Ramosetron|oral
1846459|NCT00918411|Drug|Placebo|oral
1846460|NCT00918424|Drug|Oxcarbazepine Extended Release|OXC XR is a once-daily formulation of oxcarbazepine and is given at the same dosage levels.
1846461|NCT00918450|Drug|ABT-263|"Continuous dosing until disease progression using one of the following formulations:
25 mg/mL oral solution OR 50 mg/mL oral solution OR 2.0 grams/bottle powder for oral solution of 25 mg/mL when mixed OR 2.0 grams/bottle powder for oral solution of 50 mg/mL when mixed"
1846462|NCT00918463|Drug|dasatinib|100 mg daily dosing
1846463|NCT00918476|Drug|filibuvir + Oral Contraceptives|This is an open-label, fixed sequence study to investigate the effect of filibuvir (600 mg BID on the pharmacokinetics of oral contraceptives steroids. Sixteen subjects who have been on any combination of ethinyl estradiol and levonorgesterol oral contraceptives for at least one consecutive month prior to Period 1 will be enrolled into the study. The study will be conducted over two 28 day menstrual cycles and Day 1 of each period is defined as the first day of dosing OC in each cycle. During the first cycle (Period 1), the subjects will receive OC QD for 21 days and filibuvir BID on Days 22 through 28. During the second cycle (Period 2) the subjects will receive OC QD and filibuvir BID for 21 days. The dosing of filibuvir will start in Period 1 (Days 22 - 28).
1846464|NCT00918489|Drug|Vorinostat|Daily administration of 400mg vorinostat on 28 days (one therapy cycle). Seven days of therapy break between two consecutive cycles.
1846465|NCT00918502|Device|AVIVO system|Non invasive external monitoring device
1846466|NCT00918515|Drug|AZD3043|intravenous solution given once as intravenous infusion over 30 minutes
1846467|NCT00918528|Procedure|Internal urethrotomy|
1846468|NCT00918528|Drug|Mitomycin C - local injection|
1846469|NCT00918554|Drug|Methotrexate|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
1846470|NCT00918554|Drug|Placebo|All patients will receive three pulses of methylprednisolone (5 mg/kg) followed by four weeks of prednisone (1 mg/kg daily). After randomization, patients will receive either prednisone (1 mg/kg daily) plus methotrexate (0.3 mg/kg weekly) or prednisone (1 mg/kg daily) plus placebo. Therapies will be administered orally. Corticosteroids will be progressively tapered when macular oedema completely resolve. Unilateral macular oedema relapses will be treated with a single local injection of triamcinolone acetonide. Increasing dose of prednisone will be administered in case of bilateral macular oedema relapses.
1846666|NCT00920088|Drug|Midazolam|Midazolam 3mg
1846473|NCT00918580|Biological|13-valent Pneumoccocal Conjugate Vaccine|2 doses of 13vPnC will be administered by intramuscular injection separated by approximately 6 months.
1846474|NCT00918593|Drug|Electrochemotherapy|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
1846475|NCT00918593|Radiation|Radiotherapy|Radiotherapy according to hospital procedures.
1846476|NCT00918593|Drug|Bleomycin|Intratumoral or intravenous bleomycin followed by electric pulses. Once only treatment.
1846477|NCT00918606|Drug|LIPO-102|LIPO-102
1846478|NCT00918619|Device|Sangustop|Application of Sangustop haemostatic agent on resection area
1846479|NCT00918619|Drug|Tachosil|Application of Tachosil fibrin sealant on resection area
1846480|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> B -> C. Each of these treatments will be separated by a 7 day washout period.
1846481|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order A -> C -> B. Each of these treatments will be separated by a 7 day washout period.
1846482|NCT00918632|Drug|AG-013736|A single dose of an FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> C -> A. Each of these treatments will be separated by a 7 day washout period.
1846483|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order B -> A -> C. Each of these treatments will be separated by a 7 day washout period.
1846484|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> A -> B. Each of these treatments will be separated by a 7 day washout period.
1846485|NCT00918632|Drug|AG-013736|A single dose of a FCIR tablet of AG-013736 will be administered under overnight fasting (Treatment A), high-fat, high-calorie meal (Treatment B), or moderate-fat, standard-calorie meal (Treatment C) in the following order C -> B -> A. Each of these treatments will be separated by a 7 day washout period.
1846487|NCT00918658|Other|biologic sample preservation procedure|All specimens will be collected using the Pathology Residual Tissue Procurement.
1846488|NCT00918658|Other|immunologic technique|Information about HLA type and immunophenotype of the malignant cells is collected from the patient's medical record.
1846489|NCT00918658|Other|laboratory biomarker analysis|Bone marrow aspirates and/or peripheral blood samples are collected and used as target cells in standard cytotoxicity assays, with notch-induced natural killer (N-NK) cells as the effector cells, to determine whether N-NK cells are capable of killing malignant cells and/or non-malignant cells. Receptor-blocking antibodies may be added to determine which NK cell receptors are responsible for malignant cell recognition and killing.
1846490|NCT00918671|Other|No new specific intervention|No new specific intervention
1846491|NCT00918684|Drug|Escitalopram|10mg tab daily
1846492|NCT00918697|Procedure|Mechanical debridement|For mechanical epithelial removal, an 8.0-mm optical zone marker was applied to the cornea, centering over the entrance pupil. A hockey spatula was used to remove the central corneal epithelium.
1846493|NCT00918697|Procedure|Alcohol-assisted debridement|For alcohol-assisted debridement, 20% ethyl-alcohol solution was instilled into an 8.0-mm well and kept in contact with epithelium for 20 seconds (being careful to avoid spillage over the areas not being treated). It then absorbed using a dry cellulose sponge followed by copious irrigation with BSS. The epithelium of the central cornea was removed using a blunt spatula.
1846498|NCT00918736|Drug|sodium hyaluronate|3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan) into the ankle joints.
1846499|NCT00918749|Drug|150 mg|150 mg immediate release (IRBB) risedronate tablet administered orally at least 30 minutes before breakfast.
1846500|NCT00918749|Drug|75 mg|75 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
1846501|NCT00918749|Drug|100 mg|100 mg delayed release (DRFB) risedronate tablet administered orally immediately after ingesting breakfast
1846502|NCT00918762|Procedure|assessment of therapy complications|
1846503|NCT00918762|Procedure|diagnostic endoscopic surgery|
1846504|NCT00918762|Procedure|quality-of-life assessment|
1846505|NCT00918762|Procedure|therapeutic conventional surgery|
1846506|NCT00918762|Procedure|therapeutic endoscopic surgery|
1846507|NCT00918762|Procedure|transoral robotic surgery|
1846508|NCT00918762|Procedure|video-assisted surgery|
1846509|NCT00918775|Other|Evaluation|Evaluation during and after surgery: vital signs, performance status, physical exam, chest x-ray, CT and MRI plus health questions.
1846510|NCT00918788|Other|biologic sample preservation procedure|Ex vivo samples of normal and malignant breast tissue; biopsy specimens are then fixed in formalin and submitted for histopathologic studies
1846511|NCT00918788|Other|immunohistochemistry staining method|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
1846512|NCT00918788|Other|light microscopy|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC).
1846513|NCT00918788|Other|medical chart review|Medical records are reviewed to obtain information from the pathology report on patient demographics, pathological characteristics of the surgical specimen, and clinical indication for the surgical procedure.
1846514|NCT00918788|Procedure|histopathologic examination|The biopsy specimens are then fixed in formalin and submitted for histopathologic studies using standard light microscopy techniques (i.e., H&E staining and IHC). Additional histochemical, immunohistochemical, and fluorescent in situ stains may be performed to support the diagnosis or to better understand the spectroscopy results.
1846515|NCT00918788|Procedure|needle biopsy|Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle.
1846516|NCT00918788|Procedure|spectroscopy|Optical spectra are acquired from ex vivo samples of normal and malignant breast tissue using diffuse reflectance, fluorescence, and Raman spectroscopy. Tissue spectra are measured using a portable clinical spectroscopy device with front- and side-viewing optical fiber probes that are inserted into the breast tissue through a hollow biopsy needle. After the probes are withdrawn through the needle, cutting biopsies are obtained and the tissue is marked at the site of the spectral measurements.
1846517|NCT00918814|Drug|LIPO-102|Subcutaneous Injection
1846518|NCT00918814|Drug|Placebo|Placebo
1846519|NCT00918840|Biological|DermaVir|DermaVir is a synthetic nanomedicine. The active pharmaceutical ingredient is a single plasmid DNA expressing 15 HIV proteins that assemble to HIV-like particles. DermaVir is topically administered with DermaPrep medical device to target the nanomedicine to Langerhans cells of the skin.These Langerhans cells migrate to the lymph node to induce cytotoxic T cells that can kill HIV-infected cells
1846520|NCT00918840|Biological|Placebo|Dextrose/glucose solution
1846521|NCT00918840|Drug|HAART|Three or more antiretroviral drugs that can fully suppress HIV RNA
1846522|NCT00918853|Procedure|resection of adenocarcinoma of the head of the pancreas|quality standard for the resection of adenocarcinoma of the head of the pancreas
1846523|NCT00918866|Drug|Definity|one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight
1846524|NCT00918879|Drug|Saxagliptin|Oral tablet, once daily for 24 weeks
1846525|NCT00918879|Drug|Placebo|Oral tablet, once daily for 24 weeks
1846526|NCT00918892|Genetic|gene expression analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
1846527|NCT00918892|Other|immunohistochemistry staining method|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
1846528|NCT00918892|Other|laboratory biomarker analysis|Previously collected breast cancer tissue samples (paraffin embedded blocks) and normal adjacent tissue are used for immunohistochemistry studies of expression of candidate genes.
1846529|NCT00918905|Device|Telemonitor|"Within 24 hours after the patient was discharged due to exacerbation in COPD the telemedicine equipment was installed at the patient's home. The patients were included for four weeks followed by a visit to the outpatient clinic with. The patient had the equipment for approximately one week and had at least one follow-up phone call. Televideo consultations could be made from 8 AM to 3 PM every day. The patient could call the telemedicine department in the same period.
During the televideo consultations the nurse made clinical observations (i.e. dyspnoea, anxiety), measured saturation and lung function and informed the patients how to prevent exacerbations. The telemedicine consultation was agreed on with the patient and the telemedicine nurse from day to day."
1846530|NCT00918918|Dietary Supplement|Alcohol + orange juice|100 mL Vodka (37.5 vol%; 30 gram of alcohol/day) + 200 mL orange juice
1846531|NCT00918918|Dietary Supplement|Orange juice|200 mL orange juice
1846532|NCT00918931|Drug|Obatoclax Mesylate|30 mg given by vein over 3 hours on Days 1-3 of each 14-day study cycle.
1846533|NCT00918944|Other|Control|"The asthma disease management toolkit available to all practices in the EHR will consist of four elements:
A data entry tool for capturing asthma control data
Standardized documentation templates to facilitate severity classification
Order sets to facilitate ordering controller medications
An asthma care plan that can be supplied to families"
1846534|NCT00918944|Other|Intervention|"Three alerts and two reminders will be programmed:
Alert providers to enter asthma severity classification if none is on file
Alert providers to prescribe controller medications for persistent asthma if none on file
Alert providers to complete an asthma care plan if none on file
Remind providers to review the asthma care plan if it is already on file by providing a link to the form
Remind providers that educational content is available on-line by providing a web link"
1846535|NCT00918957|Drug|Tobramycin Inhalation Powder|Tobramycin Inhalation Powder as produced by a modified manufacturing process TIP. TIP was provided in hard capsules each containing 28 mg active ingredient (tobramycin); Capsules were packaged in blister cards and administered by the T-326 Inhaler.
1846536|NCT00918957|Drug|Placebo|Placebo inhalation powder consisting of the excipients used for TIP. Placebo was provided in hard capsules, containing 20 mg placebo powder, which were packaged in blister cards, matching in appearance to TIP. Capsules were administered by the T-326 Inhaler.
1846537|NCT00918983|Drug|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
1846538|NCT00918983|Drug|Placebo|Single intraprostatic injection of placebo
1846539|NCT00918996|Procedure|Omission of Bladder Flap Creation|Omission of bladder flap creation by making uterine incision 1 cm above the vesico-uterine reflection without incision and dissection of the bladder peritoneum.
1846540|NCT00919009|Procedure|TACE (Transcatheter Arterial Chemoembolization )|"TACE will be performed according to National Cancer Center protocol:
Briefly, an arterial catheter was inserted into the femoral artery by the Seldinger method and placed in the hepatic artery. Tumor feeding vessels were superselected where possible, the catheter was inserted to the level of the segmental arteries, subsegmental arteries, or lobar branches, and a solution containing 20-60 mg of doxorubicin hydrochloride (ADM; Dong-a Pharmacy, Seoul, Korea) and 2-20 mLof iodized oil (lipiodol) was infused through the catheter (5 French) or microcatheter (2.8 or 3 French). The dosage of doxorubicin and lipiodol was determined according to the tumor size, the presence of arteriovenous shunts or extrahepatic collateral vessels, and the underlying liver functions"
1846667|NCT00920088|Drug|Dextromethorphan|Dextromethorphan 30mg
1846668|NCT00920088|Drug|Flurbiprofen|Flurbiprofen 50mg
1846541|NCT00919022|Drug|Cyproterone Acetate (Androcur, BAY94-8367)|Patients in regular clinical practice receiving Androcur according to local drug information
1846542|NCT00919035|Drug|torisel|Patients will receive Torisel 25 mg weekly. Treatment continues until disease progression, patient's withdrawal, unacceptable toxicity or the investigator's discretion
1846543|NCT00919061|Drug|Gemcitabine|Gemcitabine: 800 mg/m^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
1846544|NCT00919061|Drug|Cisplatin|20 mg /m^2 over 30 minutes IV, weekly for 2 weeks, followed by a week off treatment.
1846545|NCT00919061|Drug|Sorafenib|400 mg PO once a day continuously.
1846546|NCT00919074|Procedure|Pancreatic duct stent|Placement of a pancreatic duct stent to facilitate bile duct cannulation
1846547|NCT00919074|Procedure|Pancreatic wire placement|Placement of a pancreatic wire to facilitate bile duct cannulation
1846548|NCT00919087|Device|Avivo System|Non invasive external monitoring deive
1846549|NCT00919100|Device|Buzzy|"Buzzy is a vibrating cold pack attached with Velcro strap or tourniquet 5-10cm proximal to the site of venipuncture. The vibration is activated and the device remains in place throughout the procedure. The distraction cards are offered to the parents to show the children, with questions on the back and pictures on the front."
1846550|NCT00919100|Other|vapocoolant|venipuncture with vapocoolant spray offered
1846551|NCT00919113|Drug|2% sodium chondroitin sulfate|Weekly 20 mL Intravesical instillation
1846552|NCT00919113|Drug|Placebo|The identical buffer used in Uracyst for the same administration
1846553|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 50% and propofol infusion adjusted to depth of anaesthesia.
1846554|NCT00919126|Drug|Xenon|Maintenance of anaesthesia obtained with Xenon 70% and propofol infusion adjusted to depth of anaesthesia.
1846555|NCT00919126|Drug|Medical Air in Oxygen|Maintenance of anaesthesia obtained with propofol infusion adjusted to depth of anaesthesia.
1846556|NCT00919139|Other|biologic sample preservation procedure|Blood and 3-4 cc bone marrow aspirate collected at same time (in association with treatment protocols on which patient is registered)
1846557|NCT00919178|Biological|DEN4 Vaccine Candidate|"DEN4 Vaccine Candidate
Participants will receive a single immunization on Study Day 0. Vaccine will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
1846558|NCT00919178|Biological|DEN4 Vaccine Placebo|"DEN4 Vaccine Placebo
Participants will receive a single immunization on Study Day 0. Placebo will be delivered by subcutaneous injection in the upper arm, at a volume of 0.5 mL."
1846559|NCT00919191|Drug|Tretinoin gel|Tretinoin gel 0.04% used once daily in a split-face model
1846560|NCT00919191|Drug|Adapalene and Benzoyl peroxide|Adapalene .1% and Benzoyl peroxide 2.5%
1846561|NCT00919204|Drug|AG-013736 (axitinib)|Three single oral-doses of AG-013736 (5-mg, 7-mg and 10-mg) will be successively administered (each separated by a washout period of at least 7 days) to healthy Chinese volunteers in the fed state.
1846563|NCT00919243|Drug|prednisone|1 mg/kg/day with a maximum dose of 60 mg/day given orally
1846564|NCT00919243|Drug|allopurinol|allopurinol, the dose of allopurinol is adjusted by patients' renal function, and with a maximum dose of 300mg/day.
1846565|NCT00919269|Other|biologic sample preservation procedure|
1846566|NCT00919269|Other|laboratory biomarker analysis|Correlative studies
1846567|NCT00919282|Drug|gemcitabine, folinic acid, 5-FU|gemcitabine 1g/m² - 30 minutes folinic acid 500mg/m² - 2 hours 5-FU 750mg/m² - over 24hours
1846568|NCT00919295|Drug|mirtazapine|mirtazapine 15 mg or 30 mg tablet daily at bedtime for 13 weeks
1846569|NCT00919295|Drug|placebo|placebo
1846570|NCT00919308|Other|Competency based simulation training|Completion of a hands-on ultrasound guided simulation training protocol on a partial task training simulator until competence is achieved as measured by the ability to cannulate a simulated vein under ultrasound guidance on first pass in five consecutive attempts and correct insertion of a central venous catheter on a partial task training simulator with no technical errors.
1846571|NCT00919321|Biological|Pneumococcal polysaccharide vaccine (PPV)|One intramuscular injection
1846572|NCT00919334|Device|Defocus Incorporated Soft Contact (DISC) lens|Use of simultaneous vision bifocal soft contact lenses with myopic defocus to control the progression of myopia
1846573|NCT00919347|Other|ANSAR ANX 3.0 Software|"Three values are calculated by the ANSAR ANX 3.0® software of the spectral analysis of HRV and respiration:
RFa an indicator of parasympathetic function with normal values between 0.5 and 10 bpm2;
LFa an indicator of sympathetic function also with normal values between 0.5 and 10 bpm2;
SB or the ratio of LFa/RFa with normal reference values of 0.4 to 3.0.
The ANSAR ANX 3.0® software defines three different levels of autonomic neuropathy (autonomic dysfunction) as follows (see Figure 1):
Cardiovascular Autonomic Neuropathy (CAN): resting parasympathetic insufficiency (not enough parasympathetic protection for the heart) or RFa < 0.1 bpm2.
Diabetic Autonomic Neuropathy (DAN), or advanced autonomic dysfunction in non-diabetics, is defined as low autonomics: LFa < 0.5 bpm2 or 0.1 < RFa < 0.5 bpm2.
Autonomic Dysfunction: normal resting LFa and RFa, but low LFa response to Valsalva or low RFa response to deep breathing."
1846574|NCT00919360|Procedure|collection of maternal blood specimen prior to delivery|approximately 5 cc. of maternal blood will be drawn prior to delivery
1846575|NCT00919360|Procedure|collection of placental cord blood after delivery|approximately 5 cc. of fetal cord blood from the umbilical cord blood vessel will be collected after cord is clamped
1846576|NCT00919360|Procedure|collection of placental tissue|within 10 minutes of delivery, the placenta will be radially transected, and a full-thickness slice from the central region removed using sterile technique by scalpel.This will be placed into a pre-prepared container of RNA preservation medium.
1846577|NCT00919360|Procedure|collection of strip of decidua from uterine lining from cesarean section deliveries|A strip of decidua will be removed from the upper lip of uterine incision by the surgeon and placed in RNA preservation medium.
1846578|NCT00919373|Procedure|Substrate modification|Catheter Ablation procedure - Substrate modification in sinus rhythm in case of unstable induced monomorphic Ventricular Tachycardia (VT) which does not allow mapping and ablation in tachycardia, or noninducible stable clinical VT.
1846579|NCT00919373|Procedure|VT ablation|Catheter Ablation of Ventricular Tachycardia (VT) in case of stable VT
1846580|NCT00919373|Procedure|ICD Implantation|Implantation of a marked released Implantable Cardioverter Defibrillator manufactured by St. Jude Medical
1846581|NCT00919399|Drug|Exemestane|25mg a day during 4 months
1846582|NCT00919399|Drug|tamoxifen|One 20 mg tablet a day started 1 week after the first Aromasine intake
1846583|NCT00919425|Other|biologic sample preservation procedure|
1846584|NCT00919438|Device|AVIVO™ Mobile Patient Management System|Non Invasive monitoring device
1846585|NCT00919451|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
1846586|NCT00919464|Device|Pressure monitoring device|monitoring device inserted to measure thigh compartment pressures
1846587|NCT00919464|Device|Compartmental fracture pressure monitoring|
1846588|NCT00919464|Device|This small project is designed to be a non-randomized, investigational prospective trial of compartment pressures in the thigh following femoral fracture|
1846589|NCT00919490|Drug|ABT-333|Tablet, see arms for interventional description
1846590|NCT00919490|Drug|Placebo|Tablet, see arms for interventional description.
1846591|NCT00919503|Procedure|Allogeneic Bone Marrow Transplantation|Infused IV
1846592|NCT00919503|Biological|Anti-Thymocyte Globulin|Given IV
1846593|NCT00919503|Drug|Cyclosporine|Given IV or PO
1846594|NCT00919503|Drug|Fludarabine Phosphate|Given IV
1846595|NCT00919503|Other|Laboratory Biomarker Analysis|Correlative studies
1846596|NCT00919503|Drug|Methotrexate|Given IV
1846597|NCT00919503|Drug|Mycophenolate Mofetil|Given IV or PO
1846598|NCT00919503|Procedure|Peripheral Blood Stem Cell Transplantation|Infused IV
1846599|NCT00919503|Drug|Tacrolimus|Given IV or PO
1846600|NCT00919503|Radiation|Total-Body Irradiation|Undergo total body irradiation
1846601|NCT00919503|Drug|Treosulfan|Given IV
1846602|NCT00919503|Procedure|Umbilical Cord Blood Transplantation|Single or double unit umbilical cord blood transplant, infused IV
1846603|NCT00919516|Procedure|Bone marrow mononuclear cell implantation|Dual intramuscular and intra-arterial injections of bone marrow mononuclear cells harvested from the iliac crest. Injection sites are determined by location of stenosis and/or occlusion on angiogram obtained prior to implantation and typically occur in three medial and three lateral sites approximating the disease location.
1846604|NCT00919542|Drug|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
1846605|NCT00919542|Drug|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
1846606|NCT00919555|Drug|Pioglitazone and Tretinoin|Tretinoin: 1 pill twice a day (10 mg/bid) Pioglitazone HCL: 1 pill once a day (30 mg/qd)
1846607|NCT00919555|Drug|Tretinoin and Pioglitazone HCL|Tretinoin 10 mg 1 pill po twice a day Pioglitazone HCL 30 mg 1 pill po once a day
1846608|NCT00919555|Drug|Placebo|Placebo
1846609|NCT00919594|Behavioral|Interpersonal Psychotherapy for Mothers (IPT-MOMS)|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed nine sessions. In addition to standard IPT techniques, IPT-MOMS includes a specific focus on the challenges associated with managing a child who suffers from psychiatric problems.
1846610|NCT00919594|Behavioral|Brief Supportive Psychotherapy|Interventions will be administered during the 3 Month Acute Randomized Phase and will consist of nine individual 45-minute sessions conducted over the course of three months. Treatment cannot exceed 9 sessions. Brief supportive therapy (BSP) is a manualized form of supportive psychotherapy which emphasizes reflective listening and elicitation of affect (Markowitz et al., 2008). Therapists are instructed to allow patients to determine the focus of each session, pulling for emotion, validating emotions when possible, and offering empathic comments.
1846611|NCT00919607|Drug|quetiapine fumarate extended-release|200mg,oral,single dose
1846612|NCT00919607|Drug|quetiapine fumarate extended-release|300mg,oral,single dose
1846613|NCT00919620|Behavioral|stage-specific case-management|Stage-specific case-management for psychosis by designated key-workers according to specified protocol
1846614|NCT00919633|Drug|interferon alfa-2b|subcutaneous continuous infusion at one of three doses for 48 weeks
1846615|NCT00919633|Drug|peginterferon alfa-2b|1.5 μg/kg subcutaneous weekly for 48 weeks
1846616|NCT00919633|Drug|ribavirin, USP|All patients will receive oral ribavirin
1846617|NCT00919633|Device|external drug infusion pump|pump delivery system for continuous subcutaneous infusion of interferon alfa-2b
1846618|NCT00919659|Dietary Supplement|parenteral nutrition|25kcal/kg bw with parenteral nutrition
1846619|NCT00919672|Device|Sacral nerve stimulation|The stimulation is set individually to provide the best possible stimulation for each individual person. This setting is found before the study starts and will not be altered during the study.
1846620|NCT00919685|Biological|blood sample|from rest of blood sample collected for other measurements
1846621|NCT00919711|Drug|Actonel®|Oral Actonel® (Risedronate) in total a 150mg per month (one 75mg tablet to be taken on each of 2 consecutive days per month).
1846622|NCT00919711|Drug|Denosumab|Denosumab 60 mg, once every 6 months, Subcutaneous
1846623|NCT00919737|Drug|NPC-08|Polifeprosan 20 with Carmustine 3.85%
1846624|NCT00919750|Other|cytology specimen collection procedure|Correlative studies
1846625|NCT00919763|Drug|CD 2027|Topical Ointment; two applications daily, once in the morning and once in the evening for 4 weeks
1846626|NCT00919763|Drug|CD 2027 Vehicle|Topical Ointment, two applications daily, once in the morning and once in the evening for 4 weeks
1846627|NCT00919776|Drug|prednisolone|prednisolone 40mg daily then reducing regimen over 16 weeks
1846628|NCT00919776|Drug|ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 16 weeks (additional prednisolone given for the first four weeks)
1846629|NCT00919802|Drug|Oxytocin|A single dose of oxytocin 40 IU (20 IU to each nostril) will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of saline as an alternate agent on the second day if needed.
1846630|NCT00919802|Other|Saline as a nasal spray|A single dose of saline will be dispensed in a random fashion to subjects. A log will be kept so that the subject will receive a single does of oxytocin 40 IU as an alternate agent on the second day if needed.
1846631|NCT00919815|Drug|Ciclosporin|Ciclosporin 7.5mg/kg - reducing regimen over 24 weeks (additional prednisolone given for the first four weeks)
1846632|NCT00919815|Drug|Prednisolone|prednisolone 40mg daily then reducing regimen over 24 weeks
1846633|NCT00919828|Device|Avivo System|Non invasive external monitoring device
1846634|NCT00919841|Other|Ultrasound examination|Sequential three-dimension sonographic examination for the uterine size after vaginal delivery. The examination will be performed once a week, until the completion of 7 weeks after delivery.
1846635|NCT00919854|Drug|Darunavir|Darunavir oral suspension (100 mg/mL) will be administered as 20 mg per kg body weight twice daily for children weighing between 10 and <20 kg before dose adjustment. Darunavir oral suspension will be administered 25 mg per kg body weight twice daily if weight less than 15 kg, and fixed dose of 375 mg darunavir tablets twice daily if weight more than or equal to 15 kg after dose adjustment.
1846636|NCT00919854|Drug|Ritonavir|Ritonavir oral solution (80 mg/mL) will be administered as 3 mg per kg body weight twice daily before dose adjustment and after dose adjustment fixed dose of 50 mg twice daily if weight more than or equal to 15 kg.
1846637|NCT00919867|Drug|SPD503|SPD503 extended-release 4mg orally administered tablets. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
1846638|NCT00919867|Drug|VYVANSE|VYVANSE 50mg orally administered capsules. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
1846639|NCT00919867|Drug|SPD503 and VYVANSE|SPD503 4mg tablets + VYVANSE 50mg capsules orally administered together. There are 3 dosing periods in the study. Subjects will receive one dosing regimen (arm) as a single oral dose on the first day of each dosing period. The order in which the subjects receive each arm (regimen) is randomly assigned. There is a 7-day break between each dosing period in which no medication is taken.
1846640|NCT00919880|Drug|carboplatin+ paclitaxel|carboplatin AUC 2mg/mL*min/week, 3 week cycle up to 4 cycles; paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
1846641|NCT00919880|Drug|paclitaxel|paclitaxel 80mg/m2/week, 3 week cycle up to 4 cycles
1846642|NCT00919893|Drug|Cernilton|Oral Cernilton, 2 capsules every 8 hours with the active substance consisting of 23 mg Extractum Pollens siccatum, 4 mg L-glutamate and 0.23 mg Stigmasterol per capsule for 12 weeks.
1846643|NCT00919893|Drug|Placebo|Oral placebo, 2 capsules every 8 hours with identical capsulation and weight only containing the inactive substances in proportional doses as compared with Cernilton for 12 weeks.
1846644|NCT00919906|Device|My Scrivener(R)|Twenty 20-minute sessions of the Handwriting Without Tears(R) instructional handwriting program, with substitution of hand-over-hand or self-generated repetitive motion writing by computer guided repetitive motion.
1846645|NCT00919919|Drug|progesterone|Daily use of 100 mg progesterone vaginal tablet, and Estrofem; estradiol 1 mg administrated orally. for 6 month
1846646|NCT00919919|Drug|activella|Daily use of 1 mg estradiol and 0.5 mg norethindrone acetate administrated orally
1846647|NCT00919932|Behavioral|Paper and pen homework|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The homework will be done on a preprinted form which is assigned weekly and reviewed with their therapists at weekly sessions for 4 weeks.
1846648|NCT00919932|Device|Text message system homework.|Homework will be standardized through the use of Judith Beck's dysfunctional thought record (DTR), which is a primary tool for patients to evaluate and respond in writing to their automatic thoughts (Beck 126). The novel text-messaging system allows homework to be submitted directly through an adolescent's cellular phone, includes text-messaged homework reminder prompts, and collates all homework for therapists to review with patients during therapy sessions. This is assigned and reviewed weekly for 4 weeks.
1846649|NCT00919945|Other|Continuous feeding at time 1 and NPO at time 2|Continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 1 and NPO at time 2 (12 hours later)
1846650|NCT00919945|Other|NPO at time 1 and continuous feeding at time 2|NPO at time 1 and continuous nasogastric formula feeding (using Enfalac with iron 2400 kJ/L at a volume of 1ml/kg/h) at time 2 (12 hours later).
1846651|NCT00919958|Biological|PLX-PAD IM injection|Single treatment; multiple injections
1846652|NCT00919984|Drug|IP chemotherapy|IV Paclitaxel 175mg/m2 + IV Carboplatin (AUC4.5) AT DAY 1; IP Paclitaxel 60 mg/m2 at day 8; every 21 days, 6 cycles
1846653|NCT00919997|Genetic|DNA analysis|Anal pap smear, penile pap smear, blood collection, and saliva collection at a single study visit for HPV DNA analysis.
1846654|NCT00919997|Genetic|polymerase chain reaction|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
1846655|NCT00919997|Other|fluorescence activated cell sorting|Blood and saliva samples collected at a single study visit will be analyzed for for HPV DNA.
1846656|NCT00919997|Other|questionnaire administration|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
1846657|NCT00919997|Other|study of socioeconomic and demographic variables|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
1846658|NCT00919997|Procedure|study of high risk factors|Describe risk factors for penile, anal and oral HPV infection in Indian HIV-seropositive MSM.
1846659|NCT00920010|Other|biologic sample preservation procedure|
1846660|NCT00920023|Drug|Superparamagnetic Iron Oxide Magnetic Resonance Imaging|Two MRIs will be performed over a two day period. The second scan will be done 48 hours after intravenous infusion of ferumoxytol
1846661|NCT00920036|Device|StressEraser|A hand-held biofeedback device that facilitates resonant frequency of respiration
1846662|NCT00920049|Behavioral|Persuasion|
1846663|NCT00920075|Drug|Alendronate (Fosamax)|Pill, 35mg or 70mg depending upon the body weight for 12 months. This was given for participants during the open label or double blind study. Current study is a post study evaluation of the current status of bone density after the participants completed the study. In this post study, no treatment is involved.
1846664|NCT00920088|Drug|darunavir/ritonavir|DRV/RTV 600/100mg
1846670|NCT00920101|Drug|Atorvastatin|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study. The subjects are administered with 10mg/day for 3 months, if LDL-cholesterol levels does not decrease less than 80mg/dl, the dose is increased up to 20mg/day. If LDL-cholesterol levels decrease less than 60mg/dl, the dose is decreased down to 5mg/day or less.
1846671|NCT00920101|Behavioral|Lifestyle counseling|Subjects are advised to keep dietary habits according to the National Cholesterol Education Program (NCEP) from the run-in period throughout the study.
1846672|NCT00920114|Biological|blood sample|
1846673|NCT00920127|Dietary Supplement|AKL1|"Each dose of AKL1 or placebo will consist of two capsules which will be swallowed twice daily for 8 weeks.
The morning dose of study medication should be taken at approximately the same time each morning between 7:00 am and 10:00 am and should consist of two 500 mg capsules and then repeated between 7.00 pm and 10 pm."
1846674|NCT00920140|Drug|GSK1120212|Starting dose based on GSK protocol MEK111054 and then dose escalation based on Dose Limiting Toxicities per protocol.
1846675|NCT00920140|Drug|GSK1120212|Dose will be maximum tolerated dose based on Phase I results.
1846676|NCT00920153|Biological|bleomycin sulfate|Given IV
1846677|NCT00920153|Drug|ABVD regimen|Given IV
1846678|NCT00920153|Drug|carmustine|Given IV
1846679|NCT00920153|Drug|cisplatin|Given IV
1846680|NCT00920153|Drug|cytarabine|Given IV
1846681|NCT00920153|Drug|dacarbazine|Given IV
1846682|NCT00920153|Drug|dexamethasone|Given orally
1846683|NCT00920153|Drug|doxorubicin hydrochloride|Given IV
1846684|NCT00920153|Drug|etoposide|Given IV
1846685|NCT00920153|Drug|gemcitabine hydrochloride|Given IV
1846686|NCT00920153|Drug|ifosfamide|Given IV
1846687|NCT00920153|Drug|melphalan|Given IV
1846688|NCT00920153|Drug|methylprednisolone|Given IV
1846689|NCT00920153|Drug|mitoguazone|Given IV
1846690|NCT00920153|Drug|vincristine sulfate|Given IV
1846691|NCT00920153|Drug|vindesine|Given IV
1846692|NCT00920153|Drug|vinorelbine tartrate|Given IV
1846693|NCT00920153|Procedure|allogeneic hematopoietic stem cell transplantation|Patients undergo allogeneic stem cell transplantation
1846694|NCT00920153|Procedure|autologous hematopoietic stem cell transplantation|Patients undergo autologous stem cell transplantation
1846695|NCT00920166|Dietary Supplement|Pétunia 1|Infant formula used for non breastfed children
1846696|NCT00920166|Dietary Supplement|Regular formula|Infant formula used for non breastfed children
1846697|NCT00920192|Drug|Foretinib|Phase I starting dose 30 mg/day escalated to 45 mg/day; de-escalated to 30 mg/day. MTD for Phase II dose was 30 mg/day,
1846698|NCT00920205|Drug|MPC-3100 (an Hsp90 inhibitor)|oral daily dose for 21 days in a 28-day cycle
1994294|NCT03034954|Device|Active HD-tDCS|Participants will receive active HD-tDCS at 3mA for 20 minutes
1846701|NCT00920231|Device|initial system|The computer vision system is used to assist blind subject to navigate an extended path with multiple turns within a hospital setting.The initial prototype system would have been successfully tested for outdoor navigation and basic object recognition tasks.
1846702|NCT00920231|Device|modified system|The problems associated with the initial system were identified and modified. This modified system was tested with a second separate group of subjects. The redesigned system is used to assist blind subject to navigate the same extended path with multiple turns within a hospital setting.
1846703|NCT00920244|Procedure|Cardiopulmonary resuscitation (CPR)|CPR is performed according to international and national guidelines on all patients.
1846704|NCT00920244|Drug|Epinephrine|According to guidelines epinephrine 1 mg i.v. is administered every 3 minutes during cardiopulmonary resuscitation.
1846705|NCT00920244|Drug|Atropine|According to CPR guidelines atropine 3 mg i.v. is administered if asystole og PEA with frequency < 60 beat/min.
1846706|NCT00920244|Drug|Amiodarone|According to guidelines amiodarone 300 mg i.v. is administered if recurrent ventricular fibrillation/tachycardia (VF/VT) during CPR.
1846707|NCT00920244|Device|External defibrillator|According to CPR guidelines patients with shockable rhythms may receive DC shocks. The defibrillator also stores physiological information regarding cardiac rhythm, pulse-oximetry, and end-tidal carbon dioxide (CO2) from endotracheal tube.
1846708|NCT00920257|Drug|GSK2141795|GSK2141795 is an oral AKT inhibitor.
1846709|NCT00920270|Drug|nebulized colistin|nebulized colistin 75 mg every 12 hours
1846710|NCT00920270|Drug|antibiotics|conventional parenteral antibiotics
1846711|NCT00920283|Device|Chrono Carbostent Carbofilm™ Coated Coronary Stent|
1846712|NCT00920283|Device|Driver Cobalt Alloy Coronary Stent|
1846713|NCT00920296|Drug|GSK1265744|GSK drug
1846714|NCT00920309|Drug|Rapamycin|The starting dose of rapamycin will be 1 mg daily. The dose will be increased as needed to achieve a 24 hour trough level of 4-6 ng/ml.
1846715|NCT00920309|Other|Standard of Care-Placebo|
1846716|NCT00920322|Device|rTMS 5 x weekly|Patients will receive rTMS five times weekly for 4 weeks
1846717|NCT00920322|Device|rTMS 3 times weekly|Patients will receive rTMS 3 times weekly for 4 weeks
1846718|NCT00920335|Other|tumoral sample|Ependymoma tumoral sample
1846719|NCT00920361|Drug|Follitropin beta|Normally, Follistim Injection 150 or 225 IU will be administered (s.c. or i.m.) once a day for 4 days as follitropin beta (genetical recombination). The dosage will be adapted to growth of follicles (75-375 IU for 6-12 days, in general). If more than 3 follicles of mean diameter 16-20 mm are confirmed by ultrasound tomography, ovulation will be stimulated by using Human Chorionic Gonadotropin (hCG) drugs.
1846720|NCT00920374|Biological|Fluarix™/Influsplit SSW®|single intramuscular dose on Day 0
1846721|NCT00920387|Drug|Experimental 200 mcg Lysergic acid diethylamide|Administering 200 mcg LSD orally once at the start of each of two day-long psychotherapy session
1846722|NCT00920387|Drug|Active Comparator 20 mcg lysergic acid diethylamide|Administer 20 mcg LSD orally once at the start of each of two day-long psychotherapy session
1846723|NCT00920387|Behavioral|Psychotherapy|Psychotherapy provided by a male and a female psychotherapist
1846724|NCT00920413|Dietary Supplement|Vitamin C|vitamin C 500mg orally once a day
1846725|NCT00920413|Dietary Supplement|placebo|
1846726|NCT00926315|Drug|calcitriol|Post menopausal patients will receive Calcitriol 0.50 mcg PO per day for 1 month.
1846727|NCT00926315|Drug|Calcitriol|calcitriol 0.25 mcg PO bid
1846728|NCT00926328|Drug|Triclosan, fluoride|Six Month study, brush twice daily
1846729|NCT00926328|Drug|Fluoride|twice daily usage
1846730|NCT00926341|Drug|Pioglitazone|Tab. Pioglitazone-30 mg/day, oral, 24 weeks
1846731|NCT00926341|Drug|Telmisartan|Tab. Telmisartan- 40 mg/day, oral, 24 weeks
1846732|NCT00926354|Drug|AS101|intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
1846733|NCT00926367|Drug|Clindamycin and benzoyl peroxide|Once-daily applications, to the randomized side of the face either left or right, of a topical antibiotic and benzoyl peroxide gel. This contains a topical antibiotic and benzoyl peroxide gel.
1846734|NCT00926367|Drug|benzoyl peroxide 2.5% and adapalene 0.1% gel|Once-daily applications, to the randomized side of the face either left or right,benzoyl peroxide and adapalene gel
1846735|NCT00926380|Drug|denosumab|denosumab: 60 mg SC every 6 months
1846736|NCT00926380|Drug|teriparatide|teriparatide: 20 mcg SC QD
1846737|NCT00926393|Drug|Quetiapine Immediate Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
1846738|NCT00926393|Drug|Quetiapine Extended Release|Oral, 3 tablets daily: (2 x 25 mg + 1 x 50 mg) at one time each day
1846739|NCT00926406|Drug|lead chelation therapy|Patients with lead poisoning (BLL> 20μg/dl) are randomly assigned to a control or chelation group, on the 1:1 proportion. During the 3 months, 50 chelation group patients receive 2-hour weekly intravenous infusions of one vial (1 g) of calcium di-sodium EDTA mixed with 200 ml of normal saline until BLB is BLL < 5 μg/dl. Fifty control patients receive weekly 2-hour infusions of one vial (20 ml) of 50% glucose mixed with 200 ml of normal saline over a period of 12 weeks9.
1846740|NCT00926419|Biological|Varicella Vaccine|Lyophilized Varicella virus vaccine, live, attenuated (Oka-strain)
1846741|NCT00926419|Biological|Hepatitis A Vaccine|Hepatitis A virus vaccine, inactivated, Single dose
1846742|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
1846743|NCT00926432|Device|EOS™ Acquisition|Double Incidence Postero Anterior and Lateral full body low-dose X-ray acquisition on EOS™ device following SOP of the service of radiology.
1846744|NCT00926471|Behavioral|Cognitive Behavioral Therapy (CBT) Program|12 to 14 weekly sessions of individual CBT and parent training with 5 sessions of group counseling every other week
1846745|NCT00926497|Other|Procalcitonin-guided decision making|Procalcitonin-guided decision making on duration of antibiotic therapy in suspected neonatal early onset sepsis
1846746|NCT00926510|Behavioral|Language toolkit|Simple toolkit of interactive things to stimulate language.
1846747|NCT00926510|Behavioral|Safety counseling|Smoke detector and general safety counseling
1846748|NCT00926523|Other|Blood Gas|Subject will have both venous and arterial blood draws to assess for the bloods content of MIF
1846749|NCT00926523|Other|Pulmonary Exercise Test|Subject will ride exercise bike to assess their pulmonary function level.
1846750|NCT00926523|Other|Spirometry|To assess subjects lung function
1846751|NCT00926523|Other|Breath Condensate Collector|Subject with use breathing apparatus to allow researchers to collect breath condensate to assess level of MIF in breathe condensate.
1846752|NCT00926536|Device|C-arm CT + DSA as needed|C-arm CT images obtained and supplemented with DSA if needed
1846753|NCT00926536|Device|DSA only|DSA imaging only
1846754|NCT00926549|Device|Spectral domain-OCT (Cirrus™ HD-OCT, Carl Zeiss Meditec AG)|macular cube scanning
1846755|NCT00926562|Drug|Iopromide (Ultravist)|Iopromide (contrast agent), 370 mgl/ml, an nonionic, monomeric, LOCM
1846756|NCT00926562|Drug|Iodixanol (Visipaque)|Iodixanol (contrast agent) 320 mgl/ml, a nonionic, dimeric, IOCM
1846757|NCT00926575|Drug|oral beclomethasone 17,21-dipropionate|Two tablets QID for 50 days
1846758|NCT00926575|Drug|Placebo|Two tablets QID for 50 days
1846759|NCT00926588|Drug|Stepped care|Structured algorithms for stepped care analgesic management and explicit decision rules for adjusting treatment are new tools developed for this study.
1846760|NCT00926614|Drug|pioglitazone (Actos)|pioglitazone 30 mg qd for 30 days, then increase to 45 mg
1846761|NCT00926614|Drug|atorvastatin (Lipitor)|atorvastatin 40 mg for 30 days then increase to 80 mg daily
1846762|NCT00926627|Drug|bosentan|62.5 mg tablets b.i.d. administered orally for 4 weeks followed by the maintenance dose of 125 mg b.i.d. (62.5 mg b.i.d. if body weight < 40 kg/90 lb)
1846763|NCT00926627|Drug|placebo|identical preparation as the study drug, but without the active substance, administered b.i.d.
1846767|NCT00926991|Other|No intervention|No intervention; observation only
1846768|NCT00927004|Drug|Etoricoxib (Arcoxia)|60 mg, daily dose, oral delivery, 14 days duration
1846769|NCT00927004|Drug|Sugar pill|Daily dose (1 pill), oral delivery, 14 days
1846770|NCT00927017|Other|Liquorice 66 g/day|Liquorice 66 g/day for two weeks
1846771|NCT00927017|Other|Liquorice 102 g/day|Liquorice 102 g/day for two weeks
1846772|NCT00927030|Drug|supplemental liquid melatonin|Liquid melatonin will be given to the parent. There are 4 dose levels (1mg, 3mg, 6 mg, and 9mg)of melatonin that will be used at 3 week intervals. The child will start with 1mg and the dose will be increased at 3 week intervals until the child is falling asleep within 30 minutes of bedtime on 5/7 nights per week. Once this goal is reached the child will stay on that dose through the remainder of the study.
1846773|NCT00927030|Drug|flavored liquid or liquid supplemental melatonin|Single blind for parents at initial 3-weeks dose period of 1 mg melatonin for 18 children where 3/18 children will receive placebo and 15/18 children will receive melatonin study drug. Each bottle will be labeled as: Flavored liquid placebo/or liquid melatonin. After this initial 3-week period all children will receive known melatonin in bottles that state this.
1846774|NCT00927043|Other|Epidemiological study according to clinical practice|Epidemiological study according to clinical practice.
1846775|NCT00927056|Procedure|Microdiscectomy|Minimally invasive microdiscectomy versus conventional open microdiscectomy
1846776|NCT00927069|Drug|Adalimumab every other week|Adalimumab 40mg injection every other week for 24 weeks
1846777|NCT00927069|Drug|Adalimumab Every Week|Adalimumab 40mg injection every week for the last 12 weeks of study.
1846778|NCT00927082|Drug|peginterferon alfa-2a [Pegasys]|90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
1846779|NCT00927095|Drug|Continuous OC (EE/DROS)|Continuous EE(20ug)+DROS(3mg) daily for 3 months
1846780|NCT00927095|Drug|Intermittent OC (EE/DROS)|Intermittent EE(20ug)+DROS(3mg) daily for 21 days each month
1846781|NCT00927095|Drug|placebo|daily placebo
1846782|NCT00927108|Other|Progenitor Stem Cell Culture|
1846783|NCT00927121|Device|Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset|"The CR-stimulation was originally developed by Prof. Dr. Dr. Peter Tass for deep brain stimulation (DBS). The CR-stimulation through high frequency short pulses causes a neuronal reorganization in the stimulated brain area establishing a normal neuronal activity.
Based on intensive modeling studies, experimental proof of concept (POC) animal studies and a clinical POC, we proved that the pathologic activity can be recuperated to a desynchronized/healthy state with the acoustic CR-stimulation.
The acoustic CR-stimulation signal will be generated by the ANM CR-Stimulator and transmitted to the ears through a speaker system"
1846784|NCT00927134|Genetic|retroviral SF71-gp91phox transduced CD34+ cells|autologous ex-vivo transduced (SF71-gp91phox)CD34+ cells
1846785|NCT00927147|Radiation|BNCT|Boronophenylalanine infusion followed by neutron irradiation
1846786|NCT00927147|Drug|cetuximab|cetuximab infusion 250 to 400 mg/kg intravenously, 1 to 3 infusions
1846787|NCT00927173|Device|Brainsway H-Coil Deep TMS System|Deep Transcranial Magnetic Stimulation (DTMS) is a new form of TMS which allows direct stimulation of deeper neuronal pathways than the standard TMS. The H-coil is a novel DTMS coil designed to allow deeper brain stimulation without a significant increase of electric fields induced in superficial cortical regions
1846788|NCT00927173|Device|Brainsway H-Coil Deep TMS System (Sham treatment)|In the sham treatment,the electrical field induced by the sham coil cannot invoke any action potentials and if no action potentials are induced, then the electric field is insignificant and there is no treatment effect on the brain.
1846789|NCT00927186|Drug|Teriparatide|"20 microgram (mcg) subcutaneous (SC) injection per day for 12 months. Placebo intravenous (IV) infusions were given to maintain blind.
After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
1846790|NCT00927186|Drug|Zoledronic Acid|"5 milligram (mg) intravenous (IV) infusion administered once during 1 year study. Placebo subcutaneous (SC) injections were given to maintain blind.
After completing 12 months of treatment, all participants are eligible to participate in an additional 12-month extension."
1846791|NCT00927199|Dietary Supplement|High-Oleic Canola Oil|Diets contained 35% energy as fat; of which 70% was provided by high-oleic canola oil (high in monounsaturated fat (oleic acid))
1846792|NCT00927199|Dietary Supplement|High-Oleic Canola/Flaxseed Oil Blend|Diets contained 35% energy as fat; of which 70% was provided by a 1:1 blend of high-oleic canola oil and flaxseed oil (high in monounsaturated fat (oleic acid) and omega-3 polyunsaturated fat (alpha-linolenic acid))
1846793|NCT00927199|Dietary Supplement|Western Dietary Control|Diets contained 35% energy as fat; of which 70% was provided by a blend of oils typical to the Western diet (high in saturated fat and omega-6 polyunsaturated fat (linoleic acid))
1846794|NCT00927212|Drug|AS101 ointment|Twice daily topical application
1846795|NCT00927225|Drug|ropivacaine 0.2%, 50 mL|
1846796|NCT00927225|Drug|normal saline|
1994295|NCT03034954|Device|Sham HD-tDCS|Participants will receive sham HD-tDCS
1846799|NCT00927251|Device|Pacing Lead (Model 4296 LV Lead)|Implant and follow-up of study device
1846800|NCT00927264|Behavioral|Motivational Interviewing Intervention for ETS Reduction|The intervention is designed to motivate caregivers to reduce a child's ETS exposure by establishing a complete home and car smoking ban and by considering smoking cessation. Caregivers will receive 2 home visits & 2 telephone session, both with a health counselor. Caregivers will be provided with feedback on air nicotine levels and child salivary cotinine levels. The main target for the intervention will be the primary caregiver of the child because the primary caregiver is ultimately responsible for protecting the child from ETS exposure. Any and all household members may participate in the intervention visits but are not required to do so.
1846801|NCT00927264|Behavioral|Educational Program for ETS Reduction|An Environmental Protection Agency-based educational program that will consist of information about reducing tobacco smoke exposure.
1846802|NCT00927277|Device|Erchonia(R) LipoLASER PL; Erchonia(R) EML Laser|The Erchonia(R) EML Laser is a low level laser light therapy medical device that was applied during the liposuction procedure, by emitting 1 mw of red (635nm wavelength) light via a Class II electric laser diode energy source (CDRH classification). The fluence is considered to be at 10.8 joules per area treated.
1846803|NCT00927277|Device|Erchonia(R) LipoLASER PL|
1846804|NCT00927290|Drug|Pioglitazone|Pioglitazone, 45 mg QD (30 mg QD the first month)
1846805|NCT00927290|Drug|Placebo|Placebo 45 mg QD (30 mg QD the first month)
1846806|NCT00927303|Device|Cirrus-Spectralis|512x128 cúbe program of Cirrus OCT first retinal volume 121 line of Spectralis OCT thereafter
1846807|NCT00927303|Device|Spectralis-Cirrus|retinal volume program 121 lines Spectralis OCT first 512x128 program Cirrus OCT thereafter
1846808|NCT00927316|Biological|E. coli 83972|"Active arm: Intravesical inoculation (by urethral catheterization) on three subsequent days with 30 ml E. coli 83972 (100 000 cfu/ml).
Placebo arm: Identical procedure but with saline, 30 ml."
1846809|NCT00927329|Biological|dust mite inhalation|Nasal allergen challenge will be provided in a graded dose fashion of 0 AU, 100 AU, 500 AU, and 1000 AU separated by 20 minutes.
1846810|NCT00927342|Other|Vivostat|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Vivostat sealant applied to the surface of the lung in an attempt to eliminate air leak
1846811|NCT00927342|Other|BioGlue|Patients with an air leak at the end of thoracic surgery despite conventional measures(diathermy, suturing and/or stapling) will receive Bioglue sealant applied to the surface of the lung in an attempt to eliminate air leak
1846812|NCT00927355|Drug|Pioglitazone|6 month treatment with pioglitazone 15mg for four weeks with dose increased to 30mg if no adverse effects (swelling of lower extremities, liver enzyme elevation) noted at the four week mark.
1846813|NCT00927355|Drug|Placebo|"The placebo pills also start out with one (15mg) pill qday and are increased to 2 tablets (30mg) qday after 4 weeks if no adverse effects are noted by study physician."
1846814|NCT00927368|Procedure|ultrasound guidance alone|The Tuohy needle was inserted in out-plane approach. Needle placement was considered adequate when the tip was visualized beneath the fascia iliaca; the catheter was then introduced 5 cm beyond the needle tip. Electrical stimulation was not used.
1846815|NCT00927368|Procedure|ultrasound guidance and needle stimulation|For the ultrasound guidance and needle stimulation group, the Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA (2 Hz, pulse width 0.1 msec). Subsequently, the catheter was threaded 5 cm beyond the needle tip without additional electrical stimulation.
1846816|NCT00927368|Procedure|ultrasound guidance and catheter stimulation|The Tuohy needle was positioned with the tip beneath the fascia iliaca under ultrasound guidance. The needle tip was then adjusted as necessary to obtain a quadriceps muscle response with a stimulating current ≤0.5 mA. At that point, the peripheral nerve stimulator was then disconnected from the stimulating needle and connected to the proximal end of the catheter. The catheter was then advanced 5 cm past the needle tip. If the motor response disappeared during catheter advancement, the catheter was withdrawn slightly until the response returned. Needle orientation and catheter advancement were adjusted as necessary to elicit quadriceps contractions via the catheter with a stimulating current ≤0.5 mA.
1846817|NCT00927394|Drug|Aliskiren|Aliskiren 150 mg tablet
1846818|NCT00927394|Drug|Valsartan|Valsartan 160 mg capsules
1846819|NCT00927394|Drug|Placebo for Aliskiren|Placebo for Aliskiren 150 mg tablets
1846820|NCT00927394|Drug|Placebo for Valsartan|Placebo for Valsartan 160 mg capsules
1846821|NCT00927407|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to the scalp for 30 minutes
1846822|NCT00927407|Drug|Malathion lotion 0.5%|Malathion lotion 0.5% applied to scalp for 12 hours
1846823|NCT00927433|Behavioral|Psychoeducational intervention for cancer-related fatigue|Patients received education on fatigue management in groups of ten patients over two weeks in three two hour sessions
1846824|NCT00927446|Procedure|Endoscopy screening with narrow band imaging|Narrow Band Imaging (NBI) system, an optical technology that enhances the visualization of superficial vascular network, may be superior to the conventional white light endoscopy for the detection of neoplastic lesions.
1846825|NCT00927459|Drug|PRO-040201|Single dose IV infusion
1846826|NCT00927459|Drug|Placebo|placebo
1846827|NCT00927472|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
1846828|NCT00927472|Drug|Permethrin 1% rinse|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head lice are still present.
1846829|NCT00927485|Drug|Calcumin (Curcumin)|Patients will be randomized to curcumin (3 curcumin pills twice a day for 12 months).
1846830|NCT00927485|Other|Risk Factor Questionnaire|Questions about current and past lifestyle, health background, and medications. This will take about 20 minutes.
1846831|NCT00927485|Other|Blood samples|Three tubes of blood at visits 0, 4 and 12 months.
1846832|NCT00927485|Other|Biopsies (Sigmoidoscopy)|Flexible sigmoidoscopy at baseline and every 4 months for the length of the study (4 months, 8 months, 12 months and 16 months). We will take 2-4 tissue samples of the colon lining by a pinch biopsy.
1846833|NCT00927485|Other|Biopsies (Upper endoscopy)|Other: Biopsies (Upper endoscopy) Upper endoscopy at baseline and at 12 months. We will take 2-4 tissue samples of the small intestine lining by a pinch biopsy.
1846834|NCT00927498|Drug|conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.
Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4."
1846835|NCT00927498|Drug|Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),|"Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.
Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.
Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1."
1846836|NCT00927511|Drug|Fulvestrant|Fulvestrant 500 mg days 0, 14, 28, then 250 mg every 2 weeks for 5 administrations, then 250 mg every 28 days, until progression or unacceptable toxicity vs Fulvestrant 250 mg every 28 days until progression or unacceptable toxicity
1846837|NCT00927524|Drug|Insulin glulisine|Dose injection of insulin glargine (Lantus®) given subcutaneously in the abdomen 1 hour prior to breakfast and a dose of insulin glulisine (Apidra®) at a dose based upon your (body wt.) carbohydrate intake for each of the three meals (breakfast, lunch and dinner).
1846838|NCT00927524|Drug|Insulin|Dose based on carbohydrate intake given subcutaneously in the abdomen prior to breakfast and dinner.
1846839|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Kinzal according to local drug information.
1846840|NCT00927537|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291) + Hydrochlorothiazide|Patients under daily life treatment receiving Kinzalplus according to local drug information.
1846841|NCT00927550|Drug|lithium|Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.
1846842|NCT00927550|Drug|usual care|Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
1846843|NCT00927563|Drug|Tolcapone|pill, 100-300mg/day for 8 weeks
1846844|NCT00927576|Behavioral|Digit span testing|Testing of short-term verbal memory with digit span
1846845|NCT00927576|Behavioral|Spatial span testing|Testing of short-term visuospatial memory with spatial span.
1846846|NCT00927576|Behavioral|Finger tapping|Testing motor speed with a finger tapping test.
1846847|NCT00927576|Behavioral|Simple reaction time|Testing the time to respond to the appearance of a visual stimulus.
1846848|NCT00927576|Behavioral|Choice reaction time|Testing the time needed to discriminate and respond to different visual stimuli.
1846849|NCT00927576|Behavioral|Verbal fluency|Evaluating how many words are produced in 90s.
1846850|NCT00927576|Behavioral|Verbal list learning|Evaluating short-term memory, learning, and memory interference in the recall of 12-word lists, presented three times. Evaluating long-term memory and recognition after a 20 min interval.
1846851|NCT00927576|Behavioral|Trail making test|Evaluating visuomotor speed and executive function in Trail Making Tests, A and B. In the first, subjects connect successive numbers with the mouse. In the second, they connect numbers and letters in alternation.
1846852|NCT00927576|Behavioral|Design fluency|Subjects create the maximal number of 4-line patterns in 90 s.
1846853|NCT00927576|Behavioral|Questionnaire completion|Question completion time is measured on each question of the Post-Traumatic Stress Disorder check list (PCL) and on the cognitive failures questionnaire.
1846854|NCT00927589|Drug|carboplatin|Intravenous repeating dose
1846855|NCT00927589|Drug|docetaxel|Intravenous repeating dose
1846856|NCT00927589|Drug|trastuzumab|Intravenous repeating dose
1846857|NCT00927602|Drug|fondaparinux|once daily sc injection, 1,5 mg, max 14 days
1846858|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intracoronary)
1846859|NCT00927615|Drug|abciximab|0.25 mg/kg body weight (intravenous)
1846860|NCT00927628|Procedure|Vitrectomy|Patients underwent vitrectomy with or without internal limiting membrane (ILM) peeling for an idiopathic full-thickness macular holes. Simultaneous phacoemulsification with intraocular lens implantation was performed on all phakic patients who were >40-years-of-age.
1846861|NCT00927641|Drug|Ketoprofen Patch|Two Ketoprofen HKT-500 patches applied to target ankle once daily for 14 days
1846862|NCT00927641|Other|Placebo Patch|Two placebo patches placed on target ankle once daily for 14 days
1846863|NCT00927654|Drug|Iloprost (Ventavis)|Twice 20 µg at day 0 (total dose 40 µg) intraoperatively
1846864|NCT00927654|Drug|Isotonic Sodium Chloride solution 0.9 % (placebo)|Twice at day 0 intraoperatively
1846865|NCT00927667|Procedure|No Drug|Patients have received primary FVIII prophylaxis (started < 2 years of age)
1846866|NCT00927667|Procedure|No Drug|Patients have received secondary FVIII prophylaxis (started 2 - < 6 years of age)
1846867|NCT00927667|Procedure|No Drug|Patients have received secondary FVIII prophylaxis (started 6 - < 12 years of age)
1846868|NCT00927667|Procedure|No Drug|Patients have received secondary VIII prophylaxis(started 12 - 18 years of age)
1846869|NCT00927667|Procedure|No Drug|Patients have received on-demand therapy
1846870|NCT00927693|Other|Coronary Artery Calcium (CAC) Scan|A coronary artery calcium (CAC) scan is performed during the baseline clinic visit. The results including the actual images from the scan are viewed by the subject during the risk factor consultation with the nurse practitioner. Results are available for the subjects' physicians upon request.
1846871|NCT00927706|Device|Assistive technology updating and tune up intervention|This intervention includes 4 components: 1) an in-residence assessment of the mobility preferences of the older person and his/her caregiver; 2) a detailed review of forms of assistance, technological and human, that are currently being used; 3) recommendations by an occupational therapist for possible changes in the older person's mobility assistive technology or assistance strategy; and 4) therapist negotiation of an mobility assistive technology updating and tune-up intervention plan with the individual and his or her caregiver.
1846872|NCT00927719|Biological|ACAM2000® smallpox vaccine|Previous vaccination, no vaccine is administered in this study.
1846873|NCT00927732|Drug|hydroquinidine|capsules of 300 mg LP, 1 or 2 or 3 times per day : frequency will be determined by tests after patient inclusion before her/his randomization
1846874|NCT00927732|Drug|placebo (sugar)|capsules of placebo have same design and color than capsules of hydroquinidine except for their content as they contain sugar and not hydroquinidine
1846875|NCT00927745|Device|AutoFlow mode on Evita 4 Dräger ventilators|Activation of AutoFlow mode during assist-controlled ventilation
1846876|NCT00927745|Device|Evita 4 Dräger ventilators|Assist-controlled ventilation without activation of AutoFlow mode
1846877|NCT00927758|Drug|fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg|fluticasone propionate/salmeterol diskus
1846878|NCT00927771|Drug|azelaic acid gel|azelaic acid 15% gel twice a day for 6 months
1846879|NCT00927771|Drug|hydroquinone cream|hydroquinone 4% cream twice a day for 6 months
1846882|NCT00927797|Drug|Cyclophosphamide, Pentostatin, Rituximab|
1846883|NCT00927810|Drug|Canakinumab|
1846884|NCT00927823|Drug|PF-04691502|Once daily continuous dosing. Dose escalation to Maximally tolerated dose (MTD) until progression or discontinuation.
1846885|NCT00927836|Biological|Filgrastim|135 μg/kg body weight total dose Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
1846886|NCT00927836|Drug|Sodium chloride solution|Short term infusion (20 to 30 minutes) and continuous infusion over 3 days
1846887|NCT00927849|Procedure|lateral internal sphincterotomy (LIS)|closed lateral internal sphincterotomy was done under local anesthesia at 3 o'clock in lithotomy position reaching up to the dentate line.
1846923|NCT00927966|Drug|CP-751,871|Given intravenously on Day 1 of a 21-day cycle
1846888|NCT00927849|Drug|Glycerin trinitrate (GTN)|All were instructed to apply the GTN ointment 0.2 % twice a day to the edge and just inside the anal canal for 8 week course.
1846889|NCT00927849|Drug|botulinum toxin injection (BTX A)|All were injected with botulinum toxin injection (BTX- A) in the left lateral position; anesthesia was not required. A volume of 0.5 ml of dissolved toxin, i.e., 100 u Dysport, is injected in each patient. The injection is given with an insulin syringe fitted with a needle size of 21 gauze and 3.75 lengths. Injection into the IAS, with the patients awake in the left -lateral position in the outpatient clinic in the 3 and 9 o'clock position.
1846890|NCT00927862|Genetic|IWPC adapted genotype-guided dosing algorithm for warfarin|"Within the first or second dose, apply an International Warfarin Pharmacogenetics Consortium (IWPC) adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin, based on clinical factors (age, sex, weight, height, etc.), and VKORC1 and CYP2C9 genotypes, to individualize the initial dosing of warfarin. (IWPC algorithm submitted for publication, 5-08)
Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
1846891|NCT00927862|Genetic|Modified IWPC genetic-guided warfarin dosing algorithm|"Within the first or second warfarin dose, apply a modified International Warfarin Pharmacogenetics Consortium (IWPC)-adapted genotype-guided dosing algorithm to determine the daily maintenance dose of warfarin. The active comparator algorithm (see above) will be further modified to account for the temporal pharmacodynamics of warfarin metabolism, e.g., by ignoring the CYP2C9 variants for the first 2 days.
Note that a second comparison will be made between the combined genotype-guided dosing groups (standard and modified IWPC warfarin dosing algorithms) and a historical comparator group."
1846892|NCT00927862|Other|Standard of care treatment|The parallel, standard-dosing patient control cohort was identified by a query of the electronic medical records databases of the 3 participating hospitals for the time interval spanning enrollment of the randomized pharmacogenetic cohorts (July 2008-December 2010). Patients >=18 years of age initiating warfarin therapy with a baseline and at least 1 follow-up INR level between days 3 and 14 were selected. Initial dose selection and therapy modification was at individual Intermountain-credentialed physician/healthcare provider discretion. Standard management is non-PG-based. A standard (fixed) initial maintenance dose of 5 mg/d is generally assumed.
1846893|NCT00927875|Drug|BMS-833923|Capsule, Oral, starting dose 30 mg, once daily, continuous
1846894|NCT00927875|Drug|Carboplatin|Vial, Intravenous (IV), dose to yield 5 mg/mL - min, once every 21 days, 1 day per cycle up to 4 cycles
1846895|NCT00927875|Drug|Etoposide|Vial, Intravenous (IV), 100 mg/m²/dose, days 1, 2, & 3 of each 21 day cycle, 3 days per cycle for up to 4 cycles
1846896|NCT00927888|Drug|Bupivacaine Block|Bupivacaine local anesthesia block prior to start of FESS procedure.
1846897|NCT00927888|Drug|Placebo|placebo is identical in appearance in comparison to active drug.
1846898|NCT00927901|Drug|Indacaterol maleate 400 μg|Indacaterol maleate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
1846899|NCT00927901|Drug|Indacaterol acetate 400 μg|Indacaterol acetate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
1846900|NCT00927901|Drug|Indacaterol xinafoate 400 μg|Indacaterol xinafoate 400 μg was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler. The dose refers to 400 μg of free base indacaterol.
1846901|NCT00927901|Drug|Placebo to indacaterol|Placebo to indacaterol was provided in powder filled capsules with the Concept1 single-dose dry-powder inhaler.
1846902|NCT00927914|Drug|Ranirestat|Ranirestat 40 mg tablets
1846903|NCT00927914|Drug|Placebo|Placebo tablets
1846904|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
1846905|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
1846906|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
1846907|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
1846908|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
1846909|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
1846910|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
1846911|NCT00927927|Drug|NNC0142-0002|Single dose, ranging from 0.0002 mg/kg up to max 7.5 mg/kg, administered subcutaneously (under the skin) on day 1
1846912|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
1846913|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
1846914|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
1846915|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
1846916|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
1846917|NCT00927927|Drug|NNC0142-0002|Multiple dose, ranging from 0.02 mg/kg up to max 4.0 mg/kg, administered subcutaneously (under the skin) four times biweekly
1846918|NCT00927927|Drug|placebo|Single dose of 0 mg/kg administered subcutaneously (under the skin); cohort 1-7b on day 1, cohort 8-11 biweekly four times
1846919|NCT00927940|Device|MDT-4107 Drug Eluting Stent|Implantation of a MDT-4107 Zotarolimus-Eluting Coronary Stent
1846920|NCT00927953|Biological|MGAWN1|Humanized monoclonal to West Nile virus. Dose = 30 mg/kg actual body weight intravenous, one dose at Day 0.
1846921|NCT00927953|Biological|Placebo - normal saline|Normal Saline intravenous, volume same as active comparator, one dose at Day 0
1846922|NCT00927966|Drug|RAD001|Taken orally once a day.
1848394|NCT00940966|Dietary Supplement|standard ADA diet|standard ADA diet
1846924|NCT00927979|Drug|10 mLRopivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
1846925|NCT00927979|Drug|Water for injection|Intraperitoneal nebulization of 10 mL water for injection
1846926|NCT00927979|Drug|10 mL Ropivacaine 1%|Intraperitoneal nebulization of 10 mL Ropivacaine 1%
1846927|NCT00927992|Other|Epidemiological Non interventional|Epidemiological Non interventional
1846928|NCT00928005|Behavioral|Weight loss diet|The weight loss diet will follow the American Diabetes Association guidelines and be nutritionally balanced with a reduced saturated fat content.
1846929|NCT00928005|Behavioral|Weight loss diet plus exercise|The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training.
1846930|NCT00928018|Drug|Sirolimus|Taken orally for at least 12 months
1846931|NCT00928018|Drug|Methotrexate|Given intravenously on the first, third and sixth day after transplant
1846932|NCT00928018|Drug|Tacrolimus|Taken orally or given intravenously for at least 6 months
1846933|NCT00928018|Drug|Cyclosporine|Taken orally or given intravenously for at least 6 months
1846934|NCT00928018|Drug|MMF|Taken orally for about 2 months
1846935|NCT00928057|Device|4mm x 32G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 4mm PN, with no pinch up.
1846936|NCT00928057|Device|8mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
1846937|NCT00928057|Device|5mm x 31G pen needle|For 3 weeks, subjects used this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects followed their usual insulin regimen and there was no upper limit on total daily insulin dosage or number of injections. Subjects were advised to inject straight in when using the 5mm PN, with no pinch up.
1846938|NCT00928070|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg
1846939|NCT00928070|Drug|Placebo|Placebo sham 4 mg and 8 mg
1846940|NCT00928083|Drug|OZ439 50mg API capsules|
1846941|NCT00928083|Drug|OZ439 200mg API capsules|
1846942|NCT00928083|Drug|OZ439 400mg aqueous dispersion|
1846943|NCT00928083|Drug|OZ439 800mg aqueous dispersion|
1846944|NCT00928083|Drug|OZ439 100mg API capsules|OZ439 100mg (2x50mg API capsules)
1846945|NCT00928083|Drug|OZ439 400mg API capsules|OZ439 400mg (2x200mg API capsules)
1846946|NCT00928083|Drug|OZ439 1600mg aqueous dispersion|
1846947|NCT00928083|Drug|OZ439 800mg API capsules|OZ439 800mg (4x200 API capsules)
1846948|NCT00928083|Drug|OZ439 1200mg API capsules|OZ439 1200mg (6x200mg API capsules)
1846949|NCT00928083|Drug|Placebo|
1846950|NCT00928083|Drug|OZ439 200mg aqueous dispersion|
1846951|NCT00928109|Behavioral|CBCT|Cognitive Behavioral Couples Therapy - weekly manualized couples therapy
1846952|NCT00928109|Behavioral|Family Supportive Therapy|Couples meet once a week for an hour for a period of 20 weeks for couples therapy. Family Supportive Therapy is not manualized and is the standard form of care at the UNC Eating Disorders Program
1846953|NCT00928122|Device|Intrastromal Correction of Presbyopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
1846954|NCT00928122|Device|Intrastromal correction of Myopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
1846955|NCT00928122|Device|Intrastromal Correction of Hyperopia|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
1846956|NCT00928122|Device|Intrastromal Correction of Myopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
1846957|NCT00928122|Device|Intrastromal Correction of Hyperopia incl. Astigmatism|Applying defined, pre-programmed patterns (e.g. rings and/or radial cuts)into the human eye cornea. It is a minimal-invasive procedure which changes the topography of the cornea and by that the refraction ability.
1846958|NCT00928135|Drug|Xylitol|15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
1846959|NCT00928135|Drug|Saline|7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
1846960|NCT00928148|Drug|SPD465|50 or 75 mg once daily for 7 days
1846961|NCT00928148|Drug|Immediate Release Amphetamine Salt|25 mg once daily for 7 days
1846962|NCT00928148|Drug|Placebo|Once daily for 7 days
1846963|NCT00928161|Drug|Dexlansoprazole|Dissolving tablet taken by mouth (60 mg tablet), once a day. Take dose first thing in morning on empty stomach, then nothing but water for 30-45 minutes afterwards.
1846964|NCT00928174|Drug|IV administration of fluorine-18 fluorocholine followed by PET/CT imaging|Imaging intervention performed prior to and 30-75 days post a change in anti-androgen therapy.
1846965|NCT00928187|Drug|emtricitabine/tenofovir + lopinavir/ritonavir (WHO recommended second line)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets in the morning and 2 tablets in the evening
1846966|NCT00928187|Drug|abacavir + didanosine + lopinavir/ritonavir (WHO recommended second line)|Didanosine 1 entero-coated capsule/day in fasting conditions (dosage 250 mg if weight < 60 kg, 400 mg if weight > 60 kg) + abacavir 300 mg 1 tablet in the morning and in the evening + Lopinavir 200 mg/Ritonavir 50 mg 2 tablets morning and evening
1846967|NCT00928187|Drug|emtricitabine/tenofovir + darunavir + ritonavir (Second line strategy under evaluation)|Emtricitabine 200 mg/tenofovir 300 mg 1 tablet/day with food + darunavir 400 mg 2 tablets + ritonavir 100 mg 1 capsule, in a single dose with food
1846968|NCT00928200|Drug|Erwinase|The dose of Erwinase will be assigned at study entry. Erwinase will be administered as a 2-hour intravenous infusion. A total of 10 doses will be given on a Monday-Wednesday-Friday schedule.
1846969|NCT00928200|Drug|Vincristine|1.5 mg/m2/dose IV push on days 1, 8, 15 and 22
1846970|NCT00928200|Drug|Dexamethasone|10 mg/m2/day divided BID. Give by mouth days 1-14
1846971|NCT00928200|Drug|Doxorubicin|60 mg/m2/day IV over 15 minutes on day 1
1846972|NCT00928200|Drug|Cytarabine|Given Intrathecally at the dose defined by age on day 1. 30 mg for age 1-1.99 50 mg for age 2-2.99 70 mg for age 3 and older
1846973|NCT00928200|Drug|Methotrexate|Given Intrathecally to all patients with CNS negative disease at study entry. Dose defined by age. Given on day 15 8mg for age 1-1.99 10 mg for age 2-2.99 12 mg for age 3-8.99 15 mg for age 9 and older
1846974|NCT00928200|Drug|Triple Intrathecal Therapy|Methotrexate, Cytarabine and Hydrocortisone given Intrathecally on day 8, 15 and 22 for patients who are CNS positive at study entry. Doses determined by age.
1846975|NCT00928213|Drug|Progesterone|40 units daily admission
1846976|NCT00928213|Drug|Low molecular weight Heparin|40-80 mg/day
1846977|NCT00928213|Drug|No Drug|no treatment
1846978|NCT00928226|Procedure|Fractionated Stereotactic Radiosurgery|Standard of care
1846979|NCT00928226|Device|Linear accelerator|Standard of care
1846980|NCT00928239|Procedure|laparoscopic sacropexy with mid vaginal attachment|"supracervical hysterectomy for uterine prolapse
exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior
dissection up to ventrolateral part of the levator ani muscle
Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder
Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment
suturing of posterior mesh caudally to levator ani muscle and proximally 4cm from the apex of the vagina or cervical stump
placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex
suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
1846981|NCT00928239|Procedure|laparoscopic sacropexy with caudal vaginal attachment|"supracervical hysterectomy for uterine prolapse
exposure of the anterior longitudinal ligament of sacrum and recto-vaginal septum posterior
dissection up to ventrolateral part of the levator ani muscle
Anterior dissection of vesico-vaginal fascia up to the lower third of the vagina below the trigonum of bladder
Two separate meshes, Gynemesh® (Johnson&Johnson) a polypropylene mesh, for anterior and posterior compartment
suturing of posterior mesh caudally to the levator ani muscle and proximally at caudal part of the vagina or cervical stump
placement of anterior mesh underneath bladder and attachment to caudal part of the vagina and the apex
suturing together anterior and posterior mesh are sutured together at level of vaginal apex and attachment to longitudinal sacral ligament at level of S2"
1846982|NCT00928252|Drug|IV fluorine-18 labeled methylcholine before PET/CT|Intervention at pre-treatment, and at two timepoints post treatment intiation.
1846983|NCT00928265|Device|Endovascular treatment of intracranial aneurysm.|"Neuroform stent is used in conjunction of occlusives devices such as coils. Neuroform Stent allows the treatment of wide neck aneurysm with embolic coils. Put in front of the wide neck, it keeps the coils into the aneurysm and avoids them to fall in the parent artery, preventing coil protrusion.
Accomplishes this by providing coil support at the neck of the aneurysm"
1846984|NCT00928278|Drug|Treatment A|Inhaled, 300/150, single dose
1846985|NCT00928278|Drug|Treatment B|Inhaled, 300/150, single dose
1846986|NCT00928278|Drug|Treatment C|Inhaled, 300/150, single dose + oral activated charcoal block
1846987|NCT00928278|Drug|Treatment D|Inhaled, 300/150, single dose + oral activated charcoal block
1846988|NCT00928291|Other|procalcitonin|plasma PCT measurement
1846989|NCT00928291|Drug|antibiotic therapy|antibiotic therapy use
1846990|NCT00928304|Drug|Florbetaben (BAY94-9172)|300 megabecquerels (MBq) as single IV injection of 2 to 10 mL
1846991|NCT00928317|Drug|ART621|3.0mg/kg s.c.
1846992|NCT00928317|Drug|ART621|1.5mg/kg s.c.
1846993|NCT00928317|Drug|ART621|0.75mg/kg s.c.
1846994|NCT00928317|Drug|Placebo|Placebo s.c.
1846995|NCT00928330|Drug|GDC-0941|Oral repeating dose
1846996|NCT00928330|Drug|Trastuzumab|Intravenous repeating dose
1846997|NCT00928330|Drug|trastuzumab-MCC-DM1|Intravenous repeating dose
1846998|NCT00928343|Drug|GLPG0187|Single ascending subcutaneous doses (subcutaneous solution), and single oral dose (oral solution)
1846999|NCT00928343|Drug|Placebo|Matching subcutaneous or oral placebo
1847000|NCT00928356|Procedure|Hybrid CABG/PCI|Same sitting hybrid, robotic CABG/PCI
1847001|NCT00928356|Procedure|Off Pump CABG|Standard of Care Off Pump CABG
1847002|NCT00928395|Device|Urgent PC|The Urgent PC Neuromodulation System is a minimally invasive neuromodulation system designed to deliver retrograde access to the sacral nerve through percutaneous electrical stimulation of the tibial nerve. The method of treatment is referred to as Percutaneous Tibial Nerve Stimulation (PTNS).
1847003|NCT00928408|Drug|Cinacalcet|
1847004|NCT00928421|Drug|Polidocanol Endovenous Microfoam 0.125%|Polidocanol Endovenous Microfoam 0.125%, single dose
1847005|NCT00928434|Drug|Degarelix|Degarelix treatment provided for first seven months (one starting dose and six maintenance doses) followed by no treatment for next seven months period.
1847006|NCT00928434|Drug|Degarelix|Degarelix treatment provided for complete study period (one starting dose and 13 maintenance doses).
1847007|NCT00928434|Drug|Leuprolide|Leuprolide treatment for complete study period (one starting dose and 5 maintenance doses of 3-month depot each)
1847008|NCT00928447|Drug|rHuPH20|ID syringe push bolus injection of either rHuPH20 or placebo control. Each injection will be administered once daily for 5 days.
1847009|NCT00928460|Procedure|Removal of preoperative electrocardiogram|A new preanesthesia evaluation strategy without routine ECG. Initially, all patients in the participating centers are assessed following the regular strategy (with routine ECG). The new strategy (without routine ECG) is rolled out to the participating hospitals sequentially. At the end of the trial all participating centers will use the new preoperative strategy.
1847061|NCT00928772|Other|NO SEDATION WITH SHAM CRANIAL ELECTROSTIMULATION AND PLACEBO VERSED|NO ACTIVE SEDATION, ONLY SHAM ELECTRODES AND NORMAL SALINE SIMULATING MIDAZOLAM.
1847062|NCT00928785|Biological|REPEVAX|1 dose of 0.5 mL at Day 0
1847010|NCT00928473|Behavioral|Weightloss treatment program|The obese children will start a treatment for obesity in the Children's Obesity Clinic. This treatment includes lifestyle counseling, objective examination, weight-controls, visiting a psychologist, visiting a dietician and blood samples, DXA-scan, eventually MRI.
1847011|NCT00928486|Drug|Lenalidomide|Lenalidomide 25mg PO for (days 1 - 21) of a 28-day cycle
1847012|NCT00928486|Drug|Dexamethasone|Dexamethasone 40 mg by mouth (PO) daily (QD) on days 1-4, 9-12 and 17-20 of each 28 day cycle
1847014|NCT00928512|Drug|Secukinmab|Secukinumab was supplied as a 150mg lyophiized cake in individual glass vials each. The study drug dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
1847015|NCT00928512|Drug|Placebo|Secukinumab placebo was supplied as a 150mg lyophiized cake in individual glass vials each. The placebo dose levels were 25mg, 75mg, 150mg and 300mg and was administered subcutaneously.
1847016|NCT00928525|Drug|Imatinib Mesylate|800 mg p.o./day (400 mg b.i.d.) for a maximum of 24 months
1847017|NCT00928538|Other|Enhanced NFP Care|Usual NFP care plus the enhanced care that includes contraceptive administration and distribution during nurse home visits. Participants will have a choice of combined hormonal contraception (oral, patches or vaginal rings)or progestin-only contraception (oral or depomedroxyprogesterone acetate injections.
1847018|NCT00928551|Drug|vabicaserin|
1847019|NCT00928564|Drug|Pudendal block|8ml of 0.5% bupivicaine, 1ml of 10mg/ml triamcinolone, 1ml of 8.4% sodium bicarbonate for a total volume of 10ml. Five ml will be used at each block site.
1847020|NCT00928564|Drug|Placebo|5ml of saline at each block site.
1847021|NCT00928590|Drug|Travoprost/Timolol Maleate Fixed Combination solution|
1847022|NCT00928603|Procedure|Focal Cryoablation|Cryotherapy is administered via the perineum under ultrasound guidance by third-generation 17-gauge cryoprobes using gas and thermal couples. Under transrectal ultrasound guidance cryoprobes are placed approximately 1 cm apart and within 5 mm of the capsule on the side of tumor. The extent of freezing was limited to the area or lobe of the gland with histologically proved tumor.
1847023|NCT00928616|Dietary Supplement|margarine + plant sterol esters|margarine supplemented with plant sterol esters (3g/day) over the time period of 4 weeks
1847024|NCT00928616|Dietary Supplement|margarine (placebo)|non-sterol ester supplemented margarine
1847025|NCT00928629|Procedure|Ankle-brachial index (ABI) Screening Test|Patients will undergo an ABI measurement
1847026|NCT00928642|Drug|imatinib mesylate by mouth|imatinib mesylate - 400mg orally, daily on Days 1-5 and 8-12 of a 21 day cycle.
1847027|NCT00928642|Drug|Gemcitabine Intravenous|Gemcitabine - 1000 mg/m2 IV on Day 3 and Day 10 of a 21 day cycle
1847028|NCT00928655|Drug|acetazolamide|acetazolamide 250mg 1/0/2
1847029|NCT00928655|Procedure|nocturnal continuous positive airway pressure|continuous positive airway pressure
1847030|NCT00928655|Drug|placebo|placebo capsules
1847031|NCT00928668|Drug|Placebo|Placebo device for comparison
1847032|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
1847033|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
1847034|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
1847035|NCT00928668|Drug|Olodaterol (BI1744CL)|Olodaterol comparison of low, medium low, medium high and high doses
1847036|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
1847037|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
1847038|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
1847039|NCT00928681|Biological|Single dose-group A|PF-00547659, single iv dose
1847040|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
1847041|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
1847042|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
1847043|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
1847044|NCT00928681|Biological|Single dose-group A|PF-00547659, single dose
1847045|NCT00928681|Biological|Multiple dose-Group B|PF-00547659, multiple dose
1847046|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
1847047|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
1847048|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
1847049|NCT00928681|Biological|Multiple dose- Group B|PF-00547659, multiple dose
1847050|NCT00928681|Biological|Multiple dose-Group B|PF-00547659, multiple dose
1847051|NCT00928694|Drug|fenofibrate (U.S. formulation)|Single dose of 160 mg fenofibrate U.S. formulation (Tricor®) in one of two treatment periods.
1847052|NCT00928694|Drug|fenofibrate (UK formulation)|Single dose of 160 mg fenofibrate UK formulation (Supralip®) in one of two treatment periods.
1847053|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea|50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
1847054|NCT00928707|Drug|GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea|50 mg b.i.d. of GIVINOSTAT + MTD HU monotherapy
1847055|NCT00928720|Device|CES device|Participants will use the device for 60 continuous minutes each day for 8 weeks. The CES device will be preset at the factory to provide a maximum of 60 minutes of modified square-wave biphasic stimulation at 0.5 Hz and 100µA, the lowest setting that has been used in previous studies with patients with FM.
1847056|NCT00928720|Device|sham device|The sham device will look the same as the active CES (Alpha-Stim); however, no electrical stimulation will be present in the sham device.
1847057|NCT00928733|Device|Gastroduodenoscopy- Intraduodenal intubation|20 g ethanol diluted up to 10% in tap water
1847058|NCT00928746|Device|Ipratropium bromide|
1847059|NCT00928772|Device|CRANIAL ELECTROTHERAPY (Alpha Stim) + SHAM MIDAZOLAM|APPLYING OF ELECTRODES ON THE EAR LOBES AND TEMPLES WHICH ARE SENDING AN ACTIVE MICROCURRENT THROUGH THE MIDBRAIN PRODUCING SEDATION WITHOUT PHARMACOLOGICAL AGENTS AND GIVING NORMAL SALINE AS A SHAM DRUG SEDATION
1847060|NCT00928772|Drug|MIDAZOLAM + SHAM ELECTRODES SIMULATING CRANIAL ELECTROTHERAPY|CONVENTIONAL METHOD OF PERIOPERATIVE SEDATION
1847063|NCT00928785|Biological|Monovalent Tetanus vaccine|1 dose of 0.5 mL at Day 0
1847064|NCT00928798|Drug|Rapamycin|Application of rapamycin 1 mg/ml oral solution to one predefined skin area on one facial half, twice daily 0,25 ml, during 6 months. The other facial half will be similarly treated with a placebo.
1847065|NCT00928798|Drug|placebo|Application of placebo to one predefined skin area on one facial half, during 6 months. The other facial half will be similarly treated with rapamycin 1 mg/ml oral solution
1847068|NCT00928824|Dietary Supplement|traditional Japanese diet|10 days of nitrate rich diet (Japanese traditional). After that switch to nitrate low diet for 10 days (European foods). Study nitrate/nitrite in blood, saliva and blood pressure 3 times in each person (10 min each time). A list of Nitrate rich foods are provided.
1847069|NCT00928837|Dietary Supplement|Flavocoxid 500 mg|flavonoid mixture
1847070|NCT00928837|Drug|Naproxen|non-steroidal anti-inflammatory drug
1847071|NCT00928837|Other|Placebo|Placebo
1847072|NCT00928837|Other|flavocoxid 250 mg|Medical food product
1847073|NCT00928850|Procedure|radical prostatectomy with urethral irrigation but no fascial suturing, QOL forms|"Cancer cells can spill during surgery and this can cause cancer to return (recur). Some surgeons believe that irrigating could help stop spilling of cancer cells. Irrigating means washing the surgical area with sterile water and sucking the water back up through a tube. As a result, surgeons vary as to how they irrigate. In this study, we will examine irrigation of the urethra. This is the part of the body that carries urine from the bladder to the penis. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
1847074|NCT00928850|Procedure|radical prostatectomy with fascial suturing but no urethral irrigation, QOL forms|"Surgeons believe that what happens to the urethra can affect the risk of incontinence. This is when a patient cannot control urine, and drips or leaks urine. One idea is that additional stitches (sutures) to the connective tissue (fascia) could be helpful, but this is not known for sure. Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery"
1847075|NCT00928850|Procedure|radical prostatectomy with both urethral irrigation and fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
1847076|NCT00928850|Procedure|radical prostatectomy with neither urethral irrigation nor fascial suturing, QOL forms|Quality of life are assessed for clinical evaluation approximately 3, 6, 9, 12, 18, 24, 36 and 48 months after surgery
1847077|NCT00928863|Other|implementation aids|testing a taylor made strategy for implementation NVOG guideline and MOET instruction in 3 hospitals
1847080|NCT00928889|Drug|Nateglinide 120 mg|Nateglinide 120 mg was supplied as tablets.
1847081|NCT00928889|Drug|Acarbose 50 mg|Acarbose 50 mg was supplied as tablets.
1847082|NCT00928902|Drug|low-dose IL-2|low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
1847083|NCT00928902|Biological|melanoma vaccine|six melanoma vaccines given over a 6-week period
1847084|NCT00928915|Drug|Prothrombin complex concentrate (PCC); fresh frozen plasma (FFP)|intravenous, repeated until INR ≤ 1.2
1847085|NCT00928928|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
1847086|NCT00928928|Procedure|laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
1847087|NCT00928941|Behavioral|cognitive training|A cognitive training program (Posit Science) or an active control (video game) will be implemented for at least 3-4 hours a week for 40 training units/hours.
1847088|NCT00928941|Behavioral|video game|An active control condition (computer game without increasing difficulty) will be implemented for at least 3-4 hours a week for 40 hours.
1847089|NCT00928954|Drug|gabapentin|increasing to 1200 mg/day
1847090|NCT00928954|Drug|memantine|increasing to 40 mg/day
1847091|NCT00928967|Drug|Interferon beta-1b, (Betaseron BAY86-5046)|The cohort included is described in section 8.5 (inclusion criteria)
1847092|NCT00928980|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness Based Cognitive Therapy is an 8-week during group intervention encompassing meditation practice and cognitive therapy techniques.
1847093|NCT00928980|Drug|Optimal Medical Care|Therapeutic dose of antidepressant medication
1847094|NCT00929006|Drug|Micronized progesterone suspension|Micronized progesterone 0.8 mg/kg at 0700, 1500, 2300 and 0700 h. Progesterone is a natural hormone.
1847095|NCT00929006|Drug|Placebo|Placebo contains only inert ingredients and is not expected to exert any direct physiological effects
1847096|NCT00929019|Biological|autologous dendritic cells electroporated with mRNA|Autologous mature monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
1847097|NCT00929032|Radiation|Nanocoll®|To determine reticuloendothelial system (RES) phagocytosis activity and liver phagocytic function respectively we will measure plasma clearance of 99mTc labelled micro-aggregated human albumin without any imaging studies.
1847098|NCT00929045|Drug|Growth Hormone Replacement|
1847099|NCT00929058|Drug|Bevacizumab|Intra-arterial infusion during 6 minutes
1847100|NCT00929071|Device|Evolence|Injectable collagen
1847101|NCT00929071|Device|Lidocaine|admix anesthetic
1847102|NCT00929071|Drug|topical anesthetic|
1847103|NCT00929084|Other|The Survivor Stories Tablet|The Survivor Stories Tablet is a tablet computer where participants can browse an archive of 1-3 minute videotaped survivor stories told by African American Breast Cancer Survivors. Stories contain five main topics: coping, relationships, experiences with the health care system, follow-up care, and quality of life (QOL) living with breast cancer.
1847106|NCT00929110|Drug|Glycopyrronium bromide|Glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
1847107|NCT00929110|Drug|Placebo to glycopyrronium bromide|Placebo to glycopyrronium bromide was supplied in powder-filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
1847108|NCT00929110|Drug|Tiotropium|Tiotropium was supplied in powder-filled capsules together with the Handihaler® device.
1847109|NCT00929123|Procedure|neural mobilization|manual therapy technique known to directly stress the median nerve
1847110|NCT00929123|Procedure|sham neural mobilization|sham technique mimicking the neural mobilization which is not specific to the median nerve
1847111|NCT00929123|Other|healthy controls|People without carpal tunnel syndrome for comparison
1847112|NCT00929136|Biological|USP endotoxin|Continuous intra-arterial infusion
1847113|NCT00929162|Drug|ZD4054 Zibotentan|10 mg oral tablets once daily
1847114|NCT00929162|Drug|Paclitaxel|175mg/m2 IV on day 1 every 3 weeks
1847115|NCT00929162|Drug|Carboplatin|Carboplatin AUC of 5.0 IV on day 1 every 3 weeks
1847116|NCT00929162|Drug|Placebo|matching placebo for ZD4054 10 mg
1847117|NCT00929175|Device|active CPAP|auto-PAP with pressure between 6 and 12 cm H2O or sham CPAP will be administered to randomized patients
1847118|NCT00929175|Device|sham-CPAP|The sham-CPAP was the same equipment used for active CPAP (Respironics Remstar-Auto, Murraysville, PA) fixed in the lowest pressure (4cmH2) and modified as recommended by Farré et al. The differences between the two were undetectable except for the pressure generated in the facial mask in the sham-CPAP that was no greater than 1cm H2O.
1847119|NCT00929188|Drug|JNJ-42160443|Type=1, unit=mg, number=10, form=solution for injection , route=subcutaneous use. SC injection (10mg/ml) once every 4 weeks for up to 52 weeks
1847120|NCT00929188|Drug|Placebo|Form=solution for injection, route=subcutaneous use. SC injection (0.9 mL matching placebo) once on Day 1
1847121|NCT00929201|Drug|Sitagliptin phosphate/metformin hydrochloride FDC|Single dose sitagliptin/metformin 50/500 mg FDC tablet after consumption of a high-fat meal in one of two treatment periods.
1847122|NCT00929201|Drug|Sitagliptin phosphate|Single dose sitagliptin 50 mg tablet after consumption of a high-fat meal in one of two treatment periods.
1847123|NCT00929201|Drug|Metformin hydrochloride|Single dose metformin 500 mg tablet after consumption of a high-fat meal in one of two treatment periods.
1847124|NCT00929214|Drug|Standard Therapy|"Chemotherapy and/or Endocrine Therapy:
For 3 - 9 months, all patients will receive systemic chemotherapy agents appropriate for the tumor characteristics and patient's prior treatment history, and may also be placed on endocrine therapy as determined by the treating medical oncologist."
1847125|NCT00929214|Procedure|Local Therapy|"Surgery and/or Radiation Therapy
With no more than 3 bone metastases, local treatments including high-dose radiation therapy and/or surgery will be given. Radiation therapy involves daily treatments during weekdays that may last 5 to 7 weeks in a row. Each daily treatment may last 30 - 40 minutes. Surgery, including recovery, may last 4 to 6 weeks."
1847126|NCT00929240|Drug|bevacizumab [Avastin]|15 mg/kg iv on day 1 of each 3 week cycle (maintenance phase)
1847127|NCT00929240|Drug|capecitabine [Xeloda]|1000 mg/m2 po bid on days 1-14 of each 3 week cycle (maintenance phase)
1847128|NCT00929253|Drug|Suboxone|Dosage Form: Oral Tablet; Dosage 6, 12, or 18 mg; Frequency; Daily; Duration 12 weeks
1847129|NCT00929253|Behavioral|CRA|Computer-delivered Community Reinforcement Approach
1847130|NCT00929253|Behavioral|Therapy|Therapist-delivered therapy
1847131|NCT00929253|Behavioral|CM|Contingency management (vouchers) for providing a drug negative urine sample.
1847132|NCT00929266|Biological|intravenous injection of labeled cRBC|This step will take place within 2 months after stem cell collection. Direct intravenous injection of labeled cRBC in a volume of 1 mL, in a room reserved for the administration of radioactive drugs, situated in the nuclear medicine clinic and adjacent to the preparation laboratory, for regulatory reasons.
1847133|NCT00929279|Drug|bolus+infusion|Abciximab bolus of 0.25mg /Kg, followed by a 12-h infusion 0.125 microg/Kg/min (to a maximum of 10 µg/min) and immediate clopidogrel at 300 mg loading regimen
1847134|NCT00929279|Drug|abciximab bolus only regimen|Abciximab bolus of 0.25mg /Kg followed by placebo infusion and immediate clopidogrel at 600 mg loading dose
1847135|NCT00929292|Other|Modilac Dahlia 1|Infant formula used for non breastfed children with colic
1847136|NCT00929292|Other|Modilac 1|Infant formula used for non breastfed children
1847137|NCT00929305|Device|Erchonia PL2000|The Erchonia PL2000 Laser emits 1 mW of red (635nm wavelength) light via an electric diode energy source. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
1847138|NCT00929305|Device|Placebo laser|Inactive laser light
1847139|NCT00929318|Procedure|blood sampling|
1847140|NCT00929318|Procedure|blood sampling|
1847141|NCT00929331|Biological|Fluviral®|Intramuscular injection, one dose
1847142|NCT00929344|Drug|Pregabalin|Two 150 mg capsules, 150 mg/am and 150 mg/pm (Total dose, 300mg/d), 12 week duration. Dose may be increased up to 600 mg/d or reduced to 150 mg/d based on subject response and tolerability.
1847143|NCT00929344|Drug|Duloxetine|40 mg capsule, Once daily/am, 12 week duration, placebo capsule administered pm. Dose may be increased up to 60 mg/d or reduced to 20 mg/d based on subject response and tolerability.
1847144|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
1847145|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
1847146|NCT00929344|Drug|Placebo|Matched placebo capsule administered 1 capsule am and 1 capsule pm for 12 week duration.
1847147|NCT00929344|Behavioral|Standardized behavioral therapy|Standardized behavioral therapy 1 time per week for 12 week duration.
1847148|NCT00929357|Drug|DMARDs or Biologics|
1847149|NCT00929370|Drug|Glycine Transporter-1 inhibitor|GSK1018921 is a potent and selective inhibitor of the glycine transporter-1 (GlyT-1).
1847225|NCT00929578|Drug|Fluphenazine|Intralesional injection of Fluphenazine
1847226|NCT00929578|Drug|Placebo|Intralesional injection of placebo
1847227|NCT00929591|Drug|cyclophosphamide|
1847228|NCT00929591|Drug|doxorubicin hydrochloride|
1847229|NCT00929591|Drug|endocrine therapy|
1847150|NCT00929383|Device|Wingspan Stent System with Gateway PTA Balloon Catheter|"The Wingspan Stent System is used in conjunction with Gateway PTA Balloon Catheter to improve cerebral artery lumen diameter in patients with intracranial atherosclerotic disease.
The Gateway Balloon Catheter is indicated for balloon dilation of the stenotic portion of intracranial arteries prior to stenting the artery for the purpose of improving intracranial perfusion."
1847151|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
1847152|NCT00929396|Biological|50 microg. antigen + adjuvant (500 nmol KLK + 20 nmol ODN1a)|o,5 mL suspension for injection x 2 with 2 months interval
1847153|NCT00929409|Drug|Ferric carboxymaltose|Intravenous infusion of Ferric carboxymaltose in a dose calculated to meet the individual patient's requirements following the Ganzoni formula
1847154|NCT00929409|Drug|Ferrous sulfate tablets|Standard tablets containing 100 mg ferrous sulfate, 1 tablet two times daily
1847155|NCT00929461|Drug|Lipovenoes® 10% and Omegaven®,|All patients received TPN for 5 days postoperatively, according to a standard protocol: 3 g/kg BW glucose (5% Dextrose in Ringer's Lactate, Biosel, Istanbul), 1.2 g/kg BW amino acids (Aminosteril 10%, Fresenius-Kabi) and 0.8 g/kg BW omega-6 fatty acids (Lipovenoes® 10%, Fresenius-Kabi) were provided to both groups through an indwelling central venous catheter. In the omega-3 group, the lipid content of TPN was replaced partially by omega-3 fatty acids (Omegaven®, Fresenius-Kabi) up to 0.2 g/kg BW per day.
1847156|NCT00923273|Drug|FDG-PET|PET CT will be performed at baseline and after two cycles of treatment.
1847157|NCT00923273|Drug|Pemetrexed|
1847158|NCT00923273|Drug|Sirolimus|
1847159|NCT00923273|Dietary Supplement|Vitamin B12|1000 micrograms intramuscularly every 63 days administered the preceding first dose of pemetrexed
1847160|NCT00923273|Dietary Supplement|Folic acid tablets|1 mg dose every 63 days administered during the week preceding first dose of pemetrexed and will be continued for 21 days following last dose of pemetrexed.
1847161|NCT00923273|Drug|Dexamethasone tablets|4 mg dose twice daily the day before, the day of, and the day after pemetrexed.
1847162|NCT00923299|Biological|cetuximab|
1847163|NCT00923299|Biological|trastuzumab|
1847164|NCT00923312|Biological|CV9201|CV9201 is a vaccine consisting of five drug product components. Treatment will be administered on 5 timepoints.
1847165|NCT00923338|Device|Surgisis Biodesign (Vesico-vaginal fistula plug)|Vesico-vaginal fistula plug
1847175|NCT00923390|Genetic|2G-1 TCR Retroviral Vector-Transduced lyn|
1847176|NCT00923390|Drug|Aldesleukin|
1847177|NCT00923390|Drug|Cyclophosphamide|
1847178|NCT00923390|Drug|Fludarabine|
1847179|NCT00923390|Drug|(PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte|
1847180|NCT00923403|Dietary Supplement|plant sterol enriched soymilk|plant sterol enriched soymilk
1847181|NCT00923403|Dietary Supplement|control dairy milk|control dairy milk
1847182|NCT00923429|Procedure|Stay-active care|No other treatment than the stay-active care
1847183|NCT00923429|Procedure|Stay-active care+stretching|Stay-active care and muscle stretching at home and during physiotherapist appointments
1847184|NCT00923429|Procedure|Stay-active+stretching+manual therapy|Manual therapy in addition to stay-active care and stretching given during GP or physiotherapist appointments and matching home exercises
1847185|NCT00923429|Procedure|Stay-active+stretching+manual therapy+steroid injections|Manual therapy including steroid injection when indicated in addition to stay-active care and stretching during GP appointments (injections) and during GP or physiotherapist appointments (remaining treatment modalities)
1847186|NCT00923481|Drug|Fostamatinib disodium|200 mg BID was the administered dose for the initial part of the study and then a phase I dose escalation was added with 100 mg as the starting dose.
1847187|NCT00923494|Drug|20 ml of ropivacaine 0.5%|Patient will receive 20 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
1847188|NCT00923494|Drug|30 ml of ropivacaine 0.5%|Patient will receive 30 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
1847189|NCT00923494|Drug|40 ml of ropivacaine 0.5%|Patient will receive 40 ml of ropivacaine 0.5% for their ultrasound guided supraclavicular block.
1847191|NCT00923533|Drug|Fimasartan|Fimasartan (7day) Fimasartan + Hydrochlorothiazide (7day)
1847192|NCT00923533|Drug|Hydrochlorothiazide|Hydrochlorothiazide (7day) Fimasartan + Hydrochlorothiazide (7day)
1847230|NCT00929591|Drug|endocrine-modulating drug therapy|
1847231|NCT00929591|Drug|fluorouracil|
1847232|NCT00929591|Drug|tamoxifen citrate|
1847233|NCT00929591|Radiation|brachytherapy|
1847234|NCT00929591|Radiation|low-LET electron therapy|
1847235|NCT00929591|Radiation|low-LET photon therapy|
1847236|NCT00929591|Radiation|radiation therapy|
1847195|NCT00923572|Drug|EE30/DRSP (Yasmin, BAY86-5131)|Patients in daily life clinical practice treatment receiving Yasmin according to indication on the label.
1847196|NCT00923598|Drug|0.1% and 0.4% perineural ropivicaine|Patients will be randomized to one of two groups: Ropivicaine 0.1% infusion on the right leg and Ropivicaine 0.4% infusion on the left leg, or Ropivicaine 0.4% infusion on the right leg and Ropiviciane 0.1% infusion on the left leg for treatment of postoperative pain following bilateral TKA. Both groups will receive the same total dose of medication and will have the infusion for the two days following surgery.
1847197|NCT00923611|Drug|Fimasartan|
1847200|NCT00923637|Drug|Pemetrexed/Oxaliplatin|In the first cycle, patients received Pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) on day 1 of a 21-day cycle. From 2nd cycle, patients received pemetrexed 500 mg/m2 (i.v. infusion over 10 minutes) then oxaliplatin 120 mg/m2 (i.v. infusion over 120 minutes) on day 1 of a 21-day cycle. Study drug administration is to begin on d14 to d28 after R0 resection of the tumor. A total of three cycles is intended for patients with stage IB NSCLC, and four cycles for II-IIIA NSCLC, respectively.
1847202|NCT00923676|Drug|fenofibrate|pill 145 mg, 145 mg/day, for 12 months
1847203|NCT00923676|Drug|Rosuvastatin|pills of 10 mg, 10 mg/day, 12 months
1847204|NCT00923676|Drug|fenofibrate + rosuvastatin|fenofibrate 145 mg/day + rosuvastatin 10 mg/day for 12 months
1847205|NCT00923702|Biological|Prophylactic quadrivalent HPV vaccine Merck (Gardasil®)|The participants will be randomly allocated in equal numbers to receive either two or three doses of the vaccine. Each injection contains 20 microgram type 6, 40 microgram type 11, 40 microgram type 16, and 20 microgram type 18. Girls in the two-dose group will receive the vaccine at Day 1 and Day 180, girls in the three-dose group will receive the vaccine at Day 1, Day 60, and Day 180.
1847206|NCT00923715|Drug|Insulin|Dose will be as per usual home regimen.
1847207|NCT00923715|Drug|Insulin and Exenatide|Exenatide 1.25 up to 2.5 mcg will be given before breakfast and before supper
1847208|NCT00923715|Drug|Insulin and Pramlintide|Pramlintide 15 to 45 mcg will be given before breakfast and supper
1847209|NCT00923728|Drug|AVN944|
1847210|NCT00923741|Drug|Talactoferrin|
1847211|NCT00923741|Procedure|Apheresis|
1847212|NCT00923793|Device|Titanium implant (CranioConstruct™)|One to three weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Titanium implant is ordered.
1847213|NCT00923793|Device|Hydroxylapatite (CustomBone)|Six to eight weeks before operation the skull defect is well defined using Computer tomography. Based on these results the Hydroxylapatite implant is ordered.
1847214|NCT00929474|Device|QuickOpt - SJM CRT (Group 1)|The patient's device is programmed to sequential Bi-V pacing mode with paced/sensed AV and V-V delays optimized using QuickOpt. For Group 1 patients, optimization using QuickOpt is performed at enrollment, 3, 6, 9 and 12 month visits.
1847215|NCT00929474|Device|Control - SJM CRT (Group 2)|The patient's device is programmed to either simultaneous or sequential Bi-V pacing mode as per physician's discretion. The paced/sensed AV and V-V delays could be programmed empirically or optimized using any non-intracardiac electrogram (IEGM) based method as per sites standard of care. However, the Group 2 patients can be optimized only once within the first 4 weeks post CRT replacement. Any paced/sensed AV and V-V delay optimizations performed after 4 weeks post CRT replacement in Group 2 patients will be considered a protocol deviation.
1847216|NCT00929487|Device|Contact lens multi-purpose solution|Lens care solutions CE-marked for intended use. A fresh pair of contact lenses was soaked overnight in the test contact lens solution and a pre-cycled lens case prior to study visit, then worn for two hours on the day of the study visit. Up to four solutions were evaluated in randomized order with the same brand of contact lenses, and a minimum of 12 hours of no lens wear separated each wear period.
1847217|NCT00929487|Other|Saline/blister pack solution|A fresh pair of contact lenses was soaked overnight in saline prior to study visit or was inserted directly from the blister pack, then worn for two hours on the day of the study visit.
1847218|NCT00929487|Device|Contact lenses|CE-marked silicone hydrogel contact lenses soaked overnight for at least 10 hours prior to the study visit, then worn for two hours on the day of the study visit. A fresh pair of the same brand of contact lenses was used for each overnight soak (ie, 4 solutions plus saline/blister pack solution), and a minimum of 12 hours separated each wear period.
1847219|NCT00929500|Behavioral|MAST program|MAST program: twice a week for 4 months
1847220|NCT00929526|Procedure|Liquid-based cytology (LBC) sampling|LBC samples will be collected at Months 36 and 48 for cytology and HPV DNA testing (by PCR)
1847221|NCT00929526|Procedure|Blood sampling|Blood samples will be collected at Months 36 and 48 for antibody determination
1847222|NCT00929539|Drug|JTT-130|Tablets
1847223|NCT00929539|Drug|JTT-130 Placebo|Tablets
1847224|NCT00929552|Dietary Supplement|Dietary oils (fish, vegetable oil)|6g pr day.
1847237|NCT00929604|Other|HIV-1 viral load testing|Plasma HIV-1 RNA viral load testing performed at ART initiation (baseline) and at 3, 6, 12, 18, 24, 30, and 36 months thereafter. Routine viral load results are provided to clinicians for the management of the participant's HIV treatment.
1847238|NCT00929617|Behavioral|Experimental 1: exercise with 2 counseling types|Patients will participate in 12 individual exercise sessions with an exercise specialist which will include stretching exercises and aerobic treadmill walking; plus attend 6 discussion group sessions with a trained facilitator; plus 3 face-to-face, individual counseling sessions with an exercise specialist
1847239|NCT00929617|Other|Usual Care - written materials|Patients will receive written materials about exercise for cancer survivors
1847240|NCT00929630|Procedure|transsphincteric Seton positioning|A cutting seton is applied into the fistula tract
1847241|NCT00929630|Procedure|glue (Tissucol) treatment|After preparation of the fistula, a quantity of biological glue (Tissucol) is injected into the fistula tract
1847242|NCT00929630|Procedure|Fistula closing with biological glue|After cleaning and disinfection of the fistula tract, abot 1-2 ml of Tissucol (biological Glue) is inserted into the fistula tract to close it
1847243|NCT00929630|Procedure|Seton positioning into the fistula tract|Under spinal anesthesia a Seton is positioned into the fistula tract.
1847244|NCT00929643|Other|no intervention|success of the initial empiric treatment
1847245|NCT00929656|Procedure|Real rTMS|rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
1847246|NCT00929656|Procedure|Sham rTMS|sham rTMS application to lesioned hemisphere; 10 Hz, 1000 pulses
1847247|NCT00929656|Procedure|Unimanual paretic UE Training|UE exercise for 4 hours (two hours 1:1 with therapist and two hours independent at home) for 16 sessions (4 sessions/week for 4 weeks)
1847249|NCT00929682|Drug|Randomization between two referenced treatments|"Levobupivacaine 0.568 mg.mL-1 and sufentanil 0.45 g.mL-1, 20 mL epidurally for induction, then by a patient-controlled regimen with 5-mL self-administered boli in addition to a continuous infusion of 5 mL.hr-1.
Same protocol, with levobupivacaine 1.136 mg.mL-1 and sufentanil 0.45 g.mL-1."
1847250|NCT00929695|Drug|prednisone|immunosuppressive drug
1847251|NCT00929695|Drug|methylprednisolone|immunosuppressive drug
1847252|NCT00929695|Other|questionnaire administration|Ancillary studies
1847253|NCT00929708|Drug|AZD3199|Dry powder for inhalation, o.d., 4 weeks
1847254|NCT00929708|Drug|formoterol|Dry powder for inhalation, b.i.d., 4 weeks
1847255|NCT00929708|Drug|Placebo|Dry powder for inhalation, b.i.d., 4 weeks
1847256|NCT00929721|Procedure|Blood draw|culture for Streptococcus pneumoniae Frequency-1
1847257|NCT00929721|Procedure|Chest X-ray|image of the lungs to assess changes consistent with pneumonia Frequency-1
1847258|NCT00929721|Procedure|urine specimen|assay for the presence of Streptococcus pneumoniae Binax and UAD
1847259|NCT00929721|Procedure|Nasopharyngeal swab|culture for Streptococcus pneumoniae Frequency-1
1847260|NCT00929721|Procedure|sputum|culture for Streptococcus pneumoniae Frequency-1
1847261|NCT00929734|Drug|Rosuvastatin|10mg tablets, once daily in three months
1847262|NCT00929734|Drug|Placebo|1 tablet, once daily in three months
1847263|NCT00929747|Device|Toric|Unilateral implantation of the AcrySof IQ Toric IOL
1847264|NCT00929747|Procedure|Limbal Relaxing Incision|Unilateral implantation of a AcrySof IQ (SN60WF) IOL with concomitant LRI at the time of surgery
1847265|NCT00929760|Behavioral|specialised renal care|"Combined management PCP - nephrologists (at least 4 nephrology visits/year). Agreement of the PCP is required for this combined management.
Management by PCPs only, with the help of written instructions from our nephrology unit based on EBPG. Requested Email or over the phone advices to PCPs will be provided by the nephrology division of HUG."
1847266|NCT00929773|Device|Erchonia PL2000 Laser|Low level laser light therapy device that emits 1 mW of red (635 nm wavelength) light. It is a hand-held device that uses rechargeable batteries or a separate power adapter.
1847267|NCT00929773|Device|Placebo laser|Inactive laser light.
1847268|NCT00929799|Drug|recombinant human Growth Hormone (Genotropin® )|Once daily by subcutaneous injection using a Genotropin pen in the abdomen at 22:00 h. Maximal GH dose of 0.003 mg/kg/day.
1847269|NCT00929812|Drug|Glucagon hydrochloride (GlucaGen®)|1 mg/1 ml of glucagon hydrochloride intramuscularly
1847270|NCT00929812|Drug|NaCl 0.9%|1 ml NaCl 0.9% intramuscularly
1847271|NCT00932139|Procedure|Electro-acupuncture|First visit, blood pressure monitoring for 60 minutes at rest, then monitoring for subsequent 24 hours to measure BP and heartrate. At next 6-8 visits, Electro-acupuncture (EA) treatment for 30 minutes will be administered. BP and heart rate measurements will be taken 30 minutes before and after EA.
1847276|NCT00932165|Drug|Exemestane|"Aromasin® Tablets 25mg, depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  The usual adult dose is 25 mg of exemestane administered orally once daily after a meal."
1847277|NCT00932178|Behavioral|Calmer Life|Calmer Life is a modified version of an existing Cognitive Behavioral Treatment manual. Participants have the option of including religion and spirituality into coping skills taught as a way of treating anxiety with or without depression in older adults.
1847278|NCT00932191|Procedure|Standard phacoemulsification|Cataract nucleus removal using standard amounts of ultrasound energy
1847279|NCT00932191|Procedure|Reduced ultrasound phacoemulsification|Cataract nucleus removal using less ultrasound energy and more mechanical energy.
1847321|NCT00932516|Behavioral|Calorie restricted diet with South Beach Diet™ Products|
1847322|NCT00932516|Behavioral|Calorie Restricted Diet|
1847280|NCT00932204|Device|repetitive transcranial magnetic stimulation (Magstim rapid magnetic stimulator)|"For the active group, rTMS over the right prefrontal cortex and the SMA was sequentially performed. The rTMS of the right dorsolateral prefrontal cortex was conducted at a point 5 cm anterior to the point at which the MT was determined, and it was administered at an intensity of 110% of the RMT, a frequency of 1 Hz, for 10 minutes, and with an inter-train interval of 2 minutes (1200 stimuli/d).
The vertex (Cz) was measured for each patient, and the SMA was defined at 15% of the distance between the inion and nasion anterior to Cz on the sagittal midline, according to the international 10-20 EEG system. The rTMS over the SMA was administered at an intensity of 100% of the RMT, a frequency of 1 Hz, for 10 minutes and with an inter-train interval of 2 minutes (1200 stimuli/d).
For the sham group, the sham stimulation was applied with the coil angled at 45° from the scalp using the same parameters as the active stimulation group over the same area."
1847281|NCT00932217|Drug|filgrastim|subcutaneous filgrastim administration
1847282|NCT00932217|Drug|lenograstim|subcutaneous lenograstim administration
1847283|NCT00932230|Other|KinesioTape|An elastic tape that will be placed on subject's ankles to determine whether ankle proprioception is improved
1847284|NCT00932256|Drug|STAHIST NDC #58407-536-01|Oral tablet containing Pseudoephedrine hydrochloride 90mg, chlorpheniramine maleate 8mg, atropine sulfate .24mg, one tablet BID.
1847285|NCT00932282|Drug|Peanut Oral Immunotherapy|Peanut flour taken by mouth, given every day. Dose ranges from 0.2mg of peanut flour to 8000mg of peanut flour during the maintenance phase.
1847286|NCT00932282|Drug|Omalizumab|Omalizumab (anti-IgE) will be given for 4 months prior to starting oral immunotherapy. The medication is given as a subcutaneous injection with dose based on total IgE levels and weight at the beginning of the study. This medication is given for a total of 10 months.
1847287|NCT00932295|Other|OB|10 puffs from the participants own brand brand of cigarette (lit; 30 second inter puff interval)
1847288|NCT00932295|Other|Sham smoking|10 puffs from the participants own brand brand of cigarette (NOT lit; 30 second inter puff interval)
1847289|NCT00932295|Other|CROWN SEVEN|"10 puffs from a so-called electronic cigarette named CROWN SEVEN (16 mg cartridge; 30 second inter puff interval)"
1847290|NCT00932295|Other|NJOY|"10 puffs from a so-called electronic cigarette named NJOY(16 mg cartridge; 30 second inter puff interval)"
1847291|NCT00932308|Dietary Supplement|Western-style diet (WD)|Will comprise of approximately 40% fat, 40% carbohydrates, 20% protein, and 350mg calcium, prepared by the Bionutrition Department using the USDA Nutrient Database.
1847292|NCT00932308|Dietary Supplement|Prudent Diet (PD)|Will contain approximately 20% fat, 60% carbohydrate, 20% protein, and 1100mg calcium; the diets will consist of a 2-day rotating metabolic menu.
1847293|NCT00932321|Drug|Norethindrone Acetate/Ethinyl Estradiol 24 Days|One tablet per day for 24 days of each 28 day cycle followed by 4 placebo tablets
1847294|NCT00932321|Drug|Norethindrone Acetate /Ethinyl Estradiol 21 Days|One tablet per day for 21 days of each 28 day cycle followed by 7 placebo tablets
1847295|NCT00932334|Behavioral|TALK PLUS|Participants receive and educational video and booklet about living kidney donation and meet with a social worker
1847296|NCT00932334|Behavioral|TALK Standard|Participants receive and educational video and booklet about living kidney donation
1847297|NCT00932334|Behavioral|Usual Care|Participants receive their usual care
1847298|NCT00932347|Drug|Camellia sinensis mouthwash|mouthrinsing, 2 times/day, for 28 days
1847299|NCT00932347|Drug|Placebo mouthwash|mouthrinsing, 2 times/day, for 28 days
1847303|NCT00932373|Drug|trastuzumab-MCC-DM1|Intravenous escalating dose
1847304|NCT00932386|Drug|Dexmedetomidine Hcl infusion|0.5mcg/kg/hr
1847305|NCT00932386|Drug|normal saline|0.9% normal saline infusing
1847306|NCT00932412|Drug|CLARA|Clofarabine 30 mg/m2/day IV (2h) on days 2 to 6 (administered as a 2h infusion in 250 ml of 0.9% normal saline solution) Cytarabine 1 g/m2/day intravenous (2h) 4 hours later on days 1 to 5 (administered as a 2h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 6 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
1847307|NCT00932412|Drug|HDAc|Cytarabine 3 g/m2/12h intravenous (3h) on days 1, 3, 5 (administered as a 3h infusion in 250 ml of 5% dextrose in water) G-CSF 5 microg/kg/day intravenous from day 1 to day 5 (administered as a 30 mn infusion in 20 ml of dextrose 5% in water)
1847308|NCT00932425|Device|Cardionet Mobile Cardiac Outpatient Telemetry (MCOT)|Patients will be assigned to wear the telemetry device for 21 days
1847311|NCT00932451|Drug|PF-02341066|PF-02341066, 250 mg BID, will be administered orally on a continuous schedule
1847312|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose under fasted conditions
1847313|NCT00932464|Drug|Neratinib|240-mg oral tablet; single dose with high-fat breakfast
1847314|NCT00932477|Drug|Formulation 1: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
1847315|NCT00932477|Drug|Formulation 2: Carboxymethylcellulose Sodium, Glycerin and Polysorbate 80, based artificial tear|1 to 2 drops into each eye three times per day
1847316|NCT00932477|Drug|Glycerin and Polysorbate 80 based artificial tear|1 to 2 drops into each eye three times per day
1847317|NCT00932490|Behavioral|Nurse Coaching|Tailored adherence intervention that will be based on the particular needs of patients and advanced practice nurses will suggest individualized strategies to overcome barriers to adherence
1847318|NCT00932503|Device|Vicryl plus|triclosan-coated polyglactin 910 suture materials with antiseptic activity (Vicryl plus®, Ethicon GmbH, Norderstedt, Germany)
1847319|NCT00932516|Behavioral|South Beach Diet™ with South Beach Diet™ Products|
1847320|NCT00932516|Behavioral|South Beach Diet™|
1847323|NCT00932529|Drug|Olanzapine|Olanzapine tablets 2.5mg - 20 mg per day once daily, or at the treating clinicians discretion
1847324|NCT00932529|Drug|Quetiapine|Tablets, 25 mg-800 mg given twice daily, or at the treating clinicians discretion.
1847325|NCT00932529|Drug|Risperidone|Tablets, 1mg-6mg per day, once or twice daily, or at the treating clinicians discretion.
1847326|NCT00932529|Drug|Ziprasidone|Tablets, 20mg - 160 mg twice daily, or at the treating clinicians discretion
1847327|NCT00932542|Drug|Eutectic mixture|The eutectic mixture of lidocaine + prilocaine + bupivacaine.
1847328|NCT00932542|Drug|placebo|placebo
1847329|NCT00932542|Drug|lidocaine 2,5%; prilocaine 2,5%|lidocaine 2,5%; prilocaine 2,5%
1847330|NCT00932555|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
1847331|NCT00932581|Other|Bradykinesia UPDRS Motor Full Examination|The first group will receive the full motor examination section in its original order.
1847332|NCT00932581|Other|Bradykinesia subscale of UPDRS Motor Examination|The second group will receive the bradykinesia subscale first followed by the remainder of the motor examination section.
1847333|NCT00932594|Procedure|Adjust the TMJ Pressure to Normal Value|Adjust the TMJ Pressure by the Operation Only Once for Each Patient
1847334|NCT00932594|Other|Do not adjust the pressure of TMJ|Do the treatments normally without additional treatment
1847335|NCT00932607|Drug|sublingual immunotherapy|"Start with 1 drop daily of SUBLIVAC Birch and increase by 1 drop daily, until the maintenance dose of 5 drops is reached. This maintenance dose should then be taken daily. Or 1 puff of Staloral Birch 10 I.R./ml on day one, 2 puffs on day two and increase by 2 puffs until at day six 10 puffs are reached. At day seven 1 puff of Staloral Birch 300 I.R./ml is taken, at day eight 2 puffs and day nine 4 puffs. From then on 4 puffs daily are taken.
Route of administration: Sublingual application. Drops (for SUBLIVAC Birch) or puffs (for Staloral Birch) are to be held underneath the tongue and then will be swallowed.
Duration of treatment: 16-20 weeks per subject (at least 12 weeks for subjects with hazel or alder allergy)."
1847336|NCT00932620|Drug|SIMVASTATIN 40 mg|SIMVASTATIN 40 mg/day for 3 months
1847337|NCT00932620|Drug|SIMVASTATIN/EZETIMIBE 10/10 mg|SIMVASTATIN/EZETIMIBE 10/10 mg/day for 3 months
1847338|NCT00932646|Drug|BI 1744 (Olodaterol) Low Dose|BI1744 Respimat low dose once daily and placebo Foradil
1847339|NCT00932646|Drug|BI 1744 (Olodaterol) Medium Dose|BI1744 Respimat medium dose once daily and placebo Foradil
1847340|NCT00932646|Drug|Placebo|Placebo Respimat once daily and placebo Foradil
1847341|NCT00932646|Drug|Foradil|12 mcg twice daily and placebo Respimat
1847342|NCT00932659|Device|continuous cardiac monitoring device (REVEAL, Medtronic)|hemodialysis patients without a prior history of cardiac arrhythmias will undergo implantation of a continuous cardiac monitoring device, and will undergo 6 months of follow-up
1847343|NCT00932672|Behavioral|Atkins Diet|Patients are given an outline of the Atkins diet and are asked to follow it for 6 months
1847344|NCT00932685|Drug|Midazolam|Midazolam 0.5mg/kg
1847345|NCT00932685|Device|Game Boy|Children given video game as a distraction in preop holding and were permitted to continue playing the game in OR during induction
1847346|NCT00932698|Drug|Oral IXAZOMIB|Phase 1: Patients will be administered IXAZOMIB orally on Days 1, 4, 8, and 11 during a 21-day treatment cycle. Doses will increase until a maximum tolerated dose (MTD) is established.
1847347|NCT00932711|Behavioral|Educational brochures|A locally developed educational brochure containing information about smoking cessation, influenza and pneumococcal vaccination, regular exercise, compliance with prescribed COPD therapy and recognition of symptoms, along with a goal setting questionnaire
1847348|NCT00932724|Drug|CY-503|Ampoules with 1 ml 350 ng CY-503 solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
1847349|NCT00932724|Drug|Placebo|Ampoules with 1 ml placebo solution for s.c. injection twice weekly. One cycle is defined as 4 consecutive weeks
1847350|NCT00932737|Drug|Placebo|1-5 tablets per episode
1847351|NCT00932737|Drug|Placebo|1-5 tablets per episode
1847352|NCT00932737|Drug|HBB 20 mg|Active drug, one to five tablets per episode
1847353|NCT00932750|Dietary Supplement|Coffee mannooligosaccharide|2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.
1847354|NCT00932750|Dietary Supplement|Coffee mannooligosaccharides|Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo
1847355|NCT00932763|Drug|Amlodipine besylate|10 mg tablets (Torrent Pharmaceuticals, India)
1847356|NCT00932763|Drug|Norvasc|10 mg dose (Pfizer, USA)
1847357|NCT00932776|Device|TBA care device|Tracheal suction maneuvers are performed according to the indications provided by the TBA care device or to clinical parameters whichever occurs first.
1847358|NCT00932776|Device|Control|In this group suction maneuvers are performed according to clinical indications or on a fixed schedule whichever comes first.
1847359|NCT00932802|Drug|Moxifloxacin (Avelox, BAY12-8039)|AECB patients under daily life treatment receiving moxifloxacin according to the local product information.
1847360|NCT00932828|Drug|Low Dose Peanut Protein|Peanut flour mixed with placebo will be given in gradually increasing doses.
1847361|NCT00932828|Drug|High Dose Peanut Protein|Peanut flour will be given in gradually increasing doses.
1847362|NCT00932841|Other|Placebo|One packet PO daily x 8 weeks.
1847363|NCT00932841|Drug|VSL#3 900 billion bacteria|One packet PO daily, x 8 weeks
1847364|NCT00932841|Drug|VSL#3 90 billion bacteria|One packet PO daily, x 8 weeks.
1847366|NCT00932867|Drug|Kinzal/Pritor (Telmisartan, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
1847367|NCT00932880|Drug|Amlodipine Besylate|10 mg tablets (Torrent Pharmaceuticals, India)
1847368|NCT00932880|Drug|Norvasc|10 mg dose (Pfizer, USA)
1847369|NCT00932893|Drug|PF-02341066|PF-02341066, 250 mg BID will be administered orally on a continuous schedule
1847370|NCT00932893|Drug|Pemetrexed|Pemetrexed, 500 mg/m^2, will be administered by i.v. infusion over 10 minutes on Day 1 of each 21-day cycle
1847371|NCT00932893|Drug|Docetaxel|Docetaxel, 75 mg/m^2, will be administered by i.v. infusion over 1 hour on Day 1 of each 21-day cycle
1847372|NCT00932906|Other|Different self-training methods|Self training with MiniAnne Training Kit
1847373|NCT00932906|Other|Standard training|Instructor-based training meeting ERC directions
1847374|NCT00932919|Behavioral|Thought field therapy|5 sessions with Thought field therapy
1847375|NCT00932919|Behavioral|Cognitive therapy|12 sessions of Cognitive therapy
1847376|NCT00932919|Behavioral|Wait list|3 months waiting, then randomized to either thought field therapy or cognitive therapy
1847377|NCT00932945|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
1847378|NCT00932971|Drug|PEG-IFN alfa-2a, Tenofovir|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally
1847379|NCT00932971|Drug|PEG-IFN alfa-2a, placebo|Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
1847380|NCT00932984|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative during 5 weeks (treatment period).
1847381|NCT00932997|Behavioral|telephone-based intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
1847382|NCT00932997|Other|counseling intervention|"Participants receive a Survivorship Kit and telephone sessions based upon responses to initial survey"
1847383|NCT00932997|Other|educational intervention|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
1847384|NCT00932997|Other|questionnaire administration|Baseline and 9 months after enrollment and intervention
1847385|NCT00932997|Procedure|psychosocial assessment and care|"Participants receive a Survivorship Kit alone or in combination with telephone sessions based upon responses to initial survey"
1847386|NCT00932997|Procedure|quality-of-life assessment|Baseline and 9 months after enrollment and intervention
1847387|NCT00933023|Drug|hydrocortisone|1%hydrocortisone topical once daily for 8 weeks
1847388|NCT00933023|Drug|Betamethasone|Betamethasone 0.1% topical once daily for 8weeks
1847389|NCT00933036|Device|Crosstrees Pod system for PVA|Minimally invasive spine surgery
1847390|NCT00933049|Drug|Amoxicillin|Oral amoxicillin (25mg/kg/dose)for 5 days
1847391|NCT00933049|Drug|Cotrimoxazole|Cotrimoxazole (8 mg/kg/dose trimethoprim + 40 mg/kg/dose sulphamethoxazole)
1847392|NCT00933049|Drug|Amoxicillin placebo|
1847393|NCT00933049|Drug|Cotrimoxazole placebo|
1847394|NCT00933062|Drug|SRT2104|2.0 g of SRT2104 will be supplied in hard gelatin capsules each containing 250 mg SRT2104. SRT2104 will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of SRT2104 will be orally-administered with approximately 200 mL water.
1847395|NCT00933062|Drug|Placebo|Placebo will be supplied in hard gelatine capsules containing an appropriate amount of placebo. Placebo will be administered within 30 minutes following the start of consumption of a standardized non-high-fat meal (approximately 650 kcal with approximately 30% of calories derived from fat). The eight capsules of placebo will be orally-administered with approximately 200 mL water.
1847396|NCT00933075|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 5 weeks (treatment period).
1847397|NCT00933088|Other|questionnaires|"The study instruments will be given in the following order to the adolescent daughters: 1. Responses to Stress questionnaire; 2. Inventory of Peer and Family Attachment; 3. Youth Self-Report; and, 4. Adolescent data form.
Mothers will be asked to complete data form."
1847398|NCT00933114|Procedure|MRI and PET imaging|Dynamic Enhanced Magnetic Resonance Imaging (DEC-MRI) and positron emission tomography (PET) scan at baseline and after 1 week of radiation therapy
1847399|NCT00933127|Genetic|DNA analysis|
1847400|NCT00933127|Genetic|polymerase chain reaction|
1847401|NCT00933127|Genetic|polymorphism analysis|
1847402|NCT00933127|Other|laboratory biomarker analysis|
1847403|NCT00933153|Dietary Supplement|Ensure Plus|Ensure plus supplement with meals
1847404|NCT00933153|Dietary Supplement|Meals on Wheels|Two Meals on Wheels twice daily
1847405|NCT00933166|Device|Lotrafilcon A contact lens|Investigational silicone hydrogel, single vision, soft contact lens worn on a daily wear basis, flexible wear basis, or extended wear basis for three months
1847406|NCT00933179|Drug|Gestodene/EE Patch (BAY86-5016)|21-day regimen per cycle (1 patch a week for 3 weeks followed by a 7-day patch-free period) for 3 cycles
1847407|NCT00933179|Drug|EE/Levonorgestrel (Microgynon, BAY86-4977)|21-day regimen per cycle (1 tablet a day for 3 weeks followed by a 7-day tablet-free period) for 3 cycles
1847408|NCT00933192|Device|Siemens Acuson Antares ultrasound|skeletal muscle ultrasound of the musculus quadriceps, on two different days, two observers
1847409|NCT00933205|Drug|Tipranavir|
1847410|NCT00933218|Dietary Supplement|polyphenols (non-alcoholic beer)|1.0 - 1.5 l non-alcoholic beer per day; 3 weeks before and during a marathon run
1847411|NCT00933218|Dietary Supplement|beverage without polyphenols|1.0 - 1.5 l of beverage without polyphenols (otherwise the same composition as non-alcoholic beer) per day; 3 weeks before and during a marathon run
1847419|NCT00933244|Dietary Supplement|High Dose Vitamin D3|Yellow gel-cap vitamin D3 at 50,000 International Units daily for 15 days then two times a month for 350 days. Daily white placebo pills.
1847420|NCT00933244|Dietary Supplement|Low Dose Vitamin D3|White gel-cap vitamin D3 at 800 International Units to take orally, daily for 365 days. Intermittent yellow placebo pills.
1847421|NCT00933244|Dietary Supplement|Placebo|Yellow gel-cap placebo pills to take orally, daily for 15 days then two times a month for 350 days. White gel-cap placebo pills once daily for 365 days.
1847422|NCT00933257|Drug|LACTIC ACID(ND)|Treatment duration 5 weeks
1848808|NCT00943423|Other|No further treatment|
1847423|NCT00933270|Device|SUPERA® Nitinol Stent System|Percutaneous Angioplasty of the Superior Femoral Artery with placement of a SUPERA® Stent at time of PTA
1847424|NCT00933283|Drug|Telaprevir|Telaprevir 750 mg will be administered orally, every 8 hours from Day 1 to Day 7, along with methadone, once daily.
1847425|NCT00933283|Drug|Methadone|Methadone 30 to 130 mg will be administered as a stable oral therapy from Day -14 to Day -1, in combination with telaprevir from Day 1 to Day 7, and then alone as a continued intake dose for an additional 30 to 32 days.
1847426|NCT00933309|Drug|Exemestane|25 mg tablets orally once a day
1847427|NCT00933309|Drug|Avandamet|Beginning dose 2 mg rosiglitazone with 500 mg metformin hydrochloride (2mg/500 mg) tablets taken orally once a day
1847428|NCT00933322|Dietary Supplement|diet enriched with industrial trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with margarine enriched with industrial trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
1847429|NCT00933322|Dietary Supplement|diet enriched with ruminant trans fatty acids|After run-in phase of 2 weeks with margarine without TFA, 4 weeks with butter enriched with ruminant trans fatty acids following. TFA-percentage of total energy consumption is 2% or 6% of total fat energy consumption.
1847430|NCT00933322|Dietary Supplement|diet without any trans fatty acids|6 weeks with margarine without any trans fatty acids.
1847431|NCT00933335|Biological|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
1847432|NCT00933348|Drug|OPAL A|OPAL A will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the OPAL A Filtrate will only be administered once every 72 hours.
1847433|NCT00933348|Drug|Placebo|Placebo will be supplied in two formulations: as a Filtrate (0.5 mL per cm2 of ulcer area, applied into the ulcer cavity) and as a Cream (about 1 to 5 g applied as a thin smear on surrounding skin). Both formulations will be applied daily. However, if the ulcer begins to hypergranulate, the Placebo Filtrate will only be administered once every 72 hours.
1847434|NCT00933361|Drug|ghrelin|As starting dose the investigators choose a dose level which was shown in our last study to be safe in human beings, i.e. 8μg/kg intravenously. With an assumed bioavailability of 25% of subcutaneously administered ghrelin the corresponding dose for dose level 1 is therefore 32 μg/kg. In the first 4 dose levels for each subsequent dose level the dose is increased by 50% compared to the previous one, from the 5th dose level onwards the increase is 25%: Dose level 1 = 32 μg/kg Dose level 2 = 48 μg/kg Dose level 3 = 72 μg/kg Dose level 4 = 108 μg/kg Dose level 5 = 135 μg/kg Dose level 6 = 169 μg/kg Dose level 7 = 211 μg/kg The investigators define the maximum tolerable dose as 20mg ghrelin (equivalent to 5ml) for reasons of the high drug volume to be administered subcutaneously.
1847435|NCT00933374|Drug|paclitaxel|Paclitaxel (175 mg/m3)will be administered as a 3 hour continuous IV infusion after standard premedication every 3 weeks
1847436|NCT00933374|Drug|RAD001|10 mg RAD001 once daily starting at day 1 of a 21 days treatment cycle
1847437|NCT00933387|Drug|Cetuximab,Paclitaxel,Cisplatin|Cetuximab 500 mg/m2 iv infusion (120 min for the 1st infusion, 90 min for the 2nd , and 60 min for the subsequent) Paclitaxel 120 mg/m2 3-hour iv infusion Cisplatin 50 mg/m2 2-hour iv infusion
1847438|NCT00933400|Procedure|CT Coronary Angiography|CT coronary angiography will be performed without and with contrast in participants randomized to receive imaging as well as traditional care. (For applicable purposes, the decision to perform contrast-enhanced imaging in the presence of a large amount of calcium should be made according to procedures at each individual site.) The imaging test will be considered positive if the participant has a greater than 50% stenosis of the right coronary, left main, left anterior descending, or circumflex arteries or of their branches in contrast-enhanced CT coronary angiography. Results will be communicated to the responsible ED and treating staff immediately upon interpretation; ED staff will determine appropriate course of management. Negative results will result in patient discharge.
1847439|NCT00933400|Procedure|Traditional, Standard of Care|Participants randomized to traditional care will be assessed and discharged/treated according to routine standard-of-care procedures in the institution's emergency department.
1847440|NCT00933413|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
1847441|NCT00933426|Drug|Lenalidomide|Lead-In beginning dose of 5 mg capsules by mouth once a day for 21 days in a row, followed by 7 days of rest (Days 22-28) for a 28 day cycle.
1847442|NCT00933426|Drug|Paclitaxel|50 mg/m^2 given by vein over 1 hour on Days 1, 8, and 15 of each 28 day cycle.
1847443|NCT00933439|Drug|Duloxetine|Approximately 30 participants with major depressive disorder and concentration and/or cognition difficulties, recruited from the community and physician referrals, will be treated with duloxetine for 12 weeks. Their cognitive performance will be assessed pre- and post-treatment with a cognitive testing battery.
1847444|NCT00933452|Drug|duloxetine|30mg, oral administer; step 1: single dose; step 2: multiple dose, 7 days
1847445|NCT00933452|Drug|duloxetine|15mg, oral administer
1847446|NCT00933452|Drug|duloxetine|60mg, oral administer; step 1: generic duloxetine; step 2: Innovator duloxetine
1847447|NCT00933465|Drug|Imodium (Loperamide Hydrochloride) syrup|"syrup (orally), max dose per day; 16x 5ml spoonfuls (80ml) Titrated from low dose to clinically relevant dose as described by the patient and their symptoms.
Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most."
1847448|NCT00933465|Drug|Imodium (Loperamide hydrochloride) tablets|"tablets (orally) max dose per day; in chronic diarrhea, 8 capsules (16 mg) titrated from low dose to clinically relevant dose as described by patient and their symptoms.
Taken at times suitable for the patient, either at regular intervals as defined by patient needs, or as single dose when needed the most"
1847449|NCT00933478|Device|Clay|Small dime sized piece of clay.
1847450|NCT00933504|Drug|LACTIC ACID(ND)|Treatment duration: 6 weeks.
1847451|NCT00933517|Drug|vectibix|9mg/kg at D1 of each 21-days cycle
1847452|NCT00933517|Drug|fluorouracile|500 mg/m2 at D1 of each 21-days cycle
1847453|NCT00933517|Drug|Epirubicine|100 mg/m2 at D1 of each 21-days cycle
1847454|NCT00933517|Drug|cyclophosphamide|500 mg/m2 at D1 of each 21 dyas cycle
1847455|NCT00933517|Drug|docetaxel|100 mg/m2 at D1 of each 21 days cycle
1849328|NCT00939133|Drug|vehicle gel|Placebo
1847456|NCT00933530|Drug|SRT2104|SRT2104 (0.03, 0.1, 0.25, 0.5, 1.0, 2.0, or 3.0 g/day) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. The dosing vehicle is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
1847457|NCT00933530|Drug|Placebo|Placebo (at the matched dosage as SRT2104) will be supplied as a powder which will be prepared by the Pharmacist/designee into a liquid suspension. Placebo will consist of titanium dioxide USP and prepared for oral administration identically to the SRT2104 investigational product. Test material will be administered orally, in a single dose and subsequently, once daily for seven consecutive days. The subjects enrolled will be blinded to treatment assignment. A trained staff member will prepare individual solutions of test material that the subject will drink once daily in the clinic following a 10-hour (minimum) fast.
1847458|NCT00933543|Drug|Visonac PDT (MAL PDT)|Cream application followed by illumination with red light.
1847459|NCT00933543|Drug|Vehicle cream (placebo)|Cream application followed by illumination with red light.
1847460|NCT00933543|Procedure|PDT|Photodynamic Therapy - Light dose 37 J/cm2
1847461|NCT00933556|Dietary Supplement|VSL#3|6 gms of powder formulation to be given once a day for 4 weeks
1847462|NCT00933556|Dietary Supplement|sugar pill (placebo)|placebo identical to the active product will be given
1847463|NCT00933569|Drug|LACTIC ACID(ND)|treatment period: 21 consecutive days
1847464|NCT00933582|Drug|JNJ-39439335; Placebo; Naproxen|
1847465|NCT00933595|Other|Smoking Cessation|"A Motivational Interview session (~40-50 minutes) will be delivered by a trained nurse coordinator.
Treatment with varenicline (1 mg daily during week 1 (pre-quit week) followed by 1 mg twice daily for weeks 2-12)or nicotine replacement therapy (21 mg of a skin patch + nicotine gum 4 mg ad lib added for breakthrough craving up to 20 pieces/day."
1847466|NCT00933608|Drug|memantine|participants will be asked to take memantine (20mg/day) for 16 weeks
1847467|NCT00933608|Drug|Placebo|participants will be asked to take 2 tablets per day to match active drug
1847468|NCT00933621|Procedure|Autologous bone marrow intracoronary infusion|Percutaneous intracoronary mononuclear bone marrow cell infusion
1847471|NCT00933647|Dietary Supplement|Yerba Mate Tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
1847472|NCT00933647|Dietary Supplement|Green tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
1847473|NCT00933647|Dietary Supplement|Apple tea|Before and after 8 weeks, serum lipids, C-reactive protein and fibrinogen will be measured. They will also be tested for glycemia, insulin, aminotransferases, bilirubin. Anthropometric measurements will be also performed at week 0 and 8. The subjects will receive instructions to maintain their usual dietary intake and normal physical activity.
1847474|NCT00933660|Other|ERC-training by instructor|Standard way of training with an instructor
1847475|NCT00933660|Other|Web-based training only|Experimental way of training with a web based training application
1847476|NCT00933660|Other|Web-based training with a personal training manikin|Experimental way of training with a web based training application and a simple personal training manikin
1847477|NCT00933673|Drug|L-asp, DXM, IFO, VP-16, DDP|L-asp 6000 u/m2; DXM 40 mg d1-4; IFO 1200mg/m2 d1-4; Mesna 400mg, tid, d1-4; VP-16 60 mg/m2 d1-4; DDP 20mg/m2 d1-4; q3w. Efficacy was evaluated every two cycles. If patients hadn't diseases progression, two more cycles and radiation would be administered.
1847478|NCT00933686|Drug|Saizen®|Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.
1847479|NCT00933686|Drug|Placebo and Saizen®|Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.
1847480|NCT00933699|Drug|LACTIC ACID(ND)|Treatment duration: 21 consecutive days
1847481|NCT00933712|Drug|LACTIC ACID(ND)|Dermacyd Silver Floral (Lactic Acid) sample will be applied like a curative for 6 weeks.
1847482|NCT00933725|Other|TCM intervention|"Drug: Particle of compound Chinese herbs(produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.
One tablet placebo of Tibolone (provided by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China, once every two days, taken orally, for two months.
Behavioral: TCM emotion treatment: made under the guide of TCM theory, administered by qualified TCM physician, for three times in two months."
1847483|NCT00933725|Other|Western intervention|"Drug: Tibolone, (produced by Oujianong corporation, Nanjing, China), 2.5mg, once every two days, taken orally, for two months; Particle placebo of compound Chinese herbs (produced by San_jiu Medical & Pharmaceutical Limited Company, Guangzhou, Guangdong Province, China), mixing with boiled water, free of decoction, taken orally, twice a day, for two months.
Behavioral: supportive psychotherapy, administered by qualified physician, for three times in two months."
1847484|NCT00933751|Device|Central vein catheterization|Blood samplings from IVC catheter
1849468|NCT00940251|Drug|Mersina|capsule, 3g/day, 3 months
1847485|NCT00933777|Drug|Combination of sorafenib and everolimus|Dose finding: Treatment with defined dose of sorafenib of 2x400 mg with increasing dose of everolimus (2.5 mg, 5 mg, 7.5 mg, 10 mg) Extension: Treatment with defined dose of sorafenib of 2x400 mg with everolimus 7.5 mg
1847486|NCT00933790|Drug|ATT (Ethambutol, Pyrazinamide, INH, Rifampicin)|Ethambutol 800 mg for daily, 1200 mg for intermittent therapy, Pyrazinamide 1500 mg for both daily and intermittent, INH 300 mg for daily and 600 mg for intermittent therapy, Rifampicin 450 mg for both daily and intermittent therapy for patients below 60 kg, 600 mg for both daily and intermittent therapy for patients 60 kg and above
1847487|NCT00933816|Drug|sorafenib, cisplatin, fluorouracil|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in the all patients. Cisplatin at the dose of 10-20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 170-330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days and 3 cycles of this combination therapy will be continued.
1847488|NCT00933829|Procedure|Absorbable Suture Arm|use of irradiated polyglactin 910
1847489|NCT00933829|Device|Non-absorbable suture (Prolene)|suture
1847490|NCT00933829|Procedure|suture|non-absorable sutures and absorable sutures
1847491|NCT00933842|Drug|LACTIC ACID(ND)|Treatment duration: 5 weeks
1847492|NCT00933855|Behavioral|Questionnaires and training workshop|"We will recruit a minimum of 1 and maximum of 12 patients for each workshop.
The workshop will follow the approximate time table below:
10 minutes: Sign-in, welcome and introductions 25 minutes: Didactic session, videos and discussion 10 minutes: Group discussion 15 minutes: Closing plenary and final assessment"
1847493|NCT00933868|Drug|Magnesium Chloride|An infusion of magnesium chloride will be given over 4 to 10 minutes in patients breathing 100% oxygen
1847494|NCT00933868|Drug|Placebo|A saline placebo will be given as an infusion (six infusions over a three week period) in a double blind manner with the active test agent
1847495|NCT00933881|Other|Determining a change in heart rate variability post delivery of the baby|Determining a change in heart rate variability post delivery of the baby
1847496|NCT00933894|Drug|Telaprevir; Escitalopram|
1847497|NCT00933907|Drug|LACTIC ACID(ND)|Treatment duration: 6 weeks
1847498|NCT00933920|Drug|Aliskiren|
1847499|NCT00933920|Drug|Aliskiren|
1847500|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the normal healthy population or pregnant female population at risk for HIV infection are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw.
1847501|NCT00933933|Device|ARCHITECT HIV Ag/Ab Combo|Test blood samples with investigational HIV assay. If results for specimens from the at risk population are reactive, samples will be tested with supplemental HIV assays. If all supplemental HIV assays are negative, subject will be asked to return for a follow-up blood draw when possible.
1847502|NCT00933946|Drug|LACTIC ACID(ND)|Dermacyd Silver Frutal (Lactic Acid) sample will be applied like a curative for 21 consecutive days.
1847503|NCT00933959|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
1847504|NCT00933959|Behavioral|Sleep Hygiene|Treatment as usual
1847505|NCT00933972|Drug|RO4998452|20mg po single dose
1847506|NCT00933985|Drug|dexrazoxane hydrochloride|Given IV
1847507|NCT00933985|Drug|doxorubicin hydrochloride|Given IV
1847508|NCT00933985|Drug|obatoclax mesylate|Given IV
1847509|NCT00933985|Drug|liposomal vincristine sulfate|Given IV
1847510|NCT00933985|Other|pharmacological study|Correlative studies
1847511|NCT00933985|Other|laboratory biomarker analysis|Correlative studies
1847512|NCT00933998|Other|Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)|One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.
1847513|NCT00934011|Other|C-reactive protein guided antibiotic therapy|plasma CRP measurement to guide the duration of antibiotic therapy
1847514|NCT00934011|Other|Procalcitonin guided antibiotic therapy|plasma PCT measurement to guide the duration of antibiotic therapy
1847515|NCT00934024|Drug|varenicline|Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.
1847516|NCT00934037|Procedure|320 Volume Detector Computed Tomography|Single Arm Study. All patients undergo Volume (Multidetector) CT.
1847517|NCT00934037|Other|Other: Multidetector Computed Tomography - 320 detectors|Multidetector computed tomography angiography
1847518|NCT00934050|Drug|ELND005 (scyllo-inositol)|"Prior to 15Dec2009: ELND005 2000 mg PO BID for 48 weeks
After 15Dec2009: ELND005 250 mg PO BID for 48 weeks"
1847519|NCT00934063|Drug|somatropin|For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation
1847520|NCT00934063|Other|No treatment given|Control group not receiving treatment
1847521|NCT00934076|Drug|Tarceva plus AT-101|"150 mg of Tarceva taken once daily in a continuous regimen expressed in 3 week cycles.
Oral AT-101 at 40 mg twice daily for 3 days of each 3 week cycle on an outpatient basis."
1847522|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
1847523|NCT00934089|Drug|latanoprost vehicle|Topical ocular solution, once-daily for 14 days
1847524|NCT00934089|Drug|PF-04217329|Topical ocular solution, once-daily for 14 days
1847525|NCT00934089|Drug|latanoprost|Topical ocular solution, once-daily for 14 days
1847526|NCT00934102|Device|Narafilcon A contact lens|Investigational, silicone hydrogel, spherical soft contact lens
1847527|NCT00934102|Device|Lotrafilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
1847528|NCT00934102|Device|Galyfilcon A contact lens|Commercially marketed, silicone hydrogel, spherical soft contact lens
1847529|NCT00934128|Device|Vapotherm|Deliver air in and out of the lungs, warmed, filtered for bacteria, and then delivered through the nose using a tube under the nostrils.
1847530|NCT00934128|Device|BIPAP|Air given through a mask, and amount can be set to different levels allowing more air in and out of lungs without using as much effort as regular breathing.
1849518|NCT00940550|Drug|Zolpidem|10 mg capsule, once
1847531|NCT00934141|Other|Learning Session|Learning Sessions occur bi-annually as change teams convene to learn and gather support from each other and outside experts who offer advice on how best to adopt the innovations and learn about new directions for the collaborative (e.g., the need to create business cases for improvements). Learning Sessions and Interest Circles (see below) have similar objectives—to help agencies learn and gather support from each other and from outside experts.
1847532|NCT00934141|Other|Interest Circle Calls|Interest Circles are monthly teleconferences where agency change leaders discuss change-related issues and progress. Circles address how to improve timeliness, continuation, admissions, dropouts and transitions. They also address specialty topics (e.g., programs for women, adolescents). Participants discuss successes, failures, and challenges, and get advice and assignments for their improvement plans. Meeting summaries appear on the Web site. Interest Circles are inexpensive, but are they are sufficient? Should Interest Circles prove effective, they would provide a low-cost, convenient diffusion approach
1847533|NCT00934141|Other|Coaching|Coaching assigns an expert in process improvement to work with an agency to make, sustain, and spread process improvement efforts. Consultations focus on executive directors, change leaders and improvement teams. Coaches help agencies address key issues, but also broker relationships with other agencies, offer process improvement training, and promote the innovations to make and how to make them. Coaching takes place during site visits, monthly phone conferences, and via email.
1847534|NCT00934141|Other|Website|The NIATx Web site features resources central to improvement. The site includes: 1) a catalog of change ideas and case studies; 2) a toolbox providing just-in-time training on topics such as conducting a walk-through and key innovations; 3) on-line tools to assess organizational (or project) readiness for and ability to sustain change; 4) electronic communication services to ask questions of experts, and participate in peer discussion groups; 5) links to relevant process improvement Web sites; and 6) a secure portion for treatment agencies to report and track progress. Hence, our control group will have access to the entire website.
1847535|NCT00934154|Drug|Thalidomide|100 mg/day continuously for 12 months
1847536|NCT00934154|Drug|Melphalan+Prednisolone|Melphalan 2 mg, Prednisolone 16 mg
1847537|NCT00934167|Biological|heparin sodium - Hipolabor|5.000 UI/0,25mL
1847538|NCT00934167|Biological|Heparin sodium - APP|5.000 USP/mL
1847539|NCT00934180|Drug|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
1847540|NCT00934180|Drug|Zofran®|1 x 8 mg ODT
1847541|NCT00934193|Drug|Gabapentin|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
1847542|NCT00934193|Drug|Placebo|Treatment will consist of a 600 mg dose of gabapentin or placebo given preoperatively the night before surgery, based on a computer generated randomized assignment. The treatment group will continue to be medicated with gabapentin 300 mg twice daily for one month following surgery. Those not included in the treatment arm of the study will continue to take a placebo for the same duration. Follow-up will consist of a postoperative visit at approximately 48 hours and a one month clinical visit.
1847543|NCT00934206|Behavioral|Endurance training|running / walking at 60 % heart rate reserve 4 times per week for 4 weeks
1847544|NCT00934219|Drug|Omega-3-Acid Ethyl Esters|LOVAZA, 1 g caps; High Dose Arm for 4 months, while on a standard therapy for hypertriglyceridemia (fibrates, +/-metformin). Standard Dose Arm for 3 months, while on a standard, unchanged therapy for hypertriglyceridemia (fibrates +/- metformin).
1847545|NCT00934232|Drug|Busulfan|Busulfan (Bu) is a bifunctional alkylating agent currently used almost exclusively as a component of conditioning regimens for both autologous and allogeneic stem-cell transplants.
1847546|NCT00934245|Biological|Inactivated Trivalent Influenza Vaccine|Vaccine administration will occur twice, one month apart, in the first year of participation in the study. This will occur as TIV vaccine becomes available in India, in the early autumn. Subsequent years will provide one immunization. Due to the inclusion of the pandemic 2009 influenza A H1N1 virus in the 2010-2011 northern hemisphere vaccine formulation and recommendations that children should receive 2 doses of this vaccine this study will administer 2 doses of vaccine in the second year of the study.
1847547|NCT00934245|Biological|Inactivated polio vaccine (IPV)|Vaccine administration will occur twice, one month apart, in the first year of participation in the study to parallel administration of TIV (experimental intervention). Subsequent years will provide one immunization except 2011 schedule modified to accommodate changes in TIV schedule as per above..
1847548|NCT00934258|Drug|rosuvastatin,fenofibrate|Rosuvastatin 10 mg once daily Rosuvastatin 5 mg + SFC fenofibrate 80 mg
1847549|NCT00934258|Genetic|CYP2C9, UGT1A1, UGT1A3, OATP2, BCRP|All potential patients will be screened for the eligibility in a screening visit. Those who fill the inclusion criteria at screening will be invited for the registry study into different groups. The follow-up will take place at months 6, 12, 18, and every year thereafter for another 3 years, through clinical visiting, phone follow-up, or records from the NHIB Taiwan. At each clinical visit, vital signs, clinical endpoints, adverse events, concurrent medication information and laboratory specimens will be obtained as complete as possible. With phone or records from NHIB, only clinical endpoints will be recorded. If the primary care physician intends to treat the patient's lipid profile to the target, he/she can add, delete or adjust the LLT by his/her clinical judgement
1847550|NCT00934271|Radiation|fractionated stereotactic radiotherapy|Audit of outcome
1847551|NCT00934284|Other|Lumbar injection|Patients are instructed to resume normal activity as tolerated.
1847552|NCT00934284|Other|Rehabilitation following lumbar injection|Participants are referred to an average of four weeks of physical therapy after receiving a lumbar injection. Physical therapy designed to include end-range directional preference exercises and/or mechanical traction to reduce lower extremity symptoms and progress activity tolerance.
1847553|NCT00934323|Drug|Amaryl M SR 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group
1847554|NCT00934323|Drug|Amaryl M SR 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 2 for RT sequential group
1847763|NCT00935948|Drug|Placebo|Patients in this arm received placebo, with the exact same appearance of the Imescard ointment, and were instructed to apply it at the same intervals and period.
1847555|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
1847556|NCT00934336|Other|Therapeutic and preventive strategies|These results may help us to define a post prandial insulin treatment regimen (which is more flexible as regards meals) or a pre prandial insulin treatment regimen (less flexible for meals but maybe less harmful in terms of limitation of oxidative stress).
1847557|NCT00934362|Drug|Lucinactant first|lucinactant 120 mg (20 mg/ml) x 5 doses over 24 hours, then washout period x 14 days, then vehicle x 5 doses over 24 hrs
1847558|NCT00934362|Drug|Placebo first|6 mL normal saline x 5 doses over 24 hours, then washout period x 14 days, then lucinactant x 5 doses over 24 hours
1847559|NCT00934375|Drug|Aricept (donepezil hydrochloride)|5 mg or 10 mg of donepezil hydrochloride (Aricept) taken orally once a day.
1847560|NCT00934375|Drug|placebo|
1847561|NCT00934388|Procedure|Pre peritoneal mesh placement|
1847562|NCT00934388|Procedure|Laparoscopy|
1847563|NCT00934414|Drug|Technosphere Insulin Inhalation Powder|30U
1847564|NCT00934427|Drug|0.9% nitroglycerin in TAM cream|0.5 g of Vascana (0.9% nitroglycerin in proprietary vehicle cream) is applied topically BID for one day before certain planned cold exposures, once just before same planned cold exposures, and, if needed, right after the start of symptoms during same planned cold exposures
1847565|NCT00934427|Drug|vehicle cream|0.5g of vehicle cream is topically administered BID for one day before certain planned cold exposures, once just before certain planned cold exposures, and, if needed, right after the start of symptoms during certain planned cold exposures
1847566|NCT00934440|Drug|Bevacizumab|"First treatment: 10 milligram per kilograms (MG/KG) intravenously (IV) on Day 1every two weeks over 90 minutes.
Second treatment: 10 MG/KG IV on Day 1 every two weeks over 60 minutes.
Third and subsequent treatments: 10 MG/KG IV on Day 1 every two weeks over 30 minutes (minimum of two cycles)."
1847567|NCT00934440|Drug|Azacitidine|"Dose level 1: 35 mg/m2/day for 7 days.
Dose level 2: 55 mg/m2/day for 7 days.
Dose level 3: 75 mg/m2/day for 7 days.
mg/m2/day = dose based on height and weight"
1847568|NCT00934453|Biological|Lactobacillus rhamnosus GG ATCC 53103|Study drug capsules (1x10^10 LGG/capsule) are to be taken orally twice a day every day dissolved in cow's milk or soy milk on an outpatient basis for six months.
1847569|NCT00934453|Biological|Placebo|Placebo capsules composed of microcrystalline cellulose are to be taken orally twice a day dissolved in cow's milk or soy milk on an outpatient basis for six months.
1847570|NCT00934466|Drug|MK2637|Single dose of 120 mg MK2637 capsules in one of five treatment periods.
1847571|NCT00934466|Drug|Comparator: MK2637|Single dose of 50 mg MK2637 capsules in one of five treatment periods.
1847572|NCT00934466|Drug|Comparator: Placebo|Single dose of placebo only in one of five treatment periods.
1847573|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 220 mg dextromethorphan capsules in one of five treatment periods.
1847574|NCT00934466|Drug|Comparator: Dextromethorphan|Single dose of 110 mg dextromethorphan capsules in one of five treatment periods.
1847575|NCT00934479|Drug|Lubiprostone|Following the initial stool and breath collections and because of differences in the FDA-approved dosing for the 2 subtypes of chronic constipation, (that is, chronic constipation (CC) versus constipation due to irritable bowel syndrome (C-IBS), the CC subjects received open-label lubiprostone 24 mcg orally twice daily for 4 weeks; while the C-IBS subjects received open-label lubiprostone 8 mcg orally twice daily for 4 weeks.
1847576|NCT00934492|Drug|Cotrimoxazole dispersible tablet|Cotrimoxazole dispersible tablets 120/240mg daily for six consecutive months.
1847577|NCT00934492|Drug|Placebo dispersible tablet|Placebo dispersible tablets 120/240mg daily for six consecutive months.
1847578|NCT00934518|Radiation|Radiation|Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
1847579|NCT00934518|Drug|Cetuximab|"Radiation Therapy 60 Gy total dose in 30 fractions: 2.0 Gy/fraction once daily five fractions per week
Cetuximab 400 mg/m2 of body surface area over a period of 120 minutes day 1 250 mg/m2 of body surface area over a period of 60 minutes weekly during radiation"
1847580|NCT00934531|Drug|Donepezil|"Participants with MCI will be randomized to either the experimental (donepezil) or placebo arm of the study.
Experimental Arm: Participants with MCI will receive 5 mg/day of donepezil p.o. for 4 weeks, and thereafter 10 mg/day of donepezil p.o. for a period of 5 months, yielding a total period of intervention of 6 months from baseline.
Placebo Arm: Participants with MCI will receive a matched placebo p.o. for 4 weeks, and thereafter will receive a new matched placebo p.o. for the next 5 months, yielding a total period of intervention of 6 months from baseline."
1847581|NCT00934544|Drug|INC424/INCB018424|Oral 5 mg tablets with packaged as 60-count in high-density polyethylene bottles.
1847582|NCT00934544|Drug|Best Available Therapy (BAT)|Best available investigator-selected therapy (oral or parenteral therapies) was commercially available and was administered according to manufacturer's instructions and investigator discretion. Instructions for prescribing and taking these therapies were found in their respective package inserts.
1847583|NCT00934557|Drug|ATG Fresenius|
1847584|NCT00934557|Drug|ATG Fresenius|
1847585|NCT00934557|Drug|ATG Fresenius|
1847586|NCT00934557|Drug|ATG Fresenius|
1847587|NCT00934557|Drug|ATG Fresenius|
1847588|NCT00934557|Drug|ATG Fresenius|
1847589|NCT00934557|Drug|ATG Fresenius|
1847590|NCT00934557|Drug|ATG Fresenius|
1847591|NCT00934570|Drug|Metformin and standard exercise|Metformin 1500 mg daily for 2 years
1847592|NCT00934570|Drug|Metformin Intensive exercise|Metformin 1500 mg daily for 2 years
1847593|NCT00934570|Behavioral|Placebo Standard exercise|Standard exercise
1847594|NCT00934570|Behavioral|Intensive exercise|Placebo Intensive exercise
1847595|NCT00934583|Behavioral|Image and Mood (IaM) program|A 10-week Internet-based intervention focused on (1) identifying and challenging automatic thoughts in order to improve body image and reduce negative affect, (2) developing adaptive emotion and behavior regulation skills associated with preventing disordered eating and negative affect, and (3) teaching relapse prevention skills. The program includes an online discussion group moderated by a study clinician.
1847847|NCT00936637|Other|Extensively hydrolyzed infant formula|
1847596|NCT00934596|Procedure|Lund de-airing technique|In these patients the pleura will be opened on both sides and the ventilator will be disconnected before aorta is cross-clamped and cardioplegia administered. At the conclusion of the surgical procedure, the LV preload will first now be successively increased. When no air is seen on TEE monitoring in the left heart (LA, LV & Aorta), half the calculated minute ventilation with 100% oxygen and a PEEP of 5 cm H2O will be started. Deairing will be continued and when the TEE shows no or minimal air in left heart, full ventilation with unchanged PEEP will be restored. The patient will be weaned successively from the CPB. When TEE will show no air in the left heart, the de-airing will be considered complete.
1847597|NCT00934596|Drug|carbon-dioxide insufflation|In these patients (n=10) the pleurae will not be opened. During aortic cross-clamp period the ventilator will be adjusted to provide dead space ventilation only i.e. 5cm PEEP, ventilator frequency 5/min and the minute ventilation = 1,5 liter. Fio2 = 50%. The operating field will be insufflated with Co2 at a flow rate of 10 L / minute starting 2 minutes before cardiac cannulation and continued until 10 minutes after termination of the CPB.At the end of the cardioplegic arrest, the de-airing procedure is similar to that in the Lund de-airing group.
1847598|NCT00934609|Behavioral|Endurance training|45 min ergometer cycling at the ventilatory anaerobic threshold 4 times per week for 12 weeks
1847599|NCT00934622|Device|AcrySof® ReSTOR® Aspheric IOL|AcrySof® ReSTOR® Aspheric Intraocular Lens (IOL) implanted into the study eye following the cataract extraction surgery
1847600|NCT00934635|Drug|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 2 hours
1847601|NCT00934635|Drug|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 2 hours
1847602|NCT00934635|Other|PET Scan|PET Scan
1847603|NCT00934635|Drug|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 24 hours
1847604|NCT00934635|Drug|Oral risperidone|4 mg tablet once a day followed by PET scan in approximately 2 hours
1847605|NCT00934635|Drug|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 2 hours
1847606|NCT00934635|Drug|Paliperidone ER|6 mg tablet once a day followed by PET scan in approximately 24 hours
1847607|NCT00934635|Drug|Oral risperidone|6 mg tablet once a day followed by PET scan in approximately 24 hours
1847608|NCT00934635|Drug|Paliperidone ER|9 mg tablet once a day followed by PET scan in approximately 24 hours
1847609|NCT00926653|Drug|Escitalopram|10 to 20 mg daily as part of another study in which participants are enrolled
1847610|NCT00926666|Drug|Levobupivacaine|Dose finding study for levobupivacaine in fractured neck of femur patients. Ultrasound guided anterior psoas compartment nerve block to determine EC50 using up/Down methodology in patient before surgery to fix broken hip.
1847611|NCT00926692|Other|Blood draw|Subject will have blood draw.
1847612|NCT00926705|Drug|Dexmedetomidine and Fentanyl|Dexmedetomidine in a dose of 1 ug/kg initial dose then continuous infusion of 0.7 ug/kg/hr . Combined with Fentanyl at a dose of 2 ug/kg initially plus boluses of fentanyl to keep the patient hemodynamically stable.
1847613|NCT00926705|Drug|Fentanyl|This group received Fentanyl at a dose of 2 ug/kg initially, followed by boluses to keep the patient hemodynamically stable.
1847614|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 2ng ml-1
1847615|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 2ng ml-1
1847616|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 2ng ml-1
1847617|NCT00926718|Drug|remifentanil infusion|rocuronium dose 0 mg/kg + remifentanil infusion of 8ng ml-1
1847618|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.4 mg/kg+ remifentanil infusion of 8ng ml-1
1847619|NCT00926718|Drug|rocuronium dose + remifentanil infusion|rocuronium dose 0.6 mg/kg+ remifentanil infusion of 8ng ml-1
1847620|NCT00926731|Drug|AZD1152|Variable dose via a 7-day continuous infusion
1847621|NCT00926731|Drug|LDAC (low dose cytosine arabinoside)|20 mg subcutaneous injection given twice daily
1847622|NCT00926744|Behavioral|physical activity|The targets of amount of physical activity are 3.3METs•h/day (MVPA) and 10,000 step counts/day.
1847623|NCT00926757|Drug|Entecavir prophylaxis|Entecavir 0.5mg daily from day 1 of chemotherapy to 3 months after completing chemotherapy
1847624|NCT00926757|Drug|Therapeutic entecavir|Entecavir 0.5cm daily since hepatitis flare and HBV reactivation, till hepatitis remission
1847625|NCT00926783|Procedure|CFAE ablation|CFAE ablation (targeted vs. generalized)
1847626|NCT00926796|Drug|Azithromycin|Four 500 mg tablets will be administered orally to equal a 2 gm dose.
1847627|NCT00926796|Drug|Gentamicin|Fixed dose of 240 mg intramuscular one time for patients >45 kg and a 5 mg/kg dose for patients less than or equal to 45 kg based on their measured weight in clinic. Most patients will require 2 injections of gentamicin in separate large muscle groups.
1847628|NCT00926796|Drug|Gemifloxacin|One 320 mg tablet administered orally.
1847629|NCT00926809|Drug|Lansoprazole (proton pump inhibitor), amoxicillin, clarythromycin|Lansoprazole, Amoxicillin 1000 mg, Clarithromycin 500 mg
1847630|NCT00926809|Drug|Lansoprazole (proton pump inhibitor), placebo|Lansoprazole, Amoxicillin placebo, Clarythromycin placebo
1847631|NCT00926835|Drug|paroxetine|6 weeks, 20-50mg/day
1847632|NCT00926835|Drug|Escitalopram|10-20mg/day for 6 weeks
1847633|NCT00926835|Drug|Venlafaxine XR|Venlafaxine 75-225mg/day for 6 weeks
1847634|NCT00926835|Drug|Paroxetine+Bupropion|paroxetine 20-50mg/day + bupropion 150-400mg/day for 6 weeks
1847635|NCT00926835|Drug|Paroxetine+Lamotrigine|Paroxetine 20-50mg/day + lamotrigine 100-400mg/day for 6 weeks
1847636|NCT00926835|Drug|Paroxetine+Lithium|Paroxetine 20-50mg/day + lithium 0.5-1.2 mEq/L
1847637|NCT00926835|Drug|Escitalopram+Mirtazapine|escitalopram 10-20mg/day + mirtazapine 15-45mg/day for 6 weeks
1847638|NCT00926835|Drug|Escitalopram+Aripiprazole|escitalopram 10-20mg/day + aripiprazole 5-15mg/day for 6 weeks
1847639|NCT00926835|Drug|Paroxetine + Venlafaxine XR|Paroxetine 20-50mg/day + Venlafaxine 75-225mg/day for 6 weeks
1847848|NCT00936650|Drug|placebo|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
1850397|NCT00946686|Drug|Leflunomide 20 mg Tablets (Geneva Pharmaceutical)|
1847641|NCT00926861|Device|ultrasound|A-scan and B-scan ultrasound at baseline and month 6,12,24
1847642|NCT00926861|Device|OCT|Volume scans of spectralis OCT at baseline and month 6,12,24
1847643|NCT00926887|Device|Erchonia(R) EML Laser|Low level laser red light of 635 nm and delivering 1.5 joules/cm2.
1847644|NCT00926887|Device|Placebo Laser|Inactive light
1847647|NCT00926926|Drug|Oxybutynin Chloride Gel|Once daily for 7 days, followed by single dose of acetaminophen
1847648|NCT00926926|Drug|Placebo Gel|Once daily for 7 days, followed by single dose of acetaminophen
1847649|NCT00926939|Behavioral|Reinforcement for the abstinence of smoking|Participants in this intervention group will receive vouchers contingent upon a CO sample of 4ppm or less.
1847650|NCT00926939|Behavioral|Reinforcement for submission of videos with CO sample|This intervention group will receive vouchers contingent on their submission of videos of their CO breath tests.
1847651|NCT00926952|Drug|Methylaminolevulinate (Metvix, Metvixia)|2-4 g of cream applied to entire face at Day 0 for 90 minutes without occlusion prior to light treatment. If any actinic keratoses remained after 4 weeks the treatment was repeated at Week 4.
1847652|NCT00926952|Device|Photodynamic Therapy (Aktilite)|Device set to 37 J/cm². Red light wavelength is approximately 630 nm.
1847653|NCT00926965|Drug|amisulpride|amisulpride tablet 100-1200mg/day for 24 months
1847654|NCT00926965|Drug|Olanzapine|Olanzapine tablet 2.5 to 30 mg/day for 24 months
1847655|NCT00926965|Drug|Conventional antipsychotics|the subjects were randomized to the conventional antipsychotic group to maintain their original conventional antipsychotics
1847656|NCT00926978|Radiation|Radioactive Iodine 124|"After TSH stimulation with Recombinant human TSH (rhTSH) for 2 days, a dose of radioactive iodine 124 ( I-124) 1.7 mCi is administrated orally and PET imaging is done for 5 continuous days including the day of the dose administration. On each day, just before imaging, 5 ml of blood is drawn.
Patients will be randomized to either the sequence above (e.g. I-131 followed by I-124) or to the reverse sequence in which the I-124 is given first followed by the I-131. If I-124 is administered first and as long as the whole body retention is < 2% by the start of the second rhTSH stimulation, the I-124 will not interfere with the I-131."
1847657|NCT00934648|Drug|rituximab [MabThera/Rituxan]|1000mg iv on days 1 and 15
1847658|NCT00934648|Drug|methotrexate|10-25mg weekly
1847659|NCT00934661|Drug|Extended Release Epidural Morphine (EREM)|A single Four mg (0.4 ml)dose of EREM will be administered into the epidural space and flushed with 1 ml of saline
1847660|NCT00934661|Drug|Placebo|A single epidural injection will be a placebo consisting of 0.4 ml of saline followed by 1 ml saline flush
1847661|NCT00934674|Drug|SKI-606 (Bosutinib)|"Arm 1 - Commercial Tablet manufactured by Excella
Arm 2 - Clinical Tablet manufactured by Wyeth Montreal"
1847662|NCT00934687|Drug|clostridium botulinum toxin type A neurotoxin complex|A total of 20-50 U of clostridium botulinum toxin type A neurotoxin complex (Allergan) will be injected at four to six sites in the glabella region according to standard protocols of cosmetic botulinum toxin applications.
1847663|NCT00934687|Other|0.9% NaCl solution|0.9% NaCl solution will be injected in analogy to clostridium botulinum toxin type A neurotoxin complex as a placebo comparator.
1847664|NCT00934700|Other|Xenon gas|30% Xenon gas inhaled for 24 hours
1847665|NCT00934713|Drug|montelukast|montelukast 4mg once per day for 8 weeks period
1847666|NCT00934739|Drug|Thalidomide, Celebrex|Immediately after operation starts thalidomide (50) 4# per day and celecoxib (Celebrex)(200) 2# bid for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
1847667|NCT00934739|Drug|Cyclophosphamide, Dexamethasone|Immediately after operation starts cyclophosphamide (50) 1# per day and dexamethasone (0.5) 2# qd for three weeks, in addition to standard postoperative concurrent chemoradiotherapy
1847668|NCT00934752|Device|Lutonix Paclitaxel-Coated Balloon|Percutaneous transluminal coronary angioplasty (PCTA)
1847669|NCT00934765|Behavioral|weight loss|self-directed weight loss, guided weight loss, weight loss by gastric by-pass surgery
1847670|NCT00934778|Procedure|Confocal microscopy and endocytoscopy|2 probe based imaging systems for use via the working channel of the bronchoscope. 0.5ml of methylene blue injected into airways for endocytoscopy. Each procedure takes about 2-3 minutes.
1847671|NCT00934791|Drug|Tacrolimus|Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
1847672|NCT00934791|Drug|Sirolimus|Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
1847673|NCT00934791|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 750 mg twice daily
1847674|NCT00934791|Drug|Prednisone|Prednisone tapered to 5 mg/day by day 92
1847675|NCT00934804|Device|Galilei dual Scheimpflug analyzer|The Galilei dual Scheimpflug analyzer is a non-invasive, diagnostic system that combines dual rotating Scheimpflug camera measurements and Placido optical system for corneal topography and 3D analysis of the anterior eye segment.
1847676|NCT00934817|Drug|Amaryl-M 2/500 mg|single oral administration in period 2 for TR sequential group, and in period 1 for RT sequential group, respectively
1847677|NCT00934817|Drug|Amaryl-M 1/500 mg|single oral administration in period 1 for TR sequential group, and in period 2 for RT sequential group, respectively
1847678|NCT00934830|Drug|Antibiotic (Amoxicillin)|500 mg, 3 times per day for 10 days
1847679|NCT00934830|Other|Therapeutic ultrasound|1.0 W/cm2 in continuous mode for 10 minutes once a day for 4 consecutive days.
1850398|NCT00946686|Drug|Arava 20 mg Tablets (Aventis Pharmaceutical, Inc.)|
1847680|NCT00934843|Drug|methylprednisolone (IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive ONE doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP (2 dose steroid)to intraoperative IVMP alone (single dose steroid) on the inflammatory response to CPB cardiopulmonary bypass.
1847681|NCT00934843|Drug|methylprednisolone (two doses IVMP)|Neonates with congenital heart disease requiring surgery utilizing a cardiopulmonary bypass (CPB)machine in the first month of life that receive TWO doses intravenous methylprednisolone (IVMP) prior to heart surgery.Compare the effects and preoperative and intraoperative IVMP to intraoperative IVMP alone on the inflammatory response to CPB cardiopulmonary bypass. The hypothesis is that neonates treated with preoperative IVMP as well as the standard intraoperative IVMP will have decreased production of pro-inflammatory cytokines.
1847682|NCT00934856|Drug|Docetaxel|Docetaxel will be administered on Day 1 of each 3-week cycle at a dose specified in the respective arms (as per summary of product characteristics [SmPC]).
1847683|NCT00934856|Drug|Pertuzumab|Pertuzumab at a loading dose of 840 mg IV infusion on Day 1 of Cycle 1 followed by maintenance dose of 420 mg IV infusion on Day 1 of each 3-week cycle.
1847684|NCT00934856|Drug|Trastuzumab emtansine|T-DM1 will be administered on Day 1 or Day 2 of each 3-week cycle at a dose specified in the respective arms.
1847685|NCT00934882|Drug|Regorafenib (BAY73-4506)|Administration of the multi-kinase inhibitor BAY73-4506 (160 mg once daily from Day 4 to Day 10 and from Day 18 to Day 24) as oral treatment in combination with the chemotherapy regimen mFOLFOX6 or FOLFIRI in patients with metastatic Colorectal Cancer
1847688|NCT00934908|Dietary Supplement|Green Tea|Green tea capsules taken twice a day.
1847689|NCT00934908|Other|Placebo|"Non-active sugar pill."
1847690|NCT00934921|Drug|Ondansetron|1 x 8 mg Orally Disintegrating Tablet
1847691|NCT00934921|Drug|Zofran®|1 x 8 mg ODT
1847692|NCT00934934|Other|Normal Saline|Normal Saline
1847693|NCT00934934|Drug|anidulafungin|TBA
1847694|NCT00934947|Drug|Propranolol|40 mg
1847695|NCT00934947|Drug|Placebo|sugar pill
1847696|NCT00934947|Drug|Propanolol|120 mg twice per day
1847697|NCT00934973|Drug|mebeverine|overencapsulated mebeverine 135 mg tds for 6 weeks
1847698|NCT00934973|Drug|methylcellulose|overencapsulated methylcellulose 3 tablets bd for 6 weeks
1847699|NCT00934973|Drug|placebo|overencapsulated placebo tablets 1 tds for 6 weeks
1847700|NCT00934973|Behavioral|CBT website with support|cognitive behavioral therapy with nurse telephone session and email support
1847701|NCT00934973|Behavioral|No website|No CBT website
1847702|NCT00934973|Behavioral|CBT website with minimal support|
1847703|NCT00935441|Behavioral|case management with telemonitoring|telephone contact with a case manager, home telemonitoring equipment for blood sugar and blood pressure, home HbA1c measurement
1847704|NCT00935441|Behavioral|usual case management|telephone contact with a case manager
1847705|NCT00935454|Procedure|Hepatocyte matrix implantation|"First operation:
Removal of liver tissue and biopsy of pancreas
Second operation:
Implantation of hepatocyte matrix implant into small bowel mesentery"
1847706|NCT00935467|Drug|Saxagliptin|Tablets, oral, 2.5 mg, twice daily, 7 days
1847707|NCT00935480|Drug|Isentress®|P.O, 1 tablet containing 400 mg every 12 hours
1847708|NCT00935480|Drug|Celsentri®|p.o.: 1 tablet containing 150 mg morning and evening (due to combination with PI/r) or containing 300 mg if fosamprenavir/r is used as the PI (MA)
1847709|NCT00935493|Drug|Guanfacine|Guanfacine 0.1 mg po qhs
1847710|NCT00935493|Drug|Guanfacine|Guanfacine 0.5 mg po qhs
1847711|NCT00935493|Drug|Placebo|Placebo po qhs
1847712|NCT00935506|Drug|Clopidogrel|Tablets, Oral, 75 mg, Once daily, 8 days
1847713|NCT00935506|Drug|Aspirin|Tablets, Oral, 325 mg, Once daily, 8 days
1847714|NCT00935519|Device|4th generation ceramic bearing composite ceramic bearing|THA with use of the new alumina-zirconia(4th generation ceramic bearing) composite ceramic bearing at a minimum of 5 years follow-up.
1847715|NCT00935532|Drug|exenatide once weekly|subcutaneous injection, 2.0mg, once a week;
1847716|NCT00935532|Drug|insulin glargine|subcutaneous injection, titrated to achieve fasting serum glucose target, once a day
1847717|NCT00935545|Biological|Montanide|Montanide is an oil-based immunoadjuvant similar to Incomplete Freund´s Adjuvant, which is commonly used in combination with peptide vaccines. Although its precise mode of action is not known, it acts to enhance the immune response to vaccination. It has a depot effect that depending on the type of emulsion will release the antigen slowly from the injection site.
1847718|NCT00935558|Biological|DC vaccine|DC vaccination regime consist of primary 10 intradermal injections of 1-2 weeks interval. At the time of each vaccine 6 MIU/m² IL-2 will be administered sc. Zadaxin 1.6 mg is injected sc twice a week. and tablet Aromatase inhibitor is administered ; Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
1847719|NCT00935558|Drug|aromatase inhibitor|Exemestane 25 mg (tablet) is administered PO daily or Femar 2,5 mg (tablet) is administered PO daily or Arimidex 1 mg (tablet) is administered PO daily
1847720|NCT00935571|Drug|propofol, remifentanil, sevoflurane|Propofol: using target controlled infusion (TCI); 1-3ug/ml remifentanil: using TCI by 5-20 ng/ml sevoflurane: 2-3volume% (1-2 MAC)
1847721|NCT00935584|Behavioral|Physician training in patient-centered emr use|This intervention was performed in between the pre-intervention (Baseline) clinic visit and post intervention clinic visit.
1847849|NCT00936650|Drug|cinacalcet|Subjects were titrated to doses of 30, 40, or 50 mg BID every 4 weeks in a 12 week titration period, depending on their serum calcium concentration. The dose was kept constant for the ensuing 40 weeks except for dose reductions for hypocalcemia.
1850399|NCT00946699|Biological|MEDI-551|0.1 mg/kg
1847722|NCT00935597|Biological|MSSM/BIIR HDC Vax-001 (Host Dendritic Cells)|Patients who have minimal residual disease or minimal volume relapse, and are at least four weeks post immunosuppression following allogeneic stem cell transplantation will receive a series of four HDC infusions (100,000 HDC/kg per infusion, one every four weeks(group 1). Those patients who have greater than minimal residual disease will receive HDC infusions, one every four weeks in conjunction with donor lymphocyte infusion (DLI) (group 2).
1847723|NCT00935610|Dietary Supplement|Immunocal|20 grams per day of Immunocal for 135 days.
1847724|NCT00935610|Dietary Supplement|Casein|20 grams per day for 135 days
1847725|NCT00935623|Biological|Malaria Challenge|Malaria challenge
1847726|NCT00935649|Device|PinPointe FootLaser|Medical laser
1847727|NCT00935662|Drug|AZD8329|Oral solution, single ascending doses
1847728|NCT00935662|Drug|Placebo|Oral solution, placebo
1847729|NCT00935675|Drug|Escitalopram|Escitalopram 10 mg once a day
1847730|NCT00935688|Other|Rapid diagnostic test|Dual species test for P. vivax and P. falciparum malaria
1847731|NCT00935701|Device|Acupressure and Acupuncture|Acupressure involves the stimulation of specific acupoints by firm pressure, while acupuncture involves the insertion of very fine needles (the size of a strand of hair). The needles may be quickly inserted and removed or left in up to 5 minutes at a time.
1847732|NCT00935714|Other|Exercise|
1847733|NCT00935714|Other|Exercise|
1847734|NCT00935727|Other|Elastographic imaging|ultrasound imaging using a specialized computer that processes the data for tissue hardness
1847735|NCT00935753|Drug|sapropterin|oral 100mg tablets taken intact or dissolved in water or apple juice with morning meal for up to 60 days
1847736|NCT00935766|Drug|Omega-3|Subjects meeting eligibility criteria will be randomized to receive a supply of omega-3-acid ethyl esters or placebo, and instructed to take 4 capsules daily. A 3-month supply of study drug will be given following randomization and at 3, 6, and 9 months. Subjects will be asked to bring unused supplies to each quarterly visit for ascertainment of adherence.
1847737|NCT00935766|Drug|Placebo|
1847738|NCT00935792|Drug|alemtuzumab|Given subcutaneously
1847739|NCT00935792|Drug|everolimus|Given orally
1847740|NCT00935805|Drug|Metformin|850 mg TID
1847741|NCT00935805|Drug|Glybenclamide|10 mg BID
1847742|NCT00935805|Drug|NPH insulin|Variable SC dose
1847743|NCT00935805|Drug|Hydrochlorothiazide|25 mg QD introduced as initial therapy for hypertension
1847744|NCT00935805|Drug|Propranolol|40 mg BID
1847745|NCT00935805|Drug|Captopril|50 mg TID
1847746|NCT00935805|Drug|Amlodipine|10 mg QD
1847747|NCT00935818|Drug|Varenicline|varenicline - 1 mg bid for 12 weeks
1847748|NCT00935818|Drug|placebo|placebo for 12 weeks
1847749|NCT00935818|Drug|bupropion SR|bupropion sr - 150 mg bid for 12 weeks
1847750|NCT00935831|Drug|GSK1278863A|50mg, 150mg
1847751|NCT00935831|Drug|Placebo|matching placebo
1847752|NCT00935844|Drug|TAK-901|"This study consists of three sequential parts.
Part 1: Escalating doses of TAK-901 will be administered via IV infusion over a 3-hour period on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.
Part 2: Escalating doses of TAK-901 (starting at one-third of the dose identified as the MTD in Part 1) will be administered as a 1-hour infusion on Days 1, 4, 8, 11, 15, and 18 of each 28-day cycle.
Part 3: TAK-901 will be administered to approximately 20 patients using the dose identified as the MTD in the escalation phase. The infusion duration of TAK-901 will be determined after completion of Part 2."
1847753|NCT00935857|Device|Single Balloon Colonoscopy|Use of the single balloon enteroscopy system (enteroscope and balloon-overtube) to complete colonoscopy.
1847754|NCT00935857|Device|Standard Colonoscopy|Use of the standard adult colonoscope to complete colonoscopy.
1847755|NCT00935870|Device|Bioactive glass and/or autogenous bone|No intervention in the current study (10-year follow-up study)
1847756|NCT00935883|Drug|Eculizumab|"Induction Period: patient will receive eculizumab 600 mg or 900 mg via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by 900 mg or 1200 mg eculizumab for the fifth dose 7 days later (7 ± 2 days).
Maintenance Period: patient will receive eculizumab 900 mg or 1200 mg via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.
Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
1847757|NCT00935883|Drug|Saline|"Induction Period: patient will receive saline via IV infusion over approximately 30 minutes once a week (7 ± 2 days) for 4 weeks followed by saline for the fifth dose 7 days later (7 ± 2 days).
Maintenance Period: patient will receive saline via IV infusion over approximately 30 minutes every 2 weeks (14 ± 2 days) until week 24.
Observation period: patient will then be observed for 6 months off treatment with follow-up visits scheduled for 9 months and 12 months."
1847758|NCT00935896|Procedure|Low tidal volume|twenty patients were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4).
1847759|NCT00935896|Procedure|Low tidal volume|Immediately after ICU admission, once all inclusion and exclusion criteria were met and consent obtained, twenty patients (16 men, 4 women, median age of 49 yrs) were randomly (opaque sealed envelopes) assigned to receive mechanical ventilation in volume-controlled mode either with VT of 10-12 ml/kg predicted body weight (high VT group, n=10) or with VT of 5-7 ml/kg predicted body weight (low VT group, n=10) with an inspiratory fraction of oxygen (FIO2) set at the minimal level at which an arterial oxygen saturation of > 90% and minimal PEEP (4-5cmH2O). The predicted body weight of male patients was calculated as equal to 50+0.91(centimeters of height-152.4); that of female patients was calculated as equal to 45.5+0.91(centimeters of height-152.4)
1847760|NCT00935896|Other|low tidal volume|tidal volume of 5-7 ml/kg predicted body weight
1847761|NCT00935922|Dietary Supplement|Flaxseed|Flaxseed omega-3 fatty acids and lignans
1847762|NCT00935948|Drug|Imescard compound water smartweed ointment|Patients in this arm were instructed to apply the ointment after waking up, after evacuations and before bedtime, for 5 days.
1847764|NCT00935961|Drug|RAD001 + docetaxel + cisplatin|Patients will receive daily RAD001 (everolimus, per dose escalation scheme) plus concurrent docetaxel (75 mg/m2 intravenously every 3 weeks) + cisplatin (75 mg/m2 intravenously every 3 weeks). Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle. Patients will be followed for toxicity for 30 days after the last dose of RAD001. Patients should undergo re-staging imaging studies within 2 - 6 weeks after the final treatment with cisplatin/docetaxel. After the completion of induction chemotherapy and the 30-day observation period after treatment, patients are removed from the study.
1847765|NCT00935987|Drug|CYT387|"For the Part 1 dose-escalation portion of the study, patients will be assigned to dose levels in successive cohorts starting with a dose in the first cohort of 100 mg/day. CYT387 will be orally self-administered as a single daily dose beginning on Day 1 of the study, and thereafter at approximately the same time each day of the 28-day cycle. It is recommended that all doses be preceded by a 2-hour fast from food and beverages, and be followed by a 1-hour post-dose fast from food and beverages.
Twenty additional patients will be assigned to a 150 mg BID (twice daily) dosing schedule. CYT387 will be orally self-administered twice-daily with doses approximately 10-12 hours apart beginning on Day 1 of the study, and thereafter at approximately the same times each day of the 28-day cycle.
For the Part 2 dose confirmation portion of the study, patients will be assigned to either 150 mg or 300 mg QD (once daily) dose groups."
1847766|NCT00936000|Dietary Supplement|Protandim|The dosage of Protandim will be 1350 mg per day given p.o. in two equally divided doses
1847767|NCT00936013|Drug|oseltamivir|75mg p.o Bid for 5 days
1847768|NCT00936013|Drug|oseltamivir and chinese medicinal herbs|oseltamivir: 75mg p.o bid for 5 days chinese medicinal herbs:200ml p.o qid for 5 days
1847769|NCT00936026|Drug|Neramexane|Drug-Drug Interaction Study
1847770|NCT00936039|Behavioral|unloading|2 weeks of unloading of a single leg
1847771|NCT00936052|Other|Hyperbaric Oxygen Therapy|in addition to standard radiation and chemotherapy, you will also receive the experimental hyperbaric treatment prior to each radiation treatment (Monday-Friday) during the initial six weeks of treatment. Prior to the first hyperbaric treatment. The hyperbaric treatment lasts approximately thirty minutes. During the hyperbaric treatment, the participant will lie on a stretcher in the hyperbaric chamber and breathe oxygen at greater than normal atmospheric pressure. The investigator will monitor the increased oxygen levels in the tissue by placing a noninvasive electrode on your skin. After each hyperbaric treatment, we will measure your blood sugar by finger-stick to check for hypoglycemia (low blood sugar). If detected, hypoglycemia will be treated by standard medical measures.
1847772|NCT00936065|Drug|Etanercept|Etanercept at a dose of 50mg twice weekly for 12 weeks followed by 25mg twice weekly for 12 weeks
1847773|NCT00936065|Drug|Etanercept + Acitretin|Combination of etanercept at a dose of 25mg twice weekly and acitretin 10mg BID for 24 weeks
1847774|NCT00936065|Drug|Acitretin|Acitretin at a dose of 10mg BID for 24 weeks
1847775|NCT00936091|Drug|vitamin A supplements|gelatinous and reddish opaque capsules containing 200 000 IU vitamin A
1847776|NCT00936091|Drug|Placebo|125 children received placebo capsules
1847777|NCT00936117|Drug|Posaconazole|200 mg (liquid) by mouth 3 times per day.
1847778|NCT00936130|Procedure|Laparoscopic Roux-en-Y gastric bypass|Laparoscopic Roux-en-Y gastric bypass surgery
1847779|NCT00936130|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding surgery
1847780|NCT00936130|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy surgery
1847781|NCT00936130|Behavioral|Low Calorie Diet|Low Calorie Diet Program
1847782|NCT00936143|Drug|infliximab|100mg/bottle 5mg/kg inject intra-venous on baseline, 2nd week, 6th week, 12th week, 24th week
1847783|NCT00936156|Drug|Chemotherapy (carboplatin, etoposide, thiotepa)|Conventional chemotherapy: carboplatin injection (160 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Etoposide injection (100 mg/m²/day by infusion over one hour in 5 % glucose saline) administered from D1 to D5 and from D22 to D26. Double intensification by high-dose chemotherapy followed by autologous PBSC rescue: thiotepa injection (200 mg/m²/day as an infusion over one hour in 200 ml/m² of 5 % GS) administered from D42 to D44 and from D63 to D65. Autologous PBSC rescue on D47 and D68. Surgical resection of any tumor residue. Irradiation of the primary tumor site and cerebrospinal axis: 54 Gy to primary tumor, 36 Gy to cerebrospinal axis. Maintenance treatment: Temozolomide 150 mg/m²/day orally for 5 days every 28 days, from 1 month after the end of irradiation. 6 cycles planned. Duration of treatment: 13 months
1847784|NCT00936169|Procedure|IVUS optimised DES implantation|Ivus optimised stent implantation
1847785|NCT00936169|Procedure|angiographically guided DES implantation|angiographically guided DES implantation
1847786|NCT00936182|Drug|Fluconazole|Fluconazole daily for 30 days
1847787|NCT00936195|Drug|Efavirenz-Tenofovir-Emtricitabine|Atripla (R) : Efavirenz 600 mg - Tenofovir 300 mg - Emtricitabine 200 mg; Dosage : 1 pill/day
1847788|NCT00936195|Drug|Zidovudine-Lamivudine-Lopinavir/Ritonavir|"Combivir (R) : Zidovudine 300 mg - Lamivudine 150 mg Dosage : 1 pill twice a day
Kaletra (R) or Aluvia (R) : Lopinavir 200 mg / Ritonavir 50 mg Dosage : 2 or 3 pills twice a day"
1847789|NCT00936221|Drug|AZD6244|oral capsules, 75mg twice daily
1847790|NCT00936221|Drug|Dacarbazine|1000 mg/m2 iv infusion over at least 60 min. on day 1 of each 21 cycle
1847791|NCT00936221|Drug|Placebo|Placebo
1847792|NCT00936234|Drug|Vildagliptin|Vildagliptin, 50 mg twice a days, orally for 30 days followed by placebo
1847793|NCT00936247|Drug|HES 130/0.42 + electrolyte solution|Tetraspan 6% as colloid component combined with Sterofundin ISO as electrolyte component
1847794|NCT00936247|Drug|Albumin + electrolyte solution|Albumin 5% as colloid component and NaCl 0.9% as electrolyte component
1847795|NCT00936260|Drug|alendronate|several duration of treatment
1847796|NCT00936286|Device|SpiroTiger|Respiratory muscle training with SpiroTiger device, 1 week training initiation and 4 weeks training period with 5 training days per week, training duration 30 min each. Respiratory bag volume set at 50% VC, respiratory frequency starting from 50% MVV. Weekly control trainings.
1847798|NCT00936338|Behavioral|splint and joint mobilization self exercise|
1847945|NCT00937274|Other|T4 phage cocktail test|T4 phages 106 PFU/ ml up to 5 days
1850400|NCT00946699|Biological|Placebo|0.3 mg/kg
1847799|NCT00936351|Behavioral|Mindfulness Meditation|Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses. This intervention has been adapted from mindfulness based stress reduction treatment.
1847800|NCT00936351|Behavioral|Support Group (control)|A support group during which participants can discuss with each other any issues, problems, or successes at work will be conducted as the control portion.
1847801|NCT00936364|Other|Short-term fasting|No calories will be consumed during periods of fasting. Good oral hydration will be encouraged. Water may be consumed, as well as non-caloric beverages (i.e. zero calorie soft drinks, black coffee or tea).
1847802|NCT00936364|Other|Modified fast|Minimal caloric intake on days -2 and -1
1847803|NCT00936364|Other|Fasting|Day -1
1847804|NCT00936364|Other|Fasting|Days -2 and -1
1847805|NCT00936364|Other|Fasting|Days -3, -2, and -1
1847806|NCT00936364|Other|Fasting|48-hour fast with minimal caloric intake on days -2 and -1
1847807|NCT00936377|Drug|Dexmedetomidine|Dexmedetomidine at 0.4 or 1.2 µg/kg per hour is administered for a maximum duration of five days
1847808|NCT00936377|Other|Placebo|Normal saline for five days.
1847809|NCT00936390|Drug|bicalutamide|Given orally
1847810|NCT00936390|Drug|buserelin|Given subcutaneously or as an injection
1847811|NCT00936390|Drug|flutamide|Given orally
1847812|NCT00936390|Drug|goserelin acetate|Given subcutaneously or as an injection
1847813|NCT00936390|Drug|leuprolide acetate|Given subcutaneously or as an injection
1847814|NCT00936390|Drug|triptorelin|Given subcutaneously or as an injection
1847815|NCT00936390|Radiation|3-dimensional conformal radiation therapy|Given as external-beam radiation therapy
1847816|NCT00936390|Radiation|intensity-modulated radiation therapy|Given as external-beam radiation therapy
1847817|NCT00936403|Drug|NNC126-0083|One single dose administered in four dose levels in an escalating order
1847818|NCT00936403|Drug|somatropin|A daily dose of Norditropin NordiFlex® for seven days. Dose will remain constant
1847819|NCT00936416|Procedure|Inulin and PAH clearance and MRI|"GFR and renal blood flow estimation by Inulin and PAH clearance will be performed in the Renal Physiology Lab for approximately 2.5 hours;
The MRI test will be performed afterwards at Medical Imaging department and last about 45 minutes."
1847820|NCT00936429|Biological|DEN1-80E (HBV-001 D1 + 3.5 mg Alhydrogel)|3 doses of DEN1-80E vaccine administered as 0.5 ml intramuscularly in deltoid.
1847821|NCT00936429|Biological|Placebo for DEN1-80E|3 doses of placebo vaccine administered as 0.5 ml intramuscularly in deltoid.
1847822|NCT00936442|Drug|Anastrozole|(Standard Treatment) 12-month follow-up of anastrozole treatment according to SmPC and current clinical practice.
1847823|NCT00936442|Other|Educational materials|Reception of educational material on regular basis.
1847824|NCT00936468|Biological|Fluzone® vaccine with JVRS-100 adjuvant or Fluzone alone|One vaccination on Day 0 of Fluzone® vaccine at 45ug mixed with one of three doses (3.75ug, 7.5ug, 25ug) of JVRS-100 adjuvant versus Fluzone® vaccine at 45ug alone.
1847825|NCT00936494|Procedure|Cold ablation inferior turbinate reduction|The procedure usually takes 30 minutes and involves the surgeon inserting the coblation inferior turbinate reduction wand into the inferior turbinates and allowing for the radiofrequency cold ablation to ablate soft tissues, with a resultant thermal lesion allowing for additional soft tissue attenuation and contracture with time.
1847826|NCT00936507|Other|Energy Density/Portion Size|
1847827|NCT00936520|Drug|SAR 1118 0.1%|Daily eye drops (twice daily, ~50 microliter [uL] each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
1847828|NCT00936520|Drug|SAR 1118 1.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
1847829|NCT00936520|Drug|SAR 1118 5.0%|Daily eye drops (twice daily, ~50 uL each drop) approximately 10 to 12 hours apart; morning and in the evening just prior to bedtime) to the study eye only for 8 consecutive days
1847830|NCT00936533|Drug|Dysport® (Botulinumtoxin A (Btx A))|Single injection in patients´ soles with Btx A in one foot and sodium chloride in the other, with the possibility of a second injection after 12 weeks. The drug will be given in general anaesthesia after curettage of the focal hyperkeratoses. Only the areas with focal hyperkeratoses will be injected with 50 ul per injection.The active drug Btx A (Dysport®, solution for injection) has a concentration of 100 U/ml, and the maximum dose is 300 U per foot.
1847831|NCT00936533|Drug|Placebo|Placebo preparation without active compound, administered as the active drug.
1847832|NCT00936546|Drug|Rituximab|Mabthera, Rituximab 1000 mg I.V.
1847833|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information
1847834|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information.
1847835|NCT00936559|Biological|BMP-655/ACS or Standard of Care|Decision was made by Legal to withhold this information,
1847836|NCT00936572|Procedure|Probiotics (La1, BB536)|
1847837|NCT00936572|Biological|probiotics (La1, BB536)|
1847838|NCT00936572|Biological|placebo|Maltodoxtrin
1847839|NCT00936585|Other|Immunologic Monitoring|blood draws and colonoscopy before and after receiving study drug
1847840|NCT00936598|Drug|zolpidem|Participants will receive the FDA approved dose of zolpidem, (10 mg for women <65; 5 mg for women = or > 65 years) during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
1847841|NCT00936598|Drug|sugar pill|Participants will receive placebo (sugar) pills during their presurgery visit and will be instructed to take the single capsule by mouth immediately before bedtime the night before surgery.
1847842|NCT00936611|Drug|LBH589|Orally on Mondays, Wednesdays and Fridays
1847843|NCT00936624|Drug|SOTB07|SOTB07 100mg
1847844|NCT00936624|Drug|SOTB07|SOTB07 200mg
1847845|NCT00936624|Drug|placebo|placebo
1847846|NCT00936624|Drug|montelukast|montelukast 10mg po, bid, 12week
1847850|NCT00936663|Drug|Sitagliptin|Active drug dose will be 100 mg per day for estimated GFR above 50 ml/min. The dose will be decreased to 50 mg per day for estimated GFR 30-50 ml/min. The dose will be decreased further to 25 mg for those with estimated GFR below 30 ml/min or on dialysis.
1847851|NCT00936663|Drug|Placebo|Drug will be available as 100, 50, and 25 mg size with identical placebo.
1847852|NCT00936676|Drug|rasagiline mesylate|During the Core follow-up study period, subjects will continue to receive 1 mg rasagiline once a day. During the Extended follow-up study period, only subjects who are still on rasagiline at Visit 9 will continue to receive treatment with rasagiline 1 mg per day. Tablets will be supplied by the Sponsor and given according to the label.
1847853|NCT00936689|Procedure|Selective TACE via microsphere loaded with Doxorubicin|Chemoembolization with microspheres: doxorubicin (maximum dose of 75 mg x vials of microspheres) loaded with non-reabsorbable microspheres (sulfate hydrospheres) at the dose of 2 ml per vial (definitive embolization).
1847854|NCT00936689|Procedure|Selective traditional TACE|Traditional chemoembolization: epirubicin (maximum dose of 75 mg) conjugated with Lipiodol at the maximum dose of 15 ml + Spongel.
1847855|NCT00936702|Drug|carboplatin|Given IV
1847856|NCT00936702|Drug|everolimus|Given PO
1847857|NCT00936702|Drug|paclitaxel|Given IV
1847858|NCT00936715|Drug|FTC/TDF|200/300 mg tablet administered orally once daily
1847859|NCT00936728|Other|therapeutic nutritional supplementation|Given orally
1847860|NCT00936728|Dietary Supplement|white wine|Given orally
1847861|NCT00936728|Other|questionnaire administration|Ancillary studies
1847862|NCT00936741|Drug|mifepristone|Mifepristone 300 mg to 1200 mg once daily
1847863|NCT00936754|Dietary Supplement|Brown seaweed powder|500 mg (in two 250 mg capsules) taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
1847864|NCT00936754|Dietary Supplement|Placebo|Two capsules similar in aspect and weight to active product, taken with 250 ml of water 30 minutes before test meal (110g of plain white bread with 250 ml of water)
1847865|NCT00936767|Drug|Artemisone/Mefloquine (AmiM3)|Artemisone 4 mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
1847866|NCT00936767|Drug|Artesunate|Artesunate 4mg/kg/day for 3 days plus mefloquine 15mg/kg on day 3 and 10mg/kg on day 4
1847867|NCT00936780|Device|Infinnium-Core™ Paclitaxel eluting Coronary Stent|Infinnium-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Drug concentration is 1.36 µg/mm2.
1847868|NCT00936793|Drug|Darunavir|
1847869|NCT00936793|Drug|Ritonavir|
1847870|NCT00936793|Drug|Beclomethasone Dipropionate HFA|
1847871|NCT00936819|Biological|Plasma-Lyte A and 25% Autologous Plasma|Single dose of 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
1847872|NCT00936819|Biological|Autologous EPCs|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
1847873|NCT00936819|Biological|Autologous EPCs Transfected with human eNOS|Single dose of 20 million cells in 8 mls given by investigator via intracoronary injection into stent of infarct-related artery
1847874|NCT00936832|Drug|FOLFIRI regimen|
1847875|NCT00936832|Drug|fluorouracil|
1847876|NCT00936832|Drug|irinotecan hydrochloride|
1847877|NCT00936832|Drug|leucovorin calcium|
1847878|NCT00936832|Drug|sunitinib malate|
1847879|NCT00936832|Other|laboratory biomarker analysis|
1847880|NCT00936832|Other|pharmacogenomic studies|
1847881|NCT00936832|Other|pharmacological study|
1847882|NCT00936858|Drug|RAD001|Taken orally once a day in the morning
1847883|NCT00936871|Drug|Lersivirine|Lersivirine 2400 mg single dose
1847884|NCT00936871|Drug|Placebo|Placebo single dose
1847885|NCT00936871|Drug|Lersivirine (if necessary)|Lersivirine 2100 mg single dose (if necessary)
1847886|NCT00936871|Drug|Lersivirine|Lersivirine 2400 mg single dose (dose may be decreased pending Part A tolerability results)
1847887|NCT00936871|Drug|Placebo|Placebo single dose
1847888|NCT00936871|Drug|Moxifloxacin|Moxifloxacin 400 mg single dose
1847889|NCT00936884|Drug|MOA728|"0.6 ml (12 mg), qod if weight=>62kg;
0.4ml (8 mg), qod if weight between 38 and <62;
0.0075ml/kg (0.15mg/kg), qod if weight between 27 and <38kg; study duration: 2 weeks"
1847890|NCT00936884|Drug|MOA728|"0.6 ml, qod if weight=>62kg;
0.4ml, qod if weight between 38 and <62;
0.0075ml/kg, qod if weight between 27 and <38kg; study duration: 2 weeks"
1847891|NCT00936897|Drug|Ibandronate|Ibandronate 150mg PO QM (tablet)
1847892|NCT00936897|Drug|Denosumab|denosumab 60mg SC Q6M (pre-filled syringe)
1847894|NCT00936923|Drug|furosemide|patients will take furosemide 60 or 120mg oral per day for 1 years .
1847895|NCT00936936|Drug|Gemcitabine|1800 mg/m^2 IV over 3 hours on Days -5 to Day -2.
1847896|NCT00936936|Drug|Docetaxel|Docetaxel 300 mg/m^2 IV over 2 hours on Day -5.
1847897|NCT00936936|Drug|Melphalan|50 mg/m^2 IV over 15 minutes on Days -4 to Day -2.
1847898|NCT00936936|Drug|Carboplatin|"Cycle 1: 333 mg/m^2 IV over 2 hours on Days -4 to -2.
Cycle #2: 300 mg/m^2 IV over 2 hours on Days -6 to -3."
1847899|NCT00936936|Drug|Mesna|3,000 mg/m^2 per day in 96-hour continuous infusion, starting 30 minutes prior to the first dose of ifosfamide, on Days -6 to -4.
1847900|NCT00936936|Drug|Ifosfamide|3,000 mg/m^2 IV over 6 hours on Days -6 to -3
1847901|NCT00936936|Drug|Etoposide|200 mg/m^2 IV over 3 hours, every 12 hours on Days -6 to -4.
1847902|NCT00936936|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
1847946|NCT00937274|Other|Commercial T4 phage cocktail|Treatment as recommended by the manufacturer (Microgen phages)
1992727|NCT03310099|Behavioral|Increasing daily unsaturated fatty acid consumption|Investigators will provide participant with detailed information about the consumption of food rich in unsaturated fatty acids (UFA) like extra-virgin olive oil, canola oil or mixed nuts, and they will provide specific recommendations based on the participant's diet. The investigators will follow up with a weekly phone call to assure that the dietary recommendations are clear and that the participants can integrate the suggestions into their daily diets.
1847903|NCT00936949|Procedure|surgical approach|Using a gluteus maximus split, the posterolateral approach remains posterior to the gluteus medius and minimus. Exposure of the hip and proximal femur requires division of the posterior hip capsule and the external rotators. The exposure and dislocation are completed with flexion and internal rotation of the femur. After arthroplasty, the external rotators and posterior capsule was routinely repaired using a heavy absorbable suture.
1847904|NCT00936949|Procedure|modified lateral approach|The operative technique described modified lateral approach as described by Mulliken et al.
1847905|NCT00936962|Biological|NeisVac C vaccine (12mth)|NeisVac C Meningococcal C Conjugate vaccine given IM 0.5mL in the deltoid muscle at 12 mths of age
1847906|NCT00936975|Radiation|Fluorine F 18 Sodium Fluoride|Undergo fluorine F 18 sodium fluoride PET scan
1847907|NCT00936988|Drug|cinacalcet|Subjects began open-label treatment with 30 mg cinacalcet twice daily (BID) at the start of the current study. The study consisted of 2 phases planned to total approximately 4¾ years: a 12-week dosetitration phase (visits at weeks 2, 3, 4, 6, 9, and 12) during which 1 possible dose increase of cinacalcet from 30 mg BID to 50 mg BID could occur at week 6, and a maintenance phase (week 12 to 234; visits approximately every 4 weeks until week 24 and approximately every 14 weeks thereafter) during which doses also could be titrated. After July 2004, because of a change in dose strengths, the daily doses used in the study were 30 and 60 mg BID with the option to reduce to 30 mg once daily (QD), if necessary. Ongoing subjects receiving 50 mg BID were switched at that time to 60 mg BID.
1847908|NCT00937001|Procedure|Biopsy/Ultrasound|obtain muscle biopsies at approximately 14 days of ICU, muscle ultrasound at 3-4 timepoints
1847909|NCT00937014|Other|standard infant formula|Standard infant formula given during the first 9 months of life, as per standard requirement
1847910|NCT00937014|Other|Test formula|Test formula enriched in lactoferrin given during the first 9 months of life, as per standard requirement.
1847911|NCT00937027|Drug|Aminopterin|oral tablets, 1.0 mg dose, once weekly, two weeks
1847912|NCT00937040|Drug|OROS MPH|Optimal Patient Dose (18 mg-72 mg) once daily for 6 weeks
1847913|NCT00937040|Drug|Placebo|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily for 6 weeks
1847914|NCT00937040|Drug|OROS MPH Tablets|Optimal Patient Dose (18 mg-72 mg) once daily by mouth for 6 weeks
1847915|NCT00937040|Drug|Placebo Tablets|Optimal Patient Dose (placebo to match 18 mg - 72 mg) once daily by mouth for 6 weeks
1847916|NCT00937053|Other|Transfusion level 120 g/dL|Patients whose hemoglobin falls below 120 g/dL will be transfused with red cells within 24 hours.
1847917|NCT00937053|Other|Transfusion level 70 g/dL|Patients whose hemoglobin falls below 70 g/dL will be transfused with red cells within 24 hours
1847918|NCT00937053|Other|Platelet transfusion|Patients whose platelets fall below 10 x 10*9 will be transfused with platelets
1847919|NCT00937079|Other|111In-exendin-4 imaging|90-100 megabecquerel (MBq) (30 microgram or less) 111In-exendin-4 IV once
1847920|NCT00937092|Drug|Furosemide|High-dose furosemide(HDF, furosemide 20 mg/h intravenously)
1847921|NCT00937092|Drug|low-dose dopamine + low-dose furosemide|low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)
1847922|NCT00937105|Device|lotrafilcon A contact lenses|FDA approved soft contact lenses
1847923|NCT00937105|Device|Renu Multiplus|
1847924|NCT00937105|Device|Clear Care|
1847925|NCT00937131|Drug|Rituximab|Concentrate for solution for infusion, Intravenous use, 375mg/m2, Maximum 8 weekly infusions
1847926|NCT00937144|Drug|Viagra (Sildenafil)|Viagra treatment to patients with sickle cell anemia.
1847927|NCT00937144|Drug|placebo|
1847928|NCT00937157|Drug|Copaxone|12 MS patients will be enrolled on GA (Copaxone®) monotherapy (20mg/day sc). Initial intravenous steroid treatment will be given on day 0. 1.5T and 3T scans will be obtained and according to the following schedule: 1 gm Solumedrol i.v. daily for three days. Intravenous steroids will be also allowed for treatment of MS attacks according to the following schedule: 1 gm Solumedrol i.v. daily for three days.
1847929|NCT00937170|Device|Zimmer LPS flex Gender Specific Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
1847930|NCT00937170|Device|Zimmer High Flex LPS Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
1847931|NCT00937170|Device|Stryker Triathlon Implant (Total knee replacement)|Outcomes comparison between a gender specific total knee implant, a standard total knee implant by the same company, and a standard total knee implant from another company
1847932|NCT00937183|Biological|autologous lymphoma cell lysate-pulsed autologous dendritic cell vaccine|
1847933|NCT00937183|Biological|autologous lymphoma cell/allogeneic dendritic cell electrofusion hybrid vaccine|
1847934|NCT00937183|Biological|autologous lymphoma cell/autologous dendritic cell electrofusion hybrid vaccine|
1847935|NCT00937196|Drug|Placebo globuli|placebo globuli administered together with verbal suggestions of a hypotensive drug effect
1847936|NCT00937196|Drug|Histaminum hydrochloricum globuli|
1847937|NCT00937222|Dietary Supplement|Peanuts and peanut butter|Peanuts and peanut butter
1847938|NCT00937235|Drug|Varenicline|1 mg tablets, orally, twice daily x 12 weeks
1847939|NCT00937235|Behavioral|Medication Management Counseling|15-minutes weekly counseling x 12 weeks, focused on medication adherence and smoking cessation
1847940|NCT00937235|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
1847941|NCT00937248|Device|prone pillow and simple ankle fixation device|Patients will lie face down (prone) on a soft cushion made of foam under their face and upper chest. Additionally, there is a foam support placed at the ankles.
1847942|NCT00937248|Device|Customized Vacuum Immobilization Device (CVID)|This device is a bean bag like cushion that is placed from the abdomen to the thighs. When a patient is comfortably lying on this device, air within the bag is suctioned out resulting in an impression or cast of a patient.
1992728|NCT03309644|Other|Peripheral nerve blockade|Participants who receive a peripheral nerve block identified through the medical chart.
1847947|NCT00937274|Other|standard oral rehydration solution (ORS)|Standard hospital treatment with ORS
1847948|NCT00937287|Other|There is no intervention in this study.|No intervention is provided in this study as it is exploratory.
1847949|NCT00937300|Biological|cyclophosphamide, fludarabine, T-cell infusion, and Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks.
1847950|NCT00937313|Other|Champagne wine intervention|Placebo-controlled randomised cross-over human trial
1992729|NCT03309644|Other|No peripheral nerve blockade|Participants who did not receive a peripheral nerve block identified through the medical chart.
1992730|NCT03309631|Diagnostic Test|In vitro Diagnostic|
1847953|NCT00937339|Device|Whole body vibration therapy|Experimental group: One session per day, 3 sessions per week, for consecutive 8 weeks. The total duration of whole body vibration therapy will be about 10 minutes per session.
1847954|NCT00937339|Device|Exercise on the vibration platform with the device turned off|Control group: One session per day, 3 sessions per week, for consecutive 8 weeks. The subjects will perform the same exercises on the vibration platform but no vibration will be applied.
1847955|NCT00937352|Drug|Bapineuzumab|"0.5 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years.
1.0 mg/kg, administered via IV (in the vein) infusion every 13 weeks for 4 years."
1847956|NCT00937365|Behavioral|Exercise|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
1847957|NCT00937365|Procedure|Spinal Manipulation|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
1847958|NCT00937365|Procedure|Neuroemotional Technique (NET)|Study visits follow the normal prenatal care schedule (once monthly until 28 weeks, twice monthly until 36 weeks, weekly thereafter). Additional study visits may be necessary if the pain is too intense and requires additional visits.
1847959|NCT00937378|Drug|SER120|Nasal Spray, once a day
1847960|NCT00937378|Drug|Placebo|Nasal Spray
1847961|NCT00937391|Drug|Gadopentetate dimeglumine (Magnevist, BAY86-6661)|For stage 1: Participants received an IV injection of 0.05 mmol/kg Body Weight (BW) (0.1 mL/kg BW) Magnevist. Upon completion of the MR imaging, the participants received another injection of 0.05 mmol/kg for a total cumulative dose of 0.1 mmol/kg BW (0.2 mL/kg BW). For stage 2: Participants received the optimal efficacious dose established in Stage 1 as a single IV injection of Magnevist Injection (0.1 mmol/kg BW (0.2 mL/kg BW)).
1847962|NCT00937404|Biological|Poliorix™|Three dose, intramuscular administration
1847963|NCT00937417|Drug|docetaxel|
1847964|NCT00937417|Drug|vandetanib|
1847965|NCT00937417|Genetic|proteomic profiling|
1847966|NCT00937417|Other|laboratory biomarker analysis|
1847967|NCT00937417|Other|pharmacological study|
1847968|NCT00937430|Other|Bowel preparation (Fleets enema)|Use of Bowel preparation (Fleets enema)
1847969|NCT00937443|Other|Physical Fitness|Does intensity of aerobic walking exercise modify cardiac reparative factors
1847970|NCT00937443|Biological|Walking Exercise Group|Walking Group will increase intensity, duration, and steps of walking per week.
1847971|NCT00937456|Procedure|Laparoscopically-assisted esophagectomy|To compare during the abdominal approach the laparoscopic route to the open route for gastric mobilization. Thoracic approach will be the same between the 2 arms through thoracotomy with extended two field lymphadenectomy
1847972|NCT00937469|Behavioral|Social skills training, parental tr. and standard tr.|Social skills training will consist of 8 weeks of group treatment with weekly sessions of one and a half hours and includes role play, exercises and games as well as home work which will include the parents. At the same time the parents are participating in parental training groups,that will focus on supporting the children's social training. Both the children and the parental groups are lead by two group therapists. The intervention will be additional to the received standard treatment.
1847973|NCT00937469|Other|Standard treatment|The standard treatment consists of medical treatment, briefing, consulting and supporting conversations with a focus on securing compliance to the treatments´ and on aiding children and their families with the difficulties arising with the children's illness. Furthermore the parents participate in parental groups three times during the 8 weeks in which the experiment takes place. This group lasts 2 hours and is managed by two nurses who are attached to the ADHD- treatment group.
1847974|NCT00937482|Drug|cediranib maleate|Given orally
1847975|NCT00937482|Radiation|whole-brain radiation therapy|Undergo whole-brain radiotherapy
1847976|NCT00937495|Drug|vorinostat|400 mg given PO
1847977|NCT00937495|Drug|bortezomib|1.3 mg/m^2 given IV
1847978|NCT00937508|Behavioral|Smoking counseling|Preoperative and postoperative counseling sessions provided by a trained smoking counselor along with placebo.
1847979|NCT00937508|Drug|varenicline|varenicline (an approved medication for smoking cessation)
1847980|NCT00937508|Drug|placebo|sugar pill without any active medication
1847981|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation I
1847982|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation II
1847983|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation III
1847984|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation IV
1847985|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation V
1847986|NCT00937521|Biological|Meningococcal B vaccine|Vaccine candidate formulation VI
1847987|NCT00937521|Biological|Control|Control
1847988|NCT00937521|Biological|Meningococcal B vaccine with antipyretic|Vaccine candidate formulation I with antipyretic
1847989|NCT00937534|Drug|Fimasartan|Fimasartan 240mg/day
1847990|NCT00937560|Drug|Bevacizumab|Bevacizumab was supplied as a sterile solution for infusion.
1847991|NCT00937560|Drug|Paclitaxel|Paclitaxel was supplied locally in commercial batches.
1847992|NCT00937560|Drug|Carboplatin|Carboplatin was supplied locally in commercial batches.
1847993|NCT00937599|Dietary Supplement|Brazil Nut|During 16 weeks the adolescents consumed 3-5 nuts/day
1847994|NCT00937612|Radiation|Radiotherapy|postoperative radiotherapy, 60-66 Gy/30-33 fractions, concurrently with triweekly chemotherapy by Cisplatin
1847995|NCT00937625|Biological|cyclophosphamide, fludarabine, T-cells, Interleukin-2|Two days of cyclophosphamide (60 mg/kg i.v.) and five days of fludarabine (25 mg/m2 i.v.). Infusion of Tumor Infiltrating Lymphocytes (10e9-10e10 cells). Followed by daily sc injections of 2 MIE Interleukin-2 for two weeks. After the first 6 patients the dose of IL-2 has been changed to an i.v. decrescendo regimen using 18 MIU/m2 infused over 6, 12 and 24 hours and then 4.5 MIU/m2 infused over 24 hours for three days.
1847996|NCT00937638|Dietary Supplement|BOLD Diet|Low-fat, high fruit and vegetable diet that includes lean beef (5oz/day)
1847997|NCT00937638|Dietary Supplement|BOLD-X Diet|Low-fat, moderate-high protein diet (BOLD+) that is higher in total protein (from mixed sources including lean beef, 7oz/day) than the BOLD diet. Also high in fruits and vegetables
1847998|NCT00937638|Dietary Supplement|Modified DASH Diet|Low-fat, high fruit and vegetable diet which has become the Gold Standard for the management of cardiovascular disease (CVD) risk factors and metabolic syndrome
1847999|NCT00937651|Drug|Placebo|Placebo
1848000|NCT00937651|Drug|Fimasartan (BR-A-657•K) 20 mg|Fimasartan 20 mg, 1 tablet + placebo, 2 tablets
1848001|NCT00937651|Drug|Fimasartan (BR-A-657•K) 60 mg|Fimasartan 20 mg, 1 tablet + 40 mg, 1 tablet + placebo 1 tablet
1848002|NCT00937651|Drug|Fimasartan (BR-A-657•K) 180 mg|Fimasartan 20 mg, 1 tablet + 80 mg, 1 tablet + 80 mg 1 tablet
1848003|NCT00937664|Drug|AZD7762|solution, intravenous, weekly
1848004|NCT00937664|Drug|gemcitabine|intravenous, weekly
1848005|NCT00937677|Drug|Tysabri|"Infusion of TYSABRI® 300 mg in 100 mL 0.9% Sodium Chloride Injection, USP over approximately one hour at month 0 and 12 and 24 months. After the infusion is complete, flush with 0.9% Sodium Chloride Injection, USP.
Use of filtration devices during administration has not been evaluated. Other medications should not be injected into infusion set side ports or mixed with TYSABRI®.
TYSABRI® concentrate is supplied as 300 mg natalizumab in a sterile, single-use vial free of preservatives. Each package contains a single-use vial."
1848006|NCT00937703|Device|placebo|paper support for glycaemia face to face visit at T4mounths
1848007|NCT00937703|Device|IVS|"patients transmit their glycaemia to the IVS, which advises them the insulin amount recommended by their physician in this situation.
Face to face visit at T4mounths plus telephone visits each 2 weeks."
1848008|NCT00937703|Device|PDAphone|Patients will receive PDA phone system. They will hace face to face visit at T4mounths and telephone visits each 2 weeks
1848009|NCT00937742|Dietary Supplement|Tomato products|Specified amounts of tomato products (i.e. tomato juice, ketchup, salsa, tomato soup, spaghetti sauce) to be consumed daily during a 6 week intervention phase.
1848010|NCT00937768|Drug|Goserelin Acetate|Given SC
1848011|NCT00937768|Other|Laboratory Biomarker Analysis|Correlative studies
1848012|NCT00937768|Drug|Leuprolide Acetate|Given IM
1848013|NCT00937768|Other|Quality-of-Life Assessment|Ancillary studies
1848014|NCT00937781|Genetic|RNA analysis|
1848015|NCT00937781|Genetic|gene expression analysis|
1848016|NCT00937781|Genetic|microarray analysis|
1848017|NCT00937781|Genetic|polymerase chain reaction|
1848018|NCT00937781|Other|immunohistochemistry staining method|
1848019|NCT00937781|Other|laboratory biomarker analysis|
1848020|NCT00937794|Behavioral|Neurobehavioral testing|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to assess his neurodevelopmental status using a standardized battery of neurobehavioral testing.
1848021|NCT00937794|Other|Visual and auditory assessments|If the patient is found to be eligible after completion of a telephone interview, he will undergo further testing to evaluate his visual and auditory function.
1848022|NCT00937807|Drug|xenon|Inhalational gas; dose allowed: 60 % Xenon; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
1848023|NCT00937807|Drug|sévoflurane|Inhalation gas; dose allowed: 1,4 %; the duration of the treatment will be defined through anesthesia-time for a carotid surgery
1848024|NCT00937820|Drug|YM150|oral
1848025|NCT00937833|Procedure|Prostatectomy|
1848026|NCT00937833|Device|Surgisis Male Sling|
1848027|NCT00937846|Drug|GSK1034702|Single oral 5 mg dose in liquid formulation
1848028|NCT00937859|Drug|SER120|SER120
1848029|NCT00937859|Drug|Placebo|Placebo
1848030|NCT00937872|Drug|250 mg SRT2104 Suspension|Single 10 mL oral dose of 250 mg SRT2104 delivered as a suspension formulation.
1848031|NCT00937872|Drug|Carbon-14 radio-labeled SRT2104|Single 10 mL IV dose containing 100 microgram (not more than 250 nCi, 9.25 kBq) Carbon-14 radio-labeled SRT2104, administered by IV infusion over 15 minutes, starting 2 hours and 45 minutes after the oral dose is administered.
1848032|NCT00937885|Behavioral|Implementation of reminiscence|
1848033|NCT00937898|Dietary Supplement|BOLD+ Diet|Comparison of lean beef based, high protein diet to DASH diet and Average American diet on cardiovascular disease risk factors
1848034|NCT00937898|Dietary Supplement|BOLD diet|Comparison of lean beef based diet to DASH diet and Average American diet on risk factors of cardiovascular disease
1848035|NCT00929825|Device|mechanical stimulation (Elastomers)|The instrument of mastication, sialogogue should be used 4 times a day for 10 minutes each time always after meals
1848036|NCT00929825|Procedure|TENS|transcutaneous electrical stimulation
1848037|NCT00929838|Behavioral|Diabetes Knowledge/Information|This group will receive telephone-delivered diabetes knowledge/information lasting 30 minutes for 12 weeks.
1848038|NCT00929838|Behavioral|Motivation/Behavioral Skills|This intervention consists of patient activation, patient empowerment, and behavioral skills training delivered via telephone lasting 30 minutes every week for 12 weeks.
1848039|NCT00929838|Behavioral|Combined Intervention|This group will receive all components of the diabetes knowledge/information and the motivation/behavioral skills interventions via telephone lasting 30 minutes every week for 12 weeks.
1848040|NCT00929838|Behavioral|Usual Care|This group will receive telephone-delivered general health education lasting 30 minutes for 12 weeks to control for attention and content.
1850401|NCT00946699|Biological|MEDI-551|1.0 mg/kg
1848041|NCT00929851|Drug|CHF1535|Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose
1848042|NCT00929851|Drug|Formoterol fumarate|Formoterol fumarate 12 µg per metered dose
1848043|NCT00929864|Drug|Abatacept|Syringes, Subcutaneous, 125 mg/syringe for Subcutaneous, Weekly Subcutaneous injections, 24 months (729 days)
1848044|NCT00929864|Drug|Adalimumab|Syringes, Subcutaneous, 40 mg, Biweekly Subcutaneous injections, 24 months (729 days)
1848045|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
1848046|NCT00929877|Drug|KETOPROFEN(RP19583)|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
1848047|NCT00929877|Drug|Placebo|Oral administration up to a maximum of 5 lozenges within a 24-hour period during 3 days
1848048|NCT00929890|Behavioral|General lifestyle, diet and physical activity counselling|Low-calorie, balanced diet and a general advice on the importance of regular physical activity
1848049|NCT00929890|Behavioral|Exercise training|Subject will receive dietary counselling (low-calorie, balanced diet) and will be enrolled in a supervised, 3 times a week, exercise training program
1848050|NCT00929903|Drug|pazopanib hydrochloride|Given orally
1848051|NCT00929903|Other|pharmacological study|Correlative studies
1848052|NCT00929929|Dietary Supplement|L-leucine.|10 g of leucine per day, during 12 weeks.
1848053|NCT00929929|Dietary Supplement|Maltodextrin.|10 g of maltodextrin per day, during 12 weeks.
1848054|NCT00929929|Behavioral|Exercise program.|Progressive resistance exercise program 4 days a week, during 12 weeks.
1848055|NCT00929942|Device|SX-ELLA Stent Degradable DV Bronchial (DV Stent)|"Intervention SX-ELLA Stent Degradable DV Bronchial (DV Stent) will be implanted in the target lesion in general anesthesia under fluoroscopy or by direct vision. Before dilatation, extension of the airway complications will be measured by bronchoscopy and documented."
1848056|NCT00929955|Drug|Ondansetron|ondansetron added to TAU Ondansetron will be administered in 8mg once daily dose
1848057|NCT00929955|Drug|Simvastatin|Simvastatin added to TAU Simvastatin 20mg taken as once daily dose
1848058|NCT00929955|Drug|Placebo|Placebo added to TAU
1848059|NCT00929968|Biological|Placebo|
1848060|NCT00929968|Biological|VAK694|
1848061|NCT00929968|Drug|Fluticasone|
1848062|NCT00929981|Drug|Tablet Methylprednisolone (4 or 16 mg)|Oral Methylprednisolone tablets (4mg, 16mg) will be given as per locally approved prescribing information
1992763|NCT03302689|Drug|Levobupivacaine Solution|TAP-block with Levobupivacaine 0,3% - 25 ml from each side
1848064|NCT00930007|Other|Blood sampling|Blood sampling for later hormone measurements
1848065|NCT00930020|Drug|Minocycline (Borymycin)|oral dose, 200 mg once a day for 5 days
1848066|NCT00930020|Drug|Matched placebo|matched placebo (cornstarch) once a day for 5 days
1848067|NCT00930033|Procedure|Nephrectomy|Current surgery
1848068|NCT00930033|Other|Sunitinib alone|Sunitinib alone without nephrectomy
1848069|NCT00930046|Device|Wound catheter|19 gauge fenestrated wound catheter inserted into the fascial planes of the surgical site prior to skin closure with a separate exit site.
1848070|NCT00930046|Device|wound catheter|19 gauge fenestrated wound catheter will be inserted into the fascial planes of the surgical site prior to wound closure
1848071|NCT00930059|Drug|PF-04447943|tablets, 25 mg every 12 hours for 12 wks
1848072|NCT00930059|Drug|Placebo|matching placebo tablets, every 12 hours for 12 wks
1848073|NCT00930072|Drug|Cervical Sympathetic Block (bupivicaine, clonidine)|12-15ml solution of bupivicaine .5% containing 50 mcg of clonidine for cervical sympathetic block administered in a single injection.
1848074|NCT00930085|Other|SELDI-TOF MS for plasmatic proteic profile|An extra blood sample is required to determine the plasmatic proteic profile used to identify one or several signatures which are correlated to the clinical evolution (mortality at D30).
1848075|NCT00930098|Drug|clofarabine|
1848076|NCT00930111|Other|2-week rotation|Attending physician is assigned to a 2-week rotation.
1848077|NCT00930111|Other|4-week rotation|Attending physician is assigned to a 4-week rotation.
1848078|NCT00930124|Procedure|Orthognathic surgery|Patients with moderate maxillary hypoplasia needing an advancement of 4-10mm
1848079|NCT00930124|Procedure|Distraction osteogenesis|
1848080|NCT00930137|Other|isocaloric for week diet|"Consumption of the 2 experimental diets
a diet rich in ruminant trans fatty acids (4.1 g/2500 kcal);
a control diet (minimal dietary ruminant trans fatty acids, 0.7 g/2500 kcal)."
1848081|NCT00930150|Behavioral|Targeted cognitive training|Adaptive computer exercises that systematically increase in task difficulty as each participant's performance ability improves
1848082|NCT00930150|Behavioral|Computer control|Commercially available computer games selected based on quality, ability to hold interest, and lack of disturbing content
1848083|NCT00930150|Behavioral|Bridging groups|Weekly group meetings that help participants apply their cognitive skills to everyday functioning, promote group identity, and promote socialization
1848084|NCT00930150|Behavioral|Health and wellness groups|Weekly group meetings that teach participants health and wellness skills
1848085|NCT00930163|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
1848086|NCT00930163|Drug|placebo|Subcutaneous repeating dose
1848087|NCT00930176|Biological|Human Coagulation FACTOR X|Standard dose 25IU/kg to be administered at the Baseline Visit (1st PK assessment) and at the repeat PK assessment. Also administered to treat a bleed or to prevent a bleed.
1848088|NCT00930189|Drug|intravitreal injection of ranibizumab|
1848089|NCT00930189|Drug|intravitreal injection of triamcinolone|
1848090|NCT00930189|Procedure|photodynamic therapy|
1848091|NCT00930202|Drug|Conivaptan (Vaprisol)|Conivaptan (Vaprisol) will be administered in a single dose of 20 mg, mixed with 100 mL of 5% dextrose in water, and delivered over 30 minutes.
1848092|NCT00930215|Drug|D961H|Oral gelatin capsule
1848093|NCT00930215|Drug|D961H|Oral HPMC capsule
1848094|NCT00930228|Drug|Flutamide|Flutamide, 250 mg capsule for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
1992764|NCT03302689|Drug|Ropivacaine Solution|TAP-block with Ropivacaine 0,3% - 25 ml from each side
1848095|NCT00930228|Drug|Placebo|Placebo, for oral administration, twice a day for 4 weeks (or menstrual cycle length in normally-cycling controls)
1848096|NCT00930241|Drug|Advagraf®|Advagraf® (one daily dose of Tacrolimus)
1848097|NCT00930241|Drug|Prograf®|Prograf® (two daily doses of Tacrolimus)
1848098|NCT00930254|Procedure|IV puncture guided by ultrasound|Comparisons between traditional and ultrasound group
1848099|NCT00930293|Behavioral|Interpersonal Psychotherapy for Depression with Panic and Anxiety Symptoms (IPT-PS)|16 weekly IPT-PS sessions, each lasting approximately 45 minutes
1848100|NCT00930293|Behavioral|Brief Supportive Psychotherapy (BSP)|16 weekly BPS sessions, each lasting approximately 45 minutes
1848101|NCT00930293|Drug|Citalopram hydrobromide|A 20-week regimen of citalopram hydrobromide monotherapy on a flexible dosing schedule ranging from 10 to 60 mg/day
1848102|NCT00930306|Drug|AZD2066|12 doses, Given as capsule, 2 mg & 8 mg
1848103|NCT00930306|Drug|Caffeine|2 doses, Given as Tablet, 2x50 mg
1848104|NCT00930306|Drug|Tolbutamide|2 doses, Given as Tablet, half of 500 mg
1848105|NCT00930306|Drug|Omeprazole Tablet, 20 mg|2 doses, Given as Tablet, 20 mg
1848106|NCT00930306|Drug|Midazolam Tablet, 7.5 mg|2 doses, Given as Tablet, 7.5 mg
1848107|NCT00930319|Other|Firmagon given by prescription according to SPC|Non-interventional,observational Firmagon given by prescription according to SPC
1848108|NCT00930332|Drug|methadone hydrochloride|"Level 1: 1 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA** per day)
Level 2: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
Level 3: 3mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
OR
Level 1: 2 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
Level 2: 3 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)
Level 3: 4 mg q8h, breakthrough 1 mg q2h* (maximum 6 BTA per day)"
1848109|NCT00930332|Other|questionnaire administration|within 48 hours of registration
1848110|NCT00930332|Procedure|management of therapy complications|if required
1848111|NCT00930345|Drug|Sunitinib (SUTENT)|"Sunitinib, SUTENT, 50 mg daily p.o., on schedule 4/2, for 2 cycles. Two weeks of rest prior to surgery (week 11 and 12).
Radical nephrectomy at the end of week 12. Sunitinib 50 mg/d, schedule 4/2, reintroduced 2 weeks after surgery (week 14, may be postponed by one or two weeks if wound healing delay or surgical complications). Treatment until disease progression, unacceptable toxicity or consent withdrawal. Dose reduction depending on the type and severity of toxicity.
At the end of the treatment period patients will be treated at the discretion of the Investigator."
1848112|NCT00930358|Drug|MEOPA|anaesthetic gaz inhalation
1848113|NCT00930358|Drug|general anaesthesia|Anaesthetic intravenous route
1848114|NCT00930371|Other|high fat/high saturated fat diet|4 weeks 55% fat/25% saturated fat isocaloric diet
1848115|NCT00930371|Other|low fat/low saturated fat diet|4 weeks 20% fat/8% saturated fat isocaloric diet
1848116|NCT00930410|Procedure|Endoscopic Retrograde Cholangio-Pancreatography (ERCP)|Utilisation of the Intra-ductal confocal endomicroscopy to obtain any exploitable image for the anatomopathology.
1848117|NCT00930436|Drug|sodium bicarbonate|Serum creatinine will be measured on Days 3,7, 30, 90, and 180
1848118|NCT00930449|Other|Cogmed Working Memory Training Program.|"This program includes a set of visual-spatial and auditory-verbal WM tasks presented via the computer (see Appendix 1 for a description of these tasks). All tasks involve: a) maintenance of simultaneous mental representations of multiple stimuli; b) unique sequencing of stimulus order in each trial; and c) progressive adaptation of difficulty level as a function of individual performance.
Training will require about 30 minutes per day, 5 days per week, for 5-6 weeks: participants are required to complete 90 WM trials on each training day. Training plans are individualized and are modified according to performance, but the typical plan includes 13 tasks, with 15 trials of 8 tasks each day."
1848119|NCT00930449|Other|Academy of Math|"This is an established evidence-based program designed to help at-risk learners (Grades K-12) develop mathematical proficiency by incorporating a mastery-learning approach to foster conceptual understanding, computational fluency, and strategic competency across 10 mathematical subject areas.
Training is will require about 30 minutes, 5 days per week, for the same duration as the WM program (5-6 weeks), with a counselor or teacher acting as the training aide."
1848120|NCT00930449|Other|Special Education/Individualized Tutoring|Students in this group will receive an additional 30 minutes daily of individualized supplemental instruction in their area of greatest academic need.
1848121|NCT00930462|Device|Cap (Olympus Medical Systems: D-201-15004, D-201-14304 and D-201-12704)|Plastic cap fitted on the colonoscope
1848122|NCT00930475|Drug|RAD001 (Everolimus) in combination with carboplatin|phase I: dose levels: 2,5 mg, 5 mg, 7,5 mg and 10mg daily in combination with carboplatin AUC2 weekly until progress
1848123|NCT00930475|Drug|RAD001 (Everolimus) in combination with carboplatin|phase 2: 10mg RAD001 in combination with carboplatin
1848124|NCT00930488|Drug|Avelox (Moxifloxacin, BAY12-8039)|Patients with a diagnosis of acute bacterial sinusitis who take moxifloxacin
1848125|NCT00930501|Biological|blood tests|time 0 is pretreatment time 3, 6 , 9, 12 months from the end of chemotherapy
1848126|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 1400 mg dose level, administered every 2 or 3 months.
1848127|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection at 800 mg/m^2 dose level, administered every 2 or 3 months.
1848128|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 625 mg/m^2 administered every 2 or 3 months.
1848129|NCT00930514|Drug|Rituximab|Rituximab intravenous infusion 375 milligram per square meter (mg/m^2) administered every 2 or 3 months.
1848130|NCT00930514|Drug|Rituximab|Rituximab subcutaneous injection 375 mg/m^2 administered every 2 or 3 months.
1848131|NCT00930527|Dietary Supplement|Omega-3 Fatty Acid|4g per day for 3 weeks
1848132|NCT00930553|Biological|alemtuzumab|Alemtuzumab 12 mg/day IV infusion on 5 consecutive days if the participants had no prior alemtuzumab exposure (ie, first treatment course). All subsequent treatment courses were for 3 days only.
1848179|NCT00930891|Drug|Experimental Treatment (PCDE or PE + bevacizumab)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression
PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles Bevacizumab 7.5 mg/kg, D1, until progression"
1848276|NCT00931697|Drug|Racemic Mefloquine|Single dose delivered as over-encapsulated tablet at ascending dose
1848133|NCT00930566|Drug|methoxsalen|"UVADEX® is supplied in a 10 mL single-use vial. Each mL of solution contains 20 mcg of UVADEX®.
In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button. The dose of UVADEX used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, usinge the following formula :
Treatment Volume in mL x 0.017 = Dose of UVADEX® (in mLs) required for administration into the recirculation bag.
After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
1848134|NCT00930566|Procedure|Extracoporal Photopheresis (ECP)|"In the ECP process, UVADEX® will be injected directly into the Recirculation Bag of the extracorporeal circuit after completion of the buffy coat collection, just prior to pressing the photoactivation button.
After the cells are inoculated with UVADEX, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then reinfused back into the patient."
1848136|NCT00930605|Drug|CHOP regimen alternate with ESHAP regimen|CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
1848137|NCT00930605|Drug|Alemtuzumab|Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5.
1848138|NCT00930618|Drug|IMN|Administration of 2 x 20 mg of isosorbide mononitrate at each administration with a maximum of three administrations
1848139|NCT00930618|Drug|Placebo|Administration of 2 X 20 mg of placebo of IMN at each administration with a maximum of three administration
1848140|NCT00930631|Drug|[3H] BMS747158|Single bolus intravenous injection of [3H] BMS747158
1848141|NCT00930644|Drug|teduglutide|0.05 mg/kg/day subcutaneously taken once per day for 24 months
1848142|NCT00930670|Drug|Rosuvastatin-omeprazole|Rosuvastatin 20 mg for 1 month. Then rosuvastatin 20mg and omeprazole 20mg for 11 months
1848143|NCT00930670|Drug|Rosuvastatin-pantoprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and pantoprazole 40 mg for 11 months
1848144|NCT00930670|Drug|Rosuvastatin-esomeprazole|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and esomeprazole 40 mg for 11 months
1848145|NCT00930670|Drug|Rosuvastatin-ranitidine|Rosuvastatin 20 mg for 1 month, then rosuvastatin 20 mg and ranitidine 300mg for 11 months
1848146|NCT00930670|Drug|Atorvastatin-omeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and omeprazole 20 mg for 11 months
1848147|NCT00930670|Drug|Atorvastatin-pantoprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and pantoprazole 40 mg for 11 months
1848148|NCT00930670|Drug|Atorvastatin-esomeprazole|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and esomeprazole 40 mg for 11 months
1848149|NCT00930670|Drug|Atorvastatin-ranitidine|Atorvastatin 80mg for 1 month, then atorvastatin 80 mg and ranitidine 300mg for 11 months
1848150|NCT00930683|Drug|MEDI-546|0.1 mg/kg MEDI-546 as a single IV dose
1848151|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a single IV dose
1848152|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a single IV dose
1848153|NCT00930683|Drug|MEDI-546|3.0 mg/kg MEDI-546 as a single IV dose
1848154|NCT00930683|Drug|MEDI-546|10.0 mg/kg MEDI-546 as a single IV dose
1848155|NCT00930683|Drug|MEDI-546|0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses
1848156|NCT00930683|Drug|MEDI-546|1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
1848157|NCT00930683|Drug|MEDI-546|5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses
1848158|NCT00930683|Drug|MEDI-546|20.0 mg/kg MEDI-546 as a single IV dose
1848159|NCT00930696|Procedure|Extensive abdominal lavage|Extensive lavage of the abdomen with 8 liters of saline at the end of the surgical procedure
1848160|NCT00930696|Procedure|Rinsing of the abdomen|Standard rinsing of the abdomen with some 0,5 liters of saline at the end of the surgical procedure
1848161|NCT00930709|Drug|Botulinum toxin type A (Botox®, Allergan)|Two injections of 10-60 units of botulinum toxin type A. Injections are administered with ENMG assisted technique at the baseline and after 13 weeks.
1848162|NCT00930709|Behavioral|Active strength training and stretching|Training duration 9 weeks, intensified every 3 weeks in supervision of physiotherapist. Training program includes progressive, slow, repetitive wrist and forearm stretching, eccentric muscle strengthening, occupational exercises and upper limb neural mobilization training.
1848163|NCT00930722|Drug|quinapril|per label as non interventional study
1848164|NCT00930748|Device|MR imaging with endorectal coil|MR imaging with endorectal coil
1848165|NCT00930748|Device|MRI with endo-rectal coil|MRI with endo-rectal coil
1848166|NCT00930761|Behavioral|Music therapy|Music therapy sessions systematically offered to all mothers in the intervention group, three times a week, not mandatory, conducted by two music therapists in an appropriate room, during 60 minutes.
1848167|NCT00930774|Device|FM system|Frequency modulation assistive device
1848168|NCT00930774|Behavioral|Auditory training|Participation in computerized auditory training program for eight weeks
1848169|NCT00930787|Device|Strattice Reconstructive Tissue Matrix (Hernia Repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
1848170|NCT00930787|Device|Proceed Surgical Mesh (Hernia repair)|Hernia repair will be performed, in an open fashion and defect will be closed or reduced in size using musculofascial centralization procedures to reestablish midline.
1848171|NCT00930800|Other|Exercise|Using a video game so-called Dance Dance Revolution (DDR)
1848172|NCT00930813|Device|Lutonix Catheter|Paclitaxel Coated Balloon Catheter
1848173|NCT00930813|Device|Standard uncoated Balloon Angioplasty Catheter|plain, uncoated angioplasty balloon catheter
1848174|NCT00930839|Drug|Niacin and aspirin|1000 mg Niacin, 325 mg aspirin
1848175|NCT00930865|Drug|Bumetanide|Tablets, Oral, 1 mg, Single Dose, 7 Days
1848176|NCT00930865|Drug|Dapagliflozin|Tablets, Oral, 10 mg. Single Dose, 7 Days
1848177|NCT00930878|Device|Cardiac Stenting|Drug Eluting stent
1848178|NCT00930891|Drug|Standard Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2 ; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 4 cycles
PE: cisPlatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 4 cycles"
1848180|NCT00930891|Drug|Prerandomization Chemotherapy (PCDE or PE)|"PCDE: cisPlatin 75 mg/m² D2; Cyclophosphamide 300 mg/m² D1 to D3; 4'-epiDoxorubicin 30 mg/m² D1; Etoposide 75 mg/m² D1 to D3, 2 cycles
PE: cisplatin 80 mg/m², D2; Etoposide 120 mg/m² D1 to D3, 2 cycles"
1848181|NCT00930917|Device|Polyethylene cap|In the cap group, the head of the infant was covered with a polyethylene cap immediately after birth
1848182|NCT00930917|Device|Polyethylene wrap|Infants in the wrap group were placed into the polyethylene bag, while still wet, up to their necks; only the head was dried.
1848183|NCT00930917|Other|conventional treatment|Infants in the control group were dried completely, according to International Guidelines for Neonatal Resuscitation.
1848184|NCT00930930|Drug|cisplatin|Given IV
1848185|NCT00930930|Drug|everolimus|Given orally
1848186|NCT00930930|Drug|paclitaxel|Given IV
1848187|NCT00930930|Other|placebo|Given orally
1848188|NCT00930930|Procedure|Venous blood draw|Venous blood (2-3 tablespoons) will be taken for germline DNA analysis to complement the correlative studies in the tumor tissue. Blood can be drawn at any time prior, during, or after completion of study treatment
1848190|NCT00930956|Dietary Supplement|Resistant Starch|30 g of carbohydrate per Arm
1848191|NCT00930969|Device|ICD|Subjects implanted with an ICD.
1848192|NCT00930982|Drug|Ciprofloxacin (Cipro, BAYQ3939)|Inhalation of 32,5mg Ciprofloxacin inhaled twice a day
1848193|NCT00930982|Drug|Placebo|Inhalation of matching placebo twice a day
1848194|NCT00930995|Drug|Candesartan|16mg po daily
1848195|NCT00930995|Drug|Placebo|once daily
1848196|NCT00931008|Drug|SID530, Taxotere|75mg/m2
1848197|NCT00931021|Drug|Varenicline (Chantix)|2 mg
1848198|NCT00931021|Drug|Nicotine Patch|21 mg
1848199|NCT00931034|Behavioral|South Beach Diet with South Beach Diet Products|
1848200|NCT00931034|Behavioral|American Diabetes Association Diabetes Meal Plan|
1848201|NCT00931060|Dietary Supplement|Branched chain amino acids|Branched chain amino acids 0.45g/kg BW. Oral supplement. Administered once on study day
1848202|NCT00931073|Drug|Dimebon alone|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
1848203|NCT00931073|Drug|Dimebon + Ketoconazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 4 during the daily administration of ketoconazole (400 mg, Day 1-11) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
1848204|NCT00931073|Drug|Dimebon + Omeprazole|Pharmacokinetics of a single oral dose of 10 mg Dimebon (tablet) will be assessed on Day 5 during the daily administration of omeprazole(40 mg, Day 1-12) in subjects with a CYP2D6 extensive and poor metabolizer status based on genotyping as screening
1848205|NCT00931086|Drug|belimumab|IV 10mg/kg q28days
1848206|NCT00931112|Other|individualized exercise training|Lower extremities resistance exercise and bicycle training
1848207|NCT00931125|Drug|ranibizumab and vitrectomy|ranibizumab 10mg/ml intravitreal injection, 0,05 ml
1848208|NCT00931125|Procedure|vitrectomy without preoperative ranibizumab|sham intravitreal injection before vitrectomy surgery
1848209|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Daunorubicin : 80 mg/m2 d1-d3
1848210|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin :12 mg/m2 d1-d3
1848211|NCT00931138|Drug|chemotherapy (Aracytine + Daunorubicin)|Aracytine : 200 mg/m2 d1-d7 Idarubicin : 12 mg/m2 d1-d4
1848212|NCT00931151|Dietary Supplement|Postprandial metabolic and functional measures|After ingestion of a high fat meal containing the different protein sources, the subjects undergo a series of measures of endothelial dysfunction and blood and urine sampling for the assessment of proinflammatory cytokines levels and metabolomics determinations.
1848213|NCT00931164|Drug|Sodium Oxybate|dosage is by weight
1848214|NCT00931177|Other|weight|weight and dehydration scores
1848215|NCT00931177|Other|weight and dehydration score|weight and dehydration score
1848216|NCT00931203|Drug|Celecoxib|Celecoxib (400 mg/d) will be continued from day 1 to 65
1848217|NCT00931216|Procedure|Integrated ANC, PMTCT, HIV services|Of the 12 study clinics, 6 will be randomized to receive the intervention. At these 6 facilities, health care providers within the ANC department will be trained to also provide HIV/PMTCT care. Women testing positive within ANC clinics at integrated facilities will receive ANC, PMTCT and HIV services within the same visit/same service provider rather than being referred for HIV care and treatment.
1848218|NCT00931229|Drug|entecavir|All eligible patients will receive rituximab-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisolone) chemotherapy according to current treatment guidelines. The primary endpoint of this study is the incidence of HBV reactivation, defined by a greater than 10-fold increase, compared with previous nadir levels, of HBV DNA during rituximab-CHOP chemotherapy and within 1 year after completion of the last course of rituximab-CHOP chemotherapy. Patients who have HBV reactivation during the study period will receive free entecavir treatment, one of the standard treatment for chronic hepatitis B, for 48 weeks.
1848219|NCT00931242|Drug|Apremilast|Apremilast is being evaluated at daily doses of 20 mg by mouth (PO) twice daily (BID) for 12 weeks of treatment (treatment phase) in subjects with recalcitrant plaque-type Atopic Dermatitis (AD) or Allergic Contact Ddermatitis (ACD).
1992766|NCT03302091|Drug|BI 1467335|28 day treatment period
1848222|NCT00931268|Device|Macrolane VRF 30|One administration
1848223|NCT00931281|Drug|ABT-450|capsules, QD or BID, 14 days, ascending doses
1848224|NCT00931281|Drug|ritonavir|capsules, QD or BID, 14 days, ascending doses
1848225|NCT00931281|Drug|Placebo for ABT-450|capsule, QD or BID, 14 days
1848226|NCT00931281|Drug|Placebo for ritonavir|capsule, QD or BID, 14 days
1848227|NCT00931294|Behavioral|Choir singing|"Choir group participated in various relaxation, breathing and vocal exercises with the choir leader, and received the material To Live with IBS for home studies, weekly for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months."
1848228|NCT00931294|Behavioral|Information Group|Meet in groups, studying and discussing on the same materials under the direction of a group leader, weekly, for 1 year. Saliva testosterone assessed 6 times per occasion; baseline, after 6, 9 and 12 months.
1848229|NCT00931307|Device|Lotrafilcon A contact lens|Silicone hydrogel, spherical, soft contact lens
1848230|NCT00931333|Procedure|non percutaneous vertebroplasty|The patient will undergo general anaesthetic. With a low invasive approach, 4 screws will be placed in pedicles of vertebra under and above the fractured vertebra. The reduction of the fracture will be realised by a smooth movement, and screws positions will be verified by a radio control, with a guided navigation system. The stems will be placed and locked. After the screw positioning, the fractured vertebra pedicles will be reached by a low invasive approach, using a 6 mm trocar, to raise, if necessary, the vertebral plate. Then the cement will be injected in the vertebral body, under radio control. When the maximal volume (6 to 8 ml) is reached, or if an extra vertebral leak is detected, the cement injection is stopped. Then the incision is closed. The next day, the patient will be placed in a corset for a 2 months period.
1848231|NCT00931346|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
1848232|NCT00931346|Drug|Placebo|Placebo
1848233|NCT00931359|Device|DTS-G2 System|Treatment with microwave energy
1848234|NCT00931359|Device|DTS System (Sham treatment)|Sham treatment - no energy is delivered
1848235|NCT00931372|Drug|Lixisenatide (AVE0010)|Solution for subcutaneous injection 100 µg/mL
1848236|NCT00931372|Drug|Placebo|Subcutaneous injection
1848237|NCT00931385|Drug|BI 1744|BI1744 Respimat Med Dose Once Daily
1848238|NCT00931385|Drug|bi1744|1744 low dose
1848239|NCT00931385|Drug|Placebo|Placebo Respimat and Foradil Placebo
1848240|NCT00931385|Drug|Foradil|Foradil 12 mcg twice daily and Placebo Respimat
1848241|NCT00931398|Drug|methylphenidate HCl (Concerta)|Concerta 18 mg, 36 mg, 54 mg, and 72 mg q.am.
1848242|NCT00931398|Drug|Placebo|Matched placebo for all Concerta doses.
1848243|NCT00931411|Other|Formulation 609580 20|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
1848244|NCT00931411|Other|Formulation 609209 (Lipikar Baume)|Moisturizer, applied topically to whole body, twice a day, morning and evening, after bathing.
1848245|NCT00931424|Procedure|valve reconstruction|reconstruct valve at the same time of superficial vein surgery
1848246|NCT00931437|Dietary Supplement|vitamin K-rich dairy product|several forms of vitamin K: phylloquinone, menaquinone-7,-8,-9,and -10.
1848247|NCT00931450|Drug|exemestane|Given orally
1848248|NCT00931450|Drug|sunitinib malate|Given orally
1848249|NCT00931450|Other|placebo|Given orally
1848250|NCT00931463|Drug|raltegravir|400 mg raltegravir tablet taken every 12 hours
1848251|NCT00931463|Drug|2N(t)RTI|2N(t)RTIs as prescribed
1848252|NCT00931463|Drug|Ritonavir-boosted lopinavir|2 heat-stable tablets of ritonavir-boosted lopinavir taken every 12 hours
1848253|NCT00931476|Drug|somatropin|
1848254|NCT00931476|Drug|placebo|
1848255|NCT00931489|Drug|ranibizumab (Lucentis(R))|0.5 mg intravitreal injection once a month for 4 months, then as needed for 2 months
1848256|NCT00931515|Device|NuBac|NuBac device implanted at the L4/5 level.
1848257|NCT00931515|Device|Prodisc-L|Prodisc-L implanted at the L4/5 level.
1848258|NCT00931528|Drug|Tadalafil|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral tadalafil 5mg once daily for 24 weeks.
1848259|NCT00931528|Other|Placebo|Beginning ≤ 7 days after the start of radiotherapy, patients receive oral placebo once daily for 24 weeks.
1848260|NCT00931541|Drug|AZD6088|Oral solution. Each subject will receive a single-dose of AZD6088.
1848261|NCT00931541|Drug|Placebo|Oral solution. Each subject will receive a single-dose of placebo.
1848262|NCT00931554|Procedure|Postoperative drain removal|removal of postoperative drainages at different time points (postoperative day 3 versus postoperative day 5)
1848263|NCT00931567|Biological|Autologous platelets gel|"Application of autologous platelets gel (Platelet Rich Fibrin) after the  open palm  surgical treatment of Dupuytren's disease."
1848264|NCT00931567|Device|Vaselitulle|"application of standardized wound dressing after the  open palm  surgical treatment of Dupuytren's disease."
1848265|NCT00931580|Dietary Supplement|Vitamin D3|vitamin D3 supplementation at 400 IU vs 1,000 IU vs 2,000 IU vs 4,000 IU vs placebo for 12-weeks
1848266|NCT00931593|Device|Esophageal high resolution manometry associated or not with manometry with perfused Dentsleeve probe (as determined by randomization)|"Visit V0 (day 0 - 2 to 14 days):
Subject selection
Obtaining of written informed consent
Visit V1 (day 0):
Fasting subject
Randomization to determine the examination order
Esophageal high resolution manometry (Sierra Scientific Instruments, California CA) associated or not with manometry with perfused Dentsleeve probe (as determined by randomisation): 3-hour recording (1 hour fasting, ingestion of a 600-kcal liquid meal in 10 minutes, 2 hours post prandial)
Visit V2 (day 0 + 1 day): Phone contact
Visit V3 (day 0 + 2 to 7 days):
Same as V1
Visit V4 (V3 + 1 day): Phone contact and end of the study"
1848267|NCT00931606|Biological|Biological: ACE-011|up to 4 subcutaneous doses of ACE-011 given once every 28 days
1848268|NCT00931606|Drug|Placebo|up to 4 subcutaneous doses of placebo given once every 28 days
1848271|NCT00931645|Procedure|Autologous stem cell transplantation|TBI (10 grays, d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
1848272|NCT00931645|Procedure|DHAP rescue and Autologous stem cell transplantation|DHAP :IV cisplatin 100 mg/sqm d1, IV cytarabine 2 g/sqm d2,, IV dexamethasone 40 mg/sqm d1-4, TBI (10 grays d-3-1), cyclophosphamide (60 mg/sqm d-5-4)
1848273|NCT00931645|Procedure|DHAP rescue and F+C|DHAP :IV cisplatin 100 mg/sqm d1, IV Cytarabine 2 g/sqm d2, IV dexamethasone 40 mg/sqm d1-4, Followed by 3 monthly cycles with IV d1-3 fludarabine (25 mg/sqm) & cyclophosphamide (300 mg/sqm)
1848274|NCT00931671|Other|Exercise training|aerobic exercise training
1848275|NCT00931697|Drug|AD 452 (+) mefloquine|Single dose delivered as over-encapsulated tablet at ascending doses
1848277|NCT00931697|Drug|Placebo|Over-encapsulated placebo to maintain blinding
1848278|NCT00931710|Drug|valsartan, amlodipine, HCTZ|combination Valsartan/amlodipine160/5 mg tablet for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (6 weeks) of the study
1848279|NCT00931710|Drug|Losartan, HCTZ followed by valsartan, amlodipine, HCTZ|losartan 100mg capsule for 3 weeks; losartan 100mg capsule +HCTZ 25 mg capsule for 3 weeks; Valsartan/amlodipine 160/5mg tablet +HCTZ 25 mg capsule for 3 weeks; valsartan/amlodipine 320/10 mg tablet + HCTZ 25mg capsule for remainder (3 weeks) of the study
1848280|NCT00931723|Drug|Quetiapine fumarate XR|Oral treatment, once daily, Day 1 = 300 mg, Day 2 and thereafter 600 mg. Dose might be adjusted as from Day 3 by the discretion of the investigator.
1848281|NCT00931723|Drug|Lithium|Oral treatment, twice daily, Days 1 and 2 = 600 mg/day, Days 3-8 = 900 mg/day. Dose adjustment from day 9 to end of study will be at the discretion of the investigator.
1848282|NCT00931723|Drug|Placebo|Oral treatment twice daily.
1848283|NCT00931736|Drug|Isoniazid|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 300mg if subject weighs ≥ 42 kg, otherwise 200 mg. Total duration of treatment is for 9 months.
1848284|NCT00931736|Drug|Rifampin|The dosage of the medication is determined according to the weight of the subject. The dose is once per day, in pill format, for a total daily dose of 600 mg if the subject weighs ≥ 50 kg, 450 mg if the subject weighs ≥ 36 kg and < 50 kg, otherwise 300 mg for those weighing < 36 kg. Total duration of treatment is for 4 months.
1848285|NCT00931749|Device|Low intensity pulsed ultrasound therapy|1 MHz, Spatial Average Intensity of 0.2 W /cm2, pulsed duty cycle 20%, 9.5 minutes, Therapeutic dose= 112.5 J/cm2. Fixed application on the medial side of the knee joint. Three sessions per week, during 2 months ( 24 sessions)
1848286|NCT00931749|Device|Sham Low intensity pulsed ultrasound therapy|The Ultrasound device will not have the transducer´s crystal, so no ultrasonic energy will be provided.
1848287|NCT00931762|Drug|Panobinostat|Panobinostat will be administered orally once a day on Monday, Wednesday and Friday at a fixed dose of 40 mg. A cycle is defined as 28 days of treatment.
1848288|NCT00931775|Drug|Pindolol|Pill orally administered. 15 mg/day t.i.d.
1848289|NCT00931788|Drug|Antihypertensive agents and lipid lowering therapy|The above agents will be initiated/titrated in accordance to guidelines approved by Canadian Hypertension Education Program and the Canadian Best Practice Recommendations for Stroke Care
1848290|NCT00931788|Other|Usual Care|Monthly education and reinforcement of risk factor modification, and blood pressure measurement.
1848291|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir/r 300/100mg once daily plus raltegravir 400mg twice daily
1848292|NCT00931801|Drug|atazanavir/raltegravir|Atazanavir 300mg twice daily plus raltegravir 400mg twice daily
1848293|NCT00931801|Drug|atazanavir/tenofovir/emtricitabine|Continue baseline regimen of atazanavir/r 300/100mg once daily plus tenofovir and emtricitabine
1848294|NCT00931814|Other|exercise training|A progressive and structured, small-group exercise training 3 times a week, 30-40 min a session at intensity of 12-14 in rate of perceived exertion (RPE) for 8 weeks
1848295|NCT00931827|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Patients under daily life treatment receiving Mirena according to local drug information.
1848296|NCT00931827|Drug|Implanon (Etonogestrel)|Patients under daily life treatment receiving Implanon according to local drug information.
1848297|NCT00931840|Drug|EZN-2208, Cetuximab and Irinotecan|"Patients with mutated K RAS tumors will be treated with single-agent EZN-2208 (Arm A). PLEASE NOTE THAT ENROLLMENT IN EXPERIMENTAL ARM (ARM A) IS COMPLETE. NO NEW PATIENT IN THIS ARM IS ALLOWED TO ENROLL.
Patients with wild-type K-RAS tumors will be randomly assigned in a 2:1 ratio to EZN-2208 + cetuximab (Arm B) or the benchmark of irinotecan + cetuximab (Arm C)."
1848298|NCT00931853|Drug|SENNA+CASSIA(Naturetti)|Daily administration (oral) of one spoon (5g) of Naturetti (SENNA+CASSIA) jelly sugar free at bedtime, during 30 days
1848299|NCT00931866|Drug|Diclofenac Sodium|Topical diclofenac patch applied once daily to area of pain
1848300|NCT00931866|Drug|Matching Placebo Patch|Matching placebo patch, containing identical constituents to the active comparator except for diclofenac sodium; applied once daily
1848301|NCT00931879|Drug|omega-3-ethyl esters|Lovaza (TM) (omega-3-ethyl esters) 1 gram Capsules are indicated as an adjunct to diet to reduce very high (>500 mg/dL) triglyceride (TG) levels in adult patients.
1848302|NCT00931879|Drug|Placebo|Subjects are males or non-pregnant, non-lactating females age 18-80 years. All subjects must have been diagnosed with type 2 diabetes mellitus a minimum of two years according to the current ADA criteria and triglyceride levels above 149 mg/dL. Subjects in this arm will be taking placebo for 6 months.
1848303|NCT00931892|Dietary Supplement|Gluten|3g
1848304|NCT00931892|Dietary Supplement|Gluten|10g
1848305|NCT00931905|Drug|Homeopathic medication Plumbum metallicum|The homeopathic medication Plumbum metallicum 15CH was used and was diluted and dynamized using the Hahnemann centesimal scale, whose matrix was obtained from the Schraiber laboratory in 4CH in 70% ethanol. From this solution, the matrix was elevated to 14CH in 70% ethanol. The 15CH dynamization was prepared in 30% ethanol, which was the recommended solution for administration.The drugs were administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
1848306|NCT00931905|Other|Hydroalcoholic solution|The placebo was composed of a hydroalcoholic solution also prepared in 30% ethanol. It was administered orally (ten drops) twice daily - at the beginning and the end of the shift and under supervision for 30 days. The patients were instructed not to take other medication without medical guidance during the time they were participating in the research.
1848307|NCT00931918|Drug|Bortezomib|Bortezomib IV
1848308|NCT00931918|Drug|Rituximab|Rituximab IV
1848309|NCT00931918|Drug|Cyclophosphamide|Cyclophosphamide IV
1848310|NCT00931918|Drug|Doxorubicin|Doxorubicin IV solution
1848311|NCT00931918|Drug|Vincristine|Vincristine IV
1848312|NCT00931918|Drug|Prednisone|Prednisone tablet
1848313|NCT00931931|Biological|HSV1716|
1848314|NCT00931944|Drug|KNS-760704|150 mg Q12H KNS-760704 given orally (300 mg total daily dose)
1848315|NCT00931957|Drug|Etanercept, Methotrexate, Prednisolone|"In: Arm A, Etanercept-MTX-Prednisolone:
Etanercept 50 mg weekly (subcutaneous injection) for 12 months. Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses.
In Arm B:
Methotrexate 15 mg weekly for 12 months. Prednisolone: 30 mg daily, in divided doses, as initial dose. The dose will be reduced and adjusted to the eye's inflammation. Discontinuation if no inflammation with very low doses."
1848316|NCT00931996|Drug|Antipsychotic|Risperidone is the first line antipsychotic followed by others per clinician choice. Flexible dosing QD x 4-6 weeks.
1848317|NCT00932022|Drug|Trospium Chloride, Extended Release (XR)|Trospium chloride extended release 60 mg capsule taken orally once daily for 12 weeks.
1848318|NCT00932022|Other|placebo|Placebo capsule taken orally once daily for either 2 weeks or 14 weeks.
1848319|NCT00932035|Procedure|axillary lymph node dissection|Undergo reverse mapping-guided axillary lymph node dissection
1848320|NCT00932035|Drug|isosulfan blue based lymphatic mapping|
1848321|NCT00932035|Procedure|axillary lymph node dissection|Undergo standard axillary lymph node dissection
1848322|NCT00932035|Procedure|quality-of-life assessment|Ancillary studies
1848323|NCT00932035|Other|Questionnaire administration|Ancillary studies
1848324|NCT00932048|Drug|Atorvastatin|Atorvastatin 10mg once daily for 12 weeks
1848325|NCT00932061|Other|Traditional Acupuncture|"Fibromyalgia subjects will be randomized to receive 9 acupuncture treatments over the course of four weeks.
Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
1848326|NCT00932061|Other|Sham Treatment|"Fibromyalgia subjects will be randomized to receive 9 sham treatments over the course of four weeks.
Subjects enrolled in the study may have 1) only fMRI or 2) fMRI scans and PET scans, depending on their eligibility criteria."
1848327|NCT00932074|Drug|KP-413 Ointment|Study drug ointment to be applied topically to the selected treatment areas on the head/neck and torso/limbs twice a day for 4 weeks.
1848328|NCT00932087|Procedure|Blood sample|Blood sample for lipidomic study
1992767|NCT03301714|Behavioral|Oral Health Education|Group based oral health education vs Individual motivational interviewing
1848331|NCT00932113|Drug|Methotrexate|"2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
Methotrexate-treated patients will then receive 16 weeks of adalimumab at the end of study."
1848332|NCT00932113|Drug|Adalimumab (Humira)|2 cohorts (Randomized 1:1 adalimumab:methotrexate). Subjects will receive treatment on Day 1 (baseline visit) and then weekly or every 2 weeks for 16 weeks.
1848333|NCT00932126|Drug|PF-03758309|Oral PF-03758309 will be administered in capsules (once or twice daily) until toxicity, progressive disease, or patient refusal to continue on therapy. The starting dose is 1 mg once daily.
1848334|NCT00937911|Drug|YM150|oral
1848335|NCT00937924|Drug|Saline|Saline solution injections
1848336|NCT00937924|Drug|Diphenhydramine|Diphenhydramine injections
1848337|NCT00937924|Drug|Promethazine|Promethazine
1848339|NCT00937950|Procedure|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to four years.
1848340|NCT00937963|Dietary Supplement|Palm DAG Oil|Use of Palm DAG Oil to replace palm oil traditionally used in foods
1848341|NCT00937976|Procedure|Periodontal Scaling and Root Planing|Participants will take antibiotics prior to dental treatment. Periodontal treatment or a deep cleaning (with local anesthesia or numbing) will be performed to remove plaque and tartar around the teeth and gums. A small amount of antibiotics (minocycline) will be placed around the gums to help fight bacteria and inflammation.
1848342|NCT00937989|Other|educational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
1848343|NCT00937989|Other|informational intervention|Occurs weekly during the first 8 weeks of the study and thereafter a minimum of monthly through the 9th month of the study.
1848344|NCT00937989|Other|medical chart review|Baseline, 3, 6 and 9 months after starting the study
1848345|NCT00937989|Other|questionnaire administration|Baseline, 3, 6 and 9 months after starting the study
1848346|NCT00937989|Other|study of socioeconomic and demographic variables|Baseline, 3, 6 and 9 months after starting the study
1848347|NCT00937989|Procedure|quality-of-life assessment|Baseline, 3, 6 and 9 months after starting the study
1848348|NCT00938015|Other|Questionnaire|This is a non-interventional study
1848349|NCT00938015|Other|Questionnaire|This is a non-interventional study
1848350|NCT00938041|Biological|Tositumomab and Iodine I 131 Tositumomab|Tositumomab and Iodine I 131 Tositumomab
1848351|NCT00938067|Behavioral|Staying Connected|The overarching goal of the Staying Connected intervention is to establish a compassionate and culturally sensitive treatment trajectory that diminishes posttraumatic suffering by reducing symptomatic distress, improving functional recovery, and reducing the risk of injury recurrence. This trajectory begins with surgical treatment and extends through outpatient care and community rehabilitation. The collaborative care intervention fundamentally restructures the delivery of mental health care within trauma care systems by bringing together providers currently working independently to form an interdisciplinary mental health team. Team members work together and in a liaison capacity with other trauma center providers and community practitioners in order to bridge care across service delivery sectors.
1848352|NCT00938080|Biological|AG013|Mouth rinse once a day for 14 days
1848353|NCT00938080|Biological|AG013|Mouth rinse three times a day for 14 days
1848354|NCT00938080|Biological|AG013|Mouth rinse six times a day for 14 days
1848355|NCT00938080|Other|Placebo|Mouth rinse once a day for 14 days
1848356|NCT00938080|Other|Placebo|Mouth rinse three times a day for 14 days
1848357|NCT00938080|Other|Placebo|Mouth rinse six times a day for 14 days
1848358|NCT00938093|Behavioral|Cognitive behavioral therapy|Participants receive 10 telephone therapy sessions and an accompanying workbook focused on cognitive-behavioral techniques for managing anxiety.
1848359|NCT00938093|Behavioral|Enhanced usual care|Participants receive written information about anxiety, referrals for treatment, and an optional letter to their primary care physician.
1848360|NCT00938106|Radiation|optimised magnetic resonance image-guided intra-uterine brachytherapy|Brachytherapy treatment will be planned based on the MRI test and will be individualized for each study participant,based on participant's cancer and body inside.Brachytherapy will be as an inpatient over 2-3 days. All other care will follow standard procedures.
1848361|NCT00938132|Drug|fimasartan, warfarin|Warfarin(1d) Fimasartan(8d-16d) Fimasartan + Warfarin(11d)
1848362|NCT00938145|Procedure|Specimen Ultra-High field MRI|Immediately following removal of the bladder and lymph nodes, the specimens will be transported to the ultra-high-field MRI scanner for high resolution imaging.
1848363|NCT00938145|Drug|chemotherapy|The majority of patients will be candidates to receive neoadjuvant chemotherapy prior to radical cystectomy as part of standard clinical care. Patients will most often receive cisplatin based therapy for a period of three months (four 21 day cycles).
1848364|NCT00938145|Procedure|Cystectomy and Lymphadenectomy|The patient will undergo radical cystectomy and pelvic lymph node dissection with no deviation from standard surgical care. A urinary tract reconstruction will follow as either a continent or incontinent form of diversion.
1848365|NCT00938158|Biological|albiglutide|single dose of subcutaneously injected albiglutide
1848366|NCT00938171|Procedure|Local anesthesia|All patients will be then given adequate sedation with propofol and local anesthetic given by dermal infiltration in incision site and regional breast and axillary areas. The local anesthetic of choice will be 2 % lidocaine (Xylocaine) and 0.5% Bupivacaine (Marcaine) mixed with 7 % sodium bicarbonate and epinephrine (Bosmine)
1848367|NCT00938171|Procedure|General anesthesia|The method of general anesthesia for the GA group will be induced with fentanyl (1-2 μg/kg) and propofol (2.5 mg/kg). After placement of a laryngeal mask or endotracheal tube airway, anesthesia will be maintained with sevoflurane (end-tidal concentrations 1%-3%) in a 50% oxygen/nitrous oxide mixture.
1848368|NCT00938184|Drug|Paroxetine 12.5 milligrams tablet|Single dose of paroxetine 12.5 milligrams controlled release tablet will be administered orally.
1848369|NCT00938184|Drug|Paroxetine 25 milligrams tablet|Single dose of paroxetine 25 milligrams controlled release tablet will be administered orally.
1848370|NCT00938184|Drug|Paroxetine 50 milligrams tablet|Single dose of paroxetine 50 milligrams controlled release tablet (as two tablets of 25 milligrams) will be administered orally.
1848371|NCT00938197|Drug|Fimasartan|Fimasartan (1d~7d) Amlodipine (12d~14d) Fimasartan + Amlodipine(15d~21d)
1848372|NCT00938197|Drug|Amlodipine|Amlodipine (1d~10d) Amlodipine (25d~27d) Fimasartan + Amlodipine(28d~34d)
1848373|NCT00938210|Procedure|Laparoscopic colonic surgery|Laparoscopic removal of colonic cancer
1848374|NCT00938223|Biological|4-peptide and 12-peptide melanoma vaccines|"Each vaccination will be administered over a 6-week period (days 1, 8, 15, 29, 36, 43). Patients will be randomized into one of two groups, Group A or Group B.
Group A will receive 4 class I MHC-restricted synthetic melanoma peptides (1 each restricted by HLA-A1, -A3, and two restricted by HLA-A2) and a tetanus helper peptide.
Group B will receive the 12 class I MHC-restricted synthetic melanoma peptides (4 each restricted to HLA-A1, -A2, and -A3) and a tetanus helper peptide.
All vaccines will contain GM-CSF-in-adjuvant and will be administered intradermally and subcutaneously. Concurrent with the first three of these vaccinations, each patient will also receive an additional set of 3 identical vaccinations in a distal site, the response to which will be evaluated at the draining lymph node. This node will be harvested using lymphatic mapping and sentinel node biopsy methods and will be referred to as the sentinel immunized node (SIN)."
1848375|NCT00938236|Drug|Cyclosporine Inhalation Solution (CIS)|Cyclosporine (USP) Inhalation Solution; 300mg/4.8 mL in propylene glycol (USP) at a concentration of 62.5 mg/mL; 3 times a week for study duration
1848376|NCT00940849|Dietary Supplement|Plant sterol containing drink|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
1848377|NCT00940849|Dietary Supplement|Standard macaroni meal|The test products used in the study will be a commercially available PS drink and a ready to eat macaroni meal
1848378|NCT00940862|Biological|adalimumab|Injection of adalimumab (80 mg followed by 40 mg at week 1 and 40 mg EOW thereafter for 15 weeks)
1848379|NCT00940862|Device|UVB Phototherapy|This intervention can be applied alone or in combination with topical treatment. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening.
1848380|NCT00940862|Other|Topical treatment|"This intervention can be applied alone or in combination with UVB phototherapy. It will be performed between Day 0 and Day 112. The investigator is free to introduce or modify the topical and/or UVB regimens at any time after screening. The investigator will prescribe to patients randomized in this arm a select topical product from the list:
Calcipotriol, Calcipotriene, Dovonex, Tazorac, Tazarotene Anthralin, Corticosteroids."
1848381|NCT00940875|Drug|erlotinib [Tarceva]|150mg po on days 15-28 of each 4 week cycle
1848382|NCT00940875|Drug|gemcitabine|1250mg/m2/day on days 1 and 8 of each 4 week cycle
1848383|NCT00940875|Drug|gemcitabine|1000mg/m2/day on days 1, 8 and 15 of each 4 week cycle
1848384|NCT00940888|Device|SJ4 connector and RV high voltage SJ4 lead|Standard of care implantation of SJ4 device system
1848385|NCT00940901|Drug|sildenafil|sildenafil 50 mg tablet daily for first 8 weeks (phase 1), and then sildenafil 50 mg tablet daily for final 8 weeks (phase 2)
1848386|NCT00940901|Other|placebo|placebo 50 mg tablets daily for first 8 weeks (phase 1), and then sildenafil 50mg tablet daily for final 8 weeks (phase 2)
1848387|NCT00940914|Drug|ioflupane 123I (DATSCAN®)|One administration (2,5 ml) of ioflupane 123I 0,07-0,13 µg/ml; 74 MBq/ml; IV (in the vein)
1848388|NCT00940927|Drug|albuterol|Albuterol administered sequentially 180mcg (MDI), 90mcg (MDI), 90mcg(MDI), 90mcg (MDI), 90mcg (MDI), 2.5mg (nebulized)
1848389|NCT00940940|Biological|Zostavax (Live attenuated herpes zoster vaccine)|0.6 mL subcutaneous
1848390|NCT00940940|Biological|Placebo vaccine|0.65 mL subcutaneous
1848391|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray per nostril at time 0 plus one spray Placebo
1848392|NCT00940953|Drug|Budesonide + Azelastine|nasal spray, one spray of each per nostril at time 0
1848393|NCT00940953|Drug|Placebo|nasal spray, one spray per nostril from each of 2 bottles at time 0
1848395|NCT00940966|Dietary Supplement|energy restricted very-low carbohydrate diet|energy restricted very-low carbohydrate diet
1848396|NCT00940966|Dietary Supplement|low glycemic diet|restricted ketogenic diet
1848397|NCT00940979|Procedure|Application of Integuseal sealant|Microbial sealant (integuseal) applied with a sponge applicator
1848398|NCT00940992|Drug|DER 45 EV|Topical application to face for 12 weeks
1848399|NCT00940992|Drug|Vehicle|Topical application to face for 12 weeks
1848400|NCT00941005|Device|Electroacustimulation|Electroacustimulation (EAS) is a derivative form of acupuncture therapy where a small current of electricity instead of a needle is used to stimulate an acupoint on the human body in an effort to create therapeutic effects.
1848401|NCT00941018|Drug|RX-10001|RX-10001 or vehicle control will be administered as an oral solution. Doses will be determined according to the pk results of the preceding cohorts.
1848402|NCT00941031|Drug|AIN457|
1848403|NCT00941031|Drug|AIN457A|"Induction with monthly injections - Monthly: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 5, 9"
1848404|NCT00941031|Drug|AIN457A|"Early loading induction - Early: secukinumab (AIN457) 150 mg s.c. administered at weeks 1, 2, 3, 5"
1848405|NCT00941031|Drug|Placebo|"Placebo - Placebo: Placebo administered at weeks 1, 2, 3, 5, 9"
1848406|NCT00941044|Device|Neurally adjusted ventilatory assist|application of non-invasive NAVA in healthy volunteers
1848407|NCT00941057|Drug|BAY 98-7079, Estradiolvalerate (EV) / Dienogest (DNG) / Levomefolate calcium|Oral, single dose, 2 mg EV + 3 mg DNG + 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
1848408|NCT00941057|Drug|BAY 86-5027,Estradiolvalerate(EV) / Dienogest (DNG)|Oral, single dose, 2 mg EV + 3 mg DNG washout phase between treatments: at least 7 days
1848409|NCT00941057|Drug|BAY 86-7660,levomefolate calcium|Oral, single dose, 0.451 mg levomefolate calcium washout phase between treatments: at least 7 days
1848410|NCT00941070|Drug|triapine|Given IV
1848411|NCT00941070|Drug|cisplatin|Given IV
1848412|NCT00941070|Radiation|external beam radiation therapy|Undergo pelvic external beam radiation therapy
1848413|NCT00941070|Procedure|quality-of-life assessment|Ancillary studies
1848414|NCT00941070|Other|questionnaire administration|Ancillary studies
1848415|NCT00941070|Radiation|fludeoxyglucose F 18|Undergo FDG-PET/CT
1848416|NCT00941070|Procedure|positron emission tomography|Undergo FDG-PET/CT
1848417|NCT00941070|Procedure|computed tomography|Undergo FDG-PET/CT
1848418|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL QD: RAL 800 mg/24 hs
1848419|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL BID 400 mg/12 hs
1848420|NCT00941083|Drug|Raltegravir (Use RAL as a simplification strategy)|RAL BID to QD
1848421|NCT00941096|Drug|Bimatoprost and Bimatoprost/Timolol fixed combination.|Following an appropriate wash-out period, participants were given a 5-week long treatment with Bimatoprost 0.03% once daily in the evening followed by a further 5-week long treatment with the Bimatoprost 0.03%/Timolol 0.5% fixed combination administered in the evening.
1848422|NCT00941109|Drug|decitabine|Cohort 1: 30 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
1848423|NCT00941109|Drug|decitabine|Cohort 2: 60 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
1848424|NCT00941109|Drug|decitabine|Cohort 3: 120 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
1848425|NCT00941109|Drug|decitabine|Cohort 4: 240 mg oral on Day 1 and 20 mg/m^2 1-hour IV infusion on Days 2-5 of Cycle 1.
1848426|NCT00941122|Device|Eluted Swab|Comparison of Eluted Swab with AMIES swab for detection of MRSA/VRE
1848427|NCT00941135|Other|Docetaxel+Cisplatin+5-FU+ Radiotherapy+Cetuximab|"Docetaxel:75 mg/m2/d IV Cisplatin:75 mg/m2/d IV 5-FU:750 mg/m2/d IV TPF 3 cycles every 3 weeks
Radiotherapy: Total 72 Gy in 42 fractions Cetuximab: 250 mg/m2/d Days 1, 8, 15, 22, 29, 36 and 43"
1848428|NCT00941148|Drug|Insulin Glargin|
1848429|NCT00941148|Drug|NPH insulin|
1848430|NCT00941148|Drug|Insulin detemir|
1848431|NCT00941148|Drug|metformin|metformin (2000 mg/day)
1848432|NCT00941161|Drug|metformin/glimepiride combination|long acting metformin/glimepiride 1g/2mg
1848433|NCT00941161|Drug|metformin|long acting metformin 1g once a day with fasting glucose 130-199mg/dL or long actin metformin 1g twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
1848434|NCT00941161|Drug|glimepiride|glimepiride 2mg once a day with fasting glucose 130-199mg/dL, or glimepiride 2mg twice a day (before dinner and before breakfast) with fasting glucose 200-270mg/dL
1848435|NCT00941174|Drug|13C5-Calcium-L-Leucovorin|This drug will be used in a clinical trial the objective of which is to determine whether, and to what extent, a physiological concentration of natural folate is absorbed across the large intestine with an intact microflora.
1848436|NCT00941187|Other|diffusion NO/CO method|pulmonary capillary blood volume (Vc), measured by the double diffusion NO/CO method: this method is to inhale during a deep inspiration with a mixture of helium (8-10%), CO (2000 ppm) and NO (20-40 ppm), the O2 (21%)
1848437|NCT00941200|Biological|Blood collection|
1848438|NCT00941213|Device|ultrasound scissors - Harmonic ACE|preparation with ultrasound scissors during operation
1848439|NCT00941213|Device|electroscalpel (Erbe Vio 300; Aesculap AG)|preparation with electroscalpel during operation
1848440|NCT00941239|Drug|metformin ER|850mg daily for 30 days
1848441|NCT00941239|Drug|metformin|850 mg daily for 30 days
1848442|NCT00941252|Drug|Topical imiquimod therapy|therapy consists of treatment with topical vaginal suppositories for 16 weeks, each vaginal suppository contains 6.25mg of imiquimod, frequency (one time a week in treatment week 1+2, two times a week in treatment week 3+4, three times a week in treatment week 5-16)
1848443|NCT00941265|Drug|levodopa and benserazide|Daily Monday to Friday CAT with Daily Monday to Friday levodopa 100 mg with benserazide 25 mg , in the morning 1 h after breakfast, during 2 weeks .
1848444|NCT00941265|Drug|placebo|Daily CAT Monday to Friday with daily placebo Monday to Friday , in the morning 1 h after breakfast, taken 5 out of 7 days during the 2 weeks of one of the two treatment periods.
1848445|NCT00941278|Drug|PH-10 (0.001% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
1848446|NCT00941304|Drug|Oxycodone|Single-dose of over-encapsulated oral 5-mg oxycodone capsule
1848447|NCT00941304|Drug|Buprenorphine|Single-dose of buprenorphine HCl buccal film
1848448|NCT00941304|Drug|Placebo Film|Single-dose of placebo buccal film
1848449|NCT00941304|Drug|Placebo Capsule|Single-dose of oral placebo capsule
1848450|NCT00941317|Device|Pathformer (micro-drilling device)|The micro-drilling device drills the nail with a prespecified diameter drill bit and to a prespecified depth in the nail, using skin impedance (also referred to as equivalent resistivity level) as a feedback mechanism for stopping the drilling intervention at a preset trigger level value.
1996453|NCT02477501|Drug|Norepinephrine|continuous infusion
1848454|NCT00941343|Drug|Alfuzosin (XATRAL® - SL770499)|One tablet of XATRAL® 10mg OD once a day at the end of an evening meal. The tablets had to be swallowed whole without being chewed or crushed
1848455|NCT00941356|Dietary Supplement|Bio-K+ CL1285|2 capsules per day before breakfast
1848456|NCT00941356|Dietary Supplement|Placebo|2 capsules per day before breakfast
1848457|NCT00941369|Drug|Insulin Glargine (HOE901)/NPH Insulin|"Arm 1: Subcutaneous injection of Insulin Glargine with the TactiPen® injector pen once daily at any time, but each day at the same time
Arm 2: Subcutaneous injection of Protamine Hagedorn basal insulin with the TactiPen® injector pen once or twice daily at the discretion of the treating physician
The starting dose is 10 I.U. (NPH basal insulin) resp. 10 U (insulin glargine) per day.
The dose adjustments will be based on the results of self-monitoring."
1996454|NCT02477501|Drug|Ephedrine|continuous infusion
1996455|NCT02475954|Behavioral|TH-CBT|The TH-CBT group will receive the study intervention and standard care. The study treatment has been previously manualized and modified for remote administration, as described in the introduction to the revised application.12 PD Veterans will receive 10 weekly individual sessions (60 minutes each) of CBT, delivered via V2H.
1848461|NCT00941395|Behavioral|Survey|Completion of 3 surveys on the internet over the 3 months between the 1-week visit and the 3-month visit. The surveys should take about 20 minutes to complete.
1848462|NCT00941395|Behavioral|Counseling|In-person end of study visit at 6 months.
1848463|NCT00941395|Behavioral|Survey|3 Internet-based surveys over 3 months, each taking approximately 20 minutes.
1848464|NCT00941395|Behavioral|Counseling|Individual in-person study visits at 1 week, 3 months, and 6 months.
1848465|NCT00941408|Procedure|Diagnostic tumor core biopsy|
1848466|NCT00941421|Device|oesophagal videocapsule and oeso-gastro-duodenal fiberoptic endoscopy|each patient receive one OVC and one OGDFE the same day
1848467|NCT00941434|Dietary Supplement|RUTF|Children with severe malnutrition will be treated with a daily dose of RUTF till their weight for age z scores no longer fall in severe malnutrition group
1848468|NCT00941447|Behavioral|Dietary|All participants in the investigation will receive a standard 12-week behavioral intervention with seven 30-45 minute phone interventions and education sessions. The intervention includes a reduced caloric prescription (1200-1500 kcal/day),fat gram prescription (30% or less kcals from fat) and carbohydrate gram prescription (150-190 grams).
1848469|NCT00941447|Behavioral|Physical Activity|There is a physical Activity of 150 minutes/week of moderate-intense physical activity.
1848470|NCT00941447|Behavioral|Self-Regulatory Approaches|Participants in this arm will receive extensive feedback based on their self-monitoring diary in which the researcher will be reinforced in areas that they are doing well in regarding their blood glucose and also assist in problem solving in areas that need improvement.
1848471|NCT00941460|Drug|Temozolomide in both arms|initial dose 120 mg/m2 in arm A
1848472|NCT00941460|Drug|Temozolomide in both arms|initial dose 80 mg/m2 in arm B
1848473|NCT00941473|Drug|Triamcinilone (kenalog)|Epidural steroid injection of 80mg of Triamcinilone.
1848474|NCT00941486|Drug|FST-100 (0.1% dexamethasone) Ophthalmic Suspension|A regimen of 2 drops 4 times a day while awake for 5 days.
1848475|NCT00941486|Drug|Placebo|A regimen of 2 drops 4 times a day while awake for 5 days.
1848476|NCT00941499|Drug|HAI Oxaliplatin|140 mg/m^2 by HAI (hepatic arterial infusion)over 2 hours on Day 1 of each 21 day cycle
1848477|NCT00941499|Drug|5-FU|900-1750 mg/m^2 HAI infusion over 24 hours on Days 1 - 2 of each 21 day cycle.
1848478|NCT00941499|Drug|Bevacizumab|10 mg/Kg by vein on Day 1 of 21 day cycle.
1848479|NCT00941499|Drug|Cetuximab|Loading dose of 250-500mg/m^2 and Maintenance dose of 125-250 mg/m^2 by vein on Day 1 of 21 day cycle.
1848480|NCT00941499|Drug|Leucovorin|200 mg/m^2 by vein on Days 1 and 2 of each 21 day cycle.
1848481|NCT00941499|Drug|5-FU|300-400 mg/m^2 bolus + 600-1000 mg/m^2 infusion over 22 hours on Days 1-2 of each cycle.
1848482|NCT00941499|Drug|Bevacizumab|7.5 - 15 mg/Kg by vein on Day 1 of 21 day cycle.
1848483|NCT00941525|Drug|Latanoprost|1 eyedrop of latanoprost (0.005%) dosed once a day at 8:00pm for a 4-weeks period
1848484|NCT00941551|Drug|levothyroxine|levothyroxine 75-125 ug/day
1848485|NCT00941551|Drug|no levothyroxine|observation only without prophylactic levothyroxine
1848486|NCT00941564|Other|Infant Formula milk based|Consume ad lib
1848487|NCT00941564|Other|Infant formula milk based|consume ad lib
1848488|NCT00941577|Drug|AIR645|AIR645 (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
1848489|NCT00941577|Drug|Physiologic saline solution|Placebo (blinded) by nebulization, range of doses, maximum of one dose per day, maximum of 6 doses in 22 days.
1848490|NCT00941603|Drug|SCH 900271 15mg|oral tablets; SCH 900271 - 15 mg taken once daily for 8 weeks
1848491|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271 10 mg taken once daily for 8 weeks
1848492|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 5 mg taken once daily for 8 weeks
1848493|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 2.5 mg taken once daily for 8 weeks
1848494|NCT00941603|Drug|SCH 900271|oral tablets; SCH 900271- 1 mg taken once daily for 8 weeks
1848495|NCT00941603|Drug|Placebo|oral tablets; placebo administered once daily during the 5-week single-blind placebo run-in and diet stabilization period and during the 8 week double-blind treatment period.
1848496|NCT00941616|Biological|Biostate®|80 IU vWF/kg administered as a bolus intravenous infusion on Day 1 and approximately Day 180
1848497|NCT00941616|Biological|Biostate®|Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
1848498|NCT00941629|Behavioral|Cognitive Processing Therapy (CPT)|Patients with PTSD receive a trauma-focused, cognitive-behavioral intervention in Face-to -Face treatment.
1848499|NCT00941629|Behavioral|Cognitive Processing Therapy (CPT)|Provision of Cognitive Processing Therapy over teleconference network (telemental health; telehealth)
1848500|NCT00941642|Drug|Lovaza|Approximately 50% of study subjects will be randomized to the active treatment arm -Lovaza. Subjects will be dosed with 4g of Lovaza gel capsules daily for a minimum of 48 weeks duration.
1848501|NCT00941642|Drug|placebo control|Approximately 50% of study subjects will be randomized to the placebo arm of this study. Placebo arm subjects will receive 4g of placebo gel caps daily for a minimum of 48 weeks duration.
1848502|NCT00941655|Drug|Oxaliplatin|"Oxaliplatin 460 mg/m^2 diluted in 2.0 L/m^2 of dextrose 5% in water (D5W) given as a heated intraperitoneal perfusion.
Systemic chemotherapy - Oxaliplatin 85 mg/m^2 over 120 minutes,"
1848503|NCT00941655|Drug|Irinotecan|Irinotecan 165 mg/m^2 IV over 90 minutes
1848504|NCT00941655|Drug|5-Fluorouracil|"Surgery and heated intraperitoneal chemotherapy with Fluouracil (5-FU) 400 mg/m^2 intravenous (IV) over 5 minutes.
systemic chemotherapy -3200 mg/m^2 continuous intravenous over 48 hours."
1848505|NCT00941655|Drug|Leucovorin|"surgery and heated intraperitoneal chemotherapy -20 mg/m^2 intravenous over 5 minutes.
systemic chemotherapy - 200 mg/m^2 intravenous over 120 minutes."
1848506|NCT00941655|Procedure|Gastrectomy and/or metastasectomy|"Gastrectomy: tumor resection and a bypass; palliative treatment for pain, bleeding, obstruction and/or if deemed in the best interest of the patient.
Metastasectomy: anatomical segmental resection to render the patient no evidence of disease (NED) with at least 1cm negative margins when possible, followed by systemic chemotherapy."
1848507|NCT00941668|Drug|Triclosan/Copolymer/fluoride toothpaste|Twice daily usage
1848508|NCT00941668|Drug|sodium monofluorophosphate toothpaste|Twice daily usage
1848509|NCT00941681|Drug|CK-1827452|50 mg MR CK-1827452 BID for 10 days
1848510|NCT00941681|Drug|CK-1827452|37.5 mg IR CK-1827452 TID for 10 days
1848511|NCT00941681|Drug|CK-1827452|100 mg MR CK-1827452 BID for 10 days
1848512|NCT00941694|Behavioral|Self management intervention|Intervention arm will receive 6 group or individual sessions over a 7 week period
1848513|NCT00941694|Behavioral|placebo group|3 phone calls not related to asthma self-management
1848514|NCT00941707|Drug|JNJ 38518168|JNJ-38518168 100 milligram (mg) capsules orally (by mouth) once daily for 12 weeks.
1848515|NCT00941707|Drug|Placebo|Placebo capsules matching to JNJ-38518168 orally once daily for 12 weeks.
1848516|NCT00941720|Drug|busulfan|IV busulfan 0.8 mg/kg every 6 hours x 16 doses
1848517|NCT00941720|Drug|cyclophosphamide|IV cyclophosphamide 60 mg/kg over 4 hours x 2 days
1848518|NCT00941720|Procedure|autologous hematopoietic stem cell transplantation|infusion of autologous hematopoietic stem cells of at least 2.0 x 106 CD34+ cells/kg on day 0
1848519|NCT00941733|Device|IN.PACT Amphirion|Balloon Angioplasty
1848520|NCT00941733|Device|Standard PTA|Balloon Angioplasty
1848521|NCT00941746|Biological|PG110|Single, slow intravenous infusion
1848522|NCT00941746|Biological|PG110|Single, slow intravenous infusion
1848523|NCT00941746|Biological|PG110|Single, slow intravenous infusion
1848524|NCT00941746|Biological|PG110|Single, slow intravenous infusion
1848525|NCT00941746|Biological|PG110|Single, slow intravenous infusion
1848526|NCT00941746|Biological|PG110|Single, slow intravenous infusion
1848527|NCT00941746|Biological|PG110|Single, slow intravenous infusion
1848528|NCT00941746|Biological|PG110|Single, slow intravenous infusion
1848529|NCT00941746|Biological|Placebo|Single, slow intravenous infusion that matches PG110 in appearance
1848530|NCT00941772|Other|Ultrasonography|Verify nasogastric tube placement with ultrasonography and compare its accuracy with plain radiography
1848531|NCT00941785|Drug|DHA-PQ|"Three monthly administrations of Duocotexcin (DHA-PQ):
dihydroartemisinin 2.1mg/kg and piperaquine phosphate 16.8 mg/kg once daily for three days"
1848532|NCT00941785|Drug|SP-AQ|"Three monthly administrations of sulfadoxine-pyrimethamine plus amodiaquine:
One dose of Sulfadoxine 25mg/kg and pyrimethamine 1.25mg/kg Three daily doses of amodiaquine phosphate 10mg/kg"
1848533|NCT00941798|Drug|QMF149 Twisthaler®|Once daily via multi-dose dry-powder inhaler
1848534|NCT00941798|Drug|Mometasone Twisthaler®|Once daily via multi-dose dry-powder inhaler
1848535|NCT00941811|Drug|Imiquimod|Local Imiquimod three times weekly for 16 weeks
1848536|NCT00941824|Drug|mycophénolate acid|"Day 0 to Day 7, 720 mg twice daily
Day 8 to Day 30, 540 mg twice daily
Day 30 to Day 90, 360 mg twice daily"
1848537|NCT00941837|Dietary Supplement|Olive Oil, Palm Olein Oil, Coconut Oil|Effect of dietary fat type in combination with high protein on plasma homocysteine levels; 5 wk each with 2 wk wash out in between
1848538|NCT00941850|Procedure|Upgrade to triple ventricular site CRT|Patients in this arm will continue to receive CRT via the original unit, but some will have a change in the mode of delivery of therapy (by placing a second pacing lead to reach a different part of the left ventricle from the part originally paced).
1848539|NCT00941863|Drug|Sorafenib 100 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 100 mg twice daily (50-mg tablet)
1848540|NCT00941863|Drug|Sorafenib 200 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 200 mg twice daily (50-mg tablet)
1848541|NCT00941863|Drug|Sorafenib 400 mg (50-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (50-mg tablet)
1848542|NCT00941863|Drug|Sorafenib 400 mg (200-mg tablet)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet)
1848543|NCT00941863|Drug|Sorafenib 400 mg (Expansion)|Sorafenib (Nexavar, BAY43-9006) 400 mg twice daily (200-mg tablet) expansion
1848544|NCT00941876|Behavioral|Facilitated Referral|Seven key steps carried out by CTC and FP staff to encourage completion of FP referral by CTC.
1848545|NCT00941889|Drug|Saline|0.5 ml
1848546|NCT00941889|Drug|Quadrivalent Human Papillomavirus (Types 6,11,16,18) Recombinant Vaccine|0.5mL intramuscular injection of Gardasil (quadrivalent HPV vaccine) in their upper extremity initially and again at two months and six months after enrollment.
1848547|NCT00941915|Radiation|SBRT Prostate|Five fractions of 7.4 Gy. The total dose will be 37 Gy. A minimum of 36 hours and a maximum of 96 hours should separate each treatment. No more than 3 fractions will be delivered per week. The total duration of treatment will be no shorter than 10 days and no longer than 18 days.
1848548|NCT00941928|Drug|Epratuzumab|360 mg/m^2 once a day by vein on Day -4, Day -1 and Days 3, 6, 10, 13 and 17.
1848549|NCT00941928|Drug|Fludarabine|25 mg/m^2 once a day by vein on Day -6 through Day -2 over 30 minutes.
1848550|NCT00941928|Drug|Cyclophosphamide|60 mg/kg once a day by vein on Days -5 and -4 over 2 hours.
1848551|NCT00941928|Drug|Mesna|12 mg/kg by vein 5 times per day on Days -5 and -4 over 15 minutes.
1848552|NCT00941928|Procedure|Infusion of NK cells|Transplant of Haploidentical NK cells by vein on Day 0.
1848553|NCT00941928|Drug|Interleukin-2|Subcutaneous injections three times a week for 9 doses on Days 0 to 21.
1848556|NCT00941954|Behavioral|Structured Education|The intervention group will be offered a group−based structured educational programme aimed at promoting increased ambulatory activity by targeting perceptions and knowledge of diabetes risk, physical activity self−efficacy, barriers to physical activity and self−regulatory skills based on pedometer use. The programme will employ a person−centred approach to patient education that is based on self−management programmes for individuals with type 2 diabetes and prediabetes that have been developed and tested by our research group. The programme will be designed to be delivered to 5−10 participants by two trained educators and is 3.5 hours long. Brief follow−up counselling will be offered once every 6 months.
1848557|NCT00941954|Behavioral|Written Information|Control subjects will receive a booklet detailing information on risk factors for type 2 diabetes (T2DM) and cardiovascular disease (CVD) and how physical activity can be used to prevent T2DM and CVD.
1848558|NCT00941967|Drug|gemcitabine hydrochloride|Given IV
1848559|NCT00941967|Drug|oxaliplatin|Given IV
1848560|NCT00941967|Drug|sorafenib tosylate|Given orally.
1848561|NCT00941980|Biological|Osteocel Plus|biologic
1848562|NCT00941993|Device|Iontophoresis System (Acclarent)|Iontophoresis system will deliver iontophoresis simultaneously to both ears. Active elements of this drug delivery system are lidocaine and epinephrine.
1848563|NCT00942006|Drug|doxycycline|100 mg bid, 14 days
1848564|NCT00942006|Drug|ceftriaxone|2g x 1 iv, 14 days
1848565|NCT00942045|Biological|Biologic - Osteocel Plus|Osteocel Plus
1848566|NCT00942058|Other|Serum and urinary CA9 level|Blood and urinary samples are collected before treatment and at 1, 3, 6, 9 and 12 months.
1848567|NCT00942071|Biological|MVA-NP+M1|1. Intradermal injection at 5 x 10^7 pfu at day 0
1848568|NCT00942071|Biological|MVA-NP+M1|2.Intramuscular injection at 5 x 10^7 pfu/ml at day 0. Intramuscular injection at 2.5 x 10^8 pfu/ml at day 0
1848569|NCT00942071|Biological|MVA-NP+M1|3.Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
1848570|NCT00942084|Drug|Acyclovir|"Protocol V2 & up: Acyclovir 7mg/ml to be administered IV at 10 mg/kg IV q12 or 20 mg/kg IV q12 or 20 mg/kg IV q8 for a total of 6-9 doses(3 days).
Protocol V1: Acyclovir 5 mg/mL to be administered IV at 500 mg/m2 IV q8h for a total of approximately 15 doses (10 days)."
1848571|NCT00942097|Drug|Sulph, Puls, Lyc, Lack t, Con, Sep, Nux v, Calc c, Phos|CH 12 preparation, 6 drops, twice a day, 4 days per week, until the end of pregnancy. One medication per appointment.
1848572|NCT00942097|Drug|Homeopathy and Nutritional oriented diet|Homeopathy 6 drops twice a day 4 days per week, active and placebo and Balanced nutritional oriented diet for both groups.
1848573|NCT00942110|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
1848574|NCT00942136|Drug|GSK1349572|GSK1349572 250 mg suspension as a single dose. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
1848575|NCT00942136|Drug|GSK1349572|GSK1349572 50 mg tablets as a single dose on three separate occasions. GSK1349572 is an investigational (not approved by the FDA) medication for the treatment of HIV in the class of integrase inhibitors.
1848576|NCT00942136|Drug|Placebo|Placebo Suspension as a single dose.
1848577|NCT00942136|Drug|Omeprazole|Omeprazole 40 mg once a day for 5 days. Omeprazole is approved by the FDA currently to reduce stomach acid, treat stomach ulcers, and gastroesophageal reflux disease.
1848578|NCT00942149|Drug|Daptomycin|single dose of 6 mg/kg of daptomycin
1848580|NCT00942175|Drug|Clopidogrel|Clopidogrel 75 mg, tablets, orally, once daily days 1-9.
1848581|NCT00942175|Drug|Clopidogrel and Lansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Lansoprazole 30 mg, capsules, orally, once daily days 1-9.
1848582|NCT00942175|Drug|Clopidogrel and Dexlansoprazole|Clopidogrel 75 mg, tablets, orally, once daily and Dexlansoprazole 60 mg, capsules, orally, once daily days 1-9.
1848583|NCT00942175|Drug|Clopidogrel and Omeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Omeprazole 80 mg, capsules, orally, once daily days 1-9.
1848584|NCT00942175|Drug|Clopidogrel and Esomeprazole|Clopidogrel 75 mg, tablets, orally, once daily and Esomeprazole 40 mg, capsules, orally, once daily days 1-9.
1848589|NCT00942214|Drug|Natalizumab|300mg, IV, every 4 weeks
1848590|NCT00942227|Other|Physical therapy rehabilitation|Extension oriented exercises. Subjects will be instructed in a progression of extension oriented exercises for the lumbar spine
1850402|NCT00946699|Biological|MEDI-551|3.0 mg/kg
1848591|NCT00942227|Other|Physical therapy rehabilitation|Mechanical lumbar traction will be applied with subjects in prone utilizing 40-60% of subject's body weight to create a distraction force in the lumbar spine. Following traction, subjects will be instructed in a progression of extension oriented exercises and manual therapy to increase extension as described for the comparator group.
1848592|NCT00942240|Drug|ACU-4429|administered orally once a day for 14 days
1848593|NCT00942240|Drug|matching placebo tablet|administered orally once a day for 14 days
1848594|NCT00942253|Other|Dopamine Agonist and Exercise|Dialysis patients will receive dopamine agonist or placebo for 24 weeks following a 24 weeks period of combined treatment with dopamine agonist or placebo and aerobic intradialytic exercise.
1848595|NCT00942266|Drug|fluorouracil|Given IV
1848596|NCT00942266|Drug|leucovorin calcium|Given IV
1848597|NCT00942266|Drug|vorinostat|Given orally
1848598|NCT00942266|Other|pharmacological study|Correlative study
1848599|NCT00942292|Dietary Supplement|Lipidem- fish oil emulsion BBraun UK|
1848600|NCT00942292|Procedure|Digital Contrast MRI scan|
1848601|NCT00942305|Drug|CMX001|CMX001 200mg twice weekly for a total of up to 18 doses.
1848602|NCT00942305|Drug|Placebo|Placebo tablets once weekly for a total of up to 11 doses.
1848603|NCT00942318|Drug|Detemir insulin, Aspart insulin, Metformin|Insulin doses adapted by patients according to self monitoring blood glucose results.
1848609|NCT00942344|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg, 5/100mg, 10/50mg, 10/100mg
1848610|NCT00942344|Drug|Amlodipine|amlodipine 5mg, 10mg
1848611|NCT00942344|Drug|Losartan|Losartan 50mg, 100mg
1848612|NCT00942357|Drug|Carboplatin|Given IV
1848613|NCT00942357|Drug|Cisplatin|Given IV
1848614|NCT00942357|Radiation|Internal Radiation Therapy|Undergo brachytherapy
1848615|NCT00942357|Drug|Paclitaxel|Given IV
1848616|NCT00942357|Other|Quality-of-Life Assessment|Ancillary studies
1848617|NCT00942357|Radiation|Radiation Therapy|Undergo radiation therapy
1848618|NCT00942370|Device|non invasive mechanomyographic device based on a 3 axes accelerometer|"This biomedical research consists specifically in the simultaneous acquisition of:
EMG and MMG Signals of rectus abdominis of the abdomen,
Respiratory flow,
An electrocardiogram (ECG).
These acquisitions will be conducted on 16 healthy volunteers according to a standardized protocol, at rest and during voluntary cough and various physical exercises often resulting in urinary leakage in the incontinent person."
1848619|NCT00942383|Device|IOUS - Siemens Anteras|additional IOUS to acquire ultrasound elasticity imaging
1848620|NCT00942396|Device|Full Field Digital Mammogram (Planmed Sophie Nuance)|Full Field Digital Mammogram
1848621|NCT00942409|Biological|ISF35|Subjects participating in this study will be treated with multiple doses of Ad-ISF35 given via intranodal injection using a fixed dose of 3.3 x 10^10 ISF35 viral particles. Intranodal injections will be administered every 2-4 weeks up to six total injections.
1848622|NCT00942422|Dietary Supplement|defined green tea catechin extract|Polyphenon E, an oral capsule form of EGCG extracted from green tea, 800 mg administered daily on an empty stomach (at least 1 hour before or 2 hrs after a meal)Patients receive oral green tea catechin extract (Polyphenon E) daily on days 1-28. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
1848623|NCT00942422|Genetic|gene expression analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
1848624|NCT00942422|Genetic|protein analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
1848625|NCT00942422|Other|laboratory biomarker analysis|Blood and bone marrow samples will be obtained prior to the start of treatment and at the conclusion of the study for correlative studies. An additional peripheral blood sample will be obtained on day 8 of the first cycle of therapy.
1848626|NCT00942435|Drug|YM150|oral
1848627|NCT00942435|Procedure|mechanical prophylaxis|The investigator will determine the method of mechanical prophylaxis
1848628|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
1848629|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
1848630|NCT00942448|Drug|Diclofenac HPBCD|1 single injection at day of dental surgical extraction
1848631|NCT00942448|Other|Placebo s.c.|1 single injection at day of dental surgical extraction
1848632|NCT00942461|Procedure|Laparoscopic colectomy|Laparoscopic colectomy. Epidural anaesthesia used
1848633|NCT00942461|Procedure|Open colectomy|Open colectomy. Epidural anaesthesia used
1848634|NCT00942474|Device|Facilitate nerve stimulation lead placement with the nerve access tool|
1848635|NCT00942487|Drug|Nebilet|Trade-mark: Nebilet® (Berlin-Chemie Menarini) INN: nebivolol Dosage and route of administration: 5 mg tablets, o.d. for oral administration
1848636|NCT00942487|Drug|Corvitol|Trade-mark: Corvitol (Berlin-Chemie Menarini) INN: metoprolol Dosage and route of administration: 50 mg tablets, b.d. (100 mg/day) for oral administration
1848637|NCT00942500|Procedure|Post-conditioning|Coronary angiogram is performed to allow identification of the culprit coronary artery and to check no reperfusion before PCI (TIMI grade <2). Restoration of coronary blood flow can be achieved by thrombus aspiration, balloon angioplasty, direct stenting or together.In the postconditioning group, immediately after restoration (TIMI grade ≥2) of coronary flow (without regard to method of achieving restoration), angioplasty balloon will be positioned at the culprit lesion or stented segment and inflated 4 times for 1 minute with low-pressure (4 to 6 atm) inflations, each separated by 1 minute of reflow. When restoration of coronary flow is achieved by thrombus aspiration or balloon angioplasty and residual stenosis is remained ≥30%, stent will be deployed.
1848713|NCT00943124|Drug|Simvastatin|Single dose simvastatin (Zocor™) 20 mg in one of two treatment periods.
1848638|NCT00942513|Other|trt 1|Fructose - 14 g; Lactose - 10 g; Sucrose - 16 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
1848639|NCT00942513|Other|trt 2|Fructose - 30 g; Lactose - 10 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
1848640|NCT00942513|Other|trt 3|Fructose - 24 g; Lactose - 8 g; Sucrose - 8 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
1848641|NCT00942513|Other|trt 4|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
1848642|NCT00942513|Other|trt 5|Fructose - 0 g; Lactose - 0 g; Sucrose - 40 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
1848643|NCT00942513|Other|trt 6|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 40 g; Soy Protein Isolate - 0 g
1848644|NCT00942513|Other|trt 7|Fructose - 0 g; Lactose - 40 g; Sucrose - 0 g; Starch - 40 g; Whey Protein Isolate - 0 g; Soy Protein Isolate -40 g
1848645|NCT00942526|Drug|Mycostatin oral suspension|peroperative Mycostatin oral suspension ( 0.1MU/cc, 24cc/bt; 5cc qid)for 7 days
1848646|NCT00942526|Other|Water|perioperative gargling with water
1848647|NCT00942539|Drug|Midazolam|Intravenous infusion of 0.05 mg/kg of Midalolam
1848648|NCT00942565|Drug|tramadol/acetaminophen|
1848649|NCT00942565|Drug|acetaminophen|
1848650|NCT00942578|Drug|Bevacizumab|15 mg/kg cycle 1 day 1, repeated every 21 days
1848651|NCT00942578|Drug|Lenalidomide|Once daily days 1-14 of every 21
1848652|NCT00942578|Drug|Docetaxel|75 mg/m2 IV over 60 minutes on cycle 1 day 1, repeated every 21 days (a 3-week cycle)
1848653|NCT00942578|Drug|Prednisone|10 mg orally every day
1848654|NCT00942591|Drug|Interferon beta 1b|
1848655|NCT00942591|Drug|Atorvastatin|
1848656|NCT00942604|Drug|PEP005 (ingenol mebutate) Gel|two day treatment
1848657|NCT00942604|Drug|Vehicle gel|two day treatment
1848658|NCT00942617|Drug|Aspirin|40 mg non-enteric coated ASA once daily for 21 + or - 2 days
1848659|NCT00942643|Device|CPAP machine|a machine delivers positive airway pressure into the upper airway via a nasal mask
1848660|NCT00942656|Other|PHVO|base diet plus 3.0% energy mixed isomers of trans fatty acids from partially hydrogenated vegetable oil
1848661|NCT00942656|Other|CLA|base diet plus 1.0% energy added from cis-9, trans-11 conjugated linoleic acid
1848662|NCT00942656|Other|VA|base diet plus 3.0% energy added from vaccenic acid
1848663|NCT00942656|Other|base|base diet containing approximately 0.1% energy of mixed trans fatty acid isomers
1848664|NCT00942669|Device|SleepStrip OTC(TM)|self contained SAS screening device
1848665|NCT00942682|Drug|Sorafenib|Taken orally twice daily
1848666|NCT00942682|Drug|RAD001|Taken orally once daily in the morning
1848667|NCT00942695|Other|1.5PD|average American diet plus 1.5 oz per day pistachios
1848668|NCT00942695|Other|3.0PD|average American diet plus 3.0 oz per day pistachios
1848669|NCT00942695|Other|control|average American diet without pistachios
1848670|NCT00942708|Drug|Fluoxetine|"Total dose How to take:
Week 1-2 20 mg daily Week 3-4 40 mg daily Week 5-6 40 mg BID Week 7-12 40mg BID"
1848671|NCT00942721|Behavioral|Web-based CBT for PPD|A cognitive behavioral intervention that will provide participants with the following: online interactive tools to clarify their attitudes and reasons for wanting to change, information about some of the symptoms and mechanisms associated with feeling depressed during the postpartum period, and guidance on using behavioral and cognitive strategies proven to help reduce depressive symptoms
1848672|NCT00942734|Drug|Erlotinib|One tablet (150 mg) by mouth every day of each 28 day study cycle.
1848673|NCT00942734|Drug|RAD001|1 tablet (5 mg) by mouth every day of each 28 day study cycle.
1848674|NCT00942747|Drug|temsirolimus|Weekly infusion of 25mg Temsirolimus (first 3 patients) or 75mg Temsirolimus (all other patients) up to a maximum of 12 months in the case of continuing response to treatment
1848675|NCT00942760|Device|3T MRI|The introduction of the 3T scanners provides a potential opportunity to improve the quality of imaging in neuro-oncology.
1848676|NCT00942773|Drug|Voriconazole|
1848677|NCT00942799|Drug|Genz-644282 (28-day dosing schedule)|Genz-644282 will be administered as a 60-minute IV infusion. The initial dose of Genz-644282 will be 0.5 mg/m2 and will be administered once weekly for 3 consecutive weeks on Day 1, Day 8, and Day 15 of the 28 day cycle. Each 28-day period will represent one treatment cycle. Study drug will continue to be given until disease progression or unacceptable toxicity is observed.
1848678|NCT00942799|Drug|Genz-644282 (21-day dosing schedule)|The starting dose of Genz-644282 for the 21-day schedule will be prescriptive and will be based on review of available safety data from the 28-day dosing schedule by the Investigator and Sponsor. Patients will receive Genz-644282 once-weekly for 2 consecutive weeks on Day 1 and Day 8 of a 21 day cycle. Each 21-day period will represent 1 treatment cycle. Patients enrolled in subsequent cohorts will receive higher doses until the MTD is established.
1848679|NCT00942812|Other|Diarrhea Pack|Low osmolality ORS, Zinc tablets, water purification tablets and pictorial chart
1848680|NCT00942812|Other|ORS|ORS has been supplied to diarrheal cases as standard care through the LHW program at community level
1848681|NCT00942825|Drug|CBP501 + Cisplatin + Pemetrexed|"CBP501, pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).
CBP501 25 mg/m² will be administered as an i.v. infusion of 1 hour.
Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes, immediately after the CBP501 infusion.
Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
1848682|NCT00942825|Drug|Cisplatin + Pemetrexed|"Pemetrexed and cisplatin will be administered on the same day (Day 1), every 3 weeks for a maximum of six cycles. A cycle is considered to be 3 weeks (21 days).
Pemetrexed 500 mg/m² will be administered as an i.v. infusion over 10 minutes.
Cisplatin 75 mg/m² will be administered as a 1-hour i.v. infusion immediately after the pemetrexed infusion."
1848752|NCT00935129|Device|OmniPod system|Patients will be treated with the OmniPod system for 12 weeks
1848753|NCT00935129|Device|Patient's conventional pump|patients will be treated with their conventional pump for 12 weeks
1848754|NCT00935142|Drug|[18F]VM4-037|Bolus IV injection of [18F]VM4-037
1848755|NCT00935155|Procedure|Acupuncture|Westerns style acupuncture. Twice a week for 12 weeks
1848683|NCT00942838|Drug|Cisplatin|PLATINOL®-AQ (cisplatin injection) is a clear, colorless, sterile aqueous solution, each mL containing 1 mg cisplatin and 9 mg Sodium Chloride, USP. HCl and/or Sodium Hydroxide is added to adjust pH of the solution. The active ingredient, cisplatin, is a yellow to orange crystalline powder with the molecular formula PtCl2H6N2, and a molecular weight of 300.1. Cisplatin is a heavy metal complex containing a central atom of platinum surrounded by two chloride atoms and two ammonia molecules in the cis position. It is soluble in water or saline at 1 mg/mL and in dimethylformamide at 24 mg/mL. It has a melting point of 207°C.
1848684|NCT00942838|Radiation|Whole Abdomen Radiotherapy|Whole abdominal radiotherapy will be delivered with an open-field anterior-posterior/posterior-anterior technique. Radiation will be administered in a dose escalating fashion to determine toxicity. The maximal dose of radiation will be defined as a mean midplane dose to the abdomen of 3,000 Gy through parallel-opposed single ports with a 1-cm margin that will cover the entire abdomen including the diaphragm.
1848685|NCT00942851|Drug|Acetyl-Hexapeptide Topical Treatment|AH-8 containing topical treatment
1848686|NCT00942851|Drug|placebo|topical treatment NOT containing AH-8
1848687|NCT00942864|Drug|ranibizumab|ranibizumab 0.5mg (0.05ml volume), intravitreal injection first 3 injection every 4 weeks additional injection (optional) according to the judgement of doctor
1848690|NCT00942903|Device|Provox Xtra HME|Heat and Moisture Exchanger for pulmonary Rehabilitation after total laryngectomy
1848691|NCT00942968|Drug|dalteparin|Daily subcutaneous injection 200IU/kg dalteparin
1848692|NCT00942994|Drug|Aliskiren/Amlodipine|"Amlodipine capsule (5 mg)
Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)"
1848693|NCT00942994|Drug|Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)|"Aliskiren/Amlodipine tablets (150/5 mg, 300/5 mg, 300/10 mg)
HCTZ capsule (12.5 mg, 25mg)"
1848694|NCT00943007|Device|Stealth Station|Neuronavigation based on preoperative MRI
1848695|NCT00943007|Device|PoleStar N20|Intraoperative MRI guided surgery
1848696|NCT00943020|Dietary Supplement|Nutricia PreOp nutritional supplement|nutritional supplement
1848697|NCT00943020|Dietary Supplement|Lipid|Drink
1848698|NCT00943020|Dietary Supplement|Glutamine|Drink
1848699|NCT00943033|Behavioral|Mindfulness-Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy for the prevention of depressive relapse/recurrence
1848701|NCT00943059|Drug|Acipimox|A capsula is given with 250mg Acipimox, 3dd; 1 after each meal. This will be done during 14 days.
1848702|NCT00943059|Drug|Cellulosum Mycrocryst|Capsule with cellulosum powder; this has to be taken 3 dd; 1 after each meal during 14 days.
1848703|NCT00943072|Biological|VEGF Trap-Eye 2.0mg|Monthly intravitreal injection out to the Week 24 Primary endpoint
1848704|NCT00943072|Drug|Sham|Monthly sham intravitreal injection out to Week 24 Primary Endpoint
1848705|NCT00943085|Behavioral|Family-focused therapy|12 therapy sessions involving the at-risk child or adolescent, parents, and available siblings. Therapy will include psychoeducation about mood disorders, communication enhancement training, and problem-solving skills training. Ongoing medication management from a study psychiatrist will be available.
1848706|NCT00943085|Behavioral|Brief educational treatment|Thorough diagnostic assessment by a study evaluator, separate evaluation by a child psychiatrist, feedback session with parents and child, and provision of reading materials pertinent to managing childhood mood disorders. Ongoing medication management and crisis-oriented family sessions will be available as needed.
1848707|NCT00943098|Drug|Diclofenac HPBCD s.c. 75mg/ml|1 single injection at day of dental surgical extraction
1848708|NCT00943098|Drug|Voltarol 75mg/3ml i.m.|1 single injection at day of dental surgical extraction
1848709|NCT00943111|Drug|Eliglustat tartrate|"Primary analysis period (PAP): Eliglustat tartrate capsule 50 milligram (mg) twice daily (BID) orally from Day 1 to Week 4 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 8, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to Week 52. Dose adjustments after Week 4 and Week 8 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was less than (<) 5 nanogram per milliliter [ng/mL] next higher dose was administered whereas if Genz-99067 trough plasma concentration was greater than or equal to (>=) 5 ng/mL same dose was continued. Pharmacokinetic (PK) assessment at Week 2 and 6 were used for dose adjustment after Week 4 and Week 8, respectively.
Long-term treatment period (LTTP): Participants originally randomized to eliglustat in PAP continued to receive eliglustat dose, based on their Genz 99067 plasma trough concentration at Week 6."
1848710|NCT00943111|Drug|Imiglucerase|"PAP: Imiglucerase intravenous infusion every other week (q2w) up to Week 52 in doses equivalent to participant's past ERT dose prior to any unanticipated treatment interruption, dose reduction, or regimen change.
LTTP: Participants originally randomized to imiglucerase received eliglustat tartrate capsule 50 mg BID orally from Week 52+1 Day to Week 56 followed by eliglustat tartrate 50 mg or 100 mg capsule BID up to Week 60, and then eliglustat tartrate 50 mg or 100 mg or 150 mg capsule BID up to 5 years. The dose adjustments after Week 56 and Week 60 were based on Genz-99067 (active moiety of eliglustat tartrate in plasma) trough plasma concentrations. If Genz-99067 trough plasma concentration was <5 ng/mL the next higher dose was administered whereas if the Genz-99067 trough plasma concentration was >=5 ng/mL the same dose was continued. The PK assessment at Week 54 and Week 58 were used for dose adjustment after Week 56 and Week 60, respectively."
1848711|NCT00943124|Drug|MK0524B (ER niacin (+) laropiprant (+) simvastatin)|Single dose of MK0524B (ER niacin 900 mg/ laropiprant 20 mg/ simvastatin 20 mg) in one of two treatment periods.
1848712|NCT00943124|Drug|MK0524A (ER niacin + laropiprant)|Single dose of MK0524A (ER niacin 1000 mg/ laropiprant 20 mg) in one of two treatment periods.
1848714|NCT00943137|Drug|5-Fluorouracil|"Chemotherapy will be one of the following:
de Gramont: folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.
FOLFIRI: Irinotecan 180mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2.
Modified FOLFOX-6: Oxaliplatin 85mg/m2 on day 1, folinic acid 400mg/m2 day 1, 5-FU 400 mg/m2 bolus on day 1 followed by 46 hour continuous infusion of 5-FU 2400mg/m2."
1848715|NCT00943150|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the abdominoplasty procedure.
1848716|NCT00943150|Procedure|Standard of Care (SOC)|The scalpel and electrocautery will be used for the abdominoplasty procedure.
1848717|NCT00943176|Drug|Modafinil|100 mg tablets of modafinil or matched placebo will be given for a total of 12 weeks. Patients will be instructed to start one capsule once daily (modafinil or placebo), and dose will be titrated according to tolerability and response.
1848718|NCT00943202|Biological|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine, 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm or in the anterolateral thigh muscle (1 injection in each arm or each thigh if receiving 2 doses).
1848719|NCT00943202|Biological|Trivalent Inactivated Influenza Vaccine|Licensed seasonal trivalent influenza vaccine (TIV) (2009-2010 season). For subjects greater than or equal to 6 - <36 months, licensed TIV will be administered as a single 0.25 mL intramuscular (IM) injection in the deltoid muscle of the arm or in the anterolateral thigh muscle. For subjects greater than or equal to 36 months - 17 years, licensed TIV will be administered as a single 0.5 mL IM injection in the deltoid muscle of the arm or in the anterolateral thigh muscle.
1848720|NCT00943228|Drug|mycophenolate mofetil|High dose 4gms daily
1848721|NCT00943254|Other|High-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently watch two 10-minute videos on the metabolic syndrome and on getting started with exercise. They also receive all the paper-based educational material as in arm 2
1848722|NCT00943254|Other|Low-Tech Education|Patients will be told that they have the metabolic syndrome and will subsequently receive paper-based educational material on the metabolic syndrome,pre-diabetes, and hypertension. They also receive pamphlets on dietary management of high cholesterol and triglycerides, and the importance of exercise and weight loss.
1848723|NCT00943267|Drug|Drotrecogin alpha|Drotrecogin alpha is given intrabronchially by bronchoscopy at t=0
1848724|NCT00943267|Drug|Saline (NaCl 0.9%)|Normal saline is given intrabronchially by bronchoscopy at t=0
1848725|NCT00943267|Drug|Endotoxin|Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
1848726|NCT00943267|Procedure|Bronchoscopy|Bronchoscopies are performed at t=0 (for instillation of LPS and Drotrecogin alpha) and at t=6 (for performing a bronchoalveolar lavage)
1848727|NCT00943267|Procedure|Blood sampling|Blood sampling is done by venapuncture at t=0 and t=6
1848728|NCT00943293|Drug|Fludarabine|Fludarabine 30 mg/m2 intravenously daily at the same time over 30 minutes on days -7,-6,-5,4,-3.
1848729|NCT00943293|Drug|Melphalan|Melphalan 140 mg/m2 IV on day -2.
1848730|NCT00943293|Drug|Campath|Campath, 20 mg IV on day -7, 6, -5, -4, and -3.
1848732|NCT00943319|Drug|Busulfan|Daily intravenous dosing to target AVC
1848733|NCT00943319|Drug|Fludarabine|Fludarabine dosing will be based on actual body weight. Fludarabine will be infused over 30 minutes before busulfan treatment dose.
1848734|NCT00943319|Drug|Campath|All patients will receive premedication for Campath (daily doses of 20 mg are repeated for up to five times).
1848735|NCT00943319|Procedure|Stem Cell Transplant|Infusion of bone marrow and donors(related/ unrelated).
1848736|NCT00943332|Procedure|femur fracture repair|all participants will have undergone surgical intervention to repair a femur fracture, the investigators will simply be collecting data after the procedure; participants will not be consented until after the procedure
1848737|NCT00934986|Other|Surface expression of functional biomarkers of the NK cell|"An extra blood sample of 40 ml is required :
Stage A patient who does not require a treatment: one sample the day of enrollment.
Stage B or C patient who require RFC treatment: sample at D0 of the 1st and 4th cure of RFC, and 3 months after the end of the treatment."
1848738|NCT00934999|Procedure|Burch urethropexy|Patients will undergo a Burch modified Tanagho procedure (in which the anterior vagina is suspended to Cooper's ligament bilaterally using two non-absorbable sutures).
1848739|NCT00934999|Procedure|Synthetic mid-urethral sling (TVT)|Patients will undergo a polypropylene mid urethral sling as described by the manufacture (Align, Bard Urological, Covington, GA).
1848740|NCT00935012|Drug|tafamidis|Once daily 20 mg oral tafamidis (soft gelatin capsule)
1848741|NCT00935025|Drug|AZD1305|single and multiple oral doses, extended-release capsule
1848742|NCT00935025|Drug|Placebo|single and multiple oral doses, capsule
1848743|NCT00935051|Other|Picture + MMPs and TIMP1 at week 0 and week 4|Sample of wound fluid will be collected using a non traumatic procedure at week 0 and week 4. This will allow to assess the level of MMP9, MMP13, MMP1 and TIMP1. A numeric photograph of the wound will be taken at week 0, week 4 and week 12 in order to assess wound area.
1848744|NCT00935064|Drug|Aliskiren|Pill, 300 mg, once daily, for 6 weeks
1848745|NCT00935064|Other|Placebo|Placebo orally one tablet once a day for 6 weeks.
1848746|NCT00935077|Other|PPCM Asthma|Pharmacists collaborate with physicians to manage asthma
1848747|NCT00935077|Other|24 Month PPCM BP|Pharmacists collaborate with physicians for 24 months to manage hypertension.
1848748|NCT00935077|Other|9 Month PPCM BP|Pharmacists collaborate with pharmacists for 9 months to manage hypertension
1848749|NCT00935090|Device|3'-deoxy-3'-[18F]fluorothymidine|The tracer compound [F-18] FLT will be injected into the patient's veins in a small volume of normal saline solution. The PET scan data collection is started immediately and is continued for 2 hours. This procedure will measure tumor growth within the body. Blood may be withdrawn (through the catheters) up to a total volume of 30 milliliters (or 2 tablespoons) for each scan. A urine sample may be collected at the end of the imaging of the tracer compound to analyze its breakdown products.
1848750|NCT00935103|Behavioral|Psychoeducation|
1848751|NCT00935116|Drug|etoricoxib|"G1 (CONTROL): Oral NSAID (diclofenac, three times a day) administrated pre-operatively and for 3 days after surgery.
G2: Etoricoxib 120 mg, pre and post-operatively for 3 days after surgery"
1848756|NCT00935155|Procedure|exercises|Coordination, mobilizing, endurance, strength
1848757|NCT00935168|Drug|6% Hydroxy-ethyl starch (130/0.4)|Maximum dose of 50ml/kg/day of 6% hydroxy-ethyl starch (130/0.4) for intravascular volume fluid resuscitation
1848758|NCT00935168|Drug|Saline|Maximum dose of 50ml/kg/day of saline for intravascular volume fluid resuscitation
1848759|NCT00935181|Behavioral|respiratory muscle stretching|stretching exercises for respiratory muscles like diaphragm, pectoral, dorsalis etc
1848760|NCT00935194|Drug|oseltamivir|75mg,bid,for 5 days
1848761|NCT00935194|Other|blank|no antiviral therapy
1848762|NCT00935194|Drug|chinese medicinal herbs|200ml,p.o,qid,for 5 days
1848763|NCT00935194|Drug|oseltamivir and chinese medicinal herbs|oseltamivir:75mg,p.o,bid,for 5 days; chinese medicinal herbs:200ml,p.o,qid,for 5 days
1848764|NCT00935207|Other|Pediatric Pain Diary|Pain diary designed for pediatric patients
1848765|NCT00935220|Drug|linagliptin QD (once daily) for 7 days|dipeptidyl peptidase IV (DPP-4) activity will be measured as PD response to drug administration
1848766|NCT00935233|Genetic|DNA analysis|
1848767|NCT00935233|Genetic|polymorphism analysis|
1848768|NCT00935233|Genetic|protein analysis|
1848769|NCT00935233|Other|laboratory biomarker analysis|
1848770|NCT00935233|Other|questionnaire administration|
1848771|NCT00935233|Other|survey administration|
1848772|NCT00935246|Drug|Escitalopram|Antidepressant administration of Escitalopram for 8 weeks under therapeutic dose
1848773|NCT00935259|Drug|Simvastatin|40 mg once daily for 2 weeks
1848774|NCT00935259|Drug|Placebo|Placebo, matching the simvastatin (40 mg) tablet as a single oral daily dose for 2 weeks
1848775|NCT00935272|Device|Restylane®|Restylane® injections in the lips
1848776|NCT00935272|Device|Non-Treatment|Non- Treatment
1848777|NCT00935298|Drug|Tacrolimus|The genotyping of gene CYP3A5 will be carried out in the 4-7days before renal transplantation. After transplantation, the patients will be treated by MMF, corticosteroids and tacrolimus at a dosage adapted to their genotype(CYP3A5*1/*1 type and CYP3A5*1/*3 type administer 0.15mg/kg/d，CYP3A5*3/*3 type administer 0.08mg/kg/d).
1848778|NCT00935311|Drug|ABT-712 Extended-release|ABT-712 extended-release tablet
1848779|NCT00935311|Drug|Hydrocodone/Acetaminophen Immediate-release|Hydrocodone/acetaminophen immediate-release tablet
1848780|NCT00935311|Drug|Placebo|Placebo tablet
1848781|NCT00935337|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
1848782|NCT00935337|Behavioral|Sleep Hygiene|treatment as usual
1848783|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|2.5 grams of PGX
1848784|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|5.0 grams of PGX
1848785|NCT00935350|Dietary Supplement|PolyGlycopleX (PGX)|0 grams of PGX
1848786|NCT00935363|Drug|glyburide|single oral dose
1848787|NCT00935363|Drug|glyburide + fluconazole|single dose oral glyburide single dose iv fluconazole
1848788|NCT00935363|Drug|glyburide + rifampin|single dose oral glyburide single dose iv rifampin
1848789|NCT00935363|Drug|glyburide + fluconazole + rifampin|single dose oral glyburide single dose iv fluconazole single dose iv rifampin
1848790|NCT00935376|Behavioral|Sleep Education Program|Treatment as usual.
1848791|NCT00935376|Behavioral|Mind-Body Bridging Program|Bridging aims to reduce the impact of negative thought patterns that contribute to stress in the body.
1848792|NCT00935376|Behavioral|Mindfulness Meditation Program|Mindfulness Meditation Program is based on Mindfulness-Based Stress Reduction, which teaches participants awareness and mindfulness skills using techniques that include a basic meditation practice and yoga.
1848793|NCT00935389|Drug|tripterygium glycosides|The onset dosage should be 30mg/q.d. and can be reduced into 20mg b.i.d if CR obtained in 3 months. Without CR in 3 months, the dosage of 90mg/d will last for another 3 months and then reduced to 60mg/d.
1848794|NCT00935402|Behavioral|Sleep|Subjects are randomly assigned to one of 2 arms sequence: short followed by regular or regular followed by short. Each arm is 6 days in length and separated by a 2-4 week washout period.
1848795|NCT00935415|Drug|Montelukast|Montelukast 5 mg
1848796|NCT00935415|Drug|Placebo|capsules of matching placebo
1848797|NCT00943345|Drug|indometacin|"capsule for oral consumption
at 22h00 evening before test day: 75 mg
at 7h30 on the test day: 50 mg This intervention will be applied 4 times (4 arms)."
1848798|NCT00943358|Biological|MF59 H1N1 vaccine|3.75-7.5ug dose
1848799|NCT00943358|Biological|Plain H1N1 vaccine|7.5-15ug
1848800|NCT00943371|Drug|MK6349|Panel A: MK6349 in single doses beginning at 16 mg and rising to 90 mg in up to four treatment periods Panel B: MK6349 in single doses beginning at 90 mg and rising to 160 mg in up to four treatment periods Panel C: MK6349 in divided doses beginning at 20 mg q.a.c. (before each meal) and rising to 50 mg q.a.c. in up to four treatment periods
1848801|NCT00943371|Drug|Comparator: Placebo to MK6349|Panel A: Placebo to MK6349 in single doses in up to four treatment periods Panel B: Placebo to MK6349 in single doses in up to four treatment periods Panel C: MK6349 in divided doses q.a.c. (before each meal) in up to four treatment periods
1848802|NCT00943384|Device|chronOS Strip|chronOS strip combined with bone marrow aspirate plus local bone
1848803|NCT00943397|Drug|montelukast sodium|Montelukast 4 mg oral granules mixed with 1 tablespoon soft food once daily at bedtime for 52 weeks
1848804|NCT00943397|Drug|Comparator: Usual Care|Usual care defined as inhaled/nebulized cromolyn or inhaled nedocromil or inhaled/nebulized corticosteroids, according to the investigator's usual clinical practice for 52 weeks
1848805|NCT00943410|Radiation|external beam radiation therapy|Radiation therapy will consist of 50Gy in 2Gy fractions to the breast/chest wall and regional lymphatics for 5 consecutive days up to 5 weeks for surgical candidates and 7 weeks for non-surgical candidates
1848806|NCT00943410|Drug|Herceptin|Patients who are already receiving weekly Herceptin® will continue weekly Herceptin®, 2mg/kg IV on day 1 of each week of radiotherapy. Patients who have not been receiving weekly Herceptin® as a component of systemic therapy will begin Herceptin® one week prior to beginning radiotherapy with a loading dose of 4mg/kg followed by weekly Herceptin® at 2mg/kg on day 1 of each week of radiotherapy
1848807|NCT00943423|Radiation|Involved Field Radiotherapy|IFRT 30Gy delivered in daily fractions of 1.8 - 2.0Gy
1848809|NCT00943436|Other|Exercise Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Exercise Session will consist of the participant coming into the lab and completing 45 min bout of exercise on an exercise bike, followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
1848810|NCT00943436|Other|Rest Session|"This study consists of two laboratory sessions. Participants will be randomly assigned to the order in which they go through these two sessions. The Rest Session will consist of the participant coming into the lab and completing a 45 min period of reading followed by a 60 min resting period, followed by the lunch buffet portion of the session where they will have 25 min to eat ad libitum."
1848811|NCT00943449|Drug|4SC-201|oral administration
1848812|NCT00943449|Drug|Sorafenib|oral administration
1848813|NCT00943462|Radiation|External-beam radiation therapy|60 Gy of external beam radiotherapy using a standard technique will be administered in 2‑Gy fractions, for a total of 30 fractions
1848814|NCT00943462|Drug|Temozolomide|The chemotherapy will have to be administered in accordance with the protocol used in the CAN-NCIC-CE3 study, which established the current standard for treatment of GBM with the administration of temozolomide as adjuvant therapy at the same time as radiotherapy (clinicaltrials.gov ID NCT00006353).
1848816|NCT00943488|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
1848817|NCT00943501|Drug|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
1848818|NCT00943501|Drug|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 5 weeks (0.3 - 1.8 mg)
1848819|NCT00943501|Drug|liraglutide|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
1848820|NCT00943501|Drug|placebo|Increasing dose for self-injection subcutaneously (under the skin) daily over 3 to 4 weeks (0.6 - 1.8 mg).
1848821|NCT00943540|Drug|raltegravir QD|Raltegravir 800mg QD
1848822|NCT00943540|Drug|atazanavir|atazanavir
1848823|NCT00943540|Drug|lamivudine (or emtricitabine)|lamivudine (or emtricitabine)
1848824|NCT00943553|Drug|decitabine Induction Chemotherapy|Arm A - 12 days (5 days of intravenous (IV) decitabine 20 mg/m^2 followed by 7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day)
1848825|NCT00943553|Drug|Induction Chemotherapy|Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m^2 and cytarabine 100 mg/m^2/day only)
1848826|NCT00943566|Drug|Sufentanil|Transdermal Delivery System; Apply up to six 3 cm2 sufentanil TDS patches every 3 days for 12 days of observation. The 12 days of observation begin after a 7 day conversion to sustained release morphine sulfate. If the subject continues on the pharmacokinetic portion of the study, an additional 6 days of intervention will be evaluated (at the same dose as the primary efficacy study).
1848827|NCT00943566|Drug|Sustained Release Morphine Sulfate|Sustained Release Morphine Sulfate tablets every 12 hours; up to 400 mg every day for 19 days (7 days of conversion to sustained release morphine sulfate and 12 days of observation)
1848828|NCT00943579|Drug|Kuvan®|Brand-name Kuvan® (sapropterin) will be administered to all subjects at a dose of 20 mg/kg/day for 16 weeks.
1848829|NCT00943592|Drug|Clofarabine|Clofarabine will be administered as a 2-hour IV infusion on Days 1 through 5 at approximately the same time everyday (4 dose levels).
1848830|NCT00943592|Drug|Melphalan|Doses ranging from 100 to 140 mg/m2
1848831|NCT00943592|Drug|Campath|20mg/d x5
1848832|NCT00943592|Procedure|Stem Cell Transplant|Infusion of donor, bone marrow and auto.
1848833|NCT00943605|Device|Scalpel and Traditional Electrosurgery|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
1848834|NCT00943605|Device|PEAK PlasmaBlade|The entirety of the mastectomy will be performed with the PEAK PlasmaBlade, including the skin incision.
1848835|NCT00943618|Drug|Varenicline|On Days 1-3, .5mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, .5mg tablet by mouth in the morning and .5mg tablet by mouth in the evening (for a total of 2 doses).
1848836|NCT00943618|Drug|Bupropion|On Days 1-3, 150 mg tablet by mouth in the morning. Beginning on Day 4, and then every day after that, 150 mg tablet by mouth in the morning and 150 mg tablet by mouth in the evening (for a total of 2 doses).
1848837|NCT00943618|Other|Placebo|On Days 1-3, 1 tablet by mouth of placebo that looks like the study drug in the morning. Beginning on Day 4, and then every day after that, 1 tablet by mouth in the morning and 1 tablet by mouth in the evening for a total of 2 doses of the placebo each day.
1848838|NCT00943618|Behavioral|Counseling/Phone Calls|Brief-behavioral counseling sessions (10-15 minutes) provided to all participants once per week for 12 weeks. One support phone call conducted 3 days after the target quit date.
1848839|NCT00943631|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 mcg per dose.
1848840|NCT00943644|Device|Molecular Breast Imaging (MBI)|To determine the sensitivity of MBI
1848841|NCT00943644|Device|CZT semiconductor detectors|Dual headed CZT semiconductor detectors
1848842|NCT00943657|Biological|Preflucel [Trivalent seasonal influenza vaccine (split virus, Vero cell-derived)]|Single intramuscular injection of vaccine
1848843|NCT00943670|Biological|pertuzumab|Intravenous repeating dose
1848844|NCT00943670|Biological|Trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
1848845|NCT00943761|Drug|Vaniprevir 600 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, four in the morning and four in the evening, for 48 weeks
1848846|NCT00943761|Drug|Vaniprevir 300 mg b.i.d.|Oral capsules containing 150 mg vaniprevir, two in the morning and two in the evening, for 48 weeks
1848847|NCT00943761|Drug|Pegylated interferon|Prefilled syringe containing 180 µg/0.5 mL peg-IFN, for weekly subcutaneous injection, for 48 weeks
1848848|NCT00943761|Drug|Ribavirin|Oral tablets containing 200 mg RBV, 5 or 6 tablets, dosage based on the participant's weight (<75 kg or ≥75 kg, respectively), for 48 weeks
1848880|NCT00943917|Drug|Exenatide Injection|twice daily (BID) injections of exenatide commercially available Byetta: 5 mcg/dose first 12 weeks then 10 mcg/dose for 8 weeks
1848849|NCT00943774|Other|Physiological maneuvers|These healthy subjects undergo physiological testing, which includes aortic augmentation index, pulse wave velocity, orthostatic stress, baroreflex sensitivity (modified Oxford protocol), mental stress, cold pressor test, isometric handgrip, heart rate variability, 24-hour ambulatory blood pressure monitoring.
1848850|NCT00943787|Procedure|Hyperinsulinemic, euglycemic and hypoglycemic clamp|At 21:30h, an overnight insulin infusion was titrated to control the subjects' BG overnight between 100 and 150mg/dL by blood sampling for plasma glucose via a YSI analyzer every 30min and adjusting the rate of insulin infusion as needed. At the beginning of the clamp, the overnight insulin was replaced by an insulin infusion via a Harvard pump given as a 20mU/kg priming over a 10-min period, followed by a constant rate delivery of 1mU/kg/min until the end of the clamp. Blood was sampled for plasma glucose, and glucose was clamped at basal levels for the euglycemic control period of 150min via a variable-rate infusion of 20% dextrose. Then the glucose concentration was lowered at a rate of 1mg/dL/min to a minimum of 50mg/dL, where it was held constant for 30min. Finally, the glucose concentration was increased at a rate of 1mg/dL/min to 90mg/dL, where it was held for an additional 30min. Blood was sampled for epinephrine during euglycemia, hypoglycemia, and recovery.
1848851|NCT00943800|Drug|Fludarabine-Melphalan & Rabbit antithymocyte globulin (r-ATG)|Fludarabine is given through the vein daily for 5 days. Melphalan is given through the vein daily for 2 days. ATG is given every day in the vein for four days.
1848852|NCT00943800|Procedure|Stem Cell Transplant|Infusion of haploidentical donor, umbilical cord blood
1848853|NCT00943800|Procedure|Stem Cells Collections|Haploidentical cells will be T-cell depleted using the Miltenyi Clinimax device.
1848854|NCT00943800|Drug|Fludarabine, Thiotepa, Antithymocyte globulin (ATG), and Total Body Irradiation (TBI)|Fludarabine is given through the vein daily for 5 days. Thiotepa is given through the vein daily for 2 days. ATG is given through the vein every other day for 4 days. TBI is given twice a day for 3 days.
1848855|NCT00943800|Drug|Fludarabine, Busulfan, and ATG|Fludarabine is given through the vein daily for 5 days. Busulfan is given through the vein daily for 4 days. ATG is given through the vein every other day for 4 days.
1848856|NCT00943813|Behavioral|video-recording and completing a survey|"Video record MD consult before MD has completed Comskill training. Post-Video Recording Survey (5 minutes): This is a 22-item self-report scale that measures patient satisfaction and patient reports of communication behavior (Roter et al 1977). Items are rated using a five-point Likert-type scale ranging from 1, I disagree completely  to 5, I agree completely ."
1848857|NCT00943826|Drug|Bevacizumab|10 mg/kg intravenously q2w in the Concurrent and Maintenance Phases. 15 mg/kg intravenously q3w in the Monotherapy Phase.
1848858|NCT00943826|Drug|Temozolomide|75 mg/m^2 once daily for 6 weeks, followed by 150-200 mg/m^2 once daily on days 1-5 of six 4 week cycles.
1848859|NCT00943826|Radiation|Radiation therapy|30 fractions of 2 Gy delivered on days 1-5 per week for 6 weeks.
1848860|NCT00943826|Drug|Placebo|Intravenously q2w in the Concurrent and Maintenance Phases and q3w in the Monotherapy Phase.
1848861|NCT00943839|Drug|sunitinib malate|
1848862|NCT00943839|Other|laboratory biomarker analysis|
1848863|NCT00943839|Other|pharmacological study|
1848864|NCT00943852|Drug|losartan potassium|Single dose losartan 100 mg in one of five treatment periods
1848865|NCT00943852|Drug|Comparator: isosorbide mononitrate (ISMN)|Single dose ISMN 60 mg in one of five treatment periods
1848866|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 15 mg in one of five treatment periods
1848867|NCT00943852|Drug|Comparator: losartan + ISMN|Single dose losartan 100 mg and ISMN 60 mg in one of five treatment periods
1848868|NCT00943852|Drug|Comparator: Placebo|Single dose placebo only in one of five treatment periods
1848869|NCT00943865|Behavioral|hypocaloric diet|patients received individually tailored hypocaloric diet, with 20% of total calories as fat (with 7-8 % of saturated fats), 50 to 65% carbohydrates and 15% to 20% proteins. Total of calories for each patient calculated assuming the ideal body weight to fulfill a BMI of 25 kg⁄ M2. Total daily amount of calories estimated calculating 30 calories/Kg of ideal weight for each subject. Subjects were advised against consuming high fat snacks or additional fats. Alimentary plans specified the number of servings from each food group, and dairy intake was held constant.
1848870|NCT00943865|Behavioral|Exercise recommendations|Exercise was advised but not measured: they received recommendations to be physically active and perform 1 hour of aerobic exercise as preferred, everyday.
1848871|NCT00943865|Behavioral|Pragmatic diet|Patients received a portable colored handbook with evidence- based recommendations on healthy eating attitudes and pragmatic menus, with low carbohydrates and high protein and vegetables. It included controlled portions (adjusted for individual hand size) for the six meals, with low glucose aliments and whole grains, legumes, yogurt, fruits, olive oils, eggwhite and low fat milk, fiber and a handful of nuts. Portions were tailored according to individual hand size, without calories counting. Beans, farofa and white cheese bread, which are commonly present in Brazilian food, and red meat were allowed, but with portion control.
1848872|NCT00943865|Behavioral|Pedometer-based fitness (10,000 steps)|Subjects were provided with pedometers and were instructed to perform at least 10,000 steps daily, diary recorded.
1848873|NCT00943865|Behavioral|Structured assisted exercise (fitness)|They were scheduled for a more structured assisted exercise intervention: three bicycle ergometer sessions per week, under direct supervision of the same trained exercise physiologists in each session. Heart rate monitors were used to adjust workload to achieve the target heart rate (75% of the maximum attainable heart rate), as determined by their individual maximal treadmill exercise test. All patients were trained by the same staff, Borg scale was registered in every session and persuasive goal setting was made during exercise sessions
1848874|NCT00943878|Biological|Trivalent inactivated influenza vaccine|Licensed trivalent influenza vaccine (TIV) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
1848875|NCT00943878|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine, 15 mcg per dose, administered as a single 0.5 milliliters (mL) intramuscular injection in the deltoid muscle.
1848876|NCT00943878|Drug|Placebo|Normal saline (placebo control) administered as a single 0.5 mL intramuscular injection in the deltoid muscle.
1848877|NCT00943891|Procedure|Tumor biopsies|
1848879|NCT00943917|Other|ITCA 650|ITCA 650 (continuous delivery of exenatide in DUROS)
1848881|NCT00943917|Other|Ex Inj/ITCA 650|twice-daily (BID) exenatide injection: 5 mcg/dose for 4 weeks then 10 mcg/dose for 8 weeks, followed by ITCA 650
1848882|NCT00943930|Drug|THC (delta-9 tetrahydrocannabinol), d-amphetamine, oral THC|During each study session participants will be asked to smoke a cigarette. The cigarette may contain marijuana or it may contain placebo (a blank). Participants will also be asked to swallow a capsule 2-hours prior to smoking the cigarette. The capsule could contain placebo (a blank), THC (delta-9 tetrahydrocannabinol, or d-amphetamine.
1848883|NCT00943943|Drug|G-CSF|10 microgram/kg subcutaneous injection based on adjusted ideal body weight and administered in the evening (prior to the Plerixafor). The 1st dose on day -1 and every other day for 7 total doses. G-CSF administration of 7 every-other-day doses will be repeated every 28 days.
1848884|NCT00943943|Drug|Plerixafor|A fixed dose of 240 mcg/kg subcutaneous injection in the abdomen, calculated on ideal body weight. The 1st dose on day -1 and every other day for 7 total doses. Plerixafor administration of 7 every-other-day doses will be repeated every 28 days.
1848885|NCT00943943|Drug|Sorafenib|"First dose will be given right after G-CSF and plerixafor injections. Drug doses will be separated by intervals of approximately 12 hours (+/-2 hours).
Dose Level 0 = 400 mg orally twice daily."
1848886|NCT00943956|Drug|bicalutamide|
1848887|NCT00943956|Drug|everolimus|
1848888|NCT00943956|Drug|leuprolide acetate|
1848889|NCT00943956|Radiation|external beam radiation therapy|
1848890|NCT00943969|Procedure|gastric bypass|gastric bypass combines restrictive and malabsorptive procedures
1848891|NCT00943982|Drug|Interferon Gamma 1-b|
1848892|NCT00943995|Drug|somatropin|0.35 mg/Kg/week divided into 3 doses, each dose being given at the end of the dialysis treatment.
1848893|NCT00944008|Drug|DepoCyte|
1848894|NCT00944021|Drug|PA-824|50mg
1848895|NCT00944021|Drug|PA-824|100mg
1848896|NCT00944021|Drug|PA-824|150 mg
1848897|NCT00944021|Drug|Rifafour e-275 mg|275 mg
1848898|NCT00944021|Drug|PA-824|200 mg
1848899|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
1848900|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
1848901|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 12 months of age
1848902|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 18 months of age
1848903|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 months of age
1848904|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 18 months of age
1848905|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 12 and 14 months of age.
1848906|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 4, and 6 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
1848907|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 18 and 20 months of age
1848908|NCT00944034|Biological|rMenB+OMV NZ|rMenB+OMV NZ at 2, 4, and 6 months of age and routine vaccinations at 3, 5 and 7 months of age; random allocation in a 1:1:1 ratio to receive a booster dose of rMenB+OMV NZ at 24 months of age
1848909|NCT00944034|Biological|two doses of rMenB+OMV NZ|two catch-up doses of rMenB+OMV NZ at 24 and 26 months of age
1848910|NCT00944034|Biological|rMenB+OMV NZ with routine vaccinations|rMenB+OMV NZ with routine vaccinations at 2, 3 and 4 months of age; random allocation in a 1:1:1 ratio to receive 1 booster dose of rMenB+OMV NZ at 12 (Group 3a), 18 (Group 3b) or 24 (Group 3c) months of age
1848911|NCT00944047|Drug|nab-paclitaxel|100 MG/M2 IV over 30 minutes once a week for 12 weeks
1848912|NCT00944047|Drug|trastuzumab|4 MG loading dose followed by 2 MG/KG every week for a total of 12 weeks
1848913|NCT00944047|Drug|Doxorubicin|60 MG/M2 every two weeks for a total of 4 cycles
1848914|NCT00944047|Drug|cyclophosphamide|600 MG/M2 every 2 weeks for 4 cycles (administered with Doxorubicin above)
1848915|NCT00944060|Other|lifestyle intervention|
1848916|NCT00944073|Biological|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly as 15 or 30 micrograms per dose. Both doses of the vaccine will be administered as a single 0.5 mL injection in the deltoid muscle of the preferred arm or into the anterolateral thigh muscle.
1848917|NCT00944086|Other|Recruitment Manoeuvre|Recruitment Manoeuvre
1848918|NCT00944099|Behavioral|Behavioral weight loss intervention|both conditions will receive an identical dietary prescription, low-calorie and less than 30% calories from fat and an identical physical activity goal of 200 minutes of moderate-intense physical activity per week during a 6 month behavioral weight loss program
1848919|NCT00944112|Biological|Restrictive RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤70 g/L with a target Hb concentration of 71-90 g/L during the intervention period.
1848920|NCT00944112|Biological|Liberal RBC Transfusion|Patients will receive single unit RBC transfusions with a transfusion trigger of ≤90 g/L with a target Hb concentration of 91-110 g/L during intervention.
1848921|NCT00944125|Device|Dual Site LV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
1848922|NCT00944125|Device|BiV Pacing|Dual Site LV Pacing vs. BiV Pacing for a total of six months which includes two three crossover periods.
1848923|NCT00944138|Behavioral|Relaxation methods|Relaxation methods will include mindful meditation techniques for the intervention and listening to music for the control arm
1849113|NCT00945425|Drug|AZD7325|oral capsule, once or twice daily, 7 days
1848924|NCT00944151|Procedure|TAP Catheter and Infusion of Study Solution|Subject will be randomized to one of two groups: Saline infused TAP catheter following surgery for 0-2 days or ropivacaine infused TAP catheter following surgery for 0-2 days. All patients will be given a single injection of ropivacaine prior to surgery. Research staff will follow all patients for two days following surgery or while they have TAP catheter in.
1848925|NCT00944164|Behavioral|Healthy eating and physical activity|Parent counseling and coaching regarding healthy eating and physical activity habits for their child
1848926|NCT00944164|Behavioral|Safety and injury prevention|Parent counseling and coaching regarding general personal and household safety
1848927|NCT00944177|Drug|Metformin HCl|
1848928|NCT00944190|Behavioral|Self-management intervention|Brief counseling technique, self-management,
1848929|NCT00944190|Behavioral|Education|Educational information about pain, fatigue, depression, and cognitive difficulties in multiple sclerosis.
1848930|NCT00944203|Drug|Ipomea pes-caprae ointment|Ipomea pes-caprae ointment will be applied twice a day as an add-on therapy.
1848932|NCT00944229|Drug|LOVAZA (Omega-3)|LOVAZA 4 gm q24 for 8 weeks Each 1-gram capsule of LOVAZA (omega-3-acid ethyl esters) contains at least 900 mg of the ethyl esters of omega-3 fatty acids. These are predominantly a combination of ethyl esters of eicosapentaenoic acid (EPA - approximately 465 mg) and docosahexaenoic acid (DHA - approximately 375 mg).
1848933|NCT00944229|Drug|Placebo|4 capsules of placebo every 24 hours
1848934|NCT00944242|Drug|Sertraline|
1848935|NCT00944242|Drug|Sertraline Hydrochloride|
1848936|NCT00944268|Drug|Passiflora, Crataegus e Salix|Comparison of different pharmaceutics forms of drug
1848937|NCT00944281|Dietary Supplement|LNS-Zn5|Daily consumption of 20 g LNS containing 5 mg of zinc and daily placebo supplement
1848938|NCT00944281|Dietary Supplement|LNS-Zn10|Daily consumption of 20 g LNS containing 10 mg of zinc and daily placebo supplement
1848939|NCT00944281|Dietary Supplement|LNS-Zn0|20 g of LNS containing 0 mg of zinc and a daily placebo supplement
1848940|NCT00944281|Dietary Supplement|Suppl-Zn5|Daily 5 mg zinc supplement ant consumption of 20 g LNS containing 0 mg of zinc
1848941|NCT00944294|Drug|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
1848942|NCT00944294|Drug|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
1848943|NCT00944307|Drug|raltegravir|raltegravir 400mg orally once
1848944|NCT00944307|Drug|antacid|aluminum, magnesium, simethicone-containing antacid 30mL orally once
1848945|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 6 months
1848946|NCT00944333|Drug|Clopidogrel|300-600 loading dose 75 mg/die for 12 months
1848947|NCT00944346|Drug|Metformin HCl|
1848948|NCT00944359|Dietary Supplement|Daily preventive Zn; placebo treatment|7 mg zinc / day and placebo supplement during diarrhea episodes
1848949|NCT00944359|Dietary Supplement|Therapeutic Zn; daily placebo|20 mg zinc / day for 10 days during diarrhea episodes and daily placebo supplement
1848950|NCT00944359|Dietary Supplement|Intermittent Zn; placebo treatment|10 mg zinc for 10 days every 3 months, placebo supplements daily for all other days during 12 months; placebo supplements during diarrhea episodes
1848951|NCT00944359|Other|Surveillance control group|Active weekly morbidity surveillance for 3 months. New surveillance control group will be randomly assigned to intervention groups every 3 months
1848952|NCT00944372|Drug|Indium In-111 pentetreotide|Single intravenous injection of 222MBq (6.0 mCi) Indium In-111 pentetreotide
1848953|NCT00944385|Drug|ulinastatin|Administer 30000U/ulinastatin. Comparison of different dosages of drug.
1848954|NCT00944398|Dietary Supplement|Zinc fortified food|Daily consumption
1848955|NCT00944398|Dietary Supplement|Zinc supplement|Liquid supplement containing zinc sulfate
1848956|NCT00944398|Other|Placebo supplement|Liquid placebo supplement
1848957|NCT00944398|Dietary Supplement|Non-fortified food|Non-fortified complementary food.
1848958|NCT00944424|Drug|Docetaxel + High dose Vitamin D2|Docetaxel + High dose Vitamin D2
1848959|NCT00944424|Drug|Docetaxel + Standard dose Vitamin D2|Docetaxel + Standard dose Vitamin D2
1848960|NCT00944437|Device|Helmet|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
1848961|NCT00944437|Device|Full-face mask|Continuous positive airway pressure for up to 24 h. Initial pressure will be 5 cmH2O, and will be increased by 2-3 cmH2O up to 10 cmH2O, in order to maintain SpO2 ≥90%.
1848962|NCT00944450|Drug|Sitagliptin phosphate anhydrous formulation|Single dose sitagliptin 100 mg tablets (anhydrous form) in one of two treatment periods.
1848963|NCT00944450|Drug|Comparator: sitagliptin phosphate monohydrate form|Single dose sitagliptin 100 mg tablets [monohydrate Final Market Image (FMI) form] in one of two treatment periods.
1848964|NCT00944463|Drug|Gemcitabine+simvastatin|Gemcitabine and simvastatin
1848965|NCT00944463|Drug|Gemcitabine+Placebo|Gemcitabine plus Placebo
1848966|NCT00944476|Procedure|Fat-free MRI images utilizing standard magnetization, Questionnaire before the MRI exam|In addition to the traditional MRI exam for clinical use, a fat-free MRI based on standard magnetization transfer magnetic resonance imaging will be acquired. Pts will spend 20 extra minutes and 20 minutes total for volunteers in the MRI scanner. Patients/volunteers will complete the MR Screening Questionnaire before the MRI exam.
1848967|NCT00944502|Drug|Dexamethasone|"Group A: Vitatonus DEXA injectable:
1 ampoule intramuscularly every 3 days for 10 days.
Group B: Vitatonus DEXA tablets:
1 tablet orally every 8 hours for 10 days.
Group C: Dexamethasone Injectable:
1 ampoule intramuscularly every 3 days for 10 days.
Group D: Dexamethasone tablets:
1 tablet orally every 8 hours for 10 days."
1848968|NCT00944515|Drug|placebo|placebo tablet or syrup 3 days/week
1848969|NCT00944515|Drug|azithromycin|azithromycin 3 days/week
1848970|NCT00944528|Radiation|Radiosurgery|Single dose or radiation in 15Gy, 18Gy or 21Gy
1848971|NCT00944541|Drug|maraviroc|maraviroc 150 mg or 300 mg or 600 mg twice a day for 24 weeks
1848972|NCT00944554|Drug|Varenicline|Varenicline given twice a day or five weeks.
1848973|NCT00944554|Drug|Placebo|Placebo given twice a day or five weeks.
1848974|NCT00944580|Biological|MAGE-A1, MAGE-A3, and NY-ESO-1 Vaccine|A regimen of three vaccines every two weeks. Each vaccine will contain 3,000,000-5,000,000 peptide pulsed dendritic cells. Imiquimod, a topical cream, will be applied to the vaccination site before and after each vaccination.
1848975|NCT00944593|Dietary Supplement|Jejunal Feed|Liquid nutrient (Ensure 200ml (300kcal) over 60 minutes) will be delivered by naso-jejunal feeding tube (previously placed by endoscopy)
1848976|NCT00944593|Dietary Supplement|Normal Saline|200ml Normal Saline 0.9%
1848977|NCT00944606|Dietary Supplement|Vitamin D|2000-3000 IU Vitamin D daily x 6 weeks
1848978|NCT00944606|Other|Placebo candy|candy gum drops
1848979|NCT00944619|Device|Closed loop|Subcutaneous delivery of Novorapid insulin, dose calculated by control algorithm, based on continuous glucose sensor readings
1848980|NCT00944619|Device|Conventional insulin pump delivery|Subcutaneous delivery of Novorapid insulin according to usual pump regime
1848981|NCT00944632|Drug|ZK 245186|Once daily topical non-occlusive application for up to 4 weeks
1848982|NCT00944632|Drug|Placebo (vehicle ointment)|Once daily topical non-occlusive application for up to 4 weeks
1848983|NCT00944645|Drug|niacin (+) laropiprant (Source 1)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 1 in one of two treatment periods.
1848984|NCT00944645|Drug|Comparator: niacin (+) laropiprant (Source 2)|Single dose of MK0524A (ER Niacin/laropiprant 1000/20 mg) from Source 2 in one of two treatment periods.
1848985|NCT00944658|Drug|Apremilast|As per protocol
1848986|NCT00944658|Drug|Placebo (sugar pill)|As per protocol
1848987|NCT00944671|Drug|famotidine (+) calcium carbonate (+) magnesium hydroxide tablet|A single dose of famotidine/antacid tablet with 120 mL of water in one of three treatment periods
1848988|NCT00944671|Drug|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet without water|A single dose of famotidine/antacid combination EZ Chew tablet without water in one of three treatment periods
1848989|NCT00944671|Drug|Comparator: famotidine (+) calcium carbonate (+) magnesium hydroxide EZ Chew tablet with water|A single dose of famotidine/antacid combination EZ Chew tablet with 120 mL of water in one of three treatment periods
1848990|NCT00944684|Drug|High ribavirin dose|Ribavirin dose started according to kidney function (usually 1,800mg) and adapted according to plasma level during follow-up
1848991|NCT00944684|Drug|Standard ribavirin dose|Ribavirin dose started at 1,000mg (body weight <65kg) or 1,200mg (body weight equal or >65kg)
1848992|NCT00944697|Drug|Oxycodone Naloxone|Oxycodone Naloxone tablets
1848993|NCT00944697|Drug|Placebo tablets|Placebo Oxycodone Naloxone tablets
1848994|NCT00944710|Drug|Atropine|Weekend atropine 1%
1848995|NCT00944710|Device|Plano lens|plano lens over the sound eye
1848996|NCT00944710|Drug|Atropine|Weekend atropine 1%
1848997|NCT00944723|Dietary Supplement|Zinc-fortified bread|Bread made with zinc-fortified wheat flour
1848998|NCT00944723|Dietary Supplement|Zinc supplement|Liquid supplement with zinc
1848999|NCT00944723|Dietary Supplement|Non-fortified bread|Daily consumption of non-fortified bread
1849000|NCT00944723|Dietary Supplement|Placebo supplement|Daily intake of placebo supplement
1849001|NCT00944736|Dietary Supplement|VSL#3|1 packet BID
1849002|NCT00944736|Dietary Supplement|Placebo|1 inactive packet BID
1849003|NCT00944749|Drug|h-ATG (ATGAM )|
1849004|NCT00944749|Drug|Cyclosporine (Gengraf )|
1849005|NCT00944762|Behavioral|Ecosystem Focused Therapy (EFT)|12 therapist-led sessions over 25 weeks, in which a participant will learn problem-solving skills, the participant's physical environment will be modified, and the family or caregiver will facilitate the participant's adaptation. Active participation in treatment and rehabilitation for stroke will also be targeted by EFT's problem-solving approach, creating synergy among treatments.
1849006|NCT00944762|Behavioral|Education in stroke and depression|Information and resources on living with stroke and depression will be provided in 12 sessions over 25 weeks.
1849008|NCT00944788|Other|qi-gong|Physical activity similar to tai-chi
1849009|NCT00944801|Drug|Pegylated Liposomal Doxorubicine|In the dose escalation phase of the study, PEG-Dox is raised in steps of 5 mg/m2 in a 3-by-3 design, starting with 5 mg/m2 (group 1) up to 20 mg/m2 (group 4). In the phase II part of the study, the targeted dose of 20 mg/m2 is administered up to a cumulative dose of 550 mg/m2 or until tumor progression.
1849010|NCT00944814|Dietary Supplement|LNS with zinc|Lipid-based nutrient supplement (LNS) containing 10 mg zinc/20 g LNS dose
1849011|NCT00944814|Dietary Supplement|LNS without zinc|LNS containing no zinc
1849012|NCT00944827|Dietary Supplement|Green Tea Extract - Catechins|Combination treatment with 20 mg atorvastatin and 600mg green tea extract, daily for 12 weeks
1849013|NCT00944827|Dietary Supplement|Placebo|Combination treatment with 20 mg atorvastatin and 600mg placebo, daily for 12 weeks
1849014|NCT00944840|Drug|SP plus amodiaquine|SP plus amodiaquine or placebo at monthly interval during September, October and November
1849015|NCT00944840|Drug|SP placebo plus amodiaquine placebo|monthly treatment with amodiaquine and SP or placebo during September, October and November
1849016|NCT00944853|Dietary Supplement|Liquid zinc syrup|Liquid zinc syrup containing 5 mg zinc as zinc sulfate
1849017|NCT00944853|Dietary Supplement|Zinc tablet|Dispersible zinc tablet containing 5 mg zinc
1849018|NCT00944853|Dietary Supplement|Liquid placebo supplement|Liquid placebo supplement containing 0 mg zinc
1849019|NCT00944892|Drug|REGN475|2 Administrations of REGN475 within 24 weeks.
1849020|NCT00944892|Other|Placebo|Placebo to match REGN475 doses
1849021|NCT00944905|Biological|MDX-1203|Assigned Interventions: Single dose of MDX-1203 will be administered every 21 days as an intravenous (i.v.) infusion. Subjects will receive one dose of MDX-1203.
1849022|NCT00944918|Drug|fulvestrant|Intramuscular injection on days 1, 15, and 29 and then once monthly until disease progression.
1849023|NCT00944918|Drug|anastrozole|Tablet, oral, once daily until disease progression.
1849024|NCT00944918|Drug|exemestane|Tablet, oral, once daily until disease progression.
1849025|NCT00944931|Device|DC Brain Polarization|
1849114|NCT00945425|Drug|Placebo|oral capsule, once or twice daily, 7 days
1849026|NCT00944944|Behavioral|limb volume measurements and GCLQ lymphedema symptom assessment questionnaire|Upon obtaining consent, the participants without a history of lower extremity lymphedema will be asked to undergo limb volume measurements to ensure the accuracy of group assignment to the nonlymphedema group. Participants will then be asked to complete the one time GCLQ lymphedema symptom assessment questionnaire. The survey tool and Limb volume (LV) data and feedback from participants about the GCLQ will be collected. We expect the study survey to take approximately 5-10 minutes to complete and 5-10 minutes to collect LV data.
1849027|NCT00944944|Behavioral|GCLQ lymphedema symptom assessment questionnaire|The gynecologic cancer survivors with lymphedema group will have documented lower extremity lymphedema. Participants will be asked to complete a one time assessment, the Gynecologic Cancer Lymphedema Questionnaire to identify lower extremity lymphedema symptoms in gynecologic cancer survivors. They will also be asked to provide feedback about their satisfaction with and the feasibility of the GCLQ as a brief assessment tool that could be used in the clinical care setting.
1849032|NCT00944970|Drug|binodenoson|30-second intravenous injection (bolus) of binodenoson (1.5 mcg/kg) and a 6-minute intravenous infusion of placebo
1849033|NCT00944970|Drug|adenosine|30-second intravenous injection (bolus) of placebo and a 6-minute intravenous infusion of adenosine (140 mcg/kg/minute)
1849034|NCT00944996|Drug|SSRI; SNRI; TCA|Tablets or Pills, 1 or 2 per day, more than 2 month
1849035|NCT00945009|Biological|Dactinomycin|Given IV
1849036|NCT00945009|Drug|Doxorubicin Hydrochloride|Given IV
1849037|NCT00945009|Drug|Vincristine Sulfate|Given IV
1849038|NCT00945009|Drug|Carboplatin|Given IV
1849039|NCT00945009|Drug|Cyclophosphamide|Given IV
1849040|NCT00945009|Drug|Etoposide Phosphate|Given IV
1849041|NCT00945009|Radiation|Radiation Therapy|Undergo radiation therapy
1849042|NCT00945009|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
1849043|NCT00945009|Procedure|Adjuvant Therapy|Undergo adjuvant therapy
1849044|NCT00945009|Procedure|Neoadjuvant Therapy|Undergo neoadjuvant therapy
1849045|NCT00945022|Device|wetting lips following surgery using anesthesia|The investigator will position the Lipsus device in accordance with the instructions for use
1849046|NCT00945035|Drug|etoricoxib|Single dose etoricoxib 120 mg 20% final market image tablet in one of two treatment periods.
1849047|NCT00945035|Drug|Comparator: etoricoxib|Single dose etoricoxib 120 mg 30% unmilled, roller compaction tablet in one of two treatment periods.
1849048|NCT00945048|Device|electrical velocimetry|determination of cardiac output by electrical velocimetry
1849049|NCT00945048|Device|inert gas rebreathing|determination of cardiac output by inert gas rebreathing
1849050|NCT00945048|Device|spirometry|spirometry for testing the ventilatory function
1849051|NCT00945048|Device|cardiac magnetic resonance imaging (CMR)|CMR examination which delivers the hemodynamic reference parameters
1849052|NCT00945061|Radiation|intracavitary balloon brachytherapy|Patients undergo brachytherapy
1849053|NCT00945061|Radiation|intraoperative radiation therapy|Patients undergo radiotherapy
1849054|NCT00945074|Other|Standard Acupuncture/Moxibustion (fixed protocol)|Acupuncture/Moxibustion
1849055|NCT00945074|Other|Individualized Acupuncture/Moxibustion|Individualized Tailored Acupuncture/Moxibustion Protocol based on TCM Diagnosis
1849056|NCT00945074|Other|Sham/Placebo Acupuncture/Moxibustion|Sham/Placebo Acupuncture/Moxibustion Protocol: Not-Active
1849057|NCT00945087|Other|Bacteriophage preparation|Bacteriophage lysates or purified phage formulations containing phages lytic for Staphylococcus, Enterococcus, Pseudomonas, Escherichia, Klebsiella, Proteus, Citrobacter, Acinetobacter, Serratia, Morganella, Shigella, Salmonella, Enterobacter, Stenotrophomonas, or Burkholderia strains isolated from a patient used for oral, rectal and/or topical application.
1849058|NCT00945100|Device|Eye Patch|42 hours patching per week (averaging 6 hours patching daily)
1849059|NCT00945100|Device|Eye Patch|2 hours patching daily
1849060|NCT00945113|Behavioral|One-week speech therapy group|One-week cross-district speech therapy group for older children (aged 8 to 15) who stammer
1849061|NCT00945126|Other|Hematopoietic stem cell product from haploidentical or unrelated donor CD3/CD19 depleted with CliniMACS|The aim is to transplant 7x106 CD34+/kg of recipient body weight.
1849062|NCT00945139|Drug|Doxil|Open label study of Doxil given as 30 mg/m2 every three weeks by itself in cycle 1
1849063|NCT00945139|Drug|Avastin|First agent (Doxil) will be following by Avastin 15 mg/kg on cycle 2 and every cycle thereafter until disease progression
1849064|NCT00945152|Drug|Vancomycin 1.25-1.50% in a complex gel formulation trademarked Vancogel(R)|Topical use for open wounds culturing out MRSA. One to three applications of the compound over a weeks time. Consists of Vancomycin 1.25-1.50% in a complex gel formulation.
1849065|NCT00945152|Drug|Placebo, complex gel formulation without Vancomycin|Complex gel formulation applied as the placebo and is unknown because of the trial design. Complex gel formulation without Vancomycin
1849066|NCT00945165|Behavioral|Exercise intervention|various exercise characteristics
1849067|NCT00945165|Behavioral|No exercise|No exercise control period
1849068|NCT00945178|Drug|AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
1849069|NCT00945178|Drug|Placebo for AZD1386|Single ascending and multiple (twice daily) oral doses, capsule
1849070|NCT00945178|Drug|Naproxen|Tablet, single oral dose, 500mg
1849071|NCT00945178|Drug|Placebo for Naproxen|Tablet, single oral dose
1849072|NCT00945191|Drug|CS-1008|CS-1008 IV infusion up to 10 mg/kg once every 3 weeks (1 cycle) for 6 cycles
1849073|NCT00945191|Drug|paclitaxel|paclitaxel 175 mg/m2 IV infusion once every 3 weeks (1 cycle) for 6 cycles
1849074|NCT00945191|Drug|carboplatin|carboplatin (target area under the concentration versus time curve of 6.0 using the Calvert Formula) IV infusion once every 3 weeks (1 cycle) for 6 cycles
1849075|NCT00945204|Other|intermediate care clinics (ICCs)|The ICCs will be community based. Their aim is to support primary care, particularly smaller practices that have the most difficulty achieving good control. They will comprise a multidisciplinary team, and be led by specialist nurses who will place an emphasis on education and self management. Medical care will be provided by a diabetologist. The ICC will work closely with hospital based specialist teams and community services including podiatry and dietetics. Team members will work to local guidelines, adapted from national evidence based guidelines. Guidelines for referral to the ICCs will be common across all sites, and will include people with poorly controlled type 2 diabetes and those with poorly controlled cardiovascular risk factors.
1849076|NCT00945230|Procedure|Re-section of a large left anterior cranial fossa meningioma|Neurosurgical re-section of an incidental large left anterior cranial fossa meningioma
1849077|NCT00945243|Device|Zero-P|The Zero-P PEEK is a stand-alone device intended for use in cervical interbody fusion. The device consists of a plate and a spacer with four rigid screws to provide similar stability to a traditional cervical plate and interbody spacer. It is intended for use in skeletally mature patients with symptomatic cervical disc disease (SCDD) with accompanying radicular symptoms, at one level from C3 to C7.
1849078|NCT00945256|Other|Aerobic Exercise|45 minuties of treadmill walking was completed at 40% VO2 peak
1849079|NCT00945256|Drug|Sodium Nitroprusside|Sodium Nitroprusside was given in a constant infusion for 180 minutes at a rate of 0.114 ug/kg/min
1849080|NCT00945256|Dietary Supplement|Amino Acid Drink|7.5 gram Amino Acid drink
1849081|NCT00945269|Biological|therapeutic autologous lymphocytes|Given IV
1849082|NCT00945269|Biological|aldesleukin|Given SC
1849083|NCT00945269|Biological|denileukin diftitox|Given IV
1849084|NCT00945269|Procedure|biopsy|Optional correlative studies
1849085|NCT00945269|Other|immunohistochemistry staining method|Correlative studies
1849086|NCT00945269|Other|laboratory biomarker analysis|Correlative studies
1849087|NCT00945269|Genetic|polymerase chain reaction|Correlative studies
1849093|NCT00945295|Drug|Botulinum toxin type A, BoNT-A|Participants will receive IM injections of BoNT-A between 200 and 400 Units with the total dose not to exceed 6 U / kg. The primary targets for BoNT-A injection are the wrist and finger flexor muscles (flexor carpi radialis, flexor carpi ulnaris, flexor digitorum profundus, flexor digitorum superficialis).
1849094|NCT00945295|Other|Rehabilitation Therapy|Rehabilitation therapy
1849095|NCT00945308|Drug|Eptifibatide|Intracoronary injection of Eptifibatide injected in two consecutive bolus of 180 mcg/kg each, followed immediately by continuous infusion of 2 mcg/kg/min for 12 hs.
1849096|NCT00945308|Drug|Eptifibatide|Intravenous injection of Eptifibatide in two consecutive boluses of 180 mcg/kg followed by continuous intravenous injection dosing 2 mcg/kg/min for 12 hours
1849097|NCT00945321|Drug|aprepitant 165 mg|Single dose of aprepitant 165 mg tablet in the fasted state during treatment period 1,2, or 3.
1849098|NCT00945321|Drug|Comparator: aprepitant 185 mg|Single dose of aprepitant 185 mg tablet in the fasted state during treatment period 1, 2, or 3.
1849099|NCT00945321|Drug|Comparator: fosaprepitant 150 mg|Single dose of fosaprepitant 150 mg intravenous infusion in the fasted state during treatment period 1,2, or 3.
1849100|NCT00945321|Drug|Comparator: aprepitant with food|Single dose of aprepitant 165 mg or 185 mg tablet in the fed state during treatment period 4.
1849101|NCT00945334|Drug|Neomycin|500 mg po bid for 14 days
1849102|NCT00945334|Drug|Placebo|placebo for 14 days tid
1849103|NCT00945334|Drug|Rifaximin|550 mg po tid
1849104|NCT00945347|Drug|Miglustat|Nasal instillation of miglustat
1849105|NCT00945347|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Miglustat instillation
1849106|NCT00945360|Drug|Letrozole (aromatase inhibitor)|Letrozole at a dose of 2.5 mg/day for 8 weeks.
1849107|NCT00945373|Drug|calcium dobesilate|2.5% gel
1849108|NCT00945373|Procedure|pulsed dye laser|All study patients will be treated with 595 nm PDL (Vbeam, Candela Corp, Wayland, Mass) with an initial test spot using a fluence of 10 J/cm2, 7-mm spot size and 1.5-ms pulse duration. Based on the biologic response of the test area, the fluence will accordingly be adjusted up or down to find a fluence that produces a transient purpuric effect for a few seconds only.
1849109|NCT00945399|Procedure|CARTIPATCH® procedure|Cartilage is harvested and treated for chondrocytes isolation and culture. After multiplication, the chondrocytes are transferred into a biomaterial support and surgically implanted.
1849110|NCT00945399|Procedure|Microfracture|Tiny fractures are created at the cartilage surface to stimulate cartilage growth.
1849111|NCT00945412|Device|Micropolysaccharide Hemospheres (Arista)|"MPH is applied as an aerosolized powder which is applied to the bleeding fossa, immediately after suctioning the freshly completed tonsillotomy site to expose the tonsil bed. A separate aerosolizer is used for each patient in order to maximize uniformity per standard dose applied. Each initial dose remains in situ for up to 60 seconds in an attempt to achieve complete hemostasis with a single dose. (Prior data from MPH use has shown that 30-60 seconds is the time typically required for hemostasis for diffuse, non-arterial bleeds.) If there is persistent bleeding after this timeframe, then the bed is irrigated and suctioned and a second equivalent dose is applied.
No pressure pack and no oxymetazoline or other topical vasoconstrictor is applied in either group during these initial hemostatic steps, since they are potential confounders of hemostatic effect."
1849112|NCT00945412|Device|Electrocautery (Monopolar suction cautery)|Monopolar suction electrocautery is used at 20 Watts. Cautery is applied with a light surface touch until bleeding has stopped. In addition, any prominent visible vessels are cauterized.
1849115|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.1 mL, Intradermal
1849116|NCT00945438|Biological|Influenza virus vaccine 2009-2010 formulation|0.5 mL, Intradermal
1849117|NCT00945451|Device|CK|Cyberknife Irradiation
1849118|NCT00945464|Other|Blood/saliva samples, historic breast imaging|Subjects are required only to provide a blood or saliva sample, relevant personal and family history (if available), and 5 years of historic breast imaging reports.
1849119|NCT00945477|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks
1849120|NCT00945490|Drug|NX-1207|Single intraprostatic injection of 2.5 mg NX-1207
1849121|NCT00945490|Drug|Placebo|Single intraprostatic injection of placebo
1849122|NCT00945503|Drug|GSK1018921|GSK1018921 is a GT1 recepor antagonist
1849123|NCT00945516|Device|Bona stent® (Flared end FCSEMS)|Flared end FCSEMS for benign bile duct stricture will be inserted with ERCP.
1849124|NCT00945516|Device|Hanarostent® (Anchoring FCSEMS)|Anchoring FCSEMS for benign bile duct stricture will be inserted with ERCP.
1849125|NCT00945529|Drug|inhaled nitric oxide|Inhaled nitric oxide 40ppm for 48 hours followed by a 6-hour wean.
1849126|NCT00945542|Other|Massive transfusion protocol|"Patients randomized to this arm will be transfused based on a pre-defined massive transfusion protocol. Blood bank will release blood a pre-defined packages. Blood will be received in aliquots containing 4 units off FFP, 1 pool of buffy coat platelet (4 units) and 4 units of RBC. As discussed previously, this would correspond to an FFP:RBC transfusion ratio of 1:1.
Patients randomized to the study protocol will be receiving the FFP and PTL at pre-defined ratios to RBC (1:1:1) up to 12h of hospitalization or earlier if cessation of the massive transfusion requested at the discretion of the treating physicians."
1849127|NCT00945542|Other|Standard of care|Patients randomized to this arm will be treated as per Sunnybrook's current standard of care massive transfusion protocol. Crystalloid and red cell transfusions are performed to maintain volume status, and to maintain haemoglobin levels above 70 g/L. FFP is transfused based in 3-4 unit aliquots, for INR>1.5. Platelets are transfused 1 pool at a time (4 units Buffy coat platelets) to maintain platelet counts above 50 x 109/mL. Cryoprecipitate is transfused 8-12 units at a time to keep fibrinogen above 0.8 gram/L.
1849128|NCT00945555|Drug|Antibacterial agent for the treatment of febrile neutropenia|The antibacterial agent used by the investigators for febrile neutropenia will be determined and classified in the preference order
1849130|NCT00945581|Other|Experimental Nutritional Powder Formula|Powder twice a day
1849131|NCT00945581|Other|Placebo comparator|Powder twice a day
1849133|NCT00945607|Other|GRT (Guided Relaxation Training)|Weekly on-site GRT sessions at the center in combination with twice daily independent GRT sessions at home.
1849134|NCT00945620|Drug|ropivicaine|30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
1849135|NCT00945620|Drug|placebo|Placebo
1849136|NCT00945646|Drug|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops times two times a day.
1849137|NCT00945646|Drug|Vehicle|Instill four times two times a day
1849138|NCT00945659|Device|Continuous Glucose Sensor|Education and medical management to promote optimal therapeutic benefit from adding use of a continuous glucose sensor to daily diabetes management.
1849139|NCT00945659|Other|Standard Care|Intensified diabetes management based on either insulin pump or multiple daily injection insulin regimen, employing carbohydrate counting and a bolus dose correction factor for adjusting insulin doses.
1849140|NCT00945659|Behavioral|CGS + Behavior Therapy|Patients in this group will receive 6 scheduled encounters with a behavior therapist who will assist the adolescent and parent in reducing or eliminating common behavioral and psychological barriers to achieving optimal benefit from CGS use in diabetes care.
1849141|NCT00945672|Biological|PF-04360365 10 mg/kg|10 mg/kg every 90 days (5 total doses)
1849142|NCT00945672|Biological|PF-04360365 7.5 mg/kg|10 mg/kg loading dose followed by 7.5 mg/kg monthly maintenance dosing (total of 13 doses)
1849143|NCT00945672|Drug|placebo|placebo administered every 90 days or monthly to match experimental treatment arms.
1849144|NCT00945685|Device|Endymion Imagine™ System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):
Pulse energy (J);
RF frequency (1MHz);
Pulse duration (30 sec);
Treatment hand piece (skin tightening);"
1849145|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 10gM|"140 g of milk-containing LNS (LNS-10gM) 2-weekly (10 g / day) between 6 and 18 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
1849146|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 20gM|"280 g of milk-containing LNS (LNS-20gM) 2-weekly (20 g / day) between 6 and 18 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
1849147|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 20gNoM|"280 g of milk-free LNS (LNS-20gNoM) 2-weekly (20 g / day) between 6 and 18 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
1849148|NCT00945698|Dietary Supplement|Lipid-based nutrient supplement, 40gM|"560 g of milk-containing LNS (LNS-40gM) 2-weekly (40 g / day) between 6 and 18 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
1849149|NCT00945698|Dietary Supplement|Lipid-based Nutrient Supplement, 40gNoM|"560 g of milk-free LNS (LNS-40gNoM) 2-weekly (40 g / day) between 6 and 18 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
1849150|NCT00945698|Dietary Supplement|Maize-soy flour|"No food supplement during the primary trial period (6 to 18 months of age)
1 kg fortified maize / soy flour (Likuni phala, LP) 2-weekly (71 g / day) between 18 and 30 months of age
Normal under-five clinic follow-up, including EPI-vaccinations, vitamin A supplementation, and growth monitoring"
1849192|NCT00946010|Biological|blood sampling and abdominal sonography|10cc blood sampling and abdominal sonography
1849326|NCT00939120|Drug|Pre-randomization Dutasteride|All participants were on Dutasteride 0.5mg orally once daily prior to randomization.
1849151|NCT00945724|Drug|Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisolone, liposomal cytarabine, methotrexate|"Weeks 1-15:
6 cycles of CHOP on Days 1 to 5, to be repeated q21 Days
Rituximab 375 mg/m2 on Day 0 or Day 1 of every CHOP cycle
IT chemoth:Depocyte 50 mg on Day 0 of cycles 2,3,4&5 of R-CHOP
Weeks 18-22:
• Methotrexate 1.5 g/m2 q14 Days x 2
From Week 24:
• Scrotal prophylactic radiotherapy or involved field radiotherapy(but can be planned concomitantly to R-CHOP in pts with bilateral disease)"
1849152|NCT00945737|Dietary Supplement|Soy protein; 25 grams/day|Soy protein
1849153|NCT00945737|Dietary Supplement|Control protein|Milk protein
1849154|NCT00945750|Drug|Famotidine FCT|Famotidine 20 mg oral film-coated tablet taken once daily
1849155|NCT00945750|Drug|Famotidine CT|Famotidine 20 mg oral chewable tablet taken once daily
1849156|NCT00945763|Drug|N1539|30 mg
1849157|NCT00945763|Drug|placebo|tablets
1849158|NCT00945763|Drug|N1539|15 mg
1849159|NCT00945763|Drug|N1539|60 mg
1849160|NCT00945763|Drug|Motrin|400 mg
1849161|NCT00945776|Behavioral|Weekly phone calls|Calling weekly to answer questions regarding CPAP usage.
1849162|NCT00945776|Behavioral|Frequently asked questions|Answers to frequently asked questions in pre-printed form.
1849163|NCT00945776|Behavioral|Usual care|Answers will be provided by the renter of the equipment, and the sleep center if asked in addition to explanations by the sleep specialist.
1849164|NCT00945789|Drug|Human recombinant erythropoietin|Epo dse is 2500 IU/kg subcutaneous daily for 5 days.
1849165|NCT00945789|Procedure|EEG and Brain MRI|EEG to be done twice in hte first 48 hours and at 2-3 weeks. MRI to be done at 3 weeks of age.
1849166|NCT00945789|Biological|Nitric oxide measurement in the blood|Concentration of nitric oxide is measured in the blood at enrollment. For the 2 groups with asphyxia, measurement to be repeated in 2 weeks.
1849167|NCT00945802|Drug|FST-201 (dexamethasone 0.1%) Otic Suspension|Instill four drops two times a day
1849168|NCT00945802|Drug|ciprofloxacin 0.3%, dexamethasone 0.1%|Instill four drops two times a day
1849169|NCT00945815|Biological|epratuzumab|
1849170|NCT00945815|Drug|clofarabine|
1849171|NCT00945815|Drug|cytarabine|
1849172|NCT00945815|Other|laboratory biomarker analysis|
1849173|NCT00945828|Behavioral|Annual Intervention Group|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP once per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
1849174|NCT00945828|Behavioral|Quarterly Monitoring of IEP|Parents/caregivers and the teacher of participants will be asked to evaluate the effectiveness of the child's IEP four times per academic calendar year. The evaluation is done through the use of an IEP Questionnaire developed for this study. This questionnaire addresses the child's academic performance, progress, and adherence to the IEP developed.
1849175|NCT00945841|Biological|inactivated split influenza vaccine|1 dose of inactivated split influenza vaccine, using the strain composition 2009/2010
1849176|NCT00945854|Other|Wholegrain cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on wholegrain cereals and foods with low glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
1849177|NCT00945854|Other|Refined cereal diet|Thirty subjects with metabolic syndrome, after an initial run-in period of 4 weeks, during which they stabilise their own diet and other lifestyle habits, are assigned to a diet based on refined cereals and foods with high glycemic index for a period of 12 weeks. Before and after the dietary treatment, a frequently samples intravenous glucose tolerance is carried out to measure the effects of the intervention on glucose and insulin metabolism. At beginning and at the end of intervention, the subjects consume also a standard test meal to evaluate the postprandial response of glucose, insulin, lipids, oxidative parameters and inflammatory molecules.
1849178|NCT00945880|Drug|clemizole hydrochloride|Two 50 mg capsules containing clemizole hydrochloride are to be administered orally twice a day for 28 days for a total daily dose of 200 mg. Followed immediately by standard of care treatment consisting of interferon and ribavirin
1849179|NCT00945893|Biological|MEDI3414 [Influenza A/H1N1 live attenuated, intranasal]|0.5 mL; (intranasal sprayer)
1849180|NCT00945893|Other|Placebo|(intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer)
1849181|NCT00945906|Biological|FXIII Concentrate (Human) (FXIII)|"Doses will be guided by the individual subject's most recent FXIII activity levels, with the objective of dosing every 28 days to maintain a trough FXIII activity level of approximately 5 to 20%.
Subjects enrolled in this study who have not received at least 3 doses of FXIII Concentrate in a previous study of this product (i.e., NCT00640289, NCT00885742, or NCT00883090) will initially receive a dose of 40 U/kg by intravenous (IV) infusion."
1849182|NCT00945919|Drug|Oxymorphone ER|Rapid Opioid rotation/titration
1849185|NCT00945945|Drug|Duloxetine (DLX)|dose daily by mouth
1849186|NCT00945945|Drug|Placebo (PLA)|Placebo Comparator daily by mouth
1849187|NCT00945958|Drug|SPARC0913|One drop of SPARC0913 in affected eye once daily for 24 weeks
1849188|NCT00945971|Other|Physical activity|The intervention group will engage in exercise program, including aerobic and anaerobic components,twice a week, for 3 months. Exercise testing, blood sampling and cognitive assessment will be used at the start and in the end of this study.
1849189|NCT00945984|Procedure|Radical nephrectomy|Surgical options to treat localized renal cell carcinoma
1849190|NCT00945997|Drug|misoprostol|mifepristone 200 mg followed by 200 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
1849191|NCT00945997|Drug|misoprostol|mifepristone 200 mg followed by 400 µg misoprostol per vaginam 36- 48 hours later at 4 hourly intervals (with a maximum of 10 administrations in 48 hours) until the foetus was delivered.
1849193|NCT00946023|Drug|Bone marrow transplantation|"Nonmyeloablative conditioning regimen: Patients receive fludarabine IV over 30 minutes on days -6 to -2 and cyclophosphamide IV over 1-2 hours on days -6 and -5. Patients undergo total body irradiation on day -1.
Allogeneic bone marrow transplantation: Patients undergo donor bone marrow infusion on day 0.
Post-transplantation therapy: Patients receive cyclophosphamide IV over 1-2 hours on days 3 and 4. Beginning day 30, rituximab IV is administered once per week for 8 weeks.
Graft-vs-host disease prophylaxis: Beginning on day 5, patients receive oral mycophenolate mofetil until day 35 and tacrolimus (IV then changing to orally) until day 180."
1849194|NCT00946036|Drug|Sertraline Hydrochloride|
1849195|NCT00946049|Device|Vicryl Plus|
1849196|NCT00946049|Device|Vicryl|
1849197|NCT00946062|Other|orientation and mobility training|orientation and mobility training
1849198|NCT00946088|Drug|Progesterone|Progesterone 400 mg per vagina qhs.
1849199|NCT00946088|Drug|Polyethylene glycol&hydrogenated vegetable oil.|Placebo Comparator: Polyethylene glycol 400 distearate & hydrogenated vegetable oil per vagina qhs.
1849200|NCT00946101|Biological|MEDI3414 [Influenza A(H1N1) live attenuated, intranasal]|0.5 mL: (intranasal sprayer)
1849201|NCT00946101|Biological|Placebo|Placebo was supplied in intranasal sprayers containing 0.5 mL of sucrose-phosphate buffer
1849202|NCT00946114|Drug|sildenafil|tablets, 20mg, TID, 112 weeks at the maximum
1849203|NCT00946114|Drug|sildenafil|tablets, 20mg x 4 (80mg), TID, approximately 70 weeks
1849204|NCT00946127|Procedure|Ventriculoperitoneal Shunt Placement|In the subjects who choose this arm, at the start of study- CSF (Cerebrospinal fluid ) will be shunted to peritoneum by placing a ventriculoperitoneal shunt catheter with or without shunt valves or anti-siphon device.
1849205|NCT00946127|Procedure|Endoscopic Third Ventriculostomy(ETV)|Patients who choose to undergo ETV arm would undergo a ventriculostomy at the start of study.
1849206|NCT00946140|Procedure|DCE-MRI scans|Initially you will be given safety information about MRI scans and a questionnaire to determine your compatibility with the MRI scanner. For each patient, DCE-MRI data sets will be acquired three times - at baseline just prior to the start of the drug therapy, within 24-48 hours of the start of the therapy, and within 6-8 weeks of the start of the therapy.
1849207|NCT00946153|Drug|E7080|In the Dose-Escalation Component of the study, E7080 will be administered as continuous once-daily oral dosing. Dose-escalation will occur based on safety information obtained during Cycle 1. The recommended dose for the Expansion Component of the study will use the MTD in Cycle 1.
1849208|NCT00946166|Drug|simvastatin|40 mg daily in the evening for a maximum of 14 days
1849209|NCT00946166|Drug|Placebo|Simvastatin-like placebo administered daily in the evening for a maximum of 14 days
1849210|NCT00946179|Biological|Influenza virus (split virion, inactivated) vaccine|0.5 mL, Intramuscular
1849211|NCT00946192|Drug|Transdermal 17Beta-estradiol, progesterone|100 mcg/day 17Beta-estradiol; transdermal twice weekly application for 12 months (with cyclic micronized progesterone pills (Prometrium): 200 mg taken orally daily Day 1 to Day 12 each month) + Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
1849212|NCT00946192|Drug|Ethinyl Estradiol + Desogestrel|Oral ethinyl estradiol (0.03 mg) + desogestrel (0.15 mg) + Elemental calcium 1200 mg and Vit D 400 IU taken once daily
1849213|NCT00946192|Dietary Supplement|Sham Comparator|Elemental calcium 1200 mg and Vit D 400 IU taken orally daily
1849214|NCT00946205|Procedure|Laparoscopic posterior rectopexy|The rectum is mobilised down to the os coccygeus, then it is elevated cephalic and sutured with a multifilament suture to the presacral fascia just below the sacral promontory. The lateral stalks should be left intact.
1849215|NCT00946205|Procedure|Laparoscopic anterior mesh rectopexy|The peritoneum is incised over the right side of the promontory. The incision is extended in an inverted J-form along the right side of rectum and over the deepest part of the pouch of Douglas. Denonvilliers fascia is incised and the rectovaginal (women)/rectovesical (men) septum is broadly opened. A prosthetic mesh (3 x 17 cm) is sutured with nonabsorbable sutures to the ventral aspect of the rectum in the rectovaginal/rectovesical septum and to the lateral seromuscular borders of rectum and fixed upon the promontory using a stapler. The posterior fornix of vagina (women)/floor of the bladder (men) is elevated and sutured to the anterior aspect of the mesh. The incised peritoneum is then closed over the mesh.
1849216|NCT00938366|Drug|Cladribine|Subjects will receive two single doses of 10 mg cladribine orally in either first or second intervention period followed by a washout period of 10-25 days.
1849217|NCT00938366|Drug|Pantoprazole|Subjects will receive a pantoprazole 40 mg orally for 2 consecutive days either in first or second intervention period.
1849218|NCT00938379|Drug|20% deet insect repellent|skin-applied repellent lotion
1849219|NCT00938379|Drug|placebo control|Identical base formulation of lotion but without any deet active
1849220|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, aged lot|Single dose, intramuscular injection
1849221|NCT00938392|Biological|GSK investigational FluNG vaccine GSK2186877A, fresh lot|Single dose, intramuscular injection
1849222|NCT00938405|Drug|Colesevelam HCl|3.75 gms/day of colesevelam HCl in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
1849223|NCT00938405|Drug|Placebo|Placebo: 3.75 gms/day in the form of three 625 mg tablets with lunch and dinner or six 625mg tablets once daily with dinner.
1849224|NCT00938418|Radiation|Dose escalated, accelerated, hypofractionated radiotherapy|Intensity modulated radiotherapy with concurrent chemotherapy
1849225|NCT00938431|Drug|Lacosamide|Lacosamide oral solution (syrup) 10 mg/mL or 15 mg/mL
1849226|NCT00938457|Radiation|stereotactic radiation therapy|Patients undergo stereotactic body radiation therapy
1849227|NCT00938457|Procedure|implanted fiducial-based imaging|radiation therapy treatment planning
1849228|NCT00938457|Procedure|cone-beam computed tomography|radiation therapy treatment planning
1849229|NCT00938470|Drug|capecitabine|Given PO
1849230|NCT00938470|Drug|docetaxel|Given IV
1849231|NCT00938470|Drug|fluorouracil|Given IV
1849232|NCT00938470|Drug|oxaliplatin|Given IV
1849233|NCT00938470|Radiation|radiation therapy|Undergo radiation therapy
1849234|NCT00938470|Procedure|therapeutic conventional surgery|Undergo surgery
1849235|NCT00938483|Other|Nutramigen Lipil (Infant formula)|
1849236|NCT00938509|Drug|ibuprofen suppositories|5-10 mg/kg/day-suppositories
1849237|NCT00938522|Drug|Cilostazol|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the cilostazol group received 200 mg of cilostazol (loading dose) 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
1849238|NCT00938522|Drug|Placebo|Eligible patients were randomly assigned to cilostazol group or placebo group via the internet by the online randomization system. At least 12 h before the procedure, all patients received aspirin (300 mg loading if not taking before) and clopidogrel (300 mg loading dose). Patients in the placebo group received 200 mg of placebo 12 hours and 2 hours before the procedure, followed by 100 mg twice daily for 3 months.
1849239|NCT00938535|Behavioral|Obesity Prevention|This arm includes an action plan, tailored print materials, telephone support calls, interactive self-monitoring, and a 12-month YMCA membership for the participant.
1849240|NCT00938548|Drug|Pregabalin|Pregabalin 75 mg orally
1849241|NCT00938548|Drug|Vitamin Complex (placebo)|Vitamin Complex orally
1849242|NCT00938561|Drug|Inulin|
1849243|NCT00938574|Drug|Atu027|
1849244|NCT00938587|Drug|PF-04171327 10 mg|PF-04171327 10 mg tablet every day for 14 days
1849245|NCT00938587|Other|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
1849246|NCT00938587|Drug|PF-04171327 25 mg|PF-04171327 25 mg tablet every day for 14 days
1849247|NCT00938587|Other|Prednisone Placebo|Placebo for Prednisone 5 mg tablet every day for 14 days
1849248|NCT00938587|Drug|Prednisone 5 mg|Prednisone 5 mg tablet every day for 14 days
1849249|NCT00938587|Other|Placebo for PF-04171327|Placebo for PF-04171327 every day for 14 days
1849250|NCT00938587|Other|Placebo|Placebo tablet every day for 14 days
1849251|NCT00938587|Other|Placebo for PF-04171327|Placebo tablet every day for 14 days
1849252|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU once
1849253|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 oral liquid 70,000 IU as loading dose, then 35,000 IU weekly thereafter for 10 weeks (non-pregnant) or until delivery (pregnant)
1849254|NCT00938600|Dietary Supplement|Vitamin D3|Vitamin D3 14,000 IU per week by mouth, starting at 27-30 weeks gestation and continued until delivery.
1849255|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
1849256|NCT00938613|Drug|Placebo|nasal spray, one spray per nostril at time 0
1849257|NCT00938613|Drug|Budesonide|nasal spray, one spray per nostril at time 0
1849258|NCT00938626|Biological|anti-CD3 x anti-CD20 bispecific antibody-armed activated T cells|After completion of induction or salvage chemotherapy, patients receive immunotherapy comprising anti-CD3 x anti-CD20-armed ATC IV weekly for 2 weeks.
1849259|NCT00938626|Procedure|autologous hematopoietic stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation. Patients then undergo leukapheresis for G-CSF-mobilized autologous T-cells.
1849260|NCT00938626|Procedure|peripheral blood stem cell transplantation|At least 1-3 weeks after the second infusion, patients receive high-dose chemotherapy and then undergo autologous peripheral blood stem cell transplantation.
1849261|NCT00938639|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
1849262|NCT00938639|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume)
1849263|NCT00938652|Drug|gemcitabine/carboplatin|"Gemcitabine 1000 mg/m2 intravenous infusion (30 ± 10 minutes)
Carboplatin AUC 2 intravenous infusion (30 ± 10 minutes or 60 ± 10 minutes)"
1849264|NCT00938652|Drug|Iniparib|"Body weight adjusted dose
intravenous infusion (60 ± 10 minutes)"
1849265|NCT00938665|Device|COGNISION™ System|30 minute ERP test and 3 minute resting EEG data collected from cognitively healthy and AD to validate ERP and qEEG as useful cognitive biomarkers for AD.
1849266|NCT00938678|Drug|Pegfilgrastim Hospira|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
1849267|NCT00938678|Drug|Neulasta (Amgen)|Subjects in both treatment groups will have safety assessments and will be followed for all adverse and serious adverse events.
1849268|NCT00938691|Procedure|Intradermal Suture|
1849269|NCT00938691|Procedure|Intradermal Suture|
1849270|NCT00938704|Drug|carboxymethylcellulose 0.5% +glycerin 0.9%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
1849271|NCT00938704|Drug|sodium hyaluronate 0.18%|To open, twist and pull tab to remove. Instill study medication as needed, but at least one drop 3 times a day as instructed in the protocol and then discard the container.
1849272|NCT00938717|Drug|Linaclotide or Matching Placebo|Linaclotide or Matching Placebo, administered orally, once daily, for the duration of the trial
1849273|NCT00938730|Drug|YM150|oral
1849274|NCT00938730|Drug|Warfarin|oral
1849275|NCT00938743|Drug|Atomoxetine|40-80 mg atomoxetine once daily, including titration 10 weeks
1849276|NCT00938756|Other|diagnostic laboratory biomarker analysis|
1849277|NCT00938756|Other|immunoenzyme technique|
1849278|NCT00938756|Procedure|magnetic resonance imaging|
1849279|NCT00938769|Other|Self-Efficacy Training for Caregivers|"The Enhanced Caregiver Training intervention will be delivered to informal caregivers of cancer patients before hospital discharge who are randomly selected to receive this intervention. Subjects in the treatment group will receive an individualized experiential caregiver training in strategies for managing patient's symptoms and in the use of pleasant imagery and muscle relaxation to manage stress.
2-hour in-person instruction of home care issues for caregivers of patients with cancer."
1849280|NCT00938769|Other|Comparison Conditions for Caregivers|"Subjects randomly selected to participate in the attention control training will receive an informational session about cancer and resources for caregiving.
2-hour counseling session for cancer caregivers to locate community support resources"
1849281|NCT00938782|Device|Sedline|
1849282|NCT00938795|Other|Uncertainty Management Intervention|Six 30-minute telephone calls with a nurse to discuss emotional and physical aspects of liver disease and awaiting liver transplant
1850403|NCT00946699|Biological|MEDI-551|10.0 mg/kg
1849283|NCT00938795|Other|Comparison Conditions for Liver Transplant|Six 30-minute telephone calls that provide structured education about liver disease.
1849284|NCT00938808|Dietary Supplement|day formula diet|The Cambridge Programme. Formula diet
1849285|NCT00938821|Procedure|Caudal block|Chart review of patients that received very low dose morphine administered caudally (M) and plain caudal block with Ropivacaine or Marcaine (B)from October 2008 to October 2009.
1849286|NCT00938834|Other|CFQ Qigong|CFQ Qigong training session training will consist of three half days of training in the technique. Following the training sessions, participants will return to the study site on a weekly basis for the first 8 weeks.
1849287|NCT00938847|Device|PCI|Stent implantation after acute myocardial infarction
1849288|NCT00938860|Drug|cyclosporin (Neoral)|Neoral capsules bid, Doses were to be adjusted as necessary to achieve and maintain recommended C0 (monitoring of trough levels) or C2 concentration 2 hours post dosing) target ranges
1849289|NCT00938860|Drug|tacrolimus (Prograf)|Tacrolimus capsules bid, doses were adjusted as necessary to achieve and maintain recommended C0 target ranges.
1849290|NCT00938873|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|Mindfulness based cognitive therapy (MBCT) is a group psycho-educational treatment designed to reduce the risk of recurrent depression by integrating mindfulness based meditation practices with cognitive therapy techniques. MBCT comprises eight weekly two-hour group sessions with an additional one hour daily 6 days a week for meditative homework practice.
1849291|NCT00938886|Drug|Naltrexone|Daily 50 mg naltrexone
1849292|NCT00938886|Drug|Placebo|Matched naltrexone placebo
1849293|NCT00938899|Drug|TMC435350; Placebo|
1849296|NCT00938925|Procedure|Nail lacquer plus aggressive debridement|Nail lacquer plus aggressive debridement: Will be applied abrasion ungual aggressive, this abrasion will be applied in the beginning of the study, week 0 (baseline), the week 12 and the week 24 and he will follow standard treatment with nail lacquer (Odenil 5%) with 2 weekly applications during 36 weeks.
1849297|NCT00938925|Procedure|Nail lacquer alone|Nail lacquer alone: Will be applied exclusively standard treatment with nail lacquer during 36 weeks, according to the usual care
1849298|NCT00938938|Other|Press Guide|The press guide is a 1-page summary of the study findings, written by the investigators.
1849299|NCT00938951|Other|Systane® Ultra|Polyethylene Glycol 400 0.4% / Propylene Glycol 0.3%
1849300|NCT00938964|Drug|Lidocaine|Lidocaine versus placebo infusion for 48 hours
1849301|NCT00938964|Drug|Placebo|Lidocaine versus placebo infusion for 48 hours
1849302|NCT00938977|Device|CPAP|Before and after effect of treatment with CPAP
1849303|NCT00938977|Device|Bilevel Support Ventilation (Non-Invasive Ventilation)|before/after effect of Bilevel support ventilation
1849304|NCT00938990|Drug|Etomidate|
1849305|NCT00938990|Drug|Midazolam|
1849306|NCT00939003|Biological|Adalimumab|40 mg every other week up to Week 12
1849307|NCT00939003|Biological|Placebo|Placebo every other week up to Week 12
1849308|NCT00939003|Biological|Open-label Adalimumab|40 mg every other week, Week 12 through Week 156
1849309|NCT00939016|Other|Lunch meal with 24 hour dietary recall|Each participant will come into the laboratory for a buffet-style lunch meal, where they are instructed to sample each of the foods served. On the next day, a 24 hour dietary recall is performed to test the participants ability to accurately report amounts and types of food consumed. Measures of dietary restraint and social desirability are taken prior to the laboratory meal via phone interview.
1849310|NCT00939029|Drug|nicotine replacement therapy (nicotine patches)|2- 21 mg patches per day for 8 weeks
1849311|NCT00939029|Drug|placebo NRT|2 placebo patches (containing no active ingredient)per day for 8 weeks
1849312|NCT00939042|Procedure|Percutaneous Coronary Intervention|common Percutaneous Coronary Intervention
1849313|NCT00939042|Procedure|BMNC therapy|Injection of BMNC after common PCI
1849314|NCT00939055|Device|StomaphyX|Transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
1849315|NCT00939055|Procedure|Sham procedure|False procedure
1849316|NCT00939068|Drug|Telbivudine|Subjects start dosing Telbivudine orally at 20-32 gestational weeks, with 600 mg daily, continued to one month after delivery.
1849317|NCT00939068|Biological|engineered HB vaccine|All the newborns in control group are given HBIG 200IU by injection immediately after born and at day 15. They are also injected with genetically engineered HB vaccine 20 ug respectively at age of 0, 1 and 6 months.
1849318|NCT00939081|Behavioral|Adaptive step recommendation|Participants in this group receive 3 education sessions: at baseline, at 3 months and at 6 months. The adaptive recommendation will update the participant's recommended step count attainment from 7,000 to 8,000, then 10,000 steps/day. The SMS-based self-monitoring system will collect three data points each day from participants in this group: 1) total number of steps/d recorded by the pedometer during the previous day (steps/d); 2) performance on 2nd weight loss goal; and 3) performance on 3rd weight loss goal.
1849319|NCT00939081|Behavioral|10,000 step/day recommendation|Participants will receive a standard 10,000 step/day recommendation and 3 education sessions: at baseline, at 3 months and at 6 months.
1849320|NCT00939094|Drug|AZD2066|Capsule, once daily
1849321|NCT00939094|Drug|Placebo|Capsule, once daily
1849322|NCT00939107|Procedure|spinal manipulation|Spinal manipulation to the lumbopelvic spine in combination with information about examination findings and advice about back care
1849323|NCT00939107|Procedure|McKenzie exercises|McKenzie exercises according to the principles of Mechanical Diagnosis and Therapy
1849324|NCT00939120|Drug|Tolterodine ER 4mg|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4 mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
1849325|NCT00939120|Drug|Placebo|1:1 randomization to either Dutasteride 0.5mg orally once daily plus Tolterodine ER 4mg orally once daily or Dutasteride 0.5mg orally once daily plus placebo once daily
1849327|NCT00939133|Drug|tretinoin microsphere 0.04% gel|Applied daily to entire face for six months
1849329|NCT00939146|Other|Outlook Attention Control|Subjects in the relaxation meditation group will meet with a facilitator three times, for a period of forty-five minutes each; they will listen to a non-guided relaxation CD.
1849330|NCT00939146|Other|Outlook Intervention|The Outlook intervention is designed to assist patients self-manage role changes by guiding them through life review, current issues of forgiveness and conflict resolution, and future orientation, with planning heritage and legacy.
1849331|NCT00939159|Drug|LBH589|20 mg capsules by mouth 3 times a week for 3 weeks in a 28-day cycle.
1849332|NCT00939172|Drug|TTP607|3.3 mg/m^2 given by central venous catheter over 1-4 hours, each day for 5 days in a row, for a 15 day cycle.
1849333|NCT00939185|Drug|Azithromycin|Zithromax was dispensed according to the Summary of Product Characteristics (SPC) as either a tablet or suspension. Zithromax was administered as a total dose of 30 mg/kg which was given as single daily doses of 10 mg/kg for 3 days, or as a 5 day dose starting with 10 mg/kg on Day 1, then 5 mg/kg on Days 2-5.
1849334|NCT00939198|Biological|Na-ASP-2 Skin Test Reagent|Na-ASP-2 Hookworm Skin Test Reagent, 1-1000 mcg/mL solution
1849335|NCT00939211|Drug|AZD9164|Solution for inhalation through nebulization, single dose
1849336|NCT00939211|Drug|Tiotropium|Dry powder for inhalation, single dose
1849337|NCT00939211|Drug|Placebo|Placebo
1849338|NCT00939224|Device|Model 7600 Regional Oximeter System|Non-invasive regional oxygen saturation measurements
1849339|NCT00939237|Drug|Ateronon|7 mg lycopene dietary supplement supplied as one Ateronon capsule taken daily
1849340|NCT00939237|Drug|Placebo|
1849341|NCT00939250|Behavioral|Diabetes and depression intervention|Disease self management for diabetes and depression
1849342|NCT00939250|Behavioral|Diabetes intervention|Disease self management for diabetes
1849343|NCT00939263|Other|assessment of disease activity using the EEsAI|disease activity index
1849344|NCT00939276|Drug|Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
1849345|NCT00939276|Drug|Nepafenac ophthalmic suspension vehicle|One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
1849346|NCT00939289|Device|Continuous Glucose Monitoring|Real-time continuous glucose monitoring with 2 commercially available Systems (DexCom SEVEN and Abbott Navigator)
1849347|NCT00939328|Biological|rituximab|
1849348|NCT00939328|Drug|bendamustine hydrochloride|
1849349|NCT00939341|Drug|Symbicort (Budesonide/Formoterol)|Turbuhaler 160/4.5 µg delivered dose, twice daily (one inhalation in the morning and one inhalation in the evening) and as need (prn) in response to symptoms
1849350|NCT00939367|Drug|Zolpidem Tartrate Tablets 10 mg|
1849351|NCT00939367|Drug|'Sanofi-Synthelabo's Ambien® 10 mg Tablets|
1849352|NCT00939380|Behavioral|Behavioral intervention sessions|Participants undergo five 60-minute behavioral intervention sessions once or twice weekly for 3 weeks to learn how to engage in effective social and cognitive processing to deal with fears and worries about the transplant and transplant-related concerns.
1849353|NCT00939380|Other|CD-ROM|Participants receive a laptop computer and a CD-ROM after the first session of behavioral intervention.
1849354|NCT00939380|Other|DVD and pamphlet|"Participants receive a Discovery to Recovery DVD and pamphlet developed by the National Marrow Donor Program (NMDP) describing psychological issues associated with hematopoietic stem cell transplantation (HSCT), the booklet Top Tips for Parent Caregivers During the BMT Process published by National Marrow Donor Program-Link describing caregiver issues during HSCT and advice on how to handle them, 2 walkie-talkies, a laptop to view the DVD."
1849355|NCT00939380|Other|Respite care|Participants receive 5 hours of respite care from a child-life specialist once or twice weekly for 3 weeks.
1849358|NCT00939406|Device|Hyalospine|Intervention group consists of subjects randomized to the treatment arm who will receive lumbar decompression surgery (laminotomy or laminectomy) and HyaloSpine.
1849359|NCT00939419|Other|Health workers TB care group|Patients received daily tuberculosis care in public health facilities by trained health worker during the first 8 weeks followed by self-treatment for the remaining 6 months. Patients were expected to visit public health facility every month for follow up. Supervisory support was given to TB focal persons by the respective district TB coordinators on a monthly basis. Anti-TB drugs were delivered to health institutions on a quarterly basis by district TB coordinators during supervision
1849360|NCT00939419|Other|Community health workers TB care group|Patients had daily TB care including observation of treatment by the CHWs in their villages for the second month. Thereafter, treatment was self-administered with a monthly follow up visit to a CHW home for the remaining 6 months. Technical support and anti-TB drugs were given to CHWs by the respective public health facility TB health worker every fortnight.
1849361|NCT00939419|Other|Self-administered treatment group|Patients took their medication at home for seven months after one month of daily care in public health facilities by TB health workers. They were taught by the TB health worker to collect their anti-TB drugs fortnightly and report missed daily doses. Follow up assessment and continued support was made by TB health worker on a monthly basis in their nearby health facility.
1849362|NCT00939445|Procedure|Online HDF|Online HDF
1849363|NCT00939445|Procedure|Short Daily Hemodialysis|Short Daily Hemodialysis
1849365|NCT00939471|Device|Relieva™ Balloon Sinuplasty™ System|Balloon dilation will be performed using endoscopic equipment with video documentation capability.
1849366|NCT00939484|Other|Pharmacological Study|Correlative studies
1849367|NCT00939484|Drug|Vismodegib|Given PO
1849369|NCT00939510|Biological|sargramostim|All patients will receive GM-CSF at a dose of 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week. No dose escalation or de-escalations will be made to GM-CSF.
1849421|NCT00939887|Drug|PF-04455242|Single dose of up to 30 mg PF-04455242, delivered in capsule.
1850404|NCT00946699|Other|Placebo|Placebo
1849370|NCT00939510|Drug|lenalidomide|Lenalidomide will be administered at 25 mg/day orally on days 1-21 of a 28-day cycle. Initially 6 patients will be entered at the 25 mg/day level. If 0 or 1 patients have a dose limiting toxicity, then the 25 mg lenalidomide + GM-CSF 250 mcg subcutaneously on Mondays, Wednesdays and Fridays every week will be accepted as the phase II dose.
1849371|NCT00939510|Other|laboratory biomarker analysis|Prior to the initiation of each cycle of therapy for the first 3 cycles, and at discontinuation from study blood will be collected for assessments of a prostate cancer specific immune response.
1849372|NCT00939523|Drug|Lapatinib|All participants will be asked to take Lapatinib daily for six months during the research study.
1849373|NCT00939536|Drug|Zolpidem Tartrate Tablets 10 mg|
1849374|NCT00939549|Drug|Cyclophosphamide/Glatiramer acetate|Cyclophosphamide 50 mg/kg IV each day for four consecutive days. Glatiramer acetate 20 mg SC daily for 1 year.
1849375|NCT00939562|Drug|doxycycline monohydrate tablet|Tablet, 100 mg, Single dose
1849376|NCT00939562|Drug|doxycycline carragenate tablet|Tablet, 100 mg, Single dose
1849377|NCT00939588|Drug|Aliskiren/ Valsartan|
1849378|NCT00939588|Drug|Telmisartan/ Ramipril|
1849379|NCT00939601|Behavioral|Motivational Enhancement Therapy|
1849380|NCT00939601|Behavioral|Educational Counseling|
1849382|NCT00939627|Biological|cetuximab|Given IV
1849383|NCT00939627|Other|placebo|Given orally
1849384|NCT00939627|Drug|sorafenib tosylate|Given orally
1849385|NCT00939627|Other|laboratory biomarker analysis|Correlative studies
1849386|NCT00939627|Procedure|quality-of-life assessment|Ancillary studies
1849388|NCT00939653|Drug|clofarabine|40 mg/m2/day IV over 2 hours (given at hours 0 to 2) on days 1 through 5.
1849389|NCT00939653|Drug|etoposide|100 mg/m2/day IV over 2 hours (given at hours 2 to 4) on days 1 through 5.
1849390|NCT00939653|Drug|cyclophosphamide|440 mg/m2/day IV as a 30-60 minute infusion (given at hours 4 to 5) on days 1 through 5.
1849391|NCT00939653|Drug|filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is > 1000 x 2 days.
1849392|NCT00939653|Drug|cytarabine|Given intrathecally on day 1 at the dose defined by age below. 30 mg for patients age 1-1.99 50 mg for patients age 2-2.99 70 mg for patients >3 years of age
1849393|NCT00939666|Procedure|Wait&see or TEM with intensive follow-up|Wait&see or TEM with intensive follow-up
1849394|NCT00939679|Procedure|Roux-en-Y gastric bypass surgery|Briefly, RYGB is characterized first by creation of a small stomach pouch. The small intestine is then divided approximately 75 cm distal to the ligament of Treitz, creating a proximal intestinal limb that transports the secretions from the stomach remnant, liver, and pancreas, and a 'Roux' limb, that is attached to the new stomach pouch to drain consumed food. The distal end of the proximal limb is then reattached approximately 100 cm distal to the new stomach drainage site, creating a common channel where digestive enzymes mix with ingested food.
1849395|NCT00939679|Dietary Supplement|low calorie diet (1,000 kcal/day)|"Patients will consume a daily diet composed of:
4 powder diet portions (Cambridge Diets, UK)
plain yogurt (100-125g)
skim milk (1L)
a limited variety of vegetables
The diet will be consumed by both groups for a 10 week period."
1849396|NCT00939692|Drug|Topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
1849397|NCT00939705|Drug|topiramate|Topiramate (brand name Topamax) is an anticonvulsant (antiepilepsy) drug. IUPAC name 2,3:4,5-Bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate
1849398|NCT00939718|Dietary Supplement|Vitamin B12|Vitamin B12 injections containing methylcobalamin 1000 mcg given once every six months along with the routine antidepressant treatment.
1849399|NCT00939731|Drug|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Powder-in-Capsule and 2 x 100-mg Powder-in-Capsules
1849400|NCT00939731|Drug|PF-02341066|A 250-mg single dose of PF-02341066 administered as 1 x 50-mg Immediate Release Tablet and 2 x 100-mg Immediate Release Tablets
1849401|NCT00939757|Drug|mirabegron|oral tablet
1849402|NCT00939770|Drug|crizotinib|
1849403|NCT00939770|Other|pharmacogenomic studies|
1849404|NCT00939770|Other|pharmacological study|
1849405|NCT00939783|Drug|Dimebon|Tablet for oral administration
1849406|NCT00939796|Device|Acclarent Tympanostomy Tube Delivery System|A device which provides a means to create a myringotomy with insertion of a proloaded tympanostomy tube (TT) for placement of the TT in patients indicated for such treatment for Otitis Media
1849407|NCT00939809|Biological|Urokinase-Derived Peptide A6|Given SC
1849408|NCT00939809|Other|Laboratory Biomarker Analysis|Correlative studies
1849409|NCT00939822|Drug|Simvastatin|40 mg Simvastatin/day
1849410|NCT00939822|Drug|Placebo|Matching Placebo
1849412|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
1849413|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
1849414|NCT00939848|Drug|Placebo|20mg od (continuous dosing) until evidence of disease progression has been confirmed
1849415|NCT00939848|Drug|cisplatin|cisplatin 25 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
1849416|NCT00939848|Drug|cediranib|cediranib 20mg oral daily (continuous dosing)until evidence of disease progression has been confirmed
1849417|NCT00939848|Drug|gemcitabine|gemcitabine 1000 mg/m2 on days 1 and 8 of a 21-day cycle for 24 weeks in the absence of disease progression
1849418|NCT00939861|Procedure|laparoscopy|colorectal resection
1849419|NCT00939861|Procedure|laparotomy|colorectal resection
1849420|NCT00939874|Drug|Raltegravir|Raltegravir tablet 400mg is taken orally, twice daily with or without food for 48 weeks.
1849422|NCT00939900|Drug|zoledronic acid (aclasta)|Once-yearly administration of 5mg zoledronic acid intravenously (dosage of treatment of osteoporosis) (+ calcium:1,200mg/day, VitD:800IU/day) during study period
1849423|NCT00939913|Drug|intravenous NAC|intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours)
1849424|NCT00939913|Drug|Placebo|Study participants will be randomized to receive an intravenous regimen of NAC (1,200 mg bolus followed by 200 mg/hour for 24 hours) or placebo.
1849426|NCT00939939|Drug|sitagliptin|sitagliptin 100 mg/d for 10 weeks
1849427|NCT00939939|Drug|glimepiride|glimepiride 1 mg/d for 10 weeks
1849428|NCT00939952|Drug|ertapenem|500 mg IV once
1849429|NCT00939965|Drug|isotretinoin|
1849430|NCT00939965|Genetic|DNA analysis|
1849431|NCT00939965|Genetic|polymerase chain reaction|
1849432|NCT00939965|Other|laboratory biomarker analysis|
1849433|NCT00939965|Other|pharmacological study|
1849434|NCT00939978|Drug|rhEPO|recombinant human erythropoietin(rhEPO)
1849435|NCT00939991|Drug|Vorinostst/Bevacizumab/Temozolomide|Bevacizumab will be administered intravenously at the dose 10 mg/kg every other week. Temozolomide will be administered on a continuous daily dosing schedule at 50 mg/m2/day. Vorinostat will be administered daily on days 1-7 and 15-21 of each 28 day cycle. The dose of Vorinostat will be escalated in successive cohorts of patients to determine the MTD of this regimen. Bevacizumab doses may be given by the local oncologists under the direction of the Duke investigators.
1849436|NCT00940004|Biological|autologous dendritic cell vaccination|Autologous monocyte-derived dendritic cells electroporated with mRNA encoding gp100 and tyrosinase and matured with either cytokines or TLR ligands. Dendritic cells are vaccinated intradermal/intravenously 3 times with biweekly intervals every 6 months, if no signs of progression, for a total of 9 vaccinations.
1849437|NCT00940017|Drug|anidulafungin and voriconazole|Subjects will be admitted to the clinical research unit on Day 0. Subjects will receive anidulafungin intravenously in a loading dose of 200 mg on Day 1, followed by maintenance doses of 100 mg Q24h on Day 2 and Day 3. Simultaneously, using a separate intravenous access, subjects will receive voriconazole in a loading dose of 6 mg/kg Q12h on Day 1, followed by a maintenance dose of 4 mg/kg Q12h on Day 2, and a 4 mg/kg morning dose on Day 3.
1849438|NCT00940030|Other|mechanical bowel preparation|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. From 16 p. m. to 20 p. m. assumption of Polyethylene Glycol Macrogol 70 mg per 1 liter of water 4 times (1L each hour). A bowel enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
1849439|NCT00940030|Other|enema|fiberless diet starting 2 days before surgery. Drugs containing iron and coal plant will be stopped. Free breakfast the day before surgery. Lunch: meat broth and white meat. Dinner: meat broth and fasting starting from midnight. A bowel single enema (2L, glycerin 5%) will be administered at 6 a. m. the day of surgery.
1849440|NCT00940056|Procedure|Endoscopic ablation of AF|"The procedure is conducted in general anaesthesia. The right chest is entered with three working ports .
After a complete cycle of ablation creating a box lesion in the left atrium, conduction block is tested. A chest tube is placed through the most caudal port and the port incisions are closed. A Reveal loop recorder is then implanted subcutaneously. The patient is extubated and transferred to postoperative care."
1849441|NCT00940056|Drug|Rate control|Anti-arrhythmic protocol The control group is using a rate-control strategy. All patients keep their anti-arrhythmic/beta-blocker/digoxin medication during the entire follow-up. No attempts are made to rhythm-control the patients, unless subjective symptoms make it necessary.
1849442|NCT00940069|Drug|pemetrexed|"'TS high expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks.
'TS low expression genotype': pemetrexed 500 mg/m2 and cisplatin 75 mg/m2 on day 1 of each 21 day,for not less than 4 cycle, administered intravenously every 3 weeks."
1849443|NCT00940095|Drug|Clazosentan|5 mg/h
1849444|NCT00940095|Drug|Clazosentan|15 mg/h
1849445|NCT00940095|Drug|Placebo|Matching Placebo
1849446|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
1849447|NCT00940108|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free
1849448|NCT00940121|Drug|mirabegron|oral tablet
1849449|NCT00940121|Drug|mirabegron|IV solution
1849450|NCT00940134|Biological|PYY 3-36|0.8 pmol/kg/min x 3 hours
1849451|NCT00940134|Biological|GLP-1|1.0 pmol/kg/min x 3 hours
1849452|NCT00940134|Biological|saline infusion|saline infusion x 3 hours
1849453|NCT00940160|Drug|QAX576|
1849454|NCT00940160|Drug|QAX576|
1849455|NCT00940160|Drug|QAX576|
1849456|NCT00940160|Drug|Placebo|
1849461|NCT00940212|Drug|AZD2423|oral, single administration
1849462|NCT00940212|Drug|Placebo|oral administration and single dose
1849463|NCT00940225|Drug|XL184|All subjects receive 100 mg XL184 (supplied at 19.7-, 50-, and 60-mg strength capsules) daily for 12 weeks. Subjects with a partial or complete response will continue daily XL184 administration until disease progression. Subjects with stable disease will be randomized to Arm 2 or 3.
1849464|NCT00940225|Drug|Placebo|After 12 weeks of open-label daily XL184, subjects with stable disease randomized to Arm 3 will receive capsules of placebo that are size- and color-matched to XL184 administered daily until disease progression. Subjects will be unblinded at disease progression and, if found to be receiving placebo, given the option to receive XL184.
1849465|NCT00940225|Drug|XL184|After 12 weeks of open-label daily XL184, subjects with stable disease randomized to Arm 2 will continue to receive XL184 (blinded) administered daily until disease progression.
1849466|NCT00940225|Drug|XL184|All subjects receive open-label, 100 mg XL184 (supplied at 19.7-, 50-, and 60 mg strength capsules) daily until disease progression.
1849469|NCT00940264|Procedure|transvaginal hybrid cholecystectomy|transvaginal hybrid cholecystectomy: using one trans-umbilical 5mm trocar and 2 (one 12mm trocar, one 5-mm trocar)inserted through the posterior colpotomy. Removal of the gallbladder through the transvaginal access.
1849470|NCT00940277|Behavioral|Group Counseling|Group counseling
1849471|NCT00940290|Other|Graded Clinical Recommendation|Graded recommendation in reference to a clinical condition written as it would be in a clinical practice guideline
1849472|NCT00940303|Drug|5-FU|3200mg/m2 continuous iv infusions, day 1 every 2 weeks
1849473|NCT00940303|Drug|bevacizumab [Avastin]|5mg/kg iv infusion, day 1 every 2 weeks
1849474|NCT00940303|Drug|irinotecan|165mg/m2 iv infusion, day 1 every 2 weeks
1849475|NCT00940303|Drug|leucovorin|200mg/m2 iv infusion, day 1 every 2 weeks
1849476|NCT00940303|Drug|oxaliplatin|85mg/m2 iv infusion, day 1 every 2 weeks
1849477|NCT00940316|Biological|panitumumab|Given intravenously 6mg/kg every 2 weeks
1849478|NCT00940316|Drug|erlotinib hydrochloride|Given orally 150mg daily
1849479|NCT00940316|Drug|irinotecan hydrochloride|Given intravenously 120mg/m2 for 6/6 genotype and 60mg/m2 for 6/7 genotype
1849480|NCT00940329|Drug|Roflumilast|Treatment A (500 μg/d roflumilast from day 2 to day 18 and 48 μg/d formoterol from day 12 to day 18)
1849481|NCT00940329|Drug|Roflumilast|Treatment B (48 μg/d formoterol from day 2 to day 18 and 500 μg/d roflumilast from day 9 to day 18)
1849482|NCT00940342|Drug|GM-CSF (Sargramostim)|250 mcg injection under the skin, three times a week for eight weeks.
1849483|NCT00940342|Drug|Rituximab|375 mg/m^2 administered intravenously once weekly for four weeks
1849484|NCT00940355|Behavioral|Intervention pulmonary nurse|The intervention is conducted by a pulmonary nurse, directed at increasing awareness of problems in health status, and increasing motivation to engage in additional treatment, and improving health status.
1849486|NCT00940381|Drug|Sirolimus|Beginning dose 3 mg by mouth on Day 1, and 1 mg on Days 2 - 28 for a 28 day cycle.
1849487|NCT00940381|Drug|Cetuximab|Beginning dose 100 mg/m^2 by vein over two hours on Day 1, and 65 mg/m^2 on Days 8, 15 and 22 for a 28 day cycle.
1849488|NCT00940394|Behavioral|mutual support group|bi-weekly, 12-session, family-led mutual support group
1849489|NCT00940394|Behavioral|psychoeducation group|bi-weekly, 12-session, family psychoeducation group
1849490|NCT00940394|Other|Standard care|Routine mental health care services provided by the outpatient clinic and related agencies for families of people with schizophrenia
1849492|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 24 weeks
1849493|NCT00940420|Drug|Copegus (ribavirin)|800 - 1200 mg po daily for 48 weeks
1849494|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 24 weeks
1849495|NCT00940420|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly for 48 weeks
1849496|NCT00940433|Procedure|open properitoneal hernia repair|suprapubic retro-inguinal approach
1849497|NCT00940433|Procedure|Lechtestien hernia repair|onlay mesh repair
1849498|NCT00940433|Procedure|Laparoscopic transperitoneal approach|intraperitoneal insufflation followed by re-exiting to the hernia site
1849499|NCT00940433|Procedure|Laparoscopic totally extraperitoneal approach|avoiding the peritoneum altogether
1849502|NCT00940459|Device|Senofilcon A contact lens (Acuvue Oasys)|Silicone hydrogel contact lens CE-marked for the intended usage.
1849503|NCT00940459|Device|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens CE-marked for the intended usage.
1849504|NCT00940459|Device|Lotrafilcon B contact lens (Air Optix)|Silicone hydrogel contact lens CE-marked for the intended usage.
1849505|NCT00940459|Device|Balafilcon A contact lens (PureVision)|Silicone hydrogel contact lens CE-marked for the intended usage.
1849506|NCT00940459|Device|Etafilcon A contact lens (Acuvue 2)|Hydrogel contact lens CE-marked for the intended usage.
1849507|NCT00940459|Device|Contact lens care system (EasySept)|Contact lens care system CE-marked for the intended usage.
1849508|NCT00940472|Drug|DMMET-01|90 days: 15 days daily dose 1050.6 mg (before dinner)+75 days dose twice a day 1050.6 mg (before breakfast) 1050.6 mg (before dinner).
1849509|NCT00940472|Drug|Metformin Hydrochloride|90 days: 15 days daily dose 850 mg (before dinner)+ 75 days dose twice a day 850 mg (before breakfast) 850 mg (before dinner)
1849510|NCT00940485|Drug|entecavir|0.5mg po daily for 8 weeks
1849511|NCT00940485|Drug|entecavir|0.5mg po daily for 48 weeks
1849512|NCT00940485|Drug|peginterferon alfa-2a [Pegasys]|180 micrograms sc/week for 48 weeks
1849514|NCT00940511|Behavioral|Coordinated care|
1849515|NCT00940524|Drug|Dasatinib, Mitoxantrone, Cytarabine|"INDUCTION- Dasatinib† (dose levels 1-3) *continuously Cytarabine 3 g/m2 IV over 3 hours Mitoxantrone 80 mg/m2 IV Myeloid growth factor on day 7 until ANC > 1,000/μl x 2 days Allopurinol 300 mg BID-TID x 7 days (starting 6-12 hours prior to chemotherapy) Dexamethasone 0.1% eye drops q6h while on cytarabine (start prior to the first dose of cytarabine and continuing at least 24 hours after the last dose) IT Methotrexate 12 mg days 2 and 4
CONSOLIDATION A-Dasatinib† (dose levels 1-3) *continuously Vincristine 2 mg IV Dexamethasone 10 mg/m2/d days 2 to 29, then taper over 10 days Sulfamethoxazole/Trimethoprim 1 DS BID three times weekly days 2 to 29, then BID daily days 30 to 45 IT Methotrexate 12 mg days 8, 15, 22 and 29"
1849516|NCT00940550|Drug|Prolonged-release melatonin|2 mg tablet, once.
1849517|NCT00940550|Drug|Temazepam|20 mg capsule, once
1849519|NCT00940550|Drug|Placebo to match melatonin, zolpidem and temazepam|Placebo to match melatonin: tablet, once. Placebo to match zolpidem: capsule, once. Placebo to match temazepam: capsule, once.
1849520|NCT00940563|Drug|Imatinib|
1849521|NCT00940576|Dietary Supplement|mare´s milk|oral intake of 250 ml mare's milk first, then placebo drink daily during 8 weeks of each (cross over design)
1849522|NCT00940576|Other|placebo drink|oral intake of 250 ml placebo drink first, then mare's milk daily during 8 weeks of each (cross over design)
1849523|NCT00940589|Drug|Circadin|Prolonged Release melatonin (Circadin) 2mg tablets
1849524|NCT00940589|Drug|Placebo|Matched placebo tablets, with identical features to the Circadin tablets
1849525|NCT00940602|Drug|Deferasirox|Deferasirox will be provided as 125 mg, 250 mg, and 500 mg dispersible tablets packaged in bulk high density polyethylene (HDPE) bottles with induction seals and child resistant closures.
1849526|NCT00940602|Drug|Deferasirox placebo|Placebo will be formulated and packaged to be indistinguishable from the 125 mg, 250 mg, and 500 mg tablets of deferasirox.
1849527|NCT00940615|Other|aerobic exercise|, participants assigned to the exercise treatment group of the proposed study will participate in an aerobic exercise regimen of brisk walking on a treadmill for a 60 minute interval, three times a week
1849528|NCT00940615|Other|stretching/toning|Individuals in the control group will participate in a low intensity stretching and toning session for 60 minutes, three times a week
1849529|NCT00940628|Behavioral|Diet and Exercise|mildly hypocaloric diet and physical exercise
1849530|NCT00940628|Drug|orlistat [Xenical]|120mg po tid
1849531|NCT00940641|Drug|AZD7325|IV Dose
1849532|NCT00940641|Drug|AZD7325|oral dose
1849533|NCT00940654|Other|Antipyretic therapy|External cooling;Internal cooling;Non steroid anti inflammatory drugs; Acetaminophen; Steroid
1849534|NCT00940667|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/50mg q.d.
1849535|NCT00940667|Drug|Amlodipine|amlodipine 5mg q.d.
1849536|NCT00940680|Drug|Amlodipine plus Losartan|amlodipine/losartan 5/100mg q.d.
1849537|NCT00940680|Drug|Losartan|losartan 100mg q.d.
1849538|NCT00940693|Drug|duloxetine|60 mg capsule once per day for 6 weeks
1849539|NCT00940693|Drug|placebo|one capsule of placebo taken one a day for 6 weeks
1849540|NCT00940706|Device|TreadMill|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes
TreadMill training: During each session the subject will first exercise with basic stretching and muscle strengthening and then walk on the treadmill. According to the subject's rate of improvement, a therapist will determine the rate of increase in the velocity and slope. The treating therapist will make a written report after each session."
1849541|NCT00940706|Other|Physical activity in groups|"Each subject will undergo 36 intervention sessions, 3 times a week, 12 weeks. Each session - up to 45 minutes.
Activity Focus Training: this involves performing gross motor activities at exercise stations that involve repetitive, reciprocal and coordinated movements to facilitate strength and endurance conducted by physical therapists and instructing parents or other caregivers to be involved in the program. These activities are performed in a group, having a minimum of 6 children at one time."
1849542|NCT00940706|Behavioral|Monitoring physical activity|Activity monitoring with accelerometers
1849543|NCT00940719|Dietary Supplement|vitamin D3|Oil-based solution, 1 dose of 500 microgram each day, during 3 months.
1849544|NCT00940732|Other|Destigmatisation and Mental Health Literacy|"Written material delivered over 2 weeks via the Internet, including mythbusters, debunking common myths around anxiety and depression, as well information about a range of celebrities who have identified themselves as having depression or anxiety. Also contains mental health literacy information."
1849545|NCT00940732|Other|Help-seeking list|List of sources for mental health help-seeking delivered over 2 weeks.
1849546|NCT00940732|Other|Feedback|Written material delivered over 2 weeks via the Internet, including two short self-report measures (Goldberg Anxiety, Goldberg Depression), which will provide feedback to the participant about levels of depression and anxiety.
1849547|NCT00940745|Device|Stereotactic Aspiration and Thrombolysis|"Device: YL-1 type of intracranial hematoma puncture needle YL-1 type of intracranial hematoma puncture needle(Pat. NO.is ZL：93244252•8) was originated by Beijing WanTeFu Medical Apparatus Co.Ltd in 1997. With integration of needle and bur drill it is designed as hard tunnel.By the technique of skull self-holding, the puncture needle can being fixed in the target of haematoma for several days.This technique is convenient, simple and safe.
To position haematoma's location, drills 3 millimeter holes in the localization point of puncture, then insert the drainage tube to inhale haematoma, gives the filament resolver interrupted for liquefication drainage afterward."
1849548|NCT00940745|Drug|conservative treatment|dehydrating agent, haemostatic In the treatment, under the convention we use the dehydrator for patients, the ultra early patient may use anti-filament medicinal preparation 6- amino-caproic acid 6-12g/d, intravenous drip, the period of revolution does not surpass for 24 hours, then just right for the illness treatment.
1849549|NCT00940758|Drug|PEP02|Dose escalation: 50-100 mg/m2 biweekly
1849550|NCT00940771|Drug|Boosted Atazanavir|Boosted atazanavir, once a day dose adjusted for child's weight for 6 months.
1849551|NCT00940784|Drug|Clopidogrel (Plavix)|Clopidogrel, aspirin plus hydroxyurea 75mg qd (Plavix) + 81 - 100 mg qd (aspirin) + hydroxyurea
1849552|NCT00940784|Drug|Placebo|Placebo, aspirin (81-100 mg qd) plus hydroxyurea
1849553|NCT00940784|Drug|Aspirin|81-100 mg qd
1849556|NCT00940810|Procedure|Plasma Disc Decompression/Nucleoplasty|"Subjects assigned to the PDD Group will be scheduled to receive the plasma disc decompression procedure using the Coblation® method.
Similarly to in Conservative Care group, subjects will be followed-up at 2, 8 weeks, 6 and 12 months (calculated from the date of the PDD procedure). The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
1849635|NCT00948662|Drug|Placebo of SAM-760|SAM-760 matching placebo capsule, single dose, 1 day,
1849636|NCT00948662|Drug|ketoconazole|Ketoconazole oral tablets, 200 mg bid, 14 days
1849557|NCT00940810|Procedure|Conservative Care (physiotherapy)|"Subjects assigned to the Conservative Care Group will be scheduled to receive physical therapy according to standard and customary care locally.
Subjects will be followed-up at 2, 8 weeks, 6 and 12 months . (Calculated from the time of first going through the individual training programme).The follow-up visits will consist of a brief physical examination in the clinic and completion of study questionnaires."
1992771|NCT03299452|Drug|Non Chemotherapy|Drugs screened by accelerated PDX model will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
1849560|NCT00940836|Drug|Resfenol|Each capsule of the active drug contains 400mg of acetaminophen, 4mg of chlorpheniramine and 4mg of phenylephrine. Patients will receive up to five capsules a day.
1849561|NCT00940836|Drug|Placebo|Patients in this group will receive placebo capsules up to five times a day, with the exact same taste and appearance as the active comparator.
1849562|NCT00940836|Drug|Co interventional acetaminophen|All patients received, along with the assigned intervention, 12 acetaminophen 500mg pills, that they were instructed to take only in case of persisting PAIN or FEVER, up to 4 times a day.
1849563|NCT00946257|Drug|Otelixizumab|A humanized, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb) directed against the ε domain of the human lymphocyte antigen CD3.
1849564|NCT00946270|Drug|CC-4047|0.5 mg capsules daily by mouth day 1 through day 28.
1849565|NCT00946270|Drug|Prednisone|30 mg by mouth daily during cycle 1, 15 mg/day during cycle 2, and 15 mg every other day during cycle 3, and then it will be discontinued.
1849566|NCT00946283|Dietary Supplement|Lactobacillus rhamnosus GG|Culturelle DS (Lactobacillus GG) will be administered one capsule (10 billion live lactobacillus GG) daily with water
1849567|NCT00946296|Drug|Potassium Iodide|8 drops of Potassium Iodide in a glass of water taken daily for 7 days prior to thyroidectomy. This is the current standard of care.
1849568|NCT00946309|Drug|High Sulforaphane Extract (Broccoli Sprout Extract)|100 umol sulforaphane, every other day for 5 weeks
1849569|NCT00946309|Drug|Microcrystalline Cellulose NF (placebo)|250 mg every other day for 6 weeks
1849570|NCT00946322|Behavioral|Couple-Based Treatment for Alcohol Use Disorders and PTSD|This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
1849571|NCT00946335|Drug|veliparib|Given PO
1849572|NCT00946335|Drug|temozolomide|Given PO
1849573|NCT00946335|Other|pharmacological study|Correlative studies
1849574|NCT00946335|Other|laboratory biomarker analysis|Correlative studies
1849575|NCT00946348|Drug|Dronabinol|Dronabinol 10 mg or 15 mg
1849576|NCT00946348|Drug|Cannabis|Cannabis cigarette
1849577|NCT00946361|Other|Examinations|Growth hormone stimulation testing, Protein turnover, Dexa scan, Bone age x-ray
1849578|NCT00946374|Drug|Immunochemotherapy|R-CHOP: Rituximab 375 mg/m²,intravenous ( iv ), day 0 ; Cyclophosphamide 750 mg/m²,iv, day1; Vincristine 1,4 mg/m² but at the maximum 2 mg,iv,d1; Doxorubicin 50 mg/m², iv, d1; Prednisone 100 mg, peroral ( po ), day 1 to day 5
1849579|NCT00946374|Drug|High-dose BEAM plus autologous SCT|High-dose BEAM: Carmustine 300mg/m², iv, day -7; Cytarabine 2 x 200 mg/m², iv, day -6 to day -3; Etoposide 2 x 100 mg/m², iv, day -6 to day -3; Melphalan 140 mg/m², iv, day -2 followed by Autologous stem cell transplantation ( > 2,5 x 10e6 CD34 positive autologous stem cells, iv, day 0
1849580|NCT00946374|Other|HLA-identical allogenic SCT|Fludarabine 30 mg/m², iv, day -4 to day -2; Cyclosporin A 2 x 3mg/kg, iv, day -1 to day 0 plus total body irradiation with 2 Gy, day 0 followed by allogenic stem cell transplantation immediately after Radiation.
1849581|NCT00946387|Drug|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
1849582|NCT00946387|Drug|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
1849583|NCT00946400|Other|Scoring 4Ts and Chong scale|Two physicians will independently score both the 4Ts and the Chong scale on all patients enrolled in this study.
1849584|NCT00946400|Other|Blood draw|Patient serum will be collected to perform Serotonin Release Assay testing to verify the presence of HIT.
1849585|NCT00946413|Behavioral|CBT plus parent education|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution. The issues taught and discussed included an introduction to adolescent depression and suicide, their etiology, symptoms, treatment, and prognosis, as well as stress management. A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
1849586|NCT00946413|Behavioral|CBT alone|The 10-session group CBT with two-session parental education in our study was derived from the CWDA, with some modifications made based on cultural considerations. Skills taught and discussed included mood monitoring, improving social skills, increasing pleasant activities, decreasing anxiety, reducing depressogenic cognitions, improving communication, and conflict resolution.A 1-year individual follow-up program was used to maintain the effect of the experimental intervention and to provide necessary individual interventions for students such as CBT, support, and counseling.
1849587|NCT00946426|Other|Clamp|Insulin sensitivity, Hepatic glucose production, Evaluation of inflammation, Socioeconomic status, Ethnicity and family history
1849588|NCT00946439|Device|Wheel assisted running training|'Race-Runner' uses the principle of body weight reduction and wheel assisted running training. This is a three-wheel device specifically designed in the 1990s for athletic purposes. The participant is walking or running with the feet on the ground while using a triangular frame equipped with three large bicycle wheels. Support to the participant's body is provided by a regular cycle saddle, a frontal body support plate, and the steering handlebars. The vertical and horizontal distance of the saddle and frontal support from the steering handlebars are adaptable to the participant's body dimension and comfort. This equipment is commonly used in competition in Scandinavia and Central Europe
1849589|NCT00946465|Drug|Ramipril 10 Capsule (Sandoz)|
1849590|NCT00946465|Drug|Altace (Ramipril) 10 Capsule (Aventis Pharmaceutical)|
1849888|NCT00950404|Drug|Formulation D ODT tablet 50 mg|ODT, 50 mg, single dose, administered without water
1849889|NCT00950417|Drug|Nimotuzumab|
1849591|NCT00946478|Drug|Pimecrolimus|"20 AD patients will be given pimecrolimus 1% to apply twice daily for up to three weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.
Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
1849592|NCT00946478|Other|Vehicle cream|"20 AD patients will be treated with vehicle cream twice daily for up to 3 weeks on each lesional site predetermined at baseline. Lesional target site and non-lesional site will be determined at Visit 1.
Two 2 mm biopsies will be obtained from a target AD lesion and non-lesional sites at Visit 2, and Visit 3 (four biopsies each visit)."
1849593|NCT00946491|Drug|Haloperidol 10 mg Tablets (Cord Laboratories)|
1849594|NCT00946491|Drug|Haldol 10 mg Tablets (McNeil Pharmaceuticals)|
1849595|NCT00946504|Drug|Glipizide 10 mg Tablets (Geneva Pharmaceutical, Inc.)|
1849596|NCT00946504|Drug|Glucotrol 10 mg Tablets (Roerig Pharmaceutical, Inc.)|
1849597|NCT00946517|Other|Questionnaires|Parenting and behavioral questionnaires
1849598|NCT00946530|Device|Bright light|Participants uses bright light
1849599|NCT00946530|Device|Control|Participants uses dim light
1849600|NCT00946543|Radiation|hypofractionated radiation therapy|
1849601|NCT00946543|Radiation|intensity-modulated radiation therapy|
1849604|NCT00948363|Other|Kiwi fruits|Daily intake of 3 kiwi fruits for 8 weeks
1849605|NCT00948363|Other|Apple|Daily intake of 1 apple (equivalent in energy) for 8 weeks
1849606|NCT00948376|Genetic|IFT80 screening|Natural History
1849607|NCT00948389|Drug|Dasatinib|Tablets, Oral, 100 mg, Once or Twice daily (depending on safety cohort), Until progression or toxicity
1849608|NCT00948389|Drug|Lomustine|Tablets, Oral, 110 mg/m², Every 6 weeks, until progression or toxicity
1849609|NCT00948402|Drug|Metformin|metformin 1250 mg three times daily
1849610|NCT00948402|Drug|oral contraceptive|30 µg ethinylestradiol plus 30 mg drospirenone 21 day/month.
1849611|NCT00948415|Behavioral|Evaluation of the Shape Up RI Campaign|The SURI enhanced group will receive the standard Shape Up RI program. In addition, participants will be asked to record and report their daily calorie intake, body weight, minutes of physical activity, and pedometer steps. Participants will receive automated feedback on progress as well as a behavioral lesson delivered online during each week of the program. Participants assigned to the SURI Standard arm will receive the standard Shape Up RI program. The intervention will take place during the 12-week Shape Up RI campaign.
1849612|NCT00948428|Drug|imiquimod|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
1849613|NCT00948428|Drug|Aldara™|5% topical cream dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
1849614|NCT00948428|Drug|Vehicle Cream|Topical cream vehicle matching Generic imiquimod dispensed in individual 0.25 g sachets applied twice a week for 16 weeks
1849615|NCT00948441|Drug|25% ethanol|Study Lock -25% Ethanol- The ethanol lock therapy consists of placing up to 2.3 ml of 25% ethanol into the central venous catheter and allowing it to dwell for 4 to 12 hours per day.
1849616|NCT00948441|Other|heparin lock|Placebo Lock - Heparin - These will be prepared in a sterile fashion in the Pharmacy of Children's Hospital of Pittsburgh in 10 day supplies as 1ml lock syringes utilizing 100 units/ml if the central venous catheter is accessed once daily and 10 units/ml if accessed more than once daily. The lock solution will be instilled and allowed to dwell for 4 to 12 hours.
1849617|NCT00948467|Drug|TAK-733|"The Initial Escalation Stage will enroll approximately 30 patients with advanced nonhematologic malignancies. TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days.
The Expansion Stage will enroll approximately 30 patients with advanced metastatic melanoma. The recommended phase 2 dose determined in the Initial Escalation Stage of TAK-733 will be administered orally in 28-day treatment cycles consisting of intermittent dosing with 21 days of continuous treatment, followed by a rest period of 7 days."
1849618|NCT00948480|Biological|Autologous tumor cells plus dendritic cells|A series of 8 vaccinations are administered over 6 months
1849619|NCT00948480|Drug|GM-CSF|500 mcg
1849620|NCT00948493|Drug|Buccal insulin spray|Oral insulin spray absorbed in buccal mucosa
1849621|NCT00948506|Drug|1% topical cidofovir|1% topical cidofovir
1849622|NCT00948506|Drug|3% topical cidofovir|3% topical cidofovir
1849623|NCT00948506|Drug|Placebo|topical placebo
1849624|NCT00948519|Device|Laser + ICG|ICG arm- will be defined as local application on a pledget soaked with ICG with a concentration of 200µg, upon removal of the pledget a NIR diode laser set at 6W with light emittance introduced intranasally with a 30mm diffuser fiber capable of radiating light circumferentially allowing the light energy to reach all treatable areas. Laser will be activated for 180 seconds. Assuming an approximate radius of the nasal cavity is 3mm, energy density will be around 200J/cm². Treatment will be repeated twice, 5-7 day apart. Cultures will be collected at the end of all treatments
1849625|NCT00948519|Device|Laser only|same only without ICG
1849626|NCT00948532|Biological|biologic, Osteocel Plus|Osteocel® Plus
1849627|NCT00948545|Other|Observational study - there is no intervention|Observational study - there is no intervention
1849628|NCT00948584|Other|Insulin dose titration system using a SMS|We applied 'Insulin dose titration system in diabetic patients using a short messaging service automatically produced by a knowledge matrix' for 12 weeks in the intervention group. In the control group, a conventional insulin titration schedule was used. The insulin used in this study was Lantus (insulin glargine).
1849629|NCT00948610|Drug|Remicade|Remicade/ Infliximab Study Material 10mg/kg Total Volume=250cc in saline I.V. route.
1849630|NCT00948623|Behavioral|physical activity counseling program|
1849631|NCT00948623|Behavioral|sham counseling program|
1849632|NCT00948649|Drug|Placebo|Participants will take placebo pills for 21-days using the same regimen as the varenicline study period.
1849633|NCT00948649|Drug|Varenicline|Day 1 - Day 3 0.5mg once daily Day 4 - Day 7 0.5mg twice daily Day 8 - End of Treatment 1.0mg twice daily
1849634|NCT00948662|Drug|SAM-760|SAM-760 capsule, 0.25, 0.75, 2.25, 5, 10, 15, 20, 25, 35 and 45mg, single dose, 1 day
1850405|NCT00946712|Biological|Bevacizumab|Given IV
1849637|NCT00948675|Drug|Pemetrexed|Induction therapy: 500 milligrams/square meter (mg/m²) given intravenously every 21 days for 4 cycles. Maintenance therapy: 500 mg/m² given intravenously every 21 days until disease progression or treatment discontinuation.
1849638|NCT00948675|Drug|Carboplatin|Induction Therapy (every 21 days for 4 cycles): Area Under the Curve (AUC) 6 [maximum possible dose of 900 milligrams (mg)] intravenously infused over 30 minutes.
1849639|NCT00948675|Drug|Paclitaxel|Induction Therapy (every 21 days for 4 cycles): 200 mg/m² intravenously infused over 3 hours
1849640|NCT00948675|Biological|Bevacizumab|Induction therapy: 15 milligrams/kilogram (mg/kg) given intravenously every 21 days for 4 cycles. Maintenance therapy: 15 mg/kg given intravenously every 21 days until disease progression or treatment discontinuation.
1849641|NCT00948688|Radiation|Radiation therapy|Once per day, 5 days a week for 6 weeks
1849642|NCT00948688|Drug|5-FU|Intravenously over 24 hours, 7 days per week during each week of radiation therapy
1849643|NCT00948688|Drug|Vorinostat|Taken orally. Dose will depend upon time of enrollment and how well previous participants tolerated the drug
1849644|NCT00948701|Behavioral|Moving Forward Together 2|RTR volunteers from the ACS will be trained to offer a 12-week telephone-based PA program as a supplement to standard 12-week RTR services.
1849645|NCT00948714|Behavioral|Peer Coach Phone Calls|Subjects will receive 3 phone calls from a trained peer coach over 6 months.
1849646|NCT00948714|Behavioral|Health Educator Visits|Subjects will meet 2 times with a trained health educator in the practice
1849647|NCT00948714|Other|written materials|Subjects will receive written material and brochures and a cookbook from the American Heart Association addressing healthy lifestyle
1849648|NCT00948727|Behavioral|Dose adaptation according to CN activity monitoring|The protocol of the CALCICLO trial consisted in a CsA dose adaptation during the first 100 days following transplantation. This dose adaptation was performed according to both residual CsA blood and CN activity levels only if the safety of vital functions - especially renal, liver, and neurological - was preserved as assessed by clinical evaluations and laboratory analyses such as creatinine clearance higher than 40 ml/min, serum bilirubin lower than 40 µM and absence of neurological signs. According to the protocol, CsA blood levels and CN activity were measured concomitantly at least once a week from day 0 to day 15, twice a week from day 16 to day 35 and then once a week until day 100.
1849649|NCT00948727|Drug|Cyclosporine (CsA)|Cyclosporine (CsA)
1849650|NCT00948740|Drug|vitamin D (ergocalciferol)|The intervention is oral ergocalciferol 50,000 IU per week for 8 weeks
1849651|NCT00948753|Drug|Maraviroc|Maraviroc 300 mg bid (in addition to the standard prophylaxis therapy of tacrolimus and methotrexate) beginning after last dose of chemotherapy conditioning regimen until day 30 after stell-cell infusion.
1849652|NCT00948766|Drug|Rivastigmine 4.6 mg/24 h (5 cm^2)|Rivastigmine was supplied in a 5 cm^2 patch which released 4.6 mg/24 h. Patches were changed daily.
1849653|NCT00948766|Drug|Rivastigmine 9.5 mg/24 h (10 cm^2)|Rivastigmine was supplied in a 10 cm^2 patch which released 9.5 mg/24 h. Patches were changed daily.
1849654|NCT00948766|Drug|Rivastigmine 13.3 mg/24 h (15 cm^2)|Rivastigmine was supplied in a 15 cm^2 patch which released 13.3 mg/24 h. Patches were changed daily.
1849655|NCT00948766|Drug|Placebo|Placebo patches were identical in size and composition to the corresponding rivastigmine patches, except that they did not contain rivastigmine. Patches were changed daily.
1849656|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral, and Organizational intervention to improve the use of oral antibiotics in children under 6 years
1849657|NCT00948779|Other|antibiotic education for children in an emergency care unit|Educational, Behavioral and Organizational intervention to improve the antipyretic therapy in children under 6 years.
1849658|NCT00948792|Procedure|Short platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets administered over 30 minutes
1849659|NCT00948792|Procedure|Long platelet transfusion|15cc/kg of non-centrifuged, non-refrigerated, leukoreduced, AB-negative pheresis platelets given over two hours.
1992772|NCT03299452|Drug|Chemotherapy and target therapy|Drugs screened by accelerated PDX model will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
1992773|NCT03299452|Drug|Chinese herb medicine|Drugs screened by accelerated PDX model will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.
1849662|NCT00948818|Drug|Linaclotide 290 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
1849663|NCT00948818|Drug|Matching placebo|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
1849664|NCT00948831|Biological|Osteocel Plus|biologic
1849665|NCT00948844|Device|Hybrid (3-d accelerometers, and gyroscopes)|A 3 D accelerometer worn on the lower back or leg
1849666|NCT00948857|Dietary Supplement|Dehydroepiandrosterone|25 mg PO TID
1849667|NCT00948857|Dietary Supplement|Placebo|Blinded placebo
1849668|NCT00948870|Drug|Shugan decoction|Decoction ,two times a day,one bag of decoction one time
1849669|NCT00948896|Drug|trimethoprim-sulfamethoxazole (TS; TMP/SMX)|daily dosing, 20mgTMP/100mgSMX tabs, 80mgTMP/400mgSMX tabs
1849670|NCT00948896|Drug|sulfadoxine-pyrimethamine (SP)|monthly dosing given as a single dose, 500mg/25mg tabs
1849671|NCT00948896|Drug|dihydroartemisinin-piperaquine (DP)|monthly dosing given once a day for 3 consecutive days, 40mg/320mg tabs
1849672|NCT00948909|Drug|Placebo|Placebo intervention
1849673|NCT00948909|Drug|ABT-126|Experimental intervention
1849674|NCT00948909|Drug|donepezil|Active comparator intervention
1849930|NCT00950677|Drug|Symlin (pramlintide)|pramlintide 60 mcg subcutaneously
1850406|NCT00946712|Drug|Carboplatin|Given IV
1849681|NCT00948935|Drug|Gemcitabine, Irinotecan, Panitumumab|Gemcitabine 1000 mg/m2 over 100 minutes(Days 1, 8), irinotecan 100 mg/m2 IV over 60 minutes(days 1, 8) and panitumumab 9 mg/kg IV (day 1) every 3 weeks as a cycle. Continue until disease progression or unacceptable toxicities.
1849682|NCT00948948|Device|Silicone Gel-Filled Mammary Prostheses|"Mentor Gel-Filled Mammary Prostheses are comprised of a shell made of medical grade silicone elastomer. Gel-filled implant devices manufactured by Mentor will be used in this study:
Gel-filled device which is available in smooth surface and textured surface (Siltex®)
Becker Expander/Mammary Prosthesis which is available in both the smooth and the textured (Siltex) version
Both of these devices were originally indicated for both augmentation and reconstruction mammaplasty procedures, however for purposes of this study, indications are for reconstruction only."
1849683|NCT00948961|Biological|CDX-1401 in combination with Resiquimod and/or Poly-ICLC|CDX-1401 is administered as an injection into the skin every 2 weeks for 4 doses. It is given in combination with Resiquimod and/or poly-ICLC. Resiquimod is administered as a topical gel applied to the skin or given as an injection under the skin, and poly-ICLC is given as an injection under the skin. Depending on the treatment group assignment, either one or both of the immune stimulants will be given on the day of and the day after CDX-1401 administrations. This treatment may be repeated every 12 weeks.
1849684|NCT00948961|Biological|CDX-1401|
1849685|NCT00948961|Biological|Resiquimod|
1849686|NCT00948961|Biological|poly-ICLC|
1849689|NCT00948987|Drug|Aspirin|325 mg enteric coated single dose p.o.
1849690|NCT00949000|Device|ICD Implantation|Implantation of a commercially available AnalyST or AnalyST Accel ICD
1849691|NCT00949013|Other|immunohistochemistry staining method|
1849692|NCT00949013|Other|laboratory biomarker analysis|
1849693|NCT00949026|Drug|Temsirolimus (Torisel)|Dose de-escalation dependent on microdialysis results
1849694|NCT00949039|Drug|Isolated pelvis perfusion|injection of TNF-α 0.3 mg followed 5 minutes later by melphalan 1,5mg/kg
1849695|NCT00949039|Radiation|radiotherapy|chemotherapy and/or radiotherapy and/or surgery
1849696|NCT00949039|Procedure|Surgery|
1849697|NCT00949052|Genetic|DNA analysis|
1849698|NCT00949052|Genetic|polymorphism analysis|
1849699|NCT00949052|Other|laboratory biomarker analysis|
1849700|NCT00949052|Other|medical chart review|
1849701|NCT00949052|Other|questionnaire administration|
1849702|NCT00949052|Procedure|assessment of therapy complications|
1849703|NCT00949052|Procedure|evaluation of cancer risk factors|
1849704|NCT00949065|Biological|intravenous immunoglobulins|0.36-0.44g/Kg IvIg intravenous, 3x, every 4 weeks
1849705|NCT00949078|Drug|omalizumab|omalizumab subcutaneously every 2-4 weeks depending on participant weight and total IgE
1849706|NCT00949091|Drug|TAK-875|"Randomized, multiple ascending-dose sequence over 14 consecutive days to include the following:
TAK-875 25 mg tablets, orally
TAK-875 50 mg tablets, orally
TAK-875 100 mg tablets, orally
TAK-875 200 mg tablets, orally
TAK-875 400 mg tablets, orally
TAK-875 placebo-matching tablets, orally."
1849707|NCT00949104|Drug|Sucrose|1 ml of 24% sucrose was administered 2 minutes prior to the procedure
1849708|NCT00949104|Drug|Double distilled water|1 ml of double distilled water (Placebo) was administered 2 minutes prior to the procedure
1849709|NCT00949117|Dietary Supplement|Ensure|Given orally
1849710|NCT00949117|Dietary Supplement|PediaSure|Given orally
1849711|NCT00949117|Drug|cyproheptadine hydrochloride|Given orally
1849712|NCT00949130|Drug|NXL103|BID for 7-14 days
1849713|NCT00949130|Drug|Linezolid|BID for 7-14 days
1849714|NCT00949143|Other|rear axle position|Wheelchair axle position located as far towards the rear of the wheelchair as possible.
1849715|NCT00949143|Other|forward axle position|Wheelchair will have the axle at least 5cm farther forward than the most rear axle position.
1849716|NCT00949156|Procedure|Different surgical approach and techniques being used to treat three subtype of CP|According to the presurgical MRI, with the analysis of the morphological characteristic of three subtype of CP, different surgical approach and intrasurgical skills were used to treat tumors with trying to total remove tumor and avoid the hypothalamus injury.
1849717|NCT00949182|Drug|sorafenib tosylate, HACE : Doxorubicin Hydrochloride and Mitomycin C|After Sorafenib Tosylate has been administered the actual HACE procedure is performed using Doxorubicin Hydrochloride or Mitomycin C
1849718|NCT00949182|Other|laboratory biomarker analysis|
1849719|NCT00949195|Other|Measure pulmonary artery pressure change during exercise|Semi-supine echocardiography test
1849720|NCT00949195|Other|Pulmonary pressure response during exercise|Semi-supine echocardiography test
1849721|NCT00949221|Device|monitor Paradigm 754 VEO, MINILINK Real Time, Medtronic, CE|"group 1: continuous glucose monitoring for 3 months, then conventional blood glucose self-monitoring for 9 months;
group 2: intensive strategy using continuous glucose monitoring for 12 months;
group 3: intermediate strategy using continuous glucose monitoring for 3 months, then discontinuous use of the device for 9 months (approximately 40% of the time, alternating with conventional blood glucose self-monitoring)."
1849723|NCT00949247|Biological|bevacizumab|Bevacizumab IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
1849724|NCT00949247|Biological|trastuzumab|Trastuzumab IV over 30-90 minutes on days 1, 8, and 15. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
1849725|NCT00949247|Drug|carboplatin|Carboplatin IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
1849726|NCT00949247|Drug|docetaxel|Docetaxel IV over 30-90 minutes on day 1. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, treatment modifications may apply according to response.
1849727|NCT00949247|Other|laboratory biomarker analysis|Tumor tissue and bone marrow samples may be collected for further laboratory analysis.
1849728|NCT00949273|Procedure|cylindrical abdominoperineal resection|Extended abdominoperineal resection with human acellular dermal matrix reconstruction of the pelvic floor for rectal cancer
1849729|NCT00949299|Drug|buprenorphine|intradermal injection
1849730|NCT00949312|Genetic|RNA marker analysis of lymph node and primary tumors|
1849731|NCT00949312|Genetic|microarray profiling of primary tumors|
1849732|NCT00949312|Genetic|reverse transcriptase-polymerase chain reaction of lymph node specimens|
1849733|NCT00949312|Other|diagnostic laboratory RNA and DNA biomarker analysis of primary tumors|
1849734|NCT00949312|Procedure|regional lymph node dissection|
1849735|NCT00949312|Other|lymph node staining for H&E and pancytokeratin IHC|
1849737|NCT00949338|Procedure|pre-procedural preparation|Patients empty their bladders and consume 6 cups or 3 cups of water 30 minutes before undergoing radiotherapy.
1849738|NCT00949351|Drug|Aliskiren 300mg/d|Aliskiren 300mg/d v.s. placebo for 12wk
1849739|NCT00949364|Drug|Pomalidomide|"Treatment starts with pomalidomide as single agent therapy: 0.5 mg/day. Prednisolone will be started in the absence of PD as randomized either at start of cycle 4 or start of cycle 7 (starting dose: 30 mg/day for 28 days followed by 15 mg/day and 10 mg/day for 28 days), if no response acc. to IWG-MRT (no CR, PR, CI, TI) was achieved.
If PD: treatment is stopped. Otherwise, continuous treatment at least until end of cycle 12 is intended. For patients responding to the combination treatment (pomalidomide/prednisolone) a concom. treatment after cycle 6 or 9 (depending on the randomization result) with prednisolone in doses equal or below 7.5 mg/day are allowed.
If a patient may benefit from treatment with pomalidomide the invest. and the PI will discuss the possibility of further treatment including maintenance treatment with pomalidomide on a case-by-case decision (max. duration: 12 cycles)."
1849740|NCT00949377|Drug|Methylnaltrexone Bromide (MNTX)|The recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg.
1849741|NCT00949377|Drug|Placebo|Normal saline
1849742|NCT00949390|Behavioral|Questionnaire|Survey given at appointment time, then dropped in specified box anonymously.
1849743|NCT00949442|Drug|Insulin Glargine (HOE901) [Lantus]|100 Units/ml solution for injection in a pre-filled pen SoloStar® (3 ml)
1849744|NCT00949442|Drug|Glimepiride|tablets of 1 and 2 mg
1849745|NCT00949442|Drug|human insulin [NPH]|100 IU/ml suspension for injection in a prefilled pen OptiSet® (3 ml)
1849746|NCT00949455|Drug|lapatinib ditosylate|Given orally
1849747|NCT00949455|Other|Placebo|Given orally
1849748|NCT00949481|Other|Pregnancy Test|Free pregnancy test strips will be supplied to family planning clinics
1849749|NCT00949481|Other|Job aid|"A new job-aid will be given to immunization providers that will guide them in assessing a mother's risk for pregnancy (based on LAM criteria), and guide them in making family planning referrals, including when a woman should start to use a family planning method if she wants to prevent pregnancy. The providers in immunization clinics will be asked to make such an assessment each time a woman has her baby vaccinated.
Additionally, in family planning clinics located in the same facilities as the immunization clinics, family planning providers will be trained to use and provided with the pregnancy checklist (see links for more information on the checklist)"
1849750|NCT00949494|Device|Synvisc|intra-articular, 3 weekly injections
1849751|NCT00949520|Other|coronary dual source computed tomography (DSCT)|coronary dual source computed tomography during dipyridamole injection
1849752|NCT00949520|Other|myocardial single photon emission computed topography (SPECT)|myocardial single photon emission computed topography during dipyridamole injection
1849753|NCT00949533|Drug|Oseltamivir|Standard dose (30 - 75 mg orally bid) or double dose (60 - 150 mg orally bid); for 5 days
1849754|NCT00949546|Drug|etanercept|etanercept 50 mg sc twice weekly
1849755|NCT00949559|Drug|EP-100|as a single agent administered intravenously twice weekly x 3 with 1 week off (total 28 days)
1849931|NCT00950690|Drug|Xalatan 0.005% eye drops|ophthalmic solution dosed once daily for 3 months
1992780|NCT03298802|Drug|Hydrochlorothiazide 50mg Tablet|Hydrochlorothiazide 50 mg per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum.
1849756|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 intramuscular dose (0.5 ml) on month 0, 1 and 4 containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
1849757|NCT00949572|Biological|Human Papillomavirus 6,11,16,18 Vaccine Recombinant alum ads|1 sublingual application on month 0, 1 and 4 of 0.5 ml containing approximately: Human Papillomavirus Type 6 L1 protein 20 micrograms Human Papillomavirus Type 11 L1 protein 40 micrograms Human Papillomavirus Type 16 L1 protein 40 micrograms Human Papillomavirus Type 18 L1 protein 20 micrograms
1849758|NCT00949585|Other|Dietary intake of potassium|Comparison of two diets: one contains 100 mmol potassium per day, and the other contains 40 mmol potassium per day
1849759|NCT00949598|Drug|letrozole|Given orally
1849760|NCT00949598|Drug|tamoxifen citrate|Given orally
1849761|NCT00949611|Behavioral|FRAX + Decision Aid|Clinicians will present patient's with their individualized risk of osteoporotic fracture in 10 years, based on the FRAX risk calculator, as well as sharing a decision aid with them, which shows their risk of fracture, risk reduction on medications, as well as the downsides of the medications.
1849762|NCT00949611|Behavioral|FRAX estimated fracture risk|The clinician is provided with the patient's estimated risk of fracture as computed by the FRAX
1849763|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
1849764|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
1849765|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
1849766|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
1849767|NCT00949624|Drug|CP-868,596|Oral tablet 100 mg BID continuous
1849768|NCT00949624|Drug|Docetaxel|Intravenous 100 mg/m2 every three weeks
1849769|NCT00949624|Drug|CP-868,596|Oral tablet 60 mg BID continuous
1849770|NCT00949624|Drug|AG-013736|Oral tablet 5 mg BID continuous
1849771|NCT00949624|Drug|Docetaxel|Intravenous 75 mg/m2 every three weeks
1849772|NCT00949637|Behavioral|Scouting Nutrition and Activity Program|Intervention group will receive a curriculum based on social cognitive theory, wherein children will be taught skills in a supportive environment to improve their self efficacy and proxy efficacy toward eating healthful meals and being physically active with a parent. Troop leaders and parents will provide support, and help girls to create healthy opportunities in the home environment. Simultaneously, girls will be taught skills to improve the family mealtime environment, to bolster asking skills toward healthy behavior, to self-monitor healthy behavior, and to set goals for healthy behavior.
1849773|NCT00949637|Behavioral|Standard-care attentional control|Control troops complete usual troop meeting activities. Control troops receive equal observation time, equal pretest and posttest assessment, and equal study scrutiny.
1849774|NCT00949650|Drug|Pemetrexed|Pemetrexed IV given once every 3 weeks for up to 6 cycles
1849775|NCT00949650|Drug|BIBW 2992|BIBW 2992 once daily until progression
1849776|NCT00949650|Drug|Cisplatin|Cisplatin IV given once every 3 weeks for up to 6 cycles
1849777|NCT00949663|Drug|Placebo|Intravenous infusion of 1% human albumin in normal saline
1849778|NCT00949663|Drug|Glucose-dependent Insulinotropic Polypeptide (GIP)|Intravenous infusion of GIP (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
1849779|NCT00949663|Drug|Xenin-25|Intravenous infusion of xenin-25 (4 pmoles x kg-1 x min-1) in 1% human albumin in normal saline
1849780|NCT00949663|Drug|Glucose-dependent Insulinotropic Polypeptide plus Xenin-25|Intravenous infusion of GIP plus xenin-25 (4 pmoles each x kg-1 x min-1) in 1% human albumin in normal saline
1849781|NCT00949689|Behavioral|Cognitive Behavioral Therapy for insomnia and depression|Experimental arm: Participants will receive sessions of cognitive behavioral treatment for insomnia followed by sessions of cognitive behavior treatment for depression for a total of about 10-12 therapy sessions Control arm: Participants will receive brief sleep hygiene and time management techniques and cognitive behavior treatment for depression for a total of about 10-12 therapy sessions.
1849782|NCT00949702|Drug|vemurafenib|960 mg b.i.d. continuous oral dosing
1849783|NCT00949715|Device|Medtronic or Vitatron Dual-Chamber Pacemaker|A Medtronic or Vitatron market-approved dual-chamber implantable pulse generator (IPG) with atrial tachycardia/atrial fibrillation (AT/AF) trending ability
1849784|NCT00949715|Device|Medtronic SelectSecure 3830 Lead|Medtronic market-approved SelectSecure Model 3830 bipolar pacing lead
1849785|NCT00949728|Procedure|Conjunctival autograft using fibrin glue|Conjunctival autograft using fibrin glue in pterygium surgery
1849786|NCT00949754|Drug|honeybee venom (Apitoxin (Korea) Apitox (USA))|multiple intradermal injections of 100 ug pure honeybee venom
1849787|NCT00949767|Drug|BMS-866949|(Panel 1 - 0.5 mg) - Oral Solution, Oral, once, 14 days
1849788|NCT00949767|Drug|BMS-866949|(Panel 2 - 2.5 mg) - Oral Solution, Oral, once, 14 days
1849789|NCT00949767|Drug|BMS-866949|(Panel 3 - 10 mg) - Oral Solution, Oral, once, 14 days
1849790|NCT00949767|Drug|BMS-866949|(Panel 4 - 25 mg) - Oral Solution, Oral, once, 14 days
1849791|NCT00949767|Drug|BMS-866949|(Panel 5 - 50 mg) - Oral Solution, Oral, once, 14 days
1849792|NCT00949767|Drug|BMS-866949|(Panel 6 - 100 mg) - Oral Solution, Oral, once, 14 days
1849793|NCT00949767|Drug|BMS-866949|(Panel 7 - 150 mg) - Oral Solution, Oral, once, 14 days
1849794|NCT00949767|Drug|Placebo|(Matching volume) - Oral Solution, Oral, once 14 days
1849795|NCT00949780|Drug|Chloral Hydrate|
1849796|NCT00949793|Device|Endomicroscope|Endomicroscopic images are taken at several positions on the tumor.
1849797|NCT00949806|Drug|BNT (intradermal injection)|"Patients with severe RLS will receive a one-time intradermal administration of BNT into the most symptomatic areas of both legs.
Injections will be distributed in a grid distribution pattern covering a total of 20 equidistant sites per symptomatic area. Each symptomatic area will receive a maximum 250 units of BNT (12.5 units per injection). The total BNT injected units should not exceed 1000 units per patient."
1849798|NCT00949819|Other|Active surveillance|Serial, long term data collection and active surveillance
1849799|NCT00949832|Dietary Supplement|Vitamin D + Calcium|Vitamin D 50,000 IU orally once monthly for 6 months; Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months
1850050|NCT00951431|Drug|Placebo|Placebo in the form of study drug
1850051|NCT00951444|Biological|dalotuzumab|Given IV
1849800|NCT00949832|Dietary Supplement|Calcium|Calcium carbonate (as powdered limestone) 500 mg orally twice daily for 6 months; Vitamin B complex (used as placebo) 1 tablet monthly for 6 months
1849801|NCT00949832|Dietary Supplement|Vitamin D2|50,000 IU given orally once
1849802|NCT00949832|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 IU given orally once
1849803|NCT00949845|Drug|Endotoxin|
1849804|NCT00949871|Other|communication analysis|
1849805|NCT00949871|Other|questionnaire administration|
1849806|NCT00949871|Procedure|psychosocial assessment and care|
1849807|NCT00949871|Procedure|support group therapy|
1849808|NCT00949884|Drug|olmesartan medoxomil|Oral tablets, once daily, at either 20mg or 40mg daily.
1849809|NCT00949884|Drug|Placebo|placebo oral tablets once daily for two weeks
1849810|NCT00949884|Drug|losartan potassium|losartan potassium oral tablet at either 50mg or 100 mg daily dose.
1849811|NCT00949897|Device|Biofoam|Device
1849812|NCT00949897|Other|Iliac Crest Allograft with locked plate|
1849813|NCT00949910|Drug|Erlotinib|Erlotinib will be given orally as 150 milligrams (mg) once daily until unacceptable toxicity, disease progression, or withdrawal for any other reason.
1849814|NCT00949923|Dietary Supplement|tea capsule|3 tea capsules daily for 3 weeks
1849815|NCT00949936|Device|CAdisc™-L (Total Disc Replacement)|
1849816|NCT00949949|Drug|everolimus|Given PO
1849817|NCT00949949|Drug|gemcitabine hydrochloride|Given IV
1849818|NCT00949949|Drug|cisplatin|Given IV
1849819|NCT00949962|Drug|antiandrogen therapy|Given systemically
1849820|NCT00949962|Drug|leuprolide acetate|Given subcutaneously
1849821|NCT00949962|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
1849822|NCT00949975|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
1849823|NCT00949975|Drug|AZD9668|2 x 10 mg oral tablets twice daily (bid) for 12 weeks
1849824|NCT00949975|Drug|AZD9668|2 x 2.5 mg oral tablets twice daily (bid) for 12 weeks
1849825|NCT00949975|Drug|AZD9668 Placebo|2 x Matched placebo to oral tablet twice daily (bid) for 12 weeks
1849826|NCT00949988|Drug|Dasatinib and Rituximab|"In Phase I, subjects will be enrolled into a 3+3 dose escalation scheme with two dasatinib cohort doses of 70 mg QD and 100 mg QD to be given continuously during each 28-day cycle. All subjects will also receive rituximab 500 mg/m2 on day 1 of each cycle (375 mg/m2 on day 1 of cycle 1 only). There will be a pre-phase for each dose cohort when subjects will receive single-agent dasatinib from days -7 to -1 to allow for PK and PD assessment. Cohorts will be assessed for dose-limiting toxicities for two cycles before accrual of additional"
1849827|NCT00950001|Procedure|Stereotactic Radiosurgery (SRS)|1 day outpatient radiation procedure using stereotactic frame to target radiotherapy to surgical area found by MRI scan.
1849828|NCT00950001|Procedure|MRI|Standard MRI scans of the brain after surgery, at 5-8 weeks after surgery, every 6-9 weeks for a year, and then every 3-4 months after that.
1849829|NCT00950014|Other|Presentation of drug efficacy and side effect data|Data presented in 1 of 5 numeric formats in each arm: percentage only, fixed frequency only, variable frequency, variable combination and fixed combination format.
1849830|NCT00950027|Drug|povidone iodine|oropharyngeal decontamination every 4 hours
1849831|NCT00950027|Drug|Placebo|oropharyngeal decontamination every 4 hours
1849832|NCT00950040|Behavioral|Brief alcohol intervention|The intervention consists of educational information, aspects of motivational interviewing, feedback concerning alcohol use and measures of glycemic control, alcohol use monitoring, and formulation of a change plan.
1849833|NCT00950040|Behavioral|General health education|The intervention will consist of information about several general health behaviors.
1849834|NCT00950053|Procedure|Achilles decompression & debridement|Surgical intervention
1849835|NCT00950053|Procedure|Achilles decompression and debridement with FHL transfer|surgical intervention
1849836|NCT00950066|Drug|IRBESARTAN (SR47436)|Oral administration of Irbesartan 150mg or 300mg once a day
1849837|NCT00950066|Drug|Amlodipine|Oral administration of Amlodipine 5mg once a day
1849838|NCT00950066|Drug|Irbesartan / Amlodipine|Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day
1849839|NCT00950066|Drug|Placebo|Oral administration of a placebo once a day
1849840|NCT00950079|Drug|Sodium bicarbonate|3 mL/kg for 1 hour immediately before contrast injection , 1mg/kg/hr during procedure and 6 hours after procedure
1849841|NCT00950079|Drug|saline|0.9% normal saline with 1 mL/kg/hr infusion 12 hours before procedure and 12 hours after procedure
1849842|NCT00950092|Device|Numeris-AF Tethered Coagulation System with VisiTrax|Surgical radiofrequency (RF) epicardial ablation using the nContact Numeris-AF Tethered Coagulation System
1849843|NCT00950105|Drug|CPSI-2364 or placebo|Single, oral dose of CPSI-2364 or placebo
1849844|NCT00950131|Other|Presentation of information about drug approval and level of warning|Presentation of information about date of drug approval with no new drug warning, a non-directive drug box warning or a directive drug box warning
1849845|NCT00950144|Other|medical chart review|
1849846|NCT00950144|Other|questionnaire administration|
1849847|NCT00950144|Other|study of socioeconomic and demographic variables|
1849848|NCT00950144|Procedure|quality-of-life assessment|
1849849|NCT00950157|Other|Presentation of information on approval based on a surrogate outcome and levels of caution|"Presentation of information that one drug is approved on a surrogate outcome only while another drug has clinical outcomes. Participants are randomized to 1 of 3 caution (e.g. open question) statements: no open question statement, non-directive open question statement or directive open question statement."
1992781|NCT03298802|Drug|Placebo oral capsule|Placebo per os once daily as soon as the subjects can tolerate sips of water after delivery and for a total of fourteen days postpartum
1849851|NCT00950183|Device|Iceman® Cold Therapy unit (djOrtho)|postoperative cold therapy
1849852|NCT00950183|Other|Ice|postoperative cold therapy
1849853|NCT00950196|Drug|amantadine sulphate|amantadine 5/mg/kg for 2 month- tapered up during 2 weeks at 1 month possibility to increase dosage to 8 mg/kg or reduce it if there are side effects
1992782|NCT03298607|Dietary Supplement|Placebo|2 months treatment
1849854|NCT00950209|Dietary Supplement|saline infusion|"In the first step of the protocol, all the patients will have a kinetic study of the TRL-apoB48 in conditions of a saline infusion to measure the basal production and clearance rates of the TRL-apoB48"
1849855|NCT00950209|Other|euglycaemic hyperinsulinic clamp|an euglycaemic hyperinsulinic clamp to maintain plasma glucose around 1g/l
1849856|NCT00950209|Dietary Supplement|infusion of Endolipide and heparin|an infusion with Endolipide 20 % (12,5 ml/h) and heparin (250 U/h) to prevent the suppressive effect of insulin on plasma free fatty acids
1849857|NCT00950209|Other|hyperglycaemic hyperinsulinic clamp|a hyperglycaemic hyperinsulinic clamp to maintain plasma glucose around 2 g/l to prevent the decreasing effect of insulin on plasma glucose.
1849858|NCT00950222|Drug|Imipenem/Amikacin|patients will received as empirical therapy for VAP imipenem associated with amikacin.
1849859|NCT00950235|Behavioral|Weight Management|Two individual counseling session on nutrition and once weekly group sessions including use of food diaries for the remaining weeks of their pregnancy
1849860|NCT00950235|Other|Usual Care|Standard nutrition counseling from Health Plan
1849862|NCT00950261|Radiation|tri-weekly cisplatin|cisplatin 75mg/m2 every 3 weeks, intravenous, 3 cycles
1849863|NCT00950274|Drug|CD133+ autologous bone marrow stem cell|Intramyocardial injection of 5 mL CD133+ cells (0.5-5x10e6 cells) suspended in physiological saline + 10% autologous serum intramyocardially during CABG surgery
1849864|NCT00950274|Drug|Placebo|Intramyocardial injection of 5 mL of physiological saline + 10% autologous serum intramyocardially during CABG surgery
1849865|NCT00950287|Device|No intervention|The recordings will be performed in neonatal units with the preterm infant remaining in usual condition with limitations of external stimulation during the study period. The usual monitor will remain in function. The intervention of the nurses in case of apnea will not be modified during the study period. The recording will be obtained from derivation of the signal usually recorded by the monitor in use completed in one centre by a polysomnographic recording (Medtronics France SA), in order to test a possible influence of the sleep status on the detection.
1849872|NCT00950313|Other|Self Assessment|Self assessment used to determine current risk of diabetes and likelihood of requiring further testing
1849873|NCT00950313|Other|Electronic risk score|Patients current risk of diabetes is determined by a electronic risk algorithm. They are then invited to attend fof further testing.
1849874|NCT00950326|Procedure|Physiotherapy|In intervention group B1, patients with osteoarthritis of the hip or knee will receive specific physiotherapy of the affected hip or knee joint three times a week, but without any disease-specific hydrotherapy. Because of the holistic approach of the clinic, however, these patients will still receive hydrotherapy at sites other than the affected joint, for example, alternate cold and warm affusions of the back or an ascending lumbar affusion.
1849875|NCT00950326|Procedure|Affusion|Patients will receive a specific hydrotherapeutic procedure in the form of alternate cold and warm thigh affusions ( pouring on water) which will consist of repeated cold and warm water stimulation of the knee and hip region (daily). Physiotherapy of other regions, such as the back, is permitted but there will be no specific physiotherapy of the hip or knee joint.
1849876|NCT00950326|Procedure|Affusion/ Physiotherapy|Patients with active osteoarthritis of the hip or knee will receive specific, joint-related hydrotherapy in the form of a (daily) alternate cold and warm thigh affusions as well as joint-specific physiotherapy (three times a week).
1849877|NCT00950339|Drug|omeprazole, 20mg twice daily|"Each patient will undergo 3 phases of drug therapy:
A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).
At the end of each phase- each patient will undergo the following evaluation:
Platelet reactivity"
1849878|NCT00950339|Drug|famotidine 40mg twice daily|"Each patient will undergo 3 phases of drug therapy:
A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).
At the end of each phase- each patient will undergo the following evaluation:
Platelet reactivity"
1849879|NCT00950339|Drug|pantoprazole 40mg once daily|"Each patient will undergo 3 phases of drug therapy:
A- 4 weeks of PPI treatment (omeprazole, 20mg twice daily)) B- 4 weeks of H2 blocker treatment (famotidine 40mg twice daily) C- 4 weeks of PPI treatment (pantoprazole 40mg once daily).
At the end of each phase- each patient will undergo the following evaluation:
Platelet reactivity"
1849880|NCT00950352|Drug|Citicoline|Subjects will be given 1g citicoline twice daily for a total of 8-9 weeks.
1849881|NCT00950352|Drug|Placebo|Subjects will be given 1 capsule of placebo twice daily for 8-9 weeks. They will be taking the same quantity as the citicoline group.
1849882|NCT00950365|Drug|Pemetrexed|500 mg/m2 IV over 10 minutes on day 1 every 21 days
1849883|NCT00950365|Drug|pemetrexed and erlotinib|pemetrexed 500 mg/m2 IV over 10 minutes on day 1 every 21 days and erlotinib 150 mg PO once daily on days 2-17 every 21 days
1849884|NCT00950391|Drug|Tacrolimus|Tacrolimus 3 mg/day taken twice daily to maintain blood level of 3-6 ng/ml for duration of 1 year or less
1849885|NCT00950404|Drug|Viagra 50 mg tablet|Commercial tablet, 50 mg, single dose administered with water
1849886|NCT00950404|Drug|Formulation B ODT tablet 50 mg|Oral disintegrating tablet (ODT), 50 mg, single dose administered without water
1849887|NCT00950404|Drug|Formulation C ODT tablet 50 mg|ODT, 50 mg, single dose administered without water
1849890|NCT00950430|Drug|Pittsburgh Compound B (C-11 PiB)|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
1849891|NCT00950430|Drug|F-18 FDG|Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss.
1849892|NCT00950430|Drug|Tau (18-F-AV-1451)|"PIB PET scan, Tau PET scan and/or FDG PET scan
Repeat these scans approximately every 24-30 months for up to 10 years in those with all three PETs or 20 years in those with only PiB PET and FDG PET. A second PiB PET, TAU PET and/or FDG PET may be administered within a year if needed to ensure a completed exam for analysis in the rare case of exam failure or data loss. ECG will be performed on subjects who have not had previous ECG test at Mayo to rule out prolonged QT interval prior to PET TAU scan."
1849893|NCT00950443|Device|Acoustic reflection method|Acoustic reflection gives the longitudinal cross-sectional area profile along airway.Based on planar acoustic wave propagating in a rigid duct connected to airway.
1849894|NCT00950443|Device|Acoustic method and breathing/endoscopic evaluation|Endoscopic evaluation done under general anaesthesia.
1849895|NCT00950456|Biological|H1N1 Pandemic Influenza Vaccine (whole virion, Vero Cell-derived, inactivated)|It is anticipated that subjects will receive two intramuscular injections approximately 3 weeks apart. The vaccine will be provided in two doses, one for adults, the other for children.
1849896|NCT00950482|Procedure|TA|In Traditional acupuncture (TA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
1849897|NCT00950482|Other|AA|In Alternative acupuncture (AA), in which eight acupuncture points are selected, subjects will undergo three 30-minute sessions weekly for 12 weeks. Disposable acupuncture needles (1-1.5 inch sterilized stainless steel)will be inserted up to one inch deep through a plastic needle tube that is secured with adhesive tape to the skin.
1849898|NCT00950482|Other|WC|Waiting Group
1849899|NCT00950495|Device|Mandibular Advancement Device (MAD)|This oral appliance keeps the mandible and the tongue in a protruded position. This results in an upper respiratory tract widening and/or reduced collapsibility of the upper airway, thereby preventing the upper airway collapse during sleep.
1849900|NCT00950495|Device|nasal CPAP|The CPAP machine delivers a stream of compressed air via a hose to a nose mask, splinting the airway (keeping it open under air pressure) so that unobstructed breathing becomes possible, reducing and/or preventing apneas and hypopneas
1849901|NCT00950495|Device|placebo|as a placebo, a thin (< 1 mm), hard acrylic-resin palatal splint with only a partial palatal coverage was used
1992783|NCT03298607|Dietary Supplement|Serelys PMS|2 months treatment
1992784|NCT03297424|Drug|PLX2853|tablets
1849904|NCT00950521|Procedure|Intercerebral implantation of Autulogous Stem Cells|2-8 millions Stem cell per patients plus convention therapy
1849905|NCT00950521|Drug|convention therapy|antiplatelet
1849906|NCT00950534|Drug|INSULIN GLARGINE (HOE901)|The dose of insulin glargine will be titrated toward a fasting plasma glucose (FPG) target of 5.5 mmol/L. Treatment with oral antidiabetic drugs (OADs) prescribed before study entry may continue (except Sitagliptin, Acarbose, Rosiglitazone)
1849907|NCT00950534|Drug|Oral Anti Diabetics (OAD)|Patients treated with the usual standard of care (OAD dose titration, addition of a second or third OAD or referral to an endocrinologist) until optimal doses are reached to maintain a FPG of 5.5 mmol/L
1849908|NCT00950547|Device|CARDIOPAT|Cell Saver System at bedside for ICU stay
1849909|NCT00950547|Device|Traditional Chest Drains|Chest drains as usual with no possibility to reinfuse lost blood
1849910|NCT00950586|Drug|GSK1043702|Oral dose in liquid or tablet formulation
1849911|NCT00950586|Drug|Dextromethorphan|30mg Oral dose
1849912|NCT00950586|Drug|Placebo|To match GSK1034702
1849913|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, once daily, 12 weeks
1849914|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 5 mg, once daily, 12 weeks
1849915|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 10 mg, once daily, 12 weeks
1849916|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 20 mg, once daily, 12 weeks
1849917|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 40 mg, once daily, 12 weeks
1849918|NCT00950599|Drug|Saxagliptin|Tablets, Oral, 100 mg, once daily, 6 weeks
1849919|NCT00950599|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 6 and 12 weeks
1849920|NCT00950612|Biological|GSK's investigational vaccine 692342|Intramuscular injection, 2 doses
1849921|NCT00950612|Biological|Placebo|Intramuscular injection, 2 doses
1849922|NCT00950625|Drug|lignocaine|200 mg of intraperitoneal lignocaine will be given once during surgery
1849923|NCT00950625|Drug|bupevacaine|100 mg of bupevacaine will be given once during laparoscopic cholecystectomy
1849924|NCT00950638|Drug|ARC1905|intravitreal injection
1849925|NCT00950651|Drug|Tramadol HCl Contramid® Once A Day|The patients orally self-administered the study medication: either 100, 200, 300 or 400 mg Tramadol HCl Contramid® Once A Day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
1849926|NCT00950651|Drug|Tramadol HCl Twice a day|The patients orally self-administered the study medication: either 200, 300 or 400 mg Tramadol HCl Twice a day. Each patient was titrated to his or her optimum dose (up to a maximum of 400 mg) during the Titration Phase, which lasted between 4 and 12 days. The optimum dose was taken throughout the study.
1849927|NCT00950664|Drug|Dysport® (abobotulinumtoxinA)|Cross over injection of Dysport® (<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
1849928|NCT00950664|Drug|Botox® (onabotulinumtoxinA)|Cross over injection of Dysport® (<500IU), Botox® (200IU)assuming a bioequivalence ratio of 2.5:1 units
1849929|NCT00950677|Drug|Byetta (exenatide)|exenatide 5 mcg subcutaneously
1849932|NCT00950716|Behavioral|Patient Peer Support and Empowerment|30 mentors are themselves diabetes patients who have good self care and are motivated to support their peers. The mentors will be trained to deliver peer support intervention under supervision by a program manager. The 300 diabetes patients (mentees) randomized to the peer support group are the intervention targets of these 30 mentors. Telephone-Linked-Communication (TLC) system will be a tool of the mentors for education to the mentees. TLC system utilizes an automatic, interactive, computer-controlled telephone system to monitor and promote diabetes self-management.
1849933|NCT00950716|Behavioral|Usual Care|Subjects in Usual CAre will receive standard care with clinicians' usual follow-up and referral with education to diabetes nurses if deemed necessary at in-charge clinicians' discretion.
1849934|NCT00950729|Procedure|Driving with running shoes|Participant was asked to do all the experiments with their own running shoes
1849935|NCT00950729|Procedure|Plaster cast|The participant was ask to do all the experiments with a plaster cast molded on his right leg
1849936|NCT00950729|Procedure|Driving with Aircast|The participant was ask to do all the experiments with a aircast on his right leg
1849937|NCT00950742|Drug|Trastuzumab|Load: 4mg/kg-maintain:2mg/kg/week
1849938|NCT00950742|Drug|BIBW 2992|Increased dose cohorts from low dose to MTD
1849939|NCT00950755|Biological|tositumomab and Iodine I 131 tositumomab (anti-B1 antibody)|For the treatment of 1st or 2nd relapsed indolent B cell lymphomas or B cell lymphomas that have transformed to a more aggressive histology
1849940|NCT00950768|Procedure|Autologous transplantation|Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
1849941|NCT00950781|Procedure|ACTH|During the ACTH test an IV will be placed in subjects arms, 25mL of blood will be drawn at -30 minutes and 6mL of blood will be drawn at -15 minutes and 0 minutes respectively. Following, 0.25mg of ACTH will be injected intravenous over 60 seconds, and a final 12mL of blood will be drawn 60 minutes later. That is, a total of 50mL of blood will be drawn to test serum blood hormone levels from the subjects during the ACTH (Hormone) Stimulation Test.
1849942|NCT00950794|Drug|Salmeterol(SN408D)|Salmeterol(SN408D)：long-acting Beta2-agonist
1849943|NCT00950794|Drug|Hokunalin (tulobuterol) tape|Hokunalin (tulobuterol) tape:long-acting Beta2-agonist
1849944|NCT00950807|Drug|Tiotropium|long-acting muscarinic receptor antagonist; 18mcg once-daily
1849945|NCT00950807|Drug|Placebo|Inactive/ excipients only
1849946|NCT00950807|Drug|GSK573179|GSK573179 investigational drug
1849947|NCT00950820|Drug|Oxaliplatin, Capecitabine, Panitumumab|"Panitumumab at a dose of 9 mg/kg BW every three weeks will be administered on day 1 of each cycle just prior to administration of chemotherapy.
The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15."
1849948|NCT00950820|Drug|Oxaliplatin, Capecitabine|The XELOX regimen is defined as a 2 hour infusion of oxaliplatin 130 mg/m² on day 1 followed by capecitabine 1000 mg/m² bid per os. Capecitabine administration will commence on the evening of day 1 and complete after the morning dose on day 15.
1849949|NCT00938249|Dietary Supplement|Monascus Garlic Fermented Extract|
1849950|NCT00938249|Dietary Supplement|Placebo|
1849951|NCT00938262|Drug|Fimasartan, Ketoconazole, Rifampicin|"Fimasartan (1 day)
Ketoconazole (3 days) Ketoconazole + Fimasartan (1 day)
Rifampicin (9 days) Rifampicin + Fimasartan (1 day)"
1849952|NCT00938275|Drug|0.5g SRT2104|"SRT2104 will be supplied in two forms: as 0.5g powder which will be prepared by the pharmacist/designee into a liquid suspension and as two hard gelatin capsules, each containing 0.25g SRT2104. The dosing vehicle for the liquid suspension is 1% (by weight) hypromellose acetate succinate in water, which is used as a suspension aid and a dispersant for the SRT2104.
Each formulation of test material will be administered orally, in a single dose to the subjects in the fasted state and following consumption of a standard meal. Neither the investigator nor the subjects enrolled will be blinded to treatment assignment."
1849953|NCT00938288|Drug|KW-3357|50IU/mL, IV single dose
1849954|NCT00938301|Drug|PF-04455242|Powder-in Capsule (EP-PIC), will be used to administer doses from 0.5 mg up to and including 56 mg of a single rising dose over 3 treatment periods receiving two doses of PF-04455242 and one dose of placebo. A one-week (minimum) washout will separate each treatment period.
1849955|NCT00938301|Drug|Placebo|PIC matching in appearance to PF-04455242 will be used to administer placebo.
1849956|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 4,000 IU, IV, on Day 7, 8, and 9 of study participation
1849957|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 12,000 IU, IV, on Day 7, 8, and 9 of study participation
1849958|NCT00938314|Drug|human chorionic gonadotropin (hCG), then epoetin alfa (EPO)|hCG 385 µg (10,000 IU), SC, on Day 1, 3 and 5 of study participation, then EPO 20,000 IU, IV, on Day 7, 8, and 9 of study participation
1849959|NCT00938314|Drug|Saline Placebo|Saline SC, on Day 1, 3, and 5 of study participation, then Saline IV, on Day 7, 8, and 9 of study participation
1849960|NCT00938327|Biological|Rotarix™|Two doses of oral vaccine.
1992785|NCT03298061|Drug|Mepolizumab|Mepolizumab will be available as lyophilized powder for injection to be reconstituted with sterile water for injection, prior to use. Subjects will be dosed with mepolizumab at a dose of 300 mg which will be administered as three separate 100 mg SC injections every 4 weeks. The injections will be administered into any of the upper arm, thigh or anterior abdominal wall.
1849964|NCT00938353|Drug|beclomethasone dipropionate suspension for nebulisation 800 mcg/2 ml|Single dose 1600 mcg/4 ml
1849965|NCT00938353|Drug|Placebo solution for nebulisation 2 ml|single dose: 4 ml
1849966|NCT00943683|Drug|montelukast sodium|Montelukast 4-mg oral granules mixed with applesauce once daily at bedtime for 6 weeks
1849967|NCT00943683|Drug|Comparator: Placebo|Placebo oral granules mixed with applesauce once daily at bedtime for 6 weeks
1849968|NCT00943696|Dietary Supplement|Ingestion of white wine vs. tea during and an alco|4 x 50ml glasses of white wine (12% alcohol) or tea will be taken according to a randomization scheme After the meal 1 x 20ml of Kirsch (40% alcohol) or tea will be taken
1849969|NCT00943709|Biological|insulin glargine recombinant|Given subcutaneously
1849970|NCT00943709|Drug|therapeutic insulin|Given subcutaneously
1849972|NCT00943735|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg QD
1849973|NCT00943735|Behavioral|Your Way|early intervention after treatment initiation and before patients have an opportunity to discontinue medication; reinforcing the treatable nature of OAB
1849974|NCT00943748|Drug|deferiprone|A standard dose-escalation phase will be initiated, with a 3 ml of the deferiprone oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of deferiprone oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
1849975|NCT00943748|Drug|placebo|A standard dose-escalation phase will first be initiated, with a 3 ml of the placebo oral solution twice a day (breakfast and dinner) increase every 3 days up to a total of a fixed dose of 9 ml of placebo oral solution twice a day corresponding to 30 mg/kg/day in 2 doses
1849976|NCT00950833|Biological|Pneumococcal vaccine GSK1024850A|1 or 2 intramuscular injections
1849977|NCT00950846|Drug|Busulfan|"Day -9, -8, -7 and -6
Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses."
1849978|NCT00950846|Drug|Cytoxan|(50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
1849979|NCT00950846|Drug|Fludarabine|40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
1849980|NCT00950846|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
1849981|NCT00950859|Drug|GSK1349572 (Cohort I)|50 mg once daily
1849982|NCT00950859|Drug|GSK1349572 (Cohort II)|50 mg twice daily
1849983|NCT00950872|Device|Duet TRS|Patients will have their gastric pouch created with ENDO GIA staplers with Single Use Loading Units with Duet TRS.
1849984|NCT00950885|Biological|Low Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
1849985|NCT00950885|Biological|Placebo|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
1849986|NCT00950885|Biological|High Dose Melatonin|Melatonin and placebo will be delivered as capsules on 4 successive days. All groups will receive placebo on days 1-3. Placebo group will continue to receive placebo on days 4, while low dose group will receive 0.5mg melatonin on day 4 and high dose group will receive 3.0mg melatonin on day 4.
1849987|NCT00950898|Other|decaff|2 mugs of decaffeinated coffee
1849988|NCT00950898|Other|caffcoff|2 mugs of caffeinated coffee
1849989|NCT00950898|Other|caffeine|2 mugs of hot water containing caffeine
1849990|NCT00950898|Other|placebo|2 mugs of hot water
1849991|NCT00950911|Drug|amg 162|120 mg SC injection of denosumab Q4W until the subject has access to commercially available product or for up to 2 years, which ever comes first.
1849992|NCT00950924|Device|Simultaneous Vision Bifocal Soft Contact Lenses|Simultaneous Vision Bifocal Soft Contact Lenses will be prescribed such that the distance vision as measured by manifest subjective refraction will be properly corrected by the near vision add power and undercorrected by the distance power.
1849993|NCT00950924|Device|Single Vision Soft Contact Lenses|Single vision soft contact lenses will be prescribed to properly correct the distance vision as measured by manifest subjective refraction.
1849994|NCT00950950|Drug|AMG 785|Subjects will be randomized to receive subcutaneous dose administrations of AMG 785 or placebo at a dose of 3 mg/kg every 4 weeks for 3 months.
1849995|NCT00950950|Drug|Placebo|Subjects will be randomized to receive subcutaneous dose administrations of AMG 785 or placebo at a dose of 3 mg/kg every 4 weeks for 3 months.
1849996|NCT00950963|Behavioral|Phone Counseling|Patient were contacted on a periodic basis via telephone to address there diabetes care.
1849997|NCT00950963|Other|Standard Clinical Care|Patients in the usual care or control group were contacted at the beginning of the study only if they had not had an LDL level in the previous 12 months. A letter requesting their presentation for an LDL test was sent to their last known address along with a lab slip and a reminder to schedule an appointment with their PCP for follow-up of results. No additional contact was made with them by the study nurses.
1849998|NCT00950976|Other|citrulline|TID for 5 days
1849999|NCT00950976|Other|Lemonade|TID for 5 days
1850000|NCT00950989|Drug|AMG 827 70 mg|70 mg AMG 827 SC
1850001|NCT00950989|Drug|AMG 827 140 mg|140 mg AMG 827 SC
1850002|NCT00950989|Drug|AMG 827 210 mg|210 mg AMG 827 SC
1850003|NCT00950989|Drug|Placebo|Placebo SC
1850004|NCT00950989|Drug|Stable weekly dose of methotrexate|Methotrexate
1850005|NCT00951002|Procedure|acellular dermal matrix plug|anal fistula treated with human acellular dermal matrix plug
1850006|NCT00951015|Drug|GSK1349572|investigational HIV-1 integrase inhibitor
1850007|NCT00951015|Drug|efavirenz|approved therapy for HIV-1 infection, used as an internal study control
1850008|NCT00951028|Behavioral|Cognitive behavioral therapy (CBT) for adherence and depression (CBT-AD)|12 therapy sessions delivered over 4 months, using cognitive behavioral strategies to target depressive symptoms and adherence to HIV medications
1850009|NCT00951028|Behavioral|Life-steps adherence treatment|Single-session adherence treatment that targets informational, problem solving, and cognitive-behavioral steps geared toward improving HIV medication adherence and self-management
1850010|NCT00951028|Behavioral|Information and supportive psychotherapy (ISP) for adherence and depression (ISP-AD)|12 therapy sessions delivered over 4 months, providing education and support that target depressive symptoms and adherence to HIV medications.
1992786|NCT03298061|Drug|Prednisolone|Subjects who require a dose of prednisolone (or equivalent) of 5 mg/day for adequate control of their EGPA will be included.
1850052|NCT00951444|Drug|carboplatin|Given IV
1850053|NCT00951444|Drug|gemcitabine hydrochloride|Given IV
1850013|NCT00951054|Drug|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m^2 (or 18 mg/m^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
1850014|NCT00951067|Other|Exercise, Elevation, and Compression Garment|"Patients will be asked to daily:
exercise
elevate arm
wear an arm compression garment"
1850015|NCT00951067|Device|E0650 PCD with non-sequential waveform|Use of an E0650 PCD with non-sequential waveform for two hours every day.
1850016|NCT00951067|Device|E0651 PCD with sequential, non-gradient waveform|Use of an E0651 PCD with sequential, non-gradient waveform for two hours every day
1850017|NCT00951067|Device|E0652 PCD with sequential, gradient waveform|Use of an E0652 PCD with sequential, gradient waveform for two hours every day.
1850018|NCT00951067|Device|E0652 PCD with peristaltic pulse waveform|Use the E0652 PCD with peristaltic pulse waveform for two hours every day.
1850019|NCT00951080|Device|Traditional NPWT System|Standard wound dressing applications followed by negative pressure system application per manufacturer recommendations.
1850020|NCT00951080|Device|SNaP Wound Care System|Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.
1850021|NCT00951093|Procedure|Gastric bypass|Open Silastic® ring Roux-en Y gastric bypass was performed through an upper midline incision. A gastric pouch was created by dividing the stomach with a 10-cm stapler from the lesser curvature (7 cm vertically from the cardia) to 1 cm to the left of the Hiss angle. The estimated volume of the gastric pouch was 20 to 30 ml that was banded with a 6.5 cm long Silastic® ring. A gastrojejunal anastomosis was performed with two-layers hand sewn absorbable suture over a 1.2 cm bougie distal to the ring, keeping an alimentary limb with 100 cm in length, and a biliopancreatic limb ranging 60 and 80 cm.
1850022|NCT00951106|Drug|Pyrimethamine/sulfdoxine (Fansidar)|
1850023|NCT00951119|Device|Resperate|device-guided breathing exercises
1850024|NCT00951119|Device|Resperate|breathing device without slowing of breathing frequency
1850025|NCT00951132|Drug|rosuvastatin|10mg tablets, once daily in three months
1850026|NCT00951132|Drug|Placebo|tablet, once daily, three months
1850027|NCT00951158|Dietary Supplement|Conjugated Linoleic Acid|"This is a open-label dose-titration trial of CLA in patients with advanced, refractory malignancies. The dose a participant receives is dependent upon the cohort to with the patient is assigned.
CLA will be given as oral soft gels, once daily, with pharmacokinetic sampling and biopsies (pretreatment and on day 15). Doses will be escalated by patient cohorts, using an accelerated titration design (single-patient cohorts) with expansion to conventional cohort sizes (3-6 patients) once either inhibition of S14 expression or clinical toxicity is observed. Subjects with stable or responsive disease and who tolerate treatment may continue on CLA until the time of disease progression."
1850028|NCT00951158|Drug|Conjugated Linoleic Acid|Phase I Dose Escalation Study
1850029|NCT00951262|Behavioral|a life review program|The life review program includes reviewing a life and formalating a life booklet. Reviewing a life consists of three weekly sessions separately addressing illness experience, adulthood life and childhood and adolescence life. Each session lasts about 30 to 60mintues.A booklet with photos documented significant life events will be produced as a gift for the subjects. The edition, photos and contents fo the booklet are determined by the subjects.
1850030|NCT00951275|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks for 6 months
1850031|NCT00951275|Drug|Standard DMARDs (Disease Modifying Anti Rheumatic Drugs)|As prescribed
1850032|NCT00951288|Dietary Supplement|Saffron|Saffron 20 mg/day supplementation
1850033|NCT00951288|Dietary Supplement|Placebo|Placebo
1850034|NCT00951301|Drug|mangosteen juice|6 ounces of juice containing mangosteen taken twice daily, AM and PM, for 6 months duration of study participation.
1850035|NCT00951301|Drug|placebo juice|6 ounces of specially prepared juice not containing mangosteen taken twice daily, AM and PM, for 6 months duration of the study participation.
1850036|NCT00951340|Other|Cognitive behavioral therapy (CBT)|15 weekly therapy sessions, the first hour of which will be devoted to standard CBT techniques
1850037|NCT00951340|Behavioral|Emotional processing and interpersonal therapy|15 weekly therapy sessions, the second hour of which will be devoted to interpersonal and emotional processing therapy techniques
1850038|NCT00951340|Behavioral|Listening therapy|15 weekly therapy sessions, the second hour of which will be directed by the participant's questions and discussion
1850039|NCT00951366|Other|Patient Registry|The CHILD Clinic Patient Registry is an observational study designed to identify epidemiologic and genetic factors associated with chronic lung disease in former preterm infants or those with lung disease in the neonatal period.
1850040|NCT00951379|Drug|Pioglitazone hydrochloride|Three (3) pioglitazone 15 mg capsules by mouth once daily for 24 weeks (+/- 1 week)
1850041|NCT00951379|Other|placebo|Three (3) pioglitazone placebo capsules by mouth once daily for 24 weeks (+/- 1 week)
1850042|NCT00951379|Other|laboratory biomarker analysis|Correlative studies
1850043|NCT00951392|Drug|euglycemic hyperinsulinemic clamp|"Insulin perfusion at 1 mU.kg-1.min-1
Glucose perfusion to maintain euglycemia at 5,0 ± 0,5 mmol/l
Blood tests"
1850044|NCT00951392|Procedure|muscle biopsy|"Gene expression in muscle tissue will be studied with two approaches :
Candidate gene approach by quantitative RT-PCR : genes involved in the carbohydrates and lipids metabolism including lipid oxidation in muscle (lipid carriers, PPARs), expression of 7 sirtuins isoforms as well as some of their target genes (NFkB, PGC1a)
Global transcriptome analysis by DNA Chip"
1850045|NCT00951392|Device|indirect calorimetry|energy expenditure measurement
1850046|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 25 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
1850047|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 100 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
1850048|NCT00951405|Drug|activated recombinant human factor VII, long acting|After an observation period of 3 months, every 2nd day intravenous (i.v.) injection with 200 microgrammes/kg activated recombinant human factor VII, long acting, for 3 months
1850049|NCT00951431|Drug|Esomeprazole|Esomeprazole 20mg daily for 8 weeks
1850054|NCT00951457|Drug|Bendamustine|"Dose escalation phase:
Days -3, -2, -1: 3 - 10 - 30 mg Alemtuzumab s.c.
Treatment phase:
Bendamustine 70 mg/m2 i.v. on d1 + d2 repeat every 28 days for 4 cycles
Alemtuzumab 30 mg s.c. 3x per week (days 1, 3, 5) continuously in parallel with chemotherapy cycles for a maximum of 16 weeks"
1850055|NCT00951470|Other|Follow -Up Visits|If CDT is declined, participants will have follow-up visits at 1, 3, and 6 months after study interview.
1850056|NCT00951470|Other|Full CDT|"Monday through Friday visits to the clinic for 2 weeks of intensive outpatient therapy. The CDT will be done by the lymphedema therapist. Each session will last about 1 hour.
During the last 2 treatment visits (Visits 9 and 10), the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months."
1850057|NCT00951470|Other|Modified CDT Program|The participant will come to the clinic for 1-2 training sessions taught by the lymphedema therapist. Each training session will last about 1 hour, and the participant will be taught how to do the CDT steps at home. Then, the CDT steps will be performed at home, every day for the next 3 months.
1850058|NCT00951483|Drug|Quetiapine-XR|Quetiapine-XR (Seroquel-XR) 50-300mg daily for 12 weeks.
1850067|NCT00951509|Other|Power Mobility Road Test (PMRT)|All subjects will underwent the Power Mobility Road Test (PMRT), and the clinicians scored the driving performance within each condition.
1850068|NCT00951522|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
1850069|NCT00951522|Drug|Placebo|Inhaled placebo in sterile saline
1850070|NCT00951535|Other|questionnaire administration|
1850071|NCT00951535|Procedure|quality-of-life assessment|
1850072|NCT00951535|Radiation|image-guided radiation therapy|
1850073|NCT00951535|Radiation|intensity-modulated radiation therapy|
1850074|NCT00951535|Radiation|radiation therapy treatment planning/simulation|
1850075|NCT00951548|Dietary Supplement|VSL#3|Probiotic blend of 8 different strains of lactobacilli and bifidobacteria, dosed at 900 billion bacteria/sachet). Dosage regimen is 2 sachets b.i.d. for 8 weeks
1850076|NCT00951548|Dietary Supplement|Placebo|Corn Starch. Dosage regimen is 2 sachets b.i.d. for 8 weeks
1850077|NCT00951561|Device|Vipon|The Vipon is a tampon with a small motor unit within, which produces vibratory stimulation, used during menstruation to provide pain relief for women with dysmenorrhea.
1850078|NCT00951561|Drug|Ibuprofen|400 mg daily
1850079|NCT00951574|Drug|Nadroparin calcium|Nadroparin calcium; Pre-filled syringes of 0.4 ml (3.800 anti-Xa IU), 1 subcutaneous injection/day (every 24 hours).
1850080|NCT00951574|Drug|saline solution (placebo)|Pre-filled syringes of 0.4 ml , 1 subcutaneous injection/day (every 24 hours).
1850081|NCT00951587|Device|PillCam™ (Capsule Endoscopy)|Medical Device
1850082|NCT00951600|Drug|oxcarbazepine 300 mg/5mL oral suspension|
1850083|NCT00951613|Drug|NK012|30 minute IV infusion once every 28 days. NK012 dose is 28 mg/m^2 (or 18 mg/m^2 depending on UGT1A1 polymorphism, with potential to dose escalate). Dose escalation cannot exceed 28 mg/m^2. Dosing will proceed until progression or unacceptable toxicity develops, or decision by patient or investigator to stop.
1850084|NCT00951626|Behavioral|exercise intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.
Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
1850085|NCT00951626|Behavioral|telephone-based intervention|"Those on the Standard Nursing Intervention Program will receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
For those on the Usual Care plus Attention Control program, the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant."
1850086|NCT00951626|Dietary Supplement|dietary intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.
Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
1850087|NCT00951626|Other|educational intervention|"Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge.
Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge."
1850088|NCT00951626|Other|questionnaire administration|For both groups of participants, administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
1850089|NCT00951626|Procedure|allogeneic bone marrow transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic bone marrow transplant.
1850090|NCT00951626|Procedure|allogeneic hematopoietic stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
1850091|NCT00951626|Procedure|assessment of therapy complications|Collected throughout the 12 month study period
1850092|NCT00951626|Procedure|peripheral blood stem cell transplantation|Patient with a diagnosis of a hematologic cancer scheduled for a single allogeneic stem cell transplant.
1850093|NCT00951626|Procedure|psychosocial assessment and care|Those on the Standard Nursing Intervention Program will be offered six educational sessions spaced over the first 3 months after discharge. They will also receive phone calls from the Intervention Nurse after the first 3 months and then monthly calls up to 12 months post hospital discharge.
1850094|NCT00951626|Procedure|quality-of-life assessment|For both groups of participants, questionnaires administered at baseline (prior to hospital discharge and 3, 6, and 12 months post hospital discharge.
1850407|NCT00946712|Biological|Cetuximab|Given IV
1850095|NCT00951626|Procedure|standard follow-up care|Those on the Usual Care plus Attention Control program will be offered a copy of the complete teaching manual for Hematopoietic Cell Transplant patients which will stay with them during hospitalization and be sent home after discharge. Also the Intervention Nurse will be available by phone or email within 48 hours of request for 100 days post transplant.
1850096|NCT00951639|Dietary Supplement|Cassia cinnamon|5g encapsulated ground bark administered once in experimental session
1850097|NCT00951639|Procedure|50 minutes exercise|50 minutes treadmill endurance exercise at 70% of the heart rate reserve (correlated to VO2max)
1850098|NCT00951639|Dietary Supplement|Cellulose Powder|5g encapsulated powder administered during placebo experimental session
1850099|NCT00951652|Behavioral|CBT|
1850100|NCT00951652|Other|Interpersonal and emotional processing therapy|
1850101|NCT00951652|Behavioral|supportive listening|
1850102|NCT00951665|Drug|paclitaxel|Intravenous repeating dose
1850103|NCT00951665|Drug|pertuzumab [Perjeta]|Intravenous repeating dose
1850104|NCT00951665|Drug|trastuzumab emtansine [Kadcyla]|Intravenous escalating dose
1850105|NCT00951665|Drug|paclitaxel|Intravenous escalating dose
1850106|NCT00951665|Drug|trastuzumab emtansine [Kadcyla]|Intravenous repeating dose
1850107|NCT00951678|Other|Observational ultrasonography of venous anatomy|The patient will have ultrasound images obtained of the right and left internal jugular veins as a function of the degree of head rotation and of the right and left femoral veins. Our study is an observational study
1850108|NCT00951691|Behavioral|Enhanced acute medical rehabilitation|"Daily up to 3-hour sessions of enhanced physical and occupational therapies (see Lenze et al, Enhanced Medical Rehabilitation Increases Therapy Intensity and Engagement and Improves Functional Outcomes in Postacute Rehabilitation of Older Adults: A Randomized-Controlled Trial. J American Medical Director's Association, 2012 for details and outcome data."
1850109|NCT00951691|Behavioral|Treatment as usual|Standard treatment with physical and occupational therapies
1850110|NCT00951717|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
1850111|NCT00951730|Other|Polysomnography|Polysomnography is the method of choice for the diagnosis of sleep apnea. This test lasts for one night in hospital.
1850112|NCT00951743|Drug|Adaptavir (monomeric DAPTA)|"Intranasal (IN) Solution: 20 mL of solution in a 20 mL polyethylene screw top vial to which a metered sprayer is adapted. Each spray releases approximately 0.1 0.12 mL.
Available strength - 0.01mg/mI (active study medication), or no mDAPTA (placebo study medication), in water containing 0.25% benzyl alcohol as preservative and 250 mM mannitol (GRAS) to achieve isotonicity.
Individuals in this study will be randomized to receive mDAPTA or placebo and be instructed to administer four metered nasal spray applications two times a day, in the morning, and in the evening, as close to 12 hours after the morning dose as practical. The planned daily dose of mDAPTA is 8 μg/day."
1850113|NCT00951756|Other|High fat diet|High fat diet and low fat diet are composed of the same food, but the portion sizes are varied.
1850114|NCT00951782|Device|High frequency TMS|deep TMS HADD coil
1850115|NCT00951782|Device|Sham TMS|sham deep TMS HADD coil
1850116|NCT00951782|Device|Low frequency TMS|Deep TMS - HADD coil
1850117|NCT00951808|Biological|Single blood transfusion|Participants will receive a single transfusion of 7-13cc/kg packed red blood cells (RBCs) while in the hospital.
1850118|NCT00951808|Behavioral|Standard care|Participants will receive standard care for ACS while in the hospital.
1850119|NCT00951821|Behavioral|Concurrent treatment|Individual CBT sessions for parents and adolescents plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase. The techniques used to teach cognitive restructuring and problem solving to parents will be similar to those taught to the adolescents, except emotion regulation skills will be added to the parent treatment.
1850120|NCT00951821|Behavioral|Adolescent treatment only|Individual CBT for adolescents only plus combined parent-adolescent family sessions, delivered weekly for 3 months in the acute phase and bimonthly for 3 months in the maintenance phase
1850121|NCT00951834|Drug|Epigallocatechin-Gallate|"Epigallocatechin-Gallate (EGCG) - Sunphenon EGCg:
Months 1-3: 200 mg EGCG/die (200-0-0 mg)
Months 4-6: 400 mg EGCG/die (200-0-200 mg)
Months 7-9: 600 mg EGCG/die (400-0-200 mg)
Months 10-18: 800 mg EGCG/die (400-0-400 mg)"
1850122|NCT00951834|Drug|Placebo|Placebo
1850123|NCT00951847|Drug|oxcarbazepine 300 mg/5 mL oral suspension|
1850124|NCT00951860|Other|Autonomic Nervous System activity|Autonomic activity measured at birth and at 6, 12, 18 and 24 months is represented by time-domain indices (SDNN index, SDANN, pNN50) and frequency- domain indices(PTOT, VLF, LF, HF, ratio LF / HF, LFnu, HFnu), which reflect the short-term variability (parasympathetic branch) and medium term (ortho and parasympathetic branch) of the vegetative balance. This subtle technical assessment of autonomic functioning has been validated in the literature for two decades
1850125|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single injection of long acting activated recombinant human factor VII subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
1850126|NCT00951873|Drug|placebo|Single injection of long acting activated recombinant human factor VII placebo subcutaneously (under the skin). Each treatment dose of 0,1 mg/kg, 0,3 mg/kg and 0,5 mg/kg is assessed for safety before escalating to next dose.
1850127|NCT00951873|Drug|activated recombinant human factor VII, long acting|Single dose of 0,1 mg/kg long acting activated recombinant human factor VII injected intravenously (into a vein).
1850128|NCT00951899|Drug|Colesevelam|Colesevelam hydrochloride; three 625mg tablets taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
1850129|NCT00951899|Other|Placebo|Three placebo tablets matching the active drug colesevelam in appearance, taken orally twice per day before breakfast and before the evening meal over a 12-week treatment period.
1850130|NCT00951899|Behavioral|Diet|Subjects were instructed to follow a weight maintenance diet (~55% carbohydrate, 30% fat and 15% protein) for the 12 week study period.
1850219|NCT00952562|Dietary Supplement|placebo|Empty capsules, 3 capsules per day for 16 weeks
1850131|NCT00951899|Drug|Metformin|Subjects continued to take their pre-study therapeutic doses of metformin (Metformin 500mg tablets taken by mouth twice daily for a total daily dose of 1000 to 2000 mg) through the 12 week study period.
1850132|NCT00951912|Dietary Supplement|Placebo|10g soy protein isolated per day
1850133|NCT00951912|Dietary Supplement|Daidzein|50mg daidzein +10g soy protein isolated per day
1850134|NCT00951912|Dietary Supplement|Genistein|50mg genistein +10g soy protein isolated per day
1850135|NCT00951925|Other|Bone Marrow Aspirate Draw|5cc of Bone Marrow Aspirate will be drawn
1850136|NCT00951951|Procedure|Anterior Approach|Anterior Minimal Invasive Surgery (AMIS)
1850137|NCT00951951|Procedure|Posterior Approach|
1850138|NCT00951964|Drug|Polyphenon E before Placebo|patients receive polyphenon E during 4 months, then 2 months of wash-out and finally 4 months of placebo
1850139|NCT00951964|Drug|placebo before treatment|patients receive 4 months of placebo, then 2 months of wash out et finally 4 months of treatment
1850140|NCT00951990|Behavioral|Ergometer Cycling|Ergometer Cycling under the guidance of a physical therapist after the second postoperative week. These training sessions were scheduled to be performed three times a week for a time period of at least three weeks. The resistance of the ergometer was set to a minimum (for example 30 Watts). Physical therapists were informed to pay special attention, that the height of the saddle is set so that the forefoot reaches the pedal with the knee in extension.
1850141|NCT00951990|Behavioral|No ergometer cycling|Patients of the no ergometer cycling group did not receive any ergometer cycling after surgery
1850142|NCT00952003|Drug|Oxaliplatin, Irinotecan, Bevacizumab, Docetaxel|
1850143|NCT00952016|Drug|Methotrexate|study subjects will receive methotrexate intravenously on day 1 and day 8 of a 3 weekly cycle.
1850144|NCT00952029|Biological|bevacizumab|
1850145|NCT00952029|Drug|FOLFIRI regimen|
1850146|NCT00952029|Drug|fluorouracil|
1850147|NCT00952029|Drug|irinotecan hydrochloride|
1850148|NCT00952029|Drug|leucovorin calcium|
1850149|NCT00952042|Other|Heavy slow resistance training|Heel-raises. 12-6RM. each contraction performed slowly. three times weekly for 12 weeks
1850150|NCT00952042|Other|Eccentric resistance training|Eccentric heel-raises. 3 x 15 reps performed twice daily for 12 wks.
1850151|NCT00952068|Drug|Tramadol Contramid® OAD 200mg|1 Tramadol Contramid® OAD 200mg tablet daily.
1850152|NCT00952081|Drug|Clevidipine|Clevidipine (0.5 mg/ml in 20 % lipid solution) will be administered via peripheral vein using syringe pump; drug infusion will be initiated at 5 mg/hr (10ml/h) and titrated to effect up to a maximum rate of 32 mg/hr when SBP exceeds 130 mm Hg. The anesthesiologist will be allowed to administer the alternative antihypertensive treatment (e.g. labetalol, hydralazine) after achieving a maximum clevidipine infusion rate.
1850153|NCT00952094|Drug|KRN1493|KRN1493 25mg tablet 2,3 or 4 tablets single oral administration
1850154|NCT00952107|Device|FLARE imaging system|Testing of operation of imaging system
1850155|NCT00952120|Device|GSUC|Gauze-based wall suction negative pressure wound therapy
1850156|NCT00952120|Device|VAC|Commercially available Wound VAC negative pressure wound therapy device (KCI, Inc.)
1850157|NCT00952133|Drug|Palonosetron only|The placebo arm will be given a dose of IV palonosetron only, and saline solution prior to surgery to see how this compares with the other combination.
1850158|NCT00952133|Drug|Palonosetron with Dexamethasone|Women/Men 18-55 scheduled for surgery 1-3 hours in duration will be given .075 mg IV Palonosetron (Aloxi) with 8mg IV Dexamethasone (Decadron) before surgery to see if this reduces PONV.
1850159|NCT00952146|Procedure|Transgastric peritoneoscopy (NOTES)|Under general anesthesia an endoscope will be passed through the gastric wall into the peritoneal cavity to examine the peritoneal cavity. At the withdrawal of the endoscope, the gastric access in the stomach wall will be closed with T-tags.
1850160|NCT00952159|Biological|Monitoring seric concentrations of O-demethyl-tramadol and tramadol|The first aim of this study is the validation of monitoring seric concentrations of O-demethyl-tramadol and tramadol to make the ratio in order to detect CYP2D6 poor metabolizers in therapeutic situation, comparing the result with genotyping. The finding of a poor metabolizer status in a patient will make the choice of analgesic drugs easier, avoiding tramadol and codeine. The final objective of this research is to be able to determine the CYP2D6 phenotype in a patient treated by tramadol without a good analgesia. By a single take of blood and a rapid response, this method should be liked to improve pain management. Furthermore, CYP2D6 phenotyping is interesting for the patient because many other drugs depend on this way of metabolism.
1850161|NCT00952172|Behavioral|stair stepping exercise|Stair stepping exercise performed at home daily for eight weeks
1850162|NCT00952185|Other|cytology specimen collection procedure|
1850163|NCT00952185|Other|fluorescent antibody technique|
1850164|NCT00952185|Procedure|assessment of therapy complications|
1850165|NCT00952198|Drug|ARRY-403, glucokinase activator; oral|multiple dose, escalating
1850166|NCT00952198|Drug|Placebo; oral|matching placebo
1850167|NCT00952211|Device|CPAP|CPAP at therapeutic pressure during nighttime
1850168|NCT00952211|Device|CPAP at sub-therapeutic pressure|CPAP delivered at sub-therapeutic pressure at nighttime
1850169|NCT00952224|Other|magnetic resonance imaging|magnetic resonance imaging is used for prognosis assessment
1850170|NCT00952237|Drug|GM-CSF|"GM-CSF (Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor) The dose and duration of GM-CSF (7.5 mcg/kg/day) was selected. If used alone, this dose and duration would result in effective mobilization. GM-CSF will be started on Day #7 and will continue until completion of leukapheresis.
G-CSF will be started (5mcg/kg/d) on Day #7 and will be given each morning. G-CSF will continue until completion of leukapheresis."
1850171|NCT00952237|Drug|IL-2|"IL-2 dose escalation: IL-2 will be administered as a single daily subcutaneous injection each evening until completion of leukapheresis.
Escalation of the dose of IL-2 will be performed using the below schema with the following levels. Patients will be started on Level 1. (Level 0 is included since, if toxicity is meet in Level 1, the dose will be decreased to Level 0).
Level 0 - 3 x 105 i.u./m2/day for 11 days Level 1 - 6 x 105 i.u./m2/day for 11 days Level 2 - 1 x 106 i.u. /m2/day for 11 days as above Level 3 - 1.5 x 106 i.u. /m2/day for 11 days as above Level 4 - 2 x 106 i.u. /m2/day for 11 days as above"
1850220|NCT00952575|Drug|polyclonal anti-D immunoglobulin|single injection of 300 µg
1850172|NCT00952250|Behavioral|Targeted Feedback Reports|Sites randomized to this arm will receive specialized feedback summarizing their adherence to the guidelines and suggestions on ways to improve performance.
1850173|NCT00952250|Behavioral|Targeted Feedback Report|Report designed to target areas for local hospital-specific improvement
1850174|NCT00952263|Biological|MBL-HCV1|Single infusion of MBL-HCV1 at escalating doses as determined by cohort assignment: Cohort 1 @ 1 mg/kg, Cohort 2 @ 3 mg/kg, Cohort 3 @ 10 mg/kg, Cohort 4 @ 30 mg/kg, Cohort 5 @ 50 mg/kg.
1850175|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
1850176|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine with adjuvant|0.5 mL, Intramuscular on Day 0
1850177|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
1850178|NCT00952276|Biological|Monovalent Subvirion A/H1N1 influenza vaccine|0.5 mL, Intramuscular on Day 0
1850179|NCT00952276|Biological|Normal saline solution|0.5 mL, Intramuscular on Day 0
1850180|NCT00952289|Drug|Ruxolitinib|Ruxolitinib phosphate tablets 5 mg administered as oral doses.
1850181|NCT00952289|Drug|Placebo|Matching placebo tablets were administered as oral doses in the same manner as active drug.
1850182|NCT00952302|Drug|Iron sucrose|Single intravenous infusion of iron 200 mg
1850183|NCT00952302|Drug|Normal saline|Single intravenous infusion of normal 0.9% saline 100 mls (as placebo)
1850184|NCT00952302|Procedure|Venesection|Isolvolaemic venesection of total 2 litres of blood - 500 mls each day for 4 days, replaced with normal saline.
1850185|NCT00952302|Drug|Iron sucrose|Two intravenous infusions, each of 200 mg of iron, separated by one day.
1850186|NCT00952302|Drug|Normal saline|Two intravenous infusions of normal 0.9% saline 100 mls (as placebo), separated by one day.
1850187|NCT00952315|Device|Cyberwand|Dual probe lithotrite Cyberwand will be used to remove kidney stone. Duration will be timed and documented.
1850188|NCT00952315|Device|Stonebreaker|Stonebreaker will be used to break up the kidney stone. Duration will be timed and documented.
1850189|NCT00952315|Device|Lithoclast Select|Lithoclast Select will be used to break up and remove the kidney stone. Duration will be timed and documented
1850190|NCT00952328|Dietary Supplement|Nutramigen infant formula|Investigators will advise mothers to supplement with 10 cc of elemental formula immediately following each breastfeeding and to discontinue formula once mature milk production begins.
1850196|NCT00952367|Other|Nasopharyngeal swab|Nasopharyngeal swab
1850198|NCT00952393|Drug|Pharmacokinetic|Subject receives 150 mg of compound formulated with hypomellose and Pharmcokinetics is determined
1850199|NCT00952406|Other|Survey|This is a study to develop a survey for sexual health in women with pelvic floor dysfunction
1850200|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on Day 0 and Day 21 (6 months to 35 Months)
1850201|NCT00952419|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
1850202|NCT00952419|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular Day 0 and Day 21 (3 to 9 years); 0.25 mL, Intramuscular on day 0 and Day 21 (6 months to 35 Months)
1850203|NCT00952432|Drug|Carbamazepine|Carbamazepine 200mg, 1/2 tablet, TID for 1 month
1850204|NCT00952432|Procedure|Acupuncture|Acupuncture
1850205|NCT00952445|Drug|T0903131 Besylate|Once daily, oral
1850206|NCT00952445|Drug|Placebo|Once daily, oral
1850207|NCT00952458|Device|BIS monitoring|Neuromonitoring of depth of sedation with Bispectral Index
1850208|NCT00952471|Other|Evidence Based Intervention to order set|The order set was altered to include evidence based care items
1850209|NCT00952484|Biological|asfotase alfa|2 mg/kg subcutaneous injection three times per week for 6 months.
1850210|NCT00952484|Biological|asfotase alfa|3 mg/kg subcutaneous injection three times per week for 6 months.
1850211|NCT00952497|Drug|Cisplatin, Capecitabine, Telatinib|Subjects will receive: Chemotherapy (capecitabine and cisplatin) and telatinib Capecitabine will be administered (1000 mg/m2) twice daily for 14 days followed by a 7-day rest period. Cisplatin (80 mg/m2) will be given as a 1-3 hour infusion once every 3 weeks. Telatinib (3 tablets) will be administered orally, twice daily as a continuous administration. After a maximum of 6 cycles of cisplatin, subjects continue with capecitabine and telatinib or monotherapy with either study drug,depending on the toxicity experienced by the subject, until disease progression.
1850212|NCT00952523|Drug|Tretinoin Facial Gel|A marketed facial gel containing Tretinoin 0.04% is applied to one side of the face daily for three weeks.
1850213|NCT00952523|Drug|Adapalene/Benzoyl Peroxide Facial Gel|A marketed facial gel containing Adapalene .1% and Benzoyl peroxide 2.5% is applied to the other side of the face daily for three weeks
1850214|NCT00952536|Dietary Supplement|Daily Juice Plus+ with vegetable & fruit & berry capsule|Daily Juice Plus+ with 2 vegetable & 2 fruit & 2 berry capsule
1850215|NCT00952536|Dietary Supplement|Daily Juice Plus+ vegetable & fruit & placebo capsule|Daily Juice Plus+ with vegetable & fruit & placebo capsule
1850216|NCT00952536|Dietary Supplement|Placebo in the form of 6 capsules|Daily Placebo in the form of 6 capsules (control group)
1850217|NCT00952549|Procedure|Facial Yoga Toning Program|Patients will be instructed on 18 exercises which are intended to strengthen and tone the muscles of facial expression. DVD is provided.
1850218|NCT00952562|Dietary Supplement|cholecalciferol|Capsule cholecalciferol 1000 IU, 3 capsules per day for 16 weeks
1850267|NCT00952952|Drug|Mesalamine|
1992793|NCT03297749|Other|Observational study (no intervention)|No interventions
1992794|NCT03295825|Diagnostic Test|Biomarker|Measument of heparin-binding protein in the serum of patients
1992795|NCT03296878|Other|Own-Price Elasticity|The price of eggs will be 75%, 100%, or 125% of the reference price, but the price of other foods will remain the same.
1850221|NCT00952575|Drug|monoclonal anti-D immunoglobulin|Comparison of different dosages of LFB-R593
1850222|NCT00952588|Drug|AZD1152|1200 mg, iv, 7 day infusion
1850223|NCT00952588|Drug|LDAC|20 mg, sc, bd, 10 days
1850224|NCT00952601|Dietary Supplement|Modified Atkins diet|Low carbohydrate diet
1850225|NCT00952614|Device|fluocinolone acetonide (Retisert Implant, Bausch and Lomb)|sustained release device consisting of 0.59 mg of fluocinolone acetonide
1850226|NCT00952627|Dietary Supplement|Pycnogenol|50 mg tablet, 200 mg/day, 4 tablets/day
1850227|NCT00952627|Dietary Supplement|Placebo|
1850228|NCT00952640|Dietary Supplement|vitamin A|high dose vitamin A, 200.000 IU
1850229|NCT00952653|Drug|Desvenlafaxine Succinate Sustained Release|50 mg DVS SR tablet days 1-6, period 2 only.
1850230|NCT00952653|Drug|Midazolam|4 mg midazolam (2 mL midazolam syrup) day 1, period 1 and day 6, period 2.
1850231|NCT00952666|Device|TRUS-RALRP|During surgery, and part of this research study, the ultrasound probe (TRUS) will be placed in the rectum. Then, using the mechanical support arm to hold and adjust the probe we will take ultrasound images during a portion of the robotic LRP surgery. The ultrasound probe will then be removed, and we will complete the LRP surgery as we usually do. We expect this to add approximately 20 minutes to the regular surgery time; the maximum added time will be 30 minutes.
1850232|NCT00952679|Device|Breast Lesion Localization Needles (interv)|needles to locate sln in CT monitor guided by CT
1850233|NCT00952692|Biological|dHER2 + AS15 ASCI|"Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine.
For each dose of 500µg of dHER2 + AS15 ASCI, two sterile glass vials will be supplied:
One vial with the lyophilized preparation containing 500 ug of recombinant dHER2 antigen combined with the immunostimulant.
One vial with liquid adjuvant diluent. The final dHER2 + AS15 ASCI for administration is obtained by reconstitution of the lyophilized preparation with the adjuvant diluents. A dHER2 + AS15 ASCI dose consists of 0.5 ml."
1850234|NCT00952692|Drug|Lapatinib|The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.
1850235|NCT00952705|Biological|Q/LAIV-BFS (MEDI8662)|A single dose of Q/LAIV-BFS delivered using the BFS delivery system (0.2 mL) on Day 0.
1850236|NCT00952705|Biological|FluMist/B/Yamagata|FluMist/B/Yamagata - 0.2 mL dose at Day 0
1850237|NCT00952705|Biological|FluMist/B/Victoria|FluMist/B/Victoria - 0.2 mL dose at Day 0
1850238|NCT00952718|Other|Inspiratory muscle training|A pressure threshold device (Threshold® IMT HS730, RESPIRONICS Inc, Cedar Grove, NJ, USA) was used for the inspiratory muscle training program. The individualized training program was started at an intensity of 30% MIP, which was increased by 2 cmH2O each week, but the maximal intensity did not exceed 50% of MIP. Patients were encouraged to perform IMT for 30 minutes per day, at least 5 days a week for 8 weeks.
1850239|NCT00952731|Drug|oral placebo|Oral placebo taken daily for 4-10 weeks.
1850240|NCT00952731|Drug|afimoxifene|2mg/breast applied daily in the form of a gel for 4-10 weeks.
1850241|NCT00952731|Drug|tamoxifen citrate|20mg oral tamoxifen taken daily (taken as two (2) 10mg capsules) for 4-10 weeks.
1850242|NCT00952731|Drug|placebo gel|Placebo gel applied to breasts daily for 4-10 weeks.
1850244|NCT00952783|Drug|Lesion count|Lesion count in area treated by study drug in a prior study over a 12 month period No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
1850245|NCT00952796|Drug|moxifloxacin|moxifloxacin 400mg once daily (IV form, 60minutes)
1850246|NCT00952796|Drug|ampicillin/sulbactam|ampicillin/sulbactam 1.5g 4 times daily (IV form, administered 60minutes)
1850247|NCT00952822|Biological|Antihemophilic factor, recombinant, manufactured protein-free (rAHF-PFM). (Antihemophilic factor is also known as Factor VIII)|Subjects are randomized to receive an infusion of rAHF-PFM reconstituted in 2 mL sterile water for infusion (SWFI) followed (after a wash-out period) by rAHF-PFM reconstituted in 5 mL SWFI or in 5 mL then 2 mL SWFI(cross-over design). Each subject will receive 2 infusions.
1850248|NCT00952835|Other|regular treatment|regular treatment
1850249|NCT00952848|Other|questionnaire administration|Pain Rating Score
1850250|NCT00952848|Other|Sensory Neuropathy Scale instrument|ECOG Common Toxicity Criteria for Sensory Neuropathy scale
1850251|NCT00952848|Other|Quality of Life instrument|Uniscale 0-100 scale global quality of life
1850252|NCT00952848|Device|MC5-A Scrambler device|Electrical stimulation for 60 minutes
1850253|NCT00952861|Drug|Doxycycline|200 mg QD in 5 days
1850254|NCT00952861|Drug|Placebo (matching)|Placebo QD i 5 days
1850255|NCT00952887|Biological|ACE-031|Either 2 or 3 subcutaneous doses of ACE-031 over a period of one month, or 7 subcutaneous doses of ACE-031 over a period of 3 months.
1850256|NCT00952887|Biological|Placebo|Either 2 or 3 subcutaneous doses of placebo over a period of one month, or 7 subcutaneous doses of placebo over a period of 3 months.
1850257|NCT00952900|Behavioral|Biobehavioral|6 sessions of Biobehavioral treatment modalities that include relaxation/biofeedback, stress management, and coping skills techniques.
1850258|NCT00952900|Behavioral|Active Coping/Attention Intervention|6 sessions of didactic educational techniques to expose patients to the causes of TMD, as well as introducing them to traditional treatment modalities for intervening with acute TMD problems.
1850259|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
1850260|NCT00952913|Drug|Bosutinib|4 x 100-mg oral tablets, single dose
1850261|NCT00952913|Drug|Lansoprazole|2 x 30-mg oral tablets, single daily doses for 2 days
1850262|NCT00952939|Genetic|fluorescence in situ hybridization|At time of surgery
1850263|NCT00952939|Other|laboratory biomarker analysis|At time of surgery
1850264|NCT00952939|Procedure|fine-needle aspiration|At time of surgery
1850265|NCT00952939|Procedure|therapeutic conventional surgery|At time of surgery
1850266|NCT00952939|Other|Questionnaires|The MINI (a structured psychiatric interview) will be administered to all patients that had a pre or post-operative HADS score for suggestive or probable depression or anxiety. A semi-structured interview would be administered to those patients who had some or full decision regret pre-operatively. After completion of the interview, the MINI, a structured psychiatric interview, will be administered.
1850268|NCT00952978|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
1850269|NCT00952978|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
1850270|NCT00952991|Drug|LAF237 = vildagliptin|
1850271|NCT00953004|Dietary Supplement|fiber drink and fiber bread|fiber drink or fiber bread three times daily
1850272|NCT00953017|Drug|Miralax (PEG 3350)|Miralax 255gm bottle
1850273|NCT00953017|Drug|Amitiza (Lubiprostone)|Amitiza 24mcg gelcap
1850274|NCT00953017|Drug|Dulcolax (Bisacodyl)|Bisacodyl 5mg tab x2
1850275|NCT00953017|Drug|Golytely (polyethylene glycol)|Golytely 1 gallon
1850276|NCT00953030|Behavioral|COACH|
1850277|NCT00953030|Behavioral|RealAge|
1850278|NCT00953043|Drug|lubiprostone|Lubiprostone 24 micrograms, one dose daily for three days in 30 subjects
1850279|NCT00953043|Drug|Placebo|Placebo medication given for three days
1850280|NCT00953043|Other|Bowel preparation|Polyethylene glycol-based bowel preparation
1850281|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|"Single 2.0 mL dose V260 (RotaTeq™) administered orally at enrollment.
The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
1850282|NCT00953056|Biological|Comparator: Placebo|Single 2.0 mL dose of matching placebo to RotaTeq™ administered orally at enrollment.
1850283|NCT00953056|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|"Three 2.0 mL doses of RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
The 2-mL vaccine consists of an oral solution of 5 live human-bovine reassortant rotaviruses."
1850284|NCT00953056|Biological|Comparator: Placebo|Three 2.0 mL doses of matching placebo to RotaTeq™ administered orally at 3 separate visits scheduled 28 to 70 days apart. The third dose was administered by 32 weeks of age.
1850285|NCT00953095|Behavioral|Joint Attention Intervention|Intervention in both conditions occurs once a week for 2 hours. Participants will be randomized to 1 of 2 interventions : (1) Caregiver Mediated Model (CMM):focuses on joint attention/engagement and involves individual meetings with the parents and children at their homes. Parents will be specifically taught techniques for altering the home environment and ways to enhance children's language, social, and play development. Parents will given guided practice (input/ coaching from the interventionist) as they implement these techniques with their child. (2) Caregiver Education Model (CEM): focuses on teaching parents information about autism, behavior modification, and community services. Parents will receive information on child development each week, and will be able to ask questions and discuss the information. Parents meet in a group (without their children) in a community-based setting to receive the intervention.
1850286|NCT00953108|Drug|quetiapine|300 mg per day
1850287|NCT00953108|Drug|escitalopram|escitalopram 10 mg per day
1850288|NCT00953121|Drug|bevacizumab and CPT-11 and Carboplatin|Bevacizumab will be administered at 10mg/kg with irinotecan every other week. The dose of irinotecan will be 125 mg/m2 for patients not on CYP3A-inducing anti=epileptics (EIAEDs) and 340 mg/m2 for patients on EIAEDs. All patients will also receive carboplatin on day 1 of each 28-day treatment cycle. Carboplatin will be dosed to achieve an AUC of 4.
1850289|NCT00953134|Dietary Supplement|Ferrous fumarate (iron)|60 mg of ferrous fumarate
1850290|NCT00953134|Dietary Supplement|folic acid|400 mcg folic acid
1850291|NCT00953147|Drug|Ciclesonide HFA 80 mcg|Ciclesonide HFA Nasal Aerosol 80 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
1850292|NCT00953147|Drug|Ciclesonide HFA 160 mcg|Ciclesonide HFA Nasal Aerosol 160 mcg once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
1850293|NCT00953147|Drug|Placebo|Placebo HFA Nasal Aerosol once daily for 6 months in the treatment of Perennial Allergic Rhinitis (PAR) in subjects 12 years and older.
1850294|NCT00953160|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
1850296|NCT00953186|Device|hyperbaric air|air at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
1850297|NCT00953186|Device|HBOT|100 % oxygen at 2,5 atmospheres for 90 minutes/day, 5 days a week for 8 weeks treatment given in hyperbaric chamber
1850298|NCT00953199|Drug|Lidocaine Hydrochloride|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with lidocaine 2% (5 ml) used at ERCP. Lidocaine will only be used once, and thus a maximum dose of 100 mg will be employed. If the patient requires more contrast agent, this will be used without the addition of lidocaine.
1850299|NCT00953199|Drug|Normal Saline|1:1 combination of contrast dye Diatrizoate 60% (5 ml) diluted with normal saline 0.9% (5 ml) used at ERCP (standard of care).
1850300|NCT00953212|Drug|beta blockers|metoprolol 25mg by mouth every 6 hours
1850301|NCT00953212|Drug|amiodarone|amiodarone 600mg by mouth evening before surgery amiodarone 600mg by mouth morning of surgery amiodarone 400mg by mouth every 12 hours for 3 days postoperatively
1850302|NCT00953212|Drug|ascorbic acid|ascorbic acid 2,000mg by mouth evening before surgery ascorbic acid 2,000mg by mouth morning of surgery ascorbic acid 1,000mg by mouth every 12 hours for 5 postoperative days
1850305|NCT00953264|Behavioral|lifestyle|lifestyle intervention, including diet, physical activity and behavioral changes
1850306|NCT00953277|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve scaffold at the time of surgery.
1850307|NCT00953290|Device|Cutera Radio Frequency Device|Up to three treatments, one pass, dosage range of 15-60 kJ.
1850308|NCT00953303|Drug|glucocorticoid|One dose of Dexamethasone (20mg/day) followed by prednisone 1mg/kg/day with a maximum dose of 60mg/day.
1850309|NCT00953303|Drug|standard care|The patients will be given standard care such as diuretics, inotropic and/or vasodilator in acute decompensated congestive heart failure management.
1850310|NCT00953316|Other|Measure infant's jaw, record all information about car seat testing, and administer questionnaires.|Collect information about car seat testing of infants (until he/she transitions to a car seat), measure the infant's jaw during the first visit using a tape measure 18 different ways by Dr. Rhein or a trained research assistant, and complete a parent questionnaire about car bed use, previous testing of the infant in his/her car seat and information about the infant's home environment such as cigarette smoking, number of other children and daycare arrangements for the infant during the infant's first visit to the clinic. This short questionnaire asks information about car bed use, previous testing of your infant in his/her car seat and information about your home environment such as cigarette smoking, number of other children at your home and daycare arrangements for your infant.
1850311|NCT00953329|Drug|alefacept|Alefacept 15 mg IM once a week were to be administered for 12 weeks, which is the FDA approved dosage, duration, and frequency. This study allowed an additional 8 doses if subject did not achieve a 'clear' response with the original 12 weeks of treatment. Each enrolled subject must have failed a response to anti-TNF therapy prior to entering this study.
1850312|NCT00953342|Behavioral|Aerobic exercise|12 weeks of supervised exercise, 3 x week, 1 hour sessions
1850313|NCT00953342|Behavioral|Usual care|Standard medical care
1850314|NCT00953355|Drug|Folate plus metformin|A six-month course of metformin (1700 mg daily) plus folic acid (400 microgram daily).
1850315|NCT00953355|Drug|Placebo plus metformin|A six-month course of metformin (1700 mg daily) plus placebo
1850316|NCT00953368|Procedure|remote ischemic preconditioning|Remote ischemic preconditioning will be induced by four 5-min cycles of upper limb ischemia and 5-min reperfusion with a blood-pressure cuff inflated to 200 mmHg and be performed before and after the coronary anastomosis
1850317|NCT00953381|Drug|5 mg ilaprazole|One 5-mg ilaprazole tablet (Livzon Pharm Group Inc., China) together with three placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
1850318|NCT00953381|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with two placebo tablets and one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
1850319|NCT00953381|Drug|20 mg ilaprazole|Four 5-mg ilaprazole tablets together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks
1850320|NCT00953381|Drug|20 mg omeprazole|One 20-mg omeprazole capsule (AstraZeneca, Losec) together with four placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
1850321|NCT00953394|Drug|continuous 5 fluouracil infusion plus long-acting octreotide|long-acting octreotide acetate at a dose of 20 mg was administered intramuscularly every 4 weeks. 5fluorouracil was given as a protracted continuous infusion without interruption at a daily dose of 200 mg/m2 of body-surface area through an elastomeric pump connected to a central venous access.
1850322|NCT00953407|Device|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
1850323|NCT00953407|Device|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
1850324|NCT00953407|Device|Etafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
1850325|NCT00953407|Device|Omafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
1850326|NCT00953407|Device|Hilafilcon B contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
1850327|NCT00953420|Drug|Docetaxel|60 mg/m2 IV on Day 1
1850328|NCT00953420|Drug|Carboplatin|Target AUC of 5 (mg/ml x min) on Day 1
1850329|NCT00953420|Drug|Dexamethasone|5 mg/m2/dose (max of 8 mg/dose) po q hs on Day 0, and q am and hs on Day 1
1850330|NCT00953420|Biological|EBV-specific cytotoxic T lymphocytes|1 x 10e8 cells/m2 IV over 1 to 5 min
1850331|NCT00953420|Biological|G-CSF or Peg-GCSF|If needed per dose modification guidelines: Peg-GCSF 0.1 mg/kg ≤ 45 kg; 6 mg for > 45 kg subcutaneous on Day 2 or GCSF 5 mcg/kg/day (max of 600 mcg) subcutaneous to start 24 hours after carboplatin administration until ANC > 2500 cells/ul x 2 days after nadir.
1850332|NCT00953433|Device|Endoflex tube|Size decided upon gender.
1850333|NCT00953433|Device|Polyvinyl chloride endotracheal tube with a stylet|Size decided upon gender.
1850334|NCT00953446|Procedure|Arterial Spin Labeling Blood Flow Magnetic Resonance Imaging|Performed at baseline, 2 weeks upon initiation of therapy, after cycle 2 and/or cycle 4 of therapy, and at the end of treatment
1850335|NCT00953459|Drug|sunitinib malate|
1850336|NCT00953459|Other|laboratory biomarker analysis|
1850337|NCT00953459|Radiation|fludeoxyglucose F 18|
1850338|NCT00953472|Drug|brain natriuretic peptide|start 10 mcg/kg (2 participants), 7 mcg/kg (2 participants), 5 mcg/kg (2 participants) and 2 mcg/kg (2 participants)
1850339|NCT00953472|Other|no-added salt diet|instruction to reduce salt for one week prior to study
1850340|NCT00953485|Biological|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10^6 cells/kg body weight).
1850341|NCT00953498|Drug|pioglitazone|After randomization, patients will be treated by pioglitazone or rosiglitazone
1850342|NCT00953498|Drug|rosiglitazone|treatment with rosiglitazone at a dose between 4mg and 8 mg/day
1850343|NCT00953511|Genetic|ERCC1 pathways analysis|The gene polymorphism of ERCC1 rs11615 and the pathways of ERRC1 will be analyzed in endoscopic tumor biopsies as well as in normal tissues prior to therapy. The results will be compared with histopathologic response after neoadjuvant therapy.
1850344|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (7.5 µg of HA)|0.5 mL, Intramuscular on Day 0 and on Day 21
1850345|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (15 µg of HA)|0.5 mL, Intramuscular on Day 0 and Day 21
1850346|NCT00953524|Biological|Monovalent Subvirion A/H1N1 Influenza vaccine (30 µg of HA)|0.5 mL, Intramuscular on Day 0 and day 21
1850347|NCT00953524|Biological|Normal saline solution (placebo)|0.5 mL, Intramuscular on Day 0 and Day 21
1850348|NCT00953537|Drug|capecitabine|
1850349|NCT00953537|Other|laboratory biomarker analysis|
1850350|NCT00953537|Other|pharmacological study|
1850351|NCT00953550|Drug|Rocuronium-Sugammadex|Rocuronium 1,0 mg/kg is administered iv initially. Upon intubation Sugammadex is administered 16 mg/kg iv.
1850352|NCT00953550|Drug|Succinylcholine|1 mg/kg
1850353|NCT00953563|Device|Unite Biomatrix|collagen based, decellularized equine pericardial dressing for skin surface wounds
1850354|NCT00953576|Drug|ketoconazole|Taken orally three times daily
1850355|NCT00953576|Drug|hydrocortisone|Taken orally twice daily
1850356|NCT00953576|Drug|dutasteride|Taken orally once a day
1850357|NCT00953576|Drug|lapatinib|Starting week 5, taken orally once daily
1850358|NCT00953589|Drug|ribavirin|Ribavirin - oral administration Subjects with body weight < 65 kg: 800 mg/day Subjects with body weight 65-85 kg: 1000 mg/day Subjects with body weight 86-105 kg: 1200 mg/day Subjects with body weight > 105 kg: 1400 mg/day
1850359|NCT00953602|Other|Genetically modified potato|Genetically modified potato
1850360|NCT00953615|Drug|Thalidomide|Titrate to 400 mg daily for 6 months
1850361|NCT00953628|Drug|10000 IU urinary HCG|bolus 10000 units for ovulation triggering
1850362|NCT00953628|Drug|250 mcg recombinant HCG|bolus 250 mcg for ovulation triggering in IVF patients
1850363|NCT00953641|Drug|Misoprostol|Misoprostol 400ug, suspended in a base (Witepsol 15) as a vaginal suppository Single dose 12h or more prior to the procedure
1850364|NCT00953641|Drug|Placebo|Witepsol 15 base, vaginal suppository, Single dose, 12h or more prior to the endometrial biopsy
1850365|NCT00953654|Other|Strength Training|6 weeks of strength training exercise sessions involving leg press, leg curl, and leg extension exercises twice weekly at an intensity progressing from 50% to 75% of predicted one-repetition maximum across the 6 weeks of the trial.
1850366|NCT00953654|Other|Endurance Training|Six weeks of lower-body dynamic cycling exercise completed on an electronically-braked cycle ergometer twice weekly. The intervention will be matched to the strength training intervention on total work completed, total time actively engaged in exercise, a focus on leg muscles, and load (intensity) progression across the 6 week training protocol.
1850367|NCT00953667|Drug|Immediate Release Niacin, Extended Release Niacin, Endotoxin|Subjects receive a one-time 1000mg dose of immediate release Niacin (Niacor pills), a one-time 1000mg dose of extended release Niacin (Niaspan pill) and one-time 1ng/kg injection of endotoxin (LPS).
1850368|NCT00953680|Drug|losartan potassium (+) hydrochlorothiazide (HCTZ)|Single dose losartan 100 mg/HCTZ 12.5 mg combination tablet in one of two treatment periods.
1850369|NCT00953680|Drug|losartan potassium|Single dose losartan 100 mg tablet in one of two treatment periods.
1850370|NCT00953680|Drug|hydrochlorothiazide (HCTZ)|Single dose HCTZ 12.5 mg capsule in one of two treatment periods.
1850371|NCT00953693|Procedure|Biopsy|Skin biopsy
1850372|NCT00953706|Drug|Ivacaftor|Tablet
1850373|NCT00953706|Drug|Placebo|Tablet
1850374|NCT00953719|Device|36 mm ceramic head on a ceramic acetabular liner|Total hip replacement with a 36 mm ceramic head on a ceramic liner
1850375|NCT00953719|Device|28 mm ceramic head on a polyethylene acetabular liner|Total hip replacement with a 28 mm ceramic head on a polyethylene liner.
1850376|NCT00953732|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
1850378|NCT00953758|Drug|PF-04449913|Escalating doses of PF-04449913 administered as tablets PO QD continuously in 28 day cycles
1850379|NCT00953771|Drug|Danazol|Danazol 600 mg PO will be initiated with plasma exchange and corticosteroids at the time of enrollment.
1850380|NCT00946569|Drug|JNJ39758979|Participants will receive capsule-shaped tablet of JNJ39758979 300mg once daily orally for 12 weeks.
1850381|NCT00946569|Drug|Placebo|Participants will receive matching placebo once daily orally for 12 weeks.
1850382|NCT00946582|Behavioral|Barkley's parenting management program|It is a parent training group to teach behavior therapy techniques to parents of children with ADHD. The group will contain about 10 parents of children with ADHD. It will be conducted 1.5 hour per session, one session per week, and 11 sessions totally.
1850383|NCT00946595|Drug|efavirenz/emtricitabin/tenofovir|1x600/200/245 mg per day (one tablet) between W0 et W98
1850384|NCT00946595|Drug|lopinavir/ritonavir|4 x 200/50 mg (4 tablets) once a day between W0 and W98
1850385|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fasting Conditions (Sandoz, Inc.)|
1850386|NCT00946608|Drug|Loratadine 10 mg Tablets Under Fed Conditions (Sandoz, Inc.)|
1850387|NCT00946608|Drug|Claritin (Loratadine) 10 mg Tablets Under Fed Conditions (Schering)|
1850388|NCT00946621|Drug|Ramipril 10 mg Capsule (Sandoz)|
1850389|NCT00946621|Drug|Altace (Ramipril) 10 mg Capsule (Aventis Pharmaceutical)|
1850390|NCT00946634|Drug|Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. After a last foaming with ozone gas (Philozon, Santa Catarina, Brazil) at 40mg/L concentration.
1850391|NCT00946634|Drug|Control (no last irrigation)|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes.
1850392|NCT00946634|Drug|Aqueous Ozone|Regular endodontic protocol preconized by University of Sao Paulo. Root canal irrigation with 1% Sodium Hypochlorite associated to Endo PTC (10mL), final irrigation with EDTA-T 17% remaining for 3 minutes. A last irrigation with 10mL of ozonated water at 40mg/mL concentration
1850393|NCT00946647|Drug|Panobinostat (LBH589) and 5-Azacytidine|"Each dose of panobinostat should be taken with 240 mL of water. Patients should be instructed to swallow the capsules whole and not chew them.
If the patient forgets to take his/her dose during the morning on a scheduled treatment day then the missed dose should be taken on that same day within 12 hours. After more than 12 hours, that day's dose should be withheld, and the patient should wait to take panobinostat until the next scheduled treatment day. The patient should then continue treatment with the original dosing schedule.
The days when panobinostat and 5-Aza are scheduled together (Day 3 and Day 5 of a treatment cycle), panobinostat should be administered approximately 30 min prior to 5-Aza."
1850394|NCT00946647|Drug|5-Azacytidine|
1850395|NCT00946673|Drug|Vorinostat|Orally up to 400 mg
1850396|NCT00946673|Procedure|Radiation Therapy|Single fraction stereotactic radiotherapy - Standard of Care
1850408|NCT00946712|Other|Laboratory Biomarker Analysis|Correlative studies
1850409|NCT00946712|Drug|Paclitaxel|Given IV
1850410|NCT00946725|Drug|Atenolol (Tenormin) 100 mg Tablets Zeneca (Astra Zeneca Pharmaceutical)|
1850411|NCT00946725|Drug|Atenolol 100 mg Tablets (Geneva Pharmaceutical, Inc.)|
1850412|NCT00946738|Other|Biofeedback|Biofeedback training as behaviour treatment was performed thrice weekly for 4 week.
1850413|NCT00946738|Other|Deep oscillation|Deep oscillation providing a pulsing electromagnetic field was performed thrice weekly for 4 weeks.
1850414|NCT00946751|Drug|Levetiracetam Tablets, 750 mg (Sandoz Inc.)|
1850415|NCT00946751|Drug|Keppra (Levetiracetam) Tablets, 750 mg (UCB Pharma, Inc)|
1850416|NCT00946764|Drug|Imipramine Hydrochloride 50 mg Tablets (Sandoz Inc.)|
1850417|NCT00946764|Drug|Tofranil Imipramine Hydrochloride 50 mg Tablets (Tyco Healthcare)|
1850418|NCT00946777|Other|Systane® Ultra|Systane® Ultra 1-2 drops, 4 times per day for 30 days
1850419|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg (Geneva Pharmaceutical, Inc.)|
1850420|NCT00946790|Drug|Hydroxychloroquine Sulfate Tablets, 200 mg, Plaquenil (Sanofi Winthrop)|
1850421|NCT00946803|Behavioral|Patient-Controlled Cognitive-Behavioral Intervention|Selection of 12 recorded imagery- and non imagery-based cognitive-behavioral coping strategies provided on an MP3 player to be used at least once per day or more frequently, as needed for pain, fatigue, and sleep disturbance.
1850422|NCT00946816|Behavioral|Nutritional Intervention|Nutritional Intervention
1850423|NCT00946829|Drug|telmisartan|
1850424|NCT00946842|Drug|Treatment A|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
1850425|NCT00946842|Drug|Treatment B|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
1850426|NCT00946842|Drug|Treatment C|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose with food on Day 1, Day 30 and Day 58.
1850427|NCT00946842|Drug|Treatment D|Participants will receive phase II clinical study tablet formulation of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
1850428|NCT00946842|Drug|Treatment E|Participants will receive newly developed tablet formulation with fine particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58.
1850429|NCT00946842|Drug|Treatment F|Participants will receive newly developed tablet formulation with coarse particle size distribution of TMC207 100 mg as a single oral dose without food on Day 1, Day 30 and Day 58
1850431|NCT00946894|Procedure|Total thyroidectomy|Total thyroidectomy
1850432|NCT00946894|Procedure|Dunhill operation|Unilateral total thyroid lobectomy and contralateral subtotal thyroid lobectomy
1850433|NCT00946894|Procedure|Bilateral subtotal thyroidectomy|Bilateral subtotal thyroidectomy
1850434|NCT00946907|Drug|Aspirin|3000mg/day of aspirin during the 4th first days and 2000mg/day of aspirin during the 17th following days
1850435|NCT00946907|Drug|placebo|3000mg/day of aspirin during the 4th first days and 2000mg/day of placebo during the 17th following days
1850436|NCT00946920|Drug|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. A starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations).
1850437|NCT00946920|Drug|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. An initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants).
1850438|NCT00946933|Dietary Supplement|NH4Cl (ammonium chloride)|0.2 g/kg/day of NH4Cl (ammonium chloride)
1850439|NCT00946933|Dietary Supplement|placebo|0.025 g/kg/day of NaCl (sodium chloride)
1850440|NCT00946946|Drug|Azathioprine|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
1850441|NCT00946946|Drug|Mesalazine|4g Mesalazine tablets/day AND azathioprine placebo tablets
1850442|NCT00946946|Drug|Azathioprine placebo|4g Mesalazine tablets/day AND azathioprine placebo tablets
1850443|NCT00946946|Drug|Mesalazine placebo|2.0-2.5mg/kg/BW azathioprine /day and mesalazine placebo tablets
1850444|NCT00946959|Procedure|Cardiac surgery|A study-certified cardiothoracic surgeon must deem a patient, who otherwise fulfills all inclusion and exclusion criteria for any cardiac surgery (conventional, off-pump cardiac surgery). The procedure must be performed as soon as possible.
1850445|NCT00946972|Drug|JNJ-38431055; Placebo|
1850446|NCT00946985|Drug|paliperidone palmitate|50, 75, 100, or 150 mg eq. monthly injection for 2 years
1850447|NCT00946985|Drug|oral risperidone|2, 4, 6, or 8 mg tabs once daily for two years
1850448|NCT00946998|Drug|Sertraline|Sertraline is a serotonin-selective reuptake inhibitor (SSRI) used to treat major depression. Dosage will begin at 50 mg/d and will be escalated by 50 mg increments every 2 weeks to a maximum of 200 mg/d
1850449|NCT00946998|Drug|placebo|Placebo tablet will be identical and matched to sertraline tablet.
1850450|NCT00947011|Drug|Placebo|1 tablet 100 mg once a day
1850451|NCT00947011|Drug|Januvia|1 tablet 100 mg once a day
1850452|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered Immediately After a Standard Breakfast.|
1850453|NCT00947024|Drug|10 mg Glucotrol Tablet (Roerig), Administered Immediately After a Standard Breakfast.|
1850454|NCT00947024|Drug|10 mg Glipizide Tablet (Geneva Pharmaceutical, Inc.), Administered After an Overnight Fast.|
1850455|NCT00947037|Drug|AP-CD/LD|
1850456|NCT00947050|Other|dynamic physical exercise|dynamic supine bicycle exercise for 6 minutes
1850457|NCT00947063|Drug|Promethazine HCl 50 mg Tablets (Sandoz, Inc)|
1850458|NCT00947063|Drug|Phenergan (Promethazine HCl) 50 mg Tablets (Wyeth Laboratories)|
1850459|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Geneva Pharmaceutical, Inc)|
1850460|NCT00947076|Drug|Fluoxetine Hydrochloride Capsules, 40 mg (Prozac) (Eli Lilly)|
1850461|NCT00947089|Device|oxidized regenerated cellulose (Fibrillar SURGICEL)|one gauze made of ORC
1850462|NCT00947089|Device|iodoform gauze|one iodoform gauze
1850463|NCT00947102|Other|Observation|
1850464|NCT00947115|Procedure|Blood sampling|Blood samples will be collected at Years 5, 6, 7, 8, 9 and 10
1850465|NCT00947115|Procedure|Cervico-vaginal secretion (CVS) samples|CVS will be collected at Years 5, 6, 7, 8, 9 and 10 in subjects who volunteer for this procedure.
1850466|NCT00947128|Drug|Ondansetron HCl 24 mg Tablets (Sandoz, Inc.)|
1850467|NCT00947128|Drug|Zofran (Ondansetron HCl) 24 mg Tablets (GlaxoSmithKline)|
1850472|NCT00947154|Drug|aripiprazole|aripiprazole dose of 5 mg/d, which could be reduced to 2 mg/d if the initial dose was not tolerated. Dose was increased by up to 5 mg at intervals of 2 weeks until a maximum target dosage of 15 mg/d was reached at the beginning of week 5. Dose was not increased if the subject showed clinical improvement at a lower dose, defined as a 50% reduction in Massachusetts General Hospital Hair Pulling Scale (MGHHPS), or was intolerant of a further dosing increase. Dose was not increased after week 5; at any point, it could be decreased secondary to side effects.
1850473|NCT00947167|Drug|pertuzumab|840 mg, 420 mg, iv
1850474|NCT00947167|Drug|erlotinib|150 mg, PO
1850478|NCT00947193|Drug|Ataluren (PTC124)|Ataluren (PTC124) will be provided as a vanilla-flavored powder to be mixed with water or milk. Ataluren (PTC124) will be taken 3 times per day, with dosing based on the patient's body weight. The dose level for ataluren (PTC124) will be 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 14 days.
1850479|NCT00947206|Behavioral|LHWO about CRC|2 LHWO sessions and 2 telephone calls aimed at increasing their CRC screening receipt
1850480|NCT00947206|Behavioral|Nutrition Education + CRC brochure|Bilingual CRC brochure as well as a lecture on healthy nutrition for cardiovascular health and a post-intervention LHWO session on CRC screening.
1850481|NCT00947219|Device|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
1850482|NCT00947219|Device|Control device|Device is used 3 times a week on non-consecutive days
1850483|NCT00947232|Behavioral|Motivational interviewing|Motivational interviewing, a proven counseling method that centers on individual goals and motivations, to increase exercise and decrease depression.
1850484|NCT00947232|Behavioral|Education|Educational intervention about the benefits of physical activity to decrease depression for people aging with multiple sclerosis or spinal cord injury.
1850485|NCT00947245|Drug|BMS-791325|Capsules, Oral, 300 mg, Single Dose, One day
1850486|NCT00947245|Drug|BMS-791325|Capsules, Oral, 900 mg, Single Dose, One day
1850487|NCT00947245|Drug|BMS-791325|Capsules, Oral, ≤1200 mg, Single Dose, One day
1850488|NCT00947245|Drug|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 14 days
1850489|NCT00947245|Drug|BMS-791325|Capsules, Oral, 900 mg, once daily 14 days
1850490|NCT00947245|Drug|BMS-791325|Capsules, Oral, ≤1200 mg, Every 12 hours or once daily, 14 days
1850491|NCT00947245|Drug|Placebo|Capsules, Oral, Single Dose, One day
1850492|NCT00947245|Drug|Placebo|Capsules, Oral, Every 12 hours, 14 days
1850493|NCT00947245|Drug|Placebo|Capsules, Oral, Once Daily, 14 days
1850494|NCT00947245|Drug|Placebo|Capsules, Oral, Every 12 hours or once daily, 14 days
1850547|NCT00947570|Behavioral|Cognitive behavioral therapy for anxiety|10 sessions delivered over the course of 14 weeks and aimed at reducing pathological behaviors and patterns of thought
1850548|NCT00947583|Biological|Osteocel Plus|biologic
1850495|NCT00947258|Other|Stretching|Participants were divided into 3 groups. The group was referred to stretching 3 weekly for 4 consecutive weeks. Group B went 4 weeks without any intervention and held only one stretch before the re-test. And the group C performed passive knee mobilization. All participants were assessed for goniometry of the knee in flexion and extension and peak torque and power on the isokinetic dynamometer.
1850496|NCT00947271|Behavioral|DVD 1|The first version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident sexually transmitted diseases [STDs]) and improve health
1850497|NCT00947271|Behavioral|DVD 2|The second version of a 20-minute educational DVD aimed to help adult patients reduce sexual risk behaviors (i.e., number of partners, unprotected sex, incident STDs) and improve health
1850498|NCT00947284|Drug|nalbuphine plus naloxone|single dose administered intravenously
1850499|NCT00947284|Drug|nalbuphine plus saline|single dose administered intravenously
1850500|NCT00947284|Drug|naloxone plus saline|single dose administered intravenously
1850501|NCT00947297|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4 mL) delivers equivalent of PBA that 40 tablets of NaPBA do.
1850502|NCT00947310|Device|Standard ICD programming|Standard ICD programming
1850503|NCT00947310|Device|High rate cutoff|Programming of a high rate cutoff
1850504|NCT00947310|Device|Long delay|Programming of a prolonged delay
1850505|NCT00947323|Drug|Simvastatin|simvastatin 20 daily for six months.
1850506|NCT00947323|Drug|Placebo|
1850507|NCT00947336|Drug|Norfloxacin + Synbiotic|Norfloxacin 400 mg once daily with synbiotic capsules (Streptococcus faecalis JPC 30 million, Clostridium butyricum 2 million, Bacillus mesentericus JPC 1 million, Lactobacillus sporogenes 50 million spores) 2 t.i.d.
1850508|NCT00947336|Drug|Norfloxacin + Placebo|Norfloxacin 400 mg once daily with placebo
1850509|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
1850510|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
1850511|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
1850512|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
1850513|NCT00947349|Drug|BI 201335 NA low placebo|Placebo
1850514|NCT00947349|Drug|pegylated interferon (PegIFN) alfa-2a|pegylated interferon (PegIFN) alfa-2a
1850515|NCT00947349|Drug|ribavirin (RBV)|ribavirin (RBV)
1850516|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
1850517|NCT00947349|Drug|BI 201335 NA low|BI 201335 NA
1850518|NCT00947349|Drug|BI 201335 NA high placebo|placebo
1850519|NCT00947349|Drug|BI 201335 NA high|BI 201335 NA high
1850520|NCT00947349|Drug|Placebo|
1850521|NCT00947362|Other|Electro-thermo-coagulation|
1850522|NCT00947362|Drug|DAC N-055|moist wound treatment plus 0.05 % pharmaceutical chlorite
1850523|NCT00947362|Drug|saline|physiological saline
1850526|NCT00947388|Drug|Bendamustine Hydrochloride|Bendamustine 70 mg/m2 IV Day 8 and 9 every 28 days for 6 courses of therapy
1850527|NCT00947388|Biological|Alemtuzumab|Given subcutaneously (SC)on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, and 26.
1850528|NCT00947414|Device|Extracorporeal shockwave therapy|Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises
1850529|NCT00947414|Device|Sham extracorporeal shock wave plus gluteal strength exercise|Sham extracorporeal shock wave plus gluteal strength exercise
1850530|NCT00947427|Drug|canakinumab (anti IL-1beta)|canakinumab subcutaneous injections given at 2.0mg/kg dose on monthly basis for 12 months
1850531|NCT00947427|Drug|Placebo|Placebo subcutaneous injections
1850532|NCT00947440|Drug|ABT-072|See arm description for more information
1850533|NCT00947453|Drug|montelukast|montelukast 10 mg once daily for 8 weeks
1850534|NCT00947466|Drug|Buprenorphine|Transdermal patch
1850535|NCT00947479|Other|continuous positive airway pressure (CPAP)|After being qualified into the study according to the aforementioned inclusion criteria and after giving an informed consent the polysomnography will be performed in all patients during night rest.In all patients eligible to sleep apnea treatment according to apnea/hypopnea index (AHI, number of apneic/hypopneic episodes per 1 h of effective sleep) from diagnostic polysomnography, CPAP treatment will be introduced under polysomnographic surveillance and the same panel of clinical and biochemical parameters will be evaluated.
1850536|NCT00947492|Biological|Venous blood sample|Venous blood sample twice a year during 3 years
1850537|NCT00947505|Device|HairMax LaserComb 2009, 7 Beam|Device application 3 times week (non-consecutive days), for 26 weeks
1850538|NCT00947505|Device|HairMax LaserComb|Device application 3 times week (non-consecutive days), for 26 weeks
1850539|NCT00947518|Drug|Chlorhexidine|Baby wipes containing 0.25% free chlorhexidine (equivalent to 0.44% chlorhexidine digluconate)
1850540|NCT00947518|Drug|Normal saline|Cleansing the skin (except the face)with baby wipes containing normal saline
1850541|NCT00947531|Drug|Cerebrolysin|
1850542|NCT00947531|Drug|0.9% Saline Solution|
1850543|NCT00947544|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NapBA do.
1850544|NCT00947544|Drug|NaPBA|NaPBA tablets for oral administration and NaPBA powder for oral, nasogastric, or gastrostomy tube administration contain the active ingredient sodium phenylbutyrate. NaPBA is a prodrug and is rapidly metabolized to PAA, the metabolically active compound that conjugates with glutamine via acetylation to form PAGN, which is excreted by the kidneys.
1850545|NCT00947557|Drug|Dutogliptin|Dutogliptin oral administration once daily on background of glimepiride with or without metformin
1850546|NCT00947557|Drug|Placebo|Placebo, oral administration once daily on background of glimepiride with or without metformin
1850549|NCT00947596|Drug|atropine sulfate|dry powder for inhalation
1850550|NCT00947596|Drug|atropine sulfate|intramuscular injection
1850551|NCT00947622|Device|Transcranial direct current stimulation|Transcranial Direct current stimulation
1850552|NCT00947635|Dietary Supplement|Dietary intervention - supplements|Supplement bar & spread formulated with key nutrients (fish oil, phytosterols, almonds, soy protein) shown to help in reducing blood lipid levels
1850553|NCT00947648|Other|Raw Fruits & Vegetables|Diet containing fresh fruits and vegetables in addition to cooked food.
1850554|NCT00947648|Other|Cooked Foods|Diet containing only cooked foods.
1850555|NCT00947661|Drug|SPARC0912|Eye drops, once daily, 12 weeks
1850556|NCT00947661|Drug|Reference0912|Eye drops, once daily, 12 weeks
1850557|NCT00947674|Device|Cellsorba EX|conduct treatment twice a week for 3 weeks and once a week for 4 weeks, total 10 times
1850558|NCT00947687|Drug|PUR003|Twice-daily (BID) doses of PUR003 will be delivered via inhalation using a commercially available nebulizer for a total of 7 days
1850559|NCT00947687|Drug|Placebo|
1850560|NCT00947700|Behavioral|Assessment, Monitoring & Intervention|Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
1850561|NCT00947713|Drug|low dose human chorionic gonadotropin|patients will receive low dose human chorionic gonadotropin (HCG) in combination with clomiphen citrate
1850562|NCT00947713|Drug|Clomiphen citrate plus HMG|patients will receive Clomiphen Citrate plus HMG
1850563|NCT00947726|Drug|CeraVe|Using OTC cream on foot twice daily for two weeks.
1850564|NCT00947739|Drug|Camptothecin-20-O-Propionate Hydrate (CZ48)|CZ48 will be administered in successive cohorts of 1 patient per participating site until hints of toxicity (grade 2 or worse adverse events related to the drug) are observed. Then cohort of 3+3 patients will be treated. CZ48 will be administered orally daily for 3 weeks followed by a 1 week rest. (1 course = 4 weeks). No pre-medications will be administered. Patients will be asked to drink 2 liters of fluid daily to flush the bladder.
1850565|NCT00947752|Drug|Glatiramer Acetate|Subjects received both doses once daily in a crossover fashion, for a total treatment duration of five weeks, including a one-week run-in period. Subject-reported injection pain was recorded in a daily diary.
1850566|NCT00947752|Drug|Experimental Glatiramer Acetate|GA 20 mg/0.5 mL
1850567|NCT00947765|Biological|Autologous blood injection|Patients were infiltrated with injection of 2 ml autologous blood drawn from contra lateral upper limb vein mixed with 1 ml 0.5% bupivacaine, at the lateral epicondyle according to the standard technique.
1850568|NCT00947765|Drug|Local corticosteroid injection|Patients were infiltrated with 2 milliliters of local corticosteroid (Methyl prednisolone acetate 80mg) mixed with 1 milliliters 0.5% Bupivacaine, at the lateral epicondyle according to the standard technique
1850569|NCT00947778|Other|3 sessions of evaluation tests|3 sessions of evaluation tests, each session during 15 days
1850570|NCT00947778|Other|1 training session|20 sessions of 30 minutes by week during 24 semaines
1850571|NCT00947791|Drug|ketamine|a single IV infusion of ketamine, IV 0.5 mg/kg
1850572|NCT00947791|Drug|midazolam|a single IV infusion of midazolam, 0.045 mg/kg
1850573|NCT00947817|Other|ULTRASONOGRAPHY trans-esophageal and trans-thoracic , blood test and clinic test|
1850574|NCT00947843|Drug|aspirin + pregrel (Clopidogrel resinate)|
1850575|NCT00947843|Drug|aspirin + placebo|
1850576|NCT00947843|Drug|aspirin + plavix (Clopidogrel bisulfate)|
1850577|NCT00947856|Drug|brentuximab vedotin|Every 3 weeks by IV infusion (1.2 or 1.8 mg/kg) until disease progression, unacceptable toxicity, or study closure
1850578|NCT00947882|Drug|Placebo|Mannitol 50 mg/mL solution
1850579|NCT00947882|Drug|Degarelix 10 mg|10 mg degarelix, 40 mg/mL solution
1850580|NCT00947882|Drug|Degarelix 20 mg|20 mg degarelix, 40 mg/mL solution
1850581|NCT00947882|Drug|Degarelix 30 mg|30 mg degarelix, 40 mg/mL solution
1850582|NCT00947895|Drug|Methylprednisolone|IV 1000 mg daily for 3 days
1850583|NCT00947895|Drug|ACTH|IM ACTH 80 mg/day for 5 days.
1850584|NCT00947895|Other|IV placebo|IV placebo (saline) daily for 3 days.
1850585|NCT00947895|Other|IM placebo|IM placebo (saline) daily for 5 days.
1850586|NCT00947908|Biological|Hymenoptera venom|Patients are treated with hymenoptera (bee or wasp) venom using subcutaneous injections. The initiation of immune therapy consists of a 52-hour-period in which patients are treated with increasing doses of hymenoptera venom. Afterwards, patients are treated with monthly subcutaneous injections with a fixed dose of hymenoptera venom. Blood will be collected directly before and 1 hour after initiation of immune therapy and after 12 months of immune therapy (directly before the next subcutaneous injection of hymenoptera venom).
1850587|NCT00947921|Procedure|Plasty|Restrictive Annuloplasty
1850588|NCT00947921|Procedure|Prosthesis|Valve replacement
1850589|NCT00947934|Device|Deep brain stimulation|Electrodes (Medtronic 3389) will be implanted in a bilateral way , under local anesthesia, at fornix level in its way through the hypothalamus, very visible on the MRI just before its entrance to mammilary bodies. Electrodes will be connected under general anesthesia to the pectoral sub-cutaneous pacemaker. The electric chronic stimulation (180 Hz, 2-3 V, 120 ms) will be begun the day after the operation
1850590|NCT00947947|Behavioral|Tailored Information Program for Safer Sex|Health communication intervention delivered on a laptop computer to increase positive perceptions of condoms and increase skills to use condoms.
1850591|NCT00947960|Drug|Triheptanoin|1-2g/kg of body weight per day divided into 4 doses per day.
1850592|NCT00947960|Dietary Supplement|Vegetable Oil|1-2g/kg of body weight per day divided into 4 doses.
1850593|NCT00947973|Behavioral|Challenging Horizons Program (CHP) after-school model|Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.
1850594|NCT00947973|Behavioral|Challenging Horizons Program (CHP) consultation model|Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available
1850595|NCT00947986|Other|1% Johnson's Baby Shampoo|nasal irrigation 2x a day for 4 weeks
1850598|NCT00948038|Dietary Supplement|Milk|Milk-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate adn 350 mg Ca. Three consumed each day.
1850599|NCT00948038|Dietary Supplement|Soy|Soy-based smoothie containing 170 kcal, 10 g protein, 1 g fat, 30 g carbohydrate and 30 mg Ca. Three consumed each day for 28 days,
1850600|NCT00948051|Dietary Supplement|Follow-on formula supplemented with fructo-oligosaccharides|Follow-on formula supplemented with fructo-oligosaccharides
1850601|NCT00948051|Dietary Supplement|Follow-on formula enriched with placebo (maltodextrins)|Follow-on formula enriched with placebo (maltodextrins)
1850602|NCT00948064|Drug|Vorinostat|200 mg by mouth three (3) times per day with food for 5 days (Days 1 - 5)
1850603|NCT00948064|Drug|Azacitidine|75 mg/m^2/day given intravenously over 15 - 30 minutes daily for 5 days (Days 1 - 5)
1850604|NCT00948077|Drug|Rifater and EMB|"The main difference between Treatment A and Treatment B is the time of taking drugs, so the intervention of this study belongs to a behavioral intervention.
The patients assigned randomly the Arm Treatment A on the fifth day will be switched to the Arm Treatment B on the sixth day. On the other hand, the patients assigned randomly the Arm Treatment B on the fifth day will be switched to the Arm Treatment A on the sixth day. The flow of intervention is drawn as below.
Treatment A (5th day) ---> Treatment B (6th day) ; Treatment B (5th day) ---> Treatment A (6th day)"
1850605|NCT00948090|Drug|IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)|Pk-directed IV Busulfan (based on test dose method) for 4 days followed by Etoposide 1400mg/m2 QD for one day and Cyclophosphamide 2.5 g/m2 QD for two days followed by autologous stem cell transplant.
1850606|NCT00948103|Drug|Nitrous Oxide|nitrous oxide inhalation during intravesical injection. Dose depends on gender and pain
1850607|NCT00948103|Drug|Oxygen|oxygen
1850608|NCT00948129|Behavioral|Smoking cessation training, support, and telephone follow-up|Brief coach advice to quit smoking, nicotine replacement therapy (NRT), and self-help written materials
1850609|NCT00948129|Behavioral|Smoking cessation intervention|SC components plus a single motivational interviewing counseling session and a cell phone-delivered text/graphical messaging component
1850610|NCT00948129|Behavioral|Weekly Telephone Coaching|SC and EC components plus a series of 11 cell phone-delivered proactive counseling sessions and a cell phone-delivered text/graphical messaging component
1850611|NCT00948142|Drug|CEM-102|600 mg BID oral tablets for 10-14 days
1850612|NCT00948142|Drug|Linezolid|600 mg BID oral tablets
1850613|NCT00948142|Drug|CEM-102|1500 mg BID oral tablets on Day 1 followed by 600 mg BID oral tablets for a total of 10-14 days
1850614|NCT00948155|Drug|Varenicline|Intervention Drug (Varenicline (Chantix) will be administered in standard dosing in pill format: 0.5 mg days 1-3; 0.5 mg bid daily days 4-7; 1.0 mg bid daily days 8-21.
1850615|NCT00948168|Drug|exenatide (Byetta)|all patients receive 5 then 10 µg exenatide subcutaneously BID for 6 months
1850616|NCT00948194|Drug|Nitric Oxide|Inhalation - 40 ppm, at the initiation of anesthesia to the end of surgery
1850617|NCT00948207|Behavioral|My Living Story|"Components include:
1. Life Review Interview by phone (questions based on Chochinov, 2002 dignity enhancing interview);
2) Edited transcript is delivered in a word format on...;
3) miLivingStory, a personal social network, where participants can manage content, design and layer; invite and manage their fiends and family.
4) miStory, a life review education website and portal to websites for: cancer information, databases to do your own research, social support, interactive planning tools, and a page to add their own weblinks."
1850618|NCT00948207|Behavioral|My Own Resources|"miOwnResources is a personalized, password-protected web portal to high quality websites that provide cancer information, cancer research databases for do your own research, social support, and interactive planning tools. miOwnResources also has a page for participants to add their own weblinks."
1850619|NCT00948220|Drug|peginterferon alfa-2a and ribavirin|standard antiviral therapy with peginterferon alfa-2a 180 µg/week and ribavirin 1000-1200 mg/d
1850620|NCT00948233|Behavioral|Video Game|Educational anti-tobacco video game played on arcade-type kiosk for three 30-minute sessions, plus CD-ROM disc of game to use as needed, and series of illustrated materials to go along with computer sessions.
1850621|NCT00948233|Behavioral|Pamphlet|Self-help pamphlet about stopping and avoiding tobacco use, provided by the National Institutes of Health.
1850622|NCT00948233|Behavioral|Surveys|Computer surveys taken at 4 points throughout the study.
1850623|NCT00948246|Device|Easyband®|The Easyband adjustable gastric band device is implanted laparoscopically around the top of the stomach to create a small pouch. Adjustments to increase or decrease the stoma size are made non-invasively by telemetric connection between an internal and external antenna.
1850624|NCT00948259|Drug|NP031112|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
1850625|NCT00948259|Drug|Placebo|unidose sachets containing dry powder for oral suspension, once daily dosing 400 mg (4 to 20 weeks), 600 mg(4 to 16 weeks),800 mg (6 to 12 weeks), 1000 mg (6 weeks)
1850626|NCT00948272|Biological|Purified Vero Rabies Vaccine - Serum Free|0.5 mL, Intramuscular
1850627|NCT00948272|Biological|Purified inactivated rabies vaccine|0.5 mL, Intramuscular
1850629|NCT00948298|Drug|vitamin D|Two 50,000 IU tablets of oral Vitamin D3 will be given every 4 weeks.
1850630|NCT00948298|Drug|Placebo|Two tablets of oral placebo (microcrystalline cellulose),matching in appearance to the Vitamin D3, will be given every 4 weeks.
1850631|NCT00948324|Drug|CSII,ALA,MET,RSG|CSII along.ALA:CSII combined with two weeks α- thioctic acid (600mg/500ml NaCl, 0.9%), ivdrip QD. RSG:CSII combined with three months rosiglitazoneor 4mg QD. MET:CSII combined with metformin 500mg BID-TID.
1850632|NCT00948337|Behavioral|Brochure of Secondary Cancer Screening|One kind of printed educational material
1850633|NCT00948350|Procedure|awake intubation|two anesthesia techniques
1850714|NCT00957346|Drug|Placebo+Misoprostol|placebo resembling mifepristone followed 24 hours later by 400 mcg buccal misoprostol repeated every 3 hours until complete abortion or maximum of 5 doses.
1850635|NCT00953797|Device|Enhanced External Counterpulsation|A non-invasive method currently used for the treatment of ischemic coronary disease. During EECP therapy three compressive pneumatic cuffs are wrapped around the calves, lower thighs, and upper thighs. The cuffs inflate sequentially during diastole causing retrograde aortic flow, and increased venous return. At end diastole, the cuffs rapidly deflate resulting in unloading of the left ventricle and a decrease in systolic blood pressure.
1850636|NCT00953810|Other|Educational training regarding heart failure|Like control plus one education training regarding heart failure aspects and management
1850637|NCT00953849|Drug|Celecoxib|Celecoxib (400 mg twice daily)
1850638|NCT00953849|Drug|Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol 3 for each of 3 sequential days followed by 4 days of no treatment)
1850639|NCT00953849|Drug|Celecoxib plus Calcitriol|3 week pre-surgical enteral treatment of Calcitriol (1,25-dihydroxyvitamin D3) (3 cycles of 4 microg Calcitriol for each of 3 sequential days followed by 4 days of no treatment) plus Celecoxib (400 mg twice daily)
1850640|NCT00953862|Drug|Atomoxetine|In Phase II, atomoxetine was dispensed beginning at 25 mg/day. Dose was adjusted based on clinical response and tolerability over a 4-week period up to 120mg/day and held constant at the optimized level for the final 6 weeks of the trial.
1850641|NCT00953888|Drug|AZD5069|Single dose of oral solution.
1850642|NCT00953888|Drug|Placebo|Single dose of oral solution.
1850643|NCT00953901|Drug|Fresh Frozen Plasma Transfusion|
1850644|NCT00953914|Drug|Pyridostigmine|Pills containing 30 mg of Pyridostigmine will be orally administered 3 times daily for 1 day.
1850645|NCT00953914|Drug|Placebo|If subject is randomized to placebo, placebo pills will give 30 mg orally 3 times daily for 2 days
1850646|NCT00953927|Biological|MVA85A/AERAS-485|Attenuated virus MVA vector with insertion. Single dose vaccine, 1 x 10^8 pfu.
1850647|NCT00953927|Biological|Candida Skin Test Antigen|1 test, administered once as a placebo control.
1850648|NCT00953940|Drug|Isotonic saline|Isotonic saline administrated i.v at 1.5 ml/Kg/h , 8 to 12 h before surgery
1850649|NCT00953953|Device|Phillips ultrasound system|The tissue doppler imaging color images will be acquired from two, three, and four-chamber apical views to assess the longitudinal contraction of the left ventricle.
1850650|NCT00953966|Other|Genetically modified potatoes|Starch from genetically modified potatoes
1850651|NCT00953979|Drug|kunxian capsule|The main element of kunxian capsule is Tripterygium. Patients should take 2 tablets per time and 3 times per day for 12 weeks.
1850652|NCT00954005|Drug|Therapy with Rituximab, Gemcitabine and Oxaliplatin|Rituximab 375 mg/m² day 0 or 1, Gemcitabine 1.000 mg/m² in 30 Min. day 1 and 15, Oxaliplatin 70 mg/m² in 120 Min. day 1 and 15 (in phase 1 dose escalation of Oxaliplatin in steps of 10 mg/m²), repetition at day 29 for 4 cycles
1850653|NCT00954044|Behavioral|Randomized Exercise Intervention|"The Exercising Together training group will participate in 6 months of supervised, progressive partnered resistance exercise.
Couples will participate in 2 exercise sessions a week for 6 months."
1850654|NCT00954044|Behavioral|Randomized Exercise Intervention|Couples will continue doing their usual daily activities for 6 months
1850655|NCT00954057|Drug|LIPO-102|intraorbital injection
1850656|NCT00954057|Drug|Placebo|intraorbital injection
1850657|NCT00954070|Device|Confocal endomicroscope (Pentax Model EC3870K)|The intervention is an endoscopy procedure using a novel type of endoscope with a powerful confocal microscope attached to its tip. The endoscope (Pentax Model EC3870K) provides both white-light and confocal microscopic imaging.
1850658|NCT00954083|Behavioral|DIR/Floortime|Developmental, Individual-Difference, Relationship-Bases (DIR) focus more on relationship, social skills, and meaningful, spontaneous use of language and communication and integrated understand of human development
1850659|NCT00954083|Behavioral|Routine care|Routine care
1850660|NCT00954096|Drug|transdermal nicotine patch (7mg)|A 7mg transdermal nicotine patch will be applied to the subject's arm for an 8 hour period.
1850661|NCT00954109|Behavioral|Exercise|daily exercise: supervised treadmill walking or cycle ergometry use
1850662|NCT00954122|Drug|Quetiapine XR (Seroquel XR)|Tablet, oral, once daily
1850663|NCT00956917|Device|Akern USA EFG|Impedance measurement device
1850664|NCT00956917|Device|RJL Impedance analyzer|Impedance analyzer
1850665|NCT00956930|Radiation|yttrium Y 90 glass microspheres|Patients undergo radioembolization.
1850666|NCT00956930|Drug|Doxorubicin|75mg fixed dose
1850667|NCT00956943|Drug|Nicoderm CQ transdermal nicotine|Transdermal nicotine patch (21mg vs. 42mg), 8 weeks
1850668|NCT00956943|Drug|placebo|placebo patch
1850669|NCT00956956|Drug|PF-04455242|3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
1850670|NCT00956956|Drug|Placebo|Placebo administered orally Q6 hours for 7 days of dosing.
1850671|NCT00956969|Behavioral|Anger Awareness and Expression|Teaches patients to recognize, experience, and express emotions
1850672|NCT00956969|Behavioral|Relaxation Training|Teaches patients relaxation training
1850673|NCT00956982|Drug|Pegylated interferon alpha-2b plus ribavirin|All patients were treated with a weight-based, 1.5 μg/kg weekly dose of subcutaneous PEG-IFN alpha-2b (PegIntron A, Schering-Plough, Osaka, Japan), in combination with PEG-IFN alpha-2b, RBV (Rebetol; Schering-Plough), which was given orally at a daily dose of 600-1000mg based on bodyweight (600 mg for patients weighing < 60 kg, 800 mg for those weighing 60-80 kg, and 1000 mg for those weighing 80 kg). The length of treatment was 48 weeks for patients with HCV of genotype 1and 24 weeks for patients with genotypes 2, respectively
1850674|NCT00957008|Behavioral|Group weight loss program|Participants will be asked to attend 14 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 16 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a weight loss manual.
1850715|NCT00957359|Drug|Psilocybin|Psilocybin is a serotonergic hallucinogen that will be administered once at a dose of 0.3mg/kg
1850716|NCT00957372|Drug|eslicarbazepine acetate|oral tablet, 800 mg or 1200 mg once daily
1850717|NCT00957372|Drug|placebo (Part I)|once daily placebo comparator
1850884|NCT00958685|Dietary Supplement|placebo|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
1850675|NCT00957008|Other|Group weight loss program plus use of the Senseware Armband|Participants will be asked to attend 15 one-and-half-hour group sessions at the University of South Carolina's Public Health Research Center (PHRC) over a 17 week period. After the groups end, they will be asked to take part in 6 telephone calls during their remaining 2 months in the program. They will also receive a SenseWear Armband to wear during their 6 months in the program. One of these group sessions will be devoted to learning how to use the SenseWear Armband. They will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will receive a weight loss manual in addition to the group sessions and Armband.
1850676|NCT00957008|Device|Use of the senseware armband alone program|Participants will be asked to attend a one-hour group session at the University of South Carolina's Public Health Research Center (PHRC) to learn how to use the SenseWear Armband. They will then be asked to take part in a follow-up telephone call one week after they start wearing the armband. For the 6 months they are in the program, they will be asked to wear the Armband regularly, upload data from the Armband to a web-based application, and input nutritional and health information into a personalized web account. They will also receive a weight loss manual in addition to the Armband.
1850677|NCT00957021|Device|Triathlon® PS Total Knee System|Triathlon® PS Total Knee system
1850678|NCT00957034|Drug|placebo|placebo patch
1850679|NCT00957034|Drug|testosterone|300 or 450 micrograms/day transdermal testosterone patch
1850680|NCT00957047|Drug|eslicarbazepine acetate|oral tablets
1850681|NCT00957047|Drug|placebo|once daily placebo comparator
1850682|NCT00957047|Drug|ESL - Part II|Eslicarbazepine acetate was supplied as scored 800-mg tablets for daily oral administration.
1850683|NCT00957060|Drug|GLIMEPIRIDE (HOE490)|Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
1850684|NCT00957060|Drug|SITAGLIPTIN|Pharmaceutical form: 100 mg tablets Route of administration: oral
1850685|NCT00957073|Device|Rheos Baroreflex Activation System|Implant procedure
1850686|NCT00957073|Other|Standard of care medical management|Patients will continue with medical therapy for standard of care of their heart failure condition.
1850687|NCT00957086|Drug|Nimotuzumab|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
1850688|NCT00957086|Drug|Placebo|Administered by intravenous infusion at 200 mg absolute per dose, diluted in 250 ml of sodium chloride over 30 minutes. 8 weekly doses of study drug will be given, beginning on first week of radiotherapy.
1850689|NCT00957112|Procedure|acupuncture therapy|Patients undergo therapist-acupuncture with or without self-acupuncture
1850690|NCT00957112|Procedure|standard follow-up care|Patients receive standard care
1850691|NCT00957125|Drug|Epirubicin|75 mg/m2 i.v. infusion, 30 min, cycle day 1, cycles 1-6.
1850692|NCT00957125|Drug|Docetaxel|75 mg/m2 i.v. infusion, 60 min, cycles day 1, cycle 1-6.
1850693|NCT00957125|Drug|Bevacizumab|15 mg/kg, i.v. infusion, 90 min, cycle day 1, cycles 3-6 if PR or SD after cycle 2.
1850694|NCT00957151|Drug|Creon|
1850695|NCT00957164|Behavioral|Brief Prolonged Exposure Protocol|The PTSD treatment used in this study is an adaptation of a brief Prolonged Exposure treatment protocol for PTSD as illustrated in a 2005 paper published by Cigrang, Peterson, and Schobitz 54 in which a 4-session prolonged exposure treatment was used to address PTSD symptoms in three injured soldiers recently exposed to trauma. The authors found a 50+% decrease in PTSD symptoms after these four sessions. The present study will rely upon a similar brief PTSD intervention for treating chronic PTSD among trauma-exposed injured active duty service members. The PTSD intervention will be expanded into five sessions over 5 weeks to include an initial session for assessment and education on the co-morbidity of pain and PTSD. All PTSD treatment will be provided under the direct care or supervision of a Master Trained therapist in Prolonged Exposure.
1850696|NCT00957164|Behavioral|Chronic Pain Management Treatment|Pain treatment will involve five-sessions over 5 weeks of individual treatment protocol based on the existing chronic pain management program through the Clinical Health Psychology Service at Wilford Hall Medical Center. This treatment will involve covering the difference between chronic and acute pain, the role of cognitive, behavioral, and emotional variables in pain progression, and ways to manage these variables to prevent the development of chronic pain.
1850697|NCT00957164|Behavioral|Self-Care|participants randomized to either the Pain-only or PTSD-only groups will receive five sessions of pain- or PTSD-specific treatment followed by five sessions of self-care placebo over 5 weeks. The self-care module will be manualized for reliability and fidelity between providers and will involve 60-minute sessions covering various topics.
1850698|NCT00957177|Drug|Pregabalin|300mg pregabalin orally 1 hour before operation
1850699|NCT00957177|Drug|Placebo|Placebo
1850700|NCT00957190|Drug|Dorzolamide 20 mg and Timolol 5 mg|Twice daily in the affected eye(s)
1850701|NCT00957203|Drug|Istradefylline|Oral istradefylline (KW-6002) 20 or 40 mg once daily
1850702|NCT00957216|Drug|Placebo (sugar pill)|placebo: 2 wafers 4 times a day
1850703|NCT00957216|Drug|Coenzyme Q10|300mg wafers; 2 wafers 4 times a day
1850704|NCT00957229|Drug|GDC-0449|capsule, 150 mg, one pill daily, 18 months
1850705|NCT00957242|Drug|warfarin|Oral warfarin (1mg or 2.5mg) titrated to an INR of 2-3.
1850706|NCT00957242|Drug|placebo|Oral placebo (1mg or 2.5mg)
1850707|NCT00957255|Device|OrthoADAPT|soft tissue augmentation device
1850708|NCT00957255|Procedure|Standard of care|Standard of care rotator cuff repair
1850709|NCT00957268|Drug|Alogliptin|Alogliptin tablets
1850710|NCT00957320|Drug|Sirolimus|Sirolimus daily po days 1 through 28, Dose level 0: 0.25 mg/m2 po daily Dose level 1: 0.5 mg/m2 po daily Dose level 2: 1 mg/m2 po daily Dose level 3 1.5 mg/m2 po daily Dose level 4 2 mg/m2 po daily
1850711|NCT00957320|Drug|PEG-asparaginase|Subjects will receive PEG-asparaginase at a fixed weekly dose, as per published reports in relapsed childhood ALL.
1850712|NCT00957333|Other|ketamine|N.A.
1850713|NCT00957346|Drug|Mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 400 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses.
1850885|NCT00958698|Other|Communication Intervention|Ancillary studies
1850718|NCT00957372|Drug|ESL - Open-label Extension (Part II)|Part II was a 1-year open-label extension for patients who had completed Part I. Starting at 800 mg/day, the dosage could be titrated at 400 mg intervals down to a minimum of 400 mg/day or up to a maximum of 1200 mg/day
1850719|NCT00957385|Drug|Revlimid|10mgs PO daily for 21 days of each 28 day cycle. Number of cycles: total of 24 or until subject relapses or unacceptable toxicity develops.
1850720|NCT00957411|Biological|cetuximab|Given IV
1850721|NCT00957411|Drug|cisplatin|Given IV
1850722|NCT00957424|Behavioral|telephone-based intervention|10-15 minute web-based survey on a computer
1850723|NCT00957424|Drug|nicotine replacement therapy|One week supply
1850724|NCT00957424|Other|informational intervention|
1850725|NCT00957424|Other|internet-based intervention|
1850726|NCT00957424|Other|questionnaire administration|Given out week 2, 3 and 4.
1850727|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 1
1850728|NCT00957437|Drug|AZD1305|ER formulation 1, bid for 5 days
1850729|NCT00957437|Drug|AZD1305|Single Oral Dose, ER formulation 2
1850730|NCT00957476|Dietary Supplement|Omega-3 Fish Oil|800mg DHA and 1200mg EPA or the equivalent of a placebo PO (by mouth) once a day from enrollment (prior to 16 weeks gestation) until delivery.
1850731|NCT00957489|Other|Dynamax appliance|
1850732|NCT00957489|Other|Twin-block appliance|
1850733|NCT00957502|Device|ENTact™ Septal Stapler|1 year aged septal staples
1850734|NCT00957502|Device|ENTact™ Septal Stapler|18 Month Aged Staples
1850735|NCT00957528|Drug|Testosterone|Weekly im injections of 100 mg testosterone enanthate.
1850736|NCT00957528|Drug|Placebo|Weekly IM injections of sesame oil.
1850737|NCT00957541|Device|Paradym CRT + Physiological Diagnosis (PhD)|All subjects will undergo CRT therapy with the Physiological Diagnosis (PhD) feature enabled.
1850738|NCT00957554|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily
1850739|NCT00957554|Drug|irbesartan|Pharmaceutical form: 150 and 300 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily
1850740|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg twice daily (BID) on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 60 mg BID, and 75 mg BID) until Maximum Tolerated Dose (MTD) is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
1850741|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 8 mg BID on Days 1 to 21 of a 28-day cycle. The dose will be escalated to 15 mg BID, 23 mg BID, 30 mg BID, 42 mg BID, 45 mg BID, 60 mg BID, 75 mg BID, and 90 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
1850742|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally at a dose of 60 mg BID on Days 1-28 of a 28-day cycle. The dose escalation will proceed to 75 mg BID until MTD is reached. The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
1850743|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 5, 8 to 12, 15 to 19, and 22 to 26 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
1850744|NCT00957580|Drug|Pimasertib|Pimasertib will be administered orally twice daily on Days 1 to 21 of a 28-day cycle. Dose will be determined by Part 1 of the trial (could be the MTD or lower dose level). The treatment will be continued until disease progression, intolerable toxicity, or Investigator/subject decision.
1850745|NCT00957593|Drug|Oxytocin|Continuation of oxytocin once in active labor
1850746|NCT00957593|Drug|Oxytocin discontinuation|Oxytocin will be stopped once in active labor
1850747|NCT00957606|Procedure|blood sampling, DXA-scan, bone scintigraphy|Blood sampling 5 times DXA-scan 5 times Bone scintigraphy 3 times
1850748|NCT00957619|Drug|pentoxyfilline|The total dose of 1 mg/kg/h will be used. At the preoperative day half of the daily dose will be given as a 4-hour short-term infusion within 24 hours before surgery. Afterwards, a continuous intravenous infusion of PTX 1 mg/kg of body weight per hour will be started intra-operatively and will be continued for a total of 72 hours after surgery.
1850749|NCT00957619|Drug|Placebo|This group will be treated with saline solution at the same time points. The infusion volume and infusion rate of saline solution correspond to that of the PTF group.
1850750|NCT00957658|Device|Accolade® TMZF® Hip Stem|Accolade® TMZF® Hip Stem
1850751|NCT00957671|Drug|Human Growth Hormone|200 mcg daily for two months, followed by 400 mcg daily for two months followed by 600 mcg daily for term of treatment period (one year total)
1850752|NCT00957671|Drug|Placebo|Inert agent given in same manner as active drug for control purposes
1850753|NCT00957684|Drug|eslicarbazepine acetate|once-daily oral tablet
1850754|NCT00957684|Drug|placebo|once daily placebo comparator
1850755|NCT00957710|Behavioral|Errorless learning|Language testing,20 sessions of language therapy, and 2 neuroimaging sessions for participants with progressive aphasia Language testing and 1 imaging session for healthy controls
1850757|NCT00957736|Genetic|polymorphism analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
1850850|NCT00958399|Dietary Supplement|Resistant starch + soluble fiber|25 g fiber as resistant starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
1850886|NCT00958698|Other|Educational Intervention|Ancillary studies
1850758|NCT00957736|Other|laboratory biomarker analysis|Will assess the SNPs present in both the donor and to host and correlate the SNPs with outcome based in the NIH consensus criteria for cGVHD. Candidate SNPs will include but are not limited to TGF-β18, mannose binding lectin19, myeloperoxidase, HSP 70, minor histocompatability antigens, KIR, CCL513, NOD2/CARD1512, TNFα11, TNF R II, IL-1010, 11, IL-1317, IL-620, IFN-γ20, IL-1 RA21, IL-2315, and IL-1516. Other candidate genes will be assessed on current review of the literature and candidate SNPs will be added based on their relationship to aGVHD, cGVHD, autoimmune disease, pharmacogenetics, and other immunologic processes. The genes will be assessed for gene frequency using the HapMap and SNP databases prior to statistical analysis.
1850759|NCT00957749|Drug|cPMP|Intravenous solution administered daily. Dose titrated from 80 μg/kg on Days 1-12 to 120 μg/kg on Days 13-34 to 160 μg/kg for days 35-90.
1850760|NCT00957762|Other|Body composition|Day 1 testing will incorporate underwater weighing, Bod Pod, DXA, BIA and anthropometrics. Day 2 will include RMR, MRI, and testing at GCRC
1850761|NCT00957775|Behavioral|Usual care|Participants will receive the usual care (e.g., individual therapy, group therapy, family therapy, self-help groups) provided at the treatment site.
1850762|NCT00957775|Behavioral|Computer-delivered ACRA|Participants and willing caregivers will receive a computer-delivered intervention for 12 weeks, based on the Adolescent Community Reinforcement Approach to substance abuse treatment.
1850763|NCT00957788|Drug|NST-001|Comparison of different dosages of drug.
1850764|NCT00957801|Drug|Testosterone injection|150 mg single IM injection
1850765|NCT00957801|Drug|Testosterone gel|Testosterone gel 10 mg. administered topically daily for seven days
1850766|NCT00957814|Behavioral|Nutritional education|Systematic nutritional orientation program
1992796|NCT03296878|Other|Cross-Price Elasticity|The price of eggs will remain the same, but the price of other foods will be 75%, 100%, or 125% of the reference price.
1850769|NCT00957840|Procedure|NIRS, aEEG, and CSF concentration of biomarkers|NIRS and aEEg will be done twice weekly, and CSF will be analyzed with each reservoir tap
1850770|NCT00957853|Drug|Cetuximab|First dose of 400 mg/m^2 by vein on Days 1 and 8 over 2 hours, second dose of 250 mg/m^2 on week 2 and 3 (if applicable) given over 1 hour.
1850771|NCT00957853|Drug|IMC-A12|6 mg/kg/week by vein on Days 1 and 8 over 1 hour on weeks 1 and 2 and 3 (if applicable).
1850772|NCT00957853|Procedure|Surgical tumor resection|Surgical tumor resection on Day 10.
1850773|NCT00957866|Drug|Pegylated Interferons (Peg-IFN) and Ribavirin|A anti-viral regimen with a combination of pegylated Interferons (Peg-IFN) and Ribavirin
1850774|NCT00957879|Dietary Supplement|Ergocalciferol|Ergocalciferol 50000 international units by mouth weekly for 12 weeks
1850775|NCT00957879|Dietary Supplement|Calcitriol|Calcitriol 0.5 mcg by mouth daily for 12 weeks
1850776|NCT00957905|Drug|Alvocidib Hydrochloride|Given IV
1850777|NCT00957905|Drug|Fluorouracil|Given IV
1850778|NCT00957905|Drug|Leucovorin Calcium|Given IV
1850779|NCT00957905|Drug|Oxaliplatin|Given IV
1850780|NCT00957918|Drug|nicotine|Oral capsule self administered in escalating doses from 1 mg to 6 mg, 4 times a day. Each dose is is taken for two weeks, except the highest dose, which is taken for 4 weeks. At the end of 10 weeks, the dose is tapered down over 9 days. Subject is continued on study through week 14.
1850781|NCT00957918|Other|placebo comparator|oral capsules containing only excipient will be self-administered with the same regimen as the active drug, 4 times a day, approximately every 6 hours for 10 weeks and nine days. Study is continued through week 14.
1850782|NCT00957931|Procedure|Bone marrow transplantation|Bone marrow transplantation using matched unrelated donors, reduced intensity conditioning regimen, and co-transplanting mesenchymal stromal cells derived from parental bone marrow.
1850783|NCT00957931|Biological|Mesenchymal Stromal Cells|
1850784|NCT00957944|Drug|rotigotine transdermal patch (Neupro®)|Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours
1850785|NCT00957970|Device|Stemless femoral component|Total hip femoral component anatomically designed for a proximal fit without a stem
1850786|NCT00957970|Device|IPS, Depuy cementless femoral stem|Anatomical proximal fitted cementless stemmed femoral component
1850787|NCT00957983|Drug|BGC20-1531|oral administration followed by Prostaglandin E2 infusion
1850788|NCT00957996|Drug|Peramivir|300 mg twice daily
1850789|NCT00957996|Drug|Peramivir|600 mg once daily
1850790|NCT00958009|Device|Rebidose®|The device is a ready to use single use auto injector containing Rebif® 44 mcg in a 0.5 mL prefilled syringe for sc injection
1850791|NCT00958022|Drug|LBH589 and carboplatin with etoposide|"LBH589 will be given in oral formulation starting at a dose of 10 mg (Dose Level 1) 3x/week (2 days apart, e.g. Mon, Wed, Fri), during 2 weeks out of 3-weekly dosing schedule. After establishing the MTD at a 2 out 3 weeks dosing schedule, a 3 out of 3 weeks dosing schedule will be tested at that dose. This schedule will be adopted in the absence of limiting toxicities. Will be continued weekly after completion of 6 cycles of combo chemotherapy until progression or intolerable toxicities.
Etoposide: Cycles 1-6: 100 mg/m² IV over 60 mins, Days 1-3 every 21 days for 6 cycles Carboplatin: commercially available as a sterile lyophilized powder available in single dose vials containing 50mg, 150mg, or 450mg of carboplatin. Each vial contains equal parts by weight of carboplatin & mannitol. Commercial supplies will be used for this study. It will be administered as an i.v. infusion over 30 minutes. The dose will be calculated based on patient's body weight at each treatment visit."
1850792|NCT00958035|Drug|bimatoprost ophthalmic 0.03% solution|Apply one drop of study medication along the upper eyelid margin once daily in the evening
1850793|NCT00958035|Drug|vehicle sterile solution (placebo)|Apply one drop of study medication along the upper eyelid margin once daily in the evening
1850794|NCT00958048|Device|non-invasive ventilation|CPAP, BiPAP
1850795|NCT00958074|Drug|vorinostat|Given PO
1850796|NCT00958074|Other|flow cytometry|correlative study
1850797|NCT00958074|Other|laboratory biomarker analysis|correlative study
1850798|NCT00958100|Drug|tenofovir emtricitabine raltegravir|switch from current antiretroviral regimen to raltegravir with tenofovir/emtricitabine as backbone
1850799|NCT00958100|Drug|Lamivudine Abacavir Raltegravir|Switch from current antiretroviral regimen to raltegravir with abacavir/lamivudine as backbone
1850883|NCT00958685|Dietary Supplement|ginger|Study group received 1200 mg of ginger extract and control group 2 gram of coconut oil as placebo
1850800|NCT00958100|Drug|Abacavir free|Patients will receive raltegravir with tenofovir/emtricitabine; data will be added to those of Tenofovir Emtricitabine Raltegravir arm in a separate longitudinal analysis comparing data at baseline and at 48 weeks. In this separate analysis, data will not be compared to those obtained from the Lamivudine Abacavir Raltegravir arm. The number of patients in this arm is not pre-established.
1850801|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal-free.
1850802|NCT00958126|Biological|CSL425|CSL's 2009 H1N1 Influenza Vaccine, thimerosal 0.01% (weight/volume).
1850803|NCT00958126|Biological|Placebo|Vaccine diluent, thimerosal 0.01% (weight/volume).
1850804|NCT00958139|Other|Permethrin|Permethrin 0.5% treatment of clothing one time
1850805|NCT00958139|Other|Placebo|water sprayed on clothing one time
1850806|NCT00958152|Drug|VCH-222|Capsules, Oral, 400 mg, q12h, Days 1-10 and Days 28-37
1850807|NCT00958152|Drug|VCH-222|Capsules, Oral, 750 mg, q12h, Days 1-10 and Days 28-37
1850808|NCT00958152|Drug|VCH-222|Capsules, Oral, 1000 mg, q12h, Days 1-10 and Days 28-37
1850809|NCT00958152|Drug|telaprevir|Tablet, Oral, 1125 mg, q12h, Days 18-37
1850810|NCT00958165|Device|CardioFocus EAS-AC|PVI for PAF
1850811|NCT00958178|Drug|Oxygen|Experimental: Low flow Oxygen for 30 seconds then high flow for 3.5 minutes. Active comparator: High flow Oxygen for 4 minutes.
1850812|NCT00958191|Device|Trident® X3 Polyethylene Insert|Trident® X3 Polyethylene Insert
1850813|NCT00958204|Procedure|Light treatment|Light therapy: from a 10,000 lux fluorescent white light box, for 30 minutes per day upon waking in the morning, for 8 weeks.
1850814|NCT00958204|Procedure|Negative ion therapy|Negative ion therapy: from a negative ion generator with an output of 200 trillion ions per second per cubic centimeter, for 30 minutes per day upon waking in the morning, for 8 weeks
1850815|NCT00958204|Drug|Placebo|Placebo Pill: one oral tablet each day, for 8 weeks.
1850816|NCT00958204|Drug|Fluoxetine|Fluoxetine: 20 mg oral tablet each day, for 8 weeks
1850817|NCT00958217|Behavioral|Cognitive Processing Therapy-Modified (CPT-M)|Psychotherapy that focuses on thoughts associated with traumatic experiences with the goal of developing skills to reduce trauma-related symptoms. We have modified this therapy to include substance relapse prevention skills, reduce depression and substance relapse. CPT-M was delivered in individual 1-hour sessions once weekly.
1850818|NCT00958217|Behavioral|Integrated Cognitive Behavioral Therapy (ICBT)|Psychotherapy that focuses on thoughts and behaviors associated with depression with the goal of developing skills to reduce depression symptoms. We have integrated substance relapse prevention skills. ICBT was delivered in individual 1-hour sessions once weekly.
1850819|NCT00958230|Device|dCell Vascular Patch|Implantation of a dCell Vascular Patch as part of an Endarterectomy
1850820|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.5 mL intramuscular injection on Day 0 and Day 21
1850821|NCT00958243|Biological|CSL's 2009 H1N1 Influenza Vaccine (CSL425)|0.25 mL intramuscular injection on Day 0 and Day 21
1850822|NCT00958243|Biological|Placebo|Placebo
1850823|NCT00958256|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 given intravenously over 3-5 seconds at the end of infusion of Rituximab on Day 1 of every cycle, then on Days 4, 8 and 11 of every cycle.
1850824|NCT00958256|Drug|Rituximab|375 mg/m^2 given intravenously over 6-8 hours on Day 1 of every 21-day study cycle.
1850825|NCT00958256|Drug|Cyclophosphamide|300 mg/m^2 intravenously over 3 hours 2 times each day (6 hours total each day) on Days 2, 3, and 4 of every cycle
1850826|NCT00958256|Drug|Mesna|600 mg/m^2 intravenous continuous infusion (IVCI) over 24 hours daily for 3 days, 1 hour prior to Cyclophosphamide and complete by 12 hours after last dose of Cyclophosphamide.
1850827|NCT00958256|Drug|G-CSF|5 micrograms/kg subcutaneously daily starting 24-36 hours for 7 days after last dose of Bortezomib until granulocytes are more than 4 x 103/dl.
1850828|NCT00958269|Drug|dutogliptin|100 mg QD
1850829|NCT00958269|Drug|dutogliptin|200 mg QD
1850830|NCT00958269|Drug|placebo|
1850831|NCT00958269|Drug|sitagliptin|25 mg QD
1850832|NCT00958269|Drug|sitagliptin|50 mg QD
1850833|NCT00958282|Drug|lisdexamfetamine/Behavior Therapy|
1850834|NCT00958282|Other|placebo|
1850835|NCT00958308|Other|BIO-K+ CL-1285®|A mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
1850836|NCT00958308|Other|Placebo|Placebo is devoid of microorganisms.
1850837|NCT00958321|Procedure|computed tomography|
1850838|NCT00958321|Radiation|3-dimensional conformal radiation therapy|
1850839|NCT00958321|Radiation|fludeoxyglucose F 18|
1850840|NCT00958321|Radiation|radiation therapy treatment planning/simulation|
1850841|NCT00958334|Drug|Proellex®|25 mg daily (two 12.5 mg capsules)
1850842|NCT00958334|Drug|Proellex®|12.5 mg daily
1850843|NCT00958334|Drug|Placebo|Treatment with no active ingredients
1850844|NCT00958347|Device|Omnifit HA Hip Stem|Total Hip Replacement with Omnifit HA Hip Stem
1850845|NCT00958360|Other|Interdisciplinary Low Vision Service|Services are provided by optometrist(s) and low vision therapist(s), and include low vision therapy to improve use of remaining vision and low vision devices, and structured homework to practice use of low vision devices that are prescribed and dispensed.
1850846|NCT00958360|Other|Basic Low Vision Service|Service is provided by the optometrist alone and includes demonstration of low vision device use and maintenance of prescribed low vision devices, without low vision therapy or homework and with less contact time.
1850847|NCT00958386|Drug|Panitumumab+irinotecan|"Panitumumab will be administered as a 60 minute ± 15 minutes IV infusion, just prior to administration of chemotherapy at a dose of 6 mg/kg on day 1 of each cycle. A cycle of Panitumumab is defined as 14 days.
Irinotecan chemotherapy (180 mg/m2 in 90 min on day 1 of each cycle) will be administered after the administration of Panitumumab.
Each treatment cycle will have a duration of 14 days."
1850848|NCT00958399|Dietary Supplement|Placebo|Low fiber muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
1850849|NCT00958399|Dietary Supplement|Resistant Starch|25 g resistant starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
1850887|NCT00958698|Other|Internet-Based Intervention|Ancillary studies
1850851|NCT00958399|Dietary Supplement|Fiber made from corn starch|25 g fiber made from corn starch, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
1850852|NCT00958399|Dietary Supplement|Fiber made from corn starch + soluble fiber|25 g fiber as a fiber made from corn starch and a soluble fiber, administered in a muffin, hot cereal and beverage (acute phase) or fiber bars and beverage (chronic phase)
1850854|NCT00958425|Device|Hyaluronic acid gel|Hyaluronic acid gel (20 mg/mL), 0.9 mL, intradermal over 2 cm area, once
1850855|NCT00958425|Device|Saline|Normal saline, 0.9 mL, intradermal over 2 cm area, once
1850856|NCT00958438|Drug|Placebo|Placebo loading dose followed by placebo subcutaneous (SC) injection (2 mL) once a week for 16 weeks.
1850857|NCT00958438|Drug|Rilonacept|Rilonacept 160 mg SC loading dose followed by Rilonacept 80 mg/2 mL SC injections once a week for 16 weeks.
1850858|NCT00958438|Drug|Rilonacept|Rilonacept 320 mg SC loading dose followed by Rilonacept 160 mg/2 mL SC injections once a week for 16 weeks.
1850859|NCT00958451|Drug|Paricalcitol|"Patients will receive 1mcg once daily orally if iPTH is less than 500pg/ml;
Patients will receive 2mcg once daily orally if iPTH is more than 500pg/ml. Duration of administration will be 16 weeks."
1850860|NCT00958451|Drug|Ergocalciferol|"If baseline 25 OHD level is less than 5ng/mml: ergocalciferol 50,000 units once a week orally for 12 weeks, then 50,000 units monthly for total duration of 16 weeks.
If baseline 25 OHD is between 5 and 15mg/ml: Ergocalciferol 50,000 units once a week orally for 4 weeks, then 50,000 units once a month for total duration of 16 weeks.
If baseline 25 OHD level is between 16 and 30ng/ml: Ergocalciferol 50,000 units orally once every 4 weeks for 16 weeks."
1850861|NCT00958464|Procedure|MRI|MRI protocol consists of intravenous injection of 0.4 ml/kg dose of gadopentetate dimeglumine 2- [Gd-DTPA2-] contrast agent (Magnevist, Bayer) 90 minutes prior to imaging.
1850862|NCT00958477|Biological|EMD 525797|Subjects will be administered with 250 milligram (mg), 500 mg, 1000 mg or 1500 mg of EMD 525797 intravenously over 1 hour every 2 weeks for 6 weeks. Subjects who will be clinically benefitted at the end of week 6 were continued at the same dose-level until disease progression, intolerance to treatment, withdrawal of consent or if the subject is no longer benefitted from the treatment as per Investigator's discretion.
1850863|NCT00958490|Other|Walking program|4 week physical activity walking program
1850864|NCT00958503|Drug|Thiamphenicol|750 and 1500 mg/day;tablets
1850865|NCT00958503|Drug|Placebo|Matched tablets without active ingredient
1850866|NCT00958516|Drug|LEO 29102 cream|LEO 29102 cream in different doses and the cream vehicle
1850867|NCT00958529|Dietary Supplement|Inulin Fiber Supplement|Orange juice fortified with 0, 5g, and 10g of 2 inulin products
1850868|NCT00958542|Procedure|Surgical fusion|Surgical intervention for correction of scoliotic or kyphotic curvatures of the spine will include either the posterior approach or the anterior + posterior approach, with either the unit or custom rod, depending on the choice of the surgeon.
1850869|NCT00958568|Drug|Olanzapine and Fluoxetine combination (OFC)|"Open label acute phase: introductory dose for 4 days then 3 milligram (mg) Olanzapine and 25 mg Fluoxetine Combination (3/25), 6/25, 12/25, 6/50, 12/50 or 18/50, oral, daily, for 6-8 weeks.
Open label stabilization phase: 6/25, 12/25, 6/50, 12/50 or 18/50 mg, oral, daily for 16-20 weeks.
Double blind relapse prevention phase: dose determined during stabilization phase at Week 17, oral, daily, for 27 weeks."
1850870|NCT00958568|Drug|Fluoxetine|25 or 50 mg/day fixed dosing for 27 weeks
1850871|NCT00958581|Drug|Tranexamic Acid|For TXA, the loading dose is 10mg/kg infused over 15 minutes, while the maintenance dose is 1/mg/kg hr.
1850872|NCT00958581|Drug|Normal Saline|
1850873|NCT00958581|Drug|Epsilon aminocaproic acid|For EACA, the loading dose is 100mg/kg infused over 15 minutes, while the maintenance dose is 10mg/kg hr.
1850874|NCT00958607|Behavioral|Timing it Right Stroke Family Support Person Intervention|Intervention delivered by a stroke support person (SSP) in-person during acute care & by telephone during inpatient rehabilitation and community discharge. SSP provides support, information & guidance and gives caregivers Stroke Family Support guide as a resource. SSP will have 1 contact with the caregiver during acute care and a 2nd contact during the last week of inpatient acute or rehabilitation care. The 1st contact while the caregiver is at home will occur 2-3 weeks after the stroke survivor has been discharged from inpatient care and then every four weeks until the caregiver passes the marker question. SSP will then encourage caregiver to contact them if they have any specific questions. The SSP will make one final contact about 8 weeks later
1850875|NCT00958607|Behavioral|Self-directed program|Participants in this arm of the trial will have family caregivers self-direct their use of the Timing it Right Stroke Family Support guide. The research assistant will instruct the caregivers how to self-manage their support needs by providing instruction on how to use the guide, which has an additional section regarding self-management. Caregivers will also be instructed that the guide is organized according to the phases of a stroke survivors' recovery. They will be instructed to review the information in each chapter as it becomes relevant to their current situation
1850876|NCT00958620|Procedure|Shock Wave Therapy|Extracorporal shock-wave therapy
1850877|NCT00958633|Drug|Escitalopram|"Escitalopram will be prescribed in the dose range 10-30 mg daily.
In patients randomized to the 8-week group, escitalopram will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.
The dose of escitalopram (or matching placebo) may be decreased in 10 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 10-30 mg daily at all time points."
1850878|NCT00958633|Drug|Wellbutrin XL|"Bupropion XL will be prescribed in the dosage range 150-450 mg daily.
In patients randomized to the 8-week group, bupropion XL will be tapered, discontinued, and replaced with placebo over a period of 2 weeks, beginning at the week 6 study visit.
The dose of bupropion XL (or matching placebo) may be decreased in 150 mg increments only in the case of intolerable side effects. The dose must remain within the protocol-defined range of 150-450 mg daily at all time points."
1850879|NCT00958646|Other|Osteopathic Manipulation|Standardized rib raising protocol
1850880|NCT00958646|Other|Placebo|Light touch control procedure
1850881|NCT00958659|Other|laboratory biomarker analysis|Correlative studies
1850882|NCT00958672|Other|Endoscopic capsule|Endoscopic capsule
1850888|NCT00958698|Procedure|Psychosocial Assessment and Care|Ancillary studies
1850889|NCT00958698|Other|Quality-of-Life Assessment|Ancillary studies
1850890|NCT00958698|Other|Questionnaire Administration|Ancillary studies
1850891|NCT00958711|Device|Unite Biomatrix|Collagen based, decellularized equine pericardial dressing for skin surface wounds
1850892|NCT00958711|Other|Saline and Gauze|gauze moistened with sterile saline
1850894|NCT00958737|Drug|FOLFOX regimen|Given IV
1850895|NCT00958737|Drug|fluorouracil|Given IV
1850896|NCT00958737|Drug|leucovorin calcium|Given IV
1850897|NCT00958737|Drug|oxaliplatin|Given IV
1850898|NCT00958737|Drug|XELOX regimen|
1850899|NCT00958737|Drug|Capecitabine|oral
1850900|NCT00958750|Drug|minoxidil|the investigators compared two different formulations and concentrations of minoxidil in this study
1850901|NCT00958763|Behavioral|Motivational Interviewing, Single - MIS|The Motivational Interviewing Single Arm is delivered individually to participants in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
1850902|NCT00958763|Behavioral|Motivational Interviewing Group|The Motivational Interviewing Group Arm is delivered to participants in groups in 3 separate sessions to address a specific concept (alcohol use, cravings and what to do with them, and concomitant behaviors and/or consequences of alcohol use). Participants will be encouraged to explore the pros and cons for each of these topics with the facilitator and with the group, who will remain non-judgmental. Participants who are eligible for the Hepatitis A/B vaccine are also offered the vaccine in conjunction with each session.
1850903|NCT00958763|Other|Usual Care Group - UCG|The Usual Care Arm is delivered to participants in three brief time-equivalent health promotion sessions. Each session focuses on health promoting activities such as the importance of diet and exercise, need for physical and mental health assessment and enhanced coping for those afflicted with a history of drug and alcohol addiction. In addition participants receive liver health promotion education. Participants are also provided referrals to alcohol treatment programs in the community and offered the 3 series hepatitis A/B vaccine
1850904|NCT00958776|Drug|Peramivir+SOC|"Adults (≥ 18 years): Peramivir (BCX-1812) 600 mg, administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
Adolescents (12-17 years): Peramivir (BCX-1812) 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care."
1850905|NCT00958776|Drug|Placebo+SOC|Placebo Peramivir (BCX1812) administered intravenously, once daily (every 24 hrs) for 5 days (5 doses) in addition to institution's standard of care.
1850906|NCT00958789|Device|Triathlon TS Knee System|Total knee replacement for revision cases
1850907|NCT00958802|Other|Platelet-rich plasma (PRP)|PRP was extracted from total blood and TGF-b1 was used as indicator
1850908|NCT00958802|Other|Chondrocyte culture with FBS medium|Microtia chondrocyte culture with FBS medium only
1850909|NCT00958828|Device|Nelfilcon A contact lens|Spherical, soft contact lens for daily disposable wear
1850910|NCT00958828|Device|Narafilcon A contact lens|Spherical, soft contact lens for daily disposable wear
1850911|NCT00958841|Drug|pasireotide LAR|Investigational drug pasireotide LAR was supplied in vials with 20 mg or 40 mg powder and 2 mL vehicle was supplied in ampoules for reconstitution.
1850912|NCT00958854|Drug|cyclophosphamide|
1850913|NCT00958854|Drug|fludarabine phosphate|
1850914|NCT00958854|Drug|thalidomide|
1850915|NCT00958854|Other|laboratory biomarker analysis|
1850916|NCT00958867|Behavioral|Exercise program (AT)|Six-month, twice-weekly aerobic training (AT) program
1850917|NCT00958867|Behavioral|Exercise training (RT)|Six-month, twice-weekly resistance training (RT) program
1850918|NCT00958867|Behavioral|Exercise training (S & R; control)|Six-month, twice-weekly stretch & relax (S & R; control) program
1850919|NCT00958880|Behavioral|Group Cognitive Behavioral Therapy|"5 weeks of group CBT for Social Anxiety. The aim of CBT is to help participants become more comfortable with social situations
One arm will receive placebo augmented Group Cognitive Behavioral Therapy and the other will receive yohimbine hydrochloride augmented cognitive behavioral therapy."
1850920|NCT00958880|Drug|Yohimbine Hydrochloride|Participants in the Yohimbine augmented arm will receive 4 doses of Yohimbine Hydrochloride before 4 of the 5 group cognitive behavioral therapy sessions.
1850921|NCT00958880|Drug|Sugar Pill|Participants in the placebo (sugar pill) augmented arm will receive 4 doses of a sugar pill before 4 of the 5 group cognitive behavioral therapy sessions.
1850922|NCT00958893|Drug|25 mg Proellex|one 25 mg capsules
1850923|NCT00958906|Drug|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
1850924|NCT00958919|Drug|naloxone|10 mg naloxone in 25 ml total volume
1850925|NCT00958919|Drug|normal saline|25 ml
1850928|NCT00958958|Other|multifaceted strategy|"There are multifaceted Interventions Including
Distribution of educational materials: distribution of published or printed recommendations for clinical care.
Case manager: Use of a trained person who works in the hospital and will be responsible to assure that all interventions were used
Reminders
Practical training"
1850929|NCT00958971|Drug|TKI258|
1850930|NCT00958997|Drug|18F-FP-DTBZ (18F-AV-133)|The subjects will receive a single IV bolus of approximately 10 mCi 18F-AV-133.(Injection will contain no more than 25 µg of non-radiolabeled 19F-AV-133).
1850931|NCT00958997|Biological|Arginine-hydrochloride|A bolus injection of 5g of 10% arginine-hydrochloride will be given over a period of 1 minute.
1850932|NCT00959010|Dietary Supplement|omega-3 triglycerides|capsules containing 300mg of omega-3 triglycerides with 100mg DHA and 150mg EPA, 60mg/kg/day 3 times a day during 12 months.
1850933|NCT00959010|Dietary Supplement|Placebo|capsules containing middle chain triglycerides
1850934|NCT00959023|Other|laboratory biomarker analysis|
1850935|NCT00959023|Other|medical chart review|
1850936|NCT00959023|Other|questionnaire administration|
1850937|NCT00959036|Drug|ATN-103|10 mg every 4 weeks until week 12
1850938|NCT00959036|Drug|ATN-103|10 mg every 8 weeks until week 12
1850939|NCT00959036|Drug|ATN-103|30 mg every 4 weeks until week 12
1850940|NCT00959036|Drug|ATN-103|80 mg every 4 weeks until week 12
1850941|NCT00959036|Drug|ATN-103|80 mg every 8 weeks until week 12
1850942|NCT00959036|Drug|Placebo|Placebo every 4 weeks
1850943|NCT00959036|Drug|Methotrexate|
1850944|NCT00959049|Biological|CSL's Influenza Virus Vaccine (Afluria)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
1850945|NCT00959049|Biological|Influenza Virus Vaccine (Fluzone)|0.25 mL (one or two doses) or 0.5 mL (one or two doses) by intramuscular injection as directed by immunization guidelines
1850948|NCT00959075|Dietary Supplement|Vitamin B1|100 mg Twice a day
1850949|NCT00959075|Dietary Supplement|Placebo|Sugar pill
1850950|NCT00959101|Drug|repaglinide and metformin combination tablet|Combination tablet of repaglinide (1.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
1850951|NCT00959101|Drug|repaglinide and metformin combination tablet|Combination tablet of repaglinide (2.0 mg)/metformin (500 mg) given just prior to a standard normal breakfast
1850952|NCT00959101|Drug|repaglinide|Co-administration of metformin 500 mg tablet and repaglinide 2 mg tablet given just prior to a standard normal breakfast
1850953|NCT00959101|Drug|metformin|Concomitant administration: Metformin 500 mg tablet and Repaglinide 2 mg tablet
1850954|NCT00959114|Biological|ALV003|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
1850955|NCT00959114|Biological|ALV003 placebo|ALV003 is an orally administered mixture of two enzymes (cysteine endoprotease B-isoform 2 and prolyl endopeptidase).
1850956|NCT00959127|Drug|ARRY-438162 (MEK162), MEK inhibitor; oral|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule; Part 3: multiple dose, single schedule.
1850957|NCT00959140|Device|CD3+ T cell depletion|"The peripheral blood stem cell product is engineered to deliver a dose of 15 to 20 x10^7 CD3+ cells/kg recipient body weight. Other components of the graft will not be manipulated and the recipient will receive the total number of cells collected with the exception of minimal losses that occur during the process of CD3+ T cell isolation. Following collection, CD3+ T cells will be enumerated and a portion of the product containing 15 to 20 x10^7 CD 3+ cells/kg will be set aside. The remainder of the product will be depleted of CD3+ T cells.
Following CD3+ T cell depletion, the CD3+ T cell depleted product will then be combined with the unmanipulated product to provide the specified levels of CD3+ T cells/kg recipient body-weight. The graft is infused into the patient on the same day as selected and within 24 hours of donor aphaeresis."
1850958|NCT00959153|Device|LithoSpace Extracorporeal Shockwave Lithotripter|Shockwave therapy to break up kidney stones
1850959|NCT00959192|Biological|ACC-001|IM injection, dose of 3, 10 and 30 micrograms, at Day 1, month 1, 3, 6 and 12
1850960|NCT00959192|Other|QS-21|IM injection, dose of 50 micrograms, at Day 1, month 1, 3, 6 and 12
1850961|NCT00959192|Other|QS-21|IM injection, dose 50 micrograms, at Day 1, month 1, 3, 6 and 12
1850962|NCT00959205|Device|CARTO 3D|CARTO (3D Electroanatomic imaging)
1850963|NCT00959205|Device|Angiography|Conventional fluoroscopically guided activation mapping
1850964|NCT00959218|Drug|Dronabinol|oral solution, daily dose up to 15 mg, treatment up to 2.5 years
1850965|NCT00959218|Drug|Placebo|oral solution
1850966|NCT00959231|Drug|cyclophosphamide|
1850967|NCT00959231|Drug|cyclosporine|
1850968|NCT00959231|Drug|fludarabine phosphate|
1850969|NCT00959231|Drug|mycophenolate mofetil|
1850970|NCT00959231|Other|laboratory biomarker analysis|
1850971|NCT00959231|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|
1850972|NCT00959231|Procedure|umbilical cord blood transplantation|
1850973|NCT00959231|Radiation|total-body irradiation|
1850974|NCT00959244|Other|high performance liquid chromatography|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
1850975|NCT00959244|Other|laboratory biomarker analysis|The biomarkers of interest will be the metabolites 4-OHE1(E2), estrogen-GSH conjugates and depurinating estrogen-DNA adducts.
1850976|NCT00959244|Other|mass spectrometry|Analyses of urine will be conducted by ultraperformance liquid chromatography with detection by tandem mass spectrometry.
1850977|NCT00959244|Other|medical chart review|Information about age, race, general health, any endocrine disorders, history of cancer, estrogen and progesterone receptor status, menopausal status and breast disease, body mass index, age at menarche, menopausal status (pre- or peri- menopausal or postmenopausal), age at menopause if applicable, chemotherapy regimen (if applicable), radiation therapy (if applicable), smoking history, alcohol consumption, pregnancy history including age at each pregnancy, lactation, history of benign breast disease, hysterectomy and disease type.
1850978|NCT00959283|Genetic|DNA analysis|
1850979|NCT00959283|Genetic|RNA analysis|
1850980|NCT00959283|Genetic|cytogenetic analysis|
1850981|NCT00959283|Genetic|fluorescence in situ hybridization|
1850982|NCT00959283|Genetic|gene expression analysis|
1850983|NCT00959283|Genetic|microarray analysis|
1850984|NCT00959283|Genetic|mutation analysis|
1850985|NCT00959283|Genetic|polymerase chain reaction|
1850986|NCT00959283|Genetic|polymorphism analysis|
1850987|NCT00959283|Other|flow cytometry|
1850988|NCT00959283|Other|laboratory biomarker analysis|
1850989|NCT00959283|Other|pharmacological study|
1850990|NCT00959296|Device|Various|Patients implanted and consented at a study center with a market-released Medtronic implantable drug pump, spinal cord stimulator, deep brain stimulator, or sacral nerve stimulator.
1850991|NCT00959309|Behavioral|Strategies to decrease screen time in children|"15 minute session about the health impact of screen time in children and strategies to decrease screen time (removing televisions from the child's bedroom, budgeting screen time, providing a contingency plan for time spent not watching TV, encouraging family meal time, and implementing a one week television turn off, where children are encouraged to spend one week without watching TV/videos). Activities for the child include reading a story about television viewing (The Berenstain Bears and Too Much TV), and creating a list of non TV related activities to replace TV time. The intervention group will receive a CPS handout titled 'Promoting Good Television Habits' and a calendar with stickers for the television turn off.
Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')"
1850992|NCT00959309|Behavioral|Non-Strategical Media Education|Educational session on good media use (information on television rating systems, internet safety, and limiting exposure to violent programming, and the CPS handout entitled 'Managing Media in the Home')
1850993|NCT00959322|Device|LenSx 550 Laser System|Femtosecond laser used to create capsulotomy incision.
1850994|NCT00959335|Drug|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
1850995|NCT00959335|Drug|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
1850996|NCT00959361|Behavioral|pharmaceutical care|consultation with the pharmacists and usual care
1850997|NCT00959374|Device|V-Loc 180/90 Wound Closure Device|Barbed absorbable suture
1850998|NCT00959374|Device|3-0 Monocryl Absorbable Sutures|3-0 Monocryl Absorbable Suture (non-barbed)
1850999|NCT00959387|Drug|Induction TP chemotherapy|3 cycles of paclitaxel 175mg/m2 and cisplatin 80mg/m2 q3w. All patients received supportive care during radiotherapy, including dietary measures, local antiseptics and laser therapy as preventive and curative support for oral mucositis.
1851000|NCT00959387|Radiation|Chemoradiotherapy (CRT)|Patients were treated with 2-dimensional radiation therapy planning (6MV photon beams). A combination of lateral-opposed portals, anterior and lateral wedged fields was used to treat the primary tumor and the lymph nodes. The primary tumor, macroscopically affected lymph nodes and bilateral cervical plus supraclavicular lymph chains were treated with five fractions of 2Gy per week for 5 weeks (up to a total of 50Gy). Gross tumor volume was defined as the primary gross tumor or involved node, and this measure was based on clinical, radiological and endoscopic examinations. An additional margin of 1.0cm was added to the GTV to create the CTV. A boost of five fractions of 2Gy per week for 2 additional weeks (up to a total dose of 70Gy) was prescribed to the CTV plus a margin of 1.0cm.
1851001|NCT00959400|Drug|Fentanyl Transdermal|Fentanest® 25 mcg/h. Each patch delivers 25 mcg of fentanyl per hour continuously for 72 hours. Therefore paches must be changed every 3 days.
1851002|NCT00951171|Procedure|Intrauterine Insemination|The intervention arm will undergo temporary (15 minutes) cervical occlusion with the eliptosphere intracervical catheter. This catheter is typically used to perform saline infusion ultrasounds to image the uterine cavity in our practice.
1851003|NCT00951171|Procedure|IUI with the standard inseminator|The control arm will undergo insemination with the standard inseminator (TOmcat catheter).
1851004|NCT00951184|Behavioral|telephone-based intervention|
1851005|NCT00951184|Other|screening questionnaire administration|
1851006|NCT00951184|Other|study of socioeconomic and demographic variables|
1851007|NCT00951184|Procedure|assessment of therapy complications|
1851008|NCT00951184|Procedure|psychosocial assessment and care|
1851009|NCT00951197|Other|Neuroimaging|Three successive MRI acquisitions to measure FA, MTR and T2 parameters.
1851010|NCT00951210|Biological|PLX-PAD|IM injection
1851011|NCT00951223|Drug|Infergen® (Interferon alfacon-1)|Infergen at either the 15 mcg or 9 mcg dose given per Providers instructions, with or without weight based ribavirin
1851012|NCT00951236|Drug|One cortisone injection|Patients in this arm will receive one cortisone injection for the treatment of his/her symptoms
1851013|NCT00951236|Drug|Two cortisone Injections|Subjects randomized to this treatment will receive two cortisone injections, 4-6 weeks apart
1851014|NCT00951249|Behavioral|Referral of Partners|Referral of up to five sexual partners by index participants for enrollment into the study
1851015|NCT00951249|Behavioral|Screening for STIs and counseling|Identification of STIs and treatment or referral for treatment, if applicable
1851016|NCT00951249|Behavioral|Peer health care system navigators|HIV/STI treatment and other medical and social services
1851017|NCT00951249|Behavioral|Enhanced counseling|Counseling and referral for care offered to participants for issues such as substance use and mental health
1851018|NCT00959426|Drug|PF-04620110|Multiple oral doses of PF-04620110 will be given. The specific dose will depend on the cohort to which the subject is assigned Initial planned doses are 1, 3, 5, 10 and 20 mg but may be modified based on emerging PK and safety data.
1851019|NCT00959426|Drug|Placebo|Subjects will be given placebo or PF-04620110. Anticipated total daily doses for Cohorts A, B, C, D, E, F and G are 1, 3, 5, 10 and 20 mg. In each Cohort 9 subjects will receive active treatment and 3 will receive placebo for 14 days. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses during the study based on ongoing safety, tolerability and PK results, but will not be projected to exceed established PK stopping criteria.
1851020|NCT00959439|Drug|Naproxen Delayed Release Tables, 375 (Gevena Pharmaceuticals, Inc.)|
1851021|NCT00959439|Drug|Naproxen (EC-Narosyn) Delayed Release Tables, 375 (Syntex (USA), Inc.)|
1851022|NCT00959452|Behavioral|Cognitive behavioural therapy|16 sessions vs 5 sessions of cognitive behavioural therapy
1851023|NCT00959465|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero Cell-derived, inactivated)|Two injections at a 21-day interval (Days 1 and 22)
1851070|NCT00961116|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered after an overnight fast of at least 10 hours
1851119|NCT00961480|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablet
1851534|NCT00955461|Procedure|Fractionated Laser treatment|
1851024|NCT00959478|Behavioral|Educational Tool & Carbon Monoxide Alarm|Based on the recommendations from the expert panel and focus group meetings, Fast Facts about Carbon Monoxide was developed to be an educational tool aimed at helping parents understand the dangers of CO and the need CO alarms in every home. In addition, this tool will help parents select and purchase the correct CO alarm, as well as properly install and maintain the alarm in their home. Each parent assigned to the intervention group will be given a Fast Facts about Carbon Monoxide educational tool and a Kidde Nighthawk Carbon Monoxide Alarm at enrollment.
1851025|NCT00959517|Drug|artesunate (AS)|Recommended dosage over 3 days (for all interventions)
1851026|NCT00959517|Drug|sulphadoxine-pyrimethamine (SP)|
1851027|NCT00959517|Drug|Chloroquine (CQ)|
1851028|NCT00959517|Drug|primaquine (PQ)|
1851029|NCT00959530|Procedure|lingualized occlusion|occlusal surface arranged by lingualized occlusion
1851030|NCT00959530|Procedure|Full Bilaterally Balanced Articulation|occlusal surface arranged by Full Bilaterally Balanced Articulation
1851031|NCT00959543|Other|MRI|MRI and clinical investigation
1851032|NCT00959556|Other|laboratory biomarker analysis|
1851033|NCT00959569|Drug|Esmolol|esmolol (1-3 mg/kg) during cardiac surgery
1851034|NCT00959569|Drug|Placebo|normosaline (same ml of the study drug)
1851035|NCT00959582|Procedure|Comparator: 18-F-FDG PET/CT and Volumetric CT|Patients will receive standard-of-care therapy (carboplatin or cisplatin monotherapy, or a two-drug combination where one is platinum). FDG-PET/CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, and if patients are progression-free at the end of Cycle 6. Volumetric CT scans will be performed at baseline following enrollment, after Cycles 1 and 2 of chemotherapy, after Cycle 3 of chemotherapy (optional), and if patients are progression-free at the end of Cycle 6 and at 40 weeks after Cycle 1 dosing.
1851036|NCT00959595|Drug|EMLA cream|The study subjects are treated either by 50 g of a local anesthetic agent containing 2.5% Lidocaine and 2.5% Prilocaine (EMLA®, AstraZeneca - Södertälje, Sweden) or a placebo cream, applied to the lower leg. The cream is applied under occlusive bandage (plastic foam and a tube) for 1.5 hours circumferential to the lower leg 10-12 cm distally of the tibial tuberosity and the malleolus at ankle level. Administration of the treatment cream as well as removal after 1,5 hour and at sensory assessment after 1.5 hour and 24 hours, and interviewing the patient about subjective experience from the treatment are performed by an independent research nurse, not involved in the sensory assessment.
1851037|NCT00959595|Drug|EMLA cream|50g applied according to description of intervention
1851038|NCT00959608|Behavioral|Think Health! program|Brief 10-15 minute counseling with Primary Care Provider for weight management, Participant binder with eating, physical activity and stress management educational materials, adapted from the Diabetes Prevention Program (DPP)(Knowler et al, 2002; DPP Research Group, 2002), physical activity resource guide, and telephonic health related messages (year 2).
1851039|NCT00959608|Behavioral|Basic Plus program|15 minute counseling sessions with lifestyle coach, in addition to the Basic Think Health! program intervention.
1851040|NCT00959621|Drug|Aspirin|ASA 100 mg once daily per os
1851041|NCT00959621|Drug|Klexane|Klexane 40 mg sc once daily (HABENOX 1 and 2), Klexane 40 mg twice daily in HABENOX 3
1851042|NCT00959621|Drug|Klexane and ASA|Klexane 40 mgx 1 sc and ASA 100 mg po
1851043|NCT00959634|Drug|ABT-126|Dose administered twice daily on Study Days 1-10
1851044|NCT00959634|Drug|Placebo|Dose administered twice daily on Study Days 1-10
1851045|NCT00959647|Drug|Vismodegib|Vismodegib was supplied in capsules.
1851046|NCT00959647|Drug|FOLFOX|FOLFOX (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and oxaliplatin [OX]) was supplied as solutions for intravenous administration.
1851047|NCT00959647|Drug|FOLFIRI|FOLFIRI (folinic acid [FOL, leucovorin], fluorouracil [F, 5-FU], and irinotecan [IRI]) was supplied as solutions for intravenous administration.
1851048|NCT00959647|Drug|Bevacizumab|Bevacizumab was supplied as a solution for intravenous administration.
1851049|NCT00959660|Behavioral|Exercise|walking, treadmill and bicycle exercise
1851050|NCT00959660|Dietary Supplement|Dietary Intervention|Subjects will be provided meals and instructions for individual food selections.
1851051|NCT00959660|Behavioral|Diet and exercise|Combination of the exercise and diet group as previously described.
1851052|NCT00959660|Other|Attention Control|control group- continue their previously randomized life style
1851053|NCT00959686|Drug|Bendamustine|Bendamustine at the dose of 120 mg/m2 IV over 60 minutes on days 1 and 2 every 21 days for 6 cycles
1851054|NCT00959699|Drug|PegIFN-2b|PegIFN-2b (1.5 μg/kg/week subcutaneously)
1851055|NCT00959699|Drug|RBV|Ribavirin (600-1400 mg/day, orally, divided into two daily doses)
1851056|NCT00959699|Drug|Placebo to Boceprevir|Placebo to boceprevir (orally, three times per day)
1851057|NCT00959699|Drug|Boceprevir|Boceprevir (800 mg, orally, three times per day)
1851058|NCT00959712|Behavioral|ECA Interaction|The technology uses a computer character (Embodied Conversational Agent (ECA)) that simulates face-to-face conversation. The ECA talks to the patient and the patient responds by tapping a touch-screen.
1851059|NCT00959725|Drug|Infliximab (intravitreal, 2.0mg/0.05ml)|One injection of intravitreal infliximab (2.0mg/0.05ml).
1851060|NCT00959738|Procedure|Diverting loop ileostomy with rod|Diverting loop ileostomy with rod
1851061|NCT00959738|Procedure|diverting loop ileostomy without rod|diverting loop ileostomy without rod
1851062|NCT00959751|Drug|NXN-188|200 mg capsules, 600 mg, PRN
1851063|NCT00959751|Drug|Placebo|200 mg capsules with no active ingredient designed to match the NXN-188 capsules
1851064|NCT00959764|Drug|Oral Calcitonin Tablets|Oral Calcitonin tablets along with matching placebo intranasal spray
1851065|NCT00959764|Drug|Intranasal Calcitonin|Intranasal Calcitonin Spray
1851066|NCT00959764|Drug|Placebo tablets and placebo intranasal spray|Oral Placebo Tablets/Intranasal placebo spray
1851067|NCT00961077|Drug|S-1 (TS-1) and Oxaliplatin (Oxalitin)|"S-1(TS-1) 60mg/m2/day (D1-14) Oxaliplatin: 85mg/m2 + 5DW 250mL MIV over 2-hours
every 3 weeks"
1851068|NCT00961090|Drug|Aminolevulinic Acid|20 mg/kg mixed in water and taken orally prior to surgery
1851069|NCT00961116|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered after an overnight fast of at least 10 hours
1851071|NCT00961142|Drug|Fludarabine, Thiotepa, Melphalan, Thymoglobuline (ATG)|Conditioning with Fludarabine 30 mg/m2/24h day-8 to -4, Thiotepa 2x5 mg/kg day -3, Melphalan 60 mg/m2 day -2 to -1 and Thymoglobuline (ATG)1.5mg/kg/day day -9 to -6. PBSC depleted of CD3 and CD19 cells by immunomagnetic depletion on CliniMACS.
1851072|NCT00961155|Drug|cyklezonid|160 mcg once daily
1851073|NCT00961155|Drug|montelukast sodium|5 or 10 mg according to age once daily
1851074|NCT00961155|Drug|placebo|fluticasone placebo twice daily, montelukast placebo once daily
1851075|NCT00961155|Drug|formoterol 12 mcg twice daily|formoterol 12 mcg twice daily will be given to children for 3 months
1851076|NCT00961168|Other|Volume Control Ventilation|Mechanical ventilation at a constant tidal volume of 6 mL/kg.
1851077|NCT00961168|Other|Pressure Control Ventilation|Mechanical ventilation at a constant airway pressure of 25-30 cm H2O
1851078|NCT00961181|Device|Paclitaxel Releasing Balloon|Percutaneous coronary intervention with paclitaxel releasing balloon
1851079|NCT00961194|Drug|Ketamine|"Initial dosage: 250 mg/5 ml
Three doses of ketamine will be tested:
0.35 mg/kg
0.7 mg/kg
1.4 mg/kg Each patient will receive the indicated dose of oral ketamine or placebo once and if there are not adverse events, he will be able to continue the treatment three times a day, during 7 days (between visit 2 and 3).
The oral ketamine will be administered in form of syrup."
1851082|NCT00961220|Drug|Carmustine|Applied topically
1851083|NCT00961220|Other|Laboratory Biomarker Analysis|Correlative studies
1851084|NCT00961220|Drug|O6-Benzylguanine|Given IV
1851085|NCT00961233|Drug|inhaled/swallowed budesonide|medication will be nebulized and then swallowed
1851086|NCT00961233|Drug|viscous/swallowed budesonide|viscous suspension of budesonide will be swallowed
1851087|NCT00961246|Behavioral|general health information|participants received general health information
1851088|NCT00961246|Behavioral|individually-tailored intervention|participants received individually-tailored intervention
1851089|NCT00961259|Drug|Fenofibric Acid 35 mg Tablet|1 x 35 mg tablet administered after an overnight fast of at least 10 hours
1851090|NCT00961259|Drug|Fenofibric Acid 35 mg Tablet|3 x 35 mg tablets administered after an overnight fast of at least 10 hours
1851091|NCT00961259|Drug|Fenofibric Acid 105 mg Tablet|105 mg tablet administered after an overnight fast of at least 10 hours
1851092|NCT00961298|Drug|Duloxetine|All subjects will receive single-blind placebo for the first two weeks, and then duloxetine for the next 12 weeks, followed by an up to 2 week taper off of the duloxetine. After 2 weeks of placebo daily, subjects will receive 30 mg per day of duloxetine for two weeks, then titrated up to 60 mg per day of duloxetine at week 2. A dosage decrease to 30 mg daily is permittable after week 2. This will be a flexible dose study with doses of duloxetine progressively increasing at weeks 4 (90 mg daily) and 6 (120 mg daily) in conjunction with CGI-I scores, to reach 120 mg daily or the maximum tolerated dose, if less than 120 mg daily at Week 12. There will be a post-taper follow up appointment at Week 14. Of Note: Amendment IRB Approved 6/14/11 Study Ending at Week 12 with removal of Week 14 visit as part of study.
1851093|NCT00961311|Procedure|Percutaneous Coronary Intervention|Balloon angioplasty of a severely stenotic coronary lesion with the Sprinter Legend 1.25mm Balloon.
1851094|NCT00961311|Device|Sprinter Legend 1.25mm Balloon Catheter|Balloon Angioplasty
1851097|NCT00961337|Biological|Trivalent inactivated influenza vaccine|one dose
1851098|NCT00961350|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
1851099|NCT00961350|Drug|EC Aspirin 325|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
1851100|NCT00961363|Drug|Sitagliptin|sitagliptin 100 mg per day
1851101|NCT00961363|Drug|Placebo|Placebo
1851102|NCT00961376|Biological|PBMC re-infusion|Autologous PBMC re-infusion
1851103|NCT00961376|Biological|CD25 depletion|Autologous, CD25-depleted PBMC re-infusion
1851104|NCT00961402|Behavioral|Wellness Control|6-month wellness control
1851105|NCT00961402|Behavioral|Exercise Intervention|6 month exercise intervention
1851106|NCT00961415|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3-week cycle
1851107|NCT00961415|Drug|cisplatin|75mg/m2 iv on day 1 of each 3-week cycle
1851108|NCT00961415|Drug|pemetrexed|500mg/m2 iv on day 1 of each 3-week cycle
1851109|NCT00961441|Drug|Keppra XR|"Keppra XR 500 mg tablets and Keppra XR 750 mg tablets
Dosage: Keppra XR 1000-3000 mg/day taken once daily. Duration: 4-7 days"
1851110|NCT00961454|Device|Photobiomodulation with a super-luminous light emitting diode|The treatment will consist of applying PBM in the form of a super-luminous LED with an output of 250 mW/cm2 at a wavelength of 815 nm with a full width half maximum of 40 nm when applied at 4 mm from the skin. The treatment will consist of the exposure to the light for 4 minutes (total delivered fluence per spot of 60 J/cm2) at each of 4 sites on the forehead that correspond to the 10-20 EEG sites, F3, and F4.
1851111|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 50 mg/day.
1851112|NCT00961467|Drug|Revlimid, Melphalan, Prednisone, Thalidomide|Thalidomide was administered at 100 mg/day.
1851113|NCT00961480|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
1851114|NCT00961480|Drug|Comparator: metformin 500mg|A single dose of metformin 500 mg tablet
1851115|NCT00961480|Drug|Comparator: sitagliptin|A single dose of 50 mg sitagliptin tablet
1851116|NCT00961480|Drug|Comparator: FMI sitagliptin / metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
1851117|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
1851118|NCT00961480|Drug|Comparator: FMI sitagliptin/metformin 50 mg/850 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/850 mg FDC tablet
1851120|NCT00961480|Drug|Comparator: metformin 850 mg|A single dose of metformin 850 mg tablet
1851121|NCT00961493|Behavioral|Acceptance based behavioral therapy|16 individual psychotherapy sessions focused on psychoeducation about anxiety, anxious responding, the function of emotions, mindfulness, and problems with efforts to constrict one's emotional experience; training in mindfulness skills; practice applying mindfulness skills in daily life, including acceptance of, rather than efforts to control, internal experience; and identification of values in areas of life and practice engaging in chosen actions.
1851122|NCT00961493|Behavioral|Applied relaxation|16 sessions of individual psychotherapy focused on psychoeducation about anxiety and anxious responding; training in multiple forms of relaxation; early cue detection; and practice applying relaxation in daily life.
1851123|NCT00961506|Procedure|LESS cholecystectomy|LESS cholecystectomy
1851124|NCT00961506|Procedure|Laparoscopic cholecystectomy|laparoscopic cholecystectomy
1851125|NCT00961532|Drug|DDAVP injection (desmopressin acetate)|0.4 mcg/kg in 250 mL NS intravenously once over 30 minutes
1851126|NCT00961558|Procedure|Varicocelectomy|Varicocelectomy
1851127|NCT00961571|Drug|sunitinib and capecitabine|Sunitinib 37.5 mg po once daily Capecitabine 1000 mg po twice daily
1851128|NCT00961597|Procedure|Meniscus repair for red/white tears without PRP|Same operation as experimental, only without the use of platelet rich plasma.
1851129|NCT00961597|Procedure|Meniscus repair with PRP|Meniscus repair with platelet rich plasma using vertical divergent suture techniques.
1851130|NCT00961610|Behavioral|Internet peer-support group|"The Internet peer-support groups provided a self-guided space for communication, including an Internet discussion forum, a live chat room and a personal message system. No therapeutic content or information services were offered within the groups.
All Internet groups were run in a browser-based software platform with access through the website of the Danish Cancer Society (http://www.cancer.dk). All discussions were protected by a password and communication was encrypted.
The Internet groups in this study were all closed peer-support groups, accessible only by an invitation received by e-mail after registration for the study. The groups were open to access 24 h a day for 13 months from their individual starting date."
1851131|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20 mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 28 weeks
1851132|NCT00961636|Drug|ER niacin (+) laropiprant (ERN/LRPT)|One 1g/20mg tablet ERN/LRPT once daily for 4 weeks, then two 1g/20 mg tablets daily (2g/40 mg total) for 16 weeks.
1851133|NCT00961636|Drug|Extended-release niacin (ERN)|Two 1g tablets ERN (2g total) once daily for 12 weeks.
1851134|NCT00961636|Drug|Placebo to ERN/LRPT|One tablet placebo to ERN/LRPT once daily for 4 weeks, then two tablets placebo to ERN/LRPT daily for 28 weeks
1851135|NCT00961649|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
1851136|NCT00961649|Drug|Brinzolamide ophthalmic suspension, 1%|
1851137|NCT00961649|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
1851138|NCT00961649|Other|Vehicle|Inactive ingredients used as placebo
1851139|NCT00961662|Drug|D-Tagatose|powder to be dissolved in water prior to dosage.
1851140|NCT00961675|Drug|FST201 (dexamethasone 0.1% with povidone-iodine 1%)|4gtt BID
1851141|NCT00961675|Drug|Ciprodex (Ciprofloxacin 0.3%; dexamethasone 0.1% )|4 gtt BID
1851143|NCT00961727|Other|Bedside Paediatric Early Warning System (Bedside PEWS)|The Bedside PEWS is comprised of 4 components; [1] an expert derived, multi-centre validated severity of illness score, [2] an inter-professionally developed documentation record into which the severity of illness score is embedded, [3] a series of score-matched care recommendations based on the opinions of over 280 paediatric health care professionals, and [4] an educator-developed education-implementation program.
1851144|NCT00961740|Behavioral|Cognitive Behavioural Therapy|See summary
1851145|NCT00961740|Other|Waitlist condition|See Summary
1851146|NCT00961753|Drug|optimized ibuprofen|day of life 0-3 - 10, 5, 5 mg/kg/dose at 24 hour intervals day of life 4-6 - 14, 7, 7 mg/kg/dose at 24 hour intervals day of life 7-29 - 20, 10, 10 mg/kg/dose at 24 hour intervals
1851147|NCT00961753|Drug|Standard Ibuprofen|day of life 0-29 - 10,5, 5 mg/kg/dose at 24 hour intervals
1851148|NCT00961766|Drug|BG00010 (Neublastin)|Single dose, weight-based IV administration
1851149|NCT00961766|Drug|Placebo|Single dose IV matched placebo
1851150|NCT00961779|Drug|NNZ-2566|Glycyl-L-2-Methylprolyl-L-Glutamic Acid (NNZ-2566) supplied as a lyophilized powder (2g in 50mL vials) for reconstitution with bicarbonate buffer and normal saline.
1851151|NCT00961779|Drug|Placebo|Normal saline infusion
1851156|NCT00961805|Behavioral|Dance|Belly dance classes twice a week for 16 weeks. Each class had a maximum of eight students. The classes were administered by a physiotherapist with eight years of experience in belly dance. Classes began with a warm-up exercise, followed by the predetermined movements for the day, choreography and a cool-down exercise. The participants received a compact disc with music and an exercise book with the history and movements proposed for the program. Beginning in the fourth week, a set sequence of movements in the form of choreography was established for memorization and training at home.
1851157|NCT00961805|Other|Control Group|The control group did not receive any intervention. They attended all assessments and remained on the waiting lis (after the end of the study was offered to this group the same treatment in the intervention group).
1851158|NCT00961831|Drug|F-18 (BAY85-8050)|Cancer patients, injection of BAY 85-8050, PET/CT
1851159|NCT00961831|Drug|F-18 (BAY85-8050)|Healthy volunteers, injection of BAY 85-8050, whole body PET/CT for determination of effective dose, kinetics of BAY 85-8050 in blood
1851160|NCT00961844|Biological|Dendritic cells - transfected with hTERT-, survivin- and tumor cell derived mRNA + ex vivo T cell expansion and reinfusion|
1851161|NCT00961844|Drug|Temozolomide|
1851162|NCT00961857|Drug|sitagliptin phosphate (+) metformin hydrochloride|place holder - do not post
1851163|NCT00961857|Drug|Comparator: metformin 500 mg|A single dose of metformin 500 mg tablets
1851164|NCT00961857|Drug|Comparator: sitagliptin|A single 50 mg tablet of sitagliptin
1851165|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/500 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/500 mg FDC tablet
1851166|NCT00961857|Drug|Comparator: FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet|A single dose of FMI sitagliptin/metformin 50 mg/1000 mg FDC tablet
1851167|NCT00961857|Drug|Comparator: metformin 1000 mg|A single dose of metformin 1000 mg tablets
1851168|NCT00961870|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups.
1851169|NCT00961883|Biological|NYVAC-B|New York Vaccinia (NYVAC) vector for HIV-1, delivered intramuscularly by injection at a dose of 1 x 10 ^7 PFU
1851170|NCT00961883|Biological|Placebo|Sodium Chloride for injection, delivered intramuscularly
1851171|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^10 PFU
1851172|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^9 PFU
1851173|NCT00961883|Biological|rAd5|Recombinant adenoviral serotype 5 (rAd5) vector vaccine, delivered by injection intramuscularly at a dose of 1 x 10^8 PFU
1851174|NCT00961896|Drug|Vehicle|Placebo cream
1851175|NCT00961896|Drug|LDE225 0.25%|
1851176|NCT00961896|Drug|LDE225 0.75%|
1851177|NCT00961909|Drug|RO5095932|cohorts receiving multiple ascending doses, sc once weekly for 4 weeks
1851178|NCT00961909|Drug|RO5095932|dose titration to target dose, sc once weekly for 6 weeks
1851179|NCT00961909|Drug|metformin|stable dose
1851180|NCT00961909|Drug|placebo|sc once weekly for 4 weeks
1851183|NCT00961961|Drug|Lithium / Fluoxetine|Individualized Daily Dosage
1851184|NCT00961961|Drug|Lithium / Placebo|Individualized Daily Dosage
1851185|NCT00961974|Behavioral|Care Ambassador Intervention|Care Ambassador provides additional monthly outreach (by phone or e-mail) to families between clinic visits.
1851186|NCT00961974|Behavioral|Psychoeducational Intervention|"A psychoeducational intervention module is reviewed with the family by the Care Ambassador at each clinic visit. The intervention focuses on incorporating intensive therapy into the daily routine of the child through positive family support for blood glucose monitoring and healthy eating. The intervention modules review positive family communication, realistic expectations, ways to avoid perfectionism and maintain family involvement, prevention of hypoglycemia, avoidance of diabetes-specific family conflict, and approaches to reducing diabetes burnout."
1851187|NCT00961987|Other|Collaborative model|Patients will be referred (if necessary) to an obstetrician who will be co-located in the Maternity Centre and who will be part of the collaborative model of maternity care.
1851188|NCT00961987|Other|Usual care|At present, if Maternity Centre patients require the specialized services of an obstetrician, the current standard of care is to refer them to obstetricians located offsite with no professional ties to the Maternity Centre
1851189|NCT00962000|Other|Dialysis Flow Rate Start 600mL/min|ABAB sequence where A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min and B represents three consecutive treatments with a dialysate flow rate of 800 mL/min.
1851190|NCT00962000|Other|Dialysis Flow Rate Start 800mL/min|BABA sequence where B represents three consecutive treatments with a dialysate flow rate of 800 mL/min and A represents three consecutive dialysis treatments with a dialysate flow rate of 600 mL/min.
1851191|NCT00962013|Device|Restoration® Modular Revision Hip System|Restoration® Modular Revision System
1851192|NCT00962026|Drug|Rilonacept|Rilonacept given subcutaneously, dose per package labeling, once weekly.
1851194|NCT00962065|Drug|LX4211 Low Dose|A low dose of LX4211; daily oral intake for 28 days
1851195|NCT00962065|Drug|LX4211 High Dose|A high dose of LX4211; daily oral intake for 28 days
1851196|NCT00962065|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days
1851197|NCT00962078|Other|continuous endurance training|at 60 percent of peak Watt
1851198|NCT00962078|Other|interval training|at 100 percent of peak Watt
1851199|NCT00962091|Drug|MLN8237|"Prior to initiation of Part A, an accelerated dose escalation cohort will be evaluated. The first cohort will be administered a single 15-mg dose of the oral solution administered on Day 1 of Cycle 1. Once the safety and tolerability of study drug is established in this cohort, Part A will commence as described below.
Part A: patients will receive either a single 25 mg dose of MLN8237 (oral solution) or a 50 mg powder in capsule (PIC) dose of MLN8237 on Day 1 of Cycle 1, followed by administration of a single dose of the respective alternate formulation on Day 1 of Cycle 2. Dosing at 50 mg twice a day of the PIC formulation for 7 days (Days 3-9) will then be resumed after the single-dose administration of the oral solution or PIC for both Cycle 1 and Cycle 2 followed by a 14 day rest period. Beginning with Cycle 3, MLN8237 will be administered at 50 mg PIC twice a day for 7 days followed by a 14 day rest period in 21-day cycles."
1851227|NCT00962299|Drug|Placebo|Placebo once a day by metered dose inhaler with spacer for 6 months
1851228|NCT00962312|Drug|capecitabine|
1851229|NCT00962312|Drug|lapatinib ditosylate|
1851230|NCT00962325|Behavioral|Intervention to increase physical activity|This will be a 6-week preoperative intervention to increase structured walking activity. This will be accomplished through weekly individual face-to-face sessions involving tailored instruction in use of standard behavior change strategies such as self-monitoring, goal-setting, stimulus control, etc.
1851533|NCT00955461|Procedure|RevLite laser treatment|Electro-optic Q-Switched Nd: YAG Laser treatment
1851200|NCT00962091|Drug|MLN8237|Patients will receive a single dose of MLN8237 (oral solution) with or without a standard high fat breakfast on Day 1 of Cycle 1, followed by administration under the respective alternate food intake condition (fasted to fed, or fed to fasted; N = 7 per sequence) on Day 1 in Cycle 2. The dose of MLN8237 (oral solution) to be administered in this food effect assessment will be determined from the relative bioavailability estimate in Part A. Dosing at X mg twice/day MLN8237 (oral solution) for 7 days will be resumed after the single dose administration of the oral solution for both Cycle 1 and Cycle 2 followed by a 14-day rest period. Beginning with Cycle 3, MLN8237 will be administered at the 50 mg twice/day PIC formulation with 7 days of dosing followed by a 14 day rest period in 21-day cycles.
1851201|NCT00962091|Drug|MLN8237|"Patients will receive a single 50-mg dose of MLN8237 enteric-coated tablet (ECT) with or without a standard high fat breakfast on Day 1 of Cycle 1, followed by administration under the respective alternate food intake condition (fasted to fed, or fed to fasted; N = 7 per sequence) on Day 1 in Cycle 2.
Dosing at 40 mg twice/day MLN8237 ECT for 7 days will be resumed after the single dose administration of ECT for Cycle 1, followed by a 14-day rest period. In Cycle 2, MLN8237 ECT will be administered as a single dose of 50 mg on Day 1, followed by either 40 or 50 mg twice/day for Day 3 through the morning dose of Day 9 and followed by a 14-day rest period. Beginning with Cycle 3, MLN8237 ECT will be administered twice a day for 7 days followed by a 14 day rest period in 21-day cycles."
1851202|NCT00962104|Drug|Atomoxetine|40-120 milligrams (mg) taken by mouth, once daily for 10 weeks.
1851203|NCT00962104|Drug|Placebo|Taken by mouth, once daily for 10 weeks.
1851205|NCT00962143|Device|Achilles repair with OrthADAPT augmentation|Achilles repair with OrthADAPT augmentation
1851206|NCT00962143|Procedure|Achilles repair without OrthADAPT Augmentation|Achilles repair without OrthADAPT Augmentation
1851207|NCT00962156|Drug|6% Hydroxyethyl starch 130/0.4|Infusion for volume expansion in the ICU
1851208|NCT00962156|Drug|Ringers acetate|Infusion for volume expansion in the ICU
1851209|NCT00962169|Other|Behavioral and managerial|The quality improvement program is a multi-level intervention program to increase adherence to the Dutch physical therapy Guidelines for Low Back Pain. It consists of two program parts, one for practice quality managers and the other for individual therapists. The management part aims to increase commitment amongst practice owners towards high quality of care, including the appropriate use of guidelines, and addresses the structure and the culture of the physical therapy practice. This part of the program is based on the INK management model and the colour model of De Caluwé. The individual part of the intervention is aimed at increasing physical therapists' guideline adherence by raising awareness and improving recording and clinical reasoning. This part of the intervention is based on psychosocial and educational theories and especially on the principles of Self Regulation.
1851210|NCT00962169|Other|Behavioral and IT|The interventions makes use of an improved EPD for physical therapists. Compared to the existing EPDs, the EPD for the present study presents decision information for physical therapists. This decision information is directly based on the recently revised physical therapy guidelines for Low Back Pain and attached to the subsequent steps of clinical reasoning that are inherent to the diagnostic and treatment stages of the usual process of physical therapy care.
1851211|NCT00962182|Drug|STAN1|3-4 capsules/day at meals
1851212|NCT00962182|Drug|Placebo enzyme|3-4 capsules/day at meals
1851213|NCT00962182|Drug|STAN1+gluten|3-4 capsules/day at meals plus 500 mg gluten b.i.d
1851214|NCT00962195|Dietary Supplement|purple sweet potato (PSP)-juice|Daily oral intake of 3x 125 ml of PSP-juice or control juice
1851215|NCT00962208|Device|orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error for a period of two years
1851216|NCT00962208|Device|single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
1851217|NCT00962221|Procedure|laboratory analysis|laboratory analysis
1851218|NCT00962234|Other|Blood draws|Up to 4 blood draws will be required, in the amount of about 10 mL each
1851219|NCT00962234|Biological|Oral administration of stable isotope (deuterium)|1 mg deuterium-labeled water/kg body water (loading dose), and 0.5 mg/kg body water diluted in 1 L of normal water (maintenance dose) to be consumed over the following 16 hours
1851220|NCT00962234|Procedure|Metabolic rate testing|Metabolic rate testing is a painless, non-invasive test that takes about 1h. A metabolic cart is used, which detects the amount of oxygen and carbon dioxide the body uses. Patients will lie down on a bed for 30 minutes with lights dimmed and soft music to help them relax. After 30 minutes, a canopy will be placed over the patient's head and shoulders for 30 minutes for the analysis of breath samples. This test will be performed only once for this study.
1851221|NCT00962247|Device|Television reduction device|A TV allowance helps turn off the television when the time limits have been met.
1851222|NCT00962260|Drug|Plant cell expressed recombinant glucocerebrosidase (prGCD)|Intravenous infusion every two weeks at the dose level equal to each patient's previous imiglucerase dose before reduction or discontinuation due to shortage
1851223|NCT00962273|Behavioral|Interactive computerized learning resource|"In a series of interactive scenarios, participants can see themselves in stressful work situations that could arise during an influenza pandemic and reflect on effective ways to work out personal and interpersonal difficulties."
1851224|NCT00962273|Behavioral|Didactic computerized learning resource|In a non-interactive format (i.e., a series of audio presentations with accompanying PowerPoint-type slides) participants are given information on how to handle stressful work situations that could arise during an influenza pandemic.
1851225|NCT00962286|Drug|Furosemide|"Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.Intravenous catheters will be placed in each upper limb for infusion of clearance markers and blood sampling.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered. Thereafter, inulin and p-aminohippuric acid will be infused continuously. A 200-300 ml water load will be given during the first 60-min prime.
Subjects will be started on furosemide p.o. 20 mg every 12 hours, starting on day 1 at 15.00 after the renal function studies. Nine doses will be taken, the last dose on day 4 at 7 am.
In case the blood pressure does not decrease following 20 mg bid furosemide administration, the study will be repeated after 4 weeks using a dose of 40 mg p.o. bid."
1851226|NCT00962299|Drug|Beclomethasone|Beclometasone 100 ug b.i.d. by metered dose inhaler with spacer for 6 months
1851231|NCT00962338|Behavioral|Information|Information on short convalescence (1 day). Example: Operated today and getting started with normal activities again tomorrow.
1851232|NCT00962351|Procedure|Total Hip Replacement|
1851233|NCT00962364|Biological|autologous bone marrow-derived cells|autologous bone marrow-derived cells isolated by density gradient centrifugation from 50 ml bone marrow aspirate obtained under local anesthesia
1851234|NCT00962377|Procedure|Endomyocardial biopsy|Right ventricular endomyocardial biopsy in monitoring of asymptomatic heart transplant patients for acute cellular rejection
1851235|NCT00962377|Procedure|AlloMap Molecular Testing|Gene expression profiling in the monitoring of asymptomatic heart transplant patients for acute cellular rejection.
1851236|NCT00962390|Drug|S-equol|10mg S-equol 50mg S-equol, & 150mg S-equol
1851237|NCT00962390|Drug|Placebo|Placebo
1851238|NCT00962403|Behavioral|Yoga treatment|The 10-week Kripalu-style yoga treatment will consist of 20 biweekly 90-minute group training/practice sessions. In addition, subjects will also receive CD's and written instructions for the daily 15-minute sessions, which they will use to guide them through the yoga procedures to be done at home.
1851239|NCT00962416|Device|Biolimus eluted from an erodable stent coating (Biomatrix)|The Biolimus-eluting stent (Biomatrix) has a corrugated ring design available in six and nine cell models and is laser cut from 316L VM stainless steel hypotube. The nominal dosage of Biolimus A9 goes from 133 to 442 microgram. The producer of the drug is Nippoon Kayaku Co., Ltd Takasaki Plant, 239, Iwahanamachi, Takasaki-shi, Gumma 370-1028 Japan. The biodegradable polymer is polylactic acid, which has become one of the most commonly used biodegradable polymers. Polylactic acid, its co-polymers, and mixtures have been evaluated in the preclinical, and clinical studies, revealing a favorable biocompatability profile. The polymer has been demonstrated to be safe when used as implant of drug release-control polymer for both animals and humans.
1851240|NCT00962416|Device|bare-metal stent (Gazelle)|A bare-metal stent of identical design without surface application of polymer and drug.
1851241|NCT00962429|Drug|lipoic acid|Subjects will be started on a single daily dose of 600 mg of alpha lipoic acid or placebo for the first 4 weeks and then increased to 1200 mg for the remainder of the study.
1851242|NCT00962442|Drug|N-Acetylcysteine|300 mg/kg for 14 days, intravenously
1851243|NCT00962442|Drug|placebo|Glucosé 5% perfusion for 14 days, intravenously
1851244|NCT00962455|Other|e-learning & performance feedback|Initial e-learning by studying CD-Rom 'Spirometry Fundamentals', followed by repeated periodic performance feedback on spirometry test quality
1851245|NCT00962455|Other|usual practice|Usual practice regarding spirometry execution in family practice
1851247|NCT00962481|Drug|Bimosiamose|
1851248|NCT00962481|Drug|Placebo|
1851249|NCT00962494|Behavioral|Cancer: Thriving and Surviving Online Workshop|
1851250|NCT00962507|Drug|everolimus|Beginning with 5 mg every other day Monday, Wednesday or Friday for a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
1851251|NCT00962507|Drug|panobinostat|10 mg every Monday and Thursday of a 28 day cycle. Dose escalation will be determined by the toxicities associated with treatment.
1851252|NCT00962507|Other|laboratory biomarker analysis|Pre-study, day 1 and day 26 samples to evaluation how the study drugs work in vitro (in a test tube).
1851253|NCT00962507|Other|pharmacological study|Pre-study, day 1 and day 26
1851254|NCT00962520|Drug|Erlotinib|Erlotinib 100 mg PO QD (1 hour prior to Capecitabine) (both given daily without interruption)
1851255|NCT00962520|Drug|capecitabine|Capecitabine 800 mg/m2 PO BID (1600 mg/m2 total) (5 days on/2 days off regimen)
1851256|NCT00962520|Radiation|Radiation Therapy|Radiotherapy 50.4 Gy delivered over 28 fractions (Mon-Fri)
1851257|NCT00962520|Drug|gemcitabine|Gemcitabine 1000 mg/m2 D1,8, and 15 every 28 days x 4 cycles
1851258|NCT00962520|Drug|erlotinib|Erlotinib 100 mg PO QD x 4 months
1851259|NCT00962533|Drug|telbivudine|telbivudine, 600mg, oral, daily
1851260|NCT00962533|Drug|telbivudine|telbivudine, 600mg, oral, daily
1851261|NCT00962572|Behavioral|Patient management|"Aggressive patient management will be implemented by a corps of patient manager volunteers backed by a transportation, nutrition, and social services network. The social services professionals will work with the volunteers to establish the support needed for each patient. The volunteer managers will in turn constantly monitor that such support is addressing the patient's ability to be treated. Access to sponsored housing will be coordinated. Nutritional support will be coordinated by the Dietary department and will consist of counseling, and supplements when necessary. Provision of supplemental feeding for housed patients will be arranged."
1851262|NCT00962585|Drug|Placebo|
1851263|NCT00962585|Drug|S-equol|"Eligible patients meeting all study entry criteria were randomly assigned to receive one of the following active treatments for 4 weeks:
S-equol 10 mg BID (20 mg total daily dose)
S-equol 50 mg BID (100 mg total daily dose)
S-equol 150 mg BID (300 mg total daily dose)"
1851264|NCT00962598|Drug|Omega 3 Fatty Acids|The study medication will consist of combined EPA/DHA with a ratio of 2:1. Dosage will be titrated based on clinical response and side effects. The initial dose will be 1.2g/d. This will be increased gradually by 0.6 per 2 weeks to a possible maximum daily dose of 3.6 g/d. Patients will have to remain on a dose for 2 weeks to provide the opportunity to assess clinical response at any one dose. The total duration of the intervention will be 10 weeks.
1851265|NCT00962598|Dietary Supplement|Corn oil|The dosage will correspond to the titration schedule of the Omega-3 Fatty Acid experimental treatment. Placebo (corn oil) and omega-3FA capsules will be identical in color and smell.
1851266|NCT00962611|Drug|Copanlisib (Aliqopa, BAY80-6946)|BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
1851267|NCT00962624|Drug|meningococcal B vaccine & meningococcal ACYW conjugate vaccine|Meningococcal B vaccine will be administered at 0, 2 and 6 months and a single dose of meningococcal ACYW vaccine will be administered at 0 months, concomitantly with the first dose of the meningococcal B vaccine.
1851268|NCT00962637|Drug|Androxal|12.5 mg once daily
1851269|NCT00962637|Drug|Androxal|25 mg once daily
1851310|NCT00962975|Drug|peginterferon alfa-2a [Pegasys]|dosage at discretion of investigator based on standard of care (180mcg sc weekly) for up to 48 weeks
1851270|NCT00962637|Drug|AndroGel|5 g applied topically daily. The subject was to return to the clinic every 2 weeks for the first 2 months to monitor serum testosterone levels. If testosterone concentration remained below the normal level, the dose of AndroGel® could have been increased to 10 g and then to 15 g according to the guidance provided in the product package insert.
1851271|NCT00962637|Drug|Placebo|1 capsule daily
1851272|NCT00962650|Device|Transgastric diagnostic peritoneoscopy with laparoscopic assistance|Device: Natural Orifice Transgastric Endoscopic (NOTES GEN 1 Toolbox): Articulating Hook Knife(IN2505), Articulating Snare (IN2503), Articulating Needle Knife(IN2504), Articulating Graspers(IN2501 or IN2506), Articulating Biopsy Forceps(IN2502), Steerable Flexible Trocar (IN0501) with Rotary Access Needle (IN0502), Flexible Bipolar Hemostasis Forceps (IN0301), and/or Flexible Maryland Dissector(IN1601)
1851273|NCT00962663|Drug|ICA-105665|Subjects randomized to receive ICA -105665 will receive 200 mg BID
1851274|NCT00962663|Drug|Ibuprofen|Subjects randomized to receive Ibuprofen will receive placebo to ICA-105665 at all scheduled dosing times on Days 1 to 4 and a single dose of 800 mg Ibuprofen on the morning of Day 4.
1851275|NCT00962663|Drug|Placebo|"Subjects randomized to receive placebo will receive placebo to ICA
-105665 at all scheduled dosing times on Days 1 to 4 and placebo to Ibuprofen on the morning of Day 4."
1992797|NCT03296462|Other|Hip external rotation exercise|Standardised HER exercise training by physiotherapist (plus video recording of exercises)
1851277|NCT00962715|Biological|Influenza Vaccine Trivalent Inactivated (TIV)|15 μg (0.5 ml) through needle into arm muscle on Days 1 and 28.
1851278|NCT00962715|Drug|Pegylated interferon (PEGrIFN-α, Pegasys)|180 μg (0.5 ml) before receiving TIV, through a needle under the skin.
1851279|NCT00962715|Drug|Interferon (IFNα, Roferon-A)|3 million units (0.5 ml) before receiving TIV, through a needle under the skin.
1851280|NCT00962728|Device|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
1851281|NCT00962728|Device|Sham Inspiratory Threshold Device|Breathing through a respiratory particulate filter (Model 002850P, Sims Portex Inc, Keene NH) which will have minimal resistance.
1851282|NCT00962741|Drug|Etanercept|Etanercept 0.8 mg/kg QW up to a maximum dose of 50 mg
1851283|NCT00962754|Procedure|physician no insight in the fluid balance chart|physician had no insight in the fluid balance chart during the first 3 days of admission of the patient when the balance is recorded
1851284|NCT00962767|Drug|gemtuzumab ozogamicin|2 IV infusions 6 mg/m2 administered monthly
1851285|NCT00962767|Drug|ATRA plus 6-MP and MTX|6-MP 50 mg/m2/day PO; MTX 15 mg/m2/q week IM; ATRA 45 mg/m2/day PO
1851286|NCT00962780|Biological|13-valent Pneumococcal Conjugate Vaccine (13vPnC)|13vPnC; 3 vaccinations given at approximately 1 month intervals at visits 1-3
1851287|NCT00962780|Biological|23-valent Pneumococcal Polysaccharide Vaccine (23vPS)|23vPS; 1 vaccination given at visit 4 (approximately 1 month after visit 3)
1851288|NCT00962780|Procedure|Blood draw|Blood draw; 5 blood draws approximately 1 month apart taken prior to vaccination at visits 1-4 and visit 5 (approximately 1 month after visit 4).
1851289|NCT00962780|Procedure|Blood draw|1 or 2 blood draws for CD4+ T cell count and HIV viral load at least 6 weeks apart, if subject does not have 2 CD4+ T cell counts and HIV viral load counts within 6 months before visit 1.
1851290|NCT00962806|Behavioral|Exercise|8 weeks of intensive exercise, 60-90 minutes 3 days each week
1851291|NCT00962806|Behavioral|Lifestyle counseling|Baseline and final visit dietary and activity advice and weekly healthy lifestyle messages
1851292|NCT00962819|Biological|MMR vaccine|People with no antibodies to either mumps, measles and rubella will be offered the MMR vaccine (they may choose to or choose not to receive the MMR vaccine)
1851293|NCT00962832|Drug|Placebo|Placebo was supplied as a sterile liquid solution.
1851294|NCT00962832|Drug|Rontalizumab|Rontalizumab was supplied as a sterile liquid solution.
1851295|NCT00962845|Drug|hydroxychloroquine|200 mg twice daily in the first ten patients. If the first ten patients tolerate this dosage schedule (200 mg bid) without significant side effects (Grade 3 or greater gastrointestinal upset, skin toxicity, myopathy or any visual disturbances whatsoever), the second ten patients will be enrolled at a dose of 400 mg bid
1851296|NCT00962871|Drug|peginterferon alfa-2a [Pegasys]|360 micrograms sc/week for 2 weeks
1851297|NCT00962871|Drug|tenofovir|300mg po daily for 2 weeks
1851298|NCT00962884|Device|Inspiratory Threshold Device (Res-Q-Gard ITD)|Patient will breathe through this device attached to a mouthpiece during assessment of orthostatic tolerance.
1851299|NCT00962884|Device|Sham Inspiratory Threshold Device|Breathing through device similar to active device but with the one-way threshold valve removed.
1851300|NCT00962897|Procedure|Femoral-popliteal bypass|Surgical bypass of blockage in the thigh
1851301|NCT00962897|Procedure|Stent-graft placement|Patients that underwent treatment of blockage in the thigh arteries with balloon angioplasty with stent-graft placement.
1851303|NCT00962923|Biological|Allogeneic Mesenchymal Stem Cells (AlloMSC)|Allogeneic mesenchymal stem cells will be infused intravenously (single dose, 10^6 cells/kg body weight).
1851304|NCT00962936|Drug|CT-011|CT-011
1851305|NCT00962949|Drug|Angiotensin II|Angiotensin II infusion for 1 hour
1851306|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,000 calories per week equaling approximately 10 miles per week OR 2.5-3.5 hours per week
1851307|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 50% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 4-6 hours per week
1851308|NCT00962962|Behavioral|Aerobic Exercise|Aerobic exercise at 75% peak oxygen use/consumption expending approximately 1,600 calories per week equaling approximately 16 miles per week OR 2-3 hours per week
1851309|NCT00962962|Behavioral|Exercise and Diet|"Exercise - 150 minutes per week (30 minutes / 5 days per week) of aerobic exercise at 50% peak oxygen use/consumption equaling approximately 10 miles per week
Diet - The Clinical Lifestyle Intervention sessions will provide training on needed skills (e.g., calorie counting, portion size estimation) as well as motivation and support in a group counseling setting designed to achieve a weight loss goal of 5 to 7% of baseline body weight."
1851526|NCT00955435|Drug|releasing hormone agonist therapy|
1851311|NCT00962988|Drug|Cost-Free Pharmacotherapy Group|"Participants assigned to the cost-free pharmacotherapy group will be provided with a 12-week supply of NRT, or a 12-week supply of bupropion or varenicline.
Patients smoking 10 cigarettes or less will be prescribed 7mg/24hours for 12 weeks. Those who smoke 11- 20 cigarettes per day will be prescribed 14 mg/24 hours for 8 weeks and then nicotine patch 7mg for 4 weeks. Those smoking ≥ 20 cigarettes per day will be prescribed 21 mg/daily for 6 weeks and then nicotine patch 14mg/daily for 4 weeks and then nicotine patch 7 mg/daily for 2 weeks.
For patients who are prescribed varenicline, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 0.5mg once/day; Days 4-7: 0.5 mg BID; Day 8-12 weeks 1.0 mg twice daily.
For patients who are prescribed bupropion, they will start the medication 8 days before the quit date using the following regime: Days 1-3: 150 mg daily (in the morning); Day 4-30: 150 mg BID for 3 months."
1851312|NCT00962988|Other|Prescription Only Group|Participants assigned to the prescription only usual care group will be asked to have their prescription for smoking cessation pharmacotherapy filled at their own cost at their local community pharmacy
1851313|NCT00963001|Drug|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth within 10 minutes of consuming each of four standardized meals on Study Days 1, 8, 15, and 22.
1851314|NCT00963001|Other|Standardized meals|Each subject will receive one of four different standardized meals of varying caloric and fat content in a randomized sequence such that all subjects will receive all four meals over the course of the study. Each subject will receive one standardized meal for breakfast on Study Days 1, 8, 15, and 22.
1851315|NCT00963027|Drug|Treprostinil diethanolamine|Subjects will each receive a single 1 mg sustained release tablet of treprostinil diethanolamine by mouth immediately following breakfast before and after repeated daily dosing with esomeprazole.
1851316|NCT00963027|Drug|Esomeprazole|Each subject will receive a single 40 mg capsule of esomeprazole by mouth in the morning for seven days.
1851317|NCT00963040|Drug|Syntocinon (Oxytocin)|4 actuations in each nostril for a total dose of 32 IU
1851318|NCT00963040|Drug|Sterile water|4 actuations in each nostril
1851319|NCT00963053|Drug|VA111913 TS and placebo|VA111913 TS twice daily for a maximum of 6 days during one menstrual cycle followed by placebo twice daily for up to a maximum of 6 days during a second menstrual cycle in a cross over design
1851320|NCT00963066|Device|PSV - pressure suppot ventilation|Gold standard partial ventilator support: Pressure Support Ventilation performed with Servo-i® ventilator (MAQUET,Critical Care, Sweden). Different levels of pressure support ventilator assistance are tested.
1851321|NCT00963066|Device|NAVA - Neurally Adjusted Ventilatory Assist|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. Positive pressure, delivered by the machine, is driven using inspiratory flow trigger.
1851322|NCT00963066|Device|NAVA - EMG|Partial ventilator support with new partial ventilation mode (NAVA) performed with Servo-i® ventilator (Maquet,Critical Care, Sweden). Different levels of neurally adjusted ventilatory assist are tested. The machine applies positive pressure throughout inspiration in proportion to the electrical activity of the diaphragm (Eadi). Eadi was obtained trhough a naso-gastric tube with multiple array of electrodes placed at its distal end (Eadi catheter® , Maquet Critical Care, Sweden).
1851323|NCT00963079|Procedure|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
1851324|NCT00963079|Procedure|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
1851325|NCT00963092|Genetic|DNA analysis|
1851326|NCT00963092|Genetic|RNA analysis|
1851327|NCT00963092|Genetic|microarray analysis|
1851328|NCT00963092|Genetic|protein analysis|
1851329|NCT00963092|Other|cytology specimen collection procedure|
1851330|NCT00963092|Other|laboratory biomarker analysis|
1851331|NCT00963092|Other|questionnaire administration|
1851332|NCT00963105|Drug|lenalidomide|"Depending on the starting dose, subjects will be allocated in a double-blind fashion to three different regimens and will escalate every 28 days, based on individual subject tolerability, as follows:
Treatment Arm 1: 5 mg →10 mg →15 mg →20 mg →25 mg/daily
Treatment Arm 2: 10 mg →15 mg →20 mg →25 mg/daily
Treatment Arm 3: 15 mg →20 mg →25 mg/daily Subjects will continue treatment until disease progression or unacceptable toxicity"
1851333|NCT00963118|Dietary Supplement|plant based nutrition bar|Nutrition bars made from Angelica keiskei (5g), glycine max (5g), Angelica keiskei (2.5g) + Glycine max (2.5g) or rice powder (12g) will be supplemented twice/day for 4 wks.
1851334|NCT00963131|Drug|antioxidants tablets|vitamin A 6600 IU, vitamin C 400 mg, vitamin E 150 IU, riboflavin 10 mg, zinc 60 mg, copper 4 mg, selenium 40 mg, manganese 4 mg and lutein/zeaxanthin 4000 micrograms.
1851335|NCT00963157|Drug|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg inactivated H1N1 vaccine.
1851336|NCT00963157|Biological|Influenza Virus Vaccine, Monovalent A/H1N1 A/California/7/2009 NYMC X-179A|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of the vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
1851337|NCT00963183|Drug|AZD5423|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD5423 or placebo. Starting dose 8.4µg (lung deposited dose) with up to 8 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
1851338|NCT00963183|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive a single-dose.
1851339|NCT00963196|Dietary Supplement|Omega-3 fatty acid|2400mg daily of fish oil containing 1440mg combined EPA and DHA for 12 weeks
1851340|NCT00963196|Drug|Bovine gelatin capsules|Bovine gelatin capsules that appear similar to active drug acting as placebo.
1851341|NCT00963209|Drug|tamoxifen citrate|
1851342|NCT00963209|Other|laboratory biomarker analysis|
1851343|NCT00963209|Other|pharmacological study|
1851344|NCT00963222|Drug|vitamin A|1 cap vitamin A 25000 IU/day for 3 month
1851345|NCT00963222|Drug|placebo|1 cap placebo/day for 3 month
1851527|NCT00955435|Genetic|protein expression analysis|
1851346|NCT00963235|Biological|13-valent pneumococcal conjugate vaccine|Three doses of 13vPnC given 6 months apart.
1851347|NCT00963235|Procedure|Blood draw|Six blood draws pre-vaccination and 1 month post-vaccination, doses 1-3.
1851348|NCT00963261|Behavioral|psycho-oncological intervention|stepped care treatment program with different elements (patient information, exercise, psychoeducation, individual and group therapy, psycho-pharmacology)
1851349|NCT00963274|Drug|Bortezomib|Starting dose: 1.3 mg/sq m
1851350|NCT00963274|Drug|Romidepsin|Starting dose: 8 mg/sq m
1851351|NCT00963287|Drug|bascial prescription plus or minus herbs depend on symptoms|Decoction ,two times a day
1851352|NCT00963300|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
1851353|NCT00963300|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1851354|NCT00963300|Procedure|magnetic resonance spectroscopic imaging|
1851355|NCT00963300|Procedure|tissue-oxygen-level-dependent functional magnetic resonance imaging|
1851356|NCT00963313|Drug|Adalimumab (HUMIRA®)|Prefilled syringes containing 40 mg Adalimumab in 0.8 ml injection solution. Study drug will be subcutaneously self-administered every 2 weeks during 24 weeks.
1851357|NCT00963326|Other|laboratory biomarker analysis|
1851358|NCT00963339|Device|Foresee Home|Home Monitoring
1851359|NCT00963365|Drug|AZD6765|Single oral dose and single IV infusion of AZD6765
1851360|NCT00963365|Drug|AZD6765|Once-daily oral dose of AZD6765 or placebo on Day 1 and on Days 4 through 9.
1851361|NCT00963391|Other|ABHS use|"Centers assigned to the intervention group were provided with ABHS dispensers with a gel solution with ethyl alcohol at 62% as active ingredient (Purell®, GOJO Industries, Dayton, Ohio). A total of 85 dispensers were installed, one dispenser was installed in each center of size less than 14 children, and one per classroom plus an additional one for common areas in centers with more than 28 children. Proper safety measures were followed.
Standardized ABHS training workshops for staff and children in centers allocated to the intervention were carried out simultaneously with dispenser installation. Thirty minute refresher sessions about ABHS technique were provided to staff and children on a monthly basis, for a total of 8 sessions per center."
1851362|NCT00963404|Radiation|Radiation boost|Radiation boost of the bladder-tumor: 10 Gy/5 fractions, 2 Gy per fraction.
1851363|NCT00963417|Other|laboratory biomarker analysis|Serial serum levels of several biomarkers will be analyzed at different time points, up to 72 months after randomization.
1851364|NCT00963417|Procedure|dual x-ray absorptiometry|Serial bone mineral density measurements of the L1-L4 (postero-anterior, PA) region of the spine and hip by dual-energy X-ray absorptiometry (DEXA).
1851365|NCT00963430|Biological|Inactivated H1N1 Vaccine|Two doses of inactivated influenza H1N1 vaccine delivered intramuscularly (IM) as 15 or 30 mcg dose. The 15 mcg dose will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as a single 1.0 mL injection in the deltoid muscle.
1851366|NCT00963443|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|2 Sachets of 500 mg Aspirin Complex.
1851367|NCT00963443|Drug|Pseudoephedrine|2 Sachets of 30 mg Pseudoephedrine
1851368|NCT00963443|Drug|Placebo|Matching Placebo
1851369|NCT00963469|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily in the morning for 4 weeks
1851370|NCT00963469|Drug|Comparator: loratadine|loratadine 10 mg tablet orally once daily in the morning for 4 weeks
1851371|NCT00963469|Drug|Comparator: placebo|placebo tablet orally once daily in the morning for 4 weeks
1851372|NCT00963482|Behavioral|Cognitive-behavioural smoking cessation program|It's a cognitive-behavioural intervention for smoking cessation. Originally based on a 6 week program designed for outpatients (Batra & Buchkremer 2004). This program was then specifically tailored for inpatient use with additional information addressing the interaction of smoking and drinking and its consequences.
1851373|NCT00963482|Behavioral|Autogenic training|Learning and exercising of autogenic training. There's evidence that autogenic training is not effective in smoking cessation.
1851374|NCT00963495|Drug|Clioquinol|Patients will take Clioquniol at escalating doses depending on when they enter into the trial.
1851375|NCT00963508|Drug|Malathion gel 0.5%|Malathion gel 0.5% applied to scalp for 30 minutes. May be repeated in 1 week if head lice are still present.
1851376|NCT00963508|Drug|Permethrin 1% rinse (Nix Crème)|Permethrin 1% shampooed into scalp for 10 minutes. May be repeated in 1 week if head head lice are still present.
1851377|NCT00963521|Biological|therapeutic autologous dendritic cells|
1851378|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|"Phase I: Maximally tolerable dose of lenalidomide will be determined, starting with 5 mg per day, and up to maximally 25 mg per day. This treatment is given in combination with bendamustine and rituximab.
Phase II: Determination of progression free survival with treatment with lenalidomide (dosing determined in phase I) in combination with bendamustine and rituximab."
1851379|NCT00963534|Drug|lenalidomide, bendamustine, rituximab|lenalidomide: day 1-21, maximum 13 cycles bendamustine: days 1-2, cycle 1-6 rituximab: day1, cycle 1-6
1851380|NCT00963547|Drug|MK2206|Part 1: MK2206 tablets will be given starting at a dose of 45 mg every other day and escalated to 60 mg if tolerated OR starting at a dose of 135 mg weekly and escalated to 200 mg weekly if tolerated. Dose reduction to 30mg every other day or 90 mg weekly may be permitted. The dose of MK2206 will be increased or decreased as required to find the maximum tolerated dose of MK2206 for both the every other day and weekly dosing schedules in combination with trastuzumab. The Part 2 dosing level and schedule of MK2206 will be chosen from the maximum tolerated dose of either the every other day or weekly dosing schedules depending on the toxicity profile and preliminary efficacy.
1851381|NCT00963547|Drug|Comparator: MK2206|Part 2: The maximum tolerated dose of MK2206 determined in Part 1 will be administered in combination with trastuzumab and lapatinib to determine the maximum tolerated dose of the three-drug combination.
1851382|NCT00963547|Biological|Comparator: trastuzumab|Trastuzumab will be administered as a 90-minute intravenous infusion at a loading dose of 8 mg/kg followed by 6 mg/kg every 3 weeks.
1851383|NCT00963547|Drug|Comparator: lapatinib|Lapatinib tablets will be administered orally in doses of 500 mg, 750 mg, or 1000 mg.
1851384|NCT00963560|Device|ReSTOR +3|Bilateral implantation of the AcrySof ReSTOR Aspheric +3 Model SN6AD1 Intraocular lens (IOL) for the treatment of cataract.
1851528|NCT00955435|Genetic|proteomic profiling|
1851385|NCT00963560|Device|Crystalens HD|Bilateral implantation of the Crystalens HD intraocular lens (IOL) for the treatment of cataract.
1851386|NCT00963560|Device|Crystalens AO|Bilateral implantation of the Crystalens AO intraocular lens (IOL) for the treatment of cataract.
1851387|NCT00963573|Drug|Loratadine|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
1851388|NCT00963573|Drug|Betamethasone|loratadine/betamethasone oral solution (1 mg/0.05 mg/1 mL), at a dose of 10 mg/0.5 mg
1851389|NCT00963599|Drug|Comparator: montelukast/loratadine|montelukast 10 mg/loratadine 10 mg tablet taken once daily at bed time for 2 weeks
1851390|NCT00963599|Drug|Comparator: montelukast|montelukast 10 mg tablet taken once daily at bed time for 2 weeks
1851391|NCT00963599|Drug|Comparator: loratadine|loratadine 10 mg tablet taken once daily at bed time for 2 weeks
1851392|NCT00963599|Drug|Comparator: placebo|placebo tablet taken once daily at bed time for 2 weeks
1851393|NCT00963612|Procedure|BOLD MRI test|Additional MR pulse sequence performed on BOLD MRI is expected to increase the regular scan time by an additional 5-10 minutes. No intravenous contrast is required for BOLD acquisition.
1851394|NCT00963625|Procedure|Embryo cryopreservation|Cohort cryopreserved as bipronuclear (2pn) oocytes, then thawed and cultured to the blastocyst stage before transfer to the uterus.
1851395|NCT00963625|Procedure|Fresh blastocyst transfer|Fresh blastocyst transfer following cycle of controlled ovarian stimulation.
1851396|NCT00954447|Drug|Placebo|Placebo, identical to Linagliptin tablet
1851397|NCT00954447|Drug|Linagliptin|intended final marketed dose
1851398|NCT00954460|Drug|velaglucerase alfa|up to 60 U/kg, every other week via intravenous infusion
1851399|NCT00954473|Other|laboratory biomarker analysis|Correlative studies
1851400|NCT00954486|Drug|Epoetin alfa|Epoetin alfa will be administered at 10,000 units/week
1851401|NCT00954499|Behavioral|Tactile stimulation added to Standard care|"Parent rubs the infant's skin near the injection site just before, during and after the injection.
Fast injection technique without aspiration.
Oral sucrose 2 minutes before first injection.
Parent holds infant close."
1851402|NCT00954499|Behavioral|Standard care|"Fast injection technique without aspiration.
Oral sucrose 2 minutes before first injection.
Parent holds infant close."
1851403|NCT00954512|Drug|Carboplatin|
1851404|NCT00954512|Drug|Epirubicin|
1851405|NCT00954512|Biological|Trastuzumab|
1851406|NCT00954512|Drug|Everolimus|
1851407|NCT00954512|Drug|Gemcitabine|
1851408|NCT00954512|Biological|Robatumumab|In Part 1, robatumumab was to be administered at 10 mg/kg, 15 mg/kg (for Regimens B and C), or 20 mg/kg together with the assigned standard treatment. For Part 2, robatumumab was to be administered at the dose selected during Part 1, based upon the maximum tolerated dose (MTD) or maximum administered dose (MAD), pharmacokinetic (PK) and pharmacodynamic (PD) data.
1851409|NCT00954512|Biological|Cetuximab|
1851410|NCT00954512|Drug|Paclitaxel|
1851411|NCT00954512|Drug|Cisplatin|
1851412|NCT00954512|Drug|5-FU|
1851413|NCT00954512|Drug|Erlotinib|
1851414|NCT00954512|Drug|Irinotecan|
1851415|NCT00954512|Drug|Folinic Acid|
1851416|NCT00954525|Drug|Gemcitabine and Erlotinib|Gemcitabine (dose according to study protocol), Erlotinib (100 mg/day)
1851417|NCT00954525|Dietary Supplement|Intravenous Vitamin C|50 grams, 75 grams, or 100 grams of intravenous vitamin C, three times per week for 8 weeks.
1851418|NCT00954538|Drug|[18F]MK-3328|IV dose of ~150 megabecquerel (MBq) [18F]MK-3328
1851419|NCT00954564|Other|aromatase inhibition therapy - OBSERVATIONAL ONLY|Observational only - as prescribed
1851420|NCT00954564|Other|medical chart review|Observational only
1851421|NCT00954564|Other|questionnaire administration|Observational only
1851422|NCT00954564|Procedure|assessment of therapy complications|Observational only
1851423|NCT00954577|Behavioral|Nutrition, health, and exercise education|The classroom intervention is part of the routine science curriculum and consists of 14 sessions taught by the investigators. Topics covered include the development of type 2 diabetes, nutrition education, exercise education, and overall healthy lifestyle education (both at home and in school). The intervention is offered in each year to all grades and to all students, regardless of whether or not they are enrolled in the study. The exercise intervention is optional and consists of 2-3 sessions per week of aerobic exercise (dancing) taught by pediatric trainers and offered in lieu of regular gym classes.
1851424|NCT00954590|Drug|Dimebon (latrepirdine)|20 mg orally three times daily
1851425|NCT00954590|Drug|Placebo|Placebo orally three times daily
1851426|NCT00954603|Drug|quetiapine|25-100 mg
1851427|NCT00954603|Drug|haloperidol|0.5-2 mg
1851428|NCT00954629|Drug|strontium chloride hexahydrate|Topical solution to be applied twice daily for 26 weeks. Dosage of up till 4 ml per application.
1851429|NCT00954629|Drug|Placebo|Topical solution to be applied twice daily for 26 weeks. Dosage up till 4ml per application.
1851430|NCT00954642|Drug|bevacizumab|Intravenous repeating dose
1851431|NCT00954642|Drug|MNRP1685A|Escalating intravenous dose
1851432|NCT00954642|Drug|paclitaxel|Intravenous repeating dose
1851433|NCT00954655|Genetic|mutation analysis|
1851434|NCT00954655|Genetic|polymorphism analysis|
1851435|NCT00954655|Other|laboratory biomarker analysis|
1851436|NCT00954668|Procedure|immediate angiography and revascularization|immediate angiography < 2 hours after randomization
1851437|NCT00954668|Procedure|early invasive angiography|early invasive angiography 12-72 h after randomization
1851438|NCT00954681|Drug|quetiapine|Quetiapine treatment from 25 mg daily to 300 mg twice daily
1851439|NCT00954694|Device|NuStep fitness apparatus|The NuStep is a mode of exercise that has recently been used in clinical settings to determine appropriate intensity recommendations and energy expenditures. The NuStep exercise implement provides simultaneous upper and lower body movement while in a seated position. The machine stimulates all major muscle groups while putting minimal strain on joints. Ten resistance settings are offered and the device is fully adjustable to accommodate users of varying sizes (NuStep, 2009).
1851529|NCT00955435|Other|laboratory biomarker analysis|
1851530|NCT00955435|Radiation|radiation therapy|
1851440|NCT00954707|Drug|Clopidogrel & Aspirin, Prasugrel & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of thienopyridine treatment in addition to aspirin.
1851441|NCT00954707|Drug|Placebo & Aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
1851442|NCT00954720|Other|No Intervention|There is no intervention on this trial
1851443|NCT00954733|Other|Arterial blood draw|One arterial blood draw
1851444|NCT00954759|Procedure|Chiropractic treatment|
1851445|NCT00954759|Procedure|Visit without active treatment|The child is brought in for chiropractic treatment, but no active treatment is delivered. The parents are unaware whether treatment is delivered or not.
1851446|NCT00954785|Device|Ankle brace|Sports Stirrup ankle brace (Aircast)
1851447|NCT00954785|Drug|Diclofenac 50 mg tds|In the diclofenac group, each subject will receive 50 mg diclofenac in the morning, at mid-day and in the evening
1851448|NCT00954785|Drug|Etoricoxib 120 mg mane|In the etoricoxib group, each subject will receive 120 mg etoricoxib in the morning, and placebo medication in the evening and at mid-day
1851449|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants); and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
1851450|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and day 21 (all participants), and 0.5 mL of trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
1851451|NCT00954798|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21
1851452|NCT00954811|Drug|300IU rec-LH|luteal alternate doses
1851453|NCT00954811|Drug|progesterone 600mg|luteal support
1851454|NCT00954824|Biological|Endotoxin (LPS)|Single administration low-dose (3 ng/kg) endotoxin (LPS).
1851455|NCT00954837|Procedure|Fine needle aspiration|Classical needle biopsy techniques will be used, with patients lying on their backs with their necks in hyperextension. An initial ultrasound scan will be used to determine the site or sites at which the needle should be inserted. Following extensive disinfection of the skin of the neck, the needle will be inserted under ultrasound guidance. The needle will be moved gently backwards and forwards and displaced radially in a clockwise direction to recover cellular material by capillarity. In general, several (two or three) passages of the needle are required for a given nodule. It is possible to carry out FNA on up to three nodules in a single session. For each passage, a new, sterile, single-use needle will be used. The insertion of each needle will be preceded by an ultrasound scan.
1851456|NCT00954876|Drug|capecitabine and cetuximab|"Cetuximab 500 mg/m2 IV infusion over 1-2 hours Once every 2 weeks
Capecitabine 1500 mg/m2 PO BID Days 1-7 followed by 7 days of no treatment and repeated every 2 weeks"
1851457|NCT00954889|Drug|tamsulosin|Treatment: tamsulosin 0.2mg, 2T /day Posology: two 0.2 mg tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
1851458|NCT00954889|Drug|placebo|(tamsulosin 0.2mg + placebo)/day Posology: two tablet to be taken after an evening meal tamsulosin Tablet is an orally. (smoothly ingested without water)
1851459|NCT00954902|Dietary Supplement|High Antioxidant Spice Blend|14.5 g spice blend incorporated into a delivery meal including: cloves, cinnamon, oregano, rosemary, ginger, black pepper, paprika, garlic powder, and turmeric.
1851460|NCT00954902|Behavioral|Trier Psychological Stressor|This is a psychological stressor that is used to invoked stress responses in human subjects. Subjects are told they are taped and evaluated and deliver the speech in front of a trained panel of judges.
1851461|NCT00954902|Other|Placebo antioxidant concentrate|Placebo capsules
1851462|NCT00954915|Biological|teplizumab|Cohorts 1-5: escalating doses of subcutaneously administered teplizumab; cohort 6: intravenous administration of maximum tolerated subcutaneous dose.
1851463|NCT00954941|Drug|Ondansetron|8 mg bolus by vein from 30 minutes before receiving chemotherapy followed by 24 mg by vein continuous infusion daily while receiving chemotherapy until 12 hours after chemotherapy.
1851464|NCT00954941|Drug|Aprepitant|125 mg capsule by mouth every morning while receiving chemotherapy followed by 80 mg capsule by mouth daily while receiving chemotherapy continued till 1 day after last chemotherapy dose.
1851465|NCT00954954|Device|Standard PS RP-MB (P.F.C Sigma Rotating Platform knee)|Comparison of different types of knee prosthesis
1851466|NCT00954954|Device|High-flexion PS RP-MB (P.F.C Sigma Rotating Platform Flex)|Comparison of different types of knee prosthesis
1851467|NCT00954967|Behavioral|Lifestyle Counseling|The intervention is based on lifestyle advice, motivational interviewing and the use of medications, using the Clinical Practice Guidelines of the Catalan Institute of Health. Health professionals in the intervention group receive a training on the abovementioned techniques.
1851468|NCT00954993|Drug|Vaniprevir|Period 1: Vaniprevir 600 mg twice daily on Days 1-3 and a single dose of Vaniprevir 600 mg on Day 4. Period 2: Vaniprevir 300 mg twice daily on Days 1-3 and a single dose of Vaniprevir 300 mg on Day 4. There was at least a 30-day (up to approximately 140-day) washout interval between periods 1 and 2.
1851469|NCT00955006|Biological|VRC-HIVDNA-016-00-VP|Composed of six DNA plasmids in equal concentrations that encode Gag, Pol, and Nef from clade B (strains HXB2, NL4-3, NY5/BRU) and the HIV-1 Env glycoproteins from clade A (strain 92rw020), clade B (strains HXB2/BaL), and clade C (strain 97ZA012). Vaccine will be administered intramuscularly (IM) in the deltoid via needle-free Biojector.
1851470|NCT00955006|Biological|VRCHIVADV014-00-VP|A mixture of 4 recombinant serotype 5 adenoviral replication deficient vectors, each expressing HIV-1 proteins (clade B Gag-Pol fusion, clade A Env, clade B Env, clade C Env). Administered IM via needle and syringe.
1851531|NCT00955448|Device|SIS mesh (Cook Medical)|Anterior prolapse repair will be reinforced using surgical mesh made from porcine small intestine mucosa (Cook Medical)
1851532|NCT00955448|Procedure|Anterior prolapse repair|Anterior prolapse repair will be conducted without using mesh reinforcement
1851471|NCT00955032|Device|High-Frequency Repetitive Transcranial Magnetic Stimulation|In patients randomized to receive left prefrontal rTMS, each treatment will consist of 2000 stimuli (50 - 8-second trains of 40 stimuli at 5 Hz). We will administer rTMS trains every 30 seconds for 25 minutes. Stimulus intensity for the first and second trains will be 80 and 90% of MEP threshold, respectively.
1851472|NCT00955032|Device|Sham Repetitive Transcranial Magnetic Stimulation|Patients randomized to receive sham rTMS will undergo the same procedure for identifying stimulus location used in patients receiving real rTMS. Simulated rTMS will be administered using Magstim Placebo 70 mm figure-of-8 shaped coils which produce discharge noise and vibration similar to a real 70 mm coil without stimulating the cerebral cortex. However, in addition to obvious coil discharge noise, rTMS also causes electrical stimulation of the scalp. We will simulate this experience by attaching surface electrodes underneath the sham coil and in contact with the scalp.
1851473|NCT00955045|Drug|istradefylline|
1851474|NCT00955058|Drug|OCP|Daily For 3 months
1851475|NCT00955071|Other|Exercise: LVLI|low volume, low intensity
1851476|NCT00955071|Other|Exercise: HVLI|high volume, low intensity
1851477|NCT00955071|Other|Exercise: LVHI|low volume, high intensity
1851478|NCT00955084|Drug|XL999|XL999 for injection will be supplied as a brown, sterile injectable solution at a concentration of 5 mg/mL
1851479|NCT00955097|Drug|Definity®|Definity® injections given both pre-ablation and post-ablation
1851480|NCT00955110|Drug|Oxymorphone ER|15mg or 30mg
1851481|NCT00955110|Drug|Oxycodone CR|30mg or 60mg
1851482|NCT00955110|Drug|Placebo|The placebo was a sugar pill.
1851483|NCT00955110|Drug|Hydromorphone|8 mg
1851484|NCT00955136|Device|Use of intermittent high MI impulses during echocardiogram|Using the transthoracic three dimensional imaging probe, low mechanical index (MI) will examine wall motion. Intermittent high MI impulses will be administered over the microvasculature where there are wall motion abnormalities using an imaging plan that best aligns itself with the risk area. One vial of MRX 801 to be infused intravenously during echocardiography with high mechanical index impulses.
1851485|NCT00955149|Drug|Erlotinib (Tarceva)|Patients with PSC found to be positive for Trisomy 7 on biliary brushings will be treated with Erlotinib (Tarceva) at a dose of 25 mg or 50 mg by mouth once daily for 6 months.
1851486|NCT00955162|Drug|Buprenorphine (Subutex)|Sublingual tablet
1851487|NCT00955162|Drug|Buprenorphine/naloxone (Suboxone)|Sublingual tablet
1851488|NCT00955175|Radiation|hypofractionated radiation therapy|Given 5 days a week for 20, 22, or 24 fractions
1851489|NCT00955188|Other|computer-assisted intervention|
1851490|NCT00955188|Other|educational intervention|
1851491|NCT00955188|Other|medical chart review|
1851494|NCT00955214|Device|TAXUS Liberté paclitaxel-eluting coronary stent system|diameter is 2.5mm
1851495|NCT00955227|Dietary Supplement|Flax seed oil (ALA)|2 capsules each containing 500mg of ALA will be taken once per day for 6 weeks
1851496|NCT00955227|Drug|Ezetimibe|In total, 30 patients will receive ezetimibe as a drug intervention. The dosage is 10mg pod for 6 weeks
1851497|NCT00955240|Biological|cetuximab|
1851498|NCT00955240|Drug|cisplatin|
1851499|NCT00955240|Drug|fluorouracil|
1851500|NCT00955240|Other|laboratory biomarker analysis|
1851501|NCT00955240|Radiation|radiation therapy|
1851502|NCT00955253|Drug|Guanfacine|2mg oral guanfacine (encapsulated)
1851503|NCT00955253|Drug|Placebo|placebo
1851504|NCT00955266|Drug|Calcium Chloride|Calcium chloride 10mg/kg in 50cc NS delivered over 5 minutes
1851505|NCT00955266|Drug|Placebo|Normal saline, 50cc delivered over 5 minutes
1851506|NCT00955279|Drug|Placebo|Matching Placebo will be administered subcutaneously (injected under the skin by way of a needle) every 4 weeks up to Week 24.
1851507|NCT00955279|Drug|Golimumab|Golimumab will be administered subcutaneously at a dose of 200 milligram (mg) at Week 0 and thereafter at a dose of 100 mg every 4 weeks up to Week 24.
1851508|NCT00955279|Drug|Ustekinumab|Ustekinumab will be administered subcutaneously at a dose of 180 mg at Week 0 and thereafter at a dose of 90 mg at Week 8, 16 and 24 and matching Placebo was administered subcutaneously at Week 4, 12 and 20.
1851509|NCT00955292|Drug|Quarfloxin|Escalating doses of quarfloxin administered intravenously for 24 hours once weekly for three weeks every four weeks
1851510|NCT00955305|Biological|Bevacizumab|Given IV
1851511|NCT00955305|Drug|Carboplatin|Given IV
1851512|NCT00955305|Biological|Cixutumumab|Given IV
1851513|NCT00955305|Drug|Paclitaxel|Given IV
1851514|NCT00955318|Drug|KW-6500|Subcutaneous injection of 1to 6 mg of KW-6500 for the OFF state
1851515|NCT00955344|Behavioral|eToolbox|Participants randomized to the Web-based intervention will be automatically routed to a URL that will contain the Web-based intervention.
1851516|NCT00955344|Behavioral|no link to eToolbox|Participants randomized to the Practice Improvement Module will not be automatically routed to a URL that will contain the Web-based intervention.
1851517|NCT00955357|Drug|Lacosamide|"Oral Lacosamide:
Subjects Titration Phase (6 Weeks):
Week 1 - 50 mg tablet Twice daily (bid); Week 2 - 100 mg tablet bid; Week 3 - 150 mg tablet bid; Week 4 - 200 mg tablet bid; Week 5 - 200 mg tablet bid; Week 6 - 150 mg tablet bid OR Week 6 - 200 mg tablet bid
Maintenance Phase (24 Weeks):
200 mg tablet bid OR 150 mg tablet bid
Taper Phase (1 - 3 Weeks):
50 mg tablet bid for 1 week OR 100 mg tablet bid for 1 week OR 150 mg tablet bid for 1 week"
1851518|NCT00955383|Drug|GSK2190915|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
1851519|NCT00955383|Drug|Placebo|Matching placebo
1851525|NCT00955435|Drug|bicalutamide|
1851535|NCT00955474|Drug|Quetiapine|Quetiapine XR 100 mg/h.s. will be the starting dose and increased by 100 mg q h.s. q day to a target dose of 300 mg/h.s. by day three and continued on 300 mg/h.s. through week three. Between weeks four and eight, there will be flexible dosing up to 800 mg/h.s. or reductions in doses to no lower than 200 mg/h.s. Incremental increases or decreases in dose will be no more than 100 mg/h.s. over a minimum of one week, unless a patient is unable to tolerate the current dose. Patients unable to tolerate at least 200 mg/h.s. will be discontinued from the study.
1851536|NCT00955474|Drug|escitalopram|"Active comparator arm:
Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
1851537|NCT00955474|Drug|Sertraline|"Active comparator arm:
Sertraline 50 mg/a.m. starting dose; increased to 100 mg/a.m. at week 2; continued on 100 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 200 mg/a.m. or reductions in doses to no lower than 50 mg/a.m.
Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m.
Escitalopram 5 mg/a.m. starting dose; increase to 10 mg/a.m. at week 2 and continued at 10 mg/a.m. through week 3. Weeks 4-8: flexible dosing up to 20 mg/a.m. or reductions in doses to no lower than 5 mg/a.m."
1851538|NCT00955474|Drug|Citalopram|"Active comparator arm:
Citalopram 20 mg/a.m. starting dose; increased to a target dose of 40 mg/a.m. at week 2; continued on 40 mg/a.m. through Week 8: reductions in doses to no lower than 20 mg/a.m."
1851539|NCT00955487|Drug|Inhaled Nitric Oxide (iNO)|iNO will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
1851540|NCT00955487|Drug|Nitrogen (placebo)|Nitrogen will be delivered using the iNOVent device to provide 10 ppm proximally (yielding approximately 5 ppm to the posterior pharynx).
1851541|NCT00955500|Dietary Supplement|Branched-chain amino acids|30 grams of oral branched-chain amino acids (leucine: 13.5 grams, isoleucine: 9 grams, valine: 7.5 grams) daily
1851542|NCT00955500|Dietary Supplement|Maltodextrin|30 grams of oral maltodextrin daily
1851543|NCT00955513|Drug|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% twice a day
1851544|NCT00955513|Drug|diclofenac diethylamine gel 2.32%|diclofenac diethylamine gel 2.32% three times a day
1851545|NCT00955513|Drug|Placebo|Placebo
1851546|NCT00955526|Drug|Istradefylline|20 mg KW-6002 per day (two 10 mg tablets orally once daily for 12 weeks)
1851547|NCT00955526|Drug|Istradefylline|40mg KW-6002 per day (two 20 mg tablets orally once daily for 12 weeks)
1851548|NCT00955526|Drug|Placebo|Two placebo tablets once daily for 12 weeks
1851549|NCT00955539|Device|AV-optimization followed by AV- and VV-optimization|Patients are AV-optimized the first 4 months,then AV- and VV-optimized the next 4 months.
1851550|NCT00955539|Device|AV- and VV-optimization followed by AV-optimization only.|Patients are AV- and VV-optimized the first 4 months,then AV-optimized the next 4 months.
1851553|NCT00955565|Procedure|Navigated|Subjects receive receive computer assisted placement of the sacroiliac screws. The computer assisted placement will be performed by using the BrainLab Vector Vision®Trauma Navigation Software. Two approaches will be used, the 2D navigation and 3D navigation.
1851554|NCT00955565|Procedure|Conventional|Subjects receive standard fluoroscopic placement of the sacroiliac screw.
1851555|NCT00955578|Procedure|Punch Biopsy|5-6 punch biopsies of affected areas
1851556|NCT00955591|Other|Papanicolaou test|
1851557|NCT00955604|Drug|Group R+AD Rasagiline + Antidepressant|Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
1851558|NCT00955604|Drug|Group R Rasagiline|At least 2 months of rasagiline
1851559|NCT00955604|Drug|Group AD Anti-PD + Antidepressant|An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
1851560|NCT00955617|Other|Contrast-enhanced MRA - Imaging examination|Administration of 0.1 mmol/kg of contrast product (Dotarem and Gadovist)
1851563|NCT00955643|Other|oxygen|
1851564|NCT00955643|Other|other|
1851565|NCT00955669|Biological|Symptoms and Objective Examination|5.0*108~5.0*109 MSCs and MNCs were transplant into impaired lower limbs by intramuscular injection
1851568|NCT00955695|Drug|erlotinib hydrochloride|
1851569|NCT00955695|Drug|gefitinib|
1851570|NCT00955695|Other|questionnaire administration|
1851571|NCT00955695|Procedure|quality-of-life assessment|
1851572|NCT00955695|Radiation|whole-brain radiation therapy|
1851573|NCT00955708|Device|ACUITY Spiral Left Ventricular Lead|The implant of the ACUITY Spiral Lead
1851574|NCT00955721|Drug|Gemcitabine|Intravenously (IV) on Day 1 of each 14 day cycle, until progression or unacceptable toxicity develops.
1851575|NCT00955721|Drug|Oxaliplatin|Intravenously (IV) on Day 2 of each 14 day cycle, until progression or unacceptable toxicity develops.
1851576|NCT00955721|Drug|Sorafenib|Orally, twice daily for each 14-day cycle, until progression or unacceptable toxicity develops.
1851577|NCT00955734|Other|Early motion|One set of patients will begin wrist motion at 1 week after surgery.
1851578|NCT00955734|Other|Immobilization|This set of patients will be casted for 6 weeks after surgery.
1851579|NCT00955747|Drug|Tagatose|powder; 15 grams three times daily; one year
1851580|NCT00955747|Drug|Sugar Substitute Splenda|1.5 g powder tid
1851581|NCT00955760|Drug|Neramexane|Drug-Drug Interaction Study
1851617|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21
1851790|NCT00963924|Drug|Placebo|Placebo by mouth one hour before first cognitive remediation session each week for eight weeks.
1851582|NCT00955773|Drug|GSK1120212 plus everolimus|Dose escalation will begin at low doses of GSK1120212 and everolimus, then gradually increase in future cohorts. Dose escalation will continue until a recommended combination dose is identified. The recommended combination dose will be used to treat pancreatic and lung cancer patients in later groups in this study.
1851583|NCT00955786|Drug|CX-3543|Escalating doses of CX-3543 administered intravenously daily for 5 consecutive days every 21 days.
1851584|NCT00955799|Drug|Neramexane mesylate|Double-blind treatment period of 29 weeks up to 75 mg Neramexane mesylate per day
1851585|NCT00955799|Drug|Placebo|Double-blind treatment period of 29 weeks placebo
1851586|NCT00955812|Drug|OPB-31121|50 mg by mouth 2 times a day on Days 1-21 of each 28-day cycle.
1851587|NCT00955825|Drug|300 IR|300 IR grass pollen allergen extract tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
1851588|NCT00955825|Drug|Placebo|Placebo sublingual tablet taken daily for approximately 6 months starting 4 months before the grass pollen season and over the grass pollen season
1851589|NCT00955838|Other|Rehabilitation technique|12 therapy session
1851590|NCT00955851|Other|Pre and post vaccination titers|Titers will be obtained pre vaccination and 4 weeks post vaccination
1851591|NCT00955877|Drug|Extended-release Epidural morphine (EREM) 80|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (80μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
1851592|NCT00955877|Drug|Extended-release Epidural Morphine (EREM) 120|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Epidural DepoDur (120μg/kg) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
1851593|NCT00955877|Drug|Control: Saline|After completion of the rhizotomy, the dura will be closed in the standard water-tight fashion with running suture. Preservative-free normal saline (2.5 ml) will be placed under direct vision in the L1 laminectomy defect. It will also be dispensed 1-2 levels above and 1-2 levels below using a flexible angiocatheter.
1851594|NCT00955890|Drug|Dexrazoxane hydrochloride|pink power 250mg/bottle DEX:EPI,10:1 every 3 weeks
1851595|NCT00955890|Drug|Dexrazoxane hydrochloride|pink powder 250mg/bottle DEX:EPI,15:1 every 3 weeks
1851596|NCT00955903|Behavioral|Exercise|Participants will participate in supervised exercise sessions
1851597|NCT00955903|Behavioral|Reduced Calorie Diet|Participants will follow a reduced calorie diet
1851598|NCT00955903|Behavioral|Weight Maintenance Diet|Participants will follow a weight maintenance diet
1851599|NCT00955916|Drug|CLAG Regimen|The CLAG regimen consisted of: Cladribine, 5 mg/m^2 administered via 2 hour IV daily for 5 consecutive days starting on day 2; Cytarabine, 2 mg/m^2 administered through a 4 hour IV starting 2 hours after the ignition of Cladribine for 5 days starting on day 2; granulocyte colony-stimulating factor (G-CSF): 300 mcg subcutaneous (SC) for 6 days starting 12-24 hours (Day 1) before the first dose of Cladribine.
1851600|NCT00955916|Drug|Gleevec®|Imatinib mesylate 400 mg orally twice daily was administered on day 2 to day 15. Re-induction was allowed if participant had partial response (PR).
1851601|NCT00955929|Drug|Placebo QHS and sildenafil and questionnaires|Pts will be offered sildenafil 100 mg to be used before intercourse on an as-required basis. They will be given six 100 mg doses, per month, for a 12-month duration. Each patient in this group will use a placebo pill (blinded) each night, except on a nights that 100mg is taken for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
1851602|NCT00955929|Drug|Sildenafil and questionnaire|Patients will be instructed to take sildenafil 50 mg QHS (blinded) except on nights that they are interested in sexual relations, they will then be instructed to use sildenafil 100mgs (open-label) and skip the 50mg dose. Sildenafil treatment will start within 24-48 hours post-surgery. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window
1851603|NCT00955929|Drug|Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires|Intracavernous injections of a trimix combination (Papaverine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mL) will be injected three times a week, and sildenafil 50mg taken on the other four (non-injection) nights. Injection therapy can be used for the purpose of sexual relations. Patients will be evaluated in the clinic and will complete the questionnaires at baseline (pre-treatment evaluation), 3, 6, 9, 12, 18 and 24 months after the operation. At 12 months postoperatively, all patients will stop treatment. Visits 3, 6, 9, 12, 18, and 24 months will have ±2 week window.
1851604|NCT00955942|Dietary Supplement|flaxseed|Given orally
1851605|NCT00955942|Other|placebo|Given orally
1851606|NCT00955955|Other|6(S)-5-MTHF(Deplin)|Deplin is a medical food. Patients will take 15 mg/day of deplin.
1851607|NCT00955955|Other|Placebo|Inactive substance
1851608|NCT00955968|Drug|Highly active antiretroviral therapy (HAART)|A combination of three or more HIV medications belonging to two or more drug classes
1851611|NCT00955994|Drug|asimadoline|
1851612|NCT00956007|Biological|cetuximab|Given IV
1851613|NCT00956007|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy.
1851614|NCT00956020|Biological|Platelet rich fibrin matrix|Single treatment with platelet rich fibrin matrix
1851615|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
1851616|NCT00956046|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
1851788|NCT00963911|Procedure|quality-of-life assessment|
1851618|NCT00956059|Drug|prednisone, FK506, MMF|1.in the initial 3 months，prednisone dosage is 30mg per day；in the following 4~6 months，prednisone dose decreased to 20mg per day，then tapered gradually to 10mg per day；2.the initial dosage of FK506 is 0.2mg/kg/d, twice per day，the maintenance dosage is adjust to the serum concentration of FK506 (is maintained at the level of 6~10μg/L)；3. the initial dosage of MMF is 1.0g, twice per day，then reduce to 0.75 g, twice per day after 3 months
1851619|NCT00956059|Drug|prednisone|In the initial 16~24 weeks，prednisone is given at full dose of 1mg/kg/d，then prednisone is tapered gradually，the whole course of treatment is 52 weeks
1851620|NCT00956072|Drug|imatinib mesylate|Patients receive imatinib mesylate
1851621|NCT00956072|Procedure|therapeutic conventional surgery|Patients undergo surgery
1851622|NCT00956085|Drug|Memantine|Open label memantine titrated in 5mg increments weekly to target dose of 10mg po bid for up to 6 weeks. Memantine was continued to 12 weeks in those with treatment response,13 either previous response to ketamine (≥ 35% Y-BOCS reduction 1 week after IV ketamine) or current response to memantine (≥ 35% Y-BOCS reduction from pre- to post-6 weeks of memantine).
1851623|NCT00956098|Drug|oltipraz|60mg bid 90mg qd
1851624|NCT00956098|Drug|placebo|
1851625|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 7.5 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 7.5μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
1851626|NCT00956111|Biological|split-virion, adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, adjuvanted H1N1 vaccine 21 days apart.
1851627|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 15μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
1851628|NCT00956111|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg per dose|100 adults, 100 adolescents and 100 children were assigned to receive 2 doses of 30μg split-virion, non-adjuvanted H1N1 vaccine 21 days apart.
1851629|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 5 μg per dose|100 adults were assigned to receive 2 doses of 5μg whole-virion, adjuvanted H1N1 vaccine 21 days apart.
1851630|NCT00956111|Biological|whole-virion, adjuvanted H1N1 vaccine of 10 μg per dose|100 adults were assigned to receive 2 doses of 10μg whole-virion, adjuvanted H1N1 vaccine 21 days apart. 100 elders were assigned to receive 1 doses of 10μg whole-virion, adjuvanted H1N1 vaccine
1851631|NCT00956111|Biological|placebo control|100 adults were assigned to receive 2 doses of placebo 21 days apart.
1851632|NCT00956137|Procedure|Ultrasound guidance|ultrasound imaging
1851633|NCT00956137|Procedure|Manual palpation|Manual Palpation of vertebra
1851634|NCT00956150|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
1851635|NCT00956150|Drug|Rifaximin|Rifaximin 600 mg three times a day by mouth (TID PO) x 10 days
1851636|NCT00956150|Drug|Placebo|Placebo TID PO x 10 days
1851637|NCT00956163|Procedure|magnetic resonance imaging|Undergo whole-body MRI
1851638|NCT00956163|Radiation|fluorine F 18 sodium fluoride|Undergo fluorine F 18 sodium fluoride PET/CT scan
1851639|NCT00956163|Procedure|positron emission tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
1851640|NCT00956163|Procedure|computed tomography|Undergo fluorine F 18 sodium fluoride PET/CT scan
1851641|NCT00956163|Radiation|technetium Tc 99m methylene diphosphonate|Undergo technetium Tc 99m methylene diphosphonate bone scan
1851642|NCT00956163|Other|laboratory biomarker analysis|Correlative studies
1851643|NCT00956176|Drug|Cidofovir|Single dose of 5 mg/kg administered in 100 ml of normal saline solution through a foley catheter to bladder. The catheter will be clamped for 2 hours to keep the drug in bladder.
1851644|NCT00956189|Drug|amisulpride|Amisulpride dosage was increased from 200 up to a maximum of 1000 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
1851645|NCT00956189|Drug|aripiprazole|Aripiprazole dosage was increased from 5-7.5 up to a maximum of 30 mg/day and the dosage of their previous antipsychotics can be tapered gradually under stable clinical condition.
1851646|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset)
1851647|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and Day 21 (all participants); and 0.5 mL of a trivalent influenza vaccine (TIV) at Month 13 (antibody persistence subset).
1851648|NCT00956202|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated + Adjuvant)|0.5 mL, Intramuscular on Day 0 and day 21
1851649|NCT00956215|Drug|Aprepitant|80 mg tablet of Aprepitant with 50 ml of water 30 minutes before surgery
1851650|NCT00956215|Drug|Aprepitant placebo|80 mg placebo tablet with 50 ml of water no later than 30 minutes before induction of anesthesia.
1851651|NCT00956228|Radiation|radioimmuniguided intenstiy modulated radiotherapy|All patients recieved 75.6 Gy in 42 fractions to the prostate and the region of the prostate which enhanced on prostascint scan was simaltaneously boosted to a total dose of 82 Gy
1851652|NCT00956241|Procedure|j-pouch coloanal anastomosis|
1851653|NCT00956241|Procedure|side-to-end coloanal anastomosis|
1851654|NCT00956254|Drug|Fentanyl sublingual spray|Fentanyl was supplied in single-dose glass vials assembled into a delivery device to be used as a sublingual spray.
1851655|NCT00956267|Drug|Letrozole|2.5 mg letrozole oral tablets daily from day 3 of the menses for 5 days up to 6 cycles
1851656|NCT00956267|Procedure|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
1851657|NCT00956293|Drug|Basiliximab|On day 0, 2 hours prior to transplant and day 4 post-transplant, 20 mg x2 were given to all participants. Post randomization, 20mg at weeks 7 and 12 were given to the Everolimus group.
1851872|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
1851658|NCT00956293|Drug|Enteric Coated Mycophenolic Acid (MPA)|A loading dose regimen of 2880 mg/day during weeks 1 and 2 (pre-randomization) were given. During weeks 3 - 6 (pre-randomization), 2160 mg/day were given and during weeks 7 - 24, 1440 mg/day were given if tolerated. Dose reductions due to side effects were possible.
1851659|NCT00956293|Drug|RAD001|Upon randomization, 3 mg (od) on Day 1, and 3 mg (1.5 mg every 12 hours) on Day 2 was given. Afterwards, the dosage was based on blood trough level (5 - 10 ng/mL).
1851660|NCT00956293|Drug|Cyclosporin A (CsA)|Dosage was based according to blood level
1851661|NCT00956293|Drug|Corticosteroids|Dosage was administered according to local standards and administration was optional as per clinical need and the Investigators' discretion. Steroid withdrawal occurred after week 2 (pre-randomization).
1851662|NCT00956306|Drug|Udenafil|100mg Single Oral Dose of Udenafil
1851663|NCT00956319|Drug|Zolpidem MR|oral
1851664|NCT00956319|Drug|Estazolam|oral
1851665|NCT00956332|Biological|MultiGeneAngio|Low-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
1851666|NCT00956332|Biological|MultiGeneAngio|Intermediate-therapeutic dose of MultiGeneAngio in suspension administered as one treatment, intra-arterially
1851667|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 25U/kg nonacog beta pegol administered intravenously (into the vein)
1851668|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 50U/kg nonacog beta pegol administered intravenously (into the vein)
1851669|NCT00956345|Drug|nonacog beta pegol|Cohort to receive a single dose of 100U/kg nonacog beta pegol administered intravenously (into the vein)
1851670|NCT00956371|Drug|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
1851671|NCT00956371|Drug|ONO-7746|5mg, 10mg, 20mg, 50mg, 100mg, 200mg, 400mg, 800mg, 1200mg QD/1 day
1851672|NCT00956384|Procedure|One-stage dermal matrix/implant procedure|One-stage breast reconstruction with dermal matrix and implant
1851673|NCT00956384|Procedure|Two-stage tissue expander/implant procedure|Two-stage breast reconstruction with tissue expander and implant
1851674|NCT00956397|Drug|Rifaximin|rifaximin 550 mg TID PO x 10 days
1851675|NCT00956397|Procedure|Lactulose Breath Test|Test will begin with a baseline breath sample followed by ingestion of 10g of lactulose (Xactdose, South Beloit, IL) in 100ml of water. Breath samples will be collected every 15 min for 180 min. Gas samples will be analyzed for hydrogen and methane using a gas chromatograph (Model SC, Quintron Instruments, Milwaukee, WI).
1851676|NCT00956397|Drug|Placebo|placebo TID x 10 days
1851677|NCT00956410|Biological|CAD106|
1851678|NCT00956423|Behavioral|moderate-intensity aerobic and resistance training|Individuals will complete four days of aerobic exercise of moderate intensity (60% of maximal VO2, approximated from heart rate). Duration of aerobic activity will gradually increase from weeks 1 through 4 until 180 min of aerobic exercise at the prescribed intensity is performed each week. Following aerobic exercise on two days per week, moderate-intensity resistance training will be performed using eight different resistance machines. One set of 8-12 repetitions will be performed during weeks 1-4; from week 5-on, 2 sets of 8-12 repetitions will be performed.
1851679|NCT00956423|Behavioral|low-intensity stretching|Individuals will perform supervised whole-body flexibility exercises on two days per week. Two sets of each exercise will be performed, with the duration of each stretch gradually increasing from 15 sec to 30 sec. A total of 15-20 stretches, focusing on whole-body flexibility, will be performed.
1851680|NCT00956436|Drug|BIIB022|IV Q3W
1851681|NCT00956436|Drug|Sorafenib|Standard dosing of Sorafenib
1851682|NCT00956449|Biological|Seasonal Influenza Vaccine|1 dose of Influenza Vaccine Surface Antigen, Inactivated
1851684|NCT00956475|Behavioral|telephone-based intervention|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
1851685|NCT00956475|Other|questionnaire administration|Patients are assessed in a telephone interview using a brief demographic and clinical data form. Patients then undergo quality-of-life assessment by the Cancer Patient/Cancer Survivor Version questionnaire via telephone.
1851686|NCT00956475|Procedure|assessment of therapy complications|questionnaire via telephone
1851687|NCT00956475|Procedure|fatigue assessment and management|questionnaire via telephone
1851688|NCT00956475|Procedure|psychosocial assessment and care|questionnaire via telephone
1851689|NCT00956475|Procedure|quality-of-life assessment|questionnaire via telephone
1851690|NCT00956488|Behavioral|Treadmill Exercise|The intervention will consist of 30 minutes of exercise, performed 3 times per week for 8 weeks (24 sessions). Patient will walk on a treadmill with up to 40% of their body weight supported by a body weight support system with an overhead harness. The training session duration will be 60 minutes consisting of six intervals of 5 minutes exercise, interspersed with 6 intervals of 5 minutes rest to avoid overwork weakness and fatigue. Five minute exercise intervals should be sufficient for patients to reach a steady state. Patients will build up their endurance to this training level at their own pace as tolerated. Walking speed will be determined as tolerated by each patient. Exercise intensity will be guided by each patient's own perception of exertion, but not to exceed level 12-13 (mild to moderate) on the modified Borg perceived exertion scale, and by oxygen saturation (Sa O2) ≥ 90% monitor by handheld pulse Oximeter.
1851691|NCT00956514|Device|Transcranial Magnetic Stimulation|Neurophysiologic Predictors of Outcome with rTMS Treatment of Major Depressive Disorder
1851692|NCT00956527|Behavioral|Modified traditional martial arts training|"Twice weekly hour-long training sessions. Classes will not vary significantly from those classes already taught at the karate school, with the following exceptions: 1) the focus of training will be primarily on the non-combative components of martial arts training, 2) there will be a higher instructor to student ratio, 3) belt advancement will be based not only on mastery of karate techniques, but also on achieving the predetermined goals as described above, and 4) weekly 5-10 minute talks will be delivered by the primary instructor and will consist of concepts relevant to substance abuse treatment (including both issues directly relating to drug use and the common skills deficits seen in at risk youth) and how these issues relate to martial arts concepts."
1853925|NCT00979888|Procedure|dyspnea management|
1851693|NCT00956540|Procedure|Deflating tracheal cuff|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for prolonged weaning or ventilatory support.
1851694|NCT00956540|Procedure|Deflating tracheal cuff 2|Deflating tracheal cuff during ventilatory disconnections along the weaning phase in patients tracheostomized for low level of consciousness or inability to adequate manage the airway.
1851695|NCT00956553|Biological|Cervarix|Three doses of Cervarix at month 0, 1 and 6.
1851696|NCT00956553|Biological|Gardasil|Three doses of Gardasil at month 0, 1 and 6.
1851697|NCT00956566|Behavioral|dietary intervention|dietary counseling, group teaching
1851698|NCT00956592|Device|CMAC video laryngoscope|Intubation utilizing the assistance of video enhancement
1851699|NCT00956592|Device|Macintosh laryngoscope|Patients will be intubated utilizing either a Macintosh 3 or Macintosh 4 designed blade
1851700|NCT00956605|Behavioral|Computer attention training systems for children with ADHD|Computer attention training systems for children with ADHD, one with and one without EEG-biofeedback, were delivered via approximately 20 sessions to the participants
1851701|NCT00956631|Procedure|Interlaminar Decompression|The MILD® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompression.
1851702|NCT00956644|Drug|irbesartan/amlodipine|Pharmaceutical form: 150/5 mg and 150/10 mg tablets (fixed combination) Route of administration: oral Dose regimen: 1 tablet once daily in the morning
1851703|NCT00956644|Drug|amlodipine|Pharmaceutical form: 5 and 10 mg tablets Route of administration: oral Dose regimen: 1 tablet once daily in the morning
1851704|NCT00956657|Behavioral|Psychological Intervention Session|One-off session aimed at changing participants beliefs around illness control and consequences, applied using a motivational interviewing style.
1851705|NCT00956670|Other|Quality-of-Life Assessment|Ancillary studies
1851706|NCT00956670|Other|Questionnaire Administration|Ancillary studies
1851707|NCT00956670|Procedure|Study of High Risk Factors|Undergo lymphedema assessment
1851708|NCT00956670|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1851709|NCT00956670|Procedure|Therapeutic Laparoscopic Surgery|Undergo surgery
1851710|NCT00956670|Procedure|Therapeutic Lymphadenectomy|Undergo lymphadenectomy
1851711|NCT00956683|Procedure|Ultrasound Guided Infraclavicular Nerve Block|Use of Ultrasound to help guide needle placement and local anesthetic injection during infraclavicular nerve block.
1851712|NCT00956683|Procedure|Dual-Endpoint nerve stimulation|Use of dual-endpoint nerve stimulation to guide needle placement and local anesthetic injection during infraclavicular nerve block.
1851713|NCT00956696|Drug|topiramate|oral, daily dose or twice daily dose, total daily dose 25-200mg per day duration: 16 weeks
1851714|NCT00956709|Drug|levobupivacaïne 0,5 %|20mL de levobupivacaïne 0,5 % 20mL de ropivacaïne 0,5 %
1851715|NCT00956709|Drug|ropivacaïne 0,5 %|20mL de ropivacaïne 0,5 %
1851716|NCT00956722|Drug|Bovine Colostrum Powder|Bovine Colostrum Powder (Biogard)
1851717|NCT00956735|Other|Pistachio|3.0 oz (2 servings) of roasted and salted or unsalted pistachios
1851718|NCT00956748|Drug|Ciprodex|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
1851719|NCT00956748|Drug|Ciprodex and 2% NAC|Administer 3 to 5 drops tid for 14 days. Continue treatment for another 14 days if otorrhea persists.
1851720|NCT00956761|Biological|Seasonal Influenza Vaccine (MF59C.1)|1 dose of a surface antigen, inactivated, adjuvanted with MF59C.1, seasonal influenza vaccine, formulation 2009-2010
1851721|NCT00956774|Procedure|HSG with acorn-tipped cannula|Use of acorn-tipped cannula for HSG to evaluate tubal patency
1851722|NCT00956774|Procedure|HSG with cervical vacuum cup|cup placed over cervix to create vacuum pressure.
1851723|NCT00956774|Procedure|HSG with balloon catheter|balloon inserted via catheter into cervic for dilation.
1851724|NCT00956787|Drug|AR-67 (20S)-7-t-Butyldimethylsilyl-10-hydroxycamptothecin)|Patients will receive AR-67 at an initial dose of 7.5 mg/m2 IV over 1 hour daily for 5 days. In patients with stable disease, treatment may continue for up to a total of 12 courses of therapy; about 1 to 2 years.
1851725|NCT00956800|Other|Accu-Chek 360 software|Study group which will receive 3 routine office visits in the same time, and have two visits conducted by computer interaction, using the Accu-Chek 360 software.
1851726|NCT00956800|Other|Normal care|Control group will receive 5 routine office visits in one year
1851727|NCT00956813|Dietary Supplement|flaxseed|Given orally
1851728|NCT00956813|Other|placebo|Given orally
1851729|NCT00956826|Device|Agit Vacuum|With an electrode and a regular vacuum device
1851730|NCT00956839|Drug|Vitamin D3 (Cholecalciferol)|"Arm 1 - Intramuscular vitamin D3 3,00,000 Units single dose
Arm 2 - Intramuscular vitamin D3 6,00,000 Units single dose
Arm 3 - Oral vitamin D3 500 Units/day for 6 months"
1851731|NCT00956865|Other|Voucher|Vouchers given to reimburse transportation
1851732|NCT00956865|Other|Telephone Call|Telephone reminder calls
1851733|NCT00956865|Other|Contact|Contact at senior center to encourage follow up
1851734|NCT00956904|Device|3-D TRUS navigation software during T-RALP|A new solution for guiding the surgeon in RALP is image-guided navigation using transrectal ultrasound (TRUS). A TRUS-guided intraoperative navigation system using a robotic ultrasound probe manipulator (TRUS Robot) has been developed. The research is a pilot clinical trial of the TRUS Robot and three-dimensional (3-D) navigation software to test its image-guidance ability of helping the surgeon during RALP. This is a dual robot approach, a Tandem-RALP (T-RALP). The TRUS Robot allows a steady holding as well as remote manipulation of the TRUS probe. In addition, the TRUS Robot can track the accurate position of TRUS probe which allows 3-D reconstruction of the images.
1851735|NCT00963638|Dietary Supplement|MagTabSR|MagTabSR/placebo 168 mgs BID for 6 six weeks
1851736|NCT00963638|Dietary Supplement|Placebo|MagTabSR/placebo 168 mgs BID for 6 six weeks
1851737|NCT00963651|Device|Chest tomosynthesis and X-ray|VolumeRAD tomosynthesis; Conventional Chest X-ray; Dual energy (bone and soft tissue PA chest images)
1851738|NCT00963664|Drug|lovastatin|lovastatin tablets, oral administration, daily dose 1.5 mg/kg, divided into three or four essentially equal doses with meals
1851789|NCT00963924|Drug|D-cycloserine|50 mg by mouth one hour before first cognitive remediation session each week for eight weeks.
1851739|NCT00963664|Drug|interferon alfa-2b|interferon alfa-2b for subcutaneous injection, each injection 100,000 international units per kg body mass, three injections weekly
1851740|NCT00963677|Procedure|Nasotracheal Intubation through seeing optical stylet (SOS)|Nasotracheal intubation using seeing optical stylet in the patients with the anticipated difficult intubation. Arm 1:routine anesthesia induction,0.1mg/kg midazolam, 3-8mcg/kg fentanyl, 0.08-0.15mg/kg vecuronium and 0.3mg/kg etomidate, Nasotracheal intubation with seeing optical shikani; Arms 2: Sevoflurane combined with oxyge, 0.3mg/kg Etomidate and 1-2mg/kg succinylcholine for intubation, nasotracheal intubation with seeing optical shikani
1851741|NCT00963690|Device|CloSys Hemostatic Device (HD)|Deploy CloSys HD to achieve hemostasis
1851742|NCT00963690|Procedure|Standard compression|Use standard compression to achieve hemostasis
1851743|NCT00963703|Drug|Rituximab|Rituximab 1000 mg Intravenously day 1 and day 15
1851744|NCT00963716|Device|Hot biopsy forceps|Endobronchial biopsies taken with the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
1851745|NCT00963716|Device|Cold biopsy forceps|Endobronchial biopsies taken without the application of an electrocoagulation current by an electrocoagulation-capable biopsy forceps
1851746|NCT00963729|Drug|cyclophosphamide|Given IV
1851747|NCT00963729|Drug|docetaxel|Given IV
1851748|NCT00963729|Drug|epirubicin hydrochloride|Given IV
1851749|NCT00963729|Drug|fluorouracil|Given IV
1851750|NCT00963729|Drug|letrozole|Given orally
1851751|NCT00963742|Device|Lenstec Softec HD IOL implantation|surgical removal of cataract and implantation of Softec HD PCIOL
1851752|NCT00963768|Drug|JNJ 28431754|A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
1851753|NCT00963768|Drug|Placebo|A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
1851754|NCT00963781|Device|Medtronic Endeavor Stent|The study population was to consist of 900 consecutive, eligible patients with ischemic heart disease scheduled to undergo elective percutaneous coronary revascularization and amenable to treatment with an Endeavor drug-eluting stent with reference vessel diameter between 2.5 and 4.0 mm. Patients will be assigned to 6 month duration of post-procedure thienopyridine treatment with indefinite aspirin (minimum 81 mg daily) according to protocol. Recruitment was terminated early due to difficulty recruiting patients and difficulty achieving patient compliance with the six month anti-platelet protocol.
1851755|NCT00963781|Drug|Reduced duration (6 months) DAPT|
1851757|NCT00963807|Drug|Cisplatin|Given IV
1851758|NCT00963807|Procedure|CT|Undergo FDG PET/CT, FLT PET/CT and thoracic CT
1851759|NCT00963807|Drug|Docetaxel|Given IV
1851760|NCT00963807|Drug|FDG|Undergo FDG PET/CT
1851761|NCT00963807|Drug|FLT|Undergo FLT PET/CT
1851762|NCT00963807|Procedure|PET/CT|Undergo FDG PET/CT and FLT PET/CT
1851763|NCT00963807|Procedure|Surgery|Undergo surgery
1851764|NCT00963820|Drug|Ixazomib citrate|Ixazomib citrate capsules
1851765|NCT00963833|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients under daily life treatment receiving Betaferon according to local product information.
1851770|NCT00963859|Procedure|Robotic-assisted laparoscopic surgery|During radical cystectomy, robotic-assisted technique used to perform cystectomy and pelvic lymph node dissections. Each patient will undergo a second-look open lymph node dissection once the incision is made at the end for the urinary diversion.
1851771|NCT00963872|Drug|cyclophosphamide|50 mg/kg intravenously (IV) over 2 hours on Day -6.
1851772|NCT00963872|Drug|fludarabine phosphate|40 mg/m^2 over 1 hour on Days -6 through -2.
1851773|NCT00963872|Radiation|Total body irradiation|200 cGy on Day -1
1851774|NCT00963872|Biological|Umbilical cord blood unit with C3a fragment|On Day 0, the C3a primed UCB unit will be infused intravenously SECOND, within 30 minutes of the completion of the infusion of the unmanipulated UCB unit, through a central line without in-line filtration in a manner identical to the unmanipulated UCB unit.
1851775|NCT00963872|Biological|Unmanipulated UCB Unit|On Day 0, the unmanipulated UCB unit will be infused FIRST through a central line without in-line filtration per institutional guidelines.
1851776|NCT00963885|Drug|Copegus|1000 or 1200mg po daily for 24 or 48 weeks
1851777|NCT00963885|Drug|Pegasys|180micrograms sc weekly for 24 or 48 weeks
1851778|NCT00963885|Drug|Placebo|po for 12 weeks
1851779|NCT00963885|Drug|Placebo|po for 24 weeks
1851780|NCT00963885|Drug|RO5190591 (Danoprevir)|300mg po q8h for 12 weeks
1851781|NCT00963885|Drug|RO5190591 (Danoprevir)|600mg po q12h for 12 weeks
1851782|NCT00963885|Drug|RO5190591 (Danoprevir)|900mg po q12h for 12 weeks
1851783|NCT00963885|Drug|RO5190591 (Danoprevir)|300mg po q8h or 600mg po q12h or 900po q12h for 24 weeks
1851784|NCT00963898|Device|Target controlled infusion(TCI), Bispectral index(BIS)|Using TCI and BIS or not
1851785|NCT00963911|Other|medical chart review|
1851786|NCT00963911|Other|screening questionnaire administration|
1851787|NCT00963911|Procedure|comparison of screening methods|
1851791|NCT00963924|Behavioral|Cognitive Remediation|40 one-hour daily sessions of cognitive remediation (Brain Fitness Program) over eight weeks.
1851792|NCT00963937|Drug|Sumatriptan 25 mg|One Sumatriptan 25mg tablet and one Matching Placebo tablet should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
1851793|NCT00963937|Drug|Sumatriptan 50 mg|Two Sumatriptan 25mg tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
1851794|NCT00963937|Drug|Placebo|Two Matching Placebo tablets should be administered as soon as possible (within 30 minutes) after the development of a migraine associated with 3 or more pain on a 5-grade scale.
1851795|NCT00963950|Procedure|transvaginal cholecystectomy|Transvaginal approach to gallbladder removal.
1851796|NCT00963950|Procedure|laparoscopic cholecystectomy|laparoscopic cholecystectomy
1851797|NCT00963963|Behavioral|Healthy Futures parent education|Multi-year audio CD parent education
1851798|NCT00964444|Device|Peisner device|The doctor/midwife stands on the device while the baby is delivered. The device measures how much force is exerted on the baby.
1851799|NCT00964457|Drug|cetuximab|cetuximab 500mg per meter square every second week
1851800|NCT00964470|Device|AWBAT™-D and XEROFORM™ OR GLUCAN II™ dressings|Dressing, donor site dressings
1851801|NCT00964483|Behavioral|DASH diet|The intervention will consist of a 12-week pilot trial in which participants will be given intervention materials tailored to their community, focusing on DASH. Intervention content will be designed to provide participants with the knowledge and skills to adopt the DASH eating pattern, specifically to increase fruit, vegetable, and low-fat dairy intake, and to decrease saturated fats and sodium. They will follow this diet for 12 weeks.
1851802|NCT00964483|Behavioral|Delayed Intervention|"The participants will receive a guide written by NHLBI entitled, Your Guide to Lowering Blood Pressure."
1851803|NCT00964496|Drug|Thalidomide|Patients were randomly assigned to receive a four-month course of 25 mg of thalidomide (Pharmaceutical Co., Ltd. of Chang-zhou, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
1851804|NCT00964496|Drug|Iron|Patients were randomly assigned to receive a four-month course of 100 mg of iron (Pharmaceutical Co., Ltd. of Nanjing, China). Medications were taken orally four times daily at 6 a.m., 12 noon, 6 p.m., and 10 p.m.
1851805|NCT00964522|Other|Nurse education and care program|Random allocation of the patients in two arms according to the nursing cares. The arm A is the one of standard education and care. They consist of receiving programmed oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle of treatment. Also, the patients will be able to ask for information to the nurses when they need it. Arm B is the one of experimental education and care. They consist of receiving oral and written information by the specialist before initiating the chemotherapy treatment and before each cycle. In addition, the patients assigned to arm B will receive programmed education and care about the chemotherapy by a Oncology nurse before the beginning of the treatment and in each cycle, in a specific nurse consultation.
1851806|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
1851807|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose
1851808|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
1851809|NCT00964535|Drug|budesonide and formoterol 200/6 microg|2 inhalations as a single dose with the concurrent charcoal blockage
1851810|NCT00964548|Drug|Dantrolene|1.25 mg/kg IV once over 60 min
1851811|NCT00964548|Drug|Dantrolene|2.5 mg/kg IV once over 60 min
1851812|NCT00964561|Drug|Ciprofloxacin and Valortim|Days 1-3 400mg IV Ciprofloxacin BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
1851813|NCT00964561|Drug|Placebo Antibiotic and Valortim|Days 1-3 20mg/kg IV Normal Saline BID over 60 minutes. Day 4 20mg/kg Valortim IV over 60 minutes.
1851814|NCT00964561|Other|Placebo Antibiotic and Placebo Valortim|Days 1-3 200mL IV Normal Saline for Placebo Antibiotic over 60 minutes. Day 4 200mL IV Normal Saline for Placebo Valortim over 60 minutes.
1851815|NCT00964574|Drug|INSULIN GLULISINE (HMR1964)|"Pharmaceutical form:
APIDRA 100U/ml flacon for the titration period in the hospital APIDRA 100U/ml solution for injection in cartridge in OptiSet
Route of administration:
3-4 subcutaneous injections per day"
1851816|NCT00964574|Drug|INSULIN GLARGINE|"Pharmaceutical form:
LANTUS 100U/ml solution for injection in cartridge
Route of administration:
Once daily subcutaneous injection in the evening"
1851817|NCT00964587|Behavioral|Education + Problem-Solving Training Self-Study|"Education + Problem-Solving Training Self-Study
One session of Literacy-Adapted Diabetes and CVD Risk Education
Instructions and a schedule for use of the Literacy-Adapted Problem-Solving Workbook for self-study will be given to each participant."
1851818|NCT00964587|Behavioral|Education + Group Problem-Solving Training|"Education + Group Problem-Solving Training
One session of the Literacy-Adapted Diabetes and CVD Risk Education
Group problem-solving training eight, 90-minute sessions"
1851819|NCT00964587|Behavioral|Education + Individual Problem-Solving Training|"Education + Individual Problem-Solving Training
One session of the Literacy-Adapted Diabetes and CVD Risk Education
Individual problem-solving training (eight, 60-minute sessions)"
1851820|NCT00964587|Behavioral|Usual Care|"Packet of print patient education materials about CVD and diabetes from the American Heart Association (AHA) and the American Diabetes Association (ADA)given at baseline following randomization to Arm 1
Scripted set of instructions will be given along with a verbal description of the materials and the content provided."
1851822|NCT00964626|Drug|cisplatin|
1851823|NCT00964626|Drug|paclitaxel|
1851824|NCT00964639|Drug|Ropivacaine|During the surgery infiltration with Naropine 2 mg/ml. The dosage in the infiltration is 2 mg/kg. Thereafter bolus 3 times a day
1851825|NCT00964639|Drug|Saline|During the surgery infiltration with saline. Thereafter bolus 3 times a day
1851873|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 1 mg, single dose, one dose
1851874|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 2 mg, single dose, one dose
1851875|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
1851826|NCT00964652|Other|Treadmill walking training with additional body load|"The training program was divided into three phases (A1-B-A2):
treadmill training with additional body load (A1), control condition (conventional physical therapy) (B). and treadmill training with additional body load again (A2). Each phase lasted six weeks, totaling 18 weeks. Both evaluations and training were performed during on-phase of the medication cycle."
1851827|NCT00964665|Drug|albinterferon alfa-2b|
1851828|NCT00964665|Drug|albinterferon alfa-2b|
1851829|NCT00964665|Drug|albinterferon alfa-2b|
1851830|NCT00964665|Drug|albinterferon alfa-2b|
1851831|NCT00964665|Drug|Pegasys®|
1851832|NCT00964678|Drug|Carvedilol|twice daily oral treatment in escalating dose
1851833|NCT00964691|Drug|Sulphadoxine-pyrimethamine|3 tablets of SP (500 mg sulfadoxine and 25 mg pyrimethamine per tablet) by mouth under supervision at enrolment, and 3 tablets of SP under supervision 4 to 12 weeks later in pregnancy (timing of second dose depends upon gestation at first dose)
1851834|NCT00964691|Drug|Chloroquine prophylaxis|300 mg weekly by mouth from the enrolment date until delivery. Only the enrolment dose will be supervised.
1851835|NCT00964704|Drug|bevacizumab [Avastin]|15mg/kg iv every 3 weeks
1851836|NCT00964704|Drug|capecitabine [Xeloda]|added at time of disease-progression, 1000mg/m2 bid po days 1-14 of every 3-week cycle
1851837|NCT00964704|Drug|docetaxel|background therapy at time of disease progression, 100mg/m2 iv every 3 weeks
1851838|NCT00964704|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg every 3 weeks
1851839|NCT00964717|Procedure|real chiropractic|real chiropractic manipulation
1851840|NCT00964717|Procedure|Sham Chiropractic|Placebo stimulation using 'activator' thumper
1851841|NCT00964730|Drug|Talampanel|titrated to 50mg three times a day over 9 days and a single dose administered on Day 10
1851842|NCT00964730|Drug|Moxifloxacin|Placebo administered three times a day over 9 days and a single dose of moxifloxacin administered on Day 10
1851843|NCT00964730|Drug|Placebo|administered three times a day over 9 days and a single dose administered on Day 10
1851844|NCT00964743|Drug|DepoCyt|Patients were to receive DepoCyt through a reservoir every 2 weeks for 5 doses, then every 4 weeks for an additional 5 doses.
1851845|NCT00964743|Drug|Sorafenib|Patients received oral sorafenib at 400 mg twice a day
1851846|NCT00964756|Genetic|Ad5.SSTR/TK.RGD|Group 1 Day 1-3 IP 1 x 10 9th vp/d Group 2 Day 1-3 IP 5 x 10 10th vp/d Group 3 Day 1-3 IP 1 x 10 12th vp/d
1851847|NCT00964756|Drug|Ganciclovir (GCV)|GVC Day 5-18 IV 5 mg/kg BID all groups
1851848|NCT00964769|Biological|pneumococcal polysaccharide vaccine|single intramuscular injection of 0.5 ml Pneumo23® (Sanofi-Aventis, Lyon France)
1851849|NCT00964782|Drug|sildenafil|oral suspension, 0.5mg/kg, taken once prior to exercise stress test
1851850|NCT00964782|Other|placebo|Patient will receive a look-alike placebo
1851851|NCT00964795|Drug|Intravitreal Aflibercept Injection 2mg|
1851852|NCT00964808|Drug|Buprenorphine|Start: Day 0 (T=0), 10 micrograms/t until the day of discharge from the Hospital. New plaster at T= 7 days.
1851853|NCT00964808|Drug|Oxycodone|Start: 10 hours (+/- 2 hours) after the operation. Dosage: 10 mg * 2 pr. day until time to discharge from the Hospital or latest at day 12.
1851854|NCT00964821|Biological|trivalent influenza vaccine|Patients or normal volunteers who will be vaccinated against the flu.
1851855|NCT00964821|Other|immunoenzyme technique|This test will determine the level of antibodies in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
1851856|NCT00964821|Other|laboratory biomarker analysis|This test will count the number of T cells (the cells that kill the flu virus) in participants who have been vaccinated against the flu and those who have not been vaccinated against the flu.
1851857|NCT00964834|Drug|Doxycycline and Valortim|Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
1851858|NCT00964834|Drug|Placebo Antibiotic and Valortim|Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
1851859|NCT00964834|Drug|Placebo Antibiotic and Placebo Valortim|Days 1-5 200mL IV Normal Saline for Placebo Antibiotic BID over 60 minutes. Day 6 20mg/kg IV Normal Saline for Placebo Valortim over 60 minutes.
1851860|NCT00964847|Behavioral|Yoga exercise program|Subjects in the yoga exercise program participate in structured bi-weekly 1.5 hour yoga classes held at a yoga studio as well as develop a weekly hour-long home practice over the 6 months of the study.
1851861|NCT00964847|Behavioral|Blood pressure education/walking program|The program will consist of small group health education classes and a walking program. Subjects will be expected to attend a dietician-led nutrition class twice a month. On alternate weeks the subjects will be given either motivational talks about a variety of topics including weight loss, walking programs, and healthy lifestyle choices or they will be given educational DVDs or literature to read on the weeks that they are not attending a BPEP class. These subjects will all receive 12 nutrition classes and 12 motivational experiences. The subjects will also be expected to walk 6 days a week gradually increasing to 180 minutes of walking per week or 10,000 steps per day.
1851862|NCT00964860|Device|Glide dental floss|Glide waxed dental floss
1851863|NCT00964873|Drug|STA-9090 (ganetespib)|Chemotherapy agent
1851864|NCT00964886|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
1851865|NCT00964886|Drug|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
1851866|NCT00964886|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, a type of psychotherapy oriented towards restoring function and reducing impact of pain on everyday life
1851867|NCT00964886|Drug|benztropine mesylate 0.125 mg daily|benztropine mesylate is a placebo, some of whose side effects mimic those of experimental intervention, desipramine hydrochloride
1851868|NCT00964886|Drug|desipramine hydrochloride|desipramine hydrochloride, with dose targeted to achieve a serum concentration of 5-60ng/ml
1851869|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.025 mg, single dose, one dose
1851870|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.1 mg, single dose, one dose
1851871|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.25 mg, single dose, one dose
1851876|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 5 mg, single dose, one dose
1851877|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 8 mg, single dose, one dose
1851878|NCT00964912|Drug|Placebo|Oral Solution, Oral, 0 mg, single dose, one dose
1851879|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 3 mg, single dose, one dose
1851880|NCT00964912|Drug|BMS-820836|Oral Solution, Oral, 0.5 mg, single dose, one dose
1851881|NCT00964938|Device|Quadripolar LV lead (pacing configurations)|Quadripolar LV lead will be used to deliver a combination of pacing configurations
1851882|NCT00964951|Biological|AS03|AS03 adjuvant administered with 3.75, 7.5, or 15 mcg Inactivated H1N1 Vaccine.
1851883|NCT00964951|Biological|Inactivated H1N1 Vaccine|Inactivated influenza H1N1 vaccine with AS03 adjuvant, delivered intramuscularly (IM) as 3.75, 7.5, or 15 micrograms per dose; and inactivated influenza H1N1 vaccine without adjuvant, delivered intramuscularly as 7.5 or 15 micrograms per dose. All doses of vaccine with or without adjuvant will be administered as a single 0.5 mL IM injection in the deltoid muscle of the preferred arm.
1851884|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) three times weekly
1851885|NCT00964964|Drug|insulin degludec|Insulin degludec injected s.c. (under the skin) once daily for one week
1851886|NCT00964964|Drug|placebo|Placebo injected s.c. (under the skin) four times weekly
1851887|NCT00964977|Radiation|Radiation therapy|Patients receive radiation within 6 weeks after surgery. At primary tumour site and involved lymph node level a total dose of 59.4 Gy in 33 fractions within 45 days is scheduled according to the rules of ICRU report 50.
1851888|NCT00964990|Drug|JNJ-42160443|Type=exact number, unit=mg, number= 1, 3, or 10, form=solution for injection, route=Subcutaneous use. One injection of 1, 3, or 10 mg of JNJ-42160443 every 28 days for up to 52 wks and then every 4, 8, or 12 weeks for up to an additional 52 weeks
1851889|NCT00964990|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
1851890|NCT00965003|Procedure|MRI scan|Standard of Care
1851891|NCT00965016|Procedure|hypothermia|Core temperature --> 34.9℃ within 30 min --> 33.5℃ within 120min --> 33℃for 24 H Decrease temperature in 0.9℃/hour
1851892|NCT00965042|Drug|Ceftobiprole|ceftobiprole 500 mg by intravenous infusion every 8 hours for 7 days
1851893|NCT00965055|Drug|Ezetimibe|10 mg
1851894|NCT00965055|Drug|Atorvastatin|"Visit 1: (atorvastatin open label challenge): Those who complete the initial screening and washout period will receive open label atorvastatin 10 mg daily for 6 weeks to verify compliance and confirm hyporesponse to statin therapy.
Visit 2: After 6 weeks of therapy repeat baseline fasting cholesterol. Those with LDL-c reduction of 25% or less will be able to proceed to next phase. Patients with greater than 25% LDL-C reduction will be excluded. We expect to randomize 80 patients
Visit 2a: Dispensing of first randomized drug allocation- all patients receive open label atorvastatin 10 mg with additional ezetimibe 10 mg or matching placebo. No blood test during this visit.
Visit 3, 4, 5: Dose titration to atorvastatin to 20 mg, 40 mg, 80 mg, respectively, after fasting blood test
Blood collected in visits 3, 4, and 5 will be stored for additional tests regarding cholesterol metabolism and inflammation.
Visit 6: Final cholesterol panel and conclusion of study period"
1851895|NCT00965068|Other|Cholesterol|
1851896|NCT00965081|Drug|Duloxetine|30 milligrams (mg) dose daily (QD) by mouth (po) at the same time each day for 12 weeks
1851897|NCT00965081|Drug|Placebo|QD po at the same time each day for 12 weeks
1851898|NCT00965094|Drug|Everolimus|One tablet containing 0.25, 0.5mg or 0.75 mg. Initially 2 mg/day. Afterwards based on blood level (target 6-10 ng/mL)
1851899|NCT00965094|Drug|Tacrolimus (FK506)|Capsules 0.5 mg, 1 mg. Dosing according to blood level.
1851900|NCT00965094|Drug|Basiliximab|One vial containing 20 mg lyophilisate. 2 x 20 mg [day 0 (2 hrs prior to Tx) and day 4 post Tx] to be applied as 10 sec. bolus injection, i.v.
1851901|NCT00965094|Drug|Enteric Coated Mycophenolate Sodium (EC-MPS)|One tablet containing 180 mg or 360 mg. 1440 mg/day (2x720 mg). If tolerated, dose reduction due to side effectis were possible (min. dose at BL@: 720 mg/day)
1851902|NCT00965094|Drug|Corticosteroids|Used according to Israeli standards. A minimum dose of 5mg [prednisone, or equivalent, was used throughout the study period.
1851903|NCT00965107|Drug|Thiopental|Thiopental given as a bolus dose of 2,5 mg/kg.
1851904|NCT00965107|Drug|Propofol|Propofol given as a bolus dose of 1 mg/kg.
1851905|NCT00965120|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
1851906|NCT00965120|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140).
1851907|NCT00965120|Drug|Placebo (saline)|Systemic infusion of placebo (saline).
1851908|NCT00965133|Other|Endurance training intervention|High intensive interval training of walking / running on treadmill for 1 1/2 - 4 minute,repeated minimum 4 times, at an intensity equalling at least 80% of maximal heart frequency. Performed 2-5 times per week for 4-8 weeks, totally 24 sessions.
1851909|NCT00965146|Device|Scorpio® CR Total Knee System|All subjects will be implanted with a femoral component, a tibial insert, a tibial tray and a resurfaced patella.
1851910|NCT00965172|Other|Caphosol|Oral rinse of calcium phosphate solution five times daily beginning on day one of chemotherapy.
1851911|NCT00965172|Other|Baking Soda|Oral rinse of baking soda solution as per standard of care five times daily beginning on day one of chemotherapy.
1851912|NCT00965185|Drug|atorvastatin|20 mg PO QD for the first 3 months, followed by 40 mg PO QD for the final 9 months.
1851913|NCT00965185|Drug|Placebo|Placebo
1851914|NCT00965211|Device|HBDL-coil Repetitive Deep Transcranial magnetic stimulation (rdTMS)|a session of rdTMS includes 4 cycles of 5 minutes of stimulation at a frequency of 1 Hz to the supplementary motor cortex and then a 2 minute recess.each subject would undergo 5 sessions a week for 4 weeks.
1851915|NCT00965224|Biological|dendritic cell vaccination (active specific immunotherapy)|
1851916|NCT00965237|Device|lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
1851917|NCT00965237|Device|lotrafilcon B single vision contact lens|Commercially marketed, silicone hydrogel, single vision contact lens for daily wear use
1852310|NCT00960583|Other|Exercise program|24 group exercise sessions during 12 weeks
1851918|NCT00965237|Other|Over-reader spectacles|Reading glasses worn over single vision contact lenses for near vision work on an as-needed basis
1851919|NCT00965250|Drug|IMC-12|20 mg/kg intravenously once every three weeks
1851921|NCT00965289|Drug|Rituximab|Rituximab infusion on day 1 dose: 375mg/m²
1851922|NCT00965302|Procedure|Laparoscopic sleeve gastrectomy|Laparoscopic sleeve gastrectomy, also known as vertical sleeve gastrectomy, sleeve gastroplasty, or sleeve gastrectomy, will be performed over a 32 to 40 French sizing bougie.
1851923|NCT00965302|Behavioral|Intensive medical management|Intensive medical therapy for Diabetes mellitus, Type 2, will include weight management counseling, exercise, glucose control, and healthy dietary choices.
1851924|NCT00965315|Drug|Rosuvastatin,SFC fenofibrate|"Rosuvastatin 10 mg once daily
Rosuvastatin 5 mg + SFC fenofibrate 160 mg"
1851925|NCT00965328|Procedure|CVVH 4 to 2 L/h|CVVH is initiated at 4L/h and is converted to 2L/h after 60 min
1851926|NCT00965328|Procedure|CVVH 2 to 4L/h|CVVH is initiated at 2L/h and is converted to 4L/h after 60 min
1851927|NCT00965341|Drug|Testosterone|Starting dose of 150 or 200 mg testosterone enanthate/cypionate by injection into buttock muscle, every 15 days through Day 72.
1851928|NCT00965341|Drug|Placebo|Starting dose of 150 mg or 200 mg sesame seed oil by injection into buttock muscle, about every 15 days through Day 72.
1851929|NCT00965367|Device|Acustimulation|Acupressure in P6 bilaterally given after induction of anaesthesia for 20 minutes, followed by acupressure wrist bands applied on the same acupoints for 24 hours.
1851930|NCT00965393|Procedure|Forearm vascular study|Forearm blood flow measured by venous occlusion plethysmography during interarterial infusion of vasodilators (Ach). Venous blood sampling via cannula in antecubital fossa.
1851931|NCT00965393|Drug|Placebo|Systemic infusion of placebo (saline)
1851932|NCT00965393|Drug|bradykinin receptor antagonist (HOE-140)|Systemic infusion of bradykinin receptor antagonist (HOE-140)
1851933|NCT00965406|Drug|GIK and intensive insulin therapy|GIK infusion (1000 ml of Glucose 10%, 20 UI Insulin, 70 mEq of Potassium) within 24 hours. Intravenous intensive insulin therapy is simultaneously administered according to our protocol in the ED
1851934|NCT00965419|Drug|LY2216684|0.1 mg/kg/day or patient specific known stable dose (rollover patients) up to 0.3 mg/kg/day, oral, daily for up to 5 years.
1851935|NCT00965432|Drug|STX107|Single dose of an oral suspension
1851938|NCT00965471|Drug|cipher prescription 1|Drug granules include ginseng,RADIX NOTOGINSENG,prepared RHIZOMA PINELLIAE with alumen radix glyrrhigae calcaren once daily for 180 days
1851939|NCT00965471|Drug|cipher prescription 2|Placebo include amidon、bitter principles and diluents bases once daily for 180 days
1851940|NCT00965484|Device|New Genotropin Pen|Subjects will use the genotropin pen for 2 months. After 2 months patients and caregiver will be asked to fill out a questionnaire to assess perception of the genotropin pen
1851941|NCT00965497|Drug|escitalopram|After confirmation of diagnoses and safety screening escitalopram will be started at 10 mg per day and augmented weekly in 10 mg per day increments, the maximum dose being 20 mg per day. The dose will be titrated upward or downward based on clinical response and tolerability. No other psychotropic medications will be permitted during the study. Medications for coexisting medical problems (e.g. hypertension) will be permitted. Study visits will include weekly visits for first 2 weeks and biweekly visits for next 6 weeks. Medications will be dispensed weekly or biweekly and the participants will be followed for 8 weeks.
1851942|NCT00965510|Behavioral|care coordination|patients receive care coordination to improve their type II diabetes
1851943|NCT00965523|Drug|Eribulin Mesylate|Eribulin mesylate 1.4 mg/m^2 intravenous infusion (IV) given over 2 to 5 minutes on Day 1 and 8 every 21 days.
1851944|NCT00965549|Drug|INSULIN GLARGINE (HOE901)|LANTUS®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
1851945|NCT00965549|Drug|Insulin aspart|NovoMix® 30: Suspension for injection. 100U/mL in a prefilled pen (FlexPen®)
1851946|NCT00965549|Drug|Insulin Glulisine|APIDRA®: Solution for injection. 100U/mL in a prefilled pen (SoloStar®)
1851947|NCT00965562|Drug|Fluoxetine|Fluoxetine 20 mg per day for 4 menstrual cycles. For the fifth menstrual cycle, all women will receive calcium. Women on Fluoxetine will continue taking it in addition to 1200mg of calcium.
1851948|NCT00965562|Drug|Calcium|1200 mg of calcium to be taken for 5 menstrual cycles.
1851949|NCT00965562|Drug|Placebo|For 5 cycles, women will receive placebo. At the end of the fourth cycle, all women will receive 1200 mg of calcium in addition to the placebo medication.
1851951|NCT00965588|Biological|UB 311|Single liquid dose by intramuscular route at weeks 0, 4, 12.
1851952|NCT00965601|Behavioral|Cognitive Behavioral Therapy|Subjects randomized to the Active Arm will receive workbook assignments a series of six phone intervention interviews of Cognitive Behavioral Therapy (CBT)
1851953|NCT00965614|Other|MCG|Cardiac Arrhythmia,Heart Disease
1851954|NCT00965640|Drug|Botulinum Toxin - A injections|
1851955|NCT00965653|Drug|folic acid|>/= 5 mg po weekly
1851956|NCT00965653|Drug|methotrexate|7.5 - 25 mg weekly (oral or parenteral)
1851957|NCT00965653|Drug|tocilizumab [RoActemra/Actemra]|162 mg sc weekly (QW)for 12 weeks
1851958|NCT00965653|Drug|tocilizumab [RoActemra/Actemra]|162 mg sc every other week (Q2W) for 12 weeks
1851959|NCT00965666|Drug|Etanercept|All qualified subjects receive 24 weekly subcutaneous injections of Etanercept.
1851960|NCT00965705|Behavioral|Therapy|Individual Therapy and Group Therapy
1851961|NCT00965718|Biological|activated T lymphocyte|intravenous dripping of 200 ml (109~2 1010 lymphocytes/60 kg adult) for 1 hour.
1851962|NCT00965731|Drug|Erlotinib|Erlotinib, 150 mg, QD will be administered orally on a continuous schedule (Phase 2 only)
1852115|NCT00954135|Drug|letrozolo+cyclophosphamide|Letrozole 2,5 mg/daily + metronomic cyclophosphamide 50 mg/daily for 6 months
1851963|NCT00965731|Drug|Erlotinib|For Phase 1 - escalating doses of erlotinib will be administered orally on a continuous schedule. The planned doses to be evaluated are 100 and 150 mg QD. The dose determined in Phase 1 will be used in Phase 2
1851964|NCT00965731|Drug|PF-02341066|For Phase 1 - escalating doses of PF-02341066 will be administered orally on a continuous schedule. The planned doses to be evaluated are 200 and 250 mg BID. The dose determined in Phase 1 will be used in Phase 2
1851965|NCT00965744|Device|Vessel sealing system LigaSure|Patients in VS group undergoing esophagogastric decongestion (Azygoportal Disconnection) and splenectomy with or without esophageal transaction with the vessel sealing system LigaSure.
1851966|NCT00965757|Drug|T-614|T-614 is administered twice daily in combination with methotrexate. The daily dose of T-614 is 25 mg for the first 4 weeks and 50 mg for subsequent weeks.
1851967|NCT00965757|Drug|Placebo|Placebo is administered twice daily in combination with methotrexate. In placebo group, patients will receive T-614 after completing 28 weeks of treatment.
1851968|NCT00965770|Device|Intrauterine device (IUD)|Women choosing to have an intrauterine device (IUD) inserted immediately post-abortion
1851969|NCT00965783|Other|Restriction|Time in bed for each subject is restricted by two hours per night for 4 nights
1851970|NCT00965783|Other|Extension|Bedtime is extended by 2 hours per night for 4 nights
1851971|NCT00965796|Drug|Lidocaine|Lidocaine 2 mg/kg/h- during surgical procedure Saline
1851972|NCT00965809|Drug|Tetrahydrocannabinol|Five mg. of THC in 6 drops of olive oil orally twice a day for 6 weeks.
1851973|NCT00965809|Other|Placebo|Subjects will take 6 drops of olive oil orally twice a day from an identical vial than those in the active arm
1851974|NCT00965822|Other|North American ginseng|3 day, once daily, dosing
1851975|NCT00965822|Other|Placebo|3 day, once daily dosing
1851976|NCT00965848|Drug|Doripenem|Doripenem 500 mg will be administered as 1 or 4 hours intravenous infusion, after every 8 hours up to maximum of 14 days.
1851977|NCT00965861|Other|Tissue Registry Study|If a patient consents to allowing the use of their tumor tissue sample(s) for testing/analysis at a future date, their name and information will be stored electronically in a registry that will be managed by SCRI. SCRI may then use the information contained in this registry (such as disease indication, demographic information, etc.) at any time in the future to select tissue samples on which to perform testing/analyses.
1851978|NCT00965874|Drug|Magnesium Sulfate high dose|9 g infusion once during 30 minutes
1851979|NCT00965874|Drug|Magnesium Sulfate low dose|4.5 g magnesium sulfate infusion
1851980|NCT00965874|Drug|Placebos|serum salin
1851981|NCT00965887|Drug|MK0974 Ethanolate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
1851982|NCT00965887|Drug|Comparator: MK0974 Hydrate formulation|Single dose MK0974 280 mg tablet in one of two treatment periods
1851983|NCT00965900|Procedure|Endoscopic band ligation|"Perform EBL within 7 days after randomization
Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)
Acid suppression using proton pump inhibitor until eradicated.
After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
1851984|NCT00965900|Drug|Propranolol|"start with 20 mg of propranolol b.i.d
Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min
After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
1851985|NCT00965900|Procedure|EBL+Propranolol|"EBL
Perform EBL within 7 days after randomization
Apply 1-2 band/column/session to varices in the distal 5-7 cm of the esophagus till they are eradicated (disappearance or too small to apply band) with interval of 4 weeks (at 4,8,12 weeks after initial treatment)
Acid suppression using proton pump inhibitor until eradicated.
After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months).
Propranolol
start with 20 mg b.i.d
Adjust by 20-40 mg/day reaching reduction by 25 percent in HR or HR less than 55/min
After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
1851986|NCT00965913|Drug|Nicotine Patch|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
1851987|NCT00965913|Drug|Nicotine Patch Comparator|15 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days
1851988|NCT00965913|Drug|Placebo Patch|Placebo patch applied on the lower back, according to treatment sequence, daily for 21 days
1851989|NCT00965926|Drug|YM178|oral
1851990|NCT00965965|Behavioral|New colorectal cancer screening patient education document|The newly developed educational document was created accounting for health behavioral models (such as the Expanded Health Behavior Model, Social Cognitive Theory, and the Transtheoretical Model) and related research studies indicating the factors that most strongly and positively influence patients' cognitions regarding colorectal cancer screening and are, in turn, predictive of actual colorectal cancer screening behavior.
1851991|NCT00965965|Behavioral|Traditional colorectal cancer screening education document|The traditional educational document is a slightly edited version of materials freely available on the National Cancer Institute (NCI) web site, used in this study with the permission of the NCI.
1851992|NCT00965978|Drug|ONO-5920 / YM529|oral
1851993|NCT00965991|Drug|metformin|patients received glyburide initial dose of 500 mg PO BID. Increased as necessary to a maximum dose of 2000 mg QD to control blood glucose
1851994|NCT00965991|Drug|Glyburide|Initial dose of 2.5mg PO BID increased as necessary to a maximum dose of 20 mg (10mg BID) QD to control blood glucose
1851995|NCT00966004|Drug|YM178|oral
1851996|NCT00966004|Drug|Placebo|oral
1851997|NCT00966004|Drug|tolterodine|oral
1851998|NCT00966030|Drug|MK0974 tablet|MK0974 280 mg tablet in one of two treatment periods
1851999|NCT00966030|Drug|Comparator: MK0974 liquid filled capsule|MK0974 300 mg liquid filled capsule in one of two treatment periods
1852000|NCT00966056|Drug|Mitomycin C|Cotton wick soaked with 1mg/ml of mitomycin c placed for 2 minutes between the raw surfaces after synechiolysis with surgical blade no.15
1852116|NCT00954135|Drug|letrozolo+sorafenib+cyclophosphamide|"Letrozole (2,5 mg/daily) + metronomic cyclophosphamide (50 mg/daily) + Sorafenib (400 mg/bid/daily) for 6 months"
1852001|NCT00966056|Device|Teflon nasal septal splint|Teflon internal nasal septal splint placed between the raw surfaces and secured at the anterior end of septum with catgut 3-0 sutures, following synechiolysis with surgical blade no.15. Splint removed at the end of one week
1852002|NCT00966069|Other|Parent collection|Parent collection of anterior nose specimen when child has an acute respiratory illness, and mailed return of the specimen to the laboratory.
1852003|NCT00966069|Other|Healthcare worker home visit|Healthcare worker performs home visit for collection of respiratory specimen (anterior nose) when study child has an acute respiratory illness.
1852004|NCT00966082|Procedure|endoscopic band ligation|Perform EBL until esophageal varices are eradicated, and then follow-up endoscopy with 3-6 months interval
1852005|NCT00966082|Procedure|endoscopic band ligation+Propranolol|Perform EBL same as EBL group. In addition, take propranolol to reduce 25% in HR or HR ≤55/min
1852006|NCT00966108|Device|SENSIMED Triggerfish|Ocular Telemetry Sensor for IOP monitoring
1852007|NCT00966121|Procedure|endoscopic band ligation|"Perform EBL within 7 days after randomization
Apply 1-2 band/column/session to varices in the distal 5-7cm of the esophagus till they are eradicated (Disappearance or too small to apply band) with interval of 4weeks (at 4,8,12 weeks after initial treatment).
Acid suppression using proton pump inhibitor until eradicated.
After eradication, then follow-up endoscopy according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3-6 months until 36 months)."
1852008|NCT00966121|Procedure|EBL+Propranolol|"Start with 20 mg b.i.d
Adjust by 20-40 mg/d reaching reduction by 25% in HR or HR ≤55/min
After reaching target HR, then FU according to a preset schedule (at 1, 2, 3 months after initial treatment, then every 3 months until 36 months)"
1852009|NCT00966134|Other|exposure to high altitude|
1852010|NCT00966147|Other|Increasing oxygen delivery .|The target is increasing oxygen delivery above 600ml/min/mr2 by either bolus of iv colloid or a continuous infusion of dopamine, dobutamine or noradrenaline. The fluids and drug administration will be directed and monitored by the lidco system and transesophageal echocardiography.
1852011|NCT00966160|Drug|Lopinavir/Ritonavir plus Lamivudine/Zidovudine|400 mg lopinavir and 100 mg ritonavir (Kaletra capsules, Abbott Laboratories) twice daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
1852012|NCT00966160|Drug|Efavirenz plus Lamivudine/Zidovudine|600 mg efavirenz (Sustiva tablets, Bristol-Myers Squibb) once daily plus 150 mg lamivudine (Epivir tablets, GlaxoSmithKline) and 300 mg zidovudine (Retrovir tablets, GlaxoSmithKline) twice daily over 476 weeks
1852013|NCT00966173|Device|SciBase III Electrical Impedance Spectrometer|Following enrollment, patients will undergo measurements with SciBase III Electrical Impedance Spectrometer. Electrical impedance of the skin will be measured with a microinvasive spiked probe.
1852014|NCT00966186|Procedure|Insertion fo ProSeal laryngeal mask airway|Insertion fo ProSeal laryngeal mask airway using each of Standard technique or Rotational technique
1852015|NCT00966199|Drug|anti-hypertensive medication|8-12 weeks of anti-hypertensive treatment with 2 weekly titration using registered hypertensive medication
1852016|NCT00966212|Behavioral|parent education|Especially for Daughters audio-cd parent education
1852017|NCT00966225|Dietary Supplement|LIP-01|comparison of different dosages of natural health product
1852018|NCT00966238|Biological|VAX125|STF2.HA1(SI) (VAX125), which is a recombinant fusion protein that consists of Salmonella typhimurium flagellin type 2 (STF2), a Toll-like receptor 5 (TLR5) ligand, fused at its C-terminus to the globular head domain of the hemagglutinin (HA) antigen of influenza A HA1 Solomon Islands (SI).
1852019|NCT00966251|Drug|CT-011|CT-011
1852020|NCT00966264|Drug|LNG-IUS|LNG-IUS releasing 25 microg of levonorgestrel
1852021|NCT00966264|Procedure|Hysterectomy|operation
1852022|NCT00966277|Drug|Dalteparin|5000 units subcutaneous, by injection under the skin, daily for 16 weeks
1852023|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Anticoagulant clinic based shared-care group
1852024|NCT00966290|Drug|Anticoagulant (warfarin, acenocoumarol, fluindione)|Usual care group
1852025|NCT00966303|Other|Cardiac Rehabilitation with diaphragmatic muscle training|Stretching and aerobic exercises and respiratory muscle training with a Threshold ® device, with load of 40% of the maximal inspiratory pressure (MIP), two times a week during one hour.
1852026|NCT00966316|Drug|aspirin，chinese herbs；|aspirin 300mg/100mg,qd,chinese herbs, one dose ，qd
1852027|NCT00966329|Drug|maraviroc|HAART regimen including 2 NRTI/NtRTIs plus maraviroc
1852028|NCT00966329|Drug|control group|"HAART regimen including 2 NRTI/NtRTIs plus one of the following :
1 PI/ritonavir (lopinavir/ritonavir, atazanavir/ritonavir, fosamprenavir /ritonavir, tipranavir/ritonavir, darunavir/ritonavir)
or ATV/unboosted (in a regimen without tenofovir)
or 1 NNRTI (nevirapine or efavirenz)."
1852029|NCT00966342|Drug|Fluviral 2009/10|single dose given IM .05 mL
1852033|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 1, 0.4U/kg body weight injected subcutaneously (under the skin)
1852034|NCT00966368|Drug|insulin degludec|Single dose of NN1250, formulation 2, 0.4U/kg body weight injected subcutaneously (under the skin)
1852036|NCT00966420|Device|traction assisted endoscopic mucosa resection|A haemoclip is connected to suture material and will be fixed (next) to a polyp to allow traction and lifting the lesion in order to facilitate its resection with a loop.
1852037|NCT00966433|Procedure|Spontaneous ventilation|The patient will breathe spontaneously (on their own)while under general anesthesia throughout the duration of the surgery.
1852038|NCT00966433|Procedure|Pressure support Ventilation|The patient will breathe on their own and with a little assistance from the anesthesia machine while under general anesthesia throughout the duration of the surgery.
1852039|NCT00966433|Procedure|Pressure control ventilation|The patient's ventilation will be completely supported by the anesthesia machine while under general anesthesia throughout the duration of the surgery.
1852042|NCT00966459|Procedure|Computed Tomography|1 low-dose CT is taken
1852043|NCT00966472|Drug|Erlotinib + Rosuvastatin|Patients will receive Erlotinib 150mg po daily. They will also receive Rosuvastatin at escalating dose levels starting at 1mg/kg po daily for 3 weeks, followed by a 1-week rest period. Patients may continue to receive rosuvastatin and erlotinib in the absence of disease progression or unacceptable toxicity.
1852044|NCT00966485|Drug|80 mg ASA dosing|
1852045|NCT00966485|Drug|500 mg ASA dosing|
1852046|NCT00966498|Procedure|Peripheral Blood Stem Cell Transplant|Peripheral Blood Stem Cell Transplant
1852047|NCT00966511|Procedure|Lung resection surgery|The study is designed in a way that will not alter the surgeon's decision based on routine assessment of candidates for resection (lobectomy or greater). Namely, the VRI data will be gathered prospectively; however, the analyses using VRI data will be performed retrospectively.
1852048|NCT00966524|Procedure|Endotracheal intubation|Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
1852049|NCT00966550|Other|Tomato|Tomato with high carb/fat meal
1852050|NCT00966550|Other|Non-tomato|Non-tomato with high carb/fat meal
1852051|NCT00966563|Drug|Mangafodipir|Administered dose: 2 µmol/kg b.w. Administration form: Ready-to-use formulation (solution). Mangafodipir or placebo (0.2 ml/kg b.w.) will be administered as an intravenous (iv.) infusion over 2-5 min prior to reopening of occluded coronary artery during PCI
1852052|NCT00966563|Drug|Placebo|
1852053|NCT00966576|Drug|Brinzolamide/Timolol Maleate Fixed Combination (AZARGA)|1 drop of study medication into the study eye(s) beginning the evening of Visit 1 and continuing twice daily (morning and evening) for 12 weeks
1852054|NCT00966589|Procedure|laparoscopic hernioplasty (TEP)|Insertion of polypropylene mesh behind pubic bone
1852055|NCT00966602|Drug|VX-809|VX-809 capsule, once daily for 14 days
1852056|NCT00966602|Drug|VX-770|VX-770 tablet, once every 12 hours for 14 days
1852057|NCT00966602|Drug|VX-809 & VX-770|VX-809 capsule, once daily, and VX-770 tablets, once every 12 hours, for 14 days
1852058|NCT00966602|Drug|Placebo|Matching Placebo
1852059|NCT00966615|Other|double-chamber bag Stay-Safe Balance system|2-L exchange; three times a day
1852060|NCT00966615|Other|glucose-based dialysis solution|2-L exchange; three times a day
1852061|NCT00966628|Drug|Hypertonic sodium lactate|Hypertonic sodium lactate 5 ml/kg BW administered within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study solution infused again at same dose. After recovery from shock state, patients receive maintenance dose at 1 mL/kgBW/hour for 12 hours. After 12 hr. infusion with study fluid, patients receive RL infusion as per standard protocol of DSS management at site.In case of repeated shock within 12 hours, study drugs can be infused again. If patient still not recovered from shock state, the patients will be given HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
1852062|NCT00966628|Drug|Ringer's lactate|Ringer lactate infused at dose 20 mL/kgBW within 15 minutes to restore hemodynamic status. If shock state did not recover with first infusion, study fluid infused again at same dose. After recovery from shock, patient received maintenance dose of RL. In case of repeated shock, patients received HES (Hydroxy-Ethyl Starch) infusion at dose of 20 mL/kgBW/15-30 min with maximum dose of 50 mL/kgBW/24 hours.
1852063|NCT00966641|Drug|Naproxen|Single orally administered dose of 500 mg naproxen
1852064|NCT00966641|Drug|PL 3100|Single orally administered dose of PL 3100 (500 mg naproxen)
1852065|NCT00966654|Drug|Placebo|1.5 pmol/kg/min (5 ng/kg/min) saline infused continuously over 72 hours.
1852066|NCT00966654|Drug|GLP-1 (7-36) amide|1.5 pmol/kg/min (5 ng/kg/min) GLP-1 infused continuously over 72 hours.
1852067|NCT00966680|Other|Anesthesia|How long anesthesiologists take to administer general and spinal anesthesia.
1852068|NCT00966693|Drug|Lenalidomide|Starting dose:15 mg daily by mouth on Days 1-21 followed by 7-day rest every 28 day cycle for Cycles 1-8
1852069|NCT00966693|Drug|Thalidomide|Starting dose:100 mg daily by mouth on Days 1-28 of Cycles 1-8
1852070|NCT00966693|Drug|Dexamethasone|"40 mg by mouth on Days 1-4, 9-12, and 17-20 of Cycles 1-2.
40 mg by mouth on Days 1, 8, 15, and 21 of Cycles 3-8."
1852071|NCT00966706|Drug|capecitabine|Given systemically
1852072|NCT00966706|Drug|cisplatin|Given systemically
1852073|NCT00966706|Drug|docetaxel|Given systemically
1852074|NCT00966706|Drug|epirubicin hydrochloride|Given systemically
1852075|NCT00966706|Drug|gemcitabine hydrochloride|Given systemically
1852076|NCT00966719|Other|Lactation Consultant support|Meeting with lactation consultant once while in hospital and up to 3 times after discharge, in addition to current standard of care for jaundice.
1852113|NCT00966966|Drug|SAM-531 and gemfibrozil|2 single doses of 5 mg SAM-531 (capsules) a daily dose of 1200 mg Gemfibrozil (one tablet of 600mg at approximately 8 a.m. and one tablet of 600 mg at approximately 6 p.m.) for 14 days
1852114|NCT00966979|Device|Triathlon PKR|Triathlon PKR is a unicondylar knee resurfacing system designed to replace a single osteoarthritic compartment of a patient's natural knee.
1852117|NCT00954148|Procedure|PET/CT|5 visits with PET/CT as only testing
1992798|NCT03296462|Other|Pelvic floor muscle exercise|Standardised PFM exercise training by physiotherapist (plus video recording of exercises)
1992799|NCT03295201|Other|Active cycle of breathing techniques (ACBT)|ACBT involves three phases (Breathing control, chest expansion exercise, and huff coughing). These phases will apply with a sequence to remove secretion. ACBT will apply 1 per a week for 6 weeks.
1992800|NCT03295201|Other|Postural Exercise|Postural exercise program will include thoracic vertebra mobilization, pectoral stretching, scapula and thoracic extensors strengthening and core stability exercises. Postural exercise program will apply 1 per a week for 6 weeks.
1852077|NCT00966732|Behavioral|Yoga of Awareness Program|The 8 week yoga program will meet in groups of about 8-10 persons. Each 2-hour session will include gentle stretching, strengthening, and balance poses; meditation exercises; breathing techniques; study of pertinent topics (eg, mind/body stress reactivity), and group discussions (eg, experiences while practicing yoga). Participants will be asked to practice yoga methods at home, guided by a DVD (or audio recordings). The program will be taught by a certified yoga teacher (RYT) who has extensive experience in teaching yoga to medical patients.
1852078|NCT00966745|Drug|milrinone|
1852079|NCT00966745|Drug|placebo|
1852080|NCT00966758|Procedure|Computed Tomography|1 low dose CT scan is taken
1852081|NCT00966758|Procedure|Single Photon Emission Computed Tomography|1 SPECT scan is taken
1852082|NCT00966771|Drug|Copper T380 IUD|copper T 380 IUD
1852083|NCT00966771|Drug|Oral levonorgestrel|1.5 mg
1852084|NCT00966784|Other|Dietary Fibers|
1852085|NCT00966810|Procedure|Stem cell transplantation|Patients were conditioned with oral busulfan 12mg/kg (days -6 to -4), cyclophosphamide 120mg/kg (days -3,-2), rabbit antithymocytic globulin, (Fresenius, Bad Hamburg, Germany) 25mg/kg (days -5 to -1) and fludarabine 200 mg/kg (days -7 to-3). CD34 cells were positively selected using anti-CD34 antibody conjugated to iron-dextran microbeads using CliniMACS device (Miltenyi Biotech, Bergisch Gladbach, Germany) with an aim to collect > 5.0 x 106 CD34 cells/kg. DLI was administered in escalating dose regimen starting from 3 x 106 cells/kg followed as necessary by 1 x 107 cells/kg, 5 x 107 cells/kg and 1 x 108 cells/kg.
1852086|NCT00966823|Device|Fetal tracheal obstruction with detachable balloon (device)|"Fetal tracheal obstruction with detachable balloon (device): Endoscopic placement of a detachable balloon in the fetal trachea at 28-30 weeks gestation.
- Ultrasound-guided puncture of balloon or, if not feasible, repeat endoscopic tracheoscopy with puncture and retrieval of the balloon at 34 weeks gestation."
1852087|NCT00966836|Drug|Pre-emptive strategy with valganciclovir plus everolimus|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Everolimus plus cyclosporine and prednisone will be used for maintenance immunosuppression
1852088|NCT00966836|Drug|Prophylaxis with valganciclovir plus mycophenolate|Patients will receive 3 months of oral valganciclovir with mycophenolate and standard cyclosporine and prednisone for maintenance immunosuppression
1852089|NCT00966836|Drug|Prophylaxis with valganciclovir plus everolimus|Patients will receive valganciclovir for 3 months after transplant. Everolimus plus reduced cyclosporine and prednisone will be used for maintenance immunosuppression
1852090|NCT00966836|Drug|Pre-emptive mycophenolate|Patients will be monitored for CMV infection and receive valganciclovir only for positive PCR or antigenemia. Mycophenolate plus standard cyclosporine and prednisone will be used for maintenance immunosuppression
1852091|NCT00966849|Other|Conditional Cash Transfer|"Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will only be given the cash if they comply with the following conditions:
An application for a birth certificate must be made for all children under 18 years in the household who do not already have a birth certificate, including all newborn children within 3 months of birth.
All children under 5 years in the household must be up-to-date with vaccinations.
All children under 5 years must attend a growth monitoring clinic twice per year.
All children 6-17 years in the household attended school at least 90% of days in the last month.
At least one adult from each household attended at least 2 of the 3 most recent parenting skills classes."
1852092|NCT00966849|Other|Unconditional Cash Transfers|Households will receive bimonthly payments of US$18 plus US$4 per child under 18 years living in the house up to a maximum of 3 children i.e. transfers will vary from $22 to $30. Households will not be required to comply with conditions in order to receive the cash.
1852093|NCT00966849|Other|Standard Agricultural Package|A standard agricultural package (e.g. seeds, fertiliser etc.) will be distributed in all study arms including the control arm as a gesture of goodwill to all those participating in the study.
1852094|NCT00966849|Other|Parenting Skills Classes|2-3 parenting skills classes will be held annually in each study cluster.
1852095|NCT00966862|Other|Other: Dietary Fibers|
1852096|NCT00966875|Biological|LY2439821|Subcutaneous
1852097|NCT00966875|Drug|Placebo|Subcutaneous
1852098|NCT00966888|Procedure|standard follow-up care|No intervention
1852099|NCT00966888|Radiation|radiation therapy|Chest wall radiotherapy
1852100|NCT00966901|Drug|Nicotine Patch|25 mg nicotine patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
1852101|NCT00966901|Drug|Placebo Patch|As a positive control, a placebo patch applied on the assigned marked site on the lower back or buttock. Induction (23 days): six treatment applications for 24 h. Challenge (five days): one treatment application for 24 h.
1852102|NCT00966901|Drug|No Patch Control|As a negative control, a marked site on the lower back or buttock was assigned as test area, but no patch was applied.
1852103|NCT00966901|Radiation|UVA and UVB irradiation|All three test sites exposed to UV radiation after patch removal. Induction: 10 J/cm2 UVA and 0.5 MED UVB, one treatment after first patch removal; and 3 MED UVB at the 5 following treatments. Challenge: 4 J/cm2 UVA and 0.5MED UVB, one treatment.( MED: Minimal Erythema Dose determined during screening)
1852104|NCT00966914|Drug|Tavocept(BNP7787) in combination with cisplatin and either docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Tavocept(BNP7787) 18.4gm/m2 IV every 3 weeks
1852105|NCT00966914|Drug|Placebo in combination with cisplatin and docetaxel or paclitaxel|Paclitaxel 200 mg/m2 IV or Docetaxel 75mg/m2 IV every 3 weeks plus Cisplatin 80 mg/m2 IV every 3weeks plus Placebo IV every 3 weeks
1852106|NCT00966940|Drug|Travoprost 0.004% ophthalmic solution (TRAVATAN)|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
1852107|NCT00966940|Drug|Tafluprost 0.0015% ophthalmic solution|One drop in the qualifying eye(s) each evening at 6:00 PM for 6 weeks, topical administration
1852108|NCT00966953|Drug|Fluoride|Brush twice daily
1852109|NCT00966953|Drug|Triclosan/Fluoride toothpaste|Brush twice daily
1852110|NCT00966953|Drug|Fluoride|Brush twice daily
1852111|NCT00966953|Drug|Fluoride|Brush twice daily
1852112|NCT00966953|Other|antibacterial plant extract|Brush twice daily
1852118|NCT00954148|Procedure|NCCN recommendations for solid tumor post treatment|12-14 visits with exams, blood tests, CTs and PET/CT
1852119|NCT00954161|Other|Helping behaviour curriculum|The objective of the helping behaviour curriculum is to sensitise participants to develop a helping reaction, and to teach participants how to deal with barriers to helping. The helping behaviour curriculum is being taught in 2hours.
1852120|NCT00954161|Other|First aid only curriculum|Two hours training on first aid for alcohol and drug incidents
1852121|NCT00954174|Drug|Carboplatin|Given IV
1852122|NCT00954174|Drug|Ifosfamide|Given IV
1852123|NCT00954174|Drug|Paclitaxel|Given IV
1852124|NCT00954174|Other|Quality-of-Life Assessment|Ancillary studies
1852125|NCT00954187|Drug|Gabapentin|Gabapentin - 300 mg three times a day starting two hours prior to surgery and will continue for a total of four days
1852126|NCT00954187|Drug|pregabalin|50 mg PO TID
1852127|NCT00954200|Drug|ibuprofen|ibuprofen 10mg/kg syrup, single dose vs placebo
1852128|NCT00954200|Drug|ibuprofen|10mg/kg syrup - single dose
1852129|NCT00954213|Behavioral|DIR/Floortime parent intervention|Parent will be trained to observe their autistic child's cues, follow their child's lead and techniques to enhance his/her development.
1852130|NCT00954226|Drug|Erlotinib|"Standard Dose: 1 tablet of 150 mg erlotinib once a day, every day leading up to surgery.
Higher Dose: 200 mg or 300 mg in 2 tablets once a day, every day leading up to surgery.
Depending on your assigned dose level, the 2 tablets may contain the same drug amount or 2 different drug amounts."
1852131|NCT00954252|Drug|CHF 5074|1x, oral capsule, single dose
1852132|NCT00954252|Drug|placebo|placebo, oral capsule, single dose
1852133|NCT00954252|Drug|CHF 5074|2x, oral capsule, single dose
1852134|NCT00954252|Drug|CHF 5074|4x, oral capsule, single dose
1852135|NCT00954252|Drug|CHF 5074|8x, oral capsule, single dose
1852136|NCT00954252|Drug|CHF 5074|16x, oral capsule, single dose
1852137|NCT00954252|Drug|CHF 5074|24x, oral capsule, single dose
1852138|NCT00954265|Drug|10000 IU urinary HCG|ovulation triggering
1852139|NCT00954265|Drug|250 mcg recombinant HCG|ovulation triggering
1852140|NCT00954278|Drug|sorafenib|sorafenib (400mg or 600mg or 800mg) by mouth twice daily, for 28 days
1852146|NCT00954317|Procedure|epidural placed low|epidural placed low
1852147|NCT00954317|Procedure|high epidural|high epidural
1852148|NCT00954330|Procedure|lateral ligament surgery|. The disrupted FTA or/and FC and superficial retinacular structures were repaired by using absorbable sutures. In case of avulsion from the bone, the ligament was reapproximated with the use of sutures that were passed through 2.0 millimeter drill-holes in the bone.
1852149|NCT00954330|Device|functional treatment|Twenty-six patients randomized to the functional treatment received a functional light-weight orthotic device (Air-Cast ankle brace, Summit, New Jersey) for 3 weeks. Full weight bearing was allowed. The ankle brace allowed dorsi- and plantarflexion but it restricted inversion and eversion of the ankle.
1852150|NCT00954343|Procedure|Extracorporeal Shock Wave|
1852151|NCT00954343|Procedure|Extracorporeal Shock Wave|
1852152|NCT00954343|Procedure|Extracorporeal Shock Wave|
1852153|NCT00954343|Procedure|Extracorporeal Shock Wave|
1852154|NCT00954356|Drug|XPF-001|Single oral administration of 500 mg XPF-001 capsules (5 x 100 mg capsules)
1852155|NCT00954356|Drug|placebo|Single oral administration of 5 x 100 mg Placebo capsules.
1852156|NCT00954369|Drug|[F-18]W372|"The individual doses of [F-18]W372 contain a maximum of 20 mCi for normal volunteers and 10 mCi for high probability AD subjects.
The single IP dose is administered to the study subject immediately prior to the start of PET imaging."
1852157|NCT00954395|Other|D-dimer|D-dimer is performed at the time of anticoagulation suspension. If above or below age and gender specific cut-offs, anticoagulation is stopped and D- dimer repeated after 15, 30, 60 and 90 days.
1852158|NCT00954421|Device|Deep Brain Stimulation|Use of two ipsilateral thalamic Deep Brain Stimulation electrodes (one at the ventralis intermedius nucleus/ventralis oralis posterior nucleus border or VIM and one at the ventralis oralis anterior nucleus/ventralis oralis posterior nucleus border or VO) for treatment of disabling and medication refractory tremor secondary to head trauma or multiple sclerosis.
1852159|NCT00954434|Dietary Supplement|red wine|intake of red wine on a daily basis
1852160|NCT00959777|Drug|DA-3031|
1852161|NCT00959777|Drug|Filgrastim|
1852162|NCT00959790|Dietary Supplement|Vegetables|200 or 50 grams of vegetables daily for four weeks
1852163|NCT00959790|Dietary Supplement|energy restriction|Consume about 1000 kcal less daily, for four weeks, as a positive control to the vegetables interventions.
1852164|NCT00959803|Drug|PF-04447943|3 mg solution, oral single dose.
1852165|NCT00959803|Drug|PF-04447943|10 mg solution, oral single dose.
1852166|NCT00959803|Drug|PF-04447943|25 mg solution, oral single dose.
1852167|NCT00959803|Drug|Placebo|Solution, oral single dose.
1852168|NCT00959803|Drug|PF-04447943|25 mg solution, oral twice daily for 7 days.
1852169|NCT00959803|Drug|Placebo|Solution, oral twice daily for 7 days.
1852170|NCT00959816|Drug|ABT-614|Single dose administered on Study Day 1 in Part 1, daily dose administered on Study Days 1-14 in Part 2.
1852171|NCT00959829|Other|Music and message|Experimental group: music and message Control group: silence
1852172|NCT00959842|Drug|Lovaza|1 gram gel capsule 4 capsules per day for 8 weeks
1852220|NCT00960115|Biological|Tecemotide (L-BLP25)|After receiving a single low-dose cyclophosphamide, participants will receive weekly subcutaneous vaccinations with tecemotide (L-BLP25) (930 microgram [mcg]) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with tecemotide (L-BLP25) (930 mcg) will be administered every 6 weeks until progressive disease (PD).
1852311|NCT00960583|Other|Routine follow-up|Advice to stay active
1852412|NCT00967135|Drug|Pregabalin|150 mg oral dose of pregabalin twice daily for 5 consecutive days.
1852173|NCT00959855|Other|Pulmonary Rehabilitation|Sixteen, two hourly pulmonary rehabilitation sessions over an eight week period. The first hour will consist of an individualized exercise programme based on exercise field tests. The second hour will consist of an educational component. A home exercise programme of inspiratory muscle training (Threshold(R)IMT (respiratory muscle trainer re:HS730EU-001 single patient use) starting between 15% -30% of PiMax and progress weekly to 60% for 30 mins a day/ 5 dats a week with an inspiratory/expiratory ratio of 3:4. Patients will also be encouraged to walk or undertake an home exercise programme based on a Borg score of between 3 and 5 an additional 3 days a week.
1852174|NCT00959868|Drug|OGX-427|OGX-427 drug product is in 25mg/mL injection in a mannitol-phosphate buffer solution packaged to deliver at least 8mL volume from a 10mL Type I, clear glass vial (ammonium sulfate treated) with Teflon coated bromobutyl rubber stopper and sealed with an aluminum, red, flip-off over seal. The drug product is aseptically compounded and sterilized via sterile filtration prior to aseptic filling.
1852175|NCT00959881|Drug|Donepezil plus placebo|5- and 10-mg tablets, single dose
1852176|NCT00959881|Drug|Donepezil|5- and 10-mg tablets, single dose
1852177|NCT00959881|Drug|Begacestat|6 x 50-mg capsules, single dose
1852178|NCT00959894|Drug|Etravirine (Intelence)|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
1852179|NCT00959894|Drug|Truvada|Etravirine 400 mg (four 100 mg or two 200 mg tablets) taken orally once a day with one pill of Truvada (200 mg of emtricitabine and 300 mg of tenofovir) taken orally once a day
1852180|NCT00959907|Drug|BOTULINUM TOXIN TYPE-A|"On Visit 1 (Day 0):
Botulinum toxin A (Dysport® and Botox®) will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.
Dysport®: 4 units will be injected in the left or right forehead side.
Botox® : 2 units will be injected in the left or right forehead side.(opposite side of dysport injection)"
1852181|NCT00959920|Procedure|Indwelling catheter|Indwelling bladder catheter will remain in place until time of delivery.
1852182|NCT00959920|Procedure|Intermittent straight catheterization|intermittent straight catheterization will be performed on an as needed basis until time of delivery.
1852183|NCT00959933|Drug|Ribavirin 200 Capsules (Geneva Pharmaceutical, U.S.A.)|
1852184|NCT00959933|Drug|Rebetol 200 Capsules (Schering Corporation, U.S.A.)|
1852185|NCT00959946|Drug|Bosutinib|Doses in part 1 include bosutinib 200 mg QD; bosutinib 300 mg QD. Depending on safety bosutinib can be administered at 200 mg/m2 QD. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
1852186|NCT00959946|Drug|Capecitabine|Doses in part 1 include capecitabine 750 mg/m2 BID on days 1-14; capecitabine 625 mg/m2 BID on days 1-14. Depending on safety, capecitabine can also be administered at 1000 mg/m2 BID. The MTD of the combination treatment determined from part 1, will be administered in part 2 (phase 2).
1852187|NCT00959959|Drug|TOK-001|2 capsules (325 mg each), once per day
1852188|NCT00959959|Drug|TOK-001|4 capsules (325 mg each), once per day
1852189|NCT00959959|Drug|TOK-001|6 capsules (325 mg each), once per day
1852190|NCT00959959|Drug|TOK-001|3 capsules (325 mg each), once per day
1852191|NCT00959959|Drug|TOK-001|3 capsules (325 mg each), once per day with supplement
1852192|NCT00959959|Drug|TOK-001|6 capsules (325 mg each), split dose (3 capsules with breakfast, 3 capsules with dinner)
1852193|NCT00959959|Drug|TOK-001|8 capsules (325 mg each), once per day
1852194|NCT00959959|Drug|TOK-001|8 capsules (325 mg each), split dose (4 capsules with breakfast, 4 capsules with dinner)
1852195|NCT00959972|Drug|Varenicline|Participants randomized to varenicline will be administered 0.5 mg/day for 3 days, 0.5 mg twice daily for 4 days, then 1 mg twice daily thereafter for an additional 11 weeks.
1852196|NCT00959972|Drug|Transdermal Nicotine Patch|Participants randomized to NRT will apply the patch immediately on the first day and each morning thereafter for 12 weeks. Doses of NRT will be 21 mg/day for the first 6 weeks, 14 mg/day for 4 weeks, then 7 mg/day for 2 weeks.
1852197|NCT00959985|Device|Compression Sleeve|Worn for a minimum of 12 hours per day
1852198|NCT00959985|Device|Short-Stretch Compression Bandage|Worn overnight at least 5 nights of the week
1852199|NCT00959998|Other|Self-administered Acupressure|
1992885|NCT03280563|Drug|Exemestane|Exemestane will be given as 25 mg orally QD in each 21-day cycle.
1852204|NCT00960037|Dietary Supplement|Oral vitamin D3|Vitamin D3 50-100 mcg capsule(depending on baseline serum 25(OH)D concentration) daily for 8 weeks.
1852205|NCT00960037|Dietary Supplement|Placebo equivalent|One capsule daily for 8 weeks
1852206|NCT00960063|Drug|Temozolomide|
1852207|NCT00960063|Drug|Vincristine|
1852208|NCT00960063|Drug|Ifosfamide|
1852209|NCT00960063|Drug|Irinotecan|
1852210|NCT00960063|Biological|Robatumumab|
1852211|NCT00960063|Drug|Doxorubicin|
1852212|NCT00960063|Drug|Cyclophosphamide|
1852213|NCT00960063|Drug|Etoposide|
1852214|NCT00960076|Drug|Saxagliptin|5mg oral tablet once daily
1852215|NCT00960076|Drug|Metformin XR|500mg oral tablet once daily
1852216|NCT00960076|Drug|Metformin XR|750mg, 2 tablets once daily
1852217|NCT00960089|Device|LIQUICURE|Topical treatment, 1 time/day, 5 days/week
1852218|NCT00960102|Device|cochlear implant|Multichannel Nucleus cochlear implant
1852219|NCT00960102|Device|hearing aid|Phonak Valeo hearing aid
1852221|NCT00960115|Drug|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg/m^2) of cyclophosphamide will be administered 3 days prior to tecemotide (L-BLP25), the first vaccine treatment.
1992886|NCT03280563|Drug|Fulvestrant|Fulvestrant will be given as 500 mg intramuscularly on Days 1 and 15 of Cycle 1 and thereafter on Day 1 of each 28-day cycle.
1992887|NCT03280563|Drug|Ipatasertib|Ipatasertib will be given as 400 mg orally QD on Days 1-21 of each 28-day cycle.
1992888|NCT03280563|Drug|Tamoxifen|Tamoxifen will be given as 20 mg orally QD in each 21-day cycle.
1852222|NCT00960115|Biological|Placebo|After receiving single dose of saline, participants will receive weekly subcutaneous vaccinations with placebo that matches with tecemotide (L-BLP25) for 8 weeks, followed by a maintenance treatment phase starting at Week 14, in which subcutaneous vaccinations with placebo will be administered every 6 weeks until PD.
1852223|NCT00960115|Other|Saline|A single dose of saline (sodium chloride, 9 grams per liter [g/L]) will be administered intravenously, 3 days prior to the start of placebo.
1852226|NCT00960141|Drug|montelukast sodium|montelukast 10 mg tablet, taken orally once daily at bed time for 2 weeks
1852227|NCT00960141|Drug|Comparator: loratadine|loratadine 10 mg tablet, taken orally once daily at bed time for 2 weeks
1852228|NCT00960141|Drug|Comparator: placebo|placebo tablet, taken orally once daily at bed time for 2 weeks
1852229|NCT00960154|Device|PEAK PlasmaBlade|The entirety of the lumpectomy will be performed with the PEAK PlasmaBlade including the skin incision
1852230|NCT00960154|Procedure|Traditional Electrosurgery with scalpel|The skin incision will be performed using a standard scalpel; the subcutaneous dissection will be performed with traditional electrosurgery using the Cut and Coagulation modes.
1852231|NCT00960167|Radiation|3DCRT or IMRT|"All enrolled patients will receive 3.5 Gy per fraction (five fractions per week) at the following levels;
Dose escalation by 7 Gy in 2 fractions to maximum of 63 Gy, as follows:
Dose Level I: 3.5 Gy for 12 fractions (42 Gy total) Dose Level II: 3.5 Gy for 14 fractions (49 Gy total) Dose Level III: 3.5 Gy for 16 fractions (56 Gy total) Dose Level VI: 3.5 Gy for 18 fractions (63 Gy total)"
1852232|NCT00960180|Drug|MR1817|
1852233|NCT00960180|Drug|Placebo|
1852234|NCT00960193|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1 and a single dose of 0.6 mg colchicine administered with Seville orange juice in the morning on Day 18 after an overnight fast of at least 10 hours.
1852235|NCT00960193|Other|Seville Orange Juice|240 mL of Seville orange juice administered in the morning and evening on Days 15 to 18.
1852236|NCT00960206|Device|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell|Trident® Ceramic Insert/Trident® AD HA Acetabular Shell
1852237|NCT00960206|Device|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell|Alumina Insert/PSL® Microstructured Acetabular Shell or Secur-Fit® HA PSL® Acetabular Shell
1852238|NCT00960206|Device|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell|OmniFit® Series II Insert/OmniFit® PSL® Microstructured Acetabular Shell
1852239|NCT00960219|Drug|D-amino acid oxidase inhibition (DAAOI-1)|1g/day(500mg BID), oral, for 6 weeks
1852240|NCT00960219|Drug|placebo|1# BID, oral, for 6 weeks
1852241|NCT00960232|Drug|Cholecalciferol|40.000 IU cholecalciferol per week for 6 months
1852242|NCT00960232|Drug|placebo|placebo
1852243|NCT00960245|Drug|Nadolol (1 x 80 mg) Tablets (Invamed, Inc)|
1852244|NCT00960245|Drug|Corgard (1 x 80 mg) Tablets (Bristol Laboratories)|
1852245|NCT00960258|Drug|Regorafenib (BAY73-4506)|The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
1852246|NCT00960271|Procedure|EBUS|a minimally invasive technique of mediastinal lymph node staging using an integrated videoendoscopic device equipped with ultrasound for the localization and transbronchial sampling of lymph nodes in real time
1852247|NCT00960284|Drug|capecitabine|Given orally
1852248|NCT00960284|Drug|cisplatin|Given IV
1852249|NCT00960284|Drug|epirubicin hydrochloride|Given IV
1852250|NCT00960284|Drug|fluorouracil|Given IV
1852251|NCT00960284|Drug|gemcitabine hydrochloride|Given IV
1852252|NCT00960297|Drug|Carboplatin|Carboplatin: AUC=6, given IV on Days 1, 22, 43, and 64
1852253|NCT00960297|Drug|Paclitaxel|Paclitaxel: 200 mg/m2, given IV on Days 1, 22, 43, and 64
1852254|NCT00960297|Drug|Bevacizumab|Bevacizumab: 15 mg/kg, given IV on Days 1, 22, and 43 (Note: bevacizumab will not be dosed on Day 64 prior to surgery)
1852255|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Sandoz Inc., USA)|
1852256|NCT00960310|Drug|Bicalutamide 50 mg Film-Coated Tablets (Casodex) (Astrazeneca Pharmaceutical LP, USA)|
1852257|NCT00960323|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone in the morning on Day 1.
1852258|NCT00960323|Drug|Atorvastatin|Atorvastatin (1 x 40 mg tablet) administered once daily on Days 15-28.
1852259|NCT00960323|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with a single dose of 40 mg atorvastatin in the morning on Day 28 after an overnight fast.
1852260|NCT00960336|Drug|pegylated liposomal doxorubicin hydrochloride|
1852261|NCT00960349|Drug|Cediranib|Given orally at a dose of 20mg/day everyday until the patient meets any discontinuation criterion.
1852262|NCT00960349|Drug|Cisplatin|Given as a intravenous infusion at a dose of 80mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
1852263|NCT00960349|Drug|S-1|Given orally at a dose of 80 - 120mg/day according to BSA for 3 weeks followed by a 2-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
1852264|NCT00960349|Drug|Cisplatin|60mg/m2 over 2hours on Day 1 of each cycle followed by a 5-week rest period. A maximum of 8 cycles of cisplatin will be given.
1852265|NCT00960349|Drug|Capecitabine|Given orally at a dose of 1000mg/m2 twice daily for 2 weeks followed by a 1-week rest period in each cycle. Will be continued indefinitely until the patient meets any discontinuation criterion.
1852266|NCT00960362|Drug|AGS-009|Single dose in the range of 0.01 to 30 mg/kg administered intravenously (in the vein)
1852267|NCT00960362|Drug|placebo|Single dose of 0 mg/kg administered intravenously (in the vein) cohort 1-6.
1852308|NCT00960570|Drug|Efavirenz 600 mg|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
1852309|NCT00960570|Drug|Fenofibric Acid|Co-administered single oral doses of Efavirenz 600 mg and Fenofibric Acid 105 mg on Day 31.
1852268|NCT00960375|Behavioral|BTSCS|BTSCS lasts 3 months, includes two 60-minute group meetings per week (24 group meetings total), and is delivered in small groups of 4-8 participants run by a trained interventionist. BTSCS includes: (1) An individual motivational enhancement meeting during the first week of treatment to help participants think about individual reasons for smoking cessation; (2) Breath carbon monoxide monitoring and goal-setting at the beginning of each meeting; (3) Skills for reducing smoking; (4) Social Skills Training; (5) Education about the biology of SPMI and smoking and the physiological harm caused by smoking; (5) Relapse prevention training; (6) Education about and assistance with nicotine replacement therapy for participants who are interested in learning about and trying it.
1852269|NCT00960375|Behavioral|StSST|The StSST program is adapted from a 9-session weekly smoking cessation group program developed at the Outpatient Research Program of the Maryland Psychiatric Research Center and designed for people with schizophrenia. In this study, the StSST program meet twice per week for 3 months (24 sessions total). Participants complete a breath carbon monoxide (CO) test at the start of each group. StSST groups provide education about smoking and support for quitting.
1852270|NCT00960414|Behavioral|SHINE|Both groups will receive a diet and exercise based intervention aimed at eating a caloric intake that will maintain ideal body weight and increasing exercise. SHINE A will emphasize awareness of hunger and satiety cues, while SHINE B will receive more detained nutritional education.
1852271|NCT00960427|Drug|systemic chemotherapy|
1852272|NCT00960427|Genetic|RNA analysis|
1852273|NCT00960427|Genetic|gene expression analysis|
1852274|NCT00960427|Genetic|reverse transcriptase-polymerase chain reaction|
1852275|NCT00960427|Other|immunohistochemistry staining method|
1852276|NCT00960427|Other|laboratory biomarker analysis|
1852277|NCT00960427|Procedure|endoscopic biopsy|
1852278|NCT00960427|Procedure|neoadjuvant therapy|
1852279|NCT00960427|Procedure|sigmoidoscopy|
1852280|NCT00960427|Radiation|radiation therapy|
1852281|NCT00960440|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily for 6 months during the double-blind, placebo-controlled period.
1852282|NCT00960440|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily for 6 months during the double-blind, placebo-controlled period.
1852283|NCT00960440|Drug|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, study period.
1852284|NCT00960440|Drug|CP-690,550|Oral tablets administered at 5 mg BID daily during the second 3 months of the double-blind, study period.
1852285|NCT00960440|Drug|Placebo|Oral placebo tablets administered BID daily during the first 3 months of the double-blind, placebo-controlled period.
1852286|NCT00960440|Drug|CP-690,550|Oral tablets administered at 10 mg BID daily during the second 3 months of the double-blind, study period.
1852287|NCT00960453|Drug|Sitagliptin|"Dosage form: 25mg, 50mg ,100mg
Amount: 25mg, 50mg, 100mg
Frequency and duration: once a day, for 4 days, including 5 days washout periods"
1852288|NCT00960466|Behavioral|Distress Thermometer and Problems List|When using the distress thermometer and problem list (DT&PL), the nurse or radiographer asks the patient to indicate distress over the past week on a visual analogue scale from 0 (no distress) to 10 (high distress). Next, from a list of 42 items, patients identify practical, family, emotional, spiritual or physical problems that have caused distress. The completion of the DT&PL should be a collaborative exercise with patients able to review what is written on the assessment sheet. Potential solutions will be discussed which may involve the following: i) concerns that can be resolved immediately (e.g. providing information, prescribing an analgesic); ii) concerns that require patient actions (e.g. participating in support groups); iii) concerns that require a referral (e.g. mental health specialist, social or pastoral care). The meeting will end with a summary plan of action.
1852289|NCT00960466|Behavioral|Usual psychosocial support|If patients express concerns about psychosocial issues, then clinic staff will discuss these issues, offer advice or make a referral as they see fit. However, no formal time will be set aside to monitor patient distress using the DT, elicit problems using the PL or develop a plan of action based on these tools. Because of the nature of the intervention, both the patient and the therapist will be aware of treatment assignment.
1852290|NCT00960479|Drug|Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)|
1852291|NCT00960479|Drug|Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)|
1852292|NCT00960492|Drug|XL184|XL184 will be administered daily as a single oral agent supplied as 25- and 100-mg capsules
1852293|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 75 mg/m2/day given daily with concurrent RT for 6 weeks
1852294|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules. The starting dose will be 200 mg/m2/day given for 5 consecutive days and repeated every 28 days.
1852295|NCT00960492|Radiation|Radiation Therapy|Subjects will receive RT consisting of fractionated focal irradiation administered using 1.8-2 Gy/fraction, daily for 5 days/week for 6-7 weeks, for a total dose of up to 60 Gy.
1852296|NCT00960492|Drug|temozolomide|TMZ will be supplied as 5-, 20-, 100-, 250-, 140-, and 180-mg capsules.
1852300|NCT00960518|Drug|adefovir|adefovir at 10 mg daily for 48 weeks
1852301|NCT00960518|Procedure|TACE|An emulsion that consisted of 50 mg of cisplatin and 10 mL of lipiodol at a volume ratio of 1:1 was injected into the blood supply artery of the tumor under fluoroscopic guidance. The injection could be slowed or discontinued if retrograde flow occurred. Embolization was subsequently performed with granules of gelatin sponge particles.
1852302|NCT00960531|Biological|ACC-001+ QS21 (3mcg)|ACC-001 3mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
1852303|NCT00960531|Biological|ACC-001 (10 mcg) + QS-21|ACC-001 10mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
1852304|NCT00960531|Biological|ACC-001+QS-21 (30mcg)|ACC-001 30mcg + QS-21 50 mcg Intra-muscular (IM) q 6 mo
1852305|NCT00960544|Drug|Capecitabine|Routine administration of twice daily dosing for days 1-14 of a 21-day cycle.
1852306|NCT00960557|Drug|Combretastatin A1 Diphosphate (OXi4503)|OXi4503 administered IV on Days 1, 8, and 15 of each 28-day cycle.
1852307|NCT00960570|Drug|Efavirenz 600 mg|Efavirenz 600 mg administered as a single oral dose on the morning of Day 1.
1852312|NCT00960596|Behavioral|Health promotion and health education for smoking habits|We provide the education to intervention group.
1852313|NCT00960609|Procedure|Ultrasound guided liver resection|
1852314|NCT00960622|Drug|Truvada|Truvada (tenofovir 300mg / emtricitabine 200mg) capsule once daily for 6 months
1852315|NCT00960622|Drug|Combivir|Continue on Combivir (150 mg of lamivudine, 300 mg of zidovudine) two tablets daily for 6 months
1852316|NCT00960622|Drug|Trizivir|Continue on Trizivir (300 mg of abacavir as abacavir sulfate, 150 mg of lamivudine, and 300 mg of zidovudine)
1852317|NCT00960635|Drug|1,25-dihydroxy-vitamin D3 (calcitriol)|
1852318|NCT00960635|Drug|placebo|pill without agent
1852319|NCT00960648|Device|Xience/Promus|Active prospective registration of patients receiving everolimus-eluting stent
1852320|NCT00960648|Device|Cypher|Retrospective historical controls that received sirolimus-eluting stent
1852321|NCT00960661|Drug|exenatide|subcutaneous injection, 5mcg (4 weeks) followed by 10mcg (26 weeks), twice a day
1852322|NCT00960661|Drug|insulin lispro|titrated based on pre-meal glucose level; three times a day
1852323|NCT00960661|Drug|Metformin|
1852324|NCT00960661|Drug|Insulin/ Glargine|
1852325|NCT00960674|Procedure|Tactile massage|Gentle massage given for one hour by specially educated massage therapists, usually registered nurses.
1852326|NCT00960674|Behavioral|Relaxation|Relaxation by a CD with relaxation exercises, at least one hour per week for ten weeks
1852327|NCT00960687|Drug|Fenofibric Acid (Fibricor™) 105 mg Tablet|1 x 105 mg fenofibric acid (Fibricor™) tablet administered 30 minutes after the initiation of a standard breakfast.
1852328|NCT00960687|Drug|Fenofibrate (Tricor®) 145 mg Tablet|1 x 145 mg Fenofibrate (Tricor®) tablet administered 30 minutes after the start of a standard breakfast.
1852329|NCT00960700|Device|Visual Acuity|Assessment of visual acuity
1852330|NCT00960700|Device|Contrast sensitivity|Assessment of contrast sensitivity
1852331|NCT00960700|Device|Reading Speed|Assessment of reading speed
1852332|NCT00960700|Procedure|Eye Health|Examination of eye health through use of a slitlamp/ photography. Assessment of Intraocular Pressure.
1852333|NCT00960713|Drug|Rituximab (MABTHERA® or RITUXAN®).|patients can be included in the study whatever the dosage used. Most patients will receive a classical 375 mg/m2 dose every week during four times (J0-J7-J14-J21).
1852334|NCT00960726|Drug|NOV-002|60 mg delivered daily subcutaneously for up to 12 months.
1852335|NCT00960739|Drug|Topotecan hydrochloride|The topotecan hydrochloride is administered intravenously over five days to dose of 0.7 mg/ m²/day from day 1 to day 5 (first cycle), then from day 21 to day 25 (second cycle)
1852336|NCT00960739|Procedure|Autologous hematopoietic stem cell transplantation|Hematopoietic stem cells are reinjected 10 days after the second injection of 131-iodine MIBG
1852337|NCT00960739|Radiation|iobenguane I 131|444 MBq / kg of 131-iodine MIBG is administered on day 1 with activity
1852338|NCT00960739|Radiation|total-body irradiation|the dose of total-body irradiation of 4 Gy is reached during the first cycle, the second cycle is canceled (131-iodine MIBG and Topotecan)
1852339|NCT00960752|Drug|gp100|1 ml of gp100 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
1852340|NCT00960752|Drug|R848 gel|Applied to the gp100 vaccine injection site immediately following the injection, allowed to air dry for 30 minutes then covered with gauze dressing.
1852341|NCT00960752|Drug|MAGE-3|1 ml of MAGE-3 peptide vaccine: 0.5 ml administered intradermally and the other 0.5 ml subcutaneously in the same extremity weekly (every 7 days +/- 2 days) for 8 weeks.
1852342|NCT00960778|Drug|nicotine patch (Nicoderm CQ, Habitrol)|Nicotine patch 21 mg every 24 hours will be utilized for the three days after the first scanning session.
1852343|NCT00960778|Other|denicotinized cigarettes (Quest 3 cigarettes)|Cigarettes that contain trace levels of nicotine (less than .05 mg per cigarette) will be utilized ad lib in the study for 4 days after the nicotine patch.
1852344|NCT00960791|Device|AZD1656|Oral single dose
1852345|NCT00960804|Biological|Tanezumab|IV, 5 mg dose, q 8 weeks, for up to 80 weeks
1852346|NCT00960804|Biological|Tanezumab|IV, 10 mg dose, q 8 weeks, for up to 80 weeks
1852347|NCT00960804|Other|Placebo|IV, q 8 weeks, for up to 80 weeks
1852348|NCT00960817|Drug|Statin, aspirin|
1852349|NCT00960817|Drug|Dipyridamole|
1852350|NCT00960830|Drug|mirtazapine|mirtazapine 15 mg daily tablets
1852351|NCT00960830|Drug|mirtazapine|15 mg daily
1852352|NCT00960843|Device|Intraband pressure recording system|Intraband pressure will be measured by a pressure recording system.
1852353|NCT00960843|Other|Conventional Adjustment|Band adjustments will be made via conventional standard of care (e.g., volume, hunger).
1852354|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a low-fat breakfast.
1852355|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a standard breakfast
1852356|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered 30 minutes after the initiation of a high-fat/high-calorie breakfast.
1852357|NCT00960856|Drug|Fenofibric Acid 105 mg Tablet|One 105 mg tablet administered after an overnight fast of at least 10 hours.
1852358|NCT00960869|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole
1852359|NCT00960869|Drug|EC-Aspirin 325 mg|The comparator aspirin 325 mg enteric coated tablet (PA32540 minus omeprazole)
1852360|NCT00960882|Drug|DMMET-01|1050.6 mg daily for 30 days
1852361|NCT00960908|Device|Endeavor Resolute stents|2nd generation ZES
1852362|NCT00960908|Device|Endeavor Sprint stent|1st generation ZES
1852363|NCT00960921|Drug|Iron sucrose|An intravenous infusion of 100 mg of iron is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six iron infusions for each participant in the iron group over the course of the 28-day study period.
1852364|NCT00960921|Drug|Normal saline|An intravenous infusion of 100 ml of normal (0.9 %) saline is administered on days 0, 4, 8, 12, 16 and 20 of the study, giving a total of six saline (placebo) infusions for each participant in the saline group over the course of the 28-day study period.
1853926|NCT00979888|Procedure|management of therapy complications|
1852365|NCT00960934|Drug|MK-5442|MK-5442 2.5 mg, 5 mg, 7.5 mg, 10 mg, or 15 mg tablet once daily for at least 6 months.
1852366|NCT00960934|Drug|Placebo|Dose-matched oral placebo to MK-5442
1852367|NCT00960934|Dietary Supplement|Vitamin D3|Vitamin D3, two 400 IU tablets daily throughout the study.
1852368|NCT00960934|Dietary Supplement|Calcium carbonate|Participants who had a calcium intake of less than 1200 mg/day at baseline received a daily 500 mg calcium supplement throughout the study.
1852369|NCT00960960|Drug|Bevacizumab|Bevacizumab will be administered IV at a dose of 10 mg/kg on Days 1 and 15 of each 28-day cycle.
1852370|NCT00960960|Drug|Pictilisib|Pictilisib will be administered PO QD on escalating doses.
1852371|NCT00960960|Drug|Letrozole|Letrozole will be administered PO at a dose of 2.5 mg QD for for each 28-day cycle.
1852372|NCT00960960|Drug|Paclitaxel|Paclitaxel will be administered IV at a dose of 90 mg/m^2 on Days 1, 8, and 15 of each 28-day cycle.
1852373|NCT00960960|Drug|Trastuzumab|Trastuzumab will be administered IV at a dose of 2-4 mg/kg on on Days 1, 8, 15, and 22 of each 28-day cycle.
1852374|NCT00960973|Drug|Menatetrenone|Menatetrenone 30 mg, 3 times a day for 4 weeks
1852375|NCT00960973|Drug|Placebo|Placebo
1852376|NCT00960986|Drug|Duloxetine hydrochloride|po, QD
1852377|NCT00960999|Radiation|Single-fraction stereotactic body radiation therapy (SBRT)|34 Gy in 1 fraction to the prescription line at the edge of the planning target volume (PTV). The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
1852378|NCT00960999|Radiation|Multiple-fraction stereotactic body radiation therapy (SBRT)|48 Gy in four 12 Gy fractions to the prescription line at the edge of the planning target volume (PTV). Treatments are given on 4 consecutive calendar days, but at least 18 hours apart. The maximum dose must exist within the PTV, and the prescription isodose surface must be ≥ 60% and < 90% of the maximum dose. 99% of the PTV must receive a minimum of 90% of the prescription dose. The maximum dose to any point ≥ 2 cm away from the PTV in any direction must be at least < 50% of the prescription dose. The percent of the lungs (excluding PTV) receiving 20 Gy or more must be < 10%.
1852379|NCT00961012|Procedure|The Big Squeeze|Trunk release as per MSIP protocol. Standing at the foot of the bed, facing the subject, Experimenter A grasps both ends of the flat sheet to pull the trunk forward and away from the mattress surface. As the trunk release procedure is performed, Experimenter A checks to verify that the laser beam shines through to the opposite wall to confirm that the shoulders have cleared the mattress.
1852380|NCT00961025|Drug|DA-1229|"single dose study : DA-1229 1.25,2.5,5,10,20,40,60mg
multiple dose study : DA-1229 5,10,20,40mg"
1852381|NCT00961025|Drug|Placebo|placebo
1852382|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
1852383|NCT00961038|Drug|Ciprofloxacin (PulmoSphere, BAYQ3939)|48,75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin PulmoSphere inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), the same dose will be given twice daily, with a concluding single dose (on day 12)
1852384|NCT00961038|Drug|Placebo|Placebo inhalation powder will be given as an initial single-dose inhalation (day 0).During the multiple-dose phase (day 2 to day 11), placebo will be given twice daily, with a concluding single dose (on day 12)
1852385|NCT00961051|Device|Investigational MPS|Multi-purpose solution
1852386|NCT00961051|Device|Opti-Free|Multi-purpose solution
1852388|NCT00966992|Drug|Zoledronic acid|
1852389|NCT00967005|Drug|N Acetyl Cysteine|N-Acetyl Cysteine, 1200mg-3000mg each day for 24-weeks
1852390|NCT00967005|Other|Sugar Pill|placebo control
1852391|NCT00967018|Drug|Degarelix|
1852392|NCT00967031|Drug|capecitabine|
1852393|NCT00967031|Drug|lapatinib ditosylate|
1852394|NCT00967031|Other|circulating tumor cell analysis|
1852395|NCT00967031|Other|laboratory biomarker analysis|
1852396|NCT00967044|Drug|Panobinostat|Starting dose of 10 mg by mouth per day, self-administered (by patients), three times per week
1852397|NCT00967044|Drug|Everolimus|Starting dose of 5 mg every day by mouth with 1 cup (8 ounces) of water, in morning after eating a low-fat meal.
1852398|NCT00967057|Drug|asparaginase|Given intramuscularly
1852399|NCT00967057|Drug|dexamethasone|Given orally
1852400|NCT00967057|Drug|idarubicin|Given IV
1852401|NCT00967057|Drug|methotrexate|Given intrathecally
1852402|NCT00967057|Drug|mitoxantrone hydrochloride|Given IV
1852403|NCT00967057|Drug|pegaspargase|Given intramuscularly
1852404|NCT00967057|Drug|vincristine sulfate|Given IV
1852405|NCT00967070|Drug|Nicotine Patch|25 mg nicotine patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
1852406|NCT00967070|Drug|Placebo Patch|Placebo patch applied on the assigned marked sites on the lower back. Induction phase (21 days): left side, six treatment applications for 48 or 72 h. Challenge phase (five days): right side, one treatment application for 48 h.
1852407|NCT00967083|Behavioral|Questionnaires/Interviews|Baseline assessment of distressed caregivers within 4-6 weeks a new visit to the thoracic clinic. Three-month follow-up assessment of caregivers. Qualitative phone interviews with a subsample of 30 caregivers within 3 weeks of follow-up.
1852408|NCT00967096|Drug|Rifaximin|Rifaximin for Bone marrow transplant patients
1852409|NCT00967109|Other|Allowed drop in hemoglobin to level between 4,5-5,6 mmol/L|Transfusion with red blood cells to hemoglobin level between 4,5-5,5 mmol/L
1852410|NCT00967109|Other|Allowed drop in hemoglobin to level between 5,6-6,5 mmol/L|Transfusion with red blood cells to hemoglobin level between 5,6-6,5 mmol/L
1852411|NCT00967122|Procedure|Band adjustment and specimen collection|Clinical evaluation and sample collection before and after band adjustment
1852413|NCT00967135|Drug|Placebo|Matching oral placebo twice daily for 5 consecutive days.
1852415|NCT00967161|Procedure|Total Knee Arthroplasty|Total Knee Arthroplasty
1852416|NCT00967161|Procedure|Motion analysis|Motion analysis (Gait/EMG during walking and functional tasks)
1852417|NCT00967174|Drug|Nicotine Patch|25 mg nicotine patch applied on the lower back, according to treatment sequence, daily for 21 days.
1852418|NCT00967174|Drug|Placebo Patch|Placebo Patch applied on the lower back, according to treatment sequence, daily for 21 days.
1852419|NCT00967174|Drug|SLS Comparator Patch|0.1% (w/v) SLS patch applied on the lower back, according to treatment sequence, daily for 21 days.
1852420|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326 200mg monotherapy for 14 days. Once the Day 15 viral load results become available, patients, who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
1852421|NCT00967187|Drug|bevirimat dimeglumine|Patients will be treated with MPC-4326, 300 mg monotherapy for 14 days. Once the Day 15 viral load results become available patients who achieve at least a 0.5 log10 reduction in viral load by Day 15 will have the option to continue on both MPC-4326 and an optimized background regimen (OBR) through Week 72.
1852422|NCT00967200|Other|laboratory biomarker analysis|laboratory biomarker analysis
1852423|NCT00967200|Other|pharmacogenomic studies|pharmacogenomic studies
1852424|NCT00967213|Drug|ranibizumab|Lucentis® (ranibizumab) 0.3mg (0.05ml volume) intravitreal injection. Eligible patients will be initially received three session of monthly injection of Lucentis® (week 0, 4, 8). After 4 weeks from third injection, a session of verteporfin PDT (week 12) and fourth injection of Lucentis® (week 16) will be added at intervals of 4 weeks. Two more combined treatment with verteporfin PDT and Lucentis® injection 4 weeks apart can be added at the treating physician's discretion in 3-month intervals (week 28, week 40).
1852425|NCT00967226|Drug|propranolol|propranolol 0.5 mg/kg orally, 4 per day - 4-6 months
1852426|NCT00967226|Drug|Prednisolone|1.0 mg/kg orally, 2 per day 4-6 months
1852427|NCT00967239|Genetic|DNA analysis|
1852428|NCT00967239|Genetic|polymorphism analysis|
1852429|NCT00967239|Other|laboratory biomarker analysis|
1852430|NCT00967239|Other|pharmacogenomic studies|
1852431|NCT00967252|Drug|Atorvastatin|Atorvastatin 10 mg daily or equivalent dose in another statin
1852432|NCT00967252|Drug|Atorvastatin|Atorvastatin 20 mg daily or equivalent dose in another statin
1852433|NCT00967252|Drug|Atorvastatin|Atorvastatin 40 mg daily or equivalent dose in another statin
1852434|NCT00967252|Drug|Atorvastatin|Atorvastatin 80 mg daily or equivalent dose in another statin
1852435|NCT00967252|Other|Control|No statin being taken
1852436|NCT00967265|Behavioral|Introduction seminar|The seminar will be held over two half days, each lasting 2.5 hours. Up to 30 patients can participate in each seminar. The details of the content of the program will be developed based on study one. The preliminarily plans are to give general information about the community mental health centre, the available treatment options and patients rights by presentations from health personnel and user representatives. At the end of each day, the patients will be divided into small groups mentored by health personnel were they can discuss the presentations and ask questions. In the breaks, literature and other type of information for patients will be on display. All participants will get a folder with details of the program and leaflets from patient organisations and governmental agencies.
1852437|NCT00967265|Other|Usual care|Usual care
1852438|NCT00967291|Drug|ifosfamide|2,500 mg/mq on days 1-3 every 28 days
1852439|NCT00967291|Drug|mitomycin C|8 mg/mq on day 1 every 28 days
1852441|NCT00967317|Drug|Auris-Sedina|"Drip 2 drops of the medication with the head tilted and protect with a cotton swab. Repeat the process one at a time until the pain relief. Continue the administration of medication every 3 hours until the pain ceases.
The medication should be used for a maximum of 3 days when they should return to the doctor."
1852442|NCT00967317|Drug|Otosynalar®|Drip 3 drops in the ear 2 times a day. The medication should be used by more than 3 days after which the patient must return to the doctor.
1852443|NCT00967759|Drug|Bronpheniramine and fenilefrine (Decongex Plus)|Oral Solution: Bronpheniramine (2mg/ml) and fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
1852444|NCT00967759|Drug|Bronpheniramine isolated|Oral Solution: Bronpheniramine (2mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
1852445|NCT00967759|Drug|Fenilefrine isolated|Oral Solution: Fenilefrine (2,5mg/ml) 2 drops/kg/day divided into 3 doses; maximum of 60 drops/day QID, during 5 days.
1852446|NCT00967772|Drug|Naftopidil|25mg/ 50 mg/ 75mg dosage tablets
1852448|NCT00967798|Drug|Sitagliptin|100 mg of sitagliptin is taken orally each morning with breakfast. Duration is 12 months or conversion to CF diabetes, whichever comes first.
1852449|NCT00967811|Drug|Formulation E1 of L-PPDS|Control of IOP compared to baseline for Formulation E1 of the experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
1852450|NCT00967811|Drug|Formulation E2 of L-PPDS|Control of IOP compared to baseline for Formulation E2 of experimental dose of Latanoprost-PPDS for 6 weeks or until loss of efficacy.
1852451|NCT00967824|Other|informational intervention|
1852452|NCT00967824|Other|questionnaire administration|
1852453|NCT00967824|Other|survey administration|
1852503|NCT00968227|Biological|Red blood cell transfusion|Transfusion of 1 unit of packed red blood cells over 1 hour.
1852454|NCT00967837|Procedure|Pulsatile Intravenous Insulin Therapy|Diabetic pts that meet trial criteria referred by an endocrinologist are given Pulsatile intravenous insulin therapy on a weekly basis. Weekly orders for insulin dosage is based upon pt response to therapy monitored by RQ and insulin resistance.
1852455|NCT00967850|Drug|Intravitreal Injection|Intravitreal injection of 1,25 mg in 0,05 ml
1852456|NCT00967850|Drug|Photodynamic Therapy (Visudyne)|Photodynamic therapy on day 1 as described in standard clinical guidelines.
1852457|NCT00967863|Radiation|3-dimensional conformal radiation therapy|Patients undergo radiotherapy
1852458|NCT00967863|Radiation|intensity-modulated radiation therapy|Patients undergo radiotherapy
1852459|NCT00967889|Genetic|gene expression analysis|
1852460|NCT00967889|Genetic|protein analysis|
1852461|NCT00967889|Other|biologic sample preservation procedure|
1852462|NCT00967889|Other|laboratory biomarker analysis|
1852463|NCT00967902|Device|coronary stenting|Balloon dilatation of obstructive coronary artery disease with deployment of a metallic stent to scaffold the dilated lesion; stent incorporating sustained release of anti-proliferative agent to control neointimal proliferation and reocclusion; test device incorporates affinity surface for circulating EPCs
1852464|NCT00967915|Procedure|Frentomy|Frenotomy will be performed. This procedure involves crushing frenulum tissue with straight hemostat for hemostasis and anesthesia while tongue is elevated with elevator. Frenulum then cut to desired length with iris scissors. Patient then returned to parents and immediately breastfeeds without parent observing infant's mouth.
1852465|NCT00967915|Other|Sham procedure|Infant taken into room away from parents and no frenotomy performed. Infant's mouth is examined but no interventions made.
1852466|NCT00967928|Drug|RAD001|RAD001 will be administered orally as 5 mg qod, 5 mg qd, or 10mg qd continuously from study Day 1 until the end of whole pelvic radiation therapy unless the patient develops progression of disease or unacceptable toxicity prior to that.
1852467|NCT00967928|Drug|Cisplatin|Cisplatin will be administered intravenously once weekly at 40mg/m2 for 6 weeks. The preferred administration day is Monday.
1852468|NCT00967928|Radiation|External Beam Whole Pelvis Radiation Therapy|Patients will receive 180 cGy daily fraction Monday through Friday x 25 days (4500 cGy total) using a four field technique throughout the entire treatment with all fields treated each day.
1852472|NCT00967954|Drug|antiandrogen therapy|
1852473|NCT00967954|Drug|releasing hormone agonist therapy|
1852474|NCT00967954|Genetic|DNA analysis|
1852475|NCT00967954|Genetic|RNA analysis|
1852476|NCT00967954|Genetic|comparative genomic hybridization|
1852477|NCT00967954|Genetic|gene expression analysis|
1852478|NCT00967954|Other|laboratory biomarker analysis|
1852479|NCT00967954|Procedure|diffusion-weighted magnetic resonance imaging|
1852480|NCT00967954|Procedure|magnetic resonance spectroscopic imaging|
1852481|NCT00967967|Drug|Medication Mometasone furoate and desloratadine|One month treatment with both drugs
1852482|NCT00967980|Procedure|Femoral Nerve Block vs. Psoas Compartment Nerve Block|Patients, undergoing hip arthroplasty or hip resurfacing will be randomized to one of two groups: femoral nerve block or psoas compartment nerve block. Patients randomized to femoral nerve block will receive this block prior to surgery. Patients randomized to psoas compartment nerve block will receive this block prior to surgery. Both patients will receive Mepivicaine via catheter prior to surgery and following surgery, Ropivicaine via pain pump.
1852483|NCT00967993|Drug|ferric citrate|KRX-0502 will be supplied as one caplet of ferric citrate containing 210 mg of ferric iron as ferric citrate
1852484|NCT00968006|Drug|Sitagliptin|100 mg once daily for 4 weeks
1852485|NCT00968019|Device|Presillion stent|Centers will use commercially available Presillion Stents as recommended according to the Instruction For Use (IFU).
1852486|NCT00968032|Device|Nit-Occlud® PFO|Transcatheter implantation of a PFO occluder (Nitinol double Umbrella)
1852487|NCT00968045|Drug|Fibrinogen|Fibrinogen 2 gr in 100 ml sterile water. The infusion is given during 15 minutes
1852488|NCT00968058|Procedure|Leak Test Recording|Recording of the Leak Pressure by the Leak Test at 0, 5, 10, 15, 20, 30 min timepoints
1852489|NCT00968071|Drug|Decitabine|20 mg/m^2 IV over an hour and half daily for 5 days.
1852490|NCT00968071|Drug|Gemtuzumab Ozogamicin|3 mg/m^2 IV on day 5.
1852491|NCT00968097|Drug|123-I MNI-340|To assess the dynamic uptake and washout of 123-I MNI-340, a potential imaging biomarker for β-amyloid burden in brain
1852492|NCT00968110|Drug|omalizumab|Dosing table established for omalizumab
1852493|NCT00968149|Drug|montelukast sodium|one montelukast chewable tablet daily at bed time for 2 weeks, 4 mg for patients aged 2-5 years and 5 mg for patients 6-14 years
1852494|NCT00968149|Drug|Comparator: Placebo|one placebo chewable tablet daily at bed time for 2 weeks
1852495|NCT00968162|Drug|fludarabine|Conduct a pilot trial using a transplant protocol, in which the standard busulfan, cyclophosphamide and anti-thymocyte globulin conditioning regimen is modified by adding fludarabine, a highly immunosuppressive agent, in order to determine the feasibility of reducing the total dose of cyclophosphamide from its present standard of 200 mg/kg to 90 mg/kg and of busulfan from its present standard of 12.8 mg/kg (IV) to 6.4 mg/kg, using a four step dose de-escalation schema.
1852496|NCT00968175|Procedure|Ultrasound guided celiac plexus neurolysis (CPN)|Initial procedure and rescue procedure if applicable
1852497|NCT00968188|Behavioral|Keep It Up!|Online HIV Intervention Prevention Website tailored to Young Men that Have Sex with Men. Website is tailored to be more engaging, includes videos and games.
1852498|NCT00968188|Behavioral|Information only|Medically fact based HIV information delivered online.
1852499|NCT00968201|Drug|montelukast sodium|one chewable 4-mg montelukast tablet, once daily at bedtime for 12 weeks
1852500|NCT00968201|Drug|Comparator: Placebo|one chewable placebo tablet, once daily at bedtime for 12 weeks
1852501|NCT00968214|Genetic|polymorphism analysis|
1852502|NCT00968214|Other|laboratory biomarker analysis|
1852504|NCT00968240|Drug|Super-Selective Intraarterial Intracranial Infusion of BEVACIZUMAB|"This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival of patients with relapsed/refractory GBM/AA.
Day 0: Intraarterial Avastin single dose (starting at 2mg/kg and up to 10mg/kg) after Mannitol to open the blood brain barrier."
1852515|NCT00968266|Behavioral|Patient-centered group intervention|"Session 1: Group discussion about the personal barriers for medication adherence. Supervisor: Pharmacist. Duration: 90 minutes. Goal: After this session the patient is aware of the benefits and barriers of adherence. The individual barriers to adherence (concerns and practical problems) and necessity beliefs about medication are identified and discussed.
Session 2: Group based education on benefits of medication and discussing personal concerns about medication, practical barriers and beliefs about the necessity of medication. Supervisor: Pharmacist and rheumatologist. Duration: 90 minutes. Goal: Improving realistic beliefs about medication, stimulating an equal relationship between patient and health professional and motivating patients to be adherent."
1852516|NCT00968292|Device|Experimental prosthetics foot (K3 Promoter)|The tests will be unblinded randomized studies of the subject's current prosthetic foot and the K3 Promoter on traumatic/congenital amputees and dysvascular/diabetic amputees. Assessments will be made after a 30-day accommodation period with each foot prosthesis. In order to randomize the treatment and factor out habituation to the testing site and the protocol, two cohorts will be used. Half of the volunteers will be randomly assigned to be fitted with the K3 Promoter by their regular prosthetist or will continue wearing their current foot prothesis. Both cohorts will have a 30-day accommodation period. Subjects in either cohort will then visit the CGMA to be tested. Volunteers will then use the other prosthesis for 30 days. After that second 30-day period, height and weight will again be recorded, and the tests will be repeated. Because of anticipated difficulty with scheduling, volunteers will be given a +3 day grace period on the 30 day-accommodation time.
1852517|NCT00968318|Procedure|Excision of strip of deep fascia|operative technique to excise deep fascia.
1852518|NCT00968331|Drug|Lenalidomide plus Rituximab|Oral Lenalidomide is initiated on day 1 of cycle 1 at the dose of 20 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles. Rituximab is administered on day 1 and day 21 of each cycle at the dose of 375 mg/m2 for a total of 4 cycles.
1852519|NCT00968344|Dietary Supplement|Leucine|3-4g Leucine added to daily meals
1852520|NCT00968344|Dietary Supplement|Leucine|Powered amino acid
1852521|NCT00968357|Drug|SCV-07|"SCV-07 dosage will remain the same throughout the study for each cohort. Monotherapy Lead-in Phase Treatment (SCV-07) for 4 weeks. Combination Treatment (SCV-07 and ribavirin) for 4 weeks, following Lead-in Phase. Re-treatment with peg INF and RBV will be offered in the Follow-up to patients who in the opinion of the investigator may benefit from treatment. All patients will have a total of 3 follow-up visits for safety assessments. Women of childbearing potential will be followed up monthly for approximately up to 6 months after the end of treatment visit. If pregnancy occurs within the follow-up period, it needs to be followed through 8 weeks after the end of pregnancy."
1852522|NCT00968370|Other|Day-care clinic|Inj. Ceftriaxone and other micronutrients will be given to children at the day-care clinic from 8:00 a.m. to 5:00 p.m. daily.
1852523|NCT00968370|Other|Hospital Management|Inj. Ceftriaxone and other micronutrients will be given to children at the hospital from admission till discharge.
1852524|NCT00968383|Drug|Beta adrenergic blockers|Participants will receive beta adrenergic blockers.
1852525|NCT00968383|Drug|Platelet inhibitors|Participants will receive platelet inhibitors.
1852526|NCT00968383|Drug|Statins|Participants will receive statins.
1852527|NCT00968383|Drug|ACE inhibitors and/or ARB and/or AA|Participants will receive ACE inhibitors and/or ARB and/or AA
1852528|NCT00968383|Procedure|PCI with stenting|Participants will undergo percutaneous coronary intervention (PCI) and coronary stenting.
1852529|NCT00968396|Procedure|Apheresis|On Day 5, 3 hour process to separate blood (stem cells from other cells) done 1 time a day for 1-6 days, or until enough stem cells are collected. Stem cells are cultured with donated stem cells from a relative for two weeks before being returned via transplantation.
1852530|NCT00968396|Procedure|Stem Cell Transplantation|Co-culture Stem Cell Infusion on Day 0.
1852531|NCT00968396|Drug|Melphalan|100 mg/m^2 IV over 30 minutes daily on Days -2 and -1
1852532|NCT00968409|Radiation|PET|PET imaging following injection of F18-FFNP to image hormone receptor status in patients with newly diagnosed breast cancer
1852533|NCT00968409|Other|Laboratory Testing|Blood and urine samples for standard laboratory testing and radioactive counts will be obtained during the imaging sessions. Testing will include: urinalysis, complete blood count, comprehensive metabolic panel, and progesterone levels
1852534|NCT00968409|Other|Safety Testing|ECG tracings and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during and after the imaging sessions.
1852535|NCT00968409|Drug|F18-FFNP|injection of F18-FFNP
1852536|NCT00968422|Drug|ABT-384|3 escalating doses will be administered daily for 21 days
1852537|NCT00968422|Drug|Matching placebo to ABT-384|Doses will be administered daily for 21 days
1852538|NCT00968435|Other|bevacizumab, cisplatin, cetuximab, radiation therapy|Patients will receive intensity-modulated radiation therapy (IMRT) in once-daily fractions. A total dose of 70Gy is planned for the primary tumor site over approximately 33 treatment days. Day 1 will refer to the first day of radiation therapy. Concurrent with radiation therapy, patients will receive cisplatin (50 mg/m2 IV on Days 1, 2 and 22, 23) and bevacizumab (15 mg/kg IV on Days 1 and 22). Cetuximab will be administered according to the Bonner regimen (4),with a loading dose approximately 7 days prior to the start of radiation therapy (400 mg/m2 IV once, on approximately Day minus 7), followed by weekly cetuximab infusions (250 mg/m2 IV weekly X 7 infusions) until the completion of radiation therapy.
1852539|NCT00968448|Behavioral|Respiratory muscle training|Daily training with a handheld device (Pressure threshold loading). 1x50 breaths with adjustments (gradually increasing levels).
1852540|NCT00968448|Behavioral|Sham training|Sham training with same handheld device. 50 breaths daily on the lowest level
1852541|NCT00968461|Drug|Phenethyl Isothiocyanate (PEITC)|Starting dose 40 mg capsules by mouth, 4 times a day, on Days 1-3 and 8-10 of each cycle.
1852542|NCT00968487|Biological|Lyophilized Plasma|Lyophilized Plasma is serves as a source of plasma proteins for subjects who are deficient in plasma proteins. The donor and recipient are the same person, therefore the process is autologous. HemCon's lyophilized plasma originates from FFP from screened individual donors to significantly reduce the risk of bloodborne disease transmission and undesired transfusion-associated reactions. Each single-donor unit is tested (per required of the blood supply) to reduce the risk of transmission of infectious agents and hence, maximize subject safety.
1852543|NCT00968487|Other|Fresh Frozen Plasma|The fluid portion of one unit of human blood that has been centrifuged, separated, and frozen solid at −18 °C (−0.4 °F) (or colder) within 6 hours of collection.
1852544|NCT00968500|Behavioral|Questionnaires/Interviews|"Prior to the interview, the measure of prolonged grief disorder symptoms, the PG-13, will be re-administered to participants as a quality assurance check. We will administer 7 self-report measures, which participants can complete in our office, at home, or via telephone, depending on their preferences. These questionnaires should take approximately 75 to 80 minutes to complete. If you are asked to take part in the in-depth interview and you choose to take part, the interview that will take approximately 60 to 90 minutes to complete, depending on the length of the responses to the questions asked.
The participant may also be asked if they would be willing to fill out an additional questionnaire about parents' thoughts on the most appropriate timing for raising the topic of a postmortem examination and factors that are important to include in discussions. Despite its importance, autopsy is often not discussed with parents whose child is dying from cancer."
1852552|NCT00968552|Procedure|Self-expandable stent placement via endoscopy|Self-expandable stent placement via endoscopy
1852553|NCT00968565|Drug|sodium citrate|Continuous infusion of 4% sodium citrate at 300 ml/hour into ECMO circuit
1852554|NCT00968578|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
1852555|NCT00968578|Drug|Placebo|Saline iv pre-operatively in equivalent volume (placebo)
1852556|NCT00968591|Drug|Everolimus|
1852557|NCT00968604|Genetic|BikDD Nanoparticle|Starting dose 0.04 mg/kg once weekly by vein over 10 minutes.
1852558|NCT00968617|Drug|MK2578|MK2578 1.0 mcg/kg/month
1852559|NCT00968617|Drug|MK2578|MK2578 2.0 mcg/kg/month
1852560|NCT00968617|Drug|MK2578|MK2578 3.6 mcg/kg/month
1852561|NCT00968617|Drug|Comparator: darbepoetin alfa|darbepoetin alfa
1852562|NCT00968630|Other|Laboratory Biomarker Analysis|Correlative studies
1852563|NCT00968630|Procedure|Leukapheresis|Undergo leukapheresis
1852564|NCT00968643|Radiation|radiation therapy|Given in multiple fractions or as a single fraction
1852565|NCT00968656|Radiation|PET/CT|Patients receive F-18-ISO-1 i.v. and undergo PET/CT imaging at 2-3 time points following the injection.
1852566|NCT00968656|Other|Laboratory Testing|Blood and urine samples for laboratory analysis and radioactive counts will be obtained during the imaging sessions
1852567|NCT00968656|Other|Safety Testing|ECG tracings, and vital signs (blood pressure, heart rate, body temperature and respiration rate) are obtained at several time points before, during, and after the imaging sessions.
1852568|NCT00968656|Other|Immunohistochemistry staining|If available tissue from a biopsy or surgery will be tested cellular proliferation markers such as Ki67 and sigma 2 receptors
1852569|NCT00968656|Drug|F-18-ISO|Patients receive F-18-ISO-1 i.v.
1852570|NCT00968669|Biological|MEDI528 30 mg|MEDI-528 at a dose of 30 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
1852571|NCT00968669|Biological|MEDI528 100 mg|MEDI-528 at a dose of 100 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
1852572|NCT00968669|Biological|MEDI528 300 mg|MEDI-528 at a dose of 300 mg administered as a subcutaneous injection every 2 weeks for 24 weeks
1852573|NCT00968669|Other|Placebo|Placebo administered as a subcutaneous injection every 2 weeks for 24 weeks
1852574|NCT00968682|Biological|trastuzumab|
1852575|NCT00968682|Other|laboratory biomarker analysis|
1852576|NCT00968682|Procedure|assessment of therapy complications|
1852791|NCT00964236|Drug|Sapropterin|Sapropterin (Kuvan) 20mg/kg/day taken once daily or as otherwise prescribed by physician as standard care.
1852577|NCT00968695|Drug|Albumin|The pattern of administration of 20% human albumin is 1'5g/kg every week to infuse in 6 hours with a minimum of 90 g up to 150 g in patients weighing less than 60 kg and more than 100 kg, respectively. Treatment duration is 12 weeks, which are 13 administrations of albumin.
1852578|NCT00968708|Drug|Alogliptin|Alogliptin tablets
1852579|NCT00968708|Drug|Placebo|Alogliptin placebo matching tablets
1852580|NCT00968734|Dietary Supplement|colecalciferol|50.000UI single oral dose
1852581|NCT00968747|Behavioral|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
1852582|NCT00968747|Behavioral|Fasting|Participants will fast for 72 hours and may consume only water and vitamins.
1852583|NCT00968747|Behavioral|Diet|Participants will follow a low-calorie diet until they lose 3-5% of their body weight.
1852584|NCT00968747|Dietary Supplement|oral carbohydrate challenge|Participants will fast for 16 hours and then drink a beverage containing glucose, fructose or a mixture of both
1852585|NCT00968760|Procedure|Leukapheresis|"Leukapheresis #1 - For Collecting T Cells
Leukapheresis #2 - For Collecting Stem Cells, month following #1
Blood drawn through vein, passed through a machine to collect specific blood cells, then remaining blood returned, about 3 hours to complete."
1852586|NCT00968760|Procedure|Stem Cell Transplant|Stem cell infusion by vein over 30-45 minutes on Day 0
1852587|NCT00968760|Procedure|CD19-specific T Cell Infusion|T Cell Infusion (Gene Transfer) by vein over 15-30 minutes sometime between Day +2 through Day +7.
1852588|NCT00968760|Drug|IL-2|Group 2 or 4, IL-2 dose of 0.3 x 10^6 U/m^2 injected under skin, once a day for up to 14 days; first dose on day of T cell infusion.
1852589|NCT00968760|Drug|Carmustine|300 mg/m^2 IV over 1 hour on Day -6
1852590|NCT00968760|Drug|Etoposide|200 mg/m^2 IV over 3 hours every 12 hours on Days -5 to -2
1852591|NCT00968760|Drug|Cytarabine|200 mg/m^2 by vein over 1 hour every 12 hours on Days -5 to -2.
1852592|NCT00968760|Drug|Melphalan|140 mg/m^2 IV over 30 minutes on Day -1
1852593|NCT00968773|Device|Rebound HRD|Laparoscopic TEP inguinal hernia repair using the Rebound HRD and no fixation
1852594|NCT00968773|Device|Standard hernia mesh (VitaMesh)|Laparoscopic TEP inguinal hernia repair using standard hernia mesh with fixation
1852595|NCT00968786|Device|Home monitoring|automated measuring devices for patients using at home
1852596|NCT00968799|Procedure|Hyperthermic intraoperative intraperitoneal chemotherapy|Perfusion of the peritoneum with 42°C warm 25 mg/l cisplatin solution.
1852597|NCT00968799|Procedure|Cytoreduction|"Surgical removal of tumor nodules
including resection of organs infested with tumor"
1852598|NCT00968799|Drug|Cisplatin|Cisplatin is applied as chemotherapy during surgery
1852599|NCT00968812|Drug|Glimepiride|Glimepiride will be given orally (by mouth), as over-encapsulated tablets, starting at a dose of 1mg once daily and increasing to a maximum of 6 mg or 8 mg once daily for 104 weeks.
1852600|NCT00968812|Drug|Canagliflozin (JNJ-28431754)|Canagliflozin (JNJ-28431754) will be given orally as over-encapsulated tablets, at a dose of 100 mg or 300 mg once daily for 104 weeks.
1852601|NCT00968812|Drug|Metformin|Metformin will be given orally at the protocol-specified dose for 104 weeks.
1852602|NCT00968825|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose D applied topically at Baseline (Day 0) to the lateral canthal lines
1852603|NCT00968825|Drug|Placebo|Placebo (Dose E) applied topically at Baseline (Day 0) to the lateral canthal lines
1852604|NCT00968838|Procedure|White Blood Cell Transfusion|"4 Transfusions, each taking approximately 1 hour:
Patients <50 years of age receive 4 standard transfusions before they are randomized to receive further radiated or non radiated transfusions.
Patients >50 years of age are randomized to receive either radiated or non radiated transfusions."
1852609|NCT00968877|Drug|Cholecalciferol|capsule 40 000 IU (p.o.) once per week, in 8 weeks.
1852610|NCT00968890|Biological|Pandemrix (Influenza vaccine GSK2340272A)|Intramuscular injection, 2 doses
1852611|NCT00968890|Biological|Fluarix™|Intramuscular injection, 1 dose
1852612|NCT00968890|Biological|Placebo|Intramuscular injection, 1 dose
1852613|NCT00968903|Drug|Methylprednisolone|Methylprednisolone 125 mg iv pre-operatively
1852614|NCT00968916|Drug|ombrabulin (AVE8062)|"Pharmaceutical form: injection solution
Route of administration: intravenous infusion"
1852615|NCT00968929|Drug|Recombinant Streptokinase|Recombinant streptokinase: 1.5 million IU continuously intravenous infusion for 2 hours
1852616|NCT00968929|Drug|Urokinase|Urokinase: 20,000 IU/kg continuously intravenous infusion for 2 hours
1852617|NCT00968942|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel) Dose A applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
1852618|NCT00968942|Drug|Placebo|Placebo (Dose B) applied topically at Baseline (Day 0) and at Week 4 on the lateral canthal areas
1852619|NCT00968955|Drug|Ropivacaine|Local infiltration with ropivacaine 0,2% (150 ML)
1852620|NCT00968968|Drug|Lapatinib|Oral Lapatinib 1000 mg once daily. Lapatinib is a small molecule, reversible inhibitor targeting HER2 tyrosine kinase receptor.
1852621|NCT00968968|Biological|Trastuzumab|IV Trastuzumab 6 mg/kg every three weeks. Trastuzumab is a humanized, monoclonal antibody directed against the extracellular domain of the HER2 tyrosine kinase receptor.
1852622|NCT00968981|Drug|GDC-0449|Daily oral repeating dose
1852623|NCT00968981|Drug|GDC-0449|Three times weekly oral repeating dose
1852624|NCT00968981|Drug|GDC-0449|Once weekly oral repeating dose
1852792|NCT00964249|Drug|GW642444|Long acting Beta 2 agonist
1852627|NCT00969007|Behavioral|Lifestyle modification counselling|Patients meet individually every six weeks, a nurse or kinesiologist, and a dietitian (as well as a psychologist, if needed) and every three months an endocrinologist. A unique patient chart is shared by members of the interdisciplinary team, allowing sharing of the information and avoiding repetitions. Individualized behavioural intervention is proposed and focuses on attainable goals and progressive but sustained small changes in nutrition and physical activity. In addition, the participants have access to 24 weekly group seminars, on different aspects of excess weight and modification of lifestyle, to reinforce behaviour and commitment to lifestyle changes. Our approach meets all criteria suggested for clinical intervention in the 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children.
1852628|NCT00969020|Procedure|remote rehabilitation support|An information technology solution containing RRS. The way it supports,, informs and educates the patient and support person, provides an opportunity for communication between the patient and the surgeons, physiotherapists and nurses at the hospital.
1852629|NCT00969033|Drug|CS-1008|CS-1008
1852630|NCT00969033|Drug|irinotecan|irinotecan
1852631|NCT00969046|Drug|EPO906 (patupilone)|
1852634|NCT00969072|Drug|GI198745 0.05mg|GI198745 (drug) - benign prostatic hyperplasia
1852635|NCT00969072|Drug|GI198745 0.5mg|GI198745 (drug) - benign prostatic hyperplasia
1852636|NCT00969072|Drug|GI198745 2.5mg|GI198745 (drug) - benign prostatic hyperplasia
1852637|NCT00969085|Drug|Curcumin (Turmeric)|"Chew then swallow 2 sticks per day for up to 6 months.
2 sticks = 1 packet of curcumin = 8 grams"
1852638|NCT00969085|Behavioral|Questionnaires|Quality of life (QOL) questionnaires completed on Day 1, Weeks 2, 4, 8, 12, 16, 20, and at end of treatment visit.
1852639|NCT00969085|Other|Photos|Photos of up to 6 selected skin lesion(s) and half-body photos taken on Day 1, Weeks 2, 4, 12, and at end of treatment visit.
1852640|NCT00969111|Radiation|IMRT to 45 Gy; prostate bed proton boost of 21.6 CGE|Postop High Risk
1852641|NCT00969111|Radiation|Proton (prostate bed) to 70.2 CGE|Salvage Non-High Risk
1852642|NCT00969111|Radiation|IMRT to 45 Gy; proton boost to prostate bed to 25.2 CGE|Salvage High Risk
1852643|NCT00969111|Radiation|Proton to 66.6 CGE|Post-Op Non High Risk
1852644|NCT00969124|Device|Third Eye Retroscope|Third Eye Retroscope is used in conjunction with a standard colonoscope while performing colonoscopy
1852645|NCT00969137|Drug|saline|intravenous saline
1852646|NCT00969137|Drug|Nicotine|Intravenous nicotine
1852647|NCT00969150|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (flexible dose) Study drug is to be given orally, in capsule form, once daily, for 8 weeks.
1852648|NCT00969150|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
1852649|NCT00969163|Drug|testosterone gel|300 ug or 2.5 mg transdermal testosterone gel daily for 6 weeks
1852650|NCT00969163|Drug|Comparator: placebo|transdermal placebo gel for 6 weeks
1852651|NCT00969176|Drug|paracetamol|Intravenous paracetamol administration in neonates, loading dose 20 mg/kg, followed by a Gestational age-dependent maintenance dose of 10-20 mg/kg/24 h, divided in 4 doses (each 6h)
1852652|NCT00969202|Radiation|Stereotactic Radiosurgery using the Novalis Tx|Five treatments given every other day.
1852653|NCT00969215|Device|Lumenis fractional carbon dioxide laser|Laser resurfacing of a burn scar
1852654|NCT00969228|Biological|Rotarix ™|Two oral doses
1852655|NCT00969228|Biological|Placebo|Two oral doses
1852656|NCT00969254|Drug|Pílulas de Lussen|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.
* Drug A: Pílulas de Lussen®
** Drug B: placebo."
1852657|NCT00969254|Drug|Pyridium®|"Take one dragee of drug A* and one dragee of drug B** every 8 hours for three days.
* Drug A: Pyridium®
** Drug B: placebo."
1852658|NCT00969267|Other|ear-acupuncture A|with needle stimulation
1852659|NCT00969267|Other|stimulation B|with bread stimulation on ear acupuncture point
1852660|NCT00969267|Other|stimulation C|without needle stimulation
1852661|NCT00969280|Device|Standardized Acupuncture|"Acupuncture treatment will be applied 3 times per week, total 9 times for 3 weeks.
According to the guideline of WHO standard acupuncture point locations in the western pacific region, acupuncture treatment will be offered in all 17 acupoints: both BL2, GB14, TE23, Extra-1(Taiyang), ST1 and GB 20, and GV23, and Left SP3, LU9, LU10 and HT8, which are located in periorbit, forehead or temple of the head and Lt. forearm and back of the Lt. foot by a disposable 20*30mm (Dongbang Co., korea) acupuncture needle.
All the acupuncture needles will be inserted, induced strong 'deqi' sensation and retained for 20 minutes."
1852662|NCT00969280|Device|Non-acupuncture point shallow penetration acupuncture|"Acupuncture treatment will be applied 3 times per week, all 9 times for 3 weeks.
Acupuncture treatment will be offered in 17 non-acupuncture points by a disposable 20*30mm acupuncture needle. A strong 'deqi' sensation will not be induced, but inserted acupunctures will be leaved for 20 minutes."
1852663|NCT00969293|Drug|FOV2302 (Ecallantide)|"Single intravitreal injection into the relevant eye.
Five dose levels will be studied from 5 to 90µg and a maximum of 6 subjects will be included at each dose level.
Duration of Treatment: Single injection with 3 months follow-up."
1852664|NCT00969306|Drug|Chloroquine, A-CQ 100|"Administration:
Orally
Timing: Once daily
Tablets of 100 mg
During or after meals
In case of missed dose: intake of the missed dose is still possible up until 12 hours before the next dose.
Patients should always note date and time of intake on the chloroquine monitoring form."
1852665|NCT00969319|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Patients under daily life treatment receiving Kogenate according to local drug information.
1852666|NCT00969332|Drug|Omegaven|0.5 gm/kg/d intravenous every day for 2 days, then 1 gm/kg/d intravenous everyday
1852667|NCT00969345|Other|Stretching Exercises|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
1852668|NCT00969345|Other|Respiratory Exercises conducted twice a day for 10 minutes|Conducted twice a week, with instructions for home exercises twice a day, and registering each session on a log sheet.
1852669|NCT00969371|Device|posterior chamber IOL implantation|
1852670|NCT00969371|Device|Experimental TetraFlex Study IOL|TetraFlex IOL implanted
1852671|NCT00969384|Behavioral|Active awareness/Lifestyle counseling|"Intervention (active awareness):
In the intervention institutions, a detailed feedback of all index measures will be distributed to the patients and the staff. The project leader and a medical specialist in psychiatry will advise on medical aspects and health promotion. In connection with this feedback, guidance on psycho-pharmacological treatment will be provided."
1852672|NCT00969397|Drug|Topical Antiangiogenic|Topical Antiangiogenic
1852673|NCT00969397|Device|Pulsed Dye Laser|Pulsed Dye Laser
1852674|NCT00969410|Biological|AV-299|AV-299 will be given as an intravenous infusion in dose-escalating doses of 2, 10, and 20 mg/kg once every 2 weeks.
1852675|NCT00969423|Device|5mm videoscope|use of 5mm videoscope
1852676|NCT00969423|Device|10mm videoscope|use of 10mm videoscope
1852677|NCT00969436|Biological|GSK Biological's investigational MMRV vaccine 208136|Subcutaneous injection
1852678|NCT00969436|Biological|Priorix™|Subcutaneous injection
1852679|NCT00969436|Biological|Varilrix™|Subcutaneous injection
1852680|NCT00969449|Drug|Naproxen Sodium, (BAY H6689)|One dose of Naproxen sodium extended release 660 mg under fasting conditions
1852681|NCT00969449|Drug|Naprelan, (BAY H6689)|One dose of Naprelan 500 mg (2 tablets) under fasting conditions
1852682|NCT00969462|Drug|Doxorubicin|measurements of serum Doxorubicin levels
1852684|NCT00969488|Other|High protein diet|"INTERVENTION is to stimulate the consumption of high protein foods and restrict the consumption of carbohydrates in the experimental group.
The women in the intervention group will be incentivized to substitute breads and pastas for high protein foods (legumes, milk and its derivatives, eggs, fish, and lean meats)."
1852685|NCT00969501|Drug|EUFLEXXA|2.5 mL of EUFLEXXA (per injection) x 3 injections
1852686|NCT00969527|Dietary Supplement|Oncoxin + Viusid|50 ml of Oncoxin + Viusid (Orally administered) twice a day, for 12 weeks.
1852687|NCT00969527|Dietary Supplement|Placebo|50 ml of Placebo (orally administered) twice a day, for 12 weeks.
1852688|NCT00969540|Device|Active Mattress Cover|Active Mattress Cover
1852689|NCT00969540|Device|Placebo Mattress Cover|Placebo Mattress Cover
1852691|NCT00969566|Drug|sitagliptin, metformin|sitagliptin 100mg once daily and metformin 500mg twice daily, orally, for 24 weeks.
1852692|NCT00969592|Drug|insulin glulisine, insulin aspart|single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during second euglycemic glucose clamp
1852693|NCT00969592|Drug|insulin aspart, insulin glulisine|single subcutaneous dose of 0.2 units per kg body weight of insulin aspart during first euglycemic glucose clamp, single subcutaneous dose of 0.2 units per kg body weight of insulin glulisine during second euglycemic glucose clamp
1852694|NCT00969605|Procedure|Comparison of two different modes for weaning from mechanical ventilation|Chronic obstructive pulmonary disease patients under mechanical ventilation were randomized to adaptive or pressure support ventilation modes when they met the weaning criteria.
1852695|NCT00969618|Drug|Atomoxetine|40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
1852696|NCT00969631|Drug|metformin HCl (Cidophage®; CID,Cairo, Egypt), CC (Clomid®; Global Napi Pharmaceuticals,Cairo, Egypt),Cairo, Egypt)|metformin HCl 1500 daily for 6-8 weeks then 100 mg CC for 5 days starting from day 3 of menstruation up to 6 cycles.
1852697|NCT00969631|Procedure|Laparoscopic ovarian diathermy (LOD)|Three-puncture technique. Each ovary was cauterized at four points, each for 4 seconds at 40 W for a depth of 4 mm with a mixed current, using an monopolar electrosurgical needle.
1852698|NCT00969644|Drug|Somatropin|s.c injections once daily 10-30 mícrogram/kg/day
1852699|NCT00969644|Drug|Pegvisomant|s.c. injections once daily (10-15 mg/day)
1852700|NCT00969683|Device|Tracheal intubation|Tracheal intubation using a Double lumen tube without a hook
1852701|NCT00969683|Device|Tracheal intubation|Tracheal intubation with a Double lumen tube with a hook
1852702|NCT00969696|Drug|Placebo|8Mg a day of a sugar pill
1852703|NCT00969696|Drug|Galantamine|8mg of Galantamine
1852704|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 40 mg, oral administration, in capsule form, once daily for 8 weeks.
1852705|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 80 mg, oral administration, in capsule form, once daily for 8 weeks.
1852706|NCT00969709|Drug|Levomilnacipran ER|Levomilnacipran ER, 120 mg, oral administration, in capsule form, once daily for 8 weeks.
1852707|NCT00969709|Drug|Placebo|Matching placebo capsules, oral administration, once daily for 8 weeks.
1852708|NCT00969722|Biological|MAb-3F8|
1852709|NCT00969722|Biological|Subcutaneous Granulocyte Macrophage Colony Stimulating Factor (GM-CSF)|
1852710|NCT00969722|Biological|13-cis-Retinoic Acid|
1852711|NCT00969735|Device|Pulmonary vein cryoablation|A deflectable over-the-wire cryoablation balloon catheter (Arctic Front®) will be inflated and be positioned at each PV antrum. Then, cryoenergy will be delivered for 300 seconds. During cryoablation of the right PVs, the right phrenic nerve integrity will be monitored by the observation of right hemi-diaphragm contractions in response to right phrenic nerve pacing at the superior vena cava. Once the 4 PVs are cryoablated, the Arctic Front® catheter will be replaced by a decapolar PV mapping circular catheter (Lasso®, Biosense Webster, Diamond Bar, California, EEUU) to evaluate PV conduction. A second cryoablation application may be delivered at each PV, if necessary. Crossover to RF ablation to complete PV isolation is discouraged.
1852793|NCT00964249|Drug|Placebo|Matching placebo
1852794|NCT00964262|Drug|SR Exenatide (PT302)|0.5 mg, 1.0 mg, 2.0 mg and 4.0 mg dosage(dose escalation), single subcutaneous injection
1852795|NCT00964262|Drug|Placebo|Plcacebo of each doasage, single subcutanoeus injection
1852796|NCT00964275|Procedure|diagnostic procedure|Standard diagnostic procedures followed
1852712|NCT00969735|Device|Pulmonary vein radiofrequency ablation|Ablation approach is ostial electrical isolation of all PVs with simultaneous use of the CARTO® electroanatomic mapping system (Biosense Webster, Tirat-Ha-Carmel, Israel). PV isolation will be performed by delivering RF energy at ostial sites with earliest PV potentials. Flow rate during the RF applications will be set at 15 mL/min (baseline 2 mL/min). Temperature and power limits will be set at 45ºC and 35 W. It will be allowed a 5 W reduction in power limit setting for small PVs (angiographic supero-inferior diameter > 12 mm), and a 5 W increase in areas located away from the esophagus, and for focal applications at sites resistant to ablation or recurrent gaps. The end-point of ablation will be to achieve bidirectional PV conduction block.
1852715|NCT00969787|Drug|DWP05195|tablets, oral administration, single and multiple administrations
1852716|NCT00969800|Device|Cleverin Gel|Chlorine dioxide gas concentration at a range of 0.005 to 0.03 ppm.
1852717|NCT00969800|Device|Inactive Cleverin Gel|Seemingly same chlorine dioxide gas-generating device, but no gas is generated.
1852718|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
1852719|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
1852720|NCT00969813|Drug|CP-690,550|Single 10 mg dose of CP-690,550
1852721|NCT00969826|Drug|GCPGC, Neulasta, Placebo|A single subcutaneous administration of GCPGC 30 μg/kg, GCPGC 100 μg/kg, GCPGC 300 μg/kg, placebo or Neulasta 100 μg/kg
1852722|NCT00969839|Device|NovaLign Intramedullary Fixation System|Intramedullary fixation of broken humerus
1852723|NCT00969852|Drug|Sertraline|Multiple doses of 5, 25, and 50 mg Sertraline for 6 days each period.
1852724|NCT00969878|Drug|TA-CD Vaccination|On Day 1, subjects will be randomized to receive vaccination. Day 1 to Week 16 (3 visits per week) Subsequent vaccinations will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between vaccinations. Three times per week visits will be scheduled during this period through Week 16. The assessments for the active phase will be scheduled. Therapy sessions will be provided by a qualified professional such as a master's level counselor.
1852725|NCT00969878|Other|Placebo Injection|On Day 1, subjects will be randomized to receive placebo injection. Day 1 to Week 16 (3 visits per week) Subsequent placebo injections will be administered at the beginning of Weeks 3, 5, 9 and 13. There should be at least 10 days between injections. Three times per week visits will be scheduled during this period through Week 16. The assessments for the efficacy and safety monitor will be scheduled.Therapy sessions will be provided by a qualified professional such as a master's level counselor.
1852726|NCT00969891|Other|PK-PD analysis|The danish medicines agency regards new knowledge in pharmacokinetics and pharmacodynamics as an intervention.
1852727|NCT00969904|Drug|N-acetylcysteine|600 mg TID for 12 weeks
1852728|NCT00969904|Drug|placebo|placebo tablet TID for 12 weeks
1852729|NCT00969917|Drug|IPI-504|IPI 504 administered twice weekly at 225 mg/m2 for 2 weeks followed by 1 week off treatment
1852730|NCT00969969|Device|Arthrodesis|arthrodesis using screws and/or a plate
1852731|NCT00969969|Device|Cartiva|Cartiva Synthetic Cartilage Implant
1852732|NCT00969982|Drug|mifepristone+misoprostol|single dose of 200 mg mifepristone followed 24 hours later by 800 mcg misoprostol administered buccally and repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
1852733|NCT00969982|Drug|misoprostol+placebo|placebo resembling mifepristone followed 24 hours later by 800 mcg buccal misoprostol repeated every 3 hours for a maximum of 5 doses per 24 hours up to 48 hours.
1852734|NCT00970008|Other|Massage 30 min 2x/wk x4 wks then 1x/wk x4 wks|Swedish massage session of 30 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 360 minutes.
1852735|NCT00970008|Other|Massage 60 min 2x/wk for 4 wks then 1x/wk for 4 wks|Swedish massage session of 60 minutes duration, twice weekly for four weeks followed by once weekly for four weeks over a eight (8) week period. Total intervention = 12 sessions for 720 minutes.
1852736|NCT00970008|Other|Massage 30 min sessions 1x/wk for 8 wks|Swedish massage session of 30 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 240 minutes.
1852737|NCT00970008|Other|Massage 60 min session 1x/wk for 8 wks|Swedish massage session of 60 minutes duration, once weekly for eight weeks over a eight (8) week period. Total intervention = 8 sessions for 480 minutes
1852738|NCT00970021|Dietary Supplement|Intake of 60 ml placebo daily in addition to chemotherapy|The patients will drink 60 ml of placebo daily from start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment is approximately 7 weeks.
1852739|NCT00970021|Dietary Supplement|Intake of 60 ml agaricus daily in addition to chemotherapy|The patients will drink 60 ml of agaricus extract from the start of stem cell mobilizing treatment until one week after the end of aplasia after high dose melphalan. Duration of treatment: Approximately 7 weeks
1852740|NCT00970060|Behavioral|Exercise|Supervised moderately-intense exercise, including both aerobic and strengthening activities. Sessions are 3-4 days per week for 10 weeks.
1852741|NCT00970073|Biological|Thymoglobulin 3mg total|1.5 mg/kg induction on Day 0 and 1.5 mg/kg induction on Day 2 (total of 3 mg/kg)
1852742|NCT00970073|Biological|Thymoglobulin 4.5mg total|1.5 mg/kg induction on Days 0, 2 and 4 (total 4.5 mg/kg)
1852743|NCT00970073|Drug|Mycophenolate mofetil|1000 mg PO/IV BID for up to 6 months
1852744|NCT00970073|Drug|tacrolimus 3-8|Trough concentration between 3 ng/mL and 8 ng/mL starting on Day 10 and continuing beyond Day 180
1852745|NCT00970073|Drug|tacrolimus 8-12|Trough concentration between 8 ng/mL and 12 ng/mL on Days 0-10; between 6 ng/mL and 12 ng/mL on Days 10-30; between 6 ng/mL and 10 ng/mL Days 31-60; between 5 ng/mL and 8 ng/mL Days 61-179; and between 3 ng/mL and 8 ng/mL beyond Day 180.
1852746|NCT00970086|Drug|Bupivacain/levobupivacaine|"Caudal block: Identification of the epidural space with a loss of resistance technique. Administration of Bupivacain 1ml/kg 0.125%.
Transversus abdominal plane block: Identification of the anatomical structures by the ultrasound technique, administration of 0.4ml/kg levobupivacaine 0.25%."
1852797|NCT00964275|Radiation|fludeoxyglucose F 18|PET with flueoxyglucose F 18
1852747|NCT00970099|Behavioral|exercise|Patients exercise under supervision on either a treadmill, Stair Master, or LifeCycle apparatus. Exercise frequency, duration, and intensity will be incrementally increased to minimize the risk of injury. During weeks 1-3, you will exercise for 30 minutes 3 days per week at 70- 80 % of your maximum heart rate (MHR); weeks 4-7 will consist of exercising for 40 minutes 4 days per week at 70-80% of your MHR; and weeks 7-12 will consist of exercising for 45 minutes 4 days per week at 80-85% MHR
1852748|NCT00970099|Behavioral|Non exercise|subjects randomized to this group will not undergo exercise training for 12 weeks supervised by exercise specialist
1852749|NCT00970112|Procedure|Open Flap Debridement|Open flap debridement - access flap + scaling and root planning
1852750|NCT00970125|Behavioral|video|outline of the goals of care
1852751|NCT00970138|Drug|apatinib tablet|"A850: apatinib 850 mg qd p.o. plus placebo qd p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
B425: apatinib 425 mg bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent
Cpla: placebo bid p.o. until disease progression or intolerable toxicity or patients withdrawal of consent"
1852752|NCT00970177|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
1852753|NCT00970203|Biological|androgen ablation (AA)|Lupron 22.5 mg or Zoladex 10.8 mg
1852754|NCT00970203|Biological|DC1 vaccine|3-5 x 10e6 cells total
1852755|NCT00970216|Drug|Telbivudine|Post-marketing observation for chronic hepatitis B patients receiving Telbivudine treatment
1852756|NCT00970229|Drug|[123I]MNI-420|Subjects will be injected with 8mCi, not to exceed 8.8 mCi (not > 10% of 8 mCi limit)of [123I]MNI-420, followed by SPECT imaging.
1852757|NCT00963976|Drug|labetalol/hydralazine/enalapril|Blood pressure will be treated with intravenous labetalol (10 mg starting dose)/hydralazine (5 mg starting dose)/enalapril (1.25 mg starting dose).
1852758|NCT00963989|Device|Penumbra System|The Penumbra System is used to revascularize clotted cerebral blood vessels.
1852759|NCT00964002|Drug|efavirenz|
1852760|NCT00964015|Drug|6% Hydroxyethyl Starch 130/0.4|
1852761|NCT00964015|Drug|0.9% Normal Saline|
1852762|NCT00964028|Biological|Infanrix™-IPV/Hib|Intramuscular, three doses
1852763|NCT00964041|Drug|D-cycloserine|50 mg by mouth weekly, one hour before assessments, for eight weeks.
1852764|NCT00964041|Drug|Placebo|Placebo by mouth, weekly, one hour before any assessments, each week for eight weeks.
1852767|NCT00964067|Other|Exercise training|Interval training at 90% of max heart rate. Warm-up of 10-15 minutes up to 70% of HRmax, then 4 minutes of exercise at 90%. 3 minutes of active pause between the intervals. Total 45 minutes of exercise. Twice a week.
1852768|NCT00964080|Drug|MBP-426/Leucovorin/5-FU|MBP-426 will be administered at a dose of 170 mg/m2 every three weeks. Leucovorin will be administered at a dose of 400 mg/m2 after the MBP-426 infusion and in the absence of allergy/infusion reaction. 5-FU is administered concurrently with the leucovorin infusion and after the MBP-426 administration as a 46-hour continuous infusion of 2400 mg/m2.
1852769|NCT00964093|Device|Silver Alginate|(Algidex ™)
1852770|NCT00964106|Drug|Caffeine|Caffeine dosed at 100 mg as probe for CYP1A2 pathway
1852771|NCT00964106|Drug|Rosiglitazone|Dosed at 4 mg as probe for CYP2C8 pathway
1852772|NCT00964106|Drug|Flurbiprofen|Dosed at 40 mg, probe for CYP2C9 pathway
1852773|NCT00964106|Drug|Omeprazole|Dosed at 20 mg, probe for CYP2C19 pathway
1852774|NCT00964106|Drug|Dextromethorphan|Dosed at 30 mg, probe for CYP2D6 pathway
1852775|NCT00964106|Drug|Midazolam|Dosed at 3 mg for Part 1, Part 2 cohorts B and C and 1 mg for Part 2 Cohort A, probe drug for CYP3A4/5 pathway
1852776|NCT00964106|Drug|Rosuvastatin|Dosed at 10 mg, probe drug for OATP1B1 pathway
1852777|NCT00964106|Drug|Ketoconazole|Dosed at 400 mg once-daily Day 1 through Day 9, inhibitor of CYP3A4
1852778|NCT00964106|Drug|Fluconazole|Dosed at 400 mg x 1 dose on day 1, 200 mg once daily on days 2 through 9, inhibitor of CYP2C9 pathway
1852779|NCT00964106|Drug|Rifampin|Dosed at 600 mg x 1 dose on Day 1 and Day 8, inhibitor of OATP1B1 pathway
1852780|NCT00964106|Drug|Rosiglitazone|Dosed at 15 mg, probe drug for CYP2C8 pathway
1852781|NCT00964132|Drug|NRX194204|Once Daily, Oral
1852783|NCT00964171|Drug|efavirenz|
1852784|NCT00964171|Procedure|quality-of-life assessment|
1852785|NCT00964184|Drug|Metformin|
1852786|NCT00964184|Behavioral|Lifestyle modification|
1852787|NCT00964197|Device|FemmeJock|The participant will be fitted with the girdle. The participant will use the girdle for the next 3 months. The girdle is only to be worn during the daytime during times of physical activity. The length of time you choose to wear it during the day is the patients choice. In two weeks the participant will be asked to fill out a 5 question survey in a follow up visit. The participant will be asked to return 3 months after wearing the FemmeJock girdle and to fill out a 5 question survey, as well as to complete a 20 question survey.
1852788|NCT00964210|Drug|Licensed quadrivalent HPV vaccine, Gardasil|The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.
1852789|NCT00964223|Drug|Clindamycin and benzoyl peroxide gel (Duac® Topical Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
1852790|NCT00964223|Drug|benzoyl peroxide and adapalene gel (EPIDUO™ Gel)|Subjects will apply Duac(clindamycin and benzoyl peroxide) gel to one-half of their face and and apply Epiduo (benzoyl peroxide/adapalene) gel on the other side of their face once a day for the first 2 weeks. Starting at week 2, subjects will apply Duac (benzoyl peroxide/clindamycin gel) to the entire face for an additional 6 weeks.
1852802|NCT00964301|Other|Telemedicine Education|"Student Asthma Education. Each student will engage in 6 age-appropriate sessions on various aspects of asthma health.
Caregiver Asthma Education. The primary caregiver will engage in 2 asthma education sessions.
School Nurse Asthma Education. School nurses will participate in 2 sessions.
Primary Care Provider (PCP) Communication. The PCP of the intervention group participant will be notified of his/her patient's baseline asthma assessment. They will receive updates summarizing each telemedicine intervention."
1852803|NCT00964301|Other|Usual care|Participants will receive asthma care by their PCP with no education sessions or PCP communications by the research staff.
1852804|NCT00964314|Other|music|"Experimental Group one : Listening TCM five elements music therapy（TCMMT）based on conventional therapy in China.
Experimental Group two: Listening western music based on conventional therapy in China.
Control Group: no music therapy will be done."
1852805|NCT00964327|Drug|TMC114|
1852806|NCT00964340|Drug|Placebo|For the placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product. The ratio of active to placebo capsules will vary according to the subject's dosing level.
1852807|NCT00964340|Drug|SRT2104|SRT2104 drug substance is a new chemical entity which is supplied as a fine, yellowish/amber powder. The SRT2104 investigational product is prepared by packing 250 mg of the SRT2104 powder into a size 00 opaque capsule, which is then stored in dosing bottles.
1852808|NCT00964353|Drug|Warfarin|Dose estimates will be suggested daily for initial dose given and up to 4 consecutive doses after initial dose.
1852809|NCT00964366|Drug|clindamycin and benzoyl peroxide|Daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide
1852810|NCT00964366|Drug|Dapsone gel|Twice-daily applications of dapsone gel
1852811|NCT00964379|Procedure|intraperitoneal or extraperitoneal colostomy|creation of colostomy
1852812|NCT00964392|Procedure|Atrial fibrillation ablation|Radiofrequency ablation
1852813|NCT00964405|Drug|GSK233705|Inhaled Long acting muscarinic receptor antagonist
1852814|NCT00964405|Drug|Placebo|Matching placebo
1852815|NCT00964418|Drug|insulin degludec|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
1852816|NCT00964418|Drug|insulin glargine|0.4 U/kg body weight injected s.c. (subcutaneously) once daily for 6 days
1852817|NCT00964431|Drug|Celecoxib 400 mg|Capsules 2 x 200 mg Single-Dose
1852818|NCT00964431|Drug|Placebo|Capsules 2 Single-Dose
1852819|NCT00964431|Drug|Indomethacin Test (lower dose)|20-mg single dose
1852820|NCT00964431|Drug|Indomethacin Test (upper dose)|40-mg single dose
1852821|NCT00970255|Procedure|Lingual Frenulum frenotomy|Clipping the lingual frenulum with scissors
1852822|NCT00970255|Procedure|Sham frenotomy|Sham Clipping the lingual frenulum with scissors
1852823|NCT00970268|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
1852824|NCT00970268|Drug|Aclidinium bromide|Aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
1852825|NCT00970281|Drug|Rapid-Acting Intramuscular Olanzapine|Administered by means of intramuscular injection (IM) with the possibility of second 10 milligram (mg) injection 2 to 4 hours after first injection, for a maximum of 2 injections
1852826|NCT00970281|Drug|Placebo|Administered by means of IM with the possibility of second injection 2 to 4 hours after first injection, for a maximum of 2 injections
1852827|NCT00970294|Behavioral|Health Promotion Program|10 week health promotion program 3-4 times per week
1852828|NCT00970307|Biological|GSK2202083A vaccine|Intramuscular, three doses
1852829|NCT00970307|Biological|10-valent pneumococcal vaccine (GSK 1024850A)|Intramuscular, three doses
1852830|NCT00970307|Biological|Infanrix hexa™|Intramuscular, three doses
1852831|NCT00970307|Biological|Menjugate®|Intramuscular, two doses
1852832|NCT00970320|Other|Pelvic floor muscle training|6 months of daily pelvic floor exercise treatment with regular follow up by specialist physiotherapist.
1852833|NCT00970333|Drug|[18F]-FEPPA|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) of [18F]-FEPPA followed by serial PET imaging
1852834|NCT00970346|Drug|OligoG CF-5/20|Inhaled OligoG CF-5/20 will be given to healthy volunteers with different concentrations to test tolerability of the drug
1852835|NCT00970359|Biological|AZD6244|"Within 1 week of starting the study: Low iodine diet
The patient will receive three bottles of capsules containing the drug AZD6244. Each capsule contains 25 milligrams of AZD6244. They will take 3 capsules orally, by mouth twice a day for 4 weeks. AZD6244 should be taken on an empty stomach (either one hour before or 2 hours after meals). AZD6244 capsules should be taken with water only. Lesional dosimetry with iodine-124 PET will be done twice, at the beginning and at the end of the study. This is done the same way that a radioactive iodine scan is done and is spread out over 5 days. It requires injection with human recombinant TSH (Thyrogen) on day 1 and 2, as well as blood tests on day 1 and day 5. On day 3, you will receive the iodine-124 in form of an oral drink, and the PET scan will be obtained on day 5. You will need to follow a low iodine diet starting 5 days before and throughout the process."
1852836|NCT00970385|Drug|CHOP21|"CHOP regimen:
cyclophosphamide 750 mg/m2 intravenously (IV) day 1
doxorubicin 50 mg/m2 IV day 1
vincristine 1,4 mg/m2 (maximum 2 mg) day 1
prednisone 100 mg/m2/D from D1 to D5."
1852837|NCT00970385|Drug|VIP/ABVD|"VIP regimen:
etoposide 100 mg/m2/D IV from D1 to D3
ifosfamide 1000 mg/m2/D from D1 to D5
cisplatinum 20 mg/m2/D as a continuous infusion from D1 to D5
ABVD regimen:
doxorubicin50 mg/m2/D on D1 and D14
bleomycin 10 mg/m2/D
vinblastine 10 mg/m2/D
dacarbazine 375 mg/m2/D"
1852838|NCT00970385|Radiation|Radiotherapy consolidation|The treatment of Ann-Arbor stage I/II and stage III/IV patients with an initial bulky tumor (diameter ≥ 5 cm) was systematically completed by an irradiation plan. Forty grays were delivered (1,8 gray/day) over four weeks on the involved field.
1852839|NCT00970398|Other|Infant formula supplemented with bovine milk Osteopontin|Infant formula supplemented with bovine milk osteopontin at 50% and 100% levels of that of breast milk respectively.
1852840|NCT00970398|Other|Standard infant formula|Infant formula without supplementation of bovine milk Osteopontin
1852841|NCT00970411|Drug|KRN951|Orally once daily administration
1852842|NCT00970424|Drug|Placebo|placebo, oral tablet administered once daily on background of pioglitazone
1854256|NCT00974311|Drug|Enzalutamide|MDV3100, 160 mg orally per day
1852843|NCT00970424|Drug|Dutogliptin|dutogliptin, oral tablet administered once daily on background of pioglitazone
1852844|NCT00970437|Behavioral|Cognitive Behavioral Analysis System of Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
1852845|NCT00970437|Behavioral|System of Supportive Psychotherapy|Duration of intervention per patient: 20 weeks acute treatment (n=24 sessions) followed by 28 weeks of continuation treatment (n=8 sessions) Follow-up per patient: 48 weeks after randomisation
1852846|NCT00970450|Drug|Paracetamol|Paracetamol 1 g i.v. once
1852847|NCT00970450|Drug|Tropisetron|Tropisetron 5 mg i.v. once
1852848|NCT00970450|Drug|Placebo|Saline
1852849|NCT00970489|Drug|Omega -3 fatty acids|10g dose of oral omega-3 fatty acid capsules over 3-5 days before surgery (or 8 g over 2 days before surgery), including the morning of surgery, followed by 2g/d after surgery for 10 days, or until discharge, whichever occurs first.
1852850|NCT00970489|Drug|Placebo|Olive Oil capsules
1852851|NCT00970502|Drug|erlotinib + celecoxib|In this phase I/II study, patients will be treated with daily erlotinib 150 mg and twice-daily celecoxib 200 to 600 mg for 14 days. Re-irradiation with IMRT will start on day 15 and will continue for 5.5 to 6.5 weeks along with erlotinib and celecoxib. After completion of radiation, patients will be given the option of continuing on erlotinib for 2 years or until unacceptable toxicity or disease progression
1852852|NCT00970515|Procedure|Laparoscopic mesh hernia repair|The mesh is intraperitoneal
1852853|NCT00970515|Procedure|Open anterior approach|The mesh is placed by an anterior approach. It is placed after incision of the skin over or under the abdominal muscles, or is intraperitoneal
1852854|NCT00970528|Drug|Acarbose (Glucobay, BAYG5421)|uptitrated 100mg three times a day with insulin glargine alone or in combination with metformin
1852855|NCT00970528|Drug|Voglibose (Basen)|uptitrated 0.3mg three times a day with insulin glargine alone or in combination with metformin
1852856|NCT00970541|Dietary Supplement|Cinnamon Supplementation|1, 3, or 6g of cinnamon per day for 40 days
1852857|NCT00970541|Dietary Supplement|Placebo (wheat flour)|1, 3, or 6g of placebo per day for 40 days
1852858|NCT00970554|Other|Patching|Patching of the sound eye for 30 minutes a day for 17 weeks.
1852859|NCT00970554|Other|Telescopic magnification|Patching of the sound eye plus simultaneous use of a telescopic device by the amblyopic eye for 30 minutes a day for 17 weeks.
1852860|NCT00970567|Behavioral|Different insulin therapy at different time points|different insulin therapy after positive blood ketones
1852861|NCT00970593|Drug|OAP-189|Group 1: OAP-189 BID (0.2 mg BID) x 7 days Group 2: OAP-189 (0.4 mg BID) x 7 days Group 3: OAP-189 QD (0.9 mg x 7 days followed by 1.2 mg x 7 days; MR formulation) Group 4: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; MR formulation) Group 5: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation) Group 6: OAP-189 QD (1.2 mg x 7 days followed by 1.6 mg x 7 days; different MR formulation)
1852862|NCT00970593|Drug|placebo comparator|Group 1 & 2: PBO x 7 days BID Group 3: PBO QD x 14 days Group 4: PBO QD x 14 days Group 5: PBO QD x 14 days Group 6: PBO QD x 14 days
1852863|NCT00970606|Drug|Rosuvastatin (crestor)|20 mg tablets once daily x max 28 days or for an additional 3 days following ICU discharge
1852864|NCT00970606|Drug|Placebo|Placebo tablet identical to active therapy. 1 tablet per day
1852865|NCT00970619|Device|Ekos endowave system thrombolysis|Catheter directed thrombolysis will be performed with an Ekos Endowave ® system (EKOS Corporation, Bothell, WA). The system uses a standard guide wire to position the Intelligent Drug Delivery Catheter across the length of the target clot. The guide wire is introduced through the popliteal vein. Along the guide wire the catheter is positioned. The location of the dispersion catheter is controlled and if necessary adjusted by X-ray. The guide wire is then pulled out and replaced with the Microsonic core (a miniscule high frequency (2MHz) ultrasound transducer). The system automatically monitors and controls the microsonic energy delivery. This system does not fragment the thrombus but only gives a structural change by which a better penetration of the thrombolytic agent is achieved.
1852866|NCT00970632|Drug|Tadalafil 5 mg|Tadalafil 5 mg po QD for 12 weeks
1852867|NCT00970632|Drug|Placebo tablet|Placebo tablet po QD for 12 weeks
1852868|NCT00970632|Drug|Tamsulosin|Tamsulosin 0.4 mg po QD for 12 weeks
1852869|NCT00970632|Drug|Placebo capsule|Placebo capsule po QD for 12 weeks
1852870|NCT00970645|Procedure|Mediastinoscopy/thoracoscopy|Mediastinoscopy used to detect/stage lung cancer.
1852871|NCT00970645|Procedure|EBUS/EUS|Minimal invasive technique to stage/detect lung cancer.
1852872|NCT00970658|Drug|Salonsip plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
1852873|NCT00970658|Drug|Sabia plaster|The plaster should be applied at the site of injury, which must be clean and dry and changed every 8 hours for a period of 48 hours of treatment (2 days).
1852874|NCT00970671|Other|Laser treatment with Purpuric settings|Pulsed dye laser treatment at purpuric settings with pulse duration of 1.5msec.
1852875|NCT00970671|Other|Laser treatment with Nonpurpuric settings|Pulsed dye laser treatment with nonpurpuric settings with pulse duration 10msec.
1852876|NCT00970671|Other|No treatment|No laser treatment
1852877|NCT00970684|Biological|bevacizumab|15 mg/kg on day 1 of a 21-day cycle
1852878|NCT00970684|Drug|docetaxel|75 mg/m2 on day 1
1852879|NCT00970684|Drug|gemcitabine hydrochloride|900 mg/m2 on days 1, and 8,
1852880|NCT00970697|Drug|becaplermin gel|the amount of the gel to be applied was determined based on ulcer area at inclusion and remains identical during all the treatment The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Becaplermin gel is packaged into masked 15g-tubes.
1852881|NCT00970697|Drug|Duoderm Hydrogel™|The amount of the gel to be applied was determined based on ulcer area at inclusion, and remains identical during all the treatment. The posology was identical to what is recommended for Regranex gel®: a single 15g-tube is enough to treat a 5 cm2-wound during 6 weeks (1 cm of gel is applied daily for 5 cm2) Wound was then recovered by a moist saline gauze and a bandage. Hydrogel dressing is identical in appearance, color, consistency, and odor than becaplermin gel, and packaged in similar masked15g-tubes.
1852882|NCT00970710|Behavioral|Vaasa Childhood Obesity Primary Prevention Study|Intensified counselling concerning healthy diet and suitable physical activity during pregnancy to mothers in the intervention group continuing in child health care clinic visits with the offspring until child's age of 5 year.
1852883|NCT00970723|Behavioral|high blood pressure treatment|over one 14 month period: strongly recommended hygiene-dietetic measurements, complete assessment with ambulatory measurement of the blood pressure in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
1852884|NCT00970723|Behavioral|sleep apnea treatment|over one 14 month period: complete assessment with night polysomnography in D0, 3 and 12 months, a therapeutic strategy according to the results, and control every 3 months
1852885|NCT00970723|Behavioral|diabetic macular edema treatment|over one 14 month period: control every 3 months, treatments by laser (focal or grid) are authorized until 9 months, treatments by injections are authorized until 6 months
1852886|NCT00970762|Drug|Rocuronium 0.6 mg/kg intubating dose|Rocuronium 0.6 mg/kg intubating dose
1852887|NCT00970762|Drug|Rocuronium 0.9 mg/kg intubating dose|0.9 mg/kg intubating dose of rocuronium
1852888|NCT00970762|Drug|Rocuronium 0.1 mg/kg maintenance dose|Rocuronium 0.1 mg/kg maintenance dose following the intubating dose.
1852889|NCT00970762|Drug|Rocuronium 0.15 mg/kg maintenance dose|Rocuronium 0.15 mg/kg maintenance dose following the intubating dose
1852890|NCT00970762|Drug|Rocuronium 0.2 mg/kg maintenance|Rocuronium 0.2 mg/kg maintenance dose following the intubating dose
1852891|NCT00970762|Drug|Vecuronium 0.1 mg/kg intubating dose|Vecuronium 0.1 mg/kg intubating dose
1852892|NCT00970762|Drug|Vecuronium 0.025 mg/kg maintenance dose|Vecuronium 0.025 mg/kg maintenance dose following the intubating dose
1852893|NCT00970775|Drug|AZD2423|oral solution, single dose
1852894|NCT00970775|Drug|Placebo|oral solution,single dose
1852895|NCT00970788|Behavioral|Video intervention|Video of goals of care
1852896|NCT00970814|Behavioral|BBCET|11 BBCET sessions
1852897|NCT00970814|Behavioral|BBCET|11 BBCET Sessions
1852898|NCT00970814|Drug|Levetiracetam XR|500mg - 2000mg Once per day 16 weeks
1852899|NCT00970814|Drug|Sugar Pill|500mg - 2000mg Once per day 16 weeks
1852900|NCT00970827|Procedure|remote ischemic postconditioning|Three 5- minute cycles of blood pressure cuff inflation according to the assigned group. The cuff is inflated to 200 mm Hg (and at least 20 mmHg above the systolic blood pressure) for 5 minutes followed by a 5-minute deflation (reperfusion).
1852901|NCT00970840|Dietary Supplement|LNS-20gM or LNS-P&L|Participants consumed a test meal (45 g or 50 g) consisting of LNS-20gM or LNS-P&L mixed with fermented maize porridge, after which they were provided with the respective LNS supplements for use at home daily for 14 d
1852902|NCT00970853|Behavioral|MOM Program home visiting|Mixed professional home visiting program.
1852903|NCT00970853|Other|Control|Control group will receive same assessment batteries at follow-up but did not receive the home visiting program.
1852904|NCT00970866|Dietary Supplement|Iron and Folic Acid (IFA)|Pregnant women will receive one (1) Iron (60 mg) and Folic Acid (400 mcg) (IFA) tablet daily during pregnancy, and a tablet containing calcium (Ca) only (akin to a placebo) during lactation; there will be no supplementation for infants born to the women. The Fe/FA tablets will be taken each day with water after meals
1852905|NCT00970866|Dietary Supplement|Multiple Micronutrient (MMN) group|Pregnant women will receive one (1) Multiple Micronutrient tablet daily during pregnancy and the first 6 months of lactation; there will be no supplementation for infants born to the women. The MMN tablets will be taken each day with water after meals
1852906|NCT00970866|Dietary Supplement|Lipid-based Nutrient Supplements (LNS) group|"Pregnant women will receive 20 g of LNS-P&L daily during pregnancy and the first 6 months of lactation, whilst infants born to the women will receive 20 g of LNS-20gM daily from 6 to 18 mo of age.
The LNS products (LNS-P&L and LNS-20gM) will be consumed by being added to prepared food (usually mixed with complementary foods, for the child). Mothers will consume the full sachet of LNS (20 g/day) at one meal each day. Dosage and directions for use of the LNS product for children will be as follows: 20 g (~4 teaspoons) per day divided into 2 portions and consumed at two different times of the day (2 x 2 teaspoons). Mix the portion of the supplement to be consumed with 2-3 tablespoons of the already prepared food (as done previously in our study in Ghana (1)), and eat the mixture before eating the rest of the food. Do not cook food with the supplement. Store supplement at room temperature. There is no need for refrigeration."
1852907|NCT00970879|Drug|cotrimoxazole|800 mg sulfamethoxazole and 160 mg trimethoprim daily, from 28 weeks of gestation until delivery
1852908|NCT00970879|Drug|mefloquine|mefloquine 15 mg/Kg three times, between 16 and 28 weeks, 24 and 32 weeks, then 28 and 36 weeks of pregnancy
1852909|NCT00970892|Drug|Warfarin dose titration|Dosage
1852910|NCT00970905|Drug|aprepitant|aprepitant 125 mg po (Mondays), 80 mg po (Wednesdays), 80 mg po (Fridays) with doses scheduled 1-2 hours prior to the day's radiation fraction. Aprepitant will not be administered on weekend days. Aprepitant administration will continue until the last day of radiotherapy.
1852911|NCT00970905|Drug|Ondansetron|Ondansetron 8 mg po bid, with the morning dose scheduled 1-2 hours prior to the day's radiation fraction. Ondansetron will not be administered on weekend days. Ondansetron administration will continue until the last day of radiotherapy.
1852912|NCT00970918|Procedure|Measurement of the Carotid Intima Media thickness|one time, radiological procedure on both sides of the neck
1852913|NCT00970918|Biological|Blood sample testing for hs-CRP|one time, blood sample taking
1852914|NCT00970931|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone 12.5 mg plus amiloride 2.5 mg, once a day for 18 months
1852915|NCT00970931|Drug|placebo|Oral placebo once a day, for 18 months
1852916|NCT00970944|Drug|Amantadine Hydrochloride|184 patients who remain in VS or MCS 4 - 16 weeks post-TBI will be randomized in a stratified fashion to 4 weeks of amantadine (200 - 400 mg/day) followed by a 2-week washout period. The Disability Rating Scale (DRS) will be the primary dependent variable with the Coma Recovery Scale-Revised (CRS-R) serving as a supplementary measure.
1852917|NCT00970944|Drug|Placebo|Placebo administered twice daily.
1852918|NCT00970957|Drug|Avastin Intravitreal Injection|Intravitreal injection of 1.25mg Avastin (Bevacizumab) per month, during the first 3 months. Retreatments will be required if visual acuity or macular edema thickness worsen as defined per protocol
1854257|NCT00974311|Drug|Placebo|Placebo comparator
1852919|NCT00970957|Drug|Sham Avastin Intravitreal Injection|Intravitreal Injection simulation with a syringe without needle. The rest of the procedure remains the same as if intravitreal injection were to be performed (antibiotic prophylaxis, local anesthesia, ...).
1852920|NCT00970970|Other|89Zr bevacizumab PET scan|Patients will be injected intravenously with 37 MBq, protein dose 5 mg 89Zr-bevacizumab at day 0. PET scans will be done at day 4.
1852921|NCT00970983|Procedure|quadrantectomy and axillary dissection|standard quadrantectomy and axillary dissection
1852922|NCT00970983|Procedure|quadrantectomy + sentinel node biopsy|standard quadrantectomy and selective axillary dissection only if sentinel node biopsy is positive
1852923|NCT00970996|Drug|Temozolomide|250 mg/m^2 by mouth on days 1, 2, and 3 of each 21-day cycle.
1852924|NCT00970996|Drug|Abraxane|100 mg/m^2 given in a short intravenous infusion 1 hour after completion of Temozolomide and a 2nd dose of 70 mg/m^2 given on day 5 of each 21-day cycle.
1852925|NCT00970996|Drug|Cisplatin|20 mg/m^2 intravenously on days 1, 2, 3, and 4 delivered immediately after Abraxane of each 21-day cycle.
1852926|NCT00970996|Biological|Interleukin-2|9 MIU/m^2 in a continuous intravenous infusion over 24 hours on days 1, 2, 3, and 4 (total of 96 hours) beginning after completion of Cisplatin of each 21-day cycle.
1852927|NCT00970996|Biological|Interferon alpha 2b|5 MIU/m^2 in subcutaneous injection on days 1, 2, 3, 4, and 5 of each 21-day cycle.
1852928|NCT00971009|Behavioral|OPPC service|Access to a practice-integrated nurse administered online patient-provider communication (OPPC) service including access to asking questions to social counselors
1852929|NCT00971009|Behavioral|WebChoice IHCA|The additional features of WebChoice allows patients to monitor their symptoms and health problems from home; provides them with individually tailored, just-in-time information and support to manage their symptoms and illness-related problems between treatments and during rehabilitation; and a forum, or e-group community, for group discussion with other cancer patients.
1852930|NCT00971022|Behavioral|Survey|20 minute survey to determine the relationship between awareness of the discount generic prescription program and utilization of the program.
1852931|NCT00971022|Behavioral|Focus Group|5 - 8 focus groups of 6 - 10 people, lasting approximately 90 minutes
1852932|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
1852933|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
1852934|NCT00971035|Drug|lebrikizumab (MILR1444A)|Subcutaneous repeating dose
1852935|NCT00971035|Drug|placebo|Subcutaneous repeating dose
1852936|NCT00971048|Device|HP828-101|Topical test article applied once daily
1852937|NCT00971048|Device|Hydrogel/Hydrocolloid|Hydrogel for DFU and Hydrocolloid for PU (3M Tegaderm Hydrogel for DFU; ConvaTec DuoDERM Hydroactive Gel for PU); Topical test articles applied once daily
1852938|NCT00971061|Device|Ahmed valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
1852939|NCT00971061|Device|Molteno single-plate implant (MSPI)|134 mm2 surface area single-plate Molteno implant (Molteno Ophthalmic Limited, Dunedin, New Zealand)
1852940|NCT00971074|Drug|Hylan G-F 20|6 ml intra-articular injection given once. The injection takes approximately 15 seconds.
1852941|NCT00971074|Other|Sham Injection|A needle will be inserted through the knee capsule but no medication will be injected.
1852942|NCT00971087|Device|Hologic Selenia Dimensions Digital Breast Tomosynthesis System|Subjects are enrolled from either a screening population or a biopsy population. Both groups are exposed to the same number of investigational images collected on the investigational device (Selenia Dimensions Full Field Digital Mammography System). Subject enrollment occurs at the time subjects are being imaged for their standard of care mammographic work up (either screening mammogram or scheduled biopsy). All subjects recruited in the biopsy population will be imaged on the investigational device prior to their biopsy procedure.
1852943|NCT00971100|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
1852944|NCT00971113|Dietary Supplement|sc-FOS and Sideritis euboea extract|"dietary supplement: jelly with 5g sc-FOS and 0.3g Sideritis euboea extract per daily portion for 30 days
placebo food: jelly with no sc-FOS and Sideritis euboea"
1852945|NCT00971126|Drug|sorafenib (Nexavar®), thalidomide (Thado®)|"Phase I Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and Escalation dose of Thalidomide at dose Level I: 50 mg/day (50mg, p.o., qd); Level II: 100 mg/day (50mg, p.o., bid); Level III: 150 mg/day (100mg/50mg, p.o., bid); Level IV: 200 mg/day (100mg, p.o., bid).
Phase II Fixed dose of Sorafenib 800mg/day (400mg, p.o., bid); and MTD of Thalidomide at phase I study."
1852946|NCT00971139|Behavioral|Access to an OPPC service|Access to an Internet-based messaging system where patients can ask questions and receive advice and support from care providers at the hospital and social counsellors
1852947|NCT00971152|Drug|menotropins for injection|comparison of different dosages
1852948|NCT00971152|Drug|urofollitropin for injection|comparison of different dosages
1852949|NCT00971165|Drug|losartan|Oral losartan up to 100 mg daily fo 18 months
1852950|NCT00971165|Drug|Chlorthalidone plus amiloride|Oral Chlorthalidone plus amiloride up to 25 e 5 mg daily, once a day for 18 months
1852951|NCT00971178|Drug|local dexmedetomidine|Preoperative normal saline infusion and 1mcg/kg dexmedetomidine infiltrated locally to wound at the end of operation.
1852952|NCT00971178|Drug|Peripheral normal saline|Same volume of normal saline as dexmedetomidine is infiltrated and IV infusion.
1852953|NCT00971178|Drug|IV dexmedetomidine|IV dexmedetomidine 1mcg/kg peroperative and normal saline infiltrated to wound at the end of operation
1852954|NCT00971191|Drug|PF-00299804|Brief exposure (5- 11 days) to study drug prior to surgical resection
1852955|NCT00971204|Device|CardioFocus HeartLight Endoscopic Ablation System|PVI ablation
1852956|NCT00971217|Other|Exercise|Moderate intensity aerobic exercise on the bike/cross trainer/ rower/ treadmill and resistance exercise on the weights machines, twice per week for 10 weeks.
1853002|NCT00971594|Behavioral|Dietary counseling|1 hour sessions, once per week, with a registered dietitian on the American Heart Association Step I diet with caloric intake for each volunteer adjusted by the dietitian to elicit a WL of ~0.2-0.4 kg/wk
1852957|NCT00971217|Behavioral|Online Cognitive Behavioural Therapy|Participants will be asked to log-on to a website aimed at young men once per week. Participants will be asked to read a vignette or watch a specific video clip, which will be updated each week by the researcher. Participants will be asked to respond to the vignette/video clip on the website. This should take no longer than 10-15 minutes to complete. Different themes (such as those addressed by traditional cognitive behavioural therapy) will be introduced each week. Themes include: relaxation, identifying positive strengths, body image, goal-setting, problem-solving, resilience, self-care behaviour and sources of support.
1852958|NCT00971230|Drug|FTC/TDF|emtricitabine/tenofovir disoproxil fumarate
1852959|NCT00971230|Drug|Placebo|Placebo
1852960|NCT00971243|Drug|MP-513 Lowest Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
1852961|NCT00971243|Drug|MP-513 Low Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
1852962|NCT00971243|Drug|MP-513 Medium Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
1852963|NCT00971243|Drug|MP-513 High Dose and Metformin|MP-513 tablets, once a day and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
1852964|NCT00971243|Drug|Placebo and Metformin|Placebo tablets once a day, and Metformin tablets, for 24 weeks and extension treatment for up to 52 weeks.
1852965|NCT00971269|Device|Solesta (Nasha/Dx)|Gel (hyaluronic acid/dextranomer) for intersphincteric injection 4x2 ml and retreatment 4x2 ml after 4 weeks
1852966|NCT00971282|Drug|adapalen 0.1%|"Intra-individual (split-face) comparison: Differin® 0.1% (whole face) will be applied once daily for 4 weeks.
Visits will be conducted weekly for a maximum of 5 visits."
1852967|NCT00971282|Other|Cetaphil®|"Intra-individual (split-face) comparison: Cetaphil® (only one side of the face) will be applied once daily for 4 weeks.
Visits will be conducted weekly for a maximum of 5 visits."
1852968|NCT00971295|Drug|Metformin|850 mg metformin hydrochloride, once as oral single-dose and once after pre-treatment with once-daily dose of ESL 1200 mg for 6 days
1852969|NCT00971295|Drug|Eslicarbazepine acetate|
1852970|NCT00971308|Drug|BMS-824393|Capsule, Oral, 50mg, Once Daily, 3 days
1852971|NCT00971308|Drug|BMS-824393|Capsule, Oral, 100mg, Once Daily, 3 days
1852972|NCT00971308|Drug|BMS-824393|Capsule, Oral, 10mg, Once Daily, 3 days
1852973|NCT00971308|Drug|BMS-824393|Capsule. Oral, 1mg, Once Daily, 3 days
1852974|NCT00971308|Drug|BMS-824393|Capsule, Oral, Flexible, ≤100mg, Once Daily, 3 days
1852976|NCT00971347|Other|Extra sugar-free chewing gum sticks|90 minutes chewing per day after meals; mid-morning and mid-afternoon; 1 to 2 hours after dinner; and in response to hunger, cravings, preoccupation with eating, or negative feelings in general throughout the day.
1852977|NCT00971347|Behavioral|nutrition brochure|one-time at baseline visit
1852978|NCT00971360|Other|conversion disorder|Proinflammatory cytokine levels in conversion disorder
1852979|NCT00971373|Other|Vestagen scrubs|antimicrobial impregnated textile
1852980|NCT00971386|Behavioral|Slow breathing|The subjects will be given instructions in slow breathing at a rate of 6 to 10 breaths per minute and asked to practice it for some time. Hemodynamic measurements would be repeated before, during and after the trial of slow breathing. A Noninvasive Cardiac Output Monitor will be used. It uses a technology called impedance to measure cardiac output and other hemodynamic parameters by the passage of electric currents through the thorax. This device uses four electrode stickers applied to the thorax and the neck.
1852981|NCT00971399|Drug|ramosetron|ramosetron 0.1mg q.d. SL on D1-5
1852982|NCT00971399|Drug|ondansetron|ondansetron 8mg, b.i.d SL on D1-5
1852983|NCT00971425|Biological|Pandemrix (GSK investigational influenza GSK2340272A vaccine)|2 doses intramuscular injections
1852984|NCT00971425|Biological|Fluarix™|1 dose intramuscular injection
1852985|NCT00971425|Biological|Placebo|1 dose intramuscular injection
1852986|NCT00971438|Procedure|Diagnostic imaging|Patients with a scoring suggesting an equivocal diagnosis of appendicitis are randomised to diagnostic imaging (CT or US) or repeat examination after inhospital observation
1852987|NCT00971451|Other|cryotherapy|20 minutes of knee joint cryotherapy - ice bag application
1852988|NCT00971451|Other|TENS|continuous use of TENS during the exercise session
1852989|NCT00971464|Behavioral|eccentric viewing (EV) training|Eccentric viewing training for 6 weeks, minimum two 10 minutes per day.
1852990|NCT00971464|Device|Closed circuit television (CCTV)|A CCTV is an electro-optical device mainly used for reading.
1852991|NCT00971477|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via a store and forward teledermatology modality.
1852992|NCT00971477|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
1852993|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Transcutaneous electrical nerve stimulation applied onto acupuncture point
1852994|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but without electrical stimulation
1852995|NCT00971490|Device|Acu-TENS (Transcutaneous electrical nerve stimulation)|Similar to Group 1 but applied onto non acupuncture point
1852996|NCT00971503|Procedure|autologous bone marrow implantation|Filgrastim treatment before bone marrow aspiration that will then be implanted via pancreatic artery
1852997|NCT00971503|Other|Saline injection|Injection of saline solution for 5 days
1852998|NCT00971516|Procedure|Implant placement|dental implant placement
1852999|NCT00971516|Procedure|Implants surgery|dental implant surgery
1853000|NCT00971542|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy children and adolescent. Subjects will be randomized to receive 2 IM injections of low dose of antigen & adjuvant, or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups.
1853001|NCT00971581|Drug|FDC KETOPROFEN+OMEPRAZOLE|Ketoprofen + Omeprazole FDC once daily for 4 weeks
1853003|NCT00971594|Behavioral|AEX|Moderate aerobic exercise (75-80% HRR for 45 min) at the Baltimore GRECC exercise facility using treadmills 3 times per week for 6 months.
1853004|NCT00971607|Drug|Oxygen + Sevoflurane|Oxygen with end-tidal MAC of Sevoflurane 0.5 during PCI.
1853005|NCT00971607|Drug|Oxygen (placebo)|Control will receive oxygen only.
1853006|NCT00971620|Biological|Botulinum toxin type A|Given as an intralesional injection.
1853007|NCT00971620|Other|Placebo|Given as an intralesional injection
1853008|NCT00971633|Drug|Comparator: Treatment A (Zofran, ondansetron)|an over-encapsulated single 8 mg tablet of United Kingdom (U.K.) Zofran taken by mouth (PO)
1853009|NCT00971633|Drug|Comparator: Treatment B (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the U.K., taken PO
1853010|NCT00971633|Drug|Comparator: Treatment C (Zofran, ondansetron)|a single 8 mg tablet of Zofran marketed in the United States (U.S.), taken PO
1853011|NCT00971646|Other|Micturition diary|On the micturition diary patients are asked to note every void and drink. With every void they are asked to estimate their bladder volume and grade their degree of desire to void.
1853012|NCT00971646|Other|Hospital Anxiety and Depression scale|This questionnaire is designed to screen for the presence of a mood disorder.
1853013|NCT00971646|Other|EuroQol-5D|This questionnaire grades the health condition of the subject.
1853014|NCT00971646|Other|Self-consciousness questionnaire|The questions tap cognitive, emotional, and physical appearance aspects of directing their attention to the self.
1853015|NCT00971659|Drug|insulin glargine + exenatide + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, exenatide 5ug twice daily subcutaneously for 2 weeks, then 10ug twice daily for 2 weeks, continuation of preexisting metformin
1853016|NCT00971659|Drug|insulin glargine + sitagliptin + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, dose adjustment according to a treat-to-target algorithm, sitagliptin 100 mg once daily in the morning over 4 weeks, continuation of preexisting metformin
1853017|NCT00971659|Drug|insulin glargine + preexisting metformin|insulin glargine once daily subcutaneously over 4 weeks, continuation of preexisting metformin
1853018|NCT00971672|Other|Questionnaire filling and laboratory analysis|"A questionnaire that included demographic characteristics, nutrition and iron supplementation in the first year, growth status, and laboratory results will be filled for each patient.
The laboratory analysis will include complete blood count and serum ferritin analysis."
1853019|NCT00971685|Drug|Lenalidomide and dexamethasone|RD regimen: Lenalidomide 25 mg/die for 21 days every month for 6 cycles, with once-weekly dexamethasone (40 mg).
1853020|NCT00971711|Biological|Probiotic|The subjects will be randomized into either a 4 week or 8 week treatment period with the probiotic. The treatment will be open label. They will take 2 packets once daily.
1853021|NCT00971724|Drug|Placebo|Oral administration, once daily, for 15 days
1853022|NCT00971724|Drug|Prednisolone|Oral administration
1853023|NCT00971737|Biological|allogeneic GM-CSF-secreting breast cancer vaccine|Given intradermally
1853024|NCT00971737|Biological|trastuzumab|Given IV
1853025|NCT00971737|Drug|cyclophosphamide|Given IV
1853026|NCT00971763|Biological|rituximab|
1853027|NCT00971763|Drug|cyclophosphamide|
1853028|NCT00971763|Drug|gemcitabine hydrochloride|
1853029|NCT00971763|Drug|prednisolone|
1853030|NCT00971763|Drug|vincristine sulfate|
1853031|NCT00971776|Device|AB Portable Driver System|Evaluate the safety and performance of the AB Portable Driver System in home environment.
1853032|NCT00971789|Radiation|fludeoxyglucose F 18|Fludeoxyglucose is the radioactive material/compound used as an injection to have a PET scan performed.
1853033|NCT00971789|Drug|sirolimus|sirolimus 6 mg by mouth loading dose and 2 mg by mouth daily in a 28 day treatment cycle. Patients who do not have cancer take the drug for a total of two cycles (56 days) unless they develop unacceptable side effects. Those who have cancer may continue sirolimus beyond cycle 2 until their disease worsens or they develop unacceptable side effects
1853034|NCT00971789|Other|Clinical Videography|This examination involves testing of cerebellar function that controls movement, balance, and coordination.
1853035|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 20 mg or Placebo, daily for 10 days.
1853036|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 60 mg or Placebo, daily for 10 days.
1853037|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 120 mg or Placebo, daily for 10 days.
1853038|NCT00971802|Drug|PF-03882845 or Placebo|PF-03882845 185 mg or Placebo, daily for 10 days.
1853039|NCT00971815|Drug|Escitalopram|first week: 10mg/day. Then, treatment with 20mg/day is continued throughout a 3 months period of time.
1853040|NCT00971815|Drug|placebo|1/2 pill pr day first week, then 1 pill pr. day throughout a 3 months treatment period (90-118 ± 7days)
1853041|NCT00971841|Drug|Paclitaxel|
1853042|NCT00971854|Procedure|Alteration of deep brain stimulator settings|From 130Hz to 60Hz pallidal stimulation
1853043|NCT00971867|Drug|Paclitaxel|Solution, I.V., 100 mg/m2 Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
1853044|NCT00971880|Other|Clinical medical record summary|Summary of immediate and late adverse effects of blood transfusions
1853045|NCT00971893|Drug|Oral Methylprednisolone Tablets|Oral Methylprednisolone tablets given as per locally approved prescribing information
1853046|NCT00971906|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple study sites in a population of healthy adults and elderly. Subjects will be randomized to receive two IM injections of low dose of antigen & adjuvant,or high dose of antigen & adjuvant, or high dose of antigen, according to the study groups
1853047|NCT00971919|Other|questionnaire administration|
1853048|NCT00971919|Procedure|assessment of therapy complications|
1853049|NCT00971919|Procedure|psychosocial assessment and care|
1853050|NCT00971919|Procedure|quality-of-life assessment|
1853051|NCT00971932|Drug|Cetuximab|The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.
1853140|NCT00972452|Behavioral|Exercise|short period of exercise training (5-10 days)
1853052|NCT00971932|Drug|Cisplatin/Carboplatin|Subjects will receive 100 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 [AUC5]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
1853053|NCT00971932|Drug|5-Fluorouracil|Subjects will receive 1000 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
1853054|NCT00971945|Drug|Paclitaxel|Solution, I.V., 100 mg/m2, Weekly for 6 of 7 weeks, Until disease progression or unacceptable toxicity became apparent
1853055|NCT00971958|Procedure|Circumcision|Neonatal circumcision using one of three non-experimental, widely available devices.
1853056|NCT00971958|Device|Mogen Clamp|Mogen clamp is a reusable, one-size stainless steel clamp use for neonatal circumcision.
1853057|NCT00971958|Device|Plastibell|The plastibell is a one-time use device for the circumcision of male neonates, infants and children.
1853058|NCT00971958|Device|AccuCirc|AccuCirc is a device used for the circumcision of male infants approved for use by the FDA up to 10 days of life.
1853059|NCT00971971|Procedure|Dialysis|dialysate temperature (DT) reduction with Na and ultrafiltration (UF) profiling
1853060|NCT00971971|Procedure|Standard SLED|
1853061|NCT00971984|Other|Medical records summary|Summary of Medical files and laboratory results.
1853062|NCT00971997|Drug|Lispro Mix 50/50|Administered subcutaneously once daily for 16 weeks, twice daily for 16 weeks, and three times daily for 16 weeks dependent on glycemic control.
1853063|NCT00972023|Drug|DHEA|DHEA administration will begin approxiately 14 days prior to surgery.
1853064|NCT00972023|Procedure|Surgical resection|Surgical procedure of the invasive breast cancer
1853065|NCT00972036|Device|SIR-spheres® (Selective Internal Radiation Therapy)|SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
1853066|NCT00972049|Drug|AZD2516|Capsule administered once orally. Specific dose depends on dose panel.
1853067|NCT00972049|Drug|Placebo|Capsule administered once orally
1853068|NCT00972062|Other|Bach's Rescue Remedy Cream|0.5 ml of cream applied to skin site reactions as needed
1853069|NCT00972062|Other|Placebo Cream|Placebo cream 0.5 ml two times a day as needed
1853070|NCT00972075|Drug|melatonin (Circadin)|2 mg prolonged release melatonin tablets once daily 2 hours before going to bed
1853071|NCT00972075|Drug|placebo|one tablet per day 2 hours before going to bed
1853072|NCT00972088|Device|capsule endoscopy|The disposable, ingestible PillCam® SB2 Capsule acquires the video images during natural propulsion through the digestive system. The Capsule transmits the acquired images via digital radio frequency communication channel to the Given® Data Recorder unit located outside the body.
1853073|NCT00972101|Radiation|Total Body Irradiation (TBI)|3 Gy of radiation on Days -7,-6, -5 and -4.
1853074|NCT00972101|Drug|Melphalan|140 mg/m^2 by vein over 30 minutes as a single dose on Day -8
1853075|NCT00972101|Drug|Thiotepa|10 mg/kg by vein over 4 hours as a single dose on Day -7
1853076|NCT00972101|Drug|Fludarabine|40 mg/m^2 by vein over about 30 minutes 1 time each day on Days -6 through -3.
1853077|NCT00972101|Drug|Rituximab|"Regimen 1:
375 mg/m^2 may be given by vein over 4 - 6 hours on Day -9 if needed
Regimen 2:
375 mg/m^2 may be given by vein over 4 - 6 hours on Day -8 if needed"
1853078|NCT00972101|Drug|Etoposide|60 mg/m^2 by vein over 1-2 hours as a single dose on Day -3.
1853079|NCT00972101|Drug|Anti-thymocyte globulin (ATG)|"Regimen 1:
1.25 and 1.75 mg/kg by vein over 4-6 hours on the Days -4 and -3.
Regimen 2:
0.5, 1.0 and 1.5 mg/kg by vein over 4-6 hours on respective Days -3, -2, and -1."
1853080|NCT00972101|Drug|Mycophenolate Mofetil (MMF)|15 mg/kg pills twice a day starting on day -3, and continued until Day 100+ after transplant (1 gram may be given by vein if necessary).
1853081|NCT00972101|Drug|Tacrolimus|0.03 mg/kg by vein Day -2 as 24 hour continuous infusion for several weeks. After stem cell transplant, tacrolimus given by mouth 2 times a day for up to 6 months.
1853082|NCT00972101|Procedure|Cord Blood Infusion|Cord blood infusion of larger portion through vein using Central Venous Catheter (CVC) on Day 0.
1853083|NCT00972101|Drug|G-CSF|5 mcg/kg day subcutaneously (may round up to the next vial) beginning on day +1 and continuing till absolute neutrophil count is > 2.5 x 10e^9/L.
1853084|NCT00972101|Procedure|Ex vivo expanded T cell Infusion|Infusion by vein of treated cord blood beginning dose of 1 x 10e^5 T cells/kg on Day 14+.
1853085|NCT00972114|Procedure|CABG combined cardiomyoplasty|coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty
1853086|NCT00972114|Procedure|CABG combined pedicled omentum graft|Coronary artery bypass graft surgery combined pedicled omentum graft
1853087|NCT00972114|Procedure|CABG alone|Coronary artery bypass graft surgery alone
1853088|NCT00972127|Drug|Neramexane|25 mg or 2x25mg tablets
1853089|NCT00972140|Drug|Formoterol|Formoterol-HFA pMDI 12µg twice daily
1853090|NCT00972140|Drug|Formoterol|Formoterol-DPI 12 µg twice daily
1853091|NCT00972153|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the surgery site.
1853092|NCT00972153|Device|Sham Air Barrier System device|Device is deployed to the surgery site, but the airflow is not activated. This intervention is used to determine any effects that the presence of the device alone may have.
1853093|NCT00972179|Drug|AMG 157 Placebo|A total of 12 subjects will be receiving multiple doses of AMG 157 placebo. Each subject enrolled in cohorts 1-3 will receive three SC doses; each subject enrolled in cohort 4 will receive six SC doses; each subject enrolled in cohort 5 will receive 12 SC doses; and each subject enrolled in cohort 6 will receive three IV doses throughout the study period of 169 days.
1853094|NCT00972179|Drug|AMG 157|A total of 36 subjects will be receiving multiple doses of AMG 157 (dose escalating by cohort). Each subject enrolled in cohorts 1-3 will receive three SC doses; each subject enrolled in cohort 4 will receive six SC doses; each subject enrolled in cohort 5 will receive 12 SC doses; and each subject enrolled in cohort 6 will receive three IV doses throughout the study period of 169 days.
1853095|NCT00972192|Behavioral|Inpatient HIV testing|Participants who were randomized to the intervention group received free HIV testing and their results before they were discharged from the hospital.
1853096|NCT00972192|Behavioral|Outpatient HIV testing|Participants randomised to the control arm received referral for testing post-discharge
1853097|NCT00972205|Drug|paclitaxel|Paclitaxel 135 mg/m^2 intravenously on day 6 over 180 minutes. Cycles are repeated every 21 days.
1853098|NCT00972205|Drug|CBT-1(Registered Trademark)|CBT-1 500 mg/m^2 oral dose daily for 7 days in divided doses 3 times a day. Cycle days 1-7, repeated every 21 days. no antacids, H2 blocker, or gastric acid inhibiting agents will be administered within 4 hours before or after each daily dose.
1853099|NCT00972205|Radiation|Tc 99m sestamibi|20 mCI baseline scan day 0; 20 mCI scan on 6th day of CBT-1 administered.
1853100|NCT00972218|Biological|Adalimumab|Adalimumab subcutaneous injections 40 mg dose every other week for 24 weeks
1853101|NCT00972231|Other|Medical Chart Summary|Summary of the Medical Files including annual growth velocity, endocrine function and iron overload status.
1853102|NCT00972244|Drug|Dapagliflozin|once daily, 12 weeks
1853103|NCT00972244|Drug|Placebo|once daily, 12 weeks
1853104|NCT00972257|Drug|treatment with dorzolamide/timolol|24-hour IOP control with the two fixed combinations
1853105|NCT00972257|Drug|treatment with brimonidine/timolol|24-hour pressure control with brimonidine/timolol
1853108|NCT00972283|Drug|insulin degludec|Injected subcutaneously (under the skin) with main evening meal. Dose was individually adjusted.
1853109|NCT00972283|Drug|insulin glargine|Injected subcutanoeusly (under the skin) according to approved label. Dose was individually adjusted.
1853110|NCT00972283|Drug|insulin aspart|Injected subcutaneously (under the skin) at each main meal. Dose was individually adjusted.
1853111|NCT00972296|Device|Carbon fiber ankle foot orthosis versus cast boot|Relief of ankle pain and normalizing of gait using either device.
1853114|NCT00972322|Drug|MK-8245|MK-8245 50 mg twice daily for 28 days
1853115|NCT00972322|Drug|Comparator: placebo|matching placebo to MK-8245 twice daily for 28 days
1853116|NCT00972335|Drug|Everolimus|This drug will be dosed at 10 mg orally DAILY for the duration of the study.
1853117|NCT00972335|Drug|Bevacizumab|This drug will be given IV at 10 mg/kg on Days 1 and 15 of each 28-day treatment cycle for the duration of the study.
1853118|NCT00972348|Other|Online access to a personal health record|Patients in the intervention arm have full access to their online personal health record
1853119|NCT00972348|Other|No access to the PHR|Patients will not be given access to their PHR but will complete online surveys.
1853120|NCT00972374|Drug|400 ug Brimonidine Implant|400 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
1853121|NCT00972374|Drug|200 ug Brimonidine Implant|200 ug Brimonidine Tartrate Posterior Segment Drug Delivery system on Day 1 in the study eye.
1853122|NCT00972374|Other|Sham (no implant)|Sham Posterior Segment Drug Delivery system on Day 1 in the study eye.
1853123|NCT00972387|Dietary Supplement|CHO, CHO-P, CHO-CHO, PLA|The CHO supplement will be administered during trial 1. The CHO-P will be administered during trial 2. The CHO-CHO supplement will be administered during trial 3. The PLA supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
1853124|NCT00972387|Dietary Supplement|CHO-P, CHO-CHO, PLA, CHO|The CHO-P supplement will be administered during trial 1. The CHO-CHO will be administered during trial 2. The PLA supplement will be administered during trial 3. The CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
1853125|NCT00972387|Dietary Supplement|CHO-CHO, PLA, CHO, CHO-P|The CHO-CHO supplement will be administered during trial 1. The PLA will be administered during trial 2. The CHO supplement will be administered during trial 3. The CHO-P supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
1853126|NCT00972387|Dietary Supplement|PLA, CHO, CHO-P, CHO-CHO|The PLA supplement will be administered during trial 1. The CHO will be administered during trial 2. The CHO-P supplement will be administered during trial 3. The CHO-CHO supplement will be administered during trial 4. This is the order of supplement administration for subjects randomly assigned to this order group.
1853127|NCT00972400|Genetic|protein analysis|
1853128|NCT00972400|Other|laboratory biomarker analysis|
1853129|NCT00972400|Other|mass spectrometry|
1853130|NCT00972400|Other|questionnaire administration|
1853131|NCT00972400|Procedure|assessment of therapy complications|
1853132|NCT00972400|Procedure|cognitive assessment|
1853133|NCT00972400|Procedure|quality-of-life assessment|
1853134|NCT00972413|Radiation|Computed Tomography|In Group I, twelve CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
1853135|NCT00972413|Radiation|Computed Tomography|In Group II , at least fifty (50) study participants, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a breast CBCT specifically designed to image the breast.
1853136|NCT00972413|Radiation|Computed Tomography|In Group III, at least 30 study subjects, who are categorized as BI-RADS® 4, 5 based on prior diagnostic work-up and are also scheduled for breast biopsy of a lesion, will undergo a unilateral intravenous (IV) CE CBCT of the involved breast.
1853137|NCT00972426|Drug|carteolol (Mikelan), timolol (Timoptol), latanoprost (Xalatan)|Experimental: Mikelan, 1 drop/daily, for 8 weeks Active Comparator: Timoptol, 1 drop/daily, for 8 weeks
1853141|NCT00972465|Drug|Nimotuzumab and chemotherapy|"Experimental: Nimotuzumab and Irinotecan
the chemotherapy treatment: Irinotecan (180 mg/m2/time, 1 time/14 days, until disease progression)
the nimotuzumab treatment: 3 levels (200 mg/w, 400 mg/w, 600 mg/w, weekly, until disease progression)"
1853149|NCT00972491|Procedure|Insertion of Laryngeal Mask Airway|The LMA will be inserted at 0 sec, 60 sec. and 90 sec. after induction of general anesthesia
1853150|NCT00972504|Drug|GSK835726 10mg|GSK835726 10mg tablet
1853151|NCT00972504|Drug|GSK1004723 1000mcg|GSK1004723 1000mcg nasal spray solution
1853152|NCT00972504|Drug|Cetirizine 10mg|Cetirizine 10mg active comparator
1853153|NCT00972504|Drug|placebo|placebo to match actives
1853155|NCT00972530|Behavioral|immobilisation in a triangular sling|"Intervention group: Immobilisation 48 hours in a triangular sling (mitella)
Control group: normal activity without restrictions"
1853156|NCT00972543|Biological|Efalizumab (Raptiva)|"Double-blind phase 0.7mg/kg subcutaneously (sc), followed by 1mg/kg/wk sc for 12 weeks.
Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks."
1853157|NCT00972543|Biological|Placebo|Double-blind phase sc Placebo for 12 weeks. Open label extension 0.7mg/kg sc Raptiva followed by 1mg/kg/wk sc for a further 12 weeks.
1853160|NCT00972569|Drug|BNP and PDE-V|low dose BNP 0.025 u/kg/min for 3 hours then 0.005ug/kg/min 45 hours PDE-V 12.5 mg 4 time points
1853161|NCT00972569|Drug|BNP|low dose BNP at 0.025 u/kg/min if tolerated then at 0.005 ug/kg/min for 45 hours
1853162|NCT00972582|Dietary Supplement|Leucine Increase|Graded stepwise increases in leucine intakes (50, 250, 500, 750, 1000, 1250 and 1500mg/kg/day)
1853163|NCT00972595|Drug|ondansetron clinical trial formulation|Single dose of an over-encapsulated 8 mg tablet of United Kingdom (U.K.) ondansetron (ZOFRAN™) in one of two treatment periods.
1853164|NCT00972595|Drug|ondansetron marketed formulation|Single dose of an 8 mg tablet of U.K. ondansetron (ZOFRAN™) in one of two treatment periods.
1853165|NCT00972608|Other|Anatomic Reconstruction and Surgical Planning|Standard of care patient-images will be acquired and used to construct a model of the patient anatomy. The model will then be used to simulate surgical options and allow the surgeon to visually evaluate the optimal approach.
1853166|NCT00972621|Device|Vitrax II|Viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber.
1853167|NCT00972621|Device|Viscoat|Currently marketed viscoelastic administered via one or two vials as determined by cataract surgeon for maintenance of anterior chamber..
1853168|NCT00972634|Other|computer-assisted intervention|symptom assessment
1853169|NCT00972634|Other|questionnaire administration|Symptom assessment
1853170|NCT00972634|Procedure|assessment of therapy complications|Symptom assessment
1853171|NCT00972634|Procedure|quality-of-life assessment|Symptom assessment
1853172|NCT00972647|Procedure|Laser beam guidance|Using the laser centralizing beam to assist in position the body part prior to fluoroscopic imaging
1853173|NCT00972660|Biological|Mesenchymal stem cell (MSC)|"Experimental:Mesenchymal stem cell(MSC). Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus and MSC 2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally).
Refractory extensive cGVHD: receive primary treatment (prednisone + cyclosporine or tacrolimus, or plus mycophenolate mofetil, or plus methotrexate ) and MSC2×1,000,000 MSC/kg, IV twice a week for the first two weeks and weekly for the following two weeks(6 doses totally)."
1853174|NCT00972660|Drug|Prednisone and cyclosporine or primary therapies|"Patients with newly diagnosed extensive cGVHD: prednisone 1mg/kg + cyclosporine or tacrolimus
Patients with refractory extensive cGVHD: primary treatment (eg.prednisone 1mg/kg + cyclosporine or tacrolimus,or plus mycophenolate mofetil, or methotrexate.)"
1853175|NCT00972673|Drug|Placebo|comparator
1853176|NCT00972673|Drug|GW685698X|Inhaled steroid
1853177|NCT00972686|Drug|GSK2126458|GSK2126458 is an experimental treatment for patients with cancer.
1853178|NCT00972699|Behavioral|Peer support and mentoring|The intervention will be delivered in 4 non consecutive visits during pregnancy and 4 visits post-partum. The sessions will be delivered to mothers living with HIV on the days of their health care appointments either individually or in groups that can accommodate up to 30 mothers living with HIV. The intervention will focus on enhancing the mother-baby relationship through increasing the health of the mother and baby, maintaining the mother's mental health, and reducing HIV transmission.
1853179|NCT00972712|Drug|Bortezomib and Tipifarnib|"Dose level -1: Bortezomib (0.7 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)
Dose level 1: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (100 mg po BID)
Dose level 2: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (200 mg po BID)
Dose level 3: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (300 mg po BID)
Dose level 4: Bortezomib (1.0 mg/m²; days 1,4,8,11); Tipifarnib (400 mg po BID)
Schema B
Dose level 1: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (300 mg po BID)
Dose level 2: Bortezomib (1.3 mg/m²; Days 1,4,8,11); Tipifarnib (400 mg po BID)"
1853180|NCT00972725|Biological|GSK Biologicals' HIV vaccine (732461)|1 dose intramuscular injection
1853181|NCT00972725|Drug|Chloroquine|One dose of 300 mg
1853182|NCT00972738|Drug|montelukast sodium|Montelukast 10-mg tablet orally once daily at bedtime for 2 weeks.
1853183|NCT00972738|Drug|Comparator: loratadine|Loratadine 10-mg tablet orally once daily at bedtime for 2 weeks.
1853184|NCT00972738|Drug|Comparator: Placebo|placebo tablet orally once daily at bedtime for 2 weeks
1853185|NCT00972777|Drug|Besifloxacin|Besifloxacin 0.6% administered into the study eye two times a day for three days.
1853186|NCT00972777|Drug|Vehicle (Placebo)|Vehicle administered to the study eye two times a day for three days.
1853187|NCT00972790|Procedure|Bilateral Scalp Nerve Blocks|Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
1853188|NCT00972803|Drug|pistacia Mutica extract|The subjects were asked to use a mouthwash containing pistacia Mutica extract twice a day for 4 days.
1853189|NCT00972803|Drug|Placebo|The subjects were asked to use a placebo mouthwash twice a day for 4 days.
1853190|NCT00972803|Drug|Chlorhexidine|The subjects were asked to use a mouthwash containing Chlorhexidine twice a day for 4 days.
1853191|NCT00972816|Biological|MF59-eH1N1|MF59 adjuvanted with egg-derived A/H1N1 antigen. MF59-eH1N1 vaccine is the same vaccine as A/H1N1-SOIV (Swine Origin A/H1N1 Influenza Virus).
1853192|NCT00972829|Drug|Rosuvastatin|Rosuvastatin 10 or 20 milligrams once or twice a week
1853193|NCT00972829|Drug|Ezetimibe|Ezetimibe 5 or 10 milligrams
1853194|NCT00972842|Drug|Vorinostat, Lenalidomide|"Lenalidomide: Dose escalation 10 /15 /20 /25mg/d d1-21 q28d; for 6 treatment cycles
Vorinostat: 400 mg d1-21 q28d, for 6 treatment cycles"
1853197|NCT00972868|Device|A unidirectional face mask (Modified 'Respironics PerformaTrak' Mask)|The regular face mask will be replaced with the study mask and patients will receive NPPV via the study mask for 30 min. The study mask insures a unidirectional breathing pattern, in through the nose and out through the mouth or in through the mouth and out through the nose. The sequence of these two breathing patterns with opposite flow direction will be chosen randomly. Each will be applied for 30 min with data collected during and at the end of the period.
1853204|NCT00972907|Drug|Nifedipine coated suppositories|12 mg Nifedipine coated suppositories BID
1853205|NCT00972920|Procedure|Transversus abdominis plane (TAP) block|Application of local anaesthetic solution (LA) levo-bupivacaine (dose 1mg/kg for each side, concentration 2.5 mg/mL) between internal oblique abdominis muscle and transversus abdominis muscle on both sides.
1853206|NCT00972933|Drug|ipilimumab|Excisional Biopsy - baseline Induction ipilimumab 10 mg/kg IV day 0, 21 - baseline and week 3 Complete lymph node dissection - week ≥ 6 Maintenance Ipilimumab 10 mg/kg IV - Days 63 (+28 days) and, 84 (+28 days) - (3 weeks apart, starting 2-4 weeks following definitive lymphadenectomy)
1853207|NCT00972946|Biological|Administration of autologous Endorem-labelled mononuclear cells intravenously|single dose
1853208|NCT00972946|Drug|Administration of Endorem|single dose, intravenous
1853209|NCT00972959|Drug|Bortezomib|1.3 mg/m2, iv, bolus, on days 1, 4, 8 and 11 of a 21-day cycle for up to 8 chemotherapy cycles
1853210|NCT00972959|Drug|Zoledronic Acid|4 mg, iv, at a 15 min infusion, Day 1 of every cycle for up to 8 cycles, and then every 28 days for the next 18 months
1853211|NCT00972959|Drug|Dexamethasone|12 mg/m2 p.o. on days 1-2, 4-5, 8-9 and 11-12 of a 21-day cycle for up to 8 chemotherapy cycles
1853212|NCT00972972|Dietary Supplement|bilberry (European blueberries) and red grape juice|Intervention juice: 50/50 combination of 300 ml bilberry (European blueberries) and red grape juice (Merlot grapes; Vitis Vinifera L.) per day for 9 weeks
1853213|NCT00972972|Dietary Supplement|placebo juice|Placebo juice: 300 ml, similar to the intervention juice as to taste, energy, salt, and carbohydrates
1853218|NCT00972998|Drug|Phenyephrine|Phenyephrine coated suppositories
1853219|NCT00973011|Drug|FCFD4514S|Intravitreal escalating dose
1853220|NCT00973024|Drug|JNJ-42160443 3 mg|JNJ-42160443: type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 3 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
1853221|NCT00973024|Drug|JNJ-42160443 1 mg|JNJ-42160443: type=exact number, unit=mg, number= 1, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 1 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
1853222|NCT00973024|Drug|JNJ-42160443 6 mg/3mg|JNJ-42160443: type= exact number, unit= mg, number= 3 and 6, form=solution for injection, route= Subcutaneous use or Placebo: form= solution for injection, route= Subcutaneous injection. 1 inj of 6 mg of JNJ-42160443 on Day 1 followed by 1 inj of 3 mg or matching placebo every 4 wks for up to 104 wks.
1853223|NCT00973024|Drug|JNJ-42160443 10 mg|JNJ-42160443 10 mg: type=exact number, unit=mg, number= 10, form=solution for injection, route=Subcutaneous use or Placebo: form=solution for injection, route=Subcutaneous injection. One inj of 10 mg of JNJ-42160443 or matching placebo every 4 wks for up to 104 wks.
1853224|NCT00973024|Drug|Matching Placebo|Form= solution for injection, route= subcutaneous. Matching placebo given as a subcutaneous (SC) (under the skin) injection (inj) once every 4 weeks (wks).
1853225|NCT00973037|Drug|Tamoxifen|Tamoxifen 20mg qd
1853228|NCT00973063|Behavioral|Routine sterile gloving|routinely new sterile gloving just before sampling
1853229|NCT00973076|Drug|AZD8055|Tablets, orally administered, twice daily
1853230|NCT00967330|Drug|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
1853231|NCT00967330|Drug|irinotecan|125mg/m2 iv every 2 weeks
1853232|NCT00967330|Drug|temozolomide|75mg/m2 po daily during radiotherapy, followed by 150-200mg/m2/day po on days 1-5 of each 6x4 week cycle of adjuvant therapy
1853233|NCT00967343|Biological|Donor lymphocyte preparation depleted of host functional alloreactive T-cells|Single intravenous infusion with 2x10E6 T-cells/kg
1853234|NCT00967356|Drug|AZD5985|Single dose-The starting dose will be 40 mg, oral suspension, with up to 8 dose escalations not exceeding AstraZeneca predefined upper exposure limits
1853235|NCT00967356|Drug|Placebo|Oral suspension
1853236|NCT00967369|Drug|Bortezomib|1.5 mg/m^2 by vein over 5 seconds on Days 1 and 4 of each cycle.
1853237|NCT00967369|Drug|Ifosfamide|5 gm/m^2 by vein over 24 hours on Day 1 of each cycle. With Ifosfamide, receive Mesna 5 gm/m^2 by vein over 24 hours.
1853238|NCT00967369|Drug|Carboplatin|Maximum of 800 mg by vein over 1 hour on Day 1 of each cycle.
1853239|NCT00967369|Drug|Etoposide|100 mg/m^2 by vein over 2 hours each day on Days 1-3 of each cycle.
1853240|NCT00967369|Drug|Neulasta (Pegfilgrastim)|6 mg through a needle under the skin on Day 5 (If you are in Group 1) or Day 4 (if you are in Group 2) of each cycle.
1853241|NCT00967369|Drug|Mesna|2 gm/m2 by vein over 12 hours on Day 2 to start day after Ifosfamide + Mesna.
1853242|NCT00967382|Drug|dalteparin sodium|"Subject's randomize to treatment arm will receive dalteparin sodium 5,000 IU s.c. daily starting on randomization day until 20 weeks gestational age then;
dalteparin sodium 5,000 IU s.c. bid from 20 weeks to onset of labour or 37 weeks gestation (discontinued at the discretion of the investigator/obstetrician)
Within 24 hours of delivery, all subject's, regardless of randomization allocation will receive dalteparin sodium 5,000 IU s.c. daily for 6 weeks post-partum"
1853243|NCT00967395|Other|Healing|"Healing in our study is given be a healer no-touch, who just has to be present in the room."
1853244|NCT00967395|Other|Sham healing|"Sham Healing in our study is given be a student no-touch, who just has to be present in the room."
1853245|NCT00967408|Drug|Escitalopram|Rehabilitative treatment + Oral Escitalopram 5 mg/day for the first week, 10 mg/day from second to fourth week and 20 mg/day until 6th month.
1853246|NCT00967408|Drug|Placebo|Rehabilitative treatment + oral inactive placebo for 6 months
1853247|NCT00967408|Other|Rehabilitative treatment|Rehabilitative treatment
1853248|NCT00967421|Drug|ethanol|BAC level 0.5 g/dL (drink + placebo pill). Drink with 2,4 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
1853249|NCT00967421|Drug|Ethanol|BAC level 1.0 g/dL (drink + placebo pill). Drink with 3,6 grams per kilo body weight, administered orally during 60 min, administration ending 30 min prior to start of testing. Placebo pill.
1853250|NCT00967421|Other|Placebo drink|Placebo drink containing no alcohol + placebo pill
1853251|NCT00967434|Drug|Atorvastatin|atorvastatin 80 mg daily for at least 7 preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
1853252|NCT00967434|Drug|Atorvastatin|Daily placebo on the preoperative days atorvastatin 80 mg on day of surgery atorvastatin 80 mg daily for up to 7 postoperative days
1853253|NCT00967434|Drug|Placebo|Daily placebo in preoperative period Placebo on day of surgery Daily placebo for up to 7 postoperative days
1853254|NCT00967460|Behavioral|Lifestyle intervention|Promoting unstructured spontaneous physical in childcare through an adaptation of the built environment and the provision of a supportive social environment
1853255|NCT00967473|Device|ACRYSOF® Single-Piece NATURAL Toric IOL Model SN60T9 and Model SN60T8.|ACRYSOF® Single-Piece Toric NATURAL Intraocular Lens (IOL) Model SN60T9 in the first eye and either the ACRYSOF® Single-Piece Toric NATURAL IOL Model SN60T9 or Model SN60T8 in the second eye.
1853256|NCT00967486|Procedure|Carotid endarterectomy with routine shount|
1853257|NCT00967486|Procedure|Carotid endarterectomy with selective shunt|
1853258|NCT00967499|Drug|ondansetron|"Subjects will receive ondansetron 4 mg intravenously (IV) and will be followed for 72 hours.
Ondansetron is a selective 5-HT3 receptor antagonist. It is indicated for the prevention of nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy, including high-dose cisplatin and prevention of postoperative nausea and/or vomiting."
1853259|NCT00967499|Drug|palonosetron|"Subjects will receive palonosetron HCl 0.075 mg IV and will be followed for 72 hours.
Palonosetron hydrochloride (Aloxi®) is a potent and selective 5-HT3 receptor antagonist for the prevention of acute nausea and vomiting associated with initial and repeat courses of moderately and highly emetogenic cancer chemotherapy, the prevention of delayed nausea and vomiting associated with initial and repeat courses of moderately emetogenic cancer chemotherapy, and the prevention of postoperative nausea and vomiting for up to 24 hours following surgery."
1853260|NCT00967512|Drug|cenersen|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
1853261|NCT00967512|Drug|placebo|solution for injection, intravenous infusion, 0.1 mg/kg/h x 24h x 4 days, and 0.4 mg/kg/h x 3h x 4 days
1853262|NCT00967512|Drug|idarubicin, cytarabine|idarubicin, cytarabine
1853263|NCT00967525|Procedure|cord blood infusion|Receive two cord blood units. One administered by intraosseous infusion and the other by intravenous infusion. The second unit is being given as a safeguard, but will also allow the researchers to directly compare engraftment between intravenously and intraosseously infused cord blood units.
1853264|NCT00967538|Drug|etanercept 50 mg|All patients will receive etanercept 50 mg twice a week for 12 weeks followed by 50 mg once a week for an additional 12 weeks.
1853265|NCT00967551|Dietary Supplement|Micronutrient Sprinkles with zinc|Daily dose of 1 packet of sprinkles
1853266|NCT00967551|Dietary Supplement|Micronutrient sprinkles without zinc|I packet of micronutrient sprinkles without zinc
1853267|NCT00967564|Other|epidemiologic study|QoL assessment
1853268|NCT00967577|Drug|177Lu-J591|70 mCi/m2 of 177Lu-J591 will be administered on Day 1.
1853269|NCT00967590|Drug|RO5036505|380mg iv infusion once weekly for 8 weeks
1853270|NCT00967590|Drug|placebo|iv infusion once weekly for 8 weeks
1853271|NCT00967603|Drug|sunitinib|oral sunitinib 37.5 mg daily
1853272|NCT00967616|Drug|CS7017|CS-7017 (0.25mg tablet) Two CS-7017 tablets will be administered PO BID every 12 hours. FOLFIRI will be administered IV once every 2 weeks.
1853273|NCT00967616|Drug|irinotecan, leucovorin, and 5-fluorouracil (5-FU) (FOLFIRI)|"FOLFIRI will be administered IV once every 2 weeks.
The FOLFIRI regimen consists of:
Irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes
Leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion
5-FU, 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion)"
1853274|NCT00967629|Drug|Sevelamer Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
1853275|NCT00967629|Drug|Calcium Carbonate|This is a 4 month, prospective, comparative, crossover study. The study will be conducted in 20 patients with stage II, III or stage IV diabetic nephropathy. Patients will be randomized 1:1 to receive either 1,250 mg of calcium carbonate TID with meals (control arm) or Sevelamer Carbonate 1,600 mg (two 800 mg tablets) with meals. Each group of 10 subjects will take the assigned drug for 8 weeks. Following the 8 week treatment period, subjects will discontinue the assigned drug for a one week washout period. Following the washout period, those who were taking calcium carbonate will be crossed over to Sevelamer Carbonate therapy and those who were receiving Sevelamer Carbonate will be crossed over to calcium carbonate for a final 8 week treatment phase.
1853276|NCT00967642|Drug|Intravenous Insulin|continuous intravenous insulin/24h guided by glycemia (Optium, Abbott) evaluated hourly, targeting values lower than 110 mg/dl
1853277|NCT00967655|Biological|panitumumab|
1853278|NCT00967655|Drug|capecitabine|
1853279|NCT00967655|Drug|irinotecan hydrochloride|
1853280|NCT00967655|Procedure|neoadjuvant therapy|
1853281|NCT00967655|Procedure|therapeutic conventional surgery|
1853282|NCT00967655|Radiation|radiation therapy|
1853283|NCT00967668|Behavioral|Small change approach to improve physical activity and diet|"The Aspire to Lifelong Health (ASPIRE) initial treatment program draws on the strengths of traditional lifestyle change and non-dieting weight loss approaches. ASPIRE incorporates CBT elements, problem-solving therapy, and the small change approach from behavioral choice therapy. For the first week in the program, participants use a food diary to track caloric intake and a pedometer to log their daily physical activity (step counts). Baseline information provides a starting point for participants and their Lifestyle Coach to set one small, but potentially permanent, change in daily food choices and physical activity to promote a caloric deficit. Small changes are cumulative over the weeks and the participant makes their own goals within the context of their own lifestyle."
1853284|NCT00967668|Behavioral|MOVE! Usual Care|The MOVE! program offers a stepped-care framework of increasingly intensive treatment. A combination of Level 1 (self-management support) and Level 2 (group sessions and/or individual specialty consultation) will be offered to participants as part of usual care.
1853285|NCT00967681|Dietary Supplement|Oncoxin|(caplets 300 mg), three oral caplets per day for 24 weeks
1853286|NCT00967681|Dietary Supplement|Placebo|(caplets 300 mg), three oral caplets per day for 24 weeks
1853287|NCT00967694|Drug|Nitrous oxide|Nitrous oxide sedation by inhalation
1853288|NCT00967707|Drug|gabapentin and venlafaxine|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).
Week 7-12: Venlafaxine 75 mg once daily is added."
1853289|NCT00967707|Drug|gabapentin and donepezil|"Week 1-6: Gabapentin monotherapy (titration to individual maximum tolerated dose or maximum 800 mg 3 times daily).
Week 7-12: Donepezil 5 mg once daily is added."
1853290|NCT00967733|Dietary Supplement|Flaxseed oil-Olive oil|2 or 4 gr per day alpha-linolenic acid pill and olive oil used for cooking
1853291|NCT00967733|Dietary Supplement|Olive oil-olive oil|1 gr olive oil pill and olive oil used for cooking
1853292|NCT00967733|Dietary Supplement|Flaxseed oil-sunflower oil|2 or 4 gr per day alpha linolenic acid pill and sunflower oil used for cooking
1853293|NCT00967733|Dietary Supplement|Olive oil-sunflower oil|1 gr olive oil pill and sunflower oil used for cooking
1853294|NCT00967746|Drug|Etonogestrel-releasing IUS|Low dose; treatment duration of 6 months with a possible extension to 12 months
1853295|NCT00967746|Drug|Etonogestrel-releasing IUS|Intermediate dose; treatment duration of 6 months with a possible extension to 12 months
1853296|NCT00967746|Drug|Etonogestrel-releasing IUS|High dose; treatment duration of 6 months with a possible extension to 12 months
1853297|NCT00967746|Device|Multiload-cu 375®|Duration of 6 months with a possible extension to 12 months
1853298|NCT00973089|Other|Incomplete caries removal in primary teeth|Comparison between the success rate and cost-effectiveness of complete caries removal in treatment of deep carious lesions that might include wide preparations and involve pulpotomy versus incomplete removal of caries and avoiding pulp treatment.
1853301|NCT00973115|Drug|Simvastatin CR|
1853302|NCT00973128|Drug|GMCSF plus Antimony reduced dose|400 µg, divided in two doses a week apart, antimony (20mg/daily for 10 days)
1853303|NCT00973128|Drug|Meglumine antimoniate|20mg/daily for 20 days
1853304|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=1, form=solution for injection, route=Subcutaneous use. One injection of 1 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
1853305|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=10, form=solution for injection, route=Subcutaneous use. One injection of 10 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
1853306|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
1853307|NCT00973141|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 4 or 8 weeks for up to 104 weeks.
1853308|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=3, form=solution for injection, route=Subcutaneous use. One injection of 3 mg of JNJ-42160443 every 4 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
1853309|NCT00973141|Drug|JNJ-42160443|Type=exact number, unit=mg, number=6, form=solution for injection, route=Subcutaneous use. One injection of 6 mg of JNJ-42160443 every 8 weeks for up to 104 weeks (JNJ-42160443 at a concentration of 10 mg/mL was provided for use in this study).
1853310|NCT00973154|Drug|Prednisone|50mg per day of prednisone orally for 7 days versus placebo
1853311|NCT00973167|Device|Low-magnitude high-frequency vibration treatment|Stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 5 days/week
1853312|NCT00973180|Other|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
1853313|NCT00973193|Drug|panitumumab|intravenous infusion of panitumumab, 6 mg per kg body weight, once every 14 days for a total of 42 days
1853314|NCT00973219|Drug|Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate|Peg-Interferon alfa 2a 180ug/week + Adefovir dipivoxil 10mg/day, Peg-Interferon alfa 2a 180ug/week + Tenofovir disoproxil fumarate 245mg/day
1853315|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fasting conditions
1853316|NCT00973232|Drug|DDS-06C (650 mg acetaminophen and 75 mg tramadol)|DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl: two tablets, single dose, total administered of 1300 mg acetaminophen/150 mg tramadol HCl under fed conditions
1853317|NCT00973232|Drug|Zaldiar®|Zaldiar® (325 mg acetaminophen and 37.5 mg tramadol HCl): two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
1853318|NCT00973232|Drug|Ultracet®|Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)two tablets; dose of 650 mg acetaminophen/75 mg tramadol HCl administered at Time = 0 hr (fasting)and second dose at Time = 6 hr (fed) Ultracet® (325 mg acetaminophen and 37.5 mg tramadol HCl)
1853319|NCT00973232|Drug|Two tablets of DDS-06C (650 mg acetaminophen and 75 mg tramadol HCl), multiple doses, under both fed and fasting conditions|Two tablets of DDS-06C, twice daily at 12-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
1853320|NCT00973232|Drug|Zaldiar®, multiple doses,(fed & fasting):|Two tablets of Zaldiar®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
1853321|NCT00973232|Drug|Ultracet®, multiple doses, (fed & fasting)|Two tablets of Ultracet®, 4 times daily at 6-hour intervals under fed conditions for the first 4 days, then under fasting conditions for the 5th day. The total daily dose administered was 2600 mg Acetaminophen/300 mg tramadol HCl
1853322|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg od
1853323|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|15mg od
1853324|NCT00973245|Drug|Xarelto (Rivaroxaban, BAY59-7939)|20mg od
1853325|NCT00973245|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
1853326|NCT00973258|Dietary Supplement|Nutritional Intervention|Each subject in the nutritional intervention group is provided with a commercial liquid formula (Fortisip Multi Fibre, Nutricia), which should be taken every evening for a period of 24 weeks. Subjects are also given one capsule of iron and folate supplement (Sangobion, Merck; consisting of 1 mg folate and 29mg iron), one capsule of Vitamin B6 and vitamin B12 supplement (Neuroforte; consisting of 200mcg B12 and 200mg vit B6) and one tablet of Caltrate with Vitamin D (consisting of 200 IU vitamin D and 600 mg of calcium) for a duration of 24 weeks.
1853327|NCT00973258|Other|Physical Exercise|The exercise intervention group comprises a combination of 2 types of exercise: resistance exercise and in-balance exercise. Key components in both programs are balance and strength, because these are the most prominent domains that should be addressed in at risk frail elderly. The first program is administered in the first 6-week, and then followed by the second program for the next 6-week of intervention period. Both exercise programmes are tailored to the functional needs of the participants, maintaining a moderate intensity that focuses on long-term sustainability and enjoyment.
1853328|NCT00973258|Other|Cognitive Training|"The proposed cognitive training intervention program comprises:
Reasoning training focusing on inductive reasoning, the ability to solve problems that follow a serial pattern and manifest in executive functioning.
Memory training focusing on verbal episodic memory, which deals with acquisition and retrieval of information acquired in a particular place at a particular time.
Speed training focusing on visual search and the ability to identify and locate visual information quickly in a divided attention format, with and without distractors."
1853329|NCT00973258|Other|Combined|Nutritional Intervention + Physical Exercise + Cognitive Training
1853330|NCT00973258|Other|Placebo|Participants will receive their usual diet and placeboes.
1853331|NCT00973271|Drug|290 mg DCCR|290 mg diazoxide choline
1853332|NCT00973271|Drug|435 mg DCCR|435 mg diazoxide choline
1853333|NCT00973271|Drug|135 mg fenofibric acid|135 mg fenofibric acid
1853334|NCT00973271|Drug|Placebo|Placebos matching each of 2 doses of DCCR and 135 mg fenofibric acid
1853335|NCT00973271|Drug|atorvastatin|20 mg atorvastatin
1853336|NCT00973284|Biological|Norwalk VLP vaccine|Norwalk VLP vaccine dry powder
1853337|NCT00973284|Biological|mannitol and sucrose|Mannitol and sucrose as placebo-matching Norwalk VLP Vaccine dry powder
1853338|NCT00973284|Biological|Norwalk virus|Norwalk virus solution
1853339|NCT00973297|Other|Multidisciplinary falls prevention|Group education on falls risk and mobility and transfers safety; Physical therapy at the subjects' bedside consisting of balance training; Medical assessment - medications use (anxiolytics/hypnotics, neuroleptics, antihypertensives, antiarrhythmics and other vasodilators) with effort to discontinue or reduce dose when possible; orthostatic hypotension - discontinue/reduce dose of related medications; urinary frequency/incontinence - evaluation and treatment; delirium - evaluation and treatment; visual pathology - evaluation and treatment
1854387|NCT00975195|Drug|salmeterol xinafoate|
1853340|NCT00973310|Other|Radiation Therapy and EGFR-TKI target therapy|Patients with locally advanced NSCLC received oral erlotinib (150 mg, qd) for about 6-7 weeks during the course of radiation therapy (60-70Gy in a fraction dose of 2 Gy, 5 fractions per week)
1853341|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|2.5mg bid
1853342|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|5mg bid
1853343|NCT00973323|Drug|Xarelto (Rivaroxaban, BAY59-7939)|10mg bid
1853344|NCT00973323|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
1853345|NCT00973336|Drug|Calcium and vitamin D|1000mg calcium per day 800 IE vitamin D per day
1853346|NCT00973349|Biological|MF59-eH1N1_f|8 arms consisting of different antigen combinations of A/H1N1 S-OIV and different percentages of MF59 adjuvant
1853347|NCT00973362|Device|APTIMA HPV Assay|"The APTIMA HPV Assay is an in vitro nucleic acid amplification test (NAAT) that qualitatively detects human papillomavirus (HPV) E6/E7 messenger RNA (mRNA) from 14 HPV types (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68) that are associated with cervical cancer (high-risk types). The assay cannot determine the specific high-risk HPV type(s) present and does not cross-react with 5 HPV types that are considered non-oncogenic (not associated with cervical cancer; types 6, 11, 42, 43, and 44)."
1853348|NCT00973362|Device|FDA-Approved HPV DNA Test|A FDA-Approved HPV DNA Test is used as the comparator assay.
1853349|NCT00973388|Drug|Telaprevir; Moxifloxacin; Placebo|
1853350|NCT00973401|Other|Insulin pump|Patients receive an insulin pump that optimizes their glucose control.
1853351|NCT00973414|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after CSEA in cesarean section
1853352|NCT00973414|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after CSEA in cesarean section
1853353|NCT00975975|Drug|Basiliximab|Basiliximab given 1 time on Day +7 or Day +9.
1853354|NCT00975988|Drug|TYKERB® tablets|Patients administrated TYKERB® tablets according to the prescribing information
1853355|NCT00976001|Other|Information, further rehabilitation, additional drugs to prevent recurrent stroke|
1853356|NCT00976001|Other|As the general practitioner wants to do|
1853357|NCT00976027|Biological|Trivalent inactivated influenza vaccine High Dose|0.5 mL, Intramuscular
1853358|NCT00976027|Biological|Trivalent inactivated influenza vaccine|0.5 mL, Intramuscular
1853359|NCT00976040|Other|Early antiretroviral therapy|"The intervention is early initiation of antiretroviral therapy after diagnosis of Cryptococcal meningitis.
In the intervention/experimental arm, triple-drug highly active antiretroviral therapy regimens will be initiated within 7 days of diagnosis of Cryptococcal meningitis."
1853360|NCT00976053|Procedure|Myocardial perfusion imaging|Randomization assignment to one of SPECT or PET myocardial perfusion imaging
1853361|NCT00976066|Drug|Part A Assessing GSK1521498|"Each participant will receive up to three [11C]carfentanil PET scans and up to two doses of GSK1521498 in total. The doses used will span the expected receptor occupancy range providing these were well tolerated in the first-time in human study.
Each subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively), followed by two treatment sessions (Treatment Sessions 1 and 2). Treatment session 1 and 2 are followed by PET scans and an fMRI scan (session 1 only). Sessions will be separated by at least 12 days. PET scans will be timed to coincide with peak brain occupancy. fMRI will begin approximately 30-60 minutes after completion of the PET scan."
1853362|NCT00976066|Drug|Part B Assessing GSK1521498|"The purpose of Part B is to establish the timecourse of receptor occupancy of GSK1521498. Each participant in Part B will receive up to three [11C]carfentanil PET scans and one single oral dose of GSK1521498 expected to provide 50-75% receptor occupancy (selected with reference to data from Part A).
Each Part B subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of GSK1521498 followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2)."
1853363|NCT00976066|Drug|Part C Assessing Naltrexone|A range of doses of naltrexone will be tested in up to 12 participants in an adaptive design. Each Part C participant will receive up to three [11C]carfentanil PET scans and a single oral dose of naltrexone. No dose of naltrexone will exceed 50 mg, the dose usually used therapeutically in the treatment of opiate and alcohol dependence. Each Part C subject will receive baseline [11C]carfentanil PET and fMRI scans (PET Scan 1 and fMRI Scan 1, respectively) followed by a single treatment session. The treatment session will consist of a single oral dose of naltrexone followed by two subsequent PET scans (PET Scans 2 and 3) and one fMRI scan (fMRI Scan 2).
1853364|NCT00976079|Device|Transcutaneous electrical nerve stimulation (TENS)|Continuous TENS use
1853365|NCT00976079|Device|Placebo TENS|Placebo TENS use
1853366|NCT00976092|Drug|Prasugrel|60 mg prasugrel as loading dose prior to PPCI
1853367|NCT00976092|Drug|Bivalirudin|IV bolus 0.75 mg/kg of body weight followed by an infusion of 1.75 mg/kg/hour during the PPCI
1853368|NCT00976092|Drug|Clopidogrel|600 mg clopidogrel as loading dose before PPCI
1853369|NCT00976092|Drug|Heparin|i.v. bolus of 70-100 IU/kg body weight
1853370|NCT00976105|Drug|Zolpidem or placebo - Hypnotic drug given for sleep disorders|The information gathered from Part A will be used as a benchmark against which any effects of GSK1521498 can be assessed in Part B.
1853371|NCT00976105|Drug|GSK1521498 or placebo|The first group will start at a low dose (10 mg GSK1521498 or placebo) for 10 days. The study team will then assess the data gathered from the first cohort and will select the dose that the next cohort will receive for 10 days. There will be up to 4 cohorts.
1853372|NCT00976118|Drug|masitinib (AB1010)|oral masitinib 3 or 6 mg/kg/day
1853373|NCT00976118|Drug|placebo|matching placebo to masitinib
1853374|NCT00976131|Drug|Coenzyme Q10|"Dose Level 1:
300mg/d (2 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 300mg/d placebo (2 capsules)taken daily for two weeks prior to Cycle 4 infusion of doxorubicin.
Dose Level 2:
600mg/d (4 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 600mg/d placebo (4 capsules) taken daily for two weeks prior to Cycle 4 infusion of doxorubicin.
Dose Level 3:
1200mg/d (8 capsules) of CoQ10 taken daily for two weeks prior to Cycle 3 infusion of doxorubicin followed by 1200mg/d placebo (8 capsules) taken daily for two weeks prior to Cycle 4 infusion of doxorubicin."
1853407|NCT00976404|Biological|DNA + HIV-rAd5 vaccine|4 mg subcutaneous injection at weeks 8 (DNA prime), 12 (DNA prime), 16 (DNA prime), and 32 (HIV-rAd5)
1853375|NCT00976131|Other|Coenzyme Q10 Placebo|"Dose Level 1:
300mg/d placebo (2 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 300mg/d (2 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin.
Dose Level 2:
600mg/d placebo (4 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 600mg/d (4 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin.
Dose Level 3:
1200mg/d placebo (8 capsules) taken daily two weeks prior to Cycle 3 infusion of doxorubicin followed by 1200mg/d (8 capsules) of CoQ10 taken daily two weeks prior to Cycle 4 infusion of doxorubicin."
1853376|NCT00976144|Drug|GSK573719|GSK573719 is a long-acting, inhaled, muscarinic receptor antagonist or anticholinergic bronchodilator. GW642444 is a potent and selective long-acting beta-2 agonist. Both are in development for once daily monotherapies for the treatment of COPD. In this study, their effects are investigated following individual and concurrent administration.
1853377|NCT00976157|Procedure|Bronchoscopy BAL|The bronchoscope was passed through endotracheal tube via a specific adaptor without topical anesthesia. The bronchoscope was introduced and wedged into the segmental bronchial orifice where pneumonia was suspected. Five aliquots of 20ml sterile saline were instilled and aspirated gently. The first aliquot was discarded and the last 4 aliquots were pooled for analysis. Part of the retrieved specimen in the first BAL fluid was sent to the laboratory immediately after collection for measurement of sTREM-1 level, the rest of sample was sent to microbiology lab for quantitative culture.
1853378|NCT00976170|Drug|GC33(RO5137382)|IV administration at 6 escalating dose levels.
1853379|NCT00976170|Drug|Sorafenib|Oral administration at 400mg twice daily or 400mg once daily
1853380|NCT00976183|Drug|Vorinostat|Vorinostat will start at 200 mg QD on weeks 1 and 3, and escalating to 300 mg QD after safety has been evaluated following 2 cycles of treatment. If safety is acceptable, then the following patients could be treated at 400 mg QD on weeks 1 and 3.
1853381|NCT00976183|Drug|Vorinostat|Vorinostat will be given as a lead-in dose escalation starting at 200 mg QD.
1853382|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Extended Release (ER) Tablets 30 mg|Phenylephrine HCl ER tablets 30 mg taken every 12 hours, twice daily, for 3 days.
1853383|NCT00976209|Drug|Phenylephrine Hydrochloride (HCl) Immediate Release (IR) tablets, 10 mg|Phenylephrine HCl IR tablets 10 mg taken every four hours (no more than 6 times daily) for 3 days.
1853384|NCT00976222|Drug|intravitreal injection with ranibizumab|0.5 mg in 0.05 ml, monthly, 12 months
1853385|NCT00976235|Device|IMT - Implantable Miniature Telescope|Implantation of the telescope prosthesis (performed under the initial study)
1853387|NCT00976261|Drug|GSK1614235|Glucose lowering in Type 2 Diabetes Mellitus
1853388|NCT00976261|Drug|Sitagliptin|Glucose lowering in Type 2 Diabetes Mellitus
1853389|NCT00976261|Other|Placebo|Comparator
1853390|NCT00976274|Dietary Supplement|Korean red ginseng|5 capsules (300 mg/capsule) three times everyday for 12 weeks
1853391|NCT00976274|Dietary Supplement|starch|5 capsules three times everyday for 12 weeks
1853394|NCT00976300|Drug|Cyclosporine A|Cyclosporine arm (CyA group) consisted of oral cyclosporine A (CyA) 4-5mg/kg/day (given in two divided doses) for 9 months followed by gradually decreasing dose of cyclosporine (3.75-1.25 mg/kg/day) within the next 9 months. The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
1853395|NCT00976300|Drug|Cyclophosphamide|Cyclophosphamide (CPH) therapeutic arm (CPH group) consisted of 8 boluses of intravenous cyclophosphamide (10mg/kg) given within 9 months in subsequently prolonged intervals (2x3weeks, 4x4 weeks, 2x6 weeks) followed by 4-5 oral cyclophosphamide boluses (10mg/d in 6-8 week intervals). The dosage of concomitant glucocorticoids was driven and tapered according to a single treatment protocol.
1853396|NCT00976313|Procedure|Assessment of urinary micturition after thoracotomy|Post residual urine volume and voided volume will be assessed with Bladder Scan™ BVI 6100 (Bladder scan, Bothell, WA, USA) will be performed the day before surgery and on day 2 after surgery, with epidural analgesia within segments T2-4 to T10 21,22. Bladder sensitivity will be assessed at strong desire to void. On day 2 the bladder will be filled through the transurethral catheter till the patient signalised a strong desire to void, then the catheter will be removed and spontaneous micturition will be attempted. Voided volume and post void residual will be assessed.
1853397|NCT00976313|Other|International Prostate Symptom Score|International Prostate Symptom Score (IPSS) for assessment of lower urinary tract symptoms (LUTS) preoperatively
1853398|NCT00976326|Drug|insulin degludec|The dose level will be one single dose of 0.4 units per kg body weight injected s.c. (subcutaneously, under the skin)
1853399|NCT00976339|Drug|Cholecalciferol|"Cholecalciferol is a vitamin D3. Vitamin D is important for the absorption of calcium from the stomach and for the functioning of calcium in the body. Cholecalciferol is used to treat or prevent many conditions caused by a lack of vitamin D.
Cholecalciferol will be available in gel capsule form at 10,000 IU (0.25 mg cholecalciferol) each."
1853402|NCT00976365|Dietary Supplement|THL-P|20ml/bottle, TID, 24weeks
1853403|NCT00976378|Drug|NOX-A12|single ascending IV doses, ranging from 0.05 mg/kg to 10.8 mg/kg
1853404|NCT00976378|Drug|NOX-A12|single IV dose, at efficacious dose level
1853405|NCT00976391|Biological|albiglutide + insulin glargine|albiglutide in combination with insulin glargine
1853406|NCT00976391|Drug|insulin glargine + preprandial lispro insulin|insulin glargine in combination with preprandial lispro insulin
1853408|NCT00976404|Drug|ART intensification (raltegravir)|raltegravir 400 mg PO BID for 56 weeks
1853409|NCT00976404|Drug|ART intensification (maraviroc)|maraviroc 150, 300, or 600 mg PO BID (depending on PK interactions with other medications) for 56 weeks
1853410|NCT00976430|Procedure|Autologous Bone marrow derived stem cells transplant|Stem cells are derived from the bone marrow of the patient and processed at Reliance life sciences.The stem cells are the stereotactically implanted in the striatum.
1853411|NCT00976443|Drug|BTA|BTA 100 or 300 U, endoscopic ultrasound (EUS) guided injections into gastric antrum
1853412|NCT00976443|Drug|Placebo (normal saline)|Placebo (normal saline), gastric injections of normal saline
1853413|NCT00976456|Drug|Bevacizumab + Pemetrexed|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes every 3 weeks
1853414|NCT00976456|Drug|Bevacizumab + Pemetrexed + Carboplatin|Bevacizumab 7,5 mg/kg i.v. over 60 min every 3 weeks plus pemetrexed 500 mg/m2 i.v. on D1 over 10 minutes and carboplatin AUC 5 on D1 every 3 weeks
1853415|NCT00976469|Biological|H1N1 pandemic influenza vaccine (whole virion, Vero cell-derived, inactivated)|2-dose priming at a 21-day interval, intramuscular injection in either the upper arm or thigh, depending on the subject´s age
1853416|NCT00976469|Biological|Seasonal trivalent influenza vaccine (licensed) for the season 2010/2011|Booster vaccination at Day 360 after first vaccination (only in subjects who received the 7.5 µg dose of the H1N1 pandemic influenza vaccine)
1853417|NCT00976495|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, 12 weeks
1853418|NCT00976495|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 12 weeks
1853419|NCT00976495|Drug|Hydrochlorothiazide|Tablets, Oral, 25 mg, once daily, 12 weeks
1853420|NCT00976508|Drug|figitumumab|IGF-1R antibody, 20 mg/kg, IV every 3 weeks for up to 1 year
1853421|NCT00976508|Drug|pegvisomant|growth hormone antagonist, 10, 20 or 30 mg per day via subcutaneous injection for up to 1 year
1853422|NCT00976521|Drug|Abciximab local infusion|Local infusion of abciximab using the ClearWay™ RX Infusion Catheter
1853423|NCT00976521|Other|No local infusion|Intervention without local infusion
1853424|NCT00976521|Procedure|Thrombus aspiration|Thrombus aspiration
1853425|NCT00976534|Drug|AZD1386|90 mg, capsules, oral, during 3 weeks
1853426|NCT00976534|Drug|Placebo|capsules, oral, during 3 weeks
1853430|NCT00976573|Biological|bevacizumab|Given IV
1853431|NCT00976573|Drug|carboplatin|Given IV
1853432|NCT00976573|Drug|everolimus|Given orally
1853433|NCT00976573|Drug|paclitaxel|Given IV
1853434|NCT00976599|Drug|CP-690,550 + methotrexate|CP-690,550 dose is 10 mg twice daily, oral tablets, for 4 weeks Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
1853435|NCT00976599|Drug|Placebo + Methotrexate|Methotrexate dose is ≥ 7.5 mg / week and ≤ 25 mg / week
1853436|NCT00976612|Drug|Nilotinib|Nilotinib 400mg bid daily
1853437|NCT00976625|Procedure|Aortic Valve Replacement|Surgical valve replacement of the aorta
1853438|NCT00976638|Other|Chromogenic surveillance|All admitted patients are screened on admission for MRSA and VRE by chromogenic agar and isolated when positive
1853439|NCT00976638|Other|Molecular surveillance|All patients are screened for MRSA and VRE by PCR; and for ESBL by chromogenic agar on admission. Positive patients are isolated
1853440|NCT00976651|Drug|human menopausal gonadotropin|200 IU per day in the late follicular phase
1853441|NCT00976664|Device|Shoe orthotic|Shoe orthotics are devices worn in the shoe to modify the patient's stance and gait.
1853442|NCT00976664|Device|Shoe Orthotic Wait Group|This group receives the custom-made shoe orthotics at week 6 of the 12 week treatment program rather than week 1.
1853443|NCT00976677|Drug|erlotinib hydrochloride|Given PO
1853444|NCT00976677|Drug|paclitaxel|Given IV
1853445|NCT00976677|Drug|carboplatin|Given IV
1853446|NCT00976677|Biological|bevacizumab|Given IV
1853447|NCT00976690|Drug|Azathioprine OR Mesalazine|Azathioprine : 2mg/kg/day Mesalazine : 4g/day
1853448|NCT00976703|Other|weighted bag|For the weighted bag, a 500cc saline bag will be taped to an empty Foley bag which will be attached to the cervical Foley catheter. This bag will then be placed to gravity over the end of the bed. The bed will be raised so that the bag does not touch the floor. The foley and the bag will be re-assessed every 30min by the nursing staff.
1853449|NCT00976703|Other|leg taping|For the leg taping, the cervical foley catheter will be pulled to gentle traction and attached to the patient's inner thigh using a reclosable foley catheter fastener. The foley catheter and the traction will be assessed every 30min by the nursing staff. The tension will be renewed and the Foley re-adjusted if necessary at each check.
1853450|NCT00976716|Drug|Celecoxib|"Day 1
The first dose: Celecoxib 400mg
The second dose: Celecoxib 200mg during a period between 6 hours post-first dose and before bed
Days 2 to 8 (Study drug should be taken until the dose scheduled after breakfast on the day of Day 8)
- Celecoxib 200mg twice daily"
1853451|NCT00976729|Drug|NOX-E36|single ascending IV doses, ranging from 0.03 mg/kg to 2.0 mg/kg
1853452|NCT00976729|Drug|NOX-E36|single SC doses, at safe and tolerable dose level
1853453|NCT00976729|Drug|Placebo|
1853454|NCT00976742|Behavioral|Endurance exercise training|
1853455|NCT00976755|Drug|everolimus|"Everolimus:
10mg daily"
1853456|NCT00976768|Drug|oxaliplatin, 5-fluorouracil|Oxaliplatin 85 mg/㎡ IV, day 1 over 2 hours 5-FU 400 mg/㎡ IV bolus day 1 followed by 5-fluorouracil(FU) 2,400 mg/㎡ and leucovorin (LV) 100 mg/㎡ IV continuous over 46 hours (every 2 weeks)
1853457|NCT00976794|Drug|lithium plus carbamazepine|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.
Carbamazepine : Starting at 200mg daily and getting 600 mg daily at the end of the first week. Dose weekly adjusted according to blood serum level (8 and 12µg/ml), efficacy and tolerability"
1853533|NCT00977301|Drug|fosamprenavir/ritonavir|16 days 700mg/100mg RTV BID
1853458|NCT00976794|Drug|lithium plus valproate|"Lithium: Starting at 600 mg daily, dose weekly adjusted according to blood serum level (0,6 -1,2mEq/l), efficacy and tolerability.
Valproic acid: Starting at 500mg daily, dose weekly adjusted according to blood serum level (50 and 125µg/ml), efficacy and tolerability."
1853459|NCT00976807|Other|Pulmonary Rehabilitation|"Eight week programme of twice-weekly (sixteen sessions) supervised exercise and education sessions. Exercise will include aerobic cardiovascular and upper and lower limb strengthening exercises. Each session will comprise a warm-up period, followed by individualised exercises, and completed with a cool-down, and last approximately 40minutes.
Aerobic exercise will be prescribed based on the results of walking tests and include walking, step-ups, cycling, and strength prescription according to the repetition maximum principle. Patients will complete three sets using this weight.
Furthermore Borg scores will be used within each session to guide and direct exercise intensity. A home exercise programme will also be designed and accompanied by a manual detailing the individual warm-up, exercises and cool-down, and diary sections to record independent activity.
Each session will also include an education session where relevant."
1853462|NCT00976833|Other|Standardized Rehabilitation|3 component Rehabilitation approach, Passive Range of Motion, Physical Therapy and Progressive Resistance Training
1853463|NCT00976833|Other|Usual Care|Usual Physical Therapy care
1853464|NCT00976846|Device|Dialyzer Baxter Xenium XPH 210|High-Flux dialyzer
1853465|NCT00976859|Behavioral|Imagery Modification|Research via internet concerning the frequency of skin exchange and disputation of the collected information; in the guided imagery modification the therapist instructs the patient to imagine the feeling of being contaminated and the process of peeling off their former contaminated skin and the maturing of hundreds of new clean skin cells
1853466|NCT00976859|Behavioral|Waitlist control group|Patients in the wait list control group are treated after a waiting period of five weeks
1853467|NCT00976872|Drug|omega-3|"omega-3: 2 pills of Omega950®, Solgar, New Jersey, USA. Each pill contained 542mg of eicosapentaenoic acid, EPA, and 405mg of docosahexanoic acid, DHA"
1853468|NCT00976872|Drug|placebo|hard gelatin capsule of Capsugel®, France, filled with 1ml of soya oil
1853469|NCT00976898|Radiation|Proton Beam Irradiation|Given once a day, 5 days a week, for 3 weeks
1853470|NCT00976911|Drug|bevacizumab [Avastin]|10m/kg iv every 2 weeks or 15mg/kg iv every 3 weeks
1853471|NCT00976911|Drug|liposomal doxorubicin|40mg/m2 iv every 4 weeks
1853472|NCT00976911|Drug|paclitaxel|80mg/m2 iv on days 1, 8, 15 and 22 of each 4-week cycle
1853473|NCT00976911|Drug|topotecan|4mg/m2 iv on days 1, 8 and 15 of each 4-week cycle, or 1.25 mg/kg on days 1-5 of each 3-week cycle
1853474|NCT00976924|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
1853475|NCT00976937|Drug|Lixisenatide (AVE0010)|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
1853476|NCT00976937|Drug|Lixisenatide Placebo|Self-administered by subcutaneous injections once daily within the hour preceding breakfast.
1853477|NCT00976937|Device|Pen auto-injector|
1853478|NCT00976937|Drug|Sitagliptin|Administered orally once a day in the morning with or without food at approximately the same time each day.
1853479|NCT00976937|Drug|Sitagliptin Placebo|Administered orally once a day in the morning with or without food at approximately the same time each day.
1853480|NCT00976937|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
1853481|NCT00976950|Drug|Tipranavir|
1853482|NCT00976950|Drug|ritonavir|low-dose
1853483|NCT00976963|Drug|Fosfomycin|3g sachet single dose
1853484|NCT00976963|Drug|TMP/SMX DS|160/800mg BID x 3 days
1853485|NCT00976976|Drug|docetaxel, capecitabine, cisplatin|Docetaxel 60 mg/m2 IV (day 1) every 21 days capecitabine 1,875 mg/m2/day PO, divided two (day 1-day14) every 21 days Cisplatin 60 mg/m2 IV (day 1) every 21 days
1853486|NCT00976989|Drug|Pertuzumab|840 mg loading dose intravenously (IV), then 420 mg IV 3-weekly.
1853487|NCT00976989|Drug|Trastuzumab|8 mg/kg loading dose IV, then 6 mg/kg every 3 weeks.
1853488|NCT00976989|Drug|FEC|5-fluorouracil 500 mg/m^2, epirubicin 100 mg/m^2 and cyclophosphamide 600 mg/m^2.
1853489|NCT00976989|Drug|Docetaxel|75 mg/m^2 for the first dose; 100 mg/m^2 if no dose limiting toxicity occurs.
1853490|NCT00976989|Drug|TCH|Trastuzumab followed by carboplatin at target area under the plasma concentration-time curve (AUC) 6 and docetaxel at a starting dose of 75 mg/m^2. All treatments were given every three weeks by the IV route.
1853491|NCT00977002|Other|Positive Pressure Noninvasive ventilation|Patients randomized to this group are submitted to positive pressure noninvasive ventilation for 12 hours or more. Children younger than one year use nasal prong and older than one year use nasal or facial mask. A blood gas is collected in the moment of intubation and one hour after.
1853492|NCT00977002|Other|Inhalatory O2|Patients randomized to this group are submitted to inhalatory O2 using mask or nasal catheter. A blood gas is collected in the moment of intubation and one hour after.
1853493|NCT00977015|Drug|Treatment A|Inhaled, 750/150, single dose
1853494|NCT00977015|Drug|Treatment B|Inhaled, 750/150, single dose
1853534|NCT00977301|Drug|olanzapine|15 mg olanzapine single dose
1853535|NCT00977301|Drug|olanzapine|10 mg olanzapine single dose
1853536|NCT00977314|Device|The Sonitus Bone Conduction Hearing System|Comparison of HINT scores (Speech front with noise at better ear) at 30 days tested with the device in place verses with the device removed.
1853537|NCT00977314|Device|SoundBite|
1853538|NCT00977314|Device|SoundBite Hearing System|
1854388|NCT00975195|Drug|fluticasone propionate|
1997294|NCT02145949|Drug|Placebo (Alanine)|Twice daily ingestion of 20 or 23 grams Placebo (alanine) for 7 days leading up to surgery and continuing for 6 weeks after surgery [surgery = primary total knee arthroplasty]
1853497|NCT00977041|Behavioral|Neurofeedback|"Electrodes will be placed over the temporal lobes bilaterally and a ground electrode placed on the left earlobe. EEG activity will be amplified using a Procomp 2 or Nexus amplifier, and EEGer software will be used to provide subjects with feedback. Contingencies will be set such that alpha brain activity will be reinforced, and high beta and theta brain activity will be inhibited. Standard NF training procedures will be used, which involve simply asking subjects to relax while looking at the feedback screen and Do whatever is necessary to make and keep the bar wide. This protocol will be repeated for up to 40 60-minute sessions (that will include 30 minutes of NF training), scheduled at least weekly."
1853498|NCT00977054|Drug|DFPP + Peg-IFN + RBV|Double filtration plasmapheresis: day 1,2,4,8,9 from the onset of treatment (4 hours for each session) Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
1853499|NCT00977054|Drug|Peg-IFN + RBV|Peginterferon alfa-2a: week 1-48, weekly subcutaneous 180 ug Ribavirin: week 1-48, daily oral 1,000-1,200 mg (body weight < 75 kg, 1,000 mg/day; body weight loss >= 75 kg, 1,200 mg/day)
1853500|NCT00977067|Drug|GDC-0152|Intravenous escalating dose
1853501|NCT00977080|Drug|Paricalcitol|Paricalcitol dosed per label by region (participants were to receive cinacalcet if they developed hypercalcemia)
1853502|NCT00977080|Drug|Cinacalcet|On-label oral cinacalcet by region with low dose vitamin D receptor activator (VDRA) (either doxercalciferol at US sites or alfacalcidol at non-US sites)
1853503|NCT00977093|Other|Perfusion CMR for detection of coronary artery disease|Perfusion CMR is performed during adenosine infusion for vasodilation (3 minutes of 0.14mg/kg/min IV) and injection of Gd-DTPA-BMA at 0.075mmol/kg IV.
1853504|NCT00977093|Other|Perfusion cardiac magnetic resonance imaging|Perfusion CMR with Gd-DTPA-BMA to detect coronary artery disease
1853505|NCT00977106|Drug|tocilizumab [RoActemra/Actemra]|single iv infusion 8 mg/kg
1853506|NCT00977106|Drug|placebo|single iv infusion
1853507|NCT00977106|Drug|tocilizumab [RoActemra/Actemra]|iv infusion 8mg/kg every 4 weeks for 11 months
1853508|NCT00977119|Other|Side-effect questionnaires|Paper or telephone questionnaire to report specific side-effects associated with their breast cancer treatment weekly
1853509|NCT00977119|Other|research blood samples|Blood samples for research on DNA before starting treatment and after 4 cycles of treatment
1853510|NCT00977132|Drug|Valproic aicd|"Treatment with VPA starts at day1, the dose ist slowly increase according to the following scheme
day morning dose midday dose evening dose contents of 1 tablet
1+2 0 0 1 500 mg
3+4 ½ 0 1 500 mg
5+6 1 0 1 500 mg
7+8 1 ½ 1 500 mg
9+10 1 1 1 500 mg
11+12 1 1 1 500 mg
In the morning of day 13 trough level of VPA will be checked. The target range will be 50-110 µg/l. The dose of VPA will be adjusted depending on the trough level. In the first eight weeks of therapy weekly controls of VPA levels are required. Thereafter, VPA levels will be checked every four weeks."
1853511|NCT00977132|Drug|Lenalidomide|"5 mg/day, continuous therapy
Dosing will be in the morning at approximately the same time each day. Capsules may be taken before or after a meal.
Only one cycle of study drug (28 days) will be supplied to the patient every four weeks"
1853512|NCT00977145|Biological|A combination of intratumoral IFN-gamma plus systemic vaccination with MELITAC 12.1|"Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, 15. During cycle two, three vaccines will be administered over a 9-week period on days 24, 43, 64. All participants will receive 12-MP (100 mcg each peptide) plus Peptide-tet (Peptide-tet; 200 mcg) administered in Montanide ISA-51 VG adjuvant. The vaccine will be administered subcutaneously (1 ml) and intradermally (1ml) at a single vaccination site.
Intratumoral Interferon regimen: On day 22, patients will have one or more tumor sites injected with 0.5-2 million IU of IFN-gamma each, with a maximum dose of 2 million IU of IFN-gamma administered per patient. The number of lesions that are injected will be dependent on the availability and size of the lesions."
1853513|NCT00977158|Procedure|Throat Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the throat and processed for bacterial cultures and for bacterial DNA extraction.
1853514|NCT00977171|Drug|Droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes up to a 2 week titration period followed by a 12 week treatment period
1853515|NCT00977184|Procedure|50 HZ Repetitive TMS|
1853516|NCT00977184|Procedure|Sham rTMS|
1853517|NCT00977197|Drug|Pregabalin|Dose: 75 mg twice a day for three days, increasing to 150 mg (2 tablets) twice a day for three days, escalating to 225 mg (three tablets) twice a day, through week 12, day 1. Days 2-4 of week 12, participants will begin tapering and will receive 150 mg (two tablets) two times a day and then days 5-7, participants will receive 75 mg two times a day for the duration of the study.
1853518|NCT00977197|Drug|Placebo|A matching placebo will be administered twice a day
1853519|NCT00977210|Drug|OXi4503|OXi4503 will be administered weekly for 3 weeks followed by a week with no treatment. The starting dose will be 0.06 mg/m2 given as an intravenous infusion over 10 minutes.
1853520|NCT00977223|Drug|aprepitant/placebo|Aprepitant, 125 MG at day 1 then 80 MG day 2-7, once a day, per os, at 8 AM during breakfast
1853521|NCT00977236|Device|Orthokeratology lenses|Nightly use of orthokeratology to correct the refractive error and over-specs for a period of two years
1853522|NCT00977236|Device|Single-vision spectacle lenses|Daily use of spectacles to correct the refractive error for a period of two years
1853523|NCT00977249|Behavioral|support and visits|visits at weeks 0,2,4,6,9 and 12 and 12 months
1853524|NCT00977249|Drug|varenicline|
1853525|NCT00977249|Drug|placebo|
1853526|NCT00977262|Other|High saturated fat shake|milkshake containing 95 gram of fat, high percentage of saturated fat
1853527|NCT00977262|Other|High monounsaturated fat shake|milkshake containing 95 gram of fat, high percentage of monounsaturated fat
1853528|NCT00977262|Other|High polyunsaturated fat shake|milkshake containing 95 gram of fat, high percentage polyunsaturated fat
1853529|NCT00977275|Radiation|Interstitial Implant Brachytherapy|Via tubes placed at the time of wide local excision delivered over 5 days
1853530|NCT00977288|Drug|anacetrapib|10, 40 or 100 mg tablet of MK0859 , once daily for 8 weeks
1853531|NCT00977288|Drug|Comparator: atorvastatin|atorvastatin tablet, 10mg, once daily for 8 weeks
1853532|NCT00977288|Drug|Comparator: Placebo|Placebo tablet, once daily for 8 weeks
1853539|NCT00977327|Device|Intraoperative MR (PoleStar N-20, Medtronics)|intraoperative imaging for resection control of intraaxial brain lesions
1853540|NCT00977327|Device|Intraoperative Ultrasound (Sonowand, Mison)|intraoperative imaging for resection control of intraaxial brain lesions
1853541|NCT00977340|Behavioral|Imagery Rehearsal Treatment|Imagery Rehearsal Therapy
1853542|NCT00977340|Behavioral|confrontation|Confrontation
1853543|NCT00977340|Behavioral|imagination|Imagination
1853544|NCT00977353|Drug|citalopram|20-60 mg/day, oral, for 6 weeks
1853545|NCT00977353|Drug|sarcosine|500-1500 mg/day, oral, for 6 weeks
1853546|NCT00977366|Other|Hydrochloric acid (0.15 molar)|Hydrochloric acid (0.15 molar) will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
1853547|NCT00977366|Other|Saline|Normal saline will be infused in to the lower oesophagus through a distal infusion port located at the tip of an oesophageal stimulation catheter.
1853548|NCT00977379|Radiation|WBRT|3000 cGy WBRT in 10 single daily fractions over 12 to 14 days (300 cGy / fraction).
1853549|NCT00977379|Drug|Capecitabine|825 mg/m^2 orally twice daily, Days 1-14 of a 21 day cycle for 1 cycle followed by 1000 mg/m^2 orally twice daily Days 1-14 every 21 days starting with Cycle 2.
1853550|NCT00977379|Drug|Standard of Care|The choice of standard of care will be at the discretion of the treating oncologist. The protocol does not specify any particular standard of care treatment.
1853551|NCT00977392|Behavioral|compliance monitoring|
1853552|NCT00977392|Other|cervical Papanicolaou test|
1853553|NCT00977392|Other|educational intervention|
1853554|NCT00977392|Other|screening questionnaire administration|
1853555|NCT00977392|Other|survey administration|
1853556|NCT00977392|Procedure|colposcopy|
1853557|NCT00977405|Device|Collatamp Gentamicin Implant|Collatamp Gentamicin placed into subcutaneous layer of dirty abdominal wounds
1853558|NCT00977418|Behavioral|SMART- Strategic Memory and Reasoning Training|Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
1853559|NCT00977418|Other|Physical Exercise|The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
1853560|NCT00977431|Drug|Temozolomide|During RT: 75 mg/m2 daily , 4 weeks after RT: given days 1 to 5 of 28 day cycles (150 mg/m2 in cycle 1, 200 mg/m2 in cycle 2 up to cycle 6)
1853561|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
1853562|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period, fixed dose after RT
1853563|NCT00977431|Procedure|Radiotherapy|Day 1 to day 42
1853564|NCT00977431|Drug|BIBW2992|Escalating dose cohorts during Radiotherapy(RT) period , fixed dose after RT
1853565|NCT00977444|Drug|kondrium|intraarticular injections once month
1853566|NCT00977444|Drug|kondrium f|intraarticular injections once month
1853567|NCT00977444|Drug|methyl prednisolone (corticosteroid)|intraarticular injections once month
1853575|NCT00977470|Drug|Erlotinib|150 mg taken orally once daily
1853576|NCT00977470|Drug|Hydroxychloroquine|1000 mg taken orally once daily after erlotinib
1853577|NCT00977483|Drug|Thioctic Acid|600mg tablet once daily 4 years double-blind treatment period
1853578|NCT00977483|Drug|Placebo|1 tablet once daily 4 years double-blind treatment period
1853579|NCT00977496|Procedure|Nasal Swab|Swabs will be moistened in sterile 0.9% sodium chloride solution and rotated in the anterior vestibule of both nares and processed for S aureus cultures and for bacterial DNA extraction.
1853580|NCT00977522|Drug|PF-03463275|30 mg Controlled Release tablet BID for 12 weeks
1853581|NCT00977522|Drug|Placebo|Placebo tablet BID
1853582|NCT00977548|Drug|Erlotinib|Participants took erlotinib at least 1 hour before, or 2 hours after they ate a meal or snack. Participants were advised to take erlotinib at around the same time every day.
1853583|NCT00977561|Drug|figitumumab|Figitumumab (20 mg/kg)
1853584|NCT00977561|Drug|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
1853585|NCT00977561|Drug|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
1853586|NCT00977561|Drug|Cisplatin (Or Carboplatin)|Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
1853587|NCT00977561|Drug|Etoposide|Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
1853594|NCT00977587|Drug|Saccharomyces Cerevisiae CNCM I-3856|Saccharomyces cerevisiae CNCM I-3856, 500 mg per capsule (5 X109 living cells). Living cells are estimated by the method of colony forming units (cfu).subjects will take 1 capsule twice a day
1853595|NCT00977587|Drug|placebo|"Placebo: Capsules will contain 500 mg of the following formulation and will not contain Saccharomyces cerevisiae CNCM I-3856:
Calcium phosphate, Dibasic 472.0 mg
Maltodextrin DE14 112.1 mg
Vegetal magnesium stearate 5.9 mg subjects will take one capsule twice a day"
1853596|NCT00977600|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as Buphenyl. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbutyric acid (PBA). PBA is converted to phenyl acetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA that 40 tablets of NaPBA do.
1853597|NCT00977600|Drug|Ammonul|
1853598|NCT00977600|Drug|Buphenyl|
1853599|NCT00977613|Behavioral|exercise counseling|motivational counseling to exercise a minimum 18 metabolic hours per week
1853600|NCT00977626|Drug|Part 1 - AZD2423 or Placebo|AZD2423 Oral Solution, multiple dosing during 10-14 days or Placebo Oral Solution, multiple dosing during 10-14 days
1853601|NCT00977626|Drug|Part 2 - AZD2423|AZD2423 Oral solution, multiple dosing
1853602|NCT00977626|Drug|Part 3 - AZD2423|AZD2423 Oral solution, single dosing or AZD2423 Oral solution, single dosing - With Food or AZD2423 Oral solution, single dosing - Fasting Condition.
1853603|NCT00977639|Procedure|Pathwork TOO test|
1853604|NCT00977652|Procedure|active stimulation|percutaneous posterior tibial nerve stimulation with following parameters: frequency: 14hz; impulse duration: 210usec;intensity:sensibility threshold during 3 months
1853605|NCT00977652|Procedure|sham stimulation|Same location with the same device than active stimulation but amplitude of stimulation = 0
1853606|NCT00977665|Drug|rasagiline mesylate|rasagiline 1 mg tablet/day for 48 weeks
1853607|NCT00977665|Drug|placebo|placebo tablet for 48 weeks
1853608|NCT00977678|Other|open access gastroscopy|access to gastroscopy without preceding appointment
1853609|NCT00977678|Other|Gastroscopy by appointment|Gastroscopy after preceding appointment in a conventional outpatient clinic
1853615|NCT00977704|Device|Restylane and Perlane|
1853616|NCT00977730|Dietary Supplement|Protandim|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
1853617|NCT00977730|Dietary Supplement|Placebo|1 675 mg capsule Protandim PO/day vs. 1 sugar pill PO/day
1853618|NCT00977756|Drug|Raltegravir (RAL)|400 mg twice daily (BID)
1853619|NCT00977756|Drug|Atazanavir (ATV)|300 mg daily
1853620|NCT00977756|Drug|Ritonavir (RTV)|100 mg daily, dosing by weight in Group I
1853621|NCT00977756|Drug|Tenofovir (TDF)|300 mg daily
1853622|NCT00977756|Drug|Etravirine (ETV)|200 mg BID
1853623|NCT00977756|Drug|Darunavir (DRV)|Dosing by weight
1853624|NCT00977756|Drug|Maraviroc (MVC)|150 mg BID in groups J and K; 600 mg BID in group L
1853625|NCT00977756|Drug|Lopinavir/ritonavir (LPV/r)|Coformulation of 400 mg lopinavir and 100 mg ritonavir, taken twice daily
1853626|NCT00977769|Drug|carbetocin 100 µg|Hemodynamic effect of
1853627|NCT00977769|Drug|oxytocin 5 u|Hemodynamic effect of
1853628|NCT00977769|Drug|placebo (NaCl)|Hemodynamic effect of
1853629|NCT00977795|Drug|5-aminolevulinic acid|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
1853630|NCT00977808|Device|Closed-Loop, Model Predictive Control (MPC)|Subjects used the OmniPod Insulin Management System (Insulet Corp.) and Insulin lispro (Eli Lilly, Indianapolis, IN). MPC algorithm suggested insulin boluses every 15 min, which, if accepted, were programmed into the insulin pump by the attending physician. Otherwise, the admission remained the same as in the open-loop admission (i.e. meals, sleep, etc...).
1853631|NCT00977808|Device|Open-Loop|This admission was to assess the subjects' level of glucose control and created a base to compare the performance of the closed-loop system. Subjects monitored their own blood glucose values and administer their basal/bolus as they would at home. Subjects used their own insulin pumps and Insulin lispro (Eli Lilly, Indianapolis, IN). Otherwise, the admission remained the same as in the closed-loop admission (i.e. meals, sleep, etc...).
1853632|NCT00977821|Other|IVF|
1853633|NCT00977821|Other|Oocyte Vitrification|
1853634|NCT00977847|Other|Electronic Health Portals for collecting Family History data|Comparison of multiple portals for integrating patient generated family history data into the electronic health record.
1853635|NCT00977860|Radiation|Stereotactic Body Radiation Therapy|36.25 Gy in 5 fractions (7.25 Gy/fx) delivered over a 2-week period
1853636|NCT00977873|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
1853637|NCT00977873|Dietary Supplement|Miglyol oil|Miglyol oil will be administered in 2-monthly bolus doses over a period of one year
1853638|NCT00977886|Drug|Placebo|Oral, 10 days
1853639|NCT00977886|Drug|ELB353|Oral, 10 days
1853640|NCT00977899|Biological|Malaria Transmission-Blocking Pfs25-Pfs25 Conjugate Vaccine|
1853641|NCT00977912|Dietary Supplement|Probiotic supplementation|one capsule containing probiotics per day added to milk
1853642|NCT00977912|Dietary Supplement|Milk containing placebo|one capsule containing placebo per day added to milk
1853643|NCT00977925|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
1853644|NCT00977925|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control severe bleeding.
1853645|NCT00977938|Drug|Placebo & Aspirin|
1853646|NCT00977938|Drug|Clopidogrel & Aspirin, Prasugrel & Aspirin|
1853647|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
1853648|NCT00977951|Drug|Intradermal avotermin|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
1853649|NCT00977951|Drug|Placebo (vehicle)|Placebo administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 3 and again on day 4
1853735|NCT00978458|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 5½ weeks
1853650|NCT00977951|Drug|Placebo|50 ng/100 ul avotermin administered intradermally prior to wounding (day 0) and again 24 h later on day 1. Wounds were dosed again prior to wound excision on day 5 and again on day 6
1853651|NCT00977964|Other|Experimental milk protein infant formula Process A|ad lib for 1-8 days of age until 28 days of age
1853652|NCT00977964|Other|Experimental milk protein infant formula Process B|ad lib from 1-8 days of age until 28 days of age
1853653|NCT00977964|Other|Experimental milk protein infant formula Process C|ad lib from 1-8 days of age to 28 days of age
1853654|NCT00977964|Other|Experimental milk protein infant formula Process D|ad lib from 1-8 days of age until 28 days of age
1853655|NCT00977964|Other|Experimental milk protein infant formula Process E|ad lib from 1-8 days of age until 28 days of age
1853656|NCT00977964|Other|Experimental milk protein infant formula Process F|ad lib from 1-8 days of age until 28 days of age
1853659|NCT00978016|Drug|arbaclofen placarbil-Cohort 1|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
1853660|NCT00978016|Drug|Placebo-Cohort 5|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (placebo) for 7 weeks including titration and taper periods
1853661|NCT00978016|Drug|arbaclofen placarbil-Cohort 2|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
1853662|NCT00978016|Drug|arbaclofen placarbil-Cohort 3|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
1853663|NCT00978016|Drug|arbaclofen placarbil-Cohort 4|After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
1853664|NCT00978016|Drug|PPI|Allowable PPIs : Rabeprazole Sodium 20 mg QD, Esomeprazole Magnesium 20 mg or 40 mg QD, Lansoprazole 15 mg or 30 mg QD, Pantoprazole 20 mg or 40 mg QD, Omeprazole 20 mg or 40 mg QD, Omeprazole/sodium bicarbonate 20 mg or 40 mg QD, Dexlansoprazole 30 mg or 60 mg QD
1853665|NCT00978029|Drug|Placebo|Placebo sublingual tablet, once daily
1853666|NCT00978029|Biological|SCH 39641|Allergy immunotherapy tablet (sublingual)
1853667|NCT00978029|Biological|SCH 39641|Allergy immunotherapy tablet (sublingual)
1853668|NCT00978042|Device|Juvéderm® VOLUMA XC|Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
1853669|NCT00978055|Drug|1: Liothyronine Sodium Tablets|"Liothyronine Sodium Tablets, 50 mcg
2 x 50 mcg, single-dose, fasting"
1853670|NCT00978055|Drug|2: Cytomel® Tablets|"Cytomel® Tablets, 50 mcg
2 x 50 mcg, single-dose, fasting"
1853673|NCT00978081|Drug|aminolevulinic acid hydrochloride|Patients undergo continuous or fractionated photodynamic therapy.
1853674|NCT00978107|Biological|MVA-FCU1, flucytosine|"TG4023: single IT injection; possibility to re-administer once,
Percutaneous IT injections, under radiological or ultrasound imaging guidance
Dose-escalating schedule of administration: 107 pfu (Cohort #1), 108 pfu (Cohort #2) and 4x108 pfu (Cohort #3),
MTD injected to up to 3 different lesions (Cohort #4)
5-FC (5-fluorocytosine)/flucytosine
Dose and dosing schedule:
Daily starting dose of 200 mg/kg; daily dose will be adjusted after measurement of 5-FC plasma concentration at steady state, which should be kept below 100 mg/L
Duration: 2 weeks.
Possible routes of administration:
PO: 500 mg tablets, qid
IV: 1% 250 mL vials, 45-minute infusions."
1853675|NCT00978120|Biological|H1N1 vaccine high dose|30 mcg of unadjuvanted Novartis H1N1 vaccine delivered as two, 15 micrograms (mcg), intramuscular injections. Each 30 mcg dose is administered 21 days apart.
1853676|NCT00978120|Biological|H1N1 vaccine low dose|15 mcg of unadjuvanted Novartis H1N1 vaccine delivered in two intramuscular injections 21 days apart
1853677|NCT00978133|Procedure|Dermabond ProPen (2-octylcyanoacrylate)|Application of 2 layers of Dermabond to abdominal wounds after closure of deep layers
1853678|NCT00978133|Procedure|Skin closure with skin staples|Skin closure with skin staples
1853679|NCT00978146|Drug|Hydroxyurea|Patients will take oral hydroxyurea with a starting dose of 20 mg/kg daily. Patients will remain on hydroxyurea as long as there is a response or stability in tumor size and associated toxicities are manageable. Maximum treatment duration will be one year.
1853680|NCT00978159|Drug|esomeprazole|esomeprazole 20 mg po for 4 weeks
1853681|NCT00978159|Drug|Famotidine|Famotidine 40 mg po for 4 weeks
1853682|NCT00978172|Drug|artesunate and mefloquine|artesunate (50 mg/day) and mefloquine (125 mg/day) fixed dose formulation (stick pack) once daily for 3 consecutive days, orally
1853683|NCT00978185|Other|medical chart review|
1853684|NCT00978185|Other|questionnaire administration|
1853685|NCT00978185|Procedure|acupressure therapy|
1853686|NCT00978185|Procedure|quality-of-life assessment|
1853687|NCT00978185|Procedure|sham intervention|
1853688|NCT00978185|Procedure|standard follow-up care|
1853689|NCT00978198|Drug|ASP1517|oral
1853690|NCT00978198|Drug|Placebo|oral
1853736|NCT00978471|Drug|Thiotepa|Thiotepa 8-12mg/m²/day/injection Total dose for one cure:15-50mg.
1993577|NCT03174119|Device|Light therapy - active|Active light will be used for one week, as compared to placebo light.
1993578|NCT03174119|Device|Placebo light|Placebo light will be used for one week, as compared to real light exposition.
1993579|NCT03172494|Drug|Insulin degludec/liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.
For 26 weeks."
1993580|NCT03172494|Drug|Insulin degludec|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.
For 26 weeks."
1993581|NCT03172494|Drug|Liraglutide|"Subcutaneously (s.c., under the skin)administration once daily in combination with metformin.
For 26 weeks."
1853691|NCT00978211|Drug|DOTA-TOC Treatment|"Intravenous injections of DOTA-TOC. Repeated treatment cycles for responders, except in case of
renal toxicity
loss of patient transferability or
denial of further treatment."
1853692|NCT00978224|Dietary Supplement|Viusid|3 Viusid bags (Orally administered) per day, for 60 weeks
1853693|NCT00978224|Dietary Supplement|Placebo|3 Placebo bags (Orally administered) per day, for 60 weeks.
1853694|NCT00978237|Drug|EFV|one pill QD VO.
1853695|NCT00978237|Drug|LPV/r|2 pills QD VO
1853696|NCT00978250|Drug|5-Fluoro-2-Deoxycytidine (FdCyd)|FdCyd, a fluoropyrimidine nucleoside analog, has a short (10-minute) half-life and is rapidly degraded in vivo by cytidine deaminase. However, co-administration with THU, an inhibitor of cytidine/deoxycytidine deaminase, has been shown to increase the AUC of the pare compound more than 4-fold. Increased FdCyd exposure allows it to be taken up intracellularly and converted to its triphosphate, which is incorporated into DNA and inhibits the action of the enzyme DNA methyltransferase (DNMT). Inhibition of DNM and in turn DNA methylation,can result in the re-expression of tumor suppressor genes.
1853697|NCT00978250|Drug|Tetrahydrouridine (THU)|
1853698|NCT00978263|Drug|metformin-based Oral Antidiabetic Drugs|
1853699|NCT00978263|Drug|Glargine|
1853700|NCT00978302|Drug|Avotermin|Intradermal injection, 50ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
1853701|NCT00978302|Drug|Avotermin|Intradermal injection, 100ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
1853702|NCT00978302|Drug|Avotermin|Intradermal injection, 500ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
1853703|NCT00978302|Drug|Avotermin|Intradermal injection, 1000ng/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
1853704|NCT00978302|Drug|Avotermin|Intradermal injection, 1μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
1853705|NCT00978302|Drug|Avotermin|Intradermal injection, 10μg/100μl/3mm punch biopsy, once at time of biopsy and again 24 h later
1853706|NCT00978302|Drug|Placebo (vehicle)|Intradermal injection at time of biopsy and again 24 h later
1853707|NCT00978315|Dietary Supplement|Cholecalciferol|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
1853708|NCT00978315|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
1853709|NCT00978328|Drug|oxycodone immediate release (OXYRX)|Characteristics of pts. receiving prescription medications containing OXYRX
1853710|NCT00978341|Drug|Pregabalin|Pregabalin 150mg capsules BID for 7.5 days
1853711|NCT00978341|Drug|Placebo for pregabalin|Placebo capsules BID for 7.5 days
1853712|NCT00978354|Drug|Furosemide|Continuous intravenous infusion of furosemide titrated to urine output
1853713|NCT00978354|Drug|Normal Saline|Continuous intravenous infusion 0.9% normal saline placebo control
1853714|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
1853715|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
1853716|NCT00978367|Drug|Avotermin|5 ng or 50 ng/100 ul avotermin applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
1853717|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on day 5 just prior to excision of the wound with a 5 mm surgical ellipse
1853718|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1 and 2. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6 and 7.
1853719|NCT00978367|Drug|Placebo|Placebo applied by intradermal injection to one of two 3 mm punch biopsies on each arm just prior to surgery (on day 0) and again on days 1, 2, 3 and 4. Dosing is repeated on day 5 (just prior to excision of the wound with a 5 mm surgical ellipse), 6, 7, 8 and 9.
1853720|NCT00978380|Drug|catridecacog|Monthly administration of recombinant factor XIII as preventative treatment of bleeding episodes. Dose: 35 IU/kg body weight intravenous (into the vein)
1853721|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
1853722|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
1853723|NCT00978393|Drug|liraglutide|Low dose liraglutide treatment (1.8 mg) followed by high placebo treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
1853724|NCT00978393|Drug|liraglutide|High placebo treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
1853725|NCT00978393|Drug|liraglutide|High dose liraglutide treatment (3.0) followed by low placebo treatment (1.8 mg). Injected s.c. (under the skin) once daily in the evening.
1853726|NCT00978393|Drug|liraglutide|Low placebo treatment (1.8 mg) followed by high dose liraglutide treatment (3.0 mg). Injected s.c. (under the skin) once daily in the evening.
1853727|NCT00978419|Drug|Rosuvastatin|Loading dose 40mg by mouth first day, then 20 mg by mouth for up to 27 days
1853728|NCT00978419|Drug|Placebo|Placebo administered every day for up to 28 days
1853729|NCT00978432|Drug|RAD001|10 mg/day for Part 1 of the trial
1853730|NCT00978432|Drug|LBH589|40 mg on Monday, Wednesday and Friday weekly for Part 1 of the trial
1853731|NCT00978432|Drug|Doublet (RAD001 and LBH589)|RAD001 7.5 mg by mouth daily and LBH589 15 mg by mouth on Monday/Wednesday/Friday during Part 2.
1853732|NCT00978445|Other|vMetrics protocol|use vmetrics protocol and device or use standard in clinic monitoring
1853733|NCT00978458|Drug|temozolomide|Given orally
1853734|NCT00978458|Radiation|3-dimensional conformal radiation therapy|Given once daily 5 days a week for 5½ weeks
1853737|NCT00970580|Drug|BIIB022 With Paclitaxel and Carboplatin|Escalating doses of BIIB022 with fixed dose and schedule of paclitaxel and carboplatin
1853738|NCT00978484|Behavioral|Virtual Reality Exposure Therapy - Dynamic|10 weeks of Virtual Reality Exposure using full, immersive VR
1853739|NCT00978484|Behavioral|Augmented Exposure Therapy|Exposure Therapy augmented with a still computer image
1853740|NCT00978497|Drug|placebo|oral BID
1853741|NCT00978497|Drug|ANA598|oral 200mg BID
1853742|NCT00978497|Drug|ANA598|oral 400mg BID
1853743|NCT00978497|Drug|Peginterferon|180 μg dose via subcutaneous injection weekly
1853744|NCT00978497|Drug|Ribavirin|oral 1000 mg/day for patients who weighed < 75 kg and 1200 mg/day for patients who weighed ≥ 75 kg
1853745|NCT00978523|Drug|AR-12: (2-Amino-N-[4-[5-(2 phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl] phenyl]-acetamide)|Oral, dose-escalation
1853746|NCT00978536|Other|Cognitive impairment of multiple sclerosis|Patients will get a lumbar puncture in order to measure the biomarkers in the CSF, a neuropsychological exam, an evaluation of the hippocampal volume by MRI and a cerebral scintigraphy.
1853747|NCT00978549|Drug|docetaxel|
1853748|NCT00978549|Drug|steroid therapy|
1853749|NCT00978549|Other|questionnaire administration|
1853750|NCT00978549|Procedure|nausea and vomiting therapy|
1853751|NCT00978549|Procedure|pain therapy|
1853752|NCT00978549|Procedure|quality-of-life assessment|
1853753|NCT00978549|Procedure|standard follow-up care|
1853754|NCT00978549|Radiation|radiation therapy|
1853755|NCT00978562|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Undergo DCE-MRI
1853756|NCT00978562|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Undergo DSC-MRI
1853757|NCT00978562|Drug|Ferumoxytol Non-Stoichiometric Magnetite|Given IV
1853758|NCT00978562|Drug|Gadolinium|Given IV
1853759|NCT00978575|Drug|ferricarboxymaltose|Single dose of maximum 1000 mg ferricarboxymaltose intravenous
1853760|NCT00978575|Drug|Ferrosulfate|200mg daily for 12 weeks
1853761|NCT00978575|Drug|Placebo|100 mg isotonic sodium and 2 placebo tablets daily
1853762|NCT00978588|Drug|6% hydroxyethyl starch 130/0.4 and 5% albumin|Injection of 6% hydroxyethyl starch 130/0.4 and 5% albumin as priming solution for cardiopulmonary bypass
1853763|NCT00978601|Procedure|Multimodal analgesic protocol during minimally invasive myomectomy|Multimodal and preemptive analgesia using 8 mg of Dexamethasone iv,trocar ports infiltration with 5 mL of a local anesthetic, consisting of 0.26% ropivacaine HCL (7.5 mg/mL) and 0.74% of 0,9 % sodium chloride, before the skin incision. About 10 minutes before the surgery is completed, 4 mg Ondansetron iv and a mixture of 75 mg diclofenac and 600 mg of paracetamol intramuscularly (im) are administered.
1853764|NCT00978614|Drug|Neramexane|"Dosage form:
25 mg immediate release [IR] tablets (=15.9 mg neramexane free base)
37.5 mg IR tablets (=23.9 mg neramexane free base)"
1853765|NCT00978627|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily with a meal. Dose was individually adjusted.
1853766|NCT00978627|Drug|insulin detemir|Injected subcutaneously (under the skin) once daily or twice daily. Dose was individually adjusted.
1853767|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) at the remaining meals. Dose was individually adjusted.
1853768|NCT00978627|Drug|insulin aspart|Injected subcutaneously (under the skin) as meal time insulin. Dose was individually adjusted.
1853769|NCT00978640|Other|fast and exercise|fasting 36 h and exercise 1 h 50% VO2max
1853770|NCT00978640|Other|exercise|exercise 1 h 50% VO2max
1853771|NCT00978653|Drug|allopurinol|150 mg once a day
1853772|NCT00978679|Device|Orthokeratology lenses|Nightly use of orthokeratology lenses to correct the refractive errors
1853773|NCT00978679|Device|Spectacles|Daily use of single vision lenses to correct refractive errors
1853774|NCT00978692|Device|Toric Orthokeratology lenses|Children wearing toric orthokeratology at night for correcting astigmatism and myopia will be the study group
1853775|NCT00978692|Device|Single-vision spectacles|Children wearing single-vision spectacles in the daytime for correcting the refractive errors will serve as the control group
1853776|NCT00978705|Drug|Autologous cultured keratinocyte cell|3x10^7 cell/ vial
1853777|NCT00978718|Dietary Supplement|high-selenium baker's yeast|Given orally
1853778|NCT00978718|Dietary Supplement|selenium|Given orally
1853779|NCT00978718|Other|placebo|Given orally
1853780|NCT00978731|Drug|Dasatinib|"Tablets, Oral, The dosing ranges from 50mg to a total of 240mg daily with the following 3 schedules:
5 days on, 2 days off
6 days on, 1 day off
Continuous daily dosing
Once Daily (QD) or Twice Daily (BID) dosing, Subjects will be treated until progression of disease despite escalation/reductions of dose to the level deemed safe by available data, until intolerable/unacceptable toxicity or until subject withdrawal from the study or discontinuation of the study"
1853781|NCT00978757|Drug|Ketamine|Ketamine: 0.25 mg/kg, intravenously, one dose.
1853782|NCT00978757|Other|Placebo|saline solution
1853783|NCT00978770|Drug|systemic chemotherapy|
1853784|NCT00978770|Procedure|diffusion-weighted magnetic resonance imaging|
1853785|NCT00978770|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1853786|NCT00978770|Procedure|magnetic resonance spectroscopic imaging|
1853787|NCT00978770|Procedure|neoadjuvant therapy|
1853788|NCT00978783|Device|Passy Muir Valve|The Passy Muir Valve was fixed on the tracheostomy tube
1853789|NCT00978783|Device|Positive end expiratory pressure|5 cm H2O PEEP was adjusted
1997295|NCT02145026|Drug|Epoetin beta|Epoetin beta 30,000 or 60,000 IU per week SC injection
1853792|NCT00978809|Other|Epley maneuver|
1853793|NCT00978809|Other|Semont maneuver|
1853794|NCT00978887|Other|Retorna|Dosage commensurate with surface to be treated, Retorna facial cream (Topical use), twice a day, for 4 weeks.
1853795|NCT00978887|Other|Placebo|Dosage commensurate with surface to be treated, Placebo facial cream (Topical use), twice a day, for 4 weeks
1853879|NCT00979602|Biological|GSK2340273A|One intramuscular injection
1853796|NCT00978900|Dietary Supplement|Artificial sweeteners; Carbohydrate Sugars|sweetening agent dissolved in tap water, administered via intragastric tube
1853797|NCT00978900|Dietary Supplement|Water|
1853798|NCT00978913|Biological|DC vaccine|DC vaccination, one vaccine biweekly
1853799|NCT00978939|Other|Standard Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid every other day
1853800|NCT00978939|Other|Aggressive Drainage Instructions|Patients will receive specific instructions to drain up to 1 liter of pleural fluid daily
1853801|NCT00978952|Device|Large Diameter Advanta™ V12 Covered Stent|Stent placement
1853802|NCT00978965|Genetic|MPA SNP|Functional relevant MPA SNP will be sought in patients DNA isolated from leucocytes
1853803|NCT00978978|Drug|Propofol VS. midazolam and fentanyl, endoscopies, liver diseases|"Intervention group (Propofol): It will be administered as a monotherapy under direct gastroenterologists'
Control group (Midazolam with or without Fentanyl): Both drugs will be administered by the gastroenterologists"
1853804|NCT00979004|Drug|ICA-105665|Oral tablet. Dose forms of 50 and 100 mg or placebo will be used. A single dose will be administered that can range from placebo or 100 to 600 mg.
1853805|NCT00979017|Drug|Avastin|Avastin, by intravenous infusion, 10 mg/kg every 14 days
1853806|NCT00979017|Drug|Temozolomide|Oral temozolomide at 200 mg/m2 daily for 5 days
1853807|NCT00979017|Drug|Irinotecan|Irinotecan, by intravenous infusion, every other week (dose dependent upon if taking enzyme-inducing anti-epileptic drugs or if a blood test indicates the patient has the UGT 1A1 polymorphism)
1853808|NCT00979043|Behavioral|Dietary Weight-loss|The goal of the dietary weight-loss intervention was to produce and maintain a mean weight-loss of 5% initial body weight during the 18-month intervention, using dietary counseling and behavior modification.
1853809|NCT00979043|Behavioral|Exercise|Participants participated in resistance training (15 minutes) and aerobic exercise (30 minutes) 3d/week for 18-months. The first 4-months of the exercise training were facility-based. After 4-months, participants were allowed to transition to a home-based intervention if they chose to.
1853810|NCT00979056|Drug|Rifaximin|400 mg per day, oral use, maximum duration 28 days
1853811|NCT00979056|Drug|Lactose|Coated Tablet, Oral Use
1853812|NCT00979069|Behavioral|Aerobic group|12 weeks of aerobic exercise 3 times a week
1853813|NCT00979108|Other|Physical therapy rehabilitation|Mechanical cervical traction will be applied at a moderate force and adjusted based on symptom relief. In addition, subjects will be trained in cervical and postural exercises.
1853814|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in use of an over-the-door traction unit utilizing weights up to 20 pounds in sitting. In addition, subjects will be trained in neck and postural exercises.
1853815|NCT00979108|Other|Physical therapy rehabilitation|Subjects will be instructed in neck and postural exercises.
1853816|NCT00979121|Drug|Rosuvastatin|Subjects received an initial 40mg loading dose followed by 20 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study hospital.
1853817|NCT00979121|Drug|Placebo|Subjects received placebo by mouth or feeding tube daily for 28 days or until discharged from study hospital.
1853821|NCT00979147|Procedure|TKA surgery with modular polished tibial baseplate/XLK design|TKA surgery with modular polished tibial baseplate/XLK design
1853822|NCT00979147|Procedure|TKA surgery with the nonmodular APT/GVF design|TKA surgery with the nonmodular APT/GVF design
1853823|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C.® Sigma Knee System with modular XLK poly
1853824|NCT00979147|Device|P.F.C.® Sigma Knee System|P.F.C. ® Sigma Knee System with an all-poly GVF tibia
1853825|NCT00979160|Drug|Dasatinib|Starting dosage 20mg once daily, that can be escalated up to 100mg once daily. Patient will remain on treatment for 12 months.
1853826|NCT00979173|Drug|AC480|Subjects will be initiated on AC480 300mg orally BID for 14 (+/-2 days) before surgery. After surgery, subjects will continue to be dosed with AC480 until either disease progression or intolerance, and will be evaluated every other cycle (i.e., every 4 weeks).
1853827|NCT00979186|Device|NOTES GEN 1 Toolbox|Articulating Hook Knife, Articulating Snare, Articulating Needle Knife Articulating Graspers, Articulating Biopsy Forceps, Steerable Flex Trocar with Rotary Access Needle, Flexible Bipolar Hemostasis Forceps, Flexible Maryland Dissector, and Tissue Apposition System.
1853828|NCT00979199|Other|Non invasive cardiac imaging|Non invasive cardiac imaging consists of CTCA combined with one Stress Imaging Test
1853829|NCT00979212|Drug|panitumumab|Induction: 2.5 mg/kg, IV, days 1, 8, 15, 22, 29, 36 of radiation therapy before administration of chemotherapy and radiation therapy.
1853830|NCT00979212|Drug|carboplatin|Induction: AUC=2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, AUC=6, IV, days 1 and 22.
1853831|NCT00979212|Drug|paclitaxel|Induction: 50 mg/m2, IV, days 1, 8, 14, 22, 29, and 36 of radiation therapy. Consolidation, 6-12 weeks following surgery, 200 mg/m2, IV, days 1 and 22.
1853832|NCT00979212|Procedure|surgery|A lobectomy or pneumonectomy performed 4-6 weeks after completion of induction chemoradiation
1853833|NCT00979225|Other|Medication Management report|Patients receive medication management reports delivered to their clinic-based caregivers for pharmacotherapy clinical decision support at point-of-care.
1853834|NCT00979225|Other|Care manager email notices|Community-based care managers receive email notices if the patient has not seen his/her primary care provider in the past 6 months, has low adherence to medications, and has no scheduled appointment.
1853835|NCT00979238|Genetic|Gene Transfer|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant
1853836|NCT00979238|Drug|scAAV2/8-LP1-hFIXco|Peripheral vein infusion of scAAV2/8-LP1-hFIXco vector once per participant.
1853837|NCT00979251|Drug|Oseltamivir Phosphate|Oseltamivir Phosphate, q8h
1853838|NCT00979251|Drug|ADS-8902|Amantadine Hydrochloride, Ribavirin administered with Oseltamivir Phosphate, q8h
1853880|NCT00979615|Drug|Olopatadine HCL (Patanase) Nasal Spray, 0.6%|2 sprays/ nostril BID
1853839|NCT00979264|Behavioral|Intensive quality improvement tools|Personalized performance improvement interventions, including premier site data reports, personalized feedback/teleconferences, comprehensive toolkits, and focused webinars; in addition to other general QI tools typically available through participation in Get With the Guidelines Heart Failure.
1853840|NCT00979303|Device|Intracardiac echocardiography and 3D navigational system|Patients assigned to the intervention group will receive both intracardiac echocardiography as well as a 3D navigational system in addition to fluoroscopy during their ablation procedure.
1853841|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 800 mg, Once on Day 1, approximately 14 days
1853842|NCT00979316|Drug|BMS-708163|Oral Solution, Oral, 200 mg, Once on Day 1, approximately 14 days
1853843|NCT00979316|Drug|Placebo|Oral Solution, Oral, 0 mg, Once on Day 1, approximately 14 days
1853844|NCT00979316|Drug|Moxifloxacin|Tablets, Oral, 400 mg, Once on Day 1, approximately 14 days
1853845|NCT00979329|Other|Questionnaires|During the study three questionnaires must repeatedly be completed in by the patients: the BDI (PC) a depression scale, the EORTC-QLQ a quality of life assessment and the CIS20r, a fatigue scale and patients must fill in their medication on a list.
1853846|NCT00979342|Device|Hysteroscopic Morcellator|The MyoSure Tissue Removal Device consists of a hand-held tissue removal device comprising a mechanical drive assembly connected to a drive cable and associated control box on one end, and a 3 mm shaft on the other end of the device. The shaft is approximately 12 cm long and equipped with an open channel that houses an oscillating blade.When the side channel is exposed to target tissue and the motor is activated, the oscillating blade will cut the tissue within the channel. Once cut, the tissue travels down the center of the 3mm shaft via suction coupled to the proximal end of the tissue removal device, and is trapped in a vacutainer bottle.
1853847|NCT00979355|Device|GP-D-SPECT|The D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large PMTs. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient.
1853848|NCT00979368|Drug|BMS-816336|Suspension, Oral, 15 mg Active, Once on Day 1 only, 4 days
1853849|NCT00979368|Drug|BMS-816336|Suspension, Oral, 60 mg Active, Once on Day 1 only, 4 days
1853850|NCT00979368|Drug|BMS-816336|Suspension, Oral, 180 mg Active, Once on Day 1 only, 4 days
1853851|NCT00979368|Drug|BMS-816336|Suspension, Oral, 450 mg Active, Once on Day 1 only, 4 days
1853852|NCT00979368|Drug|BMS-816336|Suspension, Oral, 900 mg Active, Once on Day 1 only, 4 days
1853853|NCT00979368|Drug|Placebo|Suspension, Oral, 0 mg, Once on Day 1 only, 4 days
1853854|NCT00979381|Biological|influenza vaccine|influenza vaccination
1853857|NCT00979433|Device|Bubble CPAP|Bubble CPAP will be delivered using Fischer & Paykel CPAP system with a starting flow of 6 liters/minute. CPAP will be initially started at a pressure of 5 - 6 cm H2O and fraction of inspired oxygen (FiO2) of 0.4 - 0.5. which will be adjusted to maintain oxygen saturation (SpO2) between 87 and 93%.
1853858|NCT00979433|Device|Conventional CPAP|Conventional CPAP will be delivered using Argyle CPAP (Sherwood Medical Company, Mexico) short nasal prongs with warm, humidified gas used (34-37°C) through a thermo-statically controlled humidifier, flow @ 4-8 L/min from either SLE 2000 pressure-controlled continuous flow ventilator (Specialized Laboratory Equipment, UK) or Baby log 8000 volume guarantee ventilator.
1853859|NCT00979446|Behavioral|Guided|Engaged in a 4 month pilot of a multi-domain lifestyle intervention with a phone coach
1853860|NCT00979446|Behavioral|Self-directed|Received study materials but no phone coaching
1853861|NCT00979459|Drug|MK-1006 DFC|Each dry filled capsule contains 20 mg MK-1006
1853862|NCT00979459|Drug|MK-1006 FCT|Each film coated tablet contains 40 mg of MK-1006
1853863|NCT00979472|Drug|Solifenacin|oral
1853864|NCT00979511|Other|milk and exercise|"milk fortified with 1000mg calcium or low-calcium milk
weight-bearing exercise or passive exercise"
1853865|NCT00979524|Behavioral|Comprehensive Mental Health Services and Supports|"This study uses a quasi-experimental design to test the efficacy of a comprehensive mental health intervention to improve the mental health and employment outcomes of young adults (18-24) enrolling in the Eastside YO Program. Newly enrolling Eastside YO members will receive an array of mental health education and services based on level of need and serve as this study's intervention group. Newly enrolling Westside YO members will receive usual care services delivered by the staff at the Westside YO Program and serve as this study's comparison group."
1853866|NCT00979537|Drug|Nisoldipine Extended-release Tablets, 40 mg|
1853867|NCT00979537|Drug|Sular Tablets, 40 mg|
1853871|NCT00979576|Drug|BIBF 1120 M + Pemetrexed|BIBF 1120 medium dose bid+ Pemetrexed 500 mg/m^2
1853872|NCT00979576|Drug|BIBF 1120 H + Pemetrexed|BIBF 1120 high dose bid+ Pemetrexed 500 mg/m^2
1853873|NCT00979576|Drug|BIBF 1120 RD + Pemetrexed|confirmed dose of BIBF 1120 bid + Pemetrexed 500 mg/m^2
1853874|NCT00979576|Drug|BIBF 1120 L + Pemetrexed|BIBF 1120 low dose bid+ Pemetrexed 500 mg/m^2
1853875|NCT00979576|Drug|BIBF 1120 Placebo + Pemetrexed|placebo BIBF 1120 bid + Pemetrexed 500 mg/m^2
1853876|NCT00979589|Drug|Clopidogrel|The first group will receive a 300mg loading dose (LD) of clopidogrel on the day of randomization, followed by 75 mg clopidogrel/day from Day 2 to 3 months. ASA will be given in a total dose ranging between 75 mg and 300 mg (open label) on the first day, followed by blinded 75 mg once /day from Day 2 to Day 21st. Between Day 21st and 3-month visits, ASA 75 mg will be replaced by a placebo of ASA 75 mg.
1853877|NCT00979589|Drug|Placebo of clopidogrel and Asprin|The second group will receive open label ASA in a total dose ranging between 75 mg and 300 mg on the first day, followed by blinded 75 mg once /day from Day 2 to 3 months. A placebo for clopidogrel will be given from the day of randomization until the 3-month visit.
1853878|NCT00979602|Biological|GSK2340274A|One intramuscular injection
1853881|NCT00979615|Drug|Azelastine HCl (Astelin) Nasal Spray, 137 mcg|2 sprays/ nostril BID
1853882|NCT00979628|Drug|sliding scale regular insulin (SSRI)|four-time daily in patients with T2DM admitted to general medicine and surgery wards.
1853883|NCT00979628|Drug|Basal Bolus|glargine once daily plus glulisine before meals (plus corrective doses of glulisine as needed)
1853884|NCT00979628|Drug|Basal Plus|glargine once daily plus corrective doses of glulisine before meals and bedtime as needed
1853885|NCT00979641|Drug|bevacizumab plus docetaxel|i.v. bevacizumab 10 mg/kg and docetaxel 50 mg/square meter, q2w
1853886|NCT00979654|Drug|Sifalimumab|All participants will receive intravenous (IV) sifalimumab as fixed dose of 500 mg every 2 weeks (Q2W) on Day 1, Week 2, and Week 4, then every 4 weeks (Q4W) thereafter for a total of 156 weeks. The initial fixed dose of 500 mg is increased to 600 mg with subsequent protocol amendment.
1853887|NCT00979667|Drug|Oseltamivir|75 mg twice daily for 5 days
1853888|NCT00979667|Drug|Zanamivir|10 mg twice daily for 5 days
1853889|NCT00979667|Drug|Placebo of Oseltamivir|twice daily for 5 days
1853890|NCT00979680|Radiation|High-Dose radiotherapy|Preoperative radiotherapy of 45 Gy/25 fractions of 1.8 Gy through three fields was delivered to the pelvis over 5 weeks, followed by a 18 Gy/10 fraction boost to the primary tumor over 2 weeks.
1853891|NCT00979680|Radiation|Chemo-radiotherapy|Chemotherapy (5-fluorouracil, 200 mg per square meter of body-surface area per day) was delivered over 5 weeks concurrently with the pelvic radiotherapy.
1853892|NCT00979693|Drug|psilocybin|25 mg psilocybin administered orally once during each of the two day-long psychotherapy sessions.
1853893|NCT00979693|Drug|psilocybin|4 mg psilocybin orally administered once during each of two day-long psychotherapy session
1853894|NCT00979706|Drug|HAART|"Patients assigned to this arm will receive Trizivir and kaletra. After the first 9 months of HAART, all patients will stop HAART until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months.
All patients will be followed-up during 1 year."
1853895|NCT00979706|Drug|HAART + Immunotherapy|"Patients assigned to this arm will receive Trizivir + Kaletra + cyclosporin A during the first two months. This group also will receive GM-CSF plus pegylated-interferon-alpha until HIV viral load in plasma became detectable (>200 copies/mL). Then, they will re-start HAART plus low doses of IL-2 during 2 months. At this moment they will stop HAART.
All patients will be followed-up during 1 year."
1853896|NCT00979719|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
1853897|NCT00979719|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program which has been proven to be effective (Göhner, W. & Fuchs, R. (2007). Änderung des Gesundheitsverhaltens. MoVo-Gruppenprogramme für körperliche Aktivität und gesunde Ernährung. Göttingen: Hogrefe.)
1853898|NCT00979732|Dietary Supplement|grape seed extract|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
1853899|NCT00979732|Dietary Supplement|grape seed extract placebo|grape seed extract 150 mg twice a day (BID) in beverage or capsule form
1853900|NCT00979745|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 9 months.
1853901|NCT00979745|Drug|Placebo|One 16mg subcutaneous implant every 2 months for 9 months.
1853902|NCT00979758|Drug|Atorvastatin and mononuclear cells transplantation|Routine or intensive dose of Atorvastatin therapy and mononuclear cells transplantation
1853903|NCT00979771|Drug|GSK706769|100 mg GSK706769 twice daily orally (BID) for 28 days
1853904|NCT00979771|Drug|Placebo|GSK706769 matched-placebo twice daily orally (BID) for 28 days
1853905|NCT00979784|Behavioral|Better Weight|Standard cognitive behavioral treatment focused on dietary & exercise behavior
1853906|NCT00979784|Behavioral|Better Weight & Better Sleep|Standard CBT to support dietary and exercise change plus sleep hygiene and sleep focused CBT
1853907|NCT00979797|Other|Community-based interventions to promote maternal and child health|Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
1853908|NCT00979810|Drug|18F-FLT PET Scan|The patient will undergo MRI and 18F-FLT PET scans of the brain. A IV catheter will be placed in a superficial hand or arm vein for administration of 18F-FLT (approximately 370 MBq), prepared by the MSKCC Radiochemistry Core Facility. A second venous catheter will be placed in the opposite hand or arm for venous blood sampling. If a central venous catheter is present, it will be used for blood sampling or radiopharmaceutical administration, and only a single venous catheter will be placed. Sequential blood samples may be obtained following 18F-FLT infusion for assaying whole blood and plasma radioactivity. All catheters will be removed at the end of the day.
1853909|NCT00979823|Other|Early SimCare Diabetes Group|Residents in the early learning program group will participate in the learning cases before undergoing a knowledge and performance assessment. They will complete 18 learning cases, 4 assessment cases, knowledge survey, and a satisfaction survey.
1853910|NCT00979823|Other|Delayed SimCare Diabetes Group|Residents in the delayed learning program group will receive their usual diabetes training through their residency program for 8 months before completing the knowledge and performance assessment, and then will subsequently be offered the learning program. They will receive 4 assessment cases, knowledge survey, and satisfaction survey
1853911|NCT00979836|Drug|Calcium Dobesilate|500 mg/ three times/day for 6 months (capsules)
1853912|NCT00979849|Drug|AZD8683|Solution for nebulisation, inhaled. Each subject will receive a single-dose of AZD8683 or placebo. Starting dose 1 ug (lung deposited dose) with up to 8 dose escalation not exceeding AstraZeneca pre-defined exposure limits.
1853913|NCT00979849|Drug|Placebo|Solution for nebulisation, inhaled
1853914|NCT00979862|Drug|Cediranib Maleate|Given PO
1853915|NCT00979862|Drug|Cilengitide|Given IV
1853916|NCT00979862|Other|Laboratory Biomarker Analysis|Correlative studies
1853917|NCT00979875|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
1853918|NCT00979875|Drug|Insulin lispro|
1853919|NCT00979875|Drug|Insulin glulisine|
1853920|NCT00979875|Drug|Insulin aspart|
1853921|NCT00979888|Other|educational intervention|
1853922|NCT00979888|Other|informational intervention|
1853923|NCT00979888|Other|psychosocial support for caregiver|
1853924|NCT00979888|Other|questionnaire administration|
1853927|NCT00979901|Drug|Comparator: montelukast|10 mg montelukast tablet given once daily at bedtime for 2 weeks
1853928|NCT00979901|Drug|Comparator: loratadine|10 mg loratadine tablet given once daily at bedtime for 2 weeks
1853929|NCT00979901|Drug|Comparator: placebo|placebo tablet given once daily at bedtime for 2 weeks
1853930|NCT00979901|Drug|Comparator: montelukast/loratadine|montelukast 10-mg/loratadine 10-mg combination tablet taken orally once daily at bedtime for 2 weeks
1853931|NCT00979914|Other|Patient education programme|The intervention consisted of five group sessions, three hours for each session. The focus was on self-efficacy. Eight to ten patients participated in the programme at the same time.
1853932|NCT00979927|Drug|SPC3649|5 weekly doses
1853933|NCT00979927|Drug|saline|5 weekly doses
1853934|NCT00979940|Drug|Atorvastatin|Atorvastatin 80mg po given one time before PCI in cath lab.
1853935|NCT00979953|Drug|ADL5859|
1853936|NCT00979953|Drug|ADL5747|
1853937|NCT00979953|Drug|Oxycodone CR|
1853938|NCT00979953|Drug|Placebo|
1853939|NCT00979966|Drug|Temsirolimus|25 mg intravenously, once weekly infusion
1853940|NCT00979966|Drug|Sunitinib|50 mg oral once daily for 4 weeks, followed by 2 weeks rest.
1853941|NCT00979992|Other|Laboratory Biomarker Analysis|Correlative studies
1853942|NCT00979992|Drug|Sunitinib Malate|Given PO
1853943|NCT00980005|Biological|GSK investigational vaccine GSK1557482A|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
1853944|NCT00980005|Biological|Fluzone®|One intramuscular injection for primed subjects, two intramuscular injections for unprimed subjects
1853945|NCT00980018|Drug|Nilotinib|participants will take nilotinib 400mg twice daily by mouth every morning and every evening approximately 12 hours apart. Participants will take two 200mg capsules at each dosing. Nilotinib is taken on an empty stomach with 8 ounces of water. No food is to be eaten for 2 hours prior to the nilotinib dose or for one hour following the dose.
1853946|NCT00980031|Drug|Eplerenone|25mg PO daily (QD)for 6 months
1853947|NCT00980031|Drug|Lactose Tablet|Lactose tablet
1853948|NCT00980044|Drug|Tramadol|Oral Medication
1853949|NCT00980044|Drug|Placebo|Oral Medication
1853950|NCT00980057|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved Medtronic Vision 3D™ CRT-D implantable device (Consulta® CRT-D, Maximo II® CRT-D, or Concerto II® CRT-D)
1853951|NCT00980057|Other|Adaptive CRT (aCRT) Pacing|Adaptive CRT pacing software adjusts how the device paces the heart based on the patient's current heart status
1853952|NCT00980070|Device|Pediatric Restraint for Lumbar Puncture|Restraint for children 1-90 days of age that allows physician to position pt for optimal lumbar puncture procedure.
1853953|NCT00980070|Device|Lumbar Puncture Device|Lumbar Puncture positioner
1853954|NCT00980070|Other|Standard of Care|Lumbar Puncture positioner
1853955|NCT00980083|Drug|Saline|
1853956|NCT00980083|Drug|Exendin(9-39)amide|
1853957|NCT00980109|Drug|active oseltamivir|Oseltamivir capsules (75 mg per capsule), one capsule daily by mouth (PO) for 112 days. The dose should be administered at approximately the same time each day.
1853958|NCT00980109|Drug|placebo capsule|Placebo capsules, one capsule daily for 112 days. The capsule should be administered at approximately the same time each day.
1853959|NCT00980109|Drug|zanamivir for inhalation|Zanamivir for inhalation, (5 mg per inhalation), two inhalations, once daily using a ROTADISK/DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
1853960|NCT00980109|Drug|placebo for inhalation|Placebo (lactose powder), two inhalations, once daily using a ROTADISK/ DISKHALER for 112 days. The dose should be administered at approximately the same time each day.
1853961|NCT00980135|Device|Sinecort cream|Application over 29 days
1853962|NCT00980135|Drug|Hydrocortison cream|Application over 29 days
1853963|NCT00980135|Other|Untreated skin|n.a
1853964|NCT00980148|Drug|Azithromycin|FDA approved, a 1 gm single dose, two 500 mg tablets.
1853965|NCT00980148|Drug|Doxycycline|FDA approved, a 100 mg capsule twice a day for 7 days.
1853966|NCT00980174|Drug|60 mg denosumab|60 mg denosumab (SC injection every 6 months)
1853967|NCT00980174|Other|Placebo|Placebo for denosumab (SC injection every 6 months)
1853968|NCT00980187|Drug|Hydrochlorothiazide|orally, 25 mg, once a day, with Quinapril 10-40 mg, 6 months
1853969|NCT00980187|Drug|Indapamide|1.5 mg SR, orally, once a day,with Quinapril 10-40 mg, 6 months
1853970|NCT00980200|Drug|Dose 4 QD|QD once daily
1853971|NCT00980200|Drug|Dose 3 QD|QD once daily
1853972|NCT00980200|Drug|placebo|placebo
1853973|NCT00980200|Drug|Dose 2 QD|QD once daily
1853974|NCT00980200|Drug|Dose 1 BD|BD twice daily
1853975|NCT00980213|Drug|sunitinib|sunitinib 50 mg, per os, daily for 4 weeks then 2 weeks pause, duration months
1853976|NCT00980239|Drug|Irinotecan|Starting dose of 35 mg/m^2 given through the catheter into your liver artery (hepatic artery infusion - HAI), continuously for 72 hours (Days 1 through 2 of each cycle).
1853977|NCT00980239|Drug|Bevacizumab|10 mg/Kg by vein on Days 1 and 15 of every 28 day cycle, over 90 minutes first cycle and over 30-60 minutes subsequent cycles.
1853978|NCT00980239|Drug|Oxaliplatin|Starting dose 60 mg/m^2 by vein over 2 hours on Days 1 and 15 of every cycle.
1853979|NCT00980239|Drug|Cetuximab|500 mg/m^2 by vein on Days 1 and 15 of every cycle. The first time given over 2 hours, all other cycles over 1 hour.
1853980|NCT00980252|Behavioral|Cognitive Behavioral Therapy|Brief intervention of Cognitive Behavioral Therapy sessions compared to Team Solutions
1853981|NCT00980278|Procedure|Sinus lift augmentation and dental implant|transalveolar sinus augmentation will be performed. After 4 months, dental implants will be delivered only if primary stability can be achieved.
1853982|NCT00980278|Biological|Aastrom BRCs|sinus augmentation, BRC application, dental implant
1853983|NCT00980304|Drug|Rituximab|
1853984|NCT00980317|Procedure|Restored Kidney Transplant Between Third Parties|Tumor part of the donor kidney is surgically removed and the kidney is restored and transplanted to a third party recipient
1853985|NCT00980330|Drug|TMC435|One TMC435 100-mg capsule or two 75-mg capsules orally (by mouth) once daily for 12, 24, or 48 weeks.
1853986|NCT00980330|Drug|Placebo|One or 2 capsules of placebo identical in appearance to TMC435 taken orally once daily for 24, 36, or 48 weeks.
1853987|NCT00980330|Drug|Peg-IFN-alfa-2a (P)|180 micrograms taken as one 0.5 mL subcutaneous injection once weekly for 48 weeks.
1853988|NCT00980330|Drug|Ribavirin (R)|1000 or 1200 mg/day (5 or 6 tablets) taken orally as a twice daily regimen taken for 48 weeks.
1853989|NCT00980343|Drug|vismodegib|Given orally
1853990|NCT00980343|Procedure|therapeutic conventional surgery|undergo surgery
1853991|NCT00980343|Other|laboratory biomarker analysis|correlative studies
1853992|NCT00980343|Other|pharmacological study|correlative studies
1853993|NCT00980356|Drug|Vildagliptin|Patients receive once daily 50 mg Vildagliptin
1853994|NCT00980382|Drug|S-1, Docetaxel|"Phase I study
S-1 (level 0, 1/2, 3/4, 5: 60, 70, 80, 90 mg/m2/day) q 12 hours po Days 1-14
Docetaxel (level 0/1,2/3, 4/5: 25, 30, 35 mg/m2) iv : Days 1, 8
Phase II study
S-1 (80mg/m2/day) q 12 hours po Days 1-14
Docetaxel (35 mg/m2) iv : Days 1, 8"
1853995|NCT00980395|Drug|rituximab|375 mg/m2 IV Day 1. Repeat every 28 days for a maximum of 6 cycles.
1853996|NCT00980395|Drug|bortezomib|1.3 mg/m2 IV Days 1 and 4. Repeat every 28 days for a maximum of 6 cycles.
1853997|NCT00980395|Drug|cladribine|4 mg/m2 IV over 2 hours Days 1-5. Repeat every 28 days for a maximum of 6 cycles.
1853998|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
1853999|NCT00980408|Drug|Sugar pill|250 mg, one dose, 60 min prior
1854000|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
1854001|NCT00980408|Drug|Sugar pill|20 mg, one dose, 8 hours prior
1854002|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
1854003|NCT00980408|Drug|Glutamic Acid|250 mg, one dose, 60 minutes prior
1854004|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
1854005|NCT00980408|Drug|Memantine|20 mg, one dose, 8 hours prior
1854006|NCT00980421|Dietary Supplement|Iron Supplementation|Iron tablet group (12.5 mg/d)+ Placebo Biscuit;Iron(12.5 mg/d)+ Zinc (10 mg/d) tablet group+ Placebo Biscuit; Iron Fortified Biscuit Group (12.5 mg/d)+ Placebo Tablet; Placebo tablet +Placebo Biscuit
1854007|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 45µg three weeks apart
1854008|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 90µg three weeks apart
1854009|NCT00980447|Biological|UMN-0501|2 doses of recombinant H5N1 A/VN/1203/2004 vaccine 135µg three weeks apart
1854019|NCT00980473|Procedure|Argon Laser Iridoplasty|
1854020|NCT00980473|Drug|Travatan/ Timolol/Azopt|
1854021|NCT00980512|Behavioral|Parent Training|16 weeks of parent training led by trained group facilitator
1854022|NCT00980538|Drug|Etravirine|Dosed by weight up to a maximum dose of 200 mg bid until accessed by other means
1854023|NCT00980551|Drug|subtenon Carboplatin|Available in 50mg, 150mg, 450 mg, 600mg vials. It is provided as a premixed aqueous solution or lyophilized powder for injection given on day 1/week 10 (cycles 1-3).
1854024|NCT00980551|Drug|Topotecan Hydrochloride|Each vial contains topotecan hydrochloride equivalent to 4 mg of topotecan as free base. Given intravenously on days 1-5 of each week (cycles 1-6).
1854025|NCT00980551|Drug|Vincristine|Each vial contains vincristine sulfate, 1 mg; mannitol, 100 mg; sterile water for injection; Acetic acid and sodium acetate are added for pH control. Given intravenously on day 1/week 1 (cycles 1-6).
1854026|NCT00980551|Drug|Filgrastim|Supplied as a clear solution in 300 mcg/ml 1 ml or 1.6 ml vials and prefilled syringes containing 300mcg/0.5mL or 480mcg/0.8mL. Given intravenously on day 6 of each week (cycles 1-6).
1854027|NCT00980577|Device|NUUS|Sonosite Micro Maxx
1854028|NCT00980590|Device|Airway Scope|Tracheal intubation by Airway Scope
1854029|NCT00980590|Device|Macintosh Laryngoscope|Tracheal intubation by Macintosh Laryngoscope
1854030|NCT00980603|Drug|docetaxel|docetaxel 75 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
1854031|NCT00980603|Drug|docetaxel, cisplatin|docetaxel 60 mg/m2 and cisplatin 60 mg/m2, IV on day 1 of each 3 week cycle until progression or unacceptable toxicity develops
1854032|NCT00980603|Drug|docetaxel, S-1|docetaxel 60 mg/m2 IV on day 1 and S-1 30 mg/m2 bid PO on days 1-14 of each 3 week cycle until progression or unacceptable toxicity develops
1854033|NCT00980616|Drug|ropivacaine, physical serum and adrenalin|A: experimental group: 235 mg of ropivacaine, 5 ml physical serum and 0.5 mg of adrenalin
1854034|NCT00980629|Drug|M516102|Twice a day
1854035|NCT00980629|Drug|placebo|Twice a day
1854036|NCT00980642|Device|Draeger double-sensor|The sensor will be attached to the patient's forehead with adhesive tape, and a small amount of contact gel will be applied between sensor and skin.
1854037|NCT00980642|Device|Esophageal stethoscope temperature sensor|Esophageal temperature is measured by sensors incorporated into an esophageal stethoscope during the surgery.
1854038|NCT00980642|Device|Foley catheter temperature sensor|Urinary bladder temperature is measured via a sensor incorporated into a Foley catheter during the surgery
1854039|NCT00980655|Biological|13vPnC|"0.5mL 13vPnC dose will be administered intramuscularly into the left limb at visits 1,2,3 and 5.
Starting 3-6 months after HSCT 3 doses given at monthly intervals. 4th dose given 6 months after 3rd dose."
1854040|NCT00980655|Biological|23vPS|0.5mL dose of 23vPS will be administered intramuscularly at visit 6. 23vPS given 1 month after 4th dose of 13vPnC.
1854041|NCT00980681|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
1854042|NCT00980681|Other|Time of Flight|Each subject will undergo a TOF MRA
1854043|NCT00980694|Dietary Supplement|ubiquinol|up to 600 mg per day, oral capsules for 8 weeks
1854389|NCT00975195|Drug|placebo matched for fluticasone propionate|
1854044|NCT00980707|Drug|Inhaled corticosteroid (fluticasone)|inhaled fluticasone 220 ug/bid
1854045|NCT00980733|Dietary Supplement|Fortified Yoghurt|The study group would receive yoghurt fortified with 1/3rd RDA of iron, zinc, vitamin A and iodine. The salts used for fortification will be iron- Ferric pyrophosphate micronized, zinc - zinc gluconate, Iodine - Potassium Iodide, Vitamin A - Vitamin A acetate.
1854046|NCT00980733|Dietary Supplement|Yoghurt|Plain yoghurt same as in intervention group without fortification
1854047|NCT00980746|Drug|Eslicarbazepine acetate|Eslicarbazepine acetate tablets, scored to allow dose titration during the titration period.
1854048|NCT00980746|Drug|Placebo|oral route
1854049|NCT00980759|Radiation|EFI|Para-aortic and Pelvic Irradiation with chemotherapy(cisplatin)
1854050|NCT00980759|Radiation|Pelvic RT|Only Pelvic Irradiation with chemotherapy(cisplatin)
1854051|NCT00980785|Drug|Ramipril|Ramipril 5 mg/day
1854052|NCT00980785|Drug|Placebo|Matching Placebo
1854053|NCT00980798|Drug|OROS hydromorphone HCl|4 to 32 mg taken orally once daily for 16 weeks
1854054|NCT00980798|Drug|Placebo|placebo tablet once daily for 16 weeks
1854055|NCT00980824|Behavioral|Cognitive behavioural therapy|Six sessions brief CBT.
1854056|NCT00980824|Other|Standard treatment|Referral to NHS services appropriate to patient's needs
1854057|NCT00980850|Biological|Baxter Novel Influenza A H1N1 Whole Virus Vaccine|Two 0.5 ml doses of vaccine given within 3 weeks interval
1854058|NCT00980850|Biological|GlaxoSmithKline Novel Influenza A H1N1 Split Virion Vaccine|Two 0.25 ml doses of vaccine given within 3 weeks interval
1854059|NCT00980863|Behavioral|lifestyle intervention to increase physical activity|
1854060|NCT00980876|Drug|Cipro HC|Cipro HC (Ciprofloxacin HCl and Hydrocortisone)
1854061|NCT00980876|Drug|Ciprofloxacin HCl and Hydrocortisone|Ciprofloxacin Hydrochloride and Hydrocortisone
1854062|NCT00980889|Device|Steel|ERCP procedure insertion of Metalic Steel Stent, Wallstent®
1854063|NCT00980889|Device|Nitinol|Insertion of Metalic nitinol Stent, Wallflex® in malignant distal bile duct obstruction
1854064|NCT00980941|Dietary Supplement|soup with or without starch|
1854065|NCT00980954|Drug|carboplatin|Given IV
1854066|NCT00980954|Drug|cisplatin|Given IV
1854067|NCT00980954|Drug|paclitaxel|Given IV
1854068|NCT00980967|Other|Study of predictive factors|Identification of predictive factors for lung chronic rejection outcome in lung transplant recipients
1854069|NCT00980980|Drug|Chlorhexidine bath and nasal mupirocin|The intervention / decolonization regimen will consist of the most commonly used topical regimen in the US - a combination of daily baths with 2% chlorhexidine cloths , plus 5 days of topical intranasal mupirocin ointment (bilateral nares, twice daily)
1854070|NCT00981006|Procedure|human cardiac stem cells|Single intramyocardial Injection of autologous hCSCs : 20 cites of infarcted myocardium Implantation of gelatin hydrogel sheet incorporating bFGF: 200 microgram. CABG surgery.
1854071|NCT00981032|Behavioral|Pre-visit Summary|The intervention is a pre-visit summary given to the patient prior to their appointment. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use.
1854072|NCT00981032|Behavioral|Clinical Decision Sharing Tool|This intervention includes a pre-visit summary and a clinical decision sharing tool. Patients will receive a pre-visit summary prior to their appointment. They will also view a clinical decision sharing tool in conjunction with the physician in the office. The pre-visit summary details the patient's risk of heart attack or stroke and the benefits of daily prophylactic aspirin use. The clinical decision sharing tool informs the physician of the patient's heart attack or stroke risk and determines if the patient would benefit from aspirin use.
1854073|NCT00981045|Drug|Ferric Carboxymaltose (FCM)|2 doses at 15 mg/kg to a maximum 750 mg per dose for a total maximum cumulative dose of 1500 mg
1854074|NCT00981045|Drug|Iron Sucrose (Venofer)|5 doses of 200 mg for a total cumulative dose of 1000 mg
1854075|NCT00981058|Biological|Necitumumab|"800 milligrams (mg) Intravenously IV infusion on Days 1 and 8 of every 3 week cycle.
Continues until progressive disease, toxicity, noncompliance, or withdrawal."
1854076|NCT00981058|Drug|Gemcitabine|"1250 mg/m2 on Days 1 and 8 of every 3 week cycle.
Continues for a maximum of six cycles."
1854077|NCT00981058|Drug|Cisplatin|"75 mg/m2 IV on Day 1 of every 3 week cycle.
Continues for a maximum of six cycles."
1854078|NCT00981084|Drug|armodafinil|Half of the patients will be randomized to receive a single oral dose of placebo prior to the first testing session. After a washout period of one week, they will then receive 250mg of armodafinil prior to a second testing session (P/A group). The other half of patients will be randomized to receive the active drug first. After a washout period of one week, they will receive the placebo prior to a second testing session (A/P group). As plasma levels of armodafinil peak between 2-4 hours after administration, participants will be asked to take a single 250mg capsule 2 hours prior to the scheduled testing sessions.
1854079|NCT00981097|Genetic|polymerase chain reaction|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
1854080|NCT00981097|Other|laboratory biomarker analysis|determination of elevated serum FLC and clonal Ig detection rates in plasma and tumor
1854081|NCT00981110|Device|AQUAGEL Ag Hydrofiber Wound Dressing|Hydrofibre dressing containing ionic silver: medication performed as for frequency and duration according standard procedure
1854082|NCT00981110|Device|Mepore Self-adhesive absorbent dressing|Standard dressing: medication performed as for frequency and duration according standard procedure
1854083|NCT00981136|Procedure|Single Incision Laparoscopic Appendectomy|A single incision through the umbilicus to remove the appendix
1854084|NCT00981136|Procedure|3 port laparoscopic appendectomy|Standard 3 port laparoscopic appendectomy with intracorporeal stapling
1854086|NCT00981162|Drug|sorafenib tosylate|Given PO
1854087|NCT00981162|Drug|everolimus|Given PO
1854088|NCT00981162|Other|laboratory biomarker analysis|Correlative study
1854089|NCT00981162|Other|pharmacogenomic studies|Correlative study
1854090|NCT00981162|Other|pharmacological study|Correlative study
1854135|NCT00981513|Biological|Trivalent live attenuated seasonal influenza vaccine|One dose
1854091|NCT00981175|Biological|Live attenuated Japanese encephalitis virus, then ChimeriVax diluent|ChimeriVax™-JE, 0.5 mL subcutaneous on Day 0; ChimeriVax diluent 0.5 mL subcutaneous on Day 28
1854092|NCT00981175|Biological|ChimeriVax diluent, then Live attenuated Japanese encephalitis virus|ChimeriVax diluent, 0.5 mL subcutaneous on Day 0 and ChimeriVax™-JE, 0.5 mL subcutaneous on Day 28.
1854093|NCT00981201|Drug|Celecoxib|"Months 1-3:
As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
1854094|NCT00981201|Drug|Celecoxib|"Months 4-6:
As of October, 2003, the starting dose for celecoxib will be 400 mg by mouth twice daily. (Note: Prior to October, 2003, the starting dose for celecoxib was 200 mg by mouth twice daily.)"
1854095|NCT00981201|Drug|Placebo|"Months 1-3:
By mouth twice daily."
1854096|NCT00981201|Drug|Placebo|"Months 4-6:
By mouth twice daily."
1854097|NCT00981214|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) Microtabs contained in a capsule will be administered orally from Day 5 to Day 11 at an enzyme dose based on investigator's discretion, in dose stabilization period or the content of the capsule will be allowed to sprinkle on food, where necessary, followed by stabilized dose from Day 12 to Day 18 in treatment period, up to a maximum total dose of 10,000 lipase units per kilogram body weight per day (unit/kg/day).
1854098|NCT00981227|Drug|Eslicarbazepine acetate|Scored tablets
1854099|NCT00981227|Drug|Placebo|oral route
1854100|NCT00981240|Drug|SAR103168|"Pharmaceutical form: Concentrate for solution for infusion
Route of administration: Intravenous infusion"
1996636|NCT02429349|Procedure|surgery|Surgical Procedures- Unilateral oophorectomy will be performed by laparoscopy prior to undergoing chemo-radiation treatment as specified above. Subsequent ovarian cortex autotransplant will be performed by laparoscopy after the patients have been declared cured by their physicians.
1854103|NCT00981266|Device|Mentor Spectra/Becker 80 Breast Implant|The Mentor Smooth Spectra/Becker 80 Adjustable Breast Implant has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over a period of time via the fill tube by injecting saline through the injection dome. Once filled to the desired volume, the fill tube and injection dome are removed, and the prosthesis remains in position as a breast implant. Its purpose is to provide volume flexibility and projection adjustability.
1854104|NCT00981292|Dietary Supplement|EGCG|Acute oral administration of capsules containing either: 0mg, 135mg or 270mg. One dosage administered on each of three separate study days.
1854105|NCT00981292|Dietary Supplement|Placebo|Pharmaceutical grade silica was utilized as placebo
1854106|NCT00981305|Drug|Lactate-containing vaginal lubricant|vaginal applying at least 3cc of lactate-containing lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
1854107|NCT00981305|Drug|Placebo vaginal lubricant|vaginal applying at least 3cc of placebo lubricant at the time of sexual intercourse or before sleeping for 8 weeks (at least 3 times/week)
1854108|NCT00981318|Drug|lopinavir/ritonavir plus maraviroc|lopinavir/ritonavir 400/100 mg bid plus maraviroc 150 mg bid
1854109|NCT00981331|Procedure|Subtalar joint manipulation|The intervention is defined as a toggle-recoil, high-velocity, low-amplitude subtalar joint manipulation.
1854110|NCT00981344|Other|Wheeled Mobility in Everyday Life:Effects of Wheelchair Type on Mobility Performance of Elders in Public Environments|We are studying how wheeled mobility performance and the impact of device type on a group of community dwelling Veterans.
1854111|NCT00981357|Drug|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
1854112|NCT00981357|Drug|PF-04457845|PF-04457845 4 mg tablet once daily / matched placebo
1854113|NCT00981357|Drug|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
1854114|NCT00981357|Drug|Naproxen|Naproxen 500 mg tablet twice daily / matched placebo
1854115|NCT00981370|Drug|deferasirox|Treatment starting dose of 20mg/kg/day based on subjects baseline LIC (liver iron concentration) and gradually escalate the dose to a maximum of 35 mg/kg/day based upon toxicity. Duration is up to a max of 12 months.
1854116|NCT00981383|Dietary Supplement|Omega-3 Fatty Acid Supplement|3 capsules (3x1g) fish oil-derived concentrated ethyl esters, providing 1.9 g omega-3 fatty acids (1.2 g EPA and 0.6 g DHA, with 0.1 g other omega-3 fatty acids)
1854117|NCT00981383|Other|Placebo|3 capsules (3x1g) of 50/50 soybean/corn oil blend containing less than 0.12 g of omega-3 fatty acids with negligible EPA and DHA
1854118|NCT00981396|Behavioral|EFT (Emotional Freedom Techniques)|EFT is a brief but efficacious stress-reduction intervention. It combines exposure, cognitive structuring, and somatic stimulation.
1854119|NCT00981396|Behavioral|CBT (Cognitive Behavioral Therapy)|CBT is a behavioral intervention that seeks to challenge and change negative client cognitions about events and life circumstances.
1854120|NCT00981409|Drug|Fondaparinux sodium|The dose of Fondaparinux will be determined based on a subject's body weight (<50 kg, 5 mg; 50 to 100 kg, 7.5 mg; >100 kg, 10 mg) and administered once daily by subcutaneous (SC) injection.
1854121|NCT00981409|Drug|unfractionated heparin (UFH)|UFH therapy will be started on Day 1 while adjusting activated partial thromboplastin time (aPTT) to maintain aPTT 1.5 to 2.5 times control.
1854122|NCT00981435|Drug|Prednisolone 1%|Prednisolone 1% to lasered eye 4 times/day for 4.5 days
1854123|NCT00981435|Drug|Diclofenac 0.1%|Diclofenac sodium 0.1% to lasered eye 4 times/day for 4.5 days
1854124|NCT00981435|Drug|Artificial Tears|Artificial saline tears to lasered eye 4 times/day for 4.5 days
1854125|NCT00981448|Dietary Supplement|Zinc acetate|50mg of elemental zinc to be administered 2 times daily orally for 14 days.
1854126|NCT00981461|Device|HairMax LaserComb|Device application 3 times week, for 26 weeks
1854127|NCT00981461|Device|Control Device|Device application 3 times week, for 26 weeks
1854128|NCT00981474|Drug|blood pressure maintenance based on cerebral blood flow autoregulation measurement|Blood pressure lowered or raised
1854129|NCT00981474|Drug|Control group|Institutional standard of care.
1854130|NCT00981487|Drug|Ondansetron|24 mg one time
1854131|NCT00981487|Drug|Ondansetron|24 mg, on time in the am
1854132|NCT00981500|Procedure|gastric bypass|Roux-en-Y gastric bypass
1854133|NCT00981500|Procedure|gastric banding|laparoscopic adjustable gastric banding
1854134|NCT00981500|Procedure|sleeve gastrectomy|vertical sleeve gastrectomy
1854136|NCT00981513|Biological|Monovalent live attenuated pandemic influenza vaccine|One dose
1854137|NCT00981513|Biological|Saline|One dose
1854142|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|"Group 1: slow regimen (12+2 injections) Initial treatment: incremental weekly dose of 0.05, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.8, 1.0, 1.2*, 1.6* and 2.0* ml Additional maintenance: 2 two-weekly injections 2.0* ml
*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
1854143|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|"Group 2: intermediate regimen (9+2 injections) Initial treatment: incremental weekly dose of 0.1, 0.2, 0.4, 0.6, 0.8, 1.0, 1.2*, 1.6* and 2.0* ml.
Additional maintenance: 2 two-weekly injections 2.0* ml
*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
1854144|NCT00973453|Drug|PURETHAL Mites 20,000 AUeq/ml|"Group 3: fast initial treatment (6+2 injections) Initial treatment: incremental weekly dose of 0.2, 0.4, 0.8, 1.2*, 1.6* and 2.0*ml.
Additional maintenance: 2 two-weekly injections 2.0* ml
*Injection volumes larger than 1 ml will be given as 2 separate injections of equal volume within an area of 1 cm."
1854148|NCT00973492|Other|functional insulinotherapy class|"The functional insulinotherapy class lasts for 4 days. It is taught by 2 nurses, 2 dieticians and 2 physicians to 6 to 10 patients.
On day 1, patients describe their difficulties with diabetes. Fast-acting insulin scales are elaborated from preprandial and postprandial blood glucose levels. At dinner, patients start a 24-hour glucose-fasting period to evaluate their need for basal insulin. Meals contain virtually no carbohydrates. Correcting doses of insulin are administered if preprandial glycemia is over 1.50 g/l or postprandial glycemia is over 2 g/l. Blood glucose levels must stay within normal values during the whole 24-hour period.
Carbohydrate management is taught during meals and every afternoon through workshops about dietetics. Patients also learn how to deal with hypoglycaemia, hyperglycaemia and physical activity.
A one-day follow-up takes place 3 months later."
1854149|NCT00973505|Drug|Aromatase Inhibitor(Femara or Arimidex)|Femara(Letrozole) 2.5mg 1tab qd, Arimidex(Anastrozole) 1mg 1tab qd
1854150|NCT00973531|Device|Autotitrating Positive Airway Pressure (APAP)|Then subjects will use Autotitrating Positive Airway Pressure machine for 90 days
1854151|NCT00973531|Device|Traditional Split Titration Polysomnogram|Then subjects will use Continuous Positive Airway Pressure (CPAP) machine for 90 days
1854152|NCT00973544|Other|Cultures taken from the drain discharge|Cultures will be taken from drain's fluids discharge in Post Operative Day 4,8,10,12. When drain is removed cultures of the drain tip are taken. Clinical signs of surgical signs infections will be observed.
1854153|NCT00973570|Behavioral|TABADO program|The intervention takes place in 3 stages: (i) a general information session on tobacco consumption is delivered to all teenagers, both smokers and nonsmokers. (ii) For smokers wishing to join the program, this session is followed by individualized consultations with a team of tobacco addiction physicians. (iii) The volunteers then benefit from a small group approach, consisting of discussion sessions to share experiences, strengthen motivation, and prevent relapse. There will be 4 sessions in total, comprising individual counseling and work in groups spread over 3 months (taking into account the availability of the trainees because of their alternate-week training schedule).
1854154|NCT00973583|Dietary Supplement|vitamin D|vitamin D3 400 IU daily
1854155|NCT00973583|Dietary Supplement|placebo|placebo
1854156|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.
Following induction treatment regimen (for maintenance treatment): No maintenance treatment."
1854157|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.
Following induction treatment regimen (for maintenance treatment): Fluoropyrimidine + Bevacizumab."
1854158|NCT00973609|Drug|5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab|"Induction (and reinduction) treatment regimen for 24 weeks: Fluoropyrimidine, oxaliplatin and bevacizumab.
Following induction treatment regimen (for maintenance treatment): Bevacizumab monotherapy."
1854159|NCT00973622|Device|repetitive transcranial magnetic stimulation (rTMS) 10 Hertz (Hz)|All participants will receive 90 10-pulse trains of 1 sec duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
1854160|NCT00973622|Device|repetitive transcranial magnetic stimulation (rTMS) 20Hz|All participants will receive 45 20-pulse trains of 1 second duration with an interval of 20 seconds. Smokers will receive the treatment twice, once in a nicotine-satiated condition, and once in a nicotine-withdrawal condition.
1854161|NCT00973622|Device|SHAM repetitive transcranial magnetic stimulation (rTMS)|The look and sound of active rTMS is reproduced with the same coil used in the active conditions. The magnetic field in the sham coil is markedly attenuated at only 5% of stimulator output. The feel of active stimulation will be reproduced by delivering monophasic current pulses to the left, frontalis muscle with a Isolated Stimulator and two carbon rubber electrodes. Smokers will receive Sham rTMS in both the nicotine-satiated and nicotine-withdrawal conditions.
1854213|NCT00973973|Drug|NBI-56418|150 mg immediate release (IR) taken daily, 24 week duration
1854214|NCT00973973|Drug|Placebo|Matching placebo tablet taken daily, 8 week duration
1854526|NCT00981617|Drug|ALKS33 (RDC-0313) (10 mg)|10 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
1854162|NCT00973635|Other|Web-based education|"Patients of subjects who were required to complete 10 web-based, independent learning modules. Each subject given a course packet which includes 13 required core articles pertaining to handoff skills. Each subject receives immediate feedback to each web-case with correct answers and suggested readings. Each subject given individualized feedback on their scores for summaries, instructions, and sign outs."
1854163|NCT00973661|Behavioral|Electronic tool set for counseling overweight patients|"Physicians randomized to the electronic tools arm will receive access to a tool set to aid with counseling of overweight patients. This tool set includes the following components: automatic calculation of BMI, alert for overweight status, counseling template for weight loss goal-setting, linkage to referral options, and access to relevant patient handouts. Physicians randomized to the usual care arm will not receive access to these tools, and will continue to provide their usual care for overweight patients."
1854166|NCT00973687|Drug|Ora Sweet|A pharmaceutical suspending vehicle and flavouring agent added to the dexamethasone. All arms received the same amount of dexamethasone based on the child's weight, only in different volumes.
1854167|NCT00973687|Drug|Dexamethasone|
1854168|NCT00973700|Biological|MF59-eH1N1_f|MF59 adjuvanted (adj) egg-derived A/H1N1 with traces of Thiomersal
1854169|NCT00973700|Biological|eH1N1_f|Unadjuvanted egg-derived A/H1N1 with traces of Thiomersal
1854170|NCT00973713|Drug|RAD001|10mg/d
1854171|NCT00973726|Other|Glucose test|Subjects ingest an oral glucose tolerance test.
1854172|NCT00973739|Drug|Lapatinib|"Lapatinib is dosed according to age. Lapatinib is available in 250 mg tablets only. For pediatric dosing, the total daily dose will be rounded up or down to the nearest 250 mg increment.
Children/adolescents (<18 years of age): 1,800 mg/m2/day PO divided into twice daily doses, to a maximum of 750 mg PO (3 tablets twice daily)
Adults (>=18 years of age): 1,500 mg PO (6 tablets once daily)
Duration: Up to 12 months, depending on treatment response."
1854173|NCT00973752|Drug|Prednisone|Orally during Induction, Consolidation 1, CNS, Consolidation 2, and Continuation therapy.
1854174|NCT00973752|Drug|Vincristine|Intravenously during Induction, CNS, Consolidation 2 and Continuation Therapy
1854175|NCT00973752|Drug|Doxorubicin|Intravenously during Induction, CNS, and Consolidation 2 therapy
1854176|NCT00973752|Drug|PEG-asparaginase|Intravenously during Induction, Consolidation 1, CNS, and Consolidation 2 therapy
1854177|NCT00973752|Drug|Cytarabine|Intrathecally during Induction and CNS therapy
1854178|NCT00973752|Drug|Methotrexate|Intrathecally during Induction, CNS, and Continuation Therapy
1854179|NCT00973752|Drug|Imatinib|Orally during Induction, Consolidation 1, CNS, Consolidation 2 and Continuation Therapy
1854180|NCT00973752|Drug|Clofarabine|Intravenously during Consolidation 1 Therapy
1854181|NCT00973752|Drug|6 Mercaptopurine|Orally during CNS, Consolidation 2 and Continuation Therapy
1854182|NCT00973765|Drug|bactrim|bactrim DS (800/160) 2 pills PO BID x 7 days
1854183|NCT00973765|Drug|placebo|placebo 2 pills po BID x 7 days
1854184|NCT00973778|Other|Preoperative Chemoradiotherapy|Patient will receive pre-operative radiotherapy with intensity modulated radiotherapy to primary and any grossly enlarged pelvic nodes 5Gy in 5 fractions over 5 days with concurrent capecitabine 1500mg p.o. bid for 1 week, then undergo surgery.
1854185|NCT00973791|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after spinal anesthesia in cesarean section
1854186|NCT00973791|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after spinal anesthesia in cesarean section
1854187|NCT00973804|Drug|EPOCH-F/R|
1854188|NCT00973804|Drug|FLAG|
1854189|NCT00973804|Drug|Transplant Preparative Regimen (Flu/Cy/Mes)|
1854190|NCT00973804|Drug|GVHD Prophylaxis (tacrolimus and sirolimus)|
1854191|NCT00973804|Procedure|Double Cord Blood Transplantation|
1854192|NCT00973817|Biological|ELAD plus standard of care treatment|Use of ELAD plus standard of care
1854193|NCT00973817|Other|Standard of care|Standard of care in the treatment of AOCH will be administered
1854194|NCT00973830|Other|Diabetes Guide and Brief Counseling|If in one of the intervention arms, patients will receive a Diabetes Guide (a patient-friendly guide to help patients make healthy changes to improve their diabetes). The Diabetes Guide includes a brief counseling component, to be conducted with clinic staff (Carve-In) or an outside diabetes educator (Carve-Out).
1854197|NCT00973869|Dietary Supplement|curcumin|
1854198|NCT00973869|Other|high performance liquid chromatography|
1854199|NCT00973869|Other|laboratory biomarker analysis|
1854200|NCT00973869|Other|pharmacological study|
1854201|NCT00973869|Procedure|diagnostic endoscopic procedure|
1854202|NCT00973869|Procedure|therapeutic conventional surgery|
1854203|NCT00973882|Drug|Carboplatin|Carboplatin AUC4 on day 1 repeated every 3 weeks for a maximum of 6 cycles
1854204|NCT00973882|Drug|Etoposide|Etoposide 100 mg/m2 on day 1, day 2 and day 3 repeated every 3 weeks for a maximum of 6 cycles
1854205|NCT00973895|Biological|VRC-FLUDNA057-00-VP|DNA Vaccine Expressing H1 HA from Influenza A/California/04/2009 H1N1 Virus
1854206|NCT00973908|Drug|VSL#3|Patients will o receive one VSL #3 sachets twice a day for the duration of the antibiotic course and for one week after.
1854207|NCT00973908|Drug|Placebo|Patients will one placebo sachet twice a day for the duration of the antibiotic course and for one week after.
1854208|NCT00973934|Device|Magstim Theta|
1854209|NCT00973934|Device|Thymatron System IV|
1854210|NCT00973947|Other|questionnaire administration|
1854211|NCT00973947|Radiation|3-dimensional conformal radiation therapy|
1854212|NCT00973947|Radiation|radiation therapy treatment planning/simulation|
1996637|NCT02429193|Drug|Abiraterone + prednisone|Abiraterone acetate (1000 mg/day p.o.) + prednisone (5 mg b.i.d., p.o.)
1996638|NCT02429193|Drug|Enzalutamide|Enzalutamide (160 mg/day p.o.)
1854215|NCT00973986|Drug|Atorvastatin|The subjects will receive atorvastatin (20 mg single dose) orally with approximately 240 ml of water. Blood samples(4 mL) will be taken prior to dosing and at 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 4, 6, 9, 12, 24 and 48 h after drug administration.
1854216|NCT00973999|Drug|Botulinum Toxin|"Each parotid salivary gland will be injected with 75MU of Botulinum Toxin type-A, 0.15mls in total, with 0.09mls into the mass of the gland and another 0.06mls into the adjacent part above the masseter muscle, using a 1ml syringe and a 30 gauge needle.
Each submandibular salivary gland will be injected with 15MU of Botulinum Toxin A, administering 0.03mls, using a 1ml syringe and a 30 gauge needle."
1854219|NCT00974025|Dietary Supplement|Vitamin C|High-dose Vitamin C will be administered in 4 age-based dosing groups
1854220|NCT00974025|Dietary Supplement|Placebo|Placebo will be administered twice daily for four weeks
1854221|NCT00974038|Behavioral|psychotherapy|1) cognitive-behavioral therapy or 2) supportive psychotherapy
1854222|NCT00974051|Drug|Terbutaline|Oral (2.5mg) one time administration at 9:00pm
1854223|NCT00974051|Other|20% basal insulin reduction|Basal insulin rate is reduced by 20% the normal (home dose) for six hours.
1854224|NCT00974051|Other|Control|No treatment is given for the study. This arm is for comparison with the two intervention arms.
1854225|NCT00974077|Behavioral|Mindfulness Based Cognitive Therapy|Group treatment over 8 weeks with training in meditation, stress regulation, shift attention, stay present, in addition with cognitive and behavioral strategies (following Williams et al. Manual 2002)
1854226|NCT00974077|Other|Waiting List Control|Patients receive MBCT with a delay of 6 months.
1854227|NCT00974090|Drug|Placebo / Teneli (Teneligliptin) + SU (Sulfonylurea)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
1854228|NCT00974090|Drug|Teneli / Teneli + SU|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with sulfonylurea
1854229|NCT00974103|Other|exercise advise|Exercises
1854230|NCT00974103|Other|chiropractic treatment and exercises|Manipulation, mobilisation, soft tissue work, ergonomic and exercise advise. Maximum 12 treatments
1854231|NCT00974116|Behavioral|MEND Childhood Obesity Program|The number of children who are obese in the UK is steadily increasing with both short and long term consequences for health. The aim of this study is to determine whether the MEND Programme (a new national initiative for the treatment of childhood obesity) is a successful and sustainable treatment for childhood obesity and obesity related health problems.
1854232|NCT00974116|Behavioral|Control Group|No intervention
1854233|NCT00974142|Drug|Cyclosporine|The study population (n=30) will be divided into two patient cohorts intended to receive cyclosporine at an initial dosing of 3.0 mg/kg/day or placebo, in a randomized ratio of 1:1.
1854234|NCT00974142|Drug|Placebo|The study population (n=30) will be divided into two patient cohorts intended to receive cyclosporine at an initial dosing of 3.0 mg/kg/day or placebo, in a randomized ratio of 1:1.
1854235|NCT00974155|Drug|Escitalopram, venlafaxine, lithium|oral application, highest tolerable dose, once daily
1854236|NCT00974155|Drug|Escitalopram, venlafaxine|oral application, highest tolerable dose, once daily
1854237|NCT00974168|Radiation|Cumulative BED ≤ 100|Radiation
1854238|NCT00974168|Radiation|Cumulative BED ≤ 130 Gy2|Radiation
1854239|NCT00974181|Device|Conor Medsystems COSTAR™ stent (10 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (10 µg Paclitaxel)
1854240|NCT00974181|Device|Conor Medsystems COSTAR™ stent (30 µg Paclitaxel)|Intervention will consist of percutaneous coronary intervention for treatment of one or more de-novo coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the CoStar™ Paclitaxel-Eluting Coronary Stent System (30 µg Paclitaxel)
1854241|NCT00974194|Procedure|Single Trocar CCK|CCK using Triport
1854242|NCT00974194|Procedure|Standard CCK|CCK using three or four ports
1854243|NCT00974220|Drug|fentanyl|single dose, 50 mcg of nebulized fentanyl citrate
1854244|NCT00974220|Drug|normal saline (placebo)|single dose, 0.9% saline solution
1854245|NCT00974233|Drug|Bendamustine|90 mg/m2/day IV days 1 and 2 every 28 days for 6 cycles
1854246|NCT00974233|Drug|Rituximab|375 mg/m2 Day 1 every 28 days for 6 cycles
1854247|NCT00974233|Drug|Lenalidomide|5 mg/day days 1-28 of each 28 day cycle, up to 12 cycles maximum. Dose escalation to 10 mg/day allowed after one cycle as defined in the protocol.
1854248|NCT00974246|Drug|Advair diskus|Advair diskus 50/250 1 inhalation bid for 16 weeks
1854249|NCT00974259|Device|Management protocol based on pBrO2 and ICP values.|For patients who experience falls in pBrO2 below 20 mm Hg, a hierarchical treatment algorithm will be instituted, adapted from published recommendations49. In principle, episodes requiring therapy will fall into one of 4 scenarios (scenario A, B, C, and D, defined in figure 7), which will require different management strategies. The treatment protocol depends on which type of episode is being treated. Treatment is triggered by abnormalities in either ICP (> 20 mm Hg) or pBrO2 (< 20 mm Hg) are noted. Elevations in ICP above 20 mm Hg or decline in pBrO2 below 20 mm Hg for more than 5 minutes will trigger a treatment intervention. Treatment is directed to an episode. Patients may start in one type of episode and move to another. Therapy will depend on which type of episode they are in at any given time.
1854250|NCT00974259|Device|Management protocol based on ICP values only.|For the patients randomized to ICP treatment alone, only Scenario A and Scenario B episodes are relevant.
1854251|NCT00974272|Drug|Exenatide|Single subcutaneous injection (10 μg)
1854252|NCT00974272|Other|Normal Saline|Single subcutaneous injection
1854253|NCT00974285|Drug|Fuzheng 1|Immunity 1 (Fuzheng 1), 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
1854254|NCT00974285|Drug|Placebo|Placebo, 8.75g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
1854255|NCT00974298|Procedure|Total elbow replacement arthroplasty|Total elbow arthroplasty using pressfit technique in which no cement is used.
1854258|NCT00974324|Drug|endostar and CHOP|"endostar, 7.5m g/m2, intravenous, Day 2-15, repeat every 3 weeks
CHOP: Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone"
1854259|NCT00974350|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; 2.5 mL SABER™-Bupivacaine/Once
1854260|NCT00974350|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; 5.0 mL SABER™-Bupivacaine/Once
1854261|NCT00974350|Drug|SABER™-Placebo|Injectable Solution; 2.5 or 5.0 mL SABER™-Placebo/Once
1854262|NCT00974363|Procedure|Blood Sampling|A blood sample will be taken yearly at each long-term follow-up visit (i.e. Year 2 through Year 5) after vaccination during the primary study. No vaccines are administered in the long-term follow-up study
1854263|NCT00974376|Drug|gabapentin 1200mg/day|gabapentin 1200mg/day for 12 weeks
1854264|NCT00974376|Drug|Placebo|1200mg/day of placebo for 12 weeks
1854265|NCT00974376|Behavioral|Manual-guided behavioral counseling|Standardized manual-guided behavioral counseling performed 1 time per week for 12 weeks in conjunction with study drug or placebo.
1854266|NCT00974389|Biological|bevacizumab|
1854267|NCT00974389|Drug|tegafur-gimeracil-oteracil potassium|
1854268|NCT00974402|Behavioral|Cognitive Behavioral Therapy|The study investigators have developed a 4-session PTSD treatment plan including a behavioral health consultants (BHC) manual and a patient guide for use in primary care. Therapists will be psychologists who are functioning as behavioral health consultants (BHC) in an integrated primary care clinic. The study will adapt intervention methods for use in the time-constrained primary care environment from Cognitive Behavioral Therapy(ies) that have proven effective for PTSD in specialty mental health care settings. Study participants will receive four 30-minute treatment sessions over six weeks.
1854269|NCT00974415|Procedure|CO2|CO2 treatment delivered to randomized flank at each study visit
1854270|NCT00974415|Procedure|Sham|Sham treatment to other flank at each study visit
1854271|NCT00974428|Dietary Supplement|Wobenzym® N|4 tablets TID, 6 weeks
1854272|NCT00974428|Dietary Supplement|Placebo|4 tablets TID
1854275|NCT00974454|Drug|Fuzheng 2|Immunity 2 (Fuzheng 2), 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
1854276|NCT00974454|Drug|Placebo|Placebo, 6.25g twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
1854277|NCT00974467|Behavioral|After The Injury website|Parents participate in a web-based prevention intervention, which provides education and tips specific to coping with a child's injury.
1854278|NCT00974467|Other|Control|Usual hospital care provided.
1854279|NCT00974480|Other|Redermic|Cosmetic cream formulation 609637 43.
1854280|NCT00974480|Drug|Tretinoin (Rejuva-A)|Tretinoin 0.025% cream.
1854281|NCT00974493|Drug|Antibiotics|"The trial protocol does not specify individual antibiotics, as the trial question is one of strategy (i.e. oral vs intravenous route) rather than individual antibiotics.
Within allocated strategy (i.e. oral or intravenous) antibiotics will be selected by a clinician with reference to the subject's clinical condition, microbiological data and local guidelines."
1854282|NCT00974506|Other|CAM-intervention|Complex intervention containing exercise therapy, nutritional advice, homeopathic treatment, naturopathic treatment in addition to routine care therapy by general practitioner
1854283|NCT00974506|Other|Routine care therapy|Routine care therapy by general practitioner
1854284|NCT00974519|Drug|Fuzheng 3|"Immunity 3 (Fuzheng 3), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
1854285|NCT00974519|Drug|Fuzheng 1|"Immunity 1 (Fuzheng 1), 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
1854286|NCT00974519|Drug|Placebo|"Immunity 1 (Fuzheng 1) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days.
Immunity 3 (Fuzheng 3) simulation agent, 8.75g / twice a day, half an hour before breakfast and dinner, mixing with water, for six successive cycles of 30 days."
1854287|NCT00974532|Dietary Supplement|High calcium diet 2000 mg/day|High calcium (2000 mg elemental calcium) diet x 9 days
1854288|NCT00974532|Dietary Supplement|Low calcium diet, 800 mg/day|Low calcium (800 mg elemental calcium) diet x 9 days
1854289|NCT00974558|Device|handheld fan directed to cheeks|Handheld fan directed to cheeks for 5 minutes
1854290|NCT00974571|Drug|montelukast sodium|montelukast 10 mg tablet orally once daily at bedtime for 6 weeks
1854291|NCT00974571|Drug|Comparator: cetirizine|cetirizine 10 mg tablet orally once daily at bedtime for 6 weeks
1854292|NCT00974571|Drug|Comparator: placebo|placebo tablet orally once daily at bedtime for 6 weeks
1854293|NCT00974584|Drug|GDC-0941|The GDC-0941 at a starting dose of 60 milligrams (mg) will be administered once daily orally for 14 consecutive days (Days 1 to 14) in 3-week cycles except for the first cycle that has Day 1 of single-agent GDC-0941 preceding Day 2 with combination chemotherapy.\n\n\n\n\n\n
1854294|NCT00974584|Drug|bevacizumab|Bevacizumab 15 milligrams per kilograms (mg/kg) intravenously (IV) on Day 1 of every 3-week cycle.
1854295|NCT00974584|Drug|carboplatin|Carboplation IV on Day 1 of every 3-week cycle, at a dose to achieve an area under concentration time curve of 6 milligrams per milliliter*minute (mg/mL*min).\n
1854296|NCT00974584|Drug|cisplatin|Cisplatin 75 milligrams per square meter (mg/m^2) IV on Day 1 of every 3-week cycle.\n
1854297|NCT00974584|Drug|paclitaxel|Paclitaxel 200 mg/m^2 IV on Day 1 of every 3-week cycle.\n\n
1854298|NCT00974584|Drug|pemetrexed|Pemetrexed 500 mg/m^2 IV on Day 1 of every 3-week cycle.
1854299|NCT00974597|Device|AWBAT™-D and Mepilex® Ag dressings|Comparison of AWBAT™-D and Mepilex® Ag dressings for treatment of donor sites in burn surgery.
1854300|NCT00974623|Device|Bone graft substitute, autograft or allograft|spine fusion surgery utilizing any commercially available bone graft substitute(s), autograft or allograft
1854301|NCT00974636|Dietary Supplement|Low Salt Diet|Dietary sodium restriction of ≤2.0 g/day or ≤ 85 mmol/day
1854302|NCT00974636|Dietary Supplement|Usual Salt Diet|Usual salt intake (approximately >180-200 mmol/day in the average American diet).
1854303|NCT00974649|Behavioral|self-report questionnaire|validated self-report questionnaires on psychosocial determinants
1854304|NCT00974662|Drug|WST11|WST11-mediated VTP will consists of the combination of a single IV administration of WST11 at doses of 5, 7.5 & 10 mg/kg, using 753 nm laser light at a fixed power of 250 mW/cm and escalating fixed energy dose (200 Joules/cm and 300 Joules/cm) locally delivered to the obstructing tumor through an optical fiber placed, during endoscopy, in the endoscope operating channel with visual control, possibly video-transmission assisted. The fiber illuminating diffusion length is fixed (2 cm).
1854305|NCT00974675|Biological|CAT-354 1mg/kg|CAT-354 1 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
1854306|NCT00974675|Biological|CAT-354 5 mg/kg|CAT-354 5 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
1854307|NCT00974675|Biological|CAT-354 10mg/kg|CAT-354 10 mg/kg of body weight intravenous infusion over 30 minutes on Day 0, 28 and 56.
1854308|NCT00974675|Other|Placebo|Placebo matched to CAT-354 intravenous infusion over 30 minutes on Day 0, 28 and 56.
1854309|NCT00974688|Behavioral|Information Intervention|The information intervention is designed to ensure that the parent(s) and child have a clear understanding of the range of physical activity opportunities that are appropriate and recommended for the child. The information intervention will be comprised of discussions and written information.
1854310|NCT00974688|Behavioral|Demonstration Intervention|The demonstration intervention will be designed to demonstrate to the child and parent(s) specifically what the child is able to do in relation to fitness and motor skill activities. The demonstration intervention will consist of having the child complete a standardized exercise testing protocol on the treadmill, followed by discussions with the child and parent(s) to convey the results of the study testing of fitness and gross motor skill.
1854311|NCT00974701|Device|PillCam ESO2|The capsule to be tested in this proposed study, PillCam ESO 2 capsule Endoscopy, is an improved version with exactly the same dimensions as the current PillCam ESO capsule, both in length and diameter.
1854312|NCT00974714|Drug|L-arginine|Oral L-arginine 2 g twice a day for 14 weeks
1854313|NCT00974714|Other|placebo|oral placebo 2 g twice a day for 14 weeks
1854314|NCT00974727|Other|Garden Fit|8-week summer gardening program. 9am-12pm on Monday, Wednesday, Friday and 9am-12:30pm on Tuesday and Thursday. Activities included gardening (preparing soil for planting, planting seeds and seedlings, mulching, weeding, watering, and harvesting), preparing meals with fresh foods from the garden, and other garden activities and games.
1854315|NCT00974740|Drug|Atorvastatin|atorvastatin 40 mg (tablet for oral intake) once daily in the evening for 4 weeks, thereafter 80 mg for the remaining treatment period (total treatment period 18 months)
1854316|NCT00974740|Drug|atorvastatin matching placebo|atorvastatin matching placebo tablets once daily in the evening, corresponding to 40 mg atorvastatin for the first 4 weeks (run-in period), and corresponding to 80 mg atorvastatin thereafter (total treatment period 18 months)
1854317|NCT00974753|Drug|Ketorolac 0.5%|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
1854318|NCT00974753|Other|Saline drops|Four-times a day starting one week before surgery and continued for 4 weeks post surgery.
1854319|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 2 weeks; then 0.5 mg/kg/day for alternate days for eight weeks. Then taper by 5 mg every 2 weeks and discontinue
1854320|NCT00974766|Drug|Glucocorticoids|Prednisolone 0.75 mg/kg/day for 6 weeks; then 0.5 mg/kg/day for 6 weeks. Then taper by 5 mg every 6 weeks and discontinue
1854321|NCT00974779|Device|HCO1100 dialyzer|Thrice weekly dialysis using the HCO1100 dialyzer for 4.5h, 2 weeks
1854322|NCT00974779|Device|regular dialysis polyamide|Continuation of the regular hemodialysis using polyamide high-flux hemodialysers
1854323|NCT00974792|Biological|pegfilgrastim|
1854324|NCT00974792|Biological|rituximab|
1854325|NCT00974792|Drug|cyclophosphamide|
1854326|NCT00974792|Drug|cytarabine|
1854327|NCT00974792|Drug|doxorubicin hydrochloride|
1854328|NCT00974792|Drug|etoposide phosphate|
1854329|NCT00974792|Drug|ifosfamide|
1854330|NCT00974792|Drug|leucovorin calcium|
1854331|NCT00974792|Drug|methotrexate|
1854332|NCT00974792|Drug|vincristine sulfate|
1854333|NCT00974805|Drug|Seretide 500 Accuhaler|Seretide 500 accuhaler one inhalation BD
1854334|NCT00974818|Drug|Mitomycin C (MMC)|Patients randomized to this group will receive six weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water). Patients will receive three weekly cycles of 40 mg of intravesical MMC (dissolved in a total volume of 20 mL sterile water) 3, 6, 12, 18, and 24 months after the induction course.
1854335|NCT00974818|Biological|Bacillus Calmette-Guerin (BCG)|Patients randomized to this group will receive six weekly cycles of 81 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline). Patients will receive three weekly cycles of 27 mg of intravesical BCG (dissolved in a total volume of 53 mL of diluent and saline) 3, 6, 12, 18, and 24 months after the induction course.
1854336|NCT00974831|Other|Amino Acid Drink Mixture|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
1854337|NCT00974831|Other|Glucose drink|22 oz consumed in 7 oz, 8oz, 7 oz increments 5 minutes apart over 15 mins
1854338|NCT00974857|Device|BCM|Overhydration (OH) in liters will be estimated with the BCM (Body Composition Monitor, Fresenius Medical Care, Deutschland GmbH) in order to determine dry weight at least once a month before a dialysis session.
1854339|NCT00974857|Other|control group|BCM results obtained at the beginning, at the 6th, and 12th months will not be given to the treating physicians. Dry weight estimation will be guided by clinical findings, telecardiography, and echocardiography as used to be.
1854340|NCT00974870|Procedure|needling treatment|Needling treatment applied to half of the face at each study visit
1854341|NCT00974883|Procedure|Ultrasound of temporal and axillary arteries|Standardised assessment of temporal arteries and axillary arteries using high resolution ultrasound to detect halo, stenosis or occlusion
1854342|NCT00974883|Procedure|Temporal artery biopsy|Biopsy of temporal artery from symptomatic side
1854471|NCT00975728|Dietary Supplement|Alixir - Pomegranate, apple and Açai drink / Placebo|250 ml/day Alixir/Placebo for Group 2 for 8 weeks 500 ml/day Alixir/Placebo for Group 1 for 8 weeks
1854343|NCT00974896|Drug|AMG 479|AMG 479 is a fully human IgG1 monoclonal antibody that inhibits IGF-1R signalling. AMG 479 (6mg/kg or 12mg/kg) will be given IV every 2 weeks in combination with sorafenib (400 mg po BID) or erlotinib (150 mg po QD).
1854344|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system
1854345|NCT00974909|Device|Urgent PC neuromodulation system|Urgent PC neuromodulation system (sham)
1854349|NCT00974935|Drug|Aluminum hydroxide|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
1854350|NCT00974935|Biological|STEBVax vaccine|Single dose of recombinant staphylococcal enterotoxin B vaccine (STEBVax) in Alhydrogel adjuvant at 0.01, 0.1, 0.5, 2.5, 10 or 20 mcg intramuscular and 2 doses of 20 mcg intramuscular 21 days apart. STEBVax vaccine will be administered as a single 0.5 mL intramuscular injection into the deltoid muscle of the non-dominant arm; subjects in the 2 dose cohort will have the vaccine administered in the alternate arm.
1854351|NCT00974948|Procedure|EUS-guided celiac plexus neurolysis|Injection of 20cc of absolute alcohol + 10c of 0.5% bupivicaine on either side of the celiac axis.
1854352|NCT00974961|Drug|bupivacaine, levobupivacaine|intrathecal injection 15~20mg(for Levobupivacaine) or 10~15mg(for Bupivacaine) once
1854353|NCT00974974|Drug|IPX066|extended-release carbidopa-levodopa capsules
1854354|NCT00974974|Drug|IR CD-LD|immediate-release carbidopa-levodopa tablets
1854355|NCT00974987|Radiation|BNCT(boron neutron capture therapy)|BSH(sodium borocaptate) 100mg/kg iv for one hour starting 13 hours before irradiation, and BPA(p-boronophenylalanine) 500/mg/kg iv at a speed of 200mg/kg/hr for 2 hours starting 2 hours before irradiation. During irradiation, BPA iv continues at a speed of 100mg/kg/hr.
1854356|NCT00974987|Radiation|XRT(X-ray radiation treatment)|After BNCT, 2Gy irradiation every day for 12 days.
1854357|NCT00974987|Drug|TMZ(temozolomide)|75mg/m2 for day1-12. After XRT, repeat the cycle of 150-200mg/m2 for 5 days and cessation for 23 days.
1854358|NCT00975000|Drug|Cinacalcet|Possible sequential doses are 30, 60, 90, 120, and 180 mg.
1854359|NCT00975000|Drug|Placebo|Administered orally following the same dosing regimen as the experimental arm.
1854360|NCT00975026|Procedure|Massages ± Stretches|Chair Massage
1854361|NCT00975039|Drug|WST11|WST11-mediated VTP will consist of the combination of a single IV administration of WST11 at doses of 2.5 and 5 mg/kg, using 753nm laser light at a fixed power (150 mW/cm) and light energy (200 J/cm). Illumination in the bile duct is performed by inserting a diffusing fiber, with cylindrical uniform light distribution, in a transparent standard ERCP catheter and by positioning, under radioscopy, the illumination tip of the diffusing fiber in front of the lesion.
1854362|NCT00975052|Drug|sitagliptin phosphate|100 mg sitagliptin daily for two days in one out of four treatment periods
1854363|NCT00975052|Drug|Comparator: metformin|500 mg twice daily on Day 1 and 1000 mg once daily on Day 2 in one of four treatment periods.
1854364|NCT00975052|Drug|Comparator: sitagliptin and metformin|100 mg sitagliptin once daily and 500 mg metformin twice daily on Day 1 and 100 mg sitagliptin once daily and 1000 mg metformin once daily on Day 2 in one of four treatment periods.
1854365|NCT00975052|Drug|Comparator: placebo|Placebo only on Days 1 and 2 in one of four treatment periods.
1854366|NCT00975065|Drug|vildagliptin 50 mg bid plus metformin 1500mg (Galvus+Diabex)|vildagliptin 50 mg bid plus metformin 1500mg
1854367|NCT00975065|Drug|metformin 1500mg plus metformin 500mg or 1000mg (Diabex)|metformin 1500mg plus metformin 500mg or 1000mg
1854368|NCT00975078|Procedure|adrenal insufficiency testing|"On the day getting the baseline data we will perform a low dose cosyntropin test to asses adrenal axis function.
All participants will then undergo an overnight 0.5mg dexamethasone suppression test. Thereby participants will take 0.5mg of dexamethasone at 11 pm and a fasting blood sample will be collected the next morning at 8 am to measure the serum cortisol level.
Six days later participants will start taking 0.5mg/kg body-weight prednisone each morning for 14 days.
On day 1, 3, 7 and 21 after withdrawal of prednisone the participant will undergo a low dose cosyntropin test. The investigators will take a blood sample before and 30 minutes after i.v. administration of 1ug of cosyntropin for the measurement of cortisol."
1854369|NCT00975078|Drug|prednisone|0.5mg/kg body-weight prednisone each morning for 14 days
1854370|NCT00975091|Drug|Entecavir|Tablets, Oral, 0.5 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
1854371|NCT00975091|Drug|Entecavir|Tablets, Oral, 1.0 mg, once daily, Until ETV is commercially available in China or when Post Study Drug Program is started
1854372|NCT00975104|Drug|AMG 745 0.3 mg/kg|AMG 745 0.3 mg/kg IV QW
1854373|NCT00975104|Drug|AMG 745 1.0 mg/kg|AMG 745 1.0 mg/kg IV QW
1854374|NCT00975104|Drug|AMG 745 3.0 mg/kg|AMG 745 3.0 mg/kg IV QW
1854375|NCT00975104|Drug|Placebo|Placebo IV QW
1854376|NCT00975117|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) twice a day, for 12 weeks.
1854377|NCT00975117|Dietary Supplement|Spermotrend|One Spermotrend tablet (Orally administered) twice a day, for 12 weeks
1854378|NCT00975130|Biological|SC golimumab|Subcutaneous golimumab at a dose of 50 mg administered once monthly.
1854379|NCT00975130|Biological|IV golimumab|Intravenous golimumab administered up to 3 times (month 7, 8, 10) during a period of 6 months at a dose of 2 mg/kg of body weight.
1854380|NCT00975143|Drug|CIP-Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
1854381|NCT00975143|Drug|Isotretinoin|0.5 mg/kg/day for 4 weeks, and 1 mg/kg/day for 16 weeks, taken orally, twice daily.
1854382|NCT00975156|Other|Physical Therapy|Conventional physical therapy
1854383|NCT00975156|Device|Lokomat|Robotic-assisted walking device
1854384|NCT00975182|Drug|GDC-0941|Oral repeating dose
1854385|NCT00975182|Drug|erlotinib HCl|Oral repeating dose
1854386|NCT00975195|Drug|tiotropium inhalation|
1854390|NCT00975221|Drug|Cinacalcet|Administered orally at a starting dose of 30 mg twice a day (BID). Participants will be eligible for a dose titration once every 3 weeks during the placebo-controlled dose titration phase based on corrected total serum calcium concentration and safety assessments obtained the previous week. Doses may be sequentially increased to 60 mg BID, 90 mg BID, and 90 mg 3 times a day (TID).
1854391|NCT00975221|Drug|Placebo|Administered orally following the same tiitration regimen as the experimental arm.
1854392|NCT00975234|Procedure|Intra-lesion injection of autologous skeletal myoblasts|Intra-lesion injection
1854393|NCT00975234|Procedure|Revascularisation|Revascularisation surgery
1854394|NCT00975247|Other|Receiving an educational booklet|Patients who receive an educational booklet will be considered to be receiving an intervention
1854395|NCT00975273|Behavioral|Capnometry Assisted Respiration Training|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly, and shallowly in order to raise their PCO2 levels with the assistance of a biofeedback device.
1854396|NCT00975273|Behavioral|Breathing Awareness|Patients learn to alter their breathing pattern by breathing abdominally, slowly, regularly using a biofeedback device.
1854397|NCT00975286|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1854398|NCT00975286|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1854399|NCT00975286|Drug|Insulin glargine|Dose to be adjusted to maintain a fasting SMPG between 100 and 80 mg/dL (5.6 and 4.4 mmol/L), inclusive.
1854400|NCT00975286|Device|Pen auto-injector|Lantus® SoloStar® OptiClik®
1854401|NCT00975286|Drug|Metformin|Metformin to be continued at stable dose (at least 1.5 gram per day) up to Week 24.
1854402|NCT00975286|Drug|Thiazolidinedione (TZD)|TZD (either rosiglitazone or pioglitazone) if given, to be continued at stable dose up to Week 24.
1854403|NCT00975299|Drug|BAY86-4367|Cancer patients, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, PET/CT
1854404|NCT00975299|Drug|BAY86-4367|Healthy volunteers, single intravenous bolus injection of 300 MBq BAY86-4367 on day one of the treatment period, whole body PET/CT for determination of effective dose., kinetics of BAY86-4367 in blood
1854405|NCT00975312|Drug|Triple combination cream|The triple combination cream (hydroquinone 4%, tretinoin 0.05%, and fluocinolone acetonide 0.01%) was applied on the whole back of one hand once daily for up 12 weeks.
1854406|NCT00975312|Drug|Tretinoin 0.05%|Tretinoin 0.05% cream was applied on the whole back of the other hand once daily for up 12 weeks.
1854407|NCT00975325|Drug|Yohimbine|yohimbine 5 mg, one tablet, single dose only
1854408|NCT00975325|Drug|Yohimbine|yohimbine 5 mg, one tablet, single dose only
1854409|NCT00975338|Other|LIFEspan|Rehabilitation services provided by an inter-disciplinary team of health professionals addressing the transfer of care to adult services and emerging needs related to transition to adulthood. LIFEspan staff are cross-appointed to both a pediatric and an adult hospital through a formally linked model of care.
1854410|NCT00975338|Other|Non-LIFEspan|Standard of care in the absence of a formal partnership between a pediatric and an adult hospital.
1854411|NCT00975351|Dietary Supplement|13C5-labelled 5-methyltetrahydrofolic acid|"one intravenous bolus dose of no more than 500nmole 13C5-labelled 5-methyltetrahydrofolic acid, followed by multiple blood samplings at regular time intervals. Total 2hr intervention."
1854412|NCT00975377|Procedure|Hair clipping|Patients randomized to the hair clipping cohort will be clipped using an Allegiance 4413 hair clipper. Hair removal will occur on the day of surgery by one of the preoperative nursing staff, immediately prior to the scheduled operation.
1854413|NCT00975390|Dietary Supplement|Carbohydrate|1.2 g/kg/h
1854414|NCT00975390|Dietary Supplement|Carbohydrate and protein ingestion|1.2 g/kg/h carbohydrate plus 0.4 g/kg/h protein
1854415|NCT00975390|Dietary Supplement|Carbohydrate and caffeine ingestion|1.2 g/kg/h carbohydrate and 1.67 g/kg/h caffeine
1854416|NCT00975403|Device|Dead space breathing|Chemical loading by adding a deadspace (600ml) to the breathing circuit during a single cycle exercise test
1854417|NCT00975403|Device|Room air breathing|Sham comparator (vs deadspace) during a single cycle exercise test will entail breathing room air on the same circuit without the rebreathe valves
1854418|NCT00975416|Behavioral|Cognitive Behavioral Therapy|Intranasal oxytocin given in the context of cognitive behavioral therapy
1854419|NCT00975416|Drug|Intranasal Oxytocin|Intranasal oxytocin given in the context of cognitive behavioral therapy
1854420|NCT00975416|Drug|Placebo|Placebo given in the context of cognitive behavioral therapy
1854421|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 4mg/kg using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
1854422|NCT00975429|Drug|WST11|The WST11-mediated VTP procedure will consist of a single IV administration of WST11 at a dose of 6mg/kg in patients using a 753nm laser light at a fixed power (150mW/cm or 200mW/cm or 250mW/cm ) and light energy (200J/cm or 300J/cm) delivered through transperineal interstitial optical fibers. The fibers are introduced into transparent needles that are positioned in the prostate under ultra sound image guidance. The tumour location is established using transrectal biopsy and MR imaging. The number of fibers and the total light energy will be adapted to each patient based on a treatment planning proposed by treatment planning group.
1854423|NCT00975442|Other|Eccentric training|A home training program of eccentric training of the wrist extensors to be carried out daily with 3 sets of 15 repetitions. All subjects were instructed to use the forearm band (Epi Forsa 4061, Rehband, Sweden)
1854424|NCT00975442|Device|Forearm band|All subjects were instructed to use the forearm band during all daily activities.
1854425|NCT00975442|Device|Forearm band|All patients were instructed to use a forearm band during all daily activities.
1854472|NCT00975741|Device|OXIMAX|
1854473|NCT00975741|Device|ASMANEX TWISTHALER|
1854527|NCT00981617|Drug|Placebo|Matching placebo taken once daily for 12 weeks
1854426|NCT00975468|Other|Pressure Controlled vs. Volume Controlled Ventilation during OLV|Ventilation will be initiated with a tidal volume of 8 ml.kg-1 in Volume-controlled group and with a peak airway pressure that provided a tidal volume of 8 ml.kg-1 in pressure-controlled group. R.R will be adjusted to achieve an arterial PaCO2 4.5-6 kPa and FiO2 will be increased to 1.0 during OLV.
1854427|NCT00975481|Drug|dimebon|Oral tablet; 20 mg dimebon, single dose
1854428|NCT00975481|Drug|dimebon|Oral tablet; 40 mg dimebon, single dose
1854429|NCT00975481|Drug|dimebon|Oral tablet; 60 mg dimebon, single dose
1854430|NCT00975481|Drug|placebo|Oral tablet or capsule; placebo, single dose
1854431|NCT00975481|Drug|alprazolam|Oral capsule; 1 mg alprazolam, single dose
1854432|NCT00975481|Drug|alprazolam|Oral capsule; 3 mg alprazolam, single dose
1854433|NCT00975494|Drug|Sildenafil|
1854434|NCT00975494|Drug|Placebo|
1854435|NCT00975507|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of V221 at Day 0 and Day 90
1854436|NCT00975507|Biological|Comparator: Placebo|a single 0.5 mL subcutaneous placebo injection at Day 0
1854437|NCT00975507|Biological|Comparator: Varivax|a single 0.5 mL subcutaneous injection of Varivax at Day 0
1854438|NCT00975507|Biological|Comparator: M-M-R II|a single 0.5 mL subcutaneous injection of M-M-R II at Day 0
1854439|NCT00975520|Other|Observation|Patients will be observed after surgery until recurrence when they will be offered radiation therapy
1854440|NCT00975520|Radiation|Radiation Therapy|Patients randomised to the Investigational treatment arm, will receive adjuvant curative post-operative radiation therapy aiming to reduce the rate of local recurrence. The recommended dose prescribed is 48 Gy in 20 fractions over 4 weeks.
1854441|NCT00975533|Device|Tantalus|The TANTALUS System is implanted using minimally invasive procedure (laparoscopy). It uses leads with stitch electrodes to deliver electrical signals to the gastric wall for the treatment of obese subjects with T2DM.
1854442|NCT00975533|Drug|Insulin|Insulin treatment will be prescribed, in accordance with the common medical practice at the institute. Dosages will be recorded on a daily basis.
1854443|NCT00975546|Other|Sperm washing and testing for HIV contamination|Semen will undergo specialized washing to reduce viral contamination of sperm. The sperm are first separated from leukocytes and other seminal constituents by centrifugation over a stepwise gradient. Motile sperm will be separated from the resulting pellet by a swim-up step in which washed sperm are overlaid with fresh medium into which sperm migrate. The final sperm suspension will be stored while testing for HIV is performed by reverse transcription polymerase chain reaction (RT-PCR)
1854444|NCT00975546|Procedure|Intrauterine Insemination|Intrauterine Insemination (IUI) will be performed on the HIV-negative wife, following standard clinical practice, using washed sperm from her HIV-positive husband after testing the IUI sample for HIV.
1854445|NCT00975572|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
1854446|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 7.5 μg|440 participants (110 elders,110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 7.5 μg on day 0 and 21.
1854447|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
1854448|NCT00975572|Biological|Experimental: split-virion, adjuvanted H1N1 vaccine of 30 μg|330 participants (110 elders, 110 adults, and 110 adolescents) to receive split-virion, adjuvanted H1N1 vaccine of 30 μg on day 0 and 21.
1854449|NCT00975572|Biological|Experimental: split-virion, non-adjuvanted H1N1 vaccine of 15 μg|440 participants (110 elders, 110 adults, 110 adolescents and 110 children) to receive split-virion, non-adjuvanted H1N1 vaccine of 15 μg on day 0 and 21.
1854450|NCT00975572|Biological|Placebo Comparator: Placebo control|110 adults to receive placebo control (Phosphate Buffer Saline) on day 0 and 21.
1854451|NCT00975585|Device|senofilcon A|soft contact lens, 2-week replacement indicated
1854452|NCT00975585|Device|lotrafilcon B|soft contact lens with a 4-week replacement indicated.
1854453|NCT00975611|Drug|Amantadine Hydrochloride, USP|amantadine tablets 100 mg. BID for 4 weeks
1854454|NCT00975611|Drug|Amantadine Hydrochloride, USP|amantadine 200 mg. tablets BID for 4 weeks
1854455|NCT00975611|Drug|Placebo|tablets BID, for 4 weeks
1854456|NCT00975637|Drug|70 mg SC|70 mg SC
1854457|NCT00975637|Drug|210 mg SC|210 mg SC
1854458|NCT00975637|Drug|140 mg SC|140 mg SC
1854459|NCT00975637|Drug|280 mg SC|280 mg SC
1854460|NCT00975637|Drug|Placebo|Placebo SC
1854461|NCT00975650|Drug|Nasobol® (Intra-nasal Testosterone)|BID administration
1854462|NCT00975650|Drug|Androderm® (Positive Control)|QD administration
1854463|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
1854464|NCT00975663|Drug|Tacrolimus and MMF|Tacrolimus: daily oral dose divided into 2 doses (morning and evening). MMF: daily dose divided into 2 doses at 12 hour intervals or 3 doses at 8 hour intervals.
1854465|NCT00975676|Other|gas chromatography / tandem mass spectometry|Determination of estrogen levels through gas chromatography.
1854466|NCT00975689|Drug|N-Acetyl Cysteine|900mg effervescent tablet; Dosed as 15 mg/kg/day (maximum dose 900 mg per day) for one week, advanced to 30 mg/kg/day (maximum dose 1800 mg per day) for the second week, and then advanced to 60 mg/kg/day (maximum dose 2700 mg) for the remainder of the trial (6 additional weeks).
1854467|NCT00975702|Procedure|RIPC by Inflation of Pneumatic Tourniquet|Pneumatic tourniquets will be placed on both lower extremities in all deceased donor subjects. In the RIPC group the tourniquets will be inflated sequentially for 10 min each followed by deflation, approximately, 30-60 min prior to aortic crossclamping and organ perfusion.
1854468|NCT00975715|Drug|TRI476|TRI476 oral suspension doses, based on body weight twice daily
1854469|NCT00975715|Drug|Placebo to TRI476|Placebo oral suspension, taken twice daily
1854470|NCT00975715|Drug|Benzodiazepines|Benzodiazepines could be used as needed as rescue medication during the duration of the study.
1854474|NCT00975754|Drug|Pulmicort pMDI HFA|Inhalation aerosol, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
1854475|NCT00975754|Drug|Budesonide pMDI HFA|Inhalation aerosol, 160 μg/ metered dose. Each subject receive a single dose from 4 inhalations
1854476|NCT00975754|Drug|Pulmicort Repulses|Suspension for nebulisation, 0.5 mg/mL. Each subject receive a single dose from 100 inhalations
1854477|NCT00975754|Drug|Pulmicort Turbohaler|Inhaled powder, 200 μg/ metered dose. Each subject receive a single dose from 4 inhalations
1854478|NCT00975767|Drug|MGCD265+erlotinib|MGCD265 and erlotinib administered daily
1854479|NCT00975767|Drug|MGCD265+docetaxel|MGCD265 administered daily; docetaxel administered once every 3 weeks
1854480|NCT00975780|Other|Enhanced Oral Care|oral brushing plus oral chlorhexidine plus upright feeding positioning
1854481|NCT00975780|Other|Usual oral care|Usual oral care and feeding positioning
1854482|NCT00975793|Other|Early Goal Directed Therapy (EGDT)|Randomised allocation of early goal-directed therapy (EGDT). EGDT involves treatment with intravenous fluids, and medications to support the blood pressure and heart following a protocol. A special catheter is inserted to monitor central blood oxygen levels and the standard treatments are given according to the blood oxygen level reading. EGDT is given for 6 hours, then the patient receives standard care.
1854483|NCT00975806|Drug|Lenalidomide|Lenalidomide MTD mg by mouth (PO) daily for Days 1- 21 in combination
1854484|NCT00975806|Drug|Sunitinib|Sunitinib 37.5 mg PO daily on days 1-21 of each 21-day cycle in Cohort A or on days 1-14 in Cohorts F and G
1854485|NCT00975819|Drug|sirolimus|liquid dosing based on trough levels
1854487|NCT00975858|Procedure|Coronary Revascularization|revascularization of coronary arteries in case of symptomatic obstructive coronary artery disease
1854489|NCT00975897|Biological|bevacizumab|
1854490|NCT00975897|Biological|cetuximab|
1854491|NCT00975897|Drug|fluorouracil|
1854492|NCT00975897|Drug|irinotecan hydrochloride|
1854493|NCT00975897|Drug|leucovorin calcium|
1854494|NCT00975897|Drug|oxaliplatin|
1854495|NCT00975897|Genetic|RNA analysis|
1854496|NCT00975897|Genetic|cytogenetic analysis|
1854497|NCT00975897|Genetic|fluorescence in situ hybridization|
1854498|NCT00975897|Genetic|gene expression analysis|
1854499|NCT00975897|Genetic|mutation analysis|
1854500|NCT00975897|Genetic|protein expression analysis|
1854501|NCT00975897|Other|diagnostic laboratory biomarker analysis|
1854502|NCT00975897|Other|immunohistochemistry staining method|
1854503|NCT00975897|Other|questionnaire administration|
1854504|NCT00975897|Procedure|cognitive assessment|
1854505|NCT00975910|Drug|lidocaine|Lidocaine arm: lidocaine (2%) as an intravenous bolus (1.5 mg/kg) during induction followed by an intravenous infusion (2 mg. kg(-1).h(-1)) after induction until at the end of surgery
1854506|NCT00975910|Drug|saline|Saline arm: infused at the same rate as lidocaine
1854507|NCT00975923|Behavioral|Collaborative Group|"In addition to the Tool Kit materials and web site support, facility leaders and managers in this group agreed to participate in a Collaborative to improve critical care. The Collaborative differed from the IHI BTS model in that teams did not come together for face-to-face educational and planning sessions but instead attended web seminars and teleconferences. Between these virtual learning sessions, teams implemented some of the suggested change ideas, measured the results of those changes, and reported back to the larger group. Teams were supported through monthly educational and troubleshooting conference calls, individual coaching by faculty members, and an e-mail listserver designed to stimulate interaction among teams."
1854508|NCT00975923|Behavioral|Tool Kit|Hospitals received a tool kit:evidence-based guidelines, CLABSI/VAP fact sheets, change ideas,quality improvement and teamwork methods, standardized data collection and charting tools. Periodic reminders of their commitment to the Safe Critical Care Initiative and access to web site containing all of the educational seminars, clinical tools, and quality improvement tools. ICUs in this group were on their own to initiate and implement a local hospital quality improvement initiative preventing CLABSI and VAP.
1854509|NCT00975936|Drug|[14C]-GSK706769|50µg [14C]-GSK706769 containing 250 nCi
1854510|NCT00975936|Drug|Ketoconazole|200 mg Ketoconazole (Q12)
1854511|NCT00975949|Other|Survey|Parents of subjects were interviewed and two surveys were obtained, the Child Health Questionnaire and the Vineland-II.
1854512|NCT00975962|Drug|Actilyse|Actilyse according to guidelines without pretreatment with remote persconditioning
1854513|NCT00975962|Procedure|Thrombolysis + remote perconditioning|The rIPerC consists of 4 cycles of 5 minute total occlusion of blood flow to the non-paretic arm separated by 5 minutes of reperfusion. The occlusion is secured by inflating a standard blood pressure cuff to 25 mmHg above the systolic blood pressure. Written instruction on cuff inflation and paramedic's documentation of their procedure were written in a standard report which was turned over to a study nurse upon arrival to the hospital, and filed. The investigators were hence blinded to the prehospital rIPerC.
1854514|NCT00981539|Procedure|enema|"pre operative rectal enema
one adult bottle to be used rectally the night before surgery"
1854515|NCT00981552|Radiation|IMRT planning|
1854516|NCT00981552|Radiation|4-Field Radiation Planning|
1854517|NCT00981565|Procedure|open carpal tunnel release|surgery to release the carpal tunnel
1854518|NCT00981565|Other|Night-cast|individual night time splinting
1854519|NCT00981578|Device|ExAblate 2100|Conformal Bone System
1854520|NCT00981591|Drug|Iloprost|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours; uptitrated to effect, to maximum dose of 30 mcg every 30 minutes
1854521|NCT00981591|Drug|Placebo|Inhaled via Aerogen nebulizer, 0.5 mcg/kg every 2 hours or more
1854522|NCT00981604|Procedure|SILS|Single Incision Laparoscopic Cholecystectomy
1854523|NCT00981604|Procedure|Standard Laparoscopic Cholecystectomy|4 port technique
1854524|NCT00981617|Drug|ALKS33 (RDC-0313) (1 mg)|1 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
1854525|NCT00981617|Drug|ALKS33 (RDC-0313) (2.5 mg)|2.5 mg ALKS33 (RDC-0313) taken once daily for 12 weeks
1854528|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL,Subcutaneous
1854529|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
1854530|NCT00981630|Biological|Live attenuated Japanese encephalitis virus|0.5 mL, Subcutaneous
1854531|NCT00981630|Biological|ChimeriVax™ diluent (Placebo)|0.5 mL, Subcutaneous
1854532|NCT00981643|Behavioral|Meditation instruction and practice|Meditation techniques introduced and practiced, in a group setting, once weekly for 8 weeks
1854533|NCT00981656|Drug|cisplatin|Given IV
1854534|NCT00981656|Drug|fluorouracil|Given IV
1854535|NCT00981656|Drug|mitomycin C|Given IV
1854536|NCT00981669|Biological|rotavirus vaccine|3 doses with 6 weeks interval
1854537|NCT00981669|Biological|placebo|3 doses with 6 weeks interval
1854538|NCT00981682|Drug|SER120|once a day treatment of nocturia
1854539|NCT00981695|Biological|MVA.HIVA|1 dose of 5 x 10^7 pfu of MVA.HIVA administered intramuscularly
1854540|NCT00981708|Drug|Lenalidomide, Dexamethasone and Cyclophosphamide|"Lenalidomide capsules on days 1 to 21. the dose starts at 5 mg/day up to 25 mg/day.
Dexamethasone tablets on days 1 to 4. Dose 20 mg per day.
Cyclophosphamide tablets on days 1 to 10. The dose starts at 50 mg per day up to 100 mg per day.
The cycle is to be repeated every 28 days (4 weeks)"
1854541|NCT00981721|Drug|cediranib (RECENTIN TM, AZD2171)|20 mg or 30mg cediranib once on Days 1, then 20 mg or 30mg cediranib once daily from Days 8
1854542|NCT00981734|Other|Hiking|Three times by a week, thirty minutes, controlling heart frequency between fifty five per cent and seventy five per cent.
1854543|NCT00981747|Drug|Sildenafil|Sildenafil 20mg three times per day for 3 months
1854544|NCT00981747|Drug|Losartan|Losartan 25mg two times a day for 3 months
1854545|NCT00981747|Drug|Sildenafil and Losartan|Sildenafil 20mg three times per day and Losartan 25mg two times per day.
1854546|NCT00981747|Drug|Placebo pill|Placebo pill three times per day for 3 months
1854547|NCT00981773|Drug|Maraviroc|Maraviroc 150 mg bid
1854548|NCT00981773|Drug|Maraviroc|maraviroc 150 mg bid switch 12 weeks later
1854549|NCT00981786|Drug|Brimonidine/timolol fixed combination drops added to travoprost|twice daily administration
1854550|NCT00981786|Drug|Brinzolamide/timolol fixed combination drops added to travoprost|twice daily dosing
1854551|NCT00981799|Drug|Nelarabine|Dose will be assigned at study entry. Nelarabine will be given IV over 60 minutes (given at hours 0 to 1) on days 1 through 5.
1854552|NCT00981799|Drug|Etoposide|100 mg/m2/day IV over 2 hours (given at hours 1 to 3) on days 1 through 5
1854553|NCT00981799|Drug|Cyclophosphamide|Dose will be assigned at study entry, IV as a 30-60 minute infusion (given at hours 3 to 4) on days 1 through 5.
1854554|NCT00981799|Drug|Methotrexate|"Give between day 29 and 36 or when ANC>750 and PLTS>75,000 - whichever comes first (but not prior to day 22) at the dose defined by age below, ideally in conjunction with BM evaluation.
Given intrathecally at the dose defined by age below. 8 mg for patients age greater than or equal to 1, but <2 years of age 10 mg for patients age greater than or equal to 2, but <3 years of age 12 mg for patients greater than or equal to 3, but < 9 years of age 15 mg for patients greater than or equal to >9 years of age"
1854555|NCT00981799|Drug|Filgrastim|5 micrograms/kg/day IV or SC will begin on Day 6 and end when the ANC is > 1000/mm3 for two consecutive days.
1854556|NCT00981812|Procedure|PEM Breast Biopsy|Breast biopsy using PEM guidance and Stereo Navigator software
1854557|NCT00981825|Drug|Fluoride|Whole mouth brushing for 7 days
1854558|NCT00981825|Drug|Triclosan/Fluoride|Brush whole mouth twice daily for 7 days
1854559|NCT00981838|Drug|Rituximab|Rituximab (375 mg/m2) will be given as a single intravenous infusion after reconstitution in normal saline to a concentration of 1 mg/ml given though a 0.22 micron in line filter. The initial infusion rate will be 1 ml/kg/h and will be progressively increased up to 4 ml/kg/h according to drug tolerability. Pre-medication with steroids and/or antihistaminic agents will be done according to per-center's practice.Rituximab administration will be repeated in those patients > 5 B cells/mm3 in the peripheral blood on the day after first Rituximab administration.
1854560|NCT00981851|Drug|Tiotropium (Spiriva) + Salbutamol (Ventolin)|1 time inhalation of 5 mcg of Tiotropium bromide by Respimat and 400 mcg of Salbutamol by Volume Spacer. cigarette smoking
1854561|NCT00981851|Drug|placebo|1 time inhalation of placebo with the amount of puffs similar to the active comparator. cigarette smoking
1854562|NCT00981864|Radiation|Concurrent Boost RT|Patient will receive radiation to the tumour bed concurrently with whole breast radiation instead of receiving this treatment sequentially, that is, whole breast RT first then followed by RT directly to the tumour bed.
1854563|NCT00981877|Drug|GB (Florestor)|S. Boulardii preparation of 1 gram twice daily for 5 days
1854564|NCT00981877|Drug|GRALB|mixed probiotic preparation 1 gram twice daily for 5 days.
1854565|NCT00981877|Drug|GC (placebo)|Placebo 1 gram twice daily for 5 days.
1854566|NCT00982748|Behavioral|Pranayama (Yoga Breathing) Techniques|1-hour long yoga breathing classes, taught once per week for 2-8 consecutive weeks. Dose (Number of classes) administered is dependent on randomization arm and individuals' chemotherapy cycle length.
1854567|NCT00982774|Biological|LEISH-F2 + MPL-SE vaccine|LEISH-F2 protein (10 ug) + MPL-SE (25ug) Three injections, 14 days apart
1854568|NCT00982787|Drug|Botanical extract from Passiflora incarnata|"Dosage form: Liquid Passiflora extract
Dosage: 10ml (equivalent of 2.2 g of dried Passiflora)
Frequency: Once/Twice a day
Duration: 11 week intervention period"
1854569|NCT00982800|Drug|Gabapentin|200mg 3x/day for 3 days (9 doses total)
1854570|NCT00982800|Drug|Placebo Sugar Pill|
1854571|NCT00982813|Other|Periodontal screening|"Periodontal screening in all patients giving birth between 24 and 37 gestational weeks.
Bacteriological sampling in the periodontal pocketing. Search for specific cytokines in the periodontal pocketing. Professional prophylaxis and oral hygiene instruction."
1854572|NCT00982826|Drug|ABT-072|See Arms information for a detailed description.
1854573|NCT00982826|Drug|Placebo|See Arms information for a detailed description.
1854574|NCT00982839|Procedure|Syringe Conditioning|A syringe will be used to inflate the balloon at the end of the probe which is inside of the rectum.
1854575|NCT00982839|Procedure|Barostat Conditioning|A barostat machine will be used to inflate the balloon at the end of the probe which is inside of the rectum.
1854581|NCT00982878|Drug|Maraviroc|150mg twice daily
1854582|NCT00982891|Drug|Opioid (morphine sulphate) in low dose|individualized titration
1854583|NCT00982904|Drug|Fexinidazole/Placebo|
1854584|NCT00982917|Behavioral|Stamp-in-Safety Curriculum|30 minute curriculum on playground safety
1854585|NCT00982917|Behavioral|Stamp-in-Safety curriculum|30 minute lesson on playground supervision
1854586|NCT00982930|Drug|Tobramycin inhalation powder|Tobramycin inhaled powder
1854587|NCT00982982|Drug|THC and Iomazenil|"Iomazenil: 3.7 μg/kg intravenously over 10 minutes
Delta-9-THC (0.015 mg/kg = 1.05 mg in a 70kg individual), dissolved in alcohol. This dose is roughly equivalent to smoking approximately 1/4th of a marijuana cigarette, or joint. It is administered intravenously for 10 minutes."
1854588|NCT00982982|Drug|Placebo (control)|Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
1854589|NCT00982995|Drug|Palonosetron|Palonosetron 0.25 mg as an I.V. bolus. After Palonosetron treatment, no other nausea medication will be given for 2 hours. At that point, if no relief from nausea or vomiting has occured then other anti-nausea medications may be prescribed, and patient will be taken off study. If relief from nausea and vomiting as a result of the Palonosetron occurs, patient will not receive any more anti-nausea medication unless nausea recurs. If it does recur and patient wishes to be retreated with Palonosetron. This may be repeated for a total of 3 doses, as long as it is providing relief.
1854590|NCT00983008|Behavioral|Protected time and Dedicated time|On Sunday through Thursday nights medical intensive care unit interns will have a 5 hour protected period from 2 to 7 am. During this time they will relinquish their pager and cell phone to the Night Float PGY2 or PGY3 who is already responsible for the ICU patients. The four hours between 2 and 6 am are entirely protected. 6 AM to 7 AM is dedicated time during which the interns will be expected to start pre-rounding on the ICU patients and to begin progress notes for the remaining members of the ICU team but still have no pager, cell phone, or cross coverage duties. On Friday and Saturday nights there will be no protected time but these interns will have 42 consecutive hours off following their extended shifts.
1854591|NCT00983021|Drug|insulin degludec/liraglutide|Single, simultaneous dose of NN9068, injected s.c. (under the skin)
1854592|NCT00983021|Drug|insulin degludec|Single, simultaneous dose of NN1250, injected s.c. (under the skin)
1854593|NCT00983021|Drug|liraglutide|Single, simultaneous dose of NN2211, injected s.c. (under the skin)
1854594|NCT00983021|Drug|placebo|Single, simultaneous dose of placebo, injected s.c. (under the skin)
1854595|NCT00983034|Drug|lansoprazole, amoxicillin, clarithromycin|lansoprazole, 30 mg twice daily, plus amoxicillin, 0.75 g twice daily, plus clarithromycin, 250 mg twice daily, for 14 days
1854596|NCT00983047|Drug|Nimotuzumab and Docetaxel|"The chemotherapy treatment:Docetaxel was administered every 3 weeks 75 mg/m2, efficacy will be evaluated after two cycles,the chemotherapy will be administered continually 2 cycles if the response is CR\PR\SD. No more than 4 cycles chemotherapy was given.
Nimotuzumab treatment: Dose of 200 mg intravenous infusion per week was continued after the end of chemotherapy until disease progression or unacceptable toxicity."
1854597|NCT00983060|Drug|NIM811|BID in various doses (between 100 mg - 600 mg bid) + SOC (PEG IFN and RBV)
1854598|NCT00983060|Drug|Placebo BID + SOC|Placebo BID + SOC (PEG IFN and RBV)
1854599|NCT00983073|Drug|Tapentadol|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.
Maintenance Period: Participants continuing on the dose established in the previous period."
1854600|NCT00983086|Drug|Flavanones of orange juice|The main objective of this study is to evaluate, in healthy volunteers with young children (50 and 65) and slightly overweight according to their usual diet, the effects of single dose (in postprandial period) and made repeated orange juice or orange flavanones purified on vascular function. The selection criteria for age and weight should, within a healthy population to select individuals who exhibit cardiovascular risk factors, and thus for which it should be a priori easier to identify a beneficial effect of dietary factors on the parameters associated with cardiovascular risk.
1854601|NCT00983099|Drug|Neramexane|single and multiple dose, tablets, oral
1854604|NCT00983125|Drug|Clonidine|"Addition of a non-labeled drug (clonidine) in one of the two arm of the study, with randomisation.
To compare the effects of a systematic addition of clonidine (150 µg added in the solution bag) in the local anesthetic solution), versus no addition, on the quality of analgesia for labour."
1854605|NCT00983138|Drug|recombinant asparaginase|10 000 Units/m² adjusted to age, 6 i.v. infusions (day 15, day 18, day 22, day 25, day 29, day 33) during the induction therapy
1854606|NCT00983151|Drug|Tramadol Hydrochloride & Placebo|89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours) Subject will take the study drug for about 27 weeks
1854607|NCT00983164|Dietary Supplement|Antioxidant Supplementation|antioxidant supplementation (vitamin E 800 mg, C 500 mg and zinc 40 mg) for 24 weeks
1854608|NCT00983177|Drug|Colchicine|0.5 mg twice daily for 4 months
1854609|NCT00983177|Drug|lactose|lactose capsules twice daily
1854610|NCT00983190|Device|Left Ventricular Assist Device (HeartMate II)|The HM II is a high speed, electric, axial flow, rotary blood pump. The pump drains blood from the left ventricular apex via rigid inlet cannulae and ejects into the aortic root via an outflow cannula joined to the aorta with an end to side anastamosis. Power and control of the pump are delivered through a percutaneous cable from pump to the belt-worn System Controller. The System Controller will receive power from the Power Base Unit (PBU), or two battery modules that may be worn in shoulder holsters or on the belt
1854611|NCT00983203|Other|FID 114657 ORB Preserved Ocular Emulsion|1 drop OU
1854612|NCT00983203|Other|Soothe XP Lubricant Eye Drops|1 drop OU
1854613|NCT00983216|Drug|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:30 a.m. on Day 1.
1854614|NCT00983216|Drug|Ketoconazole|one 200 mg Ketoconazole tablet administered twice daily at 7:15 a.m. and 7:15 p.m. on Days 15-18 without regard to meals, then along with colchicine at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 200 mg administered at 7:15 p.m. on Day 19
1854615|NCT00983216|Drug|Colchicine|A single dose of colchicine 0.6 mg administered along with ketoconazole at 7:15 a.m. on Day 19 after an overnight fast of at least 10 hours
1854616|NCT00983229|Procedure|Tracheal intubation|Insertion of a plastic tube under direct vision (built-in camera, intubating fibrescope) into trachea.
1854617|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 8am on Day 1 after an overnight fast of at least 10 hours.
1854618|NCT00983242|Drug|Verapamil HCl ER|One 240 mg verapamil HCl ER tablet taken at 8am on Days 15-18 without regard to meals and along with colchicine at 8am on Day 19 after an overnight fast of at least 10 hours.
1854619|NCT00983242|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with verapamil HCL ER at 8 am on Day 19 after an overnight fast of at least 10 hours.
1854620|NCT00983255|Drug|TR-701 FA for injection, 200 mg/vial|TR-701 FA for injection will be given as a single infusion at doses of 50 mg, 100 mg, 200 mg, and 400 mg in SAD/Part A (Pilot and Cohorts 1 to 3). TR-701 FA for injection will be given as once daily infusions at doses of 200 mg and 400 mg for 7 days in MAD/Part B (Cohorts 4 & 5). TR-701 FA for injection will be given once as a 200 mg IV infusion in BA/Part C (Cohort 6). TR-701 FA 200 mg will be given daily for 3 days in Venous Tolerability/Part D
1854621|NCT00983255|Drug|TR-701 FA tablets|TR-701 FA will be given once orally as a 200 mg tablet in Part C.
1854622|NCT00983268|Drug|capecitabine|1000 mg taken by mouth on the days of radiation only.
1854623|NCT00983268|Drug|vorinostat|"Vorinostat will be given by mouth on the day of radiation and then Monday-Friday for two weeks after radiation in these 4 possible doses:
Vorinostat,at 100 mg
Vorinostat,at 200 mg
Vorinostat, at 300 mg
Vorinostat, at 400 mg"
1854624|NCT00983268|Radiation|Radiotherapy|High-dose hypofractionated radiotherapy consisting of 3000 cGy in 10 fractions, Monday-Friday for 2 weeks.
1854625|NCT00983268|Procedure|Surgery to remove tumor|Patients will be assessed for resectability within six weeks of the end of chemoradiation, if resectable, surgery will be performed.
1854626|NCT00983281|Drug|Hextend|IV fluid resuscitation to restore euvolemia after traumatic injury and surgery.
1854627|NCT00983294|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1
1854628|NCT00983294|Drug|Azithromycin|Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.
1854629|NCT00983294|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
1854630|NCT00983307|Other|Erlotinib plus hypofractionated radiotherapy|Patients will receive Tarceva, 150 mg daily on days -5 through -1 days and will start a course of hypofractionated thoracic RT on Day 1. RT will be administered daily on weekdays (Monday-Friday) and not on weekends or holidays. Tarceva administration will be continued daily during RT (also on weekends/holidays when RT is not given) and after RT will be continued daily as maintenance therapy until death or disease progression.
1854631|NCT00983320|Drug|quetiapine|flexible dosage (50 to 300 mg)
1854632|NCT00983320|Drug|placebo|placebo
1854633|NCT00983333|Device|Time to Talk CARDIO website|This interactive web-based training device involves the completion of a brief survey regarding communication experiences between patients and health care professionals. The pattern of responses to the survey generates a personalized set of short instructional videos which demonstrate effective communication skills.
1854634|NCT00983346|Drug|Bortezomib|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 8, 15, and 22 of each 42 day cycle.
Patients will undergo nine 42-day cycles. At the end of this (day 378), patients will be assessed for bone remodeling changes. Evaluation for toxicities will be evaluated at the beginning of each cycle."
1854635|NCT00983359|Radiation|Radiation Therapy|Patients undergo conformal stereotatic radiation therapy QD (every day) over 5 days.
1854636|NCT00983372|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 am on Day 1 after an overnight fast of at least 10 hours.
1854637|NCT00983372|Drug|Diltiazem ER|One 240 mg diltiazem ER capsule administered daily at 7:15 am on Days 15 to 21.
1854638|NCT00983372|Drug|Colchicine|A single dose of 0.6 mg colchicine administered along with diltiazem ER at 7:15 am on Day 21 after an overnight fast of at least 10 hours.
1854639|NCT00983385|Drug|Tapentadol PR|Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.
1854715|NCT00983918|Drug|Isoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Isoflurane
1854640|NCT00983385|Other|Observation period|Eligibilty assessment period to characterize the baseline over a one week period (week -1). Participants continued their previous treatment prior to allocation to tapentadol, if eligible.
1854641|NCT00983385|Drug|Tapentadol PR|Maintenance Period: In this period participants continued Tapentadol Prolonged Release (PR) on the dose established in the Titration and Optimal Dose Period. Tapentadol IR Participants were not permitted to exceed 500 mg of Tapentadol per day.
1854642|NCT00983398|Drug|Carboplatin|Given IA
1854643|NCT00983398|Drug|Mannitol|Given IA
1854644|NCT00983398|Drug|Melphalan|Given IA
1854645|NCT00983398|Other|Quality-of-Life Assessment|Ancillary studies
1854646|NCT00983398|Other|Questionnaire Administration|Ancillary studies
1854647|NCT00983398|Drug|Sodium Thiosulfate|Given IV
1854648|NCT00983411|Other|Non intentional leaks during non invasive ventilation|During NIV sessions (in awake state for both the 10 healthy and the 10 OHS subjects and during sleep only for the OHS subjects), the investigators will create several levels of non intentional leaks in a random order
1854649|NCT00983424|Drug|Cyclosporins|dose escalation, administered orally twice a day
1854650|NCT00983424|Drug|nab-paclitaxel|100 mg/m2 IV days 1, 8 and 15
1854651|NCT00983437|Drug|Armodafinil|
1854652|NCT00983450|Other|watching a normal walking clip|the study group will gain an intervention consisting of 12 therapy sessions, administered for 12 consecutive days (apart of weekends). The intervention will include 6 minutes of watching a movie clip alternately showing a healthy man and a healthy woman at their sixties, walking while being filmed from various angles. Immediately after watching, the subject will perform 6 minutes of walking, under the experimenters supervision, but without his or hers intervention. Immediately following the walking, the whole procedure will be repeated (watching a clip and walking).
1854653|NCT00983450|Other|watching walk backward clip|The control group will undergo 12 treatments of the same nature, but will watch the movie clip shown backwards, so that the people filmed will seem to walk backwards (it was established that watching a reversed action does not activate the MNS system activated by a regular execution of the activity [Celnik et al., 2008]), followed by 6 minutes of walking under the experimenters supervision, then watching the movie again and walking again.
1854654|NCT00983476|Behavioral|in-person MOVE! SMI|Individual and group in-person sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
1854655|NCT00983476|Behavioral|web-based MOVE! SMI|online sessions that deliver manualized MOVE! curriculum adapted for use with individuals with cognitive deficits (often found in individuals with severe mental illness (SMI))
1854656|NCT00983489|Behavioral|video demonstration|video will be shown to mothers
1854657|NCT00983489|Behavioral|counselling|breast feeding counselling
1854658|NCT00983515|Drug|Colchicine|A single dose of colchicine 0.6 mg administered alone at 7:00 a.m. on Day 1 after an overnight fast of at least 10 hours.
1854659|NCT00983515|Drug|Ritonavir|One 100 mg ritonavir capsule administered twice daily at 7:00 a.m. and 7:00 p.m. on Days 15 to 18 without regard to meals, then along with colchicine at 7:00 a.m. on Day 19 after an overnight fast of at least 10 hours; final dose of 100 mg ritonavir administered at 7:00 p.m. on Day 19
1854660|NCT00983515|Drug|Colchicine|A single dose of colchicine 0.6 mg administered along with ritonavir at 7:00 a.m. on Day 19
1854661|NCT00983528|Biological|Alemtuzumab|3mg day 1,10mg day 2, 30mg day 3, 30mg day 5, 30mg day 8, then three times per calendar week thereafter for a total 12- 30mg doses
1854662|NCT00983528|Drug|Clofarabine|"Dose Escalation
Cycle 1 (30 days or until alemtuzumab completed) Clofarabine 10,20,30 or 40 mg/m2 days 5-9
Cycle 2 and subsequent cycles (administered no more frequently than every 28 days) 10,20,30 or 40 mg/m2 days 1-5"
1854663|NCT00983541|Drug|Fluorouracil (5-FU)|5-FU Injection,USP (GeneraMedix Inc.) is effective in palliative management of carcinoma (colon, rectum, breast, stomach, pancreas) FDA approved in 1962-NDA (New Drug Application)012209. This study uses 350 mg/m2/day days 1-5 each week of radiation therapy
1854664|NCT00983541|Radiation|Brachytherapy or SBRT (Stereotactic body radiation therapy)|Patients receive 45 Gy (gray) external beam radiation therapy including the primary tumor and regular lymph nodes (25 fractions over 5 weeks). Within 1 month of external beam radiation therapy, patients will have boost treatment of 20 Gy in 4 fractions, via Ir-192 brachytherapy or SBRT (Stereotactic Body Radiation Therapy).
1854665|NCT00983541|Drug|Gemcitabine|"Pancreatic:Indicated as first line treatment for patients with locally advanced (nonresectable Stage II or III) or metastatic(Stage IV) pancreatic adenocarcinoma.
Ovarian:Gemzar with carboplatin is indicated for treatment of patients with advanced ovarian cancer relapsed 6 months after plat-based therapy.
Breast:Gemzar with paclitaxel is indicated for first line treatment of patients with metastatic breast cancer after failed anthracycline-containing adjuvant chemotherapy, unless anthracyclines.
Non-small cell lung cancer(NSCLC):Gemzar is indicated with cisplatin for first line treatment of patients with inoperable, local advanced (Stage IIIA/IIIB), metastatic (Stage IV) NSCLC."
1854666|NCT00983554|Drug|Anastrazole|Arimidex 1mg daily
1854667|NCT00983554|Drug|Testosterone|Testim 10g daily
1854668|NCT00983554|Drug|Dutasteride|Avodart 2.5mg daily
1854669|NCT00983554|Drug|GnRH antagonist|Acyline 300 µg/kg subcutaneous injections every 2 weeks
1854670|NCT00983567|Other|teen web|Min web
1854671|NCT00983580|Drug|Aspirin|Given PO
1854672|NCT00983580|Drug|Eflornithine|Given PO
1854673|NCT00983580|Other|Laboratory Biomarker Analysis|Correlative study
1854674|NCT00983580|Other|Placebo|Given PO
1854675|NCT00983580|Other|Telephone-Based Intervention|Ancillary studies
1854676|NCT00983593|Behavioral|Mind-Body Bridging|16 weeks of weekly Mind-Body Bridging group treatment lasting 60-90 minutes per session.
1854677|NCT00983619|Drug|MEDI-551|A humanized Immunoglobulin G (IgG)1 kappa monoclonal antibody (MAb) directed against human CD19.
1854678|NCT00983619|Drug|Rituximab|Anti CD-20 and MEDI-551
1854711|NCT00983905|Drug|Theophylline|single doses of 300 mg (80 mg/15 ml elixer) administered alone at 7:45 am on Day 1 and then along with colchicine at 7:45 am on Day 19
1854712|NCT00983905|Drug|Colchicine|one 0.6 mg tablet twice daily at 7:45 am and 7:45 pm on Days 5 to 19
1854713|NCT00983918|Drug|Desflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Desflurane
1854679|NCT00983632|Procedure|Selective vagus nerve stimulation|"Stimulus will be combination of quasi-trapezoidal cathodic and rectangular anodic current pulses. Precisely, the resulting current, biphasic and charge balanced combination will be composed of a quasi-trapezoidal cathodic phase with a square leading edge with different intensity ic , a plateau tc of 300 μs, and exponentially decaying phase texp of 500 μs, followed by a wide rectangular anodic phase ta of allow current magnitude ia. Anodic phase ia will be one-tenth of the magnitude in the cathodic phase. However, the width of the anodic phase ta will be dependent upon the charge injected in the cathodic phase: the greater the charge, the wider the anodic phase.
For details see detailed study description"
1854680|NCT00983632|Device|selective vagus nerve stimulation|electrical vagus stimulation
1854681|NCT00983645|Drug|Prograf|Tacrolimus (Prograf) starting dose 0.05-0.15 mg/kg PO BID
1854682|NCT00983645|Drug|Neoral|Cyclosporine (Neoral) starting dose 3mg/kg PO BID
1854683|NCT00983658|Drug|huMAb OX40L|Intravenous repeating dose
1854684|NCT00983658|Drug|placebo|Intravenous repeating dose
1854685|NCT00983684|Device|Intrabeam|A dose of 20 Gy at the surface of the applicator or 6 Gy at 1cm (in water) is prescribed by the radiation oncologist and delivered to the breast tissue. This takes approximately 30 minutes, depending on the size of the applicator.
1854686|NCT00983684|Radiation|Post-operative radiotherapy|All patients randomised to receive conventional radiotherapy within this trial should be treated in accordance with a pre-specified policy. Dosage should only be applied to the breast; axillary, supra-clavicular and internal mammary nodes should not generally be irradiated by discrete fields.
1854687|NCT00983697|Procedure|therapeutic conventional surgery|
1854688|NCT00983697|Radiation|fludeoxyglucose F 18|
1854689|NCT00983710|Behavioral|PC-PEP - Prostate Cancer Patient Education Program|Men in the intervention group will receive a new patient education intervention to help them manage side-effects related to treatment for localized prostate cancer. The intervention will be delivered by phone and by mail and is targeted to me with low health literacy. The intervention consists of written materials, audio materials, and telephone-based problem-solving education.
1854690|NCT00983710|Behavioral|Usual care|Booklet on coping with localized prostate cancer
1854691|NCT00983736|Drug|Tramadol Hydrochloride|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).
Subject will take the study drug for about 27 weeks."
1854692|NCT00983736|Drug|Placebo|"89 mg or a lesser dose of 62 mg if side effects are experienced one tablet at least two hours before sexual intercourse (maximum of one tablet every 20 hours).
Subject will take the study drug for about 27 weeks."
1854693|NCT00983749|Device|Full-pressure ECP|A one-hour treatment of ECP at full pressure, which will be applied in a tiered, dose-escalating manner, starting at 200mmHg and increasing up to 300mmHg based on assessments made.
1854694|NCT00983749|Device|Sham-pressure ECP|A one-hour treatment of ECP at an inactive pressure, which will be applied at 75mmHg and kept there for the hour while assessments are made.
1854695|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.2 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
1854696|NCT00983775|Device|jet injector (SQ pen/Novopen III)|The rapid-acting insulin analogue insulin aspart (Novorapid®), at a dose of 0.4 units per kg body weight, will be injected subcutaneously. On one experimental day insulin will be injected with the jet injector and placebo with the conventional insulin pen. On the other experimental day insulin will be injected with the conventional insulin pen and placebo with the jet injector.
1854699|NCT00983801|Drug|Ixabepilone|Vial, Injection, Intravenous (IV), 40 mg/m^2, Every 21 days, Up to 8 cycles or until disease progression or intolerable toxicity. Additional treatment was given in agreement by both the investigator and sponsor. Ixabepilone 40 mg/m^2 was administered as a 3-hour IV infusion on Day 1 of each 21-day (3 week) cycle provided the participant met the retreatment criteria.
1854700|NCT00983814|Drug|Droxidopa+Carbidopa|Droxidopa (L-dihydroxyphenylserine (L-DOPS)) (200, 400, or 600mgs TID) in combination with carbidopa (25mg or 50mg TID, provided as oral capsules taken TID from Baseline to end of Week 8
1854701|NCT00983814|Drug|Placebo|Placebo matched oral capsules taken TID from Baseline to end of Week 8
1854702|NCT00983827|Device|Aquatic treadmill training|HydroWorx aquatic therapy pool with an underwater, integrated and adjustable speed treadmill
1854703|NCT00983840|Other|Family Eats|8-session web-based program on healthy eating for African American families
1854704|NCT00983853|Drug|telaprevir or matching placebo|Tablet, Oral, 750 mg, q8h, 12 weeks
1854705|NCT00983853|Drug|telaprevir or matching placebo|Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks
1854706|NCT00983853|Biological|peginterferon alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks
1854707|NCT00983853|Drug|ribavirin (fixed dose)|Tablet, Oral, 800 mg, b.i.d., 48 weeks
1854708|NCT00983853|Drug|ribavirin (weight-based dose)|Tablet, Oral, 1000 mg for subjects weighing <75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
1854709|NCT00983866|Behavioral|Tailored Telephone Counseling|The intervention is comprised of a letter introducing patients to the idea of participating in a clinical trial as a possible treatment option, followed by a telephone call by a nurse educator who describes the clinical trials process and answers any questions patients may have. The nurse educators will use a tailored counseling protocol that will enable them to conduct an assessment of patients' understanding about and interest in clinical trials and tailor messages according to patient health literacy and language. The protocol will consist of both proactive and reactive counseling. The nurse educator will have a general list of topics to cover but will tailor the discussion and information provided to individual patients' questions and desire for particular types of information.
1854710|NCT00983892|Behavioral|Caregiver website|Website receives patient symptom assessment data from IVR and provides caregivers with weekly updates on patient status, allowing caregivers to access tailored symptom management advice and formulate an action plan.
1854714|NCT00983918|Drug|Sevoflurane|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with Sevoflurane
1854716|NCT00983918|Drug|Propofol|Patient induced for general anesthesia as per standard protocol and maintenance of anesthesia provided with intravenous Propofol infusion
1854717|NCT00983931|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1 after an overnight fast of at least 10 hours.
1854718|NCT00983931|Drug|Cyclosporine|A single dose of 100 mg cyclosporine administered with colchicine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
1854719|NCT00983931|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with cyclosporine at 7:15 a.m. on Day 15 after an overnight fast of at least 10 hours.
1854720|NCT00983944|Biological|bleomycin sulfate|Given IV
1854721|NCT00983944|Biological|rituximab|Given IV
1854722|NCT00983944|Drug|EPOCH regimen|Given IV or orally
1854723|NCT00983944|Drug|cyclophosphamide|Given IV or orally
1854724|NCT00983944|Drug|doxorubicin hydrochloride|Given IV or orally
1854725|NCT00983944|Drug|etoposide|Given IV or orally
1854726|NCT00983944|Drug|prednisone|Given IV or orally
1854727|NCT00983944|Drug|vincristine sulfate|Given IV or orally
1854728|NCT00983957|Drug|BMS-790052|Tablets, Oral, 60 mg, once daily, 10 days
1854729|NCT00983957|Drug|Ortho Tri-Cyclen®|Tablets, Oral, once daily, 78 days
1854730|NCT00983970|Behavioral|Interactive video game cycling|"Participants were required to exercise on a Gamebike® (Cat Eye Electronics Ltd, Boulder Col.) interactive video gaming system that was interfaced with a Sony Play Station 2® (Sony computer Entertainment America Inc. Foster, City, CA) and a 42 flat screen television monitor. The Gamebike® has a handlebar mounted game controller allowing the participant to play most Sony Playstation 2- race-based video games. The Gamebike® reads the participant's speed by cycling cadence and the faster the individual pedalled, the faster they moved in the virtual world on screen. Participants were told that they could exercise at any intensity and duration they desired. Participants were asked to come to the lab for two sessions per week for 60 minutes for 10 weeks. Although participants were required to stay in the lab for 60 minutes, they could take breaks or stop when they wanted, and reading materials were available for those who did not or could not cycle for the full 60 minute session."
1854731|NCT00983970|Behavioral|Cycling to Music|Each participant exercised twice weekly for 10 weeks on the Gamebike® but the games and controls were turned off. The Gamebike® was used by both groups to control for any differences between two cycle ergometers such as comfort or usability. However, participants were allowed to listen to music of their choice via radio, CD or personal music device. We incorporated music into the control condition because most youth and young adults exercise to music and this provides a more stringent test of the Gamebike® while improving the ecological validity of the research design. We also wanted to minimize drop-out and felt that expecting overweight/obese adolescents, who often report disliking aerobic exercise, to bike in a lab with no form of distraction would create a less than desirable exercise environment and result in high drop-out rates.
1854732|NCT00983983|Dietary Supplement|Oxepa|Oxepa: Tube feed containing 1.5 calories/ml of which 55% calories are from fat, including eicosapentaenoic acid and gamma-linolenic acid. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
1854733|NCT00983983|Dietary Supplement|Jevity 1.5|Jevity 1.5: Tube feed containing 1.5 calories/ml of which 29.4% are from fat. Subjects will receive 1.25 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
1854734|NCT00983983|Dietary Supplement|Jevity 1.0|Jevity 1.0: Control tube feed. Subjects will receive 1.0 times their daily caloric requirements based on their measured resting energy expenditure. Subjects will receive 4 months of tube feeds and be followed for an additional 1 month to measure adverse events and tolerability.
1854735|NCT00983996|Drug|Alendronate Sodium Tablets, 10 mg|10 mg, single-dose fasting
1854736|NCT00983996|Drug|Fosamax Tablets, 10 mg|10 mg, single-dose fasting
1854737|NCT00984009|Drug|Colchicine|A single dose of 0.6 mg colchicine administered alone at 7:15 a.m. on Day 1
1854738|NCT00984009|Other|Grapefruit Juice|240 mL of grapefruit juice ingested twice daily at 7:15 a.m. and 7:15 p.m. on Days 15 to 18.
1854739|NCT00984009|Drug|Colchicine|A single dose of 0.6 mg colchicine administered with grapefruit juice at 7:15 a.m. on Day 18 after an overnight fast of at least 10 hours.
1854740|NCT00984022|Device|Type of dressing - Iodoform|Dressing for packing a cutaneous abscess
1854741|NCT00984022|Device|Type of dressing - Aquacel|Aquacel dressing
1854742|NCT00984035|Other|urine samples (biomarkers)|Urine samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
1854743|NCT00984035|Other|blood samples (biomarkers)|blood samples collected prior to first dose of cisplatin, after each dose of cisplatin, and within 35 days of the last dose.
1854744|NCT00984035|Other|blood sample (DNA)|Blood sample collected for DNA analysis at anytime while on-study.
1854745|NCT00984048|Other|Needle core biopsies of liver metastasis|No investigational products will be administered to subjects as part of this translational research study. A first-line chemotherapy regimen consisting of FOLFOX, XELOX or FOLFIRI +/- bevacizumab will be administered as per the standard of care at each treating institution. Needle core biopsies of liver metastasis will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn monthly and stored in the tissue biobank.
1854746|NCT00984061|Drug|colchicine|0.6mg tablet administered at 9am on Day 1
1854747|NCT00984061|Drug|clarithromycin|250 mg clarithromycin tablet taken on an outpatient basis twice daily at 8am and 8pm for 14 doses (starting with 8pm dose on Day 22 and concluding with 8am dose on Day 29)
1854748|NCT00984061|Drug|colchicine|0.6 mg tablet administered at 9am on Day 29
1854749|NCT00984074|Procedure|blood-oxygen-level-dependent functional magnetic resonance imaging|
1854750|NCT00984074|Procedure|diffusion tensor imaging|
1854751|NCT00984074|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1854752|NCT00984074|Procedure|functional magnetic resonance imaging|
1854753|NCT00984074|Radiation|intensity-modulated radiation therapy|
1854754|NCT00984074|Radiation|radiation therapy treatment planning/simulation|
1854755|NCT00984087|Device|TMS with Neurostar TMS Therapy System|20 sessions with 1680 pulses per session at 10 Hz with a 4-second pulse train, stimulation at 100% motor threshold,
1854756|NCT00984100|Procedure|NOTES Transvaginal Cholecystectomy|An operation to remove the gallbladder, but instead of removing it via an incision in the abdominal wall, will be removed using an endoscope inserted through an opening in the posterior vagina (which then enters the abdominal cavity).
1854757|NCT00984113|Drug|Elinogrel|100 mg elinogrel b.i.d. with aspirin q.d. for 7 days and aspirin alone for 4 days (Dose of aspirin is 81 mg in the US and 100 mg in Germany)
1854758|NCT00984126|Drug|turoctocog alfa|The preventative treatment is administered intravenously (i.v.) at specific intervals either every second day or three times a week. Bleeding treatment will be administered if a bleed should occur.
1854759|NCT00984126|Drug|turoctocog alfa|Treatment is administered intravenously (i.v.) during bleeds and occasionally as a preventative treatment (e.g. before physical activity)
1854760|NCT00984139|Biological|Engerix™-B Kinder|Intramuscular, one dose.
1854761|NCT00984152|Drug|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily|TDF/FTC Once-Daily + Raltegravir 400 mg Orally Twice-Daily
1854762|NCT00984152|Drug|TDF/FTC + Efavirenz (Atripla) Once-Daily|TDF/FTC + Efavirenz (Atripla) Once-Daily
1854766|NCT00984178|Other|Granulocite Colony Stimulating Factor treatment (G-CSF)|G-CSF will be administered at a dose of 10 mcg/kg/day. The administration begins at the first 24 hours post-reperfusion, remaining for 5 days
1854767|NCT00984178|Other|Bone marrow mononuclear cells|Bone marrow mononuclear cells will be isolated with a Ficoll technique from 50 cc of bone marrow aspiration
1854768|NCT00984191|Radiation|99mTc-MIBI SPECT-CT|99mTc-MIBI SPECT-CT for abnormal cervical lymph node
1854769|NCT00984204|Device|Therapy Cool Path Duo|All patients will be treated with Therapy Cool Path Duo Ablation System for the treatment of typical atrial flutter.
1854770|NCT00984217|Radiation|Radiation|Radiation 64-70Gy (2.0 Gy/day, 5 days/week)
1854771|NCT00984217|Drug|Panitumumab|2.5 mg/Kg IV, weekly during RT. 6-7 weeks
1854772|NCT00984230|Other|BSF|feeding amount according to individual baby need
1854773|NCT00984230|Other|BSF + Lactoferrin + Probiotics|feeding amount according to individual baby need
1854774|NCT00984230|Other|BSF + Lactoferrin + Probiotics + OS|feeding amount according to individual baby need
1854775|NCT00984243|Procedure|PHOTODYNAMIC THERAPY (PDT)|"Photodynamic Procedure:
Photofrin II will be injected at a dosage of 2 mm/Kg intravenously. Laser treatment will take place 40-50 hours later. An argon-dye or an excimer-dye laser tuned to 620-630 nm will be used.
It is anticipated that a microlens fiber will be used in almost all cases, but a cylinder-diffusing fiber can be used to treat lesions in segmental bronchi if needed.
Argon-dye laser: Power settings 200 milliwatt (mW) microlens and 400 mW for cylinder Excimer laser: 4 milliJoules (mJoules)/pulse at 30 hertz for the microlens
Energy density:
Argon-dye laser: 200-300 Joules/cm^2 Excimer-dye laser: 100-200 Joules/cm^2"
1854776|NCT00984256|Drug|Atovaquone Proguanil|Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
1854777|NCT00984256|Other|Procedure - malaria challenge|2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
1854778|NCT00984269|Procedure|Tourniquet Use|Patients undergoing hand/wrist surgery with or without a tourniquet
1854779|NCT00984282|Drug|Sorafenib (Nexavar, BAY43-9006)|Sorafenib 400 mg will be administered orally, twice daily (approximately every 12 hours).
1854780|NCT00984282|Drug|Placebo|Placebo (2 tablets) will be administered orally, twice daily (approximately every 12 hours).
1854781|NCT00984295|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A single 0.5 mL subcutaneous injection at Day 0
1854782|NCT00984295|Biological|Comparator: Tripedia|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
1854783|NCT00984295|Biological|Comparator: Comvax|A single 0.5 mL intramuscular injection (at Day 0 or Day 42)
1854784|NCT00984295|Biological|Comparator: Varivax|A single 0.5 mL subcutaneous injection at Day 0
1854785|NCT00984295|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
1854786|NCT00984308|Procedure|CPAP Therapy for Newly Diagnosed Obstructive Sleep Apnea (OSA)|Continuous Positive Airway Pressure (CPAP) is provided for those patients who are diagnosed with OSA.
1854787|NCT00984321|Behavioral|group intervention and questionnaires|Group Session will be 90 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
1854788|NCT00984321|Behavioral|individual phone intervention and questionnaires|Individual phone sessions will be 45 minutes long. Both the group sessions and individual session will be audio recorded. GSPI is a novel, manualized psychoeducational intervention that integrates Folkman's cognitive construct and Erikson's developmental concept of the 7th and 8th stages of life. GSPI consist of 5 weekly sessions. The first 2 sessions will be held on consecutive weeks to help establish rapport and explain therapeutic concepts, and next 3 sessions will be held every other week, giving patients time to utilize the therapeutic concepts and expanding length of contact with the patient.
1854789|NCT00984321|Behavioral|expressive writing (arm will not be include in the randomization)|"intervention facilitate reappraisal through the exploration of past life events and prior successful ways of coping. Preliminary studies examining the efficacy of this writing intervention have shown its' ability to introduce patients to a new and effective coping method that can be utilized during future stressful cancer and aging related events.67 In the sessions, Wwe will explore past life events and ways of coping through manualized writing sessions."
1854790|NCT00984334|Drug|Naloxone SR 5 mg capsules|
1854791|NCT00984334|Drug|Placebo|
1854792|NCT00984334|Drug|Naloxone SR 10 mg capsules|
1854793|NCT00984334|Drug|Naloxone SR 20mg capsules|
1854794|NCT00984334|Drug|Naloxone SR 2.5 mg capsules|
1854795|NCT00984347|Drug|Oxytocin|"For low risk group (women at deliveries 1-5):
IV oxytocin 10IU/1000ml standard sol. starting at 2MU/MIN and augmenting 2MU every 20 min.
For high risk group (grandmultiparas [6th delivery and up] or women with a previous cesarean section)
IV oxytocin 5IU/1000ml standard sol. starting at 1MU/MIN augmenting 1MU every 20 MIN - in accordance with the department's protocol"
1854796|NCT00984347|Procedure|breast pump nipple stimulation|breast pump calibrated at lowest suction strength, operated alternately: 15 min one breast, 15 min second breast, 15 min rest
1854797|NCT00984360|Drug|Naltrexone|380mg extended-release, given once by intramuscular gluteal injection
1854798|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.02μg/100μl administered once before punch biopsy
1854799|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.1μg/100μl administered once before punch biopsy
1854800|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.2μg/100μl administered once before punch biopsy
1854801|NCT00984386|Drug|Zesteem|Intradermal Zesteem, 0.4μg/100μl administered once before punch biopsy
1854802|NCT00984386|Drug|Placebo|Intradermal placebo, 100μl administered once before punch biopsy
1854803|NCT00984399|Drug|Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist|The goal is to have 30 patients on letrozole and 30 on anastrozole who are initiated on vaginal estrogen for symptoms of urogenital atrophy. All subjects will receive 10mcg vaginal 17-β estradiol tablets. Each subject will serve as her own control. We will monitor serum estradiol and follicle stimulating hormone (FSH) levels closely from 0-24 weeks. We will measure serum estradiol and FSH levels at baseline, and subsequently at weeks 2, 7, 12, 18 and 24 after commencing therapy with 10mcg vaginal 17-β estradiol.
1854804|NCT00984412|Procedure|Allogeneic hematopoietic stem-cell-transplantation|2 allogeneic BMTs 6 weeks apart
1854805|NCT00984425|Drug|Lapatinib and Sorafenib|Comparison of different dosages of two drug
1854806|NCT00984438|Drug|BCNU Wafer|Implantable during surgical resection into the tumor bed
1854807|NCT00984438|Drug|Irinotecan|IV every 2 weeks for up to one year
1854808|NCT00984438|Drug|Bevacizumab|IV every 2 weeks for up to one year
1854809|NCT00984451|Biological|Plasma collection following infection or vaccination with influenza A|High titer influenza A plasma collection for use as therapeutic plasma in influenza treatment studies.
1854810|NCT00984464|Biological|REOLYSIN|3x10E10 TCID50, 1 hour intravenous infusion, administered on Days 1,2,3,4 and 5 of a 21-day cycle
1854811|NCT00984464|Drug|Carboplatin|6 AUC mg/ml min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
1854812|NCT00984464|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
1854813|NCT00984477|Drug|AZD5122|A single dose of oral suspension
1854814|NCT00984477|Drug|Placebo|A single dose of oral suspension
1854815|NCT00984477|Drug|AZD5122|A single intravenous infusion
1854816|NCT00984490|Drug|metformin hydrochloride|Metformin: 850 mg orally (PO) twice daily (BID) for 7-21 days, discontinued 24-36 hrs prior to surgery
1854817|NCT00984490|Other|laboratory biomarker analysis|Blood and tissue collection to determine the in situ biologic effect of metformin
1854818|NCT00984503|Drug|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor sites (3cm2) once just prior to wounding
1854819|NCT00984503|Drug|Placebo|Intradermal injection of Placebo at 100μl/cm2 of SSG donor site (3cm2) once just prior to wounding
1854820|NCT00984503|Drug|Avotermin|Intradermal Juvista at 50ng/100μl/cm2 of SSG donor site once just prior to wounding, followed by topical Juvista at 100ng/200μl/cm2 after wounding and again at Day 1
1854821|NCT00984503|Drug|Placebo|Intradermal placebo at 100μl/cm2 of SSG donor site once just prior to wounding, followed by topical placebo at 200μl/cm2 after wounding and again at Day 1
1854822|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding
1854823|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
1854824|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding
1854825|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
1854826|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding
1854827|NCT00984516|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
1854828|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding
1854829|NCT00984516|Drug|Placebo|Intradermal Placebo, 100μl administered once prior to wounding, once 3 hours later at 100μl/wound margin (200μl total) and again on Day 5 (200μl)
1854830|NCT00984542|Drug|bendamustine hydrochloride|Bendamustine 120 mg/m2 IV on days 1 and 2 of a 21-day treatment cycle
1854831|NCT00984568|Biological|Infliximab|Infliximab intravenous infusion at a dose of 5 mg/kg.
1854832|NCT00984568|Drug|Prednisolone|Oral prednisolone 40 mg/day or 1 mg/kg/day depending upon participant response.
1854833|NCT00984568|Drug|5-aminosalicylic acid|5-ASA administered orally at a dose of 2 g/day.
1854834|NCT00984568|Drug|Azathioprine|AZA administered orally at a dose of 2.0-2.5 mg/kg/day.
1854835|NCT00984581|Drug|Avotermin|Intradermal injection, 5ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
1854836|NCT00984581|Drug|Avotermin|Intradermal injection, 50ng/100ul/linear cm wound margin administered on Day 0, Day 1 and month 6
1854837|NCT00984581|Drug|Placebo|Intradermal injection, 100ul/linear cm wound margin administered on Day 0 and Day 1
1854838|NCT00984594|Other|Primary injury site|Autograft will be placed in the primary defect site.
1854839|NCT00984594|Other|Backfill site|Autograft will be placed in the primary defect site; CR-Plug will be placed in the harvest site.
1854888|NCT00984880|Drug|AZD3043|Intravenous solution given as bolus dose (part A) and as bolus dose followed by infusion (part B)
1854889|NCT00984893|Drug|zoledronic acid|
1854840|NCT00984607|Procedure|barium sulfate tablet|After a standard upper GI evaluation, oral administration of a standard 13 mm barium sulfate tablet was performed and swallowed with dilute liquid barium during fluoroscopic monitoring. A spot radiograph was obtained once the barium tablet was in the gastric pouch and the dilute liquid barium was passing through the gastric band stoma.
1854841|NCT00984620|Drug|BI 201335|BI 201335
1854842|NCT00984620|Drug|BI 201335|BI 201335
1854843|NCT00984620|Drug|Pegylated Interferon-alpha (IFN)|Pegylated Interferon-alpha
1854844|NCT00984620|Drug|Ribavirin (RBV)|Ribavirin (RBV)
1854845|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.6 mg/kg injection intubation dose
1854846|NCT00984633|Drug|Rocuronium bromide (Org 9426)|0.9 mg/kg injection intubation dose
1854847|NCT00984633|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
1854848|NCT00984633|Drug|Propofol|4-10 mg/kg/hr maintenance anesthesia
1854849|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 5ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
1854850|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 50ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
1854851|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 250ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
1854852|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 1000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
1854853|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 25ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
1854854|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 125ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
1854855|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 500ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
1854856|NCT00984646|Drug|Prevascar|Intradermal Prevascar, 2000ng/100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
1854857|NCT00984646|Drug|Placebo|Intradermal Placebo, 100μl/linear cm of wound site or margin administered once just prior to wounding and once 24 h later
1996642|NCT02427438|Other|Video|A video with moving demonstration and verbal instruction of the exercise to strengthen low back
1854861|NCT00984698|Behavioral|Cognitive Behavioral Social Rhythm Group Therapy|12 weeks, 2h structured group therapy
1854862|NCT00984698|Behavioral|Present Centered Group Therapy|12 weeks, 2h relatively unstructured group therapy
1854863|NCT00984724|Behavioral|Standard Treatment (ST)|Mailing of packet of materials including a letter referring smokers to the Texas Quitline, nicotine replacement therapy when participants are ready to quit and standard self-help materials; ST delivered a total of 4 times (at Baseline, 6, 12, and 18 months).
1854864|NCT00984724|Behavioral|Telephone Counseling|"MAPS-6: 6 MAPS proactive telephone counseling sessions delivered over a 2-year period
MAPS-12: 12 MAPS proactive telephone counseling sessions over a 2-year period"
1854865|NCT00984724|Behavioral|Quitline|Letter referring participants to a Quitline providing quit smoking services.
1854866|NCT00984724|Behavioral|Nicotine Replacement Therapy (NRT)|300 pieces of nicotine gum issued at baseline visit.
1854867|NCT00984737|Drug|Insulin|"Capillary glucose measurements of Group 2 and Group 3 will be performed during hospitalization and will be treated when they are over 180mg/dl.
Short acting oral anti-diabetic drugs will be given to patients who refuse insulin injection."
1854868|NCT00984750|Drug|acetyl-L-carnitine/statin (simvastatin)|"acetyl-L-carnitine: 4 tablets of 500 mg a day
simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability"
1854869|NCT00984750|Drug|placebo|placebo: 4 tablets of 500 mg a day simvastatin: 10 to 20 mg/day as deemed clinically appropriate and according to tolerability
1854870|NCT00984763|Biological|AMA1-C1/Alhydrogel® + CPG 7909|A 0.55 mL dose of AMA1-C1/Alhydrogel® + CPG 7909 (corresponds to 80 µg of AMA1-C1 and 564 µg of CPG 7909)
1854871|NCT00984776|Other|Contrast enhanced MRI with Gadofosveset|0.03 mmol/kg bodyweight of gadofosveset will only once be administered during MRI procedure via an intravenous catheter
1854872|NCT00984789|Drug|Ethinylestradiol/Gestodene (FC Patch Low BAY86-5016)|0.55mg ethinylestradiol and 2.1mg gestodene
1854873|NCT00984789|Drug|Norelgestromin/Ethinylestradiol (EVRA)|0.6mg ethinylestradiol and 6mg norelgestromin
1854874|NCT00984802|Drug|CMX-2043|Solution for IV administration at 0.8, 1.6 or 2.4 mg/kg single dose.
1854875|NCT00984802|Drug|Placebo control|Vehicle solution for IV administration single dose.
1854876|NCT00984815|Drug|HZT-501|Fixed-dose combination oral tablet 800mg Ibuprofen/26.6 mg Famotidine taken three times per day
1854877|NCT00984828|Drug|velcade|velcade 1.3mg/m2 D1, 4, 8 and 11
1854878|NCT00984841|Other|Tailored letter|
1854879|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 50mM (1.41mg/100μl) administered just prior to wounding and 200μl administered 24 h later
1854880|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 100mM (2.82mg/100μl) administered just prior to wounding and 200μl administered 24 h later
1854881|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 200mM (5.64mg/100μl) administered just prior to wounding and 200μl administered 24 h later
1854882|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 300mM (8.46mg/100μl) administered just prior to wounding and 200μl administered 24 h later
1854883|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 400mM (11.28mg/100μl) administered just prior to wounding and 200μl administered 24 h later
1854884|NCT00984854|Drug|Juvidex|Intradermal Juvidex, 100μl of 600mM (16.93mg/100μl) administered just prior to wounding and 200μl administered 24 h later
1854885|NCT00984854|Drug|Placebo|Intradermal Placebo (0.9% phosphate buffered saline, pH 7.0), 100μl administered just prior to wounding and 200μl administered 24 later
1854886|NCT00984867|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 48 weeks
1854887|NCT00984867|Drug|Placebo|Matching placebo tablet
1854890|NCT00984893|Drug|Any oral bisphosphonates marketed in Canada|
1854891|NCT00984906|Other|Empty inhalers|Empty Easyhaler inhalers (type A and type B) and empty Turbohaler inhaler
1854892|NCT00984919|Other|high performance liquid chromatography|
1854893|NCT00984919|Other|laboratory biomarker analysis|
1854894|NCT00984919|Other|mass spectrometry|
1854895|NCT00984932|Drug|Rosuvastatin|40 mg of rosuvastatin daily
1854896|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 5 µg|0.5 mL, IM, 2 injections 21 days apart
1854897|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 10 µg|0.5 mL, IM, 2 injections 21 days apart
1854898|NCT00984945|Biological|H5 VLP pandemic influenza vaccine 20 µg|0.5 mL, IM, two injections 21 days apart
1854899|NCT00984945|Biological|Placebo|0.5 mL, IM, two injections 21 days apart
1854900|NCT00984958|Device|Bulkamid|injection of Bulkamid in the urethra
1854901|NCT00984958|Device|Bulkamid expectation|expectance
1854902|NCT00984971|Drug|Tenofovir|Topical gel applied rectally
1854903|NCT00984971|Drug|HEC Placebo|Placebo gel applied rectally
1854904|NCT00984971|Drug|Open label tenofovir tablet|All participants will undergo an open label tenofovir tablet single dose administration (i.e. Tenofovir Disoproxil Fumarate 300 mg, aka Viread®)
1854905|NCT00984984|Drug|methylprednisolone PO|10 capsules Methylprednisolone 100 mg and 50 ml IV NaCl 0,9% (syringe pump 30 mn to 2 h, every day during 3 days
1854906|NCT00984984|Drug|methylprednisolone IV|IV Methylprednisolone 1 g in 50 ml NaCl 0,9% (syringe pump 30 mn to 2 h) and 10 capsules of placebo, every day during 3 days
1854907|NCT00984997|Procedure|Surgery|Segmentectomy or lobectomy with en bloc resection of the involved chest.
1854908|NCT00984997|Radiation|Chest Irradiation|Radiation therapy consists of 60 Gy in 50 fractions for negative margins, or 64.8 Gy in 54 fractions for positive margins, at 1.2 Gy per fraction, 2 fractions per day, 5 days per week.
1854909|NCT00984997|Drug|Cisplatin|50 mg/M^2 given intravenously on days 1 and 8; the cycle will be repeated beginning on day 29.
1854910|NCT00984997|Drug|Etoposide|given by mouth 30-60 minutes prior to each administration of radiotherapy, on days 1-5 and days 8-12; the cycle will be repeated beginning day 29.
1854911|NCT00984997|Radiation|Prophylactic Cranial Irradiation|25 Gy in 10 fractions of 2.5 Gy, 1 fraction per day, will be given at the completion of chest irradiation, and is optional.
1854912|NCT00985023|Procedure|Steel screw fixation of Lisfranc fracture-dislocation.|Stainless steel screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
1854913|NCT00985023|Procedure|Absorbable screw fixation of Lisfranc fracture-dislocations.|Bioabsorbable (poly-levo-lactic acid) screw fixation of unstable Lisfranc fracture-dislocations of the midfoot.
1854914|NCT00985036|Procedure|Blood test|an additional vial of blood will be obtained at the time of MRI or at the time of routine blood tests ordered by the medical oncologist. In other words, there will be no extra needle sticks. Just an extra vial of blood will be taken during a routine blood test
1854915|NCT00985062|Procedure|Mild Ovarian Stimulation Treatment|Administration of a fixed dose of 150 IU/day rFSH s.c. (Puregon® NV Organon, Oss, The Netherlands) from cycle day 5 onwards. As soon as the leading follicle reached a diameter of 14mm, a GnRH-antagonist (Orgalutran®, NV Organon, Oss, The Netherlands) was administered at 0.25 mg/day s.c.. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered.
1854916|NCT00985062|Procedure|Conventional Ovarian Stimulation Treatment|Administration of GnRH agonist Triptorelin (Decapeptyl®, Ferring BV, Hoofddorp, The Netherlands) at 0.1 mg/day s.c., starting on cycle day 21 of the menstrual cycle preceding the actual stimulation cycle. After two weeks of the GnRH regimen, co-treatment with rFSH 225 IU/day s.c. (Puregon®, NV Organon, Oss, The Netherlands) was initiated. To induce final oocyte maturation a single s.c. dose of 10.000 IE hCG (Pregnyl®, NV Organon. Oss, The Netherlands) was administered
1996643|NCT02427438|Other|Handout|A handout with a two dimensional picture and written instruction of the exercise to strengthen low back
1854920|NCT00985114|Device|EndoBarrier|EndoBarrier implant
1854921|NCT00985114|Behavioral|Diet + Lifestyle Counseling|Multidisciplinary lifestyle and nutritional counseling
1854922|NCT00985127|Drug|placebo|administered daily for 21 days
1854923|NCT00985127|Drug|BCX4208|Administered daily for 21 days.
1854924|NCT00985140|Radiation|Total Skin Electron Beam Therapy (TSEBT)|The purpose of the study is to examine the efficacy and safety of total skin electron beam therapy to a dose of 12 Gray (TSEBT 12 Gray) in patients who have mycosis fungoides (MF) staged as IB to IIIB.
1854925|NCT00985153|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|A Single 0.5 mL subcutaneous injection at Day 0
1854926|NCT00985153|Biological|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 0
1854927|NCT00985153|Biological|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 0
1854928|NCT00985166|Biological|ProQuad (Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live)|A Single 0.5 mL subcutaneous injection at Day 1
1854929|NCT00985166|Biological|Comparator: M-M-R II|A Single 0.5 mL subcutaneous injection at Day 1
1854930|NCT00985166|Biological|Comparator: Varivax|A Single 0.5 mL subcutaneous injection at Day 1
1854931|NCT00985166|Biological|Comparator: Placebo|A Single 0.5 mL subcutaneous placebo injection at Day 1
1854932|NCT00985179|Behavioral|Intervention Group (IG)|Employees in the IG will receive an interactive, computerized expert system which tailors treatment components to the individual needs of them
1854933|NCT00985192|Drug|everolimus|
1854934|NCT00985192|Other|laboratory biomarker analysis|
1854935|NCT00978822|Drug|Clevidipine butyrate injectable emulsion|Clevidipine butyrate injectable emulsion infusion starting at 2 mg/hour and titrating up for effect till 32 mg/h for up to 24 hours starting in the emergency department and continued in the critical care units.
1854936|NCT00978835|Behavioral|Tailored telephone-based case management|Telephone calls by a nurse every two months to assess adherence to diet, physical activity, and pill-taking regimens. The nurse will then identify barriers to adherence to these recommendations and use motivational interviewing approaches to offer solutions to the barriers identified. No changes to medication are made.
1854937|NCT00978835|Behavioral|Nurse Education|Didactic, non-interactive education by a nurse on general health topics. Calls are made every two months.
1854938|NCT00978861|Drug|Hydrogen Peroxide|Whitening product syringe type
1854939|NCT00978874|Radiation|fludeoxyglucose F 18|
1854940|NCT00978874|Radiation|fluorine F 18 EF5|
1854941|NCT00985205|Dietary Supplement|Enteral Glutamine|0.5g/kg/day powdered glutamine to be mixed in with water and given via nasogastric tube q4 hrs or TID if po.
1854942|NCT00985205|Dietary Supplement|Placebo|Maltodextrin mixed with water given via NG tube Q 4 hours or TID if po.
1854943|NCT00985218|Device|SMART System|microfluidic embryo culture system
1854944|NCT00985218|Device|Culture dish|Standard IVF culture dish
1854945|NCT00985231|Device|PureVision Multi-Focal contact lenses|Contact lenses to be worn on a daily wear basis for 2 weeks.
1854946|NCT00985231|Device|SofLens59 contact lens|Contact lenses to be worn on a daily wear basis for 2 weeks.
1854947|NCT00985244|Drug|Azithromycin|Subjects in this group will receive 3 times a week 500 mg of the antibiotic azithromycin during 1 year.
1854948|NCT00985244|Drug|Placebo|Persons in this group will receive 3 times a week placebo of azithromycin during 1 year.
1854949|NCT00985257|Device|DIDGET (Investigational Blood Glucose Monitoring System)|Subjects with diabetes (with parent/guardian assistance, if applicable)and health care professionals (HCPs) each performed duplicate Blood Glucose (BG) tests from the subject's capillary blood on the DIDGET. To test the full range of glucose concentrations, a venipuncture was performed on some subjects to obtain enough blood for modifying (spiking or glycolyzing) to the extreme glucose concentrations. Results were compared to a laboratory glucose method - the Yellow Springs Instrument (YSI) Analyzer.
1854950|NCT00985270|Drug|Rifampicin|
1854951|NCT00985270|Drug|Placebo|
1854952|NCT00985283|Behavioral|Preventive home visit|in-home visit by a trained occupational therapist to assess older adult's living context and occupational performance and to provide recommendations for changes or continuation of behavior or context
1854953|NCT00985283|Behavioral|minimal intervention|provision of information related to services and health promotion for older adults as a low-cost minimal alternative to the intervention
1854954|NCT00985322|Drug|ACE inhibitor Ramipril|The ACE inhibitor (Ramipril) will be started at 1.25 mg/day and will be up-titrated to 2.5 mg/day, to 5 mg/day, and then to 10 mg/day according to BP control and tolerability.
1854955|NCT00985322|Drug|non-RAS inhibitor antihypertensive therapy|Blood Pressure lowering regimen not including RAS inhibitors
1854956|NCT00985335|Other|Neem Based External Application Cream|Apply externally 3-4 times per day
1854957|NCT00985348|Drug|Levetiracetam (Keppra)|"Test Drug :
Levetiracetam dry syrup
Reference Drug :
500 mg oral tablets of Levetiracetam. Frequency: Single Dose"
1854958|NCT00985361|Dietary Supplement|Vitamin D3 2000 international units daily|Vitamin D3 2000 international unit tablets once daily for 3 months
1854959|NCT00985361|Dietary Supplement|Vitamin C 500mg daily|Vitamin C 500mg tablets once daily for 3 months
1854960|NCT00985374|Drug|RAD001|5mg or 10mg po daily
1854961|NCT00985374|Drug|RG1507|16mg/kg iv every 3 weeks
1854962|NCT00985387|Drug|Solifenacin|oral
1854963|NCT00985400|Behavioral|Exercise Program|Resistance exercising using resistance bands 2 days per week, and brief moderate-intensity walks multiple times a day for a total of 30 minutes increasing steps weekly by 10% to reach a minimum of 10,000 steps a day
1854964|NCT00985400|Behavioral|Telephone-based intervention|Patients will receive encouragement and social support from a telephone counselor once a week for the first 4 weeks and then once a month for the remaining 12 weeks.
1854965|NCT00985400|Other|Counseling intervention|Patients will receive advice from their doctor (in person), physician assistant, or other midlevel provider about exercising. They will also be given this advice in a letter.
1854966|NCT00985400|Other|Questionnaire administration|
1854967|NCT00985400|Behavioral|Relaxation Program|Relaxation techniques (breathing and meditation) provided at least 15 minutes per day for 5-7 days per week.
1854968|NCT00985426|Biological|HEPLISAV and Placebo|Intramuscular (IM) injections on Weeks 0, 4, and 24; placebo(saline) injection at Week 8
1854969|NCT00985426|Biological|Engerix-B|Intramuscular (IM) injections at Weeks 0, 4, 8, and 24
1854970|NCT00985439|Drug|Diclofenac Test (lower dose)|18-mg Single dose
1854971|NCT00985439|Drug|Diclofenac Test (upper dose)|35-mg Single dose
1854972|NCT00985439|Drug|Celecoxib 400 mg|Capsules 2 x 200 mg Single-dose
1854973|NCT00985439|Drug|Placebo|Capsules 2 Single-dose
1854974|NCT00985452|Other|GlowCaps Connect system|The GlowCaps Connect system is an electronic medication reminder system, which provides reminders to help people to remember to take their medication.
1854975|NCT00985452|Other|Glow cap system - deactivated|The Glow cap system - deactivated is an electronic medication system, which will track medication adherence.
1854977|NCT00985478|Drug|SLV342|25 mg once daily - Maximal Tolerated Dose
1854978|NCT00985478|Drug|placebo|matching placebo
1854979|NCT00985491|Device|Endobarrier Liner|Medical device placed endoscopically in the duodenum
1854980|NCT00985504|Drug|Duloxetine|60-120 milligrams (mg) taken once daily (QD) by mouth (po) for 8 weeks; with option for additional 2 weeks.
1854981|NCT00985504|Drug|Escitalopram|10-20 mg taken QD po for 8 weeks; with option for additional 2 weeks.
1854982|NCT00985517|Biological|CERE-120: Adeno-Associated Virus Delivery of Neurturin|CERE-120 2.4 X 10^12 vg
1854983|NCT00985517|Procedure|Sham Surgery|Sham Surgery
1854984|NCT00985530|Drug|Tamibarotene|Self-administered tablets BID (approximately one hour after breakfast & dinner) during each 6 week cycle
1854985|NCT00985530|Drug|Arsenic trioxide|Administered intravenously Monday thru Friday at 0.15 mg/kg - 30 doses per cycle.
1854986|NCT00988429|Drug|800 mg QD Eslicarbazepine acetate|Oral, 800 mg QD, 2-week titration period and 12-week maintenance period
1854987|NCT00988429|Drug|1200 mg QD Eslicarbazepine acetate|Oral, 1200 mg QD, 2-week titration followed by 12-week maintenance period
1854988|NCT00988429|Drug|Placebo|Placebo tablet given QD
1854989|NCT00988442|Behavioral|Enhanced nursing telephone support|Weekly phone calls by study nurses for 8 weeks and then calls every 2 weeks for 40 weeks; nurses could schedule more frequent calls at their discretion. Calls provided information, motivational enhancement, problem-solving skills, and affective support.
1854990|NCT00988442|Behavioral|Standard care|Usual ACTG site care.
1854991|NCT00988455|Radiation|photodynamic therapy|5-ALA cream 20% topical administration + photodynamic therapy (red light) 120 j/cm2
1854992|NCT00988468|Procedure|Manual Therapy|Grade 1 and 2 oscillatory manual mobilization of the tibiofemoral joint at various ranges of motion.
1854993|NCT00988468|Behavioral|Therapeutic Exercise|Subjects will perform 5 minutes of lower extremity cycle ergometer with minimal resistance followed by 10 minutes of resistance exercise to the quadriceps at 3 tibiofemoral positions (0 degrees, 30 degrees and 60 degrees of knee flexion).
1854994|NCT00988468|Behavioral|Video Observation|Subjects will watch a 15 minute video on a health topic unrelated to knee osteoarthritis.
1854995|NCT00988481|Drug|Topiramate|Topiramate titrated to 200mg/day over four weeks, for ten weeks
1854996|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
1854997|NCT00988494|Drug|DE-105 ophthalmic solution|Topical ocular application
1854998|NCT00988494|Drug|Placebo ophthalmic solution|Topical ocular application
1854999|NCT00988507|Drug|Ferroquine (SSR97193)|"Pharmaceutical form: capsule
Route of administration: oral"
1855000|NCT00988507|Drug|Placebo|"Pharmaceutical form: capsule
Route of administration: oral"
1855001|NCT00988507|Drug|artesunate|"Pharmaceutical form: tablets
Route of administration: oral"
1855002|NCT00988520|Drug|Rocuronium bromide|Continuous intravenous infusion initiated at 7 μg/kg/min and adjusted to maintain muscle relaxation
1855003|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.6 mg/kg injection
1855004|NCT00988520|Drug|Rocuronium bromide|Intubation dose of 0.9 mg/kg injection
1855005|NCT00988520|Drug|Sevoflurane|0.5-2.0% intravenous maintenance anesthesia
1855006|NCT00988520|Drug|Propofol|4010 mg/kg/hr intravenous maintenance anesthesia
1855007|NCT00988533|Drug|0.5% Ivermectin Cream|Topical 0.5% ivermectin cream applied to scalp and hair on day 1
1855008|NCT00988546|Other|Computer based template for exam documentation|exam documentation performed using computer based template
1855009|NCT00988546|Other|Dictation for exam documentation|exam documentation performed using dictation, the standard practice
1855016|NCT00988572|Other|Vestibular rehabilitation|The intervention program comprises of vestibular rehabilitation, at group sessions, twice a week for 9 weeks. The program is described in detail in table 1. Vestibular rehabilitation aims to facilitate rearrangement and recruitment of the control capacities of the vestibular system, by letting the patient be exposed to unstable body positions, such as standing on foam and performing head, trunk or eye-movements.
1855017|NCT00988585|Dietary Supplement|EPA 600|EPA 600 mg/day for 6 weeks
1855018|NCT00988585|Dietary Supplement|EPA 1800|1800 mg/day for 6 weeks
1855019|NCT00988585|Dietary Supplement|Olive Oil|600 mg/day for 6 weeks
1855020|NCT00988585|Dietary Supplement|DHA|600 mg/day for 6 weeks
1855021|NCT00988598|Drug|PF-04447943|25 mg of PF-04447943 orally every 12 hours for 7 days
1855022|NCT00988598|Drug|Placebo|25 mg matching placebo to PF-04447943 orally every 12 hours for 7 days
1855023|NCT00988611|Other|Women undergoing IVF/ART cycles at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma|Women undergoing an IVF/ART treatment cycle at OU Physicians Reproductive Health Clinic in Oklahoma City, Oklahoma, age range 18-44 years old
1855024|NCT00988624|Drug|Dimebon IR Tablet|Pharmacokinetics of a single oral dose of 10 mg dimebon immediate release tablet will be assessed on Day 1 - 3.
1855025|NCT00988624|Drug|Dimebon MR1|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR1, will be assessed on Day 1 - 3.
1855026|NCT00988624|Drug|Dimebon MR2|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR2, will be assessed on Day 1 - 3.
1855027|NCT00988624|Drug|Dimebon MR3|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR3, will be assessed on Day 1 - 3.
1855028|NCT00988624|Drug|Dimebon MR4|Pharmacokinetics of a single oral dose of 10 mg dimebon modified release formulation, MR4, will be assessed on Day 1 - 3.
1855029|NCT00988637|Drug|Vectical™ Ointment weekdays and Clobex® Spray weekends regimen|Vectical™ Ointment 3 µg/g, topical, apply twice daily on weekdays (Mon-Fri) and Clobex® Spray 0.05% twice daily on weekends (Sat-Sun) for 28 days
1855030|NCT00988637|Drug|Clobex® Spray morning and Vectical™ Ointment evening regimen|Clobex® Spray 0.05%, topical, apply once each morning and Vectical™ Ointment 3 µg/g, topical, apply once each evening for 28 days
1855031|NCT00988650|Other|isocaloric diet|
1855032|NCT00988650|Other|free living conditions|
1855033|NCT00988663|Drug|memantine|patient will receive 5mg daily for 7day then 10 mgm daily
1855034|NCT00988663|Drug|Placebo|will give placebo that looks like memantine
1855035|NCT00988689|Other|Dietary Intervention|soup with or without starch
1855036|NCT00988702|Behavioral|Dan Tian Breathing|Dan Tian Breathing for one month
1855037|NCT00988702|Behavioral|Progressive muscle training|Progressive muscle training for one month
1855038|NCT00988715|Biological|Pretargeted Radioimmunotherapy|Antibody-streptavidin conjugate and radiolabeled DOTA-biotin, each given IV
1855039|NCT00988715|Drug|Cyclosporine|Given IV
1855040|NCT00988715|Drug|Mycophenolate Mofetil|Given PO
1855041|NCT00988715|Radiation|Total-Body Irradiation|Undergo total-body irradiation
1855042|NCT00988715|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
1855043|NCT00988715|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood stem cell transplant
1855044|NCT00988715|Drug|Fludarabine Phosphate|Given IV
1855045|NCT00988715|Other|Pharmacological Study|Correlative studies
1855046|NCT00988715|Other|Laboratory Biomarker Analysis|Correlative studies
1855047|NCT00988728|Drug|SCH 900435 (Org 25935)|"Oral tablets, containing 8 mg of active substance, two tablets (i.e. 16 mg) to be taken twice daily in the morning after breakfast and in the evening after dinner during 4 weeks.
Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with SCH 900435 plus 1 capsule with placebo per day)."
1855048|NCT00988728|Drug|Placebo|"Oral capsules and tablets containing excipients only.
Because of the double-dummy design, subjects will be administered one capsule in the evening, plus two tablets in the morning after breakfast and two tablets after dinner."
1855049|NCT00988728|Drug|Olanzapine|"Oral capsules containing 15 mg of active substance, one capsule to be taken once daily after dinner for four weeks.
Because of double-dummy design, subjects will be administered two tablets in the morning, and two tablets plus one capsule in the evening (in total 4 tablets with placebo plus 1 capsule with olanzapine per day)."
1855050|NCT00988741|Drug|ARQ 197|The investigational drug ARQ 197 is supplied as capsules. A dose of 360 mg (3 capsules of 120 mg each) of ARQ 197 will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 720 mg. Under Amendment 2, a dose of 240 mg (2 capsules of 120 mg each) of ARQ 197/placebo will be administered by mouth BID, once in the morning and once in the evening with meals, for a total daily dose of 480 mg. A treatment cycle is defined as 4 weeks for both treatment arms. Cycles will be repeated every 4 weeks (28 days) based on toxicity and response.
1855051|NCT00988741|Drug|Placebo|The placebo is provided in a capsule form.
1855053|NCT00988767|Biological|DNA vaccine|patients received 1ml of DNA vaccine (1mg/ml) at Months 0,2,4,10
1855054|NCT00988780|Drug|maraviroc|"Maraviroc 600mg po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
1855055|NCT00988780|Drug|Placebo|"Placebo tablets po BID every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Efavirenz 600 mg qd every day from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops.
Tenofovir/Emtricitabine 300/200 mg qd from the entry visit until week 48 or until IRIS event or unacceptable toxicity develops."
1855056|NCT00988793|Procedure|Laparoscopic distal pancreatectomy|Comparison of two different types of surgery, laparoscopic versus distal pancreatectomy
1855057|NCT00988793|Procedure|Open distal pancreatectomy|Comparison of two different types of surgery, open versus laparoscopic distal pancreatectomy.
1855058|NCT00988806|Drug|Levosimendan|"Patients included in the intervention group receive optimal drug therapy for heart failure symptoms and also infusion of levosimendan at doses of 0.1 mcg / kg / min for 24 hours every 30 days.
Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
1855059|NCT00988806|Drug|Placebo|"Patients included in the placebo group receive optimal drug therapy for heart failure and also infusion of placebo at the same infusion rate as levosimendan doses of 0.1 mcg / kg / min for 24 hours every 30 days.
Failure to reach an appropriate level of heart failure compensation before the deadline of 30 days for the next study drug administration or placebo, the administration of them will be every 15 days. Thereafter, failure to reach an appropriate level of heart failure compensation for patients or worsen after two consecutive infusions of study drug or placebo every 15 days, proceed to open the code patient randomization and and apply the most appropriate treatment."
1855060|NCT00988832|Biological|Infliximab|Infliximab as prescribed by a physician in normal practice for Crohn's disease
1855061|NCT00988845|Dietary Supplement|Indole-3-carbinol|200 mg bid po X 8 weeks
1855062|NCT00988858|Drug|LY2603618|150 milligram per square meter (mg/m^2) intravenously on Day 2 of each 21 day cycle repeating every 21 days for a minimum of 2 cycles continuing until disease progression
1855063|NCT00988858|Drug|Pemetrexed|500 mg/m^2 intravenously on Day 1 of each 21 Day cycle repeating every 21 days for a minimum of 2 cycles or until disease progression
1855064|NCT00988871|Device|PICC, CICC|PICC insertion, CICC (advanced venous access with pulmonary artery catheter) insertion
1855065|NCT00988884|Biological|V503|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection in the deltoid muscle of the non-dominant arm at Day 1, Month 2, and Month 6
1855066|NCT00988884|Biological|Comparator: Menactra™ (Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
1855067|NCT00988884|Biological|Comparator: Adacel™ (Concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm on Day 1.
1855068|NCT00988884|Biological|Comparator: Menactra™ (Non-Concomitant)|Menactra™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
1855069|NCT00988884|Biological|Comparator: Adacel™ (Non-concomitant)|Adacel™ given as a single 0.5 mL intramuscular injection in the deltoid muscle of the dominant arm at Month 1.
1855070|NCT00988897|Drug|OXALIPLATIN (SR96669)|Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
1855071|NCT00988897|Drug|5-FLUOROURACIL (5-FU)|Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
1855072|NCT00988897|Drug|LEUCOVORIN (LV)|Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
1855073|NCT00988897|Drug|BEVACIZUMAB|Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
1855074|NCT00988910|Drug|EE30-DRSP (Yasmin, BAY86-5131)|DRSP-containing combined oral contraceptives according to the normal routine praxis
1855075|NCT00988910|Drug|Other combined oral contraceptives|Other combined oral contraceptives according to the normal routine praxis
1855076|NCT00988923|Other|group A: HYPERTHERMIA|All patients were treated for 8 sessions, twice a week, for a total of 4 weeks of treatment. All patients were evaluated at baseline (T0) and after 4 weeks (T1). The first two sessions were sham-treatment for both groups
1855077|NCT00988923|Other|No intervention|the intervention tool was switched in off, only bolus was activated
1855079|NCT00988949|Drug|PF-04455242|Single oral 18 mg dose of PF-04455242.
1855080|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
1855081|NCT00988949|Other|Placebo|Oral placebo.
1855082|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
1855083|NCT00988949|Drug|PF-04455242|Single 30 mg oral dose of PF-04455242.
1855084|NCT00988949|Drug|spiradoline|Spiradoline 3.2 mcg/kg to be administered intramuscularly once on the morning of the spiradoline challenge day.
1855085|NCT00988962|Behavioral|cognitive behavioral training|electronic diaries, compliance checklists, urine screens, individual and group motivational counseling
1855086|NCT00988975|Procedure|Insertion of pelvicol graft|Pelvicol graft
1855087|NCT00988988|Drug|AGEE cream|AGEE cream is a creatine ethyl ester based product (an amino acid) that can be purchased over-the-counter without a prescription and is not FDA controlled. It will be used immediately after injection and repeated as needed.
1855088|NCT00988988|Drug|1% Steroid Cream|comparing to AGEE cream or placebo. 1% steroid cream is available over the counter. To be used immediately after injection and as needed.
1855089|NCT00988988|Drug|topical placebo cream with no active ingredients|Cream to be applied immediately after injection and repeated as needed.
1855090|NCT00989001|Drug|Vernakalant|Maximum volume of 100 mL as per the dosing schedule, administered intravenously (IV) over 10 minutes
1855091|NCT00989001|Drug|Placebo|Injection
1855092|NCT00989014|Drug|CD07805/47|0.5% Topical Gel
1855093|NCT00989014|Drug|CD07805/47|0.18% Topical Gel
1855094|NCT00989014|Drug|CD07805/47|0.07% Topical Gel
1855095|NCT00989014|Drug|CD07805/47 placebo|Vehicle Topical Gel
1855096|NCT00989027|Drug|Oxytocin|Oxytocin, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
1855097|NCT00989027|Drug|Ergonovine|Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
1855098|NCT00989027|Drug|Carboprost|Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
1855099|NCT00989027|Drug|Oxytocin and Ergonovine|Oxytocin and Ergonovine, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
1855100|NCT00989027|Drug|Oxytocin and Carboprost|Oxytocin and Carboprost, 10-9mol/L to 10-3mol/L, in Krebs-Henseleit solution.
1855101|NCT00989040|Drug|usual treatment: Versatis|"To explore if the cognition is failed in treated patients suffering of neuropathic postzosteria pain.
To see if treated patients with patch (Versatis®) have better cognition than treated patients without patch."
1855102|NCT00989053|Drug|escitalopram|10 mg/d for a duration of 8 weeks
1855103|NCT00989053|Drug|placebo|1 pill per day for 8 weeks
1855104|NCT00989079|Drug|Ertugliflozin|Ertugliflozin will be administered as an extemporaneously prepared suspension/solution for all doses within the initially planned range.
1855105|NCT00989079|Drug|Placebo to Ertugliflozin|Correspondingly placebo doses to ertugliflozin will be administered as suspension/solution
1855106|NCT00989092|Biological|darbepoetin alfa|Administered subcutaneously.
1855107|NCT00989105|Other|immunohistochemistry staining method|
1855108|NCT00989105|Other|laboratory biomarker analysis|
1855109|NCT00989105|Other|pharmacological study|
1855110|NCT00989105|Procedure|computed tomography|
1855111|NCT00989105|Procedure|magnetic resonance imaging|
1855112|NCT00989105|Procedure|single photon emission computed tomography|
1855113|NCT00989105|Radiation|technetium Tc 99m demobesin-4|
1855114|NCT00989118|Procedure|Laser treatment of ovarian endometrioma|Laser vaporization of ovarian endometrioma
1855115|NCT00989131|Drug|Paclical®|"250 mg/m2 of Paclical® is given as a one-hour IV infusion, followed by carboplatin, on day 1 of each 21 day cycle.
Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
1855116|NCT00989131|Drug|Taxol®|"175 mg/m2 of Taxol® is given as 3 hour IV infusion, followed by carboplatin on day 1 of each 21 day cycle.
Number of Cycles: 6. Cycle 2-6 will be given with 3 weeks interval between treatments."
1855117|NCT00989157|Drug|Duloxetine|Single dose of 60 mg of duloxetine
1855118|NCT00989170|Behavioral|Family Program for the Prevention of Weight Gain|The Family Workbook is a step-by-step instruction guide for families to use throughout the 6-month period, detailing healthy lifestyle. All handouts, instructions, activities, and a timeline of the program are laid out for families in this workbook.
1855119|NCT00989170|Behavioral|Control Group|This group will not be provided the workbook and it is hypothesized those in the control group will gain excess weight.
1855120|NCT00989183|Other|Women undergoing a bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma|Women undergoing an elective bilateral or unilateral oophorectomy at OU Medical Center, Oklahoma City, Oklahoma Age range 21-55 years old
1855121|NCT00989196|Biological|Human-cl rhFVIII|50 IU/kg for PK dose
1855122|NCT00989196|Biological|Kogenate FS|50 IU/kg for PK dose
1855123|NCT00989209|Drug|Botulinum Toxin Type A|All the patients received a one-time treatment with botulinum toxin type A to the non-paralyzed side, according to the Institution Protocol,the total dose used per patient ranged from 15-69U, mean 37.9±5.4U.
1855124|NCT00989209|Procedure|myofunctional therapy|All the patients were submitted to individual myofunctional therapy with the speech therapist, once a week, by four weeks.The myofunctional therapy began with isometric maneuvers for muscular elongation on the non paralyzed side, and on the paralyzed side when microsurgical reconstruction was present. It also included isotonic maneuvers to increase muscle tonus and isokinetic maneuvers to increase force on the paralyzed side.
1855226|NCT00989807|Drug|Aztreonam lysine|Open-label, expanded access for Aztreonam lysine for inhalation 75 mg three times daily
1855125|NCT00989222|Procedure|closed reduction and external fixation|Fixation of an unstable dorsally displaced fracture of the distal radius with bridging external fixation
1855126|NCT00989222|Procedure|Internal fixation with a volar locked plate|Open reduction and fixation of a unstable dorsally displaced fracture of the distal radius with a volar locked plate
1855127|NCT00989235|Drug|Abatacept|IV solution, IV, 10 mg/Kg, Once monthly, 1 year
1855128|NCT00989235|Drug|Abatacept|IV solution, IV, 5 mg/Kg, Once monthly, 1 year
1855129|NCT00989248|Other|Aerobic and anaerobic capacity use aquatic exercises|Improve aerobic capacity use aquatic exercises in patients with Congestive Heart Failure
1855130|NCT00989261|Drug|Compound AC220|Precomplexed powder in bottle formulation supplied as 200 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
1855131|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 15 ug & trivalent|Grup 1: day 0: Vaccine trivalent (A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, and B/Brisbane/60/2008-like virus) Vaccine Sanofi A(H1N1) administrated 15 ug. (nonadjuvant); day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant);
1855132|NCT00989274|Biological|Vaccine Sanofi (H1N1) 15 ug.nonadyuvante|Grup 2: Day 0: Vaccine trivalent(A/Brisbane/59/2007 (H1N1)-like virus, A/Brisbane/10/2007 (H3N2)-like virus, y B/Brisbane/60/2008-like virus); Day 28 Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 15 ug. (nonadjuvant)
1855133|NCT00989274|Biological|Vaccine Sanofi A(H1N1) 7.5 ug|Grup 3: day 0: day 28 Vaccine Sanofi A(H1N1) administrated a 7.5 ug (non adjuvant); day 56; Vaccine Sanofi A(H1N1) administrated a 7.5 ug (nonadjuvant).
1855135|NCT00989300|Drug|Treatment A - rabeprazole|20 mg rabeprazole sodium once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
1855136|NCT00989300|Drug|Treatment B - omeprazole|20 mg omeprazole once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
1855137|NCT00989300|Other|Treatment C - placebo|placebo once daily for 7 days, in combination with 75 mg clopidogrel once daily for 7 days, oral dosing
1855138|NCT00989313|Drug|Lesion count|Lesion count in area treated by study drug in a prior study. No drug will be applied during this long-term follow up study. Drug was applied during the primary study.
1855139|NCT00989326|Other|Home Monitoring|Both patient groups are followed for 18 months and will be followed with Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
1855140|NCT00989339|Drug|Twenty-four Hour TPN and Saline Infusion|Infusion of Intralipid 20%, ClinOleic 20% or normal saline at 20 ml/hr for 24 hr.
1855141|NCT00989352|Drug|Methotrexate|3g/m² i.v. max. 9 times
1855142|NCT00989352|Drug|Lomustine|110 mg/m² p.o., max. 3 times
1855143|NCT00989352|Drug|Procarbazine|60 mg/m² p.o. for 10 days, max. 3 times 100 mg p.o. for 5 days, max. 6 times
1855144|NCT00989352|Drug|Rituximab|375 mg/m² i.v., max. 10 times
1855145|NCT00989365|Other|Aerobic training|Treadmill training
1855146|NCT00989378|Behavioral|baseline study|normal bedtimes
1855147|NCT00989391|Drug|PF-03654764|5mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
1855148|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
1855149|NCT00989391|Drug|PF-03654764|12mg orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
1855150|NCT00989391|Drug|placebo|orally once daily for 10 days. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
1855151|NCT00989391|Drug|PF-03654764|12mg orally twice daily on Days 1-9, and once on Day 10 After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
1855227|NCT00989820|Drug|hyperbaric oxygen|30 session inhalation of 100% oxygen in a pressure chamber under 2.4 ATA for 90 minutes a day before surgery and 10 session hyperbaric oxygen therapy (as mentioned before) after surgery
1855228|NCT00989833|Drug|budesonide|400 yg x 1
1855152|NCT00989391|Drug|placebo|oral twice daily on Days 1-9 and once on Day 10. After satisfactory review of the available safety, toleration and PK data, progression to the next dose will occur if the last dose was well tolerated. If the previous dose was not well tolerated, after review of the safety data, and discussion between the Pfizer Study Team and the Investigator, the same dose may be given again, a lower dose within the tolerated dose range may be given, or the study may be stopped. The dose increments will be based on emerging safety and toleration data, as well as plasma exposure estimates and forward predictions of PK. Nominal administered doses will not exceed 24 mg per day.
1855153|NCT00989404|Drug|Zanamivir|Rotahaler placebo 10mg BID 5 days
1855154|NCT00989404|Drug|Zanamivir|Rotahaler Zanamivir 10mg BID 5 days
1855155|NCT00989404|Drug|Zanamivir|Diskhaler Zanamivir 10mg BID 5 days
1855156|NCT00989417|Other|ACTIVATION of HOME MONITORING|Both patient groups will be followed for 27 months and will have Home Monitoring switched on. The data from the CONTROL group will not be presented online to the attending physician, but a retrospective analysis on differences between the two groups will be performed.
1855157|NCT00989430|Behavioral|Prism Adaptation Treatment|Wearing prism goggles and performing visuomotor tasks during therapy sessions.
1855158|NCT00989443|Drug|Cidofovir gel|topical gel applied once a week for 3 weeks
1855159|NCT00989456|Behavioral|Self management education programme|"The structured patient educational self - management programme consists of 6 weekly sessions à 2 hours. The educational programme will take place prior to one of the two weekly training sessions.
After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care. During the last month of the intervention year educational self - management will be offered twice and focus on themes that the participants wish to refresh."
1855160|NCT00989456|Behavioral|exercise only|6 week waiting list, followed by two weekly training sessions. After the initial period of 8 weeks participants are encouraged to practicing self- management on their own for a period of 9 months. They receive,in addition to standard follow - up, an offer of extra follow - up consisting of regular contact with their group supervisors in primary health care.
1855161|NCT00989469|Drug|Nexavar (Sorafenib) and irinotecan (Campto)|Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
1855162|NCT00989482|Behavioral|Computer kiosk Education|computerized patient education; guidelines for physicians
1855163|NCT00989495|Device|Brace|Wearing a Thoraco-Lumbo-Sacral-Orthosis (TLSO) for a minimum of 20 hours per day
1855164|NCT00989508|Drug|Perhexiline|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
1855165|NCT00989508|Drug|Placebo marked PEXSIG|Tablets. Dose: 200mg BD for 3 days, then 100mg BD until surgery. Duration of therapy: 5-31 days.
1855166|NCT00989521|Drug|PUR003|PUR003 for inhalation
1855167|NCT00989521|Drug|Placebo|Normal saline for inhalation
1855168|NCT00989534|Behavioral|Fixed restricted bedtimes|Sleep restricted to 5 hours per night for 8 nights
1855169|NCT00989534|Behavioral|Sleep restriction with circadian misalignment|Sleep restricted to 5 h per day for 8 days, alternating night sleep and day sleep
1855170|NCT00989547|Other|Umbilical Cord Blood VITA 34|Intervention type: Autologous Umbilical Cord Blood Transfusion
1855171|NCT00989560|Procedure|endoscopy|patients receive best treatment and care with an additional endoscopy
1855172|NCT00989573|Drug|Placebo|oral administration of placebo once-daily for 8 weeks
1855173|NCT00989573|Drug|OPC-6535|oral administration of OPC-6535 25 mg once-daily for 8 weeks
1855174|NCT00989573|Drug|OPC-6535|oral administration of OPC-6535 50 mg once-daily for 8 weeks
1855175|NCT00989586|Biological|milatuzumab|Patient will receive milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive milatuzumab on day 2. Starting in week 2, milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
1855176|NCT00989586|Biological|veltuzumab|Patient will receive veltuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
1855177|NCT00989586|Procedure|Correlative/Special Studies|To correlate Fcγ receptor polymorphisms with response to treatment with the combination of veltuzumab and milatuzumab. Whole blood will be collected pre-treatment on day 1.
1855178|NCT00989586|Procedure|Quantitative T-, B-, and NK cell subsets|Quantitative T-, B-, and NK- cell subsets will be assessed using flow cytometry to quantify the percentage and absolute number of cells expressing CD4, CD8, CD56, CD16, CD19, and CD20 pre-treatment on day 1, after induction (week 5, day 1), and prior to the start of therapy on day 1 week 12, day 1 week 36, and then every 4 months for one year.
1855179|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of veltuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 1 of weeks 1, 2, 4, 12 and 36. One additional sample will be collected each of weeks 5 through 10 (sample may be collected any day during each of these weeks).
1855180|NCT00989586|Procedure|Pharmacokinetics|To assess the pharmacokinetics of milatuzumab in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma. Pharmacokinetics will be assessed with blood samples collected at the following time points: immediately pre- and post-infusion on day 2 of week 1 and day 1 of weeks 2, 4, 12 and 36. Additional samples will be collected days 3 through 6 of week 1.
1855229|NCT00989833|Drug|terbutaline|0.4 mg as-needed
1855230|NCT00989833|Drug|budesonide/formoterol|160/4.5 yg as-needed
1855231|NCT00989846|Other|biomarker|measuring serum-biomarkers
1855232|NCT00989859|Device|Plethysmographic monitoring|Plethysmographic monitoring
1855181|NCT00989586|Procedure|Human Anti-Human Antibodies|To monitor for the development of human anti-veltuzumab antibodies and human anti-milatuzumab antibodies (HAHA) in patients receiving treatment with veltuzumab and milatuzumab. Patients will be monitored for the development of HAHA at the following timepoints: pre-treatment on day 1 of week 1, pre-treatment on day 1 of week 4, pre-treatment on day 1 of week 12, and pre-treatment on day 1 of week 36.
1855182|NCT00989586|Biological|veltuzumab and milatuzumab|Patient will receive veltuzumab and milatuzumab weekly for 4 total doses during induction therapy. Induction therapy will be defined as the first 4 weeks of study therapy. During week 1 of induction therapy, patients will receive veltuzumab on day 1 and milatuzumab on day 2. Starting in week 2, veltuxumab will be given on day 1 and milatuzumab will be given on day 4. Provided the patient does not experience excessive toxicity or disease progression during induction therapy, the patient may continue treatment with extended induction therapy, consisting of veltuzumab day 1 and milatuzumab day 4 of weeks 12, 20, 28, and 36.
1855183|NCT00989599|Other|compress of Chamomilla recutita infusion|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy were treated with a compress of Chamomilla recutita infusion for 20 minutes three times per day
1855184|NCT00989599|Other|compress of lukewarm water|Patients with phlebitis due to peripheral intravenous infusion in anti-neoplasm chemotherapy, in control group, were treated with a compress of lukewarm water for 20 minutes three times per day
1855186|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
1855187|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
1855188|NCT00989625|Drug|This is a pharmacokinetic study (Treximet)|This is a pharmacokinetic study to collect PK samples from subject after single dose.
1855189|NCT00989651|Biological|Bevacizumab|Given IV
1855190|NCT00989651|Drug|Carboplatin|Given IV
1855191|NCT00989651|Drug|Cisplatin|Given IP
1855192|NCT00989651|Other|Laboratory Biomarker Analysis|Correlative studies
1855193|NCT00989651|Drug|Paclitaxel|Given IV or IP
1855194|NCT00989651|Drug|Veliparib|Given PO
1855195|NCT00989664|Biological|Tositumomab and Iodine I 131 Tositumomab|"Dosimetric Dose: 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST, of which 1-2 mg had been labeled with 5 mCi of Iodine-131) infused over 30 minutes (inclusive of a 10-minute flush).
Therapeutic Dose: 7 to 14 days after the dosimetric dose, 450 mg of TST infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by I-131 TST (35 mg of TST labeled with enough Iodine-131 to administer the specified whole body radiation dose determined for the subject) infused over 30 minutes (inclusive of a 10-minute flush). The desired total body dose was 65 cGy for subjects with a baseline platelet count of 100,001-149,999/mm3 and 75 cGy for patients with a baseline platelet count ≥150,000/mm3. Obese patients received an attenuated dose by not including subject mass over 137% of their calculated lean body mass in their calculated lean body mass in the dose calculation."
1855196|NCT00989690|Drug|docetaxel|
1855197|NCT00989690|Drug|erlotinib hydrochloride|
1855198|NCT00989690|Drug|pemetrexed disodium|
1855199|NCT00989690|Genetic|fluorescence in situ hybridization|
1855200|NCT00989690|Genetic|mutation analysis|
1855201|NCT00989690|Genetic|proteomic profiling|
1855202|NCT00989690|Other|immunohistochemistry staining method|
1855203|NCT00989690|Other|laboratory biomarker analysis|
1855204|NCT00989690|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|
1855205|NCT00989690|Procedure|breath test|
1855206|NCT00989703|Drug|placebo|oral solution, daily for 14 days
1855207|NCT00989703|Drug|GLPG0259|oral solution
1855208|NCT00989703|Drug|Methotrexate|7.5 mg (3 tablets, 2.5 mg/tablet) on study days D-1 and D14
1855211|NCT00989729|Drug|Methylprednisolone|A single preoperative dosage 30 mg/kg Methylprednisolone suspended in physiological saline (100 ml in total) given intravenously as a 30 minute infusion, 2 hours before surgery.
1855212|NCT00989729|Drug|Physiological Saline|A single preoperative dosage 100 ml given intravenously as a 30 minute infusion, 2 hours before surgery
1855213|NCT00989742|Drug|Doxycycline|50mg od
1855214|NCT00989742|Drug|Placebo|50mg od
1855215|NCT00989755|Other|Fax to Quit (F2Q)|Clinics in this group receive electronic and hard copies of all materials necessary for implementing Fax to Quit within their clinics.
1855216|NCT00989768|Drug|Botulinum Toxin Type A (Dysport®)|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2,5:1. Both reconstituted in the same volume per point, injected in the forehead determined site.
-Dysport®: 5 units will be injected in the left or right forehead side."
1855217|NCT00989768|Drug|Botulinum Toxin Type A/Botox®|2 units will be injected in the left or right forehead side.(opposite side of dysport injection)
1855218|NCT00989768|Drug|Botulinum Toxin Type A/Dysport®|"Botulinum toxin A (Dysport®)will be administered according to an equivalence ratio of 2:1. Both reconstituted in the same volume per point, injected in the forehead determined site.
-Dysport®: 4 units will be injected in the left or right forehead side, 2:1 ratio Dysport/Botox."
1855233|NCT00989872|Drug|EDP-322|
1855234|NCT00989885|Other|Questionnaire and polysomnography|Comparison of polysomnography data records and previously made questionnaire, with the Epworth Sleepiness Scale.
1855235|NCT00989898|Other|Automated closed-loop insulin delivery|Insulin infusion rates via the insulin pump will be dictated by a computer-based control algorithm according to the CGM glucose readings and automatically adjusted on the pump.
1855236|NCT00989911|Drug|Bosentan|Bosentan 62.5 mg tablet taken orally twice daily for one month, followed by Bosentan 125 mg tablet taken orally twice daily for three months.
1855237|NCT00989937|Drug|Oxytocin|20 IU BID or 40 IU BID
1855238|NCT00989937|Drug|Placebo|20 IU BID or 40 IU BID
1855239|NCT00989950|Drug|Daytrana|Daytrana patch 10-30 mg administered once daily for 9hr
1855240|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 10 hr wear
1855241|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 11 hr
1855242|NCT00989950|Drug|Daytrana|Daytrana 10-30 mg worn once daily for 12 hrs
1855243|NCT00989963|Drug|Beraprost Sodium Modified Release|60µg Tablets, twice a day for 12 weeks
1855244|NCT00989976|Behavioral|normal sleep times|8.5 h bedtimes
1855245|NCT00989976|Behavioral|bedtime restriction|4.5 h restricted bedtimes
1855246|NCT00989989|Drug|Ranibizumab|Ranibizumab 0.5 mg intravitreal injection at day 1, month 1 and month 2. If stable vision not reached at month 3, one injection per month continued until stable vision was reached. Intravitreal injections re-initiated if needed.
1855247|NCT00989989|Procedure|Laser photocoagulation|Active laser treatment administered at day 1. Subsequent laser treatments administered if needed at intervals no shorter than 3 months from previous laser treatment.
1855248|NCT00989989|Drug|Sham ranibizumab|Sham intravitreal injections to ranibizumab at day 1, month 1 and month 2. Intravitreal injections re-initiated if needed.
1855249|NCT00989989|Procedure|Sham laser photocoagulation|Sham laser treatment administered at day 1.
1855250|NCT00990015|Drug|PF-04308515|Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
1855251|NCT00990015|Drug|Placebo|Placebo solution/suspension to match active drug QD at a single dose.
1855252|NCT00990028|Drug|Rosuvastatin|20 mg oral, for 10 days
1855253|NCT00990028|Drug|Placebo|20 mg vehicle
1855254|NCT00990054|Drug|Plerixafor|240 mcg/kg/dose and proceeding to escalating dose levels for determination of the single-dose maximum tolerated dose (MTD) provided that there are no unacceptable dose limiting toxicities
1855255|NCT00990067|Drug|3,4-Methylenedioxymethamphetamine|125 mg, single dose
1855256|NCT00990067|Drug|Duloxetine|120 mg two doses 12h and 2h before MDMA
1855257|NCT00990067|Drug|Placebo|capsules identical to MDMA or duloxetine
1855258|NCT00990080|Biological|Pediacel® and Infanrix™-IPV/Hib|0.5 mL IM at 2,4 and 6 months of age
1855259|NCT00990093|Device|test intermittent catheter|CH 12 hydrophilic coated catheter
1855260|NCT00990093|Device|Intermittent catheterization|CH 12 hydrophilic catheter
1855261|NCT00990106|Drug|prazosin hydrochloride|"Subject will be titrated up to the optimum tolerated dose based on the Dosing Algorithm. Males and females will be titrated differently with females titrated slower and to a lower maximum daily dose. The first dose will be taken while the participant is in bed for the night to avoid orthostatic syncope, an uncommon but recognized first dose effect of prazosin or any alpha-1 antagonist if started at a high dose. The first dose effect is avoidable by starting treatment with a low dose (1 mg at bedtime) then titrating the dose upward gradually."
1855262|NCT00990106|Drug|placebo|placebo
1855263|NCT00990119|Device|Vapotherm High Flow Therapy|use of high flow nasal cannula to support oxygenation and CO2 removal by flushing the nasopharynx with warmed, humidified respiratory gas at flow rates that exceed a patient's inspiratory flow rate
1855264|NCT00990132|Device|Home mechanical ventilation|Nocturnal non-invasive ventilation
1855265|NCT00990132|Device|Long term oxygen therapy|LTOT established as per national guidelines
1855266|NCT00990145|Drug|EDP-322|
1855267|NCT00990158|Drug|Phytonadione (Vitamin K1)|A daily dose of 150 micrograms of vitamin K medication given orally for a total of 7 months
1855268|NCT00990158|Drug|Placebo|A daily dose of matching placebo medication given orally for a total of 7 months
1855269|NCT00990184|Drug|Colesevelam|colesevelam HCl 3.75 g once daily orally with the evening meal
1855270|NCT00990184|Other|placebo|tablet (s) orally given with evening meal
1855271|NCT00990197|Drug|Transdermal nicotine patch|Subjects will apply the nicotine patch on the morning of their treatment day and will keep it on for 24 hours.
1855272|NCT00990223|Drug|Eplerenone or Placebo|Eplerenone 100 mg or Placebo, daily for 10 days.
1855273|NCT00990236|Device|Thrombelastography (TEG®)|TEG 5000 Series Analyzer is an FDA approved device that measures blood clotting using whole blood. Blood will be collected from subjects and analyzed using the TEG. Subjects will not have direct contact with the TEG.
1989568|NCT02461303|Other|Counseling|Subjects will be counseled on the impact of KS on the reduced fertility potential, and about providing a semen sample for semen analysis. Semen analysis is the gold standard for fertility preservation in adult patients, but is only rarely considered by post-pubertal adolescent and young adult patients and their families. Only the semen analysis parameters will be used by the study for the comparison with physical and endocrine measures to assess whether spermatogenesis in these patients coincides with pubertal development. All potential frozen samples will be stored for the patient's future use, and samples will not be used for research experiments.
1855278|NCT00990262|Radiation|Cardiac Computed Tomography|"Localization of the heart position in a projectional topographic scan of the chest.
Determination of contrast agent transit time: 10 ml contrast agent.
CT coronary angiography: CT scan in spiral acquisition mode with 330 ms rotation time, 32 x 0.6 mm collimation, a pitch of 2.8 mm/rotation, tube voltage of 120 kVp, and maximum tube current of 850 mA. 80 ml of contrast agent, followed by 40 ml saline solution will be injected at a rate of 4 ml/s. The mean breath hold duration for this acquisition is approximately 13 seconds."
1855279|NCT00990275|Other|ethanol|subjects will ingest 3 ounces of vodka mixed with fruit juice within 30 min.
1855281|NCT00990301|Drug|Moexipril HCl/ Hydrochlorothiazide 15mg/ 25mg Tablet, Paddock Laboratories, Inc.|test drug
1855282|NCT00990301|Drug|Uniretic® 15mg/25mg Tablets|reference drug
1855283|NCT00990314|Drug|Beraprost Sodium Modified Release|
1855284|NCT00990327|Drug|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
1855285|NCT00990327|Drug|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute.
1855286|NCT00990340|Device|T-jet® containing TevTropin®|Needle-free delivery method for 14 days before cross-over to other arm
1855287|NCT00990340|Procedure|TevTropin® needle-syringe injection method|comparison of delivery methods for 14 days before cross-over to other arm
1855288|NCT00990366|Device|Cook´s biliary stent with an antireflux stent, normal biliary stent|arms are assigned randomly by closed envelope method
1855289|NCT00990392|Drug|Polysporin Triple Therapy ointment|Polysporin Triple Therapy ointment applied to the insertion point at the time of CVC placement and twice within the first week.
1855290|NCT00990392|Other|Petroleum Jelly|Petroleum jelly applied to the insertion point at the time of CVC placement and twice within the first week.
1855291|NCT00990405|Drug|Lansoprzole+Amoxicillin+Clarithromycin|Lansoprazole 30 mg bid, for 7 days Clarithromycin 500 mg bid, for 7 days Amoxicillin 1000 mg bid, for 7 days
1855292|NCT00990418|Drug|Separated (Two Part) E-TRANS (fentanyl HCl) System; Integrated E-TRANS (fentanyl HCl) System|
1855293|NCT00990431|Procedure|Fractional carbon dioxide laser treatment|The CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA) employs disposable tips with a diameter of 7 mm and 15 mm, the smaller being used for the peri-orbital region. The laser beam is delivered through multiple deflective and refractive elements and focused to a spot size of approximately 120 µm in diameter at incidence to the skin to deposit an array of laser beams across the surface. Pulse energy varies from 5 to 70 mJ and density from 5 to 70 %. The pulse duration is 10 msec. In the present study, patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %.
1855294|NCT00990431|Procedure|Fractional erbium:YAG laser treatment|The Er:YAG laser used in this study has a fractional handpiece (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany). By means of a microlens array the laser beam is divided into 13 x 13 small spots with 250 µm diameter each, spread over an area of 13 x 13 mm. A coverage of 5 % of the skin is achieved with a single pass. The pulse duration is 400 μsec. In this trial, we performed 4 passes (resulting in coverage of 20 % of the treated skin) with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses) to optimize thermal exposure.
1855295|NCT00990444|Drug|Insulin in Dextran Matrix|Fixed dose capsule with 100 IU of insulin in dextran matrix. Investigational drug or placebo are administered in conjunction with food intake on a background of metformin.
1855296|NCT00990457|Behavioral|Weight Loss Diets Plus Exercise|"The weight loss diet will be either a low-carbohydrate diet or a low-fat, low-calorie diet. All participants will also be enrolled in a supervised exercise program.
The supervised exercise training sessions will take place three times a week for 6 months. Each session will last 1 to 1 ½ hours and will include aerobic exercise and weight training."
1855297|NCT00990496|Drug|Fludarabine|30 mg/m2
1855298|NCT00990496|Drug|Cyclophosphamide|600 mg/m2
1855299|NCT00990496|Biological|CMV Specific Cytotoxic T Lymphocytes (CTL)|CTL Infusion (3 - 5 x 10E6 cells/kg)
1855300|NCT00990509|Drug|Albumin|Three (3) daily IV infusions of 1.25 g/kg Albumin (25%) on Days 1-3 following enrollment.
1855301|NCT00990509|Drug|Placebo|Three (3) daily IV infusions of 1.25 g/kg Saline solution on Days 1-3 following enrollment
1855302|NCT00990509|Procedure|Brain MRI with and without contrast|"All subjects will receive 3 brain MRI studies, regardless of if they are randomized into Albumin or Placebo condition.
MRIs will be with and without contrast will be performed at:
Baseline
48 hours after enrollment(approximately Day 3)
96 hours after drug treatment begins (approximately Day 5)"
1855303|NCT00990522|Procedure|debridement|There will be two (2) subject groups in the study. Subjects will be randomized into either the monthly debridement group or the weekly debridement group.
1855304|NCT00990535|Drug|Octreotide-LAR|Octreotide-LAR 30 mg administered every 21 days until progression
1855305|NCT00990561|Drug|Ultravate ointment twice daily + LacHydrin lotion twice daily|Topical corticosteroid
1855306|NCT00990561|Drug|Ultravate ointment once daily + LacHydrin lotion twice daily|Topical corticosteroid
1855307|NCT00990574|Device|Wiley Spinal Catheter|The WSCG (wiley spinal catheter group) will have a Wiley spinal catheter placed, but it will not be dosed until the patient is in the supine position with left uterine displacement. Participants will receive the medication (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) in sequential doses.
1855308|NCT00990574|Device|Spinal Anesthesia Group (SAG)|"The SAG (spinal anesthesia group) will have their drugs (12 mg of 0.75% hyperbaric bupivacaine, 10 mcg of fentanyl, and 100 mcg of morphine) dosed intrathecally as a single shot while still in the sitting position."
1855309|NCT00990587|Drug|Ciclopirox Olamine|Patients will take Ciclopirox Olamine at various doses depending on which dose level they come into the study at. Ciclopirox olamine will be administered orally as an aqueous suspension without food. The starting dose will be 5 mg/m2/day administered as a single dose daily for 5 days (one cycle). Once a MTD has been determined, the new patients that enter into the trial will then take it at that level.
1855310|NCT00990600|Other|reduced number of pills|Switch to a fixed dose combination one pill/daily HAART
1855311|NCT00990613|Drug|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
1855312|NCT00990613|Drug|Dimebon Transdermal|A single, transdermal 5 mg dose of dimebon free base solution will be applied to the back over a 24 hour period. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
1855313|NCT00990613|Drug|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
1855314|NCT00990613|Drug|Dimebon IR|A single, oral 10 mg dose of dimebon dihydrochloride (equivalent to 8.2 mg free base) immediate release will be administered.
1855315|NCT00990613|Drug|Dimebon Transdermal|A single, to be determined dose of dimebon free base solution will be applied to the back over a 24 hour period. The dose level chosen will be determined based on the pharmacokinetic/safety profile of the 5 mg dose in Cohort 1. A double-blinded vehicle (placebo) solution will be applied concurrently to a contralateral body site.
1855821|NCT00993694|Procedure|assessment of therapy complications|
1855316|NCT00990639|Drug|candesartan for hepatic fibrosis|"Candesartan group(42 patients): oral candesartan at a daily dose of 8 mgin addition to ursodeoxycholic acid (UDCA, 600 mg/day) for 6 months.
UDCA group(43 patients): oral ursodeoxycholic acid (UDCA, 600 mg/day) only for 6 months"
1855317|NCT00990652|Drug|Bortezomib|Before surgery, an injection of bortezomib is given on days 1, 4, and 8. After surgery, bortezomib is given on days 7 and 21 of each cycle (1 cycle = 28 days).
1855318|NCT00990652|Drug|Temozolomide|After surgery, temozolomide is taken by mouth on days 1-7 and 14-21 of each cycle (1 cycle = 28 days).
1855320|NCT00990678|Drug|Rocaltrol|tablet, Vitamin 1-OH-D3, total 1.25-2.5 mg daily
1855321|NCT00990678|Drug|Vitamin D|tablets, vitamin D3, 30 microgram daily
1855322|NCT00990678|Drug|Calcium|tablets, 400 mg calcium, 3 times daily
1855323|NCT00990691|Drug|Administration of a high dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :
From 15 to 25 kg : 50 mg ;
From 26 to 35 kg : 75 mg ;
From 36 to 45 kg : 100 mg ;
> 46 kg : 150 mg."
1855324|NCT00990691|Drug|Administration of a low dose of desipramine|"Administration of a daily dose of desipramine correlated with the patient's weight :
From 15 to 25 kg : 25 mg ;
From 26 to 35 kg : 50 mg ;
From 36 to 45 kg : 75 mg ;
> 46 kg : 100 mg."
1855325|NCT00990691|Drug|Administration of a placebo|Administration of a daily dose of placebo
1855326|NCT00990704|Drug|paricalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
1855327|NCT00990704|Drug|maxacalcitol|Intravenous administration 3 times a week immediately before completion of dialysis
1855328|NCT00990717|Biological|NK-92 cells|"Cells are administered as an intravenous infusion over one hour on days 1, 3 and 5 of each cycle of treatment. Patients can receive up to 6 cycles, which are administered monthly. Cell dosage is as follows:
Level I: 1x10^9 cells/m^2
Level II: 3x10^9 cells/m^2
Level III: 5x10^9 cells/m^2"
1855329|NCT00990743|Drug|SYL040012|Administration of single and multiple doses of SYL040012 in ophthalmic drops solution
1855330|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 1.396 mg, BID for 14 days
1855331|NCT00990756|Drug|PF-03526299|dry powder for inhalation, 4 mg, BID for 14 days
1855332|NCT00990769|Other|Depth of anesthesia|The intervention in this study is the titration of the depth of anesthesia according to the BIS monitor, as maintained by a combination of routine anesthetic agents (nitrous oxide, sevoflurane, and fentanyl).
1855333|NCT00990782|Diagnostic Test|PillCam ESO Capsule Endoscope|Utilization of the PillCam ESO capsule endoscope to evaluate the condition of a patient's esophagus before and after RFA therapy to treat atrial fibrillation.
1855334|NCT00990795|Drug|cyclosporine|Cyclosporine Patients will receive a dose of cyclosporine just after they are heparinized. They will receive 2.5 mg of cyclosporine (Sandimmune, Novartis) per kilogram of body weight. It will be injected into a central venous line at the time the central venous line is inserted by the anesthesia team.
1855335|NCT00990795|Drug|saline solution|Placebo Group: Patients will undergo the cardiac surgery procedures using standard technique. They will have ischemic arrest of the heart with cold blood cardioplegia using standardized methods of myocardial protection or off-pump CABG. The patients in the placebo group will receive a volumetrically equivalent dose of normal saline to the cyclosporine dose.
1855336|NCT00990808|Drug|anacetrapib|[Intervention Name: MK0859] MK0859 100 mg tablet once daily for 8 weeks.
1855337|NCT00990808|Drug|Comparator: atorvastatin|Atorvastatin 20 mg tablet once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
1855338|NCT00990808|Drug|Comparator: placebo to MK0859|Placebo to MK0859 once daily for 4 weeks.
1855339|NCT00990808|Drug|Comparator: placebo to atorvastatin|Placebo to atorvastatin once daily for 4 weeks in Period 1 and 8 weeks in Period 2.
1855340|NCT00990821|Drug|90 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered intravenous (IV) over 15 minutes
1855341|NCT00990821|Drug|100 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
1855342|NCT00990821|Drug|100 MK-0517 (PS80) + 2 mg midazolam|MK-0517 (Non-PS80 formulation), 1 mg/mL, administered IV over 15 minutes. Midazolam is co-administered as a single oral 2-mg dose of midazolam with MK-0517.
1855343|NCT00990821|Drug|115 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
1855344|NCT00990821|Drug|150 mg MK-0517 (PS80)|MK-0517 (PS80 formulation), 1 mg/mL, administered IV over 15 minutes
1855345|NCT00990821|Drug|40 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
1855346|NCT00990821|Drug|100 mg MK-0517 (non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
1855347|NCT00990821|Drug|150 mg MK-0517 (Non-PS80)|MK-0517 (Non-PS80) is administered as single IV dose over 30 seconds.
1855348|NCT00990821|Drug|Placebo|Placebo matching MK-0517
1855349|NCT00990821|Drug|40 mg Aprepitant|Aprepitant, oral, tablet, single dose
1855350|NCT00990821|Drug|125 mg Aprepitant|Aprepitant oral tablet, single dose
1855351|NCT00990821|Drug|2 mg Midazolam|Midazolam oral tablet, single dose
1855352|NCT00990834|Drug|simvastatin|simvastatin 80 mg PO daily for one to eight months.
1855353|NCT00990847|Drug|Procaterol, Salbultamol|
1855354|NCT00990860|Drug|doxorubicin|After identifying the target artery of HCC, doxorubicin will be infused through the target artery of HCC patient with lipiodol emulsion (dependent on the tumor size)
1855355|NCT00990860|Procedure|TACE (Transcatheter arterial chemoembolization)|TACE (Transcatheter arterial chemoembolization)
1855356|NCT00990873|Genetic|gene expression analysis|
1855357|NCT00990873|Genetic|microarray analysis|
1855358|NCT00990873|Genetic|reverse transcriptase-polymerase chain reaction|
1855359|NCT00990873|Other|laboratory biomarker analysis|
1855360|NCT00990886|Drug|Placebo|Once daily for 12 weeks
1855361|NCT00990886|Drug|Oxybutynin chloride|15 mg once daily for 12 weeks
1855362|NCT00981890|Drug|Sunitinib|Sunitinib is a tablet that is taken by mouth every day. Patients will be treated with Sunitinib alone for 7 days. On the seventh day of taking the drug they will be given SRS. Sunitinib will continue for seven days per week after SRS, and depending on how far along the study is when patients join, they may continue taking the drug for up to 13 weeks after SRS.
1855363|NCT00981903|Drug|Tinzaparin sodium|Subcutaneous injection 175 U/Kg/day
1855364|NCT00981929|Drug|Tramadol|50 mg single oral dose
1855365|NCT00981929|Drug|Omeprazole, losartan, caffeine|20 mg omeprazole 25 mg losartan 200 mg caffeine
1855366|NCT00981929|Drug|Tramadol, omeprazole, losartan, caffeine|50 mg tramadol 20 mg omeprazole 25 mg losartan 200 mg caffeine
1855367|NCT00981942|Drug|Imatinib mesylate (Glivec)|400 mg, one tablet daily for 12 or 24 weeks
1855368|NCT00981955|Dietary Supplement|Caffeine and L-theanine|Acute oral administration of 75mg of caffeine, 50mg l-theanine, 75mg caffeine and 50mg l-theanine in combination or placebo. One dosage administered on each of four separate study days.
1855369|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single and multiple oral doses for 7 days
1855370|NCT00981968|Drug|Sitaxentan sodium/Placebo|100 mg and 200 mg, tablet, single oral dose
1855371|NCT00981981|Dietary Supplement|Wheat bran|21g per day of ready to eat breakfast cereal containing wheat bran with 8g of total dietary fiber and 0.5g beta-glucan.
1855372|NCT00981981|Dietary Supplement|3g high MW|20.2 grams per day of ready to eat cereal containing 6g total dietary fiber and 3g oat beta glucan with high molecular weight
1855373|NCT00981981|Dietary Supplement|4g medium MW|28.5g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with medium molecular weight
1855374|NCT00981981|Dietary Supplement|3g medium MW|21.1g of ready to eat cereal containing 6g total fiber and 3g oat beta glucan with a medium molecular weight
1855375|NCT00981981|Dietary Supplement|4g low MW|28.7g ready to eat cereal containing 8g total dietary fiber and 4g oat beta glucan with low molecular weight
1855376|NCT00981994|Behavioral|Decision Support for ARI Management|Use of history and physical examination findings to estimate probability of pneumonia in patients with acute respiratory infections and thereby guide treatment decisions
1855377|NCT00982007|Drug|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
1855378|NCT00982007|Drug|Ferrous Sulfate Tablets|325 mg Ferrous Sulfate tablets taken orally three times a day
1855379|NCT00982007|Drug|IV Iron (standard of care)|IV standard of care (other IV iron) per the Investigator's discretion
1855380|NCT00982007|Drug|Ferric Carboxymaltose (FCM)|A total maximum cumulative dose of 1500 mg administered on Days 0 and 7.
1855381|NCT00982020|Drug|Olanzapine|2.5 milligrams (mg) to 20 mg given orally, daily for 52 weeks
1855382|NCT00982020|Behavioral|Standard behavioral weight intervention|One time counseling and basic counseling information on healthy eating and exercise habits at randomization visit only.
1855383|NCT00982020|Behavioral|Intense behavioral weight intervention|Counseling provided at randomization and at all subsequent study visits by appropriately trained individual regarding healthy lifestyle habits. Participants also provided with simple tools to help enable healthy eating and exercise habits.
1855384|NCT00982033|Drug|aliskiren|aliskiren 300mg qd versus placebo for 24 weeks.
1855385|NCT00982033|Drug|placebo|placebo qd for 24 weeks
1855386|NCT00982046|Device|Opti-Free RepleniSH multi-purpose disinfecting solution|Contact lens solution CE-marked for intended use.
1855387|NCT00982046|Device|ReNu MultiPlus multi-purpose solution|Contact lens solution CE-marked for intended use.
1855388|NCT00982046|Device|Clear Care cleaning and disinfecting system|Contact lens care system CE-marked for intended use.
1855389|NCT00982046|Device|Senofilcon A contact lens (ACUVUE OASYS)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
1855390|NCT00982046|Device|Lotrafilcon B contact lens (AIR OPTIX AQUA)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
1855391|NCT00982046|Device|Comfilcon A contact lens (Biofinity)|Silicone hydrogel contact lens worn for two weeks on a daily wear basis and cleaned nightly with one of three contact lens care solutions. The order of solutions was randomized, and a fresh pair of lenses was dispensed with each solution.
1855392|NCT00982059|Other|Colonoscopic examination|All patients enrolled in the study will undergo a colonoscopic examination and complete a baseline questionnaire.
1855393|NCT00982072|Drug|tacrolimus|tacrolimus0.05mg/kg bd (levels 6-12ng/ml)
1855394|NCT00982072|Drug|prednisolone|Prednisolone 1mg/kg maximum 60mg od
1855395|NCT00982098|Procedure|BioFeedback; Functional Electrical Stimulation; Pelvic Floor Muscle training exercises|After surgery: physical therapist's assisted pelvic floor muscle biofeedback (15 min/day for 10 days), followed by patient's instruction for pelvic floor muscle training and home based exercised pelvic floor muscle for 10 days. Then pelvic floor muscle biofeedback (15 min/day for 10 days) and functional electrical stimulation of pelvic floor (30 min/day for 10 days).
1855396|NCT00982111|Drug|Pemetrexed|500 milligram per square meter (mg/m2) administered Intravenously (I.V.) on Day 1 of every 3-week cycle, for a maximum of six cycles
1855397|NCT00982111|Drug|Cisplatin|75 mg/m2 administered I.V. on Day 1 of every 3-week cycle, for a maximum of six cycles
1855398|NCT00982111|Biological|Necitumumab|800 mg (absolute dose) on Days 1 and 8 of every 3-week cycle, administered as an I.V.
1855399|NCT00982124|Drug|Zoledronic Acid|Each patient is to receive an initial dose of zoledronic acid of 0.0125 mg per kg body weight, then subsequent doses of zoledronic acid at a dose of 0.025 mg per kg body weight once every 12 to 13 weeks for 104 weeks (total of 8 doses).
1855400|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL, Subcutaneous on Day 0; STAMARIL®, 0.5 mL, Subcutaneous on Day 30.
1855401|NCT00982137|Biological|Yellow fever virus; Live attenuated Japanese encephalitis virus|STAMARIL®, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous on Day 30.
1855402|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL, Subcutaneous on Day 0; Diluent 0.5 mL, Subcutaneous on Day 30.
1855403|NCT00982137|Biological|Live attenuated Japanese encephalitis virus; Yellow fever virus|Diluent, 0.5 mL Subcutaneous on Day 0; ChimeriVax™-JE, 0.5 mL Subcutaneous and STAMARIL®, 0.5 mL Subcutaneous on Day 30.
1855404|NCT00982150|Drug|Talampanel|50mg capsules tid
1856457|NCT00997711|Device|Cypher|Sirolimus-eluting stents
1855405|NCT00982176|Other|Brain MRI and cerebral perfusion scintigraphy|"A standard neuropsychological assessment will be performed by a neuropsychologist. The daily life experience study will be performed. Questions will be asked to the patients by a pocket computer (Palm).
MRI will be performed on a 3 Tesla research MRI. Two Tc-99m-HMPAO SPECT studies will be performed The second SPECT study will be performed after intravenous injection of acetazolamide."
1855406|NCT00982189|Drug|Pravastatin|Participants randomized to take pravastatin (active) or matching placebo pill once daily
1855407|NCT00982189|Drug|Lisinopril|Participants randomized to take lisinopril (active) or matching placebo pill once daily
1855408|NCT00982202|Drug|pioglitazone|15mg tablet daily, increase by one pill at one-week intervals based on reported tolerability; maintain best tolerated dose (1 to 3 tablets daily) for ~18months
1855409|NCT00982202|Drug|Placebo|1 to 3 tablets daily for ~18 months
1855410|NCT00982215|Drug|Kinetics of plasma concentrations of paracetamol|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
1855411|NCT00982215|Drug|Placebo|Pilot study of Pharmacology Paracetamol administered per-oral mucosa PMB. Crossover study, double-blind, randomized, controlled versus placebo.
1855412|NCT00982228|Drug|insulin degludec|Injected subcutaneously once daily. Dose was individually adjusted.
1855413|NCT00982228|Drug|insulin glargine|Injected subcutaneously once daily. Dose individually adjusted.
1855414|NCT00982228|Drug|insulin aspart|Injected subcutaneously as mealtime insulin. Dose was individually adjusted.
1855415|NCT00982241|Dietary Supplement|water|drinking water / normal dietary fluids for oral intake
1855416|NCT00982254|Drug|Oral insulin|oral insulin capsule formulation (150 U insulin/200 mg 4-CNAB in one capsule); single dose administration of 300 U insulin (in two capsules) and of 150 U insulin (one capsule) on two separate dosing days.
1855417|NCT00982254|Drug|regular human insulin|subcutaneous injection of 15 U regular human insulin; single dose administration on one separate dosing visit.
1855418|NCT00982267|Drug|SU014813|Escalating doses of SU014813 from 50 to 250mg/day . Capsules administered daily either as continuous dosing or in cycles of 4 weeks on 1 week off
1855419|NCT00982280|Drug|Tapentadol PR|"Tapentadol Prolonged Release (PR) Titration and Optimal Dose Period: Starting at 50 mg, 100 mg or 150 mg Tapentadol PR twice daily, adjusting at 50 mg PR steps (upwards or downwards) as necessary to achieve a balance between pain relief and a satisfactory level of tolerability. Participants were not permitted to exceed 500 mg of Tapentadol per day.
Maintenance Period: Participants continuing on the dose established in the previous period."
1855420|NCT00982293|Device|Resonator device|Low level electromagnetic fields for whole body immersion, 3 times weekly for 13 weeks (39) sessions of approximately 11/2 hours each.
1855421|NCT00982293|Device|Resonator device - sham|"Treatment, 3 times weekly for 13 weeks (39) sessions - device will not be on"
1855422|NCT00982306|Behavioral|Brief intervention|20 minute one to one counseling session
1855425|NCT00982332|Drug|Betamethasone|betamethasone dipropionate 20 mg + betamethasone sodium phosphate 8 md as a single intramuscular injection
1855426|NCT00982332|Drug|isotonic sodium chloride solution (placebo)|4 ml intramuscular
1855427|NCT00982345|Drug|quetiapine (Seroquel XR)|Seroquel XR (starting dose 100mg and increased up to 400 mg as tolerated) treatment.
1855428|NCT00982358|Drug|Valsartan|
1855429|NCT00982358|Other|Placebo|
1855430|NCT00982384|Other|Disease management|Disease management by COPD nurses, including active follow-up and coordination of care in addition to best care according to clinical guidelines for COPD patients
1855431|NCT00982384|Other|Best care|Comprehensive care for COPD patients recommended in clinical guidelines
1855434|NCT00982410|Behavioral|cognitive-behavioral treatment|cognitive-behavioral treatment (CBT) interventions to manage pain and decrease substance use abuse/misuse
1855435|NCT00982410|Behavioral|educational supportive group|A control condition providing social support and education about pain and/or drug use.
1855436|NCT00982423|Drug|Furosemide|Subjects received their clinically prescribed dose of furosemide for a 3 week stabilization period, then were assessed for cardiorenal and humoral function. Subjects then had a 50% reduction of the furosemide dose for a 3 week stabilization period, and were assessed for cardiorenal and humoral function again.
1855437|NCT00982436|Drug|Docetaxel/cisplatin|Docetaxel 75 mg/m2 intravenous every 3 weeks for 3 cycles Cisplatin 75 mg/m2 intravenous every 3 weeks for 3 cycles
1855438|NCT00982436|Radiation|Radiotherapy|70 Gy in 35 fractions to gross tumor and lymph node metastases
1855439|NCT00982436|Drug|Carboplatin|Carboplatin AUC 1.5 intravenous weekly during radiotherapy
1855440|NCT00982449|Other|FIAU-PET-CT scans|1-3 days after chemotherapy, subject get I-FIAU 2 mCi, then have FIAU-PET-CT done 2 - 4 hours after I-FIAU
1855441|NCT00982449|Other|FIAU-PET-CT scan|1-3 days after any chemotherapy that may activate viral TK, 4 mCi, rather than 2 mCi, of I-FIAU are administered, followed 2 - 4 hours later by FIAU-PET-CT
1855442|NCT00982462|Dietary Supplement|Docosahexaenoic acid (DHA) and arachidonic acid (ARA)|Micro-encapsulated powder containing the long-chain polyunsaturated fatty acids, DHA to ARA in a 1:1 ratio. Two foil-packets containing active intervention (200mg DHA+200mg ARA) or placebo (400 mg corn oil) per day added to a selection of recommended foods.
1855443|NCT00982462|Dietary Supplement|Corn oil placebo|Micro-encapsulated powder containing corn oil as the placebo.
1855444|NCT00982475|Procedure|Pulmonary vein isolation with radiofrequency current|Pulmonary vein isolation with radiofrequency current
1855445|NCT00982488|Drug|Dasatinib|Dasatinib was supplied as 20- and 50-mg tablets.
1855446|NCT00982488|Drug|Imatinib|Imatinib was supplied as 100- and 400-mg tablets.
1855447|NCT00982501|Drug|WS® 1442 900 mg/d|
1855448|NCT00982501|Drug|WS® 1442 1800 mg/d|
1855449|NCT00982501|Behavioral|Nordic walking training 2 x 30 min/week|
1855450|NCT00982501|Behavioral|Nordic walking training 4x45 min/week|
1855451|NCT00982527|Drug|Placebo|Saline continuous infusion during cardiopulmonary by pass at 1 ml/h
1855452|NCT00982527|Drug|Fenoldopam|Fenoldopam continuous infusion at 1 mcg/kg/min during cardiopulmonary bypass. Infusion preparation is mad in order to match the rate 1 ml/h of placebo infusion.
1855453|NCT00982540|Drug|caspofungin as preemptive antifungal therapy|70 mg day 1 followed by 50 mg/day IV
1855454|NCT00982553|Drug|Ribavirin|800mg once daily
1855455|NCT00982553|Drug|Raltegravir|400mg twice daily
1855456|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 250 mg of Formulation B1 vs. single (oral) dose of 250 mg of Formulation A
1855457|NCT00982566|Drug|ABT-263|Part 1 continued. Single (oral) dose of 250 mg of Formulation B2 vs. single (oral) dose of 250 mg of Formulation A
1855458|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
1855459|NCT00982566|Drug|ABT-263|Part 1: Single (oral) dose of 200 mg of Formulation C vs. single (oral) dose of 200 mg of Formulation A
1855460|NCT00982579|Biological|MVA.HIVA|1 dose of 5 x 10^7 pfu of MVA.HIVA administered intramuscularly
1855461|NCT00982592|Drug|oxaliplatin|Given IV
1855462|NCT00982592|Drug|leucovorin calcium|Given IV
1855463|NCT00982592|Drug|fluorouracil|Given IV
1855464|NCT00982592|Other|placebo|Given PO
1855465|NCT00982592|Drug|vismodegib|Given PO
1855466|NCT00982592|Other|laboratory biomarker analysis|Correlative studies
1855467|NCT00982605|Procedure|EBUS_TBNA|EBUS during bronchoscopy
1855468|NCT00982618|Drug|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
1855469|NCT00982618|Procedure|Epidural Block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
1855470|NCT00982618|Drug|PCA Morphine|PCA Morphine is set to the patient for 48 hours postoperative. 2 mg. of morphine is given to a patient as much as patient requires, maximum at every 7 minutes.
1855471|NCT00982631|Drug|Temsirolimus/PLD|This is a dose escalation study. Patients will start with temsirolimus iv once weekly. After 2 weeks, PLD therapy is added. From then on, PLD is repeated every 4 weeks. One cycle is 28 days. The DLT period is also defined within the first 28 days of combination therapy (thus the first 6 weeks of study participation). The first dose level (DL) is DL 1. Depending on toxicity, intermediate dose levels can be added. If no MTD is found in the sixth cohort, this dose level will be considered as the recommended dose (RD), being the optimal dose for both drugs in this combination. At the MTD dose level, the dose level will be expanded to a total of 12 patients.
1855472|NCT00982644|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
1855473|NCT00982644|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
1855474|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 6.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
1855475|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 12.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
1855476|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at 15.0 mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
1855477|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
1855478|NCT00982657|Drug|CVX-060 + sunitinib|CVX-060 weekly infusions at TBD mg/kg + 50 mg sunitinib daily (4 out of 6 weeks)
1855479|NCT00982657|Drug|Sunitinib|50 mg sunitinib daily (4 out of 6 weeks)
1855480|NCT00982696|Biological|Opioid Growth Factor|250ug per kilogram weekly IV infusions
1855481|NCT00982709|Behavioral|Aerobic vs. Agility Training|High Intensity 4x's per week for 4 weeks with a physical therapist.
1855482|NCT00982722|Drug|cholecalciferol and calcium carbonate|cholecalciferol 800 IUx2 and calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
1855483|NCT00982722|Drug|calcium carbonate|calcium carbonate 500 mg x 2 one year after parathyroid adenomectomy, initiated 6 weeks after surgery
1855484|NCT00990912|Drug|Carboplatin|IV, Infusion, AUC2 mg/ml.min, Once every 21 days, until progression or unacceptable toxicity
1855485|NCT00990912|Drug|Irinotecan|IV, Infusion, 12 (9) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
1855486|NCT00990912|Drug|Irinotecan|IV, Infusion, 10 (18) mg/m²/day, Once daily x 10 days, every 21 days, until progression or unacceptable toxicity
1855487|NCT00990925|Behavioral|Nutritional Lifestyle Modification Group|Manualized group treatment to educate about basic nutritional concepts to help improve eating choices with the goal of losing weight.
1855488|NCT00990925|Other|Usual Care|Care as usual
1855489|NCT00990938|Drug|IMO-2125|IMO 2125 is a synthetic DNA-based agonist of Toll-like receptor 9, which is expressed in humans in plasmacytoid dendritic cells and B cells of the immune system.
1855490|NCT00990938|Drug|Saline|Subcutaneous injection once per week for four weeks
1855491|NCT00990951|Drug|Senna alexandrina and associations|"Drugs: Senna alexandrina Mill (sena), Cassia fistula L., Tamarindus indica L., Coriandrum sativum L., Periandra mediterranea Taub
1 tablet PO twice a day"
1855492|NCT00990964|Device|Attain Success Lead|Attain Success Lead
1855493|NCT00990977|Behavioral|mindfulness based stress reduction (MBSR)|MBSR is an 8-week course covering a total of 24 contact hours where the group of patients meet with an clinical psychologist certified as mindfulness instructor. The group will train the ability of mindfulness by specific awareness improving practises (body-scan) guided meditations and soft yoga. Between group-sessions participants are recommended to practice 45 minutes daily and to go through instructions in MBSR hand-outs. Participants will be given audio-CDs containing instructions and guides to support home practice.
1855494|NCT00990990|Drug|PNU-100480|100 mg BID for 14 days
1855495|NCT00990990|Drug|Placebo|to match 100 mg BID for 14 days
1855496|NCT00990990|Drug|PNU-100480|300 mg BID for 14 days
1855497|NCT00990990|Drug|Placebo|to match 300 mg BID for 14 days
1855498|NCT00990990|Drug|PNU-100480|600 mg BID for 14 days
1855499|NCT00990990|Drug|Placebo|to match 600 mg BID for 14 days
1855500|NCT00990990|Drug|PNU-100480|1200 mg QD for 14 days
1855501|NCT00990990|Drug|Placebo|to match 1200 mg QD for 14 days
1855502|NCT00990990|Drug|PNU-100480|600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
1855503|NCT00990990|Drug|Placebo|placebo to match 600 mg BID for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
1855504|NCT00990990|Drug|PNU-100480|PNU-100480 dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
1855505|NCT00990990|Drug|Placebo|placebo to match dose up to total of 1200 mg daily for 28 days with pyrazinamide (25 mg/kg up to 2 g) QD on Days 27-28
1855506|NCT00990990|Drug|Linezolid|300 mg QD for 4 days (open label)
1855507|NCT00991003|Procedure|Colon capsule endoscopy|The PillCam® Colon Capsule is 11mm x 31mm in size (Figure 1), is equipped with two cameras acquiring pictures from both ends of the capsule at a rate of 4 frames per second (2 pictures per second and camera). The PillCam® Colon Capsule is automatically activated when it is removed from the package. It enters sleeping mode after approximately 10 minutes and starts transmitting again 1 h 45 min later. It has a total operating time of 8 - 10 hours. During the examination the patient wears a sensor array which is attached to the abdominal skin and a data recorder for storage of the information generated by the ingested capsule. After the examination the data are downloaded into the Given Imaging workstation and a video is generated.
1855508|NCT00991003|Procedure|Conventional Colonoscopy|
1855509|NCT00991016|Drug|PF-04805712|ascending single and multiple doses starting at 30 mg
1855510|NCT00991029|Drug|Clopidogrel|Loading dose of 600mg followed by 75 milligrams, oral, one tablet daily for 89 days
1855511|NCT00991029|Drug|placebo|Loading dose of 8 tablets followed by one tablet daily for 89 days
1855512|NCT00991042|Other|blood collect|Five milliliters of venous blood was drawn in the morning from subjects and immediately centrifuged.
1855513|NCT00991055|Drug|Pioglitazone|"A total 16-week randomized, double-blind, controlled study to compare the efficacy and safety of pioglitazone 15mg once daily added to combination metformin plus sulfonylurea with those of placebo combining control group.
(4-week run in period and 12-week pioglitazone 15mg added to combination therapy of sulfonylurea plus metformin and placebo control group in patients with type 2 diabetes)"
1855514|NCT00991068|Drug|Synera (lidocaine 70 mg and tetracaine 70 mg) topical patch|Patients will apply a single Synera patch to the target wrist for 2 hours twice a day (ie, morning and evening applications) for 14 days.
1855515|NCT00991081|Behavioral|Counseling|"Three 20-minute telephone calls during which a certified tobacco treatment specialist delivered motivationally-enhanced cognitive behavioral counseling
One week prior to the target quit date (TQD)
Two weeks post-TQD
Four weeks post-TQD"
1855516|NCT00991081|Behavioral|Self-help guide|A printed self-help guide for smoking cessation (Clearing the Air, NCI)sent by mail
1855517|NCT00991081|Drug|Pharmacotherapy|"8-week course of genetically-tailored pharmacotherapy
Participants with the A1 allele (TT/CT) were assigned to receive NRT (the Patch)
Participants with the A2 allele (CC) were assigned to receive bupropion"
1855518|NCT00991081|Behavioral|Genetic feedback, verbal|During the first counseling call, GF participants were informed of their genotype and provided with the rationale for their pharmacotherapy assignment
1855519|NCT00991081|Behavioral|Genetic feedback, printed|After the first counseling call, GF participants were mailed a Personal Treatment Profile, which echoed each participant's ANNK1 genotype, the implications of this for smoking cessation treatment outcome, and which medication was chosen for them based on their genotype.
1855520|NCT00991107|Drug|HE3286|HE3286 20 mg (10 mg BID) for 28 days
1855521|NCT00991120|Device|Chronicle Implantable Hemodynamic Monitor (IHM) System, Chronicle Implantable Cardioverter Defibrillator (ICD)|Surgical implantation of chronic ambulatory hemodynamic monitoring device and intracardiac lead
1855522|NCT00991133|Drug|Clofarabine incorporated into a 5-drug regimen|Clofarabine (IV) 40mg/m2 into an intensive chemotherapy regimen of etoposide, cyclophosphamide, PEG-asparaginas, and vincristine
1855523|NCT00991146|Drug|canakinumab|canakinumab
1855524|NCT00991159|Biological|RN316|Single, escalating doses of RN316 administered IV. Doses planned for testing = 0.3, 1.0, 3.0, 6.0, 12.0, and 18.0 mg/kg.
1855525|NCT00991172|Drug|REGN475|Single Subcutaneous injection dose level 1
1855526|NCT00991172|Drug|REGN475|Single subcutaneous injection dose level 2
1855527|NCT00991172|Drug|Placebo Injection|Placebo Subcutaneous injection
1855528|NCT00991198|Drug|Topical oxygen|0.5% concentration of Topical oxygen
1855529|NCT00991198|Drug|Topical oxygen|0.25% concentration topical oxygen
1855530|NCT00991198|Drug|placebo|no O2
1855531|NCT00991211|Drug|Bendamustine|Comparison of Bendamustine + Rituximab with CHOP + Rituximab
1855532|NCT00991211|Drug|Standard chemotherapy CHOP + Ritiximab|Cyclophosphamid 750 mg/m² d 1 + Doxorubicin 50 mg/m² d 1 + Vincristin 1,4 mg/m² max. 2 mg d 1 + Prednison 100 mg absolute p.o. d 1-5 + Rituximab 375 mg/m² d 1 q3w as standard Chemotherapy
1855533|NCT00991224|Biological|WT-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
1855534|NCT00991224|Biological|α/6-gag-TCR modified T cells|Single dose of WT-gag-TCR modified T cells infused over 3 consecutive days.
1855535|NCT00991224|Other|STI or Drug Holiday|Subjects will stop taking antiviral medications for 16 weeks.
1855536|NCT00991770|Other|Massage Therapy|Two 20 minute chair massages: one before surgery and one after
1855537|NCT00991770|Other|Attention Control|Two 20 minute sessions where the Massage Therapist will talk to the patient about how they are feeling, listen, and provide empathetic support.
1855538|NCT00991783|Drug|Digoxin + Fimasartan|Digoxin (7 days), Digoxin + Fimasartan (7 days)
1855539|NCT00991796|Drug|CS-1008|CS-1008 powder for concentrate for solution for infusion. six cycles of combination therapy with 3 weeks equal to one cycle. 10 mg/kg
1855540|NCT00991796|Drug|Placebo|Placebo
1855541|NCT00991796|Drug|Paclitaxel|Paclitaxel concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 175 mg/m2
1855542|NCT00991796|Drug|Carboplatin|Carboplatin concentrate for solution for infusion. once every 3 weeks for a maximum of 6 cycles. 6 mg/m2
1855543|NCT00991809|Drug|Alfentanil|15 mcg/kg IM
1855544|NCT00991809|Drug|Diphenhydramine|25 mg IM
1855545|NCT00991822|Drug|Dorzolamide 2%|
1855546|NCT00991822|Drug|Timolol 0.5%|
1855547|NCT00991848|Drug|Lidocaine|received 240 mg lidocaine diluted in 125 mL 0.9% saline.
1855548|NCT00991861|Drug|LAS41007 o.d.|Once daily, topical application
1855549|NCT00991861|Drug|LAS41007 b.i.d.|Twice daily, topical application
1855550|NCT00991861|Drug|LAS106521|Twice daily, topical application
1855551|NCT00991887|Radiation|Radiation Therapy (XRT)|The dose will be 700 gray (derived unit of ionizing radiation dose in the International System of Units) in a single fraction, using AP-PA fields calculated to midplane. No Less than 6 MV energy photons will be used, and no bolus is placed on the skin. The field covers the entire joint, the antecubital fossa and the olecranon process. A strip of skin at the antecubital area is generally shielded, but is not an absolute requirement for this study.
1855552|NCT00991900|Device|Measurement of oxygen saturation of retinal vessels with optical reflectometer|5 repeated measurements on both study days
1855553|NCT00991926|Drug|Orlistat|orlistat (Xenical, Roche, UK)120 mg tid
1855554|NCT00991926|Other|normo-caloric diet|Food intake and dietary history were assessed by a skilled dietitian who used a computer-assisted interview (Winfood 1.5, Medimatica srl, Martinsicuro, Italy)
1855555|NCT00991939|Drug|Dexamethasone USP Micronized|The dose for dexamethasone is 30 mg/day for patients < 60 kg and 40 mg/day for patients > 60 kg. The patient will be dosed on days 1-4, 15-18 and 29-32. On the remaining days during the treatment phase of the study, the patient will receive placebo capsules.
1855556|NCT00991939|Drug|Prednisone|Prednisone will be administered to study patients at a dose of 60 mg/day for patients less than 60 kg and 80 mg/day for patients > 60 kg for 21 days. The following schedule for tapering of prednisone will be used: after three weeks of treatment at either 60 mg/day (for patients < 60 kg) or 80 mg/day (for patients ≥ 60 kg), the dose will be reduced to 40 mg/day for 1 week, then 20 mg/day for 1 week, then 10 mg/day for 1 week, then 5 mg/day for 1 week and then stopped. Placebo capsules will be added as necessary during the treatment phase of the study, to maintain blinding.
1855557|NCT00991952|Drug|alvocidib|Given IV
1855558|NCT00991952|Drug|irinotecan hydrochloride|Given IV
1855559|NCT00991952|Other|laboratory biomarker analysis|Correlative studies
1855560|NCT00991965|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
1855561|NCT00991978|Other|89Zr-bevacizumab PET|PET-scan with 89Zr-bevacizumab
1855562|NCT00991991|Genetic|gene expression analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
1855563|NCT00991991|Genetic|polymerase chain reaction|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
1855564|NCT00991991|Genetic|polymorphism analysis|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
1855565|NCT00991991|Other|matrix-assisted laser desorption/ionization time of flight mass spectrometry|Laser capture microdissection is performed on the archived tissue samples to isolate melanoma cells. DNA is then purified from the samples and amplified using PCR. Matrix-assisted laser desorption/ionization (MALDI)-time of flight mass spectrometry technology is used to detect mutations of B-Raf and N-Ras. Single nucleotide polymorphism arrays are also performed.
1855566|NCT00991991|Other|medical chart review|Information about the patient's demographics (e.g., TNM staging, sex, age, and tissue collection dates) will be gathered by chart review or from the Multidisciplinary Melanoma Conference at University Hospitals tumor conference report in order to match cases.
1855567|NCT00992004|Dietary Supplement|Arantal® (highly bioavailable turmeric extract)|4 capsules a day, before breakfast
1855568|NCT00992017|Biological|Influenza A (H1N1) monovalent vaccine|Two 15-microgram intramuscular vaccine injections given together form one dose; two doses (four total injections) are given 21 days apart
1855569|NCT00992030|Drug|Rituximab|I.V. infusion weekly x 6 weeks at a dose of 375 mg/m2
1855570|NCT00992030|Radiation|Involved field irradiation|Radiation therapy, limited to initially involved nodal sites, will start within four weeks from the last cycle of ABVD chemotherapy and after complete restaging with TAC total-body and PET total-body. The planned total dose is 30,6 Gy.
1855571|NCT00992043|Dietary Supplement|creatine|
1855572|NCT00992043|Other|Exercise training|
1855573|NCT00992056|Drug|nebivolol|5 mg titrated to 10 mg daily versus matching placebo
1855574|NCT00992056|Drug|Metoprolol|Metoprolol 50 mg titrated to 100 mg
1855575|NCT00992069|Drug|Efavirenz (EFV)|Oral dose of 600 mg daily, taken in the evening
1855576|NCT00992069|Drug|TMC207|Single oral dose of 400 mg in the morning
1855577|NCT00992082|Drug|ropivacaine, ketorolac and epinephrine|Spinal injection: bupivacaine 17.5 mg (3,5 mL) + 0.25 mL 0.9% saline. Local Infiltration Analgesia: 400 mg ropivacaine, 30 mg ketorolac and 0.5 mg epinephrine (total volume 166 ml) are infiltrated by the surgeon into the soft tissues peri-articularly during the operation. On the first and on the second postoperative morning, 200 mg ropivacaine, 30 mg ketorolac and 0.1 mg epinephrine, total volume 22 ml, are injected intraarticularly via the catheter.
1855578|NCT00992082|Drug|morphine|Spinal injection: bupivacaine 17.5 mg (3.5 mL) + 0.1 mg (0.25 mL) morphine. No intraarticular injections are given.
1855579|NCT00992095|Drug|buprenorphine hydrochloride|single dose 8 mg sublingual tablet
1855580|NCT00992108|Drug|lidocaine|1cc 1%
1855581|NCT00992108|Drug|chemodenervation|botulinum toxin
1855582|NCT00992121|Drug|Bevacizumab|Bevacizumab - 3 infusions of 10mg/kg administered at 2 week intervals - Part I
1855583|NCT00992121|Drug|Pazopanib 2 week|"Pazopanib for first 2 weeks of each 3-week cycles as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).
Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
1855584|NCT00992121|Drug|Pazopanib 3 week|"Pazopanib throughout each 3-week cycle as follows: 1) 200 mg twice weekly, 2) 200 mg every other day, 3) 200 mg qd, 4) 400 mg qd, 5) 800 mg qd, and 6) 1200 mg qd (Group 1).
Maintenance pazopanib 800 mg qd for all 3 weeks throughout repeating 3-week cycles. Number of cycles: until death, loss of clinical benefit, unacceptable toxicity, or withdrawal from the study for other reasons."
1855585|NCT00992134|Drug|Rituximab, Bendamustine, Cytarabine|"Rituximab IV 375 mg/m2 on day 1. Bendamustine IV 70 mg/m2 over a 30-60 minute infusion on day 1 and 2. Cytarabine IV 800 mg/m2, over a 2-hour infusion, 2 hours after Bendamustine, on Day 1, 2, and 3.
Four to six cycles. Recycle every 28 days."
1855586|NCT00992147|Drug|Adipocell|autologous cultured adipocytes (ANTG-adip)
1855589|NCT00992173|Drug|Ultratrace Iobenguane I 131|Subjects will receive an Imaging Dose of 0.1 mCi/kg [3.7 MBq/kg] (a minimum dose of 1.0 mCi [37 MBq] but not to exceed 5.0 mCi [185 MBq]) of Ultratrace iobenguane I 131 to have dosimetry performed and to confirm tumor uptake of the test article prior to receiving each of 2 planned Therapeutic Doses of Ultratrace iobeneguane I 131 . Within 28 days of screening, eligible subjects (as confirmed by the first Imaging dose study)will receive an Ultratrace iobenguane I 131 Therapeutic dose of of 15.0 - 18.0 mCi/kg (max. 666 MBq/kg) followed by imaging 7 days later or upon discharge from radiation isolation. A second Therapeutic Dose (preceded by a repeat Image Dose and dosimetry study)and imaging upon discharge from radiation isolation will be repeated approximately 8 weeks after the first dose.
1855590|NCT00992186|Drug|Carlumab|Carlumab diluted in 5 percent (%) dextrose administered at the dose of 15 milligram per kilogram (mg/kg) by intravenous (into a vein) infusion (a fluid or a medicine delivered into a vein by way of a needle) at a constant rate over a 90 minute period once every 2 weeks until disease progression.
1855591|NCT00992199|Drug|cisplatin, Fluorouracil|cisplatin,60mg,plus 5-Fu,1.0g,intraperitoneal administration,once a week for 3 times
1855592|NCT00992212|Biological|Monovalent A/H1N1 influenza vaccine|This trial will be performed at multiple sites; appr. 160 subjects exposed to the annual vaccine registration will be invited to take part into this study. In addition, a total of 224 healthy subjects not yet exposed to the seasonal influenza vaccines will be enrolled.
1855593|NCT00992225|Drug|LY573636|Dose is adjusted to target a specific Cmax based on patient laboratory parameters, administered intravenously every 28 days until disease progression or other criteria for patient discontinuation are met
1855594|NCT00992238|Drug|Flavoxate Hydrochloride Tablets, 100mg|
1855595|NCT00992238|Drug|Urispas® Tablets, 100mg|
1855600|NCT00992277|Procedure|Ablation and skin resurfacing|
1855601|NCT00992290|Biological|Lactobacillus GG|1 capsule of lactobacillus GG BID compared to placebo BID
1855602|NCT00992290|Biological|Placebo|1 capsule of lactobacillus GG BID compared to placebo BID
1855603|NCT00992303|Other|biologic sample preservation procedure|
1855604|NCT00992303|Other|medical chart review|
1855605|NCT00992303|Other|questionnaire administration|
1855606|NCT00992316|Drug|PF-04531083|solution. doses to be selected based upon safety/tolerability/PK at preceeding dose
1855607|NCT00992329|Drug|ciprofloxacin|ciprofloxacin 200mg tablet (single dose)
1855608|NCT00992342|Drug|PF-03893787|oral solution, 5 mg, QD for 14 days
1855609|NCT00992342|Drug|PF-03893787|oral solution, 15 mg, QD for 14 days
1855610|NCT00992342|Drug|PF-03893787|oral solution, 50 mg, QD for 14 days
1855611|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1%|
1855612|NCT00992355|Drug|Tobramycin 0.3% - Dexamethasone 0.1% plus Ketorolac tromethamine 0.5%|
1855613|NCT00992368|Procedure|reduction mammaplasty|patients submitted to reduction mammaplasty
1855614|NCT00992381|Drug|PN400|500mg Naproxen and 20mg esomeprazole
1855615|NCT00992381|Drug|Naprosyn|500mg Naproxen
1855616|NCT00992394|Drug|etanercept|etanercept 50 mg once weekly as requested.
1855617|NCT00992394|Drug|etanercept|etanercept 25 mg or 50 mg as requested.
1855726|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
1855728|NCT00993109|Drug|Adalat (Nifedipine, BAYA1040)|Nifedipine GITS/OROS 30 mg OM + Valsartan 80 mg OM
1855618|NCT00992407|Drug|Risperidone long acting injectables|Risperidone long acting injectables will be administered intramuscularly (given into the skin) at a flexible dose of 25, 37.5 or 50 milligram (mg) every 2 weeks up to Week 52. A supplementary oral antipsychotic will also be administered for 3-4 weeks after the initial dose of injection.
1855619|NCT00992407|Drug|Risperidone tablets|Risperidone tablets will be administered orally as 0.5-10 mg daily up to Week 52.
1855620|NCT00992433|Biological|Inactivated Influenza H1N1 vaccine|Two doses inactivated, licensed, Influenza A (H1N1) 2009 monovalent vaccine; 15 or 30 micrograms (mcg) per dose; slightly opalescent suspension in phosphate buffered saline. 15 mcg dose administered as a single 0.5 mL intramuscular (IM) injection. 30 mcg dose administered as two 0.5 mL IM injections.
1855621|NCT00992446|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo ASCT
1855622|NCT00992446|Drug|Bortezomib|Given IV
1855623|NCT00992446|Drug|Carmustine|Given IV
1855624|NCT00992446|Drug|Cytarabine|Given IV
1855625|NCT00992446|Drug|Etoposide|Given IV
1855626|NCT00992446|Drug|Melphalan|Given IV
1855627|NCT00992446|Drug|Rituximab|Given IV
1855628|NCT00992446|Drug|Vorinostat|Given PO
1855629|NCT00992459|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. Three teaspoons of HPN-100 (~17.4mL) delivers equivalent amount of PBA in 40 tablets of NaPBA.
1855630|NCT00992459|Drug|Buphenyl (NaPBA)|Buphenyl (NaPBA) will be the comparator drug to HPN-100 in this study.
1855631|NCT00992472|Drug|Prochlorperazine suppositories, 25mg|
1855632|NCT00992472|Drug|Compazine® suppositories, 25mg|
1855633|NCT00992485|Drug|ADIPOPLUS|autologous adipose-derived stem cell
1855638|NCT00992524|Drug|Misoprostol|Oral solution dose will be 20mcg/hour (misoprostol) or 10ml/hour (placebo) in the first six hours with an increase of 20mcg/hour (10ml/hour) of misoprostol or placebo each six hours if labour does not start, until the maximum dose of 80mcg/hour or 40ml/hour in the first 24 hours.
1855639|NCT00992524|Drug|Misoprostol|Vaginal tablets will have 25mcg of misoprostol or placebo.
1855640|NCT00992537|Drug|insulin degludec|Insulin degludec single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
1855641|NCT00992537|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
1855642|NCT00992537|Drug|insulin aspart|Insulin aspart single-dose of 0.5 U/kg body weight injected subcutaneously (under the skin).
1855643|NCT00992550|Drug|Cigarette|
1855644|NCT00992550|Drug|Hookah|
1855645|NCT00992563|Drug|AL-39324 ophthalmic suspension|
1855646|NCT00992563|Drug|Ranibizumab 10 mg/mL|
1855647|NCT00992576|Drug|Active Hydromorphone PR + Active Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
1855648|NCT00992576|Drug|Active Hydromorphone PR + Placebo Naloxone PR|Optimal pain relief and improved bowel function in constipated pain patients
1855649|NCT00992589|Drug|Rabeprazole sodium 5 mg|Rabeprazole Sodium 5 mg capsules once daily in the morning.
1855650|NCT00992589|Drug|Rabeprazole sodium 10 mg|Rabeprazole Sodium 10 mg capsules once daily in the morning.
1855651|NCT00992589|Drug|Placebo|Matching placebo capsules once daily in the morning.
1855652|NCT00992602|Drug|methotrexate|Given IV
1855653|NCT00992602|Drug|liposomal cytarabine|Given IT or via LP
1855654|NCT00992602|Other|quality-of-life assessment|Ancillary studies
1855655|NCT00992602|Other|laboratory biomarker analysis|Correlative studies
1855656|NCT00992615|Procedure|prostate biopsy|prostate cores - 12 or 20
1855657|NCT00992628|Device|Macintosh (direct vision) laryngoscope|Macintosh (direct vision) laryngoscope
1855658|NCT00992628|Device|GlideScope videolaryngoscope (indirect vision)|GlideScope videolaryngoscope (indirect vision)
1855659|NCT00992641|Other|Experimental diet|Diet based on Nordic recommendations: rich in whole grain products, berries, fruits and vegetables, recommended fat quality. Realised based on eating habits of each Nordic country.
1855660|NCT00992641|Other|Control diet|Diet based on the information of the current dietary intake and food consumption in Nordic countries.
1855661|NCT00992654|Drug|Open Label Treatment Access: Maraviroc|Oral dosing twice daily. The dose will depend on the optimized background therapy.
1855663|NCT00992680|Device|ROX Anastomotic Coupler System (ACS)|The ACS will be used to create an arteriovenous fistula in the iliac region (between the iliac artery and vein)
1855665|NCT00992706|Drug|antiperspirant cream F511|Placebo and verum cream once daily, in the morning, during the first week of the first PLD treatment only, then once daily, three times per week (in the morning). Tube R for right hand and foot, tube L for left hand and foot.
1855666|NCT00992706|Drug|pegylated liposomal doxorubicin hydrochloride|According to local practice. 1, 2 and 4 week schedules with at least 10mg/m2 per week are allowed.
1855727|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
1855667|NCT00992719|Biological|Inactivated H1N1 Vaccine|H1N1 vaccine [Influenza A (H1N1) 2009 Monovalent Vaccine] is a licensed, inactivated influenza virus vaccine. It will be provided as prefilled single dose syringes containing 0.5 mL. The 0.5 mL prefilled syringe is formulated without preservative. The 15 microgram (mcg) dose will be administered as a single 0.5 mL intramuscular (IM) injection in the deltoid muscle of the preferred arm. The 30 mcg dose will be administered as two 0.5 mL injections in the deltoid muscle of each arm.
1855668|NCT00992732|Drug|HQK-1004|1,000 mg/kg/day administered IV 24 hours/day for 5 days (Days 1-5 of each 21 day cycle)
1855669|NCT00992732|Drug|Valganciclovir (may substitute with ganciclovir)|900 mg BID oral for 21 days (Days 1-21 of each 21 day cycle). If the subject cannot tolerate or absorb valganciclovir, ganciclovir my be administered instead at 5 mg/kg intravenously BID until the subject can tolerate and absorb valganciclovir.
1855670|NCT00992745|Drug|123-I-MIP-1072|Single 10 mCi intravenous injection
1855671|NCT00992745|Drug|111-In capromab pendetide|Single 5 mCi intravenous injection
1855672|NCT00992745|Drug|123-I-MIP-1072|Single 5 mCi intravenous injection
1855673|NCT00992758|Biological|Iodine-131 Anti-B1 Antibody|"Dosimetric Dose: 450 mg unlabeled Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody of which 1-2 mg has been labeled with 5 mCi of Iodine-131 infused over 20 minutes.
Therapeutic Dose: 7-14 days after dosimetric dose, 450 mg Anti-B1 Antibody infused over 1 hour or longer followed by 35 mg of Anti-B1 Antibody labeled with the subject-specific dose of Iodine-131 to deliver the desired total body radiation, infused over 20 minutes The dose escalation will be initiated at 45 cGy and will be increased in 10 cGy increments until the maximum tolerated dose (MTD) is reached."
1855676|NCT00992784|Biological|GSK investigational vaccine 2186877A|Single dose, intramuscular injection
1855677|NCT00992784|Biological|FluarixTM|Single dose, intramuscular injection
1855678|NCT00992797|Drug|Cholecalciferol|Cholecalciferol 200.000 IU pr ampoule, 400.000 IU given at randomization day, followed by additionally 200.000 IU at week 5 if serum 25(OH)D < 100 nmol/L. If serum 25(OH)D > 100 placebo will be given. The cholecalciferol will be given in orange juice.
1855679|NCT00992797|Other|Orange juice|Orange juice at randomization day and at week 5.
1855680|NCT00992810|Procedure|Lateral-to-Medial Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a lateral-to-medial direction.
1855681|NCT00992810|Procedure|Media-to-Lateral Approach|Approach of the needle to administer the brachial plexus nerve block will be done in a medial-to-lateral direction.
1855682|NCT00992823|Drug|iron supplementation|40 doses of 30 mg of ferrous sulfate during a 10-month intervention period
1855683|NCT00992823|Biological|iron supplementation|supplementation in two 5-month cycles, each cycle consisting of one month of supplementation (20 workdays) and four months without supplementation.
1855684|NCT00992836|Biological|Influenza A (H1N1) 2009 monovalent vaccine|Two doses of vaccine, delivered 21 days apart, with each dose consisting of two 15-microgram intramuscular injections
1855685|NCT00992849|Drug|Bevacizumab|Topical 10 mg/cc or subconjunctival 2.5 mg/0.1cc
1855686|NCT00992862|Drug|Moexipril HCl 15mg Tablets, Paddock Laboratories, Inc.|
1855687|NCT00992862|Drug|Univasc® 15mg Tablets|
1855688|NCT00992875|Behavioral|Mindfulness-Based Stress Reduction|Behavioral intervention, mindfulness meditation in form of yoga, sitting meditation, body scan and mindfulness to routine activities
1855689|NCT00992888|Device|Prometheus Liver Dialysis system (Fresenius Medical Care)|6 hour dialysis for 3 consecutive days
1855693|NCT00992914|Procedure|Sympathetic nerve block with 1% lidocaine 1-2 ml|Stellate Ganglion Injection
1855694|NCT00992914|Procedure|Superficial subcutaneous injection|Superficial subcutaneous injection with saline
1855695|NCT00992927|Procedure|Capsule-Preserving Intra-articular Hydraulic Distension|Capsule-Preserving Intra-articular Hydraulic Distension (CPIHD) infuses as much volume as possible during the distension without rupturing the capsule.
1855696|NCT00992927|Procedure|Capsule-Rupturing Intra-articular Hydraulic Distension|Capsule-Rupturing Intra-articular Hydraulic Distension (CRIHD) infuses fluid into the joint space until the rupture of the capsule is observed.
1855697|NCT00992940|Procedure|Patient-Controlled Sedation/Analgesia|Patient controls delivery of sedation and analgesia requirements.
1855698|NCT00992940|Procedure|Anesthetist-Controlled Sedation/Analgesia|All sedation and analgesia requirements are determined and delivered by the attending anesthetist.
1855699|NCT00992953|Behavioral|Treatment as Usual|10 weeks of therapy and/or psychiatric medication as available
1855700|NCT00992953|Behavioral|Virtual Reality Exposure with Stimulus Control|10 weeks of therapy, up to twice a week, 90 min sessions involving Virtual Reality Exposure with Stimulus Control
1855701|NCT00992979|Procedure|Therapeutic Massage|Massage therapists with at least 5 years experience will perform the massages. On each of three consecutive days, participants (while fully clothed and in a seated position) will receive a 20-minute back, shoulder, neck and head massage. Subjects will be treated with conventional light pressure Swedish massage techniques which consisted of continuous systematic strokes including kneading and stretching to loosen and rehabilitate the soft tissues of the body and to provide general relaxation. The manual techniques include: effleurage , soothing petrissage , repetitive stroking, rocking , squeezing and mild joint mobilization. As is standard practice in massage therapy delivery, room lights will be dimmed and soft, soothing music played to enhance relaxation during therapy.
1855702|NCT00992979|Procedure|Relaxation Control|On each of three consecutive evenings, subjects in this group will participate in a 20 minute relaxation session. This session will be delivered in the same location and with the same lighting and music as with the therapeutic massage group. Each participant will be asked to choose a comfortable position in a chair and a massage therapist will sit quietly in the room approximately 4 feet behind the participant.
1855818|NCT00993694|Drug|chemotherapy|
1855703|NCT00992992|Biological|Tositumomab and Iodine I 131 Tositumomab followed by CHOP|Patients will receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of Tositumomab (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Tositumomab (450 mg) followed by an infusion of 35 mg Tositumomab containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,000-149,000 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose. Approximately 13 weeks following the therapeutic dose, CHOP will be administered every 21 days for a total of 6 cycles.
1855704|NCT00993005|Other|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 12 weeks.
1855705|NCT00993005|Other|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the scar rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
1855706|NCT00993018|Drug|JNJ-42160443 (1 mg)|JNJ-42160443 1 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
1855707|NCT00993018|Drug|JNJ-42160443 (3 mg)|JNJ-42160443 3 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
1855708|NCT00993018|Drug|JNJ-42160443 (10 mg)|JNJ-42160443 10 mg will be administered as a single, subcutaneous injection every 28 days for up to first 52 weeks in the blinded fashion and then every 28 days for up to an additional 52 weeks in the open-label fashion.
1855709|NCT00993018|Drug|Placebo|Patients will receive single injection of matching placebo every 28 days for up to 52 weeks.
1855714|NCT00993044|Drug|Irinotecan|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
1855715|NCT00993044|Drug|Vincristine|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
1855716|NCT00993044|Drug|Temozolomide|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
1855717|NCT00993044|Drug|Bevacizumab|"Dose Level 1 Irinotecan 30 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 1.5* Irinotecan 40 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level 2 Irinotecan 50 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
Dose Level -1 Irinotecan 20 mg/m2/day IV on day 1,2,3,4 and 5 Vincristine 1.5mg/m2 (2mg max dose) IV on day 1,8 Temozolomide 100 mg/m2 PO on day 1,2,3,4 and 5 Bevacizumab 15mg/kg IV on day 1
* Dose escalation will proceed from dose level 1 to dose level 2 and de-escalate to dose level 1.5 if DLT is observed on dose level 2"
1855718|NCT00993057|Drug|Insulin|Adjustable insulin infusion scale with loading doses
1855721|NCT00993083|Biological|MVA-NP+M1|Intramuscular injection at 1.5 x 10^8 pfu/ml at day 0
1855722|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
1855723|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.6 U/kg body weight injected subcutaneously (under the skin)
1855724|NCT00993096|Drug|insulin degludec/insulin aspart|Single dose of 0.8 U/kg body weight injected subcutaneously (under the skin)
1855725|NCT00993096|Drug|biphasic insulin aspart 30|Single dose of 0.4 U/kg body weight injected subcutaneously (under the skin)
1855819|NCT00993694|Drug|dapsone|
1855729|NCT00993109|Drug|Diovan (Valsartan)|Valsartan 160 mg OM (Two Valsartan 80mg tablets)
1855730|NCT00993122|Drug|ribavirin pre-treatment|patients receive ribavirin (10,4 mg/kg/day) and pegylated interferon alfa-2b (1,5 mcg/kg/week).Pre-treatment arm will receive a 8-week monotherapy treatment with only ribavirin (same dosage) and the controlled arm will receive 48 week of standard combined therapy (ribavirin plus pegylated interferon)
1855731|NCT00993135|Drug|methotrexate|
1855732|NCT00993135|Other|medical chart review|
1855733|NCT00993135|Procedure|assessment of therapy complications|
1855734|NCT00993148|Drug|maraviroc|150 mg tab by mouth once daily for 96 weeks
1855735|NCT00993148|Drug|darunavir|800 mg tab by mouth once daily for 96 weeks
1855736|NCT00993148|Drug|ritonavir|100 mg capsule by mouth once daily for 96 weeks
1855739|NCT00993174|Procedure|Topical strabismus surgery|Surgery is carried out after instilling drops for anesthesia and administering lidocaine gel during the procedure
1855740|NCT00993174|Procedure|Sub-Tenon's strabismus surgery|Surgery is carried out after sub-Tenon's injection of xylocaine
1855741|NCT00993187|Drug|Sitagliptin/Metformin FDC|Sitagliptin phosphate plus metformin hydrochloride combination tablet (MK-0431A) orally up to 50/1000 mg BID for 30 weeks
1855742|NCT00993187|Drug|Comparator: Glimepiride|Glimepiride tablet orally up to 6 mg daily for 30 Weeks
1855743|NCT00993187|Drug|Matching placebo to Sitagliptin/Metformin FDC|Matching placebo to Sitagliptin/Metformin FDC 50/1000 mg orally BID for 30 weeks
1855744|NCT00993187|Drug|Matching placebo to glimepiride|Matching placebo to glimepiride tablet orally daily for 30 weeks
1855745|NCT00993200|Genetic|warfarin pharmacogenetic dosing|Warfarin pharmacogenetic dosing incorporated into a validated clinical algorithm displayed in a computer (PERMIT) management interface
1855746|NCT00993200|Drug|Warfarin|Usual care warfarin dosing
1855747|NCT00993213|Procedure|Standard of Care with Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies, followed by Liposuction surgery.
1855748|NCT00993213|Other|Standard of Care without Liposuction|Standard of Care encompasses body composition measurements, a euglycemic clamp and fat biopsies. Liposuction surgery will not be performed.
1855749|NCT00993226|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
1855750|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
1855751|NCT00993226|Drug|Bupivacaine HCl Treatment 1c|40 ml
1855752|NCT00993226|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
1855753|NCT00993226|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
1855754|NCT00993226|Drug|Bupivacaine HCl Treatment 2c|40 ml
1855755|NCT00993239|Drug|Birinapant (TL32711)|30 minute intravenous (IV) infusion administered once weekly for three consecutive weeks followed by a one week off (Cycle) repeated every 4 weeks as tolerated
1855756|NCT00993252|Procedure|CT Scan|CT scan
1855757|NCT00993265|Drug|N-Acetylcysteine|2400 mg by mouth PO (1200 mg AM, 1200 mg PM), 12 weeks
1855758|NCT00993265|Drug|Placebo|placebo, 2 capsules by mouth in AM, 2 capsules by mouth PM, 12 weeks
1855759|NCT00993278|Dietary Supplement|Low-Carbohydrate (Modified Atkins) Diet|Low-Carbohydrate (Modified Atkins) Diet
1855760|NCT00993278|Dietary Supplement|Low-Fat (Heart Healthy) Diet|Low-Fat (Heart Healthy) Diet
1855761|NCT00993291|Procedure|Frequency change to 60 Hz|60 Hz stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
1855762|NCT00993291|Procedure|Frequency change to 130 Hz|130 Hz Stimulation for one hour, done twice over the 5 hour study period in a randomized blinded fashion.
1855763|NCT00993304|Drug|liraglutide|In the first 3-week period, the treatment will be one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg liraglutide. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of 3 weeks' treatment with placebo. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
1855764|NCT00993304|Drug|placebo|In the first 3-week period, the treatment will be with placebo. Subsequently, a wash-out period of 3 to 9 weeks occurs and then a second period of one week with 0.6 mg, one week with 1.2 mg and one week with 1.8 mg of liraglutide. At the end of each of the 2 treatment periods, a high fat meal test will be performed.
1855765|NCT00993317|Drug|Placebo of CDP870|Given every 2 weeks until Week22 (SC)
1855766|NCT00993317|Drug|CDP870 200mg|400mg CDP870 given at Week0, 2, 4 and thereafter 200mg CDP870 given every 2 weeks until Week 22(SC)
1855767|NCT00993317|Drug|Methotrexate|"Received treatment with Methotrexate(MTX)for at least 24 weeks prior to the Baseline Visit.
The dose and route of administration of MTX had to have been stable for at least 8 weeks prior to the Baseline Visit. The minimum stable dose of MTX allowed is 10mg weekly."
1855768|NCT00993343|Drug|Sirolimus/tacrolimus|Standard GVHD prophylaxis
1855769|NCT00993343|Drug|cyclosporine/methotrexate|Standard GVHD prophylaxis
1855770|NCT00993356|Drug|Preoperative lanreotide treatment|Patients received lanreotide for 16 weeks before the surgical resection [starting with 30 mg/2 weeks i.m. and increasing to 30 mg/week i.m. at week 8, if mean GH > 5 mU/L on GH day curve (GHDC)] (GHDC: 9×30-min samples collected in the morning after an overnight fast and rest, through an indwelling catheter inserted in an arm vein and while the patient was resting).
1855771|NCT00993356|Procedure|Transsphenoidal surgery|
1855772|NCT00993369|Other|Holter monitor|Record heart rate for 2 to 6 hours on day of life 1 or 2.
1855773|NCT00993382|Drug|Celivarone|"Pharmaceutical form: capsule
Route of administration: oral"
1855774|NCT00993382|Drug|Amiodarone|"Pharmaceutical form: capsule
Route of administration: oral"
1855775|NCT00993382|Drug|Matching placebo|"Pharmaceutical form: capsule
Route of administration: oral
Matching placebo added to active drug if any for a total of 3 capsules per intake"
1855776|NCT00993395|Behavioral|peer mentor-based disease management|peer mentor-based disease management focused on three domains: medical care, recovery, and social stabilization
1855777|NCT00993408|Device|ACT-293987 (NS-304)|
1855778|NCT00993421|Drug|LY377604|Given daily, orally for 24 weeks
1855779|NCT00993421|Drug|Sibutramine|given daily, orally for 24 weeks
1855820|NCT00993694|Other|medical chart review|
1855780|NCT00993421|Drug|Metoprolol|given daily, orally for 24 weeks (100 mg for 1 week followed by 200 mg for 23 weeks. Patients unable to tolerate 200 mg will be dose reduced to 100 mg), followed by a 2 week taper (1 week at 100 mg/day followed by 1 week at 50 mg/day).
1855781|NCT00993421|Drug|Placebo sibutramine|given daily, orally for 24 weeks
1855782|NCT00993421|Drug|Placebo Metoprolol|given daily, orally for 26 weeks (24 weeks plus 2 weeks of taper)
1855783|NCT00993421|Drug|Placebo LY377604|given daily, orally for 24 weeks
1855784|NCT00993434|Behavioral|Booklet on nutrition and physical activity.|Parents will be asked to read the booklet and complete a pre- and post-questionnaire.
1855785|NCT00993434|Behavioral|Safety Booklet|Parents will be asked to read a safety booklet and complete a pre- and post-questionnaire.
1855786|NCT00993447|Biological|CYD Dengue Vaccine|0.5 mL, Subcutaneous at Day 0, 6 and 12 months
1855787|NCT00993447|Biological|Tetanus Toxoid Reduced Diphtheria Toxoid Acellular Pertussis|NaCl: 0.5 mL, Intramuscular at Day 0 and 6 months; Adacel®: 0.5 mL, Intramuscular at 12 months
1855788|NCT00993473|Drug|Insulin glargine (HOE901)|"100 U/mL commercial solution for injection available as both disposable pen devices Solostar® each containing 300 U and as 10 mL vials each containing 1000 U
Dose: titrated to achieve the following glycemic targets without hypoglycemia:
Fasting blood glucose (BG) between 90 and 145 mg/dL (5.0 to 8.0 mmol/L), inclusive,
Bedtime BG between 120 and 180 mg/dL (6.7 to10.0 mmol/L), inclusive,
Nocturnal BG between 80 and 162 mg/dL (4.4 to 9.0 mmol/L), inclusive; and
HbA1c <7.5%."
1855789|NCT00993473|Drug|Neutral Protamine Hagedorn (NPH) insulin|"NPH insulin 100 U/mL commercial (Huminsulin Basal) solution for injection available as both disposable pen devices (Huminsulin Basal Pen) each containing 300 U and as 10 mL vials each containing 1000 U
Dose: titrated to achieve glycemic targets as described above for insulin glargine"
1855790|NCT00993473|Drug|Insulin lispro|Insulin lispro used as the principal bolus insulin; regular human insulin permitted. Administration: multiple injection before meals and/or at bedtime at the discretion of the Investigator.
1855791|NCT00993486|Biological|Donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR)|Single intravenous infusion
1855792|NCT00993499|Drug|BIBW 2992|Dose escalation (19-40 patients): low or high dose oral + 12 addit. pat. at MTD, until progression or undue AEs
1855793|NCT00993499|Drug|Sirolimus (rapamycin)|Dose escalation (19-40 patients): several dose levels + 12 addit. pat. at MTD until progression or undue AEs.
1855794|NCT00993512|Drug|Amphinex (TPCS2a)|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
1855795|NCT00993512|Drug|Bleomycin|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
1855796|NCT00993512|Other|Illumination with CeramOptec laser|intravenous TPCS2a, followed by standard dose of bleomycin (iv infusion) and illumination with CeramOptec laser.
1855797|NCT00993525|Drug|Intravitreal injection of ranibizumab|0.5 mg at week 0 0.5mg at weeks 12,24,36,48 if fluorescein leakage from active vessels on angiography
1855798|NCT00993538|Procedure|Blood sampling|
1855799|NCT00993538|Procedure|Bone marrow aspiration|
1855800|NCT00993551|Procedure|primary surgery for cleft palate|Surgery completed using the Sommerlad technique
1855801|NCT00993577|Other|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
1855802|NCT00993577|Device|Stretching exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
1855803|NCT00993577|Device|Exercises|Treatment consisted of eight individual sessions (once a week), over two months. At the first 10 minutes of sessions, patients rested (supine position) with all limbs relaxed. Manual therapy maneuvers were made as described by Bienfait,17 associated to breathing exercises, in order to stretch the fasciae that recover the shoulders, as well as the cervical spine muscles. After that, stretching treatment (global or static) was conducted for another 30 minutes.
1855804|NCT00993590|Behavioral|M CHESS|Smartphone with access to MCHESS, an asthma control system that provides easy-to-access, just-in-time information and support.
1855805|NCT00993603|Behavioral|8-month group lifestyle programme|Dietary and lifestyle counselling (11 sessions), weekly exercise programme and 3 fasting blood samples at baseline, 4 and 8 months.
1855806|NCT00993616|Drug|belinostat|Given IV
1855807|NCT00993616|Drug|carboplatin|Given IV
1855808|NCT00993629|Drug|pregnenolone|"Administered adjunctively to treatment as usual"
1855809|NCT00993629|Drug|placebo|adjunctive placebo
1855810|NCT00993642|Drug|Panobinostat (LBH589)|Patients will be given five 30mg doses of HDAC inhibitor (LBH) over a period of two weeks. A dose will be taken on Days 1,3,5,8 and 10. Patients will have a diagnostic tumor biopsy prior to drug administration and a diagnostic biopsy within 48 hours (2 days) of the last dose.
1855811|NCT00993655|Drug|carboplatin|Carboplatin AUC 5 if measured GFR or AUC6 if calculated GFR intravenous or intraperitoneal.
1855812|NCT00993655|Drug|cisplatin|Cisplatin 75 mg/m2 intraperitoneal day 1
1855813|NCT00993655|Drug|paclitaxel|Paclitaxel 135 mg/m2 intravenous day 1 plus Paclitaxel 60 mg/m2 intraperitoneal or intravenously day 8. Cycles given Q 21 days x 3 cycles
1855814|NCT00993668|Other|Placebo|Placebo - Two 0.9% saline subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by two sc injections of Open-Label (OL) CZP 200 mg at Weeks 6, 8 and 10, then one sc injection of OL CZP 200 mg every two weeks from Week 12 until last drug administration (up to Week 32).
1855815|NCT00993668|Biological|Certolizumab pegol|Certolizumab pegol - Two 200 mg subcutaneous (sc) injections at Week 0, Week 2, and Week 4 followed by one sc injection of Open-Label (OL) CZP 200 mg from Week 6 until last drug administration (up to Week 32).
1855816|NCT00993681|Biological|TD Vaccine System|heat labile enterotoxin of E. coli (LT)
1855817|NCT00993681|Biological|TD Vaccine System|placebo
1855822|NCT00993707|Drug|CTX-100 (formerly ETX-100) (hyaluronic acid)|"3 mL of either 0.01%, 0.03% CTX-100 (formerly ETX-100), or placebo will be dispensed into the PARI LC STAR nebulizer and inhaled using the PARI Ultra II compressors.
Number of cycles: if the study drug (0.01% CTX-100 Inhalation Solution or placebo) bid is well tolerated in the first cohort, the second cohort of subjects will begin dosing with 0.03% CTX-100 Inhalation Solution or placebo in the same manner as the first cohort."
1855823|NCT00993720|Drug|Liraglutide|after optimal treatment on insulin alone 10 patients with type 1 diabetes are treated for four weeks with Liraglutide : in the first week at 0.6 mg sc and after one week optitration to the recommended 1.2 mg sc pr day.
1855824|NCT00993720|Drug|Liraglutide|after optimal treatment with insulin alone, 10 type 1 diabetic patients are treated with Liraglutide at a dose of 0.6 mg sc. After one week the dose is optitreted to the recommended 1.2 mg sc pr. day.
1855825|NCT00993720|Other|continuous insulin therapy|after optimal treatment with insulin, patients continue on insulin for four weeks
1855826|NCT00993733|Procedure|Continuous veno-venous haemodiafiltration|Dialysis procedure administrated to the patients with acute renal failure
1855827|NCT00993746|Drug|Bupivacaine plus lidocaine|Bupivacaine 20 ml plus lidocaine 10 ml
1855828|NCT00993746|Drug|Bupivacaine 30 ml|Bupivacaine 30 ml for ultrasound guided infraclavicular brachial plexus block
1855830|NCT00993785|Device|Costar Coronary Stent Delivery System|
1855831|NCT00993798|Drug|SABER-Bupivacaine Treatment 1a|5.0 ml
1855832|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 1b|5.0 ml
1855833|NCT00993798|Drug|Bupivacaine HCl Treatment 1c|20.0 ml
1855834|NCT00993798|Drug|SABER-Bupivacaine Treatment 2a|7.5 ml
1855835|NCT00993798|Drug|Placebo SABER-Bupivacaine Treatment 2b|7.5 ml
1855836|NCT00993798|Drug|Bupivacaine HCl Treatment 2c|20.0 ml
1855837|NCT00993811|Device|Shang Ring circumcision|novel device for adult male circumcision
1855838|NCT00993824|Drug|colesevelam HCl|3.75 grams of colesevelam HCl (6 tablets)
1855839|NCT00993824|Drug|placebo|
1855840|NCT00993837|Procedure|thyroidectomy|total thyroidectomy via endoscopic approach and that convert to open procedure
1855841|NCT00993850|Behavioral|Cognitive behavioral therapy for insomnia|Attending 6-10 treatment sessions in one of our interview rooms. The sessions will be offered on a weekly basis. Each session takes approximately 50 minutes.
1855842|NCT00993850|Other|Bipolar education|Psychoeducation
1855843|NCT00993863|Drug|Placebo|single dose
1855844|NCT00993863|Drug|ADL5859 30 mg|single dose
1855845|NCT00993863|Drug|ADL5859 100 mg|single dose
1855846|NCT00993863|Drug|ADL5859 200 mg|single dose
1855847|NCT00993863|Drug|ibuprofen 400 mg|single dose
1855848|NCT00993876|Drug|citalopram|20 to 30 mg per day for 4 weeks
1855849|NCT00993876|Drug|reboxetine|4 to 8 mg per day for 4 weeks
1855850|NCT00993876|Behavioral|interpersonal psychotherapy|
1855851|NCT00993889|Behavioral|VR during Physical Therapy|Virtual Reality will be performed during a painful physical therapy procedure.
1855852|NCT00993889|Behavioral|VR Background Pain|Virtual Reality is used at anytime during the day for the background pain, not during physical therapy.
1855853|NCT00993889|Behavioral|NO VR|The subject will receive the usual standard treatment. At the end of the study, before being discharged from the hospital, the subject can experience the VR, not during a procedure.
1855854|NCT00993902|Procedure|Intrauterine insemination (single)|Single IUI after 36-38 hours of HCG
1855855|NCT00993902|Procedure|Double intrauterine insemination|Double insemination after 18 and 40 hours of HCG administration.
1855856|NCT00993915|Drug|Atorvastatin|Atorvastatin, 10- 80 mg, once daily, 6 month treatment
1855857|NCT00993928|Behavioral|Home-based sleep intervention|Participants will be asked to practice behaviors consistent with the stimulus control sheet and to read the sleep hygiene booklet.
1855858|NCT00993941|Procedure|Autologous BMSCs transplantation|10 ml autologous BMSCs(7~8log10 cells/ml) were infused to patients using interventional method via portal vein as well as conserved therapy for group B.
1855859|NCT00993941|Drug|Conserved therapy|Oral or intravenous administration
1855860|NCT00993954|Procedure|Reduction of Radial Head Subluxation|Nurse group will use hyperpronation with extension for first attempt and supination and flexion for second attempt. Physician controls will use either method at their discretion
1855862|NCT00993980|Procedure|qigong|one therapy session once a week during three months, that is 12 therapy sessions altogether
1855863|NCT00993980|Procedure|exercise therapy|one therapy session once a week during three months, that is 12 therapy sessions altogether
1855864|NCT00994006|Dietary Supplement|Magnesium oxide|520 mg of elemental magnesium q.d.
1855865|NCT00994006|Dietary Supplement|Magnesium citrate|Magnesium citrate , 98.6 mg of elemental magnesium t.i.d.
1855866|NCT00994032|Procedure|percutaneous injection of cement into the vertebral body|percutaneous injection of cement into the vertebral body
1855867|NCT00994032|Other|Medical treatment|standard antalgic medical treatment
1855868|NCT00994045|Biological|Fibrinogen concentrate|Fibrinogen concentrate will be administered initially at 2 grammes per hour by continuous infusion. This rate will be adjusted in response to the clinical picture and results of point of care coagulation tests. The infusion will be used intra-operatively.
1855869|NCT00994045|Biological|Fresh Frozen Plasma|
1855870|NCT00994058|Device|Electrical Inhibition (EI) Uterine Pacemaker|"An external powered pulse generator, pacemaker for external stimulation of the uterine muscle through the vaginal canal for the therapeutic use of preventing preterm birth.
Patients with preterm contractions (< 37 weeks gestation) will be monitored for contraction frequency for 20 minutes before, 20 minutes during use of EI and 20 minutes after EI/uterine inhibitor/pacemaker. Device generates a weak electrical current (0-10mA, 0-50 Hz, 0-50mS)."
1855871|NCT00994071|Drug|Temozolomide|
1855872|NCT00994071|Drug|ABT-888|
1855910|NCT00985673|Biological|Seasonal trivalent influenza vaccine (TIV)|Single intramuscular injection
1855911|NCT00985673|Biological|Saline placebo|Single intramuscular injection
1855873|NCT00994084|Behavioral|Healthy Kids-Houston program|Children receive 90 minutes of after-school structured physical activities and 30 minutes of nutrition and behavior lessons twice a week during three 6-week sessions at the community centers. The 6-week sessions take place once in the fall, once in early spring and once in late spring.
1855874|NCT00994084|Behavioral|Control|Children do not receive the Healthy Kids-Houston behavior modification program but will participate in the regular after-school enrichment programs offered by the community centers.
1855875|NCT00994097|Drug|NGR-hTNF|NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every 3 weeks until confirmed evidence of disease progression or unacceptable toxicity occurs
1855876|NCT00994097|Drug|Cisplatin|Cisplatin: 80 mg/m² intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
1855877|NCT00994097|Drug|Gemcitabine|Gemcitabine: 1,250 mg/m2 intravenous infusion on days 1 and 8 every 3 weeks for a maximum of 6 cycles
1855878|NCT00994097|Drug|Pemetrexed|Pemetrexed: 500 mg/m2 intravenous infusion on day 1 every 3 weeks for a maximum of 6 cycles
1855879|NCT00994110|Drug|Pasireotide (SOM230)|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.
Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
1855880|NCT00994110|Other|placebo|"Patients will receive subcutaneous injection of SOM230 or placebo (NS, equivalent volume) on the day of operation prior to resection in the pre-surgical center. The initial subcutaneous injection of drug or placebo will be given at least one hour prior but no longer than 8 hours prior to transection of the pancreas. Patients will be continuously monitored in the OR following this dose administration, and both their cardiac and respiratory status will be closely followed.
Postoperatively patients will receive study drug or placebo every 12 hours. Subcutaneous injections will continue until postoperative day 7, with the last dose administered in the evening on postoperative day 6, or until a pancreatic complication has been identified."
1855881|NCT00994123|Drug|MM-121|MM-121 (SAR256212) = intravenous solution
1855882|NCT00994123|Drug|Erlotinib|erlotinib = daily oral tablet
1855883|NCT00994136|Drug|normal saline|Ten milliliters of normal saline will be injected at the end of the intravenous therapy. Injection is performed with the start/stop method and with the positive pressure technique (clamping the catheter while injecting the last milliliters of normal saline)
1855884|NCT00994149|Drug|Diazoxide|10mg/kg/d divide every 8 hours
1855885|NCT00994149|Drug|Ora-plus|placebo, give every 8 hours.
1855886|NCT00994162|Device|EZCARE Negative Pressure Wound Therapy System|Vacuum Source and dressing kit that generates negative pressure over the wound.
1855887|NCT00994175|Drug|Pioglitazone|
1855888|NCT00994175|Drug|Placebo|
1855889|NCT00994188|Procedure|Restored Kidney Transplant Between Family Members|Tumor part of the kidney or ureter and ureteral stricture is surgically removed or repaired and the kidney is restored and transplanted to a family member recipient
1855890|NCT00994201|Other|DCE-MRI, DW-MRI and MRS|"Patients will undergo Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Diffusion-weighted magnetic resonance imaging (DW-MRI), Magnetic resonance spectroscopy (MRS) prior to the initiation of chemoradiation and before their second cycle of chemotherapy.
Healthy volunteers will undergo DCE-MRI, DW-MRI and MRS."
1855891|NCT00994214|Drug|BIM 23A760|Subcutaneous injections of BIM23A760 once a week. Until progression or unacceptable toxicity develops.
1855892|NCT00994227|Procedure|vitrectomy for macular disease|three-port pars plana vitrectomy was performed in each case using a vitreous cutter surrounded by a coaxial optic fiber connected to a xenon light source (Lausanne set, Oertli, Switzerland-developed at Jules Gonin, Lausanne, by Gonvers and Bovey). Separation of the posterior hyaloid membrane was performed when necessary. Visualization of the fundus was achieved with a special noncontact wide-angle viewing system 37 during vitrectomy and with a planoconcave contact lens for macular peeling. The MEM was peeled in the macular area using an end gripping forceps.
1855893|NCT00985543|Drug|lopinavir/ritonavir|Each participant received three sequential doses of lopinavir/ritonavir: 400/100 mg twice daily (2 heat-stable 200/50 mg tablets BID), 200/150 mg twice daily (1 heat-stable 200/50 mg tablet BID plus 1 ritonavir 100 mg capsule BID), and 200/50 mg twice daily (1 heat-stable 200/50 mg tablet BID). Each dosing phase lasted for 7 days and each phase was separated by a 7-day wash-out period.
1855894|NCT00985556|Drug|capecitabine|Given orally
1855895|NCT00985556|Drug|oxaliplatin|Given IV
1855896|NCT00985556|Drug|tegafur-gimeracil-oteracil potassium|Given orally
1855897|NCT00985608|Drug|Group A: NCA 600 mg+antibiotics|NCA 600mg once a day for a week and subsequently a culture-guided one-week regimen including a PPI plus two antibiotics
1855898|NCT00985608|Drug|Group B: antibiotic treatment (control)|patients receiving solely a culture-guided one-week antibiotic treatment including a PPI plus two antibiotics
1855899|NCT00985621|Biological|tanezumab 10 mg|tanezumab 10 mg one dose at weeks 0 and 8
1855900|NCT00985621|Biological|tanezumab 5 mg|tanezumab 5 mg one dose at weeks 0 and 8
1855901|NCT00985621|Drug|oxycodone|oxycodone CR, 10-40 mg q12h
1855902|NCT00985621|Other|placebo|placebo
1997298|NCT02144129|Other|active Whole Body Electromyostimulation|
1997299|NCT02144129|Other|Passive WB-EMS|
1855905|NCT00985647|Drug|Lamivudine (3TC)|"3TC 300mg/150mg participants will receive 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days.
3TC 150mg/300mg participants will receive 3TC 150 mg (1 x 150 mg tablet) once daily for 10 days, washout for 10 days and then 3TC 300 mg (2 x 150 mg tablet) once daily for 10 days."
1855906|NCT00985660|Drug|Nisoldipine Extended-release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
1855907|NCT00985660|Drug|Sular® Extended Release Tablets, 30 mg|1 x 30 mg Tablet under fasting conditions
1855908|NCT00985673|Biological|GSK2340274A|Two intramuscular injections
1855909|NCT00985673|Biological|GSK2340273A|Two intramuscular injections
1997300|NCT02144129|Device|WB-EMS application|
1855912|NCT00985686|Other|LEAP Project|In collaboration with experts from Alberta Health Services, the University of Calgary, and Mount Royal University, the Canadian Institute of Natural and Integrative Medicine (CINIM) has created the LEAP Project, a spirituality informed e-mental health intervention, for young people with major depressive disorders (see Appendix for sample materials). It is an online, eight module, multimedia intervention delivered over eight weeks, requiring a weekly commitment of 2-3 hours. The intervention is non-denominational and avoids a focus on any religious traditions. The program aims to treat depression by guiding depressed young people through an exploration of spiritual concepts and principles.
1855913|NCT00985699|Genetic|polymorphism analysis|
1855914|NCT00985699|Other|laboratory biomarker analysis|
1855915|NCT00985699|Other|pharmacogenomic studies|
1855916|NCT00985712|Drug|Insulin Lispro|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
1855917|NCT00985712|Drug|Huminsulin Regular|subcutaneously, daily (as determined by patient's blood glucose), for 24 weeks
1855918|NCT00985712|Device|HumaPen Memoir|subcutaneously, daily for 24 weeks
1855919|NCT00985712|Device|HumaPen Luxura|subcutaneously, daily for 24 weeks
1855920|NCT00985725|Drug|SPD489 (Lisdexamfetamine dimesylate)|Oral, 20, 30, 40, 50, 60, and 70mg capsules, once daily
1855921|NCT00985725|Drug|Matching placebo|oral, once daily
1855922|NCT00985738|Drug|Dutasteride|Dutasteride will be administered at 0.5 mg dose and it will be given every day (QD), for approximately 3 months, followed by 3D mapping biopsy.
1855923|NCT00985738|Other|Placebo|The placebo group will receive the same standard of care as the intervention group, but instead of receiving the intervention drug, Dutasteride, participants will receive a placebo drug for the same 3 month period.
1855924|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A (formulation 1)|Three doses will be administered intramuscularly, at Month 0, 2 and 6.
1855925|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A (formulation 2)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
1855926|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 3)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
1855927|NCT00985751|Biological|Pneumococcal vaccine GSK2189242A combined with pneumococcal vaccine GSK1024850A (formulation 4)|Three doses will be administered intramuscularly, at Month 0, 2 and 6
1855928|NCT00985751|Biological|Pneumococcal vaccine GSK1024850A|Three doses will be administered intramuscularly, at Month 0, 2 and 6
1855929|NCT00985764|Procedure|cesarean delivery|
1855930|NCT00985777|Drug|Vitamin E δ-Tocotrienol|Vitamin E δ-Tocotrienol is supplied as 100-mg, 200-mg, and 400-mg capsules. The investigator (or designee) will have records of the number of participants treated within a specific cohort and will determine which treatment cohort to assign newly enrolled participants.
1855931|NCT00985790|Biological|Influenza vaccine GSK2321138A|Intramuscular injection
1855932|NCT00985790|Biological|Fluarix™|Intramuscular injection
1855933|NCT00985803|Other|Physical Activity: Cardio training (CT)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.
The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
1855934|NCT00985803|Other|Physical Activity: Endurance exercise training (ET)|"The experimental group of resistance training will carry out the training with 8 kinds of training session with 12 reps with that load will vary according to the 1 RM test.
The composition of the training session is 10 minutes of heating and stretching, 40 minutes of cardiovascular training and 10 minutes of cooling."
1855935|NCT00985816|Dietary Supplement|Lactobacillus Reuteri|L. reuteri DSM 17938 will be given at a dose of 1x108 colony forming units (CFU)/day
1855936|NCT00985816|Dietary Supplement|Placebo|Placebo
1855937|NCT00985907|Drug|Doxil, melphalan, bortezomib|"Doxil®: IV over 30-60 min, Day 1 q28d
Melphalan: IV over 30 min, Day 1 q28d
Velcade®: IV bolus, Day 1, 4, 8, 11 q28d
Dose Level 1: Doxil 10 mg/m2, Melphalan 5 mg/m2, Velcade 0.7 mg/m2
Dose Level 2: Doxil 10 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 3: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 0.7 mg/m2
Dose Level 4: Doxil 20 mg/m2, Melphalan 10 mg/m2, Velcade 1.0 mg/m2"
1855938|NCT00985920|Drug|tranexamic acid|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).
The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
1855939|NCT00985920|Drug|Placebo|"Patients will receive a solution containing either 1.5g or 3 g of tranexamic acid in 50 ml of normal saline (0.9% sodium chloride) or only 50 ml of saline without TA (placebo).
The treatment solution will be prepared under sterile conditions and coded at TWH pharmacy. In the OR the sterile bag containing the solution will be given to the scrub nurse. The contents (50 ml) will be emptied in a sterile surgical bowl. TA or placebo solution (50 ml) will be then applied to the open joint and tissues by the bulb syringe and will be left in contact with the tissues for 5 minutes. Excess solution will be subsequently suctioned by placing the suction tip on the cemented component without touching the joint and surrounding tissues."
1855940|NCT00985933|Drug|AZD8529|6 capsules by mouth 1 time 12 to 24 prior to assessments
1855941|NCT00985933|Drug|Placebo to match AZD8529|6 capsules by mouth 1 time 12 to 24 hours prior to assessments
1855942|NCT00985946|Drug|panobinostat (LBH589)|Panobinostat will be taken once daily at 20 mg three times a week (every Monday, Wednesday, Friday). It will be taken as long as patients are benefiting from treatment.
1855943|NCT00985959|Drug|JNJ-26866138 0.7 mg/m2|JNJ-26866138 0.7 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles.
1855944|NCT00985959|Drug|JNJ-26866138 1.0 mg/m2|JNJ-26866138 1.0 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles
1856045|NCT00986557|Procedure|standard follow-up care|
1856046|NCT00986557|Radiation|radiation therapy|
1855945|NCT00985959|Drug|JNJ-26866138 1.3 mg/m2|Phase I: JNJ-26866138 1.3 mg/m2 will be administered intravenously on Days 1, 4, 8, 11, 22, 25, 29 and 32 of 6-week cycle up to 4 cycles. Phase II: JNJ-26866138 1.3 mg/m2 on Days 1, 8, 22 and 29 of 6-week cycle for 5 to 9 cycles.
1855946|NCT00985959|Drug|Melphalan|Melphalan 9 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
1855947|NCT00985959|Drug|Prednisolone|Prednisolone 60 mg/m2 will be taken orally (by mouth) on Days 1, 2, 3 and 4 of 6-week cycle up to 9 cycles
1855948|NCT00985972|Behavioral|Physical Activity and Nutrition Education|School-based interventions involving Physical Activity or/and Nutrition Education.
1855949|NCT00985985|Drug|Nicotine|2 mg or 4 mg nicotine lozenge
1855950|NCT00985985|Drug|Placebo|placebo lozenge
1855951|NCT00985998|Drug|Nimotuzumab and chemotherapy|"The chemotherapy treament：docetaxel( 75mg/m2/d,every21days,for4~6cycles) and cisplatin(total dose 75mg/m2 on day 2,3,4,every21days,for4~6cycles).
the nimotuzumab treatment:3 levels (200mg/w,400mg/w,600mg/w,weekly,for12~18 weeks)."
1855952|NCT00986011|Other|questionnaire administration|
1855953|NCT00986011|Other|study of socioeconomic and demographic variables|
1855954|NCT00986011|Other|survey administration|
1855955|NCT00986011|Procedure|study of high risk factors|
1855956|NCT00986024|Behavioral|aerobic exercise|carried out 3 times per week for 12 weeks
1855957|NCT00986024|Behavioral|strength training|carried out 3 times per week for 12 weeks
1855958|NCT00986037|Drug|ABT-308|Single IV doses
1855959|NCT00986037|Drug|ABT-308|Multiple SC doses x 3
1855960|NCT00986037|Drug|Placebo|Single IV dose
1855961|NCT00986037|Drug|Placebo|Multiple SC doses x 3
1855962|NCT00986050|Drug|Abciximab|Abciximab bolus 0,25mg/kg, 10-60 minutes before PCI. Infusion 0,125ug/kg/min for 12 hours after PCI.
1855963|NCT00986050|Device|bare metal stent prokinetic, chrono, skylor or bluemedical|bare metal stent in culprit artery in acute myocardial infarction
1855964|NCT00986050|Device|drug eluting stent (sirolimus eluting) - CYPHER stent|stent implantation in culprit artery in acute myocardial infarction
1855965|NCT00986063|Genetic|Genetic test for NVP induced rash|The genotype statuses that capable of predict the cutaneous side effects from nevirapine
1855966|NCT00986063|Other|3TC/D4T/NVP or 3TC/AZT/NVP|Standard HAART for AIDS patients in Thailand
1855967|NCT00986076|Drug|Enoxaparin|Enoxaparin 40 mg / 500 ml in Balanced Salt Solution
1855968|NCT00986076|Drug|Balanced Salt Solution|Intraocular infusion of Balanced Salt solution
1855969|NCT00986102|Drug|doripenem|500mg vial by injection every 8 hours for 5 to 14 days
1855970|NCT00986115|Drug|Memantine|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
1855971|NCT00986115|Drug|Placebo|After a two-month prospective baseline during which seizure frequency and neurocognitive parameters are documented, patients will be randomized to either memantine or placebo and evaluated after twelve months on study drug. The treatment period will consist of a one month dose escalation phase, followed by an eleven month maintenance phase. The dose escalation is 5 mg in PM for days 1-7, 5 mg twice daily for days 8-14, 5 mg in AM and 10 mg in PM for days 15-21 and 10 mg twice daily from day 22 and continue.
1855972|NCT00986128|Drug|topiramate|100 mg tablet twice daily for 3 weeks
1855973|NCT00986128|Drug|topiramate|One 100 mg and one 200 mg tablet twice daily for 3 weeks
1855974|NCT00986141|Procedure|Surgery|Selective Laser Trabeculoplasty for glaucoma
1855975|NCT00986141|Procedure|Selective Laser Trabeculoplasty|Glaucoma Treatment
1855976|NCT00986154|Drug|edoxaban tosylate(DU-176b)|edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
1855977|NCT00986154|Drug|low molecular weight heparin/unfractionated heparin|"LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily.
Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment"
1855978|NCT00986154|Drug|warfarin|tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
1994437|NCT03004105|Drug|Selumetinib|"Safety Run-In - Beginning dose is Selumetinib 50 mg by mouth twice a day on Days 1 through 28 of a 28 day cycle
Intermittent Arm - Participants receive Selumetinib at 75 mg by mouth twice a day for 7 days on and 7 days off.
Continuous Arm - Participants take Selumetinib twice daily on Days 1 to 28 of a 28 day cycle. Dose determined by safety run-in."
1855980|NCT00986180|Drug|NUCYNTA|50, 75, or 100 mg every 4 to 6 hours for up to 10 days as needed for pain
1855981|NCT00986180|Drug|Oxycodone IR|5, 10, or 15 mg every 4 to 6 hours for up to 10 days as needed for pain
1855982|NCT00986193|Procedure|Transapical Aortic Valve Implantation|Insertion of a stent valve using catheter-based technique through a mini thoracotomy
1855983|NCT00986193|Procedure|Conventional Aortic Valve Surgery|Operation using heart-lung machine, with insertion of a biological artificial heart valve
1855984|NCT00986206|Other|diagnostic laboratory biomarker analysis|
1855985|NCT00986206|Other|liquid chromatography|
1855986|NCT00986206|Other|mass spectrometry|
1855987|NCT00986206|Procedure|screening method|
1855988|NCT00986232|Biological|Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live|a single 0.5 mL subcutaneous injection of ProQuad (low, middle, or high dose) at Day 0 and Day 90
1855989|NCT00986232|Biological|Comparator: M-M-R II|A single 0.5 mL subcutaneous injection at Day 0
1855990|NCT00986232|Biological|Comparator: PUVV|A single 0.5 mL subcutaneous injection at Day 0
1855991|NCT00986245|Drug|Ropinirole Prolonged release|Change Ropinirole immediate release or Pramipexole immediate release to Ropinirole prolonged release (PR) once-daily or twice-daily
1856047|NCT00986570|Biological|Botulinum Toxin A|100 U DL50 lyophilized powder for reconstitution in 1 ml Saline Solution 0.9%.
1856048|NCT00986583|Drug|Succinylcholine|Succinylcholine will be administered pre-induction over a period of 5 seconds
1855992|NCT00986258|Drug|Tapentadol Prolonged Release|"Participants started with 50 mg, 100 mg or 150 mg tapentadol prolonged release (twice daily). Opioid rotation to tapentadol was scheduled as follows:
if less than 100 mg morphine equivalent start with 50 mg tapentadol prolonged release;
if on 101 to 160 mg morphine equivalent daily dose start with 100 mg tapentadol prolonged release;
if above 161 mg morphine equivalent daily dose start with 150 mg tapentadol prolonged release.
Tapentadol doses were adjusted to a level that provided adequate analgesia (upwards or downwards on a weekly basis). After 5 weeks the doses of tapentadol prolonged release was kept stable (start of Maintenance phase). Tapentadol immediate release 50 mg (no more than twice daily; at least 4 hours apart) was considered as medication for acute pain episodes however, participants were not permitted to dose tapentadol immediate release once 500 mg tapentadol prolonged release dose was reached."
1855993|NCT00986271|Procedure|EVLI was determinated by PiCCO plus system.|
1855994|NCT00986284|Drug|gefitinib|Patients with EGFR mutation in exon 19 or 21 will be administrated with gefitinib as neoadjuvant therapy. Then evaluated for response and then operation for operable patients.
1855995|NCT00986297|Radiation|hypofractionated radiation therapy|hypofractionated radiation therapy
1855996|NCT00986310|Drug|Fluoxetine|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
1855997|NCT00986310|Drug|Placebo|Subjects randomized to fluoxetine will receive 20mg/day (one pill) for one week. The dose will be increased to 40mg/day (two pills) for the duration of hospitalization for VET. The dose will be decreased to 20 mg/day (one pill) from the day of hospital discharge for one week, at which time the medication will be discontinued.
1855998|NCT00986323|Device|Temperature controlled Laminar Airflow (TLA)|Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).
1855999|NCT00986323|Device|Placebo TLA|Placebo TLA (without filtration and TLA function)
1856000|NCT00986336|Drug|topiramate|1-25 mg plus 1-100 mg tablet twice daily for 2 weeks (250 mg/day)
1856001|NCT00986336|Drug|topiramate|2-100 mg tablets twice daily for 2 weeks (400 mg/day)
1856002|NCT00986336|Drug|risperidone|Twice daily, individualized dosing to stabilization at 1-6 mg/day.
1856003|NCT00986336|Drug|topiramate|2-25 mg tablets twice daily for 2 weeks (100 mg/day)
1856004|NCT00986349|Device|EndoBarrier Liner|52 week treatment of EnoBarrier Liner
1856005|NCT00986362|Drug|Ocriplasmin|175µg ocriplasmin intravitreal injection
1856006|NCT00986362|Drug|Placebo|Placebo intravitreal injection
1856007|NCT00986375|Behavioral|Intervention Group (IG)|patients will receive an interactive, computerized expert system which tailors treatment components to the individual needs of the patients
1856008|NCT00986375|Behavioral|Active Control Group (ACG)|Patients in the ACG will get an interactive computerized standard program
1856009|NCT00986401|Drug|Trospium Chloride (Sanctura XR®)|extended release, 60 mg, oral daily
1856010|NCT00986401|Drug|Metformin hydrochloride (Glucophage®)|immediate release, 500mg
1856011|NCT00986414|Drug|AFQ056|
1856012|NCT00986414|Drug|AFQ056|
1856013|NCT00986414|Drug|AFQ056|
1856014|NCT00986414|Drug|AFQ056|
1856015|NCT00986414|Drug|AFQ056|
1856016|NCT00986414|Drug|Placebo|
1856017|NCT00986427|Drug|Restasis (cyclosporine ophthalmic emulsion) 0.05%|cyclosporine ophthalmic emulsion 0.05%
1856018|NCT00986427|Drug|Refresh® Dry Eye therapy|Emulsion contains glycerin 1% and polysorbate 80
1856019|NCT00986440|Drug|CS-7017|CS-7017
1856020|NCT00986440|Drug|Placebo|Placebo
1856021|NCT00986453|Device|PEAK PlasmaBlade|The PEAK PlasmaBlade will be used for the entirety of the breast reduction, including the skin incision.
1856022|NCT00986453|Procedure|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
1992891|NCT03279497|Behavioral|Health game|Participants allocated to the Health game intervention group get to use the health game during the four week intervention period and participants are allowed to use it on their free time.
1994438|NCT03004105|Drug|Durvalumab|Safety Run-In, Intermittent Arm, Continuous Arm - Durvalumab 1500 mg by vein on Day 1 of a 28 day cycle.
1856027|NCT00986479|Drug|AZD6765|Single IV infusion of 150 mg AZD6765.
1856028|NCT00986479|Drug|Placebo to AZD6765|Single IV infusion of Placebo to AZD6765
1856029|NCT00986505|Drug|Lidocaine|Intravenous lidocaine once a week
1856030|NCT00986518|Biological|Adaptive autologous cell immunotherapy|each patient will undergo a blood cytapheresis to collect circulating lymphocytes. Ex-vivo cell sorting procedure will deplete patient's collected lymphocytes from regulatory T cells. Autologous Treg-depleted lymphocytes will be administered to the patient following a 5-day reduced intensity chemo-therapeutic conditioning.
1856031|NCT00986531|Drug|AZD8529|2 capsules by mouth for 3 days
1856032|NCT00986531|Drug|Placebo to match AZD8529|2 capsules by mouth for 3 days
1856033|NCT00986544|Procedure|no drain|drain positioned on the skin
1856034|NCT00986544|Procedure|drain positioned|drain positioned in the subhepatic space
1856035|NCT00986544|Procedure|drain not positioned|Drain positioned in the abdominal wall
1856036|NCT00986557|Biological|adoptive immunotherapy|
1856037|NCT00986557|Biological|alemtuzumab|
1856038|NCT00986557|Biological|in vitro-treated peripheral blood lymphocyte therapy|
1856039|NCT00986557|Drug|foscarnet sodium|
1856040|NCT00986557|Drug|ganciclovir|
1856041|NCT00986557|Genetic|polymerase chain reaction|
1856042|NCT00986557|Procedure|allogeneic hematopoietic stem cell transplantation|
1856043|NCT00986557|Procedure|infection prophylaxis and management|
1856044|NCT00986557|Procedure|peripheral blood stem cell transplantation|
1856049|NCT00986596|Dietary Supplement|vitamin D3|4000 IU once daily by mouth for 4 months
1856050|NCT00986596|Dietary Supplement|Placebo|microcrystalline cellulose capsule p.o. daily (identical to vitamin D capsule)
1856051|NCT00986609|Biological|MUC-1 peptide vaccine|Given subcutaneously
1856052|NCT00986609|Biological|poly ICLC|Given intramuscularly
1856053|NCT00986609|Biological|MUC1 peptide-poly-ICLC adjuvant vaccine|Receive adjuvant vaccination
1856054|NCT00986609|Other|laboratory biomarker analysis|Correlative studies
1856055|NCT00986609|Other|enzyme-linked immunosorbent assay|Correlative studies
1856056|NCT00986609|Other|flow cytometry|Correlative studies
1856057|NCT00986661|Drug|PV-10 (10% rose bengal disodium)|Subjects will receive a single injection of PV-10 to a single Target Lesion (0.25 mL PV-10 per cc lesion volume, Lv, or 0.50 mL PV-10 per cc Lv).
1856058|NCT00986674|Biological|cixutumumab|Given IV
1856059|NCT00986674|Drug|carboplatin|Given IV
1856060|NCT00986674|Drug|paclitaxel|Given IV
1856061|NCT00986674|Biological|cetuximab|Given IV
1856062|NCT00986700|Dietary Supplement|late night meal|Three different kinds of late night meal each for 2 days.
1856063|NCT00986713|Drug|Amphotericin B|Aerosolized Amphotericin B,2mg/day or 10mg/day
1856064|NCT00986752|Device|Stenting (Smart Stent)|Nitinol stent
1856065|NCT00986752|Device|Stenting after PEB (Smart Stent, Invatec)|Stenting (nitinol stent) after dilation with Paclitaxel-eluting balloon (PEB).
1856066|NCT00986752|Procedure|Atherectomy (SilverHawk device)|Atherectomy
1856067|NCT00986765|Drug|Lovenox® (enoxaparin)|Injectable solution 4000 UI
1856068|NCT00986765|Drug|Aspegic ® (Aspirin)|100 mg/day
1856069|NCT00986778|Drug|Lamivudine|Tablets, Oral, 100mg, once daily, 48-96 weeks depending on response
1856070|NCT00986778|Drug|Entecavir|Tablets, Oral, 1mg, once daily, 48-96 weeks depending on response
1856071|NCT00986778|Drug|Adefovir|Tablets, Oral, 10mg, once daily, 48-96 weeks depending on response
1856072|NCT00986791|Other|Gold Standard Programme for Alcohol Cessation Intervention|6-week Gold Standard Programme (5 meetings in total) consisting a structured education programme, hotline, thiamine and B-vitamins (300 mg daily), Alcohol Withdrawal Prophylaxis and intervention (Benzodiazepines)and controlled Disulfiram support (200 mg x 2 weekly)
1856073|NCT00986804|Drug|Decitabine|
1856074|NCT00986817|Drug|Terlipressin|Albumin perfusions at the dose 8 g/l of removed ascites and Terlipressin (1mg), administrated before and at the end of the paracentesis.
1856075|NCT00986817|Drug|Placebo|albumin perfusion at the dose 8 g/l of removed ascites and placebo, administrated before and at the end of the paracentesis.
1856076|NCT00986830|Device|FinESS Sinus Treatment|
1856077|NCT00986843|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
1856078|NCT00986856|Drug|Fucidin® cream|
1856079|NCT00986869|Procedure|Doppler echocardiogram|All the patients will undergo a Doppler echocardiogram in the day of the bronchoscopy after the bronchoscopy
1856080|NCT00986882|Drug|SAF312A|
1856081|NCT00986882|Drug|Placebo|
1856082|NCT00986882|Drug|Ibuprofen|
1856083|NCT00986895|Drug|HPN-100|HPN-100 is a triglyceride that has a similar mechanism of action as NaPBA. It is a liquid with minimal taste and odor. HPN-100 is broken down to phenylbuteric acid (PBA). PBA is converted to phenylacetic acid (PAA) that is the active metabolite. Three teaspoons of HPN-100 (~17.4mL) delivers an equivalent amount of PBA to40 tablets of NaPBA.
1856084|NCT00986921|Drug|mifepristone 200 mg|mifepristone would be given the day before the procedure
1856085|NCT00986921|Device|osmotic dilator insertion|osmotic dilators (3-6) would be inserted as usual the day before the procedure
1856086|NCT00986947|Drug|IVIg and rituximab|"A maximum of four doses (each single dose being 2gm/kg) of IVIg will be administered over a four-month period, with one dose administered each month. Each single dose of 2gm/kg will be administered in two half-doses (1gm/kg each) to be given one day apart, with one day of hemodialysis on the intervening day between the two half-doses.
If a compatible kidney transplant organ offer is received, upon admission to the hospital and immediately prior to the transplant operation, patients will receive a single infusion of Rituximab (375 mg/m2 BSA)."
1856087|NCT00986960|Drug|repository corticotropin injection|IM ACTH: 80 units of Acthra gel I.M. once a day for 5 consecutive days at study time points 0, 3, 6, 9, and 12 months
1856088|NCT00986960|Drug|Saline|I.M. placebo - 1ml of saline I.M. once per day for 5 consecutive days at 0, 3, 6, 9, and 12 months.
1856089|NCT00986973|Drug|Sapropterin|All subjects will receive 20 mg/kg/day Sapropterin (KUVAN) for four months. Subjects will be examined with fluorodeoxyglucose positron emission tomography (FDG-PET) brain imaging, physical and neurological exam, blood tests for phenylalanine (Phe) and tyrosine levels, and neuropsychological testing before and 4 months after KUVAN therapy. Subjects Phe and tyrosine levels will be monitored weekly during the study and subjects will keep 3-day diet records to allow for calculation of Phe intake.
1856090|NCT00986986|Drug|extended release niacin|Active arm subjects will start extended release niacin (Niaspan) at 500 mg per night (by mouth once a daily) and titrate to a maximum tolerated dose (not exceeding 1500 mg per night (by mouth once a day) for 12 weeks. Titration will depend on patient tolerability of Niaspan.
1856091|NCT00986999|Drug|rosuvastatin|rosuvastatin 20 mg tablet, 1/2 tab qd increased to a full tablet qd as tolerated x 6 months with optional extension to 2 years
1856092|NCT00987012|Dietary Supplement|Pomegranate juice|Twice daily ingestion of pomegranate juice over 4-5 days
1856093|NCT00987012|Dietary Supplement|Placebo drink|Twice daily ingestion of placebo drink over 4-5 days
1856094|NCT00987025|Behavioral|Telehealth|Use of telehealth blood pressure station every week
1856095|NCT00987025|Behavioral|Educational materials|Control
1856096|NCT00987038|Drug|PF-04171327 25 mg|One 25 mg tablet administered once a day for 15 days
1856097|NCT00987038|Drug|Midazolam 2 mg|Midazolam oral syrup 2mg dose administered once on Day 1 and once on Day 15
1856098|NCT00987051|Procedure|Detection of sentinel node|Coelioscopy or laparotomy (based on the tumor size) after a colorimetric tracer injection
1856186|NCT00987675|Procedure|assessment of therapy complications|
1856187|NCT00987675|Procedure|high-intensity focused ultrasound ablation|
1856188|NCT00987675|Procedure|quality-of-life assessment|
1856099|NCT00987064|Device|Temperature controlled Laminar Airflow (Protexo)|The intervention is designed to reduce the allergen load in the patients breathing zone by vertically displacing the allergens, originating from the bed and the ambient room environment, with a temperature controlled laminar airflow (TLA) during night sleep. The airflow is filtered through a high efficiency particulate air filter(HEPA), slightly cooled and ''showered'' over the subject. Due to the higher density, the cooled air descends slowly, and displaces the allergens from the breathing zone.
1856100|NCT00987064|Device|Placebo TLA|TLA treatment with disabled filtration function
1856101|NCT00987077|Device|Selective Retina Therapy (SRT)|SRT (pulsed double-Q-switched Nd-YLF laser, wavelength 527 nm, t=1.7 µs, energy 100-370 μJ).
1856102|NCT00987090|Biological|Clinic and neuropsychologic evaluation|evaluation at the inclusion and 18 months after
1856103|NCT00987090|Radiation|MRI|intervention at the inclusion and 18 months after
1856104|NCT00987090|Procedure|PET|18-FDG (18-fluoro-2-deoxyglucose)PET imaging of the brain at the inclusion and 18 months after.
1856105|NCT00987090|Biological|Apolipoprotein E genotyping|genotyping at the inclusion
1856106|NCT00987090|Biological|Study of cerebrospinal fluid|intervention at the inclusion
1856107|NCT00987103|Drug|Tacrolimus|Oral: 0,1 mg/kg Rectal: 15 mg Sublingual: 0,04 mg/kg
1856109|NCT00987142|Drug|CX501|Cultured chimeric skin
1856110|NCT00987142|Device|Occlusive non adherent dressing|Application of an occlusive non adherent dressing in the skin donor site
1856111|NCT00987155|Device|Ergometry|MetamaxII Cortex ergospirometry system (Cortex Biophysik GmbH, Germany). Arm cycling ergometer (Ergomed 840L, Siemens, GermanyMonark, Sweden), Electrically braked wheelchair ergometer (VP 100, Handisoft France)
1856112|NCT00987168|Drug|Sandostatine LP|Intramuscular injection of Sandostatine LP, once per month Dosage : 10 mg, 20 mg, 30 mg
1856113|NCT00987207|Drug|cyclosporine A|a single bolus of 2.5 mg/kg, administered before aortic cross-declamping
1856114|NCT00987207|Other|No injection|No cyclosporine A is administered before aortic cross-declamping.
1856115|NCT00987220|Drug|Placebo|Oral
1856116|NCT00987220|Drug|donepezil (Aricept)|5mg oral
1856117|NCT00987233|Drug|triamcinolone acetonide aqueous nasal spray (Apotex Inc.)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
1856118|NCT00987233|Drug|triamcinolone acetonide aqueous nasal spray (Nasacort® AQ)|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
1856119|NCT00987233|Drug|Placebo|It is to be self-administered; the dosing regimen will be 2 sprays (actuations) into each nostril, once daily. This is the dosing regimen during placebo lead-in and randomized treatment phases. Each actuation of active treatment is equivalent to 55 ug of triamcinolone acetonide, for a total daily dose of 220ug triamcinolone acetonide per day.
1856120|NCT00987246|Drug|Placebo Gel|Topical
1856121|NCT00987246|Drug|LAS41005|Topical
1856122|NCT00987246|Drug|LAS106521|Topical
1856123|NCT00987272|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
1856124|NCT00987272|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.1%|
1856125|NCT00987272|Drug|Olopatadine 0.2% Vehicle|Inactive ingredients used as placebo comparator
1856126|NCT00987272|Drug|Olopatadine 0.1% Vehicle|Inactive ingredients used as placebo comparator
1856127|NCT00987285|Behavioral|CASM +|Computer Assisted Self Management plus Social Support
1856128|NCT00987285|Behavioral|CASM|Computer Assisted Self Management using and interactive, automated self-management program that uses web and interactive voice recognition (IVR) media
1856129|NCT00987298|Device|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
1856130|NCT00987311|Dietary Supplement|1- Dairy drink containing probiotics A|1- Dairy drink containing probiotics A
1856131|NCT00987311|Dietary Supplement|2- Dairy drink containing probiotics B|2- Dairy drink containing probiotics B
1856132|NCT00987311|Dietary Supplement|3- Dairy drink without probiotics (control)|3- Dairy drink without probiotics (control)
1856133|NCT00987324|Device|Taxus stent|Implantation of paclitaxel-eluting stent
1856134|NCT00987324|Device|SeQuent Please|Dilation with SeQuent Please (paclitaxel-eluting balloon)
1856135|NCT00987324|Device|Conventional Balloon Catheter|Ryuijin, Trek
1856136|NCT00987337|Drug|Filibuvir|300 mg BID
1856137|NCT00987337|Drug|Filibuvir|600 mg BID
1856138|NCT00987337|Drug|Placebo|BID
1856139|NCT00987350|Device|LectraJet|LectraJet is a new jet injector studied for the first time in humans. It is in the category known as disposable-syringe jet injectors that have the advantage of eliminating the risk of disease transmission between subjects. A new syringe and nozzle is used for each patient so that no splash back of blood can occur onto the jet apparatus itself.
1856140|NCT00987350|Device|TIV by jet injection|Administration of seasonal trivalent influenza vaccine (TIV) by jet injection
1856141|NCT00987350|Biological|Seasonal Trivalent Influenza Vaccine|Licensed trivalent influenza vaccine provided by either jet injection or traditional needle and syringe.
1856142|NCT00987363|Other|Intraarterial infusion of autologous bone marrow cells|Autologous bone marrow-derived mononuclear cells will be infused by an intraarterial catheter into de ischemic limb. The number of infused cells will be 1x10 E8, 5x10E8 and 1x10 E9 in the low,intermediate and high dose arms respectively
1856143|NCT00987376|Device|Diagnostic Imaging: C11 choline PET; C11 acetate PET; and MRI Spectroscopy|C11 Choline, C11 Acetate PET and MRI
1856146|NCT00987402|Other|Plain soap and water (PSW)|Presence or absence of infection
1856147|NCT00987402|Other|Alcohol-based hand rub (ABHR)|Presence or absence of infection
1856148|NCT00987415|Drug|allopurinol|Allopurinol 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
1856149|NCT00987415|Drug|sugar pill|Matching placebo 300 mg daily for one week, then 600 mg daily to complete 24 weeks.
1856150|NCT00987428|Procedure|ultrasonography with or not sphincterotomy|Early endoscopic ultrasonography and endoscopic sphincterotomy in case of common bile duct stone
1856151|NCT00987428|Procedure|Usual procedure|The control group includes patients with predicted severe ABP undergoing conservative treatment or endoscopic sphincterotomy (without EUS) within 72 hours of the onset of symptoms in case of cholangitis or biliary obstruction.
1856152|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.3 microgram
1856153|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.4 microgram
1856154|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.125% plus sufentanil 0.5 microgram
1856155|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.0625% plus sufentanil 0.4 microgram
1856156|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.1875% plus sufentanil 0.4 microgram
1856157|NCT00987441|Drug|Ropivacaine and sufentanil|Ropivacaine 0.25% plus sufentanil 0.4 microgram
1856158|NCT00987454|Drug|Epoetin Alfa|40,000 IU given as subcutaneous injection weekly up to 3 doses
1856159|NCT00987454|Drug|Sodium Chloride 0.9%|1 m/L given as subcutaneous injection weekly up to 3 doses
1856160|NCT00987467|Drug|Cyclosporin 0.05% ophthalmic|Cyclosporine 0.05% ophthalmic solution, 1 drop 6 times in both eyes daily for first month, then 1 drop 4 times in both eyes daily for next month, then dosage was adjusted based on clinical disease by investigator.
1856161|NCT00987467|Drug|Cyclosporin 0.05% ophthalmic|ophthalmic topical eye drop
1856162|NCT00987480|Drug|Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine.|There are three parts in this transplant study. 1) There will be a pre-transplant - preparation - period to see if patient qualifies for the transplant study. This will be done as an outpatient and lasts 2-4 weeks. Once this is completed, there will be 2) the transplant period itself, during which the patient will be admitted and will be an inpatient. This period usually last for 4-6 weeks. Following that, there will be a 3) post transplant period, during which the patient will be watched carefully and monitored in clinic as an out patient. The post transplant period lasts from three months to one year.
1856163|NCT00987480|Device|CliniMACS device|CD34+ T-cell depleted peripheral blood stem cell transplant
1856164|NCT00987493|Biological|rituximab|day 1 at a fixed dose of 375mg/m2
1856165|NCT00987493|Drug|bendamustine hydrochloride|Bendamustine at day 1 and 2 according to the dose escalation in phase I, and at the recommended dose in phase II: 70mg/m2.
1856166|NCT00987493|Drug|lenalidomide|Lenalidomide at days 1-21 according to the dose escalation in phase I, and at the recommended dose in phase II: 10mg
1856167|NCT00987506|Device|XIENCE V®|Participants with placement of a XIENCE V® EESS
1856168|NCT00987532|Behavioral|parent-focused intervention|The core of the parent-focused intervention is a menu of 15 easy to realize project ideas to promote the everyday physical activity of children and families. The 15 ideas are presented to the parents and teachers via a webpage, a printed book and a film. During a face-to-face meeting, parents and teachers are guided into discussions of their own preschool environment's and community's physical activity shortcomings and encouraged to generate their own ideas of how to enhance the physical activity of their families and preschools. Over the course of three structured follow-up meetings, parents and teachers are instructed to choose maximally 3 to 4 ideas from either the menu or the network's own ideas, and then are empowered to realize and implement them together.
1856169|NCT00987532|Behavioral|twice weekly gym lessons|twice weekly one-hour gym lessons delivered by a specially trained external physical education teacher over 6 months
1856170|NCT00987545|Drug|QAX576|QAX576 injection
1856171|NCT00987545|Drug|QAX576 placebo|Placebo to QAX576 injection
1856172|NCT00987558|Drug|Eslicarbazepine acetate|
1856173|NCT00987558|Drug|Simvastatin|
1856174|NCT00987597|Behavioral|Technique of in-vivo exposure (cigarette) and mental image exposure (craving)|Nicotine replacement
1856175|NCT00987597|Behavioral|conventional follow-up|nicotinic substitutes
1856176|NCT00987610|Device|Percutaneous coronary intervention (PCI)|PCI for chronic total occlusion is performed using either arm of guidewire
1856177|NCT00987623|Device|nelfilcon A contact lens|Commercially marketed, hydrogel, single-vision contact lens for daily wear, daily disposable use.
1856178|NCT00987623|Device|narafilcon A contact lens|Commercially marketed, silicone hydrogel, single-vision contact lens for daily wear, daily disposable use.
1856179|NCT00987636|Drug|Zoledronic acid|"intravenously at 28 day intervals beginning with cycle 6 of VAC/VAI consolidation chemotherapy for a total period of nine months.
Patients < 18 years will receive 0.05 mg/kg BW by IV infusion 30 min-1 h.
Patients >= 18 years will receive a bodyweight-dependent dose:
Patients >40kg receive 4 mg by IV infusion 30 min-1h Patients 20-40 kg receive 2 mg by IV infusion 30 min-1h"
1856180|NCT00987636|Drug|Busulfan|intravenously, day -6 to d -3 adults: 0.8 mg/kg body weight (BW) children and adolescents: <9 kg= 1mg/kg BW 9 - <16 kg= 1.2 mg/kg BW 16 - 23 kg= 1.1 mg/kg BW >23 - 34 kg= 0.95 mg/kg BW >34 kg = 0.8 mg/kg BW
1856181|NCT00987636|Drug|Treosulfan|12 g/m² d-5 to d-3
1856182|NCT00987662|Drug|Irbesartan|Treatment with irbesartan 300mg for 4 weeks. IF ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg.
1856183|NCT00987662|Drug|Amlodipine|Treatment with amlodipine 10 mg for 4 weeks. If ABP>135/85 mmHg add hydrochlorothiazide 12.5 mg
1856184|NCT00987675|Other|pharmacological study|
1856185|NCT00987675|Other|questionnaire administration|
1856189|NCT00987688|Other|Hypothermia|exposure: Early and sustained hypothermia. Hypothermia will initially be induced by infusion of up to 2L ice cold saline. Following a safety assessment the patient will be rapidly cooled to 33C using surface temperature control equipment. They will be maintained at 33C for 72 hours. Rewarming will occur at a rate of 1C/4hrs and will be titrated to intracranial pressure (ICP) control and BP.
1856190|NCT00987701|Drug|Ringer's Lactate|Ringer's Lactate 8 ml/kg was given intravenously before or after epidural, spinal or CSEA in cesarean section
1856191|NCT00987701|Drug|Six percent hydroxyethyl starch|Hydroxyethyl starch (6%) was given before or after epidural, spinal or CSEA in cesarean section
1856192|NCT00987714|Procedure|Protocolized care|Organ Procurement Coordinators will utilize a hemodynamic monitor and algorithm for donor management of cardiac index, pulse pressure variation and mean arterial pressure.
1856193|NCT00987727|Drug|carboxymethylcellulose 0.5% , glycerin 0.9% (OPTIVE® MD)|One drop in each eye three to six times daily, as needed
1856194|NCT00987727|Drug|sodium hyaluronate 0.18% (VISMED® Multi)|One drop in each eye three to six times daily, as needed
1856195|NCT00987740|Device|Hemolung Respiratory Assist System|Patients meeting the inclusion criteria will be placed on the Hemolung Respiratory Assist System. Patients will be weaned from non-invasive ventilation and then the Hemolung. Hemolung support will be provided for up to 7 days. Follow-up exams will be performed every 15 days until hospital discharge or 30 days from completion of Hemolung therapy, whichever is later.
1856196|NCT00987753|Drug|L-377202|For each cycle, L-377202 will be administered as a 30-minute infusion every 3 weeks. The starting dose will be 20 mg/m2/week. Doses will be doubled until a patient experiences a greater than or equal to Grade 2 toxicity.
1856197|NCT00987766|Drug|erlotinib hydrochloride|Taken daily by mouth for 6 days every other week.
1856198|NCT00987766|Drug|gemcitabine hydrochloride|Given through a vein in the arm 1 time every other week.
1856199|NCT00987766|Drug|oxaliplatin|Given through a vein in the arm 1 time every other week.
1856200|NCT00987766|Other|laboratory biomarker analysis|Blood and tissue collection.
1856201|NCT00987779|Drug|Gabapentin|Period I: Tablet in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
1856202|NCT00987779|Drug|Gabapentin|Period I: Liquid formulation in fasting state(400 mg single dose on Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period II: Tablet in fasting state(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period), Period III: Liquid formulation(400 mg single doseon Day 1 only of each Period; subjects stay in clinic for a total of 4 days for each period) in fed state
1856203|NCT00987792|Drug|Moxifloxacin (Avelox, BAY12-8039)|Hospitalized patients receiving Avelox according to local drug information
1856204|NCT00987805|Dietary Supplement|Banhasasim-tang|Form : granules Contents : It consists of seven Herbs. It contains Rhizoma Pinelliae, Radix Scutellariae, Zingiberis Rhizoma, Panax ginseng, Glycyrrhiza uralensis Fisch, Zizyphi Fructus and Coptidis Rhizoma Dosage and frequency : 9g per day (three times a day) Route of administration : Oral Administration duration : 42 days in the study
1856205|NCT00987805|Dietary Supplement|Corn-starch granules|This placebo has the same form, color, and flavor as experimental intervention.The dosage, frequency and duration is also same as experimental intervention.
1856206|NCT00987818|Other|Procalcitonin measurement|Daily procalcitonin measurement. Antibiotic discontinuation policy dependent on procalcitonin value. In the control group standard duration of antibiotic therapy.
1856207|NCT00987831|Other|Group B SLE one blood donation|Blood drawing, history, physical examination,medical record review, questionnaires, completion of disease activity measures including SLEDAI,BILAG, CLASI,PGA,PROs,LFA investigational systems, BICLA, SRI
1856208|NCT00987831|Other|Blood drawing only Group C|Blood drawing and Brief medical history to ensure status of healthy control
1856209|NCT00987831|Drug|Group A SLE prospective study|Patients have history and physical exmamination at each visit. Blood is drawn at each visit. At baseline, any background immune suppressant is stopped and patients given depomedrol up to 160 mg IM which can be repeated up to four times in the first two weeks. Patients are seen again at week 2, 4 and monthly until the final flare visit at which time they donate blood, receive appropriate treatments and exit study. Patients may elect to continue in study for up to one year. The following disease activity measures are included: SLEDAI, BILAG, CLASI, PGA, PROs (including lupus PRO and SF-36 ant ptGA), joint counts, exploratory outcome measures,BICLA,SRI
1856210|NCT00987844|Drug|Prucalopride|1 mg tablets, free dosing regiment with max. of 4 tablets o.d., treatment duration: up to 24 months
1856211|NCT00987857|Procedure|2 yearly endoscopy|2 yearly endoscopy versus endoscopy at need
1856212|NCT00987857|Procedure|comparison of screening methods|2 yearly endoscopy versus endoscopy at need
1856213|NCT00987857|Procedure|diagnostic endoscopic procedure|2 yearly endoscopy versus endoscopy at need
1856214|NCT00987857|Procedure|endoscopic biopsy|2 yearly endoscopy versus endoscopy at need
1856215|NCT00987857|Procedure|endoscopic procedure|2 yearly endoscopy versus endoscopy at need
1856216|NCT00987857|Procedure|quality-of-life assessment|QOL aims to elicit any differences in QOL between 2 yearly endoscopy versus endoscopy at need
1856217|NCT00987857|Procedure|screening method|All Barretts patients to be screened
1856218|NCT00987870|Drug|BFH772|
1856219|NCT00987870|Drug|Placebo|
1856220|NCT00987870|Drug|BFH772|
1856221|NCT00987870|Drug|Placebo|
1856222|NCT00987870|Drug|calcipotriol/betamethasone|
1856223|NCT00987896|Device|Colonoscopy with Megachannel™ device loaded|Before colonoscopy, megachannel is loaded on the endoscope, during colonoscopy megachannel will be inserted into the patient via the endoscope placed in the colon
1856224|NCT00987909|Biological|Specific allergen immunotherapy (placebo)|Drops for sublingual administration, 0 mcg (placebo), once daily administration for 16 weeks
1856225|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 4.5 mcg Fel d1/day, once daily administration for 16 weeks.
1856321|NCT00994305|Drug|N-acetylcysteine|600 mg bid po 0-7 PO
1856226|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 9.0 mcg Fel d1/day, once daily administration for 16 weeks
1856227|NCT00987909|Biological|Specific allergen immunotherapy|Drops for sublingual administration, 18.0 mcg Fel d1/day, once daily administration for 16 weeks
1856228|NCT00987922|Device|Hypothermia|Hypothermia to core temperature of 35C for 12 hours, rewarming rate 0.2C until the patient reaches 36.8C
1856229|NCT00987935|Drug|Sorafenib|400 mg twice daily
1856230|NCT00987935|Drug|BIBF 1120|Twice daily
1856231|NCT00987948|Drug|maraviroc (Selzentry)|dosage varies with other medications being taken; will follow package insert guidelines
1856232|NCT00987961|Behavioral|Linkage|This intervention provides an outpatient appointment with a Suboxone provider for medically hospitalized opioid-dependent patients to attend post-discharge.
1856233|NCT00987974|Drug|rosuvastatin|rosuvastatin 20 mg/day for 3 days.
1856234|NCT00987974|Drug|atorvastatin 3 days|atorvastatin 80 mg/day for 3 days.
1856235|NCT00987974|Drug|placebo|placebo for 3 days.
1856236|NCT00987974|Drug|rosuvastatin 7 days|rosuvastatin 20 mg/day for 7 days
1856237|NCT00987974|Drug|atorvastatin 7 days|atorvastatin 80 mg/day for 7 days.
1856238|NCT00987974|Drug|placebo 7 days|placebo 7 days
1856239|NCT00987987|Procedure|donor lymphocyte infusion|regulatory T cells depletion
1856240|NCT00988000|Other|telephone consultation|alternative to face to face consultation for new referrals
1856241|NCT00988013|Radiation|IM-TMI (3Gy)|Patients will receive 3Gy per day for 1 day.
1856242|NCT00988013|Radiation|IM-TMI (6Gy)|Patients will receive 3Gy per day for 2 days.
1856243|NCT00988013|Radiation|IM-TMI (9Gy)|Patients will receive 3Gy per day for 3 days.
1856244|NCT00988013|Radiation|IM-TMI (12Gy)|Patients will receive 3Gy per day for 4 days.
1856245|NCT00988026|Drug|Minocycline vs Lymecycline|Minocycline 100 mg OD per mouth for 8 weeks. Lymecycline 300 mg OD per mouth for 8 weeks.
1856246|NCT00988039|Drug|Aluvia + 2NRTIs|"Aluvia (lopinavir/ritonavir 400mg/100mg), twice daily
The choice of NRTIs will be at the discretion of the managing clinician and based on the local standard of care and drug availability, taking into account patient's previous drug exposure and side effects on first-line therapy."
1856247|NCT00988039|Drug|Aluvia + raltegravir|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily
raltegravir (400mg) twice daily"
1856248|NCT00988039|Drug|Aluvia monotherapy|"Aluvia (lopinavir/ritonavir 400mg/100mg) twice daily
raltegravir (400mg) twice daily for the first 12 weeks only"
1856249|NCT00988052|Drug|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
1856250|NCT00988065|Drug|Placebo run-in dose|Single-blind placebo intravenous bolus injection on Day 1 of the study, 7 days prior to randomization
1856251|NCT00988065|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
1856252|NCT00988065|Drug|Sugammadex 16 mg/kg|Sugammadex 16 mg/kg intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
1856253|NCT00988065|Drug|Placebo|Placebo intravenous bolus injection on Day 8, Day 36, and Day 78 of the study
1856254|NCT00988078|Drug|Placebo|Capsule (without biologic action) administered three times a day for six months
1856255|NCT00988078|Drug|Metformin|Metformin 500mg three times a day for six months
1856256|NCT00988091|Device|1.2% Sodium Hyaluronate|IA-BioHA is supplied in a disposable 7 ml nominal volume glass syringe containing 60 mg/5 ml of 1.2% sodium hyaluronate. Participants are given a single injection in the target knee on Day 1 of the double-blind period and optionally on the first day of the open-label period (approximately week 27).
1856257|NCT00988091|Device|Buffered Saline|IA-SA is supplied in a disposable 7 ml nominal volume glass syringe containing 5 ml of phosphate buffered saline. Participants are given a single injection in the target knee on Day 1 of the double-blind period.
1856258|NCT00988104|Behavioral|Cognitive Behavioral Therapy|CBT (4 sessions): 1) Cognitive therapy targeting key appraisals. 2) Prolonged exposure targeting trauma memories and reminders. 3) Active coping/Anxiety Management training mindfulness-based techniques.
1856259|NCT00988104|Behavioral|Supportive Counseling|Supportive counseling (4 sessions): common factors among effective psychotherapies (e.g., empathy, positive regard)
1856260|NCT00988117|Drug|Rivastigmine Patch 9.5 cm2|Subjects will be started on a 5cm2/24hr rivastigmine patch. After 4 weeks, the dose will be increased to a recommended target dose of 9.5cm2/24hr patch for 8 additional weeks.
1856261|NCT00988130|Other|laboratory biomarker analysis|
1856262|NCT00988130|Other|questionnaire administration|
1856263|NCT00988130|Procedure|assessment of therapy complications|
1856264|NCT00988130|Procedure|high-intensity focused ultrasound ablation|
1856265|NCT00988130|Procedure|quality-of-life assessment|
1856266|NCT00988143|Biological|2009-2010 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular (participants at 6 to 35 months of age - Pediatric Dose); Others 0.5 mL, Intramuscular.
1856267|NCT00988143|Biological|2008-2009 Trivalent Influenza Virus Vaccine|0.25 mL, Intramuscular; 0.5 mL, Intramuscular.
1856268|NCT00988143|Biological|Quadrivalent Influenza Virus Vaccine|0.5 mL, Intramuscular
1856269|NCT00988156|Drug|Eslicarbazepine acetate (BIA 2-093)|"Part I - 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.
The recommended target dose of double-blind study treatment will be 20mg/kg/day.
Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
1856270|NCT00988156|Drug|Eslicarbazepine acetate|"Part I: 8-week observational baseline period followed by a 6-week double-blind titration period, a 12-week double-blind maintenance period, a double-blind tapering-off period, and a 4-week observational period.
Part II: At the end of part I, there is an option to enter a long-term open-label extension period to receive Eslicarbazepine acetate for 1 year."
1856322|NCT00994305|Drug|control|No treatment: standard care provided. No N-acetylcysteine administration.
1856323|NCT00994318|Drug|FCM (Ferric carboxymaltose) high ferritin target|
1856324|NCT00994318|Drug|FCM (Ferric carboxymaltose) low ferritin target|
1856325|NCT00994318|Drug|Oral Iron (Ferrous sulphate)|
1856326|NCT00994331|Procedure|Percutaneous coronary intervention|non surgical procedure to open blocked coronary arteries
1856271|NCT00988169|Drug|oral erlotinib and pulsed doses of oral AT-101|Patients will receive oral erlotinib 100 mg daily and pulsed doses of oral AT-101 given 40 mg twice daily on days 1-3 of a 21-day cycle. If the initial combination of erlotinib and AT-101 is tolerated, dose escalation of erlotinib to 150 mg daily will be allowed at the discretion of the treating investigator at the start of cycle 2. Patients will continue receiving treatment on study until they refuse further therapy, develop evidence of progressive disease, or develop unacceptable toxicity or a medical condition that would, in the judgment of the investigator,
1856272|NCT00988182|Other|dietary intervention|whey protein
1856273|NCT00988182|Other|water control|
1856274|NCT00988195|Biological|Pegylated Recombinant Human Arginase I|Week 1 (Single Dose); Weeks 3 - 11 (Weekly Dose x 8 weeks)in 8 escalation doses
1856275|NCT00988195|Drug|Doxorubicin|Weeks 13-24 (once every 3 weeks)
1856276|NCT00988208|Drug|Lenalidomide|25 mg lenalidomide orally once each day on Days 1-14
1856277|NCT00988208|Drug|Docetaxel|75 mg/m2 intravenous docetaxel on Day 1
1856278|NCT00988208|Drug|Prednisone|5 mg prednisone orally twice daily on each day of the treatment cycle
1856279|NCT00988208|Drug|Placebo|Oral placebo once each day on Days 1-14 of the treatment cycle
1856280|NCT00988221|Drug|Tocilizumab|Tocilizumab was supplied as a sterile solution in vials.
1856281|NCT00988221|Drug|Placebo|Placebo to tocilizumab was supplied as a sterile solution in vials.
1856282|NCT00988234|Procedure|SGPP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under prone position
1856283|NCT00988234|Procedure|SGTPP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under prone position
1856284|NCT00988234|Procedure|SGLP|ultrasound guided posterior lumbar plexus block and subgluteal sciatic nerve block under lateral decubitus position
1856285|NCT00988234|Procedure|SGTLP|ultrasound guided posterior lumbar plexus block and sub-greater trochanter approach under lateral decubitus position
1856286|NCT00988247|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 30-weeks (or 52-weeks, depending upon investigator site).
1856287|NCT00988247|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 30-weeks (or 52-weeks, depending upon investigator site).
1856288|NCT00988260|Drug|Ganirelix|Ganirelix 0.125 mg subcutaneous daily (SC OD) for up to 14 days
1856289|NCT00988260|Drug|Ganirelix|Ganirelix 0.25 mg subcutaneous daily (SC OD) for up to 14 days
1856290|NCT00988260|Drug|Ganirelix|Ganirelix 0.5 mg subcutaneous daily (SC OD) for up to 14 days
1856291|NCT00988273|Device|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the control group will be compared to the diseased group.
1856292|NCT00988273|Device|Confocal endomicroscopy|Patients will undergo confocal endomicroscopy during their endoscopy, and findings of the confocal endomicroscopy in the diseased group will be compared to the control.
1856293|NCT00988286|Procedure|CEP, MEP, TMS|Patients and healthy volunteers will undergo cortical evoked potentials (CEP), motor evoked potentials (MEP) and transcranial evoked potentials (TMS).
1856294|NCT00988299|Other|exercise|exercise sessions at 45% and 60% of maximum effort
1856295|NCT00988312|Biological|autologous idiotype-protein pulsed dendritic cells|Vaccination with autologous idiotype-protein pulsed dendritic cells on 5 occasions every 4 weeks
1856296|NCT00988325|Drug|Tamiflu|oral repeating dose
1856297|NCT00988338|Biological|Trinity Evolution|Novel Allogeneic, Cancellous, Bone Matrix Containing Viable Stem and Osteoprogenitor Cells
1856298|NCT00988351|Device|Continuous positive airway pressure|continuous positive airway pressure determined by polysomnography titration
1856299|NCT00988351|Device|Auto-adjusting positive airway pressure treatment|Pressure range 4-18 centimeters of water (cm H2O)
1856300|NCT00988364|Drug|Simvastatin|Simvastatin 20mg daily for 3 months.
1856301|NCT00988364|Drug|Vytorin|Vytorin 20/10mg daily for 3 months.
1856302|NCT00988364|Drug|Placebo|Placebo one tablet daily times 3 months.
1856303|NCT00988364|Drug|Ezetimibe|Ezetimibe 10mg daily for 3 months.
1856304|NCT00988377|Other|dietary intervention|whey protein 10-40 g
1856305|NCT00988377|Other|water control|Iso-volumetric (300 ml) water control (Crystal Springs, Canada)
1856306|NCT00988390|Behavioral|Cognitive-behavioral, small-group format sessions|The intervention was delivered in either English- or Spanish-speaking groups of 5 to 8 mothers living with HIV twice weekly for 1.5 to 2 hours each over eight weeks (n = 16 sessions).
1856307|NCT00988403|Dietary Supplement|Fructan - 7.5|Subjects will consume 7.5 grams of fructan
1856308|NCT00988403|Dietary Supplement|Fructan - 10|Subjects will consume 10 grams of fructan
1856309|NCT00988403|Dietary Supplement|Fructan - 12.5|Subjects will consume 12.5 grams of fructan
1856310|NCT00988403|Dietary Supplement|Fructan -- 5 grams|Subjects will consume 5 grams fructan.
1856311|NCT00988416|Procedure|PET-CT|Pancreas Protocol PET-CT
1856312|NCT00994240|Procedure|Electrodessication & Curettage|Electrodessication & Curettage 1 or 3 cycles
1856313|NCT00994253|Drug|Aliskiren|Aliskiren will be prescribed at 150mg po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 300mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily.
1856314|NCT00994253|Drug|Hydrochlorothiazide|Hydrochlorothiazide will be prescribed at 12.5 po per day. If the subjects blood pressure is not controlled by week 5 the dose will be increased to 25mg po per day. All subjects will be prescribed lisinopril 40mg and amlodipine 5mg po daily
1856315|NCT00994266|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
1856316|NCT00994266|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks, in combination with the standard treatment consisting in two daily doses of insulin and proper diet.
1856317|NCT00994279|Behavioral|Yoga|Yoga sessions
1856318|NCT00994279|Behavioral|Education|Educational Wellness Group
1856319|NCT00994292|Drug|YM150|oral
1856320|NCT00994292|Drug|Placebo|oral
1856327|NCT00994344|Drug|Darunavir/ritonavir|Darunavir/ritonavir 800/100 mg once daily
1856328|NCT00994344|Drug|Lopinavir/ritonavir|Lopinavir/ritonavir 400/100 mg twice daily
1856329|NCT00994357|Device|Real-time CGM|See previous description.
1856330|NCT00994357|Other|Standard care|See text.
1856331|NCT00994383|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 15 mg tablet, morphine sulfate controlled release 120 mg
1856332|NCT00994396|Dietary Supplement|Placebo|Placebo soft gel pills (soy bean oil encapsulated in soft gel comprised of gelatin, glycerin and water) twice per day for 6 mos.
1856333|NCT00994396|Dietary Supplement|Vitamin D 3 cholecalciferol|4000 IU (2 soft gels at 2000 IU each) vitamin D3 per day for 6 months.
1856334|NCT00994422|Drug|Ivermectin cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1.
1856335|NCT00994422|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
1856336|NCT00994448|Drug|Bupropion SR 150mg tabs|Bupropion SR 150mg tabs (Zyban) twice daily
1856337|NCT00994448|Drug|Placebo tablets|One placebo tablet twice daily
1856338|NCT00994461|Drug|Celecoxib|Celecoxib 100mg tablet twice a day with meal for 2 weeks
1856339|NCT00994461|Drug|Loxoprofen|Loxoprofen 60mg tablet three times a day with meal for 2 weeks
1856340|NCT00994461|Drug|Placebo|Placebo tablet three times a day with meal for 2 weeks
1856341|NCT00994474|Procedure|Fractional carbon dioxide laser treatment|With the CO2 laser (Fraxel Re:pair, Solta Medical Inc., Hayward, CA), patients received two passes at 15 mJ (1st pass) and 20 mJ (2nd pass), respectively, with a total density of 20 %. We employed 'pin-point bleeding' and serosanguinous exudate as a clinical end point. The pulse duration was 10 msec.
1856342|NCT00994474|Procedure|Fractional Er:YAG laser treatment|The Er:YAG laser (MCL 30 Dermablate, Asclepion Laser Technologies GmbH, Jena, Germany) was used in 4 passes with a total fluence of 60 J/cm² and pulse stacking (6 stacked pulses); the pulse duration was 400 μsec.
1856343|NCT00994487|Other|High Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is high in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles
1856344|NCT00994487|Other|Low Energy Density Preload|Each child with a parent will attend a lunch session. In these sessions children will drink a liquid preload that is low in energy density and then they will consume an ad libitum lunch. The ad libitum lunch will be videotaped, and the videotapes will be coded for parental feeding styles.
1856345|NCT00994500|Drug|vorinostat|Given orally
1856346|NCT00994500|Drug|bortezomib|Given IV
1856347|NCT00994500|Other|pharmacological study|Correlative studies
1856348|NCT00994500|Other|laboratory biomarker analysis|Correlative studies
1856349|NCT00994513|Dietary Supplement|Alpha Lipoic Acid|1200 mg/day
1856350|NCT00994513|Dietary Supplement|Placebo|1200 mg/day
1856351|NCT00994526|Other|Ham|Ham : 180 g per day during 4 days
1856352|NCT00994526|Other|Ham + calcium|Ham : 160g/d during 4 days calcium : 1000mg/d during 4 days
1856353|NCT00994526|Other|Ham + vitamin E|Ham : 160g/d during 4 days Vitamin E : 80 mg/d during 4 days
1856354|NCT00994539|Drug|morphine sulfate|morphine sulfate 15 mg and 30 mg tablets
1856355|NCT00994552|Other|Pressure support ventilation|Pressure support ventilation
1856356|NCT00994552|Other|Pressure control ventilation|Pressure control ventilation
1856357|NCT00994565|Behavioral|Activity monitoring and distance counseling|The physical activity monitoring and distance counseling concept combines the use of a personal activity monitor with web-based tailored physical activity advice. Users can interactively plan and evaluate their own activity advice based on their actual PA scores and their PA preferences and goals.
1992892|NCT03279497|Behavioral|Sport and fitness application|Participants allocated to the Sport and fitness application intervention group get to use the sport and fitness application during the four week intervention period and participants are allowed to use it on their free time.
1856363|NCT00996853|Other|Safety follow up|Collection of reactogenicity data from diary cards, reporting of medically-attended adverse events, reporting of serious adverse events and adverse events of special interest, reporting of pregnancy outcomes and fatalities.
1992893|NCT03279458|Device|Linshom Respiratory Monitoring Device|Volunteers will breathe through a continuous positive airway pressure (CPAP) face mask fitted wth the Linshom device. The volunteers will be instructed to breathe normal through the CPAP mask on room air. The excursions of the thermistor tracings (from valley to peak) will be recorded by the Linshom device and displayed continuously on a laptop monitor in a waveform. The tidal volume will also be measured by the ventilator and the data downloaded in a Compact Flash card.
1992894|NCT03279367|Diagnostic Test|Objective speech response detection|Changes in brain activity when a speech stimulus is presented will be measured using electro-encephalography (EEG)
1856366|NCT00996879|Drug|Midazolam|Syrup, Oral, 5 mg, Single dose, 2 days
1856367|NCT00996879|Drug|BMS-791325|Capsules, Oral, 300 mg, Every 12 hours, 8 days
1856368|NCT00996892|Drug|Cobimetinib|Repeated oral dosing.
1856369|NCT00996892|Drug|Pictilisib|Repeated oral dosing.
1856370|NCT00996905|Device|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
1856371|NCT00996905|Device|Portable ultrasound machine|Each patient will have their lumbar spine scanned by ultrasound for a maximum period of 5 minutes.
1856372|NCT00996918|Drug|Bapineuzumab 0.5 mg/kg|Bapineuzumab I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
1856373|NCT00996918|Drug|Bapineuzumab 1.0 m/kg|I.V., 1.0 mg/kg, infusion every 13 weeks for a total of 16 infusions.
1856374|NCT00996931|Drug|lenalidomide|2.5 mgs per day orally for 12 weeks
1856406|NCT00997243|Biological|lintuzumab|Cycle 1 600mg as an IV infusion (flat dose for all), given on days 2, 7, 15, and 22. Subsequent Cycles (cycles to be repeated every 28 days) 600mg as an IV infusion, given every other week, twice during each cycle, including one dose given during AZA therapy. Doses should be given at least 12 days apart. By convention, dosing on days 7 and 22 of each cycle will be encouraged, but due to expected issues of patient convenience (time, travel, etc.), the study requirements are every other week, twice during each cycle, with one dose during AZA treatment.
1856375|NCT00996944|Drug|Ropinirole immediate release (IR)|"Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime. The maximum available dose is 3 mg/day. For all subjects completing short-term period and entering the long-term treatment period, the open-label treatment will be started from IR 0.25 mg/ day regardless of dose levels during short-term period. The dose will be upward titrated from 0.25 mg/day to 0.5 mg/day and after that in increments of 0.5 mg/day until sufficient efficacy is obtained (targeting much improved or very much improved in the CGI-I) without safety/tolerability problem."
1856376|NCT00996944|Drug|Placebo|Subjects completing the screening period will be randomized (1:1) to receive the IR or placebo for 12 weeks. The treatment will be started at the initial dose of 0.25 mg/day within 1 to 3 hours before bedtime.
1856377|NCT00996957|Biological|ACE-041|Subcutaneous dose of ACE-041 approximately once every 3 weeks for a total of 4 doses. If disease stays the same or gets better, additional study drug may be offered.
1856378|NCT00996983|Drug|ziconotide|intrathecal ziconotide starting at 2.4 micrograms/day, with titration daily to achieve adequate pain control up to maximum dose of 21.6 micrograms/day
1856379|NCT00996996|Biological|Tositumomab and Iodine I 131 Tositumomab (Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody)|"Dosimetric Dose: 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush) immediately followed by 5 mCi (35 mg) of Iodine-131 Anti-B1 Antibody infused over 30 minutes (inclusive of a 10-minute flush).
Therapeutic Dose: Seven to 14 days after the dosimetric dose, 450 mg of Anti-B1 Antibody infused over 70 minutes (inclusive of a 10-minute flush), immediately followed by the patient-specific milliCurie activity (35 mg) of Iodine-131 Anti-B1 Antibody to deliver a total body dose (TBD) of 75 cGy infused over 30 minutes (inclusive of a 10-minute flush). Obese patients were dosed based upon 137% of their calculated lean body mass."
1856380|NCT00997009|Drug|paclitaxel|175 mg/m2 IV day 1, every 21 days
1856381|NCT00997009|Drug|carboplatin|AUC 5 IV day 1 every 21 days
1856382|NCT00997009|Drug|cetuximab|400 mg/m2 IV, one week before starting carboplatin and paclitaxel; then 250 mg/m2 IV day 1, weekly
1856383|NCT00997022|Drug|Sorafenib|"Dose escalation:
Dose level 1: 200mg of sorafenib daily
Dose level 2: 200mg of sorafenib BID (twice daily)
Dose level 3: 200mg QAM (taken every morning) and 400mg QPM (taken every evening)
Dose level 4: 400mg BID (twice daily)"
1856384|NCT00997035|Drug|Voriconazole|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
400 mg BID PO on study day one (loading dose), then 200 mg BID PO until 3 weeks from enrollment for patients weighing greater than 50 kg. For patients 40-50 kg, the loading dose is 300 mg BID PO on study day 1, then 150 mg BID PO until 3 weeks from enrollment. For patients weighing <40 kg, the loading dose is 200 mg BID PO, then 100 mg BID PO until 3 weeks after enrollment."
1856385|NCT00997035|Drug|Placebo|"1% voriconazole (topical) plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
5% natamycin (topical), 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
Two tablets BID PO on study day one, then one tablet BID PO until 3 weeks from enrollment."
1856386|NCT00997048|Procedure|Laying open|Laying open Antibiotics Dalacin 300 mg tablets or iv infusion 600 mg
1856387|NCT00997048|Procedure|Sinus excision|Sinus excision Antibiotics Dalacin tablets 300 mg or iv infusion 600 mg
1856388|NCT00997061|Drug|HYCAMTIN|Observing patients on HYCAMTIN and other drugs for SCLC.
1856389|NCT00997074|Drug|ibuprofen|The most common side effect observed during medical abortion using mifepristone together with misoprostol is abdominal pain. The use of ibuprofen was not shown to interfere with the action of misoprostol to induce uterine contractions and pregnancy expulsion.
1856390|NCT00997087|Drug|Flumazenil|Sublingual daily
1856391|NCT00997100|Drug|paquinimod (ABR-215757)|The initial daily dose of ABR-215757 is changed to 1.5 mg/day. There will be an option to increase the dose to 3.0 mg/day following 28 days of treatment
1856392|NCT00997113|Drug|propofol|1 mg/kg IV followed by 0.5 mg/kg iv prn sedation
1856393|NCT00997113|Drug|alfentanil|alfentanil 10 ug/kg immediately prior to propofol dose
1856394|NCT00997126|Drug|Propofol|Propofol 1 mg/kg IV followed by 0.5 mg/kg prn sedation
1856395|NCT00997126|Drug|Alfentanil|Alfentanil 10 ug/kg IV followed by 5 ug/kg prn sedation
1856396|NCT00997139|Drug|Neosporin (polymyxin B 5,000units, bacitracin 400 units, neomycin 3.5mg)|2 1/32oz packages will be dispensed. If positive nasal swab for S. aureus, subjects will apply a small amount to anterior nares twice daily for 5 days.
1856397|NCT00997152|Drug|JTT-654|Tablets
1856398|NCT00997152|Drug|JTT-654 Placebo|Tablets
1856399|NCT00997178|Procedure|Non-surgical periodontal therapy|Non-surgical periodontal therapy (scaling and root planing)and supportive periodontal therapy with chlorhexidine rinse
1856400|NCT00997178|Other|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 6 month visit
1856401|NCT00997191|Procedure|Laser photocoagulation|Focal / grid photocoagulation for diabetic macular edema according to ETDRS guidelines
1856402|NCT00997191|Drug|Intravitreal triamcinolone|Intravitreal preservative-free triamcinolone (4mg) associated to focal photocoagulation for diabetic macular edema on baseline; Re-treatment at weeks 20 and 40 if CMT>275um
1856403|NCT00997191|Drug|Intravitreal bevacizumab|Intravitreal bevacizumab (1.5mg) associated to focal photocoagulation for diabetic macular edema at baseline; Re-treatment at weeks 20 and 40 if CMT>275um
1856404|NCT00997204|Drug|Icatibant|Single subcutaneous injection of icatibant, 30 mg
1856405|NCT00997217|Procedure|remote ischemic preconditioning|remote ischemic preconditioning (4 x 5 min upper limb ischemia with pneumatic cuff up to 200 mmHg with an intervening 5 min reperfusion; 2 cycles; before and after the coronary anastomosis or cardiopulmonary bypass)
1856407|NCT00997243|Drug|5-azacytidine|75mg/m2 IV/SC daily on days 1-7.
1856408|NCT00997256|Drug|Neurapas® balance (Herbal product (Hypericum, Passionflower, Valerian))|3 x 2 tablets / day over 3 days
1856409|NCT00997256|Drug|film-coated sugar-pill|3 x 2 tablets / day over 3 days
1856410|NCT00997269|Dietary Supplement|Co-enzyme Q-10|Patients will be supplemented with 300 mg of CoQ-10 1 time daily for one month
1856411|NCT00997269|Dietary Supplement|Placebo|Patients will be supplemented with CoQ-10 placebo 1 time daily for one month
1856412|NCT00997282|Drug|OPC-262 2.5 mg|orally administered once daily for 24 weeks
1856413|NCT00997282|Drug|OPC-262 5 mg|orally administered once daily for 24 weeks
1856414|NCT00997282|Drug|Placebo|orally administered once daily for 24 weeks
1856415|NCT00997308|Drug|AZD1446|Solution, oral, for 4 weeks
1856416|NCT00997308|Drug|Placebo|
1856417|NCT00997321|Drug|propofol|propofol 1 millgram per kilogram intravenous bolus followed by 0.5 milligrams per kilogram as needed for moderate procedural sedation
1856418|NCT00997321|Drug|Ketamine|ketamine milligram per kilogram followed by 0.5 milligrams per kilogram as need for moderate procedural sedation
1856419|NCT00997334|Drug|Erlotinib|
1856421|NCT00997360|Drug|PKI-179|
1856422|NCT00997373|Drug|Letrozole|2.5 mg daily from the day of enrollment to the day before surgery, generally about 3 weeks
1856423|NCT00997386|Drug|busulfan, and melphalan, and alemtuzumab|"intravenous busulfan 3.2 mg/kg/dose daily for 2 days, on days -5 and -4 (i.e., 5 and 4 days, respectively, before PBSCT).
intravenous melphalan 100 mg/m2 on day -3.
intravenous alemtuzumab 30 mg/dose for 2 days, on days -2 and -1."
1856424|NCT00997399|Drug|panobinostat (LBH589)|
1856425|NCT00997412|Drug|Mycophenolic acid|180 mg/tablet, 4 tablets twice daily
1856426|NCT00997412|Drug|AZA|1 tablet AZA (50 mg/tab) and 4 tablets MA placebo twice daily
1856427|NCT00997425|Device|Door cover/Floor cover|"Door cover - a neutral-colored canvas cloth covering the entire interior surface of the monitored door and attached to the door using a combination of Velcro and double-faced tape.
Floor cover - a 4'X 4' black, rubberized mat with an overlay of very thin strips of 2 white duct tape placed at 2 intervals, nonskid and fastened securely to the floor immediately in front of the interior face of a main exit door."
1856428|NCT00997438|Dietary Supplement|Lipoic Acid|300 mg Lipoic acid tablets from Vital Nutrients
1856429|NCT00997451|Behavioral|Cognitive-behavioral self-management|Graded activity, pacing, stress reduction, low effort pleasant activities, cognitive coping skills.
1856430|NCT00997451|Behavioral|Symptom monitoring|Daily symptom via web diary
1856431|NCT00997477|Drug|Foradil Combi (Formoterol-budesonide)|
1856432|NCT00997490|Drug|Neurapas® balance (Herbal combination out of hypericum, valerian, passionflower)|3 x 2 tablets/day over 6 weeks
1856433|NCT00997490|Drug|film-coated sugar-pill|3 x 2 tablets / day over 6 weeks
1856434|NCT00997503|Device|TAXUS Liberté Paclitaxel-Eluting Coronary Stent|The TAXUS Liberté Paclitaxel-Eluting Coronary Stent System is a device/drug combination product comprised of two regulated components: a device (Liberté Coronary Stent System) and a drug product (a formulation of paclitaxel contained in a polymer coating).The polymer coating serves as a carrier system to provide uniform and controlled biphasic release of the drug into the vessel wall once the stent is deployed.
1856435|NCT00997503|Drug|prasugrel|10mg or 5mg, oral, once daily as maintenance dose through 30-months following index procedure
1856436|NCT00997503|Drug|placebo|Oral placebo to match both 10mg and 5mg prasugrel tablets.
1856437|NCT00997503|Drug|aspirin|Oral, as prescribed by physician through end of study.
1856438|NCT00997516|Procedure|SILS appendectomy|Use of SILSPort to perform laparoscopic appendectomy
1856439|NCT00997516|Procedure|conventional laparoscopic appendectomy|conventional laparoscopic removal of the appendix
1856440|NCT00997529|Drug|nonmyeloablative stem cell transplant|Conditioning includes cytoxan 60mg/kg/d on Days 6 & 5, total dose 120mg/kg, Fludarabine 25mg/m2/d on days -5 to -1, total dose 125mg/m2. Patients with decreased cardiac or liver function pre-transplant will have their dose of cytoxan reduced by 25% - 45 mg/kg/d for 2 days or total dose of 90mg/kg. Patients will receive G-CSF (5ug/kg) to foster engraftment. PBSC progenitors will be mobilized from donor with G-CSF 5ug/kg 2x daily starting 4 days prior to stem cell collection until a target of 5-10 x106 CD34+ cells/kg is reached. Peripheral blood progenitors will be isolated from leukaphereses obtained on Days 5 & 6 with additional collections dependent on cell yields. Peripheral blood from donors will be given to patients 1 day after cytoreduction & immunosuppression. Immunosuppression will be tapered Day +60 if no signs of GVHD. Patients with residual non-regressing disease or mixed chimerism after day 100, who are off immunosuppression & do not have signs of GVHD, will receive a DLI
1856441|NCT00997542|Drug|Allopurinol|
1856442|NCT00997542|Drug|Placebo|
1856443|NCT00997555|Procedure|bronchoscopy|Scheduled bronchoscopy.
1856444|NCT00997568|Device|PET-511BTM|Transesophageal Transducer
1856445|NCT00997581|Drug|apremilast|apremilast 20 mg taken twice daily by mouth
1856446|NCT00997581|Drug|indomethacin SR|indomethacin SR 75 mg taken twice daily by mouth
1856447|NCT00997594|Procedure|Radiofrequency ablation|Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
1856448|NCT00997607|Biological|Ebola vaccine|4 mg of Ebola DNA plasmid vaccine, VRC-EBODNA023-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
1856449|NCT00997607|Biological|Marburg vaccine|4 mg of Marburg DNA plasmid vaccine, VRC-MARDNA025-00-VP, delivered via intramuscular injection on Weeks 0, 4, and 8
1856450|NCT00997607|Other|Placebo injection|4 mg of saline injection delivered at Weeks 0, 4, and 8
1856453|NCT00997659|Dietary Supplement|chromium picolinate|1000 mg per day
1856454|NCT00997672|Drug|Lithium Carbonate|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
1856455|NCT00997672|Drug|Placebo|
1856456|NCT00997685|Drug|Capecitabine plus oxaliplatin|"Xeloda: 1000mg/m2 bid, d1-14, q3w, Oxaliplatin:130mg/m2 d1, q3w,
4 pre-operative cycles, 4 post-operative cycles"
1856458|NCT00997724|Procedure|a-VATS|In brief, general anesthesia with selective lung ventilation was performed with the use of a double-lumen endotracheal tube. When postoperative mechanical ventilation was necessary, a standard endotracheal tube was substituted for the double-lumen tube. Patients were placed in the lateral decubitus position. Two thoracoports were placed in the sixth or seventh intercostal space (ICS) on the anterior axillary line and in the seventh or eighth ICS on the posterior axillary line; an anterolateral minithoracotomy (7 cm) was made in the fourth ICS for an upper lobectomy or in the fifth ICS for a middle or lower lobectomy.
1856459|NCT00997737|Device|DB, VI and FI|Two modalities of respiratory exercises based on deep and slow inspirations will be used: DB and IS. During DB, the researcher will place one hand slightly below the lower ribs in the abdominal region of the subject and the subject will be instructed to perform inspirations up to the maximum level of volume avoiding rib cage displacement; this recommendation will also be valid for exercises using incentive spirometers. IS will be executed using two different devices: Triflo II and Voldyne.
1856460|NCT00997750|Drug|Lornoxicam|lornoxicam 8mg/day and 12mg/day for 15 days
1856461|NCT00997763|Device|XIENCE V|everolimus-eluting stent
1856462|NCT00997763|Device|CYPHER|sirolimus-eluting stent
1856463|NCT00997776|Other|progressive resistance exercise|lower extremity strengthening: 3 sets of 8 repetitions at the 8 repetition maximum (8RM)for the hip and knee extensors, hip abductors, plantarflexors twice weekly for 10 weeks.
1856464|NCT00997776|Other|TENS|Transcutaneous electrical nerve stimulation (TENS) to elicit sensory information (comfortable tingling) for 7 minutes to bilateral muscle groups including the gluteal muscles, quadriceps, and gastroc-soleus muscles. TENS administered twice weekly for 10 weeks.
1856465|NCT00997789|Drug|Rebamide|Rebamipide 100 mg Tablet, three times a day
1856466|NCT00997802|Device|CT colonography and optical colonoscopy|All patients will undergo CT colonography and optical colonoscopy.
1856467|NCT00997815|Drug|Botulinum toxin A|Concentration at 2 units per 0.1 of normal saline dilution
1856468|NCT00997815|Drug|Normal saline injection|Using normal saline 2.5 ml injected in control side
1856469|NCT00997828|Device|everolimus-eluting stent|Xience V stent
1856470|NCT00997828|Procedure|coronary artery bypass graft surgery|coronary artery bypass graft surgery
1856471|NCT00997841|Procedure|Point-of-Care versus conventional coagulation management|Patients are randomized to receive either point-of-care based or conventional coagulation measurements based coagulation therapy in the case of increased perioperative bleeding tendency
1856472|NCT00997854|Other|Length of time for feed administration|Group 1 will consist of babies fed by bolus method, administered over no more than 30 minutes. Group 2 will be fed by slow infusion by pump over 2 hours.
1856473|NCT00997867|Procedure|Sciatic catheter left 0-1cm past needle tip vs. 5-6cm past needle tip|Patients undergoing orthopedic surgery who are getting a perineural catheter will be randomized to one of two groups: catheter tip placed 0-1cm past needle tip or catheter tip placed 5-6cm past needle tip. Patients will be called by research staff the day following surgery to assess their post-surgical pain using a numeric rating scale.
1856474|NCT00997880|Drug|Rosuvastatin calcium 40mg|Rosuvastatin calcium 40mg
1856475|NCT00997880|Drug|Rosuvastatin calcium10mg|Rosuvastatin 10mg
1856476|NCT00997893|Dietary Supplement|Phytoestrogen|Women in the phytoestrogen intervention group will take one active Novasoy® (55 mg) pill at breakfast and active Novasoy® (55 mg) pill at dinner, for a total daily dose of 110 mg Novasoy® and 0 mg estradiol.
1856477|NCT00997893|Drug|Estradiol|Women in estradiol intervention group will take one active estradiol pill (1 mg) at breakfast and one placebo pill at dinner, for a total daily dose of 1 mg estradiol and 0 mg Novasoy®.
1856478|NCT00997893|Drug|medroxyprogesterone acetate|At week 12 , after the participant completes her final assessments, women will begin taking MPA (10 mg/d for 10 days).
1856479|NCT00997893|Other|Placebo|Women in this intervention group will take one placebo pill at breakfast and one placebo pill at dinner, for a total daily dose of 0 mg Novasoy® and 0 mg estradiol.
1856480|NCT00997893|Other|Placebo|At week 12, after the participant completes her final assessments, women will begin taking placebo(10 days).
1856481|NCT00997906|Drug|carboplatin,|Given IV
1856482|NCT00997906|Drug|cisplatin|Given IV
1856483|NCT00997906|Drug|gemcitabine hydrochloride|Given IV
1856484|NCT00997906|Drug|paclitaxel|Given IV
1856485|NCT00997906|Radiation|intensity-modulated radiation therapy|Given once daily 5 days a week for 6½ weeks.
1856486|NCT00997919|Drug|MABT5102A|single SC dose
1856487|NCT00997919|Drug|MABT5102A|single IV dose
1856488|NCT00997932|Drug|Levonorgestrel-Releasing Intrauterine Contraceptive System (LNG-IUS), 52 Mg, 5 Year Duration|Levonorgestrel-Releasing Intrauterine Contraceptive System, 52 Mg, 5 Year Duration Postpartum placement of LNG-IUS within 10 minutes - 48 hours
1856489|NCT00997945|Drug|ZD4054 (Zibotentan)|10 mg ZD4054 (Zibotentan) once daily on Day1, Day4 to Day15
1856490|NCT00997958|Drug|Mycophenolate mofetil|"Dose escalation increasing successively from 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, and 5.0 grams p.o. bid.
Each patient will be treated for eight weeks (56 days)."
1856491|NCT00997971|Other|Modilac Rose 1|Infant formula used for non-breastfed children
1856492|NCT00997984|Drug|extended-release guanfacine hydrochloride (SPD503)|dosed in AM
1856493|NCT00997984|Drug|placebo|dosed in the AM or PM
1856494|NCT00997984|Drug|extended-release guanfacine hydrochloride|Dosed in the PM
1856495|NCT00997997|Drug|Moxifloxacin (Avelox, BAY12-8039)|400 mg, intravenous / oral, once daily, treatment duration at the discretion of the attending physician who must consult the local product information
1856496|NCT00998010|Drug|bortezomib + temozolomide+ radiation therapy|Patients will be treated with Bortezomib at 1.3 mg/m2 IV on days1,4,8,11,29,32,36 and 39 and Temozolomide on 75mg/m2 daily during radiation. External beam fractionated regional radiation will be given on consecutive week days at 200cGy daily doses to a total dose of 6000 cGy.
1856497|NCT00998023|Device|Mynx Vascular Closure Device|Comparison of two different vascular closure devices.
1856498|NCT00998023|Device|AngioSeal Vascular Closure Device|Comparison of two different vascular closure devices.
1856544|NCT00998335|Drug|Insulin detemir and pre-meal insulin aspart.|This group will receive Insulin detemir plus aspart. The group will start with Insulin detemir at bedtime. Then in three months they will Insulin aspart before breakfast, lunch and dinner.
1856499|NCT00998036|Drug|Temsirolimus, cisplatin, erlotinib|"Cisplatin at 30mg/m2 and temosirolimus will be administered intravenously weekly on days one and eight of a three week cycle. Temosirolimus will not be given on week three (usually dosed weekly) for increased tolerability given its possible plasma accumulation during week three. Cisplatin will be given first over a 30 minute infusion with prehydration and temsirolimus will be given second over a 30 minute infusion during posthydration. Erlotinib will be taken by mouth daily starting at 100mg. On days of cisplatin and temosirolimus infusions, erlotinib should be taken at least two hours after the beginning of the temosirolimus infusion.
Dose escalation will follow the standard 3 by 3 design with three set dosing levels.
Dose Level 1: Temosirolimus 15mg, Erlotinib 100mg
Dose Level 2: Temosirolimus 15mg, Erlotinib 150mg
Dose Level 3: Temosirolimus 25mg, Erlotinib 150mg"
1856500|NCT00998049|Drug|plerixafor|Plerixafor 160mg/kg/dose by IV on days 5-8
1856501|NCT00998049|Drug|filgrastim|Filgrastim (G-CSF) 10 mg/kg/dose subcutaneously on days 1-8.
1856502|NCT00998075|Drug|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
1856503|NCT00998075|Drug|Esomeprazole - Nexium|Clinical Trial Capsule or MUPS Tablet, oral, single dose
1856504|NCT00998075|Drug|ASA|Tablet, oral, single dose
1856505|NCT00998088|Other|erythropoietin and cell saver|weekly 40.000 IU s.c. for 4 weeks pre-operatively; use of cell saver includes intra- and post-operative drainage and reinfusion
1856506|NCT00998088|Drug|erythropoietin|weekly 40.000 IU s.c. for 4 weeks pre-operatively
1856507|NCT00998088|Device|OrthoPAT|for intra- and post-operative re-infusion of autologous wound blood
1856508|NCT00998088|Device|Post-operative drain device|For post-operative re-infusion of unwashed wound blood
1856509|NCT00998088|Other|Erythropoietin and OrthoPAT|weekly 40.000 IU s.c. for 4 weeks pre-operatively
1856510|NCT00998088|Other|Erythropoietin and drain device|weekly 40.000 IE s.c.for 4 weeks pre-operatively; drain use in post-operative period
1856511|NCT00998088|Device|OrthoPAT|For intra- and post-operative reinfusion of autologous blood
1856512|NCT00998101|Drug|cetuximab|400 mg/m2 Cycle 1 day 1 only over 120 minutes 250 mg/m2 Cycle 1 days 8,15 AND on all other cycles days 1,8,15 over 60 minutes
1856513|NCT00998101|Drug|carboplatin|AUC=6 Day 1 of treatment over 30 minutes every 21 days
1856514|NCT00998101|Drug|ixabepilone|30 mg/m2 , Day 1 over 3 hours every 21 days
1856515|NCT00998114|Behavioral|Exercise|Aerobic exercise for 30-45 minutes five times a week for six months
1856516|NCT00998153|Behavioral|Risk Reduction through Family Therapy|Component based intervention based on existing empirically supported treatments
1856517|NCT00998166|Drug|Pemetrexed, Cisplatin, Bevacizumab|"Pre-hydration for 1-1/2 hours at 250 ml/hour
Pemetrexed 500 mg/m2 IV over 10 minutes
Return to hydration for 30 minutes at 250 ml/hour
Cisplatin 75mg/m2 IV over 60-120 minutes
Bevacizumab 15mg/kg IV over 90 minutes"
1856518|NCT00998179|Device|Acu-TENS|Application of Acu-TENS (with electrical output from the machine)
1856519|NCT00998179|Device|Placebo-TENS|Application of Acu-TENS (without electrical output from the machine)
1856520|NCT00998192|Biological|REOLYSIN|3x10E10 TCID50 1 hour intravenous infusion, administered on Days 1,2,3,4,and 5 of a 21-day cycle
1856521|NCT00998192|Drug|Paclitaxel|200 mg/m2, 3-hour intravenous infusion, given on Day 1 of a 21-day cycle
1856522|NCT00998192|Drug|Carboplatin|6 AUC mg/mL min, 30-min intravenous infusion, given on Day 1 of a 21-day cycle
1856523|NCT00998205|Drug|Dobutamine stress echo (DSE)|Dobutamine intravenous infusion would be undertaken starting at 10 micro-grams/kg per minute in three minute intervals increased to 20, 30, 40 or 50 micro-grams/kg per minute or to a peak heart rate response of at least 85% age predicted maximum heart rate.
1856524|NCT00998205|Drug|Atropine bolus|If at the end of the Dobutamine protocol, there is inadequate heart rate response, intravenous atropine boluses of 0.5 milligrams (maximum 1.0 mg) would be used as needed to achieve a heart rate of at least 85% of age predicted maximum heart rate.
1856525|NCT00998218|Drug|Ranolazine|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
1856526|NCT00998218|Drug|Placebo|Ranolazine at 1000 mg BID (or 500 mg BID if the 1000 mg dose was not tolerated) or a comparable placebo for the next 4 weeks
1856527|NCT00998231|Biological|blood sample|Blood collections and peripheral blood mononuclear cells extraction will be operated after each evaluation and followed by RNA extraction, reverse transcription and gene expression quantification by real-time PCR.
1856528|NCT00998244|Other|Diet - very low carb or low fat|Diet comparison in Gastroesophageal Reflux Disease
1856529|NCT00998257|Drug|EE20/DRSP (YAZ, BAY86-5300)|Patients under daily life treatment with YAZ according to local drug information.
1856530|NCT00998270|Procedure|Autologous bone marrow transplantation|"Autologous transplantation:
Endoxan (for mobilization) Dose: 2.5 g/m2 IV Time: -11 Duration: 1 day
G-CSF (Neupogen) Dose: 0.5 micg/kg subcutaneous Time: -6 to -3 Duration: 4 days
Melphalan Dose: 100 mg/m2 IV Time: -2 and -1 Duration: 2 days"
1856531|NCT00998270|Procedure|Allogeneic bone marrow transplantation|"Allogeneic
Melphalan Dose: 70 mg/m2 IV Time: Duration: 2 days
Fludarabine Dose: 30 mg/m2 IV Time: Duration: 5 days"
1856532|NCT00998283|Drug|HM10460A 5μg/kg|Subcutaneously administrate at 0 hour on Day 1
1856533|NCT00998283|Drug|HM10460A 15μg/kg|Subcutaneously administrate at 0 hour on Day 1
1856534|NCT00998283|Drug|HM10460A 45μg/kg|Subcutaneously administrate at 0 hour on Day 1
1856535|NCT00998283|Drug|HM10460A 135μg/kg|Subcutaneously administrate at 0 hour on Day 1
1856536|NCT00998283|Drug|HM10460A 350μg/kg|Subcutaneously administrate at 0 hour on Day 1
1856537|NCT00998283|Drug|Placebo|Subcutaneously administrate at 0 hour on Day 1
1856538|NCT00998296|Drug|BIBW 2992|EGFR inhibitor
1856539|NCT00998296|Drug|BIBF 1120|VEGF inhibitor
1856540|NCT00998309|Drug|Azithromycin SR|Zithromax SR 2g, taking once for treatment.
1856541|NCT00998322|Biological|REOLYSIN|1E10 TCID50, 1-hour intravenous infusion on Days 1 and 2 and then Days 8 and 9 of a 21-day cycle.
1856542|NCT00998322|Drug|Gemcitabine|800 mg/m2 30-min infusion on Days 1 and 8 of a 21-day cycle.
1856543|NCT00998335|Drug|Long-acting bedtime insulin detemir (Levemir)|This group will receive Insulin detemir. Insulin detemir is given at bedtime aiming at a fasting plasma glucose between 80-100 mg/dl.
1856642|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
1856545|NCT00998348|Behavioral|Parenting Program|The parenting program is an 8-month intervention for parents with preschool-age children designed to teach strategies and skills that help parents better manage their day to day stresses of parenting while also promoting healthy lifestyle behaviors. Topics will include stress management, child management, family routines, emotion regulation, and coparenting. In later sessions parents will be encouraged to draw on these general parenting skills to promote healthier nutrition and physical practices at home. The intervention will be delivered through in-person group sessions (n=12) and tailored one-on-one telephone calls (n=11). A complementary child program will be delivered to children while parents are attending the group sessions.
1856546|NCT00998361|Procedure|Allogeneic hemopoietic stem cell transplant|administration of 15 mg/kg of thiotepa + 140 mg/sqm of melphalan followed by infusion of allogeneic hemopoietic stem cell
1856548|NCT00998413|Behavioral|Multifaceted intervention|multifaceted family-based, physical exercise, nutrition, and behavioural intervention study for 18 month, in children aged 6-16 years with asthma and overweight/obesity.
1856549|NCT00998426|Procedure|glucose monitoring before and after HepaGam B administration|Glucose monitoring before and after HepaGam B administration. Prior to receiving the dose of HepaGam B HBIG, blood glucose will be monitored in 3 manners. These will include two finger stick tests, one with a glucose-specific monitoring device and one with a glucose non-specific monitoring device; a venous blood glucose level; and a urine glucose test. Patients will receive the HBIG infusion and then immediately after the dose will have the same blood glucose tests repeated (finger sticks, venous glucose and urine glucose). Then at 60 minutes and 120 minutes after the dose is given, patients will again have finger stick tests with the glucose specific and glucose non-specific monitoring devices.
1856550|NCT00998426|Biological|HepaGam B (Hepatitis B Immune Globulin (HBIG))|Subjects will be given 20,000 IU HepaGam B after the initial blood glucose monitoring, and prior to the post-infusion blood glucose monitoring.
1856551|NCT00998439|Device|SeQuent® Please|"6 F, 7 F, or 8 F guiding catheters have to be used
after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))
additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour
Nitroglycerin (0.2 mg i.c.) prior to first contrast injection
ISR must be predilated with uncoated balloon
balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use
inflation time has to be ≥ 30 sec
select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %
each Paclitaxel-eluting balloon catheter is allowed for single use only
additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness
if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
1856552|NCT00998439|Device|SeQuent® II|"6 F, 7 F, or 8 F guiding catheters have to be used
after insertion of arterial sheath, apply heparin (7,500-10,000 Units i.a. or i.c. (or 50-100 U/kg body weight))
additional dose of 5,000 Units (75 U/kg body weight) if procedure lasts for more than one hour
Nitroglycerin (0.2 mg i.c.) prior to first contrast injection
ISR must be predilated with uncoated balloon
balloon diameter shall be 0.5 mm smaller than the Paclitaxel-eluting balloon intended for use
inflation time has to be ≥ 30 sec
select balloon with correct stent diameter to achieve a remaining stenosis of ≤ 10 %
each Paclitaxel-eluting balloon catheter is allowed for single use only
additional inflations and/or aggressive anti-platelet agents for intraluminal defects or haziness
if additional balloon is necessary, only uncoated balloon is permitted to avoid overdosing of drug"
1856553|NCT00998452|Behavioral|MOVE*VETS|Receiving 4 tailored newsletters on the study health behavior topics created from the baseline survey. Also 2-4 counseling calls from peer counselors.
1856554|NCT00998465|Other|24-hour blood pressure|Blood pressure is measured every 15 minutes in the daytime and every 30 minutes at night
1856555|NCT00998465|Other|Echocardiography|Standard 2-D and m-mode echocardiography with determination of dimensions, systolic, and diastolic function.
1856556|NCT00998465|Other|Inert gas rebreathing|Cardiac output, stroke volume and total peripheral resistance are tested at rest and during exercise (bicycle ergometer) using non-invasive equipment (inert gas rebreathing - Innocor)
1856557|NCT00998465|Radiation|Dexa-scan|Fat mass and fat free mass is determined with a whole body Dexa scan, and bone mineral density is tested with Dexa-scans of the lumbar spine and proximal femur.
1856558|NCT00998465|Radiation|Plasma volume|The test is performed using 5 MBq technetium-labeled albumine (99mTc-albumine - Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
1856559|NCT00998465|Radiation|Glomerular filtration rate (GFR)|GFR and ECV are determined following injection of 3,7 MBq 51Cr-EDTA and postinjection samples three-four hours after injection.
1856560|NCT00998465|Other|Blood samples|p-glucose, p-insulin, NT-proBNP, hemoglobin, potassium, sodium, creatinine, albumine
1856561|NCT00998465|Other|Urine analyses|24-hour urine collections with determination of u-sodium, u-potassium and u-creatinine.
1856562|NCT00998465|Dietary Supplement|Diets with low and high sodium content|Participants are subjected to 5 days of low (90 mmol/day) and high (250 mmol/day) sodium intake in a randomized order before and 1 year after laparoscopic gastric bypass surgery.
1856563|NCT00998478|Other|Activity Knowledge Circuits|The activity knowledge circuits were implemented, where in addition to regular physical education (PE) activity was increased by two hours a week over an 18-week period. Participants briskly walked 3200 m twice weekly during curriculum lessons (60 min). Short tasks, in line with current curriculum, were provided by subject teachers for participants to complete at stations set every 400 or 800 m. Crucially participants continued to follow national curriculum whilst exercising. Tasks designed by teachers lasted no longer than 60 seconds at each station. With the exception of PE, each curriculum subject delivered a total of four intervention lessons. Circuits were performed outdoors on school premises, with an indoor course of equal distance used during adverse weather conditions.
1856643|NCT00999219|Drug|FK199B|oral
1856644|NCT00999219|Drug|Zolpidem|oral
1856564|NCT00998504|Dietary Supplement|resVida|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
1856565|NCT00998504|Dietary Supplement|placebo|resVida or placebo will be given for 30 days, twice daily. One pill, which contains 75 mg of resVida, will be provided with lunch, and the other pill will be provided with diner. So in total, 150 mg/day will be given.
1856566|NCT00998517|Dietary Supplement|Soy/peanut fortified spread|75kcal/kg/day
1856567|NCT00998517|Dietary Supplement|Milk fortified corn/soy blend|75 kcal/kg/day
1856568|NCT00998517|Dietary Supplement|Supplementary Plumpy®|75 kcal/kg/day
1856569|NCT00998556|Drug|Bromocriptine|Patients randomized to the study medication have to take bromocriptine orally for the first 14 days at a dose of 5 mg/day (= 2 tablets, 1 in morning, 1 in the evening). From day 15 to day 56 they will take a dose of 2.5 mg (= 1 tablet) orally in the evening. The duration of the intervention is 8 weeks. The study medication is taken on top of standard therapy for heart failure.
1856570|NCT00998569|Behavioral|Neurocognitive Enhancement|Neurocognitive Enhancement Therapy (NET) uses behavioural treatment strategies that are designed to improve a range of cognitive skills. NET uses strategies such as coaching, repetition, practice, teaching, group discussion, and compensation for deficits by using cognitive strengths.
1856571|NCT00998569|Behavioral|Wait List|Participants will be wait listed for 10 weeks, following which time they will receive the intervention previously described.
1856572|NCT00998582|Drug|Tenofovir disoproxil|Participants taking an abacavir-based HIV treatment regimen will be randomized to switch to a tenofovir-based regimen or continue taking abacavir.
1856573|NCT00998595|Other|Promotora|The Promotora will deliver education regarding postpartum follow-up and steps to take to decrease the risk for developing type 2 diabetes. The Promotora will clarify misperceptions and answer questions related to risk of developing diabetes and contraception. If the subject has barriers to accessing care with transportation or childcare, she will help the subjects to access existing resources. The Promotora will give the subject her contact information and will also contact the subject to remind her of her appointments and reschedule if she missed an appointment.
1856574|NCT00998608|Drug|risperidone|risperidone 4mg/d
1856575|NCT00998621|Other|Adherence questionnaire|Adherence questionnaire
1856576|NCT00998634|Drug|LITHIUM CARBONATE|Lithium Carbonate will be dosed based on lithiemy, which will be in the range 0.9-1.2 mEq/L. Maximum allowed dose will be 1500mg/day.
1856577|NCT00998647|Device|modified ultrafiltration using Maquet haemoconcentrator, BC 20 plus|usage of modified ultrafiltration following extracorporeal circulation; filtration about 1,5 liters and re-fill with colloids
1856578|NCT00998660|Device|Activa RC|Patients receiving Activa RC as their first implantable neurostimulator or as a replacement implantable neurostimulator for deep brain stimulation
1856579|NCT00998673|Device|Silica Gel Fiber|Silica Gel Fiber (SGF) applications as required
1856580|NCT00998673|Device|Standard-of-Care|Standard-of-Care with dressing changes twice per week using Mepitel and Mepilex wound dressings
1856581|NCT00998686|Drug|dutogliptin|400 mg
1856582|NCT00998686|Drug|sitagliptin|100 mg
1856583|NCT00998699|Drug|Xoma 052|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
1856584|NCT00998699|Drug|Placebo|Sterile solution subcutaneously administered every 4 weeks for 12 weeks
1856585|NCT00998738|Drug|Calcium Gluconate|Given IV
1856586|NCT00998738|Drug|Magnesium Sulfate|Given IV
1856587|NCT00998738|Other|Placebo|Given IV
1856588|NCT00998738|Other|Quality-of-Life Assessment|Ancillary studies
1856589|NCT00998738|Other|Questionnaire Administration|Ancillary studies
1856590|NCT00998738|Drug|Ixabepilone|Given IV
1856591|NCT00998751|Drug|oral masitinib|7.5 mg/kg/day
1856592|NCT00998764|Drug|Bapineuzumab 0.5 mg/kg|I.V., 0.5 mg/kg, infusion every 13 weeks for a total of 16 infusions.
1856593|NCT00998777|Procedure|Shoulder Strengthening|The intervention program is a 6 week shoulder and scapular stabilizer strengthening program that is performed 3 times per week. The program includes 10 exercises that are performed with Theraband rubber tubing and 2 stretches. The exercises are: shoulder flexion, Ys, Ts, Ws, IR @ 90, ER @ 90, Throwing acceleration, Throwing deceleration, dynamic hug, and low rows. The stretches include the sleeper stretch and the corner stretch.
1856595|NCT00998816|Drug|Pregabalin|pregabalin capsules (150mg,oral) will be administered 1 hour before lateral thoracotomy, 12 hours after the thoracotomy and then 12 h BID for 10 additional days.
1856596|NCT00998829|Other|questionnaire|There is no therapeutic intervention in this study. However PASE (Psoriatic Arthritis Screening and Evaluation) and other patient questionnaires will be completed by participants.
1856597|NCT00998842|Device|Recom Model 100|Battery Operated, Ambulatory, Digital Wireless ECG Monitor System
1856598|NCT00998842|Device|GE 5000 ECG Monitor System|Wired ECG system
1856599|NCT00998855|Behavioral|Exercise|12 wk aerobic or/ resistance exercise program
1856600|NCT00998881|Drug|Teneligliptin 20 mg|
1856601|NCT00998881|Drug|Placebo|
1856602|NCT00998907|Device|PDS plus|triclosan-coated polydiaxanon 910 suture materials with antiseptic activity (PDS plus®, Ethicon GmbH, Norderstedt, Germany)
1856603|NCT00998907|Device|PDS II|polyglactin 910 suture material for abdominal wall closure
1856604|NCT00998920|Drug|S-equol|oral, BID, 14 days
1856605|NCT00998920|Drug|Placebo|oral, BID, 14 days
1856606|NCT00998933|Drug|Testosterone gel 1.62%|5 grams applied topically to upper arms/shoulder and abdomen on Day 1
1856607|NCT00998946|Drug|Pralatrexate Injection|"Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).
Initial dose: 30 mg/m2
Dose reductions: to 20 mg/m2 weekly per protocol defined criteria.
Administered on days 1, 8 and 15 of a 4-week (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met."
1856608|NCT00998946|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection
Administered within 10 weeks of start of pralatrexate dosing, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate."
1856609|NCT00998946|Dietary Supplement|Folic Acid|"1 mg orally
Administered daily for at least 7 days prior to start of pralatrexate, throughout the study and for at least 30 days after last dose of pralatrexate."
1856610|NCT00998959|Behavioral|Mindfulness Based Stress Reduction and Psychoeducation|Participants will receive six individual weekly 50-minute sessions of mindfulness based stress reduction (MBSR) as well as problem solving therapy (PST. PST is a type of therapy that focuses on psychosocial problems and using your skills and resources to function better. MBSR uses exercises in mindfulness to reduce stress.
1856611|NCT00998959|Behavioral|Psychoeducation|Participants will receive six individual weekly 50-minute sessions of psychoeducation. Psychoeducation consists of education on depression, its symptoms, its treatment, and recovery.
1856612|NCT00998972|Drug|N-acetylcysteine|600 mg intravenous before and 2 hours after cerebral arteriography
1856613|NCT00998985|Drug|Grazoprevir|10, 30, 50, 100, 200, 400, 600 or 800 mg Grazoprevir tablets, orally, once a day for 7 days
1856614|NCT00998985|Drug|Placebo|Placebo tablet, orally, once a day for 7 days
1856615|NCT00998998|Behavioral|Home stimulation|Weekly visit of one hour to the home over the course of one year to foster the mother-child relationship.
1856616|NCT00998998|Behavioral|Surveillance|Weekly visits to the home over the course of one year to record iron intake, feeding, and health information.
1856617|NCT00998998|Dietary Supplement|Iron|Six-month-old infants treated orally for 1 y with 15 mg elemental Fe/d as ferrous sulfate. Twelve-month old infants treated orally for a minimum of 6 months with 30 mg elemental Fe/d.
1856618|NCT00999011|Procedure|once daily mobility activity|in bed and out-of-bed activity including range of motion, chair sitting, sitting at edge of bed without weightbearing, standing, walking.
1856619|NCT00999011|Procedure|twice daily mobility activity|as with once daily. Goal is to progress intensity and duration of activity over time as patient condition improves for both arms
1856620|NCT00999037|Drug|Sevelamer Carbonate|Daily renvela (800 mg tid with meals) x 12 weeks
1856621|NCT00999037|Other|Placebo|1 inert tablet tid x 12 weeks
1856622|NCT00999050|Procedure|Gastric bypass for diabetic patients <35 BMI|The operation is performed under general anesthesia. It is done laparoscopically, meaning that several small openings are made in the abdomen for insertion of long, thin surgical instruments, one with an attached camera. The operation is video monitored. The top of the stomach is divided across, leaving a small pouch for food. The rest of the stomach remains but can receive no food. The gut is divided just past the stomach, and it is attached to the small stomach pouch so that food can get back into the bowel. A second connection is made so that the bile and digestive juices pass into the bowel with the food.
1856623|NCT00999089|Procedure|Conventional Coronary Artery Bypass|Coronary artery bypass grafting with extracorporeal circulation and cardioplegic arrest
1856624|NCT00999089|Procedure|Off-Pump Coronary Artery Bypass|Coronary artery bypass grafting without extracorporeal circulation or global myocardial ischemia
1856625|NCT00999089|Procedure|Pump-Assisted Coronary Artery Bypass|Coronary artery bypass grafting with a beating but unloaded heart by using extracorporeal circulation
1856628|NCT00999115|Drug|Expanded allogenic adipose-derived adult stem cells|Administration will be preceded by localization and closure of the internal opening. Cell treatment injection will be performed following Major Ambulatory Surgery standards. Patients will receive an intralesional dose of 20 million cells at baseline. 50% of the cell suspension will be placed into fistula walls of the internal opening, with the remaining 50% being injected across the wall tracts of the target fistula. Patients without healing (complete fistula closure)at week 12 will receive a second dose of 40 million cells, using the same treatment approach.
1856629|NCT00999128|Drug|GDC-0941|Oral repeating dose
1856630|NCT00999128|Drug|rabeprazole|Oral repeating dose
1856631|NCT00999141|Biological|FS VH S/D 4 s-apr|FS VH S/D 4 s-apr will be applied (using spray device provided by Sponsor) to the subcutaneous plane (intraoperative, topical administration) in both the neck and the face area.
1856632|NCT00999167|Drug|HPN-100|Part B: 6 mL BID for 16 weeks.
1856633|NCT00999167|Drug|Placebo|Part B: same as experimental arm
1856634|NCT00999180|Procedure|Botulinum toxin type A and kinesiotherapy|Stroke, Botulinum Toxin
1856635|NCT00999180|Procedure|Saline and Kinesiotherapy|Saline and Kinesiotherapy
1856636|NCT00999193|Procedure|locking plate, ORIF|Open reduction of the fracture (and GH joint), internal fixation with a locking plate. Tuberculum fragments are sutured to the plate with thick non-absorbable suture.
1856637|NCT00999193|Procedure|Hemiarthroplasty|Replacement of the humeral articular head with hemiprosthesis. Tubercles are sutured to the prosthesis with thick nonabsorbable sutures.
1856638|NCT00999193|Other|Conservative treatment|Immobilisation in a supporting brace for 3 weeks, then increasingly active rehabilitation program supported by a physiotherapist until 12 weeks of the injury.
1856639|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
1856640|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
1856641|NCT00999206|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
1857096|NCT01002963|Drug|PF-04418948|solution, 1000 mg, single
1856645|NCT00999232|Drug|Erythromycin|Subjects receive 4x250mg erythromycin i.v. daily after intubation of a self-propelled feeding tube
1856646|NCT00999232|Drug|Placebo|Subjects receive 4x placebo i.v. daily after intubation of a self-propelled feeding tube
1856647|NCT00999245|Other|High Demand / Low Infusion|HDLI dosing plan will administer either morphine or hydromorphone using PCA. Dosing will be based on body weight.
1856648|NCT00999245|Other|PCA Dosing Plan|LDHI dosing plan will administer either morphine ot hydromorphone using PCA. Dosing will be based on body weight.
1856649|NCT00999258|Drug|sirolimus|"The subjects assigned to the sirolimus conversion group will be initiated on sirolimus 5mg po daily at which time their tacrolimus dose will be decreased by 50%. Sirolimus levels will be checked within a week and adjusted in a linear fashion to achieve a trough goal of 12-15ng/ml in subjects within 1 year post-transplant, and 8-12 ng/ml in subjects more than 1 year post-transplant. Tacrolimus will be continued in these subjects until sirolimus target trough levels are achieved. Thereafter, tacrolimus will be discontinued indefinitely.
The subjects assigned to the tacrolimus maintenance group (control group) represent our present standard of care."
1856650|NCT00999271|Other|Incretin hormone - Glucose-dependent insulinotropic polypeptide (GIP)|"two different dosages:
0.8 pmol/kg/min
1.5 pmol/kg/min for 300 minutes"
1856651|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.3 mg/kg/h of ZK200775 over a period of 4 hours.
1856652|NCT00999284|Drug|ZK200775|Intravenous infusion of 0.75 mg/kg/h of ZK200775 over a period of 4 hours.
1856653|NCT00999284|Drug|Sodium Chloride|Intravenous infusion of sodium chloride over a period of 4 hours.
1856654|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
1856655|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
1856656|NCT00999297|Other|Dihydrocapsiate|Capsules will contain dihydrocapsiate 3 mg/d or 9 mg/d or placebo
1856657|NCT00985829|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
1856658|NCT00985842|Device|Pe-Lite and sleeve suspension socket|Prosthetic socket worn by the amputee that has a Pe-lite foam liner between the socket and the residual limb. It is suspended from the residual limb using a sleeve at the top of the socket.
1856659|NCT00985842|Device|Total Surface bearing a socket with a sleeve suspension but without suction|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a sleeve at the top of the socket.
1856660|NCT00985842|Device|Total surface bearing suction socket with a pin lock suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket is suspended from the residual limb using a pin that protrudes from the bottom of the liner into the socket that is then locked in place by the amputee.
1856661|NCT00985842|Device|Total surface bearing suction socket with a sleeve suspension|Prosthetic socket worn by the amputee where the fit of the socket touches every part of the residual limb. This socket using vacuum suction plus a sleeve at the top of the prosthetic socket to enhance the security of the suspension.
1856662|NCT00985842|Device|Vacuum-assisted socket system (Harmony System, Otto Bock)|Prosthetic socket worn by the amputee where the a vacuum pump, in this case a mechanically-activated pump, creates a vacuum between the socket and the limb. This vacuum suspends the prosthetic limb from the amputee's residual limb.
1856663|NCT00985855|Drug|cisplatin, vinorlebine, cetuximab|patient will receive 2 cycles of cisplatine 80 mg/m² at day 29 and day 50 more vinorelbine 15 mg/m² at day 29, day 36 and day 50 and 57 associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
1856664|NCT00985855|Drug|cisplatine, etoposide, cetuximab|patient will receive 2 cycles of cisplatine 50 mg/m² at day 29, 36, 57, and 64 + étoposide 50mg/m² during day 29-33, day 57-61associated to cetuximab 400 mg/m² at day: 22,29, 36, 43, 50, 57, 64 and 71
1856665|NCT00985868|Drug|multikinase inhibitor AT9283|
1856666|NCT00985868|Other|enzyme-linked immunosorbent assay|
1856667|NCT00985868|Other|immunohistochemistry staining method|
1856668|NCT00985868|Other|laboratory biomarker analysis|
1856669|NCT00985868|Other|pharmacological study|
1856670|NCT00985881|Device|Custom prosthetic socket with mechanical vibrators (stochastic resonance)|Application of mechanically-induced sub-threshold vibration applied to the amputee's residual limb using a custom prosthetic limb system
1856671|NCT00985881|Device|Conventional prosthetic socket (current clinical practice)|No sub-threshold vibration applied to residual limb. Amputee wears conventional prosthetic socket.
1856672|NCT00985894|Other|Online Teledermatology Care|Patients randomized to the intervention group will have their scheduled follow-up visits online via store and forward teledermatology.
1856673|NCT00985894|Other|Conventional in Office Care|Patients randomized to the control group will have their scheduled follow-up visits via conventional in office care.
1856674|NCT00991237|Other|Pulsed Radiofrequency|Pulsed Radiofrequency
1856675|NCT00991250|Biological|SentoClone®|SentoClone® are autologous tumour-reactive lymphocytes which are expanded and infused to the patient, where they have the opportunity to seek out and attack the primary tumour and metastases. The first step is to identify the tumour draining lymph node(s), which is done in parallel to surgical resection of the primary tumour or metastasis. The sentinel and/or metinel node(s), the initial meeting place between tumour antigen and the immune system, are further dissected and collected during the surgery. The lymphocytes are extracted from the collected lymph nodes and expanded in vitro, the lymphocytes are thereafter stimulated with tumour extract and returned to the patient intravenously as an autologous cell transfusion. The administered volume will be 100 ml for cell densities less than 3x106 cells/ml and 200 ml for cell densities of 3x106 cells/ml or more.
1856704|NCT00991458|Drug|Placebo (Vehicle for Cyclosporine)|Placebo eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
1856707|NCT00991497|Device|Compression bandaging|Cotton wool padding will then be placed over the treated vein and secured in place by crepe bandaging. An above-knee TED stocking will be applied on top of this.
1856676|NCT00991250|Drug|Temodal® or Dacarbazine Medac®|"Dacarbazine (5-[3,3-Dimethyl-1-triazenyl]imidazole-4-carboxamide) is a widely used systemic treatment against advanced malignant melanoma. Dacarbazine is a cytostatic agent, which inhibits tumour growth by interfering with DNA-synthesises. The DNA-synthesis is inhibited by alkylation of the DNA molecule; however, it is unclear whether dacarbazine has other cytostatic impacts on cell mechanisms. Dacarbazine is inactive until liver passage, the liver converts dacarbazine to its reactive metabolites MTIC and HMMTIC, which alkylate DNA. Dacarbazine is light sensitive and needs to be administered intravenously.
A newer analogue to dacarbazine, temozolomide (Temodal®), has been developed for oral administration. Temodal® is administered in capsules and is rapidly absorbed reaching peak concentrations after 20 minutes. Temodal® is converted to MTIC at physiological pH, the same reactive molecule as dacarbazine is metabolized to in the liver."
1856677|NCT00991263|Genetic|gene expression analysis|
1856678|NCT00991263|Genetic|polymerase chain reaction|
1856679|NCT00991263|Other|laboratory biomarker analysis|
1856680|NCT00991276|Drug|pregabalin|capsules; 300 mg once-per-day; 4 weeks of treatment
1856681|NCT00991276|Drug|placebo|capsules; 0 mg once-per-day; 4 weeks of treatment
1856682|NCT00991276|Drug|pramipexole|capsules; 0.5 mg once-per-day; 4 weeks of treatment
1856683|NCT00991289|Drug|Nitazoxanide (NTZ)|500 mg twice daily, taken orally with food
1856684|NCT00991289|Drug|Pegylated interferon alfa-2a (PEG)|180 micrograms via subcutaneous injection once weekly
1856685|NCT00991289|Drug|Ribavirin (RBV)|Weight-based dosing; 1,000 mg daily, taken orally, for people weighing less than 75 kg or 1,200 mg for people weighing at least 75 kg.
1856686|NCT00991302|Behavioral|CAP-IT|Interventions designed to improve medication adherence, modified to specifically target people first starting highly active antiretroviral therapy (HAART)
1856687|NCT00991328|Procedure|SctO2 < 60 %.|The following intervention protocol will be applied when SctO2 level falls below 60 %. First, the patients head position will be checked for suitable position and the face will be observed for plethora. Then the efforts will be made to maintain PaCO2 between 40-50 mmHg and MAP of 60 - 80 mm Hg. Cardiac index will be maintained between 2.0 - 2.5 L/min/m2. The hematocrit should be more than 20 %. The red blood cells or hemoconcentration will be used for this purpose.
1856688|NCT00991341|Biological|Red blood cell units stored <= 10 days|Pre-storage leukoreduced red blood cell units stored <=10 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
1856689|NCT00991341|Biological|Red blood cell units stored >= 21 days|Pre-storage leukoreduced red blood cell units stored >=21 days at time of transfusion. Can be AS1, AS3, or AS5. Frozen, deglycerolized, washed, and volume-reduced products are protocol violations.
1856690|NCT00991354|Biological|PENNVAX-B|DNA vaccine encoding the Gag, Pol, and Env proteins of HIV
1856691|NCT00991354|Biological|IL-12 DNA plasmids|Adjuvant for HIV vaccines
1856692|NCT00991367|Other|Cicatrix|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
1856693|NCT00991367|Other|Placebo|Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
1856694|NCT00991380|Behavioral|HEALD|A six month, two phase pedometer-based walking program. For weeks one and two of phase I, participants will attend a group-based 60 minute education/supervised walking session. They will be asked to set a daily step goal and to attempt to achieve this on a daily basis over three months. Their steps will be recorded in a step log. For weeks one and two of phase II, participants will learn how to increase the speed of a portion of their daily steps and will learn the concept of low glycemic index and how to set dietary goals related to this concept. They will attend two sixty minute group-based education/supervised walking sessions.
1856695|NCT00991380|Behavioral|Usual Care|Control
1856696|NCT00991393|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS in the area of the dental implant on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments 6 months after surgery for placement of the appropriate prosthetic, and assessment of osseointegration and stability. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
1856697|NCT00991406|Device|EMS 2000|Surface stimulation to contract the muscles in the lower extremity
1856698|NCT00991419|Drug|[18F]AZD4694|[18F]AZD4694 PET Ligand administered at Visit 1, 30 days following screening and at visit 4 for some of the participants.
1856699|NCT00991432|Device|INFUSE® Bone Graft|Patients will be treated with the commercially available INFUSE® Bone Graft material applied to an ACS concurrent with space maintenance devices for soft tissue management on Day 0 (Surgery). A follow-up visit will take place 2 weeks after implant of the INFUSE® Bone Graft material, or as regularly scheduled as per the standard of care (SOC) for the facility. Patients will return to the facility for final End of Study (EOS) assessments approximately 6 months after surgery. Between the follow-up visit and the EOS visit, patients will be seen as per the SOC schedule for the facility.
1856700|NCT00991445|Procedure|Minimal Invasive Surgery|After a 8-10 cm skin incision, a medial parapatellar capsule incision is made. The vastus medialis muscle or the rectus tendon are not incised, nor is the patella everted. The patella is merely pushed slightly aside when the bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
1856701|NCT00991445|Procedure|Conventional exposure|After a 15-20 cm midline skin incision is made, a medial parapatellar capsule incision is made. The incision is carried up through the insertion of the vastus medialis and into the rectus tendon. The patella is everted. The bone cuts are made and the prostheses are cemented in place. Local Infiltration Analgesia is used.
1856702|NCT00991458|Drug|Cyclosporine 0.010% eye drops|Cyclosporine 0.010% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
1856703|NCT00991458|Drug|Cyclosporine 0.005% eye drops|Cyclosporine 0.005% eye drops administered as 1 drop to each eye twice daily (morning and evening) for at least 2 weeks prior to LASIK surgery and up to 7 months post-LASIK surgery.
1856708|NCT00991510|Drug|mycophenolate mofetil (Myfenax)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'T' (test drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
1856709|NCT00991510|Drug|mycophenolate mofetil (Cellcept)|Each participant received at least 500 mg orally, twice daily (morning and evening) during those study periods labeled as 'R' (reference drug). Participants receive the dose equivalent to the pre-study dose (within the recommended therapeutic range) of mycophenolate mofetil.
1856710|NCT00991523|Dietary Supplement|protein|protein
1856711|NCT00991523|Dietary Supplement|placebo|placebo control
1856712|NCT00991549|Behavioral|interdisciplinary intervention or meeting-seminars|one-year individualized interdisciplinary weight loss program vs. small group seminars on healthy lifestyle
1856713|NCT00991562|Drug|IMGN901|dose escalation study. dosing on days 1, 8 and 15 every 28 days
1856714|NCT00991588|Procedure|PCL, posterolateral reconstruction|The operative procedures involve either a single- or double-strand PCL graft which is usually harvested from the patient's knee. In cases of multiple ligament procedures, allograft tissues may be used which are obtained from tissue banks certified by the American Associate of Tissue Banks and that have passed FDA inspection. The posterolateral structures, including the fibular collateral ligament (FCL), are reconstructed with one or two grafts, depending upon the severity of damage encountered at surgery.
1856715|NCT00991601|Procedure|FNAC (fine needle aspiration cytology)|UL guided biopsy
1856716|NCT00991614|Device|EVOLUTION® Duodenal Stent|EVOLUTION® Duodenal Stent
1856717|NCT00991627|Drug|Bupivacaine|10 mg of a 5 mg/ml hyperbaric solution, intrathecally
1856718|NCT00991627|Drug|Morphine|200 µg of a 100 µg/ml solution, intrathecally
1856719|NCT00991627|Drug|Lactated Ringer's solution|25 ml/min intravenously
1856720|NCT00991627|Drug|Ephedrine, continuous infusion|37.5 mg/h intravenously
1856721|NCT00991627|Drug|Ephedrine, bolus|"6.25 mg IV bolus prn.
Hypotension defined according to study protocol for each arm."
1856722|NCT00991627|Drug|Atropine|"0.1 mg/kg iv bolus prn
Bradycardia defined as 50% drop in heart rate from baseline values."
1856724|NCT00991653|Procedure|Fasting blood sample.|Fasting blood sample taken following informed consent for genotyping, glucose and insulin levels.
1856725|NCT00991666|Procedure|blood flow measurement|Fundus pulsation amplitude measurement Pulsatile ocular blood flow measurement
1856726|NCT00991692|Other|Therapy services (ACQUIREc Therapy)|Dosage levels that are associated with the efficacy of intensive therapeutic services provided by OT and PT professionals.
1856727|NCT00991705|Drug|Atorvastatin|
1856728|NCT00991705|Drug|Fimasartan|
1856729|NCT00991718|Drug|GDC-0449 oral capsules (non-labeled)|150 mg oral capsule
1856730|NCT00991718|Drug|GDC-0449 IV injection (labeled)|10 mcg (in 2 mL) IV dose of 14C-GDC-0449
1856731|NCT00991718|Drug|CDC-0449 oral suspension (labeled)|30-mL oral suspension containing 6.5 mcg 14CGDC-0449 and 150 mg GDC-0449
1856734|NCT00991744|Drug|Liposomal cytarabine|Intrathecal liposomal cytarabine combined with intrathecal prednisolone and oral dexamethasone during maintenance treatment for high-risk ALL
1856735|NCT00991744|Drug|Intrathecal triple|Intrathecal methotrexate (8-12 mg), cytarabine (20 - 30 mg) and prednisolone sodium succinate (12,5 - 20 mg) 6 times during maintenance treatment in high-risk ALL protocol
1856736|NCT00991757|Drug|carisbamate|Open-Label Extension: 400 mg/day (up to a maximum of 1200mg/day) given in 2 equally divided doses for up to 1 year (or until carisbamate is available by prescription or the sponsor terminates the study).
1856737|NCT00999323|Device|stent implantation in coronary artery|Percuatenous Coronary Intervention with implanatation of a stent
1856738|NCT00999336|Drug|Betrixaban|80 mg betrixaban qd for 8 days
1856739|NCT00999349|Drug|Silymarin (LEGALON)|Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
1856740|NCT00999349|Drug|Placebo|
1856745|NCT00999401|Drug|sapacitabine and seliciclib|sequential or concomitant administration of sapacitabine and seliciclib
1856746|NCT00999414|Drug|Carfilzomib|"Carfilzomib (20mg/m2) IV push to be given at maximum rate of 10ml/minute on Days 1 and Day 2 of Cycle 1 only.
Carfilzomib (27mg/m2) IV bolus to be given at maximum rate of 10ml/minute on Day 8, 9, 15, and 16 of Cycle 1, then through Cycle 2 and beyond if initial dosing with 20mg/m2 tolerated.
For patients who tolerated 27mg/m2 through cycle 2 Days 1 and 2, Carfilzomib dose may be escalated to 36mg/m2 on days 8, 9, 15 and 16 of cycle 2. If tolerated, subsequent cycles will utilize 36mg/m2."
1856839|NCT01000974|Biological|Pentacel™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
1997301|NCT02141074|Drug|nonacog beta pegol|For intravenous (i.v.) injection. A single dose of 40 U/kg, unless the bleeding episode is severe in which case it should be treated with 80 U/kg.
1997302|NCT02141282|Drug|ABT-199|ABT-199 monotherapy
1997305|NCT02139722|Behavioral|Video Doctor, PA + PPN|The intervention consists of a Video Doctor and Provider Alert. For the Video Doctor, we will develop a series of 30-60 seconds video clips, a branching algorithm, and a mobile application linking the baseline survey to the clips. The Provider Alert is a point-of-care reminder printout generated by the mobile application to facilitate patient-provider communication. The intervention integrates guidelines, literature, guidance from the Systems Model, our prior work, and input from patients and providers.
1997306|NCT02137265|Drug|Clomiphene|Clomiphene citrate 50 mg orally daily
1997307|NCT02137265|Drug|Placebo|One pill every other day
1997309|NCT02133183|Other|Laboratory Biomarker Analysis|Correlative studies
1997310|NCT02133183|Other|Pharmacological Study|Correlative studies
1856747|NCT00999427|Drug|Povidone-iodine|Povidone-iodine 10% solution. A piece of 10x10 cm gauze soaked in Povidone-iodine 10% solution wrapped around the index finger of the examiner is inserted into the rectum of the subject in arm A. This gauze will be wiped back and forth across the prostate with the finger at least five times from one lateral margin of the prostate gland to the other. The examiner will allow at least 2 minutes to elapse between antisepsis and the insertion of the first needle into the prostate in order to allow the Povidone-iodine to dry.
1856748|NCT00999440|Drug|Methadone|ECG (QT, QTc, Heart rate), Urine sample (opiates, benzodiazepines, THC, cocaine, amphetamines, methadone-metabolite), Questionnaire PSQI - perceived sleep - self report , Pain indices (severity, duration, cause, etc.) , usage of other medication for pain and other significant disease/disorders, history of drug abuse, age, sex, place of birth and ethnic origin, comorbidity. Follow up after 4weeks, 6months and 1 year will be done. Patients who start with any opiate and then switch to methadone, move to methadone follow up
1856749|NCT00999453|Other|LDL-cholesterol|This is a 2-arm, open label, multi-center, randomized trial comparing aggressive to standard treatment of LDL-cholesterol. After screening, randomization, participants will be seen every 3 months during the follow-up period. An LDL-cholesterol 100 mg/dL is the goal for the standard group and the target for the aggressive group is 70 mg/dL. A lipid lowering algorithm has been developed based on the NCEP-ATP III recommendation which is used as a general guideline, allowing alterations based on the individual participants needs.
1856750|NCT00999466|Drug|AZD8848|Nasal spray, solution 0.6mg/ mL. Once weekly for 7 weeks, 8 doses in total.
1856751|NCT00999466|Drug|Placebo|Nasal spray, solution. Once weekly for 7 weeks, 8 doses in total.
1856752|NCT00999479|Drug|Norethindrone acetate and ethinyl estradiol tablets, USP|"Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets.
Each white tablet contains 1 mg norethindrone acetate and 20 mcg ethinyl estradiol. Each white tablet also contains the following inactive ingredients: acacia, lactose, magnesium stearate, starch, confectioner's sugar, and talc."
1856753|NCT00999479|Drug|ferrous fumarate (placebo) tablets|Loestrin® 24 Fe provides a dosage regimen consisting of 24 white progestogen-estrogen contraceptive tablets and 4 brown ferrous fumarate (placebo) tablets. Each brown tablet contains ferrous fumarate, microcrystalline cellulose, magnesium stearate, povidone, sodium starch glycolate, and compressible sugar. The ferrous fumarate tablets do not serve any therapeutic purpose.
1992895|NCT03278392|Behavioral|Trier Social Stress Test|Task instructions provided to subject (5mins), subject prepares speech on their strengths and weaknesses (5 mins), subject delivers speech before a stern evaluative committee while being video-taped (5 mins), subject completes a mental arithmetic challenge task before the evaluative committee with critiques if errors are made (5mins).
1997311|NCT02133183|Drug|Sapanisertib|Given PO
1856757|NCT00999518|Biological|Tanezumab|1 mg dose given subcutaneously twice at an 8-week interval.
1856758|NCT00999518|Biological|Tanezumab|2.5 mg dose given subcutaneously twice at an 8-week interval.
1856759|NCT00999518|Biological|Tanezumab|10 mg dose given subcutaneously twice at an 8-week interval.
1856760|NCT00999518|Biological|Tanezumab|20 mg dose given subcutaneously twice at an 8-week interval.
1856761|NCT00999518|Other|Placebo|Placebo dose given subcutaneously twice at an 8-week interval.
1856762|NCT00999531|Drug|GS-9411|Inhaled GS-9411 dissolved in sterile saline
1856763|NCT00999531|Drug|Placebo|Inhaled Placebo, sterile saline
1856764|NCT00999544|Drug|Aprepitant 0mg|Aprepitant 0mg, p.o. pretreatment
1856765|NCT00999544|Drug|Aprepitant 40mg|Aprepitant 40mg, p.o. pretreatment
1856766|NCT00999544|Drug|Aprepitant 200mg|Aprepitant 200mg, p.o. pretreatment
1856767|NCT00999544|Drug|Oxycodone 0mg, p.o.|Oxycodone 0mg, p.o.
1856768|NCT00999544|Drug|Oxycodone 20mg, p.o.|Oxycodone 20mg, p.o.
1856769|NCT00999544|Drug|Oxycodone 40mg, p.o.|Oxycodone 40mg, p.o.
1856770|NCT00999544|Drug|Oxycodone 0mg, IN|Oxycodone 0mg, IN
1856771|NCT00999544|Drug|Oxycodone 15mg, IN|Oxycodone 15mg, IN
1856772|NCT00999544|Drug|Oxycodone 30mg, IN|Oxycodone 30mg, IN
1856773|NCT00999557|Drug|bimatoprost ophthalmic solution|Applied topically
1856774|NCT00999557|Drug|placebo|Applied topically
1856775|NCT00999570|Other|Specialty training for knee surgeons|
1856776|NCT00999583|Drug|EPOETINE ALPHA|5 injections of 40000 UI of EPO
1856777|NCT00999583|Other|Control arm|Usual take care of cardiac arrest
1856778|NCT00999609|Biological|AAV2-hRPE65v2|Subretinal administration of gene therapy vector AAV2-hRPE65v2 (1.5E11 vector genomes per eye) to both eyes via surgical procedures on separate days.
1856779|NCT00999622|Other|laboratory biomarker analysis|
1856780|NCT00999622|Other|questionnaire administration|
1856781|NCT00999635|Device|Insole|Comparison of custom made and prefabricated insoles designed for the neuropathic diabetic foot, issued for day time wear and followed for a 6 month period
1856782|NCT01000597|Drug|fluticasone furoate|"Seven inhaled doses of 200mcg FF given once daily in the morning (Part A; Days 1-7) followed by seven inhaled doses of 800mcg FF given once daily in the morning (Part B; Day 1 and Days 3-8, i.e. no dose on Day 2).
A single intravenous dose of 250mcg FF given over 20 minutes (Day 1)."
1856783|NCT01000610|Drug|rituximab [MabThera/Rituxan]|1000 mg iv infusion on days 1 and 15
1856784|NCT01000610|Drug|methotrexate|10-25 mg weekly (oral or parenteral)
1856785|NCT01000610|Drug|methylprednisolone|100 mg iv prior to each rituximab infusion
1856786|NCT01000623|Drug|venlafaxine|Given orally
1856787|NCT01000623|Drug|placebo|Given orally
1856788|NCT01000623|Procedure|hypnotherapy|Practice hypnosis
1856789|NCT01000623|Procedure|mind-body intervention procedure|Practice focused attention
1856791|NCT01000649|Drug|FE 202158 1.25|FE 202158 at dose 1.25 ng/kg/min infused.
1856792|NCT01000649|Drug|FE 202158 2.5|FE 202158 at dose 2.5 ng/kg/min infused.
1856793|NCT01000649|Drug|FE 202158 3.75|FE 202158 at dose 3.75 ng/kg/min infused.
1856794|NCT01000649|Other|Placebo|Isotonic saline infused.
1856840|NCT01000974|Biological|Pediarix™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
1857053|NCT01002625|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
1856795|NCT01000662|Radiation|Daily Radiation Therapy|15 daily radiation fractions of 2.7 Gy, Monday to Friday for 3 weeks, to the whole breast with a daily concomitant boost of 0.5 Gy to the tumor bed, for a total daily dose of 3.2 Gy to the tumor bed (2.7Gy+0.5 Gy). The overall dose will be 40.5 Gy to the breast and 48.0 Gy to the tumor bed.
1856796|NCT01000662|Radiation|Weekly Radiation Therapy|15 weekly radiation fractions of 2.7 Gy Monday to friday for three weeks to the entire breast with a Friday boost of 2.0 Gy to the tumor bed, for a total dose to the tumor bed on each friday of 4.7 Gy (2.7 Gy+ 2.0 Gy). The overall dose will be 40.5 Gy to the breast and 46.5 gy to the tumor bed.
1856797|NCT01000688|Drug|vildagliptin + acarbose|4 week treatment
1856798|NCT01000688|Drug|acarbose + vildagliptin|4 week treatment
1856800|NCT01000727|Drug|Darapladib 160 mg|Lp-PLA2 inhibitor
1856801|NCT01000727|Drug|Placebo|Placebo administered
1856802|NCT01000727|Other|Standard Therapy|Guideline mandated therapy for individual's condition
1856803|NCT01000740|Genetic|EGFR Mutation Test|Explore the EGFR mutation status from both tumour tissue sample and the free DNA in the peripheral blood using appropriate method(s) which may include ARMS assay, ME-PCR coupled sequencing and regular sequencing.
1856804|NCT01000740|Genetic|Ki-67 protein expression|Ki-67 protein expression in tissue will be analysed by IHC method.
1856805|NCT01000753|Other|biologic sample preservation procedure|
1856806|NCT01000753|Other|informational intervention|
1856807|NCT01000779|Drug|Propranolol|upto 320mg/day maximum
1856808|NCT01000779|Device|multi band ligator for esophageal varices|to obliterate esophageal varices
1856809|NCT01000792|Drug|Levocetirizine|The study drug is Xyzal® 5 mg (API: levocetirizine dihydrochloride). 28 film tablets will be dispensed. Oral intake should be performed once daily (administration in the evening).
1856810|NCT01000792|Drug|Levocetirizine|Levocetirizine
1856811|NCT01000805|Drug|Duloxetine|Participants received 30 mg duloxetine once daily (QD) by mouth (po) for 1 week followed by 60 mg QD, po for 7 weeks.
1856812|NCT01000805|Drug|Placebo|Participants received placebo QD, po for 8 weeks.
1856813|NCT01000818|Drug|MK0518 (Raltegravir)|400 mg oral tablet of MK0518 once every 12 hours. Period 1 duration is one day, Period 2 duration is one day, Period 3 duration is five days.
1856814|NCT01000818|Drug|famotidine|Single 20 mg famotidine oral tablet taken 2 hours prior to administration of AM dose of MK0518
1856815|NCT01000818|Drug|omeprazole|20 mg oral tablet of omeprazole, once daily for 5 days
1856816|NCT01000831|Biological|adjuvanted Arepanrix|Two doses of adjuvanted Arepanrix vaccine given 3 weeks apart
1856817|NCT01000857|Drug|Paroxetine CR and Paroxetine IR|Randomized, 2-period crossover repeat dosing of Paroxetine CR at 25 mg/day for 14 days and Paroxetine IR at 20 mg/day for 14 days in Japanese healthy male volunteers
1856818|NCT01000870|Drug|MNI-513-01|Subjects will be administered a single IV injection of IMP with a total activity amounting to 300MBq (8.1 mCi) +/- 20% of MNI-513 followed by PET imaging.
1856822|NCT01000896|Drug|AZD0530|film coated tablet, PO, daily
1856823|NCT01000896|Drug|Carboplatin|intravenous, 3 weeks
1856824|NCT01000896|Drug|paclitaxel|intravenous, 3 weeks
1856825|NCT01000909|Procedure|Ultrasound (venous pressure measurement)|increased venous pressure is predictive for chronic venous insufficiency
1856826|NCT01000922|Drug|Regular Human Insulin|Individual dose of RHI administered subcutaneously
1856827|NCT01000922|Drug|Lispro|Individual dose of lispro administered subcutaneously
1856828|NCT01000922|Drug|VIAject|Individual dose of VIAject administered subcutaneously
1856829|NCT01000922|Drug|VIAject 50%|Individual dose of VIAject 50% administered subcutaneously
1856830|NCT01000922|Drug|VIAject/Insulin Glargine|VIAject mixed wiht insulin glargine and administered subcutaneously
1856831|NCT01000922|Drug|Insulin Glargine/VIAject|Individual dose of VIAject and Insulin Glargine administered seperately and subcutaneously
1856834|NCT01000948|Drug|ZD4054|ZD4054 10 mg given orally, once daily in tablet form to all patients in two years or until investigator consider the drug for useless.
1856835|NCT01000961|Drug|Cystagon® (Cysteamine Bitartrate)|"Run-in Period (Weeks 1, 2, 3) and Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:
Every 6H, supplied in 150 and 50mg capsules/Duration of Treatment: 3 weeks each period used"
1856836|NCT01000961|Drug|Cysteamine Bitartrate Delayed-release Capsules (RP103)|"Period 1 (Weeks 4, 5, 6) or Period 2 (Weeks 7, 8, 9); Immediate crossover to opposite treatment than taken during Period 1:
Every 12H, supplied in 75 and 25mg capsules/Duration of Treatment: 3 weeks"
1856837|NCT01000974|Biological|GSK Biologicals' Haemophilus influenzae type b vaccine (GSK 208108)|Three doses of 3 different manufacturing lots in primary study at 2, 4 and 6 months of age as intramuscular injection and one dose as booster vaccination.
1856838|NCT01000974|Biological|ActHIB™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection and one dose as a booster vaccination
1997312|NCT02133183|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1997313|NCT02131467|Drug|Perampanel|oral drug
1997314|NCT02132065|Drug|TAP block|Patients will be scheduled to receive routine analgesic and an unilaterally dual TAP block with 2 points injections of 15 ml of 0,375 % Ropivacain( in total 30 ml 0,375% Ropivacain) in the same side of nephrectomy.
1997315|NCT02129816|Drug|Bryophyllum|
1997316|NCT02129517|Other|IMPACT intervention|Tailored, web-based educational short video clips
1997317|NCT02129517|Other|Online education materials|Online NCI-based educational materials
1997318|NCT02129517|Other|survey administration|Ancillary studies
1997319|NCT02129348|Drug|Lithium|
1997320|NCT02129348|Drug|Placebo|
1856841|NCT01000974|Biological|Prevnar 13™|Three doses in primary epoch at 2, 4 and 6 months of age as intramuscular injection
1856842|NCT01000974|Biological|Rotarix™|Two oral doses in primary epoch at 2 and 4 months of age
1856843|NCT01000974|Biological|Engerix™-B|Two or three doses in primary epoch at 2,( 4) and 6 months of age as intramuscular injection
1856844|NCT01000974|Biological|Infanrix™|One dose in the booster epoch at 15-18 months of age as intramuscular injection
1856845|NCT01000987|Drug|varenicline|1mg/day or 2 mg/day Subjects are at steady state medication levels. They are participating during the 4-week medication period of our ongoing study, NCT00580645.
1856846|NCT01000987|Drug|placebo|placebo
1856847|NCT01001000|Procedure|Ultrasound (Pressure measurement)|cut-off value for non maturationg fistulas
1856848|NCT01001013|Drug|LC15-0444, Pioglitazone|LC15-0444 200 mg (100 mg x 2) qd (12 days once daily) Pioglitazone 30 mg (15 mg x 2) qd (12 days once daily) LC15-0444 200 mg (100 mg x 2) qd + pioglitazone 30 mg (15 mg x 2) qd (12 days once daily)
1856849|NCT01001026|Biological|Arepanrix|Adults: One dose Arepanrix vaccine given IM (0.5 mL)
1856850|NCT01001026|Biological|Arepanrix|Children: Two doses of Arepanrix vaccine given IM (0.25 mL) three weeks apart
1856851|NCT01001052|Drug|Colcrys™ (colchicine)|0.6 mg taken by mouth on day 1
1856852|NCT01001065|Procedure|Vascular ultrasound|RI ist predictive for arteriosclerosis
1856853|NCT01001078|Device|I-Gel supraglottic airway device|2 attempts to secure the airway will be tried. If they both fail, there will be a crossover with a Supreme LMA.
1856854|NCT01001078|Device|LMA Supreme supraglottic airway device|In the LMA Supreme group, the same interventions will be done as in the I-Gel group. The cuff of the LMA Supreme will be inflated with 25 mL of air and then by intervals of 5 mL until no leak is heard (max 45 mL). Leak pressure will also be measure at 45 mL. Once the leak test is done, the cuff will be deflated to initial volume necessary to avoid audible leaks.
1856855|NCT01001078|Device|Standard endotracheal tube|In case both supraglottic airway devices fail, a standard endotracheal tube will be inserted
1856856|NCT01001091|Drug|AL-38583 ophthalmic solution|
1856857|NCT01001091|Drug|AL-38583 ophthalmic solution vehicle|Inactive ingredients used as a placebo comparator
1856858|NCT01001091|Drug|Dexamethasone ophthalmic suspension, 0.1%|
1856859|NCT01001104|Drug|LY2189265|Administered by subcutaneous (SC) injection, once weekly (QW) for 12 weeks.
1856860|NCT01001104|Drug|Placebo|Administered by SC injection, QW for 12 weeks.
1856861|NCT01001117|Device|LensAR laser surgery|Use of laser for cataract surgery
1856862|NCT01001117|Device|Phaco-emulsification cataract surgery|Phaco-emulsification cataract surgery
1856863|NCT01001130|Drug|fluticasone furoate group|patients who are administered fluticasone furoate at least once
1856864|NCT01001143|Drug|Decitabine|
1856865|NCT01001143|Drug|Bexarotene|
1856866|NCT01001156|Other|Comparison of different breathing muscular training|Three times per week for ten weeks, thirty minutes.
1856867|NCT01001169|Biological|GSK Biologicals' Pandemic influenza (H1N1) candidate vaccine (GSK2340274A)|Two intramuscular injections
1856868|NCT01001182|Other|non interventional|non interventional
1856869|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.1%|One drop of AGN-210669 ophthalmic solution, 0.1% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
1856870|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.075%|One drop of AGN-210669 ophthalmic solution, 0.075% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
1856871|NCT01001195|Drug|AGN-210669 ophthalmic solution, 0.05%|One drop of AGN-210669 ophthalmic solution, 0.05% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
1856872|NCT01001195|Drug|bimatoprost ophthalmic solution 0.03%|One drop of bimatoprost ophthalmic solution 0.03% in both eyes each evening from Day 1 through the evening prior to Day 29. Selected sites: One additional drop in both eyes on Day 29.
1856873|NCT01001208|Drug|Methotrexate|Methotrexate tablets over-encapsulated for blinding
1856874|NCT01001208|Drug|Etanercept|1 mL for subcutaneous injection
1856875|NCT01001208|Drug|Placebo|Matching placebo to methotrexate capsules
1856876|NCT01001221|Drug|cabazitaxel|"Pharmaceutical form: 60 mg/1.5 ml concentrate solution for infusion
Route of administration: Intravenous infusion over 60 minutes
Dosage:
Study part 1: 15, 20 or 25 mg/m^2 according to pre-defined dose escalation schedule
Study part 2: MTD as determined in Study part 1"
1856877|NCT01001221|Drug|gemcitabine|"Pharmaceutical form: According to United States Package Insert (USPI)
Route of administration: Intravenous infusion over 30 minutes
Dosage:
Study part 1: 700, 900 or 1000 mg/m^2 according to pre-defined dose escalation schedule
Study part 2: MTD as determined in Study part 1."
1856878|NCT01001234|Drug|rizatriptan|"For participants randomized to rizatriptan in Stage 1: a single 5 or 10 mg rizatriptan orally disintegrating tablet (ODT) was to be taken within 30 minutes of onset of qualifying migraine (defined as a migraine of moderate or severe intensity).
Rizatriptan dose administered was based on participant weight at Screening: those <40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
1856879|NCT01001234|Drug|placebo|For participants randomized to placebo in Stage 1: a single placebo ODT was to be taken within 30 minutes of onset of qualifying migraine.
1856880|NCT01001234|Drug|rizatriptan|"For participants randomized to rizatriptan in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder [moderate or severe pain 15 minutes after dose] to be randomized at Stage 2): a single 5 or 10 mg rizatriptan ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
Rizatriptan dose administered was based on participant weight at Screening: those <40 kg received 5 mg tablet, those ≥40 kg received 10 mg tablet."
1856881|NCT01001234|Drug|placebo|For participants randomized to placebo in Stage 2 (must have taken placebo in Stage 1 and was Non-Responder to be randomized at Stage 2) or allocated to placebo in Stage 2 (took rizatriptan in Stage 1 and was Non-Responder): a single placebo ODT was to be taken approximately 15 minutes post Stage 1 dose, to treat same qualifying migraine treated in Stage 1.
1856882|NCT01001247|Drug|TMC278; Omeprazole|
1856886|NCT01001273|Other|Hyperinsulinemic Normoglycemic Clamp|The patient receives insulin intravenous infusion at 2ml units/kg/min. Dextrose 20% (D20W ®) will be titrated to maintain blood glucose between 4 - 6 mmol/L (72 - 108 mg/dl).
1856887|NCT01001286|Behavioral|Questscope Non-Formal Education|"Participation in two-hour classes for three to five days per week. Duration involves 24 months of programming (three, eight-month learning cycles), but this randomized controlled trial will only assess impacts of participation in the first four months.
Regular presence of trained, supportive adults. Educational topics and class activities determined by the youth as a group with the support of the adult teachers (facilitators)."
1856888|NCT01001299|Drug|Drug cocktail|Drug cocktail (caffeine, warfarin + vitamin K, omeprazole, dextromethorphan, midazolam) orally once daily, day 1 and day 20
1856889|NCT01001299|Drug|RO5185426|960 mg orally twice daily
1856890|NCT01001312|Other|Daxor Blood Volume Analysis|Radiolabeled albumin for direct measurement of blood volume
1856891|NCT01001312|Other|Clinical volume status assessment|Volume assessment based on history and physical examination
1856892|NCT01001325|Biological|Fluviral influenza vaccine, 2009-2010|0.5 mL intramuscular
1856893|NCT01001325|Biological|Normal saline|0.5 mL intramuscular
1856897|NCT01001351|Drug|PRT-201|Applied topically during surgery.
1856898|NCT01001351|Drug|Placebo|Applied topically during surgery
1856899|NCT01001364|Drug|Formoterol/Budesonide|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
1856900|NCT01001364|Drug|Foraseq|formoterol will be administered at the 12 µg dosage, twice a day, and budesonide will be administered at the 200 µg dose, also twice a day for 12 weeks.
1856901|NCT01001377|Drug|Cetuximab|Administered by intravenous infusion
1856902|NCT01001377|Drug|Panitumumab|Administered by intravenous infusion
1856903|NCT01001390|Device|AFO Device|Ankle Foot Orthoses impact on net oxygen consumption.
1856904|NCT01001403|Drug|Nafamostat|0.2 mg/kg as bolus 1 minute before reperfusion
1856905|NCT01001403|Drug|Normal saline|10 ml of normal saline
1856906|NCT01001429|Drug|Dexmedetomidine infusion|bolus of 0.5ug/kg intravenously over a period of 10-15 minutes, followed by an infusion of 0.2-0.7ug/kg/hr of drug
1856907|NCT01001429|Drug|propofol|propofol 1mg/kg intravenously as a bolus followed by 25-100ug/kg/min
1856908|NCT01001442|Drug|BT062|intravenous administration
1856909|NCT01001468|Drug|VB-201|Single daily dose of oral VB-201 20 mg
1856910|NCT01001468|Drug|VB-201|Single daily dose or oral VB-201 80 mg
1856911|NCT01001468|Other|Placebo|Single daily dose of oral placebo
1856912|NCT01001481|Other|Risk status for medication adherence|Examination of risk status for medication adherence in a cohort of Australian patients diagnosed with schizophrenia
1856913|NCT01001494|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
1856914|NCT01001494|Drug|Aclidinium bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by the Eklira Genuair® inhaler: 1 puff in the morning and evening for 24 weeks
1856915|NCT01001494|Drug|Placebo|Placebo twice-daily by inhalation for 24 weeks
1856916|NCT01001507|Procedure|Integrated family planning/HIV care and treatment services|Family planning services will be provided during the patient's HIV care visit.
1856917|NCT01001520|Drug|Tolcapone|"Participants will be asked to take study medication each day for both 11-day study medication periods.
The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
1856918|NCT01001520|Drug|Placebo|"Participants will be asked to take study medication each day for both 11-day study medication periods.
The study medication assignments for each participant in this project is randomized and counterbalanced. This means that approximately 50% of participants will take tolcapone during the first medication period, followed by the placebo in the second medication period. Alternatively, approximately 50% of participants will take the placebo during the first medication period, followed by tolcapone during the second medication period."
1856919|NCT01001546|Behavioral|Internet-based|Veterans randomized to the QuitNet will immediately be given access to the Premium, lifetime membership services.
1856920|NCT01001546|Behavioral|Standard Clinic-Based|Veterans randomized to the control condition will have a consult placed to the Durham VA Medical Center (DVAMC) specialty Smoking Cessation Clinic placed on their behalf.
1856921|NCT01001559|Drug|L-methylfolate|Subjects must have been on their respective therapies for a minimum of 60 days. L-methylfolate dosing was 7.5 mg or 15 mg daily
1856922|NCT01001559|Drug|Selective serotonin reuptake inhibitor (SSRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
1856923|NCT01001559|Drug|Serotonin and norepinephrine reuptake inhibitor (SNRI)|Subject must have been on their respective therapy for a minimum of 60 days. Because this was an observational retrospective analysis, dosing of SSRI/SNRI varied on a per patient basis.
1856924|NCT01001572|Drug|Valsartan/amlodipine 160/5 mg|Valsartan/amlodipine 160/5mg film coated tablets taken orally once daily.
1856925|NCT01001572|Drug|Valsartan 160 mg|Valsartan 160 mg capsule taken orally once daily.
1856926|NCT01001572|Drug|Placebo|1 capsule or tablet taken orally once daily
1856927|NCT01001585|Drug|sevoflurane|During induction, concentration of inspired sevoflurane will begin at .5%, and slowly increased by 0.5% every two minutes, until a Bispectral Index (BIS) of 60 or less is reached, which will take approximately 10 minutes.
1856928|NCT01001598|Drug|danazol|Dosage is done according to weight; capsules are 50, 100, 200 mg
1856929|NCT01001611|Drug|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 24 weeks or 52 weeks (If extension study)
1857095|NCT01002963|Drug|PF-04418948|solution, 300 mg, single
1856930|NCT01001611|Drug|Placebo|Indistinguishable tablet from CKD-501, Orally, 1 tablet once daily for 24 weeks
1856931|NCT01001624|Other|Melanil facial cream|Dosage commensurate with surface to be treated, Melanil facial cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Melanil facial cream.
1856932|NCT01001624|Other|Hydroquinone 2% cream|Dosage commensurate with surface to be treated, Hydroquinone 2% cream (Topical use), twice a day, for 8 weeks. The affected surface will be washed and dried before application with a thin layer of Hydroquinone 2% cream.
1856933|NCT01001637|Dietary Supplement|Curcumin Formulation|2000mg or 3000mg daily BID
1856934|NCT01001637|Dietary Supplement|Placebo|Placebo
1856935|NCT01001650|Biological|Plasmodium falciparum Sporozoite (strain NF-54; Anopheles stephensi mosquitoes) Vaccine, Live, Inactivated (gamma irradiation)|"Group 1: 4 doses of 7,500 PfSPZ/immunization,
Group 2: 4 doses of 30,000 PfSPZ/immunization,
Group 3: 4 doses of 135,000 PfSPZ/immunization, and
Group 4: 4 or 6 doses of 135,000 PfSPZ/immunization.
If > 80% protective efficacy is not achieved in Groups 1, 2, or 3, volunteers in Group 4 will receive a fifth and sixth dose."
1856936|NCT01001663|Device|FemoSeal®|Closure device for femoral artery access closure
1856937|NCT01001663|Other|Manual compression|Conventional manual compression
1856938|NCT01001676|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty with the use of Conventional balloon
1856939|NCT01001676|Device|Paclitaxel Eluting Balloon Angioplasty|Angioplasty with the use of paclitaxel eluting balloon
1856940|NCT01001689|Behavioral|Nutritional counseling and twice weekly exercise groups|Two telephone consultations on nutritional topics and twice weekly exercise groups. Access to a password-protected internet site with information on healthy lifestyle during pregnancy. Two evening meetings with information on healthy pregnancy lifestyle.
1856941|NCT01001702|Drug|Aripiprazole|Flexible dose between 5 mg and 30 mg Aripiprazole tablets.
1856942|NCT01001715|Drug|REGN475/SAR164877|"Pharmaceutical form: solution
Route of administration: intravenous infusion over 30 minutes"
1856943|NCT01001715|Drug|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution
Route of administration: intravenous infusion over 30 minutes"
1856944|NCT01001728|Radiation|Imaging investigations (with radiation)|
1856945|NCT01001741|Other|Cell phone text message|We will use cellular text messages to remind patients of impending drug prescription refills and scheduled visits to their healthcare provider.
1856946|NCT01001754|Drug|PEG-rIL-29|Weekly SC injections in combination with ribavirin for up to 48 weeks
1856947|NCT01001754|Drug|Peginterferon alfa-2a|Weekly SC injections in combination with ribavirin for up to 48 weeks
1856948|NCT01001754|Drug|Ribavirin|Daily oral administration (400-600 mg BID)
1856949|NCT01001767|Drug|Lovaza|Lovaza one gram twice a day for 24 weeks
1856950|NCT01001767|Drug|Placebo|Placebo
1856951|NCT01001780|Drug|Pentostatin; Cyclophosphamide; Rituximab|Pentostatin 2mg/m2 IV day+1 (up to 6 cycles) Cyclophosphamide 600mg/m2 IV day+1 (up to 6 cycles) Rituximab 375mg/m2 IV day+1 (up to 6 cycles)
1856952|NCT01001793|Device|Levacor Ventricular Assist Device|Surgical procedure
1856953|NCT01001806|Drug|Ketorolac Tromethamine 0.45%|One drop BID the day before surgery and then 3 doses the day of surgery prior to surgery
1856954|NCT01001806|Drug|bromfenac 0.09%|One day pre operative 1 drop BID then 3 doses pre op day of surgery
1856955|NCT01001806|Drug|nepafenac 0.1%|One drop BID, 1 day pre operative and then 3 doses the day of surgery
1856956|NCT01001832|Drug|Intravenous (IV) abatacept|IV vial, 125-mg infusions on Days 1, 15, and 29, and every 28 days thereafter until Day 141.
1856957|NCT01001832|Drug|Subcutaneous (SC) abatacept|Solution in prefilled syringes, SC, 125 mg, once weekly, for 169 days and then for 52 weeks
1856958|NCT01001845|Drug|Milk Thistle extract|1 tablet equivalent to 140 mg of silymarin, 3 times daily for 3 weeks
1856959|NCT01001845|Drug|vit E|200 mg twice daily for 3 weeks
1856960|NCT01001845|Drug|vit E + Milk Thistle extract|200 mg vit E twice daily + 1 tablet of Milk Thistle 3 times daily for 3 weeks
1856961|NCT01001858|Other|Diagnosis and monitoring of OSA patients|The difference between the three strategies is given by the method used for OSA diagnosis (domiciliary RP or hospital PSG) and the type of monitoring carried out after initiating CPAP treatment (by physician at hospital or by a trained nurse in patient's home)
1856962|NCT01001871|Dietary Supplement|Sprinkles®|powdered vitamin/mineral fortificant WITH iron sprinkled onto food once a day for 5 months
1856963|NCT01001871|Dietary Supplement|vitamin/mineral fortificant without iron|powdered vitamin/mineral fortificant WITHOUT iron sprinkled onto food once a day for 5 months
1856964|NCT01001884|Other|caregiver psychoeducational consultation program (CPCP)|6-session caregiver psychoeducational consultation program (CPCP)
1989575|NCT02454608|Drug|Verapamil HCl|Verapamil represents a calcium channel blocker which binds to the alpha subunit of L-type voltage dependent calcium (Cav1) channels thereby blocking the influx of calcium ions into the host cell. While Verapamil is classically used to promote the relaxation of cardiac and smooth muscle cells, recent evidence has suggested that it may also function as an immunomodulator in astrocytes, hepatocytes, and T-cells. Further research has demonstrated that Verapamil is capable of specifically reducing Th2 associated inflammation in asthma. These findings raise the provocative question as to whether Verapamil could also be effective in reducing inflammation in chronic rhinosinusitis with nasal polyps.
1856967|NCT01001910|Drug|Carboplatin|Given IV
1856968|NCT01001910|Other|Laboratory Biomarker Analysis|Correlative studies
1856969|NCT01001910|Drug|Pemetrexed Disodium|Given IV
1856970|NCT01001923|Drug|REGN475/SAR164877|"Pharmaceutical form: solution
Route of administration: intravenous infusion over 30 minutes"
1856971|NCT01001923|Drug|Placebo (for REGN475/SAR164877)|"Pharmaceutical form: solution
Route of administration: intravenous infusion over 30 minutes"
1856972|NCT01001936|Drug|SKI-606|
1856973|NCT01001949|Dietary Supplement|Wheat Bran Extract|soft drink comprising WBE and natural flavor and coloring agent, ingestion after breakfast and after dinner
1856974|NCT01001949|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and dinner
1856975|NCT01001962|Drug|empagliflozin|ACTIVE TREATMENT FOR DIABETES
1856976|NCT01001962|Drug|Metformin|ACTIVE TREATMENT FOR DIABETES
1856980|NCT01002014|Procedure|Nipple Sparing Mastectomy|Skin sparing mastectomy with preservation of the nipple areolar complex
1856981|NCT01002027|Behavioral|CBT-Counselling|Intervention entailed six sessions of counselling-CBT delivered either by a trained Nurse, or by a Psychologist. Sessions focussed on: psycho-education about PND, main issues of concern, assessment of symptom severity, problem solving. Behavioural interventions (pleasant activities, anxiety management, relaxation, relationship communication) were used together with cognitive interventions (understanding links between thoughts and feelings, increasing positive thoughts, challenging negative self-talk and unhelpful beliefs).
1856982|NCT01002040|Biological|Arepanrix|Group A receives one dose of Arepanrix
1856983|NCT01002040|Biological|Arepanrix|Group B receives 2 doses of Arepanrix 3 weeks apart
1856984|NCT01002053|Procedure|Nerve conduction study and Ultrasound of the PTN|Nerve Conduction studies and ultrasound of PTN will be performed to the patient before the operation and 8 weeks postoperatively.
1856985|NCT01002079|Drug|BMS-708163|Capsule, Oral, 125 mg, Once daily, 1 day
1856986|NCT01002079|Drug|Rifampin|Capsule, Oral, 600 mg, Once daily, 7 days
1856987|NCT01002079|Drug|Rifampin|Capsule, Oral, 600 mg, Once daily, 6 days
1856988|NCT01002092|Drug|Chemotherapy|Week 1 day 1 MTX 8 g/m2; Week 3 day 1-2 CDP 100-120 mg/m2 day 1 ADM/THP 60 mg/m2; Week 5 day 1-6 IFO 2 g/day; Week 7 rest; Week 8 surgery; Two weeks after the surgery repeat the chemotherapy cycle 3 times (6 weeks per cycle).
1856989|NCT01002092|Drug|Endostar|In each cycle, Week 1-2 day 1-14 endostar 7.5 mg/m2/day; Week 5-6 day 1-14 endostar 7.5 mg/m2/day
1856990|NCT01002105|Drug|Baclofen|Baclofen 50mg per day for 12 weeks and psychosocial intervention
1856991|NCT01002105|Other|Control group|psychosocial intervention and placebo for 12 weeks
1856992|NCT01002118|Drug|Omega-3 Acid Ethyl Esters|1 gram capsules Omega-3 Acid Ethyl Esters for a total of 4 grams (4 capsules) per day for 16 weeks
1856993|NCT01002118|Drug|Placebo|4 capsules each day for 16 weeks
1856994|NCT01002131|Device|CBCT|Cone Beam Computer Tomography. 3D-imaging Digital Volume Tomography, compared with gold standard intraoperative findings.
1856995|NCT01002144|Other|blood sampling|
1856996|NCT01002157|Dietary Supplement|Menaquinone-7 (Vitamin K2)|Menaquinone-7 (Vitamin K2)
1856997|NCT01002157|Other|Placebo capsules|Capsules containing no Menaquinone-7
1856998|NCT01002183|Drug|Fosmidomycin|450 mg capsules, every 12 hrs for 3 days
1856999|NCT01002196|Behavioral|Stimulus fading procedures|"Core elements : 1.Behavior techniques (BT's) are used to gradually master the anxiety (stimulus fading and reward).
2. Children are first met at home where they feel most safe, and the BT's are first conducted at home in cooperation with the parents.
3.The same interventions are then continued in the environment where the problem primarily exist (kindergarten / school) not at the clinic.
4.Defocused communication- and interaction is a general treatment principle (e.g. avoid looking directly at the child, sit beside not opposite to the child, no direct questioning, and communication is based upon a motivating activity, not about the child).
5.Frequent and short interventions. 6.Information to parents and teachers on how to communicate with children with SM"
1857000|NCT01002196|Behavioral|Guidance on defocused communication|Guidance and supervision to teachers working with the children with SM. Frequency: Twice during three months
1857001|NCT01002209|Procedure|Hyperbaric Oxygen treatment (HBO)|"HBO treatment will be given in a monoplace chamber and will start on first postoperative day (study day 1). The HBO group will be treated with 100% oxygen at 2.5 bar for 100 min with two 10 min airbrakes (without mask).
HBO treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO/placebo treatment and who have a clearly uncomplicated postoperative course will terminate HBO/placebo treatment on the day of discharge from hospital."
1857002|NCT01002209|Procedure|Sham HBO|"HBO sham treatment will start on first postoperative day (study day 1). HBO sham treatment will be given twice daily first three days (study day 1-3) and then once daily for up to three days (study day 4-6). The total number of treatments will be at least 6 and at most 9 treatments. Patients who have received at least three days HBO sham treatments and who have a clearly uncomplicated postoperative course will terminate HBO sham treatment on the day of discharge from hospital.
For patient blinding purposes, the sham group will breathe air and will be given a brief compression to 1.5 bar at the beginning of each treatment after which the chamber is slowly decompressed to 1.1, 1.2 , 1.3, or 1.4 bar corresponding to 0.23 ,0.25, 0.27, and 0.29 bar inspired oxygen. Two 10 min airbrakes will also be included."
1857003|NCT01002222|Drug|MCS-2|15 or 30 mg/day of MCS-2 soft-gel capsules Qd for 24 weeks, depending on which dose level is selected after the phase 2b part of the protocol MCS-2-US-a.
1857004|NCT01002235|Genetic|VM202|Intramuscular injections in the calf on Day 0 and Day 14.
1857005|NCT01002248|Drug|Perifosine|Perifosine will be dosed as one 50 mg pill every day of each cycle.
1857006|NCT01002248|Drug|Perifosine Placebo|Perifosine placebo will be dosed as one 50 mg pill every day of each cycle.
1857007|NCT01002248|Drug|Bortezomib|Bortezomib will be dosed at 1.3 mg/m2 on Days 1, 4, 8, and 11 every 21 days.
1857008|NCT01002248|Drug|Dexamethasone|Dexamethasone will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of each 21-day cycle.
1857009|NCT01002274|Drug|MCS-2|2 soft-gel capsules Qd for 40 weeks
1857010|NCT01002287|Device|SprayShield Adhesion Barrier System|Adhesion Barrier Device
1857011|NCT01002287|Procedure|Good Surgical Technique Alone|Good Surgical Technique Alone
1857012|NCT01002300|Drug|intranasal oxytocin|Participants will receive 24 IU of oxytocin or placebo (Salinex saline nasal spray) intranasally 30 minutes prior to completing the experimental tasks. Two weeks later participants will return for a second visit and receive the alternate drug (either intranasal oxytocin or Salinex) prior to completing the experimental tasks.
1857013|NCT01002326|Behavioral|Cognitive-Behavioral Therapy|20 sessions of Cognitive-Behavioral Therapy
1857014|NCT01002339|Drug|Tacrolimus with rapid steroid withdrawal|"Basiliximab induction (4 mg i.v., days 0 and 4).
Corticosteroids: 0.5 gr of i.v. Methylprednisolone (MP) intraoperatively and 125 mg on the first day, followed by oral doses of prednisone rapidly tapered from 30 mg/day to complete discontinuation by postoperative day 7.
Tacrolimus: 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.
Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
1857015|NCT01002339|Drug|Tacrolimus with steroids minimization|"Basiliximab induction (4 mg i.v., days 0 an 4)
Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.
Tacrolimus 0.15 mg/Kg/day to achieve target trough levels of 8-12 ng/ml for the first month and then 5-8 ng/ml.
Mycophenolate mofetil 1 gr b.i.d. for the first month and then 500 mg b.i.d."
1857016|NCT01002339|Drug|CsA with steroid minimization|"Basiliximab induction (4 mg i.v., days 0 an 4)
Corticosteroids: 0.5 gr of i.v. MP intraoperatively and 60 mg on the first day, followed by oral doses of prednisone starting with 0.3 mg/Kg/day, and gradual weekly tapering to complete discontinuation over 6 months.
CsA 5 mg/Kg/day to achieve target trough of 150-200 ng/ml the first month and then 100-150 ng/ml.
Mycophenolate mofetil 1 gr b.i.d"
1857017|NCT01002365|Other|Oxygen delivery|
1857018|NCT01002365|Other|Oxygen administration|
1857019|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a high fat breakfast
1857020|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered immediately following a low fat breakfast
1857021|NCT01002378|Drug|Regorafenib (Stivarga, BAY73-4506)|A single dose of regorafenib will be administered following an overnight fast
1857022|NCT01002391|Procedure|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the first postoperative day
1857023|NCT01002391|Procedure|reduction mammaplasty|Dressing following reduction mammaplasty is removed on the sixth postoperative day
1857024|NCT01002404|Procedure|angled and straight tipped guide wire|Angled or straight tipped guide wire is used in the beginning of deep biliary cannulation in ERCP . If there is no success, other normal procedures (e.g. double wire cannulation and precut) are performed.
1857025|NCT01002417|Drug|MCS-2 15 mg/day|One MCS-2 15 mg soft-gel capsule plus one matching placebo capsule, oral daily for 12 weeks.
1857026|NCT01002417|Drug|MCS-2 30 mg/day|Two MCS-2 soft-gel capsules, oral daily for 12 weeks.
1857027|NCT01002417|Drug|Placebo|Two matching placebo soft-gel capsules, oral daily for 12 weeks.
1857028|NCT01002430|Biological|VEGF-D gene transfer|Gene transfer will be performed by using endocardial injection system (NOGATM) and an escalating dose of 1x109, 1x1010 and 1x1011 vpu of AdVEGF-D will be injected into 10 sites of the myocardium (0.2 ml per site).
1857029|NCT01002443|Drug|Helicobacter pylori eradication|Omeprazole 20 mg or Rabeprazole 10 mg bid + clarithromycin 500 mg and amoxicillin 1,000 mg bid for 7 days
1857030|NCT01002443|Drug|placebo|Omeprazole 20 mg or Rabeprazole 10 mg bid + two placebo (for antibiotics) for 7 days
1857031|NCT01002456|Other|Level 1: (provide site-specifi information)|provide site-specific information on non-adherence to guideline
1857032|NCT01002456|Other|Level 2 (Provide site- and patient-specific information)|provide site-specific information on non-adherence to guideline as well as list of patients with non-adherent prescriptions
1857033|NCT01002469|Other|sodium [1-13C] acetate|
1857034|NCT01002482|Device|CGAO-based Glucose Control|"Use of a clinical computerized decision-support system named CGAOtm designed to achieve tight glucose control in various ICU settings, and fine-tuned to reduce glucose variability without increasing the incidence of severe hypoglycemia or nurse workload.
CGAOtm is based on explicit replicable recommendations following each blood glucose measurement for insulin rates and time to next measurement, and reminders, alerts, graphic tools, trends, and individual on-line data aimed at increasing confidence of the nursing staff in the computer protocol and giving care staff a method for controlling the process during the whole ICU stay, according to a human-in-the-loop approach.
The algorithm used in the CGAOtm software for the calculation of the recommended insulin rates derived from a PID (Proportional-integral-derivative) controller, a generic control loop feedback mechanism widely used in industrial control."
1857035|NCT01002482|Device|Standard-Care Glucose Control|"Patients in the control group will receive conventional insulin therapy using the usual care protocol of each participating centre (already used in the centre before the beginning of the trial and targeting blood glucose levels inferior to 180 mg/dl)."
1857036|NCT01002495|Genetic|VM202|Endocardial injections on Day 0.
1857037|NCT01002508|Biological|Influenza vaccine|One dose of influenza vaccine
1857038|NCT01002534|Drug|Vardenafil|Nasal instillation of Vardenafil
1857039|NCT01002534|Drug|Placebo|Nasal instillation of placebo matching in appearance with the Vardenafil instillation
1857040|NCT01002547|Drug|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
1857041|NCT01002547|Drug|pioglitazone|Pioglitazone will be started on 30 mg/day, titrated to the maximal dose (45 mg/day) at two months and continued at this dose for the rest of the clinical trial.
1857042|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
1857043|NCT01002547|Drug|pioglitazone-placebo|This is a RCT in which all patients will be educated on a -500 kcal/day diet and a healthy lifestyle. Depending on randomization, subjects adjudicated to placebo will be started at the same time as the active (pioglitazone) arm following completion of the baseline measurements and continued on placebo for the rest of the clinical trial.
1857044|NCT01002547|Dietary Supplement|Vitamin E|All participants will receive vitamin E 400 IU orally twice daily.
1857045|NCT01002547|Drug|Vitamin E-placebo|Placebo of vitamin E will be given to arm 3.
1857046|NCT01002573|Drug|ibuprofen|Ibuprofen, 10 mg/kg
1857047|NCT01002573|Drug|acetaminophen|Acetaminophen, 10mg/kg
1857048|NCT01002586|Other|Wii-Fit intervention|Half hour daily, five days a week, for 8 weeks
1857049|NCT01002586|Other|Walking exercise program|walking exercise program
1857050|NCT01002599|Device|Boussignac TM CPAP|Post-operative patients will be fitted with a Boussignac TM CPAP mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
1857051|NCT01002599|Device|Venturi Face Mask|Post-operative patients will be fitted with a Venturi face mask immediately after extubation and oxygenation and pulmonary function will be measured over a 24 hour period.
1857052|NCT01002625|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
1857054|NCT01002638|Other|TEGADERM®|It consists of the occlusive application of two Tegaderm®, a plastic dressing
1857055|NCT01002638|Procedure|Surgery|It consists of pulp reconstruction by a flap (for example palmar V-Y advancement flaps of Atazoy).
1857056|NCT01002651|Dietary Supplement|wheat bran extract|soft drink comprising high WBE dose and natural flavor and coloring agent, ingestion after breakfast and after dinner
1857057|NCT01002651|Dietary Supplement|placebo|soft drink with natural flavor and coloring agent, without WBE, ingestion after breakfast and after dinner
1857058|NCT01002664|Drug|MCS-2|30 mg/day (two 15 mg capsules) Qd for 12 weeks
1857059|NCT01002664|Drug|Placebo|2 soft-gel placebo capsules Qd for 12 weeks
1857060|NCT01002677|Behavioral|Advocacy training curriculum|Day-long presentation of an advocacy training curriculum by the state's Brain Injury Association staff: One session per month for 4 consecutive months.
1857061|NCT01002677|Behavioral|Self-directed|Day-long group-based self-directed advocacy training activity: One session per month for 4 consecutive months.
1857062|NCT01002690|Drug|Etoricoxib|90 mg/day orally for 10-13 days
1857063|NCT01002703|Drug|Lenalidomide, Bendamustine, Prednisone|During the study the first cohort of subjects receive a starting dose of lenalidomide 10mg/d d1-21, bendamustine 60mg/m²/d d1-2 and prednisone 100mg/d d1-4. Escalation steps will include 15, 20 and 25 mg of lenalidomide and 75mg/m² for bendamustine.
1857064|NCT01002716|Biological|Agrippal S1 (Influenza vaccination)|Single dose of vaccine
1857065|NCT01002729|Other|Patients with a BMI < 30 given Oseltamivir|Patients with a BMI < 30 given Oseltamivir
1857066|NCT01002729|Other|Patients with a BMI > 40 given Oseltamivir|Patients with a BMI > 40 given Oseltamivir
1857069|NCT01002755|Drug|Lenalidomide|10 mg daily, started on day 9 (day after second infusion of ofatumumab) and continued daily through 24 cycles (cycle = 28 day)
1857070|NCT01002755|Drug|Ofatumumab|4 weekly IV infusions of 300 mg week 1, 1,000 mg week 2, 3 and 4, then monthly during months 2-6 and once every two months during months 7-24 (even months: 8,10,12 etc.).
1857071|NCT01002768|Drug|insulin degludec|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
1857072|NCT01002768|Drug|insulin glargine|Day 1-4: Once daily subcutaneous (under the skin) injection similar to 80% of individual basal insulin requirement. Day 5: Three times the individual basal insulin requirement.
1857073|NCT01002781|Drug|Tocilizumab|Tocilizumab, IV, 8 mg/kg, every 2 weeks
1857074|NCT01002794|Procedure|Arthroscopic partial menisectomy|Standard arthroscopic partial meniscectomy, NGD 1. Carried out at Ullevaal University Hospital.
1857075|NCT01002794|Other|Supervised neuromuscular and strength training|Supervised exercise therapy in 12 weeks, both neuromuscular- and strength training.
1857076|NCT01002807|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Single Dose
1857077|NCT01002807|Drug|Metformin XR|Tablets, Oral, 1000 mg, Single Dose
1857078|NCT01002807|Drug|Glucophage|Tablets, Oral, 1000 mg, Single Dose
1857079|NCT01002820|Drug|ganaxolone|liquid suspension, 50 mg/mL, up to 500 mg/day TID or 1500 mg/day, up to 1 year
1857080|NCT01002833|Biological|Exposure to Plasmodium falciparum infected mosquitoes|Healthy volunteers are exposed to the bites of 5 Plasmodium falciparum infected mosquitoes
1857081|NCT01002846|Procedure|acupuncture|acupuncture group : subject will undergo 20minute sessions twice a week for 8weeks. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted up to 1 cm depth sham acupuncture group : subject will undergo 20 minute. Disposable acupuncture needle(4cm sterilized stainless steel) will be inserted under 1 cm slightly.
1857082|NCT01002859|Drug|Sandimmum|Intravenous injection of cyclosporine
1857083|NCT01002859|Drug|Placebo|Intravenous Injection of NaCl solution
1857084|NCT01002872|Drug|Lanthanum Carbonate|Randomization To either Lanthanum Carbonate 1 pill TID/Placebo 1 pill TID Day 15 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID. If phosphorus <3.5mg/dL Reduce to 1 pill BID. If Phosphorus >5.5mg/dL 1 pill with breakfast 1 pill with lunch 2 pills with dinner Day 30 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus is <3.5mg/dL Reduce to 1 pill daily. If phosphorus >5.5mg/dL 1 pill with breakfast 2 pills with lunch 2 pills with dinner Day 45 If phosphorus is 3.5mg/dL-5.5mg/dL Continue with 1 pill TID If phosphorus <3.5mg/dL stop the drug If phosphorus is >5.5mg/dL 2 pills with breakfast 2 pills with lunch 2 pills with dinner
1857085|NCT01002872|Drug|Fosrenol|Initial dose of drug will be 1500mg TID
1857086|NCT01002872|Drug|placebo|Initial dose of placebo will be 1 pill three times a day
1857087|NCT01002898|Drug|lopinavir/ritonavir soft gel capsule|Ritonavir-boosted lopinavir in soft gel formulation at 400/100 mg and lamivudine at 150 mg were given twice daily.
1857088|NCT01002911|Drug|Cefazolin, Bacitracin, Cefalexin|Single does of Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision, Bacitracin wash, Cefalexin 250-500 mg TID
1857089|NCT01002911|Drug|Cefazolin|Cefazolin 1-2 g iv given over 60-120 minutes, 60-120 minutes prior to skin incision
1857090|NCT01002924|Drug|EC145|EC145 will be administered intravenously at a dose of 2.5 mg. Dosing will occur on Monday, Wednesday, and Friday of weeks 1 and 3 of each 4-week cycle. No therapy will be administered during weeks 2 and 4.
1857091|NCT01002950|Drug|ACU-4429|ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days
1857092|NCT01002950|Drug|Matching placebo|Matching placebo tablets taken orally once daily for 90 days
1857093|NCT01002963|Drug|PF-04418948|solution, 30 mg, single
1857094|NCT01002963|Drug|PF-04418948|solution, 100 mg, single
1857097|NCT01002963|Drug|PF-04418948|solution, 3000 mg, single
1857098|NCT01002963|Drug|PF-04418948|solution, 4500 mg, single
1857099|NCT01002963|Drug|PF-04418948|solution, 6000 mg, single
1857100|NCT01002989|Device|Doppler Ankle-Brachial Index measurement|Measurement of the Ankle-Brachial Index by Doppler.
1857101|NCT01002989|Device|WatchBP Office Ankle-Brachial Index measurement.|Measurement of Ankle-Brachial Index by WatchBP Office device.
1857102|NCT01003002|Drug|Levodopa (delivered intravenously)|One mg/kg/hr of Levodopa will be given intravenously during inpatient testing days from 0900 to 1100.
1857103|NCT01003015|Drug|BAY73-4506|160 mg BAY73-4506
1857104|NCT01003028|Drug|Remifentanil (Limited) - Target Controlled Infusion system|Limit max plasma concentration to 9.8 ng/ml
1857105|NCT01003028|Drug|Remifentanil (Control) - Target Controlled Infusion system|Use 20 ng/ml as max plasma concentration
1857106|NCT01003054|Drug|Busulfan|130 mg/m^2 in normal saline over three (3) hours IV every twenty-four (24) hours for four (4) consecutive days (days -7 to -4)
1857107|NCT01003054|Drug|Cyclophosphamide|60 mg/kg in 500 ml of normal saline over 4 hours on each of 2 consecutive days (day -3, -2)
1857108|NCT01003054|Drug|Imatinib Mesylate|Starting dose 100 mg/day (mg/d), escalated to maximal dose of 400 mg/d as tolerated, after day 28 when Absolute neutrophil count (ANC) is >1500/mcl and platelets >50,000 /mcl, may be titrated to maintain ANC >1.0 and platelets >50,000 /mcl.
1857109|NCT01003054|Procedure|Autologous Stem Cell Transplantation|Stem Cell Infusion: Unpurged hematopoietic stem cells administered intravenously on day 0.
1857110|NCT01003067|Device|Mesh implementation|Prophylactic intraperitoneal mesh implantation in laparoscopic surgery to prevent incisional hernia.
1857111|NCT00994578|Behavioral|CHESS|Patients randomized to the CHESS intervention will be trained to access the website. After being trained in usage of the site, they will use the available resources as desired without further input from the study team, except for technical support
1857112|NCT00994578|Behavioral|COPE|Participants in the COPE arm will receive training and access to the COPE patient intervention, an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to each of two oncologists visits over a maximum of a 9 month period, and access to the patient's audio-recorded conversations for review.
1857113|NCT00994578|Behavioral|CHESS/COPE|Participants in the CHESS/COPE arm will be given access to the University of Wisconsin CHESS modified specifically for this study. After being trained in usage of the site, they will use the available resources as desired and receive technical support. COPE arm will receive training and access to the COPE patient intervention an interactive web program based on Social Cognitive Theory that includes automated, tailored email reminders and encouragement prior to two oncologists visits over a maximum period of 9 months, and access to the patient's audio-recorded conversations for review.
1857114|NCT00994591|Drug|Pharmacokinetic dosing|Pharmacokinetic testing involves dosing with deuterated cotinine which has an associated IND#61329.
1857115|NCT00994604|Drug|broccoli sprout extract|consumption of broccoli sprout extract for 2 weeks
1857116|NCT00994617|Drug|Losartan and hydrochlorothiazide|Losartan 50 -100mg Hydrochlorothiazide 12.5mg -25mg
1857117|NCT00994617|Drug|Hydrochlorothiazide switched over with Losartan at 8 weeks|Hydrochlorothiazide 12.5-25mg crossed over with Losartan 50-100mg
1857118|NCT00994643|Biological|Rituximab|Given IV
1857119|NCT00994643|Biological|Interleukin-2|Given SC
1857120|NCT00994656|Device|Masimo multi-wavelength pulse co-oximeter|Subjects will have a finger probe that will measure the pleth variability index. They will also have an arterial line (as standard of care) from which arterial pulse tracings will be obtained.
1857121|NCT00994682|Drug|Pioglitazone study drug|30 mg per day orally for 8 weeks, and if well tolerated, titrated to 45 mg per day until the end of 18 months
1857122|NCT00994682|Drug|Placebo|An oral tablet identical to pioglitazone will be given once daily but without active drug for 18 months.
1857123|NCT00994682|Drug|Pioglitazone Open Label|Patients in both arms were placed open label pioglitazone for an additional 18 months after successfully completing the double-blind, placebo-controlled portion of the study design.
1857124|NCT00994695|Biological|Mencevax ACW Vaccine|Mencevax ACW polysaccharide vaccine subcutaneously in the left arm at 50 μg in 0.5ml(reconstituted).
1857125|NCT00994708|Drug|esomeprazole|
1989576|NCT02454608|Other|Placebo|Capsule with the same characteristics (size, color, smell) as Verapamil HCl.
1857127|NCT00994747|Other|Nutramigen (Flavor and Type of Infant Formula)|Nutramigen, protein hydrolysate formula, fed to infants as sole formula source during specified times during the first 8.5 months of life
1857128|NCT00994747|Other|Enfamil, milk-based formula|Enfamil, milk-based formula, fed as formula source during first 8.5 months of life
1857129|NCT00994760|Drug|Instanyl (Intranasal Fentanyl)|This was an observational study. Therefore, the physician decided about dosage according to individual needs.
1857130|NCT00994773|Drug|Simvastatin|daily doses for 14 days
1857131|NCT00994773|Drug|Tenofovir|
1857132|NCT00994773|Drug|Entecavir|Entecavir
1857133|NCT00994786|Drug|pregabalin|pregabalin starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin will be 600 mg/day.
1857134|NCT00994786|Drug|Placebo|Placebo starting at 75 mg/day (at Study Week 0). Doses will be titrated up in 75 mg increments until a clinical response is achieved, as tolerated in the following manner: to 150 mg/day at the end of Study Week 1, to 225 mg/day at the end of Study Week 2, 300 mg/day at the end of Study Week 4, 450 mg/day at the end of Study Week 6 and to 600 mg/day at the end of Study Week 8. The maximum dose of pregabalin/placebo will be 600 mg/day.
1857135|NCT00994799|Drug|ranibizumab|10mg/ml intravitreal injection
1857136|NCT00994799|Radiation|macular grid-pattern laser|macular grid-pattern laser therapy
1857177|NCT00995059|Drug|tacrolimus|Given oral or IV
1857178|NCT00995059|Radiation|total-body irradiation|Undergo total-body irradiation
1857137|NCT00994812|Drug|metformin|The obese women will be randomized either to metformin (2g/day) or to placebo, and the non-obese either to metformin (1.5g/day) or to placebo. All subjects will be evaluated 1 to 7 days after spontaneous menstruation (oligomenorrheic patients), or at any other convenient time (amenorrheic subjects). After the treatment of 3 months with metformin/placebo alone, another appropriate infertility treatment will be combined with metformin/placebo (clomiphene, ovulation induction, insemination or in vitro fertilization) if no pregnancy has occurred. This treatment will be continued another 6 months' period. If pregnancy occurs, subjects will be re-examined at 7-8 weeks of gestation.
1857138|NCT00994825|Drug|Levosimendan|
1857139|NCT00994825|Drug|placebo|"Soluvit ATC BO5XC (a mixture of vitamins with a yellow colour that is indistinguishable from the study drug Levosimendan) half ampul in 100 ml of glucose 5%"
1857140|NCT00994838|Other|reduced calorie diet|10% reduction in total daily calories (≈ 300 kcal reduction) from carbohydrates and fat from the usual daily energy consumption
1857141|NCT00994851|Drug|SENNA+CASSIA|Pharmaceutical form: capsule Route of administration: oral Dose regimen: once a day
1857142|NCT00994851|Drug|placebo|Pharmaceutical form: Capsule Route of administration: oral Dose regimen: once a day
1857143|NCT00994864|Drug|FOLFOX|One cycle of standard FOLFOX pre-operatively followed by 11 cycles of standard adjuvant FOLFOX chemotherapy.
1857144|NCT00994890|Biological|Tanezumab 2.5 mg|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
1857145|NCT00994890|Biological|Tanezumab 5 mg|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
1857146|NCT00994890|Biological|Tanezumab 10 mg|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for a total of 7 injections administered over approximately 1 year
1857147|NCT00994903|Drug|Simvastatin|40mg orally, given 3-7 days pre-op and continued till 14 days post-op
1857148|NCT00994903|Drug|Placebo|Placebo (Inert calcium lactate) tablets 3-7 days pre-op to 14 days post-op (as per experimental arm)
1857150|NCT00994929|Biological|Neumega (Oprelvekin, Interleukin 11, IL-11)|25 microgram/kg IL-11 by subcutaneous injection once daily for four days, followed by DDAVP 0.3 microgram/kg by intravenous infusion over 30 minutes on day 4, 30 minutes after IL-11.
1857151|NCT00994942|Drug|morphine sulfate|morphine sulfate 30 mg tablet, morphine sulfate 30 mg (10 mg / 5 mL) oral solution, morphine sulfate injection 10 mg (1 mg / mL)
1857152|NCT00994955|Device|selective retina therapy (SRT)|laser treatment
1857153|NCT00994968|Drug|cyclophosphamide|
1857154|NCT00994968|Drug|docetaxel|
1857155|NCT00994968|Drug|doxorubicin hydrochloride|
1857156|NCT00994968|Drug|tegafur-gimeracil-oteracil potassium|
1857157|NCT00994968|Procedure|neoadjuvant therapy|
1857158|NCT00994968|Procedure|therapeutic conventional surgery|
1857159|NCT00994981|Drug|magnesium|Thirty minutes after the beginning of the anhepatic phase, the patients were received a magnesium solution (MgSO4 25 mg•kg-1 mixed in 100 ml of normal saline) over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
1857160|NCT00994981|Drug|normal saline|Thirty minutes after the beginning of the anhepatic phase, the patients were received 100 ml of normal saline over 20 minutes. A resident anesthesiologist, who was blinded to the group assignment, performed intravenous administration of the study solution and assessed study outcomes.
1857161|NCT00994994|Drug|Tranexamic Acid|50 mg/kg of tranexamic acid was given as a bolus at the induction of anesthesia, followed by 15 mg/kg of continuous infusion and another 50 mg/kg into the bypass circuit in TXA group. same volume of normal saline was given in Placebo group.
1857162|NCT00995007|Drug|ZD6474 (Vandetanib)|Vandetanib is an oral medication known to block angiogenesis and has shown significant antitumor activity in laboratory and animal studies. Vandetanib appears to be well tolerated by patients at specific daily doses.
1857163|NCT00995007|Drug|Carboplatin|Carboplatin is a drug that interrupts division of cancer cells and has been shown to be a useful drug in treatment of tumors known as gliomas. It is a useful drug for treating brain tumors, but researchers are interested in gathering more information about how it works as a treatment for patients who have not responded to initial surgery, radiation, or chemotherapy.
1857164|NCT00995020|Procedure|Straight Wire Excision of Transformation Zone|Straight wire excision of transformation zone is a electrosurgical conization method,which uses a straight wire electrode as a knife to remove the dysplastic epithelium of the cervix.
1857165|NCT00995020|Procedure|Large Loop Excision of Transformation Zone (cone biopsy)|LLETZ cone is a electrosurgical conization method, which is performed with a large loop electrode of 20-25 mm depth. The loop is applied to the cervix outside the lateral margin of TZ and brought slowly to the controlateral TZ margin.
1857166|NCT00995033|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
1857167|NCT00995033|Biological|Placebo|Phosphate buffered saline and ALhydrogel of identical appearance to NicVAX; IM in 6 doses over 6 months
1857168|NCT00995033|Drug|Varenicline|Days 0-2: 0.5 mg once daily, Days 3-6: 0.5 mg twice daily (morning and evening), Day 7- 84: 1.0 mg twice daily (morning and evening)
1857169|NCT00995046|Drug|FVIII|6 months of prophylaxis treatment administered 3 or 4 times weekly according to patient's initial regimen, (standardized Malmö protocol 25 - 40 IU/kg/infusion). Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done.
1857170|NCT00995046|Drug|FVIII|"1 month period where thrombin generating capacity will be evaluated, followed by 6 months of individually tailored prophylaxis regimen according to TGT results. Medical visits will occur at 3-month intervals (+ 5 days) until the end of the study. Weekly, telephone calls to the patients (parents) will also be done."
1857171|NCT00995059|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
1857172|NCT00995059|Procedure|allogeneic bone marrow transplantation|Undergo transplantation
1857173|NCT00995059|Drug|bortezomib|Given IV
1857174|NCT00995059|Drug|melphalan|Given IV
1857175|NCT00995059|Drug|anti-thymocyte globulin|Given IV
1857176|NCT00995059|Drug|sirolimus|Given orally
1857179|NCT00995072|Drug|nebivolol and metoprolol succinate|Subjects randomized to treatment Arm A will receive nebivolol 5 mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm A will then receive metoprolol succinate 100 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
1857180|NCT00995072|Drug|metoprolol succinate and nebivolol|Subjects randomized to treatment Arm B will receive metoprolol succinate 100mg once daily for 12 weeks. After 12 weeks, double blind therapy will be discontinued and patients will undergo a wash-out period of study therapy over 2 weeks. Subjects randomized to treatment Arm B will then receive nebivolol 5 mg once daily. Subjects will continue double blind therapy for a total duration of 12 weeks.
1857181|NCT00995085|Drug|Extended Release Metadoxine|one oral 1400mg dose (2 tablets)
1857182|NCT00995098|Dietary Supplement|early enteral nutrition|Enteral nutrition will be administered within 24 hours of admission through naso-jejunal tube and continue for 7 days after admission. Naso-jejunal tube will be set up by endoscopy. X-ray will be used to place the distal end of the feeding tube and EN would not start until the distal end of the feeding tube has been placed at the remote end of Treitz ligament. Standard enteral nutrition liquid regimen (Nutrison Fibre) will be used. Patients are targeted to receive calories for 25 kcal/kg/day and nitrogen for 0.2g/kg/day.
1857183|NCT00995098|Dietary Supplement|Parenteral nutrition|PN administration will start within 12 hours of admission and continue for 7 days after admission. Patients will receive calories for 25 kcal/kg and nitrogen for 0.2g/kg. Twenty percent of the calories will be provided by fat emulsion (LCT/MCT) and the remaining will be provided by dextrose. Nitrogen will be provided by balanced amino acids injection (Novamin). All PN components will be compounded into 3-liters bags under sterile conditions. Nutrition regimen will be administered through subclavian central venous catheter.
1857184|NCT00995124|Drug|NeutraLice Lotion|Head lice topical application to be applied once for 10 minutes.
1857185|NCT00995124|Drug|NeutraLice Advance Solution|head lice application to be applied once for 10 minutes
1857186|NCT00995124|Drug|Moov Head Lice Solution|Single application for head lice with 10 min application time.
1857187|NCT00995137|Biological|NK Cell Infusion|Infusing genetically modified NK cells into research participants who have chemotherapy refractory or relapse B-lineage ALL.
1857188|NCT00995150|Drug|LNG20|levonorgestrel-releasing intrauterine system for contraception
1857189|NCT00995150|Drug|Mirena|Mirena intrauterine system
1857190|NCT00995189|Device|Opti-Free RepleniSH|Contact lens care solution containing polyquaternium-1 (PQT)
1857191|NCT00995189|Device|ReNu MultiPlus|Contact lens care solution containing polyhexamethylene biguanide (PHMB)
1857192|NCT00995189|Device|Contact lenses|Daily wear, frequent replacement contact lenses per participant's habitual brand and power.
1857193|NCT00995202|Other|diagnostic laboratory biomarker analysis|
1857194|NCT00995202|Procedure|computed tomography|
1857195|NCT00995202|Procedure|diagnostic colonoscopy|
1857196|NCT00995202|Procedure|standard follow-up care|
1857197|NCT00995202|Procedure|ultrasound imaging|
1857198|NCT00995215|Procedure|Spinal Cord Stimulation|The participant will have wire electrodes temporarily placed - by a routine surgical procedure - over the surface of the spinal cord on the lower back. These electrodes will be activated in the operating room and the degree of muscle activation assessed. The wire electrodes will then be removed. Small, disc electrodes will then be permanently implanted to stimulate expiratory muscles and restore cough. These electrodes are activated using an external control unit.
1857199|NCT00995215|Device|Expiratory Muscle Stimulator|The expiratory muscle stimulator consists of three small electrodes (metal discs) implanted over the surface of their spinal cords on the lower back to stimulate the expiratory muscles and restore cough. These electrodes are connected to an implanted receiver in the abdomen or chest wall. The device is activated through an external antenna connected to an external control box.
1857200|NCT00995241|Drug|Raltegravir|Raltegravir 800 mg / 24 hours.
1857201|NCT00995254|Behavioral|SHI counseling|The SHI will be delivered in three different individualized counseling sessions: the initial in person counseling (30-45 minutes), at 1 week in person or telephone counseling (15-30 minutes) and at 1 month in person counseling (15-30 minutes). During the initial counseling, CHWs will emphasize the health hazards of SHS exposure towards young children and its possible illness outcomes. Then subjects will be asked to assess the SHS exposure of children in the household (e.g., estimating the number of hours for SHS exposure on the child per week or day) and the source of SHS. The concept of smoking hygiene and non-smoking household policy will be discussed and any potential barriers ascertained. Furthermore, the CHWs will use the transtheoretical model of Prochaska to assess the stage of readiness of the household member to change smoking behavior existing in the household. Individuals who wish to quit smoking will receive a brief advice on quitting smoking.
1857202|NCT00995267|Behavioral|parent-child interaction/activities based on Adler's methods|"Description of the Intervention:
5 joint classroom activities (parents and children together, involving children in food choices/food preparation-sense of belonging/decision making): 1. Healthy breakfasts and 10 o'clock snacks 2. Fats and oils in the diet, cooking methods, setting limits to oily food intake. 3. Fruit and vegetables in the daily diet, adults as role models. 4. Learning about food categories & pyramid, healthy eating and growth. 5. Limiting consumption of sweets and snacks.
Workshop for Parents: Explaining nutritional needs of children; how to encourage good eating habits, how to deal with children's manipulations, providing tools to elicit change; use of food to attract parental attention; practical tools to deal with their children's eating habits/obesity/refusal to eat/chronic health problems/failure to grow; ways to prevent use of food as an answer to childhood frustrations."
1857203|NCT00995280|Device|single lumen needle oocyte retrieval|single lumen needle use during oocyte retrieval
1857204|NCT00995280|Device|double lumen needle oocyte retrieval|double lumen needle with 1 time follicle flushing with at least 2 ml during oocyte retrieval
1857205|NCT00995293|Drug|DOCETAXEL|Intravenous
1857206|NCT00995293|Drug|CISPLATIN|Intravenous
1857207|NCT00995293|Drug|5-FLUOROURACIL|Intravenous
1857208|NCT00995306|Drug|Civamide (Zucapsaicin)|"Civamide Cream 0.075%, TID for 12 weeks
Civamide Cream 0.01%, TID for 12 weeks"
1857209|NCT00995332|Drug|Cytarabine, all-trans retinoic acid, valproic acid|ATRA: 22.5 mg/m2 twice daily for 2 weeks every third month Valproic acid: continuous therapy, dosage guided by serum levels Cytarabine: 10 mg/m2 once daily for up to 10 days every third month
1857210|NCT00995345|Drug|KRP-104|Tablet
1857211|NCT00995345|Drug|Placebo|Tablet
1857212|NCT00995358|Biological|peptide|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
1857213|NCT00995371|Device|MILD® (Minimally Invasive Lumbar Decompression)|Image guided minimally-invasive lumbar decompression performed with arthroscopic devices.
1857214|NCT00995371|Drug|Epidural Steroid Injection|An Epidural Steroid Injection is injected into the space around the spinal cord and nerve roots called epidural space.
1857215|NCT00995384|Procedure|CT Scan|Cardiac CT with special attention to valves in Endocarditis patients.
1857218|NCT00995410|Drug|PA32540|PA32540 tablets contain 325 mg enteric coated (EC) aspirin and 40 mg immediate-release omeprazole to be taken by mouth once daily
1857219|NCT00995423|Device|CoroflexTM Please|highly flexible CoroflexTM Please-Stent
1857220|NCT00995423|Device|Paclitaxel-eluting stent|Paclitaxel-eluting stent
1857221|NCT00995436|Device|Extraoral anchorage|Extra oral anchorage
1857222|NCT00995436|Device|Miniscrews|Intraoral skeletal anchorage using mini screws
1857223|NCT00995436|Device|Nance|Intraoral dental anchorage by using Nance palatal arch on molars
1857224|NCT00995449|Biological|KB003|KB003 IV x5 doses
1857225|NCT00995449|Other|Placebo Comparator|Placebo IV x5 doses
1857226|NCT00995462|Behavioral|Lifestyle intervention seminars|The first sessions emphasize acquisition of new knowledge during interactive group seminars designed to maximize attendant's participation by adapting wellknown quiz-show or parlour games to deliver key concepts. A number of sessions are aimed at increasing self-efficacy through problem-solving, time-management strategies, individual self monitoring and goal-setting.During the second year, the intervention focuses on maintenance of healthy behaviour with empowerment of the participants using problem-solving, goal-setting, planning, and self-monitoring skills.
1857227|NCT00995475|Drug|Fluticasone propionate|
1857228|NCT00995475|Drug|Placebo|
1857229|NCT00995488|Drug|ABI-007 (Abraxane®)|ABI-007 is a novel albumin-bound paclitaxel combining a protein with a chemotherapeutic agent in the particle form.
1857230|NCT00995501|Drug|Dexamethasone Sodium Sulfate|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
1857231|NCT00995501|Drug|Insulin|Insulin to maintain blood glucose 80-110 mg/dl.
1857232|NCT00995501|Drug|anesthesia management|Light anesthesia to maintain BIS about 55
1857233|NCT00995501|Other|Dexamethasone - placebo|8 mg given 1-2 hours before surgery (incision time), 4 mg on the first postoperative morning, and 2 mg on the second postoperative morning
1857234|NCT00995501|Other|Insulin - Placebo|Insulin to maintain blood glucose 180-200 mg/dl.
1857235|NCT00995501|Other|Anesthesia management -Placebo|Deep anesthesia to maintain BIS about 35
1857236|NCT00995540|Drug|INGAP Peptide|100 mg INGAP Peptide tid subcutaneous injection for 12 weeks
1857237|NCT00995540|Drug|INGAP Peptide|200 mg INGAP Peptide tid subcutaneous injection for 12 weeks
1857238|NCT00995540|Drug|Placebo|Placebo tid subcutaneous injection for 12 weeks
1857239|NCT00995553|Behavioral|Cognitive Remediation|This is an adaptive, computer-based cognitive training intervention. Participants will complete 3 1-hour cognitive training sessions focused on attention and working memory processes weekly for 4 months.
1857240|NCT00995553|Behavioral|Computer Skills|This is a computer-based course in which participants will be taught how to use Microsoft Office applications and typing skills. Participants will attend a 1-hour course three times a week four 4-months.
1857241|NCT00995566|Drug|Sitaxentan sodium|Please note that this is a non-interventional study and no drug is actually given as an intervention. Instead, patients prescribed THELIN are being followed under real world circumstances. However at the request of the QA group at CT.gov, we were instructed to add sitaxentan sodium as the intervention type, regardless of the fact that this is a non-interventional study.
1857242|NCT00995592|Behavioral|Philani nutrition intervention program (mentor mothers)|Behavioral intervention was offered through mentor mothers. Mentors were mothers in community who were selected by because they were doing well. They were trained to conduct home visits, up to 16 times over one year period, ranging from 20 minutes to 2 hours. Mentor mothers worked to improve health of mother and their child and build social support in neighborhood.
1857243|NCT00995605|Drug|AMAP102|AMAP102 or Placebo
1857244|NCT00995618|Drug|Tranilast|Tranilast tablets, 300 mg, QD
1857245|NCT00995618|Drug|Febuxostat|Febuxostat Tablets, 40 mg, QD
1857246|NCT00995618|Drug|Combination - Tranilast and Febuxostat|Tranilast, 300 mg QD; Febuxostat, 40 mg QD
1857247|NCT00995631|Procedure|Femoral lipectomy|Standard (non-experimental) suction assisted liposuction surgery
1857248|NCT00995657|Drug|Fluticasone Propionate|Inhaled Fluticasone Propionate 50mcg bid
1857249|NCT00995657|Drug|Fluticasone Propionate|Inhaled Fluticasone Propionate 250mcg bid
1857250|NCT00995670|Drug|5% dextrose|Glucose is infused to prevent the anesthetic preconditioning (sevoflurane) protection against subsequent ischemia/reperfusion injury.
1857251|NCT00995670|Drug|Vitamin C|Vitamin C is intended to restore the impairment of the endothelium caused by the dextrose infusion.
1857252|NCT00995670|Drug|Simvastatin|Simvastatin will be ingested to determine the efficacy of a statin to modulate the forearm response to glucose.
1857253|NCT00995670|Drug|Sevoflurane|Sevoflurane will be given to attenuate or prevent the I/R injury during glucose.
1857254|NCT00995683|Drug|half molar sodium lactate|intravenous infusion of 0.5 ml/kg during 48 hours
1857255|NCT00995683|Drug|isotonic sodium chloride|intravenous infusion of 0.5 ml/kg during 48 hours
1857256|NCT00995696|Behavioral|PhaST IVR Calls|Participants in this condition receive 7 computer automated IVR calls.
1857257|NCT00995709|Drug|AIN457|
1857258|NCT00995709|Drug|AIN457|
1857259|NCT00995709|Drug|Placebo|
1857262|NCT00995735|Procedure|Cholecystectomy|Cholecystectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
1857263|NCT00995735|Procedure|Appendectomy|Appendectomy performed either by entering the stomach wall with the endoscope, or through a posterior vaginal opening.
1857264|NCT00995761|Drug|Docetaxel and Cisplatin|splitted administration of docetaxel and cisplatin.
1857265|NCT00995774|Device|robotic therapy|12 sessions of robot therapy for arm and hand function
1857266|NCT00995774|Other|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
1857267|NCT00995774|Device|robotic therapy|12 sessions of robot therapy for arm and hand function
1857268|NCT00995774|Other|conventional functional training|12 sessions of conventional therapy for the arm and hand from a physical therapist
1857269|NCT00995787|Drug|AZD1656|Dose titration of oral suspension of AZD165 during 3 days to a tolerable dose given twice daily. Subjects will thereafter be treated with this dose twice daily for another 6 days
1857270|NCT00995787|Drug|Placebo|Dose titration of oral suspension of placebo during 3 days given twice daily. Subjects will thereafter be for another 6 days
1857271|NCT00995800|Drug|Fluticasone propionate / Formoterol fumarate|2 dose strength vs. placebo
1857272|NCT00995813|Biological|Rotarix|A rotavirus vaccine (Rotarix) will be administered in two doses, 8 weeks apart, in infants between 6 and 14 weeks of age. The standard dosage is 1 mL administered orally or per gastrostomy tube.
1857273|NCT00995826|Drug|CS-8958|Inhaled CS-8958
1857274|NCT00995826|Other|Placebo|Inhaled placebo
1857275|NCT00995839|Drug|continuous infusion of terlipressin|Intravenous continuous infusion of terlipressin 1 µg•kg-1•h-1 for 6 hrs
1857276|NCT00995839|Drug|Arginine vasopressin|Intravenous continuous infusion of arginine vasopressin 0.04 UI•min-1 for 6 hrs
1857277|NCT00995839|Drug|terlipressin bolus administration|intravenous terlipressin bolus administration at the dose of 0.5 mg
1857278|NCT00995852|Device|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
1857279|NCT00995852|Device|IBV Implantation|"In severe cases of COPD even optimum treatment involving bronchodilatation with drugs, physical training and possibly oxygen therapy is unable to influence exercise capacity and the perception of dyspnoea to a sufficient extent. Given the assumption that the elastic recoil of the small airways can be improved by a reduction in lung volume and pulmonary function overall by more ergonomic breathing mechanics and diaphragm function, various endoscopic procedures for lung volume reduction are available. Here one of the most advanced techniques is the implantation of intrabronchial valves. The one-way mechanism of this valve allows air to escape from the downstream lung segment without any influx of new air during inspiration"
1857280|NCT00995865|Biological|XRX-001 Inactivated yellow fever vaccine|Inactivated yellow fever vaccine, alum adsorbed, High dose = 2.3 x 10^8 VE/0.5mL and Mid dose = 2.2 x 10^7 VE/0.5mL
1857281|NCT00995865|Biological|Placebo|NaCl Injectable 0.9%
1857282|NCT00995878|Procedure|Focused ultrasound (MRgFUS)|MRgFUS treatment will take place in a MRI machine and powerful ultrasound waves go through the abdominal wall to destroy the fibroid or fibroids. No incision is made during this treatment and light sedation is required. There are certain fibroids that may not be treated with this technique and there is no treatment of normal uterine tissue.ough the abdominal wall to destroy the fibroid.
1857283|NCT00995878|Procedure|Uterine artery embolization (UAE)|UAE treatment takes place on a regular x-ray machine. A small incision is made where the leg meets the trunk and a small tube is used to use very small pellets to block off the blood supply to the entire uterus. Sedation is used. Most fibroids are treated with this technique and normal uterine tissue is also affected.
1857284|NCT00995904|Drug|84ug MAP0020|84ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
1857285|NCT00995904|Drug|42ug MAP0020|42ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
1857286|NCT00995904|Drug|21ug MAP0020|21ug of unit dose budesonide inhalation suspension delivered by Aeroneb® Go (MAP0020) as per protocol
1857287|NCT00995917|Other|Vitamin K acupoint injection|Vitamin K will be injected into an acupuncture point within 2 days of the onset of painful menstrual cramps. Injections of 5 mg/0.5ml of vitamin K1 will be administered in bilateral acupuncture points. A single shot of vitamin K1 is 10mg/ml. Five mg/0.5ml will be drawn twice from one ampule and injected into each bilateral site, for a total dose of 10mg/ml of vitamin K.
1857288|NCT00995917|Other|Saline Injection|Injection of .5ml saline bilaterally into both legs within 2 days of the onset of painful menstrual cramps.
1857289|NCT00995930|Drug|ACZ885|ACZ885 150 mg was administered subcutaneously once a month for 12 months.
1857290|NCT00995930|Drug|Placebo|Matching placebo to ACZ885 was administered subcutaneously once a month for 12 months.
1857291|NCT00995969|Drug|placebo|1.0 g (w/w) placebo cream applied to both target lesions twice daily
1857292|NCT00995969|Drug|CT 327|1.0 g CT 327 cream will be applied to one target lesion twice daily and 1.0 g placebo cream will be applied to the remaining target lesion twice daily
1857293|NCT00995982|Biological|VRC-FLUDNA056-00VP|
1857294|NCT00995995|Drug|Rosiglitazone|Rosiglitazone
1857295|NCT00996008|Drug|placebo|0.5 g (w/w) placebo cream applied to each target lesion twice daily
1857296|NCT00996008|Drug|CT 327|0.5 g CT 327 cream will be applied to 2 target lesions twice daily 0.5 g placebo cream will be applied to remaining 2 target lesions twice daily
1857297|NCT00996021|Drug|GSK1349572 250 mg|This is an experimental HIV medication in the integrase inhibitor class.
1857298|NCT00996021|Drug|Placebo Suspension|Placebo is a liquid with no drug in it.
1857299|NCT00996021|Drug|Moxifloxacin 400 mg|This is an FDA approved antibiotic in the fluoroquinolone class.
1857300|NCT00996034|Biological|NicVAX|1.0 mL of Nicotine Conjugate Vaccine(x4), I.M. at 3 week intervals between SPECT studies
1857301|NCT00996034|Radiation|[123I]5-IA-85380|up to 10 mCi of [123I]5-IA-85380, I.V. on each of two SPECT Scan days
1857302|NCT00996034|Drug|Nicotine bitartrate|0.5-1.5 mg of Nicotine bitartrate, I.V. on each of two SPECT Scan days
1857303|NCT00996047|Genetic|cytogenetic analysis|
1857304|NCT00996047|Genetic|fluorescence in situ hybridization|
1857305|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort -1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
In this cohort, Hydralazine is administered at 10 mg/day."
1857306|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 0|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 25 mg/day in this cohort."
1857307|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 1|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 50 mg/day in this cohort."
1857308|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 2|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 100 mg/day in this cohort as 25 mg four times per day."
1857309|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 3|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 200 mg/day in this cohort as 50 mg four times per day."
1857310|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 4|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 300 mg/day in this cohort as 75 mg four times per day."
1857311|NCT00996060|Drug|Hydralazine and Valproic Acid: Cohort 5|"Initially, 3 patients will be enrolled into each cohort, beginning with the hydralazine 25 mg PO daily, with the valproic acid dosing beginning two weeks earlier to achieve a steady state level of valproic acid in the blood.
Hydralazine is administered at 400 mg/day in this cohort as 100 mg four times per day."
1857312|NCT00996073|Biological|Lumbar Interbody Fusion with Autograft|Single Dose Autograft Surgical Implantation
1857313|NCT00996073|Biological|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
1857314|NCT00996073|Biological|Lumbar Interbody Fusion with NeoFuse|Single Dose NeoFuse Surgical Implantation
1857315|NCT00996086|Device|CRT device implant|CRT device-recipients
1857316|NCT00996099|Device|Continuous glucose monitoring system combined with enhanced model predictive control algorithm for intensive insulin treatment|Glucose measured with a real-time continuous glucose monitoring system served as an input for the enhanced model predictive control algorithm adjusting insulin infusion every 15 minutes for the first 24 hours after elective cardiac surgery
1857317|NCT00996099|Other|Intensive insulin therapy using standard protocol|Insulin dosage according to the standard protocol for intensive insulin delivery used at Department of Cardiothoracic Surgery, General University Hospital, Prague.
1857318|NCT00996125|Biological|CervarixTM|Subjects will receive three doses of the Cervarix vaccine intramuscularly according to a 0, 1, 6-month schedule.
1857319|NCT00996125|Other|Control|Subjects will receive three doses of control intramuscularly according to a 0, 1, 6-month schedule.
1857320|NCT00996138|Biological|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
1857321|NCT00996151|Drug|Testosterone MD-Lotion|Single dose Testosterone MD-Lotion 2%
1857322|NCT00996164|Drug|Flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
1857323|NCT00996164|Drug|Placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
1857324|NCT00996177|Drug|IONSYS (fentanyl HCl) Iontophoretic TransdermalSystem|40 µg fentanyl on-demand (240µg/hr) or a maximum of 80 doses (3.2 mg) per day
1857325|NCT00996177|Drug|IV Morphine Patient-Controlled Analgesia (IV PCA)|20mg/2hr (240 mg during 24 hours)
1857326|NCT00996190|Drug|Phenylephrine|phenylephrine 120 micrograms/mL, administered either by continuous infusion or by intermittent bolus dose
1857327|NCT00996203|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks for 24 weeks
1857328|NCT00996203|Drug|DMARDs (disease-modifying antirheumatic drugs)|stable doses at investigator's prescription
1857329|NCT00996216|Drug|Eltrombopag|Eltrombopag starting at 25 mg dose and titrated in Part 1 of study to 50, 75, 100 mg. Platelet count must reach sufficient level to allow initiation of antiviral therapy. Eltrombopag dose may be adjusted during antiviral treatment phase of study to maintain platelet count to continue antiviral therapy without adjustment to antiviral dose.
1857330|NCT00996216|Drug|Antiviral therapy|Combination of either peginterferon alfa-2a or alfa-2b with ribavirin at investigator's discretion.
1857331|NCT00996229|Behavioral|Caloric restriction|20-30% CR for 6 months
1857332|NCT00996229|Dietary Supplement|Omega-3 (fish oil capsules)|2g/day DHA/EPA capsules for 6 months
1857333|NCT00996229|Dietary Supplement|Placebo|Daily corn oil capsules for 6 months
1857334|NCT00996229|Dietary Supplement|Resveratrol|daily resveratrol for 6 months
1857335|NCT00996242|Drug|L-lysine|6 g/day for four weeks
1857336|NCT00996255|Drug|PHA-793887|Escalating doses of PHA-793887 administered weekly by IV infusion for 3 consecutive weeks in 4-week cycles.
1857337|NCT00996268|Drug|GSK2212836|Treatment A - GSK2212836 test formulation 1, Treatment B - GSK2212836 test formulation 2, or Treatment C -GSK2212836 marketed formulation.
1857338|NCT00996268|Drug|GSK2212836|Treatment D - low dose of GSK2212836 test formulation, Treatment E - medium dose of GSK2212836 test formulation, Treatment F - high dose of GSK2212836 test formulation, Treatment G - GSK2212836 marketed formulation, or Placebo.
1857341|NCT00996294|Procedure|biliopancreatic diversion, gastric bypass|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
1857346|NCT00996320|Other|Reduced work hour schedule|Interns on the intervention schedule work an average of 60 hours per week over 4 weeks, with maximum shift length 16 hours.
1857347|NCT00996333|Drug|Gemcitabine, Docetaxel, Capecitabine|"1500mg/m2/day of Capecitabine for 14 days 750mg/m2 of Gemcitabine on Day 4 and 11 30mg/m2 of Docetaxel on Day 4 and 11
This 2-week regimen is followed by 1 week off for a total of a 21-day cycle. This is repeated for a total of 3 cycles."
1857348|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm1, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
1857349|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 1, Level 2|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
1857350|NCT00996346|Drug|Irinotecan&Temsirolimus:Arm 2, Level 1|Irinotecan is given first over 60 minutes followed by temsirolimus over 30 minutes. No intrapatient dose escalations are allowed. Treatment continues until disease progression or intolerable side effects develop.
1857351|NCT00996359|Biological|Irradiated haploidentical allogeneic lymphocytes|Partially HLA-matched irradiated donor lymphocytes will be infused after total body irradiation.
1857352|NCT00996359|Radiation|total-body irradiation|100 cGy TBI
1857353|NCT00996372|Drug|flibanserin|patients will be randomized to flibanserin or placebo in a double-blind manner
1857354|NCT00996372|Drug|placebo|patients will be randomized to flibanserin or placebo in a double-blind manner
1857355|NCT00996385|Drug|Velcade (bortezomib) plus Eloxatin (oxaliplatin)|One cycle is defined as an interval of 28 days. A cycle is comprised of four treatments of Velcade (Bortezomib) 1.3 mg/m2 given on days 1, 14, 15, and 18 and two treatments of Eloxatin (Oxaliplatin) 85 mg/m2 on days 4 and 18.
1857356|NCT00996398|Other|Tepid water immersion|28°C ± 1°C for the cold water immersion for 30 minutes to the level of the umbilicus
1857357|NCT00996411|Drug|Salvinorin A|This is an initial dose ranging study
1857358|NCT00996424|Drug|Acetylcysteine|Inhalation with N-Acetylcysteine
1857359|NCT00996424|Drug|normal saline|Inhalation with normal saline solution
1857360|NCT00996437|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab (Lucentis™) at baseline, 4 and 8 weeks
1857361|NCT00996437|Drug|Saline|Saline injection of 0.5mg at baseline, 4 and 8 weeks
1857362|NCT00996463|Procedure|Electro-thermo-coagulation|Electro-thermo-coagulation
1857363|NCT00996463|Drug|Sodium Stibogluconate|Intralesional injection of sodium stibogluconate
1857364|NCT00996463|Drug|DAC N-055|Moist wound treatment with DAC N-055 (German officinal drug of the German drug codex)
1857365|NCT00996476|Drug|TMC435|One 50 or 100-mg capsule orally (by mouth), once daily for 12 or 24 weeks
1857366|NCT00996476|Drug|PegIFNα-2a|One subcutaneous injection of PegIFNα-2a 180 μg once weekly for 12, 24, or 48 weeks.
1857367|NCT00996476|Drug|RBV|300, 400, or 500-mg tablets orally twice daily for 12, 24, or 48 weeks.
1857368|NCT00996489|Device|Coaptite®|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
1857369|NCT00996502|Drug|Docetaxel|"Phase I:
Cohort 1: 55mg/m2 of Docetaxel on Day 1 of the cycle
Cohort 2: 65mg/m2 of Docetaxel on Day 1 of the cycle
Cohort 3: 75mg/m2 of Docetaxel on Day 1 of the cycle"
1857370|NCT00996502|Drug|Bevacizumab|15mg/kg of Bevacizumab every 3 weeks
1857371|NCT00996502|Drug|Erlotinib|200 mg of Erlotinib PO daily days 2-16
1857372|NCT00996502|Drug|Prednisone|5 mg of Prednisone PO bid
1857373|NCT00996515|Drug|5-azacytidine, erlotinib|Erlotinib 150 mg PO daily, days 1-8, and 15-22 5-Azacytidine 75 mg/m2/day, IV days 1 and 15
1857374|NCT00996515|Drug|Erlotinib PO and Vidaza IV|Patients enrolled to 1 of 5 cohorts, with varying drug doses and dose scheduling.
1857375|NCT00996528|Behavioral|Philani Intervention Program|Offered to pregnant women / mothers through mentor mothers, i.e. mothers in community who are selected because they are doing well. They are trained to conduct home visits, 2 times a months through pregnancy. After childbirth, visits are spaced depending on the perceived need. If the baby is thriving and mother is coping well with health risks, mentor mother will visit once a month.
1857376|NCT00996541|Behavioral|STRIVE family intervention|Adolescent and parent attend a 5-session family-oriented cognitive-behavioral intervention aimed at giving runaway youths and their parents the tools to effectively deal with conflict.
1857377|NCT00996554|Procedure|double layer-suture|Hand-sutured end-to-end or end-to-side anastomosis performed by double-layer continuous technique (monofil thread)
1857378|NCT00996554|Procedure|Single-layer suture|Hand-sutured end-to-end or end-to-side anastomosis performed by single-layer continuous technique (monofil thread)
1857379|NCT00996567|Drug|Cetuximab (Erbitux)|Patients will be treated with standard chemotherapy (4-6 cycles), combined with weekly administration of Cetuximab (Erbitux) until disease progression.
1857380|NCT00996580|Drug|DR-103|"One tablet daily.
Four 91-day cycles of the DR-103 regimen:
42 days combination therapy of 20 mcg ethinyl estradiol (EE) /150 mcg levonorgestrel (LNG) followed by; 21 days combination therapy of 25 mcg EE/150 mcg LNG followed by; 21 days combination therapy of 30 mcg EE/150 mcg LNG followed by; 7 days of 10 mcg EE."
1857419|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6) + 500 nmol KLK + 20 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
1857503|NCT01004068|Drug|Clomiphene citrate|Clomiphene citrate at 150 mg daily for one cycle
1857381|NCT00996593|Biological|Anti-B1 Antibody and Iodine-131 Anti-B1 Antibody (Tositumomab and Iodine I 131 Tositumomab)|Patients will receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of Anti-B1 Antibody (35 mg) containing 5 mCi of Iodine-131 (dosimetric dose). Whole body gamma camera scans will be obtained on Day 0; Day 2, 3, or 4; and Day 6 or 7 following the dosimetric dose. Patients will then receive an infusion of unlabeled Anti-B1 Antibody (450 mg) followed by an infusion of 35 mg Anti-B1 Antibody containing a patient-specific dose of Iodine-131 calculated to deliver a 75 cGy total body radiation dose (therapeutic dose). Patients who have platelet counts of 100,001-149,999 cells/mm3 will receive 65 cGy; obese patients will be dosed based upon 137% of their lean body mass. Patients will be treated with a thyroid blocking agent 24 hours prior to the dosimetric dose and continuing for 14 days following the therapeutic dose.
1857382|NCT00996606|Drug|DMARDs|Participants may continue on a stable dose of their current DMARD therapy as prescribed. The choice of DMARD is at the discretion of the treating physician and is not specified by the protocol.
1857383|NCT00996606|Drug|Tocilizumab|Tocilizumab will be given as 8 mg/kg via IV infusion every 4 weeks for a total of 12 infusions. The maximum allowed dose is 800 mg.
1857384|NCT00996619|Procedure|An optical fiber, inside the work channel of an endoscope, is added to the endoscopic examination|"An optical fiber, inside the work channel of an endoscope, connected to a spectroscope, enables measuring the spectrum of objects seen by the endoscope"
1857385|NCT00996632|Procedure|ultrasonic knife (Ultracision®, Ethicon Endo Surgery)|mastectomy or quadrantectomy and axillary dissection by an ultrasonic knife (Ultracision®, Ethicon Endo Surgery)
1857386|NCT00996632|Procedure|conventional diarthermy knife|mastectomy or quadrantectomy and axillary dissection using conventional diarthermy knife
1857387|NCT00996645|Other|Worksheet to facilitate goal-setting and action plans|Developed based on goal-setting theory and implementation intentions, the worksheet will be mailed out with the feedback reports and is expected to facilitate improved quality of care in response to feedback reports.
1857388|NCT00996658|Drug|Placebo|Placebo matching linagliptin tablets once daily
1857389|NCT00996658|Drug|Linagliptin|Linagliptin tablets once daily
1857390|NCT00996671|Drug|GSK2256098|focal adhesion kinase inhibitor given as a single dose
1857391|NCT00996671|Drug|Placebo|Placebo to be used as comparator for GSK2256098
1857392|NCT00996684|Drug|Microplasmin|Microplasmin, 1.875 mg, will be given by intravitreal injection,on Day 0.
1857393|NCT00996684|Drug|Placebo control|The placebo control will be the microplasmin vehicle without the microplasmin.
1857394|NCT00996697|Drug|Budesonide/formoterol and tiotropium|Symbicort 200/2, 2puff bid plus tiotropium 18mcg/day
1857395|NCT00996697|Drug|Budesonide/formoterol and placebo|Symbicort 200/6 2puff bid and placebo
1857396|NCT00996723|Drug|vandetanib and dasatinib|Two oral investigational agents (vandetanib [VEGFR2, RET, and EGFR inhibitor] and dasatinib [bcr-abl, PDGFRA and B, src, lck, yes, and c-kit inhibitor] will be administered during and after local RT, which is the only standard therapy for children with DIPG.
1857397|NCT00996736|Drug|Natamycin|5% natamycin plus 0.02% preservative, one drop to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until 3 weeks after enrollment.
1857398|NCT00996736|Drug|Voriconazole|1% voriconazole plus 0.01% preservative, 1 drop applied to the affected eye every one hour while awake for 1 week, then every 2 hours while awake until three weeks after enrollment.
1857399|NCT00996749|Dietary Supplement|omega-3 fatty acid|Given PO
1857400|NCT00996749|Other|bone scan|Correlative studies
1857401|NCT00996749|Other|dual x-ray absorptometry|Correlative studies
1857402|NCT00996749|Other|laboratory biomarker analysis|Correlative studies
1857403|NCT00996749|Procedure|biopsy|Correlative studies
1857404|NCT00996762|Drug|lapatinib|1250 mg or 1500 mg lapatinib commercial tablet
1857405|NCT00996775|Behavioral|brief alcohol intervention|this intervention consists of brief assessment and feedback
1857406|NCT00996775|Behavioral|standard care|education about harmful effects of alcohol use and NIAAA recommended drinking limits
1857407|NCT00996788|Drug|Rebamipide|Rebamipide 100 mg tid for 28 days
1857408|NCT00996801|Drug|MK-5442|MK-5442 tablets (randomized to a dose of 5, 7.5, 10 or 15 mg) taken orally, once-daily, for 12 months
1857409|NCT00996801|Drug|Placebo to MK-5442|Matching placebo to MK-5442 taken orally, once-daily, for 12 months
1857410|NCT00996801|Drug|Alendronate Sodium|Alendronate tablets 70 mg, taken orally, once-weekly, for 12 months
1857411|NCT00996801|Drug|Vitamin D3|Vitamin D3 (cholecalciferol) administered orally, at a dose of 5600 IU (two tablets, 2800 IU each), once-weekly for 12 months
1857412|NCT00996801|Drug|Calcium carbonate|Participants who qualify (those who have a calcium intake of less than 1200 mg/day) will receive oral supplemental calcium carbonate, at a dose of either 400 mg or 500 mg, once-daily, for 12 months
1857413|NCT00996801|Drug|Placebo to Alendronate|Placebo to alendronate once-weekly for 12 months
1857414|NCT00996814|Behavioral|Proactive Ethics Intervention|The ethicist will: 1) meet with the patient or surrogate to assess the case and the decision-making capacity of the patient; 2) make an ethical diagnosis, framing the issues in easily understood ethical terms with the involved parties; 3) recommend the next steps, including measures to improve communication. The ethicist will help to articulate consensus or disagreement and either facilitate implementing the consensus or facilitate ways to address and resolve disagreements; 4) document the consultation in the patient's medical record, identifying the ethical issues identified, the steps taken to address those issues, the options and ethical rationales considered, the outcome and the future plan; 5) follow-up to provide ongoing support and record a follow up progress note in the chart; and 6) participate in evaluation.
1857415|NCT01003080|Device|Aquamantys Device|The Aquamantys is used for hemostasis in patients randomized to receive total knee arthroplasty with the device.
1857416|NCT01003080|Other|Standard of care treatment for hemostasis during a total knee arthroplasty.|"The active comparator arm will receive the standard-of-care for hemostasis during total knee arthroplasty. This is achieved with a unipolar Bovie electrocauterization device."
1857417|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6)|0.5 mL suspension for injection x 2 with 2 months interval
1857418|NCT01003093|Biological|50 microgram antigen (Ag85B + ESAT-6) + 100 nmol KLK + 4 nmol ODN1a|0.5 mL suspension for injection x 2 with 2 months interval
1857420|NCT01003106|Drug|Ranibizumab 0.5mg (monthly)|Branch retinal vein occlusion- Intravitreal injection of 0.5mg ranibizumab alone
1857421|NCT01003106|Drug|Ranibizumab 2.0mg (monthly)|
1857422|NCT01003106|Drug|Pro re nata (prn) ranibizumab|
1857423|NCT01003106|Procedure|Pro re nata (prn) Laser photocoagulation|
1857424|NCT01003119|Behavioral|Addiction CHESS|Smartphone with ACHESS application loaded onto the phone.
1857425|NCT01003132|Other|Acceptance and Commitment Therapy|Up to 10 sessions of a psychological therapy called Acceptance and Commitment Therapy
1857426|NCT01003145|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
1857427|NCT01003158|Drug|AZD8931|Tablet Oral bid
1857428|NCT01003158|Drug|Paclitaxel|IV once weekly for 3 weeks followed by a week off
1857429|NCT01003171|Drug|MCS-2 soft-gel capsule|MCS-2 30 mg/day
1857430|NCT01003184|Drug|exenatide once weekly|subcutaneous injection, 2mg, once a week
1857431|NCT01003184|Drug|insulin detemir|subcutaneous injection, with dosage titrated according to the determir label and published titration schedule, once or twice a day
1857432|NCT01003210|Drug|Hyland's earache drops|3-4 drops in affected ear 3 times a day as needed for up to 5 days
1857433|NCT01003223|Other|Computer algorithm management of hyperphosphatemia|The PKM algorithm is a computer based program that calculates Phosphorus intake between dialysis, phosphorus reduction during dialysis treatment and daily oral phosphate binder intake compliance. Based on pre and post dialysis serum phosphorus levels, the algorithm makes recommendations in relation to dialysate calcium, oral phosphate binder use, and dietary counseling.
1857434|NCT01003236|Drug|placebo|140 mg placebo tablets, 3 times per day for 3 months
1857435|NCT01003236|Drug|Milk Thistle extract|1 tablet equal to 140mg silymarin administered 3 times a day for 3 months
1857436|NCT01003249|Drug|Baclofen|Subjects will be randomly assigned to placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen).
1857437|NCT01003249|Drug|Placebo Comparator: Placebo|Subjects will then randomly be assigned in placebo or baclofen groups. Daily dose will be doubled every three days, up to 80 mg or when side effects appear. At the end of 4 week drug will be tapered (halved every 2 days and quitted after 2 days of using 20 mg baclofen).
1857438|NCT01003262|Other|Emergency Department Observation Protocol|The EDOSP will consist of cardiac enzyme testing, 12-24 hours of cardiac monitoring, and echocardiogram testing by explicit criteria
1857439|NCT01003262|Other|Unstructured, inpatient evaluation|This is unstructured management by an inpatient medical team.
1857440|NCT01003275|Drug|Paricalcitol|Two 1 mcg soft gels by mouth daily for 8 weeks
1857441|NCT01003275|Drug|Placebo|Two soft gels by mouth daily for 8 weeks
1857442|NCT01003288|Biological|Adjuvanted influenza H1N1split virion vaccine|"Vaccination Pandemrix suspension and emulsion for emulsion for injection. 1 dose (0.5 ml) contains Split influenza virus, inactivated, containing antigen 3.75 micrograms of A/California/7/2009 (H1N1)v-like strain (X-179A)
* Pandemic influenza vaccine (H1N1)v (split virion, inactivated, adjuvanted)"
1857443|NCT01003301|Drug|Omalizumab|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
1857444|NCT01003301|Drug|Placebo|Injections subcutaneously (up to 3) every 2 or 4 wks based on the subjects weight and baseline total serum IgE level as approved for therapy in allergic asthma. Duration of therapy is approximately 14 wks.
1857445|NCT01003314|Biological|AdCh63-MSP1 (lower dose) vaccine and MVA-MSP1 vaccine|Group 1A: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM. Group 1B: single dose of AdCh63-MSP1 vaccine 5 x 10^9 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later
1857446|NCT01003314|Biological|AdCh63-MSP1 vaccine (higher dose) and MVA-MSP1 vaccine followed by challenge|Group 2A: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM. Group 2B: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later. Group 2C: single dose of AdCh63-MSP1 vaccine 5 x 10^10 vp administered IM followed by a single dose of MVA-MSP1 vaccine 5 x 10^8 vp administered IM 8 weeks later and subsequent sporozoite malaria challenge 12-28 days post second vaccination
1857447|NCT01003327|Device|I-gel|intubation with I-gel airway
1857448|NCT01003327|Device|LMA-Unique|LMA-Unique airway is inserted first, then the I-gel
1857449|NCT01003340|Behavioral|Wee Wheezers|The intervention, Wee Wheezers, modified to the needs of the targeted population will include 6 bi-weekly 1 hour educational home visits conducted by Community Health Workers at homes of children with persistent asthma
1857450|NCT01003353|Behavioral|Maximal strength training|Training will be carried out 3 times a week for 8 weeks. Each session will include a warm up, strength training and warm down. The total time will be approximately 1 hour. The training will consist 2 exercises (leg press and plantarflexion). Participants will train each leg individually with 4 sets of 4 repetitions at 90% of the 1 repetition maximum.
1857451|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing down
1857452|NCT01003366|Device|bevel direction during central venous catheterization|approaching the IJV with the needle bevel facing up
1857453|NCT01003379|Drug|TC-5619|TC-5619-238 will be provided as hard gelatin capsules in strengths of 1mg, 5mg, and 25mg.
1857454|NCT01003379|Drug|Placebo|Placebo will be provided with exactly the same shape, size and appearance.
1857455|NCT01003405|Drug|KUC-7483|
1857456|NCT01003652|Procedure|thyroidectomy|Comparison between two groups of patients. One group is operated on using harmonic Focus for haemostasis compared to a second group of patients operated on with the conventional haemostasis using tie-and-clamp technique
1857457|NCT01003678|Drug|Clofarabine|"Dose Escalation Schedule - Level 1: 1 mg daily x 5 days (orally) followed by 23 days off drug.
Levels 2, 3, 4 and 5 are: 3, 5, 10 and 15 mg daily x 5 days followed by 23 days off drug."
1857458|NCT01003691|Biological|RN6G|Intravenous, multiple dose, dose ranging from 5 mg/kg up to a maximum of 15 mg/kg
1857459|NCT01003691|Biological|Placebo|Intravenous, multiple dose with experimental dose
1857460|NCT01003704|Procedure|Lower extremity amputation|
1857601|NCT01004718|Procedure|Computed Tomography|Undergo FDG PET/CT scans
1857461|NCT01003730|Other|Ventilator settings|Active Comparison of three different parameters of ventilator settings. Results of arterial blood gases and cytokine levels.
1857462|NCT01003743|Device|endolumenal tissue approximation|
1857463|NCT01003756|Other|Preoperative neuromuscular exercise|A neuromuscular exercise programme delivered 8-10 weeks preoperatively. The programme is developed in Lund, Sweden. A journal of this study is under peer-review
1857464|NCT01003769|Drug|Lenalidomide|Given PO
1857465|NCT01003769|Drug|R-(-)-Gossypol Acetic Acid|Given PO
1857466|NCT01003769|Other|Laboratory Biomarker Analysis|Correlative studies
1857467|NCT01003808|Biological|IMF-001|100 or 200 mcg, subcutaneously every 2 weeks. Number of Injections: 6 times. (The treatment may be continued if it is beneficial to the subject).
1857468|NCT01003834|Behavioral|Computerized brief intervention|Intervention based on Motivational Interviewing technique
1857469|NCT01003834|Behavioral|Computerized health screening|Behavioral intervention
1857470|NCT01003834|Behavioral|Computerized assessment|Behavioral intervention
1857471|NCT01003834|Behavioral|Therapist-delivered motivational intervention|Behavioral intervention
1857472|NCT01003847|Drug|fenofibrate, fatty acid, placebo|fenofibrate 160 mg, fatty acids 2 gm, placeob 8 weeks of treatment
1857473|NCT01003873|Biological|Evaluation of the endocannabinoid system|The evaluation of the endocannabinoid system consist in the determination of plasma concentration of the 2 main endocannabinoids (2AG and AEA) before (5 blood samples) and after (5 blood samples) after consumption of a calibrated food. As a comparator, ghrelin will be measured at the same time.
1857474|NCT01003873|Procedure|Biopsy of visceral and peripheral adipose tissue|The endocannabinoids will be also determined in adipose tissue. Biopsy of visceral and peripheral adipose tissue will be done during surgery and peripheral adipose tissue will be done 6 months after surgery.
1857475|NCT01003873|Biological|Evaluation of metabolic parameters|The evaluation of the metabolic status consist in evaluation of body composition (DEXA), determination of visceral adiposity (CT scan) and measurement of plasma lipids, glucose, insulin, leptin, adiponectin.
1857476|NCT01003873|Behavioral|Evolution of behavioral parameters|The behavioral evaluation will de done with different questionnaires: ORWELL 97, HAD scale, Three Factor Eating Questionnaire, Beck Depression inventory, Questionnaire of personality TCI.
1857477|NCT01003873|Behavioral|Dietician consultation|The evaluation of the metabolic status will also be seen by a dietician.
1857478|NCT01003873|Behavioral|Psychologist consultation|The behavioural evaluation will de done with a psychologist consultation
1857479|NCT01003886|Drug|Doxazosin mesylate GITS|Doxazosin mesylate GITS 4mg to 8mg once daily
1857480|NCT01003899|Drug|afatinib (BIBW 2992)|afatinib (BIBW 2992) po QD
1857481|NCT01003912|Biological|ALD-601|ALD-601 is manufactured by Aldagen from the 20% compartment of the selected umbilical cord blood unit within 24 hrs of planned injection. A dose of ALD-601 that delivers 1 x 105 - 2 x 106 cells/kg of estimated fetal weight at day - 1 is suspended in 300 microliters of dialysis media.
1857482|NCT01003925|Behavioral|Standard of care for osteoarthritis treatment|Standard of care educational materials to inform patients about choices for knee pain.
1857483|NCT01003925|Behavioral|Conjoint Analysis for Osteoarthritis|Conjoint Analysis computer software to inform patients about choices for knee pain.
1857484|NCT01003938|Drug|Topotecan|
1857485|NCT01003938|Drug|Erlotinib|
1857486|NCT01003951|Procedure|Acupuncture|"Acupuncture treatments will be given at the Integrative Medicine Outpatient Center, if needed in particular cases, at the MSKCC Breast Center. Each treatment is 30-40 minutes in duration. Each patient will receive two acupuncture treatments each week for four consecutive weeks.
Before and after each treatment, the circumference of the patient's upper arm, and forearm will be measured in both the affected and unaffected arms. The greater difference between affected and unaffected arms (either the forearm or the upper arm) for each patient will be used for outcome assessment. Photographs of the patient's affected and unaffected arms before and after each treatment will be taken to provide visual documentation of status. The patient's face will not appear in the photographs. Blood draws will be performed from the unaffected arm in serum collection tubes and will be performed within 1 week of starting acupuncture and within 1 week of completion of the 4 week protocol."
1857487|NCT01003964|Drug|Irinotecan, Cisplatin, Gemcitabine, Pemetrexed, Docetaxel|"GP:
Gemcitabine (1250 mg/m2) IV on day1, 8. Cisplatin (75 mg/m2) IV on day1 every 3 weeks
IP:
Irinotecan (65 mg/m2) IV on day 1 , 8 Cisplatin (30 mg/m2) IV on day 1 , 8 every 3 weeks
2nd or 3rd: Pemetrexed (500 mg/m2) D1 with premedication every 3 weeks Docetaxel (75 mg/m2) D1 with premedication every 3 weeks"
1857488|NCT01003990|Drug|Atazanavir|Tablets, Oral, 400 mg, once daily, indefinitely
1857489|NCT01003990|Drug|Atazanavir/Ritonavir|Tablets, Oral, 300/100 mg, once daily, indefinitely
1857490|NCT01003990|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, once daily, indefinitely
1857491|NCT01003990|Drug|Lopinavir/ritonavir|Tablets, Oral, 400/100 mg, twice daily, indefinitely
1857494|NCT01004016|Drug|KPS-0373|
1857495|NCT01004016|Drug|Placebo|
1857496|NCT01004029|Drug|Hydroxyprogesterone Caproate Injection, 250mg/mL|1 mL intramuscular injection every week until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
1857497|NCT01004029|Drug|Vehicle|Weekly intramuscular injections of 1 mL vehicle inert oil until 36 weeks, 6 days of gestation or delivery, whichever occurs first.
1857498|NCT01004042|Drug|Botulinum Toxin Type A - BOTOX|Subjects included in the study will receive injections of 20 U (as minimal dose) to 40 U (as maximum dose) of BTX-A (BOTOX®/Allergan, USA) diluted in 0.9% saline, according to standard injections of 4U in 5 points of glabellar area as the treatment.
1857502|NCT01004068|Other|SET-diet plus clomiphene|Two months of structured exercise program plus hypocaloric diet followed by 150 mg daily of clomiphene citrate
1857504|NCT01004068|Behavioral|Structured exercise program plus hypocaloric diet|SET plus diet
1857505|NCT01004081|Drug|BIIB021|BID orally for 28 days
1857506|NCT01004081|Drug|BIIB021|TIW orally for 28 days
1857507|NCT01004081|Drug|exemestane (Aromasin)|Daily in tablet form for 28 days
1857508|NCT01004094|Behavioral|simple goal setting|This group will set goals only
1857509|NCT01004094|Behavioral|goal setting plus action intentions|This group will set goals and form action intentions (plans)
1857510|NCT01004094|Behavioral|goal setting plus coping intentions|This group will set goals and form coping intentions (plans)
1857511|NCT01004094|Behavioral|goal setting plus action intentions plus coping intentions|This group will set goals and form action intentions and coping intentions
1998198|NCT01596816|Radiation|First part of treatment : Conformal irradiation|23 fractions (2 Gy/session), are delivered over 42 days maximum, for a total dose of 46 Gy
1857513|NCT01004120|Dietary Supplement|Bimuno|5.5g daily intake
1857514|NCT01004120|Dietary Supplement|Maltodextrin|5.5g daily intake
1857515|NCT01004146|Procedure|Incentive Spirometry|helps patient monitor their inspiratory tidal volume and assists in the preventing lower airway collapse
1857516|NCT01004159|Drug|cetuximab with irinotecan|Cetuximab administered 500mg/m2 over 120 minutes Irinotecan administered Q 3 weeks, Q 2 weeks or Q week x 4 every 6 weeks depending on patients previous treatment
1857517|NCT01004172|Drug|carboplatin|
1857518|NCT01004172|Drug|bevacizumab|
1857519|NCT01004172|Drug|herceptin|
1857520|NCT01004185|Drug|Asacol 400 mg|17-33kg = 3 Asacol 400mg AM & 2 Asacol 400mg PM; 33-<54kg = 5 Asacol 400 mg AM & 4 Asacol 400mg PM; 54-<90kg = 6 Asacol 400mg AM & PM
1857521|NCT01004185|Drug|Asacol 400 mg|17-<33kg = 2 Asacol 400mg & 1 placebo AM, 1 Asacol 400mg & 1 placebo PM; 33-<54kg = 3 Asacol 400mg & 2 placebo AM, 2 Asacol 400mg & 2 placebo PM; 54-<90kg = 3 Asacol 400mg & 3 placebo AM & PM
1857522|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
1857523|NCT01004198|Drug|MP4OX|4.3 g/dL PEG-Hb solution in lactated electrolyte solution
1857524|NCT01004198|Drug|Ringers Lactate solution|Ringers Lactate solution for Injection
1857525|NCT01004211|Procedure|Narrow band imaging transurethral resection|Transurethral resection of bladder lesion by mean of narrow band imaging
1857526|NCT01004211|Procedure|Standard transurethral resection|Transurethral resection of bladder lesion by mean of standard white light
1857528|NCT01004237|Drug|pravastatin, valsartan, pravastatin+valsartan|pravastatin 40 mg, valsartan 160 mg 8 weeks of treatment
1857529|NCT01004250|Drug|Pemetrexed|500 milligram per square meter (mg/m²) given intravenously on Day 1 of each 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity.
1857530|NCT01004250|Drug|Cisplatin|75 mg/m² given intravenously on Day 1 of 21-day cycle for a maximum of 4 cycles
1857531|NCT01004250|Drug|Bevacizumab|7.5 milligram per kilogram (mg/kg) given intravenously on Day 1 of 21-day cycle for four cycles of Induction Therapy, and continued in Maintenance Therapy until progression or unacceptable toxicity
1857532|NCT01004263|Drug|rizatriptan benzoate|Single dose of 5 mg or 10 mg orally disintegrating tablet at onset of migraine attack
1857533|NCT01004276|Other|New, improved smoking cessation management module|The intervention that will be tested is an improved smoking cessation management module in an existing chronic disease management system, P-PROMPT CDMS. This module includes the following components: a) the Patient Care Status and Update Form, b) the smoking registry and c) patient prompts.
1857534|NCT01004289|Procedure|Postconditioning|Primary angioplasty and stenting followed by brief episodes of ischemia-reperfusion performed during the first minutes of reperfusion
1857535|NCT01004289|Procedure|Primary angioplasty and stenting without additional intervention|Primary angioplasty and stenting without additional intervention.
1857536|NCT01004302|Procedure|ventral capsular/ventral striatal gamma capsulotomy|Comparison of active radiosurgical with sham radiosurgeries
1857537|NCT01004315|Drug|KUC-7483|
1857538|NCT01004315|Drug|Placebo|
1857539|NCT01004315|Drug|Tolterodine|
1857540|NCT01004328|Other|Intervention 1: Electronic medical record (EMR)-based transitional care intervention|Electronic delivery of enhanced discharge information to the ambulatory physician with plans for follow-up appointment, notice of any new medications, and recommendations for laboratory monitoring
1857541|NCT01004341|Behavioral|Family-based behavioral weight control intervention|Standard behavioral weight control program for children ages 8-12 years old and their parents in a family-based intervention.
1857542|NCT01004354|Drug|Ergocalciferols|2000 international units by mouth daily for 8 weeks.
1857543|NCT01004367|Other|Experimental|Environmental- and individual based components carried out in the school.
1857544|NCT01004367|Other|No intervention|No intervention carried out in the school
1857545|NCT01004380|Drug|Farletuzumab, Carboplatin, and PLD|All subjects will receive approximately 6 cycles with carboplatin (AUC5-6) i.v. and PLD (30 mg/m2) i.v. on Day 1 of every 4-week Combination treatment cycle. In addition, subjects will also receive weekly farletuzumab at 2.5 mg/kg administered i.v. Following completion of the Combination treatment period (carboplatin/PLD/farletuzumab therapy),maintenance treatment with single agent farletuzumab will be administered once Q3W at 7.5 mg/kg until disease progression as defined by GCIG CA-125 (i.e., CA-125 is less than or equal to 2 × (ULN) documented on 2 occasions) or modified RECIST v.1.0 using CT or MRI.
1857546|NCT01004393|Drug|Methylnaltrexone bromide|Methylnaltrexone bromide, dosage based on weight (0.15 mg/kg (round dose up to nearest 0.1 mL of volume) for weight less than 38 kg or greater than 114 kg; 8 mg (0.4 mL) for weight 38 kg to less than 62 kg; and 12 mg (0.6 mL) for weight 62 kg to 114 kg), single dose
1857547|NCT01004406|Procedure|Percutaneous coronary intervention|Widening of coronary arteries using balloons or stents.
1857548|NCT01004406|Procedure|Intravascular ultrasound with virtual histology|IVUS-VH allows for the identification of discrete plaque components using radiofrequency backscatter data. The technology can visualize the coronary artery wall and measure atherosclerosis volume.
1857549|NCT01004406|Drug|Atorvastatin|80mg daily oral dose of Atorvastatin to lower LDL in blood.
1857599|NCT01004705|Drug|Simvastatin|A once daily oral dose of simvastatin for 12 weeks.
1857600|NCT01004718|Radiation|Fludeoxyglucose F18|Undergo FDG PET/CT scans
1857550|NCT01004406|Device|LDL-apheresis|The device proposed for use in this study is the LIPOSORBER LA-15 System, manufactured by Kaneka Pharma America LLC. The Liposorber separates plasma from whole blood, then removes LDL from the plasma, recombines the plasma and blood cells, and returns the blood into the patient's body; the procedure typically takes about 3 hours. The procedure provides an immediate reduction in a patient's lipid levels. A single apheresis treatment can lower LDL by more than 80%, but levels return to baseline within 3 weeks.
1857551|NCT01004419|Drug|ZD6474 (vandetanib)|vandetanib (100 mg or 200 mg or 300 mg) by mouth once daily for 28 days
1857552|NCT01004419|Drug|Faslodex (Fulvestrant)|Fulvestrant 500 mg intra-muscular injection on Day 1 and 250 mg Day 15 of cycle 1 Cycles 2 and beyond: Fulvestrant 500 mg intra-muscular injection on Day 1, every 28 days.
1857553|NCT01004432|Drug|Golimumab 50 mg SC|Golimumab 50 milligram (mg) subcutaneous (SC) injection every 4 weeks.
1857554|NCT01004432|Drug|Golimumab 2 mg/kg IV|Golimumab 2 milligram per kilogram (mg/kg) intravenous infusion every 8 weeks.
1857555|NCT01004432|Drug|Methotrexate (MTX)|Participants will continue taking their current Methotrexate (MTX) treatment regimen.
1857556|NCT01004432|Drug|Placebo SC|Placebo matched to golimumab SC injection every 4 weeks.
1857557|NCT01004432|Drug|Placebo IV|Placebo matched to golimumab intravenous infusion every 8 weeks.
1857558|NCT01004445|Drug|Amikacin (BAY41-6551)|Single daily dose of 400 mg aerosolized amikacin and a single dose of aerosolized placebo on a rotating every 12hr schedule
1857559|NCT01004445|Drug|Amikacin (BAY41-6551)|Daily dose of 800 mg aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment every 12hr
1857560|NCT01004445|Drug|Placebo|Two aerosol treatments per day (one treatment every 12hr)
1857561|NCT01004458|Behavioral|Cognitive behavioral therapy|The treatment, adopted to reduce hostility and stress behavior, was given during group sessions once a week during six months with two follow-up occasions during the next six months
1857562|NCT01004458|Other|Waiting list|The group served as referents during the trial and received no intervention other than measurements at the same points in time as the intervention group
1857563|NCT01004471|Device|Prototype nasal dilator|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11
1857564|NCT01004484|Other|A probiotic yogurt with inulin|A 4 oz. cup with a probiotic yogurt containing Streptococcus thermophilus and Lactobacillus bulgaricus (at least 1x10^8 cfu/g); the probiotic bacteria Bifidobacterium lactis (Bb12) (5x10^7 cfu/g; 5x10^9 cfu/serving) and Inulin (3gr/serving), once daily.
1857565|NCT01004484|Other|Acidified dairy snack|A 4 oz. cup of acidified dairy snack, once daily.
1857566|NCT01004497|Drug|Dasatinib|After the completion of each induction and consolidation chemotherapy with recovery of leukocyte and platelet counts, dasatinib will be given as an alternative manner: 100 mg by mouth once daily for 4 weeks
1857567|NCT01004497|Drug|Cyclophosphamide|300 mg/m2, IV for 2 hours, every 12 hours x 6 doses, days 1-3
1857568|NCT01004497|Drug|Vincristine|1.4 mg/m2/day (maximum 2 mg/day), IV for 30 minutes, days 4 & 11
1857569|NCT01004497|Drug|Daunorubicin|45 mg/m2/day, IV for 1 hour, days 4 & 11
1857570|NCT01004497|Drug|Dexamethasone|40 mg/day, IV push, days 1-4 & days 11-14
1857571|NCT01004497|Drug|Cytarabine|2 g/m2, IV for 3 hours, every 12 hours x 10 doses, days 1-5
1857572|NCT01004497|Drug|Mitoxantrone|12 mg/m2/day, IV for 30 minutes, days 1-2
1857573|NCT01004510|Drug|zoledronic acid|Zoledronic acid (Zometa) 4mg IV every 4 weeks for 3 treatments with chemotherapy as selected by treating physician
1857574|NCT01004523|Genetic|fluorescence in situ hybridization|
1857575|NCT01004523|Genetic|loss of heterozygosity analysis|
1857576|NCT01004523|Genetic|polymerase chain reaction|
1857577|NCT01004523|Other|flow cytometry|
1857578|NCT01004523|Other|immunohistochemistry staining method|
1857579|NCT01004536|Device|silicone gel|twice daily application onto designated half of cesarean section wound for 12 weeks
1857580|NCT01004536|Other|no treatment|left untreated during the study period
1857581|NCT01004562|Other|informational intervention|
1857582|NCT01004575|Device|Kaname cobalt-chromium coronary stent|implantation of Kaname Cobalt-Chromium coronary stent
1857583|NCT01004588|Dietary Supplement|Protein drink|total of 15 g protein/d in a protein drink consumed every morning after breakfast during 24 weeks
1857584|NCT01004588|Dietary Supplement|placebo drink|subjects consume a placebo drink every morning after breakfast over a period of 24 weeks.
1857585|NCT01004601|Drug|docetaxel|patients at one university-affiliated hospital received low dose single docetaxel (30 mg/m2 on days 1 and 8 every 3 weeks)following failure of previous treatment stage IIIb/IV NSCLC.
1857586|NCT01004601|Drug|pemetrexed|patients at one university-affiliated hospital received pemetrexed (500 mg/m2 every 3 weeks) following failure of previous treatment stage IIIb/IV NSCLC.
1857587|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered with water
1857588|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered with water
1857589|NCT01004614|Drug|Amlodipine|3rd OD 5 mg tablet single oral dose administered without water
1857590|NCT01004614|Drug|Amlodipine|2nd OD 5 mg tablet single oral dose administered without water
1857591|NCT01004627|Procedure|Arterial and venous duplex ultrasound examination|Ultrasound mapping of all blood vessels in the upper limb of interest
1857592|NCT01004640|Genetic|DNA analysis|
1857593|NCT01004640|Genetic|Southern blotting|
1857594|NCT01004640|Genetic|cytogenetic analysis|Correlative studies
1857595|NCT01004640|Genetic|polymerase chain reaction|
1857596|NCT01004653|Biological|H1N1 influenza A Vaccine (Split virion), Inactivated|100 elders were assigned to receive one dose of 15μg H1N1 influenza A Vaccine (Split virion), Inactivated
1857597|NCT01004692|Device|Occlusal splints|The splint will be a hard acrylic-resin stabilization appliance to wear in the upper jaw. The OSS does not come in contact with the gums of the patient and does not act as an orthodontic device. The OSS will be used only for the three nights in a row, of the ambulatory-PSG recording with the OSS in situ.
1857598|NCT01004705|Drug|Cardiovascular fixed dose combination pill (acetylsalicylic acid, simvastatin and ramipril),|A once daily oral dose of the cardiovascular fixed dose combination pill ( acetylsalicylic acid, simvastatin, ramipril) for 12 weeks.
1857602|NCT01004718|Procedure|Positron emission tomography|Undergo FDG PET/CT scans
1857603|NCT01004731|Drug|Cetuximab in combination with Carboplatin/Gemcitabine|A loading dose of Cetuximab (400 mg/m2 IV over 120 minutes) will be administered 1 week prior to chemotherapy. Thereafter, Cetuximab will be infused weekly at maintenance doses of 250 mg/m2 (over 60 minutes). On the first day of each new cycle of therapy, Carboplatin will be infused with Gemcitabine (Days 1 and 8). Patients will be evaluated for a tumor response following every two cycles of therapy. In the absence of progressive disease, patients may continue to receive additional therapy.
1998199|NCT01596816|Procedure|Fiducials placement|Placement of intra-prostatic markers for the tracking
1857605|NCT01004757|Other|LOGI diet|diet based on 25% low glycemic index carbohydrates, 30% protein and 45% fat combined with heart rate controlled aerobic exercise for three weeks
1857606|NCT01004757|Other|Low Fat diet|traditional low fat diet based on 55% mixed glycemic index carbohydrates, 20% protein and 25% fat for three weeks followed by LOGI diet for two weeks, always combined with heart rate controlled aerobic exercise
1857607|NCT01004770|Drug|GE-145 (AN113111) Injection|40 healthy volunteers (10 per treatment group) will receive AH113111 320 mg I/mL at 1 of 4 possible doses (300, 450, 600, or 900 mg I/kg) as a single intravenous (IV) administration.
1857608|NCT01004770|Drug|Visipaque (iodixanol) Injection|An additional 10 subjects will receive Visipaque (iodixanol) 320 mg I/mL) at a dose of 450 mg/kg.
1857609|NCT01004783|Genetic|DNA methylation analysis|
1857610|NCT01004783|Genetic|gene expression analysis|
1857611|NCT01004783|Genetic|loss of heterozygosity analysis|
1857612|NCT01004783|Genetic|microarray analysis|
1857613|NCT01004783|Genetic|mutation analysis|
1857614|NCT01004783|Genetic|polymerase chain reaction|
1857615|NCT01004783|Genetic|reverse transcriptase-polymerase chain reaction|
1857616|NCT01004783|Other|laboratory biomarker analysis|
1857617|NCT01004796|Genetic|cytogenetic analysis|
1857618|NCT01004796|Genetic|microarray analysis|
1857619|NCT01004796|Genetic|mutation analysis|
1857620|NCT01004796|Other|immunohistochemistry staining method|
1857621|NCT01004796|Other|immunologic technique|
1857622|NCT01004796|Other|mass spectrometry|
1857623|NCT01004809|Drug|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
1857624|NCT01004822|Drug|CVX-241|0.3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
1857625|NCT01004822|Drug|CVX-241|1 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
1857626|NCT01004822|Drug|CVX-241|3 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
1857627|NCT01004822|Drug|CVX-241|6 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
1857628|NCT01004822|Drug|CVX-241|12 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
1857629|NCT01004822|Drug|CVX-241|15 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
1857630|NCT01004822|Drug|CVX-241|18 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
1857631|NCT01004822|Drug|CVX-241|25 mg/kg infusions of CVX-241 on Days 1, 8, 15, and 22 of each 28 day cycle. Weekly infusions administered until progression or unacceptable toxicity develops.
1857632|NCT01004848|Behavioral|Peer-Led Lifestyle Education on Weight Loss|Project HEED (Help Educate to Eliminate Diabetes) is a bilingual lifestyle education program written at a 4th grade reading level, and contains simple, actionable, messages, is easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes. It consists of 8 sessions (1½ hours each) held over 10-weeks. Topics include diabetes prevention, finding and affording healthy foods, label reading, fun physical activity, planning a healthy plate, making traditional foods healthy, and portion control.
1857634|NCT01004874|Drug|Bevacizumab|Bevacizumab (Avastin) at 10 mg/kg every other week during standard radiation therapy (XRT). Following XRT, bevacizumab will remain at 10 mg/kg every other week.
1857635|NCT01004874|Drug|Temozolomide|Daily temozolomide at 75 mg/ m2 daily for 6.5 weeks of radiation therapy (XRT). Following XRT, temozolomide will be dosed at 150 mg/m2 daily the first 5 days of each 28-day cycle.
1857636|NCT01004874|Radiation|Radiation Therapy (XRT)|Standard radiation therapy for approximately 6.5 weeks
1857637|NCT01004874|Drug|Topotecan|Following standard radiation therapy, patients will receive topotecan on days 2 through 6 of each 28-day cycle at a dose of 1.5 mg/m2 for patients not taking enzyme-inducing anti-epileptic drugs (EIAEDs) and 2.0 mg/m2 for patients taking EIAEDs.
1857638|NCT01004887|Other|diagnostic laboratory biomarker analysis|
1857639|NCT01004900|Procedure|Selective Laser Trabeculoplasty|This is a laser procedure used to treat glaucoma by reducing the pressure in the eye. SLT works by using laser light to stimulate the body's own healing response to lower your eye pressure. Using a special wavelength and energy, the laser affects only pigmented (melanin containing) cells of your eye. SLT improves the flow of fluid in the eye, which in turn lowers your eye pressure.
1857640|NCT01004900|Drug|Travoprost/ Timolol/ Azopt/ Brimonidine|Travoprost (Topical eye drops) administered once daily before sleep
1857641|NCT01004926|Device|Echelon foot|One Echelon foot for each subject, for a period of a month.
1857642|NCT01004939|Drug|fondaparinux|fondaparinux
1857696|NCT01005290|Drug|Ramipril|A once daily oral dose of 5 mg ramipril for one week followed by a once daily oral dose of 10 mg ramipril for 4 weeks.
1857697|NCT01005303|Drug|Placebo|1 Tablet Daily
1857698|NCT01005303|Drug|Forceval plus 50 micrograms Vitamin D3|Forceval: 1 Tablet Daily; Vitamin D3: 2 Tablets Daily
1857643|NCT01004952|Behavioral|screening questionnaire|Phase I involves in-home interviews of 25 participants to understand the factors that affect participants' decision-making about UVR protection (sunscreen use, shade-seeking, hat use, use of protective clothing). In Phase II, we plan to recruit a sample of 60 melanoma first degree relatives (FDRs) and use an electronic narrative diary to record their daily behaviors about UVR protection. They will be asked to carry a interactive voice response (IVR) system for 14 days and they should be in the continental United States.
1857644|NCT01004965|Other|laboratory biomarker analysis|
1989601|NCT02446574|Drug|Paclitaxel|starting dose 20mg/m2 qw
1989602|NCT02446574|Drug|Cisplatin|dose 25mg/m2 qw
1857653|NCT01004991|Biological|rituximab|375 mg/m2 on Day 8 of each of 6 cycles
1857654|NCT01004991|Drug|cyclophosphamide|750 mg/m2 on Day 8 of each of 6 cycles
1857655|NCT01004991|Drug|vincristine|1.4 mg/m2 on Day 8 of each of 6 cycles
1857656|NCT01004991|Drug|doxorubicin|50 mg/m2 on Day 8 of each of 6 cycles
1857657|NCT01004991|Drug|prednisone|100 mg PO days 8-12 of each of 6 cycles
1857658|NCT01004991|Drug|azacytidine|﻿Dose level 1: azacytidine 25 mg/m2 days 1-5 Dose level 2: azacytidine 50 mg/m2 days 1-5 Dose level 3: azacytidine 75 mg/m2 days 1-5
1857659|NCT01005004|Biological|HuCNS-SC cells|intracerebral transplantation
1857660|NCT01005017|Procedure|Percutaneous Radiofrequent Lesioning|One group receives PRFLSN after a positive trial block with bupivacaine, the other group receives no extra treatment besides optimal medical treatment.
1857661|NCT01005030|Other|Blood draw|Blood draw, two tubes, used for isolation of cell-free blood plasma
1857662|NCT01005043|Radiation|heavy ion radiotherapy (C12)|"Desired target of Heavy ion radiotherapy is 60 to 66 Cobalt Gray Equivalent (GyE), whenever possible. It is applied through 1 - 3 isocenter treatment portals. Dose distributions are calculated and dose volume histograms (DVH) are generated. A α/β-ratio of 2 is used for biological plan optimization. Fractionation is planned to be equivalent to 6 x 3 GyE / week. Dosage to organs at risk is minimized. Treatment continues for 20 to 22 days or until one of the following criteria applies:
Other illness that prevents further administration of treatment, Patient or legal guardian decides to withdraw from the study, or changes in the patient's condition render the patient unacceptable for further treatment in the judgment of the investigator."
1857663|NCT01005056|Drug|Ethinylestradiol + Desogestrel|All participants receive Marvelon® according to the approved dosage and administration method.
1857664|NCT01005069|Drug|DLBS-32|DLBS-32 50 mg once daily and lifestyle modification
1857665|NCT01005069|Drug|DLBS-32|DLBS-32 100 mg once daily and lifestyle modification
1857666|NCT01005069|Drug|DLBS-32|DLBS-32 200 mg once daily and lifestyle modification
1857667|NCT01005069|Drug|DLBS-32|DLBS-32 300 mg once daily and lifestyle modification
1857668|NCT01005069|Drug|Placebo capsule|Placebo capsules once daily and lifestyle modification
1857669|NCT01005082|Behavioral|Low salt diet|
1857670|NCT01005082|Behavioral|Water therapy alone|
1857671|NCT01005095|Dietary Supplement|Vitamin D3|Patients will be treated daily with 800 IU of Vitamin D3 by tablets plus a bottle of 75,000 IU vitamin D3 solution every 3 weeks
1857672|NCT01005095|Dietary Supplement|Vitamin D3|Patients will receive 800 IU of vitamin D3 by tablets plus a 3 weekly placebo solution
1857673|NCT01005108|Drug|Gabapentin|Use of Gabapentin as a control intervention to evaluate the relative effects and adverse events of acupuncture for hot flashes
1857674|NCT01005121|Drug|colchicine|2mg, per-os, once daily for six months
1857675|NCT01005147|Drug|tranexamic acid|1 gm every 6 hours for 4 days via IV for non-renal impaired subjects. Alternate IV dosing for renally-impaired subjects: 10mg/Kg BID (1.36 - 2.83 mg/dl clearance); 10mg/Kg QD (2.84 - 5.66 mg/dl clearance; and 10mg/Kg Q48H or 5mg/Kg (.5.66mg/dl clearance)
1857676|NCT01005147|Other|Placebo|Will receive placebo treatment as per the tranexamic acid schedule
1857677|NCT01005160|Drug|Metformin|CKD-501 0.5mg, metformin 1000mg
1857678|NCT01005160|Drug|CKD-501|CKD-501 0.5mg, metformin 1000mg
1857679|NCT01005186|Behavioral|Eating habits, diet and exercise|Programme of change to eating habits, diet and exercise
1857680|NCT01005199|Drug|everolimus|Sorafenib 2 x 400 mg daily plus everolimus 1 x 5 mg daily
1857681|NCT01005199|Drug|sorafenib tosylate|Sorafenib 2 x 400 mg daily
1857682|NCT01005212|Drug|Definity|An intravenous line will be placed and 1.3 mL of the ultrasound contrast agent DEFINITY® will be added to 50 mL sterile saline. Flow will be initiated at 4.0 mL/minute and adjusted for optimal imaging. A maximum of 1.3 mL or one vial of ultrasound contrast will be used per patient per session according to the manufacturer's guidelines.
1857683|NCT01005238|Drug|Lamivudine|
1857684|NCT01005238|Drug|Telbivudine|
1857685|NCT01005251|Drug|lesogaberan (AZD3355)|60 mg, oral, capsules, bid for 4 w
1857686|NCT01005251|Drug|lesogaberan (AZD3355)|120 mg, oral, capsules, bid for 4 w
1857687|NCT01005251|Drug|lesogaberan (AZD3355)|180 mg, oral, capsules, bid for 4 w
1857688|NCT01005251|Drug|lesogaberan (AZD3355)|240 mg, oral, capsules, bid for 4 w
1857689|NCT01005251|Drug|Placebo|oral,capsules, bid for 4 w
1857690|NCT01005264|Device|non-removable fiberglass|Two types of fiberglass bandages (Softcast3M®, 3M Health Care, St. Paul, MN (USA)) were used for construction of the pressure-relief apparatus
1857691|NCT01005264|Device|Stabil-D®|Stabil-D Stabil-D® is composed of a specifically designed rigid, boat shaped, and rocker sole
1857695|NCT01005290|Drug|Combination pill|A once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 5 mg ramipril) for one week followed by a once daily oral dose of the cardiovascular fixed dose combination pill (containing 100 mg acetylsalicylic acid, 40 mg simvastatin, and 10 mg ramipril) for 4 weeks.
1857699|NCT01005316|Drug|Induction Therapy|Per standard of care guidelines for immunosuppression at each clinical site.
1857700|NCT01005316|Drug|Tacrolimus|Per standard of care guidelines for immunosuppression at each clinical site.
1857701|NCT01005316|Drug|Mycophenolate Mofetil|Per standard of care guidelines for immunosuppression at each clinical site.
1857702|NCT01005316|Procedure|Intraoperative plasma exchange/pheresis|Per standard of care guidelines for immunosuppression at each clinical site.
1857703|NCT01005316|Procedure|Short-term post-operative plasmapheresis|Per standard of care guidelines for immunosuppression at each clinical site.
1857704|NCT01005316|Drug|Immunoglobulins, Intravenous|Post-transplant course of intravenous immunoglobulin therapy per standard of care guidelines for immunosuppression at each clinical site.
1857705|NCT01005316|Drug|Prednisone|Maintenance corticosteroids per standard of care guidelines for immunosuppression at each clinical site.
1857706|NCT01005329|Radiation|intensity-modulated radiation therapy|The vaginal planning target volume (PTV) and nodal PTV will receive 45 Gy in 25 fractions. Treatment will be delivered once daily, 5 fractions per week, over 5 weeks. Both target regions will be treated simultaneously with the same dose. Breaks in treatment should be minimized.
1857707|NCT01005329|Drug|cisplatin|Given IV
1857708|NCT01005329|Biological|bevacizumab|Given IV
1857709|NCT01005329|Drug|carboplatin|Given IV
1857710|NCT01005329|Drug|paclitaxel|Given IV
1857711|NCT01005342|Other|Oat bran|82 g oat bran was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12.6 g total fiber).
1857712|NCT01005342|Other|Spray-dried oat drink|62 g spray-dried oat drink was added to 250 ml blackcurrant beverage with pulp to give 2.7 g soluble fiber (3.3 g total fiber).
1857713|NCT01005342|Other|Rye bran|31 g rye bran was added to 250 ml blackcurrant beverage with pulp to give 1.7 g soluble fiber (12 g total fiber).
1857714|NCT01005342|Other|Sugar beet fiber|19 g sugar beet fiber was added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (12 g total fiber).
1857715|NCT01005342|Other|Mixture of fiber|38 g spray-dried oat drink, 30 g rye bran and 6 g sugar beet fiber were added to 250 ml blackcurrant beverage with pulp to give 5 g soluble fiber (18 g total fiber).
1857716|NCT01005342|Other|Control|No fiber was added to control meal (250 g black-currant beverage)
1857717|NCT01005355|Biological|IMC-1121B|Cycle 1: Upon completion of enrollment criteria confirmed at screening, the first dose of study medication should be administered within 7 days. The infusion will be planned every 2 weeks or every 3 weeks on the same day of the week of the first infusion. Dose escalation to Cohort 2 may occur in the absence of a dose-limiting toxicity (DLT) in the first three participants treated in Cohort 1 during the initial 6-week dosing period (Cycle 1). The same procedure will be followed for dose escalation from Cohort 2 to Cohort 3. If 1 of 3 participants in any cohort experiences a DLT in the first 6 weeks (Cycle 1), 3 additional participants will be enrolled in that cohort. Dose escalation to the next cohort may occur if less that 2 of 6 participants experience a DLT during Cycle 1.
1857718|NCT01005368|Genetic|fluorescence in situ hybridization|
1857719|NCT01005368|Genetic|mutation analysis|
1857720|NCT01005368|Genetic|nucleic acid sequencing|
1857721|NCT01005368|Genetic|polymerase chain reaction|
1857722|NCT01005368|Genetic|western blotting|
1857723|NCT01005368|Other|flow cytometry|
1857724|NCT01005368|Other|laboratory biomarker analysis|
1857725|NCT01005381|Dietary Supplement|Small Particle Size Calcium Carbonate Supplement|Small Particle Size Calcium Carbonate - tablet, 325 mg/tablet. Given once or twice daily depending on study arm.
1857726|NCT01005381|Dietary Supplement|Large Particle Size Calcium Carbonate Supplement|Large Particle Size Calcium Carbonate Supplement - tablet, 325 mg/tablet. Given twice daily.
1857727|NCT01005381|Dietary Supplement|Vitamin D|Vitamin D - capsule, cholecalciferol, 1000 IU/tablet. Given once daily.
1857728|NCT01005381|Dietary Supplement|Calcium Placebo|"Placebo tablets identical to the large and small particle size calcium carbonate tablets.
Given twice daily."
1857729|NCT01005394|Device|Navigated TMS examination|diagnostic examination using a single pulse TMS paradigm to evaluate corticospinal motor tract integrity and its evolution after stroke
1857730|NCT01005407|Biological|HEPLISAV and Placebo|Intramuscular (IM) injections on Week 0 and Week 4; placebo (saline) injection at Week 24
1857731|NCT01005407|Biological|Engerix-B|Intramuscular (IM) injections on Week 0, Week 4 and Week 24
1857732|NCT01005420|Dietary Supplement|Blueberry Powder|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
1857733|NCT01005420|Dietary Supplement|Placebo|The blueberry and placebo groups will be randomized to receive 45g of blueberry powder or control per day. Blueberry powder will be given as a smoothie to be consumed at the breakfast and dinner meals and an identical smoothie will be given as a control. The smoothies will be prepared in the metabolic kitchen and a week supply of frozen smoothies will be given to participants. Both the blueberry powder and control smoothie contain comparable energy and macronutrients.
1857734|NCT01005433|Drug|Dexmedetomidine|The dexmedetomidine groups (n = 20 for each) will receive i.v. infusion of 0.1 mL/kg/h of solution containing 2, 4, and 6 µg/mL of dexmedetomidine, at 20 min before induction of anesthesia. The placebo and the dexmedetomidine solutions will be looked identical and their infusions will be continued until skin closure, when their infusion rate will be decreased by 50% until 20 min after extubation.
1857735|NCT01005433|Drug|Placebo|The placebo group (n = 20) will receive an i.v. infusion of 0.1 mL/kg/h saline 0.9%, at 30 min before induction of anesthesia. The placebo solution will be looked identical and their infusions will be continued until skin closure, when the infusion rate will be decreased by 50% until 20 min after extubation. The test solution will be prepared by one anesthesiologist before induction of anesthesia.
1857736|NCT01005446|Device|Encore Reverse Shoulder Prosthesis (RSP®)|The RSP is indicated for use in subjects with grossly rotator cuff deficient shoulder joints with severe arthropathy or a previously failed joint replacement with a grossly rotator cuff deficient shoulder joint.
1857784|NCT01005758|Drug|hydrocortisone sodium succinate|
1857737|NCT01005459|Drug|Tetracaine|Tetracaine 2mg will be combined with Fentanyl 20 mcg and Epinephrine 50 mcg to treat labor pain.
1857738|NCT01005459|Drug|Bupivacaine|Bupivacaine 2 mg combined with fentanyl 20 mcg and Epinephrine 50 mcg will be used to treat labor pain.
1857739|NCT01005472|Drug|sunitinib malate|
1857740|NCT01005472|Drug|temozolomide|
1857741|NCT01005498|Dietary Supplement|Low carbohydrate - high fat diet|The diet has an energy content of 1600 kcal or 1800, with 50% from fat, 20% from carbohydrates and 30% from proteins.
1857742|NCT01005498|Dietary Supplement|High carbohydrate - low fat diet|The diet has an energy content of 1600 or 1800 kcal, with 30% from fat, 55-60% from carbohydrates and 10-15% from proteins.
1857743|NCT01005511|Device|Grindcare|Active treatment
1857744|NCT01005511|Device|Grindcare - inactive|Placebo treatment
1857745|NCT01005537|Biological|aldesleukin|Given IV and orally
1857746|NCT01005537|Biological|therapeutic autologous lymphocytes|Given IV
1857747|NCT01005537|Drug|cyclophosphamide|Given IV
1857748|NCT01005550|Drug|6 mg of ropivacaine|6 mg of ropivacaine are used for the spinal anaesthesia
1857749|NCT01005550|Drug|8 mg of ropivacaine|8 mg of ropivacaine are used for the spinal anaesthesia
1857750|NCT01005550|Drug|10 mg of ropivacaine|10 mg of ropivacaine for the spinal anaesthesia
1857751|NCT01005550|Drug|12 mg of ropivacaine|12 mg of ropivacaine for the spinal anaesthesia
1857752|NCT01005563|Other|Beef/Pork|Participants consuming diet containing 10, 20 or 30% dietary protein with beef/pork as the predominate sources of protein
1857753|NCT01005563|Other|Soy/Legumes|Participants consuming diet containing 10, 20, or 30% dietary protein with soy/legumes as the predominate sources of protein.
1989603|NCT02446574|Radiation|Radiation|60Gy/2Gy/30f
1857755|NCT01005602|Other|Digoxin Dosing per Nomogram|Simplified dosing nomogram for digoxin. The dose is determined by plotting a subject's creatinine clearance (x-axis) and ideal body weight (y-axis) on the nomogram. Alternatively, the dose may be determined by plotting creatinine clearance (x-axis) and gender/height (z-axis).
1857756|NCT01005602|Drug|Digoxin|All patients included in the trial were treated with digoxin as clinically indicated. The intervention for this study required determining the digoxin dose via a proposed nomogram.
1857757|NCT01005615|Device|Non-FES Upper Extremity Exercise|While undergoing the non-FES exercise intervention, the subjects will receive a specific, individualized exercise regimen, consisting of strengthening, stretching, splinting and any other therapeutic interventions that do not use electrical stimulation. Than a 1 month washout period,the subjects will remain seated in their primary wheelchair throughout the treatment. The subjects will exercise for 60 minutes/session, three times a week for 4 months.
1857758|NCT01005615|Device|RT300-SLSA, from Restorative Therapies, Inc.|They will undergo 4 months of FES assisted upper extremity ergometry followed by 1 month was out period, than by 4 months of a specific, individualized, non FES assisted exercise regimen
1857759|NCT01005628|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
1857760|NCT01005641|Drug|exemestane|25 mg daily
1857761|NCT01005641|Drug|lapatinib|taken orally, daily, at dose recommended after dose finding part of study
1857762|NCT01005667|Device|BirthTrack|Measurement of cervical dilation and head station
1857763|NCT01005680|Drug|Pemetrexed|500 milligrams/square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
1857764|NCT01005680|Drug|Gemcitabine|1250 mg/m² administered intravenously on Day 1 and Day 8 of each 21-day cycle, for 6 cycles
1857765|NCT01005680|Drug|Cisplatin|75 mg/m² administered intravenously on day 1 of each 21 day cycle, for 6 cycles
1857766|NCT01005693|Other|questionnaire administration|
1857767|NCT01005693|Procedure|cognitive assessment|
1857768|NCT01005693|Procedure|examination|
1857769|NCT01005693|Procedure|management of therapy complications|
1857770|NCT01005706|Drug|rapamune, mycophenolate mofetil and steroid|"At the time of transition patients randomized into this arm of the study will receive loading doses of sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml.
Patients randomized into this arm of the study will continue their current dosing regimen and frequency of mycophenolate mofetil. Serum trough level monitoring of mycophenolic acid will not be performed unless clinically warranted per standard of care and dosage adjustments from such levels will be made only with consent of the study primary investigator."
1857771|NCT01005706|Drug|tacrolimus, sirolimus and steroid|"Tacrolimus dosing is based on 12-hour whole blood trough concentrations. Target blood concentration is 2-5 ng/ml.
At the time of transition patients randomized into this arm of the study will receive loading doses of Sirolimus for two days and then 5mg PO daily. Twenty-four hour troughs will be checked per the schedule to ensure and monitor the therapeutic concentrations of 8-12ng/ml."
1857772|NCT01005719|Drug|Zegerid|Zegerid (20 mg omeprazole/ 1100 mg sodium bicarbonate) taken with approximately 2 oz of water once daily for 7 days.
1857773|NCT01005719|Drug|Prevacid®|Prevacid (15 mg lansoprazole) taken with approximately 2 oz of water once daily for 7 days.
1857774|NCT01005732|Device|Custom fabricated pressure garments|Cloth garments designed to apply 17-24 mmHg pressure to the 1/2 the burn wound and <5 mmHg to the other half, to be worn 23 hours per day until wounds mature, approximately 12 months
1857775|NCT01005745|Procedure|Surgery|Surgery to remove a tumor for growth of TIL
1857776|NCT01005745|Drug|Administration of Lymphodepletion|Lymphodepleting chemotherapy with cyclophosphamide and fludarabine to enhance T cell persistence and effectiveness in vivo
1857777|NCT01005745|Other|Adoptive Cell Transfer|T-cell infusion
1857778|NCT01005745|Drug|High Dose IL-2|Beginning approximately 12 - 16 hours after cell infusion.
1857779|NCT01005758|Drug|cyclophosphamide|
1857780|NCT01005758|Drug|cytarabine|
1857781|NCT01005758|Drug|dexamethasone|
1857782|NCT01005758|Drug|doxorubicin hydrochloride|
1857783|NCT01005758|Drug|etoposide phosphate|
1857792|NCT01005758|Drug|vincristine sulfate|
1857793|NCT01005758|Other|laboratory biomarker analysis|
1857794|NCT01005758|Radiation|radiation therapy|
1857795|NCT01005771|Drug|GF-001001-00|GF-001001-00 2%, 1% and 0.25% twice daily for 7 days
1857796|NCT01005771|Drug|Placebo|Matching placebo
1857797|NCT01005784|Drug|Cetrorelix (Cetrotide)|flexible antagonist administration according to specified criteria
1857798|NCT01005784|Drug|Cetrorelix (Cetrotide)|fixed antagonist administration on day 6 of ovarian stimulation
1857799|NCT01005797|Drug|Panobinostat (LBH589), Sorafenib|Starting dose of sorafenib: 400 mg bid on Day 1-28 of each 28-day cycle; of LBH589: 15 mg on days 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24, 26 of each 28-day cycle. Administered simultaneously.
1857800|NCT01005810|Drug|N-Acetylcysteine|1200 mg twice daily for 8 weeks
1857801|NCT01005810|Drug|placebo|2 capsules twice daily for 8 weeks
1857802|NCT01005810|Behavioral|Contingency Management|rewarding biologically verified marijuana abstinence during study visits, with an escalating reward schedule
1857803|NCT01005823|Drug|LEO 29102 cream|Twice daily application for 7 days
1857804|NCT01005823|Drug|LEO 29102 placebo cream|LEO 29102 placebo cream
1857805|NCT01005836|Behavioral|Cognitive behavioral therapy for youth anxiety|
1857806|NCT01005836|Other|Usual clinic care|
1857807|NCT01005836|Behavioral|Cognitive behavioral treatment for youth depression|
1857808|NCT01005849|Dietary Supplement|Protecflor|1 Capsule to be taken once a day during the entire study period
1857809|NCT01005849|Dietary Supplement|Placebo|1 Capsule to be taken once a day during the entire study period
1857810|NCT01005862|Biological|PF-04360365|10 mg/kg, single dose administered intravenously
1857811|NCT01005862|Drug|Placebo|Placebo
1857812|NCT01005875|Drug|Sorafenib|Nexavar in bottles of 120 tables
1857813|NCT01005875|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT
1857814|NCT01005888|Biological|C1 esterase inhibitor [human] (C1INH-nf)|
1857815|NCT01005888|Drug|Placebo (saline)|
1857816|NCT01005901|Drug|Glycopyrronium bromide|Glycopyrronium bromide 50µg was supplied as inhalation capsules for use via a Single Dose Dry Powder Inhaler (SDDPI)
1857817|NCT01005901|Drug|Placebo|Placebo inhalation capsules were provided for use via a SDDPI
1857818|NCT01005914|Drug|cyclophosphamide|Day 1- 3: 300 m g/m2 IV over 2-3 hours every 12 hours for 6 doses plus mesna 600 mg/ m2 /day continuous infusion Days 1-3
1857819|NCT01005914|Drug|cytarabine|Day 2 & 3: 3g/m2 IV over 2 hours q12 X 4
1857820|NCT01005914|Drug|dexamethasone|Day 1-4; 11-14: 40 mg daily
1857821|NCT01005914|Drug|doxorubicin hydrochloride|Day 4: 50 mg/m2 IV over 2 hours
1857822|NCT01005914|Drug|imatinib mesylate|600 mg/day
1857823|NCT01005914|Drug|methotrexate|Day 1: 1g/ m2 (200 mg/ m2load IV over 2 hours plus 800 mg/ m2 over 22 hours as an infusion
1857824|NCT01005914|Drug|methylprednisolone|Day 1-3: 50mg IV BID
1857825|NCT01005914|Drug|pegaspargase|Day 3/Day4: 2,500 IU/ m2 IV
1857826|NCT01005914|Drug|vincristine sulfate|Day 4 & 11: 2 mg IV
1857827|NCT01005927|Dietary Supplement|Fructooligosaccharide|Zero or 3 g of a fructooligosaccharide will be administered in a beverage containing 300 mg total calcium as well as 15 mg 44Ca (calcium carbonate). Participants will be given one of the above beverages in addition to intravenously receiving 5 mg 43Ca (calcium chloride)in 10 ml saline.
1857828|NCT01005940|Device|Mandibular advancement device|Mandibular advancement device made to subject specific specifications
1992896|NCT03278392|Behavioral|Placebo Trier Social Stress Test|Task instructions provided to subject (5mins), subject prepares speech about a movie, novel or recent holiday outing (5 mins), subject tells their story to a friendly researcher with no video recording (5 mins), subject completes a simple arithmetic task without critique from the researcher (5 mins).
1857834|NCT01005979|Drug|Lenalidomide, Rituximab, and Cyclophosphamide|"COHORT 1: Cyclophosphamide 250 mg/m2 day 1, 2 and 3, Rituximab 500 mg/m2 i.v. day 1, Lenalidomide 2.5 mg/day starting day 8-28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles
COHORT 2: Cyclophosphamide 250mg/m2 day 1, 2 and 3. Rituximab 500 mg.m2 i.v. daY Lenalidomide 5 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles
COHORT 3: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 10 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles
COHORT 4: Cyclophosphamide 250mg/m2 day 1, 2 and 3, Rituximab 500 mg.m2 i.v. day 1, Lenalidomide 15 mg/day starting day 8 -28 of Cycle 1 and then daily on Days 1-28 of subsequent cycles
Patients will receive a total of 6-8 cycles."
1857835|NCT01005992|Procedure|Fractional laser treatment|A complete treatment will consist in four laser sessions with a second-generation erbium-doped 1,550-nm fractional photothermolysis laser (Fraxel SR laser, Reliant Technologies Inc at 1-month intervals. Treatment will be delivered with a 15-mm tip and concomitant air-cooling system (Zimmer MedizinSystems, Irvine, CA). Fluence and treatment level will be registered on every session and will be adjusted according to patient tolerance.
1857836|NCT01005992|Procedure|Standard scar management|The standard treated scar arm consists of a similar lesion in an equivalent location in the same patient or the half of a lesion that is suitable to be divided (size at least 4% body surface area). This arm will be managed only with standard burn treatment modalities.
1857837|NCT01006018|Drug|Sitagliptin + Pioglitazone PLACEBO|Sitagliptin 100 mg tablet daily + Pioglitazone PLACEBO 15 mg capsule daily
1857838|NCT01006018|Drug|Sitagliptin + Pioglitazone|Sitagliptin 100 mg tablet daily + Pioglitazone 15 mg capsule daily
1857839|NCT01006018|Drug|PLACEBO|Sitagliptin placebo 100 mg tablet daily + Pioglitazone placebo 15 mg capsule daily
1857840|NCT01006031|Drug|Pegylated interferon alfa-2a and Ribavirin|"Pegylated interferon alfa-2a (360 ug per week) plus oral Ribavirin (800 mg b.i.d.) for 48 or 72 weeks. The treatment will be discontinued for patients who did not achieve a reduction with respect to baseline of at least 0.5 log10 IU/ml in plasma RNA-HCV levels at week 4 or 2 log10 UI/ml at week 12 and will be considered as viral failures.
Duration: 48 weeks for patients reaching an undetectable plasma RNA_HCV at week12 and 72 weeks for those without a negative viremia at week 12 but a reduction of at least 2 log10 IU/ml in RNA-HCV levels."
1857908|NCT01000064|Procedure|fMRI|Brain scans (fMRI) performed at baseline, 6 week visit and 12th week visit.
1857909|NCT01000064|Drug|Placebo|Placebo capsules taken every morning for 6 weeks.
1857841|NCT01006044|Biological|autologous dendritic cells|Patients will receive standard first-line therapy (surgery before radio-chemotherapy) along with the experimental treatment. The experimental treatment consists in subcutaneous vaccination with a suspension of autologous dendritic cells (cells from the same patient) produced by cell culture from monocytes from the same patient extracted by leukapheresis and pulsed with a lysate of the patient´s tumoral tissue. The first four vaccines will be administered on a monthly basis, concomitantly with the standard chemo and radiotherapy treatments, the next four vaccines, every other month and the four last vaccinations every three months.The results obtained will be compared with those of an historical control study, where patients received a standard treatment without the experimental vaccine.
1857842|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with end stage renal disease
1857843|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with mild renal impairment
1857844|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with moderate renal impairment
1857845|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in healthy volunteers
1857846|NCT01006057|Drug|insulin degludec|Single dose of 0.4 U/kg body weight injected s.c. (under the skin) in subjects with severe renal impairment
1857847|NCT01006070|Procedure|kyphoplasty|surgical kyphoplasty
1857848|NCT01006096|Drug|erlotinib|100mg tablet, once daily for 16 weeks
1857849|NCT01006096|Other|placebo tablet|placebo tablet (lactose), once daily for 16 weeks
1857850|NCT01006122|Drug|Placebo|Patients receiving placebo will undergo the same procedures as those receiving active treatment. Each patient will receive matching placebo tablets in a fixed dose escalation schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at 1.0 mg; decrease to 0.5 mg or increase to 2.0 mg based upon the clinicians judgment regarding efficacy and side effects at the 1.0 dose level. The patient will then remain at the determined dose for a 3 week stable dosing period, with a 7 (-2/+ 9) day wash out and then crossover to repeat the same sequence for the second arm of the study.
1857851|NCT01006122|Drug|PF-03654746|Each patient will receive PF-03654746 tablets in a fixed dose titration schedule beginning at 0.25 mg QD for 5 days; then up to 0.50 mg QD for another 5 days; and up to 1.0 mg QD for an additional 5 days. At the end of this fixed titration schedule, the patient will either stay at the 1.0 mg dose; decrease to 0.50 mg or increase to 2.0 mg based upon the clinician's judgement regarding efficacy and side effects at the 1.0 mg dose. The patient will remain at the determined dose for a 3 week stable dosing period.
1857852|NCT01006148|Biological|Allogenix Plus|It is a demineralized bone matrix obtained using cortical or cancellous allograft bone that is treated to remove surface lipids and then dehydrated with ethanol and ethyl esther. It is further processed leaving behind proteins, bone growth factors, and collagen. It is combined with lecithin a which is resistant to breakdown by body fluids. It contains Pro Osteon Implant 500R a naturally derived material made from a non-decorative form of coral, which is subject to a patented thermal process, which converts the coral to hydroxyapatite.
1857853|NCT00999648|Other|Myofascial trigger point pressure release (deactivation)|The deactivation of MTP will be performed always by the same physiotherapist researcher using the same technique. Afterwards, a myofascial maneuver is performed in each treated muscle. All patients of the experimental group will be advised to perform complimentary procedures at home during the 10-week period treatment in order to maintain the status of the muscle up to the next session and to avoid losing the obtained result:(1) Stretching of the treated muscles, once a day for 25 seconds each, (2)Superficial heat in each treated muscle, once a day for 20 minutes, (3) Watch the correct postures during daily activities and sleeping.
1857854|NCT00999648|Other|Placebo myofascial trigger point pressure release|The physiotherapist researcher will press in an adjacent nontender muscle fibers of the same muscle that have MTP about 3cm to the right or to the left of each diagnosed MTP, using just a slight pressure on it, not enough for deactivation.
1857855|NCT00999674|Other|An exercise program|The study subjects were recruited among those who responded to advertisements in outpatient clinics
1857856|NCT00999687|Drug|Indigo Naturalis Extract in Oil|The participants applied indigo naturalis extract in oil topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 12 weeks.
1857857|NCT00999687|Other|Olive Oil|Patients were instructed to apply olive oil on one of two bilaterally symmetrical psoriatic finger nails which were different to the INOE side twice daily for first 12 weeks, after that, indigo naturalis oil extract was applied to replace olive oil for another 12 weeks.
1857858|NCT00999700|Drug|docetaxel - cisplatin - 5-fluorouracil|docetaxel 75 mg/sqm day1 cisplatin 75 mg/sqm day1 5-fluorouracil 750 mg/sqm/d c.i. day1 to day4 q21
1857859|NCT00999700|Radiation|radiotherapy|"Conformal radiotherapy or IMRT should be employed.
Standard radiotherapy:
Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
1857860|NCT00999700|Drug|cetuximab|400 mg/sqm at the 1st infusion - before starting RT 250 mg/sqm weekly - concurrent with RT up to the last week of treatment
1857861|NCT00999700|Drug|cisplatin|Cisplatin, 100 mg/sqm every 3 weeks, three times, concurrent with RT, starting from day 1 of treatment.
1857862|NCT00999700|Radiation|radiotherapy|"Conformal radiotherapy or IMRT should be employed.
Standard radiotherapy:
Minimum radiation dose 70 Gy. Additional boost up to 10 Gy if clinically indicated."
1857863|NCT00999713|Drug|Calfactant|Endotracheal calfactant, up to 3 doses if subject qualifies
1857864|NCT00999713|Other|Air placebo|Endotracheal air administration
1857865|NCT00999739|Biological|Prevenar and Pneumo23|Two vaccines: participants will receive via intramuscular in deltoid one dose of conjugated heptavalent vaccine at day 0 (Prevenar, Wyeth-lederle)and one dose of 23valent polysaccharide vaccine (Pneumo23, AventisPasteur)at week4 One vaccine:participants will receive only one dose of 23valent polysaccharide vaccine at day 0.
1857866|NCT00999752|Drug|Nebivolol|5mg/day with increase to 10 mg/day to reach blood pressure <140/90
1857867|NCT00999752|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg/day
1857868|NCT00999765|Behavioral|Mindfulness-Based Cognitive Therapy|eight-week (two hours a week) group therapy (8-12 patients per group)
1858003|NCT01006304|Drug|JNJ-39439335, Placebo|
1857869|NCT00999778|Behavioral|Caregiver-Mediated Intervention|1 (two- 1/2 jour sessions weekly) hour of intervention per week for 10 weeks in which parents and their child meet with the interventionist together using the caregiver as a means to facilitate change in their child's development
1857870|NCT00999778|Behavioral|Caregiver-Education Intervention|The caregiver meets 1 time (1 hour each session) a week for 10 weeks with an interventionist - caregiver will receive information on child development and have the opportunity to ask questions and discuss the information vis-a-vis their own child
1857871|NCT00999791|Drug|Bevacizumab|
1857872|NCT00999791|Drug|Diclofenac|
1857873|NCT00999804|Drug|Lapatinib|1000 mg of Lapatinib by mouth daily
1857874|NCT00999804|Drug|Letrozole|Letrozole, 2.5 mg by mouth daily (for hormone receptor positive participants only)
1857875|NCT00999804|Drug|Trastuzumab|6 mg/kg intravenously, every 3 weeks
1857876|NCT00999817|Drug|reference [dextromethorphan]|single 30 mg oral dose
1857877|NCT00999817|Drug|test [PF-00299804 + dextromethorphan]|single 45 mg oral dose of PF-00299804 and a single 30 mg oral dose of dextromethorphan
1857878|NCT00999830|Drug|IPH2101|One infusion of IPH2101 every 4 weeks
1857879|NCT00999843|Drug|Sorafenib|Sorafenib is administered only to the patients with non-progression disease (CR, PR and SD) 4 weeks after the completion of radiotherapy. The dose is 400 mg, p.o., twice a day. Sorafenib is continuously given for 12 months unless intolerable toxicities and/or tumor progression.
1857880|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
1857881|NCT00999856|Device|GOMIS and Photometer|An improved insert is placed under the conjunctiva. During measurement sessions photometer will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
1857882|NCT00999856|Device|GOMIS and Photometer|Insert is placed under the conjunctiva. During measurement sessions photometer version 2 will be placed in front of the eye in which the insert is located to perform the fluorescence measuring.
1857883|NCT00999856|Device|GOMIS and Photometer|After comparing Photometer Version 1 and Version 2 the better one of them will be used for measurements in Cohort 4. A new insert will be implanted under the conjunctiva.
1857884|NCT00999856|Device|GOMIS and Photometer|The insert version with the best results will be implanted. The photometer that was used in Cohort 4 will be taken again for fluorescence measurements.
1857885|NCT00999869|Drug|Botulinum toxin type A|Using concentration at 2 units per 0.1 of dilution with normal saline Injection in the first visit and follow up at 1 week, 1,2,3 and 4 months after injection
1857886|NCT00999869|Drug|Triamcinolone acetonide|Using concentration at 10 mg/ml and equal amount of botulinum toxin A dilution
1857887|NCT00999882|Drug|AZD8055|Dose escalation phase: Tablet taken orally, a single dose of AZD8055 on Day 1, followed by twice daily continuous dosing from Day 3 onwards, till discontinuation or withdrawal.Expansion phase: twice daily continuous dosing from Day 1 onwards till discontinuation or withdrawal.
1857888|NCT00999908|Drug|Indacaterol 150 μg|Indacaterol was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
1857889|NCT00999908|Drug|Tiotropium 18 μg|Tiotropium was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
1857890|NCT00999908|Drug|Placebo|Placebo (matching indacaterol) was supplied in powder filled capsules together with a single dose dry powder inhaler (SDDPI) device.
1857891|NCT00999921|Drug|Tamoxifen|Tamoxifen is given at 10 mg once daily between Day 5 and Day 25 of menstrual cycle for 3 cycles.
1857892|NCT00999921|Drug|Evening Primrose Oil|Evening Primrose Oil is given at 1000 mg two times daily for 3 months.
1857893|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (without a simulator)|without simulator
1857894|NCT00999960|Procedure|Laparoscopic Radical Prostatectomy (with a simulator)|Learning with a simulator
1857895|NCT00999973|Drug|Mitomycin C 0.02%|
1857896|NCT00999973|Drug|Placebo|
1857897|NCT00999986|Drug|cyclophosphamide|50 mg oral per day for 7 days
1857898|NCT00999999|Procedure|Craniotomy supra- or infratentorial, dural closure|After dural closure with a water-tight suture, randomization is performed. Depending on the randomization outcome, the study drug Tachosil is applied on the dural suture or omitted.
1857899|NCT01000012|Device|Becker 50 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
1857900|NCT01000012|Device|Becker 25 Expander/Breast implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
1857901|NCT01000025|Drug|PF-00299804|PF-804 45 mg PO, daily
1857902|NCT01000025|Drug|Placebo|Placebo 45 mg PO, daily
1857903|NCT01000038|Other|Wii-Fit intervention|Half hour daily, 5 days a week for 8 weeks
1857904|NCT01000038|Other|Walking|Half hour daily, five days a week for 8 weeks
1857905|NCT01000051|Drug|Eltrombopag|Starting daily dose 50 mg orally on empty stomach (1 hour before or 2 hours after a meal) for 8 weeks. East Asians start at 25 mg daily.
1857906|NCT01000051|Drug|Placebo|Once a day, orally for 8 weeks.
1857907|NCT01000064|Drug|Vyvanse|30 mg - 70 mg capsules taken every morning for 6 weeks.
1857910|NCT01000103|Device|Real rTMS|Transcranial Magnetic Stimulation, in a low frequency (1 Hz) continuous train of 20 minutes (1200 pulses)
1857911|NCT01000103|Device|Sham rTMS|"two TMS coils will be used: a passive one which is placed flat on top of the actively targeted region which remains unplugged and generates a continuous scalp tactile sensation, and an active one located at a prudential distance from the scalp, which will deliver active pulses and its accompanying sensations"
1857912|NCT01000116|Procedure|Fibrin glue|Tissucol 2 ml
1857913|NCT01000116|Procedure|Tacks|Protacks
1857914|NCT01000129|Other|Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)|Planning CT scan performed by qualified planning radiographers
1857915|NCT01000129|Other|Cone beam CT acquisition|Cone beam CT acquisition performed by therapy radiographers who have training and experience of using cone beam CT.
1857916|NCT01000142|Procedure|Osteopathic Manipulative Treatment|Focused osteopathic musculoskeletal exam; paraspinal muscle inhibition and/or soft tissue kneading or stretching; rib raising and or rib mobilization; abdominal diaphragm release technique; abdominal mesenteric/colon release; thoracic inlet release technique; hip flexion/extension range of motion; shoulder range of motion with pectoral traction; cervical paraspinal muscle inhibition and/or soft tissue kneading or stretching; suboccipital release technique; specific OMT of significant somatic dysfunction (variable).
1857917|NCT01000142|Procedure|Light Touch|Focused osteopathic musculoskeletal exam; contact ribs to simulate rib raising and paraspinal muscle inhibition; contact lower rib margin to simulate abdominal diaphragm release; palpate the four quadrants of the abdomen to simulate abdominal mesenteric/colon release; contact shoulders to simulate thoracic inlet release; contact suboccipital region to simulate thoracic inlet release.
1857918|NCT01000155|Drug|vorinostat|
1857919|NCT01000168|Other|Treadmill therapy and conventional walking therapy.|"The experimental group received 30 sessions of treadmill therapy with body weight support for a time period of 10 weeks.
The conventional group received traditional walking therapy for the same time period."
1857920|NCT01000181|Other|PET-CT with CuATSM|PET-CT with CuATSM
1857921|NCT01000194|Dietary Supplement|High fat meal|A high fat milkshake containing 55g of fat
1857922|NCT01000207|Biological|Adjuvanted cell-derived, inactivated novel swine origin A/H1N1 monovalent subunit influenza virus vaccine|High dose group and low dose group of adjuvanted vaccines
1857923|NCT01000220|Drug|Omeprazole|
1857924|NCT01000220|Drug|Placebo|
1857925|NCT01000233|Dietary Supplement|Phytine (phytate)|300 mg tid * 24 months
1857926|NCT01000233|Dietary Supplement|Placebo|Phytine (Phytate)
1857927|NCT01000246|Biological|influenza virus vaccine (influvac or vaxigrip)|one i.m. dose of 0.5 mL
1857928|NCT01000259|Other|Laboratory Biomarker Analysis|Samples are analyzed in laboratory studies
1857929|NCT01000285|Drug|Bortezomib|
1857930|NCT01000285|Drug|Etoposide|
1857931|NCT01000285|Drug|Vincristine|
1857932|NCT01000285|Drug|Doxorubicin|
1857933|NCT01000285|Drug|Prednisone|
1857934|NCT01000285|Drug|Cyclophosphamide|
1857935|NCT01000285|Drug|Raltegravir|
1857936|NCT01000298|Drug|Placebo|liquid placebo medication given twice per day for 7 days
1857937|NCT01000298|Drug|Amoxicillin|liquid amoxicillin given twice per day for 7 days
1857938|NCT01000298|Drug|Cefdinir|liquid cefdinir given twice per day for 7 days
1857939|NCT01000311|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2, 4, 6 and 12 months of age as IM injections in the anterolateral area of the thigh.
1857940|NCT01000311|Biological|DTaP-IPV/Hib|IM injections of 3 doses of 0.5 mL each of DTaP-IPV/Hib supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
1857941|NCT01000311|Biological|HBV|IM injections of 3 doses of 0.5 mL each of HBV supplied in prefilled vial were administered at 2, 4 and 6 months of age in the anterolateral area of the thigh.
1857942|NCT01000311|Biological|PCV|IM injections of 4 doses of 0.5 mL each of PCV supplied in prefilled vial were administered at 2, 4, 6 and 12 months of age in the anterolateral area of the thigh.
1857943|NCT01000311|Biological|MMR|Subcutaneous (SC) injection of 1 dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 12 months of age in the anterolateral area of the thigh.
1857944|NCT01000324|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
1857945|NCT01000324|Biological|Engerix™-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B
1857946|NCT01000324|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies
1857947|NCT01000337|Drug|Sevoflurane|Sevoflurane concentration for induction of anesthesia 7-8%, for maintenance of anesthesia 2%.
1857948|NCT01000337|Drug|Propofol|Propofol to induce anesthesia 2.5 mg/kg, for maintenance of anesthesia 6 mg/kg/h
1857949|NCT01000350|Drug|Saline|IV Normal Saline infused over 30-60 minutes given 3-6 hours PRIOR to exercise study
1857950|NCT01000350|Other|Placebo|Placebo x1 lactose tablet
1857951|NCT01000376|Drug|Eribulin alone|Group 1 Cycle 1 (28 days): Eribulin IV 1.4 mg/m^2 alone on Day 1, then eribulin IV 0.7 mg/m^2 plus oral ketoconazole 200 mg on Day 15 and oral ketoconazole 200 mg alone on Day 16. Subsequently, subjects were able to receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days.
1857952|NCT01000376|Drug|Eribulin plus Ketoconazole|Group 2 Cycle 1 (28 days): Eribulin IV 0.7 mg/m^2 plus oral ketoconazole 200 mg on Day 1, then oral ketoconazole 200 mg alone on Day 2 and eribulin IV 1.4 mg/m^2 alone on Day 15. Subsequently, subjects were able to receive eribulin 1.4 mg/m^2 on Days 1 and 8 every 21 days.
1857953|NCT01000389|Device|Grindcare® (Biofeedback)|Active treatment with functional electrical stimulation
1858004|NCT01006317|Behavioral|clinical skills training|In addition to financial coverage (CMS) extensive in-service training of clinical skills (CS) to all doctors and MCH workers at the village and township level.
1858187|NCT01007721|Drug|fluticasone propionate nasal spray placebo|fluticasone propionate nasal spray placebo (2 puffs each nostril qd in the morning)
1859698|NCT01022879|Procedure|vitrectomy|
1857954|NCT01000402|Drug|Psychopharmacotherapy|Lithium (according to response, serum levels, and tolerance) 150-1500mg Valproate (according to response, serum levels, and tolerance) 125-2000mg Risperidone (according to response, and tolerance)0.5-6mg Olanzapine(according to response, and tolerance)2.5-20mg Ziprasidone(according to response, and tolerance)40-160mg Topiramate (according to response, and tolerance)25-300mg Quetiapine (according to response, and tolerance)25-500mg Aripiprazole (according to response, and tolerance)5-20mg Lamotrigine (according to response, and tolerance)25-200mg Fluoxetine (according to response, and tolerance) 1-40mg Sertraline (according to response, and tolerance)25-200mg Methylphenidate (according to weight, response, and tolerance)0.3 -0.7mg/kg/day
1857955|NCT01000415|Other|Neoadjuvant chemotherapy followed by surgery|Cisplatin 50 mg/m2 (in the vein)on day 1 of each 23 day cycle plus gemcitabine 1000 mg/m2 (in the vein) on day 1 and day 8, for 3 cycles: until progression or unacceptable toxicity develops.
1857956|NCT01000441|Drug|infliximab, etanercept, adalimumab|
1857957|NCT01000441|Drug|abatacept, rituximab or tocilizumab|
1857958|NCT01000467|Drug|probucol|group 3: 250 mg 1 tablet in the morning and evening
1857959|NCT01000467|Drug|probucol|group 1: 250 mg
1857960|NCT01000467|Drug|probucol|group 2: 250 mg 2 tablets at once in the morning
1857961|NCT01000480|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) intravenous infusion on Day 1 of a 21 day cycle for 2 cycles: with possibility of 2 additional cycles.
1857962|NCT01000480|Drug|Cisplatin|75 mg/m² intravenous infusion on Day 1 of a 21 day cycle for 2 cycles; with the possibility of 2 additional cycles.
1857963|NCT01000480|Radiation|Thoracic Radiotherapy|Administered at 2 gray (Gy)/fraction after completion of the pemetrexed and cisplatin infusions on Day 1 of Cycle 3 and will continue daily (5 days per week) until the total delivered dose reaches a therapeutic goal of 66 Gy, over approximately 7 weeks.
1857964|NCT01000493|Drug|orvepitant|Neurokinin-1 (NK-1) antagonist
1857965|NCT01000493|Other|Placebo|Inactive placebo to match orvepitant 60 mg dosage form
1857970|NCT01000519|Other|Aerobic Training|18 sessions over 2 months period. Each session consist of 50 minutes of aerobic training at 65-70 % of maximum predicted heart rate
1857971|NCT01000519|Other|Progressive resistance training|18 sessions completed in 2 months. each session consists of 50 minutes of resistance training which is made up of 3 sets of 10 repetitions of nine resistive exercises using machines and free weights at 65-70% of 1-repetitive maximum.
1857972|NCT01000532|Device|SIELLO JT/T|Implantation of SIELLO and BPPU pacemaker leads
1857973|NCT01000532|Device|Pacemaker therapy|Pacemaker therapy
1857974|NCT01000532|Device|BPPU JT/T|Implantation of SIELLO and BPPU pacemaker leads
1857975|NCT01000545|Drug|Sulodexide|SLX 500 LRU, SLX 1000 LRU, SLX 2000 LRU per day to be taken orally for 12 months.
1857976|NCT01000545|Drug|placebo capsules|8 soft-gel capsules per day to be taken orally for 12 months
1857977|NCT01000558|Other|biologic sample preservation procedure|
1857978|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group A: Single dose of Arepanrix and single dose of Vaxigrip 2009/2010 given concurrently
1857979|NCT01000584|Biological|Arepanrix, Vaxigrip 2009/2010|Group B: Single dose of Vaxigrip 2009/2010 given 3 weeks after single dose of Arepanrix
1857980|NCT01006161|Drug|SCH 527123|Low dose
1857981|NCT01006161|Drug|SCH 527123|Medium dose
1857982|NCT01006161|Drug|SCH 527123|High dose
1857983|NCT01006161|Drug|SCH 527123|Placebo to match SCH 527123
1857984|NCT01006174|Other|Soybean Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of soybean oil that is added to a salad.
1857985|NCT01006174|Other|Canola Oil|Depending on the experimental group assigned, each subject which will be given one of three different amounts of canola oil that is added to a salad.
1857986|NCT01006174|Other|Butter|Depending on the experimental group assigned, each subject which will be given one of three different amounts of butter that is added to a salad.
1857987|NCT01006187|Drug|Liposomal lidocaine|4% cream; approximately one gram applied to injection site under an occlusive dressing for 20 minutes prior to injection
1857988|NCT01006187|Drug|Vapocoolant spray|medium stream spray on arm for 4-10 seconds prior to injection
1857989|NCT01006187|Other|Rubbing adjacent to the injection site|rubbing adjacent to the injection site before and during injection
1857990|NCT01006187|Other|Distraction|By means of self-selected reading material or video
1857991|NCT01006213|Behavioral|Motivational intervention|Two groups will be established in geographically separate areas, one of which will receive the group motivational intervention (intervention group) and the other will receive standard follow-up (control group)
1857992|NCT01006226|Drug|64Cu-ATSM PET|2 64Cu-ATSM PET scan, one pretreatment and one 19-21 days after the first dose of bevacizumab
1857993|NCT01006239|Other|No study intervention|The is no study related intervention.
1857994|NCT01006252|Drug|Tasisulam|Individualized dose dependent on patient's height, weight, and gender and is adjusted to target a specific exposure based on a patient's laboratory parameters, administered intravenously on day 1 of 28 day cycle, until disease progression.
1857995|NCT01006252|Drug|Paclitaxel|80 mg/m2 administered intravenously on days 1, 8, and 15 of 28 day cycle, until disease progression
1857996|NCT01006265|Drug|ACT-128800 Dose 1|ACT-128800 (Dose 1) administered orally once daily
1857997|NCT01006265|Drug|Placebo|Matching placebo administered orally once daily
1857998|NCT01006265|Drug|ACT-128800 Dose 2|ACT-128800 (Dose 2) administered orally once daily
1857999|NCT01006265|Drug|ACT-128800 Dose 3|ACT-128800 (Dose 3) administered orally once daily
1858000|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily (alternative regimen). Dose was individually adjusted.
1858001|NCT01006291|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
1858002|NCT01006291|Drug|insulin glargine|Insulin glargine injected s.c. (under the skin) once daily. Dose was individually adjusted.
1858005|NCT01006317|Behavioral|health education|In addition to financial coverage extensive in-service training of health education (HE) to all doctors and MCH workers at the village and township level(Anhui, Chongqing and Shaan'xi provinces); In addition to financial coverage extensive in-service training of health education (HE) for Family planning (FP) staff at village level (Anhui).
1858006|NCT01006317|Other|financial|In addition to financial coverage of MCH care within the local reimbursement system (CMS) the coverage of ante- and postnatal care.
1858007|NCT01006343|Other|Higher Protein (HP)|
1858008|NCT01006343|Other|Lower Protein (LP)|
1858009|NCT01006356|Drug|Hydromorphone HCl OROS|Hydromorphone HCl OROS 8 mg once daily for 2 weeks.
1858013|NCT01006395|Drug|Zoledronic acid|yearly infusion
1858014|NCT01006395|Drug|Placebo|yearly infusion
1858015|NCT01006408|Procedure|Low Level Laser|Low Level Laser twice a week for 8 weeks
1858016|NCT01006408|Procedure|Placebo followed by Low Level Laser|Placebo twice a week for 4 weeks then crossover to Low Level Laser twice a week for 4 weeks
1858017|NCT01006421|Dietary Supplement|GINGKO BILOBA|MEMOREX 60 MG BID
1858018|NCT01006434|Other|Recording of body weight estimations, approximations and tPA dose|Body weight estimation, patients are weighed, actual tPA dose is recorded
1858019|NCT01006447|Behavioral|Instructor contact|
1858020|NCT01006447|Behavioral|Instructor contact|
1858021|NCT01006460|Drug|Rhodiola rosea, L|3 Capsules twice a day
1858022|NCT01006460|Drug|Rhodiola rosea, L., Eleutherococcus senticosus, Schisandra chinensis|3 capsules twice a day
1858023|NCT01006460|Drug|Panax ginseng|3 capsules twice a day
1858024|NCT01006460|Drug|Placebo - dark brown sugar|3 capsules twice a day
1858025|NCT01006473|Other|Exercise training|
1858026|NCT01006486|Other|Anticoagulation clinic|Patients randomized to this arm will be cared at an anticoagulation clinic, with educational measures and standardized procedures related to the use of coumarins.
1858027|NCT01006486|Other|Standard anticoagulation care|Patients randomized to this arm will be cared by their physician, with standard care. No standardized protocol of the use of coumarins will be established.
1858028|NCT01006772|Other|Solid Ankle Foot Orthosis|Polypropylene (homopolymer) AFO with carbon fiber reinforcements is provided to experimental group patients as an adjunct therapy to conventional physical therapy.
1858029|NCT01006785|Drug|DLBS1425|3 X 150 mg daily for 12 - 16 weeks of treatment
1858030|NCT01006785|Drug|DLBS1425|3 X 300 mg daily for 12 - 16 weeks of treatment
1858031|NCT01006798|Other|Placebo|enteric coated capsule containing no vaccine virus
1858032|NCT01006798|Biological|Ad4-H5-Vtn|a live, replication-competent, recombinant Ad4 virus expressing the HA of H5N1 influenza (A/Vietnam/1194/2004) in an enteric capsule for oral administration
1858033|NCT01006798|Biological|Sanofi Pasteur Influenza Virus Vaccine, H5N1|Single administration of a heterologous boost given to volunteers 3 to 15 months following their last vaccination with Ad4-H5-Vtn or placebo.
1858034|NCT01006811|Dietary Supplement|modified Atkins diet|"Modified Atkins Diet administration
Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)
Fats (e.g. cream, butter, oils, ghee) encouraged.
Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.
Clear carbohydrate-fluids not restricted.
Calcium and multivitamin supplementation will be provided."
1858035|NCT01006811|Other|modified Atkins diet|"Modified Atkins Diet administration
Carbohydrates intake restricted to 10 grams/ day. (Carbohydrate values of various food items will be explained in detail, and exchange lists provided. Four 2.5 grams carbohydrate exchange items will be allowed in a day.)
Fats (e.g. cream, butter, oils, ghee) encouraged.
Proteins (cheese, fish, eggs, chicken, soya products) unrestricted.
Clear carbohydrate-fluids not restricted.
Calcium and multivitamin supplementation will be provided."
1858036|NCT01006824|Other|Capsule endoscopy|Capsule endoscopy
1858037|NCT01006824|Other|Dedicated small bowel contrast radiography|Dedicated small bowel contrast radiography
1858038|NCT01006850|Drug|Hydromorphone|2mg IV hydromorphone
1858039|NCT01006863|Drug|Ephedrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
1858040|NCT01006863|Drug|Placebo|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing either saline 0.9% solution [group 1 (n=30)], ephedrine 0.7 mg/mL [group 2 (n=30)], ephedrine 1 mg/mL [group 3 (n=30)] or ephedrine 1.5 mg/mL [group 4 (n=30)]or phenylephrine 15 mcg/mL [group 5 (n=30)]. All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo and the ephedrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
1858091|NCT01007175|Biological|ATN-103 10 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
1858267|NCT01008397|Drug|AHIST NDC#58407-012-01|Oral tablet containing chlorpheniramine tannate 12mg.
1858041|NCT01006863|Drug|Phenylephrine|Subjects were allocated randomly to five groups by drawing sequentially numbered sealed opaque envelopes containing a computer-generated randomization code. The subjects received intravenous injection of 0.1 mL/kg of a study solution containing 15 mcg/ml of phenylephrine [group 5 (n=30)] All study solutions were injected over 1 min at 1 min before induction of anesthesia. The placebo, the ephedrine, and the phenylephrine solutions were prepared in identical syringes labeled 'study drug' by the local pharmacy department before induction of anesthesia.
1858042|NCT01006876|Drug|Coumadin|Continuous oral Coumadin therapy through the catheter ablation procedure
1858043|NCT01006876|Drug|Coumadin|Patients discontinue Coumadin 3-4 days prior to ablation and replace it with heparin until the end of the procedure and bridge low molecular weight heparin (LMWH) with Coumadin 48-72 hours after ablation.
1858044|NCT01006876|Drug|Coumadin|Oral tablets, daily dose, till the therapeutic INR of 2-3 is achieved
1858045|NCT01006889|Drug|Exenatide|The participants with T2DM well-controlled on an intensified insulin regimen for the previous 6 months with the combination of a premeal insulin injection of the drug aspart (Novolog) three times a day and a bedtime insulin injection of the drug detemir (Levemir). The dosage of the insulin is determined by the need by the need of the participant. The Exenatide treatment will consist of an injection of the insulin twice daily and will replace the premeal insulin regiment of aspart.
1858046|NCT01006915|Procedure|Surgery|Surgical decompression of the common peroneal, tibial, and deep peroneal nerves
1858047|NCT01006928|Other|Questionaire|Questionaire to mothers
1858048|NCT01006941|Biological|Trichuris suis ova|2500 ova per dose, orally, every second week, during 12 weeks
1858049|NCT01006954|Drug|Microdose GnRh|Microflare protocol in poor responders for IVF/ICSI
1858050|NCT01006954|Drug|Flare up|Flare up protocol in poor responders for IVF/ICSI
1858051|NCT01006967|Device|ActiveStep Treadmill|The ActiveStep treadmill is a device that trains patients to effectively react to simulated slips and trips while the patient is safely held in a harness.
1858052|NCT01006967|Other|Physical Therapy|Standard program of physical therapy for gait and balance
1858053|NCT01006980|Drug|Vemurafenib|960 mg (as 240 mg tables) orally twice daily
1858054|NCT01006980|Drug|Dacarbazine|1000 mg/m2 intravenously every 3 weeks
1858055|NCT01006993|Device|NeuroFlo catheter|NeuroFlo™ catheter 45 minute treatment
1858056|NCT01007006|Device|TMRDU|The TMRDU will assist study subjects with taking their medications as prescribed by notifying them when the next dose is due and tracking whether and when it was taken.
1858057|NCT01007019|Drug|YH4808 30mg|YH4808 30mg (single dose)
1858058|NCT01007019|Drug|YH4808 50mg|YH4808 50mg (single dose)
1858059|NCT01007019|Drug|YH4808 100mg|YH4808 100mg (single dose)
1858060|NCT01007019|Drug|YH4808 200mg|YH4808 200mg (single dose)
1858061|NCT01007019|Drug|YH4808|YH4808 400mg (single dose)
1858062|NCT01007019|Drug|YH4808 100mg (repeat dose)|YH4808 100mg (repeat dose)
1858063|NCT01007019|Drug|YH4808 200mg (repeat dose)|YH4808 200mg (repeat dose)
1858064|NCT01007019|Drug|YH4808 600mg|YH4808 600mg
1858065|NCT01007019|Drug|YH4808 800mg (single dose)|YH4808 800mg (single dose)
1858066|NCT01007019|Drug|YH4808 400 mg (repeat doses)|YH4808 400 mg (repeat doses)
1858067|NCT01007019|Drug|Placebo|10 volunteers will be administered matched placebo.
1858068|NCT01007019|Drug|Esomeprazole 40mg|24 volunteers will be administered Esomeprazole 40mg
1858069|NCT01007032|Biological|IMC-A12|IMC-A12 intravenously
1858071|NCT01007084|Drug|Propranolol|40 mg
1858072|NCT01007084|Drug|Propranolol ER|120 mg twice per day
1858073|NCT01007084|Drug|Sugar pills|sugar pill
1858074|NCT01007097|Drug|TAK-875|TAK-875 6.25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
1858075|NCT01007097|Drug|TAK-875|TAK-875 25 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
1858076|NCT01007097|Drug|TAK-875|TAK-875 50 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks.
1858077|NCT01007097|Drug|TAK-875|TAK-875 100 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
1858078|NCT01007097|Drug|TAK-875|TAK-875 200 mg, tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
1858079|NCT01007097|Drug|Glimepiride|TAK-875 placebo-matching tablets and Glimepiride 2 mg or 4mg, capsules, orally, once daily for up to 12 weeks.
1858080|NCT01007097|Drug|Placebo|TAK-875 placebo-matching tablets and Glimepiride placebo-matching capsules, orally, once daily for up to 12 weeks
1858081|NCT01007110|Dietary Supplement|DHA|Docosahexaenoic Acid (DHA) from algal oil
1858082|NCT01007110|Other|Placebo|Placebo capsule
1858083|NCT01007123|Drug|A3309|A3309 in three different dosage levels or placebo once daily for the duration of the study
1858084|NCT01007136|Device|tDCS|1 mA electric current will be delivered over the lesioned motor cortex for the first 20 minutes during the one hour physical therapy.
1858085|NCT01007136|Device|Sham tDCS|Electric current will be ramped up and down over the lesioned motor cortex for the first seconds during the one hour physical therapy.
1858086|NCT01007149|Drug|omalizumab|Omalizumab was supplied in 5mL vials with solution for subcutaneous injection.
1858087|NCT01007149|Drug|Placebo|Placebo was supplied in vials with solution for subcutaneous injection.
1858088|NCT01007175|Biological|ATN-103 10 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.1 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
1858089|NCT01007175|Biological|ATN-103 30 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.3 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
1858090|NCT01007175|Biological|ATN-103 80 mg q4wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 4-week intervals for a total of 4 SC injections.
1858186|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
1858092|NCT01007175|Biological|ATN-103 80 mg q8wks|ATN-103 160-mg vials (lyophilized) and placebo vials (lyophilized) Each subject will be given a single SC injection (0.8 mL) of either ATN-103 or placebo at 8-week intervals for a total of 2 SC injections.
1858093|NCT01007188|Other|1.5PD almonds|average American diet plus 1.5 oz per day almonds
1858094|NCT01007188|Other|3.0PD almonds|average American diet plus 3.0 oz per day almonds
1858095|NCT01007188|Other|Base (without almonds)|average American diet without almonds
1858096|NCT01007201|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|
1858097|NCT01007214|Procedure|Prostatectomy|Elective prostatectomy
1858098|NCT01007227|Other|Lifestyle instruction|Instruction dietetic and exercise therapy
1858099|NCT01007240|Device|polyethylenimine (PEI) nanoparticles.|
1858100|NCT01007253|Drug|PL nasal spray|2 puffs of PL nasal spray (from GlaxoSmithKline) in each nostril once a day for 1 week
1858101|NCT01007253|Drug|fluticasone furoate (FF)|2 puffs of FF nasal spray in each nostril once a day for 1 week
1858102|NCT01007253|Drug|PL eye drops|1 drop of placebo eye drops (lubricant eye drops with active ingredients 0.3% glycerin) in each eye once a day for 1 week
1858103|NCT01007253|Drug|olopatadine (OLO)|1 drop of OLO eye drops in each eye once a day for 1 week
1858104|NCT01007266|Behavioral|Assignment of a Lay Patient Partner|
1858105|NCT01007279|Drug|ROSUVASTATIN|40 mg before procedure
1858106|NCT01007292|Drug|YM155|intravenous infusion
1858107|NCT01007292|Biological|Rituximab|intravenous infusion
1858108|NCT01007305|Procedure|Bilateral salpingo-oophorectomy|Removal of both ovaries and fallopian tubes at the time of hysterectomy
1858109|NCT01007305|Procedure|Ovarian conservation|Both ovaries and fallopian tubes not removed at the time of hysterectomy
1858110|NCT01007318|Procedure|Single port laparoscopic appendectomy|Single port through the transumbilical 2-cm incision
1858111|NCT01007318|Procedure|3 port laparoscopic appendectomy|3 trocars was inserted in infraumbilical, left lower quadrant, and suprapubic area
1858112|NCT01007331|Behavioral|Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bi-07|10^10 colony forming units pr day of probiotics
1858113|NCT01007344|Dietary Supplement|flaxseed|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
1858114|NCT01007344|Dietary Supplement|whole wheat flour|1 muffin for breakfast, 1 muffin for afternoon snack and 1 slice of bread for evening snack every day for 4 weeks
1858115|NCT01007357|Device|Body MR imaging|Body MR imaging will be performed to optimize sequences
1858116|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(LMA-Fastrach).
1858117|NCT01007370|Procedure|Tracheal intubation|Tracheal intubation through a supraglottic airway device(I-gel).
1858118|NCT01007383|Drug|LEO 27847|First in man
1858119|NCT01007396|Other|1-step tuberculin skin test (TST) and blood sampling|In only new healthcare workers, the 1-step TST and quantiFERON-TB Gold In-Tube test were performed.
1858120|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast Period 2: administration of fimasartan 240mg at 9:00am, without the breakfast
1858121|NCT01007409|Drug|Fimasartan|Period 1: administration of fimasartan 240mg at 9:00am, without the breakfast Period 2: administration of fimasartan 240mg at 9:00am, 30 minutes after the breakfast
1858122|NCT01007422|Behavioral|telephone-based intervention|
1858123|NCT01007422|Other|communication intervention|
1858124|NCT01007422|Other|intervention by caregiver|
1858125|NCT01007422|Other|medical chart review|
1858126|NCT01007422|Other|survey administration|
1858127|NCT01007422|Procedure|end-of-life treatment/management|
1858128|NCT01007422|Procedure|pain therapy|
1858129|NCT01007422|Procedure|psychosocial assessment and care|
1858130|NCT01007435|Drug|Tocilizumab|Tocilizumab was supplied in vials.
1858131|NCT01007435|Drug|Placebo to tocilizumab|Placebo to tocilizumab was supplied in vials.
1858132|NCT01007435|Drug|Methotrexate|Initially, patients received methotrexate 7.5 mg (3, 2.5 mg tablets) orally once a week. If a patient had swollen or tender joints, the dose was increased to 15 mg and 20 mg weekly, at the Week 4 and Week 8 visits, respectively.
1858133|NCT01007435|Drug|Placebo to methotrexate|Patients received placebo to methotrexate orally once a week.
1858134|NCT01007448|Drug|bexarotene|150 mg/m2/day oral bexarotene capsules
1858135|NCT01007448|Drug|bexarotene|300 mg/m2/day oral bexarotene capsules
1858136|NCT01007461|Drug|Sodium Sulfide (Na2S) for Injection|IK-1001 is Na2S administered as an isotonic solution for intravenous (IV) injection or continuous infusion. IK-1001 will be administered as a 3-hour continuous IV infusion started > 5 minutes but < 20 minutes (approximately) prior to coronary artery reperfusion.
1858137|NCT01007461|Drug|Placebo|0.9% Sodium Chloride (NaCl) will be administered in the same manner as the experimental drug.
1858138|NCT01007474|Device|Implantable Cardioverter-Defibrillator (ICD)|Medtronic market-released implantable cardioverter-defibrillator
1858139|NCT01007474|Device|Implantable Pacemaker Generator (IPG)|Medtronic market-released implantable pacemaker generator
1858140|NCT01007474|Device|Implantable Loop Recorder (ILR)|Medtronic market-released implantable loop recorder
1858141|NCT01007474|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Medtronic market-released cardiac resynchronization therapy defibrillator
1858142|NCT01007474|Device|Implantable devices working as neurostimulators, stents, spinal/bone devices or other applications|Medtronic market-released implantable devices used as neurostimulators, stents, spinal/bone devices or for other applications
1858143|NCT01007500|Drug|Dexamethasone|Experimental: Dexamethasone 8 mg IV after induction of anesthesia, Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
1858144|NCT01007500|Drug|Ondansetron|Active comparator: Ondansetron 4 mg IV at the end of surgery and 12 mg mix to intravenous patient controlled analgesia device.
1858145|NCT01007513|Procedure|Transvaginal ultrasound|A transvaginal ultrasound with an endocavitary probe will be done as required by the medical condition of the patient. The cervical and supracervical factors will be noted.
1858268|NCT01008410|Drug|Budesonide|2mg/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks
1858146|NCT01007513|Procedure|Vaginal secretion sampling|Vaginal secretion swab will be collected each time patient will have a transvaginal ultrasound. The sample will be centrifuged, frozen and store to be analysed at the end of the study with multiplex antibody arrays.
1992899|NCT03278106|Other|Laboratory Biomarker Analysis|Correlative studies
1858148|NCT01007539|Dietary Supplement|CDP-choline|The subjects will be given 1g citicoline twice daily for a total of 8 weeks.
1858149|NCT01007539|Dietary Supplement|Placebo (fructose)|The Subjects will be given 2 tablets of placebo twice daily for 8 weeks. They will be taking the same quantity as the CDP-choline group.
1858150|NCT01007552|Drug|Gemcitabine, Capecitabine and Bevacizumab|Bevacizumab 15 mg/ kg every 3 weeks, starting day 1; Capecitabine 650 mg/m2 bid x 14 days starting day 1, Gemcitabine 1000 mg/m2 days 1 and 8, cycles to be repeated every 21 days.
1858151|NCT01007565|Procedure|periarticular anesthetics injection|Members in the PI group received intra-operative periarticular injections and additional sensory nerve blocks just before skin closure . For the periarticular injections and additional sensory block, local analgesic solution was injected into the wrist joint, joint capsule, periosteum, subcutaneous tissue, skin, and around the anterior and posterior interosseous nerves and the superficial radial nerve. A volume of 2ml was injected into the joint capsule and periosteum, and of 3ml into the wrist joint, subcutaneous tissue, skin and into each nerve.
1858152|NCT01007578|Device|Paclitaxel-coated balloon catheter angioplasty|Paclitaxel-coated balloon catheters for the treatment of peripheral arterial occlusive disease (POAD) of the femoro-popliteal arteries
1858153|NCT01007591|Drug|LEO 80190|Applied once daily
1858154|NCT01007591|Drug|Hydrocortisone|Applied once daily
1858155|NCT01007604|Device|Peristaltic pulse PCD|Daily use for two hours
1858156|NCT01007604|Other|Exercise and lifestyle counseling|Patients will receive standard recommendations for ambulatory exercise and standard educational discussion of risk factor control, including smoking cessation.
1858157|NCT01007617|Device|LLLT :low level laser therapy|"The patients will be randomized in 2 groups according to the delivered dose: 2 J/cm2/d or 8 J/cm2/d.
Main evaluation criteria: mucositis maximal intensity (WHO scale).
Secondary evaluation criteria: mucositis duration, mucositis survival free, pain, opioid treatment, hospitalization, fever and infection, nutrition."
1858158|NCT01007630|Drug|Rasagiline|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
1858159|NCT01007630|Drug|Placebo|0.5mg for 14 days, then switch to 1mg for remainder of the study (approximately 10 weeks total)
1858160|NCT01007643|Other|Wii Fit (TM) Interactive Video Game|Use of interactive video game exercise program on a daily basis focusing on quadriceps and hamstring flexibility along with VMO strengthening.
1858161|NCT01007643|Other|Traditional Home Exercise Program|Completion of daily home exercise program for quadriceps and hamstring flexibility and VMO strengthening.
1858162|NCT01007656|Dietary Supplement|GD Antrodia camphorata|Three 500mg capsules per oral dose, twice daily with an interval of 12 hours for 90 days
1858163|NCT01007669|Behavioral|Physical activity and Health check|Strength training, aerobic capacity training.
1858164|NCT01007669|Behavioral|Health check only|Health check
1858165|NCT01007682|Other|Show distressing movie and tell half of the two study groups to suppress memories of the movie|A distressing movie is presented to two groups (one group with high and one group with low working memory capacity). For each of the two groups, half of the participants are instructed to suppress thoughts of the movies after viewing it, while the remaining participants are instructed to allow the occurrence of memories of the movie.
1858166|NCT01007695|Drug|Valproic Acid|Valproic Acid is FDA approved and indicated as monotherapy and adjunctive therapy in the treatment of patients with complex partial seizures that occur either in isolation or in association with other types of seizures. Valproic Acid is indicated for use as sole and adjunctive therapy in the treatment of simple and complex absence seizures, and adjunctively in patients with multiple seizure types which include absence seizures.
1858167|NCT01007708|Drug|IDP-108|Topical application once a day for 48 weeks
1858168|NCT01007708|Drug|Vehicle|Topical application once a day for 48 weeks
1858169|NCT01007721|Drug|BI 67100 ED 25 mg|2 capsules of BI 671800 ED 25 mg
1858170|NCT01007721|Drug|BI 671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
1858171|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
1858172|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
1858173|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
1858174|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
1858175|NCT01007721|Drug|fluticasone propionate placebo nasal spray|fluticasone propionate placebo nasal spray (2 puffs each nostril qd in the morning)
1858176|NCT01007721|Drug|BI 671800 ED 100 mg|4 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
1858177|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
1858178|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
1858179|NCT01007721|Drug|BI 671800 ED placebo|4 capsules of BI 671800 ED placebo (bid in the morning and evening)
1858180|NCT01007721|Drug|BI 671800 ED 100 mg|2 capsules of BI 671800 ED 100 mg (bid in the morning and evening)
1858181|NCT01007721|Drug|671800 ED placebo|2 capsules of BI 671800 ED placebo (bid in the morning and evening)
1858182|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
1858183|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
1858184|NCT01007721|Drug|montelukast placebo tablet|1 over-encapsulated montelukast placebo tablet (qd in the morning)
1858185|NCT01007721|Drug|montelukast 10 mg tablet|1 over-encapsulated montelukast 10 mg tablet (qd in the morning)
1858269|NCT01008410|Drug|Placebo|Placebo foam/25mL BID for 2 weeks followed by QD for 4 weeks
1992900|NCT03278106|Drug|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
1992901|NCT03278028|Drug|A-101 Topical Solution|A-101 Topical Solution
1858188|NCT01007721|Drug|Fluticasonepropionate nasal spray 200 mcg|Fluticasonepropionate nasal spray 200 mcg (qd, 2 puffs of 50 mcg per nostril)
1858189|NCT01007747|Other|Geranium oil|Daily topical application over neuropathic pain
1858190|NCT01007760|Other|Respirable suspended particles (RSP) PM 2.5 dose of second-hand smoke|acute one time exposure
1858191|NCT01007773|Drug|Precedex|Once this patient is deemed stable on the propofol infusion, the patient will be started on a dexmedetomidine infusion at 0.4 mcg/kg/hr. The dexmedetomidine infusion will be titrated to a Richmond Agitation Sedation Scale (RASS) of 0 to -1 (maximum rate of 1.5 mcg/kg/hr). In the meantime, once sustained ICP control has been achieved, the initial sedative agent (usually propofol) will be weaned. Dexmedetomidine will be infused for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued. When the patient is ready to come off sedation, the dexmedetomidine will be weaned by 50% every hour over a 4-hour period to off.
1858192|NCT01007773|Drug|Propofol|Propofol will be initiated at 25 mcg/kg/min and titrated to achieve an ICP < 20 mm Hg (up to a maximum of 75 mcg/kg/min). Propofol will be continued for up to 7 days or until removal of the ICP or when mechanical ventilation is discontinued.
1858193|NCT01007773|Drug|Fentanyl|Fentanyl will be initiated and titrated to achieve adequate pain control.
1858194|NCT01007773|Drug|Propofol|Propofol will be titrated to an ICP < 20 mm Hg until achievement of sustained ICP control.
1858195|NCT01007799|Dietary Supplement|vitamin D placebo|12 weeks of placebo
1858196|NCT01007799|Dietary Supplement|Vitamin D|12 weeks supplementation based on serum vitamin D levels
1858197|NCT01007812|Device|Lotrafilcon B contact lens|Silicone hydrogel, toric, soft contact lens
1858198|NCT01007812|Device|Comfilcon A contact lens|Silicone hydrogel, toric, soft contact lens
1858199|NCT01007838|Other|Progressive resistance training programme|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
1858200|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
1858201|NCT01007838|Other|Progressive resistance training|Progressive resistance training programme using a dialysis specific fitness machine: 80 % of predicted one repetition max, weight lifted will be increased when three sets of ten repetitions can be completed without failure.
1858202|NCT01007838|Other|Sham exercise|Lower body stretching exercise using the easiest rehabilitation elastic Theraband
1858203|NCT01007851|Drug|triptorelin acetate|single dose of 0.1 mg triptorelin subcutaneous injection on the 3rd day after embryo transfer
1858204|NCT01007851|Drug|NaCl %0.9|0.1 ml sterile saline sc injection 3 days after embryo transfer
1858205|NCT01007864|Drug|piribedil|Oral application of piribedil at an equivalent dose of pramipexole or ropinirole according to a defined equivalence scheme (dose range 100 - 300 mg per day) for 11 weeks.
1858206|NCT01007864|Drug|pramipexole or ropinirole|continuation of pre-study treatment regimen
1858207|NCT01007877|Other|Red Bull Energy drink|During a 15 minute break, subjects consume 250 ml of Red Bull® Energy Drink or placebo. Before and after the break, a 2 hour driving test is scheduled.
1858208|NCT01007890|Other|ChemoFX Assay|Test of an algorithm to predict pathologic response in patients treated with neoadjuvant chemotherapy for breast cancer.
1858209|NCT01007903|Behavioral|Tai Chi exercise|12-week tai chi exercise class
1858210|NCT01007916|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, spherical contact lens having a recommended replacement schedule of monthly.
1858211|NCT01007916|Device|Habitual contact lens|Habitual soft spherical contact lens having a recommended replacement schedule of 2 weeks or monthly.
1858212|NCT01007929|Drug|14C-AZD1236|Oral solution 1mg/mL
1858213|NCT01007942|Drug|everolimus|Oral everolimus was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
1858214|NCT01007942|Drug|Placebo|Oral everolimus placebo was taken once 5 mg/day (2 × 2.5 mg tablets) and were packaged into blister packs.
1858215|NCT01007942|Drug|vinorelbine|intravenous vinorelbine (25 mg/m2 weekly)
1858216|NCT01007942|Drug|trastuzumab|intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)
1858217|NCT01007968|Drug|LBH589|
1858218|NCT01007994|Drug|New Medication: Enalapril, Isradipine, Propranolol|"Enalapril will be added in the evening at 8 pm. If the subject is already on an ACEI or there is a contraindication to starting an ACEI the subject will be started on isradipine instead. If the subject is already on an ACEI and calcium channel blocker at baseline, propranolol will then be the new medication added.
Dosing will be as follows:
ACEI: Enalapril < 40 kg starting dose 2.5 mg titrate to 5 mg > 40 kg starting dose 5 mg titrate to 10mg Calcium Channel Blocker: Isradipine < 40 kg 2.5 mg > 40 kg starting dose 2.5 mg titrate to 5 mg Beta Blocker: Propranolol <40 kg starting dose 10 mg titrate to 20 mg >40 kg starting dose 20 mg titrate to 40 mg"
1858219|NCT01008007|Dietary Supplement|Viusid|One Viusid bag (4 grams, orally administered) every 8 hours, for 6 days in combination with the conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
1858220|NCT01008007|Drug|Conventional treatment|Conventional treatment consisting in: intramuscular injection of one bulb of Dipyrone (600 mg) every 8 hours if fever is greater or equal to 38 ºC; intramuscular injection of one bulb of dimenhydrinate (50 mg) every 8 hours if vomiting; oral rehydration solution (8 ounce) after each diarrhea.
1858221|NCT01008020|Dietary Supplement|tea catechin extracts|Tea catechin extracts 540 mg/day, are consumed for 5 months.
1858222|NCT01008033|Drug|IDP-108|Topical application once a day for 48 weeks
1858223|NCT01008033|Drug|Vehicle|Topical application once a day for 48 weeks
1858224|NCT01008046|Drug|combined N-acetyl cysteine -CC|N-acetyl cysteine(1.8 g orally daily)for 5-6 weeks from the 1st day of spontaneous or induced menstruation followed by 100 mg CC for 5 days from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
1858270|NCT01008423|Drug|Budesonide|2mg/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks
1858271|NCT01008423|Drug|Placebo|Placebo foam/25mL BID for 2 weeks followed by 2mg/25mL QD for 4 weeks
1858225|NCT01008046|Drug|combined metformin-CC|Patients received metformin HCl (1500 mg daily) for 5-6 weeks from the 1st day of spontaneous or induced menstruation, followed by 100 mg CC for 5 days starting from day 3 of spontaneous or induced menstruation. With persistent anovulation,CC increased by 50 mg for the next cycle. Treatment continued for three successive cycles
1858226|NCT01008059|Drug|grapefruit juice|grapefruit juice consumed within 24 hours of inducing CYP3A liver activity rifampin 500mg daily for 5 days ketoconazole 400 mg daily for 3 days
1858227|NCT01008059|Drug|delayed alfentanil|Alfentanil bolus .5-1.0mg IV, then labeled alfentanil administered orally 4 hours later
1858228|NCT01008059|Drug|concomitant alfentanil|Alfentanil .5-1.0 mg IV + labeled alfentanil one time bolus
1858229|NCT01008085|Device|Stentys coronary stent|Self-expanding Nitinol stent
1858230|NCT01008085|Device|Balloon-expandable stent|VISION/Driver
1858231|NCT01008098|Drug|escitalopram (lexapro)|0 - 4 week: 10 mg escitalopram a day 5 - 8 week: 20 mg escitalopram a day
1858232|NCT01008111|Drug|Dermabond|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
1858233|NCT01008111|Drug|Hydrogen Peroxide Oxygen producing gel|On Day 0 patients will undergo bilateral inguinal surgery. One side will be dressed using a standard surgical dressing, while the other will use a combination hydrogen peroxide/baking soda gel placed over the wound and covered with a sealing dressing. The study team will determine which side gets assigned standard surgical dressing by the flip of a coin.
1858234|NCT01008124|Other|Liberatory Maneuver|3 cycles of the liberatory maneuver initial session.
1858235|NCT01008124|Other|Placebo maneuver|3 cycles placebo maneuver initial session.
1858236|NCT01008137|Biological|H1N1 influenza A Vaccine (PANFLU.1)|H1N1 influenza A Vaccine (PANFLU.1), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm)
1858237|NCT01008137|Biological|Trivalent Inactivated Influenza Vaccine (ANFLU)|Trivalent Inactivated Influenza Vaccine (ANFLU), 15 micrograms per dose. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (injected in the other arm)
1858238|NCT01008150|Drug|Paclitaxel|
1858239|NCT01008150|Drug|Trastuzumab|
1858240|NCT01008150|Drug|Neratinib|
1858241|NCT01008150|Drug|Doxorubicin|
1858242|NCT01008150|Drug|Cyclophosphamide|
1858243|NCT01008163|Drug|YY-351/Placebo|comparison of different dosages of drug
1858244|NCT01008163|Drug|YY-351/Placebo|comparison of different dosages of drug
1858245|NCT01008163|Drug|YY-351|comparison of different dosages of drug
1858246|NCT01008163|Drug|Placebo|comparison of different dosages of drug
1858247|NCT01008176|Behavioral|Sleep extension|Habitual sleep duration is extended by 60min/night over a 6-week time period.
1858248|NCT01008189|Behavioral|Self- study comparison group|Caregivers, children and adolescents each received three books about coping with grief following the death of a loved one plus a syllabus to guide reading
1858249|NCT01008189|Behavioral|Family Bereavement Program|12 session groups for caregivers and bereaved children and adolescents plus two individual sessions
1858250|NCT01008215|Other|Algorithm|Warfarin Dosing algorithm (paper and electronic version)
1858251|NCT01008228|Procedure|exsufflation|exsufflation will be performed with a specific thoracentesis system after introducing the device into chest pneumothorax, aspiration will be performed during 30 minutes
1858252|NCT01008228|Procedure|thoracic tube drainage|thoracic tube drainage will be performed with a tube Ch 16 or ch 20
1858253|NCT01008254|Behavioral|Musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 12 months.
1858254|NCT01008254|Behavioral|Delayed musical prompt|Repositioning and mobility education program administered to all facility staff combined with tailored musical prompt reminder that played every two hours, every day, during a 12 hour period, for 6 months.
1858255|NCT01008254|Other|No musical prompt|No intervention.
1858256|NCT01008280|Drug|baclofen|baclofen 10 mg tid
1858257|NCT01008280|Drug|placebo|placebo pill tid
1858258|NCT01008293|Drug|VSL#3|VSL#3 (2 capsules bid.for 2 months, Each containing 112.5 billion viable lyophilized bacteria). Each capsule contains 4 strains of Lactobacillus (L. casei, L. plantarum, L. acidophilus, and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacterium (B. longum, L. breve, and B. infantis), and 1 strain of Streptococcus salivarius subsp. thermophilus (designated hereafter as S. thermophilus)
1858259|NCT01008293|Drug|Lactulose|30-60 ml of lactulose per day for 2 months to ensure 2-3 soft stools.
1858262|NCT01008332|Biological|Toleromune HDM|ToleroMune HDM dose 1x4 administrations 4 weeks apart
1858263|NCT01008332|Biological|Placebo|Placebo comparator, 1x4 administrations 4 weeks apart
1858264|NCT01008345|Drug|ezetimibe|Patients will receive 10 mg/day of ezetimibe for 8 weeks
1858265|NCT01008358|Biological|CP 675,206|
1858266|NCT01008384|Dietary Supplement|Vitamin D3|50,000 units taken orally once a week for 8 weeks
1858272|NCT01008436|Drug|Omni-stat Celox|Topical administration of 6 gr of Omnistat Celox
1858273|NCT01008436|Drug|Control|Traditional surgical Hemostasis
1858274|NCT01008449|Device|Surgical staples|Surgical staples will be used once for wound closure.
1858275|NCT01008449|Device|Absorbable Surgical Suture|Absorbable surgical suture will be used for subcuticular closure at the time of wound closure for cesarean delivery.
1858276|NCT01008462|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor HCT
1858277|NCT01008462|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo donor HCT
1858278|NCT01008462|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSC transplant
1858279|NCT01008462|Procedure|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-donor tandem HCT
1858280|NCT01008462|Drug|Carmustine|Given IV
1858281|NCT01008462|Drug|Cyclophosphamide|Given IV
1858282|NCT01008462|Drug|Cytarabine|Given IV
1858283|NCT01008462|Drug|Etoposide|Given IV
1858284|NCT01008462|Drug|Fludarabine Phosphate|Given IV
1858285|NCT01008462|Other|Laboratory Biomarker Analysis|Correlative study
1858286|NCT01008462|Drug|Melphalan|Given IV
1858287|NCT01008462|Drug|Mycophenolate Mofetil|Given PO
1858288|NCT01008462|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo donor HCT
1858289|NCT01008462|Drug|Tacrolimus|Given IV or PO
1858290|NCT01008462|Radiation|Total-Body Irradiation|Undergo TBI
1858291|NCT01008475|Drug|EMD 525797 250 mg|EMD 525797 will be administered at a target dose of 250 mg as a 1-hour intravenous infusion for every 2 week until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
1858292|NCT01008475|Drug|EMD 525797 500 mg|"Safety part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
Randomized part: EMD 525797 will be administered at a target dose of 500 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
1858293|NCT01008475|Drug|EMD 525797 750 mg|EMD 525797 will be administered at a target dose of 750 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
1858294|NCT01008475|Drug|EMD 525797 1000 mg|"Safety part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
Randomized part: EMD 525797 will be administered at a target dose of 1000 mg as a 1-hour intravenous infusion for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
1858295|NCT01008475|Drug|Cetuximab|"Safety part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly until DLT.
Randomized part: Cetuximab will be administered at a dose of 400 milligram per square meter (mg/m^2) on Day 1 Cycle 1 (Week 1) as IV infusion for 2 hours, and then at a dose of 250 mg/m^2 on Day 8 (Week 2) once weekly until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
1858296|NCT01008475|Drug|Irinotecan|"Safety part: Irinotecan will be administered at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent .
Randomized part: Irinotecan will be administered at a dose of 180 mg/m^2 as IV infusion for 30-90 minutes for every 2 weeks until radio-graphically documented PD (as assessed by the investigator), unacceptable toxicity or eligibility for curative resection (investigator's assessment), or withdrawal of consent."
1858297|NCT01008488|Drug|Antibiotic|Antibiotic according to local treatment routine against bowel pathogenesis
1858298|NCT01008514|Procedure|adjuvant therapy|
1858299|NCT01008514|Radiation|accelerated partial breast irradiation|
1858300|NCT01008514|Radiation|intracavitary balloon brachytherapy|
1858301|NCT01008527|Drug|CP 870,893|Study drug will be administered open-label as an intravenous solution, followed by observation. Study drug will be supplied as a liquid intravenous solution in vials containing 10 mg/mL of CP870,893. CP 870,893 will be administered at a dosage of 0.01, 0.025 or 0.05 mg/kg at 0.24 mg/mL infused via a syringe pump over 15 minutes, or at 0.1 or 0.2 mg/kg/dose as an i.v. infusion in saline at a concentration of 0.24 mg/mL in an IV bag of up to 100 mL over 30 minutes (controlled by a volumetric pump) for not more than 30 minutes, with a 10 cc flush at the end that should be administered at the same rate as the CP 879,893 infusion.
1858302|NCT01008527|Biological|Peptides|NY-ESO-l 157-165 (165V) and gpl002 80-288 (288V) peptides each at a dose of 0.5 mg will be emulsified with Montanide ISA 51 VG and administered to all patients in the study at Weeks 1,3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53. Peptides will be administered as a total of 6 deep subcutaneous (s.c.) injections into alternating lower extremities one hour after CP 870,893 infusions.
1858303|NCT01008527|Biological|Oncovir poly IC:LC|The dosage of poly IC:LC chosen for the current trials has been used safely in over one hundred patients with central nervous system (CNS) malignancies enrolled in nitrates and bone turnover (NABT) trials. The injection of 1000 mcg will be made deeply subcutaneously into the same limb as the peptides/Montanide ISA 51 VG, at least 5 cm. proximal to the peptides vaccination site. Poly IC:LC will be administered to all patients in the study at Weeks 1, 3, 5, 7, 9, 11, 17, 21, 25 33, 41, and 53 one hour after CP 870,893 infusion.
1858304|NCT01008540|Biological|depistage|Virus isolation from urine, blood, or any suitable sample in case of CMV disease Resistance phenotype to antivirals UL97 and UL54 genes sequencing from blood, urines or any suitable samples for resistance mutations detection and polymorphism study
1858339|NCT01008852|Drug|SBI-087|200 mg SC Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
1858305|NCT01008553|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
1858306|NCT01008553|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm and thigh and replaced every day.
1858307|NCT01008566|Biological|Cixutumumab|Given IV
1858308|NCT01008566|Other|Laboratory Biomarker Analysis|Correlative studies
1858309|NCT01008566|Drug|Sorafenib Tosylate|Given orally
1858310|NCT01008592|Drug|levocetirizine or placebo|oral administration, single tablet, 5 mg.
1858311|NCT01008605|Other|delivery system|syringe
1858312|NCT01008618|Drug|Fentanyl|One-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
1858313|NCT01008618|Drug|Placebo|Placebo patch indistinguishable from one-day adhesive transdermal patch containing fentanyl 12.5 to 50 mcg/hr applied to chest, abdomen, upper arm or thigh and replaced every day.
1858314|NCT01008631|Drug|Sodium thiosulfate|6g of Sodium Thiosulfate are applicated in a short infusion over a time of 5 min
1858315|NCT01008644|Other|Water|The subjects will drink tap water for 2 hours, volume calculated according to weight: 20ml/kg/hour.
1858316|NCT01008644|Other|Saline 3%|The subjects will receive saline 3% intravenously for 2 hours, the volume calculated as 0.1 ml/kg/min
1858317|NCT01008657|Procedure|Radiofrequency ablation|Percutaneous multipolar radiofrequency ablation.
1858318|NCT01008696|Drug|Rabeprazole|Rabeprazole 20 mg tablet orally once daily before breakfast for 28 to 56 days.
1858319|NCT01008696|Drug|Lansoprazole|Lansoprazole 30 mg capsule orally once daily before breakfast for 28 to 56 days.
1858320|NCT01008709|Device|Teleflex HemoLock clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
1858321|NCT01008709|Device|Aesculap U-clip|Patients randomized to the Aesculap U-clip device or the HemoLock clip will undergo their respective surgery (robotic prostatectomy and laparoscopic and robotic renal surgery) as per standard protocols. During the surgical procedure, when primary vascular control is warranted the appropriate clip to which the patient has been randomized will be utilized. Immediate assessment of the vascular pedicle will subsequently occur; if hemostasis is not adequate, additional clipping, endomechanical stapling or suture ligation will then be performed as necessary.
1858322|NCT01008748|Drug|Nicotine Replacement Therapy (NRT)|NRT for participants who smoke >10 cigarettes/day will consist of 2 weeks of 21 mg nicotine patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Nicotine Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 2 weeks of 14 mg patches and 2 weeks of 7 mg patches. Patch dispensation will occur at weekly treatment visits.
1858323|NCT01008748|Behavioral|Questionnaire|Computerized questionnaires at each of 5 visits and will take 1 1/2 hours to complete each time.
1858324|NCT01008748|Behavioral|Counseling|Each counseling session, whether face-to-face or over the phone, will last approximately 15 minutes. In-person counseling sessions occur at weeks -1, 0, and 3, with telephone counseling sessions occurring at weeks 0.5, 1, and 2. Counselors will conduct all sessions in Spanish.
1858325|NCT01008748|Behavioral|Self-Help Materials|Spanish-language self-help materials currently used by the NCI's Cancer Information Service.
1858326|NCT01008761|Drug|Azithromycin|Azithromycin given at 10 mg/kg/day for day 1, then 5 mg/kg for 4 days Each syringe will contain 12.5 mls (250 mgs) sufficient drug to adequately dose children who with up to 25 kgs (95%tile for weight for 60 month old child)
1858327|NCT01008761|Drug|Suspension Placebo|Placebo suspension will be administered on day 1 at 10mg/kg and then for the next 4 days at 5 mg/kg
1858328|NCT01008774|Device|Paxman Cooling Machine|Scalp cooling procedures
1858329|NCT01008774|Device|Cold Caps|Scalp cooling procedures
1858330|NCT01008787|Behavioral|Training|In-person 8-hour group physical activity training session (either over 1 or 2 days) and receive workbook and pedometer.
1858331|NCT01008787|Behavioral|Questionnaire|Weekly during Weeks 2-7, complete question form given at training course about conversations with study partner, 5 minutes to complete.
1858332|NCT01008787|Behavioral|Interview|Weeks 4 and 8, 30 minute phone interview about mood and physical activity.
1858333|NCT01008787|Behavioral|PA Newsletter|At Weeks 5 and 9, receive a physical activity (PA) newsletter.
1858334|NCT01008800|Behavioral|Social Communication|The Center-Based classroom intervention focuses on providing children with an invigorating, motivating learning environment in which emerging skills and knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement week may offer the children experiences that they would not otherwise have (Ramey & Ramey, 1998). Parent training sessions will focus on strategies aimed at improving child social engagement and communication and on topics related to autism characteristics, learning styles, interventions, and resources.
1858335|NCT01008800|Behavioral|Social communication|Parent training sessions will focus on teaching parents strategies for enhancing their child's social engagement and communication. Since parents will be using these strategies across all activities throughout the day, there is an increased likelihood of generalization. For parents of minority and underserved children, this may be the first exposure to responsive interaction strategies (Rudy & Grusec, 2001).
1858336|NCT01008813|Biological|adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (3,8 microgram) adjuvanted with AS 03A
1858337|NCT01008813|Biological|non-adjuvanted A(H1N1)v influenza vaccine|Two intramuscular injections at day 0 and day 21 of FLU D-PAN H1N1 [A/California/7/2009 (H1N1)v] (15 microgram)
1858338|NCT01008826|Dietary Supplement|broccoli sprouts extract|Glucoraphanin-rich broccoli sprouts extract: 800 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice Sulforaphane-rich broccoli sprouts extract: 150 micromoles daily for 7 days dissolved in 100 mL of dilute mango juice
1859808|NCT01023646|Other|Carbohydrate load|Carbohydrate
1858340|NCT01008852|Drug|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, Placebo Day 84 + Methotrexate
1858341|NCT01008852|Drug|SBI-087|200 mg SC Day 1, Placebo Day 15, 200 mg SC Day 84 + Methotrexate
1858342|NCT01008852|Drug|SBI-087|200 mg SC Day 1, 200 mg SC Day 15, 200 mg SC Day 84 + Methotrexate
1858343|NCT01008852|Drug|Placebo|Placebo Day 1, Placebo Day 15, Placebo Day 84 + Methotrexate
1858344|NCT01008865|Procedure|Studer Pouch orthotopic urinary diversion|
1858345|NCT01008865|Procedure|T-Pouch orthotopic urinary diversion|
1858346|NCT01008878|Behavioral|interdisciplinary intervention|
1858347|NCT01008891|Device|Augment™ Injectable|Beta-TCP/Bovine Collagen matrix + rhPDGF-BB
1858348|NCT01008891|Procedure|Standard of care|Autologous Bone Graft
1858349|NCT01008904|Drug|magnesium oxide|Given PO
1858350|NCT01008904|Other|questionnaire administration|Ancillary studies
1858351|NCT01008904|Procedure|quality-of-life assessment|Ancillary studies
1858352|NCT01008917|Drug|sorafenib with temsirolimus|Weekly intravenous temsirolimus with daily oral sorafenib
1858353|NCT01008930|Procedure|HR PEM Scan|PEMFlex Solo II, a high-resolution camera for PET scan imaging, on an area of body that has, or is suspected to have cancer following routine, standard, positron emission tomography/computed tomography (PET/CT) scan
1858354|NCT01008943|Biological|Autologous Muscle Derived Cells|Urethral injection of autologous muscle-derived cells
1858355|NCT01008956|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injection, one dose
1858356|NCT01008969|Other|SPECT-CT imaging|SPECT/CT for 3-dimensional mapping of 99mTc-sulfur nanocolloid in order to identify personalized lymphatic drainage patterns
1858357|NCT01008982|Drug|LimphoStat-B|subjects will receive 10 mg/kg belimumab, in solution for infusion, monthly
1858358|NCT01008995|Drug|placebo|Subcutaneous injection at Week 0 and 4
1858359|NCT01008995|Drug|ustekinumab|45 mg subcutaneous injection at Week 12 and 16
1858360|NCT01008995|Drug|placebo|Subcutaneous injection at Week 12
1858361|NCT01008995|Drug|ustekinumab|45 mg subcutaneous injection at Week 0, 4 and 16
1858362|NCT01009008|Device|Patient Activated Controlled Expansion Device|Patient activated controlled expansion for post-mastectomy breast reconstruction
1858363|NCT01009021|Drug|potassium diclofenac|potassium diclofenac 50 mg, one tablet 45 minutes before laser treatment
1858364|NCT01009034|Other|Measuring semen samples|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of maraviroc in semen, the variability in the penetration of maraviroc into the seminal compartment over the raltegravir dosing period.
1858365|NCT01009047|Drug|Paliperidone extended release (ER)|Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.
1858366|NCT01009047|Drug|Aripiprazole|Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.
1858367|NCT01009060|Drug|GSK239512|Histamine H3 Antagonist
1858368|NCT01009060|Drug|Placebo|Placebo to match GSK239512
1858369|NCT01009073|Drug|ABT-263|"ABT-263 is taken orally.
Note - The dose and schedule is variable based on Arm and subject to change based on the toxicities observed."
1858370|NCT01009073|Drug|erlotinib|150 mg of erlotinib is taken orally once daily.
1858371|NCT01009073|Drug|irinotecan (3-week schedule)|"180 mg/m2 over 90 minutes, irinotecan will be given by intravenous infusion on Day 1 of each 21 day cycle.
Note - The dose and schedule is subject to change based on the toxicities observed."
1858372|NCT01009073|Drug|irinotecan (weekly schedule)|"75 mg/m2 over 45 minutes, irinotecan will be given by intravenous infusion on Days 1 and 8 of each 21 day cycle.
Note - The dose and schedule is subject to change based on the toxicities observed."
1858373|NCT01009086|Drug|Placebo|SC injections
1858374|NCT01009086|Drug|Ustekinumab 45 mg|SC injections
1858375|NCT01009086|Drug|Ustekinumab 90 mg|SC injections
1858376|NCT01009099|Other|breathing retraining|breathing retraining using a metronome
1858377|NCT01009099|Other|exercise training|treadmill exercise training
1858378|NCT01009112|Behavioral|PTSD + IRT/CBT-I|6 weeks of prolonged exposure, 5 weeks of imagery rehearsal therapy, and 7 weeks of cognitive behavioral therapy for insomnia
1858379|NCT01009112|Behavioral|PTSD + Supportive Care Therapy|6 weeks of prolonged exposure + 12 weeks of supportive care therapy
1858380|NCT01009125|Other|$2 cash|$2 cash incentive will be included in the mailed survey
1858381|NCT01009125|Other|$5 cash|$5 cash incentive will be included in the mailed survey
1858382|NCT01009138|Behavioral|Diabetes-Specific CBT (DS-CBT)|"5 Group Sessions with a duration of 90 Minutes each, including the following cognitive-behavioral Intervention Methods focusing on Diabetes Distress and Hassles:
Problem Analysis and Definition
Problem Solving Intervention
Cognitive Restructuring
Activation of personal and social Resources
Goal Definition and Agreement"
1858383|NCT01009138|Behavioral|Standard Diabetes Education|"Standard Diabetes Education Lesson including
Health Care and specific Topics (e. g. Blood Pressure)
Social Aspects of Living with Diabetes
Diabetes Complications
Sports, Activities and Exercise
Healthy and unhealthy Food, Vitamins, Cooking Recommendations and Recipes
Foot Care: Exercises, Care and Control, Sensibility, Injuries, diabetic Neuropathy"
1858384|NCT01009151|Behavioral|Heart Self Care Tracker|Web-based home tele-monitoring system serving congestive heart failure patients at the University of Michigan Health System. The intervention consists of daily reporting via the Internet on parameters specified in clinical protocols, including weight, blood pressure, heart rate and heart failure symptoms. These protocols contain automated trigger mechanisms when certain values are exceeded to alert the provider and the patient for the need to take appropriate remedial action. The system provides links to educational material on heart failure and reminders for self-care measures.
1858385|NCT01009151|Behavioral|Heart Care Self Tracker|Web-based Home Tele-monitoring System
1858386|NCT01009177|Drug|Bosentan|Bosentan 500 mg bid
1858387|NCT01009177|Drug|Placebo|Placebo
1858388|NCT01009190|Drug|PF-01367338|Increasing doses of single lead-in (Day -10) intravenous and daily oral PF-01367338 administered from Day 1 to Day 14 every 3-week cycle
1858389|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
1858390|NCT01009190|Drug|PF-01367338|RP2 doses of oral PF-01367338 administered daily from Day 1 to Day 14 every 3-week cycle
1858391|NCT01009190|Drug|Carboplatin|Standard doses of intravenous Carboplatin administered every 3 weeks
1858392|NCT01009203|Drug|Erlotinib|Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
1858393|NCT01009203|Drug|Temsirolimus|In the absence of Grade 3 or higher toxicity, a single, intra-patient dose increase of temsirolims to 20 mg intravenously weekly is permitted after the first 28 day cycle. Treatment will continue until disease progression, unacceptable toxicity, or withdrawal of informed consent.
1858394|NCT01009216|Drug|ABT-384|Doses will be administered daily for 5 days.
1858395|NCT01009229|Dietary Supplement|Low and high salt diets|High salt diet: 150mmol/d Low salt diet: 30mmol/d
1858396|NCT01009242|Biological|CDP6038|"Single dose:
1 mg/kg CDP6038 IV"
1858397|NCT01009242|Biological|CDP6038|"Single dose:
0.1mg/kg CDP6038 IV"
1858398|NCT01009242|Biological|CDP6038|"Single dose:
1.0mg/kg CDP6038 SC"
1858399|NCT01009242|Other|Placebo IV|"Single dose:
Placebo IV"
1858400|NCT01009242|Other|Placebo SC|"Single dose:
Placebo SC"
1858401|NCT01009242|Drug|CDP 6038 SC|Optimized CDP6038 SC doses based on outcome of Cohort 1 with placebo
1858407|NCT01003431|Biological|Rotavirus Vaccine, Live, Oral, Pentavalent|[Intervention name: RotaTeq™ administered concomitantly with Tritanrix™ HepB (DTwP)] Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration.
1858408|NCT01003431|Biological|Comparator: Rotarix™ administered concomitantly with Tritanrix™ HepB (DTwP)|Two 1.0 mL oral doses of Rotarix™ and three 0.5 mL intramuscular injections of Tritanrix™ HepB will be given at the same time with about 1 month between each administration (the second administration will be Tritanrix™ HepB only).
1858409|NCT01003431|Biological|Comparator: RotaTeq™ administered concomitantly with INFANRIX™ (DTaP)|Three 2.0 mL oral doses of RotaTeq™ and three 0.5 mL intramuscular injections of INFANRIX™ will be given at the same time with about 1 month between each administration.
1858410|NCT01003444|Procedure|Muscle biopsy|Collection of muscle biopsies of the vastus lateralis will be performed by a consulting specialist. The first muscle biopsy (Day 1, 2 hour) will be obtained from the vastus lateralis muscle of the non-dominant leg. The second biopsy (Day 1, 4 hour) will be obtained from the same vastus lateralis muscle on the same leg approximately 10 centimeters from the first muscle biopsy site.
1858411|NCT01003457|Other|ultrasonography|transvaginal ultrasonography of bladder wall thickness
1858412|NCT01003470|Other|acupuncture|Xing Nao Kai Qiao Acupuncture
1858413|NCT01003470|Behavioral|rehabilitation|Kinesitherapy
1858414|NCT01003470|Other|acupuncture and rehabilitation|Xing Nao Kai Qiao Acupuncture plus Kinesitherapy
1858415|NCT01003483|Drug|orlistat|Tablet,120mg,three times a day,three months
1858416|NCT01003496|Behavioral|Treatment as Usual (TAU)|Outpatient substance abuse treatment
1858417|NCT01003496|Behavioral|TAU + Long-Term Recovery Management|Long-Term Recovery Management (LTRM) combines 3 established treatment techniques (Community Reinforcement Approach, Contingency Management, and Facilitated Therapeutic Alliance), each with demonstrated efficacy, into a chronic disease model. In addition, patient cases are kept open, thereby removing potential obstacles to re-engagement with stepped-up care, when indicated. Patients randomly assigned to LTRM will be asked to participate in group sessions each month for 12 months.
1858418|NCT01003509|Procedure|modified shouldice and double|one arm modified shouldice, other one is double repair
1858419|NCT01003522|Other|Arterial puncture|Patients will undergo arterial blood gas sampling from the radial artery. This will be done by experienced doctors who are highly skilled in this procedure.
1858420|NCT01003522|Other|Venepuncture|Blood samples for baseline biochemistry, full blood count, and clotting screen will be taken. In patients additionally providing optional consent blood will be taken for laboratory based basic science research into lung cancer carcinogenesis and pharmacogenetics. Blood will be taken by qualified and experienced nurses, doctors and phlebotomists.
1858421|NCT01003522|Procedure|General anaesthetic|Patients randomised into the stenting arm will undergo rigid bronchoscopy under general anaesthetic.
1858422|NCT01003522|Procedure|Inpatient stays|Patients randomised into the stenting arm will be admitted overnight for the procedure
1858423|NCT01003522|Other|Walking test|All patients will be asked to complete a 6 minute walking test at baseline and on day 15. Patients randomised into the stent arm (Arm A) will complete a further 6 minute walking test at 24 hours post-stent
1858424|NCT01003522|Other|Spirometry & flow volume loop assessment|All patients will undergo spirometry and flow volume loop assessments at baseline and on day 15.
1858425|NCT01003522|Other|Biopsy material|For patients randomised to stenting and giving additional voluntary consent, 2 pairs of biopsies of tumour tissue, and 1 pair of biopsies of normal airways tissue will be taken for basic scientific research into lung cancer carcinogenesis, and pharmacogenetics.
1858426|NCT01003548|Device|SMART dynamic system of embryo culture|Embryos will be cultured in a dynamic system of microfluidics.
1858427|NCT01003548|Device|Static culture|Embryos cultured in 40 microliters microdrops of G-IVF plus series V
1858428|NCT01003561|Procedure|spinal anesthesia for surgery|spinal anesthesia (T10) for elective TURP surgery
1858429|NCT01003574|Behavioral|lifestyle modification and telephone counseling|A mailed individualized cancer treatment summary with recommendations for CV follow-up and lifestyle modification (standard care).
1858430|NCT01003574|Behavioral|lifestyle modification and telephone counseling|Standard care plus motivational, autonomy-supportive APN counseling (2 phone sessions) that targets two categories of behavioral constructs likely to influence screening.
1858431|NCT01003587|Behavioral|District health information package|"The intervention package consists of:
A report on disease burden, disease control priorities and health system performance in India
Condensed fact sheet based on the report
District health report cards (DRCs) comparing performance on key health indicators with other districts, information on causes of death in each district, and actionable messages to reduce deaths in the district
Customized speech for district level officials detailing key actions to reduce deaths
Reminder materials including poster version of the DRCs and video on key points and actionable messages"
1858432|NCT01003600|Behavioral|Questionnaire|The questionnaire will be administered by telephone and will take approximately 20-30 minutes. The questionnaire will elicit survivor responses along five domains: knowledge about diagnosis and treatment, knowledge about ongoing risks and recommended testing, history of health care utilization since the end of treatment, preferences for relevant information about these topics, and employment after the end of cancer treatment.
1858433|NCT01003613|Drug|Tranilast, and Tissucol|1.0%, 0.1 ml, subconjunctival route, single dose
1858434|NCT01003613|Other|Beriplast P|0.1 ml to attach graft
1858435|NCT01003626|Procedure|Tumor Interstitial Fluid Pressure (IFP) assessments|The tip of a needle will be inserted in a skin lesion (similar to a biopsy needle) for up to 3 tumors. The needle is connected to a machine that reads the pressure inside the tumor. The whole process, including cleaning and numbing the lesion, will take about 3-4 minutes.
1858436|NCT01003626|Device|Transducer-catheter SPC-320 + Amplifier|Transducer-tipped catheter Mikro-Tip SPC-320 and transducer Millar with Power Lab used to assess the interstitial fluid pressure in a malignant melanona nodule
1858440|NCT01009268|Procedure|Orthogeriatric intervention|The intervention group will be transferred as soon as possible to the orthogeriatric ward, stabilised there preoperatively, and transferred back to the same ward postoperatively for further treatment and rehabilitation, while the control group will be treated in a traditional orthopaedic ward. Operative and anaesthesiologic procedures will be the same in the two groups.Clinical routines for the orthogeriatric service has been developed during the pilot phase in 2008 and 2009, and are documented in the electronic library of clinical handbooks at Department of Geriatric Medicine.
1858441|NCT01009281|Drug|AIN457|
1858442|NCT01009294|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (20 mg/kg with breakfast, 20 mg/kg with lunch, and 40 mg/kg with dinner) for up to 48 weeks.
1858443|NCT01009307|Genetic|polymorphism analysis|
1858444|NCT01009307|Other|laboratory biomarker analysis|
1858445|NCT01009307|Other|medical chart review|
1858446|NCT01009333|Device|InterStim Therapy at rate 5.2 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
1858447|NCT01009333|Device|InterStim Therapy at rate 14 Hz|All subjects enrolled in this study were programmed to this rate setting for a 1-week period.
1858448|NCT01009333|Device|InterStim Therapy|All subjects enrolled in this study were programmed to each rate setting (low, medium, high) for a 1-week period.
1858449|NCT01009346|Drug|RAD001|"Dose Level -1 2.5mg/day
Dose Level 1 5mg/day*
Dose Level 2 10mg/day
MTD RAD001"
1858450|NCT01009346|Drug|Cetuximab|250mg/m2/week
1858451|NCT01009346|Drug|Cisplatin|40mg/m2 Day 1, 8 every 28 days
1858452|NCT01009346|Drug|Carboplatin|"Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:
Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance."
1858453|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Alzheimer Disease patients: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
1858454|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for brain imaging: Single intervenous bolus injection of 250 MBq BAY85-8102 on day one of the treatment period, PET/CT
1858455|NCT01009359|Drug|F-18 DPA-714 (BAY85-8102)|Healthy volunteers for whole body imaging: Single intervenous bolus injection of 150 MBq BAY85-8102, whole body PET/CT for evaluation of effective dose, kinetics of BAY85-8102 in blood
1858456|NCT01009372|Behavioral|IPP|Institution of intraoperative breaks for the surgeon with release of pneumoperitoneum for patient
1858457|NCT01009385|Procedure|cervical epidural steroid injection|"After aseptic preparation and skin infiltration with 1% lidocaine
20-gauge Tuohy needle (Tae-Chang Industrial Co., Kongju, Korea) was inserted in the midline at the C6 - C7 level
identification of the epidural space confirmed by injection of contrast medium under fluoroscope
injection of 5 mL of solution containing 10 mg of triamcinolone acetonide suspension and 1.5 mL of 0.75% levobupivacaine hydrochloride, and 3.5 mL of physiologic saline (0.9% NaCl).
Post-procedure, patients were observed for any adverse effects and followed with a neurological examination"
1858458|NCT01009385|Procedure|epidural pressure measurement|"The stylet within the Tuohy needle is removed when the needle was placed in C6-7 ligamentum flavum under fluoroscopic true lateral view.
Identification of the epidural space and measurement of EP was performed with a closed measurement system."
1858459|NCT01009398|Other|Fluoroscopic examination|Localisation of the paravertebral catheter tip and documentation of the spread of contrast dye injected through the catheters by fluoroscopic examination
1858460|NCT01009424|Drug|R7103|escalating inhaled dose
1992902|NCT03278028|Drug|A-101 Vehicle Solution|A-101 Vehicle Solution
1992904|NCT03278340|Behavioral|Sun Safe Workplaces - Technology|After randomization, program staff will contact managers at the recruited employer and schedule the initial web-enabled visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption, and managers will schedule employee education using the SSW-T online training. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2). Electronic materials will be published on KB's state-of-the-art web server for employers to access and use.
1998200|NCT01596816|Radiation|Second part : hypofractionated stereotactic boost|3 fractions (6Gy/session) are delivered over 5 to 9 days (at least 48 hours between sessions) for a total dose of 18 Gy
1858463|NCT01009450|Procedure|LC was done using traditional method|LC was done using traditional method by dissection of calot's triangle and clipping of both cystic duct and artery by metal clips. Then dissection of gall bladder from its bed by hook using electrocautery technique. Finally we insert abdominal drain in Morrison pouch.
1858464|NCT01009450|Procedure|LC was done using harmonic ACE|LC was done using harmonic ACE (Ethicon Endo-Surgery) by dissection of calot's and then occlusion of both cystic duct and artery using harmonic ACE. For closure of and division of cystic pedicle we set the instrument at a power 2 i.e. more coagulation. And when dissecting the gall bladder from the bed we set it to the level 5 i.e. more cutting power. And control of any bleeding from the bed using the active blade of harmonic ACE. Finally we insert abdominal drain in Morrison pouch.
1858465|NCT01009463|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) delivered within one dry powder inhaler (DPI) device for COPD
1858466|NCT01009463|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder via DPI
1858467|NCT01009476|Drug|Galantamine|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of galantamine (8 mg,16 mg, 24 mg retard capsule) was to be in accordance with the recommendations given in the summary of product characteristics.
1858468|NCT01009476|Drug|Nootropics (ginkgo biloba, nicergoline, piracetam, or others)|Therapeutic measures were not predefined in the protocol but remained at the discretion of the treating physician. The treatment regimen of nootropics was to be in accordance with the recommendations given in the relevant summary of product characteristics.
1858469|NCT01009502|Drug|sodium stibogluconate|Sodium stibogluconate 900 mg/m2/day will be given on Monday through Friday every other week for the first 16 weeks of the study (on the 1st, 3rd, 5th, 7th, 9th, 11th, 13th and 15th weeks). On the alternate weeks patients will not receive any study treatment.
1858471|NCT01009528|Device|Electronic feedback system on diabetes care|An electronic feedback system was introduced in randomized primary care clinics providing an overview of quality of care. The intervention ran for 15 months.
1858472|NCT01009541|Drug|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for three days.
1858473|NCT01009541|Drug|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for three days.
1858474|NCT01009541|Drug|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for three days.
1858475|NCT01009541|Drug|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for three days
1858476|NCT01009554|Device|Potassium Oxylate Mouthwash|Rinse with 10 mL for 60 seconds, twice daily after brushing in usual manner with a sodium fluoride dentifrice
1858477|NCT01009554|Drug|Sodium Fluoride Dentifrice|Brush in usual manner, twice daily, with a sodium fluoride dentifrice
1858478|NCT01009567|Drug|Cabergoline|Receive cabergoline tablet (0/5 mg) daily until 6 days after oocytes retrieval
1858479|NCT01009567|Drug|Control|Receive human albumin 20% infusion
1858480|NCT01009580|Drug|insulin degludec/insulin aspart|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
1858481|NCT01009580|Drug|biphasic insulin aspart 30|Injected s.c. (under the skin) with the breakfast meal and main evening meal. The dose were individually adjusted. Subjects continued their pre-trial OADs (oral antidiabetic drug(s)) treatment of Metformin, the specific DPP-4 Inhibitor and Pioglitazone.
1858482|NCT01009593|Drug|ABT-869|Tablets, Oral, 17.5 mg, Once Daily, Until disease progression or unacceptable toxicity
1858483|NCT01009593|Drug|Sorafenib|Tablets, Oral, 400 mg, Twice Daily, Until disease progression or unacceptable toxicity.
1858484|NCT01009606|Other|Usual strategy|Usual strategy
1858485|NCT01009606|Other|Modified strategy|Proposition to a relative to witness the cardiopulmonary resuscitation of a family member and debriefing ot the situation
1858486|NCT01012154|Device|Endomicroscope|Endomicroscopic images and biopsies are taken at several positions on the tumor.
1858487|NCT01012167|Drug|Oxytocin|Oxytocin: 24 IU in the morning and 24 IU in the evening given by nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
1858488|NCT01012167|Drug|Galantamine|Galantamine: 4 mg twice a day for 1 week, then 8 mg twice a day for 1 week, then 12 mg twice a day for 4 weeks
1858489|NCT01012167|Other|Placebo-Oxytocin|Saline nasal spray with a total of 6 puffs of the spray, 3 in each nostril at each administration
1858490|NCT01012167|Other|Placebo-Galantamine|Placebo tablets twice a day for 6 weeks
1858491|NCT01012193|Drug|cilostazol 100mg bid or clopidogrel 150-mg daily|Adjunctive cilostazol: cilostazol 100-mg bid +clopidogrel 75mg daily+aspirin 200mg daily High-MD clopidogrel: clopidogrel 150mg daly +aspirin 200mg daily
1858492|NCT01012206|Behavioral|Intervention regarding food habits and physical activity.|Children in the intervention group participated in an intervention program regarding food habits and physical activity.
1858493|NCT01012219|Drug|niacin (+) laropiprant|open-label, single dose Tredaptive (1000mg ER niacin/ 20mg laropiprant) 2 oral tablets
1858494|NCT01012219|Drug|Comparator: aspirin|81 mg oral tablet once daily for 7 days
1858495|NCT01012219|Drug|Comparator: clopidogrel|75 mg oral tablet once daily for 7 days
1858496|NCT01012219|Drug|Comparator: laropiprant|40 mg oral tablet once daily for 7 days
1858497|NCT01012219|Drug|Comparator: placebo|placebo oral tablet once daily for 7 days
1858498|NCT01012232|Drug|20 mL ropivacaine 5 mg/mL|
1858499|NCT01012232|Drug|10 mL ropivacaine 10 mg/mL|
1858500|NCT01012245|Other|no intervention|
1858583|NCT01012830|Drug|Huperzine A|Huperzine A in 200 microgram (mcg) capsules taken twice daily for 8 weeks.
1860353|NCT01026987|Procedure|Stem Cell Infusion|
1858501|NCT01012258|Biological|Cetuximab + concomitant boost radiotherapy|"Cetuximab 400 milligram/square meter (mg/m^2) intravenous (IV) infusion over 120 minutes for 1 week, subsequently followed by 250 mg/m^2 IV infusion over 60 minutes, from week 2 to 7 along with concomitant boost radiotherapy: 72.0 Gray (Gy) total for 42 fractions in 6 weeks, initially
Once-daily fractions: 32.4 Gy in 18 fractions of 1.8 Gy for 3.6 weeks (5 fractions/week), followed by
Twice-daily fractions 39.6 Gy in 24 fractions for 2.4 weeks: morning dose 1.8 Gy/fraction for a total of 12 fractions 5 fractions/week; evening dose 1.5 Gy/fraction for a total of 12 fractions 5 fractions/week. Doses are separated by at least a 6-hour interval"
1858502|NCT01012271|Other|MRI|MR arthrography is used to evaluate wrist abnormalities
1858503|NCT01012284|Drug|TMC207|400 mg (4 tablets of 100 mg) of TMC207 will be administered as a single dose on Day 1 of the treatment period to participants of both the Panels (Panel A and Panel B)
1858504|NCT01012297|Biological|Bevacizumab|Given IV
1858505|NCT01012297|Drug|Docetaxel|Given IV
1858506|NCT01012297|Biological|Filgrastim|Given SC
1858507|NCT01012297|Drug|Gemcitabine Hydrochloride|Given IV
1858508|NCT01012297|Biological|Pegfilgrastim|Given SC
1858509|NCT01012297|Other|Placebo|Given IV
1858510|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 100mg PF-04531083 or placebo for 14 days.
1858511|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 300mg PF-04531083 or placebo for 14 days.
1858512|NCT01012310|Drug|PF-04531083 or Placebo|Subjects will receive multiple oral doses of less than or equal to 500mg PF-04531083 or placebo for 14 days.
1858513|NCT01012310|Drug|PF-04531083 or Placebo|A fourth cohort may be used to investigate alternative dosing regimens, formulations or food effects.
1858514|NCT01012323|Biological|NewGam|The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as minimum trough levels of serum immunoglobulin G (IgG) was above 5 g/L. If serum IgG trough levels dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
1858515|NCT01012336|Drug|Aprepitant/Ramosetron/Dexamethasone|"Aprepitant: The first day, one 125 mg capsule will be administered per oral, 1 hour before chemotherapy. Thereafter one 80 mg capsule will be repeated daily between 8 to 10 a.m. during days 2 to 3.
Ramosetron: 0.3 mg i.v. a single dose on day 1, administered over 30 seconds, 30 minutes prior to chemotherapy.
Dexamethasone: 20mg diluted in 50ml of 0.9% saline i.v. a single dose on day 1, administered over 30minutes prior to chemotherapy (taxane). Because all patients are premedicated with dexamethasone 20 mg before taxane administration, the dose of dexamethasone can not be reduced to 12 mg."
1858516|NCT01012349|Drug|Association: acetylsalicylic acid (500mg), sodium bicarbonate (1625) and citric acid (965)|1 tablet in an episody of headache
1858517|NCT01012349|Drug|Aspirin - Bayer|1 tablet in an episody of headache (Aspirin 500mg)
1858518|NCT01012362|Drug|Pazopanib|Escalating doses 400-800 mg by mouth once daily beginning day 1 and continuing.
1858519|NCT01012362|Drug|Ixabepilone|Escalating doses 25-32 mg/m2 by intravenous infusion on day 1 of each 21 day cycle
1858524|NCT01012388|Device|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspected in an aqueous based gel carrier
1858525|NCT01012401|Other|CHESS website for lung cancer patient + internet access if needed|The Comprehensive Health Enhancement Support System (CHESS), a non-commercial, home-based system created by clinical, communication, and decision scientists at the University of Wisconsin, is distinguished by its quality, depth, and ease of use. It employs data on user health status to help users monitor their condition, guide them to tailored information and social support, make and implement important health decisions, and learn coping skills. Our tests and clinical trials demonstrate that an ICCS such as CHESS can be widely accepted and used, improve quality of life, information competence, and in some cases lead to more efficient use of health services. An Internet-based system, CHESS-LC integrates over 14 services to provide tailored cancer information, support, interactive tools, and communication with the clinical team.
1858526|NCT01012414|Drug|paricalcitol|2 mcg oral paricalcitol daily
1858527|NCT01012414|Drug|placebo|placebo
1858528|NCT01012427|Procedure|percutaneous cryoablation|All patients will have percutaneous image guided core biopsies of the treatment site and CT or MR imaging at approximately 5-7 months following the cryoablation. They will have repeat imaging every 5-7 months for a period of two years, and if there is evidence of recurrence (ablation zone increase > 5 mm or increased enhancement 15 HU), then repeat biopsy will be obtained. Imaging follow-up past the two year point will be at the discretion of the patient's physicians.
1858529|NCT01012440|Device|PEM Flex Solo II PET Scanner|Subjects will receive bilateral (both sides) breast and axillary PEM scans.
1858530|NCT01012440|Device|MRI scan|Subjects will receive bilateral (both sides) breast and axillary MRI scans.
1858531|NCT01012453|Behavioral|A randomised clinical trial of the effect of classification and individual counselling|The trial to be conducted is a randomised single-blinded parallel study. It is divided in two stages, T = 0 and follow-up at T = 6 months. All included participants will have a clinical examination at the beginning and at follow-up in the trial. Half of the participants will be randomised to intervention, the other half to control. The participants in the intervention group will, after the first clinical examination, pass on directly to the intervention which includes an allergological examination (patch and prick testing). Three days later they will be examined by a physician who will interpret the patch test and give a thorough, individual guidance in skin protection and occupational safety. The clinical examination of all participants at follow-up will reveal the difference in outcomes in the intervention and the control group.
1858532|NCT01012479|Drug|Candesartan cilexetil and hydrochlorothiazide|Candesartan cilexetil 16 mg, tablets, orally, once daily for 1 week; increased to candesartan cilexetil 16 mg and hydrochlorothiazide 12.5 mg combination tablet, orally once daily for 2 weeks; then increased to candesartan cilexetil 32 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for up to 6 weeks
1860354|NCT01027000|Biological|rituximab|
1858534|NCT01012505|Other|adding pad with maternal milk in hte incubator|"2 days prior to intervention - recording infants data and taking saliva cortisol adding pad with maternal milk - during 2 days - recording infants data and taking saliva cortisol.
stopping intervention and for other 2 days recording infants data and taking saliva cortisol"
1858535|NCT01012518|Device|Standard PCT|The standard technique, performed without video guidance
1858536|NCT01012518|Device|Video-guided PCT|PCT performed with the guidance of a camera-embedded ETT wired to a monitor
1858537|NCT01012531|Biological|Subcutaneous injections with highly polymerized allergen extract|cluster schedule
1858538|NCT01012531|Biological|Subcutaneous injection with placebo|cluster schedule
1858539|NCT01012544|Drug|Clopidogrel|both arms of the study (patients with a history of stent thrombosis as well as patients who did not suffer from a stent thrombosis) will be given a 600 mg loading dose of clopidogrel
1858540|NCT01012557|Biological|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular)x 1
1858541|NCT01012557|Biological|Focetria|3.75 mcg H1N1v half MF59 adjuvant i.m.(intramuscular)x 1
1858542|NCT01012557|Biological|Focetria|15 mcg N1N1v unadjuvanted i.m.(intramuscular) x 1.
1858543|NCT01012557|Biological|Focetria|7.5 mcg H1N1v full MF59 adjuvant i.m.(intramuscular) x 1
1858544|NCT01012570|Drug|Application of Adalimumab|Adalimumab will be applied according to manufacture's instruction and official guidelines.
1858545|NCT01012596|Behavioral|Creighton Model System of Natural Family Planning|Participants will learn the Creighton Model, a standardized method of natural family planning, from FertilityCare Practitioners from established FertilityCare Centers. The learning can be done in-person or long distance.
1858546|NCT01012609|Other|cetuximab in conjunction with external beam radiation therapy, followed by cetuximab and irinotecan|External beam radiation therapy (5940 cGy in 180 cGy fractions) with weekly cetuximab (250 mg/m2/dose).4-8 weeks rest, 10 cycles of irinotecan (16 mg/m2/day x 5 consecutive days x 2 weeks) with weekly cetuximab (250 mg/m2/dose) at about 21 day intervals. Research biological evaluations will be performed in consenting patients as an optional portion of the study. Cetuximab is to be given every 7 days (+/- 2 days). Cetuximab does not need to be given on Day 1 of each week.
1858547|NCT01012622|Drug|Osmotic Release Oral System (OROS) Methylphenidate Hydrochloride|OROS methylphenidate hydrochloride (HCL) will be given orally once daily at an initial dose of 18 milligram (mg) for participants below 30 Kilogram (kg) and 27 mg for those over 30 kg of body weight. The dose will be increased by 9 mg or 18 mg every week for up to Week 8, followed by a maximum maintenance dose of 54 mg orally once daily up to Week 12 during which the dose can be decreased by 9 mg depending on tolerability.
1858548|NCT01012635|Other|Hypnosis|Hypnosis Training: Verbal suggestions from an audio recording (via headphones).
1858549|NCT01012635|Other|Meditation|"Meditation: focus on a single word (one) for the entire session."
1858550|NCT01012635|Other|Neurofeedback training|Neurofeedback Training: Two electrodes will be placed on your scalp, and one electrode clipped on your head. There is no risk of electrical shock.
1858551|NCT01012635|Other|Two different levels of tDCS|Direct stimulation of the brain by using a weak electrical current. There is no risk of electrical shock.
1858552|NCT01012648|Drug|Fluid resuscitation|Volume resuscitation
1858553|NCT01012648|Drug|HES 130/0.4 (6%), Voluven balanced vs. Lactated Ringer's solution|Volume Resuscitation
1858554|NCT01012661|Device|Radiesse® Injectable Dermal Filler Mixed with Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier mixed with 2% lidocaine hydrochloride (HCl)
1858555|NCT01012661|Device|Radiesse® Injectable Dermal Filler without Lidocaine|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier without 2% lidocaine hydrochloride (HCl)
1858556|NCT01012674|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
1858557|NCT01012674|Other|TOF MRA|Each subject will undergo a Time Of Flight Magnetic Resonance Angiography (TOF MRA)
1858558|NCT01012687|Drug|perindopril erbumine|8 mg tablet
1858559|NCT01012700|Drug|Hiltonol (poly ICLC)|2 mg administered subcutaneously or intranasally to healthy volunteers
1858560|NCT01012713|Drug|Clobex Spray|Clobex Spray BID for Weeks 1-4 and weeks 9-12
1858561|NCT01012713|Drug|Vectical Ointment|Vectical ointment BID for weeks 5-8 and 9-12
1858562|NCT01012713|Procedure|Excimer Laser|Laser treatment for weeks 1-6 study and as needed for patients with less than PASI-75 response thereafter.
1858563|NCT01012726|Procedure|Colonoscopy|During the colonoscopy, we instill Acetylcystein and Doxycyline into the fistula.
1858564|NCT01012739|Drug|Indacaterol 150 μg via the Concept1 dry-powder inhaler|Indacaterol maleate 150 μg was provided in powder filled capsules with the Concept1 dry-powder inhaler.
1858565|NCT01012739|Drug|Indacaterol 60 μg via the Simoon dry-powder inhaler|Indacaterol 60 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
1858566|NCT01012739|Drug|Indacaterol 120 μg via the Simoon dry-powder inhaler|Indacaterol 120 μg was provided in powder filled capsules with the Simoon dry-powder inhaler.
1858567|NCT01012739|Drug|Placebo to indacaterol via the Concept1 dry-powder inhaler|Placebo to indacaterol was provided in powder filled capsules with the Concept1 dry-powder inhaler.
1858568|NCT01012752|Biological|modified allergen extract|subcutaneous injections
1858569|NCT01012752|Biological|Placebo|subcutaneous injections
1858570|NCT01012765|Drug|Indacaterol|Indacaterol 150µg once daily (o.d.) delivered via single-dose dry powder inhaler (SDDPI)
1858571|NCT01012765|Drug|Tiotropium|Tiotropium 18µg o.d. delivered via a proprietary inhalation device.
1858572|NCT01012765|Drug|Placebo|Placebo to indacaterol o.d. delivered via SDDPI
1858573|NCT01012778|Behavioral|Climb Up ADHD and Dyslexia Program|Using a peer mediated multimodal intervention program for ADHD and Dyslexia use Yoga, Meditation, Play therapy administered by (trained) high school volunteers
1858574|NCT01012791|Other|Zumba exercise|Subjects with do Zumba exercise for approximately 60 minutes twice a week for 6 months.
1858575|NCT01012804|Genetic|western blotting|
1858576|NCT01012804|Other|immunohistochemistry staining method|
1858577|NCT01012804|Other|laboratory biomarker analysis|
1858586|NCT01012856|Behavioral|Cognitive-Behavioral Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on cognitive restructuring without emotion-focused interventions
1858587|NCT01012856|Behavioral|Exposure-Based Cognitive Therapy for Depression|22 weekly sessions and 2 booster session of face to face outpatient psychotherapy; focus on emotion-focused interventions
1858588|NCT01012869|Device|everolimus-eluting stent|everolimus-eluting stent (Xience, Abbott Vascular) or Promus (Boston Scientific)
1858589|NCT01012882|Biological|sublingual immunotherapy with allergen extract|sublingual application
1858590|NCT01012882|Biological|sublingual immunotherapy with placebo|sublingual application
1858591|NCT01012895|Drug|BMS-790052|Tablets, Oral, 60 mg, once daily, 24 weeks
1858592|NCT01012895|Drug|BMS-650032|Tablets, Oral, 600 mg, twice daily, 24 weeks
1858593|NCT01012895|Drug|BMS-650032|Tablets, Oral, 200mg, twice daily, 24 weeks
1858594|NCT01012895|Drug|BMS-650032|Tablets, Oral, 200 mg, once daily, 24 weeks
1858595|NCT01012895|Drug|Pegylated-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly
1858596|NCT01012895|Drug|Ribavirin|"Tablets, Oral
For subjects weighing < 75 kg: 1000 mg; For subjects weighing ≥ 75 kg: 1200 mg
Twice daily (< 75 kg: 400 mg in ante meridian (AM) and 600 mg in post meridian (PM); ≥ 75 kg: 600 mg in AM and PM), 24 weeks"
1858597|NCT01012908|Dietary Supplement|Norzyme - Bergamo|2 - 8 tablets per day.
1858598|NCT01012908|Dietary Supplement|Creon|2 - 8 tablets pet day
1858602|NCT01012934|Drug|Alendronate Sodium Tablets, 70 mg|1 x 70 mg, single-dose fasting
1858603|NCT01012934|Drug|Fosamax Tablets, 70 mg|1 x 70 mg, single-dose fasting
1858604|NCT01012947|Behavioral|Lifestyle Counseling Usual Care|Usual care participants in the group A received no additional services.
1858605|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Bimonth|Participants in the group B received bimonthly telephonic care management based on manual.
1858606|NCT01012947|Behavioral|Lifestyle Counseling Telephone, Month|Participants in the group C received monthly the same telephonic care management and educational materials as those in the group B.
1858607|NCT01012947|Behavioral|Lifestyle Counseling Visit, Bimonth|Participants in the group D received health educator-initiated visit counseling bimonthly.
1858608|NCT01012947|Behavioral|Lifestyle Counseling Visit, Reward|Participants in the group E received health educator-initiated visit counseling bimonthly and reward.
1858609|NCT01012960|Drug|methylnaltrexone|0,15 mg/kg sc ( subcutaneously)once per volunteer
1858610|NCT01012973|Biological|Aflibercept Injection (EYLEA, VEGF Trap-Eye, BAY86-5321)|Intravitreal injection. Weeks 0 to 20 of Aflibercept Injection every 4 weeks; Weeks 24 to 52 every 4 weeks PRN (pro re nata, on demand); plus additional on Week 60 and 68.
1858611|NCT01012973|Other|Sham treatment|Sham treatment. Weeks 0 to 52 sham treatment every 4 weeks; plus additional on Week 60 and 68.
1858612|NCT01012986|Other|Assessment of reading skills|
1858613|NCT01012999|Drug|sufentanil|Intra-nasal delivery, dosing range 0.5 mcg/kg, administered once at the beginning of the 30 minute study period
1858614|NCT01013012|Drug|ramosetron with saline|Group A : saline 1 ml, ramosetron 6μg/kg
1858615|NCT01013012|Drug|ramosetron with dexamethasone|Group B : dexamethasone 4 mg, ramosetron 6μg/kg
1858616|NCT01013025|Procedure|Ultrasound or CT or MRI to locate implant|Scanning methods (eg, ultrasound, CT, or MRI) were used to locate the implant.
1858617|NCT01013038|Procedure|Thrombus aspiration followed by stent implantation|Export aspiration catheter 6F (Medtronics)
1858618|NCT01013038|Procedure|conventional PCI|balloon angioplasty and/or stent implantation
1858619|NCT01013064|Drug|HM10760A or Placebo|0.04 mcg/kg to 2.0mcg/kg once intravenously
1858623|NCT01013090|Drug|Ringer's Lactate|Ringer's Lactate 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
1858624|NCT01013090|Drug|Six percent hydroxyethyl starch|Six percent hydroxyethyl starch 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 15 ml/kg is given to patients pre-, co- and post-neuraxial blocks
1858625|NCT01013103|Drug|Atorvastatin, high vs low dose|In this arm patients with ischemic heart disease will be recruited. In a double-blind crossover design heart failure patients (n=30) naïve to statins treatment will be randomized to receive oral atorvastatin 10mg/day 1x1(n=15) or oral atorvastatin 40mg/day 1x1 (n=15) for 4 weeks. At the end of 4 weeks a 2-week wash out period will follow and then all patients will switch atorvastatin dose and continue treatment for 4 weeks (e.g all patients that were under atorvastatin 10mg/day will be switched to atorvastatin 40mg/day and vice versa).
1858626|NCT01013103|Drug|Atorvastatin vs Placebo|In this arm, patients undergoing cardiac surgery (CABG, valve replacement or aortic surgery) that are not under statins treatment will be recruited. Patients will be randomized in a double-blind fashion to atorvastatin 40mg/day or placebo for 3 days before surgery date.
1858627|NCT01013116|Biological|modified allergen extract of house dust mites|subcutaneous injections
1858628|NCT01013116|Biological|placebo|subcutaneous injections
1860355|NCT01027000|Drug|busulfan|
1858636|NCT01013142|Drug|MN-221 (Dose Group 1)|i.v. infusion of MN-221 (300 mcg) or placebo over 1 hour
1858637|NCT01013142|Drug|MN-221 (Dose Group 2)|i.v. infusion of MN-221 (600 mcg) or placebo over 1 hour
1858638|NCT01013142|Drug|MN-221 (Dose Group 3)|i.v. infusion of MN-221 (1,200 mcg) or placebo over 1 hour
1858639|NCT01013155|Drug|perindopril erbumine|8 mg tablet
1858640|NCT01013168|Procedure|Apheresis using the OncoSorb column|device is intended to specifically adsorb three soluble receptors (sTNF-R1, sTNF-R2 and sIL-2R α)
1858641|NCT01013194|Other|Human Fetal Liver Cell Transplantation|"Human Fetal Liver Cell Transplantation. Cell source: Non-purified and non-selected fetal liver cells from fetuses aborted between the 16th and 26th week of gestation.
Infusion technique: Isolation and incannulation of the femoral artery.Splenic artery infusion under radiological guidance.
Cell infusion: between 5 and 10x10^8 cells. Number of sessions: up to 2."
1858642|NCT01013207|Device|CPAP Pre Nexus (S9)|This is the patient's own CPAP prior to trialling the Nexus (S9). 4 weeks of data will be downloaded from this device and compared to 4 weeks using Nexus (S9), and 4 weeks usage post trialling Nexus (S9)
1858643|NCT01013207|Device|Nexus (S9)|The patient will use the new Nexus (S9) CPAP for four weeks in place of their usual CPAP every night when they sleep to treat their OSA. Compliance data will be compared between four weeks on this device to the last four weeks on their current device (CPAP Pre S9). After using the Nexus (S9) CPAP for four weeks, participants will return to their current device for four weeks. Data from this post-trial period will be compared with both the Nexus (S9) four weeks, and the four weeks pre Nexus (S9) usage.
1858644|NCT01013207|Device|CPAP Post Nexus (S9)|After trialling the Nexus (S9) for four weeks, patients will return to their usual CPAP. Data from the patient's usual CPAP for four weeks will be compared to data while using the Nexus (S9), and data from the patient's usual device pre trialling S9 (CPAP Pre Nexus)
1858645|NCT01013220|Other|Depression Product Detailing|"two hour academic detailing of depression management products to employees with responsibility for purchasing health care benefits
technical assistance in purchasing high quality depression management products"
1858646|NCT01013220|Other|Depression HEDIS detailing|"academic detailing to employees responsible for purchasing health care benefits on how to use HEDIS indicators for depression to assure their depressed employees receive high quality care for the condition
technical assistance"
1858647|NCT01013233|Behavioral|cognitive training|cognitive training over 6 weeks, consist of 6 meetings (a 45minutes), three sessions focus on concentration tasks and three sessions on memory problems.
1858648|NCT01013233|Other|control group|no intervention
1858649|NCT01013246|Other|1-hour video game play|FIFA 2009, a football video game played on Xbox 360
1858650|NCT01013259|Drug|Mutaflor|1 capsule contains 2.5 - 25 billion viable bacteria of the strain E. coli Nissle 1917, 1 capsule daily over the first 4 days, 2 capsules daily until the end of treatment
1858651|NCT01013259|Drug|Placebo|1 placebo capsule matching the experimental treatment, according to the experimental arm
1858652|NCT01013272|Drug|Entecavir|Entecavir 0.5mg orally daily
1858653|NCT01013272|Drug|Lamivudine|Lamivudine 100mg orally, daily
1858657|NCT01013298|Device|video-guided PCT|extubation and then re-intubation with the ETT-TVT, followed by video monitoring of the PCT procedure via the ETT-TVT
1858658|NCT01013324|Drug|XL147 (SAR245408)|dosed as capsules taken orally daily
1858659|NCT01013337|Procedure|acupuncture therapy|
1858660|NCT01013337|Procedure|sham intervention|Placebo acupuncture
1858661|NCT01013350|Drug|Cladribine|This is an observational study. Subjects who had already participated in the cladribine clinical trials will be observed.
1858662|NCT01013363|Other|iPod Nano digital music player|Digital music player pre-loaded with 10 playlists to be used intra-operatively by the participant randomized to the intervention group.
1858663|NCT01013376|Drug|MC-1101|MC-1101 1.0%
1858664|NCT01013376|Drug|Vehicle|Vehicle
1858665|NCT01013389|Procedure|Actifuse ABX|bone substitute used for posterolateral instrumented lumbar fusion with interbody fusion
1858666|NCT01013389|Procedure|INFUSE, plus master granules (MGG)|bone substitute in posterolateral instrumented lumbar fusion with interbody fusion
1858667|NCT01013402|Drug|Human insulin|The test was performed in the morning after an overnight fasting and the patients remained supine during the procedure. Two intravenous lines in both arms were established before the procedure. Venous blood was obtained for serum glucose before regular insulin (0.1 U/kg ) is injected and 30 and 45 minutes thereafter. If adequate hypoglycemia was not achieved at this period, a second dose of regular insulin (0.05U/kg) was injected intravenously. In subjects who had not reached the aimed hypoglycemia levels, the test was performed in another day with a higher initial insulin dosage (0.2U/kg).
1858668|NCT01013402|Drug|Human Insulin|0.1U/kg IV pulse.
1858669|NCT01013415|Drug|HAART|
1858670|NCT01013415|Biological|T cells|
1858671|NCT01013428|Other|Ultrasound|Ultrasound will be used to evaluate tendons.
1858672|NCT01013441|Biological|Infusion of CD3/CD28 stimulated T cells|Receive CD3/CD28 stimulated T cells after fludarabine or alemtuzumab based chemotherapy
1858673|NCT01013454|Drug|varenicline free base patch|varenicline transdermal delivery system (6.0 mg payload [drug amount loaded in each patch]) will be applied to the upper back over a single 24 hour period
1858723|NCT01013753|Drug|Placebo|Determine efficacy and safety of Placebo inhaled once daily from the Respimat inhaler and/or twice daily from the Aerolizer inhaler
1858674|NCT01013467|Behavioral|"CoCo colour coded blood pressure control"|The patients in the intervention group will receive a colour-coded blood pressure record booklet. The corresponding colour coded areas are divided into three areas of green, yellow and red following a traffic light system. The green area covers blood pressure readings up to a maximum of 140/90 mmHg, the yellow area includes systolic readings over 140 to 180 mm Hg and diastolic readings over 90 to 110 mmHg. The red area covers systolic readings over 180 mmHg and diastolic readings over 110 mmHg.
1858675|NCT01013480|Drug|Arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
1858676|NCT01013506|Drug|IGF-1R inhibitor OSI-906|Given orally
1858677|NCT01013506|Drug|erlotinib hydrochloride|Given orally
1858678|NCT01013506|Drug|goserelin|Given subcutaneously
1858679|NCT01013506|Drug|letrozole|Given orally
1858689|NCT01013545|Behavioral|JAE Intervention|The overall goal in each session will be for the caregiver-child dyad to be in a state of supported or coordinated joint engagement. In this state the child is aware of the other's activity, and may actively coordinate their attention between an object/toy and the caregiver. The interventionist will coach the caregiver and child while they engage in play routines established through collaboration between caregiver and interventionist.
1858690|NCT01013558|Drug|Remifentanil|0.15 microgram/kg/min continuous infusion.
1858691|NCT01013558|Drug|saline|continuous infusion
1858692|NCT01013571|Drug|insulin glargine|pre-filled disposable pen, in package of 5.
1858693|NCT01013571|Drug|Apidra (insulin glulisine)|pre-filled disposable pen, in package of 5
1858694|NCT01013584|Dietary Supplement|cholecalciferol|daily dose
1858695|NCT01013597|Drug|LBH589|LBH589 20mg by mouth three times weekly (Monday/Wednesday/Friday) for 28-day cycles.
1858696|NCT01013610|Drug|LNK-754|Escalating dose
1858697|NCT01013610|Drug|Placebo|Escalating dose
1858698|NCT01013623|Procedure|Surgery|surgical resection to remove all known disease
1858699|NCT01013623|Procedure|Surgery plus 2 adjuvant doses of BCG|Patients in the surgical resection + BCG arm will have an additional two visits to receive BCG. The first dose of BCG will be given no earlier than 4 weeks after surgery, and the second BCG dose will follow 2 weeks later. The actual doses are determined by the patient's pre-study tuberculin-reactivity status. Patients with a pre-study PPD induration of ≥10 mm will be given half the normal dose of BCG. Those with PPD induration of ≥20 mm will be given 25% of the normal dose.
1858700|NCT01013623|Other|best medical therapy|Patients randomized to the Best Medical Therapy arm will decide on a course of medical therapy based on what the patient's medical oncologists feels is best for the patient. Best systemic medical therapy may include clinical trials of new agents or standard non-protocol treatments. Patients who progress on the best medical treatment arm may switch to a different medical therapy or, if still appropriate, may receive surgery.
1858701|NCT01013636|Procedure|Blood sampling|"Anaplasma diagnosis test : serology and PCR
If presence of Anaplasma infection, proposition of treatment with doxycylin 200 mg once-a-day during 10 days"
1994439|NCT03004105|Behavioral|Phone Calls|About every 6 months, participant called by a member of the study staff to ask how participant is doing and if participant has started any new treatments outside of the study. These calls should last about 10 minutes each time.
1994440|NCT03003169|Other|Medical questionnaire|"quality of life questionnaire (EORTC QLQ-C30 and QLQ-BR23)
Hospital Anxiety and Depression scale
satisfaction care questionnaire (IN-PATSAT32)"
1994441|NCT03000608|Drug|SAN021 Serum|SAN021 is a serum containing 10% East Indian Sandalwood Oil. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
1994442|NCT03000608|Drug|SAN021 Placebo|SAN021 Placebo is a serum that does not contain East Indian Sandalwood Oil however, does contain a synthetic sandalwood fragrance. It is packaged in an amber glass bottle with a dropper top. The dose is 5 drops per 1% BSA involvement twice daily.
1994443|NCT03001141|Other|Observational|Device: MultiPoint Pacing will be enabled in enrolled patients at the discretion of the physician.
1858711|NCT01013662|Procedure|glycemic control|exogenous insulin
1858712|NCT01013675|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in cell cultures
1858713|NCT01013675|Biological|Influenza Vaccine|surface antigen, inactivated, prepared in egg (influvac ®)
1858714|NCT01013688|Procedure|Cardioblate® Surgical Ablation System|Using Cardioblate® Surgical Ablation System to perform left atrial or bi-atrial radiofrequency ablation procedure during valve surgery
1858715|NCT01013701|Drug|fluticasone furoate|nasal steroid spray
1858716|NCT01013701|Other|placebo|nasal steroid vehicle without drug
1858719|NCT01013727|Radiation|SPECT : ECD-Tc99m - Neurolite, Bristol-Myers Squibb Medical Imaging|
1858720|NCT01013740|Drug|Vinorelbine|Vinorelbine
1858721|NCT01013740|Drug|Lapatinib|Lapatinib
1858722|NCT01013740|Drug|Capecitabine|Capecitabine
1860356|NCT01027000|Drug|cyclophosphamide|
1994446|NCT03000920|Other|SMS before invitation|A couple of days before the invitation letter, an SMS will be sent to announce the arrival of the invitation letter to the mammogram
1994447|NCT03000920|Other|SMS Reminder 1|If it is necessary for the women to have a reminder 1, the usual mail will be replaced by an SMS.
1858724|NCT01013753|Drug|Olodaterol (BI 1744) high|Determine efficacy and safety in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
1858725|NCT01013753|Drug|Olodaterol (BI 1744) medium|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
1858726|NCT01013753|Drug|Olodaterol (BI 1744) very low|Determination of efficacy in 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
1858727|NCT01013753|Drug|Formoterol 12 mcg|Determine efficacy and safety of 12 mcg Formoterol dose inhaled orally twice daily from the Aerolizer in comparison to other treatment groups
1858728|NCT01013753|Drug|Olodaterol (BI 1744) low|Determine efficacy and safety of 4 different doses of Olodaterol (BI 1744) inhaled once daily via the Respimat
1858729|NCT01013766|Drug|GSK1362885|100mg in the AM, 100mg in the PM, 50mg BID
1858730|NCT01013766|Drug|GSK1362885|100mg in the PM, 100mg in the AM, 50mg BID
1858731|NCT01013779|Drug|Carboplatin|"During radiotherapy: Carboplatin (AUC2) commences on day 1 of radiation and is repeated at weekly intervals on days 8, 15, 22 and 29 (of radiation).
After radiotherapy: 3 weeks after completing radiotherapy, 3 cycles of 3 weekly carboplatin (AUC4.5) intravenously on day 1."
1858732|NCT01013779|Drug|Etoposide|After Radiotherapy: 3 weeks after completing the radiation therapy, 3 cycles of 3 weekly etoposide (80mg/M2/day) intravenously days 1-3
1858733|NCT01013779|Radiation|Radiotherapy|"Microscopic Disease: 50Gy delivered in 2Gy doses over 25 fractions
Macroscopic Disease: 54Gy delivered in 2Gy doses over 27 fractions"
1858734|NCT01013792|Device|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs)
1858735|NCT01013792|Device|Wound Dressing|Acetate mesh carrier with ointment (water, PEGs, cations, citric acid)
1858736|NCT01013805|Radiation|External Beam Radiotherapy|"Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy.
Weeks 8-10: as per Weeks 3-5"
1858737|NCT01013805|Drug|Oxaliplatin|"Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU).
Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1."
1858738|NCT01013805|Drug|Fluorouracil|"Week 1: (after Oxaliplatin and leucovorin)5-FU 400mg/m2 bolus Day 1, then 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1.
Weeks 3 to 5: radiotherapy 25.2 Gy in 14 fractions over 3 weeks with 85 mg/m2 oxaliplatin on the first day and continuous infusion 5-FU 200 mg/m2/day on the days of radiotherapy Week 6: as per Week 1, Weeks 8-10: as per Weeks 3-5 Weeks 11: as per Week 1.
Leucovorin 200 mg/m2 Day 1 concurrent with Oxaliplatin over 2 hrs, then 2nd: 5-FU 400 mg/m2 bolus Day 1, then 3rd: 5-FU continuous infusion 2.4 g/m2 over 46 hours from Day 1"
1858739|NCT01013805|Drug|Leucovorin|Week 1: Oxaliplatin 100 mg/m2 Day 1 (over 2 hours), leucovorin 200mg/m2 Day 1 concurrent with oxaliplatin over 2 hrs (then 5-FU) Week 6: as per Week 1, Weeks 11: as per Week 1.
1858740|NCT01013805|Procedure|Surgical Resection|Surgery is to be performed according to the standard procedure for locally advanced rectal cancer 4 to 6 weeks after completion of the integrated preoperative radiotherapy with FOLFOX chemotherapy regimen.
1858741|NCT01013818|Drug|HGS1029|HGS1029 will be given as a 15-minute IV infusion (in the vein) once weekly for 3 consecutive weeks, followed by 1 week off.
1858742|NCT01013831|Drug|Erlotinib Hydrochloride|Given PO
1858743|NCT01013831|Other|Laboratory Biomarker Analysis|Correlative studies
1858744|NCT01013831|Other|Pharmacological Study|Correlative studies
1858745|NCT01013844|Behavioral|Skin Self Examination Information and ABCDE Rule|Card with condensed information about skin self examination (SSE) and color illustrations of the ABCDE (asymmetry of shape, border irregularity, color variation, diameter > or equal to 6 mm, and evolution of the lesion) rule. A research assistant gave a skill demonstration using a magnifying lens.
1858746|NCT01013857|Behavioral|Health coaching|Calling patients every week to discuss medication adherence
1858747|NCT01013857|Behavioral|Health coaching plus home titration|Calling patients every week and intensifying medications if appropriate based on physician-created algorithm
1858748|NCT01013870|Drug|Atorvastatin|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. The dosage for subjects in the treatment group will be weight-based at 1mg/kgm, up to 80 mg, which will be the maximal dose. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
1858749|NCT01013870|Drug|Placebo|In this Phase II randomized clinical trial of 200 MTBI subjects to evaluate atorvastatin as a neuroprotective agent, subjects will receive either active drug or placebo (1:1 randomization) for 7 days, starting within 24 hours of the brain injury. For the placebo group, subjects will take a daily dose of an inert preparation, visually indistinguishable from the active agent. They will take this preparation for seven days, started within 24 hours of MTBI, and their outcome will be compared with the group of subjects receiving active drug. Subjects will be monitored at 3-4 days after injury by phone, then with follow-up visits at 1 week, 1 month, 3 months.
1858750|NCT01013896|Behavioral|Motivational Interviewing|Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
1858751|NCT01013896|Other|Cystic Fibrosis Education|"Among a group of older adolescents and adults with CF, we propose to evaluate the relative efficacy of a Motivational Interviewing-focused intervention (MI) in improving adherence and reducing CF-related morbidity compared to a CF education intervention (CFE; attention control group).
The Cystic Fibrosis Education serves as the attention control group."
1858752|NCT01013909|Drug|Bifonazole spray once daily|Application of one dose daily by means of an metered dose
1858753|NCT01013909|Drug|Bifonazole spray twice daily|Application of two dose daily by means of an metered dose
1858754|NCT01013909|Drug|Placebo|Application of one dose daily by means of an metered dose
1858755|NCT01013909|Drug|Placebo|Application of one dose daily by means of an metered dose
1858756|NCT01013909|Drug|Lamisil Once|One application of Lamisil Once
1858859|NCT01006603|Drug|Glimepiride|1, 2, 3, 4 or 6 mg, oral encapsulated tablet, once daily
1858757|NCT01013935|Other|CARE+ Spanish computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 12 months total.
1858758|NCT01013935|Other|CARE+ Spanish brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 12 months total.
1858759|NCT01013948|Other|Non-Interventional|Non-Investigational Product (Survey Study)
1858760|NCT01013961|Biological|alemtuzumab|Given IV
1858761|NCT01013961|Biological|rituximab|Given IV
1858762|NCT01013974|Drug|GSK573719 250 μg|Strip 1 of the dry powder inhaler will contain GSK573719 250 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
1858763|NCT01013974|Drug|GSK573719 500 μg|Strip 1 of the dry powder inhaler will contain GSK573719 500 μg micronized drug with lactose along with magnesium stearate. Strip 2 will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
1858764|NCT01013974|Drug|GSK573719 1000 μg|Strips 1 and 2 of the dry powder inhaler will contain 500 μg each of GSK573719 micronized drug with lactose along with magnesium stearate. It will be available as dry off white powder for inhalation.
1858765|NCT01013974|Drug|GSK573719 matching Placebo|Strip 1 and 2 of the dry powder inhaler will contain lactose powder along with magnesium stearate. It will be available as dry off white powder for inhalation.
1858766|NCT01013987|Drug|maraviroc|maraviroc: one 150 mg pill twice daily
1858767|NCT01013987|Drug|Raltegravir|raltegravir : one 400 mg pill twice daily
1858768|NCT01013987|Drug|Darunavir/ritonavir|"darunavir : two 300 mg pills twice daily with meal
ritonavir: one 100 mg pill twice daily with meal"
1858769|NCT01014000|Device|Empirical group|Empirical implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
1858770|NCT01014000|Device|Echocardiography-guided approach|Echocardiography-guided implantation of the left ventricular lead during cardiac resynchronization therapy device implantation
1858771|NCT01014013|Drug|ertapenem sodium (MK0826)|a single daily dose of ertapenem sodium 1.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy if needed)
1858772|NCT01014013|Drug|Comparator: ceftriaxone sodium|a single daily dose of ceftriaxone 2.0g IV infused over 30 minutes, for 7-14 days (patients may be switched to oral ciprofloxacin after 3 doses of IV therapy)
1858773|NCT01014026|Other|Screening test|Two Vaginal self sampling devices and HPV test
1858774|NCT01014039|Procedure|Flexible Sigmoidoscopy Screening arm|sigmoidoscopy screening
1858775|NCT01014052|Drug|QLT091001|oral QLT091001 administered once daily for 7 days
1858776|NCT01014078|Drug|Azithromycin Ophthalmic Solution, 1%|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
1858777|NCT01014078|Drug|Placebo|1 drop BID for the first 2 days and then 1 drop once a day for the remainder of the study (29 ± 1 days)
1858778|NCT01014091|Biological|GSK pandemic vaccine GSK2340272A|2 intramuscular injections
1858779|NCT01014104|Drug|Methylprednisolone|Administration of Methylprednisolone
1858780|NCT01014104|Drug|Control|Normal salin injection
1858781|NCT01014117|Drug|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
1858782|NCT01014117|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg of SRT2104.
1858783|NCT01014130|Radiation|Hypofractionated radiotherapy (HypoRT)|Highly conformal hypofractionated radiotherapy to a total dose of 54 Gy given in 3 fractions of 18 Gy each, delivered weekly on days 0, 7 and 14 with a maximum deviation of +/- 2 days from the specified time allowed.
1858784|NCT01014130|Radiation|Conventionally Fractionated Radiotherapy (ConRT)|Standard radiotherapy to a total dose of 60-66 Gy prescribed to an isodose covering the PTV. It will be delivered as 30-33 fractions over a period of six to six and a half weeks. If the use of chemotherapy is the institutional practice for this group of patients, concurrent carboplatin and paclitaxel will be given weekly (paclitaxel (45mg/m2/wk) and carboplatin (AUC=2/wk) for 6 weeks.
1858785|NCT01014143|Drug|Fluoride|Half mouth toothbrushing twice a day for four days.
1858786|NCT01014143|Drug|Chlorhexidine digluconate|Mouth rinsing with 15 ml for 30 seconds twice a day for four days.
1858787|NCT01014143|Drug|Fluoride, triclosan|Half mouth Brushing twice daily
1858788|NCT01014156|Drug|epoprostenol|titration up to 4 ng/kg/min
1858789|NCT01014169|Behavioral|Note taking|The mothers in the intervention group will be given a pen and encouraged to take written notes in the notes section of a discharge envelope using their language of preference when receiving standard newborn discharge information.
1858790|NCT01014195|Other|Neurocognitive and behavioral evaluation|The primary neurocognitive outcome will be performance on measures of cognitive flexibility and cognitive fluency. Functional behavior will be evaluated via the child or adult version of the Behavior Rating Inventory of Executive Function, using parent respondent for each version. The presence of ADHD and common comorbid conditions (i.e. depression, anxiety) will be determined with structured diagnostic interviews. Quality of life will be re-assessed with the PedQL.
1858791|NCT01014208|Drug|OFATUMUMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. ofatumumab dose: cycle 1, day 1 - 1000 mg; cycle 1, day 8 - 1000 mg; cycle 2, day 1 and cycle 3, day 1 - 1000 mg. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
1858860|NCT01006616|Drug|Navarixin|Navarixin 10 mg and 30 mg capsules
1858861|NCT01006616|Drug|Placebo|Placebo to navarixin capsules
1858953|NCT01016496|Other|action observation therapy|15 consecutive sessions of 18 minutes, plus repetition
1858792|NCT01014208|Drug|RITUXIMAB + DHAP|3 cycles of treatment will be administered. Each cycle will last 21 days. rituximab dose: cycle 1, day 1 - 375 mg/m2; cycle 1, day 8 - 375 mg/m2; cycle 2, day 1 and cycle 3, day 1 - 375 mg/m2. DHAP regimen: dexamethasone - 40 mg on days 1, 2, 3, and 4 of dosing cycle; cisplatin - 100 mg/m2/24hrs continuous on day 1 of dosing cycle; cytarabine - 2g/m2 q12 hrs (2 doses) on day 2 of dosing cycle.
1858793|NCT01014221|Other|Acupuncture|acupuncture administered in 8 sessions over 4 weeks
1858794|NCT01014221|Drug|Prednisolone|2 weeks of prednisolone 20 mg daily followed by 2 weeks of prednisolone 10 mg daily
1858795|NCT01014234|Drug|Cyclosporins|These patients will undergo maintenance immunosuppressive treatment with cyclosporine + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
1858796|NCT01014234|Drug|Rapamycin|These patients will undergo maintenance immunosuppressive treatment with rapamycin + mycophenolate + prednisone according to established clinical practice. The dosage of drugs will be based on evaluations of serum trough levels and it will be adjusted when necessary.
1858797|NCT01014247|Drug|Avelox (Moxifloxacin, BAY12-8039)|Single dose of 400 mg
1858798|NCT01014247|Drug|Placebo|Single dose of matching tablet
1858799|NCT01014260|Drug|Placebo|This is a randomized double-blind clinical trial of doxycycline 20 mg bid versus 100mg bid versus placebo, given for 3 months, to be conducted at a single center (JHH).
1858800|NCT01014260|Drug|Doxycycline|Doxycycline 20 mg bid versus Doxycycline 100 mg bid versus placebo
1858801|NCT01014273|Procedure|Percutaneous Coronary Intervention|
1858802|NCT01014299|Other|Recruitment maneuver|"Assigned interventions:
No intervention after tracheal intubation (control group)
Alveolar recruitment maneuver (RM group) immediately after intubation"
1858803|NCT01014312|Behavioral|Depression Care Management (DCM)|Depression Care Management (DCM) includes: 1. Monitoring the course of the depressive disorder; 2. Contacting the referring primary care physician (PCP) and offering information on the patients' current psychiatric status and medical complaints and the treatment recommended by published pharmacotherapy guidelines; 3. Determining the nature and extent of stressors affecting the patients' clinical status and functioning; 4. Psychoeducation concerning depression and depression treatment, working with the patient to select an appropriate treatment based on informed treatment preferences, and emphasizing treatment adherence; and 5. Supportive psychotherapy.
1858804|NCT01014312|Behavioral|Enhanced Care|Primary Care Physicians will be informed by letter from a study psychologist of the participants' depression diagnosis and of suicidal ideation when present. They will have no direct assistance regarding depression treatment, but they will be educated on guideline-based antidepressant treatment recommendations. Moreover, research assistants will use a suicide risk protocol at baseline and at all follow-up assessment periods that mandates immediate contact with PCPs by telephone or beeper in cases with significant risk.
1858805|NCT01014325|Biological|Allergen extract|sublingual application
1858806|NCT01014325|Biological|Placebo|sublingual application
1858807|NCT01014338|Drug|Fosinopril|10mg od
1858808|NCT01014338|Other|lactose|placebo
1858809|NCT01014351|Drug|Paclitaxel|Paclitaxel, 175mg/m2 by IV infusion over 1-3 hours on day 1 of every 21 day cycle
1858810|NCT01014351|Drug|Carboplatin|Carboplatin, AUC 6 given by IV infusion over 20-30 minutes on day 1 of every 21 day cycle
1858811|NCT01014351|Drug|Everolimus|Everolimus, 5 mg by mouth (PO) once a day, continuous dosing every 21-day cycle
1858812|NCT01014364|Drug|hydrocortisone|50mg intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
1858813|NCT01014364|Drug|isotonic saline|intravenous bolus every 6 hours for one week, then every 12 hours for one week and then every 24 hours for one week
1858814|NCT01014377|Device|VascuActive|
1858815|NCT01014390|Device|WallFlex Biliary RX Fully Covered Stent System|Temporary placement of a biliary stent as a treatment of biliary obstruction resulting from benign bile duct strictures. The stent is fully covered with a silicone polymer to reduce the potential of tissue ingrowth into the stent. The stent is removed after 5 months (±1 month) after stent placement in Post-Liver Transplant patients and after 11 months (±1 month) in Chronic Pancreatitis and Post-Abdominal Surgery patients.
1858816|NCT01014403|Drug|enoxaparin|Enoxaparin 30 mg sq q 12 hours
1858817|NCT01014403|Drug|placebo|vehicle
1858818|NCT01014416|Drug|Tolvaptan 15mg or 30mg or 60mg or Placebo|Single dose of Tolvaptan 15mg or 30mg or 60mg or Placebo per day
1858819|NCT01014429|Drug|NMS-1286937|Single Arm, dose escalation study. No. of cycles: until progression or unacceptable toxicity develops.
1858820|NCT01014442|Drug|mycophenolate mofetil|1.5 g PO BID from Days 2 to 30 post-transplantation, 1 g PO BID Days 31 to 90 post-transplantation
1858821|NCT01014455|Behavioral|Informing surgical patients about CO monitoring|A brief intervention that recommends preoperative fasting from cigarettes and that informs patients that their smoking status will be checked before surgery using inhaled CO monitoring will decrease their exposure to cigarette smoke prior to surgery
1858822|NCT01014455|Behavioral|a brief intervention recommending preoperative abstinence from smoking|a brief intervention that recommends fasting but does not mention that CO will be checked
1858823|NCT01014468|Drug|Ranibizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
1858824|NCT01014468|Drug|Bevacizumab (Intravitreal injection)|Intravitreal injection of Ranibizumab 0.5 mg or Bevacizumab 1.25 mg (3 monthly injection followed by monthly
1858825|NCT01014481|Drug|tenofovir, lamivudine, efavirenz|initiate tenofovir 300 mg/day, lamivudine 300 mg/day, efavirenz 600 mg/day between at 4 weeks and at 12 weeks after tuberculosis treatment
1858826|NCT01014494|Device|Adaprev|Class III Medical Device
1858827|NCT01014507|Drug|8 cycles BEACOPPesc plus oral contraceptive|
1858828|NCT01014507|Drug|8 cycles BEACOPPesc plus Goserelin|
1858829|NCT01014520|Drug|Gabapentin , Amitriptyline|"Capsule, 300 mg, oral, single dose 2 hours before surgery
Capsule,300 mg containing 25 mg Amitriptyline, oral, single dose 2 hours before surgery"
1858862|NCT01006616|Drug|Rescue medication|Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
1858863|NCT01006629|Biological|palivizumab|palivizumab 15 mg/kg intramuscularly
1859155|NCT01018030|Drug|FFNS 110 mcg BID|Active Nasal Spray (AM) and Active Nasal Spray (PM)
1858832|NCT01014546|Drug|Arsenic Trioxide|Given PO
1858833|NCT01014546|Dietary Supplement|Ascorbic Acid|Given PO
1858834|NCT01014546|Other|Laboratory Biomarker Analysis|Correlative studies
1858835|NCT01014546|Other|Pharmacological Study|Correlative studies
1858836|NCT01014559|Drug|Oxycodone Naloxone|Oxycodone Naloxone PR Tablet taken twice daily
1858837|NCT01014559|Drug|Oxycodone PR Tablets|Oxycodone PR Tablets taken twice daily
1858838|NCT01014572|Behavioral|Aerobic Exercise Training|Aerobic exercise training consisting of exercise of choice (walking, eliptical machine, stairstepper, stationary bike, etc.) 4 times per week for 40 minutes at a base pace, and two higher intensity steady state sessions per month.
1858839|NCT01014572|Drug|Alagebrium (generic: ALT-711)|The dosage of our drug, ALT-711, will be one 100 mg caplet by mouth twice per day for 12 months. Total dose per day 200 mg.
1858840|NCT01014572|Behavioral|Tai Chi and/or Yoga Training|Tai Chi or Yoga training includes a series of exercises that improve flexibility, balance and coordination. Training will be supervised by trained instructors. This training will occur 3 times per week.
1858841|NCT01014585|Drug|Placebo|Placebo tablets administered orally twice daily
1858842|NCT01014585|Drug|Milnacipran|Milnacipran tablets administered orally twice daily
1858843|NCT01014598|Drug|Cisplatin|Given intra-arterially via isolated lung suffusion
1858844|NCT01014598|Other|Pharmacological Study|Correlative studies
1858845|NCT01014624|Drug|prasugrel|"Prasugrel 10mg tablet administered once daily for 7 days.
After a 1-day to 14-day screening period, subjects will receive active treatment with either prasugrel or clopidogrel for 7 days. If a subject has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the subject may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout period depending on the time to reach both of the exit criteria."
1858846|NCT01014624|Drug|clopidogrel|"Clopidogrel 75 mg tablet administered once daily for 7 days.
After a 1-day to 14-day screening period, subjects will receive active treatment with either prasugrel or clopidogrel for 7 days. If a subject has not missed more than 1 dose of study medication and is unable to attend Visit 3 (Washout Day 1) the day after the 7th day of study medication, the subject may take up to an additional 3 days of study medication and proceed to Visit 3 the day after the last dose. Active treatment will be followed by a 1-day to 12-day Washout period depending on the time to reach both of the exit criteria."
1858848|NCT01006525|Drug|zolpidem|placebo or zolpidem (10mg)daily for one year
1858849|NCT01006538|Device|Epimacular Brachytherapy|Strontium-90. The device delivers 24 Gray of beta radiation to the CNV lesion. Each device is calibrated for a set duration.
1858850|NCT01006538|Drug|Ranibizumab|intravitreal injection (0.5 mg) administered on a monthly basis as required, using the re-treatment criteria
1858851|NCT01006551|Drug|Ziprasidone|20mg pills, dosing will be flexible, ranging from 10 to 160 mg divided BID or TID for the duration of the 52 week trial. In very rare cases, if the subject has shown some benefit and no side effects at a dose of 160mg and the treating clinician feels a further dose increase is necessary, the case would need to be presented to all of the other Principal Investigators for special consideration of further dose increases in 20 mg increments to an absolute maximal dose of 220mg.
1858852|NCT01006564|Other|Imaging Investigations (not radiation)|Pre-hormone therapy MRI scans will be performed as an adjunct to the patients' staging MRI scan; post hormone MRI will be done wholly for research purposes.
1858853|NCT01006564|Other|Other|Insertion of gold seeds into prostate for image registration.
1858854|NCT01006577|Procedure|side-to-end anastomosis|Low anterior resection for rectal cancer < 12 cm from the anal verge with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and side-to-end colorectal/ coloanal anastomosis (STE). The blind end of the descending colon (3-5 cm long) is closed with a linear stapler. Stapling of the anastomosis is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The anastomosis is performed on the antimesenteric aspect of the descending colon. The length of the blind end is measured and the integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
1858855|NCT01006577|Procedure|colon j pouch|Low anterior resection for rectal cancer with total mesorectal excision (TME), ligation of the inferior mesenteric artery close to the aorta, mobilization of the splenic flexure, radical lymph node dissection and colon J pouch rectal/colon J pouch anal anastomosis (CJP). The colon J Pouch is formed by the descending colon by stapling with a defined pouch limb length of 5-6 cm, which is measured intraoperatively. The stapling is done by introducing the stapler from the anus by the assistant surgeon while the surgeon is holding the descending colon in the correct position. The integrity of the anastomosis is tested intraoperatively. The intended minimal distal clearance margin from the tumor is 2 cm. A protective loop ileostomy will be performed regularly which is intended to be closed 3 months postoperatively.
1858856|NCT01006590|Drug|Saxagliptin|5 mg, oral tablet, once daily
1858857|NCT01006590|Drug|Metformin|500 mg, oral tablet, 1 or 2 additional tablets per day added to background therapy
1858858|NCT01006603|Drug|Saxagliptin|5 mg, oral tablet, once daily
1994448|NCT03001219|Drug|Anti-TNF-alpha|Participants will continue their pre-trial anti-TNF-alpha therapy at a stable dose.
1994449|NCT03001219|Drug|Methotrexate|Participants will continue their pre-trial methotrexate therapy at a stable dose.
1994450|NCT03001219|Drug|Placebo|Participants will receive intravenous infusion of placebo.
1994451|NCT03001219|Drug|RO7123520|Participants will receive intravenous infusion of RO7123520.
1994452|NCT02999243|Behavioral|HIV self-testing|The intervention group will be offered HIV self-testing kits for testing HIV status
1994453|NCT02999243|Behavioral|Harm reduction education|Both arms will receive harm reduction education
1994454|NCT02997501|Procedure|T790M+ Testing|The patient will need to have T790M+ testing
1994455|NCT02997501|Procedure|Baseline Visit Blood & Urine Testing|Blood count and standard chemistry testing to ensure patient meets inclusion/exclusion criteria
1994456|NCT02997501|Procedure|Baseline ECG|ECG to ensure absence of any cardiac abnormality
1858864|NCT01006655|Drug|Beclomethasone dipropionate HFA|100µg twice a day, through inhaler autohaler, using a spacer device, preceded and followed by adenosine challenge test
1858865|NCT01006655|Drug|placebo|inhalation twice a day for one month, preceded and followed by adenosine challenge test
1858866|NCT01006668|Drug|Administration of sevoflurane|Administration of sevoflurane (SEVORANE) by inhalation until a maximal concentration of 4% of inspired gas.
1858867|NCT01006668|Drug|Administration of propofol|Administration of propofol (DIPRIVAN) by intravenous injection (1 mg/kg to turn over twice if necessary.
1858868|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mcg Hemagglutinin H1/InfluezaA/California/7/2009 ,9.75 mg squalene MF59, 1.175 mg polysort80, 1.175 mg sorbitan trioleate
Intra muscular"
1858869|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|"7.5 mg Hemagglutinin H1/InfluezaA/California/7/2009, 9.75 mg squalene MF59, 1.175 mg polysirate 80, 1.175 mg sorbitan trioleate
Intramuscular injection"
1858870|NCT01006681|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|Monovalent MF59-Adjuvanted vaccine
1858871|NCT01006694|Other|Behavioral Activation + Medication|Psychoeducation, behavioral activation therapy, and medication delivered within a collaborative care model.
1858872|NCT01006694|Drug|Guideline Antidepressant Medication|Guideline Antidepressant Medication, following the VN National Mental Health plan.
1858874|NCT01006720|Drug|Sugammadex|"Single intravenous injection of either:
Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)"
1858875|NCT01006720|Drug|Neostigmine|Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)
1858876|NCT01006720|Drug|Saline|Saline 0.9% (Saline)
1858877|NCT01006733|Genetic|Pharmacogenetic|The pharmacogenetic arm estimates therapeutic warfarin dose using cytochrome P 450 2C9 (CYP2C9), vitamin K epoxide reductase complex subunit 1 (VKORC1), and cytochrome P 450 4F2 (CYP4F2) genotype and clinical information. The clinical arm estimates warfarin dose from clinical information alone.
1858878|NCT01006733|Drug|Target INR 1.8|We will randomize patients to a target International Normalized Ratio (INR) of 2.5 or 1.8.
1858879|NCT01006746|Other|Remote monitoring by Home Monitoring system|Standard of care completed with remote monitoring for ICD patients follow-up
1858880|NCT01006759|Other|exercise and orientation|guidances for prevention of disability in leprosy with focus on hands, eyes and feet.
1858881|NCT01014637|Drug|Amorolfine (Antifungal)|Treatment with Amorolfine for 36 weeks
1858882|NCT01014637|Drug|RV4104A, Ciclopiroxolamine, Cyclopirox (Keratolytic Agents/Antifungal)|Initial treatment with RV4104A ointment for 3 weeks, followed by treatment with ciclopiroxolamine 1% cream for 8 weeks and by cyclopirox 8% film-forming solution for 25 weeks.
1858883|NCT01014650|Drug|GLYX-13|single IV or SC dose
1858884|NCT01014650|Drug|IV normal saline|Single IV dose of normal saline
1858885|NCT01014663|Behavioral|Traditional Therapeutic Exercise|The therapeutic exercise program will consist of warm-up and stretching, seated and standing range of motion activities, endurance and resistance training, balance training and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
1858886|NCT01014663|Behavioral|Non-Contact Boxing Training|Non-contact boxing training will consist of warm-up and stretching, non-contact boxing training (including punching a focus mitt, speed and heavy punching bags), endurance training activities, strength and resistance training, and a cool down. Training will take place for 36 sessions, three times/week for 60-90 minutes per session.
1858887|NCT01014676|Dietary Supplement|Probiotic|
1858888|NCT01014676|Other|Placebo|
1858889|NCT01014689|Drug|Adapalene/ BPO gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
1858890|NCT01014689|Drug|Adapalene/ BPO vehicle gel with Lymecycline capsules|Gel: Topical to the face, once daily in the evening Capsule: 1 capsule once daily in the morning
1858891|NCT01014702|Device|LensAR Laser System|Use of laser for capsulotomy and lens fragmentation
1858892|NCT01014702|Device|Conventional phacoemulsification|Use of standard techniques for capsulotomy and lens fragmentation
1858893|NCT01014715|Other|Phase II - Preoperative Radiation followed by Lumpectomy.|Sequential investigative question. All procedures are standard of care
1858894|NCT01014728|Drug|propofol|100-200mcg/kg/min by infusion
1858895|NCT01014728|Drug|sevoflurane|1-3% of sevoflurane (expired)
1858896|NCT01014741|Drug|Ibutilide|0.25mg IV ibutilide after PV isolation prior to CFE ablation
1858897|NCT01014741|Drug|Placebo|Placebo after PV isolation prior to CFE ablation.
1994457|NCT02997501|Procedure|Visual Slit-Lamp Testing|Slit-lamp testing performed to ensure patients do not have any eye abnormalities or symptoms
1994458|NCT02997501|Drug|AZD9291 Dosing|Patients to be provided with AZD9291 every 6 weeks (+/- 7 days)
1994459|NCT02997501|Procedure|Plasma AZD9291 testing|The patient will need to have plasma AZD9291 testing before treatment
1994562|NCT02974114|Drug|Paracetamol and caffeine|Test product containing 500 mg paracetamol and 65 mg caffeine
1858949|NCT01016470|Dietary Supplement|Placebo|Placebo Viusid and Placebo Alzer, 3 per day, oral, one year
1858950|NCT01016483|Drug|Pimasertib|
1994563|NCT02974114|Drug|Paracetamol|Test product containing 500 mg paracetamol
1994495|NCT02991326|Other|Sham intervention|The sham intervention will be made in the same examination table and the same position, with the use of the latex gloves, to simulate the Osteopathic Manipulative Treatment, only doing simple touches without therapeutic effect intention.
1858909|NCT01014793|Drug|cabergoline|cabergoline doses were increased at 6-week intervals, starting at 1.0mg/week followed by 2.0 and 3.5mg/week. Hormonal evaluations (IGF-I, GH and PRL) started before the first dose and were repeated at 6-week intervals after each cabergoline dose and after cabergoline withdrawal
1858910|NCT01014806|Biological|Influenza VLP Vaccine|Single dose; 0.5mL
1858911|NCT01014806|Biological|TIV|Trivalent Influenza Vaccine 15ug/strain, commercially licensed
1858912|NCT01014832|Drug|Intensive insulin therapy|Intensive insulin therapy
1858913|NCT01014845|Biological|hepatitis E vaccine|Intramuscularly given at 0, 1, 6m for three doses.
1858914|NCT01014845|Biological|Hepatitis B vaccine|Intramuscularly given at 0, 1, 6m for three doses.
1858915|NCT01014858|Drug|Donepezil|5mg donepezil daily for first 8 weeks and then increased to 10mg daily for the remainder of the study.
1858916|NCT01014871|Drug|Botulinum Toxin Type A - Azzalure|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
1858917|NCT01014871|Drug|Botulinum Toxin Type A - Vistabel|One botulinum toxin type A will be injected in one side of the forehead and the other one will be injected in the other side of the forehead at Baseline. Allocation of each BoNT-A to each side of the forehead will be randomized.
1858918|NCT01014884|Other|Multidisciplinary team interventions|The multidisciplinary team will determine which intervention should be applied to the participant in the intervention group based on their health risk assessment responses as well as medication review and visual inspection of the home.
1858919|NCT01014884|Other|Multidisciplinary team bimonthly visits either in person or via telephone.|
1858920|NCT01014884|Other|Usual case management and pharmacy management as provided by the health Plan and the pharmacy benefit manager|
1858921|NCT01014897|Device|tDCS|tDCS and sham will be applied in random order during standardized occupational therapy
1858922|NCT01014910|Other|Continuous pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive continuous pulse oximetry monitoring throughout their hospital stay regardless of their need for supplemental oxygen.
1858923|NCT01014910|Device|Intermittent pulse oximetry monitoring|Placement of a pulse oximeter to monitor oxygenation status. This is usually placed on a toe, finger, or ear lobe and held in place with adhesive tape. Patients will receive pulse oximetry monitoring during vital signs checks (every 4 hours) and as indicated clinically when not on supplemental oxygen. When patients require supplemental oxygen they will be continuously monitored by pulse oximetry until their oxygen requirement has resolved.
1858924|NCT01014923|Behavioral|Teen driving intervention|Parents of new teen drivers receive guidebook to teach driving skills and safety behaviors; individual instruction on parent-child communication about driving; DVD demonstrating safe driving communication; and, 26-page booklet on driving goals and conversation topics
1858925|NCT01014936|Drug|MSC2156119J|
1858926|NCT01014949|Other|Coronary microcirculation assessment|"Patients will arrive to the cardiac catheterization laboratory in a fasting state without discontinuation of their cardiac medications. After conventional diagnostic coronary angiography, 3000-5000 I.U. i.v. heparin will be administered, and a 6F coronary guiding catheter will be placed in the ostium of the coronary artery of interest. A 0.014 coronary pressure wire (Radi Medical Systems, Wilmington, Mass) will be calibrated, equalized to the guiding catheter pressure with the sensor positioned in the coronary ostium, and then advanced to the distal coronary artery (down to at least two thirds of the epicardial vessel length). Coronary flow reserve (CFR), fractional flow reserve (FFR) and the index of microvascular resistance (IMR) will be measured after an intravenous infusion of adenosine [140 ug/kg/min] to induce steady state maximal hyperemia."
1858927|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral once daily for 5 days
1858928|NCT01014962|Drug|Placebo|Placebo oral once daily for 5 days
1858929|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg every 12 hours for 5 days
1858930|NCT01014962|Drug|Placebo|Placebo oral every 12 hours for 5 days
1858931|NCT01014962|Drug|Albaconozole|Albaconozole 400 mg oral every 8 hours for 5 days
1858932|NCT01014962|Drug|Placebo|Placebo oral every 8 hours for 5 days
1858933|NCT01016275|Device|Misago (stent placement)|Misago iliac stent
1858934|NCT01016301|Other|Pharmacist service|Medication Review, medication report
1858935|NCT01016314|Device|Aspen Spinous Process System|Aspen Spinous Process System is an interspinous process fixation device
1858936|NCT01016314|Device|Pedicle Screw Fixation|Pedicle Screws are used for the fixation of the spine
1858937|NCT01016327|Drug|NMS-1116354|Oral daily administration for 7 consecutive days every 14 days
1858938|NCT01016340|Drug|MCS|MCS-5 Softgel 5 mg
1858939|NCT01016366|Drug|Lu AA24493|Vials with solution for i.v. injection. 325mcg Lu AA24493 dosed 3 times per week for two weeks. Vials will be supplied in concentrations ready for injection.
1858940|NCT01016366|Drug|Placebo|Vials with solution for i.v. injection. Placebo dosed 3 times per week for two weeks.
1858941|NCT01016379|Genetic|DNA analysis|
1858942|NCT01016379|Other|biologic sample preservation procedure|
1858943|NCT01016379|Other|laboratory biomarker analysis|
1858944|NCT01016418|Dietary Supplement|Bovine colostrum powder|Study treatment will consist of BCP, three 1.2 g oral tablets (equivalent to 600 mg of BCP each) for 4 weeks, from cows immunized to insulin. Patients will be followed for safety monitoring for an additional 4 weeks.
1858945|NCT01016431|Other|Rate-adaptive pacemaker programming|The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
1858946|NCT01016431|Other|VVI at 40 bpm|ICDs will be programmed in VVI mode at 40 bpm
1858947|NCT01016457|Device|Guardian RT|The sensor is inserted similarly to the insulin pump. It measures sub cutaneous glucose every 5 minutes. It alerts of high and low glucose levels, according to set limits.
1858948|NCT01016470|Dietary Supplement|VIUSID/ALZER|VIUSID/ALZER, 3 per day, oral, one year
1858954|NCT01016496|Other|repetition of gestures|15 consecutive session of visual games, plus repetition of gestures
1858955|NCT01016509|Drug|Insulin|Insulin infusion will be started when blood glucose levels exceeded 140 mg/dl and adjusted to maintain glycemia at 80-140 mg/dl. During insulin infusion, oral feeding will be stopped and parenteral nutrition (13±5 Kcal/kg-1/day-1) will be started. After the start of insulin infusion protocol a glycemic control will be provided every hour in order to obtain three consecutive values that were within the goal range. The infusion will be lasted until stable glycemic goal (80-140 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI. The treatment goal will be a fasting blood glucose level of 90-140 mg/dl and a non-fasting level of <180 mg/dl.
1858956|NCT01016509|Drug|Insulin|Continuous insulin infusion of 50 IU Actrapid HM (Novo Nordisk) in 50 ml NaCl (0.9% using a Perfusor-FM pump) will be started only when blood glucose levels exceeded 200 mg/dl and adjusted to keep blood glucose between 180 and 200 mg/dl. When blood glucose fell <180 mg/dl, insulin infusion will be tapered and eventually stopped.The infusion will be lasted until stable glycemic goal (180-200 mg/dl) at least for 24 h. After glycemic goal will be maintained for 24 h, a parenteral nutrition was stopped and feeding will be started according to European guidelines. Subcutaneous insulin will be initiated at the cessation of the infusion. After discharge from the hospital, insulin will be given as short-acting insulin before meals and long-acting insulin in the evening for 30 days from PCI in both group. The treatment goal will be fasting blood glucose and postprandial levels of <200 mg/dl.
1858957|NCT01016522|Dietary Supplement|KetoCal|Ketogenic Diet food via gastrostomy tube - 80% fat, 17% protein, 3% carbohydrates
1858958|NCT01016548|Biological|AS03-adjuvanted H1N1 pandemic influenza vaccine|One dose constitutes 0.5mL of suspended vaccine via the intramuscular route.
1858959|NCT01016561|Radiation|intracavitary balloon brachytherapy|
1858960|NCT01016561|Radiation|external beam radiation therapy|
1858961|NCT01016561|Radiation|intensity-modulated radiation therapy|
1858962|NCT01016561|Radiation|radiation therapy treatment planning/simulation|
1858963|NCT01016561|Radiation|3-dimensional conformal radiation therapy|
1858964|NCT01016561|Drug|Cisplatin|
1858965|NCT01016574|Device|Support Device for Prone radiation therapy (Giro-Couch)|Boost irradiation is applied to the ipsilateral breast in eight fractions of 2Gy/Fx
1858966|NCT01016600|Drug|Lenalidomide|
1858967|NCT01016600|Drug|Azacitidine|
1858968|NCT01016626|Drug|CKD-4101 tablet|"CKD-4101 tablet 1000 mg
500mg/tablet, PO, 2 tablet once daily for D1 and D8(crossover)"
1858969|NCT01016626|Drug|Mycophenolate Mofetil capsule|"Mycophenolate Mofetil capsule 1000 mg
250mg/capsule, PO, 4 capsule once daily for D1 and D8(crossover)"
1858970|NCT01016639|Other|oxaliplatin, capecitabine, radiotherapy|
1858971|NCT01016652|Device|etafilcon A multifocal contact lens|low-add multifocal contact lens
1858972|NCT01016652|Device|etafilcon A Contact Lens|standard sphere contact lens
1858973|NCT01016665|Drug|Anastrozole|Tamoxifen 20mg and anastrozole 1 mg
1858974|NCT01016678|Drug|Treximet|85mg Imitrex with 500mg Naproxen Sodium combination tablet for treatment of migraine headache. The adult dosage is 1 tab Q12H for migraine and no more than 2 tablets in a 24 hours period.
1858975|NCT01016678|Drug|Placebo|Dummy pill comparator
1858976|NCT01016691|Drug|High Dose Drug Device|device inserted for 4 days
1858977|NCT01016691|Drug|Low Dose Drug Device|device inserted for 4 days
1858978|NCT01016691|Drug|Placebo Device|device inserted for 4 days
1858979|NCT01016691|Drug|bimatoprost 0.03%|one drop in each eye on one day only
1858980|NCT01016704|Behavioral|Incentive|Participants assigned to the experimental condition are reinforced via monetary incentives for demonstrating superior delivery of an evidence treatment to clients
1858981|NCT01016717|Drug|Omeprazole|All patients will be taking omeprazole (Losec, Abic Inc., Israel) tablets 40 mg QD for 30 days
1858982|NCT01016717|Drug|Pantoprazole|Pantoprazole tablets (Controloc 40, 40 mg/day, Nycomed, Perrigo Inc., Israel). All patients will take pantoprazole tablets 40 mg QD for 30 days
1858986|NCT01016743|Device|repetitive transcranial stimulation (r-TMS)|Patients will be randomized into two groups: The first group of patients will receive an active unilateral stimulation over the motor cortex contralateral to the more affected body side (1Hz stimulation 110% of the MT for 15 minutes). Patients in the second group will receive a similar rTMS stimulation pattern over the motor cortex and over the prefrontal cortex (10Hz stimulation 100% of the MT, 2 seconds each train, 20 seconds between trains, for 15 minutes).
1858987|NCT01016769|Drug|Temsirolimus + Weekly Paclitaxel + Carboplatin|"Temsirolimus Per dose escalation scheme Level 1 (15 mg) 2 (20 mg) Level 3 (25 mg) IVPB 30 minutes weekly (3 weeks on, 1 week off) days 1 and 8.
Paclitaxel 80 mg/m2 IVPB 1 hour weekly (2 weeks on, 1 week off) days 1 and 8. Carboplatin AUC 1.5 IVPB 30 minutes days 1 and 8. On Day 15 of each cycle, patients begin the rest week."
1858988|NCT01016782|Drug|0444|A thin film of gel will be applied and rubbed into the entire face once daily for a period of 70 days
1858989|NCT01016795|Drug|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
1858990|NCT01016795|Drug|r-metHuSCF and Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
1859051|NCT01017237|Drug|Dexmedetomidine|Dexmedetomidine will be infused at a rate of 6 mcg/kg/hr for four minutes; resulting in a loading dose of 0.4 mcg/kg, Followed by an infusion of 0.5 mcg/kg/hr will be initiated and continued until the completion of surgery.
1858991|NCT01016795|Drug|Chemotherapy plus Filgrastim|Patients were randomized in a 1:1 ratio to either chemotherapy combined with 10 µg/kg/d Filgrastim (control arm B), administered by subcutaneous injection for 14 days, or the combination of 10 µg/kg/d Filgrastim and SCF administered subcutaneously at a dose of 20 µg/kg/d (experimental arm A) for 8 days. Different injection sites were used for each cytokine.
1858992|NCT01016808|Drug|Q8003|Q8003 is a combination of morphine sulfate and oxycodone HCl
1858993|NCT01016808|Drug|Morphine sulfate|One morphine sulfate 12 mg IR capsule q6h
1858994|NCT01016808|Drug|Oxycodone HCl|One oxycodone HCl 8 mg IR Capsule q6h
1858995|NCT01016821|Drug|Oxycodone|Intravenous, 1 mg, 5 times, in every 5 minutes, duration of drug administration 25 minutes
1858996|NCT01016834|Device|Sumavel DosePro|Needle free delivery system containing 0.5 mL of solution of 6 mg sumatriptan, subcutaneous administration
1858997|NCT01016834|Drug|Sumatriptan|subcutaneous injection, 6 mg, per migraine attack, no more than two administrations within a 24 hr period
1858998|NCT01016847|Drug|Montelukast|10 mg Q day
1858999|NCT01016847|Other|Sugar pill|Sugar pill that looks like Montelukast that will be given Q day
1859000|NCT01016860|Drug|OSI-906|OSI-906 will be given orally in tablets for one dose starting on Cycle 1 Day-3 then on Cycle 1 Day 2-4, 8-10 and 15-17. Cycle is 21 days. Subsequent cycles, dosing will start be Day 1-3, 8-10 and 15-17
1859001|NCT01016860|Drug|irinotecan|Irinotecan will be administered IV over 90 minutes on Day 1 and 8 of a 21-day cycle
1859002|NCT01016873|Device|IRay|Low voltage stereotactic radiotherapy system
1859003|NCT01016886|Drug|perindopril OR bisoprolol OR placebo|"perindopril- oral daily titrated does from 2mg up to 8mg
bisoprolol- oral daily titrated dose from 2.5mg up to 10mg"
1859004|NCT01016899|Radiation|electronic brachytherapy|Post market observational study recording data form patients with skin cancer treated with electronic brachytherapy. Treatment is standard of care, and can vary in dose and fractionation schedule from patient to patient depending on radiation oncologist's judgement for best treatment for the patient.
1859005|NCT01016912|Drug|BMS-790052|Tablets, Oral, 10 mg, daily, 24-48 weeks
1859006|NCT01016912|Drug|BMS-790052|Tablets, Oral, 60 mg, daily, 24-48 weeks
1859007|NCT01016912|Drug|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
1859008|NCT01016912|Drug|Peginterferon alfa-2b|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
1859009|NCT01016912|Drug|Ribavirin|Capsules, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
1859010|NCT01016925|Procedure|tunnelized perineural catheter|the catheter will be tunneled 2-3 cm subcutaneously.
1859011|NCT01016951|Drug|AZD9164 Turbuhaler®|"Dry powder for inhalation via Turbuhaler, MAD. Starting dose in healthy volunteers is 400 µg with up to two dose escalations not exceeding AstraZeneca pre-defined exposure limits.
The COPD patients will receive a dose of 1000 µg."
1859012|NCT01016951|Drug|Placebo Turbuhaler®|Dry powder for inhalation via Turbuhaler, MAD
1859013|NCT01016964|Device|HairMax LaserComb 2009 model 12 beam|HairMax LaserComb
1859014|NCT01016964|Device|Sham Device|Sham Device
1859015|NCT01016977|Drug|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene|Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
1859016|NCT01016977|Drug|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene|clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene
1859017|NCT01016990|Drug|valproic acid|
1859018|NCT01016990|Genetic|western blotting|
1859019|NCT01016990|Other|laboratory biomarker analysis|
1859020|NCT01016990|Other|pharmacological study|
1859021|NCT01017003|Drug|colchicine tablets|0.6mg colchicine tablet
1859022|NCT01017003|Drug|colchicine tablets|0.6mg q12 hours for 10 days
1859023|NCT01017029|Drug|Everolimus|
1859024|NCT01017029|Drug|Mycophenolate mofetil + Everolimus|
1859025|NCT01017042|Drug|colchicine tablets|colchicine 1.2mg initially; then an additional 0.6mg orally 1 hour later (1.8mg over 2 hours)
1859026|NCT01017055|Other|Voice and Swallowing evaluations|Fiberoptic exam to evaluate vocal cord and swallowing function
1859027|NCT01017068|Drug|OME|4g/100ml) dose: п gutt tid x 1/52
1859028|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
1859029|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
1859030|NCT01017068|Drug|OME|(4g/100ml) dose: п gutt tid x 1/52
1859031|NCT01017068|Drug|OME|(2g/100ml) dose: п gutt tid x 1/52
1859032|NCT01017068|Drug|OME|(1g/100ml) dose: п gutt tid x 1/52
1859033|NCT01017081|Other|Physiotherapy|Physiotherapy: three times per day, for 10 to 12 minutes, during hospital admission
1859034|NCT01017081|Other|Positioning and cough|Non-mandatory request to maintain lateral positioning to improve air exchange and cough
1859035|NCT01017094|Drug|silversulfadiazine|apply once a day
1859036|NCT01017107|Drug|Activated protein C|24 micrograms/kg/hour intravenously for 96 hours
1859037|NCT01017120|Drug|Tazarotene Foam|Tazarotene foam once a day application to the face
1859038|NCT01017120|Drug|Vehicle Foam|Vehicle Foam once a day application to the face
1859039|NCT01017133|Radiation|fludeoxyglucose F 18|Given IV
1859040|NCT01017133|Radiation|Fluorine F 18 EF5|Given IV
1859041|NCT01017133|Procedure|Positron emission tomography|Undergo scan
1859042|NCT01017146|Drug|Tazarotene foam|Tazarotene foam once a day application to the face
1859043|NCT01017146|Drug|Vehicle Foam|Vehicle Foam once a day application to the face
1859044|NCT01017159|Drug|Subcutaneous immunoglobulin|The subcutaneous immunoglobulin is infused in the subcutaneous tissue on the abdomen twice or thrice a week, with a maximal speed of 2 mL/h. Every time 20 mL is infused, the needle is removed to a new place.
1859045|NCT01017172|Other|serologic testing|Serologic testing will be performed baseline, day 21 and day 42
1859046|NCT01017185|Drug|HF10|
1859047|NCT01017198|Drug|BIIB021 and Food|Assessing the effect of food use on BIIB021
1859048|NCT01017198|Drug|BIIB0121 and Antacid|Assessing the effect of antacid use on BIIB021
1859049|NCT01017211|Other|auricular acupuncture|"Experimental group to receive ear needles in the Battlefield Acupuncture points.
Sham group to receive ear needles at points thought to be ineffective but standardized."
1859050|NCT01017224|Other|18F-FAZA|PET scan
1859052|NCT01017237|Drug|Midazolam|Midazolam 0.04 mg/kg i.v. administered after dexmedetomidine loading dose.
1859053|NCT01017237|Drug|Ketamine|Ketamine 0.25 mg/ml administered i.v. following the dexmedetomidine loading dose and the midazolam.
1859054|NCT01017250|Radiation|Stereotactic Radiosurgery (SRS)|Tumor Volume < 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
1859055|NCT01017250|Drug|Bevacizumab|Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS
1859056|NCT01017263|Drug|Lis-dexamphetamine|Eligible subjects will be dispensed open label LDX (VyvanseTM). All subjects will start at 20 mg once a day dose and will be titrated up weekly by 10 mg increments up to a maximum dose of 70 mg. If a subject experiences intolerable side effects at a particular dose, a step down to the next tolerated level is allowed.
1859057|NCT01017276|Drug|ASP1585|oral
1859058|NCT01017289|Device|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
1859059|NCT01017302|Drug|Placebo|Subcutenaous once weekly for 4 weeks
1859060|NCT01017302|Drug|Placebo|Single subcutaneous dose in week 5
1859061|NCT01017302|Drug|RO5095932|Escalating subcutaneous doses once weekly over a 4 weeks period
1859062|NCT01017302|Drug|RO5095932|Single subcutenaous dose in week 5
1859063|NCT01017315|Drug|Baby talcum|50 grams apply locally prior cast application
1859064|NCT01017341|Device|PSU hip protector|hip protetor
1859065|NCT01017354|Drug|Hidroferol® (ES)|24000 IU vitamin D3 orally and once per month plus 300 mcg 25(OH)D orally and once per month
1859066|NCT01017354|Dietary Supplement|ViDe3 (CH)|60000 vitamin D3 orally and once per month
1859067|NCT01017354|Dietary Supplement|ViDe3 (CH)|24000 Vitamin D3 orally and once per month
1859068|NCT01017367|Drug|MDX-1100|MDX-1100 10 mg/kg i.v. over 60 minutes on days 1, 15, 29, 43, 57 and 71
1859069|NCT01017367|Drug|Placebo|Placebo
1859070|NCT01017380|Drug|Celecoxib|celecoxib 400 mg 1 cap before surgery
1859071|NCT01017380|Drug|etoricoxib|120 mg 1 tab before surgery
1859072|NCT01017393|Drug|Ketamine|
1859073|NCT01017393|Drug|ketamine free|
1859074|NCT01017406|Device|PSU heel cushion and plantar fascia specific stretching exercise|"Wear heel cushion during daily activity
Plantar fascia stretching exercise 3 times per day"
1859075|NCT01017419|Behavioral|Counseling|Informational Counseling provided after hearing aid fitting
1859076|NCT01017445|Other|Boonme stick exercise|individual exercise daily
1859077|NCT01017458|Drug|MK0773|Three 25mg oral tablets MK0773 bid, for 12 weeks
1859078|NCT01017458|Drug|Comparator: testosterone enanthate|intramuscular injection 200mg testosterone enanthate q14d, for 12 weeks
1859079|NCT01017458|Drug|Comparator: placebo oral tablet|placebo oral tablet bid, for 12 weeks
1859080|NCT01017458|Drug|Comparator: placebo injection|placebo intramuscular injection q14d, for 12 weeks
1859081|NCT01017471|Procedure|Limited incision using PSU retractor|carpal tunnel release using limited incision with PSU retractor will be done by orthopaedic hand surgeons
1859082|NCT01017484|Other|DASH, Control|controlled feeding of either the DASH dietary pattern or a typical American diet at isocaloric level.
1859083|NCT01017497|Radiation|Stereotactic Radiosurgery|PTV Diameter < 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
1859084|NCT01017510|Device|Subcutaneous injection luer syringe|"Right scalp: Luer syringe.
Left scalp: syringe without a needle.
All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.
The distance between injection locations will be 1 cm."
1859085|NCT01017510|Device|DERMOJET (a syringe without a needle)|"Right scalp: Luer syringe.
Left scalp: syringe without a needle.
All injections will contain 0.1 ml of Depo Medrol - Methylprednisolone acetate 40 mg/2 ml.
The distance between injection locations will be 1 cm."
1859086|NCT01017523|Behavioral|Telephone support and behavior change|Diabetes self-management education provided over the telephone either for individual or couples
1859087|NCT01017523|Other|Diabetes self-management education|Limited diabetes self-management education provided over the telephone, serves as an enhanced usual care control intervention
1859088|NCT01017536|Biological|AERAS-402|AERAS-402 is a replication-deficient serotype 35 adenovirus containing DNA that expresses a fusion protein of three Mycobacterium tuberculosis (Mtb) antigens: 85A, 85B and TB10.4.
1859089|NCT01017536|Biological|Placebo|Placebo was the identical buffer solution in which AERAS-402 is formulated.
1859090|NCT01017549|Radiation|Electronic brachytherapy (Axxent System)|3.4 Gy per fraction for 10 fractions for a total of 34 Gy.
1859091|NCT01017575|Drug|Daclatasvir|Tablets, Oral, 10 mg, daily, 24-48 weeks
1859092|NCT01017575|Drug|Daclatasvir|Tablets, Oral, 60 mg, daily, 24-48 weeks
1859093|NCT01017575|Drug|Placebo|Tablets, Oral, 0 mg, daily, 48 weeks
1859094|NCT01017575|Drug|Peginterferon alfa-2a|Syringe, Subcutaneous, 180µg, weekly, 24-48 weeks
1859095|NCT01017575|Drug|Ribavirin|Tablets, Oral, 600 to 1000 mg based on weight, daily, 24-48 weeks
1859096|NCT01017588|Device|PSU lumbar back support|wear PSU back supprt during doing rubber tapper
1859097|NCT01017601|Biological|Seneca Valley virus-001|Given IV
1859098|NCT01017601|Other|placebo|Given IV
1859099|NCT01017614|Drug|Monofer|"administered as intravenous infusions (A1)repeated weekly until total iron repletion is obtained
administered as intravenous bolus injections (A2)as repeated bolus injections weekly until total iron repletion is obtained"
1859100|NCT01017614|Drug|Iron Sulphate|200 mg daily
1859101|NCT01017627|Other|Early anemia diagnosis and treatment|Patients returning to the unit are immediately assessed and treated for anemia
1859102|NCT01017627|Other|No change from normal routine|Normal unit policy for labs and anemia treatment
1859103|NCT01017640|Other|Laboratory Biomarker Analysis|Correlative studies
1859104|NCT01017640|Drug|Mitomycin|Given IV
1859105|NCT01017640|Drug|Veliparib|Given PO
1859106|NCT01017653|Drug|Irinotecan|Irinotecan: for those patients on an enzyme-inducing anti-epileptic drug (EIAED), irinotecan will be dosed at 340 mg/m2 every other week. For those not on an EIAED, irinotecan will be dosed at 125 mg/m2. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
1859107|NCT01017653|Drug|Panitumumab|Panitumumab, 6 mg/kg, as an intravenous infusion every other week. Treatment on both drugs will continue until tumor progression or unacceptable toxicity.
1859108|NCT01017666|Drug|BIIB014|BIIB014 100mg PO Cohort 1 - 8d Cohort 2 - 14d
1859109|NCT01017666|Drug|Placebo|Matched placebo to BIIB014 Cohort 1 - 8d Cohort 2 - 14d
1859110|NCT01017679|Drug|Gefitinib 500mg/Gefitinib 250mg|Gefitinib 500mg or 250mg is Taken Orally everyday by Experimental and controlled Arms respectively
1859111|NCT01017692|Procedure|MRI|MRI of lumbar spine for subjects presenting with spinal stenosis symptoms
1859112|NCT01017731|Biological|IMC-1121B|IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
1859113|NCT01017731|Drug|Moxifloxacin|Administered orally
1859114|NCT01017731|Drug|Diphenhydramine|Administered IV
1859115|NCT01017744|Device|Anesthetic Conserving Device|"Ventilation in PSV with the Anesthetic Conserving Device with remifentanil
Ventilation in PSV with the Anesthetic Conserving Device with sevoflurane"
1859116|NCT01017757|Procedure|High-resolution CT scanning|High-resolution CT scanning
1859117|NCT01017770|Drug|Artesunate-amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
1859118|NCT01017770|Drug|Artemether-lumefantrine|Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
1859119|NCT01017783|Behavioral|Dietary substitution A|Substitution of calorie-dense item with lower calorie choice A
1859120|NCT01017783|Behavioral|Dietary Substitution B|Substitution of calorie-dense item with lower calorie option B
1859121|NCT01017783|Behavioral|Healthy Choices|Multiple healthy choices presented with self-selection of choices used
1859122|NCT01017796|Drug|N-acetylcysteine and ascorbic acid|1200mg acetylcysteine and 2g ascorbic acid in 200 ml 0,9% normal saline at least 2 hours before the start of the index procedure, followed by 1200mg acetylcysteine and 1,5g ascorbic acid the night and the morning after the examination.
1859123|NCT01017809|Drug|Aprepitant|Cycle 1, day 2 to 17: Emend 80mg once daily in the morning on days 2 through 17 Cycles 2-6 (optional extension arm): same Emend dosing
1859124|NCT01017822|Biological|conatumumab|
1859125|NCT01017822|Drug|capecitabine|
1859126|NCT01017822|Drug|gemcitabine hydrochloride|
1859127|NCT01017822|Radiation|3-dimensional conformal radiation therapy|
1859128|NCT01017874|Drug|Pemetrexed|500 milligrams per square meter (mg/m²) administered intravenously on Day 1 of each 21-day cycle, for 6 cycles.
1859129|NCT01017874|Drug|Cisplatin|75 mg/m² administered intravenously on Day 1 of each 21-day cycle, for 6 cycles
1859130|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycle, for maintenance in participants with non-progressive disease after cisplatin/pemetrexed chemotherapy
1859131|NCT01017874|Drug|Gefitinib|250 milligrams (mg) administered orally once a day, every day of 21-day cycles administered as a monotherapy
1859132|NCT01017887|Device|Airseal access port for laparoscopic surgery|The investigators will utilize this access port that is already approved by the FDA for it's intended use in laparoscopic surgery. The investigators are simply measuring the percentage of carbon dioxide in the peritoneal cavity.
1859133|NCT01017887|Device|Standard Laparoscopy ports|Prospective monitoring of CO2 levels during laparoscopic surgery with standard access ports.
1859134|NCT01017900|Procedure|local excision|surgical excision by orthopaedic surgeon under local anesthesia
1859135|NCT01017913|Other|TENS|The TENS equipment was calibrated on 20 hertz frequency, and a pulse width of 330 ms (standing in control number seven) with two channels.
1859136|NCT01017913|Other|Interferential currents|The IFC was adjusted to a base frequency of 4000 Hz, with a modulation frequency range of 20 Hz, ∆F of 10 Hz and slope of 1/1, in quadripolar mode.
1859137|NCT01017926|Drug|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
1859138|NCT01017926|Drug|Triazolam|Tablets, 0.25 mg, single-dose, 1 period of 3 three days.
1859139|NCT01017939|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg tablets administered orally once daily beginning on Cycle 1 Day 1 up to the time of disease progression
1859140|NCT01017939|Drug|Prednisone|Prednisone 5mg tablets administered orally twice daily beginning on Cycle 1 Day 1 up to the time of disease progression
1859141|NCT01017939|Drug|Dextromethorphan hydrobromide|Dextromethorphan hydrobromide 30 mg capsules administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
1859142|NCT01017939|Drug|Theophylline|Theophylline 100 mg tablets administered orally on Cycle 1 Day -8 and Cycle 1 Day 8 under fasting conditions
1859143|NCT01017952|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
1859144|NCT01017952|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA) Inhalation Powder
1859145|NCT01017965|Device|Actimeter + blood pressure monitoring|Patients will receive an actimeter that they will wear for 3 days and an ambulatory blood pressure monitoring device that they will keep for 24 hours.
1859146|NCT01017978|Procedure|MRI Scan of soft tissue tumor|MRI scan will be completed at baseline (prior to start of subject's clinically ordered chemotherapy treatments.
1859147|NCT01017991|Other|Milk based infant formula with probiotic|formula supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days duration
1859148|NCT01017991|Other|Milk based infant formula|supplied as a powder to be constituted as commercially available formula ad libitum daily 28 days
1859149|NCT01018004|Other|follow-up care|
1859150|NCT01018004|Other|questionnaire administration|
1859151|NCT01018004|Procedure|quality-of-life assessment|
1994496|NCT02991469|Drug|Sarilumab SAR153191 (REGN88)|"Pharmaceutical form: Solution
Route of administration: Subcutaneous"
1859154|NCT01018030|Drug|FFNS 110 mcg QD|Active Nasal Spray (AM) and Placebo Nasal Spray (PM)
1859329|NCT01010100|Drug|Acarbose (Glucobay, BAYG5421)|50 mg TID
1859156|NCT01018030|Drug|Placebo Nasal Spray|Placebo Nasal Spray (AM) and Placebo Nasal Spray (PM)
1859157|NCT01018043|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
1859158|NCT01018056|Drug|D-serine|The dosage schedule will be flexible with a maximum dose for each subject being 30 mg/kg/day. In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of capsules labeled as study drug, but containing either 250 or 500 mg tablets of D-serine or placebo; capsule content to be determined by patient's weight. No changes in dosage will be made during the final week of treatment.
1859159|NCT01018056|Drug|Riluzole|The starting dose of riluzole will be 50 mg for one week; administered as one capsule (50) every morning. Dosage schedules will be flexible. If needed for tic suppression, the dose will be increased weekly by 50 mg and given in BID doses. The maximum dose will be 200 mg/day (administered as 2 capsules BID). In any individual subject, dose escalation may proceed more slowly, or the dose may be reduced if necessary. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing placebo capsules. No changes in dosage will be made during the final week of treatment.
1859160|NCT01018056|Drug|Placebo|Placebo tablets will be formulated in look-alike capsules. At the 4 week visit, if an additional dosage increase is prescribed by Dr Singer, the pharmacy will provide an additional vial of 14 capsules labeled as study drug, but containing additional placebo capsules.
1859161|NCT01018069|Drug|AEG35156|2 hr infusion of 650 mg of AEG35156 on days 1, 2, 3 and 8. Idarubicin 12 mg/m2 over 30 minutes daily on each of days 4, 5 and 6. The dose of cytarabine will be 1.5 g/m2 daily by continuous infusion x 4 days (days 4-7) in patients under age 65 and x 3 days (days 4-6) in patients age 65 and above.
1859162|NCT01018095|Drug|Metronidazole|2 gm single dose versus 7 day 500 mg BID dose
1859163|NCT01018108|Procedure|Single Photon Emission Computed Tomography|Undergo single photon emission computed tomographt imaging
1859164|NCT01018108|Procedure|Acupuncture Therapy|Undergo acupuncture
1859165|NCT01018108|Other|Questionnaire Administration|Ancillary study
1859166|NCT01018108|Other|Laboratory Biomarker Analysis|Correlative Study
1859167|NCT01018121|Behavioral|LAUNCH|A 6-month intervention consisting of two phases: Phase I (Intensive Intervention), 12 weekly sessions that alternated between group-based clinic sessions (parent and child concurrent groups) and individual home visits and Phase II (Maintenance), 12 weeks of every other week sessions, alternating between group sessions in-clinic and home sessions. Targeted 3 components: 1) Dietary education with age-specific caloric targets, healthy eating recommendations for children following the AAP guidelines used in the PC session; 2) Physical Activity education with age-specific activities for children and families; and 3) Parenting skills to achieve the diet and physical activity goals using behavioral management skills and parent modeling of eating and activity.
1859168|NCT01018121|Other|Pediatrician Counseling|A one time 45-minute visit with a board certified pediatrician for each family that focused on the AAP guidelines for eating and physical activity for children
1859169|NCT01018134|Drug|Desoximetasone 0.05% once daily|Desoximetasone topical spray 0.05% administered to affected area once daily for 28 days
1859170|NCT01018134|Drug|Desoximetasone 0.05% twice daily|Desoximetasone topical spray 0.05% administered to affected area twice daily for 28 days
1859171|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected area once daily for 28 days
1859172|NCT01018134|Drug|Desoximetasone 0.25% once daily|Desoximetasone topical spray 0.25% administered to affected areas twice daily for 28 days
1859173|NCT01018134|Drug|Vehicle once daily|Vehicle topical spray administered to affected areas once daily for 28 days
1859174|NCT01018134|Drug|Vehicle twice daily|Vehicle topical spray administered to affected areas twice daily for 28 days
1859175|NCT01018147|Procedure|4-dimensional computed tomography|Undergo 4-D CT imaging
1859176|NCT01018160|Drug|Rabeprazole Sodium|10mg - 20mg tablet once or twice daily for 12 weeks
1859177|NCT01018173|Drug|placebo|sc weekly
1859178|NCT01018173|Drug|taspoglutide|10 mg sc weekly for 4 weeks, followed by 20 mg sc weekly
1859179|NCT01018186|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
1859180|NCT01018186|Drug|Fluticasone propionate|Inhaled corticosteroid
1859181|NCT01018199|Other|CRP|C-reactive protein guided antibiotic therapy plasma CRP measurement to guide the duration of antibiotic therapy
1859182|NCT01018199|Other|PCT|Procalcitonin guided antibiotic therapy plasma PCT measurement to guide the duration of antibiotic therapy
1859183|NCT01018212|Other|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the lesions auto administration three times a day during four months, being controlled by the specialist in months consultations.
The dose of 0,1 ml of cream for each cm. of surface, To the patient will be explained the technique of the application."
1859184|NCT01018225|Drug|darifenacin|7.5 or 15 mg darifenacin, once a day for 6 weeks
1859185|NCT01018225|Drug|Placebo|Placebo pill, once a day, for six weeks
1859186|NCT01018238|Drug|NNC 0151-0000-0000|Multiple doses in the range of 0.05mg/kg to 0.30mg/kg administered subcutaneously (under the skin)
1859187|NCT01018238|Drug|placebo|Multiple doses of placebo (no active ingredients) administered subcutaneously (under the skin)
1859188|NCT01018251|Other|3'-deoxy-3'-[18F]fluorothymidine|Given IV
1859189|NCT01018251|Procedure|Positron Emission Tomography/computed tomography|
1859190|NCT01018251|Radiation|FLT-PET/CT|
1859191|NCT01018264|Drug|solifenacin succinate (VESIcare)|up to 10mg every day orally
1859192|NCT01018264|Drug|placebo|placebo matching solifenacin succinate (VESIcare) up to 10mg orally every day
1859193|NCT01018277|Other|Mobilization (walking)|25 meters twice
1859194|NCT01018303|Dietary Supplement|AquADEK|Two AquADEK softgel vitamins on a daily basis x 12 weeks
1859195|NCT01018329|Procedure|Magnetic Resonance Imaging|
1859196|NCT01018329|Procedure|Diffusion Tensor Imaging|
1859197|NCT01018329|Procedure|Magnetic Resonance Spectroscopic Imaging|
1859198|NCT01018329|Procedure|Dynamic Contract-Enhanced magnetic resonance imaging|
1859199|NCT01018329|Procedure|Diffusion-weighted magnetic resonance imaging|
1859200|NCT01018342|Drug|Nitrofurantoin Monohydrate/Macrocrystals Capsules 100 mg|
1859201|NCT01018342|Drug|Macrobid® Capsules 100 mg|
1859202|NCT01018355|Device|Percutaneous device closure of patent foramen ovale|Percutaneous device closure of patent foramen ovale
1859203|NCT01018368|Drug|VX-770|In Period 1, subjects will receive a single oral dose of VX-770 150 mg on Day 1. In Period 2, subjects will receive a single oral dose of VX-770 150 mg on Day 6.
1859204|NCT01018368|Drug|Rifampin|In Period 2, subjects will receive a daily oral dose of rifampin 600 mg on Days 1 through 10
1859205|NCT01018381|Procedure|PEIT|"For patients with HCC: Ethanol (99.5%) 3-15 ml/treatment(mean 8ml/treatment) , 2 times/week (mean 6 treatment/patient). For patients with a tumor size under 5 cm in diameter, we applied the formula of M. Ebara: V = 4/3∏ (r+0.5)3 (V: total Ethanol volume, r: radius of tumor).
Precise treatment was dependent on tumor size, outcomes after first PEIT treatment and time to recurrence of disease."
1859206|NCT01018381|Procedure|TOCE|For patients with HCC: Adriamycine was mixed with lipiodol, Adriamycine 20-60mg/treatment (mean 40mg/treatment),lipiodol 5-20ml/treatment(mean 12ml/treatment), 1-2 months between treatments, 2-5 treatments/patient (mean 3 times/patient), which depended on tumor size, outcomes after first TOCE and time to recurrence of disease.
1859207|NCT01018381|Procedure|TOCE plus PEIT|A combination of transarterial oily chemoembolization and pericutaneous ethanol injection therapy are given for patients with HCC.
1859208|NCT01018381|Procedure|TOCE plus RFA|For patients with HCC: A combination of transarterial oily chemoembolization plus radiofrequency ablation is given. For RFA: On mission 60w/s , 5minutes/circle, 2-4 circles/treatment, 1-2 treatments/week (tumor size under 2cm: 1 treatment; 2-4 cm: 2-3 treatments,over 4 cm: 3-5 treatments)
1859209|NCT01018381|Dietary Supplement|MGN-3|For patients with HCC or hepatitis B, arabinoxylan rice bran food supplement is given. 1 gram per day, every day, for a duration of 12 months. For the MGN-3 group, the interventional therapy was given with MGN-3 simultaneously.
1859210|NCT01018381|Drug|Entecavir|For patients with hepatitis B viral infection, a dose of 0.5mg/day, every day, was given for a duration of 24 months.
1859211|NCT01018394|Drug|nicotine lozenges|4 mg nicotine lozenges for a maximum duration of 12 weeks used ad lib - up to 8 nicotine lozenges per day.
1859212|NCT01018394|Drug|tobacco-free snuff|Tobacco-free snuff used ad lib for a maximum of 12 weeks
1859213|NCT01018407|Behavioral|Discrete Trial Training|"UCLA model, developed by Lovaas and colleagues (Smith, Groen & Wynn, 2000). Two 30-minute sessions daily (5 hours/week) of 1:1 intervention focusing on imitation, match-to-sample, receptive and expressive language. Using operant conditioning, the therapist works individually with a child in a distraction-free setting and administers approximately 10 trials in a sitting, with breaks between sittings.
During months 5 and 6, we will provide parents with training in an apprenticeship format one day per week for an hour per day. The clinician will demonstrate a DTT instructional program, then the parent will take a turn implementing it. The clinician and parent will give each other feedback on their implementation of the program."
1859214|NCT01018407|Behavioral|Interpersonal Developmental Approach|"Focus on teaching joint attention and symbolic play developmentally via floor play milieu teaching approach. Principles applied include following the child's lead and interest in activities, talking about what the child is doing, repeating back what the child says, expanding on what child says, giving corrective feedback, sitting close to the child and making eye-contact, and making environmental adjustments to engage the child (Kasari et al., 2006).
Parents will be incorporated into the treatment to encourage joint engagement with their child and to focus specifically on joint attention and play skills in their interactions. Each home session will last one hour (once a week) during month 5 and 6 and will involve therapist modeling, and coaching of parent in child-directed activities."
1859215|NCT01018420|Drug|Colchicine|two 0.6 mg capsules (1.2 mg dose) followed by an additional 0.6mg capsule every hour for 6 additional doses
1859216|NCT01018420|Drug|Moxifloxacin|400 mg capsule at the 6 hour point
1859217|NCT01018433|Behavioral|T-SIB|Treatment for self-injurious behaviors; study psychotherapy
1859218|NCT01018433|Other|Treatment as usual|Can include other psychotherapy and pharmacotherapy
1859219|NCT01018446|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
1859220|NCT01018459|Biological|Ad35.CS.01 Circumsporozoite Malaria Vaccine|Ad35.CS.01 appears clear to slightly opalescent with no visible particles. Each 0.75 mL dose of the assigned dosage will be administered via intramuscular injection into the deltoid muscle. Dosages: 10^9 viral particles (vp)/mL, 10^10 vp/mL, 5 x 10^10 vp/mL, and 10^11 vp/mL.
1859221|NCT01018459|Drug|Placebo|Normal saline placebo control delivered via intramuscular injection into the deltoid muscle.
1859222|NCT01018472|Dietary Supplement|Bifidobacterium infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 4 months
1859223|NCT01018472|Other|Placebo|A dilute preparation of pregestimil formula (similar in appearance to the probiotic product)
1859224|NCT01018485|Drug|Botulinum Toxin Type A|Intramuscular injection in affected limb up to 100 Units. Two doses (one placebo, one active) 3 months apart.
1859225|NCT01018498|Behavioral|Restricted FODMAPs diet|Restricted fermentable substrate diet
1859226|NCT01018511|Drug|Placebo tamsulosin hydrochloride OCAS 0.4 mg|tablet
1859227|NCT01018511|Drug|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/6 mg|tablet
1859228|NCT01018511|Drug|Placebo FDC tamsulosin hydrochloride/solifenacin succinate 0.4 mg/9 mg|tablet
1859229|NCT01018511|Drug|tamsulosin hydrochloride OCAS 0.4 mg|tablet
1859230|NCT01018511|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|tablet
1859231|NCT01018511|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|tablet
1859232|NCT01018524|Procedure|abdominal wall reconstruction|suture repair, mesh repair, onlay mesh reconstruction, sublay mesh reconstruction, recurrence rate
1859233|NCT01018550|Drug|AMG 853|AMG 853 5 mg (BID)
1859234|NCT01018550|Drug|AMG 853|AMG 853 200 mg (QD)
1859235|NCT01018550|Drug|AMG 853|AMG 853 25 mg (BID)
1859236|NCT01018550|Drug|AMG 853|AMG 853 100 mg (BID)
1859237|NCT01018550|Drug|Placebo|Placebo
1859238|NCT01018563|Drug|MORAb-003|Dose group to be determined by dose assigned in main study and patient's weight. Intravenous infusions are given every 3 weeks.
1859239|NCT01018576|Other|Delayed cord clamping|Infants will be covered with plastic and placed on a chemical warmer at delivery and then clamping of the umbilical cord will be delayed for 30-60 seconds.
1859240|NCT01018589|Other|Cicatrix cream|"We will be carried out the topical application of the product (Cicatrix cream) in the epidermic burns or post surgical scars by administration fo the patients twice a day during two months to a dose of 0,1 ml of cream for each cm of surface, being controlled by the specialist in biweekly consultations.
To the patient will be explained the technique of the application."
1859241|NCT01018602|Drug|vildagliptin|100 mg per day over 24 months
1859242|NCT01018602|Drug|inactive pill|1 pill per day over 24 months
1859243|NCT01018615|Drug|silymarin|capsules, 700 mg, twice daily, 12 days
1859244|NCT01018615|Dietary Supplement|green tea extract (EGCG)|capsules, 196.5 mg, twice daily, 12 days
1859245|NCT01018628|Drug|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 25 mg or 250 mg of SRT2379 free base equivalent (31 or 310 mg of SRT2379 monosuccinate) without any additive.
1859246|NCT01018628|Drug|Placebo|For placebo product, the SRT2379 drug substance will be replaced by Microcrystalline Cellulose (Avicel® PH 200) to match the SRT2379 investigational product.
1859247|NCT01018641|Biological|SA3Ag vaccine|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:
Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm
In stage 2 the subject will receive 0.5 mL IM of the same dose level he/she received in stage 1."
1859248|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
1859249|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
1859250|NCT01018641|Biological|SA3Ag followed by Placebo|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:
Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm
In stage 2 the subject will receive one injection of 0.5 mL IM of the placebo."
1859251|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
1859252|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
1859253|NCT01018641|Biological|Placebo|In both stage 1 and stage 2, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl for a total of 2 injections throughout the study.
1859254|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
1859255|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
1859256|NCT01018641|Biological|SA3Ag with no booster in stage 2|"In stage 1, each subject will receive 1 injection (0.5 mL) of one of the following doses:
Low dose level 10 μg of CP5 and CP8 and 20 μg of rClfAm Mid-dose level 30 μg of CP5 and CP8 and 60 μg of rClfAm High dose level 100 μg of CP5 and CP8 and 200 μg of rClfAm
In stage 2 the subject will receive no vaccine."
1859257|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
1859258|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
1859259|NCT01018641|Procedure|Placebo with no booster in stage 2|"In stage 1, recipients will receive one injection (0.5 mL) IM of 150 mM (isotonic) NaCl.
In stage 2 the subject will receive no vaccine."
1859260|NCT01018641|Procedure|Blood draw|Blood for immunogenicity will be taken at timepoints throughout stage 1 and stage 2. Blood for hematology will be done in a select subset of subjects in stage 1.
1859261|NCT01018641|Procedure|Colonization swab samples|Colonization swabs will be taken at timepoints throughout stage 1 and stage 2.
1859262|NCT01018654|Behavioral|Standard Cognitive Behavioral Treatment|Standard CBT for Substance Abuse
1859263|NCT01018654|Behavioral|Culturally Adapted Cognitive-Behavioral Treatment|Culturally Adapted CBT for Substance Abuse
1859264|NCT01018680|Drug|Duloxetine|30 milligrams (mg) taken by mouth, once daily for 1 week, followed by 60 to 120 mg taken by mouth, once daily for 9 weeks.
1859265|NCT01018680|Drug|Placebo|Taken by mouth, once daily for 10 weeks
1859266|NCT01018693|Drug|VAK694; Alutard Avanz SQ|
1859267|NCT01018693|Drug|VAK694 placebo infusion; Alutard Avanz SQ|
1859268|NCT01018693|Drug|VAK694 placebo infusion; Saline|
1859269|NCT01018719|Device|MDCT, ECG, Echocardiography|Multi-detector computed tomography to evaluate coronary artery patency; ECG and Echocardiography - to evaluate cardiac function.
1859270|NCT01018732|Biological|Novartis Meningococcal (MenACWY-CRM) vaccine|All subjects will have blood draws at Day 1, Day 8, and Day 29.
1859271|NCT01018745|Drug|BMS-907351 (XL184)|Capsules, Oral, 25, 50, 75, 100, 125 and 175 mg, Once daily, Until disease progression or unacceptable toxicity became apparent
1859272|NCT01018758|Drug|Palonosetron|Palonosetron will be given as an intravenous bolus at the dose of 250 micrograms over 30 seconds beginning 30 minutes before chemotherapy.
1859275|NCT01009697|Drug|Codeine Sulfate|15 mg, 30 mg, and 60 mg tablets
1859276|NCT01009736|Dietary Supplement|tomato-soy juice|
1859277|NCT01009736|Other|laboratory biomarker analysis|
1859278|NCT01009736|Other|pharmacological study|
1859279|NCT01009736|Procedure|therapeutic conventional surgery|
1859280|NCT01009749|Behavioral|Motivational Enhancement System for Adherence (MESA)|MESA is designed to increase motivation for adherence to Highly Active Antiretroviral Therapy (HAART) among youth newly recommended to begin medications.
1859281|NCT01009749|Behavioral|Motivational Enhancement System for Health (MESH)|Motivational Enhancement System for Health (MESH) is an attentional control providing information on nutrition and exercise.
1859330|NCT01010100|Drug|Placebo|50 mg TID
1859282|NCT01009762|Biological|peptide vaccine (AFO-18)|18 Peptides (250 ug of each peptide) in Adjuvant CAF01 (= 625/125 ug DDA/TDB), i.m. injection week 0, 2, 4, 8.
1859283|NCT01009775|Drug|YM155|intravenous infusion
1859284|NCT01009775|Drug|Docetaxel|intravenous infusion
1859285|NCT01009788|Drug|ABT-888|Capsules taken orally twice a day on days 1-7 of each 28 day cycle
1859286|NCT01009788|Drug|temozolomide|capsules taken orally once a day on days 1 through 5 of a 28 day cycle
1859287|NCT01009801|Drug|doxorubicin-eluting beads|Patients receive oral placebo or everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
1859288|NCT01009801|Drug|everolimus|Patients receive oral everolimus once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
1859289|NCT01009801|Other|placebo|Patients receive oral placebo once daily for up to 12 months and undergo TACE comprising doxorubicin-eluting beads as in phase I at the MTD.
1859290|NCT01009814|Drug|BMS-663068 with or without ritonavir|"8-day treatment with BMS-663068 with or without ritonavir
Group 1: BMS-663068 600 mg Q12H + ritonavir 100 mg Q12H
Group 2: BMS-663068 1200 mg QHS + ritonavir 100 mg QHS
Group 3: BMS-663068 1200 mg Q12H + ritonavir100 mg Q12H
Group 4: BMS-663068 1200 mg Q12H + ritonavir 100 mg QAM
Group 5: BMS-663068 1200 mg Q12H"
1859291|NCT01009827|Other|Observation|Participants will have biomedical information extracted from their medical chart, will complete the ACASI questionnaire and have a face-to-face post-ACASI debriefing interview administered. Participants who do not have a documented HIV-1 viral load and/or CD4+ T-cells count from within the previous six months will also have venipuncture performed to obtain a blood sample for these tests to be performed.
1859292|NCT01009840|Drug|IV busulfan|PK-directed dosing of IV busulfan for 4 days
1859293|NCT01009840|Drug|bortezomib|Single IV bortezomib at a dose of 1.3 mg/m^2.
1859294|NCT01009840|Procedure|Autologous Hematopoietic Stem Cell Transplant (HSCT)|
1859295|NCT01009853|Drug|Codeine Sulfate|15 mg tablet
1859296|NCT01009866|Biological|MR1-1|Based on preclinical toxicity studies, the starting total drug dose will be 0.5μg (500ng) which represents 1/20th of the MTD in rats. The infusion flow rate will be fixed at 0.5 mL/h from each of two catheters. A total of 96 mLs of drug solution will be delivered over 96 hours. MR1-1KDEL dose escalation will be accomplished by increasing drug concentration allowing flow rate and infusion volume to remain unchanged. Drug dose will be doubled in successive cohorts so long as DLTs are not observed as follows: 25 ng/mL (2.4 μg)(starting dose); 50ng/mL (4.8μg); 100 ng/mL (9.6μg); 200ng/mL (19.2μg); 400 ng/mL (38.4μg); 800 ng/mL (76.8μg); and 1600 ng/mL (153.6μg).
1859297|NCT01009879|Drug|Etanercept|Etanercept 50 mg SQ qweek
1859298|NCT01009892|Drug|Codeine Sulfate|Tablet
1859299|NCT01009905|Drug|somatropin|Safety and effectiveness data collection in connection with the use of Norditropin® (somatropin) in daily clinical practice
1859300|NCT01009918|Drug|Coreg CR®|Given orally
1859301|NCT01009918|Drug|lisinopril|Given orally
1859302|NCT01009918|Other|placebo|Given orally
1859303|NCT01009931|Drug|12-O-tetradecanoylphorbol-13-acetate|The initial dose of TPA will be 1 mg/week x 3 weeks (Day 1, 8, 15). Up to 6 cycles.
1859304|NCT01009931|Drug|Dexamethasone|Dexamethasone 10 mg PO qid will start 24h prior to TPA and continue for 24h after TPA x 3 weeks. Up to 6 cycles.
1859305|NCT01009931|Drug|Choline magnesium trisalicylate|"Choline magnesium trisalicylate 1500 mg PO TID will begin 24h prior to TPA and continue for 24h post TPA x 3 weeks.
Up to 6 cycles."
1859306|NCT01009944|Drug|Lisinopril, Atenolol|once a day for 14 weeks
1859307|NCT01009957|Drug|Everolimus|0.75 mg x 2 / day
1994564|NCT02974114|Other|Placebo|Placebo to match paracetamol 665mg sustained release tablets
1998201|NCT01595516|Drug|Nebivolol|5 mg tablet to be taken by mouth once per day for 12 weeks
1859313|NCT01009983|Biological|panitumumab|Given IV
1859314|NCT01009983|Drug|paclitaxel|Given IV
1859315|NCT01009983|Drug|carboplatin|Given IV
1859316|NCT01009983|Procedure|laboratory biomarker analysis|Correlative study
1859317|NCT01009983|Procedure|immunohistochemistry staining method|Correlative study
1859318|NCT01009996|Procedure|Kissing DEB|Provisional bare metal stenting followed by kissing drug-eluting balloons
1859319|NCT01010009|Dietary Supplement|Trans- resveratrol|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
1859320|NCT01010009|Other|Placebo (silica)|All 24 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 500mg resveratrol or placebo on separate days (with a 48hr-14day wash out period between each treatment) with the order dictated by a latin square. Treatment was administered in capsule form and in a double blind manner.
1859321|NCT01010022|Drug|6% hydroxyethyl starch 130/0.4|Up to 1000mL 6% hydroxyethyl starch 130/0.4 solution i.v., intra-operatively (from start of surgery until end of surgery)
1859322|NCT01010022|Drug|6% hydroxyethyl starch 70/0.5 (Salinhes®)|Up to 1000mL 6% hydroxyethyl starch 70/0.5 (Salinhes®) solution i.v., intra-operatively (from start of surgery until end of surgery)
1859323|NCT01010035|Other|Plasma kinetic study|this study is done with the injection of LDL-like nanoemulsion doubly labeled with 14C- cholesteryl oleate and 3H- cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood sample collected in a pre established period of time in 24 hours.
1859324|NCT01010048|Drug|progesterone,tamsulosin,propantheline Bromide and nifedipine|clearance rate of stone
1859325|NCT01010061|Drug|obinutuzumab|1000 mg obinutuzumab intravenous (IV) infusion, on Days 1 [first infusion split 100 mg on Day 1 and 900 mg on Day 2 as per protocol amendment], 8 and 15 in Cycle 1 and Day 1 in Cycles 2-6 (28-day cycles).
1859326|NCT01010061|Drug|rituximab|375 mg/m^2 rituximab intravenous (IV) infusion on Day 1 of Cycle 1 (Cycle duration is 28 days) then 500 mg/m^2 IV infusions on Day 1 of Cycles 2-6.
1859327|NCT01010061|Drug|chlorambucil|Chlorambucil 0.5 mg/kg orally on Day 1 and 15 of each 28-day cycle.
1859328|NCT01010087|Drug|Oseltamivir|standard (75 mg bid) or high-dose (225 mg bid) oseltamivir
1859331|NCT01010113|Other|Standard infant formula with prebiotics|From 0-6 months of age. As per standard requirement
1859332|NCT01010113|Other|Infant formula with synbiotics|From 0-6 months of age as per standard requirement
1859333|NCT01010126|Biological|Bevacizumab|Given IV
1859334|NCT01010126|Drug|Temsirolimus|Given IV
1859335|NCT01010139|Drug|Codeine Sulfate|15 mg, 30 mg and 60 mg Tablet
1859336|NCT01010152|Drug|Codeine Sulfate|30 mg Tablet
1859337|NCT01010178|Drug|Macrolid, Theophylline, Inhaler Corticosteroids|we have no permission to include them in detail because of privacy policy of mentioned journal for publication
1859338|NCT01010191|Other|Sugar pill|
1859339|NCT01010204|Drug|Varenicline (Chantix)|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
1859340|NCT01010204|Drug|Placebo|Patients will be randomly assigned to receive either varenicline or placebo for 12 weeks. Patients assigned to varenicline will receive 0.5mg by the oral route once a day for 3 days, followed by 0.5mg twice a day for 4 days. After the first week the dose will be increased to 1mg twice daily for the remainder of the active treatment period of the study, i.e. 11 weeks. Patients assigned to placebo will receive identical looking capsules in a dosage schedule similar to varenicline. Patients will be instructed to take study medication after meals with a glass of water.
1859351|NCT01010230|Device|LMHF mechanical stimulation active device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
1859352|NCT01010230|Device|LMHF mechanical stimulation placebo device|"Participants will be randomly assigned to stand on a low magnitude, high frequency mechanical stimulation device (vibrating) platform for 10 minutes twice daily for one year. The study hypothesizes participants in the intervention arm intervention will demonstrate improved total bone mineral content for height, spinal and tibial bone mineral density and tibial bone strength when compared to those who are randomized to the placebo intervention."
1859353|NCT01010243|Drug|Lenalidomide, Pioglitazone, dexamethasone, treosulfan|"Phase I:lenalidomide dose ( 5 mg or 10 mg or 15 mg) will be determined for phase II on the basis of DLTs in the first 4 weeks for the phase II part.
Start Phase I part: lenalidomide 10 mg p.o. daily + pioglitazone 60 mg p.o. daily + treosulfan 250 mg p.o. bid + dexamethasone initially 40 mg p.o. d1-4 and d15-18, then 20mg d1 and d15. dexamethasone 1 mg p.o. continuously within the intervals of pulsed dexamethasone therapy"
1859354|NCT01010269|Device|Vanguard Complete Knee|Vanguard Knee is a metal and polyethylene system indicated for cemented tibial and femoral use.
1859355|NCT01010269|Device|Vanguard High Flex RP|Vanguard High Flex RP is an extension to the existing Vanguard Knee and has been specifically designed to facilitate greater than 135 degrees of knee flexion.
1859356|NCT01010282|Drug|Glycerin and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
1859357|NCT01010282|Drug|Formulation 1: Carboxymethylcellulose sodium, glycerin and Polysorbate 80, based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
1859358|NCT01010282|Drug|Formulation 2: Carboxymethylcellulose sodium, glycerin, and Polysorbate 80 based artificial tear|1-2 drops in each eye, as needed, but at least twice daily
1859359|NCT01010295|Drug|doxycycline (tetracycline)|doxycycline 100 mg twice daily for 3 weeks
1859360|NCT01010308|Drug|Nadolol|Nadolol will be administered orally at home starting at 0.5 mg/kg/day divided into 2 doses. Weekly, if BP and heart rate are acceptable, the dose will be increased by 0.5 mg/kg/day up to 2 mg/kg/day.
1859361|NCT01010321|Device|confocal microscopy|non-invasive imaging
1859362|NCT01010334|Other|standard of care|All patients failing to enroll in a specific therapeutic research protocol using FDA approved drugs or CTMS accepted therapies will be screened for this study. Patients will be randomized (Patient own choice) to either standard of care described in the NCCN guidelines and published as peer-reviewed phase II or III studies which show an efficacy, OR to one of the arms of the protocol they failed to enroll in, as determined by the treating physician.
1859363|NCT01010347|Procedure|Volar Splint|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
1859364|NCT01010347|Procedure|Cast|A velcro volar splint is compared to a circumferential cast for the treatment of distal radial buckle fractures in children. These are to be worn until Pediatric Orthopaedics follows up with the patients at 3 weeks.
1859365|NCT01010373|Drug|AS101|3 mg/m2 AS101 will be given intravenously (IV) three times per week.
1859366|NCT01010386|Procedure|Atmospheric oxygen tension|Couples will have their gametes and embryos placed in the currently widely used atmospheric (20%) oxygen atmosphere
1859367|NCT01010386|Procedure|Physiologic oxygen tension|Couples will have their gametes and embryos placed in a physiologic (5%) oxygen atmosphere
1859368|NCT01010399|Dietary Supplement|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing 465 mg of eicosapentaenoic acid (EPA) and 375 mg of docosahexaenoic acid (DHA) for 18 weeks
1859369|NCT01010399|Drug|fosamprenavir/ritonavir|Lexiva (fosamprenavir calcium) 1400 mg per day, Norvir (ritonavir) 100 mg per day
1859370|NCT01010412|Device|Ultrasound (Sonosite Titan T-shaped ultrasound probe)|Ultrasonography will allow direct visualization of nerves. As local anesthetic is injected, it can be seen surrounding the nerve.
1859371|NCT01010412|Device|Electrical Nerve Stimulation (Stimuplex (B Braun) needle)|
1859372|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 1, s.c., single-dose
1859373|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 2, s.c., single-dose
1859374|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 3, s.c., single-dose
1859375|NCT01010425|Drug|ACP-001 (TransCon PEG hGH)|ACP-001, dose-level 4, s.c., single-dose
1859376|NCT01010425|Drug|Placebo|Placebo, s.c., single-dose
1859377|NCT01010425|Drug|Human Growth Hormone|Human Growth Hormone, s.c., daily for 7 days
1859378|NCT01010451|Procedure|Antimicrobial pulpotomy|Pulpotomy of inflamed or necrotic pulp using an antimicrobial paste (chloramphenicol, tetracycline, zinc oxide/eugenol)as medication.
1859379|NCT01010451|Procedure|Calcium hydroxide pulpectomy|Pulpectomy of inflamed or necrotic pulp using a calcium hydroxide paste as medication
1859380|NCT01010464|Procedure|Adhesion Reduction Plan|Lysis of adhesions and application of a minimum of 4 sheets of a sodium hyaluronate-based bioresorbable membrane
1859381|NCT01010477|Drug|Nicotine Nasal Spray|minimum 8 doses of nasal spray per day; maximum of 5 doses per hour, no more than 40 doses per day
1859382|NCT01010477|Behavioral|Behavioral counseling|Both groups will receive behavioral intervention designed for schizophrenia delivered as 15 individual counseling sessions over 26 weeks.
1859383|NCT01010490|Procedure|Torsional ultrasound (INFINITI, Alcon, USA)|Comparison of inta-operative efficacy and safety
1859384|NCT01010490|Procedure|Longitudinal U/S (Infiniti system, Alcon, USA)|comparison of efficacy and safety
1859385|NCT01010490|Procedure|Longitudinal U/S (LEGACY 20000, Alcon, USA)|Interrupted energy modality
1859386|NCT01010503|Drug|tocilizumab [RoActemra/Actemra]|tocilizumab 8 mg/kg intravenous infusion once in 4 weeks
1859390|NCT01010529|Other|occupational therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
1859391|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of ILV-095 300 mg
1859392|NCT01010542|Drug|ILV-095 300 mg in a 4 to 1 ratio|Single dose of Placebo
1859393|NCT01010555|Device|lotrafilcon B|Commercially marketed, silicone hydrogel, spherical contact lens
1859394|NCT01010555|Device|balafilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
1859395|NCT01010555|Device|senofilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
1859396|NCT01010555|Device|enfilcon A|Commercially marketed, silicone hydrogel, spherical contact lens
1859397|NCT01010568|Drug|Ofatumumab and Bendamustine|Ofatumumab 300-mg IV on Day 1 of week -1 and then 1000 mg on Day 1 of each cycle for 6 cycles Bendamustine 70 mg/m2 IV on days 1 and 2 of each cycle for 6 cycles
1859398|NCT01010581|Drug|SC12267 (4SC-101)|oral administration
1859399|NCT01010581|Drug|Placebo|oral administration
1859400|NCT01010581|Drug|Methotrexate|oral administration
1859401|NCT01010581|Drug|Folic Acid|oral administration
1859402|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment except that they are advised to restrict their fruit intake.
1859403|NCT01010594|Behavioral|dietary treatment|A standard dietary treatment.
1859404|NCT01010607|Device|Vibration and Mirror|10 treatments of 30 minutes in which vibration of 50-100 Hz will be administrated to the elbow and wrist muscles together with the use of a mirror. The patient moves his healthy hand in a certain repetitive pattern and watches its reflection on a mirror. Meanwhile he receives vibration in his affected hand in a timing that induces the illusion of movements similar to the movements of his healthy hand, thereby inducing a strong illusion of movement of his affected hand.
1859405|NCT01010607|Device|Mirror therapy|10 sessions of mirror therapy: moving the healthy hand while watching its reflection on a mirror. Meanwhile sham vibration over bone in the affected handwill be given to resemble the conditions of the experimental arm.
1859406|NCT01010607|Device|no mirror, sham vibration|10 sessions in which patient moves his healthy hand and tries to move his affected hand, which is hidden by an opaque board instead of a mirror. Sham vibration is applied to bone instead of muscle, no illusion is generated.
1859407|NCT01010620|Behavioral|Various Screening psychiatric and medical assessments|Possibly blood draws, urine samples, toxicology screens, computer-based and written psychological, psychiatric, and behavioral questionnaires and assessments.
1859408|NCT01010633|Drug|Vehicle of Loteprednol Etabonate|1 to 2 drops of vehicle administered into the study eye, 4 times a day for approximately 14 days.
1859409|NCT01010633|Drug|Loteprednol Etabonate|1 to 2 drops of study drug administered into the study eye, 4 times a day for approximately 14 days.
1859410|NCT01010646|Drug|IFN alfa-2b XL 27 MUI + Ribavirin|IFN alfa-2b XL 27 MUI administered once a week for 12 weeks by subcutaneous injections, in combination with weight dosed ribavirin daily administered orally in two divided doses
1859411|NCT01010646|Drug|IFN alfa-2b XL 36 MUI + Ribavirin|IFN alfa-2b XL 36 MUI administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
1859412|NCT01010646|Drug|IFN peg alfa-2b 1.5 µg/kg + Ribavirin|IFN peg alfa-2b 1.5 µg/kg administered once a week for 12 weeks by subcutaneous injections in combination with weight dosed ribavirin daily administered orally in two divided doses
1859413|NCT01010659|Device|Lacrimal Tube|Lacrimal Tube
1859414|NCT01010672|Drug|Ridaforolimus|Ridaforolimus, oral tablet, 40 mg once daily for 5 consecutive days followed by 2-day dosing holiday each week. Participants treated until discontinuation criteria, such as progressive disease or unacceptable toxicity, were met.
1859415|NCT01010685|Procedure|Recovery of gallbladder via gastrotomy instead of via the skin|The gallbladder is dissected as for a standard laparoscopic cholecystectomy but is then recovered via a hole in the stomach created and closed endoscopically rather than through the skin as in the standard fashion
1859416|NCT01010698|Drug|cimetidine (or acyclovir)|cimetidine (or acyclovir) 200mg (single dose)
1859417|NCT01010711|Dietary Supplement|Migra 3|powder containing coenzyme q10, blueberries, black current, vitamins, magnesium,trace elements
1859418|NCT01010724|Drug|bIAP|
1859419|NCT01010724|Drug|Placebo|
1859420|NCT01010737|Biological|Multimeric-001 250 mcg|Multimeric-001 (M-001) was administered twice at a dose of 250mcg via the IM route to 10 participants as a primer, followed by TIV boost immunization. in 19-23 days interval between them.
1859421|NCT01010737|Biological|Adjuvanted Multimeric-001 250mcg|Injection of Multimeric-001 250 mcg with Adjuvant Montonide isa 51 VG, 2 doses with interval of 19-23 days between them
1859422|NCT01010737|Biological|Placebo|Placebo injected with PBS (Phosphate Buffered Saline), 2 injections with the interval of 19-23 days between them.
1859423|NCT01010737|Biological|Adjuvant: Montonide isa 51 VG|Injection of Placebo with Adjuvant Montonide isa 51 VG, 2 injections with the interval of 19-23 days between them.
1859424|NCT01010737|Biological|Multimeric-001 500 mcg|Injection of Multimeric-001 with PBS, 2 injections with the interval of 19-23 days between them.
1859425|NCT01010737|Biological|Adjuvanted Multimeric-001 500mcg|Injection of Multimeric-001 500 mcg with Adjuvant Montonide isa 51 VG, 2 doses with the interval of 19-23 days between them
1859426|NCT01010737|Biological|TIV|Injection of the conventional flu vaccine: Vaxigrip to all study participants.
1859427|NCT01010750|Drug|Lisdexamfetamine Dimesylate (LDX)|Lisdexamfetamine Dimesylate (LDX) + Immediate Release Mixed Amphetamine Salts (MAS-IR) placebo
1859428|NCT01010750|Drug|Immediate Release Mixed Amphetamine Salts (MAS-IR)|Immediate Release Mixed Amphetamine Salts (MAS-IR) + Lisdexamfetamine Dimesylate (LDX) placebo
1859429|NCT01010750|Drug|LDX Placebo + MAS-IR Placebo|Lisdexamfetamine Dimesylate (LDX) Placebo + Immediate Release Mixed Amphetamine Salts (MAS-IR) Placebo
1859431|NCT01010776|Drug|Paliperidone Extended Release (ER)|Paliperidone ER tablets in the flexible dose ranging from 3 to 12 mg will be administered orally once daily for 26 weeks of Main Phase and for additional 26 weeks of Extension Phase to participants who continued with Extension Phase. Dosage was adjusted as per the Investigator's discretion.
1859435|NCT01010802|Drug|Erythropoietin human recombinant (EPOrh)|Administration scheme by subcutaneous via, of an EPOrh solution up to a weekly doses of 60 UI/kg for five weeks
1859436|NCT01010815|Procedure|Colonoscopy biopsy|Colonoscopy biopsy will be performed in rectum, ascending and descending colon at study entry
1859437|NCT01010815|Other|stool collection|Stool will be collected from participants at study entry
1859438|NCT01010815|Procedure|colonoscopy biopsy|colonoscopy biopsy will be conducted in rectum, ascending and descending colon from participants 2 times during study - at active phase and inactive phase
1859439|NCT01010815|Other|stool collection|stool will be collected from participants 2 times during study - at active phase and inactive phase
1859440|NCT01010828|Procedure|Incision technique|Tri-Vector Approach retains the majority of 3 vectors of quadriceps.
1859441|NCT01010828|Procedure|Incision technique|Mini Mid-Vastus Approach
1859442|NCT01010841|Dietary Supplement|UltraMealPlus 360 (Medical food)|Specific phytochemicals (soy protein, phytosterols, rho iso-alpha acids and proanthocyanidins; PED)
1859443|NCT01010841|Other|Low-glycemic-load diet|Modified Mediterranean-style low-glycemic-load diet
1859444|NCT01010854|Drug|VPA FEC100|oral VPA (60 mg/kg bid) q 12h X 6 with IV 5-Fluorouracil (500 mg/m2) Epirubicin (100 mg/m2) and Cyclophosphamide (500 mg/m2)
1859445|NCT01010867|Drug|Lactobacillus plantarum strains 299 and 299v|"Patients will receive a daily dose of Lactobacillus plantarum: 1 x10^8 CFU/kg/day. This supplement will be supplied in sachets of powder and will be mixed in water (certain water-based liquid) that is no warmer that 37o C.
Colony forming units (CFU)"
1859446|NCT01010880|Drug|BKT140|BKT-140 drug substance is a highly selective CXCR4 antagonist. BKT140 will be injected S.C once at dose of 0.03, 0.1, 0.3, 0.9 mg/kg
1859447|NCT01010893|Biological|Vaccination with Fluval P and Fluval AB influenza vaccines|Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 6 μg HA/ in both age groups, single dose) AND with Fluval AB trivalent influenza vaccine with 15 μg HA/0.5ml/strain active ingredient content and aluminium phosphate gel adjuvant (dose: 0.5 ml /total 3x15 μg HA/ in both age groups, single dose).
1859448|NCT01010893|Biological|Vaccination with Fluval P monovalent influenza vaccine|Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant
1859449|NCT01010906|Drug|Vaniprevir 300 mg|single dose administration of 300 mg oral tablet
1859450|NCT01010906|Drug|Vaniprevir 200 mg|single dose administration of 200 mg oral tablet
1859451|NCT01010919|Dietary Supplement|Chicory root extract|
1859452|NCT01010932|Drug|Dotarem|Each subject will receive one injection of Dotarem 0.2ml/kg
1859453|NCT01010932|Other|TOF MRA|Each subject will undergo a Time of Flight Magnetic Resonance Angiography (TOF MRA)
1859454|NCT01010945|Drug|erlotinib|administered orally
1859455|NCT01010945|Drug|gemcitabine|administered intravenously
1859456|NCT01010945|Drug|nab-paclitaxel|administered intravenously
1859457|NCT01010958|Drug|Valproic Acid|Subjects should initiate therapy at 10 to 15 mg/kg/day. The dosage should be increased by 5 to 10 mg/kg/week to achieve optimal clinical response. Optimal clinical response is achieved at daily doses below 60 mg/kg/day. If satisfactory clinical response has not been achieved, plasma levels should be measured to determine whether or not they are in the usually accepted therapeutic range (50 - 100 µg/mL).
1859458|NCT01010971|Drug|Ciclesonide HFA 160 μg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
1859459|NCT01010971|Drug|Ciclesonide HFA 80 μg|Ciclesonide HFA Nasal Aerosol 80 μg once daily
1859460|NCT01010971|Drug|Placebo|Placebo HFA Nasal Aerosol once daily
1859462|NCT01010997|Device|Foresee Home|using the Foresee home device
1859463|NCT01011010|Drug|doxorubicin hydrochloride|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
1859464|NCT01011010|Drug|mitomycin C|"TACE (day 18-20): Doxorubicin 50mg and mitomycin C 10mg mixed with lipoidal and injected in proportion to liver volume being treated, followed by embospheres. Administered until there is a pruned tree appearance on angiography. If a second TACE is to be performed it should be performed within 8 weeks of the first procedure."
1859465|NCT01011010|Drug|sorafenib tosylate|Sorafenib 400mg BID continuously post TACE beginning when LFTs return to entry criterion. Discontinue at time of disease progression (progression in a lobe that has already been embolized, new lesions in an untreated lobe, or evidence of extrahepatic progression).
1859466|NCT01011010|Other|laboratory biomarker analysis|Serum VEGF levels are required: pre TACE (day of procedure, time B), 24 hours post TACE (+/- 6 hours, time C), day 7 post first TACE (± 1 day, time D), day 28 post reinitiation of sorafenib (± 3 days, time E). These levels will not be repeated for patients receiving a second TACE procedure.
1859467|NCT01011010|Other|pharmacological study|Treatment with sorafenib will continue on a daily basis until disease progression (see definition protocol Section 7) or unacceptable toxicity is encountered. At the end of treatment, no further therapies are currently recommended.
1859468|NCT01011023|Other|Non application of nasogastric tube in the experimental group|Avoid the 5 post operative application of nasogastric tube in the experimental group vs the control group with the usual nasogastric tube
1859469|NCT01011036|Drug|clobazam|test substance
1859470|NCT01011036|Drug|clonazepam|positive control
1859471|NCT01011036|Drug|tolterodine|active placebo
1859472|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
1859473|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
1859474|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.5 mL, Intramuscular
1859475|NCT01011049|Biological|Influenza Virus Vaccine USP Trivalent Types A and B|0.1 mL, Intradermal
1859476|NCT01011062|Procedure|Hyperinsulinaemia|Hyperinsulinaemic (1 mIU/kg/min) euglycaemic (5 mmol/l) clamp
1859477|NCT01011062|Drug|Losartan|Acute administration of losartan 200mg total prior to clamp
1859478|NCT01011062|Drug|Saline|Infusion of Saline as a volume control intervention
1859479|NCT01011075|Drug|Imatinib mesylate|Imatinib (Gleevec) 600 mg/day, oral administration in 4-day pulses(days 1-4; 8-11; 15-18) Cycle length: 28 days Number of cycles: up to 6
1859480|NCT01011075|Drug|Paclitaxel|Paclitaxel 90 mg/m2 IV on days 3, 10, 17 Cycle length: 28 days Number of cycles: up to 6
1859481|NCT01011088|Other|Not available|Not any artificial interventions were given
1859482|NCT01011114|Drug|Cinacalcet|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
1859483|NCT01011114|Drug|Placebo|cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
1859484|NCT01011127|Drug|pravastatin, rosuvastatin|
1859485|NCT01011140|Behavioral|Survey|10-15 minute online survey to assess palliative care physicians' attitudes, beliefs and practice patterns related to parenteral hydration at the end of life in Latin America and Spain.
1859486|NCT01011166|Drug|IDX184|IDX184 50 mg white opaque capsules taken by mouth from Day 1 to Day 14.
1859487|NCT01011166|Drug|Placebo|Placebo white opaque capsules taken by mouth from Day 1 to Day 14.
1859488|NCT01011166|Biological|Peginterferon alfa-2a (Peg-IFN)|Peg-IFN was supplied as 180 ug single-use, pre-filled syringes administered once weekly from Day 1 to Day 28.
1859489|NCT01011166|Drug|Ribavirin (RBV)|RBV 200 mg capsules at a total daily dose of 1000 mg to 1200 mg (based on participant body weight) from Day 1 to Day 28.
1859490|NCT01011179|Behavioral|Teens Taking Charge|The intervention is a 12-week multi-component treatment protocol that consists of self-management strategies (e.g., how to deal with stress and treatment related symptoms like pain), information (e.g., common problems associated with treatment and disease) and social support (e.g., monitored discussion boards and narratives in the form of written stories and video clips). It will be delivered on a restricted web-site and through regular contact with a trained coach by means of email and/or telephone using standardized scripts.
1859491|NCT01011179|Behavioral|Self-Management|"Adolescents' own best efforts at managing their JIA"
1859492|NCT01011205|Drug|Advagraf|Capsule
1859493|NCT01011205|Drug|Mycophenolate Mofetil|Solution for infusion
1859494|NCT01011205|Drug|Basiliximab|IV infusion
1859495|NCT01011205|Drug|Corticosteroids|IV bolus
1859496|NCT01011218|Drug|Armodafinil|150 mg once a day
1859497|NCT01011218|Behavioral|Brief Behavioral Intervention for Insomnia (BBT-I)|2 sessions in person and additional brief sessions over the phone
1859498|NCT01011218|Drug|Placebo|Placebo pill
1859499|NCT01011231|Procedure|Gamma Knife Radiosurgery|Patient treatments will be planned with the Gamma Plan software. The dose will be prescribed to the isodose surface which encompasses the target volume within a range of 50-60% based on a local maximum of 100%. Radiosurgery dose will be prescribed based on volume within the prescribed isodose surface (not to exceed 18 cc)
1860357|NCT01027000|Drug|fludarabine phosphate|
1859500|NCT01011244|Biological|ADIPOPLUS|"autologous cultured adipose-derived stem cells
1x10e7 cells/1cm2 depending on surface area of fistula"
1859501|NCT01011257|Drug|Asprin|asprin 81mg, 1 tab, twice daily OR aspirin 81mg, 2 tab, once daily
1859502|NCT01011257|Drug|Clopidogrel|clopidogrel 75 mg bid
1859503|NCT01011283|Drug|decitabine|decitabine 20 mg/m^2 /day intravenous (IV) infusion for 5 days every 28 days
1859504|NCT01011283|Drug|azacitidine|azacitidine 75 mg/m^2 /day subcutaneous (SC) injection for 7 days every 28 days
1859505|NCT01011296|Drug|PF-04427429|Single 0.2mg dose of intravenous infusion
1859506|NCT01011296|Drug|PF-04427429|Single 1mg dose of intravenous infusion
1859507|NCT01011296|Drug|PF-04427429|Single 3 mg dose of intravenous infusion
1859508|NCT01011309|Biological|LEISH-F2 + MPL-SE|10 μg LEISH-F2 + 25 μg MPL-SE on Days 0, 28 and 56
1859509|NCT01011309|Drug|Sodium stibogluconate|20 mg/kg/day IV daily for 20 days
1859510|NCT01011322|Drug|LT-02|Comparison of different dosages of drug versus placebo. 4 times daily over 12 weeks
1859511|NCT01011322|Drug|placebo|placebo
1994565|NCT02974556|Procedure|Standard surgical treatment|Standard surgical treatment (open or laparoscopic techniques) containing at least 12 lymph-nodes for accurate pN staging.
1998202|NCT01595516|Drug|Metoprolol|100 mg tablet to be taken by mouth once per day for 12 weeks
1998203|NCT01595516|Drug|Placebo|Gelatin capsule to be taken by mouth once per day for 12 weeks
1859517|NCT01011348|Dietary Supplement|Coenzyme Q10|100mg/day for three months
1859518|NCT01011348|Dietary Supplement|Coenzyme Q10|300mg/day for three months
1859519|NCT01011348|Dietary Supplement|Placebo|Three month period
1859520|NCT01011374|Drug|ranibizumab (Lucentis)|0.5 mg, administered intravitreally every 4 weeks
1859521|NCT01011387|Procedure|NPWT System|Dressing change 3 times per week
1859522|NCT01011387|Device|NPWT system|3 dressing changes/week for maximum 4 weeks.
1859523|NCT01011413|Drug|Efavirenz|3 x EFV 200mg tablets once daily
1859524|NCT01011413|Drug|Efavirenz|2 x EFV 200mg tablets plus 1x matched EFV placebo tablet once daily
1859525|NCT01011426|Drug|Bisacodyl|5mg po 6 hours postoperatively, repeat in 12 hours if no flatus
1859526|NCT01011426|Drug|placebo|1 capsule po 6 hours after surgery; repeat in 12 hours if no flatus
1859527|NCT01011439|Drug|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.
Number of cycles: until disease progression or unacceptable toxicity."
1859528|NCT01011452|Drug|Montelukast|1 study capsule at study entry Montelukast 10mg and a further study capsule at 10pm for four weeks
1859529|NCT01011452|Drug|Placebo|1 placebo capsule at study entry and a further placebo capsule at 10pm for four weeks
1859530|NCT01011465|Drug|intranasal oxytocin|The aqueous form of oxytocin (oxytocin injection, synthetic) in 10 ml vials is inserted into a spray bottle. The spray bottle is calibrated so that emptying the spray bottle results in delivering 24 IU of oxytocin. No dilution of the original aqueous form of the oxytocin is necessary. 24 IU of oxytocin will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after 24 IUs of oxytocin have been administered. Duration of administration is anticipated to be 2-5 minutes
1859531|NCT01011465|Drug|Placebo|Participants in the placebo condition receive an equivalent amount of saline for intranasal spray administration. The placebo will be administered at one time only during the procedure. Approximately half the dose will be sprayed into each nostril. Administration will stop after the full amount in the spray bottle has been used. Duration of administration is anticipated to be 2-5 minutes
1859532|NCT01011465|Behavioral|Social support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. If instructed to bring a same-sex close friend (excluding spouses, participants are joined by their support partners join participants at the start of the stress exposure. The social support condition includes a number of strategies designed to standardize the type of support available to participants across individuals.
1859533|NCT01011465|Behavioral|No Social Support|Prior to coming to the laboratory, participants are randomly assigned to one of two conditions, requiring them to appear alone or accompanied by a partner. They are then instructed to bring a same-sex close friend (excluding spouses) with them, or to come alone. If they come to the laboratory without a friend, they engage in all the laboratory procedures without a friend present.
1859534|NCT01011478|Drug|rosuvastatin|
1859535|NCT01011478|Other|placebo|
1859536|NCT01011491|Other|Medifast 5 & 1 Plan for weight loss and weight maintenance|Medifast's 5 & 1 Plan is a meal replacement program for weight loss that uses 5 Medifast meals and 1 self-prepared meal. The weight maintenance plan incorporates 3-5 Medifast meals as well as a certain amount of food from all other food groups.
1859537|NCT01011491|Other|Food-based diet plan for weight loss and weight maintenance|The food-based group was provided a meal plan for weight loss based on the guidelines of the USDA Food Guide Pyramid providing the same number of calories as the Medifast 5 & 1 Plan. Weight maintenance calories were calculated and participants were provided meal plans from the USDA Food Guide Pyramid.
1859538|NCT01011517|Dietary Supplement|Muscadine grape seed supplement|Nature's Pearl 650 mg, two capsules daily
1859539|NCT01011530|Drug|MLN4924|Patients will be administered MLN4924 via an IV infusion. Each 21-day treatment cycle is composed of 2 weeks intermittent dosing of MLN4924 on Days 1, 4, 8 and 11, followed by a rest period of 10 days. A cohort of patients will receive a reduced first dose on Day 1, approximately half the strength of the dose received on Days 4, 8, 11 and dose will not be administered on Day 4 if the Day 1 dose is not tolerated.(Schedule A ramp-up), or continuous weekly dosing (Days 1, 8, and 15) of MLN4924 (Schedule B)
1859540|NCT01011543|Procedure|Diagnostic techniques in pulmonary tuberculosis|Two different methods to obtain a diagnosis of pulmonary tuberculosis in patients with negative classic sputum samples are compared.
1859541|NCT01011556|Drug|Subcutaneous Teriparatide|Administered subcutaneously once daily for 12 months
1859542|NCT01011556|Drug|Transdermal Teriparatide|Administered transdermally, applied once daily for 6 hours over 12 months
1859543|NCT01011595|Procedure|Cervical Mediastinoscopy|Surgical Meciastinal Lymph Node Staging
1859699|NCT01022905|Biological|Adjuvanted influenza A(H1N1) vaccines|Immunization (1-2 doses)
1859544|NCT01011595|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
1859545|NCT01011595|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
1859546|NCT01011608|Other|Medical Food Supplement|Medical Food Supplement to be given in divided portions in morning, afternoon and evening
1859547|NCT01011608|Other|standard hospital food|standard hospital diet ad. lib.
1859548|NCT01011621|Drug|0.5% prednisolone acetate cream|Small amount applied over the lesion twice a day for 14 days.
1859549|NCT01011621|Drug|0.1% betamethasone valerate cream|Small amount applied over the lesion twice a day for 14 days.
1859550|NCT01011634|Drug|Intravenous moderate sedation versus oral medication|Intravenous moderate sedation (fentanyl 100 mcg and midazolam 2 mg) versus oral analgesia/anxiolysis (lorazepam 2 mg sublingual, hydrocodone/acetaminophen 5/500 mg, and ibuprofen 800 mg)
1859551|NCT01011660|Drug|Amlodipine, Telmisartan, Amiloride Compound , Simvastatin|Amlodipine; Telmisartan; Amiloride Compound; Simvastatin
1859552|NCT01011673|Drug|Metoclopramide|metoclopramide 20mg IVSS + diphenhydramine 25mg IVSS
1859553|NCT01011673|Drug|Ketorolac|ketorolac 30mg IVSS
1859554|NCT01011686|Biological|ANT-SM|autologous adipose-derived stem cell
1859555|NCT01011699|Drug|nicotinamide|"Titration phase of nicotinamide (Nicobion) with the aim of phosphatemia control in 4 weeks with stable dose of calcic carbonate;
Increase of nicotinamide dose of Nicobion 500mg (nicotinamide 500mg), up to 4 tablets daily, as follows:
0 morning, 1 noon, 0 evening (first week), then, 0 morning, 1 noon, 1 evening (second week), then, 1 morning, 1 noon, 1 evening (third week), then, 1 morning, 2 noon, 1 evening (fourth week)."
1859556|NCT01011699|Drug|sevelamer|"Titration phase with sevelamer (Renagel) with the aim of phosphatemia control before 4 weeks of treatment, with stable dose of calcic carbonate.
Increase of sevelamer dose up to 12 tablets, as follows:
0 morning, 2 noon, 2 evening (first week), then, 0 morning, 4 noon, 4 evening (second week), then, 2 morning, 4 noon, 4 evening (third week), then, 4 morning, 4 noon, 4 evening (fourth week)."
1859557|NCT01011699|Drug|cinacalcet|"After 6 months of treatment, patient screening on PTH level:
For patients with PTH > 300pg/ml, introduction of cinacalcet by level of 30 mg every 3 weeks, up to 180mg daily (administered during the meal and before next dialysis) Cinacalcet increase will be stopped once PTH < 250 pg/ml. Calcic carbonate dose will be increase once calcemia will be < 2.25 mmol/l. If maximum tolerated dose is not sufficient to prevent hypocalcemia < 2.10 mmol/l calcium of dialysis bath wille be increased up to 1.75 mmol/l and calcic carbonate will be decreased.
A dose adjustment is possible with nicotinamide to obtain a phosphatemia between 1.10 and 1.60 mmol/l."
1859558|NCT01011725|Drug|MK 0773|25 mg oral tablet b.i.d. MK 0773 or 100 mg oral tablet b.i.d. MK 0773, for 12 weeks
1859559|NCT01011725|Drug|Placebo|Placebo oral tablet b.i.d for 12 weeks
1859560|NCT01011751|Drug|Cyproterone acetate|Cyproterone acetate tablet-in-capsule.
1859561|NCT01011751|Drug|Medroxyprogesterone acetate|Medroxyprogesterone acetate tablet-in-capsule.
1859562|NCT01011751|Drug|Venlafaxine|Venlafaxine capsule.
1859563|NCT01011751|Drug|Leuprorelin|Leuprorelin injection.
1859564|NCT01011751|Drug|Flutamide|Flutamide tablet
1859565|NCT01011751|Drug|Placebo|Cyproterone acetate, medroxyprogesterone acetate or venlafaxine placebo-matching capsule.
1859566|NCT01011764|Behavioral|SKILLS vs ENGAGE|The investigators plan to contrast 2 different models for social skills groups. Each model involves 16 45-minute bi-weekly sessions, twice a week with a small group of children with ASD. Details of the 2 intervention models are described below.
1859567|NCT01011777|Drug|MDC|After the biopsy the MDC expansion process takes approximately 21 days after which cells are harvested and cryopreserved for future injection. The MDC product is stored in single use vials, with each vial containing approximately 2.6 x 10^7 total cells. The volume of each vial will be 1.3ml. This study uses a single dose of approximately 2.0 x 10^7 cells administered endoscopically into the external urethral sphincter in 12 injections of 0.1ml each. Six months post-initial MDC injection, group 1 participants with persistent bladder capacity less than 100cc and group 2 participants with persistent urinary incontinence as defined in eligibility criteria may undergo repeat injections of MDC at 6 month intervals for up to a total of 4 injections.
1859568|NCT01011790|Behavioral|Healing Rhythms™ Meditation Program|The Healing Rhythms™ meditation program was chosen as the intervention for this study because it has a long history of use in the consumer market, it provides a dual-mode biofeedback which allows users to visually see their progress, and it provides an attractive and engaging user interface which is enjoyable to use. This is a critical factor as the research cited documents the importance of adherence in achieving optimal outcomes.
1859569|NCT01011803|Other|Combined speech therapy tools, measures of swallowing function|All subjects will be assessed using combined speech therapy tools and ordinal measures of swallowing function. The combined speech therapy tools were [diadochokinesis, glottal coup, and the Consensus Auditory-Perceptual Evaluation of Voice (CAPE-V)]. The ordinal measures of swallowing function included Dysphagia Admission Screening Tool (DAST), Modified Barium Swallow (MBS), and Fiberoptic Endoscopic Evaluation of the Swallow (FEES).
1859570|NCT01011816|Biological|BIOSTAT BIOLOGX|One injection of up to 4 mL of BIOSTAT BIOLOGX Fibrin Sealant into a single lumbar intervertebral disc using the Biostat Delivery Device
1859571|NCT01011816|Drug|Saline|One injection of up to 4 mL of saline using the Biostat Delivery Device
1859572|NCT01011829|Drug|Varenicline|Varenicline dosing will follow that which has been shown to be effective for cigarette smoking cessation. Varenicline dose will start at 0.5 mg daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
1859573|NCT01011829|Drug|Placebo|Placebo dose will start at 0.5 mg (sugar pill) daily for days 1-3, followed by 0.5 mg twice daily for days 4-7, followed by 1 mg twice daily from day 8 until completion of the medication period (end of week 8).
1859574|NCT01011842|Procedure|Radiotherapy|Standard of care
1859575|NCT01011842|Procedure|Align RT|Standard of care
1859576|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
1859700|NCT01022918|Drug|Avastin + Campto / radiotherapy + Temodal + Avastin (4 cures)|
1859577|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care provided first on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
1859578|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm.
1859579|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
1859580|NCT01011855|Device|GEHC IWS 4400 & Giraffe warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm.
1859581|NCT01011855|Device|GEHC IWS 4400 & Giraffe Warmer beds|Clinical care is first provided on a GEHC Giraffe Warmer bed with a proportional heater control algorithm, followed by care provided on a GEHC Giraffe Warmer bed with an adaptive heater control algorithm, followed by care provided on a GEHC IWS 4400 bed with a proportional heater control algorithm.
1859582|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
1859583|NCT01011868|Drug|BI 10773 low dose|BI 10773 low dose
1859584|NCT01011868|Drug|BI 10773 high dose|BI 10773 high dose
1859585|NCT01011868|Drug|BI 10773 placebo|BI 10773 placebo
1859586|NCT01011881|Other|pleural level of procalcitonin|no intervention
1859587|NCT01011894|Drug|lenalidomide|Lenalidomide will be administered orally at a starting dose of 2.5mg once daily, days 1-28. Patients will be evaluated prior to treatment and at 4 weeks, 8 weeks, 12 weeks, 16 weeks and at a minimum of 4 weeks thereafter until removal from study. Patients with stable disease or better will continue at their current dose unless they experience toxicity requiring dose reduction. For those patients who have progressive disease on their current dose and have no dose-limiting toxicity, their dose will be increased from 2.5mg, to 5mg, to 10mg, to 15mg, to 20mg one dose level at a time not more frequently than once every 4 weeks. The maximum dose will be 20mg.
1859588|NCT01011907|Drug|varenicline|12 weeks of oral tablet treatment in an escalating dosing regimen (0.5 mg 1x daily, days 1-3; 0.5mg 2x daily, days 4-7, 1.0 mg 2x daily, days 8-84).
1859589|NCT01011907|Drug|placebo|12 weeks of oral tablet treatment in an escalating dosing regimen (1 - 2x daily).
1859590|NCT01011920|Drug|Methotrexate|Methotrexate 3.5 g/m2 (0.5 g/m2 in 15 min. + 3 g/m2 in 3-hr infusion) on day 1, every 3 weeks for a maximum of 4 courses.
1859591|NCT01011920|Drug|Ara-C|Cytarabine 2 g/m2 (1 hr infusion, twice a day every 12 hours), on d 2 - 3 every 3 weeks for a maximum of 4 courses
1859592|NCT01011920|Drug|Rituximab|Rituximab 375 mg/m2 conventional infusion on day - 5 & 0 every 3 weeks for a maximum of 4 cycles
1859593|NCT01011920|Drug|Thiotepa|ARM C: Thiotepa 30 mg/m2 (30 min. Infusion) on day 4 every 3 weeks for a maximum of 4 courses ARM E: Thiotepa 5 mg/kg in 250 ml saline sol 2-hr inf. every 12 hrs days -5 & -4
1859594|NCT01011920|Radiation|radiotherapy|Photons of 4-10 Mev, 180 cGy per day, 5 weekly fractions. Whole-brain will be irradiated by two opposite lateral fields including the first two cervical vertebras and the posterior two thirds of the orbits, which must be shielded after 30 Gy (after 36 Gy in the case of evident intraocular disease at diagnosis). Tumor-bed (boost or partial-brain RT) will be irradiated by 2 to 4 isocentric treatment fields based on tumor location, with all portals treated per each RT session.
1859595|NCT01011920|Drug|BCNU|BCNU 400 mg/m2 in 500 ml saline sol 1-hr inf. day -6
1859596|NCT01011920|Other|APBSCT|Autologous peripheral blood stem cell transplant (APBSCT)
1859597|NCT01011933|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1859598|NCT01011933|Drug|Selumetinib|Given PO
1859599|NCT01011946|Device|Positron Emission Mammography|Patients will receive bilateral (both sides) breast and axillary PEM scans, bilateral mammography, DCE-MRI, US of the breast and axilla (the side of the affected breast), and ultrasound guided biopsy of axillary lymph node if suspicious. Various PEM views will be performed on both your breast and axilla (underarm).
1859600|NCT01011959|Biological|REGN88|This study will be conducted in 3 parts, and will include a total of 6 dose cohorts. Part B will not begin until the safety of Part A has been assessed. Part C will begin when enrollment into Part B is complete.
1859601|NCT01011972|Drug|XMT-1107|6 mg XMT-1107 administered by I.V. (in the vein) administered over 90 min, once every 21 days : until progression or unacceptable toxicity develops
1859602|NCT01011998|Drug|Gleevec (imatinib), valproic acid|"Valproic acid: 250 mg three times per day and then adjusted according to attain a therapeutic level.
Gleevec will be continued at the dose the patient was taking at the time of entry onto the study."
1859603|NCT01012011|Drug|Sorafenib (Nexavar, BAY43-9006)|Daily dose, dosage frequency and duration will be decided by physicians.
1859604|NCT01012037|Drug|linagliptin low dose|patient to receive tablets containing low dose linagliptin twice daily
1859605|NCT01012037|Drug|placebo|patient to receive placebo tablet(s) matching linagliptin
1859606|NCT01012037|Drug|linagliptin medium dose|patient to receive a tablet containing medium dose linagliptin once daily
1859607|NCT01012050|Device|NV|Noninvasive ventilation coupled with nebulization(Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm)
1859608|NCT01012050|Other|NEB group|Nebulization containing salbutamol (2.5mg) and ipratropium bromide (0.25mg)plus oxygen flow in 7Lpm
1859609|NCT01012063|Drug|iron sucrose, erythropoietin-β|The 200 mg of iron sucrose diluted with 100 ml of normal saline was given intravenously over one hour and the 3000 IU of Epo-β was injected subcutaneously.
1859610|NCT01012063|Drug|normal saline|100 ml of normal saline was given intravenously over one hour and 0.5ml was injected subcutaneously.
1859656|NCT01019044|Procedure|Rectal mucosa biopsy|Collection of a maximum of 15 rectal mucosa samples in the high portion of the rectum near the rectosigmoidal junction
1859701|NCT01022918|Drug|Temodal/radiotherapy|
1860358|NCT01027000|Drug|methotrexate|
1860359|NCT01027000|Drug|sirolimus|
1859611|NCT01012076|Behavioral|Active Control vs Experimental Treatment|The parent education program involves 12 in-home training sessions (90 minutes each), is administered by trained graduate and postdoctoral students in developmental psychology or a related field, and follows a standardized treatment manual (Siller, 2005). The active control involves three 90 minute in-home training sessions. These training sessions will be administered by trained graduate students or a postdoctoral student in a developmental psychology or related field. The active control will follow a standardized treatment manual (Kasari, 2008). This treatment manual was based upon the teacher training workshops created by the Center on the Social and Emotional Foundations for Early Learning.
1859613|NCT01012102|Biological|EMD 640744|EMD 640744 30μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
1859614|NCT01012102|Biological|EMD 640744|EMD 640744 100μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
1859615|NCT01012102|Biological|EMD 640744|EMD 640744 300μg, weekly in initiation phase and monthly in maintenance phase (in combination with Montanide® ISA 51 VG)
1859616|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 30ug)
1859617|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 100ug)
1859618|NCT01012102|Other|Montanide ISA 51 VG|Adjuvant. Montanide® ISA 51 VG, weekly in initiation phase and monthly in maintenance phase (in combination with EMD 640744 300ug)
1859619|NCT01012141|Dietary Supplement|phytochemical|
1859620|NCT01012141|Drug|Docetaxel|
1859621|NCT01018771|Procedure|Actifuse ABX|bone graft to be used in posterolateral instrumented lumbar fusion
1859622|NCT01018771|Procedure|INFUSE, plus Mastergraft granules|bone graft to be used in posterolateral instrumented lumbar fusion
1859623|NCT01018784|Drug|MORAb-009|MORAb-009 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle.
1859624|NCT01018797|Procedure|INTRASTROMAL CORNEAL RING SEGMENT|Corneal tunnels were created by means of mechanical dissection in all eyes. Intrastromal corneal ring segments implantation was indicated because of the existence of reduced best spectacle-corrected visual acuity (BSCVA) or contact lens intolerance.
1859625|NCT01018810|Drug|LY2525623 Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
1859626|NCT01018810|Drug|LY2525623 Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
1859627|NCT01018810|Drug|Placebo Intravenous|administered intravenously at randomization and every 2 weeks for 6 weeks
1859628|NCT01018810|Drug|Placebo Subcutaneous|administered subcutaneously at randomization and every 2 weeks for 6 weeks
1859631|NCT01018836|Drug|riluzole|The first dose of Riluzole will be day 0 of study enrollment. WBRT must begin within 48 hours of the initiation of Riluzole therapy. At the completion of radiation, Riluzole should be discontinued and steroids should be tapered over the course of 1-3 weeks, at the discretion of the treating physicians.
1859632|NCT01018836|Radiation|whole-brain radiation therapy|Standard whole brain irradiation will be carried out at 250 cGy per day fractions times 15 to a total dose of 3750 cGy using a standard opposed lateral helmet field with the inferior border inclusive of C1.
1859633|NCT01018849|Dietary Supplement|Cholecalciferol|cholecalciferol 150,000 IU by mouth every 2 months for 1 year
1859634|NCT01018849|Dietary Supplement|Placebo|placebo by mouth every 2 months for 1 year
1859635|NCT01018862|Drug|Azelastine hydrochloride nasal spray 0.15%|822 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
1859636|NCT01018862|Drug|Azelastine hydrochloride nasal spray 0.10%|548 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
1859637|NCT01018862|Drug|Placebo|0 mcg, Topical/intranasal spray, 1 spray per nostril twice daily/ 4 weeks
1859638|NCT01018875|Drug|ABT-288|Subjects will take 4 capsules once daily for 12 weeks.
1859639|NCT01018875|Drug|donepezil|Subjects will take 4 capsules once daily for 12 weeks.
1859640|NCT01018875|Drug|placebo|Subjects will take 4 capsules once daily for 12 weeks.
1859641|NCT01018888|Device|Auro KPro (Keratoprosthesis)|Front plate with optical cylinder, a back plate and a titanium ring to hold the complex together
1859642|NCT01018901|Other|Survey Administration|Patients complete survey
1859643|NCT01018914|Drug|Prograf|oral
1859644|NCT01018914|Drug|Advagraf|oral
1859645|NCT01018914|Drug|Myfortic|oral
1859646|NCT01018927|Device|Administering three additional MRI images|Three additional MRI images to determine the role of cardiac MR (CMR) in detecting features of early myocardial infiltration
1859647|NCT01018953|Drug|BIM 23A760|BIM 23A760 is a solution at a concentration of 5 mg/mL ready for subcutaneous injection. BIM 23A760 dose of 1, 2, 4, 6 and 8 mg can be given to the patient according to a dose escalation and titration process. Patients will receive 24 weekly injections of BIM 23A760 during the treatment period. Patients eligible to continue the extension phase will be administered BIM 23A760 for further 52 weekly injections.
1859648|NCT01018966|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, At least 1 cycle, (21 days)
1859649|NCT01018979|Drug|TG-0054 (2.24 mg/kg)|TG-0054: 2.24 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
1859650|NCT01018979|Drug|TG-0054 (3.14 mg/kg)|TG-0054: 3.14 mg/kg TG-0054 administrated via 15-min IV infusion(allow a maximum of six leukapheresis sessions)
1859651|NCT01018992|Drug|GSK561679|GSK561679, oral administration, 350mg/day, 6 week administration
1859652|NCT01018992|Drug|Placebo|Matching placebo, oral administration, 1 pill/day for 6 weeks
1859653|NCT01019005|Device|Catheter|Catheter inserted into either perineural tibial nerve or wound
1859654|NCT01019018|Device|subtenon block|subtenon block with stevens cannula
1859655|NCT01019018|Device|subtenon block|subtenon block with Olive tip cannula cannula
1859657|NCT01019057|Procedure|ILIF|Interlaminar lumbar instrumented fusion (ILIF™) is a compound surgical solution to spinal stenosis, combining direct neural decompression with an allograft interspinous spacer (ExtenSure® H2) to maintain the segmental distraction, and a spinous process fixation plate (Affix™) to maintain stability for eventual segmental fusion.
1859658|NCT01019070|Drug|BMS-650032|Capsules, Oral, 200 mg, BID, 7 Days
1859665|NCT01019109|Device|Posterior Spinal Fusion Device: Titanium rod arm used titanium rods, and CoCr rod arm used Cobalt Chrome rods as a part of the construct.|PASS LP Implant System is designed to contribute to correction and surgical stabilization of the thoracic, lumbar and sacral spine only. These implants are designed to stabilize the spine during normal development of solid bony consolidation which takes about 18 months. The internal fixation devices are composed of screws, hooks,rods, plates, cross links, connection and locking devices. The range of different sizes and shapes of the implants allows the surgeon to adapt to the pathology and morphology of each of his patients.
1859666|NCT01022541|Drug|Capecitabine|"Capecitabine 1700mg/m2/day in two divided doses to be administered orally for 14 days followed by 7 days rest. For 4 courses initially.
(For patients aged 75+ 1300mg/m2/day in two divided doses or 650mg/m2 twice daily)
Courses as per detailed description above."
1859667|NCT01022541|Drug|Oxaliplatin|"Oxaliplatin 130mg/m2 diluted in 5% dextrose will be given as an i.v. infusion over 2 hours. This will be administered on day 1 after bevacizumab. For 4 courses.
(Patients aged 75+ should receive oxaliplatin at a reduced dose i.e. 100mg/m2)
Courses as per detailed description above."
1859668|NCT01022541|Drug|Bevacizumab|"Bevacizumab at a dose of 7.5 mg/kg, diluted in normal saline, will be administered as an iv infusion over 30 to 90 minutes before the administration of oxaliplatin on day 1 of every cycle.
The first infusion should be administered over 90 minutes. If well tolerated, the second infusion can be administered over 60 minutes. Provided that this is tolerated subsequent infusions can be administered over 30 minutes. If a patient experiences an infusion related adverse event with the 60 minute infusion, all subsequent infusions will be administered over 90 minutes. If a patient experiences an infusion related reaction with the 30 minute infusion, all subsequent infusions will be administered over 60 minutes
Courses as per detailed description above."
1859669|NCT01022541|Procedure|Liver metastasectomy|Patients with liver metastases which have become resectable and in whom surgery is still deemed appropriate should proceed to surgery after a 6 week interval from the last administration of capecitabine chemotherapy (at least 8 weeks from last administration of bevacizumab).
1859670|NCT01022567|Procedure|Appendicectomy|Standard appendicectomy
1859671|NCT01022567|Drug|Ertapenem|ertapenem 1g x 1 i.v.for three days + after discharge levofloxacin 500 mg 1 x 1 + metronidazole 500 mg 1x3 for 7 days p.o.
1859673|NCT01022606|Other|Arterial sampling|Arterial pO2 (ABL5) Body Temperature (Vitalsens Cortemp) tcpO2 TCM400
1859674|NCT01022632|Dietary Supplement|Curcumin|Curcumin 500 mg 12 hourly after taking food in morning and evening for 6 weeks
1859675|NCT01022632|Drug|Fluoxetine|Fluoxetine ; 20 mg Once a day in morning after taking food for 6 weeks
1859676|NCT01022632|Dietary Supplement|Curcumin and Fluoxetine|Curcumin 500 12 hourly after taking food in morning and evening and Fluoxetine 20 mg Once a day in morning after taking food for 6 weeks
1859677|NCT01022645|Device|Mirena (Levonorgestrel IUD)|Release of intrauterine levonorgestrel for contraception, approved for up to 5 years' use
1859678|NCT01022645|Device|Paragard (Copper IUD ) or Tubal Ligation|Copper IUD placed to provide contraception for up to 10 years
1859679|NCT01022658|Drug|Insulin|For diabetes treatment: metformin continued with insulin (according to arms)
1859680|NCT01022671|Drug|Belotecan|3.0 mg/m2, Day 1, 8, 15 every 4 weeks
1859681|NCT01022684|Other|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship between various inflammatory markers and PET imaging at the cross section setting
1859682|NCT01022697|Other|Glucose drink|200 mL each 3 hours up to 8 cm of dilatation
1859683|NCT01022736|Drug|Gabapentin|Subjects will be administered gabapentin (600 mg, orally) 1 hour prior to cardiac bypass surgery, 1 hour following extubation, then every 8 hours for a total of 4 doses.
1859684|NCT01022749|Drug|Vaccine|MUTAGRIP (2009-2010 winter) VAXIGRIP (2010-2011 winter)
1859685|NCT01022749|Biological|Vaccine anti-H1N1|patients who received the vaccine anti-H1N1
1859686|NCT01022762|Drug|repaglinide|Individually adjusted dose for 16 weeks
1859687|NCT01022762|Drug|gliclazide|Individually adjusted dose for 16 weeks
1859688|NCT01022775|Procedure|Dynamic humeral centering|Dynamic humeral centering performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
1859689|NCT01022775|Procedure|Nonspecific mobilisation|Nonspecific mobilisation performed for 6 weeks, in 15 supervised individual outpatient sessions, plus daily home exercises for 12 months.
1859690|NCT01022788|Behavioral|Home-based counselling|
1859691|NCT01022801|Drug|Entecavir|Capsule, P.O., 0.01, 0.1 or 0.5 mg, once daily for 24 weeks
1859692|NCT01022814|Device|A disposable pad containing sensitive chemical indicators|After a urine/amniotic fluid leaking, liquid meets the diagnostic device and chemical reactions will occur in the test zones and cause a color change.
1859693|NCT01022827|Other|massage|For the massage group, a physical therapist with 8 years of clinical experience in manual therapy provided the massage on the posterior deltoid, infraspinatus, and teres minor of the involved shoulder for 18 minutes [about 6 minutes for each muscle and order was random] two times a week for 4 weeks. The techniques of massage included petrissage for 3 minutes and rolling for 3 minutes of soft tissues
1859694|NCT01022840|Drug|S-Ketamine|drug
1859695|NCT01022840|Other|Placebo Comparison|saline control
1859702|NCT01022944|Procedure|With chronic middle ear effusion|Children with chronic middle ear effusion having adenoidectomy.
1859703|NCT01022944|Procedure|Without chronic middle ear effusion|Children without chronic middle ear effusion as a control group having adenoids removed for chronic obstruction.
1859704|NCT01022957|Genetic|genetic diagnosis|to determine the long term evolution of Nephronophthisis in terms of renal disease as well as extra-renal damages for patients having a confirmed diagnosis of NPHP1, NPHP2, NPHP3, NPHP4, NPHP5, NPHP6 or NPHP8 gene mutation
1859705|NCT01022970|Drug|QAX576 placebo|
1859706|NCT01022970|Drug|QAX576|
1859707|NCT01022983|Drug|Levosimendan|At least 2 hours before surgery: Infusion of Levosimendan (0,1 microgram/kg/min.). 24 hours of infusion without a bolus.
1859708|NCT01022983|Drug|Placebo|ml/kg/hours - same infusion rate as active comparator
1859709|NCT01022996|Drug|Everolimus (RAD001)|Everolimus (RAD001) 10 mg (two 5mg tablets) given orally once daily and packed in blisters.
1859710|NCT01023009|Procedure|vitrectomy|
1859711|NCT01023022|Other|Medtronic CareLink® Network|The Medtronic CareLink® Network consists of the Medtronic CareLink® Monitor and Medtronic CareLink® Clinician Website
1859712|NCT01023035|Drug|Boceprevir|800 mg given three times a day (TID), orally (PO)
1859713|NCT01023035|Drug|Peginterferon alfa-2b (PEG2b)|1.5 µg/kg/week given subcutaneously (SC)
1859714|NCT01023035|Drug|Ribavirin (RBV)|Ribavirin weight-based dosing (WBD), 600 to 1400 mg/day given twice daily (BID), orally (PO)
1859715|NCT01023035|Drug|Erythropoietin|Initial dose of 40,000 Units given subcutaneously (SC) once weekly (QW), with dose adjustment as necessary to achieve and maintain serum hemoglobin levels of 10-12 g/dL
1859716|NCT01023048|Other|preimplantation diagnosis|genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia)
1859717|NCT01023061|Drug|abiraterone acetate|Given PO
1859718|NCT01023061|Drug|prednisone|Given PO
1859719|NCT01023061|Drug|leuprolide acetate|Given via injection
1859720|NCT01023061|Other|laboratory biomarker analysis|Correlative study
1859721|NCT01023061|Radiation|external beam radiation therapy|Undergo radiotherapy
1859722|NCT01023061|Drug|goserelin acetate|Given via injection
1859723|NCT01023074|Behavioral|Auditory training|the study was originally set up so that half of the MS subjects would received auditory training. This intervention has since been discontinued.
1859724|NCT01023087|Drug|Polymyxin E (Colistin)|Antibiotic medication; dosage to be decided according to infectious disease consultant recommendation.
1859725|NCT01023087|Drug|Non-nephrotoxic antibiotics|To be decided by the infectious disease consultant
1859726|NCT01023100|Drug|CP 690,550 oral solutions|flavored and unflavored prototype CP-690,550 formulations
1859727|NCT01023113|Procedure|PASCAL laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
1859728|NCT01023113|Procedure|Conventional laser|PRP will be completed in 2-3 sitting at 3 days interval with one spots apart and moderate intensity gray burns will be given between arcade to periphery
1859729|NCT01023126|Behavioral|Group Psychotherapy|Group psychotherapy once a week, under a psychiatrist supervision
1859730|NCT01023139|Behavioral|Sibutramine|During phase 1, sibutramine is given to all participants, 10mg po q day. If they do not meet a change in BMI of at least 2.5%,then the dosage may be increased to 15mg po q day. The main intervention in the study during phase 1 and 2is the behavioral modification
1859731|NCT01023152|Procedure|Automated cuff-inflator|RIPC protocol consisted of three 10-min cycles of lower limb ischemia at an inflation pressure of 250 mmHg induced by an automated cuff-inflator placed on the upper leg with an intervening 10 min of reperfusion during which the cuff was deflated.
1859732|NCT01023165|Procedure|Humulin, Humalog, Novolog|Supervising Physician reviews patient activation after intravenous bolus insulin treatment each week and adjusts the amounts of insulin and carbohydrates to be given in the next treatment session based on patient treatment outcomes.
1859733|NCT01023178|Drug|17beta Estradiol|Oral pill given daily at increasing doses every 6 months for 18 months.
1859734|NCT01023178|Drug|Conjugated estrogens|Oral pill, started at a low dose taken daily, dose increased every 6 months for 18 months
1859735|NCT01023178|Drug|17Beta Estradiol - transdermal|Transdermal estrogen patch, started at low dose with increasing doses eery 6 months for 18 months
1859736|NCT01023178|Drug|Progesterone, micronized|Given starting at 18 months
1859737|NCT01023191|Procedure|Percutaneous Insertion catheter|Insertion of CAPD catheter using percutaneous seldinger technique under local anaesthetic +/- sedation as required
1859738|NCT01023191|Procedure|Open insertion Catheter|Present technique of open insertion under general anaesthetic. Incision to lower abdomen and direct visualisation of catheter tip placement into pelvis.
1859739|NCT01023204|Drug|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
1859740|NCT01023217|Drug|Adefovir|Adefovir dipivoxil (Hepsera) 10 mg/day orally for 104 weeks
1859741|NCT01023217|Drug|Entecavir|Entecavir 1 mg/day orally
1859742|NCT01023217|Drug|Lamivudine|Lamivudine (Zeffix) 100 mg/day orally
1859743|NCT01023230|Drug|DV-601|Six injections of DV-601 administered over a period of 12 weeks.
1859744|NCT01023230|Drug|Entecavir|Daily dosing starting approximately 4 weeks prior to first dose of DV-601 for one year total duration.
1859745|NCT01023243|Other|Brochure: Care of the Feet for Those at Risk|Patient education materials and key messages for care of the feet for those patients at risk
1859746|NCT01023243|Other|Quality Survey: foot exam, tobacco and aspirin use|NCQA Patient Survey
1859747|NCT01023256|Drug|MOR103|MOR103 0.3 mg/kg or placebo iv x 4 doses
1859748|NCT01023256|Drug|MOR103|MOR103 1.0 mg/kg or placebo iv x 4 doses
1859749|NCT01023256|Drug|MOR103|MOR103 1.5 mg/kg or placebo iv x 4 doses
1859751|NCT01023282|Drug|ACR325|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
1859807|NCT01023646|Other|Fiber|Unrefined Carbohydrate
1998204|NCT01590199|Drug|RAD001|
1859752|NCT01023282|Drug|Placebo|Capsules, dose titration from 25 mg to 75 mg bid or matching placebo. Duration of dosing: 3 weeks
1859753|NCT01023295|Drug|fosbretabulin|single dose, intravenous infusion
1859754|NCT01023295|Drug|Saline|single dose, intravenous infusion
1859755|NCT01023308|Drug|Panobinostat|Panobinostat was administered 3x week ( 2 weeks on 1 week off)
1859756|NCT01023308|Drug|Bortezomib|Bortezomib was administered 2 x week ( 2weeks on 1 week off)
1859757|NCT01023308|Drug|Placebo|Placebo was administered 3x week ( 2 weeks on 1 week off)
1859758|NCT01023321|Drug|GLPG0555|single ascending doses, oral solution
1859759|NCT01023321|Drug|placebo|single dose, oral solution
1859760|NCT01023321|Drug|GLPG0555|multiple dose, oral solution, 7 or 14 days
1859761|NCT01023321|Drug|placebo|multiple dose, oral solution, 7 or 14 days
1859762|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral lidocaine|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral lidocaine
1859763|NCT01023334|Procedure|MSICS under topical anesthesia with intracameral balanced salt solution.|manual small incision cataract surgery(MSICS) under topical anesthesia with intracameral balanced salt solution.
1859764|NCT01023347|Drug|Paclitaxel (Genexol®)|
1859765|NCT01023347|Drug|Paclitaxel loaded polymeric micelle (Genexol-PM®)|
1859766|NCT01023360|Drug|Clopidogrel and proton pump inhibitors|"baseline detection --> clopidogrel 75 mg PO QD for 1 week --> clopidogrel 75 mg plus rabeprazole 20mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus pantoprazole 40mg PO QD for 1 week --> clopidogrel 75 mg PO QD for 1 week (wash-out phase) --> clopidogrel 75 mg plus esomeprazole 40mg PO QD for 1 week -->
1 week washout --> aspirin 100mg PO QD for 1 week"
1859767|NCT01023373|Drug|Medical treatment|hypotensive drugs, statins and anti-platelets
1859768|NCT01023373|Procedure|PTRS|Percutaneous transluminal renal artery stenting. The same medical therapy, as in group A, plus PTRS
1859769|NCT01023373|Device|renal artery stent|Non-drug intervention, percutaneous transluminal renal artery stent angioplasty
1859770|NCT01023373|Device|renal artery stent|Adding the renal artery stenting (in group B) to the optimal medical therapy (as in group A) that includes hypotensive drugs, statins and antiplatelet therapy
1859771|NCT01023386|Drug|YM155|I.V.
1859772|NCT01023399|Drug|Artesunate + Amodiaquine|Artesunate + Amodiaquine fixed dose combination
1859773|NCT01023412|Dietary Supplement|Immunonutrition|Oral Nutritional Supplement containing the amino acid arginine, omega-3 fatty acids, and nucleotides (RNA).
1859774|NCT01023425|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
1859775|NCT01023438|Other|Strategy for assisted uptitration|Active specialist support (mail, phone) and educational material provided to assist primary care physicians in drug uptitration
1859776|NCT01023438|Other|Usual care|Usual communication strategy from cardiologist to primary care physician: uptitration advised but no active support nor educational material provided
1859777|NCT01023464|Other|FID114657|artificial tears
1859778|NCT01023464|Other|SootheXP Emollient (Lubricant) Eye Drops|artificial tears
1859779|NCT01023477|Drug|Chloroquine Standard Dose (500mg/week)|Patients will receive chloroquine (500 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
1859780|NCT01023477|Drug|Chloroquine Low Dose (250mg/week)|Patients will receive chloroquine (250 mg/once a week) for 1 month prior to surgical removal of the DCIS lesion.
1859781|NCT01023477|Procedure|Breast Biopsy|Patients diagnosed with DCIS will undergo a breast biopsy prior to the start of study treatment. This biopsy is entirely voluntary and is not required to remain in the study. The biopsy will allow researchers to study the tissue for biomarkers and to determine how the DCIS tissue changes during treatment. Additional samples of the DCIS tissue will be collected at the time of surgery.
1859782|NCT01023490|Drug|Vitamin D|34,5000 IU vitamin D per week
1859783|NCT01023490|Drug|Placebo|Placebo
1859784|NCT01023516|Drug|AZD9668|2 x 30 mg oral tablets bd for 12 weeks
1859785|NCT01023516|Drug|Placebo|2 x matched placebo to oral tablet bd for 12 weeks
1859786|NCT01023529|Radiation|Palliative pelvic soft-tissue radiation (external beam)|3 Gy x 10-13 (range 30 - 39 Gy total)
1859787|NCT01023542|Drug|delayed, low-dose CNI|immunosuppression
1859788|NCT01023542|Drug|BU-CNI|Immunosuppression
1859789|NCT01023542|Drug|BU-Everolimus|Immunosuppression
1859790|NCT01023555|Other|1cc of blood in a single aerobic culture bottle|The efficacy of using 1cc of blood in a single aerobic bottle for cultures in neonatal bacteremia will will be compared with the traditional 0.5cc of blood in 2 Bottles
1859791|NCT01023568|Device|Macintosh blade|Intubation with Macintosh blade laryngoscope
1859792|NCT01023568|Device|Glidescope|Intubation with Glidescope laryngoscope.
1859793|NCT01023568|Device|Truview PCD|Intubation with Truview PCD laryngoscope.
1859794|NCT01023581|Drug|Alogliptin|Alogliptin tablets.
1859795|NCT01023581|Drug|Metformin|Metformin capsules
1859796|NCT01023581|Drug|Alogliptin Placebo|Alogliptin placebo-matching tablets.
1859797|NCT01023581|Drug|Metformin Placebo|Metformin placebo-matching capsules.
1859798|NCT01023594|Procedure|Pancreatic stent|Feeding tube insert at pancreatojejunostomy site as a stent. And then 1) tube is brought out through jejunal loop below the hepaticojejunostomy site and abdominal wall(external stent)or 2) tube is cut short (5cm length) and left in situ with fixating suture. In external stent group, tube will be removed about 1 months after operation.
1859799|NCT01023607|Drug|Atorvastatin|Atorvastatin 20mg/day
1859800|NCT01023607|Drug|Atorvastatin|Atorvastatin, 60mg/day
1859801|NCT01023607|Drug|Rosuvastatin|Rosuvastatin,10mg/day
1859802|NCT01023620|Drug|Pioglitazone|Participants will take oral Pioglitazone 45 mg daily for 16 weeks.
1859803|NCT01023620|Other|Observation|Participants will be observed for 16 weeks but will not receive drug
1859804|NCT01023633|Drug|Oxaliplatin, LV, 5-FU|"Arm B(Intervention arm) will receive FOLFOX4 for 6 cycles, maintenance with 5FU/LV for 12 cycles, and reintroduction of FOLFOX4 for 6 cycles.
FOLFOX4 regimen:
OXA 85mg/m2 , 2 hour infusion, d1 , Leucovorin 200 mg/m2 plus 5-FU 400mg IV bolus, then continuous 22 hour 600 mg/m2 infusion on day 1 and 2 Q2W"
1859805|NCT01023646|Other|Carbohydrate + Protein|Light Tuna Packed in water.
1859806|NCT01023646|Other|Carbohydrate + Fat|Butter
1859809|NCT01023659|Drug|bupropion|bupropion, 150 mg twice daily plus weekly motivational emails for 12 weeks
1859810|NCT01023659|Drug|varenicline|varenicline, 1 mg twice daily plus weekly motivational emails for 12 weeks
1859811|NCT01023659|Behavioral|motivational emails|brief motivational emails, sent weekly for 12 weeks
1859812|NCT01023672|Drug|Armodafinil|150-250 mg armodafinil by mouth daily
1859813|NCT01023685|Biological|CAD106|
1859814|NCT01023698|Procedure|laser photocoagulation|Laser photocoagulation
1859815|NCT01023711|Biological|Inactivated H1N1 vaccine|0.5 ml IM into Deltoid region of arm
1859816|NCT01023711|Biological|Inactivated H1N1 vaccine|0.5 mL IM X 1 dose
1859817|NCT01023724|Drug|Ketorolac Tromethamine 0.45%|Acuvail to be given 1 drop BID for one day prior to surgery and then 1 drop BID post operatively for 14 days.
1859818|NCT01023724|Drug|Bromfenac 0.09%|Drug given one drop BID for one day pre operatively and then BID for 14 days post operatively
1859819|NCT01023737|Drug|Hydroxychloroquine|The HCQ study dose levels are defined as 400mg/day, 600mg/day, 800mg/day and 1000mg/day (oral dosing)during the phase I MTD determination. HCQ will be administered starting on Day 2 of Cycle 1 and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
1859820|NCT01023737|Drug|Vorinostat|Oral administration of Vorinostat will be begin on Cycle 1 Day 1 at 300mg and will be continued daily thereafter until progression of disease or unacceptable toxicity develops.
1859821|NCT01023750|Drug|Fenofibrate|Participants will give a baseline blood sample and begin the 4 week course of fenofibrate. Patients will be given a 33-day dose of 145 mg of fenofibrate to be taken by mouth once a day. All doses of fenofibrate will be purchased in one batch, prepared at the pharmacy under supervision. A study nurse will collect each patient's 33-day dose of fenofibrate from the pharmacy and dispense to the study participants in the clinics. Patients will be given instructions on how to take the medication and given a 24-hr phone number to call in case of questions or need for additional care. Each patient will receive a phone call at least 2 times during the course of the trial to monitor the progress. Our co-investigators, who are also physicians will be available in case a study participant needs additional care. If not available, study participants will be able to reach the cardiologist or endocrinologist on call through an additional phone number we will provide.
1859822|NCT01023763|Other|A structured training program|A structured training program in nursing homes in the intravenous treatment of dehydration and infections.
1859823|NCT01023776|Biological|A/California/07/09 live monovalent H1N1 vaccine|0.1mL per nares intranasally, second identical dose given 28 days after first vaccine
1859825|NCT01023815|Drug|everolimus|Everolimus (Certican®) was provided in blisters containing tablets of 0.25 mg and 0.75 mg. Everolimus was initiated within 48 hours after graft reperfusion and it was administered orally.
1859826|NCT01023815|Drug|cyclosporine|Cyclosporine for microemulsion (CsA, Sandimmun® Neoral®) was coadministered with everolimus at the same time of the day. CsA was available in alu-alu blisters containing soft gelatine capsules of 100 mg, 50 mg, 25 mg and 10 mg. Oral solution, as bottles containing 50 mL of solution (100 mg/mL) has been provided and used in case the drug had been administered to patients by nasogastric tube immediately after transplant.
1859827|NCT01023815|Drug|Prednison (continuous steroids)|continuous steroids
1859828|NCT01023841|Drug|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
1859829|NCT01023841|Drug|Vehicle Sterile Solution|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margin (where the eyelashes meet the skin) once nightly for 4 months.
1859830|NCT01023854|Procedure|Continuous Paravertebral block|"The paravertébral block is a peripheral block which gets an one-sided continuous analgesia by infiltration of the spinal nerves which appear from the intervertebral foramen.
Its realization consists of a draining in 2-3 cm of the thorny apophyses ( T6-T8). During the perception of the osseous contact (cross-functional process of the vertebra), the needle is redirected in cephalic direction until a loss of resistance corresponding to the passage of the upper costo-cross-functional ligament that is in the entrance to the paravertébral space. A catheter is then inserted into the paravertébral space."
1859831|NCT01023867|Drug|donepezil|from 5mg to 10mg, once a day, 12 months
1859832|NCT01023880|Drug|CEP-18770|CEP-18770 beginning at a dose of 1.5 mg/m2. Patients will receive I.V. administration on days 1, 8, 15 (up to 8 cycles of 28 days each). When the MTD is established, additional patients will be treated at the MTD.
1859833|NCT01023919|Device|Device: Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Cypher stent or YinYi stent randomly implanted in coronary artery disease
1859834|NCT01023932|Device|Cochlear Implants|
1859835|NCT01023945|Drug|ASP1941|oral
1859836|NCT01023945|Drug|Placebo|oral
1859838|NCT01023984|Procedure|TEM - Transanal Endoscopic Microsurgery|TEM tube will be inserted in the rectum. With specialized instruments the adenoma will be dissected en bloc by a full thickness excision, after which the patient will be admitted to the hospital.
1859839|NCT01023984|Procedure|ESD - Endoscopic Submucosal Dissection|an endoscope will be inserted into the rectum and the submucosa underneath the lesion will be injected with saline to lift the adenoma. With an endoscopic knife (Insulated Tip Knife, Olympus or Water Jet, Erbe) the lesion will be resected through the submucosal plane in an eb-bloc fashion, after which the patient will be observed for at least 24h in-hospital.
1994661|NCT02951676|Procedure|Extraction|Extraction of impacted third molar teeth
1994700|NCT02942212|Drug|Nicotine Patches|Participants receive a 6-week supply of nicotine patches and instructions on how to use them. Patch therapy for participants who smoke >10 cigarettes/day consists of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day consists of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
1994701|NCT02942212|Behavioral|Advice plus Phone Counseling|Participants receive brief advice to quit smoking, as well as phone counseling for support in quitting smoking (5 sessions over the course of 6 weeks) with a counselor at the Texas Quitline.
1998205|NCT01590199|Drug|SOM230|
1860360|NCT01027000|Drug|tacrolimus|
1859847|NCT01024036|Drug|Siltuximab|Siltuximab 11 mg/kg will be administered by 1-hour intravenous infusion every 3 weeks
1859848|NCT01024036|Drug|Placebo|Placebo will be administered by 1-hour intravenous infusion every 3 weeks
1859849|NCT01024036|Drug|Best Supportive Care (BSC)|BSC included treatment for effusions, antipyretics, antipuretics, antihistamines, pain medication, treatment for infections, transfusions, management of infusion-related reactions, and corticosteroids.
1859850|NCT01024062|Drug|Paclitaxel|Solution, IV, 100 mg/m², weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
1859851|NCT01024075|Drug|Dexamethasone|4cc of Dexamethasone and 4cc of Saline mixed with Sinufoam
1859852|NCT01024075|Drug|Saline|8cc of Saline mixed with Sinufoam
1859853|NCT01024101|Drug|Paclitaxel|Solution, IV, 100 mg/m², Weekly for 6 of 7 weeks, until disease progression or unacceptable toxicity became apparent
1859854|NCT01024127|Other|Laboratory Biomarker Analysis|Correlative studies
1859855|NCT01024140|Drug|Escitalopram|Subjects were started on 5mg escitalopram. Medication was increased as tolerated in weekly 2.5, 5 or 10 mg increments, until a maximally tolerated dosage or a clinical response was achieved. The final dosage ranged from 5 to 20 mg/day.
1859856|NCT01024153|Behavioral|Active video game play|Children will get a Wii video game console and one game at week one and another at week 7. We will monitor their video game play and physical activity during this time.
1859857|NCT01024166|Behavioral|Questionnaire and Review Session|Use PRO computer system to complete 2 questionnaires about any symptoms patient may be experiencing and their overall health, 30 minutes to complete. Review session about use of computer system and suggested changes.
1859858|NCT01024166|Behavioral|Questionnaire and Review Session|Use PRO computer system to complete 4 questionnaires about symptoms their overall health of patients, 30 minutes to complete. Review session about use of computer system and suggested changes.
1859859|NCT01024179|Device|Polymer-based sirolimus-eluting stent (Partner stent )|Partner stent (polymer-based sirolimus-eluting stent) implanted in culprit coronary artery
1859860|NCT01024192|Drug|ZOLPIDEM SL800750|"Pharmaceutical form: Zopidem 12.5 mg tablets
Route of administration: Oral
Dose regimen:One tablet at bed time and as needed (the patients choose which night they take the tablet without limit of number of nights)"
1859861|NCT01024205|Drug|sunitinib malate|
1859862|NCT01024205|Other|laboratory biomarker analysis|
1859863|NCT01024205|Procedure|adjuvant therapy|
1859864|NCT01024205|Procedure|neoadjuvant therapy|
1859865|NCT01024205|Procedure|therapeutic conventional surgery|
1859866|NCT01024218|Device|NovoFine® needle 8 mm|
1859867|NCT01024218|Device|autocover needle|
1859868|NCT01024231|Drug|BMS-936558 (MDX1106-04)|
1859869|NCT01024231|Drug|Ipilimumab|
1859870|NCT01024244|Drug|Placebo|Administered po BID, prior to morning and evening meals for 12 weeks.
1859871|NCT01024244|Drug|LY2599506|Administered po for 12 weeks
1859872|NCT01024257|Radiation|beta-irradiation|
1859873|NCT01024257|Procedure|conjunctival autograft|
1859874|NCT01024270|Drug|Misoprostol|
1859876|NCT01024309|Procedure|Mini-Posterior surgical approach for total hip arthroplasty|Mini-Posterior surgical approach for total hip arthroplasty
1859877|NCT01024309|Procedure|Direct Anterior surgical approach for total hip arthroplasty|Direct Anterior surgical approach for total hip arthroplasty
1859878|NCT01024322|Drug|Ciprofloxicine or Vigamox or other.|Ciprofloxicine or Vigamox or other to be used qid till epithelialized.
1859879|NCT01024322|Drug|Nonsteroidal (Acular, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) used up to qid for up to 5-10 days post-op
1859880|NCT01024322|Drug|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid for 8 weeks.
1859881|NCT01024335|Drug|injectable naltrexone and dronabinol|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus dronabinol 15 mg bid for the first 5 weeks of treatment.
1859882|NCT01024335|Drug|Naltrexone and placebo|Injectable form of naltrexone 380 mg (Vivitrol) will be administered once per month plus placebo bid for 5 weeks.
1859883|NCT01024348|Drug|extended-release tramadol|30 minutes prior vto surgery and 24 hours afterwards, patients will take a tablet of 100 mg TRAMADEX-OD
1859884|NCT01024348|Drug|paracetamol|in the control group, postoperative pain will managed with 1 gr paracetamol (per os) as needed (up to 4 times a day)
1859886|NCT01024387|Drug|AMG 479|Given intravenously once every three weeks
1859887|NCT01024400|Biological|Non-adjuvanted A(H1N1)v influenza vaccine|15 mcg HA/0.5 ml
1859888|NCT01024413|Drug|erlotinib|study arm.erlotinib 150 mg oral till disease progression
1859889|NCT01024413|Drug|gefitinib|study arm.gefitinib 250 mg oral till disease progression
1859890|NCT01024426|Procedure|Enhanced health facility-based care|The intervention is designed to address barriers to delivering quality care at health centers and will focus on three components: (1) training in-charges in health center management, (2) providing training to health workers in fever case management and patient-centered services, and (3) ensuring adequate supplies of artemether-lumefantrine and RDTs.
1859891|NCT01024426|Other|Standard care|In the clusters randomized to standard care, standard care will include services typically provided by government-run facilities; we will not provide any additional support to these facilities. Health care will be provided to patients attending these facilities according to the usual standards; in-charges will continue to manage the facilities using their standard approach, no additional training will be provided to the health workers stationed at these facilities; and no support for staffing or supplies will be provided beyond what is supplied by the district and MoH.
1859979|NCT01009645|Behavioral|Control Educational Message|Participants randomized to this intervention will receive an educational brochure created and used by the CDC in a previous influenza season.
1859980|NCT01009658|Dietary Supplement|Monosodium glutamate|Oral intake of 2.0 g of monosodium glutamate on the examination day and 0.6 g of sodium chloride on the other examination day.
1859981|NCT01009658|Dietary Supplement|Sodium chloride|Oral intake of 0.6 g of sodium chloride on the examination day and 2.0 g of monosodium glutamate on the other examination day.
1859892|NCT01024439|Procedure|transumbilical single incision laparoscopic appendicectomy|"Patients will undergo transumbilical single incision laparoscopic appendicectomy. A single incision is made on umbilicus within the margin of umbilical skin ring. Peritoneal cavity is entered by open method and the fascia layer can be extended up to 2.5cm in length. A single incision laparoscopic device (Olympus) will be inserted. Conventional laparoscopic instruments will be used. Umbilical fascia will be closed by PDS-1 J-shape needle. Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. The umbilicus is reconstructed by interrupted 3-0 nylon by tacking the skin onto the fascia layers.
Three non-transparent dressings will be placed as if conventional laparoscopic appendicectomy has been done."
1859893|NCT01024439|Procedure|conventional laparoscopic appendicectomy|"Patients will undergo conventional laparoscopic appendicectomy. A 10-mm subumbilical port will be inserted by open method. Two 5-mm working ports will be inserted under laparoscopic view at patient's left lower quadrant and suprapubic area. Umbilical fascia will be closed by PDS-1 J-shape needle.
Local anaesthetic agent , Marcain 0.5% should be infiltrated into the fascial layers as well as the skin layers with dosage up to 20ml. All skin wound will be approximated with 3-0 nylon interrupted stitches and covered with non-transparent dressings."
1859894|NCT01024452|Device|DAWN AC|computerized dosing management system for anticoagulation clinics
1859895|NCT01024452|Device|Hamilton Nomogram|simple nomogram for warfarin maintenance dosing
1859896|NCT01024465|Device|ReShape Duo Balloon|ReShape Duo Balloon
1859897|NCT01024491|Drug|paroxetine|daily dose of paroxetine 15mg for 12 weeks
1859898|NCT01024491|Drug|paroxetine|active daily treatment with paroxetine 20 mg
1859899|NCT01024491|Drug|placebo|active daily treatment with placebo
1859900|NCT01024504|Drug|Oxaliplatin|Oxaliplatin at the dose of 85 mg/m2 over a 4 hour intravenous infusion at day 1 every 2 weeks for a maximum of 12 consecutive cycles
1859901|NCT01024504|Drug|Capecitabine|Capecitabine at the dose of 1500 mg/m2 per os at days 1 to 7 every 2 weeks for a maximum of 12 consecutive cycles
1859902|NCT01024504|Drug|Bevacizumab|Bevacizumab at the dose of 5 mg/Kgr (intravenous infusion) at day 1, every 2 weeks for a maximum of 12 consecutive cycles
1859903|NCT01024517|Drug|GLPG0259 solution|single oral dose, GLPG0259, 50 mg oral solution
1859904|NCT01024517|Drug|GLPG0259|single oral dose, GLPG0259, 50 mg solid formulation
1859905|NCT01024530|Biological|immune killer cells (IKC)|autologous immune killer cells
1859906|NCT01024543|Drug|Angiotensin II|Angiotensin II
1859907|NCT01024543|Drug|Phenylephrine|Phenylephrine
1859908|NCT01024543|Drug|Placebo|
1859909|NCT01024569|Behavioral|Wellness Recovery Action Planning (WRAP)|WRAP consists of 8 sessions lasting for 2-½ hours, convened once a week over a period of 8 weeks.
1859910|NCT01024582|Procedure|biopsy|before treatment a biopsy will be taken to confirm breast cancer type
1859911|NCT01024582|Procedure|fine-needle aspiration|at FNA tumor material will be collected and fresh frozen for micro-analyses; parafin embedded tissue will bestored for tissue-array analysis
1859912|NCT01024582|Radiation|accelerated partial breast irradiation|
1859913|NCT01024582|Radiation|image-guided radiation therapy|
1859914|NCT01024608|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for two weeks.
1859915|NCT01024608|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered each morning for two weeks.
1859916|NCT01024621|Device|Endomicroscope|Pentax EC3870K, Tokyo, Japan
1859917|NCT01024621|Device|Standard endoscopy|Pentax EG-2931 gastroscope
1859918|NCT01024634|Behavioral|Endurance Exercise|8 weeks of Endurance exercise training, 3-4 times per week, 45-60 minutes perr session
1859919|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 200 mg every 2 weeks
1859920|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
1859921|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 4 weeks
1859922|NCT01024647|Biological|certolizumab pegol|certolizumab pegol 400 mg every 2 weeks
1859923|NCT01024660|Drug|Donepezil|5 mg capsule, orally, once daily, first 14 days of treatment
1859924|NCT01024660|Drug|Donepezil|10 mg, orally, once daily, for remaining 70 days of treatment
1859925|NCT01024660|Drug|Placebo to match Aricept|Placebo capsule, orally, 84 days of treatment
1859926|NCT01024686|Biological|p52-/p36- GAP Vaccine|Administered by five bites from GAP-infected Anopheles mosquito
1859927|NCT01024686|Biological|p52-p36- GAP Vaccine|Administered by 200 bites from GAP-infected Anopeles mosquito
1859928|NCT01024686|Biological|p52-/p36- GAP Vaccine|Five doses separated by 4-weeks, each administered by 200 bites from GAP-infected Anopheles mosquito
1859929|NCT01024712|Drug|carboplatin|
1859930|NCT01024712|Drug|gefitinib|
1859931|NCT01024712|Drug|paclitaxel|
1859932|NCT01024712|Procedure|quality-of-life assessment|
1859933|NCT01024725|Other|Follow-up|Nasopharyngeal/oropharyngeal and blood samples, interviews, questionnaires, register data
1859934|NCT01024738|Drug|Fluoride|Brush half mouth twice daily for four days.
1859935|NCT01024738|Drug|Triclosan, fluoride|Brush twice daily
1859936|NCT01024738|Drug|Chlorhexidine Gluconate|Rinse mouth twice a day
1859937|NCT01024751|Device|Bausch & Lomb Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
1859938|NCT01024751|Device|Ciba's Multi-Purpose Solution|Lens care product for disinfecting lenses on a daily basis.
1859939|NCT01024777|Drug|Cholecalciferol|Cholecalciferol (Vitamin D3) 10,000 IU in tablet form will be taken once daily for the duration of the trial (6 months)
1859940|NCT01024777|Drug|Cholecalciferol|Cholecalciferol (Vitamin D3) 400 IU in tablet form will be taken once daily for the duration of the trial (6 months)
1859941|NCT01024790|Behavioral|Exercise group|24 week group exercise class supplemented with behavioral activation strategies
1859942|NCT01024803|Device|"Device name: Retina Implant model Alpha. Surgical implantation of medical device into eye"|"Surgical implantation of medical device named Retina Implant into eye to restore vision partially.
Randomized intra-individual implant activation in patient under test conditions such as: FrACT, BaLM, BaGA, maze, ADL."
1859943|NCT01024816|Behavioral|Restorative yoga|"Group yoga sessions: Participants will attend 90 minute yoga group classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. We plan a progressive series of classes, with a subset of poses for each class and then selecting individual poses to focus on in each class.
Home yoga practice: Participants will be given a video disk (DVD) of the yoga postures at the start of the yoga intervention practice. We will also provide the yoga participants with a written manual with pictures and descriptions of each posture that they will be taught in the group sessions. The participants will be asked to practice the postures taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given a set of yoga props for their use at home. We will ask all participants to keep a log of their home practice sessions"
1859944|NCT01024816|Behavioral|Stretching|"Group classes: Participants will attend 90 minute group stretching classes for 48 weeks: twice a week for 6 weeks, then once weekly during weeks 7 to 12, then every other week for weeks 13 - 24, and once a month for 6 months. The stretches will address all body parts, including cervical, upper extremity, thoracic, lumbar, pelvic, and lower extremity musculature.
Home stretching practice: Each participant will receive a written manual with pictures and descriptions of each stretch that they will be learning in group sessions and a DVD with instruction on each of the stretches. The participants will be asked to practice the stretches taught during their group sessions at home at least three times a week with the assistance of the DVD and manual. Each participant will be given stretching supplies. We will ask all participants to keep a log of their home practice sessions."
1859945|NCT01024829|Radiation|Radiotherapy|Radiotherapy
1859946|NCT01024842|Biological|MVA.HIVconsv low dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 1x10^8 pfu at week 0, 4 and 12.
1859947|NCT01024842|Other|Placebo low dose|Three intramuscular injections of placebo alone (200ul) at week 0, 4 and 12.
1859948|NCT01024842|Biological|MVA.HIVconsv high dose|Three intramuscular injections of MVA.HIVconsv alone at a dose of 4x10^8 pfu at week 0, 4 and 12.
1859949|NCT01024842|Other|Placebo high dose|Three intramuscular injections of placebo alone (800ul) at week 0, 4 and 12.
1859950|NCT01024855|Device|RevitaLens OcuTec MPS (Investigational MPS) and Opti-Free RepleniSH MPS (control)|multi-purpose lens care solution
1859951|NCT01024868|Drug|Ropivacaine 0,5%|Injection of ropivacaine 0,5% 20 ml bilaterally before surgery
1859952|NCT01024881|Procedure|neutral shoulder position|neutral shoulder position during infraclavicular subclavian catheterization
1859953|NCT01024881|Procedure|lowered shoulder position|lowered shoulder position during infraclavicular subclavian catheterization
1859954|NCT01024894|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
1859955|NCT01024907|Radiation|proton beam radiation therapy|Undergo radiation
1859956|NCT01024907|Procedure|quality-of-life assessment|Ancillary study
1859957|NCT01024907|Other|questionnaire administration|Ancillary study
1859958|NCT01024920|Drug|BIBF 1120|VEGF inhibitor
1859959|NCT01024920|Drug|sunitinib|VEGF inhibitor
1859960|NCT01024933|Behavioral|Positive Affect/Self-Affirmation/Motivational Interviewing|The PASA group-intervention will receive small gifts one week prior to their scheduled follow up. The PASA intervention involves reminding participants to think about their proud and positive moments. The motivational interviewing intervention includes assessing the patient's motivation and confidence; elicit barriers and concerns; summarize in a non-threatening manner the 'pros' and 'cons' of patient's concerns, thereby eliciting positive self-motivational statements about the behavior. Follow up will be every two months.
1859961|NCT01024933|Behavioral|Educational and Behavioral|The Education and Behavioral Contract (Control group)will receive an educational workbook and behavioral contract. In addition, each patient will receive a home blood pressure device for self-monitoring, and will be called every two months.
1859962|NCT01024946|Drug|everolimus|Everolimus will be administered at a dose of 10mg orally once daily continuously. Dose reduction may be required depending on the type and severity of toxicity encountered. One cycle will be considered 28 days. Patients will have CT scans to evaluate for response after cycle 1 and cycle 2, and then every two cycles thereafter.
1859963|NCT01024959|Other|PCA3 Assay|Post-Digital Rectal Exam (DRE) urine collected prior to prostate biopsy
1859964|NCT01024972|Drug|Dantrolene|Dantrolene 1.25mg/kg IV (includes 5% mannitol) every 6 hours x 7 days
1859965|NCT01024972|Drug|Placebo|equiosmolar volume (5% mannitol) every 6 hours x 7 days
1859966|NCT01024998|Biological|AAV2-sFLT01|2 x 10^8 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
1859967|NCT01024998|Biological|AAV2-sFLT01|2 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
1859968|NCT01024998|Biological|AAV2-sFLT01|6 x 10^9 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
1859969|NCT01024998|Biological|AAV2-sFLT01|2 x 10^10 vector genomes (vg) AAV2-sFLT01. Single intravitreal injection to a single eye, using a fixed volume of 100 μL.
1859970|NCT01025011|Device|Fundus photography, cubital blood draw|blood draw from a cubital vein to measure hemoglobin concentration taking a fundus photography with a Nidek AFC-230, no pupil dilation needed
1859971|NCT01009619|Drug|Azithromycin|Azithromycin 250 mg daily during 5 days followed by 250 mg three times a week on Mon., Wed. and Fri. during study-period.
1859972|NCT01009619|Drug|Placebo|Placebo once daily during 5 days, followed by one placebo three times a week on Mon., Wed. and Fri during rest of study-period.
1859973|NCT01009632|Behavioral|Resonant voice|4-hr of resonant voice exercise
1859974|NCT01009632|Behavioral|Voice rest|4-hr of complete refrain from any voice use
1859975|NCT01009632|Behavioral|Spontaneous speech|
1859976|NCT01009645|Behavioral|Fact Only Education Message|Participants randomized to this intervention will receive an educational brochure listing the facts of the influenza vaccine.
1859977|NCT01009645|Behavioral|Fact and Myth Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts and myths of the influenza vaccine.
1859978|NCT01009645|Behavioral|Fact, Myth, Why Educational Message|Participants randomized to this intervention will receive an educational brochure listing the facts, myths, and refutation of the myths of the influenza vaccine.
1859982|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 20 mg, delivered through a catheter into a thrombus
1859983|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 40 mg, delivered through a catheter into a thrombus
1859984|NCT01014975|Biological|Plasmin (Human)|Plasmin (Human), 80 mg, delivered through a catheter into a thrombus
1859985|NCT01014988|Drug|zanamivir aqueous solution|Zanamivir aqueous solution 10mg/mL is a clear, colorless, single use, sterile non-preserved preparation containing 10mg of zanamivir in each milliliter, and made isotonic with sodium chloride. It is presented in 20mL clear glass vials closed with rubber stoppers. Each vial contains 200mg of zanamivir.
1859986|NCT01015001|Procedure|Active rTMS x sham (placebo) rTMS|"Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations."
1859987|NCT01015001|Procedure|sham rTMS|same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region
1859988|NCT01015001|Procedure|(1Hz) rTMS applied over the left temporoparietal cortex|20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
1859989|NCT01015014|Drug|AN3365|LP, 600 mg vial; reconstituted in Normal Saline
1859990|NCT01015014|Drug|Placebo|0.9% sodium chloride for injection
1859991|NCT01015027|Biological|REGN668|4 IV Cohorts (Dose 1, 2, 3, & 4)
1859992|NCT01015040|Drug|solifenacin succinate suspension|Oral
1859993|NCT01015040|Drug|solifenacin succinate tablet|Oral
1859994|NCT01015053|Procedure|bilateral ultrasound-guided rectus sheath block|Ultrasound is used to guide the deposition of Ropivacaine 0.2% 1cc/kg in the posterior sheath of the rectus muscle containing the peripheral nerves that innervate the abdomen.
1859995|NCT01015053|Procedure|Wound infiltration|Ropivacaine 0.2% 1cc/kg is injected subcutaneously at the site of incision by the surgeon.
1859996|NCT01015066|Drug|Buprenorphine/naloxone|Sublingual tablets, 2/0.5mg (ratio buprenorphine:naloxone = 4:1), three times a day for six months (doses may be adjusted based on an individual's response)
1859997|NCT01015066|Drug|Naltrexone|Oral tables, 50 mg/d, once a day for six months
1859998|NCT01015105|Other|observation|observation
1959829|NCT03312582|Drug|1% local metformin gel|After providing manual debridement in deep peri-implant probing depths, 1% metformin gel will be applied.
1959830|NCT03312582|Procedure|Placebo|
1994500|NCT02989753|Dietary Supplement|VAL070-A|After randomization (V1 visit), 8 capsules per day of VAL070-A during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
1860005|NCT01015131|Radiation|18F-FLT-PET/CT Imaging|Participants receive the investigational radiotracer 18F-FLT intravenously and undergo Positron Emission Tomography (PET)/Computed Tomography (CT) scans at the following three times: prior to initiation of chemotherapy, at the end of the first cycle of treatment, and at the conclusion of chemotherapy.
1860006|NCT01015144|Drug|Tulip|Patients were divided into two groups: A, who were administered atorvastatin 40 mg daily for two months and 10 mg for next 4 months; and group B, 4 who were treated according to current guidelines without statin therapy.
1860007|NCT01015157|Procedure|Roux-en-Y laparoscopic gastric bypass for morbid obesity|Primary bariatric surgery. Standard laparoscopic procedure with linear stapling divising of the stomach (Echelon 60 stapler, GOLD cartridges) with or with Seamguard reinforcement
1860008|NCT01015170|Drug|bupropion HCl|150mg BID for up to 8 weeks + counseling
1860009|NCT01015183|Drug|Zinc Sulfate|Zinc Sulfate: 100 mg of zinc element, per day, bid for two weeks start with chemotherapy
1860010|NCT01015183|Drug|Placebo|Placebo: as the same of intervention group
1860011|NCT01015196|Drug|Zavedos|
1860012|NCT01015196|Drug|Cerubidine|
1860013|NCT01015209|Device|Chitosan- N- Acetylcysteine eye drops|Cohort 1: 1 drop once Cohort 2: 2 drops daily for 5 days
1860014|NCT01015222|Drug|Dasatinib|Starting dose of 50 mg daily PO for 28 day cycle
1860015|NCT01015222|Drug|Bevacizumab|Starting dose 5 mg/kg IV Day 1 and 15
1860016|NCT01015222|Drug|Paclitaxel|Starting dose 40 mg/m2 IV Day 1, 8 and 15
1860017|NCT01015235|Drug|Placebo|Subcutaneous infusion-once over 4 hours
1860018|NCT01015235|Drug|KAI-1678|Subcutaneous infusion-once over 4 hours
1860019|NCT01015235|Drug|Ketorolac Tromethamine|Active comparator, IV infusion, once
1860020|NCT01015248|Drug|Rituximab and Bendamustine|Rituximab 375 mg/m2 iv. day 1 Bendamustine 90 mg/m2 iv. day 1 and 2
1860021|NCT01015261|Procedure|Bone Marrow Transplantation|Allogenic Bone Marrow Transplantation
1860022|NCT01015261|Procedure|Chemotherapy|"Cyclophosphamide 1200 mg/m2 D15
Daunorubicin 45 mg/m2 D15—D18
Vincristine 1 mg/m2 D15, D22
Dexamethasone 24 mg/d D12—D28"
1860023|NCT01015287|Drug|Placebo|Administered once orally
1860024|NCT01015287|Drug|Prasugrel|Administered orally
1860025|NCT01015300|Drug|Avastin|Patients will receive Bevacizumab (Avastin) 10mg/kg IV every two weeks for 6 months
1860026|NCT01015313|Other|intensive sodium management|"dietary sodium restriction
avoiding positive sodium balance during dialysis by: aligning dialysate sodium with plasma sodium, avoiding sodium profiling, and avoiding saline solutions to treat intradialytic symptoms"
1860027|NCT01015326|Other|Questionnaire|Administered questionnaire
1860028|NCT01015326|Other|Questionnaire|Administered questionnaire
1860029|NCT01015339|Drug|Paclitaxel|80mg/m2 infusion,d1,d8 every 3 weeks
1860030|NCT01015339|Drug|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
1860031|NCT01015339|Drug|capecitabine|Dosing schedule: 1000mg/m2 bid, days 1-14, every 3 weeks
1860032|NCT01015339|Drug|cisplatin|80mg/m2, day 1 of every 3 weeks
1860033|NCT01015352|Drug|Azacitidine|Azacitidine 75mg/sqm SQ per day for 5 days every 28 days
1860034|NCT01015352|Drug|Epoetin beta|"Epoetin beta : 60000U weekly SQ injections
NeoRecormon®"
1860035|NCT01015365|Procedure|Cementless one-stage surgical revision|A Cementless one-stage surgical revision is to be performed for all included in the cohort.
1860036|NCT01015378|Procedure|laparoscopid sigmoid resection|A second episode of diverticulitis will be treated with IV antibiotics and documented with CT scan and blood tests
1860037|NCT01015391|Drug|T2|1.5mg/kg/day, PO (per oral),three times a day: until progression or unacceptable toxicity develops
1860038|NCT01015391|Drug|Azathioprine|2.5mg/kg, PO (per oral) one time a day:until progression or unacceptable toxicity develops the first month:1.5mg/kg,PO,one time a day the second month:2.0mg/kg,PO,one time a day since the third month:2.5mg/kg,PO,one time a day
1860039|NCT01015404|Drug|Trafermin|Administered to the bone defect during flap operation
1860040|NCT01015417|Drug|Amoxicillin clavulanic acid|Postoperative administration of 2g, 3 times daily, since 5 days, of amoxicillin clavulanic acid (Augmentin or generic) oral form or parenteral form according to clinical patient and by the choice of medical teams
1860041|NCT01015417|Other|No medication|no postoperative antibiotics
1860042|NCT01015430|Drug|Placebo (for RO4917523 ascending doses)|Placebo daily po
1860043|NCT01015430|Drug|Placebo (for RO4917523 fixed dose)|Placebo daily po
1860044|NCT01015430|Drug|RO4917523|RO4917523 ascending doses daily po
1860045|NCT01015430|Drug|RO4917523|RO4917523 fixed dose daily po
1860046|NCT01015443|Biological|Tecemotide|Subjects will receive 8 consecutive weekly subcutaneous vaccinations with 918 microgram (mcg) of tecemotide (L-BLP25) at Week 1, 2, 3, 4, 5, 6, 7, and 8 (primary treatment phase) and then at 6-Week intervals, beginning at Week 14 (maintenance phase) until disease progression (PD) is documented or the subject discontinues for any other reason.
1860047|NCT01015443|Drug|Single low dose cyclophosphamide|A single intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first administration of tecemotide.
1860048|NCT01015443|Drug|Placebo|Subjects will receive 8 consecutive weekly subcutaneous vaccinations of tecemotide (L-BLP25) matching placebo at Week 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance treatment at 6-Week intervals, beginning at Week 14, until PD is documented or the subject discontinues for any other reason.
1860049|NCT01015443|Other|Saline|A single IV infusion of 0.9 percent (%) sodium chloride (saline) will be given 3 days before first placebo vaccination.
1860050|NCT01015443|Other|Best Supportive Care (BSC)|The BSC will be provided as per the investigator's discretion, and is not limited to palliative radiation, psychosocial support, analgesics and nutritional support.
1860051|NCT01015456|Drug|mycophenolate sodium|per oral, twice daily, for 12 months
1860052|NCT01015456|Drug|cyclophosphamide|intravenous, monthly, for 6 months
1860053|NCT01015469|Procedure|Conventional laparoscopic Roux-en-Y gastric bypass|Conventional laparoscopic Roux-en-Y gastric bypass
1860054|NCT01015469|Procedure|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring|conventional laparoscopic Roux-en-Y gastric bypass with additional restrictive silastic ring (GaBP-Ring)
1860055|NCT01015482|Drug|Remifentanil|Remifentanil Infusion
1860056|NCT01015482|Drug|Midazolam|Midazolam Infusion
1860057|NCT01015495|Drug|ranibizumab|0.5 mg dose of ranibizumab. Treatment will be given at baseline, month 1, and month 2, and then monthly until OCT shows absence of subretinal fluid and FA shows absence of leakage
1860058|NCT01015508|Other|Very Low Energy Diet (VLED)|a VLED (Modifast) for 2 months in order to reduce body weight
1860059|NCT01015508|Other|Weight maintenance|10 months
1860060|NCT01015521|Drug|Aminoflavone Prodrug|Aminoflavone Prodrug administered D1, D8 of 21-day cycle
1860061|NCT01015534|Drug|Temozolomide|
1860062|NCT01015534|Radiation|Whole brain irradiation|
1860063|NCT01015547|Drug|Infliximab plus methotrexate|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
1860064|NCT01015547|Drug|Combination of DMARDs|IFX given 3-5mg/kg every 6 weeks, oral MTX given 15mg/m2 weekly, SSZ 40mg/kg up to 2000mg daily, HCQ 5mg/kg daily. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
1860065|NCT01015547|Drug|Methotrexate alone|Oral MTX given 15mg/m2 weekly. If ACR Pedi 75 is not reached by week 12, MTX dose is doubled up to parenteral 30 mg/m2 weekly dose. If patient does not reach ACR Pedi 30 after dose escalation, failure.
1860066|NCT01015560|Drug|anti-CCR2 monoclonal antibody MLN1202|
1860067|NCT01015560|Genetic|polymorphism analysis|
1860068|NCT01015560|Other|laboratory biomarker analysis|
1860069|NCT01015573|Device|magnetic sensor system to measure the movements of finger tapping|
1860070|NCT01015586|Drug|Lamotrigine|Six week titration from 25 mg/day to 200 mg/day, then 200 mg/day maintenance for additional six weeks
1860071|NCT01015586|Drug|Placebo|Placebo once daily for 12 weeks
1860072|NCT01015599|Behavioral|HOP'N After-school Program|Daily 30 minutes of physical activity following CATCH guidelines, Daily healthful snack with fruit/vegetables, Weekly nutrition and physical activity education based on social cognitive theory.
1994501|NCT02989753|Dietary Supplement|VAL070-B|After randomization (V1 visit), 8 capsules per day of VAL070-B during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
1860074|NCT01015625|Procedure|Surgery|lumpectomy or mastectomy with or without radiotherapy. Sentinel biopsy followed by axillary dissection (level I-II)
1860075|NCT01015625|Procedure|Surgery on Demand|if necessary local therapy on demand
1860076|NCT01015638|Drug|Clindamycin and BPO 5% gel|Once-daily applications, to the randomized side of the face either left or right, of clindamycin and benzoyl peroxide (BPO) 5% gel.
1860077|NCT01015638|Drug|Clindamycin phosphate and benzoyl peroxide 2.5% gel.|Once daily application of clindamycin phosphate and benzoyl peroxide (BPO) 2.5% gel
1860078|NCT01015651|Drug|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 2 ng/ml.
1860079|NCT01015651|Drug|remifentanil|anesthesia is induced and maintained with a target-controlled infusion of remifentanil at 4 ng/ml.
1860080|NCT01015664|Drug|temsirolimus|10, 15, or 25 mg IV over 30 minutes on Days 1, 8, 15 and 22
1860081|NCT01015664|Drug|cisplatin|75 mg/m2 IV over 60 minutes on day 1
1860082|NCT01015664|Drug|cetuximab|400 mg m2 on Day 1 of Cycle 1, then 250 mg/m2 IV over 60 minutes on Days 1, 8, 15, and 22
1860083|NCT01015677|Drug|MK-6913|
1860084|NCT01015677|Drug|17-β estradiol|
1860085|NCT01015677|Drug|Placebo to MK-6913|
1860086|NCT01015677|Drug|Placebo to 17-β estradiol|
1860087|NCT01015677|Drug|MK-6913 25 mg|
1860088|NCT01015703|Biological|CoVaccine HT|intramuscular injection, dose escalation
1860089|NCT01015716|Behavioral|Intervention-group|Physical exercise, dietary counseling and cognitive behavioral training as a combined intervention
1860090|NCT01015716|Behavioral|Control-group|Invitation to attend a monthly seminar of 2 hour duration on a wide range of health related topics
1860091|NCT01015729|Drug|Esomeprazole/ASA Fixed Combination|Capsule, oral, single dose
1860092|NCT01015729|Drug|Esomeprazole|oral, single dose
1860093|NCT01015729|Drug|ASA|Tablet, oral, single dose
1860094|NCT01015742|Drug|Stem cell Transplantation|"Busulfan: 3.2 mg/kg IV daily on days -7 to -4
Cyclophosphamide : 60 mg/m² daily on days -3 to -2
Rabbit Thymoglobulin 2.5mg/kg IV daily on days -3 to -2
Cyclosporin will begin on day -2 (IV or oral) for at least 180 days. Target trough level for cyclosporin is 200 ng/ml. In the absence of GVHD, Cyclosporin tapering will begin on day +90
Methyl prednisolone (1mg/kg/d IV) will begin on day -2 to +7 and then 0.5mg/kg until +14 posttransplant."
1860095|NCT01015755|Behavioral|combined therapy treatment|mouth care
1994702|NCT02942212|Behavioral|Advice plus Counseling Sessions|Participants receive brief advice to quit smoking, as well as 5 individual, in-person smoking cessation treatment counseling sessions.
1994703|NCT02942212|Behavioral|Self Assessment Questionnaires|Participants complete self assessment questionnaires the week before quitting smoking, the day that they quit, and 1, 2, and 4 weeks after quitting, and at 3 month follow up.
1860098|NCT01015781|Procedure|Progressive Tinnitus Management|"The program follows a five-level progressive intervention model that addresses the various needs of tinnitus patients in a systematic and hierarchical manner-from initial contact with a VA provider through long-term treatment. The five levels of progressive intervention are: 1) Triage; 2) Audiologic Evaluation; 3) Group Education; 4) Interdisciplinary Evaluation; 5) Individualized Support"
1860099|NCT01015781|Procedure|Wait List Control|VA audiologists typically (a) perform an audiologic evaluation; (b) fit hearing aids if necessary; and (c) provide basic information about tinnitus in the form of one-time, one-on-one informational counseling and/or a tinnitus handout. We therefore will provide these procedures for subjects who are randomized to receive usual care. Usual care subjects also can be referred for other clinical services as deemed appropriate.
1860100|NCT01015794|Drug|ephedrine hydrochloride|single oral dose, 1mg/kg body weight
1860101|NCT01015794|Drug|ephedrine hydrochloride|single dose of 1 mg/kg body weight
1860106|NCT01015820|Procedure|EGD with EUS|EUS was performed in order to measure blood flow in duodenum.
1860107|NCT01015820|Device|4D-ELF|During the EUS, blood flow was measured in the duodenum with the 4D-ELF device.
1860108|NCT01015833|Drug|Doxorubicin Hydrochloride|Given IV
1860109|NCT01015833|Other|Laboratory Biomarker Analysis|Correlative studies
1860110|NCT01015833|Other|Pharmacogenomic Study|Correlative studies
1860111|NCT01015833|Drug|Sorafenib Tosylate|Given PO
1860112|NCT01015846|Other|Exercise|Redcord (sling exercise) and traditional exercise
1860113|NCT01015846|Other|Core stability exercise|Traditional core stability exercise
1860114|NCT01015859|Device|Pacing mode|To determine which mode (DDD vs AAI SafeR)minimizes ventricular pacing
1860115|NCT01015872|Device|CPAP treatment|CPAP treatment is to improve airway obstruct for obstructive sleep apnea, and after 3 months' treatment, we evaluate the effects.
1860116|NCT01015898|Radiation|photodynamic therapy|treatment of bcc with 5_ALA cream 20% topical administration once monthly+ photodynamic therapy (red light) 120 j/cm2 once monthly
1860117|NCT01015911|Drug|SGN-75|SGN-75 (IV) in 21- or 28-day cycles; dose range: 0.3-9 mg/kg
1860118|NCT01015924|Procedure|plate osteosynthesis|Patients are operated upon within 3 w of the fracture
1860119|NCT01015924|Procedure|ESIN|Elastiv stable intramedullary nailing
1860120|NCT01015937|Drug|Turmeric extract|turmeric 500 mg TID for 45 days
1860121|NCT01015937|Drug|Angiotensin-converting enzyme (ACE) inhibitor + Angiotensin-II type 1 receptor (ATI) blocker|maximum dosage as patient tolerated for 45 days
1860122|NCT01015950|Dietary Supplement|Plumpy'Sup|Lipid-based (vegetable oil, peanut paste, soy protein-containing) fortified nutrient supplement to provide 500 kcal/d
1860123|NCT01015950|Dietary Supplement|Local food supplement|"Local foods (millet flour, cowpea flour, sugar, vegetable oil) and a multiple micronutrient powder (Mix Me) are provide, according to the national Mali CMAM protocol when special processed foods are not available."
1860124|NCT01015950|Dietary Supplement|Misola|Locally produced, millet-soy-peanut-based fortified complementary food (Misola)
1860125|NCT01015950|Dietary Supplement|SCSB|Processed, fortified, corn-soy-milk-based food blend (SCSB for malnourished children, to be supplied by the World Food Program) to provide an additional 500 kcal/day
1860126|NCT01015963|Other|laboratory biomarker analysis|Perform DNA sample analysis
1860127|NCT01015976|Procedure|bariatric surgery|Roux en Y bariatric surgery
1860128|NCT01015976|Other|control|No surgery
1860129|NCT01015989|Other|CARE+ Kenya brief computer risk assessment session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. We will repeat the session every 3 months up to 9 months total.
1860174|NCT01025076|Device|StomaphyX|StomaphyX with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) is a transoral incisionless fastening device that allows for GI tissue approximation and creation of full-thickness (serosa-to-serosa) plications.
1860204|NCT01025960|Procedure|Dual Inspection Colonoscopy|The large bowel will be inspected for polyps during the insertion of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
1860205|NCT01025999|Other|No intervention|
1860206|NCT01026012|Drug|regadenoson|Regadenoson dose of 400 mcg will be infused over 10-20 seconds followed by a saline flush.
1860130|NCT01015989|Other|CARE+ Kenya computer counseling session|The computer will ask patients questions about taking HIV medicine. The computer will also ask patients questions about sexual and substance use activities. The computer will let patients look at short videos on various HIV medicine and HIV risk reduction topics and will then help patients create a health plan. Patients will get an anonymous print out at the end of the session and can choose to share with health care provider. There are questions about depression, suicide, or domestic violence. If a patient's answers indicate that they may be depressed, suicidal, or currently in an abusive relationship, we will refer them to a health worker at the clinic. We will repeat the session every 3 months up to 9 months total.
1860131|NCT01016002|Drug|Temoporfin|"Drug treatment: Temoporfin 0.15 mg/kg body weight, intravenous injection within at least 6 min.
Laser Treatment: 652nm wavelength; 30 Joules/cm diffusor length ( 200 sec at 150mW/cm diffusor length), within 96 h after Foscan"
1860132|NCT01016015|Biological|Cixutumumab|Given IV
1860133|NCT01016015|Other|Laboratory Biomarker Analysis|Correlative studies
1860134|NCT01016015|Drug|Temsirolimus|Given IV
1860135|NCT01016028|Behavioral|Questionnaire|3 questionnaires to collect information about any pain and/or symptoms experienced, general well-being, and personal information such as age and marital status. One (1) will be a symptom assessment questionnaire where asked to rate symptoms on a scale of 0-10.
1860136|NCT01016028|Behavioral|Sensory Tests|Test of sensitivity to things such as cold and touch, involve feeling cold objects, feeling bumps on a rectangular board, and putting pegs into holes on a board; and marking on computerized drawings areas experience pain, numbness, and/or cold sensitivity.
1860137|NCT01016028|Behavioral|Interview|First 5 patients receiving platinum agents, taxanes, and bortezomib (15 patients total) will be asked to describe their symptoms in an open-ended, semi-structured 20-30 minute interview.
1860138|NCT01016041|Device|everolimus stent|stenting
1860139|NCT01016041|Device|paclitaxel stent|stenting
1860140|NCT01016054|Biological|AGS-8M4|IV infusion
1860141|NCT01016054|Drug|Pegylated liposomal doxorubicin (PLD)|IV infusion
1860142|NCT01016054|Drug|gemcitabine|IV infusion
1860143|NCT01016054|Drug|carboplatin|IV infusion
1860144|NCT01016067|Device|INFUSE/MASTERGRAFT|INFUSE® (rhBMP-2) on an absorbable collagen sponge (ACS) and MASTERGRAFT® granules with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
1860145|NCT01016067|Procedure|Autograft bone|Autogenous bone graft with appropriate rigid internal fixation hardware (reamed IM nail or plate/screws)
1860146|NCT01016080|Drug|glutathione|250 mg capsules, twice daily, orally
1860147|NCT01016080|Drug|placebo|250 mg capsules, twice daily, orally
1860148|NCT01016093|Drug|Zoledronic acid|Zoledronic acid 4 mg adjusted dose based on renal function IV 15-minute infusion every 3 months for a total of one year ( 4 doses ) beginning as soon as possible after randomization.
1860149|NCT01016093|Drug|Placebo|Placebo
1860150|NCT01016106|Genetic|Buccal Swab|During a single visit, a subject data collection form will be completed and DNA will be extracted from samples (buccal swabs) and then analyzed at IBT laboratories in Lenexa, Kansas.
1860151|NCT01016119|Drug|Folrex|Folrex cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
1860152|NCT01016119|Drug|Placebo|Placebo cream, in the early rehabilitations in the upper extremity, before daily rehabilitation
1860153|NCT01016132|Device|lotrafilcon A contact lens|Investigational silicone hydrogel, single-vision, soft contact lens worn for four weeks at least as often as and on the same basis as participant's habitual lenses, as prescribed by participant's eye care practitioner -- ie., on a daily wear, flex wear, or extended wear basis.
1860154|NCT01016145|Drug|Antipsychotics|Quetiapine 25-800 mg; ziprasidone 80-160 mg; olanzapine 5-20mg; risperidone 2-8 mg; aripiprazole 15-30 mg
1860155|NCT01016145|Drug|Antipsychotics|Haloperidol 2,5-10 mg; chlorpromazine 25-600 mg.
1860156|NCT01016158|Drug|Umbilical cord serum eyedrops|20% umbilical cord serum eye drops 3 to 4 times a day
1860157|NCT01016184|Dietary Supplement|Vitamin D|Oral vitamin D 100,000 IU
1860158|NCT01016184|Dietary Supplement|Placebo|Placebo
1860159|NCT01016197|Procedure|extensor tendon repair|Surgical repair of extensor tendon with bone anchor and splinting
1860160|NCT01016197|Procedure|Mallet splint for 4 weeks|"The patient will wear a mallet splint for fours weeks and then mobilise their finger."
1860161|NCT01016210|Drug|Leuveris|IV
1860162|NCT01016210|Drug|Leuveris|All recruited women will be treated similarly employing the recombinant FSH and the fixed GnRH antagonist. Concomitantly, on the same day of the antagonist administration r-LH will be administered daily and continued until human chorionic gonadotropin (hCG) day.
1860163|NCT01016223|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate 80 mcg two puffs twice daily for 8 weeks
1860164|NCT01016223|Drug|placebo|Matched placebo swallowed two puffs twice daily
1860165|NCT01016249|Drug|Treatment 1. (5% Hypertonic saline + Epinephrine)|Nebulization of 4ml 5% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
1860166|NCT01016249|Drug|Treatment 3. (3% Hypertonic saline + Epinephrine)|Nebulization of 4ml 3% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
1860167|NCT01016249|Drug|Treatment 2. (Normal saline + Epinephrine)|Nebulization of 4ml 0.9% saline mixed with 1.5 ml of epinephrine on enrollment and every 4 hours thereafter until ready for discharge.
1860171|NCT01025024|Genetic|SNP analysis of the DNA|SNP analysis of the DNA obtained from peripheral blood sample
1860172|NCT01025037|Device|Conexa Reconstructive Tissue Matrix|Conexa will be placed as a soft tissue reinforcement in primary open or mini-open rotator cuff repair procedures
1860173|NCT01025050|Procedure|Intrastromal Correction of Presbyopia|On all patients an intrastromal pattern consisting of concentric rings will be applied.
1860175|NCT01025089|Drug|Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide|Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients will receive single agent cetuximab infusion starting with a 400mg/m2 IV loading dose on day 1 of week 1, followed by weekly infusions (250mg/m2) on day 1 of weeks 2 3, and 4. Patients who have completed the neo-adjuvant treatment regimen, who have no evidence of distant progression, and who are medically operable will proceed to surgical resection within 6 weeks of the last infusion.
1860176|NCT01025102|Drug|Naropin 0.1% cum sufentanil|20ml of Naropin 0.1% cum sufentanil 1mikrog per ml
1860177|NCT01025115|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
1860178|NCT01025115|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 months, together with the standard treatment for metabolic syndrome consisting in appropriate diet according to patient's weight and physical activity, and appropriate hypertensive drugs (generally ACE inhibitors) for hypertension. Patient´s were also verbally encouraged to increase physical activity (to walk for 30-45 minutes a day 3-4 days a week).
1860179|NCT01025128|Drug|25 OH vitamin D|oral supplementation of 25 OH vitamin D at dose of 2000 units/d for 3 months then 1000 units/d for 3 months
1860180|NCT01025141|Device|Skeletal anchorage (MINISCREW)|Skeletal anchorage
1860181|NCT01025141|Device|dental anchorage|dental anchorage (reference)
1860182|NCT01025154|Drug|Clofarabine|Induction Cycle: 20 mg/m^2 IV over approximately 1 hour daily for 5 days (days 1-5)
1860183|NCT01025154|Drug|Idarubicin|Induction Cycle: 10 mg/m^2 IV over approximately 30 minutes daily for 3 days (days 1-3), following clofarabine by 1 to 2 hours
1860184|NCT01025154|Drug|Cytarabine|Induction Cycle: 1 g/m^2 IV over approximately 2 hours daily for 5 days (days 1-5), follow clofarabine by 3 to 6 hours.
1860185|NCT01025167|Dietary Supplement|Supportan(R) (Disease-specific enteral tube feed, food for special medical purposes)|500 ml per day / treatment period 11-14 weeks
1860186|NCT01025167|Dietary Supplement|Fresubin(R)|500 ml/a nutritionally complete enteral standard feed (isoenergetic)
1860187|NCT01025180|Other|Procalcitonin level|"The duration of antibiotic treatment is based on PCT level:
< 0.25 ng/ml: antibiotic should be stopped
0.25 < PCT <0.5: antibiotic prescription is not recommended
> 0.5 ng/ml: antibiotic should be used"
1860188|NCT01025193|Drug|Belimumab|Belimumab is a fully human monoclonal antibody that recognizes and inhibits BLyS ®. BLyS ® is a B-lymphocyte stimulator protein which plays a role in the development of B lymphocyte cells into plasma B cells, which then produce antibodies that can sensitize a potential transplant recipient. At the time of this trial, belimumab was not yet FDA approved and was being studied in clinical trials for the treatment of systemic lupus erythematosus. Until this trial, it had not yet been used in the transplant setting.
1860189|NCT01025206|Biological|BI-505|Anti-ICAM-1 monoclonal antibody given as a i.v infusion every second week for four weeks,
1860190|NCT01025219|Genetic|Collect 10 ml of Saliva for DNA extraction|After signed written informed consent, all patients and controls have clinical and neuropsychological evaluations (DIGS, WURS, BROWN, BIS, SSS and IGT) for phenotypic diagnosis and collection of saliva for DNA extraction and genotyping diagnosis.
1860191|NCT01025232|Drug|Ranibizumab|Intravitreal Injection of 2.0mg formulation
1860192|NCT01025245|Drug|remifentanil, MgSO4|Patients undergoing thyroidectomy will be randomly assigned to one of three groups. Remifentanil will be infused intraoperatively at 0.05 ㎍/㎏/min (group Ⅰ) or 0.2 ㎍/㎏/min (group Ⅱ & Ⅲ). Patients in group Ⅲ will be received 30 ㎎/㎏ MgSO4 at the induction of general anesthesia followed by a maintenance infusion of 10 ㎎/㎏/hr intraoperatively until skin closure.
1860193|NCT01025258|Behavioral|Frequent Scheduled CF clinic visits|Mandatory scheduled visit at the CF clinic every 1-2 months or sooner, if needed, for an evaluation by a a specialized CF team member such as: a pulmonary physician, a gastroenterologist, a dietitian, a clinical pharmacist
1860194|NCT01025258|Behavioral|frequent telephone calls to patients pre and post visits to the clinic|Frequent telephone calls for monitoring, educating and identifying barriers in adherence will be made by a designated CF team member such as the CF nurse or the CF clinical pharmacist.
1860195|NCT01025271|Drug|Daptomycin|one dose of daptomycin (10 milligrams of the drug per kilogram of the subject's body weight
1959831|NCT03312569|Procedure|Intracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. The right mesocolon is mobilized and the ileal mesentery is divided. The transverse colon and ileum are then divided with the stapler. Next, attention is turned to constructing the anastomosis. For this purpose, the terminal ileum and the transverse colon stump are brought together. A colotomy and ileostomy is created to form a common channel. The common enterotomy is then closed as per the surgeon's standard of care. The specimen is extracted through an off-midline incision (muscle splitting transverse incision, Pfannenstiel).
1860197|NCT01025297|Drug|Interleukin-7|3 dose levels: 3, 10 & 20 µg/kg. 4 administrations, 1 per week
1860198|NCT01025323|Behavioral|Lifestyle modification|DASH diet and exercise advice
1860199|NCT01025323|Behavioral|Lifestyle modification|DASH diet, exercise with systematic instruction by a dietician and/or coordinator
1860202|NCT01025349|Drug|Bevacizumab, docetaxel, cisplatin|"Bevacizumab 8 mg/kg(over 60 minutes) on first day of first cycle, followed by 5 mg/kg on first day of the rest cycles, repeat every 2 weeks.
docetaxel 45 mg/m2(over 60 minutes) on day 1 of each cycle, repeat every 2 weeks.
cisplatin 50 mg/m2(over 4 hours) on day 1 of each cycle, repeat every 2 weeks."
1860203|NCT01025960|Procedure|Standard Inspection Colonoscopy|The large bowel will be inspected for polyps during the withdrawal of the colonoscope to the cecum, and during the withdrawal of the scope from the large bowel.
1860207|NCT01026025|Device|Duet TRS|This is a single arm study.
1860361|NCT01027000|Procedure|allogeneic stem cell transplant|
1860208|NCT01026038|Biological|13-valent pneumococcal conjugate vaccine|All subjects will receive 1 dose (0.5 mL), IM of 13vPnC vaccine. (at least 24 months after toddler dose).
1860209|NCT01026051|Biological|MKC1106-MT|Cancer Vaccine, Immunotherapy, Melanoma
1860210|NCT01026064|Other|Cantharidin|Cantharone topical liquid containing 0.7% cantharidin (blistering agent) is applied as 25 µL of 0.1% cantharone solution in acetone
1860211|NCT01026064|Drug|Azithromycin|Zithromax (250 mg oral capsule).
1860212|NCT01026064|Drug|Placebo|Matching placebo
1860213|NCT01026090|Drug|Dronedarone|"Film-coated tablet
Oral administration under fed conditions (during breakfast and dinner)"
1860214|NCT01026090|Drug|Placebo (for dronedarone)|"film-coated tablet strictly identical in appearance
Oral administration under fed conditions (during breakfast and dinner)"
1860215|NCT01026103|Device|Tri Staple Technology stapler|This is a single arm study.
1860216|NCT01026116|Drug|A|epirubicin/cyclophosphamide followed weekly paclitaxel
1860217|NCT01026116|Drug|B|epirubicin/paclitaxel followed by weekly paclitaxel
1860218|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0,25 mcg/kg given once before emergence of general anesthesia.
1860219|NCT01026129|Drug|Remifentanil|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
1860220|NCT01026129|Drug|lidocaine|Bolus dose of intravenous remifentanil 0.5 mck/kg given once before emergence of general anesthesia.
1860221|NCT01026142|Drug|capecitabine [Xeloda]|1000 mg/m2 po twice daily for 14 days every 3 weeks
1860222|NCT01026142|Drug|capecitabine [Xeloda]|1250 mg/m2 po twice daily for 14 days every 3 weeks
1860223|NCT01026142|Drug|pertuzumab|840 mg iv loading, then 420 mg iv every 3 weeks
1860224|NCT01026142|Drug|trastuzumab [Herceptin]|8 mg/kg iv loading, then 6 mg/kg iv every 3 weeks
1860225|NCT01026155|Other|Respiratory muscle training|Respiratory muscle endurance training by means of isocapnic voluntary hyperpnoea
1860226|NCT01026194|Drug|Placebo / Teneli (Teneligliptin) + pio (pioglitazone)|Placebo for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
1860227|NCT01026194|Drug|Teneli / Teneli + pio|Teneligliptin for 12 weeks (double-blind period) followed by teneligliptin for an additional 40 weeks (open-label period) in combination with pioglitazone.
1860228|NCT01026207|Device|Polysomnography|Sleep study polysomnography compared with portable monitoring
1860229|NCT01026220|Biological|bleomycin sulfate|Given IV or SC
1860230|NCT01026220|Drug|doxorubicin hydrochloride|Given IV
1860231|NCT01026220|Drug|liposomal vincristine sulfate|Given IV
1860232|NCT01026220|Drug|vinorelbine tartrate|Given IV
1860233|NCT01026220|Drug|cyclophosphamide|Given IV
1860234|NCT01026220|Drug|etoposide phosphate|Given IV
1860235|NCT01026220|Drug|prednisone|Given IV
1860236|NCT01026220|Biological|filgrastim|Given IV or SC
1860237|NCT01026220|Drug|ifosfamide|Given IV
1860238|NCT01026233|Drug|brentuximab vedotin|1.8 mg/kg IV every 21 days
1860239|NCT01026246|Drug|Placebo|The placebo used will be normal saline (0.9 percent NaCl).
1860240|NCT01026246|Biological|EBA-175 RII-NG Malaria Vaccine|EBA-175 RII-NG malaria vaccine is supplied as a white, translucent, cloudy, nonparticulate liquid suspension in single-dose clear glass vials pre-mixed with Adju-Phos aluminum phosphate adjuvant. Each 2-mL vial of EBA-175 RII-NG vaccine contains: 0.7 mL (0.5 mL per dose) EBA-175 RII-NG, at the required dose concentration, 5 percent sucrose, 1.0 mg/mL (0.5 mg/0.5 mL per dose) aluminum as aluminum phosphate adjuvant, sodium phosphate buffer (10 mM sodium phosphate and 150 mM sodium chloride), and no preservative.
1860241|NCT01026259|Other|Warming of surgical incision|A warming pack (chemical activation) is applied to the dressing over the surgical incision, warming to 38 degrees C, for a period of 90 minutes times 6 treatments. The first treatment occurs in the PACU.
1860242|NCT01026259|Other|Warming dressing without actual warming|The same type of surgical incision dressing is used but no warming treatments are administered.
1860243|NCT01026285|Drug|Risperidone Long-Acting injectable or oral antipsychotics|According to label
1860245|NCT01026311|Drug|Coenzyme q 10|200 mg of Coenzyme q 10
1860246|NCT01026311|Drug|placebo|1 placebo q d during treatment period
1860247|NCT01026324|Drug|dinaciclib|Given IV
1860248|NCT01026324|Other|pharmacological study|Correlative studies
1860249|NCT01026324|Other|laboratory biomarker analysis|Correlative studies
1860250|NCT01026337|Genetic|mutation analysis|Correlative study
1860251|NCT01026337|Other|pharmacological study|Correlative study
1860252|NCT01026337|Procedure|dynamic contrast-enhanced magnetic resonance imaging|Undergo DCE-MRI
1860253|NCT01026337|Drug|sunitinib malate|Given orally
1860254|NCT01026337|Other|immunohistochemistry staining method|Correlative study
1860255|NCT01026337|Other|laboratory biomarker analysis|Correlative study
1860256|NCT01026350|Dietary Supplement|colostrum enriched with anti flu antibodies|each volunteer will receive six 1.2 g oral tablets (equivalent to 600 mg of bovine colostrum powder each) once a day for two weeks.
1860257|NCT01026363|Drug|Ergocalciferol|Ergocalciferol 50,000 IU capsule, one dose every other day x 5 doses
1860258|NCT01026363|Drug|Calcitriol|0.25 mcg tablet once daily for 14 days
1860259|NCT01026376|Drug|decitabine|Cycles of 15mg/m2 infusion during 3h, 3 times a day, per 3 days
1860260|NCT01026376|Drug|decitabine|Cycles of 20mg/m2 infusion during 1h, once a day, per 5 days
1860261|NCT01026389|Drug|Dotarem|DOTAREM, 0.1 mmoL/kg (0.2 mL/kg), intravenous (I.V.) bolus
1860262|NCT01026389|Drug|Gadovist|Gadovist, 0.1mmol/kg (0.1mL/kg), intravenous (I.V.) bolus
1860314|NCT01026675|Procedure|50 g oral glucose challenge test - 75 g oral glucose tolerance test|50 g oral glucose challenge test at 6-13 weeks of gestation and 75 g oral glucose tolerance test at 24-28 weeks of gestation.
1860350|NCT01026987|Drug|G-CSF|Unrelated donors will receive only G-CSF (10 ug/Kg S/C qDay x5-6 days) prior to pheresis (collection of the stem cells). Unrelated donors will only be followed per NMDP guidelines.
1860351|NCT01026987|Drug|AMD3100|
1860352|NCT01026987|Procedure|Leukapheresis|
1860263|NCT01026402|Drug|AZD2014|Dose escalation phase: a single dose taken orally (solution or tablet) of AZD2014 on single dose day 1 (visit 2), followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or Single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal. Expansion phase: twice daily dosing from day 1 until discontinuation or withdrawal or a single dose taken orally of AZD2014 on single dose day 1 (visit 2), followed by a single dose on second single dose day 1 (visit 3) after a washout period (48 hours - 7 days) followed by once or twice daily continuous dosing after a washout period (48 hours - 7 days) at visit 4, until discontinuation or withdrawal or single or multiple doses taken orally (solution or tablet) of AZD2014 taken intermittently until discontinuation or withdrawal.
1860264|NCT01026415|Drug|brentuximab vedotin|1.8 mg/kg IV every 21 days
1860265|NCT01026415|Drug|rifampin|600 mg/day PO
1860266|NCT01026415|Drug|midazolam|1 mg IV
1860267|NCT01026415|Drug|ketoconazole|400 mg/day PO
1860268|NCT01026415|Drug|brentuximab vedotin|1.2 mg/kg IV every 21 days
1860269|NCT01026428|Drug|Safinamide + Levodopa|Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
1860270|NCT01026428|Other|Placebo + Levodopa|Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
1860271|NCT01026441|Device|Vela100 (Aesthetic)|6 treatments once a week
1860272|NCT01026454|Drug|acyclovir|acyclovir 400 mg orally, twice daily for 12 weeks
1860273|NCT01026454|Drug|valacyclovir|valacyclovir 1.5 g orally, twice daily, for 12 weeks
1860274|NCT01026467|Drug|cisplatin|Given IV
1860275|NCT01026467|Drug|carboplatin|Given IV
1860276|NCT01026467|Other|questionnaire administration|
1860277|NCT01026493|Drug|temozolomide 60 mg x 21 days|Temozolomide 60 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
1860278|NCT01026493|Drug|temozolomide 75 mg x 21 days|Temozolomide 75 mg/m2 x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
1860279|NCT01026493|Drug|ABT-888 20 mg x 21 days|20 mg bid x 21 days, with a 28-day cycle. Treatment will continue until progressive disease unless toxicity or the discretion of the treating physician precludes further therapy.
1860280|NCT01026493|Drug|ABT-888 40 mg x 21 days|40 mg bid x 21 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude further therapy
1860281|NCT01026493|Drug|Temozolomide 150 mg x 5 days|150 mg/m2 x 5 days (up to 200 mg/m2 after 2nd cycle)*, with a 28-day cycle; dose reduction to 125 mg/m2 if necessary. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
1860282|NCT01026493|Drug|ABT-888 40 mg x 5 days|40 mg bid x 5 days/28-day cycle. Treatment continues until progressive disease unless toxicity or the discretion of the treating physician preclude
1860283|NCT01026506|Dietary Supplement|conjugated linoleic acid|3 g/d of an esterified CLA preparation free of t10,c12-CLA (75% c9,t11-CLA, 87% purity) or placebo oil mixed in yoghurt for 12 weeks
1860284|NCT01026519|Drug|REGN88|Single dose of REGN88 and 43 day follow up.
1860285|NCT01026519|Other|Placebo|Placebo to match REGN88 administration
1860287|NCT01026545|Drug|PF-04287881|500 mg once daily for 10 days
1860288|NCT01026545|Drug|Placebo|To match 500 mg dose once daily for 10 days
1860289|NCT01026545|Drug|PF-04287881|750 mg once daily for 10 days
1860290|NCT01026545|Drug|Placebo|To match 750 mg dose once daily for 10 days
1860291|NCT01026545|Drug|PF-04287881|1100 mg once daily for 10 days
1860292|NCT01026545|Drug|Placebo|To match 1100 mg dose once daily for 10 days
1860293|NCT01026545|Drug|PF-04287881|Optional cohort with dose not greater than 1100 mg
1860294|NCT01026545|Drug|Placebo|Optional cohort to match dose not greater than 1100 mg
1860295|NCT01026545|Drug|PF-04287881|750 mg dose once daily for 10 days
1860296|NCT01026545|Drug|Placebo|To match 750 mg dose once daily for 10 days
1860297|NCT01026545|Drug|PF-04287881|1100 mg dose once daily for 10 days
1860298|NCT01026545|Drug|Placebo|To match 1100 mg dose once daily for 10 days
1860299|NCT01026558|Drug|Ceftobiprole|Ceftobiprole, 500 mg as single iv infusion over 2 hours
1860300|NCT01026584|Drug|Aripiprazole|6 week prospective study
1860301|NCT01026597|Drug|REGN727|5 IV cohorts (dose 1, 2, 3, 4, and 5)
1860302|NCT01026597|Drug|Placebo|5 IV cohorts (dose 1, 2, 3, 4, and 5)
1860303|NCT01026610|Drug|LB80380 90 mg|LB80380 90 mg + placebo tablets, once daily, for 48 weeks
1860304|NCT01026610|Drug|LB80380 150 mg|LB80380 60 mg + 90 mg tablets, once daily, for 48 weeks
1860305|NCT01026610|Drug|entecavir 0.5 mg|entecavir 0.5 mg tablet, once daily, for 48 weeks
1860309|NCT01026636|Drug|Ceftobiprole|
1860310|NCT01026649|Procedure|Central venous catheterization|Approach the internal jugular vein in a traditional one stage fashion during central venous catheterization
1860311|NCT01026649|Procedure|Central venous catheterization|Approach the internal jugular vein in a 2 stage fashion during central venous catheterization
1860312|NCT01026662|Procedure|Ablation and skin resurfacing|Subjects will receive treatment on the abdomen at different timepoints prior to a scheduled abdominoplasty. Following tissues excision samples of the treated tissue will be taken for analysis.
1860313|NCT01026662|Device|eMatrixCO2|
1860315|NCT01026688|Other|Toolkit|Cardiovascular Disease Toolkit mailed by the Canadian Diabetes Association to family physicians, accompanying the Spring/Summer 2009 edition of the quarterly newsletter, Canadian Diabetes. (Mailed in June 2009.) The Toolkit includes a summary of selected sections of the practice guidelines targeted towards primary care physicians; a synopsis of the key messages pertaining to cardiovascular disease risk; a laminated card with a simplified algorithm for cardiovascular risk assessment and treatment; and a pad of tear-off sheets for patients with a cardiovascular risk self-assessment tool.
1860316|NCT01026688|Other|Control|The Spring/Summer 2009 issue of the quarterly newsletter, Canadian Diabetes, mailed on its own. The Cardiovascular Toolkit was mailed to Control arm physicians with the May 2010 issue of the newsletter.
1860317|NCT01026701|Drug|bortezomib|injection into a vein 1.3 mg/m2 twice a week for 21 days
1860318|NCT01026714|Drug|flurbiprofen|assessment of flurbiprofen plasmatic and capillary rates
1860319|NCT01026714|Drug|flurbiprofen, rifampicin|assessment of flurbiprofen plasmatic and capillary rates
1860320|NCT01026714|Drug|flurbiprofen + fluconazole|assessment of flurbiprofen plasmatic and capillary rates
1860321|NCT01026727|Drug|MPC-4326 plus a 2-3 drug optimized background regimen (OBR)|For treatment arm #1: the MPC-4326 dose will be selected based on the inclusion of raltegravir (i.e., will be limited to 300 mg BID) or inclusion of darunavir (i.e., will be assigned 400 mg BID) in the OBR. If both raltegravir and darunavir are included in the OBR for a subject, the subject will be limited to 300 mg BID
1860322|NCT01026727|Drug|3-4 commercially available antiretroviral drugs|For treatment arm #2: the antiretroviral regimen, dosage and frequency will be selected by the investigator.
1860323|NCT01026740|Drug|Ceftobiprole|single intravenous (i.v.) infusion, 500 mg ceftobiprole administered over 2 hours.
1860324|NCT01026753|Behavioral|Refrigerator Magnet|The refrigerator magnet contains a telephone number for a Provincial Health Contact Centre and a URL for a colorectal cancer Website that patients can access to learn more about colorectal cancer, screening and the fecal occult blood test. Patients can also have their questions answered.
1860325|NCT01026792|Drug|Temsirolimus|Given IV
1860326|NCT01026792|Other|Laboratory Biomarker Analysis|Correlative studies
1860327|NCT01026805|Device|Interlace Medical 1st Generation Hysteroscopic Morcellator|The Interlace Medical hysteroscopic morcellator system has been cleared by the FDA(K073690)and consists of a motor drive unit connected to a 3mm morcellator. The morcellator is approximately 12 cm long and is equipped with an open channel that houses a reciprocating blade. When the motor is activated, the reciprocating blade will cut the tissue within the channel. The tissue travels down the 3mm morcellator shaft cannula via suction coupled to the proximal end of the morcellator and is captured in a tissue trap in a suction canister for pathological diagnosis following the procedure.
1860328|NCT01026818|Drug|Tadalafil|Administered by mouth for 9 months
1860329|NCT01026818|Drug|Placebo|Administered by mouth, daily or on demand for 9 months
1860330|NCT01026831|Drug|Preservative-Free Tafluprost|One drop of preservative-free vehicle per eye in the morning, and one drop of preservative-free tafluprost (0.0015%) per eye in the evening for 12 weeks
1860331|NCT01026831|Drug|Comparator: timolol|One drop of preservative-free timolol maleate (0.5%) per eye twice daily for 12 weeks
1860332|NCT01026844|Drug|erlotinib|Taken orally once a day
1860333|NCT01026844|Drug|hydroxychloroquine|Taken orally once a day
1860334|NCT01026857|Drug|Propionyl-L-Carnitine|PLC colon release tablet 1 g/die for 4 weeks
1860335|NCT01026857|Drug|Propionyl-L-Carnitine|PLC colon release tablet 2 g/die for 4 weeks
1860336|NCT01026857|Drug|Placebo|Placebo PLC colon release tablet 2 g/die for 4 weeks
1860337|NCT01026870|Drug|SCH 32088 mometasone furoate (MF) metered-dose inhaler|2 inhalations from a MF 50 mcg inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
1860338|NCT01026870|Drug|Placebo metered-dose inhaler BID|2 inhalations from a placebo metered-dose inhaler each morning and evening, approximately 12 hours apart, for 12 weeks.
1860339|NCT01026883|Other|Blood draw|A venous blood sample will be taken (15 ml). Blood will be collected in 5 tubes. To avoid hematocrit variations due to the blood draw procedure, the first tube will be discarded. After that, the tourniquet which is used for venipuncture will be removed and 4 EDTA tubes (each 3 ml) will be filled with blood for hematocrit determination, one tube will be sent to the Department of Laboratory Medicine, and the other ones will be processed at the Department of Clinical Pharmacology.
1860340|NCT01026896|Behavioral|Affected Arm Therapy + Mental Practice|Subjects will be administered 10 weeks of rehabilitative therapy targeting the affected arm. Mental practice of the rehabilitative exercises performed will occur directly after therapy.
1860341|NCT01026896|Behavioral|Affected Arm Therapy + Stroke Information|Patients will be administered 10 weeks of rehabilitative therapy targeting their affected arms. Directly after their therapy sessions, subjects will be administered information on stroke and exercises targeting their affected arms.
1860342|NCT01026909|Drug|Aristospan 20mg|Triamcinolone hexacetonide injectable suspension, USP, 20mg/mL Parenteral. One single dose.
1860343|NCT01026935|Device|Open inguinal hernia repair|Altogether 400 patients are randomized to receive an open mesh repair with either sutured light weight mesh (38g/m2) or with a non-sutured light weight polypropylene mesh that adheres to tissues with polylactic micro hooks
1860344|NCT01026948|Drug|Dinoprostone|Propess© vaginal delivery system consists of a non-biodegradable polymeric drug delivery device containing 10 mg Dinoprostone (PGE2) dispersed throughout its hydrogel matrix. The retrieval vaginal insert expands to twice its size and releases a continuous and predictable dose of Dinoprostone at a rate of approximately 0.3 mg/hr over 24 hours (4-5 mg PGE2 over 12 hours) in women with intact membranes whereas release is higher and more variable in women with premature rupture of membranes.
1860345|NCT01026948|Device|Monica AN 24|AN24 Monica is a portable, battery powered device designed to passively monitor a pregnant mother and unborn baby. The device is attached via a suitable cable assembly which in turn attaches to 5 standard disposable electrodes placed on the abdomen of a pregnant woman and is intended for use in either the home or hospital environment.
1860346|NCT01026961|Drug|Phenylephrine HCL|Phenylephrine HCL 10mg
1860347|NCT01026961|Drug|Phenylephrine HCL/Acetaminophen/Dimethindene Maleate|Phenylephrine HCL 10mg/Acetaminophen 500mg/Dimethindene Maleate 1mg
1860348|NCT01026974|Biological|rMenB|
1860349|NCT01026974|Biological|rMenB+OMV NZ|
1860362|NCT01027013|Drug|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
1860363|NCT01027013|Drug|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
1860364|NCT01027026|Other|Early discharge|The patients are discharged the same day as coronary angiography.
1860365|NCT01027026|Other|Care as usual. No intervention. (Control group)|The patients are admitted and cared as usual in cardiology ward.
1860366|NCT01027052|Other|Hamburger meat patty with salt|hamburger meat cooked with salt
1860367|NCT01027052|Other|Hamburger meat patty with spice blend|hamburger meat cooked with spice mixture
1860368|NCT01027065|Drug|CYT107+GenHevac+entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107 and vaccine) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
1860369|NCT01027065|Drug|CYT107+ entecavir or tenofovir|4 patients per arm for each dose level. 3 patients receiving experimental treatment (CYT107) in addition to current antiviral treatment and 1 control patient only the current antiviral treatment
1860370|NCT01027104|Other|Education|Firearm injury prevention anticipatory guidance curriculum
1860371|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
1860372|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
1860373|NCT01027117|Drug|Revatio|Three treatments as described in study design, single dose, three way crossover. The treatment duration will be minimum 3 days for each subject.
1860374|NCT01027143|Dietary Supplement|omega-3 polyunsaturated fatty acids|ProEPA Xtra 1000mg softgels: 3 softgels twice daily
1860375|NCT01027143|Drug|Omega-3 Fatty Acid|Soybean oil: 3(age 12-25) matched softgel caps twice daily
1860376|NCT01027156|Behavioral|High Intensity Exercise|In this study, participants will be instructed to sprint maximally for a period of 30 seconds. Following 30s rest, the participants will be instructed to repeat this procedure a further 3 times. This equates to 2 minutes of maximal effort sprinting interspersed with 2 minutes recovery. Participants will be requested to perform this protocol 3 times weekly. Training progression will be implemented by increasing the number of repeats from four repetitions during weeks 1 and 2, to five repetitions during weeks 3 and 4, to six repetitions during weeks 5 and 6. Finally, during week 7 participants will still perform six repetitions but interspersed by only 20 s recovery.
1860377|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
1860378|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
1860379|NCT01027169|Drug|safinamide|single dose of 50mg safinamide on Day 1
1860380|NCT01027182|Drug|Raltegravir|One 400mg tablet on day 1.
1860381|NCT01027195|Device|Bipolar Radiofrequency (Aquamantys 6.0)|
1860382|NCT01027195|Device|Standard Bovie Electrocautery|
1860383|NCT01027208|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m²
1860384|NCT01027221|Radiation|neoadjuvant Photonradiation|single fraction, 4D planned, image guided, Radiation at a dose of 0,5 Gy in IMRT-technique 2 days before resection
1860385|NCT01027221|Radiation|neoadjuvant Photonradiation|single fraction, 4D-planned, image guided, 2 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
1860386|NCT01027221|Radiation|neoadjuvant Photonradiation|single fraction, 4D-planned, image guided, 5 Gy Radiation to the tumor with a safety margin, in IMRT-technique 2 days before resection
1860387|NCT01027234|Drug|AZD8418|Single oral dose
1860388|NCT01027234|Drug|Placebo|single oral dose
1860389|NCT01027247|Device|Ologen TM|
1860390|NCT01027260|Drug|Itopride HCI 50 mg|Variable dosing
1860391|NCT01027260|Drug|Itopride HCI 100 mg|Variable dosing
1860392|NCT01027260|Drug|Placebo|Variable dosing
1860393|NCT01027273|Behavioral|Prevent Return of Stroke|Prevent Return of Stroke is a community-based, peer-led stroke recurrence prevention program. This is a bilingual (English/Spanish) education program written at a 4th grade reading level, and contains simple, actionable, messages, easily taught by lay leaders, and focuses on enhancing self-efficacy to make lifestyle changes, to help reduce stroke recurrence risk factors. It consists of 6 sessions (1½ hours each) held over 6-weeks. Topics include learning the risk factors for stroke, controlling hypertension, LDL cholesterol, preventing blood clots, medication adherence, and stress management.The intervention arm will participate in the intervention shortly after enrolling in the trial.
1860394|NCT01027273|Behavioral|Prevent Return of Stroke|The intervention arm will participate in the intervention shortly after enrolling in the trial. The usual care arm will be offered the intervention after 12 months from enrolling in the trial.
1860395|NCT01027286|Device|Vitagel|Vitagel applied just prior to closure during primary total knee arthroplasty
1860396|NCT01027299|Device|Biventricular pacing|Optimised temporary biventricular pacing.
1860397|NCT01027325|Other|Dietary Intervention|Starch digestibility and carbohydrate quantity
1860398|NCT01027338|Other|Tai chi exercise|
1860399|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine.|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB+OMV NZ) or two catch-up doses.
1860400|NCT01027351|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine, without Outer Membrane Vesicles (OMV)|Subjects received either one or two booster doses of the same vaccine they had received in the parent trial (rMenB).
1860401|NCT01027364|Drug|Factor IX (rFIXFc)|
1860402|NCT01027364|Drug|rFIX|
1860403|NCT01027377|Drug|rFVIIIFc|Single dose
1860404|NCT01027377|Drug|rFVIIIFc|Single dose
1860405|NCT01027390|Behavioral|physical training exercise|physical exercise training at the work site during work time
1860407|NCT01027429|Drug|procaine penicillin and gentamicin|procaine penicillin 50,000 units/kg by intramuscular injection once daily for 7 days; gentamicin, 5 mg/kg once daily by intramuscular injection for 7 days
1860408|NCT01027429|Drug|amoxicillin and gentamicin|oral amoxicillin 80-90 mg/kg divided in two doses for 7 days intramuscular gentamicin, 5 mg/kg once daily for 7 days
1860741|NCT01020812|Procedure|TACE|Standard of Care
1860409|NCT01027429|Drug|procaine penicillin, gentamicin, amoxicillin|procaine penicillin, 50,000 IU/kg once daily intramuscular injection plus gentamicin 5 mg/kg once daily intramuscular injection for 2 days, followed by 5 days of oral amoxicillin, 80-90 mg/kg divided in two doses.
1860410|NCT01027442|Device|Mucosa-supported single-type guides|Compute generated Mucosa-supported single-type guides
1860411|NCT01027442|Device|Bone-supported guides|Computer generated, Multiple type Bone-supported guides
1860412|NCT01027442|Device|Dental Implants|Dental implants placed via conventional free-hand method
1959832|NCT03312569|Procedure|Extracorporeal Anastomosis|With the patient under general anesthesia, pneumoperitoneum is achieved by a method of choice of the operating surgeon. Port Placement is completed as per the standard of care. Dissection is performed and the ileocolic vessels are identified. Intracorporeal devascularization may be performed at the surgeon's discretion. The gastrocolic ligament is taken down and the hepatic flexure is mobilized. After complete mobilization of the right colon, the midline incision is extended to serve as the extraction site. The specimen is delivered through the midline extraction incision and the anastomosis is conducted in a standard open technique. The two cut ends of the bowels are aligned for extracorporeal anastomosis.
1959833|NCT03312556|Device|continuous positive airway pressure (CPAP)|Continuous positive airway pressure(CPAP) will be applied during the night starting from 20:00. CPAP level will be determined during an acute CPAP trial.
1959834|NCT03312556|Drug|Placebo|Placebo pill or patch. Single dose
1860416|NCT01027468|Drug|Bevacizumab|intraocular bevacizumab injection
1860417|NCT01027481|Drug|Lucentis|intravitreally administration of 0.05 ml Lucentis
1860418|NCT01027494|Drug|Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension|Four drops in the outer ear canal of infected ear(s) while awake 2 times per day for 7 days
1860419|NCT01027520|Other|application of coban dressing|application of a intraoperative coban dressing with reapplications following dressing removal.
1860420|NCT01027533|Other|Implantation of a multifocal Intraocular lens|Bilateral implantation of a multifocal IOl
1860421|NCT01027546|Drug|Tranexamic Acid|Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
1959835|NCT03312543|Device|Active Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the active light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
1959836|NCT03312543|Device|Sham Mask|A facial cleanser will be used twice daily (morning and evening). In the morning after washing, the moisturizer with SPF will be applied full-face. For the first 12 weeks of the study, the sham light therapy mask will be used for 10 minutes in the evening after washing/drying the face. For the second 12 weeks of the study, mask usage will be discontinued.
1860424|NCT01027572|Device|Implantable neurostimulation system (Medtronic)|Thalamic stimulation will be performed using an implantable neurostimulation system
1860425|NCT01027598|Drug|Pazopanib|Pazopanib: 600 mg orally daily
1860426|NCT01027598|Drug|Erlotinib|Erlotinib: 150 mg orally daily
1860427|NCT01027611|Drug|proparacaine HCL 0.5%|
1860428|NCT01027611|Drug|proparacaine HCL 0.5% + 4% lidocaine solution|
1860429|NCT01027611|Drug|3.5% viscous lidocaine gel|
1860430|NCT01027637|Other|5 mm vessel clips|evenly placed vessel clips placed at surgery and tracked by ultrasound
1860431|NCT01027650|Drug|AGN208397 intravitreal injection|AGN208397 intravitreal injection on Day 1.
1860432|NCT01027650|Drug|dexamethasone intravitreal implant|Dexamethasone 700 ug intravitreal implant on Day 1.
1860433|NCT01027663|Dietary Supplement|Iron Supplement|Iron supplementation (325 mg of ferrous sulfate) once daily for the 2 month duration of the study.
1959837|NCT03312530|Drug|Cobimetinib|Cobimetinib will be administered as per the schedule specified in the respective arm.
1860435|NCT01027689|Drug|alprazolam commercial immediate release oral tablet|1 mg tablet, single dose
1860436|NCT01027689|Drug|alprazolam test sublingual tablet|1 mg tablet, single dose
1959838|NCT03312530|Drug|Venetoclax|Venetoclax will be administered as per the schedule specified in the respective arm.
1860438|NCT01027715|Other|EEG monitoring and treatment of EEG seizures|Seizures will prompt treatment with loading doses of phenobarbital (20mg/kg), fosphenytoin (20mg/kg),and midazolam (0.05mg/kg bolus and .15mg/kg/hr infusion tapered over 48 hours)in that order for persisting seizures.
1860439|NCT01027728|Drug|CCX 354-C|"Cohort 1: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days;
Cohort 2: Eight subjects will be randomized to receive 100 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) twice daily for 14 days; and
Cohort 3: Eight subjects will be randomized to receive 200 mg CCX354-C or placebo in a ratio of 3:1 (CCX354-C:placebo) once daily for 14 days."
1860440|NCT01027741|Behavioral|Phone Referral|Participants receive phone referral to cancer control and prevention services.
1860441|NCT01027741|Behavioral|Tailored Cancer Communication|Mailed material with messages tailored to participant's age, gender, race/ethnicity, whether he or she has kids in the home, reason for calling 211, and cancer control need.
1860442|NCT01027741|Behavioral|Cancer Control Navigator|A cancer control navigator is assigned to each participant. This navigator helps the participant make and keep cancer control and prevention appointments, as well as providing resources and guidance to help address participant barriers to use of needed cancer control and prevention services. Intervention is phone-based.
1959839|NCT03312530|Drug|Atezolizumab|Atezolizumab will be administered as per the schedule specified in the respective arm.
1959840|NCT03312517|Drug|Suvorexant 10 mg|Subject will receive suvorexant 10mg
1860445|NCT01027767|Device|Molecular Breast Imaging|Molecular Breast Imaging
1860520|NCT01028365|Other|No intervention|Study participants will not be asked to make any changes to their daily lifestyle or existing health care routine. Participants also will not be asked to take any medications or change their diet.
1860742|NCT01020812|Procedure|SBRT|Standard of Care
1959841|NCT03312517|Drug|Suvorexant 20 mg|Subject will receive suvorexant 20mg
1959842|NCT03312517|Drug|Placebo oral capsule|Subject will receive placebo.
1860446|NCT01027780|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
1860447|NCT01027793|Drug|Tretinoin cream 0.005%|Group 1 will receive tretinoin cream 0.05%(Vitanol A, Stiefel) that should be applied daily in areas affected by stretch marks, in both sides, for a period of 16 weeks.
1860448|NCT01027793|Device|Superficial Dermabrasion|Group 2 will receive 16 sessions of dermabrasion that would be held in the research center
1860449|NCT01027806|Drug|Montelukast|1 pill per day for 4 months
1860450|NCT01027819|Device|Mobile bearing|Mobile bearing in total knee arthroplasty
1860451|NCT01027819|Device|Fixed bearing|Fixed bearing in total knee arthroplasty
1860452|NCT01027832|Drug|Piperacillin/Tazobactam for 7 days|Piperacillin/Tazobactam for 7 days
1860455|NCT01027858|Behavioral|Aerobic-based exercise training|Six months of thrice-weekly walking program that will gradually progress in intensity. Each training session will be 60 minutes (10 minutes of warm-up, 40 minutes of training, and 10 minutes of cool-down).
1860456|NCT01027858|Behavioral|CON (control; usual care)|Nutrition education and usual care as prescribed by neurologist
1860457|NCT01027871|Drug|LY2605541|subcutaneous injection of LY2605541 every morning with dose titration based on blood glucose measures for 12 weeks
1860458|NCT01027871|Drug|insulin glargine|subcutaneous injection of insulin glargine every morning with dose titration based on blood glucose measures for 12 weeks
1860459|NCT01027884|Drug|Placebo|Placebo (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
1860460|NCT01027884|Drug|Idebenone|Idebenone (900 mg/day) 2 tabl (150 mg each) x 3 times orally with meals
1860461|NCT01027897|Drug|Doripenem|Doripenem 1 gm administered over 4 hours X 3 doses
1860462|NCT01027910|Drug|PCI-24781|Capsules taken orally for 5 consecutive days starting on Day 1 of each 3 week cycle
1860463|NCT01027910|Drug|Doxorubicin|Administered intravenously on Day 4 of each 3 week cycle
1860464|NCT01027910|Drug|GCSF|Administered on Day 5 of each 3 weeks cycle in Arm 1 if determined to be clinically indicated, and in all patients enrolled into Arm 2
1860465|NCT01027923|Drug|Plerixafor|
1860466|NCT01027923|Drug|Mitoxantrone|
1860467|NCT01027923|Drug|Etoposide|
1860468|NCT01027923|Drug|Cytarabine|
1860469|NCT01027949|Drug|Treprostinil diethanolamine|Oral sustained release tablet, twice or thrice daily. Open label study with active drug, no other intervention arms.
1860470|NCT01027962|Other|ICBT Program|Intensive Computerized Brain Training.
1860471|NCT01027975|Procedure|laparoscopic Nissen/laparoscopic Thal|
1860472|NCT01028014|Drug|Pseudoephedrine|Pseudoephedrine ER 120 mg by mouth once daily for 2 weeks
1860473|NCT01028014|Drug|Tamsulosin|Tamsulosin 0.4mg by mouth daily for 2 weeks
1860474|NCT01028014|Drug|Imipramine|Imipramine 25mg daily by mouth for 2 weeks
1860475|NCT01028014|Drug|Cyclobenzaprine|Cyclobenzaprine 10mg daily by mouth for 2 weeks
1860476|NCT01028014|Drug|Lactose capsule|Lactose capsule 1 by mouth daily for 2 weeks
1860477|NCT01028014|Drug|Solifenacin|Solifenacin 5mg by mouth daily for 2 weeks
1860478|NCT01028027|Drug|Loteprednol and tobramycin|Loteprednol etabonate and tobramycin ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
1860479|NCT01028027|Drug|Tobramycin and dexamethasone|Tobramycin and dexamethasone ophthalmic suspension administered to study eye 4 times a day (QID) for 14 days.
1860480|NCT01028040|Drug|AZD3043|Intravenous, single dose
1860481|NCT01028040|Drug|AZD3043|Infusion, single dose
1860482|NCT01028053|Drug|Flutemetamol (18F) Injection|All subjects will receive an i.v. dose of (18F) flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of (18F) flutemetamol will be 185 MBq.
1860483|NCT01028066|Other|Traditional|The control group will have access to the nutritionist to clear any doubts about the diet prescribed when went out the hospital and will be invited to attend a meeting nutrition in dialogic character at the end of 1 year to ensure fairness in action.
1860484|NCT01028066|Behavioral|Behavioral|The intervention group will go through 4 meetings of food education, to be held within the institution, with approximately 1 hour long, composed of 3 to 8 patients, who may or may not be accompanied by a relative. The first three meetings will be monthly and the fourth will be 6 months after the last one. Each meeting will be developed within the context of dialogic and participatory education, directed to the adoption of a healthy diet and prevention and control of cardiovascular risk factors. The meetings will follow the order: Investigation, Contextualization, Awareness and Strengthening the nutritional concepts, according to the didactics of educator Paulo Freire.
1860485|NCT01028079|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Aspirin 1000 mg (solid dose caplet) to be given three times daily as for 2 consecutive days (48 hours), followed by Aspirin 1000 mg (solid dose caplet) to be taken as per need, but not more than three times daily for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 3000 mg Aspirin.
1860486|NCT01028079|Drug|Ibuprofen|Ibuprofen 400 mg caplet to be given three times a day as for 2 consecutive days (48 hours), followed by ibuprofen 400 mg caplet to be given as per need, but not more than three times a day for the following 3 days (72 hours). Total treatment period has not to exceed 5 days and total daily dose has not to exceed 1200 mg ibuprofen.
1860487|NCT01028079|Drug|Placebo|Placebo (two placebos: Placebo Aspirin and Placebo Ibuprofen) to be given three times a day for a maximum of 5 consecutive days in the same regimen as for Experimental Drug and Active Comparator.
1860488|NCT01028092|Drug|Anti R-IL2 + Cyclosporine|"anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)
Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0
cyclosporine A (Neoral ®) started from 6 to 8 mg/kg adjusted to C2
corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
1860489|NCT01028092|Drug|Thymoglobulin + Everolimus|"Thymoglobulin ® induction started at 1.5mg/kg/j then adjusted to CD2 or total lymphocytes count, for 5 days
Mycophenolate Mofetil (Cellcept ®) 3 grams per day beginning at D0
everolimus (Certican ®): 4 to 6 mg/day started at D5, adjusted to achieve a residual level between 6 et 10 ng/ml
corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
1860490|NCT01028092|Drug|Anti R-IL2 + Cyclosporine then Everolimus|"anti R-IL2 induction (Simulect ®, 20 mg D0 and D4)
Mycophenolate Mofetil (Cellcept ®) 3 g/d beginning at D0
cyclosporine A (Neoral ®) beginning at 6 to 8 mg/kg adjusted to C2, then switch to everolimus (Certican ®) between at W6, started at 3 mg/d, then adjusted to achieve a residual level between 6 et 10 ng/ml
corticosteroids 250 mg IV before and after surgery, then 1 mg/kg one week and 20mg/j the week after, then tapered until 10 mg/j at M1, 5 mg at M3 and stop between M4 and M6"
1860491|NCT01028105|Other|Preoperative MRSA screening|MRSA preoperative screening and post operative infection rate, 30 days post operative
1860492|NCT01028118|Other|Identifying experience with violence|Asking about life experience with violence and Cognitive Behavior Therapy.
1860493|NCT01028131|Behavioral|Computer-delivered brief intervention (5As)|After completing the brief assessment battery, participants will interact with the computer for approximately 20 minutes, with structure being based on the Five A model and Motivational Interviewing.
1860494|NCT01028131|Behavioral|Contingency Management|Participants randomized by the computer into this condition will view a 20-minute music and tv videos after completing the brief assessment. The research assistant will then briefly describe the CM process, with a period for questions to assure understanding. The CM condition will involve participant-initiated submission of urine samples at prenatal visits. Clinic staff will have no responsibility for the CM component other than calling research staff when a participant wishes to submit a sample. Clinic staff will not schedule any new, additional, or unnecessary prenatal visits.
1860495|NCT01028144|Behavioral|Physical Activity Program|A 17-week motivational and behavioral skills after-school intervention for increasing moderate to vigorous physical activity in low income and minority adolescents.
1860496|NCT01028144|Behavioral|General Health Program|A 17-week general health afterschool intervention (comparison program) focused on nutrition, stress management, drug prevention, and drop-out prevention.
1860497|NCT01028157|Behavioral|STARS: Sistas Talking About Real Solutions|The intervention consisted of 2, 4-hour workshops. The first workshop focused on enhancing ethnic/gender pride, self-esteem, realizing values/setting goals, healthy/unhealthy relationships, partner violence, HIV/STD knowledge, heightening awareness of HIV susceptibility, safer-sex options/skills. The second workshop covered realistic choices in sexual decision making, consistent/proper condom use, setting limits/boundaries, communication styles, and condom skills negotiation. Participants received 3-hour booster sessions at 6- and 9-months to reinforce materials from the initial intervention. Bi-monthly phone calls and quarterly mailings were used to reinforce workshop material and facilitate retention.
1860498|NCT01028157|Behavioral|General Health & Nutrition|Participants in this condition received a 2 hour group session which consisted of general health information and women's health brochures facilitated by a trained health educator. The control group received bi-monthly phone calls and quarterly mailings for retention purposes only, with no intervention material provided.
1860499|NCT01028170|Drug|furosemide and hypertonic saline solution|250-500 mg furosemide (30 min IV Q 12 hours) with 150 mL of 2.4% NaCl
1860500|NCT01028170|Drug|furosemide|80-160 mg furosemide (Given over 5 min IV twice a day)
1860501|NCT01028209|Drug|[18F] PBR06|Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of [18F]PBR06, followed by PET imaging.
1860502|NCT01028222|Drug|Nilotinib|Nilotinib was provided as 200 mg hard gelatin capsules for oral use.
1860503|NCT01028222|Drug|DTIC|DTIC was supplied locally as sterile powder for i.v. infusion.
1860504|NCT01028248|Drug|Ranibizumab (Lucentis)|0.5mg and 2.0mg dose of Ranibizumab 0.05ml administered intravitreally
1860505|NCT01028261|Drug|ZGN-433|Subjects will receive placebo or ZGN-433 twice weekly over 6 weeks treatment period for a total of 12 doses. A range of doses will be evaluated.
1860506|NCT01028274|Dietary Supplement|Placebo|Two capsules, twice daily with meals for 12 weeks.
1860507|NCT01028274|Dietary Supplement|Investigational Product 1|Two capsules, twice daily with meals for 12 weeks.
1860508|NCT01028274|Dietary Supplement|Investigational Product 2|Two capsules, twice daily with meals for 12 weeks.
1860511|NCT01028300|Device|ProDisc™-L Total Disc Replacement (TDR)|The design is based on a ball and socket articulation, one surface being metal and the other an ultra-high molecular weight polyethylene (UHMWPE). Three components comprise this modular prosthesis.
1860512|NCT01028313|Drug|LBH589|20 mg PO three times weekly
1860513|NCT01028313|Drug|Methylprednisolone|1 mg/kg/day PO continuously
1860514|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 60 and a 0.5 mL intramuscular dose of DTaP on day 180.
1860515|NCT01028326|Biological|PCV10 and DTaP|A nurse will administer a 0.5mL intramuscular dose of PCV10 on day 0 and day 180 and a 0.5 mL dose of DTaP on day 60.
1860516|NCT01028326|Biological|hepatitis A vaccine, DTaP, PCV10|A nurse will administer a 0.5mL intramuscular dose of hepatitis A vaccine on day 0 and day 180; a 0.5 mL intramuscular dose of DTaP on day 60; and a 0.5 mL dose of PCV10 on day 180.
1860517|NCT01028339|Drug|Hypertonic saline|2 mL/kg of 7.5% hypertonic saline associated to hydroxyethyl starch
1860518|NCT01028339|Drug|Mannitol|Mannitol
1860519|NCT01028352|Drug|Duloxetine|"Patients will be treated with open-label duloxetine:
30 mg daily x 7 days, then
60 mg daily x 3 weeks, then
If a patient believes she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will continue taking 60 mg daily for weeks 5-8
If a patient does not believe she has experienced a sufficient reduction in pain after 4 weeks of therapy, she will have the option of increasing the dose to 60 mg twice daily for weeks 5-8.
After completion of 8 weeks of therapy, patients who wish to discontinue therapy will taper off the drug over 1 week (50% decrease for 4 days, then additional 50% decrease for 3 days). Patients may continue therapy off-study at the discretion of their treating physician."
1860521|NCT01028378|Device|T-CAT topography-guided LASIK treatment with the Allegretto Wave Eye-Q 400 Hz Excimer Laser|
1860522|NCT01028391|Drug|Sitagliptin 100 mg q.d.+ Pioglitazone 45 mg q.d.|Patients will receive combination therapy with blinded sitagliptin 100 mg q.d. (q.d. = once daily) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. Sitagliptin 100 mg q.d. and pioglitazone 45 mg q.d. will be administered as oral tablets.
1860523|NCT01028391|Drug|Pioglitazone 45 mg q.d. + Sitagliptin 100 mg placebo q.d.|Patients will receive placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. during the up to 30 week extension study. The placebo to match sitagliptin 100 mg q.d. (blinded) and open-label pioglitazone 45 mg q.d. will be administered as oral tablets.
1860524|NCT01028391|Drug|Metformin|Patients not meeting specific glycemic goals during the 30-week extension study will receive open-label metformin at a dose determined by the investigator.
1860525|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952, at escalating dose levels. Progression to next dose will be based on safety evaluation.
1860526|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at all dose levels.
1860527|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952, at all dose levels.
1860528|NCT01028404|Drug|NN1952|Subjects will be randomised to receive a single dose of NN1952 with or without a meal, on two of four separate study visits. The dose will be selected based on the results of part 1.
1860529|NCT01028404|Drug|insulin aspart|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit.
1860530|NCT01028404|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN1952 at one study visit.
1860531|NCT01028417|Device|Platinum microcoil|Coil Name: Vortx-18, Diamond Shape, Boston Scientific, Cork, Ireland; Coil Description: 80 mm long, fibre coated 0.018 inch diameter platinum microcoil
1860532|NCT01028443|Drug|Sandimmune|
1860533|NCT01028443|Drug|Artelose|
1860534|NCT01019122|Radiation|Dexa Scan|Dexa scan of left and right distal femur, then lumbar spine, and whole body when possible
1860535|NCT01019135|Behavioral|Cardiac Rehabilitation|comparison of multiple cardiac rehabilitation program models
1860536|NCT01019161|Drug|AZD1152|100mg Lyophile, 5mL Diluent IV infusion
1860537|NCT01019161|Drug|C14 AZD1152|radiolabelled IV solution, 1.05 mg/ml presented as 15 ml fill in 20ml vial infusion
1860538|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
1860539|NCT01019174|Drug|Cyclophosphamide|comparison of lenalidomide/low-dose dexamethasone in combination with continuous oral cyclophosphamide to lenalidomide/low-dose dexamethasone combined with single cyclophosphamide doses intravenous
1860540|NCT01019187|Procedure|Quality-of-Life Assessment|Ancillary Studies
1860541|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
1860542|NCT01019187|Other|Placebo|Given orally
1860543|NCT01019187|Procedure|Fatigue Assessment and Management|
1860544|NCT01019187|Procedure|Sleep Disorder Therapy|
1860545|NCT01019187|Drug|Armodafinil|Given orally
1860546|NCT01019187|Procedure|Quality-of-life assessment|Ancillary studies
1860547|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
1860548|NCT01019187|Procedure|Fatigue Assessment and Management|
1860549|NCT01019187|Procedure|Management of Therapy|
1860550|NCT01019187|Procedure|Sleep disorder therapy|
1860551|NCT01019187|Procedure|cognitive assessment|
1860552|NCT01019187|Procedure|Quality of Life assessment|Ancillary Studies
1860553|NCT01019187|Other|Questionnaire Administration|Ancillary studies
1860554|NCT01019187|Other|Placebo|Given orally
1860555|NCT01019187|Procedure|Fatigue assessment and management|
1860556|NCT01019187|Procedure|Management of therapy and complications|
1860557|NCT01019187|Procedure|Sleep disorder therapy|
1860558|NCT01019187|Drug|Armodafinil|Given orally
1860559|NCT01019187|Procedure|Cognitive Assessment|
1860560|NCT01019187|Procedure|Quality of Life Assessment|Quality of Life Assessment
1860561|NCT01019187|Other|Questionnaire Administration|Ancillary Studies
1860562|NCT01019187|Procedure|Fatifue assessment and management|
1860563|NCT01019213|Other|Septal pacing|Septal lead activated
1860564|NCT01019213|Other|His lead activated|His lead will be activated 80 ms before septal lead
1860565|NCT01019239|Procedure|Laparoscopic Washout|Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. Peritoneal lavage will be performed in all four quadrants using at least 4 litres of warmed saline until the drainage is clear. Two non-suction Penrose drains will be placed.
1860566|NCT01019239|Procedure|Hartmann's Procedure/ Primary Resection and Anastomosis|24 Pneumoperitoneum will be established via a blunt entry 12mm umbilical port. Two 5mm ports will be placed in the suprapubic and right lower quadrants to facilitate triangulation of instruments during manipulation and lavage. The peritoneal cavity will be thoroughly examined and stage classified according to Hinchey. . In the absence of faeculant peritonitis, patients will be randomised to undergo Hartmann's procedure or primary resection and anastomosis (depending on standard practice in the individual unit).
1860568|NCT01019265|Drug|Buprenorphine 5mg, 10mg, 20mg vs Tramadol 100mg|Comparing pain intensity between intervention drugs (Norspan® and Tridol®)
1860569|NCT01019278|Radiation|proton beam radiation therapy|Undergo external proton beam radiation
1860570|NCT01019278|Radiation|radiation therapy treatment planning/simulation|
1860571|NCT01019278|Drug|cisplatin|Given IV
1860572|NCT01019291|Other|Formaldehyde and NO2 (Exposure to indoor pollutants)|Exposure to indoor pollutants (Formaldehyde and NO2) in a randomized way, followed by bronchial challenge test with house dust mite extract.
1860573|NCT01019291|Other|Placebo (Exposure to indoor pollutants)|Exposure to indoor pollutants (placebo) in a randomized way, followed by bronchial challenge test with house dust mite extract.
1860574|NCT01019317|Drug|Cytarabine|0.5 grams/m^2 over 2 hours(+/- 15 minutes) IV every 12 (+/-2) hours for 5 days (4 days in patients > 65 years and 3 days in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) > 3).
1860575|NCT01019317|Drug|Fludarabine|15 mg/m^2 to be given IV over 15-30 minutes every 12 (+/- 2) hours for 5 days. (4 days in patients > 65 years and 3 days in patients with PS > 3).
1860576|NCT01019330|Other|Allen's test|The Allen's test checks to make sure that radial and ulnar arteries that supply blood to the hand are not blocked. A pulse oximeter is placed on the index finger of the hand. The subject is asked to make a fist for 10 seconds.At this time, pressure is applied over the ulnar and radial arteries as to occlude (block) both of them. The pulse oximeter reading will begin to fall. Radial arterial pressure is then released. If the artery is patent (working), the pulse oximeter reading will begin to rise.
1860577|NCT01019330|Other|Distal pulses|Practitioner will check that the dorsalis pedis and posterior tibialis are palpable.
1860578|NCT01019356|Drug|Rosiglitazone|4 mg twice daily for 8 weeks orally
1860579|NCT01019356|Drug|Acarbose|100 mg three times daily for 8 weeks orally
1860580|NCT01019369|Drug|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
1860581|NCT01019369|Drug|Medroxyprogesterone 17-Acetate|Depot medroxyprogesterone acetate, SC, every 12 weeks for 1 year
1860582|NCT01019382|Drug|Lipidem fish oil infusion + Gemcitabine chemotherapy|500mls intravenous infusion once a week of lipidem in addition to standard starting dose of gemcitabine (1000mg/m2) Dose can be reduced if poorly tolerated
1860583|NCT01019395|Drug|Daptomycin|"Group 1: Ages 13 months to 24 months inclusive. Six subjects dosed at 6 mg/kg as a 30 minute infusion;
Group 2:Ages 7 months to 12 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion;
Group 3: Ages 3 months to 6 months inclusive: Six subjects will receive a dose of 4 mg/kg as a 30 minute infusion."
1860584|NCT01019408|Drug|Chloroquine|Comparison of two different dosages of chloroquine for treatment of falciparum malaria in Afghan refugee camps in Northwest Frontier Province, Pakistan
1860585|NCT01019421|Drug|Lu AE58054|Add-on treatment to donepezil
1860586|NCT01019421|Drug|Placebo|Add-on treatment to donepezil
1860587|NCT01019434|Drug|temozolomide|TMZ will be given at 75 mg/m2 daily for the whole period of RT including weekends as registered.
1860588|NCT01019434|Drug|temsirolimus|CCI-779 will be given i.v. once every week at 25 mg. Each treatment should be preceded by supportive medication with a histamine H2-receptor antagonist. A first dose of CCI-779, being 25 mg, will be given on day -7 from RT start.
1860589|NCT01019447|Other|Vicryl Plus|Triclosan-coated polyglactin 910 antimicrobial sutures (Vicryl Plus)
1860590|NCT01019447|Other|Vicryl|Polyglactin 910 antimicrobial sutures (Vicryl)
1860591|NCT01019460|Procedure|Magnetic resonance imaging, computed tomography scanning and capsule endoscopy|All patients are examined with ileo-colonoscopy, capsule endoscopy, MRI and CT of the small bowel within 14 days. Capsule endoscopy will not be performed in patients with small bowel stenosis confirmed at ileo-colonoscopy, MRI and/or CT.
1860592|NCT01019473|Drug|AFQ056|
1860593|NCT01019473|Drug|Placebo|
1860594|NCT01019486|Drug|Regadenoson myocardial perfusion imaging|Myocardial perfusion imaging at rest and following 400mcg Regadenoson IV bolus pharmacologic stress with 30 mCi of Tc-99m sestamibi injected at both but the studies performed 48 hours apart.
1860595|NCT01019486|Drug|Regadenoson MRI myocardial blood flow|CMR assessment of stress myocardial perfusion and blood flow after 400 mcg Regadenoson pharmacologic using gadolinium contrast (gadoteridol) 0.05mmole/kg at stress and rest.
1860596|NCT01019499|Other|berry products|"effects of berry consumption on cardiovascular indicators
two portions daily"
1860597|NCT01019499|Other|control products|two portions daily
1860598|NCT01019512|Other|questionnaire administration|Ancillary studies
1860599|NCT01019512|Other|lymphedema management|
1860600|NCT01019538|Other|Pre-flight test with supplemental oxygen|The Hypoxia-altitude simulation test, which is established in clinical practice, is compared to the gold standard of hypobaric chamber while giving supplemental gaseous oxygen without and with oxygen conserving device, and with oxygen concentrator.
1860601|NCT01019551|Drug|ART Intensification|Current ART regimen plus raltegravir and maraviroc Raltegravir : 400 mg PO BID for 56 weeks Maraviroc : 150, 300 or 600 mg PO BID depending on concomitant ART treatment, for 56 weeks
1860602|NCT01019551|Biological|Immunomodulation|Starting at Week 8, 1 cycle of 3 injections (1 per week) of recombinant human Interleukin-7 (r-hIL-7 / CYT107) at a 20 µg/kg dose.
1860603|NCT01019564|Device|Complete Easy Rub Formula MPS|Multi-purpose solution
1860604|NCT01019564|Device|Aquify MPS|Multi-purpose solution
1860605|NCT01019577|Drug|Ixabepilone|Lyophilized and solvent, IV, 10-50 mg/m2, Q3W, Maximum 9 cycles
1860606|NCT01019590|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
1860607|NCT01019590|Drug|Benicar HCT ® Tablets 40 mg/25 mg|
1860608|NCT01019603|Drug|Tazarotene|Topical Tazarotene foam applied daily for 22 days.
1860609|NCT01019603|Drug|Tazaroc Gel|Topical tazarotene gel applied daily for 22 days.
1860610|NCT01019616|Drug|paclitaxel/anthracycline|standard chemotherapy regimen(containing paclitaxel or anthracycline) different from primary chemotherapy(containing anthracycline or paclitaxel)
1860611|NCT01019642|Drug|cholecalciferol|4,000 IU per day during 6 months. Capsule form.
1860612|NCT01019642|Drug|placebo|no active principles given.
1860613|NCT01019655|Drug|Nadroparin calcium|nadroparin calcium (fraxiparin®) 0.3 mL daily during pregnancy and six weeks post partum
1860614|NCT01019668|Drug|Verteporfin PDT, half-dose|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
1860615|NCT01019668|Drug|verteporfin PDT, half-fluence|half the regular dose or half the regular laser fluence to treat prolonged unresolved CSCR
1860733|NCT01020760|Behavioral|Face down posture|Patients are requested to maintain a strict face down posture for 50 minutes out of every hour for seven days after surgery.
1860734|NCT01020773|Behavioral|spontaneous breathing trial|
1860740|NCT01020799|Drug|Placebo tablets|Placebo tablets to match encapsulated escitalopram
1860616|NCT01019681|Biological|Cord blood stem cell injection|"The cord blood stem cells will be simply injected intramuscularly in the leg. 30 minutes prior to stem cell injection the patients will receive Vancomycin 1 gram IVPB x1 as a prophylactic measure. Patients will also receive Ativan 0.5 to 1 mg PO x 1 and Dilaudid 0.5 to 1 mg IV x1 to alleviate the discomfort of the procedure.
Cells will be injected by means of a 22 gauge sterile spinal needle after topical anesthesia of the injection site. The concentration will be at least 2 x 107 total nucleated cells per ml in phosphate buffered saline (PBS) with 5% human serum albumin (Baxter, Deerfield Illinois)."
1860617|NCT01019694|Drug|Combivent CFC-MDI|36/206 mcg Four times a day (QID)
1860618|NCT01019694|Drug|Combivent Respimat 20/100 mcg|Open label randomized parallel
1860619|NCT01019694|Drug|Atrovent HFA 42 mcg + Albuterol HFA 200 mcg|Open label randomized parallel
1860620|NCT01019707|Drug|Atomoxetine, then Placebo|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
1860621|NCT01019707|Drug|Placebo, then Atomoxetine|As this is a within-subject, crossover design, all subjects complete both study medication assignments in a double-blind fashion. Based on random assignment to start on either atomoxetine or placebo, study drug will be administered once daily at 40 mg/day on the first 2 study days, then twice daily for the third, fourth and fifth study days, and once daily on the sixth study day.
1959843|NCT03312504|Other|Neuromuscular training program|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 15 components; nine of which are aerobic exercises (forward running, forward run with skipping, forward run with knee lifts, forward run with heel kicks, sideways shuffles, zigzag running, forward running with intermittent stops, speed runs, and squat/skate jumps), and six of which are balance/strengthening exercises (front plank, side plank, nordic hamstring exercise, lunges, balancing on the wobble board, and balancing on foam balance pads).
1860623|NCT01019746|Drug|propofol|propofol administration
1860624|NCT01019759|Procedure|pulmonary vein isolation|The off-pump beating heart ablation procedure is performed. Using a Microwave (MW) energy ablation tool (Microwave generator by Guidant), epicardial ablation line isolating the pulmonary veins are applied during open heart surgery
1860625|NCT01019772|Biological|LBVH0101 (Hib vaccine)|
1860626|NCT01019772|Biological|Hiberix™ Vaccine|
1860627|NCT01019785|Dietary Supplement|Ergocalciferol|100 000 U drops is given once
1860628|NCT01019785|Dietary Supplement|Ergocalciferol|500 U drops given once
1860629|NCT01019798|Drug|sunitinib, docetaxel, cisplatin|"Sunitinib given 10 days within 14 days of each cycle。
Sunitinib 25 mg/day with adjust dosage according to patient's condition, but should return to 25 mg when feasible or should withdraw from this study.
Docetaxel 40-50 mg/m2, cisplatin 50 mg/m2 every 2 weeks.
Overall 12 cycles (24 weeks)"
1860630|NCT01019811|Procedure|The innervated sensory cross-finger flap|The innervated sensory cross-finger flap is a modified method for repair fingertip degloving injury
1860631|NCT01019824|Drug|Ralfinamide|Ralfinamide Oral Tablets, 160 or 320 mg per day
1860632|NCT01019837|Biological|Focetria (Monovalent MF59-Adjuvanted vaccine)|Biological: Focetria (Monovalent MF59-Adjuvanted vaccine)
1860633|NCT01019850|Drug|Vorinostat|Patients on study will receive vorinostat orally once daily on days 1 to 14 of treatment.This is a single course treatment. The study has a planned dose escalation schedule, the starting dose level is 180 mg/M2.The maximum absolute dose of vorinostat is 400 mg.
1860634|NCT01019850|Radiation|131- I Metaiodobenzylguanidine|Patients will receive 131-I MIBG on day 3 , one hour after vorinostat dosing.Patients will initially receive 8 mCi/kg 131-I MIBG with 180 mg/m2/dose vorinostat. The dose of 131-I MIBG will be escalated in subsequent cohorts to 15 mCi/kg and then to 18 mCi/kg.If the starting dose exceeds the maximum tolerated dose, patients will be treated with a lowering of vorinostat dose initially (150 mg/m2/day . Dose level -1). If this combination still exceeds the maximum tolerated dose, then a dose level using reduced dose 131-I MIBG will be studied (6 mCi/kg. Dose level -2).
1860635|NCT01019850|Procedure|Peripheral Blood Stem Cell Infusion|Stem cell infusion is planned for 2 weeks after MIBG infusion (day 17). However, stem cells may be infused on day 18 or day 19 to avoid weekend or holiday stem cell infusions.The dose for Purged PBSC is a minimum of 2 x 106 viable CD34+ cells/kg and for Unpurged PBSC: a minimum of 2 x 106 viable CD34+ cells/kg must be available. Stem cells must be infused over 15-30 minutes and within 1.5 hours of thawing.Stem cells will be infused following institutional guidelines for prophylaxis of hypersensitivity reactions and monitoring.
1860636|NCT01019850|Drug|Filgrastim|All patients will receive filgrastim following hematopoietic stem cell infusion according to institutional guidelines (section 4.2.3 of protocol).
1860637|NCT01019863|Drug|oxaliplatin|oxaliplatin 100mg/m2 + Rituxan 375 mg/m2 + Gemcitabine 1000mg/m2 every 2 weeks for 8 cycles
1860638|NCT01019876|Drug|Fludarabine|Fludarabine/Busulfan/Alemtuzumab
1860639|NCT01019876|Drug|Cyclophosphamide|Cyclophosphamide/Fludarabine/TMG
1860640|NCT01019876|Drug|Cyclophosphamide 40|Cyclophosphamide/Fludarabine/ATG/TBI
1860641|NCT01019876|Drug|Cyclophosphamide 30|Cyclophosphamide /Fludarabine/TMG
1860645|NCT01019915|Device|CRT|Insertion of CRT in patients with left bundle branch block. Assessment of skeletal muscle and infalmmatory profile
1860646|NCT01019928|Drug|AZD1386|95 mg, oral solution, single dose
1860647|NCT01019928|Drug|Placebo to AZD1386|Placebo, oral solution, single dose
1860648|NCT01019941|Drug|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, CKD-810 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
1860649|NCT01019941|Drug|CKD-810, Taxotere inj.|Patients will receive docetaxel 75mg/㎡ on Day 1 of each cycle(1 cycle = 3 weeks) as a 1-hour IV infusion. At the 1st cycle, Taxotere inj. 75mg/㎡ administered. If the hematologic or non-hematologic toxicity was not appeared when the 1st cycle intervention was finished, keep going the 2nd cycle intervention.
1860650|NCT01019954|Drug|Levulan|
1860651|NCT01019980|Drug|Diclofenac potassium|Diclofenac potassium
1860652|NCT01019980|Drug|Acetaminophen|Acetaminophen
1860653|NCT01019993|Procedure|conventional OLV followed with IL-HFPPV|The patients' lungs were mechanically ventilated with intermittent positive pressure ventilation using fraction of inspired oxygen (FiO2) of 0.5 in air, tidal volume (VT) of 8 mL/kg, inspiratory to expiratory [I: E] ratio of 1:2.5, zero positive end-expiratory pressure (PEEP), respiratory rate (R.R) was adjusted to achieve an arterial carbon dioxide tension (PaCO2) 35-45 mm Hg and peak inspiratory pressures were limited to 35 cm H2O. After pleurotomy, OLV was initiated with the same ventilatory settings for the dependent lung. After 30 min, the non-dependent collapsed lung was ventilated using HFPPV mode (IL-HFPPV) with another identical ventilator, with an internal circuit of low compliance, using FiO2 of 0.5 in air, VT 3 mL/kg, I: E ratio <0.3 and R.R 60 breaths/min.
1860654|NCT01020006|Drug|PCI-27483|"Part A: Closed to enrollment.Part B: Approximately 20 patients will be randomized to the control arm that will receive a standard regimen of gemcitabine and 20 patients will be randomized to the PCI-27483 arm and treated with both gemcitabine and PCI-27483. PCI-27483 will be administered as subcutaneous (SC) injections, nominally at a dosage of 1.2 mg/kg BID. Patients receiving PCI-27483 with a tumor response or stable disease at 12 weeks will have the option to continue PCI-27483 treatment until disease progression or the investigator considers the study treatment no longer tolerable. Treatment with gemcitabine may continue per standard of care.
All evaluable patients will roll over into Part C at week 16 (Day 113±5). If 2 consecutive INRs at 2 hours postdose are >3.50,a reduced dosage will be calculated."
1860655|NCT01020006|Drug|Gemcitabine|
1860656|NCT01020058|Procedure|Mesh repair for primary inguinal hernia|Open Lichtenstein repair in local anesthesia using a polypropylene mesh compared to totally extra-peritoneal laparoscopic repair using a polypropylene mesh
1860657|NCT01020071|Procedure|pattern scanning laser iridotomy and iridoplasty|peripheral laser iridotomy and iridoplasty using pattern scanning laser technique
1860658|NCT01020097|Drug|fluorine F18 EF5|Given IV
1860659|NCT01020097|Procedure|immunohistochemistry staining method|Correlative study
1860660|NCT01020097|Procedure|biopsy|Correlative study
1860661|NCT01020097|Procedure|Positron Emission tomography|Undergo scan
1860662|NCT01020123|Drug|AZD1656|Different doses of AZD1656 administered to 5 groups of patients
1860663|NCT01020123|Drug|Placebo|AZD1656 placebo and glipizide placebo administered to 1 group of patients
1860664|NCT01020123|Drug|Glipizide|Glipizide administered to 1 group of patients
1860665|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
1860666|NCT01020136|Drug|AG-013736|single oral dose 5-mg tablet (Form IV for Treatment A and Form XLI for Treatment B under fed conditions)
1860667|NCT01020149|Other|MR Imaging|MRI is used to evaluate nerve regeneration after traumatic transsection and nerve repair.
1860668|NCT01020162|Drug|Amitryptiline, gabapentin|For amitryptiline starting dose 20-30 mg at night, increasing until clinical effect. For gabapentin was the initial dose 300 mg tid with rapid increases up to 800 mg tid.
1860669|NCT01020162|Procedure|Resection of the ilioinguinal nerve|In general anaesthesia the nerve was identified and resected as central as possible
1860670|NCT01020175|Procedure|Bone marrow transplantation|Patients received bone marrow transplantation
1860671|NCT01020175|Procedure|Peripheral blood stem cell transplantation|Patients received filgrastim-mobilized peripheral blood stem cell transplantation
1860672|NCT01020214|Drug|Olmesartan Medoxomil and Hydrochlorothiazide Tablets 40 mg/25 mg|
1860673|NCT01020214|Drug|Benicar HCT® Tablets 40 mg/25 mg|
1860674|NCT01020227|Behavioral|Integrative Therapies Intervention|Patients in the intervention group were given a cardiac yoga video, a guided imagery audiotape, instruction in diaphragmatic breathing, and an educational booklet outlining recommendations for dietary change. Patients were followed for 6 months by a health educator who provided ongoing education and encouragement
1860675|NCT01020240|Behavioral|Avolition|- avolition for cesarean discomforts
1860676|NCT01020240|Behavioral|Orientation|"avolition of cesarean discomfort
physiotherapy orientation"
1860677|NCT01020240|Behavioral|Guide|"avolition of cesarean discomfort
physiotherapy orientation
guide orientation"
1860678|NCT01020253|Drug|alendronate, alfacalcidol|Alendronate: 5mg per day, Tablet, Duration is 48 weeks. Alfacalcidol: 1μg per day, Tablet, Duration is 48 weeks.
1860679|NCT01020266|Procedure|non electroacupuncture stimulation|The same procedure as electroacupuncture except stimulation
1860680|NCT01020266|Procedure|Electroacupuncture pretreatment|According to the theory of traditional Chinese medicine, Baihui(GV20) acupoint was chosen and the acupuncture points were identified according to traditional anatomical localization. Once insertion was made at the acupuncture point, the needle was stimulated electrically with the intensity of 0.8-1.9 mA and frequency of 5/30 Hz for 30 min per day using an Electronic Acupuncture Treatment Instrument for 5 consecutive days before the heart valve replacement surgery．
1860681|NCT01020279|Drug|Celecoxib, Ketoprofen|"Ketoprofen in Transfersome® gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d.
Celecoxib, 200 mg, one capsule b.i.d."
1860682|NCT01020279|Drug|Ketoprofen|Placebo gel, 2 g gel on the calf, 4 g gel on the quadriceps, b.i.d. Oral placebo, one capsule b.i.d
1860683|NCT01020292|Drug|Nelfinavir|
1860684|NCT01020305|Drug|Temsirolimus|"Temsirolimus is an inhibitor of the mammalian target of rapamycin (MTOR, aka HGNC:3942)
IUPAC name: (1R,2R,4S)-4-{(2R)-2-[(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-1,5,11,28,29-pentaoxo-1,4,5,6,9,10,11,12,13,14,21,22,23,24,25,26,27,28,29,31,32,33,34,34a-tetracosahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontin-3-yl]propyl}-2-methoxycyclohexyl 3-hydroxy-2-(hydroxymethyl)-2-methylpropanoate"
1860685|NCT01020305|Drug|Casodex (bicalutamide)|Casodex (bicalutamide) 50 mg/day PO
1860686|NCT01020331|Drug|Memantine|
1860687|NCT01020344|Procedure|Lung volume reduction surgery|Lung volume reduction surgery
1860735|NCT01020786|Drug|Pemetrexed|"Induction Therapy: 500 milligrams per square meter (mg/m^2) given intravenously (IV) on Day 1 of every 21-day cycle for 4 cycles.
Maintenance Therapy: 500 mg/m^2 given IV on Day 1 of every 21-day cycle until disease progression or unacceptable toxicity."
1860736|NCT01020786|Drug|Carboplatin|Dosage equal to area under the curve (AUC)6 milligrams per milliliter per minute (mg/mL/min) for participant, given IV on Day 1 of every 21-day cycle for 4 cycles.
1860737|NCT01020799|Drug|AZD7268|15 mg, oral, twice daily (BID)
1860738|NCT01020799|Drug|Escitalopram|20 mg, oral, once daily (QD)
1860688|NCT01020357|Drug|Caffeine citrate injection|"Loading dose: 20 mg/kg administered over at least 30 minutes via IV infusion or over at least 10 minutes via slow IV injection.
Daily maintenance dose (to commence at least 24 hours after loading dose): 5 mg/kg, administered over at least 10 minutes via IV infusion, or over at least 5 minutes via slow IV injection. Maintenance dose to be adjusted for body weight every 7 days. If indicated, maintenance dose may be increased to a maximum of 10 mg/kg. May be given orally once full enteral feeds are established.
Duration of treatment: discontinue after infant has tolerated at least 5 consecutive days without positive pressure support AND when the infant is judged by the attending clinician to be no longer a candidate for methylxanthine therapy."
1860689|NCT01020357|Drug|placebo|normal saline
1860690|NCT01020383|Drug|ALX-0081|4 i.v. bolus injections, once every 6 hours; first dose of 6 mg, three subsequent doses of 4 mg
1860691|NCT01020383|Drug|ReoPro®|0.25 mg/kg i.v. bolus injection followed by continuous i.v. infusion of 0.125 µg/kg/min (to a max. of 10 µg/min) for 12 hours
1860692|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
1860693|NCT01020396|Drug|Metronidazole|Vaginal Gel, 0.75%
1860694|NCT01020409|Procedure|cardiac surgery with CPB use|cardiac surgery with CPB use or ascending aorta surgery performed with use of cardiopulmonary bypass with or without aortic cross clamping.
1860695|NCT01020422|Procedure|Reduction mammaplasty|Sexual function of patients undergoing reduction mammaplasty will be assessed by the Female Sexual Function Index (FSFI) preoperatively and 3 and 6 months postoperatively.
1959844|NCT03312504|Other|Standard-of-practice Warm-up (Control)|This is a 15-minute warm-up program designed to be implemented at the beginning of junior high school physical education classes. This warm-up is comprised of 16 components; seven of which are aerobic exercises (forward running, forward running with arm swings, side shuffling, lunging, skipping, arm running with arm swings, and cool-down running), and nine of which are static stretching exercises (standing quadriceps, standing hamstrings, standing calf, standing groin, rotating ankle, lunges, standing shoulder, standing triceps, standing neck).
1860698|NCT01020448|Drug|Triptorelin (Decapeptyl®)|One intramuscular injection of triptorelin (Decapeptyl®) 22.5mg performed once all baseline procedures and assessments have been completed.
1860699|NCT01020461|Device|Accuvein|Accuvein will be used to facilitate venous blood sampling
1860700|NCT01020461|Device|Accuvein|Accuvein will be used to facilitate peripheral IV catheter placement
1860701|NCT01020474|Drug|placebo|matching placebo capsules twice daily.
1860702|NCT01020474|Drug|pregabalin (Lyrica)|75-450mg/day pregabalin dose optimised at start of study
1860703|NCT01020487|Drug|Paricalcitol|Paricalcitol capsules taken with water.
1860704|NCT01020487|Drug|Placebo|Placebo capsules taken with water
1860705|NCT01020526|Drug|pregabalin|Oral capsule 75-450 mg/day
1860706|NCT01020539|Drug|Fludarabine|Conditioning Regimen
1860707|NCT01020539|Drug|Busulfan|Conditioning Regimen
1860708|NCT01020539|Drug|GVHD Prophylaxis|Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
1860709|NCT01020539|Drug|Gemtuzumab Ozogamicin|Dose Escalation
1860710|NCT01020539|Drug|Anti-Thymocyte Globulin|Unrelated Donors only
1860711|NCT01020539|Drug|Isotretinoin|JMML patients only
1860712|NCT01020552|Other|Provision of PAC job aids and provider training on the use of the job aids|Facility-level intervention applied to all study facilities
1860713|NCT01020565|Drug|Entecavir|Tablet, P.O., 0.1 OR 0.5 mg, once daily, 52 weeks
1860714|NCT01020578|Other|Plasma kinetic study|This study is done with the injection of an artificial lipid nanoemulsion doubly labeled with 14C-cholesteryl oleate and 3H-cholesterol, with a total radioactivity injection dose of 0.03mSV. Blood samples collected in a pre established period of time in 24 hours.
1860715|NCT01020591|Other|Osteopathic evaluation|evaluation of movement and tissue mobility
1860716|NCT01020591|Other|Osteopathic evaluation with treatment|osteopathic evaluation followed by osteopathic manual therapy release of tissues identified as tight or restricted
1860717|NCT01020617|Dietary Supplement|Ls-33|10~10 CFU/day
1860718|NCT01020630|Drug|Sunitinib|Sunitinib will be orally administered at 25 mg once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
1860719|NCT01020630|Drug|Placebo|Placebo will be orally administered once daily (in the morning without regards to meals) for 4 consecutive weeks followed by a 2-week rest period to comprise a complete cycle of 6 weeks.
1860720|NCT01020643|Drug|controlled administration of propofol|comparison of propofol sedation
1860721|NCT01020708|Drug|mesalamine|4.0g mesalamine rectal suspension, rectally administered enema, 60ml volume, 4.0g mesalamine, once daily
1860722|NCT01020708|Drug|ALTH12-1:4|ALTH12-1:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 1.0g N-acetylcysteine
1860723|NCT01020708|Drug|ALTH12-2:4|ALTH12-2:4 rectal suspension, rectally administered enema, 60mL volume, 4.0g mesalamine, 2.0g N-acetylcysteine
1860724|NCT01020734|Biological|anti-thymocyte globulin|
1860725|NCT01020734|Drug|busulfan|
1860726|NCT01020734|Drug|cyclophosphamide|
1860727|NCT01020734|Drug|cyclosporine|
1860728|NCT01020734|Drug|fludarabine phosphate|
1860729|NCT01020734|Drug|methotrexate|
1860730|NCT01020734|Procedure|allogeneic hematopoietic stem cell transplantation|
1860731|NCT01020747|Drug|Avastin® (bevacizumab)|Bevacizumab injections (~7.5-12.5mg in 0.3 - 0.5 c.c.) into diseased vocal folds in conjunction with 532 nm pulsed-KTP laser photoangiolysis, administered every 6 ±1 weeks, for a total of 5 treatments. No patient will have an injection volume exceed 0.5 cc. for any single treatment. If initial results indicate a benefit, as described below, an extension of the active treatment period will be permitted up to a total treatment duration of 18 months.
1860732|NCT01020747|Drug|Saline|A sham injection with saline (0.3-0.5 cc) has been administered to the other vocal fold as the control. This therapy will be administered once every 6 ± 1 week for 6 months, with the same vocal fold selected for the initial treatment always getting the drug injection.
1860739|NCT01020799|Drug|Placebo capsules|Placebo capsules to match AZD7268
1959846|NCT03312465|Device|AS Domelock System|Hemi or Total Shoulder Arthroplasty
1860743|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million.
1860744|NCT01020825|Drug|Fibrin glue|After curettage, the fistulous tract was sealed with fibrin glue.
1860745|NCT01020825|Drug|ASCs|Intralesional injection of adult-stem-cells at a dose of 20 and 40 million in combination with fibrin glue.
1860746|NCT01020838|Drug|Florbetaben (BAY94-9172)|Single intravenous injection 1-5ml, 300 MBq (+/- 20%)
1860747|NCT01020851|Behavioral|tailored intervention|6 monthly telephone calls focusing on diet, medication and exercise adherence using the framework of the transtheoretical model
1860748|NCT01020851|Behavioral|attention placebo|6 monthly telephone-delivered sessions focusing on general health topics
1860749|NCT01020864|Drug|Cetuximab|Cetuximab 500 mg/m² i.v. day 1, every 2nd week
1860750|NCT01020864|Drug|Carboplatin|Carboplatin AUC = 3 i.v. day 1, every 21nd week
1860751|NCT01020864|Drug|Vinorelbine|Vinorelbine 25 mg/m² i.v. day 1, every 2nd week
1860752|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
1860753|NCT01020877|Drug|Metronidazole|Vaginal Gel, 0.75%
1860754|NCT01020903|Procedure|Aprepitant|40 mg po pre-op
1860755|NCT01020903|Drug|Placebo|Orally, pre-op
1860756|NCT01020916|Procedure|Target temperature 36°C|In hospital target temperature management to achieve a core body temperature of 36°C for 24 hours
1860757|NCT01020916|Procedure|Target Temperature 33°C|In hospital target temperature management to achieve a core body temperature of 33°C for 24 hours
1860758|NCT01020929|Device|Blunt Coude|Type of needle tip
1860759|NCT01020929|Device|Quincke|Type of needle tip
1860760|NCT01020929|Device|Trucath|Type of needle tip
1860761|NCT01020942|Procedure|Electroacupuncture stimulation|According to the theory of traditional Chinese medicine, bilateral Neiguan (PC 6) acupoints were chosen and identified according to traditional anatomical localizations. Once insertion of original needles was made at the acupoints, the needle was stimulated electrically with the intensity of 2-6 mA and frequency of 2/30 Hz using the Electronic Acupuncture Treatment Instrument until the patient felt the so-called 'Teh Chi' sensation of heaviness, numbness and swelling. The pretreatment was individualized based on patients sex, age, weight and felt and given 1 time per day for 5 consecutive days before the heart valve replacement surgery．
1860762|NCT01020942|Procedure|No intervention|The control patients were only placed needles at the bilateral Neiguan (PC 6)acupoints without electric stimulus.
1860763|NCT01020955|Drug|NutropinAq (GH) and Increlex (IGF-I)|NutropinAq (GH)(0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and Increlex (IGF-I) (15 µg/kg/d for 1 month, 30 µg/kg/d for 5 months)
1860764|NCT01020955|Drug|NutropinAq and placebo|NutropinAq (0.15 mg/d for 1 month, 0.3 mg/d for 5 months) and placebo for 6 months.
1860765|NCT01020968|Biological|Ixmyelocel-T|CRCs will be administered via catheter-based injection to the endocardial surface of the left ventricle.
1860766|NCT01020968|Other|Standard of Care|
1860767|NCT01020994|Drug|LAS41003|Once daily, topically
1860768|NCT01020994|Drug|LAS189962|Once daily, topically
1860769|NCT01020994|Drug|LAS189961|Once daily, topically
1860770|NCT01021007|Drug|Iodine|Rinse 2 times per day for 6 weeks
1860771|NCT01021007|Other|water|Use 2 times per day for 6 weeks
1860772|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a fast of at least 10 hours
1860773|NCT01021020|Drug|Colchicine|0.6mg tablet administered after a standardized high-fat, high-calorie breakfast
1860774|NCT01021020|Drug|Colchicine/Probenecid|0.5mg/500mg tablet administered after a fast of at least 10 hours
1860775|NCT01021046|Procedure|DALK using GCCT|Deep anterior lamellar keratoplasty (DALK) using glycerin-cryopreserved corneal tissue
1860776|NCT01021046|Procedure|DALK using FCT|Deep anterior lamellar keratoplasty (DALK) using fresh corneal tissue
1860777|NCT01021059|Biological|rh IL-15|rh IL-15 daily for 12 days of 42 days cycle. Additional cycles may be given if patient is responding to therapy.
1860778|NCT01021072|Drug|MABp1|0.25 mg/kg,0.75 mg/kg,1.25 mg/kg, 3.75 mg/kg IV (in the vein) on day 1 of each 21 day cycle until progression or unacceptable toxicity develops.
1860779|NCT01021111|Device|Activity Training with Feedback|The feedback system consisted of three small inertial measurement units affixed on the chest, thigh, and shank segment respectively. These units were connected to a computer that recorded the signal from the inertial sensors at 240 Hz during the jump task. Using custom software, the knee flexion angle, trunk lean, and coronal thigh angular velocity were calculated immediately after the subject completed the jump trial. A projector was used to display the results of the jump analysis. It took less than 10 minutes to place this system on a subject and less than five seconds to analyze a jump.
1860780|NCT01021150|Drug|ombrabulin (AVE8062)|"Pharmaceutical form:injection solution
Route of administration: intravenous infusion"
1860781|NCT01021150|Drug|cisplatin|"Pharmaceutical form: injection solution
Route of administration: intravenous infusion"
1860782|NCT01021163|Drug|N-acetylcysteine, saline|Inject 100 mg/kg of N-acetylcysteine or the equivalent amount of saline for 15 minutes before the skin incision, then continuously inject 40 mg/kg/day of N-acetylcysteine or the equivalent amount of saline during the next 24 hours.
1860783|NCT01021176|Other|Placebo spray|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray yet no drug will be administered
1860784|NCT01021176|Drug|Diltiazem|0, 30, 60, 90, 120, 180, and 240 minutes following the nasal spray Three Dilutions would be 5.5, 6.0 and 6.3 and the fourth at the filp of a coin randomly diluted.
1860785|NCT01021189|Drug|AZD1446|Oral solution Dose single and followed by 7-day multiple dosing.Specific doses depend on panel.
1860786|NCT01021189|Drug|Placebo|Oral solution Dose single and followed by 7-day multiple dosing.
1860787|NCT01021202|Procedure|Percutaneous dilation tracheostomy|Percutaneous dilation tracheostomy using Ciaglia blue rhino system (Cook medical, Limerick, IRELAND). Tracheostomy is conducted by two experienced physicians with (video-)bronchoscopic control and continuous monitoring of ECG, blood pressure, pulse and peripheral oxygen saturation.
1860788|NCT01021215|Drug|Zileuton|1200 mg twice daily given orally (PO) for 6 days
1860789|NCT01021215|Drug|Celecoxib|200 mg twice daily given orally for 6 days
1860790|NCT01021215|Other|laboratory biomarker analysis|Correlative studies
1860791|NCT01021241|Biological|Uricase-PEG 20|Intravenous infusion of Uricase-PEG 20 over one hour; no premedication
1860793|NCT01021293|Biological|Poliorix™|3 doses, intramuscular administration
1860794|NCT01021293|Biological|Oral Poliovirus vaccine|3 doses, oral administration
1860795|NCT01021306|Device|Chiropractic w/Activator & Self Care|This technique uses a hand held instrument to deliver a quick, shallow thrust in a well defined manner. The instrument has two handles that are squeezed together until it clicks, resulting in a shallow, very quick thrust to the segment that is to be adjusted. The AMCT protocol is a structured method of chiropractic treatment that utilized a number of simple biomechanical tests in order to determine where to adjust. These tests are mostly well defined movements of body parts such as extending the head or laterally moving the mandible relative to the rest of the skull. This protocol includes treatment of the full spine and appendages as well as the area immediately around the jaw.
1860796|NCT01021306|Device|Dental Care & Self Care|Following the dental exam, patients will have maxillary and mandibular polyvinyl siloxane impressions made. Interocclusal records will be made with a fast setting silicone using a metal tray. A commercial laboratory will then wax and heat process a clear acrylic resin splint attempting to capture the mandibular cusp tips in the occlusal plan of the splint. The splint will be adjusted to provide uniform posterior centric occlusal stops followed by evaluation for canine guidance. The splint will then be polished and home care instruction provided. Patients will be instructed to wear the splint at night and two hours per day.
1860797|NCT01021306|Other|Sham AMCT|This protocol will attempt to follow all of the procedures of the actual AMCT protocol except that when a thrust is given with the Activator instrument, the clinician will place the thumb of his left hand over the spot that would normally be adjusted. The tip of the instrument them will be placed very close to, but not touching the thumb. Consequently, the patient will feel the contact of the clinician's thumb on the spot that would be normally adjusted, and will hear the click of the instrument, but no thrust will be delivered to the patient.
1860798|NCT01021306|Other|Self-Care Only Group|Self care consists of an initial set of standard patient self performed treatments which will include jaw relaxation exercises, reduction of parafunction, thermal packs, low dose NSAIDs, passive opening stretches and suggestions for stress reduction.
1860799|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/6 mg)|oral
1860800|NCT01021332|Drug|tamsulosin hydrochloride/solifenacin succinate fixed dose combination (0.4 mg/9 mg)|oral
1860801|NCT01021358|Drug|ABT-263|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
1860802|NCT01021358|Drug|Ketoconazole|Subjects will be dosed with ABT-263, then dosed with ABT-263 in combination with Ketoconazole.
1860803|NCT01021371|Behavioral|Two step intervention including patient interview followed by an extended information routine to the patients' GP about the patients' rehabilitation needs|The intervention consists of an extended information routine from hospital to GP based on individual interviews with the patients in the intervention group and a specific encouragement of the patients' GP to play a proactive role in the patients' rehabilitation course. The individual needs concerning the different types of consequences of the disease and following rehabilitation needs will be brought into focus. The control group is assigned to usual procedures.
1860804|NCT01021384|Behavioral|Problem Solving Education|Problem Solving Education (PSE) is an evidenced-based empowerment strategy, targeted to mothers of young children to promote family well-being by decreasing the burden of maternal depressive symptoms and maternal parenting stress and improving social functioning.
1860805|NCT01021397|Drug|rHPIV3cp45|10^5 TCID50 nasal drops
1860806|NCT01021397|Drug|rHPIV3cp45 placebo|1X-L15 nasal drops
1860807|NCT01021423|Drug|Lenalidomide|15 mg orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
1860808|NCT01021423|Other|Placebo|Placebo (identical matched capsule) orally once daily on Days 1-21 of every 28-day cycle for a maximum of 2 years or until disease progression, unacceptable toxicity develops or voluntary withdrawal.
1860809|NCT01021436|Drug|Amikacin inhalation solution (BAY41-6551)|Daily dose of 800 mg of aerosolized amikacin delivered in two divided doses of 400 mg per aerosol treatment 12 hour
1860810|NCT01021462|Procedure|Comparator: graded infusion of intravenous glucose|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12mg/kg/min. Procedure will be identical in Period 1 and Period 2.
1860811|NCT01021475|Procedure|Visceral Manipulation|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks and 4 VM visits with weekly frequency with first VM visit at day 1 of drug therapy.
1860812|NCT01021475|Drug|PPIs and/or Domperidone|Usual FD drug therapy (PPIs and/or Domperidone in base of symptom complain) for 4 weeks
1860813|NCT01021488|Drug|Rosuvastatin 20mg/d for 14days|Rosuvastatin 20mg/day for 7days before and 7days after index surgery (total knee replacement arthroplasty, TKRA) Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered at the same time with rosuvastatin.
1860814|NCT01021488|Drug|enoxaparin only|enoxaparin 40mg sq/day only starting 12hr before TKRA and from on day 1 to 7 after index surgery
1860815|NCT01021501|Drug|nifedipine controlled release tablets|nifedipine controlled release tablets 60mg/day for at least 4 weeks
1860816|NCT01021527|Other|Comparator: Treatment A|No Treatment
1860817|NCT01021527|Drug|Comparator: Treatment B|single dose administration of exenatide 5ug by subcutaneous injection
1860818|NCT01021527|Drug|Comparator: Treatment C|single dose administration of exenatide 10ug by subcutaneous injection
1860819|NCT01021527|Procedure|Comparator: graded glucose infusion|A stepwise graded infusion of glucose (20% dextrose [D20]) with a stable rate of infusion maintained for 40 minutes for each of 5 steps, with steps at 2,4,6,8 and 12 mg/kg/min. Infusion will be performed during each of the 4 treatment periods.
1860820|NCT01021540|Drug|Repository corticotrophin|Acthar 80 IU SQ once a week and titrated up to twice a week
1860821|NCT01021553|Drug|GSK557296|50 mg GSK557296
1860822|NCT01021553|Drug|GSK557296|150 mg GSK557296
1860823|NCT01021553|Drug|placebo|placebo
1860824|NCT01021566|Device|Combined hemoperfusion-hemodialysis|Combined hemoperfusion-hemodialysis for opiate detoxification for 3 days
1860900|NCT01022190|Drug|Etoricoxib (Arcoxia)|Oral intake of 90 mg Etoricoxib (Arcoxia) during 7-days
1860825|NCT01021566|Drug|Methadone|On admission all patients will undergo a 3-day stabilization period. Then they will begin the 10-day methadone treatment regimen. The starting dose of methadone is determined by the mean daily dose requirement during the stabilization period and the dose will be reduced to zero at a linear rate over the 10 days treatment.
1860826|NCT01021579|Drug|Metformin plus Placebo|PCOS patients(n=42) will be assigned to the placebo (once/day) plus metformin (500mg three times a day, n=42; group 2)
1860827|NCT01021579|Drug|Metfomin plus Simvastatin|
1860828|NCT01021592|Drug|bortezomib|Injection into a vein 1.3 mg/m2 twice a week for 21 days
1860829|NCT01021618|Drug|Regadenoson|Regadenoson (0.4mg/5 mL) injection during symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
1860830|NCT01021618|Other|Symptom-limited exercise|Dipyridamole (0.56 mg/kg) over 4 minutes followed by symptom-limited exercise with technetium-99m SPECT myocardial perfusion imaging
1860831|NCT01021631|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be given when hematocrit fall below 30% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 30% or higher, no additional transfusion is necessary.
1860832|NCT01021631|Other|Red blood cell transfusion|Red blood cell (RBC) transfusion will be only given when hematocrit fall below 24% since intraoperative until the discharge of intensive care unit. Following administration of the 1 RBC unit, a repeat hematocrit is performed;if a patient's hematocrit is 24% or higher, no additional transfusion is necessary.
1860833|NCT01021644|Behavioral|aerobic exercise-training|3 times per week for 6 months
1860834|NCT01021644|Behavioral|stretch exercise|3 times per week for 6 months
1860835|NCT01021657|Procedure|trabeculectomies, non penetrating deep sclerectomies|
1860836|NCT01021670|Drug|Dapoxetine hydrochloride|One 30 mg tablet up to a maximum of one 60 mg tablet approximately 1 to 3 hours prior to prior to sexual activity once every 24 hours as needed for 12 weeks
1860837|NCT01021670|Other|Alternate care/non-dapoxetine hydrochloride treatment(s)|As prescribed or directed
1860838|NCT01021683|Drug|Itraconazole|Itraconazole will be administered as an infusion (a fluid or a medicine delivered into a vein by way of a needle) over one hour at the dose of 200 milligram (mg) per dose twice daily for 2 days, followed by 200 mg once daily for 12 days, followed by itraconazole oral solution at the dose of 200 mg per dose twice daily for 14 days until clinically significant neutropenia is recovered.
1860839|NCT01021696|Drug|Paracetamol|Paracetamol Max. dose: 3g/d
1860840|NCT01021696|Drug|Morphine|Morphine ret. Tab. 5mgx2/d; max. dose:10mgx2/d
1860841|NCT01021696|Drug|Buprenorphine plaster|5ųg/h, change each 7.day; max. dose: 10ųg/h
1860842|NCT01021696|Drug|Pregabalin|25mgx1/d; max 300mg/d
1860843|NCT01021709|Device|tDCS (Eldith DC-Stimulator (CE certified))|tDCS session lasting continuously for 20 minutes at 2 mA. Conductive rubber electrodes (7 x 5 cm = 35 cm2 & 10 x 10 cm = 100 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
1860844|NCT01021722|Procedure|modified suture technique|Both internal and external anal sphincter was sutured separately end to end
1860845|NCT01021735|Drug|etanercept or adalimumab|etanercept 50mg/week by s/c injection adalimumab 40mg eow by s/c/ injection
1860846|NCT01021735|Drug|Rituximab|1g x2 by IV infusion repeated every 5 months or more
1860847|NCT01021748|Drug|MK-2206 plus AZD6244|MK-2206 (tablets) orally, in a once every-other-day (starting dose 45 mg) or once-weekly (starting dose 90 mg) schedule, and AZD6244 (capsules), orally, twice a day (starting dose 75 mg). Doses will be escalated to the MTD.
1860848|NCT01021761|Drug|Ketorolac Tromethamine|ketorolac to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
1860849|NCT01021761|Drug|Bromfenac|Drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
1860850|NCT01021761|Drug|nepafenac|drug to be given 1 drop BID the day before surgery and 3 doses pre op the day of surgery prior to surgery
1860851|NCT01021774|Procedure|Anal fistula treatment|A comparison of collagen plug vs advancement flap surgery
1860852|NCT01021787|Drug|Titanium dioxide|Topical cream
1860853|NCT01021800|Biological|MIS|Cell infusion
1860854|NCT01021813|Drug|Suvorexant|Oral tablet (30 mg and 10 mg), administered daily before bedtime
1860855|NCT01021813|Drug|Dose-matched Placebo to Suvorexant|Oral tablet, administered daily before bedtime
1860856|NCT01021839|Procedure|Grafts placement|Graft placement (upper or lower extremity); surgical or radiographic revision as needed.
1860857|NCT01021852|Drug|MK-6096|MK-6096 2.5 mg or 5 mg tablets equaling 2.5 mg dose, 5 mg dose, 10 mg dose, or 20 mg dose (depending upon allocation) were taken daily before bedtime for 4 weeks.
1860858|NCT01021852|Drug|Dose-matched Placebo to MK-6096|Dose-matched placebo tablets to MK-6096 were taken daily before bedtime during 2-week single-blind run-in, for 4 weeks as a treatment period, and during 2-week washout between treatment periods.
1860859|NCT01021865|Drug|Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere|"GLP-1 at a rate of 1.2 pmol/kg/min
Regadenoson as a stress agent 0.4mg IV given during MCE
Definity:0.6 ml of Definity diluted with 30ml of 0.9% saline infused by SYRINGE Infusion Pump"
1860860|NCT01021878|Other|icodextrin|glucose sparing dialysis solution
1860861|NCT01021878|Other|Dianeal|glucose based dialysis solution
1860862|NCT01021891|Drug|Technosphere®/Insulin|
1860863|NCT01021904|Biological|Gardasil (VLP, HPV Quadrivalent prophylactic vaccine)|0.5cc I/M Site deltoid Lt Rt 3-dose regimen: 0, 2, 6 months
1860864|NCT01021930|Device|Polymer-based sirolimus-eluting stent(Cypher stent ) and Polymer-free paclitaxel-eluting stent (YinYi stent)|Polymer-based sirolimus-eluting stent( Cypher, Cordis ) and Polymer-free paclitaxel-eluting stent (YinYi ),randomly implanted in two vessels of one patients
1860865|NCT01021943|Drug|spironolactone|Half of the subjects will be assigned to receive 25 mg of spironolactone for 6 months
1860866|NCT01021943|Drug|Placebo|Half of the subjects will be assigned to receive placebo for 6 months
1860944|NCT01028508|Procedure|ECT|Procedure: ECT RUL ultra brief pulse ECT, 4 treatments in one month and then treatment on an as-needed basis for 5 months Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
1860868|NCT01021969|Other|Fructose|Subjects consume different amounts of fructose, glucose and sucrose in a crossover design
1860869|NCT01021995|Drug|echinacea|drops, 0.9 ml, tid for 4 months
1860870|NCT01021995|Drug|placebo|drops, 0.9 ml tid for 4 months
1860871|NCT01022008|Device|Osteodistraction techniques|Treatment based on craniofacial osteotomies and osteodistraction techniques.
1860872|NCT01022021|Drug|Rituximab|Day 1 - rituximab, 375 mg/M2 IV (drug dosage is based on body weight)
1860873|NCT01022021|Drug|Bendamustine|Days 2 and 3 bendamustine, 90 mg/M2 IV over 30-60 minutes (drug dosage based on body weight)
1860874|NCT01022034|Procedure|sacral rectopexy with sutures or meshes|
1860875|NCT01022034|Procedure|full rectal mobilization from the sacrum without sacral rectopexy|
1860876|NCT01022047|Drug|Noex|The patients shall use the Noex drug only once a day (one application in each nostril) during the 12 weeks of treatment
1860877|NCT01022047|Drug|Budecort Aqua|The patients shall use the Budecort Aqua drug only once a day (one application in each nostril) during the 12 weeks of treatment.
1860878|NCT01022060|Dietary Supplement|Renalof|One Renalof tablet (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
1860879|NCT01022060|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) three time a day (just before each meal: breakfast, lunch and dinner), for 12 weeks
1860880|NCT01022086|Procedure|Cardiac MRI|Cardiac magnetic resonance (CMR) imaging, otherwise called a cardiac (heart) MRI is a safe and standard clinical test that creates detailed images of your heart. It uses a computer to create images of your heart as it is beating, producing both still and moving pictures of your heart and major blood vessels. This test will allow the health professionals to obtain images of your beating heart and to look at the structure and function. Cardiac MRIs can help diagnose and evaluate a number of diseases conditions (such as heart failure, and heart valve disease) and will help doctors decide how to treat or manage patients who have heart problems.
1860881|NCT01022086|Biological|Biomarker Testing|"In addition to undergoing CMR imaging, patients will also have blood tests for two proteins, which serve as markers of heart injury and heart failure. These are called BNP and Troponin. These blood tests are currently used in clinical practice, but their precise role in monitoring heart function in cancer patients has not been well studied. Since the precise cause of Trastuzumab-induced heart damage is currently unknown, it is hoped that these two blood markers will provide valuable insights into how this happens.
Peripheral venous blood samples will also be drawn at each CMR time-point. TGF β1, amino terminal propeptide of procollagen type I (PINP) and type III (PIIINP) and the carboxy-terminal telopeptide of collagen type 1 (CITP) will be measured by radioimmunoassay."
1860882|NCT01022099|Procedure|Implantation of a Total Knee Arthroplasty|"In all patients a cemented, unconstrained, cruciate-retaining TKA with a rotating platform (ScorpioTM PCS, Stryker Orthopaedics, Mahwah, NJ) was implanted. No patellar resurfacing was performed. A medial parapatellar approach with a femur-first preparation was done in all cases.
The Stryker Navigation System, Knee Navigation Software V3.1 (Stryker Orthopaedics, Mahwah, NJ) was used for computer-assisted implantation.
The conventional implantation was performed with femoral intramedullary and tibial extramedullary standard alignment guides."
1860883|NCT01022112|Drug|TA-7284-Low|TA-7284-Low
1860884|NCT01022112|Drug|TA-7284-Low-middle|TA-7284-Low-middle
1860885|NCT01022112|Drug|TA-7284-High-middle|TA-7284-High-middle
1860886|NCT01022112|Drug|TA-7284-High|TA-7284-High
1860887|NCT01022112|Drug|Placebo|Placebo
1860888|NCT01022125|Drug|TMC435|
1860889|NCT01022138|Biological|HER2Bi-armed activated T cells|Immediately after pheresis, the lymphocytes are activated with soluble monoclonal anti-CD3 antibody, which cross-links the CD3 receptors on T cells and activates them.
1860890|NCT01022138|Drug|Cyclophosphamide|After recovering from the last cycle of chemotherapy (approx. two-four weeks) patients will be re-staged. If there are no residual chemotherapy related toxicities, they will be given lymphodepleting chemotherapy consisting of one dose of Cyclophosphamide 1.0 gm/m2 on day -7. Appropriate anti-emetics will be given as pre-medications before the dose of Cyclophosphamide
1860891|NCT01022138|Other|Laboratory biomarker analysis|The association between the [18F]-FDG PET/CT assessments (percent changes from baseline in SUVpeak) and immunologic biomarker changes as well as tumor response will be explored.
1860892|NCT01022151|Drug|Placebo [group P]|receive intravenous injection of 0.2 mL/kg of saline 0.9%L [group P]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
1860893|NCT01022151|Drug|0.2 mL/kg of aminophylline 10 mg/mL [group A2]|receive intravenous injection of 0.2 mL/kg of aminophylline 10 mg/mL [group A2]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
1860894|NCT01022151|Drug|0.2 mL/kg of aminophylline 15 mg/mL [group A3]|receive intravenous injection of 0.2 mL/kg of aminophylline 15 mg/mL [group A3]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
1860895|NCT01022151|Drug|0.2 mL/kg of aminophylline 20 mg/mL [group A4]|receive intravenous injection of 0.2 mL/kg of aminophylline 20 mg/mL [group A4]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
1860896|NCT01022151|Drug|0.2 mL/kg of aminophylline 25 mg/mL [group A5]|receive intravenous injection of 0.2 mL/kg of aminophylline 25 mg/mL [group A5]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
1860897|NCT01022151|Drug|Doxapram 1 mg/kg [group D]|receive intravenous injection of 0.2 mL/kg of doxapram 5 mg/mL [group D]. All study solutions were injected within 1 min at T0 after discontinuation of sevoflurane. No stimulation was applied to patients during this period.
1860898|NCT01022164|Procedure|fibrin glue|
1860899|NCT01022177|Procedure|acupuncture|acupuncture of the eye in traditional chinese schematics
1863304|NCT01041573|Biological|Havrix®720|0.5 ml im. at day 0 and month 7
1860901|NCT01022203|Behavioral|Structured Approach Therapy|The Structured Approach Therapy intervention includes education about the impact of PTSD on relationships; skills training to teach couples recognize and stop avoidance behavior; behavior activation training; emotion regulation training; and a couple-based intervention to teach Veterans with PTSD to identify and disclose trauma memories and related emotions to their partners. The couple is then trained to support disclosure while practicing empathic communication.
1860902|NCT01022203|Other|PTSD Family Education|The PTSD Family Education intervention provides education for Veterans with PTSD and their partners explaining the signs and symptoms of PTSD; psychological problems that are comorbid with PTSD; and treatments for PTSD. Skills training and psychotherapy are not included.
1860903|NCT01022216|Device|Procellera™ Wound Dressing with V.A.C.® Therapy|Dressing indicated for partial and full-thickness wounds. Weekly dressing changes, more frequently if needed. Used as a primary contact layer in conjunction with NPWT.
1860904|NCT01022216|Device|V.A.C.® Therapy|Vacuum Assisted Closure device that uses controlled negative pressure, with dressing changes 1x/week.
1860905|NCT01022229|Dietary Supplement|Compound Natural Health Product|"15-35 mg zinc citrate
150-350 mg magnesium lactate
30-70 mg pyridoxine hydrochloride
150-350 mg calcium ascorbate
Doses are weight based. Chewable tablets are taken 2 times/day with food for the duration of the study"
1860906|NCT01022229|Dietary Supplement|Placebo|Placebo
1860907|NCT01022242|Drug|PXL01|PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
1860908|NCT01022242|Drug|Placebo|Placebo is a physiological sodium chloride solution, which is clear and colourless.
1860909|NCT01022255|Biological|Autologous FL vaccine|1.0 mg of vaccine subcutaneously (s.c.) on Day 1, and followed by 125 µg GM-CSF s.c. at Day 1 -4, monthly until 8th vaccination, bimonthly until 12th vaccination (month 16)
1860910|NCT01022294|Drug|Nitrousoxide-oxygen and atmospheric air|Nitrousoxide-oxygen and atmospheric air
1860911|NCT01022294|Drug|Atmospheric air; nitrousoxide-oxygen|Atmospheric air; nitrousoxide-oxygen
1860912|NCT01022320|Procedure|Lateral Pharyngoplasty|surgery lateral pharyngoplasty: consists on the section and rotation of the superior constrictor pharyngeal muscle associated with the ressection of the palatopharyngeus preserving the palatoglossus and mucosa of posterior and anterior tonsilar pillar , bilaterally.
1860913|NCT01022333|Dietary Supplement|Diindolylmethane (DIM)|300 mg per day of DIM for six weeks.
1860914|NCT01022346|Drug|Placebo|Placebo matched to RO5217790 will be administered subcutaneously on Days 1, 8, and 15.
1860915|NCT01022346|Drug|RO5217790|RO5217790 will be administered at a dose of 5*10^7 pfu subcutaneously on Days 1, 8, and 15.
1860916|NCT01022359|Device|TesioCath|Insertion of the TesioCath(TM) central venous catheter for haemodialysis vascular access
1860917|NCT01022359|Device|LifeCath Twin|Insertion of the LifeCath Twin central venous catheter for haemodialysis vascular access
1860918|NCT01022372|Procedure|Endometrial biopsy|For all the groups
1860919|NCT01022385|Dietary Supplement|24-hour low-residual diet|
1860920|NCT01022398|Drug|cholecalciferol/placebo|10,000 IU by mouth weekly for 6 months
1860921|NCT01022411|Dietary Supplement|Brown rice/White rice|ad libitum intake of brown rice/white rice at every lunch and dinner for 16 weeks
1860923|NCT01022437|Other|Geranium Oil with component PN-34|Geranium oil as a topical application to the body that is numb, time to determine how long it takes for the feeling to return, if it does so, and if the return of feeling is maintained by daily topical application of oil over 12 weeks. This including the process of absorption, distribution and localization.
1860924|NCT01022463|Drug|Ivabradine|Ivabradine 5 mg BId for 4 weeks
1860925|NCT01022463|Drug|Atenolol|50 mg od for 4 weeks
1860926|NCT01022476|Drug|Raltegravir potassium|one pill of raltegravir 400 mg twice a day
1860927|NCT01022489|Device|Transcranial magnetic stimulation: rTMS|4 sessions of 13 minutes, with 2 sessions a day, at 20Hz frequency and at an intensity of 80% of rest motor threshold will be delivered
1860928|NCT01022489|Device|Placebo (sham coil) treatment|Sham coil treatment
1860929|NCT01022502|Drug|refined indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
1860930|NCT01022502|Drug|crude indigo naturalis ointment|The patients applied either refined oil extract or crude indigo naturalis ointmnet topically to each of two bilaterally symmetrical psoriatic plaque lesions for 8 weeks.
1860931|NCT01022515|Other|plasma EM66 & CgA levels assessment|After inclusion checking to eliminate the presence of pheochromocytoma / paraganglioma, a blood sample will be drawn to assess plasma EM66 and CgA levels.
1860932|NCT01022515|Other|usual follow up with regular EM66 & Cga levels assessment|"Patients with pheochromocytoma / paraganglioma will be followed-up as the international standards recommend.
Regularly, blood samples will be drawn for the usual assessment of CgA levels and also EM66 (research purpose) levels."
1860933|NCT01022528|Drug|Dexamethasone (0.1 mg/kg)|
1860934|NCT01022528|Drug|Dexamethasone (0.2 mg/kg)|
1860935|NCT01022528|Other|Saline|
1860936|NCT01028456|Other|Light Therapy|10,000 lux / 30 minutes a day
1860937|NCT01028456|Other|100 lux|Placebo light
1860938|NCT01028469|Device|Artelon MTP Spacer|Metatarsophalangeal hemi-implant
1860939|NCT01028482|Drug|Sertraline|"group A- sertraline 50-100 mg/day and weekly psychotherapy for 3 months
group B- weekly psychotherapy- for 3 months
group C- sertraline 50-100 mg/day-for 3 months"
1860940|NCT01028482|Drug|placebo|placebo
1860941|NCT01028482|Other|psychotherapy|psychotherapy
1860942|NCT01028495|Drug|RX-0201 plus Gemcitabine|RX-0201 3 week cycle at 250mg/m2/day of continuous infusion for 14 days with 7 days off. Gemcitabine at 1000 mg/day once a week for a 4 week cycle; 3 weeks of treatment at 30 minutes infusion once a week and one week off.
1860943|NCT01028508|Drug|lithium and Venlafaxine|Drug: VLF Target dose 225 mg/day Drug: Li Target serum concentration 0.7 mEq/l
1864234|NCT01048593|Drug|IBI-10090|Single intraocular injection
1860945|NCT01028521|Drug|CM3.1-AC100|Solution for sc injection, single ascending doses
1860946|NCT01028521|Drug|Placebo|Solution for sc injection
1860947|NCT01028534|Drug|Olmesartan and Azelnidipine|"Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, increase Olmesartan to 40mg per day for the next 3 months
Olmesartan 20mg per day for 3 months and, if hypertension is not controlled, add Azelnidipine 16mg per day for the next 3 months
Azelnidipine 16mg per day for 3 months, and, if hypertension is not controlled, add Olmesartan 20mg per day for the next 3 months"
1860948|NCT01028547|Drug|dexamethasone|single Bolus dose of dexamethasone 8mg
1860949|NCT01028547|Other|normal saline|2 ml 0.9% saline
1860950|NCT01028560|Biological|Allergen extracts (subcutaneous injections)|Allergy immunotherapy consists of regular subcutaneous injections of an individualized mixture of allergen extracts according to the allergy sensitization profile of each child. Increasing doses of allergen extract are given in 1-2 injections until a predetermined maintenance dose is reached. This maintenance dose varies by extract and accords to the general practice guidelines of immunotherapy. To increase safety the cumulative monthly maintenance doses are divided into biweekly visits during the maintenance phase (year 2-3)
1860951|NCT01028560|Other|Standard of care|standard of care asthma and allergy treatment
1860952|NCT01028573|Drug|PEG-ELS (Golytely)|4L consumed evening before colonoscopy
1860953|NCT01028573|Drug|PEG-ELS (Golytely)|2L consumed on the evening before and 2L consumed on the morning of Colonoscopy
1860954|NCT01028573|Drug|Miralax mixed with Gatorade|238g of PEG-3350 (Miralax) mixed with 2L of Gatorade consumed on the evening before colonoscopy
1860955|NCT01028573|Drug|Miralax|1L of PEG-3350 + Gatorade consumed on the evening before and 1L of PEG-3350 + Gatorade consumed on the morning of Colonoscopy
1860956|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 50 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
1860957|NCT01028586|Drug|Safinamide, MAO-B inhibitor|Safinamide, MAO-B inhibitor 100 mg: once-daily orally for 78 weeks in addition to their dose of DA-agonist.
1860958|NCT01028586|Drug|Placebo|matching placebo tablets
1860959|NCT01028599|Other|Intensive physical exercise|Intensive physical exercise 1 hour three times per week
1860960|NCT01028612|Radiation|thermal ablation with external beam radiation|thermal ablation with external beam radiation
1860961|NCT01028625|Behavioral|Cognitive Behavior Therapy|CBT utilizes a variety of strategies and techniques to modify cognitions and behaviors that contribute to depression such as behavioral activation; identifying and challenging distressing thoughts, beliefs, and attitudes; and systematic problem-solving. In this trial, CBT will be integrated with an intervention aimed at improving heart failure self-care, and with attention to primary caregiver stress. The CBT sessions will usually last about 50 minutes and will be scheduled weekly for up to 6 months, with additional maintenance contacts after that. The frequency of sessions will be tapered prior to 6 months if the participant meets the study criteria for depression remission and has acquired relapse-prevention skills.
1860962|NCT01028625|Other|Heart Failure Self-care Education|Participants in both arms will receive heart failure educational material from the Heart Failure Society of America. In addition, a RN will review educational material with participants during baseline visit and with 3 weekly follow up phone calls.
1860963|NCT01028638|Other|89Zr-bevacizumab PET scan|"A tracer dose of 89Zr-bevacizumab (37 MBq, 5 mg protein dose) is given intravenously at day -3, day 11 and day 39.
PET scans are made on day 1, day 15 and day 43."
1860964|NCT01028651|Drug|Treprostinil|"Remodulin is supplied in concentrations of 1, 2.5 , 5, and 10 mg/mL and can be administered as supplied or diluted for intravenous (IV) infusion prior to administration.
Remodulin is indicated for subcutaneous (SC) or IV use only as a continuous infusion. Remodulin is preferably infused subcutaneously, but can be administered by a central IV line if the SC route is not tolerated. The infusion rate is initiated at 1.25 ng/kg/min. If this initial dose cannot be tolerated because of systemic effects, the infusion rate should be reduced to 0.625 ng/kg/min."
1860965|NCT01028664|Device|SENSIMED Triggerfish|2-hour continuous IOP monitoring
1860966|NCT01028677|Drug|intranasal spray with oxytocin|6 insufflations (24 IU of oxytocin total) given twice daily for 6 weeks
1860967|NCT01028677|Other|nasal spray without oxytocin|6 insufflations of nasal spray without oxytocin (0.1 metered dose/insufflation) twice daily for 6 weeks
1860968|NCT01028690|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri is a mixture of L. reuteri DSM 17938 and L. reuteri ATCC PTA 6475; will be delivered at a dose of 1x108 CFU of each strain. One dose is to be taken once per day giving a dose of L. reuteri of 2x108 CFU/day. Will be taken daily throughout the entire study, from the day of inclusion to the final analysis at the end of follow-up after eradication therapy. Will be delivered either in a chewable tablet form
1860969|NCT01028690|Dietary Supplement|Placebo|placebo
1860970|NCT01028716|Drug|Cyclophosphamide|Given IV
1860971|NCT01028716|Biological|Filgrastim|Given IV
1860972|NCT01028716|Drug|Fludarabine Phosphate|Given IV
1860973|NCT01028716|Procedure|Laboratory Biomarker Analysis|Correlative studies
1860974|NCT01028716|Drug|Mycophenolate Mofetil|Given PO
1860975|NCT01028716|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC
1860976|NCT01028716|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC
1860977|NCT01028716|Drug|Tacrolimus|Given IV or PO
1860978|NCT01028716|Radiation|Total-Body Irradiation|Undergo total-body irradiation (TBI)
1860979|NCT01028729|Drug|Endostar|7.5mg/m2/day, iv, from day 1 to day 14
1860980|NCT01028729|Drug|Gemcitabine-Cisplatin chemotherapy|Gemcitabine 1000 mg/m2, iv, on day 1, 8 Cisplatin 80mg/m2, iv, on day 1, 2, 3
1860981|NCT01028755|Drug|BAY79-4620|BAY79-4620 will be administered as 1 hour IV infusion. Dose escalation will be dependent on any dose limiting toxicities
1860982|NCT01028768|Drug|Teduglutide|10 mg, one-time subcutaneous
1860983|NCT01028781|Drug|Thalidomide|Pill form, 50mgs with increasing dosage up to a maximum of 250 mg qd based on pain reports, taken once daily for 14-16 weeks with one 6 month follow-up appointment.
1860984|NCT01033344|Biological|Placebo|Intradermal injection 1x8 administrations 2 weeks apart
1860985|NCT01033344|Biological|Cat-PAD|Intradermal injection 1x8 administrations 2 weeks apart
1860986|NCT01033344|Biological|Cat-PAD|Intradermal injection, 1x8 administrations 2 weeks apart, alternating active and placebo
1860987|NCT01033357|Device|Graft, Vascular Wrap|Lifespan® ePTFE Vascular Graft and Vascular Wrap Paclitaxel-Eluting Mesh (0.9 µg/mm2 paclitaxel)
1860988|NCT01033357|Device|Lifespan® ePTFE Vascular Graft Only|Vascular Graft only
1860989|NCT01033370|Drug|clevidipine.|Clevidipine administered per IV infusion, starting dose of 2 mg/h (4 mL/hr) for 3 minutes & titrated to the desired BP lowering effect to SBP goal of < 120 mmHg, max infusion rate may not exceed 32 mg/h (64 mL/hr).
1860990|NCT01033383|Dietary Supplement|Placebo|36 milligram (mg) placebo capsule taken before quiet hours of sleep (qhs).
1860991|NCT01033383|Dietary Supplement|Cranberry Capsule|36 milligram (mg) cranberry capsule, taken before quiet hours of sleep (qhs).
1860992|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
1860993|NCT01033396|Drug|Allegra|Fexofenadine single dose 60 mg
1860994|NCT01033396|Drug|PF-03654764|PF-03654764 single dose 5 mg
1860995|NCT01033396|Drug|Allegra-D|Fexofenadine 60 mg combined with pseudoephedrine 120 mg single dose
1860996|NCT01033396|Drug|Placebo|Placebo single dose
1860997|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^7 CFU in 10 mL phosphate-buffered saline
1860998|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^8 CFU in 10 mL phosphate-buffered saline
1860999|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^9 CFU in 10 mL phosphate-buffered saline
1861000|NCT01033409|Biological|Salmonella Typhi-vectored pneumonia vaccine|Liquid, oral dosage administered once at 10^10 CFU in 10 mL phosphate-buffered saline
1861003|NCT01033435|Other|No intervention|
1861004|NCT01033448|Drug|COPEGUS|COPEGUS 800 mg or 1000-1200 mg po for 24 weeks
1861005|NCT01033448|Drug|peginterferon alfa-2a [Pegasys]|PEGASYS 180 micrograms sc once weekly for 24 weeks
1861006|NCT01033461|Dietary Supplement|calcium and probiotic|the subjects consumed for 4 weeks a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 and a bread enriched with 1 g pentacalcium phosphate per day
1861007|NCT01033461|Dietary Supplement|probiotic|the subjects consumed a yoghurt drink enriched with 10e+10 cfu/d L. paracasei LPC 37 for 4 weeks
1861008|NCT01033461|Other|placebo|the subjects consumed a yoghurt drink without L. paracasei LPC 37 and a bread without pentacalcium phosphate
1861009|NCT01033487|Drug|placebo|oral inhaled formulation, single dose
1861010|NCT01033487|Drug|active comparator|oral inhaled formulation, single dose
1861011|NCT01033487|Drug|Low Dose PF-03635659|oral inhaled formulation, single dose, low dose
1861012|NCT01033487|Drug|Mid Dose PF-03635659|oral inhaled formulation, single dose, mid dose
1861013|NCT01033487|Drug|High Dose PF-03635659|oral inhaled formulation, single dose, high dose
1861014|NCT01033500|Drug|Belatacept|Belatacept 10mg/kg on Days 0, 4, 14, 28, 56, and 84 post-transplant, and then 5mg/kg every 4 weeks for the duration of the study.
1861015|NCT01033526|Drug|Aspirin (Acetylsalicylic acid, BAYE4465)|1-2 tablets Acetylsalicylic Acid 400 mg (in combination with Ascorbic Acid 240 mg) as needed every 4-6 hours over a maximum of 5 days
1861016|NCT01033526|Drug|Placebo|1-2 tablets matching Placebo as needed every 4-6 hours over a maximum of 5 days
1861017|NCT01033539|Other|Probiotic strain ATCC PTA 4659|Placebo control containing no probiotic strain of ATCC PTA 4659 High dose of ATCC PTA 4659 1*10 10 CFU/bag Low dose of ATCC PTA 4659 1*10 8 CFU/bag
1861018|NCT01033552|Drug|Cyclophosphamide|Cyclophosphamide 50 mg/kg/day IV over 2 hours x 1 day, total dose 50 mg/kg will be administered on Day -6.
1861019|NCT01033552|Drug|Fludarabine|40 mg/m^2/day intravenously on Days -6, -5, -4, -3 and -2.
1861020|NCT01033552|Drug|Anti-thymocyte globulin|30 mg/kg on Days -4, -3 and -2.
1861021|NCT01033552|Drug|Cyclosporine A|Days -3 to 100+ to maintain a level of >200 ng/ml; initial dose 2.5 mg/kg over 2 hours every 8-12 hours for children.
1861022|NCT01033552|Drug|Mycophenolate mofetil|15 mg/kg intravenous twice per day on days -3 through 30.
1861023|NCT01033552|Procedure|Mesenchymal stem cell transplantation|infused via intravenous drip on Day 0
1861024|NCT01033552|Radiation|Total body irradiation|300 cGY on Day -1 administered in a single fraction at a dose rate of 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
1861025|NCT01033552|Procedure|Bone marrow or umbilical cord blood (UCG) stem cell transplantation|Bone marrow or UCB products will be infused as soon as the product arrives and within 30 minutes. The product is infused via IV drip.
1861026|NCT01033565|Drug|Natrol|5mg of sustained released melatonin. One tablet given 30 minutes prior to bedtime.
1861027|NCT01033578|Other|PVIC, TACE|"PVIC：5-fluorouracil (650 mg/m2 for 24 hours on days 1), doxorubicin (10 mg/m2 for 6 hours on days 2), and cisplatin (20 mg/m2 for 6 hours on days 3) were continuously infused into portal vein through tube by a infusion pump. Treatment started 2 weeks after the operation and was repeated every 4 weeks for 6 cycles.
TACE: 5-fluorouracil (650 mg/m2), doxorubicin (10 mg/m2), cisplatin (20 mg/m2), and lipiodol 5ml were injected into hepatic artery by puncturing the common femoral artery in the right groin and passing a catheter through the abdominal aorta, through the celiac axis and common hepatic artery, into the proper hepatic artery. Treatment started 4 weeks after the operation and was repeated at 6-8 weeks intervals for 3 cycles."
1861028|NCT01033591|Behavioral|Supervised progressive exercise program with an aerobic and a strength component + Optimized treatment|Three month supervised progressive exercise program with an aerobic (high intensity intervals) and a strength component; and the programme will continue linked with community resources for 9 months
1861029|NCT01033591|Behavioral|Optimized treatment according to the European Society of Cardiology guidelines|Optimized treatment according to the European Society of Cardiology guidelines
1861030|NCT01033604|Procedure|Glyaderm and split skin graft|Full thickness defects treated with Glyaderm and split skin graft.
1861031|NCT01033604|Procedure|Split skin graft alone.|Full thickness defects treated with split skin graft alone.
1861128|NCT01034319|Behavioral|Diabetes Genetic Counseling|Subjects will be genotyped based on a 37-allele aggregate score and counseled regarding the implications of the results prior to enrollment in a 12-week diabetes prevention program
1861033|NCT01033630|Drug|D&G 2g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 2g per Day
1861034|NCT01033630|Drug|D&G 1g|Danshen consists of the dried root and rhizome of the perennial herb Salvia miltiorrhiza Bge. Gegen is the dried roots of Pueraria lobata (willd.). The combination in the ratio of 7:3 of the raw herbs. Capsule form, Orally taken 1g per Day
1861035|NCT01033630|Drug|Placebo|Image-matched placebo, made with starch.
1861036|NCT01033643|Drug|MK3614|0.25 mg BID every 12 hours for 10 days
1861037|NCT01033643|Drug|Comparator: MK3614 .75 mg 1st|0.50 mg in the AM, 0.25 mg in the PM 12 hours apart for 10 days
1861038|NCT01033643|Drug|Comparator: MK3614 titrating down dose|Day 1 subjects will receive 0.50 mg three times a day every 8 hours. Days 4-13 subjects will receive 0.50 mg twice a day every 12 hours.
1861039|NCT01033643|Drug|Comparator: MK3614 multiple rising dose|Day 1 subjects will receive 0.50 mg twice a day every 12 hours. Day 2 subjects will receive 3 doses (0.50/0.50/0.25 mg) each 8 hours apart. Days 3-4 subjects will receive 3 doses of 0.50 mgs 8 hours apart. Days 5-14 subjects will receive 0.75 mgs twice a day every 12 hours.
1861040|NCT01033643|Drug|Comparator: Placebo Panel A|Oral Placebo BID every 12 hours for 10 days
1861041|NCT01033643|Drug|Comparator: Placebo Panel B-C|Oral Placebo in the AM, 0.25 mg in the PM 12 hours apart for 10 days
1861042|NCT01033643|Drug|Comparator: Placebo Panel D|Day 1 subjects will receive oral placebo three times a day every 8 hours. Days 4-13 subjects will receive oral placebo twice a day every 12 hours.
1861043|NCT01033643|Drug|Comparator: Placebo Panel E|Day 1 subjects will receive oral placebo twice a day every 12 hours. Day 2 subjects will receive 3 doses of oral placebo each 8 hours apart. Days 3-4 subjects will receive 3 doses of oral placebo 8 hours apart. Days 5-14 subjects will receive oral placebo twice a day every 12 hours.
1861044|NCT01033656|Drug|anakinra|100 mg subcutaneous injection daily
1861045|NCT01033656|Drug|comparators|po drugs, comparators
1861046|NCT01033669|Device|CRC-749|There is no drug being used. This is a device.
1861047|NCT01033669|Device|Diskus|There is no drug being used. This is a device.
1861048|NCT01033669|Device|Twisthaler|There is no drug being used. This is a device.
1861049|NCT01033669|Device|Miat Monohaler|There is no drug being used. This is a device.
1959850|NCT03312426|Drug|BMS-986205|Single dose, 100 mg administered at Day 1 and at Day 15.
1861051|NCT01033721|Drug|Palomid 529|comparison of different dosages of drug
1861052|NCT01033734|Drug|oseltamivir [Tamiflu]|5-day course (10 doses), intravenous administration, may be switched to oral administration at the discretion of the investigator; up to 5 additional days of treatment possible.
1861053|NCT01033747|Drug|Deferasirox|10 mg/kg or 30 mg/kg orally daily
1861054|NCT01033747|Drug|Deferasirox|5 mg/kg or 30 mg/kg orally daily
1861055|NCT01033760|Drug|raltegravir; maraviroc; darunavir; ritonavir; tenofovir/emtricitabine|raltegravir (Isentress®): 400 mg bid. maraviroc (Celsentri®): 150 mg bid. darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
1861056|NCT01033760|Drug|darunavir; ritonavir; emtricitabine/tenofovir|darunavir (Prezista®): 800 mg QD. ritonavir tablet (Norvir®): 100 mg QD. tenofovir/emtricitabine (Truvada®): one 245/200 mg tablet QD.
1861057|NCT01033773|Drug|Antihyperglycemic medication guideline for management of uncontrolled hyperglycemia presenting to the ED using metformin, sulfonylurea and/or insulin|Diabetes medications (including sulfonylureas, metformin and/or insulin) were initiated and/or adjusted at each visit using the intervention algorithm per presenting blood glucose and prior diabetes medications.
1861058|NCT01033773|Behavioral|Diabetes survival skills self-management education|Survival skills DSME based upon current JCAHO and ADA joint recommendations for persons with diabetes prior to discharge to the outpatient setting was initiated in the ED and continued at the follow-up encounters.
1861059|NCT01033799|Other|Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
1861060|NCT01033799|Other|Non fermented dairy product (control)|
1861061|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 320 mcg|Ciclesonide HFA Nasal Aerosol 320 μg once daily
1861062|NCT01033825|Drug|Ciclesonide HFA Nasal Aerosol 160 mcg|Ciclesonide HFA Nasal Aerosol 160 μg once daily
1861063|NCT01033825|Drug|HFA Nasal Aerosol placebo|HFA Nasal Aerosol placebo once daily
1861064|NCT01033825|Drug|Ciclesonide Aqueous Nasal Spray 200 mcg|Ciclesonide Aqueous Nasal Spray 200 mcg once daily
1861065|NCT01033825|Drug|AQ Nasal Spray Placebo|AQ Nasal Spray Placebo once daily
1861066|NCT01033825|Drug|Placebo plus Dexamethasone HFA|Dexamethasone capsules 6 mg once daily
1861067|NCT01033825|Drug|Placebo AQ plus Dexamethasone 6 mg|Placebo AQ plus Dexamethasone 6 mcg capsules once daily
1861068|NCT01033838|Procedure|rectosigmoid resection|
1861069|NCT01033851|Behavioral|Mindfulness Based Stress Reduction|8 week course
1861070|NCT01033851|Behavioral|Stress Management Education|8 week course
1861071|NCT01033864|Drug|MMF|1 g per day b.i.d. p.o. for at least 1 month
1861072|NCT01033864|Drug|EC-MPS|720 mg b.i.d. p.o. for at least 1 month
1861073|NCT01033864|Drug|Prednisone|5 mg per day p.o.
1861074|NCT01033877|Biological|TdaP vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d), 20 microgram pertussis toxoid (aP)
1861075|NCT01033877|Biological|Td vaccine SSI|1 vaccine dose of 0.5 mL suspension for injection in a pre-filled syringe: >= 20 I.U. tetanus toxoid (T), >=2 I.U. diphtheria toxoid (d)
1861076|NCT01033903|Drug|misoprostol|800 micrograms intravaginally ONCE
1861077|NCT01033916|Other|LIBERAL|The LIBERAL arm of the study will have a target Blood Glucose level ranging from 121-180 mg/dL. As opposed to the standard of less than 120 mg/dL.
1959851|NCT03312413|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.2 μg·kg-1·h-will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
1959852|NCT03312413|Drug|Normal Saline|Normal saline 0.5 mL·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
1861078|NCT01033929|Biological|rdESAT-6 + rCFP-10 (C-Tb)|rdESAT-6 + rCFP-10 (C-Tb) skin test +/- phenol administered intradermally by the mantoux injection technique. Each patient receives the unpreserved version in one arm and the preserved version in the other arm in double blind manner.
1861079|NCT01033942|Drug|coformulated emtricitabine (FTC) and tenofovir disoproxil fumarate (TDF) as PrEP|Subjects receive PrEP and receive clinical follow-up visits every four weeks for 24 weeks.
1861080|NCT01033942|Drug|Placebo|Subjects receive placebo and receive clinical follow-up visits every four weeks for 24 weeks.
1861081|NCT01033942|Behavioral|Many Men, Many Voices (3MV)|Behavioral HIV-prevention intervention. Behavioral and biomedical data will be collected at baseline and every 4 weeks thereafter for 24 weeks.
1861082|NCT01033955|Drug|Rosuvastatin|Loading dose: 40 mg (day 1) Maintenance dose: 20 mg (days 2-14)
1861083|NCT01033955|Drug|Placebo|identical appearing encapsulated placebo.
1861084|NCT01033968|Procedure|retina photocoagulation|Each patient had one eye treated with infrared laser (diode, 810nm wavelength) and the other eye treated with green laser (frequency-doubled solid state laser, diode-pumped, with 532-nm wavelength
1861085|NCT01033981|Drug|Sunitinib|Treatment for mRCC as indication approved and physician criterium
1861086|NCT01033994|Biological|AS902330|10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
1861087|NCT01034007|Device|Tissue Engineered Vascular Grafts|Patients will undergo EC TCPC interposition grafting with a tissue engineered vascular graft and serial magnetic resonance angiography (MRA)
1861088|NCT01034020|Drug|Nicotine|
1861089|NCT01034046|Other|Low Carbohydrate Diet|Low carbohydrate diet (45% carbohydrate, 35% fat and 20% protein diet) administered utilizing meal replacements.
1861090|NCT01034046|Other|Low Fat Diet|Low fat diet (60% carbohydrate, 20% fat and 20% protein diet) administered utilizing meal replacements.
1861091|NCT01034111|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet by mouth once daily for 4 weeks.
1861092|NCT01034111|Drug|Metformin|Stable dose of metformin tablet(s) by mouth (at least 1000 mg/day) for 4 weeks.
1861093|NCT01034124|Drug|warfarin, vitamin K, midazolam|warfarin tablet single dose (10 mg) vitamin K tablet single dose (10 mg) midazolam syrup single dose (5 mg)
1861094|NCT01034137|Drug|methotrexate|orally weekly in ascending dosages, starting at 10mg/week
1861095|NCT01034137|Drug|placebo MTX|orally weekly
1861096|NCT01034137|Drug|placebo TCZ|iv every 4 weeks
1861097|NCT01034137|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg iv every 4 weeks
1861098|NCT01034150|Device|Relief band (Somatosensory stimulation)|Electrical median nerve stimulation
1861099|NCT01034150|Device|Placebo stimulation|Placebo stimulation
1861100|NCT01034163|Drug|Panobinostat|
1861101|NCT01034163|Drug|Placebo|Placebo
1861102|NCT01034176|Drug|levofloxacin|500 mg tablet, daily, 30 days
1861103|NCT01034176|Drug|placebo|no dose, tablet, daily, 30 days
1861104|NCT01034189|Drug|Cetuximab|Cetuximab: loading dose 400 mg/m2, 2h- IVF, 3~ 5 days prior to starting CCRT (on week-1); followed by 250 mg/m2/ week, 1h- IVF, for 4 weeks (i.e., week 1 to week 4. during CCRT).
1861105|NCT01034189|Drug|Paclitaxel|T: Paclitaxel 35 mg/m2, 1h IVF, on day 1 and day 4 of each week, week1 to week4 during CCRT.
1861106|NCT01034189|Drug|Cisplatin|P: Cisplatin 15 mg/m2, 1 h IVF, on day 2 and day 5 of each week, week1 to week4 during CCRT.
1861107|NCT01034189|Radiation|Radiotherapy|Radiotherapy: (three-dimensional conformal radiotherapy or intensity modulated radiotherapy) 200 cGy/fraction, once daily, 5 days a week, to a total dose of 4000 cGy.
1861108|NCT01034202|Drug|NNC126-0083|One of five dose levels administered subcutaneously (under the skin)
1861109|NCT01034202|Drug|Norditropin® SimpleXx®|One of two dose levels, followed by NNC126-0083, administered subcutaneously (under the skin)
1861110|NCT01034202|Drug|placebo|Placebo comparator
1861111|NCT01034202|Drug|NNC126-0083|One of three dose levels administered subcutaneously (under the skin)
1861112|NCT01034202|Drug|Norditropin® SimpleXx®|One of two dose levels, followed by placebo, administered subcutaneously (under the skin)
1861113|NCT01034215|Behavioral|Envision the Rhythms of Life Program|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered with trainer present in the room.
1861114|NCT01034215|Behavioral|Envision the Rhythms of Life Program/Distance|Patients learn to practice passive, active and targeted imagery for the purpose of improving mood state, modifying physiology (HRV, Body temperature, pain reduction) and also to mitigate the effects of their treatments, as defined by the IOM: chemo brain, fatigue, sleep deprivation, stress, anxiety, depression, and/or PTSD. Program is delivered by videoconference equipment
1861115|NCT01034228|Other|ORS + Isoleucine|ORS with Isolelucine for treatment of diarrhoeal in children
1861116|NCT01034228|Other|ORS without Isoleucine|ORS without Isoleucine for the treatment of diarrhoea in children
1861117|NCT01034241|Dietary Supplement|Control|Diet consists of 15 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
1861118|NCT01034241|Dietary Supplement|High dairy protein|Diet consists of 25 En% dairy protein and low GI, 55 En% carbohydrates and 30 En% fat
1861119|NCT01034241|Dietary Supplement|vegetable protein|Diet consists of 15 En% vegetable protein and low GI, 55 En% carbohydrates and 30 En% fat
1861120|NCT01034241|Dietary Supplement|High GI|Diet consists of 15 En% dairy protein and high GI, 55 En% carbohydrates and 30 En% fat
1861121|NCT01034254|Biological|influenza vaccine|Pregnant women will receive FDA approved influenza vaccine.
1861122|NCT01034254|Biological|saline placebo|Vaccination of pregnant women with saline placebo.
1861123|NCT01034267|Drug|F2695 SR|Drug F2695 SR (flexible dose) to be given orally in capsule form once daily
1861124|NCT01034293|Dietary Supplement|low feeding frequency (3x)|3 meals a day
1861125|NCT01034293|Dietary Supplement|High feeding frequency (14x)|14 meals a day
1861126|NCT01034306|Drug|CF101|orally q12h
1861127|NCT01034306|Drug|Placebo control|orally q12 hours
1861129|NCT01034319|Behavioral|No genetic counseling|These subjects will not be genotyped or counseled prior to enrollment in a 12-week diabetes prevention program
1861130|NCT01034332|Procedure|TP-HDFL,TP-CCRT, Esophagectomy|To determine whether clinical response to one cycle of induction chemotherapy (TP-HDFL) could predict the pathologic complete response to preoperative chemoradiotherapy (TP-CCRT) in patients with locally advanced esophageal cancer.
1861131|NCT01034345|Drug|Sirolimus|Switch from calcineurin inhibitor maintenance immunosuppression to sirolimus treatment at the doses needed to reach trough blood levels 8-15 ng/mL.
1861132|NCT01034345|Drug|Calcineurin inhibitor|Patients will maintain the same immunosuppressive regimen based on calcineurin inhibitors. No modifications in the treatment will be conducted.
1861133|NCT01034358|Biological|Human Papillomavirus Vaccine|0.5mL intramuscular for 3 doses at 0, 2, and 6 months
1861134|NCT01034371|Procedure|Minimally invasive direct coronary artery bypass|MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
1861135|NCT01034371|Procedure|PCI-Drug eluting stents|"PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.
Device: Polymer-based Sirolimus-Eluting Stents (SES)."
1861136|NCT01034371|Procedure|Off-pump coronary artery bypass|Procedure: coronary artery bypass without cardiopulmonary Coronary artery bypass surgery with no associated or concomitant surgical procedures, using full median sternotomy, without cardiopulmonary bypass (CPB) and cardioplegia.
1861137|NCT01034397|Drug|tocilizumab [RoActemra/Actemra]|8mg/kg (minimal dose 480mg, maximum dose 800mg) iv infusion every 4 weeks for 24 weeks
1861138|NCT01034397|Drug|placebo|iv every 4 weeks for 24 weeks
1861139|NCT01034397|Drug|non-biological DMARDs|stable dose at investigator's prescription
1861140|NCT01034410|Drug|AS1411|AS1411 40mg/kg/day or AS1411 80mg/kg/day
1861141|NCT01034410|Drug|Cytarabine|Cytarabine 2g/m2 bid Days 4-7
1861142|NCT01034423|Dietary Supplement|Omega-3|Capsules with omega-3 fatty acids.
1861143|NCT01034423|Dietary Supplement|sun flower oil|Capsules with sun flower oil.
1861144|NCT01034436|Dietary Supplement|fatty acid quality and overweight|Duration 12 weeks
1861145|NCT01034449|Other|allogeneic transplant|ex vivo amplification of a unit of placental blood for transplantation
1861146|NCT01034462|Drug|Levomilnacipran ER|Levomilnacipran ER capsules, flexible dose, oral administration, once daily dosing. Study drug is to be given orally, in capsule form, once daily, for 8 weeks
1861147|NCT01034462|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily, for 8 weeks.
1861148|NCT01034475|Drug|CPI-613|"This is a Phase I open label trial using a 2-stage dose-escalation scheme (single-patient & traditional stages):
Single-Patient Dose-Escalation Stage: In the single-patient stage, a single patient will be accrued per dose level. The starting dose will be 420 mg/m². Dose level will be escalated (by doubling the previous dose) if there is no toxicity or if the toxicity is grade 1 or less. If toxicity is >Grade 1, the traditional dose-escalation stage will be triggered.
Traditional Dose-Escalation: All dose escalations conducted in this Traditional Dose-Escalation stage will be escalated according to the modified Fibonacci Dose-Escalation scheme."
1861149|NCT01034488|Biological|Suine|5000UI /mL
1861150|NCT01034488|Biological|Suine|5000UI/mL
1861151|NCT01034501|Device|sham procedure|non activated laser tip
1861152|NCT01034501|Device|photodynamic therapy|photodynamic therapy 660 nm,40 mW,60 Hz
1861153|NCT01034514|Device|Real-time Position Management system|Standard of Care
1861154|NCT01034514|Device|Discovery ST multislice PET/CT scanner|Standard of Care
1861155|NCT01034514|Device|Infinia Hawkeye SPECT/CT gamma camera|Standard of Care
1861156|NCT01034514|Device|Pinnacle3 treatment planning system|Standard of Care
1861157|NCT01034514|Device|SKYLight nuclear camera|Standard of Care
1861158|NCT01034514|Drug|DTPA|1 mCi; inhalation
1861159|NCT01034514|Drug|TECHNETIUM TC 99M MAA|3 mCi; iv
1959853|NCT03312413|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.5 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
1959854|NCT03312413|Drug|Dexmedetomidine Hydrochloride|Dexmedetomidine Hydrochloride 0.7 μg·kg-1·h-1 will be administered to participants by intravenous infusion from incision to 20-30 minutes before the end of surgery
1861162|NCT01034540|Drug|POM3|4 g/day
1861163|NCT01034540|Drug|Placebo|matching placebo capsule, 4 g/day
1861164|NCT01034553|Drug|Aurora A kinase inhibitor MLN8237|Given orally
1861165|NCT01034553|Drug|bortezomib|Given IV
1861166|NCT01034566|Radiation|Proton Beam Radiation Therapy|
1861167|NCT01034579|Other|Blood sampling|Subjects who had received Rebif® 44 microgram (mcg) three times a week for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
1861168|NCT01034579|Other|Blood sampling|Subjects who had received Copaxone® (Glatiramer Acetate) 20 milligram once daily for 96 weeks in study 24735 (NCT00078338) and not participated in the initial PGx sub-study will be enrolled in this retrospective cohort study wherein single blood sampling will be performed for pharmacogenetic markers analysis.
1861169|NCT01034592|Drug|Lenalidomide|2.5 mg/wk up to 5 mg 3x/wk
1861170|NCT01034605|Dietary Supplement|PinnoThin|6.0 gram of the oil extract from the korean pine nut (PinnoThin) as a single dose
1861171|NCT01034618|Dietary Supplement|Protein hydrolyzation|
1861172|NCT01034631|Drug|Everolimus|Everolimus 10 mg. Taken orally, every evening, 1 hr before or 2 hrs after meals
1861173|NCT01034631|Drug|BNC105P|BNC105P, up to 16 mg/m^2
1861174|NCT01034657|Drug|LBH589|LBH589 was supplied at dose strengths of 5 mg or 20 mg hard gelatin capsules.
1861175|NCT01034657|Drug|Epoetin Alfa|Epoetin alfa was supplied as 10000 IU/1 mL in a ready-to-use syringe.
1861176|NCT01034670|Device|Dual axis endoscopic microscope|This is a device that is used in the accessory port of a standard endoscope and allows visualization of microscopic areas of mucosa.
1861177|NCT01034670|Device|wide field fluorescence system|This is a modification to the existing narrow band endoscope from Olympus that incorporates different filters on the source and collecting optics to enable fluorescence imaging. It is used as is a standard endoscope.
1861178|NCT01034670|Device|CellVizio|Minimicroscope--this is an FDA approved fiber-based microscope that we will use according to the manufacturers protocols.
1861179|NCT01034670|Drug|fluorescent Peptide|microdosing; Topical through the endoscope
1861180|NCT01034670|Drug|fluorescein|100 mcg topical
1861181|NCT01034670|Drug|indocyanine green|100 mcg topical
1861182|NCT01034683|Drug|lobaplatin , 5-FU ,leucovorin|Participants received 2-hour lobaplatin (30 mg/m2 on day 1) and a 2-hour infusion of leucovorin (LV; 200 mg/m2 on days 1-5) followed by a 4-hour infusion of 5-FU (650 mg/m2 on days 1-5). Treatment was repeated every 21 days.
1861183|NCT01034735|Biological|r-hGH liquid (Saizen)|Treatment Arm A: r-hGH liquid multidose formulation 5.83 mg/mL, needle injection (0.686 mL)
1861184|NCT01034735|Biological|r-hGH liquid (Saizen)|Treatment Arm B: r-hGH liquid multidose formulation 8.0 mg/mL, needle injection (0.5 mL)
1861185|NCT01034735|Biological|r-hGH freeze-dried|Treatment Arm C: r-hGH 8 mg (8.8 mg/1.51 ml) freeze-dried formulation ( reconstituted in metacresol 0.3% w/v) needle injection (0.686 mL)
1861186|NCT01034748|Drug|[14C]PF00299804|Single 45 mg oral dose of radiolabelled PF-00299804
1861187|NCT01034761|Behavioral|Pop-up alert|Pop-up alert in the electronic medical record whenever the provider enters an order for a specified high risk medication from the Beers list.
1861188|NCT01034774|Drug|ACHN-490 Injection|ACHN-490 Injection at 15mg/kg is given either 1 or 5 consecutive days. Cohort 1 receives 5 consecutive days of treatment and Cohort 2 receives a single dose of treatment.
1861189|NCT01034774|Drug|Placebo (normal saline)|Placebo is given at the same volume as ACHN-490 Injection to maintain the blind.
1861191|NCT01034852|Procedure|Totally Thoracoscopic Maze|Epicardial pulmonary vein isolation with additional lesions as determined to be necessary by physician
1861192|NCT01034878|Drug|Sunitinib|Sunitinib will be administered orally at a dose of 50 mg once daily, in six weeks cycles consisting of 4 weeks of treatment followed by 2 weeks without treatment.
1861193|NCT01034917|Drug|Etravirine 400 mg dissolved in water every 24 hours|Switch from the PI to Etravirine 400 mg dissolved in water every 24 hours
1861194|NCT01034917|Drug|Continue with the same antiretroviral regimen|Continue with the same antiretroviral regimen
1861195|NCT01034930|Procedure|Insertion of dental implants|Each patient will receive 2 screw-type Straumann (Institut Straumann AG, Basel, Switzerland) standard implants Ø4.1 mm, with SLA surface in the canine region of the mandible with an interconnecting line approaching parallelism with the terminal mandibular hinge axis, according to a standard surgical protocol.
1861196|NCT01034943|Procedure|External fixation|Operation with external fixation and optional addition of k-wire
1861197|NCT01034943|Procedure|Volar plate|Operation with a Synthes volar two column plate (TCP)
1861198|NCT01034956|Device|hyaluronic acid or calcium hydroxylapatite filler|Intradermal and subdermal injection of facial soft tissue filler within the past 24 months; survey of patients to assess satisfaction and determine the presence of treatment related adverse events.
1861199|NCT01034982|Drug|AZD9668|20 mg
1861200|NCT01034982|Drug|AZD9668|60 mg
1861201|NCT01034995|Drug|SSR125543|"Pharmaceutical form: capsule
Route of administration: oral"
1861202|NCT01034995|Drug|escitalopram|"Pharmaceutical form: encapsulated tablets
Route of administration: oral"
1861203|NCT01034995|Drug|placebo|"Pharmaceutical form: capsule
Route of administration: oral"
1861204|NCT01035008|Procedure|Endoscopic Ultrasound (EUS)|The investigators will do the standard EUS procedure. If a cyst is seen in the pancreas during EUS, the investigators will administer a special dye called fluorescein through the IV, and then use the new fiber-shaped microscope to take pictures of the lining of the cysts.
1861206|NCT01035034|Procedure|Hybrid MIDCAB/PCI|"MIDCAB with no associated or concomitant surgical procedures, using partial ministernotomy, without cardiopulmonary bypass (CPB) and cardioplegia. PCI with drug eluting stents (DES) performed by cardiologists on the non-LAD lesions in the same operating suite immediately following MIDCAB.
Device: Polymer-based Sirolimus-Eluting Stents (SES)."
1861207|NCT01035034|Procedure|PCI with DES|Polymer-based Sirolimus-Eluting Stents (SES)
1861208|NCT01035047|Other|Clinical decision unit care, coupled with cardiac MRI|After ED evaluation, patients are randomized to clinical decision unit care or inpatient care. Patients in the clinical decision unit will also undergo a stress cardiac MRI. Patients in the inpatient care arm may undergo any desired testing, including cardiac MRI, as determined by their treating physician.
1861209|NCT01035073|Drug|Duloxetine|30-60 mg daily for 8 weeks
1861210|NCT01035086|Dietary Supplement|fabricated food|The subjects consumed a high-fibre diet containing 25 g fibre (citrus- or lupin fibre) per day and a low-fibre diet (placebo) for four weeks each. After a one-week run-in period, each volunteer had to pass all three periods (arms) in different order with a two-week wash-out period between each.
1861211|NCT01035099|Drug|Letrozole|"Letrozole titrated regimen may be started on day 2 of menstrual cycle:
Serum Estradiol level <150 pg/ml- No Letrozole; Serum Estradiol Level 150-250 pg/ml- 2.5mg; Serum Estradiol Level 251-350 pg/ml- 5 mg; Serum Estradiol Level >350 pg/ml - 7.5 mg;"
1861212|NCT01035099|Drug|Letrozole|Fixed dose of 5 mg per day Letrozole will be started on the second day of their menstrual cycle
1861213|NCT01035112|Procedure|MRI|
1861214|NCT01035125|Behavioral|Self-management program|Participants will receive a one week inpatient self-management program
1861373|NCT01025778|Drug|Melfalan in conditioning before transplantation|
1861215|NCT01035138|Drug|semagacestat|140mg administered orally, once daily for 24 months; dose reduction to 100mg or 60 mg possible due to intolerability
1861216|NCT01035151|Behavioral|Sister to Sister|Neighborhood level interventions, peer group (counseling, NRT), and individual level (Coach/CHW)
1861217|NCT01035151|Behavioral|Control|Written Cessation Materials
1861218|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
1861219|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY85-8101 on day one of the treatment period, PET
1861220|NCT01035164|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 185 MBq BAY85-8101, whole body PET for evaluation of effective dose, kinetics of BAY85-8101 in blood
1861221|NCT01035190|Drug|Budesonide|Inhalation, 200 µg/puff
1861222|NCT01035203|Behavioral|Exercise|Endurance exercise 3 times weekly for 45 minutes, 4 weeks long
1861223|NCT01035203|Behavioral|Cognitive behavioural therapy|Teaching of techniques to reduce fatigue and to improve stamina
1861224|NCT01035216|Drug|GNKG168|GNKG168 will be administered as a 60 minute IV infusion once daily for 5 days followed by a 9 day rest period.
1861225|NCT01035229|Drug|Everolimus|Everolimus (labeled as RAD001) was formulated as tablets of 2.5 mg strength and blisterpacked in units of 10 tablets.
1861226|NCT01035229|Drug|Everolimus Placebo|Everolimus Placebo matched to the everolimus 2.5 mg tablet strength was blister-packed in units of 10 tablets. Matching placebo tablets were formulated to be indistinguishable from the everolimus tablets. Everolimus placebo was taken as a daily oral dose of 7.5 mg and was defined as the control drug.
1861227|NCT01035229|Other|Best Supportive Care (BSC)|BSC was defined as drug or non-drug therapies, nutritional support, physical therapy or anything that the Investigator believed to be in the patient's best interest, but excluding other antineoplastic treatments. BSC administered to the patient throughout the study was to be reported on the Concomitant Medication/Significant Non-Drug Therapy electronic case report from (eCRF). Permitted BSC treatments during the study included, but were not limited to, the following: Pain medication to allow the patient to be as comfortable as possible, Bisphosphonates for bone metastases, Localized radiotherapy, for the treatment of pre-existing, painful bone metastases, Nutritional support or appetite stimulants (i.e. megestrol) as recommended by the Investigator, Oxygen therapy and blood products or transfusions
1861228|NCT01035242|Behavioral|"association splitting"|"Association splitting is a cognitive intervention which aims at reducing obsessive thoughts. Association splitting is based on the so called fan effect (Anderson, 1974) and aims at reducing the strength of obsessive cognitions. For this purpose core intrusive thoughts are identified with the patient (such as cancer - illness) and the patient is encouraged to find non-OCD associations that are (semantically or phonologically) related to the OCD cognition (such as cancer - (zodiac) sign, cancer - great crab). To strengthen the novel connections, these associations are elaborated by the use of pictures, music, or smells. By enhancing OC-unrelated associations it is assumed that the influence of OC-related concepts is weakened."
1861229|NCT01035242|Behavioral|cognitive remediation|Computerized cognitive remediation (CogPack training). A fixed sequence is administered, which covers a wide range of neuropsychological exercises involving memory, reasoning, selective attention and psychomotor speed. The difficulty level for each patient is adapted automatically depending on to the subject's performance on prior exercises. At the end of each session, the patient receives individual feedback on his or her performance. To match with association splitting, six sessions are administered. Each session lasts approximately 45-60 minutes.
1861230|NCT01035255|Drug|LCZ696 200 mg BID|LCZ696 200 mg BID
1861231|NCT01035255|Drug|Enalapril 10 mg BID|Enalapril 10 mg BID
1861232|NCT01035268|Procedure|fatty tissue transfer|It will be proceeded to aspiration of the fat at the level of the natural steatomeries (hip, stomach), then in a transfer of the fat prepared in the breast by following the standardized protocol.
1861233|NCT01035281|Drug|Nabilone, flexible dosing|nabilone at 0.5 - 4 mg/day
1861234|NCT01035294|Behavioral|mindfulness based intervention (MBI)|Eight, phone delivered, individual mindfulness sessions. Each training session will last 30 minutes (20 minutes for intervention + an additional 10 minutes for questions, answers, and for scheduling the next intervention. Patients will also receive instructions to practice at home every day, at least once a day, for at least 15 minutes. An audio CD containing guided mindfulness exercises will be given to the patient at the beginning of the study, to guide them during their home practice. The CD consists of sequences of different mindfulness techniques, consistent with the techniques learned during each session with the instructor. Each patient will record the minutes of mindfulness practice in a diary to be kept daily.
1861235|NCT01035294|Behavioral|usual care|The UC group will be offered the standard care planned by the hospital, which includes the routine care provided by the electrophysiology team and other health care professionals that the patient may see over the course of the ICD experience. All patients receive a number of printed education materials and participate to support meetings for ICD patients four times a year. Being part of the standard care offered at UMass Memorial Medical Center, these meetings are offered to all patients regardless of their assignment (thus including patients assigned to the MBI arm).
1861236|NCT01035307|Genetic|gene expression analysis|
1861237|NCT01035307|Genetic|microarray analysis|
1861238|NCT01035307|Genetic|proteomic profiling|
1861239|NCT01035307|Other|laboratory biomarker analysis|
1861240|NCT01035320|Drug|Ezetimibe|After a placebo only run-in period patients (two groups) are treated with simvastatin + ezetimibe and simvastatin + placebo in a cross-over trial. Ezetimibe effects on top of simvastatin will be evaluated as the primary aim; simvastatin effects compared to run-in on placebo will be evaluated as a secondary aim.
1861241|NCT01035333|Drug|Orlistat|60mg capsule three times a day for up to 6 months
1861242|NCT01035346|Drug|Ibuprofen|Single dose of a novel ibuprofen formulation (equal to 400mg ibuprofen)
1861243|NCT01035346|Drug|Placebo|Single dose of a placebo
1861244|NCT01035359|Procedure|External fixation|Bridging external fixation of a distal radius fracture with an optional addition of k-wire(s)
1861245|NCT01035359|Procedure|Volar plate|Operation of distal radius fracture with open reduction and fixation with a plate from the volar side of the wrist.
1861477|NCT01038102|Other|SFA diet|Diet high in saturated fat (15E%)
1861247|NCT01035385|Drug|FOFLOX4|FOLFOX4:Oxaliplatin 85mg/m2 ivgtt d1 2hr calcium leucovorin:200mg/m2 ivgtt d1 d2 2hr fluorouracil:400mg/m2 iv d1 d2 fluorouracil:600mg/m2 civ d1 d2 22hr 2 weeks repeated one cycles
1861248|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLE494
1861249|NCT01035411|Drug|AZD9668|2 x 30 mg batch DLF497
1861250|NCT01035411|Drug|AZD9668|2 x 30 mg tablet variant 1
1861251|NCT01035437|Drug|HPPH 2-1[1-hexyloxyethyl]-2-devinyl Pyropheophorbide-a)|HPPH in D5W, 4.0 mg/m2 infused over 1 hour
1861252|NCT01035450|Device|Everolimus-eluting stent|Everolimus-eluting stent
1861253|NCT01035450|Device|Sirolimus-eluting stent|Sirolimus-eluting stent
1861254|NCT01035463|Drug|lenalidomide|Given PO
1861255|NCT01035463|Biological|rituximab|Given IV
1861256|NCT01035463|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous hematopoietic stem cell transplant
1861257|NCT01035463|Drug|carmustine|Given IV
1861258|NCT01035463|Drug|etoposide|Given IV
1861259|NCT01035463|Drug|cytarabine|Given IV
1861260|NCT01035463|Drug|melphalan|Given IV
1861261|NCT01035476|Behavioral|Data Card Report|Patients received detailed report of acceptance and adherence base don data card information, with linked recommendations, to optimize use.
1861262|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
1861263|NCT01035489|Device|CRT in heart failure; Right ventricular apex v.s. high posterior septum|RV lead is randomized to either apex or high posterior septum
1861264|NCT01035502|Drug|Elacytarabine plus idarubicin|"Elacytarabine 1000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
Idarubicin will be administered IV at a fixed dose of 12 mg/ m2/d IV on d 1-3 q3w.
It is intended that patients receive remission-induction treatment either as two combination courses, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d or one combination course, elacytarabine 1000 mg/m2/d + idarubicin 12 mg/m2/d followed by one course elacytarabine 2000 mg/m2/d single therapy."
1861265|NCT01035515|Drug|Placebo|Single dose oral capsule placebo comparator
1861266|NCT01035515|Drug|BIIB014 50mg|Single dose oral capsule 50mg BIIB014
1861267|NCT01035515|Drug|BIIB014 100mg|Single dose oral capsule 100mg BIIB014
1861268|NCT01035528|Drug|insulin glargine|antidiabetic treatment with insulin glargine sc o.d. titrated to the target fasting glucose type 2 diabetes ≤110 mg/dl
1861269|NCT01035528|Drug|metformin|use of oral metformin o.d or b.d titrated up to 2000 mg daily for to the target fasting glucose ≤110 mg/dl
1861270|NCT01035541|Device|PiCCO® Monitoring|Fluid and vasopressor management according to PiCCO measruements
1861271|NCT01035554|Other|Self-Paced Programmed Instruction (SPPI)|If participants are assigned to SPPI, they will be asked to complete a series of educational modules at their own pace on the laptop that is provided. They will be informed that there is no grading and that the program is set up so that they can go at their own pace. The SPPI modules will be designed directly from the information provided on the Printed Materials (PM) from the National Institutes of Health.
1861272|NCT01035554|Other|Home Blood Pressure Monitor|The home blood pressure monitor will allow the participant to measure their blood pressure anytime and anywhere precisely, quickly and easily on their upper arm.
1861273|NCT01035554|Other|Usual Care|Standard care
1861274|NCT01035554|Other|Printed Materials|National Institutes of Health Printed Materials on hypertension
1861275|NCT01035567|Procedure|Hybrid revascularization|First stage: implantation of the internal mammary artery into LAD in MIDCAB/TECAB procedure Second stage: PCI with drug eluting stents in other coronary arteries qualified for revascularization within 36 hours after surgery
1861276|NCT01035567|Procedure|Coronary Artery Bypass Grafting|Coronary artery bypass grafting with sternotomy on or off the pump at discretion of the operator.
1861277|NCT01035580|Drug|Curcumin|Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg
1861278|NCT01035580|Drug|curcumin|all patients received the drug
1861279|NCT01035593|Procedure|plasmapheresis and IVIG|Plasmapheresis with either 5% human albumin or FFP replacement, plus IVIG 100mg/kg IV after each PP session, every other day x 5 treatments
1861280|NCT01035593|Drug|recombinant C1 inhibitor|100units/kg IV for seven consecutive days (once daily on PP/IVIG days, twice daily on non-PP/IVIG days).
1959858|NCT03312374|Genetic|ctDNA|to elucidate the correlation between the postoperative ctDNA status and the prognosis of patients with early and intermediate-stage colorectal cancer
1959860|NCT03312348|Device|Infrared imaging|Infrared image image acquisition of study participants
1861284|NCT01035619|Drug|moxidectin|Single Dose Moxidectin 4 mg
1861285|NCT01035645|Drug|GSK1070806|"The study drug, GSK1070806, is a humanised monoclonal antibody. Antibodies are proteins that are made by white blood cells during an immune reaction. They circulate in the blood and attach to foreign proteins called antigens in order to destroy or neutralise them.
Humanised monoclonal antibodies are a type of protein that is genetically engineered to resemble a human protein (humanised). GSK1070806 is designed to block a specific protein that exists in the body called Interleukin-18. Interleukin-18 works within the immune system, i.e. the body's defence system, which helps protect it from disease, bacteria and viruses. Interleukin-18 activates the immune system to fight infections and may also occasionally cause inflammation."
1861286|NCT01035658|Drug|Pazopanib|All patients will begin treatment with a 7-day run in period of single-agent pazopanib. Patients will receive pazopanib orally days 1-28 of a 28 day cycle.
1861287|NCT01035658|Drug|Doxil|Liposomal doxorubicin (Doxil) will be administered IV on day 1 of a 28-day treatment cycle
1861288|NCT01035671|Drug|alpha-tocopherolquinone (A0001)|28 days of low dose (1.0 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
1861289|NCT01035671|Drug|alpha-tocopherolquinone (A0001)|28 days of high dose (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
1861290|NCT01035671|Drug|placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
1861291|NCT01035749|Biological|GSK Biologicals' Influenza investigational vaccine GSK2340274A|One or two doses administered intramuscularly
1861574|NCT01038804|Drug|Docetaxel|intravenous infusion
1861292|NCT01035749|Biological|GSK Biologicals' Influenza investigational vaccine GSK2340273A|Two doses intramuscularly
1861293|NCT01035749|Biological|Placebo (saline)|One dose intramuscularly
1861294|NCT01035775|Procedure|Inspection during insertion|The colonic mucosa will be inspected for lesions during insertion of the instrument, and during withdrawal of the instrument.
1861295|NCT01035775|Procedure|Inspection during withdrawal|The colonic mucosa will be inspected for lesions only during withdrawal of the instrument from the cecum. The instrument will be inserted to the cecum without deliberate inspection.
1861296|NCT01035788|Behavioral|Mindfulness Based Cognitive Behavioral Conjoint Therapy|This intervention combines Cognitive Behavioral Conjoint Therapy for PTSD and mindfulness skills. Cognitive Behavioral Conjoint Therapy for PTSD includes PTSD psychoeducation, communication skills training and cognitive restructuring. Mindfulness involves teaching individuals skills that improve their ability to attend to their experience in the present moment while suspending judgment and to purposefully shift their attention. Thus mindfulness enhances the ability to monitor and manage emotions and thought processes so that individuals can reflect on, choose, and implement more effective responses.
1861297|NCT01035788|Behavioral|CBCT for PTSD - Communication Skills|This control intervention will provide psychoeducation including the communication skills content from sessions 1-7 of Cognitive Behavioral Conjoint Therapy for PTSD.
1861298|NCT01035801|Drug|IN-105|Prandial Oral Insulin
1861299|NCT01035801|Drug|Insulin Lispro Injection|Insulin Lispro Injection
1861300|NCT01035853|Drug|Colistin|Sino-Nasal inhalation, approximately 1 ml / day in each nostril
1861301|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
1861302|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
1861303|NCT01035879|Drug|MBX-2982|tablets and capsule once daily
1861304|NCT01035879|Drug|Sitagliptin|tablets and capsule once daily
1861305|NCT01035879|Drug|placebo|tablets and capsule once daily
1861306|NCT01035905|Device|Nelfilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
1861307|NCT01035905|Device|Narafilcon A contact lens|Daily disposable contact lens worn in a daily wear, daily disposable mode
1861308|NCT01035944|Device|HemCon Dressings and HemCon ChitoGauze; chitosan-based.|Perform debridement of chronic wounds using HemCon chitosan-based dressings and HemCon ChitoGauze both at bedside and in the Operating Room (OR) settings. Control for both settings will be gauze and saline dressings.
1861309|NCT01035944|Device|Gauze and saline dressings.|Control for both settings will be gauze and saline dressings.
1861310|NCT01020019|Drug|Dronabinol|Dronabinol: 20 mg/TID
1861311|NCT01020019|Drug|Placebo|Placebo control
1861312|NCT01020019|Drug|Lofexidine|Lofex: .6 mg/ TID
1861313|NCT01020032|Other|"Individual receptive music therapy by U sequence method"|During the hospitalization, the intervention group benefited from at least 2 daily sessions of music therapy between day 0 and day 10, and continued the musicotherapy at home until day 60.
1861314|NCT01025362|Behavioral|Lactation counseling|The Baby-Friendly Community Health Service intervention to improve quality of lactation counseling.
1861315|NCT01025362|Behavioral|Standard care|Child Health Services offered standard care
1861316|NCT01025375|Dietary Supplement|inulin|10gram/day inulin for 13-day treatment
1861317|NCT01025375|Dietary Supplement|inulin|16gram/day inulin for 13-day treatment
1861318|NCT01025375|Dietary Supplement|placebo|16gram/day maltodextrin (placebo) for 13-day treatment
1861319|NCT01025401|Device|3-D accelerometric and magnetic sensors|sensors are positioned on the right wrist, the left wrist and on the head.
1861320|NCT01025414|Drug|enteral nutrition|Group A - enteral feeding was started 2 to 4 hours after catheter placement via enteral tube inserted via endoscope below the Treitz's ligament into first intestinal loop (location of the tip) (Nutricial Ltd. Flocare). The initial flow rate was 10 ml/ hour, final 125 ml/ hour. Energy requirements was calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Diet: Peptisorb (Nutricia Ltd.) - oligopeptide diet well tolerated by intestines
1861321|NCT01025414|Drug|Parenteral nutrition|Parenteral nutrition was started 2 to 4 hours after venous catheter placement (standard Arrow type, the tip located 5 cm over right vestibule, the location confirmed on chest X-ray) and continued until oral diet covering at least 60% of daily caloric and protein demand. The energy requirements were calculated using following rule: 0.15-0.2 gN/ kg and 130-170 kcal/ gN. Parenteral diets: Aminoplasmal 10%, Lipofundin LCT/MCT 10 and 20%, 40% Glucose, Tracutil (microelements and trace elements), Cernevit (vitamins), electrolytes
1861323|NCT01025440|Device|Continuous Positive Airway Pressure|"Continuous Positive Airway Pressure (CPAP) Dose: A flow (35 L/min) or pressure (btw 4 and 20 cmH20 -individual to each subject) is set on the device.
Duration: 1 night - the duration of the subject's sleep period (minimum of 3 hrs of sleep required)
Duration:"
1861324|NCT01025453|Drug|Temsirolimus and Sorafenib|Treatment will be with sorafenib 200 mg orally twice a day and temsirolimus 25 mg intravenous weekly. A cycle will be equivalent to 4 weeks of treatment.
1861325|NCT01025466|Drug|Rivastigmine transdermal patch (Exelon patch), memantine|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
1861326|NCT01025466|Drug|Rivastigmine transdermal patch|All patients start on a 5-cm2 rivastigmine patch and their dose is increased to a 10-cm2 patch after 4 weeks. Patients will be randomly allocated to 1 of 2 treatment groups of rivastigmine patch monotherapy and combination therapy with memantine at the baseline visit (week 9)and treated with the drugs for 16 weeks.
1861327|NCT01025492|Drug|Trilipix|135 mg po daily
1861328|NCT01025492|Drug|placebo|one tablet po daily
1994502|NCT02989753|Dietary Supplement|Placebo|After randomization (V1 visit), 8 capsules per day of placebo during 12 weeks (from visit V1 to visit V2). They will consume 3 capsules at the beginning of their breakfast, 2 capsules at the beginning of their lunch and 3 capsules at the beginning of their dinner.
1994503|NCT02989480|Radiation|PET CT|PET CT scans
1864568|NCT01057667|Drug|Ribavirin [Copegus]|1000mg or 1200mg po daily
1994504|NCT02989480|Other|Cardiac MRI|Cardiac MRI
1994505|NCT02989454|Other|Assessment of exercise capacity and cardiac energetics|Cardiopulmonary exercise testing and Magnetic Resonance Spectroscopy
1861331|NCT01025518|Other|Resistance training|12 weeks of resistance training in combination with protein and creatine or placebo ingestion
1861332|NCT01025518|Dietary Supplement|Protein and creatine|30 g of protein with each training session, 5 g of creatine pr day
1861333|NCT01025518|Dietary Supplement|Placebo|Maltodextrine
1861334|NCT01025544|Biological|Vaxem Hib (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
1861335|NCT01025544|Biological|Hiberix (Haemophilus influenzae type b (Hib) vaccine)|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines.
1861336|NCT01025557|Other|Dietary intervention|Dietary treatments with beverages
1861337|NCT01025570|Drug|Gemcitabine, Bosutinib|Gemcitabine, 1000 mg/m2 on D1,8,15 over 30 mins standard infusion rate Bosutinib 400 mg, oral, once daily
1861338|NCT01025583|Dietary Supplement|hypotonic oral rehydration solution|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
1861339|NCT01025583|Dietary Supplement|Hypotonic oral rehydration solution with Zn and prebiotics|30-50 ml/kg of ORS in 3-4 h for mild dehydration and with 50-100 ml/kg of ORS in 3-4 h for moderate dehydration, and to administer 10 ml/kg/die of ORS in a graduated glass or bottle for dehydration prevention until cessation of symptoms.
1861340|NCT01025596|Drug|Interleukin-7|4dose levels: 3, 10, 20 and 30µg/kg. 4 administrations, 1 per week
1861341|NCT01025622|Biological|autologous highly purified CD133+ stem cells (SCs)|Intrahepatic reinfusion in cirrhotic patients
1861342|NCT01025635|Drug|Azelaic acid foam 15%|Applied topically twice daily for 12 weeks
1861343|NCT01025635|Drug|Vehicle foam|Applied topically twice daily for 12 weeks
1861344|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 90 mcg/actuation|E004 (epinephrine inhalation aerosol), 90 mcg/actuation, 2 actuations, single dose crossover, 1 -14 day washout period
1861345|NCT01025648|Drug|E004 Placebo|E004 Placebo, 0 mcg epinephrine inhalation aerosol, 2 actuations, 1 -14 day washout period
1861346|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 125 mcg|E004 (epinephrine inhalation aerosol), 125 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 day washout period
1861347|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 220 mcg|E004 (epinephrine inhalation aerosol), 220 mcg - 220 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
1861348|NCT01025648|Drug|epinephrine inhalation aerosol, CFC propelled|epinephrine inhalation aerosol, 220 mcg/actuation, 2 actuations, single dose crossover, 1 14 day washout period
1861349|NCT01025648|Drug|E004 (epinephrine inhalation aerosol), 160 mcg|E004 (epinephrine inhalation aerosol), 160 mcg/actuation, 2 actuations, single dose crossover, 1 - 14 days washout period
1861350|NCT01025661|Other|Chiropractic care|Clinical examinations and treatments were performed at the outpatient clinic. The patients were assessed and treated by research assistants and the clinical care was supervised by state registered chiropractors. The choice of therapy and modality was pragmatic and based on the analysis of different functions such as mobility, tenderness, muscle tension and tone, and each patient's relative symptoms. Chiropractic care included high-velocity and low-amplitude techniques, soft-tissue or myofascial techniques, and arthrokinematic stabilizing exercises or a combination of these. Patients were treated in 1-2 sessions per week during the trial.
1861351|NCT01025674|Behavioral|Positive Action program|Components of the Positive Action program (6 units) use research-supported educational strategies/methods that include active learning, positive classroom management, teacher training, detailed curriculum with almost daily lessons, school-wide climate-change program, and family program of parent support/involvement.
1861352|NCT01025687|Dietary Supplement|water with noncalorie sweetener|
1861353|NCT01025687|Dietary Supplement|water with glucose|
1861354|NCT01025687|Behavioral|TV program showed while feeding|
1861355|NCT01025687|Behavioral|TV program showed while feeding|
1861356|NCT01025700|Drug|Cesemat|1 mg capsule per day for 21 days
1861357|NCT01025713|Drug|GS-9411|Inhaled GS-9411
1861358|NCT01025713|Drug|Placebo|Inhaled Placebo
1861359|NCT01025726|Behavioral|Police Patrolled Walking plus Social Marketing|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs PLUS grass-roots social marketing campaign to promote walking on the route
1861360|NCT01025726|Behavioral|Police Patrolled Walking Program Only|Identify walking route, hire walking leaders and police support, maintain route and monitor stray dogs
1861361|NCT01025726|Behavioral|General Health Education|Host community events for chronic disease education
1861362|NCT01025739|Device|EsophyX™ system with SerosaFuse fasteners|The EsophyX™ system with SerosaFuse fasteners (EndoGastric Solutions, Redmond, WA, USA) was designed to reconstruct the gastroesophageal junction through anterior partial fundoplication with tailored delivery of multiple fasteners during a single-device insertion.
1994706|NCT02940769|Device|light glasses|light glasses
1861365|NCT01025765|Drug|Pioglitazone|Pioglitazone(30mg qd) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg).
1861366|NCT01025765|Drug|Acarbose|Acarbose (50 mg/per meal) for 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg).
1861367|NCT01025765|Drug|Metformin|Metformin (500 mg tid) 4 weeks of run-in period and 8 weeks of combination treatment with Peginterferon alfa-2b (1.5/μg per kg) per week plus Ribavirin 1000-1200 mg/day (≥ 75 kg, 1200 mg; < 75 kg, 1000mg). From week 13, all the subjects will receive pegylated interferon alfa plus ribavirin for 40 weeks.
1861368|NCT01025778|Drug|Clofarabine for remission induction|
1861369|NCT01025778|Drug|Etoposide for remission induction|
1861370|NCT01025778|Drug|Cyclophosphamide for remission induction|
1861371|NCT01025778|Drug|Clofarabine in conditioning before transplantation|
1861372|NCT01025778|Drug|Thiotepa in conditioning before transplantation|
1861374|NCT01025778|Procedure|Haploidentical transplantation of T-cell depleted graft|
1861375|NCT01025778|Procedure|Donor lymphocyte infusion|
1861376|NCT01025791|Drug|MK8266|single rising oral doses of 0.1 to 24 mg of MK8266
1861377|NCT01025791|Drug|Placebo|single dose administration of placebo oral capsule
1861378|NCT01025817|Drug|Everolimus and tacrolimus|"Everolimus:
Dosage form: 0.75 mg, 0.25 mg, and 0.5 mg tablets
Dose: 1.5 mg per day
Frequency: 0.75 mg twice daily
Tacrolimus:
Dose adjusted to maintain specific blood levels"
1861379|NCT01025817|Drug|mycophenolate mofetil and tacrolimus|Mycophenolate mofetil: - Dose form: 250 mg capsule - Dose: 2g per day - Frequency: 1g twice daily Tacrolimus: - Dose adjusted to maintain specific blood levels
1861380|NCT01025830|Drug|Triomune|Stavudine (40mg) Lamivudine (150mg) Nevirapine (200mg)All twice a day
1861381|NCT01025830|Drug|Zerit/Epivir/Viramune|Stavudine (40mg) Lamivudine (150mg) and Nevirapine (200mg) All taken twice daily.
1861382|NCT01025843|Drug|MK-5478|In Part I: Single dose administration of MK-5478 oral capsules, total doses of 1, 2, 5, 8, 12, 18, 24 or 38 mg.
1861383|NCT01025843|Drug|Comparator: Candesartan cilexetil|Single dose administration of candesartan, 32 mg oral tablet
1861384|NCT01025843|Drug|Comparator: Pbo|Placebo
1861385|NCT01025856|Other|Rich in MUFA diet -PA|The patients will follow a rich in MUFA diet without a physical activity program.
1861386|NCT01025856|Other|high fiber/low glycemic index diet + pa|patients will follow for two months a high fibre/ low glycemic index diet with a physical activity program.
1861387|NCT01025856|Other|Rich in MUFA diet+PA|Patients will follow for two months a rich in MUFA diet with a physical activity program.
1861388|NCT01025856|Other|High fibre/low glycemic index diet-PA|Patients will follow for two months a high fibre/low glycemic index diet without a physical activity program.
1861389|NCT01025869|Device|Cinatra™ Corolimus Eluting Coronary Stent System|Stent implantation
1861390|NCT01025882|Drug|gemcitabine hydrochloride|Given IV
1861391|NCT01025882|Radiation|stereotactic body radiation therapy|Given as a single fraction
1861392|NCT01025895|Procedure|acl reconstruction - double bundle technique|
1861393|NCT01025895|Procedure|acle reconstruction - single bundle technique|
1861394|NCT01025908|Behavioral|Psychotherapy|Cognitive Behavioral Therapy
1861395|NCT01025908|Behavioral|Supportative psychotherapy|Supportative psychotherapy
1861396|NCT01025921|Drug|colistin (Tadim)|500.000 units of inhaled colistin three times daily for 10 days
1861397|NCT01025921|Other|inhaled normal saline|inhalation of 2,5cc Normal Saline via nebulisation
1861398|NCT01025934|Drug|Bevacizumab|
1861399|NCT01025934|Other|sham|
1861400|NCT01035983|Drug|Frovatriptan 2.5 mg|
1861401|NCT01036009|Other|Withdrawal of immunosuppression and donor lymphocyte infusion|Intervention will involve fast withdrawal of immunosuppression and DLI until full donor chimerism is achieved.
1861402|NCT01036022|Drug|GSK1399686|Each dose level of GSK1399686 will be subsequently tested in a cohort of approximately 20 patients, who will be randomized in a 3:1:1 ratio to receive GSK1399686 (once daily over 4 weeks, followed by 2 weeks dosing with placebo), placebo, or ASACOL (t.i.d. for 6 weeks), respectively.
1861403|NCT01036035|Drug|Tolterodine|Comparison of different dosages of drug
1861404|NCT01036035|Drug|Pilocarpine|Comparison of different dosages of drug
1861405|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
1861406|NCT01036035|Drug|THVD-201|Comparison of different dosages of drug
1861407|NCT01036035|Drug|placebo capsule|Comparison of different dosages of drug
1861408|NCT01036048|Device|drug eluting stent|pts with cabg disease treated with drug eluting stent
1861409|NCT01036048|Device|bare metal stent|pts with cabg disease treated with bare metal stent
1861410|NCT01036061|Drug|GSK618334 Low Dose|GSK618334 low dose
1861411|NCT01036061|Drug|GSK618334 PET subjects|PET subjects
1861412|NCT01036061|Drug|GSK618334 Medium Dose|Medium Dose
1861413|NCT01036061|Drug|GSK618334 High Dose|GSK618334 High Dose
1861414|NCT01036087|Drug|Panitumumab|2.5 mg/kg IV on Day 1 of Week 1 over 60 minutes, followed by 2.5 mg/kg weekly Weeks 2-12.
1861415|NCT01036087|Drug|Nab-paclitaxel|100 mg/m2 IV over 30 min on Day 1 of Weeks 2-13 over 30 minutes.
1861416|NCT01036087|Drug|Carboplatin|AUC 2 IV over 30 min on Day 1 of Weeks 2-13 after completion of Abraxane through separate IV line.
1861417|NCT01036087|Drug|5-Fluorouracil|500 mg/m2 IV every 3 weeks, starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
1861418|NCT01036087|Drug|Epirubicin|100 mg/m2 IV over 30 min every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
1861419|NCT01036087|Drug|Cyclophosphamide|500 mg/m2 IV every 3 weeks starting on Day 1 of Week 14 (4 cycles, each 3 weeks long, over 12 weeks).
1861420|NCT01036113|Drug|EZN-2208|EZN-2208 will be administered as an i.v. infusion on weekly basis for 3 weeks and repeated every 28 days.
1861421|NCT01036139|Drug|BF2.649 (pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
1861422|NCT01036165|Device|RebiSmart™|The RebiSmart™ autoinjector contains Rebif® 132 mcg multidose cartridges for sc injection.
1861423|NCT01036243|Dietary Supplement|test formula 1|hydrolyzed formula with probiotics
1861424|NCT01036243|Dietary Supplement|test formula 2|acidified hydrolyzed formula
1861425|NCT01036243|Dietary Supplement|test formula 3|hydrolyzed formula without probiotics
1861426|NCT01036243|Dietary Supplement|reference formula|standard infant formula
1861427|NCT01036282|Behavioral|Computerized Cognitive Skill Training|Behavioral: Cognitive Remediation 45 mins 2 times per week sessions of cognitive remediation (COGPACK) over twelve weeks.
1861428|NCT01036282|Behavioral|CRT and Social Cognition|Mind Reading, The Interactive Guide to Emotions for one 45 minute session per week for 12 weeks.
1861429|NCT01036308|Dietary Supplement|pure fibre-product|The subjects consumed 25 g pure fibre-product per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
1861430|NCT01036308|Dietary Supplement|reference fibre|The subjects consumed 25 g reference fibre (citrus fibre: Herbacel AQ Plus; Herbafood Ingredients) per day over two weeks. One half a portion of the fibres was stirred into a selected milk product and the other half in juice.
1861433|NCT01036360|Other|metabolic chamber|20 adolescent boys (10 obese and 10 leans) and 20 men (10 obese and 10 lean) will complete a sub-maximal test on a ergo cycle to draw their linear relationship between VO2 and Fc. Then they will enter a metabolic chamber three times, for 24 hours each
1861434|NCT01036399|Drug|Lenalidomide|Oral Lenalidomide is initiated on day 1 of cycle 1at the dose of 25 mg daily for 21 days with 7 days rest (28 day cycle) for a total of 4 cycles.
1861435|NCT01036412|Drug|1% Chlorhexidine Gluconate Gel|Following two 2.5 ml 5-minute applications performed in clinic on Day 1, 2 x 5.0 ml syringes of chlorhexidine gel self-administered for one 5-minute application using the custom-made carriers carriers on week 2 (12-14 days from baseline visit study drug administration) and week 4 (12-14 days from Week 2 study drug administration).
1861436|NCT01036412|Behavioral|Surveys|M. D. Anderson Symptom Inventory for Head and Neck Cancer (MDASI-HN) questionnaire, in addition to a 2nd subjective, study-specific questionnaire administered during visit taking about 5 minutes to complete each assessment.
1861437|NCT01036438|Device|Mepilex Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
1861438|NCT01036438|Device|Mepilex without Ag|Mepilex is designed for a wide range of exuding wounds such as leg and foot ulcers, pressure ulcers and traumatic wounds, e.g. skin tears and secondary healing wounds.
1861439|NCT01036490|Other|Exercise|Exercise training for 12 weeks followed by home exercise for 40 weeks
1861440|NCT01036529|Device|Precision Spinal Cord Stimulator|Programming settings will be specific to the individual needs in accordance with the labeling
1861441|NCT01036529|Procedure|Back Surgery|Different types of back surgery may be performed
1861442|NCT01037816|Drug|FS-67 Patch|One FS-67 patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
1861443|NCT01037816|Other|Placebo Patch|One placebo patch applied to target ankle every 12 hours for three days (up to 6 FS-67 patches in three days)
1861444|NCT01037829|Other|Non-intervention observational study|Non-intervention observational study
1861445|NCT01037842|Drug|Mitiglinide|"mitiglinide 10 mg three times a day added to metformin 500 mg three times a day
for 16 weeks"
1861446|NCT01037842|Drug|Placebo|placebo three times a day added to metformin 500 mg three times a day for 16 weeks
1861447|NCT01037855|Other|Non-intervention observational study|Non-intervention observational study
1861448|NCT01037868|Other|Supportive SMS text messages|Patients in the intervention group would receive twice daily supportive SMS text messages for 3 months from the treating team which would encourage/motivate them to refrain from drinking alcohol and comply with their medication. They would also receive a fortnightly phone call from an unblinded member of the research/treating team which would only serve the purpose of confirming that they still uses the mobile phone and receive the text messages.
1861449|NCT01037881|Drug|LEO 29102|comparison of different dosages of drug
1861450|NCT01037881|Drug|Elidel®|comparison
1861451|NCT01037894|Procedure|Acupuncture|Acupuncture from physiotherapist (with accredited training in acupuncture) in Shatin Hospital, three sessions per week for six weeks, and each session 30 minutes.
1861452|NCT01037894|Procedure|Conventional rehabilitation|In-patient physiotherapy, occupational therapy and speech therapy.
1861453|NCT01037907|Drug|Pleneva TM BGC20-0134|Placebo or 5 g dose
1861454|NCT01037907|Drug|Placebo|Placebo or 5 g dose
1861455|NCT01037920|Behavioral|Self-affirmation exercise|The intervention exercise asks subjects to reflect on a list of 11 personal values and to circle 2 or 3 items that are most important to them. Subjects are asked then to write a few sentences to describe why they are important.
1861456|NCT01037920|Behavioral|Control|The control exercise is the same as the intervention exercise except that subjects reflect and write about values important to someone else.
1861457|NCT01037933|Other|Humor intervention|"A 45-minute humorous DVD (Bananas Bunch) using a portable DVD player."
1861458|NCT01037933|Other|Non-humor intervention (distraction)|"A 45-minute non-humorous DVD (The A to Z of Steam Railways) using a portable DVD player"
1861459|NCT01037946|Behavioral|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Thai to People Living with HIV and their caregivers once a week for 13 weeks (n=13 sessions).
1861460|NCT01037959|Drug|Norfloxacin|400 mg/day (per os) for 6 months
1861461|NCT01037959|Drug|Placebo|1 pill/day (per os) for 6 months
1861462|NCT01037972|Behavioral|Conventional physiotherapy|3 times weekly 30 minutes of conventional physiotherapy to strengthen muscular strength and balance in the lower extremity.
1861463|NCT01037972|Behavioral|Whole body vibration|3 times weekly 30 minutes of exercises on a whole body vibration device to strengthen muscular strength and improve muscular balance in the lower extremity.
1861464|NCT01037985|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
1861465|NCT01037985|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
1861466|NCT01037998|Drug|UFUR and Iressa|Iressa 250 mg daily plus UFUR 1# bid
1861467|NCT01038011|Drug|drug treatment|
1861468|NCT01038024|Dietary Supplement|1 tablet composed of antioxidants and minerals|1 tablet daily
1861469|NCT01038037|Drug|Carboplatin|i.v. day 1: AUC 5 x (GFR + 25) mg q3w
1861470|NCT01038037|Drug|Vinorelbine|i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w
1861471|NCT01038037|Drug|panitumumab|i.v. day 1: 9 mg/kg q3w
1861472|NCT01038050|Drug|Ginkgo Biloba Extract (GBE)|Ginkgo Biloba Extract 40 mg 1# tid per day for 3 months(90 days)
1861473|NCT01038063|Drug|Artemether-lumefantrine combination|
1861474|NCT01038076|Behavioral|MedCHEC Tablet Computer & Adherence Care|Patients answer questions about their medication, medication-taking behavior and risks for non-adherence on the MedCHEC tablet touch-screen computer, which generates patient and provider reports. Patients may be referred to an Adherence Care Manager on the basis of the reports.
1861475|NCT01038089|Dietary Supplement|Resveratrol|Resveratrol
1861476|NCT01038102|Other|PUFA Diet|Diet high in polyunsaturated (rich in linoleic acid, omega-6) fat (15 E%).
1861478|NCT01038115|Procedure|Atrial fibrillation ablation|Comparison of three different techniques for pulmonary vein isolation
1861479|NCT01038128|Drug|Memantine|Drug: Memantine, 10-40 mg daily
1861480|NCT01038141|Procedure|Surgery for advanced haemorrhoidal disease|Milligan Morgan vs Recto Anal Repair
1861481|NCT01038154|Drug|Pravastatin|Receive one tablet of 40 mg of pravastatin, orally every 24 hours (at breakfast) for 2 years.
1861482|NCT01038167|Drug|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-11 of Period 2
1861483|NCT01038167|Drug|telaprevir|Tablet, Oral, 750mg, every 8 hours, Day 1-13 of Period 2
1861484|NCT01038167|Drug|cyclosporine|Solution, Oral, 100mg, Day 1 of Period 1
1861485|NCT01038167|Drug|cyclosporine|Solution, Oral, 10mg, Day 1 and Day 8 of Period 2
1861486|NCT01038167|Drug|tacrolimus|Capsule, Oral, 2mg, Day 1 of Period 1
1861487|NCT01038167|Drug|tacrolimus|Capsule, Oral, 0.5mg, Day 8 of Period 2
1994707|NCT02940769|Device|sham glasses (placebo)|sham light glasses
1861489|NCT01038206|Behavioral|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV. Consistent with our prior Familias Unidas efficacy studies, all parent group sessions and all family visits will be conducted in Spanish and will take place in the evenings and on Saturdays at the school or at a community site that is preferred by the families.
1861490|NCT01038258|Procedure|PET scan after course 1 and surgery after 8 courses|PET scan and surgery
1861491|NCT01038271|Other|Standard Palliative Care Group|Participant is referred to the Palliative Care Team at any time.
1861492|NCT01038271|Other|Integrated Palliative Care Intervention|Participant meets with the Palliative Care Team within 3 weeks of being randomized
1861493|NCT01038284|Behavioral|Patient education|Pharmaceutical care of patients with PAH
1861494|NCT01038284|Other|Data collection|Clinical and biological data, treatment, medication errors and ADEs
1861495|NCT01038297|Drug|EXC 001|Intradermal injections of EXC 001 and placebo given on various schedules.
1861496|NCT01038297|Drug|Placebo|Intradermal injections of EXC 001 and placebo given on various schedules.
1861497|NCT01038323|Other|CBT and milnacipran|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
1861498|NCT01038323|Behavioral|CBT with a placebo|"Participants will receive a series of eight telephone sessions of CBT along with a 21-week regimen of a placebo. Dosing for the placebo begins with a one week starter pack. Dosage: 12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
1861499|NCT01038323|Drug|Educational with milnacipran|"Participants will receive a series of eight telephone sessions of fibromyalgia related education along with a 21-week regimen of milnacipran. Dosing for milnacipran begins with a one week starter pack. Dosage:12.5 mg on day 1,12.5 mg twice daily on days 2 and 3, then 25 mg twice daily on days 4,5,6,and 7. On day 8 participants will begin taking 50 mg twice daily for the balance of the study."
1861500|NCT01038336|Behavioral|Multimedia Hearing Loss Prevention Program|Interactive, multimedia, computer-based HLPP that provides hands-on education and training about hearing loss, tinnitus, hearing protection, and general hearing health care for Veterans.
1861501|NCT01038336|Behavioral|Hearing Conservation Brochure|Hearing Conservation brochure provides knowledge-based information similar to that of the multimedia HLPP, but in written form.
1861502|NCT01038349|Other|Avise PG - Diagnostic test|Eligible patients will receive an Avise PG test
1861503|NCT01038362|Other|NCEP Step 1 diet plus Almonds|NCEP Step 1 Diet Plus Almonds 3 oz per day for 6 weeks
1861504|NCT01038362|Other|No Almonds|NCEP Step 1 diet without almonds
1861505|NCT01038375|Behavioral|lifestyle counseling, home blood pressure monitoring|monthly telephone counseling over 6 months for intervention group no health provider initiated contact for control group
1861506|NCT01038388|Drug|Bortezomib|1.3mg/m² given IV or subcutaneously
1861507|NCT01038388|Drug|Lenalidomide|25 mg given PO
1861508|NCT01038388|Drug|Dexamethasone|20 mg given PO
1861509|NCT01038388|Drug|Vorinostat|100, 200, or 300 mg given PO
1861510|NCT01038401|Procedure|GI endoscopy and GALT biopsies|This project aims to characterize the residual replication of HIV-1 in subjects on HAART, particularly in the gut-associated lymphoid tissue (GALT)
1861511|NCT01038401|Biological|A sample of venous blood will also be collected|These samples of blood will be use to characterize the residual viral populations on effective HAART in three compartments, plasma, monocytes, and GALT
1861512|NCT01038414|Behavioral|Extended Duration Behavioral Smoking Cessation Counseling|Subjects are randomized to one of 3 behavioral treatments: (1) Brief Duration (3 month) smoking-cessation counseling; (2) Moderate Duration (6 month) counseling; or (3) Extended Duration (12 month) counseling
1861513|NCT01038427|Drug|Mometasone Furoate|Test product - 200 mcg per day
1861514|NCT01038427|Drug|Mometasone Furoate|Reference listed drug - 200 mcg per day
1861515|NCT01038427|Drug|Placebo|Placebo
1861516|NCT01038440|Dietary Supplement|Safflower Oil|One softgel consumed daily with food
1861517|NCT01038440|Dietary Supplement|EPA|Three different doses of EPA (0.5, 1.5 and 3.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
1861518|NCT01038440|Dietary Supplement|SDA|Four different doses of SDA (0.5, 1.5, 3.0 and 6.0 g/d) consumed with food daily.Subjects consuming more than 1 softgel/day (as in the groups with 1.5 and 3.0 g/d) are instructed to consume the softgels in 2 or 3 separate servings.
1861705|NCT01039948|Drug|Gefitinib|Gefitinib is a small molecule (drug) which selectively inhibits epidermal growth factor receptor's (EGFR) tyrosine kinase domain.
1994708|NCT02941926|Drug|Ribociclib (LEE011)|Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD
1861522|NCT01038479|Dietary Supplement|Xylitol consumption|Mothers will eat 6 grams of xylitol per day
1861523|NCT01038479|Behavioral|Childsmile preventative programme|Mothers will receive the childsmile preventative programme
1861524|NCT01038492|Behavioral|p16 Methylation and Lung Cancer Education|"patients shown a presentation on p16 methylation and the development of lung cancer, asked to complete a questionnaire on items from presentation, desire to have p16 methylation test, views regarding their health and lung cancer, current smoking habits, and demographic details
patients given a sputum cup which they are asked to spit into on three consecutive mornings and then return to the lab for processing
a results letter is mailed to them and then followed up with a phone call at one month to discuss the results as well as any changes in their attitudes or smoking habits
patients are called again at three months and asked about any changes in their attitudes or smoking habits."
1861525|NCT01038505|Drug|Tacrolimus, Myfortic and Sirolimus|Immunosuppressive drugs
1861526|NCT01038531|Other|low-tidal-volume ventilation|goal tidal volume of 6 cc/kg ideal body weight
1861527|NCT01038531|Other|APRV|APRV is a time cycled, inverse-ratio, pressure controlled strategy that allows spontaneous breathing through the respiratory cycle.
1861528|NCT01038544|Procedure|Endoscopic Ultrasound (EUS)|Minimally Invasive Echo-Endoscopic Lymph Node Evaluation and Biopsy
1861529|NCT01038544|Procedure|Endobronchial Ultrasound (EBUS)|Minimally Invasive Echo-Bronchoscopic Lymph Node Evaluation and Biopsy
1861530|NCT01038557|Biological|Red Blood Cells|
1861531|NCT01038570|Drug|Syntocinon®/- Spray|3 sprays corresponding to 24 IU in each nostril
1861532|NCT01038570|Drug|Physiological serum (Sodium chloride)|Sodium chloride 0.9 % (0.3 ml) in each nostril
1861533|NCT01038583|Drug|100 mg enteric-coated aspirin|100 mg enteric-coated aspirin, taken daily
1861534|NCT01038583|Drug|Placebo|100 mg enteric-coated placebo
1861535|NCT01038609|Drug|Hydrocodone/Acetaminophen Extended Release|
1861536|NCT01038609|Drug|Acetaminophen|
1861537|NCT01038609|Drug|Morphine Extended Release|
1861538|NCT01038609|Drug|Placebo|
1861539|NCT01038622|Drug|L-arginine|5-day L-arginine treatment
1861540|NCT01038622|Drug|placebo|5-day placebo treatment
1861541|NCT01038635|Drug|5-Azacytidine|75 mg/m^2 IV daily x 5 days on days 1 to 5.
1861542|NCT01038635|Drug|Lenalidomide|Starting dose 10 mg orally daily x 5 days on days 6 to 10.
1861543|NCT01038648|Drug|Sitagliptin|100mg/day
1861544|NCT01038648|Other|life style modification at base line|Advice on physical activity, diet and drug adherence.
1861545|NCT01038661|Drug|Docetaxel|"Formulation: concentrated solution for intravenous infusion (IV)
Route(s) of administration: 1-hour IV"
1861546|NCT01038661|Drug|Cisplatin|"Formulation: concentrated solution for intravenous infusion (IV)
Route(s) of administration: 1-3-hour IV"
1861547|NCT01038661|Other|Best supportive care (BSC)|Any treatment including palliative radiotherapy for pain relief—but not chemotherapy — that is considered appropriate by the investigator
1861548|NCT01038674|Drug|anti-IL-20|Anti-IL-20 injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
1861549|NCT01038674|Drug|placebo|Placebo injected subcutaneously (under the skin) with 1 dose once weekly during a 6 week period (in total 7 doses) at 2 dose levels.
1861550|NCT01038687|Drug|A3309|A3390, a bile acid transport inhibitor was provided in either 15 mg or 20 mg oral tablets
1861551|NCT01038687|Drug|placebo|placebo
1861552|NCT01038713|Device|Biliary stent placement|Patient's with a malignant biliary obstruction will undergo placement of a biliary stent via ERCP.
1861553|NCT01038726|Other|Exercise Training|Aerobic exercise training program designed by the Cardiac Rehabilitation department
1861554|NCT01038726|Other|Cognitive Training|Based on cognitive training program Brain Fitness®
1861555|NCT01038726|Other|Flexibility Training|Non-aerobic flexibility training program designed by the Cardiac Rehabilitation department
1861556|NCT01038726|Other|Educational Sessions|DVD-based educational programs on history, art, and literature
1861557|NCT01038739|Drug|Mesalazine|3 g per day
1861558|NCT01038739|Drug|Mesalazine|1.5 g per day
1861559|NCT01038739|Drug|Placebo|0 g per day
1861560|NCT01038752|Drug|Suramin Drug:Docetaxel Drug: Carboplatin|Suramin dosage will be determined by nomogram and administered over 30 minutes. Suramin is followed by docetaxel (56 mg/m2, administered over 1 hour), followed by carboplatin (dosage calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
1861561|NCT01038752|Drug|Placebo Drug: Docetaxel Drug: Carboplatin|Placebo (100 ml of 0.9% sodium chloride or 5% dextrose in water) will be administered over 30 minutes, followed by docetaxel (75 mg/m2, administered over 1 hour), followed by carboplatin (dose calculated by Calvert equation to have a target AUC of 6, administered over 1 hour).
1861562|NCT01038765|Behavioral|Mindfulness Based Cognitive Therapy|8-weeks group based intervention of mindfulness and cognitive behavioural techniques
1861563|NCT01038778|Biological|Aldesleukin|Given IV
1861564|NCT01038778|Procedure|Computed Tomography|Undergo FDG-PET/CT
1861565|NCT01038778|Drug|Entinostat|Given PO
1861566|NCT01038778|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
1861567|NCT01038778|Other|Laboratory Biomarker Analysis|Correlative studies
1861568|NCT01038778|Other|Pharmacological Study|Correlative studies
1861569|NCT01038778|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
1861570|NCT01038791|Device|heated humidification|temperature 35°
1861571|NCT01038791|Device|heat and moisture exchanger|single patient device
1861572|NCT01038791|Device|usual mechanical ventilation without humidification|mechanical ventilation with usual parameters
1861573|NCT01038804|Drug|YM155|intravenous infusion
1861575|NCT01038817|Drug|Duraphat|After prophylactic cleaning of the mouth and teeth, application of fluoride varnish according to the manufacturer's recommendations (up to 0.75 ml per application)
1861576|NCT01038843|Drug|VA106483|"Drug: VA106483 Once daily oral dose of 1 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 2 mg VA106483 or matching placebo for 14 (+3) days. Once daily oral dose of 4 mg VA106483 or matching placebo for 28 days.
Placebo: as above"
1994709|NCT02941926|Drug|Letrozole|Ribociclib oral (3 weeks on/1 week off) in combination with oral once daily letrozole: 600 mg ribociclib QD + 2.5 mg letrozole QD
1861578|NCT01038869|Drug|Azelaic acid|Apply sparingly to the face twice a day (morning and night). Massage gently into the skin until vanishing. Approximately 0.5g (2.5cm strip) is sufficient for the entire facial area.
1861579|NCT01038882|Drug|Midazolam|Sedation started by injecting a 4 ml drug bolus with midazolam (0.07-0.1 mg/kg dose). Supplemental doses of midazolam (2 mg) were administrated at an interval of >2 min to maintain conscious sedation
1861580|NCT01038882|Other|Physiological serum|We started by injecting a 4 ml drug bolus and we ad supplemental doses (2 ml) to maintain the conscious sedation
1861581|NCT01038895|Drug|Ramipril|tablet; 10 mg; od; 3 months
1861582|NCT01038895|Drug|Experimental|tablet; 300 mg; od; 3 months
1861583|NCT01038908|Other|Isosulfan Blue (Patent Blue Dye V)|"Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe
Pre-incision: SLN is identified
Inject blue dye into patient's arm
Complete procedure (SLNB and/or ALND)"
1861584|NCT01038908|Other|Isosulfan Blue (Patent Blue Dye V)|"Inject radioactive isotope and scan for sentinel node (SLN) using gamma probe
Pre-incision: SLN is not identified (No localization)
Inject blue dye into breast (nothing in arm)
i. No localization: Inject blue dye into arm and perform ALND ii. Localization: Complete procedure (SLNB and/or ALND)"
1861585|NCT01038921|Drug|Melatonin|8 mg dose of Melatonin
1861586|NCT01038921|Drug|Placebo|Placebo
1861587|NCT01038934|Procedure|samples collected by buccal cytobrush|
1861588|NCT01038947|Biological|Uricase-PEG 20|Intramuscular injection of Uricase-PEG 20 without premedication
1861589|NCT01038960|Behavioral|Exercise training|3 months supervised interval training
1861590|NCT01038986|Biological|CureXcell|The CureXcell™ dosage form consists of an aseptically-processed activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.
1861591|NCT01038999|Biological|Peripheral blood biological tests|A group and B group will be evaluated three times, at baseline, then every 12 months during 3 years. In case of initiation or changing of antiretroviral therapy, patients will be evaluated once more. Control subjects will be only evaluated at baseline.
1861592|NCT01039012|Other|Tai Chi|Participants randomized to the Tai Chi group select a Tai Chi school from a pre-screened list of community-based Tai Chi programs and enroll for 9 months. Participants are asked to attend classes twice a week for the first month and once a week for the remaining 8 months. They are also asked to practice at home, or attend more classes for 2-3 additional hours per week. While in the study they are also encouraged to follow the standard care as recommended by their physician.
1861593|NCT01039012|Other|Standard Care|Participant follow the standard care recommended by their physician.
1861594|NCT01039025|Drug|Topotecan|After stem cells are collected, Topotecan 3.5 mg/m^2 intravenously given over 30 minutes on Days 1 - 5.
1861595|NCT01039025|Drug|Cyclophosphamide|After stem cells are collected, Cyclophosphamide 1 g/m^2/day intravenously given over 2 hours on Days 1 - 3.
1861596|NCT01039025|Drug|Melphalan|After stem cells are collected, Melphalan 70 mg/m^2/day intravenously given on Days 4 and 5.
1861597|NCT01039025|Other|Peripheral Blood Stem Cells|On Day 7, some or all of the stem cells will be reinfused.
1861598|NCT01039038|Radiation|curietherapy and radiotherapy|boost of curietherapy(40 Gy)and external radiotherapy (34 Gy)
1861599|NCT01039051|Behavioral|Diet and Lifestyle Intervention in Chinese Postpartum Women|For individual postpartum woman, we will set antepartum participatory training courses, provide specially prepared brochures and supporting VCD, set up a specialized counseling hotline and give individual bedside guidance after birth. For their family members, we will invite every postpartum woman's husband and mother to take part in workshops or seminars, making them know some basic knowledge of postpartum care, and persuading them to promote adoption of the diet and lifestyle we advocated by the postpartum woman. For community environment, we will put up posters about basic knowledge of postpartum care in the community bulletin boards for general population educating and mobilize community leaders and heads from and maternal and child health centers for maximum support.
1861600|NCT01039077|Procedure|Laparoscopic gastric banding|Laparoscopic gastric banding for the treatment of morbid obesity.
1861601|NCT01039090|Drug|Continuous Apomorphine infusion|Continuous Apomorphine infusion during 6 months
1861602|NCT01039090|Drug|Usual dopaminergic per os treatment|No specific change in the dopaminergic per os treatment
1861603|NCT01039103|Drug|PEG-liposomal prednisolone sodium phosphate|PEG-liposomal prednisolone sodium phosphate 300 mg intravenous (IV), single dose 500 ml infusion over at least 2 hours on day 1
1861604|NCT01039103|Drug|Methylprednisolone|Methylprednisolone 1 g, IV, infusion over 2 hours on days 1, 2 and 3
1861605|NCT01039116|Behavioral|High Intensity|High-intensity intervention, Experimental. Participating children were invited to attend a 2 week summer day camp at the beginning of each intervention year, and to attend a weekly, 2 hr interactive session for children. Activities provided hand-on experiences preparing and tasting healthy food alternatives, engaging in a range of physical activities and self-esteem boosting via activities that promoted communication and positive behavioral development.
1861606|NCT01039116|Behavioral|Low Intensity|Low-intensity intervention, Active comparator. Participants were provided with educational materials 4 times yearly.
1861607|NCT01039129|Procedure|Endoscopic Cholecystectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus.
1861704|NCT01039948|Biological|AV-299 + gefitinib|AV-299 is a humanized anti-HGF IgG1 monoclonal antibody directed against free HGF, ligand for c-Met tyrosine kinase receptor.
1861706|NCT01039961|Drug|losmapimod 1 mg|IV infusion
1861608|NCT01039129|Procedure|Endoscopic Appendectomy|An incision will be made in the vagina and a flexible surgical camera (endoscope) and instruments will be introduced. The surgical procedure for each given arm will be performed with the aid of an additional surgical instrument inserted through a small incision in the umbilicus
1861609|NCT01039129|Procedure|Endoscopic Peritoneoscopy|A diagnostic peritoneoscopy with or without biopsy for any indication
1861610|NCT01039142|Drug|Acitretin|capsule acitretin in dose of 25 mg, 35 mg or 50 mg/ day for 12 weeks or reduction in PASI score by 75% whichever is earlier
1861611|NCT01039155|Drug|Azacitidine|Given IV
1861612|NCT01039155|Other|Laboratory Biomarker Analysis|Correlative studies
1861613|NCT01039155|Drug|Oxaliplatin|Given IV
1861614|NCT01039155|Other|Pharmacological Study|Correlative studies
1861615|NCT01039168|Behavioral|Workplace dialogue|
1861616|NCT01039168|Other|Care as usual|
1861617|NCT01039181|Drug|Calcitriol|12 mcg Calcitriol will be given orally three times per week for 6 months. In this portion of the study, all patients will get the same dose of calcitriol along with the standard chemotherapy (5-fluorouracil-mitomycin C-leucovorin).
1861618|NCT01039194|Drug|galantamine|Capsule, Oral, 8 mg (ER), once daily, Days 1-7
1861619|NCT01039194|Drug|galantamine|Capsule, Oral, 16 mg (ER), once daily, Days 8-24
1861620|NCT01039194|Drug|BMS-708163|Capsule, Oral, 125 mg, once daily, Days 15-24
1861621|NCT01039207|Other|Laboratory Biomarker Analysis|Correlative studies
1861622|NCT01039207|Biological|Rilotumumab|Given IV
1861623|NCT01039220|Biological|naso-pharyngeal swab|Selected patients will be asked to contact the clinical staff on site as soon as any influenza like symptoms appear. In the case of influenza like illness patients are requested to attend to the clinic within 24 hours for physical examination and naso-pharyngeal swab for diagnosis of A(H1N1)v infection.
1994710|NCT02941926|Drug|Goserelin|Only for men and premenopausal women: administered as an injectable subcutaneous implant on Day 1 of each 28 days cycle
1861625|NCT01039259|Device|piercings of four different materials|randomly assigned sterile piercings are inserted for two weeks
1861626|NCT01039285|Drug|Curosurf|2.5 ml/kg instilled in the trachea
1861627|NCT01039285|Other|Air|2.5ml/kg of Air will be instilled in the trachea
1861628|NCT01039298|Procedure|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the control arm (using conventional white light approach).
1861629|NCT01039298|Procedure|Fluorescence visualization device|The trial will randomize 200 patients - 100 in the FV arm (using FV guided the surgery margin)
1861630|NCT01039311|Device|Optical Coherence Tomography|Obtain OCT images.
1861631|NCT01039324|Other|Reports|Primary care event reports and patient letters
1861632|NCT01039324|Other|Reports and Notices|Primary care event reports, patient letters and care manager notices
1861633|NCT01039324|Other|Usual care|This is the study's control group
1861634|NCT01039337|Other|Hip School|The hip school consists of one initial personal interview, three group sessions, and one follow-up personal interview. The hip school is a patient education programme which involves anatomy/physiology, epidemiology, disease progression and pain, advice on self-help and exercises.
1861635|NCT01039337|Other|Hip School and Manual Treatment|Hip school as above. Patients receive manual treatment twice a week for 6 weeks. Manual treatment consists of joint manipulation and muscle energy techniques to the articular and soft-tissue structures of the hip.
1861636|NCT01039337|Other|Minimal control intervention|As control group, an information leaflet is used with instructions to live as usual during the 6 weeks intervention period. The exercise sheet of the hip school is given to the patients with no further instruction.
1861637|NCT01039350|Drug|Darbepoetin alfa|Darbepoetin alfa will be initiated at a weekly (QW) subcutaneous dose of 300 mcg over 8 weeks.
1861638|NCT01039363|Drug|Salvage reinduction chemotherapy including Gemtuzumab ozogamicin, Idarubicin and Cytarabine and Vorinostat|"Salvage reinduction therapy:
Vorinostat 200mg BID po (D1-14) Gemtuzumab ozogamicin 3 mg/m2 once (D1) Idarubicin 12mg/m2 for 2 days (D2-3) Cytarabine 500mg/m2 bid IV for 5 days (D2-6)
Maintenance:
Once achieved CR, then Vorinostat 200mg BID po for 2 weeks, then 1 week's rest (1 cycle) for 11 cycles
Vorinostat should be stopped at least 2 weeks ahead of starting of consolidation therapy.
Gemtuzumab will be omitted in a consolidation schedule.
Allogeneic hematopoietic stem cell transplantation (HSCT) can be performed if HLA-matched sibling or unrelated donor is available. Vorinostat will be stopped 2 weeks prior to starting of conditioning regimen for allogeneic HSCT."
1861639|NCT01039376|Biological|Ofatumumab|Ofatumumab for maintenance therapy as IV infusions every 8 weeks . The first dose will be 300 mg followed 1 week later by 1000 mg and 1000 mg every 8 weeks thereafter for up to 2 years).
1861640|NCT01039376|Other|Observation|Observation/Safety Evaluation
1861641|NCT01039389|Drug|Ivabradine|bid administration of 5mg ivabradine (max 7.5mg) aiming to reduce resting heart rate to 60/min
1861642|NCT01039389|Drug|Placebo|bid placebo
1861643|NCT01039428|Dietary Supplement|HS219|Chewing for 30 min three time a day far after meal
1861644|NCT01039428|Dietary Supplement|Placebo|Chewing for 30 min three times a day far after meal
1861645|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine|A mixture of 50ml solution (20ml of 0.5% bupivacaine + 30ml normal saline) is instilled under the diaphragm.
1861646|NCT01039441|Procedure|CO2 removal by means of a pulmonary recruitment maneuver|CO2 is removed by means of a pulmonary recruitment maneuver consisting of five manual inflations of the lung with a maximum pressure of 30 cm H2O
1861647|NCT01039441|Procedure|Intraperitoneal instillation of bupivacaine +CO2 removal by means of a pulmonary recruitment maneuver|
1861648|NCT01039441|Other|normal saline|
1861649|NCT01039454|Drug|GSK598809 Capsules|GSK598809 is being developed for the treatment of substance dependence and potentially other impulse control disorders.
1861650|NCT01039454|Drug|GSK598809 Placebo Capsules|Treatment of substance dependence and potentially other impulse control disorders.
1861652|NCT01039506|Drug|CPT-11 based regimens|FOLFIRI, CPT-11+S-1, CPT-11
1861703|NCT01039909|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
1861653|NCT01039519|Drug|Ganetespib|Ganetespib 200 mg/m^2 during an approximately 1-hour infusion once weekly for three consecutive weeks followed by a treatment-free week. Participants who demonstrate acceptable tolerability and objective clinical benefit (defined by at least stable disease or objective response per RECIST) can continue to receive ganetespib until disease progression or appearance of unacceptable toxicity.
1861654|NCT01039545|Drug|Diclofenac|Diclofenac retard 75mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
1861655|NCT01039545|Drug|Norfloxacin|Norfloxacin 400mg twice daily for 3 days, followed by fosfomycin 3g single dose on day 4 if deemed necessary
1861656|NCT01039558|Drug|ecabet sodium|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
1861657|NCT01039558|Drug|lansoprazole|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
1861658|NCT01039558|Drug|placebo|Active comparator group patients will take lansoprazole 15 mg once daily and ecabet sodium 1.0 g three times daily and placebo group patients will take lansoprazole 15 mg once daily and placebo 1.0 g three times daily for total 8 weeks.
1861659|NCT01039571|Procedure|double row repair|double row repair for torn rotator cuff were performed to compare with the conventional single row repair
1861660|NCT01039584|Drug|Butoconazole Nitrate Vaginal Cream|vaginal cream
1861661|NCT01039584|Drug|Placebo|vaginal cream
1861662|NCT01039584|Drug|Gynazole 1 vaginal cream|vaginal cream
1861663|NCT01039597|Drug|ORE1001|Oral capsules containing 300 mg of the active, study drug
1861664|NCT01039597|Drug|Placebo|placebo capsules
1861665|NCT01039610|Drug|GSK945237|Dose detailed in Arm description
1861666|NCT01039610|Drug|Placebo|matching placebo tablet
1861667|NCT01039610|Drug|Linezolid|600 mg BID, 14 Days
1861668|NCT01039610|Drug|Moxifloxacin|40 mg single dose
1861669|NCT01039623|Biological|Pandemrix® (H1N1 pandemic influenza)|vaccinated against H1N1 pandemic influenza. One group will receive the adjuvant vaccine while the other group will get intradermal antigen, without the adjuvant.
1861670|NCT01039636|Drug|FBS0701|Oral FBS0701 for 7 days at one of the following doses: 3 mg/kg/day or 8 mg/kg/day or 16 mg/kg/day or 32 mg/kg/day or 40 mg/kg/day
1861671|NCT01039662|Dietary Supplement|L-arabinose and indigestible dextrin|
1861672|NCT01039662|Dietary Supplement|Placebo|
1861673|NCT01039675|Drug|500mcg/25mcg once daily|GSK573719/GW642444
1861674|NCT01039675|Drug|Placebo once daily|Inactive, excipients only
1959862|NCT03312322|Other|High-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.
Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.
It is explained to the patient that he might or no experience the electrical stimulation sensation.
Current characteristics : 100Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm < 60 during more than 10s."
1994711|NCT02939573|Drug|Colchicine|Randomized to colchicine 0.6 mg x 2/day
1994712|NCT02939573|Drug|Dapsone|Randomized to dapsone 150 mg/day
1861680|NCT01039727|Other|care as usual + 5 specific CDs|care as usual + 5 specific CDs (3 'General pain relief' + 2 'Short relaxations')
1861681|NCT01039727|Other|care as usual + email assistance + AurelisOnLine (AoL) + CDs|care as usual + email assistance (password protected) + AurelisOnLine (AoL) + 5 CDs at the start (same as in arm 2) + more CDs as needed after 1 month
1861682|NCT01039740|Drug|Mirtazapine|Mirtazapine administration for 6 weeks under therapeutic dose
1861683|NCT01039766|Drug|Oxytocin|A single intranasal administration of 40 IU of oxytocin will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months.
1861684|NCT01039766|Drug|placebo - saline nasal spray|A single intranasal administration of saline will be given to patients up to 6 hours after a traumatic event, with consecutive follow up for 13 months as the control to the oxytocin arm
1861685|NCT01039779|Behavioral|Exercise|Exercise will be taught every week over the 6-month intervention period at a subject's residence by instructors.
1861686|NCT01039792|Drug|Methyl B12|75 µg/Kg subcutaneously injected once every 3 days
1861687|NCT01039792|Dietary Supplement|Placebo|placebo
1861691|NCT01039818|Radiation|Radioiodine|A unique dose of 200µCi of ¹³¹I/ml/24-RAIU
1861692|NCT01039818|Radiation|Radioiodine|A unique dose of 250µCi of ¹³¹I/ml/24-RAIU
1861693|NCT01039844|Drug|LOC-paclitaxel|"Phase I Starting Dose: 100 mg/m^2 IV (intravenously) 1 hour infusion on Day 1, 8, 15, 22 and 29; and repeated every 42 days (6 weeks) per cycle.
Phase II Starting Dose: Maximum tolerated dose from Phase I."
1861694|NCT01039857|Behavioral|Neuropsychological Therapy, cognitive behavioral therapy, solution focused therapy|
1861695|NCT01039857|Behavioral|Integrative Neuro-Psychotherapy|Neuropsychological therapy, cognitive-behavioral therapy, emotion-focused techniques, clarification and interpersonal therapy techniques
1861696|NCT01039870|Procedure|paravertebral block|postoperative pain is controlled with local analgesics delivered via PVB
1861697|NCT01039870|Procedure|thoracic epidural analgesia|postoperative pain is controlled with local analgesics and fentanyl delivered via thoracic epidural catheter
1861698|NCT01039883|Drug|Albaconazole tablet 400mg|Albaconazole tablet 400mg single dose, then four albaconazole capsule 100mg single dose
1861699|NCT01039883|Drug|Albaconazole 100mg capsules, then albaconazole 400mg tablet|Four albaconazole capsule 100mg single dose, then albaconazole tablet 400mg single dose
1861700|NCT01039896|Drug|Period I : SLM0807, Period II : HKB0701 and SLM0807|
1861701|NCT01039896|Drug|Period I : HKB0710 and SLM0807, Period II : SLM0807|
1861702|NCT01039909|Drug|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
Eight size 00 Swedish orange opaque hard gelatin capsules containing placebo are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
1861707|NCT01039961|Drug|losmapimod|IV infusion (dose to be determined based on PK from first dose)
1861708|NCT01039961|Drug|losmapimod 15 mg|oral, two 7.5 mg tablets
1861709|NCT01039974|Drug|GSK962040|"GSK962040. Planned doses per cohort as follows:
Cohort 1 planned dose = 10 mg; Cohort 2 to be determined based on data from Cohort 1"
1861710|NCT01039974|Drug|Ketoconazole|400 mg
1861711|NCT01040000|Drug|NPC-1C/NEO-102|Subjects will receive NPC-1C at a dose of 3.0 mg/kg. NPC-1C will be given intravenously (by vein) over approximately 1-6 hours, once every 2 weeks for 4 doses per course. Courses will be repeated in the absence of disease progression or unacceptable toxicity.
1861712|NCT01040013|Procedure|Laparoscopy|Laparoscopic Left-Colectomy
1861713|NCT01040013|Procedure|left colectomy by laparotomy|PatientS will be operated by laparotomy
1861714|NCT01040026|Other|Treatment with in vitro expanded haploidentical NK cells|10 expanded NK-DLI will be applied at fixed intervals and to each patient within 30 days (3 applications per week, Mo/We/Fr) starting with increasing CD56+CD3- NK cell doses at 3 dose levels (1.5x10e6/kg, 1.5x10e7/kg and 1x10e8/kg) and, if safe, continuing with maximally 7 doses of 1x10e8/kg. Maximal cumulative T-cell dose is fixed at <1x10e5/kg
1861715|NCT01040052|Biological|Adacel® (Tetanus, Reduced Diphtheria Toxoid and Acellular Pertussis)|0.5 mL, Intramuscular
1861716|NCT01040065|Procedure|distal clavicle resection|Presence of tenderness at 2 years after surgery
1861717|NCT01040078|Biological|7.5ug H1N1 Influenza vaccine|0.25 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
1861718|NCT01040078|Biological|15ug H1N1 vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
1861719|NCT01040078|Biological|seasonal influenza vaccine|0.5 mL intramuscular injection into the deltoid region of the arm on Day 0 and day 21
1861720|NCT01040091|Drug|Emtricitabine (FTC)|200 mg once a day
1861721|NCT01040091|Drug|Tenofovir disoproxil fumarate (TDF)|300 mg once a day
1861722|NCT01040091|Drug|Efavirenz (EFV)|600 mg once a day
1861723|NCT01040091|Drug|Truvada|200 mg emtricitabine + 300 mg TDF once a day
1861724|NCT01040104|Other|Skin sample|Taken from regularly discarded tissue during routine operation
1861725|NCT01040104|Other|Skin biopsy|Skin biopsy from regions exhibiting normal and/or hypertrophic scarring at day 0 and day 90
1861726|NCT01040104|Other|Skin biopsy|Biopsy from skin graft harvest site during routine operation on day 0 and follow-up on day 90
1861727|NCT01040104|Other|Blood taking|Blood taking on day 0
1861728|NCT01040104|Other|Blood taking|Blood taking on day 90
1861729|NCT01040117|Procedure|Sensory-motor Integration Training|Exercises will be divided into 3 levels. 1 Starting from the patient's most stable and comfortable standing position. 2 Patient will perform a single-step simulation, shifting his/her weight from one foot to the other in a frontal direction. 3 Patient will perform rapid movements, alternating feet in many directions, progressively increasing weight shifting and decreasing the support base amplitude. In the first five sessions exercises will be performed on a stable surface. During the remaining sessions patients will perform exercises on a compliant surface. During the two training periods the patient's visual condition will be progressively changed.
1861730|NCT01040117|Procedure|Conventional neurorehabilitation treatment|"The treatment will be consist in active joint mobilization, muscle stretching and strengthen and motor coordination exercises. In the first part of each session the active joint mobilization will be carried out while the patient was lying on a carpet in supine, prone. The training will continue with muscle stretching and strengthen exercises performed while patient will be in supine, prone (when possible) and standing.
Motor coordination exercises will be carried out in supine position while sitting on a bench and in the standing position with a front support or with against a wall. The patient will be required to performed a total of 10 exercises with the following sequence: 6 exercises in supine position, 2 exercises in sitting position and 2 in standing position."
1861731|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
1861732|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high doses on exercise endurance time in COPD patients
1861733|NCT01040130|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
1861734|NCT01040130|Drug|Olodaterol (BI 1744)|Comparison of low and high dose
1861735|NCT01040130|Drug|Olodaterol (BI 1744) Placebo|Placebo that represents olodaterol
1861736|NCT01040169|Device|Arginine/Calcium Carbonate|One application
1861737|NCT01040169|Device|Mint Prophy paste - Fluoride free|one application
1861738|NCT01040195|Drug|Methotrexate, Hydroxychloroquine|Methotrexate will be prepared as unmarked tablets of 2.5 mg strength each and Hydroxychloroquine as unmarked tablet of 200 mg strength. Patients will be started on Methotrexate/placebo at 10 mg once weekly and increased every week by 2.5 mg to maximum dose of 20 mg per week in the absence of side effects. These patients will also be started on Hydroxychloroquine 200 mg per day or placebo.
1861739|NCT01040195|Drug|Placebo|Identical placebos (for methotrexate and hydroxychloroquine)will be prepared and prescribed in identical fashion as the methotrexate and hydroxychloroquine in the combination DMARD arm.
1861740|NCT01040208|Drug|flibanserin 50 mg to 100 mg qhs|50 to 100mg qhs
1861741|NCT01040208|Drug|flibanserin 100 mg qhs|100mg qhs
1861742|NCT01040208|Drug|placebo 2 tablets qhs|50 mg placebo
1861743|NCT01040221|Drug|Trichuris Suis Ova|TSO will be administered in vials prepared by Coronado Biosciences. Vials will be diluted with a commercial drink and given to subjects to ingest. Subjects will receive a dose of 2500 ova every two weeks for 12 weeks.
1861744|NCT01040234|Procedure|Bilateral dual TAP block|Bupivacaine 2.5 mg/ml 15 ml per injection. 4 injections per patient according to dual TAP block procedure
1861745|NCT01040247|Other|Embryo Transfer|In the study group embryo transfer will be performed on the day of oocyte aspiration and fertilization while in the control group it will be done 2 or 3 days later as is common practice.
1861746|NCT01040260|Other|Counseling|Smoking cessation counseling
1861747|NCT01040260|Behavioral|Contingency management|Use of tangible rewards for abstinence from smoking
1861748|NCT01040260|Drug|Nicotine patches|Nicotine patches
1861749|NCT01040273|Drug|Bupivacaine|
1861750|NCT01040273|Drug|Placebo|
1861751|NCT01040286|Drug|Flurbiprofen|2.0 mg
1861752|NCT01040286|Drug|Chlorhexidine|2.5mg
1861753|NCT01040299|Device|GangTrainer and tDCS|The experimental group patients receive a total of 10 treatments of repetitive locomotor training with electromechanical gait device (duration 30 min) + tDCS (duration first 7 min) with the anodal electrode is place over the presumed lower limb area of the lesioned hemisphere, and the cathodal electrode is place above the controlateral orbital.
1861754|NCT01040299|Device|control group1|The control group 1 receive a total of 10 treatments with only GT (duration 30 min) with sham-stimulation.
1861755|NCT01040299|Other|Control group2|The control group 2 receive a total of 10 treatments with convectional physiotherapy.
1861756|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 25ml of bone marrow on day 7-10 after stroke (only once in that period)
1861757|NCT01028794|Biological|autologous bone marrow mononuclear cells|intravenous administration of autologous bone marrow derived mononuclear cells obtained from 50ml of bone marrow on day 7-10 after stroke (only once in that period)
1861758|NCT01028807|Other|Early feeding|after 24 hours fasting period, with good abdominal conditions (once flatus passage of bowel movements without abdominal distention, vomiting, nausea or ileus) the oral fluids during 24 hours and then advanced to a regular diet as tolerated.
1861759|NCT01028807|Other|5 day fasting|Obligatory 5-day fasting because it was the therapeutic gold standard at our hospital and our country. Both groups without NGT and antiemetic drug. 5-day antibiotic regimen, ranitidine and appropriate analgesics were used. Once the regular diet was tolerated, the patients were discharged and followed up at clinic 30 days afterwards.
1861760|NCT01028820|Drug|Aripiprazole|8 weeks, starting dosage 5mg titrating up 5mg every week as needed to maximum dosage of 25mg daily
1861761|NCT01028833|Other|Power mobility|Project staff will use structured power mobility training program to teach the children to use the power mobility devices. Project staff will schedule 1-hour sessions with each family 3 times per week for the first month of the project and will decrease in the following manner as the child becomes proficient and develops basic wheelchair maneuvering skills: two one-hour session per week for 4 weeks; one one-hour session per week for 4 weeks; two one-hour sessions per month for 4 weeks; one one-hour session per month for the remainder of the study.
1861762|NCT01028846|Drug|Diazoxide|4mg-6mg/kg orally once before study
1861763|NCT01028846|Drug|Glyburide|Administered orally at beginning of study
1861764|NCT01028846|Device|Vagal Nerve Stimulator|Device approved for the purpose of decreasing seizure frequency in patients with poorly-controlled epilepsy
1861765|NCT01028859|Drug|CKD-516 inj|5.0 mg/2ml; 1.0, 2.0, 3.3, 5, 7, 9 ~ mg/m2; Day 1, Day 8 every 3 weeks
1861766|NCT01028872|Device|Intraocular lens|
1861767|NCT01028872|Device|Intraocular lens|
1861768|NCT01028872|Device|Intraocular lens|
1861769|NCT01028885|Procedure|radiation therapy treatment planning/simulation|
1861770|NCT01028885|Procedure|intensity-modulated radiation therapy|
1861771|NCT01028885|Procedure|image-guided radiation therapy|
1861772|NCT01028885|Procedure|magnetic resonance imaging|
1861773|NCT01028885|Procedure|computed tomography|
1861774|NCT01028911|Drug|PF-03654746|PF-03654746 capsule of 0.25 mg, 0.5 mg, and 1.0 mg strength. Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator.
1861775|NCT01028911|Drug|Placebo|"Matching placebo capsules to PF-03654746 with strengths of 0.25 mg, 0.5 mg, and 1.0 mg.
Drug is dosed orally once a day. Forced titration dosing for the first 15 days of the study being at 0.25 mg for 5 days, then 0.5 mg for days 6-10, then 1.0 mg for days 11-15. Flexible dosing for the next 15 days depending on tolerability and safety assessments done by the investigator."
1861776|NCT01028924|Drug|Teduglutide|subcutaneous (SC), single dose
1861777|NCT01028937|Device|Optimal Keratoplasty|Laser treatment in 16 spots at treatment energy densities up to 48 mJ per spot
1861778|NCT01028950|Drug|YM150|oral
1861779|NCT01028963|Drug|Placebo|Placebo capsules once daily
1861780|NCT01028963|Drug|pioglitazone|pioglitazone 30 mg tablet once daily
1861781|NCT01028963|Drug|CCX140-B|CCX140-B capsules once daily (Group C)
1861782|NCT01028963|Drug|CCX140-B|CCX140-B capsules once daily (Group D)
1861783|NCT01028976|Dietary Supplement|Vitamin C (ascorbic acid)|1000 mg/day (two 500-mg tablets), 8 weeks
1861784|NCT01028976|Dietary Supplement|Placebo tablet|Placebo tablet (two 500-mg tablets), 8 weeks
1861785|NCT01028989|Dietary Supplement|Reduced Glycemic Load Diet|"36-40% fat; 40-42% carbohydrate; 18-22% protein
Glycemic Load <=46 per 1000 calories"
1861786|NCT01028989|Dietary Supplement|Standard Diet|"25-27% fat; 55-57% carbohydrate; 18-22% protein
Glycemic Load >=77 per 1000 calories"
1861787|NCT01029002|Drug|Vitamin D|Vitamin D, ergocalciferol, 50000 IU, weekly for 12 weeks, with open label extension for another 3 months
1861788|NCT01029002|Other|Placebo|Patients randomized to this arm will receive one placebo pill once weekly.
1861789|NCT01029015|Procedure|cystometry|recording device measuring pressures though catheters placed in bladder and rectum
1861790|NCT01029015|Procedure|polysomnography|recording device measuring sleep activity through electrodes attached to the subject
1861791|NCT01029041|Other|Strengthening Exercises|Exercises that aim the improvement of muscular strength of arms and legs
1861792|NCT01029041|Other|Stretching exercises|Exercises that aim the improvement of muscular flexibility of arms, legs and spine
1861793|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|"Phase I: Carfilzomib will be administered at the dosage assigned for the subject's cohort as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.
Dexamethasone 40 mg will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push."
1861834|NCT01029366|Biological|CART-19|Autologous T cells purified from the peripheral blood mononuclear cells of subjects, transduced with TCR-ζ/4-1BB lentiviral vector, expanded in vitro and then frozen for future administration.
1861835|NCT01029392|Drug|Vitamin D|2000iu once a day
1861836|NCT01029405|Drug|AN2728|Ointment B, 2% or 0.5% applied once or twice daily
1861794|NCT01029054|Drug|carfilzomib, lenalidomide plus dexamethasone|"Phase II: Carfilzomib will be administered at the Maximum Tolerated Dose (MTD) established in Phase I as an IV infusion on Days 1, 2, 8, 9, 15, and 16 of a 28-day cycle for Cycles 1 - 8 (induction) and on Days 1, 2, 15, and 16 of a 28-day cycle for Cycles 9+ (maintenance).
Lenalidomide will be administered PO daily at 25 mg on Days 1- 21 of the 28-day cycle for Cycles 1 - 8+.
Dexamethasone will be administered PO or IV between 30 minutes and 4 hours preceding the carfilzomib push on Days 1, 8, 15, and 22 as follows: Cycles 1-4: 40 mg; Cycles 5-8: 20 mg; and Cycles 9 and higher: 10 mg."
1861795|NCT01029067|Behavioral|Metacognitive training|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
1861796|NCT01029067|Behavioral|Cognitive Remediation|Group (8 sessions) and individualized metacognitive training (9 sessions), delivered by psychologists versus cognitive remediation (8 sessions) delivered by either psychologists or psychology students at an advanced master level
1861797|NCT01029080|Other|no interventions|No interventions
1861798|NCT01029093|Other|no intervention, MRI and motor skill test|Two MR Investigations at two different times
1861799|NCT01029106|Procedure|Gynecare TVT Secur|Implant of the Gynecare TVT Secur
1861800|NCT01029132|Drug|galantamine|8 mg/day (4 mg bid) during the first 4 weeks, up to a maximum of 24 mg/day (12 mg bid) at intervals of 4 weeks, from 16 to 24 mg/day based on the patient's tolerability
1861801|NCT01029158|Drug|Juvista (Avotermin)|250 ng, twice, intradermal injection, standard formulation
1861802|NCT01029158|Drug|RN1006 (Avotermin)|250 ng, intradermal injection, twice
1861803|NCT01029158|Drug|RN1006 (Avotermin)|205 ng, Intradermal injection, once
1861804|NCT01029158|Drug|RN1006 (Avotermin)|500ng, intradermal injection, once
1861805|NCT01029158|Drug|Juvista (Avotermin)|250 ng, intradermal injection, twice
1861806|NCT01029158|Drug|Juvista (Avotermin)|500 ng, intradermal injection, once
1861807|NCT01029158|Drug|Juvista (Avotermin)|500 ng, intradermal injection, once
1861808|NCT01029158|Drug|RN1006 (Avotermin)|500 ng, intradermal injection, twice
1861809|NCT01029158|Drug|Placebo|Placebo
1861810|NCT01029171|Behavioral|Home-based balance and strength retraining exercise program.|A 12-month home-based balance and strength restraining program delivered by a physical therapist
1861811|NCT01029171|Behavioral|control; usual care|Usual care as prescribed by geriatrician.
1861812|NCT01029184|Other|commercialized complete cereals|complete cereals suitable for the weaning period
1861813|NCT01029184|Other|commercialized complete cereals with additional ingredient|complete cereals suitable for weaning period
1861814|NCT01029197|Behavioral|CBT and exposure therapy for PTSD|The CBT intervention will be administered twice weekly in group therapy sessions for 7 weeks, and then twice weekly individual sessions for 4 weeks.
1861815|NCT01029197|Other|Treatment as Usual|Participants in the treatment as usual condition will receive their usual services at the community clinic where they receive mental health and substance abuse services
1861816|NCT01029223|Drug|ivabradine|
1861817|NCT01029223|Drug|metoprolol|
1861818|NCT01029223|Drug|placebo|
1861819|NCT01029236|Other|Medifast Metabolism-boosting Beverages|Medifast metabolism-boosting beverages containing 90 mg EGCG and 100 mg caffeine.
1861820|NCT01029262|Drug|Lenalidomide|One 10 mg Lenalidomide capsule + 2 placebo capsules or (3 placebo capsules) once daily for subjects with a creatinine clearance ≥ 60 mL/min. Alternatively-one 5 mg Lenalidomide capsule + 2 placebo capsules (or 3 placebo capsules) once daily for subjects with a creatinine clearance between 40 and 60 mL/min. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
1861821|NCT01029262|Other|Placebo|3 placebo capsules once daily. Subjects may take study drug for at least 168 days unless there are intolerable side effects or disease progresses. Subjects may continue study drug beyond 168 days if they have an erythroid response (increase in their hemoglobin levels and fewer transfusions administered than before starting study drug)
1861822|NCT01029275|Drug|Pre-treatment with octreotide|Pre-treatment with octreotide
1861823|NCT01029288|Other|Diabetes Medication Choice Decision Aid|Diabetes Medication Choice cards
1861824|NCT01029288|Other|Statin Choice Decision Aid|Statin Choice Cards
1861825|NCT01029288|Other|Usual care for lipid therapy medication|Clinicians will follow their clinic's usual care practice for lipid therapy medication (statin) discussions.
1861826|NCT01029288|Other|Usual care for antihyperglycemic medication|Clinicians will follow their clinic's usual care practice for antihyperglycemic medication discussions.
1861827|NCT01029301|Device|Device: EndyMed Pro System for Skin Tightening|"Based on patient skin type and area of treatment the physician will choose the following parameters (some parameters are fixed):
Pulse energy (J); RF frequency (1MHz); Pulse duration (30 sec); Treatment hand piece (skin tightening);"
1861828|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Single dose of BAY81-8973 crossed over to single dose of Kogenate FS
1861829|NCT01029340|Biological|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Single dose of Kogenate FS crossed over to Single dose of BAY81-8973
1861830|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received IV injections of BAY81-8973 at 20-50 IU/kg 2-3 times per week with BAY81-8973 measured by Chromogenic Substrate Assay Potency Per European Pharmacopeia (CS/EP) for 6 months and by Chromogenic Substrate Assay/Adjusted to Label Potency (CS/ADJ) for 6 months, sequence according to randomization.
1861831|NCT01029340|Biological|Recombinant Factor VIII (BAY81-8973)|Participants received a loading dose of approximately 50 IU/kg of BAY 81-8973 before the first surgical incision followed by further treatment with BAY 81-8973 according to surgical requirements for up to 3 weeks
1861832|NCT01029353|Procedure|Laparotomy|Initial laparotomy will be performed. Standard procedures will be used, including inspection of the bowel with removal of diseased areas, creation of stoma(s), and other procedures deemed indicated by the surgeon.
1861833|NCT01029353|Procedure|Drainage|Initial drainage will involve placing a Penrose drain in the abdomen.
1861837|NCT01029405|Drug|Placebo|Ointment B Vehicle applied once or twice daily
1861838|NCT01029418|Drug|AZD6244 and sorafenib|dose escalation of AZD6244; sorafenib 400mg bd
1861839|NCT01029431|Device|AirQ Intubating Laryngeal Airway|After induction of anaesthesia in each child, either a PLMA or an Air-Q® ILA of the weight-appropriate size will be inserted & the evaluation described below will be conducted. The first LMA will then be removed & the other device inserted & assessed. The order in which the LMA devices are inserted will be determined using block randomisation, with random block sizes, after recruitment & before induction of anesthesia. The anesthesiologist will insert the LMAs using the manufacturer's recommended technique, & inflate the cuff to the manufacturer's recommended intracuff pressure of 60 cm H2O. Intracuff pressure will be measured with a digital pressure cuff monitor.
1861840|NCT01029444|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin, Humulog, Novolog )|Patients receive weekly treatments of Pulsatile Intravenous insulin therapy. The patient's Endocrinologist determines the insulin dosage each week based upon the patient's response to treatment RQ levels and their insulin resistance.
1861841|NCT01029470|Drug|Luveris|Luveris 75IU or 150IU depending on the patient conditions, subcutaneous injection, Qd, from Day 8 till hCG Day
1861842|NCT01029483|Other|Low carbohydrate diet|Ad libitum low carbohydrate diet (<28g carbohydrate/day). Participants provided with research diet at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the food desired.
1861843|NCT01029483|Other|High-carbohydrate ad libitum intervention|Participants provided with a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at 120% of estimated energy needs for weight maintenance and allowed to eat as much or as little of the foods provided as desired
1861844|NCT01029483|Other|High carbohydrate diet-energy matched intervention|Participants provided a high complex carbohydrate diet (55% carbohydrate, 18% protein, and 27% fat) at ~70% of estimated energy needs to maintain weight. Participants required to eat all food provided and nothing else.
1959863|NCT03312322|Other|Low-frequency transcutaneous electrical nerve stimulation|"4 self adhesive surface electrodes are positioned by pair at the L3-L4 level, laterally.
Stimulation is setted at rest, 10min before constant workload testing. During this period, intensity is increased every 3minutes to the maximum tolerated by the patient (pain threshold). Thereafter, intensity is not increased anymore during the test.
It is explained to the patient that he might or no experience the electrical stimulation sensation.
Current characteristics : 4Hertz, 100ms, bidirectional. Constant workload testing : 60-70rpm ; 75% Wpic ; up to exhaustion or rpm < 60 during more than 10s."
1861846|NCT01029509|Drug|OPB 31121|Starting dose of 200 mg (two 100 mg tablets) twice a day for 21 days followed by 7 days of rest.
1861847|NCT01029522|Drug|Atorvastatin (Lipilou)|treatment of dyslipidemia administration : PO, qod
1861848|NCT01029522|Drug|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
1861849|NCT01029535|Device|Cross-linked hyaluronic acid gel|Cross-linked hyaluronic acid gel (Juvederm® VOLUMA™) up to 4 mLs injected in each side of the face.
1861850|NCT01029561|Device|CPAP|Treatment with Continuous Positive Airway Pressure
1861851|NCT01029561|Behavioral|Diet|Conventional diet treatment that undergo patients in the Bariatric Surgery Program
1861852|NCT01029574|Other|Platelet rich plasma|Ultra-centrifuged PRP, 40ml, in the liquid way, after portal closure.
1861853|NCT01029587|Drug|Eculizumab|Eculizumab will be administered by intravenous infusion. Eculizumab will be administered at a dose of 1200mg by intravenous (IV) infusion on the day of or on the day prior to kidney transplantation, and at a dose of 900mg IV on post-operative day 1. Subsequently, the post-operative dosing regimen would be comprised of an induction phase of weekly doses of 900mg IV per dose followed by a maintenance phase of every other week dosing of 1200mg IV per dose. The weekly induction dosing regimen would begin on postoperative day 8, and would continue for three doses (specifically, doses of 900mg IV would be given on postoperative days 8, 15, and 22). The maintenance phase of dosing would begin with a dose of 1200mg on postoperative day 29, and would continue for a total of 5 doses (specifically, doses of 1200mg IV would be given on postoperative days 29, 43, 47, 72, and 85). In most cases, eculizumab would be discontinued after the 5th maintenance dose.
1861854|NCT01029600|Procedure|Arthroscopic capsular release|Surgical division of thickened capsule in the shoulder
1861855|NCT01029600|Procedure|Distention with steroid|Intraarticular distention with steroid, saline, contrast and local anaesthetic
1861856|NCT01029613|Drug|Adalimumab|sc. inj. Humira 40 mg every other week from week 0 to 52
1861857|NCT01029626|Procedure|Endoscopy|Realization of an upper GI endoscopy
1861858|NCT01029639|Procedure|Pulsatile Intravenous Insulin Therapy (Humulin R, Novolog)|Endocrinologist reviews patient activation after treatment each week and adjust the amounts of insulin and carbohydrates to be given in the next session
1861859|NCT01029652|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
1861860|NCT01029652|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
1861861|NCT01029652|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
1861862|NCT01029652|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
1861863|NCT01029678|Drug|Cisplatin IV|Cisplatin IV 30 mg/m2/ (Day 1, Day 8, Day 15, Day 22, Day 29, Day 36)
1861864|NCT01029678|Drug|Vinorelbine|Vinorelbine per os 30 mg/m2/(day1, day8, day15, day22, day29, day36
1861865|NCT01029678|Radiation|Radiotherapy|66Gy, 33 fractions, 6 week
1994713|NCT02939573|Drug|Azathioprine|Randomized to azathioprine 2 mg/kg/day
1861867|NCT01029704|Drug|EGT0001442|"Segment 1 is a single center, open labeled, ascending dose study in diabetic subjects who will receive 5, 10, 20, or 50 mg of EGT0001442 capsules orally once daily for 28 days.
Segment 2 is a multi-center, double-blind, placebo-controlled parallel group study. Diabetic subjects will be randomly assigned to receive oral EGT0001442 at 5, 10, 20, or 50 mg/day for 28 days."
1861868|NCT01029704|Drug|Placebo capsules to match EGT0001442|"Segment 1: Not applicable.
Segment 2: Diabetic subjects will be randomly assigned to receive oral placebo once daily for 28 days."
1862025|NCT01030952|Drug|Nateglinide|Nateglinide tablets, oral administration, three times daily, 120 mg orally 10 minutes immediately before 3 meals three times daily.
1861869|NCT01029717|Device|Standard polyurethane Central Venous Catheter|Standard polyurethane Central Venous Catheter, All CVCs used in the trial are CE marked medical devices used for their intended purpose.
1861870|NCT01029717|Device|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin)|Antibiotic impregnated polyurethane CVC (minocycline and rifampicin. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
1861871|NCT01029717|Device|Heparin bonded polyurethane CVC|Heparin bonded polyurethane CVC. All CVCs used in the trial are CE marked medical devices used for their intended purpose.
1861872|NCT01029730|Drug|Bendamustine|Bendamustine: 90 mg/m2 Days 1 and 2 of 6, 28-day cycles
1861873|NCT01029730|Drug|Bortezomib|Bortezomib: 1.6 mg/m2 given IV on Day 1, Day 8, and Day 15 of 6, 28-day cycles
1861874|NCT01029730|Drug|Rituximab|Rituximab, Cycle 1: 375 mg/m2 given IV on Day 1, Day 8, and Day 15 Rituximab, Cycles 2-6: 375 mg/m2 given IV on Day 1
1861875|NCT01029743|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Daily dose, a treatment duration of 5 weeks for patients undergoing major hip surgery and a treatment duration of 2 weeks for patients undergoing major knee surgery are recommended
1861876|NCT01029743|Drug|Pharmacologic agents (e.g. LMWH/VKA/Fondaparinux/Aspirin and etc.)|Daily dose, dosage frequency and duration will be decided by physicians
1861877|NCT01029756|Device|Macintosh Laryngoscope|Device used to gain a direct view of the vocal cords, to enable an endotracheal tube to be passed into the trachea at induction of anaesthesia.
1861878|NCT01029756|Device|Pentax AWS Videolaryngoscope|Self-contained video laryngoscope with an integral colour-viewing screen mounted on the handle. A camera at the tip transmits an indirect image, which obviates the need to obtain a direct view of the vocal cords, when passing an endotracheal tube on induction of anaesthesia.
1861879|NCT01029769|Drug|Olanzapine or amisulpride|Oral olanzapine 5mg to 20mg/d OR oral amisulpride 200mg to 800mg/d; both preferably once daily, both encapsulated for blinding
1959864|NCT03312322|Other|Sham transcutaneous electrical nerve stimulation|The procedure is the same as high-frequency transcutaneous electrical stimulation but intensity is progressively setted back to 1mA (over a 45sec period) after every increment so that constant workload testing is performed with 1mA.
1861882|NCT01029795|Drug|LY2599506|Administered orally (po), twice daily (BID) prior to morning and evening meals for 12 weeks
1861883|NCT01029795|Drug|Glyburide|Administered po, BID daily prior to morning and evening meals for 12 weeks
1861884|NCT01029795|Drug|Placebo|Matching placebo capsules administered po, BID prior to morning and evening meals for 12 weeks
1861885|NCT01029821|Drug|Low-Molecular-Weight Heparin|Isolated Ankle Fracture Single planned operation
1861886|NCT01029834|Behavioral|family based lifestyle and behavioral counseling|16 group meetings
1861887|NCT01029834|Behavioral|counseling focused on the child|16 meetings
1861888|NCT01029847|Drug|Adalimumab|Sc. inj. Humira 40 mg every other week for 42 to 48 weeks
1861889|NCT01029847|Drug|Placebo|sc. inj. placebo every other week, week 0, 2, and 4. Active treatment from week 6.
1861890|NCT01029873|Drug|Cisplatin|Intravenous infusions; 2 treatment courses; 2 treatment cycles for each course; 70mg/m2 on day 1 of cycle 1 for each course
1861891|NCT01029873|Biological|ALT-801|"Intravenous infusions; cycle 1: day 3 and 5; cycle 2: day 1, 3 and 5; nine day rest period between cycles; seven day recovery period between courses
Stage 1: dose escalation (0.04 mg/kg, 0.06 mg/kg, 0.08 mg/kg)
Stage 2: dose expansion (dose at MTD)"
1861892|NCT01029886|Drug|exenatide once weekly|subcutaneous injection, 2mg, once weekly
1861893|NCT01029886|Drug|liraglutide|subcutaneous injection, forced titration to 1.8mg, once daily
1861895|NCT01029925|Drug|Dichloroacetate (DCA)|Dichloroacetate, 6.25mg/kg orally, twice daily, administered with food around the same time every day and at approximately 8-12 hours apart
1861896|NCT01029938|Procedure|Covered stent|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
1861897|NCT01029938|Procedure|Coil|Consecutive patients with CICA aneurysms were endovasculartreated with a Willis covered stent (group A) or coil embolization (group B)
1861898|NCT01029951|Procedure|manipulation|
1861899|NCT01029951|Procedure|Mobilisation|
1861900|NCT01029951|Device|Activator instrument|
1861901|NCT01029964|Behavioral|Individually and in groups|During three year in a clinical setting.
1861902|NCT01029990|Other|Telephone arm|Midwifes at 72 antenatal care units in West region of Sweden receive lists with names and telephone numbers on women who have no record of screening during two screening rounds (6 - 10 years depending on age). The midwife will make up to ten attempts to reach each woman and is instructed to use no more than 30 minutes on this. If the midwife get in touch with the woman she will encourage participation in regular screening (run by midwives in Sweden) and help the woman to get an appointment.
1861903|NCT01029990|Other|Self-test arm|Women receive an offer to order a vaginal self test for HPV. The woman can return a coupon in a postage free envelope and she will receive a self testing kit (dry method) within a couple of days. She will return the test in another postage free envelope. A reminder will be sent to women who order a test but do not return it.
1861904|NCT01030016|Drug|atenolol|25 mg/day, twice a day for 6 weeks
1861905|NCT01030029|Device|electrical auricular acupuncture|Patients in the acupuncture group received titan disposable needles (27-gauge, 3 mm length; Biegler GmbH, Mauerbach, Austria), which were inserted in the dominant ear at the following acupuncture points: shen men, thalamus and one segmental organ-specific point [2]. Acupuncture points were identified by measuring skin resistance, using an electrical conductance meter (multipoint selection pen™, Biegler GmbH, Mauerbach, Austria). The needles were connected to the P-Stim™ device and received continuous low frequency electro acupuncture using P-Stim™ (constant current: 1 Hz biphasic, 2 mA) for 72 hours postoperatively. Acupuncture was performed by a specialist with 15 years experience in this technique.
1861906|NCT01030029|Device|P-Stim™ devices were applied without electrical stimulation and acupuncture.|Patients in the control group received electrodes without needles and the P-Stim™ devices were applied without electrical stimulation.
1861907|NCT01030042|Drug|FOLFOX-4|Day 1: OXA will be administered as a 85 mg/m2 iv infusion over 2 hours; Leucovorin as a 100 mg/m2 infusion over 2 hours, 5-FU will be given as a 400 mg/m2 bolus injection, and then as a 600 mg/m2 continuous infusion over 22 hours after the first infusion Day 2: Leucovorin 100 mg/m2 (alone), followed by 5-FU 400 mg/m2 bolus injection, and 5-FU 600 mg/m2 continuous infusion after the first infusion Cycle length is 2 weeks comprising approximately 48 hours of infusion and 12 days of rest. Cycles are to be repeated every second week for a total of either 6 (12 weeks) or 12 cycles (24 weeks).
1861908|NCT01030042|Drug|Irinotecan/Cetuximab|"CET 400 mg/m2 intravenously via infusion pump given over a 120 min time and weekly CET infusions at a maintenance dose of 250 mg/m2 given over a 60 min time.
IRI 180 mg/m2 iv infusion over 30-90 min. Cycle length is 2 weeks and it is to be repeated until disease progression."
1861909|NCT01030055|Drug|TKI258 (dovitinib)|bioavailability (anhydrate capsules) food (monohydrae capsules)
1861910|NCT01030068|Behavioral|Yoga|Yoga twice weekly
1861911|NCT01030068|Behavioral|Wellness|Health and wellness classes twice weekly
1861912|NCT01030068|Other|Smoking cessation therapy|Smoking cessation therapy
1861913|NCT01030081|Drug|Amlodipine (Norvasc®)|Amlodipine (Norvasc®), tablet, 5 mg
1861914|NCT01030081|Drug|Nifedipine GITS (Adalat® XL 30|Nifedipine GITS (Adalat® XL 30), controlled released tablet, 30 mg
1861915|NCT01030094|Drug|Topiramate|This is an observational study. Female participants with epilepsy will be observed, who were receiving topiramate for more than one year.
1861916|NCT01030094|Drug|Carbamazepine|This is an observational study. Female participants with epilepsy will be observed, who were receiving carbamazepine for more than one year.
1861917|NCT01030094|Drug|Valproic acid|This is an observational study. Female participants with epilepsy will be observed, who were receiving valproic acid for more than one year.
1861918|NCT01030094|Drug|Normal control|This is an observational study. Healthy female participants will be observed in Normal control group.
1861919|NCT01030107|Behavioral|Increase Sleep|Children are asked to increase their sleep by approximately 1 1/2 hours/night for 1 week.
1861920|NCT01030107|Behavioral|Decrease Sleep|Children are asked to decrease their sleep by approximately 1 1/2 hours/night.
1861921|NCT01030120|Drug|etanercept|etanercept 50mg BIW S.Q.
1861922|NCT01030120|Drug|placebo|placebo
1861924|NCT01030146|Drug|NeilMed® Sinus Rinse™ System with Isotonic Saline|NeilMed® Sinus Rinse™ System with Isotonic Saline twice a day
1861925|NCT01030159|Other|Adult Cancer Patients|Tracking anemia management in Adult Cancer Patients
1861926|NCT01030185|Device|NovaShunt's Automated Fluid Shunt implantation|The Automated Fluid Shunt (AFS) Device consists of an implantable sealed housing which contains an internally powered pump with supportive electronic components and circuits, an implantable Peritoneal Catheter, implantable Bladder Catheter and a non-implantable Charger used for wireless recharging an AFS battery and collecting data from the Device.
1861928|NCT01030211|Procedure|Platelet transfusion|4 units of platelets for patients with platelet count <20x10^3/uL
1861929|NCT01030211|Other|Supportive care|Supportive care includes symptomatic treatment, fluid therapy and monitoring of full blood count and blood pressure
1861930|NCT01030224|Drug|AZD9742|Increasing single IV infusion doses of AZD9742 given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo). Specific doses will be selected by the safety review committee
1861931|NCT01030224|Drug|Placebo to match AZD9742|Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo)
1861932|NCT01030237|Other|FID 114657|1 drop both eyes four times a day for 6 weeks
1861933|NCT01030237|Other|Soothe XP Lubricant Eye Drops|1 drop both eyes four times a day for 6 weeks
1861934|NCT01030263|Other|Fluorescence-aided confocal endomicroscopy guided biopsy.|Fluorescence-aided confocal endomicroscopy guided biopsy.
1861935|NCT01030263|Other|Random four-quadrant biopsies.|Random four-quadrant biopsies.
1861936|NCT01030276|Other|Bright light therapy|Bright light therapy
1861937|NCT01030276|Other|"Inactive placebo-light"|In this arm, patients will not get any bright-light therapy in a double-blind setting
1861939|NCT01030302|Drug|bortezomib|bortezomib injection into a vein 1.3 mg/m2 twice a week for 21 days
1861940|NCT01030315|Drug|HM10760A or placebo|Once, 0.04 mcg/kg to 2.0mcg/kg once intravenously
1861941|NCT01030328|Drug|Placebo|2 sugar pills by mouth once a day.
1861942|NCT01030328|Drug|TriLipix|135 mg of TriLipix + 40 mg of Atorvastatin by mouth once a day
1861944|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass
1861945|NCT01030354|Dietary Supplement|Herbalife Meal Replacements|Higher protein meal replacement diet based on 1 gram of protein per pound of lean body mass will improve weight loss in comparison to a standard protein meal replacement diet based on ½ gram of protein per pound of lean body mass.
1861946|NCT01030367|Drug|PETN, ISDN|Oral dosing of organic nitrates PETN 2x 80mg per day ISDN 2x40mg per day
1861947|NCT01030380|Device|Slendertone Face|Slendertone Face 20 minutes/day, 5 days/week for 12 weeks.
1861948|NCT01030393|Drug|human chorionic gonadotrophin|intrauterine injection of 100 iu (group1) or 200 iu (group2) of hCG before embryo transfer in IVF/ICSI And intrauterine injection of 500 iu hCG before embryo transfer .
1861949|NCT01030406|Drug|Drug A|Tablets
1861950|NCT01030406|Drug|Drug B|Tablets
1861951|NCT01030406|Drug|Drug C|Tablets
1861952|NCT01030406|Drug|Drug D|Tablets
1861953|NCT01030406|Drug|Placebo|Tablets
1861988|NCT01030666|Drug|0.12% chlorhexidine gluconate solution|Furthermore, all patients were advised to rinse with a 0.12% chlorhexidine gluconate solution (ParoEx; Butler, Kriftel, Germany) for 2 min. twice daily for 5-7 weeksafter surgery.
1861954|NCT01030419|Behavioral|Home-based, DVD-delivered physical activity|Subjects will be participating in a home-based physical activity program that focuses on flexibility, toning and balance. Exercises will be progressive over the six-months and will highlight modifications for varying levels. This program will be delivered on 3 DVDs. Participants will be asked to exercise with the DVD at least three times per week. Additionally, they will be encouraged to add two days of aerobic activity (e.g. walking) each week.
1861955|NCT01030419|Behavioral|Usual care/Wait list|Participants in this arm will receive a DVD that focuses on healthy aging topics but does not include physical activity. They will receive the FlexToBa DVD afer the completion of the 12-month follow-up testing.
1861956|NCT01030432|Drug|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 48 weeks
1861957|NCT01030432|Drug|BMS-650032|Tablets, Oral, 200 mg, Twice Daily, 12 or 24 weeks, depending on response
1861958|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 48 weeks
1861959|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 0 or 12 weeks (depending on response) beginning at Week 12
1861960|NCT01030432|Drug|Placebo|Tablets, Oral, 0 mg, twice daily 24 weeks
1861961|NCT01030432|Drug|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 48 weeks
1861962|NCT01030432|Drug|Peginterferon Alfa-2a|Syringe, Subcutaneous injection, 180 mcg / 0.5 mL, Weekly, 24 or 48 weeks, depending on response
1861963|NCT01030432|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 48 weeks
1861964|NCT01030432|Drug|Ribavirin|Tablet, Oral, 500 or 600 mg based on weight, Twice Daily, 24 or 48 weeks depending on response
1861965|NCT01030458|Drug|amlodipine 5/10 mg per day plus valsartan 160 mg/day|Amlodipine 5/10 mg/day plus valsartan 160 mg/day, once daily, in the morning
1861966|NCT01030458|Drug|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day|hydrochlorothiazide 6.25 mg/day plus bisoprolol 5/10 mg/day, once daily, in the morning
1861967|NCT01030471|Behavioral|Family-based cognitive-behavioral treatment|Participants will engage in ten weekly sessions aimed at improving depressive symptoms and medication compliance via reducing family conflict and improving communication among family members.
1861968|NCT01030510|Drug|the order of drug administration|In group R, remifentanil was infused first before administrating propofol and rocuronium and in group P, it was administered last after the rocuronium injection. In other words, the order of drug infusion in each group is remifentanil-propofol-rocuronium in group R and propofol-rocuronium-remifentanil in group P, respectively.
1861969|NCT01030523|Device|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)|ASTRA TECH Implant System, OsseoSpeed™ 4.0 S (length: 6 mm)
1861970|NCT01030523|Device|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm)|ASTRA TECH Implant System, OsseoSpeed™ implants (lengths: 11, 13, 15 mm)
1861972|NCT01030575|Drug|Inositol lower volume|5 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
1861973|NCT01030575|Drug|Inositol mid-level volume|20 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
1861974|NCT01030575|Drug|Inositol high volume|40 mg/kg/dose inositol every 12 hours, given intravenously over 20 minutes
1861975|NCT01030575|Drug|Placebo low volume|Glucose 5% given in volumes equal to that of the comparator drug
1861976|NCT01030601|Drug|Dexamethasone sodium phosphate|0.5mg in 0.05cc of Dexamethasone from a 10mg/ml vial
1861979|NCT01030627|Device|Springfusor infusion pump|Women will receive a loading dose and maintenance therapy using an IV infusion administered by the Springfusor® pump. Women will receive a 8 mL loading dose containing 4g magnesium sulfate heptahydrate (MgSO4*7H2O) 50% solution, which is approximately 2 mmoL magnesium/mL. The loading dose of 8mL with 4 g MgSO4 will be administered using the Springfusor® pump. The administration of the loading dose will be immediately followed by a maintenance infusion. The maintenance dose of 4 g (8 cc, 50% MgSO4) will be administered with the Springfusor® pump continuously over four hours. The pump will be started immediately after the initial bolus and the 4g dose repeated (and syringe replaced) every four hours. Maintenance therapy will be administered for at least 24h. Treatment will be discontinued when clinically indicated. Drug administration will be initiated at the sites and, when necessary, the patient will be transferred, with the Springfusor pump in situ, to the local referral site.
1861980|NCT01030640|Other|placebo|single dose of the drug formulation
1861981|NCT01030640|Biological|tanezumab|single dose of the active drug tanezumab at a dose level of 20 mg
1861982|NCT01030653|Drug|Voriconazole low dose|Voriconazole 400 mg po x 2 doses (loading dose)then 200 mg po twice daily x 7 doses
1861983|NCT01030653|Drug|Voriconazole high dose|Voriconazole 400 mg po x 2 doses (loading dose)then 300 mg po twice daily x 7 doses
1861984|NCT01030666|Drug|Doxycycline|The patients of the doxycycline group will take 200 mg doxycycline once a day for 7 days after regenerative therapy of an infrabony defects.
1861985|NCT01030666|Drug|Placebo|The patients of the doxycycline group will take 200 mg placebo once a day for 7 days after regenerative therapy of an infrabony defects.
1861986|NCT01030666|Procedure|modified/simplified papilla preservation flap; scaling|Following an intra-crevicular incision a mucoperiosteal flap was reflected to a height of 5 mm exposing the bony margin of the defect and allowing complete visualization of the infrabony lesion. The flap was designed according to the modified or simplified papilla preservation technique to obtain primary closure of the wound and the membrane respectively. The flap was extended at least one tooth mesially and distally of the defect side. After complete removal of inflammatory granulation tissue, the root surfaces were thoroughly scaled and root planed.
1861987|NCT01030666|Biological|Prefgel/Emdogain|When using EMD the root surfaces facing the infrabony defect were conditioned with EDTA (prefgel; Institut Straumann AG, Basel, Switzerland) for 2 min. first. Then the EDTA was washed out with plenty of saline. After drying the surfaces EMD was applied starting at the bottom of the defect and proceeding coronally.
1861989|NCT01030666|Drug|Ibuprofen 400 mg (if necessary)|400 mg ibuprofen qd was prescribed for patient's comfort if necessary.
1861990|NCT01030666|Drug|1% chlorhexidine gluconate gel (if necessary)|If soft tissue dehiscence was noted the patient was advised to use a 1% chlorhexidine gluconate gel (Chlorhexamed 1% Gel; GlaxoSmithKline, Bühl, Germany) twice daily
1861991|NCT01030679|Drug|CKD-501 0.5mg|0.5 mg/tablet, orally, 1 tablet once daily for 8 weeks
1861992|NCT01030679|Drug|CKD-501 1mg|1 mg/tablet, orally, 1 tablet once daily for 8 weeks
1861993|NCT01030679|Drug|CKD-501 2mg|2 mg/tablet, orally, 1 tablet once daily for 8 weeks
1861994|NCT01030679|Drug|Placebo|orally, 1 tablet once daily for 8 weeks
1861995|NCT01030692|Drug|Placebo|The placebo groups will receive the same dosage throughout the study.
1861996|NCT01030692|Drug|Rivastigmine 3 mg|The 3 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-9, and 3 mg in the morning of Day 10.
1861997|NCT01030692|Drug|Huperzine A 0.4 mg|The 0.4 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-9, and 0.2 mg in the morning of day 10.
1861998|NCT01030692|Drug|Rivastigmine 6 mg|The 6 mg rivastigmine group will receive 3 mg rivastigmine only in the evening of Day 1, 3 mg in the morning and 0 mg in the evening of Days 2-5, 3 mg in the morning and evening of Days 6-9, and 3 mg in the morning of Day 10.
1861999|NCT01030692|Drug|Huperzine A 0.8 mg|The 0.8 mg HupA group will receive 0.2 mg HupA only in the evening of Day 1, 0.2 mg in the morning and evening of Days 2-5, 0.4 mg in the morning and evening of Days 6-9, and 0.4 mg in the morning of Day 10.
1862000|NCT01030718|Drug|dasatinib|Tablet, Oral, (50mg, 70mg or 90mg BID on a continuous daily dosing schedule), allowed to modify within the range of 50 mg twice daily (BID) to 90 mg BID
1862001|NCT01030731|Drug|Ceftobiprole|Ceftobiprole 250mg single dose over 2 hours.
1862002|NCT01030757|Radiation|Tomotherapy treatment|"A total of 60 Gy using 12 Gy per fraction over 5 fractions to be given within 10 calendar days
Each fraction of 12 Gy will be divided into 2 fractions of 6 Gy given in one day within 6 hours
Dose will be prescribed to the isodose line which covers at least 90% of the PTV
Dose homogeneity +/- 5%"
1862003|NCT01030770|Drug|Ranibizumab|Single intravitreal injection of 500 micrograms of ranibizumab (0.05mls).
1862004|NCT01030770|Drug|0.9% Sodium Chloride|Single subconjunctival injection of 0.05mls of 0.9% w/v sodium chloride
1862005|NCT01030783|Drug|tivozanib (AV-951)|Tivozanib: 1.5 mg orally once daily. Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
1862006|NCT01030783|Drug|Sorafenib|Sorafenib: 400 mg orally twice daily. Subjects will receive 400 mg (2 x 200 mg tablets) sorafenib twice daily continuously, beginning on Day 1. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
1862007|NCT01030796|Behavioral|Caffeine abstinence|Brief instruction on beginning and maintaining caffeine abstinence.
1862008|NCT01030809|Other|Treatment Algorithm for Crohn's Disease|Practitioners assigned to the intervention arm will be educated on the use of the treatment algorithm.
1862009|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, administered as a single dose
1862010|NCT01030822|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 3 doses
1862012|NCT01030861|Drug|Teplizumab|intravenous infusions
1862013|NCT01030874|Other|Medication review|Current scheduled and as needed medications will be reviewed. Those medications with potentially hypotensive actions will be identified. There will be a joint review by Provider, Pharmacist, and Research staff of those medications and the patient's current clinical status. Plan to continue, decrease, discontinue, or substitute will be made. Examples include substitution of tamsulosin for prazosin in treating benign prostatic hypertrophy, reduction of furosemide dose for patient with stable congestive heart failure, change of sleeping medication from trazodone to lorazepam or zolpidem; change of antidepressant therapy or neuroleptic therapy to one with less hypotensive effects.(Mader 1989); (Poon and Braun 2005);(Mader 2006); (2008).
1862014|NCT01030874|Dietary Supplement|Nutrition/Salt intake|Current diet orders and meal consumption will be reviewed for sodium and fluid intake. Liberalization of calories, fluid, addition of salt packets to tray, or addition of salty foods/beverages (V8) will be considered as appropriate. Subjects receiving tube feedings will have water flushes replaced with saline flushes. Subjects with a history of congestive heart failure will be liberalized slowly and monitored closely by both the research and treatment team.
1862015|NCT01030874|Other|Education|The research intervention staff will review symptoms of OH with patient/family and explain pathophysiology using a standardized pt information handout (NINDS 2007), subjects will be encouraged to spend maximal time out of bed, and to ambulate on ward as much as possible.
1862016|NCT01030874|Other|Exercise|The patient's PT and/or Provider will review patient function for the ability to perform appropriate exercises and train patients (Ten Harkel, van Lieshout et al. 1994); (Bouvette, McPhee et al. 1996). Research staff will reinforce using these exercises while standing.
1862017|NCT01030874|Drug|Drug|Fludrocortisone may be given 0.05mg at bedtime up to 0.2mg twice a day (Ten Harkel, Van Lieshout et al. 1992). Subjects with a history of congestive heart failure or peripheral edema will be carefully monitored. Sodium chloride tablets may be given starting at 1gm daily and increased to 2 gms twice daily [Mukai 2002; Grubb 2003]. Subjects with a history of congestive heart failure or peripheral edema will be carefully reviewed and monitored closely by the research staff and the treatment team. Midodrine may be given 2.5-5mg daily to three times daily [Low, 1997]. The dose will be started at 2.5mg every morning and then increased to 5mg every morning, then 5mg every morning and afternoon, then 5mg three times a day.
1862018|NCT01030887|Behavioral|Exercise programme|Moderate intensity exercise
1862022|NCT01030926|Drug|insulin degludec|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
1862023|NCT01030926|Drug|insulin glargine|0.4 U/kg body weight injected subcutaneously (under the skin), single dose
1862024|NCT01030939|Drug|SB-649868|In each of all cohorts, 18 subjects will be randomised in a 2:1 ratio to receive either SB-649868 or placebo
1862026|NCT01030952|Drug|Acarbose|Acarbose tablets, oral administration, three times daily, dosage of 50 mg orally chewing with the first bite of a meal three times daily.
1862027|NCT01030965|Drug|GSK573719 125mcg|125mcg once-daily
1862028|NCT01030965|Drug|GSK573719 250mcg|250mcg once-daily
1862029|NCT01030965|Drug|GSK573719 500mcg|500mcg once-daily
1862030|NCT01030965|Drug|Placebo|once-daily
1862031|NCT01030978|Behavioral|Bright Bodies Healthy Lifestyle Program|Subjects attend program with a caregiver or parent twice per week for 6 mos. Exercise is 2x/wk, behavior mod/nutrition 1 x/wk, and parent class 1 x/wk. Smart Moves curriculum is utilized for nutrition and behavior mod.
1862032|NCT01030978|Behavioral|Control|Subjects will be given basic instruction by clinical provider and goals will be followed up every 3 months.
1862033|NCT01031004|Device|narafilcon B|contact lens
1862034|NCT01031004|Device|etafilcon A|contact lens
1862035|NCT01031017|Drug|progesterone|ovules, 200mg per vagina, once a day from 18 weeks
1862036|NCT01031017|Drug|placebo|placebo
1862037|NCT01031030|Drug|cyclophosphamide|
1862038|NCT01031030|Drug|epirubicin hydrochloride|
1862039|NCT01031030|Drug|fluorouracil|
1862040|NCT01031030|Drug|methotrexate|
1862041|NCT01031030|Other|laboratory biomarker analysis|
1862042|NCT01031030|Procedure|adjuvant therapy|
1862043|NCT01031043|Drug|Bethanechol|Taking part in this research study is voluntary. Patient may choose not to take part in this research study or may withdraw consent at any time. Their choice will not at any time affect the commitment of the health care providers to administer care. If the patient decides not to participate or withdraw from the study there will be no penalty or loss of benefits to which they are otherwise entitled.
1862044|NCT01031056|Procedure|Blood Draw|
1862045|NCT01031056|Procedure|Frozen Tumor Specimens|
1991123|NCT01495988|Drug|Vemurafenib|Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients until disease progression, intolerable toxicity, patient request for discontinuation, or study termination by the sponsor.
1991124|NCT01495988|Drug|Bevacizumab|Patients assigned to the combination arm will also receive bevacizumab at 15mg/kg, intravenously, every 3 weeks.
1862048|NCT01031082|Procedure|Middle ear fluid, nasopharyngeal aspirate and urine sample.|Middle ear fluid, nasopharyngeal aspirate and urine sample collection.
1862049|NCT01031095|Other|coronary intervention|elective coronary intervention
1862050|NCT01031108|Drug|Placebo|"For the placebo product, SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
Eight placebo capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion."
1862051|NCT01031108|Drug|SRT2104|SRT2104 investigational product is a size 00 Swedish Orange opaque hard gelatin capsule containing 0.25 g of SRT2104, a new chemical entity which is supplied as a micronized, yellowish/amber powder. Eight SRT2104 capsules are stored in a dosing bottle and provided to all participating subjects for oral ingestion.
1862052|NCT01031134|Behavioral|Shared Decision Making|Shared decision-making, in contrast to traditional medical decision-making, involves a collaborative process where patients discuss personal values and preferences and clinicians provide information to arrive at an agreed upon treatment decision. The focus of the intervention is to empower elderly depressed primary care patients and help them efficiently arrive at a treatment decision that can be successfully implemented.
1862053|NCT01031134|Other|Usual Care|Usual Care reflects the standard of care in primary care practice: following physician recommendation for treatment. Physicians will recommend some form of depression treatment. This may take the form of an antidepressant prescription or psychotherapy referral. The physician will encourage patients to telephone with any questions. Following the treatment recommendation provided to the patient, the physician will provide care as usual.
1862054|NCT01031147|Other|Examination|3D−TOF−MRA was performed for suspected patients to detect intracranial aneurysm, and subsequently underwent digital subtraction angiography
1862055|NCT01031173|Biological|agalsidase alfa|0.2 mg/kg body weight, administered by an intravenous infusion over 40 minutes, every other week.
1862056|NCT01031186|Drug|GSK356278|GSK356278
1862057|NCT01031186|Drug|PLACEBO|PLACEBO
1862058|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|MS/CIS patients: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
1862059|NCT01031199|Drug|F-18 FEDAA1106 (BAY85-8101)|Healthy controls: Single intravenous bolus of 140 MBq BAY85-8101 ± 15% (ca. 5 mSv), applied mass of tracer < 5 µg, PET
1862060|NCT01031212|Drug|ASA404|Administered intravenously over 20 minutes weekly after chemotherapy
1862061|NCT01031212|Drug|Cetuximab|Administered at 400mg/m2 over 120 minutes on day -7 and then 250mg/m2 over 60 minutes weekly thereafter
1862062|NCT01031212|Drug|Carboplatin|Administered at fixed dose of AUC 6 intravenously on day 1 of each 3-week cycle
1862063|NCT01031212|Drug|Paclitaxel|Administered over 3 hours at a fixed dose of 175mg/m2 intravenously on day 1 of each 3-week cycle
1862064|NCT01031225|Drug|STA 9090|STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
1862065|NCT01031290|Device|Repetitive Transcranial Magnetic Stimulation|daily sessions for 5 days
1862066|NCT01031303|Biological|DTacP-IPV combined vaccine (TETRAXIM™)|0.5 mL, Intramuscular
1862067|NCT01031316|Other|Nondisclosure of screening echocardiogram results|Subjects will be randomized to nondisclosure of screening echocardiogram results.
1862068|NCT01031316|Other|Disclosure of screening echocardiogram results|Subjects will be randomized to disclosure of screening echocardiogram results.
1862069|NCT01031329|Procedure|Tympanocenthesis and urine collection|Fluid using needle aspiration is obtained from middle ear fluid. Urine is collected using a urine bag.
1862070|NCT01031342|Procedure|Early colonoscopy|Colonoscopy within 12 hours of presentation
1862071|NCT01031342|Procedure|Elective colonoscopy|Colonoscopy 36-60 hours after presentation
1862072|NCT01031355|Drug|Estradiol Valerate (EV) / Levomefolate Calcium (BAY98-7078)|Oral, single dose, 3 mg EV + 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
1862073|NCT01031355|Drug|Estradiol Valerate (EV) (BAY86-4980)|Oral, single dose, 3 mg EV, washout phase between treatments: at least 7 days
1862074|NCT01031355|Drug|Levomefolate Calcium (BAY86-7660)|Oral, single dose, 0.451 mg levomefolate calcium, washout phase between treatments: at least 7 days
1862075|NCT01031368|Drug|cytarabine|Given IV
1862076|NCT01031368|Drug|clofarabine|Given IV
1862077|NCT01031368|Drug|filgrastim|Given SC
1862078|NCT01031368|Procedure|ex vivo-expanded cord blood progenitor cell infusion|Undergo ex vivo-expanded cord blood progenitor cell infusion
1862079|NCT01031368|Other|laboratory biomarker analysis|Correlative studies
1862080|NCT01031381|Drug|RAD001|RAD001 10mg is taken orally (by mouth) once daily on a continuous basis. RAD001 is provided in tablet form and should be taken with a big glass of water on an empty stomach or after a low-fat meal.
1862081|NCT01031381|Drug|bevacizumab|bevacizumab will be administered intravenously (IV) once every 14 days.
1862082|NCT01031394|Other|Frequency of Aerobic/Resistance Training - 3 to 3|comparing group results based upon frequency of exercise
1862083|NCT01031420|Drug|single arm dose dense MVAC|standard doses of methotrexate, vinblastine, adriamycin, and cisplatin given every 14 days.
1862084|NCT01031446|Drug|cisplatin|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
1862085|NCT01031446|Drug|everolimus|Taken daily by mouth.
1862086|NCT01031446|Drug|paclitaxel|Given through a vein in the arm 1 time a week for 3 weeks, then a one week break and then begin the process again.
1862087|NCT01031446|Other|laboratory biomarker analysis|Blood collection
1862088|NCT01031459|Drug|Betaseron (Interferon beta-1b, BAY86-5046)|Telephone survey of all patients.
1862089|NCT01031472|Drug|GSK2248761 formulation 1|100mg GSK2248761 formulation 1- fasted 100mg GSK2248761 formulation 1 - with food (moderate fat meal)
1862090|NCT01031472|Drug|GSK2248761 reference formulation|GSK2248761 100mg Gelucire reference capsule with food
1862091|NCT01031472|Drug|GSK2248761 formulation 3|100mg GSK2248761 formulation 3 fasted 100mg GSK2248761 formulation 3 with food (moderate fat meal)
1862092|NCT01031472|Drug|GSK2248761 formulation 2 or 4|100mg GSK2248761 formulation 2 or 4 - fasted 100mg GSK2248761 formulation 2 or 4 - with food (moderate fat meal)
1862093|NCT01031485|Dietary Supplement|Milk peptides and plant sterols|
1862094|NCT01031485|Other|Placebo|
1862095|NCT01031498|Drug|Ondansetron|8 mg IV as bolus followed by 24 mg IV from 30 minutes before chemotherapy until 12 hours after chemotherapy ends.
1862096|NCT01031498|Drug|Palonosetron|"Palonosetron Group 1: 0.25 mg IV bolus over 30 seconds daily for 5 days, 30 minutes before cytarabine chemotherapy.
Palonosetron Group 2: 0.25 mg IV bolus over 30 seconds on Days 1, 3, and 5 of cytarabine chemotherapy, 30 minutes before chemotherapy."
1991125|NCT01495988|Drug|Cobimetinib|Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle.
1862099|NCT01031524|Biological|PfCS102|Antigen of the sporozoite protein
1862100|NCT01031524|Biological|Montanide ISA 720|adjuvant alone
1862101|NCT01031537|Biological|FSME-IMMUN 0.5ml Baxter|Vaccine
1862102|NCT01031550|Drug|isoflurane|isoflurane an anesthetic gas agent administered at specific times at a flow of 2 MAC
1862103|NCT01031550|Drug|propofol|standard of care
1862104|NCT01031589|Drug|TMC278 (Rilpivirine) LA; Placebo|
1862105|NCT01031602|Behavioral|Surveys|Surveys -- Female Sexual Function Index (FSFI), the Hospital Anxiety and Depression Scale (HADS), and a demographic questionnaire completed at time of clinic appointment, taking about 20 minutes.
1862106|NCT01031615|Behavioral|Child and Family Traumatic Stress Interv (CFTSI)|4 sessions involving both the target child and a parent/caregiver
1862107|NCT01031615|Behavioral|Psychoeducational Comparison|4 individually focused sessions including psychoeducation and relaxation.
1862108|NCT01031628|Drug|Imatinib mesylate|400 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
1862109|NCT01031628|Drug|Imatinib mesylate|600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
1862110|NCT01031628|Drug|Imatinib mesylate|400, 600 or 800 mg daily. Number of cycles: until disease progression or unacceptable toxicity develops
1862111|NCT01031667|Drug|Cilostazol, Probucol / placebo of probucol|An investigator-initiated, placebo-controlled, randomized, multi-center study. Enrolled patients will be randomized after PCI either to the combination therapy group or to the control group. In the combination therapy group, cilostazol 200 mg and probucol 500 mg will be administered daily, whereas the control group will receive cilostazol 200 mg daily only.
1862112|NCT01031680|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
1862113|NCT01031680|Drug|Placebo|Matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
1862114|NCT01031693|Device|Transcranial Magnetic Stimulation|daily sessions for 5 days
1862115|NCT01031706|Drug|Hypertonic Saline|inhaled HS (6% NaCl, 4mL) three times a day for 28 days
1862116|NCT01031706|Drug|Placebo|4 ml 0.12% NaCl inhaled three times a day x 28 days
1862117|NCT01031719|Biological|adjuvanted A(H1N1) influenza vaccine|7.5 ug of HA antigen; adjuvanted; monovalent
1862118|NCT01031719|Biological|non-adjuvanted A(H1N1) influenza vaccine|15ug of HA antigen, non-adjuvanted; trivalent
1862119|NCT01031719|Biological|non-adjuvanted A(H1N1) influenza vaccine|15 mcg of antigen; non-adjuvanted; trivalent
1862120|NCT01031732|Procedure|MIS-2 THA|MIS two-incision THA
1862121|NCT01031732|Procedure|MIS-WJ|MIS-Watson Jones THA
1862122|NCT01031732|Procedure|MIS-AL THA|Transgluteal approach
1862123|NCT01031732|Procedure|MIS-PL THA|Posterolateral approach
1862124|NCT01031745|Behavioral|Contingency|Participants are provided a non-monetary incentive for achieving particular tasks between study visits. Tasks include initiation of HAART, timely refill of medications from the government ART centers, suppression of HIV RNA
1862125|NCT01031745|Other|Prize bowl drawings|"Control participants receive counseling and referral, but no incentives for engagement in HIV care. At study visits they are eligible to receive bonuses through prizebowl drawings to offset the inability to earn incentives."
1862206|NCT01032343|Dietary Supplement|Omega-3 PUFA|One capsule (4g omega-3 PUFA) daily for 3 months
1862126|NCT01031758|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
1862127|NCT01031784|Device|holmium-166 poly lactic acid microspheres|Intra arterial administration of radioactive Holmium 166 microspheres; 600 mg with a specific activity ranging from 1260 MBq per kilo liver weight to 5040 MBq in the highest dose
1862128|NCT01031784|Device|holmium 166 microspheres|intra arterial administration of holmium 166 microsphers in the hepatic artery
1862129|NCT01031810|Drug|tranylcypromine|MAO-Inhibitor 60mg-120mg
1862130|NCT01031823|Behavioral|Multi-Media Social Skills Training Program|All individuals will participate in a twelve week social skills training program designed to enhance the social skills of adolescents with Asperger's Disorder or high-functioning autism. The intervention is comprised of both group therapy and peer generalization.
1959868|NCT03312270|Behavioral|Multimodality information comprehension|Evaluate various aspects of multimodality presentation of materials through text-to-speech systems used by people with aphasia.
1862137|NCT01031849|Drug|Kaletra|Each tablet of Kaletra contains 200 mg of Lopinavir and 50mg of ritonavir. The patients will take two tablets of Kaletra bid.
1862138|NCT01031862|Other|3H-Cholesterol|A single dose of 25-50 μCi 3H free cholesterol -albumin complexes (containing approximately 0.1 - 0.3 mg of cholesterol) will be administered intravenously as a slow bolus injection within 1-2 minutes.
1862139|NCT01031875|Drug|pazopanib hydrochloride|
1862140|NCT01031875|Radiation|fludeoxyglucose F 18|
1862141|NCT01031888|Drug|Topical insulin eye drops|Regular insulin injection diluted to 100U/ml After the day of surgery, besides topical steroid, antibiotic and mydriatics, the patient receives topical insulin eye drops every two hours, except from 10pm to 8am, until the epithelial defect is totally closed
1862142|NCT01031888|Drug|Conventional postoperative eye drops|topical steroid, antibiotic and mydriatics
1862143|NCT01031901|Drug|Skincerity|Study subjects will apply a study product containing polyvinylidene fluoride coating alone to either facial angiofibromas or cutaneous neurofibromas
1862144|NCT01031901|Drug|Skincerity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 1 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
1862145|NCT01031901|Drug|Skinercity plus sirolimus/rapamycin|Study subjects will apply a study product containing polyvinylidene fluoride coating plus 5 mg of sirolimus/rapamycin to either facial angiofibromas or cutaneous neurofibromas
1862146|NCT01031914|Device|Paced Breathing|The Paced Breathing (PB) feature(when activated) will work to relax the user and help them fall asleep by encouraging them to take deep slow breaths until they reach 10 breaths (or less) per minute. The feature will also detect when the subject has fallen asleep so the Continuous Positive Airway Pressur (CPAP) device will automatically switch from PB mode to regular CPAP mode.
1862147|NCT01031927|Drug|N-methyl glycine|staring from 500mg/day, increased by 500mg biweekly, up to maximin of 2000mg/day
1862148|NCT01031940|Device|macintosh laryngoscope|intubate with the macintosh laryngoscope
1862149|NCT01031940|Device|C-MAC laryngoscope|intubate with the C-MAC laryngoscope
1862150|NCT01031940|Device|Airtraq device|intubate with the Airtraq device
1862151|NCT01031953|Drug|fosaprepitant dimeglumine|A 150 mg dose will be given to study patients as rescue therapy after chemotherapy only in the event of breakthrough nausea or vomiting.
1862152|NCT01031953|Drug|systemic chemotherapy|Patients will receive chemotherapy on Day 1 of their scheduled therapeutic regimen in combination with the pre-defined standard 5-Hydroxytryptamine-3 (5HT3) antagonist, corticosteroid regimen, with or without benzodiazepine based on published guidelines3 or as clinically indicated
1862153|NCT01031953|Other|survey administration|Prior to the first dose of chemotherapy patients will be instructed on how to complete their patient diary
1862154|NCT01031953|Procedure|quality-of-life assessment|Patients will also be provided the Functional Living Index - Emesis (FLIE) quality of life survey to be completed at time zero and then after 24 hours
1862155|NCT01031966|Biological|MF59 adjuvanted H1N1 influenza monovalent vaccine|One/two single administration
1862156|NCT01031966|Drug|Thymosin alpha 1|1.6 mg, 3.2 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
1862157|NCT01031966|Drug|Thymosin alpha 1|1.6 mg, 6.4 mg seven days before vaccination (study day -7) and at the same day of vaccination (study day 0)
1862158|NCT01031979|Drug|Yohimbine|alpha-2 adrenergic receptor antagonist
1862159|NCT01031979|Drug|Placebo|Placebo
1862160|NCT01031992|Drug|Tranexamic acid first, than placebo|For 3 months Tranexamic acid 3 times daily 1 g taken orally, followed by placebo for 3 months.
1862161|NCT01031992|Drug|First placebo, than Tranexamic acid.|First placebo for 3 months, than tranexamic acid 3 times daily 1 g for 3 months.
1862162|NCT01032005|Other|double fortified salt|Refined salt of particle size < 1 mm iodized with potassium iodate (KIO3) at a concentration of 30 µg I/g salt at the factory will be purchased and blended with encapsulated Ferrous Fumarate premix containing 15% iron. Premix to salt ratio of 1 to 150 will be used to arrive at 1000 ppm elemental iron in the final product.
1862207|NCT01032343|Dietary Supplement|Gelatine|One capsule daily for 3 months
1862593|NCT01043354|Behavioral|stage-matched intervention|6 monthly tailored telephone-delivered counseling sessions of transtheoretical model-based counseling
1862163|NCT01032018|Behavioral|Problem Solving Therapy|Problem Solving Therapy (PST) will be administered by a trained provider. The concepts of PST will be taught to the participant in the first session and reinforced across subsequent sessions. Sessions will last between 30 and 60 minutes each and continue weekly for the duration of the study (6 months).
1862164|NCT01032018|Drug|Sertraline, citalopram, or bupropion|"Antidepressants should be started at the lowest dose, but should be adjusted upward to be within the therapeutic range within 1 week,with further adjustment higher in the therapeutic range possible at 3-4 weeks. Dosage of the first medication selected will be in the therapeutic range by 3 weeks of the initial step, as tolerated. If a patient cannot tolerate a particular treatment (i.e., intolerable side effects even with careful titration and clinical management), a switch to an alternative antidepressant or PST-PC after 2-4 weeks and 'restart' step 1.
Sertraline: 25-150qam Citalopram: 10-40qam Bupropion: 100-450qam"
1862165|NCT01032018|Other|Standard care|Participants will receive standard of care from the current physicians
1862166|NCT01032031|Dietary Supplement|Green tea + vitamin C high dose|One green tea capsule (1250mg catechin) and one vitamin C tablet (100mg) daily for 3 months
1862167|NCT01032031|Dietary Supplement|Placebo capsule|One capsule daily for 3 months
1862168|NCT01032044|Device|Standard endoscopic evaluation|Treatment modalities can include endoscopic mucosal resection, radio-frequency ablation or photodynamic therapy
1862169|NCT01032044|Device|pCLE guided evaluation|Treatment modalities include endoscopic mucosal resection, radio-frequency ablation, or photodynamic therapy. probe-based Confocal Laser Endomicroscopy is used to decide on re-treatment or not, and to guide and evaluate the treatment during the same endoscopic procedure.
1862170|NCT01032057|Drug|capecitabine|
1862171|NCT01032057|Drug|gemcitabine hydrochloride|
1862172|NCT01032057|Procedure|quality-of-life assessment|
1862173|NCT01032057|Radiation|3-dimensional conformal radiation therapy|
1862174|NCT01032070|Drug|erlotinib|oral
1862175|NCT01032070|Drug|etoposide|oral
1862176|NCT01032083|Drug|Citalopram|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
1862177|NCT01032083|Drug|Placebo|Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.
1862178|NCT01032109|Drug|Bevacizumab|A single intravitreal injection of 1.25 mg of bevacizumab (0.05 mL of solution prepared from Avastin, 100 mg/4 mL vial) was performed within 2 weeks after PDT treatment.
1862179|NCT01032122|Drug|rituximab|induction phase: 375mg/m² qw, 4wks; followed by maintenance phase: 375mg/m², every 8 wks; duration: 2 years.
1862180|NCT01032135|Behavioral|Motivational Interviewing|2 sessions at week 2, potential 2 sessions at week 8 if the participant drops out.
1862181|NCT01032135|Behavioral|Telephone counseling|one telephone counseling session per week for 10 weeks.
1862182|NCT01032135|Behavioral|Cognitive Behavioral Therapy (CBT) Counseling|One CBT session per week, for 10 weeks.
1862183|NCT01032135|Drug|medication management|Prescription for naltrexone
1862184|NCT01032135|Behavioral|Intensive OutPatient Therapy|Return to IOP, group therapy 3 times weekly for about three hours a day.
1862185|NCT01032148|Drug|LBH589|LBH589 will be administered orally as once daily dose of 20 mg po q M, W, F on a q28 day cycle.
1862186|NCT01032174|Drug|Azithromycin SR|Azithromycin SR, 2.0 g by mouth (PO) x 1
1862187|NCT01032174|Drug|Amoxiclav 1000 mg|Amoxiclav 1000 mg x twice daily, 10 days
1862188|NCT01032187|Drug|Meglumine antimoniate|20mg/kg/day IV for 20 days
1862189|NCT01032187|Drug|Amphotericin B-deoxycholate|Amphotericin B-deoxycholate 1 mg/kg/day IV for 14 days
1862190|NCT01032200|Drug|Armodafinil|Given orally
1862191|NCT01032200|Other|placebo|Given orally
1862192|NCT01032213|Drug|Magnesium Sulfate|Group M received 50 mg/kg of magnesium sulphate on 100 ml of isotonic saline over 10 minutes during the anesthesia induction, followed by the 15 mg/kg/h by continuous infusion during the operation
1862193|NCT01032213|Drug|normal saline|Group S received the same volume of isotonic saline as same method.
1959869|NCT03312257|Combination Product|Multifocal D +2.50 add & 0.01% atropine|Biofinity Multifocal D +2.50 add is a monthly disposable contact lens commercially available from CooperVision; 0.01% atropine is low-dose atropine compounded by local pharmacy.
1862195|NCT01032252|Other|Exercise intervention|"16 week exercise once a week of 60 minutes intervention by trained fall prevention instructors and a home program.
Intervention includes strength/power training, balance/gait training, behavioral aspects and perceptual and functional training."
1862196|NCT01032265|Behavioral|Web-based treatment with PFMT and elements of CBT|125 women with stress urinary incontinence(SUI) participate in web-based treatment for 3 months. Treatment consists of information, PFMT and uses elements of CBT. It includes regular email contact with urotherapist.
1862197|NCT01032265|Behavioral|Pamphlet treatment|125 women with SUI receive a pamphlet with information and a programme for PFMT.
1862198|NCT01032278|Other|Laboratory Biomarker Analysis|Blood drawn for biomarker analysis at baseline, before each chemotherapy visit, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
1862199|NCT01032278|Behavioral|Questionnaires|Symptom questionnaire completion at baseline, beginning of every third cycle of chemotherapy, 6 months after starting chemotherapy, and 12 months after completion of chemotherapy.
1862200|NCT01032291|Drug|cetuximab|Intravenous infusions of cetuximab (400 mg/m^2 Cycle 1 Day 1, thereafter 250 mg/m^2), administered on days 1, 8, 15 and 22 of each 28 day cycle.
1862201|NCT01032291|Drug|lenalidomide|Daily oral lenalidomide 25mg on days 1 to 28 of each 28 day cycle
1959870|NCT03312244|Drug|Pyridostigmine Bromide|Pyridostigmine 90mg/day p.o.
1959871|NCT03312244|Drug|Placebo|Placebo
1862204|NCT01032317|Device|Radiofrequency Catheter Ablation|The Biosense Webster EZ Steer ThermoCool NAV Diagnostic / Ablation Deflectable Tip Catheter with Contact Force Sensing Capability is designed to facilitate electrophysiological mapping and transmit radiofrequency current as well as provide a real-time measurement of contact force.
1959872|NCT03312231|Drug|AS03|Oil-in-water emulsion based adjuvant system
1864569|NCT01057667|Drug|peginterferon alfa-2a [Pegasys]|180mcg sc weekly
1862208|NCT01032356|Device|Wrist Extension Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
1862209|NCT01032369|Other|Nutritional intervention and physical activity|"Nutritional intervention:
Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.
Physical activity:
All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking)."
1862210|NCT01032369|Other|Nutritional intervention, physical activity and behavioral treatment|"Nutritional intervention:
Subjects will be asked to attend weekly nutritional group's sessions and individual meetings with the dietician for nutritional treatment and follow up.
Physical activity:
All participants will be engaged in physical activity comprising 45-60 min training sessions 3 times a week (gym or walking).
Behavioral treatment:
This group will undergo behavioral treatment focusing on self control techniques using the CBT technique (cognitive behavioral therapy) which will be conducted by a clinical psychologist from ONIM in weekly group sessions."
1862211|NCT01032382|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
1862212|NCT01032382|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
1862213|NCT01032395|Biological|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
1862214|NCT01032395|Biological|Fluad®|15 ug of HA antigen; adjuvanted; trivalent
1862215|NCT01032395|Biological|Begrivac®|15 ug of antigen; non-adjuvanted; trivalent
1862216|NCT01032408|Biological|Focetria®|7.5 ug of HA antigen; adjuvanted; monovalent
1862217|NCT01032408|Biological|Begrivac®|15 ug of HA antigen; non-adjuvanted; trivalent
1862218|NCT01032421|Procedure|IVF procedure|
1862219|NCT01032434|Drug|sertraline|sertraline: 50-200mg/day
1862220|NCT01032447|Behavioral|Navigator Support|Standard of Care
1862221|NCT01032460|Device|intubate with the macintosh laryngoscope|intubate with the macintosh laryngoscope
1862222|NCT01032460|Device|intubate with the C-MAC laryngoscope|intubate with the C-MAC laryngoscope
1862223|NCT01032460|Device|intubate with the Airtraq device|intubate with the Airtraq device
1862224|NCT01032486|Drug|Rasagiline mesylate|Azilect® tablets (0.5mg or 1.0 mg) administered orally once daily
1862225|NCT01032499|Drug|oxytetracycline, taro elixir|comparison of treatment efficacy between oxytetracycline and taro elixir
1862226|NCT01032499|Drug|Taro Elixir|Taken orally one tablespoon (15 mL) of Taro Elixir 3 times daily for breakfast, lunch and dinner.
1862227|NCT01032512|Dietary Supplement|SUPPORTAN + GLUTAMINE PLUS|600 ML OF AN ENERGY DENSE DRINK PLUS 20 G GLUTAMINE POWDER (to give 900 Kcal and 80 g protein/day)
1862228|NCT01032512|Dietary Supplement|NO PREOPERATIVE NUTRITION SUPPORT|Patients will be assessed and followed, but will receive no special nutritional support before the surgical procedure
1862229|NCT01032551|Behavioral|Vascular Access Decision Aid|The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
1862230|NCT01032564|Other|The elastography (elasticity imagery)|This diagnosis mean use the ultrasonography to measure the tissues answer under pressure
1862231|NCT01032590|Behavioral|Internet weight loss intervention|Participants will be advised to login to the website twice a week during the intervention period. They will be prompted to report their weight, to review and update their reasons for weight loss, to indicate their success with implementing each of their weight loss strategies, to rate the perceived effectiveness of each weight loss strategy,and to revise or create new strategies, as needed.
1862232|NCT01032603|Procedure|Bilateral lateral rectus recession (BLRrec)|Bilateral lateral rectus recession surgery
1862233|NCT01032603|Procedure|Unilateral lateral rectus recession with medial rectus resection (R&R)|A unilateral lateral rectus recession combined with a medial rectus resection in the same eye. Choice of eye at investigator discretion based on any interocular difference, position under anesthesia, fixation preference, or forced duction testing. Reason for choice of eye will be recorded.
1862234|NCT01032616|Other|Threonine Experimental: Study Period 1|Enteral and parenteral infusion of threonine isotope
1862235|NCT01032616|Other|Lysine Experimental: Study Period 2|Both intravenous (iv) and intragastric (ig) Lysine isotopes.
1862236|NCT01032629|Drug|Placebo|One placebo capsule taken orally (by mouth) once daily
1862237|NCT01032629|Drug|Canagliflozin (JNJ-28431754) 100 mg|One 100 mg capsule taken orally (by mouth) once daily
1862238|NCT01032629|Drug|Canagliflozin (JNJ-28431754) 300 mg|One 300 mg capsule taken orally (by mouth) once daily
1862239|NCT01032642|Device|device for hysterosalpingography|a thin catheter originally designed for IUI (sperm processor cat. No. SP/PL/01, Aurangabad, India) connected to a 10 mL syringe filled with urographin 76% (Scherring, Germany) will be introduced through the cervical canal into the lower part of the uterine cavity. After introducing the catheter, the screw of the vaginal speculum will be loosened to allow the two valves of the speculum to press on the portiovaginalis of the cervix to prevent leakage of the dye. Then the dye will be injected slowly and the procedure will be watched on the screen and x-ray films will be taken.
1862240|NCT01032655|Drug|susceptibility test guided sequential therapy|"susceptibility test driven sequential therapy D1- D7 Nexium ,40mg, bid Amolin, 1gm bid D8-14 Nexium ,, 40mg, bid Flagyl, 500mg, bid
plus either one of the following
Klaricid, 500 mg, bid
Cravit, 250 mg, bid
Tetracycline, 500 mg, bid"
1862241|NCT01032668|Drug|Clopidogrel|high dose clopidogrel continuing after percutaneous coronary intervention
1862242|NCT01032681|Biological|EMD 521873|"Dose escalation steps:
Group 1: 0,075mg/kg - 0,15mg/kg - 0,225mg/kg - 0,3mg/kg - 0,45mg/kg - 0,6mg/kg - 0,9mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)
Disease control and decision of continuation in patient who benefit from the treatment:
Every second cycle"
1862243|NCT01032681|Biological|EMD 521873|"Dose escalation steps:
Group 2: CPA plus 0,6mg/kg - 0,9mg/kg
Disease control and decision of continuation in patient who benefit from the treatment:
Every second cycle"
1862244|NCT01032681|Biological|EMD 521873|"Dose escalation steps:
Group 3: 0,9mg/kg - 1,2mg/kg - 1,5mg/kg (-1,8mg/kg - 2,1mg/kg - 2,5mg/kg - 3,0mg/kg)
Disease control and decision of continuation in patient who benefit from the treatment:
Every second cycle"
1862245|NCT01032694|Drug|Azithromycin SR|Azithromycin SR, 2.0 g PO x 1 dose for treatment period
1862246|NCT01032694|Drug|Amoxiclav|Amoxiclav 1000 x twice daily, 10 days duration
1862247|NCT01032720|Procedure|Ultrasound|Ultrasound will be used to image knee joint and guide needle for intra-articular corticosteroid injection.
1862248|NCT01032720|Procedure|Sham ultrasound|Knee CS injection will be performed in the same method as the US-guided injection except that the US machine will be turned off. Study patient will be unaware of whether US machine is on or off.
1862249|NCT01032733|Behavioral|Lifestyle Counseling|In the WL+E group, participants attended a group-based weight management session plus three supervised exercise sessions each week.
1862250|NCT01032733|Other|Educational Control|Participants in the educational control group attended monthly health education lectures on topics unrelated to weight loss (e.g., skin protection).
1862251|NCT01032746|Other|educational intervention|
1862252|NCT01032746|Other|internet-based intervention|
1862253|NCT01032746|Procedure|evaluation of cancer risk factors|
1862254|NCT01032746|Procedure|fecal occult blood test|
1862255|NCT01032746|Procedure|screening colonoscopy|
1862256|NCT01032759|Drug|Memantine|20 mg, BID
1862257|NCT01032759|Drug|Placebo|BID
1862258|NCT01032772|Behavioral|Choices Plus|Participants in this condition will receive two brief, motivational-interviewing-based counseling sessions.
1862259|NCT01032772|Behavioral|Information|Participants are provided with informational materials about healthy lifestyle and local resources.
1862260|NCT01032785|Device|no interventions|no interventions
1862261|NCT01032798|Drug|mepivacaine|One intra-oral injection at four different sessions, of the following formulations: 2% mepivacaine with 1:100,000 epinephrine, 3% mepivacaine, 2% and 3% liposome-encapsulated mepivacaine.
1959873|NCT03312231|Biological|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
1959874|NCT03312218|Behavioral|Spaced educational intervention|A spaced educational intervention will be provided to participants
1959875|NCT03312205|Biological|Autologous CAR-T cells|Patients will be drawn 50-100 ml blood to obtain enough peripheral blood mononuclear cells (PBMC) for CAR-T manufacturing. The T cells will be purified from the PBMC, transduced with CAR lentiviral vector, expanded in vitro and then frozen for future administration. Chemotherapy will then be given. Following tumor burden reassessment, CAR-T cells will be infused.
1862265|NCT01032837|Drug|Oseltamivir|Oseltamivir capsules for participants ≥ 13 years.
1862266|NCT01032837|Drug|Oseltamivir|Pediatric suspension for participants aged ≤ 12 years.
1862267|NCT01032837|Drug|Placebo|Matching placebo provided as capsules and as a suspension.
1862268|NCT01032850|Drug|Sorafenib & Capecitabine|Intervention: Sorafenib twice a day by mouth (400mg), Capecitabine twice a day by mouth (850mg). One cycle of treatment will consist of capecitabine on days 1-7 and 15-22 while sorafenib will be given daily continuously. Cycles will be repeated every 28 days.
1862269|NCT01032876|Procedure|Deep Hypothermic Circulatory Arrest|DHCA will be employed for a maximum of 60 minutes. If more time (>60 min) is needed for the arch reconstruction the surgeon will proceed with ACP, which will be continued for the rest of the operation (= DHCA+ACP).
1862270|NCT01032876|Procedure|Antegrade Cerebral Perfusion|One cannula will be advanced into the brachiocephalic/ innominate artery via the usual arterial cannulation site in the aorta ascendens. A flow of 20-25% of the maximum CPB-flow will be used, which corresponds to a flow rate of 40-50 ml/ kg/ min.
1862271|NCT01032889|Drug|Deoxycholic acid injection|
1862272|NCT01032889|Drug|Placebo|Phosphate buffered saline placebo for injection
1862273|NCT01032902|Device|In Vitro Diagnostic Device|For the detection of antibodies to HIV in serum, plasma, blood and oral fluid
1862274|NCT01032915|Biological|AIN457|AIN457 300mg s.c weekly for 3 weeks then every 2 weeks
1862275|NCT01032915|Biological|AIN457|AIN457 300mg s.c at baseline and Week 2 then every 4 weeks
1862276|NCT01032915|Biological|AIN457|AIN457 150mg s.c at baseline and Week 2 then every 4 weeks
1862277|NCT01032915|Drug|Placebo|Placebo s.c weekly for 3 weeks then every 2 weeks
1862278|NCT01032928|Behavioral|Respiratory-Swallow Phase training|Patients were presented with visually guided respiratory feedback to train optimal respiratory-swallow coordination patterns.
1862279|NCT01032941|Drug|Probiotic|Patients in this group will be given the probiotic VSL#3 2 packets BID for a total of 8 weeks.
1959876|NCT03312192|Device|Interbody Cage|Anterior cervical discectomy and fusion with interbody cage placement
1862281|NCT01032967|Procedure|Esophagectomy|The patients will receive standard open esophagectomy with two-field lymphadenectomy
1862282|NCT01032967|Radiation|Definitive chemoradiation|3-weekly cycles of cisplatin and 5-fluorouracil chemotherapy and radical radiotherapy delivered in a three-dimensional conformal mode (total of 50-60 Gy given in 25-30 fractions) will be given over a period 5-6 weeks.
1862283|NCT01032993|Dietary Supplement|Coenzyme Q10|300 mg of CoQ10 (three 100 mg chewable tablets) 2 times daily for 4 weeks
1862284|NCT01032993|Other|Placebo|Placebo (three chewable tablets) 2 times daily for 4 weeks
1862285|NCT01033006|Procedure|Active Comparator: Arm 1: catheter injection|
1862286|NCT01033006|Procedure|Active Comparator: Arm 2: transarterial injection|
1862287|NCT01033006|Procedure|Active Comparator: Arm 3: catheter and transarterial injection|
1862288|NCT01033019|Drug|LDE225 0.75%|0.75% cream
1862289|NCT01033019|Drug|Vehicle|matching placebo cream to 0.75% LDE225 cream
1863057|NCT01047072|Radiation|total-body irradiation|Undergo total-body irradiation
1959877|NCT03312192|Device|Interbody Cage and Anterior Plating|Anterior cervical discectomy and fusion with interbody cage placement and anterior plating
1862290|NCT01033032|Drug|Amrubicin|"Phase I: dose escalating portion with the starting dose of amrubicin at 90mg/m2 IV q21 days. Dose escalations are as follows:
DL2 - 100mg/m2; DL3 - 110mg/m2; and DL4 - 120mg/m2. All cycles are q21 days
Phase II: Amrubicin will be administered at the maximum tolerated dose established in Phase I by IV every 21 days"
1862291|NCT01033058|Drug|atorvastatin|80mg atorvastatin immediately after enrollment, emergency PCI,atorvastatin 40mg/d and other usual medication after PCI
1862292|NCT01033058|Drug|atorvastatin|No loading dose of statin after enrollment, emergency PCI, atorvastatin 20mg/d and other usual medication after PCI
1862293|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to azilsartan medoxomil 40 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
1862294|NCT01033071|Drug|Azilsartan medoxomil and chlorthalidone|"Azilsartan medoxomil 40 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily and olmesartan and hydrochlorothiazide placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to azilsartan medoxomil 80 mg and chlorthalidone 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to azilsartan medoxomil 80 mg and chlorthalidone 25 mg combination tablets, orally, once daily for the next 4 weeks."
1862295|NCT01033071|Drug|Olmesartan medoxomil and hydrochlorothiazide|"Olmesartan medoxomil 20 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily and azilsartan medoxomil and chlorthalidone placebo-matching tablets, orally, once daily for up to 4 weeks.
Participants will be force titrated at Week 4 to olmesartan medoxomil 40 mg and hydrochlorothiazide 12.5 mg combination tablets, orally, once daily for the next 4 weeks.
Participants will then be force titrated at Week 8 to olmesartan medoxomil 40 mg and hydrochlorothiazide 25 mg combination tablets, orally, once daily for the next 4 weeks."
1862296|NCT01033084|Device|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively and two extra stimulations at week 4 and 6.
1862297|NCT01033084|Drug|Sertraline|Patient will receive sertraline 50mg/day.
1862298|NCT01033084|Other|double placebo|double placebo arm (sham stimulation/placebo pill)
1862299|NCT01033097|Drug|DNK333 5 mg|5 mg oral
1862300|NCT01033097|Drug|Placebo to 5 mg|5 mg placebo oral
1862301|NCT01033097|Drug|DNK333 25 mg|25 mg oral
1862302|NCT01033097|Drug|Placebo to 25 mg|25 mg placebo oral
1862303|NCT01033097|Drug|DNK333 100 mg|100 mg oral
1862304|NCT01033097|Drug|Placebo to 100 mg|100 mg placebo oral
1862305|NCT01033097|Drug|Betamethasone 4 mg|4 mg oral
1862306|NCT01033097|Drug|DNK333 1mg|1 mg oral
1862307|NCT01033097|Drug|Placebo to 1mg|1 mg placebo oral
1862308|NCT01033110|Behavioral|Exercise and Nutrition Education|Guided nordic walking training and 12 presentations about diet and health.
1862309|NCT01033123|Drug|BSI-201|IV infusion, 5.6 mg/kg
1862312|NCT01033149|Drug|N-acetylcysteine|N-acetylcysteine, flexible dose 1200-2400mg/day
1862313|NCT01033162|Behavioral|Enhanced ICCS with KPNW web resources and the Comprehensive Health Enhancement Support System (CHESS.)|"Half of the participating women will be randomly assigned to use an informative but static website (Basic ICCS), and half will be offered a fully interactive CHESS (Enhanced ICCS + the Basic ICCS). Study outcome data will be gathered from patients, clinicians, and the healthcare system (i.e., from the electronic medical record: EMR) for at least 8 months after study entry. We propose that the Enhanced ICCS relative to the Basic ICCS, will:
Improve patients' sense of cancer information competence (perceived ability to obtain and use relevant information)
Reduce patients' negative affect and increase their emotional well being
Improve patients' sense of social support
Improve patients' health self-efficacy
Improve patients' ratings of experience with cancer specialty care services
Improve patients' health related quality of life (HRQL)
Improve clinicians' ratings of quality of patient contacts
Reduce healthcare utilization and costs (obtained via the EMR)"
1862314|NCT01033175|Procedure|maximal cardiopulmonary exercise testing|Cardiopulmonary exercise testing (CPET) will be performed on a cyclic ergometer with continuous monitoring of a 12-lead electrocardiogram, heart rate and blood pressure. While breathing with a mask, the patients will perform a ramp protocol which includes 2-minutes free pedaling and progressive increase of power by 10, 15 or 20 watts/minute; power size will be selected after considering the patient' s daily activity and parameters of pulmonary function. CPET will be performed until exhaustion, unless the subjects reveal symptoms or signs indicating the exercise should stop (e.g. severe breathlessness).
1862315|NCT01033175|Procedure|peripheral blood samples|Peripheral venous blood samples will be collected again in the morning after a fasting period of ≥12 hours. After immediate centrifugation, aliquots will be stored at -75˚C until analysis. Inflammatory markers and erythropoietin will be analyzed by flow cytometry and by enzyme-linked immunosorbent assay, using commercially available kits.
1862316|NCT01033188|Procedure|Single bundle|"Procedure:
Transarthroscopic technique with medial portal placement of the femoral tunnel. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus. The femoral tunnel is positioned at the anatomic foot print determined by the anatomic landmarks. The graft will be fixed with an Endobutton CL on the femur and with an Biosure PK screw in the tibia with the knee close to extension. Prior to the final fixation, the knee will be taken through flexion and extension movements.The surgery will be carried out by an experienced knee surgeon."
1862388|NCT01041872|Drug|Propofol-lipuro B. Braun plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
1959881|NCT03312153|Drug|Neem|A natural irrigant solution act as anti-inflammatory and anti bacterial
1959882|NCT03312140|Drug|Choline Chloride|
1862317|NCT01033188|Procedure|Double bundle|"Procedure:
Transarthroscopic technique. Harvest of the semitendinosus/gracilis (ST/G) tendons through a 3-5 cm incision at the pes anserinus.Through a medial portal 2 tunnels will be anatomically placed in the foot print on the femur and the two tibial tunnels will be placed using the Smith & Nephew drill guide. The graft will be fixed with 2 Endobuttons on the femur and with 2 Biosure PK screws in the tibia. Prior to the final fixation, the knee will be taken through 20 flexion and extension movements. The PL bundle will be fixed with the knee close to ful extension. The surgery will be carried out by an experienced knee surgeon."
1862318|NCT01033201|Other|Confocal imaging|At the time of the standard of care bronchoscopy, confocal images will be obtained from each consented patient.
1862319|NCT01033214|Device|Endovascular repair of TAA in the descending Thoracic Aorta|Usage of the TAArget thoracic stent graft for treatment of TAA in the Descending Thoracic Aorta.
1862321|NCT01033240|Drug|CS-1008|On a once a week basis CS-1008 will be administered intravenously starting at 2 mg/kg, followed by 4 mg/kg if tolerated, followed by 6 mg/kg if tolerated.
1862322|NCT01033240|Drug|sorafenib|On a daily basis, one sorafenib tablet, 400 mg, is taken orally twice a day. The total daily dose of sorafenib is 800 mg. The sorafenib tablets are taken at least 1 hour before or 2 hours after a meal.
1862323|NCT01033253|Behavioral|Health in Motion|Students interacted with the 30-minute program through a series of Transtheoretical Model (TTM) based assessments and tailored feedback messages. A full TTM intervention was delivered for physical activity, in which each of the appropriate constructs of the TTM based on stage of change was addressed. Optimally tailored interventions were delivered for fruit and vegetable consumption and limited TV viewing. These interventions offered feedback on the most important TTM constructs based on stage of change for each behavior. Multimedia components, including audio, video, and animations helped to capture students' interest.
1862324|NCT01033266|Device|CPAP|CPET will be done on patients with overlap syndrome before and after CPAP treatment
1862325|NCT01033279|Other|Self-monitoring and adjustment of oral anticoagulation|Weekly self-monitoring of oral anticoagulation with a portable coagulometer and predefined adjustment algorithms for 4 months following a training program led and designed by hospital pharmacists
1862326|NCT01033292|Drug|BSI-201|IV infusion, 5.6 mg/kg
1862327|NCT01033305|Drug|CyCol™|Orally, once per day for 4 weeks
1862328|NCT01033305|Drug|Placebo|Orally, once per day for 4 weeks
1862329|NCT01033318|Drug|MK1809|single oral doses of MK1809
1862330|NCT01033318|Drug|Comparator: Losartan|single oral doses of 100 mg Losartan
1862331|NCT01033318|Drug|Comparator: Placebo|Placebo to MK1809
1862332|NCT01040312|Drug|CPT-11 and platinum analogues|platinum analogues (cisplatin, carboplatin and nedaplatin)
1862333|NCT01040325|Biological|TD Vaccine System|TD Vaccine System containing heat labile enterotoxin of E. coli (LT)
1862334|NCT01040325|Biological|TD Vaccine System|TD Vaccine System Containing Placebo Product
1862335|NCT01040338|Drug|Nicotine|Participants shall receive an intravenous injection of nicotine during their practice session and one of their PET scans (double-blind). The dose of IV nicotine will be 1mg/70kg and the maximum dose that shall be injected is 1.2mg.
1862336|NCT01040351|Procedure|ultrasound guided aspiration of hydrosalpingeal fluid|Under deep sedation, the retrieval of oocytes is done and then an aspiration needle is inserted into the hydrosalpinx under ultrasonographic guidance and suction is applied to aspirate the hydrosalpingeal fluid completely . If there are bilateral hydrosalpinges, the process is repeated on the opposite side.
1862337|NCT01040390|Drug|Lappa Arctium|To start with subjects will be prescribed Lappa Arctium in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
1862338|NCT01040403|Drug|olodaterol (BI 1744) low|olodaterol (BI 1744) low
1862339|NCT01040403|Drug|low tiotropium bromide|low tiotropium bromide
1862340|NCT01040403|Drug|olodaterol (BI 1744) high|olodaterol (BI 1744) high
1862341|NCT01040403|Drug|medium tiotropium bromide|medium tiotropium bromide
1862342|NCT01040403|Drug|high tiotropium bromide|high tiotropium bromide
1862343|NCT01040403|Drug|Placebo|Placebo
1862344|NCT01040403|Device|Respimat|Respimat inhaler
1862345|NCT01040429|Drug|Clonidine|"Day 1-56 (week 1-8): 25 microgram (1 capsula) x 2/day for patients < 35 kg; 50 microgram (2 capsula) x 2/day for patients > 35 kg.
Day 57-63 (week 9): 25 microgram (1 capsula) x 1/day for patients < 35 kg; 25 microgram (2 capsula) x 2/day for patients > 35 kg."
1862346|NCT01040429|Drug|Lactose capsula|"Day 1-56 (week 1-8): 1 capsula x 2/day for patients < 35 kg; 2 capsula x 2/day for patients > 35 kg.
Day 57-63 (week 9): 1 capsula x 1/day for patients < 35 kg; 1 capsula x 2/day for patients > 35 kg"
1862347|NCT01040442|Other|vibration stimuli|A single physical therapist performed the intervention using a Novafon SK2‡ vibratory stimulation device at a frequency of 100 Hz and sway amplitude of 2 mm. The participants of the experimental group received vibratory stimulation, applied slowly by sliding the head of the device over the entire plantar region for ten minutes for each foot at every session. During the intervention, the participants remained in the supine position on an examination table.
1862348|NCT01040455|Drug|Lansoprazole|lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
1862349|NCT01040455|Drug|placebo|placebo once daily for eight weeks
1862350|NCT01040468|Procedure|Roux-en-Y Gastric Bypass surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
1862351|NCT01040468|Procedure|Laparoscopic Adjustable Gastric Banding surgery|Surgical intervention for weight loss. This is a one-year study and participants will attend five study visits.
1862389|NCT01041872|Drug|Propofol Fresenius plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
1862594|NCT01043354|Behavioral|framing effects intervention|6 monthly telephone-delivered counseling sessions based on prospect theory
1862352|NCT01040468|Behavioral|Intensive Lifestyle Modification|Intensive lifestyle modification program for weight loss. Participants randomized to this condition will receive an weekly individual treatment of 30 minutes for the first 6 months and every-other-week sessions from months 7 to 12. Treatment will be provided by a behavioral psychologist or registered dietitian following a structured curriculum used in our prior studies. During the first 4 months, participants will be prescribed a 1000-1200 kcal/d diet that provides four daily servings of meal replacement products (liquid shakes, cereals, meal bars, etc), combined with an evening dinner entree. Each serving of the meal replacement (HMR 170; Boston, MA) will provide 170 calories, with 16 g of protein, 22 g of carbohydrate, and 2 g of fat. Dinner entrees (containing at least 20 g of protein and approximately 220-260 kcal) will be consumed with a garden salad and a serving of fruit (and other vegetables allowed ad libitum throughout the day).
1862353|NCT01040494|Drug|Aliskiren|all eligible patients will be randomized to receive aliskiren 150 mg on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
1862354|NCT01040494|Drug|Placebo|all eligible patients will be randomized to receive placebo on top of optimal HF therapy, including ACEI, ARB, beta blockers as considered appropriate by the investigator and in accordance with standard therapy guidelines for 6 months
1862355|NCT01040546|Behavioral|Individualized education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into individualized health education group received consulting services provided by a doctor, nutritionist and fitness expert. The interventions were 12 sessions over 6 months."
1862356|NCT01040546|Behavioral|Grouped education|"We conducted a randomized controlled trial to evaluate the effects of three types of weight control educational intervention programs. Obese subjects were randomly allocated into individualized health education group, group weight control education and mail-delivered health education group.Obese subjects who were randomly allocated into grouped health education group attended 12 sessions of group intervention over 6 months."
1862357|NCT01040559|Drug|idarubicin|Transarterial chemoembolization (in the hepatic artery) with idarubicin 5mg or 10 mg or 15 mg or 20 mg or 25 mg injected in a solution of 2ml DC Bead (300 µm-500µm); 1 unique course
1862358|NCT01040585|Drug|Linezolid|Treatment for VAP as indication approved and as physician criterium.
1862359|NCT01040598|Biological|Omalizumab|Omalizumab, an anti-IgE monoclonal antibody is dosed on the basis of subject's weight and IgE levels. It is administered as a subcutaneous injection every 2 weeks or 4 weeks based on the total dose required.
1862360|NCT01040611|Behavioral|Music therapy|Patients who fit the inclusion criteria were random assigned to either experimental or control group. Patients in experimental group could choose a piece of CD and listen to music with earphone for 30 minutes. Patients in control group just rest for 30 minutes. The procedure was implemented once a day, and sustained for total 5 days.
1862361|NCT01040624|Radiation|< 15% risk of + LN|Total of 54 Cobalt gray equivalent (CGE) over 30 treatments to prostate + seminal vesicles (SV), then proton boost total of 23.4-27 CGE over 13-15 treatments to prostate +/- SV. Low dose docetaxel every week during radiation therapy (RT) followed by androgen deprivation therapy for 6 months.
1862362|NCT01040624|Radiation|> 15% risk of + LN|Total of 45 Gy over 25 treatments to prostate + SV + LN, then proton boost total of 32.4-36 CGE over 18-20 treatments to prostate + SV. Low dose docetaxel every week during RT followed by androgen deprivation therapy for 6 months.
1862363|NCT01040637|Drug|TD-1211|Dose level 1
1862364|NCT01040637|Drug|TD-1211|Dose level 2
1862365|NCT01040637|Drug|TD-1211|Dose level 3
1862366|NCT01040637|Drug|TD-1211|Dose Level 4
1862367|NCT01040637|Drug|TD-1211|Ascending doses
1862368|NCT01040637|Drug|TD-1211|Ascending doses
1862369|NCT01040637|Drug|TD-1211|Ascending doses
1862370|NCT01040637|Drug|TD-1211|Ascending doses
1862371|NCT01040637|Drug|TD-1211|Ascending doses
1862372|NCT01040637|Drug|Placebo|Ascending doses
1862373|NCT01041781|Drug|carboplatin|Given IV
1862374|NCT01041781|Drug|celecoxib|Given orally
1862375|NCT01041781|Drug|gemcitabine hydrochloride|Given IV
1862376|NCT01041781|Drug|pemetrexed disodium|Given IV
1862377|NCT01041781|Other|placebo|Given orally
1862378|NCT01041807|Drug|amlodipine/losartan|amlodipine/losartan (COZAAR XQ) prescribed according to the current local label
1862379|NCT01041820|Behavioral|Exercise|Children will be exposed to a 10-week exercise intervention
1862380|NCT01041833|Drug|atRA|atRA group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus atRA 45 m2/day before one week before treatment and during all the treatment
1862381|NCT01041833|Drug|Placebo|Placebo group will receive six cycles of 80 mg/m2 of cisplatin and 175 mg/m2 of paclitaxel plus placebo before one week before treatment and during all the treatment
1862382|NCT01041846|Drug|No intervention|This is an observational study. Patients receiving 20 mg/m2 of decitabine injection intravenously (into a vein) once daily for 5 days every 4 weeks will be observed.
1862383|NCT01041859|Drug|Tapentadol extended release (ER)|Type= range, unit= mg, number= 100 to 250, form= tablet, route= oral use. Tapentadol ER optimal dose ranging between 100 mg and 250 mg twice daily for 15 weeks.
1862384|NCT01041859|Drug|Placebo|Form= tablet, route= oral use. Matching placebo twice daily.
1862385|NCT01041872|Drug|Propofol Astrazeneca plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
1862386|NCT01041872|Drug|Propofol Astrazeneca plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
1862387|NCT01041872|Drug|Propofol-lipuro B. Braun plain|Propofol with saline is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of saline.
1862479|NCT01042392|Drug|Aliskiren|150 mg Aliskiren as film-coated tablet
1862480|NCT01042392|Drug|Ramipril|Ramipril 5 mg was given in capsule form.
1862390|NCT01041872|Drug|Propofol Fresenius plus lidocaine|Propofol with lidocaine 1¨% is administered using a closed-loop algorithm which permits to reach a Bispectral Index target of 50. The blinded syringe contains 45 ml of propofol and 5 ml of lidocaine.
1862391|NCT01041885|Device|INSTRUCT|INSTRUCT PolyActive scaffold implantation
1862392|NCT01041911|Drug|Euphorbia tablets|50 mg, tablet, once daily, 14 days
1862393|NCT01041911|Drug|Euphorbia tablets|100 mg, tablet, once daily, 14 days
1862394|NCT01041911|Drug|Euphorbia tablets|200 mg, tablet, 2 tablets of 100 mg Euphorbia prostrata, 14 days
1862395|NCT01041911|Drug|Placebo tablets|placebo, tablet, once daily, 14 days
1862396|NCT01041924|Other|Carbon dioxide|2% inhaled CO2 for up to 8 hours.
1862397|NCT01041924|Other|Carbon dioxide|Up to a maximum of 2% CO2, only delivered for a maximum of up to 20 seconds per 60 seconds for 8 hours
1862398|NCT01041937|Procedure|Cemented Tibia|Total knee arthroplasty with cemented or cemented tibia, and post operative clinical outcome tracking
1862399|NCT01041937|Procedure|Cementless Tibia|Assessing the clinical outcomes of the different type of fixation
1862400|NCT01041950|Procedure|Lumbar drainage|Lumbar CSF drainage is started after communication between the internal and external CSF-spaces is seen on CT.
1862401|NCT01041963|Drug|Enalapril|Patients with hypertension will take 20-40mg enalapril per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
1862402|NCT01041963|Drug|Enalapril plus Losartan|Patients with hypertension will take 20-40mg enalapril plus 25-50mg losartan per day, antihypertensive agents other than ACE inhibitors and ARBs and spironolactone will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
1862403|NCT01041963|Drug|Placebo|Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
1862404|NCT01041976|Behavioral|Adapted Motivational Interviewing (AMI)|Veterans assigned to the AMI condition will be scheduled for up to 6 sessions over 6 months. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). Sessions will utilize a variety of motivational enhancement strategies including evocative questions, importance and confidence scales, collaborative problem solving, and planning.
1862405|NCT01041976|Behavioral|Support and Education for Recovery (SER)|Veterans assigned to the control condition will be seen for 6 sessions over 6 months of basic support and education about VA and non-VA psychiatric rehabilitation and recovery services. Up to 3 of these 6 sessions will be joint sessions with the Veteran's significant other (if available). The session topics include information about Bedford VA and Boston VA recovery services, as well as those offered by local non-profits.
1862406|NCT01041989|Behavioral|Nutritional guidance|Individual counseling sessions and group meetings will be organized.
1862407|NCT01041989|Behavioral|Exercise|Guided muscle strength training and aerobic exercise.
1862408|NCT01041989|Behavioral|Cognitive training|Cognitive training will be implemented through 8 group sessions lead by a psychologist and a computer-based cognitive training program available to participants via the internet.
1862409|NCT01041989|Other|Reduction of vascular risk factors|Monitoring and maintenance of metabolic and vascular risk factors
1862410|NCT01042002|Behavioral|High intensity exercise|High intensity exercise 3xweek for minimum 6 weeks
1862411|NCT01042015|Combination Product|Emergency preservation and resuscitation|This involves the induction of profound hypothermia using a flush of ice-cold saline into the aorta. Once hypothermia is achieved, the subject would undergo rapid operative interventions to control bleeding followed by resuscitation/rewarming with cardiopulmonary bypass.
1862412|NCT01042015|Other|Standard resuscitation|Standard resuscitation includes an emergency department thoracotomy, open cardiac massage, and fluid resuscitation.
1862413|NCT01042028|Drug|Everolimus, Cetuximab, Irinotecan|Cetuximab 500 mg/m² iv biweekly Irinotecan 180 mg/m² iv biweekly Everolimus in daily MDT dosage
1862414|NCT01042028|Drug|Capecitabine, Oxaliplatine|Capecitabine 1250 mg/m² bid. Oxaliplatin 70 mg/m² biweekly
1862415|NCT01042041|Drug|sorafenib tosylate|Given orally
1862416|NCT01042041|Drug|doxorubicin hydrochloride|Given via transarterial/hepatic chemoembolization
1862417|NCT01042041|Drug|cisplatin|Given via transarterial/hepatic chemoembolization
1862418|NCT01042041|Drug|mitomycin C|Given via transarterial/hepatic chemoembolization
1862419|NCT01042041|Procedure|transarterial chemoembolization|
1862420|NCT01042041|Procedure|hepatic artery embolization|
1862421|NCT01042054|Other|Standard optimised recovery protocol.|"Epidural analgesia for the first 48 hours postoperatively.
Sham wound catheter attached to anterior abdominal wall, for purposes of blinding.
Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.
Optimised recovery protocol followed throughout."
1862422|NCT01042054|Other|Wound catheter plus patient-controlled analgesia.|"Continuous infusion of local anaesthetic administered via wound catheters for the first 48 hours postoperatively.
Additional patient-controlled intravenous opiate analgesia available to patient during this time period.
Sham epidural catheter applied to the patient's back for purposes of blinding.
Standard oral analgesic regime commenced at 48 hours, and continued until discharge from hospital.
Optimised recovery protocol followed throughout."
1862423|NCT01042067|Other|Blood specimens (whole blood, serum, plasma)|The patients follow standard warfarin treatment regimens and the only intervention is the sampling of blood specimens.
1862424|NCT01042080|Device|NAVA|Assisted mechanical ventilation according to the electrical activity of the diaphragm recorded with a 16-FR naso-gastric tube mounted with EMG electrodes
1862425|NCT01042080|Other|Expiratory trigger (ET)|Varying the cycling criterion according to the percentage of peak inspiratory flow
1862426|NCT01042093|Drug|Ropivacaine|Ropivacaine 5mg/ml (49.25 ml)
1862427|NCT01042093|Drug|Toradol|Toradol 30mg/ml (1 ml)
1862428|NCT01042093|Drug|Clonidine|Clonidine 0.1 mg/ml (0.08mg - 0.8 ml)
1862429|NCT01042093|Drug|Epinephrine|Epinephrine 1 mg/ml (0.5 ml)
1862430|NCT01042106|Drug|DSP-8658|Ascending doses of DSP-8658 - 2.5, 10, 20, 40 mg orally once daily
1862431|NCT01042106|Drug|Placebo|Placebo 2.5, 10, 20, 40 mg orally once daily
1862432|NCT01042132|Procedure|the effect of delayed intramedullary reaming|in one group intramedullary reaming and nailing is performed immediately, femoral fractures in the second group are external fixated and than secondary nailed.
1862433|NCT01042132|Procedure|the reaming of the femoral canal is performed with two different reaming devices|the reaming of the femoral canal is performed with two different reaming devices; a traditional reamer (TR)and the reamer-irrigator-aspirator (RIA)
1862434|NCT01042145|Drug|Prednisone|2 mgs/kg for 3 days
1862435|NCT01042145|Drug|Dexamethasone|0.6 mgs for one day, then placebo for 2 days
1862436|NCT01042158|Drug|tadalafil and ambrisentan upfront combination therapy|tadalafil 20 mg qd and ambrisentan 5 mg qd. Up-titration of study medications will occur at week 4 (ambrisentan 10 mgs daily and tadalafil 40 mg qd). If a subject experiences an intolerable adverse event as a result of an uptitration in the study drug dose, the dose of study drug maybe down titrated to 20 mg of tadalafil and/or 5mg of ambrisentan. If the subject is still experiencing an intolerable adverse event, then the investigator will withdraw the subject from the study.
1862437|NCT01042184|Drug|Sequential therapy for 14 days|D1-D7: (lansoprazole 30mg + amoxicillin 1gm) bid D8-D14: (lansoprazole 30mg + clarithromycin 500mg + metronidazole 500mg) bi
1862438|NCT01042184|Drug|Sequential therapy for 10 days|D1-D5: (lansoprazole 30mg + amoxicillin 1gm) bid D6-D10: (lansoprazole 30mg+clarithromycin 500mg+metronidazole 500mg) bid
1862439|NCT01042184|Drug|Triple therapy for 14 days|D1-D14: (lansoprazole 30mg + clarithromycin 500mg + amoxicillin 1gm) bid
1862440|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
1862441|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
1862442|NCT01042197|Radiation|Broadband UVB|UVB dose: 0.75 SED. Four UVB sessions with 2 days in between.
1862443|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
1862444|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
1862445|NCT01042197|Radiation|Broadband UVB|UVB dose: 1.5 SED. Four UVB sessions with 2 days in between.
1862446|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
1862447|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
1862448|NCT01042197|Radiation|Broadband UVB|UVB dose: 3.0 SED. Four UVB sessions with 2 days in between.
1862449|NCT01042236|Drug|Fesoterodine|Fesoterodine 4 mg and 8 mg and placebo - each dosed for 7 days with 7 day washout between dosing periods
1862450|NCT01042249|Other|Pelvic Floor Muscle training|12 week training program including home exercises
1862451|NCT01042262|Other|Oxygen|100% Oxygen at a flow of 2 L/min
1862452|NCT01042262|Other|Placebo|No oxygen flow
1862453|NCT01042288|Drug|Carboplatin|Carboplatin AUC=6IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
1862454|NCT01042288|Drug|Pemetrexed|Pemetrexed 500mg/m² IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
1862455|NCT01042288|Drug|Panitumumab|Panitumumab 9mg/kg IV, Day 1 of Cycles 1-6 (Cycles are 3 weeks / 21 days in length)
1862456|NCT01042301|Other|Blood samplings|
1862457|NCT01042314|Drug|Donepezil|Tablets, Oral, 5 mg, Once Daily, Days 1-28
1862458|NCT01042314|Drug|BMS-708163|Capsule, Oral, 125 mg, Once Daily, Days 15-28
1862459|NCT01042327|Device|ELISIO dialyzer|3 x week dialysis using ELISIO dialyzer for 12 weeks
1862460|NCT01042327|Device|Fresenius FX100 dialyzer|
1862461|NCT01042340|Other|Calogen® - an energy dense oleic acid based formula|A daily dose of 3 x 30 ml of Calogen®, strawberry flavour, distributed at the same time as the pharmaceutical prescriptions, i.e. at 7.00, 14.00 and 20.00.
1862462|NCT01042353|Procedure|E test|At the time of BAL collection, a rapid antibiogram will be performed by placing E-test antibiotic strips (AB Biodisk) directly onto Mueller-Hinton agar plates seeded with the BAL specimen (both by flooding and swabbing). E-test strips will be impregnated with cefoxitin, piperacillin-tazobactam, cefepime, imipenem, ciprofloxacin and amikacin. At 24 h, the E-test plates will be photographed and then examined separately by both a bacteriologist and a medical ICU physician following a consensus method. The final E-test results will be compared with the standard MIC cultures.
1862463|NCT01042353|Procedure|standard culture method|BAL samples will be cultured by standard methods and the minimal inhibitory concentration (MIC) of bacteria to the usual antibiotics will be determined using standard procedures
1862464|NCT01042366|Biological|Vaccination|Subjects will receive as an outpatient 4 weekly ultrasound-guided intra/peri-lymph nodal administrations of the autologous tumor dendritic cell vaccine. The dose of the autologous tumor cell dendritic cells/vaccine will be 1-5 X 106.
1862481|NCT01042392|Drug|Matching placebo to Aliskiren|The tablet of matching placebo to aliskiren 150 mg for period I and III. In period II, matching placebo to Aliskiren was given to Ramipril active treatment arm.
1862482|NCT01042392|Drug|Matching placebo to Ramipril|The placebo capsule to ramipril 5 mg for period I and III. In period II, matching placebo to Ramipril was given to Aliskiren active treatment arm.
1862483|NCT01042418|Other|Effect of breakfasts with whole vs milled rye kernels on appetite|Iso-caloric portions of the three breakfast foods along with identical additional foods are tested in a cross over design
1862484|NCT01042431|Other|No Intervention|No intervention
1862485|NCT01042444|Device|GARDEX™|"GARDEX is an embolic protection system to contain and remove embolic material (thrombus/debris) during cardiovascular interventions.
The diameter of the vessel at the site of filter basket placement should be between 3.5 mm to 6.0 mm. The GARDEX Embolic Protection System may be used with commercially available 0.014 guide wires."
1862486|NCT01042457|Drug|Mycophenolate mofetil|Drug : Mycophenolate Mofetil. Starting doses : 1000-1500 mg/day with titration based on Mycophenolic 1-hour post dose level.
1862487|NCT01042483|Device|LaborPro device|monitoring labor progression by using a new device The LaborPro system (Trig Medical Inc) allows determination of fetal head station and position using ultrasound and position tracking system.
1862488|NCT01042496|Drug|Lamotrigine|12 week open trial: 25mg/day for 2 weeks, 50mg/day for 2 weeks, 100mg/day for 2 weeks, 200mg/day for 6 weeks. Flexible titration for early response and/or side effects.
1862489|NCT01042496|Procedure|1H-MR|Proton magnetic resonance spectroscopy (1H-MR) evaluation of medial anterior cingulate cortex (MACC) and left dorsal lateral prefrontal cortex (LDLPC).
1862490|NCT01042509|Drug|Alemtuzumab and rituximab|Alemtuzumab at 10mg subcutaneously daily for 3 doses (days 1, 2 and 3) Rituximab at 100mg intravenously weekly for 4 doses (days 4, 11, 18 and 25
1862491|NCT01042522|Biological|Bleomycin Sulfate|Given IV
1862492|NCT01042522|Drug|Carboplatin|Given IV
1862493|NCT01042522|Drug|Cisplatin|Given IV
1862494|NCT01042522|Drug|Etoposide Phosphate|Given IV
1862495|NCT01042522|Other|Laboratory Biomarker Analysis|Correlative studies
1862496|NCT01042522|Drug|Paclitaxel|Given IV
1862500|NCT01042561|Dietary Supplement|Vitamin D3|400 IU of vitamin D3 daily. Pts will recieve 1 mL a day with a feeding for 28 days.
1862501|NCT01042561|Dietary Supplement|vitamin D3 placebo|Placebo designed by research pharmacist. Pts will recieve 1 mL a day with feedings for 28 days.
1862502|NCT01042574|Drug|Clevidipine butyrate|Cleviprex will be administered according to current package insert instructions, with a starting dose of 2.0mg/hr for 1.5 minutes and thereafter titrated to lower blood pressure to a target goal of 110 mmHG to 140mmHG.
1862503|NCT01042587|Other|exposure to bright light|Elders will be engaged in an activity period which will focus their attention in the direction of bright light, thus ensuring viewing the light source for a daily exposure of thirty minutes.
1862504|NCT01042587|Other|low luminosity red light|Low level red light should not entrain circadian rhythm and will serve as a placebo control
1862505|NCT01042600|Device|Endotracheal tube insertion|Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
1862506|NCT01042600|Device|Laryngeal mask airway insertion|Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
1862507|NCT01042613|Procedure|Cannulation using Accuvein device|If the research participant has been randomized to the AV300 device group A, then intravenous cannulation will be attempted using the AV300 device following manufacturer's instructions by four anesthesiologists.
1862508|NCT01042613|Procedure|Standard Cannulation method|If the research participant has been randomized to the standard treatment group B then cannulation will be attempted in the standard manner. A research team member will time cannulation access for all participants. Participation ends once successful cannulation is achieved or when a maximum of 4 skin punctures have been made.
1862509|NCT01042626|Other|Oral peptones load|Enrolled subjects will receive 10 g Liebig meat extract diluted in 250ml of 0.9% saline
1862510|NCT01042639|Behavioral|passive physical activity|extension and flexion range-of-motion exercise against passive resistance of both the upper and lower extremities. Both extension and flexion were performed five times at the wrist, elbow, shoulder, ankle, knee, and hip joints
1862511|NCT01042652|Drug|Raltegravir|Raltegarvir 400mg bid
1862512|NCT01042665|Drug|latanoprost 0.005%|Active comparator
1862513|NCT01042665|Drug|Placebo|Placebo comparator
1862514|NCT01042678|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye
1862515|NCT01042691|Drug|Oxaliplatin|The starting dose of oxaliplatin administered via isolated hepatic perfusion will be the safe tolerated dose of intra-arterial infusion and pharmacokinetics from intravenous studies. The dose will be 5 mg/m2 and will be escalated.
1862516|NCT01042704|Drug|Bendamustine|Bendamustine is given intravenously (into a vein or IV infusion) on days 1 and 2 of each cycle. Each bendamustine infusion will take 60 minutes
1862517|NCT01042704|Drug|Lenalidomide|Lenalidomide is taken orally (by mouth) in the morning on days 1 through 21 of each cycle.
1862518|NCT01042704|Drug|Dexamethasone|Dexamethasone is taken orally (by mouth) on days 1, 8, 15, and 22 of each cycle.
1862519|NCT01042704|Drug|Aspirin|All patients will receive enteric coated aspirin, 325 mg, QD while on study. If patient is unable to tolerate aspirin, patient should receive other types of anti-coagulation like Coumadin or low molecular weight heparin.
1862520|NCT01042704|Drug|Prophylaxis|All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
1862521|NCT01042704|Drug|Antibiotic|PCP antibiotic prophylaxis with a Bactrim will be recommended. In case of history of zoster or fungal infection a prophylaxis with Acyclovir or Diflucan should be also considered.
1862549|NCT01042938|Drug|Placebo|Patients take 2.0 grams placebo (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
1863058|NCT01047072|Drug|tacrolimus|Given orally
1862522|NCT01042704|Other|Biweekly Follow Up|Vital signs (heart rate, breathing rate, blood pressure, and temperature) will be measured, and Blood tests to check CBC, Calcium, Electrolytes, serum, creatinine, and BUN. This follow up will take place at the Hillman Cancer Center, or whichever cancer center in which the subject is treated.
1862523|NCT01042704|Other|Cyclical Follow Up|At the beginning of each treatment cycle subjects will undergo a Physical exam, a Performance status check, Recording of any new symptoms or side effects and any new medications, Blood tests (including blood chemistry, organ function and indicators of disease), Urine test, and pregnancy test (if applicable).
1862524|NCT01042704|Other|Restaging|Every other cycle subjects' disease will be restaged. This will be accomplished by their treatment physician. Re-staging procedures includes a regular office visit, x-ray, and a bone marrow biopsy. Subjects will spend approximately 4 hours at the Hillman Cancer Center or the UPMC Cancer Center location where they are being treated for this re-staging.
1862525|NCT01042704|Other|Post-Treatment Follow Up|"After subjects stop receiving the study drugs, they will be followed every 3 months for the first two years, every 6 months for years 2-5, and annually thereafter. The following procedures, which are considered routine for their cancer care, will be done as part of this follow-up:
Physical exam
Performance status (check of ability to perform daily functions)
Recording of any new symptoms and any new medications being taken
Blood tests to check blood counts (numbers of red and white blood cells and platelets), blood chemistry (to check organ function), and indicators of disease (immunoglobulins)
Urine test (24hr urine)
Women who are able to have children will have a pregnancy test (4 weeks after their last dose of lenalidomide).
A check of the status of disease (includes bone marrow biopsy, skeletal survey, and blood and urine tests). Bone marrow biopsy will be done at the end of treatment, if subjects have a complete response, and their disease gets worse."
1862526|NCT01042717|Drug|Plerixafor|Plerixafor administered at 16 hours prior to apheresis
1862527|NCT01042730|Drug|Pitavastatin 1 mg daily or 4 mg daily|Patients who met all inclusion criteria and did not meet exclusion criteria (1) are entered in run-in period, loading pitavastatin 1 mg/day for more than 1 month when informed consent was given. (Primary registration) After 1 month, patients who did not meet exclusion criteria(2) are randomized to take pitavastatin 1 mg/day or 4 mg/day.
1862528|NCT01042743|Procedure|robot-assisted surgery|da Vinci surgical system® (Intuitive Surgical, Sunnyvale, CA, USA)
1862529|NCT01042743|Procedure|laparoscopic right-hemicolectomy|Conventional laparoscopic procedures
1862530|NCT01042769|Drug|Aleglitazar|aleglitazar 150 micrograms po daily
1862531|NCT01042769|Drug|Placebo|placebo control po daily
1862532|NCT01042782|Drug|RAD001 and MitomycinC|"RAD001 tablets daily, 5mg, 7.5 mg or 10 mg (3 cohorts)
Mitomycin C 5 mg/m2 i.v. every 3 weeks"
1862533|NCT01042795|Drug|Sunitinib|Sunitinib 37.5 mg daily X 16 weeks
1862534|NCT01042821|Procedure|partial rectal wall advancement flap|The flap comprised mucosa, submucosa and circular muscle fibers. It is raised from the dentate line and mobilized 4-6 cm cephaled and advanced to the new dendentate line (1 cm below the dentate line) and sutured with absorbable sutures (vicryl; ethicone 3/0). Also the defect is closed with absorbable sutures.
1862535|NCT01042821|Procedure|mucosal advancement flap|Fistulectomy, closure of internal sphincter and rectal advancement flap includes mucosa and submucosal layer sutured 1cm below the level of internal opening
1862536|NCT01042834|Other|Air pollution study on healthy volunteers.|"The subjects are examined three times:
First the volunteers get used to equipments.
Second and third the volunteers sleep in a pollution or purified air."
1862537|NCT01042860|Dietary Supplement|Lutein|Lutein supplement, 10 mg daily
1862538|NCT01042860|Dietary Supplement|Placebo|Placebo
1862539|NCT01042873|Drug|3 hours intravenous dobutamine|Intravenous dobutamine will be infused during 3 hours. At the first and last 0.5 hors of infusion dose will be increased gradually, while in the middle 2 hours dose will remain constant.
1862540|NCT01042886|Behavioral|PILI 'Ohana Lifestyle Program|9-month weight loss and weight loss maintenance intervention focusing on family and community resources/supports.
1862541|NCT01042886|Behavioral|Standard Behavioral Weight Loss Maintenance Program|9-month weight loss and weight loss maintenance intervention based on empirically-supported behavioral foci and strategies.
1862542|NCT01042899|Behavioral|Teen Online Problem Solving (TOPS)|The TOPS program has 10 sessions that provide training in stress management, problem solving, communication, and social skills to all enrolled families, while the remaining 6 sessions address content related to the stressors and burdens of individual families. Each self-guided online session includes real adolescents talking about how TBI affected them, content regarding the skill, video clips showing adolescents and/or families modeling the skill, and exercises giving the family an opportunity to practice the skill. After the completion of the self-guided web pages, the family will meet with the therapist via videoconference; the therapist will review the exercises and help the family implement the problem-solving process with a problem or goal identified by the family.
1862543|NCT01042899|Behavioral|Teen Online Problem Solving--Teen Only (TOPS-TO)|TOPS-TO targets the same skills as TOPS and includes largely the same website and intervention content. However, it differs with respect to the extent of family involvement in the sessions. In TOPS-TO, sessions will be conducted with the child or adolescent alone, rather than with the family as whole. Parents will be given access to the TOPS-TO website content via their own password protected site so they will understand the skills that their child is learning. However, only the adolescent, and not the parents, will participate in the synchronous videoconferences with the therapist.
1862544|NCT01042899|Behavioral|Internet Resources Comparison (IRC)|Families in the IRC group will also receive a computer, printer, and high-speed internet access if they do not currently have these. Additionally, IRC families receive access to a home page of brain injury resources and links (identical to those given on the TOPS and TOPS-TO homepage) but will not be able to access specific session content. This will enable us to equate the groups with respect to access to the information and resources available on the Web.
1862545|NCT01042925|Drug|XL147 (SAR245408)|administered orally once daily as tablet(s)
1862546|NCT01042925|Biological|trastuzumab|administered by IV once every 3 weeks
1862547|NCT01042925|Drug|paclitaxel|administered by IV once every week
1862548|NCT01042938|Drug|Curcumin C3 Complex|Patients take 2.0 grams curcumin (four 500mg capsules) three times daily by mouth for prescribed course of radiation treatment (~4-7 weeks)
1862592|NCT01043341|Behavioral|educative folder|folder about HPV infection and vaccines
1959883|NCT03312127|Device|ILIAC ENDOPROSTHESIS GORE EXCLUDER|Set up of GORE ® Excluder Iliac Branch Endoprosthesis in endovascular barring of complex aneurysms without distal neck. In the immediate post-operating follow-up visit and at the 3 months visit and the 12 months visit after surgery, an ultra-sound scan, a tomodensitometric exam and a walking test on a treadmill with oximetric gluteal region exploration will systematically be performed.
1959884|NCT03312114|Drug|Avelumab|Avelumab* (MSB0010718C; anti-PD-L1 is a fully human anti-PD- L1 IgG1 antibody
1862552|NCT01042964|Drug|revacept (PR-15)|single intravenous administration of revacept (PR-15), an inhibitor of platelet adhesion, in various strengths (10, 20, 40, 80, 160 mg) in healthy male volunteers.
1862553|NCT01042977|Drug|Dapagliflozin|10 mg tablet, oral, once daily, 24- week treatment and 80-week extension period
1862554|NCT01042977|Drug|Placebo|matching placebo tablet, oral, once daily, 24- week treatment and 80-week extension period
1862555|NCT01042990|Other|Adaptive Physical Activity|Structured gait, balance, and progressive walking program performed in a group gym setting 3x/week for 6 months
1862556|NCT01043003|Other|educational intervention|Undergo Bilingual Breast Cancer Educational Intervention
1862557|NCT01043003|Procedure|quality-of-life assessment|Ancillary studies
1862558|NCT01043003|Other|Questionnaire Administration|Ancillary studies
1862559|NCT01043003|Other|psychosocial support for caregiver|Support for caregiver
1862560|NCT01043003|Procedure|assessment of therapy complications|Ancillary study
1862561|NCT01043003|Other|informational intervention|Undergo evaluation sessions
1862562|NCT01043016|Procedure|Photodynamic therapy|patient undergo Photocyanine Injection via venous infusion followed by photodynamic therapy with 670nm diobe laser 24 hours later
1862563|NCT01043029|Drug|aleglitazar|Aleglitazar 150 mcg po daily for 52 weeks
1862564|NCT01043029|Drug|pioglitazone|Pioglitazone 45 mg po daily for 52 weeks
1862565|NCT01043042|Other|No interventions will be used in this study|No interventions will be used in this study
1862566|NCT01043068|Drug|Cancer pain management|Interventions based on published pain guideline. The interventions consisted of the following: (1) nursing pain assessment of current pain, worst pain, pain relief, and acceptability of pain; (2) feedback to guide analgesic prescribing by physician.
1862567|NCT01043094|Drug|Pitavastatin 4mg|Pitavastatin 4mg single dose
1862568|NCT01043120|Drug|Barusiban|IV bolus of 20 mg for 1 minute followed by an IV infusion of 19 mg for up to 59 minutes. The maximum total duration of administration was 60 minutes.
1862569|NCT01043120|Drug|Placebo|IV bolus of saline (sodium chloride 0.9%) for 1 minute followed by an IV infusion of saline (sodium chloride 0.9%) for up to 59 minutes. Details on injection volume, infusion rates and doses are tabulated below.
1862570|NCT01043133|Behavioral|social marketing-based medical education intervention|social-marketing based medical education intervention designed to influence medical student use of evidence-based templates. Led by physician instructor.
1862571|NCT01043146|Drug|COR-1|single intravenous administration of 10, 40, 80, 160 or 240 mg of COR-1
1862572|NCT01043146|Drug|placebo|intravenous 0.9 % NaCl
1862573|NCT01043172|Drug|Gemcitabine|Gemcitabine : 1000 mg/m2/day D1,8,15 Repeated every 4 weeks 6 cycles
1862574|NCT01043185|Drug|AZD3355|30 mg orally in the morning and 30 mg in the evening for 1 day
1862575|NCT01043185|Drug|AZD3355|90 mg orally in the morning and 90 mg in the evening for 1 day
1862576|NCT01043185|Drug|AZD3355|120 mg orally in the morning and 120 mg in the evening for 1 day
1862577|NCT01043185|Drug|AZD3355|240 mg orally in the morning and 240 mg in the evening for 1 day
1862578|NCT01043185|Drug|placebo|Placebo capsules orally in the morning and placebo capsules in the evening for 1 day
1862579|NCT01043198|Genetic|Clinical examination and blood sampling for biological and genetic analysis|"Clinical examination and precise description of the phenotype (questionnaire)
Standardized screening with :
radiological (hands, feet, spine ; and renal ultrasonography)
biological (hormonal, metabolic, and basic genetic investigations (karyotype, FISH 22q11.2, Fragile X, and other depending on the clinical data))"
1862580|NCT01043211|Drug|Lidocaine Hydrochoride Injection, without epinephrine|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision. Immediately thereafter, lidocaine (1%, 10 mg/ml) will be administered on a standardized 0.3 ml/hr/kg (3 mg/kg/hr, maximum 200 mg/hr = 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the lidocaine infusion will be decreased by 50% to 0.15 ml/hr/kg (1.5 mg/kg/hr, maximum 100 mg/hr = 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
1862581|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg intravenous bolus dose of preservative-free normal saline will be given after anesthetic induction but prior to skin incision. Immediately thereafter, normal saline will be administered on an equal 0.3 ml/hr/kg (maximum 20 ml/hr) basis using a continuous infusion pump during the surgical procedure. Immediately after skin closure, the normal saline infusion will be decreased by 50% to 0.15 ml/hr/kg (maximum 10 ml/hr) and continued for 90 minutes postoperatively. The infusion will be stopped before the patient is discharged from the post-anesthesia care unit (PACU).
1862582|NCT01043211|Drug|Normal Saline|A standardized 0.2 ml/kg (2 mg/kg) intravenous bolus dose of lidocaine (1%, 10 mg/ml) is given after anesthetic induction but prior to skin incision.
1862583|NCT01043224|Drug|Combination of clobetasol propionate plus calcipotriol ointment, clobetasol propionate ointment, calcipotriol ointment, and the ointment vehicle|Once daily application
1862584|NCT01043263|Drug|EN3324 (axomadol)|twice daily dosing
1862585|NCT01043263|Drug|Placebo|twice daily dosing
1862586|NCT01043276|Drug|Treatment A|PF-00258210 220 µg using inhaler A
1862587|NCT01043276|Drug|Treatment B|PF-00258210 220 µg using inhaler A and 450 µg PF-00610335 using inhaler A
1862588|NCT01043276|Drug|Treatment C|PF-00258210 440 µg and 450 µg PF-00610335 using inhaler A
1862589|NCT01043276|Drug|Treatment D|PF-00258210 350 µg and 450 µg PF-00610335 using inhaler A
1862590|NCT01043276|Drug|Treatment E|PF-00258210 220 µg using inhaler B
1862591|NCT01043289|Other|Light therapy|During the 5-week treatment period, subjects sit in front of a light box for 60 minutes daily after awakening, at a specified distance that provides the required light intensity.
1862595|NCT01043354|Behavioral|attention placebo intervention|6 monthly counseling sessions about general health topics
1862596|NCT01043367|Dietary Supplement|Deprexil|One 600 mg Deprexil tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
1862597|NCT01043367|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) half an hour after each meal (breakfast, lunch and dinner), for 24 weeks. A 20 minutes relaxation psychotherapy will also be provided once a week.
1862598|NCT01043380|Drug|Combination therapy with Lipitor [Atorvastatin] and Zetia [Ezetimibe]|Zetia 10 mg/dl + Lipitor. The dosage of Lipitor will be titrated up to a maximum of 20 mg/day with a treatment goal of lowering LDL-C below 70 mg/dl.
1862599|NCT01043380|Drug|Lipitor (Atorvastatin) monotherapy|The dosage will be titrated up to a maximum of 20 mg/day, which is the highest approved regimen by the Ministry of Health, Labor and Welfare of Japan, with a treatment goal of lowering LDL-C below 70 mg/dl.
1862600|NCT01043393|Drug|Desoximetasone 0.25% spray|Desoximetasone spray applied to affected areas twice daily for 28 days
1862601|NCT01043406|Device|Seizure Advisory System|Implant of Seizure Advisory System followed by data collection for algorithm training and subsequent enabling of seizure advisory indicators.
1862602|NCT01043419|Drug|xenon|Inhalational gas; dose allowed max.70 Vol.% in 30 % oxygen; the duration of the treatment will be to 30 minutes
1862603|NCT01043445|Dietary Supplement|GPR 119 agonist, 2-oleyl glycerol|Emulgation, 50 ml. containing 2g 2OG
1862604|NCT01043445|Dietary Supplement|Oleic acid|Emulgation, 50 ml. containing 1.54g of oleic acid
1862605|NCT01043445|Dietary Supplement|Vehicle|Fifty milliliters of glycerol (Sigma-Aldrich; batch 32296AK, purity 99%) plus 5 ml 96% ethanol
1862606|NCT01043458|Drug|ABT-126|ABT-126 Low Dose & ABT-126 High Dose
1862607|NCT01043458|Drug|Placebo for ABT-126|Matching Placebo for Arms 1 & 2
1862608|NCT01043471|Other|Chewing gum|Subjects were instructed to chew gum at least 6 times a day in an effort to reduce snacking.
1862609|NCT01043471|Other|Water|Subjects were instructed to drink 8 oz of water at least 6 times a day in an effort to reduce snacking.
1862610|NCT01043484|Drug|Bevacizumab + Capecitabine + Radiotherapy|Bevacizumab (5 mg/kg; days 1, 15 and 29) Capecitabine (825 mg/m2/12h, 5 days/w) Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
1862611|NCT01043484|Drug|Capecitabine + Radiotherapy|Capecitabine (825 mg/m2/12h, 5 days/w) and Radiotherapy (45 Gy in sessions of 1.8 Gy 5 times/w for 5 weeks)
1862612|NCT01043510|Drug|insulin degludec|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
1862613|NCT01043510|Drug|insulin detemir|0.6 U/kg body weight injected subcutaneously (under the skin), once daily for 6 days
1862614|NCT01043523|Drug|Gadoxetic Acid Disodium (Eovist, BAY86-4873)|Participants have received Primovist/Eovist for liver Magnetic Resonance Imaging (MRI) as part of their routine care at participating institutions and additional diagnostic information are identified retrospectively from institution records
1862615|NCT01043536|Radiation|radiotherapy|patients will receive from 6 to 7 weeks 5 days a week radiations. The dose of radiation will depend on the level they will be included.
1862616|NCT01043536|Drug|temozolomide|patient will receive whatever the level 7 days a week, temozolomide at the dose of 75mg/m2 during radiotherapy period. They will then follow one month after the end the radiochemotherapy an adjuvant treatment corresponding to a 5 days treatments of temozolomide at the dose of 200mg/m2 every 28 days.
1862617|NCT01043549|Device|rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
1862618|NCT01043549|Device|Sham rTMS|Repetitive transcranial stimulation of the posterior parietal cortex
1862619|NCT01043575|Drug|Rifapentine|During the first 8 weeks of therapy for TB participants > 45 kg will receive rifapentine 600 mg orally given 5 per week and for participants < 45 kg participants will receive 450 mg orally given 5 days per week
1862620|NCT01043575|Drug|Rifampin|During the first 8 weeks of therapy participants will receive rifampin at standard doses (e.g. 600 mg) 5 days per week
1862621|NCT01043588|Procedure|TURP|TransUrethral Resection of the Prostate
1862622|NCT01043588|Procedure|PVP|Photo selective Vaporization of the Prostate
1862623|NCT01043601|Drug|Inhaled PT005|inhaled, twice daily for 1 week duration
1862624|NCT01043601|Drug|Inhaled Placebo|inhaled, twice daily for 1 week duration
1862625|NCT01043601|Drug|Formoterol Fumarate 12 µg (Foradil Aerolizer)|inhaled, twice daily for 1 week duration
1862626|NCT01043614|Behavioral|PEER group intervention|An exercise and nutrition intervention that is based on self-efficacy principles and delivered primarily by peer educators to reduce the risk for obesity in female college freshman over one academic year
1862627|NCT01043640|Drug|Campath-1H|Administered Days -21, -20 and -19, 0.3 mg/kg subcutaneously (SQ) or intravenously (IV)
1862628|NCT01043640|Drug|Cyclophosphamide|Administered days -10 through -6, 50 mg/kg/day intravenous (IV) over 2 hours - with Mesna continuous infusion or 5 times daily.
1862629|NCT01043640|Drug|Busulfan|Administered every 6 hours: If < or = 12 kg then 1.1 mg/kg/dose intravenous (IV). If > 12 kg then 0.8 mg/kg/dose IV
1862630|NCT01043640|Procedure|Allogeneic stem cell transplantation|Administered > 24 hours after last dose of busulfan.
1862631|NCT01043640|Drug|Cyclosporine A|"2.5 mg/kg/dose intravenous (IV_ beginning on day -3. Frequency of daily dosing will be based on the recipient's body weight:
If body weight is ≤ 40 kg dosing will be 3 times daily
If body weight is > 40 kg dosing will be 2 times daily An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2 times the current IV dose (maximum 12.5 mg/kg/day as initial oral dose)."
1862632|NCT01043640|Drug|Mycophenolate Mofetil|15 mg/kg/dose (max dose of 1gram) IV three times a day beginning on Day -3 at a dose based on body weight: The same dosage is used orally or intravenously. Stop MMF at day +42 or 7 days after engraftment achieved (ANC>500 x 10^6 neutrophils/L x 3 days and chimerism >90%), whichever is later.
1862633|NCT01043666|Drug|YM178|oral
1862634|NCT01043666|Drug|Placebo|oral
1862635|NCT01043666|Drug|tolterodine ER|oral
1862636|NCT01043679|Drug|Utapine|Efficacy and Safety of Utapine
1862637|NCT01043679|Drug|Seroquel|Efficacy and Safety of Seroquel
1862638|NCT01043692|Other|Acupuncture|Acupuncture in the Treatment of MUSCULOSKELETAR Pain in Hospitalised Elderly
1862639|NCT01043718|Behavioral|More-Intensive|The online lifestyle intervention will include elements of a behavioral lifestyle program developed by the Diabetes Prevention Program. The program will assist individual participants with establishing appropriate weight loss goals, implementing dietary recommendations (including analysis of current diet), and defining exercise programs. The program curriculum provides standard information about healthy lifestyle, and behavioral techniques for integrating them into daily living. In each lesson, patients provide feedback about how they interpret the information, and ideas for integrating it into their lives.
1862640|NCT01043718|Behavioral|Less-Intensive|The participants will be provided with the information to access the online Diabetes Prevention Program (DPP) intervention materials. Following the original DPP trial, all DPP materials were placed online for the public to access. This group will receive a lifestyle counseling session and tools to facilitate their intervention.
1862641|NCT01043731|Procedure|Laparoscopic transvaginal hybrid anterior resection|Transvaginal Hybrid Anterior Resection: three 5mm trocars are placed transabdominally (one trans-umbilical, the other two in the lower abdomen). Identification of the inferior mesenteric vein and artery. Clipping of the vein. Then placement of a 12mm trocar through the posterior fornix of the vagina for stapling of the inferior mesenteric artery. After mobilisation of the colon descendens and the splenic flexure stapling of the proximal rectum through the 12mm trocar placed vaginally. Afterwards the colpotomy is performed and the mobilised left hemi-colon is extracted transvaginally. The proximal colonic resection is performed extracorporeally in the conventional fashion with placement of a purse-string suture and insertion of the circular stapling anvil into the proximal end of the bowel. The bowel is then replaced into the abdominal cavity. The colpotomy is then closed. A circular stapler is inserted transanally and the end-to-end anastomosis is performed.
1862642|NCT01043744|Drug|Artemether-Lumefantrine|"Artemether-lumefantrine (Coartem; Novartis) administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of:
1 tablet (for patients weighing 5-14 kg)
2 tablets (for patients weighing 15-24 kg)"
1862643|NCT01043757|Behavioral|Financial incentives for increasing physical exercise|Throughout the 12-week intervention, participants will receive step goals. The step goals will increase by 250 steps per week, The intervention will last a total of 12 weeks. After each seven-day week, step goals will increase by an additional 250 steps - thus over the 12 weeks, participants will be asked to increase their daily step count by 3,000. Participants will receive financial incentives to attain these step goals; the incentive schemes differ according to intervention arm.
1862644|NCT01043770|Behavioral|Group lifestyle education|Structured group education programme based on lifestyle changes (dietary and increased physical activity)
1862645|NCT01043783|Other|Dietary Adherence|Subjects consumed a specified healthy, balanced, reduced calorie diet and provided timed breath samples.
1862646|NCT01043796|Other|Insecticide treated nets and wall liners|Participants will be provided a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme. Households where participants reside will be fitted with insecticide treated wall liners.
1862647|NCT01043796|Other|Insecticide treated nets alone|Participants will be provided with a long-lasting insecticide treated net recommended by the WHO Pesticide Evaluation Scheme
1862648|NCT01043809|Behavioral|Procter & Gamble school-based handwashing promotion program|Handwashing promotion lesson and materials targeting first grade students
1862649|NCT01043809|Behavioral|expanded school-based handwashing promotion|Procter & Gamble's standard school-based handwashing promotion education and materials targeting first grade students, plus a program enhancement. In China, enhancement consists of a supply of soap for school sinks. In Pakistan, enhancement consists of soap for school sinks, plus enlistment of a peer hygiene champion in each first grade class. In the Philippines, enhancement consists of enlistment of a peer hygiene champion in each first grade class.
1862650|NCT01043835|Procedure|Laparoscopy-assisted gastrectomy|A 10-mm trocar for laparoscope was inserted below the umbilicus. Another 10-mm trocar was introduced in the left preaxillary line 2 cm below the costal margin as a major hand port，and a 5-mm trocar was placed at the contralateral site for traction. A 5-mm trocar was inserted in the left midclavicular line 2 cm above the umbilicus as an accessory port, and a 15-mm trocar also as an accessory port was placed at the contralateral site. The operator stood on the left side of the patient. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction. Dissected stomach and lymph node are collected through additional 5 cm incision at a median superior abdominal incision.
1862651|NCT01043835|Procedure|Open gastrectomy|Approximately 15~20 cm length incision is made from falciform process to periumbilical area. Subtotal or total gastrectomy and D2 lymph node dissection will be performed basically. As a general rule, Billroth I, Billroth II or Roux-Y method was used for gastric reconstruction for all cases.
1862652|NCT01043848|Procedure|external electric pudendal nerve stimulation|"intervention timing: twice daily for 20 minutes during 3 consecutive months.
intervention procedure: electrodes will be placed around the penile shaft (in males) or clips will be directly placed on the clitoris (in females).
intervention device: contic+
stimulation parameters: 10 Hz, 200μs pulse width, 10mA (or less, if too uncomfortable)."
1862653|NCT01043874|Drug|Nilotinib|400 mg BID
1862654|NCT01043887|Drug|ridaforolimus|single oral dose administration 10 mg ridaforolimus
1862655|NCT01043900|Procedure|repetitive transcranial magnetic stimulation (rTMS)|30 daily sessions: each with 40 trains of 5 seconds at 10Hz, with a 25 second inter-train interval, at an intensity of 110% of motor threshold. Site: Right Dorsolateral Prefrontal Cortex
1862656|NCT01043913|Drug|Guarana extract|Guarana extract 50mg q12 hours for 21 days
1862657|NCT01043926|Drug|Suvorexant|single 20 mg dose of suvorexant will be administered as 2 x 10 mg film coated tablets on Day 1 after an overnight fast with water.
1862658|NCT01043939|Other|Purple Grape Juice|6 ounces of purple grape juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
1862659|NCT01043939|Other|Apple Juice|6 ounces of clear apple juice consumed twice daily either during first or second 4 week supplementation period, depending on sequence randomization
1862697|NCT01044212|Drug|Bowel medications|Docusate 100mg BID Metamucil fiber wafers - 2 wafers daily Miralax 1 packet daily Bisacodyl 1 suppository BID
1863059|NCT01047072|Drug|mycophenolate mofetil|Given orally
1862660|NCT01043952|Drug|Propofol|Propofol is used as an anesthetic drug on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
1862661|NCT01043952|Drug|Remifentanil|Remifentanil is used as analgesic drug, as a part of the total intravenous anaesthesia, on all patients, with the dosing depending on patient age, weight, body mass index, general status, the hemodynamic and neurophysiological response to the previously administered dose and the degree of surgical stimulation, and in the Bispectral Index Monitor arm, depending on the BIS values.
1862662|NCT01043952|Device|Bispectral Index Monitor|Bispectral Index Monitor (BIS monitor integrated in the IntelliVue Patient monitor MP70, Philips) is used to monitor the depth of anesthesia. The values this monitor reports are used as an aid in evaluating the response of the single patient to the administered anesthetics, and as a guide in adjusting the dosing of anesthetics. We follow the algorithm from: http://www.biseducation.com/assets.aspx?ac=1 (ASA Practice Advisory White Paper)
1862663|NCT01043965|Drug|Metformin|Metformin 850mg
1862664|NCT01043978|Behavioral|Use of baby bottle nipple|Participants will be assigned to either a novel nipple or a conventional nipple to use when feeding their infants with the bottle
1862665|NCT01043991|Drug|Darbepoetin alfa|
1862666|NCT01043991|Drug|Placebo|
1862667|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
1862668|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
1862669|NCT01044004|Drug|Armodafinil|Armodafinil 150 mg/day for 13 weeks
1862670|NCT01044004|Drug|placebo|Placebo 150mg/day for 13 weeks
1862671|NCT01044017|Drug|Placebo|single oral dose
1862672|NCT01044017|Drug|RO4998452|single oral doses
1862673|NCT01044030|Drug|Xylitol syrup|7.5 mL (5 grams) by mouth three times daily
1862674|NCT01044030|Drug|Placebo|7.5 mL by mouth three times daily
1862675|NCT01044043|Procedure|clinical examination and quality of life questionnaire|clinical examination and quality of life questionnaire
1862676|NCT01044056|Drug|Levonorgestrel (LNG)/Ethinylestradiol (EE) oral contraceptive tablets|LNG/EE oral contraceptive tablets (Microgynon® 30), 21 in total, containing 0.150 mg LNG and 0.030 mg EE per tablet administered once daily orally for 21 consecutive days.
1862677|NCT01044056|Drug|norelgestrominum and ethinylestradiol patch oral contraceptive patch|A contraceptive patch (EVRA ™), one patch for 7 days for three consecutive weeks, 3 patches in total, applied on the lower abdomen. Dose: per patch 6 mg norelgestromin and 0.750 mg EE releasing 0.150 mg norelgestromin and 0.020 mg EE per day.
1862678|NCT01044056|Drug|Nuvaring ™ (etonorgestrel/ethinylestradiol)|NuvaRing ™ , one ring for a period of 21 days, inserted vaginally. Dose: per ring 11.7 mg etonogestrel and 2.7 mg EE releasing a daily average amount of 0.120 mg etonogestrel and 0.015 mg EE.
1862679|NCT01044069|Biological|gene-modified T cells targeted|Pts will undergo leukapheresis. The leukapheresis product will be washed & frozen until the GTF is directed to start T cell production by the PI. CD3+ T cells will be isolated from the leukapheresis, & transduced with the 19-28z chimeric receptor & expanded. All relapsed (either MRD+ or morphologic) & refractory pts get re-induction chemo whenever feasible to optimally reduce the tumor burden prior to the T cell infusion. The re-induction chemo regimen will be selected by the treating dr. based on prior therapy, adverse reactions to chemo & highest likelihood to achieve an optimal response. Once pts recover from the toxicities of the re-induction chemo the disease status will be re-evaluated by repeating bone marrow aspirate or biopsy. Pts get conditioning chemo (min 2 weeks from end of re-induction chemo) followed 2-7 days later by the 19-28z+ T cells. Pts will be tx in 2 cohorts with diff doses of T cells according to the amount of disease immediately prior to the T cell infusion.
1862680|NCT01044082|Procedure|controlled cord traction|In the intervention group, controlled cord traction will be applied as soon as a firm uterine contraction is obtained, and until placental delivery occurs
1862681|NCT01044082|Procedure|Clinical signs of placental separation|Clinical signs of placental separation will be awaited for, and then placental expulsion may be helped through maternal pushing and/or hypogastric pressure
1862682|NCT01044095|Biological|FluMist® live, attenuated, intranasal seasonal influenza vaccine|FluMist® live, attenuated, intranasal seasonal influenza vaccine 0.2mL (0.1mL per nostril)
1862683|NCT01044095|Biological|Fluzone® inactivated influenza virus vaccine|Fluzone® inactivated influenza virus vaccine 0.5mL intramuscularly
1862684|NCT01044108|Drug|NNC 0070-0002-0453|Administration of a single subcutaneous (under the skin) dose. Up to 7 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
1862685|NCT01044108|Drug|'2-0453|Administration of multiple subcutaneous (under the skin) doses for 10 weeks. Up to 4 escalating dose levels will be investigated. Progression to next dose level will be based on a safety evaluation.
1862686|NCT01044108|Drug|placebo|Placebo will be administered as a comparator at each dose level.
1862687|NCT01044121|Other|Mattress Firmness|Current mattress and 6 experimental firmnesses of mattress as defined by a Comfort Support Analysis device.
1862688|NCT01044134|Behavioral|Dietary counseling|Participants will receive personalized dietary counseling to promote behavior change
1862689|NCT01044147|Behavioral|VLM-S|Online program for weight loss - standard
1862690|NCT01044147|Behavioral|VLM-M|Online program for weight loss - modulated
1862691|NCT01044147|Behavioral|OGR|Online program for weight loss - resources
1862692|NCT01044173|Device|MR scan|axial and coronal free breathing HASTE sequences 3D T1 weighted gradient echo breathhold
1862693|NCT01044186|Drug|ICL670|
1862694|NCT01044199|Biological|PCEC rabies vaccine given intradermally|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
1862695|NCT01044199|Biological|PCEC rabies vaccine administered intramuscularly|PCEC rabies vaccine will be given intradermally compared with intramuscular administration (standard), in 2 different schedules: Pre-Exposure schedule for participants never vaccinated against rabies before; and Booster schedule for participants vaccinated against rabies in the past.
1862696|NCT01044212|Drug|Docusate|Docusate 100mg BID
1863060|NCT01047072|Biological|rituximab|Given IV
1862698|NCT01044225|Drug|Cetuximab|An initial dose of 400 mg/m² IV over 2 hours and followed by a weekly dose of 250 mg/m² over 1 hour.
1862699|NCT01044225|Drug|Cilengitide EMD 121974|A dose of 2000 mg by IV administration 2 weekly.
1862700|NCT01044238|Drug|methylphenidate|18mg/day in week 1; 36mg/day in week 2; 54mg/day in week 3 - participants randomized to either active medication (methylphenidate) or placebo matched to active drug
1862701|NCT01044238|Drug|Methylphenidate|18mg/day for week 1; 36mg/day for week 2; 54mg/day for remainder of study - participants randomized to either active medication (methylphenidate) or placebo
1862702|NCT01044251|Drug|Frovatriptan|2.5 mg po bid for 10 days
1862703|NCT01044251|Drug|Placebo|1 tab po bid for 10 days
1862704|NCT01044264|Drug|1% Clindamycin/5% Benzoyl Peroxide Topical Gel|Topical Gel
1862705|NCT01044264|Drug|Placebo|Placebo
1862706|NCT01044277|Drug|Glutathione supplementation|500 mg, two times daily
1862707|NCT01044277|Drug|Gluthathione peroxidases|125 mg, two times daily
1862708|NCT01044277|Other|Placebo|2 times daily
1862709|NCT01036594|Drug|Ketoconazole, hydrocortisone|Ketoconazole 400mg po tid Hydrocortisone 20mg po qam and 10mg po qpm
1862710|NCT01036594|Drug|Ketoconazole, dexamethasone|Ketoconazole 400md po tid Dexamethasone 1mg po bid
1862711|NCT01036633|Device|Infrared Thermometer|The infrared thermometer will be used to grade the severity of oral mucositis in patients undergoing antineoplastic chemotherapy for multiple myeloma. The photothermal camera will be used to take intraoral digital images of the mouth.
1862713|NCT01036724|Device|Cardiac Mapping|Generating a cardiac map using the study device (CARTO 3) compared to the control device (NAVX[TM]) and measuring the amount of radiation exposure duration for each.
1862714|NCT01036802|Drug|Warfarin|Patients on the active treatment arm will receive warfarin to achieve a target international normalized ratio of between 2 and 3
1862715|NCT01036802|Drug|Placebo|
1862716|NCT01036841|Drug|desmopressin tablet|Administration of desmopressine tablet
1862717|NCT01036841|Drug|desmopressin MELT formulation|Administration of desmopressine MELT formulation
1862718|NCT01036854|Drug|EUR-1025|orally, 24 mg, daily for 6 days
1862719|NCT01036854|Drug|EUR-1025|orally, 8 mg, twice daily over 6 consecutive days
1862720|NCT01036854|Drug|EUR-1025|orally, 8 mg, three times a day over 6 consecutive days
1862721|NCT01036854|Drug|EUR-1025|orally, 8 mg, 16 mg, 24 mg, daily, for 6 days
1862722|NCT01036893|Drug|prucalopride|prucalopride 2 mg oral dosing o.d. for 6 days
1862723|NCT01036932|Drug|Granulocyte Colony Stimulating Factor|Dose of 5 µg/kg s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
1862724|NCT01036932|Drug|Normal Saline|dose of 1ml s/c at days 1, 2, 3, 4, 5, and then every 3rd day till day 28 (total 12 doses) along with the standard therapy.
1862725|NCT01037023|Drug|Topotecan|patients administrated Topotecan according to the prescribing information
1862726|NCT01037036|Drug|Latanoprost Punctal Plug Delivery System|To evaluate the control of IOP compared to baseline, for an experimental dose of Latanoprost Punctal Plug Delivery System for 4 week or until loss of efficacy. This is a single arm study.
1862727|NCT01037036|Drug|Xalatan|Subjects will administer adjunctive Xalatan eye drops once daily for 2 weeks. This is a single arm study.
1862728|NCT01037049|Other|Patients who have surgery at 12 weeks after radiotherapy/chemoradiotherapy|
1862729|NCT01037062|Drug|Entecavir|Tablet, P.O. 0.5, 1 mg, once daily
1862730|NCT01037088|Drug|Cannabis|3.53% THC by weight
1862731|NCT01037088|Drug|Cannabis|1.29% THC by weight
1862732|NCT01037088|Drug|Cannabis|0.00% THC by weight
1862733|NCT01037101|Behavioral|In Vivo Exposure Therapy|Three hours of exposure therapy in a high place
1862734|NCT01037101|Behavioral|Virtual Reality Exposure Therapy|Three hours of exposure therapy using a virtual reality system
1862735|NCT01037101|Drug|D-Cycloserine|50 mg of DCS administered 30 minutes before the session
1862736|NCT01037101|Drug|Placebo|50 mg placebo administered 30 minutes before the session
1862737|NCT01037114|Procedure|Blood sampling|Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).
1862738|NCT01037114|Biological|EngerixTM-B|Engerix-B will be administered to subjects who are not seroprotected against hepatitis B.
1862739|NCT01037114|Biological|Havrix|Havrix will be administered to subjects who are seronegative for anti-HAV antibodies.
1862740|NCT01037127|Drug|GSK1120212|Daily oral dosing
1862741|NCT01037140|Drug|Cholecalciferol|oral cholecalciferol tablets of 175 micrograms daily for 6 months
1862742|NCT01037140|Drug|placebo|oral placebo tablets similar to active comparator
1862743|NCT01037166|Drug|Entecavir|Tablet, P.O., 0.5 mg or 1mg, once daily, 52 weeks
1862744|NCT01037179|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|
1862745|NCT01037192|Drug|vancomycin|vancomycin 30 mg/kg intravenous administered once daily
1862746|NCT01037192|Drug|vancomycin|vancomycin 15 mg/kg intravenous administered twice daily (standard dosing)
1862747|NCT01037205|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
1862748|NCT01037205|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
1862749|NCT01037218|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
1862750|NCT01037218|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
1862751|NCT01037231|Biological|Oxalobacter formigenes|NLT (not less than) 10^7 CFU oxalobacter formigenes twice daily for 24 weeks
1862752|NCT01037231|Drug|Placebo|placebo
1862753|NCT01037244|Drug|Udenafil|Tablets via oral administration before an attempt at sexual intercourse.
1862754|NCT01037244|Drug|Placebo|Tablets via oral administration before an attempt at sexual intercourse.
1862755|NCT01037283|Behavioral|Interpersonal and Social Rhythm Therapy|Interpersonal and Social Rhythm Therapy delivered in two individual therapy sessions and six group therapy sessions.
1862756|NCT01037296|Procedure|catheter ablation|ablation procedure performed with Hansen robotic navigation system
1862757|NCT01037296|Procedure|catheter ablation|Ablation will be performed as normal treatment
1862758|NCT01037309|Drug|PRO044 SC|Subcutaneous injection, once a week, for five weeks
1862759|NCT01037309|Drug|PRO044 IV|Intravenous injection, once a week, for five weeks
1862760|NCT01037322|Drug|cannabidiol|cannabidiol given in olive oil drops, 5 mg twice daily
1862761|NCT01037322|Drug|placebo in drops|olive oil containing no drug given in drops twice daily
1862762|NCT01037335|Drug|morphine|Group 1 (control group) was given 10 ml normal saline (NS) infiltrated into the harvest site, and 1 ml NS was administered intramuscularly. Group 2 (intramuscular morphine) was given 10 ml NS infiltrated into the harvest site and 5 mg morphine (1 ml) intramuscularly. Group 3 (donor site morphine) was given 5 mg morphine (10 ml) infiltrated into the harvest site and 1 ml NS intramuscularly.
1862763|NCT01037348|Drug|ranibizumab 0.5mg|
1862764|NCT01037374|Other|Preoperative assessment form|(based on the american society of anesthesiologists)components of the form include: neck measurements; neck mobility; mallampati; wilson's test; pre-existing conditions; and predictions of difficult mask ventilation, supraglottic airway, laryngoscopy, intubation, and surgical airway.
1862765|NCT01037387|Drug|Control|Current treatment according to the ATS/ERS guidelines
1862766|NCT01037387|Device|NIMV group|Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
1862767|NCT01037413|Drug|EXC 001|Multiple intradermal injections of EXC 001 and placebo
1862768|NCT01037413|Drug|Placebo|Multiple intradermal injections of EXC 001 and placebo
1862769|NCT01037426|Other|Fill out Questionnaire|"Questionnaire at time of Implantation and 12 months after pacemaker implantation to collect
History of falls and fractures during the 12 months before pacemaker implantation
Risk markers for falls based on FRAX risk calculator (age, gender, weight, height, history of previous fracture, family history of hip fracture, current smoking habits, glucocorticosteroid intake, rheumatoid arthritis, secondary osteoporosis, alcohol intake)
History of falls and fractures during the 12 months after pacemaker implantation
Medical and Arrhythmia History
Cardiovascular Events
Cardiovascular Medication
Device programming information"
1862770|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide/Lansoprazole 15 mg|Tablet
1862771|NCT01037452|Drug|Lansoprazole|Tablet
1862772|NCT01037452|Drug|Calcium carbonate/magnesium hydroxide|Tablet
1862773|NCT01037452|Drug|Placebo|Tablet
1862774|NCT01037465|Drug|N-acetylcysteine|N-acetylcysteine
1862775|NCT01037465|Drug|Placebo|Placebo
1862776|NCT01037478|Drug|Resminostat (4SC-201)|oral administration
1862777|NCT01037491|Drug|rabeprazole plus aspirin versus rabeprazole plus clopidogrel|The primary end point is treatment success (ulcer healing rate). The secondary end point is incidence of ulcer bleeding within 12 weeks.
1862778|NCT01037504|Drug|AZD5423|Suspension for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days. Starting dose as determined from SAD study and with up to 4 dose escalations not exceeding AstraZeneca pre-defined exposure limits.
1862779|NCT01037504|Drug|Placebo|Solution for nebulisation, inhaled. Each subject will receive an inhaled dose of AZD5423 or placebo once daily for 14 days.
1862780|NCT01037517|Drug|Plerixafor|Plerixafor will be administered at 23:00 of Day -1 to experimental subjects at a dose of 240 mcg/kg subcutaneously, and possibly repeated the following day
1862781|NCT01037517|Other|Observation: Nonintervention|Nonintervention group, no drug will be given, observation only
1862782|NCT01037530|Drug|Ramipril|5 mg/day for 2 weeks then 10 mg/day for 22 weeks
1862783|NCT01037543|Drug|HM10460A or placebo or Neulasta|Single SC injection of the appropriate dose of drug ranging from 1.1 mcg/kg to 270 mcg/kg.
1862784|NCT01037556|Drug|PR104|Nine pre-defined dose levels for specific subsets of subjects will be administered by IV (in the vein). PR104 will be administered initially as induction therapy followed by administration as consolidation therapy, as is typical of established treatment regimens in AML.
1862785|NCT01037582|Drug|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924, at escalating dose levels. Progression to next dose will be based on safety evaluation.
1862786|NCT01037582|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9924, at all dose levels.
1862787|NCT01037582|Drug|NN9924 (oral)|Subjects will be randomized to receive a single dose of NN9924 in one of three different concentrations. The dose will be selected based on the results of part 1.
1862788|NCT01037582|Drug|placebo|Subjects will be randomized to receive a single dose of placebo.
1862789|NCT01037582|Drug|NN9924 (s.c.)|As an active comparator, one standard dose will be given s.c. (under the skin) at one study visit
1862790|NCT01037582|Drug|NN9924 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit.
1862791|NCT01037595|Drug|turmeric|turmeric 500 md tid orally for 8 weeks
1862792|NCT01037595|Drug|placebo|placebo 3 time orally for 8 weeks
1862793|NCT01037595|Drug|turmeric|500 mg tid orally for 8 weeks
1862794|NCT01037608|Drug|Sativex(Registered Trademark)|
1862795|NCT01037608|Drug|THC|
1862796|NCT01037621|Drug|Valacyclovir|Valacyclovir 500 mg, 2 caplets twice daily for eight weeks
1862797|NCT01037634|Drug|Oseltamivir|3 mg/kg given orally for 5 days for seasonal influenza, 7 days for 2009 H1N1 influenza (in Vietnam only), or 10 days for avian influenza, for children whose renal function is greater than or equal to 30 mL/min/1.73m2
1862798|NCT01037647|Other|Hyperinsulinemic euglycemic glucose clamp|Hyperinsulinemic euglycemic glucose clamp, duration 5 hours, plasma glucose 5 mmol/l, insulin dosage 1,0 mU•kg FFM/min, human insulin (Actrapid; Novo Nordisk A/S).
1862799|NCT01037660|Drug|Metformin|Metformin 1 gram per day
1862800|NCT01037673|Procedure|Exercise program|A progressive program where load and complexity increases during a 3 month period. Initially PT-tutored every week and then every other week.
1862801|NCT01037673|Procedure|Movement exercises|A program with the same movements to maintain flexibility in the neck and shoulder. Initially PT-tutored every week and then every other week.
1862888|NCT01045863|Drug|PF-03382792 Cohort 2|Second cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
1863061|NCT01047072|Drug|cyclophosphamide|Given orally
1862802|NCT01037686|Radiation|Injection of 15mCi of Tc-ECD and scanning by SPECT camera|All subjects (PD patients with or without DBS and healthy controls) will be injected with 15mCi of Tc-ECD and afterwards will be scanned by an Irix SPECT camera.
1862803|NCT01037686|Behavioral|Semantic verbal fluency task performance|All Subjects (PD patients with or without DBS and healthy controls) before one of the two scans will perform the semantic verbal fluency task during the Tc-ECD uptake for 9 minutes. Before the other scan subjects will be at rest.
1862804|NCT01037686|Device|Turning off the stimulator|For PD patients treated with DBS, the neurologist will turn off the stimulator after the injection of Tc-ECD for ten minutes and then turn it back on.
1862805|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone|
1862806|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone|
1862807|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
1862808|NCT01037699|Drug|rFSH: Follicle Stimulating Hormone and rLH: Luteinizing Hormone (Recombinant Luteotrophin alfa)|
1862809|NCT01037712|Drug|Valacyclovir (ZELITREX)|2g, 8g/day, 4 a day 23 weeks maximum.
1862810|NCT01037712|Drug|Placebo|placebo
1862811|NCT01037725|Drug|AZD5847|"Part A - Oral doses given to approximately 6 cohorts of 8 subjects (6 on active and 2 on placebo) on Day 1.
Part B - Oral doses of AZD5847 given to 1 cohort of 8 subjects on Days 1 and 8 in either a fasted state or with a high fat meal"
1862812|NCT01037725|Drug|Placebo to AZD5847|In Part A - Single oral doses of AZD5847placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) on Day 1
1862814|NCT01037751|Behavioral|Interview|1-on-1 interview with study doctor or staff member, during regularly scheduled, standard of care clinic visit taking 30 minutes.
1862815|NCT01037751|Behavioral|Survey|Complete 3 Questionnaires during clinic visit, about 10 minutes to complete all.
1862816|NCT01037764|Procedure|alloHCT|"[ alloHCT arm ] Bu-Cy conditioning; Busulfan (Bu) 3.2 mg/kg*/day iv daily on days -7 and -4. Cyclophosphamide (Cy) 60 mg/kg* in D5W 200 mL iv over 1-2 hours daily on days -3 and -2.
BuFluATG conditioning; Bu 3.2 mg/kg*/day iv daily on days -7 and -6. Fludarabine (Flu) 30 mg/m2/day in D5W 100 ml iv over 30 minutes starting at 4 pm daily on days -7, -6, -5, -4, -3, and -2.
Anti-thymocyte globulin (ATG, Thymoglobulin, Genzyme Transplant, Cambridge, MA, USA) 1.5 mg/kg/day (for HLA-matched sibling HCT) or 3.0 mg/kg/day (for HLA-matched unrelated donor HCT or HLA-mismatched familial donor HCT) in N/S 500-800 ml (less than 4 mg/ml) iv over 4 hours starting at 8 am daily on days , -3, -2 and -1."
1862817|NCT01037790|Drug|PD-0332991|Given orally, 125 mg QD on a 21-day
1862818|NCT01037790|Other|pharmacological study|Correlative study
1862819|NCT01044290|Other|Life Completion|Subjects discussed life review, issues of forgiveness and heritage and legacy.
1862820|NCT01044290|Other|Attention Control|Subjects listened to a non-guided relaxation CD
1862821|NCT01044303|Drug|Myfortic Escalation|Dose increases of 180 mg every 3 months until DSA titer is zero or until maximum tolerable dose of EC-MPS is achieved. Maximum dose will not exceed 2160 mg daily.
1862822|NCT01044316|Biological|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines - a monovalent glycoprotein-conjugated (diptheria toxin - CRM197) vaccine and a tetanus toxoid-conjugated vaccine.
1862823|NCT01044329|Drug|Bevacizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
1862824|NCT01044329|Drug|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
1862825|NCT01044342|Drug|AZD1446|capsule; single oral dose
1862826|NCT01044342|Drug|AZD1446|capsule, single oral dose
1862827|NCT01044342|Drug|donepezil|capsule, single oral dose
1862828|NCT01044342|Drug|Placebo|capsule, single oral dose
1862829|NCT01044355|Device|CPAP|6 weeks treatment with fixed CPAP
1862830|NCT01044355|Device|APAP|6 weeks of treatment with auto-titrating positive airway pressure
1862831|NCT01044368|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
1862832|NCT01044381|Drug|Luliconazole Solution, 10%|28 days of daily application
1862833|NCT01044394|Drug|polyethylene glycol (PEG-ELS) and bisacodyl tablets|2 liters of PEG-ELS and 10mg of bisacodyl tablets once the morning of the colonoscopy
1862834|NCT01044407|Device|Pacemaker manipulation|Alternation of cardiac output by modulation of heart rate, atrioventricular delay and modulation from biventricular pacing to right ventricular pacing (where applicable)via a cardiac pacemaker
1862835|NCT01044420|Drug|mFOLFIRI|mFOLFIRI irinotecan 130-150mg/m2 iv d1 LV 200 mg/m2 iv 2h d1 5-FU 400 mg/m2 IV d1 5-FU 2.4-3 g/m2 CI 46-h repeat every 2 weeks
1862836|NCT01044433|Drug|lapatinib ditosylate|Given orally
1862837|NCT01044433|Drug|capecitabine|Given orally
1862838|NCT01044446|Drug|Icodextrin|one exchange daily
1862839|NCT01044446|Drug|glucose-based peritoneal dialysate|original exchange frequency
1862840|NCT01044459|Drug|Aclidinium Bromide 200 µg|aclidinium bromide 200 μg, oral inhalation twice per day for 52 weeks of treatment
1862841|NCT01044459|Drug|Aclidinium Bromide 400 µg|aclidinium bromide 400 μg, oral inhalation twice per day for 52 weeks of treatment
1862842|NCT01044485|Drug|lapatinib|escalation dose from 1250 to 1500 mg in association with docetaxel
1862843|NCT01044485|Drug|docetaxel|escalation dose from 75 mg/m2 to 100 mg/m2 in association with lapatinib
1862844|NCT01044498|Drug|Tocilizumab|Tocilizumab 8 mg/kg was administered in a single 1-hour infusion on Day 1 of Cycle 2.
1862845|NCT01044498|Drug|Ortho-Novum® 1/35|Each Ortho-Novum® 1/35 tablet contained 1 mg of norethindrone and 0.035 mg of ethinyl estradiol.
1862846|NCT01044511|Behavioral|Home visits|home visits by specialist nurse 2 times and 1 phonecall
1862847|NCT01044511|Behavioral|standard|hotline
1862848|NCT01044524|Radiation|SLV 334|2000 mg via i.v. solution
1862849|NCT01044537|Drug|Placebo|Placebo to match PF-04937319 will be provided.
1863015|NCT01046786|Drug|Methylprednisolone|30 mg/kg methylprednisolone
1862850|NCT01044537|Drug|PF-04937319|The initial planned dosing schedule is: 10, 30, 100, 200, and 400 mg, with one cohort to be determined. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as a single oral dose as a powder-in-capsule (PIC) formulation. PF-04937319 will be supplied as 10 mg and 80 mg (and potentially 1 mg) PIC.
1862851|NCT01044550|Procedure|Laparoscopy|Treatment group will undergo a laparoscopy, with repair of the diaphragm if injury found
1862852|NCT01044550|Other|Clinical follow up|Control group will undergo no treatment except suturing of wounds and drainage of the hemo-pneumothorax, if present. Then clinical follow up.
1862853|NCT01044563|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
1862854|NCT01044563|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
1862855|NCT01044589|Device|Biodesign Tissue Repair Graft|Biodesign Tissue Repair Graft reinforcement
1862856|NCT01044589|Other|Overlapping Sphincter Repair|Overlapping Sphincter Repair Alone
1862857|NCT01044602|Other|Laboratory evaluations, sleep study|Fasting plasma glucose, liver function tests, chem-7, HOMA-IR, HBA1C, lipid profile, indirect calorimetry.
1862858|NCT01044602|Other|Best Medical Management|Standard of care.
1862859|NCT01044602|Procedure|Roux-en-Y gastric bypass surgery|Surgical treatment.
1862862|NCT01045629|Other|Consent form education|Randomly stratified schizophrenic patients group, some receive consent form education, the others not.
1862863|NCT01045642|Drug|Omeprazole|Omeprazole Magnesium DR Capsules 20 mg
1862864|NCT01045655|Behavioral|MOMCare|8 sessions of brief interpersonal psychotherapy or medication management; maintenance sessions through 12 months postpartum.
1862865|NCT01045668|Procedure|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT
1862866|NCT01045668|Procedure|Radiofrequency Catheter Ablation (RFCA)|RFCA of clinical VT as well as VT substrates
1862867|NCT01045681|Drug|Bendamustine, Velcade and Dexamethasone|Bendamustine : 70 mg/m2 iv on D1 and 8, for each cycle Velcade : 1.3 mg/m2 iv on D1, 8, 15 and 22, for each cycle Dexamethasone : 20 mg/day po on D1, 8, 15 and 22, given prior to Bendamustine and Velcade
1862868|NCT01045694|Drug|Botulinum Toxin Type A|One-time injection of 50 units of Botulinum Toxin A suspended in 2 mL of normal saline, with approximately 1 mL injected or sufficient quantity to fill joint capsule
1862869|NCT01045694|Drug|Steroid - Triamcinolone Acetonide|Single injection of 1 - 3 mL of 40mg/mL Triamcinolone acetonide solution
1862870|NCT01045694|Drug|Lidocaine|Single injection of 1 - 3 mL of 2% Lidocaine
1862871|NCT01045707|Drug|insulin degludec/insulin aspart|Injected s.c. (under the skin) once daily with the breakfast meal. Dose was individually adjusted.
1862872|NCT01045707|Drug|insulin glargine|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
1862873|NCT01045720|Drug|Suo Quan Wan, Wu Lin San|Suo Quan Wan Wu Lin San Placebo 2/daily
1862874|NCT01045720|Drug|Placebo|Placebo (starch)
1862875|NCT01045733|Device|AcrySof IQ Toric IOL|AcrySof IQ Toric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
1862876|NCT01045733|Device|AcrySof IQ Aspheric IOL|AcrySof IQ aspheric intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient.
1862877|NCT01045733|Procedure|Limbal Relaxing Incision (LRI)|An incision was made at the corneal-limbal junction during cataract surgery for the purpose of relaxing corneal curvature, ie., correcting astigmatism.
1862878|NCT01045746|Device|Stochastic resonance whole-body vibration A|over four weeks, three times a week with 5 Hz, Noise 4 and than over four weeks three times a week with 1 Hz, Noise 1.
1862879|NCT01045746|Device|Stochastic resonance whole-body vibration b|over four weeks, three times a week with 1 Hz, Noise 1 and than four weeks three times a week with 5 Hz, Noise 4.
1862880|NCT01045772|Drug|rilonacept|160mg of rilonacept 1x/week
1862881|NCT01045798|Drug|Caspofungin acetate|70 mg of caspofungin administered intravenously (IV) on Day 1 followed by 50 mg daily for at least 6 additional days (maximum duration study therapy is 14 days)
1862882|NCT01045798|Drug|Placebo|Placebo to caspofungin (normal saline) on Day 1 followed by placebo daily for at least 6 additional days (maximum duration study therapy is 14 days)
1862883|NCT01045811|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
1862884|NCT01045811|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
1862885|NCT01045837|Drug|Prednisolone and Gluten free diet|Gluten free diet and Oral Prednisolone in a dose of 1 mg/ kg will be given for a period of 4 weeks, thereafter Gluten free diet alone will be continued
1862886|NCT01045837|Behavioral|Gluten free diet|Only gluten free diet will be given in this group
1862887|NCT01045863|Drug|PF-03382792 Cohort 1|First cohort for: Single oral ascending dose of PF-03382792, formulated in solution.
1865129|NCT01055314|Drug|Ifosfamide|Given IV
1959887|NCT03312075|Other|Sputum and blood samples|The cystic fibrosis patient will have a first series of sputum as well as a blood sample. On the same day of consultation, a second expectoration will be performed as far as possible.
1959890|NCT03312023|Drug|Ledipasvir-Sofosbuvir|1 pill once daily for 12 weeks
1862889|NCT01045863|Drug|PF-03382792|Optional cohort 3: Single oral ascending dose of PF-03382792, formulated in solution.
1862890|NCT01045863|Drug|Food Effect cohort|Single oral dose, cross-over to determine effect of food on PF-03382792 pharmacokinetics. Dose will be decided after reviewing data from the ascending dose portion.
1862891|NCT01045863|Drug|CSF cohort|Single oral dose of PF-03382792 formulated in solution. Dose will be decided after reviewing data from the ascending dose portion.
1862892|NCT01045876|Drug|Dexamethasone|One dose of 8 mg of Dexamethasone intravenously at induction of anesthesia
1862893|NCT01045876|Other|Placebo|2 ml of 0.9% Saline Solution administered intravenously at induction of anesthesia
1862894|NCT01045889|Other|Rituximab and CHOP regimen + PBSCT|
1862895|NCT01045902|Drug|Avelox (Moxifloxacin, BAY12-8039)|Moxifloxacin, 400 mg iv, od, switch after 6 doses (6 days) to 400 mg Moxifloxacin oral, od
1862896|NCT01045902|Drug|Sulbactam/Ampicillin|Sulbactam/Ampicillin, 3 g iv, tid, switch after 18 doses (6 days) to 750 mg Sulbactam/Ampicillin oral, bid
1862897|NCT01045915|Biological|naked DNA coding for protein AMEP|2 injections 1 week interval of 4 increasing doses of plasmid with electrotransfer
1862898|NCT01045928|Drug|lenalidomide|Given orally
1862899|NCT01045928|Biological|rituximab|Given IV
1862900|NCT01045928|Genetic|polymerase chain reaction|Correlative study
1862901|NCT01045928|Genetic|nucleic acid sequencing|Correlative study
1862902|NCT01045928|Genetic|polymorphism analysis|Correlative study
1862903|NCT01045928|Other|flow cytometry|Correlative study
1862904|NCT01045928|Other|laboratory biomarker analysis|Correlative study
1862905|NCT01045941|Drug|Gemcitabine/Gemzar|Six cycles of Gemcitabine will be given. Each cycle of Gemcitabine comprises of Gemcitabine 1000 mg/m2 as a 30 minute infusion once weekly for 3 weeks with a fourth week off.
1862906|NCT01045941|Procedure|Laparoscopic Distal pancreatectomy|Laparoscopic resection of the distal pancreas
1862908|NCT01045967|Drug|Lansoprazole|30 mg delayed-release Capsule
1862909|NCT01045967|Drug|Prevacid®|30 mg delayed-release Capsule
1862910|NCT01045980|Drug|Bioimpedance and Vitamin D|Intervention subjects will undergo BIA assessment monthly for 1 year, and then every 3 months until the end of the planned 3-year study. Protocolized interventions to achieve euvolemia will occur based on the BIA result and they include sodium restriction, addition of diuretics, use of icodextrin, and additional rational changes to the PD prescription.
1862911|NCT01045980|Drug|Usual care and placebo|Usual care (not bioimpedance guided volume management) and Placebo
1862912|NCT01045980|Drug|Usual care and Vitamin D|Usual care (not bioimpedance guided volume management) and Vitamin D
1862913|NCT01045980|Device|Bioimpedance and Placebo|Bioimpedance guided volume management and Placebo
1862914|NCT01045993|Device|Heat Device|8-Hour Heatwrap
1862915|NCT01045993|Device|Sham Device|Inactive wrap worn for 8 hours
1862916|NCT01045993|Drug|marketed analgesic|2 x 200 mg ibuprofen tablets
1862917|NCT01045993|Drug|Placebo|2 x placebo tablets
1862918|NCT01046006|Drug|Bortezomib, Rituximab, Dexamethasone|"Bortezomib as an iv push over 3 to 5 seconds at a dose of 1.3mg/m2/day on days 1,4,8 and 11 of cycle 1.
On cycles 2-5 bortezomib will be given at a dose of 1.6mg/m2/day on days 1,8,15 and 22 of each 35-day cycle.
Dexamethasone IV 40 mg will be given on cycles 2 and 5 on days 1,8,15,22 Rituximab IV will be given on cycles 2 and 5, 375 mg/m2, on days 1,8,15,22 iv"
1862919|NCT01046032|Drug|Metformin|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
1862920|NCT01046032|Drug|Placebo|Women were randomised to receive either metformin or placebo starting three weeks before initiation of a GnRH agonist during an IVF treatment cycle (seven weeks prior to oocyte collection and then stopped at oocyte collection). Seventy identical packs of metformin and 70 identical packs of placebo were supplied by DHP Ltd, Crickhowell, Powys (UK) a commercial clinical trial supplier. The randomisation service was provided by DHP Ltd.
1862921|NCT01046045|Drug|everolimus|everolimus at an initial daily loading dose between 1 and 4 mg dose of everolimus will be adjusted to maintain a trough everolimus level between 5 and 12 ng/mL
1862922|NCT01046058|Drug|TMC435|150 mg (two 75-mg capsules) orally (by mouth) once daily for 7 days
1862923|NCT01046071|Procedure|transversus abdominis plane block|UL-guided TAP block with 20 ml of ropivacaine 0,5% bilateral, single dose.
1862924|NCT01046071|Procedure|TAP block placebo|UL-guided TAP block with 20 ml of saline bilaterally, single dose.
1862925|NCT01046084|Drug|Lansoprazole|30 mg Delayed-Release Capsule
1862926|NCT01046084|Drug|Prevacid®|30 mg Delayed-Release Capsule
1862927|NCT01046097|Biological|Synflorix™|Intramuscular administration of three doses/two doses/one dose of primary vaccination/the booster dose/ catch-up dose(s) of Synflorix according to local prescribing information.
1862928|NCT01046110|Drug|insulin degludec|Injected under the skin once daily for 26 weeks. The doses will be individually adjusted.
1862929|NCT01046110|Drug|sitagliptin|Sitagliptin tablets administered orally once a day at the same time every day for 26 weeks
1862930|NCT01046123|Radiation|whole brain radiotherapy (WBRT) and a simultaneous integrated boost (SIB) using volumetric modulated arc therapy|Patients will be treated with WBRT/SIB using VMAT, delivering a total of 20 Gy in 5 fractions to the whole brain and 50Gy in 5 fractions to the brain metastases, delivered once daily on working days.
1862931|NCT01046136|Drug|guaifenesin (Mucinex)|bid 7 days
1862932|NCT01046136|Drug|placebo|bid 7 days
1862933|NCT01046149|Behavioral|Breathing training|Respiratory sinus arrhythmia biofeedback-assisted deep breathing training
1862934|NCT01046149|Behavioral|Stress management|Cognitive reconstructive strategies for stress management
1862935|NCT01046162|Drug|Alprazolam|Single tablet
1862936|NCT01046162|Drug|Alprazolam|Single tablet
1865130|NCT01055314|Drug|Irinotecan Hydrochloride|Given IV
1862937|NCT01046175|Procedure|Air-stacking with a manual resuscitator|Stacking air into the lungs up to maximal insufflation capacity (MIC)with a manual resuscitator
1862938|NCT01046175|Procedure|Air-stacking with ventilator|Stacking air into the lungs to maximal insufflation capacity (MIC) with ventilator
1959891|NCT03312010|Device|Spinal Cord Stimulator HF|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
1959892|NCT03312010|Device|Spinal Cord Stimulator Sham|A needle and catheter is carefully inserted near your spinal column. The stimulator is then placed through the catheter close to your spinal column. The proximal end of the stimulator is then sutured underneath the skin of your back to the fascia to prevent migration.
1959893|NCT03311997|Procedure|Surgical reattachment of hamstring tendons|operatively reattachment of the tendons using suture anchor
1959894|NCT03311984|Diagnostic Test|anti Xa level|monitoring the anti-Xa level according to LMWH emploing
1862944|NCT01046214|Drug|Bupropion HCl|Budeprion XL™ 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the reference-placebo tablet
1862945|NCT01046214|Drug|Bupropion HCl|Wellbutrin XL® 300 mg Extended Release Tablet dosed once daily for 8 days, in the morning, after an overnight fast of at least 10 hours, with the test-placebo tablet
1862946|NCT01046227|Biological|Influenza A (H1N1) 2009 monovalent vaccine, inactivated|Serology study before and after Influenza A (2009) monovalent vaccine, inactivated
1862947|NCT01046240|Drug|Palonosetron|Palonosetron 3 mg administered SC or IV
1862948|NCT01046253|Drug|Lansoprazole|30 mg Delayed-Release Capsules
1862949|NCT01046253|Drug|Prevacid®|30 mg Delayed-Release Capsule
1862950|NCT01046266|Drug|RO5083945|700mg iv weekly
1862951|NCT01046266|Drug|cetuximab|400mg/m2 iv 1st dose, 250mg/m2 iv subsequent weekly doses
1862952|NCT01046279|Drug|Bevacizumab|Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV) assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons
1862953|NCT01046292|Drug|Ginkgo biloba|The participants will be randomly allocated to either the intervention group or the placebo control group at a ratio of 1:1. After six months, GBE will be administered to all participants for another 6 months for free. The daily administered dose (taken with meals in the morning and evening) will consist of either twice-daily 1 capsule of Symfona® forte 120mg GBE or identically appearing placebo.
1862957|NCT01046318|Drug|OPC-262|OPC-262 5 mg will be orally administered once daily fro 52 weeks.
1862958|NCT01046357|Drug|AZD7687|Single oral dose
1862959|NCT01046357|Drug|Placebo|Single oral dose
1862960|NCT01046370|Behavioral|Amygdala Retraining Program|Mind-body intervention.
1862961|NCT01046383|Dietary Supplement|IMN1207|20 grams of IMN1207 per day for 40 weeks.
1862962|NCT01046383|Dietary Supplement|Casein|20 grams of Casein per day for 40 weeks
1862963|NCT01046396|Drug|adapalene cream 0.1% and adapalene lotion 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
1862964|NCT01046396|Drug|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
1862965|NCT01046409|Other|Measuring collateral flow|Measuring collateral flow using pressure and/or velocity coronary wire
1862966|NCT01046422|Drug|BMS-770767|Capsule, Oral, 15mg, Active, Daily, 28 days
1862967|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg, Active, Daily, 28 days
1862968|NCT01046422|Drug|BMS-770767|Capsule, Oral, 150mg, Active, Daily, 28 days
1862969|NCT01046422|Drug|BMS-770767|Capsule, Oral, 50mg BID, Active, Daily, 28 days
1862970|NCT01046422|Drug|Placebo|Capsule, Oral, 0mg, Daily, 28 days
1862971|NCT01046422|Drug|Metformin|Tablet, Oral, ≥ 1500mg, Active, Daily, 28 days
1862972|NCT01046435|Procedure|metronidazole and amoxicillin|Metronidazole 250 mg three times a day per 7 days
1862973|NCT01046435|Procedure|Two placebos|Two placebos 3 times a day for 7 days
1862975|NCT01046474|Behavioral|lifestyle|"Based on beliefs and behaviors of children sections of education will be delivered via classroom activities.
Activities will be facilitated by trained research assistants. Printed instructions and orientations on the facilitation process will support the assistants' efforts. The activities will require 20 to 30 minutes, and teachers will be encouraged to reiterate the message during their lesson. The goal is to promote ten one-hour sessions of activity for each class.
Children will also be stimulated to increase everyday activities such as walking and playing games at home and school. Also, activities with parents and family members such as walking around the neighborhood on weekends will be promoted."
1862976|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 1 )|"CYCLE 1 (42 days):
Day 1 to 14 Imatinib mesylate : 400 mg/day, per os
Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os
NEXT CYCLE (28 days):
Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 400 mg/day, per os"
1862977|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 2)|"CYCLE 1 (42 days):
Day 1 to 14 Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os
Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening) per os
NEXT CYCLE (28 days):
Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 600 mg/day,(300 mg in the morning and 300 mg in the evening)per os"
1863016|NCT01046786|Drug|Lithium|oral lithium, titrated to maintain 0.6-1.0 mM serum level
1863017|NCT01046799|Drug|Entecavir|Entecavir monotherapy after short-term HBIg therapy for patients transplanted for hepatitis B induced end-stage liver disease; in case of prior lamivudine treatment, tenofovir will be added to the reinfection prophylaxis
1862978|NCT01046487|Drug|Imatinib mesylate, Cyclophosphamide (Dosing level 3)|"CYCLE 1 (42 days):
Day 1 to 14 Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os
Day 15 to 42 Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening) per os
NEXT CYCLE (28 days):
Cyclophosphamide : 50 mg x 2/day, per os Imatinib mesylate : 800 mg/day,(400 mg in the morning and 400 mg in the evening)per os"
1862979|NCT01046487|Procedure|Blood sampling|"ONLY FOR CYCLE 1, at day 15 and day 28 :
11 sampling for dosing level 1 (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12 , +24 hours, cyclophosphamide + 12 hours) 10 sampling for the next dosing level (pre-dose, imatinib mesylate + 30 min, +1, +2, +3, +4, +6, +10, +12,cyclophosphamide + 12 hours)"
1862980|NCT01046500|Dietary Supplement|myo-inositol|2 grams twice a day
1862981|NCT01046500|Drug|Metformin|pill, 250 mg, twice a day
1862982|NCT01046539|Drug|RDC-0313 + Buprenorphine|1 and 4 mg (1 dose for each) + 8 mg
1862983|NCT01046539|Drug|Placebo|0 mg
1862984|NCT01046552|Procedure|preoperative ERCP and LC|preoperative ERCP followed by LC
1862985|NCT01046552|Procedure|Intraoperative ERCP and LC|LC and intraoperative ERCP
1862986|NCT01046565|Drug|adapalene cream 0.1%|adapalene cream 0.1% - apply once daily on one side of the face for 3 weeks
1862987|NCT01046565|Drug|adapalene lotion 0.1%|adapalene lotion 0.1% - apply once daily on the opposite side of the face for 3 weeks
1862988|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 12 mm in diameter
1862989|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting on the day the dominant follicle reaches 18 mm in diameter
1862990|NCT01046578|Drug|Letrozole|20 mg, one tablet a day for one day, starting 24-48 hours after ovulation of the dominant follicle is observed
1862991|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting 24-48 hours after ovulation of the dominant follicle is observed
1862992|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
1862993|NCT01046578|Drug|Letrozole|2.5 mg, one tablet a day for five days, starting on the day the dominant follicle reaches 18 mm in diameter
1862994|NCT01046591|Procedure|Polysomnography|Overnight sleep studies will be performed on all children.
1862995|NCT01046604|Drug|Lovaza group|Patients who are scheduled for mitral valve repair surgery at least 3 weeks removed from the initial consult will be recruited to take 4 capsules of Lovaza (omega 3 fatty acids) daily, for 3 weeks prior to their surgery.
1862996|NCT01046617|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for 21 days
1862997|NCT01046630|Drug|AZD6765|single infusion
1862998|NCT01046630|Drug|Ketamine|single infusion
1862999|NCT01046630|Drug|Placebo|single infusion
1863000|NCT01046643|Drug|Estradiol (E2)|One Estradiol capsule (1mg) once a day, at the same time each day, for 90 days; followed by one Progesterone (200mg) once a day, at the same time each day, for 10 days to slough endometrial lining; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
1863001|NCT01046643|Drug|Progesterone (P10) x90|One Progesterone capsule (200mg) once a day, at the same time each day, for 90 days; followed by one Placebo capsule (to mirror Progesterone capsule to slough endometrial lining in Estradiol recipients) once a day, at the same time each day, for 10 days ; followed by one Placebo capsule once a day, at the same time each day, for 90 days.
1863002|NCT01046643|Drug|Progesterone (P10) x10|One Progesterone (200mg) capsule once a day for 10 days, to slough endometrial lining for patients taking Estradiol. Patients taking Progesterone will take an equivalent Placebo capsule during this time period.
1863003|NCT01046656|Dietary Supplement|Lactobacillus reuteri (DSM 17938)|5 drops once daily (10(8) CFU) for the entire duration of hospital stay
1863004|NCT01046669|Device|TORAYMYXIN PMX-20R (PMX cartridge)|Extracorporeal hemoperfusion device Each treatment will target 2 hours with a minimum of 1 ½ hours, at a flow rate of approximately 100 ml/minute, (range of 80 to 120 ml/minute).
1863005|NCT01046682|Drug|Salsalate|Salsalate 2 grams orally twice a day for 13 weeks. This is the maximum dosage. During the initial 9 days of the study salsalate dose will be titrated to reach this goal dosage.
1863006|NCT01046695|Device|TENS Unit|TENS is a method of pain relief that uses a battery operated electronic device with cutaneously applied electrodes that deliver electrical signals to peripheral nerves through the intact skin. The TENS Unit is a low voltage system that will only be used to a level to create alternative to pain sensation and will not create muscle response.
1863007|NCT01046708|Drug|micronized progesterone|600mg in 3 separate doses per day
1863008|NCT01046721|Drug|Exenatide|single dose of 5 microg Exenatide. Subcutaneous administration
1863009|NCT01046721|Drug|Saline|subcutaneous administration of 0.9% saline solution (0.02 ml)
1863010|NCT01046747|Procedure|Placement of external fixation pins|The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
1863011|NCT01046760|Behavioral|Language Assessment|Patients underwent an assessment performed with School Performance Test, Syntactic Awareness Test and a Peabody Picture Vocabulary Test.
1863012|NCT01046773|Drug|Cholecalciferol|Children less than 35 kg will receive 2,000 IU oral cholecalciferol daily for 6 months.
1863013|NCT01046773|Drug|Cholecalciferol|Children 35 kg or greater will receive 4,000 IU oral cholecalciferol daily for 6 months.
1863014|NCT01046786|Biological|Umbilical Cord Blood Mononuclear Cell|The cord blood mononuclear cells are obtained from thawed units of HLA-matched human umbilical cord blood. The cells will be slowly injected into the posterior gray matter after laminectomy and opening of the dura.
1863018|NCT01046812|Drug|Caphosol|Caphosol 2-4 times daily oral rinse for two weeks duration minimum up to one month.
1863019|NCT01046825|Drug|COPAD|Vincristine Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF
1863020|NCT01046825|Drug|COP, COPD M3, CYM|GROUP B Treatment Details Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3 Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF, Rituximab Consolidation (2 cycles): Methotrexate, Leucovorin, Cytarabine, IT medications, G-CSF, Rituximab
1863021|NCT01046825|Drug|COP, COPADM8, CYVE|"Treatment: Intravenous fluids should be given at a rate of 3000 mL/m2/day. Use of rasburicase may preclude the need for HCO3.
COP Pre-Phase: Cyclophosphamide, Vincristine, Prednis(ol)one, IT medications, Leucovorin.
COPADM8 Induction (2 cycles): Vincristine, Prednis(ol)one, Methotrexate, Leucovorin, Cyclophosphamide, Doxorubicin, IT medications, G-CSF CYVE Consolidation (2 cycles): Cytarabine, High-Dose Ara-C, Etoposide, G-CSF. Maintenance No.1: Vincristine, Prednis(ol)one, Cyclophosphamide, Methotrexate, Leucovorin, Doxorubicin, IT medications, G-CSF.
Maintenance No.2: Cytarabine, Etoposide, G-CSF, IT Medications. Maintenance No.3: Vincristine, Prednis(ol)one, Cyclophosphamide, Doxorubicin, G-CSF, IT Medications.
Maintenance No. 4: Cytarabine, Etoposide, G-CSF, IT Medications."
1863022|NCT01046838|Drug|Sildenafil|40 mg three times daily for 9 weeks
1863023|NCT01046838|Drug|Placebo|tablet 3 times daily for 9 weeks
1863024|NCT01046851|Drug|Nopan|Nopan(0.2-1.6 mg/day, starting dose=0.2 mg/day, N=40)
1863025|NCT01046851|Drug|Placebo|Placebo in a manner similar to the active comparator
1863026|NCT01046864|Drug|5-FU|IV solution, IV bolus over 2-4 minutes, 400 mg/m², Every 14 days, Until disease progression/toxicity
1863027|NCT01046864|Drug|Leucovorin|IV solution, IV over 2 hours, 400 mg/m², Every 14 days, Until disease progression/toxicity
1863028|NCT01046864|Drug|5-FU|IV solution, IV infusion over 46 hours, 2400 mg/m², Every 14 days, Until disease progression/toxicity
1863029|NCT01046864|Drug|Irinotecan|IV solution, IV over 90 minutes, 180 mg/m², Every 14 days, Until disease progression/toxicity
1863030|NCT01046864|Drug|Brivanib|Tablets, Oral, 400 - 800 mg, once daily, Until disease progression/toxicity
1863031|NCT01046864|Drug|Brivanib|Tablets, Oral, 600 - 800 mg, once daily, Until disease progression/toxicity
1863032|NCT01046864|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, Until disease progression/toxicity
1863033|NCT01046877|Device|Tympanostomy Tube Delivery System|Placement of the Tympanostomy Tube by the Acclarent Tympanostomy Tube Delivery System (TTDS)
1863034|NCT01046890|Drug|Echinacea|darunavir/ritonavir 600/100 mg + root of Echinacea purpurea 500 mg every 6 hours
1863035|NCT01046903|Drug|Fragmin® (Dalteparin Sodium)|Administered per prescribing physician
1863036|NCT01046916|Drug|TAK-700|TAK-700 will be administered orally (PO) twice daily (BID) on a continuous schedule
1863038|NCT01046942|Drug|Clopidogrel+acetylsalicylic acid|loading dose clopidogrel 300mg on second postoperative day. Thereafter 75mg clopidogrel daily for 3 months Aspirin 75mg daily, started within 24 hours after surgery
1863039|NCT01046942|Drug|acetylsalicylic acid|aspirin 75 mg daily, started 6-24 hours after surgery
1863040|NCT01046955|Drug|Anti-Thymocyte Globulin vs Campath-1H vs Daclizumab|comparison of induction therapies.
1863041|NCT01046968|Dietary Supplement|Lepticore|300 mg twice daily
1863042|NCT01046981|Procedure|Tumescent Antibiotic Delivery of cefazolin with or without metronidazole|TAD of cefazolin with or without metronidazole followed by sequential serum and interstitial fluid samples over 14 to 24 hours for antibiotic concentrations
1863043|NCT01046981|Procedure|Intravenous Antibiotic Delivery|Intravenous antibiotic delivery of cefazolin with or without metronidazole followed by sequential serum sampling for antibiotic concentration of subsequent 12 to 24 hours.
1863044|NCT01046994|Procedure|biliopancreatic diversion|biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve
1863045|NCT01046994|Drug|antidiabetics|patients are treated with conventional antidiabetic drugs according to the rules of good clinical practice
1959895|NCT03311971|Device|Virtual reality glasses|Patients will be treated with virtual glasses
1959896|NCT03311971|Device|No VR glasses|Patients will not use VR glasses
1959897|NCT03311958|Drug|Nivolumab, IV, 240 mg|Patients would be given an infusion of 240 mg nivolumab over 30 min
1863049|NCT01047033|Behavioral|Health education|30 minutes of a health education module delivered to clients by loan officers during monthly repayment meetings, over the course of 8 months.
1863050|NCT01047033|Other|Microcredit|Small loans administered to clients through the collaborating microcredit organization, to be repaid monthly over the course of six months in the context of monthly loan group meetings.
1863051|NCT01047046|Other|Retrospective chart review|"This study is a retrospective chart review including all patients who received surgical placement of a SNM device with Dr. Noblett from 2001 to the present.
The following data will be collected from patient charts: age at time of surgery, gravidity/parity, body mass index, pre-existing medical conditions/surgical history, current medications, menopausal status, form and severity of OAB symptoms, other previously or currently used interventions, method of SNM device placement, observed motor/sensory response, percent improvement of symptoms, follow-up OAB symptoms, frequency of InterStim settings adjustments, adverse events, significant changes in health, and incidence/reason for drop out."
1863052|NCT01047059|Drug|Erlotinib, Bevacizumab|Erlotinib 150mg/d d1-d43 p.o. Bevacizumab 15mg/kg b. w. d1, d22, d43 i.v.
1863053|NCT01047059|Drug|Fluoro-D-glucose|Tracer for PET imaging
1863054|NCT01047059|Drug|Fluoro-L-thymidine|FLT-PET tracer for imaging
1863055|NCT01047059|Drug|Gadolinium-DPTA|Contrast agent for DCE-MRI imaging
1863056|NCT01047072|Drug|fludarabine phosphate|Given IV
1959898|NCT03311945|Drug|Raltegravir|Raltegravir (1200 mg QD)
1959899|NCT03311945|Drug|Lamivudine|Lamivudine (300 mg QD)
1959900|NCT03311932|Drug|Infacort|Immediate release multiparticulate formulation (granules) of hydrocortisone
1959901|NCT03311932|Drug|Cortef|Immediate release hydrocortisone tablets
1959902|NCT03311139|Drug|Antithrombotic agents|Antiplatelets and anticoagulants purchased 4 months before and within 7 days after the index date
1863062|NCT01047072|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo transplantation
1863063|NCT01047072|Procedure|peripheral blood stem cell transplantation|Undergo transplantation
1863064|NCT01047085|Procedure|impedance pH measurement|Impedance pH measurement: Impedance-pH is a recently developed technique used to monitor all kinds of reflux (gas, liquid, acides and non-acides), reflux level and the clearance period of the esophagus.
1863065|NCT01047098|Dietary Supplement|Iron|Iron as iron sulfate
1863066|NCT01047098|Dietary Supplement|Iron|Iron as iron sulfate
1863067|NCT01047098|Dietary Supplement|Placebo|Placebo capsule
1863068|NCT01047111|Procedure|Esophagectomy|Esophagectomy Through Right Side Thoracotomy plus Midline Laparotomy Approach: Ivor-Lewis Procedure VS Esophagectomy Through Left Side Thoracotomy Approach: Sweet Procedure
1863069|NCT01047124|Other|Specialist Mood Disorders Team|The specialist mood disorders team will include a psychiatrist and health professionals providing cognitive behaviour therapy. Together the team will assess participants and then provide a co-ordinated and supervised combination of pharmacological and psychological treatment according to guidelines developed by NICE and the British Association of Psychopharmacology. Each participant will receive a treatment plan that is tailored to his/her specific needs.
1863070|NCT01047137|Behavioral|Psychological Stress Intervention|Intervention group participants will meet with a psychiatry resident once a week for six consecutive weeks to be educated on psychological stress intervention techniques focusing on relaxation, mindfulness, emotion regulation and acceptance and willingness.
1863071|NCT01047137|Behavioral|General Supportive Therapy|There is no focus on stress intervention.
1863072|NCT01047189|Drug|clindamycin phosphate 1.2% and tretinoin 0.025%|applied once daily for 12 weeks
1863073|NCT01047189|Drug|clindamycin 1% gel|Topical clindamycin applied each morning for 12 weeks
1863074|NCT01047189|Drug|tretinoin 0.025% cream|Tretinoin 0.025% cream each evening for 12 weeks
1863075|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
1863076|NCT01047202|Biological|Pandemic influenza A/H1N1 vaccine|Pandemic influenza A/H1N1 vaccine (PANFLU.1), 15 micrograms per dose per 0.5 millilitre. Vaccines will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
1863077|NCT01047202|Biological|Seasonal trivalent vaccine|Trivalent Inactivated Influenza Vaccine (ANFLU), 7.5 micrograms of each strain per dose per 0.25 millilitre. Vaccines will be administered as a single 0.25 mL intramuscular injection in the deltoid muscle of the arm (randomized in one arm) at the first dose and the other arm for the second dose
1863078|NCT01047215|Drug|Aripiprazole; Quetiapine|Aripiprazole Quetiapine
1863079|NCT01047241|Drug|Intranasal sufentanil/ketamine|Nasal spray sufentanil+ketamine, 0,5 microg/kg sufentanil+0,5 mg/kg ketamine, single dose
1863080|NCT01047254|Drug|Elontril|flexible dose of Bupropion 150-300 mg
1863081|NCT01047254|Drug|placebo|
1863082|NCT01047280|Dietary Supplement|Clarinol G-80 ® treatment|dietary supplement of 3.5g/day 50-50 mixture of t10, c12 and c9, t11 CLA. In addition, the amount of mixed natural tocopherols is 5mg/g (0.05%).
1863083|NCT01047280|Dietary Supplement|Safflower oil|3.5 g/d of safflower oil
1863084|NCT01047280|Dietary Supplement|G-c9, t11|3.5 g/day of c9, t11 CLA
1863085|NCT01047293|Drug|RAD001|"RAD001 (everolimus) is a novel oral derivative of rapamycin.
RAD001 is being investigated as an anticancer agent based on its potential to act:
Directly on the tumor cells by inhibiting tumor cell growth and proliferation
Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells."
1863086|NCT01047293|Drug|FOLFOX|FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.
1863087|NCT01047293|Drug|Bevacizumab|Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
1863088|NCT01047306|Other|assessment|Physical, developmental, neurological, behavioral, and neurocognitive assessments
1863089|NCT01047319|Drug|Laquinimod|One capsule containing 0.6 mg laquinimod to be administered orally once daily.
1863090|NCT01047332|Device|Partially Covered Wallstent|Partially covered wallstent
1863091|NCT01047332|Device|Uncovered Wallstent|Uncovered wallstent
1863092|NCT01047345|Biological|V503|V503 (9vHPV) vaccine given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study or the Study Extension
1863093|NCT01047345|Biological|Placebo to V503|Placebo to V503 (saline) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6 of the Base Study
1863094|NCT01047358|Drug|Aromasin|25 mg table QD
1863095|NCT01047358|Drug|Aromasin|25 mg table QD
1863096|NCT01047384|Procedure|acupuncture-moxibustion therapy|
1863097|NCT01047384|Procedure|Regular therapy|
1863098|NCT01047397|Drug|1278863A|25mg, 50mg, 100mg
1863099|NCT01047397|Drug|Placebo|matching placebo
1863144|NCT01047683|Drug|Placebo|Placebo 2 capsules/day for 12 weeks (Weeks 1-12)
1863145|NCT01047696|Device|Plancha|locally developed chimney stove
1863100|NCT01047410|Other|Exercise intervention|Patients assigned to the exercise intervention participate in a 12 weeks lasting, intensive, standardized and supervised physical training program which consists of a combination of endurance and strength training. After completion of the training program, patients receive an individual sport- and physical activity advice and lifestyle coaching.
1863101|NCT01047410|Other|Exercise intervention and dietary advice|The exercise intervention in this group is identical to the exercise-only group. The nutritional intervention runs throughout the entire 15 month intervention. The nutritional intervention aims to critically discuss pre-transplantation nutritional habits, and to set goals for healthier, better quality nutrition to prevent over eating and weight gain. These goals are set together with the subject to facilitate an autonomy supportive coaching climate.During the dietary consults, special attention goes out to saturated fat intake, whole-wheat and high fibre foods, fruit and vegetable intake, dietary salt consumption, and the use of energy-rich beverages such as soda, dairy drinks and fruit juices.
1863102|NCT01047423|Drug|Simvastatin|40mg encapsulated once daily for 12 weeks
1863103|NCT01047423|Drug|Placebo|Encapsulated oral once daily for 12 weeks
1863104|NCT01047436|Drug|Quinine|20 mg/kg intravenous quinine loading dose, followed by 10 mg/kg intravenously every 8 hours until resumption of normal oral therapy
1863105|NCT01047436|Drug|Artemether|Artemether sublingual spray 3 mg/kg at protocol specified timepoints until resumption of normal oral therapy
1863106|NCT01047449|Procedure|No-touch SVG harvest vs conventional SVG harvest technique|Saphenous vein harvested using the pedicled (no-touch) technique or using the conventional technique. Fish oil supplements/placebo (1g taken orally twice daily for 1 year post-op)
1863107|NCT01047449|Dietary Supplement|Fish oil supplementation vs placebo|Fish oil supplementation [1g tablets (55% fish oils - EPA:DHA 33%:22%)] taken twice daily for 1 year post-op
1863108|NCT01047462|Procedure|Surgery for acute perforated diverticulitis|Primary resection vs laparoscopic lavage
1863109|NCT01047475|Drug|MB-6|6# TID with meal
1863110|NCT01047475|Drug|Placebo|6# TID with meal
1863111|NCT01047488|Drug|Imipramine|Tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks
1863112|NCT01047488|Drug|Pregabalin|Capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
1863113|NCT01047488|Drug|Imipramine, pregabalin|Imipramine: tablet 25 mg, 3 tablets evening (extensive metabolizers) or 1 tablet evening (poor metabolizers), daily, 5 weeks Pregabalin: capsule 75 mg, 2 capsules twice daily, daily, 5 weeks
1863114|NCT01047488|Drug|Placebo|Placebo tablets to imipramine 25 mg, 3 or 1 tablet evening, daily, 5 weeks Placebo capsules to pregabalin 75 mg, 2 capsules daily, daily, 5 weeks
1863115|NCT01047501|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks
1863116|NCT01047501|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 2 capsules/day for 12 weeks
1863117|NCT01047501|Drug|Placebo|Placebo 4 capsules/day for 12 weeks
1863118|NCT01047501|Drug|Placebo|Placebo 2 capsules/day for 12 weeks
1863119|NCT01047514|Behavioral|Chronic Disease Self-Management Online Workshop|6 week, online, small group self-management workshop
1863120|NCT01047527|Drug|Transdermal nicotine patch|Transdermal nicotine, 21mg/day
1863121|NCT01047540|Drug|AIC316|Oral administration
1863122|NCT01047540|Drug|AIC316|Oral administration
1863123|NCT01047540|Drug|AIC316|Oral administration
1863124|NCT01047540|Drug|AIC316|Oral administration
1863125|NCT01047540|Drug|Placebo|Oral administration
1863126|NCT01047553|Drug|Formoterol (OT)|9 μg/dose, Inhaled, twice daily for 52 weeks
1863127|NCT01047566|Drug|Dronedarone|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg twice daily for 12 weeks (+/- 5 days)
1863128|NCT01047566|Drug|Beta blocker or calcium antagonist or digoxin|Dose increase of beta blocker or calcium antagonist or digoxin
1863129|NCT01047579|Drug|Rivastigmine transdermal|
1863130|NCT01047592|Drug|sarcosine|sarcosine, 2 g/d , oral, for 12 weeks
1863131|NCT01047592|Drug|sarcosine+ BE|sarcosine(2 g/d) + BE (1 g/d ), oral, for 12 weeks
1863132|NCT01047592|Drug|placebo|placebo,oral, for 12 weeks
1863133|NCT01047605|Drug|Neurapas balance|6 tablets single dose
1863134|NCT01047605|Drug|Pascoflair 425 mg|3 tablets , single dose
1863135|NCT01047605|Drug|P-Tabletten weiß|3 tablets, single dose
1863136|NCT01047631|Behavioral|Functional circuit training and lifestyle counseling|"Tests are performed at the beginning, and repeated after 12 and 24 weeks:
Measure general fitness levels such as walking, strength and balance.
Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.
Blood and urine tests and a heart ultrasound.
Questionnaires & activity measures.
Group assignment for 12 weeks:
-Exercise classes & activity guidance: Twice-weekly class that focuses on exercises that are similar to daily activities, such as walking and carrying objects. Obtain customized information and education to help you exercise and follow a low salt diet.
Follow-up:
-Monthly phone calls during the 12 week follow up period."
1863137|NCT01047631|Behavioral|Health education and independent walking|"Tests are performed at the beginning, and repeated after 12 and 24 weeks.
Measure general fitness levels such as walking, strength and balance.
Walk on a treadmill to measure your maximum fitness while wearing a mask to analyze your oxygen use.
Blood and urine tests and a heart ultrasound.
Questionnaires & activity measures.
Group assignment for 12 weeks:
-Health education and walking: Weekly health education classes covering general topics related to heart failure, like medications, diet and exercise. Receive a pedometer for an at-home walking program.
Follow-up:
-No follow up support"
1863138|NCT01047644|Other|Reduced port-flush schedule|3-month port-flushing
1863139|NCT01047657|Behavioral|Low caloric diet plus orlistat and sibutramine|All subjetcs
1863140|NCT01047670|Drug|Hydrocortisone|Hydrocortisone 6 mg/kg/day, 8 hourly, during 7 days or during the vasoactive drug infusion
1863141|NCT01047683|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 4 capsules/day for 12 weeks (Weeks 1-12), then AMR101 (ethyl icosapentate) 4 capsules/day for 40 weeks (Weeks 13-52)
1863142|NCT01047683|Drug|AMR101 (ethyl icosapentate)|AMR101 (ethyl icosapentate) 2 capsules/day for 12 weeks (Weeks 1-12), then AMR101 (ethyl icosapentate) 4 capsules/day for 40 weeks (Weeks 13-52)
1863143|NCT01047683|Drug|Placebo|Placebo 4 capsules/day for 12 weeks (Weeks 1-12), then AMR101 (ethyl icosapentate) for 40 weeks (Weeks 13-52)
1863146|NCT01047709|Device|Positional therapy including the use of a special pillow|Avoidance of supine sleep via a special pillow and other measures.
1863147|NCT01047722|Drug|Aspirin ingestion followed by doing a Bleeding Volume Test|Patient drinks a glass of Gatorade containing 325 mg of aspirin, then one hour later a bleeding volume test is performed.
1863148|NCT01047722|Procedure|Gatorade Placebo followed by Bleeding Volume Test.|Patient drinks a glass of Gatorade, then one hour later a bleeding volume test is performed.
1863149|NCT01047735|Procedure|Roux-en-Y Gastric Bypass Surgery|Participants assigned to the Roux-en-Y Gastric Bypass treatment group will undergo a surgical procedure that limit foods intake and causes nutrients malabsorption. The procedure is performed with small incisions or laparoscopically. A small stomach pouch is created, the size of an egg, and the small intestine is connected to the pouch. Some of the stomach and small intestine are consequently bypassed by this anatomic change. Those in this treatment group will begin a gradual diet post surgery and will take life long vitamin supplements.
1863150|NCT01047735|Procedure|Laparoscopic Adjustable Gastric Banding|Those assigned to the Laparoscopic Adjustable Gastric Banding study group will undergo a surgical procedure where an adjustable silicone band is placed around the upper stomach to decrease its capacity so that you will feel full sooner. It will assist in weight loss by helping you to limit intake of calories. The band will be placed by using several small incisions and telescopic instruments. A thin tube connects the band to an access port just under the skin that you may be able to feel but you will not be able to see it. This allows the band to be tightened or loosened to decrease or increase your stomach capacity as needed. The surgery will take on average 30-45 minutes.
1863151|NCT01047735|Behavioral|Lifestyle Weight Loss Intervention|Participants will receive a standard behavior weight control program in an in-person format over a period of 12 months conducted by an experienced team of weight loss counselors. During the initial 6 months of study treatment, will attend weekly in-person individual sessions with a weight loss counselor. During months 7-12, will attend in-person sessions on the 1st and 3rd week of the month and will receive a brief (less than 10 minutes in duration) telephone call on the 2nd and 4th week of the month. Each session will focus on a specific behavioral topic related to weight loss, eating behaviors, or exercise behaviors.
1863152|NCT01047748|Drug|intra-fetal digoxin injection|Single transabdominal injection of digoxin 1 mg into the fetus
1863153|NCT01047748|Drug|intra-amniotic digoxin injection|Single transabdominal injection of digoxin 1 mg into the amniotic fluid
1863154|NCT01047761|Other|Exercise|"3 month exercise intervention, three days a week Progressive in duration - up to 1 hour daily; Progressive in intensity
Multi-modal exercise program includes a) aerobic - walking, b) resistive training with therabands and core exercises, and c) breathing exercises"
1863155|NCT01047774|Dietary Supplement|Isolated soy protein|30-50g of protein powder daily for 2 weeks.
1863156|NCT01047774|Dietary Supplement|Isolated milk protein|30-50g of protein powder daily for 2 weeks.
1863157|NCT01047787|Other|Polysomnography|examination for sleep disorders
1863158|NCT01047800|Behavioral|Counseling|"Two extra counseling sessions will be arranged for the Counseling group immediately after visiting the physician in First and Final visits. Each session lasts for about 15 minutes with the following content:
First visit: prevalence of FGID in Hong Kong, chronicity nature of the disease, negative endoscopy result to be expected, time to answer patient's questions
Final visit : prevalence of FGID in Hong Kong (reinforcement), chronicity nature of the disease (reinforcement), explanation of the endoscopy result, management of disease via lifestyle modification, use of medication, need for further or repeated investigation, time to answer patient's questions."
1863159|NCT01047826|Procedure|Minimally Invasive Plate Osteosynthesis|Fractures well be treated with locked plates using M.I.P.O. Technique
1863160|NCT01047826|Procedure|intramedullary tibial Nailing|Fractures well be fixed using intramedullary nails
1863161|NCT01047839|Biological|IC51|0.25 ml, 2 i.m. vaccinations at Day 0 and 28
1863162|NCT01047839|Biological|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
1863163|NCT01047839|Biological|IC51|0.5 ml, 2 i.m. vaccinations at Day 0 and 28
1863164|NCT01047852|Procedure|Noninvasive ventilation|NIV will be delivered using a sequential mode (a minimum of 1 hour every 3 hours) immediately after extubation for a schedule period of 48 h after extubation. In between NIV courses ((NIV-free periods) O2 will be administered through nasal cannula in order to obtain a SaO2 ≥ 90%. Afterward, NIV will be withdraw and oxygen will be administered by nasal cannula
1863165|NCT01047891|Drug|Sorafenib|Topotecan 1,25 mg/m²/d administered as an i.v. infusion over 30 minutes once daily on days 1-5, every 21 days and Sorafenib 400 mg orally twice daily (total daily dose 800 mg) administered
1863166|NCT01047904|Device|Acclarent Iontophoresis System|Administration of local anesthesia using the Acclarent Iontophoresis System
1863167|NCT01047917|Behavioral|Meditation DVD|Participants will undergo a one-hour group instruction session in meditation held by Dr. Amit Sood. Participants will then receive a DVD to practice the intervention at home daily for a total of 4 weeks. The DVD will have 3 different programs of 5, 15, and 30 minutes each loaded on it with a menu option to choose one of the programs.
1863168|NCT01047930|Behavioral|Exercise|"Each 3-day experimental period will include one of the following conditions:
Morning exercise - subject will exercise on each of the three mornings in the sleep laboratory, starting 30 minutes after their habitual rise-time;
Evening exercise - subject will start exercise 4 hours before their habitual bedtime on each of the three evenings;
No exercise - subject will watch television or read and they will be required to remain sedentary."
1863169|NCT01047943|Drug|Topical application of STA-21 ointment for treatment of psoriasis|
1863170|NCT01047956|Drug|Methadone; NAC|Methadone NAC
1863171|NCT01047956|Drug|Methadone|Methadone
1863172|NCT01047969|Drug|Adjuvant Chemotherapy|If after MRI + FDG-PET 8 weeks post CRT the patient shows no visible tumour or further regression adjuvant chemotherapy will be considered.
1863173|NCT01047969|Procedure|Surgery|If after MRI + FDG-PET 8 weeks post CRF no further regression or growth of disease occurs the patient will be referred for surgery.
1863174|NCT01047982|Dietary Supplement|myo-inositol|myo-inositol 2 grams plus folic acid 400 mcg twice a day
1863175|NCT01047982|Other|folic acid 400 mcg|2 pills a day
1863217|NCT01040845|Drug|Placebo (for Colchicine)|placebo tablet every 12 hours on Days 8 to 21
1863218|NCT01040858|Behavioral|Cognitive Strategy Training|Cognitive Strategy Training will consist of weekly 120-minute group sessions for 10 weeks.
1863176|NCT01047995|Drug|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days
Phase 2 Group 1 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 400 mg twice daily for 14 days
Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
1863177|NCT01047995|Drug|Raltegravir plus Darunavir/ritonavir|"Phase 1, all subjects (n = 24): Raltegravir 400 mg twice daily for 21 days
Phase 2
Group 2 (n = 12): Darunavir/ritonavir 800/100 mg once daily plus raltegravir 800 mg once daily for 14 days
Phase 3, all subjects (n = 24): Darunavir/ritonavir 800/100 mg once daily for 14 days."
1863178|NCT01048008|Drug|DM-CHOC-PEN|"DM-CHOC-PEN will be dosed @ 39 mg/M2, escalated in 1-patient cohorts at 40% dosage.
At the 1st DLT - expand to 3-6 patient cohorts/dose with escalations at 33% increments.
The MTD will be where 2 DLTs are noted and the study is discontinued."
1863179|NCT01048021|Procedure|Supraclavicular Block|"Baseline values of forced expiratory volume in one second (FEV1), forced vital capacity (FVC), and peak expiratory flow rates (PEFR) will be measured in both the sitting and supine position. Ultrasound-guided supraclavicular brachial plexus blocks will be performed in the supine position with a Pajunk 22g block needle and nerve stimulator. The patients will receive local anesthetic injection with 15 mL of 0.75% Bupivicaine. A maximum of 3 cc of 5% Dextrose will be utilized as contrast to confirm needle tip placement and fluid spread prior to injection of the local anesthetic.
At 60 minutes post-injection, FEV1, FVC, and PEFR measurements will be taken in the sitting and supine position."
1863180|NCT01048034|Drug|Azacitidine|100 mg / m(2) subcutaneously day 1-5 every 4 weeks for 6 cycles. Another three cycles will be given together with epo for those not responding to the first 6 cycles of Azacitidine
1863181|NCT01048034|Drug|Erythropoetin|For those patients not responding to Azacitidine alone, the combination of Azacitidine and erythropoetin 60 000 U / week for 16 weeks will be given.
1863182|NCT01048047|Drug|aliskiren/amlodipine|aliskiren 300 mg /amlodipine 10 mg
1863183|NCT01048060|Procedure|Bone marrow specimen banking|
1863184|NCT01040663|Other|Dietary intervention|Subjects will be randomly assigned to receive 1 of 3 diets for 4 weeks.
1863185|NCT01040676|Behavioral|Automated Telephone Nutrition Support|See Intervention Group description.
1863186|NCT01040689|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
1863187|NCT01040689|Drug|Placebo (for olodaterol BI1744)|Placebo (olodaterol low and high dose)delivered by Respimat
1863188|NCT01040689|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
1863189|NCT01040689|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
1863190|NCT01040689|Drug|Tiotropium 18 mcg|18mcg inhaled once daily from Handihaler
1863191|NCT01040702|Drug|methylphenidate|a single doses of 10-20 mg in each one of two visits
1863192|NCT01040702|Dietary Supplement|sweetener pill|a capsule containing a sweetener pill
1863193|NCT01040715|Biological|TNFa Kinoid|TNFa kinoid
1863194|NCT01040715|Biological|TNF kinoid|IM administration 2 or 3 injections within 28 days
1863195|NCT01040728|Drug|Olodaterol (BI1744) Low|Low dose inhaled orally once daily from Respimat inhaler
1863196|NCT01040728|Drug|Olodaterol (BI1744) High|High dose inhaled orally once daily from Respimat inhaler
1863197|NCT01040728|Drug|Tiotropium 18 mcg|18 mcg inhaled once daily from HandiHaler
1863198|NCT01040728|Drug|Placebo (for Olodaterol (BI1744)l)|Placebo (olodaterol low and high dose) delivered by Respimat
1863199|NCT01040728|Drug|Placebo (for Tiotropium)|Placebo (Tiotropium 18 mcg) delivered by HandiHaler
1863200|NCT01040741|Other|Non-intervention observational study|Non-intervention observational study
1863201|NCT01040754|Other|Acupuncture|This study follows a standardized acupuncture protocol for OA knee pain. Approximately 6 acupuncture needles are placed in the skin of the leg for 25 minutes.
1863202|NCT01040767|Other|Didactic training in basic ultrasound and the EFAST|Physicians in the classroom group (class) listened to traditional lectures, while the web group (web) watched narrated lectures online. All participants completed a pre- and post-test, and a second post-test eight weeks later. Both groups underwent hands-on training after the first post-test.
1863203|NCT01040780|Drug|Icotinib|125 mg three times daily (375 mg per day) by mouth
1863204|NCT01040780|Drug|Gefitinib|250 mg every 24 hours by mouth
1863205|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
1863206|NCT01040793|Drug|Olodaterol (BI 1744)|Comparison of low and high dose on exercise endurance time in COPD patients
1863207|NCT01040793|Drug|Placebo|Comparison of low and high dose and placebo on exercise endurance time in COPD patients
1863208|NCT01040793|Drug|Olodaterol (BI1744)|Comparison of low and high dose on exercise endurance time in COPD patients
1863209|NCT01040793|Drug|Olodaterol (BI 1744) placebo|Placebo that represents olodaterol
1863210|NCT01040806|Behavioral|Usual care|Patients will receive their usual medical care
1863211|NCT01040806|Behavioral|Health coaching|Peer health coaches will counsel patients with diabetes
1863212|NCT01040819|Drug|Pioglitazone|Patients will receive PIO 15 mg/d for one month, then 55 patients continue with the same dose for one additional month, and in 55 patients the dose will be increased to 30 mg/d for an additional one month. Other non-diabetes drugs should not be changed. Other hypoglycemic agents, including insulin may be adjusted, if clinically indicated. NSAID, COX2 inhibitors, aspirin >162 mg/d, steroids and prostaglandin analogs will be prohibited.
1863213|NCT01040832|Drug|Cetuximab|Cetuximab weekly (initial dose 400 milligram per square meter [mg/m^2] over 120 minutes followed by 250 mg/m^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
1863214|NCT01040832|Drug|EMD 1201081|EMD 1201081 weekly (0.32 milligram per kilogram [mg/kg] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
1863215|NCT01040845|Drug|Norethindrone/Ethinyl Estradiol|one tablet daily - 1 mg norethindrone/0.035 mg ethinyl estradiol on Days 1 to 21; inert ingredients on Days 22 to 28
1863216|NCT01040845|Drug|Colchicine|0.6mg tablet every 12 hours on Days 8 to 21
1863219|NCT01040858|Other|Placebo comparison group|Participants in the experimental group will receive the Cognitive strategy intervention during the first ten weeks of their participation in the study, whereas comparison group participants will continue to receive usual care (no cognitive strategy intervention) during their participation in the study (but will be offered cognitive strategy intervention after the end of the study).
1863220|NCT01040871|Drug|VELCADE|VELCADE intravenous on Days 1, 4, 8, and 11 of a 21 day (3 week) cycle for 6 cycles.
1863221|NCT01040871|Drug|Rituximab|Rituximab intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
1863222|NCT01040871|Drug|Cyclophosphamide|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
1863223|NCT01040871|Drug|Doxorubicin|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
1863224|NCT01040871|Drug|Prednisone|Orally on Day 1 to Day 5 of a 21 day (3 week) cycle for 6 cycles
1863225|NCT01040871|Drug|Vincristine|Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
1863226|NCT01040884|Other|ActiSight Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera
1863227|NCT01040897|Behavioral|Health Communication and Obesity Prevention|Pediatric residents will be training in effective health communication skills and given a literacy/numeracy sensitive toolkit (GreenLight) to use with parents during all well child visits from 2 months to 18 months.
1863228|NCT01040897|Behavioral|Injury Prevention Arm|Pediatric residents will be trained to address injury prevention using the American Academy of Pediatrics (AAP) TIPP materials.
1959903|NCT03311893|Procedure|natural orifice surgery|evaluation of the awareness of the use of transvaginal, transoral and transcranial approach in surgical excision and the difference between the health staff and the pathology
1959904|NCT03311880|Behavioral|Cognitive remediation|Participants will be taught compensatory strategies for subjective cognitive impairment in addition to learning about lifestyle modifications that are known to be beneficial on cognition.
1863231|NCT01040923|Device|CardioSond Cardiac Sonospectrographic Analyzer|The CardioSond is a completely noninvasive, FDA 510(k) cleared digital electronic stethoscope designed to detect heart sounds and murmurs using ultrasensitive acoustic technology.
1863232|NCT01040936|Drug|Atorvastatin|patients admitted for Non-ST elevation ACS will be treated by atorvastatin 20md/d for one year
1863233|NCT01040936|Drug|Atorvastatin|patients admitted with Non-ST elevation ACS will be loaded with atorvastatin 80mg once, continued with 40mg/d for 30d, then change to 20mg/d, as a regular dose in China
1863234|NCT01040949|Behavioral|couple-based counseling for smoking cessation plus self-help smoking cessation guide|Culturally sensitive couple-based counseling for smoking cessation plus self-help smoking cessation guide in Latino men with pregnant partners
1863235|NCT01040949|Behavioral|Guia -a self help smoking cessation guide|A culturally sensitive smoking cessation self help program for Latinos
1863236|NCT01040975|Behavioral|Web-based intervention targeting MD communication; Summary Report|Web-based intervention targeting MD communication; Summary Report detailing 6 risk factors for adolescent overweight/obesity developed by study team
1863237|NCT01041001|Biological|Cartistem|allogeneic-unrelated umbilical cord blood-derived mesenchymal stem cell product
1863238|NCT01041001|Procedure|Microfracture treatment|
1863239|NCT01041014|Behavioral|Professional medical interpreter|All treatment interpreters were certified bilingual in Spanish and English and had completed (1) at least 40 hours of training in medical terminology, ethics, patient privacy, and basic interpreting skills; and (2) an online course in protection of human subjects.
1863240|NCT01041027|Drug|Paclitaxel|Given IV
1863241|NCT01041027|Drug|Carboplatin|Given IV
1863242|NCT01041027|Radiation|Internal Radiation Therapy|Undergo HDR brachytherapy
1863243|NCT01041027|Radiation|External Beam Radiation Therapy|Undergo EBRT
1863244|NCT01041027|Other|Laboratory Biomarker Analysis|Correlative studies
1863245|NCT01041040|Drug|gemtuzumab|gemtuzumab ozogamicin (GO) during consolidation for patients with acute myeloid leukemia (AML)
1959905|NCT03311867|Other|Ethibond Suture|Cerclage placement with ethibond
1959906|NCT03311867|Other|Prolene Suture|Cerclage placement with prolene
1863248|NCT01041092|Drug|raloxifene|Dose of raloxifene hydrochloride will be: 60mg /day. Patients are required to continue taking their regular medications throughout the duration of the study. No changes in dose will be required during the study period. Double-blind treatment will continue for 12 weeks.
1863249|NCT01041144|Behavioral|lifestyle counseling|supporting diabetes patients using Internet communication
1863250|NCT01041157|Other|Resistance training|Neck muscle trainings effect on botulinum toxin efficiency
1863251|NCT01041170|Drug|THC|
1863252|NCT01041170|Drug|Rimonobant|
1863253|NCT01041170|Drug|Rimonabant|
1863257|NCT01041209|Behavioral|Strategy based on BPS guided antibiotic use|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
1863258|NCT01041209|Behavioral|Enforced Guidelines|In this study a strategy based on BPS guided antibiotic use in children with community acquired pneumonia implementation will be compared with enforced guideline.
1863259|NCT01041222|Drug|ISIS 333611|5 arms of 12 hour infusion: Arm 1 0.15 mg, Arm 2 0.5 mg, Arm 3 1.5 mg, Arm 4 3.0 mg, matching volume of placebo
1863260|NCT01041235|Drug|ATI-1123 (active drug = docetaxel)|Dose escalation starting at 15 mg/m2 given once every 3 weeks via IV
1863261|NCT01041248|Drug|Tocilizumab|8mg/kg every 2 weeks i.v.
1863262|NCT01041261|Dietary Supplement|BariatrX Essentials 360 Treatment|Medical food
1863263|NCT01041274|Drug|Citalopram|40 mg by mouth daily for 12 months. Dosing will start at 20mg daily and may be increased after a minimum of one week to the target dose of 40 mg daily. Dose decreases will be made in the presence of side effects. Allowed dose range will be 10 mg daily to 40 mg daily.
1863264|NCT01041274|Drug|Placebo|Placebo by mouth daily for 12 months.
1863265|NCT01041274|Behavioral|Psychoeducation|16 sessions of weekly, individual psychoeducation and relapse prevention planning followed by 8 monthly sessions
1863266|NCT01041274|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants who exhibit symptoms of moderate suicidality at any point during the trial will be treated with 12 sessions of CBT, either once or twice weekly based on clinical judgment. Participants who continue to exceed suicidality criteria after 4 weeks of CBT will be dropped from double-blind treatment and may be prescribed openly an SSRI
1863267|NCT01041274|Radiation|Functional Magnetic Resonance Imaging (fMRI)|3 1-hour sessions of fMRI brain scanning, assessed at baseline, and weeks 24 and 52
1863268|NCT01041287|Drug|Nebivolol|Nebivolol 5 mg PO qday for 2 weeks, titrated up to Nebivolol 10 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Nebivolol 20 mg PO qday if BP is >125/80 for the remaining 8 weeks
1863269|NCT01041287|Drug|Metoprolol succinate|Metoprolol 50 mg PO qday for 2 weeks, titrated up to Metoprolol 100 mg PO qday if BP is >125/80 for the 2 more weeks, and then titrated up to Metoprolol 200 mg PO qday if BP is >125/80 for the remaining 8 weeks
1863270|NCT01041300|Device|Magstim Rapid2 Stimulator|"Duration: Time is takes to find motor thresholds obtained with figure-8 coil using Magstim Rapid2 Stimulator (Estimated at 15 minutes).
Total Duration of device: 15 minutes"
1863271|NCT01041300|Device|Brainsway Multi-channel Stimulator|"Finding motor thresholds using the figure-8 coil and the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).
Finding motor threshold of leg obtained with Double Cone coil using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).
Finding motor threshold of leg obtained with circular coils using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).
Finding motor threshold of thumb obtained with circular coils on multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 15 minutes).
Finding motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 1 hour).
Finding specificity of the motor thresholds of multiple channels using the Brainsway Multi-channel Stimulator (Estimated at 30 minutes).
Total Duration with Device: 2 hours and 30 minutes"
1959907|NCT03311854|Drug|NI-0501|NI-0501 will be administered at the initial dose of 6 mg/kg by intravenous infusion. NI-0501 treatment will be continued at the dose of 3 mg/kg, every 3 days until study day 15, and then twice-a-week for an additional 2 weeks, i.e. until study day 28.
1959908|NCT03311841|Drug|Midazolam oral solution|Midazolam hydrochloride 10 μg (1 mL of 10 μg/mL oral solution), administered orally as part of a microdose cocktail
1863274|NCT01041326|Radiation|Radiation|Pre-operative Radiation to Prostate, SV, and Pelvic Lymph Nodes
1863275|NCT01041326|Procedure|Radical Prostatectomy|Patients will undergo evaluation by a surgeon for consideration of resection after completion of radiation therapy. If a surgical resection is possible, it is recommended that patients undergo surgery four to eight weeks after completion of radiation therapy. This surgical procedure will be performed by one of the standard accepted approaches.
1863276|NCT01041352|Device|laryngeal mask|LMA Proseal
1863277|NCT01041352|Device|endotracheal tube|Unomedical endotracheal tube
1863278|NCT01041378|Drug|dexamethasone|Intravenous dexamethasone (0.5mg/kg) before incision
1863279|NCT01041391|Procedure|Discectomy-lumbar spine|Lumbar intervertebral discectomy performed on patients with herniated disc that chose to have surgical intervention
1863280|NCT01041404|Drug|Trastuzumab|Initial loading dose 8 mg/kg i.v. infusion on Day 1 of cycle, followed by 6 mg/kg i.v. infusion every 3 weeks until disease progression
1863281|NCT01041404|Drug|Fluorouracil|800 mg/m2 i.v. infusion on Days 1 through 5 of cycle every 3 weeks for 6 cycles
1863282|NCT01041404|Drug|Cisplatin|80 mg/m2 i.v. infusion on Day 1 of cycle every 3 weeks for 6 cycles
1863283|NCT01041404|Drug|Capecitabine|1000 mg/m2 p.o. twice daily on Days 1 through 15 of cycle every 3 weeks for 6 cycles
1863284|NCT01041417|Drug|Granulocyte-Macrophage Stimulating Factor (GM-CSF)|500 micrograms of GM-CSF
1863285|NCT01041417|Drug|Placebo|Saline injection
1863286|NCT01041430|Other|day surgery group|inguinal hernia repair, discharge from the hospital on the day of surgery
1863287|NCT01041430|Other|inpatient group|inguinal hernia repair, patient admitted overnight to hospital
1863288|NCT01041443|Drug|5-fluoro-2-deoxycytidine|Given IV
1863289|NCT01041443|Drug|tetrahydrouridine|Given IV
1863290|NCT01041443|Other|laboratory biomarker analysis|Correlative studies
1863291|NCT01041443|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
1863292|NCT01041443|Genetic|DNA methylation analysis|Correlative studies
1863293|NCT01041482|Drug|sorafenib|sorafenib 400mg twice daily
1959909|NCT03311841|Drug|Dabigatran and pitavastatin oral solution|Dabigatran etexilate 375/10 μg and pitavastatin (1 mL of 375/10 μg/mL oral solution), administered orally as part of a microdose cocktail
1959910|NCT03311841|Drug|Atorvastatin and rosuvastatin oral solution|Atorvastatin 100/50 μg and rosuvastatin (2 mL of 50/25 μg/mL oral solution), administered orally as part of a microdose cocktail
1863296|NCT01041508|Drug|Clofarabine|Clofarabine will be given as an intravenous infusion over 2 hours on days -6 though -2. The dose of Clofarabine will be assigned at study entry.
1863297|NCT01041508|Radiation|Total Body Irradiation|"Low dose (2 Gy) TBI will be administered from a linear accelerator at ≤ 20 cGy/min on day 0 according to institutional guidelines."
1863298|NCT01041508|Other|Stem Cell Infusion|Patients will be infused with 'unmanipulated' hematopoietic stem cells from a related or unrelated donor on day 0 of the treatment regimen according to institutional practice guidelines.
1863299|NCT01041508|Drug|Cyclosporins|"Cyclosporin (CSP) should be started on day -1 after completion of Clofarabine. CSP levels should be maintained between 300-400 ng/ml.
Age ≤ 6 years old: 6 mg/kg IV QD. in divided doses (e.g. 2 mg/kg q8hrs). Age > 6 years old: 3 mg/kg IV QD in divided doses (1.5mg/kg q12hrs)"
1863300|NCT01041508|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) will be at 15 mg/kg, based on adjusted body weight, every 8 hours (45 mg/kg/day; max.3g/day) PO, or IV if indicated, from the evening of day 0 (i.e. first dose 4-6 hours following stem cell infusion) to day +40 post-transplant.
1959911|NCT03311841|Drug|Rifampin|Rifampin 600 mg single dose (two 300 mg capsules) administered orally
1863302|NCT01041534|Other|Survey|Two surveys are sent to patients: Adjustable gastric band (AGB) Health Survey and a quality of life survey (EQ5D)
1863303|NCT01041573|Biological|IC51 Japanese Encephalitis|6 mcg or 3 mcg im. at day 0 and day 28
1959912|NCT03311828|Biological|Daratumumab|Given IV
1959913|NCT03311828|Drug|Imaging Agent|Given Copper 64Cu-DOTA-daratumumab IV
1863305|NCT01041573|Biological|Prevnar|0.5 ml im. at day 0 and day 56 and month 7
1863306|NCT01041586|Device|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
1863307|NCT01041612|Device|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
1863308|NCT01041612|Device|PTFE Covered ComVi [full covered] Biliary Stent|The stent is made of Nitinol wire. It is a flexible, fine mesh tubular prosthesis and it has 10 radiopaque markers; 4 in each end and 2 in the center.
1863309|NCT01041625|Drug|Apremilast (CC-10004)|Apremilast 20 mg tablet PO administered BID over 12 weeks
1863310|NCT01041638|Biological|Aldesleukin|Given IV
1863311|NCT01041638|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1863312|NCT01041638|Biological|Dinutuximab|Given IV
1863313|NCT01041638|Drug|Isotretinoin|Given PO
1863314|NCT01041638|Biological|Sargramostim|Given IV or SC
1863315|NCT01041677|Drug|R256918|10 mg capsule twice daily
1863316|NCT01041677|Drug|placebo|placebo capsule twice daily
1863317|NCT01041677|Drug|R256918|15 mg capsule twice daily
1863318|NCT01041690|Drug|Bevacizumab|
1863319|NCT01041716|Other|None - Observational study|None - Observational study
1863320|NCT01041729|Drug|Atorvastatin|Patients with Peripheral Arterial Disease in Fontaine Stage II treated with Atorvastatin 40mg/day during 12 months
1863321|NCT01041729|Drug|Standard Medical Treatment|"Patients with Peripheral Arterial Disease in Fontaine Stage II without treatment with Atorvastatin 40mg/day during 12 months.
Standard Medical Treatment."
1863322|NCT01041742|Procedure|fluid loading|fluid loading will be performed by using 6% hydroxyethyl starch solution , at 10 mL/kg.
1863323|NCT01041755|Drug|L-ornithine-L-aspartate|a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
1863324|NCT01041755|Drug|Lactose|a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
1863325|NCT01041768|Procedure|Bariatric surgery|Biliopancreatic diversion consists of a distal gastrectomy with a long Roux-en-Y reconstruction, where the enteroenterostomy is placed 50 cm proximal to the ileocecal valve; Gastric bypass consists of creating a small proximal gastric pouch by division of the upper stomach, with reconstruction of the GI continuity by means of a Roux-en-Y loop
1863326|NCT01048086|Drug|Retinoic Acid|160 mg, given orally, divided BID on Days 1-4 of each cycle for 4 cycles. Each cycle will be six weeks in duration. Dose will be adjusted to 5.33 mg/kg/day divided BID for children <12 kg.
1863327|NCT01048086|Drug|Placebo|Placebo will be given in the same manner as retinoic acid in capsules that look identical.
1863328|NCT01048099|Procedure|PRO Onc Assay and Treatment|Patients with HER2-negative metastatic breast cancer will be identified, and blood specimens will be obtained from each participant. The PRO Onc Assay will be performed on CTCs isolated from these specimens. When clinically indicated, fine needle aspiration biopsy will also be obtained and submitted for the PRO Onc Assay.
1863329|NCT01048099|Drug|Trastuzumab|8 mg/kg IV loading dose, followed by 6 mg /kg IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
1863330|NCT01048099|Drug|Pertuzumab|840 mg IV loading dose, followed by 420 IV every 3 weeks until progressive disease or unacceptable toxicity with evaluations performed every 8 weeks
1863331|NCT01048112|Biological|Campylobacter jejuni strain CG8421|Single oral dose of Campylobacter jejuni strain CG8421 in sodium bicarbonate buffer
1863332|NCT01048125|Device|Sympathetic Nerve Activity|Resting Sympathetic Nerve Activity
1863333|NCT01048125|Behavioral|Mental Stress Test (Color Word Test)|"A printed word will be shown to the subject, displayed in a color different from the color it actually names. The subject will be asked to say the color that the word is printed in as quickly as possible. For example if the word green is written in blue ink, they will say blue. This mental stress procedure will be used to cause brief changes in heart rate and blood pressure."
1863334|NCT01048125|Drug|The Modified Oxford Technique for Baroreflex Sensitivity|Sodium nitroprusside (100 µg) will be infused intravenously as a bolus, followed 60 seconds later by a bolus of phenylephrine hydrochloride (150 µg). Infusion of nitroprusside will decrease blood pressure approximately 10-15 mmHg below baseline values. Subsequent phenylephrine infusion will increase blood pressure approximately 10-15 mmHg above baseline values. Nitroprusside and phenylephrine have been used extensively to assess baroreflex sensitivity in healthy as well as heart failure populations. Additionally, the dosages being used have been shown to minimize the risk of excessive decreases or increases in blood pressure.
1863335|NCT01048125|Other|Cold Pressor Test|The subject will be asked to place their hand in ice water for 2 minutes. This procedure will be used to cause transient changes in sympathetic nerve activity, heart rate and blood pressure.
1863336|NCT01048125|Device|Echocardiographic evaluation|Transthoracic echocardiography with 2D, color and pulse Doppler will be employed in all of our subjects. Baseline left ventricular function, systolic as well as diastolic, will be quantified.
1863337|NCT01048138|Drug|Biperiden Lactate|5mg IV(in the vein)every 6 hours for 10 days
1863338|NCT01048138|Drug|Placebo|5mg IV(in the vein)every 6 hours for 10 days
1863339|NCT01048151|Biological|TNFerade™ Biologic|AdGVEGR.TNF.11D
1863340|NCT01048164|Procedure|Massage|Chair Massage
1863341|NCT01048177|Drug|Bladder instillation with heparin/ lidocaine|9 bladder instillations in 6 weeks
1863342|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
1863343|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;
1863344|NCT01048190|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
1863345|NCT01048203|Drug|ABR-215050|1 mg ABR-215050
1863346|NCT01048216|Radiation|radiation therapy|CT based 3D treatment shall be used for all patients. There will be 10 equal fractions delivered over 2 weeks. The prescribed dose and fraction will be individualised according to effective liver volume treated
1863347|NCT01048229|Drug|Rasagiline|1 mg rasagiline once daily (plus placebo twice daily)
1863348|NCT01048229|Drug|Pramipexole|pramipexole three times daily (titrated from 0.375 mg/day to 1.5 mg/day)
1863349|NCT01048242|Drug|rozerem|Ramelteon (rozerem) 8mg oral before bedtime
1863350|NCT01048242|Drug|Placebo|placebo
1863351|NCT01048255|Drug|VX-765|300mg Oral Tablet, 900mg TID
1863352|NCT01048268|Drug|glucose-dependent insulinotropic polypeptide|"For the first 20 min of the experiment the volunteers will receive GIP at 4 pmol/kg body weight.
For the following 40 minutes the volunteers will receive 2 pmol/kg body weight"
1863353|NCT01048268|Drug|Placebo|copy GIP infusion rates
1863354|NCT01048281|Procedure|Blood draw|
1863355|NCT01048281|Procedure|Tissue tumor biopsy|
1863356|NCT01048294|Device|Original Energy Light,|9000 lux, 30 minutes in the morning
1863357|NCT01048294|Device|Original Energy Light prototype|9000 lux 20 minutes in the morning
1863358|NCT01048294|Device|Original Energy Light prototype|9000 lux 30 minutes in the morning
1959914|NCT03311828|Procedure|Positron Emission Tomography|Undergo PET
1863360|NCT01048320|Drug|Gemcitabine|"The starting dose of gemcitabine will be 400 mg/m2 on day 1 of a two-week cycle.
Gemcitabine is given on day 1 every two weeks according to the dose escalation schedule below:
Dose level -1 200mg/m2 Dose level 1 400mg/m2 Dose level 2 600mg/m2 Dose level 3 800mg/m2 Dose level 4 1000mg/m2 Dose level 5 1000mg/m2 It is administered as an intravenous infusion, the lyophilized powder being diluted in normal saline, at a fixed dose of 10 mg/m2/minute."
1863361|NCT01048320|Drug|Oxaliplatin|Oxaliplatin is given by intravenous infusion on day 2 every 2 weeks according to the dose escalation schedule below: Dose level -1 - 4 85mg/m2 Dose level 5 100mg/m2 Oxaliplatin should be diluted in 250 to 500 ml of 5% glucose solution to give a concentration not less than 0.2 mg/ml. It must be infused via a central venous line or peripheral vein over 2 hours. In the event of extravasation, administration must be discontinued immediately and the extravasation managed according to local procedures.
1863362|NCT01048320|Drug|Imatinib|"Imatinib is given for 7 days every cycle starting 2 days before the gemcitabine is given, including administration on days 1 and 2 when gemcitabine and oxaliplatin are given, and for 3 days afterwards (i.e. days -2 to +5). It is thus given on a 7 days on and 7 days off intermittent dosing schedule. The dose will be fixed at 400 mg daily in tablet form and taken once daily with food.
Imatinib should commence either in the morning or lunchtime of day -2 and be taken at the same time daily for seven consecutive days in total."
1863363|NCT01048333|Drug|Formoterol|Formoterol Turbuhaler 9 μg and Placebo Diskus
1863364|NCT01048333|Drug|Salmeterol|Salmeterol Diskus 50 μg and Placebo Turbuhaler
1863365|NCT01048333|Drug|Placebo|Placebo Diskus and Placebo Turbuhaler
1863366|NCT01048346|Behavioral|Individual Placement and Support Model|Psychosocial intervention involving an employment specialist working with participants recruited into the study and assisting with employment.
1863367|NCT01048359|Behavioral|Brief advice|The American College of Surgeons (ACS) recently mandated standards of care for all level I trauma centers and currently defined standards of care at the collaborating institution requires that assessment and referral are included in treatment as usual. Therefore, our treatment as usual, or BA, consists of an initial interview conducted by study staff, a recommendation to abstain from drug use, provision of educational material supporting that recommendation, referral to hospital or community treatment resources most likely to be beneficial to the patient and information about relevant community health care agencies.
1863368|NCT01048359|Behavioral|Brief Intervention plus Booster|A brief drug use intervention based on motivational interviewing is provided to participants at baseline and a booster session incorporating personalized feedback is provided at one month
1863369|NCT01048359|Behavioral|Brief Intervention|A brief drug use intervention based on motivational interviewing is provided to participants at baseline
1863370|NCT01048385|Dietary Supplement|Coenzyme Q10 concomitant treatment|Coenzyme Q10 concomitant treatment to fertility drugs as part of an IVF treatment
1863371|NCT01048385|Dietary Supplement|Placebo|Treated with capsules containing the vehicle (Sesame oil).
1863372|NCT01048398|Drug|remifentanil|intervention: intravenous paracetamol 1g and remifentanil 1mg/100ml in 100ml of 0.9% saline.
1863373|NCT01048398|Drug|paracetamol|Control group: intravenous paracetamol 1g
1863374|NCT01048411|Drug|Naja-comp.|homeopathic remedy
1863375|NCT01048411|Drug|Placebo|s.c. injection of NaCl-solution three times a week
1863376|NCT01048697|Drug|Ethambutol|"All volunteers in each category will receive a single dose of oral ethambutol based on American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of American (ATS/CDC/IDSA) TB treatment guidelines.1 We will not use any doses higher than the maximum dose recommended for daily administration by the current ATS/CDC/IDSA TB guidelines (which use ideal body weight for dosing):
40-55kg: 800 mg (two 400 mg tablets) 56-75kg: 1,200 mg (three 400 mg tablets) 76-90kg: 1,600 mg (four 400 mg tablets) > 90 kg: No dosage recommendations so these volunteers will only receive 1,600 mg (four 400 mg tablets)"
1863377|NCT01048710|Other|No intervention|
1863378|NCT01048723|Drug|RAD001|Patients were instructed to take RAD001 in the morning, at the same time each day.
1863379|NCT01048736|Behavioral|Exercise Only|4 d/wk of aerobic exercise
1863380|NCT01048736|Behavioral|Exercise + Diet|Exercise 4d/wk with moderate caloric restriction (-250 kcal/d deficit) designed for low fat loss (EX+Low CR; ~4.5 kg weight loss).
1863381|NCT01048736|Behavioral|Exercise + Diet|Exercise 4d/wk with intensive caloric restriction (-600 kcal/d deficit) designed for high fat loss (EX+High CR; ~10.9 kg weight loss)
1863422|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
1959915|NCT03311815|Diagnostic Test|NGS techniques|Using NGS techniques we will detect the recurrently mutated genes in AML to establish the biological role of each mutation
1959916|NCT03311789|Drug|PD-1 inhibitor + Gemcitabine + Cisplatin|Gemcitabine: 1000mg/m2 on day 1 and 5 every 3 weeks. Cisplatin: 75mg/m2 on day 1 every 3 weeks. PD-1 inhibitor: Nivolumab 3mg/kg, or SHR-1210 200mg.
1863382|NCT01048749|Other|aquatic vertical suspension.|Subject is suspended in a warm water deep pool with two pool noodles around the subject and directly under the axilla. Five pound weights are placed on the ankle and the subject maintains this unloaded position for 15 minutes.
1863383|NCT01048749|Other|land-based supine flexion|The subject will lay supine with the legs supported by a foam wedge with hips flexed to 90 degrees and knees flexed to 65 degrees. They will maintain this unloaded position for 15 minutes.
1863384|NCT01048762|Other|physical exercise and dyspnoea counseling|Exercise training in group, 1 hour once a week for 10 weeks, based om aerobic exercises 60-80% of VO2 max (Borg 11-12), resistance training and dyspnea counseling. Participants are urge to exercise training for at least twice a week.
1863385|NCT01048762|Other|home training|one instruction in home based exercise training
1863386|NCT01048788|Drug|OPC-41061|OPC-41061 tablets will be orally administered once daily after breakfast at 7.5 mg on Day 1 to 7 and at either 7.5 or 15 mg on Day 8 to 14.
1863387|NCT01048801|Device|Rapid diagnostic test|Use of rapid daignostic tests for diagnosis of malaria
1863388|NCT01048801|Other|presumptive malaria treatment|Treatment of malariabased on clinical diagnosis without use of diagnostic test
1863389|NCT01048814|Other|ChemoFx|Chemoresponse Marker Assay
1863390|NCT01048827|Drug|Busulfan|"1250 uMol*min (AUC to time 6 hrs)^
1400 uMol*min (AUC to time 6 hrs
1550 uMol*min (AUC to time 6 hrs)^"
1863391|NCT01048853|Procedure|Conservative Surgery|Removal of the pelvic lymph nodes (pelvic lymphadenectomy)
1863392|NCT01048866|Drug|placebo|Sugar-based lozenge flavoured to match the active treatment lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for sore throat pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
1863393|NCT01048866|Drug|flurbiprofen|Sugar-based, flavoured flurbiprofen 8.75 mg lozenge. Instructions were to suck one lozenge until gone, every 3-6 hours as needed for pain. The participant took nothing by mouth except study medication during the first two hours while at the site. For each re-dosing during the remaining time in the study, alcohol and caffeine-containing beverages (e.g., coffee, tea, hot chocolate, caffeinated soft drinks) were not consumed within 1 hour before the participant used a study medication lozenge.
1863394|NCT01048866|Drug|acetaminophen 650mg|Rescue medication to be taken as needed. Rescue medication was not blinded.
1863395|NCT01048879|Procedure|pharmacokinetic blood sampling|blood samples collected to assess oseltamivir concentrations
1863396|NCT01048879|Procedure|pharmacokinetic blood and dialysate sampling|blood and dialysate samples collected and assayed for oseltamivir concentrations
1863397|NCT01048892|Biological|Seneca Valley virus-001|
1863398|NCT01048892|Drug|cyclophosphamide|
1863399|NCT01048892|Other|laboratory biomarker analysis|
1863400|NCT01048892|Other|pharmacological study|
1863401|NCT01048905|Drug|L-Glutamine|Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children < 15 years of age.
1863402|NCT01048905|Drug|L-Glutamine|Oral L-glutamine 10 grams TID or (0.1g/kg TID) for children < 15 years of age.
1863403|NCT01048931|Procedure|single-port LAVH|single-port LAVH
1863404|NCT01048944|Drug|Bupropion SR|150 encapsulated pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down.
1863405|NCT01048944|Drug|Nicotine Patch|Nicotine patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days
1863406|NCT01048944|Drug|Placebo Patch and Placebo Pill|150 encapsulated placebo pill,3 days 1x/day then 56/day for 2x/day, then 3 day 1x/day ramp-down. Placebo patch beginning 1st day cessation: 21 mg/24 days, 14 mg/14 days, 7 mg/7 days. The placebo patches were given beginning 1st day cessation: 21 mg size (but actually placebo)/24 days, 14 mg size (actually placebo)/ 14 mg size (actually placebo) 14 days/, 7 mg size (actually placebo)/7 days
1863407|NCT01048957|Behavioral|Real Time Feedback Training|
1863408|NCT01048970|Other|Nutritional Assessment|Patients will receive nutritional assessment one week prior to treatment until completing two courses of chemotherapy
1863409|NCT01048970|Dietary Supplement|EPA-DHA arm|Patients will be randomized to receive two cans/day of EPA and DHA containing oral supplement one week prior to treatment until completing two courses of chemotherapy
1863410|NCT01048983|Drug|Armodafinil|Initial Dose 150 mg once a day (50 mg and 100 mg oral tablets) for 10 weeks.
1863411|NCT01048983|Drug|Bupropion|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
1863412|NCT01048983|Drug|Minocycline|Initial Dose 100 mg two times a day (200 mg) for 10 weeks.
1863413|NCT01048983|Drug|Curcumin|Initial Dose 4 gm stick pack once a day (4 gm) for 10 weeks.
1863414|NCT01048983|Behavioral|Telephone Questionnaire|Weeks 1-10, 2 questionnaire calls/week; and Weeks 11-16, 1 call/week.
1863415|NCT01049009|Drug|Nebivolol|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
1863416|NCT01049009|Drug|Metoprolol XL|"Subjects will be randomized to either nebivolol or metoprolol xl, and remain on the study drug for 10 weeks. They will then cross over to take 10 weeks of the comparator drug."
1863417|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single intravenous (IV) infusion of moxifloxacin administered over 60 minutes, at an initial dosage of 5 milligram per kilogram per body weight (mg/kg/BW) with dose escalation to 6 mg/kg in subjects of age 6 years (yrs) to less than or equal to (<=) 14 years.
1863418|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 7 mg/kg/BW with dose escalation to 8 mg/kg in subjects of age 2 years to less than (<) 6 years; dose escalation was based on evaluations of the pharmacokinetic (PK) and safety data from the subjects in a preceding cohort.
1863419|NCT01049022|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single IV infusion of moxifloxacin administered over 60 minutes, at a dosage of 9 mg/kg/BW with dose escalation to 10 mg/kg in subjects of age 3 months to < 2 years; dose escalation was based on evaluations of the PK and safety data from the subjects in a preceding cohort.
1863420|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
1863421|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
1863423|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
1863424|NCT01049035|Biological|Meningococcal Polysaccharide Tetanus Protein Conjugate|0.5 mL, Intramuscular
1863425|NCT01049035|Biological|Pentacel®|As in the prescribing information (All are licensed vaccines)
1863426|NCT01049035|Biological|M-M-R®II|As in the prescribing information
1863427|NCT01049035|Biological|Varivax®|As in the prescribing information
1863428|NCT01049035|Biological|Prevnar®|As in the prescribing information
1863429|NCT01049035|Biological|RotaTeq®|As in the prescribing information
1863430|NCT01049035|Biological|Engerix-B®|As in the prescribing information
1863431|NCT01049048|Dietary Supplement|Vitamin D3|2500 IU Vitamin D3
1863432|NCT01049048|Dietary Supplement|Placebo|No (0 IU) vitamin D3 added to cookie.
1863433|NCT01049061|Drug|MORAb-003|MORAb-003 is intravenously administered to patients with solid tumor once a week for 4 weeks as 1 cycle in order to investigate dose-limiting toxicity and estimate maximum tolerated dose
1863434|NCT01049074|Other|Acupuncture Treatment|Acupuncture is a technique of inserting and manipulating fine needles into specific points on the body to relieve pain or for therapeutic purposes.
1863435|NCT01049074|Other|Sham acupuncture|Sham acupuncture is inserting needles superficially, without manipulating, into specific points on the body.
1863436|NCT01049087|Radiation|Plasma volume determination (99mTc-albumin)|The test is performed using 5MBq technetium-labeled albumin (99mTc-albumin-Vasculosis) with several postinjection samples for accurate zero-time extrapolation.
1863437|NCT01049087|Radiation|Plasma volume determination (125I-albumin)|The test is performed using 0.2MBq 125iodine-labeled albumin (125I-albumin) with several postinjection samples for accurate zero-time extrapolation.
1863438|NCT01049100|Procedure|lymphadenectomy|paraaortal and pelvic lymphadenectomy laparoscopic or open
1863439|NCT01049100|Other|Standard Staging|clinical Staging (FIGO) (examination in narcosis, biopsy, cystoscopy, rectoscopy) X-Ray Radiograph of Thorax, Ultrasound of abdomen, CT abdomen / pelvis positive, suspicious lymphnodes--> CT controlled biopsy
1863440|NCT01049113|Drug|ON 013105|2-hour intravenous infusion once a week. Starting dose is 17 mg. Maximum dose will be 1525 mg.
1863441|NCT01049126|Other|ChemoFx|Chemoresponse Marker Assay
1863442|NCT01049139|Behavioral|1-sided messages|Supplemental information with 1-sided messages (emphasizes information content related to vaccine trial randomization and unproven efficacy of vaccine).
1863443|NCT01049139|Behavioral|2-sided messages|Supplemental information with 2-sided messages (acknowledges the beliefs that are at odds with the information content and seeks to neutralize those beliefs through counter-argument).
1863444|NCT01049152|Device|Continuous Glucose Monitoring (CGM)|CGM allocated one time for 3 days
1863445|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 5 mg, Single dose, 1 day
1863446|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 20 mg, Single dose, 1 day
1863447|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 60 mg, Single dose, 1 day
1863448|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 150 mg, Single dose, 1 day
1863449|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 300 mg, Single dose, 1 day
1863450|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 600 mg, Single Dose, 1 day
1863451|NCT01049165|Drug|[14C] BMS-813160|Oral Solution, Oral, 150 mg, Single Dose, 1 day
1863452|NCT01049165|Drug|Placebo|Oral Solution, Oral, 0 mg, Single Dose, 1 day
1863453|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 1200 mg, Single dose, 1 day
1863454|NCT01049165|Drug|BMS-813160|Oral Solution, Oral, 2000 mg, Single Dose, 1 day
1863455|NCT01049178|Drug|Oral Silymarin|Dose Level 1: 1 capsules (1 cap at 140mg/cap) given three times per day for a total daily dose of 420 mg 28-days post Dose Level 1 Dose Level 2: 3 capsules (3 caps at 140mg/cap = 420 mg) given three times per day for a total daily dose of 1260 mg Day 56 (28-days post Dose Level 2) Dose Level 3: 5 capsules (5 caps at 140mg/cap = 700 mg) given three times per day for a total daily dose of 2100 mg Day 84 (28-days post Dose Level 3) We will evaluate change from baseline at each dose to determine the minimum effective dose.
1863456|NCT01049178|Drug|Oral Silymarin, maintenance dose|The maintenance Silymarin dose will be selected based on the dose escalation study and will be dosed PO three times daily as recommended. Silymarin will be provided as a capsule S. marianum (70-80% silymarin), along with an identical appearance placebo capsule created by our investigational pharmacyAt each visit a questionnaire regarding daily symptoms and disease control, the asthma control test (ACT) will be completed, eNO measured, urine collected, spirometry (lung function) measured, venipuncture performed for blood collection (20 mL), as well as assessment of acceptability, toxicity, and masking.
1863457|NCT01049178|Drug|Placebo|
1863458|NCT01049204|Drug|Maraviroc|Maraviroc 150 mg twice daily for 24 weeks
1863459|NCT01049204|Drug|placebo|Placebo twice daily for 24 weeks
1863460|NCT01049217|Drug|pregabalin|Pregabalin 75 mg-300mg twice daily during the course of the study.
1863461|NCT01049217|Drug|placebo|Subjects may be assigned to placebo during this study. The study duration is approximately 19 weeks.
1863462|NCT01049230|Radiation|Proton Beam radiation|Once a day, 5 days a week (Monday-Friday), for 4-8 weeks
1863463|NCT01049243|Drug|Fluocinonide Cream 0.1%|0.1% Cream, One Application, Twice Daily, 14 Days
1863464|NCT01049256|Other|carbon dioxide|sinusoidal carbon dioxide administration
1863465|NCT01049282|Biological|Antigen (Ag85B-ESAT-6)|Solution for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
1863466|NCT01049282|Biological|Antigen (Ag85B-ESAT-6) with adjuvant (IC31)|Suspension for injection, 0.5 mL, 50 ug antigen, 2 vaccinations with 2 months interval
1863467|NCT01049295|Dietary Supplement|oil fish|Active Comparator:640 mg oral oil fish pearls( 54% DHA, 10% EPA) 3 times a day
1863468|NCT01049295|Other|corn oil pearls|corn oil pearls 3 times a day
1863469|NCT01049321|Dietary Supplement|DASH diet|
1863470|NCT01049321|Dietary Supplement|a usual diabetic diet|
1863471|NCT01049334|Drug|Placebo|Participants were instructed to suck one placebo lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
1863604|NCT01050270|Drug|acetylcysteine|100 mg/kg over 2 hours then 200mg/kg over 10 hours, followed by glucose 5% for 8 hours
1863472|NCT01049334|Drug|Flurbiprofen|Participants were instructed to suck one flurbiprofen 8.75 mg lozenge during the initial two-hour clinic visit. Upon discharge, participants were instructed to use study medication lozenge every 3-6 hours as needed for pain, up to a total of 5 study lozenges in 24 hours.
1863473|NCT01049347|Drug|amitriptyline|150 mg oral, daily, single evening dose, 35 days
1863474|NCT01049347|Drug|paroxetine|40 mg oral, single dose, morning, 35 days
1863475|NCT01049360|Drug|Aclidinium 400 μg / Formoterol 12 μg|Aclidinium bromide 400 μg / formoterol fumarate 12 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
1863476|NCT01049360|Drug|Aclidinium 400 μg / Formoterol 6 μg|Aclidinium bromide 400 μg / formoterol fumarate 6 μg fixed dose combination administered twice-daily (BID) for a 14 day period within four different treatment periods.
1863477|NCT01049360|Drug|Aclidinium 400 μg|Aclidinium bromide 400 μg administered twice-daily (BID) for a 14 day period within four different treatment periods.
1863478|NCT01049360|Drug|Formoterol 12 μg|Formoterol fumarate 12 μg twice-daily for a 14 day period within four different treatment periods.
1863479|NCT01049360|Drug|Placebo|Placebo twice-daily delivered by inhalation for a 14 day period within four different treatment periods.
1863480|NCT01049373|Drug|HDC|(Calendula mother tincture, Condurango 2X, Phytolacca 2X, Carduus marianus 1X, Chelidonium 2X, Hydrastis mother tincture, Leptandra mother tincture, Taraxacum mother tincture, Echinacea mother tincture, Lycopodium 2X, Sanguinaria mother tincture and Arsenicum album 8X),10 drops t.i.d. for 15 weeks.
1863481|NCT01049373|Drug|Placebo solution|10 drops, t.i.d, 15 weeks
1863482|NCT01049386|Other|No intervention|In obese and lean subjects the intestinal absorption will be examined under normal conditions with sugar drink, and when disturbed by a high-fat breakfast.
1863483|NCT01049386|Procedure|Sugar absorption test|On one of the test days the subjects will consume a high-fat breakfast.
1959917|NCT03311763|Behavioral|EIM Fitness Practitioners|Exercise is Medicine Practitioners will facilitate peer groups that attend twice-weekly exercise classes for 8 weeks, with clinical monitoring and advise regarding increasing physical activity.
1959918|NCT03311763|Behavioral|Counseling and wearable device|Brief exercise counseling session and provision of a wearable fitness tracking device to promote physical activity.
1959919|NCT03311750|Drug|Panitumumab|6 mg/Kg will be administered intravenous over 1 hour on Day 1 every 2 weeks or 9 mg/Kg every 3 weeks.
1863487|NCT01049412|Drug|LY2605541|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
1863488|NCT01049412|Drug|Insulin glargine|Administered subcutaneously every morning with dose titration based on blood glucose measures for 8 weeks in each of 2 study periods.
1863489|NCT01049425|Drug|Epirubicin|4 cycles, intravenous use, day 1 every three weeks
1863490|NCT01049425|Drug|Cyclophosphamide|4 cycles, intravenous infusion, day 1 every three weeks
1863491|NCT01049425|Drug|Docetaxel|4 cycles, intravenous infusion, day 1 every three weeks after completion of EC-chemotherapy
1863492|NCT01049425|Drug|Cyclophosphamide|6 cycles, intravenous infusion, day 1 every 3 weeks
1863493|NCT01049425|Drug|Docetaxel|6 cycles, intravenous infusion, day one every three weeks
1863494|NCT01049438|Drug|nasal mupirocin|twice daily for 10 days
1863495|NCT01049438|Drug|topical 3% hexachlorophene body wash|daily for 10 days
1863496|NCT01049438|Drug|oral anti-MRSA antibiotic|The choice of oral antibiotic was based on investigators choice and antibiotic susceptibility of prior MRSA isolates in a given patient
1863497|NCT01049451|Drug|ACTH|Subjects assigned to the ACTH arm will receive ACTH (Acthar gel) as intramuscular (IM) injections once a day for 3 consecutive days on a monthly basis, for 12 consecutive months. The dosage of ACTH will be 80 units per injection, for a total of 240 units over the three day period.
1863498|NCT01049451|Drug|Methylprednisolone|Subjects assigned to the MP arm will receive intravenous (IV) infusions of 1 gram of MP once a month for 12 months
1863499|NCT01049464|Drug|Placebo|5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
1863500|NCT01049464|Drug|Magnesium sulphate|Magnesium sulphate 2g diluted with 5%D/W into 20 ml solution, intravenous infusion in 10 min then Magnesium sulphate 6g diluted with 5%D/W into 100 ml solution, intravenous infusion in 6 hours.
1863501|NCT01049477|Other|Music group|The patients randomized to the music group of the study will listen to music 30 minutes in the holding room prior to their c/s. They will then listen to music after their c/s for 30 minutes. They will complete the STAI before and after their c/s.
1863502|NCT01049477|Other|Non music group|Patients randomized to the non music group will complete the STAI before and after their c/s, but not listen to music.
1863503|NCT01049490|Biological|S-OIV H1N1 vaccine|Intramuscular: 15 mcg H1N1 vaccine: Control Intradermal: 3 mcg S-OIV H1N1 vaccine: Interventional
1863504|NCT01049503|Other|Low fluoride and conventional dentifrices with different pH|Comparison of different dentifrice fluoride concentrations and pH on caries control
1863509|NCT01049529|Dietary Supplement|Docosahexaenoic acid|DHA have oil form. Each neonate is receiving 75 mg/kg/day of DHA in 188 uL/kg/day in two doses per day, since two days before surgery and over six days following cardiovascular surgery
1863510|NCT01049529|Dietary Supplement|Placebo|Placebo have oil form. Each neonate is receiving 188uL/kg/day of sunflower oil as placebo in two doses per day, since two days before surgery and over six days following cardiovascular surgery
1863806|NCT01045226|Procedure|Proton Beam Radiation Therapy|Proton Beam Radiation Therapy
1959920|NCT03311737|Combination Product|general anesthesia|The investigators used general anesthesia preoperatively in uniportal VATS lung surgery
1959921|NCT03311737|Combination Product|epidural anesthesia|The investigators used general anesthesia combined with epidural anesthesia preoperatively in uniportal VATS lung surgery
1959924|NCT03311711|Behavioral|SPIRIT-in person|The SPIRIT-in person intervention adapted for AD will include one session and will be conducted in a private room at the clinic. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
1863511|NCT01049542|Drug|Astressin 2B|After an initial saline washout, increasing doses of Astressin 2B (at 0.032, 0.32, 3.2, 32, 320 and 3200 pmol/min) will be infused, for 10 minutes at each dose,intra arterially using forearm venous occlusion plethysmography. Forearm blood flow will be measured with each incremental dose of Astressin 2B.
1863512|NCT01049555|Other|Actigraphy and video recording signal|Actigraphy and video recording signal during 1 hour
1863513|NCT01049568|Behavioral|Cell Phone Intervention|"Cell phone support, including reminders, assessment of barriers to adherence, problem solving and referrals conducted by an Adherence Facilitator.
Data will be collected using the ACASI and CRFs at entry, weeks 6, 12, 24, 36, 48 and the premature discontinuation visits. Measures will assess social support, coping, self-efficacy, substance use, adherence, life stressors, perceived stress, psychological symptoms and health service utilization."
1863514|NCT01049581|Procedure|aquatic therapy|two hours per week, one hour per time, total 12 weeks
1863515|NCT01049607|Procedure|Clamp-Crush technique|The transectional line is marked and the liver capsule is cauterized. The liver parenchyma is then crushed stepwise using a regular Pèan clamp. Vessels and bile ducts are ligated or clipped. Vessels of less than 2mm diameter are coagulated with the irrigated bipolar forceps.
1863516|NCT01049607|Procedure|Stapler hepatectomy|The transectional line is marked and the liver capsule is cauterized. For subsequent transection of the hepatic parenchyma, the liver tissue is fractured with a vascular clamp in a stepwise fashion and subsequently divided with endo GIA vascular staplers.
1863517|NCT01049620|Drug|RAD001, Capecitabine, Oxaliplatin|"Dose level -1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 5mg po qd D1-21
Dose level 1 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 2 : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 3 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 3A : Capecitabine 800mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21
Dose level 3B : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 100mg/m2 iv D1 RAD001 10mg po qd D1-21
Dose level 4 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 7.5mg po qd D1-21
Dose level 5 : Capecitabine 1000mg/m2 po bid D1-14, Oxaliplatin 130mg/m2 iv D1 RAD001 10mg po qd D1-21"
1863518|NCT01049633|Biological|Allogeneic Pancreatic Islet Cells|200mL sterile suspension of allogeneic human pancreatic islets
1863519|NCT01049633|Drug|Sirolimus|Dosed to maintain whole blood 24-hr trough levels 10-15ng/mL for first 3 months and 8-12ng/mL thereafter daily. Sirolimus is used to prevent transplant rejection.
1863520|NCT01049633|Biological|Basiliximab|20mg intravenously (IV) 2hrs prior to islet infusion and on Day 4 post-transplant. Basiliximab is used to prevent transplant rejection
1863521|NCT01049633|Drug|Tacrolimus|Initial dose of 0.015mg/kg p.o. daily on Day 1 post transplant, and adjusted to maintain 12-hr trough levels 3-6ng/mL. Tacrolimus lowers the risk of organ rejection
1863522|NCT01049633|Drug|Antibacterial, Antifungal, and Antiviral Prophylaxis|Broad spectrum antimicrobial prophylaxis administered preoperatively
1863523|NCT01049633|Drug|Trimethoprim/sulfamethoxazole|80mg/400mg by mouth once a day starting on Day 1 for duration of the study follow-up. This medication is used to prevent bacterial infections.
1863524|NCT01049633|Drug|Clotrimazole|1 troche by mouth 4 times daily starting two days prior to transplant until 3 months after the transplant. This medication is used to prevent fungal infections.
1863525|NCT01049633|Drug|Valganciclovir|450mg dose by mouth once a day starting two days pre-transplant and increasing to 900 mg once a day by Day 12 and continuing for 14 weeks post-transplant. This medication is used to prevent cytomegalovirus infections.
1863526|NCT01049633|Drug|Heparin|70U/kg body weight of recipient given with islet infusion, followed by 3U/kg/hr for the next 4hrs. From 5th through 48th hr post-transplant heparin will be titrated to achieve and maintain a Partial Thromboplastin Time (PTT) of 50-60 seconds. This medication is used to prevent the formation of blood clots.
1863527|NCT01049633|Drug|Enoxaparin|30mg subcutaneously twice a day from 48 hrs post-transplant through Day 7 post-transplant. This medication is used to prevent the formation of blood clots.
1863528|NCT01049633|Drug|Pentoxifylline|400mg slow release tablet by mouth three times a day beginning 2 days prior to transplant and continue for 7 days post transplant. This medication improves blood flow.
1863529|NCT01049633|Drug|Aspirin|81mg enteric coated aspirin by mouth every night, starting 24hrs post-transplant. This medication prevents blood clots.
1863530|NCT01049646|Drug|Angiotensin II|Infusion of a subpressor dose of angiotensin II will be give, this will be 0.5microG/min/kg. Thereafter thre ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
1863531|NCT01049646|Drug|Saline|Infusion of saline. Thereafter three ascending doses of apelin will be given, during which time cardiac output and systemic haemodynamics will be measured.
1863532|NCT01049659|Behavioral|Neuropsychological test|Bayley test (version III) which provides several scales of development. Children are assessed just one time at two year old
1863533|NCT01049672|Drug|Alfentanil|Titrated to a maximum dose of 50mg in 24 hours subcutaneously
1863534|NCT01049672|Drug|Diamorphine|Titrated to a maximum dose of 500mg in 24 hours given subcutaneously
1863535|NCT01049685|Drug|First-line Antiretroviral Therapy|"Lopinavir/ritonavir: 02 capsules 12/12h, plus NRTI background
Efavirenz: 01 capsules day, plus NRTI background"
1863536|NCT01049698|Behavioral|Resistance Training|3 d/wk resistance training
1863537|NCT01049698|Behavioral|Resistance Training + Diet|3 d/w resistance training plus 600 kcal/d deficit
1863538|NCT01049711|Drug|erythropoietin|
1863539|NCT01049724|Other|Tear collection|Tear collection
1863540|NCT01049750|Other|type 2 diabetic patients|males; type 2 diabetic patients
1863541|NCT01049763|Drug|oseltamivir|oseltamivir 150 mg single oral dose oseltamivir 75 mg single oral dose
1863542|NCT01049776|Drug|Pazopanib (GW786034)|Pazopanib 800 mg daily x 12 weeks, (Cycle = 21 days) up to 24 months
1863605|NCT01050270|Drug|acetylcysteine|150 mg/kg over 15 mins 50 mg/kg over 4 hours 100 mg/kg over 16 hours
1863606|NCT01050283|Procedure|Comparator: [18F]-FDG PET/CT and Volumetric CT|Patients will receive gemcitabine-based therapy as prescribed by their treating physician. FDG-PET/CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy. Volumetric CT scans will be performed at baseline following enrollment, and after 3 and 6-7 weeks of therapy.
1865131|NCT01055314|Other|Laboratory Biomarker Analysis|Correlative studies
1863543|NCT01049789|Behavioral|COMB - Combination Cognitive Behavioral Therapy and Medication Management|"Phase I: 24-week intervention consisting of Cognitive Behavioral Therapy (CBT) and Medication Management (MM) manuals. Study coordinators and site clinicians will document depression symptoms and treatment regimens for all participants for 24 weeks. Site staff and participants at COMB sites will participate in an exit interview and findings will be used to revise CBT and MM intervention manuals at the end of Phase I.
Phase II: similar procedures as Phase I; COMB sites will implement the revised CBT and MM manuals. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. All Phase II participants will have 2 follow-up visits at weeks 36 and 48."
1863544|NCT01049789|Behavioral|TAU - Treatment as Usual|"Phase I: Participants enrolled at TAU sites will receive treatment for depression that is typical at that site, which may include medication management, psychosocial therapy, or a combination of the two.
Phase II: Participants at TAU sites will receive treatment for depression that is typical at that site. As in Phase I, psychopharmacological and psychosocial interventions will not be standardized and participants may receive any depression treatment recommended by the site clinicians while on study. Depression symptoms and treatment regimens for all participants will be documented for 24 weeks. Additionally, all Phase II participants will have 2 follow-up visits at weeks 36 and 48."
1863545|NCT01049802|Device|Repetititve transcranial magnetic stimulation|1 Hz rTMS to contralesional hemisphere in patients with stroke
1863546|NCT01049815|Drug|sevelamer hydrochloride|800-3200 mg with each meal
1863547|NCT01049815|Drug|Calcium Carbonate|600 mg with each meal, up to 1800 mg a day
1863549|NCT01049841|Drug|perifosine + temsirolimus|The patient will take oral tablets of perifosine at a dose and frequency to be determined their height, weight and time when they enter the study as those entering early will be treated with lower dose levels (dosing frequency will vary from once a week to daily). The patient will receive an intravenous injection of temsirolimus once a week at a dose to be determined by their height, weight and time when they enter the study as those entering early will be treated with lower doses. In addition they will be asked to keep a medicine diary.
1863550|NCT01049854|Drug|Full Intensity with TBI|Patients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5, -4, Cyclophosphamide on Days -3, -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
1863551|NCT01049854|Drug|Full Intensity|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with stem cell infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus only.
1863552|NCT01049854|Drug|Reduced Intensity|Patients will start their GVHD prophylaxis with Tacrolimus on Day -9. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
1863553|NCT01049854|Drug|Reduced Intensity (Fanconi)|Patients will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and antithymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The stem cell infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus only.
1863554|NCT01049867|Procedure|Intracoronary Infusion of CD133+ Cells|Single intracoronary infusion of a suspension consisting of 30 ml saline solution containing at least 1 million CD133+ endothelial precursor cells.
1863555|NCT01049880|Drug|Gemcitabine with escalating ascorbic acid|"Gemcitabine (1000 mg/m2) weekly for three weeks and then one week off. Ascorbic acid, given twice weekly, escalating doses weekly. Week 1: 15 grams ascorbic acid per infusion Week 2: 25 grams ascorbic acid per infusion Week 3: 50 grams ascorbic acid per infusion Week 4: 75 grams ascorbic acid per infusion Week 5: 100 grams ascorbic acid per infusion
Ascorbic acid infusion dose is maintained at the level that provides a serum level of 350-400 mg/dL."
1863556|NCT01049893|Drug|Compound AC220|Precomplexed powder in bottle formulation supplied as 135 mg in a 60 cc polyethylene terephthalate (PET) plastic bottle. Requires reconstitution by a pharmacist, must be stored securely, and protected from light.
1863557|NCT01049906|Procedure|Placement of nerve block catheter|Placement of nerve block catheter with nerve stimulator and ultrasound
1863558|NCT01049906|Procedure|Placement of nerve block catheter|Placement of nerve block catheter with ultrasound only
1863559|NCT01049919|Device|Bone marrow concentration device|Concentration of autologous bone marrow aspirate for intramuscular delivery to affected limb
1863560|NCT01049919|Procedure|Placebo procedure (sham)|Sham bone marrow aspiration, sham delivery to affected limb
1863561|NCT01049932|Drug|TMC278LA|TMC278LA 600mg injected intramuscularly (i/m)
1863562|NCT01049945|Drug|bendamustine hydrochloride|Given IV
1863563|NCT01049945|Drug|lenalidomide|Given orally
1863564|NCT01049945|Drug|dexamethasone|Given orally or IV
1863565|NCT01049971|Device|wound protector|after minilaparotomy, the wound protector is applied
1863566|NCT01049971|Device|no wound protector|use of woven drape instead of wound protector
1863567|NCT01049984|Drug|Rasagiline|1mg tablet daily for 18 weeks
1863568|NCT01049984|Drug|Placebo|one tablet daily for 18 weeks
1863569|NCT01050010|Other|MRI|dedicated extremity MRI
1863570|NCT01050023|Device|Provant Device (Wound Therapy System)|Twice daily application of the active Provant device to the wound for twelve (12) weeks.
1863571|NCT01050023|Device|Provant Device - Inactive|Twice daily application of the inactive Provant device to the wound for twelve (12) weeks.
1863607|NCT01050309|Drug|hexaminolevulinate (HAL)|Intravenous dose of HAL 0.4 mg/kg including 100 nCi (3.7 kBq) 14C infused over a one hour period. A vaginal dose HAL 150 mg including 13,9 kBq of 14C HAL will be administered for 7 hours. Following a colon cleaning, 100mg HAL enema including 14,8 kBq of 14C will be instilled for 30 minutes in colon
1863608|NCT01050322|Drug|Lapatinib Vinorelbine|The starting dose of vinorelbine is 25 mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
1863572|NCT01050036|Procedure|autologous hematopoietic cell transplantation|"Autologous peripheral blood stem cell (PBSCs) harvesting
After the second cycle of high-dose ara-C(HDAC) consolidation chemotherapy
Mobilization: recombinant human G-CSF(Filgrastim) 5mcg/kg s.c. daily starting on 10 days after start of the second cycle of HDAC chemotherapy
Harvest procedure: peripheral blood mononuclear cells will be collected. Target CD34+ cell dose is over 5x10E6/kg.
Conditioning regimen for autologous HCT
Busulfan 3.2 mg/kg/day i.v. daily on days -7 to -5 (for 3 days)
Etoposide 400mg/m2/day i.v. daily on days -3 to -2 (for 2 days)
Autologous cell infusion and waiting for engraftment"
1863573|NCT01050062|Drug|Telmisartan 80mg|Combination tablet
1863574|NCT01050062|Drug|Telmisartan 40mg|Combination tablet
1863575|NCT01050062|Drug|Hydrochlorothiazide 12.5mg|Combination tablet
1863576|NCT01050075|Procedure|acupuncture therapy|acupuncture therapy
1863577|NCT01050075|Drug|paclitaxel|Dosage to be determined by the treating physician
1863578|NCT01050075|Other|questionnaire administration|Ancillary study
1863579|NCT01050075|Procedure|management of therapy complications|To be determined by the treating physician
1863580|NCT01050088|Dietary Supplement|sucrose solution|5cc 5% sucrose solution P/O
1863581|NCT01050088|Dietary Supplement|Saline|5cc saline p/o
1863582|NCT01050101|Dietary Supplement|No fiber|"The High GI low fiber meal consists of 0 grams fiber with total kcal of 573 with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein.
Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
1863583|NCT01050101|Dietary Supplement|Low GI high fiber viscous meal|"Test meal consists of 12 grams of fiber (9 grams soluble and 3 grams insoluble). The ratio is 80:20 ratio of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).
Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
1863584|NCT01050101|Dietary Supplement|Low GI high fiber non-viscous|"Test meal consists of 11 grams of fiber (3 grams soluble and 8 grams insoluble). The ratio is 20:80 of viscous polysaccharide fiber source (psyllium husk) to insoluble non-viscous producing fiber source (cellulose).
Total kcal provided as 560 kcal with 63% energy from carbohydrates, 24% energy from fat and 13% energy from protein. Test meal consists of breakfast meals containing muffins and yogurt beverage/shake."
1863585|NCT01050114|Drug|onaBoNT-A|"onaBoNT-A will be the active formulation. Each vial of onaBoNT-A Purified Neurotoxin Complex, Formulation No. 9060X, contains: 100 units (U) of Clostridium botulinum toxin type A, 0.5 mg albumin (human), and 0.9 mg sodium chloride in a sterile, vacuum-dried form without a preservative. One U corresponds to the calculated median lethal intraperitoneal dose (LD50) in mice. A 0.9% sterile saline (without preservative) for injection will be used as diluent for onaBoNT-A.
Each treatment session will be administered as 20 injections each of 1 mL (10U/ml), evenly distributed into the bladder."
1863586|NCT01050114|Drug|Oxybutynin ER|Oxybutynin ER in a 10 mg capsule will be taken twice a day for the course of the study.
1863587|NCT01050127|Drug|ABT-436|See Arm Description for details.
1863588|NCT01050127|Drug|Placebo|See Arm Description for details.
1863589|NCT01050140|Dietary Supplement|high sugar diet|25% of dietary energy from fructose or glucose
1863590|NCT01050153|Drug|Dalteparin sodium|Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
1863591|NCT01050153|Drug|Dalteparin sodium/aspirin|Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily) po.
1863592|NCT01050166|Other|Transplantation of labeled islets|
1863593|NCT01050179|Other|carbon dioxide|sinusoidal carbon dioxide delivery
1863594|NCT01050205|Behavioral|Current Intervention|"Participants assigned to Current Intervention will receive the intervention described below immediately after randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.
GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
1863595|NCT01050205|Behavioral|Delayed Intervention|"Participants assigned to Delayed Intervention receive the same intervention as Current Intervention Group, 6 months from randomization. The one-year GLB program is an adaptation of the successful DPP lifestyle intervention. The goals of the intervention are to achieve and maintain a 7% weight loss, and to safely and progressively increase physical activity to 150 minutes per week of moderately intense physical activity.
GLB-GROUP: group meetings weekly transitioning to monthly over one year led by a trained coach. GLB-DVD: Consists of a series of taped sessions of a staged GLB group following a script which was developed to closely follow the GLB program. GLB-DVD participants complete the sessions via DVD and have telephonic contact with their coach as well as monthly group meetings."
1863596|NCT01050218|Drug|Desvenlafaxine Succinate Sustained-Release (DVS SR)|
1959925|NCT03311711|Behavioral|SPIRIT-remote|The SPIRIT-remote intervention adapted for AD will include one session and will be conducted through teleconference. SPIRIT is a structured psychoeducational intervention, targeting both patient and surrogate. The SPIRIT intervention assists patients in clarifying their end-of-life preferences and helps surrogates understand the patient's wishes and prepare for the surrogate role. The intervention is expected to last 45-60 minutes.
1863599|NCT01050244|Dietary Supplement|Whole soybean soymilk powder|
1863600|NCT01050244|Dietary Supplement|Whole milk powder|
1863601|NCT01050257|Drug|Oseltamivir IV|Oseltamivir IV infusions over 2 hours two times a day (every 12 hours) for 5 days for patients with moderate renal impairment. Patients with severe renal impairment received once daily dosing and patients on renal replacement therapy received dose/frequency according to protocol.
1863602|NCT01050257|Drug|Oseltamivir Oral|Oseltamivir (TAMIFLU®) capsules taken orally for 5 days. Twice daily (every 12 hours) for patients with moderate renal impairment, once daily for patients with severe renal impairment and dose frequency according to protocol for patients on renal replacement therapy.
1863603|NCT01050270|Drug|Ondansetron|4mgs iv bolus
1863609|NCT01050322|Drug|Lapatinib Capecitabine|The starting dose of capecitabine is 2000 mg/m2/day, to be divided and given twice daily orally, 12 hours apart, for 14 days, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
1863610|NCT01050322|Drug|Gemcitabine Lapatinib|The starting dose of gemcitabine is 1000mg/m2/ IV days 1 and 8, every 21 days. A daily dose of Lapatinib is 5 tablets (1250 mg of Lapatinib) taken approximately at the same time each day.
1863611|NCT01050335|Behavioral|Simuvision Simulator|Participants will perform common surgical procedures on the simulator
1863612|NCT01050348|Drug|Atorvastatin calcium|Eligible patients will receive 80mgs of atorvastatin orally upon admission to hospital prior to percutaneous intervention of the affected artery. Dose of post-procedural statin will be at the discretion of the cardiologist.
1863613|NCT01050348|Drug|Inactive Placebo|Eligible patients will receive a placebo orally upon admission to hospital prior to percutaneous intervention of the affected artery.
1863614|NCT01050361|Procedure|Transthoracic Echocardiogram (TTE)/Transesophageal Echocardiogram (TEE)|Duration lasts the entire operation.
1863615|NCT01050374|Drug|albendazole + praziquantel|albendazole (400 mg one dose) + praziquantel (40 mg/kg body weight)
1863616|NCT01050374|Drug|mebendazole + praziquantel|mebendazole (500 mg one dose) + praziquantel (40 mg/kg body weight)
1863617|NCT01050387|Dietary Supplement|Vitamin D|Vitamin D (either 400 IU vs 1000 IU) given orally each day
1863618|NCT01050400|Genetic|Cytochrome P450 2D6 (CYP2D6) genetic screening.|Genetic screening for cytochrome P450 2D6 (CYP2D6) polymorphism will be conducted on genetic information obtained from non-invasive salivary samples.
1863619|NCT01050426|Other|UFT, Leucovorin|UFT 300mg/m2/day in 3 equal doses and Leucovorin 90mg/day in 3 divided doses per day given daily on the days of radiotherapy only (30 days in total)
1863620|NCT01050426|Other|UFT/ Leucovorin + Cetuximab + Radiotherapy|UFT 300mg/m2 + LV 90mg/day on days of RT only (30 days in total), Cetuximab 400mg/m2 week 1, thereafter 250mg/m2 weeks 2-6
1863621|NCT01050439|Procedure|UDAlloSCT|unrelated matched donor allogeneic stem cell transplantation (UDAlloSCT)
1863622|NCT01050439|Other|Therapy|Full Intensity Therapy (myeloablative) (TBI + Thiotepa + Cyc) OR Reduced Intensity Therapy (Fludarabine, Busulfan, and Alemutuzumab (FBA))
1863623|NCT01050452|Drug|albendazole|albendazole (400 mg on dose)
1863624|NCT01050452|Drug|mebendazole|mebendazole (500 mg one dose)
1863625|NCT01050452|Drug|ivermectin|ivermectin (200 microgram/kg body weight)
1863626|NCT01050452|Drug|albendazole + ivermectin|albendazole (400 mg one dose) + ivermectin (200 mg microgram/kg body weight)
1863627|NCT01050452|Drug|mebendazole + ivermectin|mebendazole (500 mg one dose) + ivermectin (200 microgram/kg body weight)
1863628|NCT01050465|Other|health information prescription|Patients randomized to the email arm will receive a health information prescription via email on a health care topic following their clinic visit. Patients randomized to the paper arm will receive a health information prescription on paper on a health care topic following their clinic visit.
1863629|NCT01050478|Drug|Paliperidone ER|paliperidone ER at 2 dosage levels (6 and 9 mg/day)
1863630|NCT01050478|Drug|Benzodiazepine|Participants may receive the benzodiazepine lorazepam [0-7.5 milligram (mg) per day] as needed for sedation or rescue medication at the investigator's discretion.
1863631|NCT01050491|Drug|sitaxentan|100 mg once a day during one year. Bronchial fibroscopy
1863632|NCT01050491|Drug|placebo|placebo, one per day, during one year. Bronchial fibroscopy
1863633|NCT01050504|Other|Cytology Specimen Collection Procedure|Correlative studies
1863634|NCT01050504|Other|Laboratory Biomarker Analysis|Correlative studies
1863635|NCT01050517|Drug|albendazole + ivermectin + praziquantel|albendazole (400 mg one dose) + ivermectin 200 microgram/kg body weight) + praziquantel (40 mg/kg)
1863636|NCT01050517|Drug|albendazole + ivermectin + (1 week later) praziquantel|albendazole (400 mg one dose) + ivermectin (200 microgram/kg body weight) + (1 week later) praziquantel (40 mg/kg)
1863637|NCT01050530|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
1863638|NCT01050530|Drug|Placebo|Once-daily oral administration of placebo after breakfast for 7 days
1863639|NCT01050543|Drug|sugammadex|sugammadex 2.0 mg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
1863640|NCT01050543|Drug|neostigmine|neostigmine 50 mcg/kg (total dose not to exceed 5.0 mg) combined with glycopyrrolate 10 mcg/kg, single intravenous bolus dose administered within 10 seconds into a fast flowing venous infusion
1863641|NCT01050556|Other|Placebo|daily, 24 weeks
1863642|NCT01050556|Dietary Supplement|folic acid|400 ug/d for 12 or 24 weeks
1863643|NCT01050556|Dietary Supplement|folic acid|800 µg/d for 12 or 24 weeks
1863644|NCT01050556|Dietary Supplement|creatine|3 mg/d for 12 weeks
1863645|NCT01050556|Dietary Supplement|creatine + folic acid|3 mg creatine/d + 400 µg folic acid/d for 12 weeks
1863646|NCT01050569|Drug|Nicotine Patch|21 mg
1863647|NCT01050569|Other|VLNC Cigarette|Cigarette where the tobacco contains <0.1 mg of nicotine yield.
1863648|NCT01050569|Other|VLNC Cigarette Plus Nicotine Patch|21 mg nicotine patch plus use of cigarette with tobacco containing <0.1 mg nicotine yield.
1863649|NCT01050582|Drug|Risperidone|As per local prescribing practices
1863650|NCT01050582|Drug|Other atypical antipsychotic drugs|As per local prescribing practices
1863651|NCT01050595|Drug|Methylnaltrexone Bromide|The experimental group will receive the recommended dose of MNTX (Relistor) is 8 mg for patients weighing 38 kg to less than 62 kg (84 lbs to less than 136 lbs) or 12 mg for patients weighing 62 kg to 114 kg (136 lbs to 251 lbs). Patients whose weight is below 38 kg or greater than 114 kg, will be dosed at 0.15 mg/kg. If creatinine clearance <30 will decrease dose by 50%. This will be given after 72 hours of no bowel movement. Bowel management protocol will be instituted four hours afterward with the methylnaltrexone being given every other day.
1863652|NCT01050595|Drug|Placebo-Normal Saline|Control group will be given an equal amount of normal saline in an identically appearing vial every other day until a bowel movement occurs. A bowel management protocol will also be started.
1863653|NCT01050608|Device|Body worn alcohol gel dispenser|Records hand hygiene events of provider and tabulates on the group level.
1863807|NCT01045226|Other|Quality-of-Life assessment|Quality of Life Assessment
1863654|NCT01050608|Drug|62% ethanol based hand cleanser|"CDC based guidelines with regard to utilization in the health care environment the nest"
1863655|NCT01050608|Behavioral|Educational component with regard to teaching CDC guidelines|12 minute education prior to deploying device for all providers.
1863656|NCT01050608|Behavioral|Provider and group feedback|Provide feedback with regard to expected hand hygiene goals to providers and reported anonymous group results based on recorded information.
1863657|NCT01050621|Dietary Supplement|vitamin C (ascorbic acid)|ascorbic acid 1.5 g/kg body weight infused over 90 to 120 minutes two or three times weekly concurrent with standard cytotoxic chemotherapy individually selected for each patient by the treating oncologist on the basis of best current clinical practice
1863658|NCT01050634|Drug|Aromasin (exemestane)|25mg oral tablet, daily, for >1yr
1863659|NCT01050647|Drug|17-Hydroxyprogesterone Caproate|Weekly injections of 17-hydroxyprogesterone caproate.
1863660|NCT01050647|Other|Caster Oil injections|Weekly injection of Caster Oil (Placebo) until patient reached 34 weeks gestation.
1863661|NCT01050660|Other|Intravenous fat emulsion|An infusion of intravenous fat will start at 0.5 grams/kg on the first day of life, with increments of 0.5 -1.0 grams/kg every day, until a total dose of 3 grams/kg is reached.
1863662|NCT01050660|Other|Restriction of intravenous fat emulsion to 1 gm/kg/d|Intravenous fat will be started at 0.5 grams/kg on the first day of life and then increase to a dose of 1gram/kg/day the next day. There will be no further increase in the amount of intravenous fat.
1863663|NCT01050673|Device|VERSAJET|Hydro-surgery debridement
1863664|NCT01050673|Procedure|Scalpel or blade|Conventional Surgical Debridement
1863665|NCT01050686|Procedure|insertion of subcutaneous wound drain|after the abdominal fascia is closed and before skin closure, a subcutaneous wound drain is inserted
1863666|NCT01050686|Procedure|no insertion of subcutaneous wound drain|closure of abdominal wall and skin without insertion of subcutaneous wound drain
1863667|NCT01050699|Drug|Dexmedetomidine|Intravenous continuous infusion will be initiated with a (optional) loading dose of 1 mcg/Kg over 10 minutes followed by a maintenance infusion of 0.5 mcg/kg/hour for 24 hours.
1863668|NCT01050699|Drug|Midazolam and Fentanyl|"Midazolam (Versed): Loading dose 2-4 mg IV bolus followed by continuous infusion at 1-7 mg/hour.
Open label aliquots for pain (Midazolam 1- 4 mg IV bolus.)
Fentanyl: Loading dose 50-200 mcg IV bolus; Continuous infusion rate 50-300 mcg/hour. Open label aliquots for pain (Fentanyl 50 - 200 mcg IV bolus.)"
1863669|NCT01050712|Drug|Inhaled Carbon Monoxide|Concentration of Carbon Monoxide to be inhaled by patients will be determined in a safety trial performed in healthy volunteers prior to the commencement of this trial. Patients randomized to received inhaled carbon monoxide will receive this concentration by cushioned face mask for one hour prior to colon resection and for one hour after colon resection
1863670|NCT01050712|Drug|Synthetic Air|Patients randomized to this intervention will receive this gas via cushioned face mask for one hour prior to colon resection and for one hour after colon resection
1863671|NCT01050738|Procedure|Position of catheter|Position of catheter for administration of local anestesia.
1863672|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (1 x 750 mg) single dose
1863673|NCT01050751|Drug|Lersivirine|Oral Lersivirine 750 mg (3 x 250 mg) single dose
1863674|NCT01050764|Drug|Regulatory T-cells|"To ameliorate the impaired immune recovery and address the significant relapse incidence in the haploidentical setting. Cells will be selected by a tandem selection process and infused on day +14. These are the enriched but naturally-occurring regulatory T cells. Possible dose cohorts and levels are:
Cohort 1
T-reg: 1 x 10e5/kg
T-con: 3 x10e5/kg
Cohort 2
T-reg: 3 x 10e5/kg
T-con: 1 x 10e6/kg
Cohort 3
T-reg: 1 x 10e6/kg
T-con: 3 x 10e6/kg
Cohort 4
T-reg: 3 x 10e6/kg
T-con: 1 x 10e7/kg"
1863675|NCT01050764|Drug|Conventional T-cells|These are conventional (unselected) donor T-cells. Cell dosage of the infusion will be based on the CD3+ cell content and infused on day +16.
1863676|NCT01050764|Drug|Melphalan|Anti-cancer chemotherapy drug administered IV at 140 mg/m² on Day -8 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
1863677|NCT01050764|Drug|Thiotepa|Anti-cancer chemotherapy drug administered IV at 10 mg/kg on Day -7 prior to HSCT (a component of the conditioning regiment prior to infusion of cells)
1863678|NCT01050764|Device|Fludarabine|Anti-cancer chemotherapy drug administered IV at 160mg/m² on Days -6; -5; -4; and -3 prior to HSCT (a component of the conditioning regiment prior to infusion of cells
1863679|NCT01050764|Drug|Anti-thymocyte globulin, rabbit|Rabbit-derived antibodies against human T-cells used as transplant rejection prophylaxis. Administered at 6 mg/kg IV on Days -6; -5; -4; and -3 prior to HSCT
1863680|NCT01050764|Drug|CliniMACS CD34 Reagent System|An in vitro medical device system that uses antibodies conjugated to magnetic beads to select and enrich for CD34+ blood stem cells from the allogeneic donor apheresis product prior to HSCT, while removing other cells that can cause GvHD. CD34+ cell dosage will be based on the participant's body weight.
1863681|NCT01050777|Drug|Liposomal meglumine antimoniate (Glucantime)|Liposomes containing meglumine antimoniate
1863682|NCT01050777|Drug|Liposomal meglumine antimoniate|Liposomal form of meglumine antimoniate
1863683|NCT01050777|Drug|Liposomal Paromomycin|Liposomal form of 10% Paromomycin
1863684|NCT01050777|Drug|Placebo|Placebo
1863685|NCT01050790|Drug|Azacitidine|Subject will receive Vidaza (azacitidine) and Revlimid (lenalidomide) as treatment for their multiple myeloma. The Vidaza will be given for 5 days as an injection. On day 6 they will receive Revlimid taken by mouth every day for 16 days followed by 7 days of rest. The drug cycle will be repeated 0, 1 or 2 more times depending on how their blood counts recover.
1863686|NCT01050803|Behavioral|FDSME group|"In the intervention group, diabetes education sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
1863687|NCT01050803|Behavioral|FDSME|"In the intervention group, sessions which are designed based on the Intervention Mapping will be interactive and reflection in between sessions will be encouraged. Group-based problem-solving exercises will be used during the sessions. Participants receive feedback from peers and healthcare professionals at the following sessions."
1863808|NCT01045226|Other|Questionnaire Administration|Questionnaire Administration
1863688|NCT01050816|Procedure|Chondron(autologous chondrocyte) Implantation|"Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)
Directions and dosage:
Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected.
*30 subjects participated in this open clinical trial. Those who agreed to participate voluntarily went through screening to confirm the appropriateness for the clinical trial, and then received Gel type CHONDRON (fibrin mixed autologous chondrocytes) transplantation."
1863689|NCT01050829|Drug|Gadobutrol (Gadovist, BAY86-4875)|Single administration at a dose of 0.1 mmol/kg
1863690|NCT01050829|Drug|Gadopentetate Dimeglumine (Magnevist, BAY86-4882)|Single administration at a dose of 0.1 mmol/kg
1863691|NCT01050842|Drug|bicalutamide|Given orally
1863692|NCT01050842|Drug|raloxifene|Given orally
1863693|NCT01050842|Procedure|quality-of-life assessment|Ancillary study
1863694|NCT01050855|Drug|RIC: Distal Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
1863695|NCT01050855|Drug|RIC:Intermediate Campath|Campath, Fludarabine, Melphalan, Cyclosporine, Cellcept (MMF)
1863696|NCT01050855|Drug|RIC: Mini Busulfan|Campath, Fludarabine, Busulfan, Cyclosporine, Cellcept (MMF)
1863697|NCT01050868|Device|Accu-Chek Combo Kit mg DE/de|
1863698|NCT01050907|Drug|miltefosine|2.5 mg/kg/day for 28 days
1863699|NCT01050920|Biological|Blood collection|
1863700|NCT01050933|Drug|250 ppm carbon monoxide|250 ppm of inhaled carbon monoxide over one hour
1863701|NCT01050946|Biological|Haploidentical/cord transplant|"Myeloablative preparative regimen of chemotherapy and radiation followed by mismatch related(haploidentical)donor and one unit umbilical cord blood transplantation.
Conditioning Regimens Choice of regimen at the discretion of the treating physician
Fludarabine 30mg/m2(Days-7,-6,-5,-4,-3)-,Melphalan 70mg/m2(Day -3,-2), ATG 1.5mg/m2(Day-7,-5,-3,-1)
Fludarabine 50mg/m2(Day -6,-5,-4,-3,-2),Busulfan 3.2mg/kg(Day -5,-4,-3,-2),400cGY Total Body Irradiation(TBI)Day-1,ATG 1.5mg/kg(Day-7,-5,-3,-1)
Day 0 -Haploidentical donor and one umbilical cord blood unit infusion"
1863702|NCT01050959|Device|bion|
1863703|NCT01050972|Behavioral|Behavioral: Cognitive, Relaxation, Exercise Therapy|Behavioral: Cognitive, Relaxation, Exercise Therapy The intervention consists of brief shoulder and neck exercises to be performed several times a day, a relaxation exercise and instructions of how to reduce hyperfunction of the craniofacial and cervical muscles during the day
1863704|NCT01050985|Drug|Temsirolimus and capecitabine|temsirolimus in escalating doses starting at 15-mg IV on days 1 and 8 of a 14 day cycle capecitabine in escalating doses starting at 1000 mg/m2 by mouth twice a day on days 1-7 of a 14-day cycle
1863705|NCT01050998|Biological|Mavrilimumab 10 mg|Mavrilimumab (CAM-3001) 10 mg injection subcutaneously every other week for 12 weeks.
1863706|NCT01050998|Biological|Mavrilimumab 30 mg|Mavrilimumab (CAM-3001) 30 mg injection subcutaneously every other week for 12 weeks.
1863707|NCT01050998|Biological|Mavrilimumab 50 mg|Mavrilimumab (CAM-3001) 50 mg injection subcutaneously every other week for 12 weeks.
1863708|NCT01050998|Biological|Mavrilimumab 100 mg|Mavrilimumab (CAM-3001) 100 mg injection subcutaneously every other week for 12 weeks.
1863709|NCT01050998|Other|Placebo|Placebo matched to mavrilimumab injection subcutaneously every other week for 12 weeks.
1863710|NCT01051011|Drug|insulin glargine|initial dose 10 international units (IU) sc daily, titrated according to the mean FPG, 24 (-52) weeks
1863711|NCT01051011|Drug|metformin|as prescribed
1863712|NCT01051011|Drug|taspoglutide|10mg sc weekly, 24 (-52) weeks
1863713|NCT01051011|Drug|taspoglutide|10mg sc weekly the 1st 4 weeks followed by 20mg sc weekly, 24 (-52) weeks
1863714|NCT01051024|Dietary Supplement|Diamel|Two Diamel tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
1863715|NCT01051024|Dietary Supplement|Placebo|Two Placebo tablets (Orally administered) three times a day (just before each meal: breakfast, lunch and dinner), for 24 weeks.
1863716|NCT01051037|Radiation|Stereotactic Body Radiation|3 fraction of stereotactic body radiation therapy within 10 days.
1863717|NCT01051037|Radiation|Radiofrequency Ablation|Subject will undergo radiofrequency ablation within 10 days of the last fraction of SBRT.
1863718|NCT01051050|Behavioral|Mandatory use of surgery wiki|Mandatory participation in the surgery wiki. This will include adding to and reviewing information posted on the wiki. Contribution of an evidence-based review will be required at least once during the study period.
1863719|NCT01051050|Behavioral|Voluntary use of the surgery wiki|Voluntary participation in the surgery wiki. Participants can choose to use the information in the wiki as well as contribute to the wiki.
1863721|NCT01051076|Drug|VWF/FVIII concentrates|200 IU/Kg by one or two bolus injections daily. After successful confirmation the dose will be tailed off progressively until discontinuation. Patients will be treated with a VWF/FVIII concentrates according to physician/patients preference.
1863722|NCT01051089|Behavioral|Lifestyle modification|Exercise and diet education
1863723|NCT01051102|Drug|insulin degludec/insulin aspart|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
1863724|NCT01051102|Drug|biphasic insulin aspart 30|Single dose of 0.5 U/kg body weight injected s.c. (under the skin)
1863725|NCT01051115|Drug|Dasatinib|Chemo-refractory CLL patients will be treated with dasatinib monotherapy 100mg daily.Patients with less than a partial response at 4 weeks will receive fludarabine (orally 40mg/daily for 3 days q28) in addition to dasatinib for a maximum of 6 cycles. Patients with at least a partial response will continue dasatinib monotherapy. Patients that receive monotherapy after the initial 28 days and that develop progressive disease will 'cross-over' to the combination treatment.
1863726|NCT01051128|Device|Prometra Programmable Implantable Pump System|The Prometra Programmable Pump is a battery-operated, implantable, programmable infusion pump that dispenses drug solution into the intrathecal space through an implanted infusion catheter. All functions of the system (e.g., dosing) are controlled externally using a hand-held, battery-operated programmer.
1863771|NCT01044875|Procedure|Pan retinal photocoagulation laser treatment|Eyes with PDR are randomised to treatment with either the green laser 532 nm or 577 nm yellow laser.
1863809|NCT01045239|Device|Micropulse 577 nm yellow diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
1863727|NCT01051141|Behavioral|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive CBI condition will be delivered using touch-screen tablet computers with audio delivered via headphones. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
1863728|NCT01051141|Behavioral|Intervener-delivered Brief Intervention (IBI)|"The IBI condition will be delivered by a master's-level clinician with the aid of graphics. The interventions are highly individualized and designed to address the primary target behavior of alcohol use, and will include a tailored review of participants' goals/values, feedback regarding their present alcohol use patterns and consequences (either actual experiences or potential based on risk behaviors), developing a discrepancy between their alcohol use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant."
1863729|NCT01051141|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|The AMET session will have a similar general outline (~45 minutes) to the BI in the ED, including a review of participants' goals and values, alcohol use and consequences, decisional balance exercises, and change plan.
1863730|NCT01051154|Dietary Supplement|Docosahexaenoic acid (DHA)|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
1863731|NCT01051154|Dietary Supplement|Placebo|Children will be received either fish oil capsules (DHA group) or placebo capsules (placebo group) which is visually indistinguishable from DHA capsules (softgel). Each child will be receiving 100 mg/kg/day or placebo capsules without docosahexaenoic acid, during the first three months of treatment.
1863732|NCT01044628|Device|Concentrator|Patients allocated to the study group will receive oxygen overnight from an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, AirSep Corporation, Buffalo, NY, USA), to allow the oxygen saturation to be >90%
1863733|NCT01044628|Device|Sham concentrator|Patients allocated to the control group will receive ambient air delivered overnight through an electrically-powered oxygen concentrator (NewLife Intensity Oxygen Concentrator, Airsep Corporation, Buffalo, NY, USA) rendered ineffective by bypassing the sieve beds. The ineffective concentrators will have the same external appearance as the effective ones, allowing the trial to be double-blinded. We have requested approval by Health Canada in order to proceed with the modifications on the oxygen concentrators. Written permission is pending.
1863734|NCT01044654|Genetic|SB-728-T|Each infusion will be 5-30 billion ZFN modified CD4+ T-cells
1863735|NCT01044667|Drug|Myfortic|
1863736|NCT01044680|Dietary Supplement|NUTRIOSE|17 grams of NUTRIOSE consumed twice daily for 12 weeks
1863737|NCT01044680|Dietary Supplement|Placebo|17 g maltodextrin consumed twice daily for 12 weeks
1863738|NCT01044693|Drug|Placebo|Placebo capsule
1863739|NCT01044693|Drug|Nebivolol 5 mg|Nebivolol 5mg single oral dose
1863740|NCT01044693|Drug|metoprolol tartrate 50 mg|metoprolol tartrate 50 mg single oral dose
1863741|NCT01044693|Drug|Sildenafil25 mg|Sildenafil 25 mg single oral dose
1863742|NCT01044706|Drug|Bicalutamide|50 mg Oral Tablet
1863743|NCT01044719|Drug|Ceftazidime|Ceftazidime 2g TDS IV
1863744|NCT01044719|Drug|Tobramycin|Tobramycin 7mg/kg/day OD IV
1863745|NCT01044719|Drug|Meropenem|Meropenem 2g TDS IV
1863746|NCT01044732|Device|Third Eye Retroscope|Device used with colonoscope to provide second, retrograde view of the colon
1863747|NCT01044745|Drug|rituximab|Given IV
1863748|NCT01044745|Drug|mycophenolate mofetil|Given IV or PO
1863749|NCT01044745|Drug|tacrolimus|Given IV
1863750|NCT01044745|Drug|anti-thymocyte globulin|Given IV
1863751|NCT01044745|Procedure|allogeneic hematopoietic stem cell transplantation|Stem cell transplant
1863752|NCT01044745|Other|laboratory biomarker analysis|Correlative studies
1863753|NCT01044745|Biological|graft versus host disease prophylaxis/therapy|Undergo graft versus host disease prophylaxis/therapy
1863754|NCT01044745|Drug|cyclophosphamide|Given PO or IV
1863755|NCT01044745|Drug|fludarabine phosphate|Given IV
1863756|NCT01044745|Drug|busulfan|Given IV
1863757|NCT01044745|Radiation|total-body irradiation|Undergo TBI
1863758|NCT01044745|Biological|graft-versus-tumor induction therapy|Undergo graft-versus-tumor induction therapy
1863759|NCT01044745|Biological|immunosuppressive therapy|Undergo immunosuppressive therapy
1863760|NCT01044758|Drug|Levetiracetam 62.5mg|62.5mg twice daily (2 weeks)
1863761|NCT01044758|Drug|Levetiracetam 125mg|125mg twice daily (2 weeks)
1863762|NCT01044758|Drug|Levetiracetam 250mg|250mg twice daily (2 weeks)
1863763|NCT01044758|Drug|Placebo|placebo capsule twice daily (2 weeks)
1863764|NCT01044771|Drug|change from tenofovir to raltegravir|Change of the tenofovir based nucleoside part of the HIV regimen to raltegravir, 400mg BID
1863765|NCT01044810|Drug|Efavirenz-based regimens|Efavienz: 600 mg, oral, every 24 hours, continued medication until the end of study.
1863766|NCT01044823|Other|3D and thermal imaging|subjects will be imaged before and after receiving DMARD therapy
1863767|NCT01044836|Biological|HD203|Injectable form
1863768|NCT01044862|Drug|Letrozole (aromatase inhibitor)|A daily dose of 5 mg of the AI, letrozole, will be administered orally for five days starting on day three of the menstrual cycle. Future cycles can be started at 2.5-7.5 mg/d. FDA approval (IND) will be obtained.
1863769|NCT01044862|Drug|Clomiphene Citrate|CC will be administered at a dose of 100 mg/d on cycle days 3-7. Future cycles can be started at 50-150 mg/d.
1863770|NCT01044862|Drug|Follicle Stimulating Hormone (gonadotropin)|A daily injection of 150 IU of FSH will be administered subcutaneously starting on day three of the menstrual cycle and continuing until the day of hCG administration. Dosage will be able to be increased or decreased 37.5-75 IU/d beginning cycle day 7. Future cycles can be started at doses ranging from 75-225 IU/d. The same type of FSH injections will be used.
1865132|NCT01055314|Drug|Temozolomide|Given PO
1863772|NCT01044888|Drug|Heparin|150 U/kg heparin was administered intravenously at the beginning of graft anastomosis and accepted a perioperative ACT value of around 300 s. Ten minutes after the loading dose, the ACT was measured. An ACT of 300 s or greater was considered as adequate. Then follow up ACT measurement was determined after 30 min from the previous ACT measurement. If ACT fell below the target value of 300 s, an additional dose of heparin was administered. If ACT was between 250 and 299 s, additional 2000 U of heparin was administered and if ACT was between 200 and 249 s then additional 3000 U of heparin was injected. Ten minutes after additional heparin injection, ACT was remeasured.
1863773|NCT01044901|Procedure|MRI, Transthoracic Echocardiography, tonometry, EKG|Unless contraindicated, subjects will receive Regadenoson and Gadolinium contrast agent during the Cardiac magnetic resonance. The tonometer, EKG, and echo are non-invasive procedures.
1863774|NCT01044927|Other|Integrated Care|Comparison of the effect of COPD education, self-management instruction, home monitoring with a Health Buddy Telemonitor, pulse oximeter, pedometer and spirometer, and enhanced communication with a study coordinator (cell phone access)
1863775|NCT01044927|Other|Standard Therapy|No intervention was made. Data measurements were taken at 0, 3, 6 and 9 months, as in the active intervention group.
1863776|NCT01044953|Other|shortened winter break|winter break shortened by 3 weeks (from 6.5 to 3.5) within the German Professional Soccer League in season 2009/2010
1863777|NCT01044966|Drug|Intrathecal liposomal Ara-C + Temozolomide|Intrathecal liposomal Ara-C dosing will begin at 50 mg ITV every 2-4 weeks, and de-escalated based on toxicity obtained from the Phase I portion of the trial. Metronomic dosing of temozolomide will be given at 75 mg/m2 for 21 days (continuous oral dosing), followed by 7 days off in a 28 day cycle as a once daily dosing regimen.
1863778|NCT01044992|Radiation|H215O PET|H215O PET investigations will be performed during two pharmacological conditions: OFF (e.g after 12 hours of usual dopaminergic treatment discontinuation) and ON (after an acute oral levodopa challenge) in all subjects. During each PET there will be two motor conditions: rest (no movement, hand and wrist lying on the joystick) and a right-hand movement, consisting of moving joystick in 4 four different directions avoiding sequence repetition performed at rest and during a right hand movement.
1863779|NCT01044992|Drug|Levodopa|Levodopa: the dosage of levodopa challenge will be equivalent to the first morning dose increased by 100 mg of levodopa whereas the dosage will be 200 mg in healthy subjects.
1863780|NCT01045005|Other|Administration ofOxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non−harmful/non−toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
1863781|NCT01045005|Other|Administration of Oxygen and carbon dioxide|Inhalation of 100% oxygen and 4% carbon dioxide. This is non−harmful/non−toxic and will be given according to protocol previously described in the literature. It will be administered for a maximum of 4 minutes.
1863782|NCT01045018|Drug|Placebo|placebo 400 mg
1863783|NCT01045018|Drug|Mesalamine|
1863784|NCT01045018|Drug|Mesalamine|
1863785|NCT01045057|Device|Puncture Set and Flexible Protector|The Provox Vega Puncture Set will be used to create the tracheoesophageal puncture and place the voice prosthesis. In secondary punctures the Provox Flexible Protector may be used for pharynx protection.
1863786|NCT01045083|Drug|RO4917523|Oral single dose
1863787|NCT01045083|Drug|escitalopram|Oral single dose
1863788|NCT01045083|Drug|methylphenidate|Oral single dose
1863789|NCT01045083|Drug|placebo|Oral single dose
1863790|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 15 mg, delayed release capsules, orally, once daily for up to 7 days.
1863791|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 30 mg, delayed release capsules, orally, once daily for up to 7 days
1863792|NCT01045096|Drug|Dexlansoprazole|Dexlansoprazole 60 mg, delayed release capsules, orally, once daily for up to 7 days
1863793|NCT01045109|Dietary Supplement|cholecalciferol|4,000 I.U. softgel daily orally for 48 weeks
1863794|NCT01045109|Dietary Supplement|cholecalciferol|cholecalciferol or vitamin D3 4,000 IU daily for 48 weeks
1863795|NCT01045122|Drug|Propofol|For propofol, the current study will employ the Marsh parameters, with an initial effect site target concentration of 1.0 mcg/ml, a level likely to produce only mild sedation. Though our patient population is expected to be predominantly obese, a previous pharmacokinetic study has validated that constant infusions utilizing the dosing scheme of mcg-1•kg-1•min will yield similar effect site concentrations.25 The effect site target will be increased in increments approximately every five minutes until the pharmacodynamic targets defined in the study are attained.
1863796|NCT01045122|Drug|Dexmedetomidine|For dexmedetomidine, an intravenous loading dose of 0.5 mcg/kg will be infused over 10 minutes and followed by an infusion starting at 0.5 mcg/kg/hr. This infusion will be titrated up to a maximum of 1.2 mcg/kg/hr.
1863797|NCT01045148|Radiation|CyberKnife Radiosurgery|High Dose 3800 cGy/4 fractions
1863798|NCT01045148|Radiation|CyberKnife Radiosurgery|Moderate Dose 3400 cGy/5 fractions
1863799|NCT01045161|Drug|Aclidinium bromide|Aclidinium bromide 200 μg, oral inhalation twice per day 12 weeks of treatment. At week 12, patients who were on Aclidinium bromide 200 μg will receive open label 400µg aclidinium bromide for 40 weeks of treatment.
1863800|NCT01045161|Drug|Placebo|Dose-matched placebo, oral inhalation twice per day for 12 weeks. At week 12, patients who were on placebo will receive open label 400 µg aclidinium bromide for 40 weeks of treatment
1863801|NCT01045174|Device|Nebulizer (breath-actuated versus conventional continuous-output)|Participants are randomly assigned to receive bronchodilator treatments for asthma according to the standard of care using either a breath-actuated nebulizer device or a conventional continuous-output nebulizer. Standard unit doses of albuterol/ipratropium bromide or albuterol are used in both devices.
1863802|NCT01045187|Radiation|brachytherapy|Electronic brachytherapy dose 21 Gy or 22 Gy in 3-4 fractions prescribed to 5mm depth, or electronic brachytherapy 16-18 Gy if EBRT is administered.
1863803|NCT01045187|Radiation|Xoft Axxent Electronic Brachytherapy System|21-22 Gy in 3-4 fractions to 5mm or 16-18 Gy in 3 fractions prescribed to the surface.
1863804|NCT01045200|Other|Comparison of follow-up|Comparison of follow-up by nurse or surgeon after rectal cancer surgery
1863805|NCT01045213|Other|Integrated Care|Study looking at the efficacy of a combination of Guideline-based COPD education, self-management training, remote telemonitoring and enhanced communication with a coordinator.
1863810|NCT01045239|Device|532 nm green diode laser|Laser administered at beginning of study and may be repeated at 16 weeks if needed
1863811|NCT01045265|Other|Seminal plasma pharmacokinetics|Measure semen sample concentrations, obtain semen to plasma ratios across the dosing interval, the area under the concentration time curve of raltegravir in semen, the variability in penetration of raltegravir into the seminal compartment over the dosing period.
1863812|NCT01045278|Drug|Pegylated interferon-alfa-2b and ribavirin|Pegylated interferon-alfa-2b 1.5 microg/kg subcutaneously once weekly plus weight based ribavirin 800-1200 mg PO for a variable period depending on their HCV genotype and response to treatment.
1863813|NCT01045291|Device|Cardiac Resynchronization Therapy-Defibrillator (CRT-D)|Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.
1863814|NCT01045304|Drug|Iniparib|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1863815|NCT01045304|Drug|Gemcitabine|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1863816|NCT01045304|Drug|Carboplatin|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1863817|NCT01045317|Drug|PF-04776548|single intravenous or oral administration of 0.1mg PF-04776548.
1863818|NCT01045330|Behavioral|a modified NTU-HELP|The intervention consists of a daily inpatient care protocol on three core intervention protocols on top of hospital routine care.
1863819|NCT01045343|Other|Integrated diagnositic system|Heart failure will be managed using the integrated diagnostic system which consists of patient tools and a new Heart Failure Clinician's website which displays a new Heart Failure Risk score. This Heart Failure Clinician's website will be reviewed every 2 weeks in addition to scheduled in-office visits every three months.
1863820|NCT01045343|Other|Routine in office visits|Heart failure will be managed with scheduled in-office visits every three months.
1863821|NCT01045369|Drug|Kaletra and Intelence Tablets|Kaletra 400 mg twice a day and Intelence Tablets 200mg twice a day.
1863822|NCT01045382|Biological|Mesenchymal stem cells|Mesenchymal stem cell injection
1863823|NCT01045382|Other|Isotonic solution|Isotonic solution injection
1863824|NCT01045395|Dietary Supplement|Corn starch|90mg/d
1863825|NCT01045395|Dietary Supplement|Unique Marine Algae Concentrate (UMAC)|90mg/d
1863826|NCT01045395|Dietary Supplement|Golden brown algae|90mg/d
1863827|NCT01045408|Dietary Supplement|Berry extract|Berry extract for weeks
1863828|NCT01045421|Drug|MLN8237 (Alisertib)|"Phase 1:
MLN8237 will be administered orally twice a day on a 7-day dosing schedule
Phase 2:
MLN8237 will be administered orally at the maximum tolerated dose determined in Phase 1 for 7-days followed by a minimum 14-day rest period."
1863829|NCT01045434|Drug|Omeprazole|Omeprazole Magnesium DR 20 mg Capsules
1863830|NCT01045447|Drug|insulin degludec/insulin aspart|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily with main meal. Dose was individually adjusted.
1863831|NCT01045447|Drug|insulin glargine|Treat-to-target dose titration scheme, injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
1863832|NCT01045460|Biological|aMILs|Activated marrow infiltrating lymphocytes
1863833|NCT01045460|Biological|Allogeneic Myeloma Vaccine|Allogeneic granulocyte macrophage colony-stimulating factor (GM-CSF)-based myeloma cellular vaccine
1863834|NCT01045486|Drug|ATP mixed probiotics|- Patients in Group A will receive ATP mixed probiotics for 6 weeks. And after 4 weeks wash-out period, they will receive placebo for 6 weeks
1863835|NCT01045486|Drug|Placebo|- Patients in Group B will receive placebo for 6 weeks. And after 4 weeks wash-out period, they will receive ATP mixed probiotics for 6 weeks
1863836|NCT01045499|Device|Laparoscopic adjustable gastric banding (Allergan Lap Band)|Pre-op evaluation, surgical placement of a gastric band, and follow-up for a minimum of 5 years after surgery. Surgery is laparoscopic adjustable gastric band placement using a single brand of gastric band. Evaluations before and after surgery include but are not limited to history and physical examination, serum chemistry studies, imaging, sleep studies, and pulmonary function testing.
1863837|NCT01045512|Drug|fluvastatin|40-80mg once daily
1863838|NCT01045525|Procedure|Phlebotomy|From 300 to 400mL for women; From 350 to 450mL for men
1863839|NCT01045525|Behavioral|Lifestyle and diet advices|2 Booklets with Dietary and physical activity advices
1863840|NCT01045538|Drug|Vorinostat, capecitabine, and cisplatin|Vorinostat 200~400mg per day on day1-day14 combined with capecitabine 800-1,000mg/m2/dose, BID on day1-day14, and cisplatin 60-80mg/m2 on day 1
1863841|NCT01045551|Drug|Apremilast|20mg taken orally twice per day for 12 weeks
1863842|NCT01045564|Biological|GSK influenza virus H5N1 vaccine 1557484A|Three doses of GSK 1557484A administered intramuscularly (IM), the first and third in the deltoid region of the non-dominant arm and the second in the deltoid region of the dominant arm
1863843|NCT01045577|Drug|Masitinib|6 mg/kg/day
1863844|NCT01045577|Drug|Masitinib|3 mg/kg/day
1863845|NCT01045577|Drug|Placebo|Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
1863846|NCT01051167|Drug|Cetuximab|500 mg /m² cetuximab as an intravenous infusion over 120 minutes on day 1 every 2 weeks
1863847|NCT01051180|Procedure|HALO|Ligation of haemorrhoidal arteries
1863848|NCT01051193|Drug|Oxcarbazepine|
1863849|NCT01051206|Drug|6% hydroxyethyl Stach 130/0.4|After dividing patients medicated with HES 130/0.4(maximum 33ml/kg/day) during surgery and one day after from the surgery with patients medicated with crystalloid only, compare the effect on the volume of bleeding, blood transfusion, and blood coagulation when using IV fluid.
1863850|NCT01051219|Drug|Losartan|50 milligrams to be taken orally, daily
1863851|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 100 mg under fasting condition.
1863852|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
1863853|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 300 mg under fasting condition.
1863854|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
1863855|NCT01051232|Drug|Active|Six subjects will receive PF-00868554 (filibuvir) 500 mg under fasting condition.
1863856|NCT01051232|Drug|Placebo|Two subjects will receive the placebo under fasting condition.
1863857|NCT01051245|Behavioral|Case manager counseling|Patients followed-up by case manager. Interventions based on the Chronic Care Model. Interventions are self management education, motivational interviewing, individualized counseling on non-pharmacological treatment to modify and sustain healthy lifestyle behaviours, and follow-up. Close contact with primary care physician and/or specialist by case manager, if clinical targets out of recommended standards. Pharmacological treatment not suggested, managed by personal criteria of health care professionals. Focus on targets.
1863858|NCT01051245|Other|Usual care|Usual care provided by primary care physician and/or specialist according to patients' needs and professional criteria. Includes free access to educational diabetes workshops and educational brochures.
1863859|NCT01051258|Device|AeriSeal System|AeriSeal System for Lung Volume Reduction
1863860|NCT01051271|Drug|midazolam|midazolam 1.5 mg
1863861|NCT01051284|Radiation|Cyberknife radiation and gemcitabine|25 Gray of radiation will be given in 5 fractions using the Cyberknife Gemcitabine 1000 mg/m2 intravenously will be given once a week on days 1, 8, and 15 of every 28-day cycle for 6 cycles
1863863|NCT01051323|Drug|methoxy polyethylene glycol-ep [Mircera]|As prescribed by physician
1863864|NCT01051336|Device|TARIS Placebo|
1863865|NCT01051336|Procedure|Sham Procedure|
1863868|NCT01051362|Drug|PLD and Carboplatin|Pegylated liposomal doxorubicin (PLD) 30 mg/m2, followed by Carboplatin AUC (area under the curve) 5, every 21 days for 4 cycles or until progression.
1863869|NCT01051375|Behavioral|Psychoeducational Workshop and telephone support|The intervention involves completion of a single workshop (delivered by a psychiatrist and adolescent health physician), provision of psycho educational materials, and regular telephone support with a specially trained nurse-coordinator to parents of youth on our waiting list.
1863870|NCT01051388|Drug|Low-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 10 mg), once a day, for four weeks times three
1863871|NCT01051388|Drug|High-dose PPI (Rabeprazole sodium)|PPI (Rabeprazole sodium 20 mg Tablet once a day, for four weeks times three)
1863872|NCT01051388|Drug|Non-PPI (Gefarnate)|The mucosal defensive drug (Gefarnate 50 mg Capsule, twice a day, for four weeks times three)
1863873|NCT01051401|Drug|rosuvastatin|Given PO
1863874|NCT01051401|Other|placebo|Given PO
1863875|NCT01051401|Other|survey administration|Correlative study
1863876|NCT01051401|Procedure|management of therapy complications|
1863877|NCT01051414|Drug|BMS-790052|Tablets, Oral, 60 mg, daily, 24 weeks
1863878|NCT01051414|Drug|BMS-650032|Tablets, Oral, 1200 mg, daily, 24 weeks
1863879|NCT01051427|Device|Surgiflo|Before to put a nasal catheter to stop nasal bleeding when anterior packing fails, we'll try to stop bleeding with Surgiflo.
1863880|NCT01051427|Device|Nasal catheter|In patients randomized not to put Surgiflo, we use a nasal catheter to try to stop nasal bleeding.
1863881|NCT01051440|Drug|Lisdexamfetamine|Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.
1863882|NCT01051440|Drug|Placebo|Subjects will receive placebo matched to lisdexamfetamine.
1863883|NCT01051466|Drug|Duloxetine|60 milligrams (mg) administered orally daily for 8 weeks then 60-120 mg if non remitter or 60 mg if remitter for 4 additional weeks
1863884|NCT01051479|Drug|C11-Choline|15 mCi 11C-choline will be administered intravenously as a bolus. The whole body emission scans will be acquired immediately following the tracer injection.
1863885|NCT01051505|Drug|AZD5069|oral suspension dose of AZD5069. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
1863886|NCT01051505|Drug|Placebo|oral suspension dose of matched placebo. Multiple doses will be given once daily on day 1 and day 8 and twice daily on days 2 to 7
1863887|NCT01052103|Drug|LY2140023|40mg, oral tablets, twice daily: 20 mg in the morning, 20 mg in the evening, for 16 or 17 weeks. The dose may be adjusted to a minimum of 20mg or a maximum of 80mg.
1863888|NCT01052103|Drug|Placebo|Placebo oral tablets, twice daily: in the morning and in the evening, for 16 or 17 weeks.
1863889|NCT01052103|Drug|Standard of Care|U.S. label prescribed dose of one of the following Standard of Care Antipsychotics (aripiprazole, olanzapine, risperidone, quetiapine)
1863890|NCT01052116|Drug|Soy isoflavone supplement|Oral soy isoflavone supplement (100 mg/day)
1863891|NCT01052116|Drug|Placebo|Placebo
1863892|NCT01052129|Drug|Naproxen sodium|Naproxen Sodium Tablets 550 mg
1863893|NCT01052142|Biological|Lipovaxin-MM|Patients will receive three doses of Lipovaxin-MM by intravenous infusion at intervals of four weeks OR patients will receive 4 doses of Lipovaxin-MM by intravenous infusion at weekly intervals
1863895|NCT01052168|Other|skills training|participants will train using different performance goals (based on different metrics)
1863896|NCT01052181|Drug|Cholecalciferol|Oral Cholecalciferol sachets 120,000 IU monthly for 1 year
1863897|NCT01052181|Drug|placebo|2 sachets monthly for an year
1863898|NCT01052194|Drug|Placebo|tablet, placebo b.i.d. for 12 weeks
1863899|NCT01052194|Drug|VX-509|tablets, 25mg b.i.d. for 12 weeks
1863900|NCT01052194|Drug|VX-509|tablet, 50 mg b.i.d. for 12 weeks
1863901|NCT01052194|Drug|VX-509|tablet, 100 mg b.i.d. for 12 weeks
1863902|NCT01052194|Drug|VX-509|tablet, 150 mg b.i.d. for 12 weeks
1863929|NCT01052389|Drug|Haloperidol|"Patients allocated to haloperidol FGA arm will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden.
Suggested starting dose will be 1-3 mg/day and dose range 3-10 mg/day (chlorpromazine equivalents: suggested starting dose 50-100 mg/day; dose range 150-300 mg/day)."
1863930|NCT01052402|Biological|H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation|Two vaccinations, 21 days apart, followed by a heterologous booster vaccination on Day 360
1863932|NCT01052428|Drug|metoprolol succinate (Toprol XL)|Toprol XL 100 mg once a day for 2 years
1863903|NCT01052220|Behavioral|BP education and BP self-regulation|"The intervention will consist of 3 phases: 1) BP education sessions, 2) 12 week intervention and 3) 30 day post intervention follow-up period. The participants in the treatment group will be asked to monitor and record home BP daily, 24 hour fluid intake and complete a salt intake check-lists twice weekly for 12 weeks.
The PI will visit weekly with the intervention participants in the HD unit. to review BP and fluid logs and salt check lists with the participant to determine if predetermined goals for BP control were attained. When goals related to BP control are met, positive verbal reinforcement will be given to the participant. When goals related to BP control are not met, further exploration and problem solving will be done."
1863904|NCT01052220|Behavioral|Supportive Educative Nursing Intervention|BP Education, BP, salt and fluid monitoring, BP goal-setting, and reinforcement
1863905|NCT01052233|Procedure|Arthroscopic partial meniscectomy|Arthroscopic partial meniscectomy of the degenerative tear of medial meniscus
1863906|NCT01052233|Procedure|Arthroscopy (diagnostic)|Diagnostic arthroscopy of the knee
1863907|NCT01052246|Drug|Fixed combination of clindamycin 1% + benzoyl peroxide 5%|Topical monotherapy with a fixed combination of 1% clindamycin and 5% benzoyl peroxide hydrating gel (Duac® Akne Gel, Stiefel Laboratorium GmbH, Offenbach, Germany). In order to provide standardized condition within the sample, the gel was applied on the whole face regardless of the lesion location. The gel was applied once per day in the evening throughout the observation period and left in place overnight.
1863908|NCT01052246|Device|Pulsed dye laser|"Patients randomized in the experimental group received two additional treatments with a pulsed dye laser using the following parameters:
Wavelength 585 nm
Energy fluence 3 J/cm2
Pulse duration 0.35 msec
Spot size 7 mm"
1863909|NCT01052259|Drug|Deoxyspergualin|100mg/vial as active substance; Deoxyspergualin at 3-5 mg/kg/day by 1-3 iv infusion will be given once a day for 5 to 7 days each cycle every month; Total cycle treatment will be 6.
1863910|NCT01052272|Drug|Ramipril|The starting dose of Ramipril will be 2.5 mg once daily and rapidly titrated upward to 5 mg once daily after 5 days if systolic blood pressure is greater than 100 mmHg. After one month the patient will return to clinic for blood pressure check and will be titrated up to 10 mg once daily.
1863911|NCT01052272|Drug|Candesartan cilexetil|The starting dose of Candesartan cilexetil will be 4 mg or 8 mg once daily and doubled every 2 weeks, if systolic blood pressure is greater than 100 mmHg, to a maximum dose of 32 mg once daily. After one month the patient will return to clinic for blood pressure check and will be titrated up to 32 mg once daily.
1863912|NCT01052272|Drug|Allopurinol|The starting dose of Allopurinol is 300 mg daily.
1863913|NCT01052285|Procedure|Transversus abdominis plane block|UL-guided TAP block with 25 ml of ropivacaine 0,75% unilateral, single dose, ilioinguinal block with 10 ml of saline and local infiltration with 40 ml of saline
1863914|NCT01052285|Procedure|Saline|UL-guided Tap block with 25 ml of saline single dose Ilioinguinal block with 10 ml of saline and local infiltration with saline 40 ml single dose
1863915|NCT01052285|Procedure|Local infiltration|Ilioinguinal block with 10 ml of ropivacaine 0,375% single dose, local infiltration with 40 ml of ropivacaine 0,375% single dose, UL-guided Tap block with 25 ml of saline single dose
1863916|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
1863917|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|32.5 mg ciprofloxacin betaine corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given three times daily (tid) with a concluding single dose on 11d.
1863918|NCT01052298|Drug|Ciprofloxacin (Cipro inhale, BAYQ3939)|48.75 mg ciprofloxacin betaine corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as an initial single dose application on day 00d.During the multiple dose phase (day 02d to 10d) the same dose will be given twice daily (bid) with a concluding single dose on 11d.
1863919|NCT01052298|Drug|Placebo|Placebo inhalation powder will be given as an initial single dose inhalation on 00d.During the multiple dose phase placebo will be given twice/three-times daily with a concluding single dose on day 11d.
1863920|NCT01052311|Drug|Tredaptive (1 g extended release niacin+ 20 mg laropiprant)|Laropiprant (LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) is a potent, once-daily, highly selective PGD2-receptor (DP1) antagonist. A combination tablet containing 1 g of extended-release niacin and 20 mg of laropiprant (ERN/LRPT) once daily for the first 30 days. from day 31 to 90 it will be 2 g of extended-release niacin and 20 mg laropiprant once daily.
1863921|NCT01052311|Drug|Placebo|Placebo tablets once daily
1863922|NCT01052311|Drug|Tredaptive|Tredaptive 1 g [Laropiprant 20 mg(LRP; Merck & Co., Inc, Whitehouse Station, NJ, USA) and 1 g of extended-release niacin]from day 1 to 30 once daily. From day 31 to 90, the same but 2 g instead of 1 g of extended-release niacin.
1863923|NCT01052324|Drug|Remifentanil|After topical airway anesthesia with 10 % lidocaine in nostril and oropharyx, 1.5~2.0 mg of IV midazolam is injected. Awake nasotracheal fiberoptic intubation is performed with target-controlled infusion of remifentanil. Initial effect site concentration is 3.0 ng/ml. Smooth intubation is defined as absence of persistent cough with head elevation and defensive movement of extremities. In case of smooth intubation, effect site concentration is decreased by 0.5 ng/ml for the subsequent case. If intubation is not smooth, effect site concentration is increased by 0.5 ng/ml for the subsequent case. EC50 of remifentanil is determined using Dixon's up-and-down method.
1863924|NCT01052337|Drug|anaesthetics: sevofluorane|0.5%of sevofluorane with air
1863925|NCT01052363|Drug|Bevacizumab, CA4P|
1863926|NCT01052376|Device|Confocal endomicroscopy|
1863927|NCT01052389|Drug|Aripiprazole|Patients allocated to aripiprazole will be prescribed daily oral dose of drug, based on individual response and side-effects. Suggested starting dose will be 10 mg/day and dose range will be 10-30 mg/day.
1863928|NCT01052389|Drug|Olanzapine|Patients allocated to olanzapine will be prescribed daily oral dose of drug, based on individual patients' response and side-effect burden. Suggested starting dose will be 5 mg/day and dose range will be 10-20 mg/day.
1863931|NCT01052415|Behavioral|Cognitive behavioral sessions|Behavioral: Cognitive-behavioral, small group format sessions delivered in Chinese to service providers and HIV patients.
1863933|NCT01052428|Drug|Placebo|Placebo 100 mg once a day for 2 years
1863934|NCT01052454|Behavioral|Mindfulness-based stress reduction|Participants in the MBSR arm attend eight weekly classes.
1863935|NCT01052467|Drug|Xamiol® Gel|Once daily application for about 4 weeks
1863936|NCT01052480|Biological|Anti-Influenza Immune Plasma|2 units of plasma with high titer anti-influenza A or anti-influenza B antibodies at baseline
1863937|NCT01052480|Drug|Standard Care|All subjects will receive an anti-influenza antiviral (e.g., oseltamivir or zanamivir), but may include treatment with licensed antivirals in patient populations or at doses not covered in the package insert, or with medications available under a EUA. Standard care may also include antibiotics and other medications.
1863940|NCT01052506|Drug|BIIB033|Single, escalating doses of BIIB033 (8 cohorts IV, 1 cohort SC)
1863941|NCT01052506|Drug|Placebo|Single dose of placebo comparator (8 cohorts IV, 1 cohort SC)
1863942|NCT01052519|Other|Goal directed fluid therapy|Fluid will be administered to reach maximal stroke volume during the intraoperative period.
1863943|NCT01052545|Behavioral|Audit-Feedback|Applied as a post-prescription antimicrobial review based on established guidelines.
1863944|NCT01052558|Device|iStent Inject (GTS400)|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery with subsequent implantation of GTS400 stents.
1863945|NCT01052558|Procedure|Cataract Surgery|Subjects will be randomized to one of two groups. In this case, subjects will undergo cataract surgery only.
1863946|NCT01052571|Procedure|lumbar transforaminal epidural injections|with an injection of local anesthetic or with 1% lidocaine or 0.25% bupivacaine with 3 mg of steroid per level
1863947|NCT01052584|Drug|Chloroquine- P. vivax|Total of 25mg base per kg over 3 days (10 mg base/kg on Days 1 and 2, and 5 mg base/kg on Day 3)
1863948|NCT01052584|Drug|Artemether-Lumefantrine: P. vivax|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
1863949|NCT01052584|Drug|Artemether-lumefantrine: P. falciparum|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine in a fixed dose combination at a dosage
1863951|NCT01052610|Drug|sublingual house dust mites allergen extract|Staloral 300 IR, Stallergenes, France
1863952|NCT01052610|Drug|placebo in sublingual applicator|placebo for Staloral 300 IR, Stallergenes, France
1863953|NCT01052623|Drug|Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate|1 mg Estradiol valerate with for two days before GH-testing pre pubertal girls older than 8 years and pre pubertal boys older than 10 years. L-Arginin-Hydrochloride in the vein (0.5 g/kg KG maximum dose 30g) over 30 minutes. Clonidine orally (0,075 mg/m2 BSA). Somatropin-NutropinAq subcutaneum,a single one shot (dose 0.03 mg/KG, daily, over five days).
1863954|NCT01052636|Other|Interdisciplinary intervention program|The intervention program developed for this study included three components: geriatric consultation service, rehabilitation program, and discharge-planning service.
1863955|NCT01052649|Other|Blood sampling|
1863956|NCT01052662|Drug|Memantine|30mg/day Memantine orally everyday for 12 weeks
1863957|NCT01052662|Drug|Memantine|15 mg/day Memantine orally everyday for 12 weeks
1863958|NCT01052662|Drug|Placebo|Placebo orally everyday for 12 weeks
1863959|NCT01052688|Other|Maternal blood draw of 30 to 50ml|Maternal blood draw of 30 to 50mls during pregnancy. Blood may be drawn up to 5 times during the pregnancy between weeks 8 and 36 gestation.
1863960|NCT01052701|Drug|Ribavirin|"Daily Ribavirin alone 400 mg in the morning (AM) and 600 mg in the afternoon (PM) orally with 12 hours between the doses (Body Weight ≤75 kg)
OR
Daily RBV alone 600 mg orally every 12 hours (Body Weight >75 kg)"
1863961|NCT01052701|Drug|Ribavirin plus Abacavir (ABC)|"Daily Ribavirin 400 mg in AM and 600 mg in PM orally with 12 hours between the doses (Body Weight ≤75 kg)
OR
Daily RBV 600 mg orally every 12 hours (Body Weight >75 kg)
Plus
Daily Abacavir 300 mg orally every 12 hours"
1863962|NCT01052714|Behavioral|Lifestyle Balance|Patients assigned to the behavioral weight loss program (Lifestyle Balance Program) will do the following: -Meet with their psychiatrist and a nutritionist who will go over diet recommendations with the patient - Be given a 7% weight loss goal - Be assisted in obtaining a 500 calorie reduction per day -Exercise for at least 30 min/day, at least 5 days a week - Maintain weekly food and exercise diaries -Be quizzed on their knowledge of healthy eating habits and nutrition
1863963|NCT01052727|Procedure|Laparoscopic Cholecystectomy|
1863964|NCT01052766|Procedure|PET/CT and BH PET/CT|First, fiducial markers will be placed and taped on the patient's lower chest/upper abdomen. This will allow for monitoring of chest motion during breathing. A BH-CT scan will then be acquired with clinical CT scan parameters used in nuclear medicine. A BH-PET scan (acquisition time: 6 min per bed position) will follow the BH-CT scan. BH-PET images will cover the whole thorax, which, on average, corresponds to 1-3 PET FOV's (~15 cm/FOV). Data for these 1-3 bed positions are acquired to cover the entire thorax. There will be no additional radiotracer injection for the BH-PET scan.
1863965|NCT01052779|Drug|ferumoxytol|IV injection of ferumoxytol for a total cumulative dose of 1.02 g
1863966|NCT01052779|Drug|iron sucrose|IV infusion of iron sucrose for a total cumulative dose of 1.0 g
1863967|NCT01052792|Drug|Naproxen Sodium|Naproxen Sodium Tablets 550 mg
1863968|NCT01052805|Procedure|harvest nerve|harvest nerve from cadaveric donor and patients receiving nerve graft operation
1863969|NCT01052831|Drug|Naltrexone|50-100 mg qd for 8 weeks
1863970|NCT01052831|Drug|Placebo|50-100 mg qd for 8 weeks
1863971|NCT01052844|Drug|Placebo|Placebo, given orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
1863972|NCT01052844|Drug|Gabapentin|Gabapentin 300mg, orally Ranitide 50 mg, IV, before chemotherapy (D1) Ondansetron 8 mg, IV, before chemotherapy (D1) Dexamethasone 10 mg, IV, before chemotherapy (D1) Dexamethasone 4 mg, PO, 2x/day (D2, D3)
1863973|NCT01052857|Procedure|acupuncture|acupuncture application
1863974|NCT01052870|Drug|Finasteride|Effect of 1 mg finasteride on women with androgenetic alopecia depending on their AR gene polymorphism (androgen sensitivity)
1863975|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C], then after 7 days off treatment start DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D]
1863976|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation tablet/rtv 100mg tablet in the morning of Day 3 after food+ rtv 100 mg 1/day on Day 1-5 [Treatment B], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A]
1863977|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV 800 mg new formulation in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment D], then after 7 days off treatment start DRV two 400 mg commercial formulation tablets in the morning of day 3 fasting + rtv 100 mg 1/day on Day 1-5 [Treatment C]
1863978|NCT01052883|Drug|DRV commercial formulation/ DRV new formulation/ rtv 100mg tab|DRV two 400 mg commercial formulation tablets in the morning of day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment A], then after 7 days off treatment start DRV 800 mg new formulation tablet in the morning of Day 3 after food + rtv 100 mg 1/day on Day 1-5 [Treatment B]
1863979|NCT01052896|Drug|Gabapentin|300mg po TID
1863980|NCT01052896|Drug|Placebo|Look-alike of gabapentin 300mg given po tid
1863981|NCT01052909|Drug|Glimepiride|Glimepiride tablets 1 mg
1998206|NCT01588184|Drug|Bevacizumab|Bevacizumab will be administered at 7.5 or 15 milligrams per kilogram (mg/kg) intravenously every 3 weeks (Q3W), or 5 or 10 mg/kg intravenously every 2 weeks (Q2W).
1863985|NCT01052935|Biological|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.
Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P1 study."
1863986|NCT01052948|Other|Retrospective study-|
1863987|NCT01052948|Other|Retrospective study-|
1863988|NCT01052948|Other|Retrospective study-|
1863989|NCT01052948|Other|Retrospective study-|
1863990|NCT01052961|Drug|Oseltamivir|oseltamivir 150 mg bd for 5 days
1863992|NCT01052987|Drug|Tranilast|Tranilast tablets, 300 mg, QD
1863993|NCT01052987|Drug|Allopurinol|Allopurinol tablets 300 mg, QD
1863994|NCT01052987|Drug|Combination - Tranilast and Allopurinol|Tranilast, 300 mg QD; Allopurinol 300 mg QD
1863995|NCT01052987|Drug|400 mg Allopurinol|400 mg Allopurinol administered once daily for 7 days
1863996|NCT01052987|Drug|High dose combination|Combination of Tranilast 300 mg once daily for 7 days plus Allopurinol 400 mg once daily for 7 days
1863997|NCT01053000|Drug|Tazorac|compare the safety and efficacy of broad area photodynamic therapy with aminolevulinic acid (ALA-PDT) following topical retinoid pre-treatment with Tazorac vs ALA-PDT with occlusion only (no pretreatment) in subjects with dorsal hand/forearm actinic keratoses, with an incubation time of 60 minutes, using blue light.
1863998|NCT01053013|Biological|Cancer macrobead placement in abdominal cavity|8 macrobeads per kilogram
1863999|NCT01053026|Drug|olmesartan|(1) Olmesartan treatment or (2) Life modification and exercise training
1864000|NCT01053039|Drug|Intrathecal Morphine|Treatment group to receive 0.2mg of intrathecal morphine followed by PCA morphine.
1864001|NCT01053039|Drug|Intrathecal Saline|The control group will receive intrathecal saline followed by PCA. All patients will receive a standardized postoperative regimen.
1864002|NCT01053052|Device|Sonography with FemVue, and HSG|Sono HSG for FDA 510(k) cleared indication for use
1864003|NCT01053065|Drug|Atorvastatin - Cholestyramine - Sitosterol|
1864004|NCT01053078|Drug|Naltrexone|1 month treatment
1864005|NCT01053078|Drug|Naltrexone|Naltrexone 25 mg once daily with dose escalation to 50 mg BID to day 28
1864006|NCT01053091|Behavioral|exercise|The trained subjects will be trained on a bicycle ergometer at about 60-70%of heart rate reserve for 35-55 minutes (that will include 10-min warm-up, 15-35-min main exercise, and 10-min cool-down) per day, 3 days per week for 12 weeks
1864007|NCT01053117|Other|Protocolized approach to convert dialysis catheter to fistula|This group will be assigned an algorithm protocol in efforts to convert the central venous catheter to an arteriovenous fistula. A case manager will be assigned to follow these patients and implement the protocol
1864008|NCT01053130|Procedure|laparoscopic sleeve gastrectomy|laparoscopic sleeve gastrectomy plus dietary and physical activity support
1864009|NCT01053130|Behavioral|weight management program|1200-1500 kcal renal diet, increased physical activity, with optional orlistat therapy at 120 mg tds for 12 months
1864010|NCT01053143|Biological|A/H1N1 pandemic influenza vaccine (non- adjuvanted)|0.5 mL, Intramuscular
1864011|NCT01053156|Drug|minocycline hydrochloride|Minocycline hydrochloride dosed orally once a day for 3 months.
1864012|NCT01053156|Drug|Placebo|Placebo will be given daily for 3 months.
1864013|NCT01053169|Biological|Beriplex® P/N|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
1864014|NCT01053169|Biological|Fresh Frozen Plasma (FFP) and Beriplex® P/N|FFP is administered before Beriplex® P/N. Each treatment is given as an intravenous infusion, with the dosage of each calculated on an individual patient basis.
1864015|NCT01053169|Other|Fresh Frozen Plasma|Intravenous infusion, the dosage and the frequency of administration is calculated on an individual patient basis.
1864016|NCT01053182|Procedure|Ivor-Lewis Esophagectomy|Esophagectomy via Right Side Thoracotomy Plus Midline Laparotomy Approach
1864017|NCT01053182|Procedure|Sweet Esophagectomy|Esophagectomy through Left Side Thoracotomy
1864231|NCT01048567|Other|Lactobacillus acidophilus/rhamnosus|2 capsules (at least 2 billion cells per capsule) three times daily for duration of antibiotic therapy
1864018|NCT01053195|Behavioral|Lifestyle counseling|Non-diabetic high-risk subjects enrolled will be eligible for individual and/or group lifestyle counseling. The intervals of the counseling sessions depend on the glucose levels of the high-risk individuals, every three months for those having prediabetes and every six months for those with normal glucose levels but high risk score.
1864019|NCT01053208|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
1864020|NCT01053221|Drug|Mycophenolic Acid|Mycophenolate mofetil: 750mg po bid x 36 months OR mycophenolate sodium 540mg po bid x 36 months
1864021|NCT01053221|Drug|Standard of Care: CNI and MPA|Tacrolimus or cyclosporine: dosed according to trough levels per standard of care Mycophenolate mofetil 750mg po bid or mycophenolate sodium 540mg po bid x 36 months
1864022|NCT01053234|Dietary Supplement|Standardised meals|
1864023|NCT01053247|Drug|0416|Topical 0416 test product applied twice daily for 2 weeks
1864024|NCT01053247|Drug|Vehicle of 0416 test product|Vehicle of 0416 test product applied twice daily for 2 weeks
1864025|NCT01053247|Drug|tacrolimus ointment 0.1%|Reference Product for 0416 test product. Apply twice daily for 2 weeks.
1864026|NCT01053260|Behavioral|LEARN Program|Participants will receive weekly counseling based on the LEARN Program for Weight Management
1864027|NCT01053260|Behavioral|Contingency Management|Participants can earn chances to win prizes for losing weight and completing activities that promote weight loss.
1864028|NCT01053273|Procedure|Caudal Epidural Injection|Group I will receive caudal epidural injections with catheterization up to S3 with local anesthetic, steroids, and 0.9% sodium chloride solution
1864029|NCT01053273|Procedure|percutaneous adhesiolysis|Group II will receive percutaneous adhesiolysis with targeted delivery of lidocaine, 10% hypertonic sodium chloride solution, and non-particulate betamethasone.
1864030|NCT01053299|Other|open, prospective cohort-study|Specific measurements from the X-ray to assess the hip status 5-12 years from the born.
1864031|NCT01053312|Drug|[18F] Flutemetamol|All subjects will receive an intravenous (IV) dose of [18F]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 megabecquerels (MBq).
1864032|NCT01053325|Drug|Cotrimoxazole prophylaxis|Daily prophylaxis with cotrimoxazole
1864033|NCT01053325|Drug|SP IPT|Intermittent preventive treatment with sulphadoxine-pyrimethamine
1864034|NCT01053338|Drug|Ibuprofen and Diphenhydramine Citrate|Ibuprofen and Diphenhydramine Citrate 200mg/38mg Caplets
1864035|NCT01053364|Device|NL-Prow interspinous spacer implant|Interspinous spacer implant
1864036|NCT01053377|Drug|Tamiflu (verum)|
1864037|NCT01053377|Drug|Tamiflu placebo|
1864038|NCT01053390|Drug|Somatostatin|Somatostatin 3mg+NS（normal saline）60ml, a continuous intravenous infusion, q12h
1864039|NCT01053390|Drug|epirubicin, cisplatin, LV（Leucovorin）、 5-FU（5-Fluorouracil）|
1864040|NCT01053403|Drug|3,4-methylenedioxymethamphetamine or Placebo|1.5mg/kg MDMA or matched Placebo administered during 2 inpatients stays. There are 2 dosing sessions and all subjects will receive MDMA at least one time.
1864041|NCT01053416|Procedure|Yag laser iridotomy|the procedure will be performed by using a Yag laser. Single spot, 1 mJ power, beam aimed to an existing iris crypt
1864042|NCT01053429|Drug|ziprasidone|This is a non-interventional, pharmacovigilance study, therefore patients are on ziprasidone as prescribed by their doctor.
1864043|NCT01053442|Dietary Supplement|Porridge fortified with either NaFeEDTA|265g maize porridge is fortified with 2.5 mg iron as NaFeEDTA.
1864044|NCT01053442|Dietary Supplement|FeSO4|Maize porridge is fortified with 2.5 mg iron as ferrous sulphate and 45 mg ascorbic acid.
1864045|NCT01053455|Device|SiPAP|biphasic CPAP (SiPAP) to be alternated in 1 hour blocks with NCPAP
1864046|NCT01053468|Behavioral|Physical Activity Resource Kit|"The Intervention group (INT) will receive a Physical Activity Resource Kit which includes a step pedometer, a breast cancer-specific Physical Activity Guidebook (Exercise for health), a step pedometer resource (Step into survivorship), and a physical activity and step journal to record their daily step totals and daily physical activities.
Participants will be instructed to wear their pedometer for the entire duration of the study (i.e., chemotherapy duration)."
1864047|NCT01053468|Behavioral|Standard Materials|Participants in this usual care group will receive a generic physical activity leaflet from the Canadian Public Health Agency
1864048|NCT01053481|Dietary Supplement|vitamin D|Vitamin D supplement
1864049|NCT01053481|Behavioral|exercise program (rebounding on a trampoline)|40 days at 30 min/d
1864050|NCT01053494|Procedure|massage therapy|Undergo massage therapy
1864051|NCT01053494|Other|questionnaire administration|Ancillary studies
1864052|NCT01053494|Procedure|quality-of-life assessment|Ancillary studies
1864053|NCT01053494|Other|intervention by caregiver|Undergo massage by caregiver
1864054|NCT01053494|Procedure|standard follow-up care|Undergo standard follow-up care
1864055|NCT01053507|Drug|sumatriptan/naproxen sodium|Each tablet of Treximet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
1864056|NCT01053507|Drug|Placebo|Each tablet of placebo for oral administration matches Treximet. Placebo is to be administered 1 tablet per day at the same time each day x 30 days in the Treatment Period.
1864057|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation A Period 2: Single (oral) dose of 25 mg of Formulation B1 Period 3: Single (oral) dose of 25 mg of Formulation B2
1864058|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B1 Period 2: Single (oral) dose of 25 mg of Formulation B2 Period 3: Single (oral) dose of 25 mg of Formulation A
1864059|NCT01053520|Drug|ABT-263|Period 1: Single (oral) dose of 25 mg of Formulation B2 Period 2: Single (oral) dose of 25 mg of Formulation A Period 3: Single (oral) dose of 25 mg of Formulation B1
1864060|NCT01053533|Drug|Chinese herbal medicines plus western therapy|injections of Chinese herbal medicines and Chinese herbal medicines decoction& supportive therapy and antivirus therapy when necessary
1864061|NCT01053533|Drug|western therapy|supportive therapy and antivirus therapy when necessary
1864155|NCT01054248|Drug|dihydroartemisinin-piperaquine|Standard 3 days regimen DHA-piperaquine: (DHA/PPQ 40 mg/320 mg) 2.4 mg/kg DHA and 20 mg/kg PPQ once daily for 3 days
1864062|NCT01053546|Behavioral|exercise intervention|The early exercise group will start study exercises approximately two weeks prior to the onset of XRT. The late exercise group will start study exercises one month after the completion of XRT. Participants will undergo an initial/pre-radiation and 1-, 3-, 6-, and 12 month post-radiation swallowing assessments.
1864063|NCT01053546|Other|questionnaire administration|Ancillary study
1864064|NCT01053546|Procedure|quality-of-life assessment|Ancillary study
1864066|NCT01053572|Procedure|Adhesiolysis|Group I will receive adhesiolysis, local anesthetic, 10% sodium chloride solution, and non-particulate Celestone
1864067|NCT01053585|Drug|Baclofen|Baclofen suspension 40mg (single dose 90 minutes prior to physiologic measurement)
1864068|NCT01053585|Drug|Placebo|Placebo single 'dose' 90 minutes prior to study
1864069|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|remifentanil 0 ng/ml
1864070|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
1864071|NCT01053611|Drug|propofol + remifentanil 4 ng/ml|
1864072|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
1864073|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|
1864074|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
1864075|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
1864076|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
1864077|NCT01053611|Drug|propofol + remifentanil 0 ng/ml|
1864078|NCT01053611|Drug|propofol + remifentanil 2 ng/ml|
1864079|NCT01053611|Drug|propofol + remifentanil 4 ng/ml|
1864080|NCT01053611|Drug|propofol + remifentanil 6 ng/ml|
1864081|NCT01053624|Procedure|Tracheostomy|This protocol has been design to determine if tracheostomy performed immediately after lung operation (i.e. concomitant tracheotomy) could improve the postoperative outcome of high risk patients. We hypothesized that concomitant tracheotomy could reduce the length of mechanical ventilation and the number of respiratory complications
1864084|NCT01053650|Drug|Paracetamol|Clinical trial conducted in healthy volunteers, prospective, single center, randomized, open / hidden.
1864085|NCT01053663|Drug|Tamiflu|10 doses over 5 or 6 days of which the first 5 or 6 doses must be intravenous, up to 5 days (10 doses) of additional intravenously or oral treatment if virus shedding continues at day 6
1864086|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule|BAY77-1931 Granule TID for 4 days
1864087|NCT01053676|Drug|Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet|BAY77-1931 Chewable tablet TID for 4 days
1864088|NCT01053689|Drug|Glimepiride tablets 1 mg|
1864089|NCT01053702|Drug|R475|IV
1864090|NCT01053702|Drug|Placebo|Placebo
1864091|NCT01053728|Drug|SAR161271|"Pharmaceutical form:Solution for injection
Route of administration: subcutaneous"
1864092|NCT01053728|Drug|Insulin glargine HOE901|"Pharmaceutical form:Solution for injection
Route of administration: subcutaneous"
1864093|NCT01053741|Biological|Radiolabeled autologous seminal fluid|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in seminal fluid vehicle.
1864094|NCT01053741|Biological|Radiolabeled Normosol-R|Autologous lymphocytes labeled with 250 microcuries In-111 and 500 microcuries Tc-99m in Normosol-R fluid vehicle.
1864095|NCT01053754|Biological|"long synacthen stimulation test"|IM injection of 1 mg of delate synacthen which can be realized in ambulatory conditions
1864096|NCT01053767|Biological|Group B streptococcus (GBS) vaccine|"No vaccine will be administered in this study. Only one study visit is required.
Subjects will return to the clinic for a single visit at 24 months (± 3 months) after the last injection administered in the V98P2 study."
1864097|NCT01053780|Other|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
1864098|NCT01053780|Behavioral|Intercessory Prayer|A committed group of six people selected by the chief investigator prayed nine consecutive days for the patients in the intervention group; they were blind to the identity , the patients' first name, were given to the intercessors.
1864099|NCT01053793|Other|Glycemic response to different varieties of potatoes|the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
1864100|NCT01053806|Drug|5-Azacytidine and Lenalidomide|Induction:5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days a cycle for 6 cycles and Lenalidomide 10mg/d orally days 6-28 every cycle for 6 cycles Consolidation: 5-Azacytidine 75mg/m2/d S.C.or I.V. days 1-5 every 28 days for 6 cycles Maintenance: Lenalidomide 10mg/d orally days 1-21 every cycle of 28 days for 13 cycles.
1864101|NCT01053819|Drug|etanercept|Patients will receive six months of treatment with Enbrel 50mg SQ given twice a week for the first three months and 50 mg once a week thereafter.
1864102|NCT01053832|Device|VpS algorithm in EVIA and ENTOVIS pacemakers|For one group of patients, the VpS algorithm will be activated and for the other group, the VpS algorithm will be deactivated until the cross-over, where these conditions will be switched.
1864103|NCT01053845|Other|Neuropathic pain|to study the working of down inhibitor bundle at patients suffering of neuropathic pain
1864104|NCT01053858|Procedure|intravitreal injection|intravitreal bevacizumab( 1.25 mg) or triamcinolone( 4mg) injection
1864105|NCT01053871|Drug|propofol|conscious sedation using propofol
1864106|NCT01053871|Drug|midazolam with fentanyl|conscious sedation using midazolam with fentanyl
1864107|NCT01053884|Drug|Anidulafungin|"standard dose: 200mg/d on day 1, followed by 100mg/d from day 2 as maintenance dose.
Prophylaxis will be given until the recovery from neutropenia (ANC > 1,0 G/L without myelosupportive medications) and in cases of active fungal infection until best response, in case of fungemia for at least 2 weeks after the first negative culture."
1864108|NCT01053897|Biological|GBT009|Intradermal Injection following surgery
1864109|NCT01053897|Biological|Placebo|Intradermal Injection following surgery
1864110|NCT01053910|Drug|Ramipril|tablet of Ramipril once daily
1864111|NCT01053923|Other|Magnetic Resonance Imaging (MRI)|This study involves three imaging sessions (Magnetic Nuclear Resonance -MRI), with one session before radiation therapy and two sessions during radiation therapy (one at 3 weeks of RT; the other during the last week of RT). Each imaging session will last for approximately 45 to 60 minutes.
1864112|NCT01053936|Drug|Bardoxolone methyl (amorphous dispersion)|Oral, once daily
1864113|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 21 days per 28 days cycle. The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
1864114|NCT01053949|Drug|Pomalidomide|Pomalidomide 4 mg continuous daily oral route on 28 days of a 28 days cycle The proposed dose of dexamethasone is considered standard, 40mg/day once a week.
1864115|NCT01053962|Drug|SP-304|Subjects receiving SP-304 1.0 mg for 14 consecutive days
1864116|NCT01053962|Drug|SP-304|Subjects receiving SP-304 3.0 mg for 14 consecutive days
1864117|NCT01053962|Drug|SP-304|Subjects receiving SP-304 9.0 mg for 14 consecutive days
1864118|NCT01053962|Drug|Placebo|Subjects receiving Placebo for 14 consecutive days
1864119|NCT01053962|Drug|SP-304 0.3 mg|Subjects receiving SP-304 0.3 mg for 14 consecutive
1864120|NCT01053988|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
1864121|NCT01053988|Drug|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
1864122|NCT01053988|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
1864123|NCT01053988|Drug|Placebo|Placebo
1991263|NCT01314911|Drug|Oseltamivir Placebo|One capsule twice daily of oseltamivir placebo; total dose: 2 placebo capsules/day for 5 days
1864125|NCT01054014|Drug|JNJ-40346527/Placebo|Single oral dose of JNJ-40346527 (either 10, 50, 150, 300, 600, or 1000mg) or Placebo
1864126|NCT01054014|Drug|JNJ-40346527/Placebo|JNJ-40346527 once daily oral dose for 14 days (either 50, 150, 300, 500 or 750mg) or Placebo
1864127|NCT01054014|Drug|JNJ-40346527|JNJ-40346527 150mg one dose, either fasting (or with food), then after 7 days off treatment, JNJ-40346527 150mg either with food (or fasting)
1864128|NCT01054027|Drug|1% phenylephrine and 0.2% cyclopentolate|given as drops, prior to eye exam
1864129|NCT01054040|Other|Portion plate given to cardiac rehabilitation patients|Patients in the experimental group will be provided with standard care (group and individual nutrition counselling) plus be provided a portion control plate
1864130|NCT01054066|Behavioral|Chronic Kidney Disease Education|Instituting teaching programs to manage hypertension, diabetes, anemia, proteinuria and cardiovascular disease in patients.
1864131|NCT01054079|Other|laboratory biomarker analysis|Correlative study
1864132|NCT01054079|Procedure|quality-of-life assessment|Ancillary study
1864133|NCT01054079|Other|questionnaire administration|Ancillary study
1864134|NCT01054079|Drug|cinacalcet hydrochloride|Given PO
1864135|NCT01054092|Drug|ASP1941|oral
1864136|NCT01054105|Drug|Iloprost|Iloprost inhalation, 2.5 - 5mcg, 6 times per day
1864137|NCT01054118|Drug|JNJ-38431055|Liquid suspension of JNJ-38431055 administered as a single dose
1864138|NCT01054118|Drug|Sitagliptin 100 mg|Capsule containing 100 mg of sitagliptin administered as a single dose
1864139|NCT01054118|Drug|JNJ-38431055 + Sitagliptin 100 mg|Liquid suspension of JNJ-38431055 administered as a single dose, and capsule containing 100 mg of sitagliptin administered as a single dose
1864140|NCT01054118|Drug|Placebo|Placebo suspension and placebo capsule administered as single doses
1864141|NCT01054131|Behavioral|peer support|A quasi-experimental, before and after study design will obtain data for planning and implementing a larger-scale study. Exposures and outcomes will be measured at baseline, 3 months (immediate post 12-week program) and 6 months (3 months post-program). Ten individuals with EIA will be recruited by brief screening interviews to ensure they meet inclusion criteria. Each pair of peer mentor and EIA participant will meet at SHSC for an initial contact. EIA participants will receive informational, emotional and appraisal support from trained peer mentors by telephone or neutral private location at a time convenient for both parties, at least once a week for 12 weeks.
1864142|NCT01054144|Drug|Lenalidomide|"Starting Dose: 25 mg by mouth (PO) days 1-21 of a 28 days cycle;
Dose Level -1: 15 mg PO days 1-21 of a 28 days cycle;
Dose Level -2: 10 mg PO days 1-21 of a 28 days cycle;
Dose Level -3: 5 mg PO days 1-21 of a 28 days cycle;
Dose Level -4: Discontinue"
1864143|NCT01054144|Drug|Prednisone|"Starting Dose: 100 mg PO days 1-5 every 28 days;
Dose level -1: 50 mg PO days 1-5 of a 28 day cycle;
Dose level -2: 25 mg PO days 1-5 of a 28 day cycle;
Dose level -3: Discontinue"
1864144|NCT01054144|Drug|Dexamethasone|"Starting Dose: 40 mg daily on days 1 - 4 every 28 days;
Dose level -1: 20 mg daily on days 1 - 4 every 28 days;
Dose level -1a: 40 mg daily on days 1, 2, and 3 followed by 20 mg on day 4 followed by 12 mg on day 5 followed by 8 mg on day 6;
Dose level -2: 10 mg daily on days 1 - 4 every 28 days;
Dose level -3: Discontinue"
1864145|NCT01054170|Drug|AZD9668|2 x 30 mg oral tablets twice daily (bid) for 12 weeks
1864146|NCT01054170|Drug|Placebo|2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
1864147|NCT01054183|Device|GlideScope Ranger Intubation|Intubation with GlideScope Ranger Video Laryngoscope
1864148|NCT01054183|Device|Direct Laryngoscopy|Intubations will be done with direct laryngoscopy.
1864149|NCT01054196|Drug|lenalidomide|daily dose dependent on dose-escalation schedule
1864150|NCT01054196|Drug|melphalan|100 mg/m2 given Days -2 and -1
1864152|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 4 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
1864153|NCT01054222|Drug|Fesoterodine|Fesoterodine fumarate, sustained release (SR) tablet, 8 mg once daily, oral, duration - until fesoterodine is commercially available in Portugal or until 31 Dec 2011 (whichever is earlier)
1864154|NCT01054235|Behavioral|training|The intervention consisted of 1) training township midwives, 2) informing women and men in the community of the importance of prenatal care, 3) providing intervention township hospitals with basic medical instruments used in prenatal care (i.e. blood pressure monitors, weighing scales for mothers and newborns, stethoscopes).
1864232|NCT01048567|Other|Placebo|2 capsules three times daily for entire duration of antibiotic therapy.
1864156|NCT01054248|Drug|Artesunate-mefloquine|Standard three day regimen of artesunate-mefloquine (12/24 mg/kg) given as artesunate 4mg/kg/day and mefloquine 8mg/kg/day on Days 0, 1 and 2.
1864157|NCT01054248|Drug|arthemeter-lumefantrin|Augmented 4 day regimen of artemether lumefantrine 2 doses per day for 4 days. Each dose consists of 5 tablets (20/120 mg of artemether/lumefantrine per tablet).
1864158|NCT01054261|Drug|avanafil|200 mg avanafil tablet QD
1864159|NCT01054274|Device|novel stent|Patients undergo placement of a novel esophageal stent loaded with 125I seeds on day 1.
1864160|NCT01054274|Device|conventional covered stent|Patients undergo placement of a conventional covered stent on day 1.
1864161|NCT01054287|Other|Multifactorial falls prevention program|
1864162|NCT01054287|Other|No falls prevention intervention|
1864163|NCT01054300|Drug|Ertugliflozin 2 mg single dose|Ertugliflozin 2 mg dose (using 1 mg strength tablets), administered as a single dose
1864164|NCT01054300|Drug|Ertugliflozin 2 mg split into twice daily|Ertugliflozin 1 mg dose (using 1 mg strength tablets) administered twice daily x 1 day
1864165|NCT01054300|Drug|Ertugliflozin 4 mg single dose|Ertugliflozin 4 mg dose (using 1mg strength tablets), administered as a single dose
1864166|NCT01054300|Drug|Ertugliflozin 4 mg split into twice daily|Ertugliflozin 2 mg dose (using 1 mg strength tablets) administered twice daily x 1 day
1864167|NCT01054300|Drug|Placebo|Placebo to Ertugliflozin
1864168|NCT01054313|Drug|Docetaxel (Taxotere)|Starting dose 30 mg/m^2 by vein (IV) over about 1 hour on Day 1 of every 21 day cycle.
1864169|NCT01054313|Drug|Sirolimus (Rapamycin)|Starting dose 1 mg daily by mouth 1 time a day.
1864170|NCT01054313|Drug|Prednisone|5 mg by mouth twice a day with prostate cancer.
1864171|NCT01054326|Other|Exercises|
1864172|NCT01054339|Drug|rAAV1-CB-hAAT|Recombinant adeno-associated virus vector expressing human alpha-1 antitrypsin
1864173|NCT01054352|Drug|JNJ38224342|multiple ascending oral doses (100, 250, 500, 750 mg) of JNJ 38224342 or matching placebo, administered for 14 consecutive days in healthy male or female volunteers
1864174|NCT01054352|Drug|JNJ38224342/placebo|up to four (4) additional cohorts consisting of healthy male volunteers may be added
1864175|NCT01054352|Drug|JNJ38224342/placebo|.up to four (4) additional cohorts consisting of healthy male or female volunteers may be added
1864176|NCT01054352|Drug|JNJ38224342/placebo|one of six (6) single ascending doses (25, 100, 300, 600, 1250 or 2000 mg) of JNJ 38224342 or matching placebo
1864177|NCT01054378|Procedure|M-mode ultrasonography|Evaluation of diaphragmatic movement using M-mode ultrasonography before and after stellate ganglion block with 1% lidocaine
1864178|NCT01054391|Device|NEC - Neurovascular Embolization Cover|Implantation of NEC for the treatment of intracranial aneurysms and carotid/vertebrobasilar fistuale arising from a parent vessel of 2.5 to 4.5mm
1864179|NCT01054404|Drug|Furosemide|Furosemide 0.3 mg/kg
1864180|NCT01054404|Drug|Placebo|Placebo (up to 5mL)
1864181|NCT01054430|Drug|avanafil|200 mg avanafil tablets QD
1864182|NCT01054443|Drug|placebo to S-888711|Tablet
1864183|NCT01054443|Drug|S-888711|Tablet
1864184|NCT01054443|Drug|S-888711|Tablet
1864185|NCT01054443|Drug|S-888711|Tablet
1864186|NCT01054456|Drug|palonesetron|One dose administered intravenously 30 minutes pre-chemotherapy
1864187|NCT01054469|Procedure|TAP block placement with placebo|20 ml of normal saline (placebo)
1864188|NCT01054469|Procedure|Placement of block with ropivacaine|20 ml of 0.5% ropivacaine hydrochloride
1864189|NCT01054482|Drug|Pre-operative chemotherapy|Docetaxel 75 mg/m2 + Carboplatin AUC(area under the curve)=6 on D1, q3 weeks, Pre-Op & Post-Op (total 4 cycles)
1864190|NCT01054482|Other|Pre-operative concurrent chemoradiation therapy|"Chemotherapy: Docetaxel 20 mg/m2 + carboplatin area under the curve = 2 on D1 and 8, q3weeks, Pre-Op & Post-Op: 2 cycles (total 4 cycles).
Concurrent thoracic radiotherapy: Preoperative Thoracic radiation: 180cGy/fx, total: 4500cGy, 25fx"
1864191|NCT01054495|Drug|Acupuncture|"The acupuncture needles are inserted in PC 6 bilaterally at the acupuncture point Pericardium 6 (PC6) on each forearm (fig 2). According to the cun measurement system of Traditional Chinese Medicine (TCM), the points are located on the palmar surface of anterior forearm at a distance equivalent to the combined width of the women's middle three fingers, proximal to the most prominent wrist crease, and between the tendons of palmaris longus and flexor carpi radialis. We try to keep the depth of the needling to approximately 1,5 cm. At insertion of the acupuncture needle, DeQi is obtained and the needle is then left without any further manipulation/ stimulation (even method) in situ for 15 minutes."
1864192|NCT01054495|Device|Sham acupuncture|A sham acupuncture needle is placed at PC 6 bilaterally and the tactile stimuli of the skin during the procedure should be obtained. The sham acupuncture needle is then left at site for 15 minutes without any further manipulation/stimulation.
1864193|NCT01054495|Device|Laser acupuncture|A laser is placed in a stand, pointing at PC 6 bilaterally, and left at site for 15 minutes without any further manipulation/stimulation.
1864194|NCT01054508|Drug|nicotinic acid/laropiprant|Nicotinic acid/laropiprant (1g/20mg) daily for 4 weeks, then nicotinic acid/laropiprant (2g/40mg) daily for 8 weeks.
1864195|NCT01054521|Procedure|Temperature-controlled RF|"The temperature-controlled RF was done under local anesthesia (0.5% xylocaine with adrenaline 1:200,000 injection at both inferior turbinates.) The RF probe will be inserted at inferior turbinate for 5 points both left and right nasal cavity (2 at anterior end, 2 at middle part and 1 at posterior end). We apply energy of 300 J, 85 C, and 15 W each point. After procedures the patients was observed at 1 hour before discharge without any packings.
For nontemperature-controlled RF, the probe will be inserted at the same area with TCRF. We use 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF."
1864196|NCT01054521|Device|Bipolar RF|The bipolar RF probe will be inserted at the same area with TCRF. The energy used will be 2.5 watt and 3 sec for each point but will stop immediately if the burning color or sound are detected. Otherwise was the same with TCRF.
1864197|NCT01054534|Procedure|Placement of interstim lead|Placement of insterstim lead using US image fusion technology
1864198|NCT01054547|Drug|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 2.5% lidocaine and 2.5% prilocaine cream were applied once during 5 minutes.
1865133|NCT01055314|Drug|Vincristine Sulfate Liposome|Given IV
1864199|NCT01054547|Drug|Ropivacaine|100 mg of the following formulations: Liposome-encapsulated 1 and 2% ropivacaine gel, liposome placebo gel and 20% benzocaine gel were applied once during 30 minutes.
1864200|NCT01054560|Device|SOLITAIRE™ Device|The SOLITAIRE™ Device is the experimental device that will be used in the interventional procedure
1864201|NCT01054560|Device|MERCI® Device|The MERCI® Device is the control device that will be used in the interventional procedure.
1864202|NCT01054573|Drug|Telaprevir|750 mg orally every 8 hours (q8h) for 12 weeks
1864203|NCT01054573|Drug|pegylated interferon (Peg-IFN) alfa-2a|180 microgram (mcg) by subcutaneous injection once weekly for 48 weeks.
1864204|NCT01054573|Drug|ribavirin (RBV)|1,000 or 1,200 mg/day (weight based) orally twice daily for 48 weeks.
1864205|NCT01048424|Device|RESPeRATE|"RESPeRATE is a commercially available, walkman-like device manufactured by Intercure, Ltd. that measures chest/abdominal excursion during respiration using an elastic belt with a sensor placed around the torso over clothing. The device senses respiration and uses musical tones keyed to inhalation and exhalation to help the user slow respiration and prolong exhalation to a recommended goal of less than 10 breaths per minute. RESPeRATE is approved by the FDA for treatment of mild hypertension and has also been shown to decrease self-reported anxiety and stress, oxygen consumption, and respiratory rate."
1864206|NCT01048424|Other|Urinary Incontinence Pamphlet|The urinary incontinence pamphlet will provide information about classification, pathophysiology, and management of urinary incontinence, including management strategies such as timed urination and pelvic muscle exercises.
1864207|NCT01048437|Behavioral|Transplant education with video|1 hour standard transplant module is replaced with the Explore Transplant presentation and 20 minute video featuring transplant patients and donors
1864208|NCT01048437|Behavioral|Transplant education with speakers|1 hour standard transplant module is replaced with the Explore Transplant presentation and 3 live speakers: 1 deceased donor recipient, 1 living donor recipient and 1 living donor
1864209|NCT01048450|Radiation|Joint Resection- Keller Procedure|These subjects had received a surgical intervention of removing the proximal portion of the proximal phalanx of the hallux
1864210|NCT01048450|Procedure|Joint Fusion|Those who had a surgical intervention of fusion of the 1st metatarsal phalangeal joint.
1864211|NCT01048450|Procedure|Hemi-metallic Joint Implant|Those who had a surgical procedure of a hemi-metallic joint implant
1864212|NCT01048463|Drug|Nutriall|The subjects take in 150g of Nutriall (Produced by Guangdong Academy of Agriculture Science. Every 50 grams of nutriall contains 9.3mg of VitC and 0.8mg of VitE) per day. Oral administration of the liquid is divided into 3 times per day. The treatment lasts for 21d.
1864213|NCT01048463|Drug|LDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.125g of EPA and 0.125g of olive oil. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
1864214|NCT01048463|Drug|Placebo|The subjects take in 24 pils of gelatin capsule (each contains 0.25g of olive oil, provided by nutritional department of our institute) per day. The treatment lasts for 21d.
1864215|NCT01048463|Drug|HDEPA|The subjects take in 24 pils of EPA capsule per day. The medium is gelatine. Each capsule contains 0.25g of EPA. The capsules are provided by nutritional department of our institute). The treatment lasts for 21d.
1864216|NCT01048463|Drug|Chemotherapy|Oxaliplatin 135mg/m2 d1，xeloda 1000mg/m2 d1-21. (XELOX)
1864217|NCT01048476|Dietary Supplement|lutein|Dietary Supplement: 20mg Lutein; daily supplementation one year
1864218|NCT01048476|Dietary Supplement|Lutein|Dietary Supplement: 10mg Lutein; daily supplementation one year
1864219|NCT01048476|Dietary Supplement|placebo|Dietary Supplement: placebo; daily supplementation one year
1864220|NCT01048476|Drug|Lutein and zeaxanthin|Dietary Supplement: 10mg Lutein and 10mg zeaxanthin; daily supplementation one year
1864221|NCT01048489|Behavioral|Health education in the high school|"(12- 13 years old): 1.Questionnaire and measuring of carbon monoxide in air. 2.Role Games.3.Build a machine that simulates a cigarette.
(13-14 years old):1.Questionnaire and measuring of carbon monoxide in air.2. Workshop dealing with current television series broadcast in Spain in which tobacco is constantly present.3.Workshop dedicated to make young people and their families stop smoking.A competition is performed between all the schools in order to reward the bookmark with the best motto asking any close person to stop smoking or thanking them for having quit.
(14-15 years old):1.Questionnaire and measuring of carbon monoxide in air. 2. Workshop to go into depth about tobacco effects,by searching in the internet, aiming for the creation of an anti-tobacco pressure group in social networks such like Facebook.3.Workshop to create an advertising campaign to encourage non-consumption by mobile messages,use of internet..coinciding with the international day without tobacco."
1864222|NCT01048502|Drug|Fenofibrate (Tricor) tablets|One 145 mg tablet taken once daily, in the evening, with food, for 6 to 8 weeks
1864223|NCT01048502|Drug|Placebo|Two placebo capsules taken twice daily, morning and evening, with food and one placebo gel capsule taken once daily, in the evening, with food, for 6 to 8 weeks
1864224|NCT01048502|Drug|Lovaza|900 mg/day: One 900 mg capsule taken once daily, morning or evening; or 3,600 mg/day: Two 900 mg capsules taken twice daily, morning and evening; All capsules to be taken with food, for 6 to 8 weeks.
1864225|NCT01048515|Drug|Caffeine|Caffeine capsule 6 mg/kg given 1 hour before test
1864226|NCT01048528|Behavioral|Cognitive Behavioral Stress Management (CBSM)|The intervention employs CBSM techniques interwoven with information in a supportive group format. The information portion of the intervention focuses on learning to cope with daily stressors, and learning about optimal use of social support. Avoidance coping is discouraged, and acceptance and reframing are instead encouraged as coping responses. Health behavior change, framed as a coping technique, will also be discussed using motivational interviewing techniques. Relaxation techniques include progressive muscle relaxation, guided imagery, autogenics, meditation, and deep breathing. The goal of the CBSM intervention is thus to reduce distress through a variety of techniques.
1864227|NCT01048541|Device|Test Catheter - SpeediCath Compact Male|Compact catheter for intermittent catheterisation
1864228|NCT01048541|Device|SpeediCath|Catheter for intermittent catheterisation
1998207|NCT01586910|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
1998208|NCT01586910|Procedure|Surgical Aortic Valve Replacement (SAVR) (Not applicable for Single Arm)|
1864233|NCT01048580|Drug|Perifosine + Capecitabine|Perifosine 50 mg qd + Capecitabine 1000 mg/m2 BID x 14 days
1864235|NCT01048606|Behavioral|Placebo + exercise|"Placebo: Non-active capsules of the same size and appearance than phytoestrogens capsules will be used as a placebo (same posology, i.e. 4 caps/day)
Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
1864236|NCT01048606|Dietary Supplement|Phytoestrogens without exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.
Without exercise: participants will be asked to do only their usual activities without being involved in any kind of structured exercise sessions."
1864237|NCT01048606|Other|Phytoestrogens + exercise|"Phytoestrogens: The phytoestrogen supplements will consist of 70 mg/day of soy isoflavones taken as 4 caps/day. More specifically, the daily dose of isoflavones contains 44 mg of diadzein, 16 mg of glycitein and 10 mg of genestein extracted from natural soy.
Exercise intervention: Three weekly 1h-sessions will be held on 3 non-consecutive days. Each session comprises a total of 60 min of aerobic exercise (on an ergometer device) and resistance exercise (with elastic bands, free weights, exercise ball, etc.), and a 5-min cool down. Cues regarding exercise intensity will be offered to maintain intensity in a range of 60 to 80% of maximal heart rate (with the use of a target pulse, etc.). The exercise sessions will be led by a physical activity specialist."
1864238|NCT01048619|Drug|ON 01910.Na|In Part I, the bioavailability and tolerability of ON 01910.Na as single, oral, escalating doses in a fasting state (defined as no less than 30 min before next meal) is studied. Three patients get 70mg dose the 1st week. In the absence of drug-related grade 2 toxicity or higher, doses will escalate in each patient weekly (wk) to 140mg (wk 2), 280mg (wk 3), 560mg (wk 4) and 700mg (wk 5). At end of Part I all patients will be eligible for Part II. Part II proceeds if drug is measured in plasma and DLT not observed at 70mg dose in Part I. The maximum tolerated dose of oral ON 01910.Na administered in a fasting state (defined as no less than 30 min before next meal) twice a day for 14 days will be determined following an adaptive design at doses between 70 and 700mg.
1864239|NCT01048632|Drug|Oxandrolone|2.5 mg oxandrolone tablets.Based upon the patient's body weight, the coordinator, PI or sub-PI will determine the appropriate dose of oxandrolone (0.1 mg/kg/dose twice daily via the buccal mucosa.)
1864240|NCT01048645|Drug|ATRA|Patients were assigned to receive ATRA 20 mg/m2/day (RA/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
1864241|NCT01048645|Other|PLACEBO|Patients were randomized to receive or placebo (P/PC) 1 week prior to treatment until completing two courses of chemotherapy based on paclitaxel and cisplatin
1864242|NCT01048658|Drug|Sevoflurane|Subject receives Sevoflurane in addition to other standard of care drug regimens for anesthesia with this procedure.
1864243|NCT01048658|Other|No Sevoflurane|Subject only standard of care drug regimens for anesthesia with this procedure.
1864244|NCT01048671|Drug|Raltegravir|Raltegravir was administered in combination with ARV therapies at the discretion of the investigator in accordance with the product label. The recommended dose of raltegravir is 400 mg twice daily.
1864245|NCT01048671|Drug|ARV (non-raltegravir)|ARV treatments were administered in combination with raltegravir at the discretion of the investigator in accordance with the product labels, and could include nucleoside reverse-transcriptase inhibitor, non-nucleoside reverse-transcriptase inhibitor, protease inhibitor, entry inhibitor, and integrase inhibitor catagories.
1864246|NCT01048684|Drug|Mannitol|Variation of mannitol dose
1864247|NCT01048684|Drug|Mannitol|Variation of mannitol dose
1864248|NCT01054586|Drug|Intervention A Standard dose|HIV subjects with HBV or HCV co-infection but normal hepatic function, defined by receipt of FPV 700mg BID/RTV 100mg BID and a baseline AST-platelet ratio index (APRI) score of <2.0.
1864249|NCT01054586|Drug|Intervention B Reduced Dose|HIV subjects with mild hepatic impairment, defined by receipt of the recommended reduced FPV/RTV dose (700mg BID/100mg QD).
1864250|NCT01054586|Drug|Intervention C|HIV subjects with moderate hepatic impairment, defined by receipt of FPV 450mg BID/RTV 100mg QD.
1864251|NCT01054586|Drug|Intervention D|HIV subjects receiving the standard dose of FPV/RTV despite evidence of abnormal hepatic function according to APRI score: HIV subjects with HBV or HCV co-infection, receipt of FPV 700mg BID/RTV 100mg BID and a baseline APRI score of ≥2.0.
1864252|NCT01054586|Drug|Intervention E|HIV subjects coinfected with HBV or HCV who have initiated standard doses of LPV 400mg/RTV 100mg and enrolled in the same cohorts as the FPV/RTV exposed subjects.
1864253|NCT01054599|Drug|Memantine|All subjects in the treatment group will be placed on memantine. The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the first phase of the study. At the conclusion of the first 13 weeks, subjects will discontinue the treatment (memantine or placebo) and enter the open label phase.
1864254|NCT01054599|Other|Sugar Pill|In the control arm of the study, subjects will take one placebo sugar pill per day for one week, then increase to one tablet twice per day for the following 12 weeks. At the end of this phase of the study, subjects will enter the open-label phase (unblinded treatment with memantine).
1864255|NCT01054599|Drug|Memantine|Open label: When the blinded phase is complete (Weeks 1-13), all subjects will receive open-label treatment with memantine (Weeks 14-26). The dosage of memantine will begin at 5mg once per day (qday), and increase by 5mg every week. The titration will continue over a period of 3 weeks until a goal of 10mg bid is reached. The dosing will increase slowly, to minimize the risk of side effects. The subject will then remain on memantine at 10mg bid for 10 weeks, until the conclusion of the study. At the conclusion of the study, subjects will discontinue the treatment.
1864256|NCT01054612|Other|Tissue Sectioning via Electro Erosion Process|Focused RF energy can be used to produce consecutive thin sections of fresh tissue for immunohistochemical and nucleic acids analysis by electro-dissociation without thermal damage, ultimately allowing high resolution reconstruction of gene and protein expression patterns of large tissue specimens in 3D.
1864257|NCT01054625|Biological|zalutumumab|Zalutumumab is a clear to opalescent liquid. It is intended for intravenous infusion following dilution in sterile, pyrogen free, 0.9% NaCl. Patients will be treated at a specified dose of Zalutumumab over a period of 7 weeks. The dose will be 4mg/kg, 8mg/kg or 16mg/kg depending on when they enter the study. The study will begin with 6 patients on 4mg/kg, then 10 patients on 8mg/kg and lastly 10 patients on 16mg/kg.
1864258|NCT01054638|Drug|HAART Treatment|"Using pharmacy records, identify all patients with HAART dispensing during baseline & follow-up periods. For combination medications, classify person-time according to individual therapeutic components. HAART exposure classification by 1)any HAART exposure, 2)by HAART class, and 3)by specific nucleoside reverse transcriptase inhibitor exposure. Specific evaluation of fosamprenavir and amprenavir.
Subdivide person-time according to recent, past & non-use of HAART. Person-time for each patient partitioned into exposure windows of Recent use(From start of dispensing to end of days supplied plus 6 months), Past use(From end of current use to end of follow-up or new HAART dispensing following recent use), & Non-use(Time prior to first dispensing or all time for those who did not receive a dispensing).
Determine cumulative duration of exposure based on days supplied per dispensing per patient over the baseline & follow-up periods: Non-use, Less than 1 yr, 1-2 yrs, More than 2yrs."
1864259|NCT01054651|Drug|Artesunate+Sulfamethoxypyrazine/pyrimethamine|
1864260|NCT01054651|Drug|Praziquantel|
1864261|NCT01054677|Behavioral|Educational intervention on antibiotic prescribing|Small educational group sessions with nurses and physicians, feedback on prescribing, presentation of guidelines and written materials
1864262|NCT01054690|Device|Bactiguard Infection Protection (BIP) Cathter.|
1864263|NCT01054690|Device|Silicone Urinary Catheter|
1864264|NCT01054703|Device|Ethmoid Sinus Spacer|Ethmoid Sinus Spacer and Access System used for the local delivery of Kenalog-40
1864265|NCT01054729|Drug|Sofosbuvir|Sofosbuvir tablet(s) administered orally once daily
1864266|NCT01054729|Drug|Placebo|Placebo to match sofosbuvir administered orally once daily
1864267|NCT01054729|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
1864268|NCT01054729|Drug|RBV|Ribavirin (RBV) tablets were administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
1864269|NCT01054742|Drug|Standard of Care PegIntron|Commercially available PegIntron administered subcutaneously (SC) at 1.5 μg/kg weekly in accordance with the PegIntron Summary of Product Characteristics (SmPC).
1864270|NCT01054742|Drug|Standard of Care Ribavirin|Commercially available ribavirin administered orally at 800-1200 mg/day based on body weight in accordance with the ribavirin SmPC.
1864271|NCT01054768|Dietary Supplement|alpha-lipoic acid and acetyl-L-carnitine|none to report
1864272|NCT01054768|Drug|Placebo|none to report
1864273|NCT01054781|Drug|Rituximab|1st cycle R+R-CHOP 2-8th cycle R-CHOP
1864274|NCT01054794|Device|Gastric mucosal stimulation|The lead is a sterile, 2mm diameter insulated wire (Temporary Transvenous Pacing Lead 6416-200cm, Medtronic, Minneapolis, MN) with 2 electrodes on the distal end. The mucosal stimulation parameters(Current:10 mA; Frequency: 14Hz; Pulse width: 330 ms; Cycle ON: 0.1 s; Cycle OFF: 5 s) are within the range used for standard permanent implanted GES (Enterra therapy) within the serosa and muscle layers of the stomach, and which has been shown to be safe, without any tissue damage.
1864275|NCT01054807|Device|Galyfilcon A Habitual Lens|Comparison of three soft contact lens designs.
1864276|NCT01054807|Device|Galyfilcon A 8.7 BC (Investigational)|Comparison of three soft contact lens designs.
1864277|NCT01054807|Device|Galyfilcon A 8.3 BC (Investigational)|Comparison of three soft contact lens designs
1864278|NCT01054820|Drug|FLECTORÂ® Patch (diclofenac epolamine topical patch) 1.3%|One FLECTOR Patch applied to the most painful area on the subject's back every 12 hours for up to 14 days.
1864279|NCT01054833|Procedure|Needleless mid-urethral sling|The Needleless® sling is intended for use in women as a tension free, sub-urethral slings for the treatment of SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency. The Needleless sling is a macroporous, monofilament, knitted polypropylene featuring 'Pocket Positioning Anchors' which allow sling placement without needle introducers; thus eliminating a complicated aspect of the surgery (TVT/TOT) and reducing the potential for bladder injury or inguinal pain that can occur during transobturator needle passage. The Needleless sling was approved by KFDA, and now is available in worldwide including Korea.
1864280|NCT01054846|Other|Bicycle helmet from Bell Sports Inc.|As described under the respective arm
1864281|NCT01054846|Other|Bicycle helmet education only|As described under the respective arm
1864282|NCT01054859|Drug|avanafil|200 mg avanafil tablet QD plus 0.5 g/kg alcohol
1864283|NCT01054859|Other|alcohol|0.5 g/kg alcohol
1864284|NCT01054859|Drug|avanafil|200 mg avanafil tablet QD
1864285|NCT01054872|Biological|HIV-1 DNA plasmid vaccine|4 mg injection administered as 1 mL intramuscularly via Biojector in deltoid
1864286|NCT01054872|Biological|HIV-1 recombinant Ad5 vaccine|1 x 10^10 particle units (PU) administered as 1 mL intramuscularly by needle and syringe in deltoid
1864287|NCT01054885|Drug|FF Inhalation Powder|Inhaled Corticosteroid (ICS)
1864288|NCT01054885|Drug|FF/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
1864289|NCT01054885|Drug|GW642444 Inhalation Powder|Long Acting Beta Agonist(LABA)
1864290|NCT01054885|Drug|Placebo|Placebo
1864291|NCT01054898|Behavioral|advocacy intervention|A 12-week telephone social support and empowerment intervention consisting of empowerment training, scheduled weekly telephone calls, and 24-hour access to a hotline for abused women
1864292|NCT01054898|Behavioral|usual community services|standard care for abused women in the community
1864293|NCT01054911|Drug|Sunitinib|All patients will receive sunitinib 37.5 mg p.o. daily for up to 12 weeks to be taken orally.
1864294|NCT01054911|Procedure|Surgery|Following sunitinib therapy, patients will be evaluated for surgery. It is anticipated that the quality of response will allow for complete resection of residual tumor. Surgical resection, if eligible, will occur around week 14-16.
1864295|NCT01055717|Other|Avenanthramide-enriched oats|Single dose, 24 hour pharmacokinetic trial
1864296|NCT01055730|Other|Pulmonary rehabilitation|Structured education and supervised exercise program, lasting between 6 and 9 weeks.
1864297|NCT01055743|Procedure|Radical resection|Radical resection of hepatocellular carcinoma
1864298|NCT01055743|Drug|Fluorouracil Implants|Implanted during the surgical treatment
1864299|NCT01055756|Drug|Loratadine + Pseudoephedrine sulfate|Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
1864300|NCT01055769|Drug|Linezolid|"Linezolid OS 600 MG
Linezolid Tablet 600 MG"
1864301|NCT01055769|Drug|Linezolid|"Linezolid Tablet 600 MG
Linezolid OS 600 MG"
1864302|NCT01055782|Device|Endoguide|Use of endoguide to facilitate completion of endoscopy
1864303|NCT01055795|Drug|Bevacizumab, Everolimus and LBH589|"Dose Escalation Cohort #, Subjects, Bevacizumab, Everolimus, LBH589
3-6, All study drugs administered per dose level
3-6, All study drugs administered per dose level
3-6, All study drugs administered per dose level
Expanded Cohorts Cohort #, Subjects, Bevacizumab, Everolimus, LBH589 A, B & C; 30, Recommended Phase II Dose for all three compounds"
1864304|NCT01055808|Drug|Insulins|Individual dose and frequency and duration as determined by the treating physician
1864305|NCT01055821|Drug|pegylated interferon and ribavirin|48 weeks
1864306|NCT01055821|Biological|TG4040 + SOC|6 injections
1864307|NCT01055821|Biological|TG4040 + SOC|13 injections
1864308|NCT01055834|Drug|Eszopiclone 3 mg|"Group A Period I, Group B Period II:
Eszopiclone 3 mg tablet taken orally (po) with water as a single administration in the morning after fasting >=10 hours.
Except for the water taken with the drug, participants were not allowed any food/ drink from 10 hours before until 4 hours after administration of drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of drug.
Group B Period III:
Eszopiclone 3 mg tablet taken po with water as a single administration in the morning 30 minutes after the start of breakfast.
Except for the food/ drink at breakfast and the water taken with the study drug, participants were not allowed any food or drink from 10 hours before until 4 hours after administration of the drug. Except for the food/ drink at breakfast & the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration."
1864309|NCT01055834|Drug|Eszopiclone 1 mg|"Group A Period II, Group B Period I:
Eszopiclone three 1 mg tablets (total: 3 mg) taken orally with water as a single administration in the morning after fasting 10 or more hours.
Except for the water taken with the study drug, participants were not allowed any food or drink (except water) from 10 hours before until 4 hours after administration of the study drug. Except for the water taken with the study drug, participants were not permitted to drink water from 1 hour before until 1 hour after administration of the study drug."
1864310|NCT01055847|Drug|Aztreonam for Inhalation (AI)|Aztreonam for Inhalation
1864311|NCT01055847|Drug|Placebo|Saline Placebo
1864312|NCT01055873|Biological|A single blood sample (30 mL)|A single blood sample (30 mL) was drawn during a hospital visit for clinical follow-up. Immunological assays were performed on fresh blood. Cells and plasma were stored and kept frozen for additional biological evaluations
1864313|NCT01055886|Drug|nicotine patch|Nicotine patch, 7-21 mg.
1864314|NCT01055886|Drug|placebo patch|placebo patch used from weeks 4-6
1864315|NCT01055899|Biological|REGN88|Single SC Dose
1864316|NCT01055899|Biological|REGN88|Single SC Dose
1864317|NCT01055899|Biological|REGN88|Single SC Dose
1864318|NCT01055912|Drug|Lixivaptan|Capsule. Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo. One hundred (100) patients will be randomized to receive lixivaptan 100 mg once daily (QD) for 8 weeks. Fifty (50) placebo patients will receive matching oral placebo for 8 weeks.
1864319|NCT01055912|Drug|Placebo|Patients will be screened for entry into the study and will be randomized (2:1) to lixivaptan or placebo.
1864320|NCT01055925|Device|modified polyurethane film dressing (OpSite, Smith&Nephew, London, UK)|
1864321|NCT01055925|Device|Aquacel® (ConvaTec, Skillman, NJ, USA), sodium carboxy-methylcellulose hydrocolloid polymer dressing|
1864322|NCT01055938|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
1864323|NCT01055951|Device|Solo MicroPump|30 days treatment days with an optional extension period of up to 6 month of treatment.
1864324|NCT01055964|Drug|Tacrolimus|
1864325|NCT01055990|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|The influenza A (H1N1) 2009 monovalent, (Split-virion)inactivated vaccine was developed by Shanghai Institute of Biological Products, and the seed virus was prepared from reassortant vaccine virus A/California/7/2009,distributed by the Centers for Disease Control and Prevention in the United States. This strain was recommended by the World Health Organization and obtained from the Chinese Food and Drug Administration.The vaccine adopted the assessment of experts, and formally accessed to the approval document number of production and new drug certificate issued by the Chinese Food and Drug Administration.
1864326|NCT01055990|Other|blood fix|The blood fix with a hemagglutination-inhibition titer of 1:80 or more than was collected from healthy persons who are inoculated with specific H1N1 vaccine
1864327|NCT01056003|Other|Endoscopy|observational endoscopy in all patients an EGD is planned anyway
1864328|NCT01056016|Other|ADHD Collaborative|This intervention includes mapping and redesign of office flow to facilitate adherence to AAP ADHD guidelines as well as didactic sessions related to diagnosis and treatment of ADHD. Didactics emphasize the importance of obtaining parent and teacher behavioral ratings (e.g. Vanderbilt ADHD Rating Scales) at the time of the initial assessment for ADHD and during follow-up after initiating medication treatment and making a DSM-IV based ADHD diagnosis. Practices are given a web-based ADHD portal to assist them in creating a patient registry and to help in obtaining parent and teacher ratings scales.
1864329|NCT01056029|Drug|G-202|Thapsigargin is Pro-drug chemotherapy which will be administered by intravenous infusion over 1 hour on Days, 1, 2 and 3 of each 28 day cycle
1864330|NCT01056042|Drug|intramuscular depot medroxyprogesterone acetate|150 mg, Intramuscular, every 3 months
1864331|NCT01056042|Drug|ethinyl estradiol 30 micrograms, gestodene 75 micrograms|one tablet orally, everyday
1864365|NCT01056341|Drug|Propranolol|Propranolol (1 or 3 mg/kg/day for 3 or 6 months)
1864366|NCT01056341|Drug|Placebo|Treatment with placebo for 6 months
1864367|NCT01056380|Drug|Nitazoxanide|Tablet, 500 mg with food twice daily for 5 days
1864368|NCT01056380|Drug|Placebo|Tablet, twice daily with food for 5 days
1865279|NCT01065506|Drug|Nicotine Patch|Nicotine Patch
1864332|NCT01056081|Other|Inspiratory muscle training|"The training was performed using a threshold inspiratory muscle trainer (Respironics HealthScan, Inc, Cedar Grove, New York, USA).
The patients performed the IMT training in a seated position, with the upper limbs supported. The total duration of the respiratory training was 30 minutes, with sequences of three minutes of training followed by pauses of two minutes. The initial load was equivalent to 30% of the individual's MIP. This load was progressively increased over the first four weeks, according to the patients' tolerance, to reach 60% of the MIP. This level was then maintained until the end of the training."
1864333|NCT01056094|Drug|Lutein|Dietary Supplement: 20mg,10mg, 0mg Lutein; daily supplementation 12 week
1864334|NCT01056107|Drug|ROSE-010|The study medication was used in 30 mcg, 100 mcg, and 300 mcg subcutaneous injections daily, depending upon study arm.
1864335|NCT01056107|Drug|Placebo|Placebo subcutaneous injection daily
1864336|NCT01056120|Device|Pro Kinetic Energy bare metal stent|PCI
1864337|NCT01056133|Other|Omega-3 capsules-Fish Oil|Patients will take 2 capsules (1.0 g each) of n-3 PUFA (0.82/0.44 g of EPA/DHA) daily x 12 months. Since n-3 PUFA supplementation can be a potential treatment for NASH and since BMI will be< 30 kg/m2 for all subjects, patients will be told to keep their lifestyle, diet and medication stable (unless medically necessary) for the study duration in order to minimize environmental effect on gene expression.
1864338|NCT01056146|Behavioral|Internet-based Interacting Together Everyday: Recovery After Childhood TBI|Families in I-InTERACT will look through 10 web-sessions (like chapters) and participate in 10 family meetings focusing on education about traumatic brain injury, parenting skills, communication, behavior strategies, and stress management. Meetings will be conducted in their home using a computer hook-up with a trained therapist. Families will also be contacted two times per month by the counselor to discuss individual problems or concerns.
1864339|NCT01056146|Behavioral|Internet Resources Comparison|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
1864340|NCT01056159|Drug|Albuterol dry powder inhaler|Albuterol DPI (dry powder inhaler) delivers 90mcg of albuterol in the excipient lactose with each inhalation. Albuterol will be given on two treatment days (3 to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol in a DPI (dry Powder inhaler) and albuterol in an HFA MDI (hydrofluoroalkane metered dose inhaler), ProAir. One inhaler will contain active drug and one inhaler will contain placebo.
1864341|NCT01056159|Drug|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler)|Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler) delivers 90mcg of albuterol with each inhalation. Albuterol will be given on two treatment days (3to 14 days apart). On each treatment day albuterol will be given as a cumulative dose of 1440mcg as a series of inhalations using both Albuterol DPI (dry powder inhaler) and the comparator inhaler, albuterol HFA MDI (hydrofluoroalkane metered dose inhaler).One inhaler will contain active drug and one inhaler will contain placebo.
1864342|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|"PegIFN alfa-2a (PEgasys) 180 ug/week
Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)
Treatment duration: 16 weeks"
1864343|NCT01056172|Drug|Peginterferon alfa-2a and Ribavirin|"PegIFN alfa-2a (PEgasys) 180 ug/week
Weight-based ribavirin (<65kg: 800mg/day, 65-85kg: 1000mg/day, >85kg: 1200mg/day)
Treatment duration: 24 weeks"
1864344|NCT01056198|Drug|Santyl|2 mm Santyl applied once daily.
1864345|NCT01056198|Procedure|Control|Daily gauze and optional sharp debridement
1864346|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
1864347|NCT01056211|Procedure|treatment without laser|Starlux 300 Lux 1540nm Fractional laser hand piece
1864348|NCT01056211|Procedure|laser treatment|Starlux 300 Lux 1540nm Fractional laser hand piece
1864349|NCT01056224|Drug|Remifentanil|A single bolus dose of Remifentanil will be administered at the time of skull pin insertion
1864350|NCT01056237|Drug|Multi-target therapy|Tacrolimus (1-3mg/d) and mycophenolate mofetil(0.5-0.75g/d)
1864351|NCT01056237|Drug|Azathioprine|1.0-2.0mg/kg/d
1864352|NCT01056250|Procedure|SILS cholangiography|intraoperative
1864353|NCT01056263|Drug|axitinib: observational study|Non-interventional observational study
1864354|NCT01056276|Drug|Bendamustine|Treatment: 80 mg/m2 via intravenous (IV) Days 1 and 2; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
1864355|NCT01056276|Drug|Bortezomib|"1.3 mg/m2 IV Days 1, 8, 15; repeat cycles every 28-days for 8 cycles or 2 cycles beyond confirmed complete response.
Maintenance: 1.3 mg/m2 IV or SQ Days 1, 15"
1864356|NCT01056276|Drug|Dexamethasone|20 mg orally (PO) Days 1, 2, 8, 9, 15, 16 every 28-days for 8 cycles or 2 cycles beyond confirmed complete response, Maintenance: 20 mg PO Days 1, 15
1864357|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 50 mg|DVS SR 50 mg Reference Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
1864358|NCT01056289|Drug|Desvenlafaxine Succinate Sustained-Release Formulation 25 mg|DVS SR 25 mg Taper Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
1864359|NCT01056289|Drug|Placebo|DVS SR Placebo Abrupt Discontinuation Group/Arm, oral tablet, 2 tablets/day during the first week and 1 tablet/day during weeks 2 through 4 of the double-blind treatment phase.
1864361|NCT01056315|Drug|GRT3938Y|Overencapsulated tablets of GRT3983Y, 100 to 300mg daily dose, 16 weeks treatment.
1864362|NCT01056315|Drug|Placebo|Overencapsulated tablets of placebo, 16 weeks treatment.
1864363|NCT01056328|Device|SJM Irrigated Cardiac Ablation System|Irrigated ablation catheter
1864364|NCT01056328|Device|FDA approved Open Irrigated RF Ablation System|Irrigated ablation catheter
1864369|NCT01056393|Drug|ibalizumab|Ibalizumab is a humanized IgG4 monoclonal antibody and is provided as a parenteral formulation at a concentration of 25mg/mL in a 10mL glass vial, 8mLs per vial, as the investigational product. Study drug will be administered via intravenous infusion at doses of 800mg q2weeks, or 2000mg q4weeks.
1864370|NCT01056406|Behavioral|Nutrition Education|Twice monthly interaction with study nutritionist (a registered dietitian) in the form of face-to-face individual nutrition counseling sessions, telephone and electronic follow-ups, option to attend group nutrition and group exercise classes.
1864371|NCT01056419|Procedure|Total Thyroidectomy|Total thyroidectomy within 6 months after the appearance of the symptoms of ophthalmopathy
1864372|NCT01056419|Drug|Propylthiouracil|150-600 mg in two-three divided doses
1864373|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
1864374|NCT01056445|Procedure|valsalva maneuver|valsalva maneuver after carotid stenting
1864377|NCT01056471|Other|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells.Dose:4*10e6 cells/Kg.
1864378|NCT01056471|Other|Autologous mesenchymal stem cells from adipose tissue.|Intravenous infusion of autologous mesenchymal stem cells. Dose: 10e6 cells/Kg.
1864379|NCT01056484|Behavioral|Mindfulness Based Relapse Prevention for Alcohol Dependence|"All subjects receive outpatient standard of care (SOC) therapy for alcohol dependence. Experimental subjects also receive the Mindfulness Meditation Relapse Prevention ('meditation') intervention. The intervention is an extension of existing meditation-based therapies for stress, relapse prevention in addictive disorders, and depression. It has been patterned after Mindfulness Based Relapse Prevention and tailored to the specific needs of alcoholics. Its curriculum includes both meditation and traditional cognitive therapy relapse prevention components. The intervention consists of an 8-week, manualized meditation course (2 hours/week group sessions) guided by trained instructors. In addition, experimental subjects are asked to meditate at-home (30 min/day, 6 days/week) during the study."
1864380|NCT01056484|Other|"Wait-list control"|'Standard of care' (SOC) outpatient therapy for alcohol dependence is provided to all subjects through their outpatient treatment centers and as recommended by their regular providers. Subjects in the control group receive SOC only. Subjects in the experimental arm will receive the study meditation intervention in addition to SOC.
1864381|NCT01056497|Drug|alpha lipoic acid|A 2 week treatment period with either oral ALA tablets or placebo tablets, followed by 30 hour hospital stay to infuse lipid or saline and to test insulin sensitivity and insulin secretion. For two weeks prior to each admission to hospital and during each hospital admission subjects will ingest 3 tablets 2 times per day with breakfast and supper, 1800mg per day
1864382|NCT01056510|Drug|bendamustine|90mg/m2 (first-line) or 70mg/m2 (second-line) iv, days 1 and 2 every 4 weeks, cycles 1-6
1864383|NCT01056510|Drug|chlorambucil|10mg/m2 po days 1-7 every 4 weeks, for up to 12 cycles
1864384|NCT01056510|Drug|rituximab [MabThera/Rituxan]|375mg/m2 iv day 1 of cycle 1, followed by 500mg/m2 iv every 4 weeks cycles 2-6
1864385|NCT01056523|Drug|Ribavirin|Dose level 1 = 1000 mg po BID/ Dose level 2 = 1400 mg po BID/ Dose level 3 = 1800 mg po BID
1864386|NCT01056523|Drug|Cytarabine arabinoside|Previous cohorts at 20 mg bid days 1 to 10 of every 28 day cycle. Dosage modified to 10 mg bid days 1 to 10 of every 28 day cycle for more recent cohorts.
1864387|NCT01056536|Behavioral|Structured intervention for the prevention of sexually transmitted infections (STI)|The structured intervention will include information about the number of travelers engaging in new sexual relationships, the different types of STI and their prevalence in different countries and population groups. The intervention will last approximately 5 minutes. At the end of the structured intervention the subjects will be offered free condoms.
1864388|NCT01056549|Drug|exenatide|In each study, the subjects will receive s.c. injection of either exenatide or matched placebo, in the Metabolic Testing Center and 2 hours prior to the start of the lipoprotein turnover study. Subjects will be blinded with regard to the treatments.
1864389|NCT01056575|Drug|OC000459|OC000459 100mg tablet, twice daily
1864390|NCT01056588|Behavioral|CO-Contingent|In this 42 day condition, participants will receive monetary reinforcements contingent on submitting breath samples at CO levels indicating reductions or abstinence from smoking (4ppm).
1864391|NCT01056588|Behavioral|Control condition|In this condition, participants will receive monetary reinforcement for timely breath samples with no contingency for a specific breath CO level
1864392|NCT01056601|Drug|Bortezomib|1.3 mg/m^2 administered intravenously twice daily on days 1 and 8 for 2 weeks followed by 10 day rest period
1864393|NCT01056601|Drug|Panobinostat|20 milligrams administered orally 3 times weekly for 2 weeks on Days 1,3,5,8,10 and 12 followed by 9 day rest period
1864394|NCT01056614|Drug|fludarabine phosphate|Given IV
1864395|NCT01056614|Drug|busulfan|Given IV
1864396|NCT01056614|Biological|anti-thymocyte globulin|Given IV
1864397|NCT01056614|Drug|tacrolimus|Given IV and orally
1864398|NCT01056614|Drug|methotrexate|Given IV
1864399|NCT01056614|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
1864400|NCT01056614|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
1864401|NCT01056614|Other|laboratory biomarker analysis|Correlative studies
1864402|NCT01056627|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
1864403|NCT01056640|Device|Intel Health Guide|The Intel Health Guide is an FDA approved device that is placed within the patient's home and is connected to the health system via broadband internet, 3G network or phone line.
1864404|NCT01056640|Other|Usual Care|The usual care intervention will include appropriate primary care and specialty office practice visits as required.
1864405|NCT01056653|Behavioral|Standard Dose|Two intevention home visits
1864406|NCT01056653|Behavioral|High Dose|Four intervention home visits
1864407|NCT01056653|Behavioral|Comparison Group|One home visit, information only
1864514|NCT01057329|Drug|Aripiprazole|5 mg from week 1, 10 mg from week 2
1998209|NCT01586910|Device|Medtronic CoreValve® Evolut R System Transcatheter Aortic Valve Implantation (TAVI)|
1864408|NCT01056666|Device|Conveen Optima is a urisheath to be used together with a collecting bag for urine|Conveen optima urisheath is intended to be used together with a collecting bag for urine and to be changed on a daily basis
1864409|NCT01056666|Device|absorbent protection|The patient use his usual absorbent protection (same brand), and change it when needed
1864410|NCT01056679|Drug|Doxorubicine|50mg/m2 day 1 + 15
1864411|NCT01056679|Drug|DTIC|375mg/m2 day 1 + 15
1864412|NCT01056679|Drug|Lenalidomide|day 1 - 21
1864413|NCT01056679|Drug|Vinblastine|6mg/m2 day 1 + 15
1864414|NCT01056692|Drug|OC000459|Capsules twice daily for 15 days
1864415|NCT01056692|Drug|Placebo|Capsules twice daily for 15 days
1864416|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation A. 3x0.5ml intramuscular injections,one month apart.
1864417|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation B. 3x0.5ml intramuscular injections, one month apart.
1864418|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Sabin strains)|Inactivated Poliomyelitis Vaccine (Sabin strains) formulation C. 3x0.5ml intramuscular injections, one month apart.
1864419|NCT01056705|Biological|Oral Poliomyelitis Vaccine|Oral Poliomyelitis Vaccine (OPV).3x0.5mloral, one month apart.
1864420|NCT01056705|Biological|Inactivated Poliomyelitis Vaccine (Salk strains).|3x0.5ml intramuscular injections, one month apart.
1864421|NCT01056718|Drug|Nebivolol|Initial dose of 5 mg titrated (doubling of previous dose) to optimal blood pressure. The dose was titrated by doubling the previous dosage to achieve BP less than or equal to 130/80 mm Hg at 2 weeks and 4 weeks. The mean dose of nebivolol used week 4 through week 10 was 7.8 mg. It should be noted that nebivolol was added to the subject's existing stable antihypertensive regimen which included a mean of 2 other medications.
1864422|NCT01056731|Drug|Aliskiren and HCTZ|Aliskiren 150 mg and 300 mg Hydrochlorothiazide 12.5 mg and 25 mg
1864423|NCT01056744|Device|Percutaneous coronary intervention with stent implantation|"Percutaneous coronary intervention with implantation of either:
- a XIENCE® V everolimus eluting coronary stent in one of the following sizes: 3.0 x 18 mm, 3.0 x 28 mm, 2.5 x 18 mm, 2.5 x 28 mm (DES group),
or:
- a Coroflex Blue® coronary stent postdilated with a Sequent Please® paclitaxel-eluting balloon in one of the following size combinations (stent / balloon): 3.0 x 16 mm / 3.0 x 20 mm, 3.0 x 25 mm / 3.0 x 30 mm, 2.5 x 16 mm / 2.5 x 20 mm, 2.5 x 25 mm / 2.5 x 30 mm (BMS/DEB group)"
1864424|NCT01056757|Drug|Ribavirin|1000 mg bid, po, q28days
1864425|NCT01056770|Drug|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
1864426|NCT01056783|Drug|OC000459|OC000459 100mg, twice daily, tablet
1864427|NCT01056783|Drug|Placebo|Placebo tablets to match OC000459 tablets, twice daily
1864428|NCT01056796|Device|CAR™ 27|Creation of a low colorectal (side or pouch low rectal) compression anastomosis in previously radiated patients
1864429|NCT01056809|Procedure|Chemotherapy and surgery|Treatment not specified but in accordance with national guidelines
1864430|NCT01056822|Drug|1|Continue with same dose of MMF as patient was taking before randomisation
1864431|NCT01056822|Drug|2|Increase MPS by 180mg every 12h based on investigator's judgement up to a maximum of 720 mg of MPS every 12 hours
1864432|NCT01056835|Drug|prostaglandin I2 analogue|
1864433|NCT01056861|Drug|Botulinum Toxin A|Not exceeding a total dose of 400 units, once every three months.
1864434|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose
1864435|NCT01056874|Drug|Digoxin|Oral Digoxin 0.25 mg single dose on Day 5
1864436|NCT01056874|Drug|Maraviroc|Oral Maraviroc 300 mg twice daily for 6 days
1864437|NCT01056900|Procedure|Autologous Chondrocyte Implantation|"Test drug: Chondron (more than 12 million chondrocytes in 0.4ml, i.e. 1 vial)
Directions and dosage:
Suspend the cells in the vial sufficiently, and implant them in the defective part, making sure that sufficient amounts are injected."
1864438|NCT01056913|Device|Compression Anastomosis Device|Restoring intestinal continuity using the NITI CAR27 device
1864439|NCT01056913|Other|follow-up colonoscopy|endoscopic exploration of anastomosis after complete healing
1864440|NCT01056926|Behavioral|Quit smoking|Subjects will quit smoking for 2 fMRIs, each abstinence lasting 2 days
1864441|NCT01056926|Drug|Nicotine patch|Subjects will wear a 21mg patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
1864442|NCT01056926|Drug|Placebo Patch|Subjects will wear a placebo patch for 2 fMRIs, each condition lasting 2 days. They will take the patch off at night.
1864443|NCT01056939|Device|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with neurally adjusted ventilatory assist
1864444|NCT01056939|Device|Control (PC- or PRVC- ventilation), i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with PC or PRVC ventilation.
1864445|NCT01056952|Procedure|O2stand|Standard low flow oxygen therapy (O2stand). The patients will receive oxygen delivered through a face mask. The FiO2 will be adjusted in order to obtain a SaO2 > 90%. The FiO2 will be determined by a portable oxygen analyzer (MiniOX I; Mine Safety Appliances Co, Pittsburgh, Pa)
1864446|NCT01056952|Procedure|CPAP|o Continuous positive airway pressure (CPAP). CPAP will be set at 7.5 cmH2O. Airway humidification will be achieved by using a heated humidifier (MR640; Fisher & Paykel, Auckland, NZ). The FiO2 will be adjusted in order to obtain a SaO2 > 90%. A facial mask composed of a transparent mask and a soft inflatable will be used
1864447|NCT01056952|Procedure|Optiflow|High flow oxygen nasal therapy (Optiflow). The flow will be set at 40l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SaO2 > 90%
1864448|NCT01056965|Drug|davunetide (AL-108, NAP)|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with davunetide 15 mg administered intranasally.
1864449|NCT01056965|Drug|Placebo nasal spray|Subjects will be randomized 2:1 (drug:placebo). Subjects will receive twice daily treatment with placebo administered intranasally.
1864450|NCT01056991|Other|warming mattress|comparison of under patient warming mattress to forced air warming blankets in preventing peri-operative hypothermia
1864451|NCT01056991|Other|warming blanket|
1864452|NCT01057017|Biological|intervention|
1864453|NCT01057030|Drug|BMS-708163|Capsules, Oral, 125 mg, once daily, 14 days
1864454|NCT01057030|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 14 days
1864455|NCT01057043|Device|Pulsatile cupping|8 sessions cupping in 4 weeks, administered by a cupping machine. Cupping is administered in each session for 15 minutes with silicon cupping glasses to the knee (osteoarthritis) and the lower back.
1864456|NCT01057056|Other|mind-body intervention|multi-disciplinary mind-body intervention including: breathing techniques, guided imagery, meditation, touch therapy
1864457|NCT01057069|Drug|Carboplatin and Paclitaxel|Carboplatin AUC = 6, Q 3 weeks, 3 courses Paclitaxel 80 mg/m2, weekly, 9 administrations
1864458|NCT01057069|Drug|Doxorubicin, cyclophosphamide|Two-weekly administrations of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
1864459|NCT01057069|Drug|Doxorubicin, cyclophosphamide, carboplatin, thiotepa, cyclophosphamide|"One course of of 600 mg/m2 cyclophosphamide and 60 mg/m2 doxorubicin. PEG-filgrastim (Neulasta(r)) will be administered on the day following chemotherapy.
This course is followed by Peripheral Blood Progenitor Cell (PBPC) harvest and tandem intermediate-dose alkylating therapy (miniCTC, carboplatin 800 mg/m2, thiotepa 250 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion."
1864460|NCT01057082|Dietary Supplement|Juven|Participants in the treatment arm will be asked to consume 2 packets of Juven drink mix each day for a period of six months.
1864461|NCT01057082|Dietary Supplement|Juven|Participants in the placebo arm will be asked to consume two packets of an orange-flavored drink mix each day for a period of six months.
1864462|NCT01057095|Genetic|RNA analysis|
1864463|NCT01057095|Genetic|gene expression analysis|
1864464|NCT01057095|Genetic|reverse transcriptase-polymerase chain reaction|
1864465|NCT01057095|Other|laboratory biomarker analysis|
1864466|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg BID
1864467|NCT01057108|Other|FOSTRAP Chewing Gum|40 mg BID
1864468|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
1864469|NCT01057108|Other|FOSTRAP Chewing Gum|20 mg TID
1864470|NCT01057108|Other|Placebo chewing gum|
1864471|NCT01057121|Drug|Lenalidomide|Lenalidomide is administered daily on days 1-21 of a 28-day cycle. The maximum duration of treatment is 12 28-day cycles. Sequential cohorts were entered at 10 mg/day, 15 mg/day, 20 mg/day and 25 mg/day using a 3+3 design to determine the MTD
1864472|NCT01057147|Drug|rebamipide 2% ophthalmic suspension|Instill one drop in each eye four times daily for 12 weeks.
1864473|NCT01057147|Drug|placebo eye drops|Instill one drop in each eye four times daily for 12 weeks.
1864474|NCT01057160|Drug|Rizatriptan|use of rizatriptan 10 mg for one migraine attack, in comparison to previously used analgetic
1864475|NCT01057173|Procedure|Transcatheter Aortic Valve Implantation|Retrograde trans-femoral or trans-subclavian aortic valve implantation with the Medtronic CoreValve System(TM) bio-prosthesis (third generation system, 18 Fr, CE mark approved)
1864476|NCT01057173|Procedure|Surgical Aortic Valve Replacement|Conventional surgical aortic valve replacement with a bio-prosthesis using normothermic cardiopulmonary bypass and cold blood cardioplegia cardiac arrest
1864477|NCT01057186|Dietary Supplement|Alfacalcidol; phosphate.|Individual dosage form and dosage depending on phenotype and underlying cause.
1864478|NCT01057186|Drug|Sevelamer|Pills. Individual dosage depending on clinical symptoms/phenotype.
1864479|NCT01057199|Genetic|RNA analysis|
1864480|NCT01057199|Genetic|gene expression analysis|
1864481|NCT01057199|Genetic|mutation analysis|
1864482|NCT01057199|Genetic|protein expression analysis|
1864483|NCT01057199|Other|fluorescence activated cell sorting|
1864484|NCT01057199|Other|laboratory biomarker analysis|
1864485|NCT01057212|Drug|ixabepilone|Ixabepilone will be administered intravenously, 16 mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the first six patients enrolled. Ixabepilone will be administered intravenously, 20mg/m2, once weekly for 3 of 4 weeks on a 28-day schedule, to the remaining 40 patients enrolled.
1864486|NCT01057212|Drug|bevacizumab|Bevacizumab will be administered intravenously, 10 mg/kg, every two weeks.
1864487|NCT01057225|Drug|carfilzomib|Given IV
1864488|NCT01057225|Drug|cyclophosphamide|Given orally
1864489|NCT01057225|Drug|thalidomide|Given orally
1864490|NCT01057225|Drug|dexamethasone|Given orally
1864491|NCT01057238|Other|Intensive Communication System|Regular family meetings once a week, using a standard protocol
1864492|NCT01057251|Drug|Nebivolol|5 mg, titrated to 20 mg, once daily oral administration
1864493|NCT01057251|Drug|Placebo|5 mg or 20 mg once daily, oral administration
1864494|NCT01057264|Drug|HAI Abraxane|Starting dose: 120 mg/m^2 by HAI infusion over 24 hours on Day 1 of 21 day cycle
1864495|NCT01057264|Drug|Gemcitabine|Starting dose: 600 mg/m^2 by IV on Days 1 and 8 of 21 day cycle
1864496|NCT01057264|Drug|Bevacizumab|10 mg/kg IV on Day 1 of 21 day cycle
1864497|NCT01057264|Drug|Filgrastim|5 mcg/kg subcutaneously starting at least 24 hours after Day 1 completion of chemotherapy, for 3 days.
1864498|NCT01057277|Drug|RAD001(Afinitor)|Rad001 in combination withCisplatin and Concurrent RT
1864499|NCT01057290|Genetic|gene expression analysis|
1864500|NCT01057290|Genetic|protein expression analysis|
1864501|NCT01057290|Other|fluorescence activated cell sorting|
1864502|NCT01057290|Other|immunologic technique|
1864503|NCT01057290|Other|laboratory biomarker analysis|
1864504|NCT01057303|Genetic|RNA analysis|
1864505|NCT01057303|Genetic|gene expression analysis|
1864506|NCT01057303|Genetic|reverse transcriptase-polymerase chain reaction|
1864507|NCT01057303|Other|laboratory biomarker analysis|
1864508|NCT01057316|Device|Formula PTX Stent - Dose 1|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
1864509|NCT01057316|Device|Formula PTX Stent - Dose 2|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
1864510|NCT01057316|Device|Formula PTX Stent - Dose 3|Stenting of the renal artery with a PTX-coated stent (experimental) or uncoated stent (active comparator). Groups are blinded.
1864511|NCT01057329|Drug|Atomoxetine|mg according to body weight
1864512|NCT01057329|Drug|Duloxetine|30 mg / die
1864513|NCT01057329|Drug|Olanzapine|5mg 1 wwek and 10 mg from second week
1864515|NCT01057342|Drug|carboplatin|AUC 6 i.v. given after paclitaxel as the second treatment on day 1 of each 3-week cycle.
1864516|NCT01057342|Drug|paclitaxel|175 mg/m2 i.v. first treatment on day 1 of each 3-week cycle.
1864517|NCT01057342|Drug|vadimezan|1800 mg/m2 i.v. following the administration of paclitaxel and carboplatin on day 1 of each 3-week cycle
1864518|NCT01057355|Procedure|EUS and/or ERCP with ethanol injections of pancreatic cyst|Lavage of cyst with 80% ethanol
1864519|NCT01057368|Behavioral|Day of intensive meditation practice|Long-term meditators practice for ~6 hours of meditation at each time point
1864520|NCT01057368|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8-week class designed to enhance well-being through training in mindfulness meditation
1864521|NCT01057368|Behavioral|Health Enhancement Program (HEP)|8-week class designed to enhance well-being through training in physical activity, functional movement, music therapy, and nutrition
1864522|NCT01057381|Drug|Dexmedetomidine 0.75 mcg/kg|Single intra-operative administration of dexmedetomidine 0.75 mcg/kg over 10 minutes for analgesia.
1864523|NCT01057381|Drug|Morphine 50 mcg/kg|Single intra-operative administration of morphine 50 mcg/kg over 10 minutes for analgesia
1864524|NCT01057381|Drug|Morphine 100 mcg/kg|Single intra-operative dose of morphine 100 mcg/kg over 10 minutes for analgesia
1864525|NCT01057381|Drug|Dexmedetomidine 1 mcg/kg|Single intra-operative administration of dexmedetomidine 1 mcg/kg over 10 minutes for analgesia
1864526|NCT01057394|Device|Endoscopically guided PVI Ablation|Endoscopically Guided Ablation using the EAS-AC
1864527|NCT01057394|Device|RF PVI Ablation|Radiofrequency ablation
1864528|NCT01057407|Drug|ASP1585|oral
1864529|NCT01057407|Drug|Sevelamer hydrochloride|oral
1864530|NCT01057420|Drug|oxygen inhalation|Inhalation of 80% oxygen via face mask
1864531|NCT01057433|Drug|Pitavastatin (NK-104)|pitavastatin (NK-104) 4 mg once daily (QD)
1864532|NCT01057433|Drug|Lopinavir/ritonavir|lopinavir/ritonavir 800 mg/200 mg
1864533|NCT01057459|Other|laboratory biomarker analysis|Correlative studies
1864534|NCT01057485|Procedure|AF ablation and AV node ablation|AF ablation and AV node ablation
1864535|NCT01057485|Procedure|AV node ablation|AV node ablation
1864536|NCT01057498|Drug|RNS60|RNS60, 4ml nebulized twice daily for 15 minutes.
1864537|NCT01057498|Drug|RNS60 - single dose|RNS60, single 4 ml dose nebulized for 15 minutes
1864538|NCT01057511|Drug|Crinone 8%|Crinone 8%, 90mg / p.v. / Qd, 7 days totally.
1864539|NCT01057511|Drug|Progesterone|Progesterone 20mg/ i.m./ Qd, 7 days totally.
1864540|NCT01057524|Device|High Frequency Chest Wall Oscillation (HFCWO)|Airway clearance using the high frequency chest wall oscillator device
1864541|NCT01057524|Other|Usual airway clearance|Airway clearance treatments using the active cycle of breathing techniques, autogenic drainage, positive expiratory pressure, manual techniques or oscillating positive expiratory pressure
1864542|NCT01057537|Drug|polypill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):
Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg."
1864543|NCT01057537|Drug|Usual cardiovascular medications|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
1864544|NCT01057550|Procedure|Autologous fascial sling|Retropubic bottom up mid urethral sling made using autologous rectus sheath fascia
1864545|NCT01057550|Procedure|TVT|Standard TVT as described by Ulmsten 1996
1864546|NCT01057550|Procedure|Pelvicol|retropubic mid urethral sling made from Pelvicol
1864547|NCT01057563|Device|drug (paclitaxel)-eluting balloon (DEB)|BMS implantation after lesion predilation with DEB
1864548|NCT01057563|Device|bare-metal stent (BMS)|BMS implantation
1864549|NCT01057563|Device|Drug (paclitaxel)-eluting balloon (DEB)|BMS implantation followed by post-dilation with DEB
1864550|NCT01057576|Dietary Supplement|An alcoholic extract of Artemisia dracunculus L.|capsule, daily dosing
1864551|NCT01057576|Other|Placebo|capsule, daily dosage
1864552|NCT01057589|Drug|Pemetrexed|"Triplet Combination Therapy: 500 mg/m^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles
Maintenance Therapy: 500mg/m^2 administered intravenously on Day 1 of 21 day cycle until disease progression or unacceptable toxicity"
1864553|NCT01057589|Drug|Cetuximab|"Triplet Combination Therapy: 400 mg/m^2 administered intravenously on Day 1 of 21 day cycle for 1 cycle; 250 mg/m^2 administered IV infusion on Day 1 of 21 day cycle and then weekly for up to 6 cycles.
Maintenance Therapy: 250 mg/m^2 administered intravenously on Day 1 of 21 day cycle and then weekly until disease progression or unacceptable toxicity"
1864554|NCT01057589|Drug|Cisplatin|Triplet Combination Therapy: 75mg/m^2 administered intravenously on Day 1 of 21 day cycle for up to 6 cycles.
1864555|NCT01057589|Dietary Supplement|Folic Acid|Standard of care dietary supplements: 350 to 1000 µg orally 5 times a day for the 7 days preceding the first dose of first dose of pemetrexed and continuing throughout treatment and for 21 days after the last dose of pemetrexed.
1864556|NCT01057589|Dietary Supplement|Vitamin B12|Standard of care dietary supplements: 1000 µg IM during the week preceding the first dose of pemetrexed and every 9 weeks thereafter.
1864557|NCT01057615|Dietary Supplement|Fish Oil|10 fish oil (3.2g EPA + 2.0g DHA) capsules per day for 3 weeks
1864558|NCT01057615|Dietary Supplement|Ascorbic Acid|2 pharmaceutical grade ascorbic acid (1500mg) capsules per day for 3 weeks
1864559|NCT01057615|Dietary Supplement|Fish Oil Placebo|10 placebo fish oil (soy bean oil) capsules per day for 3 weeks
1864560|NCT01057615|Dietary Supplement|Ascorbic Acid Placebo|2 placebo ascorbic acid (sucrose) capsules per day for 3 weeks
1864561|NCT01057628|Drug|ASP1941|oral
1864562|NCT01057628|Drug|placebo|oral
1864563|NCT01057641|Procedure|Spacer|Implantation of a percutaneously implanted interspinous device (spacer)
1864564|NCT01057641|Other|physiotherapy|physiotherapy
1864565|NCT01057654|Drug|Pravastatin|Pravastatin 40 mg
1864566|NCT01057654|Drug|Lifibrol|Lifibrol (K12.148; 4-(4'-tert. butylphenyl)-1-(4'-carboxyphenoxy)-2-butanol) given as a 600 mg film-coated tablet
1864567|NCT01057667|Drug|RO5024048|1000mg bid po, 24 weeks
1864570|NCT01057680|Dietary Supplement|creatine monohydrate|Powder, 0.1 g per day, 12 months
1864571|NCT01057680|Dietary Supplement|sugar placebo|powder, 0.1 g/day, 12 months
1864572|NCT01057693|Drug|pregabalin (Lyrica)|Lyrica 150-300 mg/day. Medication is supplied as capsules and given 3 times daily.
1864573|NCT01057693|Drug|Placebo|Placebo is supplied as capsules and given 3 times daily.
1864574|NCT01057706|Other|chiropractic|spinal manipulation and mobilization
1864575|NCT01057706|Behavioral|exercise|strengthening, stretching, balance
1864576|NCT01057719|Other|Physiotherapy|Individual tailored physiotherapy according to the Bobath concept sixty minutes each working day for four weeks
1864577|NCT01057758|Drug|SIMVASTATIN|Patients will receive 60 mg of study drug daily by mouth or feeding tube for 28 days or until discharged from the study ICU.
1864578|NCT01057758|Drug|PLACEBO|Patients will receive one placebo by mouth or feeding tube daily for 28 days or until discharged form study ICU
1864579|NCT01057771|Behavioral|Meditation|Eight weeks of training in mindfulless meditation. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
1864580|NCT01057771|Behavioral|Exercise|Eight weeks of training in moderately strenuous exercise. Weekly group sessions of 2.5 hours, with 45 minutes/day of practice.
1864581|NCT01057784|Procedure|Bariatric surgery.|Bariatric Surgery
1864582|NCT01057797|Behavioral|Exercise-specific self-efficacy|Subjects in the experimental group will participate in a self-efficacy enhancing intervention designed to maximize (a) exercise-specific SE-UB strength training (b) self-efficacy for overcoming barriers to exercise and (c) SE-UB physical activities. The intervention incorporates strategies to maximize the primary sources of efficacy information: (a) mastery accomplishments, (b) social modeling, (c) social persuasion, (d) interpretation of physiological and affective symptoms.
1864583|NCT01057797|Behavioral|Gentle chair exercise|Gentle armchair fitness exercises will be used as a sham treatment to control for the attention that subjects receive in the two strength training groups. The armchair fitness exercises will be conducted in small groups (n=8-10 per group). Armchair exercises will include stretching of all major joints with an emphasis on the arms and shoulders, massage of muscles that can be reached from the armchair (scalp, neck, shoulders, lower back, abdomen and thighs) and imagery to promote relaxation. Each session will include: 5 minutes of slow stretching, 20 minutes of faster paced exercises, 5 minutes of slower paced stretches, followed by 5-10 minutes of massage and imagery for relaxation.
1864584|NCT01057797|Behavioral|upper body strength training|16 weeks of lab-based upper body strength training using 8: modified lateral pull down, shoulder shrug, upright row, overhead pull down, front raise, front pull down, triceps extension, biceps curl. Training load and volume will be increased progressing from 70% to 80% of the maximum strength training and from 2 sets of 8-10 repetitions progressing to 3 sets. Each week subjects will train twice in the lab and once at home. Home exercises will include 1 set of 15-20 repetitions: biceps curl, triceps extension, front raises, lateral raises, overhead press, chest press and one-arm dumbbell row.
1864585|NCT01057810|Drug|Ipilimumab|5 mg/ml solution, Intravenous, 10 mg/kg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
1864586|NCT01057810|Drug|Placebo|Solution, Intravenous, 0 mg, Every 3 weeks for up to 4 doses in the Induction Phase. Every 12 weeks in the Maintenance Phase. Up to 24 weeks in the Induction Phase. Treatment in the Maintenance Phase continues until total treatment period has reached three years,Treatment Stopping Criteria are met, withdrawal of consent, or study closure
1864587|NCT01057836|Behavioral|Neck endurance training|
1864588|NCT01057836|Behavioral|Stretching|
1864589|NCT01057849|Drug|risperidone|3-6 mg per day
1864590|NCT01057849|Drug|olanzapine|5-20 mg per day
1864591|NCT01057849|Drug|Aripiprazole|10-30 mg per day
1864594|NCT01057875|Other|caffeine|Starbuck's Grande Pike Roast coffee
1864595|NCT01057875|Other|No caffeine|Starbuck's Grande Pike Roast Decaffeinated Coffee
1864596|NCT01057888|Other|Autodialer|Autodialer telephone calls
1864597|NCT01057888|Other|Letters|Mailed reminder letters
1864598|NCT01057901|Drug|Flibanserin|Flibanserin 100mg administered at bedtime for 24 weeks
1864599|NCT01057901|Drug|Placebo|This is the matched placebo which will be administered two tablets daily at bedtime.
1864600|NCT01057914|Dietary Supplement|Nutritional supplementation with a liquid formula|The patient consumes 400 kcal from a liquid supplementation formula
1864601|NCT01057914|Other|Dietary advice|The patient receives dietary advice for one hour during the hospital stay.
1864602|NCT01057914|Other|Combination of supplement and dietary advice|The patient receives dietary advice for one hour during the hospital stay and consumes 400 kcal from liquid supplementation formula for six month after discharge.
1864603|NCT01057927|Drug|OC000459|OC000459 capsules 2x100mg BID for 28 days
1864604|NCT01057927|Drug|Placebo|Placebo capsules to match OC000459 100mg capsules, 2 tablets BID
1864605|NCT01057940|Procedure|DBE PEJ placement|One time procedure with follow-up telephone call.
1864606|NCT01057953|Genetic|Blood drawn|Blood drawn for patient
1864607|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (full strength)|Single full strength dose capsule taken one time
1864608|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Softgel (half strength)|Single half strength dose capsule taken one time
1864609|NCT01057966|Dietary Supplement|ICAPS Eye Vitamin and Mineral Supplement - Coated Tablets (full strength)|Single, full strength dose tablet taken one time
1864610|NCT01057979|Behavioral|MET + CM for Exercise|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Contingency management offers tangible rewards for completing verified exercise.
1864611|NCT01057979|Behavioral|MET + Exercise Contracting|Motivational Enhancement Therapy seeks to resolve ambivalence regarding exercise and increase intrinsic motivation to exercise. Exercise contracting consists of weekly appointment to set specific goals for exercise in the upcoming week.
1864612|NCT01057992|Device|Magnetic Esophageal Sphincter|Implantable device
1864613|NCT01058005|Drug|BG00002 (natalizumab)|300 mg intravenous injection every 4 weeks
1864614|NCT01058005|Drug|interferon beta-1a|44 mcg subcutaneous injection 3 times per week
1864615|NCT01058005|Drug|glatiramer acetate|20 mg subcutaneous injection once daily
1864616|NCT01058018|Drug|RVX000222|RVX000222 twice a day for 12 weeks
1864617|NCT01058018|Drug|Placebo|Placebo twice a day for 12 weeks
1864618|NCT01058031|Behavioral|MBSR|Mindfulness Based Stress Reduction
1864619|NCT01058044|Other|"Evaluation of adherence to 3 oral anticancer treatment using a  Medication Event Monitoring System "|"Evaluation of adherence using a  Medication Event Monitoring System  (MEMS®) for oral anticancer treatment delivered by dispensary pharmacy"
1864620|NCT01058057|Drug|atorvastatin|atorvastatin 80mg p.o. daily seven days before PCI
1864621|NCT01058070|Device|Torax Medical, Inc. LINX Reflux Management System|Implantable device, Magnetic Esophageal Sphincter
1864622|NCT01058083|Drug|BMS-770767|Active, Oral, 15 mg, Daily, 28 days
1864623|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg, Daily, 28 days
1864624|NCT01058083|Drug|BMS-770767|Active, Oral, 150 mg, Daily, 28 days
1864625|NCT01058083|Drug|BMS-770767|Active, Oral, 50 mg BID, Daily, 28 days
1864626|NCT01058083|Drug|Placebo|Placebo, Oral, 0 mg, daily, 28 days
1864627|NCT01058096|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
1864628|NCT01058096|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo.
1864629|NCT01058109|Other|calcium-rich diet|dietary calcium intake of 1500 mg/d
1864630|NCT01058109|Other|Calcium rich diet|dietary intake of 1500 mg/d from food
1864631|NCT01058122|Procedure|Collection of adverse drug events|
1864632|NCT01058135|Other|Hi-maize starch (Low dose)|resistant starch
1864633|NCT01058135|Other|Hi-maize starch (High-dose)|resistant starch
1864634|NCT01058135|Other|Control (starch)|rapidly digestible starch
1864635|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
1864636|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
1864637|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
1864638|NCT01058161|Other|high-field MRI (3 Teslas)|high-field MRI (3 Teslas)
1864639|NCT01058174|Drug|micafungin|intravenous infusion
1864640|NCT01058174|Drug|fluconazole|intravenous infusion
1864641|NCT01058174|Drug|liposomal amphotericin B|intravenous infusion
1864642|NCT01058174|Drug|caspofungin|intravenous infusion
1864644|NCT01051531|Drug|Paliperidone palmitate|One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
1864645|NCT01051544|Drug|FVIII Concentrates|Patients will be centrally randomized to receive a von Willebrand factor-free FVIII concentrate (recombinant or plasma-derived, monoclonally-purified). The choice of product brand will be based on physician / patients preferences.
1864646|NCT01051544|Drug|FVIII/VWF concentrates|Patients will be centrally randomized to receive a FVIII/VWF concentrate of 200 IU/Kg by one or two bolus injections daily.The choice of product brand will be based on physician / patients preferences.
1864647|NCT01051557|Other|Laboratory Biomarker Analysis|Correlative studies
1864648|NCT01051557|Drug|Perifosine|Given PO
1864649|NCT01051557|Drug|Temsirolimus|Given IV
1864650|NCT01051557|Procedure|Therapeutic Conventional Surgery|Undergo cytoreductive surgery
1864651|NCT01051570|Drug|carboplatin|AUC = 5 by Calvert's formula, day 1 of each 21 day cycle
1864652|NCT01051570|Drug|RAD 001|5 mg orally starting on Day 2 then continuous
1864653|NCT01051570|Drug|prednisone|5 mg orally twice a day starting on Day 1 then continuous
1864654|NCT01051570|Other|laboratory biomarker analysis|Samples will be collected from archival tissue.
1864655|NCT01051570|Other|pharmacological study|Samples will be collected Cycle 1, day 1, 2 & 8 and Cycle 2, Day 1 & 2
1864656|NCT01051583|Procedure|Diode laser cyclophotocoagulation enhanced by intravitreal injection of Avastin|The operative procedure involved retro-bulbar anesthesia, draping the patient in an aseptic manner, introduction of an eye speculum, 30 laser shots over 270 degrees of the circumference of the limbus. For our study we used the Iris Diode laser machine, the G-probe and we adjusted the settings for 2500 millisecond duration and the 3000 milli-joule and reduced the power progressively until just below the energy level that produced a pop.then after applying the laser, we performed a paracentesis with a 27 gauge needle to soften the globe, followed by intravitreal injection of the Avastin from a site 3.5 millimeter posterior to the limbus. The dose we administered was one milligram of bevacizumab (0.04 mL of 25 mg/mL).
1864657|NCT01051596|Drug|Temozolomide and ABT-888|Temozolomide 150 mg/m2 once a day on Days 1-5 of each 28-day cycle ABT-888 40-mg orally BID on Days 1-7 of each 28-day cycle
1864658|NCT01051609|Other|History and Physical Exam|The physical exam includes vital signs and ECOG performance status.
1864659|NCT01051609|Other|Grip Strength Measurement|A hand grip strength test will be used to measure and compare baseline and post-AI treatment forearm muscle strength in each hand.
1864660|NCT01051609|Behavioral|Surveys|Self-administered surveys including Health Assessment Questionnaire Disability Index, CES-D, FACIT-F, PSQI, GAD7, number of minutes of morning stiffness, and questions pertaining to vasomotor symptoms will be used in this study to assess for presence, severity, characteristics, and associations of AI-associated musculoskeletal symptoms.
1864661|NCT01051609|Other|Blood Collection|A set of blood markers will be assayed at baseline, 6 months, and 12 months.
1864662|NCT01051609|Procedure|Ultrasound of Hand/Wrist|An inflammatory arthritis ultrasound scoring method similar to the RAMRIS scoring system used in rheumatoid arthritis, will evaluate joints in the most affected hand and wrist at 6 months.
1864663|NCT01051622|Other|Labeling Ceretec|Technetium-99m is used to radiolabel cells of interest i.e PBMC's
1864788|NCT01060280|Other|Group GDS physiotherapy|Routine clinical practice (which will be substituted by Group GDS) plus education on active management.
1864664|NCT01051635|Drug|LMP 400|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
1864665|NCT01051635|Drug|LMP 776|Indenoisoquinolines are non-camptothecin inhibitors of topoisomerase 1 with improved characteristics such as better chemical stability, producing stable DNA-top1 cleavage complexes, and exhibiting a preference for unique DNA cleavage sites compared with their camptothecin counterparts.
1864666|NCT01051648|Drug|Intra ocular injection of triamcinolone acetonide|In all patients triamcinolone acetonide was prepared by keeping the bottle vertical to allow sedimentation of crystals thus removing the vehicle. It was then injected into the anterior chamber (2 ml with concentration 20 mg/ml) just prior to anterior vitrectomy. The direction of the tip of the needle was kept away from the corneal endothelium to minimize endothelial toxicity. Triamcinolone was removed as quickly & completely as possible after finishing anterior vitrectomy
1864670|NCT01051674|Other|High fiber vs. low-carbohydrate diets|High fiber diet involves at least 40 grams of dietary fiber or more per day for women and at least 50 grams of dietary fiber per day for men. Low-carbohydrate diet involves less than 120 grams of carbohydrate per day for both men and women.
1864671|NCT01051687|Drug|Botulinum toxin A|"Dilution of 1 ml of unpreserved saline per 100 U vial of BOTOX (Allergen pharmaceuticals, Irvine, CA). 2 units were injected intradermally every 1 cm2 with a 1ml syringe and 30 gauge needle.
For each patient with focal vitiligo, one vitiliginous patch - or two patches from different sites- will be treated. The other patches from the contra lateral site will be left untreated and used as control at the follow-up visit. For each patient with segmental vitiligo, half of the lesion will treated. The other half will be left untreated and used as a control at the follow-up visit."
1864672|NCT01051700|Drug|GW786034|Investigational product
1864673|NCT01051700|Other|Placebo|Placebo
1864674|NCT01051713|Behavioral|Technology Supported|Those randomized to the Technology Supported condition will record dietary intake and weight on the smartphone, using the user-friendly, persuasive interface developed in Phase I. They will be expected to enter their dietary intake into the smartphone daily throughout the day. They will also be expected to enter their weight and to wear the accelerometer daily. Time-stamped data from the smartphone will upload automatically to the study server throughout the day, where it will be visible to the lifestyle coach. The participant's real-time diet, activity, and weight data relative to goals will also be visually depicted on the participant's smartphone. The anticipated web platform will be developed specifically for the ENGAGED participants. The coach will provide feedback on diet and activity self-monitoring and goal adherence at least weekly by phone, e-mail or text during weeks 1-8 and then at least monthly through the 6 month follow-up.
1864675|NCT01051713|Behavioral|Standard|"Those randomized to the Standard condition will record everything they eat and will total their daily fat grams and calories on the Keeping Track form used in the DPP. They will turn in their self-monitoring diaries and download their accelerometer (but not see those data) at weekly group sessions 1 through 8. Thereafter they will be expected to turn in paper data monthly, in person at the months 3 and 6 assessments and via mail, fax or e-mail for months 4 and 5. Accelerometer data will be downloaded at in-person visits."
1864676|NCT01051726|Other|Aromatherapy oil|Oil consists of Clary Sage, Peppermint, Lavender and Frankincense with drops of each mixed into a carrier oil.
1864677|NCT01051726|Other|None essential oil|Baby oil
1864678|NCT01051739|Procedure|Comparison of four visual field testing strategies|We compared the ability of four perimetric strategies to detect visual field change in the glaucoma arm.
1864679|NCT01051765|Drug|irinotecan/cisplatin|irinotecan 130mg/m2 d1 cisplatin 30mg/m2, d1,d2 every 3 weeks
1864680|NCT01051778|Drug|enoxaparin 40mg plus low dose aspirin|Enoxaparin 40mg/day by subcutaneous injection ( Clexane 40 mg, Aventis international, Sanofi-aventis France ) is started when the serum pregnancy test become positive. Enoxaparin is stopped 2 days before planned induction of labor or cesarean section and twice-daily unfractionated heparin (UFH) is initiated. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop enoxaparin or UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID)) is started before conception and continued until 36 weeks gestation.
1864681|NCT01051778|Drug|Heparin calcium5,000 U twice daily plus low dose aspirin|Heparin Calcium 5,000 U twice daily (Cal-Heparine, Amoun Pharmaceutical Co, Egypt) by subcutaneous injection is started when the serum pregnancy test become positive. The evening UFH dose is cancelled before planned caesarean section . The patients are asked to stop UFH with the beginning of labor pains . Low dose aspirin (75 mg/day)(Aspocid Paediatric ,Chemical Industries Development (CID))is started before conception and continued until 36 weeks gestation .
1864682|NCT01051791|Drug|Everolimus 10mg daily|RAD001 is a pill that will be taken orally (by mouth), at a dose of 10 mg, once a day for 28 days.
1864683|NCT01051804|Other|Systane Ultra|Systane Ultra 1 to 2 drops per eye at least 4 times daily for 4 weeks
1864684|NCT01051804|Other|Optive lubricant Eye Drops|Optive Lubricant Eye Drops 1 to 2 drops per eye at least 4 times daily for 4 weeks
1864685|NCT01051817|Drug|AIN457|infusion 10 mg/Kg
1864686|NCT01051817|Drug|Placebo|infusion
1864687|NCT01051830|Other|Diabetes interdisciplinary program|Diabetes consulting, rehabilitation program
1864688|NCT01051856|Device|SEAMGUARD with bioabsorbable staple|In the SEAMGUARD group, pancreatic resection and transection of the pancreatic body will be executed using an endoscopic linear stapling device.
1864689|NCT01051856|Procedure|TissueLink with radiofrequency ablation|After pancreatic transection with the method of choice of the operating surgeon, the pancreatic remnant will be treated with Tissuelink alone for an ablation depth (thickness) of approximately 7 mm.
1864746|NCT01058330|Other|Plyometric training program|The intervention is a year long individualized plyometric exercise training program. Examples of plyometric activities include jumping, hopping, running, and throwing. The number of plyometric exercises will increase gradually to prevent over training to a total of 5 lower extremity exercises and 5 upper extremity exercises
1864690|NCT01051869|Procedure|Simple decompression|"Fracture fixation will be performed through a posterior approach, as this provides excellent visualization of the distal fragments. A triceps split will be used to expose the distal humerus. A midline incision will be made from proximally to distal onto the shaft of the ulna. Equal portions of the triceps muscle will be reflected medially and laterally, with use of sharp dissection to remove the triceps insertion from the olecranon. The ulnar nerve will be identified and protected proximal and distal to the medial epicondyle. Fracture fixation will be performed after anatomic reduction using standard fixation techniques and plate fixation on both the medial and lateral column.
In the simple ulnar nerve decompression group, no further treatment of the ulnar nerve will be undertaken."
1864691|NCT01051869|Procedure|anterior subcutaneous transposition|In the anterior transposition of the ulnar nerve group, the ulnar nerve will be placed subcutaneously anterior to the medial epicondyle free from any pressure.
1864692|NCT01051882|Biological|MSC-NTF cells transplantation (i.m.)|In early ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia, intramuscularly into patients' clinically unaffected (or only mildly affected) upper arm biceps and triceps muscles according to a pre-designed grid. Intramuscular injections will be by a 26 gauge needle to a 1.5cm depth (ensuring that injection is into muscle and not adipose tissue). The patients will be injected at 24 sites with a total of 24 million cells
1864693|NCT01051882|Biological|MSC-NTF cells transplantation (i.t.)|In progressive ALS subjects: Autologous MSC-NTF cells will be transplanted under mild anesthesia intrathecally(via a standard lumbar puncture)with a total of 60 million cells.
1864694|NCT01051895|Other|high risk HPV DNA testing|Specimens will be collected with a cervical cytobrush and cervical cells will be resuspended in 2 ml of Preservcyt® (Hologic LP), a liquid cytology preservation media. 75µl of processed sample will be hybridized with 25 µl of probe B mixture. The assay is completed as a standard enzyme immunoassay with the addition of a dioxetane-based chemiluminescent substrate. Specimens will be considered positive for HPV if the ratio of RLUs of the specimen to the mean RLUs of triplicates of positive control (at 1 pg per ml or 5000 copies of HPV genome per test) is at least one.
1864695|NCT01051895|Other|Active comparator: Routine colposcopy|Women will undergo colposcopy, with no standardized protocol; tests are left at the discretion of the treating physician, in order to document routine proactive. We will document all procedures (biopsies, endocervical curettage, cytology, etc) and their outcome.
1864696|NCT01051921|Drug|CTS-1027|CTS-1027 supplied in 5 and 10 mg tablets, 15 mg taken twice daily, for up to 48 weeks
1864697|NCT01051921|Drug|Pegylated interferon|Pegylated interferon, 180 micrograms in 0.5 ml of solution injected subcutaneously (SQ) once per week, for up to 48 weeks. Packaged in single use syringes.
1864698|NCT01051921|Drug|Ribavirin|Ribavirin, 200 mg capsules taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg for up to 48 weeks.
1864699|NCT01051934|Drug|SS1 (dsFv) PE38|
1864700|NCT01051934|Drug|Paclitaxel|
1864701|NCT01051934|Drug|Carboplatin|
1864702|NCT01051934|Drug|Bevacizumab|
1864703|NCT01051947|Drug|Nebivolol|10 mg by mouth daily for 2 weeks 20 mg by mouth daily for 2 weeks 40 mg by mouth daily for 2 weeks
1864704|NCT01051947|Drug|Metoprolol|dosage prescribed prior to starting on study
1864705|NCT01051960|Drug|Ambrisentan|Ambrisentan 5mg or 10mg once daily
1864706|NCT01051973|Behavioral|Cognitive behavior therapy|A 10-week treatment based on exposure to symptoms and related feelings.
1864707|NCT01051973|Behavioral|Stress management|A 10-week stress management treatment including applied relaxation and dietary advice.
1864708|NCT01051986|Procedure|saphenous vein composite grafting|use saphenous vein as a composite graft connected to the left internal thoracic artery
1864709|NCT01051986|Procedure|right internal thoracic artery composite grafting|right internal thoracic artery is used as a composite graft connected to the left internal thoracic artery
1864710|NCT01051999|Dietary Supplement|Glutamine|Oral glutamine powder
1864711|NCT01051999|Dietary Supplement|L-alanine|L-alanine oral powder
1864712|NCT01052012|Drug|SABER™-Bupivacaine|Injectable Extended Release Solution; SABER™-Bupivacaine /Once
1864713|NCT01052012|Drug|Bupivacaine HCl|Injectable Solution; Bupivacaine HCl /Once
1864714|NCT01052012|Drug|SABER™-Placebo|Injectable Solution; SABER™-Placebo/Once
1864715|NCT01052025|Drug|Curcumin|curcumin capsule contains 250 mg curcuminoiods, 3 capsules per time, 2 times a day before meal for 12 months
1864716|NCT01052038|Drug|Placebo administration|Placebo administration
1864717|NCT01052038|Drug|Dexamethasone 0.05mg/kr administration|Dexamethasone 0.05mg/kr administered in 100ml of sterile saline solution prior to the start of surgery.
1864718|NCT01052038|Drug|Dexamethasone 0.1mg/kg|Dexamethasone 0.1mg/kg administered in 100ml of sterile saline solution prior to the beginning of surgery.
1864719|NCT01052051|Dietary Supplement|Vitamin D|Vitamin D 2000 IU/daily
1864720|NCT01052051|Dietary Supplement|Calcium|Calcium 1200mg / daily
1864721|NCT01052064|Device|Transcranial Magnetic Stimulation|rTMS will be administered in one daily session during 5 consecutive days of 1 Hz, 90% of motor threshold for a total of 1500 stimuli. The stimulation will be focal over left dorsolateral-prefrontal cortex(F3, from the international 10-20 system)
1864722|NCT01052077|Drug|OPC-34712|Tablets, Oral, 1 - 3 mg OPC-34712
1864723|NCT01052077|Drug|Placebo|Placebo
1864724|NCT01052077|Drug|ADT|
1864725|NCT01052090|Drug|PHN121|a size 0 hard gel capsule containing 323.6 mg active ingredient, a complex mixture prepared from 5 commonly practiced botanical traditional Chinese medicines
1864726|NCT01058200|Device|iCup|new vacuum extractor: sterile disposable plastic cup
1864727|NCT01058200|Device|reference cup|reference cup of the obstetrical ward: metallic cup
1864747|NCT01058343|Biological|IFN-K|3 to 4 IM injections over 3 months
1864748|NCT01058369|Drug|Deferasirox (Novartis Pharma)|Treatment period 102 weeks. Starting dose 10mg/kg/day. Up to 30/mg/kg according to dose adjustment table as specified in the protocol
1864749|NCT01058382|Drug|Progesterone Vaginal Suppositories|Progesterone Vaginal Suppositories 200 mg three times daily for 10 weeks following embryo transfer
1864750|NCT01058382|Drug|Intramuscular Progesterone-in-Oil|Progesterone-in-Oil 50 mg IM once daily for 10 weeks following embryo transfer
1865113|NCT01055301|Drug|cyclophosphamide|
1864728|NCT01058213|Behavioral|Resistance training|Supervised training will be performed on a cable exercise system (Body Solid, Forest Park, IL) using six exercises that involve concentric and eccentric muscle actions: leg press, knee flexion, knee extension, calf raise, hip adduction, hip abduction. Subjects will perform the lower extremity exercises under the direct supervision of an exercise specialist three times per week. Subjects will perform 2 sets of 8-10 repetitions at 70% of their maximum strength for 2 weeks, then will perform 2 sets of 8-10 repetitions at 80% of their maximal strength for 2 weeks, and for the next 4 weeks they will perform 3 sets of 8-10 repetitions at 80% of their maximal strength. Sets will be separated by at least a 2-3 minute rest period for multiple-joint exercises and at least 1-2 minutes for single-joint exercises. A moderate velocity of muscle contraction (~1-2 seconds for concentric and eccentric contraction) will be used.
1864729|NCT01058213|Behavioral|Aerobic training|Cycle ergometry training will be performed in the lab on a stationary cycle ergometer, calibrated with a 4 kg weight (Monark 828E, Varberg, Sweden). Initial work rate will be 50% of peak work rate (PWR) as tolerated and will be evaluated weekly with progressive increases targeted to achieve the highest work rate tolerated for 3-5 minutes{: wks 1-2 50% PWR, wks 3-4 60% PWR, wks 5-6 70% PWR, wks 7-8 80% PWR}. An interval training protocol will be used with subjects performing four work sets of five minutes duration separated by rest intervals of unloaded cycling lasting 2-4 minutes.
1864730|NCT01058226|Biological|Malaria challenge (wild-type NF54 strain Plasmodium falciparum sporozoites)|Malaria sporozoite challenge with the wild-type NF54 strain of Plasmodium falciparum delivered by the bite of five infected Anopheles stephensi mosquitoes.
1864731|NCT01058239|Drug|bortezomib|Given intravenously on days 1, 4, 8 and 11 of every cycle
1864732|NCT01058239|Drug|rituximab|given intravenously on days 1, 8 and 15 of Cycle 1 and on Day 1 of subsequent cycles
1864733|NCT01058252|Drug|Letrozole 2.5 mg, recFSH 75 IU|"OVARIAN STIMULATION:
In previous cycles, cycle length and ovulatory status must be assessed and documented.
STEP 1: ANOVULATION by ORAL CONTRACEPTION
Place patients on monophasic low dose of oral contraceptive pills (OCP) such as Marvelon (Organon, 0.03 mg) continuously for 21 days, 22 days but no more.
Before stopping the oral contraceptive pills, perform an ultrasound to check for the absence of cysts (no cyst > 10 mm).
Give estradiol (2mg, 3 times a day) for 3 days from D21 or D22 and wait for bleeding.
STEP 2: STIMULATION and MONITORING Day one of the cycle equals the first day of bleeding (not spotting).
On Day 3 (D3), start letrozol 2.5mg (AROMEK) for 5 days (D7). LetrozolE can be pushed for 2 more days.
Start hMG or FSH (75 IU a day) on Day 3 like LetrozolE and continue for 5 to 7 days without increasing the dose. The dose of hMG OR FSH can be increased to 150 IU a day if low responder."
1864734|NCT01058252|Procedure|STEP-3: LH Suppression & Monitoring|"Baseline Day-2 Ultrasound to estimate antral follicles; Follow-up TVS scans on Day- 5,6,7,8 and 9 of the stimulated cycle. Ideally the lead follicle should be 18 mm on or around day 10 of the cycle.
• When the leading follicle reaches 14 to15 mm (D8 or D9), give Indomethacine (50 mg, 3 times a day) until the evening preceding the egg retrieval. The Indomethacine will prevent a premature ovulation.
The endometrium should be minimum 8 mm on the day of HCG (IVF-C 5000 IU x 2)
No need of LH testing, or E2 testsing during the stimulated cycle."
1864735|NCT01058252|Procedure|STEP-4: HCG Timing|"IVF-C (HCG 10000 IU) shall be injected to trigger the ovulation, when any of the following occur:
E2 level is over 150 pg/ml/per mature follicle (> 15 mm)
Domminent follicle is greater than 18 mm in mean diameter
LH Remains as Baseline, OR
The day when Urinary LH Surge is positive"
1864736|NCT01058252|Procedure|STEP-5: OPU, ET, Cancellation|"Ultrasound guided Ovum Pick-Up is performed 34-36 hours after IVF-C (HCG 10000 IU) injection.
Embryo Transfer is performed after 48-72 hours of incubation at 4-8 cell stage.
Maximum of 2 embryos are transferred, using ultrasound guided transfer.
Cancellation Criteria:
Poor patient compliance
Premature Ovulation
Premature LH Surge
Endometrium < 7 mm
Poor Follicular Development
E2 Level > 2,500 pg/ml"
1864737|NCT01058252|Procedure|INVOCell (Intravaginal Culturing)|Sperm preparation through Swim-Up or Gradient is performed 1 hour prior to the oocyte retrieval; Fill the device without air bubble. Only 30000 motile spermatozoa are added into the device; After follicle aspiration, oocyte(s) are identified in the follicular fluid and immediately placed into the device; The device is closed, placed into a protective outer rigid shell and then positioned into the vaginal cavity for 2 to 3 days; No activity restriction is required for the patient, except baths. After 2 or 3 days of incubation, the retention system and the device are removed from the vagina in sterile environment. The device is opened and the contents are observed in a sterile environment under microscope to find the embryos. The two best quality embryos are loaded into embryo transfer catheter and transferred immediately unto the uterine cavity using aseptic techniques.
1864738|NCT01058265|Other|Integrative|Integrative Medicine medical evaluation.
1864739|NCT01058265|Other|Standard|Standard general medical evaluation.
1864740|NCT01058278|Procedure|Selective Laser trabeculoplasty|The Selective Laser Trabeculoplasty is done with the Latina lens after applying a drop of iopidine in the treated eye and alcaïne in both eye. Fifty spots are done over 180°. The maximal and total energy is written in the chart. After the treatment, prednisolone acetate 1% (a corticosteroid), diclofenac 0.1% (an NSAID) or a placebo is used. The three treatments were administered 4 times a day (at breakfast, lunch, dinner and at bedtime) for five days.
1864741|NCT01058291|Drug|KW-6500|Twelve weeks subcutaneous injection of 1 to 6 mg for the OFF state
1864742|NCT01058291|Drug|KW-6500 Placebo|Twelve weeks subcutaneous injection for the OFF state
1864743|NCT01058304|Other|Group Physical Therapy for Knee OA|The group PT arm will include 6 1 to 1 hour visits (every other week) led by a physical therapist and exercise physiologist or PT Assistant, with 8 participants per group. The group PT sessions will include group instruction in joint care (activity pacing and joint projection), group discussion of exercise successes and barriers, group exercise, and scheduled individual consultations with the physical therapist (2 per participant, 15-20 minutes each) to address specific functional and therapeutic needs. Participants will also be given instructions for a home exercise program.
1864744|NCT01058304|Other|Individual Physical Therapy for Knee OA|The individual PT arm, modeled after typical PT care for knee OA at the Durham VAMC and other health care settings, will include 2 1-hour visits with a physical therapist, 2-3 weeks apart. While the individual PT sessions will differ in structure from the group PT sessions they will include the same informational, assessment, and therapeutic content as the group sessions. Participants in this group will also be given instructions for the same home exercise program.
1864745|NCT01058317|Drug|Propranolol|Propranolol 2mg/kg divided twice daily
1865114|NCT01055301|Drug|dexamethasone|
1864751|NCT01058395|Drug|Minocycline|Minocycline 800 mg loading followed by 200 mg Q12 or Minocycline 800 mg loading followed by 400 mg Q12 will be delivered in an open-label study for seven days intravenously in one of two different dosing tiers to assess safety and toxicity per FDA recommendations. There will be tow different arms or groups differing by the amount of minocycline given over 7 days.
1864752|NCT01058408|Radiation|Intensity modulated radiotherapy|Administered daily 5 days per week
1864753|NCT01058408|Drug|RAD001|Taken orally once a day
1864754|NCT01058408|Drug|cisplatin|Administered intravenously once a week
1864755|NCT01058421|Procedure|intensive physical therapy|four week course of daily intensive physical therapy
1864756|NCT01058421|Procedure|control group|four weeks of routine physical therapy
1864757|NCT01058434|Drug|TKI258|
1864758|NCT01058447|Drug|AZD1981|Oral tablet, 250 mg, single dose
1864759|NCT01058460|Procedure|HPV-cytology co-testing|Subjects will receive HPV testing and conventional cytology testing at baseline. Follow up management will be based on both results.
1864760|NCT01058486|Behavioral|Self-Management and Motivational Interviewing|"Post hospital discharge, patients will be referred (<2 weeks) to pulmonary rehabilitation (PR) (1-2 sessions per week for 6-8 weeks). PR visits (approximately 1 hour) will include education, strengthening and endurance exercise as the patient tolerates.
A counselor (RN or RRT) and patient will meet once weekly after PR session. The counselor will assess the patient's self efficacy and knowledge of self-management principles of COPD. Based on the assessment and greatest needs identified by patient, the counselor will work with the participant to collaboratively develop a specific SM plan.Motivational interviewing techniques will be used.
Following completion of PR, the counselor will contact the patient monthly to provide clinical support on SM of COPD. To ensure consistency of intervention, we will use standardized treatment procedures and phone scripts."
1864761|NCT01058499|Behavioral|Mindfulness Based Stress Reduction Program (MBSR)|Traditional eight-week MBSR Program.
1864763|NCT01058525|Procedure|median nerve block|median nerve block performed using ultrasound guidance
1864764|NCT01058525|Procedure|median nerve block after hydro-dissection|median nerve block performed after hydro-dissection (glucose 5% solution), both using ultrasound guidance
1864765|NCT01060072|Drug|Loteprednol etabonate|Topical administration of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye four times a day (QID), postoperative day 1-14.
1864766|NCT01060072|Drug|Vehicle of Loteprednol Etabonate|Topical administration of vehicle of loteprednol etabonate ophthalmic suspension 1-2 drops in study eye QID, postoperative day 1-14.
1864767|NCT01060098|Drug|anti-TNF therapy (etanercept or adalimumab)|Biological DMARD
1864768|NCT01060111|Drug|Topiramate Standard|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 1-week up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
1864769|NCT01060111|Drug|Topiramate Slow|Topiramate 25 mg will be administered once daily and the dose will be increased by 25 mg per day at an interval of 2-weeks up to a dose of 50 mg to 100 mg up to Week 6. A maintenance dose of 50 mg to 100 mg will be administered twice daily up to Week 10 as per Physician's discretion.
1864770|NCT01060111|Drug|Propranolol booster|Propranolol 80 mg will be administered once daily, 40 mg in the morning and 40 mg in the evening up to Week 6.
1864771|NCT01060124|Drug|Fentanyl D-trans|Fentanyl D-trans will be applied as transdermal patch releasing drug at the rate of 12.5 microgram per hour (mcg/hr) for 3 days with a dose ranging from 12 mcg/hr to 50 mcg/hr.
1864772|NCT01060137|Drug|fentanyl matrix|Fentanyl transdermal patch 12 - 25mcg/hr
1864773|NCT01060150|Drug|OROS Methylphenidate HCl|Osmotic Release Oral System (OROS) Methylphenidate HCl tablet will be given orally once daily at a starting dose of 18 milligram (mg) for those less than 30 kilogram (kg) of body weight and 27 mg for those more than or equal to 30 kg; the dose can be increased by 9 mg or 18 mg per week up to Week 6 depending on a participant's treatment effect and tolerability; then a maximum maintenance dose of 72 mg will be given orally once daily up to Week 12.
1864774|NCT01060163|Drug|Tranexamic Acid|A bolus of 10 mg/kg after anesthetic induction over 10 min followed by a maintenance of 10 mg/kg/h for the duration of surgery
1864775|NCT01060163|Drug|Saline|Saline served as placebo
1864776|NCT01060176|Drug|Tranexamic Acid|High, medium and low dosage, loading dose followed by continuous infusion in operation
1864777|NCT01060189|Drug|UTI & TA|Ulinastatin, tranexamic acid and the combination of the two
1864778|NCT01060202|Drug|No intervention|This is an observational study. Patients receiving bortezomib injection intravenously (into a vein) 1.3 mg/m2 twice a week for 21 days will be observed.
1864779|NCT01060215|Procedure|Normal saline|20 cc normal saline injection into the knee joint
1864780|NCT01060228|Drug|paliperidone ER|1 tablet of 500 mg once daily on Day 1 and Day 15
1864781|NCT01060228|Drug|divalproex sodium ER|2 tablets of 500 mg once daily from Days 5 through 18
1864782|NCT01060241|Other|Internet Intervention|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
1864783|NCT01060254|Drug|Placebo|Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 12 wks
1864784|NCT01060254|Drug|JNJ-42160443|Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use. One injection of 9 mg of JNJ-42160443 every 28 days for up to 12 wks
1864785|NCT01060267|Drug|Erythromycin|The patients in erythromycin group received intravenous bolus infusion of 125 mg of erythromycin lactobionate in 50 ml of normal saline
1864786|NCT01060267|Drug|Placebo|patients in placebo group 50ml of normal saline over 10 minutes, 1/2 hour before endoscopy.
1864787|NCT01060280|Behavioral|Education on active management|Routine clinical practice plus education on active management.
1864789|NCT01060280|Other|Individual GDS physiotherapy|Routine clinical practice (except for usual physiotherapy, which is substituted by Group and Individual GDS) plus education on active management.
1864790|NCT01060293|Drug|High-dose furosemide|High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours
1864791|NCT01060293|Drug|Low-dose furosemide|Low-dose furosemide (LDF): continuous IV administration of 5 mg/h furosemide
1864792|NCT01060293|Drug|Low-dose furosemide combined with low-dose dopamine|Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
1864793|NCT01060332|Other|Body Constitution Questionnaire|Body Constitution Questionnaire was a tool for the study of objective evaluation of diagnostics of Traditional Chinese Medicine. It has been well developed with good validation and consistency.
1864794|NCT01060345|Drug|Polyphenon E|three 200mg capsules (600mg total dose of the study drug) with food (within one hour of eating a substantial meal) daily for a minimum of 4 weeks, or until the day before surgery
1864795|NCT01060358|Procedure|method (non-surgical) to measure neuromuscular neutral zones|
1864796|NCT01060371|Genetic|All Participants|If you decide to participate in this study, we will collect 1 tablespoon (15 milliliters) of blood during the first/screening visit in order to extract your DNA.
1864797|NCT01060384|Drug|Lenalidomide|"Dose Cohort -1^ 10mg daily on Days 1-21 every 28 days
Dose Cohort +1^^ 15mg daily on Days 1-21, every 28 days
Dose Cohort +2 20 mg daily on Days 1-21, every 28 days
Dose Cohort #3 25 mg daily on Days 1-21, every 28 days
^Used only if Dose Cohort +1 requires further reduction
^^Starting Dose Cohort in Phase I"
1864798|NCT01060384|Drug|ofatumumab|8 weekly infusions of ofatumumab 1000mg.
1864799|NCT01060397|Behavioral|Extended Brief Intervention|Frames motivational interviewing approach
1864800|NCT01060397|Behavioral|Control|Usual care
1864801|NCT01060410|Genetic|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the bio-activation and elimination of cyclophosphamide
1864802|NCT01060410|Drug|Cyclophosphamide|intravenous injection, 0.2g, once every two days
1864803|NCT01060410|Other|Pharmacokinetic analysis|laboratory analysis of concentration of cyclophosphamide and 4-OH-cyclophosphamide in plasma
1864804|NCT01060423|Drug|Cetuximab|Starting dose of 400mg/m2, followed by weekly 250mg/m2
1864805|NCT01060423|Drug|Irinotecan|Irinotecan 180 mg/m² to be administered every two weeks
1864806|NCT01060423|Device|Irinotecan eluting BEADS|A minimum of two treatments per lobe (four bi-weekly sessions in the event of bilobar disease) at week 0 and 4 with up to 4ml (100-300µm DC Bead loaded with up to 200mg irinotecan) will be scheduled (i.e. for bilobar disease right lobe: week 0, left lobe: week 2, right lobe: week 4 and left lobe: week 6: following toxicity and extending interval if toxicity seen).
1864807|NCT01060436|Device|CPAP or BiPAP machines|Nightly use of CPAP or BiPAP at a pressure recommended by the subject's treating physician
1864808|NCT01060449|Other|LV stimulus intensity|"The voltage and pulse duration used for programmed LV pacing
Arm 1: LV lead low output Arm 2: LV lead high output"
1864809|NCT01060462|Drug|Pts. w/ neutropenic fever associated w/ hematologic malignancy|Itraconazole 200 mg twice daily for 2 days for a total of 4 doses, then 200 mg once daily for 12 days. After 14 days of IV administration, itraconazole oral solution 200 mg twice daily should be continued for a total of 14 days until clinically significant resolution of neutropenia resolves
1864810|NCT01060475|Drug|LIM-0705 and tacrolimus|Oral solution, LIM-0705 500 mg BID for 14 days plus tacrolimus BID for first 8 days.
1864811|NCT01060475|Drug|LIM-0705 and tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus tacrolimus BID for the first 8 days.
1864812|NCT01060475|Drug|Placebo LIM-0705 and tacrolimus|Placebo oral solution BID for 14 days plus tacrolimus BID for the first 8 days.
1864813|NCT01060475|Drug|Drug LIM-0705 and placebo tacrolimus|Oral solution, LIM-0705 750 mg BID for 14 days plus placebo capsule BID for the first 8 days.
1864814|NCT01060488|Other|GHRH+Arg, GHRH+Arg, ITT|GHRH+Arg repeatability test (2 tests) + comparison with one IT test
1864815|NCT01060488|Other|ITT, ITT, GHRH+Arg.|IT repeatability test (2 tests) + comparison with one GHRH+Arg test
1864816|NCT01060501|Drug|Folinic Acid, interferon-alpha|5-FU, 450 mg/m² i.v. for 60 min, weekly for 52 weeks postoperatively Folinic acid, 200 mg/m² i.v. 10 min, weekly for 52 weeks postoperatively 6x10 (high6) I.U. as subcutaneous self injection 3x weekly. Training of self injection was initiated on day 28 (duration until week 52)
1864817|NCT01060514|Drug|Pazopanib|dose escalation, administered orally, daily
1864818|NCT01060514|Drug|Vinorelbine|dose escalation, IV days 1 and 8 of every cycle (cycles begin every 3 weeks)
1864819|NCT01060540|Genetic|genetic testing for type 2 diabetes|TCF7L2, PPARG, or KCNJ11
1864820|NCT01060540|Behavioral|Conventional risk counseling|Risk based on lifetime risk, fasting plasma glucose results, and family history.
1864821|NCT01060540|Behavioral|eye disease counseling|addresses risk for age-related macular degeneration, glaucoma, cataracts
1864822|NCT01060553|Other|Acupuncture treatment|This project was initially designed as a randomized trial with one group receiving treatment and the other wait list control, with delayed treatment. Due to extremely high dropout and cancellations and failure to return for post assessment, a midpoint assessment was added. Analysis was done on pre and post measures of all subjects who completed at least the midpoint assessment. Due to the very small number of subjects in the wait list control, the ones who completed 6 or 12 weeks of acupuncture after the wait list were combined with the few who completed the initial acupuncture for a pre-post single group analysis. for those who completed both the 6 and 12 week measures, the latest one was selected for analysis
1864823|NCT01060566|Drug|VX-770|In period 1, subjects will receive a single oral dose of midazolam (2 mg) and on Day 1 and Day 8. Subjects will receive single oral dose of rosiglitazone 4 mg and on Day2 and Day 9. Subjects will receive multiple doses of VX-770 150 mg q12h Day 3-10.
1864824|NCT01060566|Drug|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from Day 1 through the morning of Day 8. On the morning of Period 2 Day 1, subjects will receive a 400 mg loading dose of fluconazole. Thereafter, subjects will receive 200 mg fluconazole qd orally from Day 2 through Day 9.
1864825|NCT01060579|Drug|AR-12286 0.5% ophthalmic solution|q.d. PM
1864826|NCT01060579|Drug|AR-12286 0.25% Ophthalmic solution|q.d. PM
1864827|NCT01060579|Drug|Latanoprost ophthalmic solution|q.d. PM
1864828|NCT01060592|Device|EndoFLIP device (FDA Device Listing Number : D091203)|The EndoFLIP balloon catheter will be introduced to the band and used to permit the band stoma size to be adjusted to 7mm.
1864829|NCT01060605|Drug|rapamycin|Pre-transplant rapamycin is administered for at least four weeks prior to the first islet infusion at the dose of 0.1 mg/kg (target trough levels: 8-10 ng/mL).
1864830|NCT01060618|Other|Maraviroc + Trofile ESTA® (diagnose test)|The Trofile ESTA® will be performed in those patients and once the results are obtained (within one month approximately), the patients will be treated with the medication Maraviroc
1864831|NCT01060631|Device|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
1864832|NCT01060631|Device|BIS values at return of consciousness in patients + predicted and measured propofol plasma concentrations|Difference between left- and rightsided BIS values in patients with supratentorial brain tumor during course and Comparison between predicted and measured propofol plasma concentrations during course of the study
1864833|NCT01060670|Device|Integra® Dermal Regeneration Template|Application of Integra® Dermal Regeneration Template in diabetic foot ulcer
1864834|NCT01060670|Other|Conventional Wound Therapy|Conventional Wound Therapy
1864835|NCT01060683|Biological|Hemoglobin determination + NaCl 0.9% bolus|
1864836|NCT01060683|Biological|hemoglobin determination + Venofundin bolus|
1864837|NCT01060696|Drug|Mefenamic acid or Hyoscine or placebo|Mefenamic acid 500 mg. single oral use 30 minutes before SIS Hyoscine 10 mg. single oral use 30 minutes before SIS Placebo single oral use 30 minutes before SIS
1864838|NCT01060722|Drug|MOD-4023 (long lasting hGH)|Single subcutaneous dose of MOD-4023
1864839|NCT01060722|Drug|Placebo|Single subcutaneous dose of placebo material
1864840|NCT01060735|Dietary Supplement|Vitamin D|Vitamin D 2000iu/ day from the 27 week of pregnancy up to delivery
1864841|NCT01060748|Biological|ACE527|ACE527 comprises a mixture of three live, attenuated ETEC strains; ACAM2025 (CFA/I+ and LTB+), ACAM2022 (CS5+, CS6+ and LTB+), and ACAM2027 (CS1+, CS2+, CS3+ and LTB+). The vaccine is administered orally as a two-dose regimen, at 9x1010 cfu, on Days 0 and 21, in 200 ml CeraVacx buffer. The required volume of each vaccine strain, supplied as a frozen suspension, is mixed into the buffer solution prior to dosing.
1864842|NCT01060748|Biological|Placebo|Placebo
1864843|NCT01060761|Behavioral|Rehabilitation program|"Patient and their relative receive three supportive, structured conversation with a trained nurse.
Patient and their relative receive 4 days Retreat Weekend with supportive talk and activities"
1864846|NCT01060787|Procedure|Fluocinolone Acetonide 0.59 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
1864847|NCT01060787|Procedure|Fluocinolone Acetonide 2.1 mg|At a single visit bilateral endothelial microscopy will be performed to determine endothelial cell density.
1864848|NCT01060813|Dietary Supplement|Leucine supplements|leucine supplements
1864849|NCT01060826|Other|fisiologic serum|250 microgramos bolus intravenous during 3 minutes and continuous infusion for 4 hours after endoscopic procedure
1864850|NCT01060826|Drug|somatostatin, intravenous bolus|250 microgramos bolus intravenous in 3 minutes and continuous infusion for 4 hours after endoscopic
1864851|NCT01060826|Drug|somatostatin|Intravenous bolus 250 micrograms
1864852|NCT01060839|Behavioral|Single session counseling|For index cases assigned to the counselling arm, a same sex counselor conducted 10-15 minutes individualized sessions. Counselors were specifically trained to deliver partner referral counselling focusing on five issues related to STI prevention and transmission: (1) risk of re-infection if partners are not treated concurrently; (2) risk of developing complications; (3) risk of further spread of infection in the community; (4) the asymptomatic nature of infection; and (5) social obligations and personal coping with an STI.
1864853|NCT01060852|Behavioral|Media Detective|10-lesson elementary school, media literacy education, substance use prevention program. Each lesson takes approximately 45 minutes to teach and was taught every school day for 2 weeks.
1864854|NCT01060865|Drug|Aliskiren|150 mg during the first two weeks , 300 mg for another 10 weeks
1864855|NCT01060878|Drug|PYM50028|IMP
1864856|NCT01060878|Drug|Placebo|Matching placebo comprising identical vehicle to active doses
1864857|NCT01060891|Drug|colimycin|
1864858|NCT01060904|Drug|brentuximab vedotin|0.6-1.2 mg/kg IV every 2 weeks
1864859|NCT01060904|Drug|doxorubicin|25 mg/m2 IV every 2 weeks
1864860|NCT01060904|Drug|vinblastine|6 mg/m2 IV every 2 weeks
1864861|NCT01060904|Drug|dacarbazine|375 mg/m2 IV every 2 weeks
1864862|NCT01060904|Drug|bleomycin|10 units/m2 IV every 2 weeks
1864863|NCT01060904|Drug|brentuximab vedotin|0.9-1.2 mg/kg IV every 2 weeks
1864864|NCT01060917|Device|Non-invasive CGMS (continuous glucose monitoring system)|A non-invasive continuous glucose monitoring device measure was applied at the wrist and measure skin glucose as an indirect measure of blood glucose every 10 min.
1864865|NCT01060917|Procedure|Hyperglycemic and hypoglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (300 mg/dL) for 1.5 h, and euglycemia (100 mg/dL) for another 1.5 h. A continuous somatostatin infusion was initiated after the 2 h run-in period to suppress endogenous insulin secretion. A glucose solution was infused to increase blood glucose towards the hyperglycemic target level. At the end of the hyperglycemic level the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level. On a second study day a hypoglycemic clamp took place, where blood glucose after the run-in period of 2 h was lowered by means of intravenous insulin administration over a period of appr. 30 min to a hypoglycemic level of 45 mg/dL, where it was kept constant for appr. 30 min, after which blood glucose was raised to euglycemia (100 mg/dL) again by means of an intravenous glucose infusion and was kept there for 1.5 hours. .
1864866|NCT01060917|Device|Non-invasive CGMS (GlucoDay)|The minimally-invasive glucose sensor GlucoDay, was used as a control measure
1865115|NCT01055301|Drug|doxorubicin hydrochloride|
1864867|NCT01060930|Drug|Intravenous infusion of L-NMMA and Nor-epinephrine|Intravenous infusion of 3mg/kg L-NMMA (L-NG-monomethyl arginine; NO synthase inhibitor) and nor-epinephrine at 50 ng/kg/min. Each infusion to run over 15 mins and separated by 45 min to allow return to baseline. Drugs infused in a randomised order. During the study, blood pressure will be measured invasively using an intra-arterial radial artery cannula, central arterial stiffness measured using peripheral arterial tonometry and cardiac output using thoracic bioimpedance.
1959926|NCT03311711|Behavioral|Usual care|At the time of the diagnosis of a dementing illness, an advanced practice nurse provides written information on advance directives to a patient and his/her family caregiver and reviews this information and encourages them to complete an advanced directive. This typically takes about 10 minutes. Patients and their family members may be referred to attorneys who can assist them in completing an advance directive. If completed, the presence of an advanced directive is documented in the electronic medical record and a copy of the advance directive is scanned to the electronic chart. Patients and families may be referred to a support group program organized by a social worker in which legal and financial issues are discussed in a group setting (by a lawyer).
1959927|NCT03311698|Behavioral|Nutrition-sensitive intervention|Nutrition-sensitive intervention using behavior change communication on home gardening, diet, nutrition, WASH, and women's empowerment.
1864870|NCT01060956|Other|reporting of two different bacteria in urine culture|reporting of two different bacteria in urine culture
1864871|NCT01060956|Other|"reporting mixed growth on urine culture"|"reporting mixed growth on urine culture"
1864872|NCT01060969|Drug|Tadalafil and acetazolamide|Experimental arm: Tadalafil 20 mg daily + acetazolamide 125 mg BID beginning above 3000 m altitude.
1864873|NCT01060969|Drug|Acetazolamide|Active comparator arm (control): acetazolamide 125 mg BID beginning above 3000 m altitude
1864874|NCT01060982|Device|Ultrasonic ablation device|One High Intensity focused ultrasound session before surgery. Use of appropriate energy for each patient
1864875|NCT01061008|Other|Post operative progressive handgrip exercise|As soon as possible post operation the patient will commence an eight week progressive handgrip training intervention
1864876|NCT01061008|Other|Treatment as usual|Continue routine care, with removal of exercise information given to patients(if anye.g. do not give out squeeze balls)
1864877|NCT01061021|Behavioral|In The Mix|Five small group + 2 individual counseling intervention designed to addresses HIV transmission risk behavior and HIV treatment adherence in men and women living with HIV/AIDS.
1864878|NCT01061021|Behavioral|Information Support Group|Five small group + 2 individual counseling session intervention that serves as an attention control group. Content included stress reduction, nutrition, and exercise for health improvement.
1864879|NCT01061034|Drug|aspirin and omeprazole|aspirin 100 mg, once daily aspirin 100 mg and omeprazole 20 mg both once daily.
1864880|NCT01061047|Drug|Ertapeneme|
1864881|NCT01061060|Drug|Prostaglandin I2|oral
1864882|NCT01061060|Drug|Placebo|oral
1864883|NCT01061073|Drug|Omexel|
1864884|NCT01061073|Drug|spasfon|
1864885|NCT01061099|Biological|Mesenchymal Stromal Cells|Both cohorts will receive multiple infusions of ex-vivo expanded MSCs. Stratum A may use previously harvested and cryopreserved bone marrow mononuclear cells from original BMT donor or freshly harvested or cryopreserved bone marrow mononuclear cells obtained from a haploidentical healthy parent or sibling. Stratum B will only receive freshly harvested or cryopreserved bone marrow
1864886|NCT01061112|Genetic|Pharmacogenetics|Fluconazole, tolbutamide, ketoprofen, flurbiprofen
1864887|NCT01061125|Other|TTM and Holter monitor|Standard of care visits recordings reviewed during clinical visits
1959929|NCT03311672|Drug|[18F]F-Ara-G|Administered after two cycles of immunotherapy +/- stereotactic radiation therapy as part of the PET/CT scan.
1959930|NCT03311672|Drug|Pembrolizumab|All study participants will receive pembrolizumab every 3 weeks, for 2 cycles.
1959931|NCT03311672|Radiation|PET/CT scan|Scan will be done after two cycles of immunotherapy +/- stereotactic radiation therapy.
1959932|NCT03311659|Biological|Boostrix|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
1864893|NCT01061177|Drug|Nilotinib|Nilotinib was supplied by Novartis as 150 mg hard gelatin capsules in bottles. Nilotinib was dosed on a flat scale and not dosed by body weight. This form of supply was continued for all participants entered into the core study.
1864894|NCT01061190|Drug|Propranolol|oral application of 160 mg Propranolol for 30 days
1864895|NCT01061203|Drug|Grazax|Treatment with 75.000 SQ-T once daily
1864896|NCT01061203|Drug|Placebo|Tablet with no active grass component.
1864897|NCT01061216|Device|Intradermal insulin delivery: BD Research Catheter Set|1 unit/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered) 2 units/hr rapid acting insulin delivered intradermally for 6 hours 4 hour washout period (no insulin delivered)
1864898|NCT01061216|Device|Subcutaneous insulin delivery:ACCU-CHEK Rapid-D Infusion Set|1 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered) 2 unit per hour of rapid acting insulin infusion for 6 hours 4 hour washout (no insulin delivered)
1959936|NCT03311620|Procedure|Endobronchial ultrasound (EBUS) transbronchial needle aspirate (TBNA)|Biopsy samples will be collected from patients scheduled to undergo EBUS TBNA using 19g and 22g needles
1959937|NCT03311607|Drug|AmBisome|A total dose of 15 mg/kg AmBisome given in doses of 3 mg/kg in a biweekly dosing schedule
1864899|NCT01061229|Drug|Homeopathic drug C12|Subjects in the intervention group are instructed to take five globules of the trial drug (potency C12), five times per day for a maximum of five days (5×5×5). The study medication is obtained from DHU (Germany), produced according to the Hahnemannian method. Subjects are asked to stop taking the medication, in agreement with their investigator, if they experience any of a predefined set of proving symptoms
1864900|NCT01061229|Other|Placebo|Placebo consists of pure sucrose globules (DHU, Germany) that are not potentiated nor impregnated with alcohol. The administration scheme is identical in the placebo control group to that of the intervention group.
1864901|NCT01061242|Behavioral|Sleep promoting interventions|MICU staff will implement multi-faceted, staged sleep promoting interventions as part of a pre-existing sleep quality improvement project.
1864902|NCT01061255|Other|Evaluation of the stress|"Medical Students having to solve a medical problem in ambulatory setting (studied group) vs. in hospitalisation setting (control group).
Measures: The French version of the Anxiety Spielberger test is administered just before and after each problem solving session.
Cortisol salivary samples are taken before and after each problem solving session. Salivary cortisol levels have been shown to be correlated to stressful situations and some personality traits but with some difference according to gender."
1864903|NCT01061268|Drug|No topical artificial tear|40 patients randomized to not using a topical artificial tear.
1864904|NCT01061268|Drug|Blink® Tears Lubricant Eye Drops|Blink® Tears Lubricant Eye Drops
1864905|NCT01061281|Device|Tecnis MF IOL|20 patients enrolled with the Tecnis MF IOL.
1864906|NCT01061281|Device|Crystalens AO IOL|20 patients enrolled with the Crystalens AO
1864907|NCT01061294|Procedure|Advanced CustomVue™ iLASIK procedure|
1864908|NCT01061294|Device|WaveScan WaveFront® System, STAR S4 IR™ Excimer Laser System and IntraLase™ FS System|
1864909|NCT01061307|Dietary Supplement|fortified extruded rice|fortified extruded rice (Fe, Zn and vitamin A) at the ratio 1:50 with normal rice
1864910|NCT01061320|Drug|alpha tocopherol|The patients were assigned to receive oral alpha tocopherol (525 IU) every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
1864911|NCT01061320|Drug|placebo|The patients were assigned to receive oral placebo every day start at five day before procedure, in the morning before procedure and 24 hr post-coronary procedure.
1864912|NCT01061333|Drug|Nedocromil|Nedocromil 4 mg, as metered dose inhaler 1 hour prior to allergen challenge
1864913|NCT01061333|Drug|Comparator: Montelukast|Montelukast single 10 mg tablet administered 2 hours prior to allergen challenge
1864914|NCT01061333|Drug|Comparator: Mometasone|Mometasone furoate 400 mcg by twisthaler, administered 2 hours prior to allergen challenge
1864915|NCT01061333|Drug|Placebo|Mometasone placebo twisthaler, Nedocromil placebo metered dose inhaler, Montelukast placebo tablet
1864916|NCT01061346|Other|40% Fat Diet, 20% Fructose Beverage|40% fat, 45% carbohydrate (with 20% fructose beverage), 15% protein
1864917|NCT01061346|Other|20% Glucose Beverage|40% fat, 45% carbohydrate (with 20% glucose beverage), 15% protein
1864918|NCT01061346|Other|20% Glucose Beverage|20% fat, 65% carbohydrate (with 20% glucose beverage), 15% protein
1864919|NCT01061359|Drug|Epirubicin: Observational Study|Observational: Chemotherapy
1864920|NCT01061372|Drug|Placebo|Placebo, orally administered once a day, 1-3 hours before bedtime for 12 weeks
1864921|NCT01061372|Drug|pregabalin|pregabalin 150 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
1864922|NCT01061372|Drug|pregabalin|pregabalin 300 mg, orally administered once a day, 1- 3 hours before the bedtime for 12 weeks
1864923|NCT01061385|Device|ReShape Intragastric Balloon|Placement of ReShape Medical Intragastric Balloon for twenty four weeks
1864924|NCT01061385|Other|Control Arm|Behavioral Modification (Diet and exercise counseling) alone
1864925|NCT01061398|Procedure|Cardiac CT Angiography|Patients randomized to CT Arm will undergo 64-slice cardiac CT angiography (single scan) in addition to the stress imaging test ordered by their physician
1864926|NCT01061398|Procedure|Stress Imaging Test (Stress Myocardial Perfusion Study or Stress Echocardiogram)|Stress imaging test as ordered by the subjects provider without option for cardiac CT angiography (no CT arm)
1864927|NCT01061411|Drug|Dalteparin|Given SC
1864928|NCT01061411|Other|Pharmacological Study|Correlative studies
1864929|NCT01061411|Drug|Sunitinib Malate|Given PO
1864930|NCT01061424|Behavioral|community health worker|community health worker provides home visits for education
1864931|NCT01061424|Behavioral|mailed information|information on asthma is mailed to the home on the same schedule as the other arm
1864932|NCT01061437|Drug|PACx14|Standard 14 day, 3 drug regimen: lansoprazole, amoxicillin, clarithromycin (PACx14)
1864933|NCT01061437|Drug|PACMx5|Concomitant therapy - 5 day, 4 drug regimen: lansoprazole, amoxicillin, clarithromycin, metronidazole (PACMx5)
1864934|NCT01061437|Drug|PAx5/PCMx5|Sequential Therapy - 10 day, 4-drug regimen: lansoprazole, amoxicillin for 5 days, followed by lansoprazole, clarithromycin and metronidazole for 5 days (PAx5/PCMx5)
1864935|NCT01061450|Drug|Simvastatin|80 mg once a day
1864936|NCT01061450|Drug|Placebo|1 pill once a day
1864937|NCT01061476|Device|Treatment sleep study (Provent™ device used)|The patient's sleep apnea severity is determined on this night while using the Provent™ device. The patient only uses the Provent™ device on this night (single night use only).
1864938|NCT01061476|Other|Baseline sleep study (No device)|The patient sleeps for 1 night in the sleep lab to determine their baseline sleep apnea severity without sleeping with the Provent device.
1864939|NCT01061476|Other|Physiology sleep study (Provent™ on/off)|During this sleep study night, the patient is sleeping with a modified Provent™ device that can be turned on and off to assess changes in airflow during the night (single night use only).Provent™ on/off is bracketed in 10 minute intervals during stable stage 2 sleep.
1864940|NCT01061489|Other|auditory discrimination training|10-week neuroplasticity-based training (5 days/week, 1 hour each, PC-based), training at home
1864941|NCT01061489|Other|physical movement training|10-week training, small groups (2 days/week, 1 hour each) plus homework (3 days/week)
1864942|NCT01061502|Device|Procellera (Bioelectric Wound Dressing)|Dressing used on one-half of the donor graft site. Dressing changes every 5-7 days, more frequently if needed
1865116|NCT01055301|Drug|etoposide|
1864943|NCT01061502|Device|Opsite (Transparent Adhesive Dressing)|Semi-occlusive wound dressing placed on one-half of the skin graft donor site. Dressing change every 5-7 days, more frequently if needed.
1864944|NCT01061515|Drug|Intraperitoneal Oxaliplatin|
1864945|NCT01061515|Drug|Bevacizumab|
1864946|NCT01061515|Drug|Capecitabine|
1864947|NCT01061528|Drug|Transdermal Nicotine|Participants will use the full strength 21mg. patch for 4 weeks, will taper to the 14 mg. patch for the next 2 weeks, and then to the 7 mg. patch for the remaining 2 weeks of treatment.
1864948|NCT01061541|Biological|Tritanrix™-HepB low thio /|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
1864949|NCT01061541|Biological|Hib 2.5|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
1864950|NCT01061541|Biological|Tritanrix™-HepB|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
1864951|NCT01061541|Biological|Hiberix™|One dose as intramuscular injection at 6, 10 and 14 weeks of age.
1864952|NCT01061541|Biological|Unconjugated Hib vaccine (plain PRP)|One dose as intramuscular injection at 10 months of age
1864953|NCT01061554|Dietary Supplement|Omega-3 oils from tri-glycerides|Single-dose administration of approximately 5 grams of omega-3 oils from triglycerides
1864954|NCT01061554|Dietary Supplement|Omega-3 oils from marine phospholipids|Single-dose administration of approximately 5 grams of omega-3 oils from marine phospholipids
1864955|NCT01061580|Device|Harvest SmartPReP2 BMAC System|Injection of 10, 15, or 20 cc of BMAC
1864956|NCT01061593|Dietary Supplement|Immunoxel|1 lozenge once per day
1864957|NCT01061593|Other|Placebo|1 lozenge once per day
1864958|NCT01061606|Drug|temsirolimus|Given IV
1864959|NCT01061632|Procedure|High intensity motor control exercise (deadlift)|12 treatment sessions over a 8 week period is planned for the high intensity motor control exercise.
1864960|NCT01061632|Procedure|Low intensity motor control exercise|12 sessions of low intensity motor control exercises over 8 weeks
1864961|NCT01061645|Drug|MOC31-PE|Immunotoxines
1864962|NCT01061658|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Higher dosage of vaccine
1864963|NCT01061658|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine|Lower dosage of vaccine
1864964|NCT01061658|Other|Placebo|Placebo
1864967|NCT01061697|Drug|Pregabalin|At week 0, pregabalin 75mgbd will be given for 1 month. If visual analogue scale is not reduced by 50% after 1 month, pregabalin will be increased to 150mgbd for the second month
1864968|NCT01061710|Drug|varenicline|Dosage form: tablet 0.5mg, tablet 1mg. The usual adult dosage for oral use is 0.5 mg once daily after eating on Days 1 to 3; 0.5 mg twice daily after eating in the morning and evening on Days 4 to 7, and 1 mg twice daily after eating in the morning and evening on Day 8 and thereafter. The drug should be administered to subjects for 12 weeks.
1864969|NCT01061723|Drug|Sarilumab|"Pharmaceutical form: Solution for injection
Route of administration: Subcutaneous"
1864970|NCT01061723|Drug|Placebo|"Pharmaceutical form: Solution for injection
Route of administration: Subcutaneous"
1864971|NCT01061736|Drug|Sarilumab|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1864972|NCT01061736|Drug|Placebo (for sarilumab)|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1864973|NCT01061736|Drug|Methotrexate|Same weekly dose as received prior to enrollment
1864974|NCT01061736|Drug|Folic Acid|According to local standard
1864975|NCT01061749|Biological|Cixutumumab|Given IV
1864976|NCT01061749|Other|Laboratory Biomarker Analysis|Correlative studies
1864977|NCT01061749|Other|Pharmacological Study|Correlative studies
1864978|NCT01061749|Drug|Selumetinib|Given PO
1864979|NCT01061762|Behavioral|Stick To It|3-counseling session adherence intervention tailored for people with poor literacy skills
1864980|NCT01061762|Behavioral|Standard medication adherence counseling|3 counseling sessions for adherence improvement derived from standard behavioral approaches.
1864981|NCT01061762|Behavioral|Health Counseling|3-session of health improvement counseling to serve as an attention control.
1864982|NCT01061775|Drug|Exenatide|5mcg twice a day for 4 weeks increased to 10 mcg twice a day for 20 weeks.
1864983|NCT01061788|Drug|AMG 479, Everolimus, Panitumumab|"Dose Escalation Cohort #, Subjects, Everolimus, AMG 479
3-6 subjects, Study drug administered per dose level
3-6 subjects, Study drug administered per dose level
Expanded Cohort Subjects, Everolimus, AMG 479 20 subjects, study drug administered per dose level
Dose Escalation, Cohort #, Subjects, Everolimus, AMG 479, Panitumumab
3-6 subjects, Study drug administered per dose level
3-6 subjects, Study drug administered per dose level
Expanded Cohort Subjects, Everolimus, AMG 479, Panitumumab 20 subjects, Study drug administered per dose level
NSCLS Cohort Subjects, Everolimus, AMG 479, 20 subjects, Study drug administered per dose level"
1864984|NCT01061801|Behavioral|Emotional expression|Caregivers are given the opportunity to express their thoughts and feelings regarding the patient's transplant and their role as caregiver
1864985|NCT01061814|Drug|mipomersen|30 mg (cohort A), 70mg (cohort B) or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
1864986|NCT01061814|Drug|Placebo|30 mg (cohort A), 70mg (cohort B), or 200mg (cohort C) subcutaneous (SC) dose of study drug daily for 3 weeks
1864987|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
1864988|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
1864989|NCT01061840|Biological|Vigil™|Patients will be treated once a month as long as sufficient material is available for up to 12 doses
1864990|NCT01061853|Drug|TOPICAL SIROLIMUS (RAPAMUNE*)|APPLICATION ON THE LESIONS OF TOPICAL SIROLIMUS (RAPAMUNE*)1mg/ml bid during 3 months
1864991|NCT01061853|Drug|TOPICAL BETAMETHASONE 0.05%|APPLICATION ON THE LESIONS OF TOPICAL BETAMETHASONE (DIPROLENE*)0.05% bid during 3 months
1864992|NCT01061866|Drug|3-phthalimidoglutarimide (Thalidomide)|Thalidomide at 200 mg dosage bid was administered during a twelve month period.
1864993|NCT01061905|Behavioral|Calorie information|Posting of Calorie information for sugar-sweetened and zero-calorie beverages
1864994|NCT01061905|Behavioral|Exercise Equivalent only|Posting of only exercise equivalents (e.g. 45 minutes on a treadmill) for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
1864995|NCT01061905|Behavioral|Calorie & Exercise equivalent information|Posting of both calorie and exercise equivalents information for both sugar-sweetened and zero-calorie beverages, prominently on a poster.
1864996|NCT01061918|Device|Tecnis MF|20 patients in the Tecnis MF group.
1864997|NCT01061918|Device|ReSTOR|20 patients in the ReSTOR group.
1864998|NCT01061931|Procedure|Arctic Front® catheter vs. HD Mesh Ablator® catheter|Pulmonary vein ablation in patients with symptomatic paroxysmal atrial fibrillation using the Arctic Front® catheter versus the HD Mesh Ablator® catheter
1864999|NCT01061970|Drug|Fispemifene|once daily for 4 weeks
1865000|NCT01061983|Device|Medtronic Activa Deep Brain Stimulation|In DBS, thin wires are used to carry electric current to the parts of the brain involved in OCD symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
1865001|NCT01061996|Drug|Basiliximab|Study Drug: basiliximab 40 mg, given as a short intravenous infusion Dosing Schedule: once every 4 weeks Concomitant Therapy: Oral corticosteroids (prednisone or equivalent) will be tapered during the first few months of the study participation Duration of Study Participation: The duration of individual study participation will vary.
1865003|NCT01062022|Behavioral|Standard of Care|Families randomized to this arm will receive the standard of care. They will be compared to the families in the FOCUS-CI arm of the study.
1865004|NCT01062022|Behavioral|FOCUS-CI|Families randomized to this arm of the study will be part of a family skill-building/resiliency training program designed to provide information and skills training
1865005|NCT01062048|Drug|Sitagliptin|Sitagliptin phosphate monohydrate 25 mg, 50 mg, or 100 mg tablet administered in general use according to the local label
1865006|NCT01062048|Drug|Sulfonylurea|Sulfonylurea administered in general use according to the local label
1865007|NCT01062048|Biological|Insulin|Insulin administered in general use according to the local label
1865008|NCT01062061|Biological|VARIVAX™|Attenuated live varicella vaccine
1865009|NCT01062087|Drug|Bupivacaine, Lidocaine|Injection at surgical port site of 0.25% Bupivicaine, 2.5 mg/mL NaCl solution and/or application of Lidocaine HCl jelly 2% aqueous, up to 5 mL
1865010|NCT01062100|Device|nuclear breast imaging using MBI Gamma camera|nuclear breast imaging using MBI Gamma camera in addition to MRI
1865011|NCT01062113|Drug|Celecoxib|"Initial dose: Celecoxib 200mg tablet x 2 will be administrated during a period from 1 to 2 hours post lateral mandibular impacted third molar tooth extraction in subjects with moderate pain or severe painrated as 45.0 mm or more on the VAS"
1865012|NCT01062113|Drug|Celecoxib|Additional dose: Celecoxib 200mg tablet x 1 will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
1865013|NCT01062113|Drug|Placebo|Additional dose: Placebo (tablet) will be administrated during a period from 5 to 12 hours post-initial dose of Celecoxib 400mg in subjects who require an additional analgesic dose for any pain
1865014|NCT01062139|Drug|Xarlin (Levocetirizine)|Combination therapy compared to mono therapy
1865015|NCT01062139|Drug|Cosalin (Petasites hybridus CO2 extract)|Combination therapy compared to mono therapy
1865016|NCT01062152|Drug|Ezatiostat Hydrochloride|Starting dose 2000 mg orally in divided doses twice daily (1000 mg in AM & 1000 mg in PM) x 21 days with one week off therapy in a 4-week cycle.
1865017|NCT01062152|Drug|Lenalidomide (Revlimid®)|10 mg orally per day in one AM dose x 21 days with one week off therapy in a 4-week cycle.
1865018|NCT01062165|Drug|Caspofungin|Caspofungin 70mg IV (each volunteer will only receive one dose of the study drug)
1865019|NCT01062178|Drug|Definity|Definity is the contrast agent which is going to be injected in a bolus and infusion forms during the ultrasound performance.
1865020|NCT01062191|Device|Aquacel AG, typical carboxymethylcellulose dressing|"4 X 4, Aquacel silver sheet"
1865021|NCT01062191|Device|Altrazeal Flexible Hydrogel Nanoparticle Wound Dressing|Wound dressing
1865022|NCT01062204|Device|Altrazeal|Sterile, odorless, crystalline white powder consisting of flakes of freeze dried HEMA and HPMA polymers. For application, the powder is distributed to the surface of the wound or burn where it forms a moist, flexible film and adheres to the surface of the wound.
1865023|NCT01062204|Device|Aquacel Ag|Textile fiber made from sodium carboxy-methylcellulose containing 1.2% silver in ionic form.
1865024|NCT01062230|Drug|Bortezomib (Velcade)|"Bortezomib will be administered as a 3-5 second bolus IV injection at the dose of 0.7 mg/m2 on days 1, 4, 8, and 11 q. 21 days times three cycles.
Patients will undergo three 21-day cycles."
1865025|NCT01062243|Behavioral|Brain Injury Education|The Brain Injury Inpatient Guide for Families and Caregivers (BIIG-FACS), developed by J. Niemeier and J. Kreutzer, is a comprehensive intervention to meet the needs of family members and significant others of patients who are undergoing acute brain injury rehabilitation.
1865026|NCT01062256|Drug|Placebo|One placebo tablet administered orally as a single dose
1865027|NCT01062256|Drug|Guaifenesin|One 400 mg immediate release tablet administered orally as a single dose
1865028|NCT01062256|Other|Buckwheat Honey|10 mL administered orally as a single dose
1865029|NCT01062269|Drug|Cholestyramine|Cholestyramine 4 grams one time dose
1865030|NCT01062269|Drug|Cholestyramine|Cholestyramine 12 grams one dose, one day
1865031|NCT01062269|Drug|Tang|Tang one dose one day
1865032|NCT01062282|Drug|Iloprost (Ventavis BAYQ6256)|Patients with pulmonary arterial hypertension, classified as New York Heart Association functional class III or IV where the treating physician has chosen Ventavis as a suitable treatment prior to inclusion into this non-interventional study. Patients should not have received prior treatment with Ventavis
1865033|NCT01062295|Device|Siesta-System|
1865034|NCT01062295|Device|Standard headrest|
1865035|NCT01062308|Procedure|Taping and Sham Taping|"Taping shoulder with Hospiplast tape.
Taping the shoulder after acute stroke to prevent shoulder injury and pain.
Taping the shoulder after acute stroke and compare with sham taping group.
Treatments:
Positioning technique
Handling technique
Range of motion exercises
Taping technique"
1865036|NCT01062308|Procedure|Sham Taping|Shoulder Taping for 14 days which will be changed after every 3 days.
1865037|NCT01062334|Procedure|Peritoneal Microdialysis, CT-scan, leakage scoring|Peritoneal microdialysis CT-scan before discharge Leakage scoring daily
1865038|NCT01062347|Biological|Zinc|
1865039|NCT01062360|Drug|Acetylsalicylic Acid (Aspirin Complex, BAYE4465) + Pseudoephedrine|Single oral dose of 1 to 2 Aspirin Complex sachets, each containing granules of 500 mg Acetylsalicylic Acid (ASA) and 30 mg Pseudoephedrine (PSE), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
1865040|NCT01062360|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of 1 to 2 sachets Acetylsalicylic Acid, each containing granules of 500 mg Acetylsalicylic Acid (ASA), to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
1865041|NCT01062360|Drug|Pseudoephedrine|Single oral dose of 1 to 2 sachets Pseudoephedrine, each containing granules 30 mg Pseudoephedrine, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
1865042|NCT01062360|Drug|Placebo|Single oral dose of 1 to 2 sachets, each containing Placebo granules, to be taken orally after dissolving in a glass of water; to be repeated as needed every 6 hours for a period of not more than 3 days.
1865043|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by TG-DHA from Decola (products from Martek) (two soft capsules per day)
1865044|NCT01062373|Dietary Supplement|Supplementation of lactating mothers who has delivered prematurely with DHA|Supplementation in DHA will be conducted for 1 month at the dose of 200 mg DHA per day provided by GPL-DHA from ASL (10 g per day) (two soft capsules per day)
1865045|NCT01062399|Drug|everolimus|Given orally
1865046|NCT01062399|Drug|temozolomide|Given orally
1865047|NCT01062399|Radiation|3-dimensional conformal radiation therapy|Given 5 days a week for 6 weeks
1865048|NCT01062399|Radiation|intensity-modulated radiation therapy|Given 5 days a week for 6 weeks
1865053|NCT01062438|Genetic|DNA analysis|
1865054|NCT01062438|Genetic|RNA analysis|
1865055|NCT01062438|Genetic|gene expression analysis|
1865056|NCT01062438|Genetic|gene rearrangement analysis|
1865057|NCT01062438|Genetic|mutation analysis|
1865058|NCT01062438|Other|laboratory biomarker analysis|
1865059|NCT01062451|Drug|Perindopril|8 mg taken orally from days 0 through 7.
1865060|NCT01062451|Drug|Placebo|Placebo treatment daily.
1865061|NCT01062451|Drug|Candesartan|16 mg taken orally from days 0 through 7.
1865062|NCT01062477|Biological|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
1865063|NCT01062477|Biological|DTaP//PRP-T Combined Vaccine|0.5 mL, Intramuscular
1865064|NCT01062477|Biological|DTaP Combined Vaccine and PRP-Tetanus Conjugate Vaccine|0.5 mL, Intramuscular (each vaccine)
1865065|NCT01062490|Drug|Treosulfan|14 g/m2/d, day -6 to -4
1865066|NCT01062503|Drug|Zoledronic acid|ZA at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
1865067|NCT01062516|Drug|esomeprazole 20 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
1865068|NCT01062516|Drug|famotidine 40 mg daily|oral famotidine 40 mg daily vs. oral esomeprazole 20 mg daily for 28 days
1865069|NCT01062529|Drug|Somatostatin|4 h of 150 microgram infusion
1865070|NCT01062542|Procedure|Blood Draw and Ultrasound|Patients will have a Blood sample taken to check hormone levels. Patients will also have an ultrasound test done to examine the ovaries. The ultrasound test is done by inserting a cylindrical probe into the vagina. The test has to be done this way to measures the ovaries accurately.
1865071|NCT01054937|Drug|4SC-203|i.v. administration
1865072|NCT01054937|Drug|Placebo|i.v. administration
1865073|NCT01054950|Behavioral|Counseling|Our food allergy nurse will contact our intervention group and discuss any questions or concerns they may have regarding their child's food allergy.
1865074|NCT01054950|Behavioral|Placebo phone call|Phone call w/ no behavioral counseling
1865117|NCT01055301|Drug|lenalidomide|
1865118|NCT01055301|Drug|melphalan|
1865119|NCT01055301|Drug|thalidomide|
1865120|NCT01055301|Genetic|gene expression analysis|
1865121|NCT01055301|Genetic|microarray analysis|
1865122|NCT01055301|Other|laboratory biomarker analysis|
1865123|NCT01055301|Procedure|autologous-autologous tandem hematopoietic stem cell transplantation|
1865124|NCT01055314|Biological|Cixutumumab|Given IV
1865125|NCT01055314|Drug|Cyclophosphamide|Given IV
1865126|NCT01055314|Biological|Dactinomycin|Given IV
1865127|NCT01055314|Drug|Doxorubicin Hydrochloride|Given IV
1865128|NCT01055314|Drug|Etoposide|Given IV
1865075|NCT01054963|Behavioral|peer mentor training|A quasi-experimental, before and after study design is proposed to obtain data for planning and implementing a larger-scale study. A training workshop for individuals with IA to become peer mentors will increase peer mentors' confidence and skills to provide one-on-one support to individuals with EIA. Using a combination of lectures, experiential learning and question/answer sessions, peer mentors will learn and practice informational, emotional, appraisal support techniques and skills (communication skills, problem-solving strategies, use of decision tools). Training will be conducted face-to-face, in small-group format by research team and others (2 sessions approx. 5 hours each), in a private meeting room at SHSC. Peer mentors will then provide support to individuals newly diagnosed with IA for 12 weeks (once per week) by telephone and /or face-to-face. Peer mentors will receive ongoing support from the research team (telephone, meetings).
1865076|NCT01054976|Drug|Galantamine|Orally administered Galantamine 8 mg/day for the first 4 weeks. Thereafter the dose will be increased to 16 mg/day. If tolerated, the dose of galantamine can be increased up to 24 mg/day.
1865077|NCT01054989|Biological|Fat/Inflammation effects|Fat infusion (Intralipid) over 6 hours Fat orally (Soy bean oil) single dose LPS infusion for 10 minutes Glycerol infusion over 6 hours
1865078|NCT01055002|Biological|Blood stage parasite (BSP) inoculum|Inoculum of human red blood cells infected with falciparum malaria administered intravenously on Day 1
1865079|NCT01055015|Drug|Flexible dose Q8003 (morphine sulfate and oxycodone hydrochloride)|IR Capsules, flexible dose, every 4 to 6 hours
1865080|NCT01055015|Drug|Low dose Q8003 (morphine sulfate and oxycodone hydrochloride)|One 3 mg/2 mg IR Capsule every 4 to 6 hours following a 6 mg/4 mg loading dose.
1959943|NCT03311581|Drug|Propofol|Propofol works by increasing GABA-mediated inhibitory tone in the CNS. Propofol decreases the rate of dissociation of the GABA from the receptor, thereby increasing the duration of the GABA-activated opening of the chloride channel with resulting hyperpolarization of cell membranes.
1865082|NCT01055041|Drug|inhaled budesonide and formeterol plus oral montelukast|1st two weeks -run in period all the participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet montelukast (10 mg/day)orally in the evening
1865083|NCT01055041|Drug|inhaled budesonide and formeterol plus oral doxophylline|1st two weeks -run in period, all participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day plus tablet doxophylline sustained release(400 mg/day)orally in the morning
1865084|NCT01055041|Drug|Doubling the dose of inhaled budesonide and formeterol|1st two weeks -run in period, all groups participants prescribed Metered dose inhaler (budesonide 200 mcg/puff + formeterol 6 mcg/puff) two times a day Next 8 weeks- Metered dose inhaler (budesonide 200 mcg /puff + formeterol 6 mcg/puff) two times a day plus metered dose inhaler of budesonide (200 mcg/puff) two times a day
1865085|NCT01055067|Drug|Tivantinib (ARQ 197)|Capsule, 120 mg, BID (360 mg), approximately 112 days
1865086|NCT01055080|Dietary Supplement|Cow's milk formula|Weaning to three different type of cow's milk formula when breast milk is not available during the first 6 months of life
1865087|NCT01055106|Drug|GW05|vaginal gel once daily regimen A
1865088|NCT01055106|Drug|GW05|vaginal gel once daily regimen B
1865089|NCT01055106|Drug|GW05|vaginal gel once daily regimen C
1865090|NCT01055106|Drug|Metronidazole|vaginal gel 0.75% once daily for 5 days
1865091|NCT01055119|Dietary Supplement|Omega-3 fatty acids|duration: 4 month
1865092|NCT01055132|Device|Etafilcon A toric contact lens|contact lens to correct astigmatism
1865093|NCT01055132|Device|Nelfilcon A toric contact lens|contact lens to correct astigmatism
1865094|NCT01055145|Drug|levofloxacin, moxifloxacin|Levofloxacin 750mg po per day for 3 months vs. Moxifloxacin 400mg po per day for 3 months
1865095|NCT01055158|Behavioral|Telephone-based CBT|A form of CBT delivered over the telephone by a trained, licensed, master's or doctoral level clinician. The intervention consists of approximately 10 sessions conducted over approximately 14 weeks. Each session is approximately 30 to 50 minutes. All sessions begin with a depression rating and agenda setting and end with task assignments and summaries.
1865096|NCT01055158|Behavioral|Enhanced Usual Care|Participants randomized to this condition will be referred to receive in-person psychotherapy. Research study staff will help participants to set up their first appointment with a psychotherapist.
1865097|NCT01055171|Drug|Propranolol|40 mg; Single Administration.
1865098|NCT01055171|Drug|Placebo|40 mg; Single Dose.
1865099|NCT01055184|Biological|2009 H1N1 Virus Vaccine|Single 0.2 mL dose of live monovalent vaccine, delivered through nasal spray
1865100|NCT01055197|Radiation|Prophylactic Cranial Irradiation|Prophylactic Cranial Irradiation (PCI) to the brain in ten once-daily fractions of 2.5 Gy, five days per week, for a total of 25 Gy.
1865101|NCT01055197|Radiation|Radiation Therapy|Radiation Therapy (RT) to locoregional and residual metastatic disease in 15 once daily fractions of 3.0 Gy, 5 days per week, for a total of 45 Gy
1865102|NCT01055210|Device|Optimisation of VV delay|Programmed VV delay altered on device
1865103|NCT01055223|Drug|TZD only (RSG or PIO or troglitazone)|Drug exposure will be inferred from prescription claims. Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
1865104|NCT01055223|Drug|TZD + spironolactone|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
In order to be eligible for inclusion in this category, the prescription days supply for TZD and spirinolactone must overlap by at least 30 days."
1865105|NCT01055223|Drug|TZD + amiloride|"Subjects who have been exposed to TZD for at least 6 months or at least 12 months will be considered for inclusion.
In order to be eligible for inclusion in this category, the prescription days supply for TZD and Amiloride must overlap by at least 30 days."
1865106|NCT01055236|Drug|hydroxyzine|75 mg of hydroxyzine orally as premedication drugs at least half an hour before operation.
1865109|NCT01055262|Device|Heatwrap 1|8 hours continuous topically-applied heat
1865110|NCT01055275|Device|Implantation with a Cook Iliac Branch Graft|Treatment of an aortic, aorto-iliac or iliac aneurysm with a CE-marked Cook Iliac Branch Graft.
1865111|NCT01055301|Drug|bortezomib|
1865112|NCT01055301|Drug|cisplatin|
1865134|NCT01055327|Drug|Lamotrigine monotherapy|Exposure to lamotrigine monotherapy in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
1865135|NCT01055327|Drug|No anti-epileptic drug exposure|No exposure to anti-epileptic drugs in the first trimester of pregnancy (time period from first day of menstrual period to 12th week of gestation).
1865136|NCT01055327|Drug|Non lamotrigine anti-epileptic drug monotherapy|Exposure to non lamotrigine monotherapy (with or without valproate) during the first trimester of pregnancy (time period from the first day of the menstrual period to the 12th week of gestation)
1865137|NCT01055340|Drug|Oxyntomodulin (OXM)|Single infusion of OXM 3.0 pmol/kg/min by IV
1865138|NCT01055340|Drug|Comparator: Oxyntomodulin (OXM)|Single infusion of OXM 0.6 pmol/kg/min by IV
1865139|NCT01055340|Drug|Comparator: Placebo [ hemaccel-containing saline]|Single Placebo infusion of hemaccel-containing saline by IV
1865140|NCT01055366|Drug|Elazop (Azarga)|Administer one drop of ELAZOP in treated eye(s) twice a day for up to 12 weeks
1865141|NCT01055379|Drug|Rasagiline|1 mg/day for 12 weeks; orally
1865142|NCT01055379|Drug|Placebo|Once daily for 12 weeks; orally
1959944|NCT03311581|Device|Sevoflurane|sevoflurane inhalation 2~4%
1959945|NCT03311581|Other|brachial plexus block with ropivacaine 0.5%|Ultrasound-guided brachial plexus block with 0.5% ropivacaine
1865145|NCT01055405|Drug|Sildenafil|Sildenafil 20mg TID orally
1865146|NCT01055405|Other|Placebo|Placebo TID orally
1865147|NCT01055418|Dietary Supplement|Vitamin C|Vitamin C will be administered at a dose of 1000mg. There will be at least a 48 hour wash out period between both conditions (placebo and vitamin C), with the order dicteted by Latin square.
1865148|NCT01055431|Other|Control bread|Control bread
1865149|NCT01055431|Other|Teff Bread|Teff bread
1865150|NCT01055444|Drug|Heated lidocaine and tetracaine topical patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch to the affected shoulder every 12 hours starting on the evening of Day 1 through the morning of Day 14 (morning and evening applications) and to remove the patch after 2-4 hours.
1865151|NCT01055457|Device|Vistakon Investigational Multi-Purpose Solution II|contact lens care solution
1865152|NCT01055457|Device|ReNu MultiPlus Multi-Purpose Solution|contact lens care solution
1865153|NCT01055470|Drug|Diclofenac|Tab. Diclofenac 50 mg 12 hrly, orally, in morning and in evening after taking food for 3 months.
1865154|NCT01055470|Drug|Lornoxicam|Tab. Lornoxicam 4 mg , orally, 8 hourly after taking food in morning , in noon and evening for 3 months.
1865155|NCT01055483|Drug|panobinostat/LBH589B|
1959946|NCT03311568|Device|ultrasound for microcirculatory assessment|"Ultrasound for microcirculatory assessment Repeated measurements within study participants for analysis of variance and explorative analyses of ultrasound signals, to identify most suitable parameters to describe microcirculatory alterations in critical disease, especially in sepsis.
Analyse blood flow velocities in several depths and from several vessels of different sizes simultaneously
US registration repeated within each study participant consecutively on seven different regions of the body surface."
1959947|NCT03311555|Drug|Apalutamide|240mg tablet daily for 36 weeks
1865158|NCT01055509|Behavioral|Cognitive Adaptation Training|All patients receive treatment as usual. Additionally, patients in the intervention arm receives training concerning solving concrete problems related to the patient's daily life using tools such as schedules, schemes and signs. Additional the patient can receive SMS messages or instructions for the use of schedules in cell-phones to prompt for activities. The intervention is conducted in the patients homes every 14th day in a period of six months.
1865159|NCT01055522|Drug|Arm 1: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Induction Phase A: Intravenous (IV) infusion of L19IL2 on days 1, 3 and 5 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.
Induction Phase B: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for four consecutive 21-day cycles.
Maintenance: Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for a maximum of 1 year after start of treatment.
DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
1865160|NCT01055522|Drug|Arm 3: Dacarbazine|Dacarbazine Dosage: 1,000 mg/m2 DTIC every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or for a maximum of 8 cycles, whichever occurs first.
1865161|NCT01055522|Drug|ARM 2: L19IL2 + Dacarbazine|"RD of L19IL2 determined in phase IIa. Intravenous (IV) infusion of L19IL2 on days 1, 8 and 15 of each 21-day cycle over 60 minutes via automated device (perfusor), for for a maximum of 1 year after start of treatment.
DTIC 1,000mg/m2 every three weeks until disease progression, unacceptable toxicity, withdrawal of consent, or one year from initiation of therapy, whichever occurs first"
1865162|NCT01055535|Drug|Microplasmin|125 µg intravitreal injection
1865163|NCT01055561|Other|Acupuncture|Participators will be stimulated at specific acupuncture points as determined for the disease by the professional acupuncturists, and acupuncture once a day,last for one week.
1865164|NCT01055600|Drug|eltrombopag|Mothers are taking PROMACTA prescribed by their physician before entering this study. No drug will be administered as part of this study.
1865165|NCT01055613|Device|Vistakon Investigational Multi-Purpose Solution I|Multi-purpose contact lens care solution.
1865166|NCT01055613|Device|ReNu MultiPlus Multi-Purpose Solution|Multi-purpose contact lens care solution
1865167|NCT01055639|Behavioral|In-Person ACT|8 individual in-person sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
1865168|NCT01055639|Behavioral|Telehealth ACT|8 individual telehealth sessions of Acceptance and Commitment Therapy (ACT): includes mindfulness, values, and committed action
1865169|NCT01055652|Drug|Dapagliflozin|10mg, oral, once daily
1865170|NCT01055665|Other|cognitive behavior therapy|6 cognitive behavior therapy groups
1865280|NCT01065506|Behavioral|Wellness Program|Wellness Program
1865171|NCT01055678|Drug|EF5|An infusion of EF5, a fluorinated 2-nitroimidazole, will be administered using the recommended dose of 21mg/kg one day prior to surgical procedure.
1865172|NCT01055678|Procedure|Partial or Total Mastectomy|A small tissue sample will be removed from the excised tissue and will be stored for later analysis.
1865173|NCT01055691|Drug|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 2.5 mg/850 mg Oral Single dose
1865174|NCT01055691|Drug|Dapagliflozin|dapagliflozin tablet 2.5 mg Oral Single dose
1865175|NCT01055691|Drug|Metformin|metformin IR tablet 850 mg Oral Single dose
1865176|NCT01055691|Drug|Dapagliflozin/Metformin|Fixed dose combination dapagliflozin/metformin IR tablet 5 mg/1000 mg Oral Single dose
1865177|NCT01055691|Drug|Dapagliflozin|dapagliflozin tablet 5 mg Oral Single dose
1865178|NCT01055691|Drug|Metformin|metformin IR tablet 1000 mg Oral Single dose
1865179|NCT01055704|Drug|Methylnaltrexone only|0.30 mg/kg subcutaneous injection daily
1865180|NCT01055704|Drug|Codeine only|30 mg taken orally four times daily for 5 days
1865181|NCT01055704|Drug|Methylnaltrexone + codeine|Methylnaltrexone 0.30 mg/kg by subcutaneous injection once daily and codeine 30 mg taken orally four times daily for 5 days
1865182|NCT01055704|Drug|Placebo + placebo|Placebo subcutaneous injection once daily and placebo taken orally four times daily for 5 days
1865183|NCT01062555|Drug|Cyclosporine & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
1865184|NCT01062555|Drug|Prograf & Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
1865185|NCT01062555|Drug|Cyclosporine, Cellcept, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
1865186|NCT01062555|Drug|Prograf, Cellcept, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
1865187|NCT01062555|Drug|Low Dose CNI (Cyclosporine or FK) and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
1865188|NCT01062555|Drug|Rapamune and Cellcept|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
1865189|NCT01062555|Drug|Low dose CNI (CSA or FK), Rapamune, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
1865190|NCT01062555|Drug|Rapamune, Cellcept, & Prednisone|Dose and frequency determined as usual by transplant physicians. The drugs are not experimental drugs. The study is looking at reducing negative side effects of some of the drugs.
1865191|NCT01062568|Drug|Adrenocorticotropin|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
1865192|NCT01062568|Drug|Dexamethasone|Subjects will have blood drawn at 1900 hr for baseline hormone measurements. At 2200 hr each subject will take a single oral dose of dexamethasone at 2200 hr. At 0700 hr the following day, subjects will have a blood sample drawn for hormone measurements. After this blood sample, 0.25 mg adrenocorticotropin (ACTH) will be administered as an iv bolus. At 30 and 60 minutes after Cosyntropin, blood samples will be obtained for repeat hormone measurements.
1865193|NCT01062594|Other|Supervised exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
1865194|NCT01062594|Other|Role of exercise|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
1865195|NCT01062594|Other|Supervised exercise program|Exercise class, this will be performed three times a week with average duration of 40 minutes for 4-6 weeks.
1865196|NCT01062620|Drug|AXL1717|Phase I study with increasing dosage and treatment duration
1865197|NCT01062633|Dietary Supplement|A, erythritol|2,5 g 3 times a day
1865198|NCT01062633|Dietary Supplement|xylitol|2,5 g 3 times a day
1865199|NCT01062633|Dietary Supplement|C, sorbitol|2,5 g 3 times aday
1865200|NCT01062646|Behavioral|Multimodal music therapy|
1865201|NCT01062646|Behavioral|Community treatment as usual|
1865202|NCT01062685|Diagnostic Test|Near-infrared spectroscopy assessment|"The InSpectra StO2 Tissue Oxygenation Monitor (model 650; Hutchinson Technology, Hutchinson, MN, USA) with probes spaced at 15 mm will be utilized to obtain StO2 measurements.
Following a minimum initial five-minute stabilization period, the initial StO2 will be measurement and then a Vasoocclusive Testing Procedure (VOT) will be performed using an automated tourniquet (Delfi Tourniquet System; Delfi Medical Innovations, Inc, Vancouver, BC, Canada), insufflated to 50 mmHg over the patient's SBP for a period of three minutes."
1865203|NCT01062698|Drug|Alteplase (rt-PA)/Actilyse|Injection of 0.9 mg/kg for 60min with an initial 10% bolus injection.
1865204|NCT01062698|Procedure|Mechanic thrombectomy (MERCI, PENUMBRA, CATCH, SOLITAIRE)|Mechanic thrombectomy
1865205|NCT01062711|Dietary Supplement|Whey or soy protein|Whey and casein are isolated milk proteins
1865206|NCT01062724|Other|Primene 10 % from Baxter|Primene solution will be calculated in g/kg/day and administered in ml/day Active Comparator: Trophamine This group of neonates will be receive the Trophamine amino acid solution from Pisa laboratories and the other arm will be receive a Primene amino acid solution (10 %) from Baxter laboratories. For infants identified, daily intakes (g/kg/d) of parenteral protein, carbohydrate and fat and daily enteral intake (ml/kg/d) of breast milk or formula will be record.
1865207|NCT01062737|Drug|ASU|
1865208|NCT01062750|Biological|adipose tissue derived stromal cells dosage|single administration of autologous adipose tissue derived stroma cells via intrahepatic arterial catheterization
1865209|NCT01062763|Drug|spironolactone|25 to 50 mg once daily
1865210|NCT01062763|Drug|placebo|addition of placebo 1 to 2 tablets daily
1865211|NCT01062776|Biological|Dehydration|Furosemide 5 mg is given intravenously over 2 hours until approximately 2 liters of body fluid is lost.
1865212|NCT01062776|Biological|Placebo|No dehydration is induced
1865213|NCT01062789|Device|Optical breath-hold control system (OBC)|The OBC system was designed to replace the IBC rubber bellows respiration sensor system that we are currently using for CT-guided lung biopsies. Unlike the IBC, the OBC is 1) unaffected by temperature changes, 2) has a linear sensitivity (for easier use and better accuracy), 3) has no pneumatic purge time when setting reference breath-hold level (reducing the chance of an inappropriate reference), 4) has no pneumatic cable that can occasionally interfere and get pinched during procedures, 5) is ambulatory (so patients can more easily familiarize themselves with the device before the procedure), 6) is capable of indicating proper fitting tension, 7) allows for easier binding (wireless pairing with other system components), and 8) is significantly less expensive (and possibly disposable).
1865214|NCT01062802|Drug|Atorvastatin|Atorvastatin 80mg, once a day for four weeks.
1865215|NCT01062802|Other|Placebo|Placebo given once daily for 4 weeks.
1865216|NCT01062815|Dietary Supplement|Parenteral Nutrition|Parenteral Nutrition infused over 20 hours cycled with dextrose solution over 4 hours compared to Parenteral Nutrition infused continuously over 24 hours.
1865217|NCT01062828|Diagnostic Test|Citrulline samples|Citrulline samples will be collected at the time of other lab work twice a week from enrollment until 40 weeks postconceptional age and once a week until 44 weeks postconceptional age (1 month corrected age) OR discharge from NICU(whichever is soonest). In subgroup developing NEC, citrulline samples will be collected twice a week from enrollment until discharge from NICU or death.
1865218|NCT01062841|Behavioral|Targeted Infection Control|"Component 1: Institute enhanced barrier precautions for all NH residents with indwelling devices; active screening for MDROs (monthly) using cultures collected from multiple body sites to identify asymptomatic MDRO carriage in these residents; and dissemination of results to clinical staff and administration.
Component 2: Structured, active surveillance for infections using standardized definitions in residents with indwelling devices and dissemination of results to clinical staff and administration.
Component 3: A hand hygiene promotion program. Component 4: A structured educational program pertaining to indwelling device care for healthcare workers."
1865219|NCT01062854|Other|Soft earplugs are worn during sleep study|"Subjects are asked to wear earplugs when possible for 3-5 nights prior to their baseline sleep study. On the night of their sleep study they are randomized to either wears earplugs or no earplugs groups."
1865220|NCT01062867|Drug|ORG25435|Intended doses: 0.25, 0.5, 1.0, 2.0, 3.0, 4.0, 5.0 and 6.0 mg/kg by intravenous infusion over 1 min Up to 25mg/kg by infusion over 30min
1865221|NCT01062880|Behavioral|self-guided internet modules|Patients are assigned at random to either unspecific (n= 1000) or individualized (n=1000) self guided internet modules.
1865222|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h
1865223|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
1865224|NCT01065077|Drug|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
1865225|NCT01065077|Drug|Placebo|Infusion of placebo during 48h
1865226|NCT01065103|Procedure|FFR (Fractional Flow Reserve)|Single FFR measurement in non-culprit vessel
1865227|NCT01065116|Drug|AL Blister-packs with Instruction leaflets|AL Blister packs with instruction leaflets will be dispensed
1865228|NCT01065116|Drug|AL unit dose age specific pre-packs|Age specific colour coded Unit dose pre-packs will be used
1865229|NCT01065129|Drug|G-CSF|
1865230|NCT01065129|Drug|Plerixafor|
1865231|NCT01065129|Drug|Azacitidine|
1865232|NCT01065142|Procedure|Therapeutic education|Improve therapeutic education efficiency on life quality of heart failure patients in general practice
1865233|NCT01065194|Drug|Levosimendan|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus
1865234|NCT01065194|Drug|Placebo|Levosimendan will be infused on an outpatient basis for six hours at a dosage of 0,2 μg/kg/min without a bolus.
1865235|NCT01065207|Biological|blood test at day one|"Epidemiological, clinical, virological, and immunological data will be collected.
Clinical events as neoplasia will be collected"
1865236|NCT01065220|Drug|Testolactone undecanoate|4ml i.m.
1865237|NCT01065220|Drug|Lynestrenol|2/day
1865238|NCT01065220|Drug|Cyproterone Acetate|50mg per day
1865239|NCT01065220|Drug|Estradiol|100 microgram TTS twice a week
1865240|NCT01065220|Drug|5-alpha reductase inhibitor|1mg daily
1865241|NCT01065233|Genetic|DNA extraction|DNA extraction of blood sample for DNAship analysis
1865242|NCT01065246|Drug|catumaxomab|4 intraperitoneal infusions within 11 days administered over 3 hours via an indwelling catheter at the following doses: 10 - 20 - 50 - 150 µg catumaxomab
1865243|NCT01065259|Drug|OROS MPH|The dosage began with 18mg Qd. It can be increased with 18mg every week until an optimal response achieved. The maximum dosage was no more than 54mg/d. The optimal dosage will maintain for 4 to 6 weeks
1865244|NCT01065259|Drug|Atomoxetine|The dosage begins with 0.5mg/kg.d. It can increased to 0.8mg/kg.d at the second week, 1.2mg/kg.d at the third week, and 1.4mg/kg.d at the 5th week according to the patients response. The optimal dosage will maintain for 4 to 6 weeks.
1865245|NCT01065272|Drug|Dexamethasone|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.
1mg/kg of oral Dexamethasone with cherry flavour is also given in the first day, then 0.6 mg/kg/day for 4 days"
1865246|NCT01065272|Drug|Placebo|"0.5 ml Salbutamol in 2 ml normal saline is given at 0,30,60,120,180 minutes and then every 2 hourly till discharge.
1mg/kg of oral Placebo is also given in the first day, then 0.6 mg/kg/day for 4 days"
1865247|NCT01065285|Biological|Evaluation of vaccines against flu|evaluate efficacy and tolerance
1865248|NCT01065298|Biological|stem cell transplantation|Group 1: 200 - 250 ml of bone marrow will be aspirated and layered on density gradient medium (Ficoll - Hyperaque) and stem cells will be separated. Separated MNC's will be tagged with FDG-PET and injected into superior pancreatico duodenal artery and an PET scan will be done 2 hours later to see the percentage of stem cells homing in to pancreas. After 8 weeks G-CSF(10mcg/Kg/day) will be given subcutaneous for 5 days to achieve a Leucocyte count of >40,000/mm3. Patients will be urged to monitor and document blood glucose readings for next 6 months. Glucagon stimulated C - peptide, plasma Insulin, HOMA-IR , HOMA-B ,HbA1c, lipid profile and biochemistry will be done at baseline and 6 months .
1865249|NCT01065311|Behavioral|Mindfulness-based Cognitive Therapy|Mindfulness-based Cognitive Therapy is based on an integration of aspects of cognitive behavioral therapy for depression (Beck et al., 1979) with components of the Mindfulness-based Stress Reduction program developed by Kabat-Zinn and colleagues (Kabat-Zinn, 1990). After an initial orientation session, the MBCT program is delivered by an instructor in eight weekly 2.5 hr group sessions
1865250|NCT01065311|Behavioral|The Cognitive Behavioral Analysis System of Psychotherapy|The Cognitive Behavioral Analysis System of Psychotherapy integrates behavioral, cognitive, and interpersonal strategies. After two initial orientation sessions, the MBCT program is delivered weekly by an instructor in eight 2.5 hr group sessions.
1865251|NCT01065311|Biological|Standard psychiatric care|"Antidepressant medication and medical care.
Standard psychiatric outpatient care:
All patients were requested to get treated individually either by a psychiatrist or by a licensed psychotherapist (not member of the study team). If patients were already in psychiatric/psychotherapeutic individual treatment at study intake they continued their treatment with this psychiatrist/psychotherapist"
1865252|NCT01065337|Biological|tissue repair cells (TRC)|expanded bone marrow cells enriched in CD90+ mesenchymal stem cells
1865253|NCT01065337|Biological|bone marrow stem cells (BMC)|bone marrow stem cells
1865254|NCT01065350|Drug|Propofol|As part of the induction, subjects will be given 2 milligrams per kilogram of body weight (mg/kg) of propofol. The clinician will receive a 20 milliliter (mL) syringe of propofol. If the dose, 2 mg/kg, does not add up to a total of 20 mL, normal saline will be added to make up for the 20 mL. The clinician and observer will be blinded to the medication and doses being administered during induction given that both syringes, syringes in the propofol and ketofol groups, will look identical (will both appear to be propofol only). The propofol group will also be given an additional 10 mL syringe of propofol due to any patient responding to stimulus after induction. The 10 mL syringe represents 1 mg/kg of propofol. If patient receives both the 20 and 10ml syringe, he or she will receive a total of 3mg/kg of propofol.
1865255|NCT01065350|Drug|Ketamine|As part of the induction, patients will be given 20ml syringe of ketofol which is weight based such that ketamine will represent 0.75mg/kg of the dose and propofol, 1.5mg/kg. The clinician and observer will be blinded to the medication and doses being administered during induction given that both 20ml syringes (propofol group and ketofol group) will look identical (will both appear to be propofol only). Additional 10ml syringe will be given due to any patient responding to stimulus after induction. The 10ml syringe will represent 0.25mg/kg of ketamine and 0.5mg/kg of propofol. If the patient receives both the 20 and 10ml rescue syringe, he or she will receive a total of 1mg/kg of ketamine and 2mg/kg of propofol.
1865256|NCT01065363|Behavioral|standardized exercise program and dietary counseling|Lecture, 12 weeks Standardized exercise program, 12 weeks Dietary counseling, 12 weeks Information platform, 12 weeks
1865257|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day of hCG
1865258|NCT01065376|Procedure|the timing cabergoline administration|received 0.5 mg oral cabergoline per day for 8 days on the day after oocyte retrieval
1865259|NCT01065389|Behavioral|Progressive Resistance Exercise Training|Progressive Resistance Exercise Training thrice a week for 12 weeks. For first two weeks, 60% of 5 repetition maximum, progressing at 5% of 5 repetition maximum each week reaching upto 110% of 5 Repetition maximum at the end of 12 weeks
1865260|NCT01065389|Behavioral|Unstructured Nonprogressive resistance exercise|Unstructured Resistance Exercise 30 minutes a day, thrice a week for 12 weeks. For 12 weeks, 20% 5 repetition maximum (which will not induce training effect and any physiological responses)and free range of motion exercises with no progression.
1865261|NCT01065402|Dietary Supplement|PPB-R-203-Based Meal|PPB-R-203 is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203 is resistant starch (RS). Resistant starch can be regarded as a component of dietary fiber. Some forms of RS are present naturally in many foods, and average global consumption is estimated at 3-10 g/day. PPB-R-203-Based is the diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
1865262|NCT01065402|Dietary Supplement|TK9-Based Meal|TK9, Taikeng 9, is one commercially available rice manufacture by Yeedon Enterprise Co., Ltd. TK9-Based Meal is a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
1865263|NCT01065441|Biological|AlloStim|Patients meeting eligibility criteria will be primed with at least three and up to nine intradermal AlloStim-TM injections at a frequency of every 2-8 days at doses between 1-4 x 10^7 cells
1865264|NCT01065441|Procedure|Cryoablation|Percutaneous cryoablation of selected tumor lesion under CT or US guidance
1865265|NCT01065441|Biological|AlloStim|intratumoral injection of AlloStim-TM into cryoablated tumor lesion at a dose of 1-6 x 10^7 cells
1865266|NCT01065441|Biological|AlloStim|intravenous AlloStim-TM at doses between 1 x 10^7 to 1 x 10^9 cells
1865267|NCT01065441|Biological|AlloStim|Intraperitoneal AlloStim-TM infusion in patients with peritoneal carcinomatosis and/or ascites
1865268|NCT01065441|Biological|AlloStim|Patients with malignant pleural effusion may receive intrapleural AlloStim-TM infusion at a dose of 5-10 x 10^7 cells.
1865269|NCT01065441|Biological|AlloStim|Patients with palpable tumors may receive alcohol ablation and intratumoral AlloStim-TM
1865270|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|up to 2 mg three times a day (increasing from 0.5 to 1 to 2 mg)
1865271|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|up to 1 mg three times a day (increasing from 0.5 to 1 mg)
1865272|NCT01065454|Drug|Riociguat (Adempas, BAY63-2521)|fixed 0.5 mg three times a day
1865273|NCT01065454|Drug|Placebo|Placebo three times a day
1865274|NCT01065467|Drug|LBH589|Taken orally three times per week.
1990431|NCT02021292|Drug|Macitentan|Macitentan 10 mg, oral tablet, to be taken once daily.
1865276|NCT01065493|Other|QuitAdvisorMD Software Algorithm|QuitAdvisorMD, a set of brief clinical assessments, counseling scripts and intervention instruments for smoking cessation in primary care settings
1865277|NCT01065493|Behavioral|Standard Smoking Cessation Counseling|Standard Smoking Cessation Counseling
1865278|NCT01065506|Behavioral|Cognitive Behavioral Treatment|Cognitive Behavioral Treatment
1990432|NCT02021292|Drug|Placebo|Matching placebo oral tablet, to be taken once daily.
1865281|NCT01065506|Behavioral|Aerobic Exercise|Aerobic Exercise
1865282|NCT01065519|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
1865283|NCT01065519|Device|Biolimus A9-eluting Biomatrix stent|Biolimus A9-eluting Biomatrix stent
1865284|NCT01065532|Device|Sequent Please Paclitaxel eluting balloon|Sequent Please Paclitaxel eluting balloon
1865285|NCT01065532|Device|Xience V everolimus eluting stent|Xience V everolimus eluting stent
1865286|NCT01065545|Drug|Clofarabine|dose escalation, administered orally, once a day for 21 days per cycle (cycles begin every 28-49 days)
1865287|NCT01065558|Drug|Ecopipam|Tablets, once daily, for two weeks up to 200 mg/day
1865288|NCT01065571|Dietary Supplement|carrageenan|The intervention is the carrageenan-free diet. Supplementary carrageenan capsules will be given to mimic the carrageenan in the normal diet.
1865289|NCT01065571|Other|dietary intervention with no-carrageenan diet|The intervention will consist of the no-carrageenan diet.
1865290|NCT01065597|Device|Nonconvulsive electrotherapy|An electrical stimulus will be given as in electroconvulsive therapy (ECT)using bifrontal electrode placement and a Thymatron System IV device; however, the device will be set at a lower energy level that is 12.5%(1/8) of the expected energy needed to induce a seizure rather than at an energy level that is at or above the seizure threshold.
1865291|NCT01065610|Drug|Oxytocin|
1865292|NCT01065610|Drug|Placebo|
1865293|NCT01065623|Drug|BAY79-4620|1-hour infusion every 14 days. Starting dose will be 0.15 mg/ kg and dose will be escalated dependent on any dose limiting toxicities
1865294|NCT01065636|Behavioral|Diet + Resistance Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and resistance exercise training 3-days/week for 24 weeks.
1865295|NCT01065636|Behavioral|Diet + Aerobic Training|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and aerobic exercise training 3-days/week for 24 weeks
1865296|NCT01065636|Behavioral|Diet + Resistance/Aerobic Exercise|Behavioral Therapy through a lifestyle modification program, Diet therapy once weekly through a dietician prescribed diet for 26 weeks, and combined resistance/aerobic exercise training 3-days/week for 24 weeks
1865297|NCT01065649|Drug|Nortriptyline|It will be administered per oral 10 mg a day in the first 7 days and then 25 mg a day in the last 14 days
1865298|NCT01065649|Drug|Placebo arm|Placebo per oral for 21 days, equal to nortriptyline
1865299|NCT01065662|Drug|temsirolimus|Given on days 1, 8, 15 and 22 of each cycle
1865300|NCT01065662|Drug|cediranib|Taken orally daily
1865301|NCT01065675|Other|Medication reconciliation completed by a RN, CPhT, or RPh|To determine which patients benefit the most from medication histories obtained by the RN, CPhT, or RPh. Patients will be admitted as inpatients through the ED with medication histories finalized electronically by the RN at the admitting unit.
1865302|NCT01065688|Procedure|Roux-en Y reconstruction|surgical procedure
1865303|NCT01065688|Procedure|Billroth-I reconstruction|surgical procedure
1865305|NCT01065714|Drug|Hydrogel vehicle|Each morning and evening, gently wash the target area with warm water and gently pat dry with soft towel. Once dry place a small amount of Hydrogel vehicle onto the tip of your finger. Place a dab of the Hydrogel vehicle on either the left or right side of the body as instructed. (Do not use Hydrogel vehicle and Eucerin lotion on the same side of the body.)
1865306|NCT01065714|Drug|Eucerin Lotion|Each morning and evening, gently wash the area with warm water and pat dry with a soft towel. Once dry, place a small amount of Eucerin lotion to the target area on either the left or right side of the body as instructed. (Do not use Eucerin and Hydrogel vehicle on the same side of the body.)
1865307|NCT01065727|Other|mitoxantrone - immunomodulator|mitoxantrone during 6 months and followed by immunomodulator during 2 years and half
1865308|NCT01065727|Other|natalizumab|monthly natalizumab during 3 years
1865309|NCT01065740|Other|Patient education|
1865310|NCT01065753|Behavioral|Lifestyle Counseling|Diet control with exercise
1865311|NCT01065766|Drug|Sitagliptin/metformin|Sitagliptin/metformin 50/500 mg, 50/850 mg, or 50/1000 mg tablet administered twice daily with meals.
1865312|NCT01065779|Drug|FOSAMAX PLUS|Patients with Osteoporosis treated with FOSAMAX PLUS (70 mg alendronate/2800 International Units (IU) Vitamin D). One tablet taken once weekly.
1865313|NCT01065779|Drug|FOSAMAX PLUS D|Patients with Osteoporosis treated with FOSAMAX PLUS D (70 mg alendronate/5600 IU Vitamin D). One tablet taken once weekly.
1865314|NCT01065805|Biological|18F-FLT|"Phase I: Radioactive dose of 2.59 MBq/kg (111-222 MGq)per injection. A single injection of 18F-FLT and PET scan will be permitted per patient.
Phase II: Radioactive dose of 2.59 MBq/kg (100-350) MBq per injection. Up to five separate injections of 18F-FLT and PET scans will be permitted per patient"
1865315|NCT01065818|Drug|Fluoro-L-Thymidine|4D-PET/CT imaging with an injection of Fluoro-L-Thymidine at pre-Neoadjuvant Therapy and post-3 weeks Neoadjuvant Therapy prior to surgery.
1865316|NCT01065831|Behavioral|Motivational interviewing (MINT-TLC)|The MINT-TLC lifestyle intervention lead by lay health advisers will be compared to the health education attention control condition (CC). Twenty churches will participate in the study and each church will be randomly assigned to receive either MINT-TLC or CC. They will be compared on blood pressure reduction, physical activity levels, intake of fruits and vegetables, and weight reduction.
1865317|NCT01065844|Drug|Nelfinavir|1250 mg Nelfinavir twice daily Monday - Sunday
1865318|NCT01065857|Drug|Sodium picosulphate, light magnesium oxide and anhydride citric acid.|2 Single-dose sachets containing sodium picosulphate (0.01g/sachet), light magnesium oxide (3.50g/sachet) and anhydrous citric acid (10.97g/sachet).
1865319|NCT01065857|Drug|Polyethylene glycol, KCl, NaCl, sodium sulphate anhydrous and sodium bicarbonate.|4 sachets containing Polyethylene glycol 3350 (59 gr), KCl (0.7425 gr), NaCl (1.465 gr), sodium sulphate anhydrous (5.685 gr), sodium bicarbonate (1.685 gr).
1865320|NCT01065870|Drug|Neoadjuvant gemcitabine, capecitabine, and docetaxel|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.
Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.
Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment."
1865321|NCT01065870|Drug|Gemcitabine, capecitabine, docetaxel followed by radiotherapy|"6 cycles of gemcitabine, capecitabine, and docetaxel. One cycle consists of a 2-week regimen followed by one week off.
Days 1-14: Capecitabine at 1500mg/m2/day divided into two doses given orally with breakfast and dinner.
Days 4 and 11: Gemcitabine at 750mg/m2 over 75 minutes IV followed by docetaxel at 30mg/m2 over 30 minutes IV with 10mg of dexamethasone IV prior to treatment.
Radiotherapy should start 2 to 3 weeks after last planned dose of GTX. Gemcitabine at 750mg/M2 days 5, 12, 26, 33 along with capecitabine 1000 mg bid for 5 days darbepoetin 200ug, every 2 weeks if the hemoglobin is less than 10.5 gms/dl while undergoing radiotherapy.
Pegfiligastrim 6mg at the end of week 2 if the WBC count is less than 2500 cells/cu mm."
1865322|NCT01065883|Behavioral|community health worker|community health workers will provide education in the home
1865323|NCT01065883|Behavioral|mailed information|information will be mailed to the home on the same schedule as the experimental intervention
1865324|NCT01065935|Drug|ALN-RSV01|Administered by nebulization once daily for 5 days
1865325|NCT01065935|Drug|Normal Saline|Administered by nebulization once daily for 5 days
1865326|NCT01065948|Device|Subcutaneous glucose monitoring device|monitor interstitial glucose level every 5 min over 4 hours
1865327|NCT01065961|Drug|Decadron|Decadron will be given at a dose of 0.2 mg/kg intraoperatively, followed by Decadron 4 mg. every 6 hours for 24 hours.
1865328|NCT01065961|Drug|Saline|Placebo saline will be given intraoperatively as well as 4 doses every 6 hours for 24 hours.
1959948|NCT03311555|Drug|Androgen deprivation|ADT will consist of treatment with a GnRH agonist or antagonist per physician and institutional preference. Either leuprolide acetate (Lupron Depot, 22.5 mg or 45 mg IM), triptorelin pamoate (Trelstar, 11.25 mg or 22.5 mg IM), goserelin acetate (Zoladex, 10.8mg SC) or degarelix (Firmagon 120 mg or 240 mg SC) will be administered monthly, every 3 months, or every 6 months, depending on institutional standards, for 36 weeks total.
1959949|NCT03311555|Radiation|Salvage radiation therapy|On week 9 (+/- 28 days), subjects will begin salvage radiation therapy to the prostate bed. The total dose to the prostate bed must be 66-74 Gy in 1.8-2 Gy daily fractions over a total of 6-8 weeks
1959950|NCT03311555|Drug|Docetaxel|About 4 weeks (+/- 2 weeks, pending recovery of adverse events from radiation to Grade 2 or less) after completing radiation, patients will start docetaxel 75mg/m2 intravenously, every 3 weeks for 6 cycles.
1865332|NCT01065987|Drug|Tizanidine|Tizanidine HCl Tablets 4 mg
1865333|NCT01066000|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|initial doses of either 120 micrograms or 200 micrograms or 360 micrograms, once monthly
1865334|NCT01066013|Other|Antimicrobial de-escalation strategy|The antimicrobial de-escalation team will record recommendations for de-escalation in the patient's progress notes for the attending physicians to review and act upon as appropriate. The attending physician will be responsible for making changes to antimicrobial therapy and following up on patient progress as per the usual practice.
1959951|NCT03311542|Biological|pembrolizumab|Each participant will receive pembrolizumab every 21 days for up to 12 month or until confirmed disease progression on MRI or CT, unacceptable toxicity, confirmed.positive pregnancy test or withdrawal of consent.
1865336|NCT01066039|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at dose of 5 milligram (mg) once daily for 24 weeks. If the blood pressure is not less than 130/80 millimeter of mercury (mmHg) during the first 8 weeks of treatment (up-titration), then the dose will be adjusted to 10 mg daily. In cases of hypotensive effect, symptomatic bradycardia or arrhythmia, the daily dose will be reduced to 2.5 mg.
1959952|NCT03311529|Behavioral|Applied Relaxation|10 training sessions (90 min. each) in Applied Relaxation (group format)
1865339|NCT01066078|Other|Echocardiography and SonR recording|
1865340|NCT01066091|Other|Mashed potatoes|Mashed potatoes: Potatoes + Skim milk powder
1865341|NCT01066091|Other|Mashed potatoes + Oleic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 75% of Oleic Acid
1865342|NCT01066091|Other|mashed potatoes + Palmitic acid|Mashed potatoes with 1g/Kg of weight, of lipids with 32% of palmitic acid
1865343|NCT01066104|Drug|Xolair placebo|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
1865344|NCT01066104|Drug|Xolair (omalizumab)|two to four weeks (dosage and frequency will be determined based on patient weight and IgE level)
1865345|NCT01066117|Other|PeeRelease gel absorbent pad|A larger gel containing pad was developed, suitable to absorb up to half a liter liquid, it eliminates odors and enables the users to wear ordinary clothes
1865346|NCT01066130|Behavioral|Intensive individualized psychosocial treatment|Each person was given psychosocial treatment and support by a medical social worker a maximum of one time each week for a period of up to 2 years after inclusion. Treatment was designed by a medical social work on the basis of the individual's personal needs.
1865347|NCT01066130|Behavioral|Minimal treatment arm|Minimal social measures were provided to individuals in this arm. No treatment that included conversational therapy was given.
1865348|NCT01066143|Drug|Seroquel XR|Seroquel XR tablets will be flexibly dosed and begun at a target dose of 50 mg on day 1, 100 mg on day 2, 150 mg on day 3 and 200 mg on day 4 with a maximal daily dose of 400 mg on subsequent days.
1865349|NCT01066156|Drug|Seroquel|This study will investigate therapeutic responses to Seroquel pharmacotherapy in PTSD
1865350|NCT01066169|Biological|Foceteria® (Novartis)|This is not an interventional study. In this observational study we monitored the immune response in a cohort of people who were vaccinated during the national vaccination campaign. The vaccine that was used in The Netherlands is the monovalent influenza A/California/2009(H1N1) MF59-adjuvanted surface-antigen vaccine. It contains 7,5 µg hemagglutinine and the MF59C.1 adjuvant, which is an oil-in-water emulsion, composed of Squalene 9.75 mg, Polysorbate 80 1.175 mg and Sorbitan trioleate 1.175 mg. This vaccine has been approved for use according to a two dose schedule.
1865351|NCT01066182|Dietary Supplement|DHA (docosahexaenoic acid)|3 x 500 mg capsules per day orally, each capsule providing 200 mg of DHA as a triglyceride. The liquid fill contains DHASCO®-S oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
1865425|NCT01066819|Drug|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
1865352|NCT01066182|Dietary Supplement|Sunflower oil capsules|The placebo will consist of 3 x 500 mg capsules per day orally containing high-oleic sunflower oil. The dimensions, taste, appearance and colour will be identical to those of the DHA capsules. The shell of the capsule will be the same as the DHA capsule. The liquid fill contains high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitat and rosemary extract (flavouring).
1865353|NCT01066195|Drug|iressa|iressa 250mg per day every day
1865354|NCT01066195|Drug|alimta|alimta 500mg/m2 every 3 weeks
1865355|NCT01066234|Radiation|concurrent chemoradiotherapy|weekly paclitaxel 50mg/m2 plus weekly cisplatin 25mg/m2 5times with concurrent radiotherapy (5000rad/25fx) for 5 weeks followed by 2 cycles of 3-weekly paclitaxel (175mg/m2) plus cisplatin 80mg/m2.
1865356|NCT01066234|Drug|chemotherapy only|four cycles of 3-weekly paclitaxel (175mg/m2) and carboplatin (AUC5.5).
1865357|NCT01066247|Drug|Morphine hydrochloride; Midazolam|intramuscular morphine 10 mg given 30 minutes before spinal blockade performing
1865358|NCT01066247|Drug|Midazolam|intramuscular midazolam 15 mg given 30 minutes before spinal blockade performing
1865359|NCT01066260|Dietary Supplement|Probiotic formulation|Twice a day for 24 days
1865360|NCT01066260|Other|Placebo|Twice a day for 24 days
1865361|NCT01066273|Device|P-Stim|The P-Stim is a battery-powered, transcutaneous electrical stimulator that delivers 1 per second bipolar 1 millisecond pulses to three points on the auricle. The device connects via three fine insulated stainless steel wires to three needles (each 0.4 mm diameter, 2 mm long) that have been applied to three different points on the auricle. The device is powered by three zinc air batteries, each with a voltage of 1.4 V. The device is on for 180 minutes, then off for 180 minutes, for a maximum period of up to 96 hours. The battery and electronics are contained in a 6 mm by 2.5 mm pack that has one adhesive surface which is applied to the skin behind the ear. The adhesive is conductive and acts as the return for the device. The battery pack is secured with tape.
1865362|NCT01066299|Drug|Syntocinon®|single dose of OXT (24 IU)
1865363|NCT01066299|Drug|inactive nasal spray|single dose (24 IU)
1865364|NCT01066325|Behavioral|Neuro Emotional Technique|"NET is considered an alternative stress-reduction technique. Its aim is to remove neurological abnormalities which have a specified physiopathological pattern. The goal of NET is to normalize the aberrant patterns through a physical correction.
During the NET procedure, various psychological components of the anxious state are considered: cognitions, emotions, and behaviours. These various components are explored for a physiological reaction in the participant. Once a physiological reaction is found, the practitioner helps the participant identify the specific emotion. The procedure is concluded when the patient no longer feels distress or discomfort. Following the intervention, patients frequently report feeling subjective relief."
1865365|NCT01066325|Other|Stretching Instruction|This arm is the Active Control Arm and will receive two 20-minute sessions of Stretching Instructions. During these instructions, participants will hold stretches for not longer than 5 seconds, which in not likely to have any therapeutic effect.
1865366|NCT01066351|Drug|beta erythropoietin|The patients were assigned to receive beta erythropoietin (Recormon) dose 200 unit/kg at 3 day before cardiac surgery and 100 unit/kg in the morning before cardiac surgery.
1865367|NCT01066351|Drug|placebo|The patients were assigned to receive normal saline same volume at 3 day before cardiac surgery and in the morning before cardiac surgery.
1865368|NCT01066364|Drug|Colesevelam Hcl|3.75 gm/day (six 675 mg tablets)
1865369|NCT01066377|Dietary Supplement|Prebiotic and probiotic mix|The probiotic strain will be Bifidobacterium longum bv. infantis CCUG 52486 (10^8 - 10^9 live bacteria per day), which was originally isolated from healthy elderly subjects, and which has been demonstrated to have particular ecological fitness and anti-pathogenic effects in vitro. A suitable prebiotic (8g/day) will be selected on the basis of ability to promote optimal growth and survival of this probiotic (inulin, fructooligosaccharides [FOS], galactooligosaccharides[GOS] and xylooligosaccharides[XOS] will be tested).
1865370|NCT01066390|Biological|TriMix-DC|eligible patients will undergo a leucapheresis for the preparation of autologous TriMix-DC vaccine.4 weeks after the leucapheresis patients will initiate therapeutic vaccination with the TriMix-DC vaccine by IV and ID administration. The vaccines will be administered at 4 different visits that will be separated with an interval of 2 weeks.
1865371|NCT01066403|Drug|Pergolide|"0,3 mg pergolide (the first two days begin with 0,05mg, then increase of dose of 0,1mg every 3 days for a maximum of 0,3mg/d, taken orally 3x 0,1mg/day). Then stable dose of 0,3mg for one week.. Subsequently slow (for 8 days) reduction of dosage of 0,1mg every 3 days for 6 days then 0,05mg every day for the last two days.
Placebo group is identical in appearance and number of placebo capsules, in the same starting and maintenance scheme as for the pergolide group."
1865372|NCT01066416|Procedure|Endoscopic Sinus Surgery|
1865373|NCT01066416|Other|medical therapy|Subjects will undergo surgery 6 months after randomization
1865374|NCT01066429|Drug|Dexamethasone and dose-dense immunochemoterapy|Administration every 14 days of the EDOCH-R scheme.
1865375|NCT01066442|Drug|BF2.649 (Pitolisant)|1 capsule of BF2.649 (5mg, 10mg , 20 mg) O.D
1865376|NCT01066468|Drug|Gleevec/Glivec|
1865377|NCT01066481|Drug|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
1865378|NCT01066481|Drug|PF-01913539 5 mg|PF-01913539 5 mg three times daily for 6 months
1865379|NCT01066481|Drug|Placebo|Placebo three times daily for 6 months
1865380|NCT01066494|Drug|Amonafide + cytarabine|Amonafide 600 mg/m2 IV over 4 hours daily on days 1-5 in combination with cytarabine 200 mg/m2 IV continuous infusion (CI) daily on days 1-7
1865381|NCT01066520|Drug|Traumeel S ointment|2 g, 3 times daily topical during 14 days
1865382|NCT01066520|Drug|Traumeel S gel|2 g, 3 times daily topical during 14 days
1865383|NCT01066520|Drug|Diclofenac gel|2 g, 3 times daily topical during 14 days
1865426|NCT01066832|Drug|Paclitaxel|Paclitaxel-coated balloon (3 µg/mm2)
1865427|NCT01066845|Drug|tadalafil|prescribed in accordance with usual clinical practice
1865428|NCT01066858|Drug|Tenofovir disoproxil fumarate (TDF)|Some participants will receive varying doses of TDF during pregnancy or breastfeeding as part of the larger study (IMPAACT 1077 PROMISE).
1865429|NCT01066871|Drug|Sprifermin (AS902330) 10 mcg|Sprifermin (AS902330) will be administered at a dose of 10 microgram (mcg) as intra-articular injection once every week for 3 consecutive weeks.
1865796|NCT01068327|Drug|leucovorin calcium|Given IV
1865384|NCT01066533|Other|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.After signed consent was given by patients,local anesthesia was applied before operative procedures. Operative procedures were performed with rubber dam placement and disinfected with 2% chlorhexidine gluconate. Class I occlusal cavities were prepared with ¼ round carbide burs under air-distilled water cooling. At the exposure site hemorrhage was controlled by sterile cotton pellets, saline and 5.25% NaOCl.In this group MTA was mixed on a slab according to manufacture's instructions.Then MTA was carried with a carrier to exposed pulp and it was packed with a slight pressure by moist cotton pellet to completely cover the exposed pulp.The cavities were sealed immediately with Fuji II glass ionomer.The teeth were then followed and extracted(8 teeth after 2 weeks and 8 teeth after 8 weeks)
1865385|NCT01066533|Other|direct pulp capping and covering the exposed pulp|In this arm 16 premolar teeth scheduled for extraction for orthodontic reasons were used.All the procedure was carried the same as the other group.But NEC cement was used as pulp capping material.It was mixed with its liquid to provide a dense creamy mixture and then was applied on exposed pulp.the cavities were immediately sealed with Fuji II glass ionomer.The patients were followed and 8 teeth were extracted after 2 weeks and 8 teeth were extracted after 8 weeks.
1865386|NCT01066546|Drug|Dimebon tablet for oral administration|10 mg TID for Week 1, followed by 20 mg TID for remainder of study
1865387|NCT01066559|Procedure|High flux polymethylmetacrylate membrane|Patients will be hemodialysed with high flux polymethylmetacrylate membranes
1865388|NCT01066559|Procedure|Polysulfone membrane|Patients be hemodialysed with polysulfone membranes
1865389|NCT01066559|Biological|Hepatitis B serological control|It will be assessed at week 16, week 20 and week 40
1865390|NCT01066559|Biological|Seric sCD40 level|Ir will be measured at inclusion and week 12 by ELISA test according to the manufacturer instructions.
1865391|NCT01066572|Drug|Lisinopril|5-10 mg Lisinopril per day for seven days, depending on blood pressure.
1865392|NCT01066572|Drug|Placebo|Matched placebo; identical tablets to Lisinopril.
1865393|NCT01066585|Drug|Ivermectin Cream|Up to 4 ounces of topical 0.5% Ivermectin Cream applied to the hair and scalp on day 1
1865394|NCT01066585|Drug|vehicle control|Up to 4 ounces of vehicle control applied to the hair and scalp on day 1
1865395|NCT01066598|Drug|Rituximab|Rituximab 375 mg/m2 IV weekly X 4 doses + Prednisone 1 mg/kg/d
1865396|NCT01066611|Drug|CAL-263|CAL-263 10 mg or placebo once daily for 7 days
1865397|NCT01066611|Drug|Placebo|CAL-263 10 mg or placebo once daily for 7 days
1865398|NCT01066624|Drug|0.9% Sodium Chloride irrigation solution|Patients randomized to this group will be instructed to rinse their mouths twice, with 1 ounce (30 ml) of room temperature 0.9% NaCl (normal saline), 4 times daily after admission and until end of study
1865399|NCT01066624|Other|Cryotherapy (ice chips)|Patients randomized to this group, on day -2 and -1, will be instructed to place approximately 1 ounce of crushed ice in their mouths 15 minutes prior to the initiation of melphalan infusion. The ice will be allowed to melt and should be replenish as soon as it had completely melted. Patients will be instructed to continue this procedure during the melphalan infusion and for 90 minutes after the end of the infusion.
1865400|NCT01066624|Device|Calcium phosphate (Caphosol) Ca2+/PO43- mouth rinse|Patients randomized to this group will be instructed to rinse their mouths with Caphosol 4 times daily after admission and until end of study.
1865401|NCT01066637|Drug|[18F](+/-)NOS|Injection of radiotracer [18F](+/-)NOS for PET imaging and kinetic data analysis
1865402|NCT01066650|Device|Endeavor Resolute (Biolinx-based Zotarolimus-eluting stent)|Drug eluting Stent
1865403|NCT01066650|Device|Xience V (Everolimus-eluting stent)|Drug eluting stent
1865404|NCT01066663|Drug|pyrimethamine|Taken orally once a day
1865405|NCT01066676|Drug|Dexibuprofen|400mg powder for oral suspension, daily dose 800mg
1865406|NCT01066676|Drug|Ibuprofen|400mg, powder for oral suspension, daily dose 1600mg
1865407|NCT01066689|Drug|MabThera|MabThera 500mg/50ml I.V. infusion, single dose : 375 mg/m2
1865408|NCT01066689|Drug|Physiological serum (Sodium Chloride, sodium citrate)|Solution for I.V. infusion Sodium Chloride (pH 6.5), polysorbate 80, sodium citrate (10.0mg/ml)
1865409|NCT01066702|Biological|NeoCart|implantation of an cartilagenous tissue implant derived from the patients own cells.
1865410|NCT01066702|Procedure|Microfracture|holes are created in bone at the base of the defect bed to encourage growth of tissue within the defect bed.
1865411|NCT01066715|Drug|XOMA 052|Sterile solution subcutaneously administered monthly for 6 months
1865412|NCT01066715|Drug|Placebo|Sterile solution subcutaneously administered monthly for 6 months
1865413|NCT01066728|Other|CO2 inhalation|Inhalation of CO2 (3% at the source, approximately 1% inhaled) with room air by nasal prongs at 0.5 l/min for 3 days
1865414|NCT01066728|Drug|Theophylline|
1865415|NCT01066741|Drug|Homeodent®|Two-minute mouthwash with 5 ml of solution diluted in 125 ml of water, 3 times per day after meals and tooth brushing.
1865416|NCT01066741|Drug|1.4% Sodium Bicarbonate solution|Two-minute mouthwash with 125 ml of solution, 3 times per day after meals and tooth brushing
1865417|NCT01066754|Drug|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
1865418|NCT01066767|Drug|Fexofenadine|Fexofenadine Hydrochloride 180 mg Tablets
1865419|NCT01066780|Device|ClearVoice|ClearVoice is a sound processing strategy designed to improve listening ability in some challenging everyday listening environments for users of the Harmony® HiResolution® Bionic Ear System (Harmony®)
1865420|NCT01066793|Drug|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
1865421|NCT01066793|Drug|Peginterferon alfa-2b [PegIntron®]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
1865422|NCT01066806|Behavioral|counseling on increasing calcium intake|The American Academy of Pediatrics recommends that adolescents ingest at least four servings of dairy food and at least 1300 mg calcium per day.
1865423|NCT01066806|Other|observation|observe normal dairy intake
1865424|NCT01066819|Drug|Peginterferon alfa-2a [Pegasys]|Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
1865797|NCT01068327|Drug|fluorouracil|Given IV
1865430|NCT01066871|Drug|Sprifermin (AS902330) 30 mcg|Sprifermin (AS902330) will be administered at a dose of 30 mcg as intra-articular injection once every week for 3 consecutive weeks.
1865431|NCT01066871|Drug|Sprifermin (AS902330) 100 mcg|Sprifermin (AS902330) will be administered at a dose of 100 mcg as intra-articular injection once every week for 3 consecutive weeks.
1865432|NCT01066871|Other|Placebo|Placebo matched to sprifermin (AS902330) will be administered as intra-articular injection once every week for 3 consecutive weeks.
1865433|NCT01066884|Drug|erlotinib [Tarceva]|150mg po daily
1865434|NCT01066897|Drug|Pramipexole|Patients will received increasing dose of pramipexole
1865435|NCT01066910|Behavioral|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
1865436|NCT01066910|Behavioral|Behavioral treatment for childhood obesity|Behavioral treatment for childhood obesity includes nutrition and physical activity recommendations, and behavior therapy skills for parent and child.
1865437|NCT01066923|Drug|Daily aspirin (ASA)|Two weeks 82 mg aspirin taken orally prior to exercise protocol
1865438|NCT01066923|Other|Active cooling|Active cooling to remediate heat stress following exercise by placing hands and forearms into cold water
1865439|NCT01066923|Drug|Acute aspirin (ASA)|325 mg chewable aspirin administered immediately following exercise
1865440|NCT01066923|Other|Passive cooling|Removing protective garments for passive cooling following exercise
1865441|NCT01066923|Drug|Daily placebo|Placebo comparator for daily aspirin therapy
1865442|NCT01066923|Drug|Acute placebo|Placebo comparator for acute aspirin therapy
1865443|NCT01066949|Behavioral|Behavioral self mangement|Seven weekly, hour long group sessions focused on enhancing patient behavioral self management skills.
1865444|NCT01066949|Behavioral|Support and discussion|Seven, weekly hour long group sessions focused on information provision and supportive discussion amongst participants
1865445|NCT01066962|Drug|darunavir/ritonavir QD + raltegravir BID|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)
ritonavir 100 mg, 1 tablet once daily (QD)
raltegravir 400 mg, 1 tablet twice daily (BID)"
1865446|NCT01066962|Drug|darunavir/r QD + tenofovir/emtricitabine QD (fixed dose combination)|"darunavir 800 mg, i.e. 2 tablets of 400 mg once daily (QD)
ritonavir 100 mg, 1 tablet once daily (QD)
tenofovir/emtricitabine 245/200 mg, fixed dose combination, 1 tablet once daily (QD)"
1865447|NCT01066988|Other|ORB Ocular Emulsion|lubricant eye drop
1865448|NCT01066988|Other|SootheXP Emollient (Lubricant) Eye Drops|lubricant eye drop
1865449|NCT01067014|Device|Baxano iO-Flex® System|Decompressive lumbar surgery using Baxano iO-Flex® System
1865450|NCT01067027|Dietary Supplement|Lactobacillus reuteri|5 drops of study product 30 minutes before feeding.
1865451|NCT01067053|Drug|bevacizumab, capecitabine, oxaliplatin|"6 cycles (3 weeks each one) of:
bevacizumab: 7,5 mg/kg (iv), 1st day of each cycle.
capecitabine: 1000 mg/m2 bid, oral. Days: 1-14 every three weeks.
oxaliplatin: 130/mg/m2(iv),1st day of each cycle.
After the first 6 cycles of treatment, continuing only with bevacizumab and capecitabine"
1865452|NCT01067066|Drug|TPI 287|Starting dose cycle 1, 90 mg/m2 by vein (IV) on Days 1, 8, 15 (+/- 1 day)
1865453|NCT01067066|Drug|Temodar (Temozolomide)|Starting dose cycle 1, 85 mg/m^2 by mouth (PO) daily, Day 1 to 5.
1865454|NCT01067079|Other|No vaccine administered; subjects only have blood sampling for immunogenicity|No vaccine administered; subjects only have blood sampling for
1865455|NCT01067092|Behavioral|Community Health Worker Intervention|A Community Health Worker makes 36 home visits to the person with diabetes over a two year period, providing diabetes education and self-management skills training. The curriculum covers recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. CHWs also deliver training in behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
1865456|NCT01067092|Behavioral|Educational Newsletter|Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
1865457|NCT01067105|Drug|ciclesonide HFA 160 μg|ciclesonide HFA 160 μg once daily
1865458|NCT01067118|Drug|LINjeta U-100 Insulin|LINjeta U-100 Insulin will be used per the subjects normal insulin carbohydrate and insulin sensitivity factors
1865459|NCT01067118|Drug|Humalog U-100|Normal short acting insulin used in participants daily life including carbohydrate ratios and insulin sensitivity factors
1865460|NCT01067131|Biological|PEV7C1|capsule intravaginal application contains antigen coupled to virosomes
1865461|NCT01067131|Biological|PEV7C9|capsule intravaginal application contains excipient only
1865462|NCT01067131|Biological|PEV7B2|reconstituted lyophilisate intramuscular application contains antigen at low dose coupled to virosomes
1865463|NCT01067131|Biological|PEV7B1|reconstituted lyophilisate intramuscular application contains antigen at high dose coupled to virosomes
1865464|NCT01067144|Drug|Gabapentin|1200mg Gabapentin preoperative dose, 300mg of Gabapentin three times a day postoperative doses for 72 hour post-surgical period.
1865465|NCT01067144|Drug|Placebo|Active placebo given pre-operatively (0.5mg Lorazepam) in a single dose. 2 capsules of inactive placebo given three times a day post-operatively for the 72 hour post-surgical period.
1865466|NCT01067157|Behavioral|LOGIC|"Experimental group:
Diet (1200-1800 kcal/d), Exercise: 11 h/wk physical activity, Behavioural therapy (group training, 1-3h/wk individualized personal instructions, 2 h parents work)"
1865570|NCT01059071|Drug|Etoposide|Starting with Cycle 2, etoposide will be given at 50mg/m2/dose PO daily for the first 14 days of each 21 day cycle. Capsules will be rounded to closest 50 mg.
1865468|NCT01067183|Behavioral|portable biofeedback tool and relaxation breathing technique|The intervention group were trained in relaxation breathing technique and the use of a portable biofeedback tool that informs them of the success of the technique...thus behavioral therapy using a biofeedback device
1865469|NCT01067222|Drug|BF2.649|BF2.649 oral capsules at 10 or 20 or 40 mg per day
1865470|NCT01067222|Drug|Modafinil|Modafinil oral capsules at 100 or 200 or 400 mg per day
1865471|NCT01067222|Drug|Placebo|Placebo oral capsules, 4 capsules per day
1865472|NCT01067235|Drug|BF2.649|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil Placebo capsules for 8 weeks
1865473|NCT01067235|Drug|BF2.649 add on Modafinil|BF2.649 oral capsules at 10, 20 or 40 mg/day associated with Modafinil capsules at 200 mg per day for 8 weeks
1865474|NCT01067261|Device|Transcutaneous mechanical nerve stimulation (TMNS)|"Device: Transcutaneous mechanical nerve stimulation by A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Danmark)
A medical vibrator (FERTI CARE personel, Multicept A/S, Albertslund, Denmark) will be used. The stimulation works through a vibrating disc of hard plastic with a diameter of 3.5 cm. The stimulation point will be the frenulum. A stimulation sequence consisting of 10 seconds of stimulation followed by a 10 second pause repeated 10 times will be used. The treatment will be initiated 1 to 4 weeks before the radical prostatectomy and re-initiated 0 to 14 days after the operation. The treatment will then continue for 6 weeks. The stimulation will be preformed daily by the patients in their own homes."
1865475|NCT01067261|Other|Pelvic floor muscle training|Regular pelvic floor training which is offered to all patients undergoing a radical prostatectomy at Herlev Hospital.
1865476|NCT01067274|Drug|Vesanoid (ATRA)|45 mg/m2/day in two divided doses from D8 to D28
1865477|NCT01067274|Drug|AZACITIDINE (VIDAZA)|75 mg/m2/12h SC from D1 to D5
1865478|NCT01067274|Drug|CYTARABINE|Cytarabine : 60 mg/m2/12h SC from D1 to D5
1865479|NCT01067287|Drug|CT-011|Infusions starting one to three months following autologous transplant at 6 week intervals for a total of 3 doses
1865480|NCT01067287|Biological|Dendritic Cell Fusion Vaccine|One week following each infusion of CT-011
1865481|NCT01067300|Procedure|Transplantation of unrelated cord blood unit(s)|Myeloablative conditioning regimen includes, according to the patient age, either total body irradiation, fludarabine and cyclophosphamide with a GvHD prophylaxis based on cyclosporine A and mycophenolate, or the association busulfan, cyclophosphamide and anti-thymocyte globulin with GvHD prophylaxis being cyclosporine A and steroids.
1865482|NCT01067313|Device|Dialyzer Ultraflux EMiC2|Dialysate flow rate = 40 ml/kg/h The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
1865483|NCT01067313|Device|Dialyzer Ultraflux AV1000S|Ultrafiltration flow rate = 40 ml/kg/h The blood flow rate will be adjusted to obtain a filtration fraction of 20%. Reinjection = 100% postdilution. The treatment duration may be variable depending on modifications in patient health status, but will not exceed 3 sessions of 48 hours each.
1865484|NCT01067326|Drug|Aliskiren|150 mg Aliskiren once daily for a period of 4 months
1865485|NCT01067326|Drug|Placebo|1 pill per day by mouth for 4 months
1865486|NCT01067339|Drug|darapladib|darapladib, tablet, 160 mg, by mouth, one time daily, 6 month duration
1865487|NCT01067339|Drug|placebo|placebo, by mouth, once daily for six months
1865488|NCT01067352|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human GH were administered subcutaneously (s.c) at the daily dose of 0.067 mg/kg of body weight to Group A1.
1865489|NCT01067365|Drug|Androxal|12.5 mg once daily
1865490|NCT01067365|Drug|Androxal|25 mg once daily
1865491|NCT01067378|Other|Peer-led debriefing|
1865492|NCT01067378|Other|Expert instructor debriefing|
1865493|NCT01067391|Drug|tadalafil|20 mg tablet, administered once per study protocol
1865494|NCT01067391|Drug|placebo|placebo tablet administered once per study protocol
1865495|NCT01067404|Biological|Trivalent inactivated influenza vaccine|0.25mL dose of 2009-10 trivalent inactivated influenza vaccine (TIV)
1865496|NCT01067417|Drug|Hydroxychloroquine|Taken orally 2x200mg capsules once daily for 48 weeks
1865497|NCT01067417|Drug|Placebo|Taken orally 2x200mg capsules once daily for 48 weeks
1865498|NCT01067430|Drug|Etoricoxib|Film coated tablet, 90 mg taken once a day for 14 days
1865499|NCT01067430|Drug|Diclofenac|Enteric coated tablet 50 mg given three times a day for 14 days
1865500|NCT01067443|Drug|Liposomal amphotericin B (AmBisome®) and sodium stibogluconate|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days of SSG at 20mg/kg body weight (IV/IM) from days 2-11
1865501|NCT01067443|Drug|Liposomal amphotericin B + miltefosine|AmBisome® one dose of 10mg/kg body weight (IV) on day 1 followed by 10 days Miltefosine at 2.5mg/kg body weight (oral) from days 2-11
1865502|NCT01067443|Drug|Miltefosine|Monotherapy course of Miltefosine at 2.5mg/kg body weight (oral) from days 1-28
1865503|NCT01067456|Radiation|Comprehensive Cardiothoracic CT arm|Subjects in this arm will receive the comprehensive cardiothoracic CT to rule out aortic dissection/pulmonary embolism/acute coronary syndrome in a single scan.
1865504|NCT01067469|Drug|Standard Dose Bevacizumab|10 mg/kg by vein (IV) over 90 minutes on Days 1, 15, and 29 of 6 week cycle.
1865505|NCT01067469|Drug|Low Dose Bevacizumab|5 mg/kg IV over 90 minutes on Day 1 and 22 (every 3 weeks) of 6 week cycle.
1865506|NCT01067469|Drug|Lomustine|Starting dose of 75 mg/m2 administered orally at sleep time on Day 3 of every 6 week cycle.
1865507|NCT01067495|Behavioral|Cardiac rehabilitation|Participants will participate in a 6-month cardiac rehabilitation exercise program. This program will include aerobic and resistance training, and education sessions on risk factor management.
1865509|NCT01067521|Drug|Glatiramer acetate (GA)|GA 40 mg administered 3 times a week by subcutaneous injection for a period of 12 months
1865510|NCT01067521|Other|Placebo|Placebo comparator
1865511|NCT01067534|Drug|Salbutamol|Inhaler salbutamol 0,1 mg/dose - 4 doses=0,4 mg
1865512|NCT01067547|Drug|Iron Sucrose.|The total dose of iron sucrose given will be individualised by calculating their iron deficit.
1865571|NCT01059084|Drug|Valacyclovir|1000 mg tid
1865572|NCT01059097|Procedure|Pancreaticoduodenectomy|
1865513|NCT01067547|Drug|Iron sucrose|300mg of iron sucrose is given intravenously. Three infusions, each one week apart is given to patients with iron deficiency without anemia. For those patient with anemia, four infusions would be given.
1865514|NCT01058538|Drug|L19IL2|Route: i.v. infusion (60 min) Patients will receive a minimum of 2 cycles of treatment. Each cycle is comprised of treatment on Days 1, 3 and 5 followed by a 16 days rest (1 cycle= 21 days). Patients may receive up to 4 further cycles of treatment (max. of 6 cycles in total). Patients will be initially recruited into the study in cohorts of 3 and the starting dose of L19IL2 will be 5 Mio IU IL2 equivalent. Five steps of dose escalation are planned: 5, 10, 20, 30 and 40 Mio IU IL2 equivalent). After the MTD has been established, the RD will be determined. A further 12 patients (with RCC) will receive the RD dose for a minimum of 2 cycles. For patients in the RD part of the study, patients can switch to maintenance therapy. Maintenance therapy consists of 15 Mio IU IL2 every 2 weeks. The maximum duration of the study for a patient is 12 months.
1865515|NCT01058551|Device|Implantable Loop Recorder Insertion|Implantable Loop Recorder Insertion. The device will be explanted after reaching outcome (First AF detected) or at 36 months
1865516|NCT01058564|Device|Torax Medical, Inc. LINX Reflux Management System|Implantable device, magnetic esophageal sphincter
1865517|NCT01058577|Device|Non-invasive CGMS|A non-invasive continuous glucose monitoring device measured was applied at the wrist and measured skin glucose as an indirect measure of blood glucose every 10 min.
1865518|NCT01058577|Procedure|Hyperglycemic glucose clamp|The automated glucose clamp technique was used to control glucose levels at baseline glycemia for 1h, hyperglycemia (16.7 mmol/L) for at least 2.5h and euglycemia (5 mmol/L) for another 2.5h. A continuous somatostatin infusion was initiated after 1h to suppress endogenous insulin secretion. A glucose solution was infused to increase the blood glucose towards the hyperglycemic target level. At approximately t=3.5h the somatostatin infusion was stopped and blood glucose was controlled at the euglycemic target level.
1865519|NCT01058603|Other|- Conventional culture medium for IVF|Embryos are cultured on conventional medium and transferred at Day 3. Supernumerary good quality embryos are frozen
1865520|NCT01058603|Other|- Endocell®|Embryos are cultured on ENDOCELL® from Day 2 to Day 5 (Blastocyst stage) One embryo is transferred at Day 5. Supernumerary good quality embryos are frozen.
1865521|NCT01058616|Drug|LTX-315 (Oncopore™)|5 mg/ml-70 mg/ml. Dosing will be done as transdermal injection of a calculated volume at day 1 and 8. Additionally weekly injections up to a maximum of 4 injections.
1865522|NCT01058629|Device|SynergEyes A2 Hybrid Contact Lens|SynergEyes A2 is a hybrid contact lens cleared by the US Food and Drug Administration (FDA) for daily wear correction of up to +20.00 and -20.00 in eyes with astigmatism up to 6.00D and for presbyopia.
1865523|NCT01058642|Drug|ADL5747|
1865524|NCT01058642|Drug|Placebo|
1865525|NCT01058642|Drug|Pregabalin|
1865526|NCT01058655|Drug|Everolimus|
1865527|NCT01058655|Drug|Tivozanib|
1865528|NCT01058668|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine for three weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
1865529|NCT01058668|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for three weeks.
1865530|NCT01058681|Dietary Supplement|effect of metabolic variations on LH pulsatility|"Isocaloric diet: 1,5 times basal metabolism. Constitution:55% carbohydrates, 15% proteins and 30% fat.
Hypercaloric diet: addition of 30% fat and 3 g of fructose/kg of weight to isocaloric diet.
PO and IV glucose during clamps: PO administration of 90 mg/kg glucose at 90 minutes intervals during the clamp, and adjustment of the IV perfusion to keep euglycemia."
1865531|NCT01058694|Behavioral|Short Message Services to Support ARV therapy adherence|Short message services were sent to randomly selected consenting subjects on ARV therapy. The frequency and content of the message is varied in a factorial design.
1865532|NCT01058707|Drug|MLN0128|MLN0128 will be administered orally with one of 4 different dosing schedules - once daily (QD), once weekly (QW), once daily for 3 days on;4 days off repeated each week (QDX3d QW), and once daily for 5 days on;2 days off repeated each week (QDX5d QW)
1865533|NCT01058720|Dietary Supplement|Vitamin D3|2000 IU orally once daily for 12 weeks
1865534|NCT01058733|Other|Internet|new clinical decision-supporting system for glucose monitoring, SARS, which could identify glucose data recorded by patients and make some optimal decisions.The SARS engine assigned subjects to one of three levels according to the glucose control status and glucose control method.
1865535|NCT01058746|Other|restrictive perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hour IV (8am to time of induction) during induction of Anesthesia. Maintenance IV Normosol or equivalent solution at 6 ml/kg/operative hour. Blood loss to be replaced volume: volume with colloid until transfusion criteria met. Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) at the discretion of the Anesthesiologist to maintain patient hemodynamic stability.
1865536|NCT01058746|Other|Liberal perioperative fluid management|Normosol or equivalent solution 0.5 ml/kg/fasted hr IV (8am to time of induction) of Anesthesia. Maintenance IV Normosol or equiv solution at 6 ml/kg/oper hr. At randomiz to the Liberal arm in the OR, an addit bolus of Normosol or equiv solution 1.5 ml/kg/fasted hr IV (8am to time of induction) will be given to bring the total to Normosol or equiv solution 2ml/kg/fasted hr IV (8am to time of induction). Pt will get an addit bolus of Normosol or equivalent solution 6ml/kg/oper hr. Maintenance IV Normosol or equivalent solution will then commence at 12ml/kg/operative hr with maximum of 1000 ml/operative hr. Blood loss replaced volume: with colloid, until transfusion criteria met (Additional fluid boluses of 100ml Normosol or equivalent solution or bolus pressors (phenylephrine 40mcg or ephedrine 5mg) used at the discretion of the Anes to maintain pt hemodynamic stability. Addit fluid boluses of 250ml Normosol or equivalent solution for urine output less than 1ml/kg for 2 hrs.
1865537|NCT01058759|Drug|Enoxaparin|
1865538|NCT01058759|Other|No Enoxaparin|
1865539|NCT01058772|Other|INDUCTION of LABOUR|Induction of labour will be performed by using dinoprostone 2 mg vaginally or dinoprostone 0.5 mg intracervically at 6-8h interval (up to 5 doses) or dinoprostone 10 mg vaginal device. Patients, in which cervical ripening does not occur (Bishop score < 7) after 5 attempts with PGE2, will be offered either oxytocin or Foley catheter induction or C-section, according to local protocols.
1865573|NCT01059110|Drug|Salicylate ointment|cream, one application every night, for 90 days
1865540|NCT01058785|Biological|Lucanix|Monthly intradermal injections of four irradiated allogeneic TGF-beta2 antisense gene modified NSCLC cell lines. Patients are randomized to receive either 12,500,000, 25,000,000 or 50,000,000 cells per injection for up to 16 injections.
1865541|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
1865542|NCT01058824|Drug|Lincomycin|Single Dose Hard Gelatin Capsule - oral - 500 mg
1865543|NCT01058850|Biological|Rindopepimut|250 or 500 mcg; intradermal injection
1865544|NCT01058863|Drug|Albuterol Spiromax®|Albuterol Spiromax® delivers 90 mcg albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
1865545|NCT01058863|Drug|ProAir® HFA|ProAir® HFA delivers 90 mcg of albuterol per inhalation. Doses of 180 mcg require two inhalations. Intervention given as double-blind medication on 2 of 5 treatment days, once at 90 mcg and once at 180 mcg.
1865546|NCT01058863|Other|Placebo Inhaler|Placebo delivered in both the Spiromax® and HFA inhalers to maintain the blind and also to support the placebo treatment arm.
1865547|NCT01058876|Drug|Deuterated nicotine and cotinine|used as a marker for pharmacokinetic studies
1865548|NCT01058889|Device|Telemedical device|Monitoring of blood glucose,insulin dose, blood pressure, lifestyle factors with the telemedical device. Monitoring of system availability, percentage of data transfer, acceptance.
1865549|NCT01058902|Drug|Aspirin 75 mg|Aspirin 75 mg
1865550|NCT01058902|Other|no aspirin|nothing
1865551|NCT01058915|Drug|Rosuvastatin 5mg|Rosuvastatin 5mg/day
1865552|NCT01058915|Drug|Rosuvastatin 40mg|Rosuvastatin 40mg/day
1865553|NCT01058928|Other|Observation of fluid leakage around tracheal tube cuffs|One milliliter of Evans blue diluted in 3.5 mL of saline solution is carefully instilled on the top of the tracheal tube cuff. In the operating room, one hour and five hours after intubation, fiberoptic bronchoscopy was performed to detect the possible presence of blue dye in the trachea. If a blue spot was seen on the trachea caudal to the tube's tip on any occasion, leakage was confirmed and the experiment was finished.
1865554|NCT01058941|Drug|Lipoic acid and fish oil concentrate|Lipoic acid (600 milligrams per day) and fish oil concentrate (3 grams per day) for 18 months
1865555|NCT01058941|Drug|Placebo|Placebo LA and placebo oil capsules for 18 months
1865556|NCT01058980|Procedure|Additional ablation until elimination of dormant conduction|Additional RF energy will be delivered at sites of re-conduction on the circular mapping catheter in each PV. Abolition of the dormant conduction will then be assessed by repeated injections of adenosine using the same doses previously used to reveal dormant conduction. Additional ablation as described will be performed until re-injection of adenosine shows no re-conduction in any of the PV.
1865557|NCT01058980|Procedure|No additional ablation|Presence of dormant PV conduction, no additional ablation.
1865558|NCT01058980|Procedure|Registry group|Among those who will be found not to have the presence of dormant conduction, and within each site, three-quarters of the patients will be randomly selected to be included in the registry group.
1865559|NCT01058980|Procedure|Usual medical care|Clinical follow-up will be performed according to the regular follow-up after AF ablation procedures in each of the participating centers. No data will be collected after discharge.One-fourth of the patients will be randomly selected to be included in the usual medical care group.
1865560|NCT01058993|Drug|AMD3100 or plerixafor|The study will examine the hematological effects/safety of plerixafor in patients with myelokathexis attributable to mutations of CXCR4. Plerixafor will be administered on days 1, 3, 5, 8, and 10. Five intrapatient escalating doses of AMD 3100, 20 micrograms per kilogram (mcg/kg), 40 micrograms per kilogram (mcg/kg), 80 micrograms per kilogram (mcg/kg), and 240 micrograms per kilogram (mcg/kg) will be examined in the patients at University of Washington General Clinical Research Center for up to 10 days, requiring subjects be available up to 14 days. Patients will be monitored for hematological effects of plerixafor and observed for adverse effects. If normal blood neutrophil count is achieved and maintained for at least 24 hours prior to highest dose, we will stop at that level.
1865561|NCT01059006|Procedure|PresbyLASIK|PresbyLASIK essentially involves the creation of a multifocal surface able to correct any visual defect for distance while simultaneously allowing freedom from near spectacle dependency in presbyopic patients.
1865562|NCT01059019|Dietary Supplement|Omega-3 Fatty Acid Supplements|Twenty patients labeled as group A (Control Group) will not receive the omega-3 supplement. The Control Group will be treated in the same standard professional way as our normal refractive patients, while another 20 patients labeled as group B (Treatment group) will be given omega- 3 supplements 1 capsule 3 x a day for 2 weeks pre op and 1 month post op plus the regular post op medications. From these supplements, this will be equivalent to 750 mg of omega 3 fatty acids (both EPH and DHA), 1000 mg of Flaxseed oil, and about 183 IU of vitamin E per day. Patients will be asking to follow up postoperatively after 2 days, 4 days, 1 week, 3 months and 6 months
1865563|NCT01059032|Other|Using a 3 dimentional post processing filter|Using a 3 dimentional post processing filter
1865564|NCT01059045|Procedure|cryocontact therapy|cryocontact therapy of hemangioma is realized by using liquid nitrogen cooled metal devices
1865565|NCT01059045|Other|Control|No intervention
1865566|NCT01059058|Procedure|MI Paste Plus|A trained staff member from the NW PRECEDENT dental/orthodontic office will give 3 tubes of MI Paste Plus (10% CPP-ACP + 900 ppm Fluoride paste) and instructions to the subject for home use. A pea-sized amount for each arch will be applied 2x/day for 8 weeks. Subjects will apply cream topically to the teeth with their finger or a cotton swab, spread around with their tongue, hold for 1-2 minutes, then expectorate.
1865567|NCT01059058|Procedure|PreviDent Fluoride Varnish|A trained staff member from the NW PRECEDENT dental/orthodontic office will provide a SINGLE application of PreviDent fluoride varnish (22,600 ppm Fluoride) to the subject. The total dosage will be 0.5 mL.
1865568|NCT01059058|Procedure|Normal Home Care|Subjects will receive non-prescription fluoride toothpaste (1100 ppm Fluoride) and oral hygiene instructions. The dosage will be 1/2 inch strip of paste 2x/day for 8 weeks. Subjects will apply paste to a toothbrush and brush teeth thoroughly for at least 1 minute then expectorate.
1865569|NCT01059071|Drug|DFMO|"Escalating doses of DFMO in a 3 +3 cohort design.
DFMO at current cohort Dose Level orally each day for 21 day cycles
Dose level 1: 500 mg/m2 PO BID Dose level 2: 750 mg/m2 PO BID Dose level 3:1000 mg/m2 PO BID Dose level 4:1500 mg/m2 PO BID"
1865798|NCT01068327|Drug|nelfinavir mesylate|Given PO
1865574|NCT01059110|Drug|Imiquimod|cream, one dose of 250 mg, one application 3 times a week during 12 hours, for 90 days
1865575|NCT01059110|Drug|5-Fluoro-Uracil|cream, one application every night, during 12 hours, for 90 days
1865576|NCT01059110|Drug|Cryotherapy|2 cycles of 5 seconds after obtention of halo of white
1865577|NCT01059123|Drug|Amoxicillin|50 mg/kg/24H ; Per Os ; 3 times/day 6 days
1865578|NCT01059123|Drug|Amoxicillin|50 mg/kg/24H in I.V. ; 3 times/day ; up to apyrexia then amoxicillin ; 50 mg/kg/24H ; Per Os ; 3 times/day up to day 14.
1865579|NCT01059136|Drug|Spironolactone|Unique 200mg IV dose of Potassium Canrenoate followed by 25 mg daily oral dose of Spironolactone for 6 months
1865580|NCT01059149|Device|repetitive transcranial magnetic stimulation|MagPro x100 (MagVenture A/S, DANEMARK)
1865581|NCT01059162|Device|Laser Assisted Non-penetrating glaucoma surgery|A layer by Layer ablation of the deep sclera (under the superficial scleral flap) to achieve functional fluid percolation of the inner eye humor without penetration.
1865582|NCT01059175|Device|Additional Endocardial or Epicardial LV Lead|Addition of a second left ventricular endocardial or epicardial lead
1865583|NCT01059175|Device|CRT-P or CRT-D|Implantable Cardiac Resynchronization Therapy Pacemaker (CRT-P) or Defibrillator (CRT-D) Device
1865584|NCT01059188|Drug|cetuximab|400 mg/m2 initial dose on day 1 250 mg/m2 weekly starting on day 8 and for 12 weeks
1865585|NCT01059188|Drug|cisplatin|50 mg/m2 on day 1 and 2 of 21 day cycles, for 3 cycles
1865586|NCT01059188|Drug|docetaxel|85 mg/m2 day 1 of 21 day cycles, for 3 cycles
1865587|NCT01059188|Radiation|Radiotherapy|44 Gy (PTV1=30 Gy, PTV2=14 Gy), for 3 weeks, after the 3 cycles of Cisplatin / Docetaxel treatment
1865588|NCT01059188|Procedure|Surgery|Ipsilateral formal mediastinal lymphadenectomy. In case of involved N3 lymph nodes, resection of the precarinal and contralateral nodes.
1865589|NCT01059253|Other|AdvanStep training program - Turtle Pop|Balance / mobility exercise program using the AdvanStep in a virtual reality context
1865590|NCT01059266|Drug|PURETHAL Grasses, 20.000 AUM/ml|subcutaneous injections of increasing doses according to the described regimen
1865591|NCT01059305|Drug|Erlotinib|150 mg daily by mouth before surgery and/or radiation therapy (Induction Treatment); and after surgery and/or radiation erlotinib for up to 1 year (Maintenance Phase).
1959955|NCT03311503|Biological|autologous CD34+ cell transduced with G2SCID vector|single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) lentiviral vector G2SCID
1865595|NCT01059331|Drug|Pregabalin|150 mg x 2 daily for 2 days
1865596|NCT01059331|Drug|Sugar pill|1 tablet x 2 daily, for 2 days
1865597|NCT01059344|Drug|Mesalamin|4.8g/day, 800 mg tablets
1865598|NCT01059357|Device|Da Vinci Robotic Transoral Robotic Surgical System|(TORS) Da Vinci Robotic Transoral Robotic Surgical System
1865599|NCT01059370|Procedure|bowel emptying|Bowel is emptied using Peristeen® irrigation system one day, by digital stimulation another trial day or filling the bladder with saline water on a third trial day. BP is measured by Finometer Pro®, respiration frequency by BIOPACK and skin conductivity measured by Biopack and nor-epinephrine and epinephrine are measured in plasma three times during each examination.
1865600|NCT01059383|Drug|VECAM 40/300|1 capsule, orally, once daily at bedtime.
1865601|NCT01059383|Drug|Esomeprazole 20 mg|1 capsule, orally, once daily 30-60 min. before dinner
1865602|NCT01059396|Drug|propranolol|GPVH ≥ 10 mmHg - responders: propranolol.
1865603|NCT01059396|Drug|carvedilol|GPVH ≥ 10 mmHg nonresponders: carvedilol.
1865604|NCT01059396|Drug|placebo|placebo propranolol / carvedilol
1865605|NCT01059409|Procedure|Meniscal Allograft|Meniscal Allograft
1865606|NCT01059422|Drug|Raltegravir; Abacavir/Lamivudine|Raltegravir: 400 mg twice daily Abacavir/Lamivudine fixed-dose combination: 600mg/300mg once daily
1865607|NCT01059435|Drug|AMG 785|Subjects will be randomized to receive 1 of 6 doses of AMG 785 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 785 or placebo as a weight-based dose of 0.1 mg/kg, 0.3, 1, 3, 5, or 10 mg/kg subcutaneously (SC, under the skin), or 1 mg/kg or 5 mg/kg intravenously (IV, in the vein), while men will receive doses of 1 mg/kg or 5 mg/kg SC or IV.
1865608|NCT01059435|Drug|Placebo|Subjects will be randomized to receive 1 of 6 doses of AMG 785 or equivalent volume of placebo administered as a single dose. Postmenopausal women will receive AMG 785 or placebo as a weight-based dose of 0.1 mg/kg, 0.3, 1, 3, 5, or 10 mg/kg subcutaneously (SC, under the skin), or 1 mg/kg or 5 mg/kg intravenously (IV, in the vein), while men will receive doses of 1 mg/kg or 5 mg/kg SC or IV.
1865609|NCT01059448|Drug|AMG 827|AMG 827 210 mg
1865610|NCT01059461|Drug|Cerebrolysin®|injection of cerebrolysin® 0.1ml/kg IM twice weekly for 10 injections after discharge from NICU (postneonatal)
1865611|NCT01059474|Drug|transdermal DMPS|"12 hr urine mercury and creatinine levels will be measured on all volunteers prior to any treatment. The urine will be collected in acid-washed or heavy-metal-free specialty containers. Each volunteer will then receive 120 mg of transdermal DMPS, applied to the bicep area of one arm. The area of application will not exceed 2% body surface area. After dosing, urine will be collected for the next 12 hours (using the same protocol and send-out procedure) and assayed for mercury and creatinine levels.
Additionally, after dosing, an intravenous catheter will be placed in the arm of each subject for blood draws. Blood samples will be obtained at 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 6 hours after application of the DMPS."
1865612|NCT01059487|Other|Traditional Chinese Medicine|Traditional Chinese Medicine includes acupuncture, herbal, tuina and other accessory techniques
1865616|NCT01059526|Drug|ecallantide|30 mg SC
1865617|NCT01059539|Drug|cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
1865618|NCT01059552|Drug|vorinostat|vorinostat once daily for 12 weeks of therapy
1865619|NCT01059565|Drug|AZLI|Aztreonam for inhalation solution (AZLI; 75 mg aztreonam/52.5 mg lysine monohydrate) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
1865620|NCT01059565|Drug|Placebo|Placebo to match AZLI (lactose and sodium chloride) was administered three times a day, with at least 4 hours between doses, using the investigational nebulizer.
1865621|NCT01059578|Drug|GSK206136|GSK206136 2mg, 10mg, 50mg, 100mg capsule
1865622|NCT01059578|Drug|PLACEBO|Placebo to match 206136 2mg, 10mg, 50mg, 100mg capsule
1865623|NCT01059578|Radiation|PET|Each subject will undergo 3 PET Scans ; one at Baseline and the others following dosing with GSK206136 at approximately 2 hours post-dose and 24 hours post-dose
1865624|NCT01059591|Drug|GSK424887|GSK424887 2mg, 10mg, 50mg, 100mg capsule
1865625|NCT01059591|Drug|Placebo|Placebo to match GSK424887 2mg, 10mg,50mg, 100mg capsule
1865626|NCT01059591|Radiation|PET|Each subject will undergo 3 PET scans : one at Baseline and the others following dosing with GSK424887 at approximately 2h post-dose and aproximately 24 hours post-dose
1865627|NCT01059604|Drug|Sumatriptan|Sumatriptan
1865628|NCT01059604|Drug|Naratriptan|Naratriptan
1865629|NCT01059604|Drug|Sumatriptan-naproxen combination|Sumatriptan-naproxen combination
1865630|NCT01059617|Biological|GSK Biologicals' FluLaval®|Intramuscular injection
1865631|NCT01059617|Biological|Placebo (saline)|Intramuscular injection
1865632|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340274A|Intramuscular injections
1865633|NCT01059617|Biological|GSK Biologicals' investigational H1N1 Influenza Vaccine - GSK2340273A|Intramuscular injections
1865634|NCT01059630|Drug|Obinutuzumab|IV infusion.
1865635|NCT01059630|Drug|Bendamustine|IV infusion.
1865638|NCT01059656|Drug|Pazopanib|Administration of pazopanib per os 800mg/ qd during 6 months until stable response according to primary endpoint, with 3 monthly successive examinations, and for a period of study not exceeding 18 months.
1865639|NCT01059669|Other|diagnostic test|
1865640|NCT01059682|Drug|Dalcetrapib|Dalcetrapib 600 mg orally once daily
1865641|NCT01059682|Drug|Placebo|Placebo orally once daily
1865642|NCT01059721|Procedure|Medialising insertion of patella tendon|surgical treatment of medialising tibial tuberosity
1865643|NCT01059734|Genetic|DNA analysis|
1865644|NCT01059734|Genetic|RNA analysis|
1865645|NCT01059734|Genetic|mutation analysis|
1865646|NCT01059734|Genetic|polymerase chain reaction|
1865647|NCT01059734|Genetic|polymorphism analysis|
1865648|NCT01059734|Other|laboratory biomarker analysis|
1865649|NCT01059747|Other|no intervention applied|no intervention applied
1865650|NCT01059760|Behavioral|Fasting First|28±4 hours of water-only fasting followed by 28±4 hours fed
1865651|NCT01059760|Behavioral|Fed First|28± 4 hours fed followed by 28± 4 hours of fasting
1865652|NCT01059773|Drug|Ustekinumab|Patients weighting ≤ 100 kg will receive ustekinumab 45 mg at Weeks 0, 4 and 16. Patients who achieve a PASI 75 response at Week 28 and 40 will continue receiving ustekinumab 45 mg at Week 28 and 40. Patients who fail to achieve PASI 75 response at Week 28 will receive ustekinumab 90 mg at Week 28 and 40. Patients who achieve a PASI 75 response at Week 28, but fail to achieve PASI 75 response at Week 40 will receive ustekinumab 90 mg at Week 40. Patients > 100 kg will receive ustekinumab 90 mg at Weeks 0, 4, 16, 28 and 40, regardless of achievement of PASI 75 response. Consideration will be given to discontinuing treatment in these patients if they show no response at Week 28.
1865653|NCT01059773|Drug|Methotrexate|Gradual reduction of methotrexate therapy over the 4 week period after Week 0. The methotrexate dose reduction regime will depend on the dose of methotrexate at screening. All patients will stop methotrexate regardless of the final dose after 4 overlapping weeks. The last dose of methotrexate will be given within the 7 day period before the second dose of ustekinumab.
1865657|NCT01059799|Drug|insulin degludec|Insulin degludec injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
1865658|NCT01059799|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily. The doses will be individually adjusted
1865659|NCT01059812|Drug|insulin degludec/insulin aspart|Injected subcutaneously twice daily. Dose was individually adjusted.
1865660|NCT01059812|Drug|biphasic insulin aspart 30|Injected subcutaneously twice daily. Dose was individually adjusted.
1865661|NCT01059825|Drug|Placebo to Ertugliflozin|Tablet(s), 1 or 2, matching placebo to 1-mg, 5-mg and/or 25-mg tablets, once daily for 84 days
1865662|NCT01059825|Drug|Ertugliflozin 1 mg|Tablet, 1 mg, once daily for 84 days
1865663|NCT01059825|Drug|Ertugliflozin 5 mg|Tablet(s), 1 or 2, 5-mg tablets once daily for 84 days
1865664|NCT01059825|Drug|Ertugliflozin 25 mg|Tablet, 25 mg, once daily for 84 days
1865665|NCT01059825|Drug|Sitagliptin 100 mg|Tablet, 100 mg, once daily for 84 days
1865666|NCT01059825|Drug|Placebo to Sitagliptin|Tablet, matching placebo to 100 mg, once daily for 84 days
1865667|NCT01059825|Drug|Metformin|Participants continued pre-study stable doses of metformin during the run-in and treatment periods of the study (maximum dose up to 2500 mg/day or 3000 mg/day where the maximum metformin dose per the local country product labels was 3000 mg/day).
1865936|NCT01069432|Other|No Intervention|No Intervention
1865668|NCT01059838|Behavioral|sentence recognition|testing the ability for sentence recognition in quiet and in noise.
1865669|NCT01059851|Drug|Suvorexant|single oral dose of 20 mg (administered as 2 x 10 mg tablets) of suvorexant administered with ~240 mL of water after an 8 hour fast
1865670|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
1865671|NCT01059864|Drug|Atorvastatin|Starting at Week 6 and continuing through Week 12 atorvastatin 10 mg oral tablets administered once daily
1865672|NCT01059864|Drug|CP-690,550|12 week open-label CP-690,550 10 mg oral tablets administered twice daily starting at Day 0 through Week 12
1865673|NCT01059864|Drug|Atorvastatin Placebo|Starting at Week 6 and continuing through Week 12 atorvastatin placebo tablets administered once daily
1865675|NCT01059890|Drug|cefotaxime|
1865676|NCT01059890|Drug|Metronidazole|
1865677|NCT01059890|Drug|Ciprofloxacin|
1865678|NCT01059890|Drug|Fosfocine|
1865679|NCT01059903|Drug|Rotigotine transdermal patch|Rotigotine 4.5 mg/10 cm^2 patch applied for 24 hours
1959957|NCT03311477|Drug|ABBV-399|Intravenous infusion
1865685|NCT01059942|Other|mock handoff exposure|Attending and house-staff physicians will analyze six video scenarios using the Hand-off CEX, rating each of the dimensions of hand-off competence for both the senders and receivers of the mock hand-off.
1865686|NCT01059942|Other|Introduction of CEX tool in Actual Hand-offs|We will teach hospitalist physicians and house-staff how to utilize the Hand-off CEX in conducting their own hand-offs.
1865687|NCT01059955|Drug|Dexamethasone Phosphate Ophthalmic Solution (EGP-437)|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only).
1865688|NCT01059955|Drug|Dexamethasone phosphate ophthalmic solution|Transcleral iontophoretic delivery of dexamethasone phosphate ophthalmic solution. Dexamethasone phosphate ophthalmic solution as a ready to use 40 mg/mL solution (preservative free and intended for single-use only)
1865689|NCT01059994|Drug|Placebo sildenafil|Oral, daily, 1 week.
1865690|NCT01059994|Drug|Sildenafil|oral, 25mg, daily for 1 week
1865691|NCT01060007|Radiation|External beam radiation|
1865692|NCT01060007|Drug|Oxaliplatin|
1865693|NCT01060007|Drug|Leucovorin|
1865694|NCT01060007|Drug|5-FU|
1865695|NCT01060007|Drug|Capecitabine|
1865696|NCT01060020|Drug|Sildenafil|Single oral dose of 40mg or 80mg of Sildenafil
1865697|NCT01060033|Device|MR Spectroscopy|
1865698|NCT01060033|Device|Fat-Saturation and Diffusion-Weighted Imaging|
1865699|NCT01060033|Device|Dynamic Contrast Enhancement MRI (MR-DCE)|
1865700|NCT01060033|Device|Diffusion Tensor Imaging (DTI)|
1865701|NCT01060059|Drug|exenatide|subcutaneous injection, 5mcg or 10mcg, twice a day
1865702|NCT01060059|Drug|basal insulin|subcutaneous injection, dosing according to physician's clinical judgment
1865703|NCT01067599|Other|Low nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
1865704|NCT01067599|Other|Medium nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
1865705|NCT01067599|Other|High nicotine|Comparison of different dosages of nicotine effect on tobacco use patterns, subjective response and biomarker levels.
1865706|NCT01067625|Device|TOGA® System|Formation of restrictive sleeve via transoral gastric stapling for treatment of obesity
1865707|NCT01067638|Drug|Tranexamic Acid|1.0g loading dose before skin incision and continuous infusion 200 mg/h during surgery
1865708|NCT01067651|Device|Plaster of Paris (POP) casting using the Ponseti Method|
1865709|NCT01067651|Device|Semi-Rigid Fiberglass softcast using the Ponseti Method|
1865710|NCT01067677|Drug|Metaclopramide|0.5 mg/kg for rescue after PONV
1865711|NCT01067677|Drug|Ondansetron|0.1 mg/kg (max 4 mg0
1865712|NCT01067677|Drug|diphenhydramine|0.25 mg/kg (max 25 mg)
1865713|NCT01067677|Drug|Saline|equal volume (5 ml)as experimental rescue medications
1865714|NCT01067690|Drug|Indinavir in association with Vinblastina +/- Bleomicina|Treatment consists in an induction phase where daily Indinavir (800 mg x 2/die, orally) will be combined together with systemic Vinblastine (10 mg intravenously) +/- Bleomycin (15 mg intramuscularly) in cycles administered every 3 weeks. As maximal response will occur, patients will undergo 2 additional Vinblastine +/- Bleomycin (consolidation) cycles upon continuous treatment with Indinavir. This will be followed by a maintenance phase with Indinavir alone (800 mg x 3/die, orally) in responder patients.
1865715|NCT01067703|Procedure|Remote Ischemic Preconditioning|RIPC will be induced during anesthesia by four 5-min cycles of upper limb ischemia and 5-min reperfusion using a blood-pressure cuff inflated to a pressure 200 mm Hg, whereas the pressure has to be at least 20 mm Hg greater than the systolic arterial pressure measured via the arterial line.
1865716|NCT01067703|Procedure|Control/sham procedure (blood pressure cuff)|Sham placement of the blood pressure cuff around a dummy arm inflated to a pressure of 200 mm Hg with four cycles of 5 min inflation and 5 min deflation.
1865717|NCT01067716|Device|STAR S4IR LASIK with VSS-R ablation profile|LASIK treatment targeted for emmetropia
1865718|NCT01067729|Device|AWBAT Wound Dressing|TBD
1865719|NCT01067729|Device|AWBAT™, Biobrane®|Comparison of burn dressings on randomized body sites using patient as own control
1865759|NCT01068119|Procedure|Same-day discharge|Patients identified as clinically stable are discharged home the same day as the PCI procedure with telephone follow-up at 12 hr, 24 hr, 3, 30, 180 and 365 days post procedure.
1865720|NCT01067755|Device|LungPoint Virtual Bronchoscopic Navigation (computer-assisted image-guided bronchoscopic navigation)|LungPoint Virtual Bronchoscopic Navigation is a product that displays images and information to aid bronchoscopists in guiding the bronchoscope and other instruments to a target location in the lung airways.
1865721|NCT01067768|Other|Daily review|"Daily nursing review of the urinary catheter´s indication. If the patient meets at least one of the entries to stay with bladder catheter, the nurse will record collection in the format but will not contact the health team. If there aren´t indication in the medical record, she contacts at the attending physician and said: Doctor, I didn´t find record in the history of the indication of the urinary catheter, can we withdraw?. If the physician reported the indication, will be recorded in the format without additional comments.
The attending physician decides withdraw or no withdraw the urinary catheter"
1865722|NCT01067781|Biological|Heat-Labile Enterotoxin of E. coli (LT)|Travelers' Diarrhea Vaccine System
1865723|NCT01067781|Biological|Placebo|Travelers' Diarrhea Vaccine System
1865724|NCT01067794|Drug|Any platinum-based doublet chemotherapy|Dosage, dosage form, frequency and duration according to daily hospital practice
1865725|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (252 mg of Gelucire and 88 mg of PEG400, original formulation) [Original], single dose
1865726|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (coated with microcrystalline cellulose, new formulation) (coated), single dose
1865727|NCT01067807|Drug|25 mg Proellex|25 mg - given as one 25 mg capsule (blended with microcrystalline cellulose, new formulation) [Blended], single dose
1865728|NCT01067807|Drug|50 mg Proellex|50 mg - given as two 25 mg capsules (blended with microcrystalline cellulose, new formulation) [Blended], single dose
1865729|NCT01067820|Drug|RVX000222|capsule, 200 mg, administer with food, 100 mg twice daily 10-12 hrs apart, 26 weeks
1865730|NCT01067820|Drug|Placebo RVX000222|capsule, administer with food, twice daily 10-12 hrs apart, 26 weeks
1865731|NCT01067833|Drug|K201 Tablet|oral tablet, x28 days
1865732|NCT01067833|Drug|Placebo Tablet|oral tablet, x28 days
1865733|NCT01067846|Drug|Seromycin (D-cycloserine, DCS)|250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
1865734|NCT01067846|Drug|Placebo|Placebo identical looking to the 250 mg DCS once weekly for 4 weeks prior to the initiation of a Computerized Cognitive Behavioral Therapy (CBT) session for drug relapse intervention.
1865735|NCT01067846|Behavioral|Computerized Cognitive Behavioral Therapy|All participants received Computerized Cognitive Behavioral Therapy sessions 3 times per week for 4 weeks as a drug relapse intervention.
1865736|NCT01067859|Drug|Cinaciguat (BAY58-2667)|Infusion of 25 µg/h during 48 hours
1865737|NCT01067859|Drug|Cinaciguat (BAY58-2667)|Infusion of 10 µg/h during 48 hours
1865738|NCT01067859|Drug|Placebo|Infusion of placebo during 48 hours
1865739|NCT01067885|Device|MARIS-stent (Invatec)|stenting of SFA with Maris nitinol stent/s
1865740|NCT01067898|Dietary Supplement|vitamin D3 (cholecalciferol)|vitamin D3 (cholecalciferol) oil 20 000 IU/ml, oral dose of 200 000 IU or 100 000 IU (10ml or 5ml) every three months for one year.
1865741|NCT01067898|Other|olive oil|10 ml (placebo group) or 5 ml (100 000 IU vitamin D3 group) oil per os every three months for one year
1865742|NCT01067898|Dietary Supplement|calcium carbonate|1000 mg calcium per os every day for one year
1865743|NCT01067911|Dietary Supplement|Butter and Vegetable oils from soy, flaxseed, high oleic safflower and canola|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
1865744|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
1865745|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
1865746|NCT01067911|Dietary Supplement|In this study subjects will consume test meals containing vegetable oils (soy, flaxseed, high oleic safflower and canola) and butter|Test meals prepared with different common fats and oils and consumed by test subjects. Postprandial lipids will be assessed for 6 hours after the consumption of the test meal.
1865747|NCT01067989|Drug|Cyclophosphamide, Capecitabine, Methotrexate, Celecoxib, Pamidronate (or Zoledronate)|"Cyclophosphamide Tab. 50mg, 1x1/day, continuously.
Capecitabine Tab. 500mg, 1+2/day, continuously.
Methotrexate Tab. 2.5mg, 1x2/day, 2 days every week.
Celecoxib Tab. 200mg, 1x2/day, continuously.
Pamidronate I.V. 90mg, every 4 weeks; or Zoledronate I.V. 4mg, every 4 weeks)"
1865748|NCT01068015|Other|behavior intervention and male circumcision|MSM in intervention arm can receive circumcision service for free, POL intervention, intensive HIV counseling and intensive condom promotion.
1865749|NCT01068028|Drug|ORM-12741|Ascending multiple doses to sequential panels
1865750|NCT01068028|Drug|Placebo for ORM-12741|
1865751|NCT01068041|Drug|PH3|Each PH3 tablet, 530 mg/tablet, contains 250 mg of active ingredient. The placebo tablet contains no active ingredient.
1865752|NCT01068054|Drug|tacrolimus|0.1% ointment,apply bid, 8 weeks
1865753|NCT01068054|Drug|cyclosporins|2% eyclosporine eye drops apply 1 drop to each eye QID
1865754|NCT01068067|Other|drug (tacrolimus and SchE) and genetics|Patients were genotyped for the polymorphisms that can influence tacrolimus pharmacokinetics before transplantation. After transplantation, initial tacrolimus dosage was based on an algorism guided by pharmacogenetics and SchE.
1865755|NCT01068067|Drug|tacrolimus|After transplantation, patients received standard initial dose of tacrolimus (0.050-0.075 mg/kg).
1865756|NCT01068093|Drug|Ezetimibe|10mg daily
1865757|NCT01068106|Device|Nobori® (Biodegradable polymer limus-eluting stents)|due randomization biodegradable polymer limus-eluting stents will be implanted
1865758|NCT01068106|Device|Xience-V® (Permanent polymer limus-eluting stent)|due randomization permanent polymer limus-eluting stent will be implanted
1865795|NCT01068327|Drug|gemcitabine hydrochloride|Given IV
1865760|NCT01068132|Drug|Cetuximab|cetuximab 500 mg/ m² starting dose, following everytwo- week doses of 500 mg/ m², given d1,
1865761|NCT01068132|Drug|FOLFIRI|irinotecan 180 mg/m2 on day 1 with LV 100 mg/m2 administered as a 2-hour infusion before FU 400 mg/m2 administered as an intravenous bolus injection, and FU 600 mg/m2 as a 22-hour infusion immediately after FU bolus injection on days 1 and 2
1865762|NCT01068145|Drug|SCH 527123|Very low dose SCH 527123, once daily for 7 days
1865763|NCT01068145|Drug|SCH 527123|Low dose SCH 527123, once daily for 7 days
1865764|NCT01068145|Drug|SCH 527123|Medium dose SCH 527123, once daily for 7 days
1865765|NCT01068145|Drug|SCH 527123|High dose SCH 527123, once daily for 7 days
1865766|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 7 days
1865767|NCT01068145|Drug|SCH 527123|Low dose capsule SCH 527123, once daily for 14 days
1865768|NCT01068145|Drug|SCH 527123|Medium dose capsule SCH 527123, once daily for 14 days
1865769|NCT01068145|Drug|SCH 527123|High dose capsule SCH 527123, once daily for 14 days
1865770|NCT01068145|Drug|Placebo|Placebo capsules to match SCH 527123, once daily for 14 days
1865771|NCT01068158|Drug|0.5% Ivermectin Cream|Up to 4 ounces of 0.5% Ivermectin Cream applied to hair and scalp on day 1.
1865772|NCT01068158|Drug|Placebo control|up to 4 ounces of topical vehicle control to head and scalp on day 1.
1865773|NCT01068171|Other|type of footwear|comparison of results between post-op shoe, air boot which the patient can remove ad lib and air boot whose removal can be monitored
1865774|NCT01068171|Other|collagen dressing with and without silver|silver-impregnated collagen dressing will be used for 2 weeks, then plain collagen dressing will be used for the remainder of the 6 months
1865775|NCT01068184|Drug|AZD6553|Single or multiple oral dose
1865776|NCT01068184|Drug|Placebo|single or multiple oral dose
1865777|NCT01068197|Behavioral|Low Glycemic Load Diet versus Low Fat Diet|"We propose a randomized controlled clinical trial to evaluate the effectiveness of a low-glycemic load diet versus low-fat diet on insulin sensitivity, body composition, and other hormonal and biochemical measures. The culturally competent and family-based Intervention program has a dietary experimental component (low-glycemic load versus low-fat diet), as well as elements of physical activity, reduction in sedentary behavior and behavior modification. The nutrition training sessions are divided into 12 modules taught over a 12-week course. Care has been taken to make the content and intensity of the low-fat and low-glycemic load programs comparable. Both treatments include 12 weekly sessions, followed by nine monthly, and four 3-monthly sessions.
Participants are obese (BMI ≥95th percentile for age and sex) Hispanic American children ages 7-14 years."
1865778|NCT01068210|Behavioral|Exercise Training|The overall goal for all the exercise training groups will be 3 supervised exercise sessions per week an intensity between 50 to 100% of the individually determined VO2peak for aerobic training and an intensity between 50% to 85% of 1-RM for resistance training. All the exercise interventions are designed such that participants begin exercising at a low intensity (~50%-60% VO2peak / 1RM) that is subsequently increased to more moderate to vigorous intensity (~70%-100% VO2peak / ~70-85% 1RM) when appropriate. All interventions will be individually tailored to each patient following the principles of aerobic or resistance training prescription guidelines for adults.
1865779|NCT01068210|Behavioral|Progressive Stretching|The ultimate goal for the progressive stretching program is 3 individual stretching sessions. All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
1865780|NCT01068223|Drug|A:JNJ-39758979/Placebo #1|Single oral dose of JNJ-39758979 600 mg and Placebo
1865781|NCT01068223|Drug|C:Cetirizine/JNJ-39758979 Matching Placebo|JNJ-39758979 Matching Placebo and Placebo #2
1865782|NCT01068223|Drug|B: JNJ-39758979 Matching Placebo /Placebo #2|A single dose of 2 different Placebos
1865783|NCT01068236|Behavioral|Healthy lifestyle managment|Exercise, yoga, food diaries, provider consultation
1865784|NCT01068249|Drug|Letrozole|2.5 mg daily by mouth every day, at same time as Everolimus.
1865785|NCT01068249|Drug|RAD001 (Everolimus)|10 mg by mouth daily
1865786|NCT01068262|Drug|Odanacatib|Oral doses of Odanacatib 50 mg administered once weekly for 4 consecutive weeks
1865787|NCT01068262|Drug|Comparator: Placebo|Oral Placebo tablet administered once weekly for 4 consecutive weeks
1865788|NCT01068275|Procedure|lumbar plexus catheter|lumbar plexus catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
1865789|NCT01068275|Procedure|femoral nerve catheter|femoral nerve catheter with 0.2% ropivacaine at 0.15 ml/kg/hr (max 10 ml/hr)
1865790|NCT01068275|Procedure|single-shot femoral block|single-shot femoral block with 0.2% ropivacaine 0.3 ml/kg (max 20 ml)
1865791|NCT01068288|Procedure|Laparoscopic or open appendectomy|
1865792|NCT01068288|Procedure|Expectant Management|"A consult to Interventional Radiology will be made at the time of admission to determine whether percutaneous drainage is feasible, and if it is the abscess will be drained by Interventional Radiology. Ultrasound and/or CT scan will be used to follow the abscess collections and/or phlegmons and guide the removal of drains.
For patients with a fecalith on imaging, a laparoscopic interval appendectomy will be performed 6-12 weeks following discharge from hospital. For those without a fecalith on imaging, a decision will be made by the family, with the guidance of the surgeon, whether or not to undergo a laparoscopic interval appendectomy."
1865793|NCT01068301|Drug|Plerixafor|Plerixafor in combination with fludarabine, thiotepa and melphalan as a conditioning regimen for patients undergoing a second allogeneic transplant procedure (bone marrow or peripheral blood). A traditional 3+3 phase I design will be employed during this study, where dose escalations are planned in groups of 3 participants. No intra-participant escalation will be allowed and dose escalation will not be considered until toxicity information is available from at least 3 evaluable participants at the current dose level.Plerixafor will be given intravenously (IV) rather than subcutaneously (SQ) to minimize discomfort associated with repeated daily injections (up to 3) to the pediatric population of this study.
1865794|NCT01068314|Other|Repetitive arm exercise|After baseline testing and randomization, subjects in this group are instructed to perform repetitive handgrip exercise with an upper arm compression band until arm fatigue occurs. After resting 1 minute this exercise is repeated 9 times daily for 6 weeks.
1865799|NCT01068327|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
1865800|NCT01068327|Radiation|hypofractionated radiation therapy|Undergo radiotherapy
1865801|NCT01068327|Procedure|therapeutic conventional surgery|Undergo surgery
1865802|NCT01068353|Biological|Etanercept|50 mg given as a once weekly subcutaneous injection
1865803|NCT01068353|Other|Placebo|Placebo injection given once weekly
1865804|NCT01068379|Procedure|criopexy|he cryopexy was performed by placement of a normal spherical probe under the bucklings, around the break. The number of cryo applications was limited in number of 3. Freezing was stopped at the beginning of retinal whitening.
1865805|NCT01068379|Procedure|laser|Laser-retinopexy was performed after proper positioning the patients; laser energy was delivered by depressing a foot pedal. Short burn duration (0.1 seconds) and low (300-miliWatts) power settings were used initially, and both the burn duration and power were gradually increased as determined by observation.
1865806|NCT01068392|Drug|Oxaliplatin, Prednisolone|"OXALIPLATIN+PREDNISOLONE (OX-P)
D1 Oxaliplatin 130mg/m2 + 5DW 500ml MIV over 2hr
D1-5 Prednisolone 40-30-30 mg/day P.O
every 3 weeks"
1865807|NCT01068405|Drug|Methotrexate|Methotrexate: 10mg/week administered in one time, the same day each week (every monday for example)during 12 months
1865808|NCT01068405|Drug|Placebo|Placebo:10mg/week administered in one time, the same day each week (every monday for example)during 12 months
1865809|NCT01068418|Dietary Supplement|Vitamin D (cholecalciferol)|cholecalciferol 15,000 IU daily for 30 days
1865810|NCT01068431|Other|bandaging with trico as active controller|In general non-elastic bandaging is the compression treatment in lymphedema
1865811|NCT01068444|Drug|Pioglitazone|"Name: GLITOS（Pioglitazone）
Dosage form: Tablets
Dose(s): 30mg
Dosing schedule: QD
Duration: 6 months"
1865812|NCT01068444|Drug|placebo|placebo 30 mg/d for 6 months
1865813|NCT01068483|Drug|BKM120|
1865814|NCT01068509|Biological|Cvac|Cvac consists of autologous dendritic cells (DCs) incubated with the antigen, mannosylated fusion protein (M-FP), to target the DCs to the specific mucin 1 antigen.
1865815|NCT01068522|Device|Parenchymal Intracranial pressure monitor|Treatment based on readings from Parenchymal intracranial pressure monitor.
1865816|NCT01068522|Other|Treatment based on clinical and imaging observations|Treatment based on clinical and imaging observations.
1865817|NCT01068548|Other|reminder|computer based reminder to change patients from IV to oral antibiotics based on evidence based clinical practice guidelines
1959958|NCT03311464|Drug|adalimumab|Study drug will be administered subcutaneously.
1865819|NCT01068574|Other|BASIC Score (Observational)|The BASIC Score will be assessed by a study staff, but there are no interventions.
1865820|NCT01068587|Drug|MET/VEGFR2 inhibitor Foretinib|"PhaseI and Phase II Arm A:
Foretinib PO daily dosing starting cycle 1 day 15 and erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I."
1865821|NCT01068587|Drug|erlotinib hydrochloride|erlotinib PO daily dosing starting cycle 1 day 1. Recommended Phase II dose to be determine in Phase I.
1865822|NCT01068587|Other|laboratory biomarker analysis|Tumour markers alone cannot be used to assess objective tumour response. If markers are initially above the upper normal limit, however, they must normalize for a patient to be considered in complete response
1865823|NCT01068600|Drug|Indacaterol|Once daily via single-dose dry powder inhaler (SDDPI)
1865824|NCT01068600|Drug|Placebo to indacaterol|Once daily via SDDPI
1865825|NCT01068613|Drug|QAX028|QAX028 60 mcg via inhalation device
1865826|NCT01068613|Drug|QAX028|QAX028 20 mcg via inhalation device
1865827|NCT01068613|Drug|Tiotropium|Tiotropium via inhalation device
1865828|NCT01068613|Drug|Placebo|Placebo to QAX028 via inhalation device
1865829|NCT01068626|Drug|Rosuvastatin|10 mg once daily
1865830|NCT01068626|Drug|Placebo for rosuvastatin|once daily
1865831|NCT01068639|Behavioral|No treatment given|No treatment given to study participants, only behaviorial patterns with respect to treatment compliance is observed.
1865832|NCT01068652|Drug|insulin detemir|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin).
1865833|NCT01068652|Drug|insulin aspart|Pending evaluation of HbA1c every 3 months, insulin aspart was added to the insulin detemir treatment (up to three does daily, injected s.c. (under the skin)
1865834|NCT01068652|Drug|biphasic insulin aspart 30|Initial dose of 0.1 U/kg once daily, injected s.c. (under the skin). Pending evaluation of HbA1c every 3 months, the dose will intensified up to 3 doses daily
1865835|NCT01068652|Drug|metformin|1000-2000 mg/day in combination with insulin treatment
1865836|NCT01068665|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
1865837|NCT01068665|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
1865838|NCT01068678|Drug|insulin degludec|Injected subcutaneously (under the skin) three times weekly. Dose was individually adjusted.
1865839|NCT01068678|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily. Dose was individually adjusted.
1865840|NCT01068691|Procedure|Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)|"Ambulatory blood pressure monitoring (to evaluate the level of blood pressure)
Blood pressure
Obstructive sleep apnea syndrome (OSAS)
Carotid-to-femoral pulse wave velocity (PWV)
Biological parameters"
1865841|NCT01068704|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, ~ 12 months depending on response
1865842|NCT01068704|Drug|Lapatinib|Tablets, Oral, 1500 mg, once daily, ~ 12 months depending on response
1865843|NCT01068704|Drug|Letrozole|Tablets, Oral, 2.5 mg, once daily, ~ 12 months depending on response
1865844|NCT01068717|Drug|Saxagliptin, 2.5 mg + Metformin, 500 mg (fasted state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
1959959|NCT03311451|Device|C2 CryoBalloon 180° Ablation System|The C2 CryoBalloon 180° Ablation System is a cryosurgical device with a nitrous oxide cooled balloon probe that is compatible with upper gastrointestinal therapeutic endoscopes.
1990505|NCT01999530|Drug|Prazosin Hydrochloride|Gradual upward titration to 15mg/day for approximately three weeks.
1865845|NCT01068717|Drug|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fasted state)|Tablets, oral, 2.5-mg saxagliptin/500-mg metformin fixed-dose combination (FDC), once daily, 1 week
1865846|NCT01068717|Drug|Saxagliptin, 2.5 mg + Metformin, 500 mg (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin, once daily, 1 week
1865847|NCT01068717|Drug|Saxagliptin, 2.5 mg /Metformin, 500 mg FDC (fed state)|Tablets, oral, 2.5-mg saxagliptin and 500-mg metformin FDC, once daily, 1 week
1865848|NCT01068730|Drug|metformin (Diabex)|Tablets, Oral, 500 mg, Once daily, single dose
1865849|NCT01068730|Drug|metformin (Glucophage™)|Tablets, Oral, 500 mg, Once Daily, single dose
1865850|NCT01068730|Drug|metformin (Glucophage™)|Tablets, Oral, 1000 mg, Once daily, single dose
1865851|NCT01068730|Drug|metformin (Diabex)|Tablets, Oral, 1000 mg, Once daily, single dose
1865852|NCT01068743|Drug|saxagliptin|Tablets, Oral, 2.5 mg, once daily, single dose
1865853|NCT01068743|Drug|metformin|Tablets, Oral, 850 mg, once daily, single dose
1865854|NCT01068743|Drug|saxagliptin + metformin (FDC tablet)|Tablet, oral, (saxagliptin 2.5 mg) (metformin 850 mg), once daily, single dose
1865855|NCT01068756|Drug|Dapagliflozin|Tablets, Oral, 10 mg, 2 single oral 10 mg doses, 2 days
1865856|NCT01068756|Drug|Rifampin|Capsules, Oral, 600 mg, Once daily on days 4 to 11, 8 days
1865857|NCT01068769|Drug|regorafenib|Taken orally, once a day in the morning for 3 weeks followed by a one week rest period
1865858|NCT01068782|Drug|XL184|given orally as capsules
1865859|NCT01068795|Drug|enoxaparin|enoxaparin dosage will be adjusted according to anti-factor Xa plasma levels
1865860|NCT01068808|Procedure|skin prick test|skin prick test to aeroallergen
1865861|NCT01068821|Other|Gel pad|A gel pad (mattress) (approximately 3cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
1865862|NCT01068821|Other|Egg crate foam mattress|An egg-crate foam mattress (approximately 5cm thick) is placed under the patient on top of the usual operating room mattress, directly in contact with patient's skin from buttocks to shoulders with the patient in dorsal lithotomy position under general anesthesia. Time in Trendelenburg's position and time operating are both recorded. The position of two bony landmarks (left anterior superior iliac spine and left acromioclavicular joint) are marked before Trendelenburg's position (30 to 45 degrees below horizontal) and immediately after returning the patient to horizontal position.
1865863|NCT01068834|Genetic|KIF6 genetic test|KIF6 carrier status with interpretation sheet provided to subject
1865864|NCT01068847|Drug|2-4 of the drugs listed below|Cycloserine: 500, 675, 750 mg oral capsules may possibly given. Naloxone: 0.15mg/70Kg or 0.2mg/70kg I.M. injection may possibly be given. Nifedipine: 10, 20 mg oral capsules may possibly be given. Placebo (sugar pill or microcrystalline cellulose): oral capsules may be given. Saline: I.M. injection may possibly be given. Tizanidine: 4, 8, 12 mg oral capsules may possibly be given. Verapamil: 30, 60, 120 mg oral capsules may possibly be given.
1865865|NCT01068860|Drug|Canakinumab 150 mg|Single subcutaneous injection of Canakinumab 150 mg.
1865866|NCT01068860|Drug|Placebo to Canakinumab|Single subcutaneous injection of Placebo to Canakinumab.
1865867|NCT01068873|Drug|lopinavir/ritonavir plus maraviroc|Lopinavir/ritonavir 400 mg/100 mg two tablets twice daily with Maraviroc 150 mg one tablet twice daily will be administered for 48 weeks to participants meeting entry criteria.
1865868|NCT01068886|Procedure|External pancreatic stent|stent through pancreatic anastomosis
1865869|NCT01068912|Drug|Favipiravir|1000 mg favipiravir BID x 1 day, and 400 mg favipiravir BID x 4 days
1865870|NCT01068912|Drug|Favipiravir|High-dose favipiravir regimen: 1200 mg favipiravir BID x 1 day, and 800 mg favipiravir BID x 4 days
1865871|NCT01068912|Drug|Placebo comparator|Placebo BID x 1 day, and Placebo BID x 4 days
1865872|NCT01068925|Drug|GSK1349572|"GSK1349572 QD x 5 days
TPV/RTV 500/200mg BID x 7 days
GSK1349572 50mg QD and TPV/RTV 500/200mg BID x 5 days"
1865873|NCT01068938|Device|three different perimeters: HFA, Octopus, MATRIX|visual fields
1865874|NCT01068951|Biological|Mesenchymal stem cells|Autologous transplantation of the patients own mesenchymal stem cells (approximately 2 x 106 cells/kg body weight) intravenously.
1865875|NCT01068964|Drug|0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost/0.5% Timolol Ophthalmic Solution Bottle 2: Vehicle Ophthalmic Solution
1865876|NCT01068964|Drug|0.03% Bimatoprost Ophthalmic Solution and 0.5% Timolol Ophthalmic Solution|One drop from each bottle, administered once daily in the evening for 4 weeks Bottle 1: 0.03% Bimatoprost Ophthalmic Solution Bottle 2: 0.5% Timolol Ophthalmic Solution
1865877|NCT01068977|Drug|bevacizumab|Repeating intravenous dose
1865878|NCT01068977|Drug|MetMAb|Repeating escalating intravenous dose
1865879|NCT01068977|Drug|MetMAb|Repeating intravenous dose
1865880|NCT01069003|Drug|Placebo Arm|Placebo and ASA (75 mg - 325 mg)
1865881|NCT01069003|Drug|Thienopyridine Therapy|Prasugrel 5 or 10 mg or Clopidogrel 75 mg plus ASA (75 mg - 325 mg)
1865882|NCT01069003|Device|Surveillance Arm|Non randomized arm to understand clinical outcomes in a commercial setting
1865883|NCT01069016|Procedure|Sacral nerve modulation|For one week the sacral nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
1865884|NCT01069016|Procedure|Pudendal nerve stimulation|For one week the pudendal nerve is continuously stimulated by an external pulse generator. Strength of stimulation can be adjusted by the patient.
1865885|NCT01069042|Drug|Enalapril|All subjects will initially receive 10mg of enalapril and be gradually titrated up to 20mg with blood pressure tolerance for 6 months.
1865886|NCT01069055|Other|Sterile Saline|Group I: 100 ml intravenous saline infusion as placebo 30 minitues before the surgery.
1865887|NCT01069055|Drug|Intravenous lornoxicam|Group II: 8 mg intravenous lornoxicam infusion in 100 ml saline 30 minitues before the surgery.
1865888|NCT01069055|Drug|Intravenous paracetamol|Group III: 1 g intravenous paracetamol infusion in 100 ml saline 30 minitues before the surgery.
1865889|NCT01069081|Drug|Arm C|Docetaxel and cisplatin chemotherapy combined with high dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 200mg p.o. d1-3 every week for 66 weeks.
1865890|NCT01069081|Drug|Arm B|Docetaxel and cisplatin chemotherapy combined with lower dose PPI. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.PPI 160mg p.o. d1-3 every week for 66 weeks.
1865891|NCT01069081|Drug|Arm A|Docetaxel and cisplatin chemotherapy. Docetaxel 75mg/m2 intravenous d1, cisplatin 75mg/m2 intravenous d1,repeated every 3 weeks.Each patient is designed to receive no more than 6 cycles of chemotherapy.
1865892|NCT01069094|Drug|Progenta|12.5 mg, administered as a once daily oral dose for 90 days.
1865893|NCT01069094|Drug|Progenta|25 mg, administered as a once daily oral dose for 90 days.
1865894|NCT01069094|Drug|Progenta|50 mg, administered as a once daily oral dose for 90 days.
1865895|NCT01069094|Drug|Lucron Depot|3.75 mg IM monthly
1865896|NCT01069094|Drug|Placebo|Administered as a once daily oral dose for 90 days.
1865897|NCT01069107|Other|Cottage Hospital Care|Care at a cottage hospital compared with care at a general hospital
1865898|NCT01069120|Drug|Proellex|2, 25 mg capsules once per day
1865899|NCT01069120|Drug|Proellex|1, 25 mg capsule once per day
1865900|NCT01069133|Drug|Rifaximin|550mg BID open-label
1865901|NCT01069133|Drug|rifaximin|550mg PO BID
1865902|NCT01069146|Procedure|Mild therapeutic hypothermia induction|Mild Therapeutic hypothermia was induced immediately after patient inclusion. Patients were cooled between 32 and 34°c (33 ± 1°C; 90 and 93°F) for 36 hours, using the automatic mode of an external water cooling blanket (Meditherm II®, Gaymar, Orchard Park, NY, USA). The machine constantly compares actual patient temperature (measured by a rectal probe) with the set point, and automatically adjusts the blanket water temperature so that the desired patient temperature is achieved. The target temperature was to be reached within eight hour following inclusion. Rewarming was only passive (blanket switched off), and paralytic agents were to be stopped when the body temperature reached back 36°C (97°F).
1865903|NCT01069159|Drug|Propranolol Hydrochloride|The protocol of the study requires that two doses of propranolol (regular propranolol 40 mg followed two hours later by long-acting propranolol 60 mg) or placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Subjects will be randomized in a 1:1 ratio to either Propranolol treatment or placebo.
1865904|NCT01069159|Drug|Placebo|The protocol of the study requires that two doses of placebo be given at the first visit, to be taken within one hour of the reactivation of the traumatic memory. Half of the subjects (33) will be randomized to receive placebo.
1865905|NCT01069172|Device|FS Laser Surgery|The Catalys System is an ophthalmic surgical laser system intended for use in cataract surgery to perform capsulotomy, lens segmentation, and lens softening, which are all part of cataract surgery when this femtosecond laser is used.
1865906|NCT01069172|Procedure|CCC Surgery|Subjects will receive the standard of care for CCC and U/S cataract surgery to facilitate removal of the crystalline lens. CCC is a procedure that is part of cataract surgery.
1865907|NCT01069185|Procedure|Necessity endotracheal suctioning|Endotracheal suctioning depends on clinical manifestations
1865908|NCT01069185|Procedure|Routine endotracheal suctioning|Endotracheal suctioning every two hours
1865909|NCT01069198|Drug|Albendazole, Iron, Zinc and Vitamin A|single oral dose of 200,000 IU Vitamin A at baseline and after six months, 35 mg and 65 oral elemental iron for subject aged <5 and >=5 years respectively everyday for two months starting from enrollment; 10 mg oral zinc for 10 consecutive days each month for 6 months; and a single 400 mg oral dose of albendazole at 3-months' intervals.
1865910|NCT01069198|Other|Placebo|Placebo
1865911|NCT01069237|Device|OPTI-FREE RepleniSH|Multi-Purpose Solution for soft contact lenses
1865912|NCT01069237|Device|Clear Care|Lens Care Solution for contact lenses
1865913|NCT01069250|Other|There are no interventions in this study|
1865914|NCT01069263|Other|Hyperbaric Oxygen Therapy|60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
1865915|NCT01069263|Drug|DMSO|50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
1865916|NCT01069276|Other|No intervention in this study|No intervention in this study
1865917|NCT01069289|Drug|Budesonide/formoterol (Symbicort Turbuhaler)|2x160/4.5 microgram, inhalation, twice daily, 12 weeks
1865918|NCT01069289|Drug|Formoterol (Oxis Turbuhaler)|2 X 4.5 microgram, inhalation, twice daily, 12 weeks
1865919|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 600mg and maintenance 150mg for 7days
1865920|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 600mg and maintenance 75mg for 7days
1865921|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 300mg and maintenance 150mg for 7days
1865922|NCT01069302|Drug|Clopidogrel|Clopidogrel loading 300mg and maintenance 75mg for 7days
1865925|NCT01069328|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 200 mg orally BID interrupted dosing
1865926|NCT01069328|Drug|Nexavar (Sorafenib, BAY43-9006)|Sorafenib 400 mg orally BID interrupted dosing
1865927|NCT01069328|Drug|Bevacizumab|Bevacizumab 2.5 mg/kg intravenously
1865928|NCT01069328|Drug|Bevacizumab|Bevacizumab 5 mg/kg intravenously
1865929|NCT01069328|Drug|Bevacizumab|Bevacizumab 7.5 mg/kg intravenously
1865930|NCT01069328|Drug|Bevacizumab|Bevacizumab 10 mg/kg intravenously
1865931|NCT01069328|Drug|Paclitaxel|Paclitaxel 200 mg/m² intravenously
1865932|NCT01069328|Drug|Carboplatin|Carboplatin AUC 6 intravenously
1865933|NCT01069341|Drug|Ranibizumab|Intravitreally administered 0.5mg ranibizumab, 3 doses administered monthly.
1865934|NCT01069367|Biological|Emulsion, Cell Culture-based, influenza HA vaccine H1N1|Cell-derived A/H1N1 influenza HA vaccine (0.25 mL as injection volume)
1865935|NCT01069393|Other|DAFNE course (Timing of delivery of education)|Education delivered over one day a week for 5 consecutive weeks, as opposed to 5 consecutive days over 1 week.
1865937|NCT01069445|Dietary Supplement|VSL#3® probiotic blend|Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
1865938|NCT01069445|Dietary Supplement|AISA-5203-L fruit extracted terpene|Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
1865939|NCT01069445|Dietary Supplement|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
1865940|NCT01069445|Behavioral|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform.
1865941|NCT01069458|Other|The high protein diet group and the low fat diet group|The High Protein Diet Group was advised to have 25 energy percent from protein, 55 energy percent from fat, 20 energy percent from carbohydrate in the diet and the Low Fat Diet Group was advised to have 30 energy percent from fat, 20 energy percent from protein, 50 energy percent from carbohydrate in the diet.
1865942|NCT01069471|Biological|Shigella vaccine|Two intramuscular injections of bioconjugate vaccine will be administrated at D0 and D60.
1865943|NCT01069484|Other|Postpartum pelvic floor muscle training|Beyond a customary leaflet and thorough initial instruction on how to contract the PFM correctly, the training participants will attend one weekly supervised exercise class led by an experienced physiotherapist, and perform daily training at home. The intervention starts 6-8 weeks postpartum and last for 4 months. General principles for strength training are followed: 3 sets of 8-12 contractions close to maximum (Bø 1990, Haskell 2007). Emphasis will be on progression in force development. The participants are provided with a DVD of the program (www.corewellness.co.uk). At week 4 during the intervention, the PFM strength will be assessed for each participant. Training adherence at home will be recorded in a training diary, whereas the physical therapist will record group session adherence.
1865944|NCT01069497|Other|Prevention of infections program|"The intervention mainly involves implementing urinary, respiratory and gastrointestinal infection prevention measures. Study nursing home medical coordinators will be in charge of training their own teams. For this, they will be provided with:
a slide-show of recommendations (commented by an expert),
recommendations guides (on paper and on computer) to be shown to their teams. Means will be provided to the intervention nursing homes : Hydro-alcoholic solutions, disinfectant detergent-impregnated tissues, mouth care kits, tec."
1865945|NCT01069510|Drug|Spironolactone|Spironolactone 25 mg daily for 12 months
1865946|NCT01069510|Other|Placebo|Placebo daily for 12 months
1865947|NCT01069523|Drug|Guanfacine Extended Release|Guanfacine is an alpha-2A agonist which is given one a day. the dose range is 1-4 mg. It is a tablet.
1865948|NCT01069523|Drug|Placebo|Table that match the 1 mg Guanfacine Extended Release Tablet. They are dosed once a day.
1865949|NCT01069536|Drug|metoclopramide 10 mg|
1865950|NCT01069562|Other|Conventional control|The isoflurane administration to deliver anesthesia will be done conventionally through a Tec 7 vaporiser to maintain the bispectral index at 50.
1865951|NCT01069562|Other|Closed loop control|The isoflurane administration to maintain anesthesia will be by infusion to the anesthesia circuit using syringe pump (injection technique). The rate of delivery of isoflurane will be regulated by computer that uses a control algorithm.
1865952|NCT01069575|Biological|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
1865953|NCT01069601|Biological|Focetria (2x H1N1 vaccine with MF59 adjuvants)|7,5µg H1N1sw monovalent vaccine with MF59 adjuvants; two doses 3 weeks apart
1865954|NCT01069614|Device|TopClosure 3S System|
1865955|NCT01069627|Drug|bevacizumab [Avastin]|15 mg/kg intravenously on day 1 of every 3 week cycle
1865956|NCT01069627|Drug|fotemustine|100 mg/m² intravenously on Days 1, 8, and 15, followed by 4 weeks of rest, then every 21 days up to 4 to 6 cycles
1865957|NCT01069640|Biological|HLA-A*0201 or HLA-A*0206-restricted URLC10 peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
1865958|NCT01069653|Biological|HLA-A*2402-restricted CDCA1 and KIF20A peptides|Escalating doses of every peptide will be administered by subcutaneous injection on days 1, 8, 15 and 22 of each treatment cycle. Planned doses of peptides are 1.0mg, 2.0mg and 3.0mg.
1865959|NCT01069692|Drug|SBR759A|SBR759A 6g daily
1865960|NCT01069692|Drug|SBR759A|Placebo Comparator 0g daily
1865961|NCT01069692|Drug|SBR759A|SBR759A 3g daily
1865962|NCT01069692|Drug|SBR759A|9g daily
1865963|NCT01069692|Drug|SBR759A|12g daily
1865964|NCT01069705|Drug|Tobramycin inhalation powder|Tobramycin inhaled powder
1865965|NCT01069757|Drug|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ 197 and orally once daily administration of erlotinib hydrochloride
1865967|NCT01069783|Drug|A3309|A3309 in two different dosage levels
1865968|NCT01069783|Drug|A3309|A3309 in two different dosage levels for the duration of the study
1865969|NCT01069783|Drug|Placebo|Placebo comparator once daily for the duration of the trial
1865970|NCT01069796|Drug|Paclitaxel|80 mg/m² weekly
1865971|NCT01069796|Drug|Bevacizumab|10 mg/kg d1 d15
1865972|NCT01069796|Drug|Capecitabine|800 mg/m² p.o. twice a day, D1 to D5 week 1, 2 & 3
1865973|NCT01069809|Biological|AGS-004|HIV-1 Immune Therapy
1865974|NCT01069809|Biological|Placebo|Inactive Placebo Injection
1865975|NCT01069822|Drug|AZD6765|IV solution
1865976|NCT01069822|Drug|midazolam|
1865977|NCT01069861|Drug|sildanefil|Intravenous sildenafil citrate will be administered as a loading dose of 0.1 mg/kg given over 30 minutes. This will be followed by a maintenance treatment consisting of an intravenous infusion of 0.03 mg/kg/hr. The duration of the infusion will be determined by the need of the individual patient, but will be reviewed at Day 7 if still ongoing, and will not continue past Day 14.
1865978|NCT01069874|Dietary Supplement|Cholecalciferol (Vitamin D/Vigantol oil)|Cholecalciferol will be administered as 2-monthly oral bolus doses of Vigantol oil over a period of one year
1865979|NCT01069874|Dietary Supplement|Miglyol oil|Miglyol oil will be administered as 2-monthly oral bolus doses of Miglyol oil over a period of one year
1865980|NCT01069900|Drug|Moxifloxacin (Avelox, BAY12-8039)|For subjects 12 to less than (<) 18 years of age and weighing at least 45 kilograms (kg), the dose of moxifloxacin will be 400 milligrams (mg), once daily (OD). Subjects 12 to < 18 years of age and weighing less than 45 kg, the dose of moxifloxacin will be 4 mg/kg twice daily (BID), every 12 hours (q12h), not exceeding 400 mg/day. Subjects 6 to < 12 years of age the dose of moxifloxacin will be 4mg/kg, q12h, not exceeding 400 mg/day. Subjects 2 to less than 6 years of age the dose of moxifloxacin will be 5mg/kg, q12h, not exceeding 400 mg/day. Subjects 3 months to less than 2 years of age the dose of moxifloxacin will be 6mg/kg q12h IV, not exceeding 400 mg/day. Subjects who were switched from IV to PO therapy, 400 mg or 50 mg moxifloxacin tablets were provided.
1865981|NCT01069900|Drug|Ertapenem|For subjects 13 to <18 years of age, the dosage of ertapenem was 1 gram (g) OD. For subjects 3 months to < 13 years of age, the dosage was 15 mg/kg q12h not to exceed 1 g/day.
1865982|NCT01069900|Drug|Amoxicillin/Clavulanate|Subjects 2 years to < 18 years of age who were switched from IV to PO therapy receive amoxicillin/clavulanate suspension. The dosage of clavulanate was 3.2 mg/kg q12h. (maximum dose of clavulanate was 125 mg q12h). The dosage of amoxicillin was 22.5 mg q12h (a maximum dose of 875 mg amoxicillin q12h must not be exceeded).
1865983|NCT01069900|Drug|Moxifloxacin placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV moxifloxacin. Tablets containing inactive ingredients were used as the placebo for PO moxifloxacin 400 mg and 50 mg tablets.
1865984|NCT01069900|Drug|Ertapenem placebo|Sterile 0.9% sodium chloride solution intended for IV use was used as the placebo for IV ertapenem.
1865985|NCT01069900|Drug|Amoxicillin/Clavulanate placebo|Suspension containing inactive ingredients was used as the placebo for PO amoxicillin/clavulanate suspension.
1865986|NCT01069913|Drug|BG00012|"Sequence 1: Oral 240 mg BG00012 Standard Formulation & Following 7 day washout period, 240 mg BG00012 API.
Sequence 2: 240 mg BG00012 API & Following 7 day washout period, 240 mg BG00012 Standard Formulation."
1865987|NCT01069926|Drug|AZD1656|Single dose oral tablet
1865988|NCT01069939|Drug|Esomeprazole|20mg, capsule, 72 weeks
1865989|NCT01069939|Drug|Placebo|Placebo, capsule, 72 weeks
1865990|NCT01069952|Device|Deep Brain Stimulation System|In DBS, thin wires are used to carry electric current to the parts of the brain involved in depression symptoms. These wires are implanted surgically and are attached to battery operated stimulators usually implanted in the chest. The study doctor will adjust the settings of the electrical stimulation to optimize treatment for each participant.
1865991|NCT01069965|Drug|BGP-15 100 mg QD|Two 50 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
1865992|NCT01069965|Drug|BGP-15 100 mg BID|One 100 mg BGP-15 capsule by mouth in the morning; and one 100 mg BGP-15 capsule by mouth in the evening
1865993|NCT01069965|Drug|Placebo BID|Two Placebo capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
1865994|NCT01069965|Drug|BGP-15 200 mg QD|Two 100 mg BGP-15 capsule by mouth in the morning; and two Placebo capsule by mouth in the evening
1865995|NCT01069965|Drug|BGP-15 200 mg BID|Two 100 mg BGP-15 capsules by mouth in the morning; and two 100 mg BGP-15 capsules by mouth in the evening
1865996|NCT01069965|Drug|BGP-15 400 mg QD|Two 200 mg BGP-15 capsules by mouth in the morning; and two Placebo capsules by mouth in the evening
1865997|NCT01069991|Behavioral|Patient education group|Patient education delivered to high school students with persistent asthma in group and individual sessions. Academic detailing was also provided to the students' primary care providers.
1865998|NCT01069991|Behavioral|Wait list control group|No intervention was provided for this group until the one year study period was completed, and then the patient education intervention was provided.
1865999|NCT01070004|Other|Real driving situation|Continuous blue light exposure during driving compared to effects of coffee (2*200 mg of caffeine) and coffee placebo on 4h night-time real driving situation. Inside this arm, each volunteer will be randomly allocated and will all receive : continuous blue light exposure, coffee and coffee placebo at each driving session with at least 1 week between each condition.
1866000|NCT01070004|Other|Driving simulator|15 minutes of physical activity at a low intensity before driving compared to effects of coffee (2*200 mg of caffeine) and coffee placebo on 4h night-time driving simulator. Inside this arm, each volunteer will be randomly allocated and will all receive : 15 minutes of physical activity, coffee and coffee placebo at each driving session with at least 1 week between each condition.
1866002|NCT01070030|Drug|Aliskiren/Amlodipine (150/5 mg/day, 300/10 mg/day) , Aliskiren/Amlodipine/Hydrochlorothiazide (300/10/12.5 mg/day, 300/10/25 mg/day)|The patients were asked for 2 week run-in phase with atenolol 50 mg qd(once a day), followed by 4 schedule visits with 4-week interval until patient achieved BP goal. The maximum follow up was 16-week treatment. At visit 2, the patients started receiving Aliskiren/Amlodipine (150/5mg per day) for 4 weeks. At visit 3, if the patients did not achieve blood pressure (BP) goal, patients were up titrated to Aliskiren/Amlodipine (300/10 mg/day) for 4 weeks. At visit 4, if the patients did not achieve BP goal, HCT 12.5 mg/day was added to Aliskiren/Amlodipine/HCT (300/10/12.5 mg/day) for 4 weeks. Finally at visit 5, if the patients did not achieve BP goal, HCT was up titrated to Aliskiren/Amlodipine/HCT (300/10/25 mg/day) for 4 weeks until visit 6. Once the patients achieved BP goal at any visit, they completed the study.
1866003|NCT01070043|Drug|Amlodipine 5mg/Valsartan 80 mg|Combination therapy of Amlodipine/Valsartan 5mg/80mg one dosage daily with one single tablet size for 8 weeks.
1866004|NCT01070043|Drug|Valsartan|"For run-in period, Valsartan 80 mg daily in one dosage with one single tablet size for 4 weeks.
Monotherapy for double blind treatment period in one dosage (Valsartan 160mg) daily with one single tablet size for 8 weeks"
1866088|NCT01063023|Drug|BMS-650032|Tablets, Oral, 600 mg, BID
1866089|NCT01063036|Drug|Entecavir|Tablets, Oral, 1 mg, once daily, 96 weeks
1866005|NCT01070056|Behavioral|Therapeutic Lifestyle Changes (MINT-TLC)|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension(HTN), which recommends weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, reducing alcohol intake, and eating a low-fat diet that is rich in fruit and vegetables. MINT-TLC will be conducted by trained research personnel. Patients will attend 10 classes over 12 weeks (intensive phase) followed by individual monthly MINT sessions for 3 months (maintenance phase). We chose the intervention schedules to pattern after the methodology of therapeutic lifestyle interventions with proven efficacy in hypertensive patients, specifically, Trial of Nonpharmacologic Approaches in Elderly Hypertensives (TONE) and PREMIER trials.
1866006|NCT01070056|Behavioral|Usual Care|Patients randomized to the Usual Care (UC) condition will receive standard hypertension (HTN) treatment recommendations as determined by their physicians. In addition, they will receive a 30-minute individual counseling session on therapeutic lifestyle modification, similar to PREMIER. We feel obligated ethically to provide this minimal intervention to patients in the UC group given that counseling on TLC is a standard recommendation for treatment of hypertension. To match the MINT-TLC group for content of intervention material, those in the UC group will receive print versions of the intervention materials.
1959960|NCT03311438|Other|Oral health intervention program|Intervention: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
1866010|NCT01070095|Other|Electronic Asthma Action Plan System|The electronic asthma action plan system consists of a tablet device in the physician waiting room which participants use to complete a simple questionnaire, a computerized clinical decision support system which then processes these data to produce a set of asthma care recommendations for the clinician, and finally, a printable asthma action plan that is given to patients, along with the URL for an asthma education website.
1866011|NCT01070108|Drug|Ketamine|group receiving one injection (25 mg) of ketamine (K1) intramuscularly (IM) at 3-4 hours before surgery or placebo (saline 0.9%, NS)
1866012|NCT01070108|Drug|ketamine|ketamine at 11-12 hours (10 mg) and 3-4 hours (25 mg) before surgery (K2), with a corresponding NS group
1866013|NCT01070108|Drug|ketamine|ketamine injected IM 17-18, 11-12, and 3-4 hours before surgery (5, 10 and 25 mg, respectively) (K3), and the second group received NS
1866014|NCT01070134|Behavioral|Mindfulness-based Behavioural Therapy (MIBT)|"The MIBT treatment consists of weekly individual MIBT therapy (45-50 min.), together with weekly mindfulness-skills training group (1.5 hours).
The treatment is based on the cognitive model of depression, but will, based on concrete problems, draw from alternative cognitive techniques in order to treat personality-related problems and will use elements from mindfulness."
1866015|NCT01070134|Behavioral|PT (psychodynamic therapy)|"The PT treatment consists of weekly individual PT therapy (45-50 min.), together with weekly PT group therapy (1.5 hours).
The main elements of PT are the free-flowing, non-therapist guided dialogue, based on classic psychoanalytical free association. Basically, the role of the therapist is to set ground rules and organise the time, place and duration, to maintain a proper tone, and ultimately to ensure that a therapeutic process takes place using relevant interventions."
1866016|NCT01070147|Other|Computerized Asthma Management System|The intervention group's clinicians will receive prompts via the computerized management system to prompt them for scoring, assessments, and disposition decisions.
1866017|NCT01070160|Drug|Endometrin (progesterone 100mg vaginal inserts)|once a day, 6-8 days as specified (prior to each EMBx)
1866018|NCT01070160|Drug|Metformin|per clinical care guidelines
1866019|NCT01070186|Drug|Sunitinib|50mg/day for 4 weeks
1866020|NCT01070186|Other|Tumor biopsy|Conducted prior to administration of sunitinib therapy
1866021|NCT01070186|Procedure|Nephrectomy|Nephrectomy 2-4 weeks after last dose of Sunitinib
1866022|NCT01070186|Other|Biomarkers|"Biomarker evaluation of blood prior to treatment, after 4 weeks of Sunitinib administration, and every three months for a year after surgery.
Biomarker evaluation of tissue prior to 4 week administration of Sunitinib"
1959963|NCT03311412|Drug|Sym021|Sym021 is a humanized antibody that binds PD-1 with sub-nanomolar affinity and blocks binding of the inhibitory ligands PD-L1 and PD-L2, thus releasing PD-1-mediated inhibition of the immune response.
1959964|NCT03311399|Other|SSI Screening Tool used in home visits by CHWs|Individuals in Arm 1 will be visited at home by the sCHW who will administer the optimized SSI protocol via the mHealth device. Following the screening, the sCHWs will use the cell phone to photograph the surgical wound and record the GPS location of the visit.
1959965|NCT03311399|Other|SSI Screening Tool used via phone call follow-up|Individuals in Arm 2 will be phoned by the sCHW who will administer the SSI protocol over the phone.
1959966|NCT03311386|Drug|Actilyse|thrombolytic therapy
1959967|NCT03311373|Drug|Regimen A|2 inhalations BGF MDI; no spacer device; no oral charcoal - reference formulation/total systemic exposure
1959968|NCT03311373|Drug|Regimen B|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; no oral charcoal - test formulation/total systemic exposure
1959969|NCT03311373|Drug|Regimen C|2 inhalations BGF MDI; no spacer device; with oral charcoal - reference formulation/lung exposure
1959970|NCT03311373|Drug|Regimen D|2 inhalations BGF MDI; AeroChamber Plus Flow-Vu spacer device; with oral charcoal - test formulation/lung exposure
1959971|NCT03311360|Device|drug-coated balloon|Orchid and Dahlia DCB
1959972|NCT03311360|Device|bare metal stent|any type of bare metal stent
1959973|NCT03311360|Drug|medical treatment|best medical treatment
1959974|NCT03311347|Other|+Gz accelerations and positive pressure breathing|
1998219|NCT01571635|Drug|Sotatercept 0.1mg/kg|
1998220|NCT01571635|Drug|Sotatercept 0.3mg/kg|
1998221|NCT01571635|Drug|Sotatercept 0.5mg/kg|
1998222|NCT01571635|Drug|Sotatercept 0.75mg/kg|
1998223|NCT01571635|Drug|Sotatercept 1.0mg/kg|
1998224|NCT01571635|Drug|Sotatercept 1.5mg/kg|
1866027|NCT01070212|Other|soft gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
1866028|NCT01070212|Other|firm gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
1866029|NCT01070212|Other|no gum|. Participants will either chew nothing or chew one of the two gum varieties (flavorless soft or hard) at a constant rate (determined by a metronome) for 15 minutes while sipping apple juice through a straw. Appetite will be measured continuously via a slide potentiometer attached to a 100mm gLMS scale. The juice will provide 10% of the participants estimated daily energy requirement (i.e., equal to 1-2 servings of most commercial snacks). It will also contain 10g of lactulose (a soluble, non-absorbable carbohydrate used to assess gastric transit time via analyses of breath hydrogen) and acetaminophen (a marker for gastric emptying).
1866030|NCT01070225|Drug|Hydrocortisone/ Placebo and Propranolol|Hydrocortisone 400mcg Propranolol 10mg or 20 mg
1866031|NCT01070238|Dietary Supplement|Isomaltulose|
1866032|NCT01070251|Behavioral|Participatory parent-focused intervention|Parent workshops and internet-based support to establish healthy physical activity routines, added to existing state-sponsored PA program
1866033|NCT01070251|Behavioral|State-sponsored PA program|Preschool children receive twice a week 60 minutes of physical activity lessons over 6 months by an external gym trainer
1866034|NCT01070264|Dietary Supplement|Noni Juice|This was an open label three-month intervention pilot study. Data were collected by pre and post intervention survey as well as laboratory testing. Inclusion criteria were: adults of both sexes aged 40 to 75, with a diagnosis of OA on the hip or knee by their primary care physician, not on prescription medicine for OA, and who were willing to drink 3 oz of TNJ a day
1866035|NCT01070277|Drug|Tinidazole and Albendazole|Tinidazole 2 gr/daily for 2 days followed by Albendazole 400mg X2 /day for 7 days
1866036|NCT01070277|Drug|Placebo control|"2 placebo pills X2 /day for 2 days followed by
1 placebo Pill X2 / day for 7 days"
1866037|NCT01070290|Drug|ARQ 197|120 mg capsule administered twice daily
1866038|NCT01070290|Drug|Oxaliplatin, capecitabine or irinotecan|Investigator's choice or oxaliplatin, capecitabine or irinotecan
1866039|NCT01070303|Biological|Adalimumab 40 mg eow or ew|Adalimumab 40 mg by subcutaneous injection every other week or every week
1866040|NCT01070316|Drug|Everolimus|Everolimus is available in tablet form. The starting dose will be 5 mg/m2/day, rounded to the nearest 2.5 mg/dose, to be taken daily. After two weeks, serum trough level will be measured and dose adjusted according to the following algorithm If Blood trough level is less than 2.5 ng/ml than increase dose by 5 mg/m2/day; If Blood trough level is 2.5-5.0 ng/ml than increase dose by 2.5 mg/m2/day; If Blood trough level is 5.1-10.0 ng/ml than increase dose by 0 mg/m2/day (no change); If Blood trough level is 10.1-15.0 ng/ml than decrease dose by 2.5 mg/m2/day
1866041|NCT01070329|Drug|Duloxetine|Participants received 30 milligrams (mg) duloxetine once daily (QD) by mouth (po) for 1 week, followed by 60 mg QD po for 7 weeks. Participants were given the option to take duloxetine 30 mg QD, po for a 2-week taper phase.
1866042|NCT01070329|Drug|Placebo|Participants received placebo QD, po for 8 weeks, followed by placebo QD, po during the 2-week taper phase.
1866043|NCT01070342|Device|Spacelabs 90217|Comparison of the two ways to measure blood pressure: using the ambulatory blood pressure device (Spacelabs 90217) versus the standard method of measuring blood pressure is done by using a stethoscope and a blood pressure cuff.
1866044|NCT01070355|Drug|Eicosapentaenoic acid free fatty acid|An enteric-coated preparation of 99% pure omega-3 polyunsaturated fatty acid (PUFA) eicosapentaenoic acid as the free fatty acid. 500mg capsules, 2 taken twice daily for 2-6 weeks before liver resection.
1866045|NCT01070355|Drug|Placebo|2 capsules taken twice daily for 2-6 weeks before liver resection.
1959975|NCT03311334|Drug|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 days until cycle 2, and then every 14 days for combination with Nivolumab arm, and every 21 days for Atezolizumab arm.
1866047|NCT01070381|Device|nelfilcon A contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
1866048|NCT01070381|Device|ocufilcon D contact lens|Commercially marketed, toric, soft contact lens for daily disposable wear
1866049|NCT01070394|Drug|LDX Treatment|30 mg, 50mg, or 70 mg. Oral capsule, once a day, for 12 weeks.
1866050|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
1866051|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
1866052|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|2 doses Ad6NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 24.
1866053|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^8vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
1866054|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 5 x 10^9vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
1866055|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|2 doses AdCh3NSmut 2.5 x 10^10vp at weeks 0 and 4 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 24.
1866056|NCT01070407|Biological|Ad6NSmut; AdCh3NSmut|1 dose Ad6NSmut 2.5 x 10^10vp at week 0 and 1 dose AdCh3NSmut 2.5 x 10^10vp at week 8.
1866057|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 2.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 2.5 x 10^10vp at week 8.
1866058|NCT01070407|Biological|AdCh3NSmut; Ad6NSmut|1 dose AdCh3NSmut 7.5 x 10^10vp at week 0 and 1 dose Ad6NSmut 7.5 x 10^10vp at week 8.
1866090|NCT01063036|Drug|Tenofovir|Tablets, Oral, 300 mg, once daily, 96 weeks
1866059|NCT01070420|Other|FFR via central venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min−1•kg−1) via Rt central femoral vein.
1866060|NCT01070420|Other|FFR via peripheral venous line|Patients with intermediate coronary artery stenosis were consecutively enrolled. FFR was measured by a standard intravenous (IV) adenosine infusion (140 μg•min−1•kg−1) via continuous peripheral vein.
1866061|NCT01070433|Drug|MEBO Wound Ointment (MEBO)|Topical application twice a day
1866062|NCT01070433|Other|Standard of Care|Topical application twice a day
1866063|NCT01070446|Dietary Supplement|Vitamin: Choline Bitartrate (2-hydroxyethyl) trimethylammonium salt 1:1|This is a prospective, repeated measures study involving children with Cystic Fibrosis. Children will be assessed (1) before starting the choline supplement, (2) after taking the supplement for 6 months and after the supplement has been discontinued for 3 months.
1866064|NCT01070459|Behavioral|Aerobic exercise group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of aerobic training 30 minutes/session, using a leg cycle bike. Patients will be trained three times a week. The heartrate will vary from 50 tot 75% of their predicted heart rate. Each patient will be provided with an progressive exercise prescription based on 50-75% of their predicted maximum heartrate. Throughout the training sessions the heart rate will be monitored continuously with a polar pulse rate. Within these 12 week exercise programme four information sessions will be offered to patients and relatives about risk factors of stroke, usefulness of an active lifestyle and healthy eating.
1866065|NCT01070459|Behavioral|Control group|The patients continue their regular therapy in the rehabilitation center. They participate in a 12-week programme of passive mobilisation of the hemiplegic knee, using a continuous passive motion device. Patients will be trained three times a week, 30 minutes/session.
1866066|NCT01070459|Behavioral|Follow-up first aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The first group will get feedback on how to train further their aerobic capacity within the following 9 months. The second group will not undergo the feedback programme.
1866067|NCT01070459|Behavioral|Follow-up control group|No intervention will be offered in a period of 9 months after the passive mobilisation programme
1866068|NCT01070459|Behavioral|Follow-up second aerobic exercise group|The experimental aerobic exercise will be divided in two groups at random after the 12 weeks aerobic exercise programme. The second group will not undergo the feedback programme. This group will be measured but not treated with an intervention programme
1866069|NCT01070472|Drug|Misoprostol|titrated oral misoprostol solution
1866070|NCT01062893|Other|Sterile normal saline 0 mls|at time of epidural needle placement there will not be any saline injected into the epidural space prior to placement of the spinal needle to administer the CSE dose of standard analgesic medications. Instead a pause will be done as by the investigator to maintain blind for the assessor.
1866071|NCT01062893|Other|15 mls sterile normal saline|After the epidural needle is placed, 15 mls of sterile normal saline will be injected into the epidural space, then the spinal needle will be placed to administer the CSE dose of standard analgesic medications.
1866072|NCT01062906|Drug|Lidocaine|1.5 mg/Kg as bolus and a continuous infusion of 2mg/Kg/hr until the end of surgery (closure of the skin)
1866073|NCT01062906|Drug|Fentanyl|Fentanyl 3 mcg/Kg as bolus at the induction and a continuous infusion of normal saline (NaCl 0.9%) until the end of surgery (skin closure)
1866074|NCT01062919|Procedure|Epidural analgesia|patients in the epidural analgesia group will receive ropivacaine 0.2% through the epidural catheter, normal saline in the wound catheter and PCA with morphine.
1866075|NCT01062919|Procedure|Wound catheter|patients in the epidural analgesia group will receive 0.2%ropivacaine through the wound catheter, normal saline in the epidural catheter and PCA with morphine.
1866076|NCT01062932|Drug|Cycloserine|Oral administration of cycloserine medication (50 mg administered prior to each exposure treatment) on Day 1, 4, 7, and 10 of the study
1866077|NCT01062932|Drug|Placebo|Oral administration of matching placebo pill on Days 1, 4, 7, and 10
1866078|NCT01062945|Drug|Placebo|Matching administration of a placebo pill.
1866079|NCT01062945|Drug|Doxazosin|The dose of doxazosin needed to alter the effects of cocaine is unknown and preclinical animal studies have not been conducted. Because of this, initially we will study the effects of a low dose of doxazosin (4 mg daily) compared to placebo daily. Because this class of medication needs to be titrated upward due to the potential for hypotension, treatment will begin at 1 mg and increased by 1 mg increments every three days until 4 mg is reached on day 12.
1866080|NCT01062958|Other|Neevo® (a medical food)|
1866081|NCT01062958|Other|Prenatal vitamins (≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12)|
1866082|NCT01062971|Drug|dorzolamide-timolol-brimonidine|Patients will be randomly divided into 2 groups, one of them treated with a new formulation of 0.5% timolol-0.2% brimonidine-2% dorzolamide in fixed combination (Krytantek Ofteno®, Laboratorios Sophia, Mexico) and the other one treated with 0.5% timolol-2% dorzolamide fixed combination (Cosopt®, MSD Laboratories, USA). Patients will received 1 drop twice a day of either formulations.
1866083|NCT01062984|Procedure|Continuous Venovenous Hemofiltration (CVVH)|The NxStage system will be used for CVVH using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid will be delivered pre-filter for CVVHthe target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
1866084|NCT01062984|Procedure|Continuous Venovenous Hemodialysis (CVVHD)|The NxStage system will be used for CVVH and CVVHD using the NxStage Cartridge Express dialyzer (polyethersulfone membrane). The blood flow rate will be set at 250 cc/min, and decreased at the discretion of the primary nephrologist's assessment of filter pressures and alarms. Replacement fluid dialysate will be infused countercurrent to blood flow the target effluent flow rate will be 35ml/kg/hr plus desired ultrafiltration (fluid removal). A maximum of 4.5 L/hr effluent will be prescribed to obese or hypercatabolic patients.
1866085|NCT01063010|Drug|Bevacizumab|Administered intravenously 10 mg/kg over 90 minutes (+ 15 minutes)
1866086|NCT01063010|Drug|Placebo|Placebo administered intravenously for 90 minutes (+ 15 minutes)
1866087|NCT01063023|Drug|Ortho Tri-Cyclen®|Tablets, Oral, 1 Tablet, once daily
1866091|NCT01063049|Drug|Gatorade/Miralax|Gatorade 64 oz (1/2 gallon), Miralax 306 g to be consumed the day before your colonoscopy as follows: Miralax 51 g at 12 noon. Gatorade 64 oz mixed with Miralax 255 g from about 5 PM to 9 PM.
1866092|NCT01063049|Drug|NuLytely|Nulytely (or Trilyte) 128 oz (1 gallon) to be consumed from about 5 PM to 9 PM the night before the colonoscopy.
1866093|NCT01063049|Drug|Bisacodyl|Bisacodyl 10 mg (two 5 mg pills) to be consumed the day before the colonoscopy at 12 noon.
1866094|NCT01063049|Drug|Placebo|Placebo (two 0.4 mg folic acid pills) to be consumed the day before the colonoscopy
1866095|NCT01063062|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks.
1866096|NCT01063062|Drug|Methotrexate|methotrexate as per standard of care in clinical practice.
1866097|NCT01063075|Drug|Cetuximab|Administered Intravenously
1866098|NCT01063075|Drug|Carboplatin|Administered Intravenously
1866099|NCT01063075|Drug|5 - FU|Administered Intravenously
1866100|NCT01063088|Biological|Seasonal influenza vaccine (split virion, inactivated, prepared in Vero Cell cultures)|Single 0.5 mL intramuscular injection
1866104|NCT01063127|Other|Study on insulin sensitivity after diet or bariatric surgery|Group A: 1 week of low calorie diet before gastric banding a new study 1 week after gastric banding Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
1866105|NCT01063127|Other|gastric bypass|Group B: 1 week of low calorie diet before gastric bypass a new study 1 week after gastric bypass
1866106|NCT01063140|Biological|Rabies Vaccine (RabAvert)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
1866107|NCT01063140|Biological|Rabies Vaccine (Imovax)|The initial booster immunization is given on Day 1; subsequent booster immunizations will be administered if the donor's titers fall below 10 IU/mL. A maximum of 4 booster immunizations may be administered over the 2 year study period.
1866108|NCT01063153|Drug|Osmotic Release Methylphenidate|During a 6 week treatment period, adult subjects with ADHD are prescribed, in an open label fashion, once daily doses of osmotic release methylphenidate to a maximum daily dose of 144 mg. Efficacy and tolerability assessments are completed, in addition to EEG and cognitive testing. Healthy adults without ADHD will not receive medication.
1866109|NCT01063179|Drug|Bortezomib, Melphalan, Prednisone, Thalidomide|"Induction therapy:
9 courses with weekly VELCADE (4 doses) in combination with oral Melphalan 9 mg/m2,oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course and Thalidomide 50 mg/day continuously. The dose of VELCADE is 1.3 mg/m2 administered as a bolus IV injection, on days 1, 8, 15, 22.
Maintenance therapy:
Thalidomide 50 mg/day continuously in combination with VELCADE 1.3 mg or maximum dose tolerated/m2/2 weeks. The maintenance will be initiated at the end of the 9th course and will be stopped after progression. The median expected duration of the maintenance treatment is approximately 2 years."
1866110|NCT01063179|Drug|Bortezomib, Melphalan, Prednisone|Induction therapy: 9 courses with weekly VELCADE(4 doses) in combination with oral Melphalan 9 mg/m2 and oral Prednisone 60 mg/m2 once daily on Days 1 to 4 of each course. No maintenance therapy is scheduled
1866111|NCT01063192|Drug|Gemcitabine|Arm 1: Gemcitabine alone on D1,8,15 every 28 days for 3 cycles
1866112|NCT01063192|Drug|Gemcitabine, Oxaliplatin, 5-Fluorouracil, Leucovorin (GOFL)|Arm 2: GOFL on D1, 15 every 28 days for 3 cycles(Gem 800mg/m2 80min, Oxa 85mg/m2 2hr, 5FU 3000mg/m2, LV 150mg/m2 iv 48hr)
1866113|NCT01063205|Drug|Placebo|Placebo administration will be started on day 2 and stopped on day 5. Methylsulonylmethane (MSM) will serve as a placebo for MA.
1866114|NCT01063205|Drug|N-acetylcysteine|Study medication (NAC 1800 mg) will be started on day 2 and stopped on day 5.
1866115|NCT01063205|Drug|N-acetylcysteine|Study medication (NAC 3600 mg) will be started on day 2 and stopped on day 5.
1866116|NCT01063218|Other|Emollient - Cetaphil Advanced|Emollient - Cetaphil Advanced - to be applied twice a day for 20 weeks.
1866117|NCT01063231|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
1866118|NCT01063244|Device|foley balloon only|place foley balloon only in cervix
1866119|NCT01063244|Device|foley balloon with weight attached|foley balloon with 1000cc IV bag attached
1866120|NCT01063257|Drug|Clofarabine|"The dosage of Clofarabine will be gradually augmented in a 3+3 design for each following dose level:
DL1 - 5mg/m2/d, DL2 - 7.5mg/m2/d, DL3 - 10mg/m2/d, DL4 - 12.5mg/m2/d (This dose may not be reached and is an optional dose level in case the MTD is not reached before and depending on further data from the ongoing MDS Phase IIa oral formulation trial).
The DLa will be the following:
DL1a - 2.5mg/m2/d, DL2a - 6.5mg/m2/d, DL3a - 8.5mg/m2/d, DL4a - 11.5mg/m2/d (In case of activation of the DL4 step). Dose levels 1a, 2a and 3a will be used for de-escalation."
1866121|NCT01063270|Drug|Clindamycin & Rifampin|Clindamycin 300mg twice daily for 10 weeks and Rifampin 300mg twice daily for 10 weeks
1866122|NCT01063270|Procedure|Clindamycin + Rifampin along with NdYag Laser treatment|Clindamycin 300mg twice daily for 2 weeks Rifampin 300mg twice daily for 2 weeks along with 3 NdYag laser sessions.
1866123|NCT01063283|Drug|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg|Carboplatin and Pemetrexed with Bevacizumab 7.5 mg/kg and bevacizumab every 3 weeks for two doses
1866124|NCT01063283|Drug|Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg|Carboplatin and Pemetrexed with Bevacizumab 15 mg/kg and bevacizumab every 3 weeks for two doses
1866125|NCT01063348|Drug|N-Acetyl Cysteine|Week 0 (Visit 1) - Week 3 (V2): 1200mg/day (600mg po qam and 600mg po qpm) Week 3 (V2) - Week 6 (V3): 2400mg/day (1200mg po qam and 1200mg po qpm) Week 6 (V4) - Week 12 (V5): 3000mg/day (1200mg po qam and 1800mg po qpm)
1866126|NCT01063348|Drug|Placebo|Matching placebo capsules taken in same amount of pills as the active medication.
1866127|NCT01063361|Dietary Supplement|Low glycemic index diet with pulses|Subjects will be advised to follow a diabetic diet, using low glycemic index foods, emphasizing pulses.
1866128|NCT01063361|Dietary Supplement|High Cereal Fibre|Subjects will be advised to follow a healthy high fibre diabetic diet.
1866129|NCT01063374|Dietary Supplement|low glycemic diet instruction|
1866130|NCT01063374|Dietary Supplement|high cereal fibre diet instruction|
1866131|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive+ Para-aortic lymph node metastasis Experimental : Radiation: Extended-field Irradiation (EFI) Prophylactic irradiation of supraclavicular lymph node
1866132|NCT01063387|Radiation|Prophylactic Irradiation of the Para-Aortic Lymph Nodes and supraclavicular lymph nodes in Locally Advanced Uterine Cervical Cancer|Sema4c positive +Common iliac lymph nodes metastasis Experimental :Radical hysterectomy+ EFI(whole pelvis + para-aortic lymph node irradiation)
1866133|NCT01063400|Other|Observation|monitoring of physical activity for 14 days using physical activity monitoring devices along with activity diary
1866134|NCT01063426|Drug|High dose Atorvastatin+enoxaparin|High dose atorvastatin 80mg/day for 7days after index surgery (total knee replacement arthroplasty, TKRA). At the same time Enoxaparin 40mg SQ/day 12hr before TKRA and from 1day to 7day after TKRA should be administered.
1866135|NCT01063426|Drug|Enoxaparin|Enoxaparin 40mg SQ/day 12hr before TKRA and on day 1 to day7 after TKRA should be administered.
1866136|NCT01063439|Drug|Busulfan, Etoposide, Cytarabine, Melphalan|Busulfan 3.2 mg/kg/d for 2 days Etoposide 400 mg/m2/d for 2days Cytarabine 1 g/m2 for 2 days Melphalan 140 mg/m2 for 1 day
1866137|NCT01063452|Device|Truvalve|Atkinson Product Design urinary slide valve
1866138|NCT01063452|Other|Control (catheter drainage bag)|urinary catheter drainage bag
1866139|NCT01063465|Device|Early weightbearing|Patients in the intervention group are after 2 weeks supposed to remove the cast twice a day and use a special training pedal for 5 weeks (until cast removal).
1866140|NCT01063478|Drug|RAD001 (in addition to standard radiation and chemotherapy)|Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
1866141|NCT01063491|Procedure|bypass graft angiography|
1866142|NCT01063504|Drug|teriparatide|
1866143|NCT01063517|Drug|olaparib|100mg BID oral tablet continuous
1866144|NCT01063517|Drug|paclitaxel|iv infusion 80mg/m2 on Day 1, 8 and 15 of a 28 day cycle
1866145|NCT01063517|Drug|Placebo|100mg BID oral tablet to match olaparib tablet
1959976|NCT03311334|Drug|Nivolumab|Nivolumab will be administered in the approved dose and schedule starting on Day 1 of the study.
1998225|NCT01570998|Radiation|Intraoperative Radiation Therapy|Undergo IORT
1866148|NCT01063556|Drug|donepezil HCl|Subjects will receive donepezil HCL 3 mg without haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg with haemodialysis.
1866149|NCT01063556|Drug|donepezil HCl|Subjects will receive donepezil HCl 3 mg with haemodialysis. After an interval of over 15 days, the subjects will receive donepezil 3 mg without haemodialysis.
1866150|NCT01063569|Drug|Solu-Cortef (hydrocortisone)|Continuous Subcutaneous Hydrocortisone infusion via insulin pump. Doses adjusted to body surface area.
1866151|NCT01063569|Drug|Cortef (hydrocortisone)|Oral treatment 3 times a day. Weight adjusted doses.
1866152|NCT01063582|Other|exposure to occupational noise|We performed the measurement of occupational noise exposure through sound level meter and Dosimeter during flight operations of F-16 fighter plane.
1866153|NCT01063582|Procedure|cardiovascular valuation|Cardiovascular valuation was performed via electrocardiogram and echocardiographic techniques to correlate the changes observed during exposure to occupational noise
1866154|NCT01063595|Biological|Octaplas LG|Octaplas LG was composed of human coagulation-active plasma treated with solvent/detergent for 1-1.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. An additional manufacturing step, involving an affinity ligand gel, removed prion proteins. Octaplas LG was provided frozen in pyrogen free plastic bags.
1866155|NCT01063595|Biological|Octaplas SD|Octaplas SD was composed of human coagulation-active plasma treated with solvent/detergent for 4-4.5 hours to remove enveloped viruses, eg, HIV, HBV, and HCV. Octaplas SD was provided frozen in pyrogen free plastic bags.
1866156|NCT01063608|Biological|Anti-H1N1v Vaccine|Inclusion of hospital personnel in the context of the anti-H1N1v prophylaxy plan.
1866157|NCT01063621|Drug|KW-6500|Subcutaneous injection of 1 to 6 mg for the OFF state during 52 weeks
1866158|NCT01063647|Drug|Treosulfan|10 g/m² i.v. infusion, day -6, -5, -4
1866159|NCT01063647|Drug|Treosulfan|12 g/m² i.v. infusion, day -6, -5, -4
1866160|NCT01063647|Drug|Treosulfan|14 g/m² i.v. infusion, day -6, -5, -4
1866161|NCT01063660|Drug|Treosulfan|14 g/m²/d day -6 to -4
1866162|NCT01063686|Device|insemination cervical cap|Primary abdominal ultrasound (US) for amniotic fluid index (AFI), Single vertical pocket, and dimensions of pocket below the presenting part. Speculum vaginal examination. In a sterile manner a cervical cap is adjusted on the cervix. the patient is kept recumbent for 6 hours. A repeat US exam is performed. The cervical cap is removed. After one hour another US is performed.
1866163|NCT01063699|Procedure|Laparoscopic Kasai operation|the Kasai procedure (hepatoportoenterostomy) is performed laparoscopically, thus not in open surgery.
1866164|NCT01063712|Device|Nit-Occlud® PDA-R|"Transcatheter implantation of a PDA Device (Nitinol) The catheterism was done under sedation, using a protocol established by inserting a catheter through a femoral artery and/or vein directed to the heart and great vessels. Invasive measurements are obtained in the descending aorta and pulmonary artery. Once in ductal position, we inject iodinated contrast medium that allows us to observe via X-ray the ductal morphology; obtaining accurate measurements to choose the appropriate device. The device is then inserted via the catheter, closing the ductus.
The catheterism provides measures of aortic and pulmonary pressure, before, during and after the closure."
1866165|NCT01063725|Dietary Supplement|Femarelle|A soy based food supplement containing 322 mg of soy extract and 108 mg of flaxseed, to be taken twice daily
1866166|NCT01063725|Other|Placebo|Capsules containing 430 mg of microcrystalline cellulose, as a placebo, to be taken twice daily
1866167|NCT01063738|Dietary Supplement|Amino acid supplement|Flavoured essential amino acid supplement and glutamine dipeptide taken twice daily for 3 months
1866168|NCT01063738|Other|PEPSE|Enhanced physiotherapy programme of 3 1 hour sessions per week for 6 weeks while in hospital and once discharged home 1 supervised outpatient session of 1 hour and 2 home exercise sessions per week (PEPSE).
1866169|NCT01063738|Other|Intensive Care Unit (ICU) Recovery Manual|Standard self-directed 6 week rehabilitation package
1866170|NCT01063738|Dietary Supplement|Placebo nutritional supplement|Cherry flavoured low calorie and low protein placebo drink
1866171|NCT01063751|Device|Tritanium® Primary Acetabular Shell|Tritanium® Primary Acetabular Shell in total hip replacement.
1866172|NCT01063764|Drug|Levetiracetam|"First Period: Dry syrup 50 %, 20 mg/kg/day or 1000 mg/day, 40 mg/kg/day or 2000 mg/day, 60 mg/kg/day or 3000 mg/day, twice daily administration Per Os (PO) for 14 weeks.
Second Period: Dry syrup 50 % or tablets (250 mg and 500 mg strengths), 20 to 60 mg/kg/day or 1000 to 3000 mg/day, twice daily administration Per Os (PO) until indication granted."
1866173|NCT01063777|Other|A 12 week exercise therapy program and patient education.|"The exercise protocol includes exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults.Patients will be required to exercise for 60 minutes, three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) will be registered by the physical therapists.
All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time."
1866174|NCT01063777|Other|Patient education|All patients included in the study will receive two individual and three small-group (6-7 patients) sessions lasting one hour each time.
1866175|NCT01063790|Behavioral|Individualized Education|The intervention consists of written information in the form of a booklet, an individualized face to face education session and two telephone support calls regarding post-discharge pain management, adverse effects of analgesics and common concerns about asking for help with pain.Participants in the intervention group will also receive two telephone support calls. The purpose of the telephone support calls is to readdress the information that patients received in the booklet and to clarify concerns regarding post-operative pain management that were discussed during the individualized education session.
1866176|NCT01063803|Drug|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
1866177|NCT01063803|Drug|ATN-103|A single subcutaneous injection of ATN-103 every 4 weeks (approx 13 SC injections during the study)
1866178|NCT01063816|Drug|veliparib (ABT-888)|Dosing orally twice daily starting Cycle 2 Day 1- through 21 adjusted for subsequent cohorts using a continuous reassessment method.
1866179|NCT01063816|Drug|carboplatin|Carboplatin will be dosed on Day 1 of each cycle, intravenously.
1866180|NCT01063816|Drug|gemcitabine|Dosing on Days 1 and 8 of each Cycle, intravenously.
1866181|NCT01063829|Drug|AIC246|Oral administration
1866182|NCT01063829|Drug|AIC246|Oral administration
1866183|NCT01063829|Drug|AIC246|Oral administration
1866184|NCT01063829|Other|Placebo|Oral administration
1866185|NCT01063842|Drug|tramadol hydrochloride /acetaminophen|1 tablet of tramadol hydrochloride/acetaminophen three times daily without titration for 14 days.
1866186|NCT01063842|Drug|tramadol hydrochloride / acetaminophen and placebo|1 tablet of tramadol/acetaminophen in the morning, 1 tablet of placebo in the afternoon and evening for 3 days, then 1 tablet of tramadol/acetaminophen in the morning, evening and 1 tablet of placebo in the afternoon for 4 days, then 1 tablet of tramadol/acetaminophen 3 times daily for next 7 days
1866187|NCT01063855|Drug|Placebo|Tablets identical in appearance to dapoxetine taken 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
1866188|NCT01063855|Drug|Dapoxetine|30 mg to 60 mg tablets 1 to 3 hours before sexual activity prn (as needed) not to be taken more than once every 24 hours for 12 weeks.
1866189|NCT01063855|Drug|PDE5I (phosphodiesterase-5 inhibitor)|Patients were to be using a stable regimen of a PDE5-I (i.e., sildenafil, vardenafil, or tadalafil), as reported by the patient for the treatment of erectile dysfunction (ED) for at least 3 months before screening and up to 12 weeks during treatment in the study.
1866190|NCT01063868|Drug|Tapentadol extended release (ER)|100, 150, 200, 250 mg twice daily for 52 weeks
1866191|NCT01063868|Drug|Oxycodone controlled release (CR)|20, 30, 40, 50 mg twice daily for 52 weeks
1866192|NCT01063881|Drug|Dapoxetine|Starting dose is one 30-mg tablet taken approximately 1-3 hours prior to sexual activity, may be increased after 4 weeks to 60mg, taken for 12 weeks. The maximum recommended dosing frequency is once every 24 hours.
1866193|NCT01063894|Other|breakfast cereal|breakfast cereal and milk
1866194|NCT01063894|Other|water|water
1866195|NCT01063907|Drug|KW-2478|Administered Days 1, 4, 8 and 11 of a 21 day cycle
1866196|NCT01063907|Drug|Bortezomib|Administered on Days 1, 4, 8 and 11 of a 21 day cycle
1866197|NCT01063920|Drug|LT-NS001|1200 mg b.i.d. p.o. for 12 weeks
1866198|NCT01063920|Drug|Naprosyn®|500 mg b.i.d. p.o. for 12 weeks
1866199|NCT01063933|Drug|Peramivir|Peramivir is a liquid for parenteral administration. Cohort I: Peramivir, 10 mg/kg intravenously (IV) every day (QD) (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort II: Peramivir 12 mg/kg IV QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Cohort III: Peramivir 16 mg/kg QD (maximum of 600 mg/day) for 5 days or until hospital discharge, whichever comes first. Proposed doses for subjects in Cohorts IV, V, VI, and VII are 18, 18, 14 and 12 mg/kg, respectively, IV, QD for 5 days or until hospital discharge, whichever comes first. IV peramivir will be administered over 60 minutes.
1866200|NCT01063946|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:concentrate solution
Route of administration: intravenous infusion"
1866201|NCT01063959|Procedure|Laparoscopic Sleeve Gastrectomy|Sleeve Gastrectomy was originally reported as the first step in an alternative two-staged procedure for the super obese patient to decrease morbidity, predominantly private pay.
1866202|NCT01063959|Procedure|Laparoscopic Gastric Bypass|Presently, the laparoscopically performed gastric bypass accounts for 80% of obesity surgery in the United States, predominantly covered by insurance.
1866203|NCT01063972|Behavioral|Centralized disease management (CDM)|Centralized Disease Management (CDM) arm will receive smoking cessation counseling with coordination of pharmacotherapy with their insurance coverage and their health care provider
1866204|NCT01063972|Behavioral|Counseling (C)|Counseling (C) arm will receive counseling without the care coordination services.
1866205|NCT01063998|Other|Urine Marker|Urinary KIM-1 measurements
1866206|NCT01064011|Procedure|Rt-PA thrombolysis|patients will be administered a total of six doses of rt-PA (each 1 mg/ml) through the external ventricular drain every eight hours.
1866340|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, bolus IV administration (~5 minutes)
1866207|NCT01064011|Procedure|endoscopic hematoma evacuation|In the operating room under general anesthesia, the external ventricular drain will be removed and the burr hole enlarged to allow for entry of the endoscope. The neuroscope will be introduced through the burr hole down the prior external ventricular drain tract into the ipsilateral ventricle. utilizing a standard technique combining gentle aspiration, continuous irrigation, and grasping forceps,the intraventricular hematoma will be evacuated. After the evacuation the endoscope will be removed and an external ventricular drain will be reattached to a closed system and permitted to drain post-operatively.
1866208|NCT01064024|Drug|Phenazopyridine Hydrochloride|Tablets, 200 mg, every 8 hours for 48 hours.
1866209|NCT01064024|Drug|Placebo|Tablets, every 8 hours for 48 hours
1866210|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 150 µg/h during 48h.
1866211|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 100 µg/h during 48h
1866212|NCT01064037|Drug|Cinaciguat (BAY58-2667)|Infusion of 50 µg/h during 48h
1866213|NCT01064037|Drug|Placebo|Infusion during 48h
1866214|NCT01064050|Device|silicone trachea-bronchial stent Dumon (Novatech)|Bronchial desobstruction under interventional bronchoscopy, for inclusion, with the insertion of silicone stent trachea-bronchial covering the entire tumor area
1866215|NCT01064063|Device|Vanguard CR|The Vanguard CR is a metal and polyethylene total condylar knee system. The system contains three primary components: femoral, tibial, and bearing components, and a peripheral component: the patella button.
1866216|NCT01064063|Device|AGC knee|The AGC knee is a metal and polyethylene total condylar knee system offering complete component interchangeability.
1866217|NCT01064076|Device|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the SQ-RX pulse generator (Model 1010), the Q-TRAK subcutaneous electrode (Model 3010), the Q-TECH programmer (Model 2020), and Q-GUIDE electrode insertion tools (Models 4010 and 4020).
1866218|NCT01064089|Drug|HSP990|
1866219|NCT01064102|Drug|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
1866220|NCT01064115|Drug|Cetirizine Hydrochloride|Cetirizine Hydrochloride Tablets 10 mg
1866221|NCT01064128|Procedure|conventional laparoscopic hysterectomy|conventional 3 or 4 ports laparoscopic hysterectomy
1866222|NCT01064128|Procedure|SPA laparoscopic hysterectomy|single-port access laparoscopic hysterectomy
1866223|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus|0.5 mL, Subcutaneous
1866224|NCT01064141|Biological|OKAVAX®:Attenuated live varicella-zoster virus and AVAXIM® 80U: Hepatitis A virus Vaccines|0.5 mL, Subcutaneous and 0.5 mL, Intravascular
1866225|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and Childhood vaccines|0.5 mL, Subcutaneous and 0.5 mL, Subcutaneous
1866226|NCT01064141|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3 and 4 virus and NaCl (Placebo)|0.5 mL Subcutaneous and 0.5 mL Subcutaneous
1866227|NCT01064154|Drug|Carvedilol|Carvedilol Tablets 25 mg
1866228|NCT01064167|Drug|Tranexamic Acid|In tranexamic acid group, tranexamic acid, 1 g, was given 20 minutes before incision and 400 mg/h during the entire surgical procedure. The patients from control group were infused with normal saline as a placebo.
1866229|NCT01064180|Drug|Carvedilol|Carvedilol Tablets 25 mg
1866230|NCT01064193|Procedure|biopsy|"The endometrium biopsy will be done as the same time as the GnRH treatment. The biopsy is realised with a Pipette de Cornier® (CDD international, PROMIDED France) following the laboratory protocol:
Apply antiseptic solution (povidone-iodine, Dakin®) on the cervix and vagina. In most cases, using Pozzi forceps is not necessary.
Insert carefully the pipelle de Cornier® in the uterus through the cervix.
Withdraw the piston to create a negative pression
Move the pipelle de cornier® in and out while twisting. Take care to no remove the pipelle form the uterus (suction lost). Twist the pipelle de Cornier® to cover an angle of 360°. Make several in and out cycle in order to collect a complete sample of the endometrium.
Withdraw the pipelle de Cornier® when filled with tissue
Reinsert internal piston to deposit sample in cup filled with a fixative."
1866231|NCT01064193|Procedure|IVF|fresh IVF-embryo transfer treated with long protocol for the controlled ovarian hyperstimulation
1866232|NCT01064219|Drug|human chorionic gonadotrophin|intrauterine injection of 100 IU hCG followed by endometrial biopsy .
1866233|NCT01064232|Drug|Risperidone|Risperidone Tablets 1 mg
1866234|NCT01064245|Drug|high-dose methacholine challenge test|nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
1866235|NCT01064245|Other|mannitol challenge test|inhaled powder, 0 - 635 mg, increments of 5,10, 20 and 40 mg
1866236|NCT01064258|Device|CPAP|CPAP at 4 cm H2O
1866237|NCT01064258|Device|autoCPAP|autoCPAP working between 4 and 15 cm H2O
1866238|NCT01064271|Drug|Risperidone|Risperidone Tablets 1 mg
1866239|NCT01064284|Drug|PLASMA DERIVED Factor VIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
1866240|NCT01064284|Drug|Recombinant FVIII|Maximum dosage : 50IU per kilo. 2-3 times per week or on demand during acute episode of bleeding
1866241|NCT01064297|Drug|Lamotrigine monotherapy|Lamotrigine monotherapy
1866242|NCT01064297|Drug|Lamotrigine polytherapy including valproate|Lamotrigine polytherapy including valproate
1866243|NCT01064297|Drug|Lamotrigine polytherapy without valproate|Lamotrigine polytherapy without valproate
1866244|NCT01064310|Drug|pazopanib|oral anti-angiogenic treatment
1866245|NCT01064310|Drug|sunitinib|oral anti-angiogenic treatment
1866246|NCT01064323|Device|Intermittent pneumatic compression of the lower extremities|IPC will be done for 3 divided hours daily for 4 weeks
1866247|NCT01064336|Drug|Eltrombopag|Eltrombopag is an orally bioavailable, small molecule thrombopoietin receptor (TPO-R) agonist for the treatment of idiopathic thrombocytopenic purpura
1866248|NCT01064349|Drug|Anti-erbB2 therapy as part of a treatment regimen for either brain metastases or primary breast cancer|Trastuzumab or Lapatinib
1866249|NCT01064362|Drug|Fondaparinux sodium|Fondaparinux sodium for thromboprophylaxis (ATC: B01AX05)
1866250|NCT01064362|Drug|Low molecular weight heparin (LMWH)|LMWH including: dalteparin, nadroparin, enoxaparin or tinzaparin (ATC:B01AB (excluding B01AB01))
1866510|NCT01072773|Drug|bortezomib|1.3 mg/m^2, by IV on days 1, 8 and 15 every 28 days
1866251|NCT01064375|Biological|tetwtCEA DNA (wt CEA with tetanus toxoid Th epitope)|Two vaccinations at week 0 and 12. Intradermal administration of 400ug DNA/dose with electroporation
1866252|NCT01064375|Device|Derma Vax (electroporation device)|Electrical pulses applied to vaccination sites in skin using Derma Vax immediately after DNA administration
1866253|NCT01064375|Biological|GM-CSF|GM-CSF will be given for 4 consecutive days starting the day before the vaccination as an intradermal/subcutaneous administration of 150 ug of GM-CSF
1866254|NCT01064375|Drug|Cyclophosphamide|One intravenous dose of 300 mg/m2 will be given three days before each vaccination with tetwtCEA DNA
1866255|NCT01064388|Drug|AZD9742|IV infusion, 15 days
1866256|NCT01064388|Drug|Placebo|IV infusion, 15 days
1866257|NCT01064401|Biological|BIIB019 (Daclizumab High Yield Process)|Daclizumab High Yield Process for subcutaneous injection
1866258|NCT01064401|Drug|Interferon beta-1a Placebo|Placebo to interferon beta-1a intramuscular injection
1866259|NCT01064401|Biological|Interferon beta-1a|Interferon beta-1a for intramuscular injection
1866260|NCT01064401|Drug|Daclizumab High Yield Process Placebo|Placebo to Daclizumab High Yield Process subcutaneous injection
1866261|NCT01064414|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
1866262|NCT01064414|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks in addition to the patient's AHA regimen used in accordance with local prescribing information
1866263|NCT01064440|Genetic|Low Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day14: 4mg of VM202 (16 injections of 0.5ml of VM202)
1866264|NCT01064440|Genetic|High Dose VM202|Day 0: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 14: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 28: 4mg of VM202 (16 injections of 0.5ml of VM202) Day 42: 4mg of VM202 (16 injections of 0.5ml of VM202)
1866265|NCT01064440|Other|Placebo|Day 0: 16 injections of 0.5ml of normal saline Day 14: 16 injections of 0.5ml of normal saline Day 28: 16 injections of 0.5ml of normal saline Day 42: 16 injections of 0.5ml of normal saline
1866266|NCT01064453|Drug|E2/DRSP (Angeliq, BAY86-4891)|Take one tablet daily, continuously
1866267|NCT01064466|Drug|ETOPOSIDE - Usual|ETOPOSIDE INJECTION plus CISPLATIN INJECTION
1866268|NCT01064466|Drug|ETOPOSIDE - Study|ETOPOSIDE INJECTION plus CARBOPLATIN INJECTION
1866269|NCT01064479|Drug|Cisplatin|75 mg/m2 by vein (IV) once on Day 1 of every 3 week cycle 2 hours after receiving Docetaxel, up to 6 cycles.
1866270|NCT01064479|Drug|Docetaxel|75 mg/m2 IV Day 1 of each 3 week cycle, up to 6 cycles.
1866271|NCT01064479|Drug|Erlotinib|150 mg by mouth (PO) daily continuously.
1866272|NCT01064479|Other|Placebo|Tablet by mouth (PO) daily continuously.
1866273|NCT01064479|Drug|Carboplatin|AUC 6 mg.min/ml on Day 1 of each 21 day cycle for a maximum of 6 cycles.
1866274|NCT01064492|Drug|PF-04620110|The three treatments are A) a single dose of 5 mg PIC under fasted condition; B) a single dose of 5 mg tablet under fasted condition: and C) a single dose of 5 mg tablet under fed condition.
1866275|NCT01064505|Drug|QPI-1007 at various doses|Single Intravitreal Injection
1866276|NCT01064518|Drug|Botulinum Toxin Type A|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) or Placebo (Dose B), applied topically at Baseline (Day 0) to the lateral canthal lines
1866277|NCT01064544|Procedure|light therapy with the device: EnergyLight|2 hr of light therapy during each hemodialysis session
1866278|NCT01064557|Drug|all-trans retinoic acid (ATRA)|
1866279|NCT01064570|Drug|all-trans retinoic acid (ATRA)|
1866280|NCT01064583|Other|cocoa|dissolved in water twice-daily intervention
1866281|NCT01064596|Other|blood samples|patients with a fondaparinux treatment who have 4 blood samples during the 10 days following surgery
1866282|NCT01064609|Procedure|Biopsy by cryoprobes|Transbronchial lung biopsy with cryoprobes.
1866283|NCT01064609|Procedure|Biopsy with conventional forceps|Transbronchial lung biopsy with conventional forceps.
1866284|NCT01064622|Drug|vismodegib|Given PO
1866285|NCT01064622|Drug|gemcitabine hydrochloride|Given IV
1866286|NCT01064622|Other|hydrocortisone/placebo|Given PO
1866287|NCT01064635|Drug|Letrozole|letrozole for 2-3 years after Tam
1866288|NCT01064635|Drug|Letrozole|Letrozole for 5 years after Tam
1866289|NCT01064648|Drug|Cediranib Maleate|Given orally
1866290|NCT01064648|Drug|Cisplatin|Given IV
1866291|NCT01064648|Other|Laboratory Biomarker Analysis|Correlative studies
1866292|NCT01064648|Drug|Pemetrexed Disodium|Given IV
1866293|NCT01064648|Other|Placebo|Given orally
1866294|NCT01064661|Dietary Supplement|Single probiotic arm of L-NCFM alone|Single probiotic of L-NCFM alone pills BID (2x10^10 cfu total bacteria per day)
1866295|NCT01064661|Dietary Supplement|Blend probiotic arm of L-NCFM and B-LBi07|Blend probiotic arm of L-NCFM and B-LBi07 pills BID (2x10^10 cfu total bacteria per day)
1866296|NCT01064674|Other|diagnostic procedure|Cardiovascular diagnostic standard procedure before renal transplantation using stress echocardiography and stress myocardial scintigraphy.
1866297|NCT01064687|Drug|LY2189265|
1866298|NCT01064687|Drug|Exenatide|
1866299|NCT01064687|Drug|Placebo|
1866300|NCT01064687|Drug|Metformin|
1866301|NCT01064687|Drug|Pioglitazone|
1866302|NCT01064700|Device|Litebook Bright Light Box|Four weeks of daily exposure to bright light (3,000 lux) for 45 min/day, beginning within 60 min of arising.
1866303|NCT01064700|Device|Litebook inactivated negation ion generator (the placebo)|Four weeks of daily exposure to inactivated negative ion generator for 45 min/day, beginning within 60 min of arising
1998226|NCT01570998|Other|Laboratory Biomarker Analysis|Correlative studies
1866305|NCT01064726|Drug|Ibuprofen|800 mg oral
1866306|NCT01064726|Drug|Fluticasone propionate|200 mcg intra-nasal
1866307|NCT01064726|Drug|Placebo|Placebo
1866308|NCT01064739|Dietary Supplement|Fava beans|Participants will receive 100g of fresh fava beans for breakfast and lunch on one study day and prior to this study day will be restricted to a fixed sodium low monoamine diet
1866309|NCT01064739|Other|Fixed Sodium Diet|Fixed sodium low monoamine diet
1866310|NCT01064752|Drug|Minocycline|100 mg po bid for 8 weeks
1866311|NCT01064778|Other|Low GI|Subjects will be instructed to consume a liquid test meal with a low GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The low GI meal corn-starch as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p<0.001). The test meals will provide 25% of individual daily energy requirements.
1866312|NCT01064778|Other|High GI|Subjects will be instructed to consume a liquid test meal with a high GI over 5 minutes after baseline laboratory evaluations. The low and high GI meal contain similar amounts of milk, oil, dried egg whites, equal, and vanilla extract. The high GI meal contains corn-syrup as a carbohydrate. Both meals have similar macronutrient composition (60% carbohydrate, 15% protein, 25% fat), micronutrient profiles, physical properties, palatability and sweetness. The high vs. low GI meals have a predicted difference in GI of 90 vs. 40, and consistent with this prediction, a pilot study in obese young adults found a 2.2-fold difference in glycemic response (p<0.001). The test meals will provide 25% of individual daily energy requirements.
1866313|NCT01064791|Drug|sotrastaurin (Dose 1) + tacrolimus + standard of care medications|sotrastaurin (100mg bid) + tacrolimus + standard of care medications
1866314|NCT01064791|Drug|sotrastaurin (Dose 2) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
1866315|NCT01064791|Drug|sotrastaurin (Dose 3) + tacrolimus + standard of care medications|sotrastaurin (300mg bid) + tacrolimus + standard of care medications
1866316|NCT01064791|Drug|mycophenolic acid + tacrolimus + standard of care medications|mycophenolic acid (720mg bid) + tacrolimus + standard of care medications
1866317|NCT01064804|Drug|PF-04191834|PF-04191834. 100mg Immediate Release Tablets or oral suspension
1866318|NCT01064817|Drug|PRM-151|PRM-151 2 milligrams (mg) (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
1866319|NCT01064817|Drug|Placebo|Placebo solution (0.1 mL volume) by subconjunctival injection Days 1 (immediately following trabeculectomy), 2, 3, 5 and 9
1866320|NCT01064830|Drug|topical cyclosporine ophthalmic suspension 0.05%|apply 2 drops to 2 target fingernails under occlusion daily
1866321|NCT01064830|Drug|vehicle|apply 2 drops to 2 target fingernails under occlusion daily for 20 weeks
1866322|NCT01064843|Device|Imtec MDI|4 Imtec MDI
1866323|NCT01064856|Biological|Adalimumab|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing adalimumab 40 mg/0.8 mL. Study drug was SC self-administered eow at approximately the same time of day.
1866324|NCT01064856|Biological|Placebo|Study drug was provided as a sterile SC injection solution in 1 mL pre-filled syringes containing matching placebo for adalimumab. Study drug was SC self-administered eow at approximately the same time of day.
1866325|NCT01064869|Behavioral|Pyscho-behavioural|"A nurse-led programme of intervention will be devised. Patients will attend weekly for a period of 12 weeks. It will have two stages incorporating:
1. Structured interview to identify demographic information and individual reasons for non-adherence and assessment of readiness to change behaviour
This will be followed by an individualised package incorporating:
A structured asthma education programme, to address any gaps in asthma knowledge or requests for information
Motivational interviewing based on stages of change model to encourage change and adherence
Psychological therapy involving (a) relaxation therapy (b) cognitive behavioural techniques looking at negative and catastrophic thoughts and (c) panic cycle adapted to respiratory patients"
1866326|NCT01064882|Drug|bimatoprost ophthalmic solution 0.005%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
1866327|NCT01064882|Drug|bimatoprost ophthalmic solution 0.015%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
1866328|NCT01064882|Drug|bimatoprost ophthalmic solution 0.03%|One drop applied to a sterile single-use-per-eye applicator and applied to upper eyelid margins (where the eyelashes meet the skin)
1866329|NCT01064895|Device|Benephit catheter for Targeted Renal Therapy|Local physician-specified agent delivery to the kidneys bilaterally via the renal arteries using the Benephit infusion system.
1866330|NCT01064908|Device|OxyMask|Novel vortex oxygen delivery mask
1959977|NCT03311334|Drug|Atezolizumab|Atezolizumab will be administered in the approved dose and schedule starting on Day 1 of the study.
1959978|NCT03311321|Dietary Supplement|Vitamin K2 (menaquinone-7; 360-mcg/d)|four 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks
1959979|NCT03311321|Dietary Supplement|Placebo-Control|four placebo softgel capsules per day for 8 weeks containing no vitamin K2 (menaquinone-7)
1959980|NCT03311308|Drug|Pembrolizumab Injection [Keytruda]|200mg, IV, every three weeks, up to two years
1866335|NCT01064934|Procedure|Lipid apheresis|Weekly lipid apheresis procedure for lipoprotein(a) lowering
1866336|NCT01064934|Other|Standard care|Standard care for maximum cardiovascular risk reduction (behavioural, exercise, nutrition, drugs, etc.)
1866337|NCT01064947|Drug|Retapamulin 1%|Apply a thin layer of Retapamulin 1% to the affected area twice daily. The treated area may be covered with a sterile bandage or gauze dressing if desired.
1866338|NCT01064960|Device|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
1866339|NCT01064973|Drug|arbaclofen|A flexible dose titration will be utilized during the first four weeks to define the optimal titrated dose (OTD) for each subject. Investigators will use clinical judgment to adjust doses to the oral OTD. The starting dose will be 1 mg BID. The dose may be increased every four to five days to 2 mg BID, 3 mg BID, 5 mg BID and then 10 mg BID
1959981|NCT03311308|Drug|Metformin|500 mg, by mouth, once a day for nine weeks.
1959982|NCT03311295|Device|ARTO System|The ARTO System directly reshapes the mitral annulus promoting leaflet coaptation and amelioration of regurgitation.
1866341|NCT01064986|Biological|Endotoxin, Lipopolysaccharide, LPS /Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 1 ng/kg, continuous IV administration (Hydrocortisone 3mcg/kg/min)
1866342|NCT01064986|Biological|Placebo|Saline vehicle (placebo)
1866343|NCT01064986|Biological|Hydrocortisone|Hydrocortisone
1866344|NCT01064999|Drug|Oxaliplatin|CRT:50mg/m2,IV,weekly*5 cycle CT: 130mg/m2,IV,d1,q 21 day
1866345|NCT01064999|Drug|Capecitabine|CRT:625mg/m2,bid,d1-5,q week RT:1000mg/m2,bid,d1-14,q 3 weeks
1866346|NCT01064999|Radiation|Radiotherapy|High intensity group:55Gy Low intensity group:50Gy
1866347|NCT01064999|Procedure|Surgery|Lower anterior resection or abdominoperineal resection
1866348|NCT01065012|Drug|Udenafil 50 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
1866349|NCT01065012|Drug|Udenafil 100 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
1866350|NCT01065012|Drug|Udenafil 150 mg|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
1866351|NCT01065012|Drug|Placebo Matching 50 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
1866352|NCT01065012|Drug|Placebo Matching 100 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
1866353|NCT01065012|Drug|Placebo Matching 150 mg Udenafil|Tablets via oral administration before an attempt at sexual intercourse. All subjects started at 100 mg and titrated up to 150 mg or down to 50 mg per Investigator and subject.
1866354|NCT01065025|Drug|4SC-205|Repeated ascending oral doses of 4SC-205.
1866355|NCT01065038|Drug|Anagrelide|
1866356|NCT01065038|Drug|Hydroxyurea|
1866357|NCT01065051|Drug|Riociguat (Adempas, BAY63-2521)|1 mg single oral dose
1866358|NCT01065051|Drug|Placebo|Single oral dose
1866359|NCT01065064|Procedure|RESTOR IOL|The U.S. Food and Drug Administration (FDA) has granted approval of Alcon's AcrySof® ReSTOR® intraocular lens (IOL) for cataract patients with and without presbyopia. This innovative lens uses a revolutionary apodized diffractive technology to give patients a full range of quality vision (near, intermediate and distance) that greatly increases their independence from glasses after surgery
1866360|NCT01070485|Drug|Radium-223 chloride (BAY88-8223)|The required volume of study drug to be administered to a patient was calculated using the patient's body weight (50 kBq/kg b.w.).
1866361|NCT01070498|Drug|Trichuris suis ova (TSO)|Subjects will receive TSO every other week for 3 months. The dose will depend on the age of the subject and vary between 100 and 2500 eggs. TSO will be administered orally as a suspension in single dose vials prepared by Ovamed GmbH, a company not directly involved in the study.
1866364|NCT01070524|Drug|CHF 5188 pMDI|CHF 5188: fixed combination budesonide/carmoterol
1866365|NCT01070524|Drug|Budesonide extrafine pMDI|Budesonide extrafine pMDI
1866366|NCT01070524|Drug|Seretide(r) Evohaler(r)|Seretide(r) Evohaler(r): fixed combination fluticasone/salmeterol
1866367|NCT01070537|Device|Bonfils fiberscope intubation|
1866368|NCT01070550|Drug|Peginterferon alfa-2a (Pegasys®)|Peginterferon (PEG-IFN) alfa-2a Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
1866369|NCT01070563|Other|Transcranial doppler|A TCD is performed on all cerebral arteries (mean cerebral arteries, anterior cerebral arteries, basilar trunk, vertebral arteries and carotid arteries) until a flow pattern compatible with brain death is found
1866370|NCT01070576|Other|no intervention|no intervention
1866371|NCT01070602|Procedure|anterior (more central) corneal paracentesis incision|3 corneal paracentesis incisions will be located 1 mm anterior to the limbus.
1866372|NCT01070615|Drug|Prucalopride|
1866373|NCT01070628|Drug|Stalevo (levodopa/ carbidopa/ entacapone)|150mg, 125 mg, 100mg, 75mg of levodopa q.i.d. in 3.5 h interval
1866374|NCT01070628|Drug|Sinemet (levodopa/carbidopa)|150 or 100 mg levodopa q.i.d. in 3.5 hr interval
1866375|NCT01070641|Drug|Carvedilol|Carvedilol 12.5mg QD
1866376|NCT01070641|Procedure|Esophageal variceal band ligation|Each patient will undergo for variceal band ligation after 3 weeks till the eradication of varices
1866377|NCT01070654|Procedure|40/30 recruitment manoeuvre|The ventilator will be switched to the continuous positive airway pressure (CPAP) mode and the pressure will be increased to 40 cmH20 for 30 seconds.
1866378|NCT01070654|Device|continuous positive airway pressure (CPAP)|continuous positive airway pressure (CPAP)
1866379|NCT01070667|Drug|Dronedarone|400mg orally once per day for 3 months
1866380|NCT01070667|Drug|Placebo|1 tablet once per day for 3 months. The tablet will appear identical to the active dronedarone tablet.
1866381|NCT01070680|Drug|Precedex|mkg/ml,continuous infusion at rate 0.7 µg/kg/h
1866382|NCT01070680|Drug|sodium chlorid 0,9%|continuous intravenous infusion
1866383|NCT01070693|Procedure|Open mesh inguinal hernia repair|Inguinal hernia repair either with the bilayer mesh or the Lichtenstein technique
1866384|NCT01070693|Device|Prolene Hernia System|Prolene Hernia System
1866385|NCT01070693|Procedure|Lichtenstein technique|Lichtenstein technique
1866467|NCT01072435|Device|Patient-controlled sedation|Administration of short-acting anesthetic propofol via self-administration device.Single bolus-dose 1ml(10mg)of propofol,lockout time 0sec.,no background infusion or dose-limit.
1866468|NCT01072435|Device|Target-controlled infusion|Anaesthesiologist´s managed target-controlled infusion of short-acting anesthetic propofol
1866756|NCT01074463|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
1866386|NCT01070706|Drug|Paclitaxel,Gemcitabine,Sunitinib|"To determine the MTD, only DLT occurring during the first cycle of treatment will be considered. And MTD is defined as the dose level at which at least one-third of patients experience a DLT during their first treatment course. The recommended dose level for the subsequent phase II study is defined as the preceding dose level before the MTD is attained.
If MTD is not reached, the recommended initial dose of the phase II part will be at the dose of paclitaxel 80 mg/m2 and gemcitabine 1200 mg/m2 (days 1, 8) with sunitinib 37.5 mg qd D2-D15."
1866387|NCT01070732|Drug|Paracetamol|All patients will receive one single dose of 1000mg paracetamol. If considered mandatory by the attending physician, similar doses may be administered latter for a maximum period of five days. The maximum allowed daily dose is 3000mg. If the attending physician believes that after the administration of at least of three doses the desired analgesic or antipyretic effect is not achieved, he may administer any other compound in his will.
1866388|NCT01070745|Drug|Indomethacin|Three doses of intravenous (IV) indomethacin at 0.2 mg/kg/dose given over 30 minutes, at intervals of 12 hours
1866389|NCT01070745|Drug|Ibuprofen|10 mg/kg infused over 30 minutes, followed by two doses of 5mg/kg each at 24 hour intervals
1866390|NCT01070758|Drug|Lanreotide autogel|The dose of Lan-ATG will be calculated according to the surface area of the patient. The dose used in adults is usually 60 mg injection once a month, and we will adapt the patient's dose according to the body surface area and also according to the daily dose of Octreotide used with the pump. The starting dose will be 40 mg/m².
1866391|NCT01070771|Device|Radi pressure wire (pressure wire assessment)|Intracoronary insertion of pressure wire at the time of diagnostic angiography.
1866392|NCT01070784|Drug|Symbicort Turbuhaler (Budesonide/formoterol)|2 x 160/4.5 microgram, inhalation, bid, 52 weeks
1866393|NCT01070784|Drug|Drug: any available COPD treatment; investigator to decide|According to investigator decision, 52 weeks, Standard COPD treatment according to investigator decision
1866394|NCT01070797|Biological|Multi-virus Specific T cells|"Subjects will receive Multivirus specific T cells on one of the following dose levels:
Level One: 5 x 10^6 rCTLs/m2
Level Two: 1 x 10^7 rCTLs/m2
Level Three: 2 x 10^7 rCTLs/m2
Level Four: 5 x 10^7 rCTLs/m2
If a patient has a partial response (as defined by a 50% fall in viral load) or receives medication (such as steroids) which may affect the persistence or function of the infused CTL they are eligible to receive up to 2 additional doses at the same initial dose. The minimum time between additional doses is 28 days."
1866395|NCT01070810|Drug|D5W|Dextrose 5%
1866396|NCT01070810|Drug|Thiamine|Thiamine 200mg in 50ml D5W
1866397|NCT01071876|Drug|BF2.649|1 capsule in the morning before breakfast
1866398|NCT01071876|Drug|Placebo|1 capsule in the morning before breakfast
1866399|NCT01071889|Drug|Flumazenil|Flumazenil- 0.4 mg per 100 µl in a sublingual spray administration
1866400|NCT01071889|Drug|Placebo|Placebo - only excipients with no API
1866401|NCT01071902|Drug|Moxidex otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
1866402|NCT01071902|Drug|Moxifloxacin otic solution|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
1866403|NCT01071902|Other|Vehicle|4 drops into the infected ear(s) twice daily (morning and evening) for 7 days
1866404|NCT01071902|Device|Tympanostomy tubes|Tubes surgically inserted through the ear drum for the treatment of recurrent otitis media in children
1866405|NCT01071915|Drug|Degarelix 240/80 mg|The degarelix doses were administered into the abdominal wall every 28 days. A starting dose of 240 mg (40 mg/mL) degarelix was administered on Day 0 as two 3 mL subcutaneous (s.c.) injections. The subsequent maintenance doses of 80 mg (20 mg/mL) degarelix were administered as single 4 mL s.c. injections at 28 day intervals from day 28 to day 168.
1866406|NCT01071928|Drug|Docetaxel|Docetaxel IV 75 mg/m2 over approximately 60 minutes on Day 1
1866407|NCT01071928|Drug|ASA404|ASA404 (given after Docetaxel)IV 1800 mg/m2 over approximately 20 minutes on Day 1
1866408|NCT01071941|Biological|administration of rRp450 into the hepatic artery|Administration of rRp450 into the hepatic artery either as a single infusion, or as four infusions administered every one to two weeks.
1866409|NCT01071954|Biological|Romiplostim|"Starting Dose of 1µg/kg romiplostim or previous dose administered weekly
Individual Subject Dose Adjustment to a Maximum Dose of 10 µg/kg based on platelet count
Rescue Medications Allowed at Discretion of Investigator
Reduction in Concurrent ITP Therapies May Occur when Platelet Count is >50 x 109/L"
1866410|NCT01071967|Other|Community-based nurse care management|The community-based nurse care management program developed by Health Quality Partners uses nurses working in the community to provide the following integrated set of services to older adults with chronic illness over the long term in order to prevent avoidable complications of their diseases and aging; geriatric assessment, care coordination, health education, self-management coaching, weight management, physical activity, gait and balance training, medication adherence, care transition support, ongoing monitoring and symptom detection, collaborative problem solving with patients, families and health care providers.
1866411|NCT01071980|Other|Work Place Adjusted Intelligent Physical Exercise Reducing Musculoskeletal Pain in Shoulder and Neck|Participants will be randomized at the cluster level to a control group or 20 weeks of specific resistance training for 3 x 20 min a week
1866412|NCT01071993|Drug|placebo|pre-treatment with placebo (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
1866413|NCT01071993|Drug|atorvastatin|pre-treatment with atorvastatin (80 mg 12 hours prior to the procedure and 40 mg pre-procedure)
1866414|NCT01072019|Other|Instrument|Randomization to instrumentation to be used for primary total knee replacement; either standard knee cutting guides or MRI generated patient specific custom cutting guides.
1866415|NCT01072032|Device|Anklebot (Ankle Robot)|Impedance controlled ankle robot provides assistance as needed for participants to perform ankle movements while playing a video game, is used to assist stroke patients to enhance motor recovery
1866416|NCT01072045|Drug|Propranolol|Oral propranolol, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
1866417|NCT01072045|Drug|Prednisone|Oral prednisone, at a dose of 2mg/kg/day, divided in 2 doses, for initial 60 days
1866469|NCT01072448|Drug|Indacaterol 75 μg|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
1866470|NCT01072448|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
1866418|NCT01072058|Drug|TNF blockers (infliximab, adalimumab, etanercept)|Subjects enrolled, who were eligible to anti-TNF therapy, were evaluated by echocardiography (conventional and tissue doppler imaging)and biomarkers (NT-proBNP and troponin T)at baseline. Then, they were treated with adalimumab 40mg subcutaneously every 2 weeks or infliximab 3 or 5mg/Kg (0, 2 and 6 weeks and thereafter every 8 weeks)or etanercept 50mg subcutaneously every week. And they were re-evaluated with 6, 12, 18 and 24 months from first dose of the TNF blocker .
1866419|NCT01072071|Drug|furosemide|"Loading dose: 0,5mg/kg Start continuous infusion at a dose of 0,1mg/kg/h and titrate according to diuretic response.
Target value for diuresis = (amount of fluids administered at inclusion/kg/h) + 0.5mL/kg/h If safety check is satisfactory: increase target diuresis with 1mL/kg/h per 4h to a maximum of (amount of fluids administered at inclusion/kg/h) + 2.5mL/kg/h Maximal dose of furosemide: 0.3mg/kg/h Safety check every 4h. Furosemide is administered for 24h. If safety checks are satisfactory, additional periods of 24 can be added up to a maximum of 72h."
1866420|NCT01072097|Drug|Atorvastatin|Atorvastatin 20mg/day for 6 months
1866421|NCT01072097|Drug|Placebo|Placebo for 6 months
1866422|NCT01072110|Procedure|Colonoscopy|Patients will undergo colonoscopy for evaluation of their symptoms.
1866423|NCT01072110|Procedure|Confocal Laser Endomicroscopy|Patients will undergo CLE during their endoscopy. Findings will be compared to group 1.
1866424|NCT01072123|Other|Quest for the Code|interactive asthma-based computer program
1866425|NCT01072136|Other|Placebo|Capsule will be filled with lactose and be identical in appearance to the capsule with the active ingredient.
1866426|NCT01072136|Drug|Azithromycin|Single dose will consist of 2 over-encapsulated capsules (500 mg each) administered orally.
1866427|NCT01072136|Drug|Cefixime|Single dose will consist of 1 over-encapsulated capsule (400 mg) administered orally.
1866428|NCT01072149|Drug|Fluticasone Furoate (FF)/GW642444 Inhalation Powder|Inhaled Corticosteroid (ICS)/ Long Acting Beta Agonist(LABA) for COPD
1866429|NCT01072149|Device|placebo|placebo
1866430|NCT01072162|Drug|Eltrombopag|25 mg tablet
1866431|NCT01072162|Drug|Eltrombopag|25 mg powder for oral suspension
1866432|NCT01072175|Drug|GSK2118436|GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.
1866433|NCT01072175|Drug|GSK1120212|GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.
1866434|NCT01072188|Device|Arginine/Calcium Carbonate|One time treatment
1866435|NCT01072188|Device|Nupro - Fluoride Free|Brush twice daily
1866436|NCT01072201|Drug|Triclosan and Fluoride|Brush twice daily
1866437|NCT01072201|Drug|Fluoride|Brush twice daily
1866438|NCT01072214|Drug|pazopanib|gw786034
1866439|NCT01072214|Drug|pazopanib|gw786034
1866440|NCT01072214|Drug|pazopanib|gw786034
1866441|NCT01072214|Drug|Placebo|placebo
1866442|NCT01072227|Procedure|Sample Collection|Tissue
1866443|NCT01072240|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
1866444|NCT01072253|Procedure|eye amputation|
1866445|NCT01072266|Drug|INCB028060|10 mg and 50 mg capsules will be provided and dosed per the dosing schedule.
1866446|NCT01072279|Other|Tubaramure (Burundi)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
1866447|NCT01072279|Other|Procomida (Guatemala)|Different combinations of family food rations, individual food rations, micronutrient supplements and behavior change communication to encourage optimal and age-appropriate infant and child feeding practices
1866448|NCT01072292|Behavioral|CBT-I|CBT-I is a six week program designed to improve sleep quality in people with COPD.
1866449|NCT01072305|Device|Intermittent pneumatic compression (IPC)|Intermittent pneumatic compression (sequential compression) using a cuff consisting of 12 chambers inflated sequentially from forefoot to groin with decremental inflation pressures (60-38 mmHg), pressure release after complete inflation, and reinflation after 4 seconds pause. ICP cuffs are covered with a frame and drapes for blinding purpose.
1866450|NCT01072305|Device|IPC - placebo|ICP cuffs are placed next to/between legs and covered with a frame and drapes for blinding purpose. IPC device is run fom induction of general anesthesia to closure of the skin.
1866451|NCT01072318|Drug|Letrozole|Letrozole 2.5mg
1866452|NCT01072331|Drug|MP-513|MP-513 10 mg, once a day, for 4 weeks
1866453|NCT01072331|Drug|MP-513|MP-513 20 mg, once a day, for 4 weeks
1866454|NCT01072331|Drug|Placebo of MP-513|MP-513 placebo, once a day, for 4 weeks
1866455|NCT01072344|Drug|Chamomile (Matricaria recutita)|500 mg 3 times daily
1866456|NCT01072357|Drug|Avastin® (bevacizumab)|One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
1866457|NCT01072357|Drug|0.9% NaCl & Refresh Liquigel|One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks
1866458|NCT01072370|Biological|Cord Blood Infusion|red-cell depleted, mononuclear cell enriched cord blood unit prepared for infusion
1866459|NCT01072370|Biological|Intravenous Sham|intravenous infusion of 5% dextrose, ¼ normal saline solution
1866460|NCT01072383|Drug|BT061|administration of BT061 either intravenous or subcutaneous
1866461|NCT01072383|Drug|placebo treatment|administration of the end formulation buffer of BT061 without active ingredient, either subcutaneous or intravenous
1866462|NCT01072396|Drug|Tiotropium|double blind randomized crossover
1866463|NCT01072396|Drug|Placebo|inhalation powder capsule identical to those containing tiotropium bromide inhalation powder
1866464|NCT01072409|Device|Nucleus 5 Cochlear implant|Cochlear implant surgery
1866465|NCT01072409|Device|Cochlear implantation|Implantation
1866466|NCT01072422|Behavioral|Counseling based on answers to the assessment protocol|Each patient in the Protocol arm will fill in a TTQ at baseline. On the basis of the patients' answers, the nurse will provide individual counseling aimed at helping this patient overcome obstacles to smoking cessation.
1866471|NCT01072461|Behavioral|HAS Training|Robotically measured and facilitated training of the hemiparetic hand and arm in isolation, in a three dimensional haptically rendered virtual environment.
1866472|NCT01072461|Behavioral|HAT training|Robotically measured and facilitated training of the hemiparetic hand and arm as an integrated functional unit, in a three dimensional haptically rendered virtual environment
1866473|NCT01072461|Behavioral|Bimanual Training|Robotically measured and facilitated training of the hemiparetic hand and non-hemiparetic hand together, in a three dimensional haptically rendered virtual environment
1866474|NCT01072474|Procedure|Capnography|Capnographic monitoring
1866475|NCT01072474|Procedure|Standard monitoring|Standard monitoring
1866476|NCT01072487|Procedure|Capnography|Monitoring of the capnography curve for early detection of apnea
1866477|NCT01072500|Behavioral|Physical Activity|The physical activity intervention consists primarily of walking at moderate intensity, lower extremity resistance exercises, balance exercises, stretching and behavioral counseling.
1866478|NCT01072500|Behavioral|Successful Aging|The successful aging intervention consists of health education seminars regarding health-related matters and upper extremity stretching exercises.
1866479|NCT01072513|Other|Semen analysis|Semen analysis before and after proton radiation therapy.
1866480|NCT01072526|Drug|Euphrasia-based homeopathic therapy|ophthalmic solution; 1 drop both eyes twice daily
1866481|NCT01072526|Drug|Cyclosporin solution|Cyclosporin solution; 1 drop both eyes twice daily
1866482|NCT01072539|Drug|tigecycline|As prescribed by physician in usual clinical practice
1866483|NCT01072565|Other|SMBG to guide clinical decisions|The investigator will base clinical decisions on A1c and modal day analysis of SMBG.
1866484|NCT01072565|Other|SMBG and CGM|The investigator will base clinical decisions on A1c, modal day analysis of SMBG and CGM data.
1866485|NCT01072578|Drug|Dapagliflozin|Dapagliflozin tablets 5 mg, Oral Twice daily dose for 5 days (total daily dose 10 mg)
1866486|NCT01072578|Drug|Dapagliflozin|Dapagliflozin tablets, 10 mg, Oral, once daily dose for 5 days
1866487|NCT01072591|Drug|MEDI-578|intravenous infusion, once
1866488|NCT01072591|Drug|Placebo for MEDI-578|Intravenous infusion, once
1866489|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 1 under fasting conditions
1866490|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAY1019036)|One oral dose of new formula Aspirin Prototype 2 under fasting conditions
1866491|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Plain Tablet under fasting conditions
1866492|NCT01072604|Drug|Acetylsalicylic acid (Aspirin, BAYE4465)|One oral dose of Aspirin Dry Granules under fasting conditions
1866493|NCT01072617|Device|Transcranial magnetic stimulation via MagPro x100 device|"Participants will receive 10 repetitive transcranial magnetic stimulation sessions to the vermis of cerebellum using the MagPro x100 TMS device. These 10 rTMS sessions will be administered from Monday to Friday in five days, twice a day with a minimum of 4-hour gap between the sessions. Repetitive TMS will be applied with the intermittent theta burst pattern (iTBS). These parameters are known to cause excitation in brain activity.
Anatomically precise localization of rTMS will be achieved using a frameless stereotactic system."
1866494|NCT01072630|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
1866495|NCT01072630|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
1866496|NCT01072643|Drug|Dexmedetomidine|This is a single center, dose escalation study of Dexmedetomidine in pediatric subjects with pulmonary hypertension (PVR>4WU) undergoing hemodynamic cardiac catheterization and vasoreactivity drug testing. Cohorts of 8 evaluable subjects will receive dose level 1, dose level 2, or dose level 3 of Dexmedetomidine.
1866497|NCT01072656|Device|Deep Brain Stimulation for Thalamic Pain Syndrome|Patients will be randomized in a 1:1 ratio to one of two groups: the Treatment Group (active stimulation and programmed to the settings found to be optimal during the titration phase) and the Control Group (sham stimulation - IPG is set to ON but the voltage is set to 0V). In order to prevent too many patients from being randomized to ON or to sham early in the study, we will use, for the first 4 patients, randomization blocks of four or six. In this fashion, the first four consecutive patients will have two patients randomized to the Treatment Group and two patients in the Control Group. In the same fashion, the final six patients will have three patients randomized to the treatment group and three patients to the control group.
1866498|NCT01072669|Drug|ambrisentan|Subjects will receive ambrisentan 5 mg orally once daily or identical placebo pills for the first 4 weeks and then increased to ambrisentan 10mg once daily[if the lower dose is tolerated] or identical placebo pills for the rest of the study. They will be instructed to take the 5mg/pink pills for 4 weeks and then switch to 10mg /red pills unless they are having any drug related side effects or concerns. There will be no routine visit planned at 4 weeks to assess drug tolerance unless a complication arises. Adherence to treatment will be assessed by pill counting at each follow up visit. Follow up digital blood flow measurements will be obtained with LDPI at 1 week and at 3 months, where the same protocol (as that in the initial visit) will be followed.
1866499|NCT01072682|Device|Selective cytopheretic device (SCD)|The selective cytopheretic device (SCD) is comprised of tubing, connectors and a hemofilter cartridge. The device is connected in series to a commercially available Continuous Renal Replacement Therapy (CRRT) device. Blood from the CRRT circuit is diverted after the CRRT hemofilter through to the extra capillary space (ECS) of the SCD. Blood circulates through this space and is returned to the patient via the venous return line of the CRRT circuit. Regional citrate anticoagulation is used for the entire CRRT and SCD blood circuits.
1866500|NCT01072695|Drug|GS-9256|75 mg BID x 28 days
1866501|NCT01072695|Drug|GS-9190|40 mg BID x 28 days
1866502|NCT01072695|Drug|Ribavirin|1000-1200 mg/day given BID
1866503|NCT01072695|Drug|Peginterferon alfa-2a|180 ug q week
1866504|NCT01072708|Other|Prospective cohort with an annual follow-up|"Annualfollow-up including :
oral glucose tolerance test
dietary survey
biological evaluation
bacteriological and respiratory measures
dual-energy x-ray absorptiometry
physical activity survey"
1866505|NCT01072721|Other|Elastometry|Fibrosis detection with FIBROSCANN
1866507|NCT01072747|Biological|bovine heparin|5.000UI/mL bottle with 5mL
1866508|NCT01072747|Biological|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
1866509|NCT01072760|Procedure|K wire|Mallet finger treatment
1866511|NCT01072773|Drug|cyclophosphamide|300 mg/m^2, orally, on days 1, 8, 15 & 22 every 28 days.
1866512|NCT01072773|Drug|dexamethasone|40 mg, orally, on days 1, 8, 15 & 22 every 28 days
1866513|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 1|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 1 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3-3´D4Δ30, 10^3 PFU of rDEN4Δ30)
1866514|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 2|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 2 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3-3´D4Δ30, 10^3 PFU of rDEN4Δ30-200,201)
1866515|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 3|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 3 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, 10^3 PFU of rDEN4Δ30)
1866516|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 4|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 4 (10^3 PFU of rDEN1Δ30, 10^3 PFU of rDEN2/4Δ30[ME], 10^3 PFU of rDEN3Δ30/31-7164, 10^3 PFU of rDEN4Δ30-200,201)
1866517|NCT01072786|Biological|Placebo|One subcutaneous injection of a placebo containing vaccine diluent but no actual vaccine
1866518|NCT01072786|Biological|TetraVax-DV Vaccine-Admixture 5|One subcutaneous injection of a recombinant live attenuated TetraVax-DV vaccine, admixture 5 (10^3 PFU of rDEN1Δ30, 10^4 PFU of rDEN2/4Δ30(ME), 10^3 PFU of rDEN3Δ30/31-7164, and 10^3 PFU of rDEN4Δ30)
1866519|NCT01072799|Biological|Placebo|Two doses (Day 1 and Day 22); 0.5mL
1866520|NCT01072799|Biological|A/H1N1 2009 Influenza VLP Vaccine|Two doses (Day 1 & Day 22); 0.5mL
1866521|NCT01072812|Drug|Posiphen® tartrate capsules|Capsules administered (240 mg/day) for 10 days Capsules administered (160 mg/day) for 10 days
1866522|NCT01072825|Other|questionnaires|a descriptive questionnaire, SF-36, , bone questionnaires, Baecke physical activity questionnaire, voice evaluation
1866523|NCT01072825|Biological|blood sampling|LFT (AST, ALT), CRP, creatinine, glucose, Total Cholesterol, Triglycerides, HDL-CH, LDL-CH, 25OH vitamin D, PSA if> 45 years, Hematocrit, testosterone, sex hormone-binding globulin, free testosterone , oestradiol, prolactin, luteinizing hormone, TSH, androgeengevoeligheids test (CAG RL), oral glucose tolerance test
1866524|NCT01072825|Other|clinical evaluation|height, weight, blood pressure, chestcircumference, waist circumference, grip strength, measuring 2 ° and 4 ° finger, and Ferriman Gallwey score
1866525|NCT01072825|Other|Dermatology evaluation|Evaluation of the hair pattern, using the Leeds acne classification scale, acne scars through ECCA scale (échelle d'évaluation clinique des cicatrices d'acné), androgenetic alopecia, and sebummetrie
1866526|NCT01072825|Other|Bone evaluation|PQCT scanner, BMD assessment
1866527|NCT01072838|Radiation|APBI (Dose Escalation)|"Accelerated, hypofractionated partial breast radiotherapy.
3 dose schemes followed for 6 months each."
1866528|NCT01072838|Device|Contura MLB Breast Brachytherapy Catheter|
1866529|NCT01072851|Behavioral|Multimedia Education|A four minute exposure to an educational video with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
1866530|NCT01072851|Behavioral|Print Media|Exposure to a printed brochure with controlled content on the importance of colorectal cancer screening and explaining the processes and procedures.
1866531|NCT01072851|Behavioral|Usual and customary waiting room process|No specialized educational intervention to promote colorectal cancer screening or to explain the process
1866532|NCT01072864|Other|Walnuts|Consumption of 5 g of walnuts.
1866533|NCT01072864|Other|Walnuts|Consumption of 20 g of walnuts.
1866534|NCT01072864|Other|Walnuts|Consumption of 30 g of walnuts.
1866535|NCT01072864|Other|Walnuts|Consumption of 40 g of walnuts.
1866536|NCT01072877|Drug|Polidocanol injectable foam (PEM)|Injection of Polidocanol injectable foam
1866537|NCT01072877|Drug|Placebo Vehicle|Placebo vehicle
1866538|NCT01072890|Drug|Temsirolimus, Pazopanib|Patients will be treated on an outpatient basis with both temsirolimus and pazopanib. All patients will receive temsirolimus intravenously (IV) weekly days 1, 8, 15, and 22. Patients will receive oral pazopanib on a daily basis starting day 1. Treatment will be administered on 28 day cycles. Patients will be in this study for a minimum of 8 weeks or 2 cycles.
1866539|NCT01072929|Drug|Armodafinil|Doses of either 150mg/day or 200 mg/day in tablet form taken orally, once daily in the morning.
1866540|NCT01072929|Drug|Placebo|Matching Placebo, also in tablet form taken orally, once daily in the morning.
1866541|NCT01072942|Drug|Ciprofloxacin (Cipro InhaIe, BAYQ3939)|Ciprofloxacin Inhale 50 and 75 mg 2 times a day (BID) for 10 days
1866542|NCT01072942|Drug|Placebo|Placebo TID for 10 days
1866543|NCT01072955|Biological|Bovine Heparin|5.000UI/mL bottle with 5mL
1866544|NCT01072955|Biological|Porcine heparin|5000 USP Heparin Units / mL vial with 10 mL vial
1866545|NCT01072968|Drug|BF2.649|1 capsule per day in the morning before the breakfast
1866546|NCT01072968|Drug|Placebo|1 capsule per day in the morning before the breakfast
1866547|NCT01072981|Biological|HyperAcute-Pancreas Immunotherapy|Up to 18 immunizations of 300 million immunotherapy cells
1866548|NCT01072981|Drug|Gemcitabine|Gemcitabine 1000 mg/m2/day once a week for 3 weeks
1866549|NCT01072981|Radiation|5FU Chemoradiation|5FU 200-250 mg/m2/day over 5 1/2 weeks with radiation.
1866550|NCT01072994|Dietary Supplement|Fish Oil|Differential proportional doses of DHA versus DHA and EPA
1866551|NCT01073007|Drug|Simvastatin|Simvastatin 40 mgrs daily for three months.
1866552|NCT01073020|Procedure|Laparoscopic Adjustable Gastric Band|Allergan Adjustable Gastric Band (Device) compared to Medical-Behavioural-Nutritional Diabetes and Weight Management (Why WAIT? Program)
1866553|NCT01073020|Procedure|Roux-en-Y Gastric Bypass (Surgery)|Roux-en-Y Gastric Bypass (Surgery) versus Medical-Behavioural-Nutritional Diabetes and Weight Management (Why WAIT? Program)
1866554|NCT01073020|Other|Intensive Medical Diabetes & Weight Management|Intensive Medical Diabetes & Weight Management
1866555|NCT01073020|Device|Allergan Adjustable Gastric Band|Allergan Adjustable Gastric Band (Device) compared to Medical-Behavioural-Nutritional Diabetes and Weight Management (Why WAIT? Program)
1866556|NCT01073033|Dietary Supplement|milk supplement 1|milk supplement with probiotics
1866557|NCT01073033|Dietary Supplement|milk supplement 2|milk supplement without probiotics
1866558|NCT01073046|Device|Naso-Gastric/Jejunal Tube|Silastic Naso-Gastric/Jejunal Tube (Rusch® distributed by Teleflex Medical Srl)
1866560|NCT01073072|Procedure|Conventional technique|Conventional technique to repair potentially contaminated incisional or abdominal wall hernias
1866561|NCT01073072|Procedure|Technique Tutomesh®|Technique of abdominal wall reconstruction or hernia repair strengthened by Tutomesh® in potentially contaminated environment.
1866562|NCT01073085|Behavioral|"Web-based automated coaching by e-mails"|
1866563|NCT01073085|Behavioral|Self-help guide|
1866564|NCT01073098|Other|Vascular occlusion test|Reperfusion slope after vascular occlusion test
1866565|NCT01073111|Device|zotarolimus-eluting stent (ENDEAVOR®)|zotarolimus-eluting stent
1866566|NCT01073111|Device|sirolimus-eluting stents (CYPHER SELECT® PLUS)|sirolimus-eluting stents
1866567|NCT01073111|Device|everolimus-eluting stents (PROMUS®)|everolimus-eluting stents
1866568|NCT01073124|Procedure|Saline Load Test|Intraarticular injection of dilute methylene blue dye (1 ml per 500 ml normal saline) or normal saline into the knee joint through a lateral suprapatellar injection site. Maximum injection of 180 ml.
1866569|NCT01073150|Drug|Tea Tree Oil|Tea Tree Oil shampoo 0.25% and ointment 5% daily and Tea Tree Oil oily solution 50% once a week for six weeks
1866570|NCT01073163|Drug|Bendamustine|Bendamustine at 90 mg/m^2 IV on Days 1 and 2 of a 28-day cycle.
1866571|NCT01073163|Drug|Rituximab|Rituximab at 375 mg/m^2 IV on Day 1 of a 28-day cycle.
1866572|NCT01073176|Other|TEAMS (Training Attention Executive and Motor Skills)|Training Executive, Attention and Motor Skills (TEAMS) is a new research program for preschool children with Attention-Deficit/Hyperactivity Disorder (ADHD) that attempts to use game-like activities and physical exercise to promote the growth of neural processes that underlie the core features of the disorder (e.g., hyperactivity, impulsivity) as well as associated areas of difficulty (e.g., socialization, motor skills). These activities are implemented at home and in supervised playgroups at no cost to families and are coupled with extensive parental education about ADHD symptoms and associated impairments.
1866573|NCT01073189|Drug|Intra-Renal Fenoldopam|Placement of an intra-renal catheter for infusion of fenoldopam mesylate
1866574|NCT01073189|Drug|Furosemide|Patients randomized to the Diuretic Control group will receive intravenous furosemide as an active control
1866575|NCT01073202|Drug|ursodeoxycholic acid|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
1866576|NCT01073202|Drug|identical-appearing placebo|13-15mg/kg/day, 250mg/capsule, given twice per day, within the first 4 weeks after liver transplantation
1866577|NCT01073215|Behavioral|Family-Based Lifestyle Modification|The Self-Guided condition will receive the same manual content and recommendations for eating and physical activity as the Group Condition. Since this approach is primarily home-based, participants in this condition will also receive additional tips and guidelines to assist the family in following the program at home. There will be 6 visits with the health coach at weeks 01, 04, 08, 24, 40, and 52. Participants will receive 2 phone calls from health coach at weeks 16 and 32. Parents and teens will be encouraged to hold weekly meetings at home to discuss program goals and progress.
1866578|NCT01073215|Behavioral|Family-Based Lifestyle Modification Program|"The Group condition will consist of a comprehensive family based lifestyle modification program of 23 visits (8 weekly, 8 bi-weekly, 7 monthly).
Intervention visits include a combination of 17 group sessions and 6 individual meetings with health coach. There will be 7 phone calls two weeks after each monthly visit. Adolescents and their parents attend concurrent group meetings. The content of the sessions will include topics related to nutrition, physical activity, and behavior modification for weight management."
1866581|NCT01073241|Procedure|transurethral ventral wall of urethra-preserving enucleation of prostate|The patients' ventral wall of the prostate urethra was preserved and enucleation of prostate was performed for the left hyperplasia in the envelop.
1866582|NCT01073241|Procedure|transurethral prostatic resection|The patients' prostate was resected with the conventional Nesbit TURP
1866583|NCT01073267|Radiation|TSEBT|Total skin electron beam therapy (TSEBT) to a total dose of 12 Gray (TSEBT 12 Gy), low-dose radiation to the skin 4-5 days a week for 3 weeks.
1866584|NCT01073280|Procedure|cerebral flexible endoscopy|The investigators will make a burrhole in the precoronal suture introducing the flexible endoscope taking a cerebral and a basal meningeal biopsy
1866585|NCT01073293|Biological|V503 Vaccine|V503 (Multivalent HPV L1 VLP vaccine) given as a 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
1866586|NCT01073293|Biological|REPEVAX™ (Concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Day 1
1866587|NCT01073293|Biological|REPEVAX™ (Non-concomitant)|REPEVAX™ given as a single 0.5 mL intramuscular injection at Month 1
1866588|NCT01073306|Biological|Investigational Vaccine for Dengue Virus Subtype 2|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
1866589|NCT01073306|Other|Placebo|Subcutaneous injection of placebo
1866590|NCT01073319|Other|Placebo|Administration of placebo pill
1866591|NCT01073319|Drug|Rivastigmine|Participants will be randomized to rivastigmine (1.5 mg bid) for 6 days of each phase.
1866592|NCT01073319|Drug|Rivastigmine|Participants will be randomized to rivastigmine (3 mg bid) for 6 days of each phase.
1866593|NCT01073332|Dietary Supplement|Arginine antioxidant supplements|The proprietary supplement Niteworks® was manufactured by Herbalife International Inc. (Century City, California, USA). Each serving contained 5.2g L-arginine in a proprietary blend with L-citrulline, 500mg ascorbic acid, 400IU vitamin E, 400ug folic acid, 300mg L-taurine, and 10mg alpha lipoic acid in a lemon-flavored powder form. One serving of supplement powder was mixed with 8 oz of water, administered at bedtime based on the rationale that nitric oxide levels are lowest during sleep due to inactivity, lack of food and low blood pressure.
1866594|NCT01073332|Dietary Supplement|Placebo|The placebo group received a powder with all active ingredients replaced with M-100 maltodextrin.
1866595|NCT01073345|Procedure|Portal venous pressure|Portal venous pressure is measured by invasive means using an arterial canula
1866596|NCT01073345|Procedure|Portal venous flow|Portal venous flow is measures using a noninvasive method (Doppler flow meter)
1866761|NCT01074541|Radiation|UVB|0.375 SED x 4 in a week
1866597|NCT01073345|Procedure|Hepatic artery flow|Hepatic artery flow will be measured using a noninvasive method (Doppler flow meter)
1866599|NCT01073371|Drug|Prilocaine|1.8mL infiltration of liposome-encapsulated 3% prilocaine, 3% plain prilocaine or 3% prilocaine with 0,03IU/mL felypressin in the buccal sulcus of the maxillary right canine
1866600|NCT01073384|Drug|SGX201 (delayed release beclomethasone 17,21-dipropionate)|Delayed release beclomethasone 17,21-dipropionate before the first administration of radiation therapy continuing for 7 days after the end of radiation therapy.
1866601|NCT01073397|Behavioral|Yoga|Integral Yoga class (90 minutes per class), Once weekly for 10 weeks
1866602|NCT01073423|Behavioral|Music Therapy|1-hour music therapy sessions, administered in group format 3 times per week for 8 weeks.
1866603|NCT01073423|Behavioral|Yoga|1-hour yoga sessions administered in group format 3 times per week for 8 weeks
1866604|NCT01073436|Other|Discontinuation of therapy|Patients with chronic-phase chronic myeloid leukemia (CP-CML) previously treated with interferon-alpha (IFN) and presently on a tyrosine kinase inhibitor (TKI) (imatinib mesylate, dasatinib, or nilotinib) with achievement of a complete cytogenetic and at least a major molecular remission.
1866605|NCT01073449|Procedure|In-hospital follow-up of cardiac device|Electrical measures taken during normal follow-up and clinical status of the patient
1866606|NCT01073475|Other|There is no intervention associated with this study.|There is no intervention associated with this study
1866607|NCT01073488|Behavioral|Community Mobilization, HBLSS and facility improvement|Mobilization of the community, with special emphasis on pregnant women and their families, to identify resources and solutions to improve maternal and neonatal mortality, home-based life savings skills (HBLSS) for community birth attendants and facility improvement activities.
1866608|NCT01073501|Drug|Pregabalin|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
1866609|NCT01073501|Drug|Placebo|Pregabalin 25 mg (Lyrica; Pfizer, Germany) or placebo will be administered orally daily at the end of hemodialysis sessions in dialysis patients or every evening in non dialysis CKD patients. The dose will be increased up to 50 mg if no improvement of pruritus will be established at the end of first week of the study
1866610|NCT01073527|Drug|hypertonic saline-salbutamol combination|hypertonic saline 5% with 0.5cc salbutamol
1866611|NCT01073527|Drug|Normal saline-salbutamol combination|normal saline - 4cc with salbutamol 0.5cc
1866612|NCT01073540|Drug|Cephalexin suspension (Optocef, BAYO5448)|Single dose of 500 mg / 10 mL
1866613|NCT01073540|Drug|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
1866614|NCT01073553|Drug|Cephalexin capsules (Optocef, BAYO5448 )|Single dose of 500 mg (One 500 mg capsule)
1866615|NCT01073553|Drug|Cephalexin capsules (Keflex)|Single dose of 500 mg (Two 250 mg capsules)
1866616|NCT01073566|Device|Finesse|Finesse Insulin Delivery Patch
1866617|NCT01073566|Device|Pen/Syringe (Usual injection device)|Pen/Syringe
1866618|NCT01073579|Drug|Sabril®|"Infantile Spasms (IS): Initiate therapy at 50 mg/kg/day twice daily increasing total daily dose per instructions to a maximum of 150 mg/kg/day.
Refractory Complex Partial Seizures (rCPS) in Adults: Initiate therapy at 500 mg twice daily, increasing total daily dose per instructions. The recommended dose is 1.5 grams twice daily."
1866619|NCT01073605|Drug|Genotonorm|0.7 IU/kg/week or 0.03 mg/kg/day, daily subcutaneous injection
1866620|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection
1866621|NCT01073605|Drug|Genotonorm|1.4 IU/kg/week or 0.06 mg/kg/day, daily subcutaneous injection Intermittent treatment (6 months with treatment and 6 months without)
1866622|NCT01073618|Drug|voriconazole IV|6 mg/kg iv q 12 hours (loading) then maintenance
1866623|NCT01073631|Drug|voriconazole tablet|200 mg PO bid (orally, twice a day)
1866624|NCT01073644|Drug|Sunitinib malate|sunitinib 50 mg, 4 weeks on, 2 weeks off
1866625|NCT01073657|Other|Supported Education|Rehabilitation counseling using peers to achieve educational goals
1866626|NCT01073657|Other|General Peer Support|Matched peer support for any personal goal other than education
1866627|NCT01073670|Drug|Indomethacin|Indomethacin was given via suppository at time of induction for anesthesia (2 x 50 mg) followed by one 50 mg suppository at 6, 12, 18 and 24 hours following cardiac bypass surgery.
1866628|NCT01073670|Drug|Acetaminophen & Indomethacin|Subjects were given a loading dose of acetaminophen (1300 mg) and indomethacin (50 mg)by suppository at the time of induction for anesthesia and then given 650mg acetaminophen + 25 mg indomethacin at 6, 12, 18 and 24 hours following cardiac bypass surgery.
1866629|NCT01073670|Drug|Acetaminophen|Subjects were given a loading dose of 2600 mg of acetaminophen (via suppository) at time of induction for anesthesia then given 1300mg at 6, 12, 18 and 24 hours following cardiac bypass surgery.
1866630|NCT01073683|Procedure|laryngoscopy|Treatment of advanced larynx cancer with induction TPF, in order to decide between chemoradiation and laryngeal preservation surgery
1866631|NCT01073683|Drug|Taxotere (Docetaxel), Cisplatin, 5FU|Taxotere 75 mg/m2 D1, Cisplatin 75 mg/m2 D1, 5FU 750 mg/m2 D1-4
1866632|NCT01073696|Drug|granisetron IV|IV
1866633|NCT01073696|Drug|granisetron patch|patch
1866634|NCT01073709|Drug|Acetaminophen|
1866635|NCT01073722|Device|Placement of double lumen tube for one-lung ventilation|The gold standard for lung isolation is the use of a double lumen tube (DLT). A DLT is a bifurcated tube with a bronchial and a tracheal lumen.
1866636|NCT01073722|Device|Placement of EZ- Blocker for one-lung ventilation|Bronchial blockers are balloon-tipped semi-rigid catheters. Different types are available. They are not easy to put in position and frequently dislocates during repositioning of the patient or during surgical manipulation. To solve these problems, a novel type of bronchus blocker, i.e. the EZ- Blocker® is developed. The EZB is also a semi-rigid catheter but it has two distal extensions, both with an inflatable cuff and a central lumen. These improvements owe to the fact that the blocker anchors itself on the carina with the two extensions.
1866637|NCT01073748|Drug|paracetamol|single dose of paracetamol 15mg/kg.
1866762|NCT01074541|Radiation|UVB|0.75 SED x 4 in a week
1866638|NCT01073761|Drug|darunavir/ritonavir then atazanavir/ritonavir|"Phase 1: Oral darunavir/ritonavir 800/100 mg once daily for 10 days
Phase 2: Oral atazanavir/ritonavir 300/100 mg once daily for 10 days"
1866639|NCT01073774|Behavioral|Side by side|
1866640|NCT01073774|Behavioral|couples control condition|
1866641|NCT01073787|Drug|Normal saline|10 ml/kg of normal saline will be administered over 30 minutes
1866642|NCT01073800|Drug|atorvastatin 80 mg per os daily|atorvastatin 80 mg per os daily
1866643|NCT01073800|Drug|placebo|placebo
1866644|NCT01073813|Drug|Minocycline|100mg twice daily
1866645|NCT01073826|Behavioral|Sport|
1866646|NCT01073826|Drug|Tocilizumab|
1866647|NCT01073826|Drug|Sitagliptin|
1866648|NCT01073839|Drug|Cisplatin and Gemcitabine|Cisplatin 25 mg/m2 days 1 and 8; next cycle starting day 22. Gemcitabine 1000 mg/m2 days 1 and 8; next cycle starting day 22. Total of 8 cycles.
1866649|NCT01073852|Drug|Placebo|Placebo pill, 1 pill orally twice daily for 9 weeks.
1866650|NCT01073852|Drug|Hydroxychloroquine|Patients will be taking hydroxychloroquine 200mg orally twice/daily.
1866651|NCT01073865|Drug|ZD9393 (Zoladex)|10.8 mg (goserelin acetate): one subcutaneous depot injection once every 12 weeks (± 7 days).
1866652|NCT01073865|Drug|ZD9393 (Zoladex)|3.6 mg (goserelin acetate): one subcutaneous depot injection once every 4 weeks (± 7 days).
1866653|NCT01073878|Device|Athena Pelvic Muscle Trainer|The Athena PMT is a vaginally inserted electrical stimulator that induces the pelvic floor muscles to contract and relax, similar to Kegel exercises intended to strengthen the pelvic floor muscles.
1866654|NCT01073891|Drug|Moxifloxacin (Avelox, BAY12-8039)|Single oral dose of moxifloxacin (Avelox, BAY12-8039) IR (immediate release) tablet 400 mg under fasting conditions
1866655|NCT01073891|Drug|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fasting conditions
1866656|NCT01073891|Drug|Moxifloxacin (BAY12-8039)|Single oral dose of moxifloxacin (BAY12-8039) oral suspension 400 mg under fed conditions
1866657|NCT01073904|Drug|Levonorgestrel Emergency Pill (BAY86-5028)|Single dose of 1.5 mg coated tablet
1866658|NCT01073904|Drug|Postinor 2|Single dose of 1.5 mg tablet
1866659|NCT01073917|Other|Spontaneous Breathing|
1866660|NCT01073917|Other|Pressure Controlled Ventilation|
1866661|NCT01073917|Other|Pressure Support Ventilation|
1866662|NCT01073930|Drug|PicoPrep|PICOPREP (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PICOPREP pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. The first pouch was taken between 5:00 PM and 9:00 PM the evening prior to the colonoscopy procedure. Subjects were to consume five (5) 8-ounce glasses of clear liquids over the next few hours. The second pouch was taken approximately 5 hours before but no more than 9 hours prior to the colonoscopy procedure. Subjects were to consume three (3) 8-ounce glasses of clear liquids.
1866663|NCT01073930|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
1866664|NCT01073930|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
1866665|NCT01073943|Drug|PicoPrep|PicoPrep (sodium picosulfate, magnesium oxide and citric acid) powder for oral solution consisted of 2 pouches of powder administered in a divided dose. Each PicoPrep pouch was reconstituted by mixing the contents in a cup with 5 ounces of cold water. Subjects randomized to the PicoPrep group will begin treatment (1st sachet) one day before colonoscopy between 4:00 and 6:00 PM, and will complete the treatment (2nd sachet) at least 6 hours later, between 10:00 PM and 12:00 AM. Subjects will consume approximately (5) 8 oz. glasses of clear liquids following the first sachet administration in the afternoon and (3) 8 oz. glasses of clear liquids following the second sachet administration in the evening, one day before colonoscopy.
1866666|NCT01073943|Drug|HalfLytely|HalfLytely contains polyethylene glycol electrolyte solution (PEG-EL), sodium chloride, sodium bicarbonate and potassium chloride. The day prior to the colonoscopy procedure and after the first bowel movement or after 6 hours following administration of the bisacodyl tablets, whichever occurred first, subjects were to drink the 2 liter HalfLytely at a rate of one 8-ounce glass every 10 minutes. The entire solution was to be consumed.
1866667|NCT01073943|Drug|bisacodyl|Two 5 mg bisacodyl tablets were taken in the afternoon on the day prior to the colonoscopy procedure.
1866668|NCT01073956|Procedure|Medium-wave 448 kHz therapy|0.5 MHz radiofrequency for 10 minutes. At SPS insertion and bicipital groove
1866669|NCT01073956|Procedure|Ultrasonic therapy|Pulsed 1 MHz ultrasound at 2 W/cm2 for 10 minutes. At SPS insertion and bicipital-groove
1866670|NCT01073956|Procedure|Inactive electrotherapy|Inactive electrotherapy, inactive head, dosage 0 W/cm2 for 10 minutes. At SPS insertion and bicipital groove.
1866671|NCT01073969|Other|wheat bran extract|Comparison of control cereal (containing no added wheat bran extract)to two test cereals containing different amounts of added wheat bran extract
1866672|NCT01073969|Other|control wheat bran extract|Comparison of control cereal (containing no added wheat bran extract) to two test cereals containing different amounts of added wheat bran extract
1866673|NCT01073982|Dietary Supplement|tart cultivar Montmorency cherry juice|21 ounces of experimental or placebo juice, consumed daily for 21 days.
1866674|NCT01073995|Drug|Kenalog and Sensorcaine|Kenalog: 40 mg/ml Sensorcaine 0.25%: 1cc
1866675|NCT01074008|Drug|ABT-450|50 mg capsules co-administered with ritonavir
1866676|NCT01074008|Drug|ABT-072|50 mg tablet
1866677|NCT01074008|Drug|ABT-333|400 mg tablet
1866678|NCT01074008|Drug|Ritonavir|100 mg capsules co-administered with ABT-450
1866679|NCT01074008|Drug|Peginterferon alpha-2a|Syringe, 180 µg/0.5 mL for subcutaneous injections
1866680|NCT01074008|Drug|Ribavirin|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
1866681|NCT01074008|Other|Placebo|Matching placebo for ABT-450/r, ABT-072, or ABT-333 monotherapy at each dose level
1866757|NCT01074476|Dietary Supplement|Glucosamine sulphate|750mg glucosamine sulphate (oral tablets), twice per day for 3 months
1866682|NCT01074021|Drug|Nimotuzumab|"Nimotuzumab:(200mg/w,weekly, 7-8 weeks, one week before radiotherapy)
Radiotherapy:
IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.
CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin
Chemotherapy:
Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
1866683|NCT01074021|Drug|placebo plus chemoradiotherapy|"Placebo treatment:4 bottles/w,weekly, 7-8 weeks, one week before radiotherapy
Radiotherapy:
IMRT: Nasopharynx: GTV 66-78. 2Gy,CTV1 60-64Gy,CTV2 54-60Gy.30-34 times, 2.20-2.30Gy/time,once a day, 5 days/w, 6-7 weeks. Neck: lymph node positive, GTVn 60-70Gy, once a day, 5 days/w, 6-7weeks; lymph node negative, CTVn50-55Gy, once a day, 5 days/w, 6-7 weeks.
CRT: Nasopharynx, 70-(76-80)Gy, 35-(38-40)times, 2Gy/time, once a day, 5 days/w, 6-8weeks. If disease residual when radiotherapy finished could increase the dose appropriate. Neck: lymph node positive, 64-70 Gy, 32-35 times, 2 Gy/time, once a day, 5 days/w, 6-7 weeks; lymph node negative, 50-56 Gy, 25-28 times,2 Gy/time, once a day, 5 days/w, 5-6weeks cisplatin
Chemotherapy: Cisplatin (100 mg/m2,1 time/21d, 3 times，on days 2, 23, 44 during the radiotherapy)"
1866684|NCT01074034|Device|AV Therapy Assessment-B301 investigational device|Atrial and ventricular tachyarrhythmia therapy delivered by the B301 investigational device
1866685|NCT01074047|Drug|Azacitidine|75 mg/m^2 subcutaneous (SC) daily for 7 days for 28 day cycles until disease progression or unacceptable toxicity
1866686|NCT01074047|Drug|Conventional Care Regimen|"Physician pre-selects prior to randomization from one of the following:
Intensive chemotherapy (cytarabine 100-200 mg/m^2 continuous intravenous infusion for 7 days + anthracycline IV x 3 days) + Best Supportive Care; induction with up to 2 consolidation cycles
Low-dose cytarabine 20 mg subcutaneous (SC) twice a day (BID) for 10 days, for 28 day cycles + BSC; until disease progression or unacceptable toxicity
Best Supportive Care only; until study end"
1866687|NCT01074060|Drug|plerixafor|Given IV
1866688|NCT01074060|Biological|filgrastim|Given SC
1866689|NCT01074060|Drug|cyclophosphamide|Given IV
1866690|NCT01074060|Procedure|autologous hematopoietic stem cell transplantation|autologous hematopoietic stem cell transplantation
1866691|NCT01074060|Other|laboratory biomarker analysis|Correlative studies
1866692|NCT01074073|Drug|Lurasidone HCl|"lurasidone HCl 40 mg tablets administered orally as three tablets (120 mg) once a day (QD).
Lithium 300 mg capsules administered orally as two capsules (600 mg) twice a day (BID).
On dosing days, breakfast will be served 30 minutes prior to the planned dosing time. Patients must consume the breakfast within 30 minutes or less. Dosing will take place 30 minutes after the start of breakfast."
1866693|NCT01074086|Drug|RAD 001|RAD 001 in steps of 3 patients from 10mg in day 1 and day 7 to 50 mg
1866694|NCT01074099|Biological|BMAC|Injection of BMAC into ischemic myocardium during CABG
1866695|NCT01074099|Procedure|CABG only|Control subjects will undergo CABG surgery without BMAC injection
1866696|NCT01074112|Device|EFAST exam|Ultrasound of the heart, morisons pouch, pelvis, spleen and both lungs
1866697|NCT01074112|Device|Pelvic Ultrasound|Ultrasound view of the pelvis. including the bladder and uterus
1866698|NCT01074112|Procedure|Ultrasound Guided Vascular Access|Use of the ultrasound machine to identify a usable vein and guide the needle into the vein. After cannulation ultrasound is used to determine correct placement and identify extravasation.
1866699|NCT01074112|Device|Focused Ultrasound Scan|Use of ultrasound to identify and measure structures in the abdomen, thorax, retroperitoneum, or other necessary places.
1866700|NCT01074112|Device|Cardiac Ultrasound|Ultrasound views of the heart
1866701|NCT01074125|Drug|ferric citrate|1, 6, or 8 g/day taken within 1 hour of meals or snacks daily for 28 days
1866702|NCT01074138|Drug|KX2-391|KX2-391 will be administered as a 40 mg oral dosing solution, twice daily, for 6 28-day cycles.
1866703|NCT01074151|Drug|duloxetine|any exposure to duloxetine that occurred during pregnancy
1866704|NCT01074164|Other|Standard-of-care treatment for AD|Subjects will receive standard of care treatment for atopic dermatitis, including moisturizers and topical corticosteroids, per their dermatologist.
1866705|NCT01074164|Device|Accu-patch pellet|The accu-patch pellets will be applied to the LI11 pressure point, located on the left arm lateral to the antecubital fossae, for 10 minutes, 3 times a week for 1 month.
1866706|NCT01074177|Drug|BIBW 2992|Taken orally once a day
1959986|NCT03311269|Device|ClariVein RES|ClariVein system
1866710|NCT01074203|Drug|Nitazoxanide|"Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.
Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery >12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses
All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given."
1866758|NCT01074476|Other|Placebo|Placebo tablets, twice per day for 3 months
1866759|NCT01074502|Drug|apremilast|apremilast 20 mgs orally twice a day for 12 weeks
1866760|NCT01074528|Behavioral|mindfulness based stress reduction program|8-week mindfulness training program
1959987|NCT03311269|Drug|Sodium Tetradecyl Sulfate 1% Injection|Sodium Tetradecyl Sulfate STS 1% Injection
1959988|NCT03311269|Drug|Sodium Tetradecyl Sulfate 3% Injection|Sodium Tetradecyl Sulfate 3% Injection
1866711|NCT01074216|Drug|vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units)|Patients will be given vitamin D repletion with Cholecalciferol (vitamin D3 50,000 International Units) three times per week until the target vitamin D level of 40 ng/ml is achieved, and vitamin D3 maintenance initiated at 2,000 International Units daily thereafter.
1866712|NCT01074229|Drug|Placebo|placebo injection
1866713|NCT01074229|Drug|Drug .5% Ropivacaine|.5% ropivacaine 20 mls on each side of abdomen
1866714|NCT01074229|Drug|20 cc of 0.25% ropivacaine|Will receive a bilateral TAP block using 20 cc of 0.25% ropivacaine
1866715|NCT01074255|Drug|EMEND|EMEND (Aprepitant,125 mg oral capsules) is administered 1 hour prior to chemotherapy on treatment Day 1. EMEND (80 mg) is administered on the morning of Days 2 and 3. EMEND is concomitantly administered with a regimen of a corticosteroid and a 5-HT3 antagonist.
1866716|NCT01074268|Drug|insulin degludec|Injected s.c. (under the skin) once daily. Dose was individually adjusted.
1866717|NCT01074268|Drug|insulin detemir|Injected s.c. (under the skin) once daily or twice daily (BID). Dose was individually adjusted.
1866718|NCT01074268|Drug|insulin aspart|Injected s.c. (under the skin) as mealtime insulin. Dose was individually adjusted.
1866719|NCT01074281|Drug|Enalapril maleate (10 mg) + nitrendipine (20 mg)|The drug was administered as per the Summary of Product Characteristics (SPC)
1866720|NCT01074294|Drug|OPDC-34712 + Stimulant Therapy|Tablets, Oral, 0.25 or 1.0 mg OPDC-34712 and FDA approved stimulant therapy
1866721|NCT01074294|Drug|Placebo + Stimulant Therapy|Placebo plus a FDA approved stimulant therapy
1866722|NCT01074307|Drug|Low Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 1.25 milligram (mg) once daily for 2 weeks. The dose will be further escalated from 1.25 mg to 2.5 mg once daily after 2 weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
1866723|NCT01074307|Drug|High Dose Bisoprolol|Bisoprolol tablet (Concor) will be administered orally at a starting dose of 3.75 mg once daily for 2 weeks. The dose will be subsequently increased to 5 mg, 7.5 mg, or 10 mg once daily every two weeks and will be administered up to 26 weeks, only if the previous administered dose is well tolerated. If the subject could not tolerate the increased dose, then the last tolerated dose will be maintained up to 26 weeks.
1866724|NCT01074320|Other|Other|Observational study
1866725|NCT01074333|Drug|Cetuximab|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. The initial dose of Erbitux is 400 mg/m2 body surface area and the subsequent weekly doses are 250 mg/m2 each administered i.v. via in-line filtration with an infusion pump, gravity drip, or a syringe pump. The recommended infusion period for the initial dose is 120 minutes and for the subsequent weekly doses is 60 minutes with the maximum infusion rate not exceeding 5 ml/min.
1866726|NCT01067924|Behavioral|Motivational interviewing|Intervention arm will receive 2 motivational interviewing session aimed at increasing maintenance of physical activity upon the completion of a supervised exercise program. Motivational interviews will occur at the end of the structured program and at 3 months post program completion. Outcomes will be collected at 6 months post-program.
1866727|NCT01067937|Procedure|appendectomy|Randomisation will apply to the 8 participating centers as follow: During a first survey period of 6 month, the algorithm is not applied; The six following months, 4 randomised centers applied the algorithm, the others being still survey; The six last month, all centers will apply the algorithm
1866728|NCT01067950|Procedure|Isolated Pancreas Transplant|
1866729|NCT01067950|Drug|Intensive Insulin Therapy|
1866730|NCT01067963|Behavioral|Computer assisted education and motivational interviewing.|9 study contact points. 3-week intervention using computer-assisted learning modules and telephone counseling using motivational interviewing.
1866731|NCT01067963|Behavioral|Group talks/social chat|9 study contact points. 3 group talk session on general topics about healthy lifestyle, printed power point handouts, telephone calls comprised of social conversation to discuss the handout content.
1866732|NCT01067976|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M 0.1mmol/kg body weight
1866733|NCT01074346|Drug|Interferon-β-1a|Interferon-β-1a according to the standard practice
1866734|NCT01074359|Drug|A0001 (alpha-tocopherolquinone)|28 days (1.5 g total daily dose) oral A0001 capsules. Treatment taken twice daily with meals.
1866735|NCT01074359|Drug|Placebo|28 days of placebo oral capsules. Treatment taken twice daily with meals.
1866736|NCT01074372|Drug|REGN727|4 cohorts (dose 1, 2, 3, 4)
1866737|NCT01074372|Drug|Placebo|4 cohorts (dose 1, 2, 3, 4)
1866738|NCT01074385|Behavioral|Dignity Therapy|Dignity therapy is a psychotherapeutic intervention developed to address psychosocial and existential distress among terminally ill patients. Basically, it invites patients to discuss topics that matter most or how they want to be remembered. This interview is recorded and then edited and returned to the patient to be used for further reflection or for sharing with loved ones.
1866739|NCT01074398|Genetic|gene expression analysis|
1866740|NCT01074398|Genetic|polymorphism analysis|
1866741|NCT01074398|Genetic|protein expression analysis|
1866742|NCT01074398|Other|immunohistochemistry staining method|
1866743|NCT01074398|Other|laboratory biomarker analysis|
1866744|NCT01074411|Drug|Bortezomib|Given IP
1866745|NCT01074411|Drug|Carboplatin|Given IP
1866746|NCT01074411|Other|Laboratory Biomarker Analysis|Correlative studies
1866747|NCT01074411|Other|Pharmacological Study|Correlative studies
1866748|NCT01074424|Genetic|proteomic profiling|
1866749|NCT01074424|Other|laboratory biomarker analysis|
1866750|NCT01074437|Drug|Prednisolone (Corticosteroid)|Oral liquid prednisolone. Dose: 1-2mg/kg/day for 7 days, and then dose will be slowly reduced and then stopped after 3 weeks.
1866751|NCT01074437|Drug|Propranolol|Oral liquid propranolol will be dosed Oral liquid propranolol will be dosed at 2 mg/kg/day.
1866752|NCT01074437|Drug|Placebo|Liquid placebo will be given during the two month treatment trial.
1866753|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
1866754|NCT01074450|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
1866755|NCT01074463|Drug|Pramipexole Dihydrochloride|0.25 mg Tablet
1866763|NCT01074541|Radiation|UVB|1.5 SED x 4 in a week
1866764|NCT01074541|Radiation|UVB|3.0 SED x 4 in a week
1866765|NCT01074554|Drug|Antibiotic Regimen|Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg QD Azithromycin 500mg on day 1, then 250 mg po QD Rifampin 5-10 mg/kg for a maximum of 300mg po QD All four drugs are given concomitanly
1866766|NCT01074554|Drug|Placebo Regimen|lactose control tablets; one for each antibiotic with equivalent pills
1866767|NCT01074567|Drug|DMSO cocktail|intra-vesical: DMSO 50% in 50 cc water for injection 10 cc heparin 5000 IU hydrocortisone 100 mg bupivacaine 0.125%
1866768|NCT01074593|Biological|Interferon beta-1a|12.000UI - single dose
1866769|NCT01074593|Biological|Interferon beta-1a|12.000UI - Single dose
1866770|NCT01074606|Device|AcrySof Toric Intraocular Lens|Implantation of the AcrySof Toric Intraocular Lens (IOL)
1866771|NCT01074619|Drug|Memantine|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
1866772|NCT01074619|Drug|Placebo|5 mg the first week, then 10 mg the second week, 15 mg the third week and finally 20 mg the fourth week until the end of the study (t0 + 1 year)
1866773|NCT01074632|Drug|Lurasidone HCl|
1866774|NCT01074645|Drug|Tenofovir disoproxil fumarate (TDF)|Tenofovir 300mg/day for 3 month
1866775|NCT01074658|Device|Medtronic CoreValve System|Transcatheter Aortic Valve Implantation of the Medtronic CoreValve System
1866776|NCT01074671|Device|CG Future Annuloplasty Ring/Band|A CG Future Annuloplasty Ring or Band will be implanted, following standard care
1866777|NCT01075061|Other|healthy volunteers|morphological and functional brain MRI; transcranial magnetic stimulation
1866778|NCT01075061|Other|Kallmann|morphological and functional brain MRI; transcranial magnetic stimulation
1866779|NCT01075061|Other|Congenital Mirror Movement|morphological and functional brain MRI; transcranial magnetic stimulation
1866780|NCT01075074|Procedure|Transversus abdominis plane block|A regional block performed in the transversus abdominis plane of the abdomen, used to provide anesthesia and analgesia for the abdominal region.
1866781|NCT01075087|Drug|Placebo|Bilateral TAP block using sterile normal saline.
1866782|NCT01075087|Drug|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.|(study group) will receive a bilateral TAP block using 20 cc of 0.5% ropivacaine on each side.
1866783|NCT01075100|Drug|Ixabepilone|20 mg/m2 on Days 1 and 8
1866784|NCT01075100|Drug|Carboplatin|carboplatin AUC=2.5 on Days 1 and 8
1866785|NCT01075113|Drug|sorafenib tosylate|Given orally
1866786|NCT01075113|Drug|vorinostat|Given orally
1866787|NCT01075126|Drug|Depakote|
1866788|NCT01075126|Drug|Lithium|
1866789|NCT01075139|Behavioral|Brief Motivational Intervention|30 minute one-on-one meeting
1866790|NCT01075139|Behavioral|Educational information|Educational handouts/brochures
1866791|NCT01075152|Drug|efavirenz|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
1866792|NCT01075152|Biological|nucleoside|Treatment strategy of when to initiate first line HIV therapy after cryptococcal meningitis diagnosis.
1866793|NCT01075165|Other|silicone spray|application of silicone spray to predefined area qd 12 weeks
1866794|NCT01075165|Other|saline spray|application of saline spray to predefined area qd 12 weeks
1866795|NCT01075204|Drug|clarithromycin modified release 500 mg|clarithromycin modified release 500 mg for 7 days
1866796|NCT01075217|Drug|iopamidol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
1866797|NCT01075217|Drug|iodixanol|Participants received at least one intraarterial injection in one of the following 3 locations: aortic bifurcation (total volume 15-20 mL), iliac arteries (total volume 10-12 mL), or superficial femoral artery (total volume 8-12 mL to view only thigh, 10-15 mL to view calf as well, 20 mL for full runoff to foot).
1866798|NCT01075230|Procedure|Total knee arthroplasty|Subject will undergo total knee arthroplasty according to established surgeon / hospital protocol.
1866799|NCT01075243|Drug|Paracetamol 1000 mg|Paracetamol 1000mg
1866800|NCT01075243|Drug|Paracetamol 650 mg|Paracetamol 650 mg
1866801|NCT01075243|Drug|Placebo|Placebo
1866802|NCT01075256|Device|5% calcium sodium phosphosilicate toothpaste|Low concentration calcium sodium phosphosilicate tubule occlusion agent
1866803|NCT01075256|Device|7.5% calcium sodium phosphosilicate toothpaste|High concentration calcium sodium phosphosilicate tubule occlusion agent
1866804|NCT01075256|Device|Placebo toothpaste|Placebo toothpaste
1866805|NCT01075282|Drug|Insulin Glargine|
1866806|NCT01075282|Drug|LY2189265|
1866807|NCT01075282|Drug|Metformin|
1866808|NCT01075282|Drug|Glimepiride|
1866809|NCT01075295|Behavioral|Behavioural Intervention for the Prevention of Weight Gain|"The intervention consists of four steps:
STEP 1 (Watchful Waiting): Measurement of body weight and Waist Circumference at the start (1 visit). Subjects that have a weight gain greater then or equal to 2% of their baseline weight will progress to Step 2
STEP 2 (Self monitoring): Self-monitoring of daily weight, daily food intake & physical activity (1 visit) Subjects that have a weight gain greater then or equal to 2% (from STEP 2) will progress to Step 3
STEP 3 (Nutrition & Exercise Counseling): Counseling for nutrition and physical activity (4 visits; 2 in-clinic, 2 telephone) Subjects that have a weight gain greater then or equal to 2% (from STEP 3) will progress to Step 4
STEP 4 (Intensive): Intensive behavioral training geared towards reducing caloric intake (4 in-clinic visits)"
1866810|NCT01075295|Other|TAU|Treatment as provided by individuals' existing healthcare providers
1866811|NCT01075308|Drug|HDAC inhibitor SB939|SB939 given orally every other day 3 times a week (i.e. Monday /Wednesday /Friday, or Tuesday /Thursday / Saturday) for 3 consecutive weeks followed by one week off-dosing. A treatment cycle is 4 weeks (28 days).
1866812|NCT01075321|Drug|everolimus|Given orally
1866813|NCT01075321|Drug|lenalidomide|Given orally
1866814|NCT01075321|Other|laboratory biomarker analysis|Correlative studies
1866815|NCT01075321|Genetic|polymorphism analysis|Correlative studies
1866816|NCT01075321|Other|immunohistochemistry staining method|Optional correlative studies
1866817|NCT01075321|Genetic|microarray analysis|Optional correlative studies
1866818|NCT01075321|Genetic|fluorescence in situ hybridization|Optional correlative studies
1866819|NCT01075334|Dietary Supplement|Porimore - A Carnitine based food supplement|A daily dose of 2 grams L-carnitine, 1 gr acetyl L-carnitine, 500mg Vitamin C, 400 IU vitamin E, 60 mg Q10, 30mg Zinc Picolinate, 500mcg Folic Acid, 200 Mcg Selenium, 100 MCG Vitamin B12.
1866820|NCT01075334|Dietary Supplement|Zinc and Folate Supplementation|500 Mcg Folic acid, 30-60 mg Zinc tablets/ day
1866821|NCT01075347|Other|autologous serum|with postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
1866822|NCT01075347|Other|Non-autologous serum|without postoperative 20% autologous serum diluted with preservative-free artificial tear application bi-hourly during waking hours
1866823|NCT01075399|Drug|[F 18]HX4|Approximately forty (40) patients who have diagnosis confirmed by histopathological examination of tumor tissue from head/neck, lung, liver, rectal or cervical cancers and will receive chemotherapy, radiation therapy or chemoradiotherapy, will be imaged under PET/CT with [F 18]HX4
1866825|NCT01075425|Drug|bortezomib|Given IV
1866826|NCT01075425|Drug|belinostat|Given IV
1866827|NCT01075425|Other|laboratory biomarker analysis|Correlative studies
1866828|NCT01075425|Genetic|western blotting|Correlative studies
1866829|NCT01075425|Other|pharmacological study|Correlative studies
1866830|NCT01075425|Other|flow cytometry|Correlative studies
1866831|NCT01075438|Biological|Prevenar® (7-valent pneumococcal conjugate vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)
Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
1866832|NCT01075438|Biological|Pneumovax® (pneumococcal polysaccharide vaccine)|"Pneumococcal vaccines (conjugate and polysaccharide)
Intramuscular Injections: 2 doses of 7-valent pneumococcal conjugate vaccine 8 weeks apart and 1 dose of pneumococcal polysaccharide vaccine 8 weeks later"
1866833|NCT01075464|Drug|MEGF0444A|Intravenous escalating dose
1866834|NCT01075464|Drug|bevacizumab|Intravenous repeating dose
1866835|NCT01075464|Drug|paclitaxel|Intravenous repeating dose
1866836|NCT01075477|Drug|rituximab [Mabthera/Rituxan]|As prescribed by physician
1866837|NCT01075490|Drug|clonidine|addition of 1 µg/kg of clonidine to bupivacaine 1 mg/kg as spinal anesthesia
1866838|NCT01075490|Drug|clonidine|equivalent volume of saline added to bupivacaine, 1 mg/kg as spinal anesthesia
1866839|NCT01075503|Procedure|brachial plexus block|0.5% Ropivacaine 40ml
1866840|NCT01075529|Drug|fluoxetine|fluoxetine 20 mg/d
1866841|NCT01075542|Device|AcrySof Toric intraocular lens, model SN60TT|The lens is made of foldable acrylic material and is implanted in the capsular bag
1866842|NCT01075542|Device|AcrySof Monofocal IOL, model SN60AT|The lens is made of foldable acrylic material and is implanted in the capsular bag
1866843|NCT01075555|Drug|pravastatin sodium|
1866844|NCT01075555|Drug|sorafenib tosylate|
1866845|NCT01075568|Dietary Supplement|Nutrigal Okara - 100|
1866846|NCT01075581|Drug|Epinephrin (Intranasal injection)|A total of 8 mL of epinephrine 1:100,000 will be injected in the lateral nasal wall, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
1866847|NCT01075581|Drug|Epinephrin (Topical administration)|An intranasal injection of saline solution, followed by placement of cotton pledgets (soaked in 1 mL epinephrine 1:1,000) in the nasal cavity when required.
1866848|NCT01075620|Device|PFC-Sigma RP|Posterior stabilizing rotating platform total knee components
1866849|NCT01075620|Device|LPS RP|non-posterior stabilized rotating platform design
1866850|NCT01075633|Procedure|Immunochemical fecal occult blood test And colonoscopy if test is positive|Annual (3 rounds), without diet restriction, 1 stool sample. Positive cut-off level: 50 ng/ml.
1866851|NCT01075633|Procedure|Colonoscopy with sedation|Colonoscopy with sedation
1866852|NCT01075646|Drug|ropivacaine|"Laparotomy of colorectal surgery: 10 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 5ml/h.
Laparoscopy of colorectal surgery: 5 ml bolus ropivacaine 0,75% + infusion with elastomeric pump with ropivacaine 0,38% at a 2 ml/h.
Hepatic surgery: 10 ml de ropivacaine 0,45% + infusion with elastomeric pump with ropivacaine 0,23 at a 5ml/h."
1866853|NCT01075646|Drug|saline solution|"Laparotomy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h.
Laparoscopy of colorectal surgery: 10 ml bolus saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 2 ml/h.
Hepatic surgery: 10 ml de saline solution 0.9% + infusion with elastomeric pump with saline solution 0.9% at a 5ml/h"
1866854|NCT01075659|Drug|Nicotine|Two single doses of experimental Nicotine Replacement Therapy (NRT) 2 mg, with five hours between treatments. Seven hours duration of total follow-up period
1866855|NCT01075659|Drug|Nicotine|Two single doses of Nicotine Lozenge 2 mg, with five hours between treatments. Seven hours duration of total follow-up period.
1866856|NCT01075659|Drug|Nicotine|Two single doses of Nicotine Lozenge 4 mg, with five hours between treatments. Seven hours duration of total follow-up period.
1866857|NCT01075672|Behavioral|Cognitive behavioral therapy (CBT)|The participant will then undergo a structured clinical interview with a supervised psychology intern/fellow, which will take approximately 1-3 hours over the course of 1-3 sessions. The initial assessment will be followed by up to 24 sessions of cognitive behavioral therapy tailored to their particular diagnosis (most diagnoses/problems require approximately 12 sessions, some require fewer, others require more). The length of treatment will depend on the primary diagnosis/ problem and the complexity and severity of the case. The clinician and patient will agree on a treatment plan after the initial evaluation, targeting a particular mental health or health related behavioral problem with Cognitive Behavioral Therapy. This treatment plan will include an agreed upon number of treatment sessions (up to 24).
1866993|NCT01076764|Drug|Eptifibatide|"Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion"
1866994|NCT01076764|Drug|Placebo (for Eptifibatide)|"Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion"
1866858|NCT01075685|Behavioral|interactive online programme to reduce alcohol consumption|"The programme includes several steps:
personalized feedback on alcohol consumption and related risks
reviewing motivations and fears regarding drinking reduction
analyse of drinking habits
reduction goal setting
follow-up tools (alcohol diary, craving scales, well-being scales)
a final screen allowing participants to monitor their progress through graphs and automatically adapted comments."
1866859|NCT01075685|Behavioral|Minimum information|"This intervention includes:
information about hazardous drinking
an alcohol diary"
1866860|NCT01075698|Drug|Non-ARB (standard therapy)|Blood pressure lowering therapy except ARB
1866861|NCT01075698|Drug|ARB (Telmisartan)|Telmisartan 20-80 mg/day
1866862|NCT01075711|Drug|Prednisone|According to SPC
1866863|NCT01075724|Device|Patient Warming with Forced Air|Forced Air warming via BairHugger
1866864|NCT01075724|Device|Resistive Warming|Resistive Warming via HotDog device
1866865|NCT01075763|Drug|Interferon beta-1a|Interferon (IFN) beta-1a [Rebif® 22 microgram (mcg), three times per week (tiw)] administered subcutaneously (sc)
1866866|NCT01075763|Drug|Placebo|The inactive substance (placebo) looks the same as Interferon beta-1a (Rebif®), and is given the same way
1866867|NCT01075776|Drug|C-type natriuretic peptide (CNP)|360 pmol/min for 15 minutes intra-arterially
1866868|NCT01075776|Drug|Saline|Sodium Chloride 0.9% intra-arterially 0.5ml/min
1866869|NCT01075776|Drug|Acetylcholine|2 stepped infusions for a total 9min per limb, totalling 1.05micromoles per limb
1866870|NCT01075789|Drug|Lignocaine|Lignocaine 10% solution administered intra nasally plus lignocaine 2% solution administered orally.
1866871|NCT01075789|Drug|Placebo|Viscous, coloured, sucrose flavoured gel solution to match xylocaine viscous in appearance, normal saline administered intranasally to the nasal turbinates and nasopharynx.
1866872|NCT01075802|Drug|Tamoxifen|Dose escalation
1866873|NCT01075815|Drug|Recombinant human luteinizing hormone (rhLH)|
1866874|NCT01075815|Drug|Recombinant follicle-stimulating hormone (rFSH)|
1866875|NCT01075828|Drug|Cetuximab|Subjects will be treated according to the national label of cetuximab in combination with radiation therapy.
1866876|NCT01075841|Drug|Cetuximab|Subjects who are eligible for Erbitux treatment according to the indication in the national label of Erbitux (i.e. where Erbitux is used in combination with platinum-based therapy for the treatment of subjects with recurrent and/or metastatic SCCHN) according to the approved national label as in routine clinical practice under the supervision of an investigator experienced in the use of antineoplastic medicinal products.
1866877|NCT01075854|Drug|Gonal-F (Follitropin alfa)|Follitropin alfa FbM solution for injection in a prefilled pen is available in three strengths: 300 IU/0.5 ml (22 µg/0.5 ml), 450 IU/0.75 ml (33 µg/0.75 ml) and 900 IU/1.5 ml (66 µg/1.5 ml). The starting dose is usually recommended to be between 150 and 300 IU. The dose is then adjusted according to the ovarian response.
1866878|NCT01075880|Drug|Rebif (Interferon beta-1a)|The treatment to be administered is interferon beta-1a on prescription, used as per SmPC, i.e. both doses 22 and 44 mcg s.c. tiw, and the titration pack 8.8 mcg and 22 mcg s.c. tiw when initiating the therapy.
1866879|NCT01075906|Drug|colchicine sprinkle capsules|0.3 mg
1866880|NCT01075906|Drug|colchicine sprinkle capsules|0.3 mg
1866881|NCT01075919|Dietary Supplement|n-3 PUFAs|1 g DHA-rich fish oil taken daily for 12 weeks
1866882|NCT01075919|Dietary Supplement|Placebo|1 g olive oil taken daily for 12 weeks
1866883|NCT01075919|Dietary Supplement|n-3 PUFAs|1 g EPA-rich fish oil taken daily for 12 weeks
1866884|NCT01075932|Dietary Supplement|DHA-rich fish oil|Either 1 g or 2 g DHA-rich fish oil taken daily for 12 weeks. Participants in the 1 g group will also consume 1 g olive oil placebo capsules per day to maintain double blind.
1866885|NCT01075932|Dietary Supplement|Placebo|2 g placebo (olive oil) taken daily for 12 weeks
1866888|NCT01075971|Drug|Buprenorphine hydrochloride marketed sublingual tablet (Subutex)|8 mg or 16 mg daily, sublingual route on Days 1 and 2
1866889|NCT01075971|Drug|Buprenorphine hydrochloride fast dissolving tablet (FDT)|8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5
1866890|NCT01075984|Drug|Posaconazole|
1866891|NCT01075984|Drug|Dextrose 5% in water|
1866892|NCT01075997|Device|cell phone delivered tele-educational|This group will receive a cell phone and cell phone service for 1 year. This group will receive a daily video reminders and tips for the first 6 months of the study. For the second 6 months this group will be seen by their providers at least every 3 months, but the video reminders and and tips will no longer be sent. The group will be instructed on how to use the cell phone.
1866893|NCT01075997|Device|cell phone|This group will receive a cell phone and cell phone service for 1 year. For the second 6 months this group will be seen by their providers at least every 3 months. The group will be instructed on how to use the cell phone.The group will be asked to check blood sugar on a schedule determined by your provider. The groups will have blood sugars downloaded from from the glucometer by your provider at every visit and reviewed.
1866894|NCT01076010|Drug|Tivozanib|Tivozanib will be orally administered once daily, at least 1 hour before or 2 hours after ingesting any food or other medication, for as long as the subject tolerates treatment in the absence of disease progression or unacceptable toxicity. Study drug will be administered beginning on Day 1 of Cycle 1.
1866895|NCT01076010|Drug|Sorafenib|Sorafenib will be orally administered twice daily (unless reduced in parent protocol). Sorafenib should be taken without food at least 1 hour before or 2 hours after ingesting any food or other medications. Study drug will be administered beginning on Day 1 of Cycle 1.
1866896|NCT01076036|Device|CorPath 200|CorPath™ 200 robotically-assisted percutaneous coronary intervention
1866897|NCT01076036|Device|CorPath 200|CorPath PCI - robotic-assisted percutaneous coronary intervention
1866898|NCT01076049|Other|observation of SOP|standard treatment of infection
1866899|NCT01076049|Device|IrriSept Irrigation|irrigation of the wound using IrriSept
1866995|NCT01076777|Behavioral|Physical exercise|Manualised Exercise performed in groups (5-8 participants per group). 3 sessions (á 60 minutes) per week for 12 consecutive weeks
1867650|NCT01082198|Biological|autologous melanoma lysate-pulsed autologous dendritic cell vaccine|
1866900|NCT01076062|Procedure|Induction of Labor|If cervical foley bulb placement is possible, the foley bulb will remain in place until either spontaneously removed or after 12 hrs, whichever is earlier. If placement is not possible, cervical ripening with misoprostol 25 micrograms (mcg) per vagina every 4 hrs (max of 4 total doses) will be initiated. Cervical examination will occur every 4 hr. Repeat doses of misoprostol will be given only if foley bulb placement is not possible and/or if palpably firm uterine contractions are less than 6 in 10 min in consecutive 10 min intervals. Once placement of a cervical foley bulb can be performed, oxytocin administration will begin at 2 mIU/min and increasing by 2 mIU/min every 20 min to ensure adequate contractions (maximum oxytocin infusion rate 36 mIU/min). Adequate contractions will be defined as 7 contractions in 15 min in consecutive 15 min intervals that palpate moderate to firm. Oxytocin infusion will begin not earlier than 4 hrs after the last misoprostol dose (if given).
1866901|NCT01076075|Drug|Sitagliptin phosphate|Phase A (Weeks 0-24): Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): Sitagliptin 100 mg once a day for 30 weeks
1866902|NCT01076075|Drug|Comparator: placebo to pioglitazone|Phase B (Weeks 24-54): placebo to pioglitazone 30 mg once a day for 30 weeks
1866903|NCT01076075|Drug|Comparator: placebo to Sitagliptin|Phase A (Weeks 0-24): placebo to Sitagliptin 100 mg once a day for 24 weeks; Phase B (Weeks 24-54): placebo to Sitagliptin once a day for 30 weeks
1866904|NCT01076075|Drug|Comparator: pioglitazone|Phase B (Weeks 24-54): pioglitazone 30 mg once a day for 30 weeks
1866905|NCT01076075|Drug|Glimepiride or gliclazide|Phase A (Weeks 0-24): stable dose, as prescribed by investigator, of glimepiride or gliclazide; Phase B (Weeks 24-54): stable dose, as prescribed by investigator, of glimepiride or gliclazide
1866906|NCT01076075|Drug|Metformin|"Phase A (Weeks 0-24): stable dose, as prescribed
by investigator, of metformin; Phase B (Weeks 24-
54): stable dose, as prescribed by investigator, of
metformin"
1866907|NCT01076075|Drug|Pioglitazone rescue therapy|Phase A (Weeks 0-24): participants not meeting specific glycemic goals will receive pioglitazone (open label) at a dose determined by the investigator. These participants will not initiate Phase B (Weeks 24-54) double blind pioglitazone.
1866908|NCT01076088|Drug|Sitagliptin 50 mg|Sitagliptin 50 mg tablet twice a day, prior to the morning and evening meal, for 24 weeks.
1866909|NCT01076088|Drug|Metformin 500 mg|Metformin 500 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
1866910|NCT01076088|Drug|Sitagliptin 100 mg|Sitagliptin 100 mg once daily for 24 weeks.
1866911|NCT01076088|Drug|Placebo|Matching placebo tablets to sitagliptin or metformin for 24 weeks.
1866912|NCT01076088|Drug|Metformin 850 mg|Metformin 850 mg tablet twice daily, prior to the morning and evening meal, for 24 weeks.
1866913|NCT01076127|Behavioral|Ketllebell training|Kettlebell training 3 x 20 min a week for 8 weeks
1866914|NCT01076127|Behavioral|Control|Receives a health examination before and after the intervention period, and are advised to stay active.
1866915|NCT01076140|Drug|Nebivolol|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
1866916|NCT01076140|Drug|Lisinopril|Nebivolol 5 or 10 mg tablets daily for 4 weeks. Lisinopril 20 or 40 mg daily for 4 weeks
1866917|NCT01076153|Drug|Clarithromycin (Klacid® MR)|Klacid MR 500mg (clarithromycin)
1866918|NCT01076166|Drug|clarithromycin (Klacid) granules for oral suspension|clarithromycin (Klacid) Granules for Oral Suspension
1866919|NCT01076218|Device|FreeStyle Navigator Continuous Glucose Monitoring System Version 1.5|This is not an interventional study. Subjects must maintain their own diabetes treatment regimen throughout the study duration.
1866920|NCT01076231|Radiation|proton beam radiation therapy|
1866921|NCT01076231|Drug|cisplatin|Given IV
1866922|NCT01076231|Drug|etoposide|Given IV
1866923|NCT01076231|Procedure|therapeutic conventional surgery|
1866924|NCT01076244|Procedure|Minimally Invasive Lumbar Decompression|This minimally invasive procedure is performed under fluoroscopic image guidance through a dorsal approach to the spine. The patient is given local anesthesia and a sedative but needs to be responsive to the surgeon's questions for neurological monitoring. Under image guidance, the mild tools are inserted and positioned on the posterior spinal lamina, to the left or right of the spinous process. The tools are used to cut and remove tissue and bone from the posterior side of the lumbar spine to create a space inside the spine that can help decompress some of the spinal nerves.
1866925|NCT01076257|Behavioral|Modified Constraint-induced Movement Therapy|"Home based CIT
Restriction of the less affected limb
Intensive practice using affected limb
Positive experience
Functional task (task)"
1866926|NCT01076270|Drug|plerixafor|Given SC
1866927|NCT01076270|Biological|filgrastim|Given SC
1866928|NCT01076270|Procedure|peripheral blood stem cell transplantation|Infusion of peripheral blood stem cells
1866929|NCT01076270|Procedure|allogeneic hematopoietic stem cell transplantation|Infusion of hematopoietic stem cells
1866930|NCT01076283|Drug|Baclofen|Baclofen 10mg t.i.d.
1866931|NCT01076283|Drug|Cyproheptadine|'active' placebo
1866932|NCT01076322|Drug|Meptin® Swinghaler|"Meptin® Swinghaler®
Ingredient: Procaterol HCL
Dosage form: 10g/puff
Dose(s): 10g
Dosing schedule: 20g (total 20g)"
1866933|NCT01076322|Drug|Ventolin® MDI|"Ventolin® MDI
Ingredient: Salbutamol sulfate
Dosage form: 100g/puff
Dose(s): 100g
Dosing schedule: 200g (total 200g)"
1866934|NCT01076335|Drug|Neoadjuvant Hormonal Therapy|Monthly or quarterly LHRH Agonist Depot injection (leuprolide or goserelin acetate) for one year.
1866935|NCT01076335|Drug|Docetaxel|35 mg/m2 by vein (IV) on Day 1, 8, 15 and 22 every 6 weeks.
1866936|NCT01076387|Procedure|open radical cystectomy|Open radical cystectomy, pelvic lymph node dissection and open urinary diversion.
1866937|NCT01076387|Procedure|robotic-assisted radical cystectomy|Robotic radical cystectomy, pelvic lymph node dissection and open urinary diversion. Robotic radical cystectomy is routinely performed by robotically trained and experienced minimally invasive surgeons.
1867064|NCT01077427|Drug|Gemcitabine|Gemcitabine: 1000 mg/m² as iv-infusion on days 1, 8 and 15 of each course (Total dose: 18 g/m²)
1866941|NCT01076413|Behavioral|skill based exercise|2 times per week for 12 weeks Pre gait and gait activities
1866942|NCT01076413|Behavioral|aerobic conditioning|2 times per week for 12 weeks. aerobic conditioning exercise consisting of treadmill walking
1866943|NCT01076426|Drug|Pro-biotics|Pro-biotics and placebo one pack per day is given to the two group. And then evaluate the peritonitis rate and nutrition status.
1866944|NCT01076426|Dietary Supplement|Oligosaccharide|oligosaccharide one pack per day
1866945|NCT01076439|Drug|Fluticasone Furoate Nasal Spray|Fluticasone Furoate Nasal Spray: 110mcg QD
1866946|NCT01076439|Drug|Olopatadine Nasal Spray|Olopatadine Nasal Spray: 2660mcg BID
1866947|NCT01076439|Drug|Saline Nasal Spray|Placebo
1866948|NCT01076452|Device|Bilateral Deep Brain Stimulation|The DBS site (STN or GPi) was assigned on a random basis at the time the patient enters the surgical phase of the trial.
1866949|NCT01076465|Other|Disease management program|1. Educational intervention on management of heart failure and comorbidity to improve patient's knowledge of his/her disease and self-care 2) Monitoring of clinical status 3) Monitoring and improvement of therapeutic adherence.
1866950|NCT01076465|Behavioral|Usual care|Usual care
1866951|NCT01076478|Drug|Cilostazol|100 mg, 200mg tablet Cilostazol
1866952|NCT01076491|Drug|mannitol|inhaled mannitol - single doses of either 70 mg or 90 mg
1866953|NCT01076504|Drug|Amrubicin|30 mg/m2 IV on Days 1-3 of each 3-week treatment cycle
1866954|NCT01076504|Drug|Carboplatin|AUC=5 IV, Day 1 of each 3-week treatment cycle
1866955|NCT01076504|Drug|Pegfilgrastim|6 mg SQ on Day 4 of each 3 week treatment cycle
1866956|NCT01076517|Device|Theraspheres|Beta-emitting 90yttrium encapsulated in glass microspheres for intraarterial administration to the liver.
1866957|NCT01076530|Drug|vorinostat|
1866958|NCT01076530|Drug|temozolomide|
1866959|NCT01076530|Other|diagnostic laboratory biomarker analysis|
1866960|NCT01076530|Other|pharmacological study|
1866964|NCT01076556|Drug|Alvocidib Hydrochloride|Given IV
1866965|NCT01076556|Drug|Cyclophosphamide|Given IV
1866966|NCT01076556|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1866967|NCT01076556|Other|Pharmacological Study|Correlative studies
1866968|NCT01076556|Biological|Rituximab|Given IV
1866969|NCT01076569|Other|laboratory biomarker analysis|Correlative studies
1866970|NCT01076582|Drug|EE20/DRSP (YAZ, BAY86-5300)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DRSP 3 mg) daily for 24 days followed by 1 placebo tablet daily for 4 days
1866971|NCT01076582|Drug|Ethinylestradiol (EE) and desogestrel (DSG) (Mercilon)|4 cycles of treatment / per cycle: 1 tablet (EE 0.02 mg / DSG 0.15 mg) daily for 21 days followed by 1 placebo tablet daily for 7 days
1866972|NCT01076595|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Betaferon 250 microgram
1866973|NCT01076621|Drug|0.5 mg estradiol / 0.1 mg norethisterone acetate (NETA)|Data collection of the use of 0.5 mg estradiol and 0.1 mg norethisterone acetate (NETA) in women in connection to a daily clinical practice.
1866974|NCT01076634|Drug|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
1866975|NCT01076634|Drug|insulin degludec|0.4 U/kg body weight. Injected subcutaneously (under the skin) once daily for 8 days.
1866976|NCT01076647|Drug|insulin degludec|Will be injected subcutaneously (under the skin) once daily three times weekly.
1866977|NCT01076647|Drug|insulin glargine|Will be injected subcutaneously (under the skin) once daily administered at the same time each day.
1866978|NCT01076673|Biological|Peripheral blood stem cells and hyaluronic acid injections|Peripheral blood stem cells and hyaluronic acid injections
1866979|NCT01076673|Drug|Hyaluronic Acid|Hyaluronic acid injections
1866981|NCT01076699|Drug|0.075 mg RVX-100|This group is taking the lowest dose of RVX-100
1866982|NCT01076699|Drug|0.125 mg RVX-100|This group is taking an average dose of RVX-100
1866983|NCT01076699|Drug|0.250 mg RVX-100|This group is taking the highest dose of RVX-100
1866984|NCT01076699|Drug|placebo|This group is taking a placebo
1866985|NCT01076712|Other|Physiotherapy Interventions|Physiotherapy interventions including strengthening exercise, balance training, gait training with visual cus and gait training with treadmill
1866986|NCT01076712|Other|Education Classes|Education Classes
1959992|NCT03311230|Behavioral|Supportive social incentive|A family member or friend will be used as a support person in this study, to receive updates and support the participant in their progress.
1866989|NCT01076764|Drug|Otamixaban|"Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion"
1866990|NCT01076764|Drug|Placebo (for Otamixaban)|"Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion"
1866991|NCT01076764|Drug|UFH|"Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion"
1866992|NCT01076764|Drug|Placebo (for UFH)|"Pharmaceutical form: Intravenous (IV) solution
Route of administration: IV bolus followed by continuous IV infusion"
1959993|NCT03311230|Behavioral|Competitive social incentive|Participants in this intervention will be competing against each other in the game.
1959994|NCT03311230|Behavioral|Collaborative social incentive|Participants in this intervention will be working with each other in the game.
1959998|NCT03311191|Device|Measurement of skin oxygenation and oxygen consumption|Oxygenation properties will be measured using a transparent paint-on bandage formulation that consists of New-Skin liquid bandage, an oxygen-sensing metallo-porphyrin exhibiting bright red phosphorescence, and the green-fluorescing reference dye fluorescein.
1866996|NCT01076777|Behavioral|Cognitive-behavioral therapy|Cognitive-behavioral therapy conducted in groups (5-8 participants per group). 1 session (á 2-2.25 hours depending on group size) per week for 12 consecutive weeks
1866997|NCT01076790|Drug|Dexmedetomidine|Dexmedetomidine infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
1866998|NCT01076790|Drug|Saline|Saline infusion 1 mcg/kg in 10 minutes; thereafter 0.7 mcg/kg/h until 30 minutes has elapsed from skin incision.
1866999|NCT01076803|Drug|Lanreotide (acetate)|Deep subcutaneous injection into the upper external quadrant of the right or the left buttock.
1867000|NCT01076816|Drug|dexmedetomidine|"dexmedetomidine will be given max 48h. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.
Additional drugs are given to every inadequately sedated patient (assessed by regular Comfort scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
1867001|NCT01076816|Procedure|Vital signs|systolic and diastolic blood pressure, heart rate, respiratory rate,oxygen saturation, temperature are assessed baseline and at least per hour reassessed after starting the dexmedetomidine.
1867002|NCT01076816|Procedure|blood sampling|Blood sampling for pharmacokinetic modelling is limited to a maximum of 1,8 ml/kg (in line with the EMEA guidelines on maximum blood sampling in children). Pharmacokinetic parameters and influence of covariates on these parameters will be assessed by a population pharmacokinetic approach.
1867003|NCT01076829|Other|Spice polyphenols|spice
1867004|NCT01076842|Drug|Insulin-Levemir|Levemir once daily, force titrated to reach a fasting plasma glucose of 100 mg/dl
1867005|NCT01076842|Drug|Exenatide-Bayetta|Exenatide twice daily, started at a dose of 5 mcg b.i.d. and increased to 10 mcg b.i.d. after 2 weeks if the fasting plasma glucose of 100 mg/dl is not reached. Exenatide will be administered immediately before breakfast and dinner meals. No further increase in the dose of exenatide will take place. For those who are unable to tolerate exenatide at a 10 mcg b.i.d. dose, it will be reduced to 5 mcg b.i.d. and continued until week 12.
1867006|NCT01076842|Drug|Insulin-Levemir and Exenatide-Bayetta|Patients from either Group A or Group B who have not reached the goal A1C of 6.5% will be assigned to this Group. They will receive the drug assigned to the other group in addition to the one they were originally assigned.
1867007|NCT01076842|Device|SenseWear Pro3® armband|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the SenseWear Pro3® armband for collection of ancillary physiologic data
1867008|NCT01076842|Device|DexCom CGM|For one-week prior to beginning the assigned medication and for one week , week 11 and week 23, the patients will wear the DexCom CGM for collection of continuous blood glucose concentrations.
1867009|NCT01076868|Drug|Primaquine|Primaquine x 14 days
1867010|NCT01076881|Behavioral|exercise training|
1867011|NCT01076894|Procedure|epidural anesthesia|In the epidural group prior to the induction of general anesthesia, a thoracic epidural catheter will be was placed at the level of the TH6-TH8. 8 ml ropivacaine 1% were administered through the epidural catheter. EDA is aimed at a sensory block level from TH2 to TH10.
1867012|NCT01076894|Procedure|intercostal anesthesia|In the intercostal group, before chest closure, each 4 ml ropivacaine 0.75 % will be injected by the surgeon under direct vision into the proximal intercostal space at the level of the thoracotomy and two spaces above and below as well as 5 ml ropivacaine 0,75 % at the thoracic drainage tube exits
1867013|NCT01076907|Other|Warm water|Warm water loading of sigmoid colon when spasms occur and waiting for them to subside.
1867014|NCT01076907|Other|Control|Air will be used instead of warm water for unsedated colonoscopy.
1867015|NCT01076920|Genetic|Mesenchymal stem cells|60x106 MSCs Trans-endocardial intramyocardial injections (n=14-16)
1867016|NCT01076933|Procedure|repetitive Transcranial Stimulation Magnetic (rTMS)|The motor threshold was determined in each subject once, before treatment. This was defined as the lowest stimulation intensity capable of inducing a visible movement at least five times out of 10 stimulations. The position of the right dorsolateral prefrontal cortex was defined as 5 cm anterior (in a parasagittal line) to the motor cortex. The stimulus intensity was 80% of the patient's motor threshold intensity. Treatments were given for 20 minutes per day over 10 working days.
1867017|NCT01076933|Procedure|sham rTMS|sham rTMS
1867018|NCT01076972|Drug|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
1867019|NCT01076985|Drug|Lopinavir/ritonavir (Kaletra)|Lopinavir/ritonavir (LPV/r) evaluated separately in patients who were naive to previous antiretroviral treatment and those who were not.
1867020|NCT01076998|Other|Lubricant eye drop FID 115958D|1 drop in each eye, one time
1867021|NCT01076998|Other|Refresh PM Ointment|1 drop in each eye, one time
1867022|NCT01077011|Other|Lubricant eye drop FID 115958D|1 drop in each eye, one time
1867023|NCT01077011|Other|GenTeal Gel|1 drop in each eye, one time
1867024|NCT01077024|Other|Smoking-cessation treatment|Smoking cessation treatment includes four components: 1. brief weekly individual smoking-cessation counseling study weeks 1-10; 2. extended-release (XL) bupropion (300 mg/day)study weeks 1-10; 3. nicotine inhaler (6-16 cartridges per day ad libitum)during the post-quit treatment phase; 4. prize-based contingency management during the post-quit treatment phase.
1867025|NCT01077037|Other|Decision Aid|Chest pain choice decision aid
1867026|NCT01077050|Device|SciBase III Electrical Impedance Spectrometer|SciBase III Electrical Impedance Spectrometer is based on Electrical Impedance Spectroscopy (EIS). EIS is a measure of the overall resistance within a skin tissue, at alternating currents of various frequencies. Enrolled subject will undergo skin measurements with SciBase III Electrical Impedance Spectrometer. The relevant skin lesion(s) will be excised and diagnosed as per routine treatment.
1867027|NCT01077063|Procedure|paracentesis|surgical drainage of malignant ascites
1867028|NCT01077063|Device|Pleurx catheter|take home catheter drainage system that the subject uses himself/herself as needed.
1867029|NCT01077076|Drug|Zegerid|Zegerid taken once daily for 11 days.
1867030|NCT01077076|Drug|Prilosec OTC™ Tablets|Prilosec OTC™ Tablets taken once daily for 11 days.
1867031|NCT01077076|Other|Placebo|Placebo taken once daily for 11 days.
1867065|NCT01077440|Genetic|DNA analysis|DNA analysis will be performed on samples collected.
1867032|NCT01077102|Other|Eccentric exercise training|The eccentric exercise training will be performed using a specially built cycle ergo meter where the pedals are driven in backward direction by an electric motor, which has to overcome the adjustable resistance of the electromagnetic brake. During eccentric cycle ergometry patients have to resist the turning pedals.
1867033|NCT01077115|Procedure|Laparoscopic cholecystectomy|
1867034|NCT01077115|Procedure|Open Surgery|
1867035|NCT01077154|Drug|Placebo|120mg SC once monthly for the first 6 months. 120mg SC every 3 months for the next 4 and a half years. Oral calcium (at least 500 mg) and vitamin D (at least 400 IU) for 5 years.
1867036|NCT01077154|Drug|Denosumab|120mg subcutaneously (SC) once monthly for 6 months. 120mg SC every 3 months for the next 4 and a half years. Oral calcium (at least 500 mg) and vitamin D (at least 400 IU) for 5 years.
1867037|NCT01077167|Drug|Omecamtiv mecarbil|Oral dosing twice each day or three times each day, depending on the cohort assignment, of Omecamtiv mecarbil for 8 days. Omecamtiv mecarbil comes in 2 formulations: modified release and immediate release, and the formulation given will depend on the cohort assignment.
1867038|NCT01077180|Device|Implantation of the Rheos System|Open label
1867039|NCT01077180|Other|Standard of care medical management|Patients will continue with medical therapy for standard of care of their hypertension.
1867040|NCT01077193|Procedure|Gastric Plication|"A laparoscope will be inserted to visualize the surgical area and confirm absence of injury to any surrounding organ or structure. A flexible endoscope will be passed transorally into the gastric lumen to provide insufflation.
The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3cm from the pylorus and ending at or near the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected.
At least two rows of at least five continuous stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. An endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure."
1867041|NCT01077206|Drug|Simvastatin|80mg daily versus 40mg daily, for 21 days.
1867042|NCT01077245|Drug|MIYA-BM Fine Granules (CBM588)|MIYA-BM Fine Granules (CBM588)
1867043|NCT01077245|Drug|Placebo Fine Granules (without CBM588)|Placebo Fine Granules (without CBM588)
1867044|NCT01077284|Drug|Febuxostat|Febuxostat capsules
1867045|NCT01077284|Drug|Allopurinol|Allopurinol capsules
1867046|NCT01077284|Drug|Placebo|Placebo-matching capsules
1867047|NCT01077297|Drug|Tezosentan|single infusion of tezosentan 5mg/h over 30 min corresponding to 2.5 mg
1867048|NCT01077310|Drug|Vivitrol- Intramuscular naltrexone (depot-formulation)|Subjects in this arm will receive monthly intramuscular gluteal injections of depot naltrexone 380mg (VIVITROL) for 6 months. The 1st injection will be administered prior to release from prison or jail.
1867049|NCT01077310|Drug|Placebo|Subjects in this arm will receive monthly intramuscular gluteal injections of placebo for 6 months. The 1st injection will be administered prior to release from prison or jail. Placebo will be provided by Alkermes pharmaceuticals, the manufacturer of VIVITROL. Placebo will be identical in shape and form to active drug.
1867050|NCT01077323|Drug|exenatide|subcutaneous injection, dosing according to normal clinical practice
1867051|NCT01077323|Drug|Other antidiabetic therapies|Includes metformin, thiazolidinediones, insulins, sulfonylureas, non-sulfonylurea secretagogues, sitagliptin, and alpha-glucosidase inhibitors; In all cases, dosing according to normal clinical practice
1867052|NCT01077323|Other|No diabetes therapy|Subjects not diagnosed with diabetes
1867053|NCT01077349|Procedure|high volume hemofiltration|(80 ml/kg/h or a maximum of 8L/h) for 48 hours following heart surgery. Hemofiltration will be stopped after 48h if diuresis >1500 ml without diuretics and if IV infusion of catecholamines is less than 0.1 microg/kg/min of epinephrine, 0.2 microg/kg/min of norepinephrine or the sum of epinephrine + nor epinephrine/2 is less than 0.1 microg/kg/min. In other cases, hemodiafiltration (CVVHDF) will be initiated until the above objectives are reached, with equal flow rate of dialysate and reinfusion fluid, the sum of which being <35 ml/kg/h (or a maximum of 3500 ml/h).
1867054|NCT01077349|Procedure|standard care|"extra-renal replacement therapy (CVVHDF mode, total effluent <35 ml/kg/h or a maximum of 3500 ml/h) will be initiated only if the following criteria are met:
Serum creatinine > 350 micromol/L or increase x3.0 from pre-operative value OR
Diuresis < 0.3 ml/kg/h for 24 hours despite adequate fluid resuscitation OR
Or serum urea > 36 mmol/l OR
Or life threatening hyperkalemia"
1867055|NCT01077362|Drug|placebo|SC injections
1867056|NCT01077362|Drug|ustekinumab 45 mg|SC injections
1867057|NCT01077362|Drug|ustekinumab 90 mg|SC injections
1867058|NCT01077375|Drug|Placebo|"Placebo tablets, oral administration, twice daily for 10 weeks during randomized, double-blind treatment period. Duloxetine capsules, oral administration, 30 mg/day for 1 week after randomization to effect a duloxetine down-taper.
Placebo tablets, twice daily for 1 week during double-blind down-taper treatment period."
1867059|NCT01077375|Drug|Milnacipran|"Milnacipran tablets, 100 to 200 mg/day, oral administration, twice daily in divided doses for 10 weeks during randomized, double-blind treatment period. Placebo capsules, 1 capsule/day administered for 1 week after randomization to maintain double-blind duloxetine down-taper.
Milnacipran tablets, 100 to 0 mg/day, oral administration, twice daily in divided doses for 1 week during double-blind down-taper treatment period."
1867061|NCT01077401|Drug|Ranibizumab|Intravitreal injections of ranibizumab 0.5mg dose for six monthly treatments then additional treatments with ranibizumab 0.5mg dose if the subject meets re-treatment criteria.
1867062|NCT01077401|Drug|ranibizumab|Intravitreal injections of ranibizumab 2.0 mg dose for six monthly treatments then additional treatments with ranibizumab 2.0 mg dose if the subject meets re-treatment criteria.
1867063|NCT01077427|Device|Gemcitabine + Cisplatin + regional hyperthermia|"Gemcitabine: 1000 mg/m² as iv-infusion on days 1 and 15 of each course (Total dose: 12 g/m²) Cisplatin: 25 mg/m² as iv-infusion on days 2, 3* and 16, 17* of each course (Total dose: 600 mg/m²) Regional hyperthermia: 60 minutes on days 2, 3*, and 16, 17* of each course
* as an exception for medical or logistic reasons RHT and cisplatin can be applied day 4 instead of 3 and day 18 instead of 17"
1867866|NCT01084057|Other|laboratory biomarker analysis|Correlative studies
1867066|NCT01077440|Genetic|polymerase chain reaction|A polymerase chain reaction (PCR) assessment will be done on the samples collected.
1867067|NCT01077440|Other|flow cytometry|Flow cytometry will be done on the samples collected.
1867068|NCT01077440|Other|laboratory biomarker analysis|Laboratory biomarker analysis will be performed on the samples collected.
1867069|NCT01077453|Drug|letrozole|Given orally
1867070|NCT01077453|Other|quality-of-life assessment|Ancillary studies
1867071|NCT01077453|Other|laboratory biomarker analysis|Correlative studies
1867072|NCT01077466|Drug|Natalizumab|300 mg Natalizumab IV for every 4 week for 56 weeks (15 doses for every patient)
1867073|NCT01077479|Drug|Metformin|Metformin 1500mg nocte for 6 months
1867074|NCT01077492|Other|Virtual Bronchoscopy Navigation|Use of dedicated virtual bronchoscopy navigation software using 4D CT-PET scan spacial data.
1867075|NCT01077505|Biological|albiglutide|albiglutide 50mg weekly subcutaneous injection
1867076|NCT01077505|Drug|Oral contraceptive (Brevicon)|Oral contraceptive (Brevicon)
1867079|NCT01070823|Drug|Tysabri® (natalizumab)|Prescribed according to the TYSABRI Outreach: United Commitment to Health (TOUCH) Prescribing Program
1867080|NCT01070836|Drug|natalizumab|Administered as specified in the treatment arm
1867081|NCT01070849|Other|educational booklet|"Participants will receive an educational booklet and the advice to return to normal activities as soon as possible from their rehabilitation practitioner in their dismissal examination. As educational booklet the German version of the back book of Burton et al. was chosen. This booklet provides information about the new approach to back pain, causes of back pain, dealing with an attack of back pain, risk factors for development of chronic back pain and the role of activity. All information that is provided is in accordance with actual scientific knowledge and is based on a bio-psycho-social model of back pain like described in Waddell."
1867082|NCT01070849|Other|IRENA|Participants will be introduced into the normal IRENA program (in German: Intensivierte Rehabilitationsnachsorge), which is usual care in Germany. Every patient will be assigned to a certified aftercare facility near their residential area. Aftercare practitioners and patients can compile an individual therapeutic package from certain appointed therapeutic services. Predominantly resistance training, gymnastics, aquatic exercise, back school and recreation exercises are prescribed by the physicians for aftercare. Most therapies are carried out in open access groups of at least 6 patients without being specific for medical indication. In the IRENA program it is possible to pass the intended 24 exercise sessions with different frequency per week. Usually participants do two or three exercise sessions per week with duration of 90 to 120 minutes per session. Every aftercare facility offers certain therapy combinations at different days in week.
1867083|NCT01070849|Other|RÜCKGEWINN|For long term sustainability and the enhancement of intensity of the rehabilitation process this investigational aftercare intervention shows formal and didactic divergences from standard programmes in rehabilitation aftercare. Three important areas for multidimensional interventions are targeted: attitude and behaviour change concerning back pain, guidance to health enhancing physical activity, improvement of health related physical fitness. Every 90 minutes taking exercise session contains parts for mediation of knowledge, for behavioural modulation and for physical exercises and interlocks them in the mediation process. To take the time into account that is necessary for the process of behavioural change RÜCKGEWINN is planned for duration of six months in one session weekly for 26 weeks.
1867084|NCT01070862|Drug|Thalidomide, Dexamethasone|Thalidomide 200 mg/d for 3 months, Dexamethasone 40 mg/d D1-D4 and D14-D17 for 28d-3 cycles
1867085|NCT01070862|Drug|Vincristin , Adriamycin, Dexamethasone = VAD|Vincristin 0.4 mg/d continUous IV infusion D1-D4, Adriamycin 9 mg/m2 continuous IV infusion D1-D4, Dexamethasone 40 mg/d oral D1-D4 and D15-D18 for 2 first cycles, D1-D4 for the 3d cycle
1867086|NCT01070862|Drug|Thalidomide, melphalan, endoxan, dexamethasone (MCDex-Thal)|Thalidomide : 200 mg/d at bedtime for 3 months , melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
1867087|NCT01070862|Drug|melphalan, endoxan, dexamethasone (MCDex)|melphalan: 6 mg/m2 oral D1-D4, endoxan 600 mg/m2 IV D1, dexamethasone 40 mg/d oral D1-D4 for 28-d 4 cycles
1867088|NCT01070862|Drug|Thalidomide, Dexamethasone|Thalidomide 200 mg/d on every other 3 months Dexamethasone 40 mg/d D1-D4, D30-D34,D60-D64, D90-D94
1867089|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive unfractionated heparin 5000 U subcutaneous two times a day.
1867090|NCT01070875|Drug|Variation of heparin dose|Study subjects will be randomized to receive heparin 5000 U subcutaneous three times a day.
1867091|NCT01070888|Drug|Budesonide/Formoterol|Budesonide/Formoterol 160/4.5, 2 puff twice daily for 2 weeks
1867092|NCT01070888|Drug|Budesonide|Budesonide 180mcg, 2 puffs twice daily for 2 weeks
1867093|NCT01070927|Drug|RO4929097|80mg po daily, 3 days on 4 days off schedule
1867094|NCT01070927|Drug|RO4929097|recommended phaseII dose, orally once daily, 3 days on 4 days off schedule
1867095|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
1867096|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
1867097|NCT01070940|Drug|NG-monomethyl-L-arginine (L-NMMA)|4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
1867098|NCT01070940|Drug|Placebo|Isotonic saline solution IV priming dose + IV infusion for 1 hour
1867099|NCT01070979|Drug|Estradiol acetate|Tablet containing 0.9 mg E3A, daily oral administration.
1867100|NCT01070979|Drug|Estradiol|Tablet containing 1 mg estradiol, daily oral administration.
1867101|NCT01070979|Drug|Conjugated equine estrogens|Tablet containing 0.625 mg CEE, daily oral administration.
1867102|NCT01071005|Drug|Lorelin Depot Bergamo|Lorelin Depot Bergamo, 3,75 mg, single dose.
1867103|NCT01071005|Drug|Lupron Depot - Abbott|Lupron Depot 3,75 mg, single dose.
1867104|NCT01071018|Drug|MK2206 every other day|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 45 mg and 60 mg, once daily every other day in repeating 4 week cycles.
1867105|NCT01071018|Drug|MK2206 once weekly|Dose escalation study: MK2206 will be administered as an oral formulation in rising dose levels of 135 mg and 200 mg, once weekly in repeating 4 week cycles.
1867106|NCT01071031|Biological|HIV-v (Low Dose)|"Low Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences) with water for injection or adjuvant
Administration: A single subcutaneous injection"
1867107|NCT01071031|Biological|HIV-v (High Dose)|"High Dose HIV-v (a sterile lyophilised mixture of polypeptide T-cell epitope sequences with water for injection or adjuvant
Administration: A single subcutaneous injection"
1867108|NCT01071031|Biological|HIV-v (Control)|"Adjuvant only or Water for injection only
Administration: A single subcutaneous injection"
1867109|NCT01071044|Drug|Lisdexamfetamine Dimesylate|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
1867110|NCT01071044|Drug|"Placebo 30, 50 or 70 mg"|Will be randomly assigned to one of two treatment arms in a 1:1 ratio of either LDX or placebo for 6 weeks. Subjects will be started with a single pill containing 30mg of LDX or comparable placebo, depending on the treatment assignment. At the week 2 visit, the dose will be increased to 50 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the Investigator. At the week 4 visit, the dose will be increased to 70 mg (or comparable placebo) if the patient exhibits no significant adverse effects as judged by the investigator.
1867113|NCT01071070|Drug|paricalcitol|Initiation dosing based on 2 approved package inserts , followed by a dose adjusted by limited chemistry test value. See Arm Description for additional details.
1867114|NCT01071083|Drug|natalizumab|300 mg intravenous every 4 weeks
1867115|NCT01071083|Drug|interferon beta 1-a|30 ug intramuscular once per week
1867116|NCT01071083|Drug|methylprednisolone|1000 mg intravenous every 4 weeks
1867117|NCT01071083|Other|IV placebo|placebo intravenous every 4 weeks
1867118|NCT01071083|Drug|glatiramer acetate|20 mg subcutaneous once daily
1867119|NCT01071096|Drug|OnabotulinumtoxinA|"Minimum dose of 155 U OnabotulinumtoxinA Purified Neurotoxin Complex administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache symptoms with a headache diary and collect saliva samples as instructed.
At investigator's discretion, additional 40 U OnabotulinumtoxinA Purified Neurotoxin Complex may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
1867120|NCT01071096|Drug|Saline|"155 U Saline administered at 31 fixed-site, fixed-dose injections across seven specific head/neck muscle areas. Subjects will continue to monitor headache using a headache diary and collect saliva samples as instructed.
At investigator's discretion, additional Saline may be administered unilaterally or bilaterally, using follow-the-pain paradigm."
1867121|NCT01071109|Procedure|Therapeutic Massage|Therapeutic Massage--subjects randomized to this group will receive weekly, one-hour therapeutic massage
1867122|NCT01071122|Drug|Nifedipine (Adalat, BAYA1040) and Valsartan|Combination treatment with nifedipine GITS 30mg and valsartan 80mg, Once daily
1867123|NCT01071122|Drug|Nifedipine (Adalat, BAYA1040)|Nifedipine 60mg, Once daily
1867124|NCT01071122|Drug|Valsartan|Valsartan 160mg, Once daily
1867125|NCT01071135|Drug|Quetiapine XR|Quetiapine XR (Seroquel Prolong®) extended-release tablets à 50 mg und 200 mg. Seroquel Prolong® should be administered as the only neuroleptics preferably once daily, preferably in the evening. The recommended initial dose is 200 mg/day. Patients should be titrated within a dose range of 400 - 800 mg/day depending on the response and tolerance of the individual patient. Dose increases can be made at intervals as short as 1 day and in increments of up to 200 mg/day. Seroquel Prolong® tablets should be swallowed whole and not split, chewed or crushed.
1867126|NCT01071161|Drug|azithromycin|azithromycin, tablets, during 12 weeks, three times a week, 250mg
1867127|NCT01071161|Drug|placebo|placebo
1867128|NCT01071174|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; One ring inserted every 28 days for 84 days (3 rings total)
1867129|NCT01071174|Other|Placebo|Vaginal Ring containing no drug substance
1867130|NCT01071187|Drug|Varenicline|Varenicline 0,5mg daily on day 1-3, Varenicline 1mg daily on day 4-7 and Varenicline 2mg on day 8-84.
1867131|NCT01071187|Drug|Placebo|Placebo
1867132|NCT01071200|Drug|Recombinant human Follicle Stimulating Hormone (r-hFSH) and Recombinant human Luteinizing Hormone (r-hLH)|One r-hFSH and one r-hLH injection subcutaneously (s.c.) once daily during the treatment phase from Day 8 of stimulation until injection of human chorionic gonadotropin (hCG) or cancellation of the treatment cycle.
1867133|NCT01071200|Drug|r-hFSH|One r-hFSH injection s.c. once daily during the treatment phase from Day 8 of stimulation until injection of hCG or cancellation of the treatment cycle.
1867134|NCT01071226|Device|CliniMACS (CD+3, CD+19 depletion)|Patient's in Stratum 1 will receive grafts that have undergone CD3+, CD19+ depletion
1867135|NCT01071226|Device|CliniMACS (CD 34+ positive selection)|Patient's in Stratum 2 will receive peripheral blood progenitor cells that have undergone CD34+ selection
1867137|NCT01071252|Drug|AIN457|
1867138|NCT01071252|Drug|Placebo|
1867139|NCT01071265|Procedure|Remote Ischemic Preconditioning|Occlusion of leg blood flow using a pneumatic tourniquet on the thigh. Tourniquets are inflated to 300 mmHg for 5 minutes followed by deflation for 5 minutes then repeated for a total of 3 inflations.
1867140|NCT01071265|Procedure|Sham|Sham procedure. A pneumatic tourniquet is placed on an upper arm and/or thigh but not inflated.
1867141|NCT01071291|Drug|Niaspan|Niaspan™
1867142|NCT01071291|Drug|Comparator: Placebo|Placebo
1867143|NCT01071304|Drug|Midazolam|A single oral dose of midazolam 2 mg (1 mL of 2 mg/mL syrup) was given on Day -2 and Day 5.
1867144|NCT01071304|Drug|Ridaforolimus|Ridaforolimus 40 mg (4 x 10 mg tablets) oral once daily on Days 1 through 5.
1867145|NCT01071317|Drug|Naproxen|Naproxen 500mg PO bid prn headache
1867146|NCT01071317|Drug|Sumatriptan|100mg po q day prn headache
1867147|NCT01071317|Behavioral|Migraine education|Educational program available through HIH/ national library of medicine/ X-plain
1867148|NCT01071317|Behavioral|Reenforcement of diagnosis|Patient told he/s he has migraine headache and how the headache meets migraine criteria
1867149|NCT01071317|Other|Typical care|Care to be determined by attending physician
1867150|NCT01071343|Device|Transcutaneous electrical muscle stimulation|After randomization of the quadriceps muscles TEMS is applied on the intervention side for 7 consecutive days, 60 minutes per day.
1959999|NCT03311178|Drug|Dobutamine|Infants who meet the definition of poor perfusion state will be treated at the discretion of the responsible physician following the standard local policies. The interventions will be dobutamine from a new neonatal formulation developed for NeoCirc and/or other treatments (including any other cardiovascular drug or volume replacement with normal saline).
1960000|NCT03311165|Other|no intervention|no intervention was given
1867153|NCT01071369|Drug|Xylocaine|0.5% Xylocaine
1867154|NCT01071369|Drug|Xylocaine and Celestone|non-particulate Celestone
1867155|NCT01071395|Drug|Amantadine|Amantadine hydrochloride 300mg daily in three divided doses
1867156|NCT01071395|Drug|Placebo|Sugar pill given 3 times daily
1867157|NCT01071408|Other|Stroke prevention care program|Stroke prevention care program consists of group clinics, telephone coordination of care, and tracking of care through registries in the first 7 months after stroke or TIA presentation. A nurse practitioner will follow algorithms to adjust medications and to motivate patients to improve lifestyle habits.
1867158|NCT01071421|Device|abbreviated polysomnography|Both groups will be studied with in-hospital respiratory polygraphy during the sleep. The group A will be studied with another respiratory polygraphy in the home one month after the resolution of CAP. Some questionnaires to measure the sleepiness (Epworth test), FOSQ test, in-home sleepiness questionnaire and symptoms questionary will be obtained in Group A and B
1867159|NCT01071434|Procedure|MR Imaging|
1867160|NCT01071447|Other|Nurse-led clinic vs rheumatologist-led clinic|The subjects are seeing a rheumatology nurse (experimental arm)instead of a rheumatologist (active comparator arm) after six months. Subjects in both arms are seeing a rheumatologist after 12 months and have the possibility to contact the rheumatology nurse.
1867161|NCT01071460|Device|FlexStent Femoropopliteal Self-Expanding Stent System|"Peri-procedural management will be no different to routine SFA/Popliteal Artery intervention Standard medical therapy
Procedural techniques will be identical to routine protocols for SFA/Popliteal Artery stenting. technique suggested:
Contralateral retrograde common femoral cross-over access or antegrade access
Target lower limb arteries fully imaged angiogram. with measurement of SFA/Popliteal Artery target lesion length and normal vessel diameter immediately above and below target lesion
Pre-stenting balloon dilatation of target lesion in all total occlusions and critical stenosis
Deployment of an appropriately sized FlexStent® to cover target lesion
Post-stent balloon dilate stent using a semi-compliant angioplasty balloon to enable accurate post-dilatation of stent to target diameter
Post stenting angiography assessing target lesion parameters, run-off vessel patency and complications"
1867162|NCT01071473|Other|12 Week Exercise Intervention|Trial of a 12-week period of combined endurance and resistance training in survivors of childhood cancer who were treated with doxorubicin and/or daunorubicin and have impaired cardiac function.
1867163|NCT01071486|Drug|Hematological Stem Cell Transplantation|Oral or Intravenous Busulfan as part of the preparative protocol for transplantation
1867164|NCT01071499|Drug|Morphine|One dose of morphine (0.1 mg/kg)
1867165|NCT01071499|Drug|Morphine|One dose of morphine (0.2 mg/kg)
1867166|NCT01071499|Drug|Morphine|One dose of morphine (0.3 mg/kg)
1867169|NCT01071538|Drug|Buprenorphine|Sublingual buprenorphine 0.2 mg will be used for the first week. The dose will be increased by 0.2 mg/week based on safety and clinical response up to a maximal dose of 1.6 mg/day.
1867170|NCT01071551|Behavioral|Life-style intervention|"The Nutrition Enrichment and Healthy Living Model (NEHLM) is an Integrative model covering variety of lifestyle issues such as nutrition, dental care, and physical activity. The model will be applied to kindergartens and a sample of their parents. Children participating will be given 10 lessons in nutrition, 5 lessons in dental-care and 20 physical activity lessons. Parents for children in this group will be given 2 nutrition-education meetings and a meeting with a dental clinician.2 additional meetings will be held for parents and children together, one in nutrition and one in dental-care."
1867171|NCT01071551|Behavioral|Physical activity only|Children allocated to this group will attend 20 physical activity classes.
1867172|NCT01071564|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1867173|NCT01071564|Other|Laboratory Biomarker Analysis|Correlative studies
1867174|NCT01071564|Other|Pharmacogenomic Study|Correlative studies
1867175|NCT01071564|Other|Pharmacological Study|Correlative studies
1867176|NCT01071564|Drug|Vismodegib|Given PO
1867177|NCT01071616|Drug|Cannabis Cigarette|
1867178|NCT01071629|Other|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 40 min in the interval training group
1867210|NCT01077622|Drug|ofatumumab 100 mg, 1000 mg / vial|ofatumumab , 300mg followed by 7 weekly infusions 2000 mg, followed by 4 monthly infusions 2000mg
1867867|NCT01084057|Other|pharmacological study|Correlative studies
1867179|NCT01071629|Other|Exercise training|Interval training (30 sec 50% of peak Work Rate achieved at the steep ramp test/60 sec recovery no exercise) for 20 min and Strength training of the quadriceps, hamstrings, muscles of the shoulder and biceps brachialis for 20 min 3 times per week for 36 sessions
1867180|NCT01071642|Drug|stop ace-i/arb 24 h before procedure and restarted 24 hours after the procedure|ACE/ARB stopped 24 hours prior to the procedure and restarted 24 hours after the procedure
1867181|NCT01071642|Drug|ACE/ARB stopped 24 hours before procedure and start immediately after|ACE/ARB stopped 24 hours prior to the procedure and restarted immediately after the procedure
1867182|NCT01071655|Drug|BVZ+XELOX or BVZ+XELIRI or BVZ+FUIRI or BVZ+FUOX|"BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
BVZ + XELIRI. Bevacizumab 7,5 mg/kg day 1; Capecitabine 800 mg/m2/12 h days 1-14; Irinotecan 200 mg/m2 day 1
BVZ + FUIRI. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Irinotecan 80 mg/m2 weekly
BVZ + FUOX. Bevacizumab 5 mg/kg biweekly; 5-FU 2.250 mg/m2 weekly; Oxaliplatin 85 mg/m2 biweekly"
1867183|NCT01071655|Drug|BVZ+XELOX|BVZ + XELOX. Bevacizumab 7,5 mg/kg day 1; capecitabine 1000 mg/m2/12 h days 1-14; oxaliplatin 130 mg/m2 day 1
1867184|NCT01071681|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients under daily life treatment receiving Pritor according to local drug information.
1867185|NCT01071694|Drug|Interferon beta 1-b (Betaferon/Betaseron, BAY86-5046)|Patients receiving Betaferon according to routine clinical practice
1867186|NCT01071720|Drug|CKD-501 1mg|This study is randomized, balanced, single-dose, two treatment (fed versus fasting), two-period, two sequence crossover design to assess the effects of food on pharmacokinetics profile.
1867187|NCT01071772|Drug|insulin|There will be used individual intravenous insulin (actrapid) infusion to prevent non-intended hyperglycemia.
1867188|NCT01071785|Dietary Supplement|guar gum|guar gum 10g/day for six weeks
1867189|NCT01071798|Drug|Rituximab|As prescribed by physician
1867190|NCT01071811|Behavioral|Pedometer-based intervention|The participants were randomly assigned to either a pedometer group or a control group by drawing a sealed envelope with a unique randomizing number. The participants in the pedometer group received a pedometer (Yamax Digi-Walker SW-200), a book with a pedometer program(18), a handout with a summary of the pedometer program, and a calendar for registration of daily steps. During the trial period they were asked to reset the pedometer every morning and to wear it during the entire day. In the evening they should take the pedometer off and register the accumulated steps in the calendar. After three, six, and nine weeks, the participants in the pedometer group got a mail to encourage them to keep using the pedometer and follow the program.
1867191|NCT01071824|Procedure|Transverse coloplasty pouch (Long limb)|Transverse coloplasty pouch with long limb
1867192|NCT01071824|Procedure|Transverse coloplasty pouch (Short limb)|Transverse coloplasty pouch with short limb
1867193|NCT01071837|Drug|APG101|400mg weekly as intravenous infusion
1867194|NCT01071837|Procedure|Blood drawing|Blood drawings, e.g. for safety labs, abdominal ultrasound, ECG. Re-Irradiation is not considered a study procedure, but standard of care (inclusion criterion)
1867195|NCT01071850|Drug|ASP1941|oral tablet
1867196|NCT01071850|Drug|Metformin|oral tablet
1867197|NCT01071850|Drug|Placebo|oral tablet
1867198|NCT01077531|Drug|Otelixizumab|Otelixizumab injection for intravenous infusion. Otelixizumab (GSK2136525) is a humanised, aglycosyl, non-mitogenic, anti CD3 monoclonal antibody (MAb).
1867199|NCT01077531|Drug|Matching placebo|Matching placebo for intravenous infusion
1867200|NCT01077544|Drug|Nilotinib|"Nilotinib capsules were delivered in bottles with dose strengths of 50mg, 150mg and 200mg.
Patients were administered nilotinib 230 mg/m2 (per BSA) bid, orally, rounded to the nearest 50 mg (max single dose 400 mg) for 28 days (1 cycle) for up to 12 cycles prior to protocol amendment 3 and up to 24 cycles post amendment 3. Capsules were to be swallowed whole with water. Apple sauce (puréed apple) may have been used as a vehicle for dosing where capsules were not able to be swallowed whole with water."
1867201|NCT01077557|Other|No Antiretroviral (ARV) Drug Exposure|No pharmacy dispensing of an ARV drug
1867202|NCT01077557|Drug|Any Antiretroviral (ARV) Drug Exposure|Pharmacy dispensing claim for any ARV drug
1867203|NCT01077570|Drug|repaglinide|Repaglinide prescribed at the discretion of the investigator, according to local labelling, and evaluated at week 0, 8 and 16 of the study
1867204|NCT01077596|Drug|Regular bupropion use|Regular use of bupropion is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
1867205|NCT01077596|Drug|Regular SSRI (Selective serotonin reuptake inhibitors) use|Regular use of SSRI is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
1867206|NCT01077596|Drug|Regular TCA (Tricyclic antidepressants) use|Regular use of TCA is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date.
1867207|NCT01077596|Drug|Regular use of any other antidepressant|"Regular use of any other antidepressants is defined as use at least 4 times per week for at least 3 continuous months at least 12 months before index date. An other antidepressant would be any antidepressant other than bupropion, a SSRI or a TCA."
1867208|NCT01077609|Drug|Intermittent, sub-chronic and chronic Flixonase use|Intermittent exposure episode is a series of fewer than four sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
1867209|NCT01077609|Drug|Intermittent, sub-chronic and chronic use of intranasal steroids other than Flixonase|Intermittent exposure episode is a series of fewer than four sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Sub-chronic use episode is a series of at least four and not more than eight sequential prescriptions for an intranasal steroid other than Flixonase with gaps of no more than 60 days between any two. Chronic use episode is a series of at least nine sequential prescriptions for an intranasal steroid other than Flixonase and gaps of no more than 60 days between any two. A span of at least 180 days must occur between the first and last prescription.
1867377|NCT01079689|Other|needle stimulation|stimulation with acupuncture needles
1867211|NCT01077635|Drug|Exposure to licensed dose of FPV (+/- 20% of 18mg/kg BID + RTV)|HIV-1 infected children currently or having ever been exposed to FPV (+/- 20% of 18mg/kg BID + RTV)
1867212|NCT01077648|Drug|Trastuzumab or Lapatinib|Anti-erbB2 therapy for breast cancer treatment will be analyzed as a class level variable; individual drugs including trastuzumab and lapatinib will also be explored as exposures if sufficient numbers of patients exist.
1867213|NCT01077661|Drug|Nebivolol|patients administrated Nebivolol according to the prescribing information
1867214|NCT01077700|Drug|ABT-288 Low Dose|
1867215|NCT01077700|Drug|Placebo|inactive substance
1867216|NCT01077700|Drug|ABT-288 High Dose|
1867217|NCT01077713|Drug|bevacizumab [Avastin]|7.5mg/kg iv on day 1 of each 3 week cycle
1867218|NCT01077713|Drug|cisplatin|60mg/m2 on day 1 of each 3 week cycle
1867219|NCT01077713|Drug|gemcitabine|1200mg/m2 on days 1-8 of each 3 week cycle
1867220|NCT01077713|Drug|gemcitabine|1000mg/m2 on days 1-8 of each 3 week cycle
1867221|NCT01077726|Drug|capecitabine [Xeloda]|1000mg/m2 po bid on days 1-14 of each 3 week cycle
1867222|NCT01077739|Drug|fluorouracil (5FU)|standard FOLFOX regimen
1867223|NCT01077739|Drug|leucovorin|standard FOLFOX regimen
1867224|NCT01077739|Drug|bevacizumab [Avastin]|7.5 mg/kg iv infusion every 3 weeks OR 5 mg/kg iv infusion every 2 weeks
1867225|NCT01077739|Drug|capecitabine [Xeloda]|standard XELOX regimen
1867226|NCT01077739|Drug|oxaliplatin|standard XELOX or FOLFOX regimen
1867227|NCT01077752|Drug|continuous ropivacaine preperitoneal infusion|Bolus of 20 mg after the surgery then 20 mg per hour during 48 hours
1867228|NCT01077752|Drug|intravenous lidocaine infusion|Bolus of 60 mg after the surgery then 60 mg per hour during 48 hours
1867229|NCT01077752|Drug|parenteral analgesia combining acetaminophen and morphine|parenteral analgesia combining acetaminophen and morphine
1867230|NCT01077752|Drug|NaCl|NaCl
1867231|NCT01077765|Device|Eutrophill|Polyacrylamide Hydrogel
1867232|NCT01077778|Procedure|Gadolinium-enhanced Magnetic Resonance Imaging|Gadolinium-enhanced Magnetic Resonance Imaging
1867233|NCT01077791|Behavioral|original cognitive therapy|12 weekly sequences of an original cognitive therapy based on videos involving the learning of a better use of contextual information to infer others' intention. Group of 5 patients trained by 2 therapeutics. Comparison with a non-cognitive psychoeducational training (same organisational design).
1867234|NCT01077817|Drug|Alendronate|
1867235|NCT01077817|Drug|Etidronate|
1867236|NCT01077817|Drug|Ibandronate|
1867237|NCT01077817|Drug|Risedronate|
1867238|NCT01077817|Drug|Raloxifene|
1867239|NCT01077843|Drug|Etoricoxib|Cox-2 inhibitor
1867240|NCT01077843|Drug|Other Cox-2 inhibitors|Cox-2 inhibitor
1867241|NCT01077843|Drug|Other Non-selective NSAIDs|Non-selective NSAID
1867242|NCT01077843|Other|No anti-inflammatory treatment|No anti-inflammatory prescription
1867243|NCT01078441|Drug|liposomal doxorubicin|Given IV
1867244|NCT01078441|Drug|bortezomib|Given subcutaneously.
1867245|NCT01078441|Drug|dexamethasone|Given orally
1867246|NCT01078441|Drug|cyclophosphamide|Given IV
1867247|NCT01078454|Drug|melphalan|Given PO
1867248|NCT01078454|Drug|dexamethasone|Given PO
1867249|NCT01078454|Drug|bortezomib|Given IV
1867250|NCT01078480|Procedure|Operation using a precontoured titanium plate and screws|Operation using a precontoured titanium plate and screws
1867251|NCT01078480|Procedure|Displaced midshaft fracture of the collar bone|Displaced midshaft fracture of the collar bone treated with an arm sling
1867252|NCT01078493|Device|MyCells® (injection of platelet rich plasma)|PRP contains at least 1,000,000 platelets per mm3 or 2-6 times the native concentration of whole blood at a pH of 6.5 to 6.7
1867253|NCT01078519|Drug|Combined epidural and spinal anesthesia|Obstetrics patients will relieve spinal anesthesia with local anesthesics and opioids associated with epidural anesthesia with local anesthetics in low concentrations with opioids
1867254|NCT01078532|Other|SMART PHR|Patient receives an active PHR
1867255|NCT01078532|Other|usual care|Usual passive PHR
1867256|NCT01078545|Drug|Leuprolide acetate Depot Susp. 11.25 mg (Poland), 3.75 mg (Ukraine)|Leuprolide acetate 11.25 mg every 3 months sc or im, number of injections during the trial - 5 in Poland, Leuprolide acetate 3.75 mg every 1 month sc or im, number of injections during the trial - 12 in Ukraine.
1867257|NCT01078571|Biological|adalimumab (HUMIRA®)|The primary objective of the study is to evaluate the safety and tolerability of adalimumab (HUMIRA®) treatment, administered both in monotherapy and combined therapy, in rheumatoid arthritis (RA) patients under usual practice conditions.
1867258|NCT01078610|Biological|adalimumab (Humira)|40 mg adalimumab (Humira) every other week.
1867259|NCT01078623|Drug|Aclidinium 200 μg / formoterol 12 μg|Aclidinium bromide 200 μg + formoterol fumarate 12 μg fixed dose combination (FDC) twice daily
1867260|NCT01078623|Drug|Placebo|Placebo control twice daily
1867261|NCT01078623|Drug|Formoterol 12 μg|Formoterol fumarate 12 μg twice daily
1867262|NCT01078623|Drug|Aclidinium 200 μg|Aclidinium bromide 200 μg twice daily
1867263|NCT01078623|Drug|Aclidinium 200 μg / Formoterol 6 μg|Aclidinium bromide 200 μg + formoterol fumarate 6 μg fixed dose combination (FDC) twice daily
1867264|NCT01078649|Drug|Debio 1143 (AT-406)|Oral Debio 1143 (AT-406) will be administered in a dose escalation study to determine the maximally tolerated dose in humans. Patients will receive Debio 1143 (AT-406) on days 1-5, and 15-19 of a 28 day cycle, or days 1-5 of a 21 day cycle, repeated until progression or unacceptable toxicity occurs.
1867265|NCT01078662|Drug|olaparib|400mg (8 x 50mg capsules), oral BID until progression of the disease
1867266|NCT01078675|Drug|rosuvastatin calcium|5 mg, oral, once daily, 24 months
1867267|NCT01078675|Drug|rosuvastatin calcium|10 mg, oral, once daily, 24 months
1867268|NCT01078675|Drug|rosuvastatin calcium|20 mg, oral, once daily, 24 months
1867269|NCT01078701|Biological|GHB11L1|GHB11L1 administration by liquid nasal spray at doses of 6.0 log10, 6.5 log10 and 7.0 log10 TCID50/volunteer
1867270|NCT01078701|Biological|Placebo|SPGN buffer
1867271|NCT01078714|Drug|bumetanide|Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)
1867272|NCT01078727|Device|A custom-made constant temperature thermal stimulation system (FIRSTEK, Model-B401L, B-300, local company, Taiwan).|The subjects meeting our criteria will be randomly assigned to either the experimental group or the control group. First stage (3 months after onset), the subjects in the experimental group will receive an upper extremity Thermal Stimulation (TS) protocol for 30 minutes (3 times a week for 8 weeks). The subjects in the control group will receive a lower extremity TS protocol.
1867273|NCT01078753|Drug|Desmopressin|Desmopressin oral lyophilisate tablet, 120 μg or 240 μg, administered sublingually once a day 1½ hours before bedtime.
1867274|NCT01078753|Drug|Placebo|Placebo oral lyophilisate tablet was administered sublingually once a day 1½ hours before bedtime.
1867275|NCT01078766|Other|CIMT+HABIT|The daily schedule included one hour of constraining the functional arm with intensive activation of the hemi-paretic arm and then 5 hours of various structured, intensive bimanual functional activities,
1867276|NCT01078779|Drug|Chloroquine|Chloroquine phosphate 250mg capsule, two capsules daily for 7 days then 2 capsules once a week for a total treatment duration of 12 weeks
1867277|NCT01078779|Drug|Placebo|Placebo capsules, 2 capsules daily for 7 days then 2 capsules weekly for a total treatment duration of 12 weeks
1867278|NCT01078792|Other|CT pulmonary angio, blood tests|
1867279|NCT01078805|Drug|FORTEO|prescribed in accordance with usual clinical practice for up to 24 months
1867280|NCT01078818|Drug|IV trivalent saccharose hydroxide ferrous|"Preoperative Period 5-10 days 200 mg Iron iv (Venofer® )in 200cc physiologic solution /24-48h x 3 dosis +1 oral placebo /24h Postoperative Period 1-3weeks 200 mg Iron iv (Venofer® )in 200cc physiologic solution/24-48h x 3 dosis + 1 oral placebo /24h One month Follow-up
1 month 1 oral placebo /24h"
1867281|NCT01078818|Drug|Oral ferrous fumarate|"200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®)
Postoperative Period:
200cc physiologic solution iv placebo /24-48h x 3 dosis + 1 oral iron tablet/24h (Ferogradumet®) One month Follow-up: 1 oral iron tablet/24h Ferogradumet"
1867282|NCT01078818|Drug|Oral and intravenous Placebo|Preoperative Period:1oral placebo/24h Postoperative Period:200cc physiologic solution iv placebo /24-48h x 3 dosis + 1oral placebo/24h One month Follow-up:1 oral placebo/24h
1867283|NCT01078831|Other|Bronchoscopy|Airway pressures, ventilation changes and blood gas changes are recorded in a group of intubated patients on mechanical ventilation before and after bronchoscope insertion. The registration is done immediately before a therapeutic/diagnostic bronchoscopy requested by a staff physician not involved n the study.
1867284|NCT01078844|Drug|memantine|memantine 5-20 mg daily
1867285|NCT01078844|Drug|Placebo|Look-alike placebo
1867286|NCT01078857|Other|Skin biopsy|A 3-mm-diameter skin biopsy punch was taken at the lateral side of the distal leg and fixed in 4% paraformaldehyde overnight. Sections of 50 m perpendicular to the dermis were cut on a sliding microtome, quenched with 1% H2O2 in methanol, and blocked with 5% normal goat serum. Sections were incubated with rabbit antiserum to protein gene product 9.5 (PGP 9.5, UltraClone, Isle of Wight, UK, 1:1000) overnight. PGP 9.5 is a ubiquitin carboxyl hydrolase, which labels myelinated and unmyelinated nerve fibers in the peripheral nervous system. Sections were then incubated with biotinylated goat anti-rabbit immunoglobulin G (Vector, Burlingame, CA) for 1 h and the avidin-biotin complex (Vector) for another hour. The reaction product was demonstrated using chromogen SG (Vector).
1867287|NCT01078870|Drug|Lexapro|10mg/cap 1~2# QD
1867288|NCT01078870|Drug|Cymbalta|30mg/cap 30~60mg/QD
1867289|NCT01078870|Drug|Placebo|1~2#/cap QD
1867291|NCT01078922|Drug|Ofatumumab|The first dose administered of ofatumumab should be 300 mg to minimize infusion reactions. The initial rate of the first infusion of 1000 mg ofatumumab (0.3mg/ml) should be 12ml/h. If no infusion reactions occur the infusion rate should be increased every 30 minutes, to a maximum of 400 ml/h. If this schedule is followed, the infusion duration will be approximately 4.5 hours.
1867292|NCT01078935|Dietary Supplement|probiotics|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
1867293|NCT01078935|Dietary Supplement|placebo|Each patient and volunteer will get the study medication for 6 weeks and will be evaluated twice - before enrollment and after 6 weeks of treatment. Routine clinical management will continue - with regular treatment as needed.
1867294|NCT01078948|Device|transcranial direct current stimulation (tDCS)|Delivery of mild current to specified brain regions.
1867295|NCT01078961|Drug|bortezomib|Given intravenously on days 1, 8 and 15 of each 28 day cycle
1867296|NCT01078961|Drug|sorafenib|400mg taken orally twice a day
1867297|NCT01078974|Drug|pomalidomide|Taken orally once a day
1867298|NCT01078974|Drug|dexamethasone|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
1867299|NCT01078974|Drug|rituximab|Given intravenously on weeks 1, 2, 3 and 4 and weeks 12, 13, 14 and 15
1867300|NCT01078987|Procedure|Plasmapheresis|A course of 5 daily treatments of plasma exchange (plasmapheresis) for one to three courses
1867301|NCT01079000|Behavioral|Opinion Leader letter|The patients' PCP will be notified by fax about the ED visit and management. The Opinion Leader letter will contain a summary of the current asthma guidelines for ambulatory care (including: asthma education, long-term recommendations, smoking cessation, and action plan) signed by a local opinion leader. A review of the patient's management within a week of the ED visit will be recommended. The patient will also receive information regarding their acute exacerbation and will be told to review the current management of their disease with their PCP.
1867302|NCT01079000|Behavioral|Involvement of a care manager|The involvement of a care manager will encourage patients' to pursue follow-up, provide management review and offer brief education via telephone within a week of being discharged
1867303|NCT01079000|Behavioral|Usual care|Usual care provided to asthma patients when discharged from the ED
1867304|NCT01079013|Drug|treosulfan|12 g/m2 x 3 days
1867305|NCT01079052|Drug|Famotidine|Tablets
1867306|NCT01079065|Drug|Famotidine|Tablets
1867307|NCT01079078|Drug|Acetaminophen|
1867651|NCT01082198|Biological|autologous melanoma lysate/KLH-pulsed autologous dendritic cell vaccine|
1867308|NCT01079091|Device|Hepa Wash|"Intervention frequency: 1-10 treatments (decision of the investigator)
Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
1867309|NCT01079091|Procedure|Standard Medical Therapy|Standard of care treatment
1867310|NCT01079104|Device|Hepa Wash|"Intervention frequency: 1-10 treatments (decision of the investigator)
Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)"
1867311|NCT01079104|Procedure|Standard Medical Therapy|Standard of care treatment
1867312|NCT01079117|Drug|Sevre-Long™|The subjects will be randomised to either 10 weeks of treatment with methadone or SROM. After an adjustment phase of one week they first will be medicated for 10 weeks with the treatment to which they have been randomised. The cross-over, in which all subjects change to their opposite treatment, will serve for an additional adjustment phase of one week. After the second and new adjustment phase they are treated for 10 weeks with the newly adjusted medication. After the end of week 22 all participants continue with or switch back to SROM for another 6 month (week 23 to 47).
1867313|NCT01079117|Drug|Slow release oral morphine|
1867314|NCT01079117|Drug|Methadone|
1867315|NCT01079130|Drug|Indacaterol|Once daily via Concept1, a single-dose dry powder inhaler (SDDPI) for two week. Dosage varies according to randomization scheme.
1867316|NCT01079130|Drug|Salmeterol|50 µg Salmeterol twice daily in the morning and in the evening via Diskus®, a MDDPI for 2 weeks.
1867317|NCT01079130|Drug|Placebo to Indacaterol|Placebo to Indacaterol once daily in the morning via Concept 1, a SDDPI.
1867318|NCT01079130|Drug|Placebo to Salmeterol|Placebo to Salmeterol twice daily in the morning and in the evening via Diskus®, a multi-dose dry powder inhaler (MDDPI).
1867319|NCT01079143|Drug|Certican®|Certican® was supplied to the participating centers by Novartis for the whole duration of the study in the form of tablets containing 0.75, 0.5 and 0.25 mg and packaged in blister packs.
1867320|NCT01079143|Drug|Neoral|Neoral® was also supplied to participating centers for the entire duration of the study in the form of soft capsules of 10 mg, 25 mg, 50 mg and 100 mg, and packaged in blister packs.
1867321|NCT01079143|Drug|Myfortic|"Myfortic ® was supplied to the participating centers for the duration of the study in the form of 180 and 360 mg gastro-resistant, film-coated tablets. Myfortic® treatment was provided to patients preoperatively or within 24 hours post-transplantation according to the practices of the center. The starting dose was generally 1,440 mg/day, in 2 daily oral fractions, administered at 12 hour intervals up to randomization. Depending on the practices of the center and for the first 6 weeks post-transplantation, a maximum daily dose of 2160 mg of Myfortic® could be administered. In the Neoral® group, the daily dose of 1440 mg was maintained throughout the study.
In the Certican® group, the dose was halved (i.e. 720 mg/day) on introducing Certican® and maintained at 720 mg/day until the end of the study.
An increase in the daily dose of Myfortic® (in the Certican® group) was not authorized unless this was a temporary increase that did not exceed a period of 14 consecutive days."
1867322|NCT01079143|Drug|Simulect®|The administration of Simulect® was part of the standard immunosuppressant therapy. This induction therapy was provided to patients in the form of commercial ampoules each containing 20 mg. Simulect® was administered to each patient at the dose of 20 mg on D0 and D4 post-transplantation.
1867323|NCT01079143|Drug|Corticosteroids|An intravenous steroid treatment could be administered peri or intraoperatively according to local practice at each center. Oral steroid treatment was quickly introduced (in the week following transplantation) at a daily dose of 20 mg and was then reduced and continued throughout the study at a minimum dose of 5 mg/day.
1867324|NCT01079169|Dietary Supplement|Cranberry capsules|Cranberry capsules, 550mg, or placebo capsules, two capsules three times daily during in-patient rehabilitation
1867325|NCT01079208|Other|test starter infant formula|infants are fed for 6 months with this starter formula
1867326|NCT01079208|Other|test starter infant formula with synbiotics|infant are fed for 6 months with this formula
1867327|NCT01079208|Other|control standard formula|infant are fed 6 months with this formula
1867328|NCT01079221|Behavioral|High intensity knee-extensor training|High intensity aerobic knee-extensor exercise training, 4x 3 minutes interval training at < 90 % of peak power, 3 days/week for 6 weeks
1867329|NCT01079234|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily
1867330|NCT01079234|Drug|insulin glargine|Insulin glargine injected subcutaneously (under the skin) once daily
1867331|NCT01079234|Drug|insulin aspart|At least three daily doses at meal-time
1867332|NCT01079247|Other|Restrictive transfusion threshold|maintain hemoglobin at 7-8 g/dL
1867333|NCT01079247|Other|Liberal transfusion threshold|Maintain hemoglobin at 10-11 g/dL
1867334|NCT01079260|Dietary Supplement|Standard ONS|Standard ONS
1867335|NCT01079260|Dietary Supplement|High Energy, low volume ONS|High energy, low volume ONS
1867336|NCT01079273|Biological|egg-derived A/H1N1 pandemic influenza vaccine|One 0.50 mL IM dose injection (7.5 µg of vaccine + 9.75 mg MF59)
1867337|NCT01079286|Drug|Nelfinavir and temsirolimus|Nelfinavir tablets of 250mg given twice daily in an escalating dosis schedule, Temsirolimus i.v. given weekly in an escalating dosis schedule
1867338|NCT01079299|Device|Intermittent, gradient, pneumatic compression device|lymphedema pump provides external compression in a segmental,gradient fashion
1867339|NCT01079312|Device|infusion pump|anaesthesiologist´s managed infusion of propofol 10 mg/ml at rate of 10-60ml/h during ERCP targeting to moderate sedation level
1867340|NCT01079312|Device|infusion pump for patient-controlled sedation|self-administration of propofol and remifentanil mixture with zero lockout time and without dose limit and background infusion via Arcomed,Syramed AG,Switzerland self-administration pump.
1867341|NCT01079312|Drug|propofol|Propofol 10 mg/ml solution is a short-acting, intravenously administered hypnotic agent.In propofol infusion group moderate sedation was initiated with propofol 40 mg bolus,thereafter propofol infusion was started at rate of 0.5 mg/kg/h.If the performance of ERCP become difficult infusion rate was increased gradually ad maximum rate of 9 mg/kg/h.Additional propofol boluses of 20-40 mg were available in both groups due to an anaesthesiollogist´s ´desigion.In patient-controlled sedation group propofol was used for preparation of sedative mixture.
1867652|NCT01082198|Biological|dendritic cell-idiotype-keyhole limpet hemocyanin vaccine|
1867653|NCT01082198|Other|flow cytometry|
1867342|NCT01079312|Drug|fentanyl|Fentanyl citrate 50 mcg/ml,solution for injection,is a narcotic analgesic.In propofol infusion group 0.05 mg of fentanyl was administered intravenously before initiation of sedation. Additional 0.05 mg boluses of fentanyl were given if nociceptive stimulus was anticipated.
1867343|NCT01079312|Drug|sedative mixture|Sedative mixture was prepared by adding 5 ml of remifentanil hydrochlorid solution (50 mcg/ml)to 20 ml of propofol (10 mg/ml)
1867344|NCT01079312|Drug|remifentanil hydrochlorid|Solution of remifentanil hydrochlorid (50 mcg/ml) was used for preparation of sedative mixture(see sedative mixture for details)
1867345|NCT01079325|Drug|SB-509|SB-509 60 mg, 3 treatments, and 5 months treatment period
1867346|NCT01079325|Other|Saline|
1867347|NCT01079338|Other|caffeine|
1867348|NCT01079351|Drug|Intravenous Carbamazepine|10 mg/mL of intravenous Carbamazepine (CBZ) dissolved in 250 mg/mL of Captisol® (cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by intravenous infusion every 6 hours.
1867349|NCT01079364|Drug|Insulin glulisine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
1867350|NCT01079364|Drug|Insulin glargine|Pharmaceutical form: boxes of 5 SoloStar® pens Route of administration: injection Dose regimen: once a day
1867351|NCT01079364|Drug|Premixed insulin (Insulin Aspart 30/70 )|Pharmaceutical form:boxes of 5 FlexPens Route of administration: Injection Dose regimen: twice daily
1867352|NCT01079390|Device|acupuncture|patient will receive high dose, low dose or sham acupuncture treatment.
1867353|NCT01079416|Device|Capsule endoscopy, Esophagogastroduodenoscopy|
1867354|NCT01079429|Genetic|Genetic study of DNA copies|Gene expression profiling, DNA copy number variation
1867355|NCT01079442|Other|Postoperative coffee|"schedule for coffee administration for the present trial was chosen as follows (starting 6 hours postoperatively):
08:00 100mL beverage
12:00 100mL beverage
16:00 100mL beverage"
1867356|NCT01079442|Other|water|"The control drink consists of 100 ml warm water which is administered according a same fixed schedule as Group A starting 6 hours postoperatively:
08:00 100mL beverage
12:00 100mL beverage
16:00 100mL beverage"
1867357|NCT01079455|Drug|Corticosterone|Hyaluronic acid 40 mg / 2 ml Corticosteroids 80 mg / 2 ml Bupivacaine 0.125% / 2 ml
1867358|NCT01079481|Drug|taxol plus everolimus|taxol 175mg/m2 every 3 weeks plus everolimus every day. The dose of everolimus will be started from 2.5mg per day, and increasing to 5mg per day and to 10mg per day.
1867359|NCT01079494|Other|pharmaceutical care services|Patients treatment related problems and therapeutic needs or complains identified by clinical pharmacist and managed collaboratively by both pharmacist and the physician.
1867360|NCT01079520|Procedure|Endobronchial ultrasound (EBUS)|Minimally invasive technique to stage lung cancers
1867361|NCT01079520|Procedure|Mediastinoscopy|Traditional surgical method to stage lung cancers
1867362|NCT01079533|Behavioral|Stepped CRCS Interventions|"In Step 1, we will evaluate a theory-based minimal cue delivered by a letter, telephone call, or automated telephone call. Persons who do not complete CRCS in Step 1 will be randomized to Step 2 using principles of Motivation Interviewing. Step 2 also will determine whether an automated approach, telephone-linked communication (TLC), is as effective as a telephone counselor in promoting initiation of CRCS. Steps 1 and 2 together will address the important issue of the dose needed to encourage completion of CRCS."
1867363|NCT01079533|Behavioral|Control|A survey-only control arm will be compared to the experimental arm to determine whether the 3 different delivery channels are equally efficacious and cost-effective.
1867364|NCT01079559|Device|Simplex™ P with Tobramycin|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
1867365|NCT01079559|Device|Simplex™ P|All patients will receive preoperative antibiotics administered within the hour prior to surgery.All patients will undergo a cemented total knee replacement (both femoral and tibial components) with the type of implant left to the discretion of the surgeon. The patella may or may not be resurfaced depending on indication and preference. All patients will receive one of the two study cements (Simplex™ P with Tobramycin or Simplex™ P) in a blinded fashion; all cement vials will be similar in size and shape and the cement will be similar in odour, color and texture. No additional antibiotics will be added to the cement. Surgeons can use their preferred cement preparation technique (i.e. manual or vacuum mixing). The use of a suction drain will depend on surgical indication and preference.
1867366|NCT01079572|Other|in-person|Follow-up appointments will be completed in-person as per usual
1867367|NCT01079572|Other|web-based|Patients who are at least 2 years following knee or hip replacement will complete a questionnaire online and routine x-rays at a PACS enabled imaging center. The patient's surgeon will receive an email from the database summarizing the patient's responses to key questions and will review the x-rays. The surgeon will determine whether the patient needs to be seen in-person.
1867368|NCT01079585|Dietary Supplement|Nutrigal Okara - 100|
1867369|NCT01079598|Device|RF Ablation (ClosureRFS Stylet)|Bipolar energy radiofrequency ablation with RFS stylet
1867370|NCT01079624|Other|Glucose-insulinotropic peptide, Glucagon-like peptide-1|GIP 2 and 5 pmol/kg min GLP-1 0.7 pmol/kg min
1867371|NCT01079637|Procedure|Surgery with Midfoot Fusion Bolt|Surgery with Midfoot Fusion Bolt
1867372|NCT01079637|Procedure|Cast treatment|Cast treatment
1867373|NCT01079663|Drug|Chlorhexidine 2.5 mg|
1867374|NCT01079663|Drug|Placebo chip|
1867375|NCT01079676|Drug|Filgrastim (Eurofarma)|Filgrastim will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
1867376|NCT01079676|Drug|Filgrastim (Granulokine, Amgen)|Granulokine will be given at the daily dose of 5 µg/kg body weight, subcutaneously. The weight considered will be the actual weight, for patients weighing up to 120 kg.
1960001|NCT03311906|Drug|0.8% Hyaluronic Acid|Application of 0.8% hyaluronic acid after scaling and root planing
1867380|NCT01079715|Drug|Propranolol|"Dosage of 0.5mg/Kg oral, every 6 hours. The study will be discontinued immediately in the presence of serious adverse effects attributable to the pharmacological actions of propranolol (severe hypotension, bradycardia or bronchospasm).
In case such events occur in any of the 3 groups of gestational age, the study could start again with half dose (0.25mg/Kg oral, every 6 hours) after notification to the Ethics Committee.
In case of surgery or induction of anesthesia during the administration of propranolol, the drug should be discontinued at least 24 hours before surgery.
In cases of severe hypotension or bradycardia may be administered one or more of the following drugs:
Atropine.
Isoproterenol hydrochloride (isoprenaline.
Terlipressin.
Glucagon In case of severe bronchospasm may be used salbutamol aerosol or salbutamol + ipratropium bromide. Betamethasone could be used for aerosol or systemic (intravenous or intramuscular)."
1960002|NCT03311906|Procedure|Scaling and Root Planing|Scaling of the teeth using hand and ultrasonic scalers followed by planing of the root with curettes
1867382|NCT01079754|Drug|Spinal morphine 0.05 mg|Patient received spinal morphine 0.05 mg
1867383|NCT01079754|Drug|Spinal morphine 0.1 mg|Patient received spinal morphine 0.1 mg
1867384|NCT01079767|Drug|temsirolimus|
1867385|NCT01079780|Biological|cetuximab|Given IV
1867386|NCT01079780|Biological|ramucirumab|Given IV
1867387|NCT01079780|Drug|irinotecan hydrochloride|Given IV
1867388|NCT01079793|Drug|ixabepilone|
1867389|NCT01079793|Procedure|adjuvant therapy|
1867390|NCT01079793|Radiation|intensity-modulated radiation therapy|
1867393|NCT01079819|Drug|BMS-708163|Capsule, Oral, 50 mg, once daily, 1 Day
1867394|NCT01079819|Drug|BMS-708163|Capsule, Oral, 125 mg, once daily, 14 Days
1867395|NCT01079819|Drug|Placebo|Capsule, Oral, 0 mg, One daily, 1 Day
1867396|NCT01079819|Drug|Placebo|Capsule, Oral, 0 mg, One daily, 14 Day
1867397|NCT01079832|Radiation|stereotactic radiosurgery|Radiation will be delivered in 3 fractions. The dose level will range between 500 to 800cGy per fraction at the discretion of the treating radiation oncologist
1867398|NCT01079832|Procedure|quality-of-life assessment|Ancillary studies
1867399|NCT01079845|Behavioral|Nutrition Education, Dietary Counseling, and Cooking|Monthly clinic visits with a dietitian, Monthly telephone calls with a dietitian, Three cooking workshops with a chef
1867400|NCT01079858|Other|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
1867401|NCT01079871|Other|FID 114657 (ORB Preserved Ocular Emulsion)|Patients will dose as needed throughout the day (PRN) for 4 weeks.
1867402|NCT01079884|Drug|esomeprazole 40 mg|40 mg daily for 4 weeks
1867403|NCT01079897|Device|Atopiclair|topical applied cream, twice daily
1867404|NCT01079897|Device|EHK02-01|topical applied cream containing 7% ectoine
1867405|NCT01079910|Drug|isopropylmethylphenol and Fluoride|0.1% isopropylmethylphenol and 1150ppm fluoride
1867406|NCT01079910|Drug|Fluoride and Silica|NaF/Silica toothpaste containing 1150ppm fluoride
1867407|NCT01079923|Dietary Supplement|Single High Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 150,000 international units orally once (Bio-tech Pharmacal 50,000 IU capsule, Fayetteville, AR).
1867408|NCT01079923|Dietary Supplement|Daily Dose Cholecalciferol|Age 18 to 40 years, non-pregnant, non-lactating, female subjects will receive cholecalciferol 5,000 IU capsule, Fayetteville, AR).
1867409|NCT01079936|Drug|Lenalidomide|Beginning dose level 25 mg by mouth (PO) on Days -8 to -2
1867410|NCT01079936|Drug|Melphalan|Dose level 100 mg/m2 by vein (IV) Days -3 and -2 over 30 minutes infusion
1867411|NCT01079936|Procedure|Stem Cell Infusion|Stem cell infusion on Day 0.
1867412|NCT01079949|Drug|r-hLH + r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from stimulation Day 1(S1) at a starting dose of 300-450 International Unit (IU) and then dose adjusted depending on the ovarian response till recombinant human choriogonadotropin (r-hCG) administration day. Recombinant human luteinizing hormone (r-hLH, Luveris®, Lutropin alfa) injection will be administered subcutaneously once daily at a constant dose of 150 IU with flexible start, depending on the follicular growth (when the lead follicle is greater than 14 mm in size), along with r-hFSH treatment as a separate injection till r-hCG administration day.
1867413|NCT01079949|Drug|r-hFSH|Recombinant human follicle stimulating hormone (r-hFSH) injection will be administered subcutaneously once daily from S1 at a starting dose of 300-450 IU and then dose adjusted depending on the ovarian response till r-hCG administration day.
1867414|NCT01079949|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered as a single dose of 250-500 microgram (mcg) subcutaneously in the same day after the last dose of the GnRH antagonist.
1867415|NCT01079949|Drug|GnRH antagonist|The GnRH antagonist will be administered at a starting at a dose of 0.25 milligram (mg) subcutaneously daily in the morning when the ultrasound discovers a follicle of greater than or equal to (>=) 14 mm, and maintained until at least one follicle of >=18 mm and two additional follicles of >=16 mm with appropriate plasma estradiol levels for the number and size of the existing follicles.
1867416|NCT01079962|Drug|Bisoprolol|Bisoprolol tablet will be administered orally at a dose of 5 milligram (mg) once daily in the morning for 12 weeks.
1867417|NCT01079962|Drug|Atenolol|Atenolol tablet will be administered orally at a dose of 50 mg once daily in the morning for 12 weeks.
1867654|NCT01082198|Procedure|adjuvant therapy|
1867418|NCT01079988|Drug|Cyclosporins|Starting dose 4.0 - 5.1 mg/kg/day until clinical improvement. Upon clinical improvement, cyclosporin dose to be tapered by 50% every two weeks.
1867419|NCT01079988|Drug|Retinoids|Starting dose 25 - 50 mg/day until clinical improvement. Upon clinical improvement, retinoid dose to be reduced by 50%. Thereafter, treatment to be continued for 8 weeks and then stopped.
1867420|NCT01079988|Drug|Systemic corticosteroids|Starting dose 0.25 - 0.5 mg/kg/day until clinical improvement. Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, corticosteroids to be weaned by 50% every 2 weeks.
1867421|NCT01079988|Drug|Methotrexate|Starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, methotrexate dose to be reduced by 25% every two weeks.
1867422|NCT01079988|Drug|Systemic corticosteroids/methotrexate|Upon clinical improvement, corticosteroid dose to be reduced by 50%. Thereafter, to be weaned by 50% every 2 weeks. Methotrexate starting dose 20 - 25 mg per week until clinical improvement. Upon clinical improvement, dose to be reduced by 25%. Thereafter, to be reduced by 25% every two weeks.
1867423|NCT01080027|Drug|Rebif® New Formulation|The recommended dose of Rebif® is 22 or 44 μg administered three times per week by subcutaneous injection.
1867424|NCT01080066|Other|No Intervention|Subjects administered with Cetuximab, once weekly by intravenous infusion at a first dose of 400 milligram per square meter (mg/m^2) body surface area for 120 minutes infusion period and subsequently at a dose of 250 mg/m^2 for 60 minutes infusion period, will be observed. The maximum infusion rate must not exceed 10 milligram per minute (mg/min).
1867425|NCT01080079|Drug|Terbinafine Hydrochloride|4% w/w Terbinafine Hydrochloride Gel
1867426|NCT01080079|Other|Purified Water|Purified Water
1867427|NCT01080092|Behavioral|breathing technique|breathing technique as a stress management technique, reinforced by biofeedback
1867428|NCT01080092|Behavioral|behavioral strategies|the control group reads a paper on the properties and components of tobacco and on behavioural strategies to cope with craving
1867429|NCT01080105|Behavioral|AIM Web based intervention + surveillance|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach. Surveillance will consist of monthly screening of depression symptoms and outreach from the coach should there be an increase in symptoms.
1867430|NCT01080105|Behavioral|AIM web based intervention|The web based intervention will include 12 weeks of Internet-based cognitive behavioral therapy combined with brief telephone and email support from a coach.
1867431|NCT01080105|Behavioral|Educational website|Participants will receive access to a static educational website for 12 weeks.
1867432|NCT01080118|Device|Airtraq|Subjects were taught with the Airtraq video laryngoscope
1867433|NCT01080118|Other|Control group, taught with a standard Macintosh laryngoscope|Subjects were taught how to use the Mackintosh blade first
1867434|NCT01080131|Drug|Canakinumab 150 mg|Canakinumab 150 mg was supplied in 6 mL glass vials each containing nominally 150 mg canakinumab (plus 20% overfill).
1867435|NCT01080131|Drug|Triamcinolone acetonide 40 mg|Triamcinolone acetonide 40 mg was supplied as a suspension.
1867436|NCT01080131|Drug|Placebo to canakinumab|Placebo to canakinumab was supplied in 6 mL glass vials containing placebo powder as a lyophilized cake.
1867437|NCT01080131|Drug|Placebo to triamcinolone acetonide|Placebo triamcinolone acetonide was supplied as a lipid emulsion similar in appearance to triamcinolone acetonide.
1867438|NCT01080144|Other|Critical flicker frequency procedure|After TIPS, patients will be followed during one year and the psychometric test and Critical flicker frequency procedure will be performed every 3 months
1867439|NCT01080157|Device|SCOUT DS measurement|Non-invasive 3-5 volar forearm scan
1867440|NCT01080183|Other|Patient feedback form|patients receive a report that feeds back their patient reported measures to them prior to their clinical visit
1867442|NCT01080209|Drug|Brimo PS DDS®|Patients who received Brimo PS DDS® intravitreal implant in a previous study.
1867443|NCT01080209|Other|Sham|Patients who recieved sham in a previous study.
1867444|NCT01080222|Drug|telaprevir|tablet, 1125-mg, twice daily
1867445|NCT01080222|Drug|VX-222|capsule, 100-mg, twice daily
1867446|NCT01080222|Drug|ribavirin|tablet, 1000-mg for subjects weighing <75-kg or 1200-mg for subjects weighing ≥75-kg, twice daily
1867447|NCT01080222|Biological|peginterferon-alfa-2a|subcutaneous injection, 180-mcg, once weekly
1867448|NCT01080222|Drug|VX-222|capsule, 400-mg, twice daily
1867449|NCT01080235|Other|ABIM Care of Vulnerable Elderly Practice Improvement Module|The ABIM CoVE PIM is a practice-performance self-evaluation instrument. It is a web-based tool based on nationally recognized guidelines that uses chart abstraction, patient surveys, and a practice system survey in order to generate a performance report focused on a key aspects of care for vulnerable elderly.
1867450|NCT01080235|Other|Geriatric and Quality Improvement toolkit|A resource toolkit about geriatrics and quality improvement was given to both study arms.
1867451|NCT01080248|Drug|Gemcitabine|
1867452|NCT01080248|Drug|Pazopanib|
1867453|NCT01080261|Device|PROMUS Element|PROMUS Element Everolimus-Eluting Coronary Stent System
1867454|NCT01080300|Drug|Gabapentin Extended Release|Gabapentin ER 1800mg daily
1867455|NCT01080300|Drug|Placebo|Sugar pill
1867456|NCT01080313|Other|Therapy for head and neck cancer|radiotherapy and/or drug therapy including chemotherapy, biologic therapy and targeted therapy
1867457|NCT01080326|Device|Endoscopic Translumenal Omental Patch|The endoscope will be gently advanced through the ulcer. Irrigation with saline will proceed. Then a viable mobile piece of omentum will be identified and pulled into the ulcer. After the omentum is located in the stomach, clips will be used to fix it in place.
1867458|NCT01080352|Drug|Ascorbic Acid (Vitamin C)|60grams of ascorbate given intravenous infusion in 1000ml sterile water.
1867459|NCT01080365|Drug|SKI-606 (Bosutinib)|500 mg commercial formulation film coated tablet, administered once daily
1867460|NCT01080365|Drug|SKI-606 (Bosutinib)|500 mg (5 ×100 mg) phase 3 formulation film coated tablets, administered orally once daily
1867694|NCT01082523|Other|Text message reminders|Subjects in this arm will receive twice daily automated text messages reminding them to apply their medications.
1867461|NCT01080378|Procedure|Dietary and Exercise Intervention|Participants will be enrolled into a 16 weeks weight loss programme that consists of (a) dietary interventions and (b) structured exercise sessions and (c) physical activity to achieve 7 - 10% decrease (more than 8 kg) in initial body weight in 16 weeks. They will be subjected to a caloric deficit of 40% of the subject's energy expenditure or 1000kcal, which ever it is higher. (allowance given for dietary control and physical activity).
1867462|NCT01080391|Drug|Dexamethasone|40 mg PO or IV on Days 1, 8, 15, 22
1867463|NCT01080391|Drug|Lenalidomide|25 mg PO on Days 1-21
1867464|NCT01080391|Drug|Carfilzomib|20 mg/m2, 27 mg/m2
1867465|NCT01080404|Procedure|Bariatric surgery|A standardized laparoscopic gastric bypass using Roux-en-Y technique
1867466|NCT01080404|Device|Continuous positive airway pressure|The patients are given standardized CPAP treatment according to current clinical guidelines.
1867467|NCT01080417|Drug|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
1867468|NCT01080430|Other|rehabilitation maneuver|rotation in the direction of the weak vestibular response, every 3-7 days over a period of a month. Each rotation lasts about 2 minutes and a total of 3-7 rotations are used per session.
1867469|NCT01080443|Drug|Mycophenolate Mofetil Capsule 250 mg|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
1867470|NCT01080456|Drug|Tacrolimus 1 mg capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
1867471|NCT01080469|Drug|Tacrolimus 1 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
1867472|NCT01080482|Drug|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
1867473|NCT01080495|Procedure|TEE (transesophageal echocardiography)|a TEE is performed in all study objects and all parameters (radial strain, fractional shortening and fractional area change) are analysed
1867474|NCT01080508|Other|tracheal ventilation with regular tube|Description of the pressure waveforms during tracheal ventilation
1867475|NCT01080508|Other|ventilation after intubation with special tube|Description of the pressure waveforms during esophageal ventilation
1867476|NCT01080521|Procedure|Cognitive Assessment|Ancillary studies
1867477|NCT01080521|Other|Quality-of-Life Assessment|Ancillary studies
1867478|NCT01080534|Drug|Tacrolimus 5 mg Capsule|Subjects will be administered either Test Product or Reference Product with 240 mL of water according to randomization schedule
1867479|NCT01080547|Procedure|Laparoscopic Surgery for Colorectal Cancer|Laparoscopic surgery for colorectal cancer using STORZ laparoscope
1867480|NCT01080547|Drug|XELOX Chemotherapy|XELOX chemotherapy
1867481|NCT01080547|Drug|mFolfox6 chemotherapy|Conventional (mFolfox6) chemotherapy
1867482|NCT01080547|Other|Fast Track Perioperative Treatment|Fast track treatment during perioperation period
1867483|NCT01080547|Other|Conventional Perioperative Treatment|Conventional treatment during perioperation period
1867484|NCT01080547|Procedure|Open Surgery for Colorectal Cancer|Open surgery for colorectal cancer using conventional methods
1867485|NCT01080560|Drug|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
1867486|NCT01080586|Drug|Cyclosporine Capsules USP (Modified) 100 mg|Subjects will be administered either Test Product or Reference Product with 240ml of water according to randomization schedule
1867487|NCT01080599|Procedure|obturator nerve block|
1867488|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 400 to 500 calorie meal
1867489|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following a 600 to 750 calorie meal
1867490|NCT01080612|Drug|330 mg pregabalin controlled release|A single dose of 330 mg controlled release tablet will be administered following an 800 to 1000 calorie meal
1867491|NCT01080612|Drug|300 mg pregabalin immediate release|A single dose of 300 mg immediate release capsule will be administered in the fasted state
1867492|NCT01080625|Drug|phenylephrine|100 mcg of phenylephrine (volume 10 ml) iv at the time of reperfusion
1867493|NCT01080625|Drug|epinephrine|10mcg of epinephrine (volume 10 ml) is administered iv at the time of reperfusion
1867494|NCT01080625|Drug|placebo control|10ml of normal saline is administered at the time of reperfusion
1867495|NCT01080638|Drug|glycoprotein IIb/IIIa inhibitor (abciximab)|patients intracoronary bolus only group and intravenous bolus and 12-hours continuous infusion group bolus:0.25mg/kg body weight,continus 12hrs-0.125ug/kg per minute(maximum: 10ug/min)
1867496|NCT01080651|Drug|Voriconazole|Day1: voriconazole 200 mg x 2, oral administration, Day2-7: rifampin 600 mg, once a day oral administration, Day8: voriconazole 200 mg x 2 + rifampin 600 mg, oral co-administration
1867497|NCT01080664|Drug|AS703569|"Dose Escalation
Regimen 1 - 3-47 mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:
Number of cycles: until progression or unacceptable toxicity develops.
Cohort Expansion
Regimen 1 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2,3 and 8, 9, 10 of a 21 day cycle:
Number of cycles: until progression or unacceptable toxicity develops"
1867498|NCT01080664|Drug|AS703569|"Dose Escalation Regimen 2 - 3-47 mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops.
Cohort Expansion Regimen 2 - Maximum tolerated dose from dose-escalation part or a lower dose in mg/m2/day, orally once daily on days 1, 2, 3, 4, 5, 6 of a 21 day cycle Number of cycles: until progression or unacceptable toxicity develops."
1867499|NCT01080677|Drug|caffeine/propranolol combination tablet|caffeine/propranolol combination tablet administered orally once daily
1867500|NCT01080677|Drug|placebo|placebo to match caffeine/propranolol combination tablet administered orally once daily
1867501|NCT01080690|Procedure|EGD|In this arm EGD will be performed before EUS.
1867502|NCT01080690|Procedure|EUS|In this arm EUS will be performed before EGD.
1867695|NCT01082549|Drug|gemcitabine/carboplatin|i.v.
1867503|NCT01080703|Other|Exercise|Lower extremity resistance exercises and aerobic exercises 3 times a week in 10 week pulmonary rehabilitation program prior to lung transplant.
1867506|NCT01080729|Drug|Recombinant-follicle stimulating hormone (r-FSH)|"The dosage and administration of r-FSH will be in accordance with the PFS and current clinical practice in the centers (300 IU/0.5 ml [22 micrograms/0.5 ml]; 450 IU/0.75 ml [33 micrograms/0.75 ml]; or 900 IU/1.5 ml [66 micrograms/1.5 ml].
The dosage and administration of recombinant-hCG (r-hCG; 250 micrograms/0.5 ml), injectable solution in a pre-filled syringe will also be in accordance with the PFS and current clinical practice in the centers (only if the doctor decides to start treatment with r-hCG)."
1867507|NCT01080742|Drug|Lodoz (Combination of bisoprolol and hydrochlorothiazide)|The investigator will decide in advance the best therapeutic strategy for each subject according to current practice, regardless of the potential participation of this subject in the study.
1867508|NCT01080768|Drug|Aliskiren/amlodipine|Aliskiren/amlodipine 150/5 mg/day
1867509|NCT01080768|Drug|Amlodipine|Amlodipine 5 mg/day.
1867510|NCT01080768|Drug|Placebo to Aliskiren/amlodipine|Placebo to Aliskiren/amlodipine 150/10 mg/day
1867511|NCT01080768|Drug|Placebo to Amlodipine|Placebo to Amlodipine 5 mg/day
1867512|NCT01080794|Device|Repetitive transcranial magnetic stimulation (rTMS)|"DLPFC Active rTMS: Each treatment will consist of 2000 stimuli (50 X 4-second trains of 40 stimuli at 10 Hz, administered every 30 seconds for 25 minutes). Stimulus intensity for the first and second trains will be 80 and 90 percent of motor evoked potential (MEP), respectively. If no adverse effects are observed following each of the first two trains, then the subsequent trains will be given at MEP threshold.
M1 Active rTMS: Stimulation will be applied one side at a time, to the motor cortex site at 90 percent of each subject's motor threshold intensity, and at a frequency of 10 Hz with 1000 stimuli per side (25 X 8-second trains of 40 stimuli).
Sham rTMS: Patients from all four centers randomized to receive sham treatment will undergo the same procedures used in patients receiving active rTMS."
1867513|NCT01080807|Drug|Armodafinil|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
1867514|NCT01080807|Drug|Matching Placebo|At the baseline visit, patients who continued to meet eligibility criteria were randomly assigned (1:1) to receive either 150 mg of armodafinil or matching placebo treatment only on nights worked for 6 weeks. Study drug was taken once nightly, 30 to 60 minutes prior to the start of the night shift, on nights worked. Armodafinil treatment was titrated as follows (only on nights worked): the first dose was 50 mg (1 tablet), the second and third doses were 100 mg (2 tablets), and the fourth and subsequent doses were 150 mg (3 tablets). Placebo tablets matching armodafinil tablets were administered on the same schedule.
1867515|NCT01080820|Drug|CMX157|One single oral dose of CMX157 will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the CMX157 dose.
1867516|NCT01080820|Drug|Placebo|One single oral dose of placebo will be administered and the option of receiving a single dose of 300mg Viread will be offered 4-8 weeks after the placebo dose.
1867517|NCT01080820|Drug|Viread|One single oral dose of 300mg Viread.
1867518|NCT01080833|Device|ERCP mechanical simulator practice|Trainees will receive ERCP mechanical simulator practice in addition to routine ERCP training
1867519|NCT01080846|Drug|Misoprostol|600 mcg of sublingual misoprostol
1867520|NCT01080859|Device|OCT|Optical coherence tomography
1867521|NCT01080859|Device|OCT|Optical coherence tomography
1867522|NCT01080872|Device|CFR|CFR will be assessed using transthoracic echocardiography with adenosine infusion.
1867523|NCT01080885|Behavioral|Busy Bodies/Better Bites|This intervention will include brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the healthy eating and physical activity home environmental strategies.
1867524|NCT01080885|Behavioral|Healthy Spots/Safe Tots|This intervention will include the same brief counseling from the pediatrician paired with a 6 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
1867525|NCT01080898|Other|tests|color photographs, FLUORESCEIN angiography and OCT
1867526|NCT01080911|Drug|Morphine|spinal morphine 0.05 mg
1867527|NCT01080911|Drug|Morphine|spinal morphine 0.1 mg plus 0.5% heavy marcaine 3.5 ml
1867528|NCT01080924|Device|Low frequency ultrasound spectroscopy after broncholysis|Low frequency ultrasound spectroscopy is a novel non-invasive approach to real-time diagnostics of the lungs. Low frequency ultrasound at 10 to 1000 kHz permits monitoring of the air and water contents of the human thorax.
1867529|NCT01074697|Drug|Fosaprepitant dimeglumine|Addition of fosaprepitant dimeglumine 150 mg IV single dose weekly (before chemotherapy) to dexamethasone and palonosetron.
1867530|NCT01074697|Drug|Placebo|Saline water
1867531|NCT01074710|Drug|[2-13C] uracil|po, in the form of semi-solid meal, granules, once a period
1867532|NCT01074710|Drug|[2-13C] uracil, placebo|po, in the form of semi-solid meal, granules, once a period
1867533|NCT01074723|Dietary Supplement|b-cryptoxanthin and phytosterols|Fruit juices containing b-cryptoxanthin (ca. 1 mg), phytosterols (ca 1.7g) or both will be consumed for 4 weeks with a 4-week washout in between.
1867534|NCT01074749|Device|Accent Pacemaker|Implantation of pacemaker
1867571|NCT01080963|Drug|Daptomycin|one infusion of 350 mg intraoperatively after disconnection from the heart-lung machine as an add-on to standard antibiotic prophylaxis
1867572|NCT01080963|Drug|Cefuroxime|1500 mg intravenous 30min preoperatively during anesthesia and 1500 mg intravenous intraoperatively after disconnection from the heart-lung machine
1867696|NCT01082549|Drug|gemcitabine/carboplatin plus Iniparib|i.v.
1867737|NCT01082926|Biological|therapeutic allogeneic lymphocytes|Given intratumorally
1867535|NCT01074762|Behavioral|Structured personal care|General practitioners (GPs) were recommended to perform regular follow up every three months and an annual screening for diabetic complications. The GP was requested to define, together with the patient, the best possible goals for blood glucose concentration, glycated haemoglobin (HbA1c), diastolic blood pressure, and lipids within three predefined categories. At each quarterly consultation, the GP was asked to compare the achievements with the goal and consider changing either goal or treatment accordingly. The doctors received annual descriptive feedback reports on individual patients. The GPs were introduced to possible solutions to therapeutic problems through clinical guidelines supported by an annual half day seminar. Patient leaflets were produced for the doctor to hand out.
1867536|NCT01074775|Biological|Gut infection challenge with M bovis|Oral delivery of 100mg viable M bovis (approximately 10,000,000 viable bacilli) in 5mL 1.5% sodium glutamate solution on three occasions on days 0, 28 and 49
1867537|NCT01074788|Behavioral|mind body therapy|mind-body therapy includes guided imagery, relaxation techniques, mediation and touch therapy.
1867538|NCT01074801|Other|Closed-loop insulin delivery|Basal subcutaneous insulin delivery to be adjusted at 15min cycles according to the computer-based algorithm advice.
1867539|NCT01074801|Other|Standard insulin pump treatment|Subcutaneous insulin delivery to be performed based on subjects' standard treatment
1867541|NCT01074827|Other|Strength training and treadmill training|Eight weeks of intensive strength training or treadmill training
1867542|NCT01074840|Other|Peanut flour|Peanut-allergic subjects will be given peanut flour in increasing amounts.
1867543|NCT01074853|Drug|propranolol|10mg twice daily escalated to 80mg once daily
1867544|NCT01074853|Drug|placebo|Matched placebo
1867545|NCT01074866|Device|Neurally Adjusted Ventilatory Assist|Non invasive ventilation under Neurally adjusted Ventilatory Assist
1867546|NCT01074879|Dietary Supplement|Whey protein|Dietary supplement after training
1867547|NCT01074879|Dietary Supplement|Milk protein|Dietary supplement after training
1867548|NCT01074879|Dietary Supplement|Carbohydrates|Dietary supplement after training
1867549|NCT01074892|Drug|Provera (medroxyprogesterone/progestin)|10 mg tablet, 1 tablet per day taken 10 days per month Duration is 6 months
1867550|NCT01074892|Drug|Provera (medroxyprogesterone)|10 mg per oral tablet. One tablet per day for 6 months
1867551|NCT01074892|Device|Mirena (levonorgestrel)|Inserted in the uterine cavity and kept in situ for 6 months
1867552|NCT01074905|Drug|Artesunate|2 mg/kg/day as single daily dose given for 5 days; maximum dose range is 1.6 to 2.4 mg/kg/day or a total of 8 to 12 mg/kg.
1867553|NCT01074905|Drug|Chloroquine|25 mg base/kg given in divided doses (10,10,5) over 3 days; Absolute range 20-30 mg/kg.
1867554|NCT01074905|Drug|Chloroquine/Primaquine|Chloroquine 3 days and Primaquine 14 days
1867555|NCT01074918|Drug|Potassium, Magnesium, Citrate|Potassium MAgnesium Citrate - 30 mEq potassium, 15 mEq Magnesium, 45 mEq Citrate in a powder mixture twice a day, mixed with a glass of water.
1867556|NCT01074918|Drug|Potassium Chloride|Potassium Chloride
1867557|NCT01074931|Drug|Lopinavir/ritonavir (Kaletra)|"Lopinavir/ritonavir(LPV/r) is an HIV protease inhibitor (PI) that is co-formulated with lopinavir and ritonavir. Lopinavir is an inhibitor of the HIV-1 and HIV-2 proteases. As co-formulated in LPV/r, ritonavir inhibits the CYP3A-mediated metabolism of lopinavir, thereby providing increased plasma levels of lopinavir.
The assignment of the patient to a lopinavir/ritonavir - containing regimen is not decided in advance by this protocol but falls within current practice and the prescription of lopinavir/ritonavir is clearly separated from the decision to include the patient in this study."
1867558|NCT01074944|Drug|Eliglustat tartrate|Oral Capsule in 50 mg or 100 mg dosages
1867562|NCT01074970|Drug|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
1867563|NCT01074970|Drug|Rucaparib|Rucaparib 24mg C1,30mg C2-4, D1,2,3 every 21 days for 4 cycles
1867564|NCT01074970|Drug|Cisplatin|Cisplatin 75 mg/m2 IV infusion over 60 minutes, D1 every 21 days for 4 cycles
1867565|NCT01074996|Drug|S-1|40-60mg bid , days 1-14, every 3 weeks
1867566|NCT01074996|Drug|S-1 plus Leucovorin|S-1 40-60mg bid, days 1-14 , every 3 weeks Leucovorin 25mg bid , days 1-14 , every 3 weeks
1867567|NCT01075022|Drug|Colecalciferol (Vitamin D3) 300.000 UI|Colecalciferol (Vitamin D3) 300.000 UI Capsule, Single Dose
1867568|NCT01075022|Drug|Placebo|Placebo Capsule, Single Dose
1867569|NCT01075048|Drug|Tivantinib (ARQ 197) + cetuximab + irinotecan|"ARQ 197 is supplied as a 120-mg capsule, administered twice daily at the dose determined in the Phase 1 portion of the study. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Cetuximab 500 mg/ m^2 intravenous infusion over 120 minutes at the first cycle, then over 60-minutes at subsequent cycles. Followed 60 minutes later with Irinotecan 180 mg/m^2 intravenous infusion over 30 - 90 minutes. Cetuximab and Irinotecan are administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met."
1867570|NCT01075048|Drug|Placebo + cetuximab + irinotecan|"Placebo to match ARQ 197, administered twice daily. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met.
Cetuximab 500 mg/ m^2 intravenous infusion over 120 minutes, then over 60 minutes at subsequent cycles. Followed 60 minutes later with Irinotecan 180 mg/m^2 intravenous infusion over 30 - 90 minutes. Cetuximab and Irinotecan are administered on Day 1 and Day 15 of each 28 day cycle. Administered until disease progression, unacceptable toxicity or other discontinuation criteria is met."
1867607|NCT01081288|Other|Invitation for breast screening|Invitation for breast screening to women in different age groups
1867573|NCT01080989|Other|diagnosis, treatment and education|"Drug:
anti-intestinal parasitic drugs:
mebendazole 500mg one dose (For Hook worm infections, Ascariasis, Trichuriasis)
albendazole(400 mg bid * 7days) or Ivermectin(200 mcg/kg/day * 2 days) (For Strongyloidiasis).
Behavior:
Education capacity building (for local health personals): promote their ability of diagnosis and education to the community and patients for the associated diseases in this study.
Assist the trained local health personals to educate the patients and the community from the design of teaching materials and the contents."
1867574|NCT01081002|Drug|Lidocaine 10%|3 min before the endoscopy under propofol sedation 4 puffs of lidocaine 10% will be sprayed on the pharynx as a pharyngeal anesthesia
1867575|NCT01081002|Drug|Diluted gentian root solution|As a basis, an infusion of water (45%), ethanol (35%) and gentian root cut will be used. The gentian root infusion is approved as a natural flavor in the food industry.3 min before the endoscopy under propofol sedation 4 puffs of this gentian root infusion will be sprayed on the pharynx as a pharyngeal anesthesia
1867576|NCT01081041|Drug|Cetuximab|Administered intravenously
1867577|NCT01081041|Drug|Cisplatin|Administered intravenously
1867578|NCT01081041|Drug|Carboplatin|Administered intravenously
1867579|NCT01081041|Drug|5-Fluorouracil|Administered intravenously
1867580|NCT01081054|Other|Ambulatory versus hospitalisation|Patients are treated with the same antibiotic agent, the difference between the two arms is endovenous treatment for hospitalized patients for the first days till oral feeding. The ambulatory group starts directly with orally administered antibiotic treatment.
1867581|NCT01081093|Procedure|additional temporary pacewire|Placement of an additional pacing wire on the left side of the heart after aortic valve replacement in patients with hypertrophic cardiomyopathy
1867582|NCT01081106|Procedure|Low-Level Laser Therapy|"A LLLT device at 670 nm will be used for light application using lasers affixed in a rotating helmet apparatus. Treatment will be given twice weekly prior to commencing chemotherapy and will be administered once a week until one week after the last chemotherapy.
administration."
1867583|NCT01081119|Behavioral|Project CHOICE|Voluntary after school program offered 1 day per week for 30 minutes
1867584|NCT01081132|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on weight.
1867585|NCT01081132|Other|Placebo|Matching placebo will be provided as 1,2,3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on weight.
1867586|NCT01081145|Drug|Extended-release Guanfacine Hydrochloride|The test product will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose between 1-7mg/day depending on age and weight.
1867587|NCT01081145|Other|Placebo|Matching placebo will be provided as 1, 2, 3, and 4mg tablets. Subjects will be administered a once-daily dose of placebo between 1-7mg/day depending on age and weight.
1867588|NCT01081158|Drug|Drug: SCH 900518 Biologic: Peginterferon alfa-2b(PegIntron)|"Drug: SCH 900518
Biologic: Peginterferon alfa-2b(PegIntron)
Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days .
Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
1867589|NCT01081158|Drug|Drug: SCH 900518 Biologic: Peginterferon alfa-2b|"Drug: SCH 900518
Biologic: Peginterferon alfa-2b
Period 1: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 7 days
Period 2: Amorphous SCH 900518 800 mg or placebo TID administered as an oral suspension for 14 days in combination with 1.5 µg/kg PegIntron administered subcutaneously weekly."
1867590|NCT01081158|Drug|Drug: SCH 900518 Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518
Drug: Ritonavir (RTV)
Biologic: Peginterferon alfa-2b (PegIntron)
Period 1: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension + ritonavir (200 mg BID) (2-100 mg oral capsules) for 7 days.
Period 2: Amorphous SCH 900518 (400 mg) or placebo BID administered as oral suspension+ ritonavir (200 mg BID) (2-100 mg oral capsules) + PegIntron (1.5 µg/kg QW) for 14 days."
1867591|NCT01081158|Drug|Drug: SCH 900518 Drug: Ritonavir (RTV) Drug: Ritonavir (RTV) Biologic: Peginterferon alfa-2b (PegIntron)|"Drug: SCH 900518
Drug: Ritonavir (RTV)
Biologic: Peginterferon alfa-2b (PegIntron)
Period 1, Amorphous SCH 900518 (400 mg) or placebo BID administered as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) for 7 days.
Period 2, SCH 900518 (400 mg) or placebo BID as an oral suspension + RTV (200 mg BID) oral capsules (2-100 mg capsules) +PegIntron (1.5 µg/kg SC QW) for 14 days."
1867592|NCT01081184|Biological|blood sample|blood sample for determination of seric and lymphocytic NT profile will be added to a standard biological analysis done for pSS follow- up
1867593|NCT01081197|Other|Psychiatric and somatic examinations and ,if clinical indicated, treatment|Patients referred to the clinic will be given optimal treatment for revealed psychiatric and/or somatic disease including conversational therapy, and if indicated therapeutic interventions with respect to any kind of disease.
1867594|NCT01081210|Other|Ultrasound examination|Screening with bedside ultrasound examination
1867596|NCT01081249|Drug|Placebo then intranasal oxytocin|Participant received intranasal placebo spray at first psychotherapy session, and received a single dose of 40 IU intranasal oxytocin at the second session.
1867597|NCT01081249|Drug|Intranasal oxytocin then placebo|Participant received a single dose of 40 IU intranasal oxytocin at the first psychotherapy session, and received a similar dose of intranasal placebo spray at the second session.
1867598|NCT01081262|Biological|Bevacizumab|Given IV
1867599|NCT01081262|Drug|Capecitabine|Given PO
1867600|NCT01081262|Drug|Carboplatin|Given IV
1867601|NCT01081262|Other|Laboratory Biomarker Analysis|Correlative studies
1867602|NCT01081262|Drug|Oxaliplatin|Given IV
1867603|NCT01081262|Drug|Paclitaxel|Given IV
1867604|NCT01081262|Other|Quality-of-Life Assessment|Ancillary studies
1867605|NCT01081275|Behavioral|CI Therapy|CI Therapy will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
1867606|NCT01081275|Behavioral|CAM treatments|CAM treatments will be given for 3.5 hours per day, Monday-Friday, for 2 consecutive weeks.
1867608|NCT01081301|Behavioral|Living with Hope Program|"The LWHP consists of the LWH film featuring caregivers of patients with advanced cancer describing their hope and a hope activity Stories of the Present. Following viewing of the video with trained research assistants (RAs), (without discussion) the RA's will instruct the subjects to take 5 minutes at the end of the day and write about their thoughts, challenges and what gave them hope over a 2 week time period. Subjects can choose to use a journal, a computer or audiotape their journals."
1867609|NCT01081873|Drug|leuprolide (Lucrin/Lucrin-Tri-depot)|Subcutaneous or intramuscular administration for all participants
1867610|NCT01081886|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the total knee replacement, including the skin incision.
1867611|NCT01081886|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
1867612|NCT01081899|Other|The LCP-I Program|The LCP-I Program is a continuous quality Improvement Program of end-of-life care implemented by a Palliative Care Unit (PCU) in a hospital Medical Ward.
1867613|NCT01081912|Drug|Placebo|Capsules, no active substance, shells identical to active comparator capsules
1867614|NCT01081912|Drug|Hydrocodone bitartrate|"dosage form: capsule
Strengths 10mg, 20mg, 30mg, 40mg, 50mg"
1867615|NCT01081938|Drug|INSULIN GLARGINE|"Pharmaceutical form: Lantus® (100 U/ml)
Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device.
Dose regimen: Single daily dose of Insulin Glargine"
1867616|NCT01081938|Drug|INSULIN GLULISINE|"Pharmaceutical form: Apidra® (100 U/ml)
Route of administration: Subcutaneous injection with SoloStar® (3 ml) pen device
Dose regimen:
Arm1: Every 6 hours Arm2: several daily dose according to sliding scale of Insulin Glargine"
1867617|NCT01081951|Drug|olaparib|Oral dose capsule 200mg BID day 1-10 of every 21 day cycle, Oral dose capsule 400mg BID continuously after completion of combination therapy
1867618|NCT01081951|Drug|paclitaxel|175mg/m2 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
1867619|NCT01081951|Drug|carboplatin|AUC6 iv for 6 cycles (18 weeks) day 1 of 21 day cycle
1867620|NCT01081951|Drug|paclitaxel|175mg/m2 iv for up to 6 cycles (18 weeks)
1867621|NCT01081951|Drug|Drug: carboplatin|AUC4 iv for up to 6 cycles (18 weeks)
1867622|NCT01081964|Drug|Zabofloxacin|Zabofloxacin 400mg capsule once daily for 3 days
1867623|NCT01081964|Drug|Levofloxacin 500mg|Levofloxacin 500mg orally for 7 days
1867624|NCT01081964|Drug|Zabofloxacin 400mg|Zabofloxacin 400mg orally for 5 days
1867625|NCT01081977|Procedure|Early Cord Clamping|Early Umbilical Cord Clamping (Clamping of Umbilical Cord within 30 seconds of shoulder delivery of neonate)
1867626|NCT01081977|Procedure|Delayed Cord Clamping|Delayed Umbilical Cord Clamping (Clamping Umbilical Cord after 2 minutes of shoulder delivery of neonate
1867627|NCT01081990|Drug|cyclobenzaprine|Cyclobenzaprine 5 mg TID for 7 days
1867628|NCT01082003|Drug|Trental|Trental (pentoxifylline) 400 milligrams three times a day in combination with vitamin E, 400 international units orally twice daily for six months.
1867629|NCT01082016|Other|Sleep Enhancement Program (SEP)|Sleep promotion in the ICU Multifaceted tool to promote sleep in ICU patients
1867630|NCT01082029|Drug|Lansoprazole|The dosage of Lansoprazole will be administered based on guidelines set out by the prescription drug information outlined in the official Lansoprazole package insert and will remain the same for each patient during the 3 month period and is as follows: a) 1 to 11 years of age, weight less then or equal to 30 kg, 15 mg orally once daily. b) 1 to 11 years of age, weight greater then 30 kg, 30 mg orally once daily. c) 12 years of age and older, 15 mg orally once daily. The doses of Lansoprazole will be prepared in liquid form by the Inpatient Pharmacy at Hamilton Health Sciences.
1867631|NCT01082029|Drug|Placebo|Lactose powder in 8.4% Sodium Bicarbonate (Liquid placebo)
1867632|NCT01082068|Drug|XL147 (SAR245408)|given orally once daily as tablets
1867633|NCT01082068|Drug|XL765 (SAR245409)|given orally twice daily as capsules
1867634|NCT01082068|Drug|letrozole (Femara)|given orally once daily as tablets
1867635|NCT01082081|Drug|Paracetamol 1000 mg|Paracetamol 1000 mg
1867636|NCT01082081|Drug|Paracetamol 500 mg|Paracetamol 500 mg
1867637|NCT01082081|Drug|Placebo|Placebo
1867638|NCT01082094|Biological|ACRX-100|Three cohorts (16 total subjects) will be studied. There will be no concurrent controls. The dose will be escalated by increasing the total amount of ACRX-100 delivered per subject from low dose (n=4 subjects) to middle dose (n=6 subjects) to high dose (n=6 subjects). ACRX-100 will be injected directly into the myocardium as a single dose at multiple sites through a percutaneous, left ventricular approach using a needle injection catheter.
1867639|NCT01082107|Other|Solar disinfection in transparent containers (plastic bottles)|Participants in the study drink solar disinfected (SODIS) water. Solar disinfected water is water (> 3 L) that has been placed in direct sunlight for 6 hours. Participants are expected to drink SODIS treated water for the duration of the study.
1867640|NCT01082120|Drug|AZD1656|Tablets orally, twice daily for 10 days
1867641|NCT01082120|Drug|Pioglitazone|Tablet oral single dose for 10 days
1867642|NCT01082133|Drug|Chemotherapy|Busulfan 0.4-1.0 mg/Kg/dose IV Q 12 hours X4 Doses Fludarabine 35 mg/m2/dose IV once daily X4 Doses Cyclophosphamide 10 mg/Kg/dose IV once daily X4 Doses Anti-thymocyte globulin - Thymoglobulin 2.5 mg/Kg/dose IV daily X4 Doses
1867643|NCT01082133|Biological|Miltenyi CliniMACS|The CliniMACs device (Miltenyi Biotec, Auburn, CA) will be employed for the CD34 selection procedure. It consists of tubing, bags, and a pair of columns, placed at appropriate locations in the Tubing Set to facilitate the cell selection process.
1867644|NCT01082146|Drug|Lurasidone|40 mg suspension, PO, for 7 days
1867645|NCT01082159|Procedure|lumbar decompression|The mild® devices used in this study are specialized surgical instruments intended to be used to perform percutaneous lumbar decompressive procedures for the treatment of various spinal conditions.
1867646|NCT01082172|Device|Implant Thoracic Stent Graft|Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
1867647|NCT01082185|Device|Ovation Abdominal Stent Graft System|Endovascular implant of Abdominal Aortic Aneurysm Stent Graft
1867648|NCT01082198|Biological|HLA-A1-binding MAGE-1/MAGE-3 multipeptide-pulsed autologous dendritic cell vaccine|
1867649|NCT01082198|Biological|HLA-A2-binding TYR/MART-1/gp100 multipeptide-pulsed autologous dendritic cell vaccine|
1867738|NCT01082926|Biological|aldesleukin|Given intratumorally
1867655|NCT01082211|Radiation|3D-Conformal External Beam|Radiation was to be delivered in 2 fractions per day, each of 1.5 Gy, separated by at least six hours, given in 15 consecutive working days to a total of 30 fractions and 45 Gy. Radiation was to be prescribed to the treatment unit isocenter, positioned at the approximate center of the planning target volume.
1867656|NCT01082224|Drug|iodinated contrast dye|iodinated Radiocontrast dye for imaging enhancement
1867657|NCT01082224|Drug|motexafin gadolinium|motexafin gadolinium
1867658|NCT01082224|Other|Eovist-enhanced MRI|A sub-study introduces the Eovist contrast agent for MRI scans at the same time points as the parent policy-assessment trial.
1867659|NCT01082237|Drug|Escitalopram|Start at 5mg per day, after four days increase to 10mg per day for the duration of the study. 20 mg will be administered at week 8 if not significantly better.
1867660|NCT01082250|Drug|Lurasidone HCl|120mg dose. 3-way cross-over for 21 days
1867661|NCT01082263|Drug|Lurasidone HCl|Day1: 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day6: 120 mg lurasidone (three 40 mg tablets) + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup) Day 7-12: 120 mg lurasidone (three 40 mg tablets) 120 mg lurasidone (three 40 mg tablets) on Day 13 + 5 mg midazolam (2.5 mL of the 2 mg/mL syrup)
1867662|NCT01082276|Drug|Lurasidone HCl|40mg, Single-dose of lurasidone 40 mg (one 40 mg tablet) on Day 1. Daily dosing of rifampin 600 mg (two 300 mg capsules) on Days 1-8. On Day 8, subjects will also receive a single-dose of lurasidone 40 mg (one 40 mg tablet).
1867663|NCT01082289|Drug|Lurasidone|
1867664|NCT01082302|Drug|Polyphenon E (Veregen) 15% ointment|3 times daily application on genital and perianal warts over 7 days
1867665|NCT01082302|Other|Green Tea Beverage with defined catechin content|3 times daily oral intake over 7 days
1867666|NCT01082315|Drug|Erbitux (Cetuximab)|In subjects with mCRC, cetuximab will be used in combination with chemotherapy or as a single agent according to the approved national label as in routine clinical practice. Cetuximab 2mg/ml will be administered intravenously via in-line filtration with an infusion pump, gravity drip or a syringe pump. For the initial dose, the recommended infusion period is 120 minutes and for the subsequent weekly doses, the recommended infusion period is 60 minutes.
1867667|NCT01082328|Drug|Kuvan®|Kuvan® (sapropterin dihydrochloride) oral solution 20 milligram per kilogram (mg/kg) will be given once daily for 28 +/- 1 days.
1867668|NCT01082341|Biological|Immunization with P. vivax irradiated sporozoites|"Anopheles albimanus mosquitoes will be infected by artificial membrane feeding using blood from P. vivax infected donors. Once mosquitoes are positive will be irradiated at 15000 cGy and kept in boxes until use.
14 Fy(+) human volunteers in the experimental group will be immunized with 1,000-2,000 P. vivax irrad-spz bites. Seven Fy(+) volunteers in the control group will be exposed to non-infected mosquito bites. Six Fy(-) volunteers will be exposed to infective mosquito bites. For the challenge both the immunized and control groups will be exposed to 3 ± 1 infective mosquito bites. Volunteers will be closely monitored post infection and will be treated with antimalarials."
1867669|NCT01082354|Drug|recombinant somatropin|as per standard practice
1867670|NCT01082367|Drug|TOBI|TOBI (tobramycin inhaled solution)
1867671|NCT01082367|Drug|Placebo|Placebo
1867672|NCT01082380|Drug|PF-02341066|oral suspension, single 250 mg dose of PF 02341066 containing approximately 100 µCi of [14C]PF 02341066
1867673|NCT01082393|Drug|topical tacrolimus treatment|4 applications (day 1,day 3, day 6 and day10)
1867674|NCT01082393|Drug|topical pimecrolimus treatment|4 applications (day 1, day 3, day 6 and day 10)
1867675|NCT01082393|Drug|local mometasone furoate treatment|4 applications (day 1, day 3, day 6 and day 10)
1867676|NCT01082393|Drug|cold cream|4 applications (day 1, day 3, day 6 and day 10)
1867677|NCT01082406|Drug|catridecacog|Single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) administered iv.
1867678|NCT01082406|Drug|recombinant factor XIII|Single dose of 35 IU/kg body weight recombinant factor XIII (Avecia) to be administered iv (into the vein) followed by a single dose of 35 IU/kg body weight recombinant factor XIII (catridecacog) (Novo Nordisk) administered iv.
1867679|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.
For group A the measurement is made by a second and a third investigator during the same examination."
1867680|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.
For all other groups (B, C, D, E) ARFI is measured only once."
1867681|NCT01082419|Device|ARFI measurement|"ARFI values are measured during a standard liver ultrasound examination, with patient lying on his back and performing a light apnea.
For groups F and G : ARFI is measured again after clinical healing."
1867682|NCT01082432|Other|electrically induced muscle activation|30 Hz frequency, 200 µs pulse duration, and 40% duty cycle (4 sec on, 6 sec off)
1867683|NCT01082445|Drug|N-acetylcysteine|600 mg, 1 tablet 3 times a day for 3 months
1867684|NCT01082445|Drug|Placebo|Placebo
1867685|NCT01082458|Drug|remifentanil / lidocaine|"Remifentanil TCI group : target controlled infusion of 2.0ng/ml of remifentanil on end of surgery.
Lidocaine IV group : Intravenous administration of 1.5mg/kg of lidocaine on end of surgery."
1867686|NCT01082471|Drug|Morphine 6-glucuronide|
1867687|NCT01082471|Drug|Morphine|
1867688|NCT01082484|Drug|treprostinil|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
1867689|NCT01082484|Drug|iloprost|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
1867690|NCT01082484|Drug|NaCl 0.9%|Cutaneous iontophoresis at 20 microA/ 100 microA during 20 min
1867691|NCT01082497|Behavioral|Mindfulness training|A course in mindfulness based stress reduction with 8 weekly group meetings and home practice between the meetings. Each meetings last for 90 minutes. Participants get workbook and cds to support home practice.
1867692|NCT01082510|Drug|Bacille Calmette-Guerin|The patients in the BCG maintenance therapy arm will be treated with 3 successive weekly intravesical administrations of BCG at 3, 6, 12 and 18 months after the start of BCG induction therapy. The dosage of BCG used for the BCG maintenance therapy will be the same as that used for BCG induction therapy.
1867693|NCT01082510|Drug|uracil-tegafur|The UFT maintenance therapy arm patients will be treated with the oral administration of 400 mg of UFT everyday for three years after the end of BCG induction therapy.
1867697|NCT01082562|Drug|BMS-844421|"Ready-to-use stock solution for SC and IV, Subcutaneous, 37.5 mg
SAD: Once, 1 Day
MAD: IV loading followed by 4 weekly doses, 29 Days"
1867698|NCT01082562|Drug|0.9% sodium chloride injection solution|"Injection solution, Subcutaneous, 37.5 mg
SAD: Once, 1 Day
MAD: IV loading followed by 4 weekly doses, 29 Days"
1867699|NCT01082575|Device|Oxygen Monitoring|No intervention
1867700|NCT01082588|Drug|Pravastatin|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
1867701|NCT01082588|Drug|Placebo|pravastatin 40mg, or placebo, once a day, shortly after baseline for 12 consecutive weeks
1867702|NCT01082601|Procedure|Pulmonary Vein Isolation (PVI)|Subjects with clinical indication for PVI, either paroxysmal or persistent AF failing medical management with rate or rhythm control medications.
1867703|NCT01082614|Device|Vigileo|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV > 12%.
1867704|NCT01082627|Drug|Somatostatin|250ug/h,Continuous I.V. infusion,maximal 14 days
1867705|NCT01082627|Other|common daily practice|common daily practice
1867706|NCT01082640|Drug|Febuxostat|Febuxostat capsules
1867707|NCT01082640|Drug|Placebo|Febuxostat placebo-matching capsules
1867708|NCT01082653|Biological|autologous bone marrow-derived stem cells|All patients will receive a unique one-time intrathecal infusion of the cell product suspended in infusion medium.
1867709|NCT01082666|Device|Continuous control of cuff pressure|Continuous control of cuff pressure using a pneumatic device (Nosten, Leved, France)
1867710|NCT01082666|Device|Manual control of cuff pressure|Manual control of cuff pressure is a routine practice in ICU patients
1867711|NCT01082679|Drug|Methadone|daily for 12 months
1867712|NCT01082679|Drug|buprenorphine (Suboxone)|daily for 12 months
1867713|NCT01082692|Biological|PENNVAX-B|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
1867714|NCT01082705|Drug|artemether-lumefantrine|administered twice daily for three days as tablets containing 20 mg of artemether plus 120 mg of lumefantrine at a dosage of: 1 tablet for patients weighing 5-14 kg, 2 tablets for patients weighing 15-24 kg, 3 tablets for patients weighing 25-34 kg, 4 tablets for patients weighing 35 kg or more
1867715|NCT01082705|Drug|Dihydroartemisinin-piperaquine|once daily for 3 days as tablets containing 40 mg of dihydroartemisinin and 320 mg of piperaquine at a total dosage of 6.4 mg/kg of dihydroartemisinin and 51.2 mg/kg of piperaquine divided equally between the three days
1867716|NCT01082718|Drug|Mefloquine Artesunate|Mefloquine-artesunate fixed dose combination (Farmanguinhos): Artesuanto 100 mg and Mefloquine 220mg per tablet, dosed once daily for 3 days such that mefloquine dose is approximately 8mg/kg/day.
1867717|NCT01082731|Drug|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
1867718|NCT01082731|Drug|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
1867719|NCT01082744|Drug|Ropivacaine + Sufentanil|Sufentanil at 0.25 µg/ml added to ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
1867720|NCT01082744|Drug|Ropivacaine|Ropivacaine at 2 mg/ml at a perfusion rate of 0.15 ml/kg/h for continuous paravertebral block over 48 hours
1867721|NCT01082770|Device|TEGO|A bung that can be attached to the end of dialysis lines that can be directly attached to the dialysis machine with minimal handling
1867722|NCT01082770|Device|Standard|Patients in this group will have a normal 'bung' placed at the end of their dialysis line, which will need to be removed by nursing staff prior to initiation of dialysis
1867723|NCT01082796|Drug|Glipizide|Each subject received 5 mg glipizide extended release tablet once daily for 7 days.
1867724|NCT01082809|Drug|Sunitinib|Sunitinib 37.5 mg orally once daily continuously, comprising a 4-week cycle
1867725|NCT01082822|Biological|cell sheet pellets and cell sheet fragment|the denuded root surface area was calculated to determine the size of the transplanted cell sheet in the of proportion of the 2cm X 2cm cell sheet to the 1cm X 1cm denuded area
1867726|NCT01082848|Drug|aripiprazole|10 mg QD during 26 weeks
1867727|NCT01082848|Drug|placebo|QD during 26 weeks
1867728|NCT01082861|Biological|Cervarix|Cervarix, HPV vaccin
1867729|NCT01082861|Biological|Engerix-B|Engerix-B, HBV vaccin
1867730|NCT01082874|Drug|Active Clonidine|Pre-op (goal 2-4 hours): 2 x 0.1mg oral tablets and transdermal patch (0.2 mg/day). Patch to be removed 72 hours post-op.
1867731|NCT01082874|Drug|Placebo Clonidine|Pre-op (goal 2-4 hours): 2 oral placebo tablets and transdermal placebo patch. Patch to be removed 72 hours post-op.
1867732|NCT01082874|Drug|Active ASA|Pre-op (goal 2-4 hours): 2 x 100mg oral tablets. Post-op: patients ingest one tablet a day (100 mg ASA) for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
1867733|NCT01082874|Drug|Placebo ASA|Pre-op (goal 2-4 hours): 2 oral placebo tablets. Post-op: patients ingest one placebo tablet a day for 7 days if patient was were taking ASA chronically prior to surgery or for 30 days if they were not chronically taking ASA prior to surgery
1867734|NCT01082887|Other|TIL-Ad-INFg|After verification of inclusion and non-inclusion criteria and after obtaining informed consent from the patients, a tumor sample will be taken for sterile production of TIL. Patients will receive intra-tumoral injections of Ad-INFg every 15 days from J-15 to M2, then every month from M3 to M11 or until disease progression. The Ad-INFg will be administered by intra-tumoral injection at a dose of 5x1010 vp (viral particles) per lesion. A maximum of 6 lesions will be treated simultaneously. They will also receive two infusion of TIL at M0 (Cycle 1) and M1 (Cycle 2) by intravenous infusion lasting 30 to 65 minutes followed by subcutaneous injections of IL2 from J1 to J5 and from J8 to J12 of each cycle.An evaluation of injected and not injected tumoral lesions including photographs will be realised at the pre-inclusion visit, J-15, M0 and every month until M12.
1867735|NCT01082900|Other|Prophylactic CPAP Administration|"EXPERIMENTAL GROUP: Babies will receive prophylactic administration of CPAP (5 cm of H2O) in the Delivery Room via T piece (Neopuff)
CONTROL GROUP: Provision of standard care in the Delivery Room"
1867736|NCT01082913|Device|SSE|Use of SSE or not use of SSE
1867739|NCT01082926|Other|laboratory biomarker analysis|Optional correlative studies
1867740|NCT01082926|Procedure|positron emission tomography|Optional correlative studies
1867741|NCT01082939|Drug|Fludarabine|25 mg/m^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
1867742|NCT01082939|Drug|Cyclophosphamide|250 mg/m^2/day IV on Days 3-5; repeated every four weeks for a total of 6 planned cycles.
1867743|NCT01082939|Drug|Alemtuzumab|30 mg IV on Days 1, 3 and 5 over 2-4 hours; repeated every four weeks for a total of 6 planned cycles.
1867744|NCT01082939|Drug|Rituximab|"Cycle 1 (Week 1): 375 mg/m^2/day IV on Day 2 over 4- 6 hours
Cycle 2 - 6 (Week 1): 500 mg/m^2/day IV on Day 2 over 4- 6 hours"
1867745|NCT01082965|Drug|Donepezil|5 mg tablets once daily for 7 days and then 10mg on 8th day
1867746|NCT01082965|Drug|Placebo|matching placebo
1867747|NCT01082978|Device|Electronic (USB) Portable Health File|Patients randomized to this arm of the trial will be given a USB memory device that contains the Portable Health File (PHF) software. The portable health files contained core medical data which functions as a subset of a comprehensive medical record. The portable health file is updated by the health care provider at each visit and could also be updated by patient between visits if necessary.
1867748|NCT01082978|Device|Paper Portable Health File|Patients randomized to this arm of the trial will be given the paper Portable Health File. The paper Portable Health File contains core medical and other important data which functions as a subset of a more comprehensive medical record. This paper-based portable health file is updated by health care providers at each visit. The PHF can also be updated by patient between visits.
1867749|NCT01082991|Other|Preemptive Rapid Response Team intervention|Non-ICU inpatients will be randomized on admission to an RRT surveillance group or standard of care. Daily risk prediction scores will be collected for all non-ICU inpatients. Those with high scores, who have been randomized to the surveillance arm, will be included on a list of patients, updated daily, that the Rapid Response Team will receive, with instructions to evaluate and intervene, if required, without waiting for formal activation by the usual channels.
1867750|NCT01083004|Procedure|Indocyanine green|Using indocyanine green as intraoperative dye
1867751|NCT01083004|Procedure|Brilliant blue arm|Using brilliant blue as intraoperative dye
1867752|NCT01083017|Drug|chlorthalidone|chlorthalidone 25mg/d vs. chlorthalidone 50mg/d
1867753|NCT01083017|Behavioral|motivational intervention for non-compliant individuals|motivational interview(s) vs. repeated calls vs. no particular intervention
1867754|NCT01083017|Drug|standardized anti-hypertensive treatment|olmesartan, amlodipine, chlorthalidone, +- spironolactone
1867755|NCT01083030|Procedure|Percutaneous transluminal angioplasty (PTA)|Angioplasty of superficial femoral artery (SFA)
1867756|NCT01083095|Biological|Sporozoite Challenge Model for Plasmodium vivax in Humans|Eighteen naïve volunteers were exposed to the bite of carrying P. vivax sporozoites. Volunteers were randomly allocated to 1 of 6 groups and exposed to different numbers of mosquito biting, for 10 min. After feeding, dissection of all mosquitoes exposed in the cage was performed, to confirm the presence of a blood meal in their midguts and sporozoites in their salivary glands. If a volunteer did not get the number of infective bites assigned for his/her group, he/she was allowed to be bitten for a new group of mosquitoes until a total of 3±1, 6±1, or 9±1 mosquito bites were achieved.
1867759|NCT01083147|Device|FORESEE HOME|Home Monitoring
1867760|NCT01083199|Device|CONTINUUM™|Performance of CONTINUUM™ in facilitating the vesico-urethral anastomosis following radical prostatectomy.
1867761|NCT01083212|Drug|AZD1656|Single dose,oral tablet
1867762|NCT01083212|Drug|Gemfibrozil|Oral tablet bid on day 1 - 5.
1867763|NCT01083212|Drug|Placebo|Oral tablet bid on day 1-5
1867764|NCT01083225|Behavioral|Client feedback|Client feedback during consultations using ORS (Outcome rating scale) and SRS (Session rating scale).
1867765|NCT01083225|Behavioral|Treatment as usual|Treatment as usual, consultations
1867766|NCT01083238|Drug|AZD5069|120mg single oral dose
1867767|NCT01083251|Drug|Peginterferon + Vitamin D|180 mcg/week + 400 IUX2/day
1867768|NCT01083251|Drug|Peginterferon|180 mcg/week
1867769|NCT01083251|Drug|Sebivo|Telbivudine 600 mg daily
1867770|NCT01083251|Drug|entecavir+ vitamin d|entecavir 1 mg daily+ vitamin d
1867771|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: buttocks
1867772|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: arm
1867773|NCT01083264|Drug|Gestodene/EE Patch (BAY86-5016)|Transdermal Patch, 0.55mg Ethinylestradiol + 2.1mg Gestodene, 4x7 days patch wearing period, patch-free interval of 7 days, application site: abdomen
1867774|NCT01083277|Device|variable ventilation|In variable ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be randomly varied by 40% on a breath-by-breath basis around a pre-set mean, using the variable ventilation software developed by Dr. Bela Suki and Dr. Arnab Majumdar. In conventional ventilation, the tidal volume on the Puritan-Bennett 840 ventilator will be set to equal the mean tidal volume used in variable ventilation and does not vary.
1867775|NCT01083277|Other|Conventional ventilation|tidal volume will be set as the patient's baseline tidal volume prior to study entry and will not vary.
1867776|NCT01083290|Drug|Spironolactone|single dose of one tablet; 25 mg tablet
1867777|NCT01083290|Drug|Spironolactone|single dose of one tablet; 50 mg tablet
1867778|NCT01083290|Drug|Spironolactone|single dose of one tablet; 100 mg tablet
1867779|NCT01083303|Behavioral|Weaning Preterm Infants from an incubator|Eligible infants are to be randomized by computer generated random numbers to either the study group weaned at 1500 gr. or the control group weaned at 1600 gr. Both groups were weaned to a warming bassinet.
1867780|NCT01083316|Drug|Bortezomib|"Induction:
Velcade 1.3 mg/m2/dose IV Days 1, 4, 8, 11 repeated every 21 days
Conditioning:
Bortezomib 1.0 mg/m2/dose will be administered on Days +6, -3, +1, + 4"
1867781|NCT01083316|Drug|Dexamethasone|"Induction:
Dexamethasone 20 mg PO/IV Days 1, 4, 8, 11 repeated every 21 days"
1867782|NCT01083316|Drug|Melphalan|"Conditioning:
Melphalan 70-100 mg/m2/day IV on days -2 and -1"
1867783|NCT01083329|Behavioral|training|the last 8 weeks, the subjects will follow a training program calculated to optimize use of lipid
1867784|NCT01083329|Drug|nicotinic acid|Obese subjects will receive nicotinic acid or placebo for 16 weeks
1867785|NCT01083329|Drug|Placebo|Obese subjects will receive nicotinic acid or placebo for 16 weeks
1867786|NCT01083342|Drug|MTX, MVD, VIA|MTX: Methotrexate,Leucovorin MVD: Methotrexate,Vincristine,Dexamethasone VIA: VP-16 (Etoposide),Ifosfamide,Mesna, Cytarabine (ara-C)
1867787|NCT01083368|Drug|temsirolimus|Given IV
1867788|NCT01083368|Biological|bevacizumab|Given IV
1867789|NCT01083368|Genetic|polymorphism analysis|Correlative studies
1867790|NCT01083368|Other|laboratory biomarker analysis|Correlative studies
1867791|NCT01083381|Drug|MS14|MS14 will be administered at an oral dose of 25-50 mg/kg/day in two divided doses for three months
1867792|NCT01083381|Drug|Risperidone|The treatment group receives Risperidone 2 mg per day in the beginning which is increased by 1 mg every day until reaching 4 mg/day; this regimen will be continued for three months.
1867793|NCT01083394|Device|PTA|PTA using a conventional balloon
1867794|NCT01083394|Device|PTA with PEB|PTA using a paclitaxel eluting balloon
1867795|NCT01083394|Procedure|Percutaneous Transluminal Angioplasty (PTA)|Percutaneous transluminal angioplasty with conventional balloon or paclitaxel-eluting balloon
1867796|NCT01083407|Drug|0.12% Chlorhexidine Digluconate|Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
1867797|NCT01083407|Other|Toothbrushing|Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
1867798|NCT01083420|Drug|Minocycline|Minocycline 0.2% mouthwash
1867799|NCT01083420|Drug|Dexamethasone|Dexamethasone 0.01% mouthwash
1867802|NCT01083446|Other|Nutritional Intervention|Cognitive and executive functions before and after standard israeli breakfast (30% of caloric value and 21 gram protein)
1867803|NCT01083446|Other|Nutritional Intervention|Cognitive and executive functions during fast
1867804|NCT01083472|Device|Strattice(TM) Reconstructive Tissue Matrix|Strattice(TM) TM will be used to support the repair of abdominal wall defect
1867805|NCT01083472|Procedure|Suture/suture with absorbable mesh|Abdominal wall defect will be repaired with suture alone or absorbable mesh with suture
1867806|NCT01083485|Drug|Oxycodone/Naloxone PR 20/10mg or 10/5mg tablets|Oxycodone/Naloxone prolonged release 20/10mg or 10/5mg tabs twice a day (BID) for 2.5 days (total 5 dosages)or Oxycodone 20mg
1867807|NCT01083485|Drug|Oxycodone|Oxycodone 20mg or 10mg BID for 2.5 days (total 5 dosages)
1867808|NCT01083498|Device|Ablative fractional laser therapy|10,600 nm ablative fractional laser Irradiance: 10 mJ/microbeam. Coverage: 35-45%. Number of treatment sessions: 3
1867809|NCT01083524|Drug|Dichloroacetate Sodium|3 mg po bid for 28 weeks
1867810|NCT01083524|Drug|Dichloroacetate Sodium|6.25 mg po bid
1867811|NCT01083524|Drug|Dichloroacetate Sodium|12.5 mg po bid
1867812|NCT01083537|Drug|Cisplatin|"1) Cisplatin administered at 60mg/m2 IV on Day 1, every 21 days for 2 cycles.
Hesketh Level 5: 5HT3 receptor antagonist IV/po 30-60 mins pre-chemo and Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; Dexamethasone 4-8mg po BID x 3 days starting 24hours post last dose of chemo; Prochlorperazine 10mg po/IV q4-6h prn, metoclopramide 10-20mg po/iv q6h prn, haloperidol 0.5-2mg po/SC q 8-12 h prn
Hydration: Pre-hydration 500-1000cc NS with 10Meq KCl over 2 hours; Infuse Cisplatin in 250-500cc NS over 1 hour; Post-hydration 1000cc NS + 20Meq KCl (+/- 2g MgSO4) over 1 hour"
1867813|NCT01083537|Drug|Paclitaxel|"2) Paclitaxel administered 80mg/m2 IV on Days 1, 8 and 15, every 21 days for 2 cycles.
Suggested prophylaxis for paclitaxel-associated hypersensitivity reactions: Dexamethasone 10-20mg po/IV 30-60 mins pre-chemo; diphenydramine 25-50mg IV 30-60 minutes pre-chemo, ranitidine 50mg IV 30-60 minutes pre-chemo
Hesketh Level 2: Prochlorperazine 10mg po/IV q4-6h prn
Hydration: Infuse Paclitaxel in 250cc NS over 1 hour"
1867814|NCT01083550|Other|Decision aid exposure|Exposure to a computerized decision aid on adjuvant radioactive iodine treatment decision-making. The exposure is during one visit.
1867815|NCT01083576|Drug|WR 279,396 (15% paromomycin + 0.5% gentamicin topical cream)|topical application to CL lesions once daily for 20 days
1867816|NCT01083576|Drug|Paromomycin Alone Cream (15% paromomycin topical cream)|topical application to CL lesions once daily for 20 days
1867817|NCT01083589|Drug|Imatinib Mesylate|Oral 400 mg daily
1867818|NCT01083589|Drug|Docetaxel|60 mg/m2 over 1 hour intravenous infusion repeated every 21 days.
1867819|NCT01083602|Drug|panobinostat|PAN 20 mg PO given TIW, weeks 1&2 of each 3-week cycle;• BTZ 1.3 mg/m2 IV push given BIW weeks 1&2 of each 3 week cycle (days 1,4,8 and 11);• Dex 20 mg PO given QIW, weeks 1&2 of each 3-week cycle (days 1,2,4,5,8,9,11 and 12)
1867820|NCT01083602|Drug|bortezomib|
1867821|NCT01083602|Drug|dexamethasone|
1867822|NCT01083615|Drug|custirsen sodium|An antisense oligonucleotide that blocks production of clusterin
1867823|NCT01083615|Drug|isotonic, 0.9% sodium chloride|Placebo for custirsen sodium
1867824|NCT01083615|Drug|docetaxel|
1867825|NCT01083615|Drug|cabazitaxel|
1867826|NCT01083615|Drug|prednisone|
1867865|NCT01084057|Drug|ixabepilone|Given IV
1867827|NCT01083628|Behavioral|Txt4Mood|Mobile phone based text messaging to inquire about mood, cognitions, and behaviors on a daily basis.
1867828|NCT01083641|Drug|Estradiol|10mg oral three times daily
1867829|NCT01083654|Behavioral|Standard Treatment Counseling|Standard Treatment Counseling will be based on recommendations in the 2008 U.S. Public Health Service Guideline (Treating Use and Dependence) including topics on preparing to quit, nicotine addiction, coping with stressors and challenging situations, coping with withdrawal symptoms, seeking support, and relapse prevention. Counseling will be delivered in an accessible, personalized manner by Ms. Fossum (an enrolled member of the Menominee Tribe) but no American Indian culturally-appropriate treatment elements will be incorporated into the counseling. In other words, the counseling in the Standard Treatment will be similar to the kind of evidence-based counseling offered to other smokers regardless of race or ethnicity.
1867830|NCT01083654|Behavioral|Culturally-Tailored Treatment|The Culturally-Tailored Treatment consists of the Standard Treatment Counseling plus culturally-appropriate treatment elements including: discussion of the long history of sacred/traditional use of tobacco (honoring and respecting native traditions) and how it differs from use of commercial tobacco use (harming health); custom booklet on smoking and smoking cessation tailored for Menominee and other American Indian smokers; and participants will be encouraged to make their own traditional tobacco pouch (symbol of long life)
1867831|NCT01083667|Drug|Pyrimethamine|Open Label, dose escalating,
1867832|NCT01083706|Drug|azacitidine|Given SC or IV
1867833|NCT01083706|Other|laboratory biomarker analysis|Correlative studies
1867834|NCT01083719|Procedure|FDG-PET|Fluoro-deoxy gluocose-Positron emission tomography for delineating volumes in Glioblastoma
1867835|NCT01083732|Drug|dabigatran etexilate|Experimental dose chosen based on age and weight
1867836|NCT01083758|Drug|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel)|Topical suspension applied once daily for up to 8 weeks
1867837|NCT01083771|Dietary Supplement|Olive Oil|Minimum of 3 tablespoon of olive oil per day
1867838|NCT01083784|Drug|Use of prophylactic anticonvulsants (valproate, clonazepam)|start at hypothermia induction valproate : 30mg/kg iv loading - 8hr after - 6mg/kg q 8hr iv till 72hr clonazepam : 1mg po bit via L-tube till 72 hr
1867839|NCT01083784|Drug|Control group|Control group
1867840|NCT01083797|Drug|Dexmedetomidine|1 μg kg-1 infused in 10 min, and thereafter maintained from 0.2 to 0.7 μg kg-1 h- 1
1867841|NCT01083797|Drug|Chloral Hydrate|Initial dose=50 mg/kg
1867842|NCT01083810|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
1867843|NCT01083823|Other|Mental health telemetry (MHT)|Use a cell phone equipped with MHT software to complete a self-report mood symptom questionnaire daily at a fixed time of day, as well as additional discretionary questionnaires following any significantly stressful events.
1867844|NCT01083862|Behavioral|Educational Intervention - Text plus DVD/VHS|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes viewing a video program developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. They also were given a booklet on the same subject material written at a 5th grade level."
1867845|NCT01083862|Behavioral|Educational Intervention - Text Only|"In conjunction with a scheduled clinical visit, consenting patients spent roughly 40 minutes reading a booklet developed by the Foundation for Informed Decision Making (FIMDM), describing life-style and behavior modification for patients Living with Coronary Artery Disease. Subject material was written at a 5th grade level."
1867846|NCT01083875|Drug|amlexanox|0.5% amlexanox oral rinse; use 5 ml every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid was be swirled around the mouth then to be swallowed. Repeated daily until completion of radiation therapy: approximately 7-8 weeks.
1867847|NCT01083875|Drug|Vehicle rinse|use 5 ml of the vehicle rinse every 2-3 hours during the awake hours of each day (a minimum of 6 times each day). The liquid is be swirled around the mouth then swallowed.
1867848|NCT01083888|Drug|ASP1517|oral
1867849|NCT01083901|Behavioral|Resistance training|high intensity progressive resistance exercise training
1867850|NCT01083927|Procedure|Rotational Narrow Strip Conjunctival Graft|Surgical technique
1867851|NCT01083927|Procedure|Full Conjunctival Graft|Surgical technique
1867852|NCT01083940|Other|Computerized reminders on hypertension intensification|Reminder generated to prompt providers to intensify therapy when patient's blood pressure remains uncontrolled
1867853|NCT01083953|Drug|Sevoflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
1867854|NCT01083953|Drug|Desflurane|Comparing the optimal end-tidal concentration sevoflurane and desflurane for LMA extubation
1867855|NCT01083966|Drug|Bevacizumab (Avastin)|"Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma
This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS"
1867856|NCT01083979|Drug|Liposomes|Intravesical instillation
1867857|NCT01083992|Drug|Galvus (vitagliptin)|Galvus (vitagliptin)
1867858|NCT01083992|Drug|Galvus + vitamin D|Galvus + vitamin D
1867859|NCT01084005|Drug|linagliptin|patients receive linagliptin 5 mg tablets once daily
1867860|NCT01084005|Drug|placebo|patients receive placebo matching linagliptin 5 mg once daily
1867861|NCT01084018|Behavioral|soulageTAVIE|VITaPaCS consists in a 30 minute-computer-tailored preoperative session, which is animated by a virtual nurse who guides the participant through a learning process about analgesic medication intake, pain communication, and cognitive restructuring. The information and the strategies provided are specifically tailored to the participants' profile, determined by a screening questionnaire, but also by their responses in real-time during the computer session. Two postoperative clinical reinforcements of ten minutes are also provided by the treating nurse based on the flags identified through the preoperative session.
1867862|NCT01084031|Drug|propofol|intravenous propofol with sevoflurane inhalation induction
1867863|NCT01084044|Drug|ulinastatin, saline solution|the ulinastatin group receiving ulinastatin (300,000 unit after anesthesia induction and another 300,000 unit during Y- graft anastomosis, n = 40), the control group receiving the same volume of saline solution(n = 40)
1867864|NCT01084057|Drug|vorinostat|Given orally
1867868|NCT01084070|Other|Early oral feeding|"Within 6-24 hours after surgery the nasogastric tube will be removed and liquids and soft diet at will indicated."
1867869|NCT01084070|Other|Traditional Care|They will have nasogastric tube and restriction of oral intake until the first sign of restoration of intestinal transit (first flatus or stool, whichever comes first). Since then withdrew nasogastric tube and liquid diet starts within 24 hours, then continues with soft diet.
1867870|NCT01084083|Biological|cetuximab|Given IV
1867871|NCT01084083|Radiation|intensity-modulated radiation therapy (IMRT)|Patients undergo low-dose OR standard dose IMRT based on their clinical response to induction therapy
1867872|NCT01084083|Drug|Paclitaxel|Given IV, 90 mg/m^2 on days 1, 8 and 15
1867873|NCT01084083|Drug|Cisplatin|Given IV, 75 mg/m^2 on day 1
1867875|NCT01084109|Other|Lyophilized meat|Daily intake of one half ounce of lyophilized meat between 6-18 months of age (0.5 oz for 6-12 mo; 0.75 oz for 12-18 mo)
1867876|NCT01084109|Other|Cereal|Daily intake of an equi-caloric fortified cereal as complementary feed from 6 to 18 months.
1867877|NCT01084122|Drug|Iron sucrose|Iron sucrose FERIV® (20 mg/ml). Dilution: 10 ml in 100 ml SF 0.9%. 25 ml in 15 minutes and the rest in others 15 minutes.
1867878|NCT01084135|Drug|Rivastigmine|At the baseline visit (week 0), the subject will begin rivastigmine treatment at a dose of 0.75 mg bid. This dose will be continued for two weeks and then increased to 1.5 mg bid for an additional eight weeks. At the week 10 safety visit, the dose will be increased to 4.5 mg/day (3.0 mg and 1.5 mg) for an additional 10 weeks. Subjects receiving placebo will maintain the same schedule. If a subject is unable to tolerate a particular dose, the dose will be lowered to the previously tolerated dose, down to a minimum of 0.75 mg bid. If the subject is unable to tolerate the 0.75 mg bid dose he/she will be dismissed from the study.
1867879|NCT01084135|Other|Liquid Placebo|Subjects receiving placebo will maintain matched titration volume increase as treatment arm. The placebo will be matched to liquid rivastigmine in consistency and taste.
1867880|NCT01084148|Drug|V0034CR01B|
1867881|NCT01084148|Drug|V0034CR01B vehicle|
1867882|NCT01084161|Drug|N1539|5 mg IV once per day
1867883|NCT01084161|Drug|N1539|7.5 mg IV once per day
1867884|NCT01084161|Drug|N1539|15 mg IV once per day
1867885|NCT01084161|Drug|N1539|30 mg IV once per day
1867886|NCT01084161|Drug|placebo|IV placebo once per day
1867887|NCT01084161|Drug|Morphine|morphine 10-15 mg IV once per day
1867888|NCT01084161|Drug|N1539|60 mg IV once per day
1867889|NCT01084174|Drug|Peanut powder|Delivered orally
1867890|NCT01084174|Drug|Peanut extract|Delivered sublingually
1867891|NCT01084174|Drug|Placebo extract|Delivered sublingually
1867892|NCT01084174|Drug|Placebo powder|Delivered orally
1867893|NCT01084187|Drug|Vardenafil|vardenafil 20 mg on demand or vardenafil daily or placebo
1867894|NCT01084200|Drug|Propofol for maintenance|Propofol 6-8mg/kg/h + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
1867895|NCT01084200|Drug|Sevoflurane|Sevoflurane 0.7-1.3MAC + Remifentail 0.1-0.2ug/kg/min for anesthesia maintenance
1867896|NCT01084200|Drug|Sevoflurane+Propofol|Sevoflurane 0.7-1.3MAC + Remifentanil 0.1-0.2ug/kg/min + Propofol 2mg/kg/h for anesthesia maintenance
1867897|NCT01084213|Drug|Intermittent screening and treatment of malaria in pregnancy (IST)|Scheduled intermittent screening of study women using rapid diagnostic test and treatment of those who are RDT positive during ante-natal clinic visits in the 2nd and 3rd trimester with arthemether lumefantrine.
1867898|NCT01084213|Drug|SP-IPTp|Study women will receive at least two doses of Sulfadoxine Pyrimethamine during their pregnancy, one at each of the recommended ante-natal visits during the 2nd and 3rd trimester.
1867899|NCT01084226|Dietary Supplement|Rye-2008|
1867900|NCT01084239|Radiation|Cardiac Computed Tomography|A contrast enhanced cardiac CT was performed in addition to standard evaluation. Reconstructed data sets were evaluated for the presence of coronary artery calcium, coronary atherosclerotic plaque and stenosis, LV function and incidental findings.
1960009|NCT03310385|Drug|GHX02|Herbal medicine originating from gualouhengryunhwan
1960010|NCT03310385|Drug|Placebo|Placebo tablets
1960011|NCT03310372|Radiation|Ultrafractionated brain irradiation|0.75 Gy a day, 5 times a week, for 6 weeks (total dose: 67.5 Gy)
1867904|NCT01084265|Drug|Recombinant human luteinizing hormone (r-hLH)|One r-hLH (75 International Units [IU]) injection s.c. once daily.
1867905|NCT01084265|Drug|Recombinant human follicle-stimulating hormone (r-hFSH)|One r-hFSH (150 IU) injection s.c. once daily.
1867906|NCT01084265|Drug|Human chorionic gonadotropin (hCG)|After adequate follicular response, ovulation induction was triggered by an injection of 10,000 IU hCG.
1960012|NCT03310372|Drug|Temozolomide|75 mg/m2/day, 7 times a week, for 6 weeks (total 42 days)
1867908|NCT01084291|Biological|Investigational Vaccine for DEN1|Subcutaneous injection in upper arm of vaccine at dose of 10 plaque-forming units (PFU)
1867909|NCT01084291|Other|Placebo injection|Subcutaneous injection of placebo
1867910|NCT01084317|Other|medical documentation and telephone interview|medical documentation analysis supplemented by telephone interview conducted with parents of the child
1867911|NCT01084330|Drug|AUY922|70mg/m2
1867912|NCT01084330|Drug|Docetaxel|Docetaxel 75mg/m2
1867913|NCT01084330|Drug|Irinotecan|Docetaxel or Iriniotecan
1868038|NCT01086423|Biological|Poliorix™|Intramuscular, three doses
1867914|NCT01084343|Biological|MYM-V101|"Panel 1: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 10 microgram or placebo each, every 8 weeks.
Panel 2: 2 vaccinations in the muscles followed by 2 vaccinations in the nose, 50 microgram or placebo each, every 8 weeks."
1867915|NCT01077869|Procedure|endoscopic examination|on a weekly basis during 7 weeks
1867916|NCT01077869|Procedure|FDG-PET|once pre-radiotherapy and once 2 weeks after initiation of radiotherapy
1867917|NCT01077882|Behavioral|education on skin disease conditions|information about several skin diseases skin function recommendation on care of skin
1867918|NCT01077882|Behavioral|Stress-reduction techniques|Physical Training yoga mindfulness-based stress reduction
1867919|NCT01077882|Behavioral|Lifestyle factors and psycho-education|by dietician and psychiatrist
1867920|NCT01077882|Other|no educational program|standard care without educational program
1867921|NCT01077895|Procedure|CVVH|"CVVH is started using following parameters:
Blood flow is started at 150 mL/min
Anticoagulation: none, heparin or low molecular weight heparin according to local protocols in study centers.
In both groups: dialysis dose of 25 mL/kg body weight administered using both pre- and postdilution
Substitution fluid temperature is started at 37°C and adjusted in function of patient body temperature (which is maintained at 35-37°C)"
1867922|NCT01077895|Procedure|ultrafiltration|"ultra filtration is started at 100 mL/h and increased according to following protocol
Ultrafiltration is increased by 100 mL/h after 2h and subsequently by 100mL/h (until a maximum of 500mL/h) every 4h unless:
Vasopressor or inotrope medication dose is increased by > 25% (provided mean arterial pressure remains constant at 65 mmHg or another target value specified by treating physician according to standard of care)
When above condition is not met UF should be kept constant and a passive leg raising test or stroke volume variation measurement should be performed. If SVV > 10% or PLR is positive 100mL of albumin 20% solution or 250 mL of Hydroxyethyl Starch 130/0.4 solution is administered according to treating physician at a maximum of 4 times per 24h
If there is no improvement after 2 colloid administration rounds, UF should be stopped for 4h and restarted at half the rate it was set at when discontinued."
1867923|NCT01077895|Procedure|ultrafiltration control group|ultrafiltration is set at 100 mL/h (and fluid administration is titrated to approach 100 mL /h)
1867924|NCT01077908|Biological|Adoptive Cellular Therapy|CMV-specific T-cells, single infusion at 27 days post-HSCT
1867925|NCT01077908|Drug|Best available antiviral drug therapy|"Intravenous ganciclovir 5mg/kg twice daily
Oral valganciclovir 900mg twice daily
Intravenous foscarnet 90 mg/kg twice daily"
1867926|NCT01077921|Drug|Propranolol|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
1867927|NCT01077921|Drug|Placebo|Treatment will be with a standard propranolol dose of 40 mg every 12 hrs.Each patient will participate in 6 weeks of treatment with placebo or study drug (propranolol), followed by a 2-week wash-out period and then 6 weeks of treatment with the other modality (placebo or propranolol).
1867928|NCT01077934|Device|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
1867929|NCT01077947|Procedure|Functional anesthetic discography|Functional anesthetic discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
1867930|NCT01077947|Procedure|Provocative Discography|Provocative Discography will be performed to diagnose discogenic pain and to correctly identify the disc levels for the surgical treatment. Proper identification for disc levels should improve the overall results of surgery for this condition.
1867931|NCT01077960|Biological|Serostim|Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment [Serono Study 24380] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)
1867932|NCT01077973|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo
1867933|NCT01077973|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg) plus placebo
1867934|NCT01077973|Drug|Placebo|Single-dose of placebo
1867935|NCT01077986|Drug|Capecitabine|Capecitabine will be administered for 14 days in a 3 weekly cycle, starting on day 8.
1867936|NCT01077986|Drug|Cetuximab|Cetuximab will be administered weekly, starting at day 8.
1867937|NCT01077986|Drug|Everolimus|Everolimus will be administered daily, starting on day 1.
1867938|NCT01077999|Drug|Carboplatin|Carboplatin AUC = 2 , weekly.
1867939|NCT01077999|Drug|Paclitaxel|Paclitaxel 50 mg/m2, weekly
1867940|NCT01077999|Drug|panitumumab|panitumumab: 6mg/kg in weeks 1-3-5.
1867941|NCT01077999|Radiation|radiotherapy|A total dose of 41.4 Gy will be given in 23 fractions of 1.8 Gy.
1867942|NCT01078012|Behavioral|Trained counselling|
1867943|NCT01078025|Procedure|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
1867944|NCT01078025|Procedure|Smear test vaginally, intraabdominally|Pre- and intraoperative smear tests of the vagina and douglas are performed.
1867945|NCT01078038|Device|Cypher|Sirolimus-eluting stent implantation
1867946|NCT01078038|Device|Xience V|Everolimus-eluting Stent implantation
1867947|NCT01078051|Procedure|Cypher, xience, Endeavor, Taxus|all species of drug-eluting stent implantation
1867948|NCT01078051|Drug|optimal medical therapy|optimal medical therapy
1867949|NCT01078129|Behavioral|cognitive remediation therapy|program consisting of 14 training sessions of 4 cognitive functions (attention/concentration, topological memory, logical reasoning, executive functions)by means REHACOM® software
1867950|NCT01078129|Behavioral|non-CRT|waiting list
1867951|NCT01078142|Drug|Temsirolimus, Rituximab, Bendamustin|"Phase I:
Temsirolimus 25 - 50 - 75mg, day 1,8,15 Bendamustin 90/m2, day 1,2 Rituximab 375/m2, day 1 Phase II at established dose, repeat day 28-42 (max)"
1867954|NCT01078181|Procedure|gastric bypass|laparoscopic gastric bypass with circular stapled 21mm gastrojejunostomy
1868039|NCT01086436|Biological|Rotarix ™|Oral, single dose
1867955|NCT01078194|Device|Secondary Bypass Banding (adjustable A.M.I. Soft Gastric Band)|Secondary Placement of the A.M.I. Soft Gastric Band for laparoscopic bypass banding
1867956|NCT01078272|Other|Remote ischemic preconditioning|Randomized subjects are treated immediately prior to stenting with remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff inflations to occlude the brachial artery in their nondominant arms, with intervening 5 minute rest periods.
1867957|NCT01078272|Other|Sham Remote Ischemic Preconditioning|Randomized subjects who are exposed immediately prior to stenting to sham remote ischemic preconditioning consisting of 3 5 minute blood pressure cuff placements without inflation on their nondominant arms, with intervening 5 minute rest periods.
1867958|NCT01078285|Behavioral|No Patient Counseling|Patients do not receive any adherence counseling, or other patient support services
1867959|NCT01078285|Behavioral|Adherence Counseling|Patients receive 3-5 minutes of adherence counseling, and other patient support services
1867960|NCT01078298|Drug|varenicline|varenicline tablets titrated to 1 mg BID during 1st week and then 1 mg BID for 11 weeks
1867961|NCT01078298|Drug|placebo|placebo tablets matched in appearance and dosage to varenicline tablets
1867962|NCT01078337|Procedure|bone marrow aspiration|
1867963|NCT01078337|Procedure|peripheral blood sampling|
1867964|NCT01078350|Procedure|tumor tissue aspiration|
1867965|NCT01078350|Procedure|phlebotomy|
1867966|NCT01078363|Drug|ramipril|Use of a ACE ( angiotension converting enzyme) inhibitors post heart Transplant for Blood pressure control.
1867967|NCT01078363|Drug|Placebo|Use of a placebo post heart Transplant for Blood pressure control.
1867968|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 80 mg, tablets, orally, one day only
1867969|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
1867970|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 20 mg to 60 mg (based on participant weight), tablets, orally, one day only
1867971|NCT01078376|Drug|Azilsartan medoxomil (TAK-491)|Azilsartan medoxomil 0.66 mg/kg participant body weight, granules, reconstituted orally, one day only
1867972|NCT01078389|Drug|Febuxostat|Febuxostat capsules
1867973|NCT01078389|Drug|Placebo for Febuxostat|Febuxostat placebo-matching capsules
1867974|NCT01078415|Device|Ablation with the NanoKnife Low Energy Direct Current (LEDC) System|90 pulses of 70 microseconds each in duration will be administered per electrode pair.
1867975|NCT01078428|Other|Topical silicone gel|Topical silicone gel will be applied to the scar twice daily for a period of 8 weeks
1867976|NCT01078428|Other|Vaseline|Topical petrolatum gel will be applied to the scar twice daily for a period of 8 weeks
1867977|NCT01084369|Drug|Testosterone|"NEBIDO ampoules containing a solution for injection of 1000mg/4ml of testosterone undecanoate. NEBIDO injection 1000mg/4ml will be given at baseline, 6 weeks, 18 weeks, 30 weeks, 42 and 54 weeks. Levitra will be given to those patients with erectile dysfunction for 2 weeks in addition to Nebido.
Concomitant medication deemed necessary by the investigator as part of the routine clinical management will be permissable."
1867978|NCT01084382|Dietary Supplement|Arthrospira platensis|"Patient take 5 gram supplement per day for 12 weeks in the first phase. In the second phase the two groups receive 5 gram per day of Arthrospira platensis for 12 weeks.
One group will so haved received Arthrospira platensis for 24 weeks."
1867979|NCT01084395|Behavioral|Adolescent Safer Sex Intervention|Adolescents are randomly assigned to the HIV risk-reduction intervention condition. Adolescents receive a theory-based intervention designed to reduce HIV risk-associated behavior. The intervention consists of six 50-minute modules implemented over the course of two days. The intervention is highly interactive and includes games, videos, discussion, and role-plays.
1867980|NCT01084395|Behavioral|Parent Safer Sex Communication Intervention|Parents are randomly assigned to the Safer Sex Communication Intervention. Parents learn about HIV and other consequences of unprotected sexual behavior. The intervention contains content that focuses on enhancing parent-adolescent communication.
1867981|NCT01084395|Other|Adolescent Health Promotion Control Condition|Adolescents are randomly assigned to the Health Promotion control condition. Adolescents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Adolescents are taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use.
1867982|NCT01084395|Other|Parent Health Promotion Control Condition|Parents are randomly assigned to the Health Promotion control condition. Parents receive an intervention aimed at significant health problems affecting Mexicans that are related, not to sexual behavior, but to other behaviors. These health problems include heart disease, certain cancers, and diabetes. Parents will be taught that these health problems can be prevented by changing personal behaviors, primarily exercise, diet, cigarette smoking, and alcohol and drug use. The intervention also provides content that emphasizes the importance of families.
1867983|NCT01084408|Device|SeQuent®Please (Paclitaxel coated balloon)|PCI of de-novo lesions
1867984|NCT01084408|Device|Taxus™Liberté™ (Paclitaxel eluting stent)|PCI of de-novo lesions
1867985|NCT01084421|Behavioral|Computer-based parent-adolescent HIV communication|The parental intervention consists of a 60 minute computer-based program delivered in two sessions (one per week). The DVD ROM provides information about adolescent sexual risk and HIV prevention, strategies to support sexual specific communication and parent-adolescent communication in general. The computer based education program is provided in Spanish.
1867986|NCT01084434|Dietary Supplement|probiotic|Bifidobacterium lactis HN019 10^9 CFU/day 1 sachet once a day for 7 weeks
1867987|NCT01084434|Dietary Supplement|prebiotic|Galactooligosaccharide 5.5 g/day 1 sachet once a day for 7 weeks
1867988|NCT01084434|Dietary Supplement|Synbiotic|(Bifidobacterium lactis 10^9 CFU + Galactooligosaccharide 5.5g) / day - 1 sachet once a day for 7 weeks
1867989|NCT01084434|Dietary Supplement|Placebo|Maltodextrin 5.5g/day - 1 sachet once a day for 7 weeks
1867990|NCT01084447|Device|inspiratory muscle training|This daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)was initially set at 40% of the maximal inspiratory pressure, obtained in the 2nd post-operative day, being adjusted to every new maximal inspiratory pressure measurement.
1867991|NCT01084447|Device|control group|In placebo muscular training the daily respiratory exercise was performed from the 2nd day following surgery by using a linear pressure resistance device (Threshold ® IMT - Health Scan Products; USA)no load until the 30th post-operative day.
1867992|NCT01084473|Drug|Dexmedetomidine|The study subjects will be given a normal loading dose (1 μg/kg in 20 minutes) of dexmedetomidine (dexmedetomidine hydrochloride 100 μg/ml, Precedex® Abbott Laboratories North Chicago, IL 60064, USA) followed by continuous infusion of 0.7 μg/kg/h for 190 min. The administration of the loading dose will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
1867993|NCT01084473|Drug|Morphine|The study subjects will be given 0.10 mg/kg morphine hydrochloride (morphine hydrochloride 2 mg/ml, Morphin® Nycomed Austria GmbH, St. Peter Strasse 25, A-4021, Linz, Austria) in 20 minutes followed by a placebo infusion for 190 min. The administration of the morphine infusion will be started at t = -30 min (30 min prior to the administration of paracetamol and lactulose).
1867994|NCT01084473|Drug|Placebo|0.9 % NaCl will be infused.
1867995|NCT01084486|Drug|Metformin|
1867996|NCT01084499|Drug|1st period - Reference drug|FEMARA Tab.[Letrozole 2.5mg] Novartis, Antineoplastics
1867997|NCT01084499|Drug|1st period - Test drug|FERATRA Tab.[Letrozole 2.5mg] Yuhan Corporation, Antineoplastics
1867998|NCT01084499|Drug|2nd period - Reference drug|FEMARA Tab.[Letrozole 2.5mg] Novartis, Antineoplastics
1867999|NCT01084499|Drug|2nd period - Test drug|FERATRA Tab.[Letrozole 2.5mg] Yuhan Corporation, Antineoplastics
1868000|NCT01084525|Drug|OTO-104 (steroid) 3 mg|OTO-104 3 mg dose cohort, single intratympanic injection.
1868001|NCT01084525|Drug|Placebo|Placebo arm will be conducted in parallel with each OTO-104 dose cohort.
1868002|NCT01084525|Drug|OTO-104 (steroid) 12 mg|Sequential dose cohort escalation to OTO-104 12 mg dose cohort will occur pending the safety evaluation of 28 day follow up safety data for the OTO-104 3 mg dose cohort. OTO-104 12mg dose cohort is also a single intratympanic injection.
1868003|NCT01084538|Drug|Zemplar iv (paricalcitol iv)|Each patient will be treated at the physician's discretion. Zemplar (paricalcitol) will be prescribed in the usual manner in accordance with the approved Summary of Product Characteristics.
1868004|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks
1868005|NCT01084551|Drug|SPM 962|once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks
1868006|NCT01084551|Drug|Placebo of SPM 962|once a daily transdermal administration for 13 weeks
1868007|NCT01084577|Device|AQUACEL® Ag|AQUACEL® Ag dressing for four weeks followed by AQUACEL® for the remaining 4 weeks.
1868008|NCT01084577|Device|Urgotul® Silver|Urgotul® Silver for four weeks followed by Urgotul® for the remaining 4 weeks.
1868009|NCT01084590|Behavioral|Healthy Eating/Physical Activity|This intervention arm will include brief pediatrician counseling regarding the child's current BMI percentile status, recommendations for home environmental changes to achieve a healthy weight gain trajectory, and home safety and injury risk reduction environmental recommendations paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the obesity prevention home environmental strategies.
1868010|NCT01084590|Behavioral|Safety/Injury Prevention|This intervention arm will include the same brief counseling from the pediatrician paired with a 12 month home-based program delivered via phone by a masters-level health behavior specialist to promote implementation of the safety and injury prevention home environmental strategies.
1868011|NCT01084603|Drug|Oral Nicotine|A new l mg oral nicotine product
1868012|NCT01084603|Drug|NiQuitinTM Nicotine Lozenge|A marketed 4 mg Nicotine lozenge
1868013|NCT01084603|Drug|Nicorette® Nicotine Gum|A marketed 4 mg Nicotine Gum
1994714|NCT02940288|Other|Auricular Acupuncture|Participants will receive bilateral auricular acupuncture using the Battlefield Acupuncture (BFA) protocol while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. Acupuncture needles will be left in place for 30 minutes.
1868017|NCT01084681|Device|Endovascular treatment of intracranial aneurysms|Endovascular treatment with the SILK Artery Reconstruction Device for occluding intracranial aneurysms.
1868018|NCT01084681|Device|Endovascular treatment of intracranial aneurysm with coils|Endovascular treatment with commercially available intracranial coils for occluding intracranial aneurysms.
1868019|NCT01086332|Drug|Nelfinavir|1250 mg twice daily
1868020|NCT01086332|Drug|Gemcitabine|Escalating doses of gemcitabine during concurrent radiation and nelfinavir therapy.
1868021|NCT01086345|Radiation|radiosurgery|Patients undergo radiosurgery 10-14 days after beginning bevacizumab.
1868022|NCT01086345|Biological|bevacizumab|Given IV
1868023|NCT01086345|Drug|irinotecan hydrochloride|Given IV
1868024|NCT01086358|Drug|Usual prescribed triptan|usual prescribed triptans may include:sumatriptan, rizatriptan, naratriptan, almotriptan, eletriptan, zolmitriptan
1868025|NCT01086358|Drug|Treximet for migraine treatment|Treximet is the combination of sumatriptan 85 mg plus naproxen sodium 500mg
1868026|NCT01086371|Other|Rhythmic auditory stimulation|Recorded music with embedded beat set 10% above the subject's baseline walking cadence.
1868027|NCT01086371|Other|Walking exercise|Subjects will be walking daily for a total of 20 minutes (may be broken down to smaller time periods.
1998233|NCT01566695|Drug|Oral Azacitidine|300mg daily, First 21 days of each 28-day cycle
1868030|NCT01086397|Procedure|Urine sample collection|All subjects have non-invasive urine sample collection performed
1868031|NCT01086410|Drug|Placebo Inhalation Powder|Placebo Inhalation powder inhaled once daily for 6 weeks' treatment
1868032|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose B inhaled once daily for 6 weeks' treatment
1868033|NCT01086410|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Dose A inhaled once daily for 6 weeks' treatment
1868034|NCT01086410|Drug|Placebo Oral Capsule|One placebo capsule taken each day on the last 7 days of the study
1868035|NCT01086410|Drug|Prednisolone Oral Capsule|Prednisolone 10mg oral capsule taken each day on the last 7 days of the study
1868036|NCT01086423|Biological|Infanrix-IPV/Hib™|Intramuscular, three doses
1868037|NCT01086423|Biological|Infanrix Hib™|Intramuscular, three doses
1868040|NCT01086436|Biological|Placebo|Oral, single dose
1868041|NCT01086449|Biological|Herpes Zoster Vaccine GSK 1437173A|Investigational vaccine (GSK 1437173A) administered intramuscularly.
1868042|NCT01086462|Drug|GSK2239633|100 ug GSK2239633 containing approximately 10kBq [14C]-GSK2239633
1868043|NCT01086475|Drug|D-cycloserine|50 mg dose administered 30 minutes prior to each of the ten Social Skill Training Sessions
1868044|NCT01086475|Drug|Placebo|Placebo pill administered 30 minutes prior to each of the ten Social Skill Training Sessions
1868045|NCT01086488|Drug|FOSCAN|Patients will be randomised to one of two treatment groups. The first group of 26 patients will receive 0.1 mg/kg Foscan® at a drug-light interval of 48 hours (2 days). A single surface illumination light dose of 20 J/cm2 fluence rate of 50 mW at 652 nm will be used. The second reference group of 26 patients will be treated by intracavitary brachytherapy
1868046|NCT01086514|Procedure|Dual Energy Contrast Enhanced Digital Mammography (DE CEDM)|Each patient will have: Bilateral digital mammography, Bilateral Breast MRI, Bilateral Contrast Enhanced Digital Mammography. The latter examination is the only change in patient management. An additional contrast injection is involved. Results of the DE CEDM will be compared with routine digital mammography and breast MRI. The reference standard is pathology. If surgery is to be done; every attempt will be made to perform all imaging exams within 30 days.
1868047|NCT01086527|Drug|10 mg tablet of montelukast (Singulair)|Fasting patients will take a single 10 mg tablet of montelukast with 240 ml of Gatorade. Eight blood samples will be drawn to assess the plasma concentration of montelukast over the subsequent 12 hours.
1998234|NCT01566695|Drug|Placebo|Placebo, First 21 days of each 28-day cycle
1868050|NCT01086553|Drug|budesonide|9mg budesonide OD
1868051|NCT01086553|Drug|budesonide|3mg budesonide TID
1868052|NCT01086566|Biological|Influenza Virus Vaccine, Monovalent A/H5N1 A/Indonesia/05/2005|Inactivated monovalent subvirion H5N1 vaccine (HA of A/Indonesia/05/05) provided in unit-dose vials containing 0.5 mL of either 30 mcg/mL A/H5N1 HA or 180 mcg/mL A/H5N1 HA. Subjects will receive 1 of 2 dose levels of vaccine, 15 or 90 mcg.
1868053|NCT01086579|Device|IN.PACT Falcon paclitaxel eluting balloon (Drug eluting balloon)|Coronary Artery Bypass Graft (CABG)
1868054|NCT01086579|Device|Taxus (Paclitaxel eluting stent)|Percutaneous transluminal coronary angioplasty (PTCA) with stent
1868055|NCT01086592|Other|No intervention|Daily life activities
1868056|NCT01086592|Other|Strong progressive strengthening exercises of lower limbs|Lower limb weight
1868057|NCT01086592|Other|Electrotherapy|Neuromuscular Electrical Nerve Stimulation
1868058|NCT01086592|Other|Electrotherapy+weights|Superimposed Neuromuscular Electric Nerve Stimulation
1868059|NCT01086605|Drug|pixantrone dimaleate|Given IV
1868060|NCT01086618|Drug|systemic chemotherapy|
1868061|NCT01086618|Procedure|adjuvant therapy|
1868062|NCT01086618|Procedure|quality-of-life assessment|
1868063|NCT01086618|Procedure|therapeutic conventional surgery|
1868064|NCT01086631|Drug|Rituximab|
1868065|NCT01086657|Biological|VRC-AVIDNA036-00-VP|H5 DNA Vaccine
1868066|NCT01086657|Biological|Monovalent Influenza Subunit Virion (Inactive H5N1) Vaccine|Inactive H5N1 Vaccine
1868067|NCT01086670|Other|Physical Exercise|Our primary objectives are to: 1) characterize and compare lower extremity motor coordination in children with cerebral palsy (CP) across mobility levels and to children without CP; and 2) evaluate the effects of two home-based exercise programs on motor coordination, as well as other physical, functional and neurological outcomes in children with CP. We hypothesize children with CP will exhibit significant coordination deficits compared to those without CP and that each exercise program will lead to significant improvements in outcomes.
1868068|NCT01086683|Behavioral|Psychosocial rehabilitation course|Groups of 20 cancer survivors participated in a 6-day multi-focused, psychosocial intervention at the Dallund rehabilitation centre. The overall aim was to strengthen each individual's physical, psychological and social functioning. Sharing experiences with other cancer patients and experiencing peer-support was a central issue. The retreat combined lectures, discussions and patient group work on themes such as the treatment of cancer, psychological reactions, spirituality, sexuality and lifestyle. Participants were involved in physical activities, and the daily menu represented a healthy diet. The course was conducted by a multi-disciplinary team. Each participant produced a personal, specific 'action plan', which was intended to serve as a 'booster' after returning to daily life.
1868069|NCT01086696|Drug|FPAC|Each subject will be administered 7 mCi of FPAC,over 10-20 seconds, followed by saline flush.
1868070|NCT01086722|Drug|"karolinska cocktail"|"The karolinska cocktail contains dextrometorphan, caffeine, losartan and omeprazol"
1868071|NCT01086735|Biological|donor lymphocyte infusion|Donor T-cell transduction
1868072|NCT01086748|Drug|Risperidone|Administered orally.
1868073|NCT01086748|Drug|Placebo|Administered orally.
1868074|NCT01086748|Drug|LY2140023|Administered orally.
1868075|NCT01086761|Biological|MP0112|Single intravitreal injection of MP0112 in the study eye.
1868076|NCT01086774|Other|Systane Ultra Lubricant Eye Drops|Single drop in both eyes
1868077|NCT01086787|Other|Surgery|Patients undergoing surgery for either cardiac surgery or orthopedic surgery
1868078|NCT01086800|Other|Healthy Lifestyles and Sleep Education plus PAP|Participants randomized to this arm will be educated on PAP and then use PAP for 3 months. They will also receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
1868079|NCT01086800|Other|Healthy Lifestyles and Sleep Education plus Supplemental Oxygen|Participants randomized to this arm will be educated on nocturnal supplemental oxygen and then use oxygen for 3 months. They also will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
1868080|NCT01086800|Other|Healthy Lifestyles and Sleep Education|Participants randomized to this arm will receive optimized medical preventive therapy according to current American Heart Association guidelines for prevention of CVD and sleep guidelines.
1868081|NCT01086813|Drug|AZD3043|single dose/IV, bolus over 60secs - infusion over 30 mins
1868148|NCT01087411|Behavioral|Physical activity|Group sessions with different kinds of physical activity is arranged for the participants in the intervention program.
1868082|NCT01086826|Drug|RT+CDDP/5-FU|RT=70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) CDDP: 20 mg/m2/day as 30 minutes IV infusion from day 1 to day 4 5-FU: 800 mg/m2/day for 4 days Both drugs will be administered during weeks 1 and 6 of irradiation, starting from day 1 of radiotherapy.
1868083|NCT01086826|Drug|RT+CETUXIMAB|RT= 70 Gy (2 Gy x1/day, 5 days per week for 7 weeks) Cetuximab= 400 mg/m2 as first dose.Subsequent doses of 250 mg/ m2, weekly, for 7 times.
1868084|NCT01086826|Drug|INDUCTION CTx(TPF)+(RT+CDDP/5-FU)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.
concomitant CTx= CDDP 20 mg/m2/day + 5-FU 800 mg/m2/day RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks)"
1868085|NCT01086826|Drug|INDUCTION CTx(TPF)+(RT+CETUXIMAB)|"INDUCTION CTx(TPF):docetaxel 75 mg/m² + CDDP 80mg/m² + 5-FU 800 mg/m²/day from day 1 to day 4 will begin after the end of cisplatin infusion on day 1.Every 3 weeks.
RT= 70 Gy(2 Gy x1/day, 5 days per week for 7 weeks) CETUXIMAB= 400 mg/m2 as first dose. Subsequent doses of 250 mg/ m2, weekly, for 7 times."
1868086|NCT01086839|Drug|sodium chloride 6%|"one ampoule sodium chloride 6% per day
inhalation use
for 28 days"
1868087|NCT01086839|Drug|sodium chloride 0,9%|"one ampoule sodium chloride 0,9% per day
inhalation use
for 28 days"
1868088|NCT01086852|Biological|FACTOR X|"Presurgery loading dose- The FX level of 70%-90% should be achieved.This will be calculated based on the patients weight on day of surgery and the required rise. Initial dose should not exceed 60IU/kg.
Post surgery- FX trough levels of 50% should be achieved.
Intravenous infusion of factor X is given at a suggested rate of 10mL/min but not exceeding more than 20mL/min."
1868089|NCT01086865|Drug|Apetiviton BC|"Administer the recommended dosage preferably one hour before the main meal:
Children (2 to 6 years): 2.5 mL 3 x daily. Adults (18 to 50 years): 5 mL 3 x daily. Elderly (60 to 80 years): 5 ml 3 x daily."
1868090|NCT01086878|Drug|cotrimoxazole|"Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:
less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim
greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim"
1868091|NCT01086891|Device|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated.
1868092|NCT01086891|Device|Oxygen conserving devices|Three 6MWT test will be performed at random with conventional oxygen continuous-flow,by Oxymizer Pendant and demand valve system. The percentage of patients correcting their desaturation and patients' acceptance of every method will be determinated
1868093|NCT01086904|Biological|inactivated non adjuvanted pandemic H1N1 vaccine|two administrations at D and D21 (15 µg HA)
1868094|NCT01086917|Biological|PfSPZ Challenge|each volunteer to receive a single dose
1868095|NCT01086930|Device|ReJoyce Workstation|The device has two parts. The first part is a muscle-stimulator garment that incorporates a wireless-triggered stimulator cuff, word on the forearm and triggered when the user clicks his/her teeth. The tooth clicks (vibrations) are detected by an earpiece, similar to a hearing aid, that sends a radio signal to the stimulator cuff. This is turn stimulates the hand to open or close, allowing patients to grasp and release objects. The second part of the device is a specialised workstation known as ReJoyce, which connects to a standard computer via a USB port. This work station will allow the user to play specialised computer games focusing on hand function. The stimulator system and the ReJoyce workstation were developed by Professor Arthur Prochazka, University of Alberta, Canada and has been approved by the Canadian Standards Association. The device is currently being used in a study conducted through the University of Alberta.
1868096|NCT01086930|Other|Standard Care|All participants will continue to receive the same standard care for the hand and upper limb as typically provided by their rehabilitation units. This will be provided as part of regular physiotherapy, vocational, recreational and occupational therapy and provided by participants' usual treating therapists. These therapists will not be involved in administering the study-specific interventions.
1868097|NCT01086943|Device|LT2420|
1868098|NCT01086956|Drug|epidural infusion of saline, ropivecaine, or ropivacaine and sufentanil|
1868099|NCT01086969|Biological|Meningococcal Polysaccharide Diphtheria Toxoid Conjugate (Menactra®)|0.5 mL, Intramuscular
1868100|NCT01086982|Drug|Octreotide acetate LAR|30 mg, single dose
1868101|NCT01086982|Drug|Sandostatin LAR ® (octreotide acetate LAR) 30 MG|30 mg, single dose
1868104|NCT01087021|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion
Route of administration: intravenous"
1868105|NCT01087034|Device|Acoustic reflection method evaluation|Evaluation of airways by acoustic relection method, with and without the bracing device
1868106|NCT01087034|Radiation|EOS™|Scoliosis and thoracic penetration index evaluation by EOS™ acquisition, with and without the bracing device
1868107|NCT01087034|Other|Non invasive respiratory muscle assessment|Non invasive respiratory muscles assessment, with and without the bracing device.
1868108|NCT01087047|Device|Acoustic reflection method|An acoustic reflection device gives the longitudinal cross-sectional area profile along airways. It is based on the analysis of a planar acoustic wave propagating in a rigid duct connected to airway.
1868109|NCT01087060|Procedure|partial or radical nephrectomy|
1868110|NCT01087073|Behavioral|Patient Activation|Culturally tailored patient activation training classes providing education and communication strategies to empower patients to be proactive in their diabetes self-management behavior. Participants attend a 10 week interactive class. Diabetes support groups after the completion of these classes help patient maintain self-management and adherence to healthy behaviors.
1868111|NCT01087073|Behavioral|Provider Training|Provider patient-centered communication training focuses on cultural competency and communication skills training to aid in shared decision-making and tailoring treatment recommendations to the patient's cultural preferences and readiness. Providers attend 4 1-hour monthly modules and one booster workshop 3 months post-class.
1868147|NCT01087411|Behavioral|Motivational Interviewing|The method motivational interviewing according to Miller and Rollnik is used as an behavioral intervention to support the child and family in their own behavioral change towards a more physically active life style.
1868221|NCT01087918|Device|RAGT|16 sessions / 4 times/week / 45 minutes Lokomat training
1868112|NCT01087073|Behavioral|Quality Improvement|Participating clinics participate in quality improvement (QI) programs which aim to redesign clinic operations to improve care for diabetes patients. QI initiatives have included instituting group visits, patient medication cards, peer support groups, flow sheets, nurse case management, and patient registries. New initiatives include improving access and tracking of specialists visits, employing community health workers/patient navigators, coordinating care, and implementing other team-based care initiatives. Provider and clinical staff members from all six project clinics attend collaborative quarterly QI sessions with project staff to discuss improvements in QI efforts, share QI methods among clinic teams, and provide brief training sessions.
1868113|NCT01087073|Behavioral|Community Outreach|The project collaborates with many community based organizations and resources to reach out to communities at high risk for diabetes on the South Side of Chicago and facilitate diabetes education, particularly in the area of nutrition and physical activity. We provide monthly health education events, nutrition tours, and frequently participate in community-based health fairs and health promotion events. We also work to promote nutrition through the Food Rx program, which utilizes a prescription to link patients at our clinics with nutrition resources on the South Side of Chicago through a coupon that gives discounts towards healthy purchases at participating stores, and have initiated a 10-week fitness program to promote physical activity among minority patients with diabetes.
1868114|NCT01087086|Behavioral|Crononutrition|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
1868115|NCT01087086|Behavioral|American Heart Association|"After the recruitment and selection of the study participants, the study will consists of a 2-month nutritional intervention (Crononutrition versus AHA) followed by second 6-month period (autonomy phase) in which the subjects of the study will continue with their ruled dietary patterns, but without any dietary or psychological support."
1868116|NCT01087099|Drug|Albendazole|Treatment with albendazole
1868117|NCT01087112|Behavioral|Mother-Infant Psychoanalytic tmt|Psychoanalytic sessions with mother and infant, at a median of 23 sessions 2 times weekly.
1868118|NCT01087112|Behavioral|Child Health Centre care|Nurse calls at Child Health Centres (CHC), with regular paediatric checkups. The nurse was encouraged to promote attachment and to detect postnatal depressions. Appointments with a psychiatrist or therapist or child psychiatric psychologist was initiated in 1/3 of the cases. This was registered at the end-point interview.
1868119|NCT01087125|Drug|No Interventions|No Interventions
1868120|NCT01087138|Behavioral|exercise|exercise class 3x's/week
1868121|NCT01087138|Behavioral|exercise and calcium|exercise class 3x's/week and 1500mg calcium intake
1868122|NCT01087151|Drug|ABT-263|Oral repeating dose
1868123|NCT01087151|Drug|rituximab|Intravenous repeating dose
1868126|NCT01087177|Other|Exposure to practice that has been trained in Pedialink CEASE|Child has had an appointment at a practice that was trained in Pedialink CEASE at the time of the interview.
1868127|NCT01087190|Drug|Isoniazid treatment|isoniazid 300 mg po qd for 9 months
1868128|NCT01087203|Biological|Tanezumab|20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
1868129|NCT01087203|Biological|placebo|Placebo to match tanezumab 20 mg subcutaneous injection every 8 weeks x 2 doses (at Baseline and week 8)
1868130|NCT01087216|Device|Group Laser = Arm A|Opposite side lesions that will receive only the treatment by topical steroids and UVB phototherapy
1868131|NCT01087216|Drug|Bras B : The group control|patient to accept habitual treatment of corticoid Opposite side lesions that will receive only the treatment by topical steroids
1868132|NCT01087229|Drug|equimolar oxygen-nitrous oxide mixture|Kinesitherapy is performed with a mask by which patient inhales an equimolar oxygen-nitrous oxide mixture.
1868133|NCT01087229|Drug|Placebo|Kinesitherapy is performed with a mask by which patient inhales a placebo.
1868134|NCT01087242|Drug|Tang-min Lin pill|Tang-min Lin pill 6g,tid,treat 12 weeks.
1868136|NCT01087268|Other|questionnaire administration|
1868137|NCT01087268|Procedure|gastrointestinal complications management/prevention|
1868138|NCT01087268|Procedure|quality-of-life assessment|
1868143|NCT01087359|Drug|Melatonin|100 mg melatonin is tested on human endotoxaemia administrated on night and day time compared to placebo
1868144|NCT01087398|Drug|Busulfan, Cyclophosphamide, Thymoglobulin, Fludarabine (Conditioning regimen)|"For sibling full match:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
ATG rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg
For haploidentical:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
Fludarabine 160 mg/m^2"
1868145|NCT01087398|Procedure|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:
Sibling full match
Other related full match
Sibling or other related with 1 mismatch antigen
Cord Blood
Haploidentical"
1868146|NCT01087398|Drug|Cyclosporin, Methotrexate (GVHD prophylaxis)|"Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in PBSCT and +11 in BMT or UCBT) then 9 mg/kg/day po
10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)"
1868332|NCT01088750|Procedure|therapeutic conventional surgery|
1998348|NCT01444729|Drug|Xiapex|Xiapex administration will follow SMPC
1998349|NCT01444729|Procedure|surgery|Non-pharmacological treatment
1868149|NCT01087411|Dietary Supplement|Supplementation with fish liver oli capsules|This group will receive capsules containing omega-3 and omega-6 fatty acids and vitamine E. The dosage is six capsules daily containing omega-3 (558 mg of eico-pentaenoic-acid, EPA, and 174 mg of docosahexaenoic acid, DHA), omega-6 (60 mg of γ-linolenic acid, GLA) plus 9.6 mg vitamin E (in natural form, d-α-tocopherol), gelatin and glycerol. Participants will be instructed to eat three capsules each morning and evening.
1868150|NCT01087411|Dietary Supplement|Placebo oil capsules|This group will receive capsules containing rape seed oil. Participants will be instructed to lead their life in the same manner as before the intervention but eat three capsules each morning and evening.
1868151|NCT01087424|Drug|RminiCHOP|Prednisone 40 mg/m2 D1 D2 D3 D4 D5 Rituximab 375 mg/m2 D1 Doxorubicine 25 mg/m2 D1 Cyclophosphamide 400 mg/m2 D1 Vincristine 1 mg/m2 D1
1868152|NCT01087437|Dietary Supplement|gastrolith calcium|
1868153|NCT01087463|Device|Quantum|Treatment of humerus fracture (according to the mentioned indications) with the Quantum Intramedullary Nailing System.
1868154|NCT01087476|Drug|Doxycycline hyclate|Sub-microbial dose of Doxycycline hyclate or placebo (50 mg per day), immediately before the initiation of induction chemotherapy and daily during the following 21 days after chemotherapy.
1868155|NCT01087489|Drug|4% lidocaine|The eye will be topically anesthetized with 0.5% proparacaine drops and 4% lidocaine drops and a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface followed in three rounds by additional 5% povidone iodine and a sterile cotton swab soaked in sterile 4% lidocaine applied with gentle pressure to the area designated for injection in the infero-temporal quadrant.
1868156|NCT01087489|Drug|3.5% ophthalmic lidocaine gel|The eye will be topically anesthetized with 0.5% proparacaine drops and 5% povidone iodine will be placed over the eye. Two drops of preservative-free 3.5% lidocaine hydrochloride ophthalmic gel will be placed into inferior conjunctival sac. The patient will be asked to close the eye for 7 minutes. Next, a 10% povidone-iodine scrub of the lids and lashes will be performed. A sterile speculum will be placed between the lids. Five percent povidone-iodine drops will then be applied over the ocular surface and allowed to remain in contact with the eye for at least 2 minutes. The eye will then be rinsed with antibiotic drops.
1868157|NCT01087502|Drug|Glimepiride|1-4 mg daily after 12 weeks
1868158|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin first 12 weeks of treatment once daily
1868159|NCT01087502|Drug|Placebo|Placebo maching Glimepiride 1-4 mg after 12 weeks of treatment
1868160|NCT01087502|Drug|Placebo|Placebo mach to 5 mg linagliptin once daily after 12 weeks
1868161|NCT01087502|Drug|Linagliptin|5 mg once daily
1868162|NCT01087515|Other|Blood donation|"In experimental part 1 to generate preclinical data 250 ml of blood will be donated at day 1 by 10 subjects to induce allergen presenting cells (APCs).
In experimental part 2 to transfer the isolation of pDC or TREGs to a GMP (good manufacturing Practice) compliant clinical grade isolation system, leukapheresis will be performed with the blood from 5 subjects.
In experimental part 3 for potency testing of the clinical grade isolation system of pDC or TREGs, 250 ml of blood will be collected at day 1 from 3 subjects."
1868163|NCT01087528|Device|PillCam™ (Capsule Endoscopy) Colon 2 capsule|Medical Device
1868164|NCT01087541|Behavioral|Educational program 6-hour standardized|6-hour standardized program for adults ( doctors and nurses )
1868165|NCT01087554|Drug|Sirolimus|"Escalation Phase: Sirolimus starting dose1 mg by mouth on Days 1 - 28.
Expansion Phase starting dose: MTD from Escalation Phase."
1868166|NCT01087554|Drug|Vorinostat|"Arm A - Escalation Phase: Vorinostat starting dose 100 mg by mouth on Days 7 - 28 of Cycle 1; For all other cycles, dose of 100 mg Days 1-28.
Expansion Phase starting dose: MTD from Escalation Phase.
Arm B + Arm C - Escalation and Expansion Phase: Vorinostat dose 300 mg by mouth on Days 7 - 28. Rest of cycles: 300 mg by mouth on Days 1 - 28."
1868167|NCT01087554|Drug|Everolimus|"Escalation Phase: Everolimus starting dose 5 mg by mouth on Days 1 - 28.
Expansion Phase: MTD from Escalation Phase."
1868168|NCT01087554|Drug|Temsirolimus|"Escalation Phase: Temsirolimus starting dose 12.5 mg by vein on Days 1, 8, 15, 22.
Expansion Phase: MTD from Escalation Phase."
1868169|NCT01087567|Drug|Intensive insulin|A weight-based basal bolus insulin regimen starting with 0.1 units/kg/day of Glargine and 4 units/meal of Glulisine.
1868170|NCT01087567|Drug|Routine Care|Treatment in routine care will be based upon the 2009 ADA treatment recommendations.
1868171|NCT01087580|Drug|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
1868172|NCT01087580|Drug|Docetaxel and Prednisone|A) Docetaxel: 75 mg/m2 IV infusion over 1 hour on day 1 of each cycle every 21 days B) Prednisone: 10 mg orally for 21 days after each dose of docetaxel
1868173|NCT01087580|Drug|Radiation Therapy|"GROUPS 1 and 2 Whole Pelvis (45 Gy) + Prostate boost (20-25 Gy) in 1.8 Gy fractions, 5 fractions/week.
GROUPS 2 Bone metastasis (bone scan index < 1.4%): 30 Gy in 10 fractions or 35 Gy in 12 fractions.
GROUPS 1,2 Abdominal Nodes (IF POSITIVE ON CT/MRI SCAN): 45-50 Gy in 1.8 Gy fractions, 5 fractions/week."
1868174|NCT01087593|Drug|17β-estradiol|Transdermal administration(50 ug daily)for a period of ten weeks with additional treatment of medroxyprogesterone (10mg daily) for the last two weeks
1868175|NCT01087619|Procedure|Parathyroid surgery|Parathyroid Surgery (regardless of surgical strategy; i.e., focused operation, unilateral- or bilateral neck exploration)
1868176|NCT01087632|Dietary Supplement|Armolipid Plus|Armolipid Plus 1 tablet QD for 18 weeks
1868177|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925, at escalating dose levels. Progression to next dose will be based on safety evaluation
1868178|NCT01087645|Drug|NN9925 (i.v.)|As an active comparator, one standard dose will be given i.v. (into the vein) at one study visit
1868179|NCT01087645|Drug|placebo|Subjects will receive a single dose of placebo as a comparator to NN9925, at all dose levels
1868180|NCT01087645|Drug|NN9925 (oral)|Subjects will be randomised to receive a single dose of NN9925 in up to three different concentrations. The dose will be selected based on the results of part 1
1868181|NCT01087645|Drug|placebo|Subjects will be randomised to receive a single dose of placebo
1868182|NCT01087658|Drug|Glutamine|Per os
1868183|NCT01087658|Drug|Calcium and Magnesium|Intravenous
1868184|NCT01087671|Drug|tafluprost|prostaglandin analogue
1868185|NCT01087684|Procedure|Argon laser trabeculoplasty|Argon laser 600-800 mW, 0.1seconds, 50 micron spot size, 45 - 55 burns over 180 degrees of trabecular meshwork
1868186|NCT01087684|Procedure|Selective laser trabeculoplasty|Selective laser trabeculoplasty 0.7 - 0.8 mJ, 400 micron spot size, 3 nanosecond, 45 - 55 burns over 180 degrees of trabecular meshwork.
1868187|NCT01087697|Device|Neo-Urinary Conduit|Implantation with the autologous Neo-Urinary Conduit
1868188|NCT01087710|Other|medical food with EPA and GLA, vitamins and minerals|1 8oz serving per day for 12 weeks
1868189|NCT01087710|Other|medical food minus EPA and GLA, antioxidant vitamins/minerals|1 8oz serving a day for 12 weeks
1868190|NCT01087723|Drug|Bivalirudin|
1868191|NCT01087723|Drug|Heparin|
1868192|NCT01087736|Drug|Topiramate|After random assignment, topiramate will be titrated up over 5 weeks. Dosing begins at 25 mg per day, and increase in the second week to 25 mg twice per day; in the third week to 50 mg twice/day; in the fourth week to 75 mg twice/day; in the 5th week to 100 mg twice/day; and in weeks 6-11 increased to and maintained at 100 mg in the morning and 200 mg at night. Patients will receive the highest dose tolerated, not to exceed 300 mg per day. Adjustments are permitted throughout titration. Once maximum tolerated dosage is reached, subjects will be asked to maintain dosage for remainder of the treatment phase. Upon completing the 6 week maintenance period subjects will taper off over a 7-day period (Week 12). If subjects experience significant side effects, the dosage may be adjusted.
1868193|NCT01087736|Other|Placebo administration|Placebo pills will be prepared by the UCSF pharmacy which will be indistinguishable from the topiramate pills used in that arm. Both topiramate and placebo will then be delivered to the VA pharmacy. A consulting biostatistician will randomly assign participants to either the topiramate or placebo group. The dosing of placebo pills will follow the same regimen as outlined for the topiramate arm. In the event of a safety issue, there will be a procedure for unblinding only that participant.
1868194|NCT01087749|Drug|Propranolol|Propranolol 40mg PO will be given with 6oz of water.Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
1868195|NCT01087749|Drug|Losartan|Losartan 50mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
1868196|NCT01087749|Drug|Eprosartan|Erythromycin 125mg PO will be given with 6oz of water. Blood samples will be obtained for 12 hours to determine the medication concentration in the plasma. There is no therapeutic effect on this study, since patients will receive a low single dose of the medication, and we'll assess the different pharmacokinetic parameters based on the concentrations of the medicine in plasma.
1868197|NCT01087762|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
1868198|NCT01087762|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
1868199|NCT01087762|Other|Placebo|Matching Placebo to CZP injection.
1868200|NCT01087775|Behavioral|Cognitive Training|Plasticity Based Adaptive Cognitive Remediation (PACR)
1868201|NCT01087788|Biological|CZP 200 mg Q2W|200 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 2 weeks (Q2W).
1868202|NCT01087788|Biological|CZP 400 mg Q4W|400 mg subcutaneous (sc) injection of Certolizumab Pegol (CZP) every 4 weeks (Q4W).
1868203|NCT01087788|Other|Placebo|Matching Placebo to CZP injection.
1868204|NCT01087801|Drug|ChiRhoStim|Human Secretin for Injection
1868205|NCT01087801|Drug|Placebo|Saline for Injection
1868206|NCT01087814|Drug|Efavirenz|Subject will take efavirenz for 5 days.
1868207|NCT01087814|Drug|Over-encapsulated efavirenz|Subject will take efavirenz that has been over-encapsulated with a gel capsule for 5 days.
1868208|NCT01087840|Drug|Raltegravir|"Drug: Raltegravir tablet 400mg is taken orally, twice daily with or without food for 28 days along with Tenofovir disoproxil fumarate/emtricitabine 300mg/200mg 1 tablet taken orally once daily with or without food for 28 days.
Arms: Raltegravir/Truvada Other Names: Isentress/Truvada"
1868209|NCT01087853|Drug|Crystalloid|2 litres intravenous infusion in 60 minutes
1868210|NCT01087853|Drug|Colloid|1 litre intravenous infusion over 30 minutes
1868211|NCT01087866|Drug|Metformin|
1868212|NCT01087866|Drug|Insulin|
1868213|NCT01087879|Drug|Desogestrel-Ethinyl Estradiol contraceptive pill|150 microg Desogestrel and 20 microg Ethinyl Estradiol combination. One pill once a day for 9 weeks, continual administration.
1868214|NCT01087879|Drug|Etonogestrel-Ethinyl Estradiol vaginal ring|Etonogestrel-Ethinyl Estradiol vaginal ring, which consists of 11,7 mg etonogestrel and 2,7 mg ethinyl estradiol. It delivers 0,120 mg etonogestrel and 0,015 mg ethinyl estradiol per day. Treatment continues continual for 9 weeks and the vaginal ring is changed every three weeks.
1868215|NCT01087879|Drug|Norelgestromin-Ethinyl Estradiol contraceptive patch|A combination transdermal contraceptive patch with 6 mg of norelgestromin and 600 microg of ethinyl estradiol. It delivers 203 microg of norelgestromin and 33,9 microg ethinyl estradiol per day. A continual use of patch for 9 weeks and the patch is changed every week.
1868216|NCT01087892|Dietary Supplement|Probiotic drink containing the live strain|Probiotic drink contains no strain
1868217|NCT01087892|Dietary Supplement|placebo probiotic|Placebo product is a sweetened flavoured, non fermented, acidified dairy drink
1868218|NCT01087905|Drug|Nicotine patch|"If > 10 cigs/day: one 21 mg nicotine patch per day
If < or = 10 cigs/day: one 14 mg nicotine patch per day"
1868219|NCT01087905|Drug|Nicotine gum|"If < 25 cigs/day, 2 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects.
If ≥ 25 cigs/day, 4 mg nicotine gum, at least 5 pieces of oral NRT per day (maximum of 1 piece every 1-2 hours), unless this amount of use produces nicotine toxicity effects."
1868220|NCT01087905|Behavioral|CMAC|CMAC consists of tailored cessation counseling to improve medication adherence during the counseling calls. The CMAC protocol was developed by study investigators and involved: (1) pre-quit assessment of beliefs that might undermine NRT adherence; (2) on-going medication adherence assessment by quitline Quit Coaches; and (3) tailored coaching based on the ongoing assessments.
1868222|NCT01087918|Other|Strength Training|16 sessions / 4 times/week / 45 minutes lower extremity strength training
1868223|NCT01087931|Drug|Bupivacaine|Single application of 10ml of bupivacaine 0.5% into the iliac crest bone harvest surgical site.
1868224|NCT01087931|Other|Normal Saline|Normal saline 0.9%, 10ml, single application directly into iliac crest bone harvest surgical site.
1868225|NCT01087944|Device|Autoinjector|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by autoinjector for 3 weeks.
1868226|NCT01087944|Device|Pre-filled syringe|Participants received Peginterferon alfa-2a 180 microgram subcutaneously once a week by pre-filled syringe for 3 weeks.
1868227|NCT01087957|Device|WalkAide|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
1868228|NCT01087957|Other|Ankle-Foot Orthosis (AFO)|Comparison of WalkAide device against Ankle-Foot Orthosis (AFO)
1868229|NCT01087970|Drug|Pemetrexed|Administered intravenously, for maximum of 6 cycles.
1868230|NCT01087970|Drug|Cetuximab|"Administered intravenously in combination therapy, for a maximum of 6 cycles.
After the completion of 6 cycles, participants who have not experienced disease progression will continue on cetuximab monotherapy until disease progression."
1868231|NCT01087970|Drug|Carboplatin|Administered intravenously, for a maximum of 6 cycles
1868232|NCT01087970|Drug|Cisplatin|Administered intravenously, for a maximum of 6 cycles
1868233|NCT01087983|Drug|Lapatinib|Starting oral dose of 500 mg daily for 21 day cycle.
1868234|NCT01087983|Drug|Sirolimus|Starting oral dose 1 mg daily.
1868235|NCT01087983|Drug|Metformin|Starting oral dose 1000 mg daily.
1868236|NCT01087996|Biological|Auto-hMSCs|Biological: Autologous human mesenchymal stem cells (Auto-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Auto-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Auto-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Auto-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
1868237|NCT01087996|Biological|Allo-hMSCs|Biological: Allogeneic human mesenchymal stem cells (Allo-hMSCs) Participants will receive 40 million cells/mL delivered in either a dose of 0.5 mL per injection x 1 injection for a total of 0.2 x 10^8 (20 million) Allo-hMSCs, a dose of 0.5 mL per injection x 5 injections for a total of 1 x 10^8 (100 million) Allo-hMSCs, or a dose of 0.5 mL per injection x 10 injections for a total of 2 x 10^8 (200 million) Allo-hMSCs. The injections will be administered transendocardially during cardiac catheterization using the Biocardia Helical Infusion Catheter.
1868238|NCT01088009|Drug|lamivudine|patients in this arm will receive oral lamivudine 100mg,daily for 24 weeks; if patients with HBV DNA higher than 1000 copies/ml at week 24, add on adefovir to week 104; otherwise, keep lamivudine monotherapy to week 104
1868239|NCT01088009|Drug|lamivudine|Patients will receive oral lamivudine 100mg,daily for 104 weeks, if HBV DNA breakthrough, add on oral adefovir 10mg daily
1868240|NCT01088009|Drug|lamivudine, adefovir|patients in this arm will receive oral lamivudine 100mg daily and adefovir 10mg for 104 weeks
1868241|NCT01088022|Drug|Aprepitant, Palonosetron, Dexamethasone|Aprepitant 125-mg capsule 80-mg capsule 80-mg capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
1868242|NCT01088022|Drug|Placebo, Palonosetron, Dexamethasone|Aprepitant 125-mg placebo capsule 80-mg placebo capsule 80-mg placebo capsule Palonosetron 0.25 mg i.v. Dexamethasone 8 mg i.v. 8 mg os 8 mg os
1868243|NCT01088035|Drug|Carboplatin|Patients will receive daily carboplatin as a radiation sensitizer prior to radiation each day.
1868244|NCT01088048|Drug|Idelalisib|Idelalisib tablet administered orally
1868245|NCT01088048|Drug|Rituximab|Rituximab administered intravenously
1868246|NCT01088048|Drug|Bendamustine|Bendamustine administered intravenously
1868247|NCT01088048|Drug|Ofatumumab|Ofatumumab administered intravenously
1868248|NCT01088048|Drug|Fludarabine|Fludarabine administered orally
1868249|NCT01088048|Drug|Everolimus|Everolimus administered orally twice daily until disease progression
1868250|NCT01088048|Drug|Bortezomib|Bortezomib administered as a subcutaneous injection
1868251|NCT01088048|Drug|Chlorambucil|Chlorambucil administered on Days 1-7 every 28 days to allow appropriate therapy for participants with CLL and to coordinate into a cycle period equivalent to other study treatment regimens.
1868252|NCT01088048|Drug|Lenalidomide|Lenalidomide administered orally
1868253|NCT01088074|Device|Histoacryl Tissue Adhesive|
1868254|NCT01088074|Device|Dermabond|
1868255|NCT01088074|Device|Staples|
1868256|NCT01088074|Device|Monocryl 4-0|
1868257|NCT01088087|Dietary Supplement|colostrum|colostrum, 2g, 2 times a day, for 3 weeks
1868258|NCT01088100|Genetic|Genotyping|Determination of 3 types of clock gene genotypes (HPER 4/4, 5/4, 5/5) on all blood samples
1868259|NCT01088126|Procedure|radiofrequency catheter ablation|radiofrequency catheter ablation, NavX system
1868261|NCT01088152|Behavioral|Celiac school|Structured education of adult celiac patients at 10 sessions.
1868262|NCT01088152|Behavioral|Usual care of celiac disease women|Written information corresponding to that offered when seeking medical advice for well treated celiac disease in the primary care.
1868263|NCT01088165|Drug|Adalimumab treatment arm|Adalimumab: day 1: 2x40 mg s.c., day 8: 40 mg s.c., thereafter 40 mg s.c. in biweekly intervals
1868264|NCT01088165|Drug|Fumaric acid esters treatment group|"First week:FAE mite (DIMETHYL FUMARATE 30mg, ETHYL FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg):day 1 and 2: 0-0-1, day 3 and 4: 1-0-1, day 5-7: 1-1-1).
Week 2: FAE forte (DIMETHYL FUMARATE 120mg ETHYL, FUMARATE CALCIUM 87mg, ETHYL FUMARATE ZINC 3mg, ETHYL FUMARATE MAGNESIUM 5mg)starting with 0-0-1 capsule daily, thereafter weekly increases by on capsule until maximum daily dose 2-2-2. In the event of side effects (in particular, gastrointestinal disturbances or flushing) adaption of the dose (reduction or no increase) depending on the type and severity of the side effect will be performed. If remission occurs at a lower than the maximum dose that dose will be maintained throughout the rest of the study period."
1868333|NCT01088763|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
1868265|NCT01088165|Other|Narrow band UVB radiation|"No reduction of 50% minimum of baseline psoriasis severity index by week 12: additional narrow band UVB radiation, 3x/week until the patients achieve PASI reduction of 75% or greater or over a maximum period of another 12 weeks.
Initial dosage: Fitzpatrick skin phototype I and II: 0,4 J/cm2, III and IV: 0,6), 10% Increments after each radiation"
1868266|NCT01088178|Device|Levonorgestrel Intrauterine System (LNG-IUS: Mirena, Bayer)|Placement of Mirena at given intervals during the postpartum period
1868267|NCT01088191|Biological|MSB-CAR001 Combined With Hyaluronan|"Knee Injection of Biological: MSB-CAR001 Combined With Hyaluronan
Single Injection Into the Knee Joint of Single Doses of MSB-CAR001 Combined With Hyaluronan"
1868268|NCT01088191|Drug|Hyaluronan|Hyaluronan alone
1868269|NCT01088204|Procedure|laparoscopy assisted distal gastrectomy|laparoscopy assisted distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
1868270|NCT01088204|Procedure|open distal gastrectomy|open distal gastrectomy with D2 lymph node dissection for patients with advanced gastric cancer
1868271|NCT01088230|Other|Botox®|the treatment group will receive a one time injection of Botox® at the wrist flexors and pronators of the affected arm. Each subject will receive a standard dose of 150 units total, 50u each to the flexor carpi radialis and flexor carpi ulnaris, and 25u each for the pronator teres and pronator quadratus muscle groups.
1868272|NCT01088230|Other|saline solution|the control group will receive a one time injection of salt water in the flexor carpi radialis and flexor carpi ulnaris, and the pronator teres and pronator quadratus muscle groups.
1998356|NCT01437306|Drug|Lofexidine HCl|400 mcg (2 x 200 mcg tablets) administered orally as a single dose
1868275|NCT01088256|Drug|Etoricoxib|the patients get etoricoxib 90mg for 8 days. They get one pill with 90mg per day
1868276|NCT01088256|Drug|placebo|patients get one pill of placebo (sugar-pill) per day for 8 days.
1868277|NCT01088282|Procedure|Cataract surgery|Implantation of multifocal or monofocal IOL
1868278|NCT01088295|Drug|Telmisartan|
1868279|NCT01088308|Procedure|High rate atrial and vetricular stimulation|The right atria and ventricle of the subject will be electrically stimulated at high rate mimicking tachycardia episodes using electrodes placed in the right atria and ventricle.
1868280|NCT01088308|Procedure|Ventricular Tachycardia induction|A programmed electrical stimulation protocol will be performed using an electrode placed in the right ventricle.
1868281|NCT01088334|Other|screening|CT-Chest/abdomen and mammography in women
1868282|NCT01088347|Drug|mapatumumab|Mapatumumab (10 or 30 mg/kg) intravenously on days 1, 22, and 45. In phase 2 the MTD established in phase 1 will be used.
1868283|NCT01088347|Drug|cisplatin|Cisplatin 40 mg/m2 intravenously on days 8, 15, 22, 29, 36, and 45
1868284|NCT01088347|Radiation|radiotherapy|Radiotherapy: a total dose of 45 Gy will be given in fractions of 1.8 Gy, five fractions per week (days 8-12, 15-19, 22-26, 29-33, and 36-40), by external beam irradiation by photon beam of at least 6 MV. After completing the five weeks of external beam irradiation, evaluation will take place to determine whether the boost can be given by brachytherapy. If brachytherapy is not feasible, the boost will be given by external beam irradiation to a total dose of 70.2 Gy in fractions of 1.8 Gy.
1868285|NCT01088373|Drug|Azacitidine combined to Lenalidomide|Azacitidine: 75mg/m2/d for 5 days per cycle of 28 days. Lenalidomide: 5mg/day during 14 days for cohort 1. Lenalidomide: 5mg/day during 21 days for cohort 2. Lenalidomide: 10mg/day during 21 days for cohort 3.
1868286|NCT01088399|Drug|Somatropin (rDNA origin)|Dose, frequency and duration are at discretion of attending physician, and determined on an individual basis.
1998357|NCT01429987|Drug|plecanatide|Subjects receive experimental study drug for 12 weeks.
1868288|NCT01088425|Other|Observation|"Alberta infant motor scale
Griffiths test
Kauffmann ABC"
1868289|NCT01088438|Behavioral|Contextualization workshop|A four-hour course on contextualization.
1868290|NCT01088451|Drug|Combined prandial insulin therapy (CPIT)|Combined prandial insulin therapy (CPIT) applies individual combination of rapid insulin analogue and human insulin according subject's individual estimation of the type of carbohydrates in concrete mixed-meal, based on thorough education. In this study subjects use two applicators, giving two injections before main meals as per basal-bolus therapy. Insulin aspart (Novorapid, Novo Nordisk) and human insulin (Actrapid, Novo Nordisk) are used.
1868291|NCT01088464|Biological|IMC-11F8|600 milligrams (mg) intravenously, Days 1 and 8 every 3 weeks
1868292|NCT01088464|Biological|IMC-11F8|800 mg intravenously, every 2 weeks
1868293|NCT01088464|Biological|IMC-11F8|800 mg intravenously, Days 1 and 8 every 3 weeks
1868294|NCT01088477|Other|Diagnostic intervention: Positron Emission Tomography with 16-alpha-[18-fluoro]-17betaestradiol|In patients with acquired antihormonal resistance, eligible for estrogen therapy, a FES-PET scan will be made to determine FES-PET tumor uptake (which corresponds to estrogen receptor expression levels). Immediately after the FES-PET scan, all patients will start with a standard accepted dose of 2mg estradiol TID. Therapy response will be monitored by regular follow-up. RECIST criteria and clinical benefit will be used as criteria. In case of disease progression before end of the study period, estradiol treatment will be stopped.
1868295|NCT01088503|Drug|ADP receptor inhibitors|Dosage regimen as determined by the treating physician.
1868296|NCT01088516|Drug|Lopinavir/Ritonavir (200/50 mg) Tablets + Zidovudine + 3TC|Zidovudine 300mg PO BID + 3TC 150 mg PO BID + Lopinavir/Ritonavir (200/50 mg) two tablets PO BID
1868297|NCT01088529|Drug|Abiraterone Acetate|1000 mg oral daily for 3 months followed by a prostatectomy.
1868298|NCT01088529|Drug|Prednisone|5 mg orally daily.
1868299|NCT01088529|Drug|LHRHa|LHRH analogue (either leuprolide or goserelin): Leuprolide is an intramuscular injection, and goserelin subcutaneous (under skin) of abdomen, given either 1 injection every 3 months or 1 injection each month for 3 months.
1868334|NCT01088763|Other|diagnostic laboratory biomarker analysis|Correlative studies
1868335|NCT01088763|Other|pharmacological study|Correlative studies
1868336|NCT01088763|Drug|dexamethasone|Given IV
1868374|NCT01081652|Drug|Progesterone|Progesterone 60 mg administered intramuscular once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
1868300|NCT01088542|Behavioral|Communities That Care|The Communities That Care (CTC) system provides communities training and ongoing technical assistance in a structured process for conducting prevention needs assessments using epidemiological data on levels of risk and protective factors for adolescent problem behaviors, selection of tested and effective preventive interventions shown to address community-prioritized factors, implementation of these interventions with fidelity, and evaluation of the community's progress toward its goals. The CTC system is designed to produce a plan for prevention services that is tailored to the needs of each community. CTC is installed in five phases through a manualized series of training events designed to build the capacity of communities to install and sustain the system over time.
1868304|NCT01088581|Drug|Adjuvant group|Adjuvant chemotherapy (5FU and cisplatin) after resection
1868305|NCT01088594|Drug|pioglitazone/rosiglitazone/placebo|single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg +single oral dose of placebo
1868306|NCT01088594|Drug|rosiglitazone/pioglitazone/placebo|single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg + single oral dose of placebo
1868307|NCT01088594|Drug|placebo/pioglitazone/rosiglitazone|single oral dose of placebo + single oral dose of pioglitazone 45mg + single oral dose of rosiglitazone 8mg
1868308|NCT01088594|Drug|pioglitazone/placebo/rosiglitazone|single oral dose of pioglitazone 45mg +single oral dose of placebo + single oral dose of rosiglitazone 8mg
1868309|NCT01088594|Drug|rosiglitazone/placebo/pioglitazone|single oral dose of rosiglitazone 8mg + single oral dose of placebo + single oral dose of pioglitazone 45mg
1868310|NCT01088594|Drug|placebo/rosiglitazone/pioglitazone|single oral dose of placebo + single oral dose of rosiglitazone 8mg + single oral dose of pioglitazone 45mg
1868312|NCT01088620|Drug|Panitumumab|"Panitumumab 9 mg/kg BW will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
In case of CR, PR or SD status at the end of the combination treatment, a panitumumab single drug treatment, consisting of 9 mg/kg BW administered every 3 weeks, will be performed until detection of disease progression."
1868313|NCT01088620|Drug|Pemetrexed|Pemetrexed 500 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
1868314|NCT01088620|Drug|Cisplatin|Cisplatin 75 mg/m² will be administered IV every 3 weeks (q3w) for a maximum of four cycles.
1868315|NCT01088633|Other|Exhaled particle analysis|"At visit 2, the exhaled particle analysis will be performed. Subjects will be asked to breath through the device and to perform several breathing maneuvers such as deep breathing, shallow breathing, rapid breathing, slow breathing. These measurements will be repeated after 2 hours on the same day.
Visit 3:
After a baseline exhaled particle analysis, the subjects will inhale nebulized saline (2.5 ml of a 0.9 % NaCl-solution). Aerosol generation and transport will be recorded immediately after the end of inhalation as well as 2 hours and 4 hours after the start of inhalation using the same techniques as in visit 2."
1868316|NCT01088646|Device|PillCam® Express Capsule Endoscopy Delivery System|"The PillCam® Express Capsule Endoscopy Delivery System is comprised of three parts: a catheter, a syringe and the capsule holder. The catheter is passed through the accessory channel of a standard endoscope and the capsule holder is snapped on to the distal end of the device. The endoscope is used to guide the Capsule Endoscopy Delivery System to the proximal duodenum. The capsule is then released pneumatically, using an air-filled syringe attached to the proximal end of the catheter.
Once the capsule is deployed, the endoscope is withdrawn and the capsule holder is cut off at the distal part of the device with scissors. The catheter is then retracted and discarded.
The PillCam® Express Capsule Endoscopy Delivery System is single-use, disposable and latex-free."
1868317|NCT01088659|Drug|peginterferon alfa-2a [Pegasys]|180mcg sc weekly, 96 weeks
1868318|NCT01088659|Drug|placebo|orally daily, 96 weeks
1868319|NCT01088659|Drug|tenofovir|245mg po daily, 96 weeks
1868320|NCT01088672|Procedure|Mechanical Thrombectomy|The Trevo device is intended to restore blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke.
1868321|NCT01088685|Device|Experimental Blister Patch|Experimental hydrogel blister patch to be applied as needed (at least every 2 days) consecutively until blister heals
1868322|NCT01088685|Device|Marketed Pflaster|Foot Blister Patch to be applied as needed (at least every 2 days) until blister heals
1868323|NCT01088698|Radiation|UVB-311nm radiation|UVB-311nm radiation given 3 times a week to one randomized body-half
1868324|NCT01088711|Drug|Omarigliptin|Once-weekly 50 mg capsule
1868325|NCT01088711|Drug|Placebo|Once-weekly placebo capsule
1868326|NCT01088724|Drug|fludarabine, cyclophosphamide, doxorubicin, rituximab|Fludarabine i.v.(30 mg/sqm/day,day 1,2,3); Cyclophosphamide i.v.(750 mg/sqm, day 1); Doxorubicin i.v.(30 mg/sqm, day 1); Rituximab i.v. (375 mg/sqm, day 4).
1868328|NCT01088750|Drug|cyclophosphamide|
1868329|NCT01088750|Drug|prednisolone|
1868330|NCT01088750|Drug|vinblastine sulfate|
1868331|NCT01088750|Other|watchful waiting|
1868337|NCT01088776|Dietary Supplement|n-3 Fatty Acid supplement|"Children will be prescribed 1600-1800 mg EPA + DHA per m2 Body Surface Area, to a maximum of the upper limit of the age-appropriate range recommended by Health Canada.
Each n-3FA gel capsule (1000 mg) will contain 400 mg EPA and 200 mg DHA derived from the oil of wild anchovies and sardines. A smaller gel capsule (500 mg; 200 mg EPA + 100 mg DHA) will be available for children unable to swallow large solid medication and a flavored liquid formulation, containing a similar proportion of EPA + DHA (2200 mg fish oil concentrate from anchovies and sardines, 750 mg EPA, 375 mg DHA per ½ teaspoon), will be available for use in toddlers and older children unable to swallow gel capsules."
1868338|NCT01088776|Dietary Supplement|Placebo|The placebo, identical in opaque appearance and citrus-flavored taste, will contain a 50:50 blend of soybean and corn oil for both gel capsule (2 sizes) and liquid formulations.
1868339|NCT01088789|Biological|PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1 neo vaccine.|"A pancreatic vaccine secreting a granulocyte-macrophage colony-stimulating factor(GM-CSF). The vaccine consists of equal numbers of pancreatic cancer cells (Panc 6.03)and (Panc. 10.05) into a single vaccine.
The vaccine is administered every 6 months."
1868340|NCT01088802|Radiation|IMRT|Dose de-escalation (from 70 Gy to 63 Gy and from 58.1 Gy to 50.75 Gy, same number of fractions (N=35) in 7 weeks)
1868341|NCT01088802|Drug|Cisplatin|Cisplatin will be administered weekly for the first 3 weeks and the last 3 weeks of radiation. Patients will not receive chemotherapy during week 4 of treatment.
1868342|NCT01088802|Drug|Carboplatin|Carboplatin will be administered weekly during the 7 weeks of radiation. Carboplatin may be given as a substitution for cisplatin when cisplatin-related toxicities occur or when patients present with greater than grade 2 sensory or motor neuropathy, greater than 2 hearing loss, or less than 60 ml/min creatinine clearance.
1868343|NCT01081314|Behavioral|Dialectical Behavior Therapy|Standard Dialectical Behavior Therapy as described in the 2 DBT treatment manuals (Linehan, 1993a,b).
1868344|NCT01081314|Behavioral|PTSD Protocol|A modified version of Prolonged Exposure therapy for PTSD
1868345|NCT01081340|Behavioral|Social network building intervention|Group support and health education sessions weekly during third trimester and once every two weeks until 6 months postpartum
1868346|NCT01081340|Behavioral|Home visit|Three home visits during third trimester and three during postpartum period until 6 months postpartum
1868347|NCT01081353|Drug|Acetylsalicylic Acid (Aspirin BAY1019036)|One tablet of new formula Aspirin under fasting conditions
1868348|NCT01081353|Drug|Alka Seltzer Extra Strength|One effervescent tablet under fasting conditions
1868349|NCT01081353|Drug|Aspirin Migraine|One effervescent tablet under fasting conditions
1868350|NCT01081353|Drug|Aspirin Aspro|One effervescent tablet under fasting conditions
1868351|NCT01081392|Biological|LPS|LPS 20mcg sd inhaled via nebulizer, 3 periods
1868352|NCT01081405|Other|TOTAL LYMPHOID IRRADIATION|Allogeneic Hematopoietic Cell Transplantation Using a Non-myeloablative Preparative Regimen of Total Lymphoid Irradiation and Anti-Thymocyte Globulin for Patients with Hematologic Malignancies
1868353|NCT01081418|Behavioral|Assertive Community Treatment (ACT)|ACT was structured and implemented according to guidelines of the Assertive Community Treatment Association (ACTA). Team members were highly educated psychosis experts consisting of a consultant psychiatrist, a psychiatrist, two psychologists, and a nurse, all of which received training in cognitive behavioral (CBT), dynamic, and/or family psychotherapy. Study participants could use all treatment options within the integrated care program such as psychoeducation groups, social skills training, family groups, motivational addiction therapy, meta-cognitive training etc.
1868354|NCT01081431|Drug|Lenalidomide|10 mg d1-d21 of a 28-day cycle
1868355|NCT01081444|Device|rTMS|effective and active cortical magnetic stimulations
1868356|NCT01081444|Device|Placebo rTMS|non active cortical magnetic stimulation
1868357|NCT01081457|Device|Deep brain stimulation|Comparison ON vs OFF
1868358|NCT01081483|Drug|ABT-072|See arm description for more information
1868359|NCT01081483|Drug|Placebo|See arm description for more information
1868360|NCT01081535|Drug|ketorolac, fentanyl|intravenous PCA
1868361|NCT01081548|Drug|atorvastatin|20 mg
1868362|NCT01081548|Drug|atorvastatin|20 mg
1868363|NCT01081561|Drug|Riboflavin|Removal of the epithelium, riboflavin drops every 2 minutes for 30 minutes follow by UV light radiation and addition riboflavin drops every 2 minutes for 30 minutes. Some subjects will be randomized to recieve INTACS prior to treatment with riboflavin.
1868364|NCT01081574|Drug|Bilastine|10 mg/qd/ 7 days.Oral dispersible tablets
1868365|NCT01081587|Procedure|Access to a Computerized Clinical Decision Support System (CCDDS)|Automatic CCDSS will alert physician for each case of malnourished using an algorithm based on age, sex, weight and size of each hospitalized children.
1868366|NCT01081587|Behavioral|Education of Healthcare workers|Education of the hospital staff to evidence-based practices in malnutrition care will be proposed in the experimental arm. Specific training will be targeted on participants according to their function.
1868367|NCT01081587|Other|Local assistance by a dietician|Assistance will be conducted locally by a local dietician. Periodic multidisciplinary meetings will be attended by the hospital staff belonging to the intervention arm, including the analysis of clinical incidents related to nutrition care.
1868368|NCT01081600|Other|Imaging with 89Zr-trastuzumab PET|Injection with 89Zr-trastuzumab and 89Zr-trastuzumab PET scan.
1868369|NCT01081613|Other|89Zr-bevacizumab PET imaging|injection 89Zr-bevacizumab and 89 Zr-bevacizumab PET scan
1868370|NCT01081626|Drug|Recombinant FSH (follitropin alpha)|A starting dose of 75 IU and a first adjustment on Day 14 or Day 7 of stimulation in Group I and II respectively, if no ovarian response is observed.
1868371|NCT01081639|Drug|Follitropin alfa liquid formulation|Follitropin alfa (Gonal-f) liquid pen (300, 450 and 900 IU) was applied by subcutaneous (sc) administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
1868372|NCT01081639|Drug|Follitropin beta liquid formulation|Follitropin beta (Puregon) liquid cartridge (300 and 600 IU) used with the Pen was applied by sc administration. Regimen of recombinant FSH-stimulation followed the standard protocol of the IVF-center
1868373|NCT01081652|Drug|Micronised Progesterone|Micronised progesterone administered intravaginally once daily from the day of ET. If pregnancy was confirmed on day 14 of progesterone administration, progesterone was continued for another 45 days.
1868375|NCT01081678|Drug|Placebo|Placebo, subcutaneous (under the skin) injection
1868376|NCT01081678|Drug|AMG 785 140 mg|140mg AMG 785, subcutaneous (under the skin) injection
1868377|NCT01081678|Drug|AMG785 70mg|AMG 785 70mg, subcutaneous (under the skin) injection
1868378|NCT01081678|Drug|AMG 785 210mg|210mg AMG 785, subcutaneous (under the skin) injection
1868379|NCT01081691|Biological|CNTO 5825|10 mg/kg single dose IV or matching placebo
1868380|NCT01081691|Biological|CNTO 5825|3 mg/kg single dose IV or matching placebo
1868381|NCT01081691|Biological|CNTO 5825|For atopic patient:10 mg/kg single IV dose or matching placebo
1868382|NCT01081691|Biological|CNTO 5825|For atopic patient: 3 mg/kg single dose SC or matching placebo
1868383|NCT01081691|Biological|CNTO 5825|0.3 mg/kg single dose IV or matching placebo
1868384|NCT01081691|Biological|CNTO 5825|0.1 mg/kg single dose Intravenously (IV) or matching placebo
1868385|NCT01081691|Biological|CNTO 5825|1 mg/kg single dose IV or matching placebo
1868386|NCT01081704|Drug|ustekinumab|Single dose of 45 mg subcutaneous injection
1868387|NCT01081704|Drug|ustekinumab|Single dose of 90 mg subcutaneous injection
1868388|NCT01081717|Drug|systemic non-biological treatments|as prescribed
1868389|NCT01081717|Biological|anti-TNF biologics|as prescribed
1868390|NCT01081717|Biological|golimumab|as prescribed
1868391|NCT01081717|Biological|non-anti-TNF biologics|as prescribed
1868392|NCT01081717|Other|general population|non-treated cohort
1868393|NCT01081730|Biological|anti-TNF biologics|as prescribed
1868394|NCT01081730|Other|general population|non-treated cohort
1868395|NCT01081730|Biological|non-anti-TNF biologics|as prescribed
1868396|NCT01081730|Biological|ustekinumab|as prescribed
1868397|NCT01081730|Drug|systemic non-biological treatments|as prescribed
1868398|NCT01081743|Other|Intervention of the social worker|Systematic home visits and regular follow-ups by phone from a social worker
1868399|NCT01081756|Drug|r-hCG|r-hCG (250 mcg) injection subcutaneously (s.c.) or intramuscularly (i.m.)
1868400|NCT01081756|Drug|Urinary-hCG|Urinary hCG (10,000 IU) injection s.c. or i.m.
1868401|NCT01081769|Drug|paliperidone palmitate injection|injection with 150 mg equivalent on Day 1, 100 mg equivalent on Day 8, 75 mg equivalent on Day 38 and flexible dosing with 25, 50, 75, 100 or 150 mg equivalent once monthly thereafter
1868402|NCT01081769|Drug|oral antipsychotics|daily treatment according to local label for maximally 24 months
1868403|NCT01081782|Drug|ONO-4641|0.15 mg once per day for 26 weeks
1868404|NCT01081782|Drug|ONO-4641|0.1 mg once per day for 26 weeks
1868405|NCT01081782|Drug|ONO-4641|0.05 mg once per day for 26 weeks
1868406|NCT01081782|Drug|ONO-4641 placebo|Placebo once per day for 26 weeks
1868407|NCT01081795|Drug|Topiramate|In the titration period, topiramate 25-mg tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks so that the total daily dose given is 50 mg or 100mg. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
1868408|NCT01081795|Drug|Placebo|In the titration period, matching placebo tablet once daily orally for 1 week, the dose will be increased by 1 tablet every week up to twice daily for a total of 4 weeks. The dose given in the final titration week will be continued for further 18 weeks (fixed dose period).
1868409|NCT01081808|Biological|EGFRBi-armed autologous activated T cells|EGFRBi-armed autologous activated T cells infused twice a week for 4 weeks for a total of 8 infusions. The doses of the armed ATC will be escalated at the dose levels of 5, 10, 20, and 40 billion armed ATC per infusion. Subcutaneous aldesleukin (300,000IU/m2/day) and Sargramostim (250 ug/m2 twice per week) both starting 3 days before the 1st infusion and ending 7 days after the last dose of armed ATC.
1868410|NCT01081821|Drug|single dose NJ-39758979/ matching placebo|Single oral dose of JNJ-39758979 (either 50, 100, 300, 600mg) or Placebo
1868411|NCT01081821|Drug|multi-dose JNJ-39758979 /matching placebo|JNJ-39758979 once daily oral dose for 14 days of 300 mg or Placebo
1868412|NCT01081834|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks (Main Study) or 26 weeks (High Glycemic Substudy)
1868413|NCT01081834|Drug|Placebo|One matching placebo capsule orally once daily for 26 weeks (Main Study)
1868414|NCT01081834|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 (Main Study)
1868415|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 720|50 ug
1868416|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 51|50 ug
1868417|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 720|100 ug
1868418|NCT01081847|Drug|Peptides (N,R&C) formulated in Montanide ISA 51|100 ug
1868419|NCT01081847|Other|Placebo|PLacebo: Isotonic saline solution
1868420|NCT01088815|Drug|Gemcitabine, nab-Paclitaxel, GDC-0449|"One cycle of Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 (28 days cycle) then
Gemcitabine 1000 mg/m2 and nab-Paclitaxel 125 mg/m2 on days 1, 8, and 15 every 28 days cycle in combination with oral GDC-0449 150 mg daily"
1868421|NCT01088828|Other|Magnetic Resonance Imaging (MRI) of calf and foot|Detailed 3-D comparison of MRI scans of children with clubfoot and controls without clubfoot in utero, in untreated infants and in older children who have been treated.
1868422|NCT01088841|Dietary Supplement|lactisole|lactisole (flavoring agent/sweet taste antagonist) dissolved with 75 g glucose in 300 mL tap water; administered via intragastric tube
1868423|NCT01088854|Device|CPAP|unique session of 30-minute of continuous airway positive pressure
1868424|NCT01088867|Other|Acupuncture|Electroacupuncture
1868425|NCT01088880|Drug|Canakinumab|
1868426|NCT01088893|Drug|Everolimus|10mg/d) for three weeks 1 week after completion of neoadjvuant treatment and before surgery
1868427|NCT01088906|Drug|Pemetrexed/Cisplatin|Pemetrexed 500 mg/m2 IV followed by cisplatin 75 mg/m2 IV every 21 days. A cycle is 21 day.
1868428|NCT01088919|Drug|ASP1941|oral tablet
1868429|NCT01088919|Drug|pioglitazone hydrochloride|oral tablet
1868430|NCT01088932|Drug|SRX246|capsules
1868431|NCT01088945|Behavioral|Enhanced Discharge process|Health Coaching prior to discharge, with an enhanced discharge binder to reinforce the teaching of the Health Coach
1868432|NCT01088958|Dietary Supplement|Micronutrient powders (Sprinkles)|"Sprinkles were developed in 1996 by Stanley Zlotkin's research group at the Hospital for Sick Children, University of Toronto as a novel approach for delivering iron and other micronutrients. They come in 1g sachets of dry powder that is then added to any home-prepared semi-solid food, intended for daily consumption by children aged 6-59 months. Formulation includes:
Iron (Ferrous fumarate) 12.5 mg, Folic acid 150 µg, Vitamin A 375 µg, Vitamin C 35 mg, Zinc 5 mg, Vitamin B1 0.5 mg, Vitamin B2 0.5 mg, Vitamin B6 0.5 mg, Vitamin B12 0.9 µg, Vitamin D3 5 µg, Vitamin E 6.0 mg, Niacin 6.0 mg, Copper 0.6 mg, Iodine 50 µg"
1960024|NCT03309709|Drug|subcutaneous progesterone|25mg daily for 7 days
1868435|NCT01088984|Drug|Bendamustine|
1868436|NCT01088997|Drug|Milrinone Lactate|Milrinone lactate will be given first as an IV bolus over one hour at the assigned dose level, followed by a 24 hour IV infusion at the assigned dose level.
1868440|NCT01089023|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv infusion, every 4 weeks for a total of 6 infusions
1868441|NCT01089049|Dietary Supplement|FemMED Breast Health Formula|Two capsules daily, with meals. FemMED Breast Health Formula containing lignans.
1868442|NCT01089062|Drug|MAP0004|1.0 mg orally inhaled MAP0004 administered in Treatment B as per protocol
1868443|NCT01089062|Drug|IV Placebo (Saline)|IV Placebo (Saline) administered in Treatment B and Treatment C as per protocol
1868444|NCT01089062|Drug|Placebo Inhaler|Orally inhaled Placebo administered in Treatment A and Treatment C as per protocol.
1868445|NCT01089062|Drug|IV Dihydroergotamine Mesylate (DHE)|IV DHE administered in Treatment A as per protocol
1868446|NCT01089075|Drug|Hydrocortisone|20 mg po for 7 days (2 tablets)
1868447|NCT01089075|Drug|Placebo|2 tablets po
1868448|NCT01089088|Drug|cisplatin|"Up to six 21 day chemotherapy cycles:
Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
1868449|NCT01089088|Drug|gemcitabine hydrochloride|"Up to six 21 day chemotherapy cycles:
Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
1868450|NCT01089088|Drug|sunitinib malate|"Up to six 21 day chemotherapy cycles:
Cisplatin 70mg/m2 (IV day 1) Gemcitabine 1000mg/m2 (IV days 1 & 8) Sunitinib 37.5mg (po days 2 to 15)"
1868451|NCT01089101|Other|Laboratory Biomarker Analysis|Correlative studies
1868452|NCT01089101|Other|Pharmacological Study|Correlative studies
1868453|NCT01089101|Drug|Selumetinib|Given PO
1868454|NCT01089127|Drug|Indacaterol|Indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
1868455|NCT01089127|Drug|Salmeterol 50 μg|Salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
1868456|NCT01089127|Drug|Placebo to indacaterol|Placebo to indacaterol was supplied in powder filled capsules together with a single-dose dry-powder inhaler (SDDPI) device.
1868457|NCT01089127|Drug|Placebo to salmeterol|Placebo to salmeterol was supplied in the manufacturer's proprietary Diskus inhaler device.
1868458|NCT01089140|Drug|Tranexamic acid 10mg/kg/hr|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator
1868459|NCT01089140|Drug|Tranexamic acid 100 mg/kg/h infusion|Tranexamic acid is a synthetic antifibrinolytic drug that competitively inhibits the lysine binding sites of plasminogen, plasmin, and tissue plasminogen activator.
1868460|NCT01089140|Drug|Saline solution|Saline placebo
1868461|NCT01089920|Other|Green tea|Infusion (tea bags) from commercially available green tea
1868462|NCT01089920|Other|Coffee|Soluble coffee commercially available
1868463|NCT01089933|Procedure|Thoracic Paravertebral Block (TPVB)|The middle of the spinous process above the nerve to be blocked is located and the overlying skin marked 2.5 centimeters lateral to this. Subcutaneous lidocaine is injected and a 22 G Tuohy tipped 8 cm needle is inserted at this level and advanced to identify the transverse process. The needle is then moved caudad off the transverse process and inserted a centimeter into the paravertebral space. Five mls of 0.5% ropivacaine with 1:200,000 epinephrine is injected at each paravertebral space. Blocks adjacent to the C7-T5 spinous processes are performed. For patients randomized to the LA group: The patients are identically positioned, sedated and identical landmarks are used to perform sham paravertebral blocks via a subcutaneous saline injection of 0.5mL with a 25G needle at each level.
1868464|NCT01089933|Procedure|Local Anesthetic|At the conclusion of surgery, the surgeon will infiltrate the incision with 10 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group). An axillary drain will be placed. After closure of the wound, 20 ml of saline 0.9% (TPVB group) or 0.5% ropivacaine (LA group) will be injected through the drain and the drain clamped for 30 minutes after injection.
1868465|NCT01089959|Drug|Esomeprazole|40 mg daily for 7 days
1868466|NCT01089959|Drug|esomeprazole|40 mg. daily, oral medication, once daily for 7 days.
1868467|NCT01089972|Device|22 gauge catheter|radial artery cannulation using 22 gauge catheter
1868468|NCT01089972|Device|20 gauge catheter|radial artery cannulation using 20 gauge catheter
1868469|NCT01089985|Drug|Autologous serum eyedrops|3 times a day for the duration of the study
1868470|NCT01089998|Drug|BAY86-9596|Healthy volunteers, single intravenous bolus injection of 200 MBq BAY 86-9596 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY 86-9596 in blood and urine
1868471|NCT01089998|Drug|BAY86-9596|Cancer patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
1868472|NCT01089998|Drug|BAY86-9596|Inflammation patients, single intravenous bolus injection of 300 MBq BAY 86-9596 on day one of the treatment period, PET/CT.
1868473|NCT01089998|Drug|Fludeoxyglucose (18F)-IBA|Subgroup of cancer patients: radiation induced inflammation. Fluordeoxyglucose (18F)-FDG PET scan will be performed approx. 4 week after radiation and compared with tracer BAY86-9596 (acc. to Amendment 4 only in the Netherlands)
1868474|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose plus high dose level of cetuximab
1868475|NCT01090011|Drug|Cetuximab|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
1868476|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose plus high dose level of cetuximab
1868477|NCT01090011|Drug|BIBW 2992|BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
1868478|NCT01090024|Drug|BI 671800|Double blind randomised cross-over study to assess efficacy, safety and tolerability
1868479|NCT01090024|Drug|BI 671800|Double blind randomised cross-over study to assess efficacy, safety and tolerability
1868480|NCT01090024|Drug|BI 671800|Double blind randomised cross-over study to assess efficacy, safety and tolerability
1868481|NCT01090024|Drug|Placebo|Patients receive placebo capsules
1868482|NCT01090037|Drug|TRK-100STP high dose|
1868483|NCT01090037|Drug|TRK-100STP low dose|
1868484|NCT01090037|Drug|Placebo|
1868485|NCT01090050|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Sumatriptan/Naproxen Sodium for oral administration contains sumatriptan 85mg / naproxen sodium 500mg. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
1868486|NCT01090050|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered 1 tablet per day x 30 days in Treatment Period Month 1. Study medication may be administered on up to 14 days per month in Treatment Period Months 2 and 3.
1868487|NCT01090063|Drug|Ustekinumab|Dosing will consist of a 45mg subcutaneous injection for patients weighing less than 100 kg and a 90 mg subcutaneous injection for patients whose weight is greater than 100 kg. Dosing will begin on week 0 followed by subsequent dosing on week 4 and week 16.
1868488|NCT01090076|Dietary Supplement|Abound (7 g of Arginine, 7 g Glutamine and 1.2 g HMB)|Active Arm : Abound x 2 sachets/d (Each sachet provides additional 7g L-Arginine, 7g L-Glutamine, 1.2 g HMB and 79 Kcal) Placebo Arm: Abound(placebo) x 2 sachets/d
1868489|NCT01090089|Drug|Lenalidomide, Dexamethasone|Rd until progression or max. 5 years (Rd = lenalidomide 25 mg d1-21/28d + dexamethasone 40 mg po d1, d8, d15, d22/28d)
1868490|NCT01090089|Drug|Lenalidomide, Dexamethasone, PBSCT|Induction with 3 cycles Rd, tandem high dose melphalan (140 mg/m²) with autologous peripheral blood stem cell transplantation (PBSCT) followed by lenalidomide maintenance (10 mg/day) until progression or max. 5 years
1868491|NCT01090102|Drug|Mesalamine (5-aminosalicylic acid, Apriso)|"Four mesalamine capsules once daily (1.5 gram/day) for the first 12 weeks, PO(by mouth).
Four placebo capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
1868492|NCT01090102|Drug|Placebo|"Four placebo capsules once daily (1.5g/d) for the first 12 weeks, PO (by mouth).
Four mesalamine capsules once daily (1.5g/d) for another 12 weeks, PO (by mouth)."
1868493|NCT01090115|Drug|ART-123|0.01ml/kg up to a volume of 1ml administered by IV boleus every 24 hours for six consecutive days
1868494|NCT01090115|Drug|placebo|0.01 ml/kg up to a volume of 1ml administered by IV boleus every 24 hours for 6 consecutive days
1868495|NCT01090128|Drug|Nanoparticle Albumin Bound Paclitaxel|IV administered over 30 minutes. 100 mg/m2 on days 1 and 8
1868496|NCT01090128|Drug|doxorubicin|50 mg/m2 every 3 weeks
1868497|NCT01090128|Drug|cyclophosphamide|500 mg/m2 given every 3 weeks
1868498|NCT01090141|Drug|Micafungin|100 mg IV infusion over 1 hour
1868499|NCT01090141|Drug|Micafungin|300 mg IV infusion over 1 hour
1868500|NCT01090154|Drug|Cimzia|Cimzia 400mg administered via two 200mg subcutaneous injections at weeks 0, 2, and 4; followed by every 4 week dosing.
1868501|NCT01090167|Drug|clofarabine|Intravenous, 20 mg/m2, 30 mg/m2, 40 mg/m2
1868502|NCT01090180|Drug|Dexamethasone|anti-inflammatory adrenocortical steroid The following dose schedule will be given: 0.15mg/kg (based on body weight) every 7 days for 4 consecutive weeks
1868503|NCT01090180|Drug|Placebo (sugar pill)|inactive
1868504|NCT01090193|Procedure|Whipple operation,Hepaticojejunostomy|Whipple operation, Hepaticojejunostomy
1868505|NCT01090206|Dietary Supplement|Vitamin D and calcium|Doses will be based on Vitamin D levels
1868506|NCT01090219|Procedure|two different meshes in the repair of inguinal hernias|A Lichtenstein tension-free hernia repair was accomplished by emplacing Heavy-weight versus low-weight polypropylene meshes for repair of incisional hernia, marked next to the lips with six titanium clips (LT200)
1868507|NCT01090232|Other|blood samples|
1868508|NCT01090232|Other|blood samples|
1868509|NCT01090245|Behavioral|Contingency management: voucher/monetary incentives for treatment attendance|Contingency management: Escalation with reset for non-attendance. Daily. Up to $841.50 in incentives for treatment attendance.
1868510|NCT01090245|Behavioral|Information|Attendance Information Group will receive an individual information session along with a pamphlet describing the benefits of remaining in treatment after release from prison and on the benefits of HIV prevention and testing.
1868511|NCT01090258|Device|Hamilton ventilator (G5 modify to S1) Automated settings|Automated settings (respiratory rate [RR], FiO2, Insp and exp pressures) Ventilator settings automatically adjusted by the evaluated system, concerning the FiO2, the respiratory rate, the inspiratory and expiratory pressures and related settings (triggers, pressurization ramp, inspiratory/expiratory time...)
1868512|NCT01090258|Other|Hamilton ventilator (G5) protocolized settings|Mechanical ventilation settings performed by the respiratory therapists according to the local protocols
1868513|NCT01090271|Device|Isokinetic eccentric training|The eccentric training for the shoulder abductors was performed for 6 consecutive weeks, twice a week, on alternate days.
1868514|NCT01090284|Device|Inguinal hernioplasty|A conventional Prosthetic Inguinal Hernioplasty (Trabucco's Technique) will be performed by using polypropylene mesh.
1868515|NCT01090297|Device|S8 Spirit 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.
These 3 types of CPAP can be set in both mode of pressure."
1868516|NCT01090297|Device|Somnosmart 2|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.
These 3 types of CPAP can be set in both mode of pressure."
1868517|NCT01090297|Device|Remstar Auto|"3 types of Continuous Positive Airway Pressure (CPAP) device: S8 Spirit 2, Somnosmart 2, Remstar Auto.
These 3 types of CPAP can be set in both mode of pressure."
1868518|NCT01090310|Drug|AIN457|AIN457 150 mg powder for solution was provided in glass vials each containing 150 mg AIN457 as a lyophilized cake
1868519|NCT01090310|Drug|Placebo|Matching placebo to AIN457
1868520|NCT01090323|Drug|ICL670|Daily doses of ICL670 were taken orally 30 minutes before breakfast. The doses range from 5-40 mg/kg and were determined based on the patient's trend in serum ferritin over time during the core study (0109) and on the frequency of blood transfusions the patient received. The treatment duration was up to 4 years.
1868521|NCT01090349|Device|Implantation of an ICD/CRT-D device|The Implantable Cardioverter Defibrillator (ICD) or Cardiac Resynchronization Therapy (CRT-D) device and leads are not the devices being evaluated in this investigation.
1868522|NCT01090349|Device|Merlin.NET PCN|The Merlin.Net™ PCN is a dedicated computer system that connects physicians to patients outside of the clinic setting by centralizing data from remote transmissions, implant procedures and in-clinic follow-ups into single location with easy export to Electronic Health Record (EHR) systems
1868523|NCT01090375|Other|Exercise|
1868524|NCT01090375|Other|Non Exercise|
1868525|NCT01090401|Device|Linox smart S DX|ICD lead
1868526|NCT01090414|Drug|Idelalisib|Idelalisib tablets administered orally
1960025|NCT03308890|Drug|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 6 months after cessation of TDF.
1960026|NCT03308890|Drug|0.5mg Baraclude(entecavir)|0.5mg Baraclude (entecavir) QD for 12 month after cessation of TDF.
1868530|NCT01090440|Drug|GSK1144814|This study is an open label, randomised, three-way cross-over study to evaluate the pharmacokinetics, effect of food, safety and tolerability of a new tablet formulation of GSK1144814 in healthy male and female (non-child bearing potential) subjects. Sixteen subjects will be enrolled to provide a minimum number of 12 evaluable subjects. The doses to be administered will be 100 mg and 200mg in the fasted state, and 100mg following a high fat breakfast.
1868531|NCT01090453|Biological|GSK2202083A vaccine|3 doses given at 2, 4 and 12 months of age
1868532|NCT01090453|Biological|Prevenar 13®|3 co-administered doses
1868533|NCT01090453|Biological|Infanrix hexa™|3 doses given at 2, 4 and 12 months of age
1868534|NCT01090453|Biological|Menjugate®|3 co-administered doses
1868535|NCT01090453|Biological|Rotarix™|Oral, two doses
1868536|NCT01090466|Drug|cisplatin|
1868537|NCT01090466|Drug|gemcitabine hydrochloride|
1868538|NCT01090466|Drug|temsirolimus|
1868539|NCT01090466|Other|pharmacological study|
1868540|NCT01090479|Drug|2% Chlorhexidine cloth|The 2% Chlorhexidine cloth will be applied to the operative extremity the night prior and the the morning of their surgery.
1960033|NCT03308656|Other|uterocervical angle|uterocervical angle is the angle between lower segment of uterus and cervix
1868549|NCT01090505|Drug|Drug: S-1 and oxaliplatin|Drug:S-1:80mg/m2;oxaliplatin 130mg/m2
1868550|NCT01090518|Behavioral|Prolonged Exposure therapy|10 weekly sessions
1868551|NCT01090518|Drug|Hydrocortisone|30mg 20 minutes prior to each PE session including imaginal exposure (8 total)
1868552|NCT01090518|Behavioral|Prolonged Exposure therapy|10 weekly sessions
1868553|NCT01090544|Device|Nasal Insufflation|Breathing therapy
1868554|NCT01090557|Other|Collection of exhaled breath|balloon collection, via the tidal breathing techniques with uncontrolled flow rate for offline feNO measurement
1868555|NCT01090570|Drug|PLX3397|Once-daily oral capsules
1868556|NCT01090583|Other|Specimen Collection|We will compare mediators from non-invasive samples (blood, urine, saliva, vaginal or cervical secretions) with traditional gold-standard invasive samples (amniotic fluid and placenta samples).
1868557|NCT01090596|Drug|Naproxen|500mg naproxen, twice daily for 7 days
1868558|NCT01090596|Drug|Placebo|1 tab,twice a day for a seven days
1868559|NCT01090609|Device|Stent implantation|Stent implantation
1868560|NCT01090622|Drug|XPF-001|Oral capsule
1868561|NCT01090622|Drug|Placebo|Oral capsule
1868562|NCT01090648|Drug|etravirine|One etravirine (ETR) 200 mg uncoated oral tablet and one etravirine (ETR) 200 mg film-coated tablet
1868563|NCT01090661|Drug|mipomersen sodium|200 mg of mipomersen intravenous (IV) (single dose)
1868564|NCT01090661|Drug|mipomersen sodium|200 mg of mipomersen subcutaneous (SC) (single dose)
1868565|NCT01090661|Drug|moxifloxacin hydrochloride (Avelox®)|400 mg of moxifloxacin intravenous (IV) single dose
1868566|NCT01090661|Drug|placebo|placebo intravenous (IV) single dose
1868567|NCT01090661|Drug|placebo|placebo subcutaneous (SC) single dose
1868568|NCT01090674|Other|No intervention|We perform in all patients respiratory functional tests, thoracic x-ray, SNIF test and diaphragmatic magnetic resonance imaging.
1998366|NCT01418378|Device|Sigma CR150|Sigma CR150 femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
1998367|NCT01418378|Device|Sigma CR|Sigma CR femoral component used in combination with the Highly Polished Cobalt Chrome fixed bearing tibial tray and the Curved (XLK) polyethylene bearing (cemented, no patellar resurfacing).
1998368|NCT01416805|Behavioral|Computerized Cognitive Behavioral Therapy|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). This group will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention for anxious children being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user in his/her own home. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
1998369|NCT01416805|Behavioral|Treatment as usual|Those who choose to participate will be enrolled in the 14 week study (18 weeks for phase II). They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 14) (and a 4th assessment for a 1 month Follow-up for Phase II at week 18). Those in this group will not receive the CCBT, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
1868569|NCT01090687|Radiation|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
1868570|NCT01090687|Device|computed tomography (CT scan)|Subjects will undergo cone beam breast CT scan
1868571|NCT01090700|Drug|TMC435|TMC435 150 mg daily for 7 days
1868572|NCT01090700|Drug|Escitalopram|Escitalopram 10 mg daily for 7 days
1868573|NCT01090700|Drug|TMC435 + Escitalopram|TMC435 150 mg + escitalopram 10 mg daily for 7 days
1868574|NCT01090713|Drug|lisdexamfetamine|oral; 20-70mg/day
1868575|NCT01090713|Drug|Placebo control|20-70mg; oral
1868576|NCT01090726|Device|Storz videolaryngoscope|Storz videolaryngoscope being used for the actual intubation
1868577|NCT01090726|Device|Airtraq|Airtraq being used for the actual intubation
1868578|NCT01090739|Device|TOPAS Treatment for Fecal Incontinence|The TOPAS Treatment for Fecal Incontinence is implanted using a minimally invasive trans-obturator approach; two needle passers deliver the sling assembly. Two small posterior incisions facilitate the post-anal placement of the mesh.
1868579|NCT01090752|Drug|Pioglitazone|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
1868580|NCT01090752|Drug|Metformin|placebo-controlled, randomized, cross-over study was to explore the effects of pioglitazone (45 mg q.d. for 6 weeks) on the renal, hormonal and blood pressure responses to changes in sodium intake in a population prone to insulin resistance
1868581|NCT01090765|Drug|TRC105|
1868582|NCT01090778|Drug|Norditropin SimpleXx (growth hormone)|3mg/subject/day over two consecutive days
1868583|NCT01090791|Device|Flotrac/Vigileo third generation software|Measurement of stroke volume according to the arterial pressure waveform
1868584|NCT01090791|Device|Transthoracic echocardiography|Measurement of stroke volume according to the aortic time-velocity integral
1868586|NCT01090817|Drug|Mesenchymal stromal cells (MSC) for infusion|MSC 2X10E6/kg recipient weight are infused over 15 minutes intravenously weekly for 4 weeks
1868587|NCT01090830|Drug|Belinostat, carboplatin, paclitaxel and bevacizumab|"Induction therapy will include 6 cycles of 5-days of medication administration followed by a 16 day rest period. Belinostat will be given once a day for 5 days total. Three dose levels will be evaluated (600mg/kg, 800 mg/kg, and 1000 mg/kg). In addition, participants will receive fixed doses of intravenous carboplatin (AUC 6), Paclitaxel (200 mg/m2), and bevacizumab (15 mg/kg) once on day 3 of each cycle. Serial disease status evaluations will be done throughout the study.
In the absence of significant toxicity or disease progression, participants may continue with a maintenance regimen of bevacizumab and Belinostat for an additional 6 cycles. The dose of Belinostat received during maintenance will be that tolerated in the initial 6 cycles."
1868588|NCT01090843|Procedure|Video capsule endoscopy (VCE)|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
1868589|NCT01090843|Device|MiroCam|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
1868590|NCT01090843|Device|Enteropro EndoCapsule|In the context of video capsule endoscopy the patient will swallow the first capsule after successful mounting of adhesive electrodes and registering tool of both capsule products. The second capsule will be swallowed two hours later. The two capsules used in our investigation are the MiroCam® (product of IntroMedic®, Seoul, Korea) and the Enteropro EndoCapsule® (product of Olympus®, Tokyo, Japan). To reduce bias made up by the sequence of the capsules used, we will randomize the capsule positions at each examination, following a computer generated list.
1868591|NCT01090856|Procedure|Pre-dilation side branch|Balloon pre-dilation of the side branch to facilitate the ulterior wire access.
1868592|NCT01090869|Behavioral|12 weeks of lifestyle change|Participants were randomly assigned to a 12-week intervention in one of four groups: Training (T), energy-reduced Diet (D), Training and increased- Diet (T-iD) or Control (C). The interventions consisted of: T: increased physical activity through daily endurance training equivalent to 600 kcal/day, unchanged diet; D: sedentary lifestyle, reduced diet by 600 kcal/day primarily through reducing serving sizes and substituting energy dense with less energy dense nutrients; T-iD: increased physical activity through daily endurance training equivalent to 600 kcal/day, increased diet by 600 kcal/day primarily through increasing serving sizes and consuming energy dense nutrients; C: sedentary lifestyle and unchanged diet.
1868593|NCT01090882|Drug|Bupivocaine|20ml 0.25% at beginning of operation
1868594|NCT01090882|Drug|0.9% normal saline solution|20ml 0.9% NaCl
1868595|NCT01090895|Drug|Vitamin C|Intravenous infusion of vitamin C (1 g) 10 minutes before percutaneous coronary intervention.
1868596|NCT01090895|Drug|Placebo|Intravenous infusion of placebo(saline solution) 10 minutes before percutaneous coronary intervention.
1868597|NCT01090908|Drug|Antibiotic|
1868598|NCT01090921|Drug|Bortezomib|"Bortezomib will be administered at a dose of 1.6 mg/m2 IV push. Treatment will be administered once a week for four weeks followed by one week off. This 5 week period is considered a treatment cycle.
Dexamethasone will also be administered at a dose of 40mg on the day of and day after each dose of bortezomib, with a dose reduction to 20mg on the same schedule if the patient cannot tolerate the higher dose of dexamethasone."
1868599|NCT01090934|Device|High Resolution EEG|High Resolution EEG
1868600|NCT01090934|Device|Stereo-electroencephalography|SEEG
1868601|NCT01090947|Device|ProtoCAD|Aquiring acoustic signals from heart patients.
1868602|NCT01090960|Drug|GDC-0068|Oral repeating dose
1868643|NCT01091285|Device|Double Balloon Catheter|Double Balloon Catheter for 16-19H
1868603|NCT01090973|Drug|LBH589|"The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.
After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses."
1868604|NCT01090999|Other|long-term maintenance respiratory rehabilitation program|To determine whether a long-term maintenance program after respiratory rehabilitation (group active comparator), in contrast to the usual minimal maintenance therapy (group no intervention), improves the cost-effectiveness through: a.- maintaining long term effects in terms of effort capacity, HRQL, and reduced exacerbations b.- reducing the total cost of care to patients, largely through reduction of exacerbations.
1868605|NCT01091012|Drug|Sildenafil 20mg oral vs Sildenafil 10mg intravenous|2 arms to comparation: Sildenafil 20mg oral vs intravenous Sildenafil 10mg
1868606|NCT01091025|Other|Glucose profile for 2 weeks|A study subject has an abnormal OGTT will be referred to a cystic fibrosis consultant who is not involved in the study.
1868607|NCT01091038|Other|Basic Clinical Decision Support|The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication. Physicians were required to enter dosage, route, and frequency for all orders. Also, CPOE ensured that all orders were legible and included the prescribing physician's signature. For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering. Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking. This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
1868608|NCT01091038|Other|Routine Care|Routine Care
1868609|NCT01091051|Drug|Ustekinumab|Patients randomized to ustekinumab (10 with PPPP and 10 with PPP) will receive ustekinumab at Day 0, Weeks 4 and 16 and placebo at Week 20
1868610|NCT01091051|Drug|Placebo (Soduim Chloride)|Patients randomized to placebo (10 with PPPP and 10 with PPP) will receive placebo at Weeks 0 and 4 and ustekinumab at Weeks 16 and 20
1868611|NCT01091064|Other|Randomization early depart|Patients will be randomized to either an early depart or for being seen by a physician.
1868612|NCT01091077|Dietary Supplement|Naringenin|1 gram of naringenin mixed with 16 grams of hydroxypropyl-β-cyclodextrin in 250 mL of water
1868613|NCT01091090|Behavioral|Cognitive behavioral|Cognitive behavioral intervention for smoking cessation
1868614|NCT01091090|Behavioral|Control|Treatment as usual
1868615|NCT01091103|Drug|Enzalutamide|
1868616|NCT01091116|Drug|MEN16132 - 0.125 mg|Intra-articular administration of two low doses of MEN16132 at 2-week interval.
1868617|NCT01091116|Drug|MEN16132 - 0.25 mg|Intra-articular injection of two intermediate doses of MEN16132 at 2-week interval
1868618|NCT01091116|Drug|MEN16132 - 0.5 mg|Intra-articular injection of two high doses of MEN16132 at 2-week interval
1868619|NCT01091116|Drug|MEN16132 - 0.5 mg|Single intra-articular injection of one high dose of MEN16132, followed by one dose of placebo at 2-week interval
1868620|NCT01091116|Drug|Placebo|Intra-articular injection of 2 doses of Placebo control at 2-week interval
1868621|NCT01091129|Device|miraDry System (treatment with energy)|Treatment with microwave energy delivery device as specified by manufacturer's instructions
1868622|NCT01091142|Drug|NP001|Cohort 1: 0.3 mg/kg NP001(6:2 active:placebo) Cohort 2: 1.1 mg/kg NP001(6:2 active:placebo) Cohort 3: 2.1 mg/kg NP001(6:2 active:placebo) Cohort 4: 4.3 mg/kg NP001(6:2 active:placebo)
1868623|NCT01091142|Drug|Placebo|Cohort 1: placebo Cohort 2: placebo Cohort 3: placebo Cohort 4: placebo
1868624|NCT01091155|Device|ColonRing (Colorectal anastomosis)|Creation of a colorectal compression anastomosis
1868625|NCT01091168|Drug|vinflunine|280 mg/m2 on day 1 of each cycle every 3 weeks
1868626|NCT01091168|Drug|alkylating agent of physician choice registered in cancer|cyclophosphamide or melphalan or mitomycin C or thiotepa or cisplatin or carboplatin
1868627|NCT01091181|Procedure|Hysterotomy|at cesarean hysterotomy is performed 2 cm above or below the bladder insertion
1868628|NCT01091194|Other|Interval-based aerobic exercise|High intensity interval-based aerobic exercise training. Duration: 1 year. Three 8-weeks supervised periods of physical training 3 times per week. Individual training 2 times per week between these periods.
1868629|NCT01091207|Drug|Sorafenib|The patients will receive daily oral administration of sorafenib 400 mg twice daily.
1868630|NCT01091220|Biological|Certolizumab pegol|400 mg certolizumab pegol in 2 x 200 mg/mL, prefilled syringes, administered once, subcutaneously
1868631|NCT01091220|Biological|Placebo|2 x prefilled syringes containing 0.9% saline, administered once, subcutaneously
1868632|NCT01091233|Procedure|paracentesis|as indicated according to the treating physician (the indication for Paracentesis is not the subject of study)
1868633|NCT01091246|Biological|Q/LAIV (MEDI3250)|10 ^7.0 ± 0.5 FFU/dose of each of 4 influenza virus strains: A/H1N1, A/H3N2, B/Yamagata, and B/Victoria
1868634|NCT01091246|Biological|FluMist/B/Yamagata|10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Yamagata
1868635|NCT01091246|Biological|FluMist/B/Victoria|10 ^7.0 ± 0.5 FFU/dose of each of 3 influenza virus strains: A/H1N1, A/H3N2, and B/Victoria
1868636|NCT01091259|Drug|Irinotecan|
1868637|NCT01091259|Drug|Bevacizumab|
1868638|NCT01091272|Drug|PF-04995274|Planned single PO 0.15mg, 1.5mg, 15mg doses of PF-04995274 interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
1868639|NCT01091272|Drug|PF-04995274|Planned single PO 0.5mg, 5mg, 50mg doses of PF-04995274, interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg interleaved with cohort 2 such that doses escalate from 0.15 mg to 50 mg.
1868640|NCT01091272|Drug|PF-04995274|Planned single PO 120mg and 210mg doses of PF-04995274
1868641|NCT01091272|Drug|PF-04995274|single PO dose of PF-04995274; dosage to be determined by safety and pharmacokinetic data
1868642|NCT01091285|Device|Foley Catheter|Foley Catheter 16-19 H
1868644|NCT01091298|Biological|Live Attenuated Tetravalent (G1-G4) Bovine-Human Reassortant Rotavirus Vaccine (BRV-TV)|Single dose (0.5 mL) of the vaccine administered orally
1868645|NCT01091298|Other|Placebo|Single dose (0.5 mL) of the placebo administered orally
1868646|NCT01091311|Device|Blephasteam|Eye lid warming goggles
1868647|NCT01091324|Drug|Dextromethorphan|60 mg, bid
1868648|NCT01091324|Drug|Silymarin|150 mg , tid
1868649|NCT01091324|Drug|sugar pill|placebo
1868650|NCT01091337|Drug|Procaterol|"Procaterol(Meptin Air) MDI, 20 ug or 2 puffs every 20 minutes
+ Hydrocortisone, 100 mg IV shall be given immediately at start of treatment"
1868651|NCT01091337|Drug|Salbutamol|Salbutamol(Ventolin Inhaler) MDI, 40 ug or 4 puffs every 20 minutes + Hydrocortisone, 100 mg IV shall be given immediately at start of treatment
1868652|NCT01091350|Device|Diprifusor (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
1868653|NCT01091350|Device|Orchestra (Target-controlled infusion)|Two TCI devices with different Teo and same Marsh PK model
1868655|NCT01091376|Drug|Erlotinib|Erlotinib 150mg/day
1868656|NCT01091376|Radiation|Thoracic radiotherapy|60-70Gy/30-35f
1868657|NCT01091389|Procedure|Totally Thoracoscopic PV isolation|Surgery is performed through three ports bilaterally in the intercostal spaces. PVI is performed with a bipolar radiofrequency clamp and confirmed with a custom made multi-electrode probe with closely spaced (1mm) electrode terminals. Additional left atrial ablation lines are created and conduction block is verified in patients with persistent and permanent AF.
1868658|NCT01091402|Procedure|autologous serum skin test, serum IL-18|
1868659|NCT01091415|Procedure|calcium phosphate bone cement injection|volar locking plate alone versus calcium phosphate bone cement as well as volar locking plate
1868660|NCT01091428|Drug|MLN8237 + Paclitaxel|"Phase 1:
MLN8237 administered orally twice daily on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel (Days 1, 8, 15) as an intravenous infusion repeated in 28-day cycles"
1868661|NCT01091428|Drug|MLN8237+Paclitaxel vs. Paclitaxel alone|"Phase 2:
Arm 1:
MLN8237 administered orally twice daily on Days 1-3, 8-10 and 15-17, combined with weekly paclitaxel (Days 1, 8, 15) as an intravenous infusion repeated in 28-day cycles
Arm 2:
Paclitaxel will be administered as an intravenous infusion on Days 1, 8 and 15 of each 28-day cycle"
1868662|NCT01091454|Drug|brostallicin|Given IV
1868663|NCT01091454|Drug|cisplatin|Given IV
1868664|NCT01091493|Drug|Moxifloxacin|Moxifloxacin 400 mg administered once a day for 5 days
1868665|NCT01091506|Other|Placebo|Placebo once a day for 12 weeks
1868666|NCT01091506|Other|L-methylfolate|L-methylfolate 15mg once a day for 12 weeks
1868667|NCT01091519|Other|Toviaz(fesoterodine) plus educational materials|Educational materials including the Self-Assessment Goal Achievement (SAGA) tool to support dialogue.
1868668|NCT01091519|Other|Toviaz(fesoterodine) without educational materials|No educational materials
1868669|NCT01091532|Drug|UK-396,082|"100mg given orally twice daily for 14 days
The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
1868670|NCT01091532|Drug|placebo|given orally twice daily for 14 days
1868671|NCT01091532|Drug|UK-396,082|"300mg given orally twice daily for 14 days
The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
1868672|NCT01091532|Drug|placebo|given orally twice daily for 14 days
1868673|NCT01091532|Drug|UK-396,082|"1000mg given orally twice daily for 14 days
The decision to proceed to the next higher dose will be made jointly by the Pfizer Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts and dosing periods. The doses will be selected such that the predicted Cmax will not exceed 2.95 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
1868674|NCT01091532|Drug|placebo|given orally twice daily for 14 days
1868675|NCT01091532|Drug|UK-396,082|"UK-396,082 given orally, once on Days 1 & 14, and twice daily on Days 3-13.
The decision to proceed to the next higher dose will be made jointly by the Study Team and the Investigator after careful review of available safety, tolerability and PK information from previous cohorts. Dependent on the emerging safety, tolerability and PK data, Cohort 4 may be recruited to study a higher (or lower) dose of UK-396,082 in order to characterize further the safety, toleration and PK and/or to define the maximum tolerated dose. The dose in Cohort 4 will be selected such that the predicted Cmax will not exceed 46 mcg/mL and/or the predicted increase in exposure will not exceed 3.5-fold that of the previously studied dose."
1868676|NCT01091532|Drug|placebo|given orally, once on Days 1 & 14, and twice daily on Days 3-13.
1868678|NCT01091571|Drug|Dipyridamole|Oral treatment with dipyridamole 200 mg twice daily during seven consecutive days
1868679|NCT01091571|Drug|Placebo|Placebo twice daily during seven consecutive days
1868680|NCT01091571|Other|LPS|The LPS derived from E. coli O:113 2ng/kg iv will be injected in 1 minute at a dosage of 2 ng/kg body weight.
1868681|NCT01091584|Device|distress thermometer|to apply the distress thermometer as written in the guideline written by 'Vereniging Integrale Kankercentra' title: 'Detecteren behoefte psychosociale zorg. The distress thermometer is collected from the experimental group and then discussed by a trained nurse
1868682|NCT01091597|Procedure|usual PV ablation|usual PV ablation, per above
1868683|NCT01091597|Procedure|Box isolation of pulmonary veins|as above
1868684|NCT01091610|Other|no intervention|purely observational retrospective study. no interventions are planned.
1868685|NCT01091623|Other|training|
1868688|NCT01091636|Procedure|Hyperthermic Intraperitoneal Chemotherapy|41.5 oC injected into the perfusion cisplatin (75 mg/m2)during 90min
1868689|NCT01091649|Drug|ABT-450|Low dose ABT-450 / ritonavir see Arm Description for more information
1868690|NCT01091649|Drug|ritonavir|ritonavir see Arm Description for more information
1868691|NCT01091649|Drug|ABT-450|High dose ABT-450 / ritonavir See Arm Description for more information
1868692|NCT01091662|Drug|Eslicarbazepine acetate 1600 mg|1600 mg once per day
1868693|NCT01091662|Drug|Eslicarbazepine acetate 1200 mg|1200 once per day
1868694|NCT01091675|Drug|Etoricoxib|Etoricoxib 90 mg/day/PO during 4 weeks Positive response to the therapy (in investigator opinion): Ongoing treatment with 90 mg/day/PO until 24 weeks.
1868695|NCT01091688|Behavioral|Just-in-Time information|Infants and physicians assigned to the intervention group will receive Just-in-Time information at the time of NICU discharge, by email and facsimile, and the parents will receive a copy to bring to their first clinic appointment.
1868696|NCT01091701|Biological|Ex vivo cultured adult allogenic MSCs|Single IV dose of allogenic MSCs
1868697|NCT01091701|Other|Plasmalyte-A|Single IV dose of Plasmalyte-A
1868698|NCT01091714|Dietary Supplement|Omega-3|Approximately 2400 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
1868699|NCT01091714|Dietary Supplement|Omega-3|Approximately 2240 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
1868700|NCT01091714|Dietary Supplement|Omega-3|Approximately 2332 mg of Omega-3s taken once daily by capsule, taken for the duration of the study.
1868701|NCT01091727|Drug|Botulinum toxin A|Comparison of intra-detrusor injection of 300U of Botulinum toxin A versus placebo for effect on neurogenic detrusor overactivity and urinary incontinence.
1868702|NCT01091740|Device|ZES resolute (Endeavor Resolute)|2nd generation drug eluting stent, which is coated with zotarolimus
1868703|NCT01091740|Device|EES (Xience)|2nd generation drug eluting stent, which is coated with everolimus
1868704|NCT01091753|Drug|Valsaltan, amlodipine|nti hypertensive medication time (nocturnal administration vs morning administration
1868705|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
1868706|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
1868707|NCT01091766|Drug|intravenous injection of test solution|test dose consists of 0.2 ml/kg body weight test solution of the assigned drug
1868708|NCT01091792|Drug|Bevacizumab|Bevacizumab every 2 weeks 10mg/kg beginning 2 weeks after start of Radiation Therapy
1868709|NCT01091818|Drug|dexmedetomidine|Dexemedethomidine is given as major sedative drug
1868710|NCT01091818|Drug|Midazolam|Midazolam is given as major sedative drug
1868711|NCT01091831|Drug|Cyclophosphamide|Cyclophosphamide will be given orally at the dose of 300 mg/m2 on days 1, 8, 15 for 6 cycles every 28 days
1868712|NCT01091831|Drug|Lenalidomide|Lenalidomide will be given orally at the dose of 25 mg/d for 21 days followed by a 7 days rest period (day 22 to 28)for 6 cycles every 28 days
1868713|NCT01091831|Drug|Dexamethasone|Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 for 6 cycles every 28 days
1868714|NCT01091831|Drug|Melphalan|Melphalan will be given iv at the dose of 200 mg/m2 for 1 day followed by stem cell support. The second MEL200 was performed 120 days after the first if ≤ PR was achieved after the 1st MEL200.
1868715|NCT01091844|Procedure|Voiding Trial|After surgery, each woman will undergo a voiding trial to assess for urinary retention after surgery. This is performed on all patients undergoing surgery involving prolapse or incontinence. There are two methods commonly used to perform a voiding trial: Spontaneous Fill and Retrograde Fill techniques. Both are considered standard of care. The goal of the study is to perform both on each patient to assess their equivalency. There are no experimental interventions taking place.
1868716|NCT01091857|Behavioral|STRIDE|
1868717|NCT01091870|Drug|Placebo|Soluble blue pigment, 3 times a day, from the third to the 14th day after subarachnoid hemorrhage.
1868718|NCT01091870|Drug|Sildenafil Citrate, 25 mg, 3 times a day.|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
1868719|NCT01091870|Drug|Sildenafil Citrate 50 mg, 3 times a day|Sildenafil Citrate 25 mg, 3 times a day (TID)from the third to the 14 day after subarachnoid hemorrhage.
1868720|NCT01091883|Device|Exablate treatment|MR Guided Focused Ultrasound
1868721|NCT01091883|Radiation|Radiation|External Beam Radiation
1868722|NCT01091896|Drug|Bevacizumab|1.25 mg of bevacizumab (0.05 ml) 7 days before vitrectomy
1868723|NCT01091896|Drug|bevacizumab|1.25 mg of bevacizumab (0.05 ml) at the end of vitrectomy
1868724|NCT01091909|Procedure|Dental extractions|All dental extractions were performed at an outpatient clinic at the USP Dental School. In addition, all extractions were performed under local anesthesia by the same experienced dentist, in accordance with the standards established by Peterson et al (2008).
1868725|NCT01091922|Dietary Supplement|Low flavanol cocoa beverage|23 mg of total flavanols from cocoa
1868726|NCT01091922|Dietary Supplement|High flavanol cocoa beverage|495 mg of total flavanols from cocoa
1868727|NCT01091948|Device|Intubation with Fiberoptic laryngoscope|Subjects will be intubated with the Fiberoptic laryngoscope.
1868728|NCT01091948|Device|GlideScope® Video Laryngoscope|Patients will be intubated with the GlideScope® Video Laryngoscope.
1868729|NCT01091961|Procedure|Preoperative ACEi/ARB management|Patients will either hold their chronic ACEi/ARB medication for at least 24 hours prior to surgery, or continue to take the ACEi/ARB medication up to and including the day of surgery
1868730|NCT01091974|Drug|armodafinil|Armodafinil P.O. daily/47 days (3-days at 50mg, then 40 days at 100mg, then 4 days at 50mg)
1868731|NCT01091974|Drug|Placebo Comparator|Placebo for 47 days
1868732|NCT01091974|Behavioral|CBT-I|Seven weekly sessions of cognitive behavioral therapy for insomnia (CBT-I)
1868733|NCT01091987|Behavioral|Non-pharmacological approach of insomnia|education on sleep, sleep hygiene, stimulus control, cognitive techniques
1868734|NCT01092000|Behavioral|Monitoring|Each week participants are asked to record electronically their fruit intake, vegetable intake and minutes of physical activity.
1868735|NCT01092000|Other|Education|Monthly exercise tips handout.
1868736|NCT01092013|Behavioral|Training on laparoscopic simulator in skills lab|Laparoscopic camera training in a skills lab following training protocol for a total of 6 hours during 3 weeks.
1868737|NCT01092013|Behavioral|Training at actual laparoscopic surgery|Assisting at 6 laparoscopic surgeries navigating the camera during 3 weeks
1868738|NCT01092013|Behavioral|Technical instruction|Technical instruction on proper handling of an angled laparoscope before randomization for 1 hour
1868739|NCT01092026|Other|cord blood transplantation|One or two cord blood transplants with co-infusion of third-party mesenchymal stem cells after pre-transplant preparative regimen
1868740|NCT01092039|Dietary Supplement|lactoferrin, L-Glutamine and beta-glucans|Subject will be given XIGO pills or placebo. two tablets to be taken by mouth 3 times per day.
1868741|NCT01092039|Dietary Supplement|Placebo Comparator|Subject will be given placebo comparator of two tablets to be taken by mouth 3 times per day.
1868742|NCT01092052|Drug|NMS-1116354|Oral daily administration for 14 consecutive days followed by 7 days of rest
1868743|NCT01092065|Drug|AFQ056 with L-dopa|hard gelatin capsule to be taken bid for six weeks
1868744|NCT01092065|Drug|Placebo|hard gelatin capsule to be taken bid for six weeks
1868745|NCT01092078|Behavioral|MINT|Motivational interviewing for lifestyle changes associated with treating hypertension
1868746|NCT01092078|Behavioral|Patient Navigation|Patient navigation for colonoscopy.
1868747|NCT01092091|Biological|Pegylated Recombinant Human Arginase I|Weekly dose of PEG-BCT-100 for at least 8 weeks (or until disease progression) at 1600U/kg
1868748|NCT01092104|Drug|TBR-652|TBR-652 25 mg
1868749|NCT01092104|Drug|TBR-652 Matching Placebo|Matching Placebo
1868750|NCT01092104|Drug|TBR-652 50 mg|TBR-652 50 mg QD for 10 days
1868751|NCT01092104|Drug|TBR-652 75 mg|TBR-652 75 mg QD for 10 days
1868752|NCT01092104|Drug|TBR-652 100 mg|TBR-652 100 mg QD for 10 days
1868753|NCT01092104|Drug|TBR-652 150 mg|TBR-652 150 mg QD for 10 days
1868754|NCT01092117|Device|Ovation™ Abdominal Stent Graft System|Implant of Ovation™ Abdominal Stent Graft System
1868755|NCT01092130|Drug|Vitamin D|2000 IU vitamin D daily, for 6 weeks
1868756|NCT01092143|Drug|BI671800|double blind randomized parallel group study
1868757|NCT01092143|Drug|BI671800|double blind randomized parallel group study
1868758|NCT01092143|Drug|BI 671800|double blind randomized parallel
1868759|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
1868760|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
1868761|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
1868762|NCT01092143|Drug|Fluticasone placebo|double blind randomized parallel
1868763|NCT01092143|Drug|Fluticasone|double blind randomized parallel
1868764|NCT01092143|Drug|BI 671800 Placebo|double blind randomized parallel
1868765|NCT01092143|Drug|BI 671800 Placebo|double blind randomized parallel
1868766|NCT01092156|Behavioral|Education|Education on Infant-led latching
1868767|NCT01092169|Other|No intervention|
1868771|NCT01092221|Drug|Allopurinol|Allopurinol 1 capsule 300 mg, BID
1868772|NCT01092221|Drug|Placebo|Placebo 1 capsule, 300 mg, BID
1868773|NCT01092234|Other|Traditional ward|provision of care in a traditional unit/ward.
1868774|NCT01092234|Other|Organizational change|Observational unit (new organizational unit) for organizing in-hospital care
1868775|NCT01092247|Other|Nutritional support with Standard diet|Nutritional support with Standard diet
1868776|NCT01092247|Other|Nutritional intervention with the Ketogenic diet|Nutritional intervention with ketogenic diet. The Diet plan will be based on each patient individually according to his nutritional needs. Age, weight, activity levels, culture and food preferences are taken in consideration
1868777|NCT01092286|Other|neuromuscular warm-up|neuromuscular warm-up exercises that take 20 minutes to perform
1868778|NCT01092299|Drug|AZD1446|ER Fast, 90mg, p.o. capsule
1868779|NCT01092299|Drug|AZD1446|ER Moderate, 90mg, p.o. capsule
1868780|NCT01092299|Drug|AZD1446|ER Slow, 90mg, p.o. capsule
1868781|NCT01092299|Drug|AZD1446|MR
1868782|NCT01092299|Drug|AZD1446|IR, 90 mg p.o. capsule
1868783|NCT01092299|Drug|Placebo|IR
1868784|NCT01092299|Drug|Placebo|ER/MR
1868785|NCT01092312|Procedure|Vanguard Knee System with Signature Knee Guide|Use of Signature Knee Guide
1868786|NCT01092312|Procedure|Vanguard Knee System with conventional Instruments|Vanguard Knee System with conventional Instruments
1868787|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020
1868788|NCT01092325|Drug|CXL-1020|Intravenous infusion of one of 3 active dosages of CXL-1020 at dosages higher than in Cohort 1
1868789|NCT01092325|Drug|Placebo for CXL-1020 Cohort 1|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
1868790|NCT01092325|Drug|Placebo for CXL-1020 Cohort 2|A 4 hour infusion of a IV solution containing 5% Dextrose in water (Sugar Water)
1868791|NCT01092325|Drug|CXL-1020 Dose for Echo Cohort A|A 4 hour fixed dose of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
1868792|NCT01092325|Drug|CXL-1020 Doses for Echo Cohort B|A 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect followed by another higher 2 hour dose level of CXL-1020 which was studied in Cohort 1 or 2 which was demonstrated to be safe and well tolerated and have some anticipated hemodynamic effect
1868793|NCT01092338|Drug|Cholecalciferol (Vit D3)|To test two oral daily doses (4000 vs. 7000 IU) of cholecalciferol (D3) dietary supplement (capsules or liquid) over a 3-month period in 44 children, adolescents and adults with HIV/AIDS.
1868794|NCT01092351|Drug|Nitrofurantoin|100 mg retard capsules to be taken twice daily for seven days
1998415|NCT01381692|Biological|Rituximab|Given IV
1998416|NCT01381692|Drug|Temsirolimus|Given IV
1998417|NCT01379924|Behavioral|Modules|
1998418|NCT01379924|Other|No intervention|
1998419|NCT01379924|Other|No intervention|
1868796|NCT01084707|Drug|Oral Nicotine|Oral Nicotine either self-administered or provided by study personnel within 12 hours
1868797|NCT01084707|Drug|Nicotine Lozenge|Nicotine lozenge marketed as NiQuitin™ 4 mg hourly within 12 hours
1868798|NCT01084707|Drug|Nicotine gum|Nicotine gum marketed as Nicorette® 4 mg hourly within 12 hours
1868799|NCT01084720|Drug|V0034 CR|
1868800|NCT01084746|Behavioral|Tailored interactive intervention to increasing CRCS|The three arms of the intervention consist of no patient intervention, printed educational materials, or PC-based tailored interactive intervention.Patients in Group 1 will not receive a patient-directed intervention. Patients in Group 2 will receive generic printed educational materials about CRCS in the PEC when they arrive at the KSC Main Campus for their appointment. Patients in Group 3 will receive a tailored interactive PC-based intervention at a freestanding kiosk in the PEC.
1868801|NCT01084759|Drug|Testosterone injection|Patients will receive an intramuscular gluteal injection with testosterone cypionate at a dose of 400 mg every month for a total of 3 injections (i.e. 3 months of therapy). This route and dose of testosterone was selected based on data demonstrating that it produces an initial supraphysiologic serum level of testosterone (i.e. > 3-5 times normal level) with eugonadal levels achieved at the end of two weeks.
1868802|NCT01084759|Drug|Etoposide|On the day of testosterone injection (i.e. day 1 of each cycle) patients will begin therapy with oral etoposide at a dose of 100 mg/day given in divided doses (one 50 mg etoposide capsule q 12 h) for 14 consecutive days. This dose was selected based on Phase II studies of the combination of oral estramustine and oral etoposide. In these trials, myelosuppression was observed when etoposide was given for 21 days out of a 28 day cycle. Therefore, to minimize toxicity, in this study etoposide will be administered for 14 days of a 28 day cycle.
1868803|NCT01084772|Other|Total Knee Arthroplasty|TKA will be performed with VISIONAIRE instrumentation or standard instrumentation, depending on randomization assignment.
1868804|NCT01084772|Other|Total Knee Arthroplasty|TKA will be performed with VISIONAIRE patient matched instrumentation or standard instrumentation, depending on randomization assignment.
1868805|NCT01084811|Procedure|biopsy|One or more biopsies from nasal mucosa will be harvested during surgery
1868806|NCT01084824|Drug|Liquid nitrogen and cantharidin|Liquid nitrogen applied to wart(s), then cantharidin 1% topical applied afterward.
1868807|NCT01084824|Drug|Liquid nitrogen and topical placebo|Liquid nitrogen applied to wart(s), then placebo vehicle applied thereafter.
1868808|NCT01084837|Drug|velcade|"INDUCTIoN (Cycles 1-4)
Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment
Dexamethasone 40 mg/p.o. days 1-4 and 9-12 cycles 1-4 (Cycles of 21 days)
For patients wich is not planned autotransplantation, add:
Cycles 5-8
Bortezomib 1,3 mg/m2 i.v. days 1, 4, 8 and 11 follow by 10 days without treatment
Dexamethasone 40 mg/v.o. days 1-4 (Cycles of 21 days)
EXTENSION TREATMENT(Cycles 9-12)
Bortezomib 1,3 mg/m2 i.v. days 1, 8, 15 and 22
Dexamethasone 40 mg/d v.o. days 1-4 (Every 6 weeks)"
1868809|NCT01084863|Drug|CT-P6|CT-P6: administered every 3 weeks
1868810|NCT01084863|Drug|Herceptin|Herceptin: administered every 3 weeks
1868811|NCT01084863|Drug|Paclitaxel|Paclitaxel: administered every 3 weeks
1868812|NCT01084876|Drug|CT-P6|Administered every 3 weeks
1868813|NCT01084876|Drug|Herceptin|Administered every 3 weeks
1868814|NCT01084876|Drug|Paclitaxel|Administered every 3weeks
1868815|NCT01084889|Device|TiLOOP® Total 6 (Surgical mesh implantation)|The standard procedure for the surgical repair of anterior prolapse is via the obturator membrane. The mesh is placed trans vaginal by the aid of surgical instruments to place the mesh arms.
1868816|NCT01084902|Drug|Latanoprost|once daily
1868817|NCT01084902|Drug|Brinzolamide|Two times daily
1868818|NCT01084928|Behavioral|Lifestyle Intervention Classes|The intervention will be based on the Diabetes Prevention Program but tailored to the needs of the community based on feedback gathered in focus groups. Classes will be group-based and will use a variety of teaching techniques and group-based work to teach participants about behavior change, diet, and physical activity. Participant will be required to attend one group exercise class per week based on traditional Indian dances and other culturally appropriate activities. In order to reach their weekly exercise goal of 150 minutes or more per week, participants will also be able to attend an additional group exercise class, an organized group walk, do a culturally-tailored work out video created by the study staff, and/or exercise on their own.
1868819|NCT01084941|Behavioral|Lifestyle Intervention group|Women on the intervention group will participate in a lifestyle program based on diet and moderate physical activity implemented shortly after first recognition of pregnancy. These women will attend monthly nutrition and physical activity educational sessions, and receive booster every 2 weeks.
1868820|NCT01084941|Behavioral|Standard of Care|Patients randomized to the standard of care group will receive counseling routinely provided to all prenatal care women as recommended by the Institute of Medicine for appropriate nutrition and weight gain and ACOG guidelines for appropriate physical activity during pregnancy.
1868821|NCT01084980|Drug|Tacrolimus|tacrolimus 0.05mg/kg bid for 12 weeks corticosteroid 0.3 - 0.5mg/kg qd
1868822|NCT01084993|Drug|Bivalirudin|Standard practice: 0.75mg/kg + infusion 1.75mg/kg/h
1868823|NCT01084993|Drug|Heparin|70 U/kg
1868824|NCT01085006|Drug|Tranexamic acid|Tranexamic acid in cases, normal saline in controls
1868825|NCT01085006|Drug|Normal saline|Tranexamic acid in cases, normal saline in controls
1868826|NCT01085019|Dietary Supplement|Cinnamon|2.8g/day of cinnamon in capsules during 4 weeks.
1868827|NCT01085019|Dietary Supplement|Oregano|2.8g/day of oregano in capsules during 4 weeks.
1868828|NCT01085019|Dietary Supplement|Ginger|2.8g/day of ginger in capsules during 4 weeks.
1868829|NCT01085019|Dietary Supplement|Rosemary|2.8g/day of rosemary in capsules during 4 weeks.
1868830|NCT01085019|Dietary Supplement|Black pepper|2.8g/day of black pepper in capsules for 4 weeks.
1868831|NCT01085019|Dietary Supplement|Placebo|2.8 g/day of placebo in capsules (corn starch) during 4 weeks.
1868832|NCT01085032|Drug|Transdermal Nicotine|Subjects in the experimental group receive six weeks of nicotine patch treatment, 24 hour dose, using a step-down algorithm. Participants who smoke greater than 10 cigarettes/day receive two weeks of 21 mg patch, followed by two weeks of 14 mg patch, and then two weeks of 7 mg patch. Participants who smoke 5-9 cigarettes per day receive four weeks of 14 mg patch, followed by two weeks of 7 mg.
1869152|NCT01096017|Other|pMDI placebo pMDI|Placebo pMDI 2 inhalations
1868833|NCT01085032|Drug|Placebo nicotine patch|"Subjects in the placebo condition receive an inert placebo patch matched for size, shape, color, and packaging.
The same step-down dosing algorithm as in the experimental condition is used."
1868834|NCT01085045|Drug|PT003 MDI|Inhaled PT003 MDI administered as two puffs BID for 7 days
1868835|NCT01085045|Drug|PT005 MDI|Inhaled PT005 MDI administered as two puffs BID for 7 days
1868836|NCT01085045|Drug|Placebo MDI|Inhaled placebo administered as two puffs BID for 7 days
1868837|NCT01085045|Drug|Tiotropium bromide 18 μg (Spiriva Handihaler®)|Inhaled tiotropium bromide 18 μg (Spiriva Handihaler®) administered QD for 7 days
1868838|NCT01085045|Drug|Formoterol Fumarate 12 μg (Foradil® Aerolizer®)|Inhaled formoterol fumarate 12 μg (Foradil® Aerolizer®) administered BID for 7 days
1868839|NCT01085045|Drug|PT001 MDI|Inhaled PT001 MDI administered as two puffs BID for 7 days
1868840|NCT01085058|Drug|lenograstim|
1868841|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-high Potassium (4.5 mmol/L)
1868842|NCT01085071|Drug|Potassium Chloride|KCl is continuously administered and titrated towards a Normal-low Potassium (4.0 mmol/L)
1868843|NCT01085084|Drug|Laquinimod|Laquinimod 0.5 mg once daily for 12 weeks
1868844|NCT01085084|Drug|Laquinimod|Laquinimod 1 mg oral once daily for 12 weeks
1868845|NCT01085084|Other|Placebo|Placebo oral once daily for 12 weeks
1868846|NCT01085097|Drug|laquinimod|Laquinimod 0.5 mg or 1 mg
1868847|NCT01085097|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil (MMF)
1868848|NCT01085097|Drug|prednisolone/prednisone|corticosteroids
1868849|NCT01085097|Drug|Placebo|Placebo
1868850|NCT01085123|Drug|Rapimelt|oral tablet , 2.5 and 5 mg, single dose. 10 mg (2x5 mg) visit 3, 5 mg visit 4, 2.5 mg visit 5.
1868851|NCT01085123|Drug|[11C]AZ10419369|solution for iv injection. Will be injected within 2 to 5 hours after administration of ZOMIG® Rapimelt
1868852|NCT01085136|Drug|Investigator´s choice of chemotherapy|BIBW 2992 in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
1868853|NCT01085136|Drug|BIBW 2992|BIBW 2992 will be given in a medium dose in combination with Paclitaxel to explore safety and efficacy versus investigator´s choice of chemotherapy
1868854|NCT01085149|Drug|Simvastatin|10 mg simvastatin, slow release in socket of extracted tooth (single application only)
1868855|NCT01085162|Drug|BMS747158|BMS747158 is a novel PET MPI agent labeled with Fluorine-18.
1868856|NCT01085175|Drug|LMI 1195|Single bolus intravenous injection of LMI 1195
1868857|NCT01085188|Behavioral|ACC|Weekly community based behavioral counseling and case management
1868858|NCT01085188|Behavioral|CM|Weekly community based prize drawing opportunities contingent upon completed verifiable pro-social activities and clean urine and breath alcohol test results
1868859|NCT01085188|Behavioral|UCC|recommendation made by discharge counselor upon leaving residential treatment to attend nearest outpatient clinic.
1868860|NCT01085201|Drug|Lexiscan|Given as an infusion
1868861|NCT01085214|Other|Laboratory Biomarker Analysis|Correlative studies
1868862|NCT01085214|Drug|Selumetinib|AZD6244 (Selumetinib), 75 mg was administered orally, twice a day, continuously for 28-day cycles
1868863|NCT01085240|Other|Mission Possible|The intervention focuses on leisure education, exercise and community re-integration.
1868864|NCT01085253|Other|3T and 7T MR imaging|all patients and controls will be explored using a 3T and 7T MR imaging
1868865|NCT01085266|Drug|Dimebon (latrepirdine)|
1868866|NCT01085279|Device|Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)|1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
1868867|NCT01085279|Drug|Modified Kligman's formula (Triple topical therapy)|Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
1868868|NCT01085292|Drug|NOX-E36|Multiple dose 0.25 mg/kg or placebo i.v. to healthy volunteers; dosing frequency q2d
1868869|NCT01085292|Drug|NOX-E36|Multiple dose of 0.0625 mg/kg, 0.125 mg/kg, 0.25 mg/kg or placebo i.v. to patients with type 2 diabetes mellitus (ratio 3:1); dosing frequency q2d
1868870|NCT01085305|Behavioral|Parent-Child Interaction Therapy|Parents will be trained in interaction with their children in ways which foster non-hostility and cooperation in their children. By means of an ear-plug they will receive instruction on how to play and set limits for their child from their therapist who watches the interaction through a one-way mirror. Treatment is given until the parent masters these skill, which commonly takes 15-20 session of 1 hour.
1868871|NCT01085305|Behavioral|TAU|Usual treatment for behavioral disorders
1868872|NCT01085318|Drug|Rebif|44 mcg tiw
1868873|NCT01085331|Drug|Pimasertib|Subjects will be administered with pimasertib orally once daily on Days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
1868874|NCT01085331|Drug|Placebo|Subjects will be administered with placebo orally once daily on days 1-5, 8-12, 15-19, and 22-26 of a 28 day cycle.
1868875|NCT01085331|Drug|FOLFIRI|Subjects will be administered with FOLFIRI (laevoleucovorin 200 milligram per square meter [mg/m^2] intravenous [i.v] infusion over 90 minutes or leucovorin [dl-leucovorin] 400 mg/m^2 i.v. infusion over 90 minutes; followed by irinotecan 180 mg/m^2 given as a 90-minute infusion in 500 milliliter [mL] dextrose 5%; followed by a bolus 5-fluorouracil [FU] 400 mg/m^2 and a 46-hour infusion 5-FU 2400 mg/m^2) at conventional doses on days 1 and 15 of the same 28 day cycle.
1868876|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose prophylaxis
1868877|NCT01085344|Biological|Recombinant Factor VIII (Advate/Helixate FS/KoegenateFS)|escalating dose
1868878|NCT01085357|Procedure|Cataract Surgery|Cataract Surgery involves the removal of the natural lens, which has become clouded (called a cataract), and insertion of an artificial lens (called an intraocular lens). This procedure is done through a small surgical incision in the eye.
1868879|NCT01085357|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye after completion of cataract surgery.
1868880|NCT01085370|Other|Early psychological intervention|3 modules: psychoeducation, reconstruction of the trauma, coping skills
1869153|NCT01096017|Other|Placebo Turbuhaler®|Placebo Turbuhaler 1 inhalation
1868881|NCT01085383|Drug|Aripiprazole|Aripiprazole will be started at 5 mg daily and increased in a treat-to-target fashion by 5 mg steps until the primary outcome or the maximum tolerated or permitted dose of 30 mg is reached
1868882|NCT01085422|Drug|ABT-888|Subjects will be given ABT-888 on Days 1 -7 every 28 days orally and temozolomide on days 1-5 on days 1-5 every 28 days orally with ABT-888
1868883|NCT01085422|Drug|temozolomide|Subjects will be given ABT-888 40 mg twice daily on Days 1 -7 every 28 days orally and temozolomide on days 1-5 every 28 days orally with ABT-888
1868884|NCT01085435|Device|S-ICD System|The S-ICD System is an implantable technology that uses a subcutaneous pulse generator and subcutaneous electrode system to treat ventricular tachyarrhythmias. The S-ICD System consists of the pulse generator, subcutaneous electrode, the programmer and electrode insertion tool.
1868885|NCT01085448|Other|Core Stabilization|"The 8-week program emphasizes use of specific local stabilizing muscles (transverse abdominis[TrA], lumbar multifidus[LM]) to restore active control to the trunk. Emphasis is on training isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.
Stage 1: neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.
Stage 2: maintenance the co-contraction while performing movements of the trunk and the upper and lower extremities. Trunk conditioning is also emphasized. Feedback is gradually reduced.
Stage 3: maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
1868886|NCT01085474|Other|1|In the pilot study the objective is to compare 2 different pharmaceutical interventions (A and B) and to assess which one improves disease control, patient adherence and patient knowledge of the medication.
1868887|NCT01085474|Other|2|The best intervention used in the pilot study will be chosen and included in the main study.
1868888|NCT01085487|Drug|Levonorgestrel (Mirena, BAY86-5028)|Women using Mirena for treatment of menorrhagia
1868889|NCT01085487|Drug|Hormonal treatment|Hormonal treatment (including combined oral contraceptives or oral or injectable progestogens)
1868890|NCT01085487|Drug|Antifibrinolytic treatment|Antifibrinolytic treatment (such as tranexamic acid)
1868891|NCT01085500|Behavioral|Mastery Learning TEP Curriculum|A simulation-based educational curriculum
1868892|NCT01085500|Procedure|Current Practice|The current practice of learning how to perform the TEP repair in the operating room is under direct supervision of the staff surgeon without any simulation pre-training.
1868893|NCT01085513|Device|PillCam SB2|The disposable, ingestible PillCam SB 2 Capsule, part no. FGS-0180, is designed to acquire video images during natural propulsion through the small bowel. The capsule transmits acquired images via RF communication channel to the DataRecorder located outside the body.
1868894|NCT01085526|Biological|Alutard phleum pratense subcutaneous immunotherapy|standard regimen of SCIT
1868895|NCT01085526|Drug|Alutard phl prat|
1868896|NCT01085552|Drug|Epoetin Beta|Epoetin Beta. A single subcutaneous dose of 50IU/kg on Day 1. The body weight recording on day -1 will be used to calculate the dosage
1868897|NCT01085565|Device|ExAblate 2100|Conformal Bone System
1868898|NCT01085578|Drug|CG400549/placebo|Period 1: a single oral dose of 80 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 320 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1280 mg CG400549 or placebo on Day 1
1868899|NCT01085578|Drug|CG400549/placebo|Period 1: a single oral dose of 160 mg CG400549 or placebo on Day 1 Period 2: a single oral dose of 640 mg CG400549 or placebo on Day 1 Period 3: a single oral dose of 1920 mg CG400549 or placebo on Day 1
1868900|NCT01085578|Drug|CG400549|Period 1: a single oral dose of 640 mg CG400549 on Day 1 in the fasted state Period 2: a single oral dose of 640 mg CG400549 on Day 1 in the fed state
1868901|NCT01085591|Drug|CB-183,315|
1868902|NCT01085591|Drug|Placebo|
1868903|NCT01085591|Drug|Vancomycin|
1868904|NCT01085604|Other|Core Stabilization|"The 8-week core stabilization program emphasizes use of specific local stabilizing muscles (transverse abdominis[TrA], lumbar multifidus[LM]) to restore active control and stability to the trunk. This program emphasizes training using isometric co-contractions and a progression (3 stages) based upon a motor learning paradigm.
Stage 1: emphasizes neutral position of the spine and activation of the TrA and LM. Performance feedback is emphasized and monitored through observation and palpation.
Stage 2: promotes maintenance the co-contraction while performing movements of the trunk and superimposing movements of the upper and lower extremities. Trunk conditioning is also emphasized (i.e., curl ups, quadruped leg/arm lifts and side support). Feedback is gradually reduced.
Stage 3: emphasis on maintenance of the co-contraction while performing exercises on an unstable surface or during perturbation of the activity. Random practice patterns are used to enhance motor learning."
1868905|NCT01085617|Biological|palifermin|
1868906|NCT01085617|Biological|rituximab|
1868907|NCT01085617|Drug|cyclophosphamide|
1868908|NCT01085617|Drug|cytarabine|
1868909|NCT01085617|Drug|daunorubicin hydrochloride|
1868910|NCT01085617|Drug|etoposide|
1868911|NCT01085617|Drug|fludarabine phosphate|
1868912|NCT01085617|Drug|imatinib mesylate|
1868913|NCT01085617|Drug|melphalan|
1868914|NCT01085617|Drug|mercaptopurine|
1868915|NCT01085617|Drug|methotrexate|
1868916|NCT01085617|Drug|nelarabine|
1868917|NCT01085617|Drug|pegaspargase|
1868918|NCT01085617|Drug|vincristine sulfate|
1868919|NCT01085617|Procedure|allogeneic hematopoietic stem cell transplantation|
1868920|NCT01085617|Procedure|assessment of therapy complications|
1868921|NCT01085617|Radiation|total-body irradiation|
1868922|NCT01085630|Drug|pemetrexed disodium|Given IV
1868923|NCT01085630|Other|clinical observation|
1868924|NCT01085643|Drug|Lubiprostone|24mcg PO taken once
1868925|NCT01085643|Drug|Placebo|24mcg placebo capsule taken once
1868969|NCT01085929|Procedure|Ultrasound Guided Aspiration|Ultrasound is used to identify the abscess cavity. An 18 gauge needle is introduced into the abscess cavity and manual aspiration of the abscess contents is attempted.
1869154|NCT01096030|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg oral once daily BAY 73-4506 for 3 weeks of every 4 week cycle (i.e. 3 weeks on, 1 week off)
1869199|NCT01096342|Other|laboratory biomarker analysis|Correlative studies
1868926|NCT01085656|Drug|OXi4503|"Two safety cohorts treating two (2) patients at a dose of 2.5 mg/m2 followed by two patients at 3.75 mg/m2 will be completed prior to beginning at the dose level of 5 mg/m2.
Dosing of OXi4503 will be an intravenous infusion (IV) over 10 minutes on Days 1, 8, 15, and 22 of each 28 day cycle.
Dose escalations and de-escalations of 25% will be made until the maximum tolerated dose is reached.
Number of cycles: After Cycle 1, subjects who achieve stable disease (SD) or greater response may continue to receive additional cycles of treatment until either disease progression (defined as greater than 25% increase in leukemia myeloblasts in the bone marrow compared to baseline examination) or unacceptable toxicity due to the investigational agent."
1868927|NCT01085669|Device|Microbiological analysis of retained VEPTR Implants|Implants have to be adapted every half a year, the retained implants during revision are analysed for biological colonization.
1868928|NCT01085682|Behavioral|Lifestyle counseling|In intervention group, counseling sessions are conducted weekly for 3 months, once per two weeks for 3 months, monthly for 18 months, and then once every two months for the remainder of the study.
1868929|NCT01085682|Behavioral|Standard care|In standard care group, counseling sessions are conducted only 6 times for 4 years
1868930|NCT01085695|Drug|rabeprazole|10 mg normal tablet
1868931|NCT01085695|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
1868932|NCT01085695|Drug|rabeprazole|Type 2 granule containing rabeprazole 10 mg
1868933|NCT01085695|Drug|rabeprazole|Type 3 granule containing rabeprazole 10 mg
1868934|NCT01085708|Drug|rabeprazole|10 mg normal tablet
1868935|NCT01085708|Drug|rabeprazole|Type 1 granule containing rabeprazole 10 mg
1868936|NCT01085708|Drug|rabeprazole|Type 2 granules containing rabeprazole 10 mg
1868937|NCT01085708|Drug|rabeprazole|Type 3 granules containing rabeprazole 10 mg
1868938|NCT01085721|Drug|Dexchlorpheniramine, pseudoephedrine, guaifenesin|5 mL (2 mg dexchlorpheniramine, 20 mg pseudoephedrine and 100 mg guaifenesin) qid for 5 days
1868939|NCT01085721|Drug|Dexchlorpheniramine|5 mL (2 mg dexchlorpheniramine) qid for 5 days
1868940|NCT01085734|Drug|Avastin|1.25mg intravitreally
1868941|NCT01085734|Drug|Osurdex|0.7mg intravitreally
1868942|NCT01085734|Drug|Avastin|1.25mg intravitreally
1868943|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
1868944|NCT01085760|Drug|Vancomycin|Comparison of different doses of drug
1868945|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
1868946|NCT01085760|Drug|Metronidazole|Comparison of different doses of drug
1868947|NCT01085760|Drug|Vancomycin|Comparison of different drug doses
1868948|NCT01085773|Behavioral|Exercise on Prescription|The physical training consisted of both aerobic and strength training and took place in supervised groups.
1868949|NCT01085773|Behavioral|Nordic Walking|Nordic Walking is a fitness type of walking; incorporating the use of specially designed walking sticks. Nordic Walking focuses on aerobic training where the additional activity of the arms increases a person's oxygen uptake and energy expenditure.
1868950|NCT01085786|Drug|14-day sequential treatment|"14-day sequential therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
14-day hybrid therapy arm: esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days"
1868951|NCT01085786|Drug|14-day hybrid treatment|esomeprazole 40 mg and amoxicillin 1 g twice daily for 7 days followed by esomeprazole 40 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg twice daily for 7 days
1868952|NCT01085799|Behavioral|Health Education Intervention|This is a health hygiene education strategy which encourages the pro-active role of both teachers and students and changes in attitudes and practices with the aim of keeping the level of parasite infection low, through increased knowledge.
1868955|NCT01085825|Procedure|D & C abortion|Participants will be randomized to receive their abortion using either manual vacuum aspiration or electric vacuum aspiration.
1868956|NCT01085838|Drug|Erlotinib|Erlotinib oral capsule, 100, 150, or 300 mg/day during 12 weeks at study start
1868957|NCT01085851|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days
1868958|NCT01085851|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
1868959|NCT01085877|Drug|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site A) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site B)
1868960|NCT01085877|Drug|estradiol, 25 mcg|Single dose of vaginal tablet containing 25 mcg estradiol (Production site B) followed by another single dose of vaginal tablet containing 25 mcg estradiol (Production site A)
1868961|NCT01085890|Behavioral|Motivational interviewing|The intervention consisted of 2 group seminars with information on hypertension and related lifestyle factors and 2 follow-up visits in which blood pressure was measured and motivational interviewing took place. The motivational interviewing focused on lifestyle factors, including physical activity, stress, tobacco use, alcohol habits, and diet.
1868962|NCT01085903|Drug|Modafinil|200 mg once daily with morning meal for three days administered only to stroke patients
1868963|NCT01085903|Drug|Placebo|Subjects will receive a placebo designed to look like 200 mg dose of modafinil. The dose will be taken once daily with the morning meal for three days and will only be administered to stroke patients
1868964|NCT01085903|Behavioral|Baseline|Observations made at baseline before any intervention
1868965|NCT01085903|Behavioral|CPS|Submerging each participant's foot into ice water (36-44 F) for 50 seconds.
1868966|NCT01085903|Behavioral|Post CPS|20 minutes following the CPS condition.
1868967|NCT01085903|Behavioral|Follow up|Follow up testing occurred at 3 months
1868968|NCT01085929|Procedure|Incision and Drainage|Surgical incision of the skin surface followed by expression of purulence with or without debridement or manual exploration of abscess cavity.
1869075|NCT01095406|Device|S1 ventilation|Ventilation with a O2 and CO2 controller
1869198|NCT01096342|Drug|dinaciclib|Given IV
1868970|NCT01085968|Behavioral|PC based training|Subjects sit at a computer and type a string of numbers that appears on the screen. As performance improves (# correct), the strings of numbers get longer. They are then instructed to repeat the string from memory. Performing these key entries from memory is a test of internally generated movement initiation.
1868971|NCT01085981|Drug|arginine 20%, nicotinamide .01%, niacin.1%, in LipodermPG 50%|On the first office visit the patient will have their baseline clitoral and uterine blood flow measured quantitatively by the same sonographer using the General electric Voluson 700 unit. Clitoral blood flow will be accessed utilizing the 12 megahertz linear probe. With light pressure, the probe will be applied sagittally and proximal to the clitoral hood with an angle less than 20 degrees. Peak clitoral artery systolic and end diastolic velocity will be measured and resistive index values will be recorded. Then utilizing the 7.5 megahertz vaginal probe baseline uterine artery flow measurements will also be obtained and recorded. With both GRAS cream and placebo.
1868972|NCT01085981|Drug|Topical study cream|One gram applied to clitoris by nurse then ten minutes later doppler study of clitoral blood flow
1868973|NCT01085981|Drug|GRAS cream|1 gram of active cream will be applied by nurse then 10 minutes later clitoral blood flow will be assessed by doppler studies see protocol
1868974|NCT01085994|Other|Literature search|Literature search followed by systematic review and meta-analysis
1868975|NCT01086020|Drug|atorvastatin|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 10mg/d for two years
1868976|NCT01086020|Drug|atorvastatin plus ezetimibe|Patients admitted with 20-70% coronary artery plaque identified by angiography will be treated with atorvastatin 5mg/d and Ezetimibe 5mg/d for two years
1868977|NCT01086046|Drug|Low molecular weight heparin|"Low molecular weight heparin sodium injection 1mg/kg 2 times in 24 hour
Low molecular weight heparin sodium injection 1mg/kg 2 times per day in 3 days."
1868978|NCT01086085|Drug|Adefovir|Adefovir 10 mg po once daily for 36 weeks
1868979|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
1868980|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 48 weeks
1868981|NCT01086085|Drug|peginterferon alfa-2a [PEGASYS]|Non-early responders: PEGASYS 180 mcg sc once weekly for 96 weeks
1868982|NCT01086150|Other|Skin biopsy|Skin biopsy specimens will processed and analyzed for Nerve fiber count, nerve and skin morphology, and sodium channel specific epitope expression in keratinocytes.
1868983|NCT01086150|Other|Skin biopsy|Skin biopsy specimens will be processed and analyzed for nerve fiber count, nerve and skin morphology and sodium channel specific epitope expression in keratinocytes.
1868984|NCT01086163|Drug|Omacor, omega-3 fatty acids in CAD patients|Omacor 1g versus 2g daily versus placebo
1868985|NCT01086176|Device|NMT (a device that can do neurostimulation and can record the response on the stimulation by Datex)|on one side, we do a post-tetanic count, on the other side we don't, after, we do train-of-four on both sides and check the difference
1960036|NCT03308175|Device|flat fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females
1868987|NCT01086241|Procedure|2D Mammogram|Those patients randomized to the mammogram arm will receive a regular 2D mammogram. Compression lasts several seconds in order to obtain 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
1868988|NCT01086241|Procedure|Tomosynthesis|Those patients randomized to the tomosynthesis arm will receive a combination of 3D and 2D screening mammogram. The additional tomosynthesis data is obtained immediately after acquisition of the 2D study, with the patient and breast remaining in the same position and compression. Compression lasts about 7 seconds longer for each of the 4 views. The x-ray tube is programmed to obtain an arc of low dose projection images through the breast.
1868989|NCT01086254|Drug|Iniparib|"Pharmaceutical form: solution for infusion
Route of administration: 60-minute IV infusion"
1868990|NCT01086254|Drug|gemcitabine|"Pharmaceutical form: solution for infusion
Route of administration: 30-minute IV infusion"
1868991|NCT01086254|Drug|cisplatin|"Pharmaceutical form: solution for infusion
Route of administration: 1- to 4-hour IV infusion, according to the local standard"
1868992|NCT01086267|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, every 12 hours (Q 12 h), Continuously
1868993|NCT01086267|Drug|BMS-908662|Capsules, Oral, (TBD) mg, Q 12 h, Continuously
1868994|NCT01086267|Drug|Cetuximab|Vial, IV, 400 mg/m² loading dose followed by 250 mg/m² maintenance dose, Weekly, Continuously
1868995|NCT01092377|Dietary Supplement|DHA and EPA Fish Oil capsule|2 DHA/EPA capsules on 4 days per week containing totally 420 mg DHA and 80 mg EPA, providing an average dose of 285.7 mg n-3 fatty acids per day
1868996|NCT01092377|Dietary Supplement|Iron tablet|1 iron tablet containing 50 mg of iron as ferrous sulfate will be administered on 4 days per week, providing an average iron dose of 28.6 mg iron per day.
1868997|NCT01092377|Other|Placebo tablet|Placebo tablet will be administered on 4 days per week and will be identical in appearance to the iron tablet.
1868998|NCT01092377|Other|Placebo capsule|Placebo capsules contain medium chain triglycerides and will be identical in appearance and total fat content to the DHA/EPA capsules.
1868999|NCT01092390|Dietary Supplement|Lovaza (fish oil)|4 grams per day
1869000|NCT01092403|Drug|ASM-024|ASM-024 50 mg of ASM-024 or 200 mg once daily by inhalation
1869001|NCT01092403|Drug|Placebo|Placebo once daily by inhalation
1869002|NCT01092416|Device|Diamondback 360 Orbital Atherectomy System|Diamondback 360 Orbital Atherectomy System. The (OAS) utilizes a diamond-coated eccentric crown that, while rotating over an atherectomy guide wire, expands the lumen diameter laterally via centrifugal forces (up to a maximum orbit diameter for a given rotational speed and crown diameter). It is a minimally invasive PCI procedure.
1869003|NCT01092442|Procedure|Echocardiogram|Patients will have a yearly echocardiogram after enrollment in the study.
1869004|NCT01092455|Drug|Heparin N reduction|Dialysis with Citrasate, acid concentrate plus 100% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 80% of patient's standard heparin N dose; Dialysis with Citrasate acid concentrate plus 66.7% of patient's standard heparin N dose.
1869005|NCT01092468|Procedure|Diathermy|flap dissection with conventional diathermy
1869006|NCT01092468|Procedure|Harmonic Scalpel|flap dissection using harmonic scalpel (FOCUS)
1869007|NCT01092481|Drug|oxaliplatin|to confirm that first 3 months of oxaliplatin in 12 cycles of modified FOLFOX-6 or 8 cycles of CAPOX treatment is not inferior to 6 months of oxaliplatin in modified FOLFOX-6 or CAPOX treatment in terms of disease free survival in patients with stage II/III colon cancer.
1869008|NCT01092507|Biological|Japanese encephalitis chimeric virus vaccine (JE-CV)|0.5 mL, Subcutaneous
1869009|NCT01092507|Biological|Japanese encephalitis live vaccine (SA14-14-2 vaccine) (CD.JEVAX®)|0.5 mL, Subcutaneous
1869010|NCT01092520|Drug|Gabapentin|Day 1 - 5mg/kg/dose per os at bedtime then 5mg/kg/dose PO b.i.d x 1 day (Day 2) then on Day 3, 5mg/kg/dose PO t.i.d . x 19 days; after 7 days, if not at maximal effect may increase over 3 days to 10mg/kg/dose (Day 8: 5 mg/kg/dose q.am and midday, Day 9: 10mg/kg/dose b.i.d. + 5mg/kg/dose midday, Day 10: 10mg/kg/dose t.i.d.) Doses may be reduced if patient experiences intolerable side effects.
1869011|NCT01092533|Drug|Myfortic|Myfortic 360 mg BID (during week 1) Myfortic 720 mg BID (from week 2 on) Maintenance dose Decortin 5mg/d
1869012|NCT01092533|Drug|Decortin|Maintenance dose 5 mg/d
1869013|NCT01092546|Drug|[18F]Flutemetamol|All subjects will receive an IV dose of [18F]flutemetamol (less than 10 mg flutemetamol). The nominal activity of a single administration of [18F]flutemetamol will be 185 MBq.
1869014|NCT01092559|Drug|Nitric Oxide generated by the GeNO nitrosyl delivery system|single short-term exposure to inhaled nitric oxide using the GeNO nitrosyl delivery system.
1869015|NCT01092572|Drug|Simvastatin|simvastatin 40 mg per day orally for 12 weeks.
1869016|NCT01092572|Drug|placebo|placebo 1 tablet once daily for 12 weeks
1869017|NCT01092585|Drug|Tesetaxel|"Tesetaxel capsules will be administered orally once every 21 days until the patient meets a withdrawal criterion or initiates nonstudy therapy for melanoma. The duration of protocol therapy will not exceed 12 months.
In Cycle 1, a flat dose of 40 mg will be administered to patients of relatively normal weight. For patients who weigh at least 25% below their ideal body weight, a flat dose of 35 mg will be administered. For patients who weigh at least 25% above their ideal body weight, a flat dose of 45 mg will be administered. Dose escalation by 5 mg in Cycle 2 and an additional 5 mg in Cycle 3 is permitted provided protocol-specified criteria are met."
1869018|NCT01092611|Procedure|Blood collection|Once a year after Visit 1 (during a maximum of 4 years). The samples will only be taken in conjunction with, and at the same time as, planned routine blood testing using the same needle-stick.
1869019|NCT01092611|Biological|GSK HIV vaccine 732462|No vaccine will be administered during this long-term follow-up study. Vaccines were administered during the primary studies.
1869020|NCT01092624|Drug|Solifenacin|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
1869021|NCT01092624|Drug|Placebo|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
1869022|NCT01092624|Device|Ring pessary with support, Cooper Surgical, Trumbell, CT Ref # MXPRS03 non-latex|There will be a two-week pessary run-in prior to randomization. If the subject completes the run-in period with no adverse reactions to the pessary, she will come in to the office for a randomization visit. She will be randomized to receive either 5 mg/day (one 5 mg tablet QD) of placebo or 5 mg/day (QD) of solifenacin for 12 weeks. At the end of week 6, patients will be assessed in the office. A standardized medication response questionnaire will be used to assess each subject's response to either the placebo or the solifenacin 5 mg. If the response is not adequate, the dose will be increased. Women whose symptoms have not improved since baseline will have their medication or placebo doses increased to 10 mg daily.
1869023|NCT01092650|Drug|Deuterated phenanthrene|Deuterated phenanthrene 10 micrograms
1869024|NCT01092663|Drug|Colesevelam HCl|Subjects will be given 3.75 g/day. Subjects will be given 3 tablets (625mg each) with breakfast and 3 tablets (625mg) with dinner for 12 weeks.
1869025|NCT01092663|Drug|Sitagliptin|Subjects will be given 100mg/day. Subjects will be given 1 tablet (100mg) with breakfast for 12 weeks.
1960037|NCT03308175|Device|modified inclined fixed anterior bite plane|It causes unlocking mandible from deep bite in growing females plus putting the mandible in a more forward position
1869028|NCT01092689|Drug|PhiP|1 capsule of 84 micrograms; 15.6 micro-curies [14C]PhIP
1869029|NCT01092702|Drug|Varenicline|During the first week varenicline will be started at a dose of 0.5 mg once daily for days 1-3; then 0.5 mg twice daily for days 4-7. Target quit date is set at day 8. Varenicline is then continued for weeks 2-12 at a dose of 1 mg twice daily.
1869030|NCT01095055|Biological|AdCh63 AMA1|Group 1A - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly Group 2A - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly
1869031|NCT01095055|Biological|AdCh63 AMa1 and MVA AMA1|Group 1B - single dose of AdCH63 AMA1 5x10^9 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly Group 2B - single dose of AdCH63 AMA1 5x10^10 vp intramuscularly and single dose of MVA AMA1 5x10^8 pfu 8 weeks later intramuscularly
1869032|NCT01095068|Behavioral|Physical exercise|
1869033|NCT01095081|Drug|Gadobutrol (Gadovist, BAY86-4875)|Patients requiring contrast enhanced MRI using Gadovist. Administration of Gadovist at the discretion of the attending physician.
1869034|NCT01095094|Drug|ritonavir|Given orally
1869035|NCT01095094|Drug|lopinavir|Given orally
1869036|NCT01095107|Dietary Supplement|Low fat intake|low fat intake : Intake 35-50 grams of fat per day between meals and snacks
1869037|NCT01095107|Dietary Supplement|Increased fat intake|increased fat intake : Intake > 50 grams of fat per day between meals and snacks
1869038|NCT01095120|Drug|Tesetaxel|"For subjects in Cohort A, a flat dose of 40 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the Cycle 1 flat dose may be increased by 5 mg in Cycle 2, and the Cycle 2 flat dose may again be increased by 5 mg in Cycle 3.
For subjects in Cohort B, a flat dose of 50 mg will be administered in Cycle 1; the dose will be adjusted based on body weight. In subsequent cycles, depending on tolerability, the dose may be increased by 10 mg in Cycle 2.
For subjects in Cohort C, a dose of 27 mg/m2 will be administered in Cycle 1. In subsequent cycles, depending on tolerability, the dose will be increased to 35 mg/m2 in Cycle 2."
1869039|NCT01095133|Drug|Amiloride|dosage form: intraesophageal amiloride infusion dosage: liquid 1 mM amiloride concentration duration: 5 minute infusion given once frequency: 1 time
1869040|NCT01095133|Drug|Placebo|dosage form: intraesophageal saline infusion dosage: normal Saline (0.91% w/v of NaCl) duration: 5 minutes given once frequency: 1 time
1869041|NCT01095159|Device|TVT-O|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator sling TVT-O™ (Gynecare™, USA).
1869042|NCT01095159|Device|TVT-S|Subjects of this group were submitted to surgical treatment of stress urinary incontinence with a transobturator mini-sling; TVT-Secur™ (Gynecare™, USA).
1869043|NCT01095172|Drug|Rituximab|375mg/m^2, single dose given 2-4 weeks prior to transplantation
1869044|NCT01095172|Drug|Tacrolimus|dose calculated to give levels of 3-7ng/ml
1869045|NCT01095172|Drug|Mycophenylate mofetil|Mycophenylate mofetil 2g/day in divided doses
1869046|NCT01095172|Drug|Hydrocortisone|100mg hydrocortisone on the evening of the day of surgery and 2 further doses of hydrocortisone on day 1 post transplant.
1869047|NCT01095172|Drug|Prednisolone|Prednisolone 0.3mg/kg on day 2, 0.25mg/kg on day 3, 0.2mg/kg on day 4 and 0.16mg/kg on day 5. On day 6 they will receive 5mg prednisolone, and on day 7 none.
1869048|NCT01095172|Drug|Prednisolone|Reducing dose of prednisolone over at least 6 months. Subsequent steroid maintenance or withdrawal will be at the discretion of the patient's clinician.
1869049|NCT01095185|Drug|Simvastatin|Simvastatin 20 mg for 15 days, then 40 mg until the end of the study.
1869050|NCT01095185|Drug|Placebo|Simvastatin placebo
1869051|NCT01095198|Device|offer of vaginal self collection|Women assigned to the intervention group will be offered the opportunity to self collect a vaginal specimen for HPV testing. They will be sent a letter explaining that a study of self testing is being performed, and will invite her to participate in this study. The letter will state that, if the patient prefers, she can perform a vaginal self-test in addition to, or instead of Pap smear testing. Patients are told that they have the option of completing the self-test on their own or in their physician's office with the help of their physician or practice staff. The letter will be accompanied by a self collection kit consisting of: a swab and test tube, pamphlet (with written instructions and diagram outlining procedure), instructional DVD and return envelope.
1869052|NCT01095198|Other|2nd reminder letter for Pap testing|Women in both groups will receive a letter informing them that they are due for cervical screening. This is a standard letter, and is signed by the patient's individual family physicians. It will advise the patient that this is the second reminder letter that she is due for cervical cancer screening, and will invite her to phone the physician's office to obtain an appointment for Pap testing.
1869053|NCT01095211|Drug|B-vitamin complex|5 mg Folic acid, plus 1 mg cyanocobalamin and 40 mg vitamin B6) oral/ day. The placebo capsule contained 400 mg of mannitol: aerosil (99.5: 0.5). In addition, 1 mg/s.c cyanocobalamin daily
1869054|NCT01095224|Biological|rAd35 Env A|1 x 10^10 particle units (PU) administered as 1 mL intramuscularly (IM) in deltoid
1869055|NCT01095224|Biological|rAd5 Env A|1 x 10^10 PU administered as 1 mL IM in deltoid
1869056|NCT01095224|Biological|rAd5 Env B|1 x 10^10 PU administered as 1 mL IM in deltoid
1869057|NCT01095237|Device|ProEndoTecc Vascular Graft|Implantation of the device as an interponate / bypass of the superficial femoral artery
1869058|NCT01095250|Drug|AIN457|
1869059|NCT01095250|Drug|AIN457|
1869060|NCT01095250|Drug|AIN457|
1869061|NCT01095250|Drug|Placebo|
1869062|NCT01095263|Device|DBS|130Hz, 90us pulsewidth, 4V Amplitude
1869063|NCT01095263|Device|No Stimulation (Sham)|130Hz, 90us pulsewidth, 0V Amplitude
1869064|NCT01095276|Drug|Pulmozyme (nebulized dornase alpha)|nebulized dornase alpha: 2.5 mg by in-line nebulizer BID
1869065|NCT01095276|Drug|Saline|Saline packaged identically to the dornase alpha intervention unit doses and coded for blinding by the company providing the intervention drug (dornase alpha).
1869066|NCT01095302|Drug|OMBRABULIN (AVE8062)|"Pharmaceutical form:injection solution
Route of administration: intravenous infusion"
1869067|NCT01095302|Drug|cisplatin|"Pharmaceutical form:injection solution
Route of administration: intravenous infusion"
1869068|NCT01095302|Drug|docetaxel|"Pharmaceutical form:injection solution
Route of administration: intravenous infusion"
1869069|NCT01095315|Other|lateral positioning|the lateral position was maintained for 6 min after spinal injection before patients were turned to the supine position
1869070|NCT01095328|Other|screening|screening for Q-fever with a single blood sampling
1869071|NCT01095341|Other|No intervention performed|
1869072|NCT01095354|Drug|Sodium Chloride Inhalation|"Spirometry: all subjects Plethysmography and exhaled nitric oxide: >6 years Multiple Breath Washout: Tidal breathing using a facemask <9 years or mouthpiece >9 years. Wash-in phase: gas mixture containing 4% SF6, 4% He, 21% oxygen and balance nitrogen inhaled until steady state. Bias flow stopped during expiration by removal of T-piece. Wash-out phase: patient inspires room air and exhales tracer gas until SF6 reaches <0.1%.
Bronchodilator response: Bronchodilator (Salbutamol 400 mcg) to asthma subjects, spirometry and MBW repeated after 15 minutes.
Induced sputum in asthma subjects >10 yrs. Post-bronchodilator spirometry, subject inhales concentrations of 3, 4 and 5% hypertonic saline for 7 minutes for 3 cycles until expectorating sputum."
1869073|NCT01095367|Procedure|Seprafilm™|"Seprafilm™ Adhesion Barrier is an approved temporary, bioresorbable adhesion barrier to reduce the incidence, extent, and severity of adhesions in patients undergoing abdominal or pelvic laparotomy.
Seprafilm sheets are size 5 x 6 individually-wrapped, sterile membranes. Three or more Seprafilm™ sheets will be placed in the randomized cohort."
1869074|NCT01095380|Other|Locomotor training|Locomotor training using body weight support with training on a treadmill or training over ground with differing forms of assistance for stepping
1869076|NCT01095419|Other|Massage Therapy|After discharge from the intensive care unit to the ward during the postoperative period, patients which were randomized for 3 nights to receive intervention (Massage Therapy)which were consisted of massage of the neck, shoulders, and back. The massage was initiated with light manual compression and progressed to deep compression. The compression was performed with the inner region of the fingers, hand-shaped clamp, and friction (digital compression with the thumb) on trigger points, cervical traction, and mobilization in all planes (front, back, and sides)
1869077|NCT01095419|Other|Control|no intervention
1869078|NCT01095432|Procedure|PWS Testing|Partial wave spectroscopy (PWS)has been developed to allow scientists to learn about any changes to the cells that may indicate a risk of developing colon cancer.
1869079|NCT01095445|Drug|Peginterferon alfa-2b (Pegetron) plus ribavirin (Rebetol)|Dosage Form: Pegetron - powder for solution; Rebetol - capsules Strength: Pegetron Redipen - 120 mcg per pen; Rebetol - 200 mg Route of Administration: Pegetron - subcutaneous; Rebetol - oral
1869080|NCT01095458|Behavioral|Phone versus Clinic Weight Management Programs|To determine if weight loss is equivalent between individuals that complete weight loss meetings in person versus on the phone.
1869081|NCT01095471|Biological|PCV13|Immunisation with the 13-valent pneumococcal conjugate vaccine (PCV13) at approximately 40 months of age.
1869082|NCT01095484|Drug|Rotigotine patch|1 patch daily for up to 48 months. Patch strength (per 24 hours): 1 mg - 8 mg based on investigator's assessment
1869083|NCT01095497|Biological|CINRYZE|C1 esterase inhibitor (human)
1869084|NCT01095510|Biological|CINRYZE|
1869085|NCT01095523|Procedure|Laparotomy+ HIPEC +/- CRS|
1869086|NCT01095549|Device|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt〈mw〉/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes for patients on each HD section for a year.
1869087|NCT01095549|Device|Placebo device|A device without far infrared therapy
1869088|NCT01095562|Drug|ABT-126|ABT-126 Dose 1, ABT-126 Dose 2
1869089|NCT01095562|Drug|Placebo|Placebo
1869090|NCT01095575|Drug|normal saline 3 ml, morphine 3mg|On the day of surgery, patients were brought to the operating room (OR) where routine monitors were placed and an epidural catheter was inserted at the level of L3-4 to a distance of 10 cm. All patients received two injections via the catheter: one injection contained 3 mg morphine (MO), and the other contained normal saline (NS) of the same volume. Patients were randomized to receive either NS preoperatively and MO postoperatively or vice versa. The first injection was administered 40 minutes before initiation of surgery, and the second one was given 15 minutes after surgery ended. All epidural catheters were removed before the patients were discharged from the post-anesthesia care unit (PACU).
1869091|NCT01095588|Drug|200 mg Avanafil|2 X 100mg tablets avanafil
1869092|NCT01095588|Drug|Placebo|2 tablets
1869093|NCT01095601|Drug|Avanafil|"Treatment A: 2x100 mg Formulation II avanafil tablet, fasted
Treatment B: 2x100 mg Formulation II avanafil tablet, fed
Treatment C: 2x100 mg Formulation I avanafil tablet, fasted
Treatment D: 1x50 mg Formulation II avanafil tablet, fasted"
1869094|NCT01095627|Other|Metacholine challenge|Exhaled breath analysis following metacholine challenge
1869095|NCT01095640|Drug|adapalene 0.3% topical gel|once a day, 84 days
1869096|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
1869097|NCT01095653|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
1869098|NCT01095653|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
1869099|NCT01095653|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
1869100|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 5 mg, Once daily, 24 weeks
1869101|NCT01095666|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 24 weeks
1869102|NCT01095666|Drug|Metformin|Tablets, Oral, 1500-3000 mg, Twice daily, 24 weeks
1869103|NCT01095666|Drug|Dapagliflozin Placebo|Tablets, Oral, 0 mg, Once daily, 24 weeks
1869104|NCT01095666|Drug|Pioglitazone|Tablets, Oral, 15-45 mg (as needed for rescue based on protocol specific criteria), Up to 20 weeks
1869105|NCT01095679|Drug|Baclofen|Breaking tablets of 10 mg of baclofen. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
1869106|NCT01095679|Drug|Placebo|Breaking tablets of 10 mg of placebo. Dosage and frequency : 5 mg 3 times a day for 3 days, then 10 mg 3 times a day for 3 days, then 15 mg 3 times a day for 3 days, then 20 mg 3 times a day for 3-5 days, then 15 mg 3 times a day for 1 day, then 10 mg 3 times a day for one day, then 5 mg 3 times a day for one day.
1869107|NCT01095692|Procedure|Pelvic Organ Prolapse and Suburethral TOT implantation|Procedure/Surgery: Pelvic Organ Prolapse intervention and Suburethral TOT implantation
1869108|NCT01095692|Procedure|Pelvic Organ Prolapse intervention|Procedure/Surgery: Pelvic Organ Prolapse intervention
1869109|NCT01095705|Procedure|Conventional procedure|Local anaesthesia (Lidocaïne)
1869110|NCT01095705|Procedure|Conventional procedure + Hypnosis|Local anaesthesia (Lidocaïne) + Hypnosis (20 minutes)
1869111|NCT01095718|Behavioral|Errorless Learning|"Errorless learning refers to the use of feedforward instruction before actions to prevent learners from making mistakes. The therapist presents steps with the following instruction and the visual cues e.g., Here are steps that you need to do to make some coffee, please repeat them.
The therapist gives cues before the completion of each step. At each step the patient receives verbal and visual cues. Then cue cards are hidden, and the therapist asks immediately to give the answer about the step involved.
The therapist allows the participant to try finding the solution, if the answer or action is not immediately given, the participant receives a cue, and moves to the next step.
During cueing the patient will mostly receive verbal and visual cues and if necessary physical help."
1869150|NCT01096017|Drug|Terbutaline Turbuhaler®|0.4 mg, inhalation, single dose
1869151|NCT01096017|Drug|Salbutamol pMDI|200 μg, inhalation, single dose
1869112|NCT01095718|Behavioral|Modeling|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.
The therapist does the steps, at the same time he/she uses verbal cues during the performance.
Then the therapist asks immediately to the patient to do the steps."
1869113|NCT01095718|Behavioral|Trial and Error|"The therapist gives the same tailored baseline information for each task. The therapist issue specific information for each step. Using tailored mastery modeling, the therapist shows the steps in front of the patient. There is a special emphasis on adjusting the modeling just above the patient's abilities.
The therapist does the steps, at the same time he/she uses verbal cues during the performance.
Then the therapist asks immediately to the patient to do the steps."
1869116|NCT01095757|Drug|Plerixafor|240 µg/kg subcutaneous injection on the day that the absolute neutrophil count (ANC) is > 1500/mm3 and on each day of apheresis for a total of 4 aphereses or the target CD34 cell dose has been reached.
1869117|NCT01095770|Procedure|AF Ablation with Ablation Frontiers Technology|AF Ablation with Ablation Frontiers Technology - PVAC, TVAC and MASC.
1869118|NCT01095770|Procedure|AF Ablation with LASSO catheter|AF Ablation with traditional LASSO catheter
1869119|NCT01095770|Device|Reveal XT|Reveal XT implantable loop recorder monitored group
1869120|NCT01095770|Device|Permanent Dual Chamber Pacemaker|This group will be monitored with a dual chamber pacemaker with advanced AF monitoring capabilities.
1869121|NCT01095783|Procedure|physiotherapeutic intervention|Twenty repetitive exercises (30 seconds per exercise) consisting of: flexion in standing, extension in standing, flexion in lying, and extension in lying position applied three times a week for eight weeks
1869122|NCT01095783|Procedure|control|The control group receive transcutaneous electrical nerve stimulation (TENS) for 20 min at 50-100 Hz frequencies for the same time frame (Anesth Analg 2004;98:1552-6)
1869123|NCT01095796|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
1869124|NCT01095796|Drug|Atripla|Atripla (EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily prior to bedtime
1869125|NCT01095796|Drug|Stribild Placebo|Placebo to match Stribild STR administered orally once daily
1869126|NCT01095796|Drug|Atripla Placebo|Placebo to match Atripla tablet administered orally once daily prior to bedtime
1869127|NCT01095809|Drug|bevacizumab|2.5mg at baseline, week 4 and 8. Beyond this initial period if needed reinjection criteria are described in protocol
1869128|NCT01095809|Drug|triamcinolone acetonide|2 mg at baseline; frequency every three months if needed. reinjection criteria are described in protocol
1869129|NCT01095822|Drug|Aliskiren + Valsartan|Comparison of combination (aliskiren + valsartan) therapy versus valsartan alone on hemostatic indices
1869130|NCT01095835|Drug|Pegylated interferon (PEG-IFN) alfa-2a, 180 mcg|PEG-IFN alfa-2a 180 micrograms (mcg) was administered subcutaneously, once weekly from Week 0 to 48.
1869131|NCT01095835|Drug|Pegylated interferon (PEG-IFN) alfa-2a, 135 mcg|PEG-IFN alfa-2a 135 mcg was administered subcutaneously, once weekly from Week 49 to 96.
1869132|NCT01095835|Drug|Lamivudine (LAM)|Lamivudine 100 milligrams (mg) was administered orally, daily from Week 0 to 48.
1869133|NCT01095848|Biological|DPX-0907 consists of 7 tumor-specific HLA-A2-restricted peptides, a universal T Helper peptide, a polynucleotide adjuvant, a liposome and Montanide ISA51 VG|Patients will receive three deep subcutaneous injections of the vaccine three weeks apart in the upper thigh region. Patients will be followed for up to 7 months.
1869134|NCT01095861|Device|FlexTip ETT (Parker FlexTip/GlideScope FlexTip)|FlexTip ETT used for endotracheal intubation
1869135|NCT01095861|Device|Control - standard flexible ETT (Mallinckrodt)|"Control - standard flexible ETT
Mallinckrodt Hi-Lo cuffed tracheal tube, Catalog # 86114, Mallinckrodt, ST. Louis, MO, 63134"
1869136|NCT01095887|Drug|Eculizumab|Subjects received eculizumab intravenously at the time of transplant, on the day after transplant, then weekly for four weeks. At four weeks post transplant, anti-blood group antibody levels were determined. Subjects may have potentially received eculizumab every two weeks for one year depending on antibody levels.
1869137|NCT01095900|Procedure|conservative lateral internal sphincterotomy|
1869138|NCT01095900|Procedure|Intra-sphincteric Botulinum-toxin injection|
1869139|NCT01095913|Drug|Indocyanine green (ICG)|Injections performed after induction of anesthesia for surgery; 25 µg ICG/injection, with injections of 0.1 cc each to be made starting in the hand, arm, and areolar regions of the breast.
1869140|NCT01095926|Drug|doxorubicin|blood sampling before, during and after doxorubicin administration
1869141|NCT01095939|Drug|Placebo|Tablets; oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
1869142|NCT01095939|Drug|Benazepril hydrochloride|Tablets (10 or 20 mg); oral administration; once a day for 6 months. After this period of 6 months blinded treatment, the treatment will be stopped for 2 weeks. At the end of this washout period, a new renal evaluation is done. At that time, opened label treatment will be proposed to the women who still show renal alterations after a 2 weeks washout period
1869144|NCT01095965|Behavioral|Nutrition education|Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
1869145|NCT01095978|Drug|Clarithromycin (Klacid SR)|Klacid SR in a dose of 1000 mg once daily
1869146|NCT01095991|Drug|AZD1656|Oral tablet bd,
1869147|NCT01095991|Drug|Sitagliptin|Oral tablet od
1869148|NCT01096004|Drug|AZD4017|oral suspension, 1200mg, once daily, for 10 days
1869149|NCT01096004|Drug|Placebo|
1869155|NCT01096043|Drug|Placebo|An infusion of an identically appearing solution of sugar water will be intravenously administered.
1869156|NCT01096043|Drug|Strata 1 CXL-1020|Intravenous infusion of CXL-1020, up-titrated, so that 3 different dosages are administered over 6 hours
1869157|NCT01096043|Drug|Strata 2 CXL-1020|One of 3 different dosages of CXL-1020 administered at a fixed dosage level for 6 hours.
1869158|NCT01096043|Drug|Strata 3 CXL-1020|A fixed dose level of CXL-1020 will be administered for the initial 6 hours of treatment in Strata 3 and then dosage will be altered up or downward based on the investigators observation of the patient's condition.
1869159|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 1|Intramuscular administration, 2 doses
1869160|NCT01096056|Biological|Influenza vaccine GSK2186877A formulation 2|Intramuscular administration, 1 dose
1869161|NCT01096056|Biological|Fluarix|Intramuscular administration, 1 dose
1869162|NCT01096082|Drug|Lithium Carbonate|300 mg tablets, starting dose 300 mg/day
1869163|NCT01096082|Drug|Placebo|Similar shape, color and taste and the same number of tablets from the experimental group
1869164|NCT01096095|Drug|Placebo|Powdered placebo in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets).
1869165|NCT01096095|Drug|Sodium Phenylbutyrate|Powdered sodium phenylbutyrate in sachets containing each 3g. At the start of the study, the dose will be 15g/day (five sachets) and may be reduced in case of mild adverse events.
1869166|NCT01096108|Behavioral|Standard contest (1 month)|Smoking abstinence, 1 prize award (month 1)
1869167|NCT01096108|Behavioral|Motivational and Problem-Solving|Counseling phone calls
1869168|NCT01096108|Behavioral|Extended Contests|Smoking abstinence, 3 contest prize awards (contests 1, 2 and 3)
1869169|NCT01096121|Drug|Enalapril|"during 1 month : 0,2 mg/kg/day
then during 2 months (if no adverse event): 0,35 mg/kg/day
and then during 6 months (if no adverse event): 0,5 mg/kg/day"
1869170|NCT01096121|Drug|Placebo|Glucose
1869171|NCT01096134|Biological|HPV Vaccine (Gardasil)|"HPV Vaccine Administration: According to the CDC, Gardasil should be delivered through a series of three intra-muscular injections over a six-month period. The second and third doses should be given two and six months after the first dose. The vaccine can be administered at the same visit as other age-appropriate vaccines, such as Tdap, Td, MCV4, influenza, and hepatitis B vaccines. Providers should consider a 15-minute waiting period for vaccine recipients following vaccination.
FDA's Approval of Gardasil (June 8, 2006) lists the following information on product Formulation: Each 0.5 mL dose of the vaccine contains:
20 mcg of HPV 6 L1 protein 40 mcg of HPV 11 L1 protein 40 mcg of HPV 16 L1 protein 20 mcg of HPV 18 L1 protein 225 mcg aluminum (as amorphous aluminum hydroxyphosphate sulfate adjuvant) 9.56 mg of sodium chloride 0.78 mg of L-histidine 50 mcg of polysorbate 80 35 mcg of sodium borate water for injection"
1869172|NCT01096147|Device|Spinal cord stimulation with eight polar electrode|In SCS a lead is positioned in the epidural space on the dorsal aspect of the spinal cord as to produce electrically induced paraesthesia in the painful area.
1869173|NCT01096160|Drug|MK8226 1 mg QD|MK8266 1 mg once daily for 10 days, as oral capsule
1869174|NCT01096160|Drug|MK8266 2 mg QD|MK8266 2 mg once daily for 10 days, as oral capsule
1869175|NCT01096160|Drug|MK8266 4 mg QD|MK8266 4 mg once daily for 10 days, as oral capsule
1869176|NCT01096160|Drug|MK8266 4 mg BID|MK8266 4 mg twice daily for 10 days, as oral capsule
1869177|NCT01096160|Drug|MK8266 4 mg TID|MK8266 4 mg three times daily for 10 days, as oral capsule
1869178|NCT01096160|Drug|Comparator: Placebo|Placebo oral capsule (once, twice or three times daily) for 10 days
1869179|NCT01096186|Drug|IPX066 95 mg|23.75 - 95 mg CD-LD capsules
1869180|NCT01096186|Drug|IPX066 145 mg|36.25 - 145 mg CD-LD capsules
1869181|NCT01096186|Drug|IPX066 195 mg|48.75 - 195 mg CD-LD capsules
1869182|NCT01096186|Drug|IPX066 245 mg|61.25 - 245 mg CD-LD capsules
1869183|NCT01096199|Drug|TS-ONE, Cisplatin, RAD001|
1869184|NCT01096212|Drug|original sevoflurane|Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v
1869185|NCT01096212|Drug|generic sevoflurane|Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v
1869186|NCT01096225|Biological|split-virion, H1N1 vaccine of 15 μg|split-virion inactivated S-OIV vaccine of 15 μg on day 0 and 21.
1869187|NCT01096251|Behavioral|CBT vs BST|The comparison between the CBT and BST will be assessed in a two-arm randomized controlled trial. Participants will be randomly allocated in 2 groups (CBT and BST).
1869188|NCT01096264|Other|SSI and SphygmoCor® evaluations|"SSI evaluation need Aixplorer vascular ultrasound machine (available in our department) with 8 MHz linear array probe applied on the carotid and femoral artery.
SphygmoCor® evaluation used pressure captors on carotid and femoral sites to record the intra-arterial pressure wave time delay after QRS wave. After distance calculation between the two sites, Aortic PWV can be derived."
1869189|NCT01096277|Drug|Sitagliptin|oral tablets 100 mg per day for two weeks
1869190|NCT01096277|Drug|Placebo|oral tablet, one per day for two weeks
1869191|NCT01096277|Other|Control|no intervention
1869192|NCT01096290|Drug|lubiprostone|24mcg BID, capsule, oral 30days
1869193|NCT01096290|Drug|Matched placebo|Twice daily for 30days, oral
1869194|NCT01096316|Behavioral|Depression Care Management|The intervention is conducted by a social worker who has the role of a Depression Care Manager (DCM). First, a unique engagement session develops rapport with the DCM, providing education and identifying health concerns. DCM meets in-person and/or by phone every 1-2 weeks for 12 weeks, then monthly for the rest of the 12-month intervention. Patients choose either medication or Problem-Solving Treatment-Primary Care therapy. Depressive symptoms are assessed at each visit with the PHQ-9, as well as response to medications or to PST, with a total of 8 PST-PC sessions. Patients with inadequate response after 8 weeks to the first choice will switch or combine treatments. Providers are given extensive feedback about the patient's health care concerns.
1869195|NCT01096329|Drug|Testosterone Spray 5% and 1%|Testosterone Spray 5% 2x90uL for 14 days Testosterone Spray 1% 2x90uL for 14 days
1869196|NCT01096329|Drug|Intrinsa® Patch and Testosterone Spray 5%|Testosterone Spray 5% 2x90uL for 14 days Intrinsa® Patch for 14 days
1869197|NCT01096329|Drug|Intrinsa® Patch and Testosterone Spray 1%|Testosterone Spray 1% 2x90uL for 14 days Intrinsa® Patch for 14 days
1869200|NCT01096355|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
1869201|NCT01096355|Other|diagnostic laboratory biomarker analysis|
1869202|NCT01096355|Other|pharmacogenomic studies|
1869203|NCT01096355|Other|pharmacological study|
1869204|NCT01096368|Drug|liposomal vincristine sulfate|Given IV
1869205|NCT01096368|Other|clinical observation|Patients undergo observation
1869206|NCT01096368|Radiation|3-dimensional conformal radiation therapy|Patients undergo conformal radiotherapy
1869207|NCT01096368|Drug|carboplatin|Given IV
1869208|NCT01096368|Drug|cyclophosphamide|Given IV
1869209|NCT01096368|Drug|etoposide|Given IV
1869210|NCT01096368|Drug|cisplatin|Given IV
1869211|NCT01096368|Other|laboratory biomarker analysis|Optional correlative studies
1869212|NCT01096381|Other|laboratory biomarker analysis|Blood collection
1869213|NCT01096381|Other|questionnaire administration|Survey regarding baseline health and activity level.
1869214|NCT01096407|Other|laboratory biomarker analysis|Collection of urine samples
1869215|NCT01096407|Other|questionnaire administration|Completion of questionnaires
1869216|NCT01096407|Procedure|assessment of therapy complications|An assessment will be completed.
1869217|NCT01096420|Procedure|acupuncture|"Each patient had a fixed and classic acupuncture points Ex-HN-3,BL-2,GB-20,EX-HN-5 bilaterally in their 24 sessions.
Acupuncture consisted of 24 sessions of 30 min duration, administrated over 12 weeks (two sessions per week).
Sterile disposable and steel needle (3210) were used .
The needles were manipulated by rotation methods to produce a characteristic sensation know as De Qi."
1869218|NCT01096420|Drug|topiramate|"The patients were submitted to the topiramate treatment also for 12 consecutive weeks.
The study phase consists of a 4-week titration and a 8-week maintenance period.
All dosages of topiramate will be initiated at 25 mg/d hs and increased by 25 mg/d weekly to a maximum of 100 mg/day (or to the maximal tolerated dose).
Study drug was administered daily in equally divided twice daily doses."
1869219|NCT01096433|Device|CPAP treatment|maintains upper airway patency and minimizes the obstructive events
1869220|NCT01096446|Drug|Intravenous Fat Emulsions|Control Group: 0.5 grams/kg/day Experimental Group: 2 grams/kg/day
1869221|NCT01096459|Procedure|Nerve Rerouting|All subjects will receive the unilateral nerve rerouting procedure.
1869222|NCT01096472|Drug|LAS41003|Once daily
1869223|NCT01096472|Drug|LAS189961|Once daily
1869224|NCT01096472|Drug|LAS189962|Once daily
1869225|NCT01096485|Drug|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of 1.5 mg coated tablet
1869226|NCT01096485|Drug|Levonorgestrel (Postday)|Single dose of two 0.75 mg tablets
1869227|NCT01096498|Drug|Levonorgestrel Emergency Pill (BAY86-5028/Opxion)|Single dose of one 0.75 mg coated tablet
1869228|NCT01096498|Drug|Levonorgestrel (Postday)|Single dose of one 0.75 mg tablet
1869229|NCT01096511|Drug|Moxifloxacin (Avelox, BAY12-8039)|The treatment with Moxifloxacin 400 mg infusion should comply with the recommendations written in the local product information. The decision about the treatment with Moxifloxacin as well as the duration of treatment is solely up to the attending physician.
1869230|NCT01096524|Other|Standard Physiotherapy|The Control group will complete the standard physiotherapy care pre and post-TKA surgery without NMES.
1869231|NCT01096524|Device|Kneehab|"NMES 2 x 20 minute sessions/day, 5 days/week, 6 weeks pre and 6 weeks post TKA.
Kneehab™ (Bio-Medical Research, Ltd., Galway, Ireland) is a NMES device with Multipath™ technology, designed to activate the quadriceps muscle. Kneehab™ is a battery operated, portable, 2-channel cutaneous electrical muscle stimulator, which operates using constant current pulses to stimulate the nerves innervating the quadriceps muscle. Kneehab™, consists of a thigh wrap with anatomically shaped electrodes and a control unit. Electrodes are placed over the quadriceps muscles and the garment is wrapped around the leg above the knee. Brief electrical impulses are delivered through the skin surface adhesive electrodes."
1869232|NCT01096550|Behavioral|Outpatient|Buprenorphine patients receiving 2 to 8 hours of outpatient counseling.
1869233|NCT01096550|Behavioral|Intensive Outpatient|Buprenorphine patients receiving 9 or more hours of outpatient counseling.
1869234|NCT01096563|Drug|AZD9164|"Dry powder for inhalation via Turbuhaler, JSMAD. A single dose of AZD9164 on Day 1 and repeated dosing on Day 4 to day 15 (JSMAD).
The starting dose will be 400 μg delivered dose and subsequent doses are planned to be 1000 μg and 2800 μg delivered dose."
1869235|NCT01096563|Drug|Placebo|Dry powder for inhalation via Turbuhaler, JSMAD.
1869236|NCT01096576|Drug|balapiravir [RO4588161]|sequential cohorts receiving doses orally twice daily for 5 days
1869237|NCT01096576|Drug|placebo|orally twice daily for 5 days
1869238|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
1869239|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
1869240|NCT01096589|Device|3M Coban 2 (Compression System)|Nonwoven cohesive backing and foam.
1869241|NCT01096589|Device|Comprilan|Commercial short-stretch bandage (Comprilan; BSN Medical Ltd, Hull, U.K).
1869242|NCT01096602|Biological|DC AML Vaccine|Group 1: 2-3 doses of the vaccine at 4 week intervals
1869243|NCT01096615|Dietary Supplement|Placebo|"Description:
- capsule size 3
Composition of the product:
45 mg of microcristalline cellulose,
132 mg of maltodextrin,
3 mg of magnesium stearate.
Composition of the capsule:
46 mg of hypromellose,
1 mg of titanium dioxide.
Packaging:
Products are packaged in aluminium tubes of 30 capsules.
Storage:
The product should be stored in a fridge. Direction for use: subject should consume 1 capsule daily together with a meal, with a glass of water.
The study products will be consumed daily for 7 weeks."
1869244|NCT01096615|Dietary Supplement|Lactobacillus paracasei LP-33|"Description:
minimum 2.0x109 CFU of Lactobacillus paracasei LP-33
capsule size 3 1 capsule daily together with a meal, with a glass of water."
1869314|NCT01097057|Procedure|Leukapheresis|Given through catheter
1869315|NCT01097057|Drug|Plerixafor|Given SC
1869316|NCT01097057|Biological|Rituximab|Given IV
1869317|NCT01097070|Drug|Bevirimat|
1869318|NCT01097083|Drug|Coriolus Versicolor|
1869319|NCT01097096|Biological|CAD106|
1869320|NCT01097096|Biological|CAD106|
1869321|NCT01097096|Biological|CAD106|
1869322|NCT01097096|Biological|CAD106|
1869245|NCT01096628|Other|Chiropractic + Exercise|"Treatment will include eight to 16 treatments provided over the 12-week period. Each treatment visit will last from 10-20 minutes and consist of manual spinal manipulation and mobilization. Light soft tissue techniques (i.e., active and passive muscle stretching, hot and cold packs, and ischemic compression of tender points) will be used as indicated to facilitate the manual therapy.
Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise."
1869246|NCT01096628|Other|Exercise|Patients will attend 8 to 16, one-on-one, 45-minute sessions over the course of 3 months. The sessions will follow a standardized approach but will be individualized to meet the patient's needs specific to their lifestyle, fitness level, and clinical characteristics. The exercise program will be comprised of three parts: 1) education, 2) supervised exercise, and 3) home exercise.
1869247|NCT01096641|Behavioral|immediate CBT|After the baseline assessment the fatigued patients will be randomized to start immediately with Cognitive Behaviour Therapy, especially designed for fatigued cancer patients
1869248|NCT01096641|Behavioral|Delayed CBT|After the baseline assessment the fatigued patients will be randomized: this group is to be placed on a waiting list. After 6 months, a second assessment will take place in the group of fatigued patients who received CBT immediately after randomization. This assessment will include the same measurements as at baseline. The fatigued patients on the waiting list will then start with CBT.
1869249|NCT01096654|Other|Ct-scan or adrenal vein sampling|Patients will be randomized to undergo either adrenal CT-scanning or AVS (with pre-AVS adrenal CT-scanning for phlebography). The result of either of these tests will determine the course of action: adrenalectomy for adenoma or MRAs for bilateral hyperplasia.
1869250|NCT01096667|Drug|Placebo to Ertuglilflozin|pill(s) (1 mg and/or 5 mg and/or 25 mg) once daily for 28 days
1869251|NCT01096667|Drug|1 mg Ertugliflozin|pill, 1 mg, once daily for 28 days
1869252|NCT01096667|Drug|5 mg Ertugliflozin|pill, 5 mg, once daily for 28 days
1869253|NCT01096667|Drug|25 mg Ertugliflozin|pill, 25 mg, once daily for 28 days
1869254|NCT01096667|Drug|HCTZ 12.5mg|capsule, 12.5 mg, once daily for 28 days
1869255|NCT01096667|Drug|Placebo to HCTZ|capsule, 12.5 mg, once daily for 28 days
1869256|NCT01096680|Drug|SPD489 20 mg|Single oral dose of 20 mg
1869257|NCT01096680|Drug|SPD489 50 mg|Single oral dose of 50 mg
1869258|NCT01096680|Drug|SPD489 70 mg|Single oral dose of 70 mg
1869259|NCT01096680|Drug|Armodafinil|Single oral dose of 250 mg
1869260|NCT01096680|Drug|Placebo|Single oral dose
1869261|NCT01096693|Drug|Urocortin 2, Urocortin 3|"After a 20 minute infusion of intra arterial saline, healthy volunteers will receive ascending doses of intra arterial Urocortin 2 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively), Urocortin 3 (3.4, 34 and 340 pmol/min to achieve estimated end-organ concentrations of 0.06, 0.6 and 6 µg/L, respectively) and Substance P (a control endothelium-dependent vasodilator that evokes endogenous t-PA release [2, 4 and 8 pmol/min]). This will be co-infused with either Astressin 2B (in one of the two doses determined from Protocol 1) or saline placebo.
Bilateral venous blood sampling will be performed at baseline, immediately before the start and after each dose of Urocortin 2 and 3, to later estimate net release of tPA and PAI-1 and for plasma measurements of Urocortins 2 and 3."
1869262|NCT01096693|Drug|Saline placebo|"After 20 minutes of intra arterial saline infusion, incremental doses of Urocortin 2, 3 and Substance P will be administered (in doses similar to Active comparator arm), co infused with saline placebo.
Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
1869263|NCT01096706|Drug|NO clamp|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence or the absence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.
Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
1869264|NCT01096706|Drug|Saline|"After a 20 minute saline washout, incremental doses of Urocortin 2, Urocortin 3 and Substance P (in doses as per Protocol 2) will be infused in the presence of saline placebo.
Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at baseline, immediately before the start of Ucn2/Ucn3 infusion and at the end of each dose of Ucn2/Ucn3 for subsequent calculation of net release of t-PA and PAI-1."
1869265|NCT01096706|Drug|Fluconazole|"After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of Fluconazole (which serves to inhibit the EDHF pathway) that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study.
Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
1869266|NCT01096706|Drug|Aspirin|"Oral Aspirin (600mg stat) will be administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of saline.
Baseline blood samples will be taken from both forearms at the start of the study for full blood count, cholesterol, glucose, renal function, plasma Ucn 2 and 3 and t-PA and PAI-1 activity and antigen concentrations. Bilateral venous blood samples will be taken at after the top dose of Ucn2/Ucn3 infusion and before and after each dose of Substance P for subsequent calculation of plasma Ucn 2/ Ucn 3 and net release of t-PA and PAI-1."
1869323|NCT01097096|Biological|CAD106|
1869324|NCT01097096|Biological|CAD106|
1869267|NCT01096706|Drug|Combined|"Oral Aspirin (600mg stat) is administered 30 minutes before start of the study. After a 20 minute saline washout period, ascending doses of Urocortin 2, Urocortin 3 and substance P (doses as per Protocol 2) will be infused intra-arterially in the presence of the 'nitric oxide clamp' that will be commenced prior to the infusion of Urocortin 2, Urocortin 3 and substance P, and will be continued throughout the study. Intra-arterial Fluconazole is also commenced at the time of the Nitric oxide clamp.
This serves to inhibit the cyclooxygenase, EDHF and NO pathways of endothelial vasodilatation.
Blood samples are taken as per previous arms."
1869268|NCT01096719|Behavioral|Standard Behavioral Weight Loss Intervention|12 week standard behavioral weight loss intervention including a physical activity goal and behavioral weight control strategies
1869269|NCT01096719|Behavioral|Dietary Goal: Reduction in Energy Density of Dietary Intake|Consume low ED foods (ED < 1.0) for at least 10 items consumed per day and limit high ED foods (ED > 3.0) to two items consumed per day.
1869270|NCT01096719|Behavioral|Dietary Goal: Reduction of Energy Intake|Limit energy intake to 1200 to 1500 kcals/day and < 30% kcals from fat.
1869271|NCT01096732|Drug|GDC-0449|Gelatine capsules of 150mg.Taken O.D. for 14 days.
1869272|NCT01096745|Drug|Gemcitabine, Cisplatin|D1,D8 Gemcitabine 1000mg/m2 + N/S 150cc miv over 30mins D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins repeated every 3weeks
1869273|NCT01096745|Drug|S-1, Cisplatin|D1-14 S-1 40mg/m2 po bid D1,D8 Cisplatin 25/m2 + N/S 150cc miv over 60mins Repeated every 3 weeks
1869274|NCT01096771|Drug|ClinOleic 20%|96 hour continuous infusion.
1869275|NCT01096771|Drug|Intralipid 20%|96 hour continuous infusion.
1869276|NCT01096784|Drug|rhIGF-I/rhIGFBP-3|Continuous intravenous infusion
1869277|NCT01096797|Drug|Sevoflurane|"Anaesthesia induction: sevoflurane 4 to 6% by mask and IV propofol 2-6 mg/kg.
Anaesthesia maintenance: sevoflurane 2-3 %
Intraoperative and postoperative analgesia: IV fentanyl 1,5-2,5 mcg/kg, IV paracetamol 15 mg/kg
Prevention of postoperative nausea and vomiting: dexamethasone 0,1 mg/kg, ondansetron 0,1 mg/kg"
1869278|NCT01096810|Drug|TBL 12|TBL 12 will be administered orally at a dose of 2 units (20 mL each) twice a day until disease progression.
1869279|NCT01096823|Behavioral|Iyengar Yoga|Iyengar Yoga classes twice a week for six weeks
1869280|NCT01096836|Other|macronutrient and energy manipulation|
1869281|NCT01096849|Drug|levofloxacin|Repeat intravenous infusion
1869282|NCT01096849|Drug|plazomicin|Repeat intravenous infusion
1869283|NCT01096849|Drug|placebo|Repeat intravenous infusion (used to maintain the blind)
1869284|NCT01096862|Drug|ASP015K|oral
1869285|NCT01096862|Drug|Placebo|oral
1869286|NCT01096875|Drug|Atorvastatin|40mg/day once daily for two weeks prior to surgery
1869287|NCT01096875|Drug|Placebo|1tb/day once daily for two weeks prior to surgery
1869288|NCT01096888|Behavioral|Enhanced WIC Program|Applying an internet based weight loss intervention to participants in the WIC program to enhance weight loss post partum.
1869289|NCT01096901|Behavioral|Behavioral Weight loss|Intervention groups will meet weekly for 12 weeks. Weekly meetings will focus on weight loss in women age 30-45 through behavioral weight loss topics. These topics are designed with the Look AHEAD protocols.
1869290|NCT01096914|Procedure|percutaneous radiofrequency ablation|"Procedure: Radiofrequency ablation For RFA, we used a commercially available system (Valleylab, Tyco Healthcare, Boulder, CO, USA) and a 17-gauge cool-tip needle electrode with a 3cm exposed tip. The needle is inserted percutaneously under ultrasound guidance in the HCC nodule and treatment lasts 12 minutes. For nodules larger than 3cm in diameter, 2 insertions are used. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used."
1869291|NCT01096914|Procedure|percutaneous laser ablation|Procedure: Laser ablation For LA, we used a commercially available system (Echolaser XVG system, Esaote El.En., Florence, Italy) and four optical fibers,inserted into the cancer through four 21-gauge needles. The treatment lasts 6 minutes. For nodules larger than 3 cm in diameter, two treatments are done. In a period of six months, treatment may be repeated for no more than three times. When, after treatment, CT or MRI show a residual nodule activity of 10% or less, percutaneous ethanol injection may be done. If the residual activity is of 50% or more transarterial chemoembolization may be used.
1869292|NCT01096927|Drug|Amoxicillin and Clavulanic Acid|7 days antibiotic therapy with Amoxicillin and Clavulanic Acid, 1 gr 3 times daily PO
1869293|NCT01096940|Drug|AZD1656|Oral tablet, BID dose
1869294|NCT01096940|Drug|simvastatin|Oral tablet, single dose
1869295|NCT01096953|Behavioral|Mental health care implemented by telepsychiatry|Care of 6-17 year-olds with ADHD
1869296|NCT01096953|Behavioral|Face-to-face care|Psychiatry provided for treatment of ADHD face-to-face in office
1869297|NCT01096966|Drug|Bupivacaine TTS (Bupivacaine Patch)|Contains bupivacaine base, in a flexible and rectangular-shaped, transdermal, delivery system. Three patches applied to the lower back every 72 hours for 12 weeks.
1869298|NCT01096966|Drug|Placebo patch|Identical in size and shape to the Bupivacaine Patch. Three patches applied to the lower back every 72 hours for 12 weeks.
1869299|NCT01096979|Drug|LIPO-102|subcutaneous injection
1869300|NCT01096979|Drug|Placebo|Placebo
1869301|NCT01096992|Drug|Bendamustine|"Phase 1: Starting Dose of 20 mg/m2 IV on Days 1,2,3 (after fludarabine)
Phase 2: 30 mg/m2 by vein (fixed) on Days 1,2,3 (after fludarabine)"
1869302|NCT01096992|Drug|Fludarabine|Course 1: 20 mg/m2 intravenous (IV) on Days 2,3,4 Courses 2-6: 20 mg/m2 IV, Days 1,2,3
1869303|NCT01096992|Drug|Rituximab|Course 1: 375 mg/m2 IV, Day 4 (after fludarabine) Courses 2-6: 500 mg/m2 IV, Day 1
1869304|NCT01097018|Drug|Capecitabine|1000 mg/m2 BID/ Days 1-14
1869305|NCT01097018|Drug|Perifosine|50 mg daily x 21 days
1869306|NCT01097018|Drug|Placebo|1 pill daily x 21 days
1869307|NCT01097031|Other|Infusion Intermittent|
1869308|NCT01097044|Drug|Afamelanotide|One 16mg subcutaneous implant every 2 months for 6 months.
1869309|NCT01097044|Drug|Placebo|One placebo subcutaneous implant every 2 months for 6 months
1869310|NCT01097057|Drug|Carboplatin|Given IV
1869311|NCT01097057|Drug|Etoposide|Given IV
1869312|NCT01097057|Biological|Filgrastim|Given SC
1869313|NCT01097057|Drug|Ifosfamide|Given IV
1869328|NCT01097122|Procedure|Forearm vibration|Mechanical loading with forearm vibration will be applied right radius in all groups
1869329|NCT01097135|Drug|Duraprep Surgical Solution|
1869330|NCT01097148|Drug|Atracurium, TBW|Dose atracurium 0.5 mg/kg based on total body weight
1869331|NCT01097161|Behavioral|speech therapy with the assistance of an acoustical analysis program|Two weekly speech sessions realized on individual basis for three months period
1869332|NCT01097174|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front into the back of they eye.
1869333|NCT01097200|Device|Elevate mesh|The correction of the prolapse can be made by this new technique.
1869334|NCT01097200|Device|Sacrocolpopexy|Attach a mesh between the vagina and the promontorium.
1869335|NCT01097213|Drug|Ethanol|Intravenous infusion of 6% ethanol in half-normal saline for approximately 1 hour: The dosage is controlled by a physiologically-based pharmacokinetic (PBPK) model of alcohol distribution and elimination, developed by O'Connor and his associates at the Indiana Alcohol Research Center (IARC) (Ramchandani et al, 1999). PBPK Parameters that determine the dosage and frequency of the infusion for a specific individual are estimated by means of morphometric variables (age, height, weight and gender).
1869336|NCT01097213|Drug|Placebo - half-normal saline|Intravenous infusion of half-normal saline for approximately 1 hour: The dosage is equal to the infusion dosage estimated by the PBPK model of alcohol distribution and elimination (Ramchandani et al., 1999) for the drug - ethanol condition.
1869337|NCT01097226|Other|Apple extract delivering 70 mg epicatechin|Delivered as a flavoured water based beverage
1869338|NCT01097226|Other|Apple extract delivering 140 mg epicatechin|Delivered as a flavoured water based beverage
1869339|NCT01097226|Other|Apple granules delivering 70 mg epicatechin|Delivered as a puree
1869340|NCT01097226|Other|Water delivering no epicatechin|Delivered as flavoured water
1869341|NCT01097239|Device|Sonablate 500 (High Intensity Focused Ultrasound (HIFU))|High Intensity Focused Ultrasound (HIFU) Delivered by the Sonablate 500 Transrectal Device
1869342|NCT01097252|Radiation|radiation|radiation with cisplatin 40mg/m2, 6 cycles, every week
1869343|NCT01097252|Drug|weekly cisplatin|weekly cisplatin 40mg/m2, 6 cycles
1869344|NCT01097252|Drug|tri-weekly cisplatin|cisplatin 75mg/m2, 3cycles, every 3 weeks
1869345|NCT01097265|Drug|capecitabine|
1869346|NCT01097265|Drug|oxaliplatin|
1869347|NCT01097265|Other|active surveillance|
1869348|NCT01097265|Other|laboratory biomarker analysis|
1869349|NCT01097265|Procedure|adjuvant therapy|
1869350|NCT01097265|Procedure|lymph node mapping|
1869351|NCT01097265|Procedure|sentinel lymph node biopsy|
1869352|NCT01097278|Dietary Supplement|cholecalciferol|Given orally
1869353|NCT01097278|Other|placebo|Given orally
1869354|NCT01097304|Drug|Ursodiol|Given PO
1869355|NCT01097304|Other|Laboratory Biomarker Analysis|Correlative studies
1869356|NCT01097317|Drug|carboplatin|
1869357|NCT01097317|Drug|vinorelbine tartrate|
1869358|NCT01097317|Other|neuromuscular electrical stimulation|
1869359|NCT01097317|Other|physiologic testing|
1869360|NCT01097317|Procedure|fatigue assessment and management|
1869361|NCT01097317|Procedure|quality-of-life assessment|
1869364|NCT01097343|Drug|clopidogrel 75 mg|75 mg once daily
1869365|NCT01097343|Drug|Clopidogrel 150 mg|clopidogrel 150 mg
1869366|NCT01097356|Dietary Supplement|probiotic drinkers|HPV+, LSIL patients in this arm will drink the probiotic study drink for a period of 6 months
1869367|NCT01097382|Drug|ZOLPIDEM|Pharmaceutical form: tablet Route of administration: oral Dose regimen: once daily
1869368|NCT01097395|Drug|ribavirin|Randomization to standard weight based ribavirin dosing (1000 or 1200 mg daily) or concentration-guided dosing based on first dose AUC0-12
1869369|NCT01097408|Drug|AZD7295|Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.
1869370|NCT01097408|Drug|Placebo comparator|Placebo capsules
1869371|NCT01097421|Drug|Pramipexole Extended Release|
1869372|NCT01097434|Device|Biodegradable polymer limus-eluting stents|due randomization biodegradable polymer limus-eluting stents will be implanted
1869373|NCT01097434|Device|Permanent polymer limus-eluting stent|due randomization permanent polymer limus-eluting stent will be implanted
1869374|NCT01097460|Drug|MM-111 + Herceptin|For Phase 1: Dose escalation cohorts, MM-111 and Herceptin are administered weekly or bi-weekly via IV
1869375|NCT01097473|Procedure|Exercise training|Exercise training in outpatient sport groups once weekly with a duration of 60 min each
1869376|NCT01097486|Biological|NeoFuse|Single Dose NeoFuse Surgical Implantation
1869377|NCT01097486|Procedure|Allograft|Single Dose Allograft Surgical Implantation
1869378|NCT01097499|Device|OsseoPulse device (Light emitting diode technology)|Patients in this group will be given the LED device and will be instructed on how and when to use it. They will receive LED treatment to the surgical site preoperatively by the surgeon for 20 minutes. Then, patients in this group will apply LED at home to the surgical site postoperatively at the day of surgery and for the following 9 postoperative days.
1869379|NCT01097512|Drug|AS703569/gemcitabine|"Gemcitabine on Days 1 and 8, AS703569 on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.
Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
1869421|NCT01089543|Drug|Rabeprazole|Rabeprazole 40 mg tablet taken orally once daily after breakfast for 8 weeks.
1869422|NCT01089543|Drug|Placebo|Rabeprazole Placebo tablet taken orally once daily after breakfast for 8 weeks.
1869423|NCT01089556|Drug|Duloxetine|Administered orally
1869380|NCT01097512|Drug|AS703569/gemcitabine|"AS703569 on Days 1 and 8, gemcitabine on Days 2 and 9, of a 21-day cycle. The starting dose (DL1) for AS703569 will be 10mg/m2/day. The subsequent dose levels of AS703569 will follow the dose-escalation scheme with an approximate 50% increase from DL1 to DL2, 40% from DL2 to DL3, and thereafter an approximate increase of 33% from one dose level to the next.
Gemcitabine will be administered at the dose of 1000mg/m2 once weekly during the first two weeks of each 21-day cycle."
1869381|NCT01097525|Procedure|WFG PRK|
1869382|NCT01097525|Procedure|WFG LASIK|
1869383|NCT01097525|Procedure|WFO PRK|
1869384|NCT01097525|Procedure|WFO LASIK|
1869385|NCT01097538|Other|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
1869386|NCT01097538|Other|Total body recumbent stepper training|Patients will train using the Nustep T4 (TRS 4000) which is a recumbent cross trainer that provides a full body workout in a seated position. The Nustep trainer allows patients to achieve a natural stepping motion against graded loads with bilateral reciprocal movement of the arms. Recumbent training is safe and easily accessible for patients of all ability levels with a swivel chair to aid in patient transfers. Foot straps, leg stabilizers and hand stabilizers may be used for added control and proper body alignment.
1869387|NCT01089166|Drug|Metformin|
1869388|NCT01089179|Drug|Metformin|
1869389|NCT01089192|Drug|Metformin|
1869390|NCT01089205|Drug|Metformin|
1869391|NCT01089218|Drug|oral amoxicillin/clavulanate 1g (875/125mg)|oral amoxicillin/clavulanate 1g (875/125mg) on the day of the procedure 30 minutes prior to the FB
1869392|NCT01089218|Drug|control|no intervention with the same procedure of FB
1869393|NCT01089231|Dietary Supplement|Fish oil|Dietary Supplement: fish oil capsules (6 per day) 3024 mg n-3 fatty acids daily (1512 mg EPA and 1008 mg DHA) about 3 months
1869394|NCT01089231|Dietary Supplement|Placebo (corn oil)|corn oil (6 capsules per day)
1869395|NCT01089296|Other|Individually customized physiotherapy|Main elements in the intervention are postural support and facilitating techniques. The intervention will be carried out twice a day over a three-week period if the infant`s condition allows it. The length of each treatment session will be adjusted dependent on the infant`s response and condition. Maximum treatment time is 10 minutes.
1869396|NCT01089309|Drug|Spironolactone|Spironolactone orally, at a dose of 50 mg/day for 12 months
1869397|NCT01089322|Drug|inhaled corticosteroid plus LABA plus oral corticosteroid|formoterol plus budesonide 12/400mcg 2times/day and 6/200 mcg as needed and prednisone 40 mcg
1869398|NCT01089335|Procedure|Histological investigation of the SN|99m Tc- nanocolloid albumin, 10-15 MBq (volume 0.1-0.3 ml) is injected under ultrasound guidance in the thyroid tumour. Imaging (lymphoscintigraphy)with anterior and oblique projections is performed at 60 and 120 min after the injection. SN are mapped intraoperatively by a dedicated SN navigator and excised for final histology.
1869399|NCT01089348|Drug|Lactofiltrum + Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days + Lactofiltrum 2 tablets 3 times per day for 14 days per os
1869400|NCT01089348|Drug|Metronidazole|Metronidazole 500 mg 1 tablet BID for 7 days per os
1869401|NCT01089361|Drug|Ketamine|The treatment group will receive 0.25mg/kg of ketamine over a period of one hour followed by a continuous infusion of ketamine at 0.1 mg/kg/hr for a further 23 hours.
1869402|NCT01089361|Drug|Normal Saline placebo|The control group will receive 0.25mg/kg of normal saline over a period of one hour followed by a continuous infusion of normal saline at 0.1 mg/kg/hr for a further 23 hours.
1869403|NCT01089374|Radiation|Partial breast radiation after lumpectomy|Radiation therapy will be administered in the vicinity of the center where the surgical resection was performed. Adjuvant radiation must start within 12 weeks of breast excision or re-excision. The radiation oncologist can choose between two methods of partial breast irradiation (PBI): external beam partial breast radiation or Mammosite® brachytherapy, based on radiation oncologist and patient preference. Radiation will be administered per guidelines used in the NSABP B-39/RTOG 0413 protocol.
1869404|NCT01089387|Biological|injection of bone marrow mononucleated cells|Four different concentration of BMMNC will be tested in four groups of 3 patients. In group 5 (n=19): one cell concentration corresponding to the best dose determined by analysis of the previous groups will be tested.
1869405|NCT01089413|Drug|bevacizumab [Avastin]|As prescribed by physician
1869406|NCT01089426|Drug|Omegaven™|1 g/kg/d of Omegaven until discontinuation of PN
1869407|NCT01089426|Other|Historical Controls|Standard of Care
1869408|NCT01089439|Drug|Nitric oxide by inhalation INOMAX|"Nitric oxide by inhalation INOMAX 800 ppm
40 ppm during 24 hours then 20 ppm during 24 hours then 10 ppm during 24 hours"
1869409|NCT01089439|Drug|Placebo|placebo
1869410|NCT01089452|Drug|Perindopril|Perindopril 5mg for 4 weeks, forced titration to 10mg for 8 weeks
1869411|NCT01089452|Drug|Perindopril/amlodipine|Perindopril/amlodipine 5/5mg, 10/5mg, 10/10mg: 4 weeks duration at each dose; forced titration.
1869412|NCT01089452|Drug|Olmesartan/amlodipine|Olmesartan/amlodipine 20/5mg, 40/5mg, 40/10mg: 4 weeks at each dose; forced titration.
1869413|NCT01089465|Other|Collection of the bedbugs and dermatological follow-up of the stings|Collection of the bedbugs and dermatological follow-up of the stings at J1 J7 J14 J21 J28
1869414|NCT01089504|Drug|phenobarbital|Phenobarbital, 4-5 mg/kg/d, by mouth, for 4 months
1869415|NCT01089504|Drug|placebo|Matched placebo, same volume as active drug, by mouth daily for 4 months
1869416|NCT01089517|Drug|E10030 plus Lucentis|once a month intravitreal injection
1869417|NCT01089517|Drug|Lucentis|10 mg/mL intravitreal injection monthly
1869418|NCT01089530|Behavioral|Lifestyle intensive group|hipocaloric diet smoking cessation physical exercise
1869419|NCT01089543|Drug|Rabeprazole|Rabeprazole 10 mg tablet taken orally once daily after breakfast for 8 weeks.
1869420|NCT01089543|Drug|Rabeprazole|Rabeprazole 20 mg tablet taken orally once daily after breakfast for 8 weeks.
1869424|NCT01089556|Drug|Pregabalin|Administered orally
1869425|NCT01089556|Drug|Placebo|Administered orally, daily as a blind for duloxetine and/or pregabalin for 8 or 16 weeks
1869426|NCT01089569|Drug|Exenatide|5 mcg BID (twice daily) for 1 month increasing to 10 mcg BID for the remainder of the study
1869427|NCT01089569|Drug|Insulin Glargine|.1 unit per kg to start, titrated based on Continuous Glucose Monitoring results
1869428|NCT01089582|Other|No intervention|
1869429|NCT01089595|Drug|Nilotinib|Nilotinib 400 mg po bid
1869430|NCT01089595|Drug|Nilotinib with Imatinib|Nilotinib 400 mg po BID Imatinib 400 mg po daily
1869431|NCT01089608|Drug|Azithromycin|"Eye drops, Dosage : 1.5%
1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
1869432|NCT01089608|Drug|Povidone|"Eye drops Single dose unit
1 drop twice daily at Day 0, then 1 drop once daily from Day 1 to Day 6 in the morning, following by a period of 2 weeks without treatment. This therapeutic scheme will be repeat 2 times."
1869433|NCT01089621|Drug|Duloxetine|30 mg to 120 mg administered orally, daily for 12 weeks
1869434|NCT01089647|Drug|budesonide nasal spray and a montelukast pill|budesonide aqua nasal spray 1 spray each nostril bid for 12 weeks Montelukast pill 10 mg po daily for 12 weeks
1869435|NCT01089647|Drug|Placebo: sugar pill and salt water nasal spray|sugar pill po daily for 12 weeks salt water nasal spray 1 spray each nostril bid for 12 weeks
1869436|NCT01089660|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.3 mL, Intramuscular (IM)
1869437|NCT01089660|Biological|Swine A/H1N1 influenza vaccine (split virion, inactivated)|0.5 mL, Intramuscular (IM)
1869438|NCT01089673|Other|data collection|retrospective data collection
1869439|NCT01089686|Procedure|Venoplasty|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Venoplasty is performed by inserting an additional catheter with a balloon at the tip. The balloon will be inflated to open the vessel. Once dilation of the vessel is confirmed, the venous sheath will be removed and manual compression applied to the groin access.
1869440|NCT01089686|Procedure|Sham procedure (non-treatment)|Venous access is obtained from the groin through the femoral vein. The catheter will be advanced into the veins in the neck and chest. Angiographic images will be taken of the extracranial venous system as well as the azygous vein. These images will be used to confirm CCSVI. Since the patient has been randomized to the non-treatment arm of the trial, the procedure will end without venoplasty. After completion of the diagnostic venogram, the venous sheath will be removed and manual compression applied to the groin access.
1869441|NCT01089699|Behavioral|online support group|online support group
1869442|NCT01089699|Behavioral|online support group|online support group
1869443|NCT01089699|Behavioral|home study support materials|self-study materials
1869444|NCT01089725|Biological|Placebo IV|1 ml of placebo administered SC and IV once every 8 weeks.
1869445|NCT01089725|Biological|Placebo SC|1 ml of placebo administered SC and IV once every 8 weeks.
1869446|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
1869447|NCT01089725|Biological|Placebo IV|1 ml placebo administered IV every 8 weeks
1869448|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
1869449|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
1869450|NCT01089725|Biological|Tanezumab SC|1 ml tanezumab injection SC administered every 8 weeks
1869451|NCT01089725|Biological|Placebo IV|1ml placebo administered IV every 8 weeks
1869452|NCT01089725|Biological|Tanezumab IV|1 ml tanezumab injection IV administered every 8 weeks
1869453|NCT01089725|Biological|Placebo SC|1ml placebo administered SC every 8 weeks
1869454|NCT01089738|Drug|PF-03382792 0.5mg|0.5 mg PF-03382792, qd, for 14 days or placebo
1869455|NCT01089738|Drug|PF-03382792 1.5 mg|1.5 mg PF-03382792, qd, for 14 days or placebo
1869456|NCT01089738|Drug|PF-03382792 5 mg|5 mg PF-03382792, qd, for 14 days or placebo
1869457|NCT01089738|Drug|PF-03382792 15 mg|15 mg PF-03382792, qd, for 14 days or placebo
1869458|NCT01089751|Drug|trospium chloride|Sanctura XR® (trospium chloride) 60 mg once daily on an empty stomach for 14 weeks
1869459|NCT01089751|Drug|placebo|Placebo once daily on an empty stomach for 14 weeks.
1869460|NCT01089764|Behavioral|Couplelinks.ca website|Participation in the Couplelinks.ca program, an online intervention.
1869461|NCT01089777|Device|ultrasound Doppler monitoring|Ultrasound Doppler monitoring throughout the stress test
1869462|NCT01089790|Drug|Dutogliptin|400 mg tablet, once daily
1869463|NCT01089790|Drug|Sitagliptin|100 mg capsule (each capsule contains two 50-mg tablets), once daily
1869464|NCT01089816|Biological|Local/Regional Public Health Notification|For any H5 positive results, notification of the result to the site's local/regional public health authorities.
1869465|NCT01089829|Other|Foot examination|"Non-invasive neurological sensory testing
Non-invasive doppler assessment of peripheral arterial system"
1869466|NCT01089842|Behavioral|Health coaching|Coaching based advice will be performed by previously trained nurses. Intervention will be directed to increase physical activity to achieve levels recommended on guidelines. Patients will receive one session per month during 6 months. Time for each session is estimated on 10 to 20 minutes. Sessions will be mostly carried out by phone, although physical attendance or internet services can also be used.
1869467|NCT01089842|Other|Usual care|Patients on control group will receive usual assistance, including physical activity counselling by their treating physician.
1869468|NCT01089855|Drug|Carbamazepine|
1869469|NCT01097551|Drug|Trinitrin|Trinitrin: 2 sublingual pulverisations of 0.3 mg/dose
1869470|NCT01097551|Drug|Neosynephrine 10% collyrium|Neosynephrine 10% collyrium: 2 drops
1869471|NCT01097551|Drug|Iontophoresis with acetylcholine delivery|Iontophoresis with acetylcholine delivery
1869472|NCT01097551|Device|Dynamic Vessel Analyzer|Dynamic Vessel Analyzer
1869473|NCT01097564|Genetic|COL4A1 genetic testing|genetic testing
1869474|NCT01097577|Drug|pregabalin|1 capsule (75 mg) PO BID starting two hours prior to surgery and continuing 4 days postoperatively.
1869898|NCT01093183|Procedure|quality-of-life assessment|Ancillary studies
1869475|NCT01097577|Drug|Placebo|1 capsule PO BID starting two hours prior to surgery and continuing 4 days postoperatively.
1869476|NCT01097590|Device|Active TLA Gut™ column|Five consecutive treatment sessions. The therapy will be administrated every second day.
1869477|NCT01097590|Device|Placebo|Five consecutive treatment sessions. The placebo therapy will be administrated every second day.
1869478|NCT01097616|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
1869479|NCT01097616|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
1869480|NCT01097616|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase and, if applicable, the optional 3-month EXT Phase. During the 1-week DB RO following the TRT/EXT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
1869481|NCT01097629|Drug|Suvorexant High Dose (HD)|Suvorexant 40 mg + placebo matching suvorexant 20 mg for participants <65 years old; Suvorexant 30 mg + placebo matching suvorexant 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month Treatment (TRT) Phase. During the 1-week double-blind (DB) Run-out (RO) following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
1869482|NCT01097629|Drug|Suvorexant Low Dose (LD)|Suvorexant 20 mg + placebo matching suvorexant 40 mg for participants <65 years old; Suvorexant 15 mg + placebo matching suvorexant 30 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Participants receive this dose during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm receive the noted suvorexant dose or placebo, in a 1:1 ratio. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
1869483|NCT01097629|Drug|Comparator: Placebo|Matching placebos to suvorexant 40 mg and 20 mg for participants <65 years old; matching placebos to suvorexant 30 mg and 15 mg for participants ≥65 years old; all study drug is tablet for oral administration, taken once daily at bedtime. Placebo is a third treatment arm for comparison to the two active (suvorexant) treatment arms during the 3-month TRT Phase. During the 1-week DB RO following the TRT phase, participants in this study arm continue to receive placebo. During the 2-week single-blind Run-in period prior to randomization all participants receive placebo to suvorexant once daily at bedtime.
1869484|NCT01097642|Drug|Cetuximab|Cetuximab will be given at 400mg/m^2 IV over 120 minutes for its initial loading dose on day 1 of the first of four 21 day cycles. It will then be administered on a weekly basis at 250 mg/m^2 IV over 60 minutes.
1869485|NCT01097642|Drug|Ixabepilone|Ixabepilone will be given at 40mg/m^2 IV over 180 minutes on day 1 of each of four 21 day cycles.
1869486|NCT01097668|Biological|ATX-MS-1467|Disease specific immune modulating treatment for multiple sclerosis
1869487|NCT01097681|Drug|ASP1941|oral
1869488|NCT01097694|Drug|Imatinib mesylate|Imatinib will be initiated at an oral dose of 200 mg (two 100 mg film-coated tables) per day during the first two weeks of treatment. If the treatment is well tolerated, an up-titration to 400 mg daily (four 100 mg film-coated tables) will occur.
1869489|NCT01097694|Drug|Placebo|Placebo
1869490|NCT01097707|Drug|LY500307|Administered orally, daily for 24 weeks
1869491|NCT01097707|Drug|Placebo|Administered orally, daily for 24 weeks
1869492|NCT01097733|Other|Randomization of Pre-knowledge of CT coronary venography|
1869496|NCT01097759|Procedure|Surgery|Hemorrhoidectomy using the LigaSure sealing device or hemorrhoidopexy using the stapler
1869497|NCT01097772|Device|Implant of Ovation Abdominal Stent Graft System|Single occurrence permanent implant of AAA device.
1869498|NCT01097785|Drug|Simvastatin|40 mg, P.O.,daily for 30 days
1869499|NCT01097785|Drug|Placebo|1 capsule daily for 30 days
1869500|NCT01097798|Drug|Aliviador|The study medication should be applied regimen of 8/8 hours over 2 days.
1869501|NCT01097798|Drug|Gelol|The study medication should be applied regimen of 8/8 hours over 2 days.
1869502|NCT01097811|Drug|Erythromycin|250 mg orally q.i.d.
1869503|NCT01097811|Drug|Neomycin|1 g orally q.i.d.
1869504|NCT01097837|Other|Non-interventional|This is an observational study conducted by anonymous survey. There is no intervention.
1869505|NCT01097850|Drug|henna paste|Henna paste will be applied to either the left hand/foot or right hand/foot, along with CeraVe moisturizer to both hands/feet
1869899|NCT01093183|Other|questionnaire administration|Ancillary studies
1871269|NCT01109784|Drug|prasugrel|prasugrel 10 mg/day
1869506|NCT01097863|Device|nelfilcon A contact lens, modified inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with modified inversion indicator
1869507|NCT01097863|Device|nelfilcon A contact lens, no inversion indicator|Investigational, nelfilcon A, toric, soft contact lens for daily disposable wear, with no inversion indicator
1869508|NCT01097863|Device|nelfilcon A contact lens, inversion indicator|Commercially marketed, nelfilcon A, toric, soft contact lens for daily disposable wear, with inversion indicator
1869509|NCT01097876|Drug|PF-04447943 25 mg|25 mg PF-04447943 BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and 25 mg PF-04447943 BID (Period 3)
1869510|NCT01097876|Drug|Placebo PF|Placebo BID for 7 days (period 1) 7 day washout (no drug) 7 days of 5 mg donepezil QD; 14 days 10 mg QD (Period 2) 7 days of 10 mg donepezil QD and Placebo BID (Period 3)
1869511|NCT01097993|Other|1-fermented dairy product|Arm 1 - Intervention 1 (probiotics)
1869512|NCT01097993|Other|2- milk-based non-fermented dairy product (control product)|Arm 2 - Intervention 2 (control)
1869514|NCT01098019|Drug|Xeomin|Patients will receive Xeomin only at Day 0.
1869515|NCT01098019|Drug|Placebo / Xeomin|Patients will receive 0.9% mL NaCl alone at Day 0. After unblinding (at week 12) patients who were randomized to placebo will receive Xeomin.
1869516|NCT01098032|Device|RenalGuard system|The RenalGuard™ System (PLC Medical Systems, Inc.) is a real-time measurement and real time matched fluid replacement device designed to accommodate the RenalGuard Therapy. The RenalGuard Therapy is based on the concept demonstrated by clinical data that high urine output is beneficial to patients with impaired baseline renal function who receive intravascular iodinated contrast medio (CM). The RenalGuard System seems to be ideal for the prevention of CI-AKI, by allowing an optimal urine flow rate >300 ml/h. It is known that excessive diuresis can cause dehydration which increases the risk to the kidneys from CM. The RenalGuard System should allow the patient to achieve high urine output safely by maintaining the intravascular blood volume and avoiding the risk of over-or-under-hydration.
1869517|NCT01098032|Drug|Systemic alone therapy|Patients allocated to the Systemic alone therapy group will receive 154 mEq/l of sodium bicarbonate in dextrose and H2O, according to the protocol reported by Merten et al. The initial intravenous bolus was 3 ml/kg per hour for 1 hour immediately before contrast injection. Following this, patients will receive the same fluid at a rate of 1 ml/kg per hour during contrast exposure and for 6 hours after the procedure. All patients will receive NAC (Fluimucil, Zambon Group SpA, Milan, Italy) orally at a dose of 1200 mg twice daily on the day before and on the day of administration of the contrast agent (total of 2 days)
1869518|NCT01098058|Other|CBT plus treatment as usual|16 one-hour therapy sessions taking place over 42 weeks in addition to usual medical follow-up appointments
1869519|NCT01098058|Other|Treatment as usual|Treatment as usual appointments at the Adult ADHD Service - typically one 30-minute appointment every three to six months
1869521|NCT01098084|Drug|Decitabine|20mg/m2/day, one hour intravenous infusion, every day during 5 days
1869522|NCT01098097|Biological|Peginterferon alpha|Peginterferon alpha given in combination with ribavirin according to local labeling guidelines
1869523|NCT01098097|Drug|Ribavirin|Ribavirin given in combination with peginterferon alpha according to local labeling guidelines
1869524|NCT01098110|Drug|Asenapine 5 mg|Asenapine 5 mg fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), on Day 1 only or for 6 weeks.
1869525|NCT01098110|Drug|Asenapine 10 mg|Participants receive on Day 2, 10 mg BID of fast dissolving tablets sublingually without water twice daily, in the morning (around 8 am) and in the evening (around 8 pm), for 6 weeks.
1869526|NCT01098110|Drug|Placebo|A matching placebo of asenapine sublingual tablet not containing asenapine
1869527|NCT01098136|Other|Chiropractic|Manual treatment of musculoskeletal complaints
1869528|NCT01098136|Other|Conventional medical intervention|Medical, physiotherapy
1869529|NCT01098136|Other|Conventional and alternative intervention|Medical and alternative methods for treatment of pelvic pain syndromes
1869530|NCT01098149|Other|BD and BVC, AFB|Some patients are randomized into the AFB, the others into the BD and BVC
1869531|NCT01098188|Drug|LFB-R603|intravenous administration, dose-escalation study
1869532|NCT01098201|Drug|Certolizumab|Subcutaneous administration on a monthly basis for six months
1869533|NCT01098240|Drug|CP-601,927|CP-601,927 1-2 mg twice per day, oral 1 mg tablets, for 6 weeks.
1869534|NCT01098240|Other|Placebo|Matching placebo tablets, taken orally, twice per day, for 6 weeks.
1869535|NCT01098253|Behavioral|Adherence Intervention|Factors affecting adherence are addressed using a problem solving process.
1869536|NCT01098266|Drug|NGR-hTNF plus Best Investigator's Choice (BIC)|"NGR-hTNF: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.
Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:
Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles
Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles
Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
1869537|NCT01098266|Drug|Placebo plus Best Investigator's Choice (BIC)|"Placebo: 0.8 mcg/m² as 60-minute intravenous infusion every week until confirmed evidence of disease progression or unacceptable toxicity occurs.
Best Supportive Care: antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, nutritional support, and focal external-beam radiation for control of pain, cough, dyspnea, or hemoptysis
Investigator's Choice: one of the following single-agent chemotherapy might be administered in combination:
Doxorubicin: 60-75 mg/m2 every 3 weeks, for a maximum of 6 cycles
Gemcitabine: 1,000-1,250 mg/m2 on days 1 and 8, every 3 weeks, for a maximum of 6 cycles
Vinorelbine: 25 mg/m2 iv (or 60 mg/m2 per os) on days 1 and 8, every 3 weeks, for a maximum of 6 cycles (or weekly for 12 weeks)"
1869936|NCT01093443|Drug|ovarian stimulation|GnRH antagonist, rFSH, GnRH antagonist
1869937|NCT01093469|Drug|Atopiclair Nonsteroidal Cream|
1869538|NCT01098305|Drug|Varenicline|Participants will be randomized to receive varenicline or placebo for 12 weeks. The dosing regimen consistent with FDA guidelines will be used: Day 1-Day 3 (0.5mg once daily); Day 4-Day 7 (0.5mg twice daily); and Day 8-Day 84 (1.0mg twice daily).
1869539|NCT01098305|Behavioral|Counseling|All participants will be provided with a structured behavioral counseling program, involving 6 counseling sessions by a trained NDDTC counselor. This will be a manual-based intervention and revised as needed for cultural relevance and sensitivity by Dr. Stigler. The intervention is designed to enhance awareness of the harmful effects of smokeless tobacco, assist the person in developing skills to quit and avoid relapse, and instruct the smokeless tobacco user on medication adherence, as recommended by experts in the field.
1869540|NCT01098318|Dietary Supplement|Herbal extract|340-1,360 mg daily
1869541|NCT01098318|Drug|Sertraline|50-200 mg daily
1869542|NCT01098318|Other|Lactose monohydrate|1-4 capsules daily
1869543|NCT01098331|Other|counseling intervention|
1869544|NCT01098331|Other|educational intervention|
1869545|NCT01098331|Procedure|quality-of-life assessment|
1869546|NCT01098331|Procedure|therapeutic conventional surgery|
1869547|NCT01098331|Radiation|iodine I 125|
1869548|NCT01098331|Radiation|palladium Pd 103|
1869549|NCT01098344|Drug|Notch signaling pathway inhibitor MK0752|
1869550|NCT01098344|Drug|gemcitabine hydrochloride|
1869551|NCT01098344|Other|imaging biomarker analysis|
1869552|NCT01098344|Other|laboratory biomarker analysis|
1869553|NCT01098344|Other|pharmacological study|
1869554|NCT01098357|Drug|Biochaperone PDGF-BB Low dose|BioChaperone PDGF-BB low dose is applied as a spray every two days at the dose of 12.5 µg/cm2 for up to 20 weeks
1869555|NCT01098357|Drug|Biochaperone PDGF-BB High dose|BioChaperone PDGF-BB high dose is applied as a spray every two days at the dose of 25 µg/cm2 for up to 20 weeks
1869556|NCT01098357|Drug|Regranex|Regranex gel is applied once daily at the dose of 6.25 µg/cm2 for up to 20 weeks
1869557|NCT01098357|Drug|Biochaperone PDGF-BB Very Low Dose|BioChaperone PDGF-BB Very Low Dose sprayed on the wound every two days (e.g., Mondays, Wednesdays and Fridays) for 20 weeks or until complete wound healing, at the dose of 4 µg/cm²/application
1869558|NCT01098383|Drug|Acetyl-Choline Esterase Inhibitors and Choline supplements|"Donepezil will be used at initial dose of 2.5 mg/day (during the first two weeks), and an increased dose of 5 mg/day (from the 3rd week and on), according to the treatment protocol listed below. The tablets will be taken during breakfast.
AChE inhibitors are considered as potent agents for clinical use in Alzheimer's and Parkinson's dementias (Wevers & Schroder, 1999) and treatment with these agents was proven to be well-tolerated, safe and effective in these populations. Cholinergic side effects are generally transient, mild and dose-related, and primarily include diarrhea, nausea, and vomiting.
Choline tablets will be taken at daily doses of 250 mg (in children with up to 40 kg body weight) and 500 mg (in children with more than 40 kg body weight), based on half of the adult daily dose."
1869559|NCT01098383|Drug|Indistinguishable placebo tablets, matching both donepezil and choline|Indistinguishable placebo tablets, matching both donepezil and choline, will be given in the same amounts and schedules
1869560|NCT01098409|Drug|sodium nitrite|0.2mcg/kg/min or 1mcg/kg/min intravenous for 30minutes at 1ml/min
1869561|NCT01098409|Drug|0.9% sodium chloride|intravenous 0.9% sodium chloride over 30minutes at 1ml/min
1869562|NCT01098422|Device|Yttrium-90 Radioactive Resin Microspheres|An injectable formulation of the radioisotope yttrium-90 encapsulated in resin microspheres with potential antineoplastic activity.
1869563|NCT01098435|Drug|RDC-0313 (ALKS 33)|Capsules for daily oral administration
1869564|NCT01098435|Drug|Placebo|Capsules containing lactose and no active drug for daily oral administration
1869565|NCT01098448|Other|scaling and root planing|scaling and root planing as a single therapy
1869566|NCT01098448|Drug|local tetracycline|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm
1869567|NCT01098448|Drug|systemic metronidazole and amoxicillin|systemic metronidazole (250 mg tid x 14) and amoxicillin (500 mg bid x 14
1869568|NCT01098448|Other|surgery|periodontal surgery in residual pockets of >4mm
1869569|NCT01098448|Drug|local antibiotics and systemic metronidazole and amoxicillin|1.7 mg/tooth tetracycline fiber plus metronidazole (250 mg tid x14d)and amoxicillin (500 mg bid x 14d)
1869570|NCT01098448|Other|local tetracycline and periodontal surgery|local delivery of tetracycline fibers releasing approximately 1.7 mg/tooth in all pockets >5mm and periodontal surgery in residual pockets of >4mm
1869571|NCT01098448|Other|periodontal surgery and systemic metronidazole and amoxicillin|surgery in residual pockets >4mm and metronidazole (250mg tidx14d) and amoxicillin (500mg bidx14d)
1869572|NCT01098448|Other|surgery, local tetracycline, systemic metronidazole and amoxicillin|periodontal surgery in residual pockets >4mm, tetracycline ibers releasing approximately 1.7 mg/tooth in pockets >5mm, systemic metronidazlo (250mg tidx14d) and amoxicillin (500 mg bidx14d)
1869573|NCT01098461|Biological|albiglutide|subcutaneous injection of albiglutide
1869574|NCT01098461|Biological|placebo|subcutaneous injection of placebo to match albiglutide
1869580|NCT01098487|Drug|Eltrombopag olamine|Thrombopoietin receptor agonist
1869581|NCT01098500|Drug|Tyrosine kinase inhibitors|Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
1869582|NCT01098513|Drug|GSK1349572 formulation AP|GSK1349572 50 mg single dose fasted.
1869583|NCT01098513|Drug|GSK1349572 formulation AW|GSK1349572 formulation AW 50 mg single dose in Part A and 75 to 200 mg fasted or with moderate or high fat meal in Part B.
1869584|NCT01098513|Drug|GSK1349572 formulation AX|GSK1349572 formulation AX 50 mg in Part A and 75-200 mg fasted or with a moderate or high fat meal in Part B
1869585|NCT01098526|Drug|GSK1349572|GSK1349572 is an experimental drug under development for the treatment of HIV. It is in the class of integrase inhibitors.
1869586|NCT01098526|Drug|Efavirenz|Efavirenz is a drug that has been approved by the FDA for the treatment of HIV. It is in the class of non-nucleoside reverse trancriptase inhibitors.
1869587|NCT01098539|Biological|albiglutide|albiglutide weekly subcutaneous injection + sitagliptin matching placebo
1869588|NCT01098539|Drug|sitagliptin|albiglutide matching placebo + sitagliptin (25mg, 50mg or 100mg depending on level of renal impairment)
1869589|NCT01098565|Device|Study device HFR0001|Study device will be tested for up to 2 hours prior to chronic device implant.
1869590|NCT01098578|Drug|Floseal|Received 1 syringe of Floseal as treatment for posterior epistaxis.
1869591|NCT01098591|Other|cell therapy|
1869592|NCT01098604|Device|32mm ceramic head group|we performed THA using 32mm ceramic head in this group.
1869593|NCT01098604|Device|28mm ceramic head group|we performed THA using 28mm ceramic head in this group.
1869594|NCT01098630|Other|Medical Chart Review|Patients' medical record information is collected and staff complete the treatment review form
1869595|NCT01098630|Other|Questionnaire Administration|Ancillary studies
1869596|NCT01098643|Other|computer-assisted intervention|
1869597|NCT01098643|Other|medical chart review|
1869598|NCT01098643|Other|questionnaire administration|
1869599|NCT01098643|Other|survey administration|
1869600|NCT01098656|Drug|lenalidomide|"The starting dose of lenalidomide is 25 mg orally once daily on days 1-21 of repeated 28-day cycles.
Dosing is continued or modified based upon clinical and laboratory findings (dose reductions: 20 mg, 15 mg, 10 mg and 5 mg)"
1869601|NCT01098695|Other|Ecological Family Intervention and Treatment (EcoFIT)|Includes the Family Check-Up (in-person intake, family video observations and Assessment questionnaires used to provide and tailored feedback using motivational interviewing techniques) as well as continued tailored intervention services using the Everyday Parenting Curriculum.
1869602|NCT01098721|Drug|WBI-1001|Comparison of two doses (0% and 1.0%) of the the WBI-1001 cream applied topically, twice daily for 12 weeks.
1869603|NCT01098734|Drug|WBI-1001|A 12-week study to assess the efficacy, safety and tolerability of topically applied WBI-1001 creams. First 6 weeks will be double-blinded, placebo-controlled and the following 6 weeks will be double-blinded, non-placebo- controlled. After 6 weeks patients in Groups 2 and 3 will continue double-blinded treatment for a further 6 weeks, but patients in Group 1 will enter a 6-week double-blinded phase with one of the two active creams (half treated with 0.5% and half with 1.0% WBI-1001 cream). All patients treated twice daily (BID).
1869604|NCT01098747|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
1869605|NCT01098747|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
1869606|NCT01098747|Drug|Standard Ibuprofen|Single-dose of standard ibuprofen (400mg)
1869607|NCT01098747|Drug|Placebo|Single-dose of placebo
1869608|NCT01098760|Drug|Sorafenib (Nexavar, BAY43-9006) Sorafenib (Nexavar, BAY43-9006) + Nerison Fatty Ointment Sorafenib (Nexavar, BAY43-9006)+Neribas Fatty Ointment|Orally taken Sorafenib tablets of 400mg (2x200mg) twice daily (bid) in a continuous schedule. - For patients in Nerisone subgroup: additionally prophylactic use of Nerisone Fatty Ointment (1 g of Nerisone contains 1 mg (0.1%) diflucortolone valerate) cream for hands and feet, twice daily for 3 weeks - For patients in Neribas subgroup: additionally prophylactic use of Neribas Fatty Ointment (non-corticosteroid containing) cream for hands and feet, twice daily for 3 weeks
1869609|NCT01098786|Biological|Cell-derived A/H1N1 influenza HA vaccine|Single group vaccinated
1869610|NCT01098812|Device|Tecnis ZCB00 IOL (control)|Tecnis 1-piece acrylic IOL
1869611|NCT01098812|Device|Toric Intraocular lens|Toric acrylic intraocular lens with various cylinder powers
1869612|NCT01098825|Other|web-based survey|Anonymous web-based survey
1869613|NCT01098838|Drug|LCL161|
1869614|NCT01098864|Device|transcranial magnetic stimulation|low frequency (1 Hz) repeated transcranial magnetic stimulation will be delivered to the dorsal lateral prefrontal cortex (DLPFC) area for a period of 15 minutes to test for effect on executive function (e.g., decision choice and subjective value). Four sessions will be conducted per subject; 2 active stimulations,(1 left DLPFC, 1 right DLPFC) and 2 sham stimulations (1 left DLPFC, 1 right DLPFC) with a minimum of 48 hours between every stimulation. Pre and post stimulations measures of cognitive and executive function will be collected and analyzed for significant differences.
1869615|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose
1869616|NCT01098877|Drug|PF-04634817|Oral solution, 1mg, single dose
1869617|NCT01098877|Drug|PF-04634817|Oral solution, 3mg, single dose
1869618|NCT01098877|Drug|PF-04634817|Oral solution, 10mg, single dose
1869619|NCT01098877|Drug|PF-04634817|Oral solution, 30mg, single dose
1869620|NCT01098877|Drug|PF-04634817|Oral solution, 100mg, single dose
1869621|NCT01098877|Drug|PF-04634817|Oral solution, 300mg, single dose
1869622|NCT01098877|Drug|PF-04634817|Oral solution, 600mg, single dose
1869623|NCT01098877|Drug|PF-04634817|Oral solution, 900mg, single dose
1869624|NCT01098877|Drug|PF-04634817|Oral solution, up to 900mg, single dose after food
1869625|NCT01098877|Drug|PF-04634817 Placebo|Oral solution, placebo, single dose after food
1869626|NCT01098890|Drug|Tissue Plasminogen Activator|2mg tPA will be given every twelve hours for a maximum of 5 doses
1869627|NCT01098890|Drug|Placebo|Placebo will be administered every 12 hours for a maximum of 5 doses.
1869628|NCT01098916|Radiation|Home X-rays|X-rays examinations performed at home
1869629|NCT01098916|Radiation|X-rays in hospital|
1869630|NCT01098955|Behavioral|Acceptance and Commitment Therapy|6 x 60-minute counseling sessions delivered over a 5-week period
1869631|NCT01098955|Behavioral|Motivational and Behavioral Counseling|6 x 60-minute counseling sessions delivered over a 5-week period
1869632|NCT01098955|Drug|Varenicline|2 mg daily for 12 weeks
1869633|NCT01098968|Behavioral|Physical activity program|School intervention program specifically designed to increase health-related physical fitness
1869634|NCT01098981|Device|Transcranial ultrasound as an adjunctive therapy to tPA|"tPA per approved labeling administered over 60 minutes
Ultrasonic headframe with active insonation for 120 minutes"
1869938|NCT01093469|Other|Aquaphor Healing Ointment|
1869939|NCT01093469|Drug|EpiCeram|
1869940|NCT01093495|Device|CPAP|CPAP
1869635|NCT01098981|Drug|Standard of care tPA therapy for acute ischemic stroke|"tPA per approved labeling administered over 60 minutes
Ultrasonic headframe with sham (inactive) insonation for 120 minutes"
1869636|NCT01098994|Dietary Supplement|Vitamin E|Daily administration of 400 IU natural d-alpha tocopherol acetate for 8 weeks
1869637|NCT01098994|Other|Dummy pills|Daily placebo administration for 8 weeks
1869638|NCT01099007|Behavioral|In Person|Participants in the In Person group have weekly visits for the 12 weeks to the research office. The first visit can last up to one and a half hours and each subsequent visit can last approximately one hour. Group meetings provide appropriate nutrition and physical activity information as well as behavioral change strategies. Sessions also include some light physical activity (equal to brisk walking).
1869639|NCT01099007|Behavioral|At Home|Participants in the At Home group receive a workbook from the research staff at their baseline visit that outlines an accepted nutrition and physical activity program to complete on their own.
1869643|NCT01099072|Drug|Methylphenidate+placebo|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Placebo
1869644|NCT01099072|Drug|methylphenidate+carnitine|methylphenidate at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)+ Carnitine 500-1500 mg/day (depending on weight )
1869645|NCT01099085|Drug|Simvastatin|simvastatin 40 mg qd daily
1869646|NCT01099085|Drug|Placebo|Placebo
1869647|NCT01099124|Drug|M2ES|polyethylene glycol rh recombinant endostatin
1869648|NCT01099137|Drug|Vildagliptin|Vildagliptin 50mg twice a day, orally, for 24 weeks
1869649|NCT01099137|Drug|Sulphonylurea dose-up|glimepiride dose will be increased by 50% to uncontrolled diabetic patients with glimepiride and metformin
1869650|NCT01099150|Dietary Supplement|Dark chocolate enriched in flavan-3-ols and procyanidins|Acute consumption (within 15 minutes) of 60 g of chocolate containing ~900 mg of total flavan-3-ols and procyanidins.
1869651|NCT01099150|Dietary Supplement|Standard dark chocolate|Acute consumption (within 15 minutes) of 60 g of chocolate containing ~400 mg total flavan-3-ols and procyanidins.
1869652|NCT01099150|Dietary Supplement|White chocolate|Acute consumption (within 15 minutes) of 60 g of white chocolate containing no flavan-3-ols and procyanidins.
1869653|NCT01099163|Dietary Supplement|Tonalin SG1000T FFA|
1869654|NCT01099176|Drug|To compare monotherapies and combined therapy with each other|"Each patient received two tablets per day. Time interval between pills - 12 hours.
In monotherapies patients received one active tablet and one placebo, in combined treatment both pills were active and in placebo group patients taken two placebo tablets"
1869655|NCT01099202|Drug|Procrit (epoetin alfa)|Starting dose 40,000 Units subcutaneously once a week during your regularly scheduled chemotherapy for up to 6 courses of chemotherapy (around 5 months).
1869656|NCT01099215|Biological|PVS-10200|PVS-10200 is composed of allogeneic human aortic endothelial cells cultured in a gelatin matrix.
1869657|NCT01099228|Other|131-I MIBG and 111-In pentetreotide|Subjects will receive 131I MIBG and 111In pentetreotide(surrogate for Y90-DOTATOC)
1869658|NCT01099228|Other|131-I MIBG and In-111 DOTATATE|131I MIBG and In-111 DOTATATE (surrogate for 177Lu DOTATATE)
1869659|NCT01099280|Drug|SYNPITAN FORT 5 IU|A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved. Once started, oxytocin infusion was continued to delivery unless otherwise indicated. The pessary has been removed if it was still present 12 h after placement; or if worrisome FHR pattern persisted
1869660|NCT01099280|Drug|Propess,SYNPITAN FORT|a single dose sustained-released dinoprostone into the posterior vaginal fornix. A standard intravenous oxytocin was administered 6 hours after the insertion of the vaginal pessary. An initial dose of 2 mU/min was increased at 30 minute intervals by 2 mU/min to a maximum dose 32 mU/min or until four contractions in 10 minutes was achieved
1869661|NCT01099306|Other|Pharmaceutical care services|Patients' metabolic components were assessed and managed collaboratively by focused care plan designed by the clinical pharmacist and approved by the physician.Pharmacist emphasized the change in lifestyle, particularly weight loss and physical activity as a first line therapy for at least 3 months, patients were started on drug therapy when needed as recommended by clinical guidelines.
1869662|NCT01099319|Dietary Supplement|Renalof|One 325 mg Renalof tablet (Orally administered) every 8 hours, for 6 months.
1869663|NCT01099319|Dietary Supplement|Placebo|One Placebo tablet (Orally administered) every 8 hours, for 6 months
1869664|NCT01099332|Other|Gastro-retentive zinc cysteine tablet|Oral, one tablet, once daily with water for 6 months.
1869665|NCT01099332|Other|Tablet identical physically to active comparator containing some lactose|Oral, once daily, with water, 6 months.
1869666|NCT01099345|Procedure|cystometry (CMG)|recording device measuring pressures though catheters placed in bladder and rectum
1869667|NCT01099345|Procedure|polysomnography (PSG)|Recording device measuring sleep activity through electrodes attached to the subject
1869668|NCT01099358|Drug|Cetuximab|Administered Intravenously
1869669|NCT01099358|Drug|Cisplatin|Administered Intravenously
1869670|NCT01099358|Drug|5 - Fluorouracil|Administered Intravenously
1869671|NCT01099371|Other|exercise|progressive resistance training
1869672|NCT01099384|Behavioral|Written self-help materials|Written materials to help adolescents stop tobacco use
1869673|NCT01099384|Behavioral|Group behavioral counseling|group behavioral counseling (2 day weekend program)
1869674|NCT01099397|Other|Oral glucose tolerance test|For assessment of dysglycemia, 75 grams of glucose solution by mouth at 3 PEAR study visits for all enrolled participants: baseline, single drug therapy assessment, and dual drug therapy assessment.
1869716|NCT01099618|Drug|Sitagliptin|The study subject will receive a sitagliptin 100mg once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
1869941|NCT01093495|Device|Nasal Cannula|Nasal Cannula
1869675|NCT01099410|Procedure|Fiberoptic bronchoscopy|"which a flexible video instrument is passed via the nose or mouth, through the vocal cords and into the lungs. During the procedure, portions of the lungs will be washed (lavaged) with a salt water solution, to collect the alveolar macrophages. This procedure involves conscious sedation, so that a driver is required on the day of the bronchoscopy. The entire procedure, including placement of an intravenous line to administer medications, local anesthetics, the bronchoscopy itself, and the recovery period, takes about 2.5-3 hours."
1869676|NCT01099410|Procedure|blood draw|Blood will be collected at the enrollment visit to test the subject to exclude disorders that would make it unsafe to perform the bronchoscopy, including severe anemia, infection, or disorders of kidney or liver function.
1869677|NCT01099410|Procedure|intravenous catheter|An intravenous catheter is placed on the day of the bronchoscopy to permit administration of sedative medications.
1869678|NCT01099423|Procedure|timing of surgery|
1869679|NCT01099423|Genetic|gene expression analysis|
1869680|NCT01099423|Other|biologic sample preservation procedure|
1869681|NCT01099423|Other|laboratory biomarker analysis|
1869682|NCT01099423|Procedure|therapeutic conventional surgery|
1869683|NCT01099436|Drug|cyclophosphamide|
1869684|NCT01099436|Drug|docetaxel|
1869685|NCT01099436|Drug|doxorubicin hydrochloride|
1869686|NCT01099436|Drug|zoledronic acid|
1869687|NCT01099436|Procedure|neoadjuvant therapy|
1869692|NCT01099462|Drug|Ibuprofen|Ibuprofen (10mg/kg BW) will be given orally if the temperature on presentation is higher than 38.0OC according to the decision of the attending physician.
1869693|NCT01099475|Procedure|Pringle manoeuvre 15 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 2-times 15 minutes with 5 minutes reperfusion
1869694|NCT01099475|Procedure|Pringle manoeuvre 30 minutes|During parenchymal transection, the hepatoduodenal ligament will be clamped by a rubber band for 30 minutes with 5 minutes reperfusion
1869695|NCT01099488|Procedure|Blood withdrawal|Healthy male or female adults between, and including, 18 and 50 years of age at the time of study start, having received GSK2231392A vaccine, were enrolled for blood withdrawal, at each study visit: Day 0, Day 14 and Day 180, to support the development of CD8+ T cell immunological detection assays.
1869696|NCT01099501|Dietary Supplement|Oxepa (enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.|Oxepa will be administered(enteral nutrition formula, ABBOTT), at a dose determined by a patient's energy expenditure and tolerance of enteral feeding
1869697|NCT01099501|Dietary Supplement|oxepa|A dose determined by a patient's energy expenditure and tolerance of enteral feeding.
1869698|NCT01099501|Dietary Supplement|Control group|Pulmocare or Jevity (enteral nutrition formula, ABBOTT)will be administered at a dose determined by a patient's energy expenditure and tolerance of enteral feeding.
1869699|NCT01099514|Drug|Nilotinib|D1~ Nilotinib 400 mg (2 capsules) PO BID q 28 days
1869700|NCT01099527|Drug|Everolimus (RAD001)|dose escalation of capecitabine, everolimus
1869701|NCT01099527|Drug|Capecitabine|dose escalation of capecitabine, everolimus
1869702|NCT01099540|Drug|Pazopanib|Pazopanib 800 mg qd daily
1869703|NCT01099553|Other|Educational video|Instructions to view an educational video about preparing for a colonoscopy
1869704|NCT01099553|Other|Written instructions|Written instructions on preparing for a colonoscopy
1869705|NCT01099566|Drug|Prasugrel|Prasugrel will be given as loading dose (60mg) on the first trial day two hours prior to endotoxin infusion. Prasugrel is an orally administered prodrug that is converted in the liver by CYP to its active metabolite.
1869706|NCT01099566|Drug|Placebo|A pharmacist not otherwise involved in the trial will encapsulate pills consisting of lactose-starch. Six pills will be administered as placebo 2 hours before LPS administration on trial day 1.
1869707|NCT01099579|Drug|Atazanavir powder|Powder, oral, dosed by weight. Participants who weighed 5 to <10 kg received atazanavir (ATV), 150 mg, and ritonavir (RTV), 80 mg; those who weighed 10 to <15 kg received ATV, 200 mg, and RTV, 80 mg; and those who weighed 15 to <25 kg received ATV, 250 mg, and RTV, 80 mg, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
1869708|NCT01099579|Drug|Ritonavir oral solution|Oral solution, 80 mg/mL, once per day for 48 weeks or until pediatric indication is locally approved and participant meets requirements to receive appropriate formulation.
1869709|NCT01099579|Drug|Atazanavir capsules|Capsules, oral, dosed by weight in Stage 2. Patients who reached the age of 6 years or a weight of ≥25 kg transitioned from the powder to the capsule formulation of atazanavir (ATV). Patients who weighed 15 to <20 kg received ATV, 150 mg with RTV, 100 mg; those who weighed 20 to <40 kg received ATV, 200 mg, and RTV, 100 mg; and those who weighed at least 40 kg received ATV, 300 mg with RTV, 100 mg. RTV capsules or tablets were ingested with food immediately before or after ATV intake.
1869710|NCT01099579|Drug|Ritonavir capsules|Oral, capsules, 100 mg, administered in Stage 2 with atazanavir capsules, dosed by weight.
1869711|NCT01099592|Drug|Citalopram|All patients will take citalopram once daily. Medication will be commercial tablets of 20 mg or 40 mg. All patients will start on a half dose of 10 mg and, if there are no severe side effects, will be increased to 20 mg after 1 week, and if the HAMD-24 at 6 weeks is not < 8, the dose will increase to 40 mg.
1869712|NCT01099605|Device|placement of a continuous infusion pump|Each infusion pump is placed below the mucosa of the rectum. Infusion of either the drug or saline will continue for approximately 3-4 days.
1869713|NCT01099605|Device|continuous infusion pump of bupivacaine|bupivacaine 0.25% at 4ml/hr for 3 to 4 days
1869714|NCT01099618|Drug|metformin|The study subject will receive metformin (MET) 1000 mg tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
1869715|NCT01099618|Drug|placebo|The study subject will receive a placebo tablet once a day as long as the patient maintains near-normoglycemic remission (BG < 130mg/dL and A1c <7%) during the 3-year follow-up period.
1869896|NCT01093183|Drug|cyclophosphamide|Given PO
1869942|NCT01093508|Drug|APD916|
1869717|NCT01099631|Biological|Salmonella typhimurium|Attenuated Salmonella typhimurium (virulent strain x4550) will be given orally in escalating dose groups: Level 1 = 10^5, Level 2 = 10^6, Level 3 = 10^7, Level 4 = 10^8, Level 5 = 10^9, Level 6 = 10^10.
1869718|NCT01099644|Biological|131 I-8H9|Patients will be administered therapeutic dose of IP 131I-8H9 per the dose escalation regimen. 131I-8H9 pharmacokinetics will be studied by serial blood draws from indwelling venous lines. 131I-8H9 biodistribution will be studied by a single gamma camera scan about 5 days after IP injection where feasible.
1869719|NCT01099657|Behavioral|Virtual Reality Hypnosis for chronic pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Hypnosis. After VRH, the will again answer Pain and anxiety questionnaires.
1869720|NCT01099657|Behavioral|Virtual Reality Distraction for Chronic Pain|At the time of their clinic visit,the subject will answer pain and anxiety questionnaires before experiencing Virtual Reality Distraction. After VRD, the will again answer Pain and anxiety questionnaires.
1869721|NCT01099670|Drug|NRL001|Rectal suppository Placebo
1869722|NCT01099670|Drug|Placebo|Placebo
1869723|NCT01099683|Drug|NRL001|Single rectal administration of 2 mg NRL001 in a 2 g suppository
1869724|NCT01099683|Drug|Placebo|All subjects will receive rectal suppository containing placebo
1869725|NCT01099696|Dietary Supplement|B. infantis 35624|B. infantis 35624 in white capsules
1869726|NCT01099696|Dietary Supplement|placebo|white placebo capsules
1869727|NCT01099709|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken with food.
1869728|NCT01099709|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
1869729|NCT01099722|Drug|Flutiform|inhaler 2 puffs bd daily
1869730|NCT01099722|Drug|Symbicort Turbohaler|2 puffs bd daily
1869731|NCT01099748|Drug|Methadone|Methadone 50 - 150 mg QD (Day 1)
1869732|NCT01099748|Drug|Lersivirine + Methadone|Lersivirine 1000 mg QD + Methadone 50 - 150 mg QD (Days 2-11)
1869733|NCT01099761|Biological|ACE-031 0.5 mg/kg q4wk|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 12 weeks.
1869734|NCT01099761|Biological|ACE-031 1.0 mg/kg q2wk|ACE-031 1.0 mg/kg subcutaneously once every 2 weeks for 12 weeks.
1869735|NCT01099761|Other|Placebo|Matching volume placebo subcutaneously every 2 or 4 weeks for 12 weeks.
1869736|NCT01099774|Drug|Bimatoprost 0.03% Formulation B Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
1869737|NCT01099774|Drug|Bimatoprost 0.03% Ophthalmic Solution|One drop administered in each eye, every evening, for 12 weeks
1869738|NCT01099826|Behavioral|Tailored counseling|education tailored to baseline beliefs by trained counselor over phone
1869739|NCT01099826|Behavioral|Motivational Interview|motivational interview by trained MI counselors by phone
1869740|NCT01099826|Behavioral|control|Usual care
1869741|NCT01099839|Drug|ASP1941|oral
1869742|NCT01099839|Drug|Miglitol|oral
1869743|NCT01099852|Other|biological sample collection|blood sample collection
1869744|NCT01099852|Other|quality of life questionnaire EuroQol®|Changes in quality of life, measured with the EuroQol® questionnaire 3 and 12 weeks after the onset of dengue fever symptoms.
1869745|NCT01099852|Other|Health Assessment Questionnaire - MDHAQ and RAPID3|Questionnaire used at the 3rd month of follow up.
1869746|NCT01099878|Device|Cycling Exercise with Functional Electrical Stimulation|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
1869747|NCT01099878|Device|cycling exercise|The subjects were randomly assigned to the cycling group (CG) performing cycling training without electrical stimulation or the FES-cycling group (FES-CG) performing the same training with the assistance of electrical stimulation. The duration of the training program was 20 minutes. The target cycling cadence was set at 45 rpm.
1869748|NCT01099891|Drug|rhEGF|rhEGF 50 μg/ml, spray type, twice a day
1869749|NCT01099891|Drug|Placebo|Placebo, Spray type, Twice a day
1869750|NCT01099904|Drug|RO5024048|multiple oral doses for 5 days
1869751|NCT01099917|Drug|Maitake|"Patients will receive the oral mushroom extract 3mg/kg by mouth twice daily for 3 months. Patients will serve as their own controls, with blood counts after Maitake compared with baseline counts. Rather than a wait list control, at study entry we will obtain from MDS patient charts 2 CBC/differential/platelet values drawn within 12-24 weeks prior to starting the protocol.
Healthy control volunteers will be recruited to this study as participants for expanding the baseline normal values for neutrophil and monocyte function as measured by the respiratory burst test."
1869752|NCT01099930|Other|immuno-ablation and autologous CD34 selected hematopoietic stem cell transplantation (HSCT),|"Stem Cell Mobilization with Cyclophosphamide 4.5 gm/m2 and rhGCSF 10 ug/kg/d x 10 day.
Stem Cell Collection with Cobe Spectra Stem Cell Purification with Miltenyi CliniMACS Stem Cell Transplant Conditioning with Busulphan 9.6 mg/kg iv, Cyclophosphamide 200 mg/kg iv, rabbit ATG 5 mg/kg iv followed by CD34 selected autologous hematopoietic stem cell transplant"
1869753|NCT01099930|Other|Standard Therapy|Patient will receive standard therapy as decided upon by their treating neurologist.
1869754|NCT01099943|Other|Intervention: Education, Decision Support Tools|Clinic sites randomized to the intervention group will participate in an educational intervention comprised of lectures on antimicrobial resistance and implement decision support tools to guide primary care providers in appropriate antibiotic prescribing for common infectious conditions.
1869755|NCT01099969|Device|Glidescope with Endotrol endotracheal tube|The patients receiving this intervention will be intubated using a Glidescope video laryngoscope with non-styletted Endotrol endotracheal tune
1869756|NCT01099969|Device|Glidescope with styletted regular endotracheal tube|The patients receiving this intervention will be intubated using the glidescope videolaryngoscope and regular endotracheal tube with gliderite stylet.
1869757|NCT01099969|Device|McGrath with Endotrol|The patients in this intervention will be intubated using McGrath videolaryngoscope and non-stlyetted Endotrol endotracheal tube
1869758|NCT01099969|Device|McGrath with Styletted regular Endotracheal tube|The patients receiving this intervention will be intubation using McGrath videolaryngoscope and regular endotracheal tube with gliderite stylet.
1869759|NCT01099995|Other|Hyperbaric oxygen therapy|one dive at 2 absolute atmosphere (1-hour plateau) with 30 min time for compression and decompression - oxygen was delivered via a full face mask at high concentration to achieve a 100% inspired fraction of oxygen or via mechanical ventilation
1869760|NCT01099995|Other|hyperbaric oxygen therapy|two dives at 2 absolute atmosphere (1-hour plateau) with 30 min of compression and 30 min of decompression - oxygen being delivered via a full face mask at 100% inspired oxygen fraction or via mechanical ventilation
1869761|NCT01100008|Procedure|Magnetic resonance imaging (MRI)|MRI cardiac and pulmonary with gadolinium
1869762|NCT01100021|Drug|Tamsulosin and avanafil|tamsulosin - 0.4mg daily for 18 days; avanafil - 200 mg 1 x 2 days
1869763|NCT01100021|Drug|Doxazosin and avanafil|doxazosin - 1 mg 1 x 1 day; 2 mg 1 x 2 days; 4 mg 1 x 4 days; 8 mg 1 x 11 days; avanafil - 200 mg 1 x 1 day
1869764|NCT01100034|Drug|Etanercept|Expected duration of 24 weeks as one course
1869765|NCT01100047|Drug|AZD5069|Oral suspension
1869766|NCT01100047|Drug|Placebo|Oral suspension
1869767|NCT01100060|Drug|azithromycin (AZ) microsphere|AZ microsphere (2000 mg) single dose on Day 1.
1869768|NCT01100060|Drug|test chloroquine (CQ) formulation|Test CQ formulation, 620 mg CQ base, single dose on Day 1.
1869769|NCT01100060|Drug|azithromycin (AZ)|AZ IR 4 x 500 mg tablets, single dose on Day 1.
1869770|NCT01100060|Drug|chloroquine (CQ)|CQ 2 x 500 mg (600 mg CQ base) tablets, single dose on Day 1
1869771|NCT01100086|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 10-mg tablet x 1 dose taken without food
1869772|NCT01100086|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 10-mg tablet x 1 dose taken without food
1869773|NCT01100099|Dietary Supplement|Gluten challenge.|The study population consists of 50 HLA-DQ2+ patients on a gluten free diet, both celiacs and uncertain celiacs. The patients will undergo a oral gluten challenge with four slices of bread daily for three days. Before challenge blood samples will be drawn for tetramer staining of gluten-specific T-cells. The analysis is done at the Institute of Immunology at Rikshospitalet, using FACS analysis. Small intestinal biopsies will be examined for morhological changes and inflammatory gene expression. These procedures with blood samples and biopsies will be repeated after gluten challenge. Registration for clinical symptoms and personality traits will be done by standardised and validated forms. A dietist will perform an interview of the patients.
1869774|NCT01100112|Drug|Budesonide|One Budesonide-MMX 9 mg tablet will be taken in the morning after breakfast for 8 weeks.
1869775|NCT01100125|Drug|sitagliptin|sitagliptin 100mg once daily, orally, for 24 weeks.
1869776|NCT01100125|Drug|insulin dose increase|insulin dose increase
1869777|NCT01100151|Drug|RDC-1036 (ALKS 37)|Capsules for oral administration
1869778|NCT01100151|Drug|Placebo|Capsules for oral administration
1869779|NCT01100164|Drug|Eszopiclone|Eszopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
1869780|NCT01100164|Drug|Zopiclone|Zopiclone - once a day (30 minutes before lying down to sleep for a period of 4 weeks of treatment)
1869781|NCT01100177|Drug|Sunitinib|Sunitinib 37.5mg/m2/d
1869782|NCT01100177|Radiation|Radiation|Radiation therapy (60Gy) 2 Gy per day during 30 days
1869783|NCT01100190|Device|NUVANCE Facial Rejuvenation System|The NUVANCE™ Facial Rejuvenation System is a partially absorbable porous mesh device implant with applicator.
1869784|NCT01100203|Drug|Eplerenone|25 mg once daily 1 week, then 50 mg once daily for another 23 weeks.
1869785|NCT01100216|Other|Nicotine Lozenge|4 mg for 12 days
1869786|NCT01100216|Other|Stonewall Dissolvable Tobacco Pieces|5.6 mg nicotine pieces for 12 days
1869787|NCT01100216|Other|Camel Snus Frost|pouches, 6.2 mg nicotine, for 12 days
1869788|NCT01100216|Other|Skoal Wintergreen|Used at baseline (Days 1 and 2, 5-11) and then at every 7 day wash-out period.
1869789|NCT01100242|Drug|Velcade and Sorafenib|Velcade will be administered intravenously; sorafenib will be self-administered on an outpatient basis. At least 2 courses will be administered to each patient unless there is early progression of disease or unacceptable toxicity. Repeated courses may be given to patients who benefit from the treatment (complete or partial remission or stabilization of disease)
1869790|NCT01100255|Drug|Ketamine infusion|0.5mg/kg IV over 40 minutes
1869791|NCT01100255|Other|Saline|saline infusion
1869792|NCT01100268|Drug|Methylphenidate ER|Subjects will start at 18mg/day; the dose will be increased in increments of 18mg per week to reach 72mg/day.
1869793|NCT01100281|Behavioral|Neuropsychological examination|Examination including especially concept formation
1869794|NCT01100281|Other|MRI|MRI performed in T1-weighted three dimensional sequence
1869795|NCT01100294|Biological|Vaccination with FLUVAL P|"Vaccination with Fluval P monovalent influenza vaccine with 6 μg HA/0.5 ml active ingredient content and aluminium phosphate gel adjuvant.
Dose: 0.25 ml (total 3 μg HA), single dose."
1869796|NCT01100307|Drug|pegaptanib sodium|Intravitreal injection of 0.3 mg every 6 weeks
1869797|NCT01100307|Other|sham injection|sham injection every 6 weeks
1869798|NCT01100320|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken with food
1869799|NCT01100320|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken with food
1869800|NCT01100333|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant hFSH prescribed according to prescriber's judgement
1869801|NCT01100346|Drug|Gonal-f (Follitropin alpha)|A starting dose of 75 IU/day subcutaneously is maintained for a period of 7 to 14 days. The follitropin alpha dose would be subsequently increased by 37.5 IU/day at weekly intervals based on the ovarian response.
1869802|NCT01100359|Drug|carboplatin|
1869803|NCT01100359|Drug|liposome-encapsulated doxorubicin citrate|
1869804|NCT01100359|Other|laboratory biomarker analysis|
1869805|NCT01100359|Procedure|quality-of-life assessment|
1869806|NCT01100372|Drug|gemcitabine hydrochloride|
1869807|NCT01100372|Drug|liposome-encapsulated doxorubicin citrate|
1869808|NCT01100372|Procedure|quality-of-life assessment|
1869809|NCT01100385|Dietary Supplement|Ateronon|Tomato extract (lycopene) capsule, taken once daily for 56 days
1869810|NCT01100385|Dietary Supplement|Placebo|Matched placebo capsule, taken once daily for 56 days
1869811|NCT01100398|Procedure|possible liver biopsy and serum collection|All patients with a positive ultrasound for hepatic steatosis offered a liver biopsy after obtaining fasting blood work that included a complete blood count, coagulation studies, liver function tests, fasting lipid panel, glucose and insulin. Patients with a negative ultrasound for fatty liver are not referred for liver biopsy and are considered as completed study patients. Serum is also stored for adipokine and cytokine analysis. A study investigator using a 14g Bard Monopty biopsy gun performs the liver biopsy.
1869812|NCT01100411|Device|Air Optix Aqua|Contact lens material: Lotrafilcon A
1869813|NCT01100411|Device|Biofinity|Contact lens material: Comfilcon A
1869814|NCT01100411|Device|Proclear|Contact lens material: Omafilcon A
1869815|NCT01100411|Device|Acuvue Oasys|Contact lens material: Senofilcon A
1869816|NCT01100411|Device|Acuvue 2|Contact lens material: Etafilcon A
1869817|NCT01100411|Device|Purevision|Contact lens material: Balafilcon A
1869818|NCT01100424|Device|Opti-Free RepleniSH|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
1869819|NCT01100424|Device|ReNu MultiPlus|Commercially available contact lens solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
1869820|NCT01100424|Device|Balafilcon A|Commercially available silicone hydrogel contact lenses removed from blister pack and soaked overnight in Opti-Free Replenish, ReNu MultiPlus, or Unisol 4, then applied to the eye and worn for 2 hours.
1869821|NCT01100424|Other|Unisol 4|Commercially available non preserved sterile saline solution used for pre-soaking balafilcon A contact lenses overnight prior to lens insertion.
1869822|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) crush|Placebo capsules plus EMBEDA capsules crushed and mixed in solution administered orally at each patient's stable dose, given either once daily or twice daily
1869823|NCT01100437|Drug|EMBEDA™ (morphine sulfate/naltrexone hydrochloride) whole|EMBEDA capsules, administered orally and intact at each patient's stable dose, given either once daily or twice daily with 150mL placebo solution
1869824|NCT01100450|Behavioral|Progressive Resistance Training|12-week progressive resistance training (PRT) exercise program
1869825|NCT01100463|Drug|Ointment|Twice daily lotion to prevent HFS
1869826|NCT01100463|Drug|0.1% Uracil Ointment|Twice daily lotion to prevent HFS
1869827|NCT01100476|Device|Endovascular Diagnostic Procedures|Patients underwent a percutaneous diagnostic procedure utilizing a 5F procedural sheath in the common femoral artery
1869828|NCT01100489|Radiation|external beam radiation therapy|External beam breast radiation therapy 5 days a week for 5 weeks in the absence of disease progression or unacceptable toxicity.
1869829|NCT01100489|Other|questionnaire administration|Ancillary studies: The patient will complete the Cosmesis /QOL form (Appendix II) and the treating physician will complete the Cosmetic Guidelines (skin assessment) form for baseline data (Appendix I).
1869830|NCT01100489|Procedure|therapeutic conventional surgery|Patients will undergo excisional biopsy or needle localization removal of the tumor. Patients with margins < 2 mm undergo re-excision of the biopsy cavity. Surgical clips should be placed at the time of tylectomy to define the excision cavities. Ideally, clips are to be placed marking the superficial, deep, right, left, inferior, and superior dimensions of the tylectomy or re-excision cavities.
1869831|NCT01092715|Procedure|Spinal mobilization|Non thrust mobilization to the cervical spine
1869832|NCT01092715|Procedure|Massage|Sedative massage to cervical paraspinal muscles
1869833|NCT01092715|Procedure|Neck exercises|Range of motion exercises to include foraminal opening
1869834|NCT01092728|Drug|Dasatinib|100 mg daily.
1869835|NCT01092728|Procedure|Surgical Resection|Complete surgical resection of tumor(s).
1869836|NCT01092741|Drug|Gleevec|400 mg P.O. twice daily (800 mg total daily dose)
1869837|NCT01092754|Procedure|MRI|contrast enhanced MRI
1869838|NCT01092754|Procedure|MRI|contrast enhanced MRI
1869839|NCT01092754|Drug|Gadoversetamide|Subjects will receive a single dose of Optimark(0.1 mmol/kg)as a bolus thru a peripheral IV line at 1-2 mL/sec followed by a saline flush during their medically necessary MRI .
1869840|NCT01092767|Device|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
1869841|NCT01092780|Drug|MK-7288|one or two 10 mg capsules, orally, single dose
1869842|NCT01092780|Drug|Placebo to MK-7288|one or two capsules, orally, single dose
1869843|NCT01092780|Drug|Modafinil|two 100 mg tablets, orally, single dose
1869844|NCT01092780|Drug|Placebo to modafinil|two 100 mg tablets, orally, single dose
1869845|NCT01092793|Dietary Supplement|Krill|
1869846|NCT01092793|Dietary Supplement|Fish oil|
1869847|NCT01092806|Drug|Tacrolimus|Two different formulations of the drug is compared. The dose is adjusted according to whole blood concentrations in accordance with center protocol. Switch between the two formulations are done by a 1:1 conversion of daily dose.
1869848|NCT01092819|Other|Current standard of care for acute ischemic stroke other than IV rtPA or other IA therapies|The objective of this study is to determine the natural history of acute ischemic stroke from large vessel thromboembolism in the brain. Patients with current standard of care other than IV rtPA or IA therapies will be studied.
1869849|NCT01092832|Drug|voriconazole|"Subjects 12 - <18 yrs (excluding subjects 12 - 14 yrs weighing <50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h.
Subjects 2 - <12 yrs, and subjects 12 - 14 weighing <50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg).
Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days."
1869850|NCT01092845|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
1869851|NCT01092845|Drug|PF-04457845 / matched placebo|PF-04457845 4 mg tablet once daily / matched placebo
1869897|NCT01093183|Other|laboratory biomarker analysis|Correlative studies
1869852|NCT01092858|Drug|Testosterone Undeconate (Nebido, BAY86-5037)|Testosterone undecanoate 1000 mg (4 ml) i.m. injection at baseline, at week 6, at week 18, at week 30 and at week 42, respectively
1869853|NCT01092858|Drug|Placebo|Matching placebo i.m. injections at baseline, at week 6, at week 18 at week 30 and at week 42, respectively
1869854|NCT01092884|Dietary Supplement|Polypodium leucotomos extract|240 mg capsule of Polypodium leucotomos extract will be taken orally three times daily
1869855|NCT01092884|Other|Placebo|This placebo capsule will be taken orally three times daily
1869856|NCT01092910|Device|Esteem Totally Implantable Hearing System|The Esteem System is a totally implantable hearing system designed to improve hearing in adult subjects suffering from mild to severe hearing loss that is sensorineural in origin.
1869857|NCT01092923|Drug|sevoflurane on air/O2|sevoflurane on air/O2
1869858|NCT01092923|Drug|sevoflurane in N2O/O2|sevoflurane in N2O/O2
1869859|NCT01092936|Other|Rating Scale administration|Movement Disorder Society_Unified Parkinson's Disease Rating Scale will be submitted to the patient (with the help of the caregiver) in a single visit lasting about 40 minutes.
1869860|NCT01092949|Device|MRI|MRI, 45 minutes
1869861|NCT01092962|Drug|Cyclophosphamide|2mg/kg/day during 12 weeks (cumulative dose 148mg/kg)
1869862|NCT01092962|Drug|Mycophenolate mofetil|1200mg/m²/jour in two divided doses during 18 months
1869863|NCT01092975|Drug|phenylephrine solution|Subjects will receive up to 40 dose of topical phenylephrine at the specified dose level.
1869864|NCT01092988|Device|Exablate 2100|MR guided focused ultrasound
1869865|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
1869866|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation
1869867|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
1869868|NCT01093001|Other|Echo|Two dimensional echocardiography will be performed to reassess Tricuspid Regurgitation.
1869869|NCT01093014|Behavioral|Low-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, using either a lab-based system or a portable system for up to 1 year.
1869870|NCT01093014|Behavioral|High-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke summated, high-force contractions, using either a lab-based system or a portable system for up to 1 year.
1869871|NCT01093014|Behavioral|Sequential low-force and high-force muscle stimulation|Electrical stimulation of paralyzed muscle in seated or standing to evoke non-summated, low-force contractions, followed by: 1) a 1-month washout period, then; 2) electrical stimulation to evoke summated, high-force contractions.
1869872|NCT01093027|Other|15 - 30|The upper limb with tremor will be cooled with 15 degrees Celsius water for 10 minutes at Visit 1 and with 30 degrees Celsius water for 10 minutes at Visit 2.
1869873|NCT01093027|Other|30 - 15|The upper limb with tremor will be cooled with 30 degrees Celsius water for 10 minutes at Visit 1 and with 15 degrees Celsius water for 10 minutes at Visit 2.
1869874|NCT01093040|Drug|CAT-354|150 mg CAT-354 or placebo given SC on Day 1
1869875|NCT01093040|Drug|CAT-354|300 mg CAT-354 or placebo given SC on Day 1
1869876|NCT01093040|Drug|CAT 354|600 mg CAT-354 or placebo given SC on Day 1
1869877|NCT01093053|Behavioral|Mind-Body Skills Groups|The mind-body skills group program teaches participants how to do meditation, guided imagery, breathing techniques, and biofeedback. These mind-body techniques are taught and practiced in small groups of 8 to 10 people and also contain an element of social support.
1869878|NCT01093053|Other|Standard Treatment|May include individual or group psychotherapy consisting of cognitive behavioral therapy or present-centered (i.e. unrelated to mindfulness) psychotherapy as well as medication management. Medications for depression, anxiety, and sleep disorders are the most commonly used in standard treatment.
1869879|NCT01093066|Drug|optimal TURB|The TURB will always try to be optically complete.
1869880|NCT01093079|Procedure|Laparoscopic partial nephrectomy|Laparoscopic partial nephrectomy
1869881|NCT01093079|Procedure|Open partial nephrectomy|Open partial nephrectomy
1869882|NCT01093092|Dietary Supplement|Calcitriol|Given PO
1869883|NCT01093092|Drug|Cisplatin|Given IV
1869884|NCT01093092|Drug|Gemcitabine Hydrochloride|Given IV
1869885|NCT01093092|Other|Pharmacological Study|Correlative studies
1869886|NCT01093118|Drug|TMI-358|Micro implant monthly x 3
1869887|NCT01093118|Drug|MMI-467|Micro implant monthly x 3
1869888|NCT01093131|Other|Oral hydration|Oral hydration with 500 mL of water to be started 4 hours prior to contrast exposure and stopped 2 hours prior to procedure followed by oral hydration with 600 mL of water post procedure
1869889|NCT01093131|Drug|Oral sodium bicarbonate|Oral hydration with 500 mL of water to be started 4 hours prior to procedure and stopped 2 hours prior to contrast exposure, with the addition of 3.9 grams (46.4 mEq) of oral sodium bicarbonate to be given 20 minutes prior to contrast exposure followed by 1.95 grams (30.4 mEq) of oral sodium bicarbonate 2 hours and 4 hours after the initial dose
1869890|NCT01093131|Other|Intravenous Hydration|Pretreatment with a 3 mL/kg bolus of intravenous normal saline solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1ml/kg per for 6 hours after the procedure.
1869891|NCT01093131|Drug|Intravenous sodium bicarbonate|Pretreatment with a 3 mL/kg bolus of intravenous sodium bicarbonate solution (154 mEq/L) over 1 hour, immediately prior to contrast exposure followed by intravenous infusion of 1 mL/kg for 6 hours after the procedure.
1869892|NCT01093144|Device|pelvic measurements using the LaborPro Device|pelvic measurements using the LaborPro Device,ultrasound non invasive measurements
1869893|NCT01093157|Drug|Adrenocorticotrophic hormone ACTH|There will be two arms to the study: one arm receive 40 units and the second arm 80 units of the ACTH gel subcutaneously both given in a dose escalating frequency beginning at once every two weeks escalating to a maximum of twice per week over a total of three months exposed.An ammendment(approved by Health Canada and the UHN IRB allows an additional 1 month of the perscribed therapy of ACTH )if there is an improvement in proteinuria at the end of the 3 month exposure.
1869894|NCT01093170|Drug|RNA-144101|Intravitreous administration of RNA-144101
1869895|NCT01093183|Drug|lenalidomide|Given PO
1869900|NCT01093196|Drug|Melphalan, Prednisone, Lenalidomide|"Induction: 9 courses every 28 days - oral Lenalidomide for 21 days followed by a 7 days rest period; oral Melphalan for 4 days, followed by a 24 days rest period [different doses according to the age of patients (65-75 or >75 years old);oral Prednisone for 4 days followed by a 24 day rest period.
Maintenance: ARM A1, B1 and C1 - oral Lenalidomide on day 1-21 followed by a 7 days rest period.
ARM A2,B2 and C2:oral Lenalidomide on day 1-21 followed by a 7 days rest period and oral Prednisone every other day.Each cycle will be repeated every 28 days, until any sign of disease progression(PD)."
1869901|NCT01093196|Drug|Cyclophosphamide, Prednisone, Lenalidomide|Induction: 9 cycles every 28 days:Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28;Cyclophosphamide will be given orally at the dose of 50 mg /day for 21 days followed by a 7 day rest period (days 1 to 28) in patients 65-75 years old and 50 mg every other day (days 1 to 20 followed by a 8 days rest period [day 21 to 28]) in patients older than 75 years.Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28.Each cycle will be repeated every 28 days, until any sign of disease progression(PD).
1869902|NCT01093196|Drug|Lenalidomide, dexamethasone|Induction: 9 course every 28 days-Lenalidomide will be given orally at the dose of 25 mg/day for 21 days followed by a 7 days rest period (day 22 to 28); Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15 and 22 every 28 days in patients 65-75 years old and at the dose of 20 mg on days 1,8,15 and 22 every 28 days in patients older than 75 years. Maintenance:After 2-3 months from the completion of the last induction cycle, patients will start maintenance therapy according to physician willing and general dose-reduction rules.ARM A1, B1 and C1:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period. ARM A2, B2 and C2:Lenalidomide will be given at the dose of 10 mg/day on day 1-21 followed by a 7 days rest period; Prednisone will be given orally at the dose of 25 mg every other day (days 1 to 28) Each cycle will be repeated every 28 days, until any sign of disease progression (PD).
1869903|NCT01093209|Device|Interferential Laser Therapy|PROCEDURE: Interventional group: Two independents and identical probes. Energy dose per point and per probe: 5 J. Continuous emission. Treatment time:8 minutes. Sessions: 10. Frequency of the sessions: daily. Irradiation technique: handily, in contact and at 7 points over distal pathway of median nerve.Control group: Sham laser:650 nm.Scanning mode.Outpout power:1 mW.
1869904|NCT01093222|Drug|Erlotinib Hydrochloride|Given PO
1869905|NCT01093222|Drug|Sorafenib Tosylate|Given PO
1869906|NCT01093235|Biological|bevacizumab|
1869907|NCT01093235|Drug|cyclophosphamide|
1869908|NCT01093235|Drug|docetaxel|
1869909|NCT01093235|Drug|epirubicin hydrochloride|
1869910|NCT01093235|Drug|fluorouracil|
1869911|NCT01093235|Procedure|assessment of therapy complications|
1869912|NCT01093235|Procedure|neoadjuvant therapy|
1869913|NCT01093235|Procedure|quality-of-life assessment|
1869914|NCT01093235|Procedure|therapeutic conventional surgery|
1869915|NCT01093261|Drug|Placebo|"Placebo:
continuous intra venous infusion of placebo n°1 for 10 days. enteral administration of placebo n°2 for 10 days."
1869916|NCT01093261|Drug|Hydrocortisone Fludrocortisone|HYDROCORTISONE: 200 mg.day-1 for 7 days, 100 mg.day-1 on day 8 and 9, 50 mg on day-10 (continuous intravenous infusion) FLUDROCORTISONE: 50 microg.day-1 for 10 days (per os)
1869917|NCT01093274|Drug|Sodium Picosulphate|2 Sachets
1869918|NCT01093274|Drug|Polyethylene Glycol|3 Liters solution
1869919|NCT01093300|Device|Paclitaxel-eluting balloon catheter|
1869920|NCT01093300|Device|Everolimus-eluting stent|
1869921|NCT01093313|Behavioral|Cognitive therapy|
1869922|NCT01093313|Behavioral|attention training|
1869923|NCT01093326|Drug|Ponesimod 10 mg|Ponesimod 10 mg oral use
1869924|NCT01093326|Drug|Ponesimod 20 mg|Ponesimod 20 mg oral use
1869925|NCT01093326|Drug|Ponesimod 40 mg|Ponesimod 40 mg oral use
1869926|NCT01093352|Procedure|Alveolar-decortication.|Following surgical exposure of the impacted tooth, the surgeon will prepare small holes (perforations) and/or grooves in the cortical bone surrounding the exposed tooth as well as in the buccal bone.
1869927|NCT01093365|Drug|Varenicline|"0.0 mg orally twice per day for three days (placebo)
0.5 mg orally twice per day for three days
1.0 mg orally twice per day for three days"
1869928|NCT01093391|Device|DRUG ELUTING STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
1869929|NCT01093391|Device|BARE METAL STENT|Site preparation and percutaneous access should be performed as per standard hospital procedures.It is recommended to cross the target lesion with 0.014-inch exchange-length guide wire. The involved lesion should be predilated with appropriately sized balloons using standard techniques. It is strongly encouraged that the Investigators use similar materials and techniques throughout the study to maintain consistency and standardization of care.A stent consists of an endovascular prosthesis with a metallic mesh structure that is implanted at the site of the artery blockage via catheterization procedure. The objective of stenting is to obtain an angiographic appearance of the expanded stent only outside the limits of the target vessel filled with contrast medium.
1869930|NCT01093404|Procedure|Thrombus aspiration|Aspiration of thrombus material before angioplasty
1869931|NCT01093417|Drug|Vitamin D|Vitamin D 4000 IU will be administered to enrollees on the active comparator arm
1869932|NCT01093417|Other|Placebo|Placebo pills will be administered to enrollees in this arm
1869933|NCT01093430|Procedure|Anterior superior iliac spine|The position of the right and left laparoscopic port sites will be determined by palpation of the nearby anterior superior iliac spine of the pelvic bone.
1869934|NCT01093430|Procedure|Control|The position of the right and left laparoscopic port sites will be determined by visual inspection of the anterior abdominal wall.
1869935|NCT01093443|Drug|ovarian stimulation|rFSH with GnRH antagonists
1869943|NCT01093521|Drug|100 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at a dose of 100 mg/m2/day
1869944|NCT01093521|Drug|200 mg/m2 dose|5 day infusion of gallium nitrate (IV Ganite®) at 200 mg/m2/day
1869950|NCT01093573|Drug|midostaurin|Given orally
1869951|NCT01093573|Drug|azacitidine|Given IV
1869952|NCT01093573|Other|laboratory biomarker analysis|Correlative study
1869953|NCT01093573|Other|bone marrow aspiration|Correlative study
1869954|NCT01093573|Other|liquid chromatography|Correlative study
1869955|NCT01093573|Other|flow cytometry|Correlative study
1869956|NCT01093573|Other|mutation analysis|Correlative study
1869957|NCT01093573|Other|pharmacological study|Correlative study
1869958|NCT01093573|Other|mass spectrometry|Correlative study
1869959|NCT01093573|Other|protein expression analysis|Correlative study
1869960|NCT01093586|Procedure|double-unit umbilical cord blood transplantation|Undergo transplantation
1869961|NCT01093586|Other|cytogenetic analysis|Correlative studies
1869962|NCT01093586|Procedure|bone marrow aspiration|Correlative studies
1869963|NCT01093586|Other|fluorescence in situ hybridization|Correlative studies
1869964|NCT01093586|Drug|busulfan|Given orally
1869965|NCT01093586|Drug|cyclophosphamide|Given IV
1869966|NCT01093586|Drug|anti-thymocyte globulin|Given IV
1869967|NCT01093586|Drug|methylprednisolone|Given IV
1869968|NCT01093586|Drug|cyclosporine|Given IV
1869969|NCT01093586|Drug|mycophenolate mofetil|Given orally or IV
1869970|NCT01093586|Other|flow cytometry|Correlative studies
1869971|NCT01093586|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo transplantation
1869972|NCT01093599|Behavioral|Quit Line plus MTS|This provides the quit line intervention plus the Mindfulness for Smokers Intervention.
1869973|NCT01093599|Behavioral|Quit Line Only|The quit line only intervention includes phone counseling, Quit Smoking Materials and 4 weeks of nicotine patches.
1869974|NCT01093612|Procedure|positron emission tomography|PET images performed on a GE Discovery 16 Ste PET-CT scanner
1869975|NCT01093612|Radiation|copper Cu 64-DOTA-trastuzumab|15 mCi of Cu 64-DOTA-trastuzumab, total trastuzumab dose less than 5 mg.
1869976|NCT01093612|Procedure|Biopsy|Correlative Studies
1869977|NCT01093612|Other|Immunohistochemistry staining method|Correlative studies
1869978|NCT01093612|Other|laboratory biomarker analysis|Correlative studies
1869979|NCT01093612|Genetic|mutation analysis|Correlative studies
1869980|NCT01093625|Device|Narafilcon B Contact Lens|
1869981|NCT01093625|Device|Spectacles|spectacle wearers
1869982|NCT01093638|Biological|Oral Formulation of Insulin|Oral formulation of insulin fed concomitantly with infant formula
1869983|NCT01093638|Biological|Placebo|Oral formulation of placebo fed concomitantly with infant formula
1869984|NCT01093651|Drug|Sitagliptin|100 mg sitagliptin daily for 4-6 months
1869985|NCT01093651|Drug|Placebo|Daily placebo for 4-6 months
1869986|NCT01093664|Biological|AFFITOPE AD02|s.c. injection
1869987|NCT01093677|Drug|LIM-0705|Oral solution 750 mg LIM 0705 BID for 14 days.
1869988|NCT01093677|Drug|Placebo|Oral solution placebo BID for 14 days.
1869989|NCT01093690|Drug|metoclopramide|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus metoclopramide 20 mg oral four times a day on day 2-5
1869990|NCT01093690|Drug|placebo|ondansetron 8 mg orally twice a day on days 2-5 and dexamethasone 8 mg orally twice a day on days 2-4 plus placebo 20 mg oral four times a day on day 2-5
1869991|NCT01093703|Other|Medication Adjustment|"Awake SBP≤135/85mmHg and patient is on once daily medications: Switch BP medications to pm period.
Awake SBP SBP≤135/85mmHg and patient is on bid medications (e.g. metoprolol bid): Increase pm dose of the medication. If medication is already is at maximal dose or there is contraindication for increasing the dose (e.g. bradycardia), add another BP medicine in the evening time.
Awake SBP≤135/85mmHg and patient is not on anti-hypertensive medications: Add BP medication at the pm period.
Awake SBP>135/85mmHg: increase dose of antihypertensive medications or add more medications. All medications to be given in the evening time."
1869992|NCT01093716|Device|Magstim Rapid® (rTMS)|Ten daily sessions of rTMS treatments using Magstim Rapid® device (10 Hz, 110% of the MT, 4.9 seconds per train, inter-train interval of 30 seconds, and 20 trains per session) with an air cooled figure-of-eight coil over either right or left DLPFC
1869993|NCT01093729|Drug|HM11260C|HM11260C 0.5mcg/kg or Placebo
1869994|NCT01093729|Drug|HM11260C|HM11260C 2mcg/kg or Placebo
1869995|NCT01093729|Drug|HM11260C|HM11260C 4mcg/kg or Placebo
1869996|NCT01093729|Drug|HM11260C|HM11260C 8mcg/kg or Placebo
1869997|NCT01093729|Drug|HM11260C|HM11260C 14mcg/kg or Placebo
1869998|NCT01093742|Drug|HM10560A|Subcutaneously administrate at 0 hour on Day 1
1869999|NCT01093742|Drug|Placebo|Placebo
1870000|NCT01093755|Drug|dexlansoprazole|Intensive acid suppression with dexlansoprazole 60-90 mg/day for 6 months
1870001|NCT01093755|Drug|Omeprazole|Escalating doses of omeprazole (20-60 mg/day) for 6 months
1870002|NCT01093768|Drug|Oxytocin|
1870003|NCT01093768|Drug|Vasopressin|
1870004|NCT01093781|Drug|Aliskiren|Aliskiren dose will begin with 150mg per day and later up-titrated to the maximum available dose of 300mg per day.
1870005|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 500 mg metformin|Co-administration of 50 mg sitagliptin and 500 mg China-sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met500) after fasting for at least 10 hours.
1871270|NCT01109784|Drug|clopidogrel|clopidogrel per os 150mg/day
1991272|NCT01290315|Drug|Ferric Carboxymaltose (FCM)|One 500 mg dose at 100 mg/minute (Cohort I) or 750 mg dose at 100 mg/minute (Cohort II)
1870006|NCT01093794|Drug|sitagliptin/metformin 50 mg/500 mg tablet|Single dose administration of the final marketing image (FMI) sitagliptin/metformin 50 mg/500 mg fixed-dose combination (FDC) tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
1870007|NCT01093794|Drug|Co-administration of 50 mg sitagliptin and 850 mg metformin|Co-administration of 50 mg sitagliptin and 850 mg China sourced metformin as individual tablets with 240 ml water on Day 1 of the relevant treatment period (Sit + Met850) after fasting for at least 10 hours.
1870008|NCT01093794|Drug|sitagliptin/metformin 50 mg/850 mg tablet|Single dose administration of the FMI sitagliptin/metformin 50 mg/850 mg FDC tablet with 240 ml water on Day 1 of the relevant treatment period (SitMet850 FDC) after fasting for at least 10 hours.
1870009|NCT01093807|Drug|Placebo|once daily for 10 weeks
1870010|NCT01093807|Drug|Lercanidipine|10 mg once daily for 10 weeks
1870011|NCT01093807|Drug|Lercanidipine|20 mg once daily for 10 weeks
1870012|NCT01093807|Drug|Enalapril|10 mg once daily for 10 weeks
1870013|NCT01093807|Drug|Enalapril|20 mg once daily for 10 weeks
1870014|NCT01093807|Drug|Lercanidipine + Enalapril|10/10 mg once daily for 10 weeks
1870015|NCT01093807|Drug|Lercanidipine + Enalapril|10/20 mg once daily for 10 weeks
1870016|NCT01093807|Drug|Lercanidipine + Enalapril|20/10 mg once daily for 10 weeks
1870017|NCT01093807|Drug|Lercanidipine + Enalapril|20/20 mg once daily for 10 weeks
1870018|NCT01093820|Drug|methoxy-polyethyleneglycol epoetin beta|Mircera® 150μg i.v., before / during reperfusion of the infarct related coronary artery followed by Mircera® 30μg s.c. at 1 and 2 months post-MI
1870019|NCT01093833|Device|BD Continuous glucose monitor (BD CGM)|Continuous glucose monitoring for 12-14 hours
1870020|NCT01093833|Device|YSI Glucose Analyzer|Continuous glucose monitoring for 12-14 hours
1870021|NCT01093833|Device|Medtronic Guardian CGM|Continuous glucose monitoring for 12-14 hours
1870022|NCT01093846|Drug|AIN457|300mg every 4 weeks
1870023|NCT01093846|Drug|AIN457|300mg every 2 weeks
1870024|NCT01093846|Drug|Placebo AIN457|Placebo to AIN457
1870025|NCT01093859|Drug|PRX-105|Sterile solution for intravenous injection
1870026|NCT01093872|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Upon recruitment, all patients will undergo a 1 week treatment consisting of 5 rTMS sessions
Repetitive TMS consists of 1000 stimulations/ day at 1 Hz and 110% of the motor threshold, for five consecutive days over the left AC."
1870028|NCT01093911|Biological|CDP7657|Ascending single doses of CDP7657
1870029|NCT01093911|Other|Placebo|Placebo: 0.9% sodium chloride aqueous solution
1870030|NCT01093924|Behavioral|PILI 'Ohana 18-month weight loss maintenance|All participants will receive a 8 lesson 3-month weight loss intervention. They will then be randomized. Those continuing with the intervention will receive 17 more lessons delivered face-to-face or via DVD over 15 months for a total of 18 months. Each lesson lasts approximately 1 hour and helps participants integrate healthy eating and physical activity into their lifestyles. Participants will also be encouraged to attend 13 community activities during the last 13 months of the intervention.
1870031|NCT01093937|Drug|varenicline|One to four 0.5 mg capsules (0.5-2.0 mg) orally per day for ten weeks.
1870032|NCT01093963|Drug|Lisdexamfetamine|oral; 20-70mg/day
1870033|NCT01093963|Drug|Placebo|oral; 20-70mg/day
1870034|NCT01093976|Drug|Dronabinol|2.5mg-15mg by mouth once a day for twelve-weeks
1870035|NCT01093989|Dietary Supplement|Ferrous Sulphate Syrup|Iron therapy will consist of a three-month course of ferrous sulphate syrup. For children with Hb ≥ 7 g/dL, each daily dose will be based on 2 mg iron/kg body weight.
1870036|NCT01094002|Other|Occupational therapy intervention|"Day 1: Physical, functional, cognitive, social, and emotional assessment. Need analysis for iatrogenic prevention, retraining in BADL and IADL, technical aids, instructions in patient mobilisation techniques, and for social and occupational motivation.
Day 2 until discharge: 45-minute sessions. Cognitive stimulation and confusional syndrome prevention, instructions to the caregivers on how to prevent complications such as immobility, delirium, falls, urinary incontinence, or pressure sores, and patient stimulation, retraining in activities of daily living.
Day of discharge: Instruction for caregivers on managing the patient's residual deficits, assessment for technical aids, recommendations for patient increased independence in ADL, and social and occupational activities."
1870037|NCT01094015|Drug|lidocaine-prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
1870038|NCT01094015|Other|gel application for the transmission of ultrasound|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5ml syringe without needle. Application, with a swab in gel ectocervix
1870039|NCT01094028|Drug|Oxytocin|20 IU of oxytocin diluted with 26 ml of saline.The medication was injected directly in the umbilical vein after clamping. The injection was performed with a 30-ml syringe and an 18-gauge needle around 1 to 2 cm from the introitus. The solution was injected slowly over 1 minute, and at the end of the injection, the solution was milked toward the cord insertion
1870040|NCT01094041|Other|Gluten free diet|A 4-week gluten free diet provided
1870041|NCT01094041|Other|Gluten rich diet|A 4-week gluten rich diet is provided
1870042|NCT01094054|Procedure|Adjustable gastric banding|Placement of adjustable gastric band - laparoscopically
1870043|NCT01094054|Behavioral|Dietary and lifestyle modification|"Dietary and lifestyle modification
Subjects will meet with a dietitian and a psychologist on a weekly basis and consume a diet matched to that of the banding arm"
1870044|NCT01094067|Drug|ACT-050089|5 mg/h intravenously, Tezosentan
1870045|NCT01094067|Other|Placebo|Matching placebo
1870046|NCT01094080|Other|standard infant formula|infants are fed a commercial formula
1870047|NCT01094080|Other|modified infant formula|the modified infant formula has a different protein content than the standard formula and long chain polyunsaturated fatty acids are added
1870048|NCT01094080|Other|breast milk|infants are breast fed
1870049|NCT01094093|Drug|AMG 139|Six dose levels of AMG 139 administered as a single dose SC or IV in healthy volunteers (Part A) and subjects with moderate-severe psoriasis (Part B).
1870050|NCT01094106|Drug|Ropivacaine 0,75%|Postoperative wound infusion 2 ml/ h/ 48h
1870051|NCT01094106|Drug|NaCl 0,9%|Postoperative wound infusion 2 ml/h/48h
1870052|NCT01094119|Device|heated blanket|heated blanket
1870053|NCT01094119|Device|heated pad|patients will be warmed with a heated pad during surgery.
1870054|NCT01094132|Device|Multispectral Digital Colposcope (MDC)|"The MDC has 2 components: an optical probe & a multispectral colposcope. The optical wand makes use of fluorescence & reflectance spectroscopy; a light is shone on the cervix and the wand reports what it sees to a computer. Since cancer & healthy cells interact differently with light, a computer can detect abnormalities. The multispectral colposcope is based on a conventional colposcope, which is already widely used. However, it is also able to produce fluorescence & polarized reflectance images of the entire cervix. Computer analysis of these images can detect abnormalities on the cervix, defining their location and shape.
This trial involves combined analysis of MDC data. This may lead to more effective diagnosis of cervical abnormalities. The MDC will be used with standard care for patients presenting with cervical abnormalities (as detected by a Pap test). The MDC will not be used to guide patient management decisions.
All study subjects will receive this same intervention."
1870055|NCT01094145|Other|Deep brain stimulation|DBS in the Nucleus basalis Meynert
1870056|NCT01094158|Drug|Aramchol|100mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
1870057|NCT01094158|Drug|Aramchol|300 mg/d tablets packaged in bottles given orally once a day in the morning within 10 minutes after breakfast for a total period time of 3 months
1870058|NCT01094158|Drug|Placebo|tablets packaged in bottles given orally once a day in the morning within approximately 10 minutes after breakfast
1870059|NCT01094171|Biological|Poliorix TM|Intramuscular administration, 3 doses
1870060|NCT01094171|Biological|Infanrix TM|Intramuscular administration, 3 doses
1870062|NCT01094210|Drug|Fluorides, Topical|500 ppm F and 1100 ppm F topical toothpastes comprise sodium fluoride in each.
1870063|NCT01094223|Behavioral|Mindfulness Based Relapse Prevention|Meditation based therapy group incorporating relapse prevention skills training
1870064|NCT01094223|Behavioral|Health Education|Psychoeducation group focused on various topics pertaining to physical health
1870065|NCT01094236|Behavioral|On the Playground behavior management program|Treatment school playground supervisors were show the CD intervention. Control school playground supervisors were given a video on playground equipment safety. All school staff subjects were assessed before the intervention and 75 days following the supervisor intervention. Students were assessed before the intervention, and then 45 days and 75 days following the supervisor intervention. School Administrators were assessed before the intervention, and then 30 and 60 days after the supervisor intervention - school administrators at treatment schools had access to a treatment binder with CDs and worksheets, while the control school administrators did not.
1870066|NCT01094249|Drug|divalproex sodium ER/paliperidone ER|Divalproex sodium ER (dose determined from the patients prescreening therapeutic dose) once daily from Day 1 through Day 7 and once daily in combination with paliperidone ER 12 mg from Day 8 through Day 12
1870067|NCT01094262|Drug|Oxycodone CR (standard pain medication)|Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
1870068|NCT01094262|Drug|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
1870069|NCT01094262|Drug|JNJ-42160443|JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
1870070|NCT01094262|Drug|Placebo|Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
1870071|NCT01094275|Drug|Clopidogrel 75mg, Omeprazole 20mg|Clopidogrel and or Omeprazole as applicable
1870072|NCT01094288|Drug|MLN8237 plus docetaxel|Patients will receive a standard starting dose of docetaxel on Day 1 in combination with escalating doses of MLN8237 administered orally twice/day Days 1 through 7, repeated in 21-day cycles, except Cycle 2 when the MLN8237 dosing will be for maximum 5 days starting on Day 3 and continuing through Day 7
1870073|NCT01094301|Device|The SPR System|The SPR System is an investigational two-staged device which delivers stimulation to the muscles in the shoulder. Subjects with chronic post-stroke shoulder pain who meet eligibility criteria for the first stage (SPR Trial Stage) will receive a temporary Lead and External Stimulator. Subjects who qualify and who agreed to proceed will advance to the second stage (SPR Implant Stage) which uses an Implantable Pulse Generator (IPG) and Implantable Lead. Subjects will be followed until 36-months after IPG stimulation has been started.
1870074|NCT01094314|Other|embryo culture medium|comparison between two types of embryo culture medium
1870075|NCT01094340|Drug|Thalidomide|fixed dose over 8 clinic visits
1870078|NCT01094366|Procedure|Paracervical Block|Subject receives 20 mL paracervical block with 18 mL of 1% Lidocaine solution buffered with 2 mL 8.4% sodium bicarbonate for pain control.
1870079|NCT01094366|Procedure|Sham Paracervical Block|In the non-intervention group, the surgeon performs a sham PCB during which 2 mL buffered lidocaine solution are injected at the tenaculum site, after which a capped needle gently simulates the standard PCB procedure.
1871304|NCT01110044|Biological|Rotarix™|Oral, two doses
1998516|NCT01285037|Drug|LY2801653|LY2801653 given orally once daily during 28-day cycles. Participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
1870080|NCT01094379|Procedure|Standard laparoscopic cholecystectomy|Laparoscopic cholecystectomy using four entry sites to the abdominal cavity
1870081|NCT01094379|Procedure|Single incision laparoscopic cholecystectomy|Laparoscopic cholecystectomy using one entry site to the abdominal cavity
1870082|NCT01094405|Biological|Recombinant Epstein-Barr Virus (EBV) Vaccine|
1870083|NCT01094418|Other|Nerve conduction studies ( NCS) of the peripheral nerves|"Standard NCS of the sural, superficial peroneal sensory nerves, peroneal, tibial motor nerves, radial and median sensory nerves, median motor nerves, F-wave studies of the Tibial and median nerves.
NCS of the distal sensory nerves; dorsal sural Medial dorsal cutaneous and medial plantar nerves."
1870084|NCT01094444|Other|Vitamin K3|Lotion containing 1.5 mM Vitamin K3
1870085|NCT01094457|Drug|aspirin, clopidogrel|patients in the standard group received standard dual antiplatelet therapy: aspirin 300mg/d for 30 days followed by 100mg/d indefinitely, clopidogrel 75mg/d for at least 1 year
1870086|NCT01094457|Drug|aspirin, clopidogrel, cilostazol|Firstly,all patients in this group were received aspirin 300mg/d and clopidogrel 150mg/d for 3 days. Then a platelet aggregation function test was performed. The regimen will lasted for another 27 days if patients were judged as responsive to current clopidogrel dose. Patients still with clopidogrel resistance were then randomly assigned to receive clopidogrel 75mg/d plus cilostazol 100mg, twice per day or clopidogrel 150mg/d plus cilostazol 50mg, twice per day for 27 days. At 30-day, a repeat platelet aggregation function test wil performed for all patients. Then a standard dual antiplatelet regimen with aspirin 100mg/d indefinitely and clopidogrel 75mg/d for at least 1 year will be prescribed for all patients.
1870087|NCT01094470|Device|Body weight support system on ground level|Gait training with body weight support on ground level with sessions of 45 minutes, three times a week, on alternating day during six weeks, completing a total of 18 sessions.
1870088|NCT01094483|Drug|PN400|naproxen 500 mg/esomeprazole 20 mg oral tablet
1870089|NCT01094483|Drug|ASA|Asprin 81 mg enteric coated tablet
1870090|NCT01094483|Drug|Placebo|
1870091|NCT01094496|Biological|CDX-1307 Vaccine Regimen|CDX-1307 vaccine co-administered with immune adjuvants (GM-CSF, Poly-ICLC and Resiquimod)
1870092|NCT01094496|Drug|Chemotherapy|
1870093|NCT01094509|Behavioral|Tai Chi|Tai Chi classes and exercises
1870094|NCT01094509|Behavioral|Guided autobiography|Autobiographical writing in class and at home
1870095|NCT01094509|Behavioral|Qigong|Qigong classes and exercises (exploratory)
1870096|NCT01094509|Behavioral|Successful aging|Seminar series on the theme of successful aging
1870097|NCT01094509|Behavioral|Combination|Combination of Tai Chi exercises and autobiographical writing
1870098|NCT01094509|Behavioral|Comparison|No assigned behavioral activity (exploratory)
1870099|NCT01094522|Drug|Methadone|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of methadone may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
1870100|NCT01094522|Drug|Morphine|"0.2 mg/kg (IV) for the Initial Loading Dose; followed by PRN (as needed) doses (given by the ICU Nurses) starting at 0.035 mg/kg (IV) every 30 minutes, for postoperative pain. The PRN dose of morphine may be increased by the ICU doctors until the dose is adequate to relieve the patient's pain."
1870101|NCT01094535|Drug|Synthetic Human Secretin|S-MRCP has recently emerged as a widely-accepted noninvasive technique to assess morphological changes in the pancreatic ducts, as well as functional secretory capacity of the gland. Twelve patients will each undergo four Secretin-enhanced magnetic resonance cholangiopancreatography (S-MRCP) evaluations, at a dose of 0.2 ucg/kg per exam, each S-MRCP will require 16-32 ucg of secretin (12 vials). Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
1870102|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving single low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 microgram (mcg) of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
1870103|NCT01094548|Biological|Tecemotide (L-BLP25)|After receiving multiple low dose of cyclophosphamide, subjects will receive 8 consecutive weekly subcutaneous vaccinations with 806 mcg of tecemotide (L-BLP25) at Weeks 1, 2, 3, 4, 5, 6, 7 and 8 followed by maintenance vaccinations (806 mcg of tecemotide (L-BLP25) at 6-Week intervals, commencing at Week 14, until disease progression requiring anti-tumor therapy is documented.
1870104|NCT01094548|Drug|Single low dose cyclophosphamide|An intravenous (IV) infusion of 300 milligram per square meter (mg/m^2) (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment.
1870105|NCT01094548|Drug|Multiple low dose cyclophosphamide|An IV infusion of 300 mg/m^2 (to a maximum 600 mg) of cyclophosphamide will be given 3 days before the first vaccine treatment plus an intravenous dose of cyclophosphamide (300 mg/m^2, to a maximum of 600 mg) 3 days prior to the tecemotide (LBLP25) administration at week 5 of the weekly treatment phase and 3 days prior to every tecemotide (L-BLP25) administration during the treatment phase with 6-Weekly administration of tecemotide (L-BLP25), commencing at Week 14 up to a maximum treatment period of 2 years.
1870106|NCT01094561|Drug|Synthetic Human Secretin|Subjects will each undergo a Secretin-Enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and a Secretin-Enhanced Endoscopic Ultrasound (S-EUS) evaluation, at a dose of 0.2 ucg/kg per exam. Synthetic Human Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
1870107|NCT01094561|Procedure|Secretin-Enhanced Magnetic Resonance Cholangiopancreatography|
1870108|NCT01094561|Procedure|Secretin-Enhanced Endoscopic Ultrasound|
1870109|NCT01094574|Drug|Alfentanil|An infusion of alfentanil 100ng/ml was administered over 3 hours using a programmable infusion pump.
1870110|NCT01094574|Drug|Propranolol|An infusion of propranolol 30ng/ml was administered over 3 hours using a programmable infusion pump.
1870111|NCT01094574|Drug|Placebo|An infusion of normal saline was administered over 3 hours using a programmable infusion pump to mimic the 2 drug arms,
1870153|NCT01094925|Drug|Gabapentin 300mg|Single oral dose of 300mg gabapentin
1870113|NCT01094600|Drug|Synthetic Human Secretin|Twelve patients will undergo S-MRCP, at a dose of 0.2 ucg/kg per exam. Secretin, provided by the Repligen Corporation, will be administered by IV bolus injection over 30 seconds followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
1870114|NCT01094613|Drug|Delayed Release 6 mercaptopurine|"Delayed Release oral tablet for ileal drug delivery, 80 mg, once nightly before bedtime, for 12 weeks.
Since the study drug must be blinded, patients randomized to this arm will receive the following: 80 mg DR-6MP: 2 active 40 mg DR-6MP tablets."
1870115|NCT01094613|Drug|6 Mercaptopurine|Oral tablet(s) to be administered once daily in the AM, for 12 weeks.Purinethol is available only as a 50 mg tablet; patients randomized to this arm will receive varying doses (dependent on baseline body weight and AE profile) throughout the study;and study drug to be blinded. Therefore, patients randomized to this arm to receive combination active Purinethol/comparable placebo. For ex: 50 mg Purinethol= 1 active 50 mg tablet, 2 comparable placebo tablets; 100 mg Purinethol = 2 active 50 mg tablets, 1 placebo tablet; 150 mg Purinethol = 3 active 50 mg tablets. Patients receiving 75 mg or 125 mg will receive alternating daily doses of 50 and 100 mg, or 100 and 150 mg, respectively, to arrive at a weekly average dose of 75 mg or 125 mg.
1870116|NCT01094626|Drug|Secretin|Subjects will each undergo an S-MRI evaluation, at a dose of 0.2 ucg/kg per exam. Secretin will be administered by IV bolus injection over 1 minute followed by a 30 second saline flush. The maximum dose of secretin will be 18.5 ucg.
1870117|NCT01094639|Procedure|Scaling root planing|Deep gum cleaning with local anesthesia
1870118|NCT01094639|Procedure|Supragingival Prophylaxis|Plaque removal
1870119|NCT01094652|Dietary Supplement|Whole grain diet|Subjects were told to consume three different kinds of study food each day. The goal was an intake of greater than or equal to 80 g of whole grains per day.
1870120|NCT01094652|Dietary Supplement|Refined grain diet|The refined grain food products were matched as closely as possible to the foods contained in the whole grain diet. Subjects were told to consume three different kinds of study food each day.
1870121|NCT01094665|Procedure|MRI Targeted Focal Laser Thermal Therapy|A 980nm wavelength diode laser will be fired for up to 30 minutes. Temperature probes will be inserted to ensure that the local temperature does not exceed 55 degrees Celsius for more than 5 minutes.
1870122|NCT01094678|Device|Zilver® PTX™ Stent|Stenting of the superfemoropopliteal artery.
1870123|NCT01094691|Procedure|Renal Allograft Biopsy|A renal allograft biopsy will be performed when the urine is determined to be Haufen negative.
1870124|NCT01094704|Drug|sodium chloride (7%)|4mL nebulized 7% sodium chloride
1870126|NCT01094730|Device|galyfilcon A prototype lens|Experimental silicone hydrogel contact lens
1870127|NCT01094730|Device|marketed galyfilcon A lens|Marketed silicone hydrogel contact lens.
1870130|NCT01094756|Dietary Supplement|meal replacements, psychotherapy, dietary education|After the screening and scan days are completed, obese subjects will begin a lifestyle intervention program that includes dietary (low-calorie diet) and behavioral education topics. Treatment will be provided in individual weekly sessions. Each hour-long session will be led by a behavioral counselor or registered dietitian in the Weight Management Center at Washington University. The behavioral program will use cognitive-behavioral techniques to foster adherence to diet prescriptions and to build a supportive environment for the participant. The program will emphasize strategies of self-monitoring and goal-setting, and will include problem-solving, overcoming high-risk situations for unhealthy eating, relapse prevention, and strategies for long-term weight maintenance. Handouts will be provided for study subjects to allow them to record the setting and reaching of dietary goals, as well as summarize the key points of the educational content.
1870131|NCT01094769|Drug|Moxonidine|Patients will receive moxonidine treatment for 12 weeks, at a dose of 0.4mg/d for the first 6 weeks of treatment followed by up-titration of the dose to 0.6 mg/d for the final 6 weeks.
1870132|NCT01094769|Drug|Placebo|lactose capsule taken once daily
1870133|NCT01094782|Other|Acupuncture, sham acupuncture or neither|Patients with radicular pain receiving acupuncture (Group 1), sham acupuncture (Group 2), or neither acupuncture nor sham acupuncture (Group 3);
1870134|NCT01094782|Other|Acupuncture, sham acupuncture or neither|Healthy subjects (no pain) receiving acupuncture (Group 4), sham acupuncture (Group 5), neither acupuncture nor sham acupuncture (Group 6).
1870135|NCT01094808|Drug|Pregabalin|FDA approved medication (capsules) at 75 mg and 200 mg doses
1870136|NCT01094808|Drug|Placebo|Placebo capsules
1870137|NCT01094808|Other|Bowel preparation|Polyethylene glycol electrolyte solution bowel preparation
1870138|NCT01094821|Drug|ATI-7505|3 mg three times daily for 9 days
1870139|NCT01094821|Drug|Placebo|Placebo capsule three times daily for 9 days
1870140|NCT01094821|Drug|ATI-7505|10 mg ATI-7505 three times daily for 9 days
1870141|NCT01094821|Drug|ATI-7505|20 mg ATI-7505 three times daily for 9 days
1870142|NCT01094834|Drug|DWP05195|tablets, oral administration, multiple administration
1870143|NCT01094847|Drug|DWJ1252|tablet(oral) administration following the schedule of each arm
1870144|NCT01094860|Drug|Nelarabine|Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.
1870145|NCT01094873|Biological|AdCh3NSmut|Genetic vaccines against Hepatitis C virus infection
1870146|NCT01094873|Biological|Ad6NSmut|Genetic vaccine against Hepatitis C virus infection
1870147|NCT01094886|Drug|Rivaroxaban|10mg tablet daily, receiving the first dose within two days after admission to the subacute unit. The total duration of combined venous blood clot prevention therapy with enoxaparin and rivaroxaban may not exceed 35 days for patients with total hip replacement or 14 days with total knee replacement
1870148|NCT01094899|Radiation|Radiography|Radiography, microscanner, osteodensitometry
1870149|NCT01094899|Other|Urine and Blood sampling|mainly dosage of bones metabolism
1870150|NCT01094899|Other|Echography|body bones echography
1870151|NCT01094912|Drug|opioids|
1870152|NCT01094925|Drug|lactose|Single oral dose
1870154|NCT01094925|Drug|Gabapentin 600mg|Single oral dose of 600mg gabapentin
1870155|NCT01094951|Behavioral|ENGAGE|"During Stage 1, study investigators will work with three Neighborhood Houses in implementing research assessments, referral patterns, and connections to mental health evaluation among their depressed senior clients. Investigators will train caseworkers to administer a brief depression screen and will also instruct caseworkers to refer depressed seniors to local community-based mental health or medical clinics. Data on successful connections to mental health evaluation will serve as the comparison to that achieved during Stage 2.
During Stage 2, study investigators will train Neighborhood House caseworkers to 1. provide psychoeducation that addresses client-specific barriers to evaluation and care; 2. use shared decision-making strategies to engage seniors and arrive at a decision about where and from whom to receive an evaluation and possible care; and 3. provide connections to preferred mental health services (primary care physician, local mental health clinic)."
1870156|NCT01094964|Biological|BCG solution|
1870157|NCT01094964|Biological|recombinant interferon alfa|
1870158|NCT01094964|Drug|epirubicin hydrochloride|
1870159|NCT01094964|Drug|mitomycin C|
1870160|NCT01094964|Other|laboratory biomarker analysis|
1870161|NCT01094964|Procedure|hyperthermia treatment|
1870162|NCT01094964|Procedure|quality-of-life assessment|
1870163|NCT01094977|Drug|Tranexamic Acid|10 mg/kg bolus with a 5 mg/kg/h infusion
1870164|NCT01094977|Drug|Tranexamic Acid|100 mg/kg bolus with a 10 mg/kg/h infusion
1870165|NCT01094977|Drug|Saline Placebo|
1870166|NCT01094990|Drug|Dexamethasone|dexamethasone 0.25 mg/kg (8 mg/m2/dose) intravenous one time
1870167|NCT01095003|Drug|Vinflunine plus Capecitabine|"Vinflunine 280mg/m² as a 20-minute i.v. infusion on day 1 of each cycle repeated every 3 weeks
Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks"
1870168|NCT01095003|Drug|Capecitabine|Capecitabine 825mg/m² per os twice per day for 14 consecutive days starting day 1 of each cycle repeated every 3 weeks
1870169|NCT01095016|Drug|Meptin swinghaler|"Dose: 10ug/puff, 2 puffs daily
Frequency: QD (total 20ug/day)
Treatment duration: 2 days"
1870170|NCT01095016|Drug|Berotec|"Dose: 100ug/puff, 2 puffs daily
Frequency: QD (total 200ug/day)
Treatment duration: 2 days"
1870171|NCT01095029|Device|Medtronic InterStim II - 3058|Stimulation with optimal pacemaker settings unilateral and bilateral with standard pacemaker settings: Amplitude sensory treshold, frequency 14 Hz and impulsduration 210 μsec.
1870172|NCT01095042|Behavioral|emotion|Show that the susceptibility in the stress (recording of Heart Rate Variability;viewing films;...) is more important at the person affected by digestive pathologies (SII or IBD) in forgiveness than to unhurt subjects of pathologies.
1870173|NCT01100502|Drug|brentuximab vedotin|Every 21 days by IV infusion (1.8 mg/kg)
1870174|NCT01100502|Drug|placebo|Every 21 days by IV infusion
1870175|NCT01100515|Other|normobaric oxygen therapy|oxygen therapy was delivered via a full face mask at high flow to achieve 100% of inspired oxygen fraction
1870176|NCT01100515|Other|Hyperbaric oxygen therapy|Hyperbaric oxygen therapy was delivered in a hyperbaric chamber, pressurized at 2 absolute atmosphere (1 hour plateau) and the patient breathed high oxygen concentration via a full face mask followed by 4 hours of normobaric oxygen therapy
1870177|NCT01100528|Biological|recombinant interferon alfa-2b|Given SC 3 times a week for 24 weeks
1870178|NCT01100528|Drug|dacarbazine|Given IV on days 1 and 29
1870179|NCT01100528|Other|laboratory biomarker analysis|Correlative studies obtained prior to therapy, every 8 weeks while on therapy, and then every 6 months during follow-up
1870180|NCT01100541|Device|Polymeric plate|Application of the polymeric plate in the shoulder for 20 minutes after warming it for 15 minutes in hot water, initially at boiling temperature.
1870181|NCT01100554|Device|Sleep endoscopy|Conscious sedation will be done under intravenous propofol infusion. The sedative level would be monitored and adjusted accord to the Bispectral Index monitor. After the adequate sedative level is achieved, a bronchoscopy (Olympus, BF) was inserted from the right nostril. The velopharynx, oropharynx, larynx, and hypopharynx obstructions were evaluated.
1870182|NCT01100567|Device|Low-magnitude mechanical stimulation platform|Low-magnitude mechanical stimulation platform
1870183|NCT01100580|Dietary Supplement|low salt diet|Daily salt intake less than 4 g/day
1870184|NCT01100580|Dietary Supplement|water therapy|abundant intake of water with a low mineral and low sodium content (at least 2 litres in winter and 3 in summer).
1870185|NCT01100593|Procedure|length of IV catheter|Subjects will be randomized to one of two IV catheter lengths
1870186|NCT01100606|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] delayed release capsule) from open capsule, mixed with a small amount of apple juice, will be given orally daily using a syringe nurser at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day.
1870187|NCT01100606|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] delayed release capsule) from open capsule, mixed with a small amount of apple sauce, will be given orally daily using a spoon at dose increments of 3,000 lipase units, for 10 days in either first treatment period or second treatment period. Total dose will not exceed 10,000 lipase units per kg of body weight per day.
1870188|NCT01100619|Drug|rosiglitazone|one 4 mg dose as a tablet followed by a second 4 mg dose 3 weeks later
1870189|NCT01100619|Drug|XL184|dosed with capsules daily
1870190|NCT01100632|Dietary Supplement|Ginseng, vitamins, minerals|2 capsules per day
1870191|NCT01100632|Other|Placebo - Gelatin capsule|2 capsules per day
1870192|NCT01100645|Drug|Sominex|Passiflora incarnata L.50 mg Valeriana officinalis L.40 mg Crataegus oxyacantha L.30 mg
1870193|NCT01100645|Drug|Placebo|Excipient
1870194|NCT01100658|Drug|Methylphenidate|1 capsule each day for 1 week, .3 mg/kg dose.
1870195|NCT01100658|Drug|Placebo|1 capsule per day for 1 week.
1870196|NCT01100671|Other|Cross section study|This is not intervention study. The purpose of the study is to examine the relationship of vascular inflammation assessed by 18FDG-PET and MDCT at the cross section setting
1870197|NCT01100684|Drug|Asimadoline|0.5 mg Asimadoline BID
1870198|NCT01100684|Drug|Placebo|Placebo
1871072|NCT01108029|Drug|memantine|2 tablets of 10 mg of memantine 1 time a day in the morning
1870199|NCT01100723|Other|Cinacalcet, active vitamin D analogue|Patients will have their mineral and bone disorders managed by the computer directed algorithm. Cinacalcet will be dose increased starting at 30 mg/day as indicated by protocol along with active vitamin D based on values of serum calcium, phosphorus and parathyroid hormone.
1870200|NCT01100736|Drug|Bosentan|Bosentan 125mg tablets, orally, twice daily for 7 days
1870201|NCT01100736|Drug|Sitaxsentan|Sitaxsentan 100mg tablets, orally, once daily for 7 days
1870202|NCT01100736|Drug|Placebo|Placebo tablets taken twice daily, orally, for 7 days (placebo arm) or once daily for 7 days (sitaxsentan arm)
1870203|NCT01100736|Biological|Endothelin-3|5 minute local intra-arterial infusion of endothelin-3 at a rate of rate of 60 pmol/min, during forearm blood flow studies
1870204|NCT01100762|Device|Cranial Electric Stimulation (CES)|We will follow the procedure described by several investigators as safe and effective. The participant will sit on a standard chair. Two commercially available surface electrodes will be embedded in an elastic head cup. Each electrode will be covered with a water soaked absorbent fabric. One positive (+) electrode will be placed over the primary motor cortex (M1) and pre-motor areas. One negative (-) electrode will be placed over the skin overlying the contra lateral supra-orbital region. The electrodes will be connected via 2 leads to a battery powered direct current stimulator. The stimulator will be programmed to deliver 0.975mA (peak 4mA) over 20 minutes.
1870205|NCT01100762|Device|Treadmill|The participant will walk on a treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
1870206|NCT01100762|Device|CES and Treadmill|Participants will have a combined session with CES while walking on the treadmill for 20 minutes at the individually self-selected velocity determined at baseline.
1870207|NCT01100775|Drug|Galantamine|A lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
1870208|NCT01100775|Drug|Galantamine or Placebo|Subjects will be randomly assigned to the two possible order of administration: the drug and then placebo, or the placebo and then drug. Subjects will be given a lead-in 3 days of 4mg/ twice a day of galantamine (or placebo) followed by 8 mg (or placebo) on the 4th day, the day of testing.
1870209|NCT01100788|Dietary Supplement|Short chain fructo-oligosaccharide (scFOS) 5 g|"Dietary Supplement: scFOS 5 g
Novel fiber administered in two 5 g doses--the first in a beverage and the second in a solid chew."
1870210|NCT01100788|Other|Placebo|Treatment without scFOS fiber
1870211|NCT01100788|Dietary Supplement|Short chain fructooligosaccharide (scFOS) 8 g|Novel fiber administered in two 8 g doses--the first in a beverage and the second in a solid chew.
1870212|NCT01100801|Drug|TS-1 with cisplatin|
1870213|NCT01100801|Drug|TS-1 with oxaliplatin|
1870214|NCT01100827|Other|EGFR mutation status in patients|
1870215|NCT01101087|Device|Taurolock|
1870216|NCT01101087|Other|Placebo|Injectable sodium chloride conditioned in exactly the same manner as the experimental product.
1870218|NCT01101113|Drug|cinacalcet|cinacalcet 25mg qd or 50 mg qd
1870219|NCT01101113|Drug|control|vit D + P binder
1870220|NCT01101126|Other|Pulmonary disease management|Comprehensive pulmonary care including patient education of self-care, coordination of care, monitoring of patient adherence, providing advice in acute exacerbations
1870221|NCT01101126|Other|Usual care|Pulmonary disease is managed by the primary practitioner and a consultant pulmonologist
1870222|NCT01101139|Drug|Sugammadex|Sugammadex (single intravenous injection 0.25 mg/kg)
1870223|NCT01101139|Drug|Placebo|Placebo: single intravenous injection Saline 0.9%
1870224|NCT01101152|Drug|Desvenlafaxine succinate|"Tablets of 50 mg,100 mg; Dosing regimen: 50, 100, 200 mg/day; 1 week for each dose regimen;
1 tablet a day for doses of 50 and 100mg/day, and 2 tablets of 100mg for dose of 200mg/day"
1870225|NCT01101165|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 40-mg tablet x 1 dose taken without food
1870226|NCT01101165|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 40-mg tablet x 1 dose taken without food
1870227|NCT01101178|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken with food.
1870228|NCT01101178|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken with food.
1870229|NCT01101191|Drug|Reformulated OXY (oxycodone HCl)|Reformulated OXY 80-mg tablet x 1 dose taken without food.
1870230|NCT01101191|Drug|Original OxyContin® (OXY) (oxycodone HCl)|Original OxyContin® (OXY) 80-mg tablet x 1 dose taken without food.
1870231|NCT01101204|Drug|Metformin 1000mg, simvastatin 10mg and fenofibrate 100mg|Patient will take three pill consisting of metformin 1000mg, simvastatin 10mg and fenofibrate 100mg.
1870232|NCT01101217|Drug|Zinc Supplement|in 50 patients zinc sulfate 220 mg per day orally for 6 weeks
1870233|NCT01101217|Drug|placebo|placebo daily for 6 weeks
1870234|NCT01101230|Other|Almonds|1.5 oz almonds/day
1870235|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every week
1870236|NCT01101243|Radiation|Broadband UVB|UVB dose: 4 SED every second week
1870237|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every second week
1870238|NCT01101243|Radiation|Broadband UVB|UVB dose: 1 SED every month
1870239|NCT01101243|Other|Control group|No intervention
1870240|NCT01101269|Drug|ACEI or ARB|Subjects will be asked to discontinue their usual ACE inhibitor or Angiotensin Receptor Blocker (ARB) for ten days, undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then resume their usual ACEI or ARB for ten days, then undergo another CEU using Definity as the contrast agent.
1870241|NCT01101269|Drug|Lisinopril|Subjects will be undergo a CEU using Definity (for renal blood flow assessment) as the contrast agent, then take Lisinopril 10 mg every day for 7 days, after which they will undergo another CEU using Definity as the contrast agent.
1870242|NCT01101282|Device|Positive expiratory pressure (PEP) mask therapy|PEP mask therapy will be performed once/day, supervised, by an experienced physiotherapist until hospital discharge or ≥ 24 hours without sputum expectoration (whichever comes first). Written instructions shall also be provided, encouraging two more independent PEP mask sessions per day. Each session will comprise up to 5 cycles of 8-10 slightly active breaths, followed by 2 huffs (FET) and 2 coughs. A target pressure of 10-20 cms H20 during the middle of expiration shall be used (monitored via a pressure manometer).
1870243|NCT01101308|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Totowa) x 1 dose taken in the fasted state.
1870244|NCT01101308|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 10-mg tablet (Wilson) x 1 dose taken in the fasted state.
1870245|NCT01101321|Drug|Reformulated OXY (Totowa) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Totowa) x 1 dose taken without food.
1870246|NCT01101321|Drug|Reformulated OXY (Wilson) (oxycodone HCl)|Reformulated OXY 80-mg tablet (Wilson) x 1 dose taken without food.
1870247|NCT01101334|Drug|CS-7017|CS-7017, Two 0.25mg Tablets administered twice daily
1870248|NCT01101334|Drug|erlotinib|Erlotinib; One 150mg tablet administered once daily
1870249|NCT01101347|Device|Aneurysm-Embolization System|
1870250|NCT01101360|Device|Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
1870251|NCT01101360|Device|Matrix RF followed by Pulse Dye Laser|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
1870252|NCT01101360|Device|Pulse Dye Laser followed by Matrix RF|Section of port wine stain to be treated 5 times every 5 weeks (+/- 1 week)
1870253|NCT01101386|Drug|Voriconazole|Patients will be started on voriconazole 6 mg/kg IV q12h on day 1, then 4 mg/kg IV q12h thereafter.
1870254|NCT01101399|Drug|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.
Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 4 (Week 2).
Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
1870255|NCT01101412|Drug|Edetate Calcium Disodium|Given through CVC or PVC.
1870256|NCT01101412|Drug|Ethanol|Given through CVC or PVC
1870257|NCT01101412|Drug|Trimethoprim-sulfamethoxazole|Given through CVC or PVC
1870258|NCT01101412|Other|Hypertonic Saline|Given through CVC or PVC
1870259|NCT01101438|Drug|metformin hydrochloride|Given orally
1870260|NCT01101438|Other|placebo|Given orally
1870261|NCT01101451|Drug|Cisplatin|Given IV
1870262|NCT01101451|Radiation|External Beam Radiation Therapy|Undergo radiotherapy
1870263|NCT01101451|Radiation|Intensity-Modulated Radiation Therapy|Undergo radiotherapy
1870264|NCT01101451|Other|Laboratory Biomarker Analysis|Correlative studies
1870265|NCT01101451|Other|Quality-of-Life Assessment|Ancillary studies
1870266|NCT01101464|Drug|Asenapine 3x5mg followed by 1x15mg|Three 5 mg sublingual tablets (15 mg) given twice daily for 2 days followed by one 15 mg sublingual tablet given twice daily for 1.5 days
1870267|NCT01101464|Drug|Asenapine 1x15mg followed by 3x5mg|One 15 mg sublingual tablet given twice daily for 2 days followed by three 5 mg sublingual tablets (15 mg) given twice daily for 1.5 days.
1870268|NCT01101477|Procedure|TCI titration by different Cet.|"Induction:
After topical xylocaine and alfentanil 5μg/kg iv 1 minute before, Cet 2.0μg/ml is started on the TCI pump ('Vial Injectomat TIVA Agilia syringe infusion pump, Fresenius Kabi, France). The sedative level will be accessed by sedation scale OAA/S every 30 seconds till OAA/S ≦3(Responds only to name called loudly). The current Ce will be set as the maintenance Cet.
If desired OAA/S is not achieved after reaching 2.0μg/ml,Cet will be increased every 90 seconds by the regimens be assigned until OAA/S ≦3. The current Ce will be set as the maintenance Cet.
Maintenance:
The Cet will be increased according to the assigned regimens if:
Patients become irritant and interfere procedures.
Patients open eyes or talk to express uncomfortable.
The Cet will be decreased if:
Systolic blood pressure is less than 90mmHg;
Mean arterial blood pressure is less than 65mmHg;
Oxyhemoglobin saturation is less than 90 %
with any duration."
1870269|NCT01101503|Drug|Intensive multifactorial group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.
The intensive multifactorial therapy group:
For blood glucose control, target HbA1c >=5.5%and <=6.0%,fasting blood glucose >=5.0 mmol/L and <=6.0 mmol/L, postprandial 2 hour glucose >= 6.0 mmol/L and <= 7.8 mmol/L. The drugs include insulin, oral hypoglycemic agents.
For blood lipids control, target LDL-C < =1.9 mmol/L, triglyceride < =1.5 mmol/L. The drugs include statin and fibrate.
For blood pressure control, target >=120/70 mmHg and <= 130/80 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.
Others, such as aspirin."
1870270|NCT01101503|Drug|conventional multifactorial therapy group|"Intensive multifactorial therapy and conventional multifactorial therapy will be taken for 1 year, and then take them together, and give same treatment for 10 years.
The conventional multifactorial therapy group:
For blood glucose control, target HbA1c >6.5%and <=7.0%,fasting blood glucose >6.0 mmol/L and <=7.0 mmol/L, postprandial 2 hour glucose > 7.8 mmol/L and <= 10.0 mmol/L. The drugs include insulin, oral hypoglycemic agents.
For blood lipids control, target LDL-C > 1.9 mmol/L and < =2.5 mmol/L, triglyceride > 1.5 mmol/L and < = 2.5 mmol/L. The drugs include statin and fibrate.
For blood pressure control, target >130/80 mmHg and <= 140/90 mmHg. The drugs include ACE inhibitor, angiotensin II-receptor antagonist, diuretic, beta-blocker and calcium-channel blocker.
Others, such as aspirin."
1870271|NCT01101529|Drug|Aprepitant (Emend)|Aprepitant will be added to the standard anti-emetic therapy. Emend is given orally, 125 mg the first day, then 80 mg daily during the chemotherapy course and 7 days after
1870272|NCT01101529|Drug|Placebo|Placebo will be administered instead of Emend
1870273|NCT01101542|Biological|Cervarix.|Subjects will receive three doses of the Cervarix vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in routine clinical practice settings.
1870274|NCT01101542|Other|Data collection|All adverse events will be recorded by all subjects or the subject's parents/guardians using diary cards.
1870275|NCT01101555|Drug|subcutanious administration|drug will be administered subcutaneously in varying amounts over a verying time period according to details stated in the 'arms' section
1870276|NCT01101555|Other|Placebo|Placebo will be given to one member of each cohort.
1870277|NCT01101568|Drug|Simvastatin|Simvastatin 40mg (single dose) on Days 1 and 10.
1870278|NCT01101568|Drug|Rosuvastatin|Rosuvastatin 10mg (single dose) on Days 3 and 12.
1870279|NCT01101568|Drug|GSK1292263|GSK1292263 300mg BID Days 6 to 14.
1870533|NCT01097928|Procedure|Catheter directed debulking of Pulmonary Embolus|A catheter will be used to break up the pulmonary embolism
1870280|NCT01101581|Drug|Veltuzumab and 90Y-Epratuzumab Tetraxetan|Veltuzumab will be administered subcutaneously in phase 2. 90Y-Epratuzumab tetraxetan will be administered intravenously. Veltuzumab is given once weekly for 4 weeks. 90Y-Epratuzumab is also given at treatment weeks 2 & 3 (days 8 & 15).
1870281|NCT01101581|Drug|90Y-epratuzumab tetraxetan|
1870282|NCT01101581|Drug|veltuzumab|Veltuzumab will be administered subcutaneously on days 1, 8, 15 and 23
1870283|NCT01101594|Drug|hLL1-DOX (the doxorubicin conjugate of milatuzumab)|hLL1-DOX will be administered intravenously (through a vein) on days 1, 4, 8 & 11 every 21 days for up to 8 treatment cycles. 4 different dose levels of hLL1-DOX will be studied for safety and tolerability.
1870284|NCT01101607|Procedure|Distal Forearm Fracture Reduction|Fracture reduction
1870285|NCT01101620|Drug|Levosimendan|
1870286|NCT01101633|Dietary Supplement|Alginate|a 500 ml alginate beverage per meal test
1870287|NCT01101633|Dietary Supplement|Alginate|a 330 ml alginate beverage per meal test
1870288|NCT01101633|Dietary Supplement|Placebo|a 500 ml placebo beverage per meal test
1870289|NCT01101633|Dietary Supplement|Placebo|a 330 ml placebo beverage per meal test
1870290|NCT01101646|Drug|rabeprazole sodium|four 2.5 mg capsules of the phase 3 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted or fed state)
1870291|NCT01101646|Drug|rabeprazole sodium|two 5-mg sachets of the phase 1 pediatric bead formulation suspended in a strawberry flavored vehicle (taken in fasted state)
1870292|NCT01101646|Drug|rabeprazole sodium|four 2.5 mg capsules of the phase 3 formulation sprinkled on 1 ounce of plain yogurt
1870293|NCT01101659|Drug|JNJ-40411813|500 mg as 20 mL of oral suspension
1870294|NCT01101659|Drug|normal saline|single dose
1870295|NCT01101659|Drug|ketamine|20 mL of oral suspension
1870296|NCT01101659|Drug|Placebo|single dose
1870299|NCT01101685|Drug|Escitalopram|7 days dosing of 10mg per day
1870300|NCT01101685|Drug|Placebo|7 days dosing at 10mg daily
1870301|NCT01101698|Drug|Vitamin K2+10μg cholecalciferol|Pills of: 90 μg vitamin K2+10μg cholecalciferol once daily during 9 months
1870302|NCT01101698|Drug|Vitamin D|Pills of: 10μg cholecalciferol (Vitamin D)once daily during 9 months
1870303|NCT01101724|Behavioral|Mandated Rest, Intervention|"In addition to CDC based discharge instructions, the intervention group will receive instructions with strict activity restriction explicitly stating No return to school and No Physical Activity for the next five days. Patients and parents in the intervention group will be provided school and work excuses for the five days post-injury."
1870304|NCT01101737|Other|Nurse-led blood pressure clinic|Blood pressure will be measured according to protocol.For patients with blood pressure above optimal targets, treatment changes will be discussed with the patient, a visiting consultant physician and the patient's GP. If they agree, the GP will intensify anti-hypertensive treatment with monthly follow up by the specialist nurse until BP targets are achieved.
1870306|NCT01101776|Drug|Interferon beta-1a (Rebif)|Interferon beta-1a 44 micrograms (12 MIU) given three times per week (tiw) by subcutaneous injection (SCI). Dose to be reduced to 22 micrograms (6 MIU) tiw by SCI for subjects who cannot tolerate the higher dose.
1870307|NCT01101789|Procedure|triclosan coated suture for surgical wound closure|triclosan coated suture for surgical wound closure
1870308|NCT01101789|Procedure|regular sutures for surgical wound closure|
1870309|NCT01101802|Drug|Mycophenolate mofetil|Arm 1 patients were given 1 gm bd mycophenolate mofetil for 8 weeks, The mycophenolate was dispensed as 500mg tablets.
1870310|NCT01101802|Drug|sugar pill|Arm 2 patients were given 2 sugar pills bd for 8 weeks
1870311|NCT01101815|Drug|Oral Naltrexone (ON)|48 weeks of oral naltrexone as compared to 48 weeks of implantable naltrexone
1870312|NCT01101815|Drug|Implantable Naltrexone (IN)|48 weeks of implantable naltrexone as compared with 48 weeks of oral naltrexone
1870313|NCT01101841|Drug|Brisdelle (paroxetine mesylate)|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
1870314|NCT01101841|Drug|Placebo capsules|Eligible subjects will be randomized to receive either Brisdelle (paroxetine mesylate) Capsules 7.5 mg or placebo capsules in a 1:1 ratio.
1991273|NCT01290315|Drug|Iron Sucrose / Iron Dextran|One 500 mg dose of IV iron sucrose administered over 4 hours (Cohort I), or a 750 mg dose of IV iron dextran administered as a 25 mg test dose over 5 minutes followed by a 725 mg dose over 3 hours if no adverse reaction to test dose is observed after 60 minutes (Cohort II)
1991274|NCT01288534|Radiation|Radiation Therapy|Patients will receive 5 fractions of radiation (you will not receive radiation therapy on two consecutive days). Each fraction size will be 7.4 Gy. The total dose will be 37 Gy. The 5 treatments will be scheduled to be delivered 2 fractions per business week (Monday through Friday). The total duration of treatment will be no shorter than 15 days and no longer than 19 days.
1991275|NCT01288183|Procedure|sham tDCS|sham condition as delivered by the stimulator (2mA during 40s and brief current pulses until the end of the stimulation) 20 minutes, 10 sessions, 2 per day
1870320|NCT01101893|Drug|Raltegravir|raltegravir 400mg q12h x 5 days (Reference Treatment)
1870321|NCT01101893|Drug|GSK2248761|GSK2248761 200mg q24h x 5 days (Reference Treatment)
1870322|NCT01101893|Drug|GSK2248761 + Raltegravir|GSK2248761 200mg q24h + raltegravir 400mg q12h x 5 days (Test Treatment)
1870323|NCT01101906|Drug|OSI-906|OSI-906 administered orally
1870324|NCT01101906|Drug|Placebo|Matching placebo administered orally
1870325|NCT01101919|Drug|CP-690,550|Days 1 and 6 dose of 10 mg once daily Days 2-5 doses of 10 mg twice daily
1870326|NCT01101932|Drug|PF-04308515|PF-04308515 will be provided as an oral solution administered at doses of 3, 10, 30 and 100 mg. If an optional cohort is needed the dose would not exceed the established toxicokinetic exposure limits. Solution will be administered orally once daily for 14 days.
1870534|NCT01097941|Biological|Live Attenuated H1N1 Influenza Vaccine|0.2 ml dose of live monovalent vaccine delivered through nasal spray, 2 doses given 28 days apart
1991276|NCT01288183|Procedure|active tDCS|anodal tDCS applied over the right DLPFC 2mA, 20minutes, 10 sessions, 2 per day
1870327|NCT01101932|Drug|Placebo|Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
1870328|NCT01101932|Drug|PF-04308515 Tablet|Tablet formulation to administer a 20 mg dose will be administered to volunteers in Part 2. The study medication will be administered orally once daily for 1 day.
1870329|NCT01101945|Drug|dutogliptin|400 mg QD
1870330|NCT01101958|Device|Chartis System|The Chartis System provides a value that represents the quantification of the average resistance to airflow through collateral airways.
1870331|NCT01101958|Device|Endobronchial Valve (EBV) Treatment|The endobronchial valve is designed to induce target lobe volume reduction.
1870332|NCT01101971|Other|Pelvic exam video tutorial|Bryden Magee (Meds 2010) and Dr. Robert Reid created an educational DVD © 2009 that outlines a step-by-step approach to the pelvic exam; utilizing real patient video clips and illustrations. Endorsed by the Association of Professors of Obstetrics and Gynaecology of Canada (APOG), this innovation has been shown to improve both knowledge and confidence in medical students learning these skills (Magee 2009). The video content has been posted on the Queen's streaming server and incorporated into a MEdTech community accessible to all Queen's faculty and students affiliated with the School of Medicine (in MEdTech Central see OBGYN Pelvic Exam Module under community courses).
1870333|NCT01101984|Drug|diquafosol ophthalmic solution|DE-089 topical ocular application, 6 times daily for 4 weeks.
1870334|NCT01101984|Drug|0.1% sodium hyaluronate ophthalmic solution.|0.1% HA topical ocular application, 6 times daily for 4 weeks.
1870335|NCT01101997|Device|The Zeltiq System|Noninvasive cooling is applied to the treatment area with a defined cooling rate and duration.
1870336|NCT01102010|Biological|Blood transfusion|An expanded indication for blood transfusion in the frail elderly
1870337|NCT01102023|Other|ordinary salt based- diet|
1870338|NCT01102036|Other|Cultura L casei F19, acidophilus La5 , B lactis Bb 12|2 weeks consumption,250 ml/day
1870339|NCT01102036|Other|Yoghurt without probiotics|Yoghurt without probiotics
1870340|NCT01102049|Dietary Supplement|fish, beef, fruit|
1870341|NCT01102062|Dietary Supplement|orange juice|
1870342|NCT01102075|Device|Electroacupuncture|We used Electrical stimulator(STN-111,Stratek)with a frequency of 24 Hz and intensity of 0.27-1.3mA(tolerable strength), asymmetric interactive pulse with continuous stimulation by the pulse generator. The participants were given treatment twice a week for 30 minutes for 5 weeks(10 sessions) by practitioner.(n=13)
1870343|NCT01102075|Device|Sham electroacupuncture procedure|We used same electroacupuncture device, number and type of needle, duration, frequency of sessions and practitioner as for the EA treatment. Specific details are as described in the arm description.(n=13)
1870344|NCT01102088|Radiation|Radiation Therapy|"Simultaneous integrated boost (SIB) used in combination with a fixed dose of radiation (180 cGy in 28 fractions = 5040 Gy PTV dose). Two dose levels (210 cGy and 225 cGy each in 28 fractions) of SIB will be considered in the phase I part of the study, starting at 210 cGy in 28 daily fractions.
For the phase II part of the study once the MTD has been achieved proton therapy will be allowed. Treatment dose will be identical to that of the photon treatment where the PTV is treated to 50.4 Gy(RBE) (RBE=1.1) while the CTV is boosted to 63 Gy(RBE) in 28 fractions."
1870345|NCT01102101|Drug|Remifentanil|Remifentanil (Ultiva; Glaxo-Smith-Kline; Vienna, Austria) will be applied intravenously during 60 minutes through a dedicated infusion pump (TCI Alaris PK Syringe Pump, Cardinal Health, Baesweiler, Germany), with a Target Controlled Infusion (following the integrated software algorithm by Minto), reaching the initial 18ng/ml plasma concentration in 180 seconds. This corresponds to approx. 0.7 µg kg-1 min-1.
1870346|NCT01102114|Biological|NicVAX Vaccine|NicVAX vaccine given 6 times over 6 months
1870347|NCT01102114|Biological|Placebo Vaccine|Placebo vaccine given 6 times over 6 months
1870348|NCT01102127|Device|Elastography|Performance of US, elastography and FNA.
1870349|NCT01102140|Drug|POMx, pomegranate polyphenol extract|1000 mg orally once daily.
1870350|NCT01102140|Drug|Sugar Pill|Matching sugar pill
1870351|NCT01102153|Device|Coolgard|invasive cooling via femoral ICY-catheter
1870352|NCT01102153|Device|ArcticSun|non-invasive surface cooling by saline-cooled thermo-vest
1870353|NCT01102166|Other|Acapella with nebulization|"st Phase In this phase the jet nebulizer was connected to the branch end of the Acapella according to manufacturer's recommendations.
The volunteer did the radio-aerosol inhalation to obtain images of the lung fields scintigraphy static during the period of 300 seconds using an array of at 256x256x16 incidence later, as that encompasses most incidence of lung volume.
nd Phase The experimental procedure of this phase was similar to the 1st stage, but what differed was it made an adjustment by placing a pipe T between the mouthpiece and the device Acapella so that the aerosol would be inhaled not pass through the device.
Stage 3 This stage was considered phase control since the aerosol inhalation was performed through the mouthpiece connected directly to the nebulizer as is routinely used in clinical practice as illustrated. The procedure of this phase followed the same protocol of previous phases."
1870354|NCT01102218|Drug|Erythropoietin|Standard of Care
1870355|NCT01102218|Drug|Erythropoietin|Standard of Care
1870356|NCT01102218|Drug|Pentoxifylline|400 mg qd po for 6 months
1870357|NCT01102231|Drug|Chemotherapy|Pemetrexed 500 mg/m², D1 (D1=D22, 4 cycles) Cisplatin 75 mg/m², D1 (D1=D22, 4 cycles)
1870358|NCT01102231|Drug|ERBITUX|The initial dose of cetuximab (ERBITUX) is 400 mg/m² intravenously administered over 120 minutes, followed by 11 weekly infusions at 250 mg/m² IV over 60 minutes
1870359|NCT01102231|Radiation|Radiotherapy|66 Gy (2 Gy by fraction, 5 fractions by week)
1870360|NCT01102244|Drug|Tobradex ST|tobramycin / dexamethasone ophthalmic suspension 0.3%/0.05% 1 drop 4 times daily for 14 days
1870361|NCT01102244|Drug|Azasite|azithromycin 1% 1 drop twice daily for 2 days, then once daily for 12 days
1870362|NCT01102257|Drug|Omega-3 EFA Supplement|"The total daily dose from the 5 capsules in treatment group will be 3.0 grams of omega-3 EFAs comprised of:
2000 mg EPA 1000 mg DHA"
1870363|NCT01102257|Drug|Olive Oil|Placebo group will take 5 capsules a day containing 3.0 grams of olive oil
1870364|NCT01102270|Drug|Eszopiclone|3mg tablet once prior to sleep
1870365|NCT01102270|Drug|Placebo|1 placebo capsule prior to sleep
1870535|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine|0.5 ml IM, 2 doses given 28 days apart
1870366|NCT01102283|Device|Evolution(R) Colonic Stent|Palliative treatment of colonic obstruction or strictures caused by malignant neoplasms and to relieve acute large bowel obstruction prior to colectomy in patients with malignant strictures.
1870367|NCT01102296|Biological|Hepatitis A vaccine|2 or 3 doses of hepatitis A vaccine to HIV-infected male homosexuals and 2 doses of hepatitis A vaccine to HIV-uninfected male homosexuals.
1870368|NCT01102309|Device|Robot therapy (NeReBot)|Rehabilitation therapy of the affected arm with NeRebot for five weeks, five times weekly for 40 minutes, plus 80 minutes of conventional therapy
1870369|NCT01102309|Other|Conventional therapy|Conventional rehabilitation therapy of the affected arm for five weeks, five times weekly for 120 minutes
1870370|NCT01102322|Behavioral|Quality|Factors associated with the use of lung protective ventilation strategy (LPV) in ALI/ARDS patients in ICU
1870371|NCT01102335|Procedure|Transcatheter arterial chemoembolization (TACE)|The procedure is performed under local anaesthesia. The femoral artery at groin region is punctured for arterial access. Angiography is performed for demonstration of vascular structures before embolization.The arteries supplying the tumor are selectively catheterized, this includes the hepatic arteries or other extrahepatic collateral arteries.The chemotherapeutic agent(s) is mixed with lipiodol (an oily contrast) to enhance tumour uptake. Following delivery of the lipiodol/chemotherapy mixture, small gelfoam particles may be injected to reinforce the effect of treatment.
1870372|NCT01102335|Drug|Telbivudine|anti-HBV drug
1870373|NCT01102348|Other|PEP-uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) were made available to all nurses, in bedside manuals and on the local intranet
1870374|NCT01102361|Procedure|Robotic Transperineal Biopsy|Saturation biopsy for previous negative patients
1870375|NCT01102374|Drug|High Dose Vitamin D|Vitamin D3 100,000 IU monthly
1870376|NCT01102374|Drug|Standard Dose Vitamin D|Vitamin D 12,000 IU monthly
1870377|NCT01102374|Drug|Placebo|Placebo monthly
1870378|NCT01102374|Dietary Supplement|Usual Care|Usual care of 0-1000 IU vitamin D daily. This is present in both study arms.
1870379|NCT01102387|Drug|LAS41003|Once daily, topically
1870380|NCT01102387|Drug|LAS189962|Once daily, topically
1870381|NCT01102387|Drug|LAS189961|Once daily, topically
1870382|NCT01102400|Drug|MEDI-575|MEDI-575 will be administered weekly or every 3 weeks as IV infusion as part of a 21-day treatment cycle. One or two doses will be selected for expansion part
1870383|NCT01102413|Drug|Monofer|Infusion or injections
1870384|NCT01102413|Drug|Iron Sulphate|Oral intake
1870385|NCT01102426|Drug|plitidepsin + dexamethasone|plitidepsin: powder and solvent for concentrate for solution for infusion. 2 mg vial + 4 ml ampoule. 5 mg/m2 intravenously (i.v.) over three hours on Day 1 and 15 every 4 weeks. dexamethasone: 4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks at least one hour before plitidepsin infusion.
1870386|NCT01102426|Drug|dexamethasone|4 mg tablet. 40 mg orally on Day 1, 8, 15 and 22 every four weeks.
1870387|NCT01102439|Drug|Clopidogrel|300 mg loading dose, then 75 mg daily
1870388|NCT01102439|Drug|Clopidogrel|600 mg loading dose, 150 mg daily day 2-7, then 75 mg daily
1870389|NCT01102439|Drug|Aspirin|81 mg daily
1870390|NCT01102439|Drug|Aspirin|325 mg daily
1870391|NCT01102452|Dietary Supplement|Commercially Available Wet Noodle|Commercially Available Wet Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of same macronutrient composition.
1870392|NCT01102452|Dietary Supplement|PPB-R-203-02 Noodle|PPB-R-203-02 Noodle is manufacture by Pharma Power Biotec Co., Ltd. The composition of PPB-R-203-02 Noodle is resistant starch (RS). By definition, resistant starch (RS) is any starch that is not digested in the small intestine but passes to the large intestine (or the colon). Therefore, resistant starch can be regarded as a component of dietary fiber. PPB-R-203-02 Noodle will be served as a diet equivalent to daily energy needs as judged by indirect calorimetry and of the same macronutrient composition.
1870393|NCT01102465|Drug|losartan potassium hydrochlorothiazide|100 mg / 25 mg tablet
1870394|NCT01102478|Drug|losartan potassium / hydrochlorothiazide|100 mg / 25 mg tablet
1870395|NCT01102491|Drug|Ramosetron|ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days
1870396|NCT01102504|Drug|Placebo|Placebo
1870397|NCT01102504|Dietary Supplement|Ateronon|Tomato extract containing 28 mg lycopene/ day
1870398|NCT01102517|Procedure|video-assisted thoracoscopic surgery|video-assisted thoracoscopic surgery
1870399|NCT01102517|Procedure|axillary thoracotomy|axillary thoracotomy lobectomy
1870400|NCT01102595|Drug|Temozolomide|"Temozolomide 85 mg/m2/d x 21 days every 28 days for 2 cycles.
Temozolomide 75 mg/m2/d x 42-49 days
Temozolomide 150 - 200 mg/m2 d1-d5 q 28d for 6 cycles."
1870401|NCT01102595|Drug|Bevacizumab|"2 cycles + bevacizumab 10 mg/kg every 15 days each two cycles.
Bevacizumab 10 mg/kg every 15 days, three dosis."
1870402|NCT01102595|Radiation|Standard radiation therapy|42-49 days with standard radiation therapy (60 Gy): 2 Gy per day.
1870403|NCT01102608|Drug|Ifosfamide|3 cycles of Ifosfamide (12g/m2) associated to Mesna (6g/m2), in i.v infusion 6 days, every 3 weeks
1870404|NCT01102634|Device|Transcutaneous electrical nerve stimulation (TENS)|Application of TENS over acupuncture points
1870405|NCT01102634|Device|Transcutaneous electrical nerve stimulation (TENS)|Placebo
1870406|NCT01102647|Dietary Supplement|phytosterol ester|1.6 g phytosterols/day for 29 days
1870407|NCT01102660|Drug|PH-797804|Tablet, 6 mg once daily for 2 weeks
1870408|NCT01102660|Drug|Placebo|Tablet, 0 mg once daily for 2 weeks
1870409|NCT01102660|Drug|Placebo|Tablet, 0 mg once daily for 2 weeks
1870410|NCT01102660|Drug|PH-797804|Tablet, 6 mg once daily for 2 weeks
1870411|NCT01102660|Drug|Naproxen|Tablet, 500 mg twice daily for 2 weeks
1870412|NCT01102660|Drug|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
1870413|NCT01102660|Drug|Naproxen + PH-797804|Tablet, 500 mg twice daily for 2 weeks and Tablet, 6 mg once daily for 2 weeks
1870414|NCT01102660|Drug|Naproxen|Tablet, 500 mg twice daily for 2 weeks
1870415|NCT01102673|Drug|PF-04991532|The tentative dosing schedule is 30, 100, 300, 600, 1200, and 2000 mg. Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as extemporaneously-prepared powder in capsule (PIC) formulation.
1870416|NCT01102673|Drug|Placebo|Placebo to match PF-04991532 will be provided
1870417|NCT01102686|Drug|Pyrimethamine|Pyrimethamine will be taken orally as a single daily dose of 25 mg/day for 4 weeks, then increasing by 25 mg per dose in three four-week steps, to a final dose of 100 mg/day
1870418|NCT01102686|Drug|Leucovorin|To eliminate or minimize potential hematologic effects of Pyrimethamine, Leucovorin is to be co-administered with Pyrimethamine at a dose level of 5 mg per day, given when Pyrimethamine is administered.
1870419|NCT01102699|Drug|Filgrastim, hrG-CSF|Single subcutaneous injection of Filgrastim (hrG-CSF) 300 microg (30 MU)
1870420|NCT01102712|Device|BTVA System|Unilateral Bronchoscopic Thermal Vapor Ablation for Lung Volume Reduction
1870421|NCT01102764|Behavioral|Telemedicine|Prolonged Exposure (PE) therapy provided at patients house via telemedicine
1870422|NCT01102764|Behavioral|In Person|PE therapy delivered in person at the VAMC
1870423|NCT01102777|Behavioral|automated internet-mediated walking program|intervention participants are encouraged to walk daily to their step-count goal while wearing a pedometer provided by the study that will measure their daily step-counts. They are also encouraged to log into their personally tailored website to upload their step counts and obtain other information about the study and progress
1870424|NCT01102777|Other|Usual Care|Control group, instructed to wear the pedometer but not provided with walking goals or instruction.
1870425|NCT01102803|Behavioral|Individual Cognitive Behavioral Therapy (CBT)|The aim of CBT is to help participants become more comfortable with heights situations. Participants will receive 2 sessions over two weeks of individual CBT.
1870426|NCT01102803|Drug|D-Cycloserine|D-Cycloserine
1870427|NCT01102803|Drug|Placebo|Sugar Pill
1870428|NCT01102816|Other|Individualized acupuncture treatment|"Individualized acupuncture treatment which focuses on each patient's symptoms and conditions will be provided twice a week for 6 weeks on a non-dialysis access day or before hemodialysis at dialysis-access day. 10-20 acupuncture needles will be inserted on the body except the arteriovenous fistula-located arm(s). Electrical stimulation of acupuncture will be conducted on 4 needles and the remained needles will be manipulated manually to elicit de-qi sensation. Needle retention time will be 20 minutes.
Routine care provided by dialysis staffs, primary physicians and other healthcare providers will be maintained.
Patients who received acupuncture treatment will be interviewed to explore patient's perceptions and experiences of acupuncture for their pain management. (Nested-qualitative study)"
1870429|NCT01102816|Other|Routine care|Patients in this group will maintain routine care provided by their dialysis staffs, primary physicians or other healthcare providers for symptomatic care and disease management of end-stage renal disease through 6 weeks. After post-treatment evaluation, acupuncture treatment will be provided to patients who want to receive acupuncture treatment.
1870430|NCT01102868|Device|Needle in acupuncture point Li11|Acupuncture needle in acupuncture point Li11
1870431|NCT01102868|Device|IMS of the musculus pronator teres|Acupuncture needle in musculus pronator teres
1870432|NCT01102881|Dietary Supplement|Glucose polymer fiber|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
1870433|NCT01102881|Dietary Supplement|Fiber made from corn starch|20 grams of fiber per day split into two 10 gram doses administered as a breakfast cereal and a muffin or no-fiber breakfast cereal and muffin
1870434|NCT01102881|Dietary Supplement|placebo|low fiber breakfast cereal and muffin
1870435|NCT01102894|Device|SmartPill|SmartPill
1870436|NCT01102907|Other|Liquid Breakfast|The liquid breakfast meal will contain 370 calories and will consist of fruit juices and skim milk
1870437|NCT01102907|Other|Solid Breakfast Meal|The solid breakfast will contain 370 calories and will consist of oatmeal, golden delicious apples, blueberries, skim milk, and brown sugar.
1870438|NCT01102920|Behavioral|Behavioural strategies to promote physical activity and weight loss|"8-10 sessions, 2-4 booster sessions Behavioural protocol in seven steps to initiate, carry out and maintain health-enhancing physical activity and sound eating habits.
Steps are standardized including: progressive goal setting, self-monitoring, functional behavioural analysis, skills training (basic and applied), generalization, and maintenance and relapse prevention. Content within each step is tailored to individual expectations and skills.
Treatments are provided by a physical therapist and a dietician."
1870439|NCT01102920|Device|CPAP|CPAP-treatment as usual (during nights)
1870440|NCT01102946|Drug|Ranibizumab|Ranibizumab (Lucentis), intravitreal injections of 0.05ml
1870441|NCT01102946|Procedure|Panretinal Photocoagulation|Panretinal photocoagulation with green laser according to ETDRS
1870443|NCT01102972|Drug|Reyataz + Norvir + Truvada|atazanavir 300mg + ritonavir 100mg + tenofovir 300mg/emtricitabine 200mg
1870444|NCT01102972|Drug|Reyataz + Epzicom|atazanavir 400mg + abacavir 600mg/lamivudine 300mg
1870445|NCT01102985|Behavioral|aerobic resistance exercise|three times per week aerobic resistance exercise for 12 months
1870446|NCT01102985|Behavioral|home based health promotion|education and support to adapt national guidelines for 30 minutes physical activity most days of the week
1870447|NCT01103011|Drug|ND0611|Continuous delivery of ND0611
1870448|NCT01103011|Drug|ND0611|Solution of ND0611 delivered continuously
1870449|NCT01103024|Biological|AIN457|
1870450|NCT01103024|Biological|AIN457|
1870451|NCT01103024|Biological|AIN457|
1870452|NCT01103024|Biological|Placebo|
1870453|NCT01103037|Drug|QAV680|QAV680 500 mg (5 x 100 mg capsules) four times per day
1870454|NCT01103037|Drug|QAV680 Placebo|Placebo to QAV680 5 capsules four times per day
1870455|NCT01103050|Drug|QAV680 + Cetirizine Placebo|
1870456|NCT01103050|Drug|QAV680 + Cetirizine|
1870457|NCT01103050|Drug|Cetirizine + QAV680 Placebo|
1870458|NCT01103050|Drug|QAV680 Placebo + Cetirizine Placebo|
1870644|NCT01105143|Behavioral|multimodal lifestyle intervention|multimodal lifestyle intervention will be performed to reduce body weight
1870459|NCT01103063|Drug|Azithromycin plus chloroquine|combination tablet of 250mg azithromycin/155 chloroquine, Once daily PO for three days per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
1870460|NCT01103063|Drug|sulfadoxine-pyrimethamine|Fansidar tablet (500 mg sulfadoxine /25 mg pyrimethamine), once daily, PO, single dose per treatment. There are total 3 treatments at 4-8 weeks intervals. The first treatment course will be administered during the second trimester (14-26 weeks of gestation as confirmed by ultrasound). The last treatment course should be given to subjects prior to or during 36 weeks of gestation.
1870461|NCT01103076|Device|Polyamide HD membrane|Single use polyamide membrane
1870462|NCT01103102|Drug|Iocide Oral Rinse|Oral Rinse; dosages vary by treatment group; once to twice daily use (depending on treatment group); 12 weeks duration
1870463|NCT01103102|Drug|Placebo|Placebo
1870464|NCT01103115|Dietary Supplement|Calcium 600mg plus Vit D 400 IU|Daily supplementation with 600mg Calcium plus 400IU Vitamin D3
1870465|NCT01103115|Dietary Supplement|Calcium 600mg plus Vit D 800 IU|Daily supplementation with 600mg Calcium plus 800IU Vitamin D3
1870466|NCT01103115|Dietary Supplement|Placebo|placebo tablets
1870467|NCT01103141|Device|Micropuncture needle set|Groin access for vascular intervention
1870468|NCT01103141|Device|Standard gauge-18 needle set|Groin access for vascular intervention
1870469|NCT01103154|Drug|carvedilol|6.25mg per day, increase to 6.25mg bid
1870470|NCT01103154|Drug|nadolol + ISMN|nadolol 40-80mg ISMN 10-20mg
1870473|NCT01103193|Drug|remifentanil injected|mixture of 60% nitrous oxide and 40% oxygen is administered through a face mask. In the first group the patient receives a constant concentration of sevoflurane. In this group the remifentanil concentration will be injected via an intravenous line in a step up protocol.
1870474|NCT01103193|Drug|sevoflurane in step up concentration|of 60% nitrous oxide and 40% oxygen is administered through a face mask.remifentanil is injected in a fixed rate and sevoflurane is administered in a step up concentration.
1870475|NCT01103206|Drug|cinacalcet|Intake of a single tablet of cinacalcet
1870476|NCT01103206|Drug|cinacalcet dose 1|PTH suppression test in primary hyperparathyroidism using cinacalcet (dose 1).
1870477|NCT01103206|Drug|cinacalcet dose 2|Parathyroid hormone suppression test in primary hyperparathyroidism using cinacalcet (dose 2).
1870478|NCT01103219|Dietary Supplement|Nutrition|The control (placebo) group will be fed according to the routines of the participating institutions. The intervention (active) group will receive increased supply of energy, protein, vitamin A and long-chain unsaturated fatty acids.
1870479|NCT01103232|Procedure|Experimental group|Electrical muscle stimulation (EMS) of the right wrist flexor muscles was applied. EMS was applied for 20 minutes. Maximum current intensity tolerated was used so as to stimulate the highest possible number of motor unit. The stimulation intensity increased every five minutes during a session. Electrical stimulation was applied for thirty sessions (one session a day, five days a week for six weeks.)
1870480|NCT01103232|Procedure|Control group|Conventional mode of transcutaneous electrical nerve stimulation (TENS) was applied for the control subjects. TENS was applied for 20 minutes. The stimulus intensity was adjusted as the lowest current at which the subject felt only a slight tickling of the impulses. A visible, and palpable muscle contraction was not provided during TENS stimulation. The stimulus intensity was not changed during the first session. Subsequently, TENS was applied at same intensity in all sessions. TENS was applied for thirty sessions (one session a day, five days a week for six weeks).
1960051|NCT03307096|Procedure|Microperc surgery|Parents are treated by Microperc Percutaneous Nephrolithotomy
1960052|NCT03307096|Procedure|FURS|Parents are treated by FURS
1870484|NCT01103258|Procedure|high ligation and stripping (surgery)|surgery consisting of high ligation in combination with long saphenous stripping
1870485|NCT01103258|Procedure|FOAM|duplex guided foam sclerotherapy
1870486|NCT01103271|Other|Open-label Placebo|Participants take open-label placebo pills - two twice daily for four weeks.
1870487|NCT01103284|Drug|DiaPep277|1.0 mg dose in 0.5 mL of solution
1870488|NCT01103284|Drug|Placebo|"40 mg mannitol in 0.5 mL of solution.
Dosing: 0, 1, 3, 6, 9, 12, 15, 18, 21, 24 months"
1870489|NCT01103297|Device|Variable Angle Distal Radius Plate ® (Surgery)|Fracture reduction with distal radius plate
1870490|NCT01103310|Drug|BAY94-9392|
1870491|NCT01103323|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg per oral once daily for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
1870492|NCT01103323|Drug|Placebo|matching placebo tablets for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
1870493|NCT01103323|Other|Best Supportive Care (BSC)|BSC includes any concomitant medications or treatments: antibiotics, analgesics, radiation therapy for pain control (limited to bone metastases), corticosteroids, transfusions, psychotherapy, growth factors, palliative surgery, or any other symptomatic therapy necessary to provide BSC, except other investigational anti-tumor agents or anti-neoplastic chemo/hormonal/immuno-therapy.
1870530|NCT01097889|Dietary Supplement|RUSF (ready-to-use supplementary foods) Supplementary Plumpy®|"Peanut-based fortified supplement
One 92g sachet eaten throughout the day Bi-weekly distributions of 14 sachets 500 kcal and 13g protein"
1870531|NCT01097902|Drug|Ibuprofen|800 mg oral one time only
1870494|NCT01103336|Drug|pretreatment with intravenous nicorandil vs. placebo before coronary angiography|"Nicorandil group: Pretreatment with intravenous Nicorandil (Sigmart for injection, Choongwae Pharma, Seoul) 12 mg in 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography
Control group: Pretreatment with intravenous 0.9% saline 100 ml over 2 hours starting from 1 hour prior to coronary angiography"
1870495|NCT01103349|Drug|BI671800|Double blind randomised parallel group study to assess efficacy and tolerability of BI617800 in patients with symptomatic asthma
1870496|NCT01103349|Drug|Placebo|Patients receive placebo capsules and/or encapsulated tablets
1870497|NCT01103349|Drug|Montelukast|Double blind randomised parallel group study to assess efficacy and tolerability of BI671800 in patients with symptomatic asthma
1870498|NCT01103362|Drug|flibanserin|all patients will receive open-label flibanserin 100mg
1870499|NCT01103375|Drug|erlotinib hydrochloride|Given PO
1870500|NCT01103375|Drug|isotretinoin|Given PO
1870501|NCT01103375|Other|laboratory biomarker analysis|Correlative study
1870502|NCT01103375|Genetic|protein expression analysis|Correlative study
1870503|NCT01103388|Drug|Rituximab|375 mg/m^2 by vein (IV) in 4 weekly doses (1 cycle) every 6 months for 4 cycles.
1870504|NCT01103401|Drug|Drug: Tobramycin 0.3% - Dexamethasone 0.1%|one drop four times per day
1870505|NCT01103401|Drug|Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine|Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
1870506|NCT01103414|Drug|Mitoglitazone|50 mg capsules, once daily for 84 days
1870507|NCT01103414|Drug|Mitoglitazone|Mitoglitazone 100 mg capsules, once daily for 84 days
1870508|NCT01103414|Drug|Mitoglitazone|Mitoglitazone 150 mg capsules, once daily for 84 days
1870509|NCT01103414|Drug|Pioglitazone|Pioglitazone 45 mg, once daily for 84 days
1870510|NCT01103414|Drug|Placebo|Placebo, once daily for 84 days
1870511|NCT01103427|Device|Internet-based behavioral coaching|"Those in the active comparator arm will benefit from automated coaching by e-mails with advice, information and support for smoking cessation. These e-mails will be adapted to their personal profile."
1870512|NCT01103427|Device|SMS based coaching|Those in the experimental SMS based coaching arm will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
1870513|NCT01103427|Device|SMS coaching - UNN recruited|Those in the experimental SMS based coaching arm- UNN recruited - will benefit from automated coaching by SMS with advice, information and support for smoking cessation. These SMS's will be adapted to their personal profile.
1870514|NCT01103427|Device|SMS craving function - UNN recruited|Those in the experimental SMS based craving/panic function arm - will in addition to the automated coaching by SMS have a panic/craving SMS function. Thus by sending a SMS they will receive instant advise and support for smoking cessation by SMS.
1870515|NCT01103440|Drug|Intravenous Glycoprotein inhibitor + ASA, Clopidogrel|IV Glycoprotein IIb/IIIa inhibitor bolus intra procedurally
1870516|NCT01103440|Drug|Antiplatelet Therapy (ASA, Clopidogrel)|Standard antiplatelet PCI treatment
1870518|NCT01103466|Device|Atlas|Altas base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
1870519|NCT01103466|Device|SenSura|SenSura base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
1870520|NCT01103466|Device|Conform 2|Conform 2 base plates are tested for 14 days (minimum 4 base plates) and the degree of leakage under the baseplate is measured and compared to two other types of base plates.
1870521|NCT01103479|Behavioral|Physician Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training
1870522|NCT01103479|Behavioral|Physician and Patient Intervention|Physicians at these clinics will participate in 6 training sessions over the course of 3 1/2 years; training sessions relate to colorectal cancer (CRC) screening guidelines, communication skills, and health literacy training; patients in this condition will also view an educational DVD on CRC and CRC screening
1870523|NCT01103492|Device|HALO90 Ablation catheter|FDA approved endoscopic device for use in coagulation of tissue in the digestive tract using radiofrequency energy.
1870525|NCT01103518|Drug|Ethinyl Estradiol + Cyproterone acetate|Ethinyl Estradiol (0.035mg) + Cyproterone acetate (2mg), coated tablets. Each treatment cycle consists of one tablet, once per day for 21 days followed by a 7-day rest period. A total of 4 treatment cycles will be completed during the study treatment period.
1870526|NCT01103531|Behavioral|Aerobic and Resistance Exercise|Aerobic and resistance exercise for 24 exercise training sessions over an 8-week period (three times weekly).
1870527|NCT01103531|Behavioral|Educational information about health topics|A counselor will meet with participants for 24 sessions (3 times/week) over an 8-week period to present and discuss information that includes topics on health and wellness, and lifestyle topics such as healthy eating, meditation, sleep hygiene, and cancer screening.
1870528|NCT01103557|Procedure|prophylactic selective lateral neck dissection|Level II, III, IV lymph node dissection
1870529|NCT01097889|Dietary Supplement|Fortified blended foods, Corn Soya Bean Flour (CSB) with oil.|A daily ration equivalent of 300g CSB and 32g vegetable oil Bi-weekly distribution of premix of 4.2kg CSB with 0.5L vegetable oil. Estimated 1413 kcal, 47g protein
1870532|NCT01097902|Drug|Placebo tablet|Placebo tablet oral one time only
1870536|NCT01097941|Biological|Influenza A (H1N1) 2009 Monovalent Vaccine/ Influenza A (H1N1) Monovalent Vaccine Live|0.5 ml IM given X1 with 0.1 ml intranasally given 28 days later
1870537|NCT01097967|Other|CPAP|
1870538|NCT01097980|Drug|Trazodone|50 mg/d trazodone was upwardly titrated to 100 mg/d over one week and then maintained
1870539|NCT01097980|Drug|Placebo|Placebo
1870540|NCT01103570|Procedure|cholecystocholangiography|a central venous pressure catheter was introduced through the anterior abdominal wall subcostally in a direction parallel to the gallbladder bed under direct vision so that it emerges close to the gall bladder. Then the catheter was advanced into the fundus of the gall bladder . The dye was prepared by diluting 20ml of 76% urografin with 20ml normal saline in a 50ml syringe
1870541|NCT01103570|Procedure|cystic duct cholangiography|Then a 14G cannula was introduced through the anterior abdominal wall subcostally, (size 4F), was introduced through this cannula. The catheter was inserted into the cystic duct no more than 1 cm, by a grasper Then a 50ml syringe with the diluted urografin dye, as above, was attached to the catheter and cholangiography was performed by slowly injecting the dye under control of C-arm image intensifier.
1870542|NCT01103583|Drug|Hydroxyurea|500 mg/die per os for two years
1870543|NCT01103583|Other|placebo|500 mg/die per os for two years
1870544|NCT01103609|Drug|Warfarin|Oral tablet od on Day 4
1870545|NCT01103609|Drug|Placebo|Oral tablet bd, stepwise increased
1870546|NCT01103609|Drug|AZD1656|Oral tablet bd, stepwise increased
1870547|NCT01103622|Drug|AZD1656|Oral tablet bd, step-wise increased dosage
1870548|NCT01103622|Drug|Digoxin|Oral tablet od on Day 4
1870549|NCT01103622|Drug|Placebo|Oral tablet bd, step-wise increased dosage
1870550|NCT01103635|Biological|CD40 agonist monoclonal antibody CP-870,893|Given IV
1870551|NCT01103635|Biological|tremelimumab|Given IV
1870552|NCT01103635|Other|laboratory biomarker analysis|Correlative studies
1870553|NCT01103648|Drug|Simvastatin|Tablets of simvastatin 20 mg administered once a day for 12 weeks
1870554|NCT01103648|Drug|Ezetimibe|Tablets of ezetimibe 10 mg administered once a day for 12 weeks
1870555|NCT01103648|Drug|Combination Simvastatin plus Ezetimibe|"Simvastatin 20 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with ezetimibe 10 mg (12 week duration).
Ezetimibe 10 mg, once a day, was administered for an additional 12-week period for the subset of individuals who took the initial monotherapy with simvastatin 20 mg (12 week duration).
This Combination represents the experimental period of the present study."
1870556|NCT01103661|Device|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the nContact Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the St. Jude Medical Therapy™ Cool Path™ Ablation Catheter endocardially.
1870557|NCT01103674|Device|Numeris®-AF Guided Coagulation System with VisiTrax®|Combined epicardial / endocardial procedure using the Numeris®-AF Guided Coagulation System with VisiTrax® epicardially and the Biosense Webster ThermoCool Catheter in conjunction with the Carto Navigation System endocardially.
1870558|NCT01103687|Biological|Ad26.ENVA.01 (rAd26)|5 x 10^10 virus particles (VP) vaccine delivered intramuscularly (IM)
1870559|NCT01103687|Biological|Placebo Vaccine|Placebo vaccine delivered IM
1870560|NCT01103713|Drug|Azithromycin plus chloroquine|Study drug is a fixed dose tablet of AZCQ containing 250 mg AZ and 155 mg CQ base. All subjects will be administered a 3 day course of AZCQ IPTp regimen: a single dose of 1000 mg AZ/620 mg CQ base (4 fixed dose combination tablets of AZCQ: 250mg/155mg) administered per os (PO, orally) once daily for 3 days (Days 0, 1, 2).
1870561|NCT01103726|Drug|PF-02545920|1 and 5 mg tablets, 6 mg single dose
1870562|NCT01103726|Drug|placebo|matching placebo tablets, single dose
1870563|NCT01103726|Drug|PF-02545920|1 mg tablets, 3 mg single dose
1870564|NCT01103726|Drug|PF-02545920|5 mg tablets, 15 mg single dose
1870565|NCT01103726|Drug|Placebo|matching placebo tablets, single dose
1870566|NCT01103739|Drug|PF-04531083|PF-04531083: 100mg to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
1870567|NCT01103739|Drug|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
1870568|NCT01103739|Drug|PF-04531083|PF-04531083: a dose to be selected depending on results from Cohort 1 to be dosed twice daily as a suspension from Day 2 through Day 14 of the study.
1870569|NCT01103739|Drug|simvastatin|Simvastatin: a single 20mg tablet to be given on Days 1 and 14 of the study.
1870570|NCT01103752|Other|no intervention, descriptive study|no intervention, descriptive study
1870571|NCT01103765|Procedure|post dilatation after stent deployment|Post-dilatation with a noncompliant balloon larger 0.25mm than stent balloon.
1870572|NCT01103765|Procedure|stent deployment without post-dilatation|stent deployment without systematic post dilatation
1870573|NCT01103778|Drug|Bortezomib (Velcade®)|Velcade® at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). A second cycle is to be given a month later for non-responders.
1870574|NCT01103791|Drug|Docetaxel-PNP|Docetaxel-PNP, Polymeric Nanoparticle Formulation of Docetaxel
1870575|NCT01103817|Dietary Supplement|Vitamin D|"Dosing If the 25 OH Vitamin D level at Baseline/Screening is less than 20 nmol/L then the subject will receive 2000 IU daily.
If the 25 OH Vitamin D level at Baseline/Screening is between 20 and 37.5 nmol/L then the subject will receive 1000 IU daily."
1870576|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3
1870577|NCT01103830|Drug|Riamet®|4 tablets of Riamet® (20mg artemether/120mg lumefantrine) on Day -1 evening, 4 tablets of Riamet® bid (with an interval of 12 ± 0.5 h), in the morning and in the evening of Day 1 and Day 2, 4 tablets of Riamet® in the morning of Day 3.
1870578|NCT01103830|Other|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.
1 tablet of Izilox® (400 mg moxifloxacin) on Day 4 morning."
1870579|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
1870580|NCT01103830|Drug|Eurartesim™|3 or 4 tablets of Eurartesim™ (40mg Dihydroartemisinin and 320 mg Piperaquine phosphate), depending of body weight (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day 1 to Day 3.
1870581|NCT01103830|Other|Placebo and finally Moxifloxacin|"3 or 4 tablets of Eurartesim™ placebo, depending of body weight, (3 tablets for subjects weighting less than 75 kg, 4 tablets for subjects weighting 75 kg or more), once daily from Day1 to Day 3.
1 tablet of Izilox® (400 mg moxifloxacin)on Day 4 morning."
1870584|NCT01103856|Behavioral|Patient Mentor Intervention|The first session includes an exploration of needs, barriers, and facilitators to HIV care. HIV educational materials are introduced to identify areas of need. Mentors will address concerns and possible barriers to care using their own experiences. Mentors will encourage participants to set goals related to acquisition of care following discharge and how to address possible barriers to that goal. The second session will reinforce the first session. Mentors will call the patient 5 times over the 10 weeks after discharge. These phone calls will be brief and goal centered, to either reinforce positive behavior if the patient is in care, or continue to help the patient re-engage in outpatient HIV care.
1870585|NCT01103856|Behavioral|HIV transmission risk reduction|The control intervention is a modification of the project RESPECT intervention. We will use material from sessions 1, 2, and 3 of the RESPECT enhanced counseling intervention. These interactions will include a personalized assessment of risk behaviors and changing condom use self-efficacy. The second interaction will build on material covered during the first interaction, with additional focus on condom use attitudes. The counselors will call the patient 5 times in the 10 weeks after discharge. These phone-based sessions will be brief and goal centered, to reinforce safe HIV transmission behaviors.
1870586|NCT01104701|Drug|exenatide once weekly|subcutaneous injection, 2 mg, once a week
1870587|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, low dose, once a month
1870588|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, medium dose, once a month
1870589|NCT01104701|Drug|exenatide once monthly suspension|subcutaneous injection, high dose, once a month
1870590|NCT01104727|Procedure|4-Ports Cholecystectomy (4PC)|a 12mmHg pneumoperitoeum is created either by a 10mm umbelical Hasson's port or by a Verress needle followed by a 10 mm umbelical port insertion; further one 10mm and two 5mm ports are placed according to the preferred technique. A straight or angulated laparoscope may be used. Laparoscopic graspers, monopolar hook, bipolar forceps, scissors and 10mm clips-applier are used. A plastic bag system might be used for gall bladder extraction if necessary. In both 10 and 12mm accesses, fascia is sutured with resorbable sutures. Skin is secured by either metallic agraffes or interrupted sutures.
1870591|NCT01104727|Procedure|Single-Port Cholecystectomy (SPC)|"a 2.5cm long skin incision around the umbilicus is performed. The subcutaneous tissue is dissected, the muscular fascia exposed and incised along the middle line (linea alba) respecting the muscular tissue. Peritoneum is identified and incised. The Single-Port device is inserted and anchored.
In order to retract the gallbladder a transcutaneous suture is placed in the right hypocondrium with a straight needle and a monofilament thread which are passed through the fundus and knotted outside the skin. The following steps reproduce the traditional laparoscopic cholecystectomy. Each centre will be left free to use dedicated instruments and which or traditional laparoscopic ones."
1870592|NCT01104740|Other|Biological sample collection|Blood (serum) sample collection
1870593|NCT01104766|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral low dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
1870594|NCT01104766|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral high dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
1870595|NCT01104766|Drug|Aripiprazole|Patients who meet eligibility criteria will be administered a once daily oral dose of aripiprazole for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
1870596|NCT01104766|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
1870597|NCT01104779|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral low dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
1870598|NCT01104779|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral high dose of cariprazine for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
1870599|NCT01104779|Drug|Placebo|Patients who meet eligibility criteria will be administered a once daily oral dose of placebo for six weeks. Upon completion of the study or early termination, patients will undergo a two week safety follow-up period.
1870600|NCT01104792|Drug|Cariprazine|Patients who meet eligibility criteria will be administered a once daily oral dose of cariprazine.
1870601|NCT01104805|Behavioral|Therapeutic Education System (TES)|Participants will received modified treatment-as-usual plus the computerized psychosocial intervention (Therapeutic Education System), including contingency management. Participants will be asked to use the self-directed TES intervention twice weekly and will be asked to complete 2 modules during each session (for a total of 4 modules per week) during the 12-week intervention. Participants will receive incentives contingent primarily upon abstinence from drugs of abuse and, secondarily, upon completion of TES modules.
1870645|NCT01105143|Behavioral|placebo|no intervention, only follow up
1870646|NCT01105156|Behavioral|VEW Questionnaire|Patient Self reported questionnaire filled in.
1870647|NCT01105169|Dietary Supplement|Magnesium glycinate|Oral administration of magnesium glycinate daily for 12 weeks
1870602|NCT01104805|Behavioral|Treatment-as-Usual (TAU)|Participants in this condition will receive TAU, consisting of standard treatment offered at each collaborating CTP and will reflect the model of treatment typically provided to most individuals in outpatient, community-based substance abuse treatment settings in the U.S. These sessions will consist of a combination of group and individual counseling.
1870603|NCT01104818|Behavioral|Siblings in foster care curriculum, Parent Management Training|Each year, approximately 800,000 youth are cared for in foster homes across the nation. About 70% of these youth are known to suffer from mental health and educational disabilities and frequently transition to adulthood with lifelong deficits. The majority of youth in foster care have siblings in care. It is anticipated that the proposed intervention will significantly improve key outcomes for youth in the study and will provide much needed information on best practices to help youth in foster care.
1870604|NCT01104831|Device|Cryotherapy|cooled sleeve placed over fracture site.
1870605|NCT01104831|Device|Room temperature cuff|sleeve with room temperature water placed over fracture site.
1870606|NCT01104844|Drug|Full Dose Strength|Acetaminophen + ibuprofen, 2 tablets every 6 hours, with food for 24 hours (i.e a total of 4 x 1000/300 mg doses of study drug comprising of 8 tablets)
1870607|NCT01104844|Drug|Quarter dose strength|Investigational drug quarter dose strength (acetaminophen 125mg + ibuprofen 37.5mg) i.e. 2 tablets equating to 1/4 the dose in the standard investigational drug.
1870608|NCT01104844|Drug|Half dose strength|Investigational drug half dose strength (acetaminophen 250mg + ibuprofen 75mg) i.e. 2 tablets equating to 1/2 the dose in the standard investigational drug
1870609|NCT01104844|Drug|Acetaminophen standard dose|Acetaminophen standard dose 500mg i.e. 2 tablets equating to the same acetaminophen dose as in the standard investigational drug
1870610|NCT01104844|Drug|Ibuprofen low dose|Ibuprofen low dose 150mg tablet i.e. 2 tablets equating to the same ibuprofen dose as in the standard investigational product
1870611|NCT01104844|Drug|Ibuprofen high dose|Ibuprofen high dose 300mg i.e. 2 tablet equating to twice the ibuprofen dose as in the standard investigational drug
1870612|NCT01104844|Drug|Placebo|2 placebo tablets
1870613|NCT01104857|Procedure|diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
1870614|NCT01104857|Procedure|Diaphragm muscle biopsy|Biopsy is obtained for biochemical analysis
1870615|NCT01104870|Drug|UT-15C|oral
1870616|NCT01104883|Procedure|Adductor-Canal-Blockade|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
1870617|NCT01104883|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
1870618|NCT01104896|Drug|Nicotine patch|One or two 15 mg nicotine patch(es) applied from 6am to 10 pm during 21 days
1870619|NCT01104896|Drug|Placebo|One or two placebo patch(es) applied from 6am to 10 pm each day for 21 days
1870620|NCT01104909|Procedure|Clinical|Each patient will be submitted a clinical evaluation, considering signals of overload.
1870621|NCT01104909|Device|electrical bioimpedance|From electrical bioimpedance data, will be fixed a revised dry weight for each patient.
1870622|NCT01104922|Other|Cetuximab and stereotactic radiosurgery|Treatments Administered: - Fractionated stereotactic radiosurgery, 8.0 Gy per fraction for 5 fractions (total: 40.0 Gy); - Cetuximab will be administered for 3 weekly doses commencing one week prior to stereotactic radiosurgery treatment as follows: * Cetuximab 400 mg / m2 day -7 (1 week prior to initiation of radiosurgery) * Cetuximab 250 mg/m2 days 0 and +8 (i.e. during the first and second week of fractionated stereotactic radiosurgery) Cetuximab will be administered at 400 mg/m2 IV over 120 minutes on day -7 (loading dose) and 250 mg/m2 IV on days 0 and 8 during the course of stereotactic radiosurgery. Administration of cetuximab may or not be the same day that a fraction of SRS is given. Infusion reactions may occurring during the administration of cetuximab and rarely post-infusion.
1870623|NCT01104935|Drug|trastuzumab monotherapy|
1870624|NCT01104935|Drug|trastuzumab and chemotherapy|
1870625|NCT01104948|Drug|DA-8031|
1870626|NCT01104948|Drug|Placebo|
1870627|NCT01104961|Device|Contact lens packaging solution|These test solutions are the intervention being tested.
1870628|NCT01104961|Device|Balanced salt solution (BSS)|BSS is isotonic to the tissues of the eyes.
1870629|NCT01104987|Drug|alendronate|One tablet of alendronate à 70 mg once a week during two years.
1870630|NCT01105013|Drug|Clotrimazole|Apply the product in sufficient quantity to cover the affected area 2 times daily (every 12 hours) for 60 days.
1870631|NCT01105026|Device|Alveolar Bone Defect Regeneration Following Tooth Extraction|"Patients underwent surgery under local anesthesia and minimally invasive periotomy was carried out with a surgical blade. Atraumatic extraction with forceps was performed. The extraction socket was carefully curetted to remove the granulation tissue and was rinsed with a physiologic solution. To evaluate the eligibility of the surgical site, the alveolar walls integrity was checked clinically and by means of extemporaneous peri-apical radiography.
Then, the socket was filled to the bone margin with Inion BioRestore™ (granules size 1 to 2 millimetres). Finally, single interrupted (5-0) sutures were tightened to promote the stability of grafted particles. Ten days after the surgery, sutures were removed."
1870632|NCT01105052|Behavioral|Self-help CBT-I|Comparison between Bibliotherapy with and without support to a wait-list control group
1870633|NCT01105065|Drug|brimonidine 0.15%|One drop in each eye three times a day for 8 weeks.
1870634|NCT01105078|Procedure|Flow rate|Different flow rate during cardiopulmonary bypass
1870635|NCT01105091|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
1870636|NCT01105091|Drug|Flolan®|Per Prescribing Information
1870637|NCT01105104|Device|MedMinder System|Participants will receive a fully activated reminder unit as well as at least one call per month from a counselor.
1870638|NCT01105104|Device|MedMinder System - deactivated|Participants will receive a one-way reminder unit that will remotely transit information on medication adherence
1870639|NCT01105117|Drug|ACT-385781A (Actelion Epoprostenol)|per Prescribing Information
1870640|NCT01105117|Drug|Flolan®|per Prescribing Information
1870641|NCT01105130|Other|Placebo|Given orally
1870642|NCT01105130|Dietary Supplement|Oral L-Arginine|Given orally 3 capsules ArginMax and 3 Placebo capsules
1870643|NCT01105130|Dietary Supplement|Oral L-Arginine|Patients will take 6 capsules of ArginMax twice daily
1870751|NCT01105702|Drug|Bevacizumab|
1870648|NCT01105169|Dietary Supplement|Placebo|Oral administration of identical-appearing placebo daily for 12 weeks
1870649|NCT01105182|Procedure|Radiofrequency Ablation|Radiofrequency ablation is an inpatient procedure typically requiring one overnight stay in the hospital.
1870650|NCT01105195|Other|DuraPrep|DuraPrep is used for skin preparation prior to surgery.
1870651|NCT01105195|Other|ChloraPrep|ChloraPrep is used for skin preparation prior to surgery.
1870652|NCT01105208|Drug|Cephalexin suspension (Optocef, BAYO5448 )|Single dose of 500 mg / 10 mL
1870653|NCT01105208|Drug|Cephalexin suspension (Keflex)|Single dose of 500 mg / 20 mL
1870654|NCT01105221|Device|Acupuncture|Participants, allocated to this group, will have twelve times of acupuncture treatment in four weeks. Seventeen acupuncture points, which are both BL2, GB14, TE23, Ex1, ST1, GB20, LI4, LI11 and single GV23, will be selected and disposable 0.20*30mm acupuncture needles(Dongbang Co., Korea) will be inserted on these points. Strong 'deqi' sensation will be induced by twisting acupuncture needles and retained for 20 minutes before removed.
1870655|NCT01105221|Drug|Refresh Plus|Participants, allocated to this group, will be offered preservative-free and single-use Refresh plus (Sodium carboxymethylcellulose). They should use artificial tear in both eyes at least once a day for four weeks.
1870656|NCT01105234|Drug|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues.|
1870657|NCT01105247|Drug|PCI-32765|420 mg daily or 840 mg daily
1870658|NCT01105273|Biological|anti-thymocyte globulin|On days -3 to -1
1870659|NCT01105273|Biological|filgrastim|Beginning on day 4 and continuing until blood counts recover
1870660|NCT01105273|Drug|Fludarabine|30mg/M2 once daily IV on days -6 to -2
1870661|NCT01105273|Drug|Cyclophosphamide|60 mg/kg IV on day-3 and -2
1870662|NCT01105273|Procedure|CD3±CD19 depleted hematopoietic stem cell transplantation|Immunogenetic depletion on CliniMACS
1870663|NCT01105286|Drug|Six different calcipotriol ointment formulations, and two currently marketed topical vitamin D analogues|Once daily application
1870664|NCT01105299|Drug|CJ anastrozole 1 mg tablet|
1870665|NCT01105312|Drug|letrozole|
1870666|NCT01105312|Drug|panobinostat|
1870667|NCT01105312|Genetic|RNA analysis|
1870668|NCT01105312|Genetic|microarray analysis|
1870669|NCT01105312|Genetic|reverse transcriptase-polymerase chain reaction|
1870670|NCT01105312|Other|enzyme-linked immunosorbent assay|
1870671|NCT01105312|Other|immunohistochemistry staining method|
1870672|NCT01105312|Other|laboratory biomarker analysis|
1870673|NCT01105338|Behavioral|Green tea drink|Green tea drink
1870674|NCT01105338|Dietary Supplement|green tea capsules|green tea capsules
1870675|NCT01105338|Other|Green tea placebo capsules|Green tea placebo capsules
1870676|NCT01105338|Dietary Supplement|Lycopene capsules|Lycopene capsules
1870677|NCT01105338|Other|Lycopene placebo capsules|Lycopene placebo capsules
1870678|NCT01105338|Other|Tomato rich diet|Tomato rich diet
1870679|NCT01105351|Dietary Supplement|folic acid plus B6 and B12|folic acid 400 µg plus vitamin B12 plus B6
1870680|NCT01105351|Dietary Supplement|folic acid|folic acid 400 µg
1870681|NCT01105364|Drug|antiangiogenesis therapy|
1870682|NCT01105364|Drug|stabilized sulphur hexafluoride microbubble-based contrast agent|
1870683|NCT01105364|Other|imaging biomarker analysis|
1870684|NCT01105364|Other|pharmacological study|
1870685|NCT01105364|Procedure|computed tomography|
1870686|NCT01105364|Procedure|magnetic resonance imaging|
1870687|NCT01105377|Drug|entinostat|Given orally
1870688|NCT01105377|Drug|azacitidine|Given SC
1870689|NCT01105377|Other|laboratory biomarker analysis|Correlative studies
1870690|NCT01105390|Biological|rilotumumab|Given IV
1870691|NCT01105390|Drug|cisplatin|Given IV
1870692|NCT01105390|Drug|pemetrexed disodium|Given IV
1870693|NCT01105390|Other|laboratory biomarker analysis|Correlative studies
1870694|NCT01105403|Drug|POL6326|IV infusion of POL6326 followed by apheresis to collect mobilized stem cells from peripheral blood
1870695|NCT01105416|Behavioral|Brief Prevention Intervention (BPI)|Brief Prevention Intervention: Participants will receive the BPI, a brief, family-focused prevention intervention in the Pediatric ED. The session will be comprised of parent-targeted skill building directed primarily at parental monitoring and the importance of parent-adolescent communication as the precursor to successful monitoring.
1870696|NCT01105416|Behavioral|ESC|Enhanced standard care
1870697|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 0.3 mg, once daily, 1 day
1870698|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 1.0 mg, once daily, 1 day
1870699|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 3 mg, once daily, 1 day
1870700|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 10 mg, once daily, 1 day
1870701|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 30 mg, once daily, 1 day
1870702|NCT01105429|Drug|BMS-820132|Oral Solution, Oral , 75 mg, once daily, 1 day
1870703|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 150 mg, once daily, 1 day
1870704|NCT01105429|Drug|BMS-820132|Oral Solution, Oral, 300 mg, once daily, 1 day
1870705|NCT01105429|Drug|BMS-820132|Capsule, Oral, (TBD), once daily, 2 days
1870706|NCT01105429|Drug|Placebo|Oral Solution, Oral, 0mg, once daily, 1 day
1870707|NCT01105429|Drug|Placebo|Capsule, Oral, (TBD), once daily, 2 days
1870708|NCT01105455|Other|Nutrition education|Group nutrition classes supplemented by handouts and provision of key study foods.
1870709|NCT01105468|Device|Breath Collecting Unit|Collect two breath gas samples per patient on one day before surgery
1870710|NCT01105468|Device|Breath Collecting Unit|Collect two or more breath gas samples on different days during adjuvant or neo-adjuvant therapy.
1870752|NCT01105702|Drug|Lithium Carbonate|
1870753|NCT01105702|Radiation|Radiation|
1870754|NCT01105728|Procedure|Endoscopic resection|Endoscopic resection of the gastric subepithelial mass
1870835|NCT01106443|Procedure|Hemi-thyroidectomy - CLND|Removal of one thyroid lobe only. No lymphatic dissection.
1870879|NCT01106664|Drug|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg, once daily for multiple-dose study; 4mg at a single dose for food effect study.
1870711|NCT01105481|Drug|Amisulpride add-on|At the beginning of the treatment phase (day 1), subjects in the combination treatment group will be started with adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. All of the add-on amisulpride will be provided to subjects at night. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
1870712|NCT01105481|Drug|Placebo add-on|For subjects randomly allocated to the placebo treatment group, they will be added with one capsule of placebo from Day 1. On Day 8, Day 15 and Day 22, the placebo will be increased to 2, 3 and 4 capsules, respectively. and adjunctive amisulpride, with a starting dose of 200 mg per day. Amisulpride is planned to increase to 400 mg/day on day 8, 600mg/day on day 15 and 800 mg/day on day 22, according to the subjects' responses and tolerability. To permit dose adjustment and ensure double-blind procedure, 200mg amisulpride is packed in capsules identical to those used for the placebo.
1870713|NCT01105494|Drug|epoetin beta [NeoRecormon]|As prescribed by physician
1870714|NCT01105507|Drug|canakinumab (company code: ACZ885D)|
1870715|NCT01105520|Procedure|Diagnostic|SCIM Spinal Cord Independence Measure ASIA scale American Spinal Injury Association
1870716|NCT01105533|Drug|PF-00337210|0.67mg Capsule Once Daily (Accelerated Dose Escalation) Continuous
1870717|NCT01105533|Drug|PF-00337210|1mg Capsule Once Daily (Dose Escalation) Continuous
1870718|NCT01105533|Drug|PF-00337210|2mg Capsule Once Daily (Dose Escalation) Continuous
1870719|NCT01105533|Drug|PF-00337210|4mg Capsule Once Daily (Dose Escalation) Continuous
1870720|NCT01105533|Drug|PF-00337210|6mg Capsule Once Daily (Dose Escalation) Continuous
1870721|NCT01105533|Drug|PF-00337210|9mg Capsule Once Daily (Dose Escalation) Continuous
1870722|NCT01105533|Drug|PF-00337210|8mg Capsule Once Daily (Dose Escalation) Continuous
1870723|NCT01105533|Drug|PF-00337210|4mg Capsule Twice Daily (Dose Escalation) Continuous
1870724|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Escalation) Continuous
1870725|NCT01105533|Drug|PF-00337210|6mg Capsule Twice Daily (Dose Expansion) Continuous
1870726|NCT01105546|Drug|recombinant activated factor VII|90 µg/kg/day i.v.
1870727|NCT01105546|Drug|recombinant activated factor VII|treatment of bleeding episodes with 270 µg/kg (first/single dose) or 90 µg/kg i.v. every 2-3 hours until bleeding resolution
1960061|NCT03303365|Radiation|stereotactic radiosurgery (SRS)|"All patients will receive a pre-treatment cranial MRI for diagnostic and treatment planning purposes.
In Arm A, the contrast-based T1-weighted SPACE sequence is utilized for GTV definition. In Arm B, the contrast-based T1-weighted three-dimensional MPRAGE sequence is utilized for GTV definition. In both cases the GTV consists of all contrasted tissue associated with the target lesion and all additional tissue judged by an experienced physician to be part of the suspect target lesion. To the GTV a PTV margin of 1 mm is added by isotropic expansion that can be slightly modified if deemed necessary by the treating physician (e.g. intersection with adjoining OAR).
Dose prescription to the PTV for target lesions will be as follows:
20 Gy to the 70%-isodose (lesions < 2 cm max. diameter)
18 Gy to the 70%-isodose (lesions 2 - 3 cm max. diameter)
6 x 5 Gy to the conformally surrounding isodose (lesions > 3 cm max. diameter)"
1870730|NCT01105585|Device|Tecnis 1-piece Aspheric Acrylic (ZCB00) IOL|Tecnis 1-piece Aspheric Acrylic (ZCB00) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
1870731|NCT01105585|Device|AcrySof Natural IQ (SN60WF) IOL|AcrySof Natural IQ (SN60WF) intraocular lens implanted in the capsular bag during cataract surgery. The IOL is intended for the lifetime of the patient.
1870732|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (ascending dose), daily for 14 days
1870733|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (optimized dose), daily for 28 days
1870734|NCT01105598|Drug|ETC-1002 or placebo|ETC-1002 (20 mg), daily for 14 days
1870735|NCT01105611|Drug|Raltegravir|400mg orally twice daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
1870736|NCT01105611|Drug|Atazanavir/Ritonavir|Atazanavir 300mg orally once daily boosted with Ritonavir orally 100mg once daily. Number of cycles: unless toxicity or treatment failure occurs, there will be no anticipated treatment discontinuation.
1870737|NCT01105624|Drug|azithromycin ophthalmic solution, 1%|1 drop BID for the first 2 days and then 1 drop QD for the remainder of treatment period (29 ± 1 day)
1870738|NCT01105624|Drug|Visine® for Contacts®|1-2 drops QID for the treatment period (29 ± 1 day)
1870739|NCT01105637|Behavioral|Augmented Exercise Program|12 week (3 x per week) exercise prescription
1870740|NCT01105650|Drug|Fludarabine|Administered intravenously, 25 mg/m^2, days -6 through -2 (5 days).
1870741|NCT01105650|Drug|Cyclophosphamide|Administered intravenously, 60 mg/kg, days -5 and -4.
1870742|NCT01105650|Drug|Cyclosporine|Administered intravenously, CsA 1.5 mg/kg for target dose range of 150-250 ng/mL day -3 through day +14
1870743|NCT01105650|Biological|Natural killer cells|Administered by infusion over less than 1 hour, no more than 8.0 x 10^7 cells/kg will be given.
1870744|NCT01105650|Drug|IL-2|Will be given subcutaneously at 9 million units 3 times a week for a total of 6 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 5 million units/m^2 3 times per week for 6 doses).
1870745|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 10 mg/kg Days -2 to +4 and 1 mg/kg Days +5 to +9
1870746|NCT01105650|Drug|Methylprednisolone|Administered intravenously (IV) 1 mg/kg Days -2 to +9
1870747|NCT01105650|Drug|Interleukin-2|Will be given subcutaneously at million units 3 times a week for a total of 3 doses, beginning 4 hours after NK cell infusion. (For patients weighing less than 45 kilograms, will be given at 3 million units/m^2 3 times per week for 6 doses).
1870748|NCT01105663|Other|Pharmacokinetic Sampling and pharmacogenetic analysis|Pharmacogenetic and pharmacokinetic samples will be obtained from a peripheral catheter, central catheter, or venipuncture coordinated with scheduled phlebotomies. Pharmacokinetic and pharmacogenetic analyses will be performed. Pharmacodynamic data will be collected.
1870749|NCT01105676|Procedure|skin biopsy|Two skin biopsies will be taken one time
1870750|NCT01105702|Drug|Temozolomide|
1870755|NCT01105754|Behavioral|Multifaceted Prompting Intervention MPI|"Practices assigned to the MPI group will receive a simple prompt given to the provider at the time of the visit with information regarding the child's symptoms, medication use, environmental exposures, and recommendations for guideline-based preventive care. Practices will receive brief interactive seminars, resource guides, access to free asthma education programs, and practice-level feedback regarding their performance on key outcome measures.
Caregivers will receive a simple prompt, community resources, and a blank asthma action plan form."
1870756|NCT01105767|Drug|Chlorhexidine gluconate|Self applied chlorhexidine body wash (4% chlorhexidine gluconate, Hibiclens®, Mӧlnlycke Heath Care, Norcross, Georgia) once a week to wash/cover the body (except the face and genitalia).
1870757|NCT01105767|Other|Supplemental training, education and hygiene|Supplemental SSTI education for trainees and drill sergeants included pocket cards and posters. Drill sergeants received briefings on SSTI and skin inspection/minor wound care. Trainees were instructed to take an additional 10-minute shower with soap and a wash cloth every week. They were also issued a first aid kit.
1870758|NCT01105780|Drug|Placebo|Matching placebo
1870759|NCT01105780|Drug|JNJ-41443532|250mg tablet once daily for 1 day
1870760|NCT01105793|Drug|Danazol|High dose FP1198 applied once daily to both breasts for 6 treatment cycles.
1870761|NCT01105806|Behavioral|(CPR) video and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
1870762|NCT01105806|Behavioral|cardiopulmonary resuscitation (CPR) narrative script and questionnaires|Baseline Assessments (10 mins),Intervention:CPR video or script (5 mins) Post intervention assessments (10 mins), Longitudinal chart review follow-up (6 months)
1870763|NCT01105819|Procedure|Lactobacillus plantarum 299 for oral care|The study group will be attended in the same manor but the swabs used for cleansing are soaked with carbonated water directly from freshly opened bottles. As the final part of the procedure oral mucosal surfaces are pencilled with a suspension of the probiotic bacterium Lactobacillus plantarum 299 Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day
1870764|NCT01105819|Procedure|Chlorhexidine for standard oral care|"A The control group will receive the standard oral care of the department (general ICU, Lund University Hospital).
This includes suction of secretions, brushing of teeth cleansing of the oral cavity with swabs soaked with a chlorhexidine solution. This procedure is performed twice a day. In between, suction whenever needed and cleansing with swabs soaked with carbonated bottled water is performed Cultures from the oropharynx and tracheal secretions are taken at inclusion (day 1) and then on days 2,3,5,7,10,14 and 21 or before extubation if this occurs on a non-culture day"
1870766|NCT01105871|Drug|naloxone|4 mg naloxone in 10 ml saline given iv bolus
1870767|NCT01105871|Drug|Placebo|10 ml of normal saline iv bolus
1870768|NCT01105884|Procedure|Normal Saline|All the subjects in Group 1 will be treated with Normal Saline for healing of their diabetic foot ulcer
1870769|NCT01105884|Procedure|Biatin Ag (Foam)|All the subjects will be treated with Biatin Ag (Foam)
1870770|NCT01105884|Procedure|Hydrocolloid|All the subjects in this group will be treated with Hydrocolloid
1870771|NCT01105884|Procedure|Hydrogel|All the subjects in this group will be treated with Hydrogel
1870772|NCT01105884|Procedure|Ceredak|All the subjects in this group will be treated with Micro-porous Ceramic Wound Dressing
1870773|NCT01105897|Procedure|Endometriosis surgery|Complete surgical excision of all visible endometriosis by multidisciplinary approach
1870774|NCT01105910|Other|Systane Ultra Lubricant Eye Drops|1 to 2 drops in each eye 4 times per day for 30 days
1870775|NCT01105910|Other|Sensitive Eyes Eye Drops (Bausch & Lomb)|1 to 2 drops in each eye 4 times per day for 30 days
1870776|NCT01105923|Other|MAPLE|MAPLE is a CDS intervention within the EHR that will alert providers to problem lists gaps and present an opportunity to correct them.
1870777|NCT01105936|Drug|Paracetamol|665 mg sustained release paracetamol caplets
1870778|NCT01105936|Drug|Placebo|Placebo caplets
1870779|NCT01105949|Device|Marketed nasal strip|Marketed nasal strip
1870780|NCT01105949|Device|NexGen AB 2R11|Nasal strip prototype
1870781|NCT01105949|Device|NexGen JB Organic PET/PE|Nasal strip
1870782|NCT01105975|Drug|LY2484595|Administered daily by mouth for 12 weeks
1870783|NCT01105975|Drug|Atorvastatin|Administered daily by mouth for 12 weeks
1870784|NCT01105975|Drug|Simvastatin|Administered daily by mouth for 12 weeks
1870785|NCT01105975|Drug|Rosuvastatin|Administered daily by mouth for 12 weeks
1870786|NCT01105975|Drug|Placebo for LY2484595|Administered daily by mouth for 12 weeks
1870787|NCT01105975|Drug|Placebo for Statins|Administered daily by mouth for 12 weeks
1870788|NCT01105988|Other|Radiologic exams|FLT PET scan x 2 MRI scan x 2
1870789|NCT01106001|Drug|Levobupivacaine|The treatment group received 150mg of levobupivicaine in 60mls of 0.9% saline. This was injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
1870790|NCT01106001|Drug|Saline|The placebo group received 60mls of 0.9% saline injected intra-operatively through the medial and anterior capsular spaces in the region of the obturator and femoral nerves and also around the short rotators and gluteus maximus in the region of the inferior and superior gluteal nerves. The timing of this was after insertion of the acetabular component. 10mls was then infiltrated around the tensor fascia lata and subcutaneously prior to closing the wound.
1870791|NCT01106014|Drug|Selexipag|Selexipag 200 mcg tablets
1870792|NCT01106014|Drug|Placebo|Selexipag matching placebo tablets
1870832|NCT01106443|Procedure|Total Thyroidectomy + CLND|Total thyroidectomy includes removing all possible thyroid tissue. Central lymph node dissection is a neck level 6 dissection. This includes removal of all central lymphatics from carotid artery to carotid artery and hyoid to sternum/clavicle.
1870833|NCT01106443|Procedure|Total thyroidectomy - CLND|Removal of all possible thyroid tissue without dissection of neck level 6.
1960062|NCT03302221|Drug|0.5% ropivacaine paravertebral block|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 0.5% ropivacaine paravertebral block
1870794|NCT01106040|Drug|Lymphoseek|The total volume of Lymphoseek injection will be between 0.1 - 1.0 mL.
1870795|NCT01106053|Drug|Pramipexole|Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).
1870796|NCT01106066|Drug|Oxaliplatin, S-1, radiotherapy|Radiotherapy 4000cGy/20 fractions S-1 ( )mg/m2 po bid daily during radiotherapy Oxaliplatin at four dose levels (___mg/m2 iv weekly x 4 weeks)
1870797|NCT01106079|Drug|Intensive management or Tight control|Those subjects randomised to the intensive management or tight control arm will be reviewed every 4 weeks (by the Principal Investigator at each site or a designated researcher) and will be treated according to a rapidly escalating regime, involving standard DMARDs and biologics. Initial therapy will be with oral methotrexate, increasing in dose rapidly over the first 8 weeks of the study. From the 12 week visit onwards, escalation of therapy in this arm will be performed if subjects do not meet the objective target of Minimal Disease Activity. Initial escalation will be to combination DMARD therapy. If patients in the tight control arm fail to meet the MDA criteria and fulfil the NICE criteria for the use of TNF blockers in psoriatic arthritis at 24 weeks, then they will be offered treatment with these medications. Therapy will continue to be modified throughout the 48 week follow-up until a state of minimal disease activity is reached.
1870798|NCT01106079|Drug|Standard management - Control group|The control group will be seen every 12 weeks in a general rheumatology clinic and will receive standard care, involving standard DMARDs and biologics as appropriate. Treatment will be prescribed as felt appropriate by the treating physicians with no set protocol and no restrictions.
1870799|NCT01106092|Biological|GSK2036874A vaccine|Intramuscular, single dose
1870800|NCT01106092|Biological|Zilbrix™/Hib vaccine|Intramuscular, single dose
1870801|NCT01106092|Biological|Poliorix™|Intramuscular, single dose
1870802|NCT01106118|Drug|Vardenafil (Levitra, BAY38-9456)|Patients with diagnosis of erectile dysfunction and metabolic syndrome who get vardenafil in routine treatment as prescribed by physician
1870803|NCT01106131|Drug|CKD-501 0.5mg|CKD-501 0.5mg, orally, 1 tablet once a day for 24weeks or 52weeks(if extension study) with metformin.
1870804|NCT01106131|Drug|Pioglitazone 15mg|Pioglitazone 15mg, orally, 1 tablet or 2 tablet(if confirmed case) once a day for 24weeks with metformin.
1870805|NCT01106157|Drug|Anti-Thymocyte Globin (ATG)|Anti-Thymocyte Globin (ATG) will be given as 0.5/mg/kg on day 1 and 2mg/kg on day 2.
1870806|NCT01106157|Drug|Placebo|Saline infusions will be given on Day 1 and Day 2 followed by placebo injections given in identical volumes in identical syringes
1870807|NCT01106157|Drug|Pegylated GCSF|6 doses of pegylated GCSF (6mg/dose) will be given subcutaneously every 2 weeks beginning after the ATG infusion.
1870808|NCT01106170|Drug|Provex CV|dietary supplement, 2 capsules per day by mouth
1870809|NCT01106170|Other|placebo|corn starch, 2 capsules per day by mouth
1870810|NCT01106183|Dietary Supplement|transfer factor|capsules, 2 per day by mouth for 7 weeks.
1870811|NCT01106183|Dietary Supplement|Placebo|cornstarch, 2 capsules per day by mouth.
1870812|NCT01106235|Biological|therapeutic autologous lymphocytes|Given IV
1870813|NCT01106235|Biological|aldesleukin|Given SC
1870814|NCT01106235|Drug|cyclophosphamide|Given IV
1870815|NCT01106235|Procedure|biopsy|Optional correlative studies
1870816|NCT01106248|Drug|Eribulin Mesylate|1.4 mg/m^2 intravenous (IV) bolus given over 2-5 minutes on Days 1 and 8 every 21 days.
1870817|NCT01106261|Procedure|Metastasectomy|Pulmonary Metastasectomy
1870818|NCT01106261|Procedure|Active monitoring|Active monitoring
1870819|NCT01106274|Radiation|ultraviolet-A|Corneal cross linking (C3R) with riboflavin and ultraviolet-A (UVA, 370 nm, 3mW/cm2) for 30 min
1870820|NCT01106287|Drug|MK-0941|A single 60, 80, 100, 120 or 140 mg oral dose of MK-0941 will be administered in each period
1870821|NCT01106287|Drug|Comparator: Placebo|a single oral placebo will be administered in the designated period (Periods 1-5)
1870822|NCT01106326|Behavioral|Intervention|"Teens participating in this study will have:
directly observed administration of their daily preventive asthma medication at school, by the school nurse, for the first 6-8 weeks of the study
three counseling sessions with a study nurse trained in principles of motivational interviewing (MI), that are designed to enhance the teen's motivation to change health behaviors, with a focus on adherence to evidence-based preventive care guidelines (e.g.; preventive medications)."
1870823|NCT01106352|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Alpharadin (Radium-223 dichloride) is administered intravenously as a bolus injection.
1870824|NCT01106352|Drug|Docetaxel|Docetaxel (75 mg/m^2) will be administered intravenously every 3 weeks with 5 mg prednisone twice a day continuously and pre-medication with dexamethasone. Step-down to 60 mg/m^2 is allowed as per the approved docetaxel label.
1870825|NCT01106365|Device|H-coil (Repetitive deep transcranial magnetic stimulation)|Repetitive deep transcranial magnetic stimulation of prefrontal cortex or motor cortex or sham stimulation
1870826|NCT01106391|Device|"Cordis AAA stent graft system INCRAFT TM"|
1870827|NCT01106404|Device|RestoreSensor Neurostimulation System|"Adjustments to stimulation settings are automatic when the AdaptiveStim feature of the device is turned ON and manual when the AdaptiveStim feature of the device is turned OFF."
1870828|NCT01106417|Procedure|NeoFuse|Single Dose NeoFuse Surgical Implantation
1870829|NCT01106417|Procedure|MasterGraft Granules|Single Dose MaterGraft Granules Surgical Implantation
1870830|NCT01106430|Drug|Lisdexamfetamine Dimesylate|Oral 30, 50, or 70mg once-daily for 9 weeks
1870831|NCT01106430|Drug|Atomoxetine Hydrochloride|Oral 10mg to 100mg once-daily for 9 weeks
1870834|NCT01106443|Procedure|Hemi-thyroidectomy + CLND|Removal of one thyroid lobe and ipsilateral central lymph nodes
1960063|NCT03302221|Drug|1% lidocaine epidural block|The investigators designed a study to assess whether there were any blood flow indexes change during induction with doppler ultrasonography after 1% lidocaine epidural block
1960064|NCT03302221|Drug|Dexmedetomidine Group infusion|0.5 μg/kg dexmedetomidine infusion before induction
1870836|NCT01106456|Behavioral|All Nations Breath of Life (ANBL)|ANBL consists of in-person group sessions and individual telephone calls. We have successfully conducted a pilot study of ANBL and have found very promising results. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence.
1870837|NCT01106456|Behavioral|Nontailored program (NT)|"The nontailored intervention includes the medicines listed above to all participants and targeted counseling delivered by non-American Indian counselors who have worked closely with the American Indian communities and respect the cultures, values, and traditions of the Indian people. Therefore, our intervention includes the current best practice recommendations for smoking cessation. At six months and 12 months post baseline, all participants will be assessed for smoking status and smoking abstinence."
1870838|NCT01106456|Drug|Pharmacotherapy|All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
1870839|NCT01106469|Drug|JNJ-41443532|25mg tablet once daily
1870840|NCT01106469|Drug|JNJ-41443532|250mg tablet once daily
1870841|NCT01106469|Drug|JNJ-41443532|1500mg once daily (with 250mg tablets)
1870842|NCT01106469|Drug|JNJ-41443532|100mg tablet once daily
1870843|NCT01106469|Drug|JNJ-41443532|1000mg once daily (with 250mg tablets)
1870844|NCT01106469|Drug|Placebo|Matching placebo
1870845|NCT01106469|Drug|JNJ-41443532|500mg once daily (with 250mg tablets)
1870846|NCT01106482|Other|Serology blood draw|Blood draw only, no vaccine
1870847|NCT01106495|Device|Enhanced External Counterpulsation (EECP)|EECP one hour per day, 5 hours a week for a total of 35- 36 hours over a 7 week period
1870848|NCT01106495|Drug|Simvastatin|Simvastatin 40 mg/d for 7 weeks as the guideline- driven standard medical treatment
1870849|NCT01106508|Drug|LEQ506|
1870850|NCT01106521|Radiation|Permanent breast seeds implant|Patients are pre-planned using CT simulation. Implant is realised under light sedation and local freezing. Stranded seeds are inserted using a brachytherapy template that is immobilised to the planned target volume using a 'localization' needle. Patients is released the same day and Quality Assurance involves a 2 months post-implant CT
1960066|NCT03301441|Other|questionnaire ef-ID Migraine|"All consecutive patients eligible to the study will be included within 7 days of their initial admission, and evaluated with a short questionnaire classifying them as migrainers whose status will undergo a detailed validation at 3 months by a migraine expert, and non-migrainers whose status will be validated by repeating the short questionnaire at the follow-up visit at 3 months.
Initial multimodal imaging, done routinely in any stroke patient, will acquire the raw data necessary to calculate the mismatch ratio (MRI DWI/PWI or CT rCBF/CTP). All radiological data will be analyzed centrally after the end of the recruitment, by investigators blinded to the migraine status."
1870854|NCT01106547|Drug|Methylprednisolone 125mg|Single dose 60-90 minutes preoperatively
1870855|NCT01106547|Drug|Sodium Chloride 2 ml|Single dose 60-90 min preoperatively
1870856|NCT01106560|Procedure|Minimally Invasive Anterior Approach|Anterior minimally invasive surgery (AMIS)
1870857|NCT01106560|Procedure|Standard postero-lateral approach|
1870858|NCT01106586|Drug|Stribild|Stribild (EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) STR administered orally once daily
1870859|NCT01106586|Drug|ATV|Atazanavir 300 mg capsule administered orally once daily
1870860|NCT01106586|Drug|Ritonavir|Ritonavir (RTV; /r) 100 mg tablet administered orally once daily
1870861|NCT01106586|Drug|FTC/TDF|FTC/TDF 200/300 mg tablet administered orally once daily
1870862|NCT01106586|Drug|Stribild Placebo|Placebo to match Stribild administered orally once daily
1870863|NCT01106586|Drug|ATV Placebo|Placebo to match ATV administered orally once daily
1870864|NCT01106586|Drug|RTV Placebo|Placebo to match RTV administered orally once daily
1870865|NCT01106586|Drug|FTC/TDF Placebo|Placebo to match FTC/TDF administered orally once daily
1870866|NCT01106599|Drug|GDC-0623|Repeating oral dose
1870867|NCT01106612|Procedure|Coronary CT angiography|EKG-gated, computed tomography angiography of the coronary arteries during heart rate control
1870868|NCT01106612|Procedure|Myocardial perfusion imaging|Stress radionuclide myocardial perfusion imaging
1870869|NCT01106625|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally (by mouth) once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
1870870|NCT01106625|Drug|Placebo|One matching placebo capsule orally once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea.
1870871|NCT01106625|Drug|Metformin|The patient's stable dose of background metformin therapy should be continued throughout the study.
1870872|NCT01106625|Drug|Sulphonylruea|The patient's stable dose of background sulphonylurea therapy should be continued throughout the study.
1870873|NCT01106638|Behavioral|Positively Smoke Free|An eight session, group therapy intervention targeting smokers living with HIV/AIDS
1870874|NCT01106638|Behavioral|Standard care|Advice to quit, smoking cessation brochure, and offer of nicotine patches
1870875|NCT01106651|Drug|Canagliflozin 100 mg|One 100 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
1870876|NCT01106651|Drug|Canagliflozin 300 mg|One 300 mg over-encapsulated tablet orally (by mouth) once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
1870877|NCT01106651|Drug|Antihyperglycemic agent(s)|Stable doses of antihyperglycemic agents (sulfonylurea agent, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4] inhibitors, metformin, insulin [all types]) and their combinations (sulfonylurea agent and insulin [all types], metformin and insulin [all types], metformin and sulfonylurea, alpha glucosidase inhibitors, thiazolidinediones, dipeptidyl peptidase 4 [DPP-4]) are used as per protocol specifications.
1870878|NCT01106651|Drug|Placebo|One matching placebo capsule orally once daily for 104 weeks with/without stable doses of antihyperglycemic agent(s) taken at the time of study entry.
1870950|NCT01107158|Biological|Whole blood sampling|Whole blood sampling for SNP polymorphism analysis
1960069|NCT03301168|Biological|BPX-501 T cells and AP1903|T cells transduced with CaspaCIDe suicide gene
1960070|NCT03301168|Drug|AP1903|AP1903 administered to treat GVHD
1870880|NCT01106664|Drug|ONO-7746|1mg, 2mg, 4mg, 8mg, 16mg once daily for multiple-dose study; 4mg at a single dose for food effect study
1870881|NCT01106677|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with protocol-specified doses of metformin immediate release.
1870882|NCT01106677|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with protocol-specified doses of metformin immediate release.
1870883|NCT01106677|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily for 52 weeks (sitagliptin 100 mg arm) or once daily beginning at Week 26 until Week 52 (placebo/sitagliptin arm). Sitagliptin will be given with protocol-specified doses of metformin immediate release.
1870884|NCT01106677|Drug|Metformin immediate release|The patient's stable dose of metformin immediate release background therapy should be continued throughout the study.
1870885|NCT01106690|Drug|Placebo|One matching placebo capsule orally (by mouth) once daily for 26 weeks with stable doses of metformin and pioglitazone.
1870886|NCT01106690|Drug|Canagliflozin|One 100 mg or 300 mg over-encapsulated tablet orally once daily for 52 weeks with stable doses of metformin and pioglitazone.
1870887|NCT01106690|Drug|Sitagliptin|One 100 mg over-encapsulated tablet orally once daily beginning at Week 26 until Week 52 with stable doses of metformin and pioglitazone.
1870888|NCT01106690|Drug|Metformin|The patient's stable dose of metformin background therapy should be continued throughout the study.
1870889|NCT01106690|Drug|Pioglitazone|The patient's stable dose of pioglitazone background therapy should be continued throughout the study.
1870890|NCT01106703|Dietary Supplement|PG102, a water soluble extract from Actinidia arguta|PG102 two tables(Actinidia arguta extract:Microcrystalline cellulose(1:1)mixed powder 1120mg) twice a day for 8weeks
1870891|NCT01106703|Other|placebo|placebo two tables(equivalent dose of Microcrystalline cellulose) twice a day for 8weeks
1870892|NCT01106716|Drug|Placebo|Placebo IV Infusion
1870893|NCT01106716|Drug|KAI-1678|KAI-1678 IV Infusion
1870894|NCT01106716|Drug|Lidocaine|Lidocaine
1870895|NCT01106729|Dietary Supplement|Cyanidin 3 glucoside|Ingestion of 500mg of Cyanidin 3 glucoside (a naturally occurring plant pigment)
1870896|NCT01106742|Dietary Supplement|AndoSan|AndoSan, 20mlx3, 12 days
1870897|NCT01106755|Device|gait training on ground level using BWS|An A1-B-A2 system was applied in which A1 and A2 corresponded to gait training on ground level using Body Weight Support (BWS). Each training phase was performed during 45 minutes, three times a week, for six weeks.
1870898|NCT01106755|Device|gait training on ground level using BWS associated to FES|An A1-B-A2 system was applied in which B corresponded to the training associated to Functional Electrical Stimulation. Each training phase was performed during 45 minutes, three times a week, for six weeks.
1870899|NCT01106807|Drug|Epiduo vehicle gel|500 microliters of Epiduo vehicle gel on one half-face twice daily for six weeks
1870900|NCT01106807|Drug|CD07223|500 microliters of CD07223 1.5% gel on one half-face twice daily for six weeks
1870901|NCT01106807|Drug|CD07223|500 microliters of CD07223 0.5% gel on one half-face twice daily for six weeks
1870902|NCT01106807|Drug|Epiduo (adapalene and benzoyl peroxide) 0.1%/2.5% gel|500 microliters Epiduo Gel on one of the half-face for the morning dose
1870903|NCT01106820|Other|Supervised progressive resistance training|Supervised progressive resistance training
1870904|NCT01106820|Other|Supervised progressive muscle relaxation training (Jacobsen method)|Supervised progressive muscle relaxation training (Jacobsen method)
1870905|NCT01106833|Drug|Sirolimus + calcineurin inhibitor + prednisone|"The target serum level for sirolimus is 3-12 ng/mL. The target serum level for tacrolimus is 5-10 ng/mL. The target serum level for cyclosporine is 120-200 ng/mL.
Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
1870906|NCT01106833|Drug|Sirolimus + prednisone|"The target serum level for sirolimus is 3-12 ng/mL.
Prednisone is administered initially as a single early morning dose of 1 mg/kg/day (or equivalent). If prednisone at a dose of 1 mg/kg/day (or equivalent) is contraindicated, patients may begin prednisone between 0.5-1 mg/kg/day."
1870907|NCT01106846|Drug|Group A: Saline Group|Saline continuous infusion
1870908|NCT01106846|Drug|Group B: 1% Ketamine group|Administration of 1% ketamine intravenously.
1870909|NCT01106859|Drug|zopiclone|7.5 mg tablet by mouth. Zopiclone is a commonly used hypnotic in Europe that is known to impair driving in the morning 9 hours after dosing.
1870910|NCT01106859|Drug|zolpidem tartrate sublingual tablet|3.5 mg zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
1870911|NCT01106859|Drug|Placebo (sublingual tablet)|Placebo matching zolpidem tartrate sublingual tablet taken either 3 or 4 hours prior to driving. Participants placed the study drug under the tongue and allowed it to dissolve there for about 2 minutes, then swallowed after dissolved.
1870912|NCT01106859|Drug|Placebo|Placebo matching zopiclone
1870913|NCT01106872|Drug|Bevacizumab, Gemcitabine, Docetaxel and Valproic Acid|
1870914|NCT01106885|Behavioral|Medication Care Management (MCM)|"Basic physical activity counseling
Notify PCP and facilitate initiation of antidepressants
Medication monitoring calls at 1, 2, 4, 6, 8, 10, and 12 weeks*
1/mo monitoring in continuation phase (mos. 4-12)*
Report & recommendations to PCP after each patient call
Note: *average of 10 minutes of telephone time each (series is repeated if second antidepressant trial is needed)"
1870915|NCT01106885|Behavioral|Cognitive-Behavioral Therapy (CBT)|"Notify PCP
CBT Manual
Weekly CBT focused counseling for 12 weeks**
Monthly CBT in months 4-12**
Behavioral physical activity counseling
Report & recommendations to PCP after each patient call
Note: **average of 50 minutes of telephone time each"
1870916|NCT01106898|Drug|cyclophosphamide|Given IV
1870917|NCT01106898|Drug|paclitaxel|Given IV
1870918|NCT01106898|Biological|trastuzumab|Given IV
1870919|NCT01106911|Device|tomosynthesis and screening mammography|All eligible subjects will undergo both full field digital mammography and digital breast tomosynthesis.
1870920|NCT01106924|Other|Probiotic|daily probiotic consumption
1870921|NCT01106924|Other|Placebo|daily placebo consumption
1871073|NCT01108029|Drug|placebo|2 tablets of placebo 1 time a day in the morning
1870922|NCT01106950|Biological|Natural Killer Cells|Given by infusion on Day 0. The product is T cell-depleted (CD3-) and B cell-depleted (CD19). Target dose for infusion is < or = 8 x 10^7 nucleated cells/kilogram.
1870923|NCT01106950|Drug|Fludarabine|Administered as a 1 hour intravenous infusion once a day for 5 doses beginning on day -6.
1870924|NCT01106950|Drug|Cyclophosphamide|Administered as a 2 hour intravenous infusion with high volume fluid flush and mesna per institutional guidelines on day -5 and -4 one hour after fludarabine infusion. (Day -4 administration may be omitted if patient has had a transplant in the previous 4 months.)
1870925|NCT01106950|Drug|Denileukin diftitox|12 ug/kg/day will be administered on day -1 and day -2 intravenously.
1870926|NCT01106950|Procedure|Donor lymphapheresis|Day -1 before planned NK cell infusion, the donor will undergo lymphapheresis (Removal of lymphocytes from donated blood, with the remainder of the blood retransfused into the donor).
1870927|NCT01106950|Drug|IL-2|Administered after NK cell infusion, 10 million units every other day for a total of 6 doses. (Patients weighing less than 45 kilograms will receive a dose of 5 million units/m^2 every other day for 6 doses).
1870928|NCT01106963|Procedure|Tibial intramedullary nailing|Patients' operations were performed using the peritendinous approach. A medial longitudinal incision was made, with care being taken not to damage the patellar tendon or its sheath. Standard proximal and distal locking screws were used. All patients were given postoperative instructions for thigh muscle rehabilitation and the same physiotherapy was performed after IM nailing during hospitalization. Nails were removed from some of the patients with the presence of knee pain or pain at the insertion points of the locking screws, however, no nails were removed earlier than one year postoperatively. Proof of the healed bone fracture was confirmed by radiologic examination.
1870929|NCT01106989|Drug|Heated lidocaine/tetracaine patch|Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).
1870930|NCT01107002|Procedure|Day 5 embryo transfer group|Embryo will transfer at blastocyst stage (day 5 after ovum pick up)
1870934|NCT01107028|Other|Standard pulmonary rehabilitation program|At the assigned time, subjects will complete a six-week, outpatient pulmonary rehabilitation program at any local center that has such a program.
1870935|NCT01107041|Behavioral|Mobilyze!|Mobilyze! delivers behavioral intervention for depression via a mobile phone, interactive website, and e-mail.
1870936|NCT01107054|Drug|PF-00610355|An orally inhaled dose of PF-00610355 450 µg on days 1 to 4
1870937|NCT01107054|Drug|PF-00610355|An orally inhaled dose of PF-00610355 1200 µg on days 1 to 4
1870938|NCT01107054|Drug|moxifloxacin|A single oral dose of moxifloxacin 400 mg on Day 4.
1870939|NCT01107054|Drug|placebo|A single oral dose of non-matched placebo on Day 4.
1870940|NCT01107067|Drug|Sustanon|250 mg/21 days
1870941|NCT01107093|Drug|CDB-2914 (ulipristal acetate)|single oral dose of 30 mg
1870942|NCT01107093|Drug|Placebo|single oral dose
1870943|NCT01107106|Drug|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
1870944|NCT01107106|Drug|ellaOne® (ulipristal acetate)|one single oral dose (30 mg tablet)
1870945|NCT01107119|Other|integrated care pathway|communication and follow-up program for integrated care
1870946|NCT01107119|Other|usual care|
1870947|NCT01107145|Drug|Mefloquine- Artesunate|Tablets of 100 mg artesunate and 220 mg mefloquine (fixed dose combination), given once daily for 3 days.
1870948|NCT01107145|Drug|Artemether-Lumefantrine|4 tablets containing 20 mg of artemether plus 120 mg of lumefantrine per tablet twice daily for three days as 2 doses 8 hours apart on the 1st day and then 2 doses 12 hours apart on the 2nd and 3rd days, administered with a fatty meal
1870949|NCT01107145|Drug|Chloroquine|Tablets containing 250 mg Chloroquine salt given as 4 tablets at once on the first day (or 10 mg/kg) followed by 3 tablets once daily for the next 2 days (or 7,5 mg/kg)
1960080|NCT03300518|Drug|Follitropin Beta;MSD|Patients will start stimulation with a daily s.c. injection of follitropin beta( 300IU Puregonon;MSD) menstrual cycle day 2 or 3.
1960081|NCT03300518|Drug|Ganirelix|A daily administration of ganirelix (0.25 mg Orgalutran; MSD) was introduced when the leading follicle is near 13mm, and was repeated up to the time of hCG administration.
1960082|NCT03300518|Drug|hCG|Ovulation was triggered when the leading follicles reach 18-20mm and at least two follicles 17-18mm , HCG 10000 IU is used to trigger
1960083|NCT03300518|Drug|estradiol valerate|Estradiol valerate (progynova,Schering) daily dose of 4 mg (2 mg twice a day) was given orally, started 7 days before the presumed onset of menses and administered up to 2 days of the next menstrual cycle
1870951|NCT01100853|Drug|VIVITROL injection and VIVITROL Placebo Injection , 24 weeks|Efficacy of 24 week course of VIVITROL with counseling as compared to 24 week course of VIVITROL placebo with counseling (monthly injections)
1870952|NCT01100866|Dietary Supplement|POMELLA™ (pomegranate extract)|in a capsule form, 2 x 500mg once daily
1870953|NCT01100866|Other|Placebo|placebo capsules
1870954|NCT01100879|Drug|Ferric carboxymaltose|"Subjects will receive a single dose of 1,000 mg iron as FCM infusion at baseline.
Subjects of bw ≤66 kg will receive a single dose of 500 mg iron as FCM infusion at baseline (Week 0) and at Visit 3 (Week 2).
Ferric carboxymaltose will be administered on the same day with chemotherapy treatment or within 24 hours before or after the chemotherapy. For subjects with bw ≤66 kg, if no chemotherapy planned for the visit 4 (Week 2), the second FCM dose should be infused independent of chemotherapy."
1870955|NCT01100892|Drug|Once-daily insulin detemir|Insulin detemir is a long-acting insulin analog. Starting dose 0.1 units/kg/day (titrated according to the results of home blood glucose monitoring).
1870956|NCT01100905|Other|Iron-containing food product|
1870957|NCT01100918|Device|BiV ICD|Biventricular ICD
1870958|NCT01100918|Device|ICD|Implantable Defibrillator
1870959|NCT01100931|Drug|YM155|"Phase I: Doses were given at different dose levels until the maximum tolerated dose (MTD) was reached. Dose level 1: 3.6 mg/m^2, dose level 2:5 mg/m^2 , dose level 3:6 mg/m^2, dose level 4:8 mg/m^2, dose level 5:10 mg/m^2 (MTD), dose level 6:12 mg/m^2. Doses were given by continuous intravenous infusion over 72 hours every 21 days.Three patients were enrolled at each dose level in the absence of dose limiting toxicity (DLT). A DLT is defined as adverse events occurring during the first cycle of therapy (e.g. every 21 days).
Phase II: 10 mg/m^2 (MTD)intravenous infusion over 72 hours every 21 days."
1870960|NCT01100931|Drug|Carboplatin|Area under curve (AUC) of 6 intravenous on day 1
1870961|NCT01100931|Drug|Paclitaxel|200 mg/m^2 intravenous on day 1
1870962|NCT01100944|Drug|PXD101with cisplatin+doxorubicin+cyclophosphamide|PXD101 will be given as a 48h continuous intravenous infusion (CIVI) starting on day 1, doxorubicin as a slow intravenous (IV) injection on days 2 and 3, cisplatin will be infused over 1 hour on day 2 and cyclophosphamide as a slow IV infusion on Day 3. Treatment will be given every 21 days for no more than 6 cycles or until disease progression. Treatment with PXD101 alone may continue until disease progression.
1870963|NCT01100957|Procedure|tracheal intubation with a single use flexible videoscope|tracheal intubation with a single use flexible videoscope
1870964|NCT01100996|Other|control enteral nutrition|This feeding consists of 20en% fat, 16en% protein and 49en% carbohydrates
1870965|NCT01100996|Other|enriched enteral feeding|This feeding contains 46 energy percent (en%) fat, 24en% protein and 30en% carbohydrates and is enriched with phospholipids.
1870966|NCT01101009|Drug|Perindopril + amlodipine + if necessary, hydrochlorothiazide|Two perindopril 4 mg tablets + 1 amlodipine 10 mg tablet + placebo tablet matching the olmesartan/amlodipine tablet. All tablets are taken once daily. The duration of administration of perindopril tablets and placebo is 24 weeks. The duration of administration of amlodipine tablets is 24-26 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
1870967|NCT01101009|Drug|olmesartan/amlodipine + hydrochlorothiazide, if necessary.|olmesartan/amlodipine tablets 40 mg/10 mg, + placebo tablets matching the perindopril tablet and amlodipine tablet. All tablets are taken once daily for 24 weeks. Hydrochlorthiazide tablets 12.5 mg or 25 mg, once daily, will be added, if necessary
1870968|NCT01101022|Drug|SPD489|1 capsule per day (30, 50 or 70 mg), daily throughout the double-blind treatment period (10 weeks)
1870969|NCT01101022|Other|Placebo|1 capsule per day, daily throughout the double-blind treatment period (10 weeks)
1870970|NCT01101035|Drug|Febuxostat|Febuxostat 40 mg or 80 mg (depending on serum uric acid levels), capsules, orally, once daily for up to 60 months.
1870971|NCT01101035|Drug|Allopurinol|Allopurinol 200 mg to 600 mg (depending on renal function), capsules, orally, once daily for up to 60 months.
1870972|NCT01101048|Drug|Placebo|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
1870973|NCT01101048|Drug|AMG 167|Subjects will be randomized to receive one of 3 doses of AMG 167 or equivalent volume of placebo administered at once every two-week or once every four-week dosing intervals. Postmenopausal women will receive AMG 167 in one of 3 fixed doses, while men will receive AMG 167 in one of 2 fixed doses by injection under the skin.
1870974|NCT01101061|Drug|AMG 785|Subjects will be randomized to receive one of 3 dose levels of AMG 785 or equivalent volume of placebo administered as a single weight-based dose. Postmenopausal Japanese women will receive AMG 785 at a dose level of 1 mg/kg, 3 mg/kg, or 5 mg/kg. Postmenopausal non-Japanese women will receive AMG 785 at a dose level of 3 mg/kg.
1870975|NCT01101061|Drug|PLACEBO|Subjects will be randomized to receive one of 3 dose levels of AMG 785 or equivalent volume of placebo administered as a single weight-based dose. Postmenopausal Japanese women will receive AMG 785 at a dose level of 1 mg/kg, 3 mg/kg, or 5 mg/kg. Postmenopausal non-Japanese women will receive AMG 785 at a dose level of 3 mg/kg.
1870976|NCT01101074|Other|This is non-intervention observational study|This is non-intervention observational study
1870977|NCT01107171|Drug|Tang-min-ling pills low dosage|low dosage:6g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
1870978|NCT01107171|Drug|Tang-min-ling pills high dosage|high dosage:12g Tang-min-ling pills every time,by 3 times every day for 12 weeks.
1870979|NCT01107171|Drug|Placebo|Tang-min-Ling pills analogue 6g,tid,po
1870980|NCT01107184|Procedure|Remote ischemic conditioning|Patients will have a automated inflator cuff placed on the upper arm during surgery. The cuff will be used to induce fore arm ischemia by inflation to 200 mmHg for 3 x 5 minutes, interspersed with 5 minutes of no-inflation and thus reperfusion.
1870981|NCT01107184|Procedure|Sham|Patients will have a automated inflator cuff placed on the upper arm during surgery which will not be inflated.
1870982|NCT01107197|Dietary Supplement|Enriched nutrition formula|oral formula enriched in arginine, zinc and antioxidant oligoelements
1870983|NCT01107197|Dietary Supplement|Control formula|Isonitrogenous isocaloric oral formula
1870984|NCT01107223|Other|Experimental: Training to antibiotic prescription|GPs assigned to the intervention group attended a two days didactic educational meeting on evidence-based guidelines for diagnosis and treatment of acute respiratory tract infection.
1870985|NCT01107223|Other|No education on antibiotic prescription rules.|GPs assigned to control group received no specific recommendations on antibiotic prescription.
1870986|NCT01107236|Drug|IW-6118|Single dose
1870987|NCT01107236|Drug|Matching Placebo|Single dose of matching placebo for IW-6118 and/or matching placebo for naproxen sodium
1870988|NCT01107236|Drug|Naproxen Sodium|Single dose
1870989|NCT01107249|Device|Boston Scientific Ultraflex or Wallstent stents|Stent used to maintain luminal patency in esophageal strictures and occlude esophageal fistulas to reduce gastric leaks, perforations and/or fistulas.
1870990|NCT01107275|Biological|rabies vaccine|intradermal vaccination
1870991|NCT01107288|Other|Music-based multitask exercises program|Subjects are entered into a 6-month Jaques-Dalcroze eurhythmics program and are followed for an additional 6 months after the intervention period. They complete assessments at baseline, 6 and 12 months. The program consists of structured 1-hour group exercises classes, conducted weekly by an experimented instructor, that include varied multitask exercises performed to the rhythm of improvised piano music, sometimes with the manipulation of objects (e.g., instruments of percussion, balls), with gradually increasing difficulty over time. Basic exercises consist of walking following the music, responding directly to changes in music's rhythmic patterns.
1870992|NCT01107288|Other|Music-based multitask exercises program|Subjects are wait-listed to receive, 6 months after randomization, the same 6-month Jaques-Dalcroze eurhythmics program as the Intervention group. They complete assessments at baseline, 6 and 12 months.
1870993|NCT01107314|Other|Phlebotomy|Blood draws (total 48 cc blood)
1870994|NCT01107327|Procedure|FDG-PET/CT|"The study is focused on two goals, both of which use a new imaging test called PET/CT. PET/CT combines a special radioactive scan with a CT scan. PET/CT is most commonly used in medical practice to evaluate cancer. Abnormal areas such as cancer light up on the PET/CT scan. However, many doctors, including us, have noticed that PET/CT also lights up in areas of blood clot formation as well. In this study, PET/CT will be used to evaluate the two goals of this project."
1870995|NCT01107340|Device|AMIStem Hip System|
1870996|NCT01107353|Drug|Imipramine Pamoate|75 mg capsule
1870997|NCT01107366|Procedure|lupiae technique|it's a new hybrid technique for the treatment of aortic aneurism and dissection.
1870998|NCT01107366|Procedure|lupiae technique|"LUPIAE technique
Hybrid repair of thoracic or thoraco-abdominal aneurysms of different etiology and type A dissections with a two-stage procedure:
surgical arch reconstruction with a Dacron multibranched surgical prothesis
endovascular implantation of a thoracic stent graft"
1870999|NCT01107379|Device|Relieva Balloon Sinuplasty System|Sinuplasty balloon tools for dilation of sinuses in patients with chronic rhinosinusitis
1871000|NCT01107392|Drug|botulinum toxin Type A|botulinum toxin Type A total dose of 200U equally divided and administered to each lateral prostatic lobe.
1871001|NCT01107392|Drug|Normal saline|Placebo (Normal saline) equally divided and administered to each lateral prostatic lobe.
1871002|NCT01107405|Drug|Loteprednol etabonate base (QD)|Loteprednol Etabonate ophthalmic base once daily dosing for 2 weeks
1871003|NCT01107405|Drug|Loteprednol etabonate base (BID)|Loteprednol etabonate ophthalmic base BID dosing for 2 weeks
1871004|NCT01107405|Drug|Loteprednol etabonate base (QID)|Loteprednol Etabonate ophthalmic base four times/day dosing for 2 week
1871005|NCT01107405|Drug|Loteprednol etabonate suspension|Loteprednol etabonate ophthalmic suspension dosed four times daily for 2 weeks.
1871006|NCT01107405|Drug|Vehicle of loteprednol etabonate|Vehicle of loteprednol etabonate ophthalmic dosed once, twice or four times daily for 2 weeks.
1871007|NCT01107418|Drug|RO5185426|dosage b) orally twice daily, days 1-15 (morning dose)
1871008|NCT01107418|Drug|RO5185426|dosage c) orally twice daily, days 1-15 (morning dose)
1871009|NCT01107418|Drug|RO5185426|dosage d) orally twice daily, days 1-15 (morning dose)
1871010|NCT01107418|Drug|RO5185426|960 mg orally twice daily, from day 22 onward
1871011|NCT01107418|Drug|RO5185426|dosage a) orally twice daily, days 1-15 (morning dose)
1871012|NCT01107431|Dietary Supplement|L-Arabinose and Chromium|Consumed 70 grams of sucrose simultaneously taking a dietary supplement
1871013|NCT01107431|Dietary Supplement|Sucrose without dietary Supplement|Repeated measures on subjects taking 70 grams of sucrose along with taking a dietary supplement containing L-Arabinose and Chromium
1871014|NCT01107444|Drug|Docetaxel|Administered intravenously
1871015|NCT01107444|Drug|LY2181308|Administered intravenously
1871016|NCT01107457|Biological|Ixekizumab|Administered subcutaneously
1871017|NCT01107457|Drug|Placebo|Administered subcutaneously
1871018|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
1871019|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (short protocol), all patients will be stimulated with hFSH (human-derived FSH).
1871020|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
1871021|NCT01107470|Drug|hFSH（Fostimon）|After down-regulation (long protocol), all patients will be stimulated with hFSH (human-derived FSH).
1871022|NCT01107496|Drug|SPN-812|Viloxazine, oral, 300mg, tid, 6 weeks
1871023|NCT01107496|Drug|Placebo|Placebo, oral, tid, 6 weeks
1871024|NCT01107600|Procedure|Immediate implant and socket preservation|Implant placed in fresh extraction sockets as part of the same surgical procedure, and placed into occlusal loading within 48 h of implant placement. Guided bone regeneration with Biomaterial to preserve bone loss after tooth extraction.
1871025|NCT01107613|Other|Opinion leader educational letter|All patients will receive prednisone X 10 days and antibiotics X 5 days, as well as an opinion leader letter sent to the primary care provider outlining the needs of this patient.
1871026|NCT01107626|Biological|bevacizumab|Given IV
1871027|NCT01107626|Drug|pemetrexed disodium|Given IV
1871033|NCT01107665|Drug|Pazopanib and Paclitaxel|Paclitaxel will be administered intravenously at a starting dose of 80mg/m2 weekly for 3 weeks followed by a 1-week rest. Pazopanib will be administered orally, in a continuous regimen, with a starting dose of 800mg daily.
1871034|NCT01107678|Other|Healthy Snacks and Organized Physical Activity|Children in the intervention group will receive healthy snacks, smaller portion sizes and participate in organized physical activity on a daily bais
1871035|NCT01107691|Other|Amount of resistance offered in training|to determine the impact of the volume (1 vs. 3 sets) of a progressive resistance training protocol for inducing muscular hypertrophy
1871036|NCT01107704|Behavioral|Family Support Intervention|Multifaceted family support intervention
1871037|NCT01107717|Drug|metformin\pioglitazone\exenatide|metformin (1000 mg), pioglitazone (15 mg) and exenatide (5 microgram bid) are started and dose is up titrated to achieve HbA1c < 6.5%
1871038|NCT01107717|Drug|metformin, glyburide and glargine|subjects are started on metformin 500 mg bid and dose is up titrated and glyburide (up to 5 mg) and glargine are sequentially added to maintain HbA1c < 6.5%
1871039|NCT01107730|Drug|Vitamin C|VitC intravenously (2g/day [500mgX4] for 2 days prior to surgery, and postoperatively for 4 days
1871040|NCT01107730|Drug|L-Carnitine|L-Carnitine intravenously (2 gr/day [1grX2] for 2 days prior to surgery, and postoperatively for 4 days
1871041|NCT01107730|Drug|Placebo|Placebo
1871042|NCT01107743|Drug|Amlodipine/Atorvastatin|"Amlodipine and Atorvastatin combination Tablet is indicated in following subjects for whom treatment with both amlodipine and atorvastatin is appropriate.
Subjects with concurrent hypertension or angina pectoris and hypercholesterolemia or familial hypercholesterolemia Indications for amlodipine and atorvastatin.
For oral use, amlodipine and atorvastatin combination tablet is given once daily. Dosage must be individualized based on dosage and administration for each individual component.
Amlodipine
Hypertension Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose.
Angina pectoris For oral use, the usual adult dosage is 5 mg of amlodipine once daily. Atorvastatin
Hypercholesterolemia For oral use, the usual adult dosage is 10-20 mg of atorvastatin once daily.
Familial hypercholesterolemia For oral use, the usual adult dosage is 10-40 mg of atorvastatin once daily."
1871043|NCT01107756|Drug|LENOGRASTIM (GRANOGYTE 34)|Pharmaceutical form: solution Route of administration: intravenous Dose regimen:recommended dosing as per Granocyte 34 package insert
1871044|NCT01107782|Drug|sildenafil|50 mg TDS orally until birth
1871045|NCT01107782|Drug|placebo|50mg tid
1871046|NCT01107795|Procedure|Transoral Robotic Surgery|Base of tongue resection with transoral robotic-assisted surgery (TORS).
1871047|NCT01107808|Drug|Calcium and Vit D|ergocalciferol (vitamin D2) treatment 50,000 IU orally, weekly for 8 weeks calcium carbonate orally 1200mg daily
1871048|NCT01107808|Drug|Metformin, Vit D and Calcium|ergocalciferol (vitamin D2)50,000 IU orally weekly for 8 weeks calcium carbonate orally 1200mg daily Metformin ER 1000mg daily with dinner for 7 days and then increased to a final dose of 2000mg orally, daily for the remainder of the study (7 weeks)
1871049|NCT01107821|Device|Engenex™ pump and Bio-Dome™ Wound Dressing|Engenex™ pump and Bio-Dome™ Wound Dressing is used.
1871050|NCT01107847|Procedure|low flow pressure volume manoeuvre|In all patients a standard low flow pressure volume manoeuvre is applied by a respirator with a constant gas flow of 4 l/min starting at a zero end-expiratory pressure up to a tidal volume of 2 l or until a maximum airway pressure of 35 cm H2O was reached.
1871051|NCT01107860|Device|Computed Tomography|In Group I, fifty CBCT studies will be performed. The objectives will be to illustrate the capacity of CBCT to image the breast in its entirety as compared with the gold standard mammographic exam.
1871052|NCT01107860|Device|Computed Tomography|In Group II , at least three hundred and fifty (350) study participants, who require diagnostic evaluation of the breast will undergo a breast CBCT . These subjects may be referred for biopsy as a result of a finding from a mammogram, ultrasound, MRI, or clinical exam.
1871053|NCT01107886|Drug|Saxagliptin|5 mg or 2.5 mg once daily
1871054|NCT01107886|Drug|Placebo|
1871055|NCT01107899|Drug|clopidogrel|taken orally, day one, single dose
1871056|NCT01107899|Drug|prasugrel|taken orally, day one, single dose
1871057|NCT01107912|Drug|prasugrel|administered orally, daily for 12 days
1871058|NCT01107912|Drug|clopidogrel|Administered orally, daily for 12 days
1871059|NCT01107925|Drug|prasugrel|Administered orally, daily for 12 days
1871060|NCT01107925|Drug|clopidogrel|Administered orally, daily for 12 days
1871061|NCT01107938|Drug|10 mg ilaprazole|Two 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of ilaprazole and one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
1871062|NCT01107938|Drug|15 mg ilaprazole|Three 5-mg ilaprazole tablets (Livzon Pharm Group Inc., China) together with one placebo tablet of esomeprazole in a package being taken orally each morning on an empty stomach for 8 weeks
1871063|NCT01107938|Drug|40 mg esomeprazole|One 40-mg esomeprazole tablet (AstraZeneca, Nexium) together with three 5-mg placebo tablets of ilaprazole in a package being taken orally each morning on an empty stomach for 8 weeks
1871064|NCT01107951|Drug|Rituximab and dexamethasone|"Rituximab 100mg IV days 1,8,15,22.
Dexamethasone 40mg PO days 1-4 (four days)"
1871067|NCT01107977|Behavioral|Iyengar yoga|Iyengar yoga twice/week for 6 weeks
1871068|NCT01108003|Drug|broccoli sprout extract|Given orally
1871069|NCT01108003|Other|laboratory biomarker analysis|Correlative studies
1871070|NCT01108003|Other|Mango Juice|given orally
1871071|NCT01108016|Behavioral|Videoconferencing support group|
1871074|NCT01108042|Drug|Taxotere, Cisplatin, 5-Fluorouracil (5-FU)|Phase 1: Intravenous infusion of 40 mg/m² Taxotere and 40 mg/m² Cisplatin followed by 24 h-infusion of 2000 mg/m² 5-FU on day 1 and day 8 every 3 weeks. If possible an escalation to 50 mg/m² Taxotere and 50 mg/m² Cisplatin can be carried out. Phase 2: Optimal dose of phase 1 will be given.
1871075|NCT01108055|Drug|Pazopanib (GW786034)|Cycle of 28 days. Pazopanib: 800mg/day
1871076|NCT01108055|Drug|Paclitaxel|Cycle of 28 days Paclitaxel: 80mg/m2 days 1,8 and 15
1871078|NCT01108081|Behavioral|Physical activity|Moderate-intensity physical activity
1871079|NCT01108081|Behavioral|Diet|Dietary weight loss
1871080|NCT01108081|Behavioral|Health education|Attention control intervention
1871082|NCT01108107|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
1871083|NCT01108107|Drug|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
1871084|NCT01108107|Drug|Oxaliplatin|130 mg/m2 intravenously on day 1 of a 3-weekly cycle
1871085|NCT01108107|Drug|Capecitabine|2000 mg/m2/day (tablets) on day 1 and 14 of a 3-weekly cycle
1871086|NCT01108107|Biological|Panitumumab|9 mg/kg intravenously on day 1 of a 3-weekly cycle
1871087|NCT01108120|Drug|continuous intra-femoral thrombolysis group|Firstly, 20 0000 u urokinase is injected to the diseased foot via catheter. Then, continuous injection of urokinase via femoral artery by a artery mini-pump (100 ml 0.9% sodium chloride + 100 0000 unit urokinase at a rate of 4 ml per hour) is taken for 7 - 9 days.
1871088|NCT01108120|Drug|Conventional therapy group|All patients receive an intravenous injection of prostaglandin E1 20 ug per day during hospitalization period.
1871089|NCT01108133|Drug|10 mg HydrocortisoneHöchst|10 mg Hydrocortisone Höchst are administered one hour before fMRI scanning
1871090|NCT01108133|Drug|Dexamethasone|2 mg Dexamethasone are administered at 10 pm the day before the fMRI experiment.
1871091|NCT01108133|Drug|Placebo|Placebo
1871092|NCT01108146|Drug|Arm 1 Hydrocortisone 10 mg|"Group 1: Administration of Hydrocortisone and/or Placebo in the following order:
1 week placebo- 1 week 10 mg hydrocortisone - 1 week placebo - 1 week 30 mg hydrocortisone"
1871093|NCT01108146|Drug|Arm 2 Hydrocortisone 30 mg|"Drug: Hydrocortisone 30 mg
Group 2: Administration of Hydrocortisone and/or Placebo in the following order:
1 week hydrocortisone 30 mg/d- 1 week placebo - 1 week hydrocortisone 10 mg/d - 1 week placebo"
1871094|NCT01108159|Procedure|Blood Draw|
1871095|NCT01108159|Procedure|Skin Biopsy|
1871098|NCT01108198|Drug|Mometasone furoate cream|Study cream was applicated once per day for 4-8 weeks.
1871099|NCT01108198|Drug|moisturizing cream|study cream was applicated once per day for 4 to 8 weeks
1871100|NCT01108211|Device|Vibration Platform|The patients receive treatment by standing on the Vibration Platform 20 minutes a day, five days a week. The platform will deliver a vibration of 0.3g with a vertical displacement of 0.085mm at 35 Hz.
1871101|NCT01108224|Behavioral|Psychosocial support|Psycho-social group intervention including patient-education for 6 h per week for 2 weeks and group therapy 2½ h for 8 weeks
1871102|NCT01108237|Other|TruMatch™ Personalized Solutions|TruMatch™ Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation. TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon.
1871103|NCT01108237|Device|Total Knee Arthroplasty with Conventional Instrumentation.|Total Knee Arthroplasty (PFC Sigma System) implanted using conventional instruments, not TruMatch™ instrumentation.
1871104|NCT01108250|Genetic|LOC387715/HTRA1 genotyping|Genomic DNA was extracted from whole blood by standard methods. Genotyping was performed using SNP Genotyping Assays.
1871105|NCT01108263|Drug|INTEGRA™ Flowable Matrix (Collagen)|INTEGRA™ Flowable Wound Matrix is an advanced 3-D porous matrix comprised of granulated cross-linked bovine tendon collagen and glycosaminoglycan. It provides a scaffold for cellular invasion and capillary growth. The collagen and glycosaminoglycan mix is hydrated with saline and applied on the wound bed.
1871106|NCT01108276|Device|Convatec engenex negative pressure wound therapy|ConvaTec Engenex® is a negative pressure wound therapy that stimulates wound healing and promotes granulation tissue formation, removal of wound exudate and infectious materials by the application of negative pressure to wounds. It utilizes Bio-Dome™ Dressing technology to effectively control infection, drainage and odor while promoting granulation and wound healing at 75mmHg pressure.
1871107|NCT01108289|Other|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
1871108|NCT01108302|Other|Oxytocin in Uniject|10 IU Oxytocin delivered intramuscularly immediately after delivery of the baby
1871109|NCT01108315|Other|Report symptoms via web or phone-based system|The participant reports their symptoms at least twice a week via the phone or web-based prototype system.
1871110|NCT01108328|Dietary Supplement|PolyGlycopleX (PGX)|powder, 5 grams, 3 times per day at each main meal (breakfast, lunch and dinner) for a total of 3 days
1871111|NCT01108341|Drug|Bendamustine hydrochloride|Bendamustine will be administered at 90 mg/m^2 as a 30-minute intravenous (iv) infusion on days 1 and 2 of each cycle.
1871112|NCT01108341|Drug|Ofatumumab|Ofatumumab will be administered at 300 mg as an iv infusion on day 1 and 1000 mg on day 8 of cycle 1 and 1000 mg on day 1 of each subsequent cycle.
1994715|NCT02940288|Other|Sham Acupuncture|Participants will receive sham acupuncture while in the Post Analgesia Care Unit (PACU) following laparoscopic surgery. During the sham procedure, needles will be inserted bilaterally in five nonspecific ear acupoints. Acupuncture needles will be left in place for 30 minutes.
1871116|NCT01108406|Device|Sonitus SoundBite System|Non Surgical Bone Conduction Device
1871117|NCT01108406|Device|SoundBite Hearing System|
1871118|NCT01108419|Other|Fermented dairy product|
1871119|NCT01108419|Other|milk-based non-fermented dairy product|
1871120|NCT01108432|Other|Electronic Referral|Dental practices in this arm will be able to have option of making electronic patient referrals to the Decide2Quit website.
1871123|NCT01108458|Drug|Pertuzumab|iv, 840 mg, 420 mg
1871124|NCT01108458|Drug|Erlotinib|PO, 150 mg
1871125|NCT01108484|Behavioral|Exercise|Supervised exercise: Three 90-minutes sessions per week.
1871126|NCT01108484|Behavioral|Exercise + Diet counseling|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake.
1871127|NCT01108484|Behavioral|Exercise + Diet counseling + psycho-emotional support|Supervised exercise: Three 90-minutes sessions per week. Diet counseling: Counseling to balance the intake. Psycho-emotional support: Weekly sessions to modify the behaviour.
1871128|NCT01108497|Procedure|Bone Marrow Aspiration|
1871129|NCT01108510|Drug|COBI|Cobicistat (COBI) 150 mg tablet administered orally once daily
1871130|NCT01108510|Drug|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily
1871131|NCT01108510|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily
1871132|NCT01108510|Drug|FTC/TDF|Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
1871133|NCT01108510|Drug|COBI placebo|Placebo to match COBI administered orally once daily
1871134|NCT01108510|Drug|RTV placebo|Placebo to match RTV administered orally once daily
1871135|NCT01108523|Device|HP828-101|
1871136|NCT01108536|Device|adaptive prosthetic socket|trans tibial socket with actuator zones (inflatable fluid bladders)
1871137|NCT01108549|Dietary Supplement|Ribose|Ribose 5 grams PO TID was taken daily
1871138|NCT01108562|Drug|Lidocaine|Patients in the experimental group will be receiving a Lidocaine infusion at 1.33 mg/kg/hr for 24 hours postoperatively.
1871139|NCT01108562|Other|Normal Saline|Patients in the control group will be receiving an infusion of normal saline for 24 hours postoperatively.
1871140|NCT01108575|Other|IMST|inspiratory muscle strength training
1871141|NCT01108575|Other|Sham IMST|sham inspiratory muscle strength training
1871142|NCT01108588|Drug|Placebo (to match Aspirin)|Placebo grossly matched Aspirin 300 mg daily
1871143|NCT01108588|Drug|Aspirin|Aspirin 300 mg daily
1871144|NCT01108588|Drug|Clopidogrel|Clopidogrel 75 mg daily
1871145|NCT01108588|Drug|Comparator: Placebo (to match Clopidogrel)|Placebo (grossly matched Clopidogrel 75 mg) daily
1871146|NCT01108601|Drug|Ringer's Lactate (0.03% Ciprofloxacin)|For each patient, only one ear will receive the Ringer's Lactate solution. The other ear will act as a control. To ensure adequate delivery of the solution to the middle ear, a small pressure equalizing tube will be inserted under local anesthesia before commencement of chemotherapy treatment. The patient will be instructed to administer four drops of RL solution to the experimental ear twice a day during their chemotherapy treatment.
1871147|NCT01108614|Behavioral|Intervention|Intensive HIV psychological counseling ,Increased methadone dosage under individualized treatment principle, enhance randomized urine test, strengthen family and social support , partner notification and routine HIV testing, condom promotion, STD referral services.
1871148|NCT01108627|Drug|open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER®|• Drugs. The study drugs are open-labeled inhaled corticosteroids (ICS); FORADIL® AEROLIZER® and FORADIL placebo. FORADIL® AEROLIZER® consists of a capsule dosage form containing a dry powder formulation of FORADIL (formoterol fumarate) intended for oral inhalation only with the AEROLIZER Inhaler. Each clear, hard gelatin capsule contains a dry powder blend of 12 mcg of formoterol fumarate and 25 mg of lactose (which contains trace levels of milk proteins) as a carrier. Ten capsules are contained in each package, which is clearly labeled. To use the delivery system, a FORADIL capsule is placed in the well of the AEROLIZER Inhaler, and the capsule is pierced by pressing and releasing the buttons on the side of the device. The formoterol fumarate formulation is dispersed into the air stream when the patient inhales rapidly and deeply through the mouthpiece.
1871149|NCT01108627|Drug|foradil placebo|open-labeled inhaled corticosteroids (ICS); foradil placebo
1871150|NCT01108627|Drug|foradil|open-labeled inhaled corticosteroids (ICS); foradil
1871151|NCT01108653|Other|Usual care sick-leave management|Patients randomized to usual care. Follow up after discharge by general practitioner (GP) according to local practice.
1871152|NCT01108653|Other|Structuralised sick-leave program|Patients randomized to the structuralized program will get full time sick-leave for 2 weeks after discharge.Cardiologist will be responsible for individual adaption of each patient`s sick-leave and follow-up.
1871153|NCT01108666|Drug|Nelfinavir|Two dose levels of Nelfinavir will be evaluated in each concurrent chemotherapy group (carboplatin/paclitaxel and cisplatin/etoposide) at the RPTD does of proton beam radiotherapy: 625 and 1250 mg PO bid.
1871154|NCT01108692|Other|Telecardiology|"Telecardiology will be switched on for both groups. For the Active group, all data will be transmitted to the physician. For the Control group, data will not be used for patients surveillance, only events regarding implant (Elective Replacement Indication) or events regarding data transmission missing will be generated and sent to the physician.
A retrospective analysis will be performed at the end of the study to compare the results in the two groups."
1871155|NCT01108705|Drug|Brivanib|Tablets, Oral, 800 mg, once daily, until disease progression or toxicity
1871156|NCT01108705|Drug|Placebo|Tablets, Oral, 0mg, once daily, until disease progression or toxicity
1871157|NCT01108718|Other|Tempur-Pedic Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the Tempur-Pedic mattress first, then the Control Mattress.
1871194|NCT01109082|Procedure|posterior spine fusion|vertebrae are fused to straighten a spinal curve
1871158|NCT01108718|Other|Control Mattress (2 months)|Female subjects, aged 18 years or older who have been diagnosed with fibromyalgia and do not possess any sleep disorder receiving the control mattress first, then the Tempur-pedic Mattress.
1871159|NCT01108731|Drug|Milnacipran|"Patients will take an increasing number of 12.5mg pills for the first 9 days during the ramp up period and then take one 50mg pill in the morning and one 50mg pill in the evening for the remaining 8 weeks of the study."
1871160|NCT01108731|Drug|Placebo|"Patients will take an increasing number of placebo pills for the first 9 days during the ramp up period and then take one pill in the morning and one in the evening for the remaining 8 weeks of the study."
1871161|NCT01108744|Drug|hypertonic saline|3% hypertonic saline, dosed by ideal patient weight
1871162|NCT01108744|Drug|Mannitol|Mannitol 20% intravenous solution, dosed by patient's ideal body weight
1994716|NCT02939638|Other|Plant-based diet|Weekly instructions will be given to the participants in the intervention group about following vegan diet.
1871165|NCT01108783|Drug|Bilastine|20 mg (encapsulated) tablets QD/14 days
1871166|NCT01108783|Drug|Desloratadine|5 mg (encapsulated) tablets QD/14 days
1871167|NCT01108783|Drug|Placebo|(encapsulated) Tablets QD/14 days
1871168|NCT01108809|Drug|Telmisartan or Telmisartan and Hydrochlorthiazide|Telmisartan 80mg +/- Hydrochlorthiazide 12.5mg or 25mg
1871169|NCT01108835|Other|Comprehensive care programme|"Intervention group:
Patients will be interviewed by a respiratory nurse and given education in 1-2 sessions
Physiotherapist assessment and training (individualized physical training programme to perform at home or a short course out-patient pulmonary rehabilitation)
Respiratory physician assessment and optimization of treatment
Patients will also be taught about a personalized action plan by the physician and respiratory nurse.
Subsequent intervention: Patients will receive monthly telephone calls by a respiratory nurse for a period of 1 year to assess their conditions and also answer their queries."
1871170|NCT01108848|Biological|Berinert® (C1 Esterase Inhibitor)|Berinert® is marketed as a lyophilized concentrate available in a single-use vial to be reconstituted with sterile water before administration as described in the prescribing information.
1871171|NCT01108861|Device|GORE VIABAHN® Endoprosthesis|GORE VIABAHN® Endoprosthesis
1871172|NCT01108861|Device|Plain old balloon angioplasty|Plain old balloon angioplasty
1871173|NCT01108874|Drug|Metaraminol|Patients will be given metaraminol every time SBP falls below baseline value.
1871174|NCT01108900|Drug|sildenafil|tables, 25,50,100 mg, on demand, 1 month
1871175|NCT01108913|Drug|Bimosiamose|
1871176|NCT01108913|Drug|Placebo|
1871177|NCT01108926|Drug|Atripla®|All subjects will be administered Atripla® (tenofovir 245 mg plus emtricitabine 200 mg plus efavirenz 600 mg), one tablet orally once daily for 14 days
1871178|NCT01108939|Drug|Antimalarial treatment|
1871179|NCT01108939|Other|Observation|
1871180|NCT01108978|Drug|Placebo|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
1871181|NCT01108978|Drug|Dehypotin|Dehypotin® 40 mg/day or placebo, once a day, shortly after baseline for 12 consecutive weeks
1871182|NCT01108991|Behavioral|Physical activity self-management|This intervention includes a manual, telephone health coach calls, and automated telephone calls. The manual has 20 chapters for the active phase and 5 maintenance phase chapters. During the first 20 weeks the health coach will call patients every other week and the automated telephone calls will occur on the alternate weeks.
1871183|NCT01108991|Other|COPD education + Usual care|Six weeks of COPD self-management education plus usual care
1871184|NCT01109004|Drug|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive a second autologous PBSC transplant with the same conditioning regimen as the first transplant. All patients will also receive maintenance lenalidomide which will start after the second transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
1871185|NCT01109004|Drug|lenalidomide, bortezomib and dexamethasone|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive consolidation therapy with RVD (lenalidomide 15 mg/day on Days 1-14, dexamethasone 40mg on Days 1, 8 and 15, and bortezomib 1.3mg/m2 on Days 1, 4, 8 and 11 of every 21 day cycle, patients will receive four cycles). All patients will also receive maintenance lenalidomide which will start after consolidation therapy. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
1871186|NCT01109004|Drug|Lenalidomide|All patients will undergo a first autologous peripheral blood stem cell (PBSC) transplant with high-dose melphalan (200 mg/m^2 IV) given on Day -2. Upon recovery from the first transplant patients will receive maintenance with lenalidomide (15 mg daily). Maintenance lenalidomide will start after the first autologous transplant. Maintenance therapy with lenalidomide will start at 10 mg daily for 3 months and increase to 15 mg daily. The duration of maintenance will be three years in all treatment arms.
1871187|NCT01109017|Drug|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, and a Quality of Life form is completed by the patient, at visits 1 to 5.
1871188|NCT01109030|Drug|Pioglitazone+Citalopram+Chlordiazepoxide|"Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.
Chlordiazepoxide 10 mg each night for first three weeks"
1871189|NCT01109030|Drug|Placebo+ Citalopram+ Chlordiazepoxide|"Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.
Chlordiazepoxide 10 mg each night for first three weeks"
1871190|NCT01109043|Drug|Bisoprolol or bisoprolol + HCTZ|Film-coated tablets containing 5 mg or 10 mg of bisoprolol hemifumarate or film-coated tablets containing 5 mg of bisoprolol fumarate (2:1) and 12.5 mg of HCTZ were given
1871191|NCT01109056|Drug|cyclosporine ophthalmic emulsion 0.05%|One drop in the study eye (or eyes) administered four times daily (QID)
1871192|NCT01109056|Drug|Vehicle|One drop in the study eye (or eyes) administered four times daily (QID)
1871195|NCT01109095|Biological|Genetically modified HER.CAR CMV-specific CTLs|"HER2.CAR CMV-specific CTLs will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The patient will get one of the following doses:
1 x 10^6/m^2
3 x 10^6/m^2
1 x 10^7/m^2
3 x 10^7/m^2
1 x 10^8/m^2"
1871196|NCT01109121|Drug|Combination 400|Tranilast 300 mg QD; Allopurinol 400 mg QD
1871197|NCT01109121|Drug|Allopurinol|Allopurinol 400 mg, QD
1871198|NCT01109121|Drug|Combination 600|Tranilast, 300 mg QD; Allopurinol 600 mg QD
1871199|NCT01109134|Drug|tirofiban intracoronary bolus-only|administer tirofiban bolus intracoronary during primary percutaneous coronary intervention with no additional maintenance infusion
1871200|NCT01109134|Drug|tirofiban intravenous bolus plus infusion|administer tirofiban bolus intravenously and maintain infusion for up to 18 hours
1871201|NCT01109147|Other|Imagery|All the subject will be submitted to an functional magnetic resonance imaging (fMRI) examination.
1871202|NCT01109147|Genetic|pharmacogenetic sampling|A pharmacogenetic sample will be done with an additional consentment.
1871203|NCT01109160|Drug|Azithromycin Dihydrate|"Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis.
Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment)."
1871204|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
1871205|NCT01109173|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye three times daily, for 16 days
1871206|NCT01109173|Other|Nepafenac Ophthalmic Suspension 0.3% Vehicle|Nepafenac 0.3% vehicle, one drop in affected eye once daily, for 16 days. An additional dose was administered between 30-120 minutes prior to surgery.
1871207|NCT01109173|Other|NEVANAC Vehicle|Nepafenac vehicle, one drop in affected eye three times daily, for 16 days
1871208|NCT01109186|Other|biological parameters|blood sample at M1, M2, M3; M4; M5, M6, M7, M8 and M9 after kidney transplantation
1871209|NCT01109199|Dietary Supplement|PolyGlycopleX (PGX)|The full dose of the study intervention is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
1871210|NCT01109199|Dietary Supplement|Rice flour|The full dose of the placebo comparator is 15 grams per day and total number of calories with the LCD is 1000 kcal/day.
1871211|NCT01109212|Drug|Bindarit|dosage form:tablet dosage:2x300 mg frequency:b.i.d duration:12 weeks
1871212|NCT01109212|Drug|Placebo|dosage form: tablet dosage: n.a. frequency: 2xplacebo b.i.d duration:12 weeks
1871213|NCT01109225|Biological|blood sample|
1871214|NCT01109225|Procedure|MRI|
1871215|NCT01109225|Procedure|echocardiography|
1871216|NCT01109225|Biological|urine sample|
1871217|NCT01109225|Procedure|pulmonary echography|
1871218|NCT01109225|Procedure|vascular check|
1871219|NCT01109225|Procedure|renal echography|
1871220|NCT01109251|Procedure|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.
The auto-measures will be performed according the methodology recommended by HAS."
1871221|NCT01109251|Procedure|Auto-measure of the tension by an autotensiometer|"All hypertended patients able to realise a serie of tensional auto-measures will be invited to realise a serie of tensional auto-measures theree days before the consultation in the neurology department.
The auto-measures will be performed according the methodology recommended by HAS."
1871222|NCT01109264|Drug|Bendamustine hydrochloride injection|d1-2, i.v.gtt, 100mg/m2, 28 days per cycle, at most 6 cycles
1871223|NCT01109264|Drug|Chlorambucil|d1-d2, d15-d16, p.o., 0.4mg/kg/day, 28 days per cycle, at most 6 cycles
1871224|NCT01109303|Procedure|TightRope System- Arthrex® / Dynamic Implant|Patients are operated on using a dynamic implant, the TightRope System by Arthrex®. The ankle is immobilized in a plaster boot for 6 weeks.
1871225|NCT01109303|Procedure|Screw fixation - Synthes® / Static Implant|Patients are operated on using a static implant, the rigid four-cortices 3,5 mm screw fixation by Synthes®. The ankle is immobilized in a plaster boot for 6 weeks.
1871226|NCT01109316|Drug|Insulin lispro 2 day reservoir in-use|Insulin lispro 2 Day (L2D) administered by infusion pump for 8 week treatment period.
1871227|NCT01109316|Drug|Insulin lispro 6 day reservoir in-use|Insulin lispro 6 Day (L6D) administered by infusion pump for 8 week treatment period.
1871228|NCT01109316|Drug|Insulin aspart 6 day reservoir in-use|Insulin aspart 6 Day (A6D) administered by infusion pump for 8 week treatment period.
1871229|NCT01109329|Biological|HMPV challenge virus|Single dose of 10^6 plaque forming units (PFU) of recombinant HMPV small hydrophobic genes (rHMPV-SHs)
1871230|NCT01109355|Other|lung mechanics ventilatory|To perform the evaluation of lung mechanics ventilatory mode was changed to control volume with the following parameters: tidal volume (Vt) = 8ml/kg weight, peak flow (PF) = 6 x minute volume, fraction of inspired O2 (FiO2) = 40%, respiratory rate (RR) = 16 bpm, sensitivity = 1 cmH2O. The following variables were monitored: PIC, Blood Pressure (BP), heart rate (HR), peak pressure in the airways (pp.) and plateau pressure of the respiratory system (Ppl.), these values were monitored with PEEP = 5 cmH2O. PEEP employed ranged from 0 to 14 cmH2O. To eliminate a possible physiological accommodation by the progressive increase of PEEP, the range of values was determined by drawing a sealed envelope for each patient, ranging from 2 to 2 cmH2O.
1871231|NCT01109355|Other|Hemodynamic and intracranial pressure|At each value of PEEP the patient was ventilated for a period of five minutes to carry out monitoring of ICP, BP, HR, PPC and peripheral oxygen saturation (SpO2). The ICP monitoring catheter was kept closed for drainage and open for monitoring, since the arrival of the surgical block, was only open for drainage if there was an increase in ICP above 20 mmHg.
1871232|NCT01109381|Drug|GT08|GT08 is the combination of omeprazole 40mg daily, lauric acid 150-300mg daily, NAC 1.2 - 2g daily
1871233|NCT01109446|Biological|Platelet Rich Plasma|27ml of autologous whole blood added to 3ml of ACD-A (Citrate Anticoagulant). After separation of the platelets, a high concentration of platelets (3-4ml Platelet Rich Plasma) is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
1871268|NCT01109771|Device|absorbable mesh fixation|Absorbable mesh fixation will be used.
1871234|NCT01109446|Procedure|Isotonic Saline Solutions|3ml of Isotonic Saline Solution is injected into the tendon through 7 perforations of the tendon, guided by ultrasound.
1871235|NCT01109446|Drug|Triamcinolonacetonid|Triamcinolonacetonid 40mg/ml. 40mg of Triamcinolonacetonid is mixed with 2ml of Lidocaine 10mg/ml. It is injected deep into the tendon, guided by ultrasound.
1871236|NCT01109459|Other|Pediatric blood pressure screening|Website presenting case-based education with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
1871237|NCT01109459|Other|Pediatric vision screening|Website presenting case-based education about amblyopia and strabismus with tailoring based on knowledge and interactive with responses collected on line. Has a tool box for office materials to promote and encourage guideline based performance.
1871238|NCT01109472|Other|patient magazine|patient magazine individually tailored to patient's prior feedback
1871239|NCT01109485|Drug|Olopatadine hydrochloride ophthalmic solution 0.1%|1-2 drops 4 times per day
1871240|NCT01109498|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 1 x E12 gc per kg body weight, injected in a single series of intramuscular injections
1871241|NCT01109498|Drug|Mycophenolate mofetil|oral, 2 g/day, day -3 till week 12
1871242|NCT01109498|Genetic|Alipogene Tiparvovec (AMT-011), Human LPL [S447X]|intra muscular, 3 x E11 gc per kg body weight, injected in a single series of intramuscular injections
1871243|NCT01109498|Drug|cyclosporine|oral, 3 mg/kg/day, day -3 till week 12
1871244|NCT01109511|Drug|naloxone|
1871245|NCT01109511|Drug|oxycodone|
1871246|NCT01109524|Drug|Cetuximab|Vial, Intravenous, 400mg/m², week 1, then 250mg/m², Weekly, Until Progressive Disease (PD)/ Toxicity/Pt-PI Decision
1871247|NCT01109524|Drug|Cisplatin|Vial, Intravenous, 80mg/m², Day 1 of each 21 day cycle, Maximum 6 cycles
1871248|NCT01109524|Drug|Vinorelbine|Vial, Intravenous, 25 mg/m², Day 1 and 8 of each 21 day cycle, Maximum 6 cycles
1871249|NCT01109550|Procedure|ERCP|endoscopic retrograde cholangiopancreatography transpapillary biopsies
1871250|NCT01109563|Behavioral|Marijuana Check-Ins|The MCI, an MET intervention, will include the provision of personalized feedback with a motivational interviewing style. The focus of these sessions will be individualized to participants based on recent marijuana use and related experiences. Feedback given to participants during the MCI session will review progress toward goals as self-reported in percent days abstinent, normative data regarding marijuana use, review of reported consequences of marijuana use, review of abuse and dependence criteria reported, comparison of consequences and abuse and dependence symptoms reported over time, review of the positive outcomes from reductions in use, and review of immediate and long-term life goals and how their marijuana goal will affect these. HEs will offer particular encouragement to take advantage of CBT sessions to participants who feel they currently need treatment.
1871251|NCT01109576|Behavioral|DSL Workshop|A series of 6 weekly 2 hour interactive workshops for Veterans with age-related Dual Sensory Loss that provide instruction, skills training, exercises and facilitated interaction among peers.
1871252|NCT01109602|Other|Yoga focused on strength, flexibility, and balance|Participants completed 8 weeks of yoga therapy. The yoga was focused on strength, flexibility, and balance therapy after stroke to impact fear of falling, balance, mobility, QoL, and blood pressure after stroke. The in-person yoga intervention included seated, standing, and floor poses. All study participants were able to complete transfers to the floor or mat table and complete all postures and breathing exercises.
1871253|NCT01109615|Drug|Pemetrexed|400 mg/m2 on day 1 of a 3 weeks cycle
1871254|NCT01109615|Drug|Gemcitabine|1000 mg/m2 intravenously on day 1 and 8 of a 3 weeks cycle
1871255|NCT01109628|Dietary Supplement|Protein drink|Twice a day during 6 months
1871256|NCT01109628|Dietary Supplement|Placebo drink|Twice a day during 6 months
1871257|NCT01109641|Device|diagnostic electrophysiology catheter|electrical measurements through a diagnostic electrophysiology catheter
1871258|NCT01109654|Drug|Cetrorelix acetate and Follitropin alfa|Cetrorelix acetate given either as a single-dose regimen of 3 mg injection or as a multiple-dose regimen of 0.25 mg daily injection.Ovarian stimulation therapy with Follitropin alfa generally starts on cycle Day 2 or 3. The starting dose of Follitropin alfa is based on the Investigators' discretion
1871259|NCT01109680|Drug|Neramexane|Multiple dose Neramexane followed by single dose 14C Neramexane
1871260|NCT01109693|Drug|Sertraline|Sertraline 50 mg/d or 100 mg/d for 6 more weeks
1871261|NCT01109693|Drug|Mirtazapine|Augment with or switch to mirtazapine 15-45 mg/d
1871262|NCT01109706|Other|biological parameters dosage|"200 patients will be enrolled in the study (n=100 patients under statin treatment, n=100 patients without statin).
After checking inclusion and non-inclusion criteria and obtaining informed consent from the patients. The SYNTAX score will be calculated and will allow to determine coronary analysis will be done at J1 and J4 (glucose, HbA1C, lipids, ApoA1, ApoB, sterols, plasmatic bile acids, insulinemia, creatinin clearance, hepatic function panel, CRPus and PCSK9 level assessment).
Then, a sub-group of 30 patients will have supplementary blood analysis at 1 and 6 months after their admission, during their usual follow-up."
1871263|NCT01109732|Other|Systematic physical training with instructor|Training 3 times per week for 6 months, the first 3 months with an instructor
1871264|NCT01109745|Other|PELICAN Primary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in primary care. The general practitioner can integrate the information of the Pelican instrument in their consultation and disease management decisions. The general practitioner will be trained and supported to negotiate the child's, and physicians' agendas based on the outcome of the instrument, and discuss possible interventions. All participating children of a GP will be allocated to the same treatment group (i.e., hierarchical or nested design).
1871265|NCT01109745|Other|PELICAN Secondary Care|The intervention is the integration of the output of the Pelican instrument in daily care to guide disease management for children with asthma treated in secondary care. The nurse can integrate the information of the Pelican instrument in their consultation and disease management decisions. The paediatricians will be trained and supported to negotiate the child's, and nurses' agendas based on the outcome of the instrument, and discuss possible interventions.
1871266|NCT01109758|Drug|Fenofibrate|145 mg
1871267|NCT01109771|Device|permanent mesh fixation|Permanent mesh fixation will be used.
1871271|NCT01109797|Behavioral|Transition Social Behavioral Intervention|"If you are assigned to the first group, you will have two all-day Saturday sessions four weeks apart on the KU campus in Lawrence. The objectives of the Saturday programs are to promote positive behavior change with respect to taking ownership of diabetes and its demands by providing transition-specific information, enabling participants to practice the life skills needed to successfully manage diabetes as an adult, and fostering peer-to-peer social networking over the 6-month period of the intervention (and beyond). You will continue to see your current provider of diabetes care outside of the parameters of this study."
1871272|NCT01109797|Behavioral|Diabetes Transition Clinic|Patients who participate in the transition clinic arm of the study will be seen six times during a six-month time period, as well as receive psychological assessment and intervention, as necessary, prior to the first clinic visit (intake) and as part of visits 2 and 4. Three of the six visits will be standard of care medical visits with either a pediatric or adult provider or both. Three will be individual or group education sessions with diabetes educators focused on transition issues such as, managing the adult health care system, talking with your care provider,and dealing with adult issues (pregnancy, genetic concerns, etc).
1871273|NCT01109823|Drug|intravenous administration of levofloxacin|Intravenous administration of levofloxacin is used.
1871274|NCT01109836|Behavioral|Motivation and lifestyle intervention|Intensive control and motivation for better compliance with medication, regular blood pressure measurements, diet changes and physical activity.
1871275|NCT01109849|Behavioral|behavior therapy|combination of individual and group parent training plus school consultation
1871276|NCT01109849|Drug|Extended release (ER) methylphenidate product|medication to be taken daily for duration of study unless assigned to weight promotion arm
1871277|NCT01109849|Other|monitoring|monthly weight, height and BMI checks
1871278|NCT01109849|Other|drug holiday|switch from seven day a week dosing to medication only on school days
1871279|NCT01109849|Dietary Supplement|caloric supplement|continue current ADHD regimen and add one 8oz liquid caloric supplement at night
1871280|NCT01109862|Procedure|Total hip arthroplasty|All cemented THA
1871281|NCT01109862|Procedure|Hemiarthroplasty|Cemented bipolar HAP
1871282|NCT01109875|Other|blood test|Dry blood spots (DBS) analysis of a- galactosidase-A activity will be used for male patients' diagnosis. Males and females with enzymatic activity bellow the test's cut-off will be further diagnosed by gene sequencing. Since females are heterozygote and may have high residual levels of active enzyme, female patients with a- galactosidase-A activity of 30% bellow averaged normal range will also be further diagnosed by gene sequencing as described before (8).
1871283|NCT01109888|Drug|Cetrotide|
1871284|NCT01109901|Procedure|anterior subcutaneous transposition|transposition of ulnar nerve into subcutaneous bed
1871285|NCT01109901|Procedure|Anterior submuscular transposition|transposition of ulnar nerve into muscular tissue
1871286|NCT01109914|Biological|Dukoral|"Two oral doses of Dukoral® (SBL Vaccines) will be administered (day 0 and day 14). Each dosage contains 3 ml of suspension in a vial and 5.6 g of effervescent granules in a sachet. Each dosage (3 ml) contains: A total of 100000 million bacteria of the following strains:
Vibrio cholerae O1 Inaba, classical biotype (heat inactivated) 25x1000 million bacteria*
Vibrio cholerae O1 Inaba, El Tor biotype (formalin inactivated) 25x1000 million bacteria*
Vibrio cholerae O1 Ogawa, classical biotype (heat inactivated) 25x1000 million bacteria*
Vibrio cholerae O1 Ogawa, classical biotype (formalin inactivated) 25x1000 million bacteria* −Recombinant cholera toxin B subunit (rCTB) 1 mg (produced in V. cholerae O1 Inaba, classical biotype strain 213)"
1871287|NCT01109927|Drug|Insulin|Insulin treatment in accordance to glucose values
1871288|NCT01109940|Biological|AIN457A|
1871289|NCT01109953|Other|Breath-Hold PET/CT image set|In addition to the standard clinical PET/CT images, we will provide a breath-hold PET/CT image set, using the same PET data for both. In order to spatially match PET, and therefore improve attenuation correction in the PET images, we will acquire a Breath-Hold CT at 310 mA over the same region covered by PET. The normal-organ doses accumulated from the additional 30 mA CT. The patient's breathing signal during CT and the whole body PET will be recorded using a video camera and in house developed software. We will compare the clinical PET/CT and Breath-Hold PET/CT in regards to lesion detection, lesion volume, and SUV quantification.
1871290|NCT01109966|Other|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.
Infants should typically consume the following amounts of formula during the study > 500mls/day up to 12 months of age > 400mls/day between 12 and 18 months of age > 300mls/day over 18 months of age."
1871291|NCT01109966|Other|Special Medical Food|"Comparison between a standard amino acid based formula and a new amino acid based formula. Subjects with CMA will take their randomised formula for 12 months. Following completion of the intervention (12 months), subjects will transfer to an age appropriate formula and be followed-up at 24 and 36 months.
Infants should typically consume the following amounts of formula during the study > 500mls/day up to 12 months of age > 400mls/day between 12 and 18 months of age > 300mls/day over 18 months of age."
1871292|NCT01109979|Drug|Estradiol+MPA|1 single pill dose daily containing estradiol 1 mg + medroxyprogesterone acetate 2.5 mg
1871293|NCT01109979|Drug|Estradiol+Drospirenone|1 single pill dose daily containing estradiol 1mg + drospirenone 0.5 mg
1871294|NCT01109992|Drug|Exercise plus Regadenoson (Lexercise)|Standard Bruce exercise stress test with regadenoson injection at maximal stress with Rubidium-82 Positron Emission Tomography
1871295|NCT01109992|Drug|Regadenoson (Lexiscan)|Regadenoson Rubidium-82 Positron Emission Tomography
1871296|NCT01110005|Other|D5 Lactated Ringer's Solution (D5LR)|D5LR IV fluid
1871297|NCT01110005|Other|Lactated Ringer's Solution (LR)|LR IV fluid
1871298|NCT01110018|Drug|GSK573719 (SOLUTION)|20μg /mL solution for IV and Oral dosing
1871299|NCT01110018|Drug|GSK573719 (INHALATION POWDER)|500μg inhalation powder delivered via Novel Dry Powder Inhaler. GSK573719 1000μg per dose (2x 500μg strips in device).
1871300|NCT01110031|Biological|Ofatumumab|Anti-CD20 monoclonal antibody
1871301|NCT01110044|Biological|251154 vaccine|Intramuscular, single dose
1871302|NCT01110044|Biological|Infanrix hexa™|Intramuscular, four doses
1871303|NCT01110044|Biological|Synflorix™|Intramuscular, four doses
1871307|NCT01110070|Device|ChonDux|Comparison of ChonDux plus microfracture to microfracture only
1871308|NCT01110070|Device|ChonDux|single use device
1871309|NCT01103908|Device|HCE101 Cardiopulmonary Support Monitor|Measurement of cardiac output using ultrasound dilution technology. The ultrasound dilution technology is in the HCE101 Cardiopulmonary Support Monitor.
1871310|NCT01103921|Other|Glucose|25% dose at 2-week intervention assigned to subjects.
1871311|NCT01103921|Other|Fructose|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
1871312|NCT01103921|Other|High-Fructose Corn Syrup|25%, 17.5%, or 10% dose at 2-week intervention assigned to subjects.
1871313|NCT01103921|Other|No sugar (Aspartame)|0% dose at 2-week intervention assigned to subjects.
1871314|NCT01103934|Drug|Vitamin D3|4000 IU once daily
1871315|NCT01103934|Drug|Placebo|Placebo taken once daily
1871316|NCT01103934|Drug|Fluticasone Propionate|200 mcg daily, intranasal
1871317|NCT01103947|Device|EcoAnaesthesia facemask first|The trial facemask will be used before the standard one.
1871318|NCT01103947|Device|Portex Adult (Standard) facemask first|The standard facemask will be applied before the trial device.
1871319|NCT01103947|Device|Portex Adult (Standard) facemask second|The standard facemask will be applied after the trial device
1871320|NCT01103947|Device|EcoAnesthesia facemask second|The trial facemask will be used after the standard one.
1871321|NCT01103960|Drug|Telmisartan80mg+Amlodipine5mg|combination therapy
1871322|NCT01103960|Drug|amlodipine 5mg|monotherapy
1871323|NCT01103960|Drug|Telmisartan80mg+Amlodipine 5mg|combination therapy
1871324|NCT01103973|Behavioral|Mind/Body Program|Ten week group mind/body program
1871325|NCT01103973|Behavioral|Control|Spa gift certificates
1871326|NCT01103986|Behavioral|Motivational/health literacy education (Test group)|"Attend a 1-hour class to learn how to use the book What to Do When Your Child Gets Sick."
1871327|NCT01103986|Behavioral|Control Group|No intervention
1871328|NCT01104012|Biological|"Classification as asthmatic or rhinitis only via proteomic analysis"|Proteomic profiles are established for each patient using plasma and serum samples
1871329|NCT01104012|Biological|"Classification as asthmatic or rhinitis only according to a metacholine test"|A positive metacholine test indicating bronchial hyperresponsiveness is currently our Gold Standard for diagnosing asthma.
1871330|NCT01104025|Drug|ATG, rabbit|ATG, rabbit (Thymoglobulin, Genzyme) will be dosed at 5 mg/kg/dose, given IV on 5 consecutive days (titrated over 4 to 8 hours).
1871331|NCT01104025|Drug|Etoposide|Etoposide will be dosed at 150mg/m2, given IV. The first dose will be given 7 days (+/- 2 days) after the first dose of ATG, and be given weekly for a total of 7 doses.
1871332|NCT01104025|Drug|Methotrexate|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
1871333|NCT01104025|Drug|hydrocortisone|Intrathecal Methotrexate and hydrocortisone will be administered to CNS+ patients (CNS+ patients are those patients which have any of the following: elevated CSF (cerebral spinal fluid) protein or white count, seizures, focal or global neurologic deficit, MRI abnormalities consistent with CNS involvement by HLH.) in the following doses: age< 1 yr: 6/8mg (MTX/HC), 1-2 yrs: 8/10mg, 2-3 yrs: 10/12mg, >3 yrs: 12/15 mg. It will be administered (+/- 3 days) on day 7, 14, 21 and 42.
1871334|NCT01104025|Drug|Dexamethasone|will be started with the ATG. It will be divided BID, given IV for at least 1 week before switching to PO. Dosing: 20mg/m2/day x7days, 10mg/m2/day x7days, 5mg/m2/day x14days, 2.5mg/m2/day x14days, 1.25mg/m2/day x14days.
1871335|NCT01104038|Behavioral|EXCEL|Children in the EXCEL intervention will receive 12 weeks of supervised physical activity, guided by principles of behavior change, in the form of exergaming (technology-mediated interactive physical activity)3 times per week for 12 weeks and will also receive weekly group nutrition education sessions
1871336|NCT01104038|Behavioral|EXCEL|Participants in the EXCEL intervention will receive 12 weeks of supervised physical activity in the form of exergaming (technology-mediated physical activity). Sessions will be held 3 times per week with 60 minutes of supervised physical activity.
1871337|NCT01104038|Behavioral|Nutrition Education ONLY|Children in the nutrition education group will receive 30 minutes per week of group nutrition education in the school environment and delivered by a registered dietitian The nutrition education sessions will be identical to those provided for the EXCEL group.
1871338|NCT01104064|Device|real rTMS combined with constraint induced therapy|10 minutes of priming followed by 10 minutes of low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
1871339|NCT01104064|Device|sham rTMS combined with constraint induced therapy|10 minutes of sham priming followed by 10 minutes of sham low-frequency is followed on the next day with constraint induced therapy. A total of 5 treatment days for each therapy is given.
1871340|NCT01104090|Device|C-MAC direct laryngoscopy|Patients assigned to this arm will be intubated using C-MAC with direct laryngoscopy first and later indirect laryngoscopy
1871341|NCT01104090|Device|C-MAC Indirect laryngoscopy|Patients for this arm will be intubated with C-MAC using indirect technique
1871342|NCT01104103|Device|BOA(R)-Constricting IV Band|Device applied in accordance with manufacturer's instructions
1871343|NCT01104103|Device|Standard elastic constricting band|Standard therapy
1871344|NCT01104116|Radiation|[18F]-FDG PET/CT imaging|Drug: F-18 Fluoro-2-Deoxyglucose (F-18 FDG)
1871345|NCT01104142|Device|CGM|Continuous Glucose Monitoring System
1871346|NCT01104155|Drug|eribulin mesylate + erlotinib|21-day Regimen: Eribulin mesylate given at a dose of 2 mg/m2 as a 2-5 min intravenous (IV) bolus on Day 1 and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 2-16 of a 21-day cycle.
1871347|NCT01104155|Drug|eribulin mesylate + erlotinib|28-day Regimen: Eribulin mesylate given at a dose of 1.4 mg/m2 as a 2-5 min IV bolus on Days 1 and 8, and 150 mg of erlotinib given orally once daily, one hour before or two hours after the ingestion of food, on Days 15-28 of a 28-day cycle.
1871392|NCT01104519|Drug|Niaspan|Oral doses of 2000 mg of Niaspan once daily for 7 days.
1960096|NCT03299296|Drug|Rivaroxaban 10 Milligrams|The first group is to be on Rivaroxaban 10 mg with dosage according to the orthopedic approved regimen (10 mg once daily 6-10 hours after the surgery; recommended total duration of therapy: 12 to 14 days; The American College of Chest Physicians (ACCP) recommendation: Minimum of 10 to 14 days; extended duration of up to 35 days suggested.
1871349|NCT01104194|Dietary Supplement|omega-3 fatty acids supplements (fish oil)|1.74g eicosapentaenoic acid (EPA) and 0.25g docosahexaenoic acid (DHA)
1871350|NCT01104194|Dietary Supplement|Placebo|softgel capsules (identical in appearance to fish oil capsules) containing olive oil. 3 capsules/day, 4 weeks
1871351|NCT01104207|Device|repetitive transcranial magnetic stimulation (rTMS)|rTMS involves application of electromagnetic pulses through a coil to the subject's scalp. Some of the electromagnetic energy is transmitted to underlying neural tissue. The goal for this study: 1 Hz rTMS will suppress neural activity responsible for tinnitus perception.
1871352|NCT01104207|Device|placebo rTMS|placebo rTMS
1871353|NCT01104233|Device|LAP Protector|The LAP Protector is a device that consists of two flexible rings made of superelasticity alloys covered with polyurethane polyamide, and a thin silicone rubber membrane that is attached to the outer rim of the two rings
1871354|NCT01104246|Drug|Testerone Transdermal System|Transdermal testosterone applied daily for 4 weeks
1871355|NCT01104259|Drug|veliparib|Given PO
1871356|NCT01104259|Drug|cisplatin|Given IV
1871357|NCT01104259|Drug|vinorelbine tartrate|Given IV
1871358|NCT01104259|Other|laboratory biomarker analysis|Correlative studies
1871359|NCT01104259|Other|pharmacological study|Correlative studies
1871360|NCT01104272|Device|LipoSonix (Ultrasound treatment of Subcutaneous Adipose Tissue)|Study of Adipose Tissue Treatment Using Focused Ultrasound
1871361|NCT01104298|Drug|Doxorubicin|A maximum of 6 cycles every 3 weeks of doxorubicin monotherapy 75 mg/square meter will be given in the absence of progression or not acceptable toxicity.
1871362|NCT01104298|Drug|Trabectedin|A maximum of 6 cycles every 3 weeks of the combination (Trabectedin 1,1 mg/square meter + doxorubicin 60 mg/square meter) will be given in the absence of progression or not acceptable toxicity.
1871363|NCT01104311|Procedure|Aggressive BP lowering|adjust the amount and number of antihypertensive drugs to lowering of systolic blood pressure to target level
1871364|NCT01104311|Procedure|modest blood pressure lowering|adjust the amount and number of antihypertensive drugs
1871365|NCT01104337|Drug|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets twice a day along with two matching placebo tablets once daily
1871366|NCT01104337|Drug|paracetamol|Treatment consisted of two paracetamol 500mg (Doliprane® 500mg, Sanofi-aventis, Paris, France) tablets three times a day
1871367|NCT01104337|Drug|Placebo|Treatment consisted of two matching placebo tablets three times a day.
1871368|NCT01104350|Other|external radiation therapy with gemcitabine|"All patients will undergo daily image-guided radiation therapy with concurrent twice weekly gemcitabine chemotherapy. Radiation therapy will begin 2-4 weeks after restaging cystoscopy/fiducial marker placement.
Dose level #1: 23.4 Gy/1.8 Gy × 13 fractions (total dose 68.4 Gy)
Dose level #2: 27.0 Gy/1.8 Gy × 15 fractions (total dose 72.0 Gy)
Dose level #3: 30.6 Gy/1.8 Gy × 17 fractions (total dose 75.6 Gy)"
1871369|NCT01104363|Procedure|Snow white plaster 2. Kerr Co. Romulus, MI, USA.|Pick-up, splinted implants impressions.
1871370|NCT01104363|Procedure|Primopattern LC gel|Pick-up, splinted implants impressions.
1871371|NCT01104363|Procedure|Smart Dentin Replacement.|Pick-up, splinted implants impressions.
1871372|NCT01104376|Drug|Efavirenz|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.
In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
1871373|NCT01104376|Drug|voriconazole|"In phase 1 day 1 (control phase) a single 100mg dose of efavirenz will be administered.
In phase 2 (voriconazole pretreatment phase), the subject will be pretreated with voriconazole (400mg twice daily on phase 2 day 8 and then 200mg twice daily for the next consecutive 8 days. In phase 3 (efavirenz plus voriconazole phase), the subject will receive on phase 3 day 10 100mg single dose of efavirenz along with 200mg of voriconazole twice daily."
1871374|NCT01104389|Device|Fluorescence imaging|Intraoperatively acquire fluorescence images of renal tumors
1960097|NCT03299296|Drug|Enoxaparin 40 Milligrams/0.4 Milliliters Prefilled Syringe|"The other group will be administered the standard of care (SOC) enoxaparin as follows:
Once-daily dosing: 40 mg once daily, with initial dose within 9 to 15 hours before surgery, and daily for at least 10 days (or up to 35 days postoperatively) or until risk of deep venous thrombosis (DVT) has diminished or the patient is adequately anticoagulated on warfarin. The American College of Chest Physicians recommends initiation ≥12 hours preoperatively or ≥12 hours postoperatively; extended duration of up to 35 days suggested."
1871382|NCT01104428|Drug|Placebo|granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
1871383|NCT01104428|Drug|"ziying granules"|granules, <10years,10g,Three times a day,take orally >10years,20g,Three times a day,take orally fore weeks a period,Observe 2 periods
1871384|NCT01104467|Drug|Desmoteplase|1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)
1871385|NCT01104467|Drug|Desmoteplase|1 bolus injection of desmoteplase 90 µg/kg (IV)
1871386|NCT01104467|Other|Placebo|1 bolus injection of placebo IV
1871387|NCT01104480|Drug|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks given by IV infusion
1871388|NCT01104493|Biological|Monovalent Frozen FluMist®|Single dose of monovalent vaccine (240 subjects) by intranasal spray on Study Day 1.
1871389|NCT01104493|Other|Placebo|Single dose of placebo (60 subjects) by intranasal spray on Study Day 1
1871390|NCT01104506|Procedure|fMRI|
1871391|NCT01104506|Procedure|mTMS|
1872884|NCT01124162|Drug|Losartan|100 mg Tablet
1871393|NCT01104519|Drug|Comparator: Placebo|Oral doses of placebo once daily for 7 days.
1871394|NCT01104532|Drug|ASP1941|oral tablet
1871395|NCT01104532|Drug|sitagliptin|oral tablet
1871396|NCT01104545|Drug|MK3614|single rising oral dose of MK3614
1871397|NCT01104545|Drug|Comparator: Placebo|single dose oral placebo
1871398|NCT01104558|Drug|Bisoprolol|Bisoprolol will be given in a starting dose of 1.25 milligram (mg) once daily for two weeks and if it is well tolerated, the dose will be increased to 2.5 mg, 3.75 mg, 5 mg once daily in intervals of two weeks, 5 mg daily as a maintenance therapy. If the subject is tolerable, the dose can be increased as 10 mg/day as maximum dose.
1871399|NCT01104571|Biological|trastuzumab|Trastuzumab 6mg/kg iv given on days 1 & 8 pre-surgery & one dose of 2mg/kg iv between days 15-19 post surgery
1871400|NCT01104571|Drug|lapatinib ditosylate|"Part 1: Lapatinib 1500mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery.
Part 2: Lapatinib 1000mg/day p.o. continuously for 28 days. Should start 11 days (+2 or -1 day) before the scheduled surgery."
1871401|NCT01104571|Other|laboratory biomarker analysis|
1871402|NCT01104571|Procedure|adjuvant therapy|
1871403|NCT01104571|Procedure|neoadjuvant therapy|
1871404|NCT01104571|Procedure|therapeutic conventional surgery|therapeutic conventional surgery
1871405|NCT01104584|Drug|Gadobutrol (Gadavist, Gadovist, BAY86-4875)|A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
1871406|NCT01104597|Procedure|Flow Mediated Doppler (FMD)|Non-invasive assessment of flow-mediated dilation (FMD) will be performed using brachial artery ultrasound.
1871407|NCT01104597|Drug|Nitroglycerin 0.4 mg sublingual|Nitroglycerin 0.4 mg (a small tablet that dissolves under the tongue) will be given to dilate the arteries. Images of the arm will be recorded via non-invasive flow-mediated doppler for 5 minutes to assess for endothelium dysfunction. as outlined above.
1871408|NCT01104610|Device|Breas Vivo 40|The Vivo 40 will be used either in CPAP mode, PSV mode without Target Volume or PSV mode with Target Volume
1871409|NCT01104636|Drug|Varenicline|varenicline tablets prescribed as per local German SmPC for 12 weeks duration
1871410|NCT01104649|Drug|riluzole|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
1871411|NCT01104649|Drug|Placebo comparator|Study drug will be orally dispensed in doses of 50 mg twice daily for 12 months.
1871412|NCT01104662|Drug|Vancomycin|
1871413|NCT01104662|Drug|Daptomycin|
1871414|NCT01104662|Drug|Semi-Synthetic Penicillin|
1871416|NCT01110083|Drug|EMD 1204831|Subjects will receive EMD 1204831 twice a day for 21 days during each treatment cycle
1871417|NCT01110096|Behavioral|Parent Management Training - Oregon (PMTO)|Method to help parents and caregivers manage the behavior of the children they are responsible for.
1871418|NCT01110096|Behavioral|Motivational interviewing|Communication method to facilitate behavioral change and empower the parents.
1871419|NCT01110096|Behavioral|Dynamic group therapy|Focuses on individual experiences within families and/or parents/children, and that the participants are their own experts.
1871420|NCT01110122|Dietary Supplement|Whey protein|20g, oral, dissolved in yoghurt-drink, after every training and match for 2 weeks
1871421|NCT01110135|Drug|bendamustine hydrochloride|Given IV
1871422|NCT01110135|Drug|dexamethasone|Given PO
1871423|NCT01110135|Biological|filgrastim|Given SC
1871424|NCT01110135|Procedure|leukapheresis|Given IV
1871425|NCT01110135|Other|laboratory biomarker analysis|Correlative studies
1871426|NCT01110135|Other|flow cytometry|Correlative studies
1871427|NCT01110135|Drug|etoposide|Given IV
1871428|NCT01110148|Other|video-based informed consent for skin biopsies|video-based informed consent for punch and shave biopsies
1871429|NCT01110148|Other|traditional informed consent|traditional informed consent (standard of care) from physicians for shave and punch biopsies
1871430|NCT01110161|Device|Visceral fat mass measurement|Total body DXA measurement, Abdominal CT scan
1871431|NCT01110174|Diagnostic Test|HD PET/CT|imaging
1871432|NCT01110187|Drug|lacosamide|200 mg IV over 60 minutes; these patients will then be started on a maintenance dose 100 mg, IV BID as prophylaxis administered as per pharmacy protocol consistent with acceptable standards of care for 7 days. The Lacosamide dose can be adjusted as needed if seizures occur for therapeutic effect up to 200 mg bid (400 mg/d) as a maximum dose.
1871433|NCT01110187|Drug|Fosphenytoin|20 mgPE/kg IV over 60 minutes and then will be started on a maintenance dose (5 mgPE/kg/day, rounded to nearest dose of 150 mgPE IV, BID administered as per pharmacy protocol consistent with acceptable standards of care for 7 days
1871434|NCT01110200|Drug|ADVAIR DISKUS 250/50 mg BID|Fluticasone propionate/salmeterol 250/50 mcg BID in the DISKUS formulation (ADVAIR DISKUS) is a combination product containing a corticosteroid and a long-acting beta2-adrenergic agonist, indicated in the US for the maintenance treatment of airflow obstruction and reducing exacerbations in patients with COPD.
1871435|NCT01110200|Drug|SEREVENT 50 mcg BID|Salmeterol xinafoate Inhalation Powder (SEREVENT DISKUS) is indicated for the long-term, twice-daily (morning and evening), administration in the maintenance treatment of bronchospasm associated with COPD (including emphysema and chronic bronchitis).
1871436|NCT01110213|Behavioral|Physical activity|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for physical activity.
1871437|NCT01110213|Behavioral|Fruit and vegetable|Participants received two individually tailored phone calls and two condition specific newsletters encouraging goal setting and weighing the pros and cons for fruit and vegetable consumption.
1960102|NCT03298178|Procedure|TAVR|All patients who underwent transcatheter aortic valve replacement in Asan medical center, republic of Korea
1872885|NCT01124162|Drug|Cozaar®|100 mg Tablet
1960103|NCT03298178|Procedure|SAVR|All patients who underwent surgical aortic valve replacement in Asan medical center, republic of Korea
1871440|NCT01110239|Procedure|remote limb preconditioning|3 cycles of up to 10 minutes leg ischemia
1871441|NCT01110252|Drug|Stem cells stimulation|Subcutaneous injection of 5mcg/kg of G-CSF 3 days before the procedure.
1871442|NCT01110252|Procedure|stem cells collection|pullout of 200ml of bone marrow through the puncture of the iliac crest
1871443|NCT01110252|Genetic|stem cells infusion|slow infusion through the brachial vein of 30ml of bone marrow mononuclear cells diluted in albuminous saline.
1871444|NCT01110265|Behavioral|attention training|
1871445|NCT01110265|Behavioral|placebo training|
1871446|NCT01110291|Drug|docetaxel + CEF|"Docetaxel 80 mg/m² of body surface area (BSA) will be given as an i.v. infusion during 60 minutes on day 0 in a 20-day schedule. The cycle is repeated three times.
Three weeks after the last docetaxel regimen, all patients will receive the CEF-combination treatment. In CEF-combination cyclophosphamide will be given 600 mg/m²of BSA as an i.v. infusion during 15 - 30 minutes on day 0 in a 20-day schedule. This is followed by fluorouracil given 600 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes . Epirubicin will be given 60 mg/m² of BSA as an i.v. infusion during 15 - 30 minutes. This combination therapy will be repeated three times."
1871447|NCT01110304|Other|Conservative treatment - brace|Patients selected for this treatment will wear a light brace for pain release and analgesics will be prescribed. They can move the elbow, the wrist and the fingers immediately. After two weeks, they will begin a training program to restore shoulder motion and strength, and they will be asked to take off the brace progressively. They are allowed to start working and sporting activities when they feel comfortable.
1871448|NCT01110304|Device|Hook plate by Synthes|The patient is in a beach-chair position with injured arm slightly out of the table, on a bracket. The incision is longitudinal, from the distal third of the clavicle to the lateral border of the acromion. The deltoid is detached anteriorly to present the clavicle and the AC joint. The width of the hook depends on the depth of the acromion. The plate will always be 5 holes 3.5mm hook plate (Synthes®), left or right. The hook is inserted after visual reduction of the AC joint at the posterior border of the distal end of the clavicle, under the acromion. Reduction is then maintained by a davier and fixation with three 3,5mm cortical screws is achieved. After washing, deltoid is reinserted. CC ligaments are not directly repaired. Wound closure and bracing for two weeks.
1871449|NCT01110317|Drug|paliperidone palmitate 100 mg|Patients will receive a single paliperidone palmitate 100 mg equivalent injection in the gluteal or deltoid muscle on Day 1, 8, 36, and 64.
1871450|NCT01110330|Drug|Placebo cream|A topical, white, homogenous cream identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
1871451|NCT01110330|Drug|Ketoconazole 2% cream (formulation F012) (Nizoral)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole identical in appearance to study drug applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
1871452|NCT01110330|Drug|Ketoconazole 2% cream (formulation F126)|A topical, white, homogenous cream containing the equivalent of 20 mg (or 2%) of ketoconazole applied sparingly to all affected areas of the foot (or feet), once daily (at night or in the evenings) for a total of 4 weeks.
1871453|NCT01110343|Behavioral|mindfulness intervention|a 6 -week behavioral intervention lasting 1.5 hours per week with a trained parent mentor, 3 monthly booster sessions and follow-up
1871454|NCT01110343|Behavioral|Conventional parent Support Group|a 6 week behavioral program, consisting of 1.5 hour weekly sessions run by a trained parent mentor with a structured curriculum based on the strengths of support groups like emotional support, advocacy and training. There are 3 monthly booster sessions and follow-up.
1871455|NCT01110356|Drug|Ferinject|Ferric carboxymaltose will be provided in 2 vials of 10 mL containing each 500 mg iron, which will be diluted in 250 mL normal saline for injection. Study drug will be administered by drip infusion immediately after preparation over a minimum of 15 minutes. Placebo patients will be administered 250 mL normal saline for injection over a minimum of 15 minutes.
1871456|NCT01110356|Other|Saline|Placebo patients will be administered 250 mL normal saline for intravenous drip over a minimum of 15 minutes.
1871457|NCT01110369|Dietary Supplement|Protein drink|Protein drink twice a day during 6 months.
1871458|NCT01110369|Other|Resistance exercise training|Resistance exercise training twice per week during 6 months.
1871459|NCT01110369|Dietary Supplement|Placebo drink|Placebo drink twice a day during 6 months.
1871460|NCT01110382|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route-intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after meropenem placebo for up to 14 days
1871461|NCT01110382|Drug|Meropenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days.
1871462|NCT01110382|Drug|Meropenem|Type=once every 8 hours infused over 30 minutes, Unit=mg, Number=20 mg/kg to 1 gram per dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv meropenem administered every 8 hours immediately before doripenem placebo for up to 14 days
1871463|NCT01110382|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately after each iv infusion of meropenem for up to 14 days
1871464|NCT01110382|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or meropenem.
1871465|NCT01110408|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg,Number=20mg/kg up to 500mg/dose, Form=solution for infusion,Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
1871466|NCT01110408|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
1871467|NCT01110408|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
1871523|NCT01115270|Other|Non-invasive measures|assessment of cerebrovascular fluid movement
1871468|NCT01110408|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
1871469|NCT01110408|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
1871470|NCT01114919|Behavioral|Check Your Drinking (CYD)|"Internet based program of lower intensity as compared to the Alcohol Help Centre. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
1871471|NCT01114919|Behavioral|Alcohol Help Centre (AHC)|"Internet based program of higher intensity as compared to the Check Your Drinking intervention. It was designed to assesses drinking patterns, increase self-awareness of individual triggers, and set and achieve goals regarding abstinence."
1871472|NCT01114945|Device|McGrath|Intubation with the McGrath device
1871473|NCT01114945|Device|GlideScope|Intubation with the GlideScope device
1871474|NCT01114945|Device|Direct Macintosh Laryngoscopy|Intubation with Direct Macintosh Laryngoscope
1871475|NCT01114945|Device|Video-Mac|Intubation with the Video-Mac device
1871476|NCT01114958|Drug|Cisplatin, Thiosulfate|Cisplatin (150 mg/m^2) is given as an intra-arterial bolus, once, on days 2 and 9 of treatment. Thiosulfate (9 g/m^2), is given concurrently with cisplatin as an intravenous push over 15-20 minutes followed by a 6-hour intravenous infusion of thiosulfate (12 g/m^2).
1871477|NCT01114971|Drug|Fentanyl|"Fentanyl 50 micrograms/ml boluses will be given:
at the induction time
at the time before surgical incision, and
as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
1871478|NCT01114971|Drug|Labetalol|"Labetalol 5 mg/ml boluses will be given:
at the induction time
at the time before surgical incision, and
as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
1871479|NCT01114971|Drug|Esmolol|"Esmolol 10 mg/ml boluses will be given:
at the induction time
at the time before surgical incision, and
as needed to maintain hemodynamic stability during the intraoperative period (MAP within 15% of the pre-induction baseline value, and/or HR > 80 bpm)"
1871480|NCT01114997|Drug|Lidocaine|Pre-Induction: Lidocaine Loading: 1 mg/kg After Induction:Lidocaine Infusion: 12.5-25 mcg/kg/min 0.75-1.5 mg/kg/h)
1871481|NCT01114997|Drug|Esmolol|Esmolol Pre-Induction: Loading dose 750 mcg/Kg (0.75 mg/kg) Esmolol Post Induction: Infusion dose 7.5 - 15 mcg /kg/min
1871482|NCT01114997|Drug|Lidocaine + Esmolol (Combo)|"Pre-induction: Lidocaine Loading dose(1 mg/kg) + Esmolol Loading dose(750 mcg/Kg)
Maintenance Infusion rate after Induction:
Lidocaine(12.5-25 mcg/kg/min) + Esmolol(7.5-15 mcg/kg/min)"
1871483|NCT01115010|Device|Colonoscope stiffening device|"Colonoscopy is performed with the unassisted colonoscope (Olympus CF-100TL). The standard stiffening wire is introduced only if there is difficulty advancing the colonoscope and only after the tip has passed the splenic flexure. Difficulty is defined as failure to advance the tip of the scope after 5 minutes of trying. If difficulty is again encountered, the firm wire replaces the standard wire. Further difficulty requires removal of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
1871484|NCT01115010|Device|Colonoscope stiffening device|"Standard stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the standard wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the firm wire and so on until cecal intubation is achieved or the procedure is abandoned."
1871485|NCT01115010|Device|Colonoscope stiffening device|"Firm stiffening wire introduced routinely on entry into transverse colon. If difficulty is encountered (as defined previously), the wire is removed and attempts made to advance the colonoscope without it. Further difficulty requires introduction of the standard wire and so on until cecal intubation is achieved or the procedure is abandoned."
1871486|NCT01115023|Other|iron cooking pot|the mother was instructed to cook the family food in the iron cooking pot for the study period (60 days) as frequently in the day as possible.
1871487|NCT01115036|Drug|panobinostat|Oral panobinostat will be administered at 20mg by mouth 3 times a week one week prior to surgical resection. Within 2-6 weeks of resection, patients will resume panobinostat at 20mg 3 times per week. A cycle will be 28 days.
1871488|NCT01115049|Drug|chlorobutanol, hexetidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
1871489|NCT01115049|Drug|Chlorhexidine|3 times per day (after breakfast, lunch and dinner) for 1 minute with 15 ml of mouthwash
1871490|NCT01115062|Drug|Synera Patch|Synera Patch (lidocaine 70 mg/ tetracaine 70 mg) will be applied for 30 minutes to the venipuncture site
1871491|NCT01115062|Drug|LMX 4 Cream|LMX 4 (4% liposomal lidocaine) cream (2g) will be applied under Tegaderm for 30 minutes to the venipuncture site.
1871492|NCT01115062|Drug|Placebo Patch|A placebo patch with the same properties as the Synera patch but without lidocaine/tetracaine will be administered for 30 minutes to the venipuncture site.
1871493|NCT01115075|Other|Dietary fat/intake of carbohydrate|Spontaneous intake of fat, carbohydrate, protein and alcohol each day for 17 days.
1871494|NCT01115075|Behavioral|Spontaneous oscillations of dietary fat/intake of carbohydrate in relation to energy intake.|Dietitians and senior level or graduate level dietetics students who are not restrained eaters to participate in food intake over 17 days. During this same time interval, integrated energy expenditure will be recorded using doubly-labeled water and day to day energy expenditure by accelerometer. Periodic blood sampling for leptin will be done completed at site intervals.
1871495|NCT01115088|Dietary Supplement|Aspartame|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
1871522|NCT01115257|Procedure|panretinalphotocoagulation|Panretinal photocoagulation was completed according to guidelines summarized in ETDRS with extensive full subconfluent panretinal photocoagulation.
1871496|NCT01115088|Dietary Supplement|Sucrose|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
1871497|NCT01115088|Dietary Supplement|Stevia|The morning breakfast after a 12-h fast and consumed a standard 469 kcal breakfast consisting of cereal, milk, toast with butter, and orange juice. Tea and crackers with cream cheese sweetened with stevia Whole Foods 365 Brand, aspartame equal sweetener, or sucrose participants consumed this preload 20 min before their test lunch and dinner meals. The Test lunch meal consisted of sandwiches, potato chips, and cookies, and the test dinner meal was a self-selected buffet-type meal (I.e., Macronutrient Self-Selection Paradigm) Geiselman et al,. 1998)
1871498|NCT01115101|Drug|Oral Oxycodon|Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
1871499|NCT01115101|Drug|Piritramid|"Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes
Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded."
1871500|NCT01115114|Behavioral|TAU|A medical assistant will provide feedback on and educational materials describing the meaning of lab values to individuals identified as needing follow-up for metabolic syndrome, and will provide educational materials regarding healthy eating and exercise. The psychiatrist will recommend that the individual contact a primary care physician to follow-up on out of range values, and alter behaviors (over eating, being sedentary) to help improve health.
1871501|NCT01115114|Behavioral|IMBED|After identifying individuals through routine screening that need medical follow-up for metabolic syndrome, these individuals will be scheduled to see the on site primary care provider. Rapid scheduling (within 2 weeks) will be attempted. Patients will be seen by the primary care provider monthly or as needed as determined per patient. The primary care provider will prescribe medications for metabolic syndrome, discuss the patient with psychiatry staff and recommend follow-up appointments for physical problems based upon recommended guidelines and clinical judgment of necessity and urgency. Referral to a specialist will be made according to standard primary care practice guidelines. During the Metabolic Syndrome Clinic, if individuals bring up other medical conditions, they will be referred for treatment of these conditions to an outside primary care provider.
1871502|NCT01115114|Behavioral|Liaison|Patients will be seen by the MCM bi-weekly or as needed as determined per patient. The MCM will discuss findings of the labs with the patient, work to get the individual an appointment with a primary care doctor, get releases of information to discuss treatment coordination between the primary care and psychiatric teams, obtain necessary records from primary care, and communicate findings to the treating psychiatrist. The MCM will also assist the patient in getting to primary care appointments by providing bus passes or other transportation, and with obtaining medications prescribed by the primary care provider. This may necessitate enrolling the patient in specific care plans as needed.
1871503|NCT01115127|Dietary Supplement|melatonin|30 subjects will take 1 tablet per day (at night-time) containing 3 grams of melatonin for 6 months
1871504|NCT01115127|Dietary Supplement|myo-inositol|30 subjects will take 2 tablets per day containing 2 grams of myo-inositol, for 6 months.
1871505|NCT01115127|Dietary Supplement|melatonin plus myo-inositol|30 subjects will take 2 grams per day of myo-inositol and 3 grams of melatonin at night-time for 6 months
1871506|NCT01115140|Drug|metformin plus placebo|metformin 850 mg cp, 2 cps daily
1871507|NCT01115140|Drug|Metformin plus folic acid|metformin 850 mg cp, 2 cps daily plus folic acid 0.4 mg daily
1871508|NCT01115140|Drug|placebo plus folic acid|Placebo 1 cp daily plus folic acid 0.4 mg daily
1871509|NCT01115140|Drug|placebo alone|placebo cp, 2 cps daily
1871510|NCT01115153|Other|prophylaxis|single doses of antibiotics before surgery in patients with gangrenous appendicitis Metronidazole 500 mg IV + amikacin 1 gr IV
1871511|NCT01115153|Other|therapy|antibiotic treatment (5 days) therapy in patients with gangrenous appendicitis metronidazole 500 mg IV three times a day + amikacin 1 gr IV per day
1871512|NCT01115179|Drug|propofol|Induction with propofol (1.5 to 2mg/kg) and maintenance of anesthesia with propofol 1% (target controlled infusion with concentration levels of 3-5 ug/ml)
1871513|NCT01115179|Drug|Intralipid 10%|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%) as well as the solvent of propofol 1% (Intralipid 10%; corresponding to a target-controlled infusion of propofol with concentration levels of 3-5ug/ml)
1871514|NCT01115179|Drug|Saline|Induction of anesthesia with thiopental (3-5mg/kg) and maintenance of anesthesia with isoflurane (end-expired concentration = 0.5%-2.0%)
1871515|NCT01115192|Procedure|Group A|Blephacura is a solution with liposomes and used for cleaning of the eye lid to treat blepharitis
1871516|NCT01115192|Procedure|Group B|Diluted Baby Shampoo is used for cleaning of the eye lid to treat blepharitis
1871517|NCT01115205|Behavioral|Supervised walking|Walk training, 3 sessions per week for 4 months, under the supervision of a qualified personal trainer.
1871518|NCT01115205|Behavioral|Standard counselling procedure|Verbal and written information about the benefits of exercise and instructions aimed to encourage physical activity. In addition, one group session of counselling on these issues.
1871519|NCT01115218|Procedure|Trabeculectomy|Trabeculectomy with mitomycin C
1871520|NCT01115244|Drug|Dapsone gel, 5%|ACZONE™ (dapsone) Gel, 5% will be applied to one elbow or knee, randomized at time of enrollment. Application will be topical to the same location twice daily (morning and evening) for six weeks.
1871521|NCT01115257|Procedure|vitrectomy|The surgical technique (Group 1) included vitrectomy, with a combination of delamination and segmentation of gliotic tractional membranes using bimanual technique. Silicone oil tamponade was used in eyes with long-standing tractional retinal detachment, as deemed necessary by the surgeon, or in eyes in which a retinal break occurred during the vitrectomy.
1871527|NCT01115296|Dietary Supplement|L. reuteri DSM 17938 and ATCC PTA 6475|L. reuteri dose of 1x108 CFU.
1871528|NCT01115296|Other|Placebo|Placebo
1871529|NCT01115309|Device|XprESS Balloon Device|Procedure completed with the XprESS Balloon Device
1871530|NCT01115322|Drug|Tazarotene Foam without irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period.
This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
1871531|NCT01115322|Drug|Tazarotene Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
1871532|NCT01115322|Drug|Tazarotene Foam with UVA, UVB, and visible light|"Each subject will be exposed to a patch with tazarotene foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
1871533|NCT01115322|Drug|Vehicle Foam without irradiation|Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
1871534|NCT01115322|Drug|Vehicle Foam with UVA and UVB irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
1871535|NCT01115322|Drug|Vehicle Foam with UVA and UVB and visible light irradiation|"Each subject will be exposed to a patch with vehicle foam during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
1871536|NCT01115322|Drug|No Treatment without irradiation|Each subject will be exposed to a blank patch during a single, 24 hour application period. This patch will then be removed and those sites will serve as nonirradiated control. Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal.
1871537|NCT01115322|Drug|No Treatment with UVA and UVB irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to ultraviolet A (UVA) and to UVA/ultraviolet B (UVB) radiation wavelengths (UV only).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
1871538|NCT01115322|Drug|No Treatment with UVA and UVB and visible light irradiation|"Each subject will be exposed to a blank patch during a single, 24 hour application period. The patch will be removed and that site will be exposed to UVA, UVA/UVB, and visible light (VIS) wavelengths (UV plus VIS).
Patch sites will be evaluated for signs of inflammatory skin responses (eg, erythema and local skin reactions) and superficial effects 1 ±0.25 hour after patch removal, and during follow-up visits at 24 ±1 hours, 48 ±2 hours, and 72 ±2 hours after patch removal."
1871539|NCT01115335|Procedure|Neonatal male circumcision|Circumcision performed on a male infant within the first month of life, using one of 3 devices
1871540|NCT01115361|Behavioral|Family planning for postpartum women|"A.Group education sessions regarding pregnancy risk, benefits of FP, and family planning options during the postpartum period.
B. IEC materials that deliver messages about the benefits of spacing pregnancies by at least 2 years, LAM, return to fecundity and pregnancy risk during the postpartum period and contraceptive options for postpartum women.
C. Use of a screening tool to assess pregnancy risk for postpartum women coupled with a brief counseling message and referral to FP services.
D.Convenient offer of FP services to women attending vaccination services for their infants."
1871541|NCT01115374|Procedure|Manual lymphatic drainage|Application of manual lymphatic drainage (one session every work day during two weeks, total 10 sessions)
1871542|NCT01115374|Device|low frequency sound waves|Application of low frequency sound waves (one session every work day during two weeks, total 10 sessions)
1871543|NCT01115387|Other|Observational-1|"Multiple questionnaires detailing family history, medical history, visual symptoms, smoking, environmental and dietary exposures.
Prospective photography of the retina to detect early ARM-related changes A saliva or blood sample for genetic testing."
1871626|NCT01116089|Drug|Bramitob® administered by PARI eFlow® rapid electronic nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
1871544|NCT01115387|Other|Observational-2|"A limited number of questionnaires and prior clinical documentation from eye care professionals of eye status with respect to ARM.
No prospective retina photographs but ongoing follow-up for reported changes in ARM status.
A saliva or blood sample for genetic testing."
1871545|NCT01115426|Drug|Ramipril or losartan|Ramipril (5 mg/day) was started soon after the enrollment and continued throughout the follow-up, having Losartan (50 mg/day) as alternative.
1871546|NCT01115439|Drug|artesunate plus sulfadoxine-pyrimethamine (AS+SP)|artesunate plus sulfadoxine-pyrimethamine (AS+SP)
1871547|NCT01115452|Drug|5% Potassium nitrate|5% potassium nitrate solution
1871548|NCT01115452|Drug|2.5% Potassium nitrate|2.5% potassium nitrate solution
1871549|NCT01115452|Other|Sterile water|Sterile water
1871550|NCT01115465|Device|Macroplastique|Macroplastique is an injectable soft-tissue bulking agent used to treat stress urinary incontinence (SUI) primarily due to intrinsic sphincter deficiency (ISD).
1871551|NCT01115478|Dietary Supplement|Vitamin A|Daily oral dose of 2500 IU from enrollment until delivery
1871552|NCT01115478|Dietary Supplement|Zinc|Daily oral dose of 25 mg from enrollment until delivery
1871553|NCT01115478|Other|Placebo|Daily oral dose from enrollment until delivery
1871554|NCT01115491|Drug|bevacizumab [Avastin]|Bevacizumab 10 mg/kg body weight will be administered intravenously every two weeks
1871555|NCT01115491|Drug|temozolomide|Daily by the oral route (dose, 150 mg/m2) on days 1 to 7 and 15 to 21 of each cycle
1871556|NCT01115504|Drug|Thiamine|300 mg daily for 30 days
1871557|NCT01115517|Drug|Bevacizumab|1.25 mg/mL applied one time intraoperatively using bevacizumab-soaked filter paper manually applied to bare sclera during pterygium surgery for 2 minutes, followed by copious rinsing with balanced salt solution.
1871558|NCT01115517|Drug|Mitomycin C|Mitomycin C 0.02% will be applied to bare sclera during pterygium surgery using a medication-soaked filter paper for a duration of two minutes. After medication administration, the ocular surface will be copiously irrigated with balanced salt solution.
1871559|NCT01115530|Other|Resistance exercise|Lower extremity resistance exercise (leg press/knee extension) twice per week for 12 weeks
1871560|NCT01115530|Dietary Supplement|Protein and HMB (see below) supplement|Ingested twice daily for 12 weeks Active components include: Protein and B-hydroxy-B -methylbutyrate
1871561|NCT01115543|Drug|alfacalcidol and calcitriol|The initial dose of alfacalcidol was twice that of calcitriol.Both were adjusted to control intact PTH within the ranges of 150-300 pg/ml.
1871562|NCT01115556|Drug|Ranibizumab|2.0 mg
1871563|NCT01115556|Drug|Ranibizumab|0.5 mg
1871564|NCT01115569|Drug|Hydrocodone Bitartrate|Open-Label, Capsule Strengths 10 mg, 20 mg, 30 mg, 40 mg, 50 mg; by mouth (PO) twice a day (BID) for up to 48 weeks
1871565|NCT01115582|Drug|Cholic acid|"The IUPAC name for cholic acid is 3 alpha,7alpha,12 alpha-trihydroxy-5 beta-cholanoic acid. The international nonproprietary name (INN) is cholic acid.
Each patient will be given a box containing a 1 month supply of study drug. Each bottle will contain 90 capsules; each capsule will contain either 50 or 250 mg of manufactured cholic acid depending upon the child's weight. The study drug will be taken orally, in divided doses (as determined by the investigator), for a total daily dose of 10-15 mg/kg body weight. Parents of infants and young children who are unable to swallow the TBM cholic acid capsule will be instructed to sprinkle the contents of the capsule over 1-2 teaspoons of plain applesauce and feed it to the child."
1871566|NCT01115595|Biological|Mite allergen extract|Dermatophagoides pteronyssinus from ALK company
1871567|NCT01115608|Other|Pharmacist follow-up|Drug review, drug conversation and written drug information. Follow-up concerning therapeutic goals and cooperation with the patient and the patient's GP to achieve these.
1871568|NCT01115621|Other|Glutenfree diet during the first year of life|Glutenfree diet during the first year of life
1871569|NCT01115634|Biological|Fibroblast|20 million cell in three injection
1871570|NCT01115634|Biological|fibroblast and gel|20 million cell in three injection plus filler
1871571|NCT01115647|Dietary Supplement|Ready-to-Use Therapeutic Food (RUTF)|A Ready-to-Use Therapeutic Food (RUTF), locally produced in Burkina Faso. The RUSF will be nutritionally characterized by chemical analysis (macronutrients, amino acids, vitamins A, C, D, E, B12, thiamin, riboflavin, niacin, calcium, iron, zinc, copper, selenium) and will be analyzed for macronutrients and energy density. All analysis methods are either based on the Official Methods of Analysis of AOAC International or in-house validated analytical methods. The pilot production phase and Hazard Analysis of Critical Control Points (HACCP) risk inventory of the production process will be performed by a food technologist from the Department of Food safety and Food quality, Ghent University.
1871572|NCT01115647|Dietary Supplement|CBS++|CSB is a low-cost combination of a cereal and a legume sometimes fortified with micronutrients. However, it presents shortcomings such as too many anti-nutrients, suboptimal micronutrient content, high bulk and viscosity. The World Food Program has recently proposed an enhanced CSB, named CSB++, which is prepared from heat treated maize and de-hulled soya beans, sugar, dried skim milk, refined soya bean oil, vitamins and minerals.
1871573|NCT01115647|Behavioral|CCC|Child-Centred dietary Counselling (CCC). Although educational/behavioral interventions can be effective to improve child growth, there is little evidence of their effectiveness for MAM. Moreover, evidence from Africa is inexistent. Currently, the main management of MAM consists of giving nutritional advice to the caretakers, but mothers of MAM children are given the same general dietary advice as mothers of well-nourished children. A more efficient, child-centred approach is therefore proposed, by adapting the counselling to the needs of the family, developing a more child-centred approach, by providing operational recommendations for MAM children and providing an adequate follow-up post-treatment.
1871574|NCT01115660|Behavioral|stroke education|call by medication coach 2 weeks after hospital discharge
1871575|NCT01115673|Drug|Acetaminophen|Acetaminophen Caplet - single dose
1871576|NCT01115673|Drug|Placebo Control|0 mg Caplet - single dose
1871577|NCT01115686|Drug|Branched-chain aminoacids|"Branched-chain aminoacids will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day. Every capsule containing 375 milligrams of branched-chain aminoacids.
The treatment will last 3 weeks."
1871578|NCT01115686|Drug|Placebo|"Placebo will be orally administered in the form of capsules, at the rate of a capsule for physical 7 Kilograms weighty and a day.
The treatment will last 3 weeks."
1872886|NCT01124175|Drug|Losartan|100 mg Tablets
1871579|NCT01115699|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|Active 10 Hz rTMS will be applied to the left dorsolateral prefrontal cortex (L-DLPFC) with an intensity of 120% motor threshold. The L-DLPFC location is defined as that area 5 cm anterior to the motor cortex for activation of abductor pollicis brevis. Subjects will receive a total of 3000 stimuli per session. The TMS trains are 4 seconds on and 26 seconds off for a total of 37 1/2 minutes. Treatment will occur 5 days per week for up to six weeks. Subjects will be monitored during rTMS for any side effects or adverse events.
1871580|NCT01115712|Drug|Placebo|Placebo (to match pioglitazone 30 mg) once daily
1871581|NCT01115712|Drug|Comparator: Pioglitazone|Pioglitazone 30 mg once daily
1871582|NCT01115712|Drug|Comparator: Hyperinsulinemic Euglycemic Clamp|Infusion of Glucose (20% dextrose) to achieve a glucose concentration of 90mg/dL; Infusion of Insulin at a rate of 10 mU/m2/minute from 0 to 180 minutes and at a rate of 40 mU/m2/minute from 180 to 360 minutes; Saline infusion at 60 minutes before the insulin and glucose infusions to keep the antecubital vein open.
1871583|NCT01115725|Drug|Gonal-f® (follitropin alfa)|Gonal-f® (follitropin alfa) will be given once daily subcutaneously at a starting dose of 150-375 international unit per day (IU/day) by self-administered injection via a pen device for first 5 days. After Day 5, Gonal-f® dose will be adjusted according to the investigator's discretion until ovarian response observed.
1871584|NCT01115738|Drug|Prasugrel|Loading dose administered once orally and maintenance dose administered orally 24 hours after loading dose, then every 24 hours for 72 hours.
1871585|NCT01115738|Drug|Clopidogrel|Loading dose administered once orally.
1871586|NCT01115738|Drug|Placebo|Loading dose administered once orally
1871587|NCT01115751|Drug|LY2780301|"Administered orally, daily for two 28-day cycles.
Starting dose is 100mg. The dose will be subsequently increased to 200mg, 300mg, 400mg, 500mg, and 600mg if no dose limiting toxicity is observed at the prior dose levels. Patients who, in the opinion of the investigator, demonstrate clinical benefit may receive treatment beyond two cycles until disease progression."
1871588|NCT01115777|Other|Quality of Life surveys completed at specified timepoints|Quality of Life surveys (no treatment)
1871589|NCT01115790|Drug|Prexasertib|Prexasertib IV on day 1 of a 14 day cycle. The expected duration is 3 cycles (2 weeks each for a total of 6 weeks). Participants receiving clinical benefit may remain on study until disease progression, unacceptable toxicity or other criteria for discontinuation are met.
1871594|NCT01115855|Drug|Eplerenone|Eplerenone 25 mg once every other day, 25mg once daily or 50 mg once daily
1871595|NCT01115855|Drug|Placebo|Placebo once daily or every once daily
1871596|NCT01115868|Drug|Prevascar 5ng|100uL of 5ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
1871597|NCT01115868|Drug|Prevascar 25ng|• 100uL of 25ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
1871598|NCT01115868|Drug|Prevascar 100ng|• 100uL of 100ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
1871599|NCT01115868|Drug|Prevascar 250ng|• 100uL of 250ng/100uL Prevascar per linear centimetre wound margin injected intradermally.
1871604|NCT01115907|Device|Freedom SOLO Stentless Heart Valve|Freedom SOLO Stentless Heart Valve
1871605|NCT01115920|Drug|MTP-131 (Bendavia™)|Single 4 hour intravenous infusion
1871606|NCT01115933|Device|XIENCE PRIME SV EECSS|Patients receiving XIENCE PRIME SV EECSS
1871607|NCT01115946|Drug|ASP1585|oral
1871608|NCT01115946|Drug|enalapril|oral
1871609|NCT01115959|Drug|valproic acid|treatment of 1 month dosage of 400 mg BID
1871610|NCT01115959|Drug|placebo bid|
1871611|NCT01115972|Drug|ASP1585|oral
1871612|NCT01115972|Drug|valsartan|oral
1871613|NCT01115985|Drug|ASP1585|oral
1871614|NCT01115985|Drug|atorvastatin|oral
1871615|NCT01115998|Other|Power wheelchair|Children used power wheelchairs for one year. They continued to receive their usual early intervention services.
1871616|NCT01115998|Other|No power wheelchairs|Children in the control group did not use power wheelchairs. They continued to receive their usual early intervention services.
1871617|NCT01116011|Drug|AZD7268|Capsule, Oral, BID
1871618|NCT01116011|Drug|Placebo|Capsule, Oral, BID
1871619|NCT01116024|Device|ATS 3f Enable Aortic Bioprosthesis Model 6000|Replacement Aortic Heart Valve
1871620|NCT01116037|Device|ATS 3f Aortic Bioprosthesis|Equine Pericardial Bioprosthesis for replacement of diseased valve
1871621|NCT01116050|Drug|Misoprostol|5 tablets of 200 microgram geach intra rectal by opaque introducer
1871622|NCT01116050|Drug|Placebo|5 tablets in opque introducer
1871623|NCT01116063|Drug|Inhaled iloprost|Inhalation Initial: 2.5 mcg/dose; if tolerated, increase to 5 mcg/dose; administer 6 times daily
1871624|NCT01116076|Behavioral|Decision+ program (to improve optimal drug prescription for ARI)|DECISION+ is a multifaceted intervention program that includes: On site course and Internet-based courses (2x120 min), reminders of expected behaviours and feedback.
1871625|NCT01116089|Drug|Bramitob® administered by PARI LC® PLUS nebulizer|(tobramycin 300mg /4mL) solution administered by inhalation twice daily for 28 days
1871811|NCT01107587|Biological|GSK Biologicals' human rotavirus vaccine 444563|Oral, two doses.
1871627|NCT01116102|Drug|Subcutaneous HYLENEX (recombinant human hyaluronidase) and Lactated Ringer's solution|Subcutaneous administration of 150 U HYLENEX, followed by 1000 mL Lactated Ringer's solution
1871628|NCT01116115|Other|InFat™ based infant formula|High sn-2 palmitic acid oil based infant formula
1871629|NCT01116115|Other|Standard vegetable oil based infant formula|Standard vegetable oil based infant formula
1871630|NCT01116128|Drug|dasatinib|100 mg QD continuously (from day 1 to day 28)
1871631|NCT01116128|Drug|melphalan|0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
1871632|NCT01116128|Drug|prednisone|1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
1871633|NCT01116141|Drug|CH-4051|Different doses CH-4051 to be compared
1871634|NCT01116141|Drug|Methotrexate (MTX)|20 mg MTX weekly
1871635|NCT01116141|Drug|Folic Acid|1 mg folic acid daily
1871636|NCT01116154|Drug|lenalidomide|Given orally
1871637|NCT01116154|Drug|vorinostat|Given orally
1871638|NCT01116154|Other|laboratory biomarker analysis|Correlative studies
1871639|NCT01116167|Drug|Letrozole -Berberine|"Letrozole
2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
Berberine
1.5g daily for 6 month."
1871640|NCT01116167|Drug|Letrozole|"Letrozole
2.5 mg letrozole daily from day 5 of the menses for 5 days for month 1 to 3, 5.0 mg letrozole daily from day 5 of the menses for 5 days for month 4 to 6.
Berberine Placebo
5 tablet tds for 6 months"
1871641|NCT01116167|Drug|Berberine|"Berberine
1.5g daily for 6 month.
Letrozole placebo
1 tablet daily from day 5 of the menses for 5 days for month 1 to 3, 2 tablets daily from day 5 of the menses for 5 days for month 4 to 6."
1871642|NCT01116180|Drug|Angiotensin II receptor antagonists (Candesartan)|Seven days of treatment with Candesartan 32 mg, capsules.
1871643|NCT01116180|Drug|Placebo|Placebo Capsule matching the active comparator. Given for 7 days once daily.
1871644|NCT01116193|Drug|Lenalidomide plus dexamethasone|Lenalidomide 25 mg p.o. once daily on days 1-21 plus Dexamethasone 40 mg p.o. once daily on days 1, 8, 15, and 22 of each 28-day cycle (4-weeks cycles) until CR achievement, progression of disease or intolerable toxicity
1871645|NCT01116206|Drug|Prucalopride|2 mg tablet, orally once daily, for 12 weeks
1871646|NCT01116206|Drug|Placebo|1 tablet, orally once dailyfor 12 weeks
1871647|NCT01116219|Biological|bevacizumab, erlotinib|"Bevacizumab 7.5 mg/kg i.v. every 3 weeks and
Erlotinib 150 mg p.o. daily until progression."
1871648|NCT01116219|Drug|bevacizumab, pemetrexed, cisplatin|"Induction chemotherapy with
Bevacizumab 7.5 mg/kg i.v. and
Pemetrexed 500 mg/m2 i.v. and
Cisplatin* 75 mg/m2 i.v. every 3 weeks for a maximum of 4 cycles or until progression. Followed by maintenance therapy in patients without disease progression with
Bevacizumab 7.5 mg/kg i.v. and
Pemetrexed 500 mg/m2 i.v. every 3 weeks until progression."
1871649|NCT01116232|Biological|anti-thymocyte globulin|Infuse the first dose over a minimum of 6 hours, and subsequent doses over a minimum of 4 hours via a 0.22 micron in-line filter.
1871650|NCT01116232|Biological|rituximab|"The total dose chosen for this protocol is 28 mg/kg divided in two doses (14 mg/kg on days -7 and +3). Initial infusion: Start rate of 50 mg/hour; if there is no reaction, increase the rate by 50 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Subsequent infusions: If patient did not tolerate initial infusion follow initial infusion guidelines. If patient tolerated initial infusion, start at 100 mg/hour; if there is no reaction, increase the rate by 100 mg/hour increments every 30 minutes, to a maximum rate of 400 mg/hour. Note: If a reaction occurs, slow or stop the infusion. If the reaction abates, restart infusion at 50% of the previous rate.
In patients who tolerated the Rituximab well in the past, a rapid infusion rate can be used over 90 minutes with 20% of the dose administered in the first 30 minutes and the remaining 80% is given over 60 minutes."
1871651|NCT01116232|Drug|sirolimus|For adults, Sirolimus will be administered at 12 mg orally loading dose on day -3, followed by 4 mg orally single morning daily dose (target serum level 3-12 ng/ml by HPLC).
1871652|NCT01116232|Drug|tacrolimus|Tacrolimus will be administered intravenously at a dose of 0.03 mg/kg (ideal body weight) q 24h by continuous infusion starting on Day -3. Intravenous Tacrolimus will be discontinued once the patient starts eating and the drug will then be given orally at a dose of approximately 4 times the intravenous dose.
1871653|NCT01116232|Other|laboratory biomarker analysis|laboratory biomarker analysis
1871654|NCT01116232|Procedure|allogeneic hematopoietic stem cell transplantation|allogeneic hematopoietic stem cell transplantation
1871655|NCT01116232|Procedure|management of therapy complications|management of therapy complications
1871656|NCT01116232|Procedure|peripheral blood stem cell transplantation|peripheral blood stem cell transplantation
1871657|NCT01116245|Biological|ADXS11-001 (Lm-LLO-E7)|ADXS11-001 at one of three dose levels given as 3 vaccinations separated by 4 weeks with an oral antibiotic regimen subsequent to dosing.
1871658|NCT01116245|Drug|Placebo Control|3 intravenous infusions of normal saline at 28 day intervals. All infusions will be preceded by prophylactic NSAID and antihistamine, and followed 3d later with antibiotic.
1871659|NCT01116258|Drug|AZD5847|oral suspension, 15 days
1871660|NCT01116258|Drug|Placebo|oral suspension, 15 days
1871661|NCT01116271|Drug|AZD6244|50 or 75mg, capsules, PO, BID, 28 days
1871662|NCT01116271|Drug|Irinotecan|180mg/m2, IV, Day 1& 15 of each cycle
1871663|NCT01116284|Procedure|Revision of gastric bypass|A laparoscopic operation will be performed to decrease the size of the enlarged gastric outlet. Three 5-mm laparoscopic trocars will be placed in the upper abdomen and suture plication of the gastrojejunostomy on the medial, lateral and anterior surface of the anastomosis will be performed. The resulting anastomosis will be evaluated with intraoperative endoscopy and leak tested intraoperatively. The patients will be evaluated in the post-operative period and are expected to be discharged from the hospital within 24 hours.
1871664|NCT01116297|Device|Imaging with S-FLARE imaging system|Tissue oxygenation measurements during plastic surgery using the S-FLARE system.
1871665|NCT01116310|Drug|Soy isoflavones (Glycine max L) and red clover extract (Trifolium pretense L)|Bottles containing 60 capsules, 53.5 mg/capsule of isoflavones
1871666|NCT01116310|Drug|Placebo|Bottles containing 60 capsules.
1871667|NCT01116336|Drug|Erlotinib|Participants will be given erlotinib orally (dose escalation from 50 mg, 75 mg, or 100 mg daily continuously for 6 cycles (each cycle is 28 days).
1871668|NCT01116336|Dietary Supplement|Green Tea Polyphenon E|Participants will also be given PPE orally (200 mg EGCG) three times daily for 6 cycles (each cycle is 28 days). PPE capsules will be taken on a full stomach, within one hour after eating a substantial meal.
1871669|NCT01116349|Procedure|Plate and screws or nailing|Patients included in the surgical group will be divided into two subgroups according to the method of fixation chosen: plate and screws or nailing. Surgeries take place under general anesthesia and a prophylaxis antibiotic is administrated. The installation and the approach will be chosen by the surgeon according to his preferences. A thoraco brachial brace is placed on the patient at the end of the intervention and it remains in place for a period of 5 to 10 days (patient comfort). A gradual mobilization of the elbow and shoulder will be initiated by the patient at home. The addition of physical therapy will be decided by the surgeon and noted down accordingly.
1871670|NCT01116349|Device|Hanging Support System (HSS) brace|Patients included in the conservative group will be taken to a plaster room where the HSS brace will be installed by a qualified technician. Advice will be provided for the care, personal hygiene and clothing. The brace will be kept for a period of 6 to 12 weeks depending on the degree of healing of fracture. The maintenance of the proximal part (Brace) may be recommended by the surgeon. The mobilization will begin with exercises at home and whether the patient does physical therapy or not is the surgeon's choice.
1871671|NCT01116362|Procedure|primary repair|during the first days,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
1871672|NCT01116362|Procedure|secondary repair|after one week,the nerve was conducted to repair as end to end (epi-epineurium, epi-epineurium) anastomosis. This was performed following the repair of present tendons and muscle injuries.
1871673|NCT01116388|Other|GFCF product with GFCF diet|"Group I: will receive the test product (product free of gluten and casein) with GFCF Diet for the 1st 6-weeks.
Group II: will receive the test product (product free of gluten and casein) with GFCF diet for the 2nd 6-weeks."
1871674|NCT01116388|Other|product containing gluten and casein (milk protein) with GFCF diet|"Group I: will receive the control product (product containing gluten and casein) with the GFCF diet for the 2nd 6-weeks.
Group II: will receive the control product (product containing gluten and casein) with the GFCF diet for the 1st 6-weeks"
1871675|NCT01116401|Drug|Leuprolide|"Leuprolide acetate 3.75-mg intramuscular injection
Leuprolide is a widely used GnRH agonist. Leuprolide is indicated for treatment of endometriosis, uterine fibroids, precocious puberty, and prostate cancer, and is used off-label for in-vitro fertilization and premenstrual syndrome. In this protocol, leuprolide will be administered at a dose routinely used for treatment of endometriosis and uterine fibroids in women.
Leuprolide can induce amenorrhea for 2-3 months after a depot injection is given. However, unpredictable menstrual bleeding and spotting can occur during this time period. Menstrual-cycle patterns will be monitored closely during the study. Although long-term administration of any GnRH agonist (i.e., >6 months) is associated with bone loss, bone effects are not expected in this protocol because GnRH agonist therapy will be used for only one month."
1871680|NCT01116453|Procedure|acupuncture|acupuncture on the acupoints of ST44 and ST43 of bilateral feet for 2 months, then followed-up for another 2months
1871681|NCT01116453|Procedure|usual care|usual care with medication and behavior therapy for 2 months, followed by acupuncture for additional 2 months
1871682|NCT01116466|Device|ActiGait|ActiGait - implantable drop foot stimulator
1871683|NCT01116479|Other|Blood transfusion|Blood transfusion with packed erythrocytes
1871684|NCT01116492|Other|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
1871685|NCT01116492|Other|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
1871686|NCT01116505|Dietary Supplement|Gluten-free diet|gluten-containing cereals removed from diet
1871687|NCT01116518|Procedure|physiotherapy|
1871688|NCT01116518|Procedure|acromioplasty|
1871689|NCT01116518|Procedure|acromioplasty and rotator cuff reconstruction|
1871690|NCT01116531|Drug|Tramadol|Initial dose of oral tramadol (depottabl Tramal retard, Orionpharma, Finland) will be 100mg once daily. If the subject is currently on opioid treatment with codeine, tramadol or buprenorphine, the opioid treatment will be stopped, and an equal dose of tramadol will be used as the initial dose. The dose will be titrated on visits V2 and V3 based on the adequacy of pain relief and tolerability. If pain intensity ≥ 4 on a numeric rating scale of 0-10 during V2 and V3 and tramadol is well tolerated, the daily dose will be increased by 100mg. The maximum daily dose of 400 mg tramadol will not be exceeded. If the subject does not tolerate the initial dose of tramadol, he/she will be dropped out of the study and replaced by another patient.
1871691|NCT01116531|Drug|Duloxetine|The initial dose of duloxetine (Cymbalta, Eli Lilly, USA) will be 30mg once daily. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is < 4 on a scale of 0-10, the dose of duloxetine dose will be 30mg daily throughout the study. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and duloxetine is well tolerated, the daily dose will be increased to 60mg once daily. If the subject does not tolerate the initial dose of duloxetine, he/she will be dropped out of the study and replaced by another patient.
1871692|NCT01116531|Drug|Pregabalin|The initial dose of pregabalin (Lyrica, Pfizer, USA) will be 75mg twice a day. The dose will be titrated on V2 based on the adequacy of pain relief and tolerability. If pain intensity during V2 is < 4 on a scale of 0-10, the initial dose of pregabalin dose will be continued. If pain intensity is ≥ 4 on a numeric rating scale of 0-10 and pregabalin is well tolerated, the daily dose will be increased to 150mg twice a day. If the subject does not tolerate the initial dose of pregabalin, he/she will be dropped out of the study and replaced by another patient.
1871812|NCT01107587|Biological|Placebo|Oral, two doses.
1871693|NCT01116544|Device|AMES Therapy (assisted movement and enhanced sensation)|Each subject will receive 30 sessions of AMES therapy in the clinic. Each session will consist of 10 min of functional testing (i.e., passive motion and strength tests) followed by 30 min of grasp therapy using the AMES device. One group of subjects will receive AMES therapy only with joint torque biofeedback (without EMG feedback), and the other group will receive AMES therapy with EMG biofeedback. While all test subjects should attempt to open the hand when the grasp mechanism is opening and close the hand when the mechanism is closing, the biofeedback information provided to aid a subject will differ for the 2 subject groups.
1871694|NCT01116557|Device|Radiofrequency Ablation procedure|Radiofrequency Ablation procedure Application of radiofrequency energy with the THERMOCOOL® catheter used in combination with the CARTO® 3 System and the LASSO® Circular Mapping Catheter to eliminate potentials arising from the pulmonary veins.
1871695|NCT01116557|Device|Radiofrequency Ablation procedure|Application of radiofrequency energy with the Pulmonary Vein Ablation Catheter® (PVAC®) to eliminate potentials arising from the pulmonary veins.
1871696|NCT01116570|Other|Physical training|Physical training during 24 weeks
1871697|NCT01116570|Other|Control|No intervention
1871698|NCT01116583|Drug|Gabapentin|"Preoperatively (2 hours before surgery): 4 gabapentin capsules each containing 300 mg gabapentin (total gabapentin dose 1200 mg)
Postoperative day 1: gabapentin 300 mg x 2 (total gabapentin dose 600 mg)
Postoperative day 2: gabapentin 300 mg x 3 (total gabapentin dose 900 mg)
Postoperative day 3: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)
Postoperative day 4: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)
Postoperative day 5: gabapentin 300 mg x 4 (total gabapentin dose 1200 mg)"
1871699|NCT01116583|Drug|Placebo|"Preoperatively (2 hours before surgery): 4 placebo capsules
Postoperative day 1: 1 placebo capsule x 2
Postoperative day 2: 1 placebo capsule x 3
Postoperative day 3: 1 placebo capsule x 4
Postoperative day 4: 1 placebo capsule x 4
Postoperative day 5: 1 placebo capsule x 4"
1871700|NCT01116596|Drug|Paracetamol|determine, in subjects aged over 70 years, the blood concentration of glutathione (GSH) and urinary loss of cysteine in the detoxification of paracetamol, when taking paracetamol treatment repeated.
1871701|NCT01116609|Drug|Epinephrine|unilateral leg infusion of Epinephrine 0.4 micrograms/m2/min
1871702|NCT01116622|Drug|Bexarotene (Targretin®)|Level -I 200 mg/m2 Level I 300 mg/m2 Level II 300 mg/m2 Level III 400 mg/m2
1871703|NCT01116622|Drug|Erlotinib (Tarceva™)|Level -1 100mg Level I 100mg Level II 150mg Level III 150mg
1871704|NCT01116635|Drug|doxorubicin, superabsorbent polymer microspheres, embolotherapy|varying doses of doxorubicin loaded onto SAP during embolization procedure. Pharmacokinetic analysis of elution profile through serum concentrations over 1 month period embolization of surgically resectable HCC with superabsorbent polymer microspheres loaded with doxorubicin from a single treatment. Phase I will follow a modified Fibonacci sequence (with pharmacokinetic analysis of serum doxorubicin) to determine mean tolerated dose (MTD), severe adverse reaction (SAE) and dose limiting toxicities (DLT) when microspheres are loaded with 25mg, 50mg, or 75mg of doxorubicin. Phase II will continue enrollment with the two highest tolerated doses. At least one month after treatment, all patients will undergo imaging and surgical resection of reference tumor, with assessment of degree of necrosis, microsphere distribution, and correlation with concentration of doxorubicin loaded onto microsphere.
1871709|NCT01116661|Drug|5-Aminolevuline Acid|Given orally at a dose of 20 mg/kg body weight 3hrs before anesthesia prior to surgery
1871710|NCT01116687|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
1871711|NCT01116687|Other|laboratory biomarker analysis|Correlative studies
1871712|NCT01116700|Drug|Dexmedetomidine|Dexmedetomidine will be administered to 2 groups: (1) Seizure disordered patients on anticonvulsants and (2) Healthy volunteers (Control group)
1871713|NCT01116713|Drug|intravenous dexamethasone|One dose of intravenous dexamethasone (8 mg) 60 minutes before skin incision.
1871714|NCT01116713|Drug|Homologated placebo.|Patients of the control group received homologated placebo 60 minutes before skin incision
1871715|NCT01116726|Behavioral|Motivational interviewing|MI sessions will involve home visits concentrating on the mitigation of behavioral risk factors for early childhood caries. These will take place shortly after childbirth and at months 6, 12, and 18.
1871716|NCT01116726|Behavioral|Enhanced community services|Enhanced community services will involve the development of culturally appropriate messages related to the mitigation of behavioral risk factors for early childhood caries through public service announcements and brochures.
1871717|NCT01116739|Device|Fluoride varnish|Fluoride varnish will be administered by the COHS quarterly for 2 years.
1871718|NCT01116739|Behavioral|Oral health education|Oral health education will be provided quarterly for 2 years. It will include information about how to mitigate the known risk factors for early childhood dental caries.
1871719|NCT01116739|Other|Dental services delivered by the Indian Health Service.|
1871720|NCT01116752|Other|Active Glycemic Control Strict (80-140mg/dL) vs. Conservative (190-220mg/dL) (with or without Continuous Glucose Monitoring)|In addition to glycemic control in 2 groups, all children <1 year old and 25% of those >1 year old, will be able to receive continuous glucose monitoring via interstitial glucometry.
1871721|NCT01116765|Other|no stimulation of the oral structure|
1871722|NCT01116765|Other|stimulation of the oral structure|
1871723|NCT01116778|Biological|eN-Lac®|One capsule with 2x10^9 colony forming unit (cfu) LP GMNL-32, once daily, po
1871724|NCT01116778|Other|Placebo|One placebo capsule, once daily, po
1871725|NCT01116791|Procedure|Cytoreductive Surgery (CRS) plus Hyperthermic Intraoperative Peritoneal Chemotherapy with Cisplatin (HIPC)|"CRS is defined as macroscopic tumour removal using surgical resection and/or local ablative therapy (LAT)
HIPC is administered immediately after CRS"
1871726|NCT01116804|Procedure|MRI of the liver before start of treatment|MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
1871727|NCT01116804|Procedure|MRI after treatment|MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
1871728|NCT01116804|Procedure|PET-scan before treatment start|PET-scan with 2 tracers is performed before treatment start
1871729|NCT01116804|Procedure|PET scan after treatment|PET-scan with 2 tracers is repeated 4 weeks following start of treatment
1871730|NCT01116817|Procedure|Lumbar puncture|Lumbar puncture at week 0
1871731|NCT01116817|Procedure|Lumbar puncture|Lumbar puncture at week 0
1871732|NCT01116830|Drug|Placebo|Orally daily for 6 weeks
1871733|NCT01116830|Drug|RO4917838|10 mg daily orally for 6 weeks
1871734|NCT01116830|Drug|Standard Antipsychotic Therapy|Participants will continue to receive their current antipsychotic treatment (as they are receiving at the time of screening). Protocol does not specify any particular standard antipsychotic therapy.
1871735|NCT01116843|Drug|PF-00299804|PF-00299804 or Placebo given pre-operatively for 7 to 11 days depending on surgery schedule.
1871736|NCT01116856|Other|Exercise|Different groups will carry out different exercise protocols during 16 weeks under the same nutritional intervention.
1871737|NCT01116882|Procedure|PCI|
1871738|NCT01116895|Drug|LEO 22811|Oral solution
1871739|NCT01116895|Drug|Placebo|Placebo
1871740|NCT01116908|Device|LifeStraw Family|LifeStraw Family is a household water treatment technology that will be implemented in the household to improve drinking water quality
1871741|NCT01116921|Device|Nasal continuous positive airway pressure (nCPAP)|nCPAP equipment used in the trial will be the standard hospital equipment used in the NICU.
1871742|NCT01116921|Device|Laryngeal Mask Airway (LMA) to deliver surfactant|Laryngeal Mask Airway (LMA Unique-Size 1, The Laryngeal Mask Company Limited, San Diego, CA)
1871743|NCT01116921|Drug|Surfactants, Pulmonary|Curosurf®, Chiesi USA, Inc., Cary, NC
1871744|NCT01116947|Other|Meals during hemodialysis accompanied by lanthanum carbonate to control phosphorus|Based on the hypothesis that the efficacy and potency of Fosrenol enables increasing dietary protein intake and provision of meals during dialysis treatment for improving nutritional status in malnourished dialysis patients with a low serum albumin (<4.0 g/dL) while serum phosphorus can be effectively controlled with the target range of 3.5 to 5.5 mg/dL
1871745|NCT01116973|Other|PICC|Peripheral inserted catheter placement to take the reading
1871746|NCT01116986|Behavioral|Counseling before quit attempt|Participants randomized to this condition will have 20-minute in-person counseling sessions 1 and 3 weeks before their target quit day and a 20-minute phone counseling session 2 weeks before their target quit day. In the in-person counseling session, the case manager will address issues such as smoking reduction, withdrawal coping, environmental restrictions on smoking, intra-treatment social support, autonomous motivation, and practice quit attempts. Participants will be asked to engage in two practice quit attempts. These attempts will each last 8 hours and will be assigned (in collaboration with the smoker) to occur on one weekend day and one weekday the second and third weeks after the quit day.
1871747|NCT01116986|Behavioral|Minimal In-person counseling during quit attempt|Participants randomized to minimal in-person counseling will receive one 3-minute in-person session occurring one week before their target quit day. The clinician will also inform the participant of the sort of phone counseling follow-up that s/he will receive in 1 and 2 weeks after their quit date. (This resembles the real-world situation in which the clinician discusses the sort of follow-up intervention a patient will receive.)
1871748|NCT01116986|Behavioral|Intensive in-person counseling during the quit attempt|Participants randomized to intensive in-person counseling will receive three 20-minute face-to-face counseling sessions: one during the week before the target quit day, one on the target quit day and one during the week after the target quite day. The counseling will include intra-treatment social support and skill-based competence intervention components.
1871749|NCT01116986|Behavioral|Minimal phone counseling during the quit attempt|Participants randomized to this condition will receive minimal phone counseling consisting of one 10-minute phone counseling session on the morning of the target quit day. This session will address motivation to quit, strategies for coping with urges to smoke and use of the medication, and will provide support. Thus, all participants will get some counseling support on the quit day, which reflects the fact that initial lapses often occur on the target quit day, and quit day smoking is an important determinant of ultimate outcome.
1871750|NCT01116986|Behavioral|Intensive phone counseling during the quit attempt|Participants randomized to this condition will receive intensive phone counseling consisting of three 15-minute phone sessions (on the morning of the target quit day and on days 2 and 10 after the quit day). The content of the target quit day phone call will emphasize intra-treatment social support, skill execution and avoidance of danger situations. The quit day phone call is intended to augment any other clinician counseling received either on the phone or in person; such interventions tend to have additive effects and produce strong dose-response effects as a function of the duration of the counseling intervention.
1871751|NCT01116986|Drug|Long Term Nicotine Patch+ Nicotine Gum During Quit Attempt|"If randomized to this condition:
After the target quit day:
Patch:
IF > 10 cigs/day: one 21 mg nicotine patch per day for 12 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.
IF < or = 10 cigs/day: one 14 mg nicotine patch per day for 12 weeks, then one 7 mg for 4 weeks.
Gum:
IF > 24 cigs/day: ten 4 mg nicotine gum per day for 16 weeks. IF < or = 24 cigs/day: ten 2 mg nicotine patch per day for 16 weeks."
1871752|NCT01116986|Drug|Short Term Nicotine Patch + Nicotine Gum during the quit attempt|"If randomized to this condition:
After the target quit day:
Patch:
IF > 10 cigs/day: one 21 mg nicotine patch per day for 4 weeks, THEN one 14 mg nicotine patch per day for 2 weeks, THEN one 7 mg nicotine patch per day for 2 weeks.
IF < or = 10 cigs/day: one 14 mg nicotine patch per day for 4 weeks, then one 7 mg for 4 weeks.
Gum:
IF > 24 cigs/day: ten 4 mg nicotine gum per day for 8 weeks. IF < or = 24 cigs/day: ten 2 mg nicotine gum per day for 8 weeks."
1871753|NCT01116986|Drug|Pre-Quit Nicotine Gum|"If randomized to only the Pre-Quit Nicotine Gum condition (and not the Pre-Quit Nicotine Patch):
Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks before the target quit day."
1871754|NCT01116986|Drug|Pre-Quit Nicotine Patch|"If randomized to only the Pre-Quit Nicotine Patch condition (and not the Pre-Quit Nicotine Gum):
Before quitting: Everyone will have one 14 mg nicotine patch per day for 2 weeks before the target quit day."
1871755|NCT01116986|Drug|Pre-Quit Nicotine Patch + Pre-Quit Nicotine Gum|"If randomized to both the Prequit Patch and Prequit Gum Conditions:
Before quitting: Everyone will have ten 2 mg nicotine gum per day for 2 weeks and one 14 mg nicotine patch per day for 2 weeks before the target quit day."
1871756|NCT01116999|Procedure|light guided tracheal intubation|Tracheal intubation light guided technique.
1871757|NCT01117012|Drug|Ivacaftor|
1871758|NCT01117025|Procedure|Circumferential PV isolation|The left atrium (LA) and pulmonary veins (PVs) are explored through a transeptal approach. Real-time 3D LA maps are reconstructed by using a nonfluoroscopic navigation system. The ipsilateral left and right PVs are encircled in one lesion line by circumferential PV isolation. Radiofrequency energy is delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and is reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. Each lesion is ablated continuously until the local potential amplitude decreased by >80% or RF energy deliveries exceeded 40 s. The endpoint of circumferential PV isolation is PV isolation. Additional ablation lines are created by connecting the left inferior PV to the mitral annulus (mitral isthmus) and the roof of the LA between the two superior PVs. After the end of the procedure the implantable loop recorder is implanted in the parasternal area of the chest.
1871759|NCT01117025|Procedure|Circumferential PVI+renal denervation|"The procedure of AF ablation is the same like in the circumferential PV isolation.
After AF ablation procedure, the angiogram of both renal arteries is performed via femoral access. After that the treatment catheter is introduced into each renal artery and is applied discrete, radiofrequency ablations lasting up to 2 min each and of 8 watts or less to obtain up to six ablations separated both longitudinally and rotationally within each renal artery. During ablation, the catheter system monitored tip temperature and impedance, altering radiofrequency energy delivery in response to a predetermined algorithm. After the procedure the control arterial angiogram should be done."
1871760|NCT01117038|Drug|avanafil and enalapril|enalapril twice a day for 11 days avanafil/placebo once a day for 2 days
1871761|NCT01117038|Drug|avanafil and amlodipine|amlodipine 5mg once a day for 16 days avanafil/placebo once a day for 3 days
1871762|NCT01117051|Drug|placebo|placebo
1871763|NCT01117051|Drug|prucalopride|1 or 2 mg prucalopride once daily before breakfast
1871764|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using CPAP (as previously titrated) for half of the night and NMTD the other half (this order will be randomized). we will monitor NMTD's influence on Apnea Hypopnea Index (AHI), sleep architecture, arousal index, and sleep efficiency compared to the same variables during CPAP use
1871765|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will have an overnight PSG using the NMTD. This device detects reduced airflow via a polymer sensor. When such event is detected, a short burst of sound is administered via earphones. We will determine NMTD's operating characteristics for treatment of OSA. The optimal duration of a detected apnea/hypopnea event before NMTD responds must first be determined. Additional adjustable features include sensitivity of respiratory event sensor, as well as pulse duration, frequency, and intensity of the delivered auditory tone. Since independent adjustment of each of the 4 parameters is not feasible, our screening analysis will test two variables at a time to identify which variables most effectively reduce AHI.
1871766|NCT01117064|Device|Neuromodulation Therapy Device (NMTD)|Subjects will undergo two sequential nights of PSG with NMTD to evaluate if there is any stimulus-response extinction over time.
1871767|NCT01117116|Drug|fluticasone propionate and salmeterol|45/4.5 two puffs twice daily
1871768|NCT01117116|Drug|budesonide and formoterol|80/4.5 two puffs twice daily
1871769|NCT01117129|Drug|rituximab [MabThera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15
1871770|NCT01117129|Drug|placebo|i.v. infusion on day 1 and 15
1871771|NCT01117129|Drug|methotrexate|10-25 mg weekly
1871772|NCT01117129|Drug|rituximab [Mabthera/Rituxan]|1000 mg by i.v. infusion on day 1 and 15, 2nd and further cycles in patients with (group A) or without (group B) clinical response in cycle 1
1871773|NCT01117181|Drug|Methylphenidate|The target dose is 20 mg per day provided as two 10 mg doses administered orally. Patients will start by taking 10 mg daily (two 5 mg over-encapsulated tablets) for three days, at which time the dose will be increased to 20 mg per day (four 5 mg over-encapsulated tablets). In the event of significant side-effects, the dose will be reduced to a minimum of 10 mg per day. The study drug will be administered for 6 weeks.
1871774|NCT01117181|Drug|placebo|Patients will start with two capsules of placebo for three days, at which time the dose will be increased to four capsules. The dose may be reduced to a minimum of two capsules per day if there appears to be significant side-effects. Placebo will be administered for 6 weeks.
1871775|NCT01117181|Other|Psychosocial intervention|"The psychosocial intervention will consist of three components: a counseling session, the provision of education materials, and 24-hour availability for crises.
The counseling session, in which a trained study clinician will counsel the primary caregiver, lasts approximately 20-30 minutes, and consists of the following elements:
Review and adjustment of the patient and caregiver supportive care plans
Emotional support and opportunity to ventilate feelings
Counseling regarding specific caregiving skills
Assistance with problem solving of specific issues that the caregiver brings to the sessions
Answers for questions regarding the educational materials
The educational materials will consist of a copy of the book The 36-Hour Day"
1871776|NCT01117194|Device|Rehabilitation Robot for Upper Limb Dysfunction (NTUH Model One)|Use an intelligent robot to assist upper limb rehabilitation.
1871777|NCT01117220|Drug|Placebo|Placebo matching the oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID) to maximum dose range of 80 mg BID (weight specific- < 45kg max dose 40 mg BID).
1871778|NCT01117220|Drug|Ziprasidone Oral Capsules|Oral ziprasidone capsules of 20,40, 60 and 80 mg in strength. Subjects will be dosed for 4 weeks using a flexible dose design with minimal dose range of 40 mg twice a day (BID to maximum dose range of 80 mg BID (weight specific- < 45kg max dose 40 mg BID).
1871779|NCT01117233|Drug|PF-04427429|single intravenous infusion of 10 mg PF-04427429 or placebo
1871780|NCT01117233|Drug|PF-04427429|single intravenous infusion of 30 mg PF-04427429 or placebo
1871781|NCT01117233|Drug|PF-04427429|single intravenous infusion of 100 mg PF-04427429 or placebo
1871782|NCT01117233|Drug|PF-04427429|single intravenous infusion of 300 mg PF-04427429 or placebo
1871783|NCT01117233|Drug|PF-04427429|single intravenous infusion of 1000 mg PF-04427429 or placebo
1871784|NCT01117246|Device|High Intensity Focused Ultrasound|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
1871785|NCT01117285|Other|3-day post-graduate course|"A 3-day course in using the COTiD program in clinical practice. The 3 days are not provided uninterrupted but there are at least two weeks between each day to provide time to practice with the guideline (for discussion on the 2nd day).
The course consists of theory on the content of the guideline and its effectiveness, Practice parts of the guideline by rol playing, and discussing each others skills through watching video material."
1871786|NCT01117285|Other|Combined implementation strategy|"The combined implementation strategy provides strategies for occupational therapists (OTs), physicians, and managers.
OTs receive:
3-day post-graduate course
2 extra training days: Lectures and skills practice focused on using the COTiD program and promoting the use of the program within their organization and network.
Coaching on the job: Barriers to using the COTiD program in practice are discussed using motivational interviewing.
Discussion platform
Web-based registration system: Provides guidance in using the COTiD program for every individual client.
Regional meetings: successes and difficulties in using the COTiD are discussed.
Managers and physicians receive:
Information on the COTiD program through a website and newsletters.
Motivational reminders."
1871787|NCT01117298|Drug|Tadalafil|Tab Tadalafil, 20 mg alternate day for 8 weeks
1871788|NCT01117298|Drug|Placebo|Tab Placebo every alternate day for 8 weeks
1871789|NCT01117311|Device|VNB on|The implanted Vagal Nerve Blocker will be on at the time of study.
1871790|NCT01117311|Device|VNB off|The implanted Vagal Nerve Blocker will be off at the time of study.
1871791|NCT01117337|Procedure|Mesh Fixation|Laparoscopic Total extraperitoneal repair of Inguinal hernia under Spinal Anesthesia - Mesh is not fixed to any structure
1871792|NCT01117350|Drug|Insulin glargine|100 Units/mL solution for injection in a pre-filled SoloStar pen
1871793|NCT01117350|Drug|Liraglutide|6 mg/mL solution for injection in a 3-mL pre-filled pen (18mg)
1871794|NCT01117350|Drug|Metformin|Metformin was a background treatment, mandatory for each patient randomized in the study (at the minimum dose of 1g/day). It was not supplied by the sponsor.
1871795|NCT01117363|Other|dietary intervention (rye porridge or wheat bread)|A breakfast consisting of either active (rye porridge) or control (wheat bread) is given during 2 3-wk intervention periods in a randomized cross-over design. The two dietary intervention periods are separated by a 3-4 wks wash out.
1871796|NCT01117376|Drug|Erythromycin|Erythromycin 250 mg intravenous Q6h for 4 doses
1871797|NCT01117376|Drug|Methylnaltrexone|Methylnaltrexone 12 mg subcutaneous Q12h for 2 doses
1871798|NCT01117402|Radiation|Radiotherapy|"Patients will receive external radiation therapy using IMRT to pelvis. Treatment volume (CTV, vault and uninvolved pelvic nodes) will receive a dose of 50-56Gy over 25-28# and gross pelvic nodes will receive 55-62Gy over 25-28 fractions over 5 weeks. Pre RT daily MV CT imaging would be done on Tomotherapy to look and correct for any set up error or anatomic variations.
Chemotherapy will be given weekly - cisplatin 40mg/m2 with prechemo medication. After completion of IMRT all patients will be evaluated for boost to vaginal vault with interstitial template brachytherapy to a dose of 16-20 Gy with HDR in 4-5 fractions. Patients not eligible for brachytherapy will get additional boost to vault and parametrium by EBRT to a dose of 15-20Gy in 6-8 fractions."
1871799|NCT01117428|Drug|Sym004|"In part A, patients in all dose cohorts will continue weekly treatment with the assigned dose of Sym004 until disease progression.
In Part B, patients will continue weekly treatment with the tolerated dose of Sym004 until disease progression.
In Part C, patients will receive weekly doses of Sym004 at the dose level below 12 mg/kg i.e. 9 mg/kg until disease progression.
In Part D and E, patients will receive doses of Sym004 administered every 2 weeks at dose level 12 mg/kg and 18 mg/kg, respectively until disease progression.
In Part F, patients will receive a single loading dose of 9 mg/kg followed by weekly doses of 6 mg/kg."
1871800|NCT01107509|Drug|everolimus|10 mg/ day everolimus in the form of an oral tablet for 12 weeks leading up to nephrectomy (with a 1-week perioperative washout period) in patients with locally advanced disease and re-initiating the drug postoperatively in patients with metastatic disease for up to 24 months, or until disease progression. Dosage may be reduced at any point to 5 mg/ day in the event of any grade 3/ 4 toxicity.
1871801|NCT01107522|Drug|CTO|Oral administration daily for 28 day cycles; starting dose of CTO = 50 mg/m2
1871802|NCT01107522|Drug|CTO and Temodar®|"Oral administration of CTO daily for 28 day cycles, starting dose of CTO = 219 mg/m2.
Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle.
Expansion Cohort of 6 patients on fixed dose of 600mg CTO/day Temodar® administered orally at fixed dose of 150 mg/m2 daily for Days 1-5 in a 28 day cycle"
1871803|NCT01107522|Drug|CTO, Temodar®, Radiation therapy|Oral administration of CTO daily for 28 day cycles; starting dose of CTO = 219 mg/m2 Temodar® administered orally at a dose of 75 mg/m2 daily during radiation therapy, then at 150mg/m2 for Days 1-5 of Cycle 1, and then up to 200 mg/m2 Days 1-5 of subsequent cycles Radiation: 3-dimensional conformal radiation therapy or, Radiation: intensity-modulated radiation therapy
1871804|NCT01107535|Biological|Synagis (palivizumab), monoclonal antibody for passive immunoprophylaxis against severe RSV disease administered according to usual clinical practice.|Synagis (palivizumab) administered according to usual clinical practice. After the enrollment visit, subjects will have monthly visits until they have received the complete Synagis immunization regimen of their hospital, then they will have 2 follow up visits, one of them 30 days after the fifth dose of Synagis and the other visit at one year of age.
1871805|NCT01107548|Other|Systematic detection of vascular risk factors and subsequent evidence-based treatment|
1871806|NCT01107561|Other|Seldinger technique|Involves blind needle insertion through the skin into the cricoid membrane followed by insertion of the guide-wire and subsequent insertion of the tube over the guidewire
1871807|NCT01107561|Device|Surgical Airway Approach|The classical open or surgical technique involves a vertical skin incision with blunt dissection and identification of the anatomy followed by incision of the cricoid membrane and tube insertion.
1871808|NCT01107574|Drug|Gabapentin|Gabapentin 900 mg po HS for 6 weeks treatment per patients enrolled in the Gabapentin Arm
1871809|NCT01107574|Procedure|Osteopathic Manipulative Medicine|Based on Osteopathic Structural Examination and Tender point Examination a 30 minute treatment of Osteopathic Manipulative Medicine was applied to each patient every week for 6 weeks.
1871810|NCT01107574|Other|Gabapentin and Osteopathic Manipulative Medicine|Combination therapy of gabapentin 900 mg po HS for 6 weeks and Osteopathic Manipulative Medicine 30 minute treatment weekly for each patient based on Osteopathic Structural Examination and Tender point Examination
1871813|NCT01117441|Drug|PEG-L-asparaginase|see detailed protocol description
1871814|NCT01117441|Drug|cyclophosphamide|see detailed protocol description
1871815|NCT01117441|Drug|cytarabine|see detailed protocol description
1871816|NCT01117441|Drug|daunorubicin hydrochloride|see detailed protocol description
1871817|NCT01117441|Drug|dexamethasone|see detailed protocol description
1871818|NCT01117441|Drug|doxorubicin hydrochloride|see detailed protocol description
1871819|NCT01117441|Drug|etoposide|see detailed protocol description
1871820|NCT01117441|Drug|ifosfamide|see detailed protocol description
1871821|NCT01117441|Drug|mercaptopurine|see detailed protocol description
1871822|NCT01117441|Drug|methotrexate|see detailed protocol description
1871823|NCT01117441|Drug|prednisone|see detailed protocol description
1871824|NCT01117441|Drug|thioguanine|see detailed protocol description
1871825|NCT01117441|Drug|vincristine sulfate|see detailed protocol description
1871826|NCT01117441|Drug|vindesine|see detailed protocol description
1871827|NCT01117441|Drug|daunoxome|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
1871828|NCT01117441|Drug|fludarabine|see detailed protocol description; only given by patients with poor MRD-response during the high risk treatment
1871829|NCT01117441|Radiation|Radiation Therapy|for eligibility for radiotherapy see detailed protocol description
1871830|NCT01117454|Drug|Flecainide Acetate|oral flecainide with the dose titrated to achieve a serum level between 0.5-0.8 mcg/ml
1871831|NCT01117454|Drug|Placebo|placebo, similar in appearance to flecainide
1871832|NCT01117454|Drug|Beta blocker|Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.
1871833|NCT01117467|Other|Simulation scenario|Students performing their scenario will be paired, not solo
1871834|NCT01117467|Other|Simulation scenario|Students will perform their simulation scenario solo and receive feedback within the group
1871835|NCT01117493|Behavioral|Expert Patient Programme|Intervention was a disease specific Expert Patient Programme in addition to usual care. The disease specific Expert Patient Programme was delivered one session per week (lasting 2½ hours) for eight weeks and included 2 weeks disease specific education followed by 6 weeks standardised Expert Patient Programme.
1871836|NCT01117493|Behavioral|Usual care|Usual care included reviews at a specialist respiratory clinic on a three monthly basis to monitor spirometry, inflammatory blood markers and sputum microbiology. The patients were prescribed inhaled therapy and antibiotics if required, and treatment adjusted to the needs of the patient as necessary, including hospital admission.
1871837|NCT01117519|Drug|Infusion Therapy|Based on changes of stroke volume measured by transoesophageal doppler patients during elective hip surgery will achieve either a unbalanced infusion solution, maximum dose of 100 ml/kg BW, or a compound of balanced infusion solution including 50% crystalloid and 50% colloid, each: maximum dose of 50 ml/kg BW. The study medication will be administered only during surgery.
1871838|NCT01117532|Behavioral|EFT (Emotional Freedom Techniques)|Four 90 minute group therapy classes of this behavioral intervention
1871839|NCT01117545|Behavioral|EFT (Emotional Freedom Techniques)|Six sessions of EFT
1871840|NCT01117571|Device|iUni® Unicompartmental Knee Resurfacing Device|The iUni® Unicompartmental Resurfacing Device is an FDA cleared and CE Marked implant designed for patients with damage isolated to either the medial or lateral tibiofemoral compartment of the knee. The patient-specific iUni is designed from a CT scan of an individual patient's knee using a design process which interactively maps the diseased area and defines the extent of misalignment present in the knee. This process allows definition of the shape and size of the femoral and tibial components of the implant, as well as the disposable instrumentation
1871841|NCT01117584|Drug|ASP1941|oral tablet
1871842|NCT01117584|Drug|Placebo|oral tablet
1871843|NCT01117597|Radiation|low RF exposure level|Exposure with 1.5 W/kg
1871844|NCT01117597|Radiation|sham exposure|intervention with sham RF exposure
1871845|NCT01117597|Radiation|high RF exposure|intervention with high RF exposure
1871848|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 20 mg|Participants in the dose-escalation cohort received a single 20 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 20 mg oral co-precipitate (CP) tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
1871849|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 40 mg|Participants in the dose-escalation cohort received a single 40 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 40 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
1871850|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 100 mg|Participants in the dose-escalation cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
1871851|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 120 mg|Participants in the dose-escalation cohort received a single 120 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 120 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
1871888|NCT01119066|Procedure|(CliniMACS) T-cell depleted PBSC Transplant|
1871889|NCT01119079|Other|Normal Saline|10ml Normal Saline instilled in the epidural space
1871890|NCT01119079|Procedure|Administration of epidural anesthesia for labor|Standard procedure
1871943|NCT01119417|Drug|BQ123|Low dose day: 50 nmol/min, single IV infusion for 15 min
1871852|NCT01117623|Drug|Escalation cohort: Regorafenib (Stivarga, BAY73-4506) 140 mg|Participants in the dose-escalation cohort received a single 140 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 140 mg oral CP tablets was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
1871853|NCT01117623|Drug|HCC Child-Pugh A expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh A in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
1871854|NCT01117623|Drug|HCC Child-Pugh B expansion cohort: Regorafenib 100 mg|Hepatocellular carcinoma (HCC) Participants with Child Pugh B in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
1871855|NCT01117623|Drug|NSCLC expansion cohort: Regorafenib 100 mg|Non-small cell lung cancer (NSCLC) participants in the expansion cohort received a single 100 mg oral CP tablet of regorafenib on Day 1 of Cycle 1 followed by 1 day off treatment. On Day 3, once-daily continuous dosing with 100 mg oral CP tablets of regorafenib was initiated. A cycle was defined as 21 days. For Cycle 2 and subsequent cycles, regorafenib was administered once daily continuously on a 21-day cycle.
1871856|NCT01117636|Drug|Acetylsalicylic acid (Fast release Aspirin, BAY1019036)|Single oral dose of fast release aspirin tablets 1000 mg (2 x 500 mg) with a full glass of water (240 milliliter [mL]) between 14 hours post dental surgery.
1871857|NCT01117636|Drug|Acetylsalicylic Acid (Aspirin, BAYE4465)|Single oral dose of regular aspirin tablet 1000 mg (2 x 500 mg) with a full glass of water (240 mL) between 14 hours post dental surgery.
1871858|NCT01117636|Drug|Placebo|Single oral dose of 2 placebo tablets with a full glass of water (240 mL) between 14 hours post dental surgery.
1871859|NCT01117649|Drug|HES 10%|HES 10% dissolved in plasma adapted Ringer's solution (balanced solution).
1871860|NCT01117649|Drug|HES 6%|HES 6% dissolved in plasma adapted Ringer's solution (balanced solution)
1871861|NCT01117649|Drug|balanced electrolyte solution|plasma adapted Ringer's solution
1871862|NCT01117662|Drug|Rituximab|Intravenous application of Rituximab 375mg/m² body surface in 250 ml NaCl 0,9 % over 4 hours
1871863|NCT01117662|Drug|Placebo|Intravenous application of placebo (NaCl 0,9 %) matching active treatment
1871864|NCT01117675|Other|Virtual Hospital|A new home care model using a telemedicine system (Virtual Hospital) to care chronic HIV-infected patients
1871865|NCT01117675|Other|Standard of Care|Standard of Care
1871866|NCT01117688|Procedure|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, endoscopic treatment is performed with a safety guidewire in place. In study arm B - without SGW, the ureteroscopy is performed without SGW.
1871867|NCT01117701|Procedure|Ureteroscopy with and without safety guidewire|In study arm A - with SGW, the force measurements are made with a safety guidewire in place. In study arm B - without SGW, the force measurements are made without SGW.
1871868|NCT01117714|Procedure|Integrated Staging for Early Detection of Metastases in Lung Cancer|To determine the accuracy of EBUS/EUS-guided FNA when compared with surgical mediastinoscopy/thoracoscopy
1871869|NCT01117727|Device|Brain Computer Interface Switch|Subjects will wear an EEG cap for 1-2 hours typical per session and use the brain computer interface to operate assistive technology. Subjects will be asked to participate in 14-20 sessions.
1871870|NCT01117740|Behavioral|MDASI Questionnaire|19 question M. D. Anderson Symptom Inventory (MDASI) before pleural effusion treatment and at each follow-up visit, takes about 5 minutes to complete each time.
1871871|NCT01117753|Behavioral|OutPatient Treatment for Adolescents (OPT-A)|
1871872|NCT01117753|Behavioral|Treatment As Usual|
1871873|NCT01117766|Drug|Pregabalin|Dose titration according to following regimen: 75mg BID for 3 days; 150mg for 4 days; 225mg BID for 4 days; 300mg BID for 17 days. Dose reduced for renally impaired patients
1871874|NCT01117766|Drug|Placebo|BID dosing for 28 days
1871875|NCT01119001|Device|P300 Brain Computer Interface Keyboard|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) per session and use the brain-computer interface to operate assistive technology. Subjects will be asked to participate in 3 sessions.
1871876|NCT01119014|Drug|Aripiprazole|pill, 2,5-20 mg/day, maximum 16 weeks
1871877|NCT01119014|Drug|Quetiapine|pill, 50-600mg/day, maximum 16 weeks
1871878|NCT01119040|Procedure|Natural Orifice Translumenal Endoscopic Surgery|"Natural Orifice Translumenal Endoscopic Surgery (NOTES) procedures involve transmural passage of flexible endoscopes introduced via a natural orifice whereby permitting access to the peritoneal cavity while avoiding skin incisions. No clear indication due to a number of physiologic, microbiologic, immunologic, and technical limitations. The concept of NOTES PEG Rescue in the setting of a dislodged naïve PEG tube may spare individual patients the physiologic stress of traditional surgery while concomitantly providing a natural segue to further study the NOTES platform in the human setting. PEG Rescue may represent a unique, practical, and empowering application of the burgeoning experience of natural orifice translumenal endoscopic surgery."
1871879|NCT01119053|Device|VNS Pulse Model 102|Individual dosage within the realm of 0,25 mA - 3,5 mA. Uninterrupted stimulation of 24 h.
1871880|NCT01119053|Device|VNS Pulse Model 102|Within this branch, study participants obtain the VNS therapy after a defined space of time of 12 weeks.
1871881|NCT01119066|Radiation|total body irradiation|dose of 1375-1500 cGy
1871882|NCT01119066|Drug|Thiotepa|5 mg/kg/day x 2 or 10 mg/kg/day x 1
1871883|NCT01119066|Drug|Cyclophosphamide|60 mg/ kg/day x 2 (or fludarabine 25mg/m2 x 5 if cyclophosphamide is contraindicated).
1871884|NCT01119066|Drug|Busulfan|0.8 mg/kg every 6 hours x 10 or 12 doses (depending on disease) with dose modified according to pharmacokinetics
1871885|NCT01119066|Drug|Melphalan|70mg/m2/day x 2
1871886|NCT01119066|Drug|Fludarabine|25mg/m2/ day x 5
1871887|NCT01119066|Drug|Clofarabine|20mg/m2/ day x 5 (or, for children <18 years of age, 30mg/m2/day x 5 if deemed suitable and with PI approval)
1871891|NCT01119092|Other|"Sham (laying of hands) intervention"|The clinician will place his/her hands in a position to perform the AP joint mobilizations but will not actually perform them. The sham treatment will be performed 3 times and each will last a period of 60 seconds with a one minute rest in between.
1871892|NCT01119092|Other|Grade IV AP joint mobilizations|3 60-second treatments of Grade IV AP joint mobilizations of the talus during each treatment session, with a one minute rest in between each treatment.
1871893|NCT01119105|Drug|BC-3781|BC-3781 dose 100mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
1871894|NCT01119105|Drug|BC-3781|BC-3781 dose 150mg is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
1871895|NCT01119105|Drug|Vancomycin|Vancomycin is administered as i.v. infusion every 12 h for 5 to 14 days depending on the clinical response.
1871896|NCT01119118|Drug|ZD4054|All patients will be treated with ZD4054 at 10 mg PO daily, repeated in four week cycles (1 cycle = 28 days). All patients will initially undergo NaF and FDG PET/CT and MRI imaging at baseline (scan#1), and then again after 4 weeks (scan#2) of ZD4054 exposure. Subsequently, ZD4054 will be held for 2 weeks followed by the final NaF and FDG-PET/CT and MRI acquisition (scan#3). After the final PET/MRI is obtained, patients will resume ZD4054 and be assessed for safety prior to each new cycle of therapy. Standard disease evaluation assessments will be conducted after cycle#3, and repeated after every third cycle (sooner if clinically indicated). Therapy will continue until radiographical/clinical disease progression or unacceptable toxicity
1871897|NCT01119131|Drug|Vitamin D3|Vitamin D3 at 10,000 IU a day
1871898|NCT01119131|Dietary Supplement|calcium|1000mg calcium daily
1871899|NCT01119131|Other|Placebo|A placebo pill with similar appearance to the vitamin D3 will be given to those in the placebo arm
1871900|NCT01119144|Device|Polycaprolactone / Tri-Calcium Phosphate|Orbital implant for reconstruction of the orbital walls
1871901|NCT01119144|Device|Titanium Mesh|Titanium mesh for comparison to Polycaprolactone / Tri-Calcium Phosphate (PCL / TCP) mesh
1871902|NCT01119157|Biological|influenza vaccine|whole virus influenza vaccine adjuvanted with aluminium phosphate, 3 x 15 μg HA / 0.5 ml, for i.m. administration subunit influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration split influenza vaccine 3 x 15 μg HA / 0.5 ml, for i.m. administration
1871903|NCT01119170|Other|Starter formula|standard starter formula given from birth to 6 months of age
1871904|NCT01119170|Other|starter formula with D-lactate producing probiotics|starter formula containing probiotics given from birth to 6 months of age
1871905|NCT01119183|Behavioral|No intervention for this arm|No educational literature will be offered to this group
1871906|NCT01119183|Behavioral|ACOG education pamphlet on preeclampsia|The ACOG pamphlet on preeclampsia will be offered to this group
1871907|NCT01119183|Behavioral|Preeclampsia education tool|The newly created preeclampsia educational tool will be offered to this group
1871908|NCT01119196|Other|Icodextrin dialysate|use of alternate SOC dialysate
1871909|NCT01119209|Drug|Ropivacaine|Approved by the Danish Medicines Agency
1871910|NCT01119209|Drug|Saline|Approved by the Danish Medicines Agency
1871911|NCT01119222|Drug|Gabapentin|Capsule, single 1200mg dose
1871912|NCT01119222|Drug|Diphenhydramine|Tablet, single 50mg dose
1871913|NCT01119222|Drug|Morphine|IV, single 10mg dose
1871914|NCT01119222|Drug|Placebo|Placebo formulations (Capsule, tablet, IV to match the active treatments and to be administered in a double-dummy fashion).
1871915|NCT01119235|Drug|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in the first cohort will be 300mg twice daily for 3 days followed by 200mg twice daily for 11 days
1871916|NCT01119235|Drug|PF-04531083|Dosed as a tablet in 100mg strengths. Dosage in this optional second cohort will be optimised based on the data arising from Cohort 1
1871917|NCT01119261|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
1871918|NCT01119261|Other|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
1871919|NCT01119274|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
1871920|NCT01119274|Other|Non-genotype-guided dosing algorithm|Loading and monitoring dose according to non-genotype-guided dosing algorithm
1871921|NCT01119287|Drug|Dexamethasone 0.1% ophthalmic suspension|Maxidex
1871922|NCT01119287|Drug|Olopatadine hydrochloride 0.1% ophthalmic solution|Patanol
1871923|NCT01119287|Other|Inactive ingredients, used as placebo|Tears Naturale II
1871924|NCT01119300|Other|Genotype-guided dosing algorithm|Loading and monitoring dose according to genotype-guided dosing algorithm
1871925|NCT01119300|Other|Standard care|Standard care
1871926|NCT01119313|Drug|LAS 41002|LAS 41002, once daily
1871927|NCT01119313|Drug|Active|Active, once daily
1871928|NCT01119326|Procedure|Autologous Fat Transfer|one site will be treated with AFT For placebo treated (control) sites, an equal number of empty cannula passes will be administered using a similar technique described for the AFT.
1871929|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 1, once daily
1871930|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 2, once daily
1871931|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 3, once daily
1871932|NCT01119339|Drug|LAS 41004|LAS 41004 dosage 4, once daily
1871933|NCT01119339|Drug|LAS 41004|LAS 41004 , dosage 5, once daily
1871934|NCT01119339|Drug|LAS 41004 dosage 6|LAS 41004, dosage 6, once daily
1871935|NCT01119339|Drug|Placebo|Placebo, once daily
1871936|NCT01119339|Drug|Reference|Reference, once daily
1871937|NCT01119352|Drug|AZD7687|Oral suspension, once daily. Starting dose of 1mg and with up to 4 dose escalations. Totally 8 doses.
1871938|NCT01119352|Drug|Placebo|Oral suspension, once daily. Totally 8 doses
1871939|NCT01119365|Other|Bright light|Bright (1000 lux) light
1871940|NCT01119378|Other|Dual isotope technique|Dual isotope technique using stable isotopes
1871941|NCT01119391|Behavioral|There was no intervention; this was a survey only study|There was no intervention; this was a survey only study
1871942|NCT01119417|Drug|BQ123|Low dose day: 25 nmol/min, single IV infusion for 15 min.
1872887|NCT01124175|Drug|Cozaar®|100 mg Tablets
1871944|NCT01119417|Drug|Bq123|High dose day: 100 nmol/min, single IV infusion for 15 min.
1871945|NCT01119417|Drug|BQ123|High dose day: 300 nmol/min, single IV infusion for 15 min.
1871946|NCT01119417|Drug|Saline|2-3 IV saline infusions for 15 min each.
1871947|NCT01119430|Drug|DU125530|20mg/twice a day
1871948|NCT01119430|Drug|Placebo|Similar pill as active comparator twice a day
1871949|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
1871950|NCT01119443|Drug|PPX ER|PPX ER 0.375mg - 1.5mg for 32 days totally
1960119|NCT03297411|Procedure|Brief Temporoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
1960120|NCT03297411|Procedure|Ultrabrief Temporoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Temporoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
1960121|NCT03297411|Procedure|Brief Frontoparietal ECT|Electroconvulsive Therapy (Brief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
1960122|NCT03297411|Procedure|Ultrabrief Frontoparietal ECT|Electroconvulsive Therapy (Ultrabrief pulse width, Frontoparietal) The intervention in this study is different combinations of pulse width and ECT electrode placements.
1871959|NCT01119469|Behavioral|Psychotherapy (CT or ET)|weekly 50-minute sessions for 12 weeks
1871960|NCT01119482|Biological|MenAfriVac™|Children, adolescents and adults aged 1 to 29 years old will receive a single intramuscular injection of the meningococcal serogroup A conjugate vaccine .
1871961|NCT01119508|Drug|Ipilimumab|Induction Phase: 10 mg/kg by vein (IV) over approximately 90 minutes on Day 1 only repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose repeated every 12 weeks.
1871962|NCT01119508|Drug|Temozolomide|Induction Phase, 200 mg/m^2 by mouth (PO) on Days 1 to 4, repeated every 3 weeks until 4 courses of therapy are given over 3 months. For the Maintenance Phase, dose delivered on Days 1 to 5, repeated every 4 weeks.
1871963|NCT01119521|Biological|BCG strain Danish|Intradermal Bacillus Calmette-Guerin (BCG) live-attenuated vaccine prepared using the Danish 1331 BCG substrain; adult dose contains 2 to 8 x 10^5 colony forming units (CFU) BCG.
1871964|NCT01119521|Drug|Isoniazid|United States Pharmacopeia 100 mg or 300 mg oral tablets [5 mg/kilogram/day (rounded up to nearest 100 mg; maximum dose 300 mg/day)].
1871965|NCT01119534|Drug|Guaiacol, eucalyptol, menthol and camphor suppository|2 times per day
1871966|NCT01119534|Drug|guaiacol suppository|2 times per day
1871967|NCT01119534|Drug|Guaifenesin syrup|4.19 mL - 4 in 4 hours
1871968|NCT01119547|Other|Exercise in a group|The patient do their individual exercise program in a group.
1871969|NCT01119547|Other|Home exercise|The patient exercise their individual program at home during 6 v.
1871970|NCT01119560|Other|laboratory biomarker analysis|Correlative studies
1871971|NCT01119560|Other|questionnaire administration|Ancillary studies
1871972|NCT01119573|Genetic|RNA analysis|
1871973|NCT01119573|Genetic|microarray analysis|
1871974|NCT01119573|Genetic|reverse transcriptase-polymerase chain reaction|
1871975|NCT01119573|Other|laboratory biomarker analysis|
1871976|NCT01119586|Genetic|DNA analysis|
1871977|NCT01119586|Genetic|genetic linkage analysis|
1871978|NCT01119586|Genetic|microarray analysis|
1871979|NCT01119586|Genetic|nucleic acid sequencing|
1871980|NCT01119586|Genetic|polymerase chain reaction|
1871981|NCT01119586|Genetic|polymorphism analysis|
1871982|NCT01119586|Other|laboratory biomarker analysis|
1871983|NCT01119599|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3-D conformal radiation therapy
1871984|NCT01119599|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1871985|NCT01119599|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1871986|NCT01119599|Other|Laboratory Biomarker Analysis|Correlative studies
1871987|NCT01119599|Other|Pharmacological Study|Correlative studies
1871988|NCT01119599|Drug|Temozolomide|Given PO
1871989|NCT01119599|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1871990|NCT01119612|Dietary Supplement|Iron|Daily oral dose of 60 mg from enrollment until delivery
1871991|NCT01119612|Other|Placebo|Daily oral dose from enrollment until delivery
1871992|NCT01119625|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, one dose
1871993|NCT01119625|Biological|Infanrix-IPV/Hib|Intramuscular injection, one dose
1871994|NCT01119638|Drug|Escitalopram|Patients in the escitalopram group will receive 5 mgs/d for the first week and than 10 mgs/d till completion.
1871995|NCT01119638|Drug|Risperidone|Patients in the risperidone group will receive 0.5 mgs/d for the first week and than 1.0 mg/d till completion.
1871996|NCT01119651|Drug|Tazarotene (Patch application in Challenge Phase)|There are 2 phases in this study. The induction phase will include 6 days of patch application to the subject's back. Patches will be removed daily and irradiated. Patch applications will be placed on the same sites, unless a strong reaction is observed. The induction phase will be followed by a rest period followed by the Challenge Phase which consists of a 24-hr application of 3 sets of 3 patches (Set C, Set D, and Set E) applied to naïve sites on the subject's back. Each set of patches will consist of a tazarotene foam patch, a vehicle foam patch, and a blank patch. After 24 hrs, Set D patch sites will be evaluated and irradiated with UVA/UVB light. Set C patch sites will be evaluated and irradiated with UVA, UVB light and visible light. Set E patch sites will be evaluated & will serve as nonirradiated controls. Patch sites will be evaluated 1 hr after patch removal and during follow up visits at 24 hrs, 48 hrs, and 72 hrs after removal of the final patch in Set E.
1871997|NCT01119664|Drug|SCH 721015|
1872184|NCT01120925|Biological|MNC|2-3 X 109 cells in 20ML suspension IPV in 4 min
1871998|NCT01119677|Drug|Avonex|Group 1 subjects will receive weekly Avonex 30 mcg (full dose) IM injections from Week 1 to Week 8. Group 2 subjects will titrate in quarter dose increments every week up to a full dose of Avonex over a 3 week period from Week 1 to Week 3 and then continue on full dose from Week 4 to Week 8. Group 3 subjects will titrate in quarter dose increments every 2 weeks up to a full dose of Avonex over a 6 week period from Week 1 to Week 6 and continue on full dose from Week 7 to Week 8
1871999|NCT01119690|Dietary Supplement|Cold-pressed turnip rapeseed oil (CTPRO)|"In the dietary period of 6 to 8 weeks: CTPRO 37 ml/day.
In the 5-hour oral glucose and fat tolerance test: glucose and CTPRO."
1872000|NCT01119690|Dietary Supplement|milk fat|"In dietary period of 6 to 8 weeks: 37.5 grams of butter.
In the 5-hour oral glucose and fat tolerance test: glucose and cream"
1872001|NCT01119703|Biological|Tetanus & Diphtheria booster vaccine (Td)|Tetanus & Diphtheria booster vaccine (Td), single intramuscular dose
1872002|NCT01119703|Biological|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine]|TwinrixTM [Hepatitis A Inactivated & Hepatitis B (Recombinant) Vaccine], intramuscular, two doses of standard three dose regimen (opposite arms)
1872003|NCT01119703|Biological|Dukoral® Traveler's Diarrhea Vaccine (WC/rBS)|Dukoral® Traveler's Diarrhea Vaccine, recombinant Cholera toxin B subunit (WC/rBS), standard two oral doses per treatment regimen
1872004|NCT01119742|Drug|Butenafine Hydrochloride 1%|Twice daily application for 7 days
1872005|NCT01119742|Drug|Butenafine Hydrochloride 1% B|Twice daily application for 7 days
1872006|NCT01119742|Drug|Butenafine Hydrochloride 1%|Twice daily application for 7 days
1872007|NCT01119742|Drug|Vehicle A|Twice daily application for 7 days
1872008|NCT01119742|Drug|Vehicle B|Twice daily application for 7 days
1872009|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 8 weeks and 24 weeks on-demand treatment
1872010|NCT01119768|Drug|Esomeprazole|20mg Esomeprazole once daily, 2 weeks and 24 weeks follow up
1872011|NCT01119781|Drug|BIIB017(peginterferon beta-1a)|peginterferon beta-1a administered by a single subcutaneous (SC) injection using a pre-filled syringe on Day 1 at a dose of either 63 or 125 mcg depending on subpopulation assignment reflecting whether a healthy volunteer or level of renal impairment.
1872012|NCT01119794|Drug|Ofatumumab and Bortezomib|Ofatumumab 1000 mg IV Cycle 1 on day 1, 8, 15 and 22 Bortezomib 1.6 mg/m2 IV Ofatumumab 1000 mg IV on day 1 maintenance phase Patients will remain until progression
1872013|NCT01119807|Device|Intravenous access during OHCA|First attempt will be a peripheral IV in the AC. If this fails, second attempt will be a tibial IO, followed by a humeral IO when indicated.
1872014|NCT01119807|Device|Humeral IO insertion|First attempt will be a humeral IO. Second attempt should occur at the tibia if the first humeral IO fails. Subsequent attempts will be for a peripheral IV or additional IOs as determined by the paramedic.
1872015|NCT01119807|Device|TIbial IO insertion|First attempt will be a tibial IO. Second attempt should occur on the opposite tibia if the first IO fails. Subsequent attempts will be for a humeral IO or peripheral IV as selected by the paramedic.
1872016|NCT01119820|Other|Tissue Donation|Females over 18 who are scheduled to undergo elective surgery will have discarded tissue collected.
1872017|NCT01119833|Drug|GMI-1070|Intravenous GMI-1070 given twice a day during hospital stay for sickle cell pain crisis
1872018|NCT01119833|Drug|Placebo|Intravenous Placebo given twice a day during hospital stay for sickle cell pain crisis
1872022|NCT01119859|Drug|Tocilizumab|The maximum dose was 800 mg for patients weighing more than 100 kg. Tocilizumab was infused into an arm vein over a 1-hour period.
1872023|NCT01119859|Drug|Adalimumab|
1872024|NCT01119859|Drug|Placebo to tocilizumab|
1872025|NCT01119859|Drug|Placebo to adalimumab|
1872026|NCT01119872|Other|Positive End-expiratory Pressure (PEEP)|"All patients were ventilated during 24 hours with low tidal volume (6-8 milliliters/kilogram of predicted body weight), plateau airway pressure limited at 35 centimeters of water, initial ventilator rate of 30 breaths/minute adjusted to maintain a pH goal of 7.30 to 7.45 to a maximum of 35 breaths/minute, fraction of inspired oxygen ensuring arterial oxygen saturation 88-95% or arterial partial pressure of oxygen of 55-80 mmHg.
Level of Positive End-Expiratory Pressure (PEEP) applied according the 2 arms of treatment."
1872027|NCT01119885|Drug|fentanyl matrix|Knee osteoarthritis, starting with 12mcg/h (flexible dose)
1872028|NCT01119885|Drug|fentanyl matrix|Hip osteoarthritis, starting with 12mcg/h (flexible dose)
1872031|NCT01119911|Other|Blood sampling from peripheral venous catheter.|Venipuncture is performed on the opposite limb of the peripheral venous catheter. Within 3 minutes, a second sample is taken from existing peripheral venous catheter used for fluid administration. Intravenous fluids are then stopped for 30 seconds and a tourniquet applied proximal to the device for another 30 seconds. A 2-mL syringe is attached and 0.5 mL of blood aspirated and discarded. Thereafter, 2 mL blood is slowly drawn during about 15 seconds, into a different 2-mL syringe, to allow a gentle pumping action that may reduce vacuum in the syringe and thus hemolysis rates. Afterwards, the intravenous device is flushed with 2 mL normal saline and infusion restarted.
1872032|NCT01119924|Drug|Smilon®|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
1872033|NCT01119924|Drug|Placebo|Smilon® tablet 15mg mg/day or placebo, once a day on the first week, and then for 7 consecutive weeks
1872034|NCT01119937|Drug|NVA237|50µg capsules for inhalation, delivered via a single dose dry powder inhaler (Concept 1®)
1872035|NCT01119937|Drug|Tiotropium|18µg capsules for inhalation, delivered via HandiHaler®
1872036|NCT01119950|Drug|NVA237 12.5 µg once daily|NVA237 12.5 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
1872185|NCT01120925|Biological|CD133|5-15 X 106 cells in 20ML suspension IPV
1872037|NCT01119950|Drug|NVA237 25.0 µg once daily|NVA237 25.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
1872038|NCT01119950|Drug|NVA237 12.5 µg twice daily|NVA237 12.5 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
1872039|NCT01119950|Drug|NVA237 50.0 µg once daily|NVA237 50.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
1872040|NCT01119950|Drug|NVA237 25.0 µg twice daily|NVA237 25.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
1872041|NCT01119950|Drug|NVA237 100.0 µg once daily|NVA237 100.0 µg via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
1872042|NCT01119950|Drug|NVA237 50.0 µg twice daily|NVA237 50.0 µg via dry powder inhaler twice daily for 28 days during either period 1 or during period 2.
1872043|NCT01119950|Drug|Placebo to NVA237 once daily|Placebo to NVA237 via dry powder inhaler once daily for 28 days during either period 1 or during period 2.
1872044|NCT01119963|Drug|17-alpha-hydroxy-progesterone caproate, Makena®|Intramuscular (IM) injection of 17P,Makena® (250mg) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
1872045|NCT01119963|Drug|Castor Oil (Placebo)|IM injections of Placebo (castor oil) beginning as early as 23w0d administered weekly until 34w0d, documented fetal lung maturity at 32w0d - 33w6d, or delivery which ever comes first.
1872046|NCT01119976|Behavioral|Reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
1872047|NCT01119976|Behavioral|Different reduced calorie diet and exercise plan|Participants will receive written diet and exercise instructions to follow for the duration of the study.
1872048|NCT01119989|Dietary Supplement|control|
1872049|NCT01119989|Dietary Supplement|Fructose+maltodextrin placebo|
1872050|NCT01119989|Dietary Supplement|amino-acid + fructose|
1872051|NCT01120002|Drug|Tamibarotene|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
1872052|NCT01120002|Drug|Placebo|Two Tamibarotene 2 mg or placebo tablet per day, once daily.
1872053|NCT01120015|Drug|diacerein|Diclofenac sodium 75mg sustained release tablet once daily was given to both groups for 3 months. Capsule diacerein 50mg in study group and matched placebo in control group were given once daily for first month and twice daily for next two months with the main meals.
1872054|NCT01120028|Drug|Alemtuzumab|Alemtuzumab 30 mg intravenously or subcutaneously Two doses 24 hours apart
1872055|NCT01120028|Drug|Basiliximab|20 mg intravenously Two doses 96 hours apart
1872056|NCT01120028|Drug|Sirolimus|Sirolimus: target trough levels 5-10 ng/mL for first 6 months, then 5-8 ng/mL
1872057|NCT01120028|Drug|Tacrolimus|Target trough level 5-12 ng/mL for first 6 months after basiliximab; 5-7 ng/mL for first six months after basiliximab. 5-7 ng/mL for all participants after 6 months.
1872058|NCT01120041|Behavioral|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal and postpartum phases
1872059|NCT01120041|Behavioral|motivational interviewing counseling|Motivational interviewing counseling given during the prenatal phase with traditional health education given during the postpartum phase
1872060|NCT01120041|Behavioral|motivational interviewing counseling|Traditional health education given during the prenatal phase with motivational interviewing counseling given during the postpartum phase
1872061|NCT01120041|Behavioral|health education|Traditional health education given during the prenatal phase and the postpartum phase
1872062|NCT01120067|Behavioral|Intensive Treatment|Participants randomized to the Intensive Treatment condition will attend 6 bi-weekly outpatient therapy sessions conducted in an individual format of 90 minutes in duration.
1872063|NCT01120067|Behavioral|Treatment as Usual|Treatment as Usual.
1872064|NCT01120080|Behavioral|Practical Counseling|To ensure that treatment effects are not due to the longer counseling intervention and additional alcohol intervention workbook in the Alcohol Intervention plus Standard Care condition, we will provide additional smoking cessation advice that will not be specific to alcohol use and an additional smoking cessation workbook for participants in the Practical Counseling plus Standard Care condition. Consistent with the Clinical Practice Guideline Update, we will include 5 minutes of practical counseling, which has been shown empirically to be effective in improving rates of smoking cessation.
1872065|NCT01120080|Behavioral|Alcohol Intervention Counseling|The Alcohol Intervention counseling protocol will be adapted from Dr. Ockene's brief alcohol intervention protocol and Dr. Kahler's brief alcohol intervention for smokers: Feedback and discussion on the relationship between drinking and smoking, and on the potential effects of alcohol consumption on smoking cessation; an emphasis on personal Responsibility for choosing to change one's behavior; Advice to avoid or minimize drinking during the smoking cessation process; a Menu of options for carrying out a change strategy; use of Empathy by the clinician; and encouragement of Self-efficacy (i.e., confidence) for successful change.
1872066|NCT01120093|Drug|Aclidinium bromide 100 μg bid|Aclidinium bromide 100 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
1872067|NCT01120093|Drug|Aclidinium bromide 200 μg bid|Aclidinium bromide 200 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
1872068|NCT01120093|Drug|Aclidininum bromide 400 μg bid|Aclidinium bromide 400 μg twice-daily via inhalation by Eklira Genuair® inhaler: 1 puff in the morning and evening for 7 days
1872069|NCT01120093|Drug|Placebo|Placebo via inhalation in the morning and evening for 7 days
1872070|NCT01120093|Drug|Formoterol 12 μg bid|Formoterol 12 μg twice-daily via inhalation by Aerolizer® dry powder inhaler: 1 puff in the morning and evening for 7 days
1872071|NCT01120106|Drug|levosimendan|patients enrolled in this group will receive a levosimendan continuous infusion at a rate of 0.1 mcg/kg/min
1872072|NCT01120106|Drug|placebo|saline continuous infusion
1872073|NCT01120119|Drug|Calcitriol|
1872074|NCT01120132|Drug|CsA high dose|Solution of Cyclosporine (high dose) administered during 28 days
1872075|NCT01120132|Drug|CsA low dose|Solution of Cyclosporine (low dose) administered during 28 days
1872076|NCT01120132|Drug|PA|Suspension of Prednisolone Acetate administered during 28 days
1872077|NCT01120132|Drug|Placebo|Placebo solution administered during 28 days
1872078|NCT01120158|Drug|Bevacizumab|Bevacizumab (IV) 10 mg/kg on day 1 and day 15. Treatment repeats every 28 days. Therapy will continue until maximum response, disease progression or unacceptable toxicity.
1872079|NCT01120158|Drug|Paclitaxel|Paclitaxel (IV) 120 mg/m2,on day 1 and day 15. Treatment repeats every 28 days Therapy will continue until maximum response, disease progression or unacceptable toxicity.
1872080|NCT01120171|Drug|Cyclophosphamide|"Cyclophosphamide (IV) 600 mg/m2 on day 1. Treatment repeats every 21 days. Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.
Therapy will continue until maximum response,or unacceptable toxicity."
1872081|NCT01120171|Drug|Liposomal-encapsulated doxorubicin|"Liposomal-encapsulated doxorubicin (IV) 50 mg/m2 on day 1. Treatment repeats every 21 days.
Primary prophylaxis with pegfilgrastim (6 mg) administered 24 hours after chemotherapy.
Therapy will continue until maximum response or unacceptable toxicity."
1872082|NCT01120184|Drug|docetaxel|75 mg/m2 or 100 mg/m2 intravenously every 3 weeks for a minimum of 6 cycles.
1872083|NCT01120184|Drug|paclitaxel|80 mg/m2 intravenously weekly for a minimum of 18 weeks
1872084|NCT01120184|Drug|pertuzumab|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
1872085|NCT01120184|Drug|pertuzumab-placebo|840 mg intravenously on day 1 of cycle 1 followed by 420 mg intravenously every 3 weeks in subsequent cycles
1872086|NCT01120184|Drug|trastuzumab [Herceptin]|trastuzumab [Herceptin] doses when administered with docetaxel: 8 mg/kg intravenously on cycle 1 followed by 6 mg/kg every 3 weeks in subsequent cycles or trastuzumab (Herceptin) doses when administered with paclitaxel: 4 mg/kg intravenously on day 1 of cycle 1 followed by 2 mg/kg weekly starting on day 8 of cycle 1.
1872087|NCT01120184|Drug|trastuzumab emtansine|3.6 mg/kg intravenously every 3 weeks
1872088|NCT01120197|Other|Exercise group|Weekly exercises
1872089|NCT01120197|Other|Control Group|No Intervention, control group only
1872090|NCT01120210|Drug|JNJ-39588146 5 ng/kg/min|1-hour infusion of JNJ-39588146 5 ng/kg/min on Day 1
1872091|NCT01120210|Drug|JNJ-39588146 15 ng/kg/min|1-hour infusion of JNJ-39588146 15 ng/kg/min on Day 1
1872092|NCT01120210|Drug|JNJ-39588146 30 ng/kg/min|1-hour infusion of JNJ-39588146 30 ng/kg/min on Day 1
1872093|NCT01120210|Drug|Placebo|1-hour infusion of matching placebo on Day 1
1872094|NCT01120210|Drug|JNJ-39588146 5, 15, or 30 ng/kg/min|18-hour infusion of JNJ-39588146 or matching placebo on Day 1 immediately folllowing the 3-hour infusion at a dose equal to the maximum dose tolerated by that patient during the 3-hour infusion in Part 1 of the study.
1872095|NCT01120223|Drug|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|Once daily application
1872096|NCT01120236|Drug|Bicalutamide|Given PO
1872097|NCT01120236|Biological|Cixutumumab|Given IV
1872098|NCT01120236|Drug|Goserelin Acetate|Given SC
1872099|NCT01120236|Other|Laboratory Biomarker Analysis|Correlative studies
1872100|NCT01120236|Drug|Leuprolide Acetate|Given IM
1872101|NCT01120236|Other|Pharmacological Study|Correlative studies
1872102|NCT01120249|Drug|everolimus|Given orally
1872103|NCT01120249|Other|placebo|Given orally
1872104|NCT01120262|Genetic|gene expression analysis|
1872105|NCT01120262|Genetic|polymorphism analysis|
1872106|NCT01120262|Other|laboratory biomarker analysis|
1872107|NCT01120275|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
1872108|NCT01120275|Other|laboratory biomarker analysis|Correlative studies
1872109|NCT01120288|Drug|EZN-2968|
1872110|NCT01120301|Device|NeuroThera® Laser System|Transcranial delivery of laser therapy or sham (no laser therapy) to the scalp
1872111|NCT01120314|Drug|OTAMIXABAN (XRP0673)|"Form: solution for injection
Route: intravenous"
1872112|NCT01120327|Drug|Placebo|Placebo
1872113|NCT01120327|Drug|Amlodipine|Amlodipine
1872114|NCT01120340|Drug|mesalamine|mesalamine: 1.6 g/die for ten days/month until 24 months
1872115|NCT01120340|Other|placebo|2 pills/day for ten days/month until 24 months
1872116|NCT01120366|Drug|Tocilizumab plus methotrexate|Tocilizumab 8mg/kg 4weeks (i.v.) plus methotrexate up to 52weeks.The dosage of MTX will be fixed at least 24 weeks from the start of the study.
1872117|NCT01120366|Drug|Tocilizumab|tocilizumab 8mg/kg/4weeks (i.v.) up to 52weeks.
1872118|NCT01120379|Device|XIENCE V® EECSS|Single-arm study designed to evaluate XIENCE V® EECSS continued safety and effectiveness during commercial use in real world settings.
1872119|NCT01120392|Other|treatment with Nintendo wii.|Participants Will receive treatment with Nintendo Wii over one months. These Patients Will Be subjected to mobilization of stem and stretching. Then Will Be Submitted to Nintendo wii games. Will Be Submitted This group three times a week to a treatment protocol with boxing exercises with wii sports and wii fit
1872120|NCT01120392|Other|Physical therapy conventional.|Conventional exercises used with the same goals for the group with wii
1872121|NCT01120405|Drug|Xenon|
1872122|NCT01120405|Drug|Sevoflurane|
1872123|NCT01120418|Drug|Besifloxacin Ophthalmic Suspension 0.6%|administered 3 times a day for 5 days to one eye.
1872124|NCT01120431|Other|Oral rehydration fluid|Oral electrolyte solution or other clinically acceptable oral rehydration fluid, 5 to 10 mL of offered with encouragement every 5 to 10 minutes
1872125|NCT01120431|Drug|Isotonic hydration fluid and recombinant human hyaluronidase|Single subcutaneous dose of 150 U recombinant human hyaluronidase, followed by infusion pump-delivered subcutaneous isotonic hydration fluid
1872126|NCT01120444|Device|BD Research Catheter with 34G x 1.5 mm needle|bolus injection of insulin given intradermal prior to standardized meal
1872127|NCT01120444|Device|Subcutaneous delivery of insulin using Disetronic Accu-Chek Rapid D infusion set|bolus delivery of insulin given subcutaneously prior to standardized meal
1872128|NCT01120457|Drug|BMS-936564 (Anti-CXCR4)|
1872129|NCT01120470|Drug|OGX-427|OGX-427: Starting within 5 days of randomization, three loading doses at 600 mg IV within the first 10 days of initiating treatment, followed by weekly doses of 1000 mg IV
1872130|NCT01120470|Drug|Prednisone|"Control Arm:
Prednisone: 5 mg BID orally starting within 4 days following randomization
Experimental Arm:
Prednisone: 5 mg BID orally starting within 4 days following randomization and at least 24 hours prior to first loading dose of OGX-427"
1872131|NCT01120496|Drug|3% hypertonic saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
1872132|NCT01120496|Drug|normal saline|Moderately to severely ill infants with bronchiolitis were randomized to receive 4 mL solution containing either 3% hypertonic saline or normal saline
1872133|NCT01120509|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
1872134|NCT01120522|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
1872135|NCT01120535|Device|Inferior Vena Cava Filter|Inplant of filter in inferior vena cava.
1872136|NCT01120548|Other|ventilation therapy|"The service provider will provide the patient with the ventilation device and will explain to the patient how to operate the device and how to fit the mask according to the specifications.
There will be an oximetry recording during ventilation on the first night. After the first night, the ventilation parameters recorded by the machine and the oximetry results will be read and used to adjust the settings.
Starting the first week and at the end of the programme, the following ventilation parameters will be collected: compliance, leaks, AHI, ventilation mode, pressures used. The threshold of length of nocturnal ventilation fixed to 3h per night on average in order to consider a compliant patient."
1872137|NCT01120561|Drug|trastuzumab-MCC-DM1|Intravenous repeating dose
1872138|NCT01120574|Other|Home mechanical ventilation|Home mechanical ventilation will be performed with a bilevel pressure ventilator.
1872139|NCT01120600|Drug|Odanacatib|One 50 mg tablet once weekly
1872140|NCT01120600|Drug|Placebo for Odanacatib|One 50 mg tablet once weekly
1872141|NCT01120613|Drug|Chronotherapy|"Patients identified with nocturnal hypertension while treated with blood pressure medications will have one medication switched from daytime to night time dosing in the following preference:
ACE or ARB
Calcium Channel Blockers
Alpha Blocker
Beta Blocker
If patient is on only one daytime BP medication, it will be switched to night time dosing. No dose adjustments will be made nor any new medications will be added. Only timing of BP medication will be changed."
1872142|NCT01120626|Drug|donepezil|donepezil (2.5 mg to 10.0 mg per day for 12 weeks)
1872143|NCT01120626|Drug|sugar pill|sugar pill (2.5 mg to 10.0 mg per day for 12 weeks)
1872144|NCT01120639|Drug|Temozolomide|75 mg/m2/day, oral
1872145|NCT01120639|Procedure|Stereotactic Radiosurgery|Standard of care
1872146|NCT01120652|Behavioral|Mind-Body Skills Training (MBST)|This is a behavioral intervention that blends cognitive-behavioral therapy methods, mind-body relaxation training, and mindfulness practices. MBST is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
1872147|NCT01120652|Behavioral|Supportive Counseling (SC)|This is a behavioral intervention consisting of support and symptom monitoring but without specific skills training or provision of advice. SC is provided in 8 individual sessions, each lasting approximately one hour. Ideally, sessions take place on a weekly basis, so that the intervention phase of the study lasts for approximately two months.
1872148|NCT01120665|Drug|Estradiol valerate|estradiol valerate, 1 mg/day, orally.
1872149|NCT01120665|Other|Aerobic training|Aerobic trainin (cycleergometer, 3x/week, moderate intensity, 50 minutes)
1872150|NCT01120665|Drug|Placebo|lactose powder, corn starch, microcrystalline cellulose, and magnesium stearate
1872151|NCT01120665|Other|Control|The control group was advised to maintain their normal habits, and not to begin any physical exercise program during the study period
1872152|NCT01120691|Drug|QVA149|QVA149 110/50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
1872153|NCT01120691|Drug|NVA237|NVA237 50 μg capsules for inhalation, once daily delivered via Novartis Single Dose Dry Powder Inhaler (SDDPI) for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
1872154|NCT01120691|Drug|tiotropium|Open-label tiotropium bromide 18 μg capsules for inhalation once daily delivered via HandiHaler® device for at least 64 weeks of double blind treatment period (study duration was up to 76 weeks).
1872155|NCT01120691|Drug|Salbutamol/albuterol|As needed throughout the study
1872156|NCT01120704|Drug|Short Term Combination Nicotine Replacement Therapy (patch + gum)|"IF participant smokes >10 cigs/day AND is randomized to a 8 week condition: they will be asked to take one 21 mg patch/day for 4 weeks, THEN one 14 mg patch/day for 2 weeks, THEN one patch 7mg/day for 2 weeks.Participants will also be asked to use 4-mg gum every 1-2 hours (9 pieces maximum per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment.
IF participant smokes 5-10 cigs/day AND is randomized to the 8 week medication condition: they will be asked to take one 14 mg patch/day for 4 weeks, THEN one 7 mg patch/day for 4 weeks. Participants will also be asked to use 2-mg gum every 1-2 hours (9 pieces max per day)for 6 weeks and decrease gum use over the 2 weeks prior to medication termination until down to one gum piece every 4-8 hours by the last week of treatment."
1872157|NCT01120704|Drug|Long Term Combination Nicotine Replacement Therapy (patch + gum)|"IF the participant smokes >10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 21 mg patch per day for 22 weeks, THEN one 14 mg patch per day for 2 weeks, THEN one patch 7 mg patch per day for 2 weeks. Participants will also be asked to use one piece of one 4-mg- gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment.
IF the participant smokes 5-10 cigs/day AND is randomized to a 26 week medication condition: they will be asked to take one 14 mg patch per day for 22 weeks, THEN one patch 7 mg patch per day for 4 weeks. Participants will also be asked to use one piece of 2-mg gum every 1-2 hours (9 pieces maximum per day)for 24 weeks and decrease gum use over the 2 weeks prior to medication termination until they are down to one gum piece every 4-8 hours by the last week of treatment."
1872186|NCT01120925|Biological|Control|Injection of 20 ml Normal saline via IPV
1872187|NCT01120964|Drug|Intravenous L-Citrulline|150mg bolus X 1 after initiation of cardiopulmonary bypass, the addition of L-citrulline at a concentration of 200 umol/L or placebo to the filtration and hemoconcentration fluid utilized during cardiopulmonary bypass in addition to a 20mg/kg bolus 30 minutes after separation from cardiopulmonary bypass immediately followed by a continuous infusion of 9mg/kg/hr IV, and ending at 48 hours continuous infusion or discharge from the PCCU.
1872158|NCT01120704|Behavioral|Intensive Maintenance Counseling|Participants randomized to this condition will receive eight 15-minute phone counseling sessions at Weeks 3, 4, 6, 8, 10, 14, 18 & 22. The counseling will encourage continued practice of coping skills, and avoidance of danger situations. Another emphasis will be the continued provision of social support as a means of enhancing motivation. Participants who have relapsed will receive counseling aimed at motivating and planning renewed quit attempts. Other aims are enhancing motivation, especially competence self-appraisals, providing intratreatment support, and encouraging pleasurable activities.
1872159|NCT01120704|Behavioral|Cognitive Medication Adherence Counseling (CAM)|Participants randomized to this condition will be given a brief (10 minute) session of CAM treatment at both Visits 1 and 2. CAM will include information on NRT such as the following: NRT reduces withdrawal and urges; sustained use reduces the likelihood of relapse; willpower and medication make a good combination; NRT will help a lapsing smoker reachieve abstinence. The tailored counseling component of the CAM intervention is based on brief evaluation of the smoker's beliefs, concerns, and possible misconceptions about smoking cessation medications.
1872160|NCT01120704|Behavioral|Electronic Medication Monitoring Device (the Helping Hand) + Feedback|If randomized to this condition, the case manager will give patients a computer-generated feedback sheet showing the patient's medication self-administration since the last visit. The case manager will provide problem-solving counseling regarding barriers to medication use. This problem-solving counseling intervention will be given in brief in-person sessions (three in-person sessions for those in the 8 week medication condition and five in-person sessions for those in the 26 week medication condition). Medication monitoring counseling will also occur via phone (two 10-minute sessions for those in the 8 week medication condition and four 10-minute sessions for those in the 26 week medication condition).
1872161|NCT01120704|Behavioral|Automated Adherence Prompting Phone Calls|"Participants in this condition will receive fully automated prompts with messages designed to encourage participants to take their medication.
Adherence prompting calls will occur two times in the first week of the quit attempt, and then once a week in weeks 2, 3, 4, 5, and 7. Those in the 26-Week medication condition who are assigned to the active adherence prompting calls intervention, will receive one prompting call a week during Weeks 11, 15, 19 & 23."
1872162|NCT01120717|Drug|QVA149|capsules for inhalation, delivered by an SDDPI
1872163|NCT01120717|Drug|Placebo|capsules for inhalation, delivered by an SDDPI
1872164|NCT01120730|Drug|fluid resuscitation|fluid resuscitation with HES
1872165|NCT01120730|Drug|Fluid resuscitation|Fluid resuscitation in standardized fashion
1872166|NCT01120756|Behavioral|Goal-oriented attentional self-regulation|This will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of home practice). In brief, the GBSM training protocol is designed to maximize the potential for improving attention regulation skills and the goal-directed functions they support, applying mindfulness-based attention regulation training to practice in redirecting attention to goal-relevant processes especially in the context of distractions is emphasized throughout training. Participants are asked to identify realistic functional goals as feasible individual and group projects, and are then trained in goal management strategies on the functional task(s) of their choice.
1872167|NCT01120756|Behavioral|Pathfinder Attention Process Training|Training tools that target goal-directed attention regulation through intensive application and practice with monitored computer-assisted 'real world' simulated scenarios extended into real life situations. Training will last a total of 6-8 weeks, approximately 36 hours of training (12 with in-person trainer interactions, and 24 at home).
1872168|NCT01120756|Behavioral|Brain Health Education|Brain Health Education (EDU) will involve 5-7 weeks of training (20 hours of group training (2 hour sessions, 2 days per week), 3 hours of individual training (1 hour at the beginning, halfway through and at the end of training), and approximately 20 hours of homework). The EDU intervention involves education in health and brain injury in a classroom format, with study materials for homework.
1872169|NCT01120756|Behavioral|Tonic and Phasic Alertness Training (TAPAT)|The Tonic and Phasic Alertness Training (TAPAT) is designed to improve alertness at two levels: tonic attention of sustained attention and phasic alertness, or the capacity to rapidly and effectively interrupt an ongoing response pattern. Subjects will be presented objects on a computer screen and make speeded responses via button press to non-targeted objects and withhold button press to targeted objects.
1872170|NCT01120769|Drug|Acetaminophen|single dose
1872171|NCT01120769|Drug|Placebo|single dose
1872174|NCT01120795|Drug|Pegylated interferon and ribavirin|Pegylated interferon 180 ug subcutaneous per week Ribavirin 1000-1200 mg /day for genotype 1 and 800 mg /day orally for genotype non 1 Duration: 48 weeks for genotype 1 and 24 weeks for gentoype non 1
1872175|NCT01120795|Drug|Pegylated interferon and ribavirin|Pegylated interferon 180 ug/ week subcutaneously Ribavrin 1000-1200 mg /day for genotype 1 and 800 mg/day orally for genotype 2 and 3 Treatment duration 48 weeks for genotype 1 and 24 weeks for genotypes 2 and 3
1872176|NCT01120808|Procedure|Paper tape|Paper tape assigned to each participant's randomly selected foot.
1872177|NCT01120821|Drug|Gleevec|400 mg once daily for 12 months
1872178|NCT01120834|Drug|azacytidine|"Dose level 1: azacitidine 55 mg/m2 on days 1-5
Dose level 2: azacitidine 75 mg/m2 on days 1-5
Dose level 3: azacitidine 55 mg/m2 on days 1-5
Dose level 4: azacitidine 75 mg/m2 on days 1-5
Each cycle = 28 days. Subjects may receive up to 6 cycles."
1872179|NCT01120834|Drug|vorinostat|"Dose level 1: oral vorinostat at 300 mg BID on Days 1-7.
Dose level 2: oral vorinostat at 200 mg BID on Days 1-7.
Dose level 3: oral vorinostat at 300 mg BID on Days 1-14.
Dose level 4: oral vorinostat at 200 mg BID on Days 1-14.
Each cycle = 28 days. Subjects receive up to 6 cycles."
1872180|NCT01120860|Device|MRI|MRI - routine imaging sequences, designed for anatomical quantification
1872181|NCT01120873|Drug|Metamin 3D|Metamin 3D is composed by red yeast rice, bitter gourd, chlorella, soy peptide and licorice extract is a commercial product designed by Uni-President enterprises corp in Taiwan
1872182|NCT01120899|Drug|Minocycline|Participants take 100 mg minocycline pills twice daily for 24 months.
1872183|NCT01120912|Drug|Oshadi Oral Insulin|Oral insulin single administration
1872188|NCT01120964|Drug|Placebo of Intravenous L-Citrulline|Placebo of Intravenous L-Citrulline given at the same prescribed times as L-Citrullne Drug
1872189|NCT01120990|Other|Blood Pressure Measurement|All patients have their blood pressure measured simultaneously by two observers using parallel connected mercury sphygmomanometers and by a supervisor using the tested device, NISSEI DM 3000. Six sets of measurements are performed.
1872190|NCT01121003|Behavioral|weight maintenance, low sugar diet|
1872191|NCT01121003|Behavioral|weight maintenance, high fructose diet|
1872192|NCT01121003|Behavioral|weight maintenance, high fructose diet+ exercise|
1872193|NCT01121016|Drug|Montelukast|10mg, qn, 4 weeks
1872194|NCT01121016|Other|placebo to montelukast|same appearance, flavor, weight, and size to montelukast pills, 1 pill daily, for 4 weeks
1872195|NCT01121029|Procedure|Autologous hematopoietic stem cell transplantation|Patients will receive a stimulation with filgrastim 10mcg/Kg per day during 4 days and cyclophosphamide 1.5g/m2 per day during 2 days and mesna 300mg/m2 i.v. in 4 hours for prophylaxis (uroprotection). Lately, the stem cells will be recollected by apheresis. After that, the patients will receive a conditioning regimen with cyclophosphamide 500mg/m2 per day during 4 days and fludarabine 30mg/m2 per day during 4 days. After the last dose of cyclophosphamide, the autologous hematopoietic stem cell transplantation will be done on day 0, by peripheral vein. Then, a standard regimen of prophylaxis with oral ciprofloxacin 500mg every 12 hours, acyclovir 400mg every 8 hours, fluconazole 100mg per day and omeprazole 20mg per day for the recovery time of each patient.
1872196|NCT01121042|Drug|Ondansetron|8mg per day oral capsule
1872197|NCT01121042|Drug|Placebo|daily oral capsule matched to active study medication. Made form 100% lactose powder
1872198|NCT01121055|Drug|Lorazepam|Lorazepam 0.5mg po at night one day before FB and Lorazepam 1mg po 30min before the FB
1872199|NCT01121055|Drug|Control|Placebo 1T po at night one day before FB and placebo 1T po 30min before the FB
1872200|NCT01121068|Other|Blood samplings|About 3.5ml of blood will be drawn from the participants monthly.
1872201|NCT01121081|Drug|Alga Dunaliella Bardawil|4 capsules per day, 2 in the morning 2 in the evening for 3 month
1872202|NCT01121081|Drug|Placebo|"Drug: Alga Dunaliella Bardawil
4 capsules per day, 2 in the morning 2 in the evening for 3 month"
1872203|NCT01121107|Device|Left Atrial Pressure Monitoring System|Left atrial lead is placed for ambulatory monitoring of left atrial pressure
1872204|NCT01121107|Device|Patient Advisory Module|Handheld device that provides medication reminders
1872207|NCT01121133|Drug|navitoclax|Subjects will be dosed with Navitoclax, then dosed with Navitoclax in combination with Rifampin.
1872208|NCT01121133|Drug|Rifampin|Subjects will be dosed with Navitoclax, then, dosed with Navitoclax in combination with Rifampin.
1872209|NCT01121146|Device|Total Hip Replacement|Comparison of Marathon and Enduron polyethylene
1872210|NCT01121159|Procedure|orbital fracture repair|All patients will receive orbital fracture repair with one of the 4 specified implants
1872211|NCT01121185|Biological|MBL-HCV1|50 mg/kg MBL-HCV1, intravenous
1872212|NCT01121185|Other|0.9% Sodium chloride Placebo|0.9% sodium chloride, intravenous
1872213|NCT01121198|Drug|ASP1941|oral
1872214|NCT01121198|Drug|placebo|oral
1872215|NCT01121211|Drug|Testosterone|Testosterone 300mcg transdermal patch x 24 weeks.
1872216|NCT01121211|Drug|Placebo|Placebo transdermal patch x 24 weeks
1872217|NCT01121224|Device|Bare Metal Stent|Patients receive one or more bare metal stents in the saphenous vein graft target lesion.
1872218|NCT01121224|Device|Drug-Eluting Stent|Patients receive one or more drug-eluting stents in the saphenous vein graft target lesion.
1872219|NCT01121224|Drug|Blinded clopidogrel|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive one or more DES in the target lesion.
1872220|NCT01121224|Drug|Placebo|For non-ACS patients with no other clinical indication for open-label thienopyridine who receive only BMS.
1872221|NCT01121224|Drug|Thienopyridine (open-label)|For ACS patients who receive BMS or DES in their saphenous vein graft or patients for whom there is another clinical indication for open-label thienopyridine. Also for patients who receive a DES in a non-target lesion.
1872222|NCT01121237|Drug|Recombinant human erythropoietin alfa (biosimilar)|Recombinant human erythropoietin alfa (biosimilar) commercially available as prescribed per treating physician
1872225|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
1872226|NCT01121276|Drug|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
1872227|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
1872228|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
1872229|NCT01121276|Drug|Faster-acting insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
1872230|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
1872231|NCT01121289|Drug|insulin aspart|0.2 U/kg body weight injected subcutaneously (under the skin)
1872232|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
1872233|NCT01121289|Drug|NN1218|0.4 U/kg body weight injected subcutaneously (under the skin)
1872234|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
1872235|NCT01121289|Drug|NN1218|0.2 U/kg body weight injected subcutaneously (under the skin)
1872236|NCT01121302|Drug|AZD5213|0.1 mg, 0.3 mg, 1 mg, 2 mg, 4 mg, 8 mg, 16 mg, 32 mg oral solution, single ascending doses
1872237|NCT01121302|Drug|Placebo|
1872238|NCT01121328|Biological|Autologous cord blood transfusion for preterm neonates|Cord blood collection after delivery of the baby. Preservation of blood in blood bank. Transfusion of blood within the first 14 postnatal days to maintain Hb level above 10gm%.
1872239|NCT01121328|Biological|Autologous cord blood transfusion|"After delivery of the baby and before placental delivery in vaginal delivery. After delivery of the baby the placental will be taken out in cesarean section. sterilization of the umbilical cord will be done. Puncture of the umbilical cord vein with the needle of blood transfusion bag will be done.
Blood will be kept in the blood bank. Blood grouping, haematocrit and CBC will be done for the cord blood.Maternal sample will be analysed simultaneously.
Mononuclear layer will be separated within 6 hours and transfused to the preterm neonate immediately.
RBCs will be separated and kept till need (Hb less than 10 gm%)."
1872240|NCT01121341|Procedure|Vein harvesting|Endoscopic versus conventional vein harvesting
1872241|NCT01121354|Drug|Cefazolin 2g for Injection USP and Dextrose Injection USP|Cefazolin 2g for Injection USP and Dextrose Injection USP in the DUPLEX® Drug Delivery System. Administration will occur three times per day (t.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
1872242|NCT01121354|Drug|Cefazolin 1.5g|Cefazolin 1.5g for Injection USP and Dextrose Injection USP in a pharmacy-prepared container. Administration will occur four times per day (q.i.d.) over an eleven (11) day period, with nine (9) days of repeated dosing.
1872243|NCT01121380|Drug|BL-1021|"BL-1021 is an orally available NCE which contains an elongated aliphatic side-chain.
Dosage:
Part 1 - Single Dose: 1 dose on Day 1, dosage will be 10, 20, 40 & 80 mg according the cohort Part 2 - Multiple Dosing: up to 7 once-daily administrations. Dosage will be determined according the first part results."
1872244|NCT01121380|Drug|1021|1021
1872245|NCT01121393|Drug|Gemcitabine+Cisplatin|Gemcitabine d1,8, Cisplatin d1, 21 days as a course, up to 6 courses.
1872246|NCT01121393|Drug|BIBW 2992|starting dose is 40 mg, in the event of no or minimal drug-related adverse events after one course, the dose will be increased to 50mg. in the event of certain drug related AE, dose reduction will be increments of 10 mg, with the lowest dose being 20mg.
1872247|NCT01121406|Drug|Paclitaxel|Patients receive paclitaxel in a 4 week schedule
1872248|NCT01121406|Drug|Gemcitabine|Patients receive gemcitabine in a 3 week schedule
1872249|NCT01121406|Drug|Topotecan|Patients receive topotecan in 3 or 4 week schedule
1872250|NCT01121406|Drug|Pegylated liposomal doxorubicin (PLD)|Patients receive PLD in a 4 week schedule
1872251|NCT01121406|Drug|BI 6727|Patients receive BI 6727 infusion every 3 weeks
1872252|NCT01121432|Procedure|endobronchial ultrasound-guided transbronchial needle aspiration|One time for aspiration/biopsy. The duration about 1-2 hour.
1872253|NCT01121445|Device|NeilMed nose and sinus irrigation|Saline irrigation used daily plus CPAP with heated humidification for 4 weeks
1872254|NCT01121458|Drug|Clevidipine|The clevidipine infusion is to be administered via IV infusion at a starting dose of 0.5 mg/hour. The dose may be doubled every three (3) minutes to a maximum dose of 32 mg/hr as tolerated, until a 20% reduction in PVR is achieved or until the patient experiences hypotension (SBP< 80 mmHg), hypertension (SBP>150 mmHg), tachycardia (120 beats per minute), bradycardia (<50 beats per minute), or symptoms of hypotension or ischemia (chest pain, anxiety, nausea, vomiting), allergic reaction (hives, urticaria) or other adverse event. Clevidipine infusion may be terminated at any time for a safety reason or at the investigator's discretion.
1872255|NCT01121471|Dietary Supplement|Conjugated Linoleic Acid (CLA)|6.4 g CLA/day, capsule form, for 16 week arms
1872256|NCT01121471|Dietary Supplement|Safflower OIl|8.0g/day safflower oil
1872257|NCT01110421|Drug|Cefepime placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem for up to 14 days
1872258|NCT01110421|Drug|Cefepime|Type=once every 8 hours, Unit=mg, Number=50 mg/kg up to 2g/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv cefepime administered every 8 hours infused over 30 minutes immediately before each iv infusion of doripenem placebo for up to 14 days
1872259|NCT01110421|Drug|Doripenem|Type=once every 8 hours infused over 60 minutes, Unit=mg, Number=20mg/kg up to 500mg/dose, Form=solution for infusion, Route=intravenous use. At least 3 days of iv doripenem administered every 8 hours immediately after each iv infusion of cefepime placebo for up to 14 days
1872260|NCT01110421|Drug|Doripenem placebo|Form=solution for infusion, Route=intravenous use, administered once every 8 hours infused over 60 minutes immediately following each iv infusion of cefepime for up to 14 days
1872261|NCT01110421|Drug|Amoxicillin/clavulanate potassium|Form=suspension or tablets, Route=oral (by mouth), may be administered at the discretion of the investigator once every 12 hours for up to 14 days following IV therapy with doripenem or cefepime.
1872262|NCT01110434|Drug|Topiramate|Topiramate (200 mg daily)
1872263|NCT01110434|Drug|Placebo|Placebo (daily)
1872264|NCT01110447|Drug|VSL#3|VSL#3® is made up of 4 strains of Lactobacilli (L. paracasei, L. plantarum, L. acidophilus and L. delbrueckii subsp. bulgaricus), 3 strains of Bifidobacteria (B. longum, B. infantis, B. breve) and 1 strain of Streptococcus thermophilus. Dose would be 1 sachet per day (Each sachet containing 900 Billion CFU). The duration of treatment would be for 24 weeks
1872265|NCT01110447|Other|Placebo|Placebo sachets contain corn starch. Dose: 1 sachet per day Duration of treatment: 24 weeks
1872266|NCT01110473|Drug|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
1872267|NCT01110473|Drug|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
1872268|NCT01110473|Drug|ABT-348 and azacitidine|An oral dose of ABT-348 on Day 1, Day 8, and Day 15 of each 28 day cycle. An IV or injection of azacitidine on Days 1-7 of each 28 day cycle.
1872269|NCT01110473|Drug|ABT-348|An intravenous dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
1872270|NCT01110486|Drug|ABT-348|An oral dose of ABT-348, once daily on Day 1, Day 8, and Day 15 of each 28 day cycle.
1872271|NCT01110486|Drug|ABT-348 and carboplatin|An oral dose of ABT-348 will begin in Cycle 2on Day 1 and Day 8; and an IV dose of carboplatin (AUC 5.0) on Day 1 of each 21-day cycle.
1872272|NCT01110486|Drug|ABT-348 and docetaxel|ABT-348 dosing will begin in Cycle 2. An oral dose of ABT-348 on Day 1 and Day 8; and an IV dose of docetaxel (75 mg/m2) on Day 1 of each 21-day cycle.
1872273|NCT01110486|Drug|ABT-348|An oral dose of ABT-348, twice daily on Day 1, Day 8, and Day 15 of each 28 day cycle
1872274|NCT01110486|Drug|ABT-348|An IV administration of ABT-348 two hour infusion on Day 1, Day 8 and Day 15 of each 28 day cycle.
1872275|NCT01110499|Drug|AGN-210961 Formulation 1|AGN-210961 Formulation 1 in one eye once daily for 7 days.
1872276|NCT01110499|Drug|AGN-210961 Formulation 2|AGN-210961 Formulation 2 in one eye once daily for 7 days.
1872277|NCT01110499|Drug|AGN-210961 Formulation 3|AGN-210961 Formulation 3 in one eye once daily for 7 days.
1872278|NCT01110499|Drug|AGN-210961 Formulation 4|AGN-210961 Formulation 4 in one eye once daily for 7 days.
1872279|NCT01110499|Drug|AGN-210961 Formulation 5|AGN-210961 Formulation 5 in one eye once daily for 7 days.
1872280|NCT01110499|Drug|AGN-210961 Formulation 6|AGN-210961 Formulation 6 in one eye once daily for 7 days.
1872281|NCT01110499|Drug|AGN-210961 Formulation 7|AGN-210961 Formulation 7 in both eyes once daily for 4 weeks.
1872282|NCT01110499|Drug|bimatoprost ophthalmic solution 0.03%|bimatoprost ophthalmic solution 0.03% (LUMIGAN®) in both eyes once daily for 4 weeks.
1872283|NCT01110512|Drug|Flavonid|"Diosmin (450 mg) + hesperidin (50 mg)
1 tablet, 2 times per day."
1872284|NCT01110512|Drug|Daflon|"Diosmin (450 mg) + hesperidin (50 mg)
1 tablet, 2 times per day"
1872285|NCT01110525|Drug|AZD1981|4X100 mg per oral, twice daily for 28 days
1872286|NCT01110525|Drug|Neovletta 21/28|Once daily with (21) or without (28) pause for bleeding.
1872287|NCT01110525|Drug|Placebo AZD1981|4X100 mg per oral, twice daily for 28 days
1872288|NCT01110551|Drug|Placebo (SC)|Phosphate buffered saline administered subcutaneously.
1872289|NCT01110551|Drug|Placebo (ID)|Phosphate buffered saline administered intradermally.
1872290|NCT01110551|Biological|Modified Live Tetravalent Chimeric Dengue Vaccine (SC)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, and D4: 2 x 10^5, total virus dose [plaque forming units (PFU)]: 2.2 x 10^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, and D4: 3 x 10^5, total virus dose (PFU): 4.7 x 10^5. DENVax administered subcutaneously.
1872291|NCT01110551|Biological|Modified Live Tetravalent Chimeric Dengue Vaccine (ID)|DENVax is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: DEN-2 PDK-53 (DENVax-2), DEN-2/1 chimera (DENVax-1), DEN-2/3 chimera (DENVax-3) and DEN-2/4 chimera (DENVax-4). The drug product is formulated in buffer and stored frozen. Low dose contains (dose volume 0.1 mL): D1: 8 x 10^3, D2: 5 x 10^3, D3: 1 x 10^4, and D4: 2 x 10^5, total virus dose [plaque forming units (PFU)]: 2.2 x 10^5. High dose contains (dose volume 0.1 mL): D1: 2 x 10^4, D2: 5 x 10^4, D3: 1 x 10^5, and D4: 3 x 10^5, total virus dose (PFU): 4.7 x 10^5. DENVax administered intradermally.
1872292|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 5.25 mg BAY60-4552 + 140 mg Vardenafil
1872293|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 140 mg Vardenafil
1872294|NCT01110590|Drug|BAY60-4552 + Vardenafil|Total dose given over 14 days: 21.0 mg BAY60-4552 + 280 mg Vardenafil
1872295|NCT01110590|Drug|Placebo|Placebo
1872296|NCT01110603|Drug|MK-4827|Capsules, orally, once daily, on Days 1 and 3 of each 21- or 28-day Cycle, at the assigned dose level, starting at 40 mg per dose.
1872297|NCT01110603|Drug|carboplatin|Intravenous infusion, at AUC 5, once, on Day 3 of each 21- or 28-day cycle
1872298|NCT01110603|Drug|paclitaxel|Intravenous infusion, 175 mg/m2, once, on Day 3 of each 21-day cycle
1872299|NCT01110603|Drug|liposomal doxorubicin|Intravenous infusion, 30 mg/m2, once, on Day 3 of each 28-day cycle
1872300|NCT01110616|Drug|MK3134|MK3134, 25 mg tablets (5 x 5 mg capsule), orally
1872301|NCT01110616|Drug|Comparator: Lorazepam|Lorazepam, 2 mg (2 x 1 mg tablet), orally
1872302|NCT01110616|Drug|Comparator: Placebo|Placebo, to match MK3134, and placebo to match Lorazepam
1872303|NCT01110629|Drug|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg 3 times a dayfor 8 weeks.
1872304|NCT01110629|Drug|Placebo|daily dose: 3 tablets TID for 8 weeks.
1872305|NCT01110642|Drug|Lovastatin|Topical lovastatin applied to red, rashy areas two times daily for 12 months
1872308|NCT01110668|Drug|Nilotinib|
1872312|NCT01110720|Drug|Davunetide|Davunetide Nasal Spray 30 mg BID IN 52 weeks
1872313|NCT01110720|Drug|Placebo|Placebo Nasal Spray BID IN 52 weeks
1872314|NCT01110746|Drug|Viaject 7|100IU/mL administered subcutaneously
1872315|NCT01110746|Drug|LISPRO|100IU/mL administered subcutaneously
1872316|NCT01110772|Device|2-octyl cyanoacrylate [InteguSEAL®]|At operating room arrival prior to surgery, povidone-iodine is applied on the skin surface on concentric circles as recommended; after drying, the cyanoacrylate device is opened and a layer of the sealant is applied on the incision and skin site(IS100 for patients undergoing mastectomy, and IS200 for patients undergoing gynecologic or digestive tract surgeries).
1872604|NCT01113671|Drug|Vitamin E (d-alpha-tocopheryl acetate)|100% natural source d-alpha-tocopheryl acetate in a soft gel cap
1994717|NCT02939638|Other|Control Diet|Participants will be asked to continue their usual diets for the 16-week study period.
1994718|NCT02940080|Other|Dietary|
1872317|NCT01110772|Device|Iodine povacrylex in isopropyl alcohol [Duraprep®, 3M]|At the operating room arrival a few minutes before the incision, cleansing and skin antisepsis is done with the prefilled device with iodine povacrylex in isopropyl alcohol as recommended by 3M.
1872318|NCT01110785|Biological|panitumumab|
1872319|NCT01110785|Drug|simvastatin|
1872320|NCT01110785|Other|laboratory biomarker analysis|
1872321|NCT01110798|Other|intraoperative complication management/prevention|
1872322|NCT01110798|Procedure|assessment of therapy complications|
1872323|NCT01110798|Procedure|gastrointestinal complications management/prevention|
1872324|NCT01110798|Procedure|quality-of-life assessment|
1872325|NCT01110798|Procedure|therapeutic conventional surgery|
1872326|NCT01110811|Procedure|Transoral Incisionless Fundoplication (TIF)|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degress around the esophagus.
1872327|NCT01110824|Drug|Enalapril and carvedilol|Enalapril 2.5 to 10 mg BID Carvedilol 6.25 to 25 mg BID
1872328|NCT01110837|Other|Allergen|Allergen nasal challenge
1872329|NCT01110837|Other|Placebo challenge|Placebo nasal challenge
1992905|NCT03278340|Behavioral|Sun Safe Workplaces -In Person|After randomization, program staff will contact managers the recruited employer and schedule the initial in-person visit in the first 6 months. Follow-up meetings will be scheduled as needed to discuss policy adoption; managers will schedule employee education with SSW-IP project staff. Printed materials will be sent to SSW-IP employers 3 times during the intervention. Staff will follow-up with managers through Month 34 (Wave 1) or Month 46 (Wave 2).
1872333|NCT01110889|Drug|Agomelatine (AGO178C)|
1872334|NCT01110889|Drug|Agomelatine (AGO178C)|
1872335|NCT01110889|Drug|Placebo|
1872336|NCT01110902|Drug|Agomelatine (AGO178C)|
1872337|NCT01110902|Drug|Placebo|
1872338|NCT01110915|Device|Medtronic Advisa MRI Implantable Pulse Generator (IPG)|Advisa MRI IPG is a dual chamber, multi-programmable IPG indicated to restore heart rates, improve cardiac output, prevent symptoms, or protect against arrhythmias related to cardiac impulse formation or conduction disorders. The IPG is indicated for use in patients who may benefit from rate-responsive pacing to support cardiac output during varying levels of activity and has been modified for use during an MRI exam.
1872339|NCT01110915|Device|Medtronic CapSureFix MRI™ active fixation MRI lead|The Medtronic CapSureFix MRI™ active fixation MRI lead is a transvenous, bipolar, silicone, steroid eluting and active fixation pacing lead. It is based on the commercially available Medtronic Model 5076 lead and has been modified for use in the MRI environment. The MRI lead is used for both atrial and ventricular applications.
1872340|NCT01110928|Drug|somatropin|Norditropin® (somatropin) prescribed at the discretion of the physician according to normal clinical practice. Safety and effectiveness data is recorded by the physician, at study initiation and every 6 months until last visit.
1872341|NCT01110941|Drug|S-1, leucovorin, oxaliplatin|S-1(20mg、25mg), capsule, 40~60mg, Bid,p.o., day1~7； LV (25 mg), tablet, 25mg,Bid,p.o., day1~7； L-OHP (50 mg),injection 85mg/m2, day1. repeated at every 2 weeks cycle till disease progression.
1872342|NCT01110954|Drug|PD L 506|Two different doses will be compared
1872343|NCT01110980|Other|Swallow therapy in combination with individual dietary counselling|Weekly swallowing therapy (by speech language therapist) from start of (chemo)radiation until 6 months after last (chemo)radiation. Weekly Individual dietary counselling (by dietician) form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation. With close interaction between the both interventions.
1872344|NCT01110980|Other|Individual dietary counselling|Weekly Individual dietary counselling form the start of (chemo) radiotherapy until 6 months after last (chemo)radiation.
1872345|NCT01111006|Device|Bidet (electronic cleansing toilet system)|The volunteers underwent rectal examinations and baseline manometry at lateral decubitus position. Subjects were then placed on a toilet with Bidet attached and manometry catheter was inserted and fixed placing the channels of the catheter at the high pressure zone (HPZ) of the anal canal. Anorectal pressures were measured before and after using the Bidet under different water pressures (4, 8, 16, 20 gram force, gf), types of water stream (narrow vs. wide), and different temperatures (24oC vs. 38oC).
1872346|NCT01111019|Drug|Recombinant human growth hormone (Somatropin)|Recombinant human growth hormone (Somatropin) will be administered at 0.057 mg/kg/day subcutaneous injection for 3 years, 5 years or until near final height is reached, if applicable. Subjects still under treatment after 31 January 2011 will be treated with a dose reduced to 0.035 mg/kg/day until the end of the study.
1872347|NCT01111045|Drug|Bone morphogenetic protein 7|Comparison of different doses of the drug via single intraarticular knee injection
1872348|NCT01111045|Drug|Placebo|Placebo
1872349|NCT01111058|Drug|Everolimus (RAD 001)|10mg of Everolimus or Placebo taken by mouth once daily for 1 year or until progression (whichever comes first).
1872350|NCT01111058|Other|Placebo|
1872351|NCT01111084|Drug|Follitropin alpha (r-FSH)|The dosage and administration of follitropin alpha was according to each centre's protocol and within technical specification recommendations.
1872352|NCT01111097|Drug|Dichloroacetate|Subjects after passing the inclusion criteria are given a dose of dichloroacetate 4mg/kg bid for thirty days. While in the clinical research center they participate in a breath test where they exhale through a straw into a glass tube. This will measure CO2. They are monitored every two weeks for side effects and return to the clinical research center for evaluation in thirty days. They undergo another breath test and if all health parameters are within normal limits they are given a month's supply of dichloroacetate. The cycles continue unless a serious adverse event occurs or the PI judges the side effects preclude another 30 days of medication
1872353|NCT01111110|Device|anti-static then static|Albuterol using static chambers
1872354|NCT01111110|Device|Static then anti-static chamber|albuterol with Static then anti-static chambers
1872355|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%) ; UItravate ointment (halobetasol propionate ointment 0.05%)|Steroid on weekends only group
1872356|NCT01111123|Drug|Lac-Hydrin lotion (ammonium lactate lotion 12%); placebo ointment|Placebo on weekends only group
1872430|NCT01111747|Procedure|Platelet-rich plasma|Intra-operative use of platelet-rich plasma in the patellar tendon after harvesting its central third for ACL reconstruction.
1872605|NCT01113671|Drug|Placebo|includes inactive Ingredients
1872357|NCT01111136|Behavioral|Stress intervention|To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
1872358|NCT01111149|Other|Sugar Pill|Sugar pill created and masked by the pharmacy to be used as a control.
1872359|NCT01111149|Drug|Varenicline|Subjects in the varenicline group will receive one 1mg pill/day for week 0, followed by two 1mg pills/day for the rest of the study.
1872360|NCT01111149|Drug|Bupropion HCl|in the Bupropion HCl group will receive one 150mg pill/day for week 0, followed by two 150mg pills/day for the rest of the study
1872361|NCT01111162|Biological|H1N1 vaccination|Novartis unadjuvanted inactivated S-OIV H1N1 influenza vaccine 15 mcg administered as single-0.5mL (15mcg) injection intramuscularly into one of the subject's deltoid muscles
1872362|NCT01111188|Drug|PD 0332991|"PD 0332991 will be given on Days 1-12 followed by 9 days of non-treatment in a 21-day cycle. Dose will depend on dose escalation schedule.
(-3a) 50 mg (-3) 50 mg (-2)75 mg (-1)75 mg (1)100 mg (2)125 mg (3)125 mg (3a)100 mg"
1872363|NCT01111188|Drug|bortezomib|"Given as intravenous bolus on days 8, 11, 15, and 18 of 21-day cycle. Dose depends on dose-escalation schedule.
(-3a)1.0 mg/m2 (-3) 0.7 mg/m2 (-2) 0.7 mg/m2 (-1) 1.0 mg/m2 ( 1) 1.0 mg/m2 ( 2) 1.0 mg/m2 ( 3) 1.3 mg/m2 (3a)1.3 mg/m2"
1872364|NCT01111201|Behavioral|questionnaires|The intervention is a self-administered anonymous questionnaire that is voluntarily completed by the patient. Questions in Section One will cover general information about the patient including gender, age, race, country of birth, current zip code of residence, and level of education. Questions in Section Two will cover information regarding the cancer (breast/lymphoma) or transplant (allogeneic/ autologous). Questions in Section Three will cover travel history including the frequency of travel outside the United States and Canada in the last 5 years. Questions in Sections Four through Seven will obtain information about their last trip outside the United States and Canada.
1872365|NCT01111214|Other|no intervention|There is no intervention. This is a non interventional study.
1872366|NCT01111227|Drug|Propofol and isoflurane|Comparison of two anesthetic drugs
1872368|NCT01111266|Device|xevonta|"Patients will be treated with 3 different sizes of xevonta (2 weeks each size) for determination of in vivo KUF following FDA Guidance for the Content of Premarket Notifications for Conventional and High Permeability Hemodialyzers. In addition blood samples will be collected for determination of removal rates of different small molecules and protein."
1872369|NCT01111279|Biological|gpASIT+TM|1 subcutaneous injection every 7 days, during 29 days.
1872370|NCT01111279|Biological|gpAST+TM/adjuvant|1 subcutaneous injection every 7 days, during 29 days
1872371|NCT01111279|Biological|Placebo solution|1 subcutaneous injection every 7 days, during 29 days
1872372|NCT01111292|Drug|Inositol|Given PO
1872373|NCT01111292|Other|Placebo|Given PO
1872377|NCT01111318|Drug|BI 10773|2 tablets BI 10773 25 mg single dose
1872378|NCT01111331|Drug|BI 10773 25 mg|25 mg BI 10773 qd for 5 days
1872379|NCT01111331|Drug|Warfarin 25 mg|25 mg Warfarin single dose
1872380|NCT01111331|Drug|BI 10773 25 mg|25 mg BI 10773 qd for 12 days
1872381|NCT01111331|Drug|Warfarin|25 mg warfarin single dose with and without 50 mg BI 10773
1872382|NCT01111344|Dietary Supplement|Glizigen + Viusid|"Glizigen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).
1 to 3.9 cm2 ______________3 daily applications
4 to 6.9 cm2 ______________4 daily applications
7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.
Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
1872383|NCT01111344|Dietary Supplement|Placebo|"Placebo Glizipen (spray, 60 mL bottle with applicator): Dosage commensurate with surface (up to a maximum of 10 cm2) to be treated. From 3 to 5 ambulatory applications (One nebulization corresponds to 2 short pulses).
1 to 3.9 cm2 ______________3 daily applications
4 to 6.9 cm2 ______________4 daily applications
7 to 10 cm2 ______________5 daily applications Treatment will last from 5 days to 8 weeks according to clinical improvement.
Placebo Viusid (Syrop, 500 mL flask): 12.5 ml every 8 hours for 12 weeks. Viusid syrop should be dissolved in water, fruit juice or milk before ingestion."
1872384|NCT01111357|Biological|Collect of 10 ml of peripheric blood for DNA extraction|After signed written consent, all patients have a clinic exam in order to assess the presence of eligibility criteria (Patient with Rheumatoid Arthritis that fulfil the ACR criteria of diagnosis)
1872385|NCT01111370|Device|DexCom™ G4 Continuous Glucose Monitoring System|Continuous Glucose Monitoring System
1872386|NCT01111383|Drug|tobramycin|"300mg/4ml solution, via a nebuliser, over a 48-week period in a twice-daily regimen, with 6 on cycles of 4 weeks duration during the 48-week period."
1872387|NCT01111409|Device|VFIX Device|Sterile, single-use instrument capable of delivering an absorbable PDS suture anchor
1872388|NCT01111422|Drug|N-acetylcysteine|N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
1872389|NCT01111448|Drug|Temsirolimus|25 mg/day 1; 8; 15; 22 of each 28-day cycle as intravenous infusion over 30 min
1872428|NCT01111734|Dietary Supplement|N-Acetylcysteine|All eligible study subjects will be treated with 600mg of N-Acetylcysteine orally twice a day for 2 weeks, then the dose will be increased to 1200mg twice a day for two weeks, and to 1800mg twice a day for 4 weeks.
1872390|NCT01111461|Drug|Lenvatinib|Lenvatinib 24 mg administered orally, once daily continuously in 28-day cycles to participants with advanced endometrial cancer and disease progression following first-line chemotherapy. Participants continued to receive study drug until disease progression, development of unacceptable toxicity or withdrawal of consent. 'Treatment interruption and subsequent dose reduction' was allowed for participants who experienced lenvatinib-related toxicity.
1872393|NCT01111487|Device|Expiratory positive airway pressure (EPAP) by face mask.|Implementation of the EPAP as group pressure, 10 or 15 cmH2O, for 20 minutes then evaluated the electromyographic activity of muscles and sternocleidomastoid parasternal the tenth and twentieth minutes of your application.
1872394|NCT01111500|Device|Donjoy ER brace|Patients will wear an external rotation brace, the Donjoy ER brace, during treatment.
1872395|NCT01111500|Device|Thoraco brachial brace|Patients will wear an internal rotation brace, a thoraco brachial brace, during treatment.
1872396|NCT01111513|Drug|48-hour ropivacaine infusions|Patients receive 20 ml of ropivacaine 0.5 % pre-operation through femoral block catheter, followed by ropivacaine infusions from 0.1 % to 0.1 ml/kg/hour for 48 hours.
1872397|NCT01111513|Drug|Single dose ropivacaine|Patients receive 20 ml of ropivacaine 0.5% pre-operation
1872398|NCT01111513|Drug|Patient controlled analgesics|Patient controlled analgesics alone, no femoral block
1872399|NCT01111526|Drug|Panobinostat (LBH589)|"Phase I Initial Treatment Plan - Intravenous (IV) Formulation: Up to 4 dose levels (DL) of LBH589 IV formulation to establish LBH589 Maximum Tolerated Dose (MTD) in acute GVHD treatment. The first 4 participants began this treatment plan, before the IV Formulation became unavailable.
DL -1: 1.25 mg/m^2 IV; DL 1: 2.5 mg/m^2 IV; DL 2: 5 mg/m^2 IV; DL 3: 7.5 mg/m^2 IV; DL 4: 10 mg/m^2 IV.
Phase I Revised Treatment Plan - Oral Formulation (to replace IV Formulation): Dose escalation levels for LBH589; participants treated with LBH589 by mouth (PO) 3 times a week (48 hours apart) every week for 4 weeks.
DL -1: 5 mg PO; DL 1: 10 mg PO (starting dose level); DL 2: 15 mg PO; DL 3: 20 mg PO; DL 4: 25 mg PO.
Phase II Treatment Plan: LBH589 PO at MTD, 3 times a week (48 hours apart) every week for 4 weeks."
1872400|NCT01111539|Drug|Escitalopram|Escitalopram monotherapy
1872401|NCT01111539|Drug|Aripiprazole|Aripiprazole monotherapy
1872402|NCT01111539|Drug|Aripiprazole/Escitalopram combination|Aripiprazole/Escitalopram combination therapy
1872403|NCT01111552|Drug|Escitalopram|Escitalopram monotherapy
1872404|NCT01111552|Drug|Aripiprazole|Aripiprazole monotherapy
1872405|NCT01111552|Drug|Aripiprazole/Escitalopram combination|Aripiprazole/Escitalopram combination therapy
1872406|NCT01111565|Drug|Escitalopram|Escitalopram monotherapy
1872407|NCT01111565|Drug|Aripiprazole|Aripiprazole monotherapy
1872408|NCT01111565|Drug|Aripiprazole/Escitalopram combination|Aripiprazole/Escitalopram combination therapy
1872409|NCT01111578|Device|Enteral feeding tube|The esophageal and gastric pressure, measured with this new device, will be recorded and compared with those ones measured with a standard esophageal catheter
1872410|NCT01111591|Drug|Cox2 inhibitor (Celecoxib)|From postoperative third day, administration will be started celecoxib 200mg bid for 6 months for administration group.
1872411|NCT01111604|Biological|IMC-1121B|8 mg/kg I.V. infusion, administered every 2 weeks
1872412|NCT01111604|Biological|IMC-18F1|15 mg/kg I.V. infusion, administered every 2 weeks
1872413|NCT01111604|Drug|mFOLFOX-6|"Oxaliplatin: 85 mg/m² I.V. infusion q2 weeks
FA: 400 mg/m² I.V. infusion q2 weeks (or LFA: 200 mg/m2 q2 weeks if FA is unavailable).
5FU: 400 mg/m² bolus + 2400 mg/m² I.V. infusion q2 weeks"
1872414|NCT01111617|Procedure|Real-time fMRI feedback|Patients receive real-time fMRI biofeedback to modulate pain
1872415|NCT01111630|Drug|recomon (Epoetin Beta)|administer once weekly
1872416|NCT01111630|Drug|recomon (Epoetin Beta)|administer three times weekly
1872417|NCT01111643|Device|Echocardiogram|An echocardiogram will be repeated at every step, from baseline to peak heart rate setting.
1872418|NCT01111656|Drug|Interferon beta-1b group|Patients receive interferon beta-1b 250ug subcutaneously every other day
1872419|NCT01111656|Drug|Interferon beta-1b/Atorvastatin group|Patients receive interferon beta-1b 250ug subcutaneously every other day AND atorvastatin 40mg every day (oral)
1872420|NCT01111669|Drug|Tranexamic Acid|The bolus of TA is prepared according to patient weight (10mg / kg loading dose). The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the TA or saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of 1mg / kg per hour or TA preparation or normal saline for the duration of the operation.
1872421|NCT01111669|Drug|Normal Saline (placebo)|The patients receiving placebo will receive an infusion of normal saline of the same volume of IV solution. Patients will receive the saline infusion on call to the operating room, approximately 30 minutes before onset of the operation. The patients would also receive a continuous infusion of saline for the duration of the operation.
1872422|NCT01111682|Drug|Mannitol|0.9% normal saline infusion and boluses of mannitol
1872423|NCT01111682|Drug|Hypertonic Saline|3% hypertonic saline continuous infusion, with intermittent boluses as needed
1872424|NCT01111695|Device|ApisSept|honey and ionic silver based dressing
1872425|NCT01111708|Procedure|Close Rectal Dissection - IPAA|Comparison between conventional IPAA and Close Rectal IPAA and INRA after (sub)total proctocolectomy for Ulcerative colitis
1872426|NCT01111721|Behavioral|Project POWER HIV Risk-reduction Intervention|Nine session group-based behavioral intervention for incarcerated female adults.
1872427|NCT01111721|Behavioral|NC DOC Standard of Care for STIs|Standard North Carolina Department of Correction intake STI testing and counseling.
1872429|NCT01111734|Drug|fMRI|All eligible subjects and controls will undergo an emotional face-viewing task in our fMRI paradigm in order to focus in on the circuitry related to affect processing.
1872431|NCT01111747|Procedure|Control group|In this group PRP will not be added to the patellar tendon donor site at the end of ACL reconstruction.
1872432|NCT01111773|Drug|Heated Lidocaine and Tetracaine Patch|Patients will apply one lidocaine 70 mg and tetracaine 70 mg topical patch to the affected knee twice daily for approximately 14 days. Patches will be applied morning and evening (applications separated by approximately 8-10 hours).
1872433|NCT01111799|Procedure|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
1872434|NCT01111799|Procedure|endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
1872435|NCT01111799|Procedure|natural cycle + IUI + endometrial biopsy|two endometrial biopsies will be taken with a PIPELLE catheter on days 12 and 21 of the spontaneous menstrual cycle that precedes the fertility treatment.
1872438|NCT01111838|Drug|STA-9090|Patients will be enrolled and receive 200mg/m2 of STA-9090. Patients will receive single agent STA-9090 intravenous (I.V.) infusion (an indwelling catheter may not be used) over 60 minutes weekly (three weeks on and one week off). Follow-up imaging will be performed every 8 weeks to evaluate response.
1872439|NCT01111851|Drug|Fosaprepitant 150 mg|a single intravenous infusion of 150 mg fosaprepitant dimeglumine over 20 minutes on Day 1 15 minutes after consumption of a standard light breakfast meal
1872440|NCT01111851|Drug|Aprepitant 165 mg|a single oral 165 mg aprepitant capsule 15 minutes after consumption of a standard light breakfast meal
1872441|NCT01111851|Drug|Aprepitant 250 mg|a single oral 250 mg dose achieved by administering two 125 mg aprepitant capsules 15 minutes after consumption of a standard light breakfast meal
1872442|NCT01111851|Drug|Dexamethasone (12-8-16-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg twice daily), and Day 4 (8 mg twice daily) with or without a meal.
1872443|NCT01111851|Drug|Dexamethasone (12-8-8-16 mg)|Dexamethasone 12 mg will be administered orally 30 minutes after after aprepitant on Day 1; Oral doses of dexamethasone will be administered on Day 2 (8 mg), Day 3 (8 mg), and Day 4 (8 mg twice daily) with or without a meal.
1872444|NCT01111851|Drug|Ondansetron|The intravenous (I.V.) infusion of ondansetron 32 mg will begin 30 minutes after the start of fosaprepitant dimeglumine or 30 minutes after aprepitant on Day 1 and will be administered as a 15-minute infusion
1872445|NCT01111851|Drug|MK0999|I.V. infusion of MK0999 containing ~100 MBq (~3 mCi) containing ≤ 5 ug of MK0999)
1872446|NCT01111864|Dietary Supplement|fortification with iron and micronutrients|Iron 0 or 2.5 mg; Copper 0.34 mg; 30 µg Iodine; 7 µg Selenium; 2.5 mg Zinc; 100 µg Vitamin A; Vitamin D 5 µg; 5 mg Tocopherol Equivalent; 30 µg Vitamin K1; 10.5 mg Thiamine; 0.5 mg Riboflavin; 0.5 mg Pyridoxine; 90 µg Folic Acid Anhydrous; 6 mg Niacinamide; 60 mg Vitamin C; 0.9 µg Vitamin B12
1872447|NCT01111864|Dietary Supplement|Sprinkles|Daily 12.5mg Ferrous fumarate iron with microntrient is compared to no iron with micronutrients. Duration of intervention is 4 months, 80 infants will be inclulded.
1872448|NCT01111890|Drug|Azarga (brinzolamide 1% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
1872449|NCT01111890|Drug|Cosopt (dorzolamide 2% / timolol 0.5%)|Dosed twice daily at 9:00 AM and 9:00 PM for 12 weeks
1872450|NCT01111903|Drug|Lenalidomide|Phase II: 20 mg/day in continuous regimen Phase I: 25 mg/day 21 days/28 with carboplatine AUC 5 + caelyx 30mg/m2
1872451|NCT01111929|Drug|Counseling for LAM+ LNG-EC|"They will be provided by the above proper LAM counseling and contraceptive counseling. Additionally, they will be provided by EC pills and advised to use these pills if one of the prerequisites of LAM expires and sexual relation with their husband had occurred before the initiation of another long term contraceptive. Each women in this group will be supplied with one packet containing two 0.75 mg Levonorgestrel EC pills and advised to swallow the two tablets as soon as possible after having sexual intercourse with their husband after the expiry of LAM. They will be informed that they should not use the method after more than 5 days of having intercourse.
They will be also advised not to use EC pills more than once. All women who have used the EC pills need to visit the clinic within few days of use for contraception advice. All the above information will be additionally given to the patient in a small flyer."
1872452|NCT01111942|Other|radiation combined with weekly carboplatin|"recommended premedications: Aloxi 0.25 mg IV; Dexamethasone 20 mg IV; Fosaprepitant 115 mg IV; Aprepitant 80 mg PO; Ativan 1.0 mg IV;
Mucositis treatment should involve local measures to maintain oral hygiene, oral nystatin or fluconazole, or valacyclovir for viral infection.
Induction Triple Therapy Treatment with TPF:
Docetaxel (Taxotere) 75 mg/m2 IV; Cisplatin (Platinol) 100 mg/m2 IV; 1500 cc Normal Saline w/20meq KCL, 1 gram MgSo4 IV; 5-Fluorouracil (Adrucil) 1000 mg/m2 day IV-continuous infusion over 4 days; Neulasta* 6 mg SC Day 5 (*Neupogen may be substituted at the investigator's discretion)"
1872500|NCT01112865|Device|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
1872501|NCT01112878|Drug|Sugar pill|"Dosage form: capsule, by mouth
Dosage: not applicable
Frequency and Dosage:
once in the preoperative holding area and once before discharge from PACU
continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
1872888|NCT01124188|Drug|Higher-dose venlafaxine|Dosing of venlafaxine will range from 187.5-300 mg/day.
1960151|NCT03287245|Drug|Idasanutlin|150 milligrams (mg) orally, once daily for 5 days, every 28 days, until treatment discontinuation or up to 2 years.
1872453|NCT01111942|Procedure|conservation surgery|Following induction triple chemotherapy, subjects will be restaged by physical examination and radiological imaging. If there is an absence of unequivocal evidence for residual disease (i.e. an apparent complete response), the subject will undergo conservation surgery under general anesthesia, using a transoral approach. Minimal tissue removal through direct access. The surgical specimen will be evaluated by a pathologist in the manner standard for the institution. The presence of residual tumor will be classified as a partial response to induction triple chemotherapy and the subject will undergo concomitant chemoradiotherapy. If there is no evidence of residual disease in the surgical specimen, the subject will be followed for recurrence.
1872454|NCT01111955|Drug|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
1872455|NCT01111955|Drug|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
1872456|NCT01111955|Drug|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
1872457|NCT01111955|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
1872458|NCT01111955|Drug|Metformin|Capsules, Oral, ≥ 1500 mg, once daily, 28 days
1872459|NCT01112449|Other|Placebo|no active medication
1872460|NCT01112449|Dietary Supplement|selenomethionine|200 µg/day of selenomethionine (SM)
1872461|NCT01112449|Dietary Supplement|low dose selenized-yeast|200 µg/day of SY
1872462|NCT01112449|Dietary Supplement|high dose selenized-yeast|285 µg/day of SY
1872463|NCT01112462|Drug|Paracetamol 500 mg/Phenylephrine 5 mg tablets|2 tablets to be administered orally with 240 ml of water with a 24 hour follow-up period
1872464|NCT01112462|Drug|Paracetamol 1000 mg/Phenylephrine 10 mg sachet|1 sachet dissolved in 240 ml water and administered orally with a 24 hour follow-up period
1872465|NCT01112488|Other|Patient Engagement Programme|Patient's Diary, Ad Hoc medical support and Ad Hoc Clinical admission, Early post discharge Home visit
1872466|NCT01112514|Drug|indocyanine green|Administered intravenously during endoscopic near-infrared (NIR) imaging
1872467|NCT01112527|Drug|PF-00299804|Taken orally once a day
1872468|NCT01112540|Drug|Morphine|0.1 mg/kg Intravenous bolus
1872469|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Heart failure therapy
1872470|NCT01112579|Device|Medtronic PrimeADVANCED Neurostimulator|Medical management
1872471|NCT01112644|Drug|Oxycodone naloxone prolonged release tablets (OXN PR)|Different daily doses; intake every 12 hours
1872472|NCT01112644|Other|Placebo (PLA)|Different daily doses; intake every 12 hours
1872473|NCT01112670|Drug|Sitagliptin|sitagliptin 100 mg x 1 dose
1872474|NCT01112670|Drug|atorvastatin|atorvastatin 40 mg x 5 doses
1872475|NCT01112683|Drug|Memantine|The drug dosage will follow memantine's standard titration schedule (i.e., 5 mg/d week one, 5 mg/BID week two, 5 & 10 mg/d divided dose week three, 10mg/BID week four).
1872476|NCT01112683|Drug|Placebo|These are identically-looking pills to those in the Memantine Arm.
1872477|NCT01112696|Device|Sensor wear|All subjects to wear sensors
1872478|NCT01112709|Behavioral|SCT-based Resistance Training exercise program|Two supervised RT sessions per week for the first 3 months, then a self-monitored RT phase for the remainder of the study, with primarily Internet-based contact.
1872479|NCT01112709|Other|Standard Intervention with minimal contact|This is the control condition for comparison; the approach will be identical to the experimental condition, but without the theoretical components (skills to increase self efficacy for RT, self regulation for RT). Contact with the study staff will be reduced from that received by the experimental group.
1872480|NCT01112722|Biological|Apitox, purified honeybee toxin, lyophilized in saline|intradermal injections of 0.1mg apitox in 0.1ml WFI over 12 weeks treatment period, injections twice weekly range from 1 to 20 injections
1872481|NCT01112722|Biological|histamine|imitates pain and erythema of honeybee venom
1872484|NCT01112748|Drug|Topical lidocaine patch|Topical lidocaine patch 5%; up to 3 patches to cover the area of maximum pain for 12 h a day.
1872485|NCT01112761|Device|Transcranial direct current stimulation|Each type of stimulation will be administered with a time interval of a week in between to prevent any carryover affects.
1872486|NCT01112774|Device|Transcranial direct current stimulation|Stimulation will be applied at 2 mA for a total of 20 minutes.
1872487|NCT01112787|Drug|Tazarotene Foam|Tazarotene Foam
1872488|NCT01112787|Drug|Vehicle Foam|Vehicle Foam
1872489|NCT01112787|Drug|Sodium Laural Sulfate|Sodium Laural Sulfate
1872490|NCT01112787|Drug|Distilled Water|Distilled Water
1872492|NCT01112826|Drug|Capecitabine|capecitabine 650 mg/m2 twice every day for 1 year.
1872493|NCT01112839|Behavioral|Less Intensive|Participants in this group would receive print materials on diet and exercise and two individual counseling sessions; one at the beginning of the study and another 6 months later.
1872494|NCT01112839|Behavioral|Intensive Group|Participants in this group would receive print materials on diet and exercise and attend group sessions that would meet weekly for the first 4 months, then every two weeks for the next 2 months, and then monthly for the next 6 months over the course of one year.
1872495|NCT01112852|Drug|pantoloc 40 mg|pantoloc iv. infusion per day
1872496|NCT01112852|Drug|somatostatin or terlipressin|Somatostatin 6mg in 500 cc 5% dextrose, 250μg slow bolus IV infusion followed by 250μg per hour (6mg/ 24 hours) or Terlipressin 2mg bolus was instituted on enrollment followed by 1mg per 6 hours for 5 days. The use of either somatostatin or glypressin was at the discretion of doctors in charge.
1872497|NCT01112865|Device|Genotropin Pen|Pen provided in 5, 5.3 and 12 mg doses, Dose based on body weight, subcutaneous injection daily for 2 months while in study.
1872498|NCT01112865|Device|MARK VII pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
1872499|NCT01112865|Device|Genotropin Pen|Pen provided in 5, 5.3 and 12mg doses, dose based on body weight, subcutaneous injection daily for 2 months while in study.
1873133|NCT01112150|Device|NormaTec Pump|Normatec Pump
1872502|NCT01112878|Drug|Gabapentin|"Dosage form: capsule, by mouth
Dosage: 600 mg
Frequency and duration:
once in the preoperative holding area and once before discharge from PACU
continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
1872503|NCT01112878|Drug|Clonidine|"Dosage form: capsule, by mouth
Dosage: 0.2 mg
Frequency and duration:
once in the preoperative holding area and once before discharge from PACU
continuation of 1 capsule twice daily with meals, 1 to 4 days after surgery."
1872504|NCT01112891|Drug|Vitamin D|10 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
1872505|NCT01112891|Drug|Vitamin D3|25 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
1872506|NCT01112891|Drug|Vitamin D|50 ug/day Vitamin D as part of standard pre-natal vitamin supplement, taken from 18 weeks gestation to 6 months postpartum.
1872507|NCT01112917|Device|VenaTech Convertible Vena Cava Filter|Prevention of Pulmonary Embolism
1872508|NCT01112917|Procedure|Vena Cava Filter Conversion|Conversion of VenaTech Convertible filter to open configuration.
1872509|NCT01112943|Other|Acupuncture|Acupuncture on predefined points for 20min once a week over seven weeks
1872510|NCT01112943|Other|Pulmonary Rehabilitation|a seven week pulmonary rehabilitation course
1872511|NCT01112943|Other|Pulmonary Rehabilitation|Twice a week for seven weeks. Each session lasting 2 hrs (1hr exercise and 1hr education
1872512|NCT01112969|Behavioral|Internet-based supportive coaching OSCAR|The Internet-based supportive coaching (OSCAR) is an scientifically based multicomponent intervention
1872513|NCT01112969|Other|Waiting-list control group (TAU)|Waiting-list control group (treatment as usual, TAU, no specific intervention)
1872518|NCT01112995|Dietary Supplement|Lactobacillus rhamnosus|1 pill formulation to be given once a day for 4 weeks
1872519|NCT01112995|Dietary Supplement|Sugar pill (placebo)|placebo identical to the active product will be given
1872520|NCT01113008|Procedure|Remote ischemic postconditioning|Patients assigned to remote ischemic postconditioning will undergo three 5-minute cycles of ischemia using a blood-pressure cuff at 200 mmHg, placed on the non-dominant arm, interrupted twice for 5 minutes with the cuff deflated
1872521|NCT01113008|Procedure|Control group|In the control group the procedure will be limited to placing a deflated blood-pressure cuff (pressure: 0 mmHg) for 25 minutes.
1872522|NCT01113021|Device|Photon stimulation by low level laser therapy|
1872523|NCT01113034|Drug|DAS181 dry powder, formulation F02|10 mg delivered dose DAS181 in clear HPMC #3 Capsules
1872524|NCT01113034|Drug|Respitose ML006 (DMV-Fonterra)|Lactose monohydrate
1872525|NCT01113047|Drug|Aliskiren/Amlodipine and Aliskiren/Amlodipine/HCTZ|Aliskiren 300 mg / Amlodipine 10 mg/HCTZ 12.5 mg
1872526|NCT01113073|Other|ventilatory protocol|Ventilatory protocol for short period with four different tidal volumes (12 min)
1872527|NCT01113073|Other|Elastic band|Placement of an elastic band around thorax to reduce thorax compliance
1872528|NCT01113073|Other|passive leg raising test|performing the passive leg raising test
1872529|NCT01113086|Device|Transcranial direct current stimulation|Subjects will receive a total of 10 stimulation sessions on consecutive days, Monday- Friday for a total of two weeks. During each session, 2 mA of tDCS will be applied for 20 minutes over the left or right DLPFC (active or sham).
1872530|NCT01113099|Other|Academic detailing|Education of physicians by pharmacists regarding indications for statins in diabetic patients
1872531|NCT01113125|Drug|Betamethason-17-valerate and fusidic acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
1872532|NCT01113125|Drug|Fusidic Acid|0.4 cm creme is applied and covered with a plaster (treatment under occlusion). Dosage every second or third day Treatment is started one week before removal of the central venous catheter and continued for four weeks
1872533|NCT01113138|Dietary Supplement|Mablet (Magnesium-supplement)|Mablet: Magnesium hydroxide/ -oxide (360 mg/tablet) 3 tablets as a single dose Produced by: Gunnar Kjems APS
1872534|NCT01113138|Drug|Magnesium Sulfate|Solution for a single bolus-infusion, containing 2 grams of magnesium sulfate.
1872535|NCT01113151|Dietary Supplement|Mablet (Magnesium-supplement)|3 tablets daily for 12 weeks of Mablet (360 mg magnesium hydroxide/ -oxide) Produced by: Gunnar Kjems APS
1872536|NCT01113151|Other|Placebo|3 placebo tablets daily for 12 weeks
1872537|NCT01113164|Drug|Ondansetron and Sertraline|capsule 0.25mg twice a day for 21 days and capsule 100mg twice a day
1872538|NCT01113177|Device|Distraction splint therapy|After the diagnosis of unilateral TMJ arthritis with clinical asymmetric mandibular growth deviations the JIA patients are offered treatment with a distraction splint. The appliance consists of an acrylic splint (distraction splint) covering the occlusal surfaces of the teeth in the upper or lower dental arch. The height of the splint is thereafter gradually increased every 6th to 10th weeks in order to optimize the mandible growth in the affected side and thereby reduce the overall asymmetric mandibular growth pattern(non-surgical distraction of the TMJ and mandibular condyle).
1872560|NCT01113398|Drug|AMG 102|AMG 102 will be administered as a continuous intravenous infusion by an infusion pump at 20 mg/kg every 2 weeks over 60 or 30 minutes.
1872561|NCT01113398|Drug|Avastin|Avastin will be administered as a continuous intravenous infusion at 10 mg/kg every 2 weeks (6-week study cycle) over 60 or 30 minutes. Avastin will be given prior to AMG 102.
1872606|NCT01113684|Device|Implantable pulse generator (deep brain stimulator)|This study evaluates the effects of subthalamic deep brain stimulation on central and peripheral nervous system activity in patients who have already had brain stimulators placed as a matter of routine clinical care.
1872539|NCT01113190|Behavioral|Computer-delivered Brief Intervention (CBI)|"The multimedia, interactive Computer BI (CBI) condition will be delivered using tablet computers. The content and format will be easily negotiated by participants. The proposed CBI condition will use actors with 'green screen' to deliver scripted therapist content that will be highly tailored to individual responses. 'Green screens' are standard recording formats that allow for inserting engaging background and other overlays onto recorded material. This program will be viewed on a touch screen tablet computer with audio delivered via headphones. The CBI will be designed in a therapist video-delivered interactive style, that provides tailoring options for reviewing patient goals, providing feedback regarding substance use patterns and consequences, completing a decisional balance exercise, and formulating a change plan. It requires active participation and is not a passive video that is merely viewed."
1872540|NCT01113190|Behavioral|Intervener-delivered Brief Intervention (IBI)|"IBI is a 30-minute intervention session with a master's-level clinician. The interventions will include FRAMES (Miller & Rollnick, 2002): personalized Feedback (regarding substance use, risk factors), emphasis on Responsibility for change, Advice, Menu of options, Empathic clinical behaviors, and support of Self-Efficacy regarding making changes. The interventions are designed to address the primary target behavior of drug use, and will include a tailored review of participants' goals/values, feedback regarding their present substance use patterns and consequences, developing a discrepancy between their substance use and ability to meet goals and values through a decisional balance exercise, and formulation of a change plan tailored for each participant. IBI will be highly individualized to participants' goals, values and substance use, and will will follow similar session outlines and length of delivery as the CBI sessions."
1872541|NCT01113190|Behavioral|Adapted Motivational Enhancement Therapy (AMET)|This session will have a similar general outline to the sessions conducted in the ED, including a review of participants' goals and values, and a review of their substance use and consequences, use of decisional balance exercises as indicated, and review and modification of their change plan. For the AMET intervention, the intervener (at least master's level) will conduct a single session (~30-45 minutes) in the community (HMC ED or our community research office). The therapist will be able to tailor their approach to each individual's needs and motivational state.
1872542|NCT01113190|Behavioral|Enhanced Usual Care (EUC)|The EUC group will receive brief advice to change their drug use, as well as a booklet including information on community support groups, location of substance use treatment centers, mental health services, suicide prevention hotlines, risk of injecting drugs including HIV and hepatitis and HIV prevention and testing information.
1872543|NCT01113203|Behavioral|Resistance training|Progressive high intensity resistance training performed twice a week for 16 weeks, and achieving in 7 exercises for the main muscles, the protocol of 4 sets of 6RM and 2 of 4RM.
1872544|NCT01113229|Drug|Misoprostol|two misoprostol tablets taken orally (400µg)
1872545|NCT01113242|Other|Neuropsychological Assessment|Included patients had clinically idiopathic PD, were over 65 years old and presented with a cognitive complain. A detailed registration of clinical history (including review of motor, cognitive, and neuropsychiatric symptoms, comorbid medical conditions, and medications) and neurologic examination was performed. Exclusion criteria included other conditions than PD that could contribute substantially to the subject's motor and/or cognitive impairment, including neurologic and major psychiatric disorders ( delirium,…) affecting the cognitive functions. Patients with major cognitive impairment (i.e. Mental State Examination (MMSE) <16/30) were also excluded.). Neuropsychological assessment explores working memory, episodic memory ,verbal fluency, executive functions and visuo constructive functions.
1872546|NCT01113255|Procedure|bench-evaluation, of three ventilators|to select in-VITRO the most appropriate ventilator for a given pathology.
1872547|NCT01113268|Other|Cohort|Our main goal is to create a prospective cohort of 1500 patients with a first large myocardial infarction allowing us, in a second step, to identify susceptibility genes for the progression of patients towards chronic heart failure using a candidate gene/candidate pathway approach.
1872548|NCT01113281|Biological|VPM1002 live vaccine|
1872549|NCT01113281|Biological|commercially available live vaccine BCG|
1872550|NCT01113294|Procedure|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
1872551|NCT01113307|Biological|Activated allogeneic white blood cells|The CUREXCELL™ dosage form consists of an activated cell suspension that has been isolated, activated and purified from the peripheral blood of healthy allogeneic donors, by hypo-osmotic shock, using the MacroCure custom closed bag system.The cell suspension is superficially injected throughout the wound bed ( 0.1ml per 1 cm2 of wound bed).
1872552|NCT01113320|Drug|Placebo|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide and identical Placebo will be provided in tablets equivalent of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
1872553|NCT01113320|Drug|Safinamide|Evaluable dose levels are 100 mg (8 days), 200 mg (10 days), and 300 mg (42 days). Intermediate dose levels are 150 mg (Study days 9-11) and 250 mg (Study days 23-25) and have a duration of three days. Safinamide will be provided in tablets of 50 mg in blisters. Dosing will be achieved using appropriate multiples of these tablet strengths
1872554|NCT01113333|Drug|placebo|"Pharmaceutical form:injection
Route of administration: intra-articular"
1872555|NCT01113333|Drug|SAR113945|"Pharmaceutical form:injection
Route of administration: intra-articular"
1872556|NCT01113346|Drug|Filtrum-STI (lignin hydrolytic)|"For children aged less than 1 y.o.: Filtrum-STI, 400mg per day (1/2 tablet 2 times a day) for 7 days.
For children aged 1-4 y.o.: Filtrum-STI, 800mg per day (1 tablet 2 times a day) for 7 days."
1872557|NCT01113346|Drug|Placebo|"For children aged less than 1 y.o.: Placebo, 1/2 tablet 2 times a day for 7 days.
For children aged 1-4 y.o.: Placebo, 1 tablet 2 times a day for 7 days."
1872558|NCT01113372|Drug|Clopidogrel|Clopidogrel 75mg daily.
1872559|NCT01113385|Drug|D-Galactose|Oral galactose will be initiated at a dose of 0.2gm/kg/dose twice daily to a maximum of 15 gm BID for a period of 4 months. The prescribed dose of D-galactose powder will be dispensed to subjects in packets, mixed with 4 ounces of water, and consumed orally.
1872562|NCT01113411|Device|PHILOS™ locked plate system by Synthes Canada©|The surgery will be performed under standardized general anesthetic with a prophylactic antibiotic. The deltopectoral approach is used in all cases. The fracture will be fixed using the PHILOS locked plate system by Synthes Canada ©. Some additional osteosutures may be used. The wound is irrigated and then closed in two layers at the end of intervention. A splint thoracic brace will be installed in all patients before the end of anesthesia.
1872563|NCT01113411|Other|Early and intensive exercise program|"A thoraco brachial brace will be worn for 48 hours following the surgery and then removed for the remainder of treatment. Patients will then start the intensive rehabilitation program without physical therapy. The exercise program will be provided to the patient.
The exercises consist of active and active assisted movements of the shoulder for a period of six weeks, limiting external rotation to 0 °. Patients are encouraged to use their affected limb for daily activities. Strengthening exercises are started the 6th week following surgery and the full program will be completed three months after surgery. Patients who wish can then continue their rehabilitation with a physiotherapist.
The patient will complete a daily diary to validate the frequency and intensity of the exercises."
1872564|NCT01113411|Other|Standard rehabilitation program|The patient will wear the thoraco brachial brace for a period of four weeks following the surgery. It may be taken off for hygiene purposes and dressing up. After the four weeks, the patient will take the brace off permanently and begins an exercise program, writing down the frequency and intensity of the exercises. Physiotherapy is allowed for the remaining part of the three months rehabilitation program.
1872565|NCT01113424|Drug|Nicotine|Single-dose of a new Nicotine Replacement Therapy (NRT) product 2 mg and 4 mg
1872566|NCT01113424|Drug|Nicorette® (Nicotine Gum)|Single-dose of marketed nicotine gum 2 mg or 4 mg
1872567|NCT01113437|Drug|Omalizumab|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.
Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
1872568|NCT01113437|Drug|Placebo|"Omalizumab or placebo by subcutaneous injections, at 4 weekly or 2 weekly intervals.
Dosage is according to manufacturer's guidance and calculated based on body weight and total serum IgE."
1872569|NCT01113463|Drug|TPI 287|Starting dose of 160 mg/m^2 as a 60-minute (± 10 minutes) IV infusion once every 3 weeks, (i.e., 1 cycle = 21 days).
1872570|NCT01113476|Drug|Nab-paclitaxel|Starting dose of 50 mg/m^2 on Day 1, 8 + 15 every 28 days (+/- 2 days)
1872571|NCT01113476|Drug|Bevacizumab|Starting dose of 5 mg/m^2 on Day 1 + 15 every 28 days (+/- 2 days)
1872572|NCT01113476|Drug|Gemcitabine|1000 mg/kg Day 1, 8 + 15 every 28 days (+/- 2 days)
1872573|NCT01113489|Drug|beclomethasone dipropionate|400 mcg/1 ml b.i.d.
1872574|NCT01113489|Drug|placebo|1 ml b.i.d.
1872575|NCT01113502|Drug|Eltrombopag|
1872576|NCT01113515|Drug|Esmolol hydrochloride|
1872577|NCT01113515|Drug|Esmolol hydrochloride|
1872578|NCT01113515|Drug|Esmolol hydrochloride|
1872579|NCT01113515|Drug|Placebo gel|
1872580|NCT01113528|Other|Regenerative therapy (omega 3 PUFA plus low dose aspirin)|Comparison between regenerative bone graft alone and bone graft + Omega-3 and low dose aspirin
1872581|NCT01113528|Drug|Sugar pill|3 times daily
1872582|NCT01113541|Drug|Ziprasidone HCL (oral)|Ziprasidone Hydrochloride 20 to 80 mg administered orally twice a day (40-160 mg total daily dose) for up to 1 year.
1872589|NCT01113567|Dietary Supplement|Lactose-free milk|3.5 g of lactose
1872590|NCT01113567|Dietary Supplement|Whole milk|Whole milk with 24 g lactose
1872591|NCT01113580|Biological|CSL's 2010/2011 Formulation of Enzira® Vaccine|45 mcg of HA antigen in 0.5 mL administered by intramuscular injection into the deltoid region of the arm on Day 0
1872592|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
1872593|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
1872594|NCT01113593|Drug|Formoterol Fumarate|Inhalation solution
1872595|NCT01113593|Drug|Foradil Aerolizer|Dry powder inhaler
1872596|NCT01113593|Drug|Foradil Aerolizer|Dry powder inhaler
1872597|NCT01113606|Other|Obagi New-Derm System|
1872598|NCT01113606|Other|Standard of Care|
1872599|NCT01113619|Drug|RP-G28 or placebo|Qualified subjects randomized to daily dosing with RP-G28 or placebo
1872600|NCT01113619|Drug|RP-G28 or placebo|Daily dosing
1872601|NCT01113632|Drug|Ofatumumab|IV infusion once weekly for a total of 8 weeks. Patients will visit the study center once weekly to receive their IV infusion of ofatumumab. To reduce the possibility of infusion reactions, the first dose of ofatumumab will be administered at a dose of 300 mg. If the initial 300 mg dose of ofatumumab is well tolerated, without occurrence of any infusion-associated AEs of ≥ grade 3, subsequent doses of ofatumumab (i.e., Week 2 through Week 8) will be at a dose of 2000 mg.
1872602|NCT01113645|Procedure|Cerebral perfusion evaluation|The patient who received a craniectomy is included in the study and an information notice given to him. All patients are evaluated by GOS (Glasgow Outcome Score) and neurocognitive tests by FAB (frontal assessment battery) and MMSE (mini mental state examination) scores 1 week prior and 6 and 24 weeks post cranioplasty. Furthermore, hemodynamic monitoring is performed by CT perfusion scan (with quantitative assessment of global and local cerebral flow) 1 week prior and 6 weeks post cranioplasty, as well as by trans-cranial Doppler 1 week prior and 6 and 24 weeks post cranioplasty.
1872603|NCT01113658|Device|SNaP Wound Care System|"The intervention is negative pressure wound therapy (NPWT) with the Spiracur SNaP Wound Care system for the treatment of a variety of acute and chronic wounds including pressure ulcers, trauma wounds, diabetic foot ulcers, venous stasis ulcers, and skin grafts.
The Spiracur SNaP Wound Care system weighs less than 4 ounces, does not utilize an electric pump (device has no electrically powered parts), is fully disposable after use, and is designed for particularly small chronic wounds that require advanced wound care management. It delivers NPWT at a constant pressure level over several days without any required adjustments by the patient or clinician."
1872662|NCT01114152|Drug|Placebo|IV Formulation
1872607|NCT01113710|Drug|Neupro®|Neupro® is the exposure/intervention of interest in this non-interventional study.
1872608|NCT01113723|Device|Fiberoptic bronchoscope|Fiberoptic bronchoscope device
1872609|NCT01113723|Device|CMAC|CMAC Device
1872610|NCT01113736|Biological|AlloMEM™|To investigate whether the use of HPM in a temporary loop ileostomy is beneficial to patients.
1872611|NCT01113749|Other|Feeding Options in Dementia Decision Aid|Structured decision aid on feeding options in dementia care with prompting to share information in discussion with primary treating health care provider.
1872612|NCT01113762|Device|articular surface replacement ASR, DePuy|posterolateral incision
1872613|NCT01113762|Device|ReCap/Magnum modular head, Biomet|posterolateral incision
1872614|NCT01113762|Device|Bimetric stem, mallory/head cup, 28 mm ceramic head, Biomet|posterolateral incision
1872615|NCT01113762|Device|28 mm CrCo head, Trilogy CH cup, VerSys Fiber stem,Zimmer)|posterolateral incision
1872616|NCT01113788|Device|tricuspid isthmus imaging with Cartosound|tricuspid isthmus imaging with Cartosound
1872619|NCT01113814|Device|FibroScan|
1872620|NCT01113814|Device|Acoustic Radiation Force Impulse (ARFI)- Imaging|
1872621|NCT01113827|Dietary Supplement|Olive Extract|Capsule form ingested 1x/day for 6 weeks
1872622|NCT01113827|Dietary Supplement|Placebo|Placebo
1872623|NCT01113840|Behavioral|Exercise|Exercise classes three times per week in a controlled, supervised environment.
1872624|NCT01113840|Behavioral|Control|Control group continues daily life as prior to randomization.
1872625|NCT01113879|Behavioral|Aphasia therapy for anomia|The treatment is a traditional lexical/semantic stimulation approach during which subjects will attempt to name drawings of objects.
1872626|NCT01113879|Behavioral|Aerobic exercise|An aerobic exercise intervention will target cardiorespiratory fitness by progressing from 50-70% of the participants' maximum heart rate.
1872627|NCT01113879|Behavioral|Stretching|Stretching will occur for 50 minutes a day, three days/week for 12 weeks.
1872628|NCT01113892|Device|vascular grafts|All devices will be used to treat patients with peripheral arterial occlusive disease
1872629|NCT01113931|Drug|Doxycyline Hyclate tablet|200 mg tablet, once daily for 7 days
1872630|NCT01113931|Drug|Vibramycin (doxycyline hyclate) capsule|100 mg capsule, twice daily for 7 days, over-encapsulated
1872631|NCT01113944|Behavioral|Program 1|
1872632|NCT01113944|Behavioral|Program 2|
1872633|NCT01113957|Drug|ABT-888|Arm-A subjects will be given ABT-888 on Days 1 -7 every 28 days orally
1872634|NCT01113957|Drug|pegylated liposomal doxorubicin|Arm B subjects randomized to pegylated liposomal doxorubicin on Day 1, every 28 days intravenously.
1872635|NCT01113957|Drug|temozolomide|Arm A subjects will be given temozolomide on days 1-5 every 28 days orally with ABT-888
1872636|NCT01113970|Drug|Indibulin|Indibulin given orally once a day for 5 days followed by a 9 day rest
1872637|NCT01113983|Drug|Transcatheter aortic valve implantation|Transcatheter aortic valve implantation via transfemoral or transapical approach
1872638|NCT01113996|Behavioral|Protein supplementation and strength training|Protein supplementation and strength training
1872639|NCT01113996|Dietary Supplement|Protein supplementation|Protein supplementation
1872640|NCT01114009|Procedure|Lung recruitment maneuver|Lung recruitment maneuver conducted with a PEEP 35 cmH2O and peak inspiration pressure up to 50 cmH2O maintain 2 mins, then find the closing pressure (if possible), after that, PEEP is set higher 2 cmH2O above closing pressure
1872641|NCT01114009|Procedure|Lung protective strategy group|Lung protective strategy group received Lung protective strategy without recruitment maneuver
1872642|NCT01114022|Device|Experimental 1|oeso pharyngeal device
1872643|NCT01114022|Device|Experimental|oeso pharyngeal device
1872644|NCT01114022|Device|experimental 3|oeso pharyngeal device
1872645|NCT01114022|Device|Active comparator|oeso pharyngeal device
1872646|NCT01114035|Genetic|blood samples and skin biopsies|to detect mutations
1872647|NCT01114035|Genetic|Skin biopsies|to detect mutations
1872648|NCT01114048|Drug|Thalidomide, cyclophosphamide, dexamethasone, bortezomib|"Induction therapy with CTD regimen for 4 cycles Thalidomide 50-100 mg P.O. HS D 1~28 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D 1~4, 15-18 Repeated every 28 days
Intensification with Vel-CD regimen for 4 cycles (patients who fail to achieve more than PR after 2 cycles of CTD) Velcade 1.3 mg/m2 IV D1, 4, 8, 11 Cyclophosphamide 150 mg/m² P.O. D 1~4 Dexamethasone 20 mg/ m² IV or P.O. D1, 4, 8, 11 Repeated every 21 days
Bactrim prophylaxis during dexamethasone administration Acyclovir prophylaxis during velcade administration Aspirin medication during thalidomide administration"
1872649|NCT01114061|Device|Insupatch|Applying heat to the infusion site using the insupatch device
1872650|NCT01114087|Drug|Imatinib treatment|Imatinib is a tyrosin-kinase inhibitor
1872651|NCT01114100|Drug|sertraline|starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
1872652|NCT01114100|Drug|placebo|patients received 1 pill, according to their complaints the number of pills was increased to maximally 3
1872653|NCT01114113|Drug|pancelipase/placebo|"ZenPep 20000 units of lipase will be provided for the participant to take with a trigger meal or an identical placebo. This will only be given to those participants willing to consume 2 more identical trigger meals and will not be given for the initial baseline non-trigger and baseline trigger meal. In both of these arms, patients will also be swallowing the SmartPill Capsule."
1872654|NCT01114113|Device|SmartPill capsule|Measurement of a baseline, non-trigger meal intestinal transit by using the SmartPill capsule.
1872655|NCT01114113|Device|SmartPill capsule|"Measurement of intestinal transit of a trigger meal baseline by using the SmartPill capsule"
1872656|NCT01114113|Device|SmartPill capsule|SmartPill capsule
1872657|NCT01114126|Drug|Neu-P11|comparison of different dosages of drug
1872658|NCT01114126|Drug|Neu-P11 placebo|comparison of different dosages
1872659|NCT01114139|Drug|Ferumoxytol|IV Ferumoxytol
1872660|NCT01114139|Other|Placebo|IV Placebo
1872661|NCT01114152|Drug|AZD9742|IV Formulation
1872663|NCT01114165|Other|Detection of microbial DNA in blood by SeptiFast Test|The SeptiFast Test is a multiplex polymerase chain reaction (PCR) test that can detect nucleic acids from the most common pathogens (approximately 90%) responsible for hospital-associated bacteremia and takes approx. 6 hours to perform
1872664|NCT01114165|Other|Pathogen detection by blood culture|Blood culture is a conventional microbiological method of pathogen detection. Results from blood cultures are usually not available until 24 to 72 hours after sampling
1872665|NCT01114178|Other|questionnaire|self completed questionnaire supervised by a technician
1872666|NCT01114191|Drug|ABT-869|2.5mg [5 mg days 1, 8 and 12. 17.5 mg on days 13 and after]
1872667|NCT01114191|Drug|ketoconazole|400 mg days 6-11
1872668|NCT01114204|Drug|Ferumoxytol|IV Ferumoxytol
1872669|NCT01114204|Drug|Iron Sucrose|IV Iron Sucrose
1872670|NCT01114217|Drug|Ferumoxytol|IV Ferumoxytol
1872671|NCT01114230|Drug|AGS-16M8F|IV
1872672|NCT01114243|Device|Ultrasound imaging|
1872673|NCT01114256|Procedure|FNA Biopsy|
1872674|NCT01114282|Drug|velcade|
1872675|NCT01114282|Drug|Pralatrexate|
1872676|NCT01114295|Device|Capsule Endoscopy|Prior to the test, patients will be on a clear liquid diet for 24 hours and will have undergone an overnight fast. If a clear liquid diet is not possible, some patients may undergo a bowel preparation the day before the procedure. On the morning of the test, patients will swallow a video capsule with water. Clear liquids will be permitted after 2 hours, and a light meal permitted 4 hours after swallowing the capsule, if appropriate. No medications will be allowed 2 hours before the procedure and drugs that can delay gastric emptying will be avoided until the study is complete. At 8 hours after ingestion, the sensor array and recorder/battery belt pack will be disconnected and the data will be downloaded onto a computer equipped with software for image viewing. Images are sent through 8 skin electrodes to the recorder, stored and viewed on a RAPID workstation. At the end of the recording, the video is transferred to a computer for analysis.
1872677|NCT01114295|Radiation|CT Enterography|CT enterography at the Brigham and Women's hospital is performed by using intravenous iodinated contrast material (Ultravist 300) and a neutral oral-enteric contrast material containing methylcellulose (Volumen). During scanning, 150 mL of nonionic intravenous contrast medium will be administered at a rate of 3mL/sec and the imaging conducted 40 and 70 seconds after the administration of the intravenous contrast medium. All imaging will be performed on a Dual-Energy multi-detector row CT scanner, Somatom Definition (Siemens Healthcare, Forcheim, Germany). Two independent X-ray tube/detector system will be used for image acquisition. One tube operates at 140 kV and the other at 80 kV . Slice collimation will be 0.6 mm and images reconstructed at 3 mm thickness with 3 mm reconstruction intervals. Coronal and sagittal images will be reconstructed at 3 mm thickness with 3 mm increments. Images will be reviewed by a radiologist experienced in the interpretation of CT enterography.
1872678|NCT01114308|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
1872679|NCT01114308|Drug|placebo implant|Implant contains ethylene vinyl acetate
1872680|NCT01114308|Drug|Buprenorphine|sublingual buprenorphine/naloxone tablets
1872681|NCT01114321|Behavioral|Protein and calorie controlled diet|Protein and calorie controlled diet Self-hypnotic relaxation
1872682|NCT01114334|Behavioral|Guideline-Based Medical Management|We used the Colorado Clinical Guidelines Collaborative treatment guideline for Major Depression. It recommends treatment options e.g. specialty mental health counseling, antidepressant treatment, physical activity, depending upon presenting symptoms severity and other factors. The assessor notifies the clinician at the baseline visit about the patient's PHQ-9 depressive symptom severity score.
1872683|NCT01114334|Behavioral|Motivational Interviewing for Depression|Intervention providers receive training to utilize Motivational Interviewing to frame discussions around depression, and to improve treatment uptake and treatment adherence for depression. Primary care providers are encouraged to apply MI to a broad conceptualization of 'treatment' including specialty mental health referral, antidepressant treatment, physical activity, and to targeting contributing factors e.g. loss of job or physical health problems.
1872684|NCT01114347|Dietary Supplement|cranberry type A pro anthocyandines|One gel capsule containing cranberry PAC (36 mg of type A pro anthocyandines: Urell, Pharmatoka) per day starting at the day of the pelvic surgery (j0) until day 10 postop (j10). The gel capsule in taken orally in the morning with a large glass of water
1872685|NCT01114347|Dietary Supplement|Placebo|One placebo gel capsule per day starting on the day of the pelvic surgery (j0) until the 10th day post-op (j10). The gel capsule is taken orally in the morning with a large glass of water. The placebo contains lactose and is conditioned in a manner to be identical in caliber and color with the experimental treatment gel capsules.
1872686|NCT01114360|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 8 mg time-release melatonin pills, orally, once per night for 4 weeks.
1872687|NCT01114360|Drug|Placebo|Subjects received placebo pills (3 pills of 8 mg each) to be taken orally once per night for 4 weeks.
1872688|NCT01114373|Drug|Melatonin|Melatonin (N-acetyl-5-methoxytryptamine) is an indoleamine compound. Subjects will receive 24mg of time release melatonin pills (3 x 8mg) to be taken orally at night for 4 weeks.
1872689|NCT01114373|Drug|Placebo|Subjects will receive placebo pills (3 pills) to be taken orally once per night for 4 weeks.
1872690|NCT01114386|Procedure|Lung function testing, echocardiography, blood sampling|"All patients will undergo to:
physical examination
6' Minute Walk test
pulmonary function testing (spirometry + volumes and reversibility testing)
carbon monoxide diffusing capacity (DLCO) with single-breathe technique
ECG
echocardiography"
1872691|NCT01114399|Dietary Supplement|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
1872692|NCT01114399|Dietary Supplement|Diet and Vascular Health|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
1872816|NCT01123512|Device|Vertebral augmentation|Vertebral augmentation for one or two osteoporotic vertebral compression fractures
1872693|NCT01114399|Dietary Supplement|Diet and Vascular Health Study|One group will consume 400g of standard broccoli each week for 12weeks; the second group will consume 400g of the high glucosinolate broccoli each week for 12weeks while the third group will consume 400g of peas each week for 12weeks. The broccoli and the peas will be consumed on top of the volunteer's standard diet.
1872694|NCT01114425|Drug|raltegravir (Isentress)|raltegravir (Isentress) 400 mg bid
1872695|NCT01114425|Drug|Truvada®|
1872696|NCT01114438|Device|EndoBarrier Gastrointestinal Liner|EndoBarrier Gastrointestinal Liner is intended to remain in vitro for 12 months.
1872697|NCT01114451|Procedure|Removal of surgical skin staples|Skin staples will be removed using standard technique with subsequent placement of steri-trips
1872698|NCT01114490|Drug|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
1872699|NCT01114503|Drug|Otelixizumab - low dose|8 day dose rising intravenous infusions of a low dose of otelixizumab
1872700|NCT01114503|Drug|Otelixizumab - medium low dose|8 day dose rising intravenous infusions of a medium low dose of otelixizumab
1872701|NCT01114503|Drug|Otelixizumab - medium high dose|8 day dose rising intravenous infusions of a medium high dose of otelixizumab
1872702|NCT01114503|Drug|Otelixizumab - high dose|8 day dose rising intravenous infusions of a high dose of otelixizumab
1872703|NCT01114503|Drug|Otelixizumab|8 day dose rising intravenous infusions of otelixizumab administered at a dose decided upon results from Part A.
1872704|NCT01114503|Drug|Methylprednisolone|Weekly intravenous infusions of methylprednisolone administered as 500 mg per week for 6 weeks and then 250 mg per week for 6 weeks
1872705|NCT01114516|Drug|Indomethacin and antibiotics (cefazolin or clindamycin)|q8hr dosing of po indomethacin 50mg X 24 hrs and q8 hr 1 g IV cefazolin or 600 mg IV clindamycin
1872706|NCT01114529|Drug|Everolimus|Early CNI to everolimus conversion
1872707|NCT01114529|Drug|Prograf or Neoral|Active CNI-based control (Prograf or Neoral)
1872710|NCT01114555|Drug|Bevacizumab, Irinotecan and Temozolomide|Patients will initially receive bevacizumab IV at 15mg/kg/dose (this is defined as Day 1 Three days later (starting day 4), they will receive concurrently, IV irinotecan at 50mg/m2/day x 5 days plus PO temozolomide 150mg/m2/day x 5 days. A second dose of bevacizumab will be administered 14 days after the first one(day 15). The treatment schedule may require minor adjustment as clinically indicated (e.g., due to PDH closure for holidays).
1872711|NCT01114568|Drug|Ertugliflozin 10 mg tablet|A single dose of 10 mg ertugliflozin administered as 2x5 mg material sparing formulation tablets.
1872712|NCT01114568|Drug|Ertugliflozin OC Fast|Formulation B) Ertugliflozin 10 mg OC Fast
1872713|NCT01114568|Drug|Ertugliflozin OC Slow|Formulation C) Ertugliflozin 10 mg OC Slow
1872714|NCT01114581|Drug|Mucinex|Mucinex 1200mg (Guaifenesin) given as 2,600mg tablets, one time on day 1 of the study
1872715|NCT01114581|Drug|Placebo|Placebo given as 2 tablets
1872716|NCT01114607|Drug|GSK1605786 ChemoCentryx: formulation A|ChemoCentryx formulation A will be an opaque Swedish orange body, blue coloured capsule with size zero, administered 30 minutes after standard breakfast.
1872717|NCT01114607|Drug|GSK1605786 GSK: formulation B|GSK1605786 formulation B will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
1872718|NCT01114607|Drug|GSK1605786 GSK direct-fill: formulation C|GSK1605786 formulation C will be an opaque Swedish orange body capsule with size 1, administered 30 minutes after standard breakfast.
1872719|NCT01114607|Drug|GSK1605786 GSK modified-process: formulation D|GSK1605786 formulation D will be an opaque Swedish orange body capsule with size 0, administered 30 minutes after standard breakfast.
1872720|NCT01114607|Drug|GSK1605786 GSK tablet: formulation E|GSK1605786 formulation D will be a pink coloured film coated tablet, administered 30 minutes after standard breakfast.
1872724|NCT01114672|Drug|50,000 Units Ergocalciferol|50,000 Units oral ergocalciferol to be given once weekly
1872725|NCT01114672|Drug|Placebo|oral placebo once weekly
1872726|NCT01114685|Dietary Supplement|AlgaeCal-1|Daily consumption of 7 capsules containing bone health ingredients
1872727|NCT01114685|Dietary Supplement|AlgaeCal-2|Taking 7 capsules a day for six months
1872728|NCT01114698|Drug|Venlafaxine XR|Venlafaxine XR 75 mg/day administered orally once daily as 2 capsules identical in appearance to JNJ26489112 during the first week increased to 150 mg/day during weeks 2 through 6.
1872729|NCT01114698|Drug|Placebo|Placebo: 2 capsules identical in appearance to JNJ26489112 and venlafaxine XR orally administered once daily for 6 weeks.
1872730|NCT01114698|Drug|JNJ26489112|JNJ26489112 500 mg/day orally administered once daily as 2 capsules for the first 3 weeks, then dose may be increased to 1000 mg/day by week 4.
1872732|NCT01114737|Drug|Sapropterin dihydrochloride|A dose of 20 mg/kg/day will be administered. Route of administration is oral (intact).
1872733|NCT01114737|Drug|Placebo|Placebo (tablet without active ingredient) is dosed once/day for the first 13 weeks of the study.
1872734|NCT01114750|Drug|Insulin in dextran matrix capsule (and placebo)|Single dose capsule (and placebo)
1872735|NCT01114789|Other|Proteolysis|protocol designed to examine the effect of obesity on muscle proteolysis in hemodialysis and control
1872736|NCT01114802|Behavioral|Project Onward website + social network|The website will include 8 weeks of Internet-based cognitive behavioral therapy combined with discussion and support from a group of up to 8 other cancer survivors.
1994722|NCT02936401|Behavioral|MBSR|Mindfulness Based Stress Reduction (MBSR) is a standardized 8 week course taught by trained instructors.
1994723|NCT02936206|Drug|Fulvestrant|fulvestrant 750 mg (three 5 ml injections slowly over 1-2 mn per injection in the buttocks) on day 1 only
1994724|NCT02936206|Drug|Tamoxifen|14 days of treatment with tamoxifen 20mg orally each day
1994725|NCT02937298|Dietary Supplement|Control Meal|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream
1994726|NCT02937298|Dietary Supplement|Berry Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a berry smoothie. The berry smoothie consists of blueberries, raspberries and blackberries.
1872737|NCT01114802|Behavioral|Project Onward website|Access to an interactive website that provides 8 weeks of Internet-based cognitive behavioral therapy.
1872738|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 3.75 mg after breakfast for 7 days
1872739|NCT01114828|Drug|OPC-41061|Once-daily oral administration of OPC-41061 at 7.5 mg after breakfast for 7 days
1872740|NCT01114841|Drug|Tazarotene Foam|"Patches containing Tazarotene Foam 0.1% will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.
There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).
These patches will then be evaluated at 24, 48, and 72 hours.
There may be a second rest period and a second 48-hour patch application and evaluation, if required."
1872741|NCT01114841|Drug|Vehicle Foam|"Patches containing Vehicle Foam will be applied to randomized sites on the subject's back and will be assessed 3 times per week for 3 weeks. Patches will be removed and evaluated every 48 to 72 hours.
There will be a 10-14 day rest period followed by a single 48-hour patch application (challenge).
These patches will then be evaluated at 24, 48, and 72 hours.
There may be a second rest period and a second 48-hour patch application and evaluation, if required."
1872742|NCT01114854|Drug|Topiramate IR|
1872743|NCT01114854|Drug|Topiramate ER|
1872744|NCT01114880|Biological|adalimumab|Prefilled syringe, 40 mg/0.8 mL administered subcutaneously every other week
1872745|NCT01114880|Other|placebo|Prefilled syringe, matching placebo administered subcutaneously every other week
1872746|NCT01114893|Drug|Travoprost 0.004%|1 drop in each eye once daily for five days, and 1 drop vehicle in each eye 7 times daily for 5 days
1872747|NCT01114893|Drug|Travoprost Vehicle|1 drop in each eye 8 times daily for 5 days
1872748|NCT01114893|Drug|Travoprost (Groups A, B and C)|1 drop in each eye 8 times daily for 5 days
1872749|NCT01121484|Drug|desvenlafaxine succinate sustained-release|50-mg DVS SR tablets taken orally once daily.
1872750|NCT01121484|Drug|placebo|Placebo tablets taken orally once daily.
1872751|NCT01121497|Drug|Physostigmine|Intravenous bolus of physostigmine 1 mg, 3-5 minutes before completion of the colonoscopy procedure
1872752|NCT01121510|Device|closure device|the invasive specialist must carefully manage the difficult balance of patient anticoagulation and coagulation for stopping the bleeding at the femoral artery puncture site. the QuickClose design 9 system is designed to benefit the patients and the medical staff by improving the process. the risks to patients associated with this study are considered reasonable in comparison to the anticipated benefits to the subjects, and the scientific knowledge that can be gained from the study.
1872753|NCT01121523|Behavioral|Cue directed tactile stimulation|Cue-based tactile stimulation delivered to medically stable premature infants three times daily by mothers or trained NICU nurses daily for 4 consecutive weeks
1872754|NCT01121536|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
1872755|NCT01121549|Drug|Aromasin|25 mg daily continuously
1872756|NCT01121562|Drug|Sunitinib|Sunitinib capsule will be given orally at continuous daily dosing with a dose of 37.5 mg in the morning (regardless fasting or non-fasting, One cycle will be 28days)
1872757|NCT01121575|Drug|PF-02341066|Arm 1: The starting dose will be 200 mg by mouth, twice a day of PF 02341066 in tablet form The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
1872758|NCT01121575|Drug|PF-00299804|Arm 1: The starting dose will be 30 mg by mouth once a day of PF-0029804 in tablet form. The dose of each drug in the combination [PF-02341066 and PF-00299804] will be escalated or de-escalated until the maximum tolerated combined dose is reached. Patients will then be treated with the maximum tolerated combined dose.
1872759|NCT01121575|Drug|PF-02341066|Arm 2: With progressive disease the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
1872760|NCT01121575|Drug|PF-00299804|Arm 2: The dose of 45 mg by mouth once a day of PF-00299804 in tablet form until progressive disease and then the maximum tolerated combined dose of PF-02341066 (given by mouth twice a day in tablet form) and PF-00299804 (given by mouth once a day in tablet form).
1872761|NCT01121588|Drug|Crizotinib|Crizotinib tablets, 250 mg BID, will be administered orally on a continuous dosing schedule
1872762|NCT01121601|Procedure|hepatic surgery of resection|after metastasis liver resection , Coseal will be administered at 4 mL by dose, administration of 1 to 3 dose in fontion of liver adherence Coseal will be administered by spray at 5 to 10 cm of liver.
1872763|NCT01121601|Procedure|hepatic surgery of resection|this is a liver metastasis resection according to liver chirurgical guidelines study drug not administered in this group
1872764|NCT01121614|Device|LOTUS|Device used to seal blood vessel
1872765|NCT01121614|Device|Ethicon Harmonic Scalpel|
1872766|NCT01121614|Device|LigaSure bipolar vessel sealing device|
1872767|NCT01121627|Other|Computerized cognitive training|A 12 week computerized cognitive training at home with the Attengo™ software program.
1872768|NCT01121640|Procedure|CA125 assay on Abbott Architect i1000SR platform|Bead-based sandwich ELISA style assay
1872769|NCT01121640|Procedure|HE4 assay on Architect i1000SR platform|Bead-based sandwich ELISA style assay
1872770|NCT01121640|Procedure|Transvaginal Ultrasound|Sonogram will be obtained only if confirmatory markers are elevated. Exam is restricted to ovarian evaluation.
1872771|NCT01121653|Drug|Magnogene ® (magnesium)|evaluate on pain scores (neuropathic pain questionnaire and pain numeric scale) and on quality of life, the effect of oral magnesium intake on patients with neuropathic pain comparing with patients receiving placebo,. The study drug will be taken during 4 weeks.
1872772|NCT01121666|Drug|Follitropin alfa|150IU per day subcutaneously for a maximum of 16 days
1872773|NCT01121692|Behavioral|Couples Intervention|The Couples intervention is a merged intervention of three interventions (Women CoOp, men as partners's and couples). Couples attend together for two half day workshops and work on exercises on communication and problem solving, including a commitment pledge of fidelity.
1872817|NCT01123525|Drug|Adenosine|1.2 mM adenosine instead of supranormal potassium in the cardioplegic solution
1872883|NCT01124149|Drug|MMX mesalamine/ mesalazine|4.8g/day given QD (four 1.2g tablets) for 8 weeks, 2.4g/day given QD (two 1.2g tablets) for 12 months
1872774|NCT01121692|Behavioral|Women's CoOp|The Women's CoOp is a gender-focused intervention discussing women's risk in relationship to HIV and also discusses issues of HIV with South African women including skills for violence prevention. During this intervention, participants will also demonstrate the proper use of male and female condoms on penile and vaginal models. They attend two half day workshops.
1872775|NCT01121692|Behavioral|Women's CoOp and Men's Intervention|The Men's CoOp is adapted from Men as Partners, the Women's CoOp and the Couples intervention and contain similar material with a concentration on gender roles and violence prevention. Men attend two half day workshops.
1872776|NCT01121705|Drug|Peg Interferon alpha2b + Ribavirin|"B 1 I or II: Experimental
variable duration of treatment group according with RVR. In case of RVR present patients will be treated for 12 weeks. Patients without RVR will be treated for 24 (B1I) or 36 (B1II)weeks: different duration of treatment for patients without RVR"
1872777|NCT01121718|Drug|ICG Intervention|NIR-guided sentinel lymph node mapping with indocyanine green (ICG)
1960163|NCT03285932|Radiation|post-operative stereotactic radiosurgery (SRS)|"For radiosurgery, patients will be immobilized. Treatment planning including the MRI and planning CT should be performed 1 -2 weeks before SRT and treatment finished at latest 3-4 weeks after surgery. Planning should be as close to SRT as possible.
Organs at risk such as the brain stem, optic nerves, chiasm and spinal cord will be contoured. The Clinical Target Volume 1 (CTV1) will be defined as the resection cavity based on MRI and CT including T1 contrast enhanced changes around the resection cavity. The Clinical Target Volume 2 (CTV2) will be defined as a 3mm margin added to CTV1 by isotropic expansion and slightly adjusted as deemed appropriated by the experienced contouring physician. The Planning Target Volume (PTV) will be an additional margin of 1mm added to CTV2 by isotropic expansion.
Treatment planning will be performed using Accuray's Multiplan or subsequent approved treatment planning systems for Cyberknife."
1872781|NCT01121744|Device|Supralimus-Core™ Sirolimus eluting Coronary Stent|Supralimus-Core™ Coronary Stent System consisting of the Coronnium® coronary stent (CE approved) having Biodegradable Polymeric Matrix on a Co-Cr alloy Platform. Sirolimus Drug concentration is 1.4 µg/mm2.
1872782|NCT01121757|Drug|azacitidine|Azacitidine 75 mg/m2 SC or IV on days 1-5; subjects will begin Part 2 at the azacitidine dose level tolerated in Part 1a.
1872783|NCT01121757|Drug|lenalidomide|Lenalidomide dose is 15mg po per day on days 1-21; starting dose during Part 2 will depend upon how well the subject tolerated drug during Part 1.
1872784|NCT01121770|Drug|fondaparinux sodium injection|1.5mg subcutaneously every day
1872785|NCT01121783|Other|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml) is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
1872786|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of lactisole solution (0.25mg/ml)is administered as a bolus (1ml/kg body weight) via intragastric tube. After 15 minutes tap water will be administered as a bolus via the intragastric tube.
1872787|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of tap water(is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes a 1M glucose solution is administered as a bolus via intragastric tube.
1872788|NCT01121783|Dietary Supplement|Lactisole|A pre-infusion of tap water is administered as a bolus (1ml/kg bodyweight)via intragastric tube. After 15 minutes tap water is administered as a bolus via intragastric tube.
1872789|NCT01121796|Dietary Supplement|Vitamin D|
1872790|NCT01121796|Other|Water or milk|
1872791|NCT01121796|Dietary Supplement|Vitamin D enriched milk|
1872792|NCT01121809|Drug|Raltegravir|Changing the dose of raltegravir from 400 mg bid to 800 mg qd
1872793|NCT01121809|Drug|Etravirine|Changing the dose of etravirine from 200 mg bid to 400 mg qd
1872794|NCT01123317|Drug|Oxytocin|Subjects will be randomly assigned to either OT-Placebo or Placebo-OT order for PET scan drug administration and will receive the first of the two intranasal doses at Pet scan 1 and the second intranasal dose of the subsequent treatment at Pet Scan 2
1872795|NCT01123330|Behavioral|Motivational Interviewing|
1872796|NCT01123343|Device|TrueVision 3D Visualization and Guidance System for MicroSurgery|Adjunct imaging tool (to the microscope oculars) that provides onscreen video guidance for alignment, orientation, and sizing during eye surgery, based on a surgeon's defined nomogram
1872797|NCT01123356|Drug|Ofatumumab|"Ofatumumab 2000 mg (300 mg on first cycle) IV on day 1 for up to 6 cycles (28 day cycles)
Treatment to be administered for up to 6 cycles"
1872798|NCT01123356|Drug|Lenalidomide|-Lenalidomide 10 mg (5 mg on first cycle) PO days 8-28 for up to 6 cycles (28 day cycles)
1991335|NCT01231633|Drug|Ozurdex|Ozurdex, 0.7mg dexamethasone
1991336|NCT01231633|Drug|Avastin|Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
1872801|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
1872802|NCT01123395|Drug|colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet dissolved in apple juice
1872803|NCT01123408|Drug|Clozapine|500 mg/day
1872804|NCT01123408|Drug|Olanzapine|20 mg/day
1872805|NCT01123408|Drug|Haloperidol|20 mg/day
1872806|NCT01123447|Procedure|Open reduction and internal fixation|Patients will undergo surgery for open reduction of the fracture and internal fixation with an LC-DC plate and screw fixation.
1872807|NCT01123447|Procedure|Closed reduction and short-arm cast|Patient will undergo a closed reduction and be placed in a short-arm (below-elbow) cast for 6 weeks.
1872808|NCT01123460|Other|enzyme-linked immunosorbent assay|
1872809|NCT01123460|Other|laboratory biomarker analysis|
1872810|NCT01123473|Drug|capecitabine|
1872811|NCT01123473|Drug|cisplatin|
1872812|NCT01123473|Drug|epirubicin hydrochloride|
1872813|NCT01123473|Drug|fluorouracil|
1872814|NCT01123473|Drug|lapatinib ditosylate|
1872815|NCT01123486|Drug|hydromorphone|hydromorphone 0.02 mg/kg
1992906|NCT03276780|Behavioral|Counseling|Both groups receive smoking cessation counseling although one is focused on medication adherence and addressing barriers to adherence while the other is focused on standard behavioral strategies to quit smoking
1872820|NCT01123551|Drug|nebulized morphine|After randomization, patients will receive 10 mg of morphine (1ml) diluted in 4 ml normal saline and nebulized with 6 l/mn during 10 min. Nebulization will be repeated systematically 3 times every twenty minutes unless the patient pain was resolved (VAPS 30%). In addition, patients receive a bolus of IV placebo(5 ml normal saline . IV placebo (2 ml) will be repeated every 10 minutes if the objective of analgesia was not reached .
1872821|NCT01123551|Drug|Intravenous morphine|After randomization, patients will receive a bolus of 5 mg of IV morphine (5 ml. Then, 2mg of IV morphine (2ml) will be added every 10 minutes if the objective of analgesia was not reached (VAPS >30%). In addition, normal saline (5ml)is nebulized with 6 l/mn during 10 min and will be repeated systematically every 20 minutes unless the patient's pain was not resolved (VAPS >30%).
1872822|NCT01123564|Drug|ranibizumab|applied monthly in the first 3 months period, and after this only if visual acuity (VA) decreases with more than 5 letters at any monthly visits
1872823|NCT01123564|Radiation|Argon laser treatment|Conventional grid pattern argon laser treatment and panretinal argon laser photocoagulation in an as needed basis.
1872824|NCT01123577|Other|Home Blood Pressure Monitor Group|Participants receive home monitors, modems, educational materials and training. Participants will send home BP readings to research database monthly and receive usual care by providers for 9 months.
1872825|NCT01123616|Procedure|abdominal wall closure|triclosan-coated (PDS-Plus) and non-coated (PDS) suture to close the abd. wall
1872826|NCT01123655|Drug|APL A12|IND 103860: The study drug APL A12 is a man made (or synthesized) fragment similar to a portion of natural type II collagen, the major collagen found in joint cartilage. Cartilage is the tough, elastic tissue found in various parts of the body, including the joints. The best dose of APL A12 to use in patients with rheumatoid arthritis is not known.
1872827|NCT01123681|Device|Choice of endotracheal tube|Types of endotracheal tube, normal cuff without sub-glottic aspiration, normal cuff with sub-glottic aspiration, Special cuff with sub-glottic aspiration
1872829|NCT01123707|Drug|Aripiprazole/Escitalopram combination therapy|Aripiprazole/Escitalopram combination therapy: 3 mg/10 mg, 3 mg/20 mg, 6 mg/10 mg, 6 mg/20 mg, 12 mg/10 mg or 12 mg/20 mg
1872830|NCT01123759|Other|Feeding low mercury fish|Subjects fed 6 oz of either tilapia (low omega-3 fish) or salmon (high omega-3 fish) for 3 months. Both fish are low in mercury
1872831|NCT01123772|Drug|INO-8875|eye drops for 14 days in one eye
1872832|NCT01123772|Other|Placebo control|Matched placebo
1872833|NCT01123785|Drug|INO-8875|eye drops for 14 days in one eye
1872834|NCT01123785|Drug|Placebo|Matched vehicle-control
1872835|NCT01123798|Device|near-infrared spectroscopy|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
1872836|NCT01123811|Drug|Cetuximab IF|Cetuximab loading dose 400 mg/m² weekly dose 250 mg/m² Irinotecan 80 mg/m2 i.v. over 2 hours day 1, 8, 15, 22, 29, 36 Folinic acid 200 mg/m2 over 24 hours day 1, 8, 15, 22, 29, 36 FA will be given as sodium folinate 5-FU 1500 mg/m2 continuous infusion over 24 hours day 1, 8, 15, 22, 29, 36
1872837|NCT01123824|Drug|CLOPIDOGREL|"Pharmaceutical form: tablets
Route of administration: oral"
1872838|NCT01123824|Drug|placebo|"Pharmaceutical form: matching tablets
Route of administration: oral"
1872839|NCT01123837|Other|Intravenous fluid|"The treatment group will receive a 250cc bolus over 2 hrs of D5LR prior to the end of surgery and continued in the PACU. Blood glucose will be checked 3 different times using an Accu-chek monitor along with the type and number of rescue medications given at 30, 60, and 120 minutes after anesthesia and the post-op morning.
The control group will receive a 250cc bolus over 2 hours of LR. Blood glucose will be monitored 3 times along with the type and how much of rescue medications are given at 30, 60 and 120 minutes post-op and the morning after surgery."
1872840|NCT01123837|Other|D5LR or lactated ringers|"The purpose of the study is to see if giving dextrose fluid in the veins (IV) decreases the risk of postoperative nausea and vomiting (PONV) in female urologic, gynecologic and breast outpatient surgery patients and at what blood sugar level.
The reason for this study is that IV dextrose may decrease the incidence of PONV and the use of medications to treat PONV, while leading to sooner discharge after surgery. This can decrease overall healthcare cost and improving patient satisfaction."
1872841|NCT01123850|Device|Copios|Bone Void Filler
1872842|NCT01123863|Other|Brigance Preschool Screen -II|Three-year-old children with SCD who are followed at the St. Jude Children's Research Hospital Sickle Cell Center will be offered developmental screening with the Brigance Preschool Screen II during their regular clinic visits. Along with the screening test, socioeconomic data will be collected using a short questionnaire. Families will be asked to participate in this study by allowing us to collect their test results, medical information and socioeconomic data to compare with data collected from the control group. Parents who decline participation in this study will still be offered the Brigance Preschool Screen II as part of their child's clinical care.
1872843|NCT01123863|Other|Brigance Preschool Screen -II|"Children in the Control Group will be given the Brigance preschool Screen-II Screening at the daycare they attend. The STARR coordinators have selected four daycare centers that have agreed to serve as control group sites. The family will be asked not to respond or aid the child during the assessment. One parent/guardian will fill out the Socioeconomic Data Collection Form while the examiner works with the child.
The screening requires the child to give both verbal and non-verbal responses. The examiner records responses on the Three-Year-Old Child Data Sheet for the Brigance Preschool Screen-II. After the screening is complete the examiner collects the Socioeconomic Data Collection Form from the parent and leaves the room to score the assessment and write recommendations. The examiner then returns to the clinic room to discuss the results with the parent/guardian."
1872844|NCT01123876|Drug|Veliparib|Subjects will be given Veliparib twice daily on Days 1-5 and 15-19 every 28 days orally
1872879|NCT01124123|Drug|Bilastine|20 mg oral tablet
1872880|NCT01124123|Drug|Bilastine|10 mg endovenous bilastine
1872881|NCT01124136|Device|Neurostimulation|Implantation of neurostimulator
1872882|NCT01124136|Other|Standard of Care Therapy|Standard of Care Therapy
1872845|NCT01123889|Biological|platelet rich plasma injection|45 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP). Under sterile conditions, patients will receive a 5 cc PRP injection (consisting of their own PRP) with 1 cc of 1% lidocaine and 1 cc of 0.5% ropivacaine into the subacromial space, administered by an orthopedic surgeon. This will be done using a posterior lateral approach. The patient will be monitored for 10 minutes in clinic for adverse reactions.
1872846|NCT01123889|Drug|corticosteroid injection|Under sterile conditions, patients will receive a 5cc injection consisting of 2cc 1% lidocaine, 2cc 0.5% ropivacaine, and 1cc kenalog corticosteroid (40mg/cc) into the subacromial space utilizing a posterior lateral approach. Patients will be observed for 10 min in clinic for any adverse reactions.
1872847|NCT01123902|Device|hand-held fan|Patients are instructed to direct the hand-held fan towards the face around the central part of the face, the sides of the nose and above the upper lip. The hand-held fan has three soft rotor blades and an unfoldable rotor unit.
1872848|NCT01123902|Device|wristband|Patients are instructed to wear the wristband continually and pull it regularly at short intervals when breathless or during breathlessness attacks.
1872849|NCT01123915|Biological|Opal-HIV-Gag(c) Low Dose|
1872850|NCT01123915|Biological|Opal-HIV-Gag(c) Medium dose|
1872851|NCT01123915|Biological|Opal-HIV-Gag(c) High dose|
1872852|NCT01123915|Other|Dimethyl Sulfoxide|
1872853|NCT01123928|Behavioral|Video and counseling for cataract patients|Intervention includes: (1) a 5-10 min video consisting of testimony from a previous cataract patient and a doctor; (2) a 10-15 min pre-operative counseling session with a trained nurse, and (3) a 5 min post-operative counseling session with a trained nurse.
1872854|NCT01123941|Biological|Typherix|1 dose, 0.5 mL containing 25 mcg of Vi polysaccharide
1872855|NCT01123941|Biological|NVGH Vi-CRM197|1 dose of 0.5 mL containing 25 mcg of Vi-CRM
1872856|NCT01123954|Biological|Seasonal flu vaccine|This phase II is performed as a monocenter study site in a population of healthy subjects aged 1 to 45 years. Enrolled subjects received one single IM dose of trivalent subunit inactivated influenza vaccine during the vaccination visit, according to the study protocol (follow-up period: 30 days)
1872857|NCT01123967|Other|proactive outreach (PRO)|a mailed invitation letter followed by telephone outreach
1872858|NCT01123967|Other|telephone counseling (TC)|free telephone counseling
1872859|NCT01123967|Other|Nicotine replacement therapy (NRT)|free nicotine replacement therapy (NRT)
1872860|NCT01123967|Other|Usual care (UC)|nicotine replacement products (patch, gum, lozenge, inhaler, and nasal spray)
1872861|NCT01123980|Drug|biphasic insulin aspart 30|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
1872862|NCT01123980|Drug|metformin|"China: Tablets, 500 mg. Min. 1500 mg/day.
Japan: Tablets, 250 mg. Min 500 mg/day."
1872863|NCT01123980|Drug|glimepiride|"China: Tablets, 2 mg. Min. 4 mg/day.
Japan: Tablets, 1 mg. Min. 4 mg/day."
1872864|NCT01123980|Drug|insulin glargine|Treat-to-target titration according to titration algorithm. Subcutaneous (under the skin) injection once daily.
1872865|NCT01123993|Device|Music CD|During 4-week interventional period of each group, a researcher gives a CD to care giver and advises him/her to open the music for patient for at least 60 minutes daily, after dinner to bedtime. Meanwhile, the care giver notes the exact duration that patient actually listens to it in the calendar provided and returns the CD and document to the researcher at the end of interventional period.
1872866|NCT01124006|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
1872867|NCT01124006|Other|Water for injection|Sterile water for injection
1872868|NCT01124032|Drug|methylphenidate|a capsule containing 20 mg
1872869|NCT01124045|Drug|Difluprednate ophthalmic emulsion, 0.05%|Topical ocular administration
1872870|NCT01124045|Drug|Prednisolone acetate ophthalmic suspension, 1.0%|Topical ocular administration
1872873|NCT01124071|Behavioral|Provision of 2 Korean meals per day 6 days per week|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Korean diet group will pick up lunch and evening meals Monday-Friday. Raw ingredients and cooking instructions will also be provided on friday for saturday meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
1872874|NCT01124071|Behavioral|Western Diet|At each participant's baseline visit, participant's will have an individualised lifestyle session addressing dietary and exercise goals and techniques to achieve weight loss. Participants in the Western diet group will be provided with a Western recipe cookbook and food vouchers (weekly) to purchase the necessary ingredients for the Western meal preparation. Ongoing lifestyle sessions will be performed weekly for participants.
1872875|NCT01124097|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
1872876|NCT01124097|Drug|Placebo|Tablets will be used.
1872877|NCT01124110|Behavioral|Tobacco Tactics Web-Based Intervention|The Tobacco Tactics Web-Based Intervention contains website, medications, and nurse counseling.
1872878|NCT01124110|Other|1-800-QUIT-NOW Telephone Hotline|The control group receives efficacious smoking cessation treatment via the 1-800-QUIT-NOW telephone hotline. The 1-800-QUIT-NOW hotline is a national program. The first time smokers call the hotline, they receive a personal coach who assists them in setting a quit date and making an individualized quit plan. The personal coach also provides on-going support with up to five telephone coaching sessions around the caller's quit date.
1872889|NCT01124188|Behavioral|Supportive management|Supportive management encourages participants to take the medication and manages any treatment-emergent side effects. Ten sessions will be delivered over the course of 14 weeks.
1872890|NCT01124188|Behavioral|Problem Solving Therapy for Depression and Pain|PST-DP will be delivered over the course of 10 sessions over 14 weeks. Along with teaching the participant 7 steps of problem solving, PST-DP also includes a medication support and management component.
1872891|NCT01124201|Other|Stabilization , strengthening and stretching|Interventions were conducted over 6 weeks, twice per week, lasting 30 minutes each. Sessions were supervised by the investigator, and participants were instructed to report any adverse event. Groups were instructed not to participate in any other physical program during the study. Forty-five patients were randomized into three groups namely: Segmental stabilization group (ES)(transversus abdominis and lumbar multifidus), superficial strengthening group (FS)(rectus abdominis, oblique abdominal muscles and erector spinae muscles) and stretching group (AL) (erector spinae, posterior connective tissues and ischiotibials muscles). Patients were evaluated for pain , functional disability,and ability to contract the TrA before and after the treatment.
1872892|NCT01124214|Procedure|endomicroscopy|endomicroscopy scope lens has capability to optically evaluate mucosa/submucosa as a microscope
1872893|NCT01124227|Drug|icodextrin|2000 ml icodextrin intraperitoneally one or two times a day. Dose will be adapted clinically as in standard peritoneal dialysis.
1872894|NCT01124240|Drug|Cilengitide|"Cilengitide 2000 mg flat i.v. twice weekly is administered over a period of 18 months without interruption.
Starting one week after the initiation of Cilengitide, RTX (60 Gy, 2 Gy per fraction) with concurrent daily temozolomide (60 mg/m2 p.o.) and daily procarbazine (PCB, 50 mg p.o. if BSA < 1.7; 100 mg p.o. if BSA ≥ 1.7) is given over a period of 6 weeks (RTX Monday to Friday, both TMZ and PCB seven days a week).
After a break of 4 weeks, adjuvant TMZ (50mg/m2 p.o in first cycle, 60 mg/m2 p.o. in subsequent cycles) and PCB (50 mg p.o. if BSA < 1.7; 100 mg p.o. if BSA ≥ 1.7) are then given daily D1 to 20. This TMZ/PCB cycle is repeated every 28 days over a total period of 6 cycles."
1872895|NCT01124253|Drug|recombinant human endostatin|recombinant human endostatin 15mg per ampul for injection 7.5mg/m2 IV (in the vein) on 1st to 14th days of a 21- day cycle, totally 4 cycles are needed
1872896|NCT01124266|Procedure|standard of care colonoscopy|Single inspection by endoscopist during colonoscopy
1872897|NCT01124266|Procedure|standard of care colonoscopy|Dual inspection by both endoscopist and nurse during colonoscopy
1872898|NCT01124279|Drug|AMG 853|Single dose administration of AMG 853 in tablet form to healthy adult subjects
1872899|NCT01124292|Procedure|Tongue Piercing|Subjects brush their teeth, and then swish and spit with chlorhexidine mouthwash for 30-60s. Subjects would be placed in a semirecumbent position in a procedure chair. After marking the piercing site using a sterilized surgical marking pen the protruded tongue would be pierced. Anesthesia may be used during the piercing at the discretion of the operator and the subject. A sterilized titanium or surgical grade stainless steel piercing tongue stud would be placed in an appropriate position on the tongue to minimize complications from the piercing but also facilitate good functionality of the TDS.
1872900|NCT01124292|Device|Usability assessment|"Computer access: Subjects wear the TDS and get trained. Then they sit 1.5 m from a 22 LCD monitor. Then they use TDS to conduct several tasks using their tongues, such as clicking on target objects and navigating through on-screen maze, while the computer registers their tongue commands and measures their performance.
Wheelchair control: Subjects wear the TDS and use it to drive an electrically powered wheelchair through an obstacle course using their tongues. The operator measured the time it takes for the subjects to drive through the course as well as the number of collisions."
1872901|NCT01124305|Device|Customized Patient Instrumentation|Custom cutting guides based on computed tomography (CT) images of the patient's leg are used to make the bone cuts and select the implant size.
1872902|NCT01124305|Device|Traditional Instrumentation|Traditional surgical instruments will be used to make bone cuts and size the components in this control group.
1872903|NCT01124318|Drug|Lactofiltrum|Lactofiltrum (hydrolytic lignin 0.355, lactulose 0.12) 2 tablets three times a day before meals during 21 days
1872904|NCT01124318|Drug|Placebo|Placebo 2 tablets 3 times a day before meals during 21 days
1872905|NCT01124331|Procedure|Higher oxygen saturation target range (91%-95%)|higher (SpO2 91-95%) functional oxygen saturation target range from birth, or soon thereafter
1872906|NCT01124331|Procedure|Lower oxygen saturation (85%-89%)|Lower (SpO2 85%-89%)functional oxygen saturation target range from birth, or soon thereafter
1872907|NCT01124344|Drug|Placebo|Oral Solution, Oral, 0 mg, Once Daily, 14 days
1872908|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 3 mg, Once Daily, 14 days
1872909|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 10 mg, Once Daily, 14 days
1872910|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 30 mg, Once Daily, 14 days
1872911|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 45 mg, Once Daily, 14 days
1872912|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 60 mg, Once Daily, 14 days
1872913|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 90 mg, Once Daily, 14 days
1872914|NCT01124344|Drug|BMS-866949|Oral Solution, Oral, 3-60 mg, Once Daily, 14 days
1872915|NCT01124357|Device|NovaSure|Bipolar radio-frequency energy ablation of the endometrium by thermal therapy under impedance control. The bipolar current generated by the device produces a tapered depth of ablation with shallower ablation in the cornual regions / lower uterine segment and a deeper ablation in the mid-body of the uterus..
1872916|NCT01124357|Device|thermachoice|ThermachoiceTM III thermal balloon ablation
1872917|NCT01124370|Device|remedē (TM) system|Implantation of the remedē (TM) system, including implantable pulse generator, stimulation lead, and (optional) sensing lead. Nightly provision of unilateral transvenous phrenic nerve therapy during sleep periods.
1872918|NCT01124383|Procedure|General anesthesia|For women in the general anesthesia group, general anesthesia is induced using midazolam 1-3 mg, sufentanil 0.15-0.25 mcg/kg and propofol 1-3 mg/kg. Rocuronium 0.6 mg/kg is allowed. Anesthesia is maintained with sevoflurane titrated to maintain a blood pressure within 20% of preoperative normal and, if needed, ephedrine can be used for this purpose. Patients are ventilated in a normocapnic range with a positive end-expiratory pressure of 3 to 5 mmHg.
1873038|NCT01125267|Behavioral|multifamily group-standard|multifamily groups held twice a month focused on general problem solving method
1873216|NCT01118078|Genetic|microarray analysis|Undergo microarray analysis
1872919|NCT01124383|Procedure|Local anesthesia with sedation|For women in the local anesthesia group a paracervical block is performed by the gynecologist using a total of 20 mL of 1% lidocaine intracervically at 2, 4, 7 and 10 o'clock positions and in the area of uterosacral ligaments. Once the block completed, the surgeon waits at least five minutes before performing cervical dilatation to allow for sufficient analgesia. Intravenous sedation consists of midazolam, sufentanil and propofol administered by the anesthesiologist in sufficient doses to maintain a spontaneous ventilation with a Ramsay score < 4.
1872920|NCT01124396|Drug|DSP-3025|
1872921|NCT01124396|Drug|Placebo|
1872922|NCT01124409|Radiation|EPID Verification|Set up error verification and correction by EPID
1872923|NCT01124409|Radiation|CBCT verification|Setup error verification and correction by CBCT
1872924|NCT01124422|Drug|fluticasone propionate/salmeterol inhalation powder DISKUS 250/50|Experimental comparator consisting of inhaled corticosteroid plus long-acting beta agonist combination also known as ADVAIR DISKUS
1872925|NCT01124422|Drug|tiotropium bromide inhalation powder HandiHaler|Open-label drug also known as Spiriva HandiHaler
1872926|NCT01124435|Drug|Carboplatin plus Celecoxib|celecoxib (200 mg tablets by mouth twice daily, day 1 to 28), associated to intravenous carboplatin (area under the curve (AUC) 5 over 30 to 60 minutes, every 28 days).
1872927|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 (colony-forming units), freeze-dried powder, daily for 21 days
1872928|NCT01124448|Biological|Lactobacillus salivarius PS2|9.5 log10 colony-forming units, oral route, freeze-dried powder, daily for 21 days
1872929|NCT01124474|Other|goal directed therapy|Pulse contour waveform analysis derived stroke volume variation will be used to guide intraoperative fluid administration. Additional fluid boluses will be given to the patient when SVV>12%.
1872930|NCT01124487|Dietary Supplement|The acute effects of dietary fat on lipid profile, insulin sensitivity and inflammatory markers|
1872931|NCT01124500|Drug|methylphenidate via transdermal patch compared to placebo|The participants will start with a 10mg MPH patch on day -4, the 1st day of the titration period. This will be increased up to 20mg over 4-day titration period as needed and tolerated, and continued on the optimal dose. Subjects will be seen on day 1 of the double-blind part of the study at a patient education room or the Dr.'s office and receive 10 identical patches including 5 MPH and 5 placebo patches that will be randomly assigned over the 10-day course. The patch will be placed at 9am and removed at 4pm daily for 10 days. During the 10 days, each subject will be monitored for continuous 240 hours by actigraphy based activity monitors to follow activity levels and energy expenditure.
1872932|NCT01124513|Procedure|Induced Erythema|Study personnel will induce erythema by sequentially applying ice for approximately 2 minutes to the 2 cm^2 target region of the upper volar arm. This erythema is a reaction to the vasoconstriction caused by skin cooling. The vasoconstriction is visually monitored to determine the onset of the vascular dilation that occurs after cessation of cooling. Images with the Digital Camera, Spectrophotometer and Videodermoscope are re-taken.
1872933|NCT01124526|Drug|Rituximab Fludarabine Cyclophosphamide|"Patients receiving from 4 to 6 cycles of chemotherapy (R F C) each 4 weeks depending on haematological tolerance:
RITUXIMAB(R)375 mg/m2 iv,day 3 C1 and day 1 C2-C6,(total dose 375 mg/m2) FLUDARABINE(F):25 mg/m2 iv, day 1-3,(total dose 75 mg/m2) CICLOPHOSPHAMIDE(C)1000 mg/m2 iv, day 1,(total dose 1000 mg/m2)"
1872934|NCT01124539|Drug|AR-67 (7-t-butyldimethylsiltyl-10-hydroxy-camptothecin)|IV AR-67 administered once daily for 5 days on an every 21-day cycle
1872935|NCT01124552|Drug|RT001 Botulinum toxin type A (Dose A)|RT001 Botulinum Toxin Type A (Dose A)
1872936|NCT01124552|Drug|RT001 Botulinum Toxin Type A (Dose B)|RT001 Botulinum Toxin Type A (Dose B)
1872937|NCT01124552|Other|Vehicle|Vehicle Control
1872938|NCT01124552|Drug|Placebo|Placebo Comparator
1872939|NCT01124565|Drug|RT001|RT001 (Botulinum Toxin Type A Topical Gel, Dose A) at Baseline (Day 0) and Week 4 to the lateral canthal areas
1872940|NCT01124591|Behavioral|Brief motivational intervention|two session delivered two weeks apart
1872941|NCT01124604|Drug|Tapentadol Hydrochloride|Tapentadol hydrochloride extended release (ER) tablets 25 to 250 milligram (mg) will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
1872942|NCT01124604|Drug|Placebo|Placebo matched to tapentadol hydrochloride ER tablets 25 to 250 mg will be administered orally twice daily for 12 weeks. Dose will be adjusted as per Investigator's discretion.
1872943|NCT01124617|Drug|Tapentadol|Tapentadol hydrochloride extended-release(ER) will be administered as oral tablet at dose ranging from 25 milligram (mg) to 250 mg twice daily for 12 weeks.
1872944|NCT01124617|Drug|Placebo|Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
1872945|NCT01124630|Drug|CS-1008|CS-1008 will be administered IV each week. The initial/loading dose (6 mg/kg) will be administered Day 1 of Cycle 1. Maintenance doses of 2 mg/kg will be administered weekly thereafter.
1872946|NCT01124630|Drug|FOLFIRI|The FOLFIRI regimen will be administered IV at Weeks 1 and 3 of each 4 week cycle, and it will begin at Week 1 of Cycle 1. It will comprise irinotecan, 180 mg/m2 IV infusion over 30 to 120 minutes; leucovorin, 400 mg/m2 IV infusion to match the duration of the irinotecan infusion; and 5-FU, 400 mg/m2 (bolus) followed by 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46 to 48 hours continuous infusion).
1872947|NCT01124643|Biological|Replagal|0.2 mg/kg administered intravenously [IV] every other week
1872948|NCT01124656|Drug|Pioglitazone-Azilsartan|Pioglitazone-Azilsartan (30 mg + 20 mg) or (45 mg + 20 mg), tablets, orally, once daily for up to 52 weeks.
1872949|NCT01124669|Genetic|DNA analysis|
1872950|NCT01124669|Genetic|mutation analysis|
1872951|NCT01124669|Other|laboratory biomarker analysis|
1872952|NCT01124682|Procedure|diagnostic cystoscopy|
1872953|NCT01124682|Procedure|diffusion-weighted magnetic resonance imaging|
1872954|NCT01124682|Procedure|implanted fiducial-based imaging|
1872955|NCT01124682|Procedure|quality-of-life assessment|
1872956|NCT01124682|Radiation|3-dimensional conformal radiation therapy|
1872957|NCT01124682|Radiation|image-guided radiation therapy|
1872958|NCT01124682|Radiation|selective external radiation therapy|
1872959|NCT01124695|Drug|tamoxifen citrate|
1872960|NCT01124695|Other|laboratory biomarker analysis|
1873377|NCT01126437|Drug|tiotropium 18 mcg|HandiHaler
1872961|NCT01124708|Drug|TC-5619-238|TC-5619-238 will be provided as white, opaque gelatin capsules in strengths of 1mg, 5mg, and 25mg (as free base). Subjects will take 1mg TC-5619, 5mg TC-5619, 25mg TC-5619, or matching placebo - one capsule once daily p.o.
1872962|NCT01124708|Drug|Placebo|Placebo will be provided as white, opaque gelatin capsules in sham strengths of 1mg, 5mg, and 25mg
1872963|NCT01124721|Behavioral|Cognitive training|Cognitive computerized training for several days per week.
1872964|NCT01124721|Behavioral|Cognitive training-placebo|Cognitive training that only minimally increases in difficulty
1872965|NCT01124734|Drug|Interleukin-2|up to a maximum of 14 doses at 600,000 IU/kg
1872966|NCT01124734|Drug|Interleukin-2|If complete response, patient would have one course of treatment. If patient has stable, disease, partial response or minor response, patient would have 2 courses courses.
1872967|NCT01124734|Drug|Temozolomide|Patients would receive temozolomide at 75 mg/m2 beginning 28 days after discharge from receipt of the second cycle of high dose IL-2. Patients would take the medication at bedtime daily. Four weeks after cycle 2 of a course, they would take it for 21 days.
1872968|NCT01124747|Drug|ASP1585|Oral
1872969|NCT01124747|Drug|14C-Labeled ASP1585|Oral
1872970|NCT01124760|Drug|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL; On Day 7, a single 150 mg IV dose, coadministered after the morning dose of ketoconazole
1872971|NCT01124760|Drug|Diltiazem|Orally, daily beginning on Day 4 for 14 consecutive days
1872972|NCT01124760|Drug|ketoconazole|200 mg, orally, every 12 hours starting on Day 4 for 10 consecutive days in which on Day 13 only the morning dose will be administered
1872973|NCT01124786|Drug|CO-1.01|1250 mg/m2 intravenous infusion weekly for 3 weeks every 4 weeks
1872974|NCT01124786|Drug|Gemcitabine|1000 mg/m2 intravenous infusion weekly for 7 weeks followed by 1 week rest, then weekly for 3 weeks every 4 weeks
1872975|NCT01124799|Drug|TMC435|one morning TMC435 dose between 75 and 150 mg and a placebo dose at noon and in the evening, for 9 days
1872976|NCT01124799|Drug|Placebo|placebo dose in the morning, at noon and in the evening, for 9 days
1872977|NCT01124799|Drug|Ciprofloxacin|one morning placebo dose and a noon and evening dose of ciprofloxacin 500 mg, for 9 days
1872978|NCT01124812|Other|131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy|"Lung tumor irradiation with a total dosage of between 60-66 Gy, fractionated in combination with the following concurrent chemotherapy options:
Cohorts 1, 2 & 3a is composed of cisplatin i.v. 80 mg/m2 on day 1, and vinorelbine i.v. 25 mg/m2 on day 1, 8, 15 for cycle 1 & 4. For patients with significant comorbidities, the dose of vinorelbine is reduced to 12.5 mg/m2 during cycles 2 & 3. Treatment cycles will be repeated every 28 days.
Protocol A (suggested for patients with comorbidities: Carboplatin 70 mg/m2, over 30 min iv, (Day 1-5 ) + Vinorelbine 12.5 mg/m2 as a 5-min bolus iv or short iv-infusion (Day 1, 8, 22), repeated on Day 28.
Protocol B (suggested for patients in good clinical condition): Paclitaxel 50 mg/m2 1 hour iv (Day 1, 15, 22, 29, 36, 43, 50) + Carboplatin AUC 2, 30 min iv on (Day 1, 15, 22, 29, 36, 43, 50).
Total treatment duration is 8-16 weeks"
1872979|NCT01124825|Device|IGEL|iGEL(TM) airway will be used for induction and maintenance of positive pressure ventilation
1872980|NCT01124825|Device|King airway|KING-LTS-D(TM) airway will be used for induction and maintenance of positive pressure ventilation
1872981|NCT01124838|Drug|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by 40 mg eow starting at Week 1.
1872982|NCT01124838|Drug|Prednisone|Administered orally, 10 - 35 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all subjects continuing in the study were to discontinue prednisone no later than Week 19.
1872983|NCT01124838|Drug|Placebo|Administered by subcutaneous injection
1872984|NCT01124851|Drug|ABT-652|See arm description for details
1872985|NCT01124851|Drug|Placebo|See arm description for details
1872986|NCT01124864|Drug|AUY922|AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.
1872987|NCT01124877|Drug|ziprasidone oral capsules|Oral ziprasidone capsules of 20 mg, 40 mg, 60 mg, and 80 mg strength will be provided. Subjects will be dosed daily for 26 weeks using a flexible dose design with a minimal dose range of 40mg twice a day (BID) to a maximum dose range of 80 mg BID. For subjects weighing <45 kg, the doses will range from 20 mg BID to 40 mg BID.
1872988|NCT01124890|Device|percutaneous coronary intervention|
1872989|NCT01124903|Procedure|Dehydration|Subjects were dehydrated by 2 - 7% of body mass over 3-5 hours using exercise-heat stress and fluid restriction.
1872990|NCT01124916|Procedure|Robotic assisted laparoscopic abdominal sacrocolpopexy|Robotic assisted laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
1872991|NCT01124916|Procedure|Standard laparoscopic abdominal sacrocolpopexy|Standard laparoscopic abdominal sacrocolpopexy for surgical repair of pelvic organ prolapse.
1872992|NCT01124929|Drug|RNTCP Category I treatment for 6 months|2H3R3Z3 E3 + 4H3R3
1872993|NCT01124929|Drug|RNTCP Category I treatment for 9months|2H3R3Z3 E3 + 7H3R3
1872994|NCT01124942|Device|MGuard net protective coronary stent|It is a new closed-cell design stent concept. with an ultra-thin flexible polyethylene terephthalate (or Dacron) mesh sleeve, anchored to the external surface of the struts. This net (string diameter 10-22 μm) minimally affects stents' trackability and deliverability. During stent deployment, the net stretches and slides over the expanding stent struts, trapping the thromboembolic debris underneath the fiber net.
1872995|NCT01124942|Device|Bare-metal stent and manual thrombectomy device|Manual thrombectomy device as an adjunctive strategy for conventional stenting with a bare-metal stent
1872996|NCT01124955|Other|Acupuncture|The intervention group (IG) are submitted to five acupuncture sessions using Yamamoto New Scalp Acupuncture(YNSA)
1872997|NCT01124955|Other|Non-penetrating acupuncture|The placebo group (PG) are submitted to five non-penetrating acupuncture sessions using YNSA.
1872998|NCT01124968|Other|eConsulta|It is a web specifically designed for the project where elected patients can consult virtually with their primary care physician and within 48 hours have an answer.
1872999|NCT01124981|Drug|Haemocomplettan® P|Dosing of study medication will be individually determined based on plasma fibrinogen concentrations (measured with Clauss method during the reperfusion period on CPB) and body weight. Intravenous infusion within 10 minutes.
1873000|NCT01124981|Drug|Human albumin (Placebo)|Human albumin with concentration 200g/L. The study bottles of 50 mL will be diluted with saline and will contain 2g in total. This concentration resembles the total protein load in the bottles with Haemocomplettan® P.
1873001|NCT01124994|Procedure|Endoscopic mucosal resection|Confocal laser endomicroscopy will be used to target endoscopic mucosal resection of Barrett's oesophagus-associated neoplasia
1873002|NCT01125007|Device|Two kind toothbrushes|a randomization was performed in which the participants were allocated to the following experimental procedures: Two quadrants (1 and 3 or 2 and 4) with medium toothbrush Two quadrants with soft toothbrush. All procedures were performed using the same dentifrice. Each quadrant was brushed for 30 seconds by the participant without specific instructions on the technique, under supervision of the person in charge of the randomization.
1873003|NCT01125020|Drug|gemcitabine and oxaliplatin|Gemcitabine 1000mg/m2 (days l, 8) and oxaliplatin 130mg/m2 (day l) delivered as an intravenous infusion, given every 28days and repeat six times.
1873004|NCT01125020|Drug|doxorubicin, 5-Fu and cisplatin|Doxorubicin 20mg/m2 (days 1, 3), 5-Fu 300mg/m2 (days 1-5) and cisplatin 20mg/m2 (days 1-3) delivered as an intravenous infusion, given every 28days and repeat six times.
1960164|NCT03285932|Radiation|Whole brain radiotherapy (WBRT)|"For WBRT, an individual head fixation mask is manufactured for each patient, and treatment planning is performed as virtual simulation or 3D-conformal RT planning based on CT-imaging. The portals include the whole brain with special focus as including the skull base areas and lamina cribrosa. For low infratentorial lesions, the treatment volume may include the whole brain down to the second cervical vertbra.
RT will be applied with two portals (e.g. 87°and 273°) using a 6 MeV linear accelerator.
For WBRT, a total dose of 30 Gy in 3 Gy fractions will be applied."
1873009|NCT01125046|Biological|bevacizumab|Given IV
1873010|NCT01125059|Drug|Methadone|0.2 mg/kg methadone IV bolus
1873011|NCT01125059|Drug|Saline|3 mL saline IV bolus
1873012|NCT01125072|Other|Echocardiography with strain analysis|Clinical routine echocardiogram with additional off line strain analysis
1873013|NCT01125085|Radiation|131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT)|"Patients will be treated with WBRT administering a total dosage of 30 Gy in fractions of 3 Gy
Dosimetric evaluation with 131I-L19SIP or 124I-L19SIP will be performed to assess eligibility for RIT.
Patients eligible for RIT will receive a therapeutic dose of 131I-L19SIP.
Total treatment duration is up to 4 weeks"
1873014|NCT01125098|Other|PRO-CT values|"continue antibiotics for 10 days if a single PRO-CT value is 0.25 mcg/L or greater, that will be judged suggestive of bacterial infection
continue antibiotics from day 3 to day 10 if one or more PRO-CT values are 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, PLUS acute respiratory failure or clinical instability
stop antibiotics on day 3, if one or more PRO-CT values are between 0.1 to 0.25 mcg/L, indicative of possible bacterial infection, BUT the patient has not acute respiratory failure or clinical instability
stop antibiotics if all the PRO-CT values are < 0.1 mcg/L or if there is a consistent trend to normalization of PRO-CT with the last value < 0.1 mcg/L, that will be judged suggestive of absence of bacterial infection."
1873015|NCT01125111|Procedure|surgery(robot versus laparoscopy)|
1873016|NCT01125124|Drug|Silver Nitrate|Instilation of silver nitrate solution through the pleural catheter. The catheter remains closed for 1h after the procedure and is then reopened. There will be 3 different dosages, corresponding to the 3 different arms.
1873017|NCT01125137|Procedure|Removal of Keloid|Keloid will be excised by Henry Ford Hospital Dermatologist, Dermatosurgeon or Plastic Surgeon.
1873018|NCT01125150|Drug|Metformin|Dosage to be determined by Endocrinologist
1873019|NCT01125150|Behavioral|Dietary Modification|To be determined by Endocrinologist
1873022|NCT01125176|Drug|thalidomide|50 mg oral dosing every other day
1873023|NCT01125176|Drug|lenalidomide|varying oral doses every other day (max 25 mg/day)
1873024|NCT01125176|Biological|rituximab|375 mg/m2 intravenously on days 1, 8, 15, and 22 of cycle 1. Then, repeated on days 1, 8, 15, and 22 of every 6th cycle thereafter (Cycle 7, 13, 19, etc.)
1873025|NCT01125189|Drug|Daclatasvir|Tablets, oral, 20 mg, once daily, 12-24 weeks, depending on response
1873026|NCT01125189|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, 12-24 weeks, depending on response
1873027|NCT01125189|Drug|Placebo|Tablets, oral, 0 mg, once daily, 24 weeks
1873028|NCT01125189|Drug|peg-interferon alfa-2a|Syringe, subcutaneous Injection, 180 µg, once weekly, 24 or 48 weeks depending on response
1873029|NCT01125189|Drug|ribavirin|Tablets, oral, 1000 or 1200 mg based on weight, once daily, 24 or 48 weeks depending on response
1873030|NCT01125202|Behavioral|SCT-based behavioral intervention|Intervention group continues to receive routine dialysis care. The intervention duration is 16 weeks. Intervention contacts are 2x/week for weeks 0-8, weekly for weeks 9-12, and every other week for weeks 13-16. Personal digital assistant dietary records are use to provide targeted counseling and engaged the participant in problem solving around dietary issues.
1873031|NCT01125202|Behavioral|Attention Control|Attention control participants continue to receive routine dialysis care. Attention control participants view 5 computerized educational programs PowerPoint slides) that summarize the various elements of the HD diet. The 5 modules evenly over the 4-month study period.
1873034|NCT01125241|Drug|wuling capsule|orally, three tablets each time,three times a day
1873035|NCT01125241|Drug|placebo of wuling capsule|orally, three tablets each time and three times a day
1873036|NCT01125254|Drug|Amlodipine|5mg po for 12 months
1873037|NCT01125267|Behavioral|multifamily group-adherence|multifamily groups held twice a month for one year focused on improving medication adherence using techniques derived from the Theory of Planned Behavior
1874131|NCT01133392|Drug|Insulin lispro B|20 U subcutaneously (SC).
1873039|NCT01125280|Procedure|Conservative treatment versus surgical treatment|Conservative treatment: starving, nasogastric tube Surgical treatment: open laparotomy, adhesiolysis, with or without small bowel resection
1873043|NCT01125306|Device|Xal-Ease|Xal-Ease device used to facilitate application of Xalatan/Xalacom eye drops.
1873044|NCT01125319|Other|blood sample|
1873045|NCT01125332|Drug|Indirect laryngoscopy in the flexible nasofibroscope|
1873046|NCT01125332|Drug|Indirect laryngoscopy in the flexible nasofibroscope|
1873047|NCT01125345|Procedure|Phacoemulsification|Phacoemulsification with IOL implantation in eyes undergoing bilateral cataract surgery
1873048|NCT01125358|Drug|LY2140023|Administered orally, twice daily for up to 7 weeks of treatment
1873049|NCT01125358|Drug|Placebo|Administered orally, twice daily for up to 7 weeks of treatment
1873050|NCT01125371|Behavioral|Computerized brief alcohol intervention + IVR booster calls|1) Computerized brief alcohol intervention + IVR booster calls: Clinic-based computerized brief alcohol intervention (delivered once) followed by three booster phone calls using interactive voice response technology + text messages
1873051|NCT01125371|Behavioral|Computerized brief alcohol intervention|Computerized brief alcohol intervention: Clinic based computer delivered brief alcohol intervention delivered one time
1873052|NCT01125371|Behavioral|Attention Control|Attention Control: 20 minute attention control condition focused on dental hygiene delivered once
1873053|NCT01125384|Other|additional swabbing|physician swabs patient`s throat according to standard rules before referral of the patient to throat swabbing by nurse.
1873054|NCT01125397|Behavioral|LEARN group|Participants will complete a 12-week behavioral weight management intervention (the LEARN program) prior to bariatric surgery, which is the current standard clinical practice at Mayo Clinic Rochester. This involves weekly group meetings, weigh-ins, and goal setting.
1873055|NCT01125410|Drug|Dequalinium chloride|Vaginal tablet, 10mg, 1 tablet daily for 6 days
1873056|NCT01125410|Drug|Clindamycin|vaginal cream, 2%, once daily for 7 days
1873057|NCT01125423|Drug|Milnacipran|Subject will then be titrated onto milnacipran over 8 days to subject reported optimal pain control or a maximal dose of 100mg/day per package insert. Subjects will be permitted to increase or decrease their dosing at any time during the study per MD discretion in order to maintain optimal pain control.
1873058|NCT01125423|Procedure|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand.
1873059|NCT01125436|Dietary Supplement|Cholecalciferol|50,000 IU weekly for 6 months
1873060|NCT01125436|Dietary Supplement|Cholecalciferol|Placebo weekly for 6 months
1873061|NCT01125449|Drug|Ascorbic acid (vitamin C)|Intravenous administration of up to 1.5gm/kg of ascorbic acid, twice weekly for up to 12-weeks.
1873062|NCT01125462|Other|Quality of Life Questionnaire (FertiQoL)|Subjects will be administered the first internationally validated Quality of Life questionnaire (FertiQoL) to assess the quality of life of infertile subjects.
1873063|NCT01125475|Device|RebiSmart|Treatment with Rebif New Formulation using RebiSmart.
1873064|NCT01125488|Device|LNG-IUS|levonorgestrel-releasing intrauterine system (LNG-IUS) 52mg, duration 5 years
1873065|NCT01125488|Drug|GnRH agonist (triptorelin)|GnRH agonist (triptorelin 3.75 mg, sc q28day)
1873067|NCT01125514|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
1873068|NCT01125514|Drug|Furosemide 60 mg|Furosemide 60 mg commercially-available tablets
1873069|NCT01125514|Drug|Placebo for Aliskiren|Matching placebo for aliskiren 150 mg and 300 mg
1873070|NCT01125514|Drug|Aliskiren 300 mg|Aliskiren 300 mg tablet
1873071|NCT01125527|Biological|Monovalent glyco-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
1873072|NCT01125527|Biological|Tetanus toxoid polysaccharide-conjugated vaccine against Haemophilus influenzae type b (Hib)|a single dose was administered
1873073|NCT01125540|Device|Acuvue (Standard Daily Disposable Contact Lens)|
1873074|NCT01125540|Device|CIBA Dailies Aquacomfort Plus (Contact Lens - enhance lubricating)|
1873075|NCT01125553|Drug|insulin degludec/insulin aspart|Each subject will be allocated to two single injections of trial product on two separate dosing visits with each of the two insulin degludec/insulin aspart formulations. The trial products will be administered as a subcutaneous injection (under the skin).
1873076|NCT01125566|Drug|BIBW 2992|patients receive BIBW 2992 tablets once daily and can reduce dose for adverse event management
1873077|NCT01125566|Drug|trastuzumab|patients receive trastuzumab 2mg/kg intravenously every week
1873078|NCT01125566|Drug|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
1873079|NCT01125566|Drug|vinorelbine|patients receive vinorelbine 25mg/m² intravenously every week
1873080|NCT01125592|Device|IonCLeanse Footbath|Application of an ionic footbath for 30 minutes per week for 4 weeks
1873081|NCT01125618|Other|Health and development intervention package|The timing and sequence of intervention vary by site, but include improved access to seed-fertilizer to increase agricultural production; improved market and capital access; proven maternal-newborn-child health interventions delivered free of cost at the point of service; improvements to school number and quality; and access to basic infrastructure including safe water, sanitation, electricity, transport and communication.
1873082|NCT01125618|Other|Routine services|Routine services and programs currently being administered using prevailing resources, at the current pace and with established partnerships. There is no attempt to limit the introduction of new interventions or agencies into comparison sites.
1873083|NCT01125631|Biological|PF-04360365 8.5 mg/kg|8.5 mg/kg every 8 weeks (4 doses total)
1873084|NCT01125631|Drug|Placebo|Placebo every 8 weeks (4 doses total)
1873128|NCT01112111|Drug|mode of gonadotropin administration|Low dose step-up administration Step down administration sequential administration
1873085|NCT01125644|Drug|SPK-843|SPK-843 is a semi-synthetic substance derived from Partricin A. 05 mg/Kg solution of SPK-843 in 10% intralipid will be administered i.v. in a hour for a treatment of 14 days
1873086|NCT01125657|Drug|YM150|oral
1873087|NCT01125670|Drug|YM150|oral
1873091|NCT01125696|Drug|Tenofovir/lamivudine/lopinavir-ritonavir|Tenofovir/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4<350
1873092|NCT01125696|Drug|Zidovudine/lamivudine/lopinavir-ritonavir|Zidovudine/lamivudine/lopinavir-ritonavir given to mothers starting at 14-28 weeks gestation till labor/delivery and continued postpartum if maternal baseline CD4<350
1873093|NCT01125722|Device|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the investigator.
1873094|NCT01125722|Device|Non-invasive neurostimulation device|Active electrode patches are worn for 4 weeks, one per week, during the treatment phase of the study. The patch is placed by the subject.
1873095|NCT01125735|Device|MIST Therapy|The MIST Therapy System is designed to deliver therapeutic ultrasound to the wound bed without direct contact of the device to the body (noncontact). The system generates and propels the therapeutic MIST Therapy towards the tissue. The saline solution is directed to the tip surface and is atomized through the vibration of the tip surface. This surface creates atomization of the fluid, breaking it apart into small particles of uniform size. Once the particles of fluid are released from the tip, a second phenomenon, the acoustic pressure wave, drives them toward the wound.
1873096|NCT01125735|Other|Standard of Care|Standard of Care with saline rinse using a sham device which is a nebulizer compressor designed to deliver a continuous saline mist to a skin treatment site. The saline mist generated has been designed to be comparable to that delivered by the MIST Therapy System, but without the ultrasound waves.
1873097|NCT01125748|Drug|Omalizumab|Omalizumab was supplied as a sterile, white, preservative-free, lyophilized powder in single-use vials that was reconstituted with sterile water for injection.
1873098|NCT01125748|Drug|Placebo|Placebo contained the same ingredients as the omalizumab formulation, excluding omalizumab.
1873099|NCT01125748|Drug|Asthma therapies|Participants could receive 1 or more of the following medications as concomitant asthma therapy: Inhaled corticosteroids; long acting beta-agonists; zafirlukast or other leukotriene receptor antagonist; zileuton or other 5-lipoxygenase enzyme inhibitors; oral, inhaled, and/or nasal anticholinergic therapy; mast-cell stabilizers; theophyllines; chronic oral corticosteroids, defined as a minimum dose of oral prednisone of 2 to 40 mg/day or 5 to 80 mg every other day.
1873100|NCT01125761|Drug|dexamethasone 0.5 mg and 1.0 mg clemastine cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
1873101|NCT01125761|Drug|Dexamethasone 0,5 mg cream|The treatment should be administered every 12 hours so that a thin layer is applied on the lesions, for 14 days.
1873102|NCT01125774|Drug|Telcagepant|Telcagepant 140 mg film coated tablet for oral administration
1873103|NCT01125774|Drug|Placebo|Placebo to match telcagepant 140 mg film coated tablet for oral administration
1873104|NCT01125787|Drug|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
1873105|NCT01111968|Biological|pandemic vaccine 1|7,5µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
1873106|NCT01111968|Biological|pandemic vaccine 2|3,75µg of A/H1N1 with MPLA adjuvant - IB, suspension (5µg) + Al(OH)3
1873107|NCT01111968|Biological|pandemic vaccine 5|7,5µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emulsion
1873108|NCT01111968|Biological|pandemic vaccine 6|3,75µg of A/H1N1 with MPLA adjuvant - IB, emultion (5µg) + Al(OH)3 + Squalene 2% emultion
1873109|NCT01111968|Biological|pandemic vaccine 9|7,5 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
1873110|NCT01111968|Biological|pandemic vaccine 10|3,75 µg of A/H1N1 with Al(OH)3 + Squalene 2% emultion
1873111|NCT01111968|Biological|pandmeic vaccine 11|7,5µg of A/H1N1 with Al(OH)3
1873112|NCT01111968|Biological|pandmeic vaccine 12|3,75µg of A/H1N1 with Al(OH)3
1873113|NCT01111968|Biological|pandmic vaccine 13|15µg of A/H1N1 with no adjuvant
1873114|NCT01111968|Biological|placebo group 14|All elements of the vaccine but antigen and adjuvant
1873115|NCT01111981|Drug|Clobetasol Propionate 0.05% Emollient Foam|Clobetasol Propionate 0.05% E Foam to be applied to affected area once a day for 16 weeks
1873116|NCT01111994|Drug|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel|Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel QD for 3 months
1873117|NCT01112020|Device|CHG Catheter Dressing Patch|2% CHG dressing applied to 7 sites
1873118|NCT01112020|Device|Biopatch|Biopatch applied to 7 sites
1873119|NCT01112020|Device|Tegaderm CHG|Tegaderm CHG IV Securement Dressing applied to 7 sites
1873120|NCT01112046|Procedure|Endoscopic submucosal dissection|Endoscopic treatment (performed under conscious sedation) using specific endoscopic knives
1873121|NCT01112046|Procedure|Laparoscopic resection|Surgical treatment performed under general anesthesia
1873124|NCT01112072|Drug|Riboflavin|Corneal epithelium removed followed by riboflavin drop administration every 2 minutes for 30 minutes followed by UV light exposure with additional riboflavin administration every 2 minutes for 30 minutes. Subjects will be randomized to receive Intacs placement either immediately before CXL or 3 months before CXL.
1873125|NCT01112085|Drug|Ranibizumab 0.05mg|Intravitreal injections of 0.05mg ranibizumab over 6 months then additional treatment with ranibizumab 0.05mg as needed (according to re-treatment criteria)
1873126|NCT01112085|Drug|Ranibizumab 0.5mg|Intravitreal injections of 0.5mg ranibizumab over 6 months then additional treatment with ranibizumab 0.5mg as needed (according to re-treatment criteria)
1873127|NCT01112098|Behavioral|Patient Pamphlet|letter informs patient of opportunity to self-schedule a DXA scan; pamphlet includes information about receiving a DXA scan
1873134|NCT01112163|Device|Enhanced external counter pulsation|While an individual is undergoing ECP, they have pneumatic stockings (also known as cuffs) on their legs and are connected to telemetry monitors that monitor their heart rate and rhythm.The cuffs should ideally inflate at the beginning of diastole and deflate at the beginning of systole. During the inflation portion of the cycle, the calf cuffs inflate first, then the lower thigh cuffs and finally the upper thigh cuffs. Inflation is controlled by a pressure monitor, and the cuffs are inflated to about 300 mmHg.
1873135|NCT01112176|Procedure|Increase in paced heart rate|The pacing rate will be increased by 10 bps at every stage
1873136|NCT01112189|Procedure|Autologous transplant|Patients will be stimulated 3 days with Filgrastrim 300 micrograms per day. On the 4th day the autologous transplant of stem cells will be performed.
1873137|NCT01112189|Other|Compressed sleeve treatment|"Week 1-2: With compressed sleeve treatment.
Week 3 -4: Without treatment.
Week 5 - 6: With compressed sleeve treatment"
1873138|NCT01112215|Drug|Azathioprine|Initial dose of 2-2.5 mg/kg (according to TMTP levels) for 6 months according the severity of the flare with progressive tapering if complete remission has been obtained
1873139|NCT01112215|Drug|Enteric-Coated Mycophenolate Sodium|Initial dose of 1440 mg/day for 6 months to be tapered progressively if complete remission had been obtained
1873140|NCT01112228|Procedure|Bariatric surgery|Gastric bypass, Sleeve gastrectomy, or Gastric banding
1873141|NCT01112241|Drug|albuterol plus tiotropium|Four separate doses of 100 μg of albuterol and 18 μg of tiotropium bromide. Albuterol will be given by a metered-dose inhaler connected to a valved-holding chamber and tiotropium by a dry-powder device.
1873142|NCT01112254|Procedure|MRI±biopsy|A MRI-guided or CT-guided preoperative biopsy will be performed in case of suspicious enhancement, multiple and large lesions (more than 3 cm for from the initial lesion), which is not viewed on the mammography or breast ultrasound. The surgery type will depends on the MRI +/- ± biopsy results.
1873143|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 tablet containing 75 mg of tramadol HCl and 650 mg of acetaminophen, once daily on Days 1to 3, then 1 tablet twice daily on Days 4 to 7
1873144|NCT01112267|Drug|Placebo|Participants will receive 1 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 4 to 7
1873145|NCT01112267|Drug|Tramadol HCl/acetaminophen Extended Release|Participants will receive 1 or 2 tablets containing 75 mg of tramadol HCl and 650 mg of acetaminophen, twice daily on Days 8 to 28
1873146|NCT01112267|Drug|Placebo|Prticipants will receive 1 or 2 matching placebo tablet once daily on Days 1 to 3, then 1 tablet twice daily on Days 8 to 28
1873147|NCT01112280|Device|cap-assisted chromoendoscopy|"A cap (irrigation cap) is a simple plastic device that can be attached to the tip of a colonoscope before performing the colonoscopy.
For chromoendoscopy, 0.15-0.2% indigocarmine was administered via irrigation cap ."
1873148|NCT01112293|Drug|GC1008|GC1008 is a human IgG4 kappa monoclonal antibody capable of neutralizing all mammalian isoforms of TGFbeta (i.e., beta1, beta 2 and beta 3). GC1008 is a high affinity antibody with dissociation constants (Kds) of 1.8 nM, 2.8 nM and 1.4 nM for TGF1,2,and 3, respectively.
1873149|NCT01112306|Drug|ACT-293987|Tablets, twice daily
1873150|NCT01112319|Device|Elf care|elfcare device
1873151|NCT01112319|Other|control group|regular physiotherapy treatment
1873152|NCT01112332|Device|SmartStep insole|Smart StepTM is an innovative biofeedback and monitoring system designed to help clinicians effectively guide patients with compromised lower limb function due to orthopedic or neurological trauma towards optimal gait performance. It records and analyzes key gait parameters and provides instantaneous and accurate audio and visual feedback.
1873155|NCT01112371|Drug|Contractubex|"Contractubex® Gel, containing 10% extractum cepae, 1% allantoin and 50/U of sodium heparin per one gram of gel.
Active drug group: The gel will be applied twice daily (morning/evening). Approximately 2 cm of the IMP are applied onto the scar by light massage rubbing carefully until the product is worked in."
1873156|NCT01112384|Drug|SB939|Given orally 3 times per week
1873157|NCT01112397|Drug|AZD1480|continuous daily oral capsule
1873158|NCT01112410|Other|Hypertonic saline|"Hypertonic saline (6%) nebulised twice a day for 4 weeks.
(Randomised crossover trial)"
1873159|NCT01112410|Other|Isotonic saline|Isotonic Saline (0.9%) nebulised twice a day for 4 weeks.
1873160|NCT01112423|Drug|BMS-823778|Capsules, Oral, 2 mg, once daily, 28 days
1873161|NCT01112423|Drug|BMS-823778|Capsules, Oral, 10 mg, once daily, 28 days
1873162|NCT01112423|Drug|BMS-823778|Capsules, Oral, 20 mg, once daily, 28 days
1873163|NCT01112423|Drug|Placebo|Capsules, Oral, 0 mg, once daily, 28 days
1873164|NCT01112436|Drug|periarticular injection of multidrug regimen|periarticular injection of combination of ropivacaine 15 mg, epinephrine 0.3mg, cefmetazole 1000mg, ketorolac 30mg, morphine HCL 10 mg
1873165|NCT01112436|Drug|none of medication preoperatively and intraoperatively|Patients in Group C wil receive none of medication preoperatively and intraoperatively
1873167|NCT01117792|Device|subcutaneous implantable defibrillator (S-ICD) system|implantable defibrillator system
1873168|NCT01117805|Behavioral|Telephone counseling intervention|self-regulation telephone counseling program for African American women with asthma
1873171|NCT01117831|Other|Epidemiological intervention|An analysis of 600 diabetic patients in the Island of PR to evaluate metabolic control.
1873215|NCT01118078|Genetic|gene expression analysis|Undergo gene expression analysis
1991424|NCT01137981|Drug|Any Antiretroviral Therapy|Any exposure to an antiretroviral therapy: Abacavir, Amprenavir, Delavirdine, Fosamprenavir, Lamivudine, Maraviroc, Zidovudine, Combivir (Zidovudine+Lamivudine), Epzicom (Abacavir+Lamivudine), and/or Trizivir (Abacavir+Lamivudine+Zidovudine)
1991429|NCT01113801|Drug|LY2382770|Subcutaneous injection given monthly for 12 months
1873172|NCT01117844|Radiation|Proton Radiation|Prons has been demonstrated for medulloblastoma and prostate cancer, and comparative treatment planning using protons versus photons have shown a clear advantage to protons in terms of dose distribution.
1873173|NCT01117857|Drug|Duloxetine|One-week placebo lead-in, followed by Duloxetine 30 mg per day for one week. After one week on 30 mg, the dosage will be increased 60 mg per day for the remaining 7 weeks of the study.
1873174|NCT01117870|Other|Pulsed Radiofrequency|120 seconds at 42 degrees celsius
1873175|NCT01117870|Other|Placebo|Needle will be continuously stimulated at a low voltage to give a sensation of PRF application.
1873176|NCT01117883|Other|Application of two different sternal weights|Two separate weights (first 10% of body weight, then 20% of body weight) will be placed on the sternum and changes in central hemodynamic measurements and intrathoracic pressure will be recorded and documented.
1873177|NCT01117896|Other|Chest compression on adult and pedi manikins|Each participant will be required to perform chest compressions on all 2 manikins, one on each of 2 assigned days. Participants will be randomized to one of 2 groups differing only in the order of manikins compressed, i.e. pediatric-adult; adult-pediatric, etc.
1873178|NCT01117896|Other|Use of stepstool during chest compressions|In the additional arm of the study, a new cohort of participants will use only the adult manikin on two separate sessions. Participants will be randomized to one of two groups differing only in the use of a stepstool.
1873179|NCT01117909|Other|Mobilization therapy in addition to standard therapy|Subject will receive three 60-second bouts of posterior joint mobilizations applied to the ankle joint during each treatment session. Standard therapy will consist of ankle strengthening exercises with elastic bands, balance, active ROM, and 20 minutes of ice bag application, elevation and compression.
1873180|NCT01117909|Other|Sham intervention|Physical therapist will lay hands as if to perform the joint mobilization but no movement will occur.
1873181|NCT01117922|Other|Psychological intervention|Subjects will be randomized into either usual care or interconceptional intervention groups. If the subject is randomized into the intervention group, she will receive targeted interventions to reduce one of several risk factors: smoking, depression, infectious disease burden and maternal stress, and achieving an appropriate BMI. A woman who is randomized to the intervention group may receive interventions on one, two, three, four, or five of the targeted intervention methods, depending on her needs.
1873182|NCT01117922|Other|Usual Care Group|
1873183|NCT01117935|Radiation|intensity modulated external beam radiation therapy|"Low risk - 69.6 Gy in 2.4 Gy fractions to prostate
Intermediate risk - delivered in 30 fractions with neoadjuvant and concurrent androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy in 1.68 Gy fractions to lymph nodes
High risk - 30 fractions with neoadjuvant, concurrent, and long term adjuvant androgen deprivation therapy: 72 Gy in 2.4 Gy fractions to prostate + 60 Gy in 2 Gy fractions to seminal vesicles +/- 50.4 Gy at 1.68 Gy fractions to lymph nodes"
1873184|NCT01117948|Drug|Lornoxicam|Lornoxicam (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
1873185|NCT01117948|Drug|Placebo|Placebo (8 mg) tablets to be taken orally two times daily (BID) for a period of 6 months.
1873186|NCT01117961|Behavioral|Lifestyle|Behavioral lifestyle intervention targeting diet and physical activity to reduce excessive gestational weight gain
1873187|NCT01117974|Procedure|liposuction of the neck|Liposuction will be performed to the surgical endpoint (skin thickness in the suctioned areas similar to that of surrounding non-treated skin).
1873188|NCT01117987|Drug|Imatinib|Participants, who received imatinib 200 mg in the core study, CQTI571A2301 (NCT00902174), and completed the core study, received imatinib 200 mg every day (qd) in the extension. Participants, who were randomized to receive imatinib 400 mg in the core study and completed the core study, received imatinib 400 mg qd in the extension. Participants, who terminated early from the core study or who were randomized to placebo and completed the core study, started the extension with imatinib 200 mg qd. After 2 weeks, the dose was increased to 400 mg qd if tolerated.
1873189|NCT01117987|Drug|Placebo|To preserve the blind of the core study until the core study, CQTI571A2301 (NCT00902174), was completed, participants received a blinded study drug package containing a 70-tablet bottle of imatinib and a 70-tablet bottle of matching placebo.
1873190|NCT01118000|Procedure|limb ischemia preconditioning|limb ischemic preconditioning consists of three 5-min cycles of left upper limb ischemia induced by a blood pressure cuff placed on the left upper arm and inflated to 200 mmHg,with an intervention 5-min of reperfusion during which the cuff was deflated.
1873191|NCT01118013|Biological|anti-thymocyte globulin|
1873192|NCT01118013|Biological|donor lymphocytes|
1873193|NCT01118013|Biological|filgrastim|
1873194|NCT01118013|Biological|therapeutic allogeneic lymphocytes|
1873195|NCT01118013|Drug|busulfan|
1873196|NCT01118013|Drug|fludarabine phosphate|
1873197|NCT01118013|Drug|methotrexate|
1873198|NCT01118013|Drug|mycophenolate mofetil|
1873199|NCT01118013|Drug|tacrolimus|
1873200|NCT01118013|Other|reduced-intensity transplant conditioning procedure|
1873201|NCT01118013|Procedure|allogeneic hematopoietic stem cell transplantation|
1873202|NCT01118013|Procedure|peripheral blood stem cell transplantation|
1873206|NCT01118039|Drug|sunitinib malate|
1873207|NCT01118039|Other|immunohistochemistry staining method|
1873208|NCT01118039|Other|laboratory biomarker analysis|
1873209|NCT01118039|Other|pharmacological study|
1873210|NCT01118039|Procedure|quality-of-life assessment|
1873211|NCT01118052|Other|Laboratory Biomarker Analysis|Correlative studies
1873212|NCT01118052|Biological|PEG-PEI-cholesterol Lipopolymer-encased IL-12 DNA Plasmid Vector GEN-1|Given intraperitoneally
1873213|NCT01118065|Drug|everolimus|
1873214|NCT01118078|Genetic|DNA methylation analysis|Undergo DNA methylation analysis
1873217|NCT01118078|Genetic|reverse transcriptase-polymerase chain reaction|Undergo RT-PCR
1873218|NCT01118078|Other|diagnostic laboratory biomarker analysis|Correlative studies
1873219|NCT01118091|Biological|Aldesleukin|Aldesleukin 720,000 IU/kg IV over 15 minute every eight hours and continuing for up to 5 days (maximum of 15 doses). Patients will receive one additional cycle of aldesleukin approximately 10-14 days after completion of the first cycle of aldesleukin.
1873220|NCT01118091|Biological|CD8 enriched Young TIL|Adoptive Cell Therapy consisting of the lymphocyte depleting preparative regimen consisting of fludarabine and cyclophosphamide, followed by infusion of between 1x10^9 to 2x10^11 CD8+ enriched tumor infiltrating lymphocytes (minimum of 5 x 10^8) and the administration of high-dose aldesleukin.
1873221|NCT01118104|Other|Vocational pulmonary rehabilitation|Multidisciplinary pulmonary rehabilitation with emphasis on vocational issues
1873222|NCT01118117|Device|Misago™ Self-Expanding Stent System|Transcatheter placement of an intravascular stent(s)
1873223|NCT01118143|Behavioral|Tailored oral health literacy instruction|The intervention includes oral hygiene instruction tailored to the level of oral health literacy, and will include information about the outcome of the clinical examination. Providing relevant information to the participant will be in focus, and there will be given a personalized demonstration as well as guidance on how to conduct proper oral hygiene practices at home. The aim of the intervention is to improve oral hygiene and attitudes towards dental care by taking the literacy level of the participant into consideration.
1873224|NCT01118156|Other|Education|75-minute training teaching utilization of new standardized suicide nomenclature
1873227|NCT01118221|Behavioral|pulmonary rehabilitation|structured exercise program
1873228|NCT01118234|Drug|Rituximab|Rituximab (MabThera, F. Hoffmann-La Roche Ltd., Basel, Switzerland) 375 mg/m² every 3 months for 24 months (8 infusions) or observation
1873229|NCT01118247|Procedure|Uncemented primary total hip arthroplasty|Total hip prosthesis partly coated with pure Ti with and without HA are compared in a RCT.
1873230|NCT01118260|Procedure|total intravenous anaesthesia|propofol and remifentanil
1873231|NCT01118260|Procedure|spinal anaesthesia|bupivacaine and fentanyl
1873232|NCT01118273|Drug|Naproxen Sodium 440 mg (BAYH6689) / DPH 50mg|Participants received 2 tablets of Naproxen Sodium 220 mg and 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg, single dose, orally.
1873233|NCT01118273|Drug|Naproxen Sodium 440 mg (BAYH6689)|Participants received 2 tablets of Naproxen Sodium 220mg and 2 tablets of placebo, single dose, orally.
1873234|NCT01118273|Drug|Naproxen Sodium 220 mg (BAYH6689) / DPH 50mg|One dose of naproxen sodium 220 mg plus diphenhydramine 50 mg
1873235|NCT01118273|Drug|Naproxen Sodium 220 mg (BAYH6689)|Participants received 1 tablet of Naproxen Sodium 220 mg and 3 tablets of placebo, single dose, orally.
1873236|NCT01118273|Drug|DPH 50mg|Participants received 2 tablets of Diphenhydramine hydrochloride (DPH) 25 mg and 2 tablets of placebo, single dose, orally.
1873237|NCT01118273|Drug|Ibuprofen 400 mg / Diphenhydramine citrate 76 mg|Participants received 2 tablets of Advil PM (ibuprofen 200 mg and diphenhydramine citrate 38 mg) and 2 tablets of Placebo, single dose, orally.
1873238|NCT01118286|Drug|Nifedipine (Adalat, BAYA1040)|Previously untreated hypertensive adult patients starting with combination therapy containing nifedipine or insufficiently controlled hypertensive patients receiving nifedipine as an add-on to existing non-CCB containing antihypertensive therapy. The decision of including the patient as well as decision on dosage and duration is taken by the investigator.
1873239|NCT01118312|Drug|Mometasone Furoate monohydrate|Intranasal mometasone, 1 spray (age < 12 yr) or 2 sprays (age >= 12 yrs) each nostril once a day for 6 months
1873240|NCT01118312|Other|Placebo|Intranasal placebo spray
1873241|NCT01118325|Drug|ticagrelor|Drug oral treatment
1873242|NCT01118325|Drug|clopidogrel|Drug oral treatment
1873243|NCT01118351|Drug|sunitinib malate|Given orally
1873244|NCT01118351|Other|immunohistochemistry staining method|Correlative studies
1873245|NCT01118351|Other|TdT-mediated dUTP nick end labeling assay|Correlative studies
1873246|NCT01118351|Other|light microscopy|Correlative studies
1873247|NCT01118351|Other|laboratory biomarker analysis|Correlative studies
1873248|NCT01118364|Other|Cannabis|"a cigarette tobacco trade mark Drum with the addition of 250 mg of cannabis resin with 8% of D9THC (20 mg per cigarette)45 minutes before simulating or real driving"
1873249|NCT01118364|Other|tobacco|"a cigarette tobacco trade mark Drum 45 minutes before simulating or real driving"
1873250|NCT01118377|Drug|Capecitabine|Capecitabine was supplied as film-coated tablets.
1873251|NCT01118377|Radiation|Radiation therapy|Local irradiation using conformal, volume-based delivery techniques. The nominal energy of the X-rays was ≥ 4 MV.
1873252|NCT01118390|Device|Laser Nd:YAG 1064nm|Patients with leg telangiectasias are treated with 3 sessions of Nd:YAG 1064nm, with 14 days interval
1873253|NCT01118390|Other|Sclerotherapy|Patients with leg telangiectasias are treated with 3 sessions of sclerotherapy, with 14 days interval
1873254|NCT01118403|Drug|Sultamicillin|Ampoules per 1.5 grams, three grams intravenously every 6 hours for 4 doses diluted in physiologic Sodium Chloride Solution
1873255|NCT01118416|Behavioral|HIV prevention intervention randomized control trial|Substance using HIV-negative young MSM who engage in sexual risk are randomized to either a motivational interviewing or an education condition to reduce sexual risk and drug use.
1873256|NCT01118429|Drug|Oxybutynin|Oxybutynin was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutynin into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
1873302|NCT01118871|Drug|Darunavir, Ritonavir and Etravirine|Darunavir 800 mg daily Ritonavir 100 mg daily Etravirine 400 mg once daily
1873303|NCT01118884|Drug|Promethazine|Syrup ,1 mg/kg, oral , 30 minutes before dental procedure , its duration is 4-6 hours
1873257|NCT01118429|Drug|Placebo|Oxybutyinine was prescribed for 12 weeks, in progressively increasing doses throughout treatment. At their first visit, the patients were given 2.5 mg of oxybutyn into be taken once a day in the evening, were instructed to increase the dose to 2.5 mg twice a day from the eighth to the 42nd day, and to contact the doctor if they experienced any side effect. After this period they were seen in a second visit, and the dose was increased to 5 mg twice a day from the 43rd to the end of the 84thday, to when a third visit was scheduled.
1873258|NCT01118455|Device|Vagus Nerve Stimulation (VNS) Therapy|Vagus Nerve Stimulation (VNS) Therapy is delivered by an implantable device similar to a pacemaker that sends mild stimulation to the left vagus nerve to help improve seizure control.
1873259|NCT01118455|Drug|Anti-Epileptic Drug (AED)|Subject has tried at least 2 appropriate AEDs tested to tolerance or to blood levels at upper end of the target range of which at least 2 had been tolerated at normal doses.
1873260|NCT01118520|Drug|perindopril arginine|10mgs orally daily for the duration of the trial
1873261|NCT01118520|Drug|amlodipine 5mgs|5 mgs taken orally daily for the duration of the trial
1873262|NCT01118520|Drug|placebo|one daily
1873263|NCT01118533|Device|metal reusable blades MacIntosh|laryngoscope blades
1873264|NCT01118533|Device|Single use plastic blades HEINE XP®|laryngoscope blades
1873265|NCT01118559|Drug|YM150|oral
1873266|NCT01118572|Drug|YM177|oral
1873267|NCT01118572|Drug|etodolac|oral
1873268|NCT01118572|Drug|Placebo|oral
1873269|NCT01118585|Procedure|Transoral Incisionless Fundoplication (TIF)|The TIF procedure results in the creation of an esophago-gastric fundoplication extending up to 4 cm above the Z-line and 270 degrees around the esophagus.
1873270|NCT01118598|Drug|tredaptive (nicotinic acid/ laropiprant)|tablet of nicotinic acid 1000 mg/laropiprant 20 mg one tablet of for 4 weeks followed by two tablets od for 8 weeks
1873271|NCT01118598|Drug|placebo|placebo tablet one a day for first 4 weeks followed by two a day for 8 weeks
1873272|NCT01118611|Drug|Aurora B/C kinase inhibitor GSK1070916A|
1873273|NCT01118611|Other|laboratory biomarker analysis|
1873274|NCT01118611|Other|pharmacological study|
1873275|NCT01118611|Procedure|diffusion-weighted magnetic resonance imaging + PET CT|
1873276|NCT01118611|Radiation|fludeoxyglucose F 18 dynomic contrast|
1873277|NCT01118624|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 3-5 minutes.
Initial dose: 190 mg/m2
Dose reductions per protocol: 150 mg/m2, 120 mg/m2, and 100 mg/m2 allowed for defined toxicities.
Administered on days 1 and 15 of a 4-week cycle (every 2 weeks) until criteria for discontinuation per the protocol are met."
1873278|NCT01118624|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection
Administered within 10 weeks prior to first dose of pralatrexate, every 8-10 weeks throughout the study and for at least 30 days after the last dose of pralatrexate."
1873279|NCT01118624|Dietary Supplement|Folic Acid|"1.0-1.25 mg orally
Administered daily for at least 7 days prior to first dose of pralatrexate, throughout the study and for at least 30 days after the last dose of pralatrexate."
1873280|NCT01118637|Behavioral|StopPulling.com|subsidized access to an interactive self-help website for TTM
1873281|NCT01118663|Drug|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free)|Acetadote EF (Ethylenediaminetetraacetic Acid (EDTA) - Free) {new formulation} 200 mg/kg in 1000 ml diluent over 4 hours; then 100 mg/kg in 1000 ml diluent over 16 hours
1873282|NCT01118663|Drug|Acetadote|Acetadote [old formulation] 150 mg/kg in 200 mL diluent over 60 minutes; then Acetadote 50 mg/kg in 500 mL diluent over 4 hours; then Acetadote 100 mg/kg in 1000 mL diluent over 16 hours.
1873283|NCT01118676|Drug|cilengitide, radiochemotherapy|"Cilengitide will be administered alone as continuous infusion two weeks before the radiochemotherapy and will then be continued during radiochemotherapy (standard radiotherapy of 66 Gy, 2 Gy per daily fraction, and cisplatin and vinorelbine based chemotherapy)as continuous infusion.
The dose levels investigated will be applied to the continuous administration of cilengitide(a maximum of 4 dose levels : 12, 18, 27 et 40 mg /hour).
After the end of concomitant radiochemotherapy, cilengitide will be administered i.v. at a dose of 2000 mg twice weekly until the end of chemotherapy."
1873284|NCT01118689|Drug|MLN0128|MLN0128 administered orally once daily for 28 days
1873285|NCT01118702|Drug|Ritalin-SR|3-20mg tablets, once
1873286|NCT01118702|Drug|Concerta|one 54mg tablet, once
1873287|NCT01118702|Drug|Novo-Methylphenidate ER-C|one 54mg tablet, once
1873289|NCT01118728|Drug|Sarilumab|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1873294|NCT01118767|Other|Cell phone intervention|Participant receives short text messages, including: antiretroviral reminders, clinic appointment reminders, and preventive/educational messages
1873295|NCT01118780|Drug|Duloxetine|Administered by mouth, daily for 10 weeks
1873296|NCT01118780|Drug|Placebo|Administered by mouth, daily for 10 weeks
1873297|NCT01118793|Drug|Clopidogrel|150 mg dosage of Clopidogrel for 7 to 10 days.
1873298|NCT01118819|Biological|Clostridium novyi-NT spores|Phase 1 study: It will be an escalating dose design, with no intracohort escalation. The first cohort dose will begin at 1 X 10(5) spores/kg and will escalate by tripling through 5 cohorts up to 100 x 10(5) spores/kg.
1873299|NCT01118845|Drug|SyB L-0501|"The administration of SyB L-0501 at 120 mg/m^2/day by intravenous infusion on day 2 and 3 of each 21-day cycle with up to 6 cycles. Dose modifications are permitted from 2nd cycle according to dose reduction schedule.
SyB L-0501 60 mg/m^2, 90 mg/m^2 or 120 mg/m^2/day on Day 2 and Day 3 will be followed by 18 days of observation."
1873300|NCT01118845|Drug|Rituximab|The administration of rituximab at 375 mg/m^2/day by intravenous infusion on day 1 of each 21-day cycle with up to 6 cycles. Dose modifications are not permitted.
1873301|NCT01118871|Drug|Darunavir, Ritonavir, Truvada|Darunavir 800 mg daily Ritonavir 100 mg daily Tenofovir 245 mg daily Emtricitabine 200 mg daily
1873304|NCT01118897|Radiation|Tomotherapy|"Radiotherapy 57-60 Gy in 25 fraction to PTV boost (SIBV - simultaneous integrated Boost volume) (2.3-2.4Gy/Fr)
Concurrent chemotherapy Weekly concurrent CT schedule: Inj Gemcitabine 300 mg/m2 weekly during RT.
Surgery: All patients will be evaluated for surgery in the joint clinic by surgeons and other treating physicians at 6-8 weeks post CT-RT. PET CT Scan will be used as the imaging modality. Patients suitable for R0 resection will be planned for surgery. Inoperable patients will be treated with palliative chemotherapy."
1873306|NCT01118923|Dietary Supplement|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
1873307|NCT01118923|Dietary Supplement|Placebo|3 placebo-tablets daily for 12 weeks
1873308|NCT01118936|Dietary Supplement|Magnesium supplement (magnesium hydroxide/ -oxide)|3 tablets of Mablet (360 mg per tablet) daily for 12 weeks Produced by: Gunnar Kjems APS
1873309|NCT01118936|Dietary Supplement|Placebo|3 tablets of placebo daily for 12 weeks
1873310|NCT01118949|Drug|Lacosamide|Lacosamide is supplied as 50 mg, 100 mg, 150 mg, and 200 mg tablets. Subjects will begin a Dose-Titration Phase of Lacosamide at 100 mg/day (50 mg bid, approx. 12 hours apart, once in the morning and once in the evening) for 1 week. Three (3) weekly increases will follow until the subject reaches a dosage of 200 mg/day, 300 mg/day, or 400 mg/day, as deemed clinically appropriate. The final titration will be followed by a 6-week Maintenance Phase. Subjects who complete the Maintenance Phase have the opportunity to enroll in an open-label extension study; those who do not enroll will begin a 3-week End-of-Study Phase when Lacosamide will be tapered off gradually at a recommended rate of 200 mg/day/week.
1873311|NCT01118962|Drug|Lacosamide|Lacosamide was supplied as 50 mg and 100 mg tablets. The starting Lacosamide dose was the same dose reached by a subject at the end of SP0961 (NCT01118949). At the beginning of SP0962, the dose may be maintained, or increased or decreased by 100 mg /day, as deemed clinically appropriate to optimize tolerability and seizure reduction. Dose increases should be no faster than 100 mg/ day per week up to a maximum of 800 mg/ day. Lacosamide was administered twice daily (approx. 12 hours apart, once in the morning and once in the evening) in 2 equally divided doses for up to a 56-week Treatment Phase. The Treatment Phase was followed by a 5-week End-of-Study Phase, during which subjects had to be tapered off Lacosamide at a recommended decrease rate of 200 mg/ day per week.
1873312|NCT01118975|Drug|Vorinostat|"300 mg 4 days on then 3 days off
As defined in the protocol, the dose of vorinostat was increased to 400 mg 4 days on then 3 days off in the pilot phase because the adverse event threshold was not met. In the Phase II cohort, the dose of vorinistat was 400 mg 4 days on and 3 days off."
1873313|NCT01118975|Drug|Lapatinib|1,250 mg once daily
1873314|NCT01118988|Behavioral|Mentorship|Subjects in this condition receive 10 sessions over 8 weeks (2 sessions for the first 2 weeks, 1 session per week for the remaining 6 weeks) with a mentor presenting information on pain self-management and coping techniques, as well as discussing concerns and feelings with the subject receiving the intervention. Information is presented on slides via internet connected home computer. Mentor-mentee interaction is conducted via telephone on a conference call line with a doctoral level psychologist monitoring call for safety of all parties.
1873315|NCT01125800|Drug|LDE225|LDE225/sonidegib capsules were supplied to the Investigators at dose strengths of 50 mg, 100 mg, 200 mg, and 250 mg.
1873316|NCT01125813|Biological|recombinant Factor VIII|intravenous infusion of factor FVIII every other day.
1873317|NCT01125852|Procedure|Angiographic embolization|Patients in the intervention arm receive supplementary angiographic embolization within 24 hours from the therapeutic endoscopy.
1873318|NCT01125852|Procedure|Therapeutic endoscopy|Patients are treated with standard therapeutic upper endoscopy including endoscopic combination therapy.
1873319|NCT01125865|Device|SEMS insertion|Self-expandable metallic stent will be inserted for malignant hilar obstruction.
1873320|NCT01125865|Device|DLS insertion|DoubleLayer plastic stent will be inserted for malignant hilar obstruction.
1873321|NCT01125878|Dietary Supplement|Placebo|placebo
1873322|NCT01125878|Dietary Supplement|Starch composite B|fiber mixture
1873323|NCT01125878|Dietary Supplement|Starch composite C|fiber mixture
1873324|NCT01125878|Dietary Supplement|Starch composite D|fiber mixture
1873325|NCT01125891|Drug|gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
1873326|NCT01125891|Drug|ON 01910.Na|The starting dose of ON 01910.Na is 600 mg/m2 as a 2 hour intravenous (i.v.) infusion on days 1, 4, 8, 11, 15 and 18 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 600 mg/m2, DL 2 = 1200 mg/m2, DL 3 = 1800 mg/m2) of new patients.
1873327|NCT01125904|Drug|crizotinib|Oral liquid. Taste assessment of new formulation. Subjects will not ingest the drug.
1873328|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear.
1873329|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear.
1873330|NCT01125917|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear.
1873331|NCT01125930|Drug|vehicle gel|Topical gel that does not contain active drug. The gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use.
1873332|NCT01125930|Drug|Atralin gel|Topical Atralin gel will be applied initially 3 times per week to the face. If no irritation seen at follow up visit, the investigator will consider increasing the frequency of use. This topical medication will not be applied more than once daily. If there is irritation, the subject will be asked to decrease frequency of use. This drug will be used for the duration of the study.
1873333|NCT01125943|Drug|Acetylcholine|Intra-arterial infusion
1873334|NCT01125943|Drug|Nitroprusside|Intra arterial infusion
1873335|NCT01125943|Drug|Bevacizumab|Intra arterial infusion
1873336|NCT01125956|Behavioral|Assigned a peer counselor|Dyads will be given $20 per month if they have contact 4 or more times during a month.
1873337|NCT01125956|Behavioral|Financial incentives|Participants will be given $100 for reduction of HbA1c by 1 point in a 6 month period and $200 for reduction by 2 points.
1873338|NCT01125969|Behavioral|Incentives|Incentives will be offered for checking blood glucose each morning and for control of blood glucose (between 80-140 mg/dL).
1873339|NCT01125969|Behavioral|Education|Standard brochure about improving blood sugar control plus warnings about dangers of persistently high sugars and hypoglycemia
1873340|NCT01125969|Behavioral|Peer mentoring|Participant is assigned a peer mentor who is matched on gender, race and age and who achieved good glucose control after previously having poor glucose control.
1873341|NCT01125982|Drug|Propofol|Continuous intravenous infusion at 3-6 µg/mL (Ce - Target Controlled Infusion) during anaesthesia to provide sleep.
1873342|NCT01125982|Drug|Desflurane|Continuous inhalation at 0.7-0.8 MAC (endtidal) during anaesthesia to provide sleep
1873343|NCT01125995|Radiation|early CCRT|"patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 & Cisplatin 70mg/m2 D1.
radiotherapy start from day 1 of 1st chemotherapy cycle and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
1873344|NCT01125995|Radiation|late CCRT|"patients will be received with 4 cycles of etoposide 100mg/m2 D1-3 & Cisplatin 70mg/m2 D1.
radiotherapy start from day 1 of the third cycle of EP chemotherapy and complete 5250cGy/25fraction (daily one fraction, 210cGy)."
1873345|NCT01126008|Drug|CCRT with weekly docetaxel & cisplatin|radiotherapy: 70Gy/35 fraction for 7 weeks chemotherapy: docetaxel 20mg/m2 and cisplatin 20mg/m2 weekly for 6 weeks
1873346|NCT01126021|Behavioral|Financial incentives|Participants are eligible for incentives if they participate in at least 30 games per day.
1873347|NCT01126021|Behavioral|No incentives|Participants will be given training and access to the software to participate in mental exercises but will not be given financial incentives for participation.
1873348|NCT01126034|Other|intervention letter|"Physicians in the intervention group were mailed a written feedback letter regarding their patients who were prescribed questionable metoclopramide therapy. Non-intervention providers received no letter. The letter consisted of the following components:
The name and medical record # of the patients involved
Information regarding the metoclopramide prescription: dates, dosage, indication recorded, and the duration of therapy
A reminder of the adverse effect of long-term metoclopramide therapy
A recommendation to consider having the patient undergo a trial of metoclopramide discontinuation if appropriate, and documentation of a discussion of risk and benefits of metoclopramide therapy with patients
A request that the physician document the discontinuation trial in the electronic medical record"
1873349|NCT01126047|Other|eCO testing|exhaled carbon monoxide testing measured in duplicate on each of 2 machines immediately prior to the carboxyhemoglobin blood draw and four minutes after the clinical measurement of DLCO
1873350|NCT01126060|Drug|Usage of Fibrin sealant|Usage of 1 vial of fibrin sealant after hemostasis in total thyroidectomy with anterior compartment neck dissection
1873351|NCT01126060|Procedure|Thyroidectomy|surgical removal of bilateral thyroid glands
1873352|NCT01126073|Drug|Niacin/laropiprant|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, willer receive ER niacin/laropiprant in addition to the statin therapy. Patients will receive ER niacin/laropiprant 1000mg/20 mg tablet for 4 weeks, after that the dose will be increased to 2000mg/40mg tablet. The intention is that all patients receive 2000 mg/40mg dose for the rest of the study period, but should they be intolerant to the higher dose, the maximum tolerated dose will be used.
1873353|NCT01126073|Drug|Placebo|After two weeks patients, who have already been on a stable dose of a statin for at least 6 weeks, will receive placebo in addition to the statin therapy. Patients will receive 1 tablet for 4 weeks, after that the dose will be increased to 2 tablets for the rest of the study period.
1873354|NCT01126086|Drug|otamixaban XRP0673|"Pharmaceutical form: solution for injection
Route of administration: intravenous"
1873355|NCT01126099|Drug|Prazosin|4 mg capsules twice daily for 12 weeks
1873356|NCT01126099|Drug|Placebo|Placebo capsules twice daily for 12 weeks
1873357|NCT01126112|Biological|Panitumumab|Panitumumab: 6 mg/Kg Q2W
1873358|NCT01126125|Dietary Supplement|Iodized oil|400 mg of iodine vs 100 mg of iodine as iodized oil
1873359|NCT01126294|Dietary Supplement|5 mg melatonin|Patients will receive 5 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
1873360|NCT01126294|Dietary Supplement|10 mg melatonin|Patients will receive 10 mg melatonin once the evening before surgery and then again at 90 minutes before surgery.
1873361|NCT01126294|Dietary Supplement|Placebo|Patients will receive placebo once the evening before surgery and then again at 90 minutes before surgery.
1873362|NCT01126307|Drug|Verapamil|80 mg tid
1873363|NCT01126307|Drug|placebo|placebo tid
1873364|NCT01126320|Device|AnapnoGuard 100,|Respiratory guard system during mechanical ventilation with routine mechanical ventilator
1873365|NCT01126320|Device|routine mechanical ventilator|routine mechanical ventilation
1873366|NCT01126346|Behavioral|HIPEC Orientation|Introduction to SRB (survivorship resource book); Clinic Tour; Lunch with Question and Answer Session
1873367|NCT01126346|Behavioral|Consultation with Survivorship Navigator|Weekly psychosocial support via phone from Survivorship Navigator for 3 weeks prior to HIPEC; Inpatient consults occurring 3 to 4 days post-HIPEC and biweekly for 2 weeks and weekly until hospital discharge; Post-Hospital Discharge consults via phone twice per month for one month
1873368|NCT01126346|Other|Questionnaires|Questionnaires Completed at 4 time points: T1 pre-HIPEC orientation, T2 with in 1 week of orientation, T3 1 month post HIPEC and T4 3 months post HIPEC. Questionnaires include Utility of SRB, Medical Outcomes Study Health Survey, Short Form (SF-12), Center for Epidemiologic Studies-Depression Scale (CES-D), The Brief Illness Perception Questionnaire, The Distress Thermometer, The State-Trait Anxiety Inventory (STAI)
1873369|NCT01126359|Drug|Lidocaine|Interventional dressing change: iv or po pain medication with injection of 1% lidocaine retrograde up the suction tube into the sponge.
1873370|NCT01126359|Drug|Placebo-Saline|Control dressing change: iv or po pain medication and injection of 0.9% normal saline retrograde up the suction tube.
1873371|NCT01126385|Device|DensiProbe Spine|Intraoperative DensiProbe Spine measurements
1873372|NCT01126398|Procedure|ankle or distal tibia surgery|internal fixation for ankle or distal tibia fracture
1873373|NCT01126411|Procedure|immunoadsorption / immunglobulin substitution|Immunoadsorption with protein-A columns on five consecutive days with subsequent human polyclonal immunoglobulin G substitution after day 5 (0,5g /kg bodyweight)
1873378|NCT01126437|Drug|tiotropium 1.25 mcg (2 actuations/day)|soft mist inhaler 2 actuations=2 puffs/day
1873379|NCT01126437|Drug|tiotropium 2.5 mcg (2 actuations/day)|soft mist inhaler (2 actuations=2 puffs/day)
1873380|NCT01126450|Drug|lenalidomide|Given orally
1873381|NCT01126450|Biological|cetuximab|Given IV
1873382|NCT01126450|Other|mutation analysis|Correlative studies
1873383|NCT01126450|Other|polymerase chain reaction|Correlative studies
1873384|NCT01126450|Genetic|polymorphism analysis|Correlative studies
1873385|NCT01126463|Drug|188Re-SSS Lipiodol|Hepatic Intra-Arterial Administration of radio-active lipiodol.
1873386|NCT01126476|Other|Proton Radiotherapy|
1873387|NCT01126502|Drug|alvespimycin hydrochloride|Given IV
1873388|NCT01126502|Other|diagnostic laboratory biomarker analysis|
1873389|NCT01126502|Other|pharmacogenomic studies|
1873390|NCT01126502|Other|pharmacological study|
1873391|NCT01126515|Procedure|Magnetic Resonance Imaging|Imaging of the brain without gadolinium will be performed with a 3 Tesla magnetic resonance (MR) System (Intera Achieva 3T; Philips Medical Systems). The protocol will include anatomical sequences, a diffusion tensor imaging sequence with fiber tracking, and auditory, visual, and motor functional magnetic resonance imaging (MRI).
1873392|NCT01126515|Procedure|Computed Tomography Angiography|Computed tomography angiography (CTA) with intravenous (IV) contrast will be performed on a 320 head computed tomography (CT) scanner, assessing brain perfusion.
1873393|NCT01126528|Dietary Supplement|Vitamin D3|35,000 IU per week, started at 26-29 weeks gestation, until delivery.
1873394|NCT01126528|Dietary Supplement|Placebo control|Miglyol 812, administered weekly from 26-29 weeks gestation until delivery.
1873395|NCT01126541|Drug|rituximab|Arm A: 1000 mg IV (one infusion) every 2 months \nArm B: 2 x 1000 mg IV (2 infusions) every 2 months
1873396|NCT01126567|Other|Sampling Rate|Both cohorts will have a lumbar catheter placed and CSF samples will be obtained. The only difference between the two arms will be the sampling rate of CSF. One arm will have a high sampling rate and the other will have a low sampling rate.
1873397|NCT01126580|Drug|Metformin|
1873398|NCT01126580|Drug|LY2189265|
1873399|NCT01126580|Drug|Placebo (oral)|
1873400|NCT01126580|Drug|Placebo (subcutaneous)|
1873401|NCT01126593|Drug|0.5% bupivacaine|Study group patients will receive a subacromial continuous standard spring loaded infusion catheter with 200cc of 0.5% bupivacaine in its reservoir. The bupivacaine will have an infusion rate of 4cc an hour.
1873402|NCT01126593|Drug|Normal Saline|The placebo group will receive the same subacromial infusion catheter however, the reservoir will be filled with 200cc of 0.9% Normal Saline.
1873403|NCT01126606|Drug|Dermacid Silver (Lactic acid)|Liquid soap, daily use
1873404|NCT01126606|Drug|Glycerine Vegetal Soap Granado Traditional|Vegetal soap, daily use
1873405|NCT01126645|Procedure|RFA|"A max.of 2 percutaneous RFA sessions is permitted per patient with a max.of 2 liver lesions treated in each RFA session. Randomization to sorafenib or placebo is performed after completion of RFA. Percutaneous RFA is to be performed according to the manufacturer's instructions and following as far as possible routine procedures of the participating hospital. Typically, RFA will be performed under conscious sedation, general anesthesia is permitted. After local anesthesia of the site of puncture, the applicator is positioned in the center of the lesion using ultrasound-, CT- or MR-guidance. The success of ablation is to be controlled directly after RFA using ultrasound, contrast-enhanced CT, or MR imaging. If for any reason RFA is deemed incomplete within the immediate follow-up (up to 2 weeks after the initial ablation), RFA is to be repeated once (in this case, the total (max.) number of RFA sessions will be three).
The study procedure guide will contain further instructions for RFA."
1873406|NCT01126645|Procedure|Radioembolization (SIRT)|"One SIRT prescription consists of the pre-treatment assessment followed by one or 2 treatment sessions The aim of pre-treatment assessment is to ensure delivery of the microspheres to the target. Evaluation includes a determination of the arterial location and any consequent necessity for coil-embolization of the gastroduodenal artery, right gastric artery and any other accessory arteries to prevent inadvertent administration of microspheres into the gastrointestinal tract or pancreas. In addition, parasitic extrahepatic supply should be coil-embolized.
Patients in whom the shunt fraction indicates potential exposure to the lung to an absorbed radiation dose of more than 30 Gy should be excluded from treatment with SIR-Spheres. Patients who are randomized to receive SIRT but who are not regarded as eligible for SIRT after the pre-treatment assessment will be switched to the sorafenib only group within the palliative treatment arm."
1873407|NCT01126658|Other|drainage of cerebrospinal fluid (CSF)|Once the ICP exceed 20-25 mmHg, 1 ml of CSF was withdrawn from EVD and the corresponding change of ICP value was recorded. The withdrawn drainage of CSF continued until the final ICP value declined to 10 mmHg.
1873408|NCT01126671|Drug|Supplemental Vitamin D|Two doses of daily supplemental vitamin D taken for 11 weeks.
1873409|NCT01126684|Drug|Atorvastatin|10 mg of atorvastatin once daily for six months
1873410|NCT01126684|Drug|Placebo|placebo once daily for six months
1873411|NCT01126697|Drug|Coenzyme Q10 and Lisinopril|Arm 1. Coenzyme Q10: taken once a day each morning by mouth OR Arm 2. Lisinopril: taken once a day each morning by mouth OR Arm 3. Coenzyme Q10 and lisinopril: each taken once a day in the morning by mouth OR Arm 4. Enhanced Standard Care (more doctor visits, muscle and breathing testing, and x-rays for monitoring, but no study medication).
1873412|NCT01126723|Other|Tai Chi|The Tai Chi intervention will consist of a 12 week, instructor-led, group-based Tai Chi training program (two, one-hour sessions per week).
1873413|NCT01126723|Other|Education-Control|The Education-Control intervention consists of a 12 week, instructor-led attention control program consisting of health education and mind-body breathing exercises (two, one-hour sessions per week)
1960177|NCT03282422|Device|Home-based protocol in specific tasks|The home-based protocol in specific tasks will be an individualized protocol designed for the child according to the results of the baseline assessment and will require active participation. It is a program that is integrated into the daily routines of the child. A study investigator will tell the family the procedure to follow.
1873667|NCT01121822|Biological|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
1991430|NCT01113801|Drug|Placebo|Subcutaneous injection given monthly for 12 months
1960178|NCT03282422|Device|Upper-limb splint|In the case that treatment with splint is also received, a researcher of this study will take measurements of the hand and will provide the appropriate splint. The intensity of the application will be 5 days a week from monday to friday, for 6 hours a day, for a period of 6 weeks.
1873417|NCT01126749|Drug|gemcitabine plus cisplatin|Eribulin Mesylate plus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin
1873418|NCT01126749|Drug|E7389 in combination with gemcitabine plus cisplatin|Eribulin Mesylate plus Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin
1873419|NCT01126762|Behavioral|Dietary advice|Dietary advice regarding consumption of low mercury, high DHA fish
1873420|NCT01126762|Behavioral|Control|Advice regarding healthful diet during pregnancy, not focused on fish intake
1873423|NCT01126814|Drug|Imatinib (Gleevec)|
1873424|NCT01126827|Behavioral|Mindfulness-Based Cognitive Behavioral Therapy or Supportive Psychotherapy|12 weekly group therapy sessions
1873427|NCT01126853|Biological|Twinrix|Up to three intramuscular doses of 1cc of Twinrix (combined hepatitis A/B vaccine) at 0, 1, and 6 months post-enrollment
1873428|NCT01126866|Drug|intensified chemotherapy (FOLFOXIRI/Bevacizumab)|intensified chemotherapy (FOLFOXIRI/Bevacizumab)
1873429|NCT01126879|Dietary Supplement|genistein|Given orally
1873430|NCT01126879|Other|placebo|Given orally
1873431|NCT01126879|Procedure|therapeutic conventional surgery|Radical prostatectomy for treatment of prostate cancer
1873432|NCT01126892|Drug|Nilotinib|
1873433|NCT01126918|Behavioral|Body Project|Participants in this intervention attend four 1-hour group meetings (one per week for four consecutive weeks) in which they complete a series of written and verbal exercises intended to increase body satisfaction.
1873434|NCT01126944|Device|heart mate II|left ventricular assist device
1873435|NCT01126957|Drug|Ketamine|Ketamine was given as a 0.5mg / Kg bolus.
1873436|NCT01126957|Drug|Placebo|Placebo given as an bolus to control group.
1873437|NCT01126957|Drug|Fentanyl|Fentanyl 0.5 - 1.5 micrograms given to both arms prior to Ketamine or placebo
1873438|NCT01126957|Drug|Propofol|Propofol given to both arms to maintain sedation throughout procedure.
1873439|NCT01126970|Drug|Placebo + Placebo|Placebo + Placebo
1873440|NCT01126970|Drug|400 mg velneperit (S-2367) + Placebo|400 mg velneperit (S-2367) + Placebo
1873441|NCT01126970|Drug|Placebo + 120 mg Orlistat|Placebo + 120 mg Orlistat
1873442|NCT01126970|Drug|400 mg velneperit (S-2367) + 120 mg Orlistat|400 mg velneperit (S-2367) + 120 mg Orlistat
1873443|NCT01126983|Device|Suture|Suture (2.0 Mono-filament nylon suture) will be used to secure the leads to the skin. Benzoin and Steri-strips will also be used.
1873444|NCT01126983|Device|Lead Anchor|Suture (2.0 Mono-filament Nylon suture) will be applied over the lead anchor(Lead Anchor St.Jude Medical Co, model-long, No# 1106) to the skin. Benzion and Steri-strips will also be used.
1873445|NCT01126996|Procedure|Venepuncture|"Venepuncture and blood sample collection in 2010 in a sample of children who received a single dose of a MenC conjugate vaccine at age 1-3 years 10 years earlier.
A booster dose of a MenC conjugate vaccine (optional)."
1873446|NCT01127009|Drug|bortezomib|Given IV
1873447|NCT01127009|Drug|mitoxantrone hydrochloride|Given IV
1873448|NCT01127009|Drug|etoposide|Given IV
1873449|NCT01127009|Drug|cytarabine|Given IV
1873450|NCT01127009|Other|flow cytometry|Correlative studies
1873451|NCT01127022|Dietary Supplement|choline chloride|Women will consume a diet providing 380 mg/d total choline plus 100 mg/d supplemental choline [from choline chloride] for a total choline intake of 480 mg/d. The choline chloride will be administered in cran-grape juice.
1873452|NCT01127022|Dietary Supplement|Choline Chloride|Women will consume a diet providing 380 mg/d total choline plus 550 mg/d supplemental choline [from choline chloride] for a total choline intake of 930 mg/d. The choline chloride will be administered in cran-grape juice.
1873453|NCT01127035|Biological|sublingual immunotherapy|
1873454|NCT01127035|Biological|placebo|
1873455|NCT01127048|Drug|Suppositories containing Ivy leaves dry extract|Suppositories containing Ivy leaves dry extract
1873456|NCT01127048|Drug|Placebo|Suppositories containing no Ivy leaves dry extract
1873457|NCT01127061|Behavioral|Exercise training|4 months of exercise training that is custom-designed based on individual cardiopulmonary stress test data. Regimen starts at low intensity (60% of heart rate reserve) and frequency (20 minutes, 3 days per week) and increases with a goal of 80% of heart rate reserve and exercising 60 minutes 4-7 days per week.
1873458|NCT01127074|Biological|KS24.22 cells|"The first four vaccinations, which were given every two weeks, were followed by four monthly vaccinations. Additional vaccinations were permitted on request for patients who exhibited stable disease (SD).
Immediately before administration, KS24.22 cells were thawed and lethally irradiated (200 gray). KS24.22 cells were adjusted to 107/ml in Ringer-Lactate-solution, transferred to 1 ml syringes and stored on ice until injected within a time frame of 2h. Vaccinations were given i.d. in the thigh with a total volume of 1 ml divided between two injection sites."
1873459|NCT01127087|Drug|Oxazyme|"Oxazyme (registered trademark) is a non-systemic orally delivered drug composed of recombinant oxalate decarboxylase (OxDC). It is formulated to enzymatically degrade available dietary oxalate prior to its absorption.
Dosing: 1gm Oxazyme containing approximately 1600 Units OxDC in a sachet administered BID together with lunch and dinner. Subjects were instructed to open the oxazyme sachets and either sprinkle on food or add to a glass of water or fruit juice and consume the contents with a meal twice daily."
1873500|NCT01127438|Drug|fospropofol disodium Subgroup 3 Lower Dose|(Dose of Initial IV (Titration) Bolus 3.9mg/kg) (Administered to Subgroup 3, Weight >/= 60 kg and Age >/= 65 years and ASA 3 or 4
1873600|NCT01128335|Drug|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
1873460|NCT01127100|Drug|transdermal fentanyl matrix, gabapentin|"transdermal fentanyl matrix: during 1st to 6th days, 12ug/h of fentanyl matrix will be applied. During 7th to 28th days, the dosage of fentanyl matrix will be increased until the pain score decrease not more than 2 every 6 days. The maximal dosage is 100ug/h. During 29th to 56th days, the dosage will be maintained.
Gabapentin: the 1st day, 300mg hs, the 2nd day, 300mg bid, the 3th to 4th days, 300mg tid, the 5th to 6th days, 300mg-300mg-600mg the 7th to 28 days, the dosage will be increased until the pain score decreased not more than 2 and the maximal dose is 2400mg per day. During 29th to 56th days, the dosage will be maintained."
1873461|NCT01127113|Other|Infusion of investigational product|The investigational product will be delivered via intravenous infusion
1873462|NCT01127113|Other|Cardiac magnetic resonance imaging|Cardiac MRI will be performed prior to infusion of investigational product and 1, 2, 7 and 30 days after.
1873463|NCT01127126|Drug|Bryophyllum pinnatum, Placebo in form of Lactose|"Comparison Bryophyllum (2100mg/d) against Placebo (2100mg/d) regarding effectivity and safety.
Bryophyllum and Placebo are both administered for 8 weeks. Bryophyllum and Placebo are both given in form of capsules, 350mg per capsule, 2-2-2/d."
1873464|NCT01127152|Procedure|Measure of arterial pressure|Measure of arterial pressure will occur every five minutes during the thirty minutes before the relay and during the fifteen minutes after the relay.
1873465|NCT01127165|Drug|zonisamide low dose group|Initial dose was 2mg/kg/day, increased after 1~2 weeks to 3~4mg/kg/day.
1873466|NCT01127165|Drug|zonisamide high dose group|Initial dose was 2mg/kg/day, increased after 2~4 weeks to 6~8mg/kg/day.
1873467|NCT01127178|Drug|E7016 + TMZ|Single-Dose PK Period (single oral dose of E7016 on Day -7) in the Dose-Escalation Component; Multiple-Dose Treatment Cycles (7 days of oral E7016 + 5 days of oral TMZ) added in Cycle 1 of the Dose-Escalation Component and in Cycles 1 through 6 of the Expansion Component.
1873468|NCT01127191|Other|military equipment|Military exercise of 24 hours
1873469|NCT01127204|Drug|AZT-3TC-LPV/r twice a day|AZT sirup (10mg/ml): 4 mg/kg or 180 mg/m2 twice daily 3TC sirup (10mg/ml): 4 mg/kg twice daily LPV/r sirup (80/20 mg/ml): 12 mg/kg twice daily
1873470|NCT01127204|Drug|ABC-3TC-EFV once a day|ABC sirup (20mg/ml): 16 mg/kg once daily in the morning 3TC sirup (10mg/ml): 8 mg/kg once daily in the morning EFV sirup (30mg/ml): 25 mg/kg once daily in the morning before food intake
1873471|NCT01127217|Drug|amlodipine/losartan|amlodipine 5mg/losartan 50mg, amlodipine 10mg/losartan 50mg (+HCTZ 12.5mg)
1873472|NCT01127217|Drug|amlodipine|amlodipine 5mg, amlodipine 10mg (+ HCTZ 12.5mg)
1873473|NCT01127243|Procedure|day-case laparoscopic supracervical hysterectomy|patients discharged home the same day of the operation
1873474|NCT01127243|Procedure|inpatient LSH|patients discharged home the day after the operation
1873475|NCT01127256|Drug|zonisamide|Initial dose was 100mg/day, increased by 100mg. The maximum dose was 600mg/day.
1873476|NCT01127256|Drug|carbamazepine|Initial dose was 100mg/day, increased by 200mg every 1 week to 600mg/day. The maximum dose was 1200mg/day.
1873477|NCT01127269|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
1873480|NCT01127295|Drug|Tamoxifen, Letrozole, Anastrozole or Exemestane|Tamoxifen 20 mg/day during 5 years Létrozole 2.5 mg/day during 5 years Anastrozole 1 mg/day during 5 years Exémestane 25 mg/day during 5 years
1873481|NCT01127308|Drug|Ertugliflozin|Ertugliflozin 25 mg will be administered as a single oral suspension containing approximately 100 uCi of [14C]ertugliflozin
1873482|NCT01127321|Other|Placebo|A single double-blind dose of placebo matched to MEDI-570 subcutaneous injection on Day 1.
1873483|NCT01127321|Biological|MEDI-570 0.03 MG|A single open-label dose of MEDI-570, 0.03 milligram (mg) subcutaneous injection on Day 1.
1873484|NCT01127321|Biological|MEDI-570 0.1 MG|A single open-label dose of MEDI-570, 0.1 mg subcutaneous injection on Day 1.
1873485|NCT01127321|Biological|MEDI-570 0.3 MG|A single double-blind dose of MEDI-570, 0.3 mg subcutaneous injection on Day 1.
1873486|NCT01127321|Biological|MEDI-570 1 MG|A single double-blind dose of MEDI-570, 1 mg subcutaneous injection on Day 1.
1873487|NCT01127360|Drug|Bevacizumab|Intravitreal injections
1873488|NCT01127360|Drug|Ranibizumab|Intravitreal injections
1873489|NCT01127373|Radiation|Multi-Beam Intensity-Modulated Radiation Therapy|IMRT with multiple beams will be utilized to treat the breast or chest wall and axillary, supraclavicular and internal mammary lymph nodes. Treatment will be delivered once a day, 5 days a week for approximately 5 weeks. All missed radiation treatment visits will be made up. Daily set-up error will be checked prior to the delivery of every treatment.
1873490|NCT01127386|Drug|Lenalidomide|25mg od, dose reduction according to toxicity
1873491|NCT01127386|Drug|Lenalidomide|start with 5mg od and increase of dosage to 10mg, 15mg or 25mg until CRP response (50% decrease)
1873492|NCT01127386|Other|basic cachexia management (prokinetics, physical activity counselling, nutritional counselling)|twice during study
1873493|NCT01127412|Behavioral|Physical activity stimulating program|
1873494|NCT01127425|Procedure|laparoscopic colonic resection|Conventional surgery compared to laparoscopic sigmoid resection
1873495|NCT01127425|Procedure|laparoscopic sigmoid resection|sigmoid resection by laparoscopic surgery
1873496|NCT01127438|Drug|fospropofol disodium Subgroup 1 Lower Dose|Dose of Initial IV (Titration) Bolus 6.5mg/kg) (administered to Subgroup 1, Weight < 60 kg and Age < 65 years and ASAI and II)
1873497|NCT01127438|Drug|fospropofol disodium Subgroup 1 Approved Dose|(Dose of Initial IV (Titration) Bolus 385mg) (Administered to Subgroup 1, Weight <60 kg and Age <65 years and ASAI and II)
1873498|NCT01127438|Drug|fospropofol disodium Subgroup 2 Lower Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (administered to Subgroup 2, Weight < 60 kg and Age >/=65 years and ASA 3 or 4
1873499|NCT01127438|Drug|fospropofol disodium Subgroup 2 Approved Dose|(Dose of Initial IV (Titration) Bolus 297.5mg) (Administered to Subgroup 2, Weight <60 kg and Age >/=65 years and ASA 3 or 4
1873596|NCT01128322|Drug|S-Amlodipine|
1873597|NCT01128322|Drug|Telmisartan|
1873501|NCT01127438|Drug|fospropofol disodium Subgroup 3 Approved Dose|Dose of Initial IV (Titration) Bolus 4.875 mg/kg) (Administered to Subgroup 3, Weight >/= 60 kg and Age >/= 65 years and ASA 3 or 4
1873502|NCT01127451|Drug|Denileukin diftitox|"Test product: dose and mode of administration:
denileukin diftitox was originally administered by intravenous infusion over 30-60 minutes according to 1 of 2 treatment arms:
12 mcg/kg/day on Days 1 through 4 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks);
12 mcg/kg/day on Days 1, 8, and 15 of each 21-day treatment cycle, for a total of 4 cycles (12 weeks)
ARM 2 is now closed. Patients experiencing clinical benefit (irSD, irPR, or irCR per irRC) after 4 cycles of treatment, may continue their denileukin diftitox treatment for up to 8 cycles."
1873503|NCT01127464|Drug|DCVax-001|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
1873504|NCT01127464|Drug|Poly-ICLC|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
1873505|NCT01127464|Drug|Placebo|Comparison of 3 different doses of DCVax-001 administered with poly-ICLC, the administration of poly-ICLC alone, or a placebo control
1873506|NCT01127477|Drug|1: Hydroxyethyl starch 130/0.4, 6 %|1: Up to 50 ml 6 % hydroxyethyl starch 130/0.4/kg body weight administered intravenously from start of surgery (skin incision) until two hours after end of surgery.
1873507|NCT01127490|Drug|Duloxetine|Subjects will be titrated onto Duloxetine over one week by taking 30 mg every day for seven days. Week 2 the subject will begin to take 60 mg per day until the end of the study. If the subject wishes to stop taking Duloxetine, she will be given 30 mg per day for one week for down titration.
1873508|NCT01127490|Procedure|Skin biopsy|3 mm skin biopsies will be obtained from the dominant trapezius and the glabrous hypothenar area of the hand
1873509|NCT01127503|Drug|Metyrosine|Metyrosine (250 mg capsules) were to be used at all dose levels (administered as multiples of that dosing unit). The starting dose was 250 mg/day of metyrosine. Dose escalation was to be carried out weekly for 8 weeks (up to a maximum of 8 capsules/day [2000 mg/day if metyrosine]) with dosage increments of 1 capsule/day per week. Weekly dose escalation was to stop based upon the investigator's assessment of safety, but not efficacy (i.e., dose escalation was to be forced to the maximum of 8 capsules/day assuming acceptable safety and tolerability).
1873510|NCT01127503|Drug|Placebo|Placebo capsules were identically matched to Metyrosine.
1873512|NCT01127542|Drug|Lenalidomide|Daily oral lenalidomide. Starting dose of 2.5mg daily, escalating to target dose of 10mg daily.
1873513|NCT01127555|Drug|5-fluorouracil, leucovorin, oxaliplatin|D1 Oxaliplatin 85mg/m2 D1, 2 LV 30mg/m2 IV push D1, 2 5-FU 1500mg/m2 CIV over 24hrs Every 2 weeks
1873514|NCT01127568|Drug|Propranolol is available in generic form as the Wyeth product under the trade name Inderal.|The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
1873515|NCT01127581|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
1873516|NCT01127581|Drug|Dinoprostone Vaginal Insert (DVI)|Dose reservoir of 10 mg of dinoprostone in a hydrogel polymer vaginal insert within a retrieval system. The DVI will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
1873517|NCT01127594|Drug|Temozolomide|Dose level selection will proceed according to the modified Accelerated Titration Design. The starting dose will be TMZ 200mg/m2 x 0.09 BSA for the upper extremity and 200mg/m2 x 0.18 BSA for the lower extremity. We will enroll one-patient cohorts with dose doubling between cohorts until 1st occurrence of a ≥ CTC (Common Terminology Criteria) grade 2 adverse event. At that time, the present cohort and all future cohorts will be extended to enroll 3 to 6 patients.
1873518|NCT01127607|Drug|lisdexamfetamine|3 week with-in subject lead in phase to find optimal dose ranging from 30 mg to 70mg
1873519|NCT01127620|Drug|Bilastine|20 mg encapsulated tablets
1873520|NCT01127620|Drug|Cetirizine|10 mg encapsulated tablets
1873521|NCT01127620|Drug|Placebo|encapsulated tablets
1873522|NCT01127633|Drug|Solanezumab|400 mg administered once every 4 weeks by intravenous infusion (IV) for up to 8 years.
1873523|NCT01127646|Drug|Atomoxetine|25-80 milligrams (mg) administered orally, once daily.
1873524|NCT01127646|Drug|Osmotic-release oral system methylphenidate|18-54 mg administered orally, once daily.
1873525|NCT01127646|Drug|Placebo|Administered orally, once daily for random nonconsecutive 6 days during 4-week treatment period.
1873526|NCT01127659|Drug|testosterone|intramuscular every 2 weeks
1873527|NCT01127659|Drug|placebo|saline intramuscular every 2 weeks
1873528|NCT01127672|Biological|platelet rich plasma|"30 ml of a patient's own blood will be collected via blood draw, maintaining sterile technique. This will then be spun down using a Magellan Autologous Platelet Separator System, yielding platelet rich plasma (PRP).
Under sterile conditions, patients will receive a 3 cc PRP injection (consisting of their own PRP) with 1 cc of 2% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.
This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.
The patient will be monitored for 10 minutes in clinic for adverse reactions."
1873529|NCT01127672|Drug|corticosteroid injection|"Under sterile conditions, patients will receive a 4 cc injection consisting of 2 cc Celestone Soluspan (6mg/ml) and 2 cc of 1% lidocaine into the origin of the plantar fascia, administered by an orthopedic surgeon.
This will be done using a plantar approach. A peppering technique spreading in clockwise manner will be used to achieve a more expansive zone of delivery, with a maximum of 10 passes through the fascia itself.
The patient will be monitored for 10 minutes in clinic for adverse reactions."
1873530|NCT01127685|Device|Smart_Step weight bearing insole|The use of a weight-bearing measuring device in determining weight-bearing deficits following Anterior Cruciate Ligament Reconstruction
1873531|NCT01127724|Drug|vitamin B12 treatment|Group I- will receive sublingual vitamin B12 treatment, 1000 mcg per day for 6 months Group II- will receive sublingual vitamin B12 treatment, 100 mcg per day for 6 months Group III- will receive sublingual vitamin B12 treatment, 2000 mcg per day for 6 months
1873532|NCT01127737|Behavioral|Educational Intervention|Mnemonic and a workbook used by kidney transplant recipients to assist with early early detection of SCCs.
1873533|NCT01127737|Behavioral|Placebo|Completed surveys
1873534|NCT01127750|Drug|FTY720|
1873535|NCT01127763|Drug|RAD001|
1873536|NCT01127763|Drug|Carboplatin|
1873537|NCT01127776|Device|APOS SYSTEM|The trial group will receive APOS walking system The control group will receive the same walking protocol as the trial group without biomechanics units
1873538|NCT01127776|Other|APOS SYSTEM without biomechanics units.|The control group will receive the same walking protocol as the trial group without biomechanics units
1873539|NCT01127789|Device|Transcranial Direct Current Stimulation|Transcranial Direct Current Stimulation
1873540|NCT01127828|Other|Arla Yoghurt with no probiotic|two servings of 200 ml of investigational products per day
1873541|NCT01127828|Other|Probiotic yoghurt (Cultura)|200 ml per day
1873543|NCT01127867|Dietary Supplement|dietary intervention|dietary intervention
1960183|NCT03279913|Device|EEG-neurofeedback training in association with TMS.|EEG-neurofeedback training in association with TMS.
1873546|NCT01127893|Biological|Tanezumab|Tanezumab 10 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
1873547|NCT01127893|Biological|Tanezumab|Tanezumab 5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
1873548|NCT01127893|Biological|Tanezumab|Tanezumab 2.5 mg administered by subcutaneous injection every 8 weeks for up to 7 injections
1873549|NCT01127906|Drug|PF-04531083 100mg|Oral PF-04531083 100mg suspension single dose
1873550|NCT01127906|Drug|PF-04531083 2000mg|Oral PF-04531083 2000mg suspension single dose
1873551|NCT01127906|Drug|Placebo suspension|Oral Placebo suspension (matched to PF-04531083 suspension)
1873552|NCT01127906|Drug|Placebo tablet|Oral Placebo tablet (matched to Oxycodone)
1873553|NCT01127906|Drug|Oxycodone 20mg|Oral Oxycodone 20mg (Oxycontin) controlled release formulation
1873554|NCT01127919|Behavioral|Aerobic Exercise Training|40 minutes, 3 times a week for 35 weeks.
1873555|NCT01127919|Other|Cognitive Component|Provide general information about health and fitness
1873556|NCT01127932|Behavioral|Psychoeducation for substance abuse|This active control provides detailed information about substance use, suicide risk, and depression to those enrolled.
1873557|NCT01127932|Behavioral|CBT for suicide in Substance abuse|The therapeutic intervention group is designed to provide beneficial coping strategies that are helpful in dealing with both substance use and suicidal thoughts.
1873558|NCT01127945|Drug|statin|"adding atorvastatin 80mg, po on day (1 to 3) acute heart failure therapy
acute heart failure therapy"
1873559|NCT01127958|Device|PCI with a drug-eluting balloon|PCI with a drug-eluting balloon for in-stent restenosis
1873560|NCT01127958|Device|PCI with a drug-eluting stent|PCI with a drug-eluting stent for in-stent restenosis
1873561|NCT01127984|Drug|tissucol|dosage: 2 or 5 ml Frequency: 1 application Duration: 5 minutes
1873562|NCT01127984|Procedure|drainage system|application of vacuum drainage system
1873563|NCT01128023|Other|Myocardial perfusion imaging using Rb-82 PET or Tc-99m or Tl SPECT|Patients will undergo a clinically indicated PET Rb-82 myocardial perfusion scan for diagnosis or risk stratification of CAD. This cohort will be matched to the SPECT perfusion database.
1873564|NCT01128049|Behavioral|Subjective Questionnaire|The team will use a one page questionnaire to obtain subjective input before the first set of measurements and after instilling the Saline drop.
1873565|NCT01128049|Procedure|Measurement with wavefront sensor (right eye, then left eye)|The wavefront instrument measures the eye's ability to create a sharp image by briefly shining a laser light from the wavefront sensor into the eye and measuring the light that bounces back through the cornea. For these measurements, subjects will sit on a chair and be instructed to place their chin in a chin rest and lean their forehead against a forehead rest. The subject will be instructed to hold his/her head steady, look in a certain direction, blink or not blink. We will obtain the measurements over a short period of up to approximately 45 seconds. We will start recording data asking the subject to either blink naturally or to hold his/her eye open for a few (up to 10) seconds, and repeat the blink and hold sequence usually for up to four times.
1873566|NCT01128049|Drug|Instill Saline Drop|One drop will be instilled in both eyes and patient will wait 5 minutes prior to repeating the questionnaire and wavefront sensor. A single drop is approximately 30 µL and will be placed into the inferior cul-de-sac while the patient looks up.
1873567|NCT01128075|Device|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
1873568|NCT01128075|Device|RebiSmart™|Electronic self-injection device (RebiSmart™) to inject Rebif®
1873570|NCT01128114|Drug|Quetiapine fumarate (Seroquel XR)|Extended Release(XR) 50 mg, 200 mg, 300 mg and/or 400 mg tablet, oral, once daily in the evening, from assignment to the end of the study.
1873598|NCT01128322|Drug|Placebo|
1873599|NCT01128335|Drug|MMF(1000mg bid) + tacrolimus + standard of care medications|MMF(1000mg bid) + tacrolimus + standard of care medications
1873571|NCT01128127|Behavioral|Group education, audit-feedback and computer support|"Psycho-educational group workshop: two theory-practice sessions on both evidence-based guidelines on PPI-NSAID prescription and communication and negotiation skills to deal with patients. All participants will fill out an initial questionnaire concerning prescribing patterns and barriers to appropriate prescription. All attendees will be given a reminder printed material designed to give the necessary information in a brief fashion and for maximal visual impact.
Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs.
CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
1873572|NCT01128127|Behavioral|Audit-feedback and computer support|"Audit-Feedback: participants will receive, monthly and by e-mail, an individualized report with data of their own appropriate/inappropriate PPI prescriptions and avoidable costs
CCDSS: interactive computer program designed to assist physicians with decision making when prescribing PPI associated to NSAID. It consists in pop-up alert screens that aim to influence prescription choice according to each patient characteristics and evidence-based clinical guidelines."
1873573|NCT01128127|Behavioral|Control|"Usual intervention includes:
Compulsory attendance both to courses (10-12 hours) and to short sessions (around 30 min.) on the rational use of drugs held in groups and during working hours. Each primary care physician attends to 1-2 courses and 3-4 short sessions per year.
Every three months, physicians receive a feedback paper with information on his/her own prescribing overall costs comparing to his/her primary care center average cost.
Distribution of a printed booklet of recommendations, delivered personally or through mass mailings, on the prescribing of PPI-NSAID."
1873574|NCT01128140|Behavioral|Motivational Enhancement Therapy|MET, a 30-60 minute telephone session, seeks to increase motivation for change by highlighting inconsistencies between substance use behaviors and beliefs and negative consequences experienced as a result of the behaviors. The counselor will guide the participant in reviewing the Personal Feedback Report (PFR), using MI strategies to elicit the participant's reactions and foster motivation for change. The PFR will show the participant's self-reported alcohol and drug use behavior, consequences of SA, and the participant's perceived and actual descriptive norms for SA behavior. The second phase will target strengthening commitment to change. Counselors will explore with participants the pros and cons of seeking treatment. As the participant verbalizes potential benefits of learning more about treatment, the counselor will use MI skills to encourage elaboration of his/her thinking with the goal of tipping the scale toward a decision to consider taking steps toward treatment.
1873575|NCT01128140|Behavioral|Education|Participants will receive educational information on the health, psychological, social, and legal consequences of substance abuse. Included in the session will be: legal and behavioral definitions of SA, the social and legal consequences of SA, impact of SA on military duty, a review of the policies on substance use in the military, and treatment resources. The session will be conducted via the telephone and will last from 30-60 minutes. Counselors will present information in a didactic manner and will avoid the use of Motivational Interviewing skills (reflective listening, developing discrepancy, reinforcing participant statements regarding change).
1873576|NCT01128153|Drug|Saxagliptin|5 mg tablet once daily for 24 weeks to be taken orally
1873577|NCT01128153|Drug|Placebo|tablet once daily for 24 weeks to be taken orally
1873578|NCT01128166|Device|COGNIS CRT-D|"Patients with existing or newly implanted COGNIS® CRT-D pulse generators (PG)are enrolled in the study. PG is modified by the download of investigational software called Sensor Research Device-1™ (SRD-1). The goal of the SRD-1 system is to collect sensor data without affecting the delivered CRT-D therapy. This is accomplished through the conversion of an implanted COGNIS PG into a SRD-1 PG by downloading investigational software. Only a market approved COGNIS model N119/N120/P107/P108 device may be converted to a SRD-1 investigational device. There will be no PG hardware changes resulting from the conversion."
1873579|NCT01128179|Drug|Lanthanum carbonate|1000 mg in chewable tablets administered three times a day (for a total of 3000 mg/day) for 12 weeks
1873580|NCT01128179|Drug|Placebo|Matching placebo chewable tablets administered 3 times a day for 12 weeks
1873581|NCT01128192|Drug|pasireotide|Pasireotide 600 μg (batch number Y050DE) or 900 μg bid (batch number Y1270908) for subcutaneous injection. Placebo (batch number Y069HC) for subcutaneous injection.
1873582|NCT01128218|Drug|Tumor fluorescence|oral doses in phase 1 study of 10mg/kg, 20 mg/kg, 30 mg/kg, 40 mg/kg and 50 mg/kg
1873583|NCT01128244|Dietary Supplement|Vitamin B6|Subjects will receive vitamin B6 supplementation.
1873584|NCT01128244|Procedure|Infusion of labeled serine, methionine and leucine|Subjects will be given an infusion of the stable isotope labeled amino acids, serine, methionine and leucine prior to vitamin B6 supplementation and after 28 days of B6 treatment. In addition, they will receive a special diet 2 days prior to the infusion and will have weekly weight, blood, and visits to the clinic.
1873585|NCT01128257|Drug|alendronate|As prescribed by physician
1873586|NCT01128257|Drug|ibandronate [Bonviva/Boniva]|As prescribed by physician
1873587|NCT01128270|Drug|Dichloroacetate environmental dose|On day 6 they receive Dichloroacetate 2.5 ug/kg orally times 1 and have pharmacokinetics.
1873588|NCT01128270|Drug|Chloral Hydrate environmental dose|Study subjects are given 1.5 ug/kg of Chloral Hydrate for 5 nights and pharmacokinetics are done on night 1 and 5.
1873589|NCT01128270|Drug|Dichloroacetate therapeutic dose|Subjects receive 25 mg/kg DCA on Day 6. Pharmacokinetics are done on nights 1 and nights 5.
1873590|NCT01128270|Drug|Chloral Hydrate therapeutic dose|Subject is given 25 mg/kg of Chloral Hydrate for five nights.
1873591|NCT01128296|Drug|Hydroxychloroquine|Oral dosing daily starting at 48 hours before first dose of gemcitabine (starting on Day -2) and for a total of 31 days (ending on Day 29), prior to surgical resection. Capsules are available in 200 mg strengths. Daily doses are 200, 400, 600, 800, 1000, or 1200 mg, and will be administered BID for doses above 200 mg.
1873592|NCT01128296|Drug|Gemcitabine|Intravenous administration on Days 1 and 15, with the infusion given at the fixed dose rate of 10mg/m2/min (e.g. 150 min for a 1500 mg/m2 dose).
1873593|NCT01128309|Behavioral|Stress Reduction Intervention|eight week group program, plus daily homework practice
1873594|NCT01128309|Behavioral|Active Control intervention|weekly group meetings for eight weeks, plus daily homework practice
1873595|NCT01128322|Drug|S-Amlodipine, Telmisartan|
1873601|NCT01128335|Drug|sotrastaurin (200mg bid) + tacrolimus + standard of care medications|sotrastaurin (200mg bid) + tacrolimus + standard of care medications
1873602|NCT01128335|Drug|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications|sotrastaurin (300 mg bid) + tacrolimus + standard of care medications
1873603|NCT01128348|Behavioral|patient advocate|patient advocate works with patient to navigate practice and social barriers and to facilitate patient-provider communication
1873604|NCT01128361|Behavioral|Aerobic Exercise|Participants randomized to this group will perform 150 minutes a week of aerobic exercise over 3-5days. Participants will begin exercising 3 times the first week for 20 minutes, increasing to three bouts of 25 minutes the second week. Thereafter, weekly exercise duration will be increased until their target duration of 150 minutes is achieved in week 6. Exercise trainers will assist participants in adjusting exercise routines to achieve their weekly exercise duration goals. Use of equipment, achievement of target HR and safety will be closely monitored by the trainer through the course of the study. Each subject will wear a Polar F4 heart monitor (Polar USA) for recording heart rate during each exercise session. Subjects unable to exercise continuously on the treadmill will perform intermittent training until the target duration is reached. The majority of the exercise sessions will involve walking on a treadmill.
1873605|NCT01128361|Behavioral|Stretching|This groups intervention is designed to match the aerobic exercise intervention with respect to participation and socialization. Stretching and toning has been repeatedly used as control intervention for exercise studies.The schedule and format will be identical to the aerobic conditioning group to best balance confounding variables such as attention, social interactions, and other unknown variables that might influence the results. An experienced and trained exercise instructor will run the stretching sessions three days a week at the local YMCA. We will monitor changes in heart rate with Polar F4 heart monitors (Polar USA) during the sessions to assess, and minimize, potential aerobic benefits from the intervention.
1873606|NCT01128374|Procedure|Periodontal Scaling and root planing|Participants will be instructed to brush their teeth using the modified Bass toothbrushing technique; the use of interproximal hygiene aids such as proximal brush or dental floss will be included. A full mouth scaling and root planning will be performed in 2 appointments (2 hours each) with the use of local anesthesia (typically 2% lidocaine with 1:100,000 epinephrine). In the control group, this treatment will be performed after all the data and samples have been collected and will encompass the last 2visits. Periodontal scaling and root planning treatment has been defined by The American Academy of Periodontology (AAP) as the standard of care for patients with periodontal disease. An ultrasonic instrument, scalers and curettes will be utilized to remove calculus and obtain a smooth root surface. The experimental subjects will be appointed 1 week later to complete the scaling and root planning procedure
1873607|NCT01128387|Drug|Panitumumab|dose escalating 1.5mg/kg or 2.5mg/kg weekly during radiation. Cisplatin on Days 1 and 29, Fluorouracil on Days1-4 and Days 29-32.
1873608|NCT01128413|Device|Cheetah NICOM® PLRT|Cheetah NICOM® (non-invasive cardiac output monitoring)PLRT (passive leg raise testing) protocol: The patient while in a semi-recumbent position (legs level, torso up 45 degrees) will have 3 minutes of stroke volume and cardiac index monitoring. Following the 3 minutes, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) for 3 minutes of stroke volume and cardiac index monitoring. NICOM® PLRT will be performed within 10 minutes after any fluid bolus in both arms with results blinded to the Routine Care arm. If saline locked or maintenance IV fluid rate, NICOM® PLRT will be performed every 30 minutes in both arms with results blinded to the Routine Care arm.
1873609|NCT01128413|Device|USCOM ® (Ultrasound Cardiac Output Monitor)|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have simultaneous USCOM® stroke volume and cardiac index monitoring. Following the 3 minutes of Cheetah NICOM® PLRT semi-recumbent positioning, the patient will be placed in a leg raised position (torso level, legs up 45 degrees) and have simultaneous USCOM® stroke volume and cardiac index monitoring. USCOM® monitoring will be blinded to the Routine Care arm unless used as part of a provider's routine practice. USCOM® changes in SVI or CI with PLRT will be calculated after the patient leaves the ED.
1873610|NCT01128413|Device|Inferior Vena Cava (IVC) Ultrasound Collapsibility|Patients while in the Cheetah NICOM® PLRT semi-recumbent position (legs level, torso up 45 degrees) will have a simultaneous 6-12 second ultrasound recording of their IVC. These recordings will be reviewed later by an ultrasonographer and graded for volume responsiveness. The reviewing ultrasonographer will be blinded to the Cheetah NICOM® PLRT results.
1873611|NCT01128413|Behavioral|CURVES Questionnaire|The CURVES (CardiovascUlar Response & Volume Estimation in Shock) Questionnaire consists of multiple provider questions aimed at defining the presumed shock etiology and anticipated responses to interventions. This will be administered to both arms.
1873612|NCT01128413|Biological|Lactate Clearance|Lactate samples will be drawn at time 0, 1, 3, & 6 hours (or at ED departure if before 6 hours). Time 0 lactate will be revealed to the Routine Care arm and subsequent lactates revealed to the Routine Care arm only if serial lactates are part of the provider's routine practice.
1873613|NCT01128413|Biological|500ml Normal Saline Bolus|Patients randomized to the experimental arm and having a >/= 15% change in stroke volume index (SVI) or cardiac index (CI) via Cheetah NICOM®PLRT will be given a 500ml normal saline fluid bolus.
1873614|NCT01128413|Biological|Clinician Discretion Intravenous Fluid Management|Clinicians caring for patients randomized to the Routine Care arm will within 10 minutes after any fluid bolus be asked to decide via their clinical discretion if they want to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate. If the patient is on a saline lock or maintenance fluid rate, clinicians will be asked every 30 minutes to decide via their clinical discretion to re-bolus, saline lock, or place the patient on a maintenance IV fluid rate.
1873615|NCT01128426|Other|No Intervention|No Intervention
1873616|NCT01128439|Other|No intervention|No intervention
1873617|NCT01128452|Drug|EVT 101|HPMC Capsule, 15 mg, once daily for 28 days
1873618|NCT01128452|Drug|Placebo|HPMC Placebo capsules, once daily for 28 days
1873619|NCT01128478|Procedure|Enteral tube feeding|Nasogastric tube feeding started within 24 h of hospital admission
1873665|NCT01128803|Procedure|injection of the cell therapy product|Between D-15 and D-30: Cytapheresis D0: 1st injection of the cell therapy product D21: 2nd injection of the cell therapy product D42: 3rd injection of the cell therapy product and 1 injection of dendritic cells not loaded D45: cutaneous biopsies if induration > 2mm
1874132|NCT01133405|Drug|LY2886721|Oral capsules
1873620|NCT01128517|Behavioral|Maternal education on complementary feeding|"CF education to the mothers in intervention arm.
Ten important key messages developed based on recommended practices (WHO/UNICEF, 2000 & 2006).
First session --> cover the importance of breast feeding, its continuation for whole two years, hand washing, hygiene and importance of CF initiation at 6 months of age.
Second session -->breastfeeding promotion, complementary food consistency, initial complementary food selection and age related complementary food education.
Third session --> previous sessions recall. protein based and iron rich food encouragement.
The control arm continue to be benefited from the lady health workers program, while breastfeeding promotion would be provided to control arm"
1873621|NCT01128517|Behavioral|Education|Maternal education on complementary food
1873622|NCT01128530|Drug|JNJ-32729463|250 mg tablet twice daily
1873623|NCT01128530|Drug|linezolid|600 mg tablet twice daily
1873624|NCT01128530|Drug|JNJ-32729463 placebo|1 placebo tablet twice daily
1873625|NCT01128530|Drug|linezolid placebo|1 placebo tablet, twice daily
1873626|NCT01128543|Drug|lapatinib and Vinorelbine|Patients will receive 1250mg lapatinib once a day and vinorelbine 25mg/sqm IV Day 1and Day 8, every 3 week for 24 weeks.
1873627|NCT01128556|Drug|Bepreve|Bepreve (bepotastine besilate ophthalmic solution 1.5%) one drop in each eye twice daily
1873628|NCT01128556|Drug|Refresh Tears|Refresh Tears one drop to each eye twice daily for 7 days after the conclusion of Bepreve treatment
1873629|NCT01128569|Drug|Fluticasone Furoate|FF
1873630|NCT01128569|Drug|FF/Vilanterol (VI; GW642444M)|FF/VI
1873631|NCT01128569|Drug|Placebo|Placebo Inhaler
1873632|NCT01128582|Drug|Rozerem (ramelteon)|dosage= take 1 tablet(8 MG) 20 min. before bedtime
1873633|NCT01128582|Drug|placebo|Comparing the effect of Rozerem vs. placebo on GERD symptomatology.
1873634|NCT01128595|Drug|FF/GW642444M|
1873635|NCT01128595|Drug|GW642444M|
1873636|NCT01128595|Drug|Fluticasone Furoate|
1873637|NCT01128595|Drug|Placebo|
1873643|NCT01128634|Drug|GSK573719|13 days dosing with GSK573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
1873644|NCT01128634|Drug|GW573719/GW573719|13 days dosing with GSK573719/GW573719, once daily dosing from day 1 to 13, concurrent dosing with verapamil from day 9 to 13.
1873645|NCT01128647|Dietary Supplement|Fructose:glucose drink|
1873646|NCT01128647|Dietary Supplement|glucose drink|
1873647|NCT01128673|Device|mRI|
1873648|NCT01128686|Other|No intervention|This study is retrospective chart review
1873649|NCT01128699|Drug|Subconjunctival Avastin|Intraoperative Subconjunctival Avastin 1.25mg; single dose as an adjunct to 184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
1873650|NCT01128699|Device|Ahmed Valve implant|184 mm2 surface area Ahmed Glaucoma Valve (AGV Model FP7; New World Medical Inc., Rancho Cucamonga, California, USA)
1873651|NCT01128712|Drug|Pregabalin|150 mg /day
1873652|NCT01128712|Drug|Pregabalin|450 mg/day
1873653|NCT01128725|Other|Alzhamyd|"The patients coming in consultation for a mnésique complaint will see each other offering the study. During a consultation, the following balance sheet will be accomplished :clinical Maintenance, collection of records and used treatments
psycho-behaviour Valuation through Neuropsychiatric Inventory (NPI) and through Inventory Apathy
Valuation of self-government in the activities of daily life (IADL). Further to this balance sheet, it is habitually offered on the subjects of advice (principally centered on the proposals of use of external helps for instance book memo, agenda and internal assistants medium notes-techniques and associations to keep information) and a new consultation 1 year afterwards including the same balance sheet.
In a supplementary way in this clinical valuation, a blood sample will be accomplished at the time of inclusion and 12 months afterwards."
1873654|NCT01128738|Drug|GSK1358820|Onabotulinum toxin type A
1873655|NCT01128738|Drug|Placebo|Placebo
1873656|NCT01128751|Procedure|Embol-X intra-aortic emboli filter|Patients in this arm receive intra-aortic filter designed to catch solid debris for neuroprotection during surgery.
1873657|NCT01128751|Procedure|DBT dynamic bubble trap|Patients in this arm receive a dynamic bubble trap to reduce gaseous micro-emboli from cardiopulmonary bypass for neuroprotection during surgery
1873658|NCT01128751|Procedure|Control group|In comparison to arm 1 and 2, patients in this arm do not receive an additional intervention during surgery
1873659|NCT01128764|Behavioral|CBT for depression and healthy lifestyle plus exercise|CBT treatment for depressed teens will be adapted into one integrated protocol that addresses depression using CBT techniques, an exercise component, and advice regarding healthy eating.
1873660|NCT01128764|Behavioral|CBT for depression|Standard CBT treatment for depressed teens that addresses depression using CBT techniques only
1873661|NCT01128777|Behavioral|Cognitive Behavioral Group Therapy|The CBT group therapy protocol will teach adolescents coping, cognitive restructuring, and affect regulation skills to remediate skills deficits that underlie depression, anxiety, and behavior problems associated with the deployment cycle. Parents will also learn stress management and parenting skills in their own group therapy sessions that occur as the same time as the adolescent group.
1873662|NCT01128777|Behavioral|Nondirective supportive group therapy|Patient initiated discussions form the basis for the intervention for both the adolescent group and the parent group
1873663|NCT01128790|Other|Remote ischemic preconditioning|4 cycles x 5 mins upper limb blood pressure cuff inflation 20mmHg above systolic blood pressure
1873664|NCT01128790|Other|Sham Control|4 cycles x 5mins blood pressure cuff inflation to 10mmHg
1873666|NCT01121822|Biological|Influenza virus vaccine (split virion, inactivated)|0.5 mL, Intramuscular
1992907|NCT03276780|Drug|combination NRT|Both groups will receive combination NRT to help with smoking cessation
1992910|NCT03277157|Dietary Supplement|B. lactis B94|A probiotic dose of 15 billion per capsule.
1992911|NCT03277157|Dietary Supplement|Placebo|Placebo capsule
1873668|NCT01121835|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous injection Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 ml)
1873669|NCT01121835|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL)
1873670|NCT01121835|Drug|PREMIXED INSULIN|"Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: - 30% soluble insulin aspart and 70 % protamine-crystallised insulin aspart in pre-filled Flexpen for all the countries except Mexico
25 % insulin lispro solution and 75% insulin lispro protamine in cartridges for Humapen Luxura for Mexico only"
1873671|NCT01121848|Drug|Leucovorin|"Pharmaceutical form:vials of 50 mg/5 mL or 500 mg/50mL Route of administration: IV
Dose regimen:"
1873672|NCT01121848|Drug|OXALIPLATIN|"Pharmaceutical form: Lyophilized powder for injection (50 mg/vial or 100 mg/vial) or aqueous solution (50 mg/10 mL and 100 mg/20 mL) Route of administration: IV
Dose regimen:"
1873673|NCT01121848|Drug|5-Fluorouracil|"Pharmaceutical form: vials of 5 g/100mL Route of administration: IV
Dose regimen:"
1873674|NCT01121861|Procedure|Phacoemulsification with implantation of toric IOL|
1873675|NCT01121874|Procedure|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system
1873676|NCT01121874|Procedure|Ligament Reconstruction with Tendon Interposition (LRTI)|commonly performed CMC arthroplasty technique, consisting of a trapeziectomy, followed by palmar oblique ligament reconstruction using a harvested flexor tendon from the wrist.
1873677|NCT01121874|Procedure|Ligament reconstruction with suture fixation system|CMC arthroplasty consisting of reconstruction of the palmar oblique ligament using a suture fixation system, with a decreased period of immobilization from 6 weeks to 2 weeks.
1873678|NCT01121887|Behavioral|Standard treatment|"Telephone-based smoking cessation counselling based on a combination of coaching and cognitive behavioural therapy (CBT) techniques. Counsellors are also trained in giving tailored advice regarding the use of smoking cessation aids.
Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
1873679|NCT01121887|Behavioral|Motivational Interviewing|"Telephone-based smoking cessation counselling with Motivational Interviewing added to the standard treatment protocol.
Clients are offered a choice between reactive treatment (clients initiate all contact) and proactive treatment (counsellors call back at appointed dates). Printed information material tailored to clients' needs is offered free of charge."
1873680|NCT01121900|Drug|Trazodone HCl|"Dosage form: Extended-release caplets containing 300 mg trazodone HCl
Dose: 300 mg trazodone HCl extended-release caplets (one caplet) at 23:30 on Day 1 of the test product treatment period following a fasting period of at least 4 hours."
1873681|NCT01121900|Drug|Trazodone HCl|"Dosage form: Immediate-release tablets containing 100 mg trazodone HCl
Dose: 100 mg trazodone HCl immediate-release tablets (one tablet per dosing time) at 23:30 on Day 1, at 07:30 and 15:30 on Day 2 of the reference product treatment period."
1873682|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
1873683|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was a single oral dose of 300 mg (one CR tablet) at 07:30 (after an overnight fast of at least 10 hours) on clinic days.
1873684|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was 2 oral doses of 150 mg each: one controlled-release (CR) tablet at 07:30 (after an overnight fast of at least 10 hours) and 19:30 (after a fast of at least 2 hours) on clinic days.
1873685|NCT01121913|Drug|Trazodone HCl|The dosage of trazodone.HCl during this treatment phase was three oral doses of 100 mg each: one immediate-release (IR) tablet at 07:30 (after an overnight fast of at least 10 hours), 15:30 and 23:30 (both dosages after a fast of at least 2 hours) on clinic days.
1873686|NCT01121926|Drug|Trazodone HCl|"Dosage form:
Extended-release caplets containing 300 mg trazodone HCl and extended-release caplets containing 150 mg trazodone HCl (the 150 mg dosage form was only used for the up and down titration, and was not evaluated in the study).
Dose regimen:
75 mg trazodone HCl (½ x 150 mg extended-release caplet) on Days 1 and 11, 150 mg trazodone HCl (one extended-release caplet) on Days 2 and 10, 300 mg trazodone HCl (one extended-release caplet) on Days 3 to 9, each at 23:30 after a fast of at least 4 hours."
1873687|NCT01121926|Drug|Trazodone HCl|"Dosage form:
Immediate-release tablet containing 100 mg trazodone HCl
Dose regimen:
100 mg trazodone HCl (one immediate-release tablet) once (at 23:30) on Days 1 and 11, 100 mg trazodone HCl (one immediate-release tablet) twice (at 23:30 and 11:30) on Days 2 and 10, 100 mg trazodone HCl (one immediate-release tablet) three times daily (at 23:30, 07:30 and 15:30) on Days 3 to 9. Evening doses were administered after a fast of at least 4 hours."
1873688|NCT01121939|Drug|Bevacizumab|"15 mg/kg IV Day 1. The first dose should be administered over
90 minutes. If no adverse reactions occur after the initial dose, the second dose should
be administered over a minimum of 60 minutes. If no adverse reactions occur after the
second dose, all subsequent doses should be administered over a minimum of 30
minutes. Bevacizumab will be infused prior to pertuzumab."
1873689|NCT01121939|Drug|Pertuzumab|"840 mg IV loading dose infused over 60 minutes. The loading dose is given on Cycle 1, Day 1 or as below. Subsequent doses of pertuzumab are 420 mg IV. If the patient tolerates the initial infusion over 60 minutes, the patient may receive subsequent infusions over 30 minutes. Otherwise, pertuzumab should be infused over 60 minutes. Patients should be observed for 30 minutes after completing the pertuzumab infusion.
If a patient misses a dose of pertuzumab for 1 cycle (i.e., 2 sequential cycles or administrations are 6 weeks or more apart), a re-loading dose (840 mg) of pertuzumab should be given. If re-loading pertuzumab is administered, subsequent doses of 420 mg will then be given every 3 weeks, starting 3 weeks later."
1873690|NCT01121939|Drug|Sandostatin LAR® Depot|30 mg will be given every 28 days by IM injection. The dose of sandostatin may be increased, at the discretion of the treating physician, if necessary to control symptoms related to tumor secretion of vasoactive peptides.
1873691|NCT01121952|Other|Chiropractic (HVLA) manipulation|Single high-velocity, low-amplitude (HVLA long axis) thrust manipulation to the talo-crural joint, once a week during a three week period
1873692|NCT01121965|Procedure|Pars plana vitrectomy with ILM peeling|Pars plana vitrectomy with ILM peeling
1873693|NCT01121978|Procedure|Early vitrectomy|Triamcinolone acetonide assisted pars plana vitrectomy with Indocyanine green dye assisted internal limiting membrane peeling
1873694|NCT01121991|Drug|Recombinant Human-Luteinizing Hormone (Luveris)|Recombinant Human-Luteinizing Hormone (Luveris) was administered once daily subcutaneously at a starting dose of 150 IU per day beginning on stimulation Day 6.
1873695|NCT01122004|Drug|Pregabalin|
1873696|NCT01122004|Drug|Pregabalin|
1873697|NCT01122017|Procedure|Retro-Tubercle Opening-Wedge High Tibial Osteotomy|Retro-Tubercle Opening-Wedge High Tibial Osteotomy (ROWHTO) is among the latest approaches for the treatment of varus deformity of knee.
1873698|NCT01122030|Drug|Naldemedine|Tablets or solution for oral administration
1873699|NCT01122030|Drug|Placebo|Tablets or solution for oral administration
1873700|NCT01122043|Device|Endoglide|Device
1873701|NCT01122056|Other|Physical exercise training|Two 2-hours long interactive training to perform safe and efficient aerobic exercise for patients with multiple sclerosis
1873702|NCT01122069|Other|Perflutren Lipid Microsphere ultrasound contrast|Perflutren Lipid Microsphere ultrasound contrast 0.01 ml/kg administered as intravenous bolus
1873703|NCT01122082|Behavioral|food preloads|Subjects will eat in the morning during breakfast 300g cottage cheese (627kJ - 147kcal; 13.2g carbohydrate, 0.3g fat, 23g protein) plus, according to the situations, either: 90g sucrose, HCB); 6g aspartame; 40g vegetable oil; 40g paraffin oil. Therefore two breakfast will have the same energy content (2072kJ - 495kcal), as did the other two(565 kJ - 135kcal).
1873704|NCT01122108|Drug|Cholestyramine|Cholestyramine 12 grams, one time dose
1873705|NCT01122108|Drug|Colesevelam HCl|Colesevelam HCl, 4 grams, one time dose
1873706|NCT01122121|Drug|Leuprorelin SR|Leuprorelin SR injection
1873707|NCT01122121|Radiation|Radiotherapy|Radiotherapy 70 +/- 4 Gy
1873708|NCT01122121|Drug|Flutamide|Flutamide tablets
1873709|NCT01122134|Drug|intravenous artesunate|Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
1873710|NCT01122147|Drug|chamomilla tincture mouthwash|The patient is directed to mouth wash chamomilla tincture lightly three times a day,ten drops for each time,until ulcers completely heal
1873711|NCT01122147|Drug|placebo mouthwash|The patient is directed to use placebo mouthwash three times a day, ten drops for each time,until the ulcers completely heal
1873712|NCT01122160|Drug|omeprazole|omeprazole 20.6 mg tablet with berries (blackberries + strawberries)
1873713|NCT01122160|Drug|placebo|Placebo with berries (blackberries + strawberries)
1873714|NCT01122173|Device|Ablation|Atrial fibrillation ablation procedure
1873715|NCT01122186|Behavioral|Motivational Interviewing + Cognitive Behavioral Skills Training|The first two sessions will be primarily Motivational Interviewing and begin with an introduction to the nature of treatment, emphasizing the client's autonomy, and explain that the purpose of the sessions is to explore feelings about their medication adherence, meth use, and any other issues, with the eventual goal of working towards any changes the client may wish to make. During the third session, the client will complete an individualized functional analysis of recent occasions when the client missed medication, used MA and/or other substances, and engaged in risky sex (not necessarily all at the same time). Sessions four through seven will focus on Cognitive Behavioral Skills Training for adherence, reducing or stopping meth use, reducing or stopping the combination of meth and other drug use, and avoiding risky sexual behavior. The final session emphasizes maintenance of behavior change and relapse prevention.
1873716|NCT01122186|Behavioral|Education Attention Control|"During the first two sessions participants watch the documentary Rock bottom to receive information on Crystal Methamphetamine, and the possible interactions between HIV medications and recreational substances. Sessions 3 and 4 focus on the importance of medication adherence, viral replication and mutation, and resistance. Session 5 focuses on the negative effects of several recreational substances as well as the negative effects of mixing substances. Session six discusses HIV stigma, transmission risk sexual behavior, and HIV disclosure. Session 7 revisits medication adherence, focusing on dealing with medication side effects and communicating with health care providers. The final session uses part of the documentary Meth which highlights issues of methamphetamine use through interviews with men in various stages of recovery."
1873717|NCT01122199|Drug|RAD001 + AMG479|Escalating doses of RAD001 + AMG479. Starting cohort will be 5 mg RAD001 once daily, continuous + AMG479 12 mg/kg on Day 1 and 15 of each 28 day cycle.
1873718|NCT01122238|Drug|Nicotine Patch|"If randomized to only the Nicotine Patch condition (and not the Nicotine Gum):
Participants randomized to this condition will receive a 6-week supply of 14 mg patches at the initial visit. Participant will be instructed to use one patch daily for 6 weeks."
1873719|NCT01122238|Drug|Nicotine Gum|"If randomized to only the Nicotine Gum condition (and not the Nicotine Patch):
Participants randomized to this condition will receive a 6-week supply of 2 mg gum at the initial visit. Participants will be instructed to use 10 pieces of gum daily for 6 weeks."
1873720|NCT01122238|Behavioral|Motivational Interviewing|"Participants randomized to this condition will receive an initial MI counseling session during the in-person clinic visit followed by three counseling phone calls over the 6-week intervention period (a total of four intervention contacts). The phone counseling sessions will occur during weeks 2, 4, and 6. Case managers will engage the participant in a series of motivation building exercises such as reviewing feelings and thoughts about the pros and cons of quitting and smoking, reinforcing the positives of quitting, helping to dispel myths and concerns about the negatives of quitting, and posing questions about the good aspects of smoking."
1873721|NCT01122238|Behavioral|Smoking Reduction|Participants randomized to Smoking Reduction will receive an initial counseling session during the in-person visit followed by 6 weekly phone counseling sessions over the 6-week intervention period. During the initial session, participants will be told that the goal is to reduce cigarette consumption by 50% over the course of the intervention (approximately 10% reduction per week). During the initial meeting and subsequent counseling calls, case managers will work with participants to problem-solve strategies for reduction (e.g., increasing time between cigarettes, delaying smoking, or eliminating smoking in specific situations). Participants will be asked to record information in a provided smoking log to help keep track of daily smoking patterns and as a feedback mechanism for identifying successes and challenges.
1873722|NCT01122238|Other|No Intervention|No Intervention
1873723|NCT01122238|Drug|Nicotine Patch + Nicotine Gum|"If randomized to both the Nicotine Patch and the Nicotine Gum conditions:
Participants randomized to this condition will receive a 6-week supply of 14 mg patches and a 6-week supply of 2 mg gum at the initial visit. Participant will be instructed to use one patch daily and to use 10 pieces of gum daily for 6 weeks."
1873724|NCT01122251|Drug|Lercanidipine + Valsartan|L10/V80, L20/V80, L10/V160, L20/V160
1873725|NCT01122251|Drug|Lercanidipine or Valsartan|L10, L20, V80, V160
1873726|NCT01122251|Drug|Placebo|Placebo of Lercanidipine and Valsartan
1873727|NCT01122264|Drug|Tadalafil|Administered orally for 24 weeks.
1873728|NCT01122264|Drug|Sildenafil Citrate|Administered orally for 24 weeks.
1873729|NCT01122316|Drug|Metformin|3. Metformin will be started at 500 mg PO BID and pending lab values may be titrated to 1000 mg PO BID at 1 month.
1873730|NCT01122329|Dietary Supplement|caprylidene|Axona® is dosed as a 40g packet mixed into 8 oz of liquid (Ensure) for 45 days
1873731|NCT01122329|Dietary Supplement|Placebo|
1873732|NCT01122342|Drug|Testosterone propionate|Testosterone USP micronized powder at a dose of 1mg/gr will be made into a paste with polysorbate 80 NF liquid and will be placed in an emollient cream base. A calibrated applicator will be supplied to measure out doses containing 300mcg of testosterone for daily application. The cream will be applied daily for 28 days. As above if safety and efficacy endpoints are met at this dose a lower dose (150mcg) will be used and if in tun this meets safety and efficacy endpoints a lower dose (75mcg) will be used.
1873733|NCT01122355|Drug|lipid modification|1) fenofibrate 160 mg po for 16 weeks, 2) niacin 500 mg po for 4 weeks, niacin 1000 mg po for 4 weeks, niacin 1500 mg po for 8 weeks
1873734|NCT01122368|Drug|micafungin|IV
1873735|NCT01122368|Drug|placebo|IV
1873736|NCT01122381|Drug|ethosuximide|ethosuximide (ESX)
1873737|NCT01122381|Other|placebo comparator|placebo
1873738|NCT01122394|Behavioral|TI|Tailored intervention based on the transtheoretical model
1873739|NCT01122394|Behavioral|AP|Attention placebo
1873740|NCT01122407|Drug|L-NMMA|L-NMMA 250 ug/Kg/min
1873741|NCT01122407|Drug|Trimethaphan|Will infuse trimethaphan for until complete autonomic blockade is achieved.
1873742|NCT01122420|Other|Goal-Setting Tool|Access to an online health-related goal-setting tool through the MyHealthAtVanderbilt patient portal
1873743|NCT01122420|Other|Health Web Sites|Access to publicly available health-related web sites
1873744|NCT01122433|Device|Endotracheal intubation using the C-MAC video laryngoscope|Using the C-MAC video laryngoscope for endotracheal intubation after failed direct laryngoscopy
1873745|NCT01122446|Other|Placebo comparator|"Placebo comparator day 1 and 30 in non-diabetic children with multiple islet autoantibodies.
Post diagnosis: Two doses of 20 microgram Diamyd day 1 and 30 in children originally receiving placebo."
1873746|NCT01122446|Drug|Diamyd|"20 microgram day 1 and 30 in non-diabetic children with multiple islet autoantibodies.
Post diagnosis: Two doses of Diamyd followed to children originally receiving Diamyd"
1873747|NCT01122459|Other|fluid administration|1.5mls/kg/hr fasting
1873748|NCT01122472|Drug|Lenalidomide|Daily for 3 weeks every 4 weeks for 24 months
1873749|NCT01122472|Drug|Placebo|Daily for 3 weeks every 4 weeks for 24 months
1873750|NCT01122485|Other|PG201|two tablets
1873751|NCT01122485|Other|Placebo|two tablets
1873752|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.015mg/mL
1873753|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.05mg/mL
1873754|NCT01122498|Biological|BMP-655/ACS+Standard of care or Standard of care|BMP-655/ACS 0.15mg/mL or 0.025mg/mL
1873755|NCT01122511|Drug|700 ug dexamethasone|Intravitreal injection of 700 ug dexamethasone into study eye
1873756|NCT01122511|Biological|ranibizumab|Intravitreal injection of ranibizumab into study eye
1873757|NCT01122511|Other|sham|Sham needle-less injection administered in the study eye
1873758|NCT01122563|Drug|Solifenacin|oral
1873759|NCT01122576|Device|Crystalens AO|Crystalens AO surgically implanted bilaterally. Study observation up to 180 days.
1873760|NCT01122576|Device|ReSTOR|ReSTOR surgically implanted bilaterally. Study observation up to 180 days.
1873761|NCT01122576|Device|Tecnis Multifocal IOL|Tecnis surgically implanted bilaterally. Study observation up to 180 days.
1873762|NCT01122589|Behavioral|Motivational Interviewing/CBT|6 sessions of in jail MI/CBT counseling will be administered.
1873763|NCT01122589|Other|CONcise Tapes Reviewing Obstacles to healthy Living (CONTROL)|a series of six weekly 30-45 minutes general wellness videos
1873764|NCT01122602|Drug|Acetylsalicyclic acid (Fast acting Aspirin, BAY1019036)|Single dose of fast acting aspirin 2 x 325 mg = 650 mg total
1873765|NCT01122602|Drug|Acetylsalicyclic acid (Aspirin, BAYE4465)|Single dose of regular aspirin 2 x 325 mg = 650 mg total
1873766|NCT01122602|Drug|Placebo|Two placebo tablets
1873767|NCT01122615|Drug|Sunitinib|12.5 to 50 mg orally (PO) daily x 14 days, 7 days off for 21 day cycle.
1873768|NCT01122615|Drug|Temsirolimus|6 to 25 mg intravenously (IV) over 30 minutes once weekly for 21 day cycle.
1873769|NCT01122628|Device|ORIF with DVR-A locking plate|Size, length of plate and number os screws decided by operating surgeon
1873770|NCT01122641|Drug|Vildagliptin|Vildagliptin 50mg bid
1873771|NCT01122641|Drug|Placebo|Matched tablets
1873772|NCT01122667|Drug|anacetrapib|single dose administration of anacetrapib (MK0859) 100 mg oral tablet
1873773|NCT01122680|Drug|Tiotropium bromide|inhalation solution, dose of 1.25 mcg (2 puffs of 0.625 mcg)
1873774|NCT01122680|Drug|tiotropium bromide|inhalation solution, dose of 2.5 mcg (2 puffs of 1.25 mcg)
1873775|NCT01122680|Drug|tiotropium bromide|inhalation solution, dose of 5 mcg (2 puffs of 2.5 mcg)
1873776|NCT01122680|Drug|Placebo|placebo inhalation solution
1873777|NCT01122693|Device|eZono - high-quality 2D ultrasound images|higher ultrasound frequencies, better image resolution, better post-processing and user-friendliness.
1873778|NCT01122693|Device|standard 2D ultrasound images|current standard in two-dimensional (2D) ultrasound images
1873824|NCT01123044|Biological|conservative|Undergo autologous transplantation of limbal epithelial cells cultured on amniotic membrane
1873825|NCT01123044|Procedure|Medical Therapy|Under usual care treatment
1873779|NCT01122706|Other|Taiji training|Taiji training during 12 weeks (twice a week for 1 hour) (Sept. 6th till Nov. 25th 2010). The first 18 sequences of a series of 37 movements of the short form Yang style Taiji will be taught. The focus will be on memorizing the series of movements, developing a regular training routine and working on body alignment and flow of the movements.
1873780|NCT01122719|Device|Drug Eluting Stent|
1873781|NCT01122771|Drug|Liposomal amphotericin B|Ambisome i.v. 5mg on days 1, 3 and 5
1873782|NCT01122771|Drug|liposomal amphotericin B + miltefosine|Ambisome 5mg single dose iv Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10)
1873783|NCT01122771|Drug|liposomal amphotericin B + paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
1873784|NCT01122771|Drug|Miltefosine + Paromomycin|Oral Miltefosine 1.5-2.5 mg/kg in 1 or 2 doses a day, for 10 days (days 1-10) + Paromomycin base 11mg/kg/day IM for 10 days (days 1-10).
1873785|NCT01122784|Biological|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
1873786|NCT01122784|Biological|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 182
1873787|NCT01122784|Biological|rF1V vaccine (with Adjuvant)|80 mcg rF1V vaccine with adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
1873788|NCT01122784|Biological|rF1V vaccine (without Adjuvant)|80 mcg rF1V vaccine without adjuvant given by intramuscular (IM) injection into the arm on Study Days 0, 56 and 121
1873789|NCT01122810|Procedure|Coronary scanner|The ECG-gated contrast-enhanced multidetector computed tomography coronary angiography will be performed with a 64 or 256-row CT Philips, Brilliance. The contrast medium mean quantity used is 80-100 ml. The CT scan parameters, adapted to the patient's weight, include 120 kV, 800mA, 0.625 mm slice thickness, 0.42-s rotation time and 0.2 pitch. To determine X-Ray exposure, Dose Length Product (Gycm) will be measured. Reconstruction will be performed at 40 and 75 % of the cycle using ECG gating. A semi quantitative analyse of coronary narrowing will be performed blindly to coronary angiogram results by two experienced radiologists. The CT quality will be determined using a quality scale from 1 to 5. A Calcification score will also be determined. A segment analyse will be performed according to AHA classification. Only more than 1.5 mm diameter vessel segments will be analysed.
1960190|NCT03276000|Procedure|office hysteroscopy|A rigid 30 4-mm hysteroscope (Karl Storz Endoscopy) will be used without anaesthesia or analgesia 3 hours after administration of misoprostol. The uterine cavity will be distended with normal saline solution at a pressure of 100-120 mm Hg. The vaginoscopic ''no touch'' technique was followed; no speculum or tenaculum was used.
1960194|NCT03276091|Behavioral|Colofit+ intervention|Personnalized phone call, done by the medical student in the name of Adémas-69, organized cancers screening in the Rhône area association. This is a motivational call to encourage patients with an immunochemical fecal test positive, to realized their colonoscopy.
1873795|NCT01122862|Drug|0.12% chlorhexidine mouthrinse|commercially available 0.12% chlorhexidine mouthrinse
1873796|NCT01122862|Other|Cosmetic mouthrinse|Commerically available cosmetic mouthrinse
1873797|NCT01122862|Other|Sterile water|Sterile water
1873798|NCT01122875|Drug|MFGR1877S|Intravenous repeating dose
1873799|NCT01122888|Drug|Cilengitide|Given IV
1873800|NCT01122888|Other|Clinical Observation|Patients undergo a 2-week rest period
1873801|NCT01122888|Other|Laboratory Biomarker Analysis|Correlative studies
1873802|NCT01122901|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
1873803|NCT01122901|Procedure|therapeutic conventional surgery|Undergo surgery
1873804|NCT01122901|Other|pharmacological study|Correlative studies
1873805|NCT01122901|Other|laboratory biomarker analysis|Correlative studies
1873806|NCT01122914|Drug|Anakinra|
1873807|NCT01122927|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg) pill taken orally once per day
1873808|NCT01122940|Drug|Epamin: Reference Drug|Single dose of 75 mg (10 ml in suspension) of Epamin
1873809|NCT01122940|Drug|Phenytoin: Study Drug|Single dose of 75 mg (10 ml in suspension) of Phenytoin
1873810|NCT01122953|Drug|Phenytoin|Single dose of Phenytoin 125 mg/5 ml suspension made by Laboratorios Pfizer, S.A. de C.V.
1873811|NCT01122953|Drug|Epamin|Single dose Epamin 125 mg/5 ml suspension made by McNeil LA LLC
1873812|NCT01122966|Drug|intraocular injections of bevacizumab|intracameral and subconjunctival injections
1873813|NCT01122979|Drug|INSULIN GLARGINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
1873814|NCT01122979|Drug|NPH insulin (insulin isophane)|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
1873815|NCT01122979|Drug|INSULIN GLULISINE|Pharmaceutical form: 100 Units/mL solution for injection in a pre-filled SoloStar pen (3 mL) Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
1873816|NCT01122979|Drug|Regular insulin|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: dose adjusted to the patient's glycemia
1873817|NCT01122992|Procedure|Limbal relaxing incision|
1873818|NCT01123005|Procedure|PET Scan|radiation calculated per patient
1873819|NCT01123005|Drug|EF5|10 mCi, IV
1873820|NCT01123005|Drug|Carbogen|Calculated per patient
1873821|NCT01123018|Behavioral|Memtrax Memory screening test|Memory Screening test
1873822|NCT01123031|Drug|lansoprazole|lansoprazole 30 mg four times daily for three days followed by 30 mg once daily for two months
1873823|NCT01123031|Drug|esomeprazole|esomeprazole 160 mg/day continuous infusion for three days followed by 40 mg once daily orally for two months
1960196|NCT03275402|Biological|131I-burtomab|Murine IgG1 monoclonal antibody radiolabeled with iodine-131
1873826|NCT01123057|Procedure|riboflavin-induced collagen cross-linking treatment|"The principle of the procedure is to induce collagen crosslinking of the corneal stroma by the using riboflavin/UVA-treatment.
The technique involves topical application of riboflavin/dextran solution onto eye after removal of corneal epithelium. After initial riboflavin application for 30 minutes, UVA light is shone onto the cornea for another 30 minutes with continued topical riboflavin application."
1873827|NCT01123057|Device|Riboflavin-UVA induced collagen cross-linking treatment for corneal ectasia|Use of riboflavin eyedrops during the procedure Use of UVA device (Peschke Meditrade)
1873828|NCT01123070|Biological|TL011, anti CD20, for the treatment of rheumatoid arthritis|TL011 administered by 2 infusions, 2 weeks apart
1873829|NCT01123070|Biological|MabThera infusions|MabThera, administered by 2 infusions, 2 weeks apart
1873830|NCT01123083|Biological|Otelixizumab|infusion
1873831|NCT01123083|Biological|Placebo|Infusion
1873832|NCT01123096|Procedure|Cough Stress Test|A cough stress test is performed by using a catheter to introduce 300ml of sterile water into the bladder. The patient is then asked to stand and cough forcefully and the clinician will observe for urine loss.
1873833|NCT01123096|Other|24 Hour Pad Test|The patient will be provided with a standard number of pads in a sealed bag that have been pre-weighed. The patient will wear the pads for 24 consecutive hours then return the all the pads within the bag for weighing post usage.
1873834|NCT01123109|Procedure|3-D Endoanal Ultrasound|The subject will be placed in the supine position with their feet in the stirrups and a drape will be used, exposing only the anus and perineum in order to introduce the probe. In order to prevent and minimize any potential discomfort, the lubricated ultrasound probe will be gently inserted into the anal canal up to the anal verge, with minimal manipulation of the probe once inserted. The scan lasts approximately two minutes and the entire exam will take no more than five minutes.
1873835|NCT01123122|Other|Strict glucose control|Blood glucose level to be maintained at 4-6 mmol/L at the time of islet transplantation until two weeks post-transplantation.
1960197|NCT03275051|Other|Safety and Efficacy assessments|Safety and efficacy assessment of GSK2696277 in subjects with transfusion dependent beta-thalassemia will be performed.
1873838|NCT01123148|Device|Using a BCI to control wheelchair tilt|Subjects will wear an EEG cap for 1-4 hours (1-2 hours typical) during each session and use a P300 based BCI to type words and control wheelchair tilt. Subjects will be asked to participate in 3 sessions.
1873839|NCT01123161|Device|hypothermia and anti-shivering treatment|Hypothermia is induced using the Celsius Control™ System. Shivering is treated with buspirone, meperidine and surface warming
1873840|NCT01123161|Drug|Group1: IV t-PA and normothermia|Group 1 will t-PA as standard of care and normothermia
1873841|NCT01123174|Behavioral|ALGOS algorithm of case management|"If the subject survives one 1st SA (first attempter): he leaves the center where he was included with a chart resource (crisis card) which contains addresses of the Web sites of associations of prevention of the suicide, as well as an accessible phone number 24/24h.
If the subject is not a first attempter : he will be recontacted on the telephone between the 10th and the 21st day following the SA. If the subject is not contacted or little observing in the plan of care, it will receive a series of postcards then regularly, with 4 recoveries: to 2, 3, 4 and 5 months after the attempt."
1873842|NCT01123187|Procedure|islet transplantation|Islet transplantation consisted of up to three sequential fresh islet infusions within three months. Access to the portal vein was gained under general anesthesia by percutaneous catheterisation of a peripheral portal branch under ultrasound guidance or by surgical catheterisation of a small mesenteric vein.
1873843|NCT01123200|Device|Brain Computer Interface for Wheelchair Tilt Control|Patients will be given the BCI for use in-home, as long as they use the BCI at least 10 hours per week and complete monthly performance assessment sessions.
1873844|NCT01123226|Procedure|spinal manipulation|A maximum of two high velocity low amplitude spinal manipulations to one dysfunctional spine joint
1873845|NCT01123226|Procedure|trigger point therapy|The thumb will apply firm pressure to a trigger point in the paravertebral multifidus and rotatores muscles associated with the spine joint dysfunction using the barrier approach. This will be held until the barrier releases and this will continue until the trigger point is inactivated or 3 minutes has passed.
1873846|NCT01123239|Behavioral|Coached Care|"Coached Care pairs patients with linguistically and ethnically matched peer coaches, who themselves have diabetes, and have been trained to meet with patients immediately before each of their regularly scheduled medical visits to encourage active involvement in information seeking and decision-making. Using a decision tree algorithm, they help patients identify relevant questions about symptoms, barriers to self-management and treatment options to discuss with doctor. They encourage mutual decision-making about tailoring the patient's medication regimen, diet and physical activities and work with the patients to overcome barriers to communication with their doctor. After the medical visit, the coach and patient review any treatment decisions and goals for self-care."
1873847|NCT01123239|Behavioral|Standard Diabetes Education|Patients randomized to the control group will receive 20 minutes of standardized diabetes education delivered by staff research assistants. Education materials have been adapted from materials developed by the American Diabetes Association. The content of these materials includes information about the causes and complications of diabetes, as well as ways to reduce complication risks. Patients in the control arm will receive 20 minutes of standardized diabetes education before each visit
1873848|NCT01123252|Dietary Supplement|Lactobacillus casei Shirota (LcS)|Subjects will receive one bottle of Yakult containing the probiotic bacterium Lactobacillus casei Shirota (active drink) once daily for 4 months (16 weeks).
1873849|NCT01123252|Dietary Supplement|Placebo|Subjects will receive one bottle of a placebo milk drink, once daily for 4 months (16 weeks).
1873850|NCT01123265|Drug|Methotrexate|Subjects will start Methotrexate which will be escalated from 7.5 mg weekly to 15 mg/weekly over a 3 week period.
1873851|NCT01123265|Drug|Anti-TNF|Anti-TNF to be administered per standard of care within the practice.
1873852|NCT01123278|Drug|Testosterone|Testosterone transdermal gel 50 mg/day (5 gr)
1873853|NCT01123278|Drug|Placebo|Placebo transdermal gel (5 gr)
1873854|NCT01123291|Procedure|follow-up coronary angiography|follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
1873855|NCT01123291|Procedure|Clinical follow-up|no routine follow-up coronary angiography at 8-12 months after discharge for percutaneous coronary intervention
1873856|NCT01123304|Drug|MORAb028|1 mg MORAb-028 will be injected at either 1 mg/cm3 per day over 5 days for a total dose of 5 mg for the first cohort and 2 mg/cm3 for the second cohort. Subjects will receive MORAb-028 injections on Days: 1-5, 8-12 and 22-26.
1873857|NCT01128816|Device|Adaptive Servo Ventilation|BiPAP autoSV ADVANCED device worn nightly during sleep
1873858|NCT01128829|Other|Water|60 ml of water were drank 10 min before doing a OGTT
1873859|NCT01128829|Other|Sucralose|60 ml of 2 millimolar sucralose were drank 10 min before doing a OGTT
1960198|NCT03273985|Other|Dry needling|Trigger point deep dry needling
1873861|NCT01128855|Drug|3 mg/kg GSK2402968|Weekly subcutaneous injection
1873862|NCT01128855|Drug|6 mg/kg GSK2402968|Weekly subcutaneous injection
1873863|NCT01128855|Drug|9 mg/kg GSK2402968|Weekly subcutaneous injection
1873864|NCT01128855|Drug|12 mg/kg GSK2402968|Weekly subcutaneous injection
1873865|NCT01128855|Other|Placebo|Weekly Placebo
1873866|NCT01128868|Device|Proximal femur locking plate|Proximal femur locking plate (PF-LCP, PF-LCP Hook Plate, Periloc)
1873867|NCT01128868|Device|Intertrochanteric nail|Intertrochanteric nail (PFNA, TFN, GN)
1873869|NCT01128894|Biological|albiglutide|albiglutide weekly subcutaneous injection
1873870|NCT01128894|Drug|liraglutide|liraglutide daily subcutaneous injection, starting at 0.6mg, then up-titrating to 1.2mg then 1.8mg in accordance with prescribing information.
1873871|NCT01128920|Behavioral|Skin and Needle Hygiene Intervention|Intervention incorporates psychoeducation, correction of false beliefs, counseling to counteract barriers to hygienic practices, motivational enhancement, and behavioral skills training in hygiene practices
1873872|NCT01128920|Other|No intervention - assessment-only condition|No intervention is assigned in this condition
1873873|NCT01128933|Procedure|Renal artery stenting|
1873874|NCT01128946|Drug|NaF|Fluoride toothpaste containing sodium fluoride as 1450 parts per million (ppm) F, 675 ppmF, 450 ppmF, 350ppmF.
1873875|NCT01128946|Drug|SnF|Fluoride toothpaste containing stannous fluoride (1100 ppmF)
1873876|NCT01128946|Drug|NaMFP|Fluoride toothpaste containing sodium monofluorophosphate (1000 ppmF)
1873877|NCT01128959|Drug|Intravenous Carbamazepine (IV CBZ)|10 mg/mL of IV CBZ dissolved in 250 mg/mL of Captisol® (sulfobutylether-beta-cyclodextrin) dosed at 70% of the patient's daily maintenance dose of oral CBZ administered after suitable dilution with D5W by IV infusion every 6 hours.
1873878|NCT01128972|Drug|Sodium fluoride|Test fluoride toothpaste and test fluoride mouth rinse
1873879|NCT01128972|Drug|Sodium monoflurophosphate|United Kingdom marketed fluoride toothpaste
1873880|NCT01128972|Drug|Sterile water|Sterile water rinse
1873881|NCT01128985|Drug|Canagliflozin 50 mg|50 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
1873882|NCT01128985|Drug|Canagliflozin 100 mg|100 mg capsule once daily for 7 consecutive days from Day 1 to Day 7
1873883|NCT01128985|Drug|Canagliflozin 300 mg|300 mg capsule once daily for 7 consecutive days from Day 1 to Day 7.
1873884|NCT01128985|Drug|Placebo|matching canagliflozin placebo once daily for 7 consecutive days from Day 1 to Day 7
1873885|NCT01128998|Drug|Sorafenib|"Name: Sorafenib
Dosage form: 200 mg / Tablet
Dosing schedule: 200 mg bid, po, everyday, since Day 8 of Cycle 1"
1873886|NCT01128998|Drug|S-1|"Name:S-1
Dosage form: 20 mg or 25 mg / Capsule
Dosing schedule: 20-40 mg/m2 bid,po, 14 days on & 7 days off"
1873887|NCT01129011|Drug|PN400 (VIMOVO)|PN400 tablets (Naproxen 500 mg and Esomeprazole 20 mg) twice daily (bid) taken orally.
1873888|NCT01129011|Drug|Naproxen|Naproxen 500 mg dosed twice daily (bid) orally
1873889|NCT01129024|Drug|0.5 mg of S-888711|tablet
1873890|NCT01129037|Other|Goal directed fluid management based on continuous monitoring of stroke volume|Baseline SV measurement, repeated volume loading (VL) with aliquots of 250 ml HES until SV increased < 10% in response to receding VL: SV is optimized, no further VL required.
1873891|NCT01129050|Dietary Supplement|Fish Oil|Fish oil capsule
1873892|NCT01129050|Dietary Supplement|Flaxseed Oil|Flaxseed oil capsule
1873893|NCT01129050|Dietary Supplement|Placebo|Soybean oil capsule
1873894|NCT01129063|Drug|Clopidogrel|"Pharmaceutical form : tablet
Route of administration: oral"
1873895|NCT01129089|Dietary Supplement|Lipid-based nutrient supplement|Lipid-based nutrient supplement for pregnant and lactating women
1873896|NCT01129089|Dietary Supplement|Lipid-based nutrient supplement|Lipid-based nutrient supplement for infant and young children
1873897|NCT01129089|Dietary Supplement|Micronutrient powder|Micronutrient powder for infant and young children
1873898|NCT01129102|Drug|NPC-01|Norethisterone 1mg, Ethinyl estradiol 0.02mg
1873899|NCT01129102|Drug|IKH-01|Norethisterone 1mg, Ethinyl estradiol 0.035mg
1873900|NCT01129102|Drug|Placebo|Placebo for NPC-01
1873901|NCT01129115|Behavioral|Nonexercise control group|Participants randomized to the nonexercise control group will be asked to maintain their current level of physical activity during the 26-week active study period. They will perform outcome assessments and receive the same telephone checks as the exercise group at baseline, 26 and 52 weeks. The purpose of including a non-exercise control group is to allow adequate comparisons with the low, medium and high exercise dose groups on changes in cognitive and physiologic outcome measures.
1873902|NCT01129115|Behavioral|Aerobic Exercise Group 1|The 50% group will perform 75 minutes a week of moderate intensity exercise spread over 3 days.
1873903|NCT01129115|Behavioral|Aerobic Exercise Group 2|The 100% group will perform 150 minutes a week of exercise over 3 - 5 days
1873904|NCT01129115|Behavioral|Aerobic Exercise Group 3|The 150% group will perform 225 minutes a week of exercise over 4 - 5 days.
1873905|NCT01129128|Biological|Echinacea purpurea product|5 ml by mouth 3 times per day for 10 days
1873906|NCT01129128|Biological|Echinacea purpurea product|1 ml by mouth 3 times per day for 10 days
1873907|NCT01129128|Biological|Placebo|either 5 ml or 1 ml by mouth three times per day for 10 days
1960199|NCT03273985|Other|Ischemic compression|Trigger point ischemic compression
1873908|NCT01129141|Procedure|Tele-PTM|Telephone-based Progressive Tinnitus Management (Tele-PTM) is a novel home-based telehealth program that involves a series of seven telephone appointments, conducted at approximately 1, 2, 3, 4, and 5 weeks, and 3 and 6 months after enrollment is finalized. Telephone education was provided by the Study Psychologist at weeks 1, 3, and 5, and month 6; and by the Study Audiologist at weeks 2 and 4, and month 3.
1873909|NCT01129141|Procedure|Wait List Control|Wait List Control subjects received Tele-PTM after completing the 6-month questionnaires. Participants assigned to Wait List Control were instructed that they could receive any available tinnitus services, and that they would receive Tele-PTM following completion of the 3- and 6-month questionnaires.
1873910|NCT01131728|Drug|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
1873911|NCT01131741|Drug|Epinephrine|This group receives 3 mL of 1% lidocaine containing epinephrine IV during operation.
1873912|NCT01131741|Drug|Control|This group receives 3 mL of saline IV during operation.
1873913|NCT01131754|Other|heparin 100U/L flushes|peripheral venous catheter flushing with 3 mL of a 100 U heparin/mL normal saline from mono-use vial (Epsodilave, Mayne Pharma, Naples, Italy) at the end of each drug infusion. Independently from the number of drug infusions, all patients will receive at least two catheter flushes every day.
1873914|NCT01131767|Drug|Naproxen Sodium & Pseudoephedrine HCl|Naproxen Sodium 220 mg and Pseudoephedrine Hydrochloride 120 mg Extended Release Tablets
1873915|NCT01131780|Drug|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
1873916|NCT01131793|Device|PowerAssert RF wire in crossing coronary in-stent chronic total occlusions|Radio frequency ablation of chronic total occlusions within a stent of a coronary artery using Niobe Magnetic Navigation System (MNS) and the PowerAssert Radiofrequency Guidewire
1873917|NCT01131806|Drug|fluticasone/ salmeterol 125/25 mcg/puff|fluticasone 125mcg/salmeterol 25mcg 2puffs/day x 52 weeks
1873918|NCT01131806|Drug|fluticasone/ salmeterol 250/25 mcg/puff|fluticasone 250mcg/salmeterol 25mcg 2puffs/day x 52 weeks
1873919|NCT01131819|Device|Nintendo Wii fit ™ balance board|Nintendo Wii fit ™ balance board will be introduced for a period of at least 20 minutes but not greater than 30 minutes per day to all the subjects for a minimum of 6 times in two weeks and a maximum of 18 times in 6 weeks.
1873920|NCT01131832|Dietary Supplement|Plant sterol|
1873921|NCT01131832|Dietary Supplement|Placebo|
1873922|NCT01131845|Drug|UT-15C SR (treprostinil diethanolamine)|Single dose, 1 mg UT-15C SR
1873923|NCT01131858|Drug|Vigantol|Vigantol 4000IU/day
1873924|NCT01131858|Drug|Placebo|Placebo
1873925|NCT01131871|Behavioral|Standard Behavioral Weight Loss Intervention|Subjects in this group will receive our standard behavioral weight control program that is delivered in an in-person group-based format. At month 7 subjects will also be given access to a study website to monitor eating and activity behaviors, and to have electronic access to standardized intervention materials. At month 7 subjects will also receive targeted study-related text messages that otherwise would have been provided in paper format.
1873926|NCT01131871|Behavioral|Enhanced Weight Loss Intervention|Subjects in this group will participate in a weight loss intervention that includes technology enhancements. These enhancements will include the addition of intervention specific targeted and tailored text messaging and the BodyMedia Fit System® beginning at Month 7. At month 7 subjects in EWLI will also receive the same targeted study-related text messages provided to SBWP that otherwise would have been provided in paper format.
1873927|NCT01131884|Drug|Fosamax|70mg of Bisphosphonate therapy (Fosamax) will be taken weekly for a year
1873928|NCT01131884|Drug|Placebo|Placebo is an inactive pill that will look similar to the active drug. You will not know whether you are receiving active drug or placebo.
1873929|NCT01131897|Drug|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
1873930|NCT01131910|Biological|TBE-vaccine|Solution of 0.5 ml for intramuscular use. Given in 2 doses separated by 1 month to healthy individuals less than 60 years old. (3 doses 0+1+3 months to those are 60 and above in Sweden)
1873931|NCT01131910|Biological|TBE-vaccine|Solution for injection 0.5 ml im. 2 or 3 doses first years, 1 dose next year
1873932|NCT01131910|Biological|Vaccination against TBE|0.5 ml im at 0 and 1 month ( less than 60 years old) or 0 and 1 and 3 months (at least 60 years old)
1873933|NCT01131923|Drug|Amlodipine|Amlodipine Tablets, 10 mg
1873934|NCT01131936|Drug|Amlodipine|Amlodipine Tablets, 10 mg
1873935|NCT01131949|Drug|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
1873936|NCT01131962|Procedure|Endoscopic control of hematemesis|Endoscopy is performed to diagnose the cause of hematemesis and to control it using band ligation or sclerotherapy
1873937|NCT01131975|Drug|Lamotrigine|Lamotrigine Tablets (chewable, dispersible), 25 mg
1873938|NCT01131988|Drug|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
1873939|NCT01132014|Biological|OCDC|OCDC,an autologous vaccine comprised of autologous dendritic cells (DC) loaded in vitro with lysate from autologous oxidized tumor cells, administered intranodally alone, or in combination with either intravenous Daclizumab, or with a combination of Daclizumab and intravenous Bevacizumab.
1873940|NCT01132027|Drug|Tacrolimus Capsules|Tacrolimus Capsules, 5 mg of Dr. Reddy's Laboratories Limited
1873941|NCT01132040|Drug|Primidone|Primidone Tablets, USP 50 mg of Dr. Reddy's Laboratories Limited
1873942|NCT01132066|Other|tDCS|tDCS will lead to an increase in cortical excitability
1873943|NCT01132066|Other|Sham|Sham will provide identical subjective sensation as tDCS
1873944|NCT01132079|Drug|cream treatment|
1873945|NCT01132105|Device|Vestibular myogenic evoked potential analyzer|
1873946|NCT01132118|Drug|Hydroxychloroquine|Hydroxychloroquine comes in 200 mg tablets and is taken orally. The dose provided will be based upon a calculation of 6.5 mg/kg (subject's weight), which is the dose range commonly used to treat rheumatoid arthritis and lupus. Dosages will be rounded to the nearest 100 mg.
1873947|NCT01132131|Other|Delegation form|The study aims to compare the use of a delegation form to identify patient's who qualify for antibiotic treatment for suspected acute cystitis with a regular doctor's consultation. The key outcomes are lack of bacteruria and symptoms of UTI at followup times.
1874133|NCT01133405|Drug|Placebo|Oral capsules
1876075|NCT01146626|Drug|Peg+ Ribavirine|Peg+ Ribavirine
1873948|NCT01132144|Procedure|Endometrial injury|"Evaluate the position and size of the uterus by transabdominal ultrasonography, with the bladder comfortably full.
Identify the cervix with a disposable speculum. Open one sealed opaque envelope for allocation.
Endometrial injury:
Slide the Pipelle de Cornier® (Laboratoires Prodimed, Neully-En-Thelle, France) gently through the cervix up to the uterine fundus. Transbadominal ultrasound might be used to confirm position.
Draw back the piston to the end of the biopsy cannula until it locks creating a negative pressure.
Sweep the uterine fundus slowly several times up to the internal orifice of the cervix, using regular to-and-fro movements while rotating the sampler to include the whole uterine cavity in the specimen, for 30 seconds or until participant ask for stopping."
1873949|NCT01132144|Procedure|Control group|The investigator will dry the cervix with gauze and forceps for for 30 seconds or until participant ask for stopping.
1873950|NCT01132157|Drug|Desflurane|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
1873951|NCT01132157|Drug|Propofol|In Desflurane group, donors and their recipients will be anesthetized with desflurane and remifentanil. In contrast, in Propofol group, donors will be anesthetized with Propofol and remifentanil and recipients will be anesthetized with desflurane and remifentanil.
1873952|NCT01132170|Drug|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
1873953|NCT01132183|Drug|Divalproex Sodium|Divalproex Sodium Coated Particles in Capsules, 125 mg of Dr. Reddy's Laboratories Limited
1873954|NCT01132196|Drug|Divalproex Sodium|Divalproex Sodium DR Tablets 500 mg
1873955|NCT01132209|Procedure|Closure of the abdominal wall after midline incisions|Closure of the midline incision after any abdominal operation. Suturing of the fascia of the abdominal wall with two different techniques
1873956|NCT01132222|Drug|Ibuprofen + Pseudoephedrine Hydrochloride|Ibuprofen 200 mg + Pseudoephedrine Hydrochloride 30 mg Tablets
1873957|NCT01132235|Biological|etanercept|50mgs subcutaneous injections twice a week for 12 weeks
1873958|NCT01132248|Drug|Mefloquine|15mg/kg mefloquine per dose Women receive two doses: One after the first trimester of pregnancy and the second at least one month after the first dose
1873959|NCT01132248|Drug|S/P|sulfadoxine-pyrimethamine IPTp will be administered following current WHO recommendations
1873960|NCT01132261|Other|"brain preservation' diet"|dietetic evaluation and advice in small group for health diet
1873961|NCT01132274|Procedure|Radiofrequency catheter ablation|Conventional radiofrequency catheter ablation through fluoroscopic guidance of supraventricular arrhythmias.
1873962|NCT01132274|Procedure|Radiofrequency catheter ablation|Radiofrequency catheter ablation through the non-fluoroscopic EnSite NavX mapping system (St.Jude Medical, St Paul, MN, USA) guidance.
1873963|NCT01132287|Other|FID 112903|lubricant eye drop FID 112903
1873964|NCT01132300|Device|Image Guided TENS (Auto-Targeted Neurostimulation, NeMa-st)|Patients will undergo 2 treatments per week during 4 weeks using the device. During the study Patients are allowed to maintain/continue taking medications/ analgesics for pain relief prescribed to them before the study. Medication use will be recorded.
1873965|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
1873966|NCT01132313|Drug|BI 201335|40 weeks, QD
1873967|NCT01132313|Drug|BI 207127|4 weeks, low dose TID
1873968|NCT01132313|Drug|BI 201335|24 weeks, QD
1873969|NCT01132313|Drug|Ribavirin|16 weeks, according to label
1873970|NCT01132313|Drug|Ribavirin|28 weeks, according to label
1873971|NCT01132313|Drug|Ribavirin|28 weeks, according to label
1873972|NCT01132313|Drug|BI 207127|40 weeks, high dose, TID
1873973|NCT01132313|Drug|BI 207127|24 weeks, very high dose, BID
1873974|NCT01132313|Drug|BI 207127|16 weeks, standard dose, BID
1873975|NCT01132313|Drug|BI 201335|24 weeks, QD
1873976|NCT01132313|Drug|Ribavirin|48 weeks, according to label
1873977|NCT01132313|Drug|Ribavirin|40 weeks, according to label
1873978|NCT01132313|Drug|BI 207127|16 weeks, high dose, TID
1873979|NCT01132313|Drug|BI 207127|28 weeks, high dose, TID
1873980|NCT01132313|Drug|BI 201335|28 weeks, QD
1873981|NCT01132313|Drug|BI 201335|16 weeks, QD
1873982|NCT01132313|Drug|Ribavirin|24 weeks, according to label
1873983|NCT01132313|Drug|BI 201335|24 weeks, QD
1873984|NCT01132313|Drug|BI 201335|28 weeks, QD
1873985|NCT01132313|Drug|BI 207127|24 weeks, standard dose, BID
1873986|NCT01132313|Drug|BI 201335|24 weeks, QD
1873987|NCT01132313|Drug|BI 201335|16 weeks, QD
1873988|NCT01132313|Drug|BI 207127|16 weeks, high dose, BID
1873989|NCT01132313|Drug|BI 201335|24 weeks, QD
1873990|NCT01132313|Drug|Ribavirin|16 weeks, according to label
1873991|NCT01132313|Drug|Ribavirin|16 weeks, according to label
1873992|NCT01132313|Drug|BI 207217|28 weeks, high dose BID
1873993|NCT01132313|Drug|BI 201335|16 weeks, QD
1873994|NCT01132313|Drug|BI 207127|24 weeks, high dose, TID
1873995|NCT01132313|Drug|Ribavirin|48 weeks, according to label
1873996|NCT01132313|Drug|BI 207127|4 weeks, high dose, TID
1873997|NCT01132313|Drug|BI 201335|28 weeks, QD
1873998|NCT01132313|Drug|Ribavirin|24 weeks, according to label
1873999|NCT01132313|Drug|Ribavirin|24 weeks, according to label
1874000|NCT01132326|Drug|Droxidopa|Oral, 100, 200, 300, 400, 500, 600 mg TID, 12 months
1874001|NCT01132352|Drug|Levetiracetam|Levetiracetam Tablets, 750 mg of Dr. Reddy's Laboratories Limited
1874002|NCT01132365|Device|any knee joint arthroplasty device|Cohort consist of all consented patients receiving knee arthroplasty
1874003|NCT01132378|Procedure|Total knee arthroplasty|staged bilateral total knee arthroplasty (not more than 7 days between surgeries)
1874004|NCT01132391|Drug|Rectogesic® (glyceryl trinitrate 0.4% ointment)|375 mg of ointment(1,5 mg of glyceryl trinitrate ) / 12h DURING 6 MONTHS
1874005|NCT01132404|Drug|Leuprorelin|Phase 2 portion of study: patients randomized to this arm will receive a subcutaneous injection of depot Leuprorelin in the abdomen once per month for up to 6 months
1874254|NCT01126190|Biological|Pegfilgrastim|Pegfilgrastim 6 mg administered approximately 24 hours following chemotherapy for 4 treatment cycles
1874006|NCT01132404|Drug|TAK-448|"Phase 1 portion of study:
Patients will be administered a single dose of depot formulation TAK-448 via subcutaneous abdominal injection and a single dose of placebo at a contralateral injection site
Phase 2 portion of the study:
Patients randomized to this arm will be administered depot formulation TAK-448 (up to 2 dose levels) via subcutaneous injection in the abdomen once per month for up to 6 months"
1874007|NCT01132417|Drug|In Vitro activity of Tigecycline among key bacterial pathogens exhibiting multidrug resistance|studies in human beings in which biomedical and/or health outcomes are assessed in pre-defined groups of individuals. Subjects in the study may receive diagnostic, therapeutic, or other interventions, but the investigator does not assign specific interventions to the subjects of the study.
1874008|NCT01132430|Behavioral|Motivational interviewing|Brief MI 3x30 minute sessions within 4-6 week period
1874009|NCT01132430|Behavioral|Usual care|Standard medical care within 4-6 week period
1874010|NCT01132443|Drug|Clindamycin 1%-Benzoyl Peroxide (BPO) 3% Gel,|Apply topically once daily
1874011|NCT01132456|Device|Drug eluting stent treatment|Endeavor RESOLUTE Zotarolimus-Eluting Coronary Stent Implantation
1874012|NCT01132469|Procedure|Endoscopic Submucosal Dissection|5-years follow-up after Endoscopic Submucosal Dissection
1874013|NCT01132482|Drug|Sildenafil|During the course of the study, patients will receive 4 weeks of therapy: 28 days of placebo orally t.i.d. or 28 days of days of sildenafil orally t.i.d. Dosing of sildenafil will be escalated after the first week (20 mg orally t.i.d for the first week, then subjects will take 40 mg orally t.i.d. for 3 weeks). Patients not tolerating dose escalation will be discontinued from the study.
1874014|NCT01132482|Drug|Placebo|Patients receiving placebo will have sham dose escalation to maintain blinding.
1874015|NCT01132495|Other|Stenting plus OMT|FFR guided PCI, plus OMT
1874016|NCT01132495|Other|OMT|OMT alone
1874017|NCT01132495|Other|Standard of care|FFR > 0.80; treatment according to local practice
1874018|NCT01132508|Device|Norian Drillable Bone Void Filler|Norian Drillable Bone Void Filler is a moldable, biocompatible bone void filler with added reinforcing fibers. Norian Drillable is intended to be placed into bony voids either before or after final fixation. The material can be drilled and tapped, and screws can be placed through it at any time during the setting process. Norian Drillable is a composite, two-component, self-setting calcium phosphate bone void filler
1874019|NCT01132521|Drug|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
1874020|NCT01132521|Drug|placebo|Resolved 4 vials of drugs in 100ml physiological saline solution, intravenously infused for 1-2h, tid, for continuous 7 days.
1874021|NCT01132547|Drug|cyproheptadine hydrochloride|Given orally
1874022|NCT01132547|Other|placebo|Given orally
1874023|NCT01132560|Genetic|RNA analysis|
1874024|NCT01132560|Genetic|gene expression analysis|
1874025|NCT01132560|Genetic|reverse transcriptase-polymerase chain reaction|
1874026|NCT01132560|Other|laboratory biomarker analysis|
1874027|NCT01132573|Drug|entinostat|Given PO
1874028|NCT01132573|Drug|clofarabine|Given IV
1874029|NCT01132573|Other|pharmacological study|Correlative studies
1874030|NCT01132573|Other|laboratory biomarker analysis|Correlative studies
1874031|NCT01132586|Drug|Lenalidomide|Given PO
1874032|NCT01132586|Drug|Cytarabine|Given IV
1874033|NCT01132586|Drug|Idarubicin|Given IV
1874034|NCT01132586|Other|Pharmacological Study|Correlative studies
1874035|NCT01132586|Other|Laboratory Biomarker Analysis|Correlative studies
1874036|NCT01132599|Dietary Supplement|C-11 choline|
1874037|NCT01132599|Radiation|18F-fluoromethylcholine|
1874040|NCT01132625|Drug|AUY922|
1874041|NCT01132638|Drug|Magnesium Pantoprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
1874042|NCT01132638|Drug|Magnesium Esomeprazole|1 capsule daily, 40 mg, orally, 30 minutes before breakfast
1874043|NCT01132651|Other|Current standard eczema treatment and standard pillow at night|Subjects will continue with their current eczema care and use their normal pillow at night.
1874044|NCT01132651|Other|Chillow cooling pillow|Subjects will use the cooling pillow to sleep on in addition to their current eczema treatment for 2 weeks.
1874045|NCT01132664|Drug|BKM120|Buparlisib (BKM120) is the investigational drug. Burparlisib was supplied as 10 mg and 50 mg hard gelatin capsules. Buparlisib was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area. Buparlisib capsules were packaged in high density polyethylene bottles with a plastic child resistant closure.
1874046|NCT01132664|Drug|Trastuzumab|Trastuzumab was used in this study according to the local regulations in each participating country. A loading dose (4 mg/kg) of trastuzumab was administered (if required as assessed by the principal Investigator based on the timing of the last trastuzumab dose prior to enrollment) on Day -7 over 90 minutes, followed by weekly intravenous infusion of 2 mg/kg maintenance doses from Day 1 of Cycle 1 (over 30 minutes if the previous infusion was well tolerated).
1874047|NCT01132664|Drug|Capecitabine|1000 mg/m2 twice a day from day 1 to Day 14 of a 21-day cycle.
1874048|NCT01132677|Device|Hylan G-F 20 (Synvisc One)|Single IA injection of 6cc's. Injections will be administered as outlined on the company label.
1874049|NCT01132677|Drug|Methylprednisolone (Corticosteroid)|Single IA injection of 80mg of methylprednisolone acetate (1cc of solution) mixed with 5cc's of 1% lidocaine without epinephrine for a total of 6cc's. The injection will be administered as outlined on the company label.
1874050|NCT01132690|Drug|Taliglucerase alfa|Taliglucerase alfa for infusion every two weeks for 12 months
1874051|NCT01132703|Drug|RP-1127 (Glyburide for injection)|RP-1127 is administered as a bolus followed by continuous infusion for 72 hours
1874052|NCT01132703|Drug|Placebo (RP-1127 excipients, excluding active)|RP-1127 excipients, excluding active
1874053|NCT01132716|Drug|Valacyclovir Hydrochloride|1000 mg caplet
1874054|NCT01132729|Drug|Valacyclovir Hydrochloride|1000 mg caplet
1874126|NCT01133366|Drug|mipomersen sodium; warfarin sodium|200 mg of mipomersen subcutaneous (SC) (4 doses) plus a single 25 mg of warfarin oral administered with the final mipomersen SC dose
1876300|NCT01147666|Drug|Epoetin Alfa|Per current label instruction
1874055|NCT01132755|Procedure|Diagnostic peritoneal lavage|The Veress needle will be inserted in the abdominal wall, at a site to be left up to the individual surgeon. Caudal traction will be applied to the abdominal wall to provide a firm abdominal wall to insert the needle through, minimizing the peritoneum from tenting down closer to visceral structures. Intraperitoneal placement of the catheter will be confirmed by injection of saline into the needle with no resistance and with the saline in the hub of the needle falling into the peritoneal cavity spontaneously. A guide wire will be placed through the Veress and utilizing the Seldinger technique, a 9Fr peritoneal catheter will be placed.
1874056|NCT01132768|Drug|Atenolol|Atenolol (ATE) 50 mg and/or 100 mg tablets, oral, once daily
1874057|NCT01132768|Drug|olmesartan medoxomil|Olmesartan medoxomil (OM), 20 mg and/or 40 mg, oral, once daily
1874058|NCT01132781|Drug|Theophylline (Intervention Group)|200 mg twice daily of slow release theophylline
1874059|NCT01132781|Drug|Placebo (Placebo Group)|200 mg twice daily of placebo drug
1874060|NCT01132794|Drug|Intranasal dexmedetomidine|1mcg per kg dexmedetomidine given intranasally 45 minutes before operation
1874061|NCT01132794|Drug|Placebo|Intranasal nasal saline
1874062|NCT01132807|Biological|Bleomycin Sulfate|Given IV
1874063|NCT01132807|Drug|Doxorubicin Hydrochloride|Given IV
1874064|NCT01132807|Drug|Procarbazine Hydrochloride|Given PO
1874065|NCT01132807|Drug|Vinblastine Sulfate|Given IV
1874066|NCT01132807|Drug|Dacarbazine|Given IV
1874067|NCT01132807|Drug|Cyclophosphamide|Given IV
1874068|NCT01132807|Drug|Etoposide phosphate|Given IV
1874069|NCT01132807|Drug|prednisone|Given PO
1874070|NCT01132807|Drug|Radiation Therapy|Undergo radiation therapy
1874071|NCT01132807|Radiation|Fludeoxyglucose F-18|Undergo FDG PET/CT
1874072|NCT01132807|Procedure|computed tomography|Undergo FDG PET/CT
1874073|NCT01132807|Procedure|Positron Emission Tomography|Undergo FDG PET/CT
1874074|NCT01132820|Drug|Cediranib Maleate|Given PO
1874075|NCT01132820|Other|Laboratory Biomarker Analysis|Correlative studies
1874076|NCT01132833|Other|enzyme-linked immunosorbent assay|Measurement of markers of coagulation and endothelial activation
1874077|NCT01132833|Other|laboratory biomarker analysis|The PPP will be used for in vitro assays to measure TF activity, coagulation markers and markers of endothelial cell damage
1874078|NCT01132833|Other|medical chart review|The patient's clinical course with respect to development of venous thromboembolism and response to treatment will be monitored for a total of 3 months from enrollment.
1874079|NCT01132846|Other|Placebo|Participants will be randomized to receive Low dose Dopamine or placebo plus optimal diuretic or Low dose Nesiritide or placebo plus optimal diuretic.
1874080|NCT01132846|Drug|Nesiritide|"Active Comparator: Low Dose Nesiritide
Participants randomized to the low dose nesiritide arm will receive nesiritide of 0.005 ug/kg/min or placebo during the first 72 hours in the trial."
1874081|NCT01132846|Drug|Dopamine|Participants randomized to the low dose dopamine arm will receive dopamine of 2ug/kg/min or placebo during the first 72 hours in the trial.
1874082|NCT01132911|Drug|Vorinostat (SAHA)|
1874083|NCT01132911|Drug|Velcade (PS-341, Bortezomib)|
1874084|NCT01132950|Behavioral|Motivational Interviewing|Two personalized sessions of motivational interviewing. The first one is given while the participant is in jail and the second one is given at 3 months post release.
1874085|NCT01132950|Other|Didactic Educational Counseling|Participant will watch an educational video while in jail and a second educational video at 3 months post release.
1874086|NCT01132963|Other|Outdoor Shoes|Patient will be wearing sturdy outdoor shoes to complete balance tests
1874087|NCT01132963|Other|Pillow Paw Slippers|Patient will be wearing Pillow Paws slippers to complete balance tests which are issued to patients who do not have shoes in NHS hospitals in the UK
1874088|NCT01132976|Behavioral|Personal Concerns Inventory|This is a pre-treatment, goal-based motivational interview which helps to patients identify their life goals, and goal-value. The interview will last approximately 2 hours and will be carried out face to face with a therapist across one or two sessions.
1874089|NCT01132976|Behavioral|Treatment as usual|No specific motivational interview
1874090|NCT01132989|Drug|Lenalidomide|Lenalidomide Starting Dose Based on Renal Function at Study Entry Baseline Calculated Creatinine Clearance (by Cockcroft-Gault) Starting Lenalidomide Dose 60 ml/min 25mg daily on Days 1-21 of each 28-day cycle 30 and < 60 ml/min 10mg daily on Days 1-21 of each 28-day cycle
1874091|NCT01133015|Device|Fractional flow reserve|Fractional flow reserve measured by pressure wire
1874092|NCT01133015|Device|IVUS|intravascular ultrasound
1874093|NCT01133028|Behavioral|Behavioral contingency management|Teachers will learn to use reinforcements and response cost procedures to encourage children's display of prosocial behaviors.
1874094|NCT01133028|Behavioral|Tolerance training|Teachers will be instructed in procedures to encourage the peer group to be accepting of children with ADHD.
1874095|NCT01133041|Other|Observation using NBI system|NBI system can improve the patterns of mucosal surface and vascularity of colonic polyp.
1874096|NCT01133041|Other|Observation using i-Scan system|I-Scan system can improve the patterns of mucosal surface and vascularity of colonic polyp.
1874097|NCT01133054|Procedure|revascularization|surgery or stenting
1874098|NCT01133080|Drug|Minocycline|minocycline 200 mg/day orally in two divided doses for the second week. From weeks 3 to weeks 5, minocycline 400 mg/day orally in two divided doses.
1874099|NCT01133080|Drug|placebo|"placebo 200 mg/day orally in two divided doses for the first week. placebo 200 mg/day orally in two divided doses for the second week.
From weeks 3 to weeks 5, placebo 400 mg/day orally in two divided doses."
1874127|NCT01133379|Device|12027-019|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
1874128|NCT01133379|Device|12027-020|Rinse with 20 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste.
1874129|NCT01133379|Device|12027-021|Rinse with 10 mL for 60 seconds twice daily after brushing in your usual manner for 1 minute using at least a one-inch strip of the assigned toothpaste
1874130|NCT01133392|Drug|Insulin lispro A|20 units (U) subcutaneously (SC).
1874100|NCT01133106|Behavioral|Brief pleasurable events/behavioral therapy|"Each participant in any arm will be given an American Stroke Association article about stroke and depression, a Stroke Smart Article about caregiver depression, and a pamphlet by the Beck Institute titled Coping with Depression.
Each participant in Arms 1 and 2 will be given their own manual for the intervention sessions. The intervention consists of one in-person orientation session and 6 weekly sessions with the following topics introducing behavioral therapy, the role of pleasant events, problem-solving skills and generalization techniques. All participants' primary care provider or stroke care provider will receive a letter informing them of their patient's participation (but not of study assignment). This letter will include recommendations for prescribing and adjusting antidepressant treatment using established guidelines adapted for treatment of medically-ill outpatients."
1874101|NCT01133106|Other|Standard care|The standard care group (Arm C, N=75) will receive standard medical treatment from their provider, including a recommendation for antidepressants. Participants or third-party payers will pay for their antidepressants, just as they would under regular care. All participants receive written materials regarding depression from the American Stroke Association, keep medication logs and receive follow-up assessment on the same time frame as the intervention groups
1874102|NCT01133119|Drug|Standard of Care|Subjects will have femoral sheaths removed under general anesthetic but without subcutaneous infiltration of bupivacaine.
1874103|NCT01133119|Drug|Standard of Care plus bupivacaine|"Subcutaneous dose of 0.25% bupivacaine infiltrated around the entry site of the femoral artery/vein sheath, just prior to sheath removal.
Participants will receive a dose of up to 0.8mL/kg (up to 2.0 mg/kg) of 0.25% bupivacaine, with the final amount at the discretion of the physician."
1874104|NCT01133132|Behavioral|Survivorship CHESS|Once the consent, baseline survey and one week accelerometer data is received by the UW research team subjects will be randomized to one of the two study conditions. Subjects will be notified of their randomization. Subjects randomized to the Survivorship CHESS condition will be offered training on the smartphone and the CHESS system. The project director (and site research coordinators) will provide training on the smartphone either in person or over the phone. Additionally, an online tutorial will be included in the Survivorship CHESS intervention for subjects to refer to as needed. Participants will then be asked to complete four surveys one baseline and then three follow up surveys.
1874105|NCT01133132|Other|Control|This person will receive usual care and a copy of the National Cancer Institute's Facing Forward booklet and the National Cancer Center Network cancer survivor toolbox.
1874106|NCT01133145|Procedure|knee joint transplantation|transplantation of a kne joint from a multi organ donor to a recipient with a severly injured knee joint
1874108|NCT01133171|Behavioral|Nurse Alone|Patients received two in-person counseling sessions by a research nurse, approximately 3-7 months apart, in methods for controlling cardiovascular risk factors.
1874109|NCT01133171|Behavioral|Dashboard Plus Nurse|Patients receive two in-person counseling sessions, six months apart, in methods for controlling cardiovascular risk factors and were asked to use a computerized dashboard to enter values for the risk factors and observe the effects of the risk factors on the overall cardiovascular risk.
1874110|NCT01133184|Biological|Sci B vac|Sci B vac
1874111|NCT01133210|Drug|Maraviroc|dosage will be a 300mg Maraviroc pill twice a day for 12 weeks
1874112|NCT01133210|Other|placebo|subjects will be given placebo pills with instructions to take one pill twice a day for 12 weeks.
1874113|NCT01133223|Device|Penumbra™ System|Patients assigned to the Thrombectomy arm will be conducted to the angio suite. Mechanical thrombectomy will be attempted with the use of the Penumbra™ System, and can be assisted by intraarterial thrombolysis (rTPA up to 20 mg)
1874114|NCT01133223|Drug|Recombinant tissue plasminogen activator|Patients assigned to Usual Care arm will be thrombolysed according to the NINDS protocol (rtPA 0,9 mg/kg, 10% IV bolus and remaining in the next hour, up to 90 mg)
1874115|NCT01133236|Dietary Supplement|Salt and fluid restriction|"I: Intervention Prescription of low-sodium diet with additional 2 g of sodium and water restriction to 800 mL/day.
II: Control Prescription without sodium and fluid restriction."
1874116|NCT01133275|Drug|Prednisone|Prednisone therapy for 6 cycles (24 weeks).
1874117|NCT01133275|Drug|Lenalidomide|Lenalidomide therapy for 6 cycles (24 weeks).
1874118|NCT01133288|Device|Yulex gloves|Study participants will be asked to wear Yulex gloves for routine bowel and bladder care (~30 minutes per day) over a 3 month period.
1874119|NCT01133301|Drug|Naltrexone|50 mg/d Naltrexone will be administrated during three weeks.
1874120|NCT01133301|Drug|Placebo|During 3 weeks of the study, Placebo will be administrated (daily)
1874121|NCT01133327|Device|Carotid Artery Stenting|"The Adapt Carotid Stent System is intended to deliver a self-expanding Stent to the extra-cranial carotid arteries via a sheathed percutaneous Monorail delivery system. The Adapt Carotid Stent is a closed cell, self-expanding, rolled nitinol (nickel-titanium alloy) sheet. The stent is thin, flexible and expands to appose the vessel wall.
The FilterWire EZ System is a temporary intravascular guide wire filtration system that is placed in the vessel distal to the lesion to be treated. It consists of either a polyurethane filter bag 1.5 cm in length or a Bionate (polycarbonate urethane) filter bag, 1.0 cm in length attached near the distal end of a 0.014 silicone coated stainless steel guide wire by means of a collapsible, self-conforming, Nitinol filter loop wire."
1874122|NCT01133340|Radiation|Radiation|No treatment intervention is planned. Patients will be scanned and treated as per department standards. The patient will have MRI at the time of their standard plan. They will then have clips inserted to mark the tumor after the standard scan is performed. The MRI and additional imaging with clips in place will be processed by 3 investigators who will contour based on the experimental image and compare this with the standard treated plan. Comparison of volumes in a blinded manner between investigators will also occur. The patients treatment will not be affected by the MRI or clip placement.
1874123|NCT01133353|Drug|Tetrabenazine MR|Modified-Release (MR) tablets containing 15 mg or 30 mg tetrabenazine, dose-escalating up to a maximum of 150 mg depending on weight, once per day for 12 weeks
1874124|NCT01133353|Drug|Placebo|1 to 5 tablets once per day depending on weight for 12 weeks
1874125|NCT01133366|Drug|warfarin sodium|25 mg of warfarin oral (single dose)
1874134|NCT01133418|Other|Computerized Progressive Attention Training|Four comprehensive training tasks were developed and programmed based on expansions and modifications of various tasks that have been extensively investigated in the attention literature and are known to reflect primary attentional functions. Each task is discussed in detail in the Research Methods (section D.6.b). Briefly, they included a Continuous Performance Task, a Conjunctive Search Task, an Orienting and Flanker Task, and a Global-Local Task. All of the tasks were modified extensively from their original neuropsychological design to make them entertaining and stimulating enough for children to enjoy. Each task began at a relatively simple level of difficulty and gradually increased in difficulty across the training as children demonstrated proficiency according to reductions in RT variability
1874135|NCT01133418|Other|Sham Comparator Cognitive Training|Same tasks at Computerized Progressive Attention Training but the tasks do not progress in difficulty
1874136|NCT01133431|Drug|CKD-501 0.5 mg tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 0.5mg is administered daily to Group 1 patients during period 1. Then on day 5,CKD-501 0.5mg and glimepiride 4mg is co-administered to overnight-fasting Group 1 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 placebo and glimepiride 4mg in Group 1.
1874137|NCT01133431|Drug|CKD-501 placebo tablet, Glimepiride 4 mg tablet|From day 1 to day 4, CKD-501 placebo is administered daily to Group 2 patients during period 1. Then on day 5,CKD-501 placebo and glimepiride 4mg is co-administered to overnight-fasting Group 2 patients at period 1. After 10 day-break, period 2 will be repeated with CKD-501 0.5mg and glimepiride 4mg in Group 2.
1874138|NCT01133444|Drug|Finasteride|Finasteride tablets 1 mg
1874139|NCT01133457|Drug|Finasteride|Finasteride tablets 1 mg
1874140|NCT01133470|Drug|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's KLaboratories Limited
1874141|NCT01133483|Drug|Fexofenadine HCl + Pseudoephedrine HCl|Fexofenadine HCl 180 mg + Pseudoephedrine HCl 240 mg ER Tablets of Dr. Reddy's Laboratories Limited
1874142|NCT01133496|Drug|Alendronate Sodium Tablets, 70 mg|Alendronate Sodium Tablets, 70 mg of Dr. Reddy's Laboratories Limited.
1874143|NCT01133509|Drug|Gardasil|0.5ml IM for three doses, Second and third dose to be given at 2 months and 6 months
1874144|NCT01133522|Biological|Evolocumab|Administered by subcutaneous injection
1874145|NCT01133522|Biological|Placebo|Administered by subcutaneous injection
1874146|NCT01133548|Drug|Testosterone Gel 1.62%|5 grams administered using an application Site Rotation
1874147|NCT01133548|Drug|Testosterone Gel 1.62%|5 grams administered using an a combination of Application sites
1874148|NCT01133561|Drug|actozone A|pioglitazone 30 mg tablet , once daily dose for 10 weeks
1874149|NCT01133561|Drug|actozone B|one tablet of vehicle without active ingredient pioglitazone
1874150|NCT01133574|Drug|SLV354 capsules|20 mg
1874151|NCT01133574|Drug|SLV354 capsules|60 mg
1874152|NCT01133574|Drug|SLV354 capsules|120 mg
1874153|NCT01133574|Drug|SLV354 capsules|250 mg
1874154|NCT01133574|Drug|SLV354 capsules|500 mg
1874155|NCT01133574|Drug|SLV354 capsules|750 mg
1874156|NCT01133574|Drug|SLV354 capsules|1000 mg
1874157|NCT01133574|Drug|SLV354 capsules|1250 mg
1874158|NCT01133574|Drug|Placebo capsules|placebo
1874159|NCT01133574|Drug|SLV354 capsules|low dose group 1
1874160|NCT01133574|Drug|SLV354 capsules|high dose group 1
1874161|NCT01133574|Drug|SLV354 capsules|low dose group 2
1874162|NCT01133574|Drug|SLV354 capsules|high dose group 2
1874163|NCT01133574|Drug|Placebo capsules|placebo
1874164|NCT01133587|Other|wait list control|"Patient-guided admissions contract regarding patient-guided admissions starting a year after."
1874165|NCT01133587|Behavioral|admissions contract|"contract regarding patient-guided admissions starting immediately"
1874166|NCT01133600|Drug|Cubicin|dosed at 6 mg/kg body weight intravenously every 24 hours with a reduction to 6mg/kg every other day if CrCl is <30ml/min.
1874167|NCT01133600|Drug|Vancomycin|dosed at 15mg/kg intravenously every 12 hours with adjustments for renal function.
1874168|NCT01133613|Drug|Bone morphogenetic protein 7|Single intraarticular injection of BMP-7 or placebo on Day 1
1874169|NCT01133626|Drug|Placebo Nasal Aerosol|Placebo nasal aerosol administered daily for 42 days of treatment
1874170|NCT01133626|Drug|Prednisone capsules|Prednisone 10 mg capsule taken each day on the last 7 days of treatment
1874171|NCT01133626|Drug|Placebo Prednisone Capsules|Placebo prednisone capsule taken each day on the last 7 days of treatment
1874172|NCT01133626|Drug|Beclomethasone dipropionate|Total daily dose of 320 micrograms per day of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) applied as a nasal aerosol each morning for 42 days.
1874173|NCT01133639|Drug|Ketorolac|30 mg IV dose intra-operatively followed by 10 mg orally every 8 hours for five days plus standard of care
1874174|NCT01133639|Drug|Placebo|Placebo plus standard of care
1874175|NCT01133652|Device|Veinviewer|Veinviewer machine
1874176|NCT01133652|Device|Ultrasound|Ultrasound
1874177|NCT01133652|Other|Conventional technique|Conventional IV placement by nurses
1874178|NCT01133665|Drug|Cetuximab and Lenalidomide|The treatment of Head and Neck Cancer with Cetuximab and Lenalidomide
1991431|NCT01112358|Drug|Follitropin alpha (r-FSH) and Lutropin alfa (r-hLH)|Recombinant-human luteinising hormone (r-hLH) was administered by subcutaneous (s.c.) route at a daily dose of 150 IU after administration of r-hFSH an GnRH antagonist. Administration of r-hFSH, GnRH antagonist, and r-hLH was stopped within 24 hours prior to r-hCG administration
1874181|NCT01133691|Dietary Supplement|clear fluid, light breakfast|clear fluid 7 ml/kg, breakfast consisting of yoghurt, muesli, mild
1874182|NCT01133704|Biological|sipuleucel-T|
1874183|NCT01133704|Biological|APC-Placebo|
1874184|NCT01133730|Drug|Active treatment|US-guided TFP block with 20ml 0.5% ropivacaine + 1:200 000 epinephrine
1874185|NCT01133730|Drug|Placebo Arm|US-guided TFP block with 20ml of 5% dextrose solution
1874255|NCT01126190|Drug|Chemotherapy|The chemotherapy regimen for this trial consists of doxorubicin 60 mg/m2 and docetaxel 75 mg/m2 in combination
1876301|NCT01147666|Drug|FG-4592|Different dose levels
1874186|NCT01133743|Drug|Lenalidomide and Dexamethasone|Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
1874187|NCT01133756|Drug|Lenvatinib|lenvatinib (as 1mg, 4mg, and 10mg tablets) was administered orally, once daily continuously for each 21-day treatment cycle.
1874188|NCT01133756|Drug|Carboplatin|Carboplatin was to be administered on Day 1 of every 21-day cycle at a dose AUC 4 over 30 minutes.
1874189|NCT01133756|Drug|Gemcitabine|Gemcitabine was to be administered on Day 1 and Day 8 of every 21-day cycle at a dose of 1000 mg/m2 over 30 minutes.
1874190|NCT01133782|Procedure|Access to diagnostic test|Randomization to receive a result of diagostic procedure the following day.
1874191|NCT01133795|Drug|Midodrine plus Albumin|MIdodrine 10mg tid for 12 weeks. Albumin 40g every 14 days for 12 weeks
1874192|NCT01133821|Drug|IPSRT plus placebo (IPSRT-PLA)|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.
The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).
Medication Dosing
The research pharmacy will dispense medication in the following unit-dose packs:
Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
1874193|NCT01133821|Drug|IPSRT plus quetiapine|"Subjects will be seen approximately weekly/biweekly during the 20 week acute phase. All subjects will return at weeks 36 and 52 for follow-up assessments to evaluate the enduring effects of treatment.
The therapist will administer IPSRT and the psychiatrist will administer medication management procedures (quetiapine or placebo).
Medication Dosing
The research pharmacy will dispense medication in the following unit-dose packs:
Dose A (50 mg of QUE or PLA) Dose B (100 mg of QUE or PLA) Dose C (separate packs of 50 mg and 100 mg QUE capsules or PLA) Dose D (200 mg of QUE or PLA) Dose E (separate packs of 50 mg and 200 mg QUE capsules or PLA) Dose F (separate packs of 100mg and 200mg QUE capsules or PLA)"
1874194|NCT01133847|Drug|Methylphenidate|Appropriate dosage to be individually determined; daily for 16 weeks
1874195|NCT01133847|Behavioral|Intensive reading instruction|Individualized phonologically-based instruction delivered 4 days per week for 45 min. per day by a highly trained tutor.
1874196|NCT01133847|Behavioral|Parent Training|Nine sessions on parenting a child with ADHD
1874197|NCT01133847|Drug|Mixed Salt Amphetamine|Appropriate dosage to be individually determined; daily for 16 weeks; prescribed only if child does not show a beneficial treatment response to Concerta
1874198|NCT01133847|Drug|Atomoxetine|Appropriate dosage to be individually determined; daily for 16 weeks
1874199|NCT01133847|Drug|Guanfacine|Appropriate dosage to be individually determined; daily for 16 weeks
1874200|NCT01133860|Drug|eltrombopag|Eltrombopag, administered orally, 50 mg/daily for 21 days. Patients with platelet counts between 100 and 150x10e9/L at day 21 will continue eltrombopag 50 mg/daily for 21 additional days. Patients with platelet count lower than 100x10e9/L at day 21 will receive eltrombopag 75 mg/daily for additional 21 days. Patients with more than 150x10e9 platelets/L at day 21 will stop therapy.
1874201|NCT01133873|Drug|Propoxyphene napsylate (XP20C)|100 mg capsules 6 times a day in ascending doses until a maximum tolerated dose is identified
1874202|NCT01133873|Drug|Placebo|6 times a day in ascending doses until a maximum tolerated dose is identified
1874203|NCT01133886|Drug|Decitabine|Patients will receive decitabine as a 20mg/m2 one hour intravenous infusion once daily on days 1 to 5 of a 4 week cycle.
1874204|NCT01133899|Dietary Supplement|guanidinoacetic acid|2.4 grams of guanidinoacetic acid
1874205|NCT01133899|Dietary Supplement|GAA-4|4.8 grams of guanidinoacetic acid
1874206|NCT01133899|Dietary Supplement|GAA-1|1.2 grams of guanidinoacetic acid
1874207|NCT01133899|Dietary Supplement|PLACEBO|celulose
1874208|NCT01133912|Drug|paclitaxel, gemcitabine, lapatinib|Patients receive paclitaxel and gemcitabine intravenously (iv) on day 1 and 8, and oral lapatinib once daily. Lapatinib with fixed dose will be given once a day p.o. from day 1 without resting during each cycle. The starting doses of paclitaxel 80mg/m2 and gemcitabine 1000mg/m2 iv, on day 1 and 8, and lapatinib 1000mg p.o., daily (dose level 1) will be administered every 21 days.
1874209|NCT01133925|Device|Resolute Sprint|Zotarolimus Eluting Stent (Resolute Sprint) implanted in overlap
1874210|NCT01133925|Device|Sirolimus Eluting Stent|Cypher stents implanted in overlap
1874211|NCT01133925|Device|Paclitaxel Eluting Stent|Taxus stents implanted in overlap
1874212|NCT01133925|Device|Zotarolimus eluting stent|Endeavor stents implanted in overlap
1874213|NCT01133951|Drug|OAC triple therapy|Omeprazole, 20mg, amoxicillin, 1000mg, and clarithromycin, 500mg, all twice a day for 2 weeks.
1874214|NCT01133951|Drug|Placebo|Omeprazole placebo, amoxicillin placebo, and clarithromycin placebo, all twice a day for 2 weeks.
1874215|NCT01133964|Dietary Supplement|dairy proteins|Protein drinks with 3.5% protein. The protein source will be whey, casein or whey and casein (20:80; normal content in the milk). In the arm with water no protein will be added.
1874216|NCT01133977|Drug|Lenvatinib|Lenvatinib tablets administered orally at doses of 16 mg, 20 mg, or 22 mg, once daily continuously over 3 weeks (21 days) during each 21-day cycle
1874217|NCT01133977|Drug|Lenvatinib|Lenvatinib 20 mg (MTD/recommended Phase 2 dose as determined in Phase 1b of the study) administered once daily continuously over 3 weeks (21 days) during each 21-day cycle
1874218|NCT01133977|Drug|Dacarbazine|Dacarbazine (1000 mg/m2) infusion over 60 minutes on Day 1 of each 21-day cycle.
1874219|NCT01133990|Drug|FOLIRI|The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 and Day 15 of each 28-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional). The 5-FU IV bolus (400 mg/m2) and CIV infusion (2400 mg/m2) over 46 hours is repeated on Days 15 and 16 of each cycle.
1874355|NCT01136187|Procedure|Access site in primary PCI|
1874220|NCT01133990|Drug|FOLIRI plus E7820|E7820 is administered orally in tablet form once daily, every day of each 28-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Phase II portion, the dose will be the MTD recommended Phase IB dose in combination with FOLFIRI, as determined during the Phase Ib portion of the study.
1874221|NCT01133990|Drug|FOLFIRI plus Bevacizumab|Bevacizumab at 5 mg/kg (IV infusion) on Days 1 and 15 of each 28-day treatment cycle
1874222|NCT01134016|Drug|Antroquinonol|"Antroquinonol was taken orally, daily, within 15 minutes after a breakfast at the assigned dose level: 50, 100, 200, 300, 450, 600 mg/day for 4 weeks.
Dose Level 1 (4 weeks) : 50 mg Antroquinonol; Dose Level 2 (4 weeks) : 100mg Antroquinonol; Dose Level 3 (4 weeks) : 200mg Antroquinonol; Dose Level 4 (4 weeks) : 300mg Antroquinonol; Dose Level 5 (4 weeks) : 450mg Antroquinonol; Dose Level 6 (4 weeks) : 600mg Antroquinonol.
The accelerated phase ended when either 1 DLT or MT was observed to start standard phase. Study ended when reach the highest dose level or DLT founded."
1874223|NCT01134029|Behavioral|Stepped Care|This group receives 2 years of a stepped care intervention including provider visits, health educator sessions, phone calls and mailings and availability of self management and group sessions, text messaging and a smoker's quit line.
1874224|NCT01134042|Drug|Fluticasone Furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol inhalation powder inhaled orally once daily for 24 weeks
1874225|NCT01134042|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone furoate inhalation powder inhaled orally once daily for 24 weeks
1874226|NCT01134042|Drug|Fluticasone Propionate Inhalation Powder|Fluticasone propionate inhalation powder inhaled orally twice daily for 24 weeks
1874227|NCT01134042|Other|Placebo Inhalation Powder 1|Placebo in novel dry powder inhaler once daily
1874228|NCT01134042|Other|Placebo Inhalation Powder 2|Placebo in Diskus inhaler twice daily
1992912|NCT03277066|Drug|Diclofenac Sodium Active Topical Patch 1|HP-5000 Active Topical Patch 1 will be evaluated against placebo topical patches.
1992913|NCT03277066|Drug|Diclofenac Sodium Active Topical Patch 2|HP-5000 Active Topical Patch 2 will be evaluated against placebo topical patches.
1874232|NCT01134068|Other|Evaluation of a modified DD cut-off to rule out PE|Evaluation of a modified DD cut-off to rule out PE
1874233|NCT01134081|Biological|CelTx™|CelTx™ is a living bilayered cell therapy product. CelTx™ is constructed of Type I bovine collagen (extracted from bovine tendons and subsequently purified) and viable allogeneic human fibroblasts and keratinocytes isolated from human neonatal foreskin. This is applied once in the oral cavity.
1874234|NCT01134081|Procedure|Free Gingival Graft|Harvested tissue from palate
1874235|NCT01134094|Procedure|Open reduction internal fixation of the ankle|The specific procedure for each patient managed operatively, both in the observational study and the RCT, will be determined by the operating surgeon. Any adverse intra-operative or post-operative event will be recorded. This includes but is not limited to death, infection and neurovascular injury. Post operatively, all patients will be NWB (non weight bearing) and placed in a POP (plaster of paris) below knee cast or walking boot. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. The treating surgeon will review the patients after 10-14 days for a wound review, removal of sutures and change of cast to a fibreglass cast or walking boot (cam walker). The patient will be WBAT (weight bearing as tolerated) for a further 4 weeks.
1874236|NCT01134094|Procedure|Non Operative|Patients who are treated non-operatively will be treated with a walking boot and allowed WBAT. Discharge from hospital will be determined by the patient walking 25m unaided by standby assistance. All patients will be reviewed between 7 and 14 days post injury with repeat x-rays by the treating surgeon.
1874237|NCT01134107|Drug|Insulin Lispro 6 Day (6D)|Administered by infusion pump for 12 week treatment period
1874238|NCT01134107|Drug|Insulin Aspart 6 Day (6D)|Administered by infusion pump for 12 week treatment period
1874239|NCT01134120|Drug|LY2784544|LY2784544 will be supplied as a capsule. The study drug will be taken by mouth daily while the patient is on study. In this study, different patients will be treated at different doses of LY2784544 until reaching the highest dose that patients can tolerate.
1874240|NCT01134133|Other|Anti-gurgling intervention|1. head of bed 30 degrees or higher, 2. swallowing evaluation-based feeding, 3. sedatives titrated to minimal effective dose.
1874241|NCT01134146|Radiation|IMRT|Delivery of whole-pleura radiation doses beginning with 1) 45 Gy to low-risk region and 60-66 Gy to high-risk region; then 2) the same dosing regimen as above with a third dosing level, 50 Gy to an intermediate-dosing region. Every weekday (Monday-Friday) for up to 5 weeks, lasting about 45-60 minutes.
1992914|NCT03277066|Drug|Placebo patch|The study will evaluate active topical patches against topical placebo patches.
1992915|NCT03276962|Biological|RTS,S/AS01E (Full dose)|Subjects will receive intramuscular injection of RTS,S/AS01E (full dose: 0.5 ml).
1874244|NCT01134185|Drug|prucalopride|single oral dose of 2 mg prucalopride
1874245|NCT01134185|Drug|prucalopride|single oral dose of 2 mg prucalopride
1874246|NCT01134185|Drug|prucalopride|single dose of 2 mg prucalopride
1874247|NCT01126138|Drug|Vinorelbine plus Capecitabine for 6 cycles, followed by Capecitabine|Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) Vinorelbine: 25 mg/m2 IV over 3 hours on day 1 and 8, every 3 weeks 21 days as one cycle and 6 cycles are required
1874248|NCT01126138|Drug|Docetaxel plus Capecitabine for 6 cycles, followed by Capecitabine|"Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14), Docetaxel: 75 mg/m2 IV over 3 hours on day 1, every 3 weeks, 21 days as one cycle and 6 cycles are required.
Followed by Capecitabine: 1,000 mg/m2 PO twice daily (day 1-14) 21 days as one cycle until progression or unacceptable toxicity"
1874249|NCT01126151|Behavioral|parent handbook|parent handbook
1874250|NCT01126164|Behavioral|Parent Handbook and Peer Basics|Parent and Peer delivered interventions
1874251|NCT01126177|Drug|Interferon beta 1a|SNG001, IFN-β1a solution for inhalation
1874252|NCT01126177|Drug|Placebo|Placebo (excipients of the SNG001 solution only)
1874253|NCT01126190|Biological|Neugranin|Neugranin 40 mg administered approximately 24 hours following chemotherapy for 4 treatment cycles
1992916|NCT03276962|Biological|RTS,S/AS01E (1/5th dose)|Subjects will receive intramuscular injection of RTS,S/AS01E (1/5th dose: 0.1 ml).
1992917|NCT03276962|Biological|Rabies vaccine|Subjects will receive intramuscular injection of rabies vaccine (0.1 ml).
1992918|NCT03276936|Drug|FMX103 1.5%|FMX103 1.5% minocycline foam
1874256|NCT01126203|Procedure|SLT|All eyes will be treated using a commercially available Q-switched Nd:YAG laser (Coherent Selecta 7000, Coherent Inc., Palo Alto , CA, USA) calibrated by the manufacturer. On the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% or 2% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens or a Latina SLT or any other goniolens will be placed on the eye to be treated with methyl cellulose 1%. The helium-neon aiming beam is focused onto the pigmented trabecular meshwork. SLT will be performed with approximately 50 applications, a 400um spot size with energies varying from 0.8-1.2 mjoules.
1874257|NCT01126203|Procedure|ALT|All eyes will be treated using Ophthalas 532 Eyelite Laser Photocoagulator (Alcon Surgical, Dallas-Fort Worth, Texas, USA. On the day of treatment, IOP will be measured, then on the day of treatment, IOP will be measured, then one drop of Apraclonidine 1% or Brimonidine 0.2% and pilocarpine 1% will be instilled. Before the patient is seated at the laser slit-lamp system a proparacaine hydrochloride drop will be instilled in the eye to be treated. A Goldmann goniolens will be placed on the eye to be treated with methyl cellulose 1%. The aiming beam is focused onto the anterior portion of the pigmented trabecular meshwork. ALT will be performed to the superior or inferior 180 degrees with ~ 50 applications, a 50um spot size with energies varying from 400-700 mW with 0.1 second duration.
1874258|NCT01126216|Drug|Paclitaxel/Cisplatin|Experimental: Paclitaxel (20mg/m^2/d) on days 2, 5, 8, 11 and 25, 30, 33, 36) and Cisplatin (20mg/m^2/d) on days 1-4 and 29-32,
1874259|NCT01126216|Radiation|Reduced RT|Experimental: 63,6 Gy accelerated hyperfractionated radiotherapy
1874260|NCT01126216|Drug|5-FU/Cisplatin|Active Comparator: 5-Fluorouracil(600mg/m^2/d) on days 1-5 and 29-33) and Cisplatin (20mg/m^2/d) on days 1-5 and 29-33
1874261|NCT01126216|Radiation|Standard RT|Active Comparator: 70,6 Gy accelerated hyperfractionated radiotherapy
1874262|NCT01126229|Dietary Supplement|Placebo|2 capsules of placebo daily for 12 weeks
1874263|NCT01126229|Drug|Low dose Resveratrol|2 capsules daily for 12 weeks containing 300 mg/d (combined) of resveratrol active ingredient
1874264|NCT01126229|Drug|High dose Resveratrol|2 capsules daily for 12 weeks containing 1000 mg/d (combined) of resveratrol active ingredient
1874265|NCT01126242|Device|Tape|Group I will be treated with non-elastic adhesive tape (Leukotape® Classic) around the affected ankle, applied by the 'van Unen-technique'.18 This technique is an alternative for the 'Coumans- technique'.15 The rationale of taping is to take the load off the injured tissue, to correct the biomechanics, to protect the injured part and to enhance proprioception and awareness of the injured tissue. Different materials can be used alone or in combination. The bandage material must have an adhesive layer which allows it to adhere to the skin and to itself. Since the direct stabilizing effect of a bandage lasts no longer than about half an hour, the positive effect is presumed to occur primarily through traction on the skin which stimulates muscular activity.
1874266|NCT01126242|Device|Semi rigid brace|Group II will be treated by application of a semi-rigid brace, the M-step® from Medi®. The foam gel in the pads continuously adapts to give an uninterrupted optimal fit to the constantly changing anatomical conditions, which therefore ensures a uniform compression. The ability of the foam gel pad to adapt allows one orthosis to be used for both the left and the right ankle. The pads are very light and have a soft fleecy surface. Even the edges of the outer moldings are generously padded. The M-step ankle orthosis can be quickly and securely applied by means of two Velcro fasteners; the Velcro fasteners can be detached from the outer shells and fixed individually.
1874267|NCT01126242|Device|Lace-up brace|Group III will be treated by application of a lace-up brace, the ASO brace. The ASO (Ankle Stabilizing Orthosis) fits into an athletic or street shoe. The ASO is made of thin, durable ballistic nylon - the same protective material used by law enforcement and military personnel. Support is achieved through exclusive non-stretch nylon stabilizing straps that mirror the stirrup technique of an athletic taping application. The calcaneus is captured, effectively locking the heel. The ASO ankle brace holds the ankle in a biomechanical neutral position, reducing either inversion or eversion type injuries or re-injuries.
1874268|NCT01126255|Drug|Clobetasol propionate 0.05%|Topical application, once daily about 2 g, during 12 weeks
1874269|NCT01126255|Drug|Progesterone 8%|Topical application, once daily about 2 g, during 12 weeks
1874270|NCT01126268|Drug|Retapamulin (Altabax)|Retapamulin ointment, applied topically twice daily for five days
1874271|NCT01126281|Procedure|Laparoscopic Cholecystectomy|Laparoscopic cholecystectomy
1874272|NCT01134198|Drug|Mifepristone|Mifepristone 600mg, 3x/wk for 4 weeks
1874273|NCT01134198|Drug|placebo|placebo
1874274|NCT01134211|Device|nelfilcon A|Commercially marketed, single-vision, soft contact lens for daily disposable wear
1874275|NCT01134211|Device|filcon II 3|Commercially marketed, single-vision, soft contact lens for daily disposable wear
1874276|NCT01134224|Drug|insulin degludec/insulin aspart|0.4 U/kg body weight injected subcutaneously (under the skin) once
1874277|NCT01134224|Drug|insulin degludec/insulin aspart|0.6 U/kg body weight injected subcutaneously (under the skin) once
1874278|NCT01134224|Drug|insulin degludec/insulin aspart|0.8 U/kg body weight injected subcutaneously (under the skin) once
1874279|NCT01134224|Drug|biphasic insulin aspart 30|0.4 U/kg body weight injected subcutaneously (under the skin) once
1874280|NCT01134224|Drug|biphasic insulin aspart 30|0.6 U/kg body weight injected subcutaneously (under the skin) once
1874281|NCT01134224|Drug|biphasic insulin aspart 30|0.8 U/kg body weight injected subcutaneously (under the skin) once
1874282|NCT01134237|Drug|urokinase|intrapleural urokinase injection
1874283|NCT01134237|Drug|placebo|Normal saline as a placebo for control arm
1874284|NCT01134250|Drug|F16IL2 in combination with paclitaxel|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 to 35 MioIU, the dose could be further increased until MTD is reached, following a pharmacokinetic-guided design) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 1 hour i.v. infusion of paclitaxel (Dose escalation: from 60 up to 90 mg/m2) on days 1, 8, 15, 29, 36 and 43.
Patients with objective tumor responses or stable disease will receive additional combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
1874285|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 mL, Subcutaneous (SC)
1874286|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 mL, Subcutaneous (SC)
1874287|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 mL, Subcutaneous (SC)
1874288|NCT01134263|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, & 4 virus|0.5 mL, Subcutaneous (SC)
1874289|NCT01134263|Biological|Placebo: NaCl 0.9%|0.5 mL, Subcutaneous (SC)
1874290|NCT01134276|Procedure|biliary drainage|biliary drainage via PTBD or ERBD/ENBD
1874291|NCT01134289|Procedure|lumbar sympathetic block|unilateral lumbar sympathetic block at L3 level using 0.2% chirocaine under C-arm fluoroscopy
1874292|NCT01134302|Procedure|Norwood management strategy|Norwood palliation will be performed as per current clinical practice at The Hospital for Sick Children.
1874293|NCT01134302|Procedure|Hybrid Strategy|"Hybrid palliation will be performed as per current clinical practice at The Hospital for Sick Children.
The 'Hybrid' management strategy utilizes catheter-based and non-open heart surgical procedures in the neonatal period to stabilize the neonate.10 The majority of the reconstruction is thereby deferred to 4-6 months of age, at which time the second stage procedure including an aortic arch reconstruction is performed. The third stage procedure (Fontan) is identical between Norwood and Hybrid strategies."
1874294|NCT01134315|Drug|Paricalcitol|
1874295|NCT01134315|Drug|Calcitriol|
1874296|NCT01134328|Drug|AC-150 Combo|1 drop in each eye for up to 14 days
1874297|NCT01134328|Drug|AC-150A 0.1%|1 drop in each eye once per day for up to 14 days
1874298|NCT01134328|Drug|AC-150B 0.005%|1 drop in each eye once per day for up to 14 days
1874299|NCT01134328|Drug|Vehicle|1 drop in each eye once per day for up to 14 days
1874300|NCT01134341|Drug|Pralatrexate Injection|"Intravenous (IV) push over 30 seconds to 5 minutes via a patent free-flowing IV line containing normal saline (0.9% sodium chloride).
10 or 15 mg/m2, depending on cohort assignment.
Dose reductions allowed for protocol-specified criteria.
Administered weekly for 3 weeks of 4-week cycle (weekly for 3 weeks with one week of rest) until criteria for discontinuation per the protocol are met."
1874301|NCT01134341|Drug|Bexarotene Capsules|"150 or 300 mg orally, depending on cohort assignment. Provided as 75 mg capsules and taken with a meal.
Dose reductions allowed for protocol-specified criteria and implemented per the Targretin® package insert.
Administered daily until criteria for study treatment discontinuation per the protocol are met."
1874302|NCT01134341|Dietary Supplement|Vitamin B12|"1 mg intramuscular injection
Administered within 10 weeks prior to start of study treatment, every 8-10 weeks throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
1874303|NCT01134341|Dietary Supplement|Folic Acid|"1-1.25 mg orally
Administered daily for at least 7 days prior to start of study treatment, throughout the study and for 30 days after last study treatment (dose of pralatrexate or bexarotene)."
1874304|NCT01134393|Drug|telmisartan/amlodipine|start low dose and uptitrate to high dose on the basis of BP goal
1874305|NCT01134406|Device|Hydros Joint Therapy|Single intra-articular injection.
1874306|NCT01134406|Device|Hydros-TA Joint Therapy|Single intra-articular injection
1874307|NCT01134406|Device|Synvisc-One|Single intra-articular injection.
1874308|NCT01134419|Other|Computerized handoff tool|Informatics tool to aid in transfer of patient care information
1874309|NCT01134419|Other|Team training|Teamwork training and revisions of handoff structure to optimize teamwork skills and verbal communications
1874310|NCT01134432|Drug|prednisolone + mabthera|"Prednisolone: 1,5 mg/kg for two weeks with gradually reduced dosis over two months.
Mabthera: 375 mg/m2 once a week for four weeks"
1874311|NCT01134432|Drug|Prednisolone|Prednisolone: 1,5 mg/kg for two weeks and then gradually reduced dosis over two months
1874312|NCT01134445|Device|DePuy Proxima™ Hip|A short, anatomic, cementless femoral component for use in total hip arthroplasty
1874313|NCT01134458|Behavioral|Web-Based Intervention|"Health Dialog Cardiac Risk Calculator
Health Dialog's Living with Coronary Heart Disease
Tailored intervention including health behavior modules such as smoking cessation, exercise, diet, and weight"
1874314|NCT01134471|Device|Ostene|applied to sternal surface
1874315|NCT01134471|Device|Bonewax|applied to sternal surface
1874316|NCT01134484|Drug|Velcade|"INDUCTION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 4, 8 and 11 (3 courses, 21 days each)
REMISSION CONSOLIDATION THERAPY: 1.3 mg/sqm as a bolus i.v. injection on days 1, 8, 15 and 22 (2 courses, 35 days each)"
1874317|NCT01134484|Drug|Thalidomide|"INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-63 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)
AFTER PBSC COLLECTION: 100 mg/d from day after last PBSC collection until the day before first course of MEL-200
AFTER FIRST TRANSPLANTATION: 100 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200
REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation): 100 mg/d days 1-70"
1874318|NCT01134484|Drug|Dexamethasone|"INDUCTION THERAPY
VTD ARM: 40 mg/d days 1-2, 4-5, 8-9 and 11-12 (3 cycles, 21 days each)
TD ARM: 40 mg/d days 1-4 and 9-12 (3 cycles, 21 days each)
AFTER PBSC COLLECTION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide)
AFTER FIRST TRANSPLANTATION: 40 mg/d for 4 days (starting the same day of resumption of Thalidomide) and repeated every 28 days, for 3 months
REMISSION CONSOLIDATION THERAPY (starting 3 months after the second autologous transplantation)
VTD ARM: 40 mg/d days 1-2, 8-9, 15-16 and 22-23 (2 cycles, 35 days each)
TD ARM: 40 mg/d days 14 and 20-23 (2 cycles, 35 days each)"
1874319|NCT01134484|Procedure|Peripheral Blood Stem Cell (PBSC) collection|"Cyclophosphamide (CTX): 4 g/sqm given in a single day (day 0)
G-CSF: 10 µcg/kg/d, starting on day +2 from CTX and continuing until completion of PBSC collection"
1874320|NCT01134484|Procedure|First Autologous Transplantation|"HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)
G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10^9/L for 3 consecutive days"
1874321|NCT01134484|Procedure|Second Autologous Transplantation|"HIGH-DOSE MELPHALAN (MEL-200): 200 mg/sqm, given as a single dose i.v. (day -2) followed by PBSC infusion 48 hours later (day 0)
G-CSF: 5 µcg/kg daily starting from day +6 after grafting and continuing until the patient's ANC is more than 0.5x10^9/L for 3 consecutive days"
1874322|NCT01134497|Drug|Placebo|The control arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus placebo by mouth on days 1-21 of a 21 day cycle
1876407|NCT01149616|Drug|Dexamethasone 8mg iv x1|Dexamethasone 8mg iv x1
1874323|NCT01134497|Drug|ZD4054|The experimental arm will consist of up to 6 cycles of carboplatin (AUC5 q21d for 6 cycles) iv over 30 minutes on day 1, plus ZD4054 (10mg daily) od by mouth on days 1-21 of a 21 day cycle.
1874324|NCT01134510|Drug|C1 Esterase Inhibitor|C1 Esterase Inhibitor 20 units/kg twice weekly x 4 weeks
1874325|NCT01134510|Drug|Placebos|NS (comparable volume as intervention) twice weekly x 4wks
1874326|NCT01134523|Drug|Epirubicin, CTX, Paclitaxel|Epirubicin 90mg/m2 and CTX 600mg/m2 on day1 of each 21-day cycle, 4 cycles; followed by Paclitaxel 175mg/m2 on day1 of each 21-day cycle, 4 cycles.
1874327|NCT01134523|Drug|Epirubicin, Paclitaxel|Epirubicin 75mg/m2 on day1 and Paclitaxel 175mg/m2 on day2 of each 21-day cycle, 6 cycles.
1874328|NCT01135953|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to to motor cortex every weekday (5 sessions), at 2mA ,during 20 minutes.Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
1874329|NCT01135953|Device|Transcranial Direct Current Stimulation (tDCS)|tDCS applied to the motor cortex every day of the week during 20 minutes, at 1mA first session, 1.5 mA second and third sessions, and 2mA fourth and fifth sessions, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased over 30 seconds (to avoid the sensation of a flash).
1874330|NCT01135953|Other|Transcranial direct Stimulation (tDCS) and D-cycloserine|"Transcranial Direct Stimulation applied to the motor cortex every day of the week (5 sessions) at 2mA, during 20 minutes. Conductive rubber electrodes (7 x 5 cm = 35 cm2) covered by sponges soaked in saline will be used, held in place by a band. The current will be gradually increased to the level of 2 mA over 30 seconds (to avoid the sensation of a flash).
D-cycloserine, administered orally (capsules), 100 mg, twice a week (Monday and Thursday), prior to the tDCS session."
1874331|NCT01135966|Behavioral|Conventional resistance training program|Conventional resistance training program is followed.
1874332|NCT01135966|Behavioral|Whole body vibration resistance training program|WBV training on FITVIBE
1874333|NCT01135992|Drug|insulin degludec|Individually adjusted insulin degludec administered three times weekly with continued unchanged pre-trial OAD (oral anti-diabetic drug) treatment for 12 weeks
1874334|NCT01135992|Drug|insulin glargine|Subjects continue their pre-trial insulin glargine once daily plus OAD (oral anti-diabetic drug) treatment for four weeks before switch to insulin degludec
1874335|NCT01136005|Other|cream|apply at least two times a day on face, chest and upper arms during the 6 week treatment period
1874336|NCT01136018|Procedure|insertion needle via intentionally lateral direction.|evaluation of iodinated contrast flow patterns in caudal epidurography with intentional lateral caudal approach
1874337|NCT01136031|Drug|Paclitaxel and irinotecan|"In phase I part, Level Paclitaxel (mg/m²) Irinotecan (mg/m²)
100 100
100 120
135 120
135 160
every 3 week"
1874338|NCT01136044|Other|septocutaneous perforator flap|Perforator flaps can be based on septocutaneous or musculocutaneous perforators. If septocutaneous perforators are present, the harvest of these flaps is more straight forward and the dissection of the pedicle is easy.
1874339|NCT01136057|Biological|Collection of Anti-Influenza A Immune Plasma|
1874340|NCT01136083|Behavioral|Exercise training|Subjects in exercise group will undergo individualized high aerobic interval training on treadmill for 30 minutes under the supervision of an experienced physical therapist 3 times a week and home exercise twice a week with accelerometer.
1874341|NCT01136083|Other|Usual care|Subjects in control group will not undergo individualized high aerobic interval training on treadmill. They will receive usual care as normally does in hospital.
1874342|NCT01136096|Behavioral|Physical activity promoting intervention|"An interview with a physiotherapist
An exercise video specially designed by this study including warm-up, aerobic, cool-down and stretching exercises, and/or a simple exerciser to use at home
An individualized home-based exercise program based on the Health Belief Model and Transtheoretical Model
The daily record to check their body weight, exercise mode and duration
Proper diet, caloric intake calculation, metabolic risk factors and prevention of diabetes were taught and a guide book was provided that included all the above mentioned details
Telephone reminders of healthy lifestyle including the ways of overcoming barriers of regular exercise every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule"
1874343|NCT01136096|Behavioral|General instruction and education|"Oral instruction and written general education information about weight control, proper diet and regular exercise in a one-page education brochure that was similar to the way used in the outpatient clinic
Telephone reminders of healthy lifestyle every 1 to 2 weeks for 3 months, 1-2 calls a month afterwards and no calls for the last month on a tapered off schedule
Without individualized exercise program and interview with a physiotherapist"
1874344|NCT01136122|Device|CPAP Treatment|Effective CPAP treatment for one month
1874345|NCT01136135|Other|CARDIAC MRI|To find a non-invasive alternative (with using cardiac MRI) to invasive endomyocardial biopsies for serial detection and follow-up of cellular rejection in heart transplant in childhood.
1874346|NCT01136148|Behavioral|A medical and mental health unit|A specialist medical and mental health unit with both physician and psychiatric medical and nursing staff, and mental health experienced therapists. Emphasis will be on early and accurate diagnosis, multidisciplinary management, rigorous communication and goal setting, discharge planning and interface with community services.
1874347|NCT01136161|Biological|RUTI|dose:5 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
1874348|NCT01136161|Biological|RUTI|dose:25 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
1874349|NCT01136161|Biological|RUTI|dose:50 micrograms of FCMtb (Fragmented cells of M. tuberculosis); given subcutaneously twice, on days 28 and 56.
1874350|NCT01136161|Biological|RUTI Matching Placebo|Placebo of the vaccine RUTI; given subcutaneously twice, on days 28 and 56.
1874351|NCT01136174|Drug|Placebo|Placebo BID for cohort 1,2,3
1874352|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
1874353|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
1874354|NCT01136174|Drug|BIBF 1120|50 mg, 100 mg, 150 mg BID will be used for Cohort 1, 2, and 3 respectively
1874356|NCT01136200|Other|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
1874357|NCT01136213|Radiation|PET (Positron Emission Tomography) Study|5-HT1a auto-receptors will be visualized in vivo using 18F-MPPF PET study. Two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
1874358|NCT01136213|Other|Brain MRI (magnetic resonance imaging)|A brain MRI (magnetic resonance imaging)will be performed the day of the first PET study.
1874359|NCT01136213|Drug|Fluoxétine / Placebo|The two PET studies will be performed, one after the intake of a single oral dose of fluoxetine and the other after placebo. The order of fluoxetine and placebo intake will be randomly assigned.
1874360|NCT01136226|Drug|Eligard (TM)|22.5 mg administered at baseline and Month 3
1874361|NCT01136239|Drug|N-acetycysteine (600mg twice daily)|N-acetycysteine (600mg twice daily) for one year
1874362|NCT01136239|Drug|Placebo|Placebo (600mg twice daily)
1874363|NCT01136252|Drug|Adalimumab|Intravitreal adalimumab injection (0,1 ml= 50 mcg) in the eye of the included patients. Patients will be followed up every week for a total of 4 weeks, and after every month until 6 months. If it is necessary, repeat the injection every month, maximum three months
1874364|NCT01136278|Drug|3,4-Methylenedioxymethamphetamine|125 mg, single dose
1874365|NCT01136278|Drug|Clonidine|150 μg per os
1874366|NCT01136278|Drug|placebo|capsules identical to MDMA or clonidine
1874367|NCT01136291|Other|physical exercise|"The exercise protocol was done under supervision once a week. Pregnant women have been told to do some exercise three more times during the week unsupervised and may be the protocol of exercises or walk in mild to moderate intensity.
The exercise protocol lasted 50 minutes with 10 minutes of stretching overall, 30 minutes of exercise for muscle strengthening and 10 minutes of relaxation.
These women also received nutrition counseling and prenatal care."
1874368|NCT01136304|Drug|Imiglucerase|Imiglucerase intravenous infusions regardless of dose or schedule of administration.
1874369|NCT01136317|Drug|Omeprazole|
1874370|NCT01136317|Drug|Rabeprazole|
1874371|NCT01136317|Drug|Lactose|
1874372|NCT01136343|Other|lifestyle modified project|education, counseling
1874373|NCT01136356|Drug|buprenorphine|parenteral buprenorphine may be administered at multiple times each day
1874374|NCT01136356|Drug|morphine|parenteral morphine may be administered multiple times each day
1874375|NCT01136369|Device|OSNA Breast Cancer System|"For in vitro diagnostic use only.
The OSNA Breast Cancer System is an automated semi-quantitative, in vitro diagnostic test for the rapid detection of greater than (>) 0.2 mm metastases in nodal tissue removed from sentinel lymph node biopsies of breast cancer patients. Results from the assay can be used to guide the intra-operative or post-operative decision to remove additional lymph nodes and to aid in patient staging. An assay positive + or ++ result indicates the presence of metastasis (> 0.2 mm). An assay positive ++ result predicts the presence of macrometastasis (> 2 mm).
Post-operative histological evaluation of permanent sections of the tissue specimen, in accordance with usual diagnostic practice and using the Sysmex lymph node cutting scheme, is required."
1874376|NCT01136382|Drug|budesonide|pMDI, inhalation, bid, 6 weeks
1874377|NCT01136382|Drug|placebo|pMDI, inhalation, bid, 6 weeks
1874378|NCT01136395|Drug|Rituximab|375mg/m2 4 weeks before ABO incompatible LD transplantation
1874379|NCT01136395|Procedure|living donor transplantation|living donor transplantation (ABO compatible) to be compared with deceased donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
1874380|NCT01136395|Procedure|deceased donor transplantation|deceased donor transplantation (ABO compatible) to be compared with living donor transplantation (ABO compatible) in its impact on immunological parameters of graft outcome and on viral replication (CMV, EBV, BK/JC), respectively
1874381|NCT01136408|Drug|Dabigatran etexilate|Dabigatran etexilate 110 mg capsule, twice a day, oral administration
1874382|NCT01136408|Drug|Dabigatran etexilate|Dabigatran etexilate 150 mg capsule, twice a day, oral administration
1874383|NCT01136408|Drug|Warfarin|Dose-adjusted warfarin based on target INR values
1874384|NCT01136421|Drug|Ipratropium bromide|Patients received ipratropium bromide (IB group, 0.5 mg in 3 mL of normal saline) delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, patients received intravenous placebo (10 mL of normal saline). Thereafter 4 doses of nebulised IB with terbutaline are administered at 30 min intervals.
1874385|NCT01136421|Drug|Magnesium Sulfate|Patients received magnesium sulfate (MgSO4 group, 150 mg in 4 mL of normal saline)delivered via aerosol mask at 10 L/min driven by pressurised air. Simultaneously, additional magnesium sulfate is given as an intravenous bolus (1.5g in 10 ml). Patients received thereafter 4 doses of nebulized magnesium sulfate with terbutaline at 30 min intervals.
1874386|NCT01136447|Procedure|Ultrasound|Block catheter will be introduced using ultraosound
1874387|NCT01136499|Drug|LBH589 (Panobinostat®)|"40 mg MWF.
40 mg of LBH589, orally administered on Monday, Wednesday and Friday (MWF) on a weekly schedule, until tumor progression or unacceptable toxicity."
1874388|NCT01136525|Drug|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
1874389|NCT01136538|Drug|Valacyclovir Hydrochloride|Valacyclovir Hydrochloride Tablets, 1000 mg of Dr. Reddy's Laboratories Limited
1874390|NCT01136551|Drug|Huperzine A|Each volunteer will receive single dose of three different formulations of Huperzine A. One immediate release formulation of 0.4mg and two different controlled release formulations at same dose. Between the study phases will be a washout period of at least 21 days.
1874391|NCT01136564|Drug|Zemplar|2 capsules of 1 microgram daily
1874392|NCT01136564|Drug|Placebo|2 capsules daily
1874393|NCT01136577|Device|Phototherapy|Phototherapy devices of ramp type placed over the incubator to treat with light in the 420-490nm range one face of the naked baby suffering jaundice.
1874394|NCT01136590|Drug|Tranexamic Acid|A 10-mg/kg dose of tranexamic acid will be administered as a bolus or as a fast, 20-minute intravenous infusion before performing the incision at the start of surgery, followed by perfusion of 2 mg/kg/hour up to the time the surgical wound is closed at completion of surgery.
1874495|NCT01137539|Device|Gynecare TVT-SECUR system|All patients in the study will receive the Gynecare TVT-SECUR to treat stress urinary incontinence
1874395|NCT01136590|Drug|fisiologic serum|The placebo will be administered according to the same regimen and infusion time as the medication in the study arm (bolus or 20-minute fast infusion before the incision at the beginning of surgery followed by perfusion of 2 mg/kg/hour until closure of the surgical wound at completion of surgery)
1874396|NCT01136603|Device|TIGR Mesh|TIGR mesh as a reconstruction material for the repair of the abdominal wall post Lipectomy, TRAM / DIEP flap.
1874397|NCT01136642|Drug|Nicotrol|
1874398|NCT01136655|Drug|80/2.25 μg Symbicort pMDI|inhalation
1874399|NCT01136655|Drug|80/4.5 μg Symbicort pMDI|inhalation
1874400|NCT01136655|Drug|Foradil Aerolizer 12 μg|inhalation
1874401|NCT01136655|Drug|40 μg budesonide HFA pMDI|inhalation
1874402|NCT01136655|Drug|placebo HFA pMDI|inhalation
1874403|NCT01136668|Procedure|Transversus Abdominis Plane Block|A high frequency (5-10 mHz) ultrasound probe (Sonosite Micromaxx, Licence No 12407) will be placed on the flank at the midpoint between the iliac crest and lower costal margin. The three muscle layers of external oblique, internal oblique, and transversus abdominis will be visualized. A 22G short-bevel block needle will be advanced in an anterior-to-posterior direction, in-plane with the probe, until the tip is visualized in the transversus abdominis plane. After negative aspiration, 0.4 ml/kg of bupivacaine 0.25% with 1:200,000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
1874404|NCT01136668|Procedure|Standard|Circumferential subcutaneous infiltration of the ostomy wound with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg by the surgeon after skin closure.
1874407|NCT01136746|Drug|Human regular insulin|Administered subcutaneously, four times daily, according to sliding scale insulin algorithm throughout hospital study period (1 to 10 days post-randomization)
1874408|NCT01136746|Drug|Insulin lispro|Administered subcutaneously, 3 to 4 times daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
1874409|NCT01136746|Drug|Insulin glargine|Administered subcutaneously, once daily, according to plasma glucose levels throughout hospital study period (1 to 10 days post-randomization)
1874410|NCT01136759|Drug|Tenofovir 1% gel|One applicator of tenofovir 1% gel administered vaginally for 7 consecutive days
1874411|NCT01136759|Other|Placebo gel|One applicator of placebo gel administered vaginally for 7 consecutive days
1874412|NCT01136772|Drug|haloperidol decanoate|haloperidol decanoate injections, 25-200 mg once a month
1874413|NCT01136772|Drug|paliperidone palmitate|Paliperidone palmitate injections, 39 mg - 234 mg once a month
1874414|NCT01136785|Device|active CPAP Therapy|7 days of active CPAP therapy
1874415|NCT01136785|Device|sham CPAP therapy|7 days of sham CPAP therapy
1874416|NCT01136798|Drug|Exenatide|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
1874417|NCT01136798|Drug|Placebo|Exenatide or placebo medication administered subcutaneously 5 mcg twice daily for 2 weeks, followed by 10 mcg twice daily for 4 weeks
1874418|NCT01136811|Device|Computer assisted surgery|"use of computer assisted surgical device in vascular surgery
completion of the proximal (femoral) anastomosis portion of a lower extremity bypass procedure"
1874419|NCT01136824|Other|Questionnaires|"Subjects will be given a series of questionnaires to assess the effect of AI chemotherapy, and the possible role of tumor load, on the amount of symptoms. The extent of nausea, vomiting, fatigue, anxiety, sleep disturbance, and cognitive changes will be measured. In adjuvant chemotherapy patients, we will also assess the relationship between tumor size and amount of chemotherapy-induced symptoms. These questionnaires will involve the following assessments:
Demographic & health Trait anxiety Quality of life Nausea Expectations Anxiety & total mood disturbance Nausea & vomiting Multiple symptoms"
1874420|NCT01136837|Other|primary pcı|
1874421|NCT01136850|Drug|chloroquine, sulphadoxine pyrimethamine, LLIN|"> 50Kg: chloroquine base 150 mg 4 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.
< 50 Kg: chloroquine base 150 mg 3 tablets daily for 3 days, plus sulphadoxine pyrimethamine 1500/75 mg single dose.
Given at enrolment, 14-26 weeks gestation, by mouth."
1874422|NCT01136850|Drug|azithromycin, sulphadoxine pyrimethamine, LLIN|"sulphadoxine pyrimethamine (1500 mg/75 mg as single dose) plus azithromycin (1 g twice daily for 2 days).
Given three times by mouth at monthly intervals, commencing at between 14 and 26 weeks gestation."
1874423|NCT01136863|Drug|Felodipine|
1874424|NCT01136863|Drug|Placebo|
1874425|NCT01136876|Drug|Iopamidol|Iopamidol 370, one time administration for percutaneous coronary intervention
1874426|NCT01136876|Drug|Iodixanol-320|Iodixanol-320 single administration for percutaneous coronary intervention procedure
1874427|NCT01136889|Other|PFMT|Women who have been successfully fitted with a vaginal pessary will be asked to attend five outpatient appointments over a 16 week period with a trained specialist women's health physiotherapist.
1874428|NCT01136902|Dietary Supplement|Oral Glucose Tolerance Test (OGTT)|75 g of glucose dissolved in 250 mL water.
1874429|NCT01136915|Drug|Iopamidol 370|one time administration for PCI
1874430|NCT01136915|Drug|Iodixanol 320|Iodixanol 320 single injection for percutaneous coronary injection
1874431|NCT01136928|Drug|American ginseng|Healthy volunteers will ge given efavirnez 600 mg daily monotherapy for 14 days followed by efavirenz 600 mg PLUS American ginseng 3000 mg daily for an additional 14 days.
1874432|NCT01136941|Drug|Zileuton|Zileuton is available as a 600 mg tablet. Dosing begins at 2.4gm/day and will be increased to 3.0gm/day. Tablets will be taken twice daily for the 6 week duration of the study.
1874433|NCT01136954|Drug|Zonisamide|Transition Period from Study E2090-E044-312: Placebo Open-Label Period: 1 to 8 mg/kg orally per day for approximately 59 weeks.
1874434|NCT01136967|Drug|Lenvatinib|Participants received lenvatinib 24 mg orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
1874488|NCT01137487|Procedure|monitoring of residual gastric volume|measurements of residual gastric volume every six hours in patients receiving early enteral feeding and mechanical ventilation
1874489|NCT01137487|Procedure|not monitoring of residual gastric volume|no measurements of residual gastric volume
1874435|NCT01136980|Device|Transoral Incisionless Fundoplication (TIF)|A novel surgical technique that creates a gastric fundoplication and restores competency of the gastroesophageal valve now exists for patients who have limited anatomic defects (small hiatal hernia). This technique is performed transorally using the EsophyX device (EndoGastric Solutions, Inc. Redmond, WA, USA) recreates a gastric fundoplication at the gastroesophageal junction by creating a flap valve at the intersection of the stomach and the esophagus by deploying polypropylene SerosaFuse fasteners (EndoGastric Solutions)
1874436|NCT01136980|Other|Sham Procedure|The Sham Procedure (control) will consist of an upper GI endoscopy that will be conducted under general anesthesia in an operating room. The surgical team will follow the same steps before, during, and after the sham procedure similar to the TIF procedure, except they will never insert the EsophyX device into the patient. The endoscope will be manipulated for 30-45 min as if the device were around it to simulate the effect of many rotations and manipulations on the esophagus.
1874437|NCT01137006|Biological|IMC-20D7S (Cohort 1A)|"5 mg/kg i.v. every 2 weeks
Administered every other week on days 1 and 15 of each treatment cycle.
If 0 dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants, then enrollment into cohort 2A."
1874438|NCT01137006|Biological|IMC-20D7S (Cohort 2A )|"10 mg/kg i.v. every 2 weeks
Administered every other week on days 1 and 15 of each treatment cycle.
If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2A then enrollment into Cohort 3A."
1874439|NCT01137006|Biological|IMC-20D7S (Cohort 3A )|"20 mg/kg i.v. every 2 weeks
Administered every other week on days 1 and 15 of each treatment cycle.
If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 3A then enrollment into Cohort 4A."
1874440|NCT01137006|Biological|IMC-20D7S (Cohort 4A )|"30 mg/kg i.v. every 2 weeks
Administered every other week on days 1 and 15 of each treatment cycle."
1874441|NCT01137006|Biological|IMC-20D7S (Cohort 1B)|"10 mg/kg i.v. every 3 weeks
Administered every 3 weeks on days 1 and 22 of each treatment cycle.
If 0 dose-limiting toxicity (DLT) in first 3 participants or 1 DLT in 6 participants in Cohort 1B, then enrollment into cohort 2B."
1874442|NCT01137006|Biological|IMC-20D7S (Cohort 2B )|"20 mg/kg i.v. every 3 weeks
Administered every 3 weeks on days 1 and 22 of each treatment cycle.
If no DLT in first 3 participants or 1 DLT in 6 participants in Cohort 2B then enrollment into Cohort 3B."
1874443|NCT01137006|Biological|Biological/Vaccine: IMC-20D7S (Cohort 3B )|"30 mg/kg i.v. every 3 weeks
Administered every 3 weeks on days 1 and 22 of each treatment cycle."
1874444|NCT01137019|Device|Biolimus-eluting stent|The biolimus-eluting coronary stent contains a stainless steel platform on which an abluminally coated polylactic acid (PLA) biodegradable polymer is placed that eludes biolimus-A9.
1874445|NCT01137019|Device|Everolimus-eluting coronary stent|The everolimus-eluting coronary stent is a cobalt chromium platform stent with a permanent fluorinated copolymer matrix that eludes everolimus
1874446|NCT01137032|Drug|Pandel Cream 0.1%|A thin coat of cream will be applied and rubbed into the affected areas, as well as normal skin, twice daily for 21 days
1874447|NCT01137045|Biological|SPEEDA and TRCS SPEEDA|"For modified TRC-ID regimen,0.1 ml of SPEEDA, TRCS SPEEDA or VERORAB will be given at each of two sites,intradermally on upper arms on days 0,3,7 and 28.
For ESSEN regimen, 1 vial of SPEEDA will be given intramuscularly at upper arm on days 0,3,7,14 and 28.
For ERIG,it would be given in a single dose 40 IU/Kg at the same time as the first dose of vaccine. ERIG will be infiltrated around and into all wounds as recommended by WHO for patients in group IV and injected intramuscular at each of both gluteal areas for participants in group III,V,VI"
1874448|NCT01137058|Device|U-healthcare service|Public switched telephone network (PSTN)-connected glucometer with U-healthcare system.
1874449|NCT01137058|Device|SMBG group|Glucose control with self monitoring of blood glucose.
1874450|NCT01137071|Biological|Monoclonal antibody Hu3S193|"30 mg/m2 of Monoclonal antibody Hu3S193, IV as a single agent every two weeks, in a total of 12 doses (treatment period duration: 23 weeks). Anti-Lewis Y humanized monoclonal antibody designated orphan drug by the FDA on March 09, 2012 for the treatment of ovarian cancer, not yet approved for the orphan designation."
1874451|NCT01137084|Drug|solu medrol|total dose 20mg/kg, including first dose 10mg/kg, rest of drug given within one weeks after liver transplantation
1874452|NCT01137084|Drug|a steroid-free immunosuppression protocol|receive immunosuppression with Basiliximab(20mg/day,twice following transplantation) and tacrolimus(0.06/kg/d,twice a day) without steroids.
1874453|NCT01137097|Procedure|Lateral sentinel lymph node biopsy|Sentinel lymph node biopsy with radioisotope. Isotope injection and lymphoscintigraphy preoperatively
1874454|NCT01137110|Drug|Levetiracetam short course|Levetiracetam 1000mg BID x 3 days
1874455|NCT01137110|Drug|Levetiracetam Long course|Levetiracetam 1000mg BID x hospital stay
1874456|NCT01137123|Drug|adjuvant chemotherapy|Docetaxel 75mg/m2 +Nedaplatin 75mg/m2,IV drip on day 1 of each 21 day cycle. Number of cycles: till unacceptable toxicity develops and no more than 4 cycles.
1874457|NCT01137123|Procedure|standard two field Lymphadenectomy|Standard two field lymphadenectomy is standard mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
1874458|NCT01137123|Procedure|Total two field Lymphadenectomy|Total two field Lymphadenectomy is total mediastinal lymphadenectomy which defined by the International Association of esophageal disease(ISDE) of thoracic esophageal cancer.
1874459|NCT01137123|Procedure|three field Lymphadenectomy|Three field Lymphadenectomy includes abdominal,mediastinal and cervical lymphadenectomy.
1874490|NCT01137513|Device|Observational Measurement of T-wave Alternans|Measurement is similar to typical EKG
1874491|NCT01137513|Device|T-wave Alternans|T-Wave Alternans will be measured in an observational fashion
1874492|NCT01137526|Drug|ABT-384|Subjects will take study drug once daily for 12 weeks
1874493|NCT01137526|Drug|donepezil|Subjects will take study drug once daily for 12 weeks.
1874462|NCT01137188|Dietary Supplement|Low calorie diet|Low calorie diet containing 800-1000 kcal/day
1874463|NCT01137201|Procedure|Suturing of mesenteric defects|
1874464|NCT01137214|Device|Non-invasive positive pressure ventilator|All patients will initially be treated with CPAP for 12 weeks as part of usual clinical treatment for sleep apnea. A sleep study will be conducted after this and prior to randomization into the study. If this repeat sleep study demonstrates persistent central sleep apnea, patients will be randomized into 2 study groups. Group 1 - CPAP for 24 weeks. Group 2 - first 12 weeks CPAP (Continuous Positive Airway Pressure. Next 12 weeks - (ASV) Adaptive Servo ventilation. If the treatment is not working well at 12 weeks the participant/patients have the option of switching to the alternate treatment. Patients will be notified if they are to be switched to ASV. Participants will be asked to fill in the Epworth Sleepiness Score Questionnaire and Sleep Apnea Quality of Life Index form at 12 and 24 weeks.
1874465|NCT01137240|Procedure|gastric emptying scan|"subjects will eat a solid meal (scrambled eggs, etc) or drink liquid (water or juice) mixed with approximately 0.5 millicuries of radioactive material. A scanner/external gamma camera will be placed over the subject's stomach at 15 minute intervals for a duration of 90 minutes (monitoring the amount of radioactivity in the stomach). As the radioactively-labeled food empties from the stomach, the amount of radioactivity in the stomach decreases. The rate at which the radioactivity leaves the stomach reflects the rate at which food is emptying from the stomach. The radioisotope has a half life of approximately. 6 hours and is totally eliminated from the body within 24 hours.
In subjects with gastroparesis, the food and the attached radioactive material remain in the stomach longer than normal (usually hours) before emptying into the small intestine. As a result, the scanner continues to show radioactivity in the area of the stomach for hours after the test meal."
1874466|NCT01137253|Drug|Trimethaphan|Trimethaphan 4 mg/min IV, for the duration of the study (approximately 2 hours)
1874467|NCT01137253|Drug|Placebo|Response to intrabrachial vasodilators during IV saline infusion
1874468|NCT01137266|Device|TENS|TENS
1874469|NCT01137292|Drug|voriconazole (VFEND®)|The use and dosage recommendations for voriconazole (VFEND®) will take place on the basis of the Summary of Product Characteristics (SmPC) and will be adjusted solely according to medical and therapeutic necessity. The formulation and dose will be managed by the treating physician according to the SmPC, disease and clinical situation. According to the SmPC, in the adults the treatment should be started with the loading dose of 6 mg/kg of voriconazole iv. every 12 hours (during the first 24 hrs) followed by the maintenance dose of 4 mg/kg BID. For peroral formulations, the initial dose should be depending on the weight of the patient 400 mg or 200 mg BID during the first 24 hrs, followed by the maintenance dose of 200 mg or 100 mg of voriconazole BID respectively For paediatric population (<12 years of age), there is no initial dose necessary. Depending on the formulation, the daily dosage should be in children 7 mg/kg iv. BID or 200 mg of voriconazole orally BID.
1874471|NCT01137318|Behavioral|Cognitive remediation and Parent Training|Cognitive Intervention is CogMed Working Memory Training program, which is a 5-week, 5days/week computerized training program completed at home. The Parent Training is a 2.0 hour, weekly, group sessions that focus on behavioral management procedures.
1874472|NCT01137331|Drug|K301|Liquid- applied once daily prior to bed
1874473|NCT01137331|Drug|Placebo|Liquid- applied once daily prior to bed
1874474|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
1874475|NCT01137357|Dietary Supplement|Yoghurt with L.casei|Intake of yoghurt during 4 weeks
1874476|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
1874477|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Yoghurt with L. plantarum strain
1874478|NCT01137357|Dietary Supplement|Yoghurt with L. plantarum strain|Intake of yoghurt during 4 weeks
1874479|NCT01137357|Dietary Supplement|Yoghurt|Intake of yoghurt during 4 weeks
1874480|NCT01137383|Drug|Pegaferon (pegylated interferon alpha 2a) + ribavirin|pegylated interferon 180 micrograms subcutaneously weekly - ribavirin (oral, in two divided daily doses) 800 mg for genotype 2 and 3, 1000 or 1200mg (weight less than or greater than 75kg) for genotypes 1 and 4 - Duration: 24 weeks for genotype 2 and 3, 48 weeks for genotypes 1 and 4
1874481|NCT01137396|Drug|Modafinil|Modafinil 400mg PO QDaily following up-titration for ~8weeks
1874482|NCT01137396|Behavioral|Cognitive Behavioral Therapy|Once weekly cognitive behavioral therapy for cocaine dependence
1874483|NCT01137435|Biological|ADACEL™:Adsorbed Diphtheria, Tetanus Toxoids and Component Pertussis Combined|0.5 mL, intramuscular (IM)
1874484|NCT01137448|Behavioral|Weight Loss|Subjects will enroll in a weight loss program and participate in weight loss counseling 6 times over the course of 6 months.
1874485|NCT01137461|Procedure|ultrasound-guided embryo transfer|Embryo transfer in oocyte recipients
1874486|NCT01137474|Drug|Dapagliflozin|Oral tablets administered as 2.5, 5, or 10 mg, once daily for up to 12 weeks
1874487|NCT01137474|Drug|Placebo-matching dapagliflozin|Oral tablets administered as 0 mg once daily for up to 12 weeks
1874494|NCT01137526|Drug|placebo|Subjects will take study drug once daily for 12 weeks
1874496|NCT01137552|Drug|AMG 780|AMG 780 will be administered by IV infusion every 2 weeks
1874497|NCT01137565|Drug|AMG 853|Single dose administration of AMG 853 or placebo in tablet form to adolescent and adult subjects with asthma
1874498|NCT01137565|Drug|Placebo|Placebo to AMG 853
1874499|NCT01137578|Procedure|Ultrasound|Ultrasounds to be performed on children with central venous catheters
1874500|NCT01137578|Drug|Magnetic Resonance Imaging with Contrast|Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
1874501|NCT01137578|Procedure|Magnetic Resonance Imaging without Contrast|Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
1874502|NCT01137591|Drug|APAP and NAC combination|APAP 650mg and NAC 600mg combination oral tablet administered once
1874503|NCT01137591|Drug|APAP and Placebo|APAP 650mg and Placebo combination oral tablet administered once
1874504|NCT01137604|Drug|Lenvatinib|24 mg lenvatinib capsules orally, once daily continuously in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
1874505|NCT01137604|Drug|Bevacizumab|Bevacizumab 10 mg/kg administered intravenously every 2 weeks in 28-day cycles until disease progression, development of unacceptable toxicity or withdrawal of consent.
1874506|NCT01137630|Drug|K40a|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
1874507|NCT01137630|Drug|K40b|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
1874508|NCT01137630|Drug|Placebo|One tablespoon is to be applied to affected areas of the scalp once daily for 4 weeks. Thereafter, a maintenance phase of 4 weeks is to follow with application 3 times per week.
1874509|NCT01137643|Other|biologic sample preservation procedure|All samples collected during routine clinical care.
1874510|NCT01137643|Other|cytology specimen collection procedure|All Samples collected during routine clinical care.
1874511|NCT01137656|Drug|Acetylcholine and Blood|The Acetylcholine solution will be infused intra-arterially at the dosage of 7.5 ug/min for 3 minutes, then 15ug/min for 3 minutes, then 30 ug/min for 3 minutes, after the infusion of normal saline. It will then be infused at 7.5ug/min for 3 minutes, followed by 15ug/min for 3 minutes, followed by 30 ug/min for 3 minutes after the infusion of autologous blood. This will be performed at 5-10 days and 35-42 days of blood storage time.
1874512|NCT01137669|Biological|Live attenuated herpes zoster vaccine|ZOSTAVAX® (Zoster Vaccine Live) is a live attenuated vaccine provided as a single-dose, sterile, lyophilized, preservative-free frozen formulation. The vaccine will be supplied in 3-mL glass vials. Sterile diluent will be used to reconstitute study vaccine. The reconstituted vial will be gently agitated to mix thoroughly. The entire contents of the reconstituted vaccine vial (approximately 0.65 mL) will be withdrawn into a syringe. The vaccine will be administered immediately subcutaneously in the deltoid region.
1874513|NCT01137669|Other|Placebo|Placebo for Zoster Vaccine Live (ZOSTAVAX®) is sterile normal saline which will be obtained from the Fisher Repository in single-dose containers. 0.9% Sodium Chloride Injection, USP is a sterile, nonpyrogenic, isotonic solution of sodium chloride and water for injection. The placebo will be administered subcutaneously in the deltoid region.
1874514|NCT01137682|Drug|Pasireotide (SOM230)|"Double-blind pasireotide LAR 40 mg i.m. injection once every 28 ± 2 days for 24 weeks or
Double-blind pasireotide LAR 60 mg i.m. injection once every 28 ± 2 days for 24 weeks"
1874515|NCT01137682|Drug|octreotide LAR 30mg|In an open-label, active control arm, continue on the same treatment with octreotide LAR 30 mg every 28 ± 2 days as received for at least 6 months prior to randomization
1874516|NCT01137682|Drug|lanreotide ATG 120mg|In an open-label, active control arm, continue on the same treatment with lanreotide ATG 120 mg every 28 ± 2 days as received for at least 6 months prior to randomization
1874517|NCT01137695|Drug|Pramlintide|120 mcg SQ three times daily for 6 months.
1874518|NCT01137695|Drug|Pramlintide|360 mcg SQ three times daily for 6 months
1874519|NCT01137695|Drug|Pramlintide|120 mcg SQ three times daily for 6 months
1874520|NCT01137695|Drug|Pramlintide|360 mcg SQ three times daily for 6 months
1874521|NCT01137708|Drug|ethinyloestradiol (EE) and levonorgestrel (LN), CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID
1874522|NCT01137708|Drug|CP-690,550 + ethinyloestradiol (EE) and levonorgestrel (LN), ethinyloestradiol (EE) and levonorgestrel (LN)|Period 1: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel plus 30 mg CP-690,550 after 9 days of CP-690,550 at 30 mg BID Period 2: 30 mcg ethinyloestradiol and 150 mcg levonorgestrel alone
1874523|NCT01137734|Device|Adjustable Annuloplasty Ring with option to adjust off pump.|Annuloplasty device repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty rean, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.
1874524|NCT01137734|Device|Device: Adjustable Annuloplasty Ring (with option to adjust off-pump)|Evaluate the performance and safety of the investigational adjustable annuloplasty ring device for the treatment of mitral regurgitation, with option to adjust on and off-pump.
1874525|NCT01137747|Drug|Carfilzomib|
1874526|NCT01137760|Dietary Supplement|Sucrose|5 g of sucrose daily for 8 weeks
1874527|NCT01137760|Dietary Supplement|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose daily for 8 weeks
1874528|NCT01137760|Dietary Supplement|Galactooligosaccharide|5.0 g galactooligosaccharide daily for 8 weeks
1874529|NCT01137773|Drug|Insulin|All patients in the trial will have blood taken hourly for glucose analysis, regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
1874530|NCT01137773|Drug|Conventional insulin treatment|All patients in the trial will have blood taken hourly for glucose analysis , regardless of their designated group. Adjustments of the insulin dose will be based on measurements of capillary blood glucose level.
1874581|NCT01138098|Biological|Engerix™-B|Intramuscular, single dose
1874531|NCT01137786|Drug|Non ionic contrast media comparator|One time administration for PCI
1874532|NCT01137786|Drug|Non ionic contrast media comparator|one time administration for PCI
1874533|NCT01137799|Drug|JNJ-39393406|50mg nanosuspension (sort of liquid formulation) once daily (single dose)
1874534|NCT01137799|Drug|placebo|Once daily (single dose)
1874535|NCT01137799|Drug|JNJ-39393406|200mg nanosuspension (sort of liquid formulation) once daily (single dose)
1874536|NCT01137799|Drug|JNJ-39393406|100mg nanosuspension (sort of liquid formulation) once daily (single dose)
1874537|NCT01137799|Drug|JNJ-39393406|10mg nanosuspension (sort of liquid formulation) once daily (single dose)
1874538|NCT01137799|Drug|JNJ-39393406|30mg nanosuspension (sort of liquid formulation) once daily (single dose)
1874539|NCT01137812|Drug|Sitagliptin 100 mg|One 100 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
1874540|NCT01137812|Drug|Canagliflozin 300 mg|One 300 mg capsule once daily for 52 weeks with protocol-specified doses of metformin and sulphonylurea
1874541|NCT01137812|Drug|Metformin|Patients will continue to take background therapy with Metformin for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
1874542|NCT01137812|Drug|Sulphonylurea|Patients will continue to take background therapy with Sulphonylurea for T2DM at maximally or near-maximally effective protocol-specified doses for the duration of the study.
1874543|NCT01137864|Other|Infectious disease specialist advice|Indication, choice, dosing and duration of antimicrobial therapy
1874544|NCT01137877|Other|Milk based infant formula powder|milk based infant formula ad lib
1874545|NCT01137877|Other|Investigational Infant Formula #1|Milk based infant formula ad lib
1874546|NCT01137877|Other|Investigational Infant Formula #2|Milk based infant formula powder ad lib
1874547|NCT01137877|Other|Human Milk|Human milk ad lib
1874548|NCT01137890|Drug|Zonisamide|Eight capsules administered daily in split doses at 22:00 and 09:00.
1874549|NCT01137890|Drug|Placebo|capsules administered in split doses at 22:00 and 09:00.
1874550|NCT01137890|Drug|Cocaine Hydrochloride|Cocaine Challenge Sessions: Human laboratory sessions with administration of moderate doses of cocaine by the intravenous route under controlled conditions and cardiovascular monitoring.
1874551|NCT01137890|Behavioral|Neurocognitive and Performance Battery|Participants will complete tests to assess their abilities and performances on a number of tasks given by a computer or other type of equipment.
1874552|NCT01137890|Behavioral|Smoking Assessments|Participants answer questions about smoking and smoking behaviors are monitored.
1874553|NCT01137903|Procedure|Conservative surgery|Osteotomy, phalangectomy, exostectomy, metatarsal head resection, articular resection, partial calcanectomy
1874554|NCT01137903|Drug|Ciprofloxacin|500 mg/ 12 hours during 90 days
1874555|NCT01137903|Drug|Amoxicillin-Potassium Clavulanate Combination|875/125 mg/12 hours during 90 days
1874556|NCT01137903|Drug|Sulfamethoxazole trimethoprim|Trimethoprim 160 mg / Sulfamethoxazole 800 mg 1/12 horas.
1874557|NCT01137916|Drug|Imatinib|800 mg
1874558|NCT01137942|Drug|clarithromycin, metronidazole, proton pump inhibitor|appropriate dose of antibiotics and proton pump inhibitor
1874561|NCT01137968|Drug|imetelstat|9.4 mg/kg over a 2 hour IV infusion on Day 1 and Day 8 of each 21 day cycle until disease progression.
1874562|NCT01137968|Drug|Bevacizumab|Dosage and duration will be according to the FDA-approved bevacizumab package insert. Bevacizumab will be administered on Day 1 of each 21-day cycle.
1874564|NCT01137994|Drug|Lapatinib|oral, reversible small molecule tyrosine kinase inhibitor of HER2 receptor
1874565|NCT01137994|Biological|Trastuzumab|monoclonal antibody directed to HER2 receptor
1874566|NCT01137994|Drug|Docetaxel|Taxane chemotherapy
1874567|NCT01137994|Drug|Paclitaxel|Taxane chemotherapy
1874568|NCT01137994|Drug|Vinorelbine|Vinka alkaloid
1874569|NCT01138007|Drug|323U66 SR 150 mg tablet|323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.
1874570|NCT01138007|Drug|323U66 SR 150 mg placebo tablet|323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
1874571|NCT01138020|Behavioral|Cognitive Intervention|Cognitive rehabilitation treatment designed specifically to address the most common cognitive complaints in executive and memory function
1874572|NCT01138020|Behavioral|Educational intervention|Educational intervention is geared at personal management of TBI-related symptoms.
1874573|NCT01138033|Drug|GSK2256098|GSK2256098 is a potent focal adhesion kinase inhibitor that will be administered orally as 20, 100 or 250 mg capsules. The starting dose in Part 1 is 80 mg twice daily. The dose will continue to be increased until the maximum tolerated dose is identified.
1874574|NCT01138046|Drug|Lapatinib in combination with weekly paclitaxel|These subjects will receive weekly paclitaxel (80 mg/m2 IV for 3 weeks in a 4 week cycle) plus lapatinib (1500 mg once daily, starting on the second day of phase I). Subjects will receive a daily dose of lapatinib until disease progression or withdrawal from study treatment due to unacceptable toxicity or withdrawal of consent. Study completion is defined as deaths after administering study treatment for more than once. Subjects will be treated with paclitaxel for standard of 6 cycles, and may be continued at the discretion of investigators. If the subject experiences progression, an unacceptable toxicity related to paclitaxel, or termination of lapatinib therapy, paclitaxel therapy must be terminated any time of study period, even before 6 cycles of paclitaxel are given.
1874575|NCT01138072|Drug|GSK2248761|200mg once daily
1874576|NCT01138072|Drug|Simvastatin|20 mg Simvastatin single dose
1874577|NCT01138072|Drug|Atorvastatin|20 mg atorvastatin single dose
1874578|NCT01138072|Drug|Rosuvastatin|10 mg rosuvastatin single dose
1874579|NCT01138085|Drug|GSK1120212|MEK inhibitor
1874580|NCT01138085|Drug|GSK2141795|AKT Inhibitor
1874582|NCT01138111|Drug|Florbetaben (BAY94-9172)|single 300 megabecquerel (MBq) intravenous injection 2 mL to 10 mL, at baseline, at 12 and 24 months
1874583|NCT01138124|Drug|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulary codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to the index date (the exposure window). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose. These parameterizations will also be examined with a 2 year lag time from the index date, limiting the exposure window from entry into the study cohort up to 2 years prior to the index date.
1874584|NCT01138137|Drug|Paclitaxel|"Dose: 135mg/m2 infused IV on Day 1 of 3 week cycle
Dose: 60mg/m2 infused IP on Day 8 of 3 week cycle
6 treatment cycles"
1874585|NCT01138137|Drug|N-acetylcysteine|"A group of 5 subjects will be evaluated at each dose level.
On Day 2 of each 3 week cycle, subject receives IV NAC followed by IP cisplatin.
6 treatment cycles
Dose escalation schema:
Level 1: 150mg/kg
Level 2: 300mg/kg
Level 3: 600mg/kg
Level 4: 800mg/kg
Level 5: 1000mg/kg
Level 6: 1200mg/kg"
1874586|NCT01138137|Drug|Cisplatin|"Dose: 100mg/m2 infused IP on day 2 of each 3 week cycle 60 min after the NAC infusion
6 treatment cycles"
1874587|NCT01138150|Drug|Treximet|One tablet of sumatriptan 85 mg and naproxen sodium 500 mg will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
1874588|NCT01138150|Drug|Placebo|One tablet of a sugar pill will be given upon subject presentation with an acute migraine attack and after blood levels have been drawn.
1874589|NCT01138163|Drug|Docetaxel plus bavituximab or placebo|Patients will be randomized to receive docetaxel plus placebo, docetaxel plus 1 mg/kg bavituximab, or docetaxel plus 3 mg/kg bavituximab in the Combination Therapy Period. The Combination Treatment Period for each patient will begin on Study Day 1. Docetaxel, 75 mg/m2, will be given on Day 1 of each 21 day cycle for up to 6 cycles, and placebo or the assigned dose of bavituximab will be given weekly. Docetaxel administration will occur every 21 days. All patients who complete the Combination Therapy Period (or discontinue for any reason other than disease progression or toxicity) will be eligible to enter the Monotherapy Period. Patients will continue to receive assigned blinded treatment (placebo or 1 or 3 mg/kg bavituximab) weekly until progression or toxicity.
1874590|NCT01138176|Procedure|Cooling|Reduction of rectal temperature to 33.5 C
1874591|NCT01138189|Procedure|Wavefront-guided LASIK|Wavefront-guided LASIK in one eye using the Allegretto excimer laser
1874592|NCT01138189|Procedure|Wavefront-optimized LASIK|Wavefront-optimized LASIK in one eye using the Allegretto excimer laser
1874593|NCT01138202|Drug|LPV/r|LPV/r 400/100 mg BID + 2 NRTI for arm 1 (total 48 weeks) LPV/r 600/150 mg BID + 2 NRTI for arm 2 (total 48 weeks)
1874594|NCT01138215|Biological|VZV vaccination|Dose : 0.5 ml Route : subcutaneous injection (SC)
1874595|NCT01138241|Other|Tc99mDTPA renal clearance|"Tc99mDTPA renal clearance only for 200 patients
Plasma and urine 24 hr for creatinin, glucose, Creatinin clearance, Phosphatemia, uric acid, HCO3, protein, Microalbuminuria, ß2- microglobulinuria
serum creatinine prior and during TDF
TDF plasma levels ( only TDF use) using a validated high-performance liquid chromatography (HPLC)-mass method and stored PBMC for intracellular TDF levels
stored samples (PBMC) for pharmacogenomic study of transporter gene ie Organic Acid Transporter (OAT)
serum for cystanin C ( stored sample prior taking ARV and present time)
intensive 24 hours pharmacokinetic study of TDF in 20 patients"
1874596|NCT01138254|Device|WSTM TY101 FIR emitter (Far infrared therapy)|A WSTM TY101 FIR emitter (WS Far Infrared Medical Technology Co., Ltd., Taipei, Taiwan) will be used for FIR therapy. The electrified ceramic plates of this emitter generate electromagnetic waves with wavelengths in the range between 3 and 25 μm (a peak between 5 to 6 μm). The irradiating power density is 10 and 20 mili watt〈mw〉/cm2 when the top radiator is set at a distance between 30 and 20 cm above the skin surface respectively. In this study, the top radiator will be set at a height of 25 cm above the surface of bilateral lower legs and the treatment time will be set at 40 minutes three times weekly (TIW) for ESRD patients for 6 months.
1874597|NCT01138254|Other|no intervention|no intervention
1874598|NCT01138280|Device|CWP 103H (Gambro, Sweden): a heat disinfection device|Heat disinfection can increase temperature to 95c in the RO water treatment system and then in the piping system link to dialysis machines in each hemodialysis center per night
1874599|NCT01138293|Device|motion detection with a motion sensor|To asses physical activity and eating habits electronic health technology was used (Fraunhofer-Institute). The system consists in a motion sensor integrated in a mobile phone (DiaTrace). The system analyses kind, intensity and duration of physical activity and eating habits.
1874600|NCT01138306|Genetic|gene expression analysis|
1874601|NCT01138306|Genetic|mutation analysis|
1874602|NCT01138306|Other|flow cytometry|
1874603|NCT01138306|Other|laboratory biomarker analysis|
1874604|NCT01138319|Genetic|DNA analysis|
1874605|NCT01138319|Genetic|mutation analysis|
1874606|NCT01138319|Genetic|polymerase chain reaction|
1874607|NCT01138319|Other|laboratory biomarker analysis|
1874608|NCT01138332|Genetic|western blotting|
1874609|NCT01138332|Other|laboratory biomarker analysis|
1874610|NCT01138345|Genetic|gene expression analysis|blood samples will be analyzed for the expression of the p16 gene.
1874611|NCT01138345|Genetic|reverse transcriptase-polymerase chain reaction|perform reverse transcriptase-polymerase chain reaction on all blood samples.
1874612|NCT01138345|Other|laboratory biomarker analysis|perform laboratory biomarker analysis on all blood samples
1874613|NCT01138345|Other|medical chart review|perform medical chart review for all subjects
1874614|NCT01138345|Other|questionnaire administration|each cohort will be given the same questionnaire
1874615|NCT01138358|Other|medical chart review|
1874616|NCT01138358|Other|study of socioeconomic and demographic variables|
1874617|NCT01138358|Other|survey administration|
1874618|NCT01138358|Procedure|quality-of-life assessment|
1874619|NCT01138371|Procedure|LDL Apheresis|LDL Apheresis
1874620|NCT01138384|Drug|Foretinib|Daily oral dosing at assigned dose beginning day 3 of cycle 1
1874621|NCT01138384|Drug|Lapatinib|Daily oral dosing at assigned dose beginning day 1 cycle 1.
1876408|NCT01149616|Drug|placebo|2 ml normal saline IV x1
1874622|NCT01138397|Biological|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
1874623|NCT01138397|Biological|Influenza virus vaccine (split virion, inactivated)|0.1 mL, Intradermal
1874624|NCT01138410|Biological|SCIB1|Aqueous solution of plasmid DNA administered by intramuscular injection using the TDS-IM electroporation device (Ichor Medical Systems, Inc.) at week 0, 3, 6, 12 and 24. Part 1 of the study will escalate through 0.4, 2.0, 4.0 and 8.0 mg dose level cohorts, each of three patients. In Part 2 of the study the 4.0 and 8.0 mg doses will be administered in the same regimen. At the discretion of the investigator, patients in both parts of the study may continue to receive SCIB1 at 3-6 month intervals for 5 years.
1874625|NCT01138423|Drug|Aliskiren|Once daily treatment with aliskiren for 8-weeks, according to the following regiment: once daily (morning time) 150 mg during the first 2 weeks, followed by once daily (morning time) 300 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 150 mg on day 1, 2, 3, 4, 5 and 7.
1874626|NCT01138423|Drug|Moxonidine|Once daily treatment with moxonidine for 8-weeks, according to the following regiment: once daily (morning time) 0.2 mg during the first 2 weeks, followed by once daily (morning time) 0.4 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 0.2 mg on day 1, 2, 3, 4, 5 and 7.
1874627|NCT01138423|Drug|Hydrochlorothiazide|Once daily treatment with hydrochlorothiazide for 8-weeks, according to the following regiment: once daily (morning time) 12.5 mg during the first 2 weeks, followed by once daily (morning time) 25 mg during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 12.5 mg on day 1, 2, 3, 4, 5 and 7.
1874628|NCT01138423|Drug|Placebo (for aliskiren)|Once daily treatment with placebo tablets for 8-weeks, according to the following regiment: once daily (morning time) 1 tablet during the first 2 weeks, followed by once daily (morning time) 2 tablets during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
1874629|NCT01138423|Drug|Placebo (for moxonidine and hydrochlorothiazide)|Once daily treatment with placebo capsules for 8-weeks, according to the following regiment: once daily (morning time) 1 capsule during the first 2 weeks, followed by once daily (morning time) 2 capsules during the remaining 6 weeks. Coincidental intake of grapefruit(juice) should be avoided. This treatment interval is followed by a one-week tapering period: 1 tablet on day 1, 2, 3, 4, 5 and 7.
1874630|NCT01138436|Drug|MEBO Wound Ointment (MEBO)|Topical application once a day
1874631|NCT01138436|Procedure|Standard of Care|Application of Profore multilayer compression bandage system
1874632|NCT01138449|Drug|Vitamin A|Retinol palmitate (50,000 IU) and minute amounts of vitamin E in soybean oil, orally as a single dose to neonates on the day of birth or in the next 2 days of birth keeping a minimum period of 2 hours between the birth and the dosing
1874633|NCT01138462|Other|intervention|"5 days topical decolonisation including nasal mupirocin tid, chlorhexidine mouth wash tid, chlorhexidine body wash once daily.
Daily direct resident's environmental disinfection during decolonisation."
1874634|NCT01129206|Drug|pralatrexate|IVP(intravenous push)over 3-5 minutes on day 1 at a dose of 120 mg/m2.
1874635|NCT01129206|Drug|docetaxel|Given Intravenous Piggyback (IVPB)as one-hour infusion at a dose of 3 mg/m2 on day 1 of a cycle. cycle defined as 14 days.
1874636|NCT01129206|Radiation|fludeoxyglucose F 18|Correlative studies
1874637|NCT01129206|Procedure|positron emission tomography|Correlative studies
1874638|NCT01129219|Other|Strength training|Strength training for 24 weeks
1874639|NCT01129232|Drug|GAD-alum|20 µg of GAD-alum injected sc after the biopsy, and repeated after one month
1874640|NCT01129232|Other|Placebo|Placebo injected after the biopsy and repeated after one month (similar to the GAD-alum-arm)
1874643|NCT01129258|Drug|PF-04991532|Subjects will be dosed wtih PF-04991532 for 14 days. The tentative dosing schedule is 30, 100, 300, 1000, and 1500 mg QD, and 150 and 500 mg BID). Doses shown may be adjusted upwards or downwards and may be adjusted to include intermediate doses. All doses will be administered as tablets (10, 50, and 150 mg strengths). In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
1874644|NCT01129258|Drug|Placebo|Placebo to match PF-04991532 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04991532 and 3 will receive placebo.
1874645|NCT01129271|Drug|clopidogrel|"Pharmaceutical form: tablet
Route of administration: oral"
1874646|NCT01129271|Drug|Matching placebo|"Pharmaceutical form: tablet
Route of administration: oral"
1874647|NCT01129284|Drug|ACTHAR gel|Patients will be treated with ACTHAR gel starting with 40 units given twice weekly subcutaneously for two weeks, then 80 units given twice weekly subcutaneously afterwards for a period of up to six months.
1874648|NCT01129310|Drug|Irinotecan-Capecitabine-Oxaliplatin|Irinotecan-160mg/m2 IV infusion over 60-90 min on Day 1 Capecitabine-1900mg/m2 daily PO in divided doses (=950mg/m2 BID) on days 2-15 Oxaliplatin- 100mg/m2 IV infusion over 2 hours Day 1
1874649|NCT01129323|Drug|Cyclophosphamide, Fludarabine, Rabbit ATG|Fludarabine 30mg/m2/dose IV and cyclophosphamide 10mg/kg/dose IV are given once per day from day -5 to -2. rATG 1.5 mg/kg/dose IV is given from day -4 to -1.
1874650|NCT01129336|Drug|Zoledronic acid|Patients with no bone metastasis (n=150) will receive Standard therapy plus Zoledronic acid administration 4 mg IV monthly during Months 1-18.
1874651|NCT01129336|Drug|Standard Therapy|Standard Therapy, including chemotherapy and hormonal therapy, was determined at the discretion of the investigator.
1874652|NCT01129349|Drug|Oprozomib|Oral administration of Oprozomib on Days 1-5 of a 14 day cycle
1874653|NCT01129362|Biological|Pentacel® (DTaP-IPV/Hib)|0.5 mL dose, Intramuscular
1874654|NCT01129362|Biological|Other Pertussis Vaccines|0.5 mL, Intramuscular
1874655|NCT01129375|Drug|clopidogrel|"Pharmaceutical form: tablet
Route of administration: oral"
1874656|NCT01129375|Drug|placebo|"Pharmaceutical form: matching tablet
Route of administration: oral"
1874657|NCT01129375|Drug|omeprazole|"Pharmaceutical form: delayed-release capsule
Route of administration:oral"
1874658|NCT01129388|Drug|clopidogrel|"Pharmaceutical form: tablet
Route of administration: oral"
1874659|NCT01129388|Drug|Placebo|"Pharmaceutical form: matching tablet
Route of administration: oral"
1874660|NCT01129388|Drug|omeprazole|"Pharmaceutical form: delayed-release capsule
Route of administration:oral"
1874661|NCT01129401|Behavioral|Stonewall Project|The Stonewall Project is an outpatient substance abuse treatment program for methamphetamine-using MSM that includes individual counseling, group counseling, and visits with a psychiatrists where indicated.
1874662|NCT01129414|Drug|Clopidogrel|"Pharmaceutical form: tablet
Route of administration: oral"
1874663|NCT01129414|Drug|Placebo|"Pharmaceutical form: matching tablet
Route of administration: oral"
1874664|NCT01129414|Drug|Omeprazole|"Pharmaceutical form: delayed-release capsule
Route of administration: oral"
1874665|NCT01129427|Drug|Clopidogrel|"Pharmaceutical form: tablet
Route of administration: oral"
1874666|NCT01129427|Drug|Placebo|"Pharmaceutical form: matching tablet
Route of administration: oral"
1874667|NCT01129427|Drug|Pantoprazole|"Pharmaceutical form: delayed-release tablet
Route of administration: oral"
1874668|NCT01129440|Device|Fluoride Varnish|Topical application of 0.25mL of fluoride varnish on each dental arch (upper and lower) at baseline and every 6 months.
1874669|NCT01129440|Device|Glass Ionomer Sealant|"Fluoroaluminosilicate glass powder and polyacrylic acid liquid are mixed together in a capsule to form the glass ionomer sealant material.
After toothbrushing and conditioning dental surfaces with 20% polyacrylic acid for 10 seconds, pink-colored fluoride releasing glass ionomer dispensed from a capsule is applied to the occlusal (biting) surface of the molar."
1874670|NCT01129453|Biological|CVD 1902, a Salmonella enterica Serovar Paratyphi A live, oral vaccine|CVD 1902 consists of ΔguaBA, ΔclpX Salmonella enterica serovar Paratyphi A vaccine strain diluted in sterile phosphate buffered saline to achieve the desired inoculum. Form: liquid. Dose: 10^6, 10^7, 10^8, or 10^9 CFU per mL. Route: oral.
1874671|NCT01129453|Other|Placebo|30 ml of buffer solution (2.0 grams of NaHCO3 dissolved in 150 ml of sterile water) without bacteria, to which food grade corn starch, USP is added, as necessary, to match the turbidity of the vaccine inoculum
1874672|NCT01129466|Dietary Supplement|Supplement A followed by Supplement B|Supplement A (3 days of Broccosprout homogenate) will be followed at least 2 weeks later by Supplement B (3 days of Broccosprout sandwich and SFN rich tea)
1874673|NCT01129466|Dietary Supplement|Supplement B followed by Supplement A|Supplement B (Broccosprout sandwich and SFN rich tea for 3 days) followed at least 2 weeks later by 3 days of Supplement A (Broccosprout homogenate)
1874674|NCT01129479|Drug|Galantamine|Galantamine XL 8 mg for 4 weeks, followed by Galantamine XL 16 mg for subsequent 12 weeks. Taken in the morning with food for total of 12 weeks.
1874675|NCT01129479|Drug|Placebo pill|Placebo pill each morning with food for 12 weeks.
1874676|NCT01129492|Device|Low-level Laser therapy|A continuous wave (CW) diode laser device (830nm, infrared) with a beam area of 0.2827cm2 and using the punctual method, continuous emission mode, output power of de 50mW and fluence of 70J/cm2 (40 seconds at the point of application).
1874677|NCT01129505|Behavioral|Nutrition & Exercise Lifestyle Intervention Program (NELIP)|"Nutrition- individualize total energy intake with a minimum of 2000 kcal/day with a restriction of not more than 33% total energy intake, total carbohydrate of 40-50% total energy intake, total fat intake of 30% of total energy intake (substituting monounsaturated fatty acids for saturated and trans-fatty acids), and approximately 30% dedicated to protein intake.
Exercise-25 minutes of walking per session, 3-4 times per week, each subsequent week increasing by 2 mins to a maximum of 40 mins/session.
Family-based Behavioural Treatment (FBBT) Coupled with the individualized NELIP for each woman, FBBT will be presented in 3 group sessions (including family members), focussing on strategies to make healthy lifestyle choices with behavioural strategies."
1874678|NCT01129518|Biological|Glyco-conjugate Neisseria meningitidis serogroup C (MenC) vaccine|"In order to ensure proper intramuscular injection of the study vaccines, a 23G (0.5mm in diameter) needle of at least 1 inch (2.54 cm) length will be used. All vaccines will be administered intramuscularly.
Then MenC vaccine will administered either once (at 3 months) or twice (at 3 and 4 months) depending on treatment group to either the thigh, deltoid or a combination of the two."
1874679|NCT01129518|Biological|Routine schedule immunisations except monovalent MenC vaccine|Routine schedule immunisations will be given according to NHS guidelines.
1874680|NCT01129531|Drug|AGN-214868|AGN-214868 injected into areas of postherpetic neuralgia pain for total dose per treatment.
1874681|NCT01129531|Drug|Placebo to AGN-214868|Placebo to AGN-214868 injected into areas of postherpetic neuralgia pain per treatment.
1874682|NCT01129544|Biological|Gene transfer|Three procedures: 1) Bone marrow harvest from the patient's posterior iliac crests. 2.) Chemotherapy conditioning with Busulfan 3)One time infusion of patient's transduced bone marrow cells.
1874683|NCT01129557|Drug|Aliskiren|
1874684|NCT01129557|Drug|Valsartan|
1874685|NCT01129570|Drug|Silybin|4 dose levels of siliphos: 2, 4, 8, and 12 grams daily in three divided doses. This study will follow a standard sequential Phase I dose escalation design.
1874686|NCT01129583|Drug|Botulinum Toxin Type A|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
1874687|NCT01129583|Drug|Saline|Injection into the biceps brachii and brachialis immediately following the initial fracture surgery
1874688|NCT01129596|Drug|donepezil hydrochloride|This is a multicenter, open-labeled, practice-based, post-marketing surveillance study. Therefore, dosing is not specified.
1874689|NCT01129609|Device|Talent Converter Stent Graft and Talent Occluder with Occluder Delivery System|All subject enrolled will be attempted to be treated with or will be treated with the Talent Converter Stent Graft
1874690|NCT01129622|Drug|letrozole|Letrozole (12.5 mg/day ) which is higher than the dose routinely used for therapeutic indications is given for a brief duration (3 successive days) aiming to promote acute aromatase inhibition suitable for pre-diagnostic regimens.
1874735|NCT01129843|Drug|Directly observed home based daily iron therapy|Directly Observed Home based Daily Iron( ferrous sulphate) therapy (DOHBIT) will be provided to the anemic women by the local village volunteers. Dose of elemental iron therapy will be 100 mg once daily for mild to moderate anemia and twice daily for severe anemia for a cumulative duration of 90 days
1874736|NCT01129856|Drug|Dexamethasone phosphate ophthalmic solution|Transscleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
1874737|NCT01129856|Drug|Sodium citrate buffer solution|Sodium citrate buffer solution 100 mM
1874691|NCT01129635|Procedure|Cardiac Resynchronization Therapy (CRT) implantation|"The impedance measurement is performed during device implantation following CMR. After the RV and LV leads are inserted, secured and tested, they will be connected to the impedance monitor. Impedance recording of at least ten beats will be acquired and stored for future analysis. Each recording will be tagged with the anatomical location of the LV lead. Subsequently, the LV lead will be moved to a different location and the same procedure will be repeated until accessible coronary sinus sites are exhausted. The ultimate LV lead location is determined by the implanting electrophysiologist and is not constrained by the study protocol. Finally, the LV lead will be tested again and the rest of the implantation procedure will proceed as routine.
Arm: CRT Candidate"
1874692|NCT01129648|Drug|Placebo|Administered daily for 21 days
1874693|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874694|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874695|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874696|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
1874697|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874698|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874699|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874700|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
1874701|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874702|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874703|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874704|NCT01129648|Drug|BCX4208|Administered daily for 21 days.
1874705|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874706|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874707|NCT01129648|Drug|Allopurinol|Administered daily for 21 days.
1874708|NCT01129648|Drug|BCX4208|Adminstered daily for 21 days
1874709|NCT01129661|Biological|CSL112 (reconstituted HDL)|Single escalating intravenous doses of CSL112
1874710|NCT01129661|Biological|normal saline (0.9%)|Single intravenous dose of normal saline (0.9%)
1874711|NCT01129674|Drug|LY2140023|Administered orally, twice daily for 104 weeks
1874712|NCT01129674|Drug|Olanzapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
1874713|NCT01129674|Drug|Aripiprazole|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
1874714|NCT01129674|Drug|Risperidone|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
1874715|NCT01129674|Drug|Quetiapine|Tablets or capsules, given orally, consistent with approved labeling and local practice for 104 weeks
1874716|NCT01129687|Procedure|Microsurgery|Patient would under to total, near-total, or subtotal resection of tumor
1874717|NCT01129687|Procedure|Stereotactic radiation therapy|Patient who has sign of growth of tumor remnant would undergo this treatment
1874718|NCT01129700|Radiation|Radiation: short-course preoperative chemoradiotherapy|"Drug: 5-Fluorouracil 5-Fluorouracil is administered intravenously at a dose of 400 mg/m2 once daily continuous regimen during RT(5 days).
Radiation: Localization, simulation and immobilization Radiation dose and planning Total dose 25Gy, 5 fractions (5 Gy/day)."
1874719|NCT01129713|Drug|Secretol|Comparing 80/80 once daily to Nexium once daily in healing erosive esophagitis.
1874720|NCT01129713|Drug|Nexium|Comparing 40 mg Nexium once daily to 80/80 Secretol once daily in healing erosive esophagitis.
1874721|NCT01129726|Device|Transillumination-guided Fiberoptic Intubation|Light guided, Non-invasive
1874722|NCT01129739|Other|Human umbilical cord-derived MSCs|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle
1874723|NCT01129739|Other|cyclosporine A (CsA)|CsA 5mg/kg po for 6 months
1874724|NCT01129752|Other|No intervention|there is no intervention for this study
1874725|NCT01129765|Device|Use of an automatic nasal irrigator/aspirator|After reading the device's user manual, parents were asked to use it on their congested children to their satisfaction. During this time, a clinical observer recorded predetermined steps that needed to be performed for success as well as presence of any adverse events.
1874726|NCT01129778|Drug|Zegerid (proton pump inhibitor)|
1874727|NCT01129778|Procedure|Bravo pH monitoring|
1874728|NCT01129791|Behavioral|Raw Milk|Organic whole raw cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. for 8 days. After a 1-week wash-out period, pasteurized cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
1874729|NCT01129791|Behavioral|Pasteurized Milk|Organic whole pasteurized cow's milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or non-dairy milk were consumed in the same fashion for another 8 days each.
1874730|NCT01129791|Behavioral|Non-dairy milk|Unflavored soy milk, consumed daily in one sitting, at incremental doses from 4 to 24 oz. After a 1-week wash-out period, raw cow's milk or pasteurized cow's milk were consumed in the same fashion for another 8 days each.
1874731|NCT01129804|Behavioral|Coping Skills Training|Patients in both treatments will be taught skills to help them keep from drinking.
1874732|NCT01129817|Other|Cognitive Functional Therapy|A novel multidimensional classification system has been developed incorporating the biopsychosocial model, which subgroups patients based on their presentation with matched interventions directed at the maladaptive cognitive, physical and lifestyle behaviours associated with the disorder. The intervention is called 'cognitive functional therapy' as it directly challenges these behaviours in a functionally specific and graduated manner.
1874733|NCT01129817|Other|Manual therapy and exercise|Patients in this group was treated with joint mobilization or manipulation techniques applied to the spine or pelvis primarily and was designed to be consistent with best current manual therapy practice in Norway. The particular dose and techniques were at the discretion of the treating therapist, based on each participant's objective and physical examination findings. In addition most of the patients in this group was given exercises or a home exercise program.
1874734|NCT01129830|Dietary Supplement|dehydroepiandrosterone|DHEA supplementation 25 mg tid for 3 months
1874738|NCT01129882|Drug|Aripiprazole|Aripiprazole IM Depot - 300mg or 400mg
1875163|NCT01140191|Drug|WR 279,396|Topical application of WR 279,396 cream (15% paromomycin + 0.5% gentamicin)once daily for 20 days
1874739|NCT01129895|Behavioral|Health promotion|In each intervention clinic 5 workshops on the initiation of health prevention projects in each clinic will be organized by the intervention team and than the clinic will be followed by the intervention team for 6 months.
1874740|NCT01129921|Device|Percutaneous Lumbar Decompression|Fluoroscopic percutaneous lumbar decompression of the central spinal canal
1874741|NCT01129921|Device|Sham lumbar decompression|Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
1874742|NCT01129934|Drug|Morphine-Promethazine|administration of intravenous morphine 0.1mg/kg and promethazine 12.5 mg in a 500 Ml 0.9% saline
1874743|NCT01129934|Drug|morphine|Administration of intravenous morphine 0.1 mg/kg
1874744|NCT01129947|Drug|DHEA|DHEA 25 mg tid
1874745|NCT01129960|Drug|Eslicarbazepine acetate (BIA 2-093)|Tablets will be used.
1874746|NCT01129960|Drug|Placebo|Tablets will be used.
1874747|NCT01129986|Device|DermaStream|Five treatment days. On each day DermaStream application for up to 4 hours of saline streaming.
1874748|NCT01129999|Behavioral|Cognitive-Behavioral Therapy|a cognitive-behavioral smoking cessation program; 6, weekly-held, group sessions (90 min each)
1874749|NCT01129999|Behavioral|Hypnotherapy|hypnotherapeutic smoking cessation program; 6, weekly-held, group sessions (90 min each)
1874750|NCT01130012|Behavioral|Lifestyle: diet and exercise|Lifestyle: The women received counseling by a clinical nutritionist six times and by a physiotherapist six times during pregnancy.
1874751|NCT01130012|Behavioral|Close follow-up: reporting diaries of food and exercise|Follow-up: The women received information of the results of a glucose tolerance test (OGTT), reported food records three times during pregnancy, exercise history and exercise diaries monthly.
1874752|NCT01130025|Drug|Warfarin|Tablets. Once daily for 6 months (180 days) to maintain therapeutic international normalised ratio (INR) levels in combination with initial (5-10 days) overlapping treatment with Innohep®.
1874753|NCT01130025|Drug|Innohep®|Solution for sub-cutaneous injection, pre-filled syringes. Once daily for 6 months (180 days). 175 anti Xa IU/kg.
1874754|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg intact tablet taken by mouth
1874755|NCT01130051|Drug|Colchicine 0.6 mg tablet|One Colcrys® 0.6 mg tablet crushed and sprinkled on applesauce
1874756|NCT01130064|Biological|QAX576|every 3 weeks via intravenous infusion
1874757|NCT01130064|Drug|Placebo|every 3 weeks via intravenous infusion
1874758|NCT01130077|Biological|HLA-A2 restricted glioma antigen peptides vaccine|Vaccine given every 3 weeks
1874759|NCT01130077|Biological|Poly-ICLC|Vaccine given every 3 weeks
1874760|NCT01130090|Device|Adjustment of back-up respiratory rate on bi-level ventilator|"3 consecutive nights in randomized order, in either S (Spontaneous) mode, ST (Spontaneous/Timed) mode with a back-up rate under spontaneous respiratory rate of the patient, or in ST (Spontaneous/Timed) mode with a back-up rate at least 2 cycles/minute above spontaneous nocturnal respiratory rate. Each assessment will include complete polysomnographic recording (sleep study) as well as SpO2, PtcCO2, pneumotachograph (flow), mask pressure, quantitative assessment of patient-ventilator synchronisation, central or obstructive apnea and hypopnea, data of built-in software, and rating of patient comfort"
1874761|NCT01130103|Drug|Paroxetine|Paroxetine (controlled release) 12.5-50 milligrams (mg) daily for 22 weeks
1874762|NCT01130103|Behavioral|Prolonged Exposure Therapy|Weekly for 10 weeks
1874763|NCT01130129|Other|Ex-vivo treatments with flavonoids|Ex-vivo treatment of platelets with a range of flavonoids
1874764|NCT01130142|Drug|IPI-926 plus gemcitabine|Daily IPI-926 (oral) at 160 mg plus gemcitabine (infusion) at 1000 mg/m2 once weekly for 3 weeks of a 28 day cycle
1874765|NCT01130142|Drug|Placebo plus gemcitabine|Daily Oral placebo/IPI-926 160 mg plus gemcitabine infusion at 1000 mg/m2 once every 3 weeks in a 28 day cycle
1874766|NCT01130168|Drug|Placebo|Placebo, capsule taken orally once daily during 4 weeks of treatment
1874767|NCT01130168|Drug|Comparator: Amlodipine|Amlodipine 10 mg, taken orally as two 5 mg capsules, single daily dose for 4 weeks
1874768|NCT01130168|Drug|Comparator: ISMN ER|ISMN ER 30 mg capsule, taken orally as single daily dose for 4 weeks
1994727|NCT02937298|Dietary Supplement|Sea Buckthorn Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream plus a sea buckthorn berry smoothie.
1874771|NCT01130194|Other|Combination of treatment modalities|"Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.
Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning."
1874772|NCT01130220|Other|Focus Group|"A single focus group will be held until a saturation of themes has been identified."
1874773|NCT01130233|Procedure|robotic assisted rectal resection|robotic assisted rectal resection
1874774|NCT01130233|Procedure|laparoscopic rectal resection|laparoscopic rectal resection
1874775|NCT01130246|Drug|A-002, varespladib methyl|A-002 administered once daily in addition to atorvastatin and standard of care
1874776|NCT01130246|Drug|Placebo|Placebo administered once daily in addition to atorvastatin and standard of care
1874777|NCT01130259|Drug|iniparib|5.6 mg/kg as a 60 (±10) minutes IV infusion. Administered on Days 1, 4, 8, and 11 of each 21 day cycle.
1874778|NCT01130272|Drug|JNJ-27018966|oral tablets
1874779|NCT01130272|Drug|Placebo|Matching placebo oral tablets twice daily
1874780|NCT01130285|Genetic|Lung Cancer Risk Test|Measurement of gene expression in normal bronchial epithelial cells obtained at time of bronchoscopy.
1874781|NCT01130298|Drug|Testosterone Gel 1.62%|5 grams
1874782|NCT01130311|Drug|Cholecalciferol|Intramuscular injection of 600,000 units of Cholecalciferol for 2 doses given at week 0 and week 4
1874783|NCT01130311|Drug|Saline injection|normal saline, intramuscular preperation,given in 2 doses at week 0 and week 4 of trial
1874784|NCT01130324|Drug|VIBATIV|Observational
1874785|NCT01130337|Drug|Capecitabine [Xeloda]|1.000 mg/m2 orally every 12 hours from day 1 to day 14 of every cycle for 6 cycles
1874786|NCT01130337|Drug|Oxaliplatin|130 mg/m2 intravenous infusion day 1 of every cycle
1874787|NCT01130337|Drug|Trastuzumab [Herceptin]|First dose 8 mg/kg, subsequent cycles 6 mg/kg, intravenously, day of every cycle for 15 cycles
1874788|NCT01130376|Biological|GTU-MultiHIV B clade vaccine1mg|Dose given is 1mg/ml administered as 10 intradermal injections of 100 µl/injection distributed as 5 intradermal injections /left and right arm
1874789|NCT01130376|Drug|Interleukin-2|5 Million Units administered twice daily for 5 days by subcutaneous injection on days 7, 8, 9, 10, and 11 after first vaccination. .
1874790|NCT01130376|Drug|GM-CSF|150 ug administered subcutaneously once daily 4 hours from IL-2 injections
1874791|NCT01130376|Drug|Growth Hormone|4mg/day will be self administered by Subcutaneous injection for 5 days on days 14, 15, 16, 17 and 18 following first vaccination
1874792|NCT01130428|Device|Juvent 1000 Vibration Platform|"As a mechanical intervention, mechanical stimulation in the form of vibration will be administered to the forearm using a Juvent 1000 Vibration Platform (Juvent Medical, Inc., Lakeland, FL, USA), which is a non-medicinal product. The device produces gentle, low-magnitude mechanical signals in the form of low-amplitude vertical displacements at a high frequency.
The intervention in the present study will be given at a fixed dosage that is defined by the intensity of vibration: frequency: 90 Hz, amplitude: 10 µm (~3.0 g). The mechanical stimulation will be administered in an intermittent fashion, as it has been shown that inserting short rest periods between loading cycles enhances the efficacy of mechanical loading [38]. Thus, the mechanical stimulation will be administered for three times 10 minutes (i.e. the vibration platform turned on), with 10-minute rest periods in between (i.e. the vibration platform turned off); the intervention will have a total duration of 50 minutes."
1874793|NCT01130441|Behavioral|psychotherapy|short problem-solving skills therapy intervention
1874794|NCT01130454|Device|Universal Electrophysiological Biofeedback Treatment|one 45 minute biofeedback treatment
1874795|NCT01130454|Device|Universal Electrophysiological Biofeedback Treatment|one 45 minute placebo treatment
1874799|NCT01130480|Device|Accu-Chek Integra Glucometer|
1874802|NCT01130506|Drug|Cytarabine|Given IV
1874803|NCT01130506|Drug|Decitabine|Given IV
1874804|NCT01130506|Other|Laboratory Biomarker Analysis|Correlative studies
1874805|NCT01130506|Other|Pharmacological Study|Correlative studies
1874806|NCT01130506|Drug|Vorinostat|Given PO
1874809|NCT01130532|Drug|Tadalafil|Administer orally
1874810|NCT01130532|Drug|Placebo|Administer orally
1874811|NCT01130558|Other|Diabetes Management|Using electronic insulin order template for basal-bolus insulin and education
1874812|NCT01130571|Procedure|Xenografts and cell cultures|
1874813|NCT01130584|Other|Pyruvate kinase isoform M2|
1874814|NCT01130597|Drug|patiromer|Active investigational drug
1874815|NCT01130597|Drug|spironolactone|
1874816|NCT01130623|Drug|Pazopanib (GW786034)|
1874817|NCT01130636|Drug|Oseltamivir|Lactating women who present with clinical symptoms indicative of influenza will receive immediate treatment with oseltamivir (Tamiflu® 75 mg hard capsules) at a standard dose of 75 mg twice daily.
1874818|NCT01130649|Device|HealthBuddy|Noninvasive device for remotely reporting health information. The device does nothing to change the health of the patient, but transmits health data that is entered by the patient directly to the physician's office. Patients will enter data on seizure frequency, medication compliance, and side effects.
1994728|NCT02937298|Dietary Supplement|Wild Garlic Treatment|This will consist of standard breakfast foods (cereal, milk, yoghurt, cheese cracker bread, butter, banana and cream. The wild garlic will be prepared and served as a dip alongside.
1874820|NCT01130675|Other|caffeinated coffee|8 oz. of caffeinated cofee/breakfast&noon meal. No intervention for 2nd arm.
1874821|NCT01130688|Drug|Zileuton|Imatinib combined with Zileuton
1874822|NCT01130701|Other|Neoadjuvant capecitabine, panitumumab and radiation|"Patients will receive six weekly doses of panitumumab (2.5mg/kg) in conjunction oral capecitabine 825 mg/m2 PO bid Mon-Friday and external beam radiation therapy. Panitumumab and oral capecitabine will begin on the first week of external beam radiotherapy and will continue throughout the course of external beam radiation therapy, and will be discontinued following the conclusion of external beam radiation therapy.
Patients will be reevaluated for surgical resection 4-6 weeks after completion of neoadjuvant therapy.
After surgical resection, adjuvant systemic chemotherapy with gemcitabine for six months is strongly recommended for all patients."
1874823|NCT01130714|Behavioral|Exercise|Resistance training with resistance bands.
1874824|NCT01130727|Other|green tea extract|1.21g of green tea extract (965 mg of flavonols)
1874825|NCT01130727|Other|cocoa extract rich in polyphenols|2.14 g of cocoa extract rich in polyphenols equivalent to 965 mg of polyphenols
1874826|NCT01130727|Other|placebo|placebo
1874827|NCT01130727|Other|low polyphenol cocoa extract|placebo
1874828|NCT01130740|Behavioral|Osteoarthritis Intervention|Primary care providers receive patient-specific osteoarthritis information and treatment recommendations two times (0 and 6 months); patients receive a 12-month intervention consisting of monthly phone calls focusing on exercise, weight management, and cognitive behavioral pain management.
1874829|NCT01130753|Drug|Erlotinib|Erlotinib 150mg per day for 8 weeks
1874830|NCT01130766|Procedure|stereotactic radiosurgery (SRS)|Stereotactic radiosurgery using γ-rays from radioactive Cobalt-60 installed in Gamma Knife (Elekta Instruments, Stockholm, Sweden)
1874831|NCT01130779|Drug|Erlotinib (TARCEVA®)|Erlotinib 150mg/day, everyday
1994729|NCT02935049|Procedure|Endoscopic resection|Endoscopic resection with technique EMR piecemeal or hybrid technique EMR/ESD
1994730|NCT02935647|Drug|Diprivan|
1994731|NCT02935543|Biological|CART 19|CART19 cells transduced with a lentiviral vector to express anti-CD19 scFv TCRz:41BB administered by IV infusion. Subjects will receive 1-5 x 10^8 transduced CAR T cells as a split dose over three days as follows:Day 1, 10% fraction: 1-5x10^7 CART19 cells, Day 2, 30% fraction: 3x10^7-1.5x10^8 CART19 cells, Day 3, 60% fraction: 6x10^7-3x10^8 CART19 cells
1994732|NCT02935426|Device|n-butyl cyanoacrylate and 2-octyl cyanoacrylate|used in cyanoacrylate group
1994733|NCT02935426|Device|5-0 Polytetrafluoroethylene (PTFE) suture|used in suture group
1994734|NCT02934334|Other|Observational|
1994735|NCT02933827|Drug|Elixcyte|Adipose-derived stem cells (ADSCs)
1874832|NCT01130792|Dietary Supplement|Lactobacillus GG|10 Billion Organisms Given Mixed In Milk As Food Supplement Once Daily For Four Weeks
1874833|NCT01130792|Dietary Supplement|Inulin|Identical appearing capsules containing a powder resembling the LGG to be given as for intervention
1874834|NCT01130805|Drug|Pazopanib in combination with capecitabine and oxaliplatin|Capecitabine 850 mg/m2 bid on day 1-14, Oxaliplatin 130 mg/m2 IV on day 1 and Pazopanib 800 mg once in a day on day 1-21, every 3 weeks
1874835|NCT01130818|Drug|GLPG0492|single ascending doses, oral solution (25 to max. 120 mg/intake, 10 to 200 mg/mL)
1874836|NCT01130818|Drug|placebo|single dose, oral solution
1874837|NCT01130818|Drug|GLPG0492|single dose, solid formulation, 50 mg (2*25 mg/capsule), fasting
1874838|NCT01130818|Drug|GLPG0492|single dose, solid formulation, 50 mg (2*25 mg/capsule), after high fat breakfast
1874839|NCT01130831|Drug|Lanthanum carbonate|
1874840|NCT01130844|Drug|MMX Mesalamine|30 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
1874841|NCT01130844|Drug|MMX Mesalamine|60 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
1874842|NCT01130844|Drug|MMX Mesalamine|100 mg/kg/day of MMX Mesalamine tablets, dosed once daily for 7 days.
1874843|NCT01130870|Device|Sensory Threshold|Sacral nerve stimulation with amplitude (sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
1874844|NCT01130870|Device|75% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (75% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
1874845|NCT01130870|Device|50% of sensory threshold - Amplitude|Sacral nerve stimulation with amplitude (50% of sensory threshold), Frequency 14 Hz and pulse width 210 mic.sec.
1874846|NCT01130909|Drug|AZD6765|75 mg
1874847|NCT01130909|Drug|AZD6765|150 mg
1874848|NCT01130909|Drug|Ketamine|0.5 mg/kg
1874849|NCT01130909|Drug|Placebo|125 mL sterile NaCl 0.9%
1874850|NCT01130922|Drug|moxifloxacin per IV|intravenous administration of 400 mg moxifloxacin (as a 1h-infusion)
1874851|NCT01130922|Drug|moxifloxacin per os|oral administration of 400 mg moxifloxacin in a single dose
1874852|NCT01130948|Other|altitude exposure|exposure to 490m, 1700m and 2590m
1874853|NCT01130974|Device|Bausch & Lomb contact lens|Bausch & Lomb daily disposable cosmetic tint contact lens
1874854|NCT01130974|Device|Marketed daily disposable contact lens|Marketed daily disposable cosmetic tint contact lens
1874855|NCT01130987|Other|Computerized handoff tool|Computer program that facilitates accurate transmission of patient information between residents
1874856|NCT01130987|Behavioral|Team training|Training in teamwork and reorganization of handoff processes to optimize transmission of information and team care
1874857|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 100 mg, Single-dose
1874858|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 200mg, single dose
1874859|NCT01131000|Drug|Ibuprofen|Intravenous ibuprofen, 400 mg, Single-dose
1874860|NCT01131000|Other|Normal Saline|Normal Saline, 100 ml, Single-dose
1874861|NCT01131013|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
1874862|NCT01131013|Drug|375 mg CK-2017357|375 mg CK-2017357 in capsules administered as a single oral dose.
1874863|NCT01131013|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
1874864|NCT01131026|Drug|Levofloxacin|tablet, 500 mg, once a day for ten days
1874865|NCT01131026|Drug|Amoxicillin|tablet, 1000 mg, once a day for ten days
1874866|NCT01131026|Drug|Lansoprazole|capsule, 30 mg, twice a day for ten days
1874867|NCT01131039|Drug|Gemcitabine/Bevacizumab|"Gemcitabine: IV, days 1,8, and every 21 days
Bevacizumab: IV, day 1 and every 21 days until disease progression"
1874868|NCT01131052|Drug|Insulin Glargine|glargine once a day
1874869|NCT01131052|Drug|Insulin|sliding scale regular insulin (SSRI) given before meals and at bedtime as needed
1874870|NCT01131052|Drug|Insulin glulisine|glulisine given as needed before meals
1874871|NCT01131065|Drug|Hepatitis B immune globulin|Daily doses of 10,000 IU of intravenous hepatitis B immune globulin during the first week post-transplantation (anhepatic phase + days 1-7), followed by weekly and monthly doses of 5,000 IU during weeks 2,3, and 4 and months 2,3,4,5,6,7,8,9,10,11 and 12, respectively.
1874872|NCT01131078|Drug|Bevacizumab [Avastin]|Bevacizumab was administered as a 7.5 mg/kg intravenous infusion over 30 to 90 minutes on Day 1 of each 3 week cycle.
1874873|NCT01131078|Drug|Capecitabine|Capecitabine was administered orally at a doses of 1000 or 1250, mg/m^2 twice daily (Day 2 to 15) or as 650 mg/m^2 twice daily on Days 1 to 21.
1874874|NCT01131078|Drug|Irinotecan|Irinotecan was administered as a 240 mg/m^2 intravenous infusion over 60 minutes (Day 1) every 3 weeks.
1874875|NCT01131091|Drug|SK-0403|SK-0403 400 mg
1874877|NCT01131130|Device|Investigational contact lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
1874878|NCT01131130|Device|Acuvue Oasys Contact Lens|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
1874879|NCT01131130|Device|Air Optix Aqua|After one week of wearing the first lens type, the participants will crossover to the second lens type for one week, and then crossover to the third lens type.
1874880|NCT01131143|Behavioral|Provider Voice|A phone call with the pre-recorded doctor's voice will be made to their patients who have been pre-screened for obesity before the patient's appointments prompting the patients to ask about physical activity, nutrition, and weight loss.
1874881|NCT01131143|Behavioral|Generic Voice|A phone call with a pre-recorded neutral voice will be made to the doctor's patients who have been prescreened for obesity before their patient's appointments. The call will prompt them to ask ask their doctor about physical activity, nutrition, and weight loss.
1874882|NCT01131156|Behavioral|Smoking Relapse Prevention|Mothers were given information about normal newborn behaviors using books, DVDs, and handouts that were appropriate for their baby's gestational age and were also encouraged to participate in frequent skin-to-skin holding of their babies.
1874883|NCT01131169|Drug|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight.
1874884|NCT01131169|Drug|busulfan, melphalan and fludarabine|Patients will be cytoreduced with IV busulfan, melphalan and fludarabine. Busulfan will be administered at a dose of 0.8mg/Kg q6hrs for 10 doses on days -9, -8, -7. Doses for busulfan should be adjusted according to pharmacokinetic studies. Melphalan will be administered at a dose of 70 mg/m2/day for 2 days on days -7, -6. Fludarabine will be administered at a dose of 25 mg/m2/day for 5 days on days -6, -5, -4, -3, -2. Patients will also receive rabbit anti-thymocyte globulin (ATG) to prevent immune mediated graft rejection. The ATG will be administered at a dose of 2.5 mg/Kg/day IV on days -3 and -2. Doses for busulfan, melphalan and ATG should be adjusted if patient is > 125% ideal body weight and should be calculated on adjusted ideal body weight.
1960216|NCT03270163|Diagnostic Test|Transcutaneous electrical stimulation|"Patient will have the day of inclusion and then again after 20 minutes in finally, 72 hours (3 days) later :
Increasing electrical stimulation until muscle contraction
three simple electrical stimulations,
three doublets (ie 2 very close electrical stimulations) at frequency 10Hz
three doublets at the frequency of 100Hz
electrical stimulation leading to a maximum contraction of the muscle (called tetanus),"
1874888|NCT01131195|Biological|bevacizumab, Paclitaxel|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Paclitaxel (90 mg/m2) i.v. is given on days 1, 8, and 15 of a 4 week cycle.
1874889|NCT01131195|Biological|Bevacizumab, Cyclophosphamide, Capecitabine|Bevacizumab (10 mg/kg) i.v. is given every two weeks. Cyclophosphamide (50 mg) and capecitabine (3x 500 mg) p.o. are given daily
1874890|NCT01131208|Genetic|gene expression analysis|
1874891|NCT01131208|Other|laboratory biomarker analysis|
1874892|NCT01131221|Other|laboratory biomarker analysis|
1874893|NCT01131234|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1874894|NCT01131234|Drug|Cediranib Maleate|Given PO
1874895|NCT01131234|Other|Pharmacological Study|Correlative studies
1874896|NCT01131234|Other|Laboratory Biomarker Analysis|Correlative studies
1874897|NCT01131247|Drug|ofatumumab + bendamustine|Loading dose of ofatumumab at 300mg IV with subsequent doses at 100mg IV on D1 of all cycles (maximum of 6 cycles) in combination with bendamustine 90mg/m2 on day 2 of all cycles. Neulasta 6mg SQ will also be given on day 8 of cycle 1 only.
1874898|NCT01131260|Device|fetal STAN monitor|The STAN monitor is a system for fetal surveillance that displays the FHR, the uterine activity and information resulting from the analysis of the ST segment of the fetal ECG.
1874899|NCT01131273|Drug|methadone|12 weeks of methadone maintenance with counseling
1874900|NCT01131273|Drug|buprenorphine-naloxone (Suboxone) for 12 weeks|12 weeks of maintenance with counseling
1874901|NCT01131299|Other|Placebo|2 tablets PO 3 times a day for 12-14 weeks
1874902|NCT01131299|Drug|Alpha cyclodextrin|2g PO 3 times a day for 12-14 weeks
1874903|NCT01131312|Device|Thinprep|Pap test
1874904|NCT01131312|Device|Hybrid capture 2|HPV DNA Test
1874905|NCT01131312|Procedure|Colposcopy|
1874906|NCT01131325|Drug|nilotinib|All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
1874907|NCT01131351|Drug|OPC-67683|Dosage-500-800 mg Strength 250-400 mg Frequency b.i.d.
1874908|NCT01131364|Drug|F16IL2 in combination with doxorubicin|"Intravenous (i.v.) infusions of F16IL2 (Dose escalation: from 5 up to 25 MioIU) on days 1, 8, 15, 29, 36 and 43 over 60 minutes via automated device (perfusor), followed by a 30-minute i.v. infusion of doxorubicin (Dose escalation: from 20 up to 25 mg/m2) on Days 1, 8, 15 29, 36 and 43.
Patients with objective tumor responses or stable disease will receive repeated cycles of treatment starting on Day 56. Patients will receive additional cycles of combination therapy for a maximum of 6 months, or until disease progression, unacceptable toxicity or withdrawal of consent."
1874909|NCT01131377|Drug|acetazolamide|"If ABGA is pH ≥ 7.43 & HCO3- ≥ 26mEq/L at 7am, they will receive acetazolamide 500mg via IV q 24h.
If ABGA is pH ≤ 7.35 at 7am, acetazolamide will skip."
1874910|NCT01131377|Drug|Saline|They will receive saline 50ml via IV q 24h.
1874911|NCT01131390|Device|Ventilator setting changes|Ventilator settings will be changed every 3 minutes as described above, simultaneously measuring respiratory mechanics and patients' comfort.
1874912|NCT01131416|Behavioral|Gum chewing|Gum chewing (30 minutes in duration each time, 4 times/days at the usual time of meal, until the first flatus) in addition to conventional postoperative feeding schedule
1874913|NCT01131429|Drug|Erlotinib|Erlotinib 150 mg/d per os until proven disease progression
1874914|NCT01131429|Drug|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks as second-line treatment
1874915|NCT01131429|Drug|Cisplatin|cisplatin 75mg/ m2 iv day 1 every 3 weeks as second-line treatment
1874916|NCT01131429|Drug|Docetaxel|Docetaxel 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
1874917|NCT01131429|Drug|Cisplatin|Cisplatin 75mg/m2 iv day 1 every 3 weeks for 6 cycles at most
1874918|NCT01131429|Drug|Erlotinib|Erlotinib 150 mg/d per os as second-line treatment
1874919|NCT01131455|Biological|Autologous Concentrated Plasma|Autologous blood products have created a growing interest for use in a number of orthopedic therapies. The healing effects of plasma are supported by growth factors released by platelets. These growth factors induce a healing process wherever they are applied. The Arthrex ACP System is a cost-effective method of concentrating growth factors for therapeutic use.
1874920|NCT01131468|Drug|N-acetylcysteine|N-acetylcysteine 600 mg twice daily or vancomycine+amikacin alone
1874921|NCT01131481|Device|Intraocular lens|
1874965|NCT01138605|Drug|Darunavir|Oral suspension 100 mg/ml, 20 mg/kg twice daily in combination with ritonavir for body weight between 10 and 20 kg
1874966|NCT01138605|Drug|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
1874922|NCT01131494|Other|Motor exercises for swallowing, breathing and phonation|This exercises aimed to increase strength and range of motion of mouth, larynx and pharynx structures. All patients made sustained vowel phonation of /a/, pushing plosive phonemes /pa/, /ta/, /ka/ in a forceful manner, suction of wet gauze, swallowing with tongue hold and modified supraglottic maneuver, in ten repetitions, ascending and descending gliding phonation of vowel /a/ and /u/, five repetitions of each vowel, and tongue rotation in oral vestibule, 3 series of 5 repetitions to each side. Patients underwent oral motor exercises twice a day, five days a week, for five weeks.
1874923|NCT01131507|Drug|EUR-1008 (APT-1008)|EUR-1008 (APT-1008) (Zenpep® [pancrelipase] 3,000 lipase units delayed release capsules) from open capsules mixed with a small amount of apple juice or apple sauce will be administered orally starting at the same dose as administered at the end of study PR-011 (NCT01100606), with dose increments of 3,000 lipase units. The dose will be adjusted based on participants' age and body weight. Total dose will not exceed 10,000 lipase units per kilogram (kg) of body weight per day unless clinically indicated. Total duration of study treatment will be up to 12 months.
1874924|NCT01131520|Behavioral|Computerized brief intervention|This is a brief computerized intervention focused on drug use of patients receiving primary care treatment in an outpatient setting. The intervention is delivered in one session.
1874925|NCT01131520|Behavioral|Counselor delivered brief intervention|This is a one session brief intervention delivered in a primary care setting that is based on motivational interviewing.
1874926|NCT01131533|Procedure|Vitrectomy|vitrectomy following intravitreal erythropoietin
1874927|NCT01131546|Drug|Levamlodipine besylate|Once daily, 7AM - 10AM
1874928|NCT01131546|Drug|Amlodipine maleate|Once daily, 7AM - 10AM
1874929|NCT01131559|Drug|Lisdexamfetamine|Oral; 20-70mg/day
1874930|NCT01131559|Drug|Placebo control|Oral; 20-70mg/day
1874932|NCT01131585|Procedure|Active laser photocoagulation|Active laser photocoagulation procedure at baseline and reapplied if needed at intervals no shorter than 3 months from the last treatment.
1874933|NCT01131585|Drug|Sham injections|Sham intravitreal injections at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
1874934|NCT01131585|Drug|Ranibizumab 0.5 mg|Ranibizumab 0.5 mg/0.05 ml intravitreal injection at baseline, 30, 60 and 90 days and if needed, reapplied at intervals no shorter than 28 days from last treatment.
1874935|NCT01131611|Behavioral|CBPT|Cognitive-Behavioral Based Physical Therapy
1874936|NCT01131611|Other|Control-Attention|Standard of Care + weekly phone calls
1874937|NCT01131624|Drug|ferrous sulphate|200 mg iron per day in a convenient dosage schedule.
1874938|NCT01131624|Drug|Ferinject|1000-1500mg diluted only in sterile 0.9% sodium chloride, The maximum single dose of FCM that can be administered by intravenous infusion is 20 mL (1,000 mg iron) but should not exceed 15 mg of iron per kg of body weight. This means that for subjects with a bw below 66 kg a maximal dose of 500 mg iron per infusion is allowed.
1874939|NCT01131637|Drug|rhNRG-1|day1~day10:0.6ug/kg/day,10hours per day for vein infusion; week3~week25:0.8ug/kg/day,10minutes per time per week for vein injection
1874940|NCT01131637|Drug|placebo|day1~day10:0.6ug/kg/day,10hours per day for vein infusion; week3~week25:0.8ug/kg/day,10minutes per time per week for vein injection
1874941|NCT01131676|Drug|BI 10773 low dose|BI 10773 tablets once daily
1874942|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
1874943|NCT01131676|Drug|BI 10773 high dose|BI 10773 tablets once daily
1874944|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
1874945|NCT01131676|Drug|Placebo BI 10773 low dose|Placebo tablets identical to BI 10773
1874946|NCT01131676|Drug|Placebo BI 10773 high dose|Placebo tablets identical to BI 10773
1874947|NCT01131689|Drug|sorafenib, TS-1|D1-14 S-1 dose of level 1/2/3/4 D1-21 Sorafenib 400mg twice daily Every 3 weeks-cycle
1874948|NCT01131702|Drug|Ranitidine|Ranitidine Tablets, 300 mg
1874949|NCT01138475|Drug|Paricalcitol|1 microgram by mouth daily for 6 weeks
1874950|NCT01138475|Drug|Cholecalciferol|5000 IU (international units) by mouth daily for 6 weeks
1874951|NCT01138475|Drug|Placebo|Inactive substance, one capsule daily for 6 weeks
1874952|NCT01138488|Drug|insulin degludec/insulin aspart|Insulin degludec/insulin aspart administered as a single subcutaneous injection (under the skin).
1874953|NCT01138501|Drug|turoctocog alfa|Subjects will be treated 3 times per week or every second day with intravenous injections of turoctocog alfa. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
1874954|NCT01138501|Drug|turoctocog alfa|Subjects will undergo half-life evaluation of their current factor VIII product and pharmacokinetic session with turoctocog alfa before entering preventive treatment (subjects with available evaluation of terminal half-life within the last year are to be excluded from receiving factor VIII). Intravenous injections. The dose range for preventive treatment is 25-60 IU/kg body weight depending on treatment regimen.
1874955|NCT01138514|Drug|Clindamycin 1% / Benzoyl Peroxide 5% (Perrigo)|Applied to the entire face twice daily for 10 weeks
1874956|NCT01138514|Drug|Clindamycin 1% / Benzoyl Peroxide 5% (Benzaclin)|Applied to the entire face twice daily for 10 weeks
1874957|NCT01138514|Drug|Placebo|Placebo
1874958|NCT01138527|Other|MRI examination|45-minute MRI examination of the prostate and surrounding tissues with T2-weighted MRI, diffusion-weighted MRI, Spectroscopic Imaging and dynamic contrast enhanced imaging
1874959|NCT01138540|Other|lateral-Trendelenburg position|lateral-Trendelenburg position of patients laying in the bed of the ICU, keeping trachea and tracheal tube horizontal, compared to the standard treatment (semirecumbent position) for the prevention of VAP
1874960|NCT01138553|Drug|Mifepristone|200mg capsules daily for 5-28 days
1874961|NCT01138579|Drug|FBTA05|
1874962|NCT01138605|Drug|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
1874963|NCT01138605|Drug|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
1874964|NCT01138605|Drug|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
1875164|NCT01140204|Device|Implantation of a bare metal stent|Bare Metal Stent
1874967|NCT01138605|Drug|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
1874968|NCT01138605|Drug|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
1874969|NCT01138605|Drug|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
1874970|NCT01138605|Drug|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
1874971|NCT01138605|Drug|Darunavir|375 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 20 and 30 kg
1874972|NCT01138605|Drug|Ritonavir|Liquid formulation, 80 mg/ml, taken in combination with Darunavir
1874973|NCT01138605|Drug|Darunavir|450 mg composed via oral solution or various tablets, twice daily in combination with ritonavir for body weight between 30 and 40 kg
1874974|NCT01138605|Drug|Darunavir|600mg composed via oral solution or various tablets, twice daily in combination with ritonavir, for body weight as of 40 kg
1874975|NCT01138605|Drug|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
1874976|NCT01138605|Drug|Ritonavir|Ritonavir powder for oral suspension 10 mg/mL taken in combination with Darunavir.
1874977|NCT01138618|Device|Venous blod sample|Regular venous blood sample withdrawn from the laboratory
1874978|NCT01138618|Device|CHEMPAQ|Capillary blood sample analyzed by CHEMPAQ
1874979|NCT01138631|Device|Embryoscope|The embryoscope is an incubator with in-built photographic equipment
1874980|NCT01138657|Biological|Adalimumab|Administered subcutaneously as an 80 mg loading dose (2 syringes) at Baseline followed by a 40 mg dose eow starting at Week 1.
1874981|NCT01138657|Drug|Prednisone|Administered orally, 60 mg/day at study entry followed by a protocol-defined mandatory taper schedule in which all participants continuing in the study were to discontinue prednisone no later than Week 15.
1874982|NCT01138657|Drug|Placebo|Administered by subcutaneous injection
1874983|NCT01138683|Procedure|ultrafiltration|Ultrafiltration through double lumen catheter, via central vein (Vena jugularis interna or Vena femoralis, 11 French, 15 cm for right jugular or 20 cm for femoralis and jugularis left-position). Based on severity of fluid overload the cardiologist determines the ultrafiltration rate. 'Multifiltrate Fresenius' (extracorporeal blood volume 72ml) in SCUF (slow continuous ultrafiltration) modus with pediatric lines (54 ml extracorporeal volume in the AV-set) and a pediatric filter (Ultraflux® AV paed, blood volume 18ml). Heparin to maintain an APTT between 65 en 85 seconds during ultrafiltration.
1874984|NCT01138683|Drug|diuretics|Bumetanide continuous infusion to reach a prescribed negative fluid balance: dose adjustment according to the diuretic response.
1874985|NCT01138696|Other|Questionnaires|KOOS, IKDC, SF-36, Lysholm, Tegner, VAS),
1874986|NCT01138696|Other|RX|X-rays and clinical investigation of the knee 20 years after surgery
1874987|NCT01138709|Device|Vitala|Vitala™ Continence Control Device
1874988|NCT01138722|Radiation|hypofractionated radiation therapy followed by surgery|hypofractionated radiation therapy followed by surgery
1874989|NCT01138735|Drug|adapalene/benzoyl peroxide|daily topical application for 12 weeks
1874990|NCT01138735|Drug|Topical Gel Vehicle|daily topical application for 12 weeks
1874991|NCT01138748|Radiation|hypofractionated radiation therapy|hypofractionated radiation therapy
1874992|NCT01138761|Behavioral|Nurse instruction|"The dermatology nurse will give additional verbal and written instruction utilizing teach-back about skin care precautions and medication usage to the caregivers/parents in the treatment group."
1874993|NCT01138774|Dietary Supplement|Double blind dietary intervention with EPA and lipoic acid|Placebo-controlled dietary intervention during 10 weeks. All groups will have a dietary treatment with a calorie restriction of 30 % the subject's energy expenditure at baseline, supplemented with eicosapentaenoic acid (EPA) and/or lipoic acid (LA).
1874994|NCT01138787|Dietary Supplement|Reference spread|Single dose (30 gr) of spread, containing 2250 mg PS
1874995|NCT01138787|Dietary Supplement|Placebo spread|Single dose (30 gr) of regular light margarine
1874996|NCT01138787|Dietary Supplement|Test spread|Single dose (30 gr) of innovatively processed spread containing 2250 mg PS.
1874997|NCT01138826|Drug|Amlodipine - reference|10 mg tablet, single dose, with water
1874998|NCT01138826|Drug|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, with water
1874999|NCT01138826|Drug|Amlodipine ODT - test|10 mg orally disintegrating tablet (ODT), single dose, without water
1875000|NCT01138839|Drug|Dexamethasone|Pregnant women in the experimental group will receive 10-mg doses (2.5 cc) of dexamethasone sodium phosphate intravenously every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 10-mg doses after delivery.
1875001|NCT01138839|Drug|sterile water|Pregnant women will receive 2.5 cc of sterile water every 12 hours until delivery and 3 additional doses after delivery. Puerperal women will receive 3 doses after delivery
1875004|NCT01138865|Device|AutoSet Spirit--Wash--Modified-AutoSet Spirit|3 months of therapeutic CPAP (auto-titrating CPAP) followed by 3 months of non-therapeutic sham-CPAP with 1 month of wash-out in between
1875005|NCT01138865|Device|Modified-AutoSet Spirit--Wash-AutoSet Spirit|3 months of non-therapeutic sham-CPAP followed by 3 months of therapeutic CPAP (auto-titrating CPAP) with 1 month of wash-out in between
1875006|NCT01138878|Other|Questionnaire|Administration of written questionnaire to assess attitudes towards the introduction of routine HIV testing programmes to that healthcare setting
1875007|NCT01138878|Other|Focus Group Discussion|FGD to explore attitudes within each group towards the introduction of routine HIV screening programmes in each medical setting
1875008|NCT01138878|Other|HIV test (serum or salivary)|An HIV test offered to all 16-65 year olds (not known already to be HIV-positive) accessing the healthcare setting during the twelve week pilot period
1875314|NCT01134601|Drug|Capecitabine|
1875009|NCT01138878|Other|Semi-structured telephone interview|Telephone interview administered to patients offered an HIV test during the pilot period
1875010|NCT01138904|Drug|irinotecan, oxaliplatin|"OXIR: FOLFOX -> FOLFIRI
IROX: FOLFIRI -> FOLFOX
FOLFOX REGIMEN
D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
Every 2 weeks
FOLFILI REGIMEN
D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
Every 2 weeks"
1875011|NCT01138904|Drug|oxaliplatin, irinotecan|"FOLFOX REGIMEN
D1 Oxaliplatin 85mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
Every 2 weeks
FOLFILI REGIMEN
D1 Irinotecan 150mg/m2 + 5DW 500ml MIV over 120min D1,D2 Leucovorin 50mg IV Push D1,D2 5-Fluorouracil 400mg/m2 IV Push D1,D2 5-Fluorouracil 600mg/m2 + 5DW 1000ml MIV over 22hr
Every 2 weeks"
1875012|NCT01138930|Drug|Berberine|1.5g daily for 3 month
1875013|NCT01138930|Drug|Placebo|placebo daily
1875014|NCT01138943|Drug|Synthodont|"15 ml, tree times/day for 07 days
Arm: Chlorhexidine alcohol-base mouthrinse"
1875015|NCT01138943|Drug|Soludent|"15ml of 01% Chlorhexidine non alcohol-based, 3 times a day for 7 days
Arm: Experimental: non alcohol chlorhexidine mouthrinse"
1875016|NCT01138956|Drug|N-acetylcysteine|N-acetylcysteine (NAC), effervescent tablets of 600mg, tid, po, 28 days
1875017|NCT01138956|Drug|Pentavalent antimonial|Pentavalent antimonial, 20mg/kg/day, 28 days, IV
1875018|NCT01138969|Drug|esomeprazole|esomeprazole 20 mg qd for 6 months
1875019|NCT01138982|Behavioral|Youth Mentoring program|
1875020|NCT01138995|Device|Ness L300|The Ness L300 delivers functional electrical stimulation (FES), which improves gait function, stroke-specific quality of life, functionality, and safety for persons with stroke.
1875021|NCT01138995|Device|Ankle-foot orthosis|"The Control Group will walk with a usual ankle-foot orthosis (AFO)."
1875022|NCT01139008|Drug|metronidazole 1% gel|Apply topically on one side of the face once daily for three weeks
1875023|NCT01139008|Drug|azelaic acid 15% gel|Apply topically on the opposite side of the face twice daily for three weeks
1875024|NCT01139021|Biological|rMenB+OMV NZ|Subjects will be assigned to a study group based on the group assignment in the parent study (follow-on subjects). In addition, one group of naïve age-matched subjects will be recruited at the same study sites. Subjects who had received 4 doses of rMenB+OMV NZ will have one visit including one blood draw. Subjects who had received two catch-up doses in V72P13E1 will receive a third dose boost and will have 3 blood samples drawn. Naïve subjects will receive two catch-up doses and have 3 blood samples drawn.
1875025|NCT01139034|Device|Self-designed surface functional electrical stimulator|Use the self-designed surface functional electrical stimulator to improve the shoulder joint subluxation.
1875026|NCT01139047|Drug|metronidazole 1% gel|Apply topically once daily on one side of the face for three weeks
1875027|NCT01139047|Drug|azelaic acid 15% gel|Apply topically twice daily on the opposite side of the face for three weeks
1875029|NCT01139099|Behavioral|Group Psychotherapy|integrated group psychotherapy, including the interpersonal and cognitive group therapy
1875030|NCT01139125|Drug|(Cystagon) Cysteamine Bitartrate|Cysteamine Bitartrate 300mg/day to 2100mg/day over a 4 month period. Number of cycles: until progression or unacceptable toxicity develops.
1875031|NCT01139138|Drug|Panitumumab|Panitumumab 6mg/kg IV every 14 days
1875032|NCT01139138|Drug|Irinotecan|Irinotecan 200mg/m2 IV every 14 days
1875033|NCT01139138|Drug|Everolimus|Everolimus daily po (dosage varies with cohort)
1875034|NCT01139151|Drug|3 Day Thiarabine|Starting dose 70 mg/m^2 IV over 1 hour (±15 minutes) daily x 3
1875035|NCT01139151|Drug|5 Day Thiarabine|Starting dose 40 mg/m2 IV over 1 hour (±15 minutes) daily x 5
1875036|NCT01139164|Drug|Regimen A|Chronic Lymphocytic Leukemia/ Chronic Prolymphocytic Leukemia, Multiple Myeloma.
1875037|NCT01139164|Drug|Regimen B|Other malignancies not addressed in A or C
1875038|NCT01139164|Drug|Regimen C|B-Cell Lymphomas
1875039|NCT01139177|Device|Stenting of atherosclerotic lesion(s)|Stenting of atherosclerotic lesions post pre-dilatation of lesion(s)
1875040|NCT01139190|Drug|PL3100|Oral administration
1875041|NCT01139190|Drug|Naproxen|Oral administration
1875042|NCT01139203|Drug|lamivudine adefovir entecavir HBIG|lamivudine 100mg orally daily adefovir 10mg orally daily entecavir 0.5mg orally daily HBIG 2000 unit intravenously during the anhepatic phase,and followed 800 unit intramuscularly daily until day 14,then 400 unit intramuscularly twice weekly
1875043|NCT01139216|Drug|Daikenchuto (TU-100)|Subjects will receive 2.5g TID (7.5g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
1875044|NCT01139216|Drug|Daikenchuto (TU-100)|Subjects will receive 5g TID (15g/day) of TU-100. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
1875045|NCT01139216|Drug|Placebo|Subjects will receive daily dose of TU-100 placebo. Dosage form is granule. Subject will take a daily dose divided 3 times per day for 4 weeks.
1875046|NCT01139229|Other|hybrid everted esophagogastric anastomosis|
1875047|NCT01139229|Other|the conventional hand-sewn anastomosis|
1875048|NCT01139229|Other|a stapled anastomosis|
1875049|NCT01139242|Behavioral|Body & Soul nutritional intervention|Pastoral and peer counseling, and church activities/menus to promote increased fruit and vegetable consumption among church members.
1875050|NCT01139242|Behavioral|Experimental: newsletters and peer counseling|Four tailored newsletters and peer counseling calls to promote CRC screening in church members who are out-of-date with screening. Four tailored newsletters and peer counseling calls to others to increase physical activity.
1875051|NCT01139255|Behavioral|Podcasting + mobile media|Use of a weight loss podcast designed with health behavior theory
1875095|NCT01139671|Drug|Remifentanil|"Wisdom teeth removal under general anaesthesia is usually suitable for ambulatory surgery.
The choice of opioid in dental day surgery is based on the need for a rapid and full recovery, as well as less morphine administration. Whether remifentanil can achieve these goals remains to be proved, especially regarding remifentanil-induced hyperalgesia, the potential prolonged Post Anesthesia Care Unit (PACU) stay, or remifentanil-induced workload for nurses."
1875052|NCT01139281|Drug|Ginkgo Biloba Extract (GBE761)|The subjects were randomized and allocated in two groups: Control Group(CG) and Study Group(SG). the study group received GBE761(120mg twice a day) plus cisplatin and was guided to ingest GBE761 just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
1875053|NCT01139281|Drug|Placebo|The subjects were randomized and allocated in two groups: control group and study group. The control group received placebo plus cisplatin and was guided to ingest Placebo just before initial cisplatin dosage. The maximum cumulative cisplatin dosage was 300mg/m². They were followed up for ninety days. Comparisons were made between baseline distortion-product otoacoustic emissions measurements and those DPOAE records after maximum cumulative cisplatin dosage.
1875054|NCT01139294|Drug|Hylenex|1ml sub-q with initiation of IVF's then every 24 hrs with a max dose of 3 inj. in 72 hours
1875055|NCT01139307|Other|cell culture procedure|
1875056|NCT01139307|Other|laboratory biomarker analysis|
1875057|NCT01139320|Genetic|DNA analysis|
1875058|NCT01139320|Genetic|polymerase chain reaction|
1875059|NCT01139320|Other|laboratory biomarker analysis|
1875060|NCT01139320|Other|pharmacological study|
1875061|NCT01139333|Genetic|gene expression analysis|
1875062|NCT01139333|Genetic|western blotting|
1875063|NCT01139333|Other|flow cytometry|
1875064|NCT01139333|Other|laboratory biomarker analysis|
1875065|NCT01139346|Drug|darinaparsin|dose escalating, starting at 200 mg twice per day for 21 days continuous followed by a 7 day rest per cycle.
1875066|NCT01139359|Drug|darinaparsin|I.V. darinaparsin given in a dose escalation manner, once a day for 5 days per cycle.
1875067|NCT01139359|Drug|CHOP|Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle; Doxorubicin 50 mg/m2 IV Day 8 of each Cycle; Vincristine 1.4 mg/m2 IV Day 8 of each Cycle; Prednisone 100 mg oral Days 8-12 of each Cycle.
1875068|NCT01139372|Other|FID 115958D (Lubricant Eye Drop)|1 drop in each eye at least twice daily
1875069|NCT01139385|Procedure|Harmonic scalpel|The Cholecystectomy is performed using only Harmonic Scalpel to mobilize the Cholecystis and to close the cystic duct and the cystic artery
1875070|NCT01139385|Procedure|Traditional|The cholecystectomy is performed using Harmonic Scalpel to mobilize the cholecystis and the cystic duct and the cystic artery are closed by titanium clips
1875071|NCT01139398|Dietary Supplement|Limicol (plant extract)|Artichoke extract, anti-caking agents: dicalcium phosphate, calcium citrate, vegetable magnesium stearate, red yeast rice, microcrystalline cellulose, natural vitamin E, garlic extract, sugar cane policosanols, inositol hexanicotinate, vitamin B3, vitamin B2.
1875072|NCT01139411|Behavioral|Behavioral Weight Control with Enhanced Parent Involvement|
1875073|NCT01139411|Behavioral|Behavioral Weight Control with Minimal Parent Involvement|
1875074|NCT01139424|Device|endoscopic suturing|endoscopic suturing of the anastomotic leak
1875075|NCT01139437|Biological|Standard Dose HPIV2 Vaccine|10^6 tissue culture infectious dose 50% (TCID50) administered intranasally in a single dose
1875076|NCT01139437|Biological|Low dose HPIV2 vaccine|10^5 TCID50 administered in a single dose
1875077|NCT01139437|Other|Placebo|Matched placebo
1875078|NCT01139450|Drug|0417|Topical 0417 test product applied twice daily for 4 weeks
1875079|NCT01139450|Drug|Vehicle of 0417 test product|Vehicle of 0417 test product applied twice daily for 4 weeks
1875080|NCT01139450|Drug|Tacrolimus Ointment 0.03%|Reference product for 0417 test product. Apply twice daily for 4 weeks
1875081|NCT01139463|Drug|Haloperidol or olanzapine|Haloperidol tablet - 5 mg twice daily (morning and evening) by mouth Olanzapine tablet - 5 mg twice daily (morning and evening) by mouth
1875082|NCT01139489|Other|procalcitonin-guidance|If procalcitonin levels decrease to predefined levels, antibiotic therapy will be discontinued.
1875083|NCT01139502|Behavioral|Work rehabilitation based on the cognitive therapeutical model|Work rehabilitation including two weekly meetings in which participant and work consultant discuss problems interfering with work and social interaction. Home work related to these problems is assigned between the meetings.
1875084|NCT01139502|Behavioral|Work rehabilitation with the addition of cognitive training|Work rehabilitation with the addition of two hours weekly training of concentration, memory, and executive function
1875085|NCT01139515|Drug|Eletriptan commercial tablet|20 mg tablet, single dose
1875086|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, single dose of 1 X 40 mg
1875087|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, single dose of 2 X 40 mg
1875088|NCT01139515|Drug|Eletriptan commercial tablet|40 mg tablet, 1 X 40 mg given two times: the second 2 hours after the first
1875089|NCT01139528|Procedure|Bouquet pinning of the 5th metacarpal bone|The fracture is reduced under general anesthesia and 2-3 K-pins are introduced in the medullar cavity to keep the fracture in the reduced position
1875090|NCT01139541|Behavioral|Social walking intervention|In this intervention, we are interested in the impact of group dynamics on the propensity to use the Walkstations. The intervention consists of 4 levels: control, individual, pair, and group.
1875091|NCT01139580|Drug|Calcipotriene Foam|Calcipotriene Foam 0.005%. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
1875092|NCT01139580|Drug|Vehicle Foam|Vehicle Foam. All treatments will be administered to the skin twice daily (am-pm) for 8 weeks for subjects in this group
1875093|NCT01139606|Other|Vibration resistance training|adding vibration to a standard resistance training with free-weights and checking the effect on muscle strength development and everyday functioning of upper limbs in untrained adults.
1875094|NCT01139645|Drug|Rabeprazole or Esomeprazole or Lanzoprazole|1/3 of the patients are taking Pariet (Rabeprazole) 20 mg once daily 1/3 of the patients are taking Nexium (Esomeprazole) 40 mg once daily 1/3 of the patients are taking Lanzor (Lanzoprazole) 30 mg once daily
1875096|NCT01139684|Behavioral|Repeated sprint test|
1875097|NCT01139697|Other|Hair sampling|Hair sampling for the measurement of cortisol and testosterone
1875098|NCT01139723|Drug|MINT1526A|Intravenous escalating dose
1875099|NCT01139723|Drug|bevacizumab|Intravenous repeating dose
1875315|NCT01134601|Drug|AZD6244|
1875100|NCT01139736|Dietary Supplement|VSL#3|IBS Patients will receive VSL#3 (450 billion lyophilized bacteria/sachet) twice daily for 4 weeks
1875101|NCT01139749|Drug|oral isotretinoin|capsules of 20 mg a day, every other day, for six months
1875102|NCT01139749|Drug|salicylic acid and ciclopirox olamine|Topical salicylic acid and ciclopirox olamine shampoo for scalp and face cleansing, every other day, for six months
1875103|NCT01139762|Drug|Tadalafil|5 milligrams (mg) administered orally, once daily for 26 weeks
1875104|NCT01139762|Drug|Placebo|Administered orally, once daily for 26 weeks
1875105|NCT01139762|Drug|Finasteride|5mg administered orally, once daily for 26 weeks
1875106|NCT01139775|Drug|Pemetrexed|Administered intravenously
1875107|NCT01139775|Drug|Cisplatin|Administered intravenously
1875108|NCT01139775|Drug|LY2603618|Administered intravenously
1875109|NCT01139788|Drug|LY2624587|"6-900 mg, administered intravenously, weekly for a minimum of one (1) 28 day cycle.
If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)."
1875110|NCT01139801|Drug|Oxytocin|Foley balloon placement with intravenous low dose oxytocin administration
1875111|NCT01139801|Drug|Misoprostol|Misoprostol, 25 mcg, is placed intravaginally into the posterior fornix of the vagina in conjunction with Foley balloon placement
1875112|NCT01139814|Device|Amigo catheter robot|The Amigo Catheter System is intended to facilitate manipulation, positioning and control of a Diagnostic Catheter.
1875113|NCT01139840|Dietary Supplement|vitamin D2|Study Supplement
1875114|NCT01139840|Dietary Supplement|vitamin D3|Study Supplement
1875115|NCT01139853|Device|Nasogastric Tube|Insertion of a 10 French Nasogastric tube prior to surgery
1875116|NCT01139879|Device|P400 mattress|The P400 mattress will be placed for a period of 12 weeks.
1875117|NCT01139892|Procedure|Surgical management|
1875118|NCT01139892|Procedure|Endovascular management|
1875119|NCT01139905|Other|lopinavir/ritonavir|standard dose of lopinavir/ritonavir 100/25 mg tablet q 12 hour.
1875120|NCT01139931|Genetic|DNA methylation analysis|
1875121|NCT01139931|Genetic|gene expression analysis|
1875122|NCT01139931|Genetic|microarray analysis|
1875123|NCT01139931|Genetic|polymorphism analysis|
1875124|NCT01139931|Other|laboratory biomarker analysis|
1875125|NCT01139944|Genetic|DNA methylation analysis|
1875126|NCT01139944|Genetic|polymerase chain reaction|
1875127|NCT01139944|Other|laboratory biomarker analysis|
1875128|NCT01139957|Procedure|Evaluation of Cancer Risk Factors|Ancillary studies
1875129|NCT01139957|Other|Quality-of-Life Assessment|Ancillary studies
1875130|NCT01139957|Other|Questionnaire Administration|Ancillary studies
1875131|NCT01139957|Procedure|Study of High Risk Factors|Ancillary studies
1875136|NCT01139983|Genetic|DNA analysis|
1875137|NCT01139983|Genetic|RNA analysis|
1875138|NCT01139983|Genetic|fluorescence in situ hybridization|
1875139|NCT01139983|Genetic|microarray analysis|
1875140|NCT01139983|Genetic|polymerase chain reaction|
1875141|NCT01139983|Genetic|reverse transcriptase-polymerase chain reaction|
1875142|NCT01139983|Other|laboratory biomarker analysis|
1875143|NCT01139996|Drug|Clonidine|An oral loading dose of Clonidine 0.3 mg and placement of Clonidine Transdermal system at a dose of 0.3-mg/day (Catapres TTS-3), with patch overlay, followed by a final dose of Clonidine 0.3mg after 12 hours
1875144|NCT01139996|Drug|Placebo|A placebo oral tablet and the overlay patch only and in 12 hours they will receive a second and final tablet
1875145|NCT01140009|Biological|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
1875146|NCT01140009|Biological|Fluviral 2010/11 Tri-valent Seasonal Influenza vaccine|Vaccination of .05mL of Fluviral vaccine will be injected once at either visit 1 or 2 depending upon randomization in the deltoid muscle of the non-dominant arm
1875147|NCT01140022|Other|CT Screening|Patients will use a kiosk module that will provide information about CT screening and assess their risk for CT. Patients choosing to get a CT screening will receive a printout instructing the provider or nurse to collect a urine sample for CT screening.
1875148|NCT01140035|Other|Administration of continuous insulin infusion for glycemic control in brain dead donors|As per protocol
1875149|NCT01140061|Drug|MK-0873 Patch|MK-0873 skin patches containing 0.05%. 0.5%, or 2% MK-0873
1875150|NCT01140061|Drug|MK-0873 Cream|MK-0873 cream containing 0.05%, 0.5%, or 2% MK-0873
1875151|NCT01140061|Drug|Placebo Patch|Placebo patches matching MK-0873 0.05%, 0.5%, or 2% patches
1875152|NCT01140061|Drug|Placebo Cream|Placebo cream matching MK-0873 0.05%, 0.5%, or 2%
1875153|NCT01140061|Drug|Plain patch|Plain patch containing no MK-0873 or placebo
1875154|NCT01140074|Drug|Zinc Sulfate|Zinc Sulfate in sugar sirup will be given orally in dosis of 10-20 mg per day for 10 days
1875155|NCT01140087|Procedure|Face Transplant|Transplantation of donor facial skin, tissue, muscle, and bone as needed
1875156|NCT01140100|Drug|propofol|
1875157|NCT01140100|Drug|thiopental,propofol|
1875158|NCT01140113|Procedure|Modified Ultrafiltration|After weaning from bypass patients had undergone to modified ultrafiltration for 15 minutes with a filtration flow at 300 ml/min
1875159|NCT01140126|Drug|Antibody UB-421|Single intravenous infusion at day 0 of a liquid dose of 1, 5, 10 or 25 mg/kg body weight.
1875160|NCT01140139|Biological|HIV DNA Vaccine|0.4 mg of DNA plasmids encoding HIV env A, B, C and Rev B, gag A, B and RT mut formulated in PEI and glucose was applied topically with the DermaPrep procedure six times during cycles of 7 weeks of active HAART. Every immunization cycle was followed by four weeks of therapy interruption.
1875161|NCT01140165|Other|cheese|the effect of cheese intake versus butter intake on blood lipids (primarily)
1875162|NCT01140178|Drug|HPPH|Given IV
1875165|NCT01140217|Drug|Norethindrone Acetate|Norethindrone Acetate Transdermal Delivery System
1875166|NCT01140243|Dietary Supplement|LCPUFA|premature infant formula supplemented with LCPUFA
1875167|NCT01140269|Other|PCR test|PCR samples will test for Staphylococcus aureus (including MRSA) from wound swab and positive blood culture samples to augment treatment decisions. Serial PCR testing will follow after positive results to catalog pathogen loads over the course of treatment in a blinded fashion.
1875168|NCT01140282|Other|questionnaire administration|Administered within 3 days of baseline testing and at post-trial visit
1875169|NCT01140282|Procedure|quality-of-life assessment|Administered within 3 days of baseline testing and at post-trial visit
1875170|NCT01140282|Procedure|management of therapy complications|Assessed within 3 days of baseline testing and at post-trial visit
1875171|NCT01140282|Behavioral|exercise intervention|12 week exercise intervention
1875172|NCT01140295|Drug|polyethylene glycol, senna|"Senna dosage: Age 6-12 years: 3 teaspoons or 3 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. Age >12 years: 6 teaspoons or 6 tablets by mouth 2 nights before endoscopy and 1 night before endoscopy. A Fleet's rectal enema is administered on the morning of the procedure.
Miralax at a dose of 1.5 grams/kg divided twice a day for two days; maximum of 51 grams per dose. Dissolve each 17 grams (1 capful) PEG-P in 240 mL water or other beverage according to the manufacturer's direction and to give the appropriate amount of PEG solution twice a day for two days."
1875173|NCT01140308|Drug|CoEnzyme Q10|Randomization to Treatment: Simvastatin 20mg + 600 mg CoQ10 (pill) Load Subjects for 2 weeks on Treatment (CoQ10) Eight weeks of Treatment
1875174|NCT01140308|Drug|Placebo|Randomization to Treatment: Simvastatin 20mg + Placebo 600mg Load Subjects for 2 weeks on Treatment Eight weeks of treatment
1875175|NCT01140321|Drug|Neridronate|"Neridronate is an aminobisphosfonate of third generation that has been proved in several clinical trials to have the ability to inhibit osteoclast-mediated bone resorption and it is generally well tollerated also at high doses. Thanks to these properties it has been used in the treatment of several bone disorders such as Paget's disease and Osteogenesis Imperfecta. Neridronate, given intravenously or orally (tablets), reduces both the levels of bone alcaline phosphatase and of the other markers of bone resorption activity. Recently it has been approved by the Italian Ministry of Health for the commercialization with the indication Osteogenesis Imperfecta."
1875176|NCT01140334|Behavioral|Voucher Reinforcement|Patients in this condition will be able to earn a voucher for each week that they have attended all scheduled psychiatric sessions. These sessions may include individual therapy appointments, group therapy appointments, or psychiatrist appointments. Each voucher will be worth $25, and can be exchanged for goods and services that will be purchased by a research assistant. The maximum amount of voucher earnings over the study is $300.
1875177|NCT01140334|Behavioral|Standard Control|Patients assigned to this condition will be treated at ATS for psychological problems. They will be scheduled to participate in individual therapy sessions with a psychiatrist and with their substance abuse counselor. They will also be referred to attend group therapy one time per week. No voucher incentive will be offered in this condition.
1875178|NCT01140347|Biological|Placebo|8 mg/kg IV every 2 weeks
1875179|NCT01140347|Biological|Ramucirumab DP (IMC-1121B)|8 milligrams/kilogram (mg/kg) intravenous (IV) every 2 weeks
1875180|NCT01140347|Other|BSC|Palliative and supportive care for disease-related symptoms and toxicity associated with treatment as deemed medically necessary and appropriate in the opinion of the investigator.
1875181|NCT01140360|Drug|Gleevec|Gleevec will be dosed orally with a starting dose of 100 mg twice daily for patients with a BSA > 1.8 m2 or 55 mg/m2 twice daily for patients with BSA < 1.8 m2. For patients with a BSA > 1.8 m2 the dose will increase by increments of 100 mg bid every two weeks as tolerated up to a maximum dose of 400 mg bid. For patients with a BSA < 1.8 m2 the dose will increase by increments of 55 mg/m2 bid every two weeks as tolerated up to a maximum dose of 220 mg/m2 bid.Treatment will continue for 6 months with an option to continue for 24 months if the patient is deriving a clinical benefit.
1875182|NCT01140373|Biological|engineered autologous T cells|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10^7 CAR+ T cells/kg, 3 x 10^7 CAR+ T cells/kg, and 1 x 108 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
1875183|NCT01140373|Drug|cyclophosphamide|Three cohorts of patients each will receive escalating doses of transduced autologous chimeric T lymphocytes at 1 x 10^7 CAR+ T cells/kg, 3 x 10^7 CAR+ T cells/kg, and 1 x 10^8 CAR+ T cells/kg, respectively. One patient will be initially added to the three already enrolled in cohort 1 using a new variant vector expressing the P28z CAR, and up to three patients may be added to each cohort, for a total of up to six each, in the case of Grade 3 toxicity and/or sub-optimal imaging. A 4th cohort of three patients may be added if an anti-PSMA effect is observed either immunologically or radiographically or if there is preferential targeting of the cells at a particular dose level. The dose level of the 4th cohort would be from a previously tested dose level. All patients will receive one dose of cyclophosphamide (Cy) at 300mg/m2 iv one day prior to infusion of T cells.
1875184|NCT01140399|Drug|Furosemide or Furosemide and Dopamine|"Patients randomized to pharmacological treatment receive
either intravenous diuretics at escalating doses up to 20 mg/h
or intravenous diuretics up to 20 mg/h and dopamine infusion at a constant rate of 3 mcg/Kg/m."
1875185|NCT01140399|Device|Ultrafiltration|"All loop diuretics will be discontinued. Rate of fluid removal will be based on the extent of fluid overload as assessed by increase in body weight vs the patient's known dry weight
less than 3 kg 200 ml/h
more than 3 kg and less than 5 kg 300 mlh
more than 5 kg 500 mlh
Criteria for achievement of target UF goals are removal of > 50% and <70% of fluid excess based on the estimated increase in body weight Diuretic infusion is allowed provided that a minimum of 3 hours after the end of the UF session have elapsed, at a maximum cumulative dose of 100 mg furosemide, till start of the next UF session The use of inotropic agents is prohibited"
1875186|NCT01140412|Drug|Maraviroc|maraviroc 300 mg BID x 5 days
1875187|NCT01140412|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
1875188|NCT01140412|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
1875189|NCT01140412|Drug|Maraviroc|maraviroc 300 mg QD x 5 days
1875190|NCT01140412|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
1875191|NCT01140412|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
1875192|NCT01140425|Drug|PF-00232798|600 mg oral solution once daily x 7 days
1875193|NCT01140425|Drug|PF-00232798|300 mg oral solution once daily x 7 days
1875194|NCT01140425|Drug|Placebo|Oral solution once daily x 7 days
1875195|NCT01140425|Drug|Moxifloxacin|400 mg tablet single dose
1875196|NCT01140438|Drug|metformin+ NPH insulin|Metformin 500 mg + 500 mg + 1000 mg NPH insulin , initially 0.20 U/kg body weight.
1875197|NCT01140438|Drug|metformin + sitagliptin +/- repaglinide|Metformin 500 mg + 500 mg + 1000 mg Sitagliptin 100 mg x 1 Repaglinide 1 mg x 3
1875198|NCT01140451|Drug|Ataluren (PTC124)|Oral powder for suspension taken 3 times per day (10 mg/kg with breakfast, 10 mg/kg with lunch, and 20 mg/kg with dinner) for up to 48 weeks.
1875199|NCT01140464|Other|Collaborative care|Provision of depression care management in the primary care setting to improve delivery of evidence based treatments
1875200|NCT01140464|Other|Enhanced Usual Care|Provision of screening results to provider, teen and parent with recommendation to seek further care
1875201|NCT01140477|Device|Toric Accommodating Lens|Toric accommodating lens implanted after cataract extraction
1875202|NCT01140477|Device|Accommodating Lens|Accommodating lens implanted after cataract extraction
1875203|NCT01140490|Procedure|Sub-total Parathyroidectomy|Sub-total Parathyroidectomy
1875204|NCT01140503|Drug|Apremilast|Apremilast 20mg PO BID
1875205|NCT01140516|Drug|Trimethoprim|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
1875206|NCT01140516|Other|Simple Syrup|2mg/kg,orally until febrile UTI occurs or until completion of the study if the patients do not develop any UTI.
1875207|NCT01140529|Drug|Dexmedetomidine|Bolus and continuous infusion
1875208|NCT01140529|Drug|Haloperidol|Bolus doses
1875209|NCT01140529|Drug|Saline|Bolus and continuous infusion
1875210|NCT01140542|Drug|Roflumilast|500µg, once daily
1875211|NCT01140555|Device|GYNECARE GYNOCCLUDE™|GYNECARE GYNOCCLUDE™ Doppler Guided Uterine Artery Occlusion Device
1875212|NCT01140568|Drug|nilotinib|400mg po (orally) BID (twice daily)
1875213|NCT01140581|Drug|DRONEDARONE|Pharmaceutical form: tablet Route of administration: oral Dose regimen: 400 mg
1875214|NCT01140594|Procedure|Photorefractive keratectomy|One eye undergoes wavefront-guided PRK with the Visx S4 CustomVue excimer laser.
1875215|NCT01140594|Procedure|Laser in-situ keratomileusis|One eye undergoes wavefront-guided LASIK using the Visx S4 excimer laser.
1875216|NCT01140607|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution for infusion
Route of administration: intravenous"
1875217|NCT01140620|Drug|ketamine|ketamine infusion to achieve plasma concentrations of 100 ng/mL. Duration approximately 3 hours
1875218|NCT01140620|Drug|risperidone|risperidone (2 mg) capsule. One dosing of 2 mg.
1875219|NCT01140620|Drug|saline|saline infusion. Duration approximately 3 hours
1875220|NCT01140620|Drug|placebo risperidone|placebo capsule to match risperidone 2 mg capsule
1875221|NCT01140646|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given orally
1875222|NCT01140646|Other|questionnaire administration|Ancillary studies
1875223|NCT01140646|Procedure|quality-of-life assessment|Ancillary studies
1875224|NCT01140659|Procedure|Video-assisted sympathectomy|All participants were randomized into two groups of 20 patients (G3 and G4) and underwent video-assisted sympathectomy, being followed for 12 months. During this period, the subjects completed a questionnaire about quality of life and carried out the measurements of sweat by VapoMeter.
1875225|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
1875226|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 3 mg will be given once daily for 14 days.
1875227|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 30 mg will be given once daily for 14 days.
1875228|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 100 mg will be given once daily for 14 days.
1875229|NCT01140672|Drug|PF-04634817|Oral solution of PF-04634817 at 300 mg will be given once daily for 14 days.
1875230|NCT01140672|Drug|PF-04634817|Cohort will only be dosed if necessary. Dose selected for this cohort may be a repeat of a previous cohort or intermediate dose not to exceed 300 mg.
1875231|NCT01140698|Other|Blood sample on Guthrie paper from cord blood, and day 3 of life and before discharge|Mass spectroscopy on the blood sample that are taken as routine for the national inborn errors survey
1875232|NCT01140711|Procedure|fMRI imaging following visual stimulation of food and non-food images|"fMRI Scans will be performed in a 3 tesla MRI scanner. All subjects will be scanned for anatomical imaging without injection of contrast material. These structural images will be used to localize the functional data obtained. Functional test will include several measurements of brain activity while viewing visual stimuli.
fMRI allows collection of information about brain activity with good spatial and temporal resolution. Protocols allow rapid assessment of regional activation in different brain regions during exposure to different visual stimuli.It provides a detailed functional map.
Scan test protocol includes anatomical measurement - 3D FSPGE T1w sequence, Asset DTI and repeated fMRI measurements (based on echo EPI, T2 * w, BOLD sequences). Test paradigms include picture collections of various foods non-food objects similar in size, color and shape."
1875233|NCT01140737|Drug|Axitinib|Patients will take axitinib tablets 5 mg by mouth twice daily continuously. There may be one dose reduction to 3mg twice daily. A four week dosing period will be considered as 1 cycle of treatment. Axitinib treatment will be continued until disease progression, or the development of limiting toxicity.
1875316|NCT01134614|Biological|Ipilimumab|Given IV
1875317|NCT01134614|Other|Laboratory Biomarker Analysis|Correlative studies
1875318|NCT01134614|Biological|Sargramostim|Given SC
1875234|NCT01140763|Device|Sysmex's 5-blade lymph node cutter|"A maximum of 3 dissected sentinel lymph nodes (SLN) per subject will be included in this study. Lymph nodes will be sliced at 1 mm intervals with Sysmex's 5-blade lymph node cutter. Alternate slices will be allocated to either reference histopathology or test histopathology. Three serial sections will be cut every 200 µm (level): the 1st section per level for hematoxylin & eosin (H&E), the middle section of the 3rd level for Immunohistochemistry (IHC)(pan- cytokeratin antibody clone AE1/AE3). All other sections will be blanks in case further analysis is needed."
1875235|NCT01140815|Device|Total Knee Replacement|Smith and Nephew Total Knee Replacement
1875236|NCT01140815|Device|Deuce|Smith and Nephew Bicompartmental Knee Replacement
1875237|NCT01140828|Drug|Rabeprazole|Rabeprazole 20mg once daily
1875238|NCT01140828|Drug|Rabeprazole Placebo|one tab once daily
1875239|NCT01140841|Drug|Fipamezole ODT|Subjects take three daily doses of Fipamezole ODT, with each dose escalating from 30 to 60, 90, 120, 150 and up to 180 mg over 8 weeks.
1875240|NCT01140841|Drug|Placebo|1 to 2 tablets three times per day to be taken according to the same schedule as the active study drug.
1875241|NCT01140854|Procedure|Lumbar spine surgery|(non-experimental) we do not intend to change the criteria of selection for simple lumbar spine surgery, anesthesia, or the postoperative management of the patients studied.
1875242|NCT01140854|Other|Neurologic/neuropsychometric examinations|To measure postoperative cognitive dysfunction.
1875243|NCT01140867|Drug|zonisamide|zonisamide 100 mg tablet
1875244|NCT01140880|Drug|Truvada|Truvada At qualifying exposure, participants will take 28 days' worth (at one pill per day) of 200 mg emtricitabine and 300 mg tenofovir DF (Truvada).
1875245|NCT01140893|Drug|Exenatide|"Research drug (exenatide or placebo), will begin at V0, after randomization. The initial dosage for the first month will be 5 µg SC BID. Injections can be administered at any time within the 60 minute period before the morning and evening meal.
From V1, research drug will be titrated from 5 to 10 µg SC BID. If gastro-intestinal adverse effects occur with 10 µg SC BID, the dosage will be back-titrated to 5 µg SC BID. Thus, the higher research drug dosage tolerated will be used during the study time."
1875246|NCT01140893|Drug|Placebo|Placebo
1875247|NCT01140906|Drug|Placebo|capsules, daily, orally
1875248|NCT01140906|Drug|Vortioxetine (Lu AA21004)|encapsulated tablets, daily, orally
1875249|NCT01140906|Drug|Duloxetine|encapsulated capsules, daily, orally
1875250|NCT01140932|Drug|Prednisolone|12 days of corticosteroids treatment (prednisolone 37,5 mg/day)
1875251|NCT01140932|Behavioral|Lifestyle change|High calorie diet (130 % of recommended daily energy intake) and relative physical inactivity (no exercise and at least 8 hours of rest/day)
1875252|NCT01140971|Drug|Misoprostol|Vaginal application of 25 micrograms every 6 hours until cervical ripening reach Bishop 6 or more
1875253|NCT01140971|Device|Foley|After Foley introduction, every 6 hours vaginal exam was performed. The cases on Bishop score increase or occurred spontaneous exit of catheter or spontaneous labour had been initiated are considered success.The failure was adopted if after48 hours occurred no cervical modifications.
1875254|NCT01140984|Drug|Methylprednisolone (Intra-arterial continuous infusion of corticosteroids)|Sedation/anesthesia of patient followed by placement of a 4F vascular sheath and a diagnostic and hepatic angiogram. Angiographic catheter tip to be placed in the proximal proper hepatic artery, secured in place externally and connected to an arterial line pressurized system which allows continuous drip infusion of methylprednisolone diluted in normal saline (600mg/m2 with maximal total dose of 100mg diluted in 480cc in normal saline administered at 20cc/hr for 24 hours).
1875255|NCT01140997|Drug|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
1875256|NCT01140997|Drug|Peginterferon alfa-2a|sc, qw, for 48 weeks.
1875257|NCT01141010|Other|Language|Plain language without psychological intervention
1875258|NCT01141010|Other|Language|Psychological linguistic intervention will be given
1875259|NCT01141023|Drug|Datscan and AV-133|
1875260|NCT01141036|Drug|propofol|Propofol will be initiated with a 30-50 mg i.v. bolus followed by repeated 10-20 mg doses at variable intervals (approximately 15 s, at the discretion of the endoscopist/nurse) until an appropriate level of sedation will be achieved.
1875261|NCT01141036|Drug|Midazolam|Midazolam (0.5-1.0 mg) will be administered in a similar fashion with incremental dosing at intervals of approximately 1-3 min until a level of sedation will be achieved
1875262|NCT01141049|Drug|Gabapentin|During week 1 the dosage will be increased 3 times. Days 1 and 2, participants will receive 400 mg of Gabapentin three times daily. During days 3 and 4 the dosage will be increased to 800 mg three times daily. On day 5 through 7, participants will receive a dose of 1200 mg three times daily, which will continue from week 2 through 8. During week 9 patients will be tapered off for the duration of the week.
1875263|NCT01141049|Other|Placebo|Placebo, TID
1875264|NCT01141062|Device|Philips MR-guided HIFU|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein denaturation, irreversible cell damage, and coagulative necrosis.
1875265|NCT01141075|Drug|Ataluren (PTC124)|Ataluren (PTC124) will be provided as a vanilla-flavored powder to be mixed with water. Ataluren (PTC124) will be taken 3 times per day, with dosing based on the patient's body weight. Ataluren (PTC124) will be taken at two different dose levels. In Cycle 1, the dose level is 5 mg/kg in the morning, 5 mg/kg at midday, and 10 mg/kg in the evening for 28 days. In Cycle 2, the dose level is 10 mg/kg in the morning, 10 mg/kg at midday, and 20 mg/kg in the evening for 28 days.
1875266|NCT01141088|Procedure|Bilateral stent-in-stent insertion|Following negotiation of both IHD by two guidewires, inserted 1st stent to left IHD side. After deployment of the 1st stent across the hilar stricture, the remaining guide wire across the 1st stent was carefully withdrawn using an ERCP catheter without pulling it back completely. Then that guidewie was inserted under fluoroscopic guidance into the undrained right IHD through the central portion of the 1st stent. The 2nd cross-wired stent was then introduced over a guidewire through the central open mesh and then was deployed into the right IHD, so that the central portion of the 2nd stent overlapped the central portion of the 1st stent, forming a Y-shape.
1875358|NCT01134900|Other|Pharmacy Dashboard Review and Intervention|Clinical pharmacist reviews patients on dashboard and makes intervention with providing team when necessary.
1876072|NCT01146613|Drug|Varenicline|0.5mg capsules x 2, 2x a day for 12 weeks
1875267|NCT01141088|Procedure|Bilateral side-by-side insertion|Following the introduction of two guidewires, the first stent was pushed and deployed into the left hepatic duct as possible, and then subsequently the second stent was pushed and deployed into the right hepatic duct, using the same method. In tight stricture during a guidewire manipulation, pneumatic biliary balloon dilation prior to insertion of first stent was performed. All stents were positioned above the level of the papilla, with their distal ends at the same level as possible. The diameter of the stent used in each case (8 or 10 mm) depended on the maximum diameter of the common bile duct (CBD).
1875268|NCT01141114|Other|Patient navigation|Letter and Colorectal Cancer Screening Brochure mailed to patients. Telephone outreach by Patient Navigators.
1875269|NCT01141114|Other|Usual care|Usual care
1875270|NCT01141127|Drug|Tranexamic Acid|Comparison of two dosage regimen of Tranexamic Acid
1875271|NCT01141140|Behavioral|Healthy|Favourable nutritional characteristics.
1875272|NCT01141140|Behavioral|Diet|Benefits of an ingredient/nutrient for weight management
1875273|NCT01141140|Behavioral|Unhealthy|Hedonic characteristics and less healthy ingredients.
1875274|NCT01141153|Drug|Acetylsalicylic Acid + clopidogrel + acenocoumarol|"Acetylsalicylic Acid 100 mg daily + Clopidogrel 75 mg daily + Acenocoumarol dosage with INR monitoring
Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent"
1875275|NCT01141153|Drug|Acetylsalicylic Acid + clopidogrel|"Salicylic Acid, 300 mg daily + Clopidogrel 75 mg daily
Treatment : 6 weeks for bare metal stent and 12 months for drug elution stent."
1875276|NCT01141166|Behavioral|nutritional and a rehabilitation plan.|The intervention consisted of recommendations to the subject and their primary physician, and others providers, telephone calls of a nutritional and a rehabilitation plan.
1875277|NCT01141179|Drug|LEO 27847|2 mL (0.1 mg) dose of oral solution
1875278|NCT01141192|Dietary Supplement|vitamin D3, cholecalciferol|1 gelcap of 50,000 IU vitamin D3 plus 2 gelcaps of 5,000 IU vitamin D3 each; a total of 60,000 IU vitamin D3 dosed four weeks apart at weeks 0, 4, 8, and 12 of the 16 week study.
1875279|NCT01141192|Dietary Supplement|Inactive comparator|The inactive comparator dose provided was identical in appearance to the active comparator but contained no vitamin D3
1875280|NCT01141205|Biological|AFO-18|18 peptides representing CD8 and CD4 epitopes mainly on HIV-1 in an adjuvants (CAF01)
1875281|NCT01141205|Drug|Saline|1.2 ml saline intramuscularly
1875282|NCT01141218|Other|internet-based protocol and physician referral|collection and review, dna and lab biomarker analysis, gene mapping
1875283|NCT01141231|Procedure|Acupuncture|Patients undergo acupuncture twice weekly for 4 weeks
1875284|NCT01141244|Drug|temsirolimus|Given IV
1875285|NCT01141244|Drug|temozolomide|Given orally
1875286|NCT01141244|Drug|irinotecan hydrochloride|Given IV
1875287|NCT01141244|Other|laboratory biomarker analysis|Correlative studies
1875288|NCT01141257|Drug|Angiocal® (PRS-050-PEG40)|Single dose of Angiocal® i.v. (intravenous) on Day 1 and further applications of Angiocal® i.v. during a repeated dosing period.
1875289|NCT01141270|Drug|AFOLIA|single sc injection, 225 IU
1875290|NCT01141270|Drug|Gonal-f|single sc injection, 225IU
1875291|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied for 7-day wear
1875292|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied for 7-day wear
1875293|NCT01141283|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied for 7-day wear
1875294|NCT01141296|Drug|fenofibrate|fenofibrate 200 mg PO daily for 1 year
1875295|NCT01141296|Drug|placebo|Placebo pill identical to active drug will be given PO once a day for 1 year
1875296|NCT01129154|Drug|infusions of Panitumumab|Patients will receive six infusions of Panitumumab 6 mg/kg every 2 weeks or until progression if earlier.
1875297|NCT01129180|Drug|azacitidine|Given SC
1875298|NCT01129180|Drug|bortezomib|Given IV
1875299|NCT01129180|Procedure|Correlative studies|Correlative studies will be collected pre-treatment, day 4 , day 15, day 29(pre-cycle 2)
1875300|NCT01129193|Other|Pharmacodynamic Studies|"Assess at baseline (pre-dose day 1 of cycle 1), approximately 24 hours after the first dose, pre-dose days 2 and 3, and pre-dose day 19 for histone acetylation of tumor cells (CLL patients) or mononuclear cells (PBMCs for lymphoma, myeloma, and solid tumor patients).
Cytokine studies will be collected pre-dose on days 1, 2, 8, 15, 19 of cycle 1, day 1 of cycle 2, and pre-dose days 1, 8, 15 of cycle 3."
1875301|NCT01129193|Other|Fatigue Inventory|Brief Fatigue Inventory should take each patient approximately 5 minutes to fill out this survey per instance on day 1 of every cycle.
1875302|NCT01129193|Other|Pharmacogenomic studies|Baseline germ line DNA from buccal swabs will be collected for analysis of drug (AR-42) metabolism SNPs and other biologic SNPs that might predict immune or disease response to therapy. Pharmacogenetic status of key metabolizing enzymes (eg, CYP3A5, UGT1A8) and transporter proteins (SLCO1B1, ABCG2) will also be considered for their role in drug clearance in individual patients.
1875303|NCT01129193|Drug|AR-42|Administered orally three times per week (Mon, Wed, and Fri preferred) in cycles of 28 days (3 weeks of 3-times-per-week dosing followed by a 7-day off-treatment period).
1875304|NCT01134536|Drug|Tapentadol (OS) Oral Solution|Tapentadol OS Bodyweight <20 kg: Type=4 unit=mg/mL form=oral solution route=oral use or Tapentadol OS Bodyweight >=20 kg: Type=20 unit=mg/mL form=oral solution route=oral use. Single oral dose administered once.
1875305|NCT01134549|Drug|Etelcalcetide|Administered as a single intravenous (IV) injection
1875306|NCT01134549|Drug|Placebo|Administered as a single intravenous (IV) injection
1875309|NCT01134575|Drug|CMC-544 (Inotuzumab Ozogamycin)|First patients > 16 years and < 16 years receive CMC-544 at a dose of 1.3 mg/m^2 by vein (IV) over 1 hour during Course 1, and 1.8 mg/m^2 IV over 1 hour during Course 2 and subsequently. In all other patients beginning dose of 1.8 mg/m^2 IV over 1 hour every 4 week cycle.
1875310|NCT01134575|Drug|Rituximab|With no improvement after 2 courses of CMC-544, addition of Rituximab dose 375 mg/m^2 IV (by vein) over 2-6 hours every 3-4 weeks.
1875311|NCT01134588|Other|Paper questionnaire|
1875312|NCT01134588|Other|Touch screen questionnaire|
1875313|NCT01134601|Procedure|Radiation Therapy|
1875319|NCT01134627|Drug|Minocycline|Participants who are self-administering Rebif® (IFN beta-1a) 44 microgram (mcg) as subcutaneous (sc) injection thrice weekly will also receive minocycline 100 milligram (mg) tablet twice daily as an add-on therapy in accordance with clinical practice for 96 weeks.
1875320|NCT01134627|Drug|Placebo|Participants who are self-administering Rebif® (IFN beta-1a) 44 mcg as sc injection thrice weekly will also receive placebo tablets twice daily for 96 weeks.
1875321|NCT01134653|Other|Jump Stretch|distraction with early mobilization
1875322|NCT01134666|Drug|Cetuximab|FOLFOX Oxaliplatin 100 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 FOLFIRI Irinotecan 180 mg/ m2 day 1 Folinic Acid 400 mg/m² (racemic) or 200 mg/m² (L-form) day 1 5- FU 400 mg/m² bolus on day 1 followed by a 46-hour continuous infusion of 2,400 mg/m² day 1 CETUXIMAB Cetuximab administered at loading dose of 400 mg/m2/week over 120 min followed by maintenance dose of 250 mg/m2/ week over 60 min, till disease progression or dose limiting toxicity
1875323|NCT01134679|Behavioral|Multi-disciplinary disease management approach|Follow up with phone calls
1875324|NCT01134692|Drug|Propranolol, Norfloxacin, VSL#3|Propranolol: as per heart rate titration Norfloxacin: 400mg BD
1875325|NCT01134705|Drug|Beclomethasone dipropionate hydrofluoroalkane HFA Nasal Aerosol|Beclomethasone dipropionate (BDP) Hydrofluoroalkane (HFA) Nasal Aerosol
1875326|NCT01134705|Drug|Placebo Nasal Aerosol|HFA Vehicle Aerosol
1875327|NCT01134718|Drug|TMC435 (G006)|one morning dose of 150 mg
1875328|NCT01134718|Drug|TMC435 (F021)|one morning dose of 150 mg
1875329|NCT01134718|Drug|TMC435 (G007)|one morning dose of 150 mg
1875330|NCT01134731|Drug|paliperidone|1-5 mg daily (QD)
1875331|NCT01134731|Drug|lithium|300-1500mg QD
1875332|NCT01134731|Drug|Placebo|1-5 placebo capsules
1875333|NCT01134757|Biological|house dust mite and alternaria allergen bronchial challenge|2 ml of saline-dissolved lyophylised house dust mite or alternaria in concentration 5000 standard biological units (SBU/ml) The challenge is the only intervention. dosed in 6 steps of 5, 10, 20, 40, 80, and 160 SBU. 10 minutes after each step up a spirometry will be performed the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given.
1875334|NCT01134783|Behavioral|CHOICES Intervention|Academic course on healthy weight behaviors followed by participation in a social networking and social support website.
1875335|NCT01134809|Procedure|Major abdominal surgery|All adult patients having major abdominal surgery
1875336|NCT01134835|Other|placebo|placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks
1875337|NCT01134835|Drug|IMP Pioglitozone|Pioglitazone 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks and placebo 30mg daily by mouth for 4 weeks then 45mg daily for 8 weeks.
1875338|NCT01134848|Drug|Morphine|10mg IM
1875339|NCT01134848|Drug|Neostigmine|1mg IM
1875340|NCT01134848|Drug|0.9% saline|0.1 ml/kg
1875341|NCT01134848|Drug|Secretin|1 unit/kg IV
1875342|NCT01134848|Drug|0.9% saline|1ml IM
1875343|NCT01134861|Drug|cisplatin|100 mg/m2 i.v. over 30-60 minutes, days 1 & 29
1875344|NCT01134861|Drug|Etoposide|Oral etoposide given 50 mg b.i.d. X 10 only on RT treatment days 1-5, 8-12, 29-33, and 36-40. 75 mg/day if body surface area < 1.7 m2
1875345|NCT01134861|Drug|Vinblastine|5 mg/m2 i.v. bolus weekly first 5 weeks of RT
1875346|NCT01134861|Radiation|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fX) beginning day 50 of protocol treatment
1875347|NCT01134861|Drug|Cisplatin|50 mg/m2 i.v. over 30-60 minutes on days 1, 8, 29, and 36
1875348|NCT01134861|Radiation|Radiation therapy|63 Gy/7 wks/34 daily fractions (1.8 Gy X 25 fx then 2.0 Gy X 9 fx) beginning day 1 of protocol treatment
1875349|NCT01134861|Radiation|Radiation therapy|69.6 Gy/6 wks/58 X 1.2 Gy twice daily fractions (at least 6 hours apart) beginning day 1 of protocol therapy
1875350|NCT01134874|Behavioral|Standard weight loss intervention|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week.
1875351|NCT01134874|Behavioral|Standard weight loss intervention plus technology|In-person weight loss sessions, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
1875352|NCT01134874|Behavioral|Technology only|One intervention telephone call per month, dietary intake prescription of 1200-1500 kcal per day, exercise progressing to 300 minutes per week, plus technology to provide real-time feedback on energy expenditure, plus a website to log dietary intake.
1875353|NCT01134887|Other|Informational Guide for Patients|"Veterans received a copy of the NIA guide for Talking with Your Doctor. This pamphlet was specifically developed for this purpose (updated in 2002). It has pictorials and is written at an 8th grade level."
1875354|NCT01134887|Behavioral|Video-Assisted Coaching|Physicians participated in an audiotaped intensive 30 minute, one-on-one educational intervention with PI Frankel after their first set of visits from their three participating patients, but before seeing them for follow-ups. The main goal of this video-assisted coaching session was to review and discuss the analysis of the physician's videotaped visits using the Four Habits framework, with a particular focus on improving communication about self-management.
1875355|NCT01134887|Other|Monograph for Physicians|"Primary care providers randomly assigned to the Intervention-Physicians arm of this study received a copy of the Four Habits of Highly Effective Physicians. The Four Habits provided practical evidence-based advice for improving patient-physician communication."
1875356|NCT01134887|Behavioral|Educational Coaching|an educator met with each Veteran in the intervention arm individually for 20-30 minutes to review the material in the pamphlet and develop a plan for enhancing communication about self-management of hypertension with their doctor [Coaching]. To facilitate communication change, the educator assisted the patient in setting a goal to achieve during their visit. The educator also provided telephone follow-up within 24 hours to review satisfaction and effectiveness of the visit and assess barriers and facilitators to communicating about self-management.
1875357|NCT01134887|Other|Control|"The primary care providers randomly assigned to the Control-Physicians arm did not receive any additional coaching or resources and conducted their practice as usual."
1875396|NCT01135290|Drug|Aquaphor|
1875397|NCT01135290|Drug|HP828-101|
1875359|NCT01134926|Drug|misoprostol|8oo mcg intravaginal, second dose after one day if there is no response
1875360|NCT01134952|Drug|Mycophenolate to sirolimus switch|Sirolimus given for 3 months instead of mycophenolate at a starting dose equivalent of 1 mg sirolimus equal to 1000 mg of mycophenolate.
1875363|NCT01134978|Behavioral|Practice Order|"Blocked order - predictable
Random order - unpredictable"
1875364|NCT01134991|Drug|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% or Placebo to be applied twice daily during 12 weeks
1875365|NCT01135004|Procedure|Thoracoscopic bullectomy|Thoracoscopic wedge resection of the diseased lung
1875366|NCT01135017|Drug|Dronedarone|"Film-coated tablet
Oral administration under fed conditions (during breakfast and dinner)"
1875367|NCT01135017|Drug|Placebo (for Dronedarone)|"Film-coated tablet strictly identical in appearance
Oral administration under fed conditions (during breakfast and dinner)"
1875368|NCT01135030|Procedure|Total knee|Primary Total knee
1875369|NCT01135043|Behavioral|education by brochure|educated with the brochure that contains figure of lung/upper respiratory tract and methods of collecting sputum.
1875370|NCT01135043|Behavioral|control|patients with control group are educated about methods of collecting sputum by a physician, only in verbal explanation without brochure
1875371|NCT01135056|Device|SIR-Spheres|One time treatment. Dose administered based on tumour volume. Each vial is 3.0GBq.
1875372|NCT01135056|Drug|Sorafenib tosylate|Oral Tablet, 400mg B.i.d, until progression or unacceptable toxicity develops
1875373|NCT01135069|Drug|Tretinoin microsphere 0.1%|Treatment of acne vulgaris
1875374|NCT01135069|Drug|Brand Retin-A Micro tretinoin microsphere gel 0.1%|Treatment of acne vulgaris
1875375|NCT01135069|Drug|placebo microsphere gel|treatment of acne vulgaris
1875376|NCT01135082|Biological|valent pneumococcal conjugated vaccine|Dosage: 0.5 ml per dose Administration: intramuscular injection Location: left deltoid area x 1 injection Frequency: depend on first dose of vaccination. If 2-6 months of age, vaccination at month 0, 2, and 4. If 7-23 months of age, vaccination at month 0 and 2. If 2-9 years of age, vaccination at month 0. If patient is HIV positive, vacciation months 0 and 2 if age is 2-9 years.
1875377|NCT01135095|Radiation|low-dose imaging|"The study is designed to assess the validity of a low dose (~5mSv) Tc99m one day protocol using D-SPECT standard protocol as the comparators.
D-SPECT cardiac scanner the D-SPECT system uses a solid-state detector, made of an alloy of Cadmium, Zinc, and Telluride, eliminating the need for thick crystals and large photomultiplier tubes. As a result, the system is significantly miniaturized, and ergonomically optimized to both user and patient"
1875378|NCT01135108|Drug|Placebo|Placebo IV Infusion
1875379|NCT01135108|Drug|KAI-1678|KAI-1678 IV Infusion
1875380|NCT01135134|Drug|Mometasone furoate|"The study drug is MFNS (50 μg spray device) and the dose will be:
5 to 11 years: one spray per nostril once daily (100 μg/day as MF) in the morning for 2 weeks
12 to 15 years: 2 sprays per nostril once daily (200 μg/day as MF) in the morning for 2 weeks"
1875381|NCT01135134|Drug|Placebo|"MF Placebo nasal spray and administration will be as follows:
5 to 11 years: one spray per nostril once daily in the morning for 2 weeks
12 to 15 years: 2 sprays per nostril once daily in the morning for 2 weeks"
1875382|NCT01135147|Behavioral|Diet|Dietary therapy and physical education
1875383|NCT01135147|Procedure|Surgery|Adenotonsillectomy along with diet and physical therapy
1875384|NCT01135173|Behavioral|Waterpipe smoking cessation|The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.
1875385|NCT01135186|Drug|sapropterin dihydrochloride|sapropterin dihydrochloride: 10mg/kg/day
1875386|NCT01135199|Drug|pomalidomide (CC-4047|
1875387|NCT01135212|Drug|Fimasartan 60mg|Fimasartan 60mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
1875388|NCT01135212|Drug|Fimasartan 120mg|Fimasartan 120mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
1875389|NCT01135212|Drug|Candesartan cilexetil|Candesartan 8mg for mild to moderate hypertension. Take a tablet(filled in Doubleblind capsule) every morning.
1875390|NCT01135225|Device|PROMUS(TM) Element (TM) Stent System|The PROMUS Element Everolimus-Eluting Coronary Stent System is a device/drug combination product composed of two components: a device (coronary stent system) and a drug product (a formulation of everolimus contained in a polymer coating.
1875391|NCT01135225|Device|Evolution Stent System|The Evolution Everolimus-Eluting Monorail Coronary Stent System is a device/drug combination comprised of two regulated components: a device (coronary stent stent) and a drug product (a formulation of everolimus contained in a biodegradable polymer coating).
1875392|NCT01135251|Drug|dimiracetam|400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
1875393|NCT01135251|Drug|sugar pill|capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
1875394|NCT01135264|Behavioral|CBT|The CBT treatment developed by Ladouceur (Consultant) will serve as control condition (outline of published treatment manual by Ladouceur & Lachance, 2006. This treatment served as a model for the cognitive-behavioral component in CMBT and has received empirical support in two studies from Ladouceur's lab (Sylvain et al., 1997; Ladouceur et al., 2004). It places strong emphasis on cognitive correction of erroneous beliefs about gambling and also focuses on coping skills training and relapse prevention. CBT also lasts 12 weekly sessions.
1875395|NCT01135264|Behavioral|CMBT|We used the NIMH-funded R21 mechanism to develop and test the CMBT intervention (Wulfert et al., 2003, 2005; 2006). Treatment will be implemented in 12 weekly sessions (3 motivational enhancement sessions, 8 sessions of cognitive-behavioral treatment, 1 session of relapse prevention)
1875398|NCT01135303|Device|VistaO2 device|Full night VistaO2 device monitoring synchronized with the gold standard polysomnography.
1875399|NCT01135316|Drug|Ablavar|One dose of Ablavar will be administered for use during a contrast MRI examination
1995111|NCT02853162|Radiation|ARREST-study|Radiotherapy will be delivered in five fractions of 7 Gy every other day. An additional contrast enhanced MRI scan will be performed after the 2nd treatment fraction, and after 6 and 12 months
1875401|NCT01135342|Behavioral|Diet and exercise|Standardized instruction to eat less and exercise more to create an energy balance deficit to promote weight loss (16 classes)
1875402|NCT01135342|Behavioral|Cognitive Behavioral Therapy|Standardized cognitive behavioral therapy for insomnia (8 classes)
1875403|NCT01135342|Behavioral|Passion and Balance|Attention-match sessions of general interest, but unrelated to diet, exercise, or sleep (8 sessions)
1875404|NCT01135368|Drug|Lansoprazole|Lansoprazole capsules
1875405|NCT01135381|Behavioral|IVR-Enhanced Care|Those randomized to e-Coach will receive initial coaching in the hospital and then will be called by the interactive voice response-supported (IVR) system at specified intervals after discharge for monitoring. Any red flags noted through the IVR monitoring system will be transmitted to the care transition coaches, who contact patients and coach them on how to address problems identified.
1875406|NCT01135394|Drug|Pioglitazone|30 mg tablet once daily for 4 weeks, then increased to 45 mg once daily for an additional 8 weeks. Total dosage period is 12 weeks.
1875407|NCT01135407|Other|Recording during computerized tests|"Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.
The computerized tests are administered in two different conditions of medication: with or without dopaminergic treatment, corresponding to two different experimental sessions."
1875408|NCT01135407|Other|Recording during computerized tests|Patients will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals. The computerized tests are administered in three different sets of electrical (without stimulation, or selective stimulation of the sensorimotor or associative/limbic part of the subthalamic nucleus) stimulation, corresponding to three different experimental sessions.
1875409|NCT01135407|Other|Recording during computerized tests|Participants will perform more than one experimental session. In each experimental session 3 computerized tasks, which are suitable to study visual attention, decision making and motor performances will be presented. During these tests, participants have to responds the most quickly and accurately possible to the appearance on a computer display of a predetermined target stimuli, presented alone or in an array of signals.The computerized tests are administered twice (in two different experimental sessions) to verify the performance repeatability.
1875410|NCT01135420|Behavioral|Telephone Monitoring (TM) with Motivational Interviewing|Patients in the TM condition will receive an in-person session while in the inpatient psychiatry program, followed by monitoring delivered over the telephone for three months after discharge. The TM intervention will have a motivational interviewing component to address patients' motivation to obtain help for and reduce their substance abuse. The purpose of the intervention condition is to monitor patients' substance use, facilitate patients' entry into outpatient substance use disorder (SUD) treatment, and encourage ongoing 12-step selfhelp group participation to support sobriety.
1875411|NCT01135420|Other|Usual care|All patients in the trial will receive usual care (i.e., the care they would have received in the absence of a study).
1875412|NCT01135433|Drug|ASP1941|oral
1875413|NCT01135433|Drug|Placebo|oral
1875414|NCT01135433|Drug|metformin|oral
1875415|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.001 mg, once on Day 1 only, 2 days
1875416|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.01 mg, once on Day 1 only, 2 days
1875417|NCT01135446|Drug|dapagliflozin|Oral Solution, Oral, 0.1 mg, once on Day 1 only, 2 days
1875418|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 0.3 mg, once on Day 1 only, 2 days
1875419|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 1 mg, once on Day 1 only, 2 days
1875420|NCT01135446|Drug|dapagliflozin|Tablets, Oral, 2.5 mg, once on Day 1 only, 2 days
1875421|NCT01135459|Drug|Lupuzor|200 mcg.
1875422|NCT01135459|Drug|Placebo|Matching placebo was administered subcutaneously every 4 weeks for 20 weeks for a maximum of 6 doses.
1875423|NCT01135472|Drug|Esomeprazole Magnesium|NEXIUM 40MG ONCE DAILY FOR 7 DAYS WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 40MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD, NEXIUM 80MG TWICE DAILY WITH A 2 WEEK WASHOUT PERIOD.
1875424|NCT01135498|Drug|bevacizumab [Avastin]|Intravenous repeating dose
1875425|NCT01135498|Drug|eloxatin|Intravenous repeating dose
1875426|NCT01135498|Drug|capecitabine [Xeloda]|Oral repeating dose
1875427|NCT01135498|Drug|erlotinib [Tarceva]|Oral repeating dose
1875428|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, low dose, dosed once/day, 8 weeks
1875429|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, medium dose, dosed once/day, 8 weeks
1875430|NCT01135511|Drug|CP-690,550 Eye drops|Ophthalmic topical solution, high dose, dosed once/day, 8 weeks
1875431|NCT01135511|Drug|CP-690,550 Eye drops-vehicle|Ophthalmic topical solution, vehicle, dosed once/day, 8 weeks
1875432|NCT01135511|Drug|Sodium Hyaluronate|Ophthalmic topical solution, dosed 6 times/day, 8 weeks
1875433|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5 mcg/h applied transdermally for 7-day wear.
1875434|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 10 mcg/h applied transdermally for 7-day wear.
1875435|NCT01135524|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 20 mcg/h applied transdermally for 7-day wear.
1875436|NCT01135537|Biological|Thymoglobulin (rATG)|"Thymoglobulin 2.5 mg/kg of body weight IV administered daily for 3 days prior to HSCT.
Thymoglobulin infused over a minimum of 6 hours for the first infusion and over at least 4 to 6 hours on subsequent days of therapy."
1875437|NCT01135550|Drug|High dose dexamethasone|"Subject will receive 5 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.
If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
1875438|NCT01135550|Drug|Low dose dexamethasone|"Subject will receive 1 mg/m2 po divided in two doses. Dexamethasone 4mg/mL solution will be compounded into a 1mg/mL dosage form.
If symptoms are well controlled over 2 weeks time, tapering of dexamethasone can be considered. It will be at the treating physician's discretion to decide the start of the tapering of dexamethasone. The weaning schedule will be the same in both intervention arms: halving the dose once weekly (week 1, week 2) while continuing to give two doses/day, one half morning dose at week 3 and every second day at week 4."
1875439|NCT01135563|Drug|Vinblastine and Sirolimus|"Patients will be enrolled to receive vinblastine and sirolimus in 28 day cycles. Using the 3+3 standard Phase1 design, vinblastine will be administered via IV push on Days 1, 8, 15, 22. The starting dose of 4 mg/m2 (Dose Level 1) is 67% of the established MTD (6 mg/m2) for this schedule in pediatrics. Dose escalation will take place in a standard 3+3 design, in which doses will increase by approximately 20 to 25% in successive 3-patient cohorts.
Sirolimus (rapamycin) will be given by mouth (tablet or suspension) once daily throughout the cycle. Ideally patients will remain on the same dose form (tablet or suspension) for the duration of the study. All patients will be assigned a target sirolimus serum trough"
1875440|NCT01135576|Dietary Supplement|non-fortified fruit juices consumed as part of the usual diet|
1875441|NCT01135576|Dietary Supplement|Iron fortified fruit juice|Consumption of micronized iron pyrophosphate supplemented fruit juices as part of the usual diet
1875442|NCT01135589|Drug|Micafungin|i.v.
1995112|NCT02851277|Drug|ASP0892 Intradermal|Intradermal injection
1875444|NCT01135615|Drug|Sevelamer|The starting dose for sevelamer was 1-2 capsules (800 mg) three times a day
1875445|NCT01135615|Drug|calcium acetate|calcium acetate (1000 mg) 1 tablet three times a day
1875446|NCT01135628|Other|Auxiliary Treatment|Lactobacillus reuteri, 1 tablet bid, each of 100,000,000 FCU for 6 months
1875447|NCT01135628|Dietary Supplement|Hyperproteic and fiber-rich diet|Hyperproteic diet consisting in 1.5 gr/kg of protein per day Fiber-rich diet
1875448|NCT01135628|Drug|Nitazoxanide|Nitazoxanide tablets 400 mg, bid, orally for 6 months
1875449|NCT01135641|Drug|Rituximab|Patients will receive in addition to ciclosporine A and corticosteroids (prednisone) 1 mg/kg/day, Rituximab at 375 mg/m²/infusion once a week for 4 consecutive weeks.
1875450|NCT01135641|Drug|Ciclosporine|
1875451|NCT01135641|Drug|Corticosteroids|
1875452|NCT01135654|Other|Training & Tech Support for Delivery of Alcohol Screening, Brief Intervention, and Referral To Treatment|"We provide training and technical support for providers to conduct Alcohol Screening, Brief Intervention, and Referral to Treatment. The training is based on the NIAAA clinician's guide to Helping Patients Who Drink Too Much."
1875453|NCT01135667|Drug|clopidogrel|clopidogrel 150 mg once daily for 30 days
1875454|NCT01135667|Drug|Prasugrel 10 mg|Prasugrel 10 mg once daily for 30 days
1875455|NCT01135680|Drug|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
1875456|NCT01135680|Drug|HPN-100 or Placebo|single oral dose of 12 mL HPN-100 given via syringes 3 times daily for 3 days
1875457|NCT01135680|Drug|Placebo|single oral (by mouth) dose of 9 mL placebo given via syringes 3 times daily for 3 days
1875458|NCT01135680|Drug|Moxifloxacin|single oral 400-mg dose on study Day 3
1875459|NCT01135680|Drug|HPN-100|single oral dose of 6 mL HPN-100 and 3 mL placebo given via syringes 3 times daily for 3 days
1875460|NCT01135680|Drug|HPN-100|single oral dose of 9 mL HPN-100 given via syringes 3 times daily for 3 days
1875461|NCT01135706|Other|No Intervention|This study does not include an intervention but is observational in nature.
1875462|NCT01135719|Procedure|LASIK and PRK|Wavefront-guided versus wavefront-optimized LASIK or PRK.
1875463|NCT01135732|Procedure|brush cytology|brush cytology during ERCP
1875464|NCT01135745|Device|Reclaim® Deep Brain Stimulation|Implant of leads in pre-defined brain area; implant of neurostimulators
1875465|NCT01135758|Drug|Ketamine|Administration of a subanaesthetic dose of Ketamine, intravenously (0.5 mg/kg)
1875466|NCT01135771|Other|glucose and insulin IV to alter blood glucose|
1875467|NCT01135784|Dietary Supplement|MIGRA-ZEN RELIEF PLUS|one 2-capsule dose per 24hrs for a total of 180 caps over 90 days
1875468|NCT01135784|Dietary Supplement|Placebo for Migrazen relief plus|2 capsule dose per 24 hours for 90 days
1875469|NCT01135810|Behavioral|Hypnosis|
1875470|NCT01135810|Behavioral|Meditation|
1875471|NCT01135823|Procedure|Patient survey|
1875472|NCT01135836|Procedure|Pulmonary recruitment maneuver|a pulmonary recruitment maneuver consisting of five manual pulmonary inflations was performed with a maximum pressure of 60 cm H2O. The anestheiologist held the fifth positive pressure inflation for approximately 5 seconds.
1875473|NCT01135836|Procedure|Intraperitoneal normal saline|the upper part of the abdominal cavity was evenly and bilaterally filled with the 0.9% normal saline in the amount of 500 cc. We will leave the fluid in the abdominal cavity.
1875474|NCT01135836|Procedure|Control group|CO2 was removed by passive exsufflation through the port site.
1875475|NCT01135862|Drug|platelets|6 packs of platelets will be administered
1875476|NCT01135875|Other|GBM Patients|2 teaspoons of blood will be collected during select clinic visits.
1875477|NCT01135875|Other|Normal Controls|2 teaspoons of blood will be collected once.
1875478|NCT01135888|Device|Skin cooling devices|Cooling vest and cooling bandana
1875479|NCT01135901|Behavioral|Behavioural change programme|The programme consists of a introductory course, organised physical activity 2-3 times a week, meetings every 3rd month with lectures and theme nights, and organising self-help groups.
1875480|NCT01135914|Drug|ranibizumab|Ranibizumab 0.5 mg fixed loading dose via intravitreal injection, given once per month for 3 consecutive months (Day 1, Month 1 and Month 2). This treatment could be reapllied, depending on symptoms.
1995113|NCT02851277|Drug|ASP0892 Intramuscular|Intramuscular injection
1875481|NCT01135914|Procedure|Laser|Laser photocoagulation treatment was administered on Day 1. Subsequent laser treatments could be administered if needed, in accordance with Early Treatment Diabetic Retinopathy Study (ETDRS) guidelines.
1875482|NCT01135927|Drug|insulin degludec|NN1250 (insulin degludec) injected s.c. (under the skin) once daily for 6 days
1875483|NCT01135927|Drug|insulin detemir|Insulin detemir injected s.c. (under the skin) once daily for 6 days
1875484|NCT01135940|Device|2-octylcyanoacrylate (Dermabond) closure|Standard procedure for closure of adipose/ subcutaneous layers. The subcuticular layer will be closed with a continuous 2-0 vicryl suture which will then be followed by Dermabond closure.
1875485|NCT01135940|Device|Standard staple closure|Standard procedure for closure of adipose/ subcutaneous layers followed by staple closure
1875486|NCT01141309|Drug|sorafenib with everolimus|"Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles *Cycle = 4 weeks of treatment.
Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study."
1875487|NCT01141322|Drug|Ursodeoxycholic Acid|ursodeoxycholic acid 13-15 mg/kg BW/day into 3 divided doses after meal till endpoint or the 8th week.
1875488|NCT01141322|Drug|Placebo|The placebo is of the same color, size and shape as UDCA, and assumed 100 mg per tab. Patients in this group will orally intake 13-15 mg/Kg BW/day of placebo into 3 divided doses after meal as UDCA treatment group, till the endpoint or the 8th week.
1875489|NCT01141335|Device|polypropylene mesh|A Lichtenstein tension-free hernioplasty is performed using a polypropylene mesh will be fixed by sutures in Polypropylene 2/0.
1875490|NCT01141335|Device|Infinit® PTFE mesh (WL Gore)|A Lichtenstein tension-free hernioplasty is performed using a PTFE mesh will be fixed by sutures in PTFE 2/0.
1875491|NCT01141348|Behavioral|Special Intervention|16 week behavioral weight loss intervention included 2 hour weekly group sessions
1875492|NCT01141348|Behavioral|Delayed Intervention|During the randomized controlled trial, the Delayed Intervention (DI) group received two newsletters with study updates and general health information. Following the trial, the DI group received a 10-week weight loss program.
1875493|NCT01141361|Procedure|GPS recording(s) of walking capacity in PAD patients|Home-based GPS recording(s) of walking capacity in PAD patients. Two evaluations will be performed. The second evaluation will be performed six months after the initial assessment (test 1) and only for patients with GPS maximal walking distance below 2000 meters at test 1. It is expected that some patients at test 2 will have undergo surgery or endovascular treatment.
1875494|NCT01141374|Other|auriculotherapy by needles|The chinese auriculotherapy is a intervention used by Chinese Traditional Medicine in order to balance the body energy and to treat several kind of diseases using semi-permanent needles in specific points of the auricular pavilion.
1875495|NCT01141374|Other|auriculotherapy by seeds|We used the three points Shenmen, Kidney, and Brain Stem with mustard seeds, 1 time per week for 8 sessions.The subjects were instructed to stimulate the points three times a day.
1875496|NCT01141426|Behavioral|Intensive Short-term Dynamic Psychotherapy|The ISTDP model is an emotion focused brief format of psychotherapy that helps the patients identify and address emotional factors that culminate into exacerbation of depression and perpetuation of depression. The emphasis is on awareness of emotions and how they affect the person's behavioral patterns and mood. The research protocol calls for the treatment to be delivered according to a 20-session time-limited format. The first session is an extended 2-3 hour appointment (21), then sessions are planned to occur on a weekly basis lasting 60 minutes in duration. Termination in fewer sessions is based upon agreement between therapist and patient.
1875497|NCT01141426|Behavioral|Secondary Care Treatment as Usual|At the four secondary health care sites, treatment as usual will consist of a multidisciplinary team approach including pharmacotherapy and clinical management, supportive or structured activities focused around symptom management and in some cases, individual or group psychotherapy. Pharmacotherapy treatment strategies will be individualized regimes informed by evidence-based recommendations. TAU will not be regulated in order to get a naturalistic assessment of standard secondary care treatment delivery with the exception that trial participants not be offered a psychodynamic / psychoanalytic based psychotherapy treatment during the course of the trial. Therapeutic interventions are likely to be heterogeneous therefore the trial coordinator will document in detail the dose and approaches delivered to each participant in order to account for this heterogeneity.
1875498|NCT01141439|Drug|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|Initiation of HFA-BDP (any dose) in steroid naive patients via MDI
1875499|NCT01141439|Drug|Extra-fine hydrofluoroalkane-beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as HFA-BDP via MDI
1875500|NCT01141439|Drug|Fluticasone propionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as FP via MDI
1875501|NCT01141439|Drug|Beclomethasone dipropionate|An increase in the baseline BDP-equivalent dose of inhaled corticosteroid as CFC-BDP via MDI
1875502|NCT01141439|Drug|fluticasone propionate|Initiation of FP (any dose) via MDI in steroid naive patient
1875503|NCT01141439|Drug|Chlorofluorocarbon beclomethasone dipropionate|Initiation of CFC-BDP (any dose) via MDI in steroid naive patient
1875504|NCT01141452|Drug|Extra-fine hydrofluoroalkane beclomethasone MDI|Step-up in baseline BDP-equivalent ICS dose
1875505|NCT01141452|Drug|Chlorofluorocarbon beclomethasone metered dose inhaler|Step-up in baseline BDP-equivalent ICS dose
1875506|NCT01141452|Drug|Fluticasone propionate metred dose inhaler|Step-up in baseline BDP-equivalent ICS dose
1875507|NCT01141452|Drug|Fluticasone propionate metred dose inhaler|Initiation of ICS therapy
1875508|NCT01141452|Drug|Hydrofluoroalkane beclomethasone metred dose inhaler|Initiation of ICS therapy
1875509|NCT01141452|Drug|Chlorofluorocarbon beclomethasone dipropionate|Initiation of ICS therapy
1875510|NCT01141465|Drug|Fluticasone / formoterol metered dose inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
1875511|NCT01141465|Drug|Fluticasone / salmeterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
1875512|NCT01141465|Drug|Budesonide / formoterol dry powder inhaler|Prescribed at the same BDP-equivalent dose as baseline ICS
1875513|NCT01141465|Drug|Fluticasone / salmeterol dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
1875514|NCT01141465|Drug|Fluticasone / salmeterol metred dose inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
1875515|NCT01141465|Drug|BUD/FOR dry powder inhaler|Prescribed at ≥twice BDP-equivalent dose as baseline ICS
1995114|NCT02851277|Drug|Placebo Intradermal|Intradermal injection
1995115|NCT02851277|Drug|Placebo Intramuscular|Intramuscular injection
1875518|NCT01141491|Biological|Trivalent ganglioside vaccine|Patients will be given 10 injections of ganglioside vaccine plus adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
1875519|NCT01141491|Biological|OPT-821|Patients will be given 10 injections of adjuvant OPT-821 as a 1.0 ml subcutaneous injection in an outpatient setting at Visit Weeks 1, 2, 3, 8, 16, 28, 40, 52, 68 and 84
1875520|NCT01141504|Dietary Supplement|PeakATP 250|The nutritional intervention provides for oral ingestion of 250 mg PeakATP per day
1875521|NCT01141504|Dietary Supplement|Placebo|Placebo capsules that are comparable in size and color to the active comparator for blinding purposes
1875522|NCT01141504|Dietary Supplement|PeakATP 400|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day
1875523|NCT01141504|Dietary Supplement|PeakATP 400 plus proprietary blend|The nutritional intervention provides for oral ingestion of 400 mg PeakATP per day plus a proprietary blend of additional nutrients
1875524|NCT01141517|Behavioral|Not-On-Tobacco smoking cessation program|Adolescent quit-smoking program; Not-On-Tobacco
1875525|NCT01141530|Other|No intervention|Because this study is a retrospective tissue bank study, there are no subjects actively participating in this study, thus no intervention. All samples studied will be obtained through the UAMS Tissue Bank.
1875526|NCT01141543|Drug|Plerixafor (mozobil)|"Cohort 1: Administration of PLERIXAFOR (240mcg/kg sc) before the first dose of FLUDARABINE and BUSULFAN Cohort 2: Administration of PLERIXAFOR (240mcg/kg sc) before the first and second dose of FLUDARABINE and BUSULFAN.
Cohort 3: Administration of PLERIXAFOR (240mcg/kg sc) before the first, second, and third dose of FLUARABINE and BUSULFAN Cohort 4: Administration of PLERIXAFOR (240mcg/kg sc) before all four doses of FLUDARABINE and BUSULFAN"
1875527|NCT01141556|Drug|Selenase|After enrollment, patients will be prospectively randomized into two groups: a placebo group without selenium and a group receiving a loading dose of selenium 4000 μg intraoperatively,followed by a daily dosage of 1000 μg until leaving the ICU (longest supplementation 13 days).
1875528|NCT01141569|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1875529|NCT01141569|Other|Laboratory Biomarker Analysis|Correlative studies
1875530|NCT01141595|Drug|sapropterin dihydrochloride|Patients will be instructed to take 20 mg/kg/day of Kuvan® orally dissolved in 4 - 8oz. of water or apple juice with breakfast.
1875531|NCT01141608|Other|Vigorous Intensity High Dose Exercise|Participants randomized to the exercise condition will begin with supervised exercise sessions 3 times per week during the 12-week acute phase of the study. Supervised sessions will be conducted as one-on-one (i.e., individual) sessions. Vigorous intensity high dose exercise will be prescribed at a dose of 12 kcal/kg/week (KKW), with intensity ranging from 70-85% maximal heart rate.
1875532|NCT01141608|Other|Health Education Intervention|Participants randomized to the health education condition will also begin with visits 3 times per week during the 12-week acute phase. The health education sessions will be conducted as one-on-one (i.e., individual) sessions. Health education sessions will consist of information on health-related topics distributed via methods such as didactics, audio and video materials, and written materials.
1875533|NCT01141634|Other|Homeopathic Remedies|Homeopathic remedies prepared according to the standards as set out by Health Canada
1875534|NCT01141647|Behavioral|Vocational Rehabilitation|SCI-VIP: PrOMOTE evidence-based supported employment implemented for Veterans with spinal cord injury or other available vocational services
1875535|NCT01142167|Procedure|Standard Colonoscopy|Standard colonoscopy will be used during colonoscopy
1875536|NCT01142167|Procedure|Ultra-thin colonoscopy|Ultra-thin colonoscope will be used during colonoscopy
1875537|NCT01142180|Procedure|TAE|The procedure will be performed within 12 hours of endoscopic therapy. This is usually performed under conscious sedation
1875538|NCT01142180|Procedure|No TAE|No TAE procedure will be performed after endoscopic treatment
1875539|NCT01142193|Drug|USL255|
1875540|NCT01142193|Drug|Placebo|
1875541|NCT01142206|Behavioral|Dietary|All participants in the investigation will receive a standard 8-week behavioral obesity intervention with 8 weekly, 1 hour group counseling and education sessions. The intervention will include a reduced caloric prescription (1200-1500 kcal/day) and fat gram prescription (30% or less kcals from fat).
1875542|NCT01142206|Behavioral|Physical Activity|All participants will receive a physical activity goal of 200 minutes/week of moderate-intense physical activity.
1875543|NCT01142206|Behavioral|TV Watching + Physical Activity|The TV Watching + physical activity arm will receive a TV watching goal of watching less than 10 hours of TV/week.
1875544|NCT01142219|Drug|L-arginine|L-arginine was administered orally at a dose of 0.1g/kg/day during 6 months.
1875545|NCT01142219|Drug|Placebo|Mannitol was administered orally at a dose of 01 g/kg/day for six months.
1875546|NCT01142232|Drug|Lenalidomide plus Melphalan during autologous stem cell transplantation|Patients will receive a fixed dose of melphalan, while the dose of lenalidomide is escalated according to the protocol defined cohorts. Lenalidomide is given on day -7 to day +2, while intravenous melphalan is given on day -2 and -1. Lenalidomide dosing will be in the morning at approximately the same time each day.
1875547|NCT01142232|Drug|Lenalidomide maintenance|Lenalidomide maintenance therapy will begin on Day +100 to Day +110 provided the protocol-defined criteria are met. The initial starting dose of lenalidomide during maintenance is 10 mg daily on Days 1-28 of each 28-day cycle.
1875548|NCT01142245|Drug|Oral esomeprazole|• Oral Esomeprazole 40mg on Day 1, 2 and Day 3 q12h
1875549|NCT01142245|Drug|Intravenous Esomeprazole|"Esomeprazole IV 80mg loading bolus
Esomeprazole intravenous infusion 8mg/hr for 72 hours"
1995116|NCT02850614|Behavioral|gaming application to encourage physical activity|
1995117|NCT02850614|Device|FitBit|
1875552|NCT01142271|Procedure|Billroth-I|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, gastroduodenostomy should be performed by circular stapler. In addition, stapler sites were re-enforced.
1875553|NCT01142271|Procedure|Roux en Y|Standard distal gastrectomy with D1 plus beta or D2 lymph node dissection would be performed for distal gastric cancer. After that, jejunojejunostomy and gastrojejunostomy should be performed by circular staplers. In addition, stapler sites were re-enforced.
1875554|NCT01142284|Drug|Cilostazol, Probucol|"Treatment Group 1 (control) No cilostazol or probucol
Treatment Group 2 (cilostazol alone) 1 tablet cilostazol 100 mg PO BID
Treatment Group 3 (probucol alone) 1 tablet probucol 250 mg PO BID
Treatment Group 4 (concomitant cilostazol and probucol) 1 tablet cilostazol 100 mg PO BID, and 1 tablet probucol 250 mg PO BID"
1875556|NCT01142310|Drug|Lamotrigine|Lamotrigine has a complex mechanism of action that appears to involve the inhibition of voltage-sensitive sodium channels resulting in a stabilization of membranes and inhibition of presynaptic glutamate release. Lamotrigine attenuates cerebral release of glutamate associated with cerebral ischemia in vitro and in vivo. Lamotrigine prevents cognitive and histologic changes in the hippocampus in animal models of ischemia. In patients with seizure disorders, decreases in plasma glutamate levels with lamotrigine are associated with a reduction in seizures. Lamotrigine or identical appearing placebo will be initiated at 25 mg/day and upwardly titrated to a dose of 400 mg/day over 10 weeks.
1875557|NCT01142310|Drug|Placebo|Placebo matching active medication in all other physical aspects.
1875558|NCT01142323|Drug|fenofibrate|160 mg po daily
1875559|NCT01142336|Drug|Simvastatin|Simvastatin 40mg qHS for 1 year
1875560|NCT01142336|Drug|Placebo|Placebo 1 tablet qHS for 1 year
1875561|NCT01142349|Behavioral|Lifestyles A|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain and insomnia
1875562|NCT01142349|Behavioral|Lifestyles B|Six weekly group sessions that last about 90-120 minutes presenting cognitive behavioral therapy for pain.
1875563|NCT01142349|Behavioral|Lifestyles C|Six weekly group sessions that last about 90-120 minutes presenting osteoarthritis education.
1875564|NCT01142362|Biological|VGX-3400X|DNA plasmids delivered via IM injection + electroporation using CELLECTRA device
1875565|NCT01142388|Biological|Cixutumumab|Given IV
1875566|NCT01142388|Other|Laboratory Biomarker Analysis|Correlative studies
1875567|NCT01142388|Drug|Paclitaxel|Given IV
1875568|NCT01142388|Other|Pharmacological Study|Correlative studies
1875569|NCT01142401|Drug|Bortezomib|Given IV
1875570|NCT01142401|Drug|Fulvestrant|Given IM
1875571|NCT01142401|Other|Laboratory Biomarker Analysis|Correlative studies
1875572|NCT01142414|Biological|panitumumab|
1875573|NCT01142414|Drug|cisplatin|
1875574|NCT01142414|Drug|fluorouracil|
1875575|NCT01142414|Other|laboratory biomarker analysis|
1875576|NCT01142414|Procedure|adjuvant therapy|
1875577|NCT01142414|Procedure|quality-of-life assessment|
1875578|NCT01142414|Radiation|3-dimensional conformal radiation therapy|
1875579|NCT01142414|Radiation|intensity-modulated radiation therapy|
1875580|NCT01142427|Other|Cytology Specimen Collection Procedure|Correlative studies
1875581|NCT01142427|Other|Laboratory Biomarker Analysis|Correlative studies
1875582|NCT01142440|Behavioral|behavioral intervention|"Dietary instructions
Oral hygiene instructions: GC plaque indicator kit
Antibacterial therapy: medident sol. one week a month, for 6 months
Fluorides: VOCO Profluorid varnish, once every 3 month
Restoration
Follow ups"
1875583|NCT01142453|Drug|Interferon beta 1a|A dosage of 44 µg interferon beta 1a subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase (depending on the respective preliminary therapy)
1875584|NCT01142466|Drug|Interferon beta-1a (Rebif)|The dosage of IFN-beta-1a , following initial dose titration, was 44 mcg injected subcutaneously (s.c.) tiw. An auto-injector device, Rebiject, was available as an optional aid for the administration of IFN-beta-1a . IFN-beta-1a was administered, if possible, at the same time (preferably in the late afternoon or evening) on the same three days at least 48 hours apart each week.
1875585|NCT01142479|Drug|Chinese herbal medicine decoction|100 ml /Qd for 6 weeks(42 days)
1875586|NCT01142492|Drug|Interferon beta-1a|Subjects first received Interferon beta-1a at a dose of 22 µg x3 over a period of 4 weeks. An attempt was then made to increase the dose of interferon beta-1a to 44 µg x3 as a self-administered subcutaneous (s.c.) injection. If intolerable interferon-specific side effects or problems of acceptance occured, the treatment with Rebif 22 µg three times weekly was continued.
1875587|NCT01142505|Drug|Mannitol|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack.
1875588|NCT01142505|Drug|Montelukast|4mg once daily granules for 10 days, given orally alone or with cold or warm food from the onset of a cold or wheezing attack
1875589|NCT01142518|Drug|Interferon beta 1a|Interferon beta 1a was administered at a dose of 44 μg x 3 as a subcutaneous self-injection.
1875590|NCT01142531|Radiation|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)
90 quality ref mAs with care-dose ON
120 kV
Pitch 1.4
Rotation time 0.33 s
Acquired images 64 x 0.6 mm"
1875591|NCT01142544|Other|Evaluation oxygenation under standard ventilator settings|Measure of PaO2 under standard FiO2-PEEP
1875592|NCT01142557|Drug|Interferon beta-1a (Rebif)|A dosage of 44 µg or 22 µg interferon beta-1a (Rebif) as subcutaneous self-injection three times a week was recommended for therapy of the included, suitable MS subjects after a creep-in phase of 4 weeks.
1875593|NCT01142570|Other|Caloric Support (Group 1)|Four group 1-dose of caloric support will be calculated by Hariss-Benedict Formula measurement of Resting Energy Expenditure(REE).
1875594|NCT01142570|Other|Caloric Support (Group 2)|For group 2- dose of caloric support will be calculated by Indirect Calorimetric measurement of Resting Energy Expenditure(REE)
1875595|NCT01142570|Dietary Supplement|Protein dose of 1.1 to 1.5 grams per kilogram weight.|Patients in the first group(Group 1A) will receive caloric support calculated by the HARRISS BENEDICT equation and protein dose of 1.1 to 1.5 grams per kilogram weight.
1875596|NCT01142570|Dietary Supplement|Protein at 1.1 grams per kilogram weight.|Patients in the second group(Group 2A) will receive caloric support as measured by indirect calorimetry and will receive protein at 1.1 grams per kilogram weight.
1875597|NCT01142570|Dietary Supplement|protein at a dose of 1.5 grams per kilogram weight.|Patients in the third group (Group 3A) will receive caloric support as measured by indirect calorimetry and will receive protein at a dose of 1.5 grams per kilogram weight.
1875598|NCT01142596|Drug|Asenapine|Asenapine 5 mg sublingual tablet BID, Asenapine 10 mg sublingual tablet BID
1875599|NCT01142596|Drug|Placebo|Placebo sublingual tablet BID (first 2 weeks, participants who were in placebo arm of P06124 study only)
1875600|NCT01142609|Behavioral|eGet|eGet individual counseling sessions from home will be scheduled weekly for 12 weeks.
1875601|NCT01142622|Drug|Ropivacaine nebulization|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity.
1875602|NCT01142622|Drug|Ropivacaine instillation|Preoperative instillation of 150 mg of Ropivacaine in the peritoneal cavity.
1875603|NCT01142635|Drug|Rocuronium bromide|Rocuronium, iv, 0,6 mg/kg diluted with saline to double volume, bolus, single dose
1875604|NCT01142635|Drug|Rocuronium bromide|Rocuronium, iv, single dose, single bolus, 1.2 mg/kg
1875605|NCT01142648|Drug|Sugammadex|Sugammadex 200 mg iv, single dose, bolus.
1875606|NCT01142648|Drug|Neostigmine and glycopyrrolate|Neostigmine 2.5 mg and glycopyrrolate 0,5 mg, iv, single dose, bolus, diluted in 2 ml volume with saline
1875607|NCT01142661|Drug|Eribulin Mesylate|Eribulin Mesylate: A dose of 1.4 mg/m^2 given intravenously on Day 1 and Day 8 of a 21 day cycle, continued until disease progression, unacceptable toxicity or death.
1875608|NCT01142687|Dietary Supplement|dihydrocapsiate capsule|"Group 1: 1 dihydrocapsiate capsule and 2 placebo capsules three times a day within 30 minutes before breakfast, lunch and dinner.
Group 2: 3 dihydrocapsiate capsules three times per day within 30 minutes before breakfast, lunch and dinner
Group 3: Placebo 3 capsules three times per day within 30 minutes before breakfast, lunch and dinner"
1875609|NCT01142700|Drug|BMS-824393|Capsule, Oral, 10 mg, once daily
1875610|NCT01142700|Drug|BMS-824393|Capsule, Oral, 30 mg, once daily
1875611|NCT01142700|Drug|BMS-824393|Capsule, Oral, 100 mg, once daily
1875612|NCT01142700|Drug|Placebo|Capsule, Oral, 0 mg, once daily
1875613|NCT01142700|Drug|Peginterferon Alpha-2a|Syringe, subcutaneous 180 mcg/0.5 mL, weekly
1875614|NCT01142700|Drug|Ribavirin|Tablet, Oral, 400 or 600 mg based on weight (am) and 600 mg (pm), twice daily
1875615|NCT01142713|Radiation|Patient Position During Radiotherapy|Two simulations, one in the supine position on a flat table and another in the prone position on belly board
1875616|NCT01142726|Drug|Abatacept|Injection, subcutaneous, 125 mg by syringe, once weekly, 12 months
1875617|NCT01142726|Drug|Methotrexate|Tablets, oral, 2.5 mg, once weekly, 12 months
1875618|NCT01142726|Drug|Abatacept placebo|Injection, subcutaneous, to match 125 mg by syringe, once weekly, 12 months
1875619|NCT01142726|Drug|Methotrexate placebo|Tablets, oral, to match 2.5-mg tablet, once weekly, 12 months
1875620|NCT01142739|Other|Clinical variables|Demography, disease duration, treatment duration, current treatment, daily intake of levodopa, Disease stage (Hoehn and Yahr, HY), motor score (UPDRS III) and dyskinesia severity (UPDRS IV). Biological variables.
1875621|NCT01142739|Other|Clinical variables|Demography, Biological variables.
1875622|NCT01142739|Other|Clinical variables|Eye movement recordings : non-invasive infra-red camera oculometry (EyeBrain) before and after (only parkinson's disease group) levodopa(10 to 15 minute/recording)
1875623|NCT01142765|Biological|AdCh63 MSP1, MVA MSP1, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
1875624|NCT01142765|Biological|AdCh63 AMA1, MVA AMA1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose MVA AMA1 2.5 x 108 pfu intramuscularly 8 weeks later (range 6-12 weeks) followed by sporozoite challenge 12-28 days later
1875625|NCT01142765|Biological|AdCh63 AMA1, AdCh63 MSP1, MVA AMA1, MVA MSP1, challenge|1 dose of AdCh63 AMA1 5 x 1010 vp intramuscularly and 1 dose AdCh63 MSP1 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA AMA1 2.5 x 108 pfu intramuscularly and 1 dose MVA MSP1 2.5 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
1875626|NCT01142765|Biological|AdCh63 MSP1, AdCh63 ME-TRAP, MVA MSP1, MVA ME-TRAP, challenge|1 dose of AdCh63 MSP1 5 x 1010 vp intramuscularly and 1 dose AdCh63 ME-TRAP 5 x 1010 vp intramuscularly co-administered into separate arms followed 8 weeks later (range 6-12 weeks) by 1 dose of MVA MSP1 2.5 x 108 pfu intramuscularly and 1 dose MVA ME-TRAP 2 x 108 pfu intramuscularly co-administered into separate arms (but the same arm as the corresponding AdCh63 vaccine) followed by sporozoite challenge 12-28 days later.
1875627|NCT01142765|Biological|Sporozoite challenge|Non-vaccinated controls for sporozoite challenge
1875628|NCT01142778|Drug|Bevacizumab|Bevacizumab at a dose of 15 mg/kg will be administered as IV infusion over 90 minutes from Cycles 3-6 (1 Cycle=21 days).
1875629|NCT01142778|Drug|Docetaxel|Docetaxel at a dose of 100 mg/m^2 will be administered as IV infusion from Cycles 1-6 (1 Cycle=21 days).
1875630|NCT01142778|Drug|Trastuzumab|Trastuzumab will be administered as a loading dose of 8 mg/kg as IV infusion in Cycle 1, followed by subsequent dose of 6 mg/kg as IV infusion in Cycles 2 to 7, and during additional 11 cycles post surgery (1 Cycle=21 days).
1875631|NCT01142778|Procedure|Surgery|All participants will undergo surgery (as per investigator's discretion) after Cycle 7 and between 4 and 6 weeks after the study treatment infusion in Cycle 6 (1 Cycle=21 days).
1875632|NCT01142778|Radiation|Radiotherapy|All participants will receive radiotherapy starting about 4 to 8 weeks after surgery, and will last around 4 to 6 weeks as per site's standard practice.
1875633|NCT01142778|Drug|Hormonal Therapy|Participants who are hormone receptors positive, will receive hormonal therapy after completion of radio therapy period as per investigator's discretion and site's standard practice.
1875634|NCT01142791|Device|ExAblate|Magnetic resonance image-guided focused ultrasound (MRgFUS) for fibroid ablation
1875635|NCT01142804|Behavioral|Group|Walking programs with various levels of support will be administered to determine which one is most effective.
1875636|NCT01142843|Drug|green propolis mouthwash|The subjects were instructed to brush their teeth as usual and to rinse with the 10mL of Mouthwash contain 5% Green Propolis, twice a day, for one minute, right after their meals in the morning and at night. The treatment was performed during three months
1875637|NCT01142856|Biological|autologous mesenchymal stem cells|single intrathecal dose of 10x6 cells by lumbar puncture.
1875638|NCT01142869|Drug|Cetuximab|The starting dose will be intravenous (IV) cetuximab 400 mg/m2 body surface area administered as a 120-minute infusion once a week . The subsequent weekly doses will be IV cetuximab 250 mg/m2 administered as a 60-minute infusion. The maximum infusion rate must not exceed 10 mg/min.
1875639|NCT01142882|Behavioral|Traditional Prevention|Participants in the traditional prevention intervention condition will complete two sessions (of approx. one hour in duration) across the course of a week, conducted by a trained HIV (and infectious disease) prevention educator; these sessions will typically be conducted in small groups of 2-4 participants but may be offered individually.
1875640|NCT01142882|Behavioral|Web-based Prevention|Participants in the web-based intervention condition will complete an interactive, web-based HIV, hepatitis and STI prevention program. Youth will be asked to complete a customized plan of approximately 2-4 hours in length using the web-based tool; participants will complete two 60-minute sessions per week until they complete their customized plan. Participants can choose to access this intervention using dedicated computer stations set up at their substance abuse treatment setting or can complete these sessions at their own home via the web.
1875641|NCT01142908|Behavioral|Pharmacist CVD|clinical pharmacist-administered intervention which focuses on behavioral and medication management for 12 months.
1875642|NCT01142921|Device|Anti-reflux Tannenbaum biliary stent|Anti-reflux Tannenbaum biliary stent
1875643|NCT01142921|Device|Ordinary Tannenbaum biliary stent|Ordinary Tannenbaum biliary stent
1875644|NCT01142934|Device|Transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG) (TegaDerm CHG)|The intervention is represented by the combination of the TegaDerm transparent adhesive dressing with an integrated gel pad containing 2% w/w chlorhexidine gluconate (CHG), an antiseptic agent with broad spectrum antimicrobial and antifungal activity.
1875645|NCT01142947|Drug|beclomethasone dipropionate|160 mcg twice a day (320 mcg per day total)
1875646|NCT01142960|Dietary Supplement|Starch|1350mg/day
1875647|NCT01142960|Dietary Supplement|Lycium Barbarum|1350mg/day
1875648|NCT01142986|Behavioral|Low intensity care|During the first 3-months (13 weeks), subjects will be scheduled to attend one individual counseling session per month. Subjects will not be required to attend any group counseling sessions during this time. After the first 3-months of care, subjects will start usual counseling care, at which time they will be required to attend one individual counseling session per week, and may be required to attend additional individual and group counseling sessions each week for missed sessions or continued use of drugs or alcohol.
1875649|NCT01142986|Behavioral|Voucher reinforcement|Subjects will receive usual counseling care during the 26 weeks of study participation.They will be required to attend one individual counseling session per week, and will be required to attend additional individual and group sessions each week for missed session or continued use of drugs or alcohol.In addition, subjects in this condition will have the opportunity to earn voucher incentives each week during the first 13 weeks of care.These incentives can be earned by taking daily methadone doses and attending all scheduled counseling sessions (individual and group).The first voucher is worth $12.00, and each voucher after that is worth an additional $13.50. Bonuses of $30.00 will be awarded for each 3 consecutive weeks of compliance.The total amount possible to earn in the study is $1329.00. Each week that the subject is not compliant,they will not earn a voucher and the value of the next voucher will be reset to $12.00.The vouchers can be used for goods and services in the community.
1875650|NCT01142999|Drug|Sunflower oil|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
1875651|NCT01142999|Drug|Control group|This group will be asked NOT to use any skin moisturizers and use only soap substitutes on their infants.
1875652|NCT01142999|Drug|Aquaphor ointment|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
1875653|NCT01142999|Drug|Cetaphil cream|One group will be instructed to use FDA-approved moisturizers and soap substitutes on their newborn infants.
1875654|NCT01143012|Other|Group eczema education session|Subjects in the intervention group will participate in a group education visit to discuss topics such as subjects' general understanding and knowledge of eczema and its treatment.
1875655|NCT01143012|Other|Control group|The control group will not attend the group eczema education session.
1875656|NCT01143025|Drug|Ropivacaine 50 mg|Preoperative nebulization of 50 mg of Ropivacaine in the peritoneal cavity
1875657|NCT01143025|Drug|Ropivacaine 100 mg|Preoperative nebulization of 100 mg of Ropivacaine in the peritoneal cavity
1875658|NCT01143025|Drug|Ropivacaine 150 mg|Preoperative nebulization of 150 mg of Ropivacaine in the peritoneal cavity
1875659|NCT01143038|Biological|Romiplostim|Romiplostim will be administered weekly by subcutaneous injection
1875660|NCT01143051|Drug|epinephrine inhalation aerosol|Single dose 220 mcg/inhalation, 10 inhalations
1875661|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 125 mcg/inhalation, 10 inhalations
1875662|NCT01143051|Drug|epinephrine inhalation aerosol|HFA propelled epinephrine inhalation aerosol, 160 mcg/inhalation, 10 inhalations
1875663|NCT01143064|Drug|Progesterone|Intravenous administration of 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
1875664|NCT01143064|Drug|Lipid emulsion without progesterone|Intravenous administration equal to 0.71mg/kg/hr for 1hr followed by 0.5mg/kg/hr administered intravenously for an additional 119 hrs.
1875665|NCT01143077|Drug|Lurasidone HCl|Lurasidone tablets, 40 mg/daily, 80 mg/daily, 120 mg/daily for 6 weeks
1875666|NCT01143090|Drug|Lurasidone HCl|40 mg Lurasidone tablets, 40 - 120 mg per day for up to 6 months
1875667|NCT01143103|Device|Cough assist (Philips,respironics)|
1875668|NCT01143103|Other|Usual respiratory therapy|
1875669|NCT01143129|Drug|Dexamethasone|Single dose (1 mg/kg) at start of cardiac surgical procedure
1875670|NCT01143129|Drug|Placebo|Placebo solution in a comparable amount to the experimental drug (0.05 mL/kg)
1875671|NCT01143142|Behavioral|Computer-based tailoring system|Both the intervention and control groups will use a computer-based tailoring system to respond to survey questions. The computer-based tailoring system will produce messages for a two-page educational brochure based on participants' responses to survey questions. Only the intervention group will receive this brochure.
1875672|NCT01143168|Biological|autologous bone marrow mononuclear cells and umbilical cord mesenchymal stem cells|First Transplantation: after finishing all required examines according to protocol on Day 0, ABM-MNCs + UCMSCs are transplanted through pancreas artery percutaneously; Second Transplantation: after finishing all required examines on Day 7±1, BM-MNCs UCMSCs are transplanted intravenously; Third Transplantation: after finishing all required examines on Day 14±2, BM-MNCs + UCMSCs are transplanted intravenously.
1875673|NCT01143181|Drug|CMX001|CMX001 administered orally twice weekly for up to 3 months. Treatment may be extended for up to 6 months depending on the patient's clinical response.
1875674|NCT01143194|Dietary Supplement|oréVida™|1 capsule 30 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 60 mg/day)
1875675|NCT01143194|Dietary Supplement|oréVida™|1 capsule 60 mg oréVida™ twice a day (one in the morning, one in the afternoon, so in total 120mg/day)
1875676|NCT01143194|Dietary Supplement|oréVida™|1 capsule 120 mg oréVida™ in the morning, one placebo capsule in the afternoon (si in total 120 mg/day)
1875677|NCT01143194|Dietary Supplement|Placebo|1 capsule of placebo twice a day
1875678|NCT01143207|Drug|Medroxyprogesterone acetate|Injectable hormonal contraceptive
1875679|NCT01143220|Other|No specific interventions|Observational investigation, only procedures according to local hospital standard.
1875680|NCT01143233|Other|control formula|infants are fed a commercial hydrolyzed formula
1875681|NCT01143233|Other|intervention formula 1|formula has hydrolysed protein and a different protein content
1875682|NCT01143233|Other|intervention formula 2|formula has hydrolysed protein, different protein content and pro- and prebiotics
1875683|NCT01143233|Other|intervention formula 3|formula has hydrolysed protein, different protein content and pro- and prebiotics
1875684|NCT01143246|Drug|Terlipressin|Blinded terlipressin reconstituted with 5 mL of sterile 0.9% sodium chloride solution for injection will be administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day).
1875685|NCT01143246|Drug|Placebo|Lyophilized mannitol reconstituted with 5 mL of sterile 0.9% sodium chloride solution administered intravenously as a slow bolus injection over 2 minutes at a dose of 1 mg (1 vial) every 6 hours (4 mg/day).
1875686|NCT01143259|Drug|Alvimopam|The treatment group will receive 12mg of Alvimopan by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.12 mg by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days.
1875687|NCT01143259|Drug|300 mg Polyethylene|The control group will receive 300mg of polyethylene glyco by mouth 30 to 90 minutes before surgery and twice daily till discharge or to a maximum of 7 days (15 doses, total) after surgery.
1875688|NCT01143272|Drug|Saccharomyces boulardii|Units: 500 mg per day Route of administration : Oral Use Hard-Capsule
1875689|NCT01143272|Drug|Placebo|Placebo
1875690|NCT01143285|Other|Early and active nutritional support.|The first nutritional consultation coincides with the 1st CT consultation. An overview of the nutritional support strategy is given, along with specific goals and the twice monthly follow-up schedule that accompanies the chemotherapy courses. The nutritionist once again goes over the various side effects of the medication. Special attention will be given to digestive side effects and their consequences on appetite levels and weight loss during treatment.A qualitative and quantitative 3-day food record will precede the 1st course of CT. This food record is given to patients during the 1st selection visit, in order to evaluate spontaneous oral food intake and dietary habits. Information from the different food groups serves as a starting point for the dietician to explain how to adapt food intake through fortification, portion control according to appetite fluctuations and the onset of side effects.
1875691|NCT01143298|Drug|LEO 27847 oral solution|
1875692|NCT01143311|Genetic|Arm A|"4 distinct biopsies will be taken
in a non UV-exposed area (inner arm)
in a UV-exposed area (external surface of the forearm)
in a pretumoral region (actinic keratosis)
inside the tumor"
1875693|NCT01143324|Device|MAST™ procedure|Single or double level instrumented fusion receiving the CD Horizon® Spinal System using PLIF or TLIF techniques via a MAST™ procedure.
1875694|NCT01143337|Drug|MP-435(dose1) + Methotrexate|MP-435 dose1 + stable weekly dose of Methotrexate
1875695|NCT01143337|Drug|Placebo + Methotrexate|Placebo + stable weekly dose of Methotrexate
1875696|NCT01143350|Other|Bras A (EHPAD Training and stimulation)|"EHPAD of the group of Training / Stimulation will benefit:
after a training in behaviours to be held or in methods of stimulation aiming at the reduction of disturbances of behaviour at type of apathy. This information will be transmitted in l 'ensemble of l 'équipe of l 'EHPAD by a training officer.
of a structuring of the activities of animation offered to the inhabitants, This information will be regrouped in chips worked out like TNM - EHPAD."
1875697|NCT01143350|Other|EHPAD Control|EHPAD of the reference group, will have their habitual functioning
1875698|NCT01143363|Behavioral|resting - control|
1875699|NCT01143363|Behavioral|Moderate intensity exercise|
1875700|NCT01143363|Behavioral|High intensity intermittent training|
1875701|NCT01143363|Behavioral|Short sprint|
1875702|NCT01143376|Behavioral|High intensity training|high-intensity intermittent sprinting (HIIS) (8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
1875703|NCT01143376|Behavioral|short springs|short duration sprints (SDS)(8 sec sprint:12 sec rest) for 12 weeks, 4 times a week
1875704|NCT01143376|Behavioral|Moderate intensity exercise|
1875705|NCT01143389|Drug|Riboflavin|Riboflavin 0.1% eye drops are applied before and during irradiation of the cornea.
1875706|NCT01143389|Device|UVX light|UVX 365 nm wavelength light source is applied with continued application of riboflavin.
1875707|NCT01143402|Drug|Dacarbazine|Given IV
1875708|NCT01143402|Other|Laboratory Biomarker Analysis|Correlative studies
1875709|NCT01143402|Other|Quality-of-Life Assessment|Ancillary studies
1875710|NCT01143402|Drug|Selumetinib|Given PO
1875711|NCT01143402|Drug|Temozolomide|Given PO
1875712|NCT01143441|Biological|DAC-HYP|
1875719|NCT01143584|Drug|Cabergoline|"In the Conventional escalation group Cabergoline 0.5 mg once a week for 4 weeks and further will be incrementally dose adjusted on the basis of individual PRL values until amelioration of hyper prolactinemia @ 0.5 mg/wk every 4 weeks, till 24 weeks or until primary endpoint.
Cabergoline will be maintained at the dose at which PRL will be first normalized till primary end point."
1875720|NCT01143584|Drug|cabergoline|"In the Rapid escalation group schedule of cabergoline dosing will be as follows:
Begin with 0.5 mg twice a week
mg twice a week - second week 1.5 mg twice a week - third week
mg twice a week - fourth week
4mg/wk would be continued for next 4 weeks. If prolactin does not normalize by 8 weeks, a repeat hike in dose of 1mg/wk will be done every 4 weekly until normalization of prolactin levels and also >50% decrease in tumor volume. Ceiling dose of Cabergoline will be 12mg/wk."
1875721|NCT01143597|Other|Arm and hand training|Individuals will receive either: somatosensory stimulation isolated or combined with a skill-based exercise protocol, or a conventional strengthening program.
1875722|NCT01143610|Procedure|Newly forming bone technique for root coverage|A granulation tissue will be obtained 21-25 days after the creation of an alveolar socket and grafted to receptor site.
1875723|NCT01143610|Other|Subepithelial connective tissue graft for root coverage.|A subepithelial connective tissue graft will be used for the treatment of Miller class I or II deep recessions.
1875724|NCT01143623|Dietary Supplement|Probiotic|L. acidophilus, L. paracasei, B. lactis; 2.5 billion cfu capsule once per day
1875725|NCT01143623|Dietary Supplement|Probiotic|L. acidophilus, L. paracasei, B. lactis; 10 billion cfu capsule once per day
1875726|NCT01143623|Other|Placebo|Placebo
1875727|NCT01143636|Device|Transcranial Direct Current Stimulation|Chronic pain subjects will be randomized to receive either active or sham stimulation for the duration of the trial. The subject will receive 10 consecutive sessions at an intensity of 2mA with each session lasting 20 minutes. If the subject receives active stimulation the current will be applied for the full 20 minutes, while in the sham group current will only be applied for 30 seconds. In the healthy cohort, subjects will receive one session of active stimulation and one session of sham stimulation. The parameters will be the same as the pain subjects, at an intensity of 2mA for 20 minutes.
1875728|NCT01143649|Device|transcranial direct current stimulation (tDCS)|Subjects will be stimulated at 1 mA for 40 minutes.
1875729|NCT01143649|Procedure|constraint induced movement therapy (CIMT)|
1875730|NCT01143649|Device|transcranial alternating current stimulation (tACS)|Subjects will be stimulated at 15Hz for 20 minutes.
1875731|NCT01143662|Drug|Ypeginterferon alfa-2b|sc, qw, for 48 weeks.
1875732|NCT01143662|Drug|Peginterferon alfa-2a|sc, qw, for 48 weeks.
1875733|NCT01143688|Drug|albuterol|
1875734|NCT01143688|Drug|placebo inhaler|
1875735|NCT01143688|Procedure|placebo acupuncture|
1875736|NCT01143701|Other|ADHD Collaborative|The ADHD Collaborative intervention model includes academic detailing, quality improvement methods, and innovative tools (e.g., web portal) designed to promote and support the systematic use of the AAP guidelines.
1875737|NCT01143714|Drug|Santyl|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
1875738|NCT01143714|Other|White Petrolatum|Apply an amount sufficient (thickness of a nickel) to cover the wound area. It will be applied once daily during the treatment phase, up to four weeks.
1875739|NCT01143727|Drug|Santyl|Apply one 24-hr period sufficient to cover the wound.
1875740|NCT01143727|Drug|Tegaderm Hydrogel|Apply once 24-hr period sufficient to cover the wound.
1875741|NCT01143740|Drug|RO5045337|orally day 1-10 each 28-day cycle, 3 cycles
1875742|NCT01143753|Drug|RO5212054|Participants will receive RO5212054 at a starting dose of 200 milligrams (mg) orally once daily in each 21 day cycle. Dose levels for escalation will be decided based on the safety assessment of previous cohort. Dose escalations in increments of 50-100 percent are planned.
1875743|NCT01143766|Drug|Gabapentin|gabapentin 900mg PO x 1 dose, 1 hour prior to the procedure
1875744|NCT01143766|Other|Standard sedation regimen|Combination opiate and benzodiazepine will be administered to achieve moderate sedation. This is the standard of care.
1875746|NCT01143792|Behavioral|Community Reinforcement Approach (CRA) + HIV prevention|12 sessions of the CRA and 2 sessions of HIV prevention.
1875747|NCT01143792|Behavioral|Case Management + HIV Prevention|12 sessions of case management and 2 sessions of HIV prevention.
1875748|NCT01143792|Behavioral|Motivational Enhancement Therapy (MET) + HIV prevention|2 sessions of MET and 2 sessions of HIV prevention.
1875749|NCT01143805|Drug|Tasocitinib 10 mg oral tablet|Treatment A: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of an oral tablet
1875750|NCT01143805|Drug|Tasocitinib 10 mg IV Infusion|Treatment B: Single-dose of tasocitinib (CP-690,550) (10 mg) in the form of a 30 minute intravenous infusion
1875751|NCT01143818|Drug|AndroGel (testosterone gel) 1%|AndroGel is topical testosterone gel 1% and is prescribed for once daily use.
1875752|NCT01143831|Dietary Supplement|Vitamin K, 20mg|Subjects will take 20mg vitamin K by mouth in capsule form everyday for 14 continuous days.
1875753|NCT01143857|Drug|Varenicline|Varenicline 2.0 mg/day or Placebo
1875755|NCT01143883|Other|Silverlon|Silverlon dressings are gauze impregnated with silver ions
1875756|NCT01143883|Other|Standard of Care Dressing|Standard dry gauze dressing
1875790|NCT01144195|Drug|Panitumumab + FOLFIRI|Panitumumab will be administered by intravenous (IV) infusion at a dose of 6 mg/kg once every 2 weeks. FOLFIRI chemotherapy will be administered once every 2 weeks after the administration of Panitumumab.
1875791|NCT01144221|Procedure|Intramyocardial Cell therapy|Intramyocardial Cell therapy in patients with chronic ischemic heart disease after ICD CRT Implantation
1875792|NCT01144234|Behavioral|Invitation letter for male spouse|In this arm the pregnant women got an invitation letter for the spouse to attend at the next antenatal visit
1875793|NCT01144234|Behavioral|Information letter|In this arm the pregnant women got an information letter
1995120|NCT02849925|Drug|Sealants to arrest microcavitated caries.|Carious lesions will be treated by minimally invasive dentistry by the use of sealants instead of eliminating carious tissues and using conventional restorative materials.
1875757|NCT01143896|Other|Depression collaborative care model|The intervention will include a stepped-care model. The 5 steps include symptom and self-management monitoring by a depression care manager (DCM) and the following: 1) watchful waiting, 2) treatment recommendations (counseling or pharmacotherapy), 3) pharmacotherapy recommended by a Clinical Pharmacist, 4) combination pharmacotherapy and specialty mental health counseling, and 5) referral to mental health. The DCM: provides education about depression and depression treatment options; assesses the patient's treatment preferences and barriers, and the patient's current depression severity and mental health comorbidity; initiates a patient self-management plan, and assess treatment adherence. The DCM uses standard alcohol screening and brief intervention. The DCM also screens for street drug use and recommends referral for to the local substance abuse treatment programs.
1875758|NCT01143909|Other|omitting FFP transfusion before an intervention|In the interventional group FFP transfusion is omitted before performing a procedure (e.g. placement of central venous catheter, tracheostomy, chest tube)
1875759|NCT01143948|Drug|Glargine & Glulisine|Basal Glargine & bolus Glulisine
1875760|NCT01143948|Drug|Regular insulin|Sliding scale regular insulin
1875761|NCT01143948|Drug|NPH & regular insulin|Basal NPH & bolus regular insulin
1875762|NCT01143961|Device|CSC100 - Verso airway access adapter CareFusion|Following randomisation patients will have a one-way valve inserted into the ventilator circuit (CSC100 - Verso airway access adapter CareFusion) prior to a non-directed bronchoalveolar lavage (NBL) being performed. Changes in regional ventilation will be recorded by electrical impedance tomography during the NBL. Recordings of ventilation will take place for upto four hours. One-way valve will stay in place until ventilator circuit is changed.
1875763|NCT01143974|Drug|pemetrexed plus cisplatin|pemetrexed 500mg/m2 plus cisplatin 80mg/m2 on day1 of each 21 day cycle, until progression
1875764|NCT01143987|Drug|Cinacalcet|starting with 25 mg daily dose with titration, maximum dose 100 mg daily
1875765|NCT01144000|Drug|Daptomycin|10mg/kg/24h i.v.(intravenous) for 2-3 weeks with/or without rifampin (depending if the prosthesis is removed or not)
1875766|NCT01144026|Biological|TUTI-16 (0.2mg)|Two subcutaneous injections of 0.2 mg at Day 0, and Week 5.
1875767|NCT01144026|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of 1.0 mg at Day 0, and Week 5.
1875768|NCT01144039|Drug|LG-group|
1875769|NCT01144039|Drug|HG-group|
1875770|NCT01144039|Drug|Placebo-group|
1875771|NCT01144052|Drug|interferon beta-1b|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 month at study entry. After a wash-out period of one month, interferon-beta-1b will be administered subcutaneously every other day as indicated by the manufacturers' instructions including the stepwise up-titration scheme as recommended for treatment start. The final dose of interferon beta-1b is 250 mcg (8 million International Units [MIU])
1875772|NCT01144052|Drug|Natalizumab|Eligible patients to this study have been treated with monthly infusions of natalizumab for at least 12 months at study entry. Natalizumab continues to be administered every four weeks by intravenous infusion from the beginning of the study as indicated by the manufacturers' instructions.
1875773|NCT01144065|Procedure|Hair sampling for the measurement of cortisol and testosterone|Hair sampling for the measurement of cortisol and testosterone
1875774|NCT01144078|Behavioral|Traditional Intensity Exercise|The exercise intensity will be set at a workload corresponding to 40% of the workload obtained at VO2peak during the baseline progressive maximal exercise tests. Based on the anticipated fitness of the participants this should to an intensity of about 3.5 METs, which is similar to walking at a moderate pace.
1875775|NCT01144078|Behavioral|High Intensity Interval Exercise|The High Intensity Interval Exercise intervention will replicate all aspects of the Traditional Intensity Exercise with the exception of exercise intensity. The High Intensity Interval Exercise protocol will involve alternating between 1-minute intervals at 100% workload obtained at VO2peak followed by 3-minute recovery intervals at 20% of workload obtained at VO2peak (average = 40% ). As many complete intervals as possible will be completed during a training session (e.g., 7 intervals can be completed in a 30 min period (7 x 4 min = 28 min), with the remaining time spent at 40% peak workload to ensure a similar work output as the Traditional Intensity Exercise.
1875776|NCT01144091|Drug|pentoxyphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
1875777|NCT01144091|Drug|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
1875778|NCT01144091|Drug|pentoxiphylline|pentoxyphylline tablets, 400 mg per tablet, 3 times a day one day before, on the day of the procedure and for another 48 hours.
1875779|NCT01144091|Drug|placebo|placebo tablets 3 times a day one day before, on the day of the procedure and for another 48 hours.
1875780|NCT01144104|Behavioral|Public Service Announcement|
1875781|NCT01144104|Behavioral|Interactive Multi-Media Computer Program|
1875782|NCT01144104|Behavioral|Sleep Hygiene Video|
1875783|NCT01144117|Drug|Erythropoietin|Erythropoietin 48000 IU given I.V. in 17 courses
1875787|NCT01144156|Drug|Treatment with Adalimumab|All patients will receive SC adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg from week 4 every 2 weeks up to 12 weeks
1875788|NCT01144169|Drug|Hydroxychloroquine (HC)|Subjects will receive HC orally for 14 days prior to surgery. The fixed dose of HC will be 400 mg/day in divided doses (200 mg bid). The final dose will be administered on the evening prior to nephrectomy.
1875789|NCT01144182|Behavioral|Comprehensive quality improvement program (QIP)|Comprehensive quality improvement program (QIP) that intervenes on patient, provider and system levels. The QIP will consist of 3 monthly phone calls to promote diet and medication adherence using the transtheoretical model as a behavioral framework and checklists to facilitate patients' self-monitoring of their diet, physical activity, weight and medication taking. Further, providers during the posttest phase will use checklists for inpatient and outpatient care of HF patients.
1875794|NCT01144247|Drug|alloreactive CTL|cellular immunotherapy with alloCTL
1876073|NCT01146613|Drug|Placebo|identical matched placebo x 2, 2xday, 13 weeks
1875795|NCT01144260|Drug|bafetinib|250 mg orally twice daily. Treatment continues until clinically significant disease progression or unacceptable toxicity is documented.
1875796|NCT01144273|Procedure|Transversus abdominis plane block|"This intraabdominal approach to TAP block is being used regularly by gynaecological surgeons in this hospital now.
To be performed bilaterally before surgical wound closure by an experienced surgeon who initially undergo initial observation by investigator to ensure uniformity in technique.
Local anaesthetic or placebo solution will be injected to TAP with blunt needle from within abdominal cavity under visual and tactile guidance at the triangle of Petit, after feeling one 'pop' through the transversus abdominis muscle to the TAP layer.
After careful aspiration to exclude vascular puncture, 1.5mg/kg of 0.5% ropivacaine or 0.3ml/kg of 0.9% saline placebo will be injected to each side slowly while observing for signs of toxicity."
1875797|NCT01144286|Drug|arasertaconazole nitrate|Arasertaconazole nitrate pessary, placebo pessary
1875798|NCT01144286|Drug|placebo|placebo, single dose
1875799|NCT01144299|Biological|Fluarix™/Influsplit SSW®|Single intramuscular dose on Day 0
1875800|NCT01144312|Drug|Fentanyl|an initial intravenous bolus of fentanyl 100 μg and infusion of fentanyl at variable rates ranging from 250 to 400 μg/hr
1875801|NCT01144325|Procedure|thoracoscopic esophagectomy|"In prone position group, patients are intubated with single lumen endotracheal tube. Surgeon and assistant stand on the right of the patient. A 10 mm camera port is placed 7th intercostals space in posterior axillary line, CO2 pneumothorax is created with pressure of 8mmHg. A 5 mm port is placed just posterior to the scapular tip. The last 10mm port is placed at 9th intercostals space in the scapular line for. The tumor and esophagus are dissected with cleaning of the lymph nodes along bilateral recurrent nerve.
In controlling group, The four chest ports were similar to that described by the University of Pittsburgh group. The left two ports are used for surgical exposure, the right two ports is to divide and dissect the esophagus. The dissection is similar to that of the prone position."
1875802|NCT01144338|Drug|Exenatide Once Weekly|Subcutaneous injection, 2 mg, administered once weekly.
1875803|NCT01144338|Drug|Placebo|Subcutaneous injection, matching volume of placebo, administered once weekly.
1875804|NCT01144351|Drug|ELND002|
1875805|NCT01144351|Drug|Placebo|
1875806|NCT01144364|Drug|rituximab [Mabthera/Rituxan]|Intravenous repeating dose
1960219|NCT03267784|Biological|allo-APZ2-DFU|Suspension of ABCB5-positive mesenchymal stem cells
1875809|NCT01144390|Behavioral|cognitive behavioral therapy|cognitive behavioral therapy, one session per week and psycho-education lecture in group once per month
1875810|NCT01144390|Drug|methadone maintenance treatment|methadone maintenance treatment
1875811|NCT01144403|Drug|Cyclophosphamide|as prescribed, 6 cycles
1875812|NCT01144403|Drug|Fludarabine|as prescribed, 6 cycles
1875813|NCT01144403|Drug|Mitoxantrone|as prescribed, 6 cycles
1875814|NCT01144403|Drug|Rituximab|375 mg/m^2 intravenously, Day 1 of each 28-day cycle, up to 8 cycles
1875819|NCT01144429|Biological|Allergoid, allergenic extract of 100% Birch|Subcutaneous injections Build-up = 1 day: 0,1mL + 0,2mL + 0,2mL s.c. in intervals on 30 minutes; Maintenance = 5 x single injection of 0,5 mL s.c. every 4 weeks
1875820|NCT01144442|Drug|Hyperthermic intraperitoneal chemotherapy with Carboplatin|Carboplatin at a dose of 1000mg/m^2 will be added to the perfusate once circulating levels reach 1000-1500cc/minute. The circulation of the chemotherapy impregnated perfusate will be performed for 90 minutes.
1875821|NCT01144442|Other|Isotonic saline (perfusate)|The HIPC infusion will be performed with a closed abdomen technique. The perfusate will be isotonic saline heated to 40-42° Celsius.
1875822|NCT01144442|Procedure|Surgery|"The abdominal incision will be performed in a vertical fashion extending from the supra-pubic region to around the umbilicus.
If cytoreductive surgery is required, it will be performed at this time and proceed in standard approach."
1875823|NCT01144442|Drug|Carboplatin|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
1875824|NCT01144442|Drug|Paclitaxel|The scheduled systemic chemotherapy is paclitaxel 175mg/m2 and carboplatin AUC 6 every 3 weeks for 6 total cycles.
1875828|NCT01144494|Drug|Brimonidine|One drop of brimonidine in each eye three times a day for six weeks.
1875829|NCT01144494|Drug|Artificial tears|Lubricating drops added three times a day for six weeks
1875830|NCT01144507|Procedure|Abdominal Ultrasound|To establish eligibility and/or markers regarding echo pattern types.
1875831|NCT01144507|Other|Sample collection procedures|Samples of urine, serum, plasma, and blood for DNA from children and blood for DNA from parents will be requested from participating subjects
1875832|NCT01144533|Procedure|isotonic saline injection into the glenohumeral joint|"Total volume of injection drugs: 8ml
isotonic saline 4ml + telebrix(contrast media) 4ml
The number of injections : only once during the study period
Injection site : glenohumeral joint
Material : 22-gauze spinal needle
Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
1875833|NCT01144533|Procedure|steroid injection into the glenohumeral joint|"Total volume of injection drugs: 8ml
triamcinolone(40mg)1ml + isotonic saline 3ml + telebrix(contrast media)4ml
The number of injections : only once during the study period
Injection Site : glenohumeral joint
Material : 22-gauze spinal needle
Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
1875834|NCT01144533|Procedure|sodium hyaluronate injection into the glenohumeral joint|"Total volume of injection drugs: 8ml
sodium hyaluronate 2ml + isotonic saline 2ml + telebrix(contrast media)4ml
The number of injections : only once during the study period
Injection Site : glenohumeral joint
Material : 22-gauze spinal needle
Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
1875835|NCT01144533|Procedure|steroid and hyaluronate injection into the glenohumeral joint|"Total volume of injection drugs: 8ml
triamcinolone(40mg)1ml + sodium hyaluronate 2ml + isotonic saline 1ml + telebrix(contrast media)4ml
The number of injections : only once during the study period
Injection Site : glenohumeral joint
Material : 22-gauze spinal needle
Anteroposterior, lateral, and axial arthrography after injection was performed to determine accuracy and patterns of the injection."
1875836|NCT01144546|Procedure|passive leg raising (45 degree leg elevation for 1-2 min)|the patient's trunk was elevated 45 degrees for the first set of measurements. Then, the lower limbs were raised to a 45° angle while the patient's trunk was lowered to a supine position to measure peak CO (usually within 1-2 min)
1875837|NCT01144559|Procedure|Continuous Infusion|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered continuously every hour by a pain pump. Outcome measures will be tested.
1875838|NCT01144559|Procedure|Bolus Administered|Extremity randomized continuous infusion will be given a peripheral nerve block and 5cc of Ropivacaine will be administered using a bolus every hour by a pain pump. Outcome measures will be tested.
1875839|NCT01144585|Procedure|remote ischemic preconditioning and postconditioning|"RIPC is done before the use of CPB. It consists of 4 cycles of 5 minutes inflation of pneumatic cuff to 200 mmHg and deflation for 5 minutes. RIPoC is exactly same procedure done after CPB."
1875840|NCT01144585|Procedure|Control|This group has same pneumatic cuff during the surgery, but it is not inflated during the surgery
1875841|NCT01144611|Drug|bIAP bolus and 8h infusion|intravenous as a bolus of bIAP (bovine intestinal alkaline phosphatase, 1000 IU) just prior to surgery followed by a 40 IU/kg bIAP infusion during the first 8 hours post surgery.
1875842|NCT01144611|Drug|placebo bolus and 8h infusion|intravenous as a bolus just prior to surgery followed by an infusion during the first 8 hours post surgery.
1875843|NCT01144624|Drug|AZD9773|A single loading dose followed by 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
1875844|NCT01144624|Drug|Placebo|Intravenous infusion of a saline solution
1875845|NCT01144637|Biological|IMVAMUNE®|0.5 ml IMVAMUNE® vaccine containing at least 1 x 10E8 TCID50 (standard dose)
1875846|NCT01144637|Other|Placebo|0.5 ml TBS
1875847|NCT01144650|Drug|Dapsone|Patients will receive either a single total dose of 250 mg dapsone or placebo IV and oral dosage
1875848|NCT01144650|Drug|Placebo|Patients will receive either a single total dose of 250 mg placebo IV and oral dosage
1960227|NCT03264482|Procedure|M-TURP|endoscopic resection of the prostatic adenoma
1960228|NCT03264482|Procedure|THUVAP|vaporization of prostatic adenoma via THULIUM laser
1875854|NCT01144676|Drug|dapivirine|"25mg dapivirine per ring.
The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days."
1875855|NCT01144676|Drug|placebo|The first vaginal ring will be removed on Day 28, and a new vaginal ring will be reinserted after 3 days, on day 31, for another 28 days.
1875856|NCT01144676|Drug|dapivirine|"25mg dapivirine per ring.
The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours."
1875857|NCT01144676|Drug|placebo|The first vaginal ring will be removed on day 35 and the new vaginal ring will be reinserted after 3 days, on day 38, for another 21 days. A third vaginal ring will be inserted immediately following removal of second ring on Day 59 and will be worn for 24 hours.
1875858|NCT01144689|Behavioral|Mindfulness Training|8 sessions of behavioral treatment for smoking cessation
1875859|NCT01144689|Behavioral|Smoking Cessation Therapy|8 sessions of behavioral treatment for smoking cessation
1875860|NCT01144702|Drug|artesunate & mefloquine combination|A therapeutic trial of a single arm for prospective evaluation of responses of individuals with uncomplicated malaria by P. falciparum treated with combination artesunate + mefloquine for three days and monitored clinically and biochemically for 42 days.
1875861|NCT01144715|Device|Hand Mentor (TM) robotic stroke therapy device|The goal of the Hand Mentor ™ (TM) device is to improve Active Range of Motion in the distal musculature of the paretic limb of patients with stroke. Development of HM patient protocols are based on basic principles of motor learning: the protocols actively engage the patient in activities, progressively increase task difficulty based on patient performance, actively assist patient if necessary (i.e. patient is not passive), provide meaningful feedback at regular intervals, require sensorimotor integration and incorporate the use of tasks that that are intended to transfer to distal motor performance.
1875862|NCT01144715|Device|Home Therapy Program|Subjects in the control group will be instructed in a self administered home therapy program
1875863|NCT01144728|Drug|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: Tablet Route of administration: oral Dose regimen : fixed dose combination of glimepiride / metformin: 1/250, 2/500
1876074|NCT01146626|Drug|Peg+ Vitamin D+ Ribavirine|Peg+ Vitamin D+ Ribavirine
1875864|NCT01144741|Other|PTSD Checklist-Civilian (PCL-C)|Completed by patients before the interview; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
1875865|NCT01144741|Other|Modified Flanagan Quality of Life Scale|Completed by patients before the interview; it is a 16-item survey designed for use in persons with chronic illness.
1875866|NCT01144741|Other|Center for Epidemiologic Studies Depression Scale (CES-D)|Completed by patients before the interview; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
1875867|NCT01144741|Other|Functional Enquiry (or Review of Systems) Form|Completed during the interview; it is a checklist of medical problems.
1875868|NCT01144741|Other|Study of Therapeutic Outcomes and Practices in Freeman-Sheldon Syndrome (STOP-FSS) Questionnaire|The STOP Questionnaire is a guided interview form that will be used to assess diagnosis, problems, treatments, and outcomes.
1875869|NCT01144741|Other|FSRG Semi-Structured Quality of Life Interview (FSRG SSQLI)|Completed after data analysis from the existing surveys, it will be a specific quality of life interview, taking into consideration individual's total health outcome.
1875870|NCT01144741|Other|Medical Records Review|Review of medical records will be used, along with STOP-FSS Survey to assess patient histories and outcomes.
1875871|NCT01144754|Drug|Rituximab|Calculated per patient
1875872|NCT01144767|Behavioral|Computer-generated advisor|Weekly sessions with a computer generated advisor who offers advice, feedback and guidance on physical activity
1875873|NCT01144767|Behavioral|Comparison control condition|Weekly/biweekly sessions with a group facilitator to receive health education and information.
1875874|NCT01144806|Behavioral|Nutrition education|Parent/care givers of children with severe malnutrition in enrolled in this group will be given nutrition education using the principles of infant and young child feeding (IYCF) and dietary diversification
1875875|NCT01144806|Dietary Supplement|RUTF|Ready to use therapeutic food (RUTF / PlumpyNut) will be provided to the parent/care givers of children with severe malnutrition in enrolled in this group
1875876|NCT01144832|Drug|ebastine|20 milligram capsule once daily
1875877|NCT01144832|Drug|placebo capsule|one capsule once daily
1875878|NCT01144845|Procedure|Thoracic surgery|Thoracoscopy or anterior thoracotomy
1875879|NCT01144858|Other|a complete transesophageal echocardiography|All patients were evaluated by a complete transesophageal echocardiography with multiplane probes with a 7-MHz transducer before catheter ablation .LA appendage flow was obtained by placing the pulsed Doppler sample volume at the orifice of the LA appendage, after which peak flow velocities were measured and averaged within each RR interval of 10 consecutive cardiac cycles
1875880|NCT01144884|Other|Procedure (education and exercise)|education/exercise
1875881|NCT01144897|Radiation|PET Acetate scan|PET Acetate scans will be done to detect prostate cancer lesions.
1875882|NCT01144910|Other|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.
the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
1875883|NCT01144910|Other|methacholine challenge test|"2 ml of liquid-dissolved methacholine in concentration of 16 mg/ml dosed in 5 steps of 0.01 mg, 0.1 mg, 0.4 mg, 0.8 mg, and 1.6 mg. 2 minutes after each step up an impulse oscillometry (IOS) and spirometry will be performed.
the challenge will be stopped in case of a ≥ 20% decrease from baseline in FEV1 (PD20) and 0,2 mg Salbutamol will be given."
1875884|NCT01144923|Other|Gabapentin and/or Nortriptyline, Physical therapy|Nortriptyline up to 125 mg po qhs, and / or Gabapentin up to 1200 mg po q8h, Physical therapy (e.g. range of motion, strengthening, therapeutic massage, TENS)
1875885|NCT01144923|Procedure|Epidural Steroid Injections (ESI)|Series of up to 3 cervical epidural steroid injections (ESI) with depo-methylprednisolone
1875886|NCT01144923|Other|Combination treatment|Series of up to 3 cervical epidural steroid injections with depo- methylprednisolone plus Nortriptyline up to 125 mg po qhs and /or Gabapentin up to 1200 mg po q8h, and Physical therapy (e.g. TENS, exercise, range of motion)
1875887|NCT01144936|Drug|VX-985 or matching placebo|low dose
1875888|NCT01144936|Drug|VX-985 or matching placebo|high dose
1875889|NCT01144936|Drug|VX-985 or matching placebo|dose TBD
1875890|NCT01144949|Drug|silodosin|one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
1875891|NCT01144949|Drug|placebo|one placebo capsule orally, once daily, with food for up to 4 weeks
1875892|NCT01144962|Procedure|Localization, curettage of the fistulous tract and closure of the internal opening without MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, without injection of MSCs.
1875893|NCT01144962|Procedure|Localization, curettage of the fistulous tract and closure of the internal opening with local MSC injection.|Patients will undergo surgical localization, curettage of the fistulous tract and closure of the internal opening, with local injection of indicated dose of MSCs
1875894|NCT01144975|Drug|XOMA 052|Sterile solution, dose level varies by dose group and study drug administration day, SC injections administered by study personnel at time points specified in the protocol (the subject will receive a total of 8 injections)
1875895|NCT01144975|Drug|Placebo|Sterile solution, SC injections administered by study personnel (the subject will receive a total of 8 injections)
1875897|NCT01145131|Other|Intact or minced beef meat|135 gram piece of intact or minced beef meat, beef steak or minced beef resp.
1875898|NCT01145144|Drug|dehydroepiandrosterone crystalline fine powder|
1875899|NCT01145157|Device|Signature Knee Guide|Total Knee Arthroplasty performed using Signature Knee Guide
1875900|NCT01145157|Device|Conventional Instrumentation|Total Knee Arthroplasty performed using Conventional Instrumentation
1875901|NCT01145157|Device|Computer Assisted Navigation|Total Knee Arthroplasty performed using Computer Assisted Navigation
1875902|NCT01145170|Radiation|Radiotherapy|Radiotherapy will be given at the standard dose between 54 and 60 Gy for irradiation of tumors of the central nervous system.
1875951|NCT01145560|Drug|AZD9773|A single loading dose following by up to 9 maintenance doses; doses to be given every 12 hours over a period of 5 days
1875903|NCT01145170|Biological|Nimotuzumab|The patients will receive the induction therapy for 12 weeks. If the patient reaches a complete, partial response (CR, PR) to the treatment or is at least evaluated as stable disease (SD) on week 12, the consolidation therapy should be initiated. The consolidation therapy will consist of the nimotuzumab administration, every 2 weeks.
1875904|NCT01145183|Drug|Doxazosin|Doxazosin is initiated at 4 mg/wk, and titrated up to a maximum of 8 mg/day over approximately 2 weeks. Participants will be maintained on 6mg-8mg daily dosing until week 13. The subjects will undergo the discontinuation from the study medication during weeks 14 -15.
1875905|NCT01145183|Drug|Placebo|Matched placebo daily dosing
1875909|NCT01145222|Drug|A. CNS 7056|Initial low dose plus supplemental doses as necessary.
1875910|NCT01145222|Drug|B. CNS 7056|Initial intermediate dose plus supplemental doses as necessary.
1875911|NCT01145222|Drug|C. CNS 7056|Initial high dose plus supplemental doses as necessary.
1875912|NCT01145222|Drug|D. Midazolam|Initial standardized dose plus supplemental doses as necessary.
1875913|NCT01145248|Device|double-balloon enteroscopy forceps biopsy|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . Then, the cannulation of the bile duct is performed by a pusher using a guidewire/guiding catheter. Subsequently, 2 histology samples are taken via a double-balloon enteroscopy (DBE) forceps (BF1725DF, Fujinon GmbH, Willich, Germany), which is placed under the guidance of the pusher.
1875914|NCT01145248|Device|Transpapillary brush cytology|An endoscopic retrograde cholangiography (ERC) with a duodenoscope Olympus TFJ 160-R (Olympus Corp., Tokyo, Japan) and endoscopic sphincterotomy with an Olympus papillotome (Olympus) is performed under analgosedation . The region of interest is then brushed five times in both directions to obtain cytology specimen.
1875915|NCT01145326|Drug|4% lidocaine gel application with sham microneedle device|Topical 4% lidocaine gel (LG4) applied to subject, after application of sham microneedle device (FMA).
1875916|NCT01145326|Drug|Microneedle-facilitated lidocaine application|Application of 4% lidocaine gel (LG4), after application of microneedle (FMA) device
1875917|NCT01145339|Drug|Lactase|1 chewable tablet of the test drug or comparative drug 30 minutes before the standard lactose dose (25 g).
1875918|NCT01145352|Drug|Etanercept (genetical recombination)|All patients who administrated ENBREL for active polyarticular juvenile idiopathic arthritis (restricted to the case of lack of effect by other treatment) during registered period (2.5 year).
1875919|NCT01145365|Procedure|Exam under anesthesia (EUA)|EUA established drainage of perianal fistulas &/or abscesses will be done before patient begins medical therapy with certolizumab (Cimzia)
1875920|NCT01145391|Other|Active Outreach to Patients and Providers|An outreach coordinator raised patient and provider awareness of unmet Blood Pressure goals, arranged Blood Pressure-focused clinic visits, and furnished providers with treatment decision support.
1875921|NCT01145404|Drug|Lapatinib|Lapatinib (Tyverb) po 1500mg daily d1-21, new cycle will be started on day 22 until progression.
1875922|NCT01145404|Drug|Lapatinib plus capecitabine|Lapatinib po 1250mg daily d1-21; new cycle will be started on day 22 until progression
1875923|NCT01145417|Drug|pregabalin (Lyrica)|150 mg-600 mg/day (twice daily)
1875924|NCT01145430|Other|Laboratory Biomarker Analysis|Correlative studies
1875925|NCT01145430|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
1875926|NCT01145430|Other|Pharmacological Study|Correlative studies
1875927|NCT01145430|Drug|Veliparib|Given PO
1875928|NCT01145443|Other|Alternative Intensivist staffing models.|During the study period, each participating ICU alternated between two distinct intensivist staffing formats: (i) in the Discontinuous arm of the study, there was a weekend cross-coverage format wherein an intensivist was responsible for care for a two week or half-month block, but colleagues covered the weekends within each block, or (ii) in the Continuous arm of the study, there was an uninterrupted staffing format, wherein a single intensivist was responsible for the entire two week, or half-month, period. In each ICU the study interval was divided into three phases, so that the models alternated twice in each ICU, beginning with either the weekend cross-coverage or the uninterrupted staffing formats, the four hospitals were randomly assigned between these two patterns.
1875929|NCT01145456|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
1875930|NCT01145456|Drug|gemcitabine hydrochloride|Given IV
1875931|NCT01145456|Other|pharmacological study|Correlative studies
1875932|NCT01145456|Other|laboratory biomarker analysis|Correlative studies
1875933|NCT01145469|Genetic|DNA analysis|
1875934|NCT01145469|Genetic|gene expression analysis|
1875935|NCT01145469|Genetic|polymorphism analysis|
1875936|NCT01145469|Other|laboratory biomarker analysis|
1875937|NCT01145469|Other|medical chart review|
1875938|NCT01145482|Drug|Insulin|20 IU of insulin was administered once daily on two occasions in either the first intervention period or second intervention period using a nasal spray bottle
1875939|NCT01145482|Other|Saline|200 micro liters of saline was administered once daily on two separate occasions in either the first intervention period or second intervention period using a nasal spray bottle
1875940|NCT01145495|Other|Laboratory Biomarker Analysis|Correlative studies
1875941|NCT01145495|Drug|Lenalidomide|Given PO
1875942|NCT01145495|Biological|Rituximab|Given IV
1875943|NCT01145508|Drug|Docetaxel|Given IV
1875944|NCT01145508|Other|Laboratory Biomarker Analysis|Correlative studies
1875945|NCT01145508|Drug|Prednisone|Given PO
1875946|NCT01145508|Biological|Recombinant Fowlpox-PSA(L155)/TRICOM Vaccine|Given SC
1875947|NCT01145508|Biological|Rilimogene Galvacirepvec|Given SC
1875948|NCT01145534|Drug|glibenclamide|5 mg as pills, taken daily during the morning for 60 days
1875949|NCT01145534|Other|medicinal plant infusion|INfusion fo Cissus verticillata L., 1 g in 150 mL water, ingested daily for 60 days.
1875950|NCT01145547|Device|Dexcom Seven® Plus Continuous Glucose Monitoring sensor|A Dexcom Seven® Plus Continuous Glucose Monitoring sensor was inserted subcutaneously into each subject.
1875952|NCT01145560|Drug|Placebo|Placebo
1875953|NCT01145573|Dietary Supplement|Calcium or Placebo|Participants are randomized to take either 1000mg of calcium or placebo from week 16 of pregnancy until delivery.
1875954|NCT01145586|Drug|Lactase Oral Tablets|3 tablets/day for 42 days Take with breakfast, lunch and dinner
1875955|NCT01145612|Drug|Losartan|Losartán dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
1875956|NCT01145612|Drug|Atenolol|Atenolol dosage: 12.5 mg /day for patients < 50 Kg or 25 mg/day for patients > 50 Kg (14 days). 50 mg/day from day 15 to the end of the study. Half of dose (25 mg/day) for patients < 50 Kg
1875957|NCT01145625|Drug|5% Minoxidil|half a cap (equivalent to 1g) 5% Minoxidil Topical Foam applied to the scalp once daily, every day, for 52 weeks
1875958|NCT01145625|Drug|2% Minoxidil|one ml of 2% Minoxidil Topical Solution applied to the scalp two times a day, every day, for 52 weeks
1875959|NCT01145638|Drug|iron isomaltoside 1000|intravenously as bolus or infusion, 500 mg or 1000mg up to full replacement dose
1875960|NCT01145638|Drug|iron sulphate|oral, 200 mg per day (100 mg bid),12 weeks
1875961|NCT01145664|Drug|Herbal concentrate-granules plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
1875962|NCT01145664|Drug|Reduning Injection plus western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
1875963|NCT01145664|Drug|Western therapy|Intervention time: 7-10 days; Follow-up time: 5 days.
1875964|NCT01145677|Drug|Topiramate|Topiramate 100-300 mg/day orally twice per day
1875965|NCT01145703|Dietary Supplement|RDA Vitamin D3 only|800 IU of Vitamin D3 daily for 6 months
1875966|NCT01145703|Dietary Supplement|Vitamin D2/3 Repletion only|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily
1875967|NCT01145703|Other|Vitamin D2/3 Repletion + AEX|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus aerobic exercise training
1875968|NCT01145703|Other|Vitamin D2/3 Repletion + RT|Vitamin D repletion with 50,000 IU of Vitamin D2/3 up to 3 x week(until levels are >75 nmol/l; 6-12wks) followed by 6 months maintenance supplementation with 2000 IU Vitamin D3 and up to 1000mg Calcium daily plus resistance training
1875969|NCT01145716|Procedure|Arthroscopy, surgery|Ulno-volar wrist approach to the TFCC
1875970|NCT01145729|Behavioral|Biomarker Feedback|Providing providers biomarker feedback on childhood secondhand smoke exposure
1875971|NCT01145742|Behavioral|home health/primary care collaboration|self-management support and telemonitoring of BP and blood glucose
1875972|NCT01145755|Drug|AZD2066|18 mg once daily
1875973|NCT01145755|Drug|Placebo|
1875974|NCT01145755|Drug|Duloxetine|60 mg once daily
1875975|NCT01145768|Drug|TC-5214|4 mg tablet, oral, BID, group 1
1875976|NCT01145768|Drug|TC-5214|TBD tablet, oral, BID, groups 2-6
1875977|NCT01145768|Drug|Placebo|
1875978|NCT01145781|Procedure|Cryotherapy|Arm 1 Single-freeze technique; 3 minutes of freeze and 5 minutes of thaw. Arm 2 Double-freeze technique: 3 minutes of freeze and 5 minutes of thaw and cycle repeated once again.
1875979|NCT01145794|Behavioral|smoking hygiene intervention|The intervention, SHI, will address SHS and quitting. It will include behavioral counseling to address health hazards of SHS for children, brief advice to quit and to adopt a no smoking policy around children and self-help materials (related to second hand smoking).
1875980|NCT01145807|Drug|TDT067|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
1875981|NCT01145807|Drug|Placebo|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
1875982|NCT01145807|Drug|Transfersome|Study treatment (TDT 067, Transfersome® vehicle, or non Transfersome® placebo) will be applied twice a day for 48 weeks to the great toenail and the other nails and areas surrounding the nails on the foot. Each application will consist of 5 sprays: 1 spray each to the dorsal, medial, anterior, and frontal part of the great toe and a final spray applied evenly to the nail area of the remaining 4 toes. Patients will be instructed not to wash the treated foot or bathe for at least 4 hours after product application.
1875983|NCT01145820|Dietary Supplement|Juice plus|Juice Plus (2 capsules bds) for 11 weeks (10 weeks preop and 1 week postop)
1960234|NCT03262792|Dietary Supplement|Placebo|Microcrystalline cellulose
1875986|NCT01145846|Drug|Cytarabine plus Daunorubicin [Arm II (AD regimen)]|Cytarabine 200 mg/m2/day by continuous iv infusion over 24 hours daily for 7 days (D 1-7) plus Daunorubicin 90 mg/m2/day iv daily for 3 days (D 1-3)
1875987|NCT01145859|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Weight adjusted dose with equivalent exposure compared to 10 mg or 20 mg doses in adults
1875988|NCT01145872|Behavioral|Mindfulness Based Cognitive Therapy|
1875989|NCT01145872|Behavioral|Health Enhancement Program|
1875991|NCT01145898|Drug|(Cosopt®, prostaglandin)|We did NOT provide any intervention, we observed groups of patients already on these drugs as observers only.
1960235|NCT03262792|Dietary Supplement|ParActin|ParActin 150 mg
1960236|NCT03262792|Dietary Supplement|ParActin|ParActin 300 mg
1960237|NCT03261999|Drug|Leuprolide Mesylate|Subcutaneous injection of 25mg Leuprolide Mesylate
1960238|NCT03261934|Other|No intervention|No intervention
1960239|NCT03261830|Drug|Cefazolin|Primary intervention
1875993|NCT01145937|Procedure|PET|Partial Endothelial Trepanation in addition to an anterior lamellar keratoplasty
1875994|NCT01145937|Procedure|DALK|Conventional DALK grafting procedure, with Big Bubble technique according to Anwar et al.
1875995|NCT01145950|Drug|LBEC0101|Etanercept 25mg, single dose
1875996|NCT01145950|Drug|Enbrel|Etanercept 25mg, single dose
1875997|NCT01145963|Other|Control pasta|control pasta
1875998|NCT01145963|Other|Experimental pasta B|experimental pasta
1875999|NCT01145963|Other|Experimental pasta C|experimental pasta
1876000|NCT01145976|Drug|Cy-ATG|"Hydration with 0.45% NaCl at 6 liters/24 hours will be started on day -5. Cy 50 mg/kg in D5W 200 ml i.v. over 1-2 hours on days -5 to -2 by pump through a central venous catheter.
Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2"
1876001|NCT01145976|Drug|Flu-ATG|Fludarabine 30 mg/m2 will be infused intravenously over 30 minutes in D5W 100 ml for 6 consecutive days (days -7 to -2) Thymoglobuline 3 mg/kg in N/S 500-800 mL (less than 0.5 mg/mL) or lymphoglobuline 15 mg/kg in N/S 500-800 mL (less than 2 mg/mL) iv daily at 8 am on days -4 to -2
1876002|NCT01145989|Drug|AT9283|Starting dose will be 40 mg/m2/day OR 30 mg/m2/day to be confirmed at registration. IV 24 hour continuous infusion Days 1 and 8 every three weeks
1960240|NCT03261830|Drug|Clindamycin|For use in Pre-operateive Antibiotics arm in cases of documented allergy to primary intervention.
1876004|NCT01146015|Biological|Trivalent influenza subunit vaccine Influvac|3x 15mcg HA per 0.5 ml,trivalent one injection at Day 1
1876005|NCT01146028|Drug|Tizanidine|Tizanidine HCl Tablets 4 mg
1876006|NCT01146041|Drug|Rivastigmine|Rivastigmine 1.5 mg Capsules
1876007|NCT01146054|Device|CyberKnife based stereotactic radiotherapy|"Initial orthogonal images will be obtained to confirm location of fiducial seeds.
Synchrony respiratory tracking system must be used to correct for respiratory associated tumor motion. This system utilizes a series of optical diodes placed upon the patient's chest wall. While the orthogonal images are obtained, the computer generates a model correlating the position of the chest wall with the position of the internal fiducials. This model is continuously updated during treatment to correct for subtle changes in tumor location.
Quality assurance will be performed as per standard practice at each participating institution."
1876008|NCT01146054|Drug|Gemcitabine|Treatment calculated per the needs of each patient and given at the instruction of the investigator; iv (intravenous).
1876009|NCT01146054|Drug|Fludeoxyglucose (18F) (FDG)|FDG-PET/CT scan is used in treatment planning. Treatment with 18F-FDG is calculated per the needs of each patient and given at the instruction of the investigator; iv
1876010|NCT01146067|Drug|Rivastigmine|Rivastigmine capsules 1.5 mg
1876011|NCT01146080|Device|Promus Element|Promus Element implanted to treat coronary artery lesions.
1876012|NCT01146080|Device|Promus|Promus stent implanted to treat coronary artery lesions
1876013|NCT01146093|Drug|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
1876014|NCT01146106|Drug|Pravastatin Sodium|Pravastatin Sodium Tablets 80 mg
1876015|NCT01146119|Biological|Multimeric-001, 500 mcg|Adjuvanted Multimeric-001 was administered twice with an interval of 19-23 days.
1876016|NCT01146119|Biological|Adjuvanted PBS|Adjuvanted PBS was administered twice with an interval of 19-23 days.
1876017|NCT01146119|Biological|PBS and TIV 15%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 15% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
1876018|NCT01146119|Biological|PBS and TIV 50%|PBS (Phosphate Buffered Saline) was administered twice with an interval of 19-23 days and then 60 days later a 50% dose of commercial seasonal trivalent vaccine (season 2011) was administered.
1876019|NCT01146132|Dietary Supplement|Conventional diet +/- wine|usual eating habits
1876020|NCT01146132|Dietary Supplement|Luxembourg variant of Mediterranean diet + physical activity +/- wine|"Walnuts, almonds, mustard and soy bean products as part of the Indo-Mediterranean diet could be recommended to ensure a variety of food constellation, as well as dark chocolate. This form of diet will be addressed to as Luxembourg variant of the Mediterranean diet"
1876021|NCT01146145|Drug|Ketamine|intravenous morphine titration combined to ketamine
1876022|NCT01146158|Procedure|Axillary dissection for breast carcinomas|surgery Axillary dissection
1876023|NCT01146171|Drug|BMS-844203 (CT-322)|Injection, IV, 1 and 2 mg/kg, Weekly, Until disease progression or unacceptable toxicity became apparent
1876024|NCT01146184|Device|Flexible endoscope and Ethicon Manually Articulating Device|Using the Flexible Endoscope and the Ethicon Manually Articulating Device, removal of the gallbladder through a single incision is improved.
1876025|NCT01146197|Drug|TREATMENT|Patients with received in random order 75mg/day indometacin(chronoindocid®), 10-20 mg/day amiloride and 50-150 mg /day eplerenone (Inspra ®). The three 6 weeks-periods of treatment will be followed by six weeks washout period. 3-6 weeks before the first period of treatment, a supplementation with potassium and magnesium will be orally given, and maintained at the same dose throughout the study and stoped 6 weeks after the end of the third period of treatment.
1876026|NCT01146210|Other|laboratory biomarker analysis|Correlative studies
1876027|NCT01146223|Other|laboratory biomarker analysis|Correlative studies
1876028|NCT01146236|Device|Sutures|Orthopedic surgical wounds closed with sutures
1876029|NCT01146236|Device|Staples|Orthopedic surgical wounds closed with metallic staples
1876030|NCT01146249|Other|Balance assessment under sensory stimulation|Balance assessment under sensory stimulation
1876031|NCT01146262|Other|cell therapy product|Patients receive for up to 5 doses of apoptotic corpse pulsed dendritic cells after CR1 ou CR2 documentation (9/10 subcutaneously and 1/10 intradermally) every week, except the last injection performed at 2 weeks from the 4th injection.
1876032|NCT01146262|Procedure|injection of the cell therapy product|Cytapheresis D0: 1st injection of the cell therapy product, J7 2nd injection of the cell therapy product, J14 third injection of the cell therapy product,J17 cutaneous biopsies, J21 fourth injection of the cell therapy product, J35 fifth injection of the cell therapy product
1876033|NCT01146275|Radiation|Radiologial breast examination|MRI of breast, mammography and ultrasound of breast
1876071|NCT01146600|Drug|Placebo then Clarithromycin|Matched placebo po bid for two weeks, then one week with no intervention, then clarithromycin 500 mg po bid for two weeks
1876034|NCT01146288|Drug|Furosemide first, then Acetazolamide|Two renal function studies will be performed: one before and after intravenous furosemide and the second before and after intravenous acetazolamide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests. A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
1876035|NCT01146288|Drug|Acetazolamide first, then Furosemide|Two renal function studies will be performed: one before and after intravenous acetazolamide and the second before and after intravenous furosemide. Subjects will receive 300 mg of lithium carbonate at 22.00 the day before the renal function tests.A priming dose of inulin (50 mg/kg) and p-aminohippuric acid (8 mg/kg) will be administered and a 200-300 ml p.o water load will be given. Thereafter, inulin and p-aminohippuric acid will be infused continuously. After the first 60 minutes, 8 accurately timed urine collections of 30 to 40 minutes will be obtained by spontaneous voiding. After the first 4 timed urine collections, participants will receive intravenous furosemide 2 mg/5min or intravenous acetazolamide 5 mg/kg/5 min.Four other times urine collections will be performed thereafter.
1876036|NCT01146301|Drug|Clopidogrel|All patients will receive a loading dose of 600mg of study medication. The first group will receive 300 mg of clopidogrel and 300 mg placebo, the second group will receive 600mg of clopidogrel at least 24h before carotid stenting
1876037|NCT01146314|Behavioral|Family Focused Lifestyle Intervention|The lifestyle intervention is a 6-month intervention study lasting 6 months. The intervention is 14 sessions and conducted by a dietician and psychologist in a group setting with each intervention session lasting 90 minutes. The sessions are conducted weekly, biweekly, and monthly over the course of 6 months.
1876038|NCT01146327|Drug|PF-04620110|Multiple oral doses of 5 mg of PF-04620110 will be given once daily for 2 weeks.
1876039|NCT01146327|Drug|PF-04620110|Multiple oral doses of 1.5 mg of PF-04620110 will be given twice daily for 2 weeks.
1876040|NCT01146327|Drug|PF-04620110|Multiple oral doses of 3 mg of PF-04620110 will be given once daily for 2 weeks.
1876041|NCT01146327|Drug|PF-04620110|Multiple oral doses of 2.5 mg of PF-04620110 will be given twice daily for 2 weeks.
1876042|NCT01146327|Drug|Placebo|Multiple oral doses of placebo will be given once daily for 2 weeks.
1876043|NCT01146340|Radiation|Hypofractionated radiotherapy|40 Gy / 5 fractions / 29 days
1876044|NCT01146379|Other|Intensive task-specific upper extremity rehabilitation|The experimental intervention consists of intensive task-specific upper extremity movement rehabilitation which are appropriately graded and progressed for each subject. This intervention will provide progressive training of these essential components required for upper extremity movement through repeated practice of various tasks, with the desired goal of building the subject's capacity to perform a multitude of UE functions. Subjects will participate in the intervention for eight weeks or more depending on the group they are randomized to.
1876045|NCT01146418|Biological|Corifollitropin alfa|Single injection of 150 μg corifollitropin alfa administered under protocol P06029
1876046|NCT01146418|Biological|recFSH (follitropin beta)|Daily recFSH 300 IU administered under protocol P06029.
1876047|NCT01146431|Drug|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of hemodynamic parameters (mean arterial pressure and heart rate greater or less than 20% compared to preoperative values).
1876048|NCT01146431|Drug|Inhaled anesthetics|Inhaled anaesthetic drugs (sevoflurane or desflurane) concentration will be changed on the basis of Bispectral Index (BIS) value which will be maintained between 40 and 50.
1876049|NCT01146444|Other|UV A and B irradiation|UV irradiation
1876050|NCT01146457|Drug|Morphine|Active dosage
1876051|NCT01146457|Drug|Saline|Saline Control
1876052|NCT01146470|Dietary Supplement|RGC|dosage of Red Grape Cells once a day, during 3 months
1876053|NCT01146470|Dietary Supplement|Placebo|dosage of Placebo once a day, during 3 months
1876054|NCT01146483|Drug|Rosuvastatin, Pantoprazole|"Rosuvastatin, 10 mg tablets, single dose on the morning
Concomitant drug: Pantoprazole; 40 mg tablets, 2 single doses administered 1 hour before rosuvastatin and 23 hours after rosuvastatin administration. A placebo is given on the other period as a crossover design study."
1876055|NCT01146496|Device|Ultraviolet light-resistant plastic in-ground pesticide storage container|In-ground pesticide storage container to be supplied to every household that uses pesticides in intervention villages
1876056|NCT01146509|Drug|Aricept (donepezil hydrochloride)|Donepezil hydrochloride tablet: initial 5 mg/day dose was taken orally, once a day. At Week 4 visit, the dose was increased to 10 mg/day at the discretion of the investigator.
1876057|NCT01146522|Drug|LCQ908|
1876058|NCT01146522|Drug|Placebo|
1876059|NCT01146535|Drug|Interferon-alpha|150 IU lozenges bid for 5 days
1876060|NCT01146535|Drug|Oseltamivir|75 mg capsules bid for 5 days
1876061|NCT01146535|Other|maltose|200 mg maltose lozenges bid for 5 days
1876062|NCT01146548|Drug|FLUOXETINE|20mg/d, oral administration for 6 weeks, then 40mg/d for 4 months.
1876063|NCT01146561|Biological|Tanezumab|single administration of tanezumab 20 mg sub-cutaneously
1876064|NCT01146561|Other|Placebo|single administration of placebo to match tanezumab, sub-cutaneously
1876065|NCT01146574|Biological|Sotatercept|Part 1: Sotatercept single dose 0.1mg/kg subcutaneous Part 2: Sotatercept starting dose groups of 0.3mg/kg, 0.5mg/kg or 0.7 mg/kg in a sequential design, dosed subcutaneously every 28 days for up to 8 doses
1876066|NCT01146574|Biological|Placebo|Placebo
1876067|NCT01146587|Device|GangTrainer GT1|30 minutes of treatment on the GangTrainer GT1 and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
1876068|NCT01146587|Device|Lokomat|30 minutes of treatment on the Lokomat and 30 minutes of Conventional Physiotherapy every workday for 8 weeks
1876069|NCT01146587|Other|Conventional Physiotherapy|60 minutes of Conventional Physiotherapy every workday for 8 weeks
1876070|NCT01146600|Drug|Clarithromycin followed by placebo|Clarithromycin 500 mg po bid for two weeks, then one week with no medication, then matched placebo po bid for two weeks.
1876076|NCT01146639|Radiation|DynaCT|One extra set of images with DynaCT including one extra injection of contrast medium.
1876077|NCT01146639|Drug|Iodixanol|One extra set of images with DynaCT including one extra injection of 50 ml contrast medium.
1876078|NCT01146652|Drug|SAR153191 (REGN88)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1960241|NCT03261830|Drug|Saline|Placebo Intervention
1960242|NCT03260504|Biological|Aldesleukin|Given SC or IV
1876081|NCT01146678|Drug|Insulin glargine HOE901|"Pharmaceutical form:solution for injection
Route of administration: subcutaneous"
1876082|NCT01146678|Drug|Lixisenatide AVE0010|"Pharmaceutical form:solution for injection
Route of administration: subcutaneous"
1876083|NCT01146691|Other|Alternative Intensivist staffing models|During the study period, each participating ICU alternated (ABAB or BABA) between two distinct intensivist staffing formats: (i) the standard staffing model, an intensivist is responsible for care in that ICU for the entire 7 days, being present during the daytime hours, and taking call from home at night, (ii) the 24-7 in-hospital, shiftwork model, enabled by splitting each 24 hour period into two shifts. There will, as in the standard model, be a single intensivist covering the ICU during the day shifts for one week. The day shift will run 8 am to 5:30 pm on weekdays, and 8 am to 3 pm on Saturday and Sunday. The night shift intensivist will arrive and take over at 5:30 pm on weekdays, and 3 pm on weekends and remain in the hospital until 8 am.
1876084|NCT01146704|Dietary Supplement|Protein powder supplement, standard dosage based on 0.5 gram protein per pound of subject's lean body mass|Standard protein diet as control, based on 0.5 gram protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 12.5% protein and 57.5% carbohydrate.
1876085|NCT01146704|Dietary Supplement|Protein powder supplement, High Level Protein, based on 1 gram of protein per pound of lean body mass: 25% protein and 45% carbohydrate|High level of protein diet, based on 1 gram of protein per pound of subject's lean body mass, isocaloric (same number of calories) and consisting of 25% protein and 45% carbohydrate.
1876086|NCT01146704|Dietary Supplement|Very high protein diet group based on 1.4 gram of protein per pound of subject's lean body mass: 35% protein and 35% carbohydrate.|Very high protein diet, based on 1.4 gram of protein per pound of lean body mass, isocaloric (same number of calories) and consisting of 35% protein and 35% carbohydrate.
1876087|NCT01146717|Behavioral|Exercise|Patients with mild cognitive impairment will undergo moderate intensity endurance exercise training for one year.
1876088|NCT01146717|Behavioral|Balance training|A group of patients with mild cognitive impairment will perform flexibility and balance training for one year as a control group.
1876089|NCT01146730|Behavioral|Workcoping and IPS|Maximum 15 sessions of CBT-based counseling with workcoping as primary focus in addition to work support according to the IPS-model (individual placement and support)
1876090|NCT01146730|Behavioral|Ordinary care by GP or NAV|Ordinary care by the participants physician or the local Labour and Welfare Administration
1876091|NCT01146743|Procedure|EUS-guided gallbladder drainage|EUS-guided gallbladder drainage was performed with a linear-array echoendoscope. The initial puncture was performed at the antrum of the stomach or bulb of the duodenum and was chosen to access the gallbladder body or neck and avoid visible vessels. After removal of the needle, a 6F or 7F bougie were inserted and then removed to dilate the tract. Afterward, nasobiliary drainage tube or stent was placed.
1876092|NCT01146743|Procedure|percutaneous transhepatic gallbladder drainage|Under ultrasound guidance, needle punctured to gallbladder via percutaneous transhepatic route.
1876093|NCT01146756|Drug|AZD6244|MEK inhibitor AZD6244 (Selumentinib) in combination with thoracic radiotherapy
1876094|NCT01146769|Other|Pelvic floor exercise|Pelvic floor strengthening exercise
1876095|NCT01146782|Device|Attune Sleep Apnea System|Console and mouthpiece sleep apnea system
1960243|NCT03260504|Biological|Pembrolizumab|Given IV
1876097|NCT01146808|Drug|Adefovir dipivoxil and hepatitis B vaccination|Adefovir 10mg po daily, or adjusted for renal function and option for Hepatitis B vaccination, double dose
1876098|NCT01146821|Dietary Supplement|0.20 gm/kg fish oil|Group 2: 7 patients will receive 0.20gm/kg of ideal body weight [IBW] fish oil in addition to standard care
1876099|NCT01146821|Dietary Supplement|0.50 gm/kg fish oil|Group 3: 7 patients will receive 0.50 gm/kg of ideal body weight [IBW] fish oil in addition to standard care.
1876100|NCT01146834|Drug|bortezomib (Velcade)|1.3 mg/m2 IVP on days 1, 4, 8 and 11
1876101|NCT01146834|Drug|cyclophosphamide|2.0 g/m2 (day 4 for Arm A and day 1 for Arm C)
1876102|NCT01146834|Drug|G-CSF|given for ten (+/- two) consecutive days starting on day 9 at a dose of 10 micrograms/kg/day (start on day 2 for Arm C)
1876103|NCT01146847|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish tight glycaemic control with a blood glucose target range of 80-110 mg/dL (4.4-6.1 mM)
1876104|NCT01146860|Drug|BNO 1016|sugar coated tablets with dry extract (80 mg) of 5 herbal drugs; dosage: 480 mg per day (2 tablets t.i.d.) duration: 15 days
1876105|NCT01146860|Drug|Placebo|sugar coated tablets with identical appearance to active treatment; frequency: 2 tablets t.i.d. duration 15 days
1876106|NCT01146873|Drug|Efavirenz (EFV)|Children are assigned to begin a EFV-based antiretroviral based regimen.
1876190|NCT01147432|Other|EMLA positive control|2g EMLA cream to be applied ONCE during study period 1
1960244|NCT03260842|Diagnostic Test|Bio-Specimen Collection|Collection of bio-specimens and observation over time.
1876107|NCT01146873|Drug|Lopinavir/ritonavir (LPV/r)|Children are assigned to stay on their current LPV/r-based antiretroviral regimen.
1876108|NCT01146873|Drug|Stavudine (D4T)|Children are assigned to stay on their current antiretroviral regimen which includes D4T.
1876109|NCT01146873|Drug|Abacavir (ABC)|Children stop taking D4T and switch to ABC.
1876110|NCT01146886|Drug|Placebo to BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on on placebo) on Day 1
1876111|NCT01146886|Drug|BI 135585|Part 1 - oral doses given to approximately 9 parallel groups of 8 subjects (6 on active and 2 on placebo) on Day 1; Part 2 - oral doses given to 12 subjects on Day 1
1876112|NCT01146899|Other|Provider Alert|Provider influenza vaccine alert
1876113|NCT01146912|Other|Text Message|Text message vaccine reminders
1876114|NCT01146912|Other|automated call|Automated call
1876115|NCT01146925|Drug|CRMD-001-Deferiprone|CRMD-001 represents unique formulations of Deferiprone. Subjects will be given one (900 mg) immediate release and two (900 mg) extended release tablets 1-3 hours prior to angiography and then every 12 hours for a total of 8 days
1876116|NCT01146925|Drug|Placebo|3 placebo tablets will be given every 12 hours for a total of 8 days, beginning 1-3 hours prior to angiography
1876117|NCT01146938|Drug|fimasartan|single administration of fimasartan 120mg
1876118|NCT01146938|Drug|fimasartan|single administration of fimasartan 120mg
1876119|NCT01146951|Drug|Rufinamide (E2080)|"Rufinamide tablets administered orally twice daily after breakfast and dinner. Treatment was divided into a Dose Titration Period (2 weeks) and a Dose Maintenance Period (10 weeks). As a general rule, the dose was increased by 1 step every 2 days until it reached the target maintenance dose determined by body weight at the start of the Observation Period.
Target maintenance dose:
15.0 - 30.0 kg: 1000 mg/day (5 tablets each in the morning and evening) 30.1 - 50.0 kg: 1800 mg/day (4 tablets in the morning and 5 in the evening) 50.1 - 70.0 kg: 2400 mg/day (6 tablets each in the morning and evening) >= 70.1 kg: 3200 mg/day (8 tablets each in the morning and evening)"
1876120|NCT01146951|Drug|Placebo|Rufinamide Matching Placebo tablets administered orally twice daily after breakfast and dinner for a total of 12 weeks.
1876121|NCT01146964|Procedure|MSSICS|Manual super small incision cataract surgery
1876122|NCT01146964|Procedure|Phacoemulsification|cataract surgery with Phacoemulsification
1876123|NCT01146977|Other|HDAC chemotherapy|If he/she decides not to participate, he/she will be treated with HDAC consolidation chemotherapy, which is the current standard treatment.
1876124|NCT01146977|Other|Autologous HCT|"After achieving CR1, patient will be invited to this protocol and will be able to decide whether to join or not after listening to the information.
If he/she decides to participate, request of health insurance support on the autologous HCT will be submitted and further processes related to autologous HCT will continue."
1876125|NCT01146990|Drug|ASQ-3, Bayley III, Neurologic exam|Developmental Scales of infant development - Children born to mothers who participated in the 17P-ES-003 study will be enrolled in this study and evaluated using the ASQ-3. Those meeting protocol criteria based on ASQ-3, will be evaluated using the Bayley III and have a neurologic examination.
1876126|NCT01147003|Drug|Investigational new drug, company code: BGG492|
1876127|NCT01147003|Drug|Placebo|
1876128|NCT01147003|Drug|Investigational new drug, company code: BGG492|
1876129|NCT01147016|Biological|HER2Bi-armed activated T cells|Total of 4 of the T cell infusions intravenously over a period of 1 month.
1876130|NCT01147016|Drug|cyclophosphamide|As prescribed by physician, standard of care.
1876131|NCT01147016|Drug|doxorubicin hydrochloride|As prescribed by physician, standard of care.
1876132|NCT01147016|Drug|paclitaxel|As prescribed by physician, standard of care.
1876133|NCT01147016|Other|laboratory biomarker analysis|Immune studies will be done pre-immunotherapy, prior to the third infusion of activated T-cells, at the time of surgery, and 1 month after immunotherapy. If there are positive findings, additional optional studies will be done at 3, 6, and 12 months, if the immune studies show changes worthy of follow-up studies.
1876134|NCT01147016|Procedure|neoadjuvant therapy|As prescribed by physician, standard of care.
1876135|NCT01147016|Procedure|therapeutic conventional surgery|As recommended by physician, post immunotherapy.
1876136|NCT01147029|Drug|angiogenesis inhibitor GSAO|
1876137|NCT01147029|Other|laboratory biomarker analysis|
1876138|NCT01147029|Other|pharmacological study|
1876139|NCT01147029|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1876140|NCT01147042|Drug|IFN-gamma|Following a washout period subjects have a subcutaneous injection of 50 mcg per meter squared once per week, Monday, for 4 weeks, twice per week, Monday and Thursday, for 4 weeks, then thrice per week, Monday, Wednesday, Friday, for 4 weeks. Total treatment period is 12 weeks.
1876141|NCT01147055|Drug|crizotinib|Treatment A: a single 250-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
1876142|NCT01147055|Drug|rifampin|Treatment B: 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 1 to Day 14.
1876143|NCT01147055|Drug|crizotinib|Treatment B: A single 250-mg dose of crizotinib will be administered in the fasted state on Day 9 as 1 × 50-mg and 2 × 100-mg Immediate Release Tablets.
1876144|NCT01147068|Biological|0.5mL Intramuscular Injection|0.5mL intramuscular injection on day 0 and day 21 in the deltoid muscle
1876145|NCT01147081|Biological|BEGRIVAC|126 healthy subjects enrolled to receive, in open-label manner, one dose of Begrivax (influenza vaccine)
1876146|NCT01147107|Drug|Raltegravir|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Raltegravir 400 mg twice daily
1876147|NCT01147107|Drug|Efavirenz|Emtricitabine/tenofovir DF* 200 mg/300 mg po daily + Efavirenz 600 mg po daily
1876148|NCT01147120|Behavioral|Progressive Muscle Relaxation (PMR)|Progressive Muscle Relaxation (PMR) will be recorded on PDAs integrated with EMA software and offered to patients who will be instructed in the techniques and PDA use by study coordinators. They will be instructed to practice 25 minutes/day the first two weeks, 35 minutes/day weeks 3 and 4, and 45 minutes/day weeks 5 through 12. These time periods (25/35/45 minute) were selected to allow a more gradual acclimation to PMR.
1876189|NCT01147432|Other|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
1876149|NCT01147120|Procedure|Clinical Massage Therapy (CMT)|PCPs will have the opportunity to refer patients with CLBP to local Licensed Massage Therapists (LMTs) to receive up to 10 clinical massage sessions over a 12-week period. CMT will be provided at no cost to the patients. At their first two sessions, the LMT will evaluate the patient and, with the patient, estimate the number of sessions and determine treatment goals. Based on previous literature, 10 sessions are anticipated over an average 12-week period. However, treatment will vary depending on assessment and progress. At the end of the treatment period, the patients will receive a list of all participating LMTs to facilitate patients' continued or future participation in massage therapy.
1876150|NCT01147133|Drug|Plavix|1x75 mg
1876151|NCT01147133|Drug|Kardogrel|1x75 mg
1876152|NCT01147146|Drug|propofol, fentanyl, atracurium|general anesthesia
1876153|NCT01147146|Drug|bupivacaine|spinal anesthesia
1876154|NCT01147146|Drug|bupivacaine, Midazolam|spinal anesthesia & sedation
1876155|NCT01147159|Other|Extracts of allergens|Skin prick test of extracts of allergens in 4 tenfold dilutions. Assessment wheal size after 15 minutes
1876157|NCT01147185|Device|Locomotor training using a robotic device|50min walking time, 3-5 trainings/week.
1876158|NCT01147185|Device|Locomotor training using a robotic device|25min walking time, 3-5 trainings/week.
1876159|NCT01147198|Dietary Supplement|Ready to Use Supplementary Food|Children received two Supplementary-plumpy® packages per day (184g) providing 1000 Kcal, 26g (10.4%) protein, 68g (61.2%) fat, and 100% of micronutrient requirements based on the Daily Recommended Nutrient Intake.
1876160|NCT01147198|Dietary Supplement|Premix CSB-oil treatment|Children received 2 kg of premix per week (226g CSB, 37g oil, and 23g sugar / day) providing 1277 Kcal, 40.7g protein (12.7%), 50.6g (35.7%) fat, and 100% of micronutrient according to the DRNI guidelines
1876162|NCT01147224|Drug|Alvesco|This is an observational study. Therefore, the physician decides about dosage according to individual needs.
1876163|NCT01147237|Device|Intracoronary stent implantation|Everolimus-eluting stent implantation in patients with long coronary artery disease
1876164|NCT01147250|Drug|Lixisenatide (AVE0010)|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast using self-injector pen device (Opticlik®). If the maintenance dose of 20 mcg was not tolerated, dose could be reduced to 15 or 10 mcg.
1876165|NCT01147250|Drug|Placebo|Pharmaceutical form: Sterile aqueous solution; Route of administration: Subcutaneous within 1-hour before breakfast.
1876166|NCT01147263|Other|Evaluation of autonomic parameters|Physical examination, ECG, Loop recorder, Heart rate variability evaluation
1876167|NCT01147276|Drug|Vildagliptin|Vildagliptin (50 mg BID) in four weeks
1876168|NCT01147289|Drug|Dextralgen|Dexalgen® will be administered at a dose equivalent to dexamethasone 1.5 mg, dipyrone 500 mg, and hydroxocobalamin 5 mg (one ampoule for each type) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
1876169|NCT01147289|Drug|Meloxicam|Meloxicam (Movatec®, Boehringer Ingelheim) will be administered as 15 mg (one ampoule) a day at a single intramuscular dose. Both drugs will be administered for 3 days, at least.
1876170|NCT01147302|Biological|Placebo|
1876171|NCT01147302|Biological|C1 Esterase Inhibitor (Human)|
1876172|NCT01147315|Procedure|Hybrid bone substitution|The patient will be treated by hybrid bone substitution with calcium-phosphate ceramic biomaterial and autologous bone marrow after necrosis exeresis
1876173|NCT01147328|Other|Virtual Health Record (VHR)|Technology that enables providers to electronically access community-wide clinical data for patients who have consented to have their clinical data accessed via a web portal.
1876174|NCT01147341|Drug|Cimzia|prefilled 200mg Cimzia syringe SC q 2 weeks
1876175|NCT01147341|Drug|Placebo|prefilled saline syringe
1876176|NCT01147354|Dietary Supplement|selenium yeast|The patients in this arm took 200 micrograms of selenium yeast daily for 12 weeks.
1876177|NCT01147354|Other|placebo capsules|The patients in this arm took one placebo capsule daily for 12 weeks.
1876178|NCT01147367|Behavioral|3 month physical activity intervention|3 month physical activity intervention involving moderate intensity walking and strength training with resistance bands
1876179|NCT01147380|Biological|Liver NK cell inoculation|Liver transplant recipients will receive once liver NK cell inoculation several days after liver transplantation.
1876180|NCT01147393|Drug|90Y-epratuzumab tetraxetan|The 90Y-epratuzumab treatment will begin one week after the 4th veltuzumab injection. Patients will receive unlabeled, unconjugated epratuzumab (1.5 mg/kg) that will be infused over ~30 minutes. All patients will then receive a 90Y-epratuzumab dose. Dose will be escalated by patient cohort either at 15 mCi/m2 or 20 mCi/m2. The second 90Y-epratuzumab treatment will be given at the same dose, 1 week after the first 90Y-epratuzumab dose.
1876181|NCT01147393|Biological|veltuzumab|Veltuzumab is given in 4 weekly doses, each 200 mg/m2.
1876182|NCT01147406|Drug|N6022|This is an injectible formulation which will be given at 5, 15 & 45 mg over 1, 3 and 9 minutes respectively, in single ascending doses.
1876183|NCT01147406|Drug|Placebo|This will be 0.9% normal saline given over 1, 3, or 9 minutes IV bolus.
1876184|NCT01147419|Device|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
1876185|NCT01147419|Device|femoral-popliteal bypass with artificial blood vessel|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
1876186|NCT01147432|Drug|PF-04427429|Single dose IV infusion up to 300mg
1876187|NCT01147432|Other|Capsaicin challenge|Capsaicin challenge: 110 mg (0.075% capsaicin) to be applied at pre-dose and at 2h, 5h, 8h and 24h post-dose as well as 1 week and 4 weeks post final treatment period
1876188|NCT01147432|Drug|Placebo|Placebo IV infusion (saline) to be administered during two of the three treatment periods
1876579|NCT01150890|Drug|AMG 827 700 MG|700 mg AMG 827 IV (in the vein)
1876191|NCT01147445|Biological|Double Mutant Heat- Labile Toxin (dmLT)|LT(R192G/L211A), or dmLT is a derivative of wild-type enterotoxigenic Escherichia coli heat labile enterotoxin. LT(R192G/L211A) is formulated as a freeze-dried (lyophilized), white to off-white cake, containing 700 micrograms of vaccine protein in a 3 mL, multi-dose, Wheaton Serum Vial. Vaccine dosage levels: 5, 25, 50, 100 micrograms as a single, oral dose.
1876192|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
1876193|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
1876194|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
1876195|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
1876196|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
1876197|NCT01147458|Drug|Naproxen placebo|Matching naproxen placebo tablets to be administered BID for 4 weeks
1876198|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
1876199|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
1876200|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
1876201|NCT01147458|Drug|Naproxen|Naproxen 500 mg tablet administered BID for a total of four weeks
1876202|NCT01147458|Drug|PF-04191834 placebo|Matching PF-04191834 placebo tablets to be administered BID for two weeks
1876203|NCT01147458|Drug|PF-04191834|100 mg tablets of PF-04191834 to provide a 600 mg BID dose administered for two weeks
1876204|NCT01147471|Device|operative rib fixation|Randomized subjects will be operated upon within 72 hours of ventilation (early fixation)to stabilize the stove-in segment using a rib fixation system.
1876205|NCT01147471|Procedure|operative rib fixation surgery|
1876206|NCT01147484|Drug|Foretinib|foretinib, at a continuous oral daily dose of 60 mg
1876207|NCT01147497|Drug|Misoprostol|400mcg of misoprostol taken buccally 2 hours prior to IUD insertion visit
1876208|NCT01147497|Drug|Placebo|Pill that is identical to the study drug in appearance, taste and smell, taken buccally 2 hours prior to IUD insertion visit
1876211|NCT01147523|Drug|Spironolactone/Vitamin E|Spironolactone, tablets, 25 mg daily plus Vitamin E, capsules, 400 mg daily, for 52 weeks
1876212|NCT01147536|Biological|HSPPC-96|HSPPC-96 intradermal injection every week for 4 weeks, followed by an injection every other week for 8 weeks
1876213|NCT01147549|Drug|[C14]AZD9668|Oral Solution 60 mg Single Dose
1876214|NCT01147562|Procedure|Collection of biospecimen|Collection of saliva, blood and tissues from subjects diagnosed with lung cancer, who are scheduled for biopsy of their lesion or surgical resection of their tumor.
1876215|NCT01147575|Dietary Supplement|Creatine monohydrate|The patients received orally 200 mg CMH per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without CMH the groups were switched for another 6 months (period 2).
1876216|NCT01147575|Dietary Supplement|Placebo|The patients received orally 200 mg Placebo per kg body weight divided in three doses per day. Following period 1 (6 months) of supplementation and a wash-out period of 4 weeks without placebo the groups were switched for another 6 months (period 2).
1876217|NCT01147588|Drug|lansoprazole|60 mg (2x30-mg capsule), once daily
1876218|NCT01147588|Drug|omeprazole|80 mg (2x40-mg capsule), once daily
1876219|NCT01147588|Drug|esomeprazole|40 mg (1x40-mg capsule), once daily
1876220|NCT01147588|Drug|clopidogrel|300 mg loading dose on Day 1 then 75 mg daily for 28 days
1876221|NCT01141660|Device|Endotracheal Tube|Patients randomized to either Laryngeal Mask Airway or Endotracheal tube prior to undergoing adenotonsillectomy.
1876222|NCT01141660|Device|Laryngeal mask airway|Randomized to either Laryngeal mask airway or endotracheal tube
1876228|NCT01141725|Drug|bendamustine hydrochloride|Given IV
1876229|NCT01141725|Drug|idarubicin|Given IV
1876230|NCT01141738|Behavioral|Caregiver Problem-Solving Intervention|Subjects will meet for two counseling sessions while their family member is hospitalized and will receive the treatment manual, which contains the content for the 10 sessions, work sheets, and handouts. The standardized content will be complemented by tailoring to the specific concerns and problems of CGs which are influenced by culture and developmental life stage as well as the stroke and other environmental and personal factors. Problems specific to stroke caregiving are emphasized. After the stroke survivor has been discharged, the counselor will contact the CG weekly by phone for 5 weeks and then bi-weekly for the next three sessions (a total of 10 sessions) at times convenient for the CG.
1876231|NCT01141738|Behavioral|Wait List Control|Subjects in the WLC condition will receive usual patient and family education. If these subjects are noted to be distressed when assessment measures are administered or during conversation, the research assistant (RA) will inform the PI or Co-PI, who will follow-up. To aid retention, a counselor who is naïve to the CPSI will call the WLC subjects in the second and fifth months post-discharge to check contact information and ask how they are doing. Access to individual or group therapy through community resources during this study will be monitored during routine data collection. Following the T3 assessment, the WLC subjects will be offered a minimal intervention (receipt of the Adapting to Stress booklet 100 and five 30 minute telephone sessions).
1876232|NCT01141764|Procedure|Positron Emission Tomography (PET) Scan|"The PET procedure consists of an intravenous injection of 18F-FDG followed by a 45-minute period of quiet resting. PET images will be acquired on an integrated PET/CT scanner.
This process will be repeated with the stimulator on during the first PET image acquisition and off during the second PET image acquisition. On and off PET image acquisitions will be performed on two separate days."
1876233|NCT01141764|Procedure|Magnetic Resonance Imaging (MRI)|MRI will be performed on a 1.5T system, using a combination of different sequences including sagittal T1, coronal and axial T2, FLAIR and proton density and axial 3D T1 weighted images.
1876234|NCT01141764|Other|Neuropsychological Testing|"On the same day or separate visit, depending on the timing of the PET imaging, they will be required to attend one half-day session for neuropsychological testing. Patients will arrive at the Toronto Western Hospital, the stimulator will be turned off for 30 minutes prior to neuropsychological testing with testing repeated with the stimulator on."
1876235|NCT01141777|Dietary Supplement|Spirulina platensis|Subjects received 19g daily of supplement averagely.This was supplied as powder daily, in packs that lasted for 2weeks each. Each subject was therefore seen every two week to obtain new stock of supplements and evaluate compliance
1876236|NCT01141777|Dietary Supplement|Soya bean|Each subject received 19g of supplement on average daily. Subjects were seen every two weeks to evaluate compliance and obtain a new stock.
1876237|NCT01141790|Other|Music and voice message|
1876238|NCT01141803|Dietary Supplement|Apples|550g of apples/day
1876239|NCT01141803|Dietary Supplement|Apple pomace|22g apple pomace/day
1876240|NCT01141816|Other|Contrast-Enhanced Ultrasound|Contrast-enhanced ultrasounds of the kidney will be performed within 7 days of routine CTs or MRIs at 3, 6, 12, 18, and 24 months post-radiofrequency ablation, with Perflutren Lipid Microsphere Injectible Suspension ('Definity') as the contrast agent.
1876241|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
1876242|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
1876243|NCT01141842|Procedure|exhalation analysis of breath sample|breath sample is presented to sniffer dog in test tube
1876244|NCT01141855|Drug|Champix|"Standard MIMS dosage (including period of titration) will be used. 0.5mg daily for 3 days 0.5mg b.d. for 4 days
1mb b.d. for 70 days (full course 3 months)"
1876245|NCT01141855|Behavioral|Counselling alone|Quit SA 5A counselling over the phone. Maximum 8 calls over a 3 month period
1876246|NCT01141868|Behavioral|Internet Intervention|online treatment for insomnia
1876247|NCT01141881|Drug|Tissue Plasminogen Activator,bevacizumab ,follow up|25 microgram in 0.05 cc,1.25 mg in 0.05 cc,nothing
1876248|NCT01141894|Other|Goal directed haemodynamic treatment|Treatment by fluids and Dobutamine to attain fixed haemodynamic goal
1876249|NCT01141894|Other|Routine fluid treatment|Protocol guided fluid treatment used in the clinical routine
1960253|NCT03256370|Procedure|milk collection|"Parents of breast-fed infant from general pediatric clinic and allergy clinic of King Chulalongkorn Memorial Hospital were approached for informed about the research and ask to join this project
After completed informed consent, demographic data was collected and filled in case record form
Milk of mother in both allergic and control groups were collected 60 ml then transferred to freeze at -80oc to for human milk oligosaccharide analysis
Method of human milk oligosaccharide analysis :
Ultra High Pressure Liquid Chromatography(UHPLC) with fluorescence method
High-Performance Anion-Exchange Chromatography with Pulsed Amperometric Detection (HPAEC-PAD) method"
1876252|NCT01141920|Behavioral|low threshold care|Low threshold care refers to a service delivery method that reduces the treatment demands for new admissions to substance abuse treatment. In the present study, participants will be scheduled to attend less counseling sessions, and will have greater access to methadone.
1876253|NCT01141920|Behavioral|stepped-based care|Stepped-based care is routine treatment at ATS. Participants begin a low intensity care, and are advanced to more intensive levels of care (i.e., more intensive schedules of counseling) based on urine samples and counseling adherence.
1876254|NCT01141933|Other|Cognitive-existential intervention|Over the past 2 years we developed a 12-week cognitive-existential intervention consisting of 12 modules. The first three modules essentially involve cognitive and behavioral techniques proposing reinforcement of the use of active behavioral (e.g., relaxation, activation) and emotional (cognitive reframing) strategies. This content comes from classical cognitive-behavioral techniques. The next 3 modules, inspired by empirically-tested interventions further explore emotional strategies. The last six modules specifically address the existential dimension. They are adapted from logotherapy techniques, which are also empirically-based, and have been adapted to a French-Canadian culture by our team. They aim to improve meaning-based and emotional coping strategies.
1876255|NCT01141933|Other|Usual care|This group receive the usual treatment only.
1876256|NCT01141946|Procedure|thoracic ultrasound|All patients will receive pre-operative pleural-based ultrasound during their initial consultation.
1876257|NCT01141946|Procedure|pleural aspiration|Before proceeding to pleural aspiration, a radiography of the chest will be performed in order to ascertain the presence of a pleural effusion.
1876258|NCT01141972|Dietary Supplement|Vitamin D|We will administer 100,000 IU Vitamin D3 orally as an observed 1-time bolus and then prescribe 1000 IU by mouth daily. These doses have achieved sufficiency in other populations.99, 100 We will use the level of sufficiency (≥30 ng/ml [≥75 nmol/L]) that is recommended by most experts in the field.89-91, 93, 95, 96, 101-105 We will repeat the bolus at 1 month if the target level is not achieved. The control group will receive matching placebo and a similar proportion will go through a dummy titration. All women consuming less than 800 mg/day of calcium (by dietary history) will receive 500 mg of calcium to ensure sufficiency.
1876299|NCT01147666|Drug|FG-4592|Different dose levels
1960254|NCT03257098|Biological|allo-APZ2-CVU|Suspension of ABCB5-positive mesenchymal stem cells
1960258|NCT03257462|Drug|SPR001|SPR001 Capsules
1876259|NCT01141972|Other|Placebo|Current standard of practice does not dictate that otherwise healthy early menopausal women have Vitamin D levels evaluated. Women with Vitamin D levels between 10 and 29 ng/ml who receive placebo will be receiving usual care (i.e., no additional Vitamin D repletion above intake at the time of screening).
1876260|NCT01141985|Device|LenSx Laser modified disposable contact lens|Modified Disposable Contact Lens Patient Interface: Like the current disposable contact lens, a single unit is used for each procedure only once, and is then discarded. It is similarly mounted onto the distal end of the system's focusing objective and serves as a sterile barrier between the patient and the laser. In place of a separate suction ring that is used in the current contact lens, the modified contact lens has an integrated suction ring and curved applanation surface. These features result in significantly lower elevation of intraocular pressure and significantly easier application by the surgeon in preliminary testing. Identical to the current contact lens, the suction ring is applied around the patient's limbus and mild suction is applied to stabilize the eye.
1876261|NCT01141998|Drug|Calcium, Dietary|400 mg calcium two times daily. From week 0 to 10 and week 14 to 52.
1876262|NCT01141998|Drug|Cholecalciferol|38 micrograms daily. Week 0-10.
1876263|NCT01141998|Radiation|UVB|Ultraviolet radiation type B administered in a tanning bed. One time weekly.
1876264|NCT01141998|Radiation|UV-filtered light.|Light from a tanning bed but a UV-filter stops all ultraviolet radiation. One time weekly.
1876265|NCT01141998|Drug|Cholecalciferol|38 micrograms daily. From week 14 to 52.
1876266|NCT01142011|Drug|Belimumab|"The first cycle of Belimumab (10mg/kg by intravenous (IV) infusion) is a loading cycle of 3 doses over 28 days (days 1, 15, 29). After the first cycle, additional cycles of belimumab (10mg/kg by intravenous (IV) infusion) will be administered every 28 ± 1 days (cycle 2 and all subsequent cycles).
The infusion will be administered over a minimum period of 1 hour."
1876267|NCT01142024|Drug|Glutathione|NS 500ml + Glutathione 1.8g intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
1876268|NCT01142024|Drug|saline|NS 500ml intravenously guttae 1-1.5ml/kg per hour,30 minutes before and during coronary angiography
1876269|NCT01142037|Dietary Supplement|Cooked parsnips with parsley|Beginning on Day 9 participants will be given cooked parsnips with parsley at a dose of 2 grams total apiaceous vegetable/kilogram body weight for period 1, and 4 gram/kilogram body weight for period 2.
1876270|NCT01142050|Biological|mesenchymal stem cells|1.1st transplantation: after finishing all required examines according to protocol in Day 0, ABM-MSCs are transplanted through pancreas artery percutaneously; 2. 2nd transplantation: after finishing all required examines in Day 7±1, BM-MSCs are transplanted intravenously; 3. 3rd transplantation: after finishing all required examines in Day 14±2, BM-MSCs are transplanted intravenously.
1876271|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
1876272|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
1876273|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
1876274|NCT01142063|Drug|Neratinib|Tablet, a 240 mg single oral dose
1876275|NCT01142076|Drug|Xinju Xiaogao Prescription|treatment group
1876276|NCT01142076|Drug|placebo|Therapeutic dose of 10%
1876277|NCT01142089|Drug|Placebo|Placebo (two matching tablets) orally twice daily for 3 days (72 hours).
1876278|NCT01142089|Drug|Rifamycin SV MMX|Rifamycin SV MMX® 400 mg (two 200 mg tablets) orally twice daily for 3 days (72 hours).
1876279|NCT01142102|Radiation|Radiation Therapy|"A radical dose of radiotherapy to be delivered to the entire bladder volume: 64Gy in 32 fractions over 6 weeks and 2 treatment days.
Conventional plan is used to deliver treatment for fractions 1 to 7 using a standard planning approach and a CTV to PTV margin of 1.5cm.
Adaptive plan is used to deliver treatment for fractions 8 through 32 using the same standard techniques as for fractions 1 to 7 but using one of three specific CTV volumes,namely: small, average or large. In all these cases the CTV to PTV margin is 0.7cm. Image guidance using a treatment unit based verification CT unit (Cone Beam CT or CT on Rails)based on soft tissue delineation is used to position the treatment fields and select the plan to best cover the CTV."
1876280|NCT01142115|Device|Intermittent catheter CP063CC|intermittent catheterisation
1876281|NCT01142115|Device|SpeediCath|intermittent catheterisation
1876282|NCT01142128|Drug|Nexium (esomeprazole magnesium)|one 40 mg capsule per day for one month
1876283|NCT01142128|Drug|Placebo to Nexium|one capsule per day for one month
1876284|NCT01142128|Drug|Viokase 16 (pancrelipase) + Nexium|Viokase 16 (pancrelipase) + Nexium capsules are given per day for one month with the addition of esomeprazole magnesium, one 40mg capsule per day for one month
1876285|NCT01142128|Drug|Viokase 16 + placebo to Nexium|Viokase 16 pancrelipase tablets are given per day for one month with one capsule of placebo to esomeprazole magnesium, one per day for one month
1876286|NCT01142141|Other|manual therapy, kinesiotherapy|
1876287|NCT01142154|Drug|Prodarsan|Prodarsan TID, oral solution, 6-8 days
1876288|NCT01147601|Drug|topical 0.5% Timolol|topical 0.5% Timolol aqueous solution, 2-3 drops to cover the hemangioma, twice daily
1876289|NCT01147601|Drug|Control (placebo) group|Control (placebo) group
1876290|NCT01147614|Behavioral|Brief Cognitive Behavioral Therapy (BCBT)|BCBT: 8-12 sessions over 16 weeks of cognitive-behavioral therapy administered by Master's-level clinicians in primary care setting
1876291|NCT01147614|Behavioral|Specialty mental health care referral (SMHC)|SMHC: specialty mental health care referrals provided
1876292|NCT01147627|Drug|exenatide injection|Patients in exenatide group will be treated with exenatide (Byetta®, Eli Lilly and Company) 5 µg BID for the first 4 weeks and then 10 µg BID thereafter.
1876293|NCT01147627|Drug|Mixed Protamine Zinc Recombinant Human Insulin Lispro 25R|Patients in insulin group will be treated with premixed insulin analog (Humalog Mix 25, Eli Lilly and Company). The initial insulin doses are 0.4 IU/kg per day(50% before breakfast and 50% before dinner). Insulin doses are titrated following a forced schedule according to blood glucose before breakfast and dinner.
1876294|NCT01147627|Drug|Pioglitazone|Patients in thiazolidinedione group will be treated with Pioglitazone 30mg daily as single dose. The dose will be increased to 45mg daily after 4 weeks.
1876295|NCT01147640|Drug|CXA-101/ tazobactam and metronidazole|CXA-101/tazobactam (1000/500 mg q8h) plus metronidazole (500 mg q8h) administered via IV infusion
1876296|NCT01147640|Drug|meropenem plus saline placebo|meropenem IV infusion (1000 mg q8h) plus a matching saline placebo (q8h) administered via IV infusion
1876302|NCT01147666|Other|Placebo|Inactive capsules matching appearance of FG-4592 capsules
1876303|NCT01147666|Drug|Epoetin Alfa|Per current label instruction
1876304|NCT01147692|Biological|simvastatin plus albiglutide|A single dose of 80mg simvastatin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 80mg simvastatin on Day 38.
1876305|NCT01147705|Drug|Allopurinol|Participants will be given blinded medication and asked to take one tab/day for the first six weeks (100mg strength for two weeks then 300mg strength for four weeks) followed by two tabs/day for the remaining 18 weeks
1876306|NCT01147705|Drug|Placebo|Same appearance/dosing as active drug.
1876307|NCT01147718|Biological|digoxin plus albiglutide|A single dose of 0.5mg digoxin on Day 1 followed by 5 weekly doses of subcutaneous albiglutide, followed by a single dose of 0.5mg digoxin on Day 38.
1876308|NCT01147731|Biological|warfarin plus albiglutide|A single dose of 25mg warfarin on day 1 followed by 5 weekly doses of subcutaneous albiglutide followed by a single dose of 25mg warfarin on day 45.
1876309|NCT01147744|Drug|Fluticasone Propionate 100mcg via ACCUHALER/DISKUS|Fluticasone propionate 100mcg twice daily via ACCUHALER/DISKUS
1876310|NCT01147744|Drug|GSK2190915 100mg|GSK2190915 100mg (1 x 100mg) once daily in the morning
1876311|NCT01147744|Drug|GSK2190915 10mg|GSK2190915 10mg (1 x 10mg) once daily in the morning
1876312|NCT01147744|Drug|GSK2190915 300mg|GSK2190915 300mg (1 x 100mg, 1 x 200mg tablets) once daily in the morning
1876313|NCT01147744|Drug|GSK2190915 30mg|GSK2190915 30mg (1 x 30mg) once daily in the morning
1876314|NCT01147744|Drug|Montelukast 10mg|Montelukast 10mg (1 x 10mg capsule) once daily in the evening
1876315|NCT01147744|Drug|Placebo GSK2190915 one tablet|Placebo tablet, one tablet once daily in the morning
1876316|NCT01147744|Drug|Placebo montelukast|Placebo capsule once daily in the evening
1876317|NCT01147744|Drug|Placebo fluticasone propionate via ACCUHALER/DISKUS|Inhaled placebo twice daily via ACCUHALER/DISKUS
1876318|NCT01147744|Drug|Placebo GSK2190915 two tablets|Placebo tablet, two tablets once daily in the morning
1876319|NCT01147757|Drug|remifentanil|During surgery, 3 different dose of remifentanil or placebo was infused.
1876320|NCT01147770|Drug|progesterone|duration
1876321|NCT01147783|Other|CT, MRI|
1876322|NCT01147796|Device|computed tomography|64 slices CT with iodine injection
1876323|NCT01147796|Device|computed tomography|64 slices CT with iodine injection
1876324|NCT01147809|Drug|Eltrombopag olamine|thrombopoietin receptor agonist
1876325|NCT01147809|Other|Placebo|Placebo tablets with no active pharmaceutical ingredient
1876326|NCT01147822|Drug|Pazopanib|800 mg administered once daily orally continuous dosing
1876327|NCT01147822|Drug|Sunitinib|50 mg sunitinib to be administered in 6-week cycle: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment
1876328|NCT01147835|Dietary Supplement|Chinese Licorice Root|Chinese Licorice Root lollipops are given to the subjects in the study group to ingest twice daily for 10 days. Then the subjects must wait 3 months, and then again ingest the lollipops twice daily for 10 days.
1876329|NCT01147848|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 24 weeks
1876330|NCT01147848|Drug|Fluticasone propionate/salmeterol Inhalation Powder|Fluticasone propionate/salmeterol Inhalation Powder inhaled orally twice daily for 24 weeks
1876331|NCT01147848|Drug|Placebo (1)|Inhalation powder inhaled orally once daily for 24 weeks
1876332|NCT01147848|Drug|Placebo (2)|Inhalation powder inhaled orally twice daily for 24 weeks
1876333|NCT01147861|Drug|GSK256073|5mg in the AM and 5mg in the PM
1876334|NCT01147861|Drug|GSK256073|10mg in the AM
1876335|NCT01147861|Drug|GSK256073|50mg in the AM
1876336|NCT01147861|Drug|GSK256073|25mg in the AM and 25mg in the PM
1876337|NCT01147861|Other|Placebo|2 placebo tablets in the AM and 2 placebo tablets in the PM
1876338|NCT01147874|Procedure|lab draws and imaging|1 set of lab draws, imaging consists of radiographic imaging or X-ray, ultrasound and MRI
1876339|NCT01147887|Drug|Drug combination/ 26489112|On Day 1 and on Day 19, a single, oral dose of a drug combination consisting of midazolam (2 mg/mL liquid), tolbutamide (a 500 mg tablet), and omeprazole (a 20 mg capsule) will be taken and on Day 4 through Day 21, a single oral dose of two 26489112 tablets will be taken.
1876340|NCT01147900|Biological|Boostrix™|Intramuscular, single dose
1876341|NCT01147900|Biological|Boostrix™-US formulation|Intramuscular, single dose
1876342|NCT01147913|Behavioral|Computerized Information-Processing Bias Retraining|The intervention consists of the presentation of three-line ambiguous scenarios via a computer program, one line at a time. A disambiguating word fragment completes the scenario (in either a positive or neutral valence, depending on the scenario), after which participants will type the first letter of the word on the keyboard to ensure they are encoding the interpretation valence. The computer will indicate if they have correctly identified the word. This is followed by a Y/N comprehension question. Each session presents 100 training scenarios.
1876343|NCT01147913|Behavioral|Attention Control Training|"Four sessions of interpretation training for filler or neutral scenarios, unrelated to themes associated with depression."
1876344|NCT01147926|Drug|Placebo|Placebo matched to Prucalopride tablet orally once daily.
1876345|NCT01147926|Drug|Prucalopride|Prucalopride 2 mg tablet orally once daily for subjects greater than or equal to (≥) 18 to less than (<) 65 years; 1 mg once daily orally for subjects ≥65 years, and in case of insufficient response, increased to 2 mg once daily orally at Week 2 or Week 4.
1876346|NCT01149057|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously, every 4 weeks for 96 weeks
1876350|NCT01149096|Biological|filgrastim|Given subcutaneously
1876351|NCT01149096|Procedure|bone marrow donation|Undergo bone marrow harvest
1876352|NCT01149096|Other|laboratory biomarker analysis|Optional correlative studies
1876353|NCT01149109|Drug|Temozolomide and lomustine|
1876354|NCT01149109|Drug|Temozolomide|
1876355|NCT01149122|Drug|Gemcitabine/Oxaliplatin|GEMOX: (Gemcitabine 100 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q (every) 2 weeks
1876356|NCT01149122|Drug|Gemcitabine/Oxaliplatin with Erlotinib (Tarceva)|GEMOX + Tarceva: (Gemcitabine 1000 mg/㎡ over 100-min, Oxaliplatin 100 mg/㎡ over 2h) q 2weeks; Tarceva 100 mg qd
1876357|NCT01149135|Device|Blue enriched light with a low intensity|30 minutes in the morning, 750 lux
1876358|NCT01149135|Device|standard light treatment|standard light treatment, 30 minutes, 10 000 lux
1876359|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|"Sequence of Interventions To Increase Cerebral Oxygen Saturation
Check head and cannula position
Increase mean arterial pressure
Increase pump flow
Increase systemic oxygenation
Increase PaCO2 > 45
Increase anesthetic depth by increasing volatile anesthetic or by administering propofol boluses
Consider PRBC transfusion for Hct < 21%"
1876360|NCT01149148|Device|INVOS Somanetics Cerebral Oximeter|INVOS Cerebral Oximetry blinded monitoring with no deviation in surgical procedures or standard of care in anesthesia.
1876361|NCT01149161|Procedure|Routine central neck dissection|Level VI neck node dissection during thyroid operation
1876362|NCT01149174|Drug|Mitomycin-C 40 mg|Intravesical instillation of Mitomycin-C
1876363|NCT01149200|Drug|TC-6499|5mg enteric-coated oral hard gelatin capsule, administered twice daily
1876364|NCT01149200|Drug|Placebo|placebo as enteric-coated oral hard gelatin capsule, administered twice daily
1876365|NCT01149213|Device|transcranial direct current stimulation|tDCS will be applied at 2mA/30 minutes, every other week during the first three months than once a month during the next three months.
1876366|NCT01149226|Drug|chloral hydrate|30 min before the induction of anesthesia, chloral hydrate (40 mg/kg) or placebo was administered to the children orally.
1876367|NCT01149252|Other|Psoralait|Cream to be used as instructed.
1876368|NCT01149252|Other|Placebo cream.|Cream to be used as instructed
1876371|NCT01149278|Drug|maintain mean arterial pressure between 80-85 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 80-85 mm Hg
1876372|NCT01149278|Other|maintain mean arterial pressure between 65-70 mm Hg|protocolized hemodynamic care aiming to maintain mean arterial pressure between 65-70 mm Hg
1876373|NCT01149304|Drug|Pentoxifylline|Pentoxifylline is given for 8 weeks since the evening of the day of intervention with a dose of 400mg applied three times daily (morning, noon, evening).
1876374|NCT01149304|Drug|Ursodeoxycholic Acid|Ursodeoxycholic acid is administered for 8 weeks since the evening of the day of intervention. Dosage is 250mg given three times daily (morning, noon, evening).
1876375|NCT01149304|Drug|Enoxaparin|Enoxaparin with a dose of 40mg is injected subcutaneously once a day for 8 weeks since the evening of the day of intervention after the HDR-brachytherapy.
1876376|NCT01149317|Procedure|Acupuncture|Weekly acupuncture treatment for up to 14 weeks to augment usual care
1876377|NCT01149330|Drug|Adapalene-BPO Gel|Apply 1 gram of the investigational drug every night on whole face.
1876378|NCT01149343|Biological|Immunotherapeutic GSK2302025A, different formulations|Intramuscular administration
1876379|NCT01149356|Drug|Exemestane|Given orally
1876380|NCT01149356|Drug|Gamma-Secretase Inhibitor RO4929097|Given orally
1876381|NCT01149356|Drug|Goserelin Acetate|Given subcutaneously to premenopausal patients
1876382|NCT01149369|Drug|Aprepitant|Aprepitant, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
1876383|NCT01149369|Drug|Placebo|Aprepitant-placebo, 125 mg, 1 capsule, q.d. (everyday) with lunch for 4 weeks
1876384|NCT01149395|Drug|Dexlansoprazole|Dosage: 30 mg once per day for 4 weeks by mouth
1876385|NCT01149408|Drug|Decitabine (Dacogen)|Decitabine; 20 mg/m2; 1 hour intravenous infusion; 1 -3 days (will be given on a 28-day cycle for up to 18 months)
1876386|NCT01149421|Drug|LY2189265|Administered as a subcutaneous injection once weekly for 26 weeks
1876387|NCT01149421|Drug|Placebo|Administered as a subcutaneous injection once weekly for 26 weeks
1876388|NCT01149434|Drug|JI-101|JI-101 inhibits angiogenesis, and subsequently tumor growth, by inhibiting three receptor tyrosine kinases: VEGF Receptor Type 2 (VEGFR 2), platelet derived growth factor receptor beta (PDGFR β and Ephrin B4 (EphB4). JI-101 selectively inhibits kinases critical for all three stages of tumor angiogenesis.
1876389|NCT01149434|Drug|Everolimus|Everolimus is a signal transduction inhibitor that selectively inhibits mTOR (mammalian target of rapamycin), a key and highly conserved serine-threonine kinase, that is present in all cells and is a central regulator of protein synthesis and ultimately cell growth, cell proliferation, angiogenesis, and cell survival. mTOR is the only currently known target of everolimus (1).
1876390|NCT01149460|Drug|Valacyclovir|Test 1000 mg Tablet
1876391|NCT01149460|Drug|Valacyclovir|Reference Listed Valacyclovir 1000 mg Tablet
1876392|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
1876393|NCT01149473|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
1876394|NCT01149486|Drug|Losartan potassium/Hydrochlorothiazide|100/25 mg Tablets
1876395|NCT01149486|Drug|Hyzaar®|100/25 mg Tablets
1876398|NCT01149525|Drug|L-Carnitine|2g oral solution , twice per day (morning/evening), during 3 months
1876399|NCT01149525|Drug|Placebo|oral solution, twice per day (morning/evening), during 3 months
1876400|NCT01149538|Drug|Choline bitartrate|Choline bitartrate 500 mg. daily, administered in fruit-flavored drink mix.
1876401|NCT01149538|Dietary Supplement|Placebo for choline bitartrate|Placebo for choline bitartrate, administered daily in fruit-flavored drink mix.
1876402|NCT01149564|Drug|iv ibuprofen|
1876403|NCT01149564|Drug|oral ibuprofen|
1876404|NCT01149577|Drug|Olanzapine|06 weeks treatment with Olanzapine in a flexible dosage schedule.
1876405|NCT01149590|Procedure|Computer Tomography Angiography|Computed Tomography Angiography
1876406|NCT01149603|Device|HeartMate II Ventricular Assist Device|The HeartMate II Left Ventricular Assist Device has been approved by the FDA for use in bridge-to-transplant therapy and destination therapy for patients with endstage heart failure.
1876409|NCT01149629|Drug|Droxidopa|One capsule containing 300 mg droxidopa, given once
1876410|NCT01149629|Drug|Droxidopa|3 capsules each containing 100 mg droxidopa, give 3 times at 4 hour intervals
1876411|NCT01149629|Drug|Droxidopa|3 capsules each containing 100 mg droxidopa, given once
1876412|NCT01149642|Dietary Supplement|Oral Impact|"The patients will benefit in each case from a similar energy supplement (either Oral Impact or placebo) during the 5 days preceding the course of chemotherapy. They will receive the supplement 3 times per day at 10am, 3pm and 5pm outside of their meals. In total, the patients will take the supplements for 15 days (3 courses of 5 days). If the patient has difficulty taking the treatment orally, it can be given via an enteral tube (nasogastric tube or percutaneous gastrostomy). All patients in the protocol will systematically receive a dietetic consultation.
This consultation by a dietician will detect malnutrition and result in nutritional counsel if necessary (advice re. enrichment of diet, CNO without immunonutrients, artificial nutrition). Follow-up appointments with a dietician will be organised every 3 weeks to maintain adherence to the suggested dietary changes."
1876413|NCT01149642|Dietary Supplement|Placebo|The placebo is an identical formula to the Oral Impact but is not enriched with specific nutrients.
1876414|NCT01149655|Drug|Aripiprazole|Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
1876415|NCT01149655|Drug|Aripiprazole|Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
1876416|NCT01149668|Drug|PCI-24781|Subjects enrolled in this study will receive PCI-24781 administered orally at the schedule and dosage from their prior protocol.
1876417|NCT01149681|Drug|APLIDIN (plitidepsin)|"Aplidin® (plitidepsin) lyophilized powder and solvent for concentrate for solution for infusion. (2 mg plitidepsin vial and 4 ml ampoule).
Plitidepsin will be administered at 5 mg/m2 intravenously diluted to a total volume of 250 ml in 0.9% saline or 5% dextrose solution on Day 1 and 15 every four weeks for a maximum period of 6 cycles."
1876418|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|187.5 mg/60 g
1876419|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|375 mg/60 g
1876420|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|750 mg/60 g
1876421|NCT01149694|Drug|PUR 0110 Rectal Enema or Placebo Enema|1500 mg/60 g
1876422|NCT01149707|Drug|PUR 0110 Rectal Enema 250 mg|PUR 0110 Rectal Enema 250 mg, once-daily, intrarectally
1876423|NCT01149707|Drug|PUR 0110 Rectal Enema 500 mg|PUR 0110 Rectal Enema 500 mg, once-daily, intrarectally
1876424|NCT01149707|Drug|PUR 0110 Rectal Enema 1000 mg|PUR 0110 Rectal Enema 1000 mg, once-daily, intrarectally
1876425|NCT01149707|Drug|Placebo Enema|Placebo Enema, once-daily, intrarectally
1876426|NCT01149720|Drug|Tivantinib (ARQ 197) Capsule|Oral BID 360 mg dose (Capsule C: 6 X 60 mg) of ARQ 197 at least 1 hour before or 2 hours after a meal for 7 days
1876427|NCT01149720|Drug|Tivantinib (ARQ 197) Tablet|Oral BID 360 mg dose (Tablet: 3 x 120 mg) of ARQ 197 under fed conditions for 7 days
1876428|NCT01149720|Drug|Tivantinib (ARQ 197) Capsule D, oral|Oral BID 360 mg dose (Capsule D: 3 x 120 mg) of ARQ 197 under fed conditions in the extension phase
1876429|NCT01149733|Drug|Tamsulosin|Test 0.4 mg Capsule
1876430|NCT01149733|Drug|Tamsulosin|Reference Listed 0.4 Capsule
1876433|NCT01149759|Drug|Cyclosporine A|5 mg/kg for first 4 weeks, followed by tapering to 1 mg/kg for 12 weeks until discontinuation at 16 weeks
1876434|NCT01149772|Behavioral|ACCESS|Participants received 6 treatment sessions (2 core and 4 electives). The two core modules are increasing awareness and controlling physical and emotional symptoms. After completion of the core modules the participant was able to choose elective modules from Managing Physical Health, The Power of Thoughts, Increasing Pleasant Activities, and Relaxation. Participants were required to complete the first session in person and subsequent sessions participants had the option to complete in-person or over the phone. Participants also had the option to receive 2 brief follow-up booster calls to aid in reinforcing the changes made.
1876435|NCT01149785|Drug|crizotinib|Treatment A: a single 150-mg dose of crizotinib will be administered in the fasted state on Day 1 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
1876436|NCT01149785|Drug|ketoconazole|Treatment B: 200 mg twice a day (approximately 12 hrs apart) doses of ketoconazole will be administered orally on an empty stomach from Day 1 to Day 16.
1876437|NCT01149785|Drug|crizotinib|Treatment B: A single 150-mg dose of crizotinib will be administered in the fasted state on Day 4 as 1 × 50-mg and 1 × 100-mg Immediate Release Tablets.
1876438|NCT01149798|Drug|Abraxane and Cisplatin combination|"Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15.
Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1."
1876439|NCT01149811|Drug|Fipamezole ODT|Subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks.
1876440|NCT01149811|Drug|Fipamezole ODT Cohort 2|Subjects will receive fipamezole ODT 30 mg three times daily for 2 weeks, followed by a 2-week washout period. Beginning at Visit 5, subjects will receive fipamezole ODT 15 mg three times daily for 1 week followed by fipamezole ODT 30 mg three times daily for 1 week.
1876441|NCT01149824|Drug|Salvinorin A|
1876442|NCT01149824|Drug|Placebo|
1876443|NCT01149837|Device|InnoLIA HTLV I/II Score line immunoassay|This intervention consists of testing a residual serum or plasma sample from a blood donation or donor follow-up sample using the InnoLIA HTLV I/II Score line immunoassay
1876444|NCT01149850|Biological|bevacizumab|Given IV
1876445|NCT01149850|Drug|temozolomide|Given orally
1876446|NCT01149850|Other|laboratory biomarker analysis|Correlative studies
1876447|NCT01149850|Other|immunohistochemistry staining method|Correlative studies
1876448|NCT01149850|Genetic|microarray analysis|Correlative studies
1876449|NCT01149850|Genetic|DNA methylation analysis|Correlative studies
1876450|NCT01149863|Drug|Plerixafor|Plerixafor 240 mcg/kg SC will be administered daily starting on the first day of stem cell apheresis, up to a total of 4 doses.
1876451|NCT01149876|Other|Nu Skin Product|Thin layer of Nu Skin product applied to face.
1876526|NCT01150487|Procedure|bone marrow aspirations|A bone marrow aspiration from each hip bone of the patients.
1876452|NCT01149876|Other|Cosmetic instrument|Cosmetic instrument with topical Nu Skin product. Thin layer of Nu Skin product applied to face followed by galvanic, used for 3 minutes.
1876453|NCT01149876|Drug|Tretinoin cream 0.05|Thin layer of tretinoin applied to face.
1876454|NCT01149876|Other|CeraVe moisturizer|Thin layer of CeraVe applied to face.
1876455|NCT01149889|Procedure|transcranial direct current stimulation|Transcranial direct current stimulation will be applied at 2mA, 30 minutes/day, for 10 weekdays consecutively
1876456|NCT01149902|Biological|Cyclophosphamide, Docetaxel, Dendritic cells, OK-432|Cyclophosphamide 50mg/day, day1-7 and 22-28 Docetaxel 30mg/m2, day6 and 27 OK-432 5KE/day, day7,14,28,35
1876458|NCT01149941|Drug|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
1876459|NCT01149954|Drug|Ibuprofen|Ibuprofen 200 mg gel capsules of Dr. Reddy's Laboratories Limited
1876460|NCT01149967|Drug|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
1876461|NCT01149980|Drug|Citalopram Hydrobromide|Citalopram Hydrobromide Tablets 40 mg of Dr.Reddy's Laboratories Limited
1876462|NCT01149993|Drug|Myfortic (mycophenolic acid)|720mg twice a day for 7 days prior to transplantation
1876463|NCT01149993|Drug|Myfortic (mycophenolic acid)|720mg twice a day after transplant
1876464|NCT01149993|Drug|Thymoglobulin (anti-thymocyte globulin)|up to 25 mg will be infused into the renal artery of a donor kidney prior to transplantation into the recipient.
1876465|NCT01149993|Drug|Thymoglobulin (anti-thymocyte globulin)|standard of care for Georgetown University Hospital: 1.5 mg/kg/day infused over 6 hours.
1876466|NCT01150006|Other|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
1876467|NCT01150019|Other|Cross sectional study|This is not intervention study. The purpose of the study is to examine the relationship between various adipokine levels and PET imaging at the cross section setting
1876468|NCT01150032|Other|Bone quality complementary exams|"realisation of following exams to evaluate fracture risk in osteopenic women:
hip and wrist Dual energy X-ray Absorptiometry (DXA)
wrist and shin High-Resolution peripheral Quantitative Computed-Tomography(HR-pQCT)
hip Quantitative Computed Tomography (QCT)
High Resolution Digital X-Ray of calcaneum using BMA(tm) system
low-dose stereoradiography using EOS(tm) system (only for a sub-group of 60 voluntary subjects)"
1876469|NCT01150045|Drug|celecoxib|Patients receive celecoxib 400 mg administered by mouth, once daily.
1876470|NCT01150045|Drug|5-fluorouracil|Patients receive 400 mg/m^2 intravenous bolus then 2400 mg/m^2 continuous intravenous infusion over 46-48 hours.
1876471|NCT01150045|Other|placebo|Patients receive placebo administered by mouth, once daily.
1876472|NCT01150045|Drug|oxaliplatin|Patients receive 85 mg/m^2 intravenous over two hours.
1876473|NCT01150045|Drug|leucovorin|Patients receive 400 mg/m^2 intravenous over two hours.
1876474|NCT01150058|Genetic|western blotting|
1876475|NCT01150058|Other|flow cytometry|
1876476|NCT01150058|Other|laboratory biomarker analysis|
1876477|NCT01150084|Other|16-week lunchtime walking intervention|10 week group led lunchtime walks (each 30 minutes) followed by 6 weeks independent walking
1876478|NCT01150084|Other|delayed treatment|to start at week 10
1876479|NCT01150097|Drug|Tacrolimus (reduced tacrolimus)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization, a level which was maintained for the duration of the study.
1876480|NCT01150097|Drug|Everolimus (reduced tacrolimus)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL for the duration of the study.
1876481|NCT01150097|Drug|Tacrolimus (tacrolimus elimination)|After everolimus whole blood trough levels were confirmed to be in the target range of 3-8 ng/mL, tacrolimus tapering began, achieving a target tacrolimus whole blood trough level of 3-5 ng/mL by 3 weeks after randomization. Tacrolimus elimination was started beginning at Month 4. Tacrolimus was tapered after everolimus whole blood trough levels were within the target range of 6-10 ng/mL. Tacrolimus was completely eliminated by the end of Month 4.
1876482|NCT01150097|Drug|Everolimus (tacrolimus elimination)|Everolimus was started within 24 hours of randomization at a dose of 1.0 mg twice a day (bid, 2 mg daily dose). The dose was adjusted to maintain everolimus trough blood levels between 3-8 ng/mL until Month 4; beginning with Month 4, the dose was adjusted to maintain everolimus trough blood levels between 6-10 ng/mL.
1876483|NCT01150097|Drug|Tacrolimus (tacrolimus control)|Tacrolimus trough levels were targeted to be maintained at 8-12 ng/mL until Month 4. At Month 4, tacrolimus whole blood trough levels were decreased to a target trough level of 6-10 ng/mL for the remainder of the study.
1876484|NCT01150097|Drug|Corticosteroids|For patients in all groups, corticosteroids were initiated at or prior to the time of transplantation according to local practice. Corticosteroids could be used for the duration of the study but could not be eliminated before Month 6. The corticosteroids were not specified in the protocol because they were adminsitered to the participants according to local practice as part of standard of care.
1876485|NCT01150110|Device|resilient occlusal splints|"A resilient occlusal splints (silicone 2mm) was fabricated on the maxillary arch, using a vacuum pressing machine. The occlusal splints were adjusted to eliminate the gross interferences and to obtain occlusal stability with maximum posterior bilateral contacts.
Patients were instructed to use the occlusal splints for 24 hours during 30 days. The use was interrupted only during meals."
1876486|NCT01150123|Biological|Group B streptococcus (GBS) vaccine- low dose|
1876487|NCT01150123|Biological|Group B streptococcus (GBS) vaccine- High dose|
1876488|NCT01150123|Biological|Placebo- Saline|
1876489|NCT01150149|Behavioral|No face touch|
1876490|NCT01150149|Device|Surgical face mask|
1876491|NCT01150149|Device|Surgical face mask + no face touch|
1876527|NCT01150500|Device|MDT-4107 Zotarolimus-Eluting Coronary Stent|
1876492|NCT01150162|Drug|Rebamipide and Omeprazole|open label, oral route, Rebamipide, 100mg tablet t.i.d and Omeprazole 20 mg tablet B.I.D. for 8 weeks
1876493|NCT01150162|Drug|Omeprazole|open label,oral route, Omeprazole 20mg tablet, B. I.D.; alone, for 8 weeks
1876494|NCT01150175|Procedure|Endomyocardial Injection of Autologous Bone Marrow Cells|Endomyocardial Injection of Autologous Bone Marrow Cells
1876495|NCT01150175|Procedure|Endomyocardial Injection of Plasma|Endomyocardial Injection of Plasma
1876496|NCT01150188|Dietary Supplement|Amino acids|11 g amino acids two times per day for eight weeks
1876497|NCT01150188|Dietary Supplement|Placebo|Placebo of inert compounds, 11 g two times per day for eight weeks
1876498|NCT01150201|Drug|Aliskiren|For CKD treatment
1876499|NCT01150201|Drug|Losartan|Control
1876500|NCT01150214|Procedure|DE-MRI|Using Delayed-Enhancement Magnetic Resonance Imaging (DE-MRI) to identify fibrotic and scarred cardiac tissue. DE-MRI is a non-invasive method of identifying the extent and the distribution of structural remodeling or fibrosis and scarring associated with atrial fibrillation both pre- and post-ablation.
1876501|NCT01150253|Dietary Supplement|L. paracasei fermented milk|
1876502|NCT01150266|Drug|Alteplase (tPA)|0.9mg/KG (maximum 90mg), 10% bolus over one minutes, remainder over one hour.
1876503|NCT01150292|Dietary Supplement|First period DHA|400 mg DHA supplementation by day for 2 weeks during the first study period
1876504|NCT01150292|Dietary Supplement|Second period DHA|400 mg DHA supplementation by day for 2 weeks during the second study period
1876505|NCT01150305|Biological|blood sample|Peripheral whole blood sample, 5 ml
1876506|NCT01150318|Drug|Administration of 131 iodine|100 mCi 131 iodine irradiation
1876507|NCT01150331|Drug|Levetiracetam/Clonazepam|Association of two anti-epileptic drugs in first line
1876508|NCT01150331|Drug|Clonazepam/Placebo levetiracetam IV|Association of placebo to an active comparator (clonazepam)
1876509|NCT01150344|Drug|Malarone (atovaquone + proguanil combination)|4 X (250mg atovaquone + 100 mg proguanil) per os, once a day on 3 days as H0, H24 and H48.
1876510|NCT01150344|Drug|RIAMET (artemether + LUMEFANTRIN combination)|4 X (20mg artemether + 120 mg lumefantrine) per os twice a day on 3 days as H0, H8, H24, H36, H48 and H60
1876511|NCT01150357|Drug|Aliskiren (6.25/12.5/25 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the low dose arm, participants used one or more of the 6.25 mg capsule (containing 2 minitablets) once daily to reach the body-weight stratified dose of aliskiren.
1876512|NCT01150357|Drug|Aliskiren (37.5/75/150 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the medium dose arm, participants used one or more of the 37.5 mg capsule (containing 12 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
1876513|NCT01150357|Drug|Aliskiren (150/300/600 mg)|Aliskiren dispensing capsules containing minitablets (3.125 mg per minitablet). For the high dose arm, participants used one or more of the 150 mg capsule (containing 48 minitablets) once daily to reach the body- weight stratified dose of aliskiren.
1876514|NCT01150370|Device|The PrePex a novel device for adult male circumcision|The PrePex System was designed to enable safe, effective, painless and bloodless male circumcision programs. The PrePex System includes a simple, disposable device that is easy to use and can be deployed by minimally trained healthcare professionals, without the need for sterile, hospital settings.
1876515|NCT01150383|Other|Physical exercise training with supplemental oxygen|"Prior to the exercise training, an intervention-free control period with usual care is planned.
Intervention group with oxygen supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed with oxygen supplementation.
After 6 weeks of intervention with oxygen supplementation, second intervention period will start with room air instead of oxygen supplementation (as described above)."
1876516|NCT01150383|Other|"Physical exercise training with room air supplementation"|"Prior to the exercise training, an intervention-free control period with usual care is planned.
Intervention group with room air supplementation: Endurance training (performed within 70-80% of the heart rate at the anaerobic threshold) as well as strength training will be performed under normoxic conditions.
After 6 weeks of intervention with room air, second intervention period will start with oxygen supplementation instead of room air (as described above)."
1876517|NCT01150409|Drug|hydrocortisone|1) Hydrocortisone 50 mg IV every 12 hours x 4 doses (2 days), followed by Hydrocortisone 50 mg IV every 24 hours x 2 doses (2 days)
1876518|NCT01150409|Drug|Normal Saline|0.9% sodium chloride (equal volume to hydrocortisone) IV every 12 hours x 4 doses (2-days), followed by 0.9% sodium chloride (equal volume to hydrocortisone) IV every 24 hours x 2 doses (2-days)
1876519|NCT01150422|Other|Alternative follow-up|After mifepristone administration, women will be provided with a second semi-quantitative pregnancy test and a self-administered checklist. Women will be instructed to complete the checklist and perform the pregnancy test at home on an assigned data two weeks after mifepristone administration. On the assigned date, women will also be contacted by phone by the clinic staff. Women will be asked to confirm whether they completed the pregnancy test and checklist and asked to report on the results of both tests. Provider will review the women's responses to the checklist and confirm whether, based on the woman's responses, she should return for a follow up visit. During the follow-up phone call, women will also be asked about the satisfaction and acceptability of the alternative follow-up procedure.
1876520|NCT01150448|Drug|Paliperidone palmitate Treatment A|All patients will receive a single IM injection of 150mg eq of study drug on Day 1. Patients who tolerate 150mg eq will receive a 2nd IM injection of 150mg eq on Day 8 followed by 12 IM injections (1 every 4 weeks) of 150mg eq. All other patients will be assigned to Treatment B.
1876521|NCT01150448|Drug|Paliperidone palmitate Treatment B|Patients not tolerating Treatment A will receive a single IM injection of study drug 100mg eq at their next scheduled visit followed by injections (1 every 4 weeks) ranging from 50 to 150mg eq
1876522|NCT01150461|Drug|losartan|Losartan 50 mg b.i.d
1876523|NCT01150461|Drug|placebo|Placebo b.i.d.
1876524|NCT01150474|Drug|Belladonna and Opium Suppositories|Belladonna (16.2 mg) and opium (60 mg) suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
1876525|NCT01150474|Drug|Placebo Suppositories|Placebo suppositories administered rectally immediately following surgery and every 8 hours for 16 hours for a total of 3 doses.
1876528|NCT01150513|Drug|EC-T|four cycles of EC (epirubicin: 90 mg/m2; cyclophosphamide :600 mg/m2, day 1) followed by four cycles of T (docetaxel : 75 mg/m2 or paclitaxel 175 mg/m2, day 1)
1876529|NCT01150513|Drug|TP|six cycles of TP (docetaxel: 75 mg/m2 or paclitaxel 175 mg/m2 d1; carboplatin AUC=5, day 1)
1876530|NCT01150526|Dietary Supplement|CaHMB|CaHMB capsules with each capsule containing 0.8 g of HMB
1876531|NCT01150526|Dietary Supplement|HMB Free Acid Gel|HMB Free acid in a gel form with each dose supplying 0.8 g of HMB free acid
1876532|NCT01150526|Dietary Supplement|Placebo|Placebo capsules similar in size and color to the CaHMB capsules used in the study
1876533|NCT01150526|Dietary Supplement|Placebo Gel Dosage|A corn syrup based placebo with flavoring and taste similar to the HMB Free Acid Gel
1876534|NCT01150539|Other|16-week exercise training program|The primary objective of the study is to investigate the effects of a 16-week exercise training program on insulin resistance and adiposity in overweight/obese women with PCOS.
1876535|NCT01150539|Other|Control Group without PCOS|A group of overweight/obese women without PCOS will be enrolled as a control group and will be studied only once at baseline to allow for comparisons between the two study populations.
1876536|NCT01150565|Drug|LiRIS low dose and LiRIS high dose|Drug delivery system containing lidocaine; LiRIS (low or high dose) is inserted into bladder via cystoscopy on Day 1 and removed via cystoscopy on Day 14. Designed to release lidocaine over a 14 day period.
1876537|NCT01150578|Drug|No intervention|No intervention
1876538|NCT01150604|Behavioral|Self-help cognitive-behavioral online course|A self-help online course based on cognitive behavioral therapy for major depression.
1876539|NCT01150617|Drug|Insulin glargine plus insulin analogues|"Intensified insulin therapy: three administrations of regular insulin or short acting insulin analogues before meals combined with long-acting insulin analogue glargine in the evening. The treatment goal will be a fasting blood glucose level of 5.5 mmol/L (99 mg/dl) and a HbA1c<6.5% at the end of the follow-up.
Standard care: treatment will be once-daily long-acting insulin and oral antidiabetic agents to achieve HbA1c levels of < 7.0% at the end of the follow-up."
1876540|NCT01150630|Drug|capecitabine|1250 mg/mq/day per os for 14 days every 14 days for 6 months
1876541|NCT01150630|Drug|cisplatin|30 mg/mq every 14 days for 6 months
1876542|NCT01150630|Drug|epirubicin|30 mg/mq every 14 days for 6 months
1876543|NCT01150630|Drug|gemcitabine|ARM A: 1000 mg/mq for 3 weekly infusions every 4 weeks for 6 months ARM B and C: 800 mg/mq every 14 days for 6 months
1876544|NCT01150643|Genetic|gene expression analysis|
1876545|NCT01150643|Genetic|microarray analysis|
1876546|NCT01150643|Genetic|polymerase chain reaction|
1876547|NCT01150643|Genetic|polymorphism analysis|
1876548|NCT01150643|Other|immunohistochemistry staining method|
1876549|NCT01150643|Other|laboratory biomarker analysis|
1876550|NCT01150656|Genetic|gene expression analysis|
1876551|NCT01150656|Genetic|microarray analysis|
1876552|NCT01150656|Genetic|protein expression analysis|
1876553|NCT01150656|Genetic|reverse transcriptase-polymerase chain reaction|
1876554|NCT01150656|Genetic|western blotting|
1876555|NCT01150656|Other|laboratory biomarker analysis|
1876556|NCT01150656|Other|pharmacological study|
1876557|NCT01150669|Other|laboratory biomarker analysis|Samples are analyzed in laboratory studies
1876558|NCT01150682|Genetic|RNA analysis|
1876559|NCT01150682|Genetic|reverse transcriptase-polymerase chain reaction|
1876560|NCT01150682|Other|enzyme-linked immunosorbent assay|
1876561|NCT01150682|Other|immunohistochemistry staining method|
1876562|NCT01150682|Other|laboratory biomarker analysis|
1876563|NCT01150695|Other|Placebo|Normal saline will be administered to all subjects as a control and will be given at the same visit as the vaccine (Day 0).
1876564|NCT01150695|Biological|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine [approximately 1x10^9 colony forming units (cfu)/mL] produced by Dynport Vaccine Company. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
1876565|NCT01150695|Biological|Undiluted Francisella tularensis live attenuated vaccine|Undiluted Francisella tularensis live attenuated vaccine (approximately 1x10^9 cfu/mL) in use by the United States Army Medical Research Institute of Infectious Diseases. Administered by scarification in the ulnar aspect of the volar surface (palm side) of the forearm midway between the wrist and the elbow.
1876566|NCT01150747|Drug|ceftriaxone|250mg IM once
1876567|NCT01150747|Drug|Azithromycin|1 gm once
1876568|NCT01150760|Drug|Alvimopan|At least 1 dose of alvimopan 12 mg during the hospitalization for bowel resection
1876569|NCT01150786|Dietary Supplement|Selenium Supplement|The patients in this arm took 200 microgram selenium yeast daily for 12 weeks.
1876570|NCT01150786|Other|placebo|The patients in this arm took one placebo capsule daily for 12 weeks.
1876571|NCT01150812|Drug|AZD8165|Oral suspension, 2 mg/mL and 20 mg/mL, single doses
1876572|NCT01150838|Drug|propofol|Initial dose: Propofol 2 mg/kg, then dose changes separately based on the last subject in the same age group and sevo time range
1876573|NCT01150851|Other|caloric restriction|10 to 15% reduction in total daily calories (300 to 500 kcal reduction) from the usual daily energy consumption for 4 months duration
1876574|NCT01150851|Other|aerobic exercise|supervised physical activity for a maximum of 30-45 minutes, 3 times per week for 4 months duration
1876575|NCT01150864|Device|Airway Conditioning|Each Passive device will be changed daily. When using Active and Passive devices as well as Active-Passive devices the ventilatory circuit will be changed every 7 days.
1876576|NCT01150877|Drug|Vitamin D|We propose to study high-dose, oral vitamin D supplementation, raising serum 25-hydroxy-vitamin D (25(OH)D) concentrations to 200 -250 nmol/L, in metastatic colorectal cancer patients with safety, tolerability and survival as the main outcome measurements. The dose is not pre-set and will depend on the individual subjects' serum 25(OH)D concentration. Subjects will be supplemented for 16 months with a daily oral dose, followed by a 12 months follow-up period.
1876577|NCT01150890|Drug|AMG 827 350 MG|350 mg AMG 827 IV (in the vein)
1876578|NCT01150890|Drug|AMG 827 210 MG|210 mg AMG 827 IV (in the vein)
1876580|NCT01150890|Drug|Placebo|Placebo IV (in the vein)
1876581|NCT01150903|Other|no intervention|non-interventional study
1876582|NCT01150903|Other|no intervention|non-interventional study
1876583|NCT01150916|Procedure|BNP, SAAG, ascites total protein, echocardiography|diagnostic tests
1876584|NCT01150929|Device|P.F.C. Sigma knee arthroplasty|Randomization to either rotating platform or fixed bearing tibial plateau and polyethylene
1876585|NCT01150942|Biological|JE vaccine|3 times, IM
1876586|NCT01150955|Dietary Supplement|Resveratrol|500 mg three times a day for five weeks.
1876587|NCT01150955|Other|Placebo|Placebo (starch capsules) 500 mg three times a day for five weeks.
1876588|NCT01150968|Behavioral|End of life education|Residents will participate in one hour, case-based, interactive teaching sessions on end of life communication.
1876589|NCT01150981|Drug|Rosiglitazone|One 8mg capsule daily for 6 weeks.
1876590|NCT01150981|Drug|Placebo|One capsule daily for 6 weeks.
1876591|NCT01150994|Behavioral|Safety Assessment and Follow-up Telephone Intervention (SAFTI).|Mental health evaluation in ED, followed by Post-ED counseling
1876592|NCT01151020|Device|Zenith® TX2® Low Profile TAA Endovascular Graft|Endovascular treatment of patients with aneurysms/ulcers of the descending thoracic aorta having morphology suitable for endovascular repair
1876593|NCT01151033|Device|Drug Eluting Stent implantation|ProNOVA XR Drug Eluting Stent implantation
1876594|NCT01151046|Drug|MM-121|MM-121 (40mg/kg loading dose week 1, then 20 mg/kg weekly) administered over 60 minutes as an intravenous infusion once per week
1876595|NCT01151046|Drug|Placebo|Placebo (histidine solution) administered over 60 minutes as an intravenous infusion once per week and exemestane (25 mg) administered orally once per day
1876596|NCT01151046|Drug|Exemestane|Exemestane (25 mg) administered orally once per day
1876597|NCT01151059|Biological|Trivalent subunit inactivated flu vaccine, Formulation 2010-2011|This phase II is performed as a multicenter study site in non-elderly adult and elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22).
1876598|NCT01151072|Drug|insulin degludec|Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
1876599|NCT01151085|Drug|Voriconazole|"Voriconazole Intravenous Solution 200 mg:
Voriconazole is administered by intravenous drip infusion at the dose of 6 mg/kg twice daily on day 1 and 3 mg/kg or 4 mg/kg twice daily from day 2 onward in adults.
Voriconazole Tablet 50 mg/ Voriconazole Tablet 200 mg:
administration for an adult (weighing 40 kg or more) is voriconazole 300mg orally twice daily between meals for day 1 and then 150 mg or 200 mg twice daily between meals from day 2 onward.
Depending on the symptoms or in cases where the effect is insufficient, the dosage may be increased.
However, the maximum dose on day 1 must be 400 mg twice daily, and the maximum dose from day 2 onward must be 300 mg twice daily.
In patients weighing less than 40 kg, voriconazole 150 mg shall be administered twice daily on day 1, and voriconazole 100 mg shall be administered twice daily from day 2 onward.
Depending on the symptoms, the maintenance dose from day 2 onward may be increased to 150 mg twice daily."
1876600|NCT01151098|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10 or 20 mcg/h applied for 7-day wear
1876601|NCT01151111|Behavioral|Relaxation guided imagery|An individualized relaxation guided imagery session will be conducted. After the session patients will be given a CD with the RGI and asked to listen to it at home.
1876602|NCT01151124|Biological|CTX0E03 neural stem cells|Single administration by surgical delivery to the damaged area of the brain
1876603|NCT01151137|Drug|Dronedarone|"Film-coated tablet
Oral administration under fed conditions (during breakfast and dinner)"
1876604|NCT01151137|Drug|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance
Oral administration under fed conditions (during breakfast and dinner)"
1876605|NCT01151176|Drug|Regular Insulin|1,8U Regular insulin/h from 180mg/dL of blood glucose increasing each hour according to capillary blood glucose. Between 100-150mg/dL keep infusion and bellow 100mg/dL stop infusion
1876606|NCT01151176|Drug|Regular Insulin|"Regular Insulin SC according to Blood Glucose(mg/dL) and Insulin Sensitive with usual dose describe and less 2U for sensitive and plus 2U for insulin resistant:
Blood Glucose >141-180=4U ;181-220=6U; 221-260=8U; 261-300=10U;301-350=12U; 351-400=14U; > 400=16U"
1876607|NCT01151189|Biological|MVA85A/AERAS-485|Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.
1876608|NCT01151189|Biological|Placebo|Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.
1876609|NCT01151202|Drug|AG NPP709syrup|
1876610|NCT01151215|Drug|AZD8931|Tablet, oral, bd
1876611|NCT01151215|Drug|anastrozole|Tablet, oral, od
1876612|NCT01151215|Drug|Placebo|Tablet, oral
1876613|NCT01151228|Other|Ultrasound examination followed by ingestion of Apple Juice prior to a second ultrasound procedure, followed by gastroscopic suctioning of stomach content.|Ultrasound scan of the stomach followed by ingestion of 0, 50, 100, 200, 300, or 400 mL of apple juice, followed by second ultrasound scan of the stomach, followed by gastroscopic suctioning of stomach content.
1876614|NCT01151241|Procedure|Elbow arthroscopy with infraclavicular nerve block and continuous local anesthetic infusion to day 3 post op.|Patients undergoing elbow arthroscopy surgery will receive standard anesthesia/analgesia, including infraclavicular nerve block and general anesthesia for surgery followed by infraclavicular catheter infusion of local anesthetic until day 3 after surgery.
1876615|NCT01151241|Other|Early Discharge|Patients will be discharged home on the first day after surgery, with infraclavicular catheter infusion of local anesthetic in place.
1876616|NCT01151241|Other|Normal Discharge|Patients will remain in hospital and be discharged per current discharge criteria, once the infraclavicular catheter has been removed on day 3 post op. Typical discharge occurs on day 3 or 4 post op.
1876617|NCT01151254|Drug|Isoflurane/sevoflurane|Volatile for sedation in the CVICU while intubated
1876618|NCT01151254|Other|Propofol|Propofol for sedation in the CVICU
1876664|NCT01145014|Drug|Placebo|matching placebo (oral drinking solution and IR tablets)
1876619|NCT01151267|Other|Standard Anesthesia management for post surgical patients|The O2 flow on the anesthetic machine will be set at 15 L/min. Ventilatory assistance will be performed to maintain O2 saturation >97% and end tidal CO2 at 35-45mmHg.
1876620|NCT01151267|Device|Hypercarbic Spontaneous Hyperpnoea|Patient will be disconnected from the anesthetic circuit and connected to the resuscitation bag attached to the IH system. With O2 flow of 2 L/min patient will be gently ventilated until recovery of the spontaneous ventilation. After starting spontaneous ventilation basal O2 flow will be adjusted to keep ETCO2 in range of 50-60 mm Hg or minute ventilation of 15-17 L/min, whichever occurs first.
1876621|NCT01151280|Device|WallFlex Biliary Fully Covered Stent|Investigational device evaluated for the treatment for benign biliary strictures
1876622|NCT01151306|Drug|Simvastatin|Simvastatin 20mg once daily (in the evening) for 6 weeks
1876623|NCT01151306|Drug|Lactose tablet|One tablet taken each evening for 6 weeks
1876624|NCT01151319|Biological|ChAdV63.HIVconsv low dose.|Attenuated chimp adenovirus. 5x10^9 virus particles.
1876625|NCT01151319|Biological|ChAdV63.HIVconsv high dose.|Attenuated chimp adenovirus at 5x10^10 virus particles.
1876626|NCT01151319|Biological|pSG2.HIVconsv|DNA at 4mg per dose.
1876627|NCT01151319|Biological|MVA.HIVconsv|Attenuated poxvirus at 4x10^8 plaque forming units per dose.
1876628|NCT01151319|Other|Placebo|Phosphate buffered saline
1876629|NCT01151345|Drug|TILACEM|At 08:00 hours on day 1, CIF-BIOTEC personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
1876630|NCT01151345|Drug|ANGIOTROFIN|At 08:00 hours on day 1, CIF-BIOTEC Pharmacy personnel will start to administer the study drug. Each volunteer will receive a single dose of 60 mg of Diltiazem. The study drugs will be ingested with 250 mL of drinking water. Research Pharmacy personnel will inspect the volunteer's oropharynx to ensure that he/she has swallowed the tablet and record their observations in the corresponding forms.
1876631|NCT01151371|Device|narafilcon B contact lens|Silicone Hydrogel Daily Disposable Contact Lenses
1876632|NCT01151371|Device|nelfilcon A contact lens|Conventional Hydrogel Daily Disposable Contact Lenses
1876633|NCT01151371|Device|lotrafilcon B contact lens|Silicone Hydrogel Monthly Replacement Contact Lenses
1876634|NCT01151384|Drug|LE-DT|Intravenous infusion, Upto 5 dose levels have been studied i.e. 50, 65, 85, 110 and 132 mg/m2, Every 3 weeks
1876635|NCT01151397|Drug|Peg + Vitamin D + Ribavirin|Peg+ Vitamin D+ Ribavirin for 3 months
1876636|NCT01151397|Drug|Peg + Ribavirin|Peg+ Ribavirin for 6 months
1876637|NCT01151410|Drug|Aliskiren|"Low weight patients: Starting dose 37.5 mg with optional titration to 75 and then 150 mg
Mid weight patients: Starting dose 75 mg with optional titration to 150 and then 300 mg
High weight patients: Starting dose 150 mg with optional titration to 300 and then 600 mg"
1876638|NCT01151410|Drug|Enalapril|"Low weight patients: Starting dose 2.5 mg with optional titration to 5 and then 10 mg
Mid weight patients: Starting dose 5 mg with optional titration to 10 and then 20 mg
High weight patients: Starting dose 10 mg with optional titration to 20 and then 40 mg"
1876639|NCT01151423|Biological|anti-vWF Nanobody|10 mg i.v. bolus injection prior to plasma exchange, followed by 10 mg s.c. injection once or twice per day. Maximum treatment duration is limited to 90 days.
1876640|NCT01151423|Biological|Placebo|10 mg i.v. bolus injection prior to plasma exchange, followed by daily 10 mg s.c. injection. Maximum treatment duration is limited to 90 days.
1876641|NCT01151423|Other|Plasma exchange|Plasma exchange
1876642|NCT01151436|Device|hyaluronic acid dermal fillers|1 injection per indication and 1 touch-up injection if necessary
1876643|NCT01151449|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
1876644|NCT01151449|Other|laboratory biomarker analysis|Correlative studies
1876645|NCT01151488|Other|Resistance Training|RT 3x/wk for 4 months
1876646|NCT01151501|Device|noninvasive positive pressure ventilation|Patients in whom the spontaneous breathing trial fail and in whom exclusion criteria are not present during this period were randomly allocated. Patients who are randomized to NPPV goup will be extubated and non-invasive ventilation (BiPAP Vision, Respironics Inc., Murrysville，Pennsylvania) will be delivered immediately after extubation using spontaneous/timed (S/T) mode. Expiratory positive airways pressure (PEEP) was initially set at 4 cmH2O and gradually increased to 6-8 cmH2O or more；and fraction of inspired oxygen (FiO2) was set to achieve pulse oximeter oxygen saturation (SpO2) >92% in cooperation with PEEP. On condition that tidal volume is no less than 6ml/kg，continuous positive airway pressure (CPAP) is permitted to apply，in which the adjusting procedures of CPAP and FiO2 is similar with PEEP and FiO2 in S/T mode. NPPV is terminated When patients can spontaneously breath oxygen provided by a Venturi device at FiO2≤0.35 for more than 24 hours with SpO2＞92%.
1876647|NCT01151514|Other|Nephrologist referral|Nephrologist specialty, renal replacement therapy
1876648|NCT01151540|Drug|E2080|The target dosage is approximately 45 mg/kg/day, taken orally twice a day.
1876649|NCT01151553|Device|CRT Therapy|Screen for enrollment criteria, consented, echocardiogram and electrocardiogram performed, demographics reviewed, obtain blood sample, pre-operative QOL questionnaire and 6 minute hall walk
1876650|NCT01145001|Behavioral|Cognitive Behavioural Therapy|Weekly CBT for all subjects
1876651|NCT01145001|Behavioral|Contingency Management|incentives given for abstinence based on urine analysis
1876652|NCT01145001|Drug|Nicotine Transdermal Patch|14mg ir 21mg doses based on weight and #cigs/day
1876653|NCT01145014|Drug|BI 660848|2 mg oral drinking solution
1876654|NCT01145014|Drug|BI 660848|10 mg oral drinking solution
1876655|NCT01145014|Drug|BI 660848|20 mg oral drinking solution
1876656|NCT01145014|Drug|BI 660848|50 mg oral drinking solution
1876657|NCT01145014|Drug|BI 660848|100 mg oral drinking solution
1876658|NCT01145014|Drug|BI 660848|150 mg oral drinking solution
1876659|NCT01145014|Drug|BI 660848|200 mg oral drinking solution
1876660|NCT01145014|Drug|BI 660848|400 mg oral drinking solution
1876661|NCT01145014|Drug|BI 660848|600 mg oral drinking solution
1876662|NCT01145014|Drug|BI 660848|10,0 mg immediate release tablet
1876663|NCT01145014|Drug|BI 660848|50,0 mg immediate release tablet
1876665|NCT01145027|Other|Breakfast tray|The sensorial stimulus will be a breakfast meal, with excellent presentation and aroma, composed by favorite food items previously related by the individual for this meal. The meal will not be offered for immediate intake, it will be placed in front of the volunteer for perception of the smell and taste.
1876666|NCT01145066|Dietary Supplement|borage/echium oil combination|borage/echium oil combination containing 0.85g/day SDA and 1.7g/day GLA
1876667|NCT01145066|Dietary Supplement|fish oil|1.6g/day EPA and 1.08g/day DHA
1876668|NCT01145066|Dietary Supplement|corn oil|contains 4.5 g/day linoleic acid
1876669|NCT01145079|Device|Zotarolimus-eluting stent|Zotarolimus-eluting stent
1876670|NCT01145079|Device|Zotarolimus-eluting stent for ACS and DM|Zotarolimus-eluting stent for ACS and DM
1876671|NCT01145079|Device|Everolimus-eluting stent for long lesion|Everolimus-eluting stent for long lesion
1876672|NCT01145079|Device|Sirolimus-eluting stent for short lesion|Sirolimus-eluting stent for short lesion
1876673|NCT01145092|Behavioral|exercise training, endurance training|The endurance training group exercised on a cycle ergometer (90% of power output determined at the respiratory compensation point = RCP). The duration of each training unit was increased with time. The resistance group trained on 8 weight machines where the workload gradually increased every 2-3 weeks. At week 13 an additional physical examination, OGTT and spiro-ergometry for adjusting the training were performed.
1876674|NCT01145105|Procedure|neural dynamics techniques treatment|Treatment group- will receive neural mobilizations techniques, to improve movement of the sciatic nerve.
1876675|NCT01145105|Procedure|placebo treatment|Control group- will receive placebo treatment that will include mobilization to the upper limb. After the placebo treatment, these patients will receive neural mobilizations techniques.
1876676|NCT01151579|Drug|Levalbuterol|inhaled Levalbuterol 0.625 mg inhaled Levalbuterol 2.5 mg
1876677|NCT01151579|Drug|Albuterol|Nebulized albuterol 2.5mg
1876678|NCT01151592|Drug|Iron Sucrose|Iron Sucrose, 1000 mg cumulative dose to be administered per the US package insert.
1876679|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
1876680|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
1876681|NCT01151605|Drug|insulin|insulin to be infused at three different rates (2, 3.5 and 5 units/hour)
1876682|NCT01151631|Device|occipital nerve stimulation|Low occipital bilateral Quad Plus, midline to laterally directed, secured by titan anchors, connected to Versitrel. No trial stimulation. Suggested stimulation parameters: Pulse width: 450, Amplitude: protocol, Rate: 60
1876683|NCT01151644|Biological|Anti-pandemic H1N1 influenza vaccine|inactivated, NON-adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
1876684|NCT01151657|Dietary Supplement|Probiotics|Capsules with probiotics containing the strains : Lactobacillus paracasei ssp paracasei F19, Lactobacillus acidophilus La5 og Bifidobacterium Bb12. Dose/capsule : 2 x 109 - 10 x 109 CFU.
1876685|NCT01151657|Dietary Supplement|Placebo|Placebo capsules containing maltodextrin
1876686|NCT01151670|Drug|pioglitazone|Pioglitazone 22.5 mg daily before, during and after radiation therapy.
1876687|NCT01151670|Drug|Pioglitazone|Pioglitazone 45 mg by mouth daily before, during and after radiation therapy
1876688|NCT01151683|Dietary Supplement|magnesium|Magnesium chelate, 300mg (2 capsules of 150mg) twice a day, per oral Total of 600mg per day
1876689|NCT01151683|Dietary Supplement|placebo|Two capsules of placebo per oral twice a day
1876690|NCT01151696|Drug|Atarax (Hydroxyzine)|One milligram per 10 kilogram, intramuscular use
1876691|NCT01151696|Drug|Placebo|Placebo
1876692|NCT01151722|Procedure|bevacizumab injection|bevacizumab injection before vitrectomy
1876693|NCT01151722|Procedure|bevacizumab injection|bevacizumab injection after vitrectomy
1876694|NCT01151735|Drug|C-1-esterase|1000 units of C-1-esterase inhibitor
1876695|NCT01151735|Drug|C-1-esterase|1500 units of C-1-esterase inhibitor
1876696|NCT01151735|Drug|placebo|placebo
1876697|NCT01151748|Procedure|Intra-arterial infusion of chemotherapy|
1876698|NCT01151761|Procedure|Stereotactic Body Radiotherapy|Standard of care
1876699|NCT01151761|Drug|Gemcitabine|100 mg/m2, IV
1876700|NCT01151761|Drug|Cisplatin|25 mg/m2, IV
1876701|NCT01151761|Drug|Carboplatin|AUC 2, based on Calvert formula, IV
1876702|NCT01151761|Drug|Capecitabine|1000 mg/m2, PO
1876703|NCT01151761|Drug|5FU|200 mg/m2
1876704|NCT01151761|Procedure|Liver transplantation|
1876705|NCT01151787|Drug|cyclobenzaprine hydrochloride|15mg daily for 3 months
1876706|NCT01151787|Drug|placebo|placebo
1876707|NCT01151800|Other|Using IVR to maintain ACS patients on best practice guidelines|
1876710|NCT01151839|Procedure|Esophagectomy|Patient with squamous cell carcinoma of esophagus will be treated with surgery alone
1876711|NCT01151839|Procedure|Neoadjuvant chemoradiation followed by surgery|Patient with squamous cell carcinoma of esophagus will be treated by neoadjuvant chemoradiation followed by surgery
1876712|NCT01151852|Drug|Imatinib|Patients will be randomly assigned to receive imatinib at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression, unacceptable toxicity, or withdrawal of consent.
1876713|NCT01151852|Drug|Placebo|Patients will be randomly assigned to receive placebo at a dose of 400mg/day, taken once daily with food, in the form of 100-mg tablets. The study medication will be administered until disease progression or withdrawal of consent.
1876714|NCT01151865|Drug|Dexmedetomidine|"Dexmedetomidine will be administered intravenously as a maintenance infusion of 0.2 to 1.5 mcg/kg/hour, commencing at 0.5 mcg/kg/hour and titrated according to effect, for as long as deemed necessary by the treating physician. Specifically, the study medication may be (as recommended by the manufacturer) continued after extubation, and if discontinued may be restarted at any time up until ICU discharge. The clinician will have the option of using a loading dose of 1.0 mcg/kg IV over 20 minutes, as recommended by the manufacturer.
Bedside nursing staff will adjust drug infusion rates as necessary, in consultation with the treating physician, aiming to achieve a Riker Sedation-Agitation Scale 20 score of 4."
1876715|NCT01151865|Drug|Saline placebo|An identical syringe containing only saline with no dexmedetomidine added will be supplied. Initial rate of infusion and subsequent adjustments will be the same as in the active comparator group.
1876716|NCT01151878|Dietary Supplement|Glucomannan|1.26 g per sachet; 2 sachets per day for 4 weeks.
1876717|NCT01151878|Dietary Supplement|maltodextrin|prepared in sachets (1.3g); 2 sachets per day for 4 weeks
1876718|NCT01152632|Other|manual acupuncture|thirty minutes duration every time, five times per week for one course, a total four courses
1876719|NCT01152645|Drug|ARQ 197|Orally twice daily administration of ARQ 197
1876720|NCT01152658|Biological|PRGF|enriched plasma fraction will be then injected to the trial group in sterile conditions under ultrasound control in the ssp gap
1876721|NCT01152658|Other|NACL|Nack 0.9 5 will be then injected to the control group group in sterile conditions under ultrasound control
1876722|NCT01152671|Drug|Placebo|single oral dose
1876723|NCT01152671|Drug|RO5024048|single oral dose
1876724|NCT01152697|Drug|haloperidol decanoate|Drug is in in injectable form and will be administered approximately every four weeks through Week 25 of the study. A participant may continue on the drug after Week 25 at the discretion of his or her treating psychiatrist. Dosage is per package insert or at the discretion of the psychiatrist.
1876725|NCT01152697|Drug|haloperidol|Drug will be administered in oral form to participants not already taking oral haloperidol and then transitioned to the injectable version. Dosage and frequency is at the discretion of the psychiatrist.
1876726|NCT01152697|Behavioral|Customized Adherence Enhancement|CAE targets key areas relevant to non-adherent populations with schizophrenia or schizoaffective disorder: 1) inadequate or incorrect understanding of mental disorder; 2) lack of medication-taking routines; 3) poor communication with care providers; and 4) substance use which interferes with adherence and healthy behaviors that promote recovery. CAE is delivered based upon initial assessment of reasons for non-adherence and only those components of CAE that are determined to be indicated for that individual are delivered (psychoeducation, modified motivational interviewing, assistance with medication routines, coaching in communication with providers).
1876727|NCT01152710|Drug|Capecitabine|Chemotherapy with capecitabine of 1650 mg/m2 daily dose will be administered orally, divided into two equal doses given 12 hours apart, during radiotherapy(45 Gy 1,8 Gy/fr), including weekends
1876728|NCT01152723|Drug|Nicotine|2 mg, Single Dose
1876729|NCT01152736|Drug|Nicotine|2 mg Single-dose
1876730|NCT01152749|Drug|Nicotine|Single-dose of new NRT product
1876731|NCT01152749|Drug|Nicotine Gum|Single-dose of marketed nicotine gum
1876733|NCT01152775|Other|This group of patients will be exposed to multimedia|This group of patients will be exposed to multimedia
1876734|NCT01152775|Other|No Media|This group will not be exposed to multimedia
1876735|NCT01152788|Drug|rIL-21|30 μg/kg IV Daily x 5, weeks 1, 3 and 5 every 8 weeks
1876736|NCT01152788|Drug|Dacarbazine|1000 mg/m2 IV Day 1, every 3 weeks
1876737|NCT01152801|Drug|Everolimus (RAD001)|
1876738|NCT01152814|Biological|Seasonal flu vaccine|This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
1876739|NCT01152827|Drug|RAD001|"RAD001 10 mg daily po medication.
Treatments will be continued until any of the following events occur
progression of disease
the subject develops unacceptable toxicity
consent to participate in the study is withdrawn"
1876740|NCT01152840|Drug|RAD001|"RAD001 10 mg po daily medication
Treatments will be continued until any of the following events occur:
progression of disease,
the subject develops unacceptable toxicity,
consent to participate in the study is withdrawn."
1876741|NCT01152853|Drug|PF00299804|PF-00299804 will be given orally once daily at 45 mg daily. Patients will take study drug continuously, with cycles of 28 days.
1876742|NCT01152866|Drug|Choriogonadotropin alpha (r-hCG)|Choriogonadotropin alpha 250 μg was administered subcutaneously on the day following the last dose of follitropin alpha (Gonal-F).
1876743|NCT01152879|Dietary Supplement|Home Parenteral Nutrition|Cancer Patients who are discharged on HPN will be monitored for quality of life, nutrition status, pain and nausea medication usage
1876744|NCT01152918|Behavioral|Linkage-to-Care Component: Financial Incentive (FI)|Test sites assigned to this arm will provide coupons to all people who are found to be HIV-infected after testing and who are not already linked to HIV care. The coupons can be redeemed at a participating HIV care site for gift cards.
1876745|NCT01152918|Behavioral|Linkage-to-Care Component: Standard of Care (SOC)|Each person who receives an HIV positive test result, and is not currently in care, will be directed to HIV care sites using the site's SOC procedures.
1876746|NCT01152918|Behavioral|Viral Suppression Component: FI|HIV-infected participants who are receiving ART will be offered FIs upon the confirmation of each suppressed viral load measurement (less than 400 copies/mL).
1876747|NCT01152918|Behavioral|Viral Suppression Component: SOC|HIV-infected participants who are receiving ART will be offered support via the site's SOC procedures to attend HIV care site visits and remain adherent to their ART regimen in order to achieve and maintain viral load suppression.
1876748|NCT01152918|Behavioral|Prevention for Positives Component: Counseling and SOC|Participants will complete a computer-delivered counseling program that emphasizes HIV prevention strategies for HIV-infected people.
1876749|NCT01152918|Behavioral|Prevention for Positives Component: SOC|Participants will receive SOC from their HIV care site.
1876750|NCT01152931|Drug|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at Artesunate 100mg stat, 50mg 8hrs later and 50mg bd x 3days
1876751|NCT01152931|Drug|Amodiaquine + Artesunate|Intervention:the intervention in this group involves the use of standard antimalarial therapy for uncomplicated malaria based on WHO recommendation. artemisinin based combination therapy will be used. amodiaquine will be administered via the oral route at a dose of 10mg/kg daily while artesunate will be administered orally at 100mg stat, 5omg 8hrs later and 50mg 12hrly for 3 days
1876752|NCT01152931|Drug|Lumefantrine + Artemether|Lumefantrine and artemether combination will be administered orally at a dose of 120/20mg daily for 3days
1876753|NCT01152931|Dietary Supplement|Artesunate + vitamin A|Artesunate will be administered orally at a dose of 100mg stat then 50 mg 8hrs later and 50mg 12hrly for 3days. vitamin A will be administered orally at a dose of 2000IU daily for 3 days
1876754|NCT01152931|Dietary Supplement|Artesunate + vitamin E|Artesunate will be administered orally at 100mg stat, then 50mg 8hrs after and 50mg 12hrly for 3 days. Vitamin E will be administered orally at 100mg dly for 3 days.
1876755|NCT01152931|Dietary Supplement|Artesunate + Zinc|Artesunate will be administered orally at a dose of 100mg stat then 50mg 8hrs after and 50mg 12mg 12hrly for 3 days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days
1876756|NCT01152931|Dietary Supplement|Artesunate + selenium|Artesunate will be administered orally at 100mg stat and 8hrs later 50mg. then 50mg 12hrly for 3 days. selenium will be administered orally at a dose of 100ug dly for 4 days
1876757|NCT01152931|Dietary Supplement|Amodiaquine + vitamin A|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Vitamin A will be administered orally dly at a dose of 2000IU for 4 days
1876758|NCT01152931|Dietary Supplement|Amodiaquine + Vitamin E|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. vitamin E will be administered orally at a dose 100mg daily for 4 days
1876759|NCT01152931|Dietary Supplement|Amodiaquine + Zinc|Amodiaquine will be administered orally at a dose of 10mg/kg dly for 3days. Zinc gluconate will be administered orally at a dose of 50mg dly for 4 days.
1876760|NCT01152931|Dietary Supplement|Amodiaquine + Selenium|Amodiaquine will be administered orally at a dose of 10mg/kg daily for 3days. Selenium will be administered orally at a dose of 100ug daily for 4 days if > 1year. 50ug daily for 4 days if < 1 year.
1876761|NCT01152931|Dietary Supplement|Artesunate + vitamin A + vitamin E|Tab Artesunate 50mg orally daily for 4 days. Vitamin A, 5000IU orally daily for 4days if < 1 year. 10,000 IU orally daily for 4 days if > 1 year.
1876762|NCT01152931|Dietary Supplement|Artesunate + Vitamin A + Zinc|Tab Artesunate 50 mg daily for 4 days. Vitamin A 5OOOIU daily for 4 days if < 1 year. 10,000IU daily for 4 days if > 1 year. All administered orally.
1876763|NCT01152931|Dietary Supplement|Artesunate + Vitamin A + Selenium|Tab Artesunate 50 mg orally, daily for 4 days. Vitamin A 5000IU orally daily for 4 days if < 1 year. 10,000IU orally daily for 4 days if > 1 year.
1876764|NCT01152931|Dietary Supplement|Artesunate + Vitamin E + Selenium|Tab Artesunate 50 mg orally daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab selenium 100 ug orally daily for 4 days if > 1 year. 50 ug orally daily for 4 days if < 1 year.
1876765|NCT01152931|Dietary Supplement|Artesunate + Vitamin E + Zinc|Tab Artesunate administered orally at 50 mg daily for 4 days. Vitamin E 100 mg orally daily for 4 days. Tab Zinc 50 mg orally daily for 4 days if < 1 year. 25 mg orally daily for 4 days if > 1 year.
1876766|NCT01152957|Behavioral|CARIÑO Project|Care Attention Resources Information Nutrition & Optimism Project (CARIÑO) is a CHW intervention that will involve 4 or more (as required) home visits, 10 group sessions, and 10 follow-up phone calls per subject over a 12-month period. The primary outcome is lower HgA1C levels. The secondary outcomes are to lower LDL levels, and systolic and diastolic blood pressure, medication adherence and improved diet and exercise. CARIÑO Project will provide outreach support services to patients with poorly controlled diabetes, such as health education, lifestyle changes, home visits, follow-up phone calls, support groups, one on one counseling and coaching, and assistance with resource referrals.
1876767|NCT01152983|Device|Rapid Ring|Rapid Ring is a ring-shaped device that encircles the distal phalanx of the middle finger and blocks the arterial blood to quickly and passively withdraw blood following a finger stick, and to reduce the pain of the lancet.
1876769|NCT01153009|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
1876770|NCT01153009|Drug|Duloxetine|Overencapsulated duloxetine delayed-release capsules
1876771|NCT01153009|Drug|Placebo|Placebo-matching capsules
1876772|NCT01153022|Other|joint mobilization techniques|In the experimental group, ankle joint mobilization was applied for five minutes, using grade II joint traction rhythmic oscillation (Mailland Scale) with the knee in 15° of flexion, subtalar in neutral and ankle in resting position (10º plantarflexion). During the control study, participants were placed under the same conditions as those of the experimental group but only the hands of the evaluator were placed in the foot, in the position of joint traction simulation.
1876773|NCT01153035|Device|Radiofrequency Ablation|Breast conservation surgery followed by Radiofrequency Ablation of the cavity
1876774|NCT01153048|Other|Intensification of education|The main objective is to assess impact of the establishment of involved patients (peer educators) network in Mali. Peer educators and persons targeted by the project will be recruited through Post-Test Club on diabetes (PTC). PTC will be a social support club that provides on going prevention counseling, education and support services to people who have diabetes. PTC represents an important link between patients, educators and general medical services. PTC will be defined as clubs, which are facilitated by well-trained peer educators, and will have 3 objectives: to provide social and emotional support to diabetic patients, to provide assistance in daily management and living with diabetes and to provide linkage to clinical care. To lead the sessions, in clubs, we will use a very innovative methodology for peer education: the learning nests method. To evaluate, we propose a classical randomized controlled experimental (RCT) design, with randomization at the person-level.
1876775|NCT01153061|Device|Fistula closure with Gore Helex Septal Occluder|The occluder will be released at the tracheoesophageal fistoulous traject through endoscopic procedures
1876776|NCT01153061|Device|Gore Helex Septal Occluder|Fistula closure with endoscopic release of occluder in the fistula traject.
1876777|NCT01153074|Device|Closure of bronchopleural fistula with Occlutech Figulla|Patients with bronchopleural fistulas will be submitted to a bronchoscopic procedure to deploy the cardiac septal defect occluder in the fistula traject.
1876778|NCT01153100|Drug|Glargine|Glargine 0.25 units per kg body weight given every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
1876779|NCT01153113|Biological|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 5x106 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
1876852|NCT01153711|Drug|Ketoconazole|400 mg tablet
1876780|NCT01153113|Biological|hTERT mRNA DC|Subjects receive 1x107 cells per infusion administered ID at study week 1, 2, 3, 4, 5, 6 then receive 1x107 cells per infusion administered ID at study weeks 10, 14, 18, 22, 26, 30, 34, 38, 42, 46 and 50.
1876781|NCT01153126|Behavioral|Comprehensive Health Enhancement Support System (CHESS.)|Half of the participating women will be randomly assigned to usual care and half will be offered a fully CHESS.
1876782|NCT01153139|Device|Repetitive Transcranial Magnetic Stimulation (Theta Burst Stimulation, TBS)|intermittent TBS (iTBS) to the left DLPFC (600 stimuli, 80% resting motor threshold) continuous TBS (cTBS) to the right DLPFC (600 stimuli, 80% resting motor threshold)
1876785|NCT01153191|Procedure|Normal saline pressurized irrigation|same
1876786|NCT01153191|Drug|sub-q gentamicin|2mg/kg of gentamicin in 20 ml of sterile saline up to max dose of 120mg injected above the abdominal wall fascia- the length of the incision will be marked and injection made with intent being to evenly distribute the volume of injection in the subcutaneous tissues in immediate vicinity of and prior to the initial incision- analogous to the technique employed when using local anesthetic
1876787|NCT01153204|Behavioral|Group Psychotherapy|
1876788|NCT01153204|Other|Group Psychotherapy plus Sildenafil citrate|
1876789|NCT01153204|Drug|Sildenafil citrate|
1876790|NCT01153217|Drug|Switch from tenofovir to abacavir|Switch from tenofovir to abacavir
1876791|NCT01153243|Drug|Ergocalciferol|"Active Comparator: Ergocalciferol
The investigators will give intervention group 12 weeks of Vitamin D (ergocalciferol 50,000 units every week)"
1876792|NCT01153243|Drug|Placebo pill|The investigators will give control group 12 weeks of 1 placebo pill every week.
1876793|NCT01153256|Drug|magnesium sulphate|The patients of group M receive 50 mg/kg of magnesium sulphate in 100 ml of isotonic saline over 10 min immediately before anaesthesia induction. After induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg), rocuronium 0.6 mg/kg is given over 5 s in a running infusion.
1876794|NCT01153256|Drug|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.6 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
1876795|NCT01153256|Drug|normal saline|Patients in the group R-0.6 receive the same volume of isotonic saline over the same period, and rocuronium 0.9 mg/kg is given after the induction of anesthesia with alfentanil (10 μg/kg) and propofol (2 mg/kg).
1876796|NCT01153269|Drug|Lopinavir/Ritonavir (Kaletra)|3 capsules 2xdaily or 2 tablets 2xdaily Kaletra
1876797|NCT01153295|Procedure|Clinical diagnosis based on symptom criteria|The diagnosis is based on ROME III criteria, abscence of danger signals and FBC, CRP
1876798|NCT01153295|Procedure|Diagnosis of exclusion|The diagnosis is based on normal investigations involving endoscopy with biopsy, stool for ova and parasites, FBC, CRP, TSH, Ca, ALT, alanine aminotransferase; alkaline phosphatase, serum bilirubin, Screening for lactose and celiac sprue
1876799|NCT01153308|Other|Observational Study|This is an Observational study
1876800|NCT01153321|Drug|AZD2423|100mg Oral dose od
1876801|NCT01153321|Drug|AZD2423 Placebo|Oral dose od
1876802|NCT01153334|Drug|Early intensive rosuvastatin therapy (40 mg for 7days, starting in ER prior to primary PCI)|1. Test group: Early intensive rosuvastatin therapy - rosuvastatin 40 mg for pre-PCI loading and 7 days post PCI and 10 mg daily thereafter 2. Control group: Conventional statin therapy - Placebo for pre-PCI loading in ER and rosuvastatin 10 mg daily after primary PCI
1876803|NCT01153347|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
1876804|NCT01153347|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
1876805|NCT01153360|Drug|liothyronine sodium|liothyronine sodium 20ug, every 12hour (before anesthetic induction, total 4 times)
1876806|NCT01153360|Drug|placebo|vitamin B12
1876807|NCT01153373|Behavioral|Self-administered computerized assessment for tobacco, substance abuse, and alcohol use.|"All patients that give consent to participate in the study (participants) who are randomly assigned to the control condition will complete the computerized DARSSA for assessment purposes only."
1876808|NCT01153373|Behavioral|Self-Administered Computerized Assessment and Counseling for Tobacco, Alcohol, and Substance Abuse|All participants randomized to the DARSSA Intervention will be given instructions for how to complete the assessment. Once completed, the treating emergency physician will be expected to (1) give substance using patients the Patient Feedback Report, (2) recommend they review it carefully, and (3) encourage them to consider following up with the referrals.
1876809|NCT01153386|Drug|Treprostinil diethanolamine|Treprostinil diethanolamine sustained release oral tablets.
1876810|NCT01153412|Other|Osteopathic Manipulative Treatment|Osteopathic manipulation to determine balance and stability in elderly
1876811|NCT01153425|Other|Virtual Bone Biopsy|MRI technology allowing generation of 3D images with considerably smaller voxel size than previous technology through the use of novel pulse sequences and advanced interpolation techniques.
1876812|NCT01153425|Drug|Teriparatide|Participants are clinically indicated for treatment.
1876813|NCT01153425|Drug|Zoledronic Acid|Participants are clinically indicated for treatment.
1876814|NCT01153451|Other|Email Notification|BWH inpatient clinical information systems will automatically file all non-finalized chemistry, hematology, pathology, and radiology tests, as well as inpatient and ambulatory provider email addresses for all study patients discharged. This process will be initiated using a time stamp most proximate to actual discharge time. At midnight on every day, all tests filed at time of discharge will be updated if final results have become available. An email with all finalized and pending test results for each patient discharged will be sent to the inpatient and primary care provider at this time. For patients discharged with more than one pending test, subsequent email notification(s) will be sent out until all pending tests are finalized (no more than one email per day).
1876853|NCT01153724|Drug|BI 1744|10 mcg solution for oral inhalation
1876815|NCT01153464|Behavioral|Recovery Support Counseling|Telephone based recovery support provided by paraprofessionals at the City of Philadelphia's Behavioral Health Department. Calls are once weekly for 8 weeks, then step down to every other week for the remainder of the year of study participation. Call frequency can be increased as a result of a rise in risk factor/protective factor ratio.
1876816|NCT01153477|Behavioral|Telephone Monitoring and Counseling - Enhanced|Calls or in-person sessions, 1x weekly for first 8 weeks, then every other week up to a year. Step up session frequency if needed based on participants' ratio of protective and risk factors.
1876817|NCT01153490|Behavioral|Behavioral Intervention|Substance-related
1876818|NCT01153503|Procedure|TAP block|"Group Intraoperative (at the end of surgery): Ketorolac 30 mg, IV + TAP block; TAP block
First 24-h Postoperative: Ketorolac 30 mg q 6h + acetaminophen 650 mg q6h + IV-PCA morphine
24-48-h Postoperative: Oral ibuprofen 800 mg q 8 h + hydrocodone/acetaminophen 5mg/500 mg 1-2 tablets q 6h, prn"
1876819|NCT01153542|Drug|VX-770|In period 1, subjects will receive a single oral dose of desipramine on Day 1.
1876820|NCT01153542|Drug|VX-770|In period 2, subjects will receive 150 mg VX-770 q12h orally from the morning of Day 1 through the evening of Day 9. Subjects will receive 50 mg Desipramine as a single dose on Day 5 of period 2.
1876821|NCT01153568|Dietary Supplement|Vitamin D 3|Patients will bew given a single capsule to take once daily
1876822|NCT01153568|Other|placebo|placebo tablets
1876823|NCT01153581|Drug|Ganirelix acetate|Ganirelix acetate: .25 ml/day by subcutaneous injection
1876824|NCT01153581|Drug|17β-Oestradiol|17 beta estradiol: 0.2 mg/day (patches)
1876825|NCT01153581|Drug|Progesterone|progesterone, 200 mg day−1 oral
1876826|NCT01153594|Behavioral|Recovery Management Checkups (RMC)|After interviewers completed the quarterly research interview and determined participants' eligibility and need for early re-intervention, they transferred RMC participants who were eligible and in need to a Linkage Manager. Using motivational interviewing, the Linkage Manager: a) provided feedback to participants regarding their current substance use and related problems, b) discussed implications of managing addiction as a chronic condition, c) discussed treatment barriers and solutions, d) assessed and discussed level of motivation for treatment, e) scheduled treatment appointments, f) accompanied participants to treatment intake and stayed through the process, and g) implemented Engagement and Retention Protocol during the 14 days of treatment
1876827|NCT01153607|Drug|BAY1006578|Alzheimer Disease patients: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
1876828|NCT01153607|Drug|BAY1006578|Healthy volunteers for brain imaging: Single intravenous bolus injection of 250 MBq BAY1006578 on day one of the treatment period, PET
1876829|NCT01153607|Drug|BAY1006578|Healthy volunteers for whole body imaging: Single intravenous bolus injection of 190 MBq BAY1006578, whole body PET for evaluation of effective dose, kinetics of BAY1006578 in blood
1876830|NCT01153620|Drug|Lavasept 0.04%|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.
Dosage Lavasept® 0.04% 50 ml 50ml or as much needed to completely saturate the compress.
Treatment Duration 60 minutes"
1876831|NCT01153620|Other|Ringer's Solution|"Method of Administration A sterile compress will be saturated with Lavasept® 0.04% / Ringers' solution and placed on the wound.
Dosage Ringers' solution 50ml or as much needed to completely saturate the compress. Treatment Duration 60 minutes"
1876832|NCT01153633|Device|Prontosan Wound Irrigation Solution and Prontosan Wound Gel|"The treatment procedures (after a 1 week run-in) include:
Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation
Secondary dressing to be a semi occlusive dressing
Secure the dressing to the wound with tubifast and short stretch compression system Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
1876833|NCT01153633|Device|Normal Saline and Placebo Gel|"The treatment procedures (after a 1 week run-in) include:
Cleansing the wound bed, at dressing change, with Prontosan® Wound Irrigation Solution or saline solution; a sterile gauze dressing impregnated with the Prontosan® or saline solution, depending on randomisation, will be placed on the wound in the form of a moist compress and removed after 15 minutes; the wound will be sparingly covered with Prontosan® Wound Gel or inactive gel, depending on randomisation
Secondary dressing to be a semi occlusive dressing
Secure the dressing to the wound with tubifast and short stretch compression system
Dressings will be changed and the treatment procedure will be repeated every 3 days (+/- 1 day) when clinical, microbiological, planimetry and photographic assessments will be made. The randomised solution will also be used for removal of the dressing from the wound at the start of dressing change."
1876834|NCT01153646|Genetic|pHIV7-shI-TAR-CCR5RZ treated CD4 cells|Single dose administration x 3 of genetically modified T-cells given at 3 infusions at 6 week intervals.
1876835|NCT01153659|Drug|E3810|RAB ER 50 mg capsule once per day on Days 1-5
1876836|NCT01153659|Drug|Aciphex (rabeprazole)|Aciphex (rabeprazole) 20 mg tablet once per day on Days 1-5
1876837|NCT01153659|Drug|Nexium (esomeprazole)|Nexium (esomeprazole) 40 mg capsule once per day on Days 1-5
1876838|NCT01153672|Drug|vorinostat|Given PO
1876839|NCT01153672|Other|laboratory biomarker analysis|Correlative studies
1876840|NCT01153672|Procedure|biopsy|Optional correlative studies
1876841|NCT01153672|Radiation|F-18 16 alpha-fluoroestradiol|Correlative studies
1876842|NCT01153672|Procedure|positron emission tomography|Correlative studies
1876843|NCT01153672|Drug|anastrozole|Given PO
1876844|NCT01153672|Drug|letrozole|Given PO
1876845|NCT01153672|Drug|exemestane|Given PO
1876846|NCT01153672|Genetic|gene expression analysis|Correlative studies
1876847|NCT01153685|Biological|Fluviral®|Intramuscular injection, one dose
1876848|NCT01153698|Drug|dabigatran|anticoagulation
1876849|NCT01153711|Drug|BI 1744|10 mcg solution for oral inhalation
1876850|NCT01153711|Drug|BI 1744|10 mcg solution for oral inhalation
1876851|NCT01153711|Drug|Ketoconazole|400 mg tablet
1876854|NCT01153724|Drug|Fluconazole|400 mg capsule
1876855|NCT01153737|Other|Manual therapy (MT)|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. MT techniques: neuromuscular technique, postisometric stretching, spray and stretching and Jones technique.
1876856|NCT01153737|Other|TENS|Ten treatment sessions of 30 minutes of MT or TENS on alternate days were provided by primary care physical therapists. TENS electrode placement were: in the painful area, in the metamere or in the nerve´s pathway. It was applied at a frequency of 80 Hz, with ≤150 µs pulse duration and adjusted amplitude.
1876857|NCT01153750|Drug|Glivec|
1876858|NCT01153763|Drug|GSK2118436|Subjects will receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
1876859|NCT01153776|Procedure|64-slice CT angiography|the sensitivity and specificity of 64-slice CT angiography for the detection of lesions at the ostia and proximal segments of the reimplanted coronary arteries
1876860|NCT01153789|Procedure|orthoptic rehabilitation|Orthoptic rehabilitation: 12 sessions (2 sessions per week) At the end of a series of 12 sessions of orthoptic, the child will be examined and will again perform an static and dynamic oculomotor evaluation and control of postural balance.
1876861|NCT01153789|Other|Orthoptic diagnostic|postural, oculomotor and orthoptics tests
1876862|NCT01153802|Drug|GSK1360707 is a potent re-uptake inhibitor of the neurotransmitters dopamine, norepinephrine and serotonin|"This is an open label, adaptive design, daily dosing, non-randomized PET occupancy study in healthy adult males.A range of doses may be evaluated. The initial dose, given in the study as a single dose was 150mg GSK1360707. The remaining subjects will be dosed either as a single or split dose, as determined by the PET and tolerability data collected in the preceding subjects. The total dose will not exceed 150mg per day, the maximum total dose given in the FTIH study.If dosing is conducted as a single dose, the dose will be administered after the baseline scan, If a dosing is performed in a split dose manner, dosing will occur after the baseline scan, and up to 12 hours later. The time period between doses will be determined by emerging PET occupancy data.
Subsequent doses, if any, will be chosen based on the observed scan results. No single dose, or total dose split over 2 dosing sessions, will exceed the maximum dose in the FTIH study."
1876863|NCT01153815|Drug|GSK1358820(Botulinum toxin type A)|"GSK1358820 (Botulinum Toxin Type A, also known as OnabotulinumtoxinA or Botox)"
1876864|NCT01153815|Drug|placebo|placebo
1876865|NCT01153828|Drug|Retapamulin|Prescription for retapamulin
1876866|NCT01153828|Drug|Co-prescription of retapamulin and topical mupirocin|Same day prescriptions for retapamulin and topical mupirocin
1876867|NCT01153828|Drug|Co-prescription of retapamulin and topical fusidic acid|Same day prescription for retapamulin and fusidic acid.
1876868|NCT01153841|Biological|Synflorix™( GSK1024850A)|Intramuscular, 3 doses
1876869|NCT01153841|Biological|Infanrix hexa™|Intramuscular, 3 doses
1876870|NCT01153854|Drug|Racecadotril|oral racecadotril (1.5mg./Kg./t.i.d. doe 5 days) in double blind assigned.
1876871|NCT01153854|Drug|Placebo groups|Placebo with feature color, appearance and tase similar to racecadotril t.i.d. for 5 days
1876872|NCT01153867|Behavioral|Schema Focused Therapy|SFT is a novel treatment approach to chronic, lifelong problems that incorporates cognitive, behavioral, experiential and psychodynamic elements and techniques. In the present study participants will receive up to 75 individual sessions of SFT depending on the individual progress in therapy.
1876873|NCT01153880|Drug|Retapamulin|Prescription sales claim of retapamulin
1876874|NCT01153880|Drug|Co-prescription of retapamulin and topical mupirocin|Same day prescription sales claims for retapamulin and topical mupirocin
1876875|NCT01153893|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
1876876|NCT01153893|Biological|InfanrixTM|Intramuscular injection, 1dose
1876877|NCT01153906|Other|Data collection|New onset of cases for endpoints of interest in the targeted population will be identified from ambulatory and inpatient electronic administrative data and will be confirmed by blinded review of the medical record by an Endpoint Adjudication Committee (EAC) that will confirm the AID case and will assess whether the onset of disease falls within the observation period. Fibromyalgia and psoriasis, for which a high number of cases are expected, will be identified from the electronic administrative data only.
1876878|NCT01153919|Biological|romiplostim|Given subcutaneously
1876879|NCT01153919|Drug|ribavirin|Given orally
1876880|NCT01153919|Other|placebo|Given subcutaneously
1876881|NCT01153919|Biological|PEG-interferon alfa-2a|Given subcutaneously
1876882|NCT01153919|Other|laboratory biomarker analysis|Correlative studies
1876885|NCT01153958|Drug|Colposeptine|Colposeptine will be administered transvaginally at a dose of 1 capsule every day for 12 consecutive days
1876886|NCT01153958|Drug|Metronidazole|Metronidazole will be administered orally at a dose of 400 mg twice a day for 7 days
1876887|NCT01153971|Drug|rituximab|1
1876888|NCT01153984|Drug|Erlotinib|Erlotinib 150 mg oral doses will be administered daily.
1876889|NCT01153997|Drug|catridecacog|Single rFXIII dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
1876890|NCT01153997|Drug|placebo|Single rFXIII placebo dose (12 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
1876891|NCT01153997|Drug|catridecacog|Single rFXIII dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
1876892|NCT01153997|Drug|placebo|Single rFXIII placebo dose (35 IU/kg). Administered via slow intravenous (i.v.) push at a rate not exceeding two mL per minute.
1876893|NCT01154010|Device|PEMF|ActiPatch will be worn by patients over the eye with anterior uveitis for 8 hours/day for 7 days. Patients will also be treated with topical steroids.
1876894|NCT01154010|Device|PEMF Placebo|Patients wear the placebo device for 8 hours/day for 7 days over the eye being treated for anterior uveitis. Patients will also be treated with topical steroids.
1876895|NCT01154023|Behavioral|stimulus control therapy, sleep restriction therapy, multi-component treatment (stimulus control therapy, sleep restriction therapy)|Treatment was given weekly for 6 weeks. Sessions 1 - 4 were in a group format. Session 5 & 6 were delivered individually by phone.
1876898|NCT01154036|Drug|Comparator: rosuvastatin|
1876899|NCT01154049|Biological|sm14 antigen plus adjuvant GLA|Healthy adults will receive 3 doses of the vaccine, on days 0, 30 and 60.
1876900|NCT01154062|Drug|Pazopanib|Pazopanib tablet
1876905|NCT01154114|Drug|darapladib|darapladib 40 mg oral dose
1876906|NCT01154127|Drug|NVA237|50 μg via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
1876907|NCT01154127|Drug|Placebo|Matching placebo via NEOHALER inhaler device single dose dry powder inhaler (SDDPI) once daily
1876908|NCT01154140|Drug|treatment|crizotinib 250mg orally continuous twice daily dosing
1876909|NCT01154140|Drug|treatment|pemetrexed 500mg/m2 IV day 1 plus cisplatin 75mg/m2 IV day 1 every 21 days OR pemetrexed 500mg/m2 IV day 1 plus carboplatin AUC 5 or 6 day 1 every 21 days investigator's choice
1876910|NCT01154153|Drug|Placebo nasal spray|1 spray/nostril, once daily in the morning, for 8 to 24 days during the screening phase.
1876911|NCT01154153|Drug|Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ)|"Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).
For children who were >=2 to <6 years old, 1 spray/nostril (110 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase.
For children who were >=6 yrs to <12 years old, either 1 spray/nostril (110 µg TAA-AQ) or 2 sprays/nostril (220 µg TAA-AQ), once daily in the morning, for 6 weeks, during the double-blind treatment phase."
1876912|NCT01154153|Drug|Placebo nasal spray|"Treatment assignment was randomized with stratification by sex and age group (>=2 to <6, >=6 to <12 years old).
For children who were >=2 to <6 years old, 1 spray/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase.
For children who were >= 6 yrs to <12 years old, either 1 spray/nostril or 2 sprays/nostril, once daily in the morning, for 6 weeks, during the double-blind treatment phase."
1876913|NCT01154153|Drug|Claritin® Syrup|Children's Claritin® Syrup [5 mg of loratadine per 5 mL] could be taken orally for the relief of AR symptoms throughout the study on an as needed basis, according to the Food and Drug Administration-approved manufacturer's label.
1876914|NCT01154166|Drug|ReQuip PR|If subjects are still eligible at the end of the placebo run-in period they will be randomized (1:1) to receive once daily doses of ropinirole PR or identical appearing placebo tablets. Dosing will start at 2 mg ropinirole PR, or placebo equivalent. During the 24 week treatment phase, the subjects dose will be adjusted according to the recommended schedule to achieve symptomatic control. All subjects must be titrated to a minimum dose of 6 mg/day.
1876915|NCT01154166|Drug|Placebo|Placebo
1876916|NCT01154179|Other|Hypocaloric feeding|This intervention group will be prescribed 60% of recommended (by Schofield) requirements.
1876917|NCT01154192|Drug|Dexamethasone|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin. Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
1876918|NCT01154192|Drug|recombinant human chorionic gonadotropin (r-hCG)|Each subject in each group will receive 1 mg of oral dexamethasone in the evening and return in the morning for an injection of 25ug of IV recombinant human chorionic gonadotropin (r-hCG). Subjects will also have blood drawn at times -0.5, 0, 0.5, and 24 hours after the injection of r-hCG for measurement of steroid hormones.
1876919|NCT01154218|Drug|crizotinib|"Treatment A (Reference 1): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg IRT and 2 × 100-mg IRTs.
Treatment B (Reference 2): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 50-mg PIC and 2 × 100 mg PICs.
Treatment C (Test for BE, Reference for Food Effect): a 250 mg single dose of crizotinib administered in a fasted state as 1 × 250-mg CIC.
Treatment D (Test High Fat): a 250 mg single dose of crizotinib administered with a high-fat meal as 1 × 250-mg CIC"
1876920|NCT01154231|Drug|Nonacog Alfa (Genetical Recombination)|"Patients with hemophilia B (congenital blood coagulation factor IX deficiency) who are administered this drug.
Patients with hemophilia B are either patients for whom treatment was already started with a blood coagulation factor IX product (Previously treated patients: hereinafter, PTPs) or patients who have no history of treatment with a blood coagulation factor IX product in the past and for whom treatment will be started with this drug for the first time (Previously untreated patients: hereinafter, PUPs).
The definition of PUPs in this survey is Patients in whom the total number of days of administration of a blood coagulation factor IX product other than this drug before administration of this drug was 3 exposure days (actual number of days of administration: hereinafter, EDs) or less."
1876921|NCT01154244|Other|HOMA-IR|Blood sampling for HOMA-IR and HbA1C, fasting glucose, C-peptide, Lipid profile
1876922|NCT01154257|Procedure|Cleaning of teeth with a toothbrush|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a toothbrush. Cleaning will be twice daily from recruitment until day seven.
1876923|NCT01154257|Procedure|Cleaning of teeth with a foam swab|This is a split mouth study where patients will have one side of their mouth randomised for teeth cleaning with a foam swab. Cleaning will be twice daily from recruitment until day seven.
1876924|NCT01154270|Radiation|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
1876925|NCT01154283|Device|Viasys® Healthcare, Pulmonetic Systems, lap-top ventilator (LTV machine)|Noninvasive positive airway pressure ventilation
1876968|NCT01154478|Other|diet rich in omega-3 and polyphenols|Fish at least 3 times x week,large leaf vegetables + extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
1877086|NCT01148095|Drug|AZD2516|Oral, single, daily, 11 days
1876926|NCT01154296|Behavioral|RESPECT-2 Counseling|Specifically designed for use with the rapid HIV test, involves a brief (approximately 20-40 minute) counseling session which includes an orientation to the rapid testing procedure, an explanation of the testing window period, routes of HIV transmission and the meaning of test results, a personalized exploration of risk, the creation of a risk-reduction plan, identification of sources for support and referrals, and HIV test results.
1876927|NCT01154309|Behavioral|Group CBT for Depression and AOD Disorders|18 sessions of 2-hour group CBT
1876928|NCT01154322|Device|Pixi pediatric mask|The study mask is designed for use with PAP therapy to treat OSA in pediatric patients aged 2-7 years. The study mask is designed to be used in the hospital and the home environment. The study subject will use the device for up to 30 days while participating in the study.
1876929|NCT01154335|Drug|OSI-906|Dose Level 1: 50 mg Twice a Day, cycle-28 days Dose Level 2: 100 mg Twice a Day, cycle-28 days Dose Level 2a: 100 mg Twice a Day, cycle-28 days
1876930|NCT01154335|Drug|Everolimus|Dose Level 1: 5mg Daily, cycle-28 days Dose Level 2: 10mg Daily, cycle-28 days Dose Level 2a: 5mg Daily, cycle-28 days
1876931|NCT01154348|Drug|S-707106|Tablet, taken once daily with morning meal
1876932|NCT01154348|Drug|Placebo|Placebo tablet, taken once daily with morning meal
1876933|NCT01154348|Drug|Metformin, S-707106 plus metformin|Metformin twice daily maintenance, S-707106 tablet taken once daily with morning meal with metformin dosed twice daily
1876934|NCT01154348|Drug|Metformin, placebo plus metformin|Metformin twice daily maintenance, placebo tablet taken once daily with morning meal with metformin twice daily
1876935|NCT01154361|Drug|Icatibant (subcutaneous) and plazebo (intravenous)|
1876936|NCT01154361|Drug|Cortisone + Clemastin (intravenous) and plazebo (subcutaneous)|
1876937|NCT01154374|Drug|MEBO Wound Ointment (MEBO)|Topical application twice a day
1876938|NCT01154374|Procedure|Standard of Care (sterile saline moistened gauze)|
1876939|NCT01154387|Drug|Anti-Thymocyte Globulin|1.5mg/kg IV on Day of Transplant and 1.0-1.5 mg/kg IV once daily for a minimum of 4.5mg/kg and a maximum of 7.5mg/kg total cumulative dose
1876940|NCT01154387|Drug|TOL101|Potential Therapeutic Dose (PTD)-A (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
1876941|NCT01154387|Drug|TOL101|Potential Therapeutic Dose (PTD)-B (0.28-56 mg to be determined in Phase 1/Part A ) IV once daily x 6-10 doses starting on Day of Transplant
1876942|NCT01154387|Drug|Steroids|IV methylprednisolone prior to first 3 doses of study drug; oral prednisone tapered to 5-10 mg over 6 months
1876943|NCT01154387|Drug|Tacrolimus|Oral administration started by 6 days post-transplantation and continued for 6 months
1876944|NCT01154387|Drug|Mycophenolate mofetil (MMF)|Oral administration started by Day 1 post-transplantation and continued for 6 months
1876945|NCT01154400|Dietary Supplement|Casein protein hydrolysates|15 g casein protein hydrolysates + 15 g maltodextrin
1876946|NCT01154400|Dietary Supplement|Whey protein hydrolysates|15 g whey protein isolate + 15 g maltodextrin
1876947|NCT01154400|Dietary Supplement|Casein protein hydrolysates + LEU|15 g casein protein hydrolysate + 2.1 g LEU (40% of EAA content) + 15 g maltodextrin
1876948|NCT01154400|Dietary Supplement|Whey protein hydrolysates + LEU|15 g whey protein isolate + 1.5 g LEU (40% of EAA content) + 15 g maltodextrion
1876949|NCT01154413|Behavioral|Intensive education of the doctor/nursing team on the protocol|
1876950|NCT01154426|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1876951|NCT01154426|Drug|Gemcitabine Hydrochloride|Given IV
1876952|NCT01154426|Other|Pharmacological Study|Correlative studies
1876953|NCT01154426|Drug|Veliparib|Given orally
1876954|NCT01154439|Drug|cytarabine|Remission induction therapy: by short i.v. infusion on days 1 and 7. Consolidation therapy: by continuous infusion on days 1-5.
1876955|NCT01154439|Drug|etoposide|Remission induction therapy: by short i.v. infusion, on days 1-7. Consolidation therapy: by short i.v. infusion, on days 1-5.
1876956|NCT01154439|Drug|everolimus|"Remission induction therapy: test dose once a day by mouth, on days 1-21 (21 days).
Consolidation therapy: dose as defined by the cohort once a day by mouth, on days 1-10."
1876957|NCT01154439|Drug|idarubicin|Consolidation therapy: by short infusion i.c. on days 1, 3 and 5.
1876958|NCT01154439|Drug|mitoxantrone hydrochloride|Remission induction therapy: by short i.v. infusion on days 1, 3 and 5
1876959|NCT01154452|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1876960|NCT01154452|Other|Laboratory Biomarker Analysis|Correlative studies
1876961|NCT01154452|Other|Pharmacological Study|Correlative studies
1876962|NCT01154452|Drug|Vismodegib|Given PO
1876963|NCT01154465|Procedure|Central Venous Catheter Insertion|"The preparation of the CVC installation will follow the procedures for skin preparation of the operator, installation of sterile fields and local anaesthesia.
The patients' skin disinfection before catheter insertion and care will follow the protocol:
Clean the area of insertion of the catheter with a solution of 4% aqueous povidone foaming (Betadine Scrub).
Rinse with sterile water and then drying.
First application of 5% alcohol povidone-iodine (alcoholic Betadine) far beyond the area of insertion.
Second application of 5% alcoholic povidone-iodine (alcoholic Betadine) by the operator after sterile draping.
After sterilisation and puncture, the Seldinger technique is employed to insert the line: a blunt guidewire is passed through the needle, and the needle is then removed."
1876964|NCT01154465|Device|Ultrasound guidance|"The ultrasound probe will be isolated by a sterile protective plastic and the operator will mount a ramp on which the puncture syringe needle is placed.
A sterile gel will be used in order to visualize the vein and directly puncture under ultrasound guidance following:
- The anterior Boulanger's incision for the internal jugular vein When venous aspiration is obtained, the needle can easily be removed from the ramp and the syringe to mount the catheter following Seldinger's method."
1876965|NCT01154478|Other|Diet rich in omega-3 fatty acids|fish at least 3 times per week, large leaf vegetables
1876966|NCT01154478|Other|Diet rich in polyphenols|extra virgin olive oil, green tea, berries,fruits rich in polyphenols, dark chocolate, decaffenated coffee
1876967|NCT01154478|Other|Control diet|low content of omega-3 fatty acids and polyphenols (low intake of fish, nuts and legumes,oil rich in monounsaturated fatty acids, vegetables and fruits poor in polyphenols)
1877087|NCT01148095|Drug|Placebo|
1877133|NCT01148498|Drug|solanezumab|400mg administered once intravenously
1876969|NCT01154491|Drug|Ferric carboxymaltose|"Ferinject®: Ferric carboxymaltose: 2 vials of 10 mL containing each 500 mg iron, diluted in 250 mL normal saline for injection. Study drug to be administered by infusion immediately after preparation.
Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
1876970|NCT01154491|Drug|Erythropoietin|Erythropoetin: 40,000 units subcutaneous (unique dose).
1876971|NCT01154491|Drug|Placebo|"Placebo for ferric carboxymaltose: 250 mL normal saline for intravenous administration.
Placebo for erythropoietin: 1 mL normal saline for subcutaneous injection."
1876972|NCT01154504|Other|clinical treatment|The clinical treatment will be optimized to gold standard international heart failure treatment
1876973|NCT01154504|Procedure|ultrafiltration|The ultrafiltration procedure will be done on Intensive Care Unit with automatic machine and HF 1400 filter. The fluid will be removed until a increased of 10% in hematocrit or clinical improvement.
1876974|NCT01154504|Procedure|isovolumetric hemofiltration|The isovolumetric hemofiltration will be done in Intensive Care Unit for 8 hours, and will be permitted the diuretic use.The dose will be 35 ml/kg/hour and will e used automatic machine and MF1400 filter.Diuretic use will be maintained.
1876975|NCT01154530|Other|Chlorhexidine|Mouthwash with a 0,2 % chlorhexidine solution for 30 seconds
1876976|NCT01154569|Drug|Azithromycin|500 mg single dose
1876977|NCT01154582|Dietary Supplement|Egg snack|subject consume 4 cooked whole eggs, providing 380 kcal
1876978|NCT01154582|Dietary Supplement|Cottage cheese|Subjects consume 200 g of cottage cheese, providing 380 kcal
1876979|NCT01154595|Dietary Supplement|Plumpy Doz(r) - Ready-to-Use Food|47g Plumpy Doz(r) per day per child
1876980|NCT01154595|Behavioral|Food-for-Training|Conditional family food supplementation (sugar, sorghum, beans, iodized salt, vegetable oil) 1800 kcal/person/day in function of attendance and participation in a sensitization program covering various themes on household, water and disease management, hygiene promotion, sanitation and dietary practices for children.
1876981|NCT01154608|Drug|Creon|
1876982|NCT01154608|Other|No enzyme therapy|Current enzyme therapy of the patient is stopped during 7 days
1876983|NCT01154621|Drug|AZD9742|Sterile solution, 620 mg (20 mg/mL) in 50 mL vial with a fill volume of 31 mL
1876984|NCT01154621|Drug|Placebo|Sterile 5% dextrose solution
1876985|NCT01154634|Drug|AZD2516, 5 mg|Capsule, oral
1876986|NCT01154634|Drug|AZD2516, 16 mg|Capsule, oral
1876987|NCT01154634|Drug|AZD2516, 40 mg|Capsule, oral
1876988|NCT01154634|Drug|Placebo|Capsule, oral
1876989|NCT01154647|Drug|citalopram|intravenous
1876990|NCT01154647|Drug|1 ml 0.9 % NaCl|intravenous
1876991|NCT01154660|Other|Tidal Volume|observation of IJV circumference and cross sectional area using ultrasonography by changing of tidal volume
1876992|NCT01154673|Drug|raltegravir|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
1876993|NCT01154673|Drug|maraviroc|Raltegravir 400 mg BID + Maraviroc 150mg BID in addition to standard HAART
1876994|NCT01154673|Drug|emtricitabine 200mg /tenofovir 300mg|emtricitabine 200mg /tenofovir 300mg QD
1876995|NCT01154673|Drug|lopinavir 400 mg/ritonavir 100mg|lopinavir 400 mg/ritonavir 100mg BID
1876996|NCT01154686|Behavioral|Cogmed|The Cogmed Working Memory Training Program will be used as the experimental program because of preliminary evidence indicating its effectiveness in enhancing WM and reducing behavioural symptoms of inattention/hyperactivity in children. This software-based training program was designed to improve WM abilities, particularly in children with ADHD or severe attention problems. Training is implemented with a software program (RoboMemo©). It includes a set of auditory verbal and visual-spatial WM tasks presented via computer. All tasks involve: maintenance of simultaneous mental representations of multiple stimuli, unique sequencing of stimulus order in each trial and progressive adaptation of difficulty level as a function of individual performance.
1876997|NCT01154699|Device|Bilevel PAP (4 weeks)|Subjects will use bilevel PAP each night for 4 weeks. The pressure levels will be adjusted by the investigators to increase lung volumes during the night.
1876998|NCT01154699|Other|Usual Care (4 weeks)|Subjects will continue with their usual asthma care. Investigators will make no changes to their medications or other habits.
1876999|NCT01154699|Other|Washout Period (4 weeks)|Subjects will continue with their usual asthma care in between the Usual Care and Bilevel PAP periods. Investigators will make no changes to their medications or other habits.
1877000|NCT01154712|Device|Real Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
1877001|NCT01154712|Device|Sham Deep TMS|Stimulation parameters : Dorso lateral prefrontal cortex,1HZ,600 pulses per session,15 sessions
1877002|NCT01154725|Behavioral|Patient education and rehabilitation|Patients in the experimental group will receive specialized and optimized care by stoma care nurses. This includes one-on-one guiding during the hospitalization, guidance by telephone after discharge and participation in patient education 3 times after discharge.
1877003|NCT01154725|Behavioral|habitual patient education|habitual patient education
1877004|NCT01154738|Drug|Lidocaine|"bolus dose of lidocaine (1.5 mg.kg-1) followed by an infusion of lidocaine (2 mg.kg-1 h-1) until the end of anesthesia.
start of the induction of anesthesia 10 minutes after the bolus dose of lidocaine"
1877005|NCT01154738|Drug|Placebo|"NaCl 9/00 (same volume as in the lidocaine group)
start of the induction of anesthesia 10 minutes after the bolus dose of NaCl 9/00"
1877006|NCT01154751|Device|SUPERA Interwoven self-expanding nitinol stent|Insertion of stent at stenotic area
1877009|NCT01154777|Behavioral|Neurofeedback training|60 sessions of Neurofeedback on 6-18 year olds with Autism
1877010|NCT01154790|Drug|CG100649|6 subjects: study drug 2 subjects: placebo
1877011|NCT01154790|Drug|Placebo|6 subjects: study drug 2 subjects: placebo
1877012|NCT01154790|Drug|Naproxen|6 subjects: study drug 2 subjects: placebo
1877013|NCT01154803|Dietary Supplement|Ready to Use Therapeutic Food (RUTF)|1 sachet/day, 500 kcal and multi micronutrients (fortified high quality food(RUTF),for 2 weeks after an illness (malaria, diarrhoea, pneumonia)
1877014|NCT01154803|Dietary Supplement|Micronutrient Powder (MNP)|2 sachets / day for 14 days after an illness (diarrheoea, malaria, pneumonia)
1877018|NCT01154829|Drug|amisulpride|Individually dosed, according to symptoms, for a period of 6 weeks
1877019|NCT01154829|Drug|aripiprazole|Individually dosed, according to symptoms, for a period of 6 weeks
1877020|NCT01154855|Procedure|Prophylaxis ; Gross debridement for diseased patients|1 per patient at 2nd visit lasting approximately 1 hour.
1877021|NCT01154868|Procedure|Alveolar ridge augmentation|Under local anesthesia, full-thickness mucoperiosteal flaps will be elevated, followed by degranulation, and collection of all clinical measurements. Crestal and vertical releasing cuts will be performed using diamond-coated discs on the edentulous ridge in need of augmentation. A sequence of bone chisels and osteotomes will be used to split the alveolar ridge in half until a desirable width for implant placement is achieved. Healos® will then be inserted between both osseous plates. Fixation screws will be used as needed to stabilize the expanded alveolar ridge. Collagen barrier membranes (Ossix Plus) will be used to cover the osseous wound. Flaps will be approximated to achieve primary wound closure.
1877022|NCT01154881|Drug|insulin degludec|Insulin degludec (IDeg) injected s.c. (under the skin) once daily for 6 days in each treatment period. Each subject was randomly allocated to 2 out of 4 treatments.
1877023|NCT01154894|Other|Aravita including arachidonic acid and docosaheaenoic acid|Nine of 13 Participants were treated with 6 capsules of Aravita per day for 16-week trial, remaining 4 participants aged under 12 years received 3 capsules per day.
1877024|NCT01154907|Drug|Praziquantel|One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
1877025|NCT01154920|Drug|Paclitaxel|135 mg/m^2 weekly, Weeks 1 - 6
1877026|NCT01154920|Drug|Carboplatin|AUC of 2 weekly, Weeks 1 - 6
1877027|NCT01154920|Drug|Cetuximab|"PCC Arm: 400 mg/m^2 by vein over about 1-2 hours on Day 1; 250 mg/m^2 weeks 2 - 6.
C-TPF Arm: 250 mg/m2 weeks 2, 4, 5, 7 and 8."
1877028|NCT01154920|Drug|Docetaxel|75 mg/m^2 by vein over 1 hour on Day 1 of each 21 day cycle for 3 cycles of induction therapy
1877029|NCT01154920|Drug|Cisplatin|100 mg/m^2 by vein over 1-3 hours on Day 1 of each 21 day cycle for 3 cycles of induction therapy
1877030|NCT01154920|Drug|Fluorouracil|700 mg/m^2 continuous infusion Days 1-4 on Day 1 of each 21 day cycle for 3 cycles of induction therapy
1877031|NCT01154920|Radiation|Radiotherapy (RT)|Radiation about 2-4 weeks after induction therapy, Monday through Friday for about 7 weeks, or as recommended by the treating radiologist.
1877032|NCT01154920|Other|Chemotherapy|PCC group receives 6 and C-TPF group receives 3 chemotherapy treatment cycles. If receiving radiation + chemotherapy, weekly Cisplatin 40 mg/m^2 by vein over 1-3 hours or Carboplatin AUC 2 by vein over 1 hour beginning 2 to 3 weeks after conclusion of induction program.
1877033|NCT01154933|Drug|exenatide 5 mcg|exenatide 5 mcg
1877034|NCT01154933|Drug|exenatide 10 mcg|exenatide 10 mcg
1877035|NCT01154933|Drug|placebo|saline sq
1877036|NCT01154959|Drug|Moxifloxacin, Isoniazid, Rifampicin Pyrazinamide, Ethambutol|Moxifloxacin (400mg), Isoniazid (300mg daily, 600mg thrice weekly), Rifampicin (450mg, and 600mg for patients weighing 60kg or more), Pyrazinamide (1500mg), Ethambutol (800mg)
1877037|NCT01154972|Procedure|Preoperative sentinel lymph node identification and marking|SLN is identified using gamma probe and ultrasound. Percutaneous wire placement carried out to mark SLN for subsequent surgical verification.
1877038|NCT01154985|Drug|Placebo capsule|3x Placebo capsules three times a day (TID) for 365 days
1877039|NCT01154985|Drug|EPA-E 300 mg capsule|2x 300 mg capsules + placebo capsule TID for 365 days
1877040|NCT01154985|Drug|EPA-E 300 mg capsule|3x 300 mg capsules TID for 365 days
1877041|NCT01155011|Behavioral|Physical Activity|"MIPARC will focus on 3 physical activity goals:
increasing walking behavior through gradually increasing step goals
increasing attendance at available on-site and local aerobic, strength and flexibility classes, as well as prompting stair use,
reducing sedentary behavior. Participants will monitor their steps with a pedometer, daily step logs and progress charts. All participants will have a gradually increasing fixed step goal for each week that will result in an total increase of 3000 steps after 3 months, which they will be supported to maintain for an additional 3 months."
1877042|NCT01155011|Behavioral|Group educational sessions|Every three weeks, participants will be required to attend a group education session, where researchers will teach behavior change strategies and allow participants to share their experiences and offer support to each other. The group sessions will follow a common format including: a group exercise (e.g. quiz), group discussion of use of behavior change strategies (e.g. overcoming barriers), and will end with a behavior change strategy instruction and goal setting component.
1877043|NCT01155011|Behavioral|Phone counseling call|"To support a tailored intervention delivery, participants will receive 4 individual phone calls (in weeks 2, 5, 8, and 11) from a trained health counselor. The phone call will follow the following format:
health check
step goal check
barrier identification
problem solving
specific goals to achieve target step counts. Counselors will prompt participants to report any adverse events, illnesses, medication changes or counter indicative symptoms. The calls will cease during the second 3 months to allow participants to practice self help techniques while still supported by the group sessions and peer mentoring."
1877044|NCT01155011|Behavioral|Peer Mentoring|"Three peer mentors at each CCRC will be trained in intervention content and delivery, measurement support, and advocacy. The peer mentors will lead a group session once every three weeks for the 6 month intervention period and once a month for the following 6 months. The peer mentors will formulate their own ideas for these sessions but we will suggest they include group walks, group activities and trips to active locations, etc.
The peers will help study staff to answer questions from participants and assist with study compliance and retention. They will also receive advocacy training from a non-profit advocacy organization to conduct walk audits of their CCRC and help mobilize participants to make changes to their community that will increase or improve the opportunities for physical activity."
1877083|NCT01148069|Procedure|Surgery combined with IMRT-IGRT|Patients will have surgery consisting in extensive pelvic dissection and ablation of seminal vesicles. Surgery will be followed by prolonged hormonotherapy (3 years) associated, after 2 months, with prostatic only irradiation.
1877045|NCT01155011|Behavioral|Policy Change|In order to increase the sustainability of the project, MIPARC will focus on addressing on-site policies and neighborhood factors that are barriers to physical activity. Peers and staff will conduct site inspections to identify these barriers (e.g. lack of facilities, limited opening hours, unsafe sidewalks, etc.) which will be prioritized and presented to CCRC management and community officials.
1877046|NCT01155011|Behavioral|Support|A binder of professionally prepared materials will be provided at the beginning of the intervention and are referred to by researchers in the group sessions and phone counseling calls. The materials provide important information to encourage knowledge, self efficacy and realistic expectations.
1877047|NCT01155011|Behavioral|Tailored environmental resources|Participants will be provided with a set of printed materials relating to the residential and neighborhood environment of their CCRC. A list of step counts for key indoor routes will be provided as well as safe walking route maps for the site an local neighborhood.
1877048|NCT01155011|Behavioral|Group educational sessions|Lectures will be delivered every three weeks to match the MIPARC intervention schedule. Sessions will include topics such as medications, foot care and nutrition. Physical activity will not e discussed in these sessions but participants will receive informational pamphlets on the benefits of physical activity.
1877049|NCT01155011|Behavioral|Health check phone call|For the first 3 months, control participants will also receive a health check phone call to match the individual attention paid to participants in the MIPARC sites.
1877050|NCT01155011|Behavioral|Pedometer|Participants will also keep the pedometer they wear during the baseline measurement week to satisfy any curiosity about the devices and the step entry criteria. They will be given instructions on its use but will not be taught the benefits of self-monitoring.
1877051|NCT01155024|Device|Traditional fabricated prosthetic socket|A prosthetic socket constructed utilizing traditional techniques. This intervention is a control and the basis for comparison.
1877052|NCT01155024|Device|Direct manufactured (DM) prosthetic socket|A prosthetic socket constructed from direct manufacturing technique. The socket will be tested under both diagnostic and definitive environments. Diagnostic testing will span several hours (4-6 hours) and definitive testing will span several months (3-6 months)
1877053|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 3.75 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
1877054|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Patients infected with HIV will receive 7.5 µg of an adjuvanted A H1N1 vaccine in two applications 21 days apart.
1877055|NCT01155037|Biological|Adjuvanted vaccine against H1N1 influenza virus (GSK)|Control group will receive 3.75 µg of an adjuvanted A H1N1 vaccine in one single application.
1877056|NCT01155050|Device|Tele-health Home Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
1877057|NCT01155050|Behavioral|TrestleTree Telephone Coaching|Weekly or bi-weekly phone calls from TrestleTree health coaches with a focus on weight loss.
1877058|NCT01155050|Device|Tele-health Home Monitoring Plus Trestle Telephone Coaching|Daily collection of data through the tele-health home monitor and weekly or bi-weekly phone calls with a Trestletree Health Coach.
1877059|NCT01155063|Other|Aromasin (exemestane)|Aromasin (exemestane), tablets 25 mg, once a day
1877060|NCT01155076|Dietary Supplement|Vitality Product|Proprietary blend of ginseng, cordyceps, and pomegranate taken twice a day for 8 weeks
1877061|NCT01155076|Dietary Supplement|Placebo|Placebo taken twice a day for 8 weeks
1877062|NCT01155089|Drug|Anastrozole|1 mg tablet
1877063|NCT01155102|Drug|Anastrozole|1 mg tablet
1877064|NCT01155115|Procedure|Sputum Collection|Each study participant will be invited to expectorate sputum for culture, sensitivity, cytology and analysis of cytokine levels. Culture and sensitivity will be performed routinely at the beginning of a pulmonary exacerbation, as per standard of care, and will only be performed at subsequent visits if there is clinical indication. A volume of 5ml of sputum will be required at each visit for analysis. If the participant is unable to expectorate this volume of sputum, he/she will be invited to induce sputum instead as per standard protocols.
1877065|NCT01155115|Procedure|Pulmonary Function Testing|Participants will perform spirometry at each visit according to the American Thoracic Society and European Respiratory Society guidelines.
1877066|NCT01155115|Procedure|Exhaled Nitric Oxide|The investigators will measure exhaled Nitric Oxide (eNO) at each visit according to the American Thoracic Society and European Respiratory Society guidelines using a chemiluminescence analyzer. Briefly, single breath exhalation are performed in triplicate at flows of 30, 50, 100, 150, 200 and 250 ml/s and eNO is measured at the end of the exhalation. The higher the flow rate the more peripheral the airways that are being sampled.
1877067|NCT01147939|Drug|Elacytarabine|Elacytarabine 2000 mg/m2/d administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w cycle.
1877068|NCT01147939|Drug|Investigator's Choice|E.g. cytarabine single agent/combinations, hypomethylating agents, best supportive care (BSC)
1877069|NCT01147952|Behavioral|Structured exercise training|randomised to 12 weeks of exercise training up to three times weekly. Training will be interval training with active recovery, with 3 min intervals conducted 10bpm below angina threshold.
1877071|NCT01147978|Behavioral|End of ICU stay conference|Conference with patient and proxies, senior physician and nurse regarding the ICU stay and the orientation of the patient
1877072|NCT01147991|Biological|EBNA1 C-terminal/LMP2 chimeric protein-expressing recombinant modified vaccinia Ankara vaccine|
1877073|NCT01147991|Other|laboratory biomarker analysis|
1877074|NCT01147991|Other|pharmacological study|
1877075|NCT01148004|Drug|Fenofibrate|
1877076|NCT01148004|Drug|Ritonavir|
1877077|NCT01148004|Drug|Lopinavir/Ritonavir|
1877078|NCT01148017|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine|
1877079|NCT01148030|Drug|3M Skin and Nasal Antiseptic|Intra-nasal dosing
1877080|NCT01148043|Drug|Hydroxychloroquine|200 mg capsule, 2 capsules QD for 24 weeks.
1877081|NCT01148043|Drug|cellulose|capsule, 2 capsules QD for 24 weeks
1877082|NCT01148056|Radiation|Intensity Modulated Radiation Therapy|Radiation therapy once a day for 5 days
1877084|NCT01148082|Procedure|Self administered Surveys|
1877085|NCT01148082|Procedure|Interviews|
1877088|NCT01148108|Drug|Canfosfamide HCl for injection|30 min. intravenous infusion of canfosfamide HCl (1000 mg/m2) every 2 weeks
1877089|NCT01148121|Other|Skeletal Status Assessment of a Down Syndrome Population|The investigators hypothesize that the bone deficits seen in Down Syndrome patients are similar to the phenotype seen in the down syndrome mouse model (Ts65Dn).The bone turnover markers, CBC, and DXA scan results will be used to assess the skeletal status of the down syndrome patients. This data will form the basis to establish the Ts65Dn as a reasonable proxy for pathogenesis and treatment in humans.
1877090|NCT01148147|Drug|Adenosine|Intracoronary adenosine administration (180 ug for LCA and 120 ug for RCA)
1877091|NCT01148147|Drug|Placebo|Intracoronary Placebo administration
1877092|NCT01148160|Drug|voriconazole|intravenous, oral administration
1877093|NCT01148173|Drug|Combined systemic and intrathecal chemotherapy followed by HD-ASCT|Methotrexate Ifosfamide Cytarabine Thiotepa Liposomal cytarabine (intrathecal) Carmustine Etoposide Autologous stem cell transplantation
1877094|NCT01148186|Behavioral|knowledge transfer tool|knowledge transfer tool for empowering patients to engage in collaborative discontinuation of potentially inappropriate medication with their pharmacist and/or physician
1877095|NCT01148199|Device|Self-expandable metalic stent|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
1877096|NCT01148199|Device|Multiple plastic stents|Comparison of self-expandable metalic stent versus multiple plastic stents in post OLT biliary stenosis.
1877098|NCT01148264|Drug|olanzapine|1x10mg per day for three days
1877099|NCT01148264|Drug|metoclopramide|3x10mg per day for three days
1877100|NCT01148277|Drug|Propofol and Remifentnyl|Intervention group (Propofol and remifentanyl): It will be administered under direct gastroenterologists' and hepatologist
1877101|NCT01148277|Drug|midazolam and fentanyl|Intervention group (Propofol and fentanyl ): It will be administered under direct gastroenterologists'and hepatologist
1877102|NCT01148277|Drug|midazolam anf fentanyl|group (Midazolam with Fentanyl): Both drugs will be administered by the gastroenterologists and/ or hepatologist and/ or anesthiologist
1877103|NCT01148290|Procedure|Tension free vaginal tape|Small incision sites in the vagina and suprapubically. Bilateral retropubic insertion of the sling by means of needles
1877104|NCT01148290|Procedure|Bulking agent injection|Three Periurethral injections of Bulkamid ® (Ethicon,Somerville, NJ, USA)
1877105|NCT01148303|Drug|Etoricoxib|Subjects will take etoricoxib 90mg by mouth just before the start of the daily fast. This will be for six days. After this they will receive placebo for eight days.
1877106|NCT01148303|Drug|Etoricoxib|This arm will receive placebo just before their fast for eight days. After this they will receive etoricoxib 90mg just before their daily fast for the next six days.
1877107|NCT01148303|Drug|Placebo|Placebo
1877110|NCT01148329|Device|Coronary stenting|The PROMUS™ Element™ Everolimus Eluting Coronary Stent System is indicated for improving coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo native coronary artery lesions. The treated lesion length should be less than the nominal stent length (8 mm, 12 mm, 16 mm, 20 mm, 24 mm, 28 mm, 32 mm, 38mm) with a reference vessel diameter of 2.25 mm - 4.0 mm.
1877111|NCT01148342|Drug|MDMA|
1877112|NCT01148342|Drug|(+/-)3,4-methylenedioxymethamphetamine Hydrochloride, MDMA HCI Capsules|0, 1.0 &amp; 1.6 mg/kg
1877113|NCT01148368|Drug|fimasartan|single administration of fimasartan 120mg
1877114|NCT01148394|Other|Multimodal rehabilitation|
1877115|NCT01148420|Drug|Medroxyprogesterone 17-Acetate|Medroxyprogesterone 20mg orally 3 times a day for 3 days
1877116|NCT01148420|Drug|medroxyprogesterone acetate|Depo Provera 150mg Intramuscular injection
1877117|NCT01148446|Drug|Cyclophosphamide|750 mg/mq IV, day 1
1877118|NCT01148446|Drug|Cyclophosphamide|50 mg/mq IV, day 1
1877119|NCT01148446|Drug|Doxorubicin|50 mg/mq IV, day1
1877120|NCT01148446|Drug|Vincristine|1,4 mg/mq (max 2 mg)IV, day 1
1877121|NCT01148446|Drug|Prednisone|75 mg/mq IV, days 1-5
1877122|NCT01148446|Drug|Prednisone|60 mg/mq IV/PO, days 1-5
1877123|NCT01148446|Drug|Epirubicin|50 mg/mq IV, day 1
1877124|NCT01148446|Drug|Vinblastine|5 mg/mq IV, day 1
1877125|NCT01148446|Drug|Rituximab|375 mg/mq IV, day 1
1877126|NCT01148446|Drug|G-CSF|300 µg tot., SC; days 7-11
1877130|NCT01148472|Drug|Escitalopram|20mg once daily; orally
1877131|NCT01148472|Drug|Duloxetine|60mg once daily; orally
1877132|NCT01148485|Other|Nasal, throat, inguinal and skin lesions swab samples will be performed|Nasal, throat, inguinal and skin lesions swab samples will be performed
1990530|NCT01978314|Device|75 mg / 6 mL VFI™|75 mg / 6 mL VFI™
1877134|NCT01148511|Drug|Ranibizumab 0.5 mg|Ranibizumab was supplied as a sterile solution in sealed glass vials.
1877135|NCT01148524|Biological|No Vaccine|
1877136|NCT01148524|Biological|rMenB+OMV-NZ|Subjects who had received either rMenB+OMV-NZ or placebo at study month 6 in V72P10 study had a blood sample drawn for serological analyses at 18 months later (-1/+3 months).
1877137|NCT01148537|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch 5, 10, 20, and 2 * 20 mcg/h.
1877138|NCT01148537|Drug|Matching placebo transdermal patch|Placebo transdermal patch to match BTDS 5, 10, 20, and 2 * 20.
1877139|NCT01148537|Drug|Avelox (moxifloxacin hydrochloride) tablet|Moxifloxacin 400 mg tablet; 1 tablet taken orally on days 6 and 13
1877141|NCT01148576|Drug|entecavir|entecavir 0.5 mg qd for 12 months
1877142|NCT01148576|Drug|entecavir|entecavir 0.5 mg qd for 12 months
1877143|NCT01148576|Drug|essentiale + entecavir|entecavir 0.5 mg qd for 12 months，Essentiale 2 tablets tid in the first 3 months and 1 tablets tid in the rest 9 months
1877144|NCT01148576|Drug|Vitamin E + entecavir|entecavir 0.5 mg qd for 12 months, Vitamin E: 100 mg bid for 12 months
1877145|NCT01148602|Other|LED stopwatch-clock timers|"We will attach a large, in-your-face red LED stopwatch-clock timers to the patient's stretcher at the moment of ED arrival to act as a constant visual reminder to all team members (physicians, RN's, CT technologists) of the urgency of the situation."
1877146|NCT01148615|Drug|Aflibercept (AVE0005)|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1877147|NCT01148615|Drug|Docetaxel (XRP6976)|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1877148|NCT01148628|Drug|RAD 001 in combination with Caelyx|RAD001 (tablets; 2.5mg) is administered daily at 5, 7.5, 10 mg. CAELYXTM (vials; 50 mg/25mL)is administered i.v.every 4 weeks at 40mg/m2. One treatment cycle is 4 weeks.
1877149|NCT01148641|Dietary Supplement|Lipid-based supplement (LNS)|Infants and young children will receive 10 g of LNS for test trial during 3 consecutive days and thereafter, 20 g per day for 14 days.
1877150|NCT01148667|Dietary Supplement|Casein hydrolysate added with LGG|Infants drink extensively hydrolysed casein formula supplemented with LGG (ATCC 53103) 5.0 x 10 7 cfu/g to achieve a daily intake of 3.4 10 9 cfu.
1877151|NCT01148667|Dietary Supplement|Infants drink casein hydrolysate without LGG|Infants drink extensively hydrolysed casein formula without added LGG
1877152|NCT01148680|Biological|Islet Graft|Iterative injection of pancreatic islets (minimum: 250,000 IEQ / injection or 3500 IEQ / kg / injection) with a threshold required total of 11,000 IEQ / kg in 2 or 3 injections per patient)
1877153|NCT01148693|Drug|gentamicin|10mg per 10ml of contrast media
1877154|NCT01148693|Drug|Placebo|Distilled water
1877155|NCT01148706|Device|ActiSight Needle Guidance System|The ActiSight™ Needle Guidance System employs a miniature video camera mounted on the needle and a reference pad attached to the skin to register the needle into the CT image space, and thus, track the needle advance towards the target. CT scans are used as needed to verify the location of the needle.
1877156|NCT01148719|Other|Index group|Diagnostic triage strategy includes; electrocardiography, echocardiography, spirometry and blood testing
1877157|NCT01148732|Procedure|ultrasonography|a Toshiba 3.75 MHz convex ultrasonography transducer (Toshiba SSA-550A, Tochigi-ken, Japan) was placed transversely on the anterior neck just superior to the suprasternal notch and bilateral hemithorax by one of two emergency physician during emergency intubation investigators.
1877158|NCT01148745|Drug|ferumoxytol|510 milligram (mg) intravenous (IV) injection (30 mg/second (sec) over 17 seconds) after at least one hour of hemodialysis (HD), second 510 mg IV injection administered at next consecutive dialysis treatment (3-5 days after first injection)
1877159|NCT01148758|Drug|RO5323441|cohorts receiving multiple doses iv
1877160|NCT01148771|Drug|ertapenem|1 gram IV bolus every 24 hours (q24h) for 3 days
1877161|NCT01148771|Drug|ertapenem|1 gram 30 minute infusion q24h for 3 days
1877162|NCT01148784|Procedure|ACL reconstruction|Randomized comparison of two different allogenic tissue types, quadrupled hamstring or doubled tibialis anterior, for anterior cruciate ligament repair.
1877163|NCT01148797|Drug|Canakinumab|
1877164|NCT01148810|Drug|BAF312|
1877165|NCT01148810|Drug|Placebo|
1877166|NCT01148823|Other|Incisions covered for 1 day|Dressing was removed on the first postoperative day.
1877167|NCT01148823|Other|Incisions covered for 6 days|Dressing was removed on the 6th postoperative day.
1877168|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Pulmonary Hypertension subjects|Take 100mg Co-Q for three times daily
1877169|NCT01148836|Dietary Supplement|Coenzyme Q-10 in Normal Control subjects|Take 100mg Co-Q for three times daily
1877170|NCT01148849|Biological|MGAH22|"MGAH22 will be administered by IV infusion once per week for 4 weeks in the following dose escalation cohorts: 0.1, 0.3, 1.0, 3.0, and 6.0 mg/kg; and once every 3 weeks in the following dose escalation cohorts: 10.0, 15.0, and 18.0 mg/kg.
An additional cohort of up to 15 patients with breast or gastric cancer will be enrolled and treated at a dose of 15 mg/kg every three weeks."
1877171|NCT01148862|Device|The MiniMed Paradigm® X54 System|"The MiniMed Paradigm® X54 System: A insulin pump equipped with a number of features to actively manage the user's glucose levels. One example is the Low Glucose Suspend (LGS) feature. The LGS feature is only available when the pump is used with the subcutaneous glucose sensor for continuous glucose monitoring. To use this feature, the user will be required to select a sensor low suspend limit, or threshold, at which the LGS feature will be triggered. When this feature is selected, if the sensor glucose reading reaches the level that is equal to or less than the programmed threshold, the user receives an alert and the pump suspends."
1877213|NCT01155310|Drug|Air/Oxygen|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.
Patients will then receive the Air/Oxygen mixture with usual devices."
1877214|NCT01155323|Device|etafilcon A|1-day soft contact lens
1877215|NCT01155323|Device|omafilcon A|1-day soft contact lens
1877216|NCT01155336|Drug|Lovaza®|Lovaza® is prescription grade EPA+DHA fish oil supplement.
1877217|NCT01155336|Drug|The placebo contained 1 gram of corn oil in each capsule.|Placebo Pill
1877172|NCT01148875|Behavioral|Mammography appointment reminders; telephone counseling|Women randomly assigned to UCR, EAPR, ELR; repeated 4 times at yearly intervals. Using claims data, supplemented by self-report, verified if women had recent mammograms. Women who remained non-adherent after reminders received Barriers-Specific Telephone Counseling Call, or an enhanced call including focus on either positive or negative consequences of getting/not getting mammograms. Prior to calls, women in each of the three phone counseling groups received priming letters to prime them to process information in the call. Priming letters should prepare women to process information from subsequent counseling calls more deeply by focusing on the positive or negative consequences of getting/not getting mammograms or on identifying and overcoming their own barriers to being screened.
1877173|NCT01148888|Drug|Magnesium|Magnesium will be administered intravenously at a dose of 50 mg/kg bolus followed by an infusion of 10 mg/kg/hr.
1877174|NCT01148901|Drug|Infliximab|Infliximab 5 mg/kg administered as an intravenous perfusion over a period of 2 hours at Weeks 0, 2, 6, and 14, as indicated in the Summary of Product Characteristics
1877175|NCT01148914|Other|Inflammatory biomarkers|tTst blood samples for cardiac biomarkers at baseline, 24-hours and 3 month post-ablation
1877176|NCT01148953|Drug|ALN-TTR01|Dose levels between 0.01 and 1.0 mg/kg by intravenous (IV) infusion
1877177|NCT01148953|Drug|Sterile Normal Saline (0.9% NaCl)|Calculated volume to match active comparator
1877178|NCT01148966|Drug|aminolevulinic acid|Given PO
1877179|NCT01148966|Other|laboratory biomarker analysis|Correlative studies
1877180|NCT01148966|Procedure|therapeutic conventional surgery|Standard brain tumor surgery with intra-operative frameless MRI stereotactic guidance and intra-operative ultrasound guidance
1877181|NCT01148979|Drug|Lisdexamfetamine Dimesylate (Vyvanse)|Lisdexamfetamine Dimesylate (Vyvanse) capsules dose ranging from 20mg to 50 mg.
1877182|NCT01148979|Drug|Placebo|Lisdexamfetamine Dimesylate (Vyvanse)-matched placebo capsules.
1877183|NCT01148992|Drug|Lofexidine|0.8mg alone and concurrent with IV cocaine infusions of 20 mg and 40 mg
1877184|NCT01148992|Drug|Placebo|0mg
1877185|NCT01149005|Drug|novorapid / humalog short acting insulin|1-4 units will be injected Subcutaneously (SC), before every main meal.
1877186|NCT01149005|Drug|Novo Rapid Insulin (Novonordisk)|Novo Rapid Insulin (Novonordisk) will be administered before each main meal 1-4 units depends on the patients weight
1877187|NCT01149018|Drug|Tetrahydrocannabinol|Oral solution of THC in concentration of 5mg/0.2ml. Dose regimen: 5mg 2-4 times/day as tolerated.
1877188|NCT01149018|Drug|Placebo|Orally administered olive oil. Dose: 0.2ml 2-4 times a day as tolerated
1877189|NCT01149031|Device|LOW LEVEL LASER SYSTEM|LASER DIODE CLASS 3B,OMEGA XP
1877190|NCT01149044|Procedure|Percutaneous Coronary Intervention with or without manual aspiration thrombectomy|
1877191|NCT01155128|Behavioral|exercise aerobic|The intervention will consist of physical exercise sessions for approximately 60 minutes and two weekly sessions. The classes will consist of an initial part to exercises heating joint flexibility and lasting 10 minutes, a major part consists of aerobic exercise, lasting 20-30 minutes, and a piece of muscular endurance with exercises upper and lower limbs and abdomen, lasting 10-20 minutes. The intensity will be controlled through the Subjective Perception Scale Borg
1877192|NCT01155141|Drug|H.P. Acthar Gel|Patients were treated with 40 units subcutaneously (SC) weekly for 2 weeks, then dose increased to 80 units SC weekly for 2 weeks followed by 80 units SC twice weekly to complete 16 weeks of therapy.
1877193|NCT01155154|Drug|cephalexin|500 mg (two 250 mg capsules) every 6 hours for 7 days
1877194|NCT01155154|Drug|clindamycin|300 mg of clindamycin (two 150 mg capsules) every 6 hours for 7 days
1877195|NCT01155154|Drug|placebo|Two placebo capsules every 6 hours for 7 days
1877196|NCT01155167|Drug|Nitroglycerin and lidocaine|Topical Nitroglycerin and lidocaine
1877197|NCT01155167|Other|Placebo|Placebo
1877198|NCT01155180|Drug|Leptin|Hormone - daily self injections for 6 months
1877199|NCT01155180|Drug|Placebo|Placebo
1877200|NCT01155206|Drug|glucagon|glucagon 3ng/kg/min
1877201|NCT01155219|Drug|Geltim LP 1 mg/g|one drop in the conjunctival sac of each eye in the morning (84 days).
1877202|NCT01155219|Drug|Xalatan|one drop in the conjunctival sac of each eye in the morning (84 days).
1877203|NCT01155232|Drug|Teriparatide|Forteo (teriparatide)pen daily for 24 months
1877204|NCT01155245|Drug|Forteo|Forteo pen
1877205|NCT01155258|Drug|temsirolimus|Given IV
1877206|NCT01155258|Drug|vinorelbine ditartrate|Given IV
1877207|NCT01155271|Other|Rehabilitation|"12 weeks : 3 sessions per week (2 supervised sessions and 1 session at home)
1 technical visit and 1 nursing visit every two months at home for the CPAP"
1877208|NCT01155284|Drug|Sitagliptin and Lansoprazole|"Sitagliptin (dispensed as 50 mg capsules)and Lansoprazole(dispensed as 30 mg capsules) or matching placebo
Subjects age 11-17 years at Visit 2 will take 1 capsule once daily
Subjects age 18-45 years at Visit 2 will take 2 capsules once daily"
1877209|NCT01155284|Drug|Placebo|Sitagliptin 50mg and Lansoprazole 30 mg or matching placebo will be given daily for 12 months. Subjects age 11-17 at visit 2 will take 1 capsule daily; age 18-45 will take 2 capsules daily.
1877210|NCT01155297|Behavioral|Physical training|"The exercise program will be held three times a week and will have three stages: local and global stretching, aerobic exercise for 30 minutes ( with 50 and 60% of maximal heart rate) and strength training. The strength training will be done after assessment of one repetition maximum (1RM) and the prescription will be made with 50% load of 1RM, where the patient will hold three sets of 10-12 repetitions. Reassessments will be conducted monthly for readjustment of the charges. The duration of the training protocol will be six months.
After completing this exercise program, patients will undergo a reassessment repeating the ET and reapplication of the SF-36, redone the collection of ADMA serum concentration."
1877211|NCT01155297|Behavioral|Stretching and metabolic exercises|At the control group will be performed stretching and metabolic exercises and will make the assessments and the reassessments after the end of the program.
1877212|NCT01155310|Drug|Helium/Oxygen 78%/22%|"The Helium/Oxygen mixture will be administered during NIV and NIV-free sessions for a maximum of 72 hours using study dedicated devices.
Patients will then receive the Air/Oxygen mixture with usual devices."
1877218|NCT01155349|Behavioral|InSight|A cognitive intervention designed to enhance speed of visual processing.
1877219|NCT01155349|Other|No contact-control group|No contact-control group.
1877220|NCT01155362|Biological|Human Placenta-Derived Cells PDA001 Intravenous Infusion|1 of 3 treatment doses (1 unit, 4 units, or vehicle control) intravenous infusion on days 0 and 7
1877225|NCT01155414|Other|Hydrolysate based infant formula|Infant formula ad lib
1877226|NCT01155414|Other|Investigational Infant Formula A|Investigational infant formula ad lib
1877227|NCT01155414|Other|Investigational Infant Formula B|Investigational infant formula ad lib
1877228|NCT01155440|Drug|Lidocaine|1% Lidocaine 1mg/kg/hr IV drip x 48hr
1877229|NCT01155440|Procedure|Thoracic epidural block|0.1% Epidural bupivacaine + Morphine 0.02 mg/ml drip via epidural x48 hr
1877230|NCT01155453|Drug|BKM120|
1877231|NCT01155453|Drug|GSK1120212|
1877232|NCT01155635|Drug|Carvedilol|Use of Carvedilol with any dose
1877233|NCT01155635|Drug|No Carvedilol|No use of Carvedilol
1877234|NCT01155648|Device|Chest wall compression plus increase of 10 cmH2O in inspiratory pressure during Pressure Support Ventilation for ten minutes in chest.|
1877235|NCT01155648|Device|Chest wall compression for ten minutes in chest|
1877236|NCT01155661|Drug|LY2216684|12mg to 18 mg administered orally, once daily for 54 weeks
1877237|NCT01155700|Drug|omalizumab|
1877238|NCT01155713|Drug|TKI258|
1877239|NCT01155726|Device|Nelfilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
1877240|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses and removed inserted by participant.
1877241|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
1877242|NCT01155726|Device|Nelfilcon A contact lens with comfort additive (DACP), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
1877243|NCT01155726|Device|Etafilcon A contact lens|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
1877244|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), unmasked|Commercially marketed, soft, hydrogel contact lens with comfort additive for daily wear, daily disposable use. Blister pack label and lens packaging visible to participant. Lenses inserted and removed by participant.
1877245|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Blister pack label and packaging not visible to participant. Lenses inserted and removed by the investigator.
1877246|NCT01155726|Device|Etafilcon A contact lens with comfort additive (1DAVM), partially masked|Commercially marketed, soft, hydrogel contact lens for daily wear, daily disposable use. Lens name and manufacturer on blister pack label concealed from participant. Lenses inserted and removed by the participant.
1877247|NCT01155752|Drug|Pulmozyme single use ampule|• Each Pulmozyme single use ampule delivers 2.5 mL (2.5 mg) of the sterile solution to the nebulizer bowl. The aqueous solution contains 1.0 mg/mL dornase alfa, 0.15 mg/mL calcium chloride dihydrate, and 8.77 mg/mL sodium chloride.
1877248|NCT01155752|Drug|placebo|identical placebo
1877249|NCT01155765|Drug|Prasugrel|Prasugrel 10 mg/day for 15 days
1877250|NCT01155765|Drug|Clopidogrel|Clopidogrel 150 mg/day for 15 days
1877254|NCT01155791|Drug|Docetaxel|IV 75 mg/m2
1877255|NCT01155791|Drug|Biosyn|IV dosage varies
1877256|NCT01155791|Drug|Prednisone|5mg, orally
1877257|NCT01155804|Behavioral|preparation of the delivery|Pregnant nulliparous women allocated to the non-interventional group will follow the routine pre-natal care. The participants of the study group will receive routine attention at the pre-natal care service and will also participate in the program of physical and educational after each routine pre-natal consultation. These activities will be organize as follow: 30 minutes of physical exercise for the prevention of pain and discomfort that may occur during pregnancy, preparation of the perineal muscles for delivery and prevention of urinary incontinence, 15 minutes for relaxation and 30 minutes for group discussion to respond to doubts that women may have and issues such as: change in posture during pregnancy and prevention of pain and discomfort; role of the perineal muscles during pregnancy, delivery and puerperium, physiology of delivery, non-pharmacological way for pain relief and breathing control during contractions of labor and delivery.
1877258|NCT01155817|Drug|Nilotinib|200, 400, 800, oral
1877259|NCT01155856|Other|Telemedical admission and treatment in the patients´ own homes instead of conventional admission and treatment at the hospital|For this study a telemedical platform has been developed on which it is possible to treat patients in their own homes. The platform consists of a videoconference part that allows the patients to make contact to qualified medical staff and a technology part that can transfer vital indicators of the patients health condition (lung function, oxygen saturation, pulse etc.)175 patients will be included with an expected drop-out of 20 % or 35 patients. The patients will be equally recruited from two hospitals (Frederiksberg and Herlev Hospital). All patients must have an exacerbation in their COPD that requires hospitalization to be included in this study. Each patient participate in the study for 6 months after discharge with follow-up at 1, 3 and 6 months.
1877260|NCT01155869|Drug|Depot naltrexone|Depot naltrexone 380 mg. IM monthly
1877261|NCT01155869|Drug|Oral Naltrexone|Naltrexone 50 mg tablet PO daily
1877262|NCT01155882|Procedure|Whipple at the Splenic Artery (WATSA)|
1877263|NCT01155895|Drug|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
1877264|NCT01155908|Drug|Amlodipine Besylate / Benazepril Hydrochloride|10 mg Amlodipine Besylate / 20 mg Benazepril Hydrochloride Capsules
1877265|NCT01155921|Drug|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
1877266|NCT01155934|Drug|Risperidone Orally Disintegrating Tablets|Risperidone Orally Disintegrating Tablets 1 mg of Dr.Reddy's Laboratories Limited
1877267|NCT01155947|Drug|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
1877268|NCT01155960|Drug|Anastrozole|Anastrozole Tablets 1 mg of Dr.Reddy's Laboratories Limited
1877269|NCT01155973|Behavioral|EDUCORE intervention|Direct exhibition of their cardiovascular risk with SCORE, visual images and documentation to the patients
1877270|NCT01155973|Other|Control group|SCORE oral information and counseling as standard practice care
1877271|NCT01155986|Drug|Lidocaine 5% medicated plaster|Topical hydrogel plaster (700mg lidocaine)
1877272|NCT01155986|Drug|Placebo topical plaster|Topical hydrogel plaster
1877273|NCT01155999|Drug|T1225|one drop twice daily (morning and evening) in each eye from Day 0 to Day 2
1877274|NCT01155999|Drug|Tobramycin|1 to 2 drops every two hours while awake on Days 0-1, up to 8×/day, then 1 to 2 drops 4 times daily on Days 2-6
1877275|NCT01156012|Drug|T2345|One drop of T2345
1877276|NCT01156012|Drug|Prostaglandin|One drop
1877277|NCT01156025|Drug|GV550|Ganciclovir 1.5 mg/g, 1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
1877278|NCT01156025|Drug|placebo|1 drop 10 times daily at D0 and D1 and 1 drop 5 times daily from D2 to D9 + additionnal treatment (Hyabak® eye drops: 5 times daily from D10 to D30)
1877279|NCT01156038|Device|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate reaction one day later(72 hrs after applying atopy patch test)
1877280|NCT01156051|Drug|Guanfacine extended-release tablets|Guanfacine extended-release tablets will be started at 1mg and then increased at weekly intervals to 2mg, 3mg, or 4mg as needed and as tolerated
1877281|NCT01156051|Drug|Placebo comparator|Placebo tablets identical to the experimental arm guanfacine extended-release tablets 1mg, 2mg, 3mg, 4mg, but without the active ingredient (guanfacine).
1877282|NCT01156064|Device|Confocal Laser Endomicroscopy (Pentax/Optiscan)|Confocal laser endomicroscopy is performed using the Pentax/Optiscan confocal endomicroscopy and 5 ml of 10% intravenous fluorescein sodium. Photos of magnified images of the digestive mucosa are taken during the procedure.
1877283|NCT01156064|Device|Narrow Band Imaging/Auto Fluorescence Imaging (Olympus)|NBI/AFI endoscope offers an alternative light source involve NBI and AFI to view digestive mucosa in real time.
1877284|NCT01156077|Drug|TR-701 FA|Oral TR-701 FA 200 mg will be given as a single oral dose
1877285|NCT01156077|Drug|TR-701 FA|TR-701 FA 200 mg will be given as a single 60 minute IV infusion in 250 cc saline
1877286|NCT01156103|Behavioral|America SCORES, Bay Area|After-school program promoting physical activity via soccer 3 days/week
1877287|NCT01156116|Device|CPAP mask|"The subjects who are randomized to CPAP treatment will undergo an overnight CPAP titration in the laboratory, which will be performed manually by a registered technician according to American Academy of Sleep Medicine (AASM) guidelines .Subjects will be admitted in the early evening and will receive positive airway pressure education, hands on demonstration, careful mask fitting and acclimatization prior to titration. The goal during the titration will be to determine the optimal CPAP pressure setting that eliminates obstructive respiratory events, restore oxygen saturations and sleep continuity.
________________________________________"
1877288|NCT01156116|Drug|Placebo|oral placebo tablet
1877292|NCT01156142|Drug|doxepin hydrochloride|Oral rinse
1877293|NCT01156142|Other|placebo|Oral rinse
1877294|NCT01156155|Radiation|Digital xray of jaw and teeth|one time xray of jaw and teeth
1877295|NCT01156155|Procedure|Blood draw|Three to four tablespoons of blood drawn.
1877296|NCT01156155|Other|questionnaires|completed questionnaires regarding patient's health and functional ability.
1877297|NCT01156155|Procedure|Periodontal Examination|Periodontal examination including measurement of gum pockets with a probe. Bacterial samples taken.
1877298|NCT01156155|Other|Bilateral digital xray of hands|One time digital xray of hands
1877299|NCT01156168|Genetic|DNA analysis|
1877300|NCT01156168|Genetic|gene expression analysis|
1877301|NCT01156168|Genetic|polymorphism analysis|
1877302|NCT01156168|Genetic|protein expression analysis|
1877303|NCT01156168|Other|immunohistochemistry staining method|
1877304|NCT01156168|Other|laboratory biomarker analysis|
1877305|NCT01156181|Procedure|Cervical discharge removal|Cervical discharge will be removed using a cotton swab before embryo transfer during ICSI cycles
1877306|NCT01156181|Procedure|control|Embryo transfer without any intervention
1877307|NCT01156194|Drug|Homeopathy 1|Arnica montana C6 and Bellis perennis C6
1877308|NCT01156194|Drug|Homeopathy 2|Arnica montana C30 and Bellis perennis C30
1877309|NCT01156194|Drug|Placebo|globule identical to true homeopathy comparators
1877310|NCT01156207|Drug|Aliskiren|300mg Aliskiren qd for 6 month
1877311|NCT01156220|Drug|Furosemide|Injection, 40 mg, single dose over 5 min
1877312|NCT01156220|Drug|aminohippurate sodium|Injection, 500 mg, single dose over 5 min
1877313|NCT01156233|Procedure|Anesthesia induction|Cuff palpation technique: identification of the cuff position in the trachea by palpation.
1877314|NCT01156233|Procedure|Anesthesia induction|Right mainstem intubation, identification of the tube tip position in the trachea by withdrawing the tube from the right mainstem until good quality breath sound in the left axilla are available.
1877394|NCT01156883|Drug|prednisone|
1877315|NCT01156246|Drug|Dapagliflozin/Metformin|oral fixed dose combination tablet 5 mg Dapagliflozin / 1000 mg Metformin given on day 1 at visit 2 and 3.
1877316|NCT01156259|Radiation|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 30Gy
1877317|NCT01156259|Radiation|3D-CRT based Involved Field Radiotherapy|CT simulation, 3D-CRT or IMRT techniques, Involved Field Radiotherapy of 40Gy
1877318|NCT01156272|Device|ATS Medical 3f® Aortic Bioprosthesis, Model 1000 19mm|Replacement aortic heart valve
1877319|NCT01156285|Other|Filling in a patient questionnaire|Filling in a patient questionnaire
1877320|NCT01156311|Drug|dimethyl fumarate|Days 1-7: 120 mg three times a day (TID) for a total daily dose of 360 mg. Day 8 to Week 24: 240 mg TID for a total daily dose of 720 mg. Drug supplied as a capsule taken orally.
1877321|NCT01156324|Behavioral|Online Stress Management Group (Upliv)|Personalized online stress management program
1877322|NCT01156324|Behavioral|Control|Control group receiving routine care along with $50 gift certificate at end of cycle
1877323|NCT01156350|Drug|Busulfan - Fludarabine - TBI|This RICE NK protocol is a multicenter study of Haplo- HSCT using RIC with fludarabine (180 mg/m2), Busulfan IV (3,2 to 4,8 mg/kg/d), TBI 2 grays and CD3/CD19 graft depletion. A minimum of 8 106 CD34+ cells/kg were infused on day 0. No post grafting immunosuppression was applied if the graft contained < 2.5 x 104 CD3+ cells/kg
1877324|NCT01156363|Procedure|Dialysis|regular haemodialysis or peritoneal dialysis
1877325|NCT01156363|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|once monthly, subcutaneously or intravenously, for 32 weeks
1877326|NCT01156376|Device|Potassium Oxalate without Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash without fluoride - Rinse with 10ml for 60 seconds, four times daily successively at 1 hour intervals for five days
1877327|NCT01156376|Device|Potassium Oxalate with Fluoride|1.40% Potassium Oxalate Sensitive Mouthwash with fluoride - Rinse with 20ml for 60 seconds, four times daily successively at 1 hour intervals for five days
1877328|NCT01156376|Device|Active Comparator PO-116-A|Rinse with comparator mouthwash 20ml for 30 seconds, four times daily successively at 1 hour intervals for five days
1877329|NCT01156389|Drug|Ritonavir and pyronaridine/artesunate|100 mg ritonavir (one soft gelatin capsule twice per day over 17 days, the evening capsule on day 1 will be omitted) and pyronaridine/artesunate 180 mg/60 mg (3 to 4 tablets once per day according to weight for 3 days).
1877330|NCT01156389|Drug|pyronaridine/artesunate|Pyronaridine/artesunate 180 mg/60 mg (3 to 4 tablets once per day according to weight for 3 days).
1877331|NCT01156402|Behavioral|Healthy Families-Childhood Obesity Prevention and Oral Health|The active intervention was adapted from the We Can! parent intervention to be culturally-appropriate for Hispanic families of children ages 5-7. The tailored intervention is based on Social Cognitive Theory and Behavioral Choice Theory to provide parents and children with cognitive and behavioral skills to enable change in the target behaviors, and to encourage them to practice using these skills to strengthen their perceived competence in using these behaviors effectively.
1877332|NCT01156415|Drug|AGO178|
1877333|NCT01156415|Drug|AGO178|
1877334|NCT01156441|Procedure|surgical mitral valve repair w/ mitral valve annuloplasty|"Mitral valve repair will be performed via median sternotomy, utilizing cardiopulmonary bypass and moderate hypothermia. The mitral valve will be approached through a left atrial incision. Following inspection of the valve, mitral valve annuloplasty will be accomplished with a complete semi-rigid annuloplasty ring. Additional techniques to address residual regurgitation will be at the discretion of the surgeon. The left atriotomy will then be closed and the patient weaned off and separated from the cardiopulmonary bypass.
Intraoperative transesophageal echocardiography will be performed on all study volunteers."
1877335|NCT01156454|Procedure|X-ray|surgical specimen taken to radiology and contents x-rayed
1877336|NCT01156467|Device|Neurally adjusted ventilatory assist, i-Servo, Maquet Nordic (Solna, Sweden)|Treatment with Edi-catheter
1877337|NCT01156467|Device|Control group, ventilation with i-Servo or Stephanie|Ventilatory support is given as routinely is done in the neonatal intensive care unit, with the ventilators available. Normal nasogastric tube is used.
1877338|NCT01156480|Drug|hydrocortisone|Subjects in hydrocortisone group will receive 3mg/kg/day divided every 8 hours via IV route for 3 days, followed by 2mg/kg/day divided every 8 hours IV for 1 day, followed by 1.5mg/kg/day divided every 8 hours IV for 1 day, followed by 1mg/kg/day divided every 12 hours for 1 day, followed by 0.5mg/kg/day in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
1877339|NCT01156480|Drug|placebo|Subjects in placebo group will receive a volume of placebo equal to the hydrocortisone group, on the same dosing schedule, with doses given every 8 hours via IV route for 3 days, followed by placebo every 8 hours IV for 1 day, followed by placebo every 8 hours IV for 1 day, followed by placebo every 12 hours for 1 day, followed by placebo in single dose for one day. The first dose of study drug will be given within 6 hours of diagnosis of NEC, once informed consent is obtained, and subjects will continue to receive study drug until all doses have been given (total of 18 doses) or consent is withdrawn.
1877340|NCT01156493|Other|Protein Hydrolyzed Premature Formula|Infants will be fed with a protein hydrolyzed premature formula until they reach full feeds
1877341|NCT01156519|Other|Salivary Cortisol|"Day 1: 1st salivary cortisol at 23 hours
Day 2: 2nd salivary cortisol at 23 hours and administration of dexamethasone (for overnight 1-mg dexamethasone suppression test)
Day 3: serum cortisol at 8 am
Between Day 4 and Month 3: if serum cortisol at 8 am > 18ng/mL:
Cortisol for 24 hours
dexamethasone suppression test (2mg/j during 2 days)
Cortisol and ACTH cycle
Noriodocholesterol scintigraphy"
1877342|NCT01156545|Drug|BIBW 2992|BIBW 2992 40mg, once a day, oral intake, every day
1877343|NCT01156545|Drug|simvastatin|simvastatin 40mg, once a day, oral intake, every day.
1877344|NCT01156571|Drug|cangrelor P2Y12 (platelet) inhibitor|
1877345|NCT01156571|Drug|Clopidogrel - 300 or 600 mg (study arm)|Over encapsulated tablets.
1877346|NCT01156571|Drug|Clopidogrel 600 mg post cangrelor|over-encapsulated clopidogrel (600 mg)
1877347|NCT01156584|Biological|Toca 511|Single, stereotactic, transcranial, intratumoral injection or intravenous injection
1877348|NCT01156584|Drug|5-FC|4-6 week cycles of Toca FC. Doses evaluated from 120 mg/kg/day or 300 mg/kg/day. Duration of dosing evaluated: 6 days, 7 days or 14 days.
1877395|NCT01156883|Drug|thioguanine|
1877349|NCT01156597|Drug|pioglitazone|30 mg daily for three weeks increase to 45 mg daily for 21 more weeks
1877350|NCT01156610|Behavioral|Tobacco Treatment|"Comparison of integrated cessation counseling tools with the normal standard of care.
Both the intervention and control clinics will be provided with tools for visit-based best practices for tobacco cessation. The LMR will provide smoking status icons and tobacco treatment reminders for the primary care physicians at the time of a visit. In addition, physicians in both arms have access to decision support around medications prescribed, including bupropion and varenicline. Physicians can refer patients to tobacco cessation groups that meet periodically at each of the sites or to the Massachusetts tobacco quitline.
Outcome Assessment: Six month IVR Call: Patients in both the intervention and control practices who have not opted-out will be called six months after completing the 12-week treatment protocol. The outcome assessment script will be largely the same for intervention and control practices (except for the questions related to satisfaction with the intervention protocol)."
1877351|NCT01156623|Procedure|EBUS-TBNA|All included patients received TBNA for lymph node study via a flexible ultrasonic bronchoscope with a linear scanning probe on the tip (BF-UC206F-OL8, Olympus). The curved-probe scanned parallel to the insertion direction of bronchoscope, and the obtained images were linked to the ultrasound scanner (EU-2000C, Olympus) incorporated with Doppler-flow imaging. Each lymph node greater than 5mm in short axis measured by cursors was selected for subsequent TBNA with a 22-gauge (NA-201SX-4022, Olympus) needle in a condition of real-time EBUS guidance. A cytology examination was sent for pathologist blinded for the clinical history and image result of patients. When a tissue core was obtained by TBNA, the specimen was also sent for pathology study.
1877352|NCT01156636|Drug|Sildenafil|50 mg 3 times/day for 1 year
1877353|NCT01156636|Drug|Placebo|
1877354|NCT01156649|Device|PAP therapy|Nightly use of automatic positive airway pressure delivered at therapeutic levels and to be delivered through a nasal interface device selected to maximize comfort for each child.
1877355|NCT01156649|Device|Sham PAP therapy|During sleep, the sham PAP device will administer a constant pressure of subtherapeutic air (approximately 1 cm of water) through a custom fit nasal interface chosen for the child's maximum comfort.
1877356|NCT01156662|Device|Endeavor resolute or Resolute integrity (Medtronic)|PCI without thrombus aspiration
1877357|NCT01156662|Device|Export Aspiration Catheter, Endeavor resolute or Resolute integrity (Medtronic)|PCI after thrombus aspiration
1877358|NCT01156675|Device|FLEXUS(TM) Interspinous Spacer|Treatment of lumbar spinal stenosis with the FLEXUS™ Interspinous Spacer
1877359|NCT01156675|Device|XSTOP® Interspinous Spacer|Treatment of lumbar spinal stenosis with the XSTOP® Spacer
1877360|NCT01156688|Drug|Misoprostol|sublingual 800mcg misoprostol 48 hours after oral 200mg mifepristone
1877361|NCT01156688|Drug|Misoprostol|buccal misoprostol 800mcg 48 hours after oral 200mg mifepristone
1877362|NCT01156701|Drug|Receiving a prescription of Relenza for prophylaxis|Receiving a prescription of Relenza for prophylaxis
1877363|NCT01156701|Other|No prophylaxis with Relenza|No prophylaxis with Relenza
1877366|NCT01156740|Drug|Penicillin G, Benzathine|IM BPG; 600,000 U > 27kg or 1,200,000 U <27 kg)
1877367|NCT01156740|Drug|Amoxicillin|750 mg/QD
1877368|NCT01156753|Drug|CDX-011|CDX-011 (1.88 mg/kg) administered as an intravenous infusion on Day 1 of each 21 day cycle.
1877369|NCT01156753|Drug|"Investigator's Choice chemotherapy"|Any of the following single-agent chemotherapy may be given at the discretion of the investigator, with a cycle length not to exceed four weeks: Capecitabine, Vinorelbine, Gemcitabine, Docetaxel, Paclitaxel, Albumin-bound paclitaxel, Doxorubicin HCL, Liposomal doxorubicin, Ixabepilone and Eribulin.
1877370|NCT01156766|Device|- locking anterior plate|"The number of osteoporotic fractures, among which the fractures of the lower extremity of the radius (16 % of fractures seen in emergencies) is going to increase. Several surgical techniques are described in particular locking plates and intrafocal pinning techniques.
The aim of the study is to compare (X-ray assessments and functional outcome) these two types of treatment by using a prospective, randomised multicentric analysis."
1877371|NCT01156779|Drug|SR-exenatide|Emulsion 0.5mg,1mg,2mg,4mg dosage (Dose-escalation) Single injection
1877372|NCT01156792|Drug|FP 100|FP 100mcg BID
1877373|NCT01156792|Drug|GSK2190915 100|GSK2190915 100mg QD (AM)
1877374|NCT01156792|Drug|GSK2190915 300|GSK2190915 300mg QD (AM)
1877375|NCT01156792|Drug|montelukast|montelukast 10mg QD (PM)
1877376|NCT01156792|Drug|placebo|placebo BID
1877377|NCT01156792|Drug|FP/SAL 100/50|FP/SAL 100/50mcg BID
1877379|NCT01156844|Drug|Indacaterol|Indacaterol inhaled via Concept1, a single dose dry powder inhaler (SDDPI) for 16 days. Dosage and frequency varied according to randomization scheme.
1877380|NCT01156844|Drug|Placebo to Indacaterol|Placebo inhaled via Concept1, a SDDPI. Frequency varied according to randomization scheme.
1877381|NCT01156857|Drug|PGL4001, placebo|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets).
1877382|NCT01156857|Drug|PGL4001, progestin|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets).
1877383|NCT01156870|Drug|SAR566658|"Pharmaceutical form:solution for infusion
Route of administration: intravenous"
1877384|NCT01156883|Drug|asparaginase|
1877385|NCT01156883|Drug|cyclophosphamide|
1877386|NCT01156883|Drug|cytarabine|
1877387|NCT01156883|Drug|daunorubicin hydrochloride|
1877388|NCT01156883|Drug|dexamethasone|
1877389|NCT01156883|Drug|doxorubicin hydrochloride|
1877390|NCT01156883|Drug|ifosfamide|
1877391|NCT01156883|Drug|mercaptopurine|
1877392|NCT01156883|Drug|methotrexate|
1877393|NCT01156883|Drug|methylprednisolone|
1877396|NCT01156883|Drug|vincristine sulfate|
1877397|NCT01156883|Drug|vindesine|
1877398|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose in the fasting state.
1877399|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
1877400|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.
1877401|NCT01156896|Dietary Supplement|Ferrous sulfate|Ferrous sulfate, ~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
1877402|NCT01156909|Drug|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.
Approved amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
1877403|NCT01156922|Drug|Rituximab|"Two infusions of Rituximab 500 mg/m2 (max 1000 mg) given two weeks apart, followed by maintenance Rituximab infusions 500 mg/m2 (max 1000 mg) at 3, 6, 10, and 15 months.
For up to 5 patients in the study, standard plasma exchange (one plasma volume, up to 5 treatments, during 1-2 weeks) will be performed 2-3 weeks prior to start of Rituximab therapy.
Amendment: for patients with gradual improvement in CFS/ME symptoms after 12 months follow-up, but not having reached a clear response, up to 6 additional Rituximab infusions (500 mg/m2, max 1000 mg) may be given during the following 12 months period."
1877404|NCT01156935|Other|Laugh Yoga|1 hour including laugh, respiratory exercises and guided imagination by a group instructor specialized in laugh yoga
1877405|NCT01156948|Drug|misoprostol|400ug vaginally the day before surgery
1877406|NCT01156948|Drug|oral misoprostol|400ug misoprostol orally the day before the surgery
1877407|NCT01156961|Drug|bevacizumab [Avastin]|10 mg/kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
1877408|NCT01156961|Drug|paclitaxel|90 mg/m2 iv days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 iv day 1 of each 21-day cycle
1877409|NCT01156974|Behavioral|education and care guide|Patients receive education about care goals, and in-person and telephone counseling of unspecified frequency over one year to achieve goals
1877410|NCT01156974|Behavioral|education only|patients receive education about care goals
1877411|NCT01156987|Device|Magnetic resonance imaging|"Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:
an IV line is placed by nurse,
patient is placed in the 4 T MRI scanner at CMRR,
initial scout images and manual linear shims are adjusted,
Pre-contrast SWIFT T1 weighted images and T1 map are obtained,
continuous SWIFT acquisition begins immediately before contrast injection,
contrast injection,
continuous SWIFT acquisition continues for 12 min after contrast,
late enhancement images may also be obtained.
10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods."
1877412|NCT01157000|Drug|Canagliflozin|On Day 1, all patients will receive a single 300-mg tablet of canagliflozin with 8 ounces of water followed 105 minutes later by a 15-minute intravenous infusion dose (15 mL) of 10 mcg of 14C-canagliflozin (200 nCi).
1877413|NCT01157013|Other|Positron emission tomography with fludeoxyglucose F 18|Patients receive fludeoxyglucose F 18 (^18FDG) IV. Beginning 1 hour later, patients undergo whole-body positron emission tomography (PET) scanning. Patients also undergo conventional radiographic staging of their disease.
1877414|NCT01157026|Dietary Supplement|Tocotrienol Rich Fraction (TRF)|Tocotrienol Rich Fraction (200mg), daily for five years
1877415|NCT01157026|Other|placebo plus tamoxifen|20mg tamoxifen daily
1877416|NCT01157039|Dietary Supplement|Glutamine|Glutamine- During the first cycle of oxaliplatin based combination therapy (mFOLFOX 6 or XELOX) no patient will receive glutamine. At cycle 2, patients will be randomized to receive for 6 days either : Glutamine 30g/day during cycle 2 and glutamine 40g/day during cycle 3 (ARM A) or glutamine 40g/day at cycle 2 and glutamine 30g/day at cycle 3 (Arm B).
1877417|NCT01157052|Other|(supplement) Calcium and Magnesium|"FOLFOX 6: Oxaliplatin (Eloxatin®): 100mg/m2 x 2hrs IV with 250ml of dextrose 5%; leucovorin 200mg/m2 with oxaliplatin; then IV bolus of 5FU 400mg/m2 and 5FU 2400mg/m2 in a 46 hr continuous IV. Each cycle is 14 days, approximately 8-12 cycles planned.
XELOX: Oxaliplatin 130mg/m2 x 2hrs IV in 250ml of dextrose 5% on day 1; plus oral capecitabine 1000mg/m2 bid on days 1-15 3 wk cycles.
Ca2+/Mg2: Ca++gluconate 1gr & Mg++sulfate 1g given IV pre & post cycle 1 (Arm A) or cycle 2 (Arm B)"
1877418|NCT01157065|Drug|AL-78898A|Investigational treatment
1877419|NCT01157065|Drug|Ranibizumab|Anti-vascular endothelial growth factor (VEGF) treatment
1877420|NCT01157078|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
1877421|NCT01157078|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
1877422|NCT01157091|Drug|pazopanib hydrochloride|Given orally
1877423|NCT01157091|Other|laboratory biomarker analysis|Correlative studies
1877424|NCT01157091|Other|immunologic technique|Correlative studies
1877425|NCT01157104|Drug|IDX320|IDX320 400 mg in tablets (8x50 mg) administered orally once daily
1877426|NCT01157104|Drug|IDX184|IDX184 100 mg in capsules (2x50 mg) administered orally once daily
1877427|NCT01157104|Drug|IDX184 placebo|IDX184 matching placebo in capsules administered orally once daily
1877428|NCT01157104|Drug|IDX320 placebo|IDX320 matching placebo in tablets administered orally once daily
1877429|NCT01157117|Biological|Placebo for omalizumab|Placebo for omalizumab is injected subcutaneously every 2-4 weeks for 16 months at a volume designed to match that of the verum treatment group (determined by the participant's IgE level and weight).
1877430|NCT01157117|Biological|Omalizumab|Omalizumab is injected subcutaneously every 2-4 weeks for 28 months at a dose determined by the participants IgE level and weight.
1877431|NCT01157117|Drug|Milk powder|Milk powder is ingested orally at a dosage of up to 3.84 grams of of milk protein daily from Month 4 through Month 28 if the Month 28 10 g milk OFC is failed, and through Month 30 if the Month 28 10 g milk OFC is passed.
1877432|NCT01157130|Other|Exercise Regimen|Exercise instruction
1877433|NCT01157143|Drug|XRP0038 (NV1FGF)|"Pharmaceutical form : solution
Route of administration : intramuscular"
1877434|NCT01157156|Drug|XRP0038 (NV1FGF)|"Pharmaceutical form:solution
Route of administration: intramuscular"
1877435|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
1877436|NCT01157169|Drug|Buprenorphine|8 mg Sublingual Tablets
1877437|NCT01157182|Drug|Estradiol/Norethindrone acetate|1/0.5 mg Tablets
1877438|NCT01157182|Drug|Activella®|1/0.5 mg Tablets
1877439|NCT01157195|Behavioral|Tele-AutoCITE|Automated, remotely-administered form of CI therapy
1877440|NCT01157195|Behavioral|CI therapy|CI therapy is a behavioral approach to physical rehabilitation that has three components: 1. intense training of the more affected arm for several hours daily for multiple consecutive days, 2. restraint of the less affected arm during training hours and afterwards during the treatment period, 3. A package of behavioral techniques designed to transfer gains from the treatment setting to daily life. In this trial, CI therapy will be administered for 3 1/2 hours per day for 10 consecutive weekdays.
1877441|NCT01157208|Other|Diet A|Subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides for a 12-week intervention.
1877442|NCT01157208|Other|Diet B|Over a 12-week intervention, subjects receive dietary counseling, food for two meals and two snacks daily, and access to a website with recipes, approved food lists, and dining out guides.
1877443|NCT01157221|Other|a standardized physical therapy program|passive mobilization, stretching techniques, physical modalities (i.e., ultrasound, shortwave diathermy, and/or electrotherapy), and active exercises
1877444|NCT01157221|Other|EMSMTA|end-range mobilization/scapular mobilization treatment approach
1877445|NCT01157234|Drug|Nebivolol|Nebivolol 5 mg once daily, titrated to a maximum total daily dose of 40 mg to achieve a blood pressure of < 140/ 90.
1877446|NCT01157234|Drug|Metoprolol|Metoprolol 25 mg twice daily, titrated to a maximum total daily dose of 400 mg to achieve a blood pressure < 140/90.
1877447|NCT01157247|Procedure|Comparison of intravenous fentanyl and local anesthetic infiltration in pain reducing during spinal needle puncture|
1877448|NCT01157260|Drug|Kremezin|AST-120 2g three times a day
1877449|NCT01157286|Device|CPAP|PATIENTS DIADNOSSED WITH MILD TO SEVERE APNEA WILL BE TREATED WITH CPAP
1877450|NCT01157312|Drug|clomiphene citrate +highly purified uFSH|
1877451|NCT01157312|Drug|clomiphene citrate|
1877452|NCT01157325|Procedure|Neuraxial analgesia|Neuraxial analgesia will be given at any time if the parturient requested analgesia
1877453|NCT01157325|Procedure|Non-neuraxial analgesia|No neuraxial analgesia will be given to those who will not want to an analgesia
1877454|NCT01157338|Procedure|diagnostic cardiac catheterization|coronary intervention: angiography
1877455|NCT01157338|Procedure|therapeutic cardiac catheterization|cardiac catheterization: angioplasty
1877456|NCT01157351|Drug|paliperidone|flexible dosing as prescribed by the study doctor for 15 months
1877457|NCT01157351|Drug|risperidone|flexible dosing as prescribed by the study doctor for 15 months
1877458|NCT01157351|Drug|haloperidole|flexible dosing as prescribed by the study doctor for 15 months
1877459|NCT01157351|Drug|perphenazine|flexible dosing as prescribed by the study doctor for 15 months
1877460|NCT01157351|Drug|aripiprazole|flexible dosing as prescribed by the study doctor for 15 months
1877461|NCT01157351|Drug|quetiapine|flexible dosing as prescribed by the study doctor for 15 months
1877462|NCT01157351|Drug|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 15 months
1877463|NCT01157351|Drug|olanzapine|flexible dosing as prescribed by the study doctor for 15 months
1877464|NCT01157364|Drug|bimatoprost ophthalmic formulation A|Single dose of bimatoprost ophthalmic formulation A administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
1877465|NCT01157364|Drug|bimatoprost ophthalmic formulation B|Single dose of bimatoprost ophthalmic formulation B administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
1877466|NCT01157364|Drug|bimatoprost ophthalmic formulation C|Single dose of bimatoprost ophthalmic formulation C administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
1877467|NCT01157364|Drug|bimatoprost ophthalmic formulation D|Single dose of bimatoprost ophthalmic formulation D administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
1877468|NCT01157364|Drug|bimatoprost ophthalmic formulation E|Single dose of bimatoprost ophthalmic formulation E administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
1877469|NCT01157364|Drug|bimatoprost ophthalmic formulation F|Single dose of bimatoprost ophthalmic formulation F administered in the study eye on Day 1, and once between 90 days and 12 months after the first dose (if applicable).
1877470|NCT01157364|Drug|Sham|Sham administration in the study eye on Day 1.
1877471|NCT01157364|Drug|timolol 0.5%|Two drops timolol 0.5% (Timoptic®) administered in the study and non-study eyes once in the morning and once in the evening daily for up to 24 months.
1877472|NCT01157364|Drug|bimatoprost ophthalmic solution 0.03%|One drop bimatoprost ophthalmic solution 0.03% (LUMIGAN®) administered in the non-study eye once daily every evening for up to 24 months.
1877473|NCT01157364|Drug|latanoprost 0.005%|One drop latanoprost 0.005% (Xalatan®) administered in the non-study eye once daily in the evening or in the non-study eye and study eye once daily in the evening for up to 24 months.
1877474|NCT01157364|Drug|timolol vehicle (placebo)|One drop of timolol vehicle administered in the study eye in the morning and evening, and 1 drop of timolol vehicle administered in the non-study eye once daily in the morning, or 1 drop of timolol vehicle administered once in the morning in both eyes for up to 24 months. Timolol vehicle is administered for masking purposes.
1877475|NCT01157377|Drug|AGN-214868|AGN-214868 injected into the bladder.
1877476|NCT01157377|Drug|AGN-214868 placebo|AGN-214868 placebo injected into the bladder.
1877477|NCT01157390|Other|Infant formula|Name: Infant formula with high proportion of palmitic acid in the sn-2 position Dosage & frequency: Fed as need Duration: at least 3 months
1877478|NCT01157390|Other|Breast feeding|Breast feeding
1877479|NCT01157403|Biological|Autologous transplantation|Autologous transplantation of bone marrow mesenchymal stem cells (approximately 2.5 x 106 cells/kg body weight) intravenously
1877480|NCT01157416|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
1877481|NCT01157416|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of the 12-session CBT protocol.
1877482|NCT01157416|Behavioral|CBT|12-session CBT protocol, called Youth PTSD Treatment.
1877483|NCT01157429|Drug|D-cycloserine|D-cycloserine 50 mg by mouth prior to sessions 5-12 of the 12-session CBT protocol.
1877484|NCT01157429|Drug|Placebo pill|Placebo pill by mouth prior to sessions 5-12 of teh 12-session CBT protocol.
1877485|NCT01157429|Behavioral|CBT|12-session CBT protocol, called Youth PTSD Treatment.
1877486|NCT01157442|Behavioral|cell phone sms text messaging|At enrollment a study nurse will send the intervention group a weekly SMS message reminding them to attend antenatal care. Starting at 36 weeks gestational age, an automated bulk SMS management system, will send the intervention group 3 SMS text messages (using non descript slogans) each week by proxy reminding them to take their nevirapine in labor. From time of delivery to 6 weeks postpartum the women will aslo receive 3 SMS messages per week reminding them to attend their 6 week checkup and 6 week infant visit.Upon receiving these messages women in the intervention group can text back if they have any concerns or questions. These women would then receive phone calls from the study nurse triaged according to the women's needs.
1877487|NCT01157455|Procedure|Everolimus Drug Eluting Stent|Implantation
1877488|NCT01157455|Drug|Aspirin|Orally take by 300mg per day at least within 24 hours before index procedure. Orally 100mg indefinitely after the procedure as a part of dual anti-platelet therapy
1877489|NCT01157455|Drug|Clopidogrel|"A loading dose of 300mg must be given at least 6 hours prior to index procedure, or a loading dose of 75mg/d 72 hours prior to index procedure.
75mg daily for at least 12 months after the procedure as a part of dual anti-platelet therapy."
1877490|NCT01157455|Drug|Heparin or Bivalirudin|During procedure or in-hospital, Heparin 100u/kg or Bivalirudin may be given,or follow up the standard practice of each site.
1877491|NCT01157481|Drug|Conventional therapy plus nifedipine|Participants will receive 10 to 60 mg of sustained-release nifedipine once a day until December 2014
1877492|NCT01157481|Drug|Conventional therapy|Conventional therapy
1877493|NCT01157494|Other|classification of hand manipulation function|To determine the criterion validity of the classification of the pattern of manipulation proposed by Ferrari et al. we correlated hand manipulation classes with both the scores of the two standard criteria chosen (AHA and Melbourne Assessment).
1877494|NCT01157507|Drug|Intravesical injection of Botulinum A Toxin|One treatment, 100 U vials diluted in 10 ml normal saline
1877495|NCT01157507|Procedure|Bladder overdistension|Bladder overdistension
1877496|NCT01157507|Drug|Placebo|One single injection of placebo
1877497|NCT01157533|Drug|Vancomycin|Loading dose 30 mg/kg via central or peripheral intravenous infusion. Subsequent doses of vancomycin (15 mg/kg) are considered standard of care.
1877498|NCT01157546|Procedure|Normal saline via TAP catheters|A bolus of normal saline (20 mL per side) followed by a continuous infusion of normal saline (7 ml/h per side. The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
1877499|NCT01157546|Procedure|Lidocaine via TAP catheters|A bolus of lidocaine 1% with epinephrine 1:200 000 (20 mL per side) followed by a continuous infusion of ropivacaine 0.2% (7 mL/h per side). The infusions will be started after the bolus doses and continued postoperatively for 48 hours.
1877500|NCT01157559|Drug|Ziprasidone|8 week prospective study
1877501|NCT01157572|Drug|Metoprolol|Patients with moderate to severe aortic valve insufficiency will be randomized to Metoprolol
1877502|NCT01157572|Drug|Placebo|Patients with moderate to severe aortic valve insufficiency will be randomized to Placebo
1877503|NCT01157585|Drug|paliperidone ER|8 week prospective study
1877504|NCT01157598|Device|bispectral index monitoring|parameter monitoring of bispectral index
1877505|NCT01157611|Behavioral|Mentoring program|mentoring program group patients should register their SMBG, exercise, food intake and insulin dose on the website designed for this study and receive advices of mentors from peer group.
1877506|NCT01157624|Drug|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
1877507|NCT01157624|Drug|oxygen|Subjects who are found to desaturate during treatment with air will be supplement with oxygen
1877508|NCT01157650|Other|Autologous mesenchymal stem cells|"The trial is divided in three phases:
I. - Selection: Patients evaluation for study eligibility will take place within two weeks after Informed Consent signature.
II.- Treatment phase includes:
Liposuction procedure to obtain adipose tissue.
Processing and production of Autologous Mesenchymal Stem Cells from adipose tissue (ASCs)
ASCs implant
III.- Follow up: Study visits post-implant will take place at the 1st week (+/- 3 days), 4th week (+/- 3 days), 8th week (+/- 7 days), 12nd week (+/- 7 days), 24th week (+/- 7 days), and 1 year (+/- 7 days) after implant."
1877509|NCT01157663|Other|Adapted balance training|during 8 weeks
1877510|NCT01157663|Other|Balance Training|Balance training with unipedal standing during 8 weeks
1877511|NCT01157676|Other|Quality of Life Questionnaires|Quality of Life Questionnaires
1877512|NCT01157676|Other|Get up and Go test|Timed Get up and Go test
1877513|NCT01157676|Other|Hand Grip test|Hand grip strength test
1877514|NCT01157702|Biological|Inactivated influenza vaccine (split virus, Vero cell-derived)|One 0.5 mL dose of inactivated influenza vaccine in a pre-filled syringe, administered by intramuscular injection into the musculus deltoideus in the upper arm
1877515|NCT01157715|Biological|intravitreal injection of KH902|
1877516|NCT01157741|Behavioral|C-C|Mx as H-C plus positioning follow up in the community clinic
1877517|NCT01157741|Other|C-SF|As C-C but with additional supplementary food (SF) (C-SF)
1877518|NCT01157741|Other|As C-C with additional psychosocial stimulation (PS) (C-PS)|Giving psychosocial stimulation
1877519|NCT01157741|Other|As C-C but with both SF & PS (C-SF+PS)|Giving both SF & PS
1877520|NCT01157741|Other|H-C|Follow-up at Hospital
1877521|NCT01157754|Drug|levonorgestrel and ethynilestradiol|
1877559|NCT01151969|Behavioral|"New multicomponent 7H intervention"|The GPs in the intervention group will undertake an interactive workshop training session (15 hours) on the '7 hypotheses' (7H) intervention. In short, this intervention encourages GPs to select from a list of seven possible hypotheses for why the patient is a frequent attender: biological, psychological, social, family, cultural, administrative-organisational, or related to the doctor-patient relationship.
1877522|NCT01157767|Other|standardized regimen of exercises, including a warm-up period, ROM arm exercises, and strength training exercises.|Module I is a group of arm movements. It consists of stretching exercises coordinated with breathing exercises to restore their physical mobility, range of motion and flexibility of shoulders. Module I is to be performed daily. In Module II the exercises are a series of copyrighted, sequential movements designed to put the body in proper alignment. It is a special series of muscle movements to help establish better body alignment, as well as increased strength and flexibility of one's arms, legs, and spine, each exercise is 4 repetitions. Module III is the walking and the resistance weight training program. The walking program is whole body exercise, multi-joint, weight-bearing, low impact and for beginners to advanced.
1877523|NCT01157780|Drug|Lovaza (fish oil)|Patients will receive fish supplementation of 1 g/kg/day with a maximum dose of 4 g/day for a 12 week period.
1877524|NCT01157793|Drug|r-hGH|r-hGH at a dose of 0.15-1.00 mg/day administered for 48 weeks by s.c. route
1877525|NCT01157793|Drug|r-hGH|Initially no treatment for the first 24 weeks followed by administration of r-hGH at a dose of 0.15 1.00 mg/day for the next 24 weeks, by s.c. route
1877526|NCT01157806|Radiation|short course of palliative radiotherapy|5x5 Gy + XELOX 7 days after radiotherapy
1877527|NCT01157819|Drug|0.3% Ciprofloxacin Ear Drops|4 gtt b.i.d. for 7 days.
1877528|NCT01157819|Drug|FoamOtic Cipro|0.3% Ciprofloxacin Otic Foam, 1 application, q.d. for 7 days
1877529|NCT01157845|Device|BreathID (Methacetin breath test)|13C-labeled methacetin (75 mg) is given to the patient by mouth in a small volume of water, and expired 13C-labeled carbon dioxide is measured from a nasal cannula.
1877530|NCT01157858|Drug|Everolimus|2.5 mg every day orally
1877531|NCT01157858|Drug|Octreotide LAR|40 mg every 28 days IM
1877532|NCT01157871|Drug|XRP0038 (NV1FGF)|"Pharmaceutical form:solution
Route of administration: intramuscular"
1877533|NCT01157871|Drug|placebo|"Pharmaceutical form:solution
Route of administration: intramuscular"
1877534|NCT01157897|Biological|Plasmodium vivax Malaria Protein 001 (VMP001) with GSK Biologicals' Adjuvant System AS01B|Cohort 1 (15ug VMP001), Cohort 2 (30ug VMP001), Cohort 3 (60ug VMP001)
1877535|NCT01157923|Device|MD Logic Pump Advisor|Insulin pump settings (i.e., basal plan, correction factor, carbohydrate ration and insulin activity time) will be adjusted using the MD-Logic Pump Advisor
1877536|NCT01157936|Drug|Allopurinol|daily dosage
1877537|NCT01157936|Other|placebo|daily dosage
1877538|NCT01157949|Drug|Thymoglobulin|Study patients will receive 1.5 mg/kg/day intravenously for 5 days.
1877539|NCT01157962|Procedure|Lymphadenectomy in cervical cancer|Sentinel lymphadenectomy vs systematic pelvic lymphadenectomy
1877540|NCT01157975|Drug|Pioglitazone|Pioglitazone will be taken at a dose of 30 mg for up to 14 days
1877541|NCT01157975|Drug|Prednisone|Prednisone will be taken at a dose of 40 mg for up to 4 days
1877542|NCT01157988|Drug|ibritumomab tiuxetan (Zevalin)|During Zevalin treatment, rituximab 250 mg/m2 will be administered with the same methods mentioned above on days 1 and 8. On day 8, within 4 hours following completion of the rituximab dose, 90Y Zevalin at a dose of 0.4 mCi/kg actual body weight for patients with a platelet count > 150,000/L and 0.3 mCi/kg actual body weight for patients with a platelet count of 100,000 - 149,000/L will be injected intravenously over a period of 10 minutes. The maximum allowable dose of 90Y Zevalin is 32 mCi regardless of the patient's body weight. 90Y Zevalin should be administered within 4 hours after radiolabeling of Zevalin with 90Y.
1877543|NCT01158001|Behavioral|Prolonged exposure therapy|Twelve sessions (90 minutes each) of prolonged exposure therapy
1877544|NCT01158014|Procedure|Fibrin Glue, Quixil|quixil 0.1 ml
1877545|NCT01158014|Procedure|Suture|vicryl 10/0
1877546|NCT01158027|Other|gait evaluation|The children will asked to walk under different conditions: (1) walking at a self-selected speed faster and slower on the GAITRite® system and on a treadmill and while listening and to a metronomeQuoting.
1877547|NCT01158053|Device|FFR and VH-IVUS|"Stable Angina(SA), Unstable Angina(UA),Non ST-segment Elevation Myocardial Infarction(NSTEMI) or ST-segment Elevation Myocardial Infarction(STEMI) >48hrs scheduled for cardiac catheterization ± PCI. All patient level inclusion and no exclusion criteria are met Signed Informed Consent
No PCI or successful and uncomplicated PCI of all non study lesions. One or more study lesions identified.
All lesion level inclusion criteria and no exclusion criteria are met.
FFR followed by VH-IVUS of study lesion(s)
Any additional PCI based on routine clinical practice and FFR/IVUS data?
If Yes: Final IVUS with VH imaging, Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years
If No: Clinical follow-up at hospital discharge, 30 days, 6 months, and then yearly for 3 years"
1877548|NCT01158053|Device|IVUS and FFR|
1877549|NCT01158066|Procedure|CT Cardiac|the patient will undergo cardiac CT
1877550|NCT01158079|Drug|ALN-VSP02|The dose of ALN-VSP02 will be administered at the same dose level and schedule received at the completion of the previous study
1877551|NCT01158092|Device|Treatment with SInergy™ System|Lateral branch denervation using the SInergy™ System
1877552|NCT01158092|Other|Conservative Treatment|Treatment with physical therapy, chiropractic care, and medication
1877553|NCT01158105|Drug|Bortezomib|1.6 mg/m2 IV infusion on days 1, 8, 15, 22 of each 35 day cycle, for up to 6 cycles.Patients who continue to respond during the initial treatment phase with no ongoing significant adverse events will be eligible to receive up to 6 additional cycles.This maintenance dose will be administered on days 1 and 15.
1877554|NCT01151904|Drug|brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution|COMBIGAN® (brimonidine 0.2%/timolol 0.5% fixed combination ophthalmic solution) administered as one drop in the morning and one drop in the evening in affected eye(s) for 12 weeks.
1877555|NCT01151904|Drug|latanoprost|Latanoprost administered in the affected eye(s) as prescribed by physician.
1877557|NCT01151943|Other|Transversus Abdominis Plane (TAP) Block|Bilateral injection of levobupivacaine (20 mL, 3.75 mg/mL)
1877558|NCT01151943|Other|Incisional Infiltration of Local Anesthetic|continuous administration of levobupivacaine (1,25 mg/mL,5 mL/h) during 48 hours.
1877727|NCT01160744|Drug|Carboplatin (AUC 6)|Day 1 of every 21-day cycle
1877560|NCT01151982|Behavioral|Psychosocial Intervention|"The intervention we propose to test has 3 actives components. The first one is the fact of giving information to the GPs about the level and risk profile of depression of their patients. The second one is the transmission of this information from the GP to the patient. The third one is the interaction GP/Patient once both have the information about the risk profile of depression and the psychoeducational intervention that the GP will provide to the patient.
We will develop psychoeducational booklet, DVDs and websites for patients included in the intervention group.
The psychoeducative intervention will be tailored to each patient based on his/her profile, risk level and patients' risk factors.
The GPs will receive a 20-hours training course in the intervention. Moreover, we will assume a communitarian view, considering the patient as an active agent for change (empowerment). That is, GPs and patients will work together in order to promote patients' resources."
1877561|NCT01151995|Other|Remote source document verification|Remote access to electronic medical records of the 5 participating sites
1877562|NCT01151995|Other|On-site source document verification|Study monitor will perform on-site source document verification during routine visit to the five participating sites
1877564|NCT01152021|Drug|Dexmedetomidine|An initial bolus of 2 mcg/kg of dexmedetomidine will be administered over 10 minutes. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a 1.5 mcg/kg/hr infusion is initiated until the MRI is complete.
1877565|NCT01152021|Drug|Propofol|An initial bolus of 1mg/kg of propofol will be administered over 1 minute. This bolus can be repeated up to 2 times if sedation conditions are not achieved. Once successful sedation has been achieved, a propofol infusion of 125 mcg/kg/min is initiated until the MRI is complete.
1877566|NCT01152034|Behavioral|psychoeducation group therapy|This program consists of 15 sessions of closed group, with each session lasting 120 minutes, each aims at improving four main issues: illness awareness, early detection of prodromal symptoms and recurrences, treatment adherence, and lifestyle regularity. The program will be in groups of 6-12, conducted by two experienced therapists. The structure of each session consists of 30-40 minutes talk on the topic of the day, followed by an exercise related to the issue and a discussion.
1877567|NCT01152047|Drug|oxytocin|40mU/min as infusion of oxytocin
1877568|NCT01152073|Dietary Supplement|Placebo|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
1877569|NCT01152073|Dietary Supplement|Second Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
1877570|NCT01152073|Dietary Supplement|Third Formulation|Each subject will be expected to consume a twice daily drink of approximately 4 ounces per serving taken with the morning and evening meals for a total of 8 weeks. Each bottle will contain two servings.
1877571|NCT01152086|Other|Mountain hiking in the Austrian and Bavarian Alps|"Regularly supervised physical exercise training program.
Duration over all: 9 weeks; Frequency: 2 times per week; Duration one training-unit: 3 hours;
Program:
Endurance training (performed within 70-85% of the maximum heart rate)
Short exercises before hiking (Mobilisation, Body and nature perception, ca. 5 min)
Stretching after hiking (ca. 5 min)
Short break at half-time (ca. 15 min)"
1877572|NCT01152099|Other|Compression Bandaging|"Group A or Control Group: ambulatory treatment is performed during one month. Specific exercises and prevention measures are taught. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.
If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month,and this time the treatment corresponding to the group B or experimental will be applied."
1877573|NCT01152099|Other|Manual Lymph Drainage (MLD) and Compression Bandaging|"Specific exercises measures of prevention are taught. MLD is carried out followed by a daily multilayer bandage during the first four weeks. The tailor-made sleeve for lymphedema with gauntlet without protection at the edges and with extension to the shoulder is placed from the first four weeks of treatment. The sleeve is used during the whole day and a night interruption is allowed. Later the patient will continue domiciliary treatment realizing specific exercises for 30 minutes twice a day without fatigue carrying the lymphedema sleeve for at least 12 hours.
If after three months of treatment a good response is not obtained an ambulatory treatment will be introduced again for one month, and this time the treatment corresponding to the group A or Control will be applied."
1877574|NCT01152112|Device|Myomectomy|Removal of fibroids and / or polyps
1877575|NCT01152125|Other|Autologous bone marrow stem cells|Stem cells isolated from the patient's own bone marrow.
1877576|NCT01152138|Device|Open cells stent|Cobalt Chromium Stent with open cell design
1877577|NCT01152138|Device|Closed Cells Stent|Cobalt Chromium stent with closed cell design
1877578|NCT01152151|Device|Postal reminder letters|Postal reminder letters if adherence is not obtained (up to four)
1877579|NCT01152151|Device|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
1877580|NCT01152151|Device|Reminder letters|up to four reminder letters in september - december 2010
1877581|NCT01152164|Behavioral|questionnaires|Quality of life assessment using questionnaires EORTC QLQ C30 and 38 at baseline, one year and two years after the surgery of rectal cancer, treated with preoperative capecitabine based radiochemotherapy
1877582|NCT01152177|Device|Electronic reminder letters|Electronic reminder letters if adherence is not obtained (up to four)
1877583|NCT01152190|Drug|Tadalafil|Administered orally, once daily for 8 weeks
1877584|NCT01152190|Drug|Placebo|Administered orally, once daily for 8 weeks
1877585|NCT01152203|Drug|Bendamustine|Starting dose of 70 mg/m^2 by vein on Days 1 and 2 of a 28 day cycle
1877586|NCT01152203|Drug|Bevacizumab|10 mg/kg by vein on Days 1 & 15 of every 28 day cycle
1877587|NCT01152216|Drug|Dimebon|20 mg orally three times daily
1877726|NCT01160744|Drug|Pemetrexed|500 milligrams/square meter (mg/m²) on Day 1 of every 21-day cycle
1877588|NCT01152242|Drug|Isoglycemic Clamp|Isoglycemic Clamp, a procedure that includes IV infusion of short-acting Insulin (Part I) and glucose (Part I and 2)
1877589|NCT01152242|Drug|Comparator: insulin glargine|Insulin glargine at 0.4 U/kg
1877590|NCT01152255|Drug|MK6186|Panel A: 40 mg oral dose once daily for 7 days Panel B: 150 mg oral dose once daily for 7 days Panel C: Oral Dose <= 150 mg once daily for 7 days (dose level will be determined based on pharmacokinetic and pharmacodynamic results of panel A and B) Panel D: Oral Dose <= 150 mg once twice or three times daily for 7 days (dose level and dose frequency will be determined based on pharmacokinetic and pharmacodynamic results of panel A, B and C)
1877591|NCT01152255|Drug|Comparator: Placebo|Placebo tablets taken orally for seven day
1877592|NCT01152281|Other|Instrumental meta intervention|30 min video with stories of people with HIV. Content describes general health and emotional benefits of counseling.
1877593|NCT01152281|Other|Empowering meta-intervention|Empowering 30 min video with stories of people living with AIDS. Emphasizes individual control over behavior change.
1877594|NCT01152281|Other|Control|Control messages to increase awareness of HIV risk
1877595|NCT01152294|Behavioral|DVD & Booklet called: Managing Menopause|DVD and booklet that provides information about treatment choices for menopause symptoms. Complete title: Managing Menopause: Choosing treatments for menopause symptoms
1877596|NCT01152307|Behavioral|DVD/Booklet: Coping with Symptoms of Depression|DVD and booklet that provides information about treatment choices for depression symptoms
1877597|NCT01152320|Behavioral|Spirometry Fundamentals™ Training CD|MD-MA pairs randomized to the intervention arm of the study received 2 copies of the Spirometry Fundamentals™ CD. Included with the CDs was a letter explaining that each member of the MD-MA pair should view the CD at their convenience within the following 3 weeks. This letter included instructions on how to access the study website in order to complete an evaluation survey after viewing the CD.
1877598|NCT01152333|Drug|Exendin-(9-39) Acetate|Exendin (9-39) will be diluted in saline 0.9% and administered through IV infusion once for a maximum of 2.5 hours in length.
1877599|NCT01152333|Drug|Saline 0.9%|Saline will be administered through IV infusion once for a maximum of 2.5 hours in length
1877600|NCT01152346|Drug|Azacitidine for Injection|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
1877601|NCT01152346|Drug|Vidaza®|75 mg/m2 sc injection on Day 1 of either cycle 1 or cycle 2 per randomization assignment
1877602|NCT01152359|Behavioral|Choice|Participants are allowed to choose between a low-carbohydrate or a low-fat diet for weight loss after receiving information about these diets and their food preferences (Choice arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm have the option to switch diets at 12 weeks.
1877603|NCT01152359|Behavioral|Control|Participants are randomly assigned to (rather than getting to choose, as in the experimental arm) a low-carbohydrate or a low-fat diet for weight loss (Control arm). Then they receive counseling on their chosen diet in a small group format. The low-carbohydrate diet limits carbohydrate intake to 20-40 grams/day initially. The low-fat diet restricts saturated fat to below 30% of daily calories and has a 500-1000 calorie deficit. Group sessions are every 2 weeks for 24 weeks then alternate with telephone calls every 2 weeks for 24 weeks. Phone calls focus on goal setting to maximize weight loss. Participants also receive counseling on behavioral techniques and physical activity. Participants in this arm do not have the option to switch diets at 12 weeks.
1877604|NCT01152372|Procedure|Insulin, glucose and staple isotopes|
1877605|NCT01152385|Drug|AZD1656|Oral tablet administered twice daily during 4 months
1877606|NCT01152385|Drug|Placebo|administered twice daily during 4 months
1877607|NCT01152398|Biological|MVA-BN-HER2|experimental vaccine, subcutaneous injection q4weeks x6
1877608|NCT01152411|Other|Autologous bone marrow stem cells|Bone marrow stem cells; Single dose; Interventional fluoroscopy-guided injection into the renal artery.
1877609|NCT01152437|Drug|BIBW 2992|Patients receive BIBW 2992 tablets once daily, and can reduce dose for adverse event management
1877610|NCT01152437|Drug|Cetuximab|Patients receive cetuximab intravenously, once a week, every week
1877611|NCT01152450|Drug|Tiotropium 2.5 µg b.i.d|2.5 µg (two actuations of 1.25 µg) delivered via Respimat® inhaler
1877612|NCT01152450|Drug|Placebo|N/A (two actuations of placebo) delivered via Respimat® inhaler
1877613|NCT01152450|Drug|Tiotropium 5 µg q.d.|5 µg (two actuations of 2.5 µg) delivered via Respimat® inhaler
1877614|NCT01152463|Procedure|thoracic ultrasound|daily thoracic ultrasound evaluation of the chest
1877615|NCT01152476|Drug|remifentanil|General anesthesia is maintained witn sevoflurane and remifentanil.
1877616|NCT01152476|Drug|normal saline|General anesthesia is maintained with only sevoflurane and with normal saline instead of remifentanil
1877617|NCT01152489|Device|Device: Buzzy|"Buzzy, the vibrating cold pack, is held in place with a velcro strap or pressed by caretaker or nurse immediately prior and during immunizations. The vibration is activated and the device remains in place during the shot, moving locations if multiple shots are given. Distraction cards with pictures on one side and questions on the other are shown to the child while the caretaker asks the finding and seeking questions on the back."
1877618|NCT01152489|Device|Buzzy: sham device|The identical device without batteries or a cold pack is held in place proximal to the site with a velcro strap or pressed by parent or nurse immediately prior to immunizations. The device remains in place throughout the procedure, moving locations to complete multiple shots.
1877620|NCT01152528|Device|VA-SENSE|The VA-SENSE contains a strip of pH indicator (color indicator) that is sensitive to the acidity level. A change in the color of the strip due to changes in the acidity level of vaginal secretions absorbed in the panty liner clearly indicates high probability of bacterial or parasitic vaginal infection. Any color change that results from contact with urine will disappear 10 minutes of drying out, and then the color of the indicator strip will fade back to the original color (yellow).
1877621|NCT01152541|Drug|Riboflavin/Dextran|Administration of riboflavin/dextran every 2 minutes for the duration of UV exposure
1877622|NCT01152541|Drug|Hypotonic Riboflavin|Administration of hypotonic riboflavin every 2 minutes for the duration of UV exposure.
1877623|NCT01152554|Drug|TC-5214|Tablet, oral, twice daily for 52 weeks
1877624|NCT01152554|Drug|Placebo|Tablet, oral, twice daily for 52 weeks
1877625|NCT01152580|Dietary Supplement|melatonin|3mg p.o. at bedtime daily
1877626|NCT01152580|Dietary Supplement|sugar pill|lactose p.o. at bedtime daily
1877627|NCT01152593|Drug|Mupirocin|Intranasal cream given to patient after confirmation of colonization
1877628|NCT01152606|Drug|trastuzumab [Herceptin]|There is no planned investigational product or a treatment regimen prescribed by this protocol. Decision about a treatment regimen will be made according to the local practice and in the best interest of individual patients.
1877629|NCT01152619|Drug|Placebo|Subcutaneous repeated dose
1877630|NCT01152619|Drug|RO4989991|Subcutaneous repeated dose
1877631|NCT01158118|Drug|Sargramostim|
1877632|NCT01158118|Drug|Plerixafor|
1877633|NCT01158131|Behavioral|Balance after Baby Lifestyle Intervention Program|Participants in this intervention will receive support from a lifestyle coach and gain access to a website with online presentations that contain healthy eating and physical activity educational tips. Weekly phone conversations with the lifestyle coach, as well as logging diet and physical activity will also be required of intervention participants.
1877634|NCT01158144|Drug|Endostar|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Endostar 7.5 mg/m2 over 3 hours d1-14, Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Endostar 7.5 mg/m2 d1-14,Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
1877635|NCT01158144|Drug|Paclitaxel/Carboplatin|Patients with non-resectable non-small Cell Lung Cancer will receive thoracic radiation therapy 60-66 Gy over 30-33 fractions and concurrent with Paclitaxel 50 mg/m2 weekly over 1 hour, Carboplatin AUC = 2 mg/mL/min over 30 min weekly. Followed by Paclitaxel 175 mg/m2 d1 and Carboplatin AUC = 5 mg/mL/min d1 every 3 weeks for 2 cycles as consolidation treatment.
1877637|NCT01158170|Radiation|Prophylactic cranial irradiation|25GY/10fraction
1877638|NCT01158170|Drug|Erlotinib /Gefitinib|Erlotinib 150mg/d or Gefitinib 250mg/d until disease progression or intolerable toxicity
1877639|NCT01158183|Drug|BAY86-5046_Interferon-beta-1b|Electronic questionnaires
1877640|NCT01158196|Device|infra-red diode laser|"laser treatment of scar after keloid excision
laser treatment of surgery scar"
1877641|NCT01158209|Procedure|Endocervical samples|Endocervical samples collection during routine gynaecological examinations.
1877642|NCT01158222|Drug|sunitinib malate|Given orally
1877643|NCT01158222|Other|laboratory biomarker analysis|Correlative studies
1877644|NCT01158222|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
1877645|NCT01158222|Genetic|polymorphism analysis|Correlative studies
1877646|NCT01158235|Drug|LTX-109|1%, 2% and 3% Lytixar (gel formulation). TID for 3 days.
1877647|NCT01158248|Biological|panitumumab|
1877648|NCT01158248|Drug|cisplatin|
1877649|NCT01158248|Radiation|brachytherapy|
1877650|NCT01158248|Radiation|external beam radiation therapy|
1877651|NCT01158261|Biological|EVICEL ™ Fibrin Sealant (Human)|Commercial Evicel
1877652|NCT01158274|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
1877653|NCT01158274|Drug|capecitabine|Given orally
1877654|NCT01158274|Other|laboratory biomarker analysis|Correlative studies
1877655|NCT01158287|Drug|sorafenib tosylate|
1877656|NCT01158287|Other|laboratory biomarker analysis|
1877657|NCT01158300|Drug|VEGF inhibitor PTC299|This is a dose escalation study. Study participants will receive .6 or 1.2 mg/kg orally twice daily or 1.2, 1.5, or 2.0 mg/kg orally three times daily for four consecutive weeks (a course). In the absence of unacceptable toxicity or disease progression, treatment may continue for up to 12 courses (approximately one year)
1877658|NCT01158313|Dietary Supplement|Thickened supplement|New thickener to be mixed to liquid to obtain different viscosities such as nectar viscosity, honey viscosity, conservative spoon-thick viscosity (CST) and extreme spoon-thick viscosity (EST
1877659|NCT01158326|Drug|Resfenol|"Paracetamol (acetaminophen), chlorpheniramine maleate, phenylephrine hydrochloride.
10 ml of oral solution acetaminophen, chlorpheniramine maleate, phenylephrine hydrochloride every 6 hours for 48 hours."
1877660|NCT01158326|Other|Placebo|10 ml of oral placebo every 6 hours for 48 hours
1877661|NCT01158339|Behavioral|Arm 2: CBGT-ISE|Intervention with active performance of the feared movements during group sessions.
1877662|NCT01158339|Behavioral|Arm 1: CBGT|Intervention according to previously mentioned methods.
1877663|NCT01158352|Dietary Supplement|Nutritional supplementation formula|Nutritional supplementation formula
1877664|NCT01158352|Dietary Supplement|Placebo Comparator|Placebo low caloric formula (Powder added to liquids or food, without added vitamins and minerals
1877665|NCT01158365|Drug|LACTIC ACID (Dermacid)|Route of administration: local
1877666|NCT01158365|Drug|Glycerine Vegetal Soap Granado Traditional|Route of administration: local
1877667|NCT01158378|Device|Adherus Dural Sealant|In situ polymerizing sealant
1877668|NCT01158391|Device|NTrainer® Intervention|
1877669|NCT01158391|Device|Control Intervention|
1877670|NCT01158404|Drug|Notch Inhibitor|"Dose Escalation: 2-120 mg administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28 day cycle.
Dose Confirmation: Dose determined by dose escalation administered orally 3 times per week (Monday, Wednesday, Friday) for 4 weeks of a 28 day cycle.
Patients experiencing clinical benefit may continue treatment unless discontinuation criteria are met."
1877671|NCT01158417|Drug|Placebo|oral
1877672|NCT01158417|Drug|Resveratrol 40 mg oral three times a day|Drug
1877673|NCT01158417|Drug|Resveratrol 500 mg oral once daily.|Resveratrol 500 mg oral once daily.
1877725|NCT01160744|Biological|IMC-1121B (ramucirumab)|10 milligrams/kilogram (mg/kg) once every 3 weeks beginning Day 1, Cycle 1
1877674|NCT01158430|Behavioral|ACT group therapy|Group therapy (ACT) in groups of 9 patients in 9 weekly 3.5-hours sessions & 1 booster session 1 month after 9th session, a total of 35.5 hours
1877675|NCT01158443|Behavioral|Behavioral Activation Therapy|8 session, manualized intervention. Homework, short-term activities and goals specified, problem solving skills.
1877676|NCT01158443|Behavioral|Supportive Counseling|8 sessions of manualized supportive counseling. Frequency and duration are designed to match the Behavioral Activation arm.
1877677|NCT01160328|Drug|Leuprolide|7.5 mg - 1 month depot, 2 doses over 7 weeks
1877678|NCT01160328|Drug|Testosterone|7.5g - 1% testosterone gel, daily x 7 weeks
1877679|NCT01160341|Drug|Testosteron|Testosteron 250mg injection per 3-4 weeks for 6 months
1877682|NCT01160367|Other|TAILORED Patient Family Decision Making|Patient-family dyads will receive TAILORED intervention on health decision making
1877683|NCT01160367|Other|standard of care|Patient-family dyads will receive standard of care in health decision-making
1877684|NCT01160380|Drug|armodafinil|Armodafinil taken at 150 mg daily. Taken as three 50 mg tablets.
1877685|NCT01160380|Drug|Placebo|Placebo taken at 150 mg daily. Taken orally as three 50 mg tablets.
1877687|NCT01160419|Drug|Docetaxel 50 mg/m2, 1-hour-Infusion, day 1|50 mg/m2, 1-hour-Infusion, day 1
1877688|NCT01160419|Drug|Oxaliplatin 85 mg/m², 2-hour-Infusion, day 1|85 mg/m², 2-hour-Infusion, day 1
1877689|NCT01160419|Drug|Folinic acid 200 mg/m², 1-2-hour-Infusion, day 1|200 mg/m², 1-2-hour-Infusion, day 1
1877690|NCT01160419|Drug|5-FU 2600 mg/m², 24-hour-Infusion, day 1|2600 mg/m², 24-hour-Infusion, day 1
1877691|NCT01160432|Drug|Methadone, naloxone|Methadone 2 mg/ml in combination with naloxone 0,04 mg/ml daily according to patient`s individual dose. At first open label pilot using single (individual) dosage for 2 patients. After that crossover study using methadone 2 mg/ml in combination with naloxone 0,04 mg/ml compared to methadone 2 mg/ml alone in one week`s periods for four weeks.
1877692|NCT01160445|Drug|Zanolimumab|14 mg/kg as an intravenous infusion weekly (+/- 3 days) for 9 weeks.
1877693|NCT01160445|Drug|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses.
1877694|NCT01160458|Drug|IMC-A12|20 mg/kg intravenous over 60 minutes or not to exceed 25 mg/minute once every 3 weeks (+ or -1 day cycle 3 and beyond)
1877695|NCT01160484|Drug|DVD-R|40 mg dexamethasone will be administered IV on Days 1, 4, 8, and 11 of each cycle. 1.0 mg/m2 Bortezomib will be administered IV over 3 to 5 seconds followed by a standard saline flush, on Days 1, 4, 8, and 11 immediately following the dexamethasone infusion. 4.0 mg/m2 PLD will be given as a 90 minute infusion on Day 1 of Cycle 1 and subsequent doses may be administered over 30 to 60 minutes on Days 4, 8 and 11 of Cycle 1 and on Days 1, 4, 8, and 11 of each subsequent cycle, following the bortezomib administration. 10 mg/day lenalidomide will be administered PO on days 1-14 of a 28-day treatment cycle, followed by a 14-day rest period, following the PLD administration.
1877696|NCT01160588|Drug|Sertraline|Oral sertraline will be started at 25 mg/day, increasing on subsequent visits to 50, 75, 100, 125, 150, and 200mg/day) Unless adverse effects become problematic, the goal is for subjects to reach 200mg/day. Dosing of sertraline is flexible, based on tolerance (absence of side effects) and clinical response.
1877697|NCT01160601|Drug|Paclitaxel / Carboplatin|Patients will receive commercially available paclitaxel (200 mg/m2) and carboplatin (target area under the concentration-time curve [AUC] 6) on Day 1 of each 21 day cycle for up to 6 cycles.
1877698|NCT01160601|Drug|bavituximab|Patients will receive 3 mg/kg bavituximab, administered weekly until progression or toxicity.
1877699|NCT01160614|Drug|Oxycodone hydrochloride controlled-release (ORF) tablets|Oxycodone hydrochloride controlled-release (ORF) tablets (10 mg, 15 mg or 20 mg) taken every 12 hours
1877700|NCT01160627|Other|Hydration|Saline hydration
1877701|NCT01160627|Drug|Acetylcysteine|Acetylcystein tablets for 2 days
1877702|NCT01160627|Drug|Sodium bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours
1877703|NCT01160627|Drug|Combined Acetylcystein and Sodium Bicarbonate|Sodium bicarbonate 500 ml followed by 100 ml/hour for 5 hours combined with acetylcystein tablets for 2 days
1877704|NCT01160640|Drug|Ceftriaxone|ceftrixone 250mg IM single dose
1877705|NCT01160640|Drug|Doxycycline|Doxycycline 100 mg PO bid x 14 days
1877706|NCT01160640|Drug|Metronidazole|metronidazole 500 mg PO bid x 14 days
1877707|NCT01160640|Drug|Placebo Oral Capsule|placebo oral capsule PO bid x 14 days
1877708|NCT01160653|Device|FES-IM|implantable Functional Electrical Stimulation
1877709|NCT01160653|Other|Cognitive training|training of impaired cognitive processes
1877710|NCT01160666|Drug|Belimumab|Belimumab will be administered at 10 mg/kg at Days 0, 14, 28 and then every 28 days until week 24 for all patients and week 48 for those considered responders at week 28.
1877711|NCT01160692|Dietary Supplement|Multivitamin/Multimineral/Ginkgo (BAY 81-2775)|Multivitamin/Multimineral/Ginkgo (BAY 81-2775), daily oral intake of film coated tablets for 3 months
1877712|NCT01160692|Other|Placebo|Daily oral intake of matching placebo tablets for 3 months
1877713|NCT01160705|Drug|docetaxel|
1877714|NCT01160705|Genetic|RNA analysis|
1877715|NCT01160705|Genetic|reverse transcriptase-polymerase chain reaction|
1877716|NCT01160705|Other|circulating tumor cell analysis|
1877717|NCT01160705|Other|laboratory biomarker analysis|
1877718|NCT01160718|Drug|fulvestrant|Arm A: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days Arm B: Fulvestrant 500mg i.m. day 1, 15, day 1 of cycle 2, then every 28 +/- 3 days
1877719|NCT01160718|Drug|selumetinib|AZD6244 75 mg p.o. bid
1877720|NCT01160731|Drug|cisplatin|
1877721|NCT01160731|Drug|etoposide phosphate|
1877722|NCT01160731|Drug|panobinostat|
1877723|NCT01160731|Other|laboratory biomarker analysis|
1877724|NCT01160731|Other|pharmacological study|
1877847|NCT01161602|Other|Placebo|
1877728|NCT01160744|Drug|Cisplatin|75 mg/m² intravenous (IV) on Day 1 of each 21-day cycle
1877729|NCT01160744|Drug|Gemcitabine|1000 mg/m² on Days 1 and 8 of every 21-day cycle
1877730|NCT01160744|Drug|Carboplatin (AUC 5)|Day 1 of every 21-day cycle
1877731|NCT01160757|Device|ultrasound|ultrasound exposure on acute acne lesions
1877732|NCT01160770|Drug|Clobazam|Clobazam will be provided in 5 mg, 10 mg and 20 mg tablets and will be dispensed in bottles as needed at each visit. Bottles may be dispensed between visits if necessary. Subjects will start at a common dose level of 0.5 mg/kg, not to exceed 40 mg/day, and must maintain the dose level for 48 hours. After the first 48 hours of the treatment period, investigators will be able to increase, decrease or maintain the subject's dose, up to an approximate maximum daily dose of 2.0 mg/kg (maximum dose of 80 mg/day).
1877733|NCT01160796|Drug|placebo|1x14-day course of treatment during 4 cycles
1877734|NCT01160796|Drug|Lcr35®|1x14-day course of treatment during 4 cycles
1877735|NCT01160809|Other|Mosquito repellent|Mosquito repellent (Buzz Off jelly) every evening applied to face, neck, hands and legs
1877736|NCT01160822|Biological|Canakinumab|Intra-articular injection
1877737|NCT01160822|Drug|Placebo to canakinumab|Intra-articular injection
1877738|NCT01160822|Drug|Naproxen|Tablets for oral administration
1877739|NCT01160822|Drug|Placebo to Naproxen|Tablets for oral administration
1877740|NCT01160835|Procedure|total knee arthroplastyinstruments|Quadriceps-sparing arthrotomy with side-cutting instruments
1877741|NCT01160848|Drug|Area cleaned with saline water and occluded with Tegaderm|
1877742|NCT01160848|Drug|Area cleaned with saline water|
1877743|NCT01160848|Drug|Area cleaned with Ethyl alcohol solution|
1877744|NCT01160848|Drug|Visonac left on the skin for 24 hours in facial area one|
1877745|NCT01160848|Drug|Visonac wiped off after one hour|
1877746|NCT01160848|Drug|Visonac left on the skin 24 hours in facial area two|
1877747|NCT01160861|Drug|MEMP1972A|Repeating ascending dose
1877748|NCT01160861|Drug|placebo|Repeating ascending dose
1877749|NCT01160874|Other|Polysomnography|Sleep study monitoring
1877750|NCT01160874|Other|Maintenance Wakefulness Test|Sleep latency testing at 10 am, 12 am, 2 pm and 4 pm.
1877751|NCT01160874|Behavioral|Neuropsychological evaluation|Neuropsychological evaluation for cognitive functions study
1877752|NCT01160874|Other|Driving test on a simulator|Driving simulator test during wich a camera register different parameters as the position of the vehicle.
1877753|NCT01160900|Procedure|Coronary angioplasty all lesions|treatment by coronary angioplasty and drug eluting stent of all lesions, adjunctive use of prasugrel and bivalirudin
1877754|NCT01160913|Procedure|Continuous wound infusion|
1877755|NCT01160913|Procedure|Continuous wound|
1877756|NCT01160926|Drug|AZD6244|"Dose finding trial AZD6244 cohort 1 - 50mg bd AZD6244 cohort 2 - 75mg bd
Capsule form, given for 10 days as single agent then for 35 days in combination with standard chemoradiotherapy"
1877757|NCT01160926|Drug|Cediranib (AZD2171)|"10 days single agent dosing with Cediranib then 35 days in combination with standard chemoradiotherapy AZD2171 cohort 1 - 15mg od AZD2171 cohort 2 - 20mg od AZD2171 cohort 3 - 30mg od
Oral tablets"
1877758|NCT01160939|Other|low intensity exercise|exercise protocol with six stages of exercise (1. upper limbs, 2. inferiors, 3. walk 35 m, 4. ½ flight of stairs, 5. walk 200 m 6. a flight of stairs) with intensity between 2-6 metabolic equivalents
1877759|NCT01160952|Drug|itraconazole|the two groups are defined by different treatment duration
1877760|NCT01160965|Drug|0.5% levobupivacaine|15mls of a 5mg/ml solution of the local anaesthetic levobupivacaine given via the epidural catheter.
1877761|NCT01160965|Drug|0.75% Ropivacaine|15mls of a 7.5mg/ml solution of the local anaesthetic ropivacaine given via the epidural catheter.
1877762|NCT01160978|Drug|Simvastatin 80mg|The transplant recipients who have received an organ from donors treated with simvastatin 80 mg.
1877763|NCT01160978|Drug|Control Rx|The transplant recipients who have received an organ from non-treated donors.
1877764|NCT01160991|Procedure|Glucose clamp technique|euglycemic hyperinsulinemic clamp with target blood glucose of 90 mg/dl (5 mmol/l), followed by hyperglycemic clamp, target blood glucose of 180 mg/dl (10 mmol/l) for measurement of insulin sensitivity and insulin secretion
1877765|NCT01160991|Drug|Amisulpride|Single dose of amisulpride 200 mg p.o. given at 8:00 a.m.
1877766|NCT01160991|Drug|Olanzapine|Single dose of olanzapine 10 mg p.o. given at 8:00 a.m.
1877767|NCT01160991|Drug|Placebo|Placebo capsules are given at 8:00 a.m.
1877768|NCT01161004|Drug|Sugammadex - Nacl 9/00|"Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses.
Nacl 9/00: same volume as Sugammadex"
1877769|NCT01161004|Drug|Nacl 9/00 - sugammadex|"Nacl 9/00: same volume as Sugammadex
Sugammadex: 4 mg/kg when post tetanic count shows at least 1 or 2 responses; 2 mg/kg when Train of four shows at least 2 responses."
1877772|NCT01161030|Other|almonds|
1877773|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 2.5 mg, given once daily for 14 days; healthy young adult volunteers
1877774|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 7.5 mg, given once daily for 14 days; healthy young adult volunteers
1877775|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 6 mg, given once daily for 7 days, then 12 mg given once daily for 7 days; healthy young adult volunteers
1877776|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 3 mg, given once daily for 7 days, then 6 mg given once daily for 7 days; healthy elderly adult volunteers
1877777|NCT01161069|Drug|PF-03049423|PF-03049423 in oral solution, 5 mg, given once daily for 7 days, then 10 mg given once daily for 7 days; healthy elderly adult volunteers
1877778|NCT01161069|Drug|Placebo|Placebo in oral solution, given once daily for 14 days
1877779|NCT01161082|Drug|REGN727(SAR236553)|subcutaneous
1877780|NCT01161095|Device|LNG-IUS|Mirena (Bayer)- Levonorgestrel-Intrauterine System
1877781|NCT01161108|Drug|Fast Release Melatonin (FR MLT)|3mg capsules of melatonin will be used. The dose of FR MLT will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily.
1877782|NCT01161108|Drug|Fast Release Placebo|"A matching FR MLT placebo will be compounded by the SickKids research pharmacy.
The dose of Fast Release Placebo will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
1877783|NCT01161108|Drug|Timed Release Melatonin (TR MLT)|"3 mg capsules will be used.
The dose of TR MLT will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
1877784|NCT01161108|Drug|Timed Release Placebo|"A matching TR MLT placebo will be compounded by the SickKids research pharmacy.
The dose of Timed Release Placebo will be will be 3 mg for children less than or equal to 20 kg, and 6 mg for children greater than 20 kg. The study medication will be given one hour before bedtime, once daily."
1877785|NCT01161121|Drug|adenosine|Measuring FFR and Coronary Flow Reserve after administration of IV adenosine 140 mcg/kg/min for 2 minutes.
1877786|NCT01161121|Drug|regadenoson|Measuring FFR and Coronary Flow Reserve after administration of IV regadenoson 0.4 mg over 10 seconds.
1877787|NCT01161134|Drug|Meloxicam|Meloxicam Tablets 15 mg
1877788|NCT01161147|Drug|Meloxicam|Meloxicam Tablets 15 mg
1877789|NCT01161160|Biological|GSK Biologicals' GSK2340274A (two different formulations)|Intramuscular injection
1877790|NCT01161160|Biological|GSK Biologicals' - GSK2340272A|Intramuscular injection
1877791|NCT01161173|Drug|Erlotinib|Erlotinib was provided in the retail versions of the product.
1877792|NCT01161186|Drug|nab-paclitaxel, gemcitabine, capecitabine|{nab-paclitaxel: Intravenous, 100 to 150 mg/m2 over 30 minutes once per cycle.} {gemcitabine: Intravenous, 750 to 1000 mg/m2 at 10mg/m2/minute once per cycle.} {capecitabine: oral, 500 to 1000 mg/m2 b.i.d. 7 days per cycle}
1877793|NCT01161199|Procedure|Leukapheresis|Blood will be taken by a needle placed in one arm and processed through a machine, which spins the blood so that the white blood cells will be separated out in the machine for purposes of this research and the rest of the blood will be returned through a needle in the other arm.
1877794|NCT01161212|Other|Physical education sessions|3(60 minutes each) or 4 (45 minutes each) short sessions of physical education (PE) sessions
1877795|NCT01161212|Other|Physical education sessions|1 (3 hours) or 2 long PE sessions (1 hour and 30 minutes each)
1877796|NCT01161225|Behavioral|Peer-assisted asthma self-management program|Intervention group: An asthma self-management program (Power Breathing™) was implemented by trained peer leaders at an asthma day camp. The program consisted of 3 sessions (appx. 45-60 min/session): basic asthma education (pathophysiology, triggers); psychosocial issues of asthma; and asthma self-management (peak flow monitoring and medication). The program was delivered by trained peer leaders paired for each small group of 6-8 teens. Group activities involved discussion, strategic thinking, knowledge-testing games and role plays.
1877797|NCT01161225|Behavioral|Adult-led asthma self-management program|Control group: The group attended an adult-led day camp where 2 NPs and a MD offered didactic asthma education based on the Power Breathing™ program.
1877798|NCT01161238|Other|Monitored for limb volume|Subjects are monitored for limb volume change using bioimpedance analysis
1877799|NCT01161264|Biological|Influenza Vaccine (Surface Antigen, Inactivated) Ph.Eur, Formulation 2010/2011|Single 0.5 mL dose administered into the deltoid muscle of (preferably) the non-dominant arm on Day 1.
1877800|NCT01161277|Drug|Aripiprazole|Dose: 5-10 mg depending on subject weight
1877801|NCT01161277|Drug|Haloperidol|Dose: 1-2 mg depending on subject weight
1877802|NCT01161277|Drug|Placebo sugar pill|Dose: 1-2 pills depending on subject weight
1877803|NCT01161290|Behavioral|synchronous interactive audio/video telecommunication|4 weekly synchronous interactive audio/video sessions on self-care management for dyspnea provided via the Internet and free downloadable software (Skype) on patients' home computer
1877804|NCT01161316|Drug|mFOLFOX-6 + cetuximab until disease progression or early withdrawal.|"Treatment regimen:
mFOLFOX-6, day 1, every two weeks; OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours
Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
1877805|NCT01161316|Drug|8 cycles of mFOLFOX-6 + cetuximab, followed by cetuximab alone until disease progression or early withdrawal.|"Treatment regimen.
mFOLFOX-6. day 1 every two weeks. OXALIPLATIN 85 mg/m2; FOLINIC ACID 400 mg/m2; 5-FU 400 mg/m2 IV bolus; 5-FU 2400 mg/m2 continuous infusion for 46 hours
Cetuximab weekly. Cetuximab 400 mg/m2 the first time the treatment is administered; 250 mg/m2 for subsequent administrations."
1877806|NCT01161329|Other|High-Intensity Functional Exercise Programmes (HIFE)|Hife include functional exercises consisting of everyday tasks challenging leg strength, postural stability, and gait ability. All exercise shall be performed in weight-bearing positions, eg squats and walking over obstacles. HIFE are performed twice a week during 1 h. for three months in a group with 6-7 seven patients with stroke. Two physiotherapists lead the group and one physiotherapist select exercises for each participant according to their functional deficits. The exercises will be progressively increased in load and difficulty.
1877807|NCT01161355|Drug|AZD9668|Tablets of AZD9668 and IV dose of [C14]AZD9668
1877808|NCT01161368|Drug|Lapatinib, Vinorelbine|"Lapatinib 1250mg orally once daily continuously
plus
Vinorelbine 20 mg/m2 intravenously (IV) once weekly [Days 1 and 8] for 2 weeks, followed by a rest week in a 3-week cycle."
1877809|NCT01161381|Device|Estimation of nonlinear indices from Polysomnography|All subjects underwent full night polysomnography. Three nonlinear indices (Largest Lyapunov Exponent, Detrended Fluctuation Analysis and Approximate Entropy) were extracted from three biosignals (airflow from a nasal cannula, thoracic movement and Oxygen saturation) providing input to a data mining application for the creation of predictive models for AHI.
1877810|NCT01161394|Drug|Pioglitazone 15mg|
1877811|NCT01161394|Drug|pioglitazone 30mg|
1877812|NCT01161394|Drug|placebo|
1877813|NCT01161407|Dietary Supplement|1500 mg/d elemental calcium as calcium carbonate|500 mg elemental calcium as calcium carbonate given 3 times per day with meals for a total of 1500 mg/d elemental calcium. Given for 21 days in conjunction with a controlled diet.
1877814|NCT01161407|Dietary Supplement|Placebo|Placebo for calcium carbonate in same capsule form. Given 3 times per day with meals for 21 days in conjunction with a controlled diet.
1877815|NCT01161420|Device|Inspire Upper Airway Stimulation System|Inspire Upper Airway Stimulation System, is a permanent, implantable therapy device, which consists of three implantable components: IPG, stimulation lead, and a sensing lead. In additional the patient receives a remote to activate the therapy.
1877816|NCT01161433|Behavioral|Virtually delivered spirometry quality improvement program|"Sites in the intervention arm receive the virtually delivered QI program.
The program includes:
Spirometry Fundamentals™ CD-ROM, a computer-based CD-ROM training program that teaches primary care providers and their staff techniques required to perform high-quality spirometry tests, and proper interpretation of spirometric data;
Case-based, interactive webinars; and
an Internet-based spirometry quality feedback reporting system."
1877817|NCT01161446|Behavioral|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|Participants in this arm will be given access to home HIV self-testing kits with the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use with oral fluids. They will be trained to use this device to test themselves for HIV and be able to request up to one self-testing kit per month throughout follow-up.
1877818|NCT01161446|Device|Home HIV self-testing with OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test|The device is the home HIV self-testing kit that includes the OraQuick ADVANCE® Rapid HIV-1/2 Antibody Test for use on oral fluids. The kit itself is not the focus of this trial. As described in the Behavioral Intervention section, the intervention is having access to home self-testing for HIV.
1877819|NCT01161459|Drug|Tripterygium wilfordii|Tripterygium wilfordii 120mg/d Prednisone 30mg/d
1877820|NCT01161459|Drug|FK506|capsule
1877821|NCT01161472|Drug|4mg fesoterodine|4mg tablet once daily for 6 days
1877822|NCT01161472|Drug|8mg fesoterodine|4mg tablet once daily for 3 days followed by 8mg tablet once daily for 3 days
1877823|NCT01161472|Drug|alprazolam 1mg|1mg tablet once on last day of treatment period at clinic
1877824|NCT01161472|Drug|Placebo|Placebo tablet for fesoterodine once daily for 6 days and placebo tablet for alprazolam once on last day of treatment period at clinic
1877825|NCT01161485|Behavioral|HIV Testing and Counseling|A manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening.
1877826|NCT01161485|Behavioral|Contingency Management|In voucher-based CM programs, drug users who submit urine samples that are negative for specified drugs are reinforced with vouchers. Based on operant conditioning, CM rewards those who comply with the targeted behavior and does not reward when compliance is not achieved. In this study a mid-value reinforcement CM schedule will be used in order to balance community cost concerns with the need to show comparative efficacy in reducing meth use and concomitant sex risk behaviors in a largely unstudied risk group. Participants in the CM arm will be asked to come to the study site three times a week to leave a urine sample, get the result, and will then be offered a voucher if their urine is clean and given brief verbal feedback.
1877827|NCT01161485|Behavioral|Strengths-based case management|Strengths-based case management (SBCM) is a specific type of case management that is based on the following principles: 1) clients are most successful when they identify and use their strengths, abilities, and assets; 2) goal-setting is guided by the clients' perceptions of their own needs; 3) the client-case manager relationship is promoted as essential; 4) a creative approach to the use of the community will lead to the discovery of needed resources; and 5) case management is conducted in the community. It differs from more traditional case management models that emphasize resource brokerage and client advocacy in its recognition that only the individual can change his/her behavior.
1877828|NCT01161498|Biological|Talimogene Laherparepvec|Administered by intratumoral injection
1877829|NCT01161498|Radiation|Radiation|70 grays of radiation administered in 35 fractions over 7 weeks
1877830|NCT01161498|Drug|Cisplatin|Administered by intravenous infusion
1877831|NCT01161511|Biological|XmAb5574|Intravenous infusion of XmAb5574 administered weekly during two 28-day cycles with an additional dose being administered during the first week of Cycle 1. (Cycle 1 on Days 1, 4, 8, 15, 22; Cycle 2 on Days 1, 8, 15, 22)
1877834|NCT01161537|Drug|VX-770|Tablet.
1877835|NCT01161537|Drug|Placebo|Tablet.
1877836|NCT01161550|Drug|Granulocyte colony-stimulating factor (G-CSF)|
1877837|NCT01161550|Drug|Cladribine|
1877838|NCT01161550|Drug|Cytarabine|
1877839|NCT01161550|Drug|All-Trans Retinoic Acid (ATRA)|
1877840|NCT01161550|Drug|Midostaurin|
1877841|NCT01161563|Drug|Triptorelin pamoate|Triptorelin pamoate for injectable suspension 22.5 mg administered as a single intramuscular injection in either buttock
1877842|NCT01161563|Drug|Leuprolide acetate|Leuprolide acetate for injectable suspension 45 mg administered as a single subcutaneous injection in the upper- or mid-abdominal area.
1877843|NCT01161576|Genetic|AAVrh.10CUhCLN2 vector 9.0x10^11 genome copies|The experimental drug for this second generation study has a genome identical to that used in our previous study and delivers the same gene, but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). The first dose that was given to the first 6 subjects is 9.0x10^11(900,000,000,000 molecules of the drug) genome copies/subject. In regards to drug administrations, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes (2 locations at 2 depths through each hole), 3 burr holes per hemisphere.
1877844|NCT01161576|Genetic|AAVrh.10CUhCLN2 vector 2.85x10^11 genome copies|The experimental drug for this 2nd generation study has a genome identical to that used in our previous study and delivers the same gene but instead of an AAV2 capsid (protein shell of the virus), the new vector has the capsid of AAVrh.10, a clade E AAV derived from rhesus macaque (a species of Old World monkeys). Group B will receive a dose of 2.85x10^11 genome copies (285,000,000,000 molecules of the drug). In regards to drug administration, we propose to perform 2 series of 6 simultaneous administrations of vector for 75 min each. Each subject will receive the assigned dose of AAVrh.10CUhCLN2, divided among 12 locations delivered through 6 burr holes, 3 burr holes per hemisphere.
1877845|NCT01161602|Drug|Pumosetrag|
1877846|NCT01161602|Drug|Pumosetrag|
1877849|NCT01161615|Drug|MRX-7EAT|Application of up to two patches for up to 7 days.
1877850|NCT01161615|Drug|Placebo|Application of up to two patches for up to 7 days.
1877851|NCT01161628|Drug|Rituximab|Rituximab 375 mg/m2/dose x 4 weekly doses on days 1, 8, 15 and 22 and then at 3, 6, 9 and 12 months.
1877852|NCT01161641|Drug|ODSH at 0.125 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 1 of 0.125 mg/kg/h.
1877853|NCT01161641|Drug|ODSH at 0.375 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 3 of 0.375 mg/kg/h.
1877854|NCT01161641|Drug|ODSH at 0.250 mg/kg/h|ODSH 1000 mg vials containing 20 cc of normal saline (50 mg/ml) to be prepared for 96-h IV infusion with normal saline based on subject's weight and dose assigned by Study Cohort 2 of 0.250 mg/kg/h.
1877855|NCT01161654|Drug|naratriptan hydrochoride|2.5 mg tablet
1877856|NCT01161667|Drug|naratriptan hydrochloride|2.5 mg tablet
1877860|NCT01161706|Other|Vegetable Juice|Participants consumed vegetable juice daily in the amount of 0, 8 or 16 fluid ounces.
1877861|NCT01161719|Behavioral|parent training|Behavioral management skill training
1877862|NCT01161732|Procedure|Early surgery|Early surgery is performed within 2 months of randomization.
1877863|NCT01161758|Other|Passive cervical mobilisation|Passive cervical mobilization which involved an oscillatory grade III unilateral postero-anterior mobilization applied to the left C5/C6 segment. The mobilization consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
1877864|NCT01161758|Other|Manual contact|Manual contact control, which involved light manual contact on the left C5/C6 segment as if to perform the treatment technique. The light manual contact consisted of 3 periods of 1 minute applications with a resting period of 1 minute in between.
1877865|NCT01161771|Procedure|Cataract Surgery and Limbal relaxing incision|Cataract extraction and limbal-relaxing incisions
1877866|NCT01161784|Dietary Supplement|Probiotics fermented milk|80ml fermented milk containing min. 30 billion live L. casei Shirota strain, administered orally once a day for 4 weeks
1877867|NCT01161784|Dietary Supplement|Nutrient drink|80ml fermented milk without L. casei Shirota strain, administered orally once a day for 4 weeks
1877868|NCT01161810|Other|Routine post burn rehabilitation therapy|No testing outside of routine clinical rehabilitation will be performed
1877869|NCT01161836|Drug|Iniparib|"Solution for infusion
60-minute intravenous infusion"
1877872|NCT01161875|Device|Neurally Adjusted Ventilatory Assistance|"In ICU following abdominal aortic surgery, in extubated patient, non-invasive ventilation was performed as follows:
facial mask with non-invasive pressure support ventilation mode to define settings for helmet ventilation
helmet use with non-invasive pressure support ventilation mode to define adequate settings
helmet use with neurally adjusted ventilatory assist mode, based on previous settings"
1877873|NCT01161888|Drug|Imiquimod|250mg sachets to be applied at a start dose of 5 days a week. Dose will be adjusted using an algorithm according to tolerability.
1877874|NCT01161901|Procedure|blood sample|"This study's hypothesis is that patients with ARDS criteria and lobar morphology on CT scan present loss of aeration but no inflammatory pulmonary oedema, whereas patients with non lobar morphology on CT scan present both characteristics.
The primary purpose of our protocol is to show that the patients who respond to ARDS criteria and have a lobar morphology on CT scan do not have an elevation of the biomarkers specific to the pulmonary aggression of ARDS."
1877875|NCT01161914|Drug|Cerezyme®|administered by IV infusion for a dose of 60 U/kg
1877876|NCT01161914|Drug|ISU302|administered by IV infusion for a dose of 60 U/kg
1877877|NCT01161927|Drug|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
1877878|NCT01161927|Drug|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
1877879|NCT01161940|Drug|Nizatidine|Nizatidine Capsules 300 mg of Dr.Reddy's Laboratories Limited
1877880|NCT01161940|Drug|Axid|Axid 300 mg Capsules of Reliant Pharmaceuticals, US
1877881|NCT01161953|Genetic|Genetic Analysis|Perform Genome Wide Association Studies.
1877882|NCT01161966|Drug|Zonisamide|Zonisamide capsules 100 mg
1877883|NCT01161966|Drug|Zonegran|Zonegran Capsules 100 mg of EISAI INC
1877884|NCT01161979|Drug|Zonisamide|Zonisamide capsules 100 mg
1877885|NCT01161979|Drug|Zonegran|Zonegran Capsules 100 mg of EISAI INC
1877886|NCT01161992|Genetic|Genetic Analysis|Perform Genome Wide Association Studies.
1877888|NCT01162018|Procedure|acupuncture|The eligible women would be randomized and stratified by sleep problems to two arms: (Acupuncture Arm vs. Sham Acupuncture) with a goal of having 48 patients complete the study (we anticipate about 20% attrition rate). The study interventions will begin after patients completed their treatment. The placebo control for acupuncture will be a validated sham acupuncture control Assessments will be made with daily diaries and with weekly questionnaires. There are ten sessions each lasting approximately 20 minutes. All participants will have PSG data collected.
1877889|NCT01162018|Other|placebo|
1877890|NCT01162031|Drug|Velcade|IV
1877891|NCT01162044|Other|Computer game|Playing with specially designed computer game while in emergency room
1877892|NCT01162070|Other|Free strategy|Free strategy followed in order to make the etiological diagnosis, which means, investigators are free to perform any examination they thought necessary.
1877893|NCT01162070|Other|Standardized strategy|Etiological diagnosis made by following a standardized two-stage strategy: first-line assessment (listed examinations and then examinations directed by the clinical or para-clinical elements of orientation) and second or third-line assessment (examinations directed by the anatomo-clinical type of uveitis).
1877894|NCT01162096|Device|Haploidentical Allogeneic Transplantation|Patients undergoing reduced intensity haploidentical hematopoietic stem cell transplant from a partially matched related donor.
1877896|NCT01162122|Biological|MF59 adjuvanted trivalent subunit influenza vaccine (aTIV)|one dose 0.5 mL administered IM in the deltoid muscle of (preferably) the non-dominant arm
1877897|NCT01162122|Biological|Non-adjuvanted trivalent subunit influenza vaccine (TIV)|one 0.5 mL dose administered IM in the deltoid muscle of (preferably) the non-dominant arm
1877898|NCT01162135|Drug|Digoxin|"The participants will take study drug digoxin, which is approved by FDA for the treatment of CHF, 125 or 250 mcg orally daily, titrated to the level of 0.8 - 2 ng/ml for total of 6 cycles (4 weeks/cycle). The lower dose of digoxin (such as 125 mcg/day) will be chosen if serum level reaches 0.8 ng/ml already. Patients may continue another 6 cycles if evident of clinical benefit.
It is possible that some patients may need to receive 500 mcg per day to reach this targeted drug level. No further titration will be allowed beyond this FDA approved digoxin dose."
1877899|NCT01162148|Behavioral|Conventional or regular pulmonary rehabilitation program alone|Conventional or regular pulmonary rehabilitation program alone
1877900|NCT01162148|Device|very low load IMT (sham IMT) alone|very low load IMT (sham IMT) alone
1877901|NCT01162148|Device|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT|Conventional or regular pulmonary rehabilitation program + targeted inspiratory resistive or threshold IMT
1877902|NCT01162148|Device|Targeted inspiratory resistive or threshold IMT alone|Targeted inspiratory resistive or threshold IMT alone
1877903|NCT01162174|Dietary Supplement|Oligonol|
1877904|NCT01162200|Radiation|Stereotactic Body Radiation Therapy|3 dose cohorts. Patients in each dose cohort will all be treated as a single group for dose escalation. The starting dose for the dose escalation portion will be 6 Gy per fraction for 5 fractions (total dose = 30 Gy). Subsequent cohorts of patients will receive an additional 0.5 Gy per treatment (total 2.5 Gy per escalation).
1877905|NCT01162213|Dietary Supplement|Lychee Fruit Extract|placebo or 100, 200 and 600 mg of lychee fruit extract for 2 weeks with one week washout period between treatments 2000 mg of lychee fruit extract given at a single visit
1877906|NCT01162226|Behavioral|gait and balance training program|The intervention will be implemented via three 50-minute training sessions per week for 12 weeks. The games will be played when the subject is receiving the maximum benefit from their anti-parkinsonian medications. The control group and the intervention group will receive weekly telephone calls to inquire about medications and falls. At baseline and end of the 12 weeks, in-home testing will determine stride length and speed; standing balance eyes open and closed on flat and foam surface.
1877907|NCT01162239|Drug|Varenicline|All participants will receive 12 weeks of varenicline treatment at standard dosage of 1 mg bid.
1877908|NCT01162239|Behavioral|Individual counseling|Five 90 minute individual counseling sessions.
1877909|NCT01162239|Behavioral|Check-ins with medical staff|Monthly brief (10-15 minutes) meetings with medical staff.
1877910|NCT01162239|Behavioral|individual counseling|Eleven individual counseling sessions across a nine month period. Each session is 30-45 minutes in duration.
1877911|NCT01162252|Behavioral|Mindfulness-Based Stress Reduction|The standardized Mindfulness-Based Stress Reduction (MBSR) program is the primary training tool used to enhance mindfulness. The eight-week-long MBSR program is designed to teach subjects how to develop their inner resources in the service of taking better care of themselves. MBSR training includes the learning and refining of a range of skills aimed at increasing relaxation and awareness of physical experiences and sensations related to physical symptoms, emotions, and thoughts. Special emphasis is placed on movement, meditation, and breathing.
1877912|NCT01162252|Behavioral|Living Well|The Living Well (LW) program involves a series of informational presentations and group discussions on a variety of topics related to the promotion of health and well-being. The 8-week program is designed to provide participants with knowledge about ways to improve their physical and emotional health as a complement to traditional medical treatments.
1877913|NCT01162278|Radiation|SBRT|Single fraction SBRT
1877914|NCT01162304|Drug|Extended Release Oxycodone|40 mg tablets one to two every 12 hours, Immediate release 5mg pills 1-2 tablets every 6 hours
1877915|NCT01162304|Drug|Immediate Release Oxycodone|IR oxycodone will be distributed to subjects in 5 mg pills and they will be instructed to take 3-4 of these pills every 4 hours
1877916|NCT01162317|Other|Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represents a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes.
1877917|NCT01162317|Other|Sham Acupuncture|Treatments will be performed by the PI, who is a licensed physician acupuncturist and has practiced acupuncture independently for 5 years with about 4000 patient/visit treatment history. A total of 10 acupuncture treatments represent a reasonable approach to optimal duration of treatment. Acupoint selection will be based on a combination of standardization and individualization for best treatment effects. At least 5 standardized body and auricular acupoints will be selected. Standardized sterile, disposable acupuncture needles will be applied for 20 minutes. Each sham or real acupuncture needle will be applied through a tube as sham needles have blunt tip and telescopic shaft, the visual effect and percutaneous sensation of sham needle mimic the real needle penetration.
1878093|NCT01163617|Device|Adalimumab delivered in Physiolis syringe|Pre-filled Physiolis glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
1877918|NCT01162330|Other|Screening urine and saliva tests for congenital Cytomegalovirus|With consent for the study babies who are referred for further hearing tests will have a urine and saliva sample sent to be analysed for CMV infection
1877919|NCT01162382|Device|Transcranial Magnetic Stimulation|Four 100-second trains and then one 65-second train, with 30-second inter-train intervals, at 1 Hz and 120% of the resting motor threshold will be applied over the right dorsolateral prefrontal cortex. Subsequently, twenty-five 30-second trains, with a 30-second inter-train interval, at 10 Hz and 120% of the resting motor threshold will be applied over the left dorsolateral prefrontal cortex.
1877920|NCT01162395|Drug|AZD3514|Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
1877921|NCT01162421|Biological|adalimumab|Study drug will be provided to participants in Early Adalimumab arm as a sterile, preservative-free solution for subcutaneous injection, contained in a pre-filled syringe housed in a pen device (pre-filled pen). 40 mg of adalimumab will be administered subcutaneously at Baseline and then every other week for 24 months. Adalimumab may be initiated in participants in standard of care (SOC) arm after a minimum of 6 months of treatment recommended by their study doctor.
1877922|NCT01162421|Drug|Methotrexate|Participants in both arms will receive a methotrexate regimen based on local guidelines and their study doctor's judgment.
1877923|NCT01162460|Drug|Eslicarbazepine acetate (BIA 2-093)|"Week 1 and 2 either 400mg/day Eslicarbazepine acetate (ESL) or 200mg/day Carbamazepine controlled release(CBZ-CR); Week 3 onwards either 800mg/day Eslicarbazepine acetate or 400mg/day CBZ-CR; this dose then to be maintained unless a subject has a seizure.
Subjects experiencing a seizure will have their assigned treatment dose increased to ESL 1200mg/day or CBZ 800mg/day.
Should a subject have another seizure, their assigned treatment is to be increased to ESL 1600mg/day or CBZ 1200mg/day.
Subjects who remain seizure free for 26 weeks at any dose in an Evaluation Period will continue to receive the allocated treatment under double-blind conditions."
1877924|NCT01162473|Dietary Supplement|Milk Oral Immunotherapy|Subjects will participate in a desensitization protocol over the course of 13 weeks to reach a goal maintenance dose of 8 ounces of cow's milk. Once reaching maintenance, subjects will continue on this dose for 12 additional weeks.
1877925|NCT01162473|Drug|Milk Protein Powder|Milk protein powder will be administered in incremental doses during the desensitization protocol.
1877926|NCT01162473|Other|Food Challenge|
1877935|NCT01162512|Behavioral|physical activity|physical activity counseling sessions will occur by telephone weekly for 2 months
1877936|NCT01162525|Procedure|Percutaneous tibial nerve stimulation (pTNS)|A 34 gauge needle in placed close to the tibial nerve about 2-3 cm above the ankle. A self-adhesive surface electrode is placed on the skin. Needle and surface electrode are connected to an electric stimulator and the stimulating current (0 - 10 mA) is increased in 20 steps. When the patient feels a tingling sensation in the foot, stimulating current is set back for one step and the treatment is started (30 min stimulation).
1877937|NCT01162551|Drug|Sirolimus and Methotrexate|"Single Arm Efficacy Trial:
Sirolimus: Oral bolus on day 1, then daily oral dose days 2-28. Dose will be altered to maintain a sirolimus trough level between ≥ 8 and ≤ 13. Trough levels will be checked weekly.
Methotrexate: Oral 20 mg/m2/week on Days 2, 9, 16, 23.
One cycle is 28 days."
1877938|NCT01162564|Device|NG-TSM|Flexible Composite Next Generation Tissue Separating Mesh
1877939|NCT01162577|Behavioral|Weight Concerns|Standard Quitline plus weight coaching
1877940|NCT01162590|Biological|Rotarix ™|Oral, single dose
1877941|NCT01162590|Biological|Placebo|Oral, single dose
1877942|NCT01162603|Device|Goldmann and Perkins applanation tonometry|IOP values will be assessed by the means of Goldmann or Perkins applanation tonometry at the following time-points: 10AM (± 1 hour), 2PM (± 1 hour), 6PM (± 1 hour), 10PM (± 1 hour), 2AM (± 1 hour) and 6AM (± 1 hour) after three months of treatment
1877943|NCT01162603|Drug|TAFLUPROST 0.0015% EYEDROPS|Tafluprost 0.0015% preservative-free ophthalmic solution
1877944|NCT01162603|Drug|LATANOPROST 0.005% EYEDROPS|Latanoprost 0.005% preservative-added ophthalmic solution
1877945|NCT01162616|Dietary Supplement|labeled iron solutions|labeled iron as 2 mg 58FeSO4, 57FeSO4 or 54FeSO4 per test portion (50g sorghum) 2 mg labeled iron as NaFeEDTA per test portion (50g sorghum)
1877946|NCT01162629|Device|Osteon bone graft|Osteon bone substitute placed to a height of 2 mm above the top of the dental implant
1877947|NCT01162642|Dietary Supplement|Green Tea|Green Tea 4 cups daily
1877948|NCT01162642|Other|Placebo|4 cups placebo tea for 6 weeks
1877949|NCT01162655|Behavioral|Cognitive-behavioral therapy for Insomnia (CBT)|6-week course of CBT delivered either using internet or telehealth
1877950|NCT01162681|Drug|A-623|High dose given subcutaneously once a week for up to 52 weeks
1877951|NCT01162681|Drug|A-623|Low dose given subcutaneously once a week for up to 52 weeks
1877952|NCT01162681|Drug|A-623|High dose given subcutaneously once every 4 weeks for up to 52 weeks
1877953|NCT01162681|Other|Placebo Comparator|Placebo comparator is a matched volume given subcutaneously once a week or once every 4 weeks for up to 52 weeks
1877954|NCT01162694|Other|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
1877955|NCT01162694|Other|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
1877956|NCT01162707|Device|CardioMEMS HF Pressure Measurement System|Implant sensor into the left or right pulmonary artery. Measure pulmonary artery pressure
1877957|NCT01162720|Procedure|Long duration tourniquet|Patients randomised to this arm will have the tourniquet applied at the commencement of surgery and removed prior to wound closure.
1877958|NCT01162720|Procedure|Short duration tourniquet|Patients assigned to this arm will have the tourniquet applied during cement fixation of the prosthesis only (ie removed just prior to wound closure).
1877959|NCT01162733|Drug|Vancomycin|15mg/kg
1877960|NCT01162733|Drug|Vancomycin|30mg/kg
1877961|NCT01162746|Drug|Intravitreal dexamethasone and intravitreal ranibizumab|"Patients will receive intravitreal dexamethasone using a special drug delivery system and same day intravitreal ranibizumab.
Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual decrease or persistence of sub-/intraretinal fluid is detected in the examination. At month 3, 6, 9 and 12 further treatments with intravitreal dexamethasone in combination with intravitreal ranibizumab are given if leakage is detected in fluorescein or indocyanine green (FLA or ICG) angiography, in case of further vision decrease or persistence of sub-/intraretinal fluid in OCT."
1877962|NCT01162746|Drug|Intravitreal ranibizumab|Patients will receive intravitreal ranibizumab monotherapy (cohort 3). Study medications are initially given at the baseline visit. At each subsequent monthly follow-up visit, ranibizumab is administered if further visual deterioration or persistence of sub-/intraretinal fluid is detected in the examination
1877963|NCT01162759|Behavioral|Home Blood Pressure Monitoring|Home blood pressure readings are taken at least 3 times a week, uploaded to a Microsoft Health Vault account through American Heart Association Heart360 at least 1 time per week. Patients are followed by a clinical pharmacist, with physician oversight, who will make adjustments to antihypertensive medications or suggest additional medications using national JNC VII and KPCO hypertension guidelines.
1877964|NCT01162785|Drug|SCH 721015|Intravesical SCH 721015 (on Day 1 and 4) at a dose concentration of 3x1011particles/mL given in a 75 mL total volume. Administered into bladder through a urinary catheter, 75 mL will be instilled, left in the bladder for 1 hour, plus or minus 10 minutes. During the dwell time, subject will be repositioned from left to right, back and abdomen to maximize bladder surface exposure, approximately every 15 minutes.
1877965|NCT01162798|Other|infant formula|test infant formula fed to infants until 6 months corrected gestational age
1877966|NCT01162798|Other|control infant formula|commercially available infant formula
1877967|NCT01155466|Drug|Preladenant 2 mg tablet|one 2 mg tablet orally twice daily
1877968|NCT01155466|Drug|Preladenant 5 mg tablet|one 5 mg tablet orally twice daily
1877969|NCT01155466|Drug|Preladenant 10 mg tablet|one 10 mg tablet orally twice daily
1877970|NCT01155466|Drug|Placebo to Preladenant Tablet|one tablet orally twice daily
1877971|NCT01155466|Drug|Rasagiline 1 mg capsule|one 1 mg capsule orally in AM
1877972|NCT01155466|Drug|Placebo to Rasagiline capsule|one capsule orally in AM
1877973|NCT01155479|Drug|Preladenant 2 mg tablet|Preladenant 2 mg oral tablet taken twice daily
1877974|NCT01155479|Drug|Preladenant 5 mg tablet|Preladenant 5 mg oral tablet taken twice daily
1877975|NCT01155479|Drug|Preladenant 10 mg tablet|Preladenant 10 mg oral tablet taken twice daily
1877976|NCT01155479|Drug|Rasagiline 1 mg capsule|Rasagiline 1 mg oral capsule taken once daily
1877977|NCT01155479|Drug|Placebo for Rasagiline 1 mg capsule|Placebo for rasagiline 1 mg oral capsule taken once daily
1877978|NCT01155479|Drug|Placebo for Preladenant|Placebo for preladenant 2 mg, 5 mg, or 10 mg oral tablet taken twice daily
1877979|NCT01155505|Drug|Lenalidomide (CC-5013)|CC-5013 given PO daily on D1-D14 every 21 days and Paclitaxel administered IV over 1 hour on d1 and 8 every 21 days until tumor progression or unacceptable toxicity
1877980|NCT01155518|Drug|testosterone|intramuscular every 2 weeks
1877981|NCT01155518|Drug|clomiphene|thrice a week
1877982|NCT01155518|Drug|placebo|intramuscular saline injections every 2 weeks
1877983|NCT01155518|Drug|placebo|oral
1877984|NCT01155531|Drug|Sertraline plus Telenzepine|oral sertraline tablets at 0, 50, 100, or 150/day plus oral telenzepine capsules at 0, 1, 2, or 3 mg/day for 7 days in each combination
1877985|NCT01155544|Behavioral|Behavioral Intervention|Preventing recurrence of substance use.
1877986|NCT01155557|Device|Specific Strength Training|10 weeks of progressive specific strength training for neck and shoulder muscles.
1877987|NCT01155557|Behavioral|Lifestyle Counseling|10 weeks of counseling by nurse and physiotherapist in lifestyle changes.
1877988|NCT01155583|Drug|azacitidine|Given SC
1877989|NCT01155583|Drug|lenalidomide|Given orally
1877990|NCT01155583|Drug|dexamethasone|Given orally
1877991|NCT01155583|Other|DNA methylation analysis|Correlative studies
1877992|NCT01155583|Other|gene expression analysis|Correlative studies
1877993|NCT01155583|Other|bone marrow aspiration|Correlative studies
1877994|NCT01155583|Other|immunohistochemistry staining method|Correlative studies
1877995|NCT01155583|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
1877996|NCT01155583|Other|flow cytometry|Correlative studies
1877998|NCT01155609|Procedure|quality-of-life assessment|Ancillary studies
1877999|NCT01155609|Procedure|management of therapy complications|Discontinue supplement; treat symptomatically
1878000|NCT01155609|Dietary Supplement|L-lysine|Given PO
1878094|NCT01163617|Device|Adalimumab delivered in current autoinjector|Pre-filled currently approved autoinjector containing 40 mg/0.8mL adalimumab to be injected subcutaneously
1878001|NCT01155622|Procedure|Endovascular Cooling|Infusion of <8°C cold saline followed by the implantation of the Icy 9.3F 38-cm catheter (ZOLL Medical Corporation, Chelmsford, MA) placed in the inferior vena cava through a femoral vein connected to the Thermogard XP Temperature Management System (ZOLL Medical Corporation). Cooling was set at a maximum rate with a target temperature of 32°C or 34°C according to randomization.
1878002|NCT01162811|Behavioral|visualization together with structured behavioural attention.|visualization and relaxation exercises together with structured behavioural attention.
1878003|NCT01162824|Drug|Acetylcholine|Incremental doses of 2, 20 and 100 µg of ACH will be injected into the left coronary artery (LCA) via the diagnostic catheter for 3 minutes each. After that 80 µg of ACH will be injected into the right coronary artery. Coronary angiography will be performed after each 3 minute dose period. After the test or when intolerable chest pain due to coronary spasm occurs, 0.2 mg of glyceryltrinitrate will be injected into each vessel. During the test, heart rate, blood pressure and ECG will be monitored continuously.
1878004|NCT01162824|Drug|Adenosine|Coronary blood flow velocity measurements will be performed in the mid segment of the left anterior descending artery with a 0.014-in intracoronary Doppler guidewire connected to the corresponding interface. Measurements will be obtained after the administration of nitroglycerin, at baseline and during maximal hyperaemia. Sustained intravenous administration of adenosine - an arteriolar vasodilator- will be used to induce maximal hyperaemia (140-180µg/kg/min).
1878005|NCT01162837|Device|BEAM device|A red/blue LED device for the treatment of acne
1878006|NCT01162850|Dietary Supplement|Polypodium Leucotomos|Oral capsule at 240 mg taken twice a day for 12 weeks
1878007|NCT01162850|Dietary Supplement|Placebo|240 mg Placebo taken orally twice daily created by company which manufactured active ingredient
1878008|NCT01162863|Drug|Lubiprostone|lubiprostone taken either at a dose of 8 mcg orally twice daily (BID) for 28 days or 24 mcg orally once daily (QD) for 28 days
1878009|NCT01162863|Drug|Placebo|taken orally for 28 days
1878010|NCT01162863|Other|Smartpill wireless motility capsule|Ingestion of a small non-digestible capsule that measures temperature, pH and pressure of the immediate surrounds as it passes through the GI tract eventually exiting the body through the anus
1878011|NCT01162876|Drug|saxaglipitin|oral administration of 5 mg tablet before breakfast for 14 consecutive days
1878012|NCT01162889|Drug|Placebo SC Injection|Single injection
1878013|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single intravenous infusion, 60 minute duration
1878014|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
1878015|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
1878016|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
1878017|NCT01162889|Drug|ATR-107 (PF-05230900) SC Injection|Single subcutaneous injection
1878018|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single subcutaneous injection
1878019|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
1878020|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
1878021|NCT01162889|Drug|Placebo IV Infusion|Single intravenous infusion, 60 minute duration
1878022|NCT01162889|Drug|ATR-107 (PF-05230900) IV Infusion|Single intravenous infusion, 60 minute duration
1878023|NCT01162902|Drug|Diltiazem treated group|Diltiazem 180mg for 9 months
1878024|NCT01162902|Drug|Bisoprolol treated group|Bisoprolol 5mg for 9 months
1878025|NCT01162902|Drug|Candesartan treated group|Candesartan 32mg for 9 months
1878026|NCT01162915|Biological|Autologous bone marrow-derived mesenchymal stem cells.|Intrathecal infusion of a single dose of ex vivo expanded MSC.
1878027|NCT01162928|Drug|Nutriflex Omega special + Oxepa|3-chamber-bag combined with enteral nutrition
1878028|NCT01162928|Drug|Nutriflex Lipid special + Pulmocare|3-chamber-bag combined with enteral nutrition
1878029|NCT01162941|Other|Steroid refractory ITP|a platelet count less than 20X109/L despite of treatment with full dose of steroid (prednisolone 1mg/kg for at least 4 weeks)
1878030|NCT01162954|Drug|DA-6034|
1878031|NCT01162954|Drug|Placebo|
1878032|NCT01162967|Drug|Benznidazole|Standard dosage
1878033|NCT01162967|Drug|Posaconazole|
1878034|NCT01162993|Procedure|Spinal Cord Stimulation|The intervention is spinal cord stimulation and will be used for 2 weeks trial stimulation. After clinical successful pain relief (≥50% relief of pain intensity on a weighted numeric rating scale (NRS) or a score of ≥6 on a seven-point Likert scale (1=very much worse; 7=very much improved) of the PGIC scale for pain and sleep) a definite spinal cord system will be implanted.
1878035|NCT01163006|Other|Polydextrose and soluble gluco fibre|Polydextrose and soluble gluco fibre
1878036|NCT01163032|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 6 months
1878037|NCT01163032|Drug|Placebo|Placebo capsules, PO daily for 6 months
1878038|NCT01163045|Procedure|thyroidectomy|total thyroidectomy and lobectomy
1878039|NCT01163071|Drug|ABI-011|ABI-011
1878044|NCT01163097|Drug|Palifermin|40 µg/kg IV bolus injections for three consecutive days
1878045|NCT01163097|Drug|Heparin|Heparin continuous IV infusion
1878046|NCT01163110|Dietary Supplement|Realbuild|Patient with chemotherapy induced thrombocytopenia takes RNA fragments orally to accelerate time to platelet recovery
1878047|NCT01163253|Drug|CP-690,550|5 mg oral BID
1878048|NCT01163253|Drug|CP-690,550|10 mg oral BID
1878049|NCT01163266|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
1878050|NCT01163266|Drug|Placebo|Vortioxetine placebo-matching capsules
1878095|NCT01163617|Device|Adalimumab delivered in Physiolis autoinjector|Pre-filled Physiolis autoinjector containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
1878096|NCT01163630|Drug|esomeprazole/ASA Fixed Dose Combination (FDC)|esomeprazole 20 mg/ASA 81 mg oral capsule
1878097|NCT01163643|Drug|0.3% BOL-303242-X ophthalmic suspension|0.3% BOL-303242-X ophthalmic suspension BID for 12 weeks.
1878051|NCT01163279|Behavioral|Real world strategy approach|The key features of the protocol are: i. Participants are actively engaged in selecting their treatment goals. The research clinician will work with the participants to identify five specific, measurable real-world goals using a standardized semi-structured interview, the Canadian Occupational Performance Measure. Three of these will be training goals, two will not be trained but evaluated post-intervention for evidence of generalization and transfer to non-trained tasks; ii. A global problem solving approach is used (Goal- Plan- Do- Check). Participants are guided by the trainer to apply this strategy to their goals.
1878052|NCT01163279|Behavioral|Psychosocial Education|The active comparator uses an information-based format and is designed to engage participants without providing any specific training techniques or strategies. During weekly sessions, participants will receive factual information on brain structure and function, age-related cognitive changes, and general brain health issues and will spend time doing non-specific cognitive exercises including crossword and Sudoku puzzles. Homework will consist of reading assignments related to the session topics.
1878053|NCT01163305|Drug|Chemotherapy|The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
1878054|NCT01163331|Other|Singing Therapy|Singing therapy as a way to improve voice quality
1878055|NCT01163357|Drug|bortezomib|Given IV
1878056|NCT01163357|Drug|fludarabine phosphate|Given IV
1878057|NCT01163357|Other|melphalan|Given IV
1878058|NCT01163357|Radiation|total marrow irradiation|Undergo TMI
1878059|NCT01163357|Drug|tacrolimus|Given IV and orally
1878060|NCT01163357|Drug|sirolimus|Given orally
1878061|NCT01163357|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
1878062|NCT01163357|Other|laboratory biomarker analysis|Correlative studies
1878063|NCT01163370|Dietary Supplement|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
1878064|NCT01163370|Other|exercise training|resistance training twice a week for 24 weeks
1878065|NCT01163370|Other|placebo (dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
1878066|NCT01163383|Drug|131 I-Metaiodobenzylguanidine (131 I-MIBG)|131 I-MIBG 1-18mCi/kg given intravenously on day 1. Subjects may receive multiple courses every 4-8 weeks depending on the dose given.
1878067|NCT01163383|Drug|131 I-MIBG|131-I-MIBG will be infused intravenously over 60-90 minutes once per course. The dose will be determined by the treating physician.
1878068|NCT01163396|Drug|Bevacizumab|
1878069|NCT01163396|Drug|Irinotecan|
1878070|NCT01163396|Drug|Oxaliplatin|
1878071|NCT01163396|Drug|5-fluorouracil/leucovorin|
1878072|NCT01163409|Procedure|exercise training|exercise training comprises aerobic and strength training
1878073|NCT01163409|Procedure|acupuncture|acupuncture involves two sessions per week, during 14 weeks.
1878074|NCT01163409|Procedure|Exercise, Acupuncture and Fibromyalgia|Set of real acupuncture treatment and supervised aerobic exercise have better efficacy in pediatric patients with fibromyalgia versus treatment with sham acupuncture and supervised aerobic exercise, as well as treatment versus combination with aerobic exercise and resistance exercise the major muscle groups, both supervised versus group control, we just get guidance for physical activity.
1878075|NCT01163422|Device|Implantation of 3-chamber pacemaker|Implantation of pacemaker with leads in right atrium, right ventricle, and coronary sinus (left ventricle) with the aim of providing right ventricular resynchronization therapy (RVRT); this is accomplished by pacing the right ventricle ahead of the left ventricle, e.g., by setting (shortening) the A-V delay between right atrium and right ventricle to an optimal level.
1878076|NCT01163435|Drug|high dose dual therapy|rabeprazole 20 mg qid,amoxicillin 750 mg qid for 14 days
1878077|NCT01163435|Drug|sequential therapy|rabeprazole 20 mg, amoxicillin 1000 mg, bid for 5 days, then rabeprazole 20 mg , metronidazole 500 mg, clarithromycin 500 mg, bid for next 5 days
1878078|NCT01163435|Drug|clarithromycin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, clarithromycin 500 mg, bid for 7 days
1878079|NCT01163435|Drug|levofloxacin-based triple therapy|rabeprazole 20 mg, amoxicillin 1000 mg, levofloxacin 250 mg, bid for 7 days
1878080|NCT01163448|Radiation|High-Dose Single-Fraction Image-Guided Radiotherapy for Men Undergoing Radical Prostatectomy|A baseline DCE-MRI will be obtained prior to the day of radiotherapy treatment. Immediately following the delivery of radiotherapy another DCE-MRI will be performed to assess for perfusion changes in the prostate resulting from irradiation. RP will be completed within 6 weeks (+ 2 weeks) of radiation and the RP specimen will be assessed for radiation treatment effect and other pathologic parameters (including surgical margin status) by a dedicated genitourinary pathologist. Following RP, participants will follow-up with their surgeon every 3 months for one year, with visits alternating between the urologist and the radiation oncologist. After the first year follow-up will occur at 6 month intervals until the patient is 3 years out from surgery.
1878081|NCT01163461|Behavioral|speech therapy|individuals will receive 60 hours of behavioral speech therapy
1878082|NCT01163474|Other|Evaluate video clinic visit prior to Face-to-Face usual care visit|Evaluate video clinic visit prior to Face-to-Face usual care visit
1878083|NCT01163487|Drug|Dichloroacetate|25-50mg/kg per day; oral
1878084|NCT01163487|Device|EF5|21 mg/kg; IV
1878085|NCT01163500|Dietary Supplement|Coenzyme Q10|coenzyme Q10 supplements 60 mg/day and 150 mg/day
1878086|NCT01163500|Other|Placebo|Placebo controlled (dextrin)
1878087|NCT01163526|Procedure|CT perfusion|
1878088|NCT01163552|Procedure|Surgical debulking and Intrathoracic Hyperthermic Chemotherapy|Surgical debulking of intrathoracic metastases will be performed, followed by perfusion of the chest with heated Cisplatin for 60 minutes.
1878089|NCT01163565|Device|Ligasure Device|Ligasure device used to seal blood vessels during left or right side of a total thyroidectomy. Traditional method of hand ties/clips on contralateral side.
1878090|NCT01163604|Drug|Argatroban|Intravenous Infusion, 20mg/day for 2 days before and 3 days after stenting, (10mg/3h, twice a day), with accompanied aspirin and clopidogrel treatment
1878091|NCT01163604|Drug|non-argatroban treated group|Patients who underwent intracranial and extracranial artery stenting were randomly chosen to receive only aspirin and clopidogrel treatment.
1878092|NCT01163617|Device|Adalimumab delivered in current syringe|Pre-filled currently approved glass syringe containing 40 mg/0.8 mL adalimumab to be injected subcutaneously
1878098|NCT01163643|Drug|2% BOL-303242-X ophthalmic suspension|2% BOL-303242-X ophthalmic suspension BID for 12 weeks.
1878099|NCT01163643|Drug|Placebo Comparator: Vehicle|Placebo Comparator: Vehicle BID for 12 weeks.
1878100|NCT01163643|Drug|1% BOL-303242-X ophthalmic suspension|1% BOL-303242-X ophthalmic suspension BID for 12 weeks.
1878101|NCT01163643|Drug|2% BOL-303242-X ophthalmic suspension AM|2% BOL-303242-X ophthalmic suspension once daily (QD) AM and vehicle QD in PM for 12 weeks.
1878102|NCT01163643|Drug|2% BOL-303242-X ophthalmic suspension PM|Vehicle QD AM and 2% BOL-303242-X ophthalmic suspension QD in PM for 12 weeks.
1878103|NCT01163656|Device|Miller Laryngoscope|Device is used to facilitate tracheal intubation.
1878104|NCT01163656|Device|Glidescope Cobalt Video Laryngoscopes|The laryngoscope design with the integration of video technology into the laryngoscope blade.
1878107|NCT01163695|Behavioral|Children's development account|Children in the experimental condition (the SUUBI program) received, in addition to the usual care, an economic empowerment intervention aimed at promoting asset accumulation for families—and consisting of three major components: 1) workshops focused on asset-building and future planning; 2) a monthly mentorship program for adolescents with peer mentors on life options; and 3) a Child Development Account (CDA), dedicated to paying for secondary schooling, vocational training and/or a family small business. The CDAs were matched savings accounts, with a match rate of 2:1 as an incentive for participants to save, but with a limit on the maximum savings that could be matched (the match cap, in this case, was equivalent to $10 a month).
1878108|NCT01163708|Device|Prophecy Technique|Navigation computerised system is used intraoperatively to correct implant the Advance knee implant. Prophecy is a pre-alignment technique where a pre-op MRI or CT scan is used to manufacture personalised cutting blocks to assist the surgeon in correct implanting the Advance knee implant intraoperatively
1878109|NCT01163708|Device|Navigation System|
1878110|NCT01163721|Drug|Ranolazine|Ranolazine ER 1000 mg (two 500 mg tablets) administered orally twice daily
1878111|NCT01163721|Drug|Placebo|Placebo to match ranolazine administered orally twice daily
1878112|NCT01163734|Drug|Ranolazine|Intravenous treatment followed oral treatment for 13 days.
1878113|NCT01163734|Other|Saline 0.9% and placebo tablet|Intravenous treatment followed by oral treatment for 13 days
1878114|NCT01163747|Biological|tocilizumab|Intravenous repeating dose
1878115|NCT01163747|Drug|methotrexate|A stable dose of between 7.5 and 25 mg/week, oral or parenteral.
1878116|NCT01163747|Biological|23-Valent Pneumococcal Polysaccharide Vaccine|Intramuscular or subcutaneous injection
1878117|NCT01163747|Biological|Tetanus Toxoid Adsorbed Vaccine|Intramuscular injection
1878118|NCT01163760|Device|etafilcon A|daily disposable contact lens
1878119|NCT01163760|Device|ocufilcon D|daily disposable contact lens
1878120|NCT01163773|Other|MILK|"Consumption of the 2 experimental diets
Milk diet
Control diet"
1878121|NCT01163786|Drug|Bortezomib|Each patient will receive 2 cycles of Bortezomib. For each cycle Bortezomib wil be given once a week, 1.3mg/m2 for 4 weeks with 2 weeks between each cycle.
1878122|NCT01163799|Drug|Alefacept (ASP0485)|Withdrawal of calcineurin inhibitor at 30 days post-transplant. Administer Alefacept 7.5 mg post-op day 0, post-op day 2 given IV; Alefacept 15 mg SQ X 12 weeks, then monthly until Month 12.
1878123|NCT01163812|Procedure|Laparoscopic D2 distal gastrectomy|"Under general endotracheal anesthesia, Five or six ports are used. Lymph node dissection and ligation of vessels are carried out in the laparoscopic field. A partial omentectomy encompassing perigastric nodes is performed laparoscopically. D2 lymphadenectomy is carried out according to the guidelines of the The Japanese Research Society for Gastric Cancer for the corresponding location of the primary tumor. A 5- to 6-cm small incision is made transversely in RUQ of the abdomen. Through the incisional window, the stomach is removed from the abdominal cavity and resected. A Billroth-I gastroduodenostomy using an EEA stapler and GIA or a Billroth-II gastrojejunostomy with a hand-sewing technique is performed. The abdomen is then closed after hemostasis is achieved."
1878124|NCT01163825|Drug|Nerve Growth Factor|Encapsulated cell biodelivery of Nerve Growth Factor (NGF) to the basal forebrain nuclei of the brain by multiple implantable devices housing NGF-secreting human cells
1878125|NCT01163838|Biological|Placebo|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
1878126|NCT01163838|Biological|1 mg/kg every 2 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
1878127|NCT01163838|Biological|2 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
1878128|NCT01163838|Biological|4 mg/kg every 4 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
1878129|NCT01163838|Biological|4 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
1878172|NCT01164163|Other|pharmacological study|
1878173|NCT01164176|Drug|everolimus|
1878174|NCT01164176|Other|laboratory biomarker analysis|
1960281|NCT03248999|Diagnostic Test|rectal swab|stool samples by rectal swab
1878130|NCT01163838|Biological|8 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
1878131|NCT01163838|Biological|12 mg/kg every 8 weeks|Subjects will receive placebo or active treatment every 2 weeks for a total of 9 doses. Duration of IV infusion is 60 minutes. Total dose is based on subjects weight.
1878132|NCT01163851|Biological|4 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
1878133|NCT01163851|Biological|0.5 mg/kg|RN316 10 mg/ml vial sd. Infusion based on weight Infusion duration = 60 minutes.
1878134|NCT01163864|Behavioral|affect regulation training|8 sessions of a 1-hour long treatment intended to help women deal more effectively with negative affect; cognitive-behavioral smoking cessation intervention
1878135|NCT01163864|Behavioral|health and lifestyle|8 sessions of a 1-hour long treatment designed to help women improve their overall health; cognitive-behavioral smoking cessation intervention
1878136|NCT01163877|Dietary Supplement|Fe-57 orally, Fe-58 intravenously|Subjects will receive a test drink containing 3 mg Fe-57 in the form of labelled FeSO4 followed by 1 ml of an aqueous solution containing 50 μg Fe-58 as iron citrate.
1878137|NCT01163890|Behavioral|Work and Health Initiative|Telephone-based multi-modal intervention, consisting of: vocational coaching, cognitive-behavioral therapy strategies and care coordination strategies provided by specially-trained EAP counselors
1878138|NCT01163890|Behavioral|Usual Medical or Behavioral Intervention|Referral to treatment as usual through personal physician, mental health professional, behavioral health program, and/or Employee Assistance Program
1878139|NCT01163903|Drug|pantoprazole sodium for injection|Single 3-weekly doses of pantoprazole using the following dose escalation scheme for successive groups of patients: 80, 160, 240 and 320mg i.v. of pantoprazole to be given every 3 weeks, 30-60 (±5) minutes prior to doxorubicin. Treatment will be repeated on Day 1 of a 21-day cycle until radiographic or symptomatic progression or unacceptable toxicity or a maximum of 4 cycles (for patients who have received prior anthracyclines), and up to 8 cycles (for those with no prior exposure to anthracyclines).
1878140|NCT01163903|Drug|doxorubicin hydrochloride injection|60 mg/m2, IV, scheduled on day 1 of every 3-week interval, 30-60 (±5) minutes after pantoprazole administration.
1878141|NCT01163929|Drug|paclitaxel|"Paclitaxel:
80mg/m2 IV TRO 3 hours every 28 days for 4 cycles
Trastuzumab:
4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks
Everolimus: 10mg PO daily 16-18 weeks"
1878142|NCT01163942|Drug|G-CSF|Yes/no addition of G-CSF
1878143|NCT01163942|Drug|Early retreatment with ATG|Yes/no early retreatment with ATG
1878144|NCT01163955|Other|Time to fatigue|5 minutes while playing video games
1878145|NCT01163968|Behavioral|MOMENTUM|The Maximizing Outcomes Needed After Percutaneous Coronary Intervention (PCI) Using Weight Management (MOMENTUM) intervention is comprised of 6 modules, totaling 52 daily sessions promoting weight reduction, and 4 coaching sessions over the duration of the 12 week MOMENTUM intervention. The MOMENTUM intervention will be delivered using telehealth methods (Viterion telehealth device will be used to deliver the module content and coaching sessions). The intervention was purposively designed to overcome access barriers by using delivery modes accessible to patients in rural settings, in their home and at times convenient to their schedule.
1878146|NCT01163981|Other|Use of ultrasound guidance in cannulation|Use of guidance with duplex ultrasound to complete cannulation of dialysis access
1878147|NCT01163994|Drug|ceftriaxone|intravenously, 2 g, qd, 15 days
1878148|NCT01163994|Drug|doxycycline|orally, 100 mg, bid, 15 days
1878149|NCT01163994|Other|erythema migrans patients treated with doxycycline|orally, 100 mg, bid, 15 days
1878150|NCT01164007|Drug|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via intravenous (IV) infusion on Days 1 and 14 of each 28-day cycle.
1878151|NCT01164007|Drug|Dacarbazine|Dacarbazine will be given as 800 milligrams per square meter (mg/m^2) via IV infusion on Day 1 of each 28-day cycle.
1878152|NCT01164020|Dietary Supplement|creatine supplementation|20g/d for 7 days followed by 5g/d for 23 weeks
1878153|NCT01164020|Other|Placebo (Dextrose)|20g/d for 7 days followed by 5g/d for 23 weeks
1878154|NCT01164020|Other|Resistance training|resistance training twice a week for 24 weeks
1878155|NCT01164033|Drug|RO5045337|single oral dose
1878156|NCT01164046|Drug|low molecular weight heparin|weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
1878157|NCT01164046|Drug|vitamin K antagonists|Target INR between 2-3. Any type allowed, if approved for use in that country.
1878158|NCT01164059|Drug|Olanzapine|Olanzapine 10, 15, or 20 mg / day
1878159|NCT01164059|Drug|Flupentixol|Flupentixol 6, 9, or 12 mg / day
1878160|NCT01164059|Drug|Quetiapine|Quetiapine 400, 600, or 800 mg / day
1878161|NCT01164059|Drug|Aripiprazole|Aripiprazole 10, 15, or 20 mg / day
1878162|NCT01164059|Drug|Haloperidol|Haloperidol 3, 4.5, or 6 mg / day
1878163|NCT01164085|Drug|Intravitreal Ketorolac|4mg of intravitreal ketorolac
1878165|NCT01164111|Other|Preoperative resistance training|preoperative resistance training: Duration 8 weeks. Intensity: 3 sets of 80 % of 1 repetition max (1 RM) in each exercise (stated as 8-10 repetitions of the exercise). Frequency: 2 times/week. The patient follows a special training program consisting of exercises with knee and hip extension. Training intensity is followed in a personalized log-book for each patient. Sessions are conducted in small teams closely supervised by specially trained physiotherapists.
1878166|NCT01164124|Dietary Supplement|Probiotic supplementation (Lactobacillus rhamnosus GG and Bifidobacterium infantis)|The probiotic regimen consisted of 500 million CFU of Lactobacillus rhamnosus GG (Culturelle, Amerifit Brand Inc.) and 500 million CFU of Bifidobacterium infantis (Align, Procter & Gamble.Inc)
1878167|NCT01164124|Other|Placebo|routine feedings
1878168|NCT01164137|Behavioral|Medication Reconciliation|A pharmacist-led home intervention conducted within 72 hours of hospital discharge aimed at correcting and identifying medication discrepancies.
1878169|NCT01164150|Radiation|45 Gy/25 fractions|Arm A 45 Gy/25 fractions pelvic radiotherapy using 3D planned technique followed by 11Gy/2 fractions vaginal vault brachytherapy
1878170|NCT01164163|Drug|ruxolitinib phosphate|
1878171|NCT01164163|Other|laboratory biomarker analysis|
1878175|NCT01164189|Biological|Bevacizumab|Bevacizumab (vial of 400mg/16mL) at a dose of 10 mg/kg bodyweight i.v. in 90 min on day 1 and day 14 of 4 week cycles
1878176|NCT01164189|Drug|Temozolomide|Temozolomide (250, 100, 20 and 5 mg caps) will be administered orally on day 1-5, 150-200 mg/m², and will be repeated every 4 weeks. This will be repeated for up to 12 cycles.
1878177|NCT01164202|Drug|sunitinib malate|placebo 3cps/days 4 weeks over 6 during 1 year
1878178|NCT01164202|Drug|Placebo|placebo 3cps/days 4 weeks over 6 during 1 year
1878179|NCT01164202|Procedure|transarterial chemoembolization|Chimioembolisation
1878180|NCT01164215|Drug|fluorouracil|200-400 mg/m2 intravenously, 1 -5 minutes, once every 2 weeks 2400 mg/m2 intravenously over a period of 46 hours, once every 2 weeks
1878181|NCT01164215|Drug|leucovorin|200-400 mg/m2, intravenously over a period of 2 hours, once every 2 weeks
1878182|NCT01164215|Drug|oxaliplatin|85 mg/m2, intravenously for 2 hours, once every 2 weeks
1878183|NCT01164228|Drug|gemcitabine hydrochloride|Given IV
1878184|NCT01164228|Drug|sunitinib malate|Given
1878185|NCT01164267|Drug|Everolimus|Everolimus (tablets, 5 mg) is given orally at the dose of 10 mg/day from day 1 to day 28 of each cycle for up to a total of 6 cycles or until progression. Patients with CR or PR may continue treatment until PD if well tolerated
1878186|NCT01164280|Other|Pulse Rate Change|Different pulse rate settings of the implantable neurostimulator
1878187|NCT01164293|Device|Atopy patch test with food allergen|Atopy patches used with food lyophilized allergen and commercial allergen were placed on back of subjects for 48 hrs then atopy patches were taken off. Subjects should return to evaluate the reaction one day later (72 hr after applying atopy patch test)
1878188|NCT01164306|Behavioral|LifeSkills Training|"LifeSkills Training (Botvin's) is an evidenced based substance abuse prevention program for elementary school students to learn skills to resist tobacco, alcohol, drug abuse, and violence.
Parent LifeSkills will also be utilized. Parents are provided a parent manual and DVD to use at home with their child to reinforce what they are taught in school-based LifeSkills sessions."
1878189|NCT01164306|Behavioral|Healthy Lifestyle Behavior Choices|"The healthy lifestyle behavior choices curriculum augments the state health curriculum in the assigned study schools.
Parents will also be given health related information by mail to parallel the information students receive in school health classes."
1878190|NCT01164306|Behavioral|NRT and Motivational Interviewing (MI)|For parent/guardian smokers who want to quit, NRT is offered in conjunction with MI.
1878191|NCT01164319|Procedure|Circumferential PVI and subcutaneous cardiac monitor implantation|"The left atrium (LA) and PVs were explored through a transeptal approach. Real-time 3D LA maps were reconstructed by using a nonfluoroscopic navigation system (CARTO, Biosense-Webster Inc.). The ipsilateral left and right PVs were encircled in one lesion line by circumferential PV isolation. Radiofrequency energy was delivered at 43°C, 35 W, 0.5 cm away from the PV ostia at the anterior wall, and was reduced to 43°C, 30 W, 1 cm away from the PV ostia at the posterior wall, with a saline irrigation speed of 17 mL/min. The endpoint of ablation was PV isolation; this was confirmed when Lasso mapping showed the disappearance of all PV potentials or the dissociation of PV potentials from LA activity.
The ICM (Reveal XT, Medtronic Inc) was implanted the day of the ablation procedure or 1 week before.The Reveal XT was implanted in the parasternal area of the chest. The requirement for defining the exact final position was an R-wave amplitude ≥0.4 mV assessed through the Vector Check."
1878192|NCT01164332|Other|NRL972|Two-hour intravenous infusion of 5 and 15 mg per hour
1878193|NCT01164345|Drug|Plerixafor|Plerixafor (mozobil) 240 mcg/kg SC will be administered in the evening, 10 hours prior to initiation of apheresis.G-CSF will be administered in the morning at 10 mcg/kg SC for 4 days prior to apheresis.
1878194|NCT01164384|Drug|Baminercept|
1878195|NCT01164423|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
1878196|NCT01164449|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
1878197|NCT01164462|Biological|blood test: rapid finger-stick blood specimen test|
1878198|NCT01164462|Biological|blood test: conventional test|
1878199|NCT01164475|Drug|Granulocyte-colony stimulating factor (G-CSF)|
1878200|NCT01164475|Drug|Fixed Dose Plerixafor|
1878201|NCT01164475|Drug|Weight-Based Plerixafor|
1878202|NCT01164488|Drug|danoprevir|Repeated daily doses
1878203|NCT01164488|Drug|ketoconazole|Repeated daily doses
1878204|NCT01164488|Drug|ritonavir|Repeated daily doses
1878205|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
1878206|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
1878207|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
1878208|NCT01164501|Drug|BI 10773|BI 10773 tablets once daily
1878209|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 low dose
1878210|NCT01164501|Drug|Placebo|Placebo tablets identical to BI 10773 high dose
1878211|NCT01164514|Biological|CPG 7909|CPG 7909 is a synthetic oligodeoxynucleotide used as an adjuvant and administered at 2 different dosages: 250 mcg and 500 mcg.
1878212|NCT01164514|Biological|J5-OMP Vaccine|J5-OMP vaccine 10 mcg to be administered with and without CpG 7909 adjuvant 250 or 500 mcg, intramuscularly on Days 0, 29 and 59.
1878213|NCT01164514|Drug|Placebo|Normal saline.
1878214|NCT01164540|Drug|Rosuvastatin (AZD4522)|Oral dose (od) 20 mg
1878215|NCT01164540|Drug|Placebo|Oral dose (od)
1878216|NCT01164553|Biological|Trivalent Inactivated Influenza Vaccine|Either a standard pediatric dose (0.25 ml) or a larger dose (0.5 ml) of Trivalent Inactivated Influenza Vaccine (TIV) (Fluzone®) administered intramuscularly (IM) in the thigh with a 25 gauge 1 inch needle. Naive cohort (enrolled over two influenza seasons (2010-11 and 2011-12)) will receive vaccine in two IM doses 28-42 days apart, Fully Primed cohort (enrolled in one influenza season (2010-11)) will receive vaccine in one IM dose.
1878217|NCT01164566|Procedure|endoscopic procedure|
1878218|NCT01164566|Other|questionnaire administration|Ancillary studies
1878219|NCT01164579|Drug|Tasocitinib plus Methotrexate|Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months
1878220|NCT01164579|Drug|Tofacitinib plus placebo methotrexate|Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.
1878221|NCT01164579|Drug|Placebo tofacitinib plus Methotrexate|Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
1878222|NCT01164592|Device|adaptive servoventilation (ASV)|Patients randomised to therapygroup should use the adaptive servoventilation (ASV) device each night at least 3 hours
1878223|NCT01164605|Drug|Raltegravir|60 tablets (30-day supply)
1878224|NCT01164618|Procedure|Remote ischemic preconditioning (RIPC)|RIPC will be induced using a standard blood pressure cuff and hand anaeroid sphygmomanometer, on the right arm. The subject will be seated, the blood pressure cuff placed on the arm and inflated to a pressure of 200mmHg for 5 minutes (ischemia). The cuff will then be deflated for 5 minutes (reperfusion) completing one cycle of ischemia reperfusion. A total of 4 inflation and deflation cycles will be applied. This protocol of RIPC will be applied daily, for 10 consecutive days.
1878225|NCT01164618|Other|Exercise|Subjects will then undergo exercise daily, for 10 consecutive days. A chronic high-intensity interval exercise training protocol standardized to subjects' aerobic power (VO¬2max) will be used. Each exercise session will consist of a 5 min warm-up period followed by 4 sets of 2 min high intensity intervals interspersed with 3 min recovery periods.
1878226|NCT01164631|Device|Bioajusta X Orthodontic treatment|Oral Appliance that promotes semi-rapid maxillary expansion, while corrects tongue positioning and jaws relationship
1878227|NCT01164644|Drug|Arnica montana|Subjects will take twelve pills by mouth three times a day over four days.
1878228|NCT01164644|Drug|Placebo|Subjects will take twelve pills by mouth three times a day over four days.
1878229|NCT01164657|Device|"BirthRite"|Randomization takes place on admission to delivery unit, study group participants seated on the birthing seat when cervix is fully dilated.
1878230|NCT01164683|Behavioral|Peer-driven intervention|Trained peers with sleep apnea will be paired with the newly diagnosed patients over a 3-month period. During this time the trained peers will share experiences on coping strategies with CPAP device and equipment (promote self efficacy), share their positive experiences (motivational effects and outcome expectancies), share their knowledge of perceived vulnerabilities due to untreated sleep apnea (promote risk perception), share methods for improving efficacy of CPAP equipment and interface (patient education) and prepare their subjects for upcoming physician or respiratory therapist appointments (patient activation).
1878231|NCT01164683|Other|Usual Care|All participants will receive usual care following initiation of CPAP therapy. Visits with respiratory therapist and sleep physician wherein patients are educated about the basics of the care and operation of the device, mask and related equipment. Subsequently, their CPAP adherence is monitored and appropriate interventions such as mask change and re-education undertaken as needed.
1878232|NCT01164696|Drug|[90]Y-ibritumomab tiuxetan (Zevalin, BAY86-5128)|Zevalin was administered according to the directives in the approved package leaflet.
1878233|NCT01164709|Drug|bortezomib|Bortezomib i.v., day 8, 11, 15, 18; 1.3 mg/m2
1878234|NCT01164709|Drug|nelfinavir mesylate|p.o., days 1 to 21; dose level: (625), 1250, 1875, or 2500 mg, 2x/d
1878235|NCT01164722|Other|clinical observation|Patients undergo observation
1878236|NCT01164722|Device|infrared photocoagulation therapy|Anal infrared coagulator ablation
1878237|NCT01164735|Other|Laboratory Biomarker Analysis|Correlative studies
1878238|NCT01164748|Radiation|Lymphoscintigraphy|in all women a lymphoscintigraphy was done to investigate drainage patterns of a previous operated breast and axilla
1878239|NCT01164761|Drug|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
1878240|NCT01164761|Drug|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
1878241|NCT01164774|Drug|Ramipril|Ramipril 10 mg Capsules of Dr. Reddy's Laboratories Limited
1878242|NCT01164774|Drug|Altace|Altace@ 10 mg capsules of Kings Pharmaceuticals, USA
1878243|NCT01164787|Drug|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
1878244|NCT01164787|Drug|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
1878245|NCT01164800|Drug|Trandolapril|Trandolapril 4 mg Tablets of Dr. Reddy's Laboratories Limited
1878246|NCT01164800|Drug|Mavik|Mavik® 4 mg Tablets of Abbott Laboratories, USA.
1878247|NCT01164813|Drug|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
1878248|NCT01164813|Drug|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
1878249|NCT01164826|Drug|Nabumetone|Nabumetone 750 mg Tablets of Dr. Reddy's Laboratories Limited
1878250|NCT01164826|Drug|Relafen|Relafen® 750 mg Tablets of Glaxosmithkline Research Triangle Park, NC.
1878251|NCT01164852|Procedure|Delivery|Termination of pregnancy (delivery)after completed corticosteroids
1878252|NCT01164865|Device|OPTI-FREE RepleniSH multipurpose disinfecting solution|FDA-approved, multipurpose disinfecting solution used according to provided instructions for cleaning, rinsing, storing, and disinfecting study contact lenses on a daily basis, 2 weeks.
1878253|NCT01164865|Device|Clear Care contact lens care system|FDA-approved, hydrogen peroxide-based, lens care system used according to provided instructions for cleaning, disinfecting, daily protein removing, and storage of study contact lenses on a daily basis, 2 weeks.
1878254|NCT01164865|Device|Contact lenses|Contact lenses per subject's habitual brand and prescription worn every day for the duration of the study, 14 days, on a daily wear basis without scheduled replacement.
1878255|NCT01164891|Drug|RO5185426|Continuous oral dosing b.i.d. , on Day 15 a C isotope labeled dose will be administered
1878256|NCT01164904|Drug|Amg 181|Ten escalating dose levels of AMG 181 administered as single dose SC or IV, in healthy volunteers and SC subjects with mild-to-moderate ulcerative colitis.
1878257|NCT01164917|Drug|AMG811|Twelve subjects will be randomized to receive AMG 811 in Period 1 and will receive AMG 811 Placebo in Period 2. The AMG 811 and AMG 811 Placebo will be administered by injection.
1878258|NCT01164917|Drug|AMG811 Placebo|8 subjects will be randomized to receive AMG 811 Placebo in Period 1 and will receive AMG 811 in Period 2. The AMG 811 Placebo and AMG 811 will be administered by injection
1878259|NCT01164930|Behavioral|Acceptance and Commitment Therapy|8-week ACT group
1878260|NCT01164943|Procedure|Stimulation with human FSH|Human FSH
1878261|NCT01164943|Procedure|Stimulation with recombinant FSH|Recombinant FSH
1878263|NCT01164969|Drug|Antibiotics to which H. pylori can not develope resistance|Amoxicillin, metronidazole and tetracyclin as primary drugs to treat H. pylori infection in duration of 10 days.
1878264|NCT01164982|Device|Mepitel One|Each subject will be followed once a week for 3 weeks or until healing if that occurs earlier
1878265|NCT01164995|Drug|MK-1775 and carboplatin|Carboplatin will be administered in a dose resulting in AUC5 (i.v. 30 min) at day 1 of each cycle. Concomittantly with the start of the carboplatin infusion 225 mg of MK-1775 will be administered as an oral capsule, followed by 4 additional doses at 12 hour increments ( = 5 BID doses of MK-1775 in 2.5 days in total). One cycle will last 21 days.
1878266|NCT01165008|Drug|Anakinra|
1878267|NCT01165021|Drug|Pemetrexed|500 milligram per square meter (mg/m²) administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
1878268|NCT01165021|Drug|Cisplatin|75 mg/m² administered as an intravenous infusion on Day 1 of 21-day cycles, for 3 cycles
1878269|NCT01165021|Drug|Folic Acid|Administered orally.
1878270|NCT01165021|Drug|Vitamin B12|Administered Intramuscular injection.
1878271|NCT01165021|Drug|Dexamethasone|Administered orally.
1878272|NCT01165034|Other|Breathlessness Support Service|Patients randomised to the intervention group (IG) will be entered into the BSS in addition to standard best usual care. Expertise in the BSS will comprise of a palliative care consultant or specialist registrar (SpR), a respiratory medicine consultant or SpR with a specialist interest in breathlessness, a respiratory physiotherapist, an occupational therapist and a respiratory nurse specialist. Patients will see 12 health professionals per visit, and multidisciplinary team meetings will take place before and after each visit. Outpatient clinics will take place once per week. The timing of interventions and data collection has been designed to allow for short disease trajectories in patients with cancer and minimise patient burden, whilst allowing time for interventions to have the desired effect. Four weeks is considered to be the minimum length of pulmonary rehabilitation programmes that give a clinically significant benefit.
1878273|NCT01165047|Drug|Nitric Oxide|Nitric oxide, 80 ppm in air or oxygen will be administered using the GeNO nitrosyl delivery system with a standard nasal cannula at a flow rate of 4 LPM.
1878274|NCT01165060|Drug|Bezafibrate|Week 0 to 12: 400 mg once daily 1 tablet. Week 13 to 24: 400 mg once daily 2 tablets.
1878277|NCT01165086|Other|Incorporating vegetables into the diet to reduce energy density|The entree portion of breakfast, lunch, and dinner meals will be manipulated to be a standard energy density, a 15% reduction in energy density, or a 25% reduction in energy density.
1878278|NCT01165099|Procedure|acupuncture|The description of the acupuncture, whether manual, electro or sham, is as described for each of the individual groups.
1878279|NCT01165112|Drug|Bendamustine Hydrochloride|Given IV
1878280|NCT01165112|Drug|Carboplatin|Given IV
1878281|NCT01165112|Biological|Rituximab|Given IV
1878282|NCT01165112|Drug|Etoposide|Given IV
1878283|NCT01165112|Other|Laboratory Biomarker Analysis|Correlative studies
1878284|NCT01165125|Drug|FF / GW642444|200mcg/25mcg Novel DPI
1878285|NCT01165125|Drug|ketoconazole|400mcg overencapsulated tablets
1878286|NCT01165125|Drug|ketoconazole (placebo to match)|placebo to match overencapsulated tablets
1878287|NCT01165138|Drug|Fluticasone furoate/Vilanterol Inhalation Powder|Fluticasone furoate/Vilanterol Inhalation Powder inhaled orally once daily for 12 weeks
1878288|NCT01165138|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate Inhalation Powder inhaled orally once daily for 12 weeks
1878289|NCT01165138|Drug|Placebo Inhaltion Powder|Placebo Inhaltion Powder inhaled orally once daily for 12 weeks
1878290|NCT01165151|Behavioral|behavioral weight loss program|weekly, group-based lifestyle weight loss program
1878291|NCT01165164|Other|FID 115958D (lubricant eye drop)|1 drop in each eye at bedtime
1878292|NCT01165177|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
1878293|NCT01165177|Biological|Placebo|Intramuscular injection
1878294|NCT01165203|Biological|Herpes Zoster Vaccine GSK1437173A|intramuscular injection
1878295|NCT01165203|Biological|Placebo|intramuscular injection
1878296|NCT01165216|Drug|Ipilimumab, 3 mg|Intervenous (IV) injection, administered every 3 weeks for up to 6 cycles
1878297|NCT01165216|Drug|Ipilimumab, 10 mg|IV injection, administered every 3 weeks for up to 6 cycles
1878298|NCT01165216|Drug|Paclitaxel|IV injection, 175 mg/m^2, administered every 3 weeks for up to 6 cycles
1878299|NCT01165216|Drug|Carboplatin|IV injection, AUC=6, administered every 3 weeks for up to 6 cycles. (AUC=area under the concentration curve)
1878302|NCT01165242|Biological|Meningococcal vaccine GSK 134612|One intramuscular injection
1878303|NCT01165242|Biological|Menactra®|One intramuscular injection
1878304|NCT01165255|Drug|3. Exposure to other antidepressants during the first trimester comparison cohort|"Exposure to other antidepressants during first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate dispensing of other antidepressants. Infants were classified according to maternal exposure to other antidepressants during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women who were exposed only to one type of an antidepressant (other antidepressant monotherapy), or more than one type of an antidepressant (other antidepressant mono or polytherapy) during the first trimester. A woman was considered exposed if there is at least one dispensing of another antidepressant during the first trimester of pregnancy."
1878334|NCT01165463|Behavioral|Crossword Puzzles|Subjects train with puzzles 10 hrs in lab.
1878335|NCT01165463|Behavioral|SOPT booster training|4 hours of subsequent booster-training
1878336|NCT01165476|Drug|Treprostinil diethanolamine|sustained release tablets. One 1mg tablet per period. Two total doses.
1878337|NCT01165502|Drug|CM3.1-AC100|MAD study with repeated subcutaneous (sc) doses
1878305|NCT01165255|Drug|2. Exposure to bupropion outside the first trimester comparison cohort|"Exposure to bupropion outside the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. The comparison cohort (bupropion exposure outside the first trimester) included women whose bupropion exposure occurred at least one month before the estimated date of conception and women whose bupropion exposure occurred after the first trimester, but before delivery. This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy) during the period outside the first trimester."
1878306|NCT01165255|Drug|1. Exposure to bupropion during the first trimester|"Exposure to bupropion during the first trimester was classified in the original study using pharmacy claims submitted electronically to the Ingenix Research Database to indicate a dispensing of bupropion. Infants were classified according to maternal exposure to bupropion during the first trimester. The first trimester was estimated as the earliest probable conception date through 91 days (13 weeks) following the latest probable conception date (based on delivery diagnosis codes). This study will refine the exposure classifications into infants born to women, who were exposed only to bupropion (bupropion monotherapy), or bupropion and another type of an antidepressant (bupropion mono-or polytherapy). A woman was considered exposed in the first trimester if there was at least one dispensing of bupropion during the first trimester of pregnancy."
1878307|NCT01165268|Drug|Dapagliflozin|Tablets, Oral, 10 mg, Once daily, 7 days
1878308|NCT01165281|Drug|Oxycodone CR|One 5 mg to 40 mg capsule twice daily for 4 weeks.
1878309|NCT01165281|Drug|R331333 (referred to as JNS024 ER or CG5503)|One 25 mg to 200 mg capsule twice daily for 4 weeks.
1878310|NCT01165294|Drug|Placebo|An intravenous bolus will be given in 5 minutes time followed by a 1 minute break after which a continuous infusion will start. Dosage lowered every 10 minutes
1878311|NCT01165294|Drug|ketamine|An intravenous bolus of 0.1 mg/kg will be given in 5 minutes followed by a 1 minute break after which a continuous infusion will start at 0.015625 mg/kg/min.
1878312|NCT01165307|Drug|Estradiol 30mcg / Levonorgestrel 150mcg monophasic oral contraceptive pills|Each packet consists of a fixed dose of 30mcg estradiol and a 150mcg dose of levonorgestrel for the first 21 days of the cycle, followed by a 7 day pill free period. Subjects will be instructed to administer the pills orally, starting 5 days after the start of menstrual blood flow, continuing cyclically, thus allowing for withdrawal bleeding after the 21 day pill cycle.
1878313|NCT01165307|Drug|Naproxen sodium pills|As an alternative to oral contraceptive pills, subjects may take Naproxen 500 mg with onset of menses, then 250 mg three times daily for the duration of the menses (or maximum of five days)
1878314|NCT01165307|Device|NovaSure® Radiofrequency Endometrial Ablation|Radiofrequency endometrial ablation is performed in the outpatient surgery department. Subjects receive intravenous medication, determined by the attending anesthesiologist, sufficient to induce conscious sedation during the procedure.
1878315|NCT01165320|Drug|Caspofungin|
1878316|NCT01165333|Drug|Cilengitide dose escalation|"Cilengitide will be administered intravenously over 60 minutes, twice a week, at a given dose.
The Cilengitide dose (mg/m²/infusion)levels are as follows :
240
480
720
1200
1800"
1878317|NCT01165333|Drug|Cilengitide|Patients will be treated at the recommended dose in order to confirm the recommended cilengitide dose and to carry out the exploratory investigations
1878318|NCT01165333|Radiation|Concomitant radiotherapy|1.8 Gy per fraction for a total of 54 Gy over 6 weeks, from monday to friday of the first cycle. The radiation will imperatively begin between 3 and 7hours after the end of Cilengitide infusion.
1878319|NCT01165333|Biological|Pharmacokinetic|A pharmacokinetic assessment for Cilengitide will be carried for all patients. The pharmacokinetic (PK) samples will be drawn during day 1 and day 2 of the first cycle of treatment.
1878320|NCT01165333|Biological|Pharmacogenetic|For every patient 1 blood sample will be taken before study treatment. These blood samples can be made at any hour of the day, and does not require to be taken on an empty stomach. DNA will be extracted in the Laboratory of Pharmacology.Constitutional polymorphisms of genes will be measured before the treatment initiation.
1878321|NCT01165333|Biological|Exploratory investigation|Evaluate the metabolic impact of the treatment with dynamic MRI (diffusion, perfusion, spectro), and with FDG-PETand sestamibi SPECT.
1878322|NCT01165346|Radiation|Fiducials|Implantation of fiducials
1878323|NCT01165346|Radiation|CyberKnife|3 fractions over 8 to 10 days, 15 Gy/fraction
1878324|NCT01165359|Drug|ITX 5061|"For Part A of the study: 150 mg of ITX 5061, once a day for 3 days; 75 mg of ITX 5061, once a day for 3 days; or 25 mg of ITX 5061, once a day for 3 days.
For Part B of the study: 150 mg of ITX 5061, once a day for 14 days; 75 mg of ITX 5061, once a day for 14 days; or 25 mg of ITX 5061, once a day for 14 days.
For Part C of the study: 150 mg of ITX 5061, once a day for 28 days; 75 mg of ITX 5061, once a day for 28 days; or 25 mg of ITX 5061, once a day for 28 days."
1878325|NCT01165359|Drug|Placebo ITX 5061|"For Part A of the study: placebo, once a day for 3 days.
For Part B of the study: placebo, once a day for 14 days.
For Part C of the study: placebo, once a day for 28 days."
1878326|NCT01165372|Drug|Artesunate or dihydroartemisinin-piperaquine|artesunate 2mg/kg/day, artesunate 4mg/kg/day or dihydroartemisinin-piperaquine once daily
1878327|NCT01165385|Drug|cisplatin|60, 75 or 100 mg/m2 , day 1 - 3 weekly
1878328|NCT01165385|Drug|Pazopanib|400 mg, 600 mg or 800 mg/day, daily
1878329|NCT01165424|Drug|mometasone furoate|"MFNS 50 μg spray device
3 to 11 years: one spray per nostril once daily (100 μg/day) in the morning.
12 to 15 years: 2 sprays per nostril once daily (200 μg/day) in the morning."
1878330|NCT01165437|Device|Blood Pressure Measurement|Systolic blood pressures will be obtained from each limb using Doppler, oscillometric, and photoplethysmographic (PPG) modalities.
1878331|NCT01165450|Drug|Nexagon|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
1878332|NCT01165450|Drug|Vehicle only|There will be 3 groups of patients with persistent epithelial defects, treated in a dose-escalation fashion from 1µg to 3µg to 10 µg. Each group will consist of 18 patients randomized to Nexagon and 6 patients randomized to placebo only.
1878333|NCT01165463|Behavioral|SOPT basic training|10 hours of basic training
1878338|NCT01165502|Drug|Placebo|Placebo for compound CM3.1-AC100 s.c.
1878339|NCT01165528|Procedure|type of mechanical ventilation|patients are randomized to receive one of the two types of mechanical ventilation for ARDS
1878340|NCT01165541|Drug|Mirtazapine|mirtazapine (7.5-45mg)
1878341|NCT01165541|Drug|Quetiapine fumarate extended release (Quetiapine XR)|Quetiapine fumarate extended release 50-400mg/d
1878342|NCT01165554|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 111 to 370 MBq (3 to 10 mCi), single intravenous injection.
1878343|NCT01165567|Drug|sarpogrelate|sarpogrelate, 300mg/day,duration: 4 weeks
1878344|NCT01165580|Drug|valganciclovir [Valcyte]|oral dose, Days 1 and 2
1878345|NCT01165593|Other|There is no intervention that is a part of this study.|There is no intervention that is a part of this study. Imaging data is gathered as part of normal care.
1878346|NCT01165606|Procedure|Chest physiotherapy|
1878347|NCT01165632|Procedure|biopsy|Correlative studies
1878348|NCT01165632|Procedure|computed tomography|Undergo computed tomography
1878349|NCT01165632|Procedure|therapeutic conventional surgery|Undergo stereotactic craniotomy
1878350|NCT01165632|Radiation|radiation therapy treatment planning/simulation|Undergo radiation therapy treatment planning/simulation
1878351|NCT01165632|Radiation|radiation therapy|Undergo radiation therapy
1878352|NCT01165632|Procedure|magnetic resonance imaging|Undergo magnetic resonance imaging
1878353|NCT01165632|Procedure|positron emission tomography|Undergo positron emission tomography
1878354|NCT01165632|Drug|fluorine F 18 fluorodopa|Given IV
1878355|NCT01165645|Drug|lopinavir|Given orally
1878356|NCT01165645|Drug|ritonavir|Given orally
1878357|NCT01165645|Genetic|polymerase chain reaction|Correlative studies
1878358|NCT01165645|Other|flow cytometry|Correlative studies
1878359|NCT01165645|Other|enzyme-linked immunosorbent assay|Correlative studies
1878360|NCT01165645|Other|laboratory biomarker analysis|Correlative studies
1878361|NCT01165658|Radiation|Proton Therapy|The regimen of 45 Gy in 15 fractions will be delivered as a baseline, and then the fraction size will be escalated in two different intervals of 0.5 Gy each, with the ultimate dose being 60 Gy in 4 Gy fractions.
1878362|NCT01165671|Radiation|Carbon Ion Radiotherapy|Carbon ion Radiotherapy up to 18 Gy E in 3 Gy E fractions to the macroscopic tumor
1878363|NCT01165671|Radiation|Proton Radiotherapy|Proton Radiotherapy up to 10 Gy E in 2 Gy E fractions to the macroscopic tumor
1878364|NCT01165684|Drug|insulin aspart|"Insulin aspart added stepwise according to the largest meal following an evaluation of HbA1c.
Doses individually adjusted."
1878365|NCT01165684|Drug|insulin aspart|Insulin aspart added before each main meal. Doses individually adjusted.
1878366|NCT01165684|Drug|insulin detemir|Insulin detemir as basal insulin, adminstered once daily. Doses individually adjusted.
1878367|NCT01165697|Other|Fluorescein angiography|Fluorescein angiography once every 6 months for 3 years
1878368|NCT01165710|Other|Patients with Atrial Fibrillation (AF)|Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.
1878369|NCT01158482|Procedure|IVC Filter Placement or Retrieval|An IVC Filter will be placed or removed using endovascular techniques.
1878370|NCT01158495|Procedure|Intubation with a cuffed ET Tube|
1878371|NCT01158495|Procedure|CT scan Radiation|
1878372|NCT01158508|Procedure|Remote ischemic preconditioning|Transient lower limb ischemia will be induced by inflation of a blood pressure cuff on the thigh. Four five minute cycles of ischemia will be performed, each followed by five minutes of reperfusion with the cuff down. This procedure will be performed in four rounds, typically on post-hemorrhage days 2, 3, 6 and 9.
1878375|NCT01158534|Drug|celecoxib|Given orally
1878376|NCT01158534|Biological|recombinant interferon alfa-2b|Given subcutaneously
1878377|NCT01158534|Other|polymerase chain reaction|Correlative studies
1878378|NCT01158534|Other|laboratory biomarker analysis|Correlative studies
1878379|NCT01158534|Other|reverse transcriptase-polymerase chain reaction|Correlative studies
1878380|NCT01158534|Other|immunologic technique|Correlative studies
1878381|NCT01158534|Other|immunohistochemistry staining method|Correlative studies
1878382|NCT01158534|Other|flow cytometry|Correlative studies
1878383|NCT01158560|Dietary Supplement|cholecalciferol (vitamin D3)|oral capsule, 10,000 IU/week vitamin D3 for 6-8 weeks
1878384|NCT01158560|Behavioral|Gargling|gargling with tap water, twice daily
1878385|NCT01158560|Dietary Supplement|Placebo|matched placebo for active vitamin D
1878386|NCT01158586|Drug|Levobupivacaine|patient control epidural analgesia using 0.2% levobupivacaine with 2ug/ml fentanyl
1878387|NCT01158599|Biological|IXIARO®|IXIARO®, 0.5 ml (6 µg), intramuscular (i.m.) injection, two vaccinations, Days 0 and 28
1878388|NCT01158612|Drug|Growth Hormone|infusion of Growth hormone in the patella tendon.
1878389|NCT01158625|Other|Change of time of administration|Change of time of administration
1878390|NCT01158638|Behavioral|Web Mediated Step Intervention|The testing of a web mediated step intervention designed to set weekly step targets, and channel participants through a series of motivational screens depending on compliance or non-compliance with set step goals.
1878391|NCT01158651|Drug|RAD001 (Everolimus)|"If you take part in this research study, you will be given a participant diary for each treatment course to help you keep track of when you take your RAD001. You will be required to bring the completed diary at each scheduled visit. A treatment course lasts 4 weeks and there will not be any breaks between courses. You may stay on study for a total of 12 courses (48 weeks).
You will take the study medication (tablets) by mouth, once a day during each course for as long as you are participating in this study. You will also be required to take an antibiotic during treatment to prevent infection."
1878392|NCT01158664|Device|0.6 mm tread pitch implant|0.6 mm tread pitch implant will be used
1878393|NCT01158664|Device|0.1 mm tread pitch implant|0.1 mm tread pitch implant will be used
1878394|NCT01158677|Procedure|Meniscectomy|patients undergoing meniscectomy will be asked to complete the KOOS-scale,Vas-scale, Tegner questionnaire, SF-36 questionnaire pre-operatively and at 3, 6 and 12 months post-operatively
1878397|NCT01158703|Drug|clopidogrel|clopidogrel 75mg daily by mouth daily for 12 months
1878398|NCT01158703|Drug|sugar pill|sugar pill by mouth daily for 12 months
1878399|NCT01158703|Drug|Aspirin|aspirin 81 mg daily by mouth for 12 months ( Standard of care in both arms)
1878400|NCT01158716|Other|Remote Ischemic Preconditioning|Patients are subjected to a 5-minute ischemia of the non-dominant arm with the use of a blood pressure cuff (inflated at 200mm Hg)
1878401|NCT01158729|Drug|Antithrombin (Recombinant)|Single dose of antithrombin (recombinant) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: ATIII dose given to patient = [(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg] X (1 mL/175 Units)
1878402|NCT01158729|Other|Placebo|Single dose of placebo (0.9% NaCl) to be given prior to initiation of cardiopulmonary bypass. Intravenous dose determined by following formula: Placebo dose given to patient = [(1.0 Units/mL - patient's measured ATIII concentration in Units/mL) X weight (kg) X 80 mL/kg] X (1 mL/175 Units)
1878403|NCT01158742|Other|Glomerular Filtration Rate with Iothalamate|used to determine kidney function
1878404|NCT01158742|Other|Glomerular Filtration Rate with Iohexol|used to determine kidney function
1878405|NCT01158755|Drug|Moxifloxacin|Subjects on both arms will further be randomized into receiving moxifloxacin either in standard dose (400 mg p.o.), high dose (800 mg p.o.) of moxifloxacin, or not receiving moxifloxacin (ethambutol 750 mg p.o., instead) Intervention drug will be given for 14 days, and the drug will be switched to ethambutol 750 mg p.o. (in accordance with National TB Program)
1878406|NCT01158781|Behavioral|Experimental: gait, balance, arm function, cognition|12 weeks of training for balance, gait, upper limb function, and cognition, including functional electrical stimulation with surface electrodes, robotics, and motor learning
1878407|NCT01158820|Drug|dexmedetomidine and ketamine Study Medication|Experimental Dexmedetomidine 200 µg in 50 ml Ketamine 30 mg Ketamine 200 mg in 20 ml Midazolam 10 mg + Fentanyl 250 µg + saline 5 ml Benadryl 25 mg
1878408|NCT01158820|Drug|placebo + Standard of Care of midazolam and fentanyl|Control Saline 50 ml Midazolam 2 mg + Fentanyl 50 µg Saline 20 ml Midazolam 10 mg + Fentanyl 250 µg + saline 5 ml Benadryl 25 mg
1878409|NCT01158833|Other|classification of gait in diplegic children with CP|To determine the criterion validity of the classification of the pattern of diplegic gait proposed by Ferrari et al. we correlated gait patterns with the score of the FMS.
1878410|NCT01158846|Drug|prasugrel/bivalirudin|60mg loading dose followed by 10mg or 5 mg (according to body weight or age)maintenance dose of prasugrel. Bivalirudin during the primary PCI (bolus plus infusion)
1878411|NCT01158846|Drug|clopidogrel/abciximab|600mg loading dose of clopidogrel followed by 75mg maintenance dose. Abciximab will be used during primary PCI, bolus plus infusion.
1878412|NCT01158859|Drug|Pregabalin|Preoperative administration of pregabalin vs placebo 1 hour before surgery
1878413|NCT01158885|Drug|Clofarabine|20 mg/m2/day intravenously (IV) over 2 hours (given at hours 0 to 2) on days 1 through 5.
1878414|NCT01158885|Drug|Cytarabine|1 gram/m2/day intravenously (IV) over 2 hours to be given 4 hours after the initiation of clofarabine on days 1 through 5.
1878415|NCT01158885|Drug|Methotrexate|"Methotrexate to be given intrathecally (IT) to all acute lymphoblastic leukemia (ALL) patients on day 1 at the dose defined by age below:
8 mg for patients age 1-1.99
10 mg for patients age 2-2.99
12 mg for patients 3-8.99 years of age
15 mg for patients >9 years of age"
1878416|NCT01158885|Drug|Cytarabine|"Intrathecal (IT) cytarabine is optional for acute myelogenous leukemia (AML) patients.
If intrathecal cytarabine is to be given, it must be given at least 72 hours but not more than 7 days prior to the initiation of intravenous cytarabine.
Dose should be given according to age as defined below:
30 mg for patients age 1-1.99
50 mg for patients age 2-2.99
70 mg for patients >3 years of age"
1878417|NCT01158898|Drug|TPI ASM8|ASM8 4mg/mL (low dose) daily for 14 days by inhalation
1878418|NCT01158898|Drug|TPI ASM8|ASM8 4mg/mL (high dose) daily for 14 days by inhalation
1878419|NCT01158898|Drug|TPI ASM8|Placebo PBS solution daily for 14 days by inhalation
1878420|NCT01158924|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
1878421|NCT01158937|Drug|Meropenem Infusion|Meropenem 2g infused intravenously over 30 mins (bolus infusion) Meropenem 2g infused intravenously over 3 hours (extended infusion)
1878427|NCT01158989|Device|PillCam|Within four days of hospital admission, qualifying critically ill patients were assigned to the study and received a gastro-jejunal tube and one PillCam video telemetry capsule (Given Imaging Ltd., Yoqneam, Israel). In each critical care patient, placement of the video capsule was coupled with the placement of the medically necessary feeding tube. A flexible endoscope was inserted into the patient's mouth, and then advanced into the esophagus, stomach, and upper small intestine. The capsule was placed into a capsule delivery device and released into the distal duodenum after it had passed beyond the sight of the scope; a wire was placed to facilitate passage of the feeding tube. An abdominal X-ray was obtained to confirm feeding tube tip placement.
1878428|NCT01159002|Device|SmartPill|Qualifying patients were assigned to the study within four days of hospital admission. They all received a gastro-duodenal tube and capsule. The motility capsule (SmartPill®) was placed into the capsule delivery device (AdvanCE™, US Endoscopy) and advanced blindly into the stomach and released
1878429|NCT01159015|Drug|KetoNaph|Ophthalmic Solution administered BID for 6 weeks
1878430|NCT01159015|Drug|Vehicle|Vehicle of KetoNaph ophthalmic solution administered bid for six weeks
1878431|NCT01159028|Drug|BP1001|Study drug (BP1001) is constituted in normal saline, administered by IV on twice weekly for 28 days.
1878432|NCT01159028|Drug|BP1001 in combination with LDAC|Study drug (BP1001) is constituted in normal saline, administered by IV twice weekly for 28 days. Low dose ara-C (LDAC) is self administered twice daily for 10 consecutive days during the 28 day cycle.
1878433|NCT01159041|Behavioral|Family Focused Treatment (FFT)|FFT is designed to specifically address the developmental needs of school-aged children and their parents through an emphasis on fostering positive and supportive parent-child interactions that scaffold the development of a positive self, to help parents provide the child additional positive feedback on his/her developmentally appropriate achievements, and to enhance family and child coping. This treatment is conducted with the child and his/her parent(s) and includes education about depression, communication training, relationship enhancement, and problem-solving.
1878434|NCT01159041|Behavioral|Individual Treatment (IP)|The goals of the treatment are to foster the therapeutic relationship, to provide a supportive and empathic setting where the child can come to better understand his/her emotions/feelings and address issues underlying current symptoms. Therapeutic goals will be addressed through reflection and clarification of feelings/emotions and understanding the child's perception of the context of depressed feelings.
1878435|NCT01159054|Drug|Extended Release Nicotinic Acid (Niaspan)|Subjects will start on 500 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1000 mg per day of Niaspan for 4 weeks, then the dose will be increased to 1500 mg of Niaspan per day for 4 weeks, after this subjects with weight of less than 60 kg will continue at 1500 mg per day of Niaspan for another 12 weeks whereas in subjects with weight of more than 60 kg the dose will be increased to 2000 mg of Niaspan per day which will be continued for 12 weeks.
1878436|NCT01159067|Drug|deferasirox|Given orally
1878437|NCT01159080|Drug|routine dose tacrolimus and less myfortic|oral regular dose of tacrolimus + less dose of myfortic trough level of tacrolimus will be 5-10 ng/mL and oral myfortic dose will be 180-360 mg twice a day
1878438|NCT01159080|Drug|reduced dose tacrolimus and conventional myfortic|low dose of tacrolimus + maximum dose of myfortic target trough level of tacrolimus should be reduced to 2-5 ng/mL for 3 months after randomization and oral MPS dose increased to 540-720mg twice a day
1878439|NCT01159093|Behavioral|Family Decision Support|Family-focused intervention includes informational vaccine reminder telephone calls prompted by an electronic health record.
1878440|NCT01159093|Behavioral|Clinician Decision Support|Clinician-focused intervention includes an electronic health record-based decision support mechanism including reminders, education, audit and feedback on vaccination success.
1878441|NCT01159093|Other|Family Decision Support and Clinician Decision Support|This will be a combination of the family-focused decision support (telephone reminder calls) and clinician-focused decision support (clinical alerts).
1878442|NCT01159093|Other|Control|Usual care
1878443|NCT01159106|Other|Pressure Support Ventilation|Spontaneous mode of ventilation whereby the patient initiates the breath and the ventilator delivers support with the preset pressure value
1878444|NCT01159106|Other|Neurally adjusted ventilatory assist (NAVA)|"Gas delivery from the mechanical ventilator is triggered, controlled and cycled by the diaphragmatic EMG signal (Edi).
The ventilator is aware of the change in diaphragmatic EMG by the insertion of a specially designed nasogastric tube with EMG electrodes that cross the diaphragm."
1878445|NCT01159119|Drug|EUR-1066-A|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
1878446|NCT01159119|Drug|Zenpep|Capsules taken for daily for 28 days during treatment period 2
1878447|NCT01159119|Drug|EUR-1066-B|Eur-1066 capsules taken daily for 28 days either during treatment period 1 or treatment period 3.
1878448|NCT01159132|Drug|raltegravir|12 hour PK will be done on day 1 while subjects is on stable regimen with RAL 400 mg BID. After performing intensive PK, subjects will be randomized to either group A (RAL 400 mg OD) or B (RAL 800 mg OD) for 14 days and on day 15, a second 24 hour full PK will be carried out. After the intensive PK, subjects in both the groups will switched to the other dosing regimen, group A (RAL 800 mg OD) and B (RAL 400 mg OD) for another 14 days and on day 29, the third 24 hour full PK will be carried out.
1878449|NCT01159145|Drug|D961H|Oral, capsule
1878450|NCT01159145|Drug|Omeprazole|Oral, tablet
1878451|NCT01159158|Drug|Nateglinide|Nateglinide Tablets 120 mg
1878452|NCT01159171|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 14 days
1878453|NCT01159171|Drug|capecitabine [Xeloda]|1000 mg/m2 orally b.i.d. , Days 1 - 14 of every 28-day cycle
1878454|NCT01159171|Drug|oxaliplatin|40 mg/m2 iv weekly
1878455|NCT01159197|Behavioral|cognitive behavioral therapy|Participants who randomized into the CBT group will receive 18 30-minute tri-weekly treatment sessions of CBT during the 6-week period
1878457|NCT01159223|Drug|ATV/r|All participants will be randomized to take ATV/r 200 mg/100 mg OD or ATV/r 300/100 mg OD. NRTIs background regimens will remain unchanged if possible. NRTIs background may include zidovudine/lamivudine, zidovudine plus ddI, ddI plus lamivudine, tenofovir plus lamivudine, tenofovir/emtricitabine, zidovudine plus tenofovir. NRTI backbone could be switched or modified due to toxicity or intolerance
1878458|NCT01159236|Drug|Paclitaxel|80 mg/m2 by vein over about 1-2 hours once every 7 days x 12 courses.
1878459|NCT01159236|Drug|Fluorouracil|500 mg/m2 for 4 courses (once every 7 days)
1878460|NCT01159236|Drug|Doxorubicin|50 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments
1878461|NCT01159236|Drug|Epirubicin|100 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments, may be given instead of Doxorubicin in Group 1 and 2.
1878462|NCT01159236|Drug|Cyclophosphamide|500 mg/m2 by vein given on day 1 and repeated once every 21 days for 4 treatments.
1878463|NCT01159236|Drug|Bevacizumab|10 mg/kg intravenously every 2 weeks, discontinued 6 weeks before surgery (i.e. after 3rd course of FEC or FAC)
1878464|NCT01159249|Drug|Vildagliptin|
1878465|NCT01159262|Drug|Midazolam|Per package insert, N-PASS (Neonatal Pain, Agitation, and Sedation Scale) scores and investigator discretion
1878466|NCT01159262|Drug|Fentanyl/Morphine|Per package insert, N-PASS scores and investigator discretion.
1878467|NCT01159262|Drug|Dexmedetomidine|
1878468|NCT01159275|Drug|Generic LPV/r and Aluvia (pharmacokinetics)|Generic LPV/r 200/50 mg BID 12 hr PK then cross over to Pediatric Aluvia 200/50 mg BID
1878469|NCT01159275|Drug|Aluvia and Generic LPV/r (pharmacokinetics)|First Pediatric Aluvia® 200/50 mg BID, then cross over to Generic LPV/r 200/50 mg BID
1878470|NCT01159288|Biological|Dex2|"Metronomic dosage of Cyclophosphamide during 3 weeks (50mg/day orally) as reported 15, before specific treatment.
Induction immunotherapyIntradermal injections of Dex once a week during 4 consecutive weeks.(Peptides pulsed onto DC, sources of Dex: PRS pan-DR, MAGE-3 DP04, MAGE-1 A2, MAGE-3 A2, NY-ESO-1 A2 et MART-1 A2)
Continuation Immunotherapy: Intradermal injections of Dex every two weeks during 6 weeks."
1878471|NCT01159301|Drug|entinostat|Given orally (PO)
1878472|NCT01159301|Drug|sorafenib tosylate|Given PO
1878473|NCT01159301|Other|pharmacological study|Correlative studies
1878474|NCT01159301|Other|laboratory biomarker analysis|Correlative studies
1878475|NCT01159314|Procedure|Baerveldt Device surgical Procedure|Implant surgery
1878476|NCT01159327|Drug|Sorafenib|Sorafenib 400mg, bid(800mg/day), daily, PO
1878477|NCT01159353|Drug|Insulin glulisine|Insulin glulisine 100 U/ml, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
1878478|NCT01159353|Drug|Insulin aspart|Insulin aspart: 100 U/mL, solution for injection in vial Dose: 0.2 U/Kg Administration: single subcutaneous injection with syringe in the periumbilical abdomen within 2 minutes before the standard meal
1878479|NCT01159366|Procedure|percutaneous coronary intervention|early timing
1878480|NCT01159379|Drug|ertapenem|intravenous, 1 gram, once
1878481|NCT01159405|Radiation|Radiolabeled (99mTc) GP (Glycopeptide)|one injection of Technetium Glycopeptide to yield a target activity of 20-25 mCi to be given by slow IV push (over 3-5 minutes) 5 mg, 10 mg & 20 mg of GP will be injected
1878482|NCT01159418|Drug|Panobinostat (LBH589), Carboplatin and Paclitaxel|"Panobinostat (LBH589) p.o. on days 1,4,8 and 11 of each cycle (20mg-45mg).Carboplatin i.v.on day 1 at a total dose corresponding to a AUC of 5 µg/ml.h. Paclitaxel as 3 hour infusion on day 1 (135 mg/m2).
Panobinostat (LBH589) p.o. on days 1, 4, 15 and 18 of each cycle (20mg-30mg).Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175mg/m2).
Once the MTD is achieved:Panobinostat (LBH589) p.o. on days 1 and 4 of each cycle(20mg-30 mg). Carboplatin i.v. on day 8 at a total dose corresponding to a AUC of 5 µg/ml.h.Paclitaxel as a 3 hour infusion on day 8 (135mg/m2-175 mg/m2).
The treatment will be repeated every three weeks until disease progression."
1878483|NCT01159431|Device|Trigeminal Nerve Stimulation|External stimulation of the supraorbital branch of the Trigeminal Nerve using a digital TENs unit
1878484|NCT01159457|Biological|Hepatitis B vaccination (Sci-B-Vac)|A dose of 5mcg (0.5 ml) (up to 10yr old) and 10mcg (1.0 ml)(above 10yr old) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
1878485|NCT01159457|Biological|Hepatitis B vaccination (EngerixB)|A dose of 10mcg (0.5 ml) of the recombinant HBV vaccine will be administered intramuscularly at zero, one and six months intervals
1878486|NCT01159483|Drug|PF-04958242|oral PIB, single dose, 0.01 mg, 0.03 mg, 0.1 mg
1878487|NCT01159483|Drug|PF-04958242|"oral PIB, single dose, 0.3 mg, 0.6 mg*, 1.0 mg*
*Unlikely to be administered as expected to exceed exposure limits."
1878488|NCT01159496|Drug|PF-05212377 (SAM-760)|Oral capsule, once daily for 14 days 1.5 mg, 5 mg, 15 mg, 30 mg and 50 mg
1878489|NCT01159496|Drug|Placebo|Oral capsule, once daily for 14 days
1878490|NCT01159509|Behavioral|sodium taste tests|The cohort group will had sodium taste tests and an interview regarding diat habits.
1878492|NCT01159535|Behavioral|Mindfulness Based Relapse Prevention|The MBRP intervention comprises 8 weekly, 2-hour sessions delivered in small group format (10-14 participants) by two therapists (Bowen, et al., 2009). In MBRP, therapists facilitate discussions and exercises and introduce the meditation practice component.Group sessions include discussions of mindfulness as a means of coping with craving and painful cognitions/sensations that precipitate relapse, role-playing exercises, meditation practice, and homework assignments.
1878493|NCT01159535|Behavioral|Relapse Prevention|intervention is composed of 8 weekly 2-hour sessions delivered in small group format (10-14 participants)
1878494|NCT01159535|Behavioral|Treatment as Usual|All participants will be enrolled in continuing care services (including attendance at AA, NA, or other self-help groups) as recommended by their treatment providers. Thus, TAU participants will have ongoing support and monitoring by their continuing care providers on a regular basis.
1878495|NCT01159548|Drug|Promethazine|
1878496|NCT01159548|Drug|Promethazine|
1878497|NCT01159561|Biological|Western Equine Encephalitis Vaccine|Subject will be vaccinated with 0.5 mL of reconstituted WEE vaccine, inactivated, TSI-GSD 210 (Lot 3-1-92) subcutaneously in the upper outer aspect of the deltoid region.
1878498|NCT01159574|Drug|dexamethasone|40mg will be given on days 1, 8, 15, 22 of a 28-day cycle
1878499|NCT01159574|Drug|clarithromycin|orally at a dose of 500 mg twice a day on days 1-28 of a 28 day cycle
1878500|NCT01159574|Drug|Pomalidomide|orally 4mg daily for days 1-21 of each 28 day cycle
1878501|NCT01159587|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Long-term secondary prophylaxis with product administered 20-30 UI /kg three times weekly
1878892|NCT01168141|Drug|ZD4054|10mg ZD4054 daily in tablet form
1878502|NCT01159587|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|On-demand treatment with product given only for bleeding episodes
1878503|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
1878504|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
1878505|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose open label
1878506|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily high dose
1878507|NCT01159600|Drug|Placebo identical to BI 10773 low dose|Placebo tablets matching BI 10773 low dose
1878508|NCT01159600|Drug|BI 10773|BI 10773 tablets once daily low dose
1878509|NCT01159600|Drug|Placebo identical to BI 10773 high dose|Placebo tablets matching BI 10773 high dose
1878510|NCT01159613|Other|Responders|Responders
1878511|NCT01159613|Other|Non Responders|Non Responders
1878512|NCT01159626|Drug|PF-03463275|Oral single 20 mg dose as two 10mg controlled release tablets
1878513|NCT01159626|Drug|PF-03463275|Oral single 40 mg dose as four 10mg controlled release tablets
1878514|NCT01159626|Drug|PF-03463275|Oral single 60 mg dose as six 10mg controlled release tablets
1878515|NCT01159626|Drug|Placebo|Oral single dose as matching placebo
1878516|NCT01159626|Drug|PF-03463275|Oral multiple 40 mg doses as four 10mg controlled release tablets for 7 days
1878517|NCT01159626|Drug|Placebo|Oral multiple doses as matching placebo for 7 days
1878518|NCT01159639|Drug|Clopidogrel|patients with inappropriate response to aspirin 300 mg after CABG, assessed by multiple electrode aggregometry are randomized to receive clopidogrel 75 mg daily dose
1878519|NCT01159652|Drug|zaleplon|10 mg
1878520|NCT01159652|Drug|zolpidem extended release|12.5 mg
1878521|NCT01159652|Drug|bedtime placebo|placebo
1878522|NCT01159652|Drug|middle of the night placebo|placebo
1878523|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
1878524|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
1878525|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
1878526|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
1878527|NCT01159665|Drug|ocriplasmin|125µg ocriplasmin intravitreal injection
1878528|NCT01159678|Behavioral|online psychoeducation|"The online psychoeducation contains 12 modules which will be administered once per week over the course of three months. The content of each module is as follows:
Important of sexuality to quality of life. & Definitions of sexual desire and arousal.
Consideration of the predisposing, precipitating, and perpetuating factors in his/her sexual difficulties.
Sexual beliefs.
Mindfulness.
Genital anatomy and physiology.
Body Image.
Relationship satisfaction and communication.
Body-oriented mindfulness exercises (focusing and self-observation).
Using Thought records.
Mindfulness and the thought stream.
Sexual aids to boost arousal.
Moving on.
In addition to these weekly modules, all participants will have access to a moderated and password-protected bulletin board to which participants can post questions and the PI will respond."
1878529|NCT01159704|Behavioral|Peer Education Model|The peer education intervention will be delivered by trained outreach workers in a group format with 8-10 indexes over five sessions spanning three weeks. The sessions will focus on knowledge of HIV transmission, self-efficacy and skills-building regarding HIV risk reduction, with an emphasis on the dissemination of such information and skills to network members.
1878530|NCT01159704|Behavioral|HIV Counseling and Education Model|"The C & E intervention is a manualized individual-level model consisting of two education and counseling sessions that structurally bracket confidential HIV antibody screening."
1878531|NCT01159730|Drug|VB-201 or Placebo|
1878532|NCT01159756|Drug|Travacom|Travacom ophthalmic solution (1 drop per day)
1878533|NCT01159769|Drug|Olopatadine hydrochloride ophthalmic solution, 0.2% (Pataday®)|Commercially marketed ophthalmic solution for the treatment of ocular itching associated with allergic conjunctivitis
1878534|NCT01159782|Other|Rhinovirus infection|All subjects (asthmatic and non asthmatic healthy)will be infected with Rhinovirus 16.
1878535|NCT01159808|Drug|INX-08189|3, 25 and 100 mg capsules; oral administration, single dose
1878536|NCT01159808|Drug|Placebo|matching placebo capsules, oral administration, single dose
1878537|NCT01159821|Drug|31001074/paroxetine|1 tablet of 31001074 will be administered on Day 1 and Day 13. One 20-mg paroxetine tablet will be administered once daily from Days 4 through 15
1878538|NCT01159847|Drug|sitagliptin|sitagliptin tablet,100 mg p.o. qd,2 year
1878539|NCT01159860|Procedure|cryosurgery|freezing of lesion with liquid nitrogen
1878540|NCT01159860|Procedure|Curettage|the lesion will be anesthetized and destroyed with a curette.
1878541|NCT01159873|Drug|CEP-37251|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of CEP-37251 (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) dose of 0.3 mg/kg will be studied.
1878542|NCT01159873|Drug|Placebo|up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
1878543|NCT01159886|Procedure|Ileal intubation|"After confirmation of cecal intubation, patient will undergo randomization to either the left-lateral decubitus or supine position. Then terminal ileal intubation will be attempted. Partial suction and scope manoeuvres for ileal intubation will be allowed.
Use of anti-peristalsis agents, use of biopsy forceps, as a guidewire or an ''anchor'' to facilitate the IC- valve intubation, and intubation in the retroflexed position will not be allowed."
1878544|NCT01159899|Procedure|Transplantation of Bone Marrow Stem Cells Activated in Knee Arthrosis|Transplantation of Activated Bone Marrow Stem Cells in Knee Arthrosis, under arthroscopy, in one-step procedure
1878545|NCT01159912|Drug|Fluticasone propionate|Fluticasone propionate inhalation powder, 250 µg
1878546|NCT01159912|Drug|Fluticasone furoate|Fluticasone furoate inhalation powder, 100 µg
1878547|NCT01159912|Drug|Placebo|Placebo inhalation powder
1878548|NCT01159925|Procedure|Serum sample|Serum samples collected
1878549|NCT01159938|Drug|Lispro|Dosage based on participants with type 2 diabetes mellitus (T2DM) normal morning insulin dose and energy content of participant's normal breakfast. Subcutaneous injection given on one occasion. Administered once on low post prandial day.
1878550|NCT01159951|Other|Epidemiologic Surveillance System of the Ministry of Health of Panama|Systematic review of the databases of epidemiologic surveillance system, Ministry of health, Panama
1878551|NCT01159964|Biological|Immunotherapeutic GSK2302032A, different formulations|Intramuscular administration
1878552|NCT01159977|Behavioral|Facilitated small groups|1 hour sessions every 2 weeks for small groups of 9 participants, 19 sessions over 9 months.
1878553|NCT01159977|Behavioral|Unstructured time.|1 protected hour every 2 weeks for 9 months, without small group structure.
1878554|NCT01159977|Behavioral|Usual practice|No protected time provided.
1878555|NCT01159990|Biological|rAd5 Gag-Pol Env A/B/C|1×10^10 particle units (PU) rAd5 Gag-Pol, Env A/B/C (3:1:1:1 mixture) delivered via intramuscular injection
1878556|NCT01159990|Biological|rAd5 Gag-Pol|5×10^9 PU rAd5 Gag-Pol delivered via intramuscular injection
1878557|NCT01160003|Drug|GW870086X|5mg and 8.75mg GW870086X once daily for 14 days in separate traetment periods.
1878558|NCT01160003|Drug|Placebo|placebo will be randomly inserted into one of the treatment periods following the treatment sequences outlined in the protocol.
1878559|NCT01160029|Drug|Nateglinide|Nateglinide Tablets 120 mg
1878560|NCT01160042|Drug|Metformin|Metformin Tablets 1000 mg
1878561|NCT01160042|Drug|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
1878562|NCT01160055|Procedure|Middle ear fluid and urine.|Middle ear fluid and urine collection.
1878563|NCT01160068|Drug|Metformin|Metformin Tablets 1000 mg
1878564|NCT01160068|Drug|Glucophage|Glucophage 1000 mg tablets of Bristol-Myers Squibb
1878565|NCT01160081|Other|Serum sample|Serum samples collected
1878566|NCT01160094|Drug|Treatment|patients treated with Lapatinib-Capecitabine after Trastuzumab Progression
1878567|NCT01160107|Drug|RP followed by MPR|Induction (4 cycles):Lenalidomide 25 mg/die for 21 days followed by a 7 days rest period and Prednisone at 50 mg three times a week continuously . Consolidation (6 cycles): Melphalan 2 mg three times a week, Prednisone 50 mg three times a week, and Lenalidomide 15 mg/die for 21 days followed by a 7 days rest period. According to the results of the first stage the decisions are as follows: 1. Starting a second stage, at the same dose of lenalidomide for MPR cycles, if grade 3-4 adverse events are 25-50% and PR > 50%; 2. The study stop (if PR <40% and grade 3-4 adverse events >25-30%) 3. A new first stage may be started: - Lenalidomide 20 mg/die if grade 3-4 adverse events are < 25-30%, independently from efficacy; - Lenalidomide 10 mg/die if grade 3-4 adverse events are > 50% and PR rate > 50%. Maintenance: Lenalidomide 10 mg/day from day 1 to 21, followed by a 7-day rest period and Prednisone 25 mg three times a week.Each cycle will be repeated every 28 days, until PD.
1878568|NCT01160120|Drug|generic FDC of TDF/3TC/EFV|Patients who were on individual TDF 3TC and EFV regimen before baseline will undergo TDM at baseline. Therapeutic drug monitoring (TDM) of generic FDC of TDF/3TC/EFV will be done after 4 weeks, to ensure steady state. At baseline and week 4 safety data will be obtained. In order to assess the efficacy and the long term safety of this drug, at week 12, 24 and 48 viral load, CD4 and safety parameters will be obtained.
1878569|NCT01160133|Other|Systane|Systane Lubricant Eye Drops (1-2 drops in each eye, four times per day)
1878570|NCT01160133|Other|Refresh Tears|Refresh Tears Lubricant Eye Drops (1-2 drops in each eye, four times per day)
1878571|NCT01160159|Other|Tests|Arterial parameters
1878572|NCT01160159|Other|Healthy volunteers|Arterial parameters and blood test
1878573|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392103A|intramuscular vaccination according to protocol schedule
1878574|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392105A|intramuscular vaccination according to protocol schedule
1878575|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392106A|intramuscular vaccination according to protocol schedule
1878576|NCT01160172|Biological|Staphylococcal investigational vaccine GSK2392019A|intramuscular vaccination according to protocol schedule
1878577|NCT01160172|Drug|Saline placebo|intramuscular vaccination according to protocol schedule
1878578|NCT01160185|Drug|paclitaxel|paclitacel
1878579|NCT01160185|Drug|cisplatin|cisplatin monotherapy
1878580|NCT01160185|Drug|topotecan|topotecan
1878590|NCT01160237|Biological|PandemrixTM|One dose intramuscular injection
1878591|NCT01160237|Biological|FluarixTM/ Influsplit SSW® 2010/2011|One dose intramuscular injection
1878592|NCT01160250|Drug|vismodegib (GDC-0449)|Oral repeating dose
1878593|NCT01160263|Drug|SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM|"123 I-FP-CIT (DATSCAN) : 185 MBq (5 mCi), 2,5 ml will be injected via an arm intravenous catheter.
123I-ADAM:185 MBq,5 ml will be injected via an arm intravenous catheter."
1878594|NCT01160276|Drug|cyclosporine+colchicine|the 14 patients of the 1st group are under cyclosporine and One pill of colchimax 1mg will be taken by all the patients at Day 3.
1878595|NCT01160276|Drug|tacrolimus|the 14 patients of the second group are under tacrolimus and One pill of colchimax 1mg will be taken by all the patients at Day 3.
1878596|NCT01160289|Drug|LY2452473|Administered orally, once daily for 12 weeks
1878597|NCT01160289|Drug|tadalafil|Administered orally, once daily for 12 weeks
1878598|NCT01160289|Drug|placebo (tadalafil)|Administered orally, once daily for 12 weeks
1878599|NCT01160289|Drug|placebo (LY2452473)|Administered orally, once daily for 12 weeks
1878600|NCT01160302|Drug|Microgranular Curcumin C3 Complex®|4 grams twice daily for 21-28 days
1878601|NCT01160315|Drug|Triptorelin|Triptorelin: intramusculAR injection every 3 months
1878602|NCT01160315|Drug|Norethisterone acetate|5 mg/day per os until during chemotherapy
1878603|NCT01165723|Biological|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
1878604|NCT01165723|Biological|PF-04427429|Intravenous dosing of 30mg on day 1 and one other day to be determined up to day 30
1878605|NCT01165736|Drug|PF-05186462|single intravenous infusion of 100 microgram
1878606|NCT01165736|Drug|PF-05186462|single oral administration of 100 microgram
1878607|NCT01165736|Drug|PF-05089771|single intravenous infusion of 100 microgram of PF-05089771
1878608|NCT01165736|Drug|PF-05089771|single oral administration of 100 microgram PF-05089771
1878609|NCT01165736|Drug|PF-05150122|single intravenous administration of 100 microgram PF-05150122
1878610|NCT01165736|Drug|PF-05150122|single oral administration of 100 microgram PF-05150122
1878611|NCT01165736|Drug|PF-05241328|single intravenous infusion of 100 microgram PF-05241328
1878612|NCT01165736|Drug|PF-05241328|single oral administration 100 microgram PF-05241328
1878613|NCT01165749|Behavioral|stop exercising|
1878614|NCT01165762|Drug|Immune Tolerance|"Immune tolerance Kidney and hematopoietic cell transplantation with a conditioning regimen of total lymphoid irradiation and antithymocyte globulin followed by immunosuppressive drugs for 18 months. Immunosuppressive drugs are stopped if stable chimerism is achieved and there is no rejection of the transplant kidney.
The IDE used in this study is the column used for hematopoietic cell sorting."
1878615|NCT01165775|Device|Dexcom Seven Plus Continuous Glucose Monitoring System|Soft sensor for continuous glucose monitoring inserted for up to 24 hours prior to administration of betamethasone. Device to be worn for duration of hospitalization or up to 7 days total, whichever time period is shorter.
1878616|NCT01165788|Procedure|Semi structured personal interview|A trained research assistant will conduct in-person, in-depth semi-structured interviews at a location of the participants choosing. Participants will be asked to discuss their experiences with cancer, focusing especially on how their cancer affected their (1) work/education (2) relationships with their family (spouse, children, parents, siblings and other relatives) (3) their other social relationships
1878617|NCT01165801|Procedure|Cataract Surgery|Fifty-four patients with cataract and non-exudative age-related macular degeneration (AMD) were randomized into an early surgery group (ES=28) with immediate cataract surgery and a control group (CO=26) where surgery was performed after six months.
1878618|NCT01165814|Drug|Naproxen Tramadol|
1878620|NCT01165853|Other|Glucose|25% dose at 8-week intervention assigned to subjects.
1878621|NCT01165853|Other|Fructose|25% dose at 8-week intervention assigned to subjects.
1878622|NCT01165866|Drug|Treatment 1. Metoclopramide|metoclopramide 0.3mg/kg maximum dose 10mg will be added in the burette and mixed with normal saline to make up 50cc of medication for intravenous administration.
1878623|NCT01165866|Drug|Treatment 2 Ondansetron|Single dose of Ondansetron 0.15 mg/kg
1878624|NCT01165892|Drug|Gadofosveset Triodium|Use of 0.03 mmol/Kg of gadofosveset trisodium (Ablavar)once with intravascular half life of up to 1 hr and optimal arterial imaging out to 20-30 minutes.
1878625|NCT01165905|Drug|ON 01910.Na|The starting dose of ON 01910.Na is 250 mg/m2 as a 24 hour intravenous (i.v.) infusion on days 1, 8 and 15 of a 28-day course. The dose of ON 01910.Na will be escalated in increments in successive cohorts (dose level (DL) 1 = 250 mg/m2, DL 2 = 650 mg/m2, DL 3 = 1050 mg/m2, DL 4= 1350 mg/m2) of new patients. A course is defined as 4 weeks in length.
1878626|NCT01165905|Drug|Gemcitabine|The dose of gemcitabine will be fixed at 1000 mg/m2 i.v. as a 30 minutes infusion on days 1, 8, and 15 every 28 days.
1878627|NCT01165931|Drug|Riociguat (BAY63-2521)|0.1 mg intracoronary infusion through coronary guide catheter. Single dose. Sequential application after initial vasoactive bolus of Adenosine (non-study drug) and Nitroglycerin (non-study drug).
1878628|NCT01165944|Drug|Pramlintide|Pramlintide administered pre-meal starting at 60 mcg and titrating up to 120 mcg within 4-6 weeks
1878629|NCT01165970|Drug|Glandosane|according to the german law the sued saliva substitute is a drug (Glandosane) whereas Saliva natura is a medical product
1878630|NCT01165970|Device|Saliva natura|Saliva substitute without restriction to be used
1878631|NCT01165983|Drug|Placebo|0mg tablet, taken orally for 12 weeks daily
1878632|NCT01165983|Drug|Aliskiren|150mg tablet, taken orally for 12 weeks daily
1878633|NCT01165996|Other|flow cytometry|Correlative studies
1878634|NCT01165996|Other|DNA methylation analysis|Correlative studies
1878635|NCT01165996|Other|cytogenetic analysis|Correlative studies
1878636|NCT01165996|Drug|decitabine|Given subcutaneously
1878637|NCT01165996|Genetic|microarray analysis|Correlative studies
1878638|NCT01165996|Genetic|gene expression analysis|Correlative studies
1878639|NCT01165996|Other|pharmacological study|Correlative studies
1878640|NCT01165996|Genetic|polymorphism analysis|Correlative studies
1878641|NCT01166022|Other|Exercise|Muscle strengthening program using hand weights and resistance bands in combination with a home based cycle ergometry. This home-based exercise program will be performed up to 5 times weekly. Each session will consist of up to 30 minutes of cycling and 30 minutes of strengthening.
1878642|NCT01166035|Drug|Lenalidomide|"Lenalidomide will be supplied as 5 mg, 10 mg, 15 mg, 20 mg and 25 mg capsules for oral administration.
Prior to Cycle 1, there will be a 21 day lead in treatment period with lenalidomide monotherapy (Days -21 to -1). Combination treatment will start at Day 1. Subjects will be enrolled in cohorts of three to receive a single, oral dose of lenalidomide administered on Days 1-28. For each cohort of subjects, the decision of whether or not to dose-escalate will be made after subjects have received the first treatment cycle of study drug. Treatment will continue until the occurrence of any of the following events.
Disease progression
Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.
Major violation of the study protocol.
Withdrawal of consent
Lost to follow up
Death
Suspected pregnancy"
1878715|NCT01166659|Device|CyPass Micro-Stent|The CyPass Micro-Stent is a small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye. The CyPass is implanted in the eye.
1878716|NCT01166685|Device|Everolimus-eluting stent|Everolimus-eluting stent
1878717|NCT01166685|Device|Bare-metal stent|Bare metal stent
1878643|NCT01166035|Drug|Cetuximab|"Combination treatment will start at Day 1. Subjects meeting will be enrolled in cohorts of three to receive infusions of cetuximab (400 mg/m2 first infusion only, then 250 mg/m2 subsequently) administered on Days 1, 8, 15, and 22 of each 28-day cycle. Cetuximab will be supplied as Erbitux® 22 mg/ml Vial à 50 ml, Erbitux 5 mg/ml Vial à 10 ml and Erbitux 5 mg/ml Vial à 50 ml for intravenous administration.
Treatment will continue until the occurrence of any of the following events.
Disease progression
Adverse event(s) that, in the judgment of the Investigator, may cause severe or permanent harm or which rule out continuation of the treatment regimen.
Major violation of the study protocol.
Withdrawal of consent
Lost to follow up
Death
Suspected pregnancy"
1878644|NCT01166048|Drug|Duloxetine|"Patients will receive 120mg of Duloxetine for the duration of 2 weeks after a dosage titration of 2 weeks according to the following scheme: (p=placebo)
day: 1 2 3 4 5 6 7: p-30mg p-30mg p-30mg p-30 mg p-30mg p-30mg p-60mg
day: 8 9 10 11 12 13 14: p-60 mg p-60 mg p-60mg p-60mg p-60mg p-60mg 60-60mg"
1878645|NCT01166048|Drug|Duloxetine|2 weeks of titration of duloxetine to 120mg, (1-0-1), 2 weeks of continuation on 120mg/day.
1878646|NCT01166139|Drug|Nilotinib (Tasigna)|Patients will be treated with Nilotinib 400 mg two times a day for 6 months.
1878647|NCT01166152|Behavioral|social skills training|meeting once a week or biweekly to play together using toys, games, and physical exercises.
1878648|NCT01166165|Drug|Cholecalciferol|3 tablets of 1000 IU daily for 20 weeks
1878649|NCT01166165|Drug|Placebo|3 placebo tablets daily for 20 weeks
1878650|NCT01166178|Drug|Zoledronic Acid|Zoledronic acid 5 mg once a year via intravenous infusion
1878651|NCT01166178|Drug|Placebo|Placebo to zoledronic acid once a year via intravenous infusion
1878652|NCT01166178|Dietary Supplement|Calcium and Vitamin D combination|Calcium 500 mg and Vitamin D 400 IU combined tablet, taken orally twice a day
1878653|NCT01166191|Radiation|Radiotherapy|Radiotherapy
1878654|NCT01166204|Radiation|Radiotherapy|Radiotherapy
1878655|NCT01166217|Drug|PF-04620110|"The five treatments are:
A) single dose of 5 mg immediate release tablets in the fasted state; B) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fasted state; C) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fasted state; D) single dose of 5 mg modified release osmotic capsule with a short duration of modified release 1 (MR1) in the fed state; E) single dose of 5 mg modified release osmotic capsule with a long duration of modified release 2 (MR2) in the fed state."
1878656|NCT01166243|Biological|Fibrin Pad|Fibrin Pad is a sterile bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of two biological components (Human Fibrinogen and Human Thrombin).
1878657|NCT01166243|Procedure|Standard of Care|Standard of Care is a composite of techniques/methods typically used by the surgeon to control bleeding.
1878658|NCT01166256|Device|Non-invasive ventilation|Noninvasive ventilation: The inspiratory(IPAP) and expiratory positive airways pressure (EPAP), and the levels of FiO2 is set achieve SpO2 >92% or PaO2 >65 mmHg.
1878659|NCT01166256|Device|High flow nasal cannula system|High flow nasal cannula system: FiO2 and flow rate of oxygen is set to achieve SpO2 >92% or PaO2 >65 mmHg.
1878660|NCT01166269|Biological|phleum pratense (grass-allergen)|6 injections of grass-allergen. Every dose will be 1000 SQ-U.
1878661|NCT01166269|Biological|phleum pratense (grass allergen)|3 injections of grass-allergen. Every dose will be 1000 SQ-U. Also 3 injections of placebo (physiological saline)
1878662|NCT01166269|Other|physiological saline|6 injections of placebo (physiological saline)in a lymph node.
1878663|NCT01166282|Biological|adalimumab|Adalimumab solution for subcutaneous injection.
1878664|NCT01166282|Biological|placebo for adalimumab|Placebo for adalimumab solution for subcutaneous injection.
1878665|NCT01166308|Radiation|Carbon Ion Radiotherapy|Carbon Ion Radiotherapy in the RD determined within the Phase I part of the Study (10 x 3Gy E to 16 x 3 Gy E)
1878666|NCT01166308|Radiation|Fractionated Stereotactic Radiotherapy (FSRT)|Standard Treatment as Re-Irradiation performed as Fractionated Stereotactic Radiotherapy (FSRT)up to 36 Gy in single doses of 2 Gy
1878667|NCT01166321|Radiation|Carbon Ion Radiotherapy|Carbon Ion Boost 18 Gy E in single Fractions of 3 Gy E
1878668|NCT01166334|Behavioral|WebQuit study group|Description withheld to protect integrity of study
1878669|NCT01166334|Behavioral|WebQuit control group|Identity and description withheld to protect integrity of study
1878670|NCT01166347|Device|HeartWare® VAS|The HeartWare® VAS is an implantable centrifugal pump that was designed to provide flows up to 10 L/min in a small device that is both lightweight and simple to use.
1878671|NCT01166347|Device|Control LVAD|Any FDA-approved LVAD for destination therapy.
1878672|NCT01166373|Behavioral|Enrollment video|Standardized video detailing the importance of long-term follow-up studies for pelvic organ prolapse prior to the informed consent process
1878673|NCT01166373|Procedure|SSLF|sacrospinous ligament fixation to suspend the vaginal apex
1878674|NCT01166373|Procedure|ULS|uterosacral ligament suspension to suspend the vaginal apex
1878675|NCT01166373|Behavioral|PMT|perioperative behavioral therapy / pelvic muscle training with formal individualized PMT program that begins two to four weeks prior to surgery and continues for three months after surgery
1878676|NCT01166373|Other|Usual Care|usual care both before and after prolapse surgery with respect to pelvic muscle training
1878677|NCT01166386|Behavioral|FANCI|compresensive neubehavioral sessions with therapist administrating treatment components
1878678|NCT01166386|Behavioral|FANCI|Watching DVDs chosen by participants on various topics.
1878718|NCT01166685|Device|Biodegradable Polymer-DES|drug-eluting stent with bioabsorbable polymer
1878719|NCT01166698|Drug|AZD9819|Inhaled single doses of suspension via SPIRA nebuliser
1878720|NCT01166698|Drug|AZD9819|Inhaled multiple doses of suspension via SPIRA nebuliser, once daily for 10 (maximum 14) days
1960312|NCT03242499|Drug|Lovastatin|Lovastatin 80mg or placebo use for 48 weeks.
1960313|NCT03242499|Drug|Placebo|placebo for 48 weeks
1878683|NCT01166425|Drug|Lithium Carbonate|Participants weighing ≥ 30 kg who are randomized to receive active lithium will begin treatment at 300 mg TID at visit 1 (total dose 900 mg). Participants weighing < 30 kg who are randomized to receive active lithium will begin treatment at 300 mg BID the day after visit 1 (total dose 600 mg). Based on the participant's response and tolerability, the dose will be increased by 300mg three days after the baseline visit and at scheduled in-office visits to the maximum tolerated dose. One mid-week dose increase will be scheduled in addition to the weekly increases at the scheduled in-clinic visits. On day 3 (+/- 2 days), a dose increase of 300 mg may occur based on the results of a telephone call placed by the study investigator to the participant's parent/guardian. During the telephone call, the prescribing clinician will assess medication adherence, adverse events, and overall improvement since baseline.
1878684|NCT01166425|Drug|Placebo|Participants who are randomized to receive placebo during the Efficacy Phase will receive matching placebo capsules. Dosing will be titrated as described for active lithium.
1878689|NCT01166451|Dietary Supplement|Low-iron formula|Infants randomly assigned at 6 months of age to receive low-iron formula (average 2.3 mg/L, range 1.6 - 2.4 mg/L) until 12 months of age. Low-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
1878690|NCT01166451|Dietary Supplement|High-iron formula|Infants randomly assigned at 6 months of age to receive high-iron formula (average 12.7 mg/L) until 12 months of age. High-iron formula distributed in powdered form. Project personnel visited infants' homes weekly to record measures of powdered formula used per day. Formula consumption was also verified by the number of cans given by the clinic nurse at each visit (regular pediatric visits and monthly clinic appointments until 12 months of age.)
1878691|NCT01166464|Behavioral|text messaging for smoking cessation|A 7-week program of daily text messages
1878692|NCT01166464|Behavioral|Generic text messages|non-smoking related text messages will be given on the same daily schedule as matches the active intervention to establish a control for contact time.
1878693|NCT01166477|Drug|Lopinavir and ritonavir|The patients will take Kaletra (lopinavir200mg/ritonavir50mg)two tablets bid
1878694|NCT01166477|Drug|Triple therapy with ritonavir|The patients will continue to take their usual triple therapy, as established in the summary of product characteristics
1878695|NCT01166490|Drug|ASG-5ME|0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles
1878696|NCT01166503|Procedure|mVEP Testing|Five small sensors are placed on the head which record the brain's response to moving stripes that are displayed on a computer screen. Each eye is tested while the other eye is patched. Each recording trial lasts about 10 seconds, and several trials are done for each eye.
1878697|NCT01166503|Procedure|Stereoacuity Testing|Subjects will have their 3D perception measured using standard clinical stereo tests (Randot, Lang, Titmus).
1878698|NCT01166503|Procedure|Optokinetic nystagmus testing|Subjects will be asked to view a screen with vertical stripes moving in both leftward and rightward directions while their eye movements are recorded using a remote video-based eye tracker.
1878699|NCT01166503|Procedure|Motion detection testing|Subjects will view a computer screen that has two panels of dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
1878700|NCT01166503|Procedure|Motion discrimination testing|Subjects will view a computer screen that has two panels of randomly moving dots on them. The subject will be required to pick which panel has a section of dots that are moving in a specific direction (ie. nasalward/temporalward).
1878701|NCT01166516|Device|Treatment with HUD IBV Valve System|Treatment involves placing one or more valves in the airways of the lung to control a prolonged air leak.
1878702|NCT01166529|Procedure|EUS-guided Celiac Plexus Neurolysis|All patients will receive anesthesia. The linear echo-endoscope will be advanced into the proximal stomach. It will be noted whether the tumor is seen in the celiac axis, if there is flow in the celiac artery, and if the celiac ganglia are seen. The celiac ganglia will be injected directly with 10cc of 0.25% bupivicaine followed by 10cc of 98% dehydrated alcohol. If the celiac ganglia cannot be identified, the posterior and anterior aspects of celiac artery take-off will be injected in a similar manner (twice the volume). Flow in the celiac axis will be confirmed. All injections will be performed with a standard EUS injection needle made especially for CPN . Prior to injection, aspiration will be performed through the needle to ensure that no blood is aspirated.
1878703|NCT01166542|Biological|REOLYSIN|3E10 TCID50, 1 hour intravenous infusion, administered on Days 1, 2, 3, 4 and 5 of a 21 day cycle
1878704|NCT01166542|Drug|Carboplatin|5 AUC mg/mL min, 30 min intravenous infusion, given on Day 1 of a 21 day cycle
1878705|NCT01166542|Drug|Paclitaxel|175 mg/m2, 3 hour intravenous infusion, given on Day 1 of a 21 day cycle
1878706|NCT01166542|Drug|Placebo|Placebo
1878707|NCT01166555|Drug|PF-04236921|single subcutaneous dose
1878711|NCT01166633|Drug|pitavastatin|pitavastatin 2mg per daily
1878712|NCT01166633|Drug|atorvastatin|atorvastatin 10mg per daily
1878713|NCT01166646|Drug|Halobetasol Proprionate Lotion 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
1878714|NCT01166646|Drug|Halobetasol Proprionate Cream 0.05%|Apply 3.5 grams twice daily for 1-2 weeks
1878721|NCT01166698|Drug|Placebo|Inhaled doses of suspension via SPIRA nebuliser given either as single (Part A) or multiple doses (Part B)
1878722|NCT01166711|Device|Coroflex Blue (BMS) followed by SeQuent Please (DEB)|"standard techniques will be used
maximal vasodilatation after nitro application
baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)
6 French guiding catheter at least
target lesion will be crossed with standard guidewire
direct stenting at the discretion of the investigator
if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)
full lesion coverage will be ensured (with one or more stents)
only insert assigned stent type
BMS needs to be fully embedded in vessel wall
post-dilation with high pressure is required before treatment with DEB
DEB will be inflated with nominal pressure (balloon equates to vessel diameter)
length of DEB should exceed the BMS by 2-3 mm on each side
if dissection, full length of dissection and optional additional stented area should be treated with additional DEB (to avoid geographic miss)"
1878723|NCT01166711|Device|Coroflex Please (DES)|"standard techniques will be used
maximal vasodilatation after nitro application
baseline angiography with at least two orthogonal views (showing target lesion free of foreshortening or vessel overlap)
6 French guiding catheter at least
target lesion will be crossed with standard guidewire
direct stenting at the discretion of the investigator
if pre-dilation, a commercially available balloon will be used (length not exceeding the stent to be implanted)
full lesion coverage will be ensured (with one or more stents)
only insert assigned stent type"
1878724|NCT01166724|Drug|Sirolimus|Tacrolimus to Sirolimus
1878725|NCT01166724|Drug|Tacrolimus|dosage per trough level
1878726|NCT01166737|Procedure|Tumor Debulking Surgery (surgery in recurrent ovarian disease)|Surgery for Patients with platinum-sensitive recurrent ovarian cancer with a positive AGO-score predictive for complete tumor resection
1878727|NCT01166750|Behavioral|CD-ROM|"Treatment Group will continue to follow their treating rheumatologist's recommendations and prescriptions. The program will contain information on the multiple components of pain (the pain puzzle) as a treatment rationale and will then teach children to use cognitive-behavioral techniques for pain management. The information will be presented via visual displays, narration, and interactive menus. Children will be able to navigate through the different lessons at their own pace and will be required to take simple quizzes to assess their learning. Various passwords and homework assignments are embedded within the program to ensure that children are going through the material."
1878728|NCT01166750|Behavioral|Wait-list Control Group|Children in the control group will continue to follow recommendations and prescriptions by their treating rheumatologist. After an 8-week wait-list control condition that involves measurement phases identical to those of the Jointstrong Treatment Group but no Jointstrong treatment, the children in the control group will enter the Jointstrong program and will then have the same immediate post-treatment measures that the Treatment Group received. The Control Group will not, however, have the Treatment Group's 12-week follow-up phase.
1878729|NCT01166763|Drug|vitamin D3|oral capsules, 10,000 IU per week for 6 months
1878730|NCT01166789|Drug|Lubiprostone|48ug daily taken as 24ug capsules twice per day, in morning and evening.
1878731|NCT01166789|Drug|Placebo|2 capsules daily, taken in morning and evening
1878732|NCT01166815|Dietary Supplement|Zinc sulphate|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
1878733|NCT01166815|Other|Placebo|Volunteers will be randomly assigned to either receive zinc sulphate supplements (20 mg/capsule) or a placebo containing no zinc. Maltodextrin serves as the carrier. The manufacturer is Tishcon Corporation, Westbury, NY.
1878734|NCT01166828|Behavioral|TELLEPUPPS|The TELEPUPPS participants will learn self care management of PUP through a program based on a social cognitive behavioral model to reinforce problem solving and self-efficacy in preventing pressure ulcers.
1878735|NCT01166841|Procedure|PSVC line clamped|A line clamp will be placed on the PSVC line while on cardiopulmonary bypass.
1878736|NCT01166854|Device|Diffuse Optical Spectroscopy|Diffuse Optical Spectroscopy
1878737|NCT01166867|Device|Photo-plethysmography monitoring|monitoring vital sign in infant
1878738|NCT01166880|Device|Laser Speckle Imaging|Laser Speckle Imaging Infant Head Blood flow
1878739|NCT01166893|Device|Modulated Imaging and Laser Speckle Imaging|wound healing
1878740|NCT01166906|Device|pain blocking|pain blocking
1878741|NCT01166919|Device|Matrix Radiofrequency|Matrix Radiofrequency Treatment of Port Wine Stain Birthmarks
1878742|NCT01166932|Drug|Amoxycillin/clavulanic acid|100mg/Kg/day/10 days.
1878743|NCT01166932|Drug|ceftriaxone/oxacillin|75 mg/Kg/day/10 days.
1878744|NCT01166945|Drug|Amoxicillin-Potassium Clavulanate Combination|All subjects will be started on treatment with 5 days of high dose amoxicillin (90mg/kg) with potassium clavulanate (6.4 mg/kg) twice daily in bottle A. The allocation to group B1 or B2 will be concealed until after the family and subject has signed the assent and consent, respectively. The maximum dose will be 2 gms twice daily. After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
1878745|NCT01166945|Drug|Placebo|After 5 days the subjects will be randomized to either continue to receive the same dose of amoxicillin clavulanate or a look-a-like and taste-a-like placebo for the next 9 days.
1878746|NCT01166958|Drug|Teriparatide|Teriparatide (TPD; Forteo) is supplied as a pre-filled syringe that dispenses 20 ug. The dose is one subcutaneous injection daily. Each pre-filled injection delivery device contains sufficient TPD for a 28-day supply of 20 mcg/day.
1878747|NCT01166958|Drug|Raloxifene|Raloxifene (RLX; Evista) is supplied as a 60 mg tablet. RLX is stored at room temperature.
1878748|NCT01166971|Device|ReSTOR +3|Bilateral implantation of ReSTOR +3 Intraocular Lenses (IOLs) after cataract extraction
1878749|NCT01166971|Device|Tecnis MF|Bilateral implantation of Tecnis Multifocal (MF) Intraocular Lenses (IOLs) after cataract extraction
1878751|NCT01166997|Device|EkoSonic Endovascular System|The EkoSonic Endovascular System will be used to deliver < 20 mg of rt-PA ( Actilyse) directly into the occlusive pulmonary thrombus.
1878752|NCT01166997|Drug|Unfractionated heparin|Intravenous unfractionated heparin used for anticoagulation treatment
1878753|NCT01167010|Drug|Formoterol/Budesonide|formoterol and budesonide will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
1878754|NCT01167010|Drug|Foraseq|foraseq will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
1878755|NCT01167010|Drug|Alenia|Alenia will be administered at the 12/400 µg dosage, twice a da for 12 weeks.
1878756|NCT01167023|Drug|Prasugrel|Administered orally, once daily for 30 days.
1878757|NCT01167023|Drug|Placebo|Administered orally, once daily for 30 days.
1878758|NCT01167036|Device|FascialEdge instrument|Stroking massage to patient tolerance over the muscle
1878759|NCT01167036|Other|Placebo electric point stimulation|Detuned electric point stimulation over the involved muscle
1878760|NCT01167049|Drug|CAPECITABINE|Capecitabine(Xeloda) 1000 mg/m2 bid, d1-14; q3w; Paclitaxel 80mg/m2 d1,d8; q3w; Repeat three cycles (approximately 3- months);
1878761|NCT01167062|Drug|Tamsulosin Hydrochloride OCAS 0.4 mg|One tablet OD for a maximum of 28 days
1878762|NCT01167062|Other|Placebo|One tablet OD for a maximum of 28 days
1878763|NCT01167075|Dietary Supplement|Fresubin Original|
1878764|NCT01167075|Dietary Supplement|Intestamin plus Fresubin Original|
1878765|NCT01167088|Drug|Mitoquinone mesylate|2 tablets to be taken daily upon wakening, with a glass of water and at least one hour before food.
1878766|NCT01167088|Drug|Placebo|Placebo
1878767|NCT01167101|Drug|Rebamipide|Rebamipide 100mg Tid for 28days
1878768|NCT01167101|Drug|pantoprazole|pantoprazole 40mg qd for 28days
1878769|NCT01167114|Drug|STA-9090|Given intravenously on Day 1, 8 and 15 of each 4 week cycle.
1878770|NCT01167127|Drug|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release|OXN Tablet, oral, BID, flexible dose design
1878771|NCT01167140|Device|Cryo-Touch II|Percutaneous treatment with the device
1878772|NCT01167153|Drug|Valsartan/Amlodipine|Valsartan/Amlodipine 80/5mg single pill combination (SPC)
1878773|NCT01167153|Drug|Nifedipine|Nifedipine GITS (Gastro-Intestinal Therapeutic System ) 30 mg
1878774|NCT01167166|Drug|rigosertib|The dose of rigosertib will be 2400 mg/24h as an intravenous continuous infusion over 72 or 120 hours every 2 weeks for 2 cycles then as oral capsules administered at a dose of 560 mg twice daily on a continuous basis.
1878776|NCT01167192|Drug|Cisplatin|
1878777|NCT01167192|Drug|Carboplatin|
1878778|NCT01167192|Radiation|Radiation therapy|
1878779|NCT01167192|Procedure|Mastectomy (recommended but not mandatory)|
1878780|NCT01167205|Dietary Supplement|astaxanthin|astaxanthin 20mg for 12 weeks
1878781|NCT01167231|Drug|Acarbose (Glucobay, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
1878782|NCT01167244|Drug|BMS-690514|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
1878783|NCT01167257|Drug|Liposome encapsulated botulinum toxin A|Liposome encapsulated BoNT-A ( mixed BOTOX 200 U/10 mL water in Liposome 80 mg/40 mL water) in single intravesical instillation, one time treatment at the treatment day
1878784|NCT01167257|Drug|Normal saline instillation|Normal saline (BoNT-A/NS) 50 mL in single intravesical instillation
1878785|NCT01167270|Behavioral|Child Safety Insights|A child safety intervention with messages focused on the infant's environment and interactions with parents. They will be guided by the American Academy of Pediatrics as well as the Academy's guide for health supervision, Bright Futures.
1878786|NCT01167270|Behavioral|Parenting Insights|Educational program contains messages to provide developmentally appropriate guidance to parents of infants on responsive parenting and healthy lifestyle that will prevent rapid weight gain in infancy and overweight at age 3 years.
1878787|NCT01167283|Device|Electrostimulation|Electrostimulation: 35 Hz, 0.4 ms, 1 h; 5 times/week
1878788|NCT01167283|Device|Sham stimulation|Sham stimulation: 1 h; 5 times/week
1878789|NCT01167296|Device|Cook balloon uterine stent|Immediately before hysteroscopic surgery, a culture tip is inserted into the uterine cavity and sent for culture. Another culture was done 30 days later, and a second-look hysteroscope is done to evaluate the healing of uterine cavity.
1878790|NCT01167309|Drug|LEO 27847|First in patient
1878791|NCT01167322|Drug|NPC-07 for oral administration|NPC-07, containing 1.5g of 5-aminolevulinic acid hydrochloride per vial, is dissolved in 50 mL of water and will be administered orally 3 hours (range 2-4 hours) prior to induction of anesthesia at a dose of 20mg/kg body weight.
1878792|NCT01167335|Drug|BGG492|
1878793|NCT01167335|Drug|Placebo|
1878795|NCT01167374|Radiation|Carbon Ion Radiotherapy|Increasing Dose of Carbon Ion Radiotherapy 4 x 10 Gy E to 4 x 14 Gy E
1878796|NCT01167387|Dietary Supplement|PREOP|a carbohydrate beverage (total carbohydrates equal to 12.6g/100 mL: 2.1 g monosaccharide, 10.0 g maltodextrine; 240 mOsm/L) in dose of 800 mL
1878797|NCT01167387|Other|water|The control group will receive plain water with the same volume and timing of treatment.
1878798|NCT01167400|Behavioral|Cybercycling|exercising on a videogame-enhanced interactive 3D stationary bicycle for 3 months, 3-5x/wk
1878799|NCT01167400|Behavioral|Traditional exercise|exercising on a traditional stationary bike for 3 months, 3-5x/wk
1878800|NCT01167413|Device|Evaluation by manual Dolorimeter|Patients will be examined by a manual Dolorimeter
1878801|NCT01167413|Other|SIJ imaging|Patients will undergo imaging of the Sacroiliac joint by plain x-ray or MRI and sacroileitis will be documented
1878802|NCT01167426|Drug|Glatiramer Acetate 20 mg/0.5 mL|20 mg/1.0 mL formulation of glatiramer acetate utilizing the autoject 2 for glass syringe.
1960328|NCT03238703|Drug|Anastrozole|Given PO
1960329|NCT03238703|Drug|Exemestane|Given PO
1960330|NCT03238703|Other|Laboratory Biomarker Analysis|Correlative studies
1960331|NCT03238703|Drug|Letrozole|Given PO
1960332|NCT03238703|Other|Quality-of-Life Assessment|Ancillary studies
1878803|NCT01167426|Drug|Glatiramer acetate 20 mg/0.5 mL|20 mg/0.5 mL formulation of glatiramer acetate utilizing the autoject 2 20 mg/0.5 mL device.
1878804|NCT01167439|Procedure|Upper esophageal sphincter myotomy|Upper esophageal sphincter release operation to allow better swallowing. The intervention is done under GA and by extra-mucosal approach.
1960333|NCT03238703|Other|Questionnaire Administration|Ancillary studies
1878806|NCT01167465|Other|Moussik Diaper Rash Mousse|To be used as instructed
1878807|NCT01167465|Other|Desitin Creamy Ointment|To be used as instructed
1878808|NCT01167478|Dietary Supplement|Caffeine|After ingestion of 6 mg.kg-1 of body mass of caffeine, subjects will perform the one exercise trial.
1878809|NCT01167478|Dietary Supplement|Caffeine|6 mg/kg of body mass of caffeine will be ingested by subjects before exercise.
1878810|NCT01167491|Biological|Physiopathology Endpoint Classification|Blood samples will be collected during a routine medical visit.
1878811|NCT01167504|Other|Saliva sample collection|Collection of either whole mouth saliva or parotid saliva. Whole mouth saliva is collected through stimulation by inert gum. Parotid saliva is collected by using a Lashley cup placed over the parotid duct and stimulated by a fruit sweet.
1878812|NCT01167517|Other|Instructional digital video disc (DVD)|Breast milk expression instructions provided by digital video disc at the time of hospital discharge
1878813|NCT01167530|Drug|Everolimus|First phase of the study:RAD001 (everolimus) will be administered per os every Monday, one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of the radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 10, 20 and 50 mg of RAD001 per week.Second phase of the study:RAD001 (everolimus) will be administered per os every day one week before then during the radiotherapy and will be continued for 3.5 weeks after the end of radiotherapy. Chemotherapy is given 4.5 weeks after the end of radiotherapy. Three patient cohorts are planned, receiving 2.5, 5 and 10 mg of RAD001 per day.The two phases of the study may be conducted independently and in parallel.
1878814|NCT01167556|Behavioral|Family Motivational Intervention|A intervention with provided parents 6 sessions of Interaction Skills training and 6 sessions Motivational Interviewing training.
1960334|NCT03238703|Drug|Tamoxifen Citrate|Given PO
1960335|NCT03238703|Drug|Toremifene Citrate|Given PO
1878817|NCT01167582|Biological|Red blood cell transfusion|Liberal versus restrictive transfusion
1878818|NCT01167595|Other|PEP uP Protocol|Protocol documents (i.e. pre-printed order, algorithm for advancing feed, and algorithm for calculating rate of administering feed as per 24hour volume) and a slide presentation coupled with educational reminders (posters and bedside notices) and practice helps (tool to remind nurse to measure and report nutritional adequacy) will be made available to all nurses, in bedside manuals and/or on the local intranet.
1878819|NCT01167608|Other|No Intervention. This is a cross-sectional survey study.|No intervention.
1878820|NCT01167634|Behavioral|Deposit contract with a 1:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
1878821|NCT01167634|Behavioral|Deposit contract with a 2:1 match|Daily weigh-in for 24 weeks and if each daily goal met daily deposit amount is paid back with an additional matched amount twice the amount equal to deposited amount. Final weigh-in at 36 weeks with no financial incentive or deposit made.
1878822|NCT01167634|Behavioral|Deposit Contract with no match|Daily weigh-in for 24 weeks and if each daily goal met the daily deposit amount is paid back. Final weigh-in at 36 weeks with no financial incentive or deposit made.
1878823|NCT01167660|Device|The Thrombo-Monitor (ThM)|Non-invasive measurement of coagulation status and comparison to standard blood coagulation tests. In healthy neonates - immediately after birth, before the administration of vitamin K. Coagulation tests will be done on an umbilical cord blood sample. In sick neonates, coagulation studies will be done according to the medical condition.
1878824|NCT01167673|Dietary Supplement|coltect|green tea 250 mg, selenium 100 micro gram, curcumin 500 mg
1878825|NCT01167673|Dietary Supplement|Placebo|placebo
1878826|NCT01167686|Dietary Supplement|Gardemont Goldtrain Plus (GT+)|Four tablets of 760 mg of GT+ administered three times a day for seven consecutive days and similar placebo tablets given to the control arm
1878827|NCT01167699|Drug|Oxycodone and naloxone|Oxycodone hydrochloride and naloxone hydrochloride combination, prolonged release
1878833|NCT01167725|Biological|bevacizumab|Given IV
1878834|NCT01167725|Biological|cetuximab|Given IV
1878835|NCT01167725|Drug|FOLFIRI regimen|Given IV
1878836|NCT01167725|Drug|FOLFOX regimen|Given IV
1878837|NCT01167725|Drug|capecitabine|Given IV
1878838|NCT01167725|Drug|fluorouracil|Given IV
1878839|NCT01167725|Drug|irinotecan hydrochloride|Given IV
1878840|NCT01167725|Drug|leucovorin calcium|Given IV
1878841|NCT01167725|Drug|mitomycin C|Given intraperitoneally
1878842|NCT01167725|Drug|oxaliplatin|Given IV
1878843|NCT01167725|Procedure|therapeutic conventional surgery|Patients undergo cytoreductive surgery
1878844|NCT01167738|Drug|capecitabine|1250 mg/mq days 1-28 every 4 weeks
1878845|NCT01167738|Drug|cisplatin|30 mg/mq on days 1 and 15 every 4 weeks
1878846|NCT01167738|Drug|epirubicin|30 mg/mq on days 1 and 15 every 4 weeks
1878847|NCT01167738|Drug|gemcitabine|800 mg/mq on days 1 and 15 every 4 weeks
1878848|NCT01167738|Drug|metformin|2 g days 1-28 every 4 weeks
1878849|NCT01167751|Biological|MNC|Implantation of BM derived MNC
1878850|NCT01167751|Biological|AC 133|Implantation of BM derived AC133
1878851|NCT01167751|Biological|Control|Injection of cell carrier
1878891|NCT01168128|Other|Tailored Change Strategy|e.g. Education, decision support tools
1878852|NCT01167764|Drug|tranexamic acid, placebo|tranexamic acid 250mg tid for 1 months vs. placebo for 1 months
1878853|NCT01167790|Procedure|buccal cavity examination|autofluorescence examination
1878854|NCT01167803|Drug|Desflurane|Patients undergo anesthesia using remifentanil associated with desflurane
1878855|NCT01167803|Drug|Xenon|Patients undergo anesthesia using remifentanil associated with xenon
1878856|NCT01167816|Drug|Vidaza|Vidaza will be administered subq daily for 5 consecutive days each 28-day cycle
1878857|NCT01167829|Drug|Oral Testosterone|Oral Testosterone: 300 mg, pills, three times daily Day 1 - 10 (total of 27 pills)
1878858|NCT01167829|Drug|Acyline|300 ug/kg injection on Day 0
1878859|NCT01167855|Other|Asthma Education Sessions|Comprehensive asthma education sessions delivered via telemedicine.
1878860|NCT01167855|Other|Asthma Health Assessment via Telemonitoring|Each intervention participant will undergo assessment of asthma via school-based telemonitoring to measure lung function and provide a self-report of asthma symptoms.
1878861|NCT01167855|Other|Provider Treatment Prompt|A treatment prompt will be mailed to the primary care provider at baseline and 3 months.
1878862|NCT01167855|Other|School Absenteeism|Absenteeism before and after the intervention will be compared in the intervention group and also will be compared to absentee rates of the usual care group.
1878863|NCT01167855|Other|Prescription Filling Profile|Study personnel will monitor participants' prescription profiles.
1878864|NCT01167868|Drug|FosD|oral tablet
1878865|NCT01167868|Drug|Placebo|oral tablet
1878866|NCT01167881|Drug|BI 10773|Medium dose once daily
1878867|NCT01167881|Drug|Glimepiride|1-4 mg once daily
1878868|NCT01167881|Drug|Placebo|Placebo matching BI 10773
1878869|NCT01167881|Drug|Placebo|Placebo matching Glimepiride
1878870|NCT01167894|Drug|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
1878873|NCT01167920|Other|Virtual Hypertension Clinic|In the VHC group, patients will be ask to regularly measure blood pressure with the Stabil-o-Graph so that these readings are transmitted to Virtual Hypertension Clinic. The data will be reviewed weekly and the patient will receive feedback and intervention if needed at every 2 week interval to achieve blood pressure goal. Once they reach goal, the feedback will be less intense and given at four week intervals until the end of the study.
1878874|NCT01167933|Drug|Simvastatin|Simvastatin 80 mg tablets Dr. Reddy's Laboratories Ltd
1878875|NCT01167946|Drug|methylprednisolone sodium succinate|Group A will receive pulse treatment for 3 consecutive days once every 2 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
1878876|NCT01167946|Drug|methylprednisolone sodium succinate|Group B will receive 2 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
1878877|NCT01167946|Drug|methylprednisolone sodium succinate|Group C will receive 3 consecutive daily pulses every 3 weeks for 24 weeks. The daily dose of each pulse treatment will consist of methylprednisolone sodium succinate 15mg/kg of ideal body weight, given orally in 200 ml of fresh orange juice.
1878878|NCT01167959|Procedure|Roux en Y gastric bypass and lap. gastric banding|Standard RYGB and LAGB procedures
1878879|NCT01167959|Behavioral|Prodimed dietary intervention|3 months of using the prodimed diet
1878880|NCT01167985|Device|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
1878881|NCT01167985|Device|IABN|patients with molar teeth diagnosed with healthy pulp or irreversible pulpitis, and need root canal treatment, will be asked to participate in the study. After cleaning the teeth following a standard protocol, a sterile cotton wool will be placed in the pulp chamber. provisional restoration with and without nanoparticles will seal the teeth between apointments. After a month the cotton wool will be taken out and tansferred to the laboratory. The root canal treatment will continue following the standard protocol.
1878882|NCT01167985|Device|IABN|Patients with single canal teeth diagnosed with infected pulp and periapical lesion, and need root canal treatment, will be asked to participate in the study. The study group will have their canal sealed with endodontic sealer + the nanoparticles. The control group will have their canal sealed with the conventional sealer alone. The patients will be invited to 4 follow ups during which a clinical and radiological examinations will be performed.While preparing the post, a sample of the sealer will be taken to evaluation in the lab.
1878883|NCT01168011|Drug|rigosertib|Doses of rigosertib up to 700 mg twice a day or three times a day for 21 days of 21-day cycles. Treatment may continue until progression.
1878884|NCT01168024|Device|CINCOR™ System and contrast conservation unit (CCS-1)|Catheter based system to reduce and remove contrast media and contrast modulator to reduce contrast media
1878885|NCT01168024|Other|Standard of Care plus peri-procedural hydration|The control group will receive a peri and post-procedural hydration rate.
1878888|NCT01168050|Drug|Nilotinib|Nilotinib 400 mg twice per day
1878889|NCT01168063|Drug|Molecular detection of antibiotic resistance|Helico DR®, triple therapy (Proton Pomp Inhibitor (PPI), amoxicillin, clarithromycin, metronidazole)
1878890|NCT01168063|Drug|standard triple therapy (PPI, amoxicillin, clarithromycin, metronidazole)|"2 lines of treatments :
1) PPI + Amoxicillin + Clarithromycin for 7 days
1) PPI + Amoxicillin + Metronidazole for 14 days"
1878893|NCT01168154|Dietary Supplement|Lactobacillus Reuterii|Lactobacillus Reuterii 10000000000 CFU per day
1878894|NCT01168154|Dietary Supplement|placebo|placebo
1878895|NCT01168180|Other|Traditional Thai massage|The participants will receive thirty minutes session of traditional Thai massage onto the scapular region for 9 sessions over a period of 3 weeks
1878896|NCT01168180|Other|Ultrasound therapy and hot pack|
1878897|NCT01168193|Other|No intervention|
1878898|NCT01168206|Dietary Supplement|TK3|Tritofano 160mg / Timina140mg and starch 150 mg
1878899|NCT01168206|Dietary Supplement|1 capsule, 3 times per day|Placebo
1878900|NCT01168219|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic stem cell transplantation
1878901|NCT01168219|Biological|Anti-Thymocyte Globulin|Given IV
1878902|NCT01168219|Drug|Azacitidine|Given SC or IV
1878903|NCT01168219|Drug|Busulfan|Given IV
1878904|NCT01168219|Drug|Fludarabine Phosphate|Given IV
1878905|NCT01168219|Other|Laboratory Biomarker Analysis|Correlative studies
1878906|NCT01168219|Drug|Methotrexate|Given IV
1878907|NCT01168219|Other|Pharmacological Study|Correlative studies
1878908|NCT01168219|Drug|Tacrolimus|Given PO or IV
1878909|NCT01168232|Drug|ixabepilone|Given IV
1878910|NCT01168232|Other|laboratory biomarker analysis|Correlative studies
1878911|NCT01168245|Device|Sham-NICE-System|sham TMS and sham cognitive training
1878912|NCT01168245|Device|NICE-System|TMS combined with cognitive training
1878913|NCT01168284|Behavioral|Coping Effectiveness Training|
1878914|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
1878915|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
1878916|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
1878917|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
1878918|NCT01168310|Drug|Fluticasone Propionate/Formoterol Fumarate|Inhalation Suspension
1878919|NCT01168310|Drug|Formoterol Fumarate|Inhalation Solution
1878920|NCT01168310|Drug|Placebo|Inhalation Solution
1878921|NCT01168323|Behavioral|Online spaced education|Spaced education is currently delivered via periodic emails that contain clinical case scenarios and multiple-choice questions. Upon submitting answers to each question online, clinicians receive immediate feedback and educational material. The questions are then repeated over spaced intervals of time to harness the pedagogical benefits of the spacing effect.
1878922|NCT01168336|Drug|Betahistine standard formulation|betahistine 24 mg tablets
1878923|NCT01168336|Drug|Betahistine Extended Release formulation|betahistine 32 mg tablets
1878924|NCT01168336|Drug|Placebo|matching placebo
1878925|NCT01168349|Drug|epoetin beta [NeoRecormon]|As prescribed by physician
1878926|NCT01168375|Drug|conventional therapy plus umbilical cord serum eye drop|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours plus umbilical cord serum eye drop 20% every 4 hours
1878927|NCT01168375|Drug|conventional therapy|chloramphenicol and betamethasone eye drops every 6 hours, cycloplegic (homatropine) eye drop every 8 hours
1878930|NCT01168414|Drug|Ganfort|Fixed combination of Bimatoprost and Timolol (BTFC; Ganfort (300 microgram + 5 mg/ml eyedrops solution)
1878931|NCT01168414|Drug|Duotrav|Fixed combination of Travoprost and Timolol (TTFC; Duotrav (40 micrograms + 5 mg/ml eyedrops solution)
1878932|NCT01168427|Device|Reveal® DX or Reveal® XT Insertable Cardiac Monitor|Reveal® DX and Reveal® XT Insertable Cardiac Monitors are implantable patient-activated and automatically-activated monitoring systems that record subcutaneous ECG.
1878933|NCT01168440|Drug|Sunitinib|Sunitinib, 50 mg PO daily, 6 weeks courses with schedule 4/2 (4 weeks of treatment followed by 2 weeks of rest).
1878935|NCT01168466|Behavioral|HEG Neurofeedback|Detects and displays real time variation in blood flow in outermost 1.5 cm of frontal cerebral cortex.
1878936|NCT01168466|Behavioral|EEG Driven Photic Stimulation|"A Brainmaster EEG monitors the variation brain's dominant frequency in real time, while a Procyon photic stimulation device provides visual stimulation at 1/2 Hz faster, encouraging or entraining a faster frequency. In half of the neurofeedback arm, EEG Driven Photic Stimulation will be provided during neurofeedback displaying dominant frequency and rewarding faster frequencies."
1878937|NCT01168466|Behavioral|Peak Alpha Neurofeedback|A Pendant EEG with Bioexplorer software detects and displays the dominant alpha frequency in real time, rewarding faster frequencies.
1878938|NCT01168479|Radiation|FLAME boost|In the experimental arm patients receive in addition to the current gold standard of 77 Gy to the prostate an integrated boost to the macroscopically visible tumour to reach a total dose of 95 Gy in 35 fractions of 2.7 Gy, 5 times per week.
1878939|NCT01168479|Radiation|standard arm|The standard arm receives the current gold standard, namely 77Gy to the prostate in 35 fractions of 2.2 Gy, 5 times per week.
1878940|NCT01168492|Drug|ketamine|0.5mg/kg ketamine iv
1878941|NCT01168505|Drug|ferric hydroxide saccharate|single dose of 200 mg (2 ampoules), 24-48 hours after administration of chemotherapy for a total of four doses
1878942|NCT01168531|Drug|Pregabalin|pregabalin: 300 mg/day, po, from operative day until third postoperative day.
1878943|NCT01168531|Drug|dexamethasone|Dexamethasone 16 mg, intravenous, before induction of anesthesia
1878944|NCT01168531|Drug|placebo|vitamin B complex formula
1878945|NCT01168544|Dietary Supplement|loading dose Vitamin D and 50.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 50.000 IU vit D3/month consolidation therapy
1990569|NCT01962558|Device|VNS Treatment|VNS is given in brief bursts over a 2.5 hour period. The subject also has headphone connected to a computer, and hears audio tones through the headphones that occur during VNS.
1990570|NCT01962558|Device|VNS Control|This is the sham-control group; subjects in this group will receive both tones and VNS, but in a manner that is expected to be ineffective.
1878946|NCT01168544|Dietary Supplement|loading dose and 25.000 IU vit D3/month|loading dose based on body weight and baseline serum 25(OH)D level + 25.000 IU vit D3/month consolidation therapy
1878947|NCT01168544|Dietary Supplement|Vitamin D 800 IU /day|800 IU vit D3/day
1878948|NCT01168557|Device|EIT (Electrical Impedance Tomography)|EIT measurement; concomitant to stress echocardiography (about 45 minutes) EIT measurements (1 minute) are performed at rest, at low dobutamine stress, at peak and at relaxation
1878949|NCT01168596|Drug|Rasagiline|"Comparison of Rasagiline versus placebo.
Rasagiline tablet, 1 mg, 1 per day, duration is approximately 12 weeks."
1878950|NCT01168596|Drug|Placebo|Comparison of Rasagiline versus placebo. Placebo tablet, 1 per day, duration is approximately 12 weeks.
1878951|NCT01163149|Drug|asfotase alfa|Cohort 1: Daily SC injections of 0.3 mg/kg asfotase alfa (total of 2.1 mg/kg/week)
1878952|NCT01163149|Drug|asfotase alfa|Cohort 2: Daily SC injections of 0.5 mg/kg Asfotase Alfa (3.5 mg/kg/week total)
1878953|NCT01163162|Drug|Paricalcitol|2 mcg oral Paricalcitol once per day for 7 days
1878954|NCT01163175|Other|Ruminant trans fats|"Consumption of the 4 experimental diets:
a diet rich in ruminant TFA (8 g/day);
a diet moderately rich in ruminant TFA (4 g/day);
a diet rich in industrial TFA (8 g/d);
a control diet (minimal dietary TFA of industrial and ruminant sources)."
1878955|NCT01163201|Biological|Treg cells|Given by infusion on Day 0 after transplantation - Five doses of Treg (3 x 10^6/kg, 10 x 10^6/kg, 30 x 10^6/kg, 100 x 10^6/kg and 300 x 10^6/kg)
1878956|NCT01163201|Biological|CD3+ Teff cells|Given by infusion on Day 0 after transplantation - 5 doses of CD3+ Teff cells (3 x 10^6 cells/kg, 6 x 10^6 cells/kg, 9 x 10^6 cells/kg, 12 x 10^6 cells/kg, and 15 x 10^6 cells/kg with the latter dose representing the median number of CD3+ cells in two UCB unit grafts
1878957|NCT01163201|Drug|Fludarabine|Given intravenously on Days -8 through -6, 25 mg/m^2 over 1 hour
1878958|NCT01163201|Drug|Cyclophosphamide|Given intravenously on Day -7 and -6, 60 mg/kg
1878959|NCT01163201|Radiation|Total body irradiation|Given on Days -4 through -2, 165 cGY twice a day.
1878960|NCT01163201|Biological|Umbilical cord blood transplantation|Infusion given on day 0
1878961|NCT01163214|Drug|Nerve Block|Regional anesthetic nerve block using an indwelling femoral nerve catheter and a single shot sciatic nerve block using 0.5% ropivacaine.
1878962|NCT01163214|Drug|Periarticular Injection|Periarticular local injection into the periarticular soft tissues at the time of knee replacement using a combination of ropivacaine, epinephrine, ketorolac, and morphine sulphate. Subjects in this arm received the injection combination based on three subject weight categories.
1878963|NCT01163227|Drug|Placebo (single and multiple doses)|
1878964|NCT01163227|Drug|AQW051 2 mg (single and multiple doses)|
1878965|NCT01163227|Drug|AQW051 15mg (single and multiple doses)|
1878966|NCT01163227|Drug|AQW051 100mg (single dose), and 50mg (multiple doses)|
1878967|NCT01168609|Procedure|Primary percutaneous coronary intervention|Primary percutaneous coronary intervention (PCI) and stenting were performed for just the culprit lesion using standard techniques and bare-metal stents in all patients. Unfractionated heparin was used for 3 days after PCI, except in some cases with contraindications, and the dose of unfractionated heparin was selected to prolong the activated partial thromboplastin time by 2-3 times. The decision to use glycoprotein IIb/IIIa inhibitors was left to the discretion of the treating physician. The measurements of LVFP were performed via a fluid-filled pig-tail catheter placed into the LV after coronary angiography if PCI was not indicated or after primary PCI.
1878968|NCT01168635|Behavioral|Spirometry 360 program - Virtually-delivered spirometry quality improvement program|"The Spirometry 360 program includes:
Spirometry Fundamentals™: A basic guide to lung function testing, a computer-based training program that teaches primary care providers how to coach patients to produce high-quality spirometry tests and accurately interpret spirometric data;
Spirometry Learning Lab: Case-based teaching of spirometry in practice guides test administrators and interpreters through clinical examples in an interactive virtual classroom setting. These sessions are led by expert clinical faculty and are archived for future reference and review;
Spirometry Feedback: Tailored analysis of providers' spirometry testing sessions offers monthly individualized feedback reports by clinical experts on spirometry tests performed in the clinic."
1878969|NCT01168648|Behavioral|Yoga as stress management|Yoga specially designed to reduce stress is practiced for approximately 30 minutes at least three times a week for three months, once in a group session led by a trained yoga instructor and twice or more at home. The yoga techniques used are physical postures or movements, meditation and breathing exercises. Every time they do the techniques, participants fill in a form detailing how they feel before and after and providing information on the experience of doing the exercises.
1878970|NCT01168648|Other|Rest without using any relaxation technique|The participants rest at home at least 30 minutes, at least three times a week for three months and without using any relaxation technique
1878971|NCT01168661|Behavioral|Yoga|Participants in this intervention arm will practice yoga (physical postures, breathing exercises, and meditation) >= 5 times a week (twice in a supervised group and the rest on their own). Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. They will follow this schedule for 20 weeks.
1878972|NCT01168661|Behavioral|Mindfulness based cog psychotherapy|Participants in this arm will attend a weekly group meeting to practice mindfulness based cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
1878973|NCT01168661|Behavioral|Cognitive psychotherapy|Participants in this arm will attend a weekly group meeting to practice cognitive psychotherapy. They will also practice >= 4 time a week on their own. Additionally, participants in this arm will practice various practical skills, such as how to plan a satisfactory day using their own definition of a satisfactory day. Participants will follow this schedule for 20 weeks.
1878974|NCT01168674|Drug|ziprasidone|Ziprasidone will be administered as a pill. The once-daily total daily dose will be 80-160 mg/d of ziprasidone. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
1879020|NCT01170494|Drug|ergocalciferol 2000 IU orally, daily|ergocalciferol 2000 IU orally, daily
1878975|NCT01168674|Drug|Sugar pill|The once-daily total daily dose will be 80-160 mg/d of the sugar pill. Dosing will begin at 20 mg BID with an escalation strategy based on target symptoms and tolerability, with a target dose range of 80-160 mg/d. Dose escalations will occur by increments of 20-40 mg weekly.
1878976|NCT01168687|Drug|Levetiracetam (Keppra)|"Group A: Twenty moderate to heavy social alcohol users (women 7-20 drinks/week --moderate 7-14 and heavy 15-20 and men 15-25 drinks/week --moderate 7-14 and heavy 15-25 drinks/week) will receive 250 mg of levetiracetam BID (500 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 500 mg of levetiracetam BID (1,000 mg/day) x 7 days.
Group B: Twenty moderate to heavy social alcohol users as described above will receive 500 mg levetiracetam BID (1000 mg/day) or placebo x 7 days and will be titrated to a maximum dose of 1000 mg levetiracetam BID (2,000 mg per day) x 7 days."
1878977|NCT01168687|Drug|Placebo|
1878980|NCT01168713|Drug|Levofloxacin|"Levofloxacin once daily for 5 days:
Levofloxacin 750 mg PO Days 1-5"
1878981|NCT01168713|Drug|CEM-101|"CEM-101 once daily for 5 days:
CEM-101 800 mg PO Day 1
CEM-101 400 mg PO Days 2-5"
1878982|NCT01168726|Behavioral|Protective Behavioral Strategies|Personalized feedback on use of protective behavioral strategies.
1878983|NCT01168726|Behavioral|Personalized Normative Feedback|Personalized feedback on how one's own drinking compares to relevant norms.
1878984|NCT01168726|Behavioral|Alcohol Education|Educational information about harms associated with heavy drinking.
1878985|NCT01168739|Dietary Supplement|Quercetin|2g/d dietary quercetin supplementation, 1g taken am; 1g taken pm
1878986|NCT01168739|Dietary Supplement|Placebo|Placebo, performed on same subjects as Quercetin Arm, used to compare results between conditions
1878987|NCT01168752|Drug|Debio 0932|"Gelatin capsules of 2 dosage strengths (25 mg or 100 mg) The maximum dose will depend on the number of dose levels necessary to determine the MTD.
In both schedules the study treatment will be continued, until one of the study treatment discontinuation criteria is met."
1878988|NCT01168765|Behavioral|Tu Salud Si Cuenta Behavioral Intervention|A behavioral intervention to assess the impact of the TSSC Media Campaign intervention outreach components with two study arms. The first arm is comprised of participants enrolled in the TSSC Media Campaign(control group) and the second arm(intervention group)consisting of participants exposed to media campaign who will be exposed to additional outreach efforts by monthly visits from lay health workers.
1878989|NCT01168778|Behavioral|Physician Workshop|Physicians that were assigned to the intervention group attended a 3.5 hour intervention workshop where they were trained in skills to communicate information about physical examination findings, treatment, and follow-up that will ultimately facilitate appropriate antibiotic prescribing and increase parent satisfaction with care.
1878990|NCT01168791|Drug|doxorubicin in combination with palifosfamide-tris|"palifosfamide-tris: 150 mg/m2 3 days every 21 days for a maximum of 6 cycles.
doxorubicin: 75 mg/m2 1 day every 21 days for a maximum of 6 cycles."
1878991|NCT01168791|Drug|doxorubicin in combination with placebo|"doxorubicin: 75 mg/m2 of doxorubicin 1 day every 21 days for a maximum of 6 cycles.
placebo: 250 mL of normal saline 3 days every 21 days for a maximum of 6 cycles."
1878992|NCT01168804|Drug|bendamustine plus bortezomib plus dexamethasone|Bendamustine 70 mg/m2 on days 1+4 Velcade 1.3 mg/m2 on days 1,4,8,11 Dexamethasone 20 mg on days 1,4,8 and 11 Repeated every 4 weeks
1878993|NCT01168817|Drug|BAY60-4552 plus Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 10 mg plus BAY60-4552 1.0 mg)
1878994|NCT01168817|Drug|Vardenafil|Treatment with 3 tablets once daily for 4 weeks (Vardenafil 20 mg)
1878995|NCT01168817|Drug|Placebo|Treatment with 3 tablets once daily for 4 weeks (Placebo)
1878996|NCT01168830|Device|AMS-3.0|
1878997|NCT01168843|Other|computerized analysis of sonographic images|Evaluation of the Symmetry between the Primary Sulci of the Two Fetal Brain Hemispheres Using 3-dimensional Ultrasound Planes
1878998|NCT01168882|Drug|RGB-286638|The starting dose is a flat-fixed dose of 40 mg given i.v. over 60 min, weekly x3, of a 28-days cycle (q4 weeks)
1878999|NCT01168895|Drug|Cipro Inhale (Ciprofloxacin, BAYQ3939)|32.5 mg ciprofloxacin corresponding to 50 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
1879000|NCT01168895|Drug|Cipro Inhale (Ciprofloxacin, BAYQ3939)|48.75 mg ciprofloxacin corresponding to 75 mg Ciprofloxacin Pulmosphere inhalation powder will be given as single dose inhalation
1879002|NCT01168921|Drug|Eltrombopag|Starting dose 75 mg by mouth (PO) daily for 28 day cycle
1879003|NCT01168934|Drug|crizotinib|Treatment A: Intravenous dose of 50 mg crizotinib will be administered as directed.
1879004|NCT01168934|Drug|crizotinib|Treatment B: Oral dose of 250 mg crizotinib as 1 × 50-mg Immediate Release Tablet and 2 × 100-mg Immediate Release Tablets will be administered in the fasted state as directed.
1879005|NCT01170364|Drug|Sibutramine|1 week of active sibutramine (15mg)
1879006|NCT01170364|Drug|Placebo|2 weeks of placebo
1879007|NCT01170390|Drug|All participants (Aviane)|20 mcg EE/0.1 mg LNG cyclically
1879008|NCT01170390|Drug|Portia|30 mcg EE/0.15 mg LNG cyclically
1879009|NCT01170390|Drug|Aviane|20 mcg EE/0.1 mg LNG continuously dosed
1879010|NCT01170416|Other|12-lead body surface mapping|An average of 20 distinct left ventricular sites will be mapped using 12-lead body surface mapping electrodes and recorded for 15 seconds, then sent to a computer for further analysis.
1879011|NCT01170429|Drug|Procaterol hydrochloride|25µg BID for 8 weeks
1879012|NCT01170429|Drug|Meptin placebo|25µg BID for 8 weeks
1879013|NCT01170442|Drug|vitamin D3 2000 IU|vitamin D3 2000 IU orally, daily for 6 months
1879014|NCT01170442|Drug|vitamin D3 5000 IU|vitamin D3 5000 IU orally, daily for 6 months
1879015|NCT01170442|Drug|Placebo|placebo orally, daily for six months
1879016|NCT01170455|Device|Macintosh laryngoscope|nasal intubation with macintosh laryngoscope after general anesthesia induction
1879017|NCT01170455|Device|Blind Intubation Device|nasal intubation using Blind Intubation Device after general anesthesia induction
1879018|NCT01170468|Drug|Vitamin D3|Vitamin D3 5000 IU orally, daily for 2 years
1879019|NCT01170468|Drug|Placebo|Placebo orally, daily for 2 years
1879021|NCT01170494|Drug|ergocalciferol 25000 IU oraly every 2 weeks|ergocalciferol 25000 IU oraly every 2 weeks
1879022|NCT01170494|Drug|ergocalciferol 50000 IU orally every 4 weeks|ergocalciferol 50000 IU orally every 4 weeks
1879023|NCT01170494|Drug|ergocal1000 IU & cholecal 1000 IU orally daily|ergocalciferol 1000 IU and cholecalciferol 1000 IU orally every day
1879024|NCT01170494|Drug|cholecalciferol 2000 IU orally daily|cholecalciferol 2000 IU orally everyday
1879025|NCT01170494|Drug|Cholecalciferol 25000 IU orally every 2 weeks|Cholecalciferol 25000 IU orally every 2 weeks
1879026|NCT01170494|Drug|Cholecalciferol 50000 orally every 4 weeks|Cholecalciferol 50000 orally every 4 weeks
1879027|NCT01170494|Drug|placebo orally everyday|placebo orally everyday
1879028|NCT01170507|Drug|vitamin D3 1000 IU orally daily for 5 months|
1879029|NCT01170507|Drug|vitamin D3 3000 IU orally daily for 5 months|
1879030|NCT01170507|Drug|vitamin D3 5000 IU orally daily for 5 months|
1879031|NCT01170507|Drug|Placebo orally daily for 5 months|
1879032|NCT01170520|Device|repetitive transcranial Stimulation|rTMS using the figure of 8 magstim for 4 weeks or 20 work days, using 100% threshold to the LDPFC 42 trains per day 4 sec pretrain inter train interval of 30 sec.
1879033|NCT01170533|Drug|omeprazole and pantoprazole|The clopidogrel dose will be a 600mg loading dose followed by a 75mg daily maintenance dose, starting the next day for 7 days. Omeprazole will be used at a daily dose of 40mg and pantoprazole at 80mg.
1879034|NCT01170546|Other|plate-loaded kneeling leg curl with internal rotation|The participant was instructed to point toes toward medial side as knee flexing. This is an open-kinetic chain (OKC) exercise and medial hamstring was emphasized.
1879035|NCT01170546|Other|plate-loaded squat press|The subject was instructed to position his back properly against the backrest on a machine, with the feet slightly apart. He was instructed to place his feet higher on the foot plate and draw his two knees as close as possible while the knees flexed so that medial hamstring would supposedly bear more tension in the course of knee flexion. This is a closed-kinetic chain (CKC) exercise and was expected to strengthen the quadriceps and hamstring with medial hamstring emphasized.
1879036|NCT01170546|Other|plate-loaded kneeling leg curl|An open-kinetic chain (OKC) exercise was intended to strengthen the hamstring muscle without lateralization emphasized.
1879037|NCT01170559|Device|Implantable Loop Recorder|
1879038|NCT01170572|Other|No intervention|No intervention
1879039|NCT01170585|Drug|Rosuvastatin|All patients will be uptitrated from an initial start dose of 5mg to 20mg rosuvastatin. This will be given once a day for 2 years.
1879040|NCT01170585|Drug|Placebo|Placebo
1879041|NCT01170598|Other|Exercise|After obtaining daily medical clearance, patients will be approached 4-5 days per week to perform 30-45 minutes of supervised exercise with a Canadian Society for Exercise Physiology (CSEP) - Certified Exercise Physiologist. All exercise sessions will be as tolerated, based on patient symptoms.
1879042|NCT01170611|Device|PACEMAKER SYMPHONY 2550|
1879043|NCT01170624|Device|ICD|Paradym CRT model 8750 - Paradym DR model 8550 - Paradym VR model 8250
1879044|NCT01170637|Drug|Ibuprofen|200 mg oral administration (RhinAdvil(R))
1879045|NCT01170637|Drug|Ibuprofen|200 mg oral administration (BI product)
1879046|NCT01170637|Drug|Pseudoephedrine-HCl|30 mg oral administration (BI product)
1879047|NCT01170637|Drug|Pseudoephedrine-HCl|30 mg oral administration (RhinAdvil(R))
1879048|NCT01170650|Drug|EC145|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
1879049|NCT01170650|Drug|Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®)|50 mg/m2 (calculated on the basis of ideal body weight) every 4 weeks. Dose reductions permitted for toxicity.
1879050|NCT01170650|Drug|placebo|IV bolus on days 1,3,5 and 15,17,19 of a 4-week cycle
1879051|NCT01170650|Drug|EC20|During the screening period participants will receive a single intravenous administration of EC20 prior to SPECT imaging
1879052|NCT01170663|Biological|Ramucirumab (IMC-1211B) DP|8 milligrams/kilogram (mg/kg) intravenous (IV) infusion on Days 1 and 15 of every 4-week cycle
1879053|NCT01170663|Drug|Placebo|Ramucirumab placebo IV infusion on Days 1 and 15 of every 4-week cycle
1879054|NCT01170663|Drug|Paclitaxel|Paclitaxel 80 milligrams per square meter (mg/m²) IV infusion on Days 1, 8, and 15 of every 4-week cycle
1879055|NCT01170676|Behavioral|Puff City GA|Puff City GA focuses on three areas of health behavior: 1) adherence to controller medications; 2) immediate availability of rescue medication; 3)smoking cessation/reduction.
1879056|NCT01170676|Behavioral|General Asthma Education|Students will be directed to generic public websites on asthma and smoking that contain helpful information on general asthma management.
1879057|NCT01170702|Drug|0.9% Normal Saline|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
1879058|NCT01170702|Drug|0.2% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
1879059|NCT01170702|Drug|0.5% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
1879130|NCT01171313|Drug|Sinemet (comparator)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed Sinemet.
1880716|NCT01183234|Drug|SPD544|two 30mg capsules, single oral dose
1879060|NCT01170702|Drug|0.75% Ropivacaine|The abdominal muscle layers will be located by placing the ultrasound transducer perpendicular to the coronal anatomic plane at the T-10 dermatome level in the patient's midaxillary line. Under ultrasound guidance, a 70mm or 90mm, 21 gauge blunted Stimuplex needle will be advanced from the skin until the tip reaches the fascial layer between the internal oblique and transversus abdominis. 15ml of the study drug will be injected incrementally. The needle will then be removed and the process repeated in the same manner on the patient's opposite side.
1879061|NCT01170728|Device|Coloplast Virtue® Male Sling|The Virtue Male sling is a class II single use implantable sub-urethral, permanent, non-absorbable, support sling indicated for the surgical treatment of male stress urinary incontinence (SUI) resulting from intrinsic sphincter deficiency (ISD). The device consists of a knitted monofilament polypropylene mesh which provides surface area for supporting the bulbous urethra. The four arms are covered with polyethylene sleeves with braided polyester sutures attached at the end of the mesh arms providing proper attachment to the introducer for positioning of the sling. The single use introducer allows for implanting both the trans-obturator arms and pre-pubic arms of the mesh sling.
1879062|NCT01170741|Behavioral|Tailored Cue Cards|The proposed intervention uses education to increase knowledge and skill building to influence behavior-specific self-efficacy and outcome expectations. In addition to providing general information regarding drug use and diseases, the cue-cards include information that is designed to raise awareness regarding perceived threats (perceived susceptibility and perceived severity) related to HIV and other STIs and blood-borne infections, which increases motivation to reduce risk behaviors. The cue-cards also provide information regarding risk reduction strategies. The cue-cards also contain instructions on how to anticipate and avoid risky situations (e.g., using alcohol or drugs prior to sex). This information is augmented with an exercise that involves modeling and guided practice. This combination of information and exercises modifies outcome expectations by increasing confidence (i.e., perceived self-efficacy) that a protective action can be performed
1879063|NCT01170754|Drug|PEG-3350 and Gatorade|255 grams of miralax mixed with 64 ounces gatorade for colonoscopy preparation.
1879064|NCT01170754|Drug|Golytely 4 liters|Golytely 4 liters
1879065|NCT01170767|Drug|Avastin|Intravitreal injection of bevacizumab at a concentration of 1.25 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
1879066|NCT01170767|Drug|Lucentis|Intravitreal injection of ranibizumab at a concentration of 0.50 mg per injection. One injection per month at the maximum and between 3 and 12 injection in the whole study.
1879067|NCT01170780|Drug|Dexamethasone|single use of dexamethasone IV 8 mg/2 ml
1879068|NCT01170780|Drug|Saline|2 ml IV
1879069|NCT01170793|Behavioral|educative telephone coaching (ETC)|a 30 to 45 minutes phone call, by appointment, by the nurse
1879070|NCT01170806|Drug|Orlistat|Capsules of 120mg of two commercial formulations of Orlistat (Lipiblock or Xenical) were taken 3 times daily for 7 dayy
1879071|NCT01170819|Device|Double balloon catheter|The balloons either side of the cervix are inflated with 50 ml of water. The catheter is removed after 12 hours if spontaneous expulsion has not occurred.
1879072|NCT01170819|Drug|Dinoprostone 10 mg controlled-release vaginal insert|Vaginal insert is placed in the posterior vaginal fornix for a maximum period of 24 hours.
1879073|NCT01170845|Drug|sivelestat sodium hydrate|saline or sivelestat sodium hydrate intravenously for 7 days starting the beginning of surgery
1879074|NCT01170858|Drug|Icodextrin PD solution|2L of Icodextrin PD solution for long-dwell one exchange per day (at least 8 hr)
1879075|NCT01170858|Drug|glucose solutions|
1879076|NCT01170871|Drug|Ixabepilone|
1879077|NCT01170871|Drug|Pemetrexed|
1879078|NCT01170884|Drug|fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution; bimatoprost 0.03% ophthalmic solution|1 drop of fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution (Combigan®) taken approximately 12 hours apart, up to 2 times a day and 1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken once every 24 hours.
1879079|NCT01170884|Drug|bimatoprost 0.03% ophthalmic solution; hypromellose 0.2% eyedrops|1 drop of bimatoprost 0.03% ophthalmic solution (Lumigan®) taken approximately every 24 hours; mild lubricant eyedrops (Gen Teal® Mild) for masking purposes
1879080|NCT01170897|Drug|PEGPH20|PEGylated Recombinant Human Hyaluronidase
1879081|NCT01170910|Procedure|Static incubation|Kidneys in this group are conserved in University of Wisconsin (eg, UW, Belzer® or Viaspan®), IGL-1, or SCOT solution before being transplanted.
1879082|NCT01170910|Procedure|Pulsatile perfusion|Kidneys in this group are placed in the pulsatile perfusion machine(RM 3) within two hours and should be kept there at least 6 hours and 8 hours if possible, before being transplanted
1879083|NCT01170923|Device|FDR-PET|FDR-PET performed after 1 cycle of chemotherapy
1879084|NCT01170923|Device|CT|CT performed after 3 cycles of chemotherapy
1879085|NCT01170936|Drug|canakinumab|Single dose of canakinumab 300mg s.c. injection
1879086|NCT01170949|Drug|Miltefosine|50 or 100 or 150mg per day
1879087|NCT01170949|Drug|Placebo|Placebo
1879088|NCT01170962|Drug|BMS-790052|Film coated tablet, Oral, 20 mg, once daily, 24 weeks
1879089|NCT01170962|Drug|BMS-790052|Film coated Tablet, Oral, 60 mg, once daily (divided dose taken BID), 48 weeks
1879090|NCT01170962|Drug|Placebo|Film coated tablet, Oral, 0mg, Once daily, 24 weeks
1879091|NCT01170962|Drug|peginterferon alfa-2a|Solution for injection, Subcutaneous injection, 180 µg, weekly, 24 or 48 weeks
1879092|NCT01170962|Drug|ribavirin|Film coated tablet, Oral, 1,000 or 1,200 mg based on weight, divided dose taken twice a day (BID), 48 weeks
1879093|NCT01170975|Drug|Tesetaxel 10 mg with and then without food|Treatment Period 1: Tesetaxel 10 mg in the fed state; Treatment Period 2: Tesetaxel 10 mg in the fasted state
1879094|NCT01170975|Drug|Tesetaxel 10 mg without and then with food|Treatment Period 1: Tesetaxel 10 mg in the fasted state; Treatment Period 2: Tesetaxel 10 mg in the fed state
1879095|NCT01170988|Procedure|T-Graft|T-Graft
1879096|NCT01171014|Dietary Supplement|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 10 billion cfu/day, once a day for 14 days
1879097|NCT01171014|Dietary Supplement|Bifidobacterium lactis HN019|Bifidobacterium lactis HN019, 1 billion cfu/day, once a day for 14 days
1879098|NCT01171014|Dietary Supplement|Placebo|Placebo, once a day for 14 days
1879099|NCT01171027|Procedure|NOTES Cholecystectomy|The transvaginal NOTES approach is accomplished by performing a posterior colpotomy. Instead of a conventional laparoscope, a flexible endoscope is used in order to provide working channels and visualization. The gallbladder is removed through the vaginal incision. The transgastric cholecystectomy requires the flexible endoscope to be placed orally. A gastrotomy is made through the stomach wall allowing the flexible endoscope to pass into the abdominal cavity. The gallbladder is removed from the abdominal cavity into the stomach and ultimately out the mouth. The goal of NOTES is to develop further so either of these approaches will not require any incisions in the abdominal wall.
1879100|NCT01171027|Procedure|Laparoscopic Cholecystectomy|This technique utilizes the introduction of a laparoscope through a 1 cm incision in the fascia in or around umbilicus. Usually three additional 0.5- 1.0 cm incisions are employed for surgical instrumentation. Once separated from its attachments, the gallbladder is usually removed through the umbilical port. Sutures are used to close the larger port sites. The most devastating complication is injury to the major bile ducts which is avoided to the extent possible (incidence .2 to less than .01%)5 by careful visualization of the ductal structures.
1879101|NCT01171040|Other|Echocardiography, including the measurements of left atrial (LA) distensibility|The LA volumes were measured at three points: 1) immediately before the mitral valve opening (maximal LV volume or Volmax); 2) at onset of the P-wave on electrocardiography (pre-atrial contraction volume or Volp); and 3) at mitral valve closure (minimal LV volume or Volmin). The LA distensibility was calculated as (Volmax - Volmin)x 100% / Volmin. The LA ejection fraction was calculated as (Volp - Volmin)x 100% / Volp. In all patients, LA volumes were indexed to body surface area (BSA).
1879102|NCT01171053|Behavioral|Internet-delivered CBT|Internet-delivered cognitive behavioral therapy with therapist support.
1879103|NCT01171053|Behavioral|Therapist support|Weekly therapist support without CBT-interventions
1879104|NCT01171079|Device|application of oxidized regenerated cellulose|
1879105|NCT01171092|Drug|bortezomib and G-CSF|"Bortezomib injection:
1.3mg/m2 11 days before and 8 days before the stem cell collection
G-CSF injection:
10mcg/kg on days -4 to day -1 once daily"
1879106|NCT01171105|Drug|AZD5213|oral solution, multiple ascending doses
1879107|NCT01171105|Drug|Placebo to AZD5213|
1879108|NCT01171118|Drug|Physostigmine|Physostigmine is a centrally acting acetylcholinesterase inhibitor that has been proposed as a treatment for sleep disordered breathing. It is currently FDA approved and used commonly by Anesthesiologists in the post anesthetic setting to reverse confusion caused by central anticholinergic medication effects.
1879109|NCT01171118|Drug|Oxygen|The administration of nasal cannula-administered oxygen at a flow rate of 2 liters/minute is commonly performed during clinical sedation practice. Thus, this experiment employed its use to compare respiratory effects of oxygen versus room air.
1879110|NCT01171118|Drug|Placebo|The administration of placebo versus physostigmine was untertaken in the same sedation conditions on the alternate day in each subject (and with both room air and oxygen)
1879111|NCT01171131|Other|Blood/saliva sampling|one-time blood sample (~ 1 TBS) and saliva sample (~ 1 tsp)
1879112|NCT01171144|Other|Epidemiologic Surveillance System of the Ministry of Health of Panama|Reviewing the Epidemiologic Surveillance System of the Ministry of Health of Panama
1879113|NCT01171144|Other|Mortality database of the Contraloria General de la Republica|Reviewing the Mortality database of the Contraloria General de la Republica
1879114|NCT01171144|Other|Hospital discharge records|Reviewing the hospital discharge records
1879115|NCT01171157|Other|Routine sample collection|Collection of routine nasal/throat swab samples
1879116|NCT01171170|Drug|carboplatin paclitaxel bevacizumab|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression
1879117|NCT01171170|Drug|Standard treatment plus nitroglycerin|paclitaxel 200 mg/m2 d1 - carboplatin AUC 6 d1 - bevacizumab 15 mg/kg d1. Cycles every 3 weeks. Paclitaxel and carboplatin 4 cycles. Bevacizumab till progression. Plus nitroglycerin transdermal patches 25 mg per day from day -3 till +2 of First combination cycle till the last bevacizumab monotherapy cycle
1879118|NCT01171183|Drug|controlled release carvedilol|carvedilol (Coreg CR) 80 mg/day in once daily dosing for 12 weeks followed by a 2-week taper
1879119|NCT01171183|Drug|Placebo|Placebo
1990575|NCT01956734|Procedure|DNX2401 and Temozolomide|"Virus injection in the brain parenchyma after pathology confirmation of recurrent glioblastoma.
Temozolomide oral 14 days after virus injection."
1879121|NCT01171261|Behavioral|Health Games Field Trial|There were 4 arms to the intervention in the field trial of this study. Participants were randomized to one of 4 arms or exergame that were manufactured by SSD/Xavix (Shiseido Co. of Japan). Each exergame consisted of a game cartridge, the XavixPort, and game controllers (e.g., tennis racquets, boxing gloves, bowling ball, or floor mat). The XavixPort interfaces the exergame with the participant's television and contains the infrared sensors that track the movement of the game controllers. Each exergame cartridge includes multiple game modes. The four arms/exergames were: XaviX Tennis, The Jackie Chan Studio Fitness (J-MAT), XaviX Bowling, and XaviX Boxing.
1879122|NCT01171274|Behavioral|Hatha Yoga|"9 weeks of Hatha Yoga, designed for treating chronic neck pain, as a group intervention.
One class of 90 minutes per week, 10 minutes training at home each day."
1879123|NCT01171274|Behavioral|Information regarding exercises and behaviour|"9 weeks of exercises practiced at home.
Patients receive detailed information regarding appropriate exercises and behaviour for chronic neck pain patients."
1879124|NCT01171287|Procedure|Driving with an Aircast Walker|
1879125|NCT01171287|Procedure|Driving with a walking cast|
1879126|NCT01171287|Procedure|Driving with a running shoe|
1879127|NCT01171300|Other|18F- FDG PET scans|We aim to investigate the value of FGD-PET for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
1879128|NCT01171300|Other|DW-MRI scans|We aim to investigate the value of DW-MRI for evaluating response before surgery. To achieve this, the patients will undergo 3 FDG-PET scans (at moment of diagnosis (staging), during chemoradiation (early response), 1-2 weeks before surgery (restaging))
1879129|NCT01171313|Drug|XP21279 and carbidopa (experimental)|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed XP21279 and Carbidopa
1881777|NCT01192308|Drug|Tamoxifen 40mg QD|Tamoxifen 40mg QD during 4 weeks
1879131|NCT01171313|Drug|Placebo for XP21279 and carbidopa|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for XP21279 and carbidopa
1879132|NCT01171313|Drug|Placebo for Sinemet|Eligible subjects entering the study will be randomized into 1 of 4 sequences where they will be dosed placebo for Sinemet
1879133|NCT01171326|Drug|Topical Minocycline Foam FXFM244|FXFM244 - 1%, FXFM244 - 4% to be applied twice daily during 7 days
1879135|NCT01171352|Procedure|Transpulmonary Thermodilution|A PiCCO femoral catheter will be placed and PiCCO parameters will be obtained using transpulmonary thermodilution after continuous dialysis is ordered or just prior to initiation of intermittent dialysis, hourly until either completion of intermittent dialysis or 8 hours of continuous dialysis is completed.
1879136|NCT01171365|Drug|Ciclesonide|Inhaled ciclesonide 320mcg twice daily
1879137|NCT01171365|Drug|Placebo|Matched placebo inhaler two inhalations twice daily
1879138|NCT01171378|Drug|Ofatumumab|"1000mg vials (50ml @ 20mg/ml), or 100mg vials (5ml @20mg/ml), to be given as an Intravenous (IV) infusion.
Ofatumumab will be infused intravenously on day 1 (300 mg), day 8 (1000 mg) and day 15 (1000mg) in the first cycle, followed by infusions every 3 weeks of 1000 mg on the first day of each cycle for a total of 6 cycles. Maintenance treatment will start 4 weeks after day 1 of cycle 6 in week 20 and consists of six infusions of ofatumumab every 8 weeks"
1879139|NCT01171391|Drug|VA106483|1 mg VA106483 on Day 3, 2 mg VA106483 on Day 5 and 4 mg VA106483 on Day 7
1879140|NCT01171391|Other|Placebo|Placebo on Day 1
1879141|NCT01171430|Device|Whole Body Dynamic Contrast Enhanced MRI (WB-DCE-MRI)|"3 Whole Body Dynamic Contrast Enhanced MRI:
1 WB-DCE-MRI before induction of chemotherapy(initial MRI).
1 WB-DCE-MRI after induction high dose therapy and before intensification of chemotherapy and auto-transplant of hematopoietic sterns cells (early MRI).
1 WB-DCE-MRI 3 months after treatment whatever (amendment n°3) (delayed MRI)."
1879142|NCT01171456|Drug|Metformin|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
1879143|NCT01171456|Drug|Placebo|Administration of Metformin or placebo prior to conception to prevent the onset of GDM.
1879144|NCT01171469|Biological|Dendritic Cells|5, 10 or 15 Million dendritic cells (DCs) - administered via intradermal injections in 0.5 ml Phosphate Buffered Saline (PBS) in the shoulders near the back of the neck to facilitate trafficking of the DCs to the cervical lymph nodes.
1879145|NCT01171469|Drug|Imiquimod|Imiquimod (INN) is a prescription medication that acts as an immune response modifier. Imiquimod is marketed as 5% Aldara cream in 250 mg packets, providing a total dose of 12.5 mg per packet and sufficient to cover 20 square centimeters. The contents of ½ of a packet will be applied as a thin film to cover approximately 10 square centimeters of skin in the area of the planned vaccination.
1879146|NCT01171482|Drug|5-FU|15mg/kg/day continuous IV from day 1 to day 6 every 28 days.
1879147|NCT01171482|Drug|Mitomycin|4mg/day IV push from day 1 to day 4 every 28 days
1879148|NCT01171482|Drug|sorafenib|400 mg BID every 28 days
1879149|NCT01171495|Dietary Supplement|Theragran-M; Ensure Plus|Theragran-M: One tablet daily for 6-months. Ensure Plus: One 8 fl.oz. bottle daily for 6-months. Nutritional counselling: at baseline, and at monthly follow-up visits.
1879150|NCT01171495|Dietary Supplement|Theragran-M|Theragran-M: One tablet daily for 6-months. Nutritional counselling: at baseline and at monthly follow-up visits.
1879151|NCT01171508|Device|Wrist-Actigraph - Octagonal Basic Motionlogger, Ambulatory monitoring Inc, New York, USA|Wrist-Actigraph to be worn on the non-dominant arm on day 0-3-17 of the study.
1879152|NCT01171508|Device|Polysomnograph - Embla A10 (Medcare, Reykjavik, Iceland)|Polysomnography on day 0-3-17 of the study. This is a portable polysomnograph with 16 digital channels for recording of electroencephalogram (EEG), electrooculograph (EOG) and electromyograph (EMG).
1879153|NCT01171508|Device|Holter monitor - Medilog AR12 (Oxford Instruments, Oxford, England)|Holter monitoring on day 0-3-17 of the study. Measurements are done by superficial skin-electrodes placed after standardised rules from the producer of the device.
1879154|NCT01171508|Procedure|Urine 6-sulphatoxymelatonin (aMT6s)|Urine sampling for measurement of the primary metabolite of melatonin - 6-sulphatoxymelatonin (aMT6s) will be done on day 0-3-17 of the study. The analysis will be done by a radioimmunoassay.
1879155|NCT01171508|Other|Karolinska Sleepiness Scale|Karolinska Sleepiness Scale to measure sleepiness will be filled out twice a day every day of the entire study period of 17 days.
1879156|NCT01171508|Other|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain|Visual Analog Scale and 10 point-scales to measure fatigue, general well-being, subjective sleep and pain will be filled out twice a day everyday of the study period of 17 days.
1879157|NCT01171508|Other|Sleep-diary|Sleep-diary to measure subjective sleep quantity will be completed every morning and after every nap in the day.
1879158|NCT01171521|Device|DermaClose Group|The DermaClose external tissue expander provides continuous expanding of the skin around a wound until it has stretched enough to suture the wound edges closed.
1879159|NCT01171534|Device|DermaClose fasciotomy closure|The DermaClose device provides continuous expanding of the skin around the wound until it has stretched enough to allow the skin edges to be sutured closed.
1879160|NCT01171534|Device|Vessel loop|Vessel loops and staples for fasciotomy closure
1879161|NCT01171547|Drug|Daptomycin|once daily over 5 days
1879163|NCT01171573|Procedure|Venepuncture|Venepuncture - Taking blood
1879164|NCT01171586|Behavioral|mDiet|"The goals of the intervention groups (SMS-only and SMS plus phone counseling) include: 5% weight loss, 500 k/cal per day deficit through reduced caloric intake and increased energy expenditure, 12,00 steps through the use of a pedometer, and a reduction in sedentary behaviors. Participants will receive daily pushed and pulled text messages, self-monitoring tools, and brief health promotion printed or wed materials on physical activity, nutrition, or other weight loss related topics."
1879165|NCT01171599|Behavioral|Fit4Life|As previously described, the purpose of this study is to develop a web and text message based weight loss intervention for childhood acute lymphoblastic leukemia survivors (ALL) survivor. The web and text message based intervention that is being developed will be evaluated in a separate ACS (American Cancer Society) funded trial randomized control trial. The web and text message based intervention (there are other intervention features that do not relate to the web & text based platforms that were developed as part of this NIH funded study) is a 16-week program that includes:
1879166|NCT01171625|Device|Implantation of CEP Magna Ease Model 3300TFX|Heart Valve Surgery
1879167|NCT01171638|Device|Near infrared spectroscopy (NIRS)|Non-invasive monitoring device applied on the surface of the skin that emits harmless red light to measure tissue perfusion.
1879168|NCT01171651|Drug|JX-594 followed by sorafenib|Patients will receive a total dose of 1e9 per treatment starting with one IV dose on Day 1 and injected intratumorally in 1-5 intrahepatic tumors on Day 8 and 22. Starting on Day 25 (3 days after the final JX-594 dose) patients will initiate oral sorafenib therapy twice daily according to standard approved guidelines. An optional maintenance JX-594 dose may be given intratumorally at Week 12 (sorafenib briefly interrupted).
1879171|NCT01171677|Behavioral|IntenSati|"IntenSati (a blending of the words intention and sati, the Pali term for mindfulness) combines simple yet vigorous physical movements taken from yoga, martial arts, kickboxing and dance with spoken positive affirmation (e.g. I believe I will succeed, I am strong and I am confident) that are recited simultaneously with the execution of the movements. Indeed, one of the most common reports of IntenSati practitioners is the power of the spoken affirmations to stick in your head long after the workout is complete. The literature suggests that both the kind of high level aerobic exercise provided by IntenSati as well as the positive affirmations may have measurable beneficial effects on cognitive function, mood, self efficacy and self esteem."
1879172|NCT01171690|Drug|Teriparatide|The dose of teriparatide will be 20 mcg twice daily for the first week and 20 mcg daily for the second week. If hypocalcemia recurs after 2nd week, teriparatide will be continued for a 3rd week and then discontinued.
1879173|NCT01171703|Device|femoral-popliteal bypass|Before operation, take aspirin 100mg every day. Groin and suprageniculate incision, PTFE graft with end to side anastomoses.
1879174|NCT01171703|Device|stent|Before operation, take aspirin 100mg every day. During the operation, stent is delivered by a catheter and positioned through the narrowing in the artery. The stent is then expanded against the wall of the blood vessel to provide a wider channel for blood. At last, use balloon dilate the stent.
1879175|NCT01171716|Other|Meal Patterning|LP intake 3 meals and 6 meals HP intake 3 meals and 6 meals
1879176|NCT01171729|Biological|Autologous dendritic cell|Autologous dendritic cells pulsed with prostate cancer antigen and KLH
1879177|NCT01171742|Procedure|Intermittent hepatic inflow occlusion (IHIO)|Intermittent hepatic inflow occlusion (IHIO)'ll be usually performed 3 times during donor liver parenchymal resection, with each IHIO consisting of clamping of the hepatoduodenal ligament for 15 minutes, followed by reperfusion for 5 minutes.
1879178|NCT01171755|Drug|Gemcitabine TS-1|Gemcitabine (1,000mg/m2) will be administered on days 1 and 8 at every 3 weeks TS-1 will be administered orally according to body surface area (BSA) as follows : BSA<1.25 M2, 80 mg/day; 1.25 M2≤BSA<1.5 M2, 100 mg/day; 1.5 M2≤BSA, 120 mg/day for 14 consecutive days followed by a 7-day rest.
1879179|NCT01171781|Drug|cisplatin (3 weekly)|radiation with cisplatin (100mg/m2) on D1,D22,D43 and followed by adjuvant chemotherapy (3 cycles of FP)
1879180|NCT01171781|Drug|cisplatin (weekly)|radiation with 7 cycles of cisplatin (40mg/m2) on D1,8,15,22,29,36,43, and followed by adjuvant chemothrapy (FP X3)
1879181|NCT01171794|Drug|Ibuprofen|3 x 200mg (600mg total) x tid and one dosing on the subsequent day ( 4 doses total)
1879182|NCT01171794|Drug|Placebo|identical number of visually identical tasteless pills as ibuprofen arm
1879183|NCT01171807|Drug|Dexamethasone 21-phosphate|6 monthly infusions of dexamethasone 21-phosphate loaded into autologous erythrocytes
1879184|NCT01171820|Device|TAXUS® Liberté™|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
1879185|NCT01171820|Device|XIENCE V® EECSS|Drug eluting stent implantation stent in the treatment of coronary artery disease in participants with Diabetes
1879186|NCT01171833|Drug|Sevoflurane|2.0 vol% prefilled in a corrugated circuit.
1879187|NCT01171833|Drug|Desflurane|6.0 vol% prefilled in a corrugated circuit.
1879188|NCT01171833|Drug|Isoflurane|1.2 vol% prefilled in a corrugated circuit.
1879189|NCT01171846|Other|Pelvic Floor Muscle training|"Women allocated to the intervention group will have five appointments with a specialist women's health physiotherapist (intervention physiotherapist) over 16 weeks who will prescribe a daily exercise programme and provide a Lifestyle Advice Sheet (focusing on weight loss, constipation, avoidance of heavy lifting, coughing and high-impact exercise) and relevant tailored advice (phase 1).
Thereafter women in the intervention group will be offered Pilates-based classes, including PFMT, as maintenance (phase 2). Classes will be led by a physiotherapist who has undertaken Pilates training and will take place in six week blocks; each woman will be offered two six week blocks over a year. An exercise DVD will be provided for home use. Each woman will be offered a one-to-one review physiotherapy appointment at one and two years after randomisation."
1879190|NCT01171859|Drug|Doxycycline + Tauroursodeoxycholic acid|doxycycline 100 mg twice a day for 12 months; tauroursodeoxycholic acid 250 mg three times a day for 12 months
1879194|NCT01171898|Drug|ARN-509 (Phase 1)|ARN-509 will be administered at a starting dose of 30 milligram per day (mg/day), with escalations to 60 mg, 90 mg, 120 mg, 180 mg, 240 mg, 300 mg, 390 mg, and 480 mg daily.
1879195|NCT01171898|Drug|ARN-509 (Phase 2)|ARN-509 will be administered at Maximum Tolerated Dose (MTD) and/or Recommended Phase 2 Dose (RP2D), determined in Phase 1.
1879196|NCT01171911|Drug|Nicardipine , Esmolol|A loading dose of Nicardipine 10mg was at a bolus injected through vein , then continuous trans-venous titration at a speed 1ug/kg was kept. A loading dose of Esmolol 0.5mg/kg/min was at a bolus injected through vein , then continuous trans-venous titration at a speed 0.2mg/kg/min was kept.
1879197|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 consecutively for 5 days on each 14 day cycle.
1879198|NCT01171924|Drug|CUDC-101|CUDC-101 administered as a 1 hour intravenous infusion at the maximum tolerated dose of 275 mg/m2 on Monday, Wednesday, Friday for three consecutive weeks of each 28 day cycle.
1879199|NCT01171937|Drug|Risperidone|children get randomized to either placebo or active risperidone
1879200|NCT01171937|Drug|Placebo|Children get randomized to either placebo or risperidone
1879201|NCT01171950|Device|CentriMag Ventricular Assist System|All patients will be treated with the CentriMag device for up to 30 days.
1879202|NCT01171963|Biological|GSK Biologicals' liquid human rotavirus vaccine 444563|Oral administration
1879203|NCT01171963|Biological|Placebo|Oral administration
1879204|NCT01171963|Biological|Infanrix™|Intramuscular administration
1879205|NCT01171963|Biological|Institute of Medical Biology Chinese Academy of Medical Sciences' Oral poliovirus vaccine (OPV)|Oral administration
1879206|NCT01171976|Drug|Ranibizumab|Ranibizumab (Lucentis®) was supplied in vials containing a dose of 0.5 mg/0.05 mL in an aqueous solution (pH 5.5) with histidine, trehalose, and polysorbate 20.
1879207|NCT01171989|Biological|GSK2202083A vaccine|Intramuscular, one dose.
1879208|NCT01171989|Biological|Infanrix hexa™|Intramuscular, one dose.
1879209|NCT01171989|Biological|Menjugate™|Intramuscular, one dose.
1879210|NCT01171989|Biological|NeisVac-C™|Intramuscular, one dose.
1879211|NCT01171989|Biological|Synflorix™|Intramuscular, one dose.
1879212|NCT01172002|Drug|Leflunomide|"Leflunomide, 20 mg/d, ORAL ,each day. Number of Cycles: until progression or unacceptable toxicity develops.
Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
1879213|NCT01172002|Drug|Azathioprine|"Azathioprine,50-100 mg/d, ORAL ,each day . Number of Cycles: until progression or unacceptable toxicity develops.
Predonine, 10 mg/d, ORAL, each day. If extra renal flare occurs, the dose of predonine may be increased to 1mg/kg/day for not more than 2 weeks."
1879214|NCT01172015|Other|blood samples|
1879215|NCT01172028|Drug|Taxotere (Docetaxel)|Taxotere is a third generation cytotoxic chemotherapy agent which is a semisynthetic taxane that inhibits cell division by promoting the rate of microtubule assembly and preventing microtubule depolymerization. It has broad antitumor activity in a range of solid tumors, and has been studied on a weekly as well as a biweekly dosing schedule.
1879216|NCT01172028|Drug|Alimta (Pemetrexed)|ALIMTA is a novel antifolate drug with three enzyme targets in the purine and pyrimidine synthetic pathway. It has broad activity in solid tumors and has been combined with a number of other chemotherapy agents. Its toxicity is modified by the use of continuous vitamin supplementation.
1879217|NCT01172041|Device|Real time position management system|Device to monitor respiration by using optical monitoring of a marker block placed on the abdomen of the patient.
1879218|NCT01172041|Device|LS PET/CT|PET/CT scanner for acquiring CT and PET images (3D and 4D)
1879219|NCT01172041|Drug|18-FDG|15mCi
1879220|NCT01172054|Biological|VAX128|one IM injection
1879221|NCT01172054|Biological|Placebo|One IM injection
1879222|NCT01172067|Device|Cardiac Resynchronization Therapy|Patients will be optimized using QuickOpt (IEGM) algorithm installed on the Merlin device programmer within 2 weeks and 3 and 6 months after device implantation.
1879223|NCT01172067|Device|Optimization using echocardiography|Optimization of the AV/PV and VV delays using echocardiography
1879224|NCT01172080|Other|protocol of reminders regarding due colonoscopy|Participants receive two standardized letters followed by a phone call if they have not scheduled or completed their upcoming due colonoscopy
1879225|NCT01172106|Behavioral|drug compliance|Mothers and their caregivers will be encouraged to comply with the given medication
1879226|NCT01172106|Behavioral|Encouragement of drug compliance|Mothers and their caregivers in the placebo comparator will receive an intervention of drug compliance encouragement
1879227|NCT01172106|Behavioral|Family psychoeducation|The experimental group will receive family psychoeducation for 12 sessions
1879228|NCT01172119|Device|Biofreedom Drug Eluting Stent|Biofreedom DES with a standard dose of Biolimus A9TM
1879229|NCT01172119|Device|Biofreedom Drug Eluting Stent|Biofreedom DES with a low dose of Biolimus A9TM
1879230|NCT01172119|Device|Tuxus Liberte Drug Eluting Stent|Standard paclitaxel dose Taxus Liberte DES
1879231|NCT01172145|Drug|Modafinil|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
1879232|NCT01172145|Drug|Placebo|100 mg in the morning for the first week and 200 mg in the morning for the remaining seven weeks
1879233|NCT01172171|Drug|Melatonin, N-acetyl-5-methoxytryptamine|The investigators will give the randomized patients 10 ml of 0,1 mg/ml melatonin intracoronarily and 490 ml of 0,1 mg/ml (49 mg) melatonin.
1879234|NCT01172171|Drug|Isotonic saline, Natrium chloride|The randomized patients will be given 10 ml of isotonic saline intracoronarily and 490 ml intravenously.
1879235|NCT01172184|Procedure|Cardiac catheterization|Before surgical intervention for severe mitral regurgitation, cardiac catheterization will be performed and left ventricular filling pressure will be assessed. Simultaneously, echocardiography, including left atrial distensibility, will be performed.
1879236|NCT01172197|Drug|Levobupivacaine|Femoral bolus 150μM followed by femoral infusion 400μM
1879237|NCT01172197|Drug|Ropivacaine|Bolus and infusion
1879238|NCT01172223|Drug|Myocet (Non-pegylated liposomal doxorubicin (NPLD))|60 mg/m^2 i.v. day 1 q3 weeks
1879239|NCT01172223|Drug|Paclitaxel|175 mg/m^2 i.v. day 1 q3 weeks
1879240|NCT01172223|Drug|Lapatinib (GW572016, Tykerb)|750-1500 mg/d orally daily until the day of the definitive surgery
1879241|NCT01172236|Drug|Lactoferrin|"Experimental group: newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.
Control group: newborns (group B) will receive only standard therapy and they will be used as controls."
1879242|NCT01172236|Drug|Lactoferrin|Experimental group: 650 newborns (group A) will receive a daily dose of 100 mg of lactoferrin (Dicorfam® Elleffe 1''% 2C supplement containing lactoferrin) + standard therapy.Control group: 650 newborns (group B) will receive only standard therapy and they will be used as controls.
1879243|NCT01172249|Drug|Glucosamine sulfate + chondroitin sulfate - MANTECORP|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
1879244|NCT01172249|Drug|Glucosamine sulfate + chondroitin sulfate - CONDROFLEX|1 capsule three times daily before meals (glucosamine sulfate 500 mg + sodium chondroitin sulfate 400 mg).
1879245|NCT01172262|Procedure|MRI|This is an observational study, no intervention will occur.
1879246|NCT01172275|Drug|N-Acetylcysteine|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial.
1879247|NCT01172275|Drug|Placebo|1 900mg tablet once a day for 1 week, then 1 900mg tablet twice a day for 1 week and then 1 900mg tablet three times a day for the remaining 10 weeks of the trial. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
1879248|NCT01172288|Drug|N-Acetylcysteine (NAC)|1 600mg capsule twice a day for 2 weeks and then 2 600mg capsules twice a day for the remaining 10 weeks of the trial.
1879249|NCT01172288|Drug|Placebo|1 600mg Capsule twice a day for two weeks then 2 600mg capsules twice a day for the remaining 10 weeks of the study. Children receiving placebo will be offered the active intervention after the double-blind portion of the trial.
1879250|NCT01172301|Dietary Supplement|Essential amino acid intake + Leucine vs total AA supplement|7 g as bolus
1879251|NCT01172314|Dietary Supplement|EAA+LEU vs total AA|15 g as a bolus
1879252|NCT01172314|Dietary Supplement|Total AA vs EAA+LEU|15 g as a bolus
1879253|NCT01172327|Behavioral|Multicomponent exercise|This intervention is a self-directed, multicomponent, exercise intervention. Participants exercise on their own and follow a progressive stepped program that occurs in the following order: cardiorespiratory exercises, flexibility exercises, strength (upper and lower body) exercises, and balance exercises. Participants also complete a daily log of their exercises and return the logs every week for 12 weeks. The active intervention phase is 12 weeks.
1879254|NCT01172327|Behavioral|Nutrition|This arm is a self-directed nutrition intervention. Participants follow a progressive stepped program that occurs in the following order: fruits, vegetables, grains, meat and beans. Participants also complete a daily log of their dietary intake and return the logs every week for 12 weeks. The active intervention lasts for 12 weeks.
1879255|NCT01172340|Behavioral|Behavioral and support intervention|Individual counseling session with diet and exercise recommendations, 16 weekly group sessions, 8 weeks of followup phone support
1879256|NCT01172340|Behavioral|Wait-listed control group|Controls receive the same individual counseling session as intervention group; receive mailed health information; are offered group sessions after last post-measure
1879257|NCT01172353|Drug|sodium bicarbonate|hydration with sodium bicarbonate 1ml/Kg/h for 6 hours
1879258|NCT01172353|Drug|saline|hydration with saline 1ml/Kg/h for 6 hours
1879259|NCT01172379|Drug|E2007|"Experimental 1 Drug: E2007
0.5 mg 1 tablet per day"
1879260|NCT01172379|Drug|E2007|"Experimental 2 Drug: E2007
1.0 mg 1 tablet per day"
1879261|NCT01172379|Drug|E2007|"Drug: E2007
2.0 mg 1 tablet per day"
1879262|NCT01172379|Other|Placebo Comparator|Placebo 1 tablet per day
1879263|NCT01172392|Drug|Pegylated interferon-alpha-2a|180 mcg / wk / SC from D0 to W48
1879264|NCT01172392|Drug|Nucleotidic or Nucleosidic Treatment|Analog treatment according to investigators practice
1879265|NCT01172405|Drug|Ibuprofen plus caffeine|One or two tablets of ibuprofen 400 mg + caffeine 200 mg when presenting headache.
1879266|NCT01172405|Drug|Ibuprofen|One or two tablets of ibuprofen 400 mg when presenting headache.
1879267|NCT01172418|Drug|Alemtuzumab|Alemtuzumab used as part of combined Induction.
1879268|NCT01172418|Drug|Daclizumab|Daclizumab used as part of combined induction.
1879269|NCT01172418|Drug|Thymoglobulin|Thymoglobulin used as part of combined induction.
1879270|NCT01172431|Drug|Indapamide|Indapamide SR 1.5mg qd
1879271|NCT01172431|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25mg qd
1879272|NCT01172444|Drug|Mesalamine|Supporitory, Once Daily, Per Rectal for 6 Weeks
1879273|NCT01172444|Drug|Canasa|Suppository, Once Daily, Per Rectal for 6 Weeks
1879274|NCT01172444|Drug|Placebo|Suppository, Once Daily, Per Rectal for 6 Weeks
1879275|NCT01172457|Procedure|Epiduroscopy with oxygen therapy|Patients in this group will receive 30 mL of oxygen by epiduroscopy.
1879276|NCT01172457|Procedure|Epiduroscopy with ozone therapy|Patients in this group will receive 30 mL of ozone at a concentration of 30 mcg / ml by epiduroscopy.
1879277|NCT01172470|Drug|Gemcitabine|4 doses of induction chemotherapy every 2weeks, IV (in the vein)
1879278|NCT01172470|Drug|Pemetrexed|"Induction Chemotherapy:
4 doses of induction chemotherapy every 2weeks(Days 1, 15, 28, and 42), through an infusion for approximately 10 minutes.
Chemoradiotherapy:
Day 1,22, and 43through IV infusion over a period of 10 minutes"
1879279|NCT01172470|Drug|Carboplatin|"Chemoradiotherapy:
Day 1, 22 and 4 through IV infusion over a period of 1 hour."
1879280|NCT01172483|Procedure|general practice in primary care and education|education of chronic disorders in PC
1879281|NCT01172483|Other|Multimodal community program|The intervention was an 8-week programme of MMPP combined with DWR, delivered by physiotherapists in groups of 8 to 10 participants. One-hour sessions were conducted 3 times per week, consisting of DWR and an individualised MMPP of therapeutic exercises combined with education based on cognitive-behavioural principles. Each session was comprised of 30 minutes of land-based exercise followed by 20 minutes of DWR, with an additional 10 minutes of warm-up and cool-down time. Deep water running stimulates running using a flotation device in water levels over head height. During the first two weeks of the intervention, participants undertook a low-intensity adaptation interval to learn proper exercise technique. For the remaining six weeks, participants were instructed to maintain a constant speed to achieve the prescribed HRAT. If experiencing pain while exercising, participants were asked to temporarily reduce intensity and return to target HR as capable.
1879282|NCT01172496|Drug|treprostinil diethanolamine|Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
1879283|NCT01172509|Drug|R-baclofen|oral R-baclofen at 0x2, 3, 10, and 25 mg
1879284|NCT01172522|Drug|Fexofenadine|Fexofenadine 1%
1879285|NCT01172522|Drug|Placebo|Placebo
1882550|NCT01197898|Other|Placebo Comparator|Topical daily application
1879286|NCT01172535|Drug|Lopinavir/ritonavir|Heat-stable tablets of 100 mg lopinavir, 25 mg ritonavir, or liquid formulation of 80 mg lopinavir, 20 mg ritonavir, dosed according to World Health Organization (WHO) pediatric weight band dosing guidelines
1879287|NCT01172548|Drug|imatinib mesylate|
1879288|NCT01172561|Behavioral|Lay Health Advisor Education Intervention|The individualized health education intervention consisted of an intensive, reinforced, face to face, interactive educational program. The program included an initial meeting of 45 60 minutes, followed by two telephone calls and reinforcement by a series of four postcards mailed at regular intervals and a second visit. Each woman will be enrolled in the intervention program for approximately 12 to 14 months.
1879289|NCT01172561|Behavioral|Usual Care Group|All women over age 18 encouraged to obtain Pap smears appropriate for their risk profile, the comparison arm included a low-literacy brochure to encourage women to receive screening. The brochure was designed to answer basic questions about Pap smears and provide instructions on how to obtain a Pap smear.
1879290|NCT01172574|Other|Motor control exercise|Participants of the exercise group were trained to consciously co-activate the transversus abdominis, pelvic floor and thoracic erector spinae muscle, relax the lumbar multifidus and use the diaphragmatic breathing pattern. They were encouraged to activate the specific muscles of the trunk regularly during daily activities, particularly in situations where they anticipated or experienced pain such as walking, twisting, lifting low-lying objects and working with the hands in sitting or standing positions
1879291|NCT01172587|Other|Behavioral Couples Therapy|Couples participate in 12 sessions of Behavioral Couples Therapy designed to reduce substance use and increase relationship functioning.
1879292|NCT01172600|Other|Entonox|Those randomized to Entonox will inhale the gas through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
1879293|NCT01172600|Other|Oxygen|Those randomized to oxygen will inhale it through a mouthpiece throughout the procedure and also continue to receive it for a total of 4 hours in the recovery.
1879294|NCT01172626|Drug|valproate sodium|oral administration,15－30mg/kg,daily
1879295|NCT01172626|Genetic|Polymorphism Analysis|Analysis of genetic polymorphisms of the drug metabolic enzymes involving in the deactivation and elimination of Valproate sodium
1879296|NCT01172626|Other|Pharmacokinetic analysis|laboratory analysis of concentration of Valproate sodium and 4-ene-Valproate in plasma
1879297|NCT01172639|Other|randomisation|Stratification according to risk factors into two groups. Random assignment to different treatment strategies within strata.
1879300|NCT01172691|Procedure|Inhaled Nitric Oxide (iNO)|iNO or placebo will be administered at 40 ppm during the procedure starting when the Warm Ischemia Time begins - liver from ice. Stop when patient transported to ICU
1879301|NCT01172704|Behavioral|Skills Building - Motivational Interviewing|"SB-MI incorporates Motivational Interviewing strategies into a psycho-educational HIV risk reduction protocol to help participants identify high-risk behaviors, reduce ambivalence about these behaviors, increase motivation to change behaviors, and develop a specific plan of action for risk reduction. Consistent with MI, information gathered at baseline regarding HIV risk behaviors is systematically reviewed in a personalized way with each participant at the outset of the intervention. This is designed to engage participants in becoming active agents in the change process and to assist participants in recognizing discrepancies between their current risk behaviors and goals and values, which typically do not include HIV infection or transmitting HIV to others. Also consistent with the principles of MI, participants are empowered to choose those educational and skills-based modules which fit their personal risk profile and values."
1879302|NCT01172717|Drug|Panitumumab|Panitumumab will be given by intravenous infusion at a dose of 9 mg/kg on day 1 of study and then every 3 weeks until progression of disease
1879303|NCT01172730|Device|Ultrasound scanning|Ultrasound scanning is used to define needle insertion point and depth of epidural space.
1879304|NCT01172756|Drug|Riociguat (BAY63-2521)|0.5 mg single oral dose
1879305|NCT01172756|Drug|Riociguat (BAY63-2521)|1 mg single oral dose
1879306|NCT01172756|Drug|Riociguat (BAY63-2521)|2 mg single oral dose
1879307|NCT01172756|Drug|Placebo|single oral dose
1879308|NCT01172769|Biological|Temsirolimus|"After dissolving and dilution 25 mg of temsirolimus will be administered i.v. once a week by 30 minute infusion.
Study treatment will continue until tumor progression or unless unacceptable toxicity is encountered."
1879309|NCT01172782|Drug|Hydromorphone|2.5, 5, 10 ug of hydromorphone, intrathecal injection, single injection. duration of intrathecal injection are not fully studied.
1879310|NCT01172795|Behavioral|Relaxation session|30 minutes relaxation session (audiotape)
1879311|NCT01172795|Behavioral|Neurocognitive test battery|the psychomotor vigilance task, span task and the stroop task on computer
1879312|NCT01172808|Drug|Placebo|Placebo that represents comparator
1879313|NCT01172808|Drug|tiotropium Respimat® low dose|IMP
1879314|NCT01172808|Drug|Placebo|Placebo that represents comparator
1879315|NCT01172808|Drug|Placebo|Placebo that represents comparator
1879316|NCT01172808|Drug|tiotropium Respimat® high dose|IMP
1879317|NCT01172808|Drug|50 mcg salmeterol HFA MDI|Active comparator
1879318|NCT01172808|Drug|Placebo|Placebo that represents BI drug
1879319|NCT01172808|Drug|Placebo|Placebo that represents BI drug
1879320|NCT01172821|Drug|placebo|Placebo that represents BI drug
1879321|NCT01172821|Drug|placebo|Placebo that represents comparator
1879322|NCT01172821|Drug|placebo|Placebo that represents comparator
1879323|NCT01172821|Drug|tiotropium Respimat® low dose|IMP
1879324|NCT01172821|Drug|placebo|Placebo that represents BI drug
1879325|NCT01172821|Drug|tiotropium Respimat® high dose|IMP
1879326|NCT01172821|Drug|50 mcg salmeterol HFA MDI|Active comparator
1879327|NCT01172821|Drug|placebo|Placebo that represents comparator
1879328|NCT01172834|Behavioral|Health Coaching|A manual-driven group Health Coaching intervention. Once a week for 3 months.
1879329|NCT01172847|Drug|oseltamivir [Tamiflu]|multiple oral doses
1879330|NCT01172847|Drug|rimantadine|multiple oral doses
1879331|NCT01166061|Biological|Placebo|Solution resembling active solution but without peptides
1879332|NCT01166061|Biological|ToleroMune Grass|1 x4 administrations 4 weeks apart
1879333|NCT01166074|Biological|Subcutaneous IgG (SCIG)|Administered according to normal clinical practice
1879334|NCT01166087|Drug|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed-Release Capsules, 90 mg of Dr. Reddy's Laboratories.
1879335|NCT01166100|Drug|Fluoxetine Hydrochloride|Fluoxetine Hydrocloride Delayed Release Capsules, 90 mg of Dr. Reddy's Laboratories.
1879336|NCT01166113|Drug|Pomalidomide, Cyclophosphamide, Prednisone|"Induction
This multicenter phase I followed by a phase II trial will evaluate the safety and efficacy of the combination Pomalidomide-Cyclophosphamide-Prednisone (PCP) in patients (pts) with MM relapsed/refractory to lenalidomide.
In the phase I we assess the maximum tolerated dose (MTD) of PCP in 25% of pts. The first 4 pts are given the second dose level, accrual continues with 4 pts per dose level for a maximum of 24 pts.
The dose level associated with an updated DLT is recommended for the next patient cohort.
Each patient is assigned to a salvage therapy including Cyclophosphamide and Prednisone (both 50 mg every other d), and Pomalidomide at one of the following doses:1 mg/d;1.5 mg/d;2 mg/d;2.5 mg/d
In the phase II a total of 43 pts will be treated with the MTD of PCP. Pts enrolled at the MTD during the phase I will be included in the Phase II trial.
Maintenance (each cycle repeated every 28 d, until PD) Pomalidomide: 2.5 mg/d; Prednisone: 25 mg every other d"
1879337|NCT01166126|Drug|temsirolimus|Given IV
1879338|NCT01166126|Drug|selumetinib|Given orally
1879339|NCT01166126|Other|laboratory biomarker analysis|Correlative studies
1879340|NCT01172860|Device|EndoVe endoscopic electroporation|The EndoVe device enables the endoscopic treatment of gastrointestinal tumor tissues. The device is placed on the tumor tissue and an electrical pulse of less than 1msec is delivered. The tumor tissue becomes permeabilised and absorbs much greater concentrations of the drug than the surrounding healthy tissue
1879341|NCT01172873|Drug|D-cycloserine|50 mg dose of D-cycloserine administered at the end of each session of Cognitive Behavioral Therapy With Exposure and Response Prevention: twice weekly CBT/ERP of 60 minutes
1879342|NCT01172873|Behavioral|Exposure and Response Prevention (EX/RP)|Exposure and response prevention treatment. Participants complete graded exposure during twice weekly treatment sessions with therapist
1879343|NCT01172899|Procedure|laparoscopic adjustable gastric band|Laparoscopic gastric band placement. Combined lifestyle interventions will continue after surgery.
1879344|NCT01172899|Behavioral|Combined life style interventions|Control group will receive standard therapy consisting of combined lifestyle interventions.
1879345|NCT01172912|Biological|filgrastim|
1879346|NCT01172912|Biological|pegfilgrastim|
1879347|NCT01172912|Drug|carboplatin|
1879348|NCT01172912|Drug|cisplatin|
1879349|NCT01172912|Drug|dexamethasone|
1879350|NCT01172912|Drug|etoposide|
1879351|NCT01172912|Drug|ifosfamide|
1879352|NCT01172912|Other|high-dose chemotherapy with autologous stem cell rescue|
1879353|NCT01172912|Other|laboratory biomarker analysis|
1879354|NCT01172912|Procedure|autologous hematopoietic stem cell transplantation|
1879355|NCT01172912|Procedure|peripheral blood stem cell transplantation|
1879356|NCT01172925|Drug|Tiotropium|Inhaler
1879357|NCT01172925|Drug|Placebo|Inhaler
1879358|NCT01172938|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
1879359|NCT01172938|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
1879360|NCT01172938|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
1879361|NCT01172938|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
1879362|NCT01172951|Other|Oral glucose tolerance test|75g anhydrous glucose powder mixed with 100mls water
1879363|NCT01172951|Other|Oral lipid tolerance test|150ml drink composed of 2 commercially available high fat products
1879364|NCT01172964|Drug|flucytosine|Given orally
1879365|NCT01172964|Other|polymerase chain reaction|Correlative studies
1879366|NCT01172964|Other|immunohistochemistry staining method|Correlative studies
1879367|NCT01172964|Biological|gene therapy|Injected at the time of the surgery to resect the tumor
1879368|NCT01172964|Other|pharmacological study|Correlative studies
1879369|NCT01172964|Other|3-Tesla magnetic resonance imaging|Correlative studies
1879370|NCT01172964|Other|laboratory biomarker analysis|Correlative studies
1879371|NCT01172964|Procedure|therapeutic conventional surgery|Surgery to resect the tumor
1879372|NCT01172964|Biological|E. coli CD-expressing genetically modified neural stem cells|Injected at the time of the surgery to resect the tumor
1879373|NCT01172990|Procedure|Immediate Invasive Management|Patients allocated to the immediate invasive strategy will be taken to the catheter lab immediately (< 90 minutes from randomisation) in accordance with local primary angioplasty policy. Angiogram +/- same sitting PCI will be performed according to local policy and guidelines
1879374|NCT01172990|Procedure|Conventional Management|Patients allocated to the conventional management group will have medical stabilisation and will undergo angiogram +/- PCI between 24 to 48 hours from randomisation according to local policy and guidelines
1879375|NCT01173003|Drug|Mifepristone, misoprostol|
1879377|NCT01173029|Drug|Anti-hypertensive drug treatment|Anti-hypertensive drug treatment was non-investigational. Drug regimen, including which drug and the number of drugs prescribed, was left at discretion of the physician who carried primary assistance.
1879378|NCT01173042|Dietary Supplement|Peanuts|Shake containing 3.0oz of peanuts (including skin) + control (heavy whipping cream, glucose and chocolate syrup)
1879379|NCT01173042|Dietary Supplement|Glucose and whipping cream|An oral liquid glucose (75g) and fat (high saturated fat from 60g heavy whipping cream) load. Chocolate syrup is added for flavor.
1879380|NCT01173042|Dietary Supplement|Oil Blend|Shake containing an oil blend (sunflower, sesame, olive and palm oils) + control (heavy whipping cream, glucose and chocolate syrup). The amount of oil added to the control will provide an equivalent amount of fat to that provided in 3 oz (85g) of peanuts
1879381|NCT01173055|Drug|milnacipran|Milnacipran will be given orally twice daily in tablet form at different times during the course of the study. The highest dose of milnacipran to be used in the study is 200mg/day.
1879382|NCT01173055|Drug|Placebo|Placebo will be given orally twice daily in tablet form at different times during the course of the study.
1879383|NCT01173068|Drug|Ertapenem|Prescribed IV Ertapenem 1gm (or renally adjusted dose) will be administered every 24 hours. The duration of treatment will be determined by the clinician and this typically is 2 weeks, or as clinically indicated.
1879384|NCT01173081|Drug|Teriparatide|20mcg once daily for 16 weeks or until study endpoint is achieved.
1879385|NCT01173081|Drug|Placebo|matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved
1879386|NCT01173094|Device|Percutaneous Transluminal Angioplasty|Before operation, take aspirin 100mg every day. During the operation, balloon is delivered by a catheter and positioned through the narrowing in the artery. Then expand the balloon against the wall of the blood vessel to provide a wider channel for blood.
1879387|NCT01173094|Device|below-knee arterial bypass|Before operation, take aspirin 100mg every day. Perform bypass to below-knee(posterior tibial，anterior tibial or peroneal)arteries, saphenous vein graft with end to side anastomoses
1879388|NCT01173107|Drug|colchicine|colchicine 1T tid
1879389|NCT01173120|Device|Abatacept combination product (ACP)|Abatacept Solution, Subcutaneous, 125 mg/device, Weekly, 3 months
1879390|NCT01173159|Drug|Omegaven|For the first two days of treatment, subjects will receive Omegaven® at 0.5 g/kg per day to assess tolerance and will progress to a maintenance dosage of up to 1g/kg per day over 12 hours at an infusion rate of 1 g/kg/12 hours (10 ml/kg/12 hours). Dosing is based on previously described dosing of fish-oil emulsions as monotherapy noted within the literature. Omegaven® will be infused intravenously through either a central or peripheral catheter in conjunction with other parenteral nutrition containing dextrose and amino acids. Omegaven® is isotonic. It is compatible with parenteral nutrition solutions and may be co-infused via y-site.
1879391|NCT01173172|Radiation|Boron Neutron Capture Therapy|Boronophenylalanine (BPA) 500 mg/kg on D1 and D30 followed by BNCT for 2 fractions (D1 and D30)
1879392|NCT01173198|Device|WAVEFRONT Optimized LASIK|30 patients
1879393|NCT01173198|Device|WAVEFRONT GUIDED LASIK|30 patients
1879394|NCT01175044|Procedure|Betadine Lavage|Following revision knee surgery, a dilute betadine lavage prior to surgical closure for 3 minutes followed by 2000 ml of sterile saline irrigation
1879395|NCT01175044|Procedure|Saline Lavage|Following revision knee surgery, 2000ml sterile saline lavage prior to closure
1879396|NCT01175070|Drug|Intravitreal injection of pegaptanib sodium|Eligible participants with ischaemic diabetic macular oedema will receive an intravitreal injection of pegaptanib sodium (Macugen [TM]) 0.3mg every 6 weeks over a 30 week period.
1996644|NCT02428439|Drug|bupropion or lamotrigine|Participants who take the standardized pharmacotherapy (bupropion or lamotrigine) for depression will be observed for 8 weeks. Drugs using in this study are the standard treatment for depression, and are NOT administered as part of this study.
1996645|NCT02428361|Drug|Biologically active human fecal material, OpenBiome|Fecal microbiota transplant
1996646|NCT02428140|Device|Medtronic Reveal LINQ|
1879400|NCT01175096|Drug|RAD001 (everolimus, Afinitor®)|"RAD001 will be provided by Novartis to the study sites. RAD001 is formulated as tablets of 5 mg strength, blister-packed under aluminum foil in units of 30 tablets. The study site will dispense an adequate supply of RAD001 to the patient for self-administration at home.
2 x 5 mg (=10 mg) RAD001 p.o., once daily, at the same time each day, One treatment cycle consists of 28 days."
1879401|NCT01175109|Drug|Imatinib + LBH589|Escalating doses of imatinib and LBH589 will be administered.
1879402|NCT01175122|Biological|H2N3 MO 2003/AA ca Vaccine|0.2 mL of H2N3 MO 2003/AA ca vaccine delivered by an Accuspray nasal spray device on Day 0 and Day 28
1879403|NCT01175135|Drug|PF-02545920|5 mg tablet every 12 hours for 28 days
1879404|NCT01175135|Drug|PF-02545920|15 mg tablet every 12 hours for 28 days
1879405|NCT01175135|Drug|Placebo|One tablet/capsule every 12 hours for 28 days
1879406|NCT01175135|Drug|Risperidone|3 mg capsule every 12 hours for 28 days
1879407|NCT01175148|Drug|Atorvastatin calcium (Lipitor)|40 mg PO daily
1879408|NCT01175161|Device|Copper T380A Intrauterine Device|the Copper T380A IUD will be placed either 10 minutes to 48 hours postpartum, or 4-6 weeks postpartum.
1879409|NCT01175200|Drug|Clopidogrel|antiplatelet agent
1879410|NCT01175200|Drug|Prasugrel|antiplatelet agent
1879411|NCT01175200|Drug|Lansoprazole|proton pum inhibitor
1879412|NCT01175200|Drug|Placebo|placebo comparator similar to lansoprazole
1879415|NCT01175226|Drug|BTA798|BTA798 twice daily
1879416|NCT01175226|Drug|Placebo|Placebo twice daily
1879417|NCT01175239|Genetic|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre|Single infusion of autologous CD34+ cells transduced with the self-inactivating (SIN) gammaretroviral vector pSRS11.EFS.IL2RG.pre
1879418|NCT01175252|Other|Database analysis|Review and collect data from database
1879419|NCT01175265|Other|respiratory biofeedback|In order to train effortless diaphragmatic breathing techniques the biofeedback loop starts at the sensor that measures the patient's breathing rhythm at both umbilical and abdominal level. The sensor is connected to an amplifier that converts the electrical impulses into acoustical and visual outputs. Patients were encouraged to regulate their breathing patterns at a 10-20% slower respiration rate resulting in increased tidal volumes. Furthermore, the patients were encouraged to reduce dynamic hyperinflation by completing the expiration prior to the initiation of the next breath while using pursed-lips breathing. Patients were trained to breath as comfortable as possible with predominant abdominal expansion during the inhalation and smooth abdominal contraction during exhalation.
1882551|NCT01197911|Drug|aleglitazar|single oral dose
1996647|NCT02428140|Device|Sorin Spiderflash-t|
1996648|NCT02427191|Other|AmnioFix® Injectable|1 mL injection of 40 mg Micronized dehydrated human amnion/chorion membrane (dHACM)
1996649|NCT02427191|Drug|Saline Injection|Injection of 1mL 0.9% Sodium Chloride Injection, USP
1996650|NCT02426957|Behavioral|motivational enhancement therapy|The intervention consists of the following components: establishing rapport, assessing motivation for change, enhancing motivation for change, envisioning the future, establishing goals, and completing goals, strategies, and change plan worksheets.
1996651|NCT02426736|Drug|Dexamethasone|
1996652|NCT02426736|Drug|Bupivacaine|
1879420|NCT01175278|Procedure|Vertebral Augmentation with Balloon Kyphoplasty|Two small metal tubes will be inserted through the skin into the collapsed bone. Inflatable bone tamps (balloon catheters) will be inserted through each of these two tubes into the bone. The balloons will be inflated with a liquid that can be seen on xrays (contrast) to return the bone toward its natural shape and create a cavity. The balloons will then be deflated and removed. The cavity in the bone will be filled with bone cement to stabilize the broken backbone.
1879421|NCT01175278|Other|Non-surgical Treatment|Non-surgical treatment means the institution of therapies other than cancer chemotherapy and surgical treatment aimed at alleviation of back pain and restoration of decreased function associated with the patient's VCF(s).
1879422|NCT01175291|Drug|MK-0646|ARM A will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil [5-FU] + Bevacizumab) + MK-0646 (Investigational).
1879423|NCT01175291|Drug|Placebo|ARM B will receive FOLFOX 7 (Oxaliplatin with leucovorin + 5-Fluorouracil [5-FU] + Bevacizumab) + placebo: standard of care chemotherapy plus placebo.
1879424|NCT01175317|Procedure|Goal-directed fluid optimization|Fluid administration and optimization based on cardiac output findings during surgery and during the first 8 hours of the postoperative phase.
1879425|NCT01175317|Other|Regimen based on expertise anaesthesist|Fluid regimen based on expertise anaesthesist
1879426|NCT01175330|Drug|Omega-3 fish oil emulsion (Omegaven)|Lipid emulsion (omegaven) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
1879427|NCT01175330|Drug|Intralipid|Lipid emulsion (Intralipid) for intravenous use, 1 ml/kg/day daily for 7 days post-surgery period (The first infusion beginning in operative period)
1879428|NCT01175343|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1879429|NCT01175343|Other|Laboratory Biomarker Analysis|Correlative studies
1879430|NCT01175356|Drug|cyclophosphamide|Given IV
1879431|NCT01175356|Drug|topotecan hydrochloride|Given IV
1879432|NCT01175356|Drug|cisplatin|Given IV
1879433|NCT01175356|Drug|etoposide phosphate|Given IV
1879434|NCT01175356|Drug|vincristine sulfate|Given IV
1879435|NCT01175356|Drug|doxorubicin hydrochloride|Given IV
1879436|NCT01175356|Radiation|iobenguane I 131|Given IV
1879437|NCT01175356|Procedure|therapeutic conventional surgery|Undergo surgery
1879438|NCT01175356|Drug|busulfan|Given IV
1879439|NCT01175356|Drug|melphalan|Given IV
1879440|NCT01175356|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
1879441|NCT01175356|Procedure|in vitro-treated peripheral blood stem cell transplantation|Undergo autologous in vitro-treated peripheral blood stem cell transplantation
1879442|NCT01175356|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
1879443|NCT01175356|Radiation|external beam radiation therapy|Undergo radiotherapy
1879444|NCT01175356|Radiation|intensity-modulated radiation therapy|Undergo radiotherapy
1879445|NCT01175356|Drug|isotretinoin|Given PO
1879446|NCT01175356|Other|pharmacological study|Correlative studies
1879447|NCT01175356|Other|questionnaire administration|Ancillary studies
1879448|NCT01175356|Other|laboratory biomarker analysis|Correlative studies
1879449|NCT01175369|Behavioral|School-based Care|The intervention includes directly observed administration of preventive medications in school and a home-based ETS reduction program (for those living with one or more smokers).
1879450|NCT01175382|Behavioral|Behavioral training|Behavioral treatment consists of skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, urge suppression techniques, delayed voiding, and daily bladder diaries to track increasing voiding intervals and enhance awareness of bladder habits. Training is supplemented with instructions for daily home practice between clinic visits. In addition to daytime training, nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies.
1879451|NCT01175382|Drug|Tolterodine + tamsulosin|Patients in drug therapy receive an anti-muscarinic (long acting tolterodine 4 mg daily) and an alpha blocker (tamsulosin 0.4 mg daily).
1879452|NCT01175382|Other|Combined Behavioral + Drug Therapy|Combined behavioral and drug therapy implemented in 4 clinic visits over a period of 6 weeks, followed by an additional 6 weeks of combined therapy. Behavioral treatment consists of behavioral training and includes skills and strategies for postponing urination, controlling urgency and preventing urge incontinence. This includes pelvic floor muscle training, incremental delayed voiding, and bladder diaries, supplemented with instructions for daily home practice. Nocturia is managed with fluid restriction (3 hours before bedtime and during the night) and with urge strategies. Drug therapy consists of an anti-muscarinic (sustained release tolterodine 4 mg) + an alpha blocker (tamsulosin 0.4mg daily).
1879453|NCT01175395|Drug|IBI-20089/Lucentis|Combining a single dose of IBI-20089 (6.9 mg or 13.8 mg) intravitreal injection adjunctively with Lucentis 0.5 mg intravitreal injection at baseline and monthly intravitreal Lucentis injection PRN based on clinical and OCT results.
1879454|NCT01175408|Other|Remote Blood Glucose Monitoring|The subjects enrolled in the Internet Therapeutic Intervention arm receive standard care by testing their blood glucose at least 3 times daily and visit the endocrinologist every 3 months; however, they are also asked to upload their blood glucose readings online every 2 weeks for the health practitioner to view and comment upon.
1879455|NCT01175408|Other|Continuous Glucose Monitoring|The use of CGMS (Sensor, receiver, transmitter) (Medtronic Diabetes) plus the uploading of results to the Internet-based software utility of CareLink Personal and generating reports that can be viewed and used at the patient's own preference. This group will not receive feedback or suggestion based on the uploaded glucose data.
1879456|NCT01175408|Other|SMBG|The SMBG patients will be told that we are testing a new meter to check the accuracy of the meter. They will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. The SMBG group will not know that we are counting strips and can not know about the SMBG With Knowledge group as it may bias the frequency that they test.
1879457|NCT01175408|Other|SMBG With Knowledge|The SMBG With Knowledge patients will be given a new meter and will be asked to test at least 3 times a day and to keep a written diary of their sugar levels. We will inform this group that we are measuring the frequency of SMBG testing.
1882552|NCT01197924|Other|IRMf Bold|IRMf BOLD of the working memory
1879458|NCT01175434|Other|School-Based Medication Delivery|For children assigned to the School-Based Medication group, an asthma coordinator will send the child's primary care physician a report indicating the child's asthma symptoms, and will recommend that the child receive a preventive asthma medication at school. If the child's doctor agrees, the preventive asthma medication will be delivered to the child's school and to his/her home by a local pharmacy. The child's school nurse begin directly observed therapy of the preventive asthma medication at school, and will routinely assess the child's asthma symptoms throughout the school year.
1879459|NCT01175447|Drug|S-1|S-1 was administered on days 1-14 and 29-42 at the following dosages: 60, 70, and 80mg/m(2)/day
1879460|NCT01175460|Drug|S-1, Nedaplatin|nedaplatin was given at a fixed dose of 75 mg/m2 on Days 1, and s-1 on Days 1-14, repeated every 4 weeks for four cycles. The dose of s-1 was initially 60 mg/m2/day and gradually increased to determine the MTD and RD of this regimen.
1879461|NCT01175473|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
1879462|NCT01175473|Device|Pen auto-injector|
1879463|NCT01175473|Drug|Liraglutide|Self administered by subcutaneous injections once daily 30 minutes before breakfast.
1879464|NCT01175473|Device|Pre-filled pen injector|
1879465|NCT01175473|Drug|Metformin|Metformin to be continued at stable dose (1.5 gram per day) up to Week 4.
1879466|NCT01175486|Drug|Actos (Pioglitazone)|Actos 30 mg for 6 months
1879467|NCT01175486|Drug|Acarbose|Acarbose 50 mg tid for 6 months
1879468|NCT01175499|Device|Direct Rigid Endoscopy|Laryngoscopy is performed under general anesthesia with a rigid laryngoscope. Mucosal surfaces of the oropharynx, hypopharynx, and glottis (base of tongue, vallecula, epiglottis, aryepiglottic folds, arytenoids, piriform sinuses, true and false vocal cords, and esophageal inlet) are systematically visualized. Areas of irregularity are biopsied with 2mm and/or 4mm cupped forceps. Esophagoscopy and bronchoscopy will be performed per the standard of care.
1879469|NCT01175499|Device|Transnasal Flexible Endoscopy with Narrowband Imaging|Transnasal flexible endoscopy with and without narrowband imaging- additional diagnostic test. This examination is performed after topical intranasal anesthesia with 2% Pontocaine spray. A fiberoptic laryngoscope is passed into the nasal cavity to the pharynx where mucosal surfaces of the UADT can be visualized. The optics of a standard fiberoptic scope are generally considered to be inferior to direct visualization. The addition of narrowband imaging does not change the procedure, but enhances visualization of the mucosal vasculature. Biopsies are performed through a second channel in the endoscope with 1.8mm cupped forceps and will require an additional dose of topical anesthesia.
1879470|NCT01175512|Drug|Naltrexone|4 days, counterbalanced dosing of 25mg, 50mg, placebo, placebo.
1879471|NCT01175525|Drug|CROMOLYN|Cromolyn 200mg (dissolved in water) given 4 times a day
1879472|NCT01175525|Drug|sugar pill|sugar pill Dissolved in water taken 4 times daily 30 minutes prior to meals
1879473|NCT01175538|Drug|Lactulose|In the Gp-L group, patients will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passes 2-3 semisoft stools per day
1879474|NCT01175538|Drug|Lactulose|lactulose will be used in 30-60ml/day
1879475|NCT01175564|Drug|TC-5214|Four increasing doses levels of a single dose and two increasing dose levels of 6 days repeated dose of TC-5214 tablet
1879476|NCT01175564|Drug|Placebo|Placebo tablet, single dose and 6 days repeated dose
1879477|NCT01175577|Dietary Supplement|Chlorophyll complex, Standard Process|One capsule, twice daily with meals for 28 days
1879478|NCT01175577|Dietary Supplement|"Betatene, sold as Full Spectrum Carotenoid Complex"|One capsule per day with meals for 28 days
1879479|NCT01175577|Other|Small carotenoid-rich meals|Single carotenoid-enriched soup or salad serving eaten daily
1879480|NCT01175577|Other|Placebo|Safflower oil-filled capsules, one twice daily with meals
1879481|NCT01175590|Drug|Besivance|Ocular administration to affected eye for 7 days
1879482|NCT01175590|Drug|Vehicle|Vehicle of Besivance administered to affected eye for 7 days
1879483|NCT01175603|Behavioral|Mothers and Babies Course (Adapted for Baltimore Home Visiting Programs)|6 weekly 2-hour cognitive-behavioral intervention sessions held in group format
1879484|NCT01175616|Drug|Creatine|Oral Creatine 5 grams daily.
1879485|NCT01175642|Behavioral|Cognitive Remediation|Computer-based, therapist-lead cognitive remediation
1879486|NCT01175642|Behavioral|FAST|Functional adaptive skills training. Group treatment to foster the acquisition of social and adaptive skills
1879487|NCT01175655|Other|MSC|mesenchymal stromal cells (MSC), aiming for 2 x 106 /kg cells recipient body weight, aiming for a frequency of twice weekly for two weeks
1879488|NCT01175668|Drug|Clonidine|This group of infants undergoing NAS will be treated with neonatal morphine sulfate and Clonidine as an adjunct medication to control the symptoms. Once stable Finnegan scores <8 for 24h, NMS will be weaned by 10% daily till off, then Clonidine will be weaned off in a stepwise manner. Infant will not go home on any medication for NAS. NMS will be dosed as mg/kd/day divided q3h and Clonidine will be dosed as microgm/kg/day divided q6h based upon the initial Finnegan scores.
1879489|NCT01175668|Drug|Phenobarbital|"Infants in this arm will be treated as current standard practice with NMS and Phenobarbital. NMS will be weaned by 10% daily to completely off during the hospital stay. Infants will be discharged home on Phenobarbital.
NMS will be dosed as mg/kg/day divided q3h and Phenobarbital will be dosed as mg/kg/day divided q8h based on the Finnegan scores."
1879490|NCT01175681|Procedure|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper arm ischaemia, which was induced by an automated cuff -inflator placed on the right upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated. There was a 5- to 10-min interval between completion of the remote ischaemic preconditioning protocol and initiation of bypass.Control patients had a deflated cuff placed on the right upper arm for 30 min.
1879491|NCT01175694|Radiation|Interstitial multicatheter brachytherapy|Interstitial PDR- and HDR-brachytherapy up to 50 Gy-eq
1879492|NCT01175707|Drug|Daptomycin|
1879493|NCT01175707|Drug|Vancomycin|
1879494|NCT01175720|Procedure|Periodontal surgery to gingival recessions|Test and control technique to treat gingival recessions.
1879600|NCT01176448|Device|Fractionated laser|Fractionated laser in the form of the Re:Pair CO2 laser manufactured by Solta Medical.
1879495|NCT01175733|Drug|Panitumumab|During the first 6 weeks Panitumumab will be administered weekly in combination with radiotherapy plus gemcitabine. From week 8 and further gemcitabine will be administered as monotherapy until disease progression or unacceptable toxicity, for a maximum duration of 1 year.
1879496|NCT01175746|Drug|Nicardipine|
1879497|NCT01175746|Drug|remifentanil|0.1-0.5 ugkg/min during hypotensive anesthesia
1879498|NCT01175759|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.
Hormones:
Progesterone 1mmol/L
Estradiol 1mmol/L
Estrone 3mmol/L
Estriol 3mmol/l
Controls:
Saline (NaCl) 0.9%
Ethyl Oleate with 10% Benzyl Alcohol
Histamine phosphate 1mg/ml (epicutaneous- prick test)"
1879499|NCT01175759|Drug|Skin test panel|"Skin testing 4 sex hormones will be performed during the luteal phase of the subject's menstrual cycle by study investigators.
Hormones:
Progesterone 1mmol/L
Estradiol 1mmol/L
Estrone 3mmol/L
Estriol 3mmol/l
Controls:
Saline (NaCl) 0.9%
Ethyl Oleate with 10% Benzyl Alcohol
Histamine phosphate 1mg/ml (epicutaneous- prick test)"
1879500|NCT01175772|Drug|Cytophosphan, Celecoxib, Methotrexate|"Metronomic Chemotherapy as maintenance treatment for patients with Ovarian Cancer
Cytophosphan tab 50 mg -1x1 per day, continuous
Celecoxib tab 200 mg - 1x2 per day, continuous
Methotrexate tab 2.5 mg - 1x2 per day, 2 days weekly"
1879501|NCT01175785|Procedure|umbilical cord blood transplantation|Undergo unmanipulated umbilical cord blood units
1879502|NCT01175785|Drug|fludarabine phosphate|Given IV
1879503|NCT01175785|Drug|cyclophosphamide|Given IV
1879504|NCT01175785|Procedure|ex vivo-expanded cord blood progenitor cell infusion|Undergo ex-vivo expanded cryopreserved cord blood progenitor cells
1879505|NCT01175785|Radiation|total-body irradiation|Undergo TBI
1879506|NCT01175785|Drug|cyclosporine|Given IV
1879507|NCT01175785|Drug|mycophenolate mofetil|Given IV and PO
1879508|NCT01175785|Other|laboratory biomarker analysis|Correlative studies
1879509|NCT01175798|Drug|Cholecalciferol|50,000 IU PO weekly x 6 weeks
1879510|NCT01175811|Drug|Insulin Lispro Premix|Participant dependent dose, administered subcutaneously for 24 weeks
1879511|NCT01175811|Drug|Insulin Glargine|Participant dependent dose, administered subcutaneously for 24 weeks
1879512|NCT01175811|Drug|Insulin Lispro|Participant dependent dose, administered subcutaneously for 24 weeks
1879513|NCT01175824|Drug|Insulin Lispro Low Mixture (LM)|Participant-dependent dose, administered subcutaneously for 24 weeks
1879514|NCT01175824|Drug|Insulin Glargine|Participant-dependent dose, administered subcutaneously for 24 weeks
1879515|NCT01175824|Drug|Prandial Insulin Lispro|Participant-dependent dose, administered subcutaneously for 24 weeks
1879516|NCT01175837|Other|questionnaire administration|Ancillary studies: Pre- and post-fasting side effect questionnaires
1879517|NCT01175837|Other|preventative dietary intervention|24, 36, or 48 hour fast prior to chemotherapy
1879518|NCT01175837|Other|laboratory biomarker analysis|Correlative studies
1879519|NCT01175850|Device|Drug-Coated Balloon (DCB)|balloon dilatation and provisional stenting with IN.PACT DCB
1879520|NCT01175850|Device|PTA Balloon: Balloon Angioplasty|balloon dilatation and provisional stenting with standard non-coated PTA balloon
1879521|NCT01175863|Device|Grey scale intravascular ultrasound (Galaxy or Virtual histology-Intravascular Ultrasound)|minimal lumen area on Intravascular ultrasound
1879522|NCT01175863|Device|Pressure wire(Radi Medical Systems)|Fractional flow reserve measured by pressure wire
1879526|NCT01175902|Drug|dorzolamide/timolol|dorzolamide/timolol fixed combination eyedrop, 2 times a day
1879527|NCT01175902|Drug|latanoprost|compare with dorzolamide/timolol fixed combination eyedrop one time a day
1879528|NCT01175915|Other|Western therapy|"Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;
Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius lasting for more than 2 hours;
No specific treatment for tetter and ulcer, but Bingpeng powder, Watermelon tablet or frost for oral herpes.
Intervention time: 3-7 days; Follow-up time: 3 days."
1879529|NCT01175915|Other|Reduning Injection|"Lifestyle counseling, vitamin supplementation if necessary, and non-use of antibiotics;
Reduning Injection, 0.5~15ml, depending on patient's condition, IV per day, or according to the instruction;
Using Ibuprofen suspension when patient's temperature higher than 39 degree Celsius lasting for more than 2 hours.
Intervention time: 3-7 days; Follow-up time: 3 days."
1879530|NCT01175915|Other|Reduning Injection plus western therapy|"General treatment including lifestyle counseling, vitamin supplementation if necessary, non-use of antibiotics, and symptomatic treatment as follows;
Symptomatic treatment by western therapy adopting the same plan in western therapy comparator group;
Symptomatic treatment by Reduning Injection adopting the same plan in Reduning Injection experimental group.
Intervention time: 3-7 days; Follow-up time: 3 days."
1879531|NCT01175928|Device|Sham device|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
1879532|NCT01175928|Device|NormaTec PCD (Peristaltic Pulse PCD)|Home treatment with PCD to both legs: 2 sessions of 1 hour duration every day
1879533|NCT01175941|Drug|NRL001|10 mg NRL001 in a 2 g suppository, administered once daily for 7 days
1879534|NCT01175941|Drug|Placebo control|Matched placebo - administered as a 2 g suppository, once daily for 7 days
1879535|NCT01175954|Drug|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period. Dose Adjustments allowed up to 400 mg/day.
1879536|NCT01175954|Drug|Lacosamide|Lacosamide will be titrated starting from visit 1 for 2 weeks (50mg bid) and maintained at 100mg bid for the rest of the study period.
1879537|NCT01175967|Other|Palliative Performance Scale version 2 (PPSv2)|PPSv2 is arrayed on a scaled from 10 (bedbound) to 100 (full ambulation) at 10 points increment. It will be administered beginning at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
1879538|NCT01175967|Other|McCorkle Symptom Distress Scale (SDS)|A 13-item scale of SDS is used to indicate the degree of distress for a given symptom on a 5 point Likert Scale, ranging from 1 (least amount of distress) to 5 (extreme distress). This will be administered at baseline, post surgery (at the first post-operative clinic visit), 14-21 days post chemotherapy (post cycle 3 and post cycle 6), and at the first follow-up visit
1879539|NCT01175967|Other|Geriatric Assessment|This will evaluate the subject's overall geriatric status. The first part will be filled out by the study team and the second half of the assessment will be populated with information provided by the subject. This will be completed at baseline, 2 weeks post-surgery and 14-21 days after completing cycle 3 and cycle 6.
1879540|NCT01175967|Other|Medical Records Abstraction|Data collected from medical records will include information on surgical complications and chemotherapy toxicities, dose reductions, and any change in choice of chemotherapy drug. This will occur continuously throughout the study.
1879541|NCT01175980|Other|Laboratory Biomarker Analysis|Correlative studies
1879542|NCT01175980|Drug|Vorinostat|Given PO
1879550|NCT01176019|Device|Information about Prenatal Screening and Diagnosis|15-20 minute interactive video about prenatal screening and diagnosis given on day of recruitment.
1879551|NCT01176032|Drug|Aliskiren|Aliskiren 300 mg film coated tablets
1879552|NCT01176032|Drug|Losartan|Losartan 100 mg tablets
1879553|NCT01176032|Drug|Amlodipine|Amlodipine 5mg was given to patients who did not achieve the required blood pressure (<140/90 mmHg) after 8 weeks (visit 3)of treatment at the maximum doses of study medication in addition to the study medication in order to reach the required BP. at visit 4 (week 18) the dose of amlodipine was increased to 10mg if the required level (<140/90 mmHg) was still not achieved.
1879554|NCT01176032|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5mg was prescribed at visit 5 (week 26) if the required values (<140/90 mmHg) had not been reached.
1879555|NCT01176058|Drug|Anidulafungin/Fluconazole|Anidulafungin:IV,100 mg daily preceded by an initial 200 mg dose on Day 1, 14 - 42 days Fluconazole: IV/Oral, 400mg,QD,14 - 42 days
1879556|NCT01176084|Behavioral|low carbohydrate diet|
1879557|NCT01176084|Behavioral|low carbohydrate diet and exercise|
1879558|NCT01176097|Drug|AZD5658|oral suspension, escalating single doses
1879559|NCT01176097|Drug|Placebo|oral suspension,single doses
1879560|NCT01176110|Device|LMA Perfect Temp|The LMA PerfecTemp™ patient warming system combines warming beneath the patient and advanced pressure reduction to combat hypothermia and decubitus ulcers. This device is used during the interventional minimal invasive valve replacement with unprecedented ease and safety
1879561|NCT01176123|Behavioral|Cognitive Behavioral Therapy for Insomnia|Cognitive Behavioral Therapy for Insomnia
1879562|NCT01176136|Behavioral|Homework, Organization, and Planning Skills (HOPS) Intervention|HOPS is a 16 session school-based intervention. School counselors and psychologists deliver the intervention during the school day. Each session lasts 20 minutes. Initially, sessions are 2 times per week and the entire HOPS intervention is completed in 11 weeks. The study uses a waitlist control design. HOPS intervention participants (Arm 1) receive the intervention in the fall quarter of the school year and Treatment As Usual participants (Arm 2) receive the intervention in the spring quarter.
1879563|NCT01176149|Behavioral|SMBG plus intensive education|
1879564|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 50 mg, intramuscular weekly injection for a total of 7 doses.
1879565|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 100 mg, intramuscular weekly injection for a total of 7 doses.
1879566|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 200 mg, intramuscular weekly injection for a total of 7 doses.
1879567|NCT01176175|Drug|Progesterone|Progesterone microspheres injectable suspension 300 mg, intramuscular weekly injection for a total of 7 doses.
1879568|NCT01176188|Other|Comfort Care|The intervention will consist of two parts: (1) A 15-20 minute period of parental soothing at the bedside comprised of calming activities which the child and parents are familiar with; (2) A quiet period will follow, in which earmuffs are applied over the child's ears to block auditory stimulation. The intervention will take place twice/24 hours, up to a maximum of 72 hours. Total time of first (daytime) intervention will be 2 hours, and of second (night-time) intervention will be 7 hours.
1879569|NCT01176188|Other|Usual care|Usual nursing care for the child in the Pediatric Intensive Care Unit, including usual parental involvement and usual exposure to unit noise levels.
1879570|NCT01176201|Drug|SLV337 suspension|400 mg experimental
1879571|NCT01176201|Drug|SLV337 capsule|5 x 200 mg immediate release capsule
1879572|NCT01176214|Procedure|Early tracheostomy|"Patients with supratentorial ICH who require mechanical ventilation, fulfill the inclusion criteria, and have been randomized to the treatment arm will receive an early tracheostomy within 72h after symptom onset."
1879573|NCT01176214|Procedure|Late tracheostomy|"Compared to the early tracheostomy-group, those patients who have been randomized to late tracheostomy will undergo conventional tracheostomy between day 12 - 14 if extubation fails"
1879601|NCT01176448|Device|Dermabrasion|Diamond Fraise Dermabrasion will be performed in standard fashion down to papillary dermis.
1879574|NCT01176227|Dietary Supplement|Kyodophilus multi-strain probiotic capsules|"The Kyo-Dophilus study product is a gelatin capsule containing three proprietary probiotic bacterial strains. The total quantity of bacteria per capsule is 1.5 billion colony forming units (1.5 x 109 cfu) and is composed of the following strains:
Lactobacillus gasseri KS-13 1.2
Bifidobacterium bifidum G9-1 0.15
Bifidobacterium longum MM-2 0.15
Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2."
1879575|NCT01176227|Dietary Supplement|Kyodophilus Matching Placebo Capsules|Subjects will be provided with two bottles containing 30 capsules each of matching placebo upon randomization. Subjects will be instructed to take one capsule with breakfast daily for the full 12 weeks duration of the trial. While one bottle contains enough capsules for the time frame between each visit, two bottles have been provided to permit a surplus in the event scheduling conflicts arise. The third bottle, providing the remainder or study capsules, will be provided at visit 2.
1879576|NCT01176240|Drug|Droxidopa|100 mg and 200 mg capsules 100, 200, 300, 400, 500, 600mg TID dosing for up to 8 weeks of treatment
1879577|NCT01176240|Other|Placebo|Placebo
1879578|NCT01176253|Procedure|Blood draw|Blood draw for Type I DM patients will be taken every 4 weeks for 1 year post diagnosis/healthy volunteers will have 1 blood draw
1879580|NCT01176279|Procedure|Manual and automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.
Obtain 2cc of blood using the arterial blood sampling syringe connected to the proximal key. This volume of rejection is reserved in the syringe itself.
In accordance with the current protocol of disinfection, the needless connector inserted on the distal key will be disinfected. With a disposable sterile syringe the needless connector is punctured and a minimum blood amount is obtained for the determination of the glycaemia.
Once the sample has been obtained, the rejection volume reserved is returned to the bloodstream. This arterial blood sampling syringe is cleaned aspirating serum manually in order to wash the line.
Additional line washing is made through the fast flow valve of the system BD DTXPlus ™."
1879581|NCT01176279|Procedure|Automated washing of the peripherical lines|"The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.
In accordance with the current protocol of disinfection, the two needless connectors inserted on the two 3-way stopcock keys will be disinfected.
With a disposable sterile syringe the needless connector on proximal 3-way stopcock is punctured and 2cc of blood are aspirated. This volume of rejection is reserved in the syringe itself and it is not disconnected.
With a second disposable sterile syringe the needless connector on distal 3-way stopcock key is punctured and a minimum blood amount is obtained for the determination of the glycaemia.
Once the sample has been obtained, the rejection volume reserved in the disposable syringe connected to the proximal 3-way stopcock is returned to the bloodstream.
Line washing will be made through the fast flow valve of the system BD DTXPlus ™."
1879582|NCT01176292|Device|Rotating Platform High-Flex Cruciate Substituting TKA|
1879583|NCT01176292|Device|Rotating Platform Cruciate Substituting TKA|
1879584|NCT01176318|Drug|Erdosteine|capsule 300mg twice daily for 10 days
1879585|NCT01176318|Drug|Placebo|placebo capsule, twice daily for 10 days
1879586|NCT01176331|Procedure|20 and 23 gauge pars plana vitrectomy|
1879587|NCT01176344|Drug|Vitamin D|50,000 IU (1.25 mg) cholecalciferol capsules once monthly for 2 years
1879588|NCT01176344|Drug|Placebo|Inert placebo capsules once monthly for 2 years.
1879589|NCT01176370|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation of a heart assist device that provide counterpulsation without blood contact for an extended period.
1879590|NCT01176370|Device|C-Pulse™ (Implantable Counterpulsation Therapy)|Implantation and activation of counterpulsation therapy for the full duration of the study period. The device may be turned off briefly for personal hygiene, etc.
1879591|NCT01176383|Genetic|Respiragene test and risk score|This 12 gene test used with other data (family history, age and spirometry result) to calculate lifetime risk of lung cancer in smokers who do not quit smoking. This intervention is expected to be a motivator to quit.
1879592|NCT01176396|Other|Caries prevention active intervention|"Subjects will be treated related to their caries risk:
Low Caries Risk
The intervention and control treatments for low caries risk are the same:
4 bitewing radiographs dental prophylaxis Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) 2x daily Periodic oral exam after 12 months Bitewings after 12 months
Moderate Caries Risk In addition to the treatment above the intervention group receives OTC fluoride rinse as well as xylitol candies or gums.
High Caries Risk The high caries risk level subjects will receive a prescription 5,000 ppm F toothpaste, will rinse 1 day for one week per months with a Chlorhexidine rinse to reduce the bacteria level, and receive a fluoride varnish in the dental office."
1879593|NCT01176396|Other|control treatment|"Subjects will be treated related to their caries risk:
Low Caries Risk
The intervention and control treatments for low caries risk are the same:
4 bitewing radiographs dental prophylaxis (if prescribed) Oral Hygiene instruction OTC toothpaste with fluoride (1,100 ppm F) as currently used by patient Periodic oral exam after 12 months Bitewings after 12 months
Moderate Caries Risk Control group receives regular dental care (placebo rinse and gums without active ingredients allow blinding).
High Caries Risk The control treatment group receives regular dental care (regular 1,100 ppm F toothpaste, a placebo rinse without antibacterial ingredients and placebo varnish to allow blinding)."
1879594|NCT01176409|Drug|Valacyclovir|Valacyclovir will be used at two different dosages (1g po BID and 500mg po BID) to be used for 12 weeks. Supplied as 500mg caplets.
1879595|NCT01176409|Drug|Placebo|Placebo, supplied as caplets identical in appearance, odour and taste to valacyclovir 500mg caplets.
1879596|NCT01176422|Genetic|Blood sample|Blood samples will be collected before and after treatment completion.
1879602|NCT01176461|Biological|MART-1|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. MART-1:26-35(27L) peptide vaccine
1879603|NCT01176461|Biological|NY-ESO-1|NY-ESO-1 peptide vaccine
1879604|NCT01176461|Biological|gp100:209-217(210M)|THIS PEPTIDE REMOVED FROM STUDY ON 1/1/2013. gp100:209-217(210M) peptide vaccine
1879605|NCT01176461|Biological|gp100:280-288(288V)|gp100:280-288(288V) peptide vaccine
1879606|NCT01176461|Drug|Montanide ISA 51 VG|Administer peptide vaccine emulsions prepared with Montanide® ISA 51 VG by deep subcutaneous injection.
1879607|NCT01176461|Biological|BMS-936558|BMS-936558 is a fully human monoclonal antibody (HuMAb) against programmed death-1 (PD-1). Level 1: 1 mg/kg cohort; Level 2: 3 mg/kg cohort; Level 3: 10 mg/kg cohort; Level 4: 3 mg/kg prior ipi gr 0/1/2 cohort; Level 5: 3 mg/kg prior ipi gr 3 cohort; Level 6: 3 mg/kg BMS-936558 (no peptide vaccine; human leukocyte antigen [HLA] unrestricted)
1879614|NCT01176487|Other|questionnaire administration|
1879615|NCT01176487|Procedure|quality-of-life assessment|
1879616|NCT01176487|Radiation|3-dimensional conformal radiation therapy|
1879617|NCT01176487|Radiation|palliative radiation therapy|
1879618|NCT01176487|Radiation|whole-brain radiation therapy|
1879619|NCT01176500|Drug|(18)Fluciclatide|
1879620|NCT01176513|Drug|GE-148 (18F)|All subjects will receive an i.v. dose of GE-148 (18F) Injection at 10 mCi (370 MBq) to provide adequate image quality throughout the specified imaging period.
1879621|NCT01176539|Device|Non-Contact Respiratory Rate Monitor|"The Non-Contact Respiratory Rate Monitor provides a measurement of respiratory rate at a single point in time for neonates, pediatrics and adults.
The Non-Contact Respiratory Rate Monitor provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults."
1879622|NCT01176552|Drug|GM-CSF, IFN alpha and IL-2|Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
1879623|NCT01176565|Drug|Intravenous nicardipine hydrochloride|"IV nicardipine is initiated at a rate of 5 mg/hr, is continued, and is increased by 2.5 mg/hr increments every 15 min until the target SBP or maximum dose of 15 mg/hr is reached. If SBP is above the target SBP despite infusion of the maximum nicardipine dose for 30 minutes, a second agent may be used (Labetalol 5-20 mg IV bolus every 15 min; diltiazem/urapidil in countries without labetalol) for another hour. Nicardipine infusion is decreased incrementally or is stopped if SBP falls below the desired treatment range.
Fluid bolus for SBP still falling below 110 mmHG (millimeters of mercury) with nicardipine off is given to prevent organ hypoperfusion. Vasopressor agents are not used unless symptoms related to or possibly exacerbated by hypoperfusion are present."
1879624|NCT01176578|Other|Aerobic Exercise Training|6 months of aerobic exercise training, 3 days per week
1879629|NCT01176643|Other|Standard care plus Yoga|Participants will be asked to complete two yoga classes weekly over a period of eight weeks.
1879687|NCT01177163|Drug|Placebo|one placebo capsule once daily for 3 days immediately prior to randomization to double-blind treatment with JNJ 28431754 or placebo
1882928|NCT01193218|Drug|BI 10773|BI 10773 tablets low dose once a day
1960362|NCT03230786|Drug|Daily injection of KBP/placebo for 12 weeks as add-on to metformin|Daily subcutaneous injection
1879630|NCT01176669|Drug|Apatinib|Apatinib was administratered at 750 mg/d in Phase IIa. The actual average dose intensity delivered was 525 mg/d due to toxicities. So, in Phase IIb, the starting dose of apatinib will be 500mg/d. Two dose reductions will be allowed to 375 and then 250 mg/d.
1879631|NCT01176695|Drug|fish oil containing lipid emulsion|medium chain triglycerides, long chain triglycerides, omega-3 fatty acid containing triglycerides
1879632|NCT01176695|Drug|MCT/LCT containing lipid emulsion|medium chain triglycerides, long chain triglycerides
1879633|NCT01176708|Drug|dipeptidyl peptidase 4 (DPP4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
1879634|NCT01176708|Other|oral glucose|50 grams glucose dissolved in 300 ml water with 1.5 grams paracetamol
1879635|NCT01176708|Other|intravenous glucose|1.5 g paracetamol dissolved in 50 ml water is to be ingested orally within the first 2 minutes. Intravenous glucose is supplied in an amount to match the plasma glucose during the oral glucose tolerance test
1879636|NCT01176721|Device|t-VNS verum|Active stimulation of the left auricle by t-VNS
1879637|NCT01176721|Device|t-VNS placebo|Sham stimulation of the left auricle with the t-VNS device
1879638|NCT01176734|Device|tVNS-Device|Active treatment with the t-VNS device.
1879639|NCT01176747|Drug|BDP/formoterol NEXT DPI|Single inhalation of radiolabelled BDP/formoterol 100/6 µg NEXT DPI (4 puffs giving a total dose of 400 µg BDP + 24 µg formoterol)
1879640|NCT01176760|Drug|Dipeptidyl peptidase 4 (DPP 4) inhibitor|One tablet (50 mg)of DPP4 inhibitor is to be taken 12 and 1 hours before start of the oral glucose tolerance test (50 g glucose and 1.5 g paracetamol dissolved in 300 ml water)on day 3
1879641|NCT01176760|Other|oral glucose|50 g glucose dissolved in 300 ml water with 1,5 g paracetamol is to be ingested orally within the first 15 minutes.
1879642|NCT01176773|Device|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment goal; 1 touch-up treatment is allowed 14 days after initial treatment. Maximum total volume per subject is 2.0 mL
1879643|NCT01176786|Other|Culture Swabs, Rodac Plate Cultures|Culture swab is taken when breast tissue expander is removed and when breast implant is placed in breast pocket. Rodac Plate cultures are taken after the surgical procedure of the surgeons dominant palm, forearm of gown and subject's drape closest to the breast.
1879644|NCT01176799|Drug|Arm A|Doxorubicin 60mg/m2 day 1 Cyclophosphamide 600mg/m2 day1, every 3 weeks x 4 cycles
1879645|NCT01176799|Drug|Arm B|Days -13 (or -7) to day 0 (total 7 or 14 days) - oral sunitinib daily Cycle 1: day 1 - Cycle 1 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 2: day 1 - Cycle 2 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 3: day 1 - Cycle 3 AC (60/600mg/m2); days 15-21 - oral sunitinib daily Cycle 4: day 1 - Cycle 4 AC (60/600mg/m2)
1879646|NCT01176825|Behavioral|cognitive-behavior therapy (CBT)|14 sessions of individual cognitive-behavior therapy. Sessions last 50-60 minutes and are held weekly. 2 optional monthly booster sessions may also be held after the end of treatment.
1879647|NCT01176851|Drug|Glycopyrrolate|Single administration of Glyco pMDI 100 µg
1879648|NCT01176851|Drug|Glycopyrrolate|Single administration of Glyco pMDI 100 µg after charcoal ingestion
1879649|NCT01176851|Drug|Glycopyrrolate|Single intravenous injection of glycopyrrolate 100 µg
1879650|NCT01176864|Procedure|Double-balloon enteroscopy|Double-balloon enteroscopy
1879651|NCT01176864|Procedure|Single-balloon enteroscopy|Single-balloon enteroscopy
1879652|NCT01176877|Behavioral|"Scripted lecture (educational information talk)"|This scripted lecture will be approximately 5 minutes in length and will include 3 picture examples of keloid and hypertrophic scarring as well as an opportunity to ask questions.
1879653|NCT01176890|Drug|GLP-1|"1.2 pmol/kg/min GLP-1 will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied"
1879654|NCT01176890|Other|Saline|"Saline (isotonic NaCl) will be infused intravenously during the four hour meal test (100 g Ny NAN1 and 1.5 g paracetamol dissolved in 300 ml water) ingested over 10 minutes.
After four hours an ad libitum meal will be supplied"
1879655|NCT01176903|Drug|Glycopyrrolate|pressurized metered dose inhaler
1879656|NCT01176903|Drug|Tiotropium|inhalation powder, hard capsule
1879657|NCT01176903|Drug|placebo|pressurized metered dose inhaler
1879659|NCT01176929|Other|Usual treatment and Prevention program|"Prevention program of recurrent suicidal acts includes three interventions:
A series of three telephone calls ( the second week , one month and three months after discharge from hospital )
A systematic telephone contact with the referring physician
A telephone helpline for people who made a suicide attempt and referring physicians."
1879660|NCT01176929|Other|Usual Treatment|Usual Treatment
1879661|NCT01176942|Dietary Supplement|Probiotic bacterium Bifidobacterium lactis|Probiotic placebo controlled intervention
1879662|NCT01176955|Behavioral|Internet survey|A weekly email link will be generated to an internet survey which questions subjects about their acne severity, compliance with the study medication, and attitudes toward acne and the study medication.
1879663|NCT01176955|Drug|Benzoyl peroxide 5% gel|Topical benzoyl peroxide 5% gel, to be used once daily to the face.
1879664|NCT01176968|Drug|Eplerenone|Maximum dose of 2x25 mg film coated tablets per day for the duration of the study (approximately 18 months maximum). Lower doses may be administered determined by blood biochemistry data.
1879665|NCT01176968|Drug|Placebo|Matching placebo tablets
1879666|NCT01176981|Drug|High Dose Methotrexate|"Methotrexate will be given by IV at a dose of 12 gram/m2/dose.
The patient will receive 4-6 hours of hydration with alkalinization, and then HD MTX will be infused over 4 hours. Following this, the patient will be discharged home to receive continuous intravenous hydration through a portable pump. The patient will return to hospital daily for a comprehensive clinical assessment, IV hydration and antiemetics, MTX level and creatinine monitoring until MTX is cleared (3-4 days)."
1879667|NCT01176994|Device|Formulations for in-vivo fixation|Formulations are comprised of non-toxic ingredients used in dermatology.
1879688|NCT01177163|Drug|JNJ 28431754 300 mg/placebo|one 300-mg capsule of JNJ-28431754 or placebo twice-daily for 4 weeks
1879668|NCT01177007|Device|TheraSphere, Yttrium-90 glass Microspheres|Patients with unilobar disease will receive 120 ± 10% Gy (dose may be lower if clinically indicated) of TheraSphere to the affected lobe. Patients presenting with bilobar disease will have their liver assessed and the lobe presenting the highest treatment priority will receive the first treatment of TheraSphere. Assigning priority of lobes to receive treatment is based on tumor bulk, associated clinical symptoms attributed to the tumor and technical/angiographic considerations. In patients with bilobar disease where the second lobe does not require immediate treatment, or in unilobar disease where tumors develop in the untreated lobe, additional TheraSphere treatment may be administered at any subsequent time. A treatment may consist of a single 120 ± 10% Gy infusion to a lobe, or, if angiography indicates the need, the 120 ± 10% Gy dose may be split into multiple infusions per lobe to ensure delivery of a total of 120 ± 10% Gy to each treated lobe.
1879669|NCT01177020|Other|Biological specimen|Biological specimen taken from placenta
1879670|NCT01177033|Other|Best endovascular treatment or Best surgical treatment|Intervention type I: Best endovascular treatment (stent-protected angioplasty). Intervention type II: Best surgical treatment (femoro-popliteal bypass above the knee with autologous vein (1° choice) or a prosthetic graft (if vein is not available).
1879671|NCT01177059|Genetic|OZ1 transduced cells|Long term follow up of previously infused OZ1 transduced cells
1879672|NCT01177072|Other|Cognitive Processing Therapy|12 sessions of cognitive processing therapy. Sessions are expected to be approximately one week apart. Although each counseling session is designed to be carried out one week apart for a total of 12 weeks, there are many reasons why a session will be missed. Our estimation is that a single client will require 4-5 months to complete the therapy.
1879673|NCT01177072|Other|Components-Based Intervention|This is a 'components-based' intervention include psychoeducation, relaxation, life-enhancing skills (problems solving and safety planning), exposure, and cognitive processing of life problems and traumatic events. The duration of sessions are approximately one hour), the expected frequency of treatment is weekly, and recommended number of sessions are 12.
1879674|NCT01177085|Behavioral|Weight-loss and weight-maintenance diets|Participants will be given a personalized diet plan, with or without use of mushrooms as part of the diet, at a calorie level sufficiently restricted to result in a 20 lb weight loss over a period of 6 months, followed by a weight maintenance diet for a further 6 months.
1879675|NCT01177098|Drug|bimatoprost /timolol formulation A fixed combination ophthalmic solution|One drop of bimatoprost/timolol formulation A fixed combination ophthalmic solution administered in each eye every morning for 12 weeks.
1879676|NCT01177098|Drug|bimatoprost/timolol fixed combination ophthalmic solution|One drop of bimatoprost 0.03%/timolol 0.5% fixed combination ophthalmic solution (Ganfort®) administered in each eye every morning for 12 weeks.
1879677|NCT01177111|Other|Sunflower seed oil|Locally manufactured refined sunflower seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
1879678|NCT01177111|Other|Mustard seed oil|Locally manufactured mustard seed oil will be provided to pregnant women late in pregnancy and community workers will promote its daily use during massage of newborns during the first month of life
1879679|NCT01177124|Behavioral|MBSR 6 Weeks Program|MBSR is a clinical program that provides systematic training to promote stress reduction by self-regulating arousal to stress. The goal of training is to teach participants to become more aware of their thoughts and feelings, and through meditation practice, to have the ability to step back from thoughts and feelings during stressful situations that contribute to increased emotional distress. The intervention incorporates simple yoga, sitting meditation, body scan, and walking meditation in a 6-week program (Kabat-Zinn et al. 1985; Teasdale et al. 1995).
1879680|NCT01177137|Device|Conventional sound generator (SG)|Conventional SGs: Tranquil model sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate low-level noise, which is set at or just below the patient's mixing point (i.e., the noise level that just blends with the study participant's tinnitus)
1879681|NCT01177137|Device|Placebo sound generator (placebo SG)|Tranquil model placebo sound generators (General Hearing Instruments, Inc.) are either inside or outside-the-ear devices that generate a sound different from the active devices.
1879682|NCT01177137|Behavioral|Standard of Care (SC)|The standard of care treatment will be similar to that typically provided to patients with severe tinnitus at participating military medical centers and as described in the American Speech-Language-Hearing Association (ASHA) Preferred Practice Patterns in Audiology (ASHA, 2006). Tinnitus management will be based on the patient's complaints, history, audiologic evaluation, and self-assessment. The goal of the tinnitus management is to reduce negative cognitive, affective, physical, and behavioral reactions to tinnitus and to improve the patient's well-being and quality of life. Specific treatment recommendations will be individualized to reflect the participant's concerns and abilities, as well as his or her engagement in the decision-making process regarding treatment options.
1879683|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
1879684|NCT01177137|Behavioral|Directive Counseling (DC)|Directive Counseling (DC): two-hour educational session during which the patient is given information regarding the nature of the tinnitus problem and related problems such as hearing loss and sound intolerance; visual aids to review the audiological/tinnitus/ hyperacusis evaluation, provide instruction on anatomy and physiology of hearing and tinnitus, introduce the Jastreboff neurophysiological model of tinnitus and related concepts of habituation, and describe and recommend the use of ST and environmental sound in the habituation process.
1879685|NCT01177150|Drug|JNJ-28431754/ Placebo|Part 1: One oral dose of JNJ 28431754 (10 mg to 600 mg) or matching placebo will be administered after an overnight fast of at least 10 hours .For patients who receive a previously tested dose as 2 equally divided doses, the evening dose will be administered at 10 hours after the morning dose.
1879686|NCT01177150|Drug|JNJ-28431754|Part 2: A single dose of JNJ-28431754 will be orally administered on 2 occasions (14 days apart) after an overnight fast of at least 10 hours with and without a standard meal.
1879689|NCT01177163|Drug|JNJ 28431754 100 mg/placebo|one 100-mg capsule of JNJ-28431754 or placebo once-daily for 4 weeks
1879690|NCT01177176|Other|Extended Care Management|Telephone-based care management of tobacco cessation for 3 months after hospital discharge that features 2 innovations: (1) to increase medication use, smokers receive a free refillable 30-day sample of their choice of FDA-approved smoking cessation medication (nicotine replacement, bupropion, or varenicline) at hospital discharge; (2) to increase counseling cost-effectiveness, interactive voice recognition (IVR) technology is used to make automated telephone calls to identify the smokers seeking or most likely to benefit from continued counseling after hospital discharge.
1879691|NCT01177176|Other|Standard Care|Usual care provided to hospitalized smokers during their inpatient stay, with no post-discharge care management plan
1879692|NCT01177189|Dietary Supplement|Vitamins C, E, and alpha lipoic acid|Oral antioxidant cocktail or placebo to be consumed daily
1879693|NCT01177202|Biological|HAC1 Vaccine|Subjects will come to the Clinical Trials Center up to 7 days prior to each vaccine dose to have blood drawn for research assays. The first dose of vaccine will be given on Day 0 and the second dose will be given 21 days later (± 3 days). Dose escalation will be staggered by at least 7 days as shown in Figure 1. Subjects from Groups G and H will be vaccinated with each of the other 6 groups. Two subjects from group A will be immunized on study day -1. The immunizations will be performed one hour apart with close monitoring. The remaining eight subjects from Group A will be immunized on study day 0. All subsequent immunizations for each group will occur on the same day. The principal investigator and the medical monitor will review all adverse events and make a determination on whether it is safe to proceed to the next higher dosage group. The control and reference vaccine groups can be vaccinated starting anytime after screening.
1879694|NCT01177215|Procedure|Thoracic Surgery|Wedge Resection Segmental Resection Lobectomy
1879695|NCT01177228|Drug|Vedolizumab|Vedolizumab for intravenous infusion
1879696|NCT01177228|Drug|Placebo|Placebo intravenous infusion
1879697|NCT01177293|Drug|Amlodipine - reference|Amlodipine capsule, 10 mg, single dose, with water
1879698|NCT01177293|Drug|Amlodipine ODT - test|Amlodipine orally disintegrating tablet (ODT), 10 mg, single dose, without water
1879699|NCT01177306|Drug|extended release guanfacine|1-4 mg daily. Dose determined by response of ADHD symptoms to drug and by body mass limitations
1879700|NCT01177319|Drug|Glutathione|
1879701|NCT01177332|Other|exercise|2 hours cycling exercise at 50 % of maximal power output
1879702|NCT01177358|Drug|Botulinum Toxin Type A|"A vial of Botulinum Toxin A containing 100U of Botox will be reconstituted with 2mL of normal saline for a concentration of 50U/mL.
5 units (0.1mL) of Botulinum Toxin a will be injected at midline and 1.5cm lateral to midline, bidirectionally, following a thyroidectomy or parathyroidectomy."
1879703|NCT01177358|Drug|Normal Saline|0.1mL of normal saline in a placebo vial containing 2mL of normal saline will be injected along three sites (midline and 1.5cm lateral from midline) following a thyroidectomy or parathyroidectomy.
1879704|NCT01177371|Drug|busulfan|Given orally
1879705|NCT01177371|Drug|cyclophosphamide|Given IV
1879706|NCT01177371|Procedure|allogeneic bone marrow transplantation|Patients undergo allogeneic bone marrow transplant IV over 2-3 hours on day 0.
1879707|NCT01177371|Drug|methylprednisolone|Given IV or orally
1879708|NCT01177371|Drug|methotrexate|Given IV
1879709|NCT01177371|Drug|cyclosporine|Given IV or orally
1879710|NCT01177384|Drug|Sitagliptin phosphate|Sitagliptin, 100 mg tablet once daily, orally for 24 weeks
1879711|NCT01177384|Drug|Comparator: Placebo|Placebo, to match sitagliptin tablet, once daily, orally for 24 weeks
1879712|NCT01177384|Drug|Acarbose|Acarbose 50 mg or 100 mg tablet, 3 times daily, orally (continuing on the stable dose established prior to screening) for 24 weeks
1879713|NCT01177384|Drug|Glimepiride|Participants not meeting specific glycemic goals during the study will use glimepiride as rescue therapy. For countries where glimepiride is not available, participants will receive a sulfonylurea marketed in that country as rescue therapy.
1879714|NCT01177397|Drug|CC-223|Part A: (closed to enrollment) Dose level starts with 7.5mg daily taken by mouth in cycles of 28 days. Level increases for different patient cohorts in 100% or 50% increments until optimal dose level is established for further study. Treatment continues for as long as patient benefits (i.e., until disease progression or unacceptable toxicity). Part B: (closed to enrollment) Optimal dose is administered in 28 day cycles until disease progression.
1879715|NCT01177410|Drug|Placebo|placebo capsules once daily for 12 weeks
1879716|NCT01177410|Drug|Mesalamine Granules 750 mg|750 mg mesalamine granules once daily for 12 weeks
1879717|NCT01177410|Drug|Mesalamine Granules 1500 mg|1500 mg mesalamine granules once daily for 12 weeks
1879718|NCT01177423|Procedure|Dental anesthesia|Pulpal and periapical molar and premolar sedation is randomly managed among studied population and Pulp-tester measures anesthesia minute by minute.
1879719|NCT01177436|Biological|Taking of urines|Urine specimens collected by vesical catheterism just before surgery. The dosage of PCA-3 and the analyse of several prostatic markers (genes coding for androgen receptor and steroid alpha-reductase type 1 and 2) will be realized on the samples of urines.
1879720|NCT01177449|Procedure|Prolotherapy|inject normal saline and 50% glugose water with 1:1 ratial in volumn
1879721|NCT01177475|Other|blood samples , feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants received mother's native milk or substitute.
1879722|NCT01177475|Other|blood samples, feces samples|After the 32nd week until the 36th week or the end of hospitalization,infants continued mother's native milk or received substitute.
1879723|NCT01177488|Behavioral|Behavioral Activation Therapeutic Exposure (BATE)|This intervention combines Behavior Activation Therapy and Exposure Therapy to treat PTSD symptoms.
1879724|NCT01177501|Drug|Topotecan|Six sequential doses established in the absence of limiting toxicity, as follows : 7.5 - 8.0 - 8.5 - 9.0 - 10.0 mg/m²
1879725|NCT01168947|Other|5% dextrose solution|The extracorporeal circuit of the dialysis machine will be primed and rinsed with a 5% dextrose solution instead of 0.9% saline.
1879726|NCT01168960|Behavioral|Cognitive behavioral therapy for alcohol dependence|12-session behavioral treatment that incorporates behavioral skills training targeting high-risk drinking behavior.
1996653|NCT02426736|Procedure|Interscalene brachial plexus block|Performed with real time ultrasound guidance.
1879727|NCT01168973|Biological|Ramucirumab|10 milligrams per kilogram (mg/kg) administered intravenously (IV) on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
1879728|NCT01168973|Drug|Placebo (for Ramucirumab)|Administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
1879729|NCT01168973|Drug|Docetaxel|75 milligrams per square meter (mg/m^2) (60 mg/m^2 for the countries of Korea and Taiwan only with protocol amendment dated 22 May 2012) administered IV on Day 1 of 21-day cycle until disease progression, unacceptable toxicity, or another withdrawal criterion is met
1879730|NCT01168986|Other|Pulstar Multiple Impulse Therapy|Use of the PulStar Multiple Impulse Therapy (Sense Technology). A mechanical manual therapy device.
1879731|NCT01168986|Other|Exercise|Participants perform an exercise to strengthen the deep neck flexors
1879732|NCT01168999|Other|spinal manipulation|Spinal manipulation commonly used in the treatment of low back pain and known to be effective for some individuals experiencing low back pain
1879733|NCT01168999|Other|sham spinal manipulation|Sham spinal manipulation intended to mimic the studied spinal manipulation
1879734|NCT01168999|Other|Enhanced sham spinal manipulation|"Sham spinal manipulation intended to mimic the studied spinal manipulation and provided with the instructions, The manual therapy technique you will receive has been shown to significantly reduce low back pain in some people"
1879735|NCT01169012|Drug|Clofarabine|Intravenous Clofarabine (10mg/m2) Oral clofarabine (30mg/m2) Cimetidine (800mg)
1879736|NCT01169025|Drug|Ketamine|Subjects receive 0.3 mg/kg IV ketamine over 5 minutes and are evaluated every 10 minutes. Residual or recurring pain will be treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, subjects are asked if they need additional pain medication every 10 minutes, unless an earlier, spontaneous request is made by the subject or the provider determines that more is needed. For the potential of rare ketamine side effects (dysphoria, anxiety, or agitation), 2 mg IV midazolam is given every 5 minutes as needed for any of these symptoms. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
1879737|NCT01169025|Drug|Fentanyl|Subjects receive 1 mcg/kg IV fentanyl over 5 minutes. After first dose administration, subjects are evaluated every 10 minutes. Residual or recurring pain is treated as needed with adjunctive open-label bolus dosing of IV fentanyl (1 mcg/kg) followed by repeat boluses as needed every 10 minutes during the flight. For this open-label portion of the flight, flight nurses will query participants regarding their desire for additional pain medication every 10 minutes unless an earlier, spontaneous request is made by the participant or the provider determines that more is needed. Vital signs are measured continuously throughout the protocol. Blood pressure is measured at 5 minute intervals.
1879738|NCT01169038|Drug|levaquin; ethambutol; rifampin and azithromycin.|"Levaquin 750 mg loading on day 1, then 500 mg po QD Ethambutol 15-25 mg/kg for a maximum of 1200mg po QD Azithromycin 500mg on day 1, then 250 mg po QD
**Rifampin 10 mg/kg for a maximum of 600mg po QD or Rifabutin 10 mg/kg for a maximum of 300 mg po QD. **We will not use both, but either one or the other based upon if the patient is on other medications that are metabolized by the cytochrome P450 pathway."
1879739|NCT01169064|Device|Silver-containing surgical dressing|Dressing placed over surgical incision and remain for 3-5 days
1879740|NCT01169064|Device|Cloth adhesive dressing|Cloth adhesive dressing placed over surgical incision and remains for 3-5 days
1879741|NCT01169077|Drug|Placebo|Injections of normal saline to be used as control; given at Days 0, 28, and 56. Administered via electroporation, using a DNA vaccine delivery device, in the deltoid.
1879742|NCT01169077|Biological|EP-1300|Single DNA plasmid dissolved in phosphate-buffered saline (PBS). Dose levels: 0.25, 1 and 4 mg based on DNA content, administered on Days 0, 28 and 56 via electroporation using a DNA vaccine delivery device, in the deltoid.
1879743|NCT01169090|Drug|SK-0403|SK-0403
1879744|NCT01169090|Drug|Placebo|Placebo
1879745|NCT01169090|Drug|Sitagliptin|Sitagliptin
1879746|NCT01169103|Drug|recombinant human growth hormone (rhGH)|Initial rhGH dose 0.4mg administered by subcutaneous injection daily. Dose will be increased to 0.6 mg after one week and then increased to 0.8mg after two weeks.
1879747|NCT01169103|Drug|Placebo|Placebo will be administered by daily subcutaneous injections. Sham increases will be used.
1879748|NCT01169116|Radiation|hypofractionated stereotactic radiotherapy|hypofractionated stereotactic radiotherapy with 4 fractions of 7 Gy at the periphery of the brain metastasis with 3 mm margin.
1879749|NCT01169129|Other|surgery|resection of brain metastases
1879750|NCT01169129|Radiation|radiosurgery|radiosurgery to brain metastases
1879751|NCT01169142|Dietary Supplement|Vitamin D3|50,000 units of Vitamin D3 weekly
1879752|NCT01169142|Dietary Supplement|Vitamin D3|Vitamin D3 50,000 units weekly
1879753|NCT01169155|Other|Smoke Alarm Stimuli|See arm descriptions for information about the smoke alarm stimuli interventions.
1879754|NCT01169181|Device|AMES + brain stimulation|Stroke survivors with plegia of affected upper extremity receive either AMES + rTMS or AMES + tDCS.
1879755|NCT01169220|Drug|Go-Lytely|Bowel cleansing agent
1879756|NCT01169220|Drug|Go Lytely|Bowel cleansing agent
1879757|NCT01169233|Device|Bright Light Box|Increased lighting used during night shifts to prevent sleepiness.
1879758|NCT01169259|Dietary Supplement|vitamin D3|Vitamin D3 (cholecalciferol), 2000 IU per day.
1879759|NCT01169259|Drug|omega-3 fatty acids (fish oil)|Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA]).
1879760|NCT01169259|Dietary Supplement|Vitamin D3 placebo|Vitamin D placebo
1879761|NCT01169259|Dietary Supplement|Fish oil placebo|Fish oil placebo
1879762|NCT01169272|Device|CRT-SonR 9770|Active implantable defibrillator with capacity of cardiac resynchronization therapy
1879763|NCT01169298|Drug|Lenalidomide|Lenalidomide: 25mg daily on day 1-21 of each 28days cycle (1st cohort), 25 mg daily of each 28 days (2nd cohort, or 35 mg daily of each 28 days (3rd cohort)
1879764|NCT01169311|Device|Hemorrhoidopexy|
1879765|NCT01169324|Other|Alteration of DBS stimulator settings|Alteration of DBS stimulator settings
1879775|NCT01169363|Genetic|proteomic profiling|
1879776|NCT01169363|Other|flow cytometry|
1879777|NCT01169363|Other|laboratory biomarker analysis|
1879778|NCT01169376|Genetic|DNA analysis|
1879779|NCT01169376|Genetic|DNA methylation analysis|
1879780|NCT01169376|Genetic|RNA analysis|
1879781|NCT01169376|Genetic|comparative genomic hybridization|
1879782|NCT01169376|Genetic|mutation analysis|
1879783|NCT01169376|Genetic|polymorphism analysis|
1879784|NCT01169389|Procedure|Intraarticular injection|Durolane, one vial
1879785|NCT01169389|Procedure|Intra-articular injection of 0.5% Bupivacaine|
1879786|NCT01169402|Drug|Fluconazole|25mg/kg intravenously once weekly while on ECMO
1879787|NCT01169415|Drug|Dexamethasone acetate|Participants will receive a protracted (30 days) course of dexamethasone after surgery.
1879788|NCT01169415|Drug|Dexamethasone|Participants will receive a protracted (14 days) course of dexamethasone after surgery.
1879789|NCT01169428|Behavioral|Mindfulness Based Weight Loss Maintenance (MBWLM)|This mindfulness-meditation based intervention is designed to increase awareness of the factors that affect weight loss maintenance after successful weight loss. Mindfulness meditation is a technique for training awareness. The program will train subjects to increase awareness of the somatic, cognitive, affective, interpersonal and environmental factors that mediate eating and physical activity by incorporating empirically-supported and theoretically-synergized components, including: general mindfulness meditation skills, mindful and intuitive eating, appetite-satiety awareness, mindful movement and yoga, a mindful approach to exercise engagement, and training in enhancing emotion regulation and stress management skills. In addition, the MBWLM group will be supported by Maintenance Partners who are trained as Integrative Health Coaches.
1879790|NCT01169428|Behavioral|Behavioral: Standard Behavioral Weight-Loss Maintenence|Attention/Education/Support Control group, designed to control for educational content as well as nonspecific treatment factors [e.g., natural history (time), amount of time and energy spent in the intervention, attention by group leaders, social support, as well as information & education]. Like the experimental group(MBWLM), this group meet once a week for 2 hours during the 12-week intervention, and then at 4 weeks, 8 weeks, and 12 weeks post the 12 week intervention. Participants also receive the same amount of telephonic support through Maintenance Partners as the experimental group, but their Maintenance Partners employed empathic listening only rather than myriad coaching techniques.
1879791|NCT01169467|Drug|Standard-of-Care plus Dexmedetomidine|Subjects who are treated with dexmedetomidine (Precedex) in addition to the standard of care sedation regiment
1879792|NCT01169467|Other|Standard-of-Care|Subjects who are treated with the standard of care sedation regiment only.
1879793|NCT01169480|Behavioral|Give a massage|Participants in this arm will give a 50-minute Swedish massage to a volunteer.
1879794|NCT01169493|Device|VVI-40|Pacing mode set to VVI-40, RV only pacing
1879795|NCT01169493|Device|RV DDD-40|ICD programmed to DDD-40, RV only pacing with aan AV interval producing QRS fusion on surface EKG.
1879796|NCT01169493|Device|BiV DDD-40|ICD programmed to BiV pacing at a lower rate of 40
1879797|NCT01169506|Device|sublingual silicon capillary|Stable patients with COPD and healthy individuals were asked to open their mouth and a small butterfly silicon capillary was placed sublingually. After 15 minutes, while the mouth was closed completely and nose breathing was performed, the capillary system was connected to a capnometer and sublingual tonometric PCO2 was measured. At the same time, PETCO2 was also measured and arterial blood was drawn for pH, PO2 and PCO2 analysis
1879798|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.125mg/kg injection over 20min
1879799|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.25mg/kg injection over 20min
1879800|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.35mg/kg by injection over 20min
1879801|NCT01169519|Drug|Sildenafil by injection|Sildenafil 0.45mg/kg by injection over 20min
1879807|NCT01169558|Drug|Bevacizumab|5 mg/kg bevacizumab administered intravenously every 2 weeks or 7.5 mg/kg bevacizumab administered intravenously every 3 weeks according to the standard chemotherapy regimen.
1879808|NCT01169558|Drug|Fluoropyrimidine-based Chemotherapy|Fluoropyrimidine-based chemotherapy administered according to standard of care.
1879809|NCT01169571|Drug|Dexmedetomidine|
1879810|NCT01169584|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|Intratumoral Injection Dosage from 1 x 10^6 pfu/kg to 3 x 10^7 pfu/kg is administered once to 1-3 injectable tumors in pediatric patients.
1879811|NCT01169597|Drug|prednisone|prednisone 12.5 mg daily po
1879812|NCT01169610|Drug|Varenicline|Varenicline is an oral medication with a recommended dosage of 0.5 mg once daily for 3 days, increasing to 0.5 mg twice daily for days 4 to 7, and then to the maintenance dose of 1 mg twice daily for the remaining 23 weeks of treatment. All subjects will receive open-label varenicline in blister packs.
1879813|NCT01169623|Other|Assessing the Effect Of Educational Intervention Based On Supportive Leadership Behavior on Iranian head nurses leadership performance|55 of head nurses who will participate in educational Intervention arm based on supportive leadership behaviour model
1879814|NCT01169636|Drug|Panobinostat|Starting Day -6 of Cycle 1, 20 mg orally on Monday, Wednesday, and Friday during Cycles 1 and 2 (Days -6, -4, and -2 of Cycle 1 and Days 1, 3, 5, 8, 10, and 12 of Cycles 1 and 2); MTD found in Phase 1 used for same schedule in Phase 2.
1879815|NCT01169636|Drug|Ifosfamide|Day 1 of Cycles 1-3, 5 grams/m2 by vein over 24 hours.
1879816|NCT01169636|Drug|Mesna|On Day 1 of Cycles 1-3, 2 grams/m2 by vein over 12 hours.
1879817|NCT01169636|Drug|Carboplatin|On Day 1 of Cycles 1-3, Standard Dose (Target area under curve (AUC) = 5mg/ml/min) by vein over 1 hour.
1879818|NCT01169636|Drug|Etoposide|On Days 1-3 of Cycles 1-3, 100 mg/m2 by vein over 2 hours.
1879819|NCT01169636|Drug|Pegfilgrastim|Beginning Day 4 of Cycles 1-3, 6 mg under the skin.
1879820|NCT01169649|Drug|MK-2206|MK-2206 will be given orally 200 mg qw as given in the prior Ph1 clinical trial that demonstrated safety, tolerability and adequate PK/PD values at this dose. Follow-up imaging scans will be performed every 12 weeks to evaluate response. Patients must take MK-2206 orally at least 2 hours before or 2 hours after food or a meal.
1879821|NCT01169662|Dietary Supplement|Vegetable/fruit juice|450ml active juice, 45ml no added sugar fruit squash (for flavour)
1879822|NCT01169662|Dietary Supplement|Placebo juice|50 ml No Added Sugar fruit squash, 45 ml Pressed Apple Juice, 405ml with water.
1879823|NCT01169675|Drug|BIBW 2992 low dose|patient receives low dose BIBW 2992 po daily on day 1 of 21 day cycle
1879824|NCT01169675|Drug|BIBW 2992 high dose|patient receives high dose BIBW 2992 po daily on day 1 of 21 day cycle
1879825|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
1879826|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
1879827|NCT01169675|Drug|BIBW 2992 high dose 6 day|patient receives high dose BIBW 2992 po daily on days 1-6 on 1 of 21 day cycle
1879828|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
1879829|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
1879830|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
1879831|NCT01169675|Drug|pemetrexed|given intravenously on day 1 of a 21 day cycle
1879832|NCT01169675|Drug|BIBW 2992 low dose 6 day|patient receives low dose BIBW 2992 po daily on days 1-6 on day 1 of 21 day cycle
1879833|NCT01169675|Drug|BIBW 2992 medium dose 6 day|patient receives medium dose BIBW 2992 po daily on day1 to 6 of a 21 day cycle
1879834|NCT01169675|Drug|BIBW 2992 medium dose|patient receives medium dose BIBW 2992 po daily on day 1 of 21 day cycle
1879835|NCT01169688|Other|Pupil dilation with phenylephrine 10% vs cyclopentolate 2%|
1879836|NCT01169701|Drug|Everolimus|Everolimus was supplied in boxes with 60 tablets. Available tablets: 1.0 mg, 0.5 mg and 0.25 mg.
1879837|NCT01169701|Drug|Tacrolimus|Tacrolimus was administrated as Prograf® or Advagraf®, but could not be changed during study.
1879838|NCT01169701|Drug|Mycophenolic acid (MPA)|Myfortic® (MFS) was given as 720-1440 mg/day or 360-1440 mg/day. Cell-Cept® (MMF) was given as 1000-2000 mg/day or 500-2000 mg/day.
1879839|NCT01169714|Drug|0.1 mg PF-04995274|0.1 mg PF-04995274, qd, for 14 days or placebo
1879840|NCT01169714|Drug|1 mg PF-04995274|1 mg PF-04995274, qd, for 14 days or placebo
1879841|NCT01169714|Drug|10 mg PF-04995274|10 mg PF-04995274, qd, for 14 days or placebo
1879842|NCT01169714|Drug|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
1879843|NCT01169714|Drug|1.0 mg PF-04995274|1.0 mg PF-04995274, qd, for 14 days or placebo
1879844|NCT01169714|Drug|15 mg PF-04995274|15 mg PF-04995274, qd, for 14 days or placebo
1879845|NCT01169740|Procedure|Measurement of bilirubin in blood and skin color|Blood sampling and analysis, measurement of skin color by transcutaneous bilirubinometry
1879846|NCT01169753|Drug|Placebo|Oral tablet every morning for 2 weeks
1879847|NCT01169753|Drug|Armodafinil|Three 50 mg tablets orally every morning for 2 weeks.
1879848|NCT01169779|Drug|Lixisenatide (AVE0010)|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1879849|NCT01169779|Drug|Placebo|Self administered by subcutaneous injections once daily within the hour preceding breakfast.
1879850|NCT01169779|Device|Pen auto-injector|
1879851|NCT01169779|Drug|Metformin|Metformin to be continued at stable dose (at least 1.0 gram per day and not more than 1.5 gram per day) up to Week 24.
1879852|NCT01169779|Drug|Sulfonylurea|Sulfonylurea if given at screening, to be continued up to Week 24. In patients with a screening HbA1c <8% the dose is decreased by 25% to 50% at randomization and then increased up to the screening dose between Week 4 and 12 as per fasting self-monitored plasma glucose (SMPG) values. In patients with a screening HbA1c >=8%, the dose is not to be changed at randomization. In any case, after Week 12, sulfonylurea is to be continued at a stable dose.
1879853|NCT01169792|Drug|tamoxifen|
1879854|NCT01169805|Drug|Ondansetron|Ondansetron/single injection/4 mg/IV
1879855|NCT01169805|Drug|Ramosetron|Ramosetron HCl/single injection/0.3mg/IV
1879856|NCT01169805|Drug|Palonosetron|Palonosetron HCl/single injection/0.075mg/IV
1879857|NCT01169805|Drug|Normal saline inj|normal saline injection 2ml
1879858|NCT01169818|Drug|Insulin Glargine|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous
Dose regimen: initial: once a day in the evening at bedtime. Titration will occur each time the middle FPG (Fasting Plasma Glucose) value is above target"
1879859|NCT01169831|Other|Exercise Training|2 weeks of daily aerobic exercise training
1879860|NCT01169831|Other|Exercise Cessation|Stopping all exercise for 2 weeks
1879861|NCT01169844|Biological|AIN457A|
1879862|NCT01169857|Drug|Velcade|Velcade at 1.3 mg/m2, on days 1, 4, 8 and 11 (=1 cycle). The study will involve 3 cycles of Velcade therapy.
1879863|NCT01169870|Drug|Genexol-PM|Treatment is given in the outpatient setting. Patients receive treatment every 3 weeks up to 6 cycles.
1879864|NCT01169870|Drug|Paclitaxel|
1879865|NCT01169883|Behavioral|Coping Peer Support|The Coping Peer Support is delivered at weekly group meetings over the 10 week active treatment phase. The Coping Peer Support consists of: group support, coping peer group problem solving, and development and recording of Coping Peer Asthma Messages. More specifically, a social worker facilitates a peer group discussion of barriers to taking their daily inhaled steroids, and ways to overcome these barriers. The social worker also facilitates peer recording of messages by the participants encouraging each other to take their daily inhaled steroid medication.
1879866|NCT01169883|Behavioral|Doctor Asthma Messages|The attention control group will receive Doctor Asthma Messages delivered during the 10 week active treatment phase. The content and number of these messages will be equivalent to those received by the intervention group. These messages are developed and recorded by an Allergist/Immunologist. The participants in the attention control group will listen to these Doctor Asthma Messages, between their favorite music tracks on their MP3 player, as they go about their day-to-day activities.
1879942|NCT01177631|Procedure|Operation|Operation for clinically evaluated resectable hepatocelluar carcinoma. Compare the different expression of protein between tumor, non-tumor and tumor with vascular invasion part.
1879943|NCT01177644|Drug|PDS 1.0|
1879867|NCT01169883|Behavioral|Coping Peer Asthma Messages|The Coping Peer Asthma Messages developed and recorded by study participants for each other at the weekly coping peer group meetings will be placed on intervention group participants' MP3 players. These Coping Peer Asthma Messages will be played on their MP3 players, between their favorite music tracks, during the course of their daily routines. This infuses the coping peer support from the coping peer group meetings into the adolescents' daily routines.
1879868|NCT01169883|Behavioral|Asthma Supervision|A member of the study team meets individually with each participant at baseline to teach proper use of a peak flow meter and spacer.
1879869|NCT01169883|Behavioral|Music Tracks|Participants receive an MP3 player (iPod Shuffle) in the baseline period. Participants receives clean, radio-edited music tracks of their choice in the baseline period and 10 week active treatment period.
1879870|NCT01169909|Drug|Ranibizumab|Subtenon injections of Ranibizumab 0.5mg will be given, and repeated twice with 30 day intervals between each dose. Note, after an amendment in February 2011, this dose was increased to 2mg with the same schedule.
1879871|NCT01169922|Behavioral|SEXUAL RISK REDUCTION + ALCOHOL RISK REDUCTION|2 hour 50 minute long intervention; includes presentation of STD/HIV facts, activities/games regarding safe sex, condom demonstration, video about sexual decision making, video about alcohol/sexual decision making, alcohol-related risk-reduction motivational interview, group discussion
1879872|NCT01169922|Behavioral|INFORMATION-ONLY SEXUAL RISK REDUCTION|1 hour 30 minute long intervention; includes presentation of STD/HIV facts, video about sexually transmitted diseases, review of STD/HIV facts
1879873|NCT01169935|Drug|Administration of intra-dermal Endorem|single dose, intradermal
1879874|NCT01169935|Biological|Mantoux test|single dose, intradermal
1879875|NCT01169935|Biological|Autologous Endorem-labelled mononuclear cells|single dose, intravenous
1879876|NCT01169935|Drug|Administration of Endorem|single dose, intravenous
1879877|NCT01169948|Radiation|Computed tomography scan|Computed tomography will be performed using a 320 multidetector computed tomography scanner and may include coronary calcium score, coronary angiography and myocardial perfusion scanning.
1879879|NCT01170013|Behavioral|Family Check-up|Two session motivational intervention to improve parent monitoring and communication with respect to adolescent risk behavior especially substance use
1879880|NCT01170013|Behavioral|Parent psychoeducation|Two sessions of psychoeducation for parents regarding adolescent risk behaviors. especially substance use
1879881|NCT01170026|Behavioral|Family Check-up/ Individual MI|The 2-session intervention protocol consists of an individual motivational interview plus the Family Check-Up (Dishion & Kavanagh, 2003), a family based motivational interview. The experimental protocol provides a thorough assessment of both individual and family strengths and weaknesses with respect to substance use prevention and school attendance/performance.
1879882|NCT01170026|Behavioral|Individual and family psychoeducation|Families in PE will return for the same number of visits as the IMI and FCU sessions of the IMI/FCU condition. An interventionist will review a set of educational materials with the parents regarding teen SU use, truancy and risk behaviors and parenting a teenager. A similar set of materials will be reviewed with the adolescent
1879883|NCT01170039|Drug|Lubiprostone|Lubiprostone will be given as 24 mcg orally twice a day.
1879884|NCT01170039|Drug|Placebo|A matched placebo pill will be given twice a day for 8 weeks.
1879885|NCT01170052|Drug|Temsirolimus|Temsirolimus 75mg i.v. day 1, 8, 15, 21 for a 28 day cycle with a maximum of 6 Cycles.
1879886|NCT01170052|Drug|Bendamustine|Bendamustin 90mg/m2 i.v. day 2 and 3 for a 28 day cycle with a maximum of 6 Cycles.
1879887|NCT01170052|Drug|Temsirolimus|Consolidation Therapy for Patients reached CR or PR with Temsirolimus 75mg weekly until progression.
1995121|NCT02850250|Drug|Cefuroxime|Patients selected and treated as per normal pathway of care. Drugs will be prescribed as per standard Alder Hey Policy at the doses defined in the hospital policy Cefuroxime 50mg/kg 8 hourly (12 hourly if less than 7 days of age, or undergoing peritoneal dialysis - maximum 1.5grams per dose)
1879892|NCT01170078|Drug|Epoetin Hospira|IV dose 3 times a week.
1879893|NCT01170078|Drug|Epogen|IV dose 3 times a week
1879894|NCT01170104|Drug|Sorafenib|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
1879895|NCT01170104|Procedure|TACE (Transcatheter arterial chemoembolization)|Sorafenib (NEXAVAR, Bayer) will be administered after TACE continuous dosing from day 1 until progression or up to 6 cycles of TACE as an oral 400mg twice-daily without food (at least 1 hour before or 2 hours after eating).
1879896|NCT01170117|Drug|Olanzapine|Dosing of olanzapine will begin at 2.5 mg and will be titrated to a maximum dose of 10 mg. The target dose of 10 mg of olanzapine was selected because published data from studies that used this dose indicated that it was helpful to patients.
1879897|NCT01170117|Drug|Placebo|Control Group will receive placebo pill
1879898|NCT01170130|Drug|Lidocaine 1% (sterile)|during the phacoemulsification surgery patients will be given intracamerally lidocaine 1% (0.2 ml) and the pupil size will be recorded after 90 seconds
1879899|NCT01170143|Drug|Trastuzumab QW, Trastuzumab Q3W|two arms using Trastuzumab QW vs Q3W
1879900|NCT01170156|Device|Hi-Lo Evac tube (Mallinckrodt Inc, USA) (Instilled blue dye)|The cuff pressure will be first checked and reset at 30 cm H2O if needed. Next, blue dye will be instilled just above the cuff through the lumen ending in the subglottic area of the Hi-Lo Evac tube. Then a suctioning manoeuvre will be performed with a suction pressure of - 400 mbar through a 16 French suction catheter. Thereafter, a fiberoptic bronchoscopy will be performed, looking for the presence of blue dye in the trachea and/or the bronchi.
1879901|NCT01170169|Drug|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
1879902|NCT01170169|Drug|Prilosec|Prilosec® 40 mg of Merck & Co.Inc.
1879903|NCT01170182|Drug|Omeprazole|Omeprazole Delayed Release Capsules 40 mg
1879904|NCT01170182|Device|Prilosec® 40 mg|Prilosec® 40 mg
1879905|NCT01170195|Dietary Supplement|Calmera-Licorice Root Extract (Licogen)|100 mg per day
1879944|NCT01177657|Procedure|Stool sampling|Stool samples collected and checked for the presence of rotavirus
1879906|NCT01170208|Device|insulin dose software|The rationale to conduct this study is that Hygieia hypothesizes the software will effectively and safely optimize glucose control in insulin-requiring patients with type-1 and type-2 diabetes. The software was designed to provide safe insulin dosage recommendations.
1879907|NCT01170221|Drug|TR-701 FA|Oral TR-701 FA 200 mg once daily for six days followed by four days of placebo.
1879908|NCT01170221|Drug|Linezolid|Oral Linezolid 600 mg twice daily for 10 days
1879909|NCT01170234|Device|NIOX MINO® Airway Inflammation Monitor|We will measure exhaled nitric oxide of patients with eosinophilic esophagitis pre-, during and post- treatment at pre-defined time intervals.
1879910|NCT01170247|Drug|Ketamine|Intranasal Ketamine (100 mg/mL)
1879911|NCT01170247|Drug|Ketamine|Intramuscular Ketamine
1879912|NCT01170260|Behavioral|INFORMATION-ONLY SEXUAL RISK REDUCTION (INFO-ONLY)|Intervention includes presentation of STD facts, safe sex activities, condom demonstration, video about sexual decision making, group discussion
1879913|NCT01170260|Behavioral|SEXUAL PLUS ALCOHOL RISK REDUCTION (SRRI+ETOH)|Intervention includes presentation of STD/alcohol facts, safe sex activities, condom demonstration, video about alcohol/sexual decision making, group discussion
1879914|NCT01170260|Behavioral|SEXUAL + ALCOHOL + MARIJUANA RISK REDUCTION|Intervention includes presentation of STD/alcohol/marijuana facts, safe sex activities, condom demonstration, video about alcohol/marijuana/sexual decision making, group discussion
1879915|NCT01170273|Dietary Supplement|vitamin D|cholecalciferol
1879916|NCT01170273|Dietary Supplement|placebo|placebo tablet
1879917|NCT01170286|Biological|Whole peanut extract|Four different doses of whole peanut extract expressed as micrograms (mcg) of peanut proteins (20, 100, 250, 500 mcg) and two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested for determination of the maximum tolerated dose during a 2-week treatment period.
1879918|NCT01170286|Biological|Placebo formulation|Matching placebo at two different dosing regimen (epicutaneous application for 24 hours every 24 hours and epicutaneous application for 48 hours every 48 hours) will be tested in parallel to the peanut proteins doses for determination of the maximum tolerated dose during a 2-week treatment period.
1879919|NCT01170299|Dietary Supplement|dietary intervention|
1879920|NCT01170299|Other|laboratory biomarker analysis|
1879921|NCT01170299|Procedure|gastrointestinal complications management/prevention|
1879922|NCT01170299|Procedure|management of therapy complications|
1879923|NCT01170299|Radiation|selective external radiation therapy|
1879924|NCT01170312|Biological|Autologous conditioned plasma (ACP)|ACP is not a drug as the patient's own blood plasma is re-injected into the surgical site.
1879925|NCT01170312|Other|Normal saline|Normal saline injection
1879926|NCT01170325|Drug|Divalproex Sodium|
1879927|NCT01170325|Drug|Placebo Comparator|
1879928|NCT01170338|Drug|Varenicline 100 mg by mouth twice daily|this is an active drug to help smoking cessation
1879929|NCT01170338|Drug|control|this is the placebo that will help us maintain a blinded study
1879930|NCT01170351|Drug|Cyclosporine-A|Cyclosprorine-A will be administered to patients in group-B according to a set protocol and the patients will be followed at regular intervals with appropriate checking of clinical and para-clinical data.
1879931|NCT01177514|Drug|Gabapentin|Gabapentin PO. (300MG) 1 capsule the night before surgery, q12hrs the day of surgery and q8hrs for the firt 3 postoperative days.
1879932|NCT01177514|Drug|Sugar pill|Sugar pill. One capsule given the night before surgery, q12hrs on the day of surgery and q8hrs for the first 3 postoperative days.
1879933|NCT01177540|Drug|Decitabine|5 day priming with decitabine followed by Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide).
1879934|NCT01177540|Drug|Decitabine|Induction Chemotherapy of ADE (daunorubicin, cytarabine, etoposide) only
1879935|NCT01177553|Procedure|selective laser photocoagulation of communicating vessels|Antibiotic prophylaxis is initiated within an hour of surgery and continued every 8 hours through the first post-operative day. The use of these medications is safe in pregnancy in the doses and schedules outlined. Surgery will be performed under local anesthesia for the mother using 1% xylocaine with epinephrine at the trocar entry site, and IV sedation. The patient will undergo either SLPCV or UCO depending on her choice. Patients will remain hospitalized for 24-48 hours. All subjects will be monitored during their hospital stay. Any unanticipated adverse events or serious adverse events will be reported to the IRB according to IRB reporting requirements. Prior to discharge from the hospital an investigator will perform a post-procedure ultrasound to assess fetal status
1879936|NCT01177553|Device|Expected Management|Patients randomized to expectant management will be referred back to their referring obstetrician of perinatologist and advised to undergo weekly ultrasound examinations including Doppler studies of the umbilical artery and amniotic fluid volume. Fetal growth will be assessed every 2-4 weeks. After 24 weeks patients may undergo frequent ultrasound examinations or fetal heart rate monitoring to assess fetal well being. These ultrasounds will be performed by the patient's perinatologist or obstetrician, and will be reported to the research team on an ongoing basis throughout the pregnancy.
1995122|NCT02848651|Drug|Atezolizumab|Atezolizumab 1200 mg will be administered by intravenous infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit (up to approximately 3 years).
1879939|NCT01177579|Dietary Supplement|Copper gluconate|4 or 8 mg copper gluconate/day will be assessed for efficacy of copper repletion
1879940|NCT01177592|Device|VerifyNow, Verigene|Subjects on chronic clopidogrel will be guided by VerifyNow P2Y12 assay, whereas clopidogrel naïve subjects will be guided by Verigene CYP2C19 genotyping assay. Patients on clopidogrel maintenance and/or in the control group will also be genotyped; conversely, clopidogrel naïve subjects will have VerifyNow testing prior to discharge for additional study analysis. Patients in the guided therapy group that have a measurement of ≥ 230 PRU will be reloaded with 60mg prasugrel and receive standard maintenance dosing. Similarly, clopidogrel naïve subjects that are considered CYP2C19*2 carriers will also be reloaded with 60mg prasugrel and receive standard maintenance dosing (see flow schematic).
1879941|NCT01177605|Other|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics|Nutritional vanilla flavored beverage - 1) Milk-based beverage containing prebiotics 2) Milk-based beverage containing no prebiotics
1879989|NCT01178970|Behavioral|Resistance training|
1879945|NCT01177683|Drug|Bendamustine|"Phase I component:
Bendamustine escalating cohorts to determine MTD, IV over 1 hour, Days 1 and 4"
1879946|NCT01177683|Drug|Doxorubicin|"Phase I and II components:
Pegylated liposomal doxorubicin, 30 mg/m2 IV over 1 hour, Day 4"
1879947|NCT01177683|Drug|Bortezomib|"Phase I and II components:
Bortezomib 1.3 mg/m2 IV bolus, Days 1, 4, 8, and 11"
1879948|NCT01177683|Drug|Bendamustine|"Phase II component:
Bendamustine at at MTD IV over 1 hour, Days 1 and 4"
1879949|NCT01177683|Drug|Filgrastim|"Phase II component:
Filgrastim (if defined in MTD) 5 µg/kg/day SC, starting day 6 until neutrophil recovery to ANC >1000"
1879951|NCT01177709|Drug|Metformin|metformin 500- 2500 mg/day. Patient received variable doses of metformin starting at 500 mg/day and increasing up to maximum of 2500 mg/day over 3-4 weeks. Dose was titrated on tolerability and side effects, especially development of hypoglycemia. This explains why different patients received different maximum doses.
1879952|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
1879953|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
1879954|NCT01177722|Biological|DTaP-IPV-Hep B-PRP-T Vaccine|0.5 mL, Intramuscular
1879955|NCT01177722|Biological|DTaP-Hep B-IPV vaccine|0.5 mL, Intramuscular
1879958|NCT01177787|Device|zeltiq|Cryolipolysis had been conducted for targeted fat area on thigh for 1 hour through Zeltiq machine made in Zeltiq Aesthetics.
1879959|NCT01177787|Device|electrical stimulation|Lipolysis would be done on controlateral thigh for 30 minutes through 3000 Hz- amplitude modulated frequency.
1879960|NCT01177800|Drug|Placebo|Placebo matched to infliximab given at Weeks 10, 12 and 16 in Infliximab arm and at Weeks 0, 2 and 6 in Placebo arm
1879961|NCT01177800|Drug|Infliximab|5 mg/kg infusion given intravenously at Week 0,2,6 (induction treatment phase) and at Week 14 and 22 in maintenance phase in infliximab arm and at Week 12 and 16 in Placebo arm.
1879962|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
1879963|NCT01177813|Drug|BI 10773|BI 10773 low dose tablet once daily
1879964|NCT01177813|Drug|BI 10773 open label|Patients receive BI 10773 high dose tablets open label once daily
1879965|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
1879966|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
1879967|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
1879968|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
1879969|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
1879970|NCT01177813|Drug|BI10773|BI 10773 high dose tablets once daily
1879971|NCT01177813|Drug|Sitagliptin|Sitagliptin tablets 100 mg once daily
1879972|NCT01177813|Drug|Placebo identical to Sitagliptin 100mg|placebo tablets once daily
1879973|NCT01177813|Drug|Placebo identical to BI10773 low dose|placebo tablets once daily
1879974|NCT01177813|Drug|Placebo identical to BI10773 high dose|placebo tablets once daily
1879975|NCT01177826|Procedure|Sample collection|Stool sample
1879976|NCT01177839|Other|Screening sheets|Reviewing screening sheets
1879977|NCT01178892|Dietary Supplement|Placebo|Three placebo gel capsules filled with vegetable oil are taken daily for a total of approximately 2 grams of vegetable oil. Each gel capsule also contains 15 IU of vitamin E, natural lemon flavoring, rosemary extract, and a small amount of non-omega-3 fish oil.
1879978|NCT01178892|Dietary Supplement|Omega-3|The study supplement, omega-3-fish oils, is taken as 3 gel capsules daily that together contain approximately 2 grams of fish oil. Each gel capsule (1/3 of the daily dose) has a total omega-3 dosage of 615 mg with two major omega-3 components of ethyl eicosapentaenoic acid (EPA; 425 mg) and docosahexaenoic acid (DHA; 100 mg). Vitamin E (15 IU), an antioxidant, is added to each gel capsule to prevent oxidation and preserve freshness. Each gel capsule also contains natural lemon oil and rosemary extract to enhance taste and freshness.
1879979|NCT01178892|Behavioral|Yoga|Yoga instruction is provided during 12 weekly 90-minute classes, designed for women without prior yoga experience. Each class includes an introductory breathing exercise, 11 to 13 gentle postures followed by deep relaxation with a visualization exercise. Study participants are expected to attend each of the 12 weekly yoga classes plus do daily 20-minute at-home practices. Classes are offered at 2 different times during the week.
1879980|NCT01178892|Behavioral|Exercise|The exercise intervention is facility-based aerobic exercise training on a treadmill, stationary bicycle or elliptical trainer performed 3 times a week for 12 weeks. The duration of each training session is determined for each woman based on the weekly total energy expenditure goal and workload required to achieve her prescribed exercise heart rate. Women train at 50-60% heart rate reserve (HRR) for the first month and then increase intensity to 60-70% HRR. To ensure that women train at their prescribed exercise heart rates, women wear Polar Heart Rate Monitors while exercising. The exercise counselor overseeing each exercise session records each participant's exercise heart rate every 5-10 minutes to document that she is in her target heart rate range.
1879981|NCT01178892|Behavioral|Usual Activity|"Women randomly assigned to the Usual Activity group will be asked to continue with their usual physical activities during the study and not make changes. At completion of the intervention, women will have the opportunity to attend a yoga class and receive the yoga booklet, CD, and DVD for home use; or receive a one-month gym membership."
1879982|NCT01178905|Procedure|ultrashort heat inactivation|
1879983|NCT01178931|Drug|Oral dydrogesterone|oral-2x10mg
1879984|NCT01178931|Drug|Crinone 8% gel|vaginal-1x90mg
1995123|NCT02846714|Behavioral|FLARE|
1879988|NCT01178957|Other|Hyperglycemia|Hyperglycemia with a blood glucose of 15 mmol/L
1879990|NCT01178983|Device|surface electromyography|Surface electromyography (SEMG) telebiofeedback
1879991|NCT01178983|Device|surface electromyography|conventional biofeedback
1879992|NCT01178996|Biological|Thymosin alpha 1|Thymosin alpha 1 (Zadaxin) 1.6 mg/day, two times weekly in the morning, by subcutaneous injection for 48 weeks.
1879993|NCT01178996|Drug|Ribavirin|Ribavirin 1000 mg (<75 kg) or 1200 mg (>75 kg) daily with food divided in two doses orally for 48 weeks
1879994|NCT01178996|Biological|PEGinterferon alfa2a|180 mcg, once weekly in the evening, by subcutaneous injection for 48 weeks
1879995|NCT01178996|Drug|Placebo|Placebo
1879996|NCT01179009|Drug|Ketamine|Controlled IV ketamine infusion (0.00225mg/kg-min. [18% (0.0125 mg/kg-min.)
1879997|NCT01179009|Drug|Clonidine|Participants will receive an approximately 5-day pretreatment of clonidine (max. dose 1mg/day divided doses) prior to and throughout the ketamine infusion.
1879998|NCT01179009|Drug|placebo|IV saline (i.e. placebo ketamine)
1879999|NCT01179035|Other|Transitions Clinic - parolee-targeted care|Subjects receive ongoing primary care from the Transitions Clinic versus ongoing primary care in the San Francisco Department of Public Health affiliated primary care network.
1880000|NCT01179035|Other|Expedited Primary Care|Following randomization, subjects receive ongoing primary care in the San Francisco Department of Public Health affiliated primary care network. Appointments are expedited with safety-net primary care providers.
1880001|NCT01179048|Drug|liraglutide|Maximum dose of 1.8 mg liraglutide, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
1880002|NCT01179048|Drug|placebo|Maximum dose of 1.8 mg placebo, injected subcutaneously (under the skin) once daily. Administered in addition to the subject's standard treatment
1880003|NCT01179061|Drug|Apelin|"Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.
Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.
Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine."
1880004|NCT01179061|Drug|Placebo|As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
1880005|NCT01179074|Procedure|oesophageal stenting with self expandable metal stent|oesophageal stent placement for high grade dysphagia in inoperable oesophageal cancer
1880006|NCT01179074|Procedure|Oesophageal stent followed by external beam radiotherapy|30 Gy in 10 fractions over 2 weeks administered in the stent followed by EBRT group
1880007|NCT01179100|Drug|Lidocaine|Lidocaine (10mg/ml) Loading: 1.5 mg/kg + Infusion: 0.035 mg/kg/min
1880008|NCT01179113|Drug|Esmolol|Esmolol group: Will receive 0.5 mg/kg IV bolus of esmolol during induction, and an infusion of esmolol at 0.3 mg/kg/hr intraoperatively.
1880009|NCT01179113|Drug|Saline|Loading: an equivalent volume for the Esmolol group Infusion: an equivalent volume for the Esmolol group
1880010|NCT01179126|Procedure|complete multivessel revascularization|After a successful primary PCI these patients will undergo complete revascularization of non-culprit lesions in a staged procedure during the index admission
1880011|NCT01179126|Procedure|stress echocardiography and revascularization if required|after successful primary PCI, this group will undergo a stress echo to evaluate the significance of non-culprit lesions. If large area of ischemia is demonstrated, the artery supplying that are will be revascularized.
1880012|NCT01179139|Other|Biopsy|Percutaneous 2-3 mm biopsies of middle turbinate mucosae and nasal polyps will be obtained with 5 mm Thrucut® (Smith & Nephew, Memphis, TN) biopsy forceps. Generally, 2-3 specimens will be obtained from each side as in previous studies. Healthy controls and subjects with CRS without NP will have biopsies from both middle turbinates. Subjects with CRS with NP will have two nasal polyp biopsies and one middle turbinate biopsy.
1880013|NCT01179152|Drug|Budesonide turbuhaler, Budesonide+Formoterol turbuhaler|Budesonide 200 mcg turbuhaler or Budesonide+Formoterol 160mcg turbuhaler
1880014|NCT01179165|Other|Diagnostic|Diagnostic non-invasive tests:Dopplerechocardiography, cardiac MRI
1880016|NCT01179204|Procedure|Preoperative heat stimulation|Preoperative short and long tonic heat stimulation
1880017|NCT01179217|Drug|L-glutamine|0.3 g/kg of L-glutamine will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration. Mixing L-glutamine with soda or highly acidic juices (such as grapefruit juice or lemonade) is not recommended.
1880018|NCT01179217|Drug|Placebo|0.3 g/kg of placebo (100% maltodextrin) will be administered twice a day orally to each patient for 48 weeks. The dosage will be in increments of 5 grams based on weight. The upper limit for daily dose of study medication will be set at 30 grams. Patients will be given verbal and written instructions for self-administration of the study medication at the Baseline visit. The powder can be mixed with water or most non-heated beverages other than alcohol, or can be mixed with most non-heated foods such as yogurt, applesauce, or cereal for administration.
1880019|NCT01179230|Other|SPECT imaging|Dipyridamole stress testing 0.57 mg/kg
1880020|NCT01179230|Other|PET imaging|Dipyridamole stress test 0.57 mg/kg with Rubidium PET images
1880021|NCT01179256|Dietary Supplement|CURCUMIN|oral supplementation of curcumin 2000mg
1880022|NCT01179256|Other|no intervention other than stopping study|no intervention other than stopping study
1880023|NCT01179269|Drug|Pazopanib plus Paclitaxel|Pazopanib daily and weekly paclitaxel IV
1880025|NCT01179295|Drug|BAY86-9766|BAY86-9766 30 mg twice a day (bid).
1880026|NCT01179295|Drug|BAY86-9766|BAY86-9766 50 mg twice a day (bid).
1880027|NCT01179295|Drug|BAY86-9766|BAY86-9766 100 mg once a day (od)
1880028|NCT01179295|Drug|BAY86-9766|BAY86-9766 60 mg once a day (od)
1880029|NCT01179308|Other|General-epidural anesthesia|General anesthesia combined with epidural anesthesia
1880030|NCT01179308|Other|Balanced general anesthesia and postoperative opioids|General anesthesia alone
1880031|NCT01179321|Other|Early referral to Dietitian for assessment and nutrition support|
1880032|NCT01179334|Drug|Riociguat (Adempas, BAY63-2521)|BAY63-2521: 1 mg tid - 2,5 mg tid oral for 12 weeks.
1880033|NCT01179334|Drug|Placebo|Placebo for 12 weeks
1880034|NCT01179334|Drug|Sildenafil|Participants continued to take daily stable sildenafil background treatment according to their prescriptions.
1880035|NCT01179347|Drug|tiotropium Respimat® inhaler|to evaluate safety and efficacy tiotropium delivered with Respimat® inhaler compared to placebo.
1880036|NCT01179347|Drug|Placebo Respimat® inhaler|patient to receive placebo matching active drug once daily
1880037|NCT01179360|Other|Integrated FDG PET/CT|Optimized PET/CT imaging with dedicated head-and-neck protocol
1880038|NCT01179373|Device|TMS, H coil|TMS, H Coil, High/ Low Frequency
1880039|NCT01179399|Drug|TAK-960|TAK-960 administered orally once a day for 21-days of a 28-day treatment cycle. A 3 + 3 dose escalation scheme will be employed.
1880040|NCT01179412|Drug|2% povidone-iodine|apply 4 times a day for one week
1880041|NCT01179412|Drug|2% povidone-iodine|apply 2% povidone-iodine 4 times per day for one week
1880042|NCT01179425|Other|Cognitive stressor|The Paced Auditory Serial Addition Task (PASAT-C), has been modified for use as a computerized laboratory-based stressor. Single digits are presented, and the patient must add each new digit to the one immediately prior to it and click on the appropriate answer. Failure to do so in the allotted time results in a noxious error sound.
1880043|NCT01179438|Drug|Dexmedetomidine|The loading does of 0.5 mcg/kg dexmedetomidine is infused over 10 minutes. The following maintenance does of dexmedetomidine is 0.5 mcg/kg/hour.
1880044|NCT01179451|Device|echocardiogram|echocardiogram
1880045|NCT01179464|Drug|Aminobiphosphonate|Patients will receive standard intravenous biphosphonate treatment
1880046|NCT01179464|Drug|Simvastatin|40 mg once daily
1880047|NCT01179477|Device|Implantation of a QuickFlex® μ Model 1258T LV Lead|Implantation of a QuickFlex® μ Model 1258T LV Pacing Lead
1880048|NCT01179490|Drug|SyB L-0501|SyB L-0501 (150 mg/m2/day) will be administered by intravenous drip infusion for 60 min for 2 consecutive days and the course will be observed for the next 26 days. This is taken as one cycle and administration is repeated for 2-9 cycles (when a plateau is not reached after nine cycles, administration of up to an additional three cycles for a maximum of 12 cycles is possible).
1880049|NCT01179490|Drug|prednisolone|Prednisolone will be administered (60 mg/m2/day) orally for 4 consecutive days and the course will be observed for the next 24 days.
1880050|NCT01179503|Dietary Supplement|calcium|600 mg calcium carbonate twice daily (total of 1200 mg/day) for 4 months
1880051|NCT01179503|Dietary Supplement|Vitamin D plus calcium|1000 IU of vitamin D3 twice daily (for a total of 2000 IU/day) plus 600 mg calcium carbonate twice daily (for a total of 1200 mg/day)
1880052|NCT01179516|Drug|Vortioxetine|Encapsulated vortioxetine immediate release tablets
1880053|NCT01179516|Drug|Placebo|Vortioxetine placebo-matching capsules
1880054|NCT01179529|Drug|Omalizumab (Xolair®)|
1880055|NCT01179555|Behavioral|Behavioral Activation|Baseline assessment plus 4 in-home problem solving therapy sessions.
1880056|NCT01179555|Behavioral|Supportive Therapy|Baseline assessment plus 4 in-home sessions of supportive therapy.
1880057|NCT01179568|Drug|Citalopram|16 weeks of medication provided flexibly up to 40 mg/day. Medication will be administered in a double-blind fashion.
1880058|NCT01179568|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided within 20 weeks.
1880059|NCT01179568|Other|Placebo|16 weeks of daily inactive medication. It will be administered in a double-blind fashion.
1880060|NCT01179581|Drug|GLPG0634|single ascending doses, oral solution (1 to 10 mg/dose) and capsules (10 to 200 mg/dose)
1880061|NCT01179581|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
1880062|NCT01179581|Drug|GLPG0634|multiple dose, capsule, 10 days
1880063|NCT01179581|Drug|placebo|multiple dose, capsule, 10 days
1880064|NCT01179594|Drug|entecavir|0.5 mg orally daily, 24 weeks (weeks 12-36)
1880065|NCT01179594|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 48 weeks
1880066|NCT01179594|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 96 weeks
1880067|NCT01179594|Drug|placebo|orally daily, 24 weeks (weeks 12-36)
1880068|NCT01179607|Drug|M0002|
1880069|NCT01179607|Drug|Placebo|
1880070|NCT01179620|Drug|Certoparin|Certoparin
1880071|NCT01179633|Device|OPLON active patch|
1880072|NCT01179633|Device|Sham patch|
1880075|NCT01179672|Drug|Duloxetine|30 mg administered orally (po), QD for 1 week; 60 mg administered po, QD for remaining 11 weeks; 30 mg administered po, QD for 1 week during taper period
1880076|NCT01179672|Drug|Placebo|Administered po, QD for 12 weeks; administered po, QD for 1 week during taper period
1880077|NCT01179685|Procedure|pleural fluid tapping|Minimally invasive technique to detect malignant pleural effusion
1880078|NCT01179698|Procedure|Navigation surgery|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
1880079|NCT01179698|Procedure|Navigation system|In en bloc resection, the osteotomy sites were determined by navigation guidance. For curettage, we monitored curette in real-time with navigation.
1880080|NCT01179711|Device|Glasses prescription|At initial visit(of study), the physician will reduce the diopter of hyperopic glasses as much as the patient can maintain their eye alignment (maximum amount 1.5D).
1880081|NCT01179724|Drug|high dose proton pump inhibitor|IV loading PPI before 2hr to conduct ESD, and IV 8mg/h continuous infusion within 48hr, and then 40mg oral pantoprazole for one month
1880082|NCT01179724|Drug|H2RB|IV 50mg loading H2 receptor antagonist before 2hr to conduct ESD, and IV 13mg/h continuous infusion within 48hr, and then 300mg oral H2 receptor antagonist for one month
1880083|NCT01179737|Drug|Nilotinib|Nilotinib capsules for oral administration at 50 mg, 150 mg twice a day and 300 mg (2 capsules of 150 mg) twice a day.
1880084|NCT01179737|Drug|Placebo to nilotinib|Placebo to nilotinib capsules for oral administration to match 50 mg, 150 mg and 300 mg capsules twice a day
1880086|NCT01179763|Other|Optical coherence tomography|Spectral domain optical coherence tomography will be conducted once when patients are enrolled.
1880087|NCT01179776|Drug|Ilomedin|Ilomedin
1880088|NCT01179776|Drug|Placebo|i.v saline
1880089|NCT01179776|Drug|Ilomedin|
1880090|NCT01179776|Drug|Ilomedin and standard low dose treatment|
1880091|NCT01179789|Behavioral|Optimal Diet|a dietician will train each subject (or the caregiver) to use the personalized diet on web platform
1880092|NCT01179789|Dietary Supplement|VSL#3®|probiotic blend Product should be administrated orally, 2 capsules b.i.d. on an empty stomach (at least 30 min. before lunch and dinner) with a glass of water
1880093|NCT01179789|Dietary Supplement|AISA-5203-L|fruit extracted terpene Product should be administrated orally, the dosage depending from the body weight of the subject enrolled in the study as already stated : 1-2 pills three times a day with a meal and a large glass of water
1880094|NCT01179789|Dietary Supplement|Argan oil|Product should be administrated orally, 25 ml once daily or during the day with a meal (bread, salad …) and a large glass of water
1880095|NCT01179802|Other|Strenuous Endurance exercise|"Jungfraumarathon: Mountain-Marathon with a length of 42km and a altitude-difference of approximately 1830meters."
1880096|NCT01179828|Drug|Oxycodone 15mg|15mg single administration p.o.
1880097|NCT01179828|Drug|Clobazam|20mg single administration p.o.
1880098|NCT01179828|Drug|Imipramine|75mg single administration p.o.
1880099|NCT01179828|Drug|Tolterodine|1 mg single administration p.o.
1880100|NCT01179841|Behavioral|Playgroup|The playgroup will be conducted at our center and focuses on providing an invigorating learning environment in which emerging skills/knowledge are skillfully brought to a higher level of maturity, integrated with existing abilities, and used functionally. Learning with and through peers, provides the opportunity to address abnormal peer relationships for developmental level. Providing an enriched environment with toys, structured learning, and opportunities for ongoing engagement we offer the children experiences that they would not otherwise have. Parent training sessions will focus on strategies aimed at improving child social engagement and communication. Parent education sessions will focus on topics related to autism, learning styles, interventions, and resources.
1880101|NCT01179841|Behavioral|Parent Training|The 1-2 hour individual therapeutic sessions with parent training in the home or clinic (1x every week over six months) are based on our own program which is in development. This program focuses on teaching parents how to encourage social and communication skills in their toddlers and also provides comprehensive information about development. Sessions will focus on knowledge of autism, current access to services, general knowledge of strategies used to facilitate child development, advocacy, knowledge of how to access services, and coping strategies.
1880102|NCT01179841|Behavioral|Parent Training|In the once-a-week 1 to 2 hour parent training/enrichment, we will ask parents to target specific play and care routines in which they may stimulate their child's development in the ways identified by the therapist. These stimulation times may be provided by the parents, other family members, friends, volunteers or hired assistants. Parents will be encouraged to have their child in direct skill-enhancing engagement for 1-2 hour per day. The therapist will work with the family to identify times during the day that best lend themselves to accomplishing this goal.
1880103|NCT01179854|Drug|Remegal|Drug/ placebo
1880104|NCT01179867|Other|Electronic Medication Reconciliation|"At admission the community drug list will be electronically retrieved from the public drug insurance administrative databases using a real-time interface, and the admitting team/pharmacist will verify the list, adding over-the-counter medications
At discharge the attending physician/resident will write the discharge prescription using the discharge reconciliation module, allowing the physician to simultaneously view the validated community drug list and the hospital pharmacy drug list for the patient
The discharge communication module will facilitate identification and transfer of information on discontinued and changed medication to the respective dispensing pharmacies and prescribing physicians along with the reasons for these changes"
1880105|NCT01179880|Drug|E6005|Four Steps of Ointment Application: Step 1: 0.01% of E6005; Step 2: 0.03% of E6005; Step 3: 0.1% of E6005; Step 4: 0.2% of E6005.
1880106|NCT01179880|Drug|Placebo|Matching placebo for each step
1880107|NCT01179893|Biological|IVIG|Intravenous immunoglobulin
1880108|NCT01179893|Procedure|PLEX|Plasma exchange: removal of pathogenic antibodies and constituents and replacement with albumin.
1880109|NCT01179906|Behavioral|Exercise training|Subjects exercise trained for 48 weeks with personal trainers at a college wellness center
1880110|NCT01179906|Behavioral|Diet modification|Exercise training using personal trainers 3 times per week. Individuals were trained at a moderate intensity
1880111|NCT01179919|Drug|Oseltamivir|Capsule, 75 mg by mouth for 9 doses
1880112|NCT01179932|Other|No Intervention Used|Our study is observational; therefore, there is no type of intervention being used.
1880113|NCT01179945|Other|benzoate containing test drinks|"Subjects will consume 500ml of water with 0.5 grams of sodium benzoate, followed by a solution of 75g sugar in 500ml water with 0.5 grams sodium benzoate 3 hours later.
Each solution will be consumed over 5 minutes."
1880180|NCT01180413|Drug|Lercanidipine|Up to 20 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
1880114|NCT01179945|Other|non sodium benzoate containing test drinks|"Subjects will consume 500ml of water followed by a solution of 75g sugar in 500ml water 3 hours later.
Each solution will be consumed over 5 minutes."
1880115|NCT01179958|Behavioral|aerobic training|24 weeks of aerobic training, 4X/week
1880116|NCT01179958|Behavioral|stretching/toning|stretches and toning exercises designed to promote flexibility and improved core strength
1880117|NCT01179971|Dietary Supplement|Fish oil, gamma-linolenic acid|3 g/d DHA + EPA
1880118|NCT01179984|Device|Bard® LifeStent® Vascular Stent System|Stent Implantation
1880119|NCT01179997|Device|Interventricular pacing delay optimization by using Tissue Doppler-derived displacement curves|
1880120|NCT01179997|Device|Electrocardiographic optimization of the interventricular pacing delay according to QRS width|
1880121|NCT01180010|Procedure|Low Dose CT|"A chest CT uses special radiographic equipment using x-rays to capture images of the chest, and with the aid of a computer, processes the images to create cross-sectional pictures or slices of the areas of interest. The images can then be printed out or examined on a monitor. The CT scanner is a large unit with a hole running directly through its center, giving the appearance of a doughnut. During the scanning, patients will lie flat on their back on a table, and they are periodically asked to hold their breath. The table will first move through the scanner to determine the correct starting position. The rest of the scans are made as the table moves more slowly through the cavity in the scanner."
1880122|NCT01180023|Procedure|Sweeping|Sweeping of membranes during digital exam
1880123|NCT01180036|Drug|Rituximab|1000 mg, I.V. on Days 1 and 15 and will be retreated at month 6 independent of CD19+ B cell count
1880124|NCT01180036|Drug|Cyclosporine|Patients randomized to the Cyclosporine arm will be started at a dose of (CsA = 3.5 mg/kg/day p.o. divided into 2 doses for 12 months). Target trough CsA blood levels, as determined in whole blood by HPLC, are 125 to 175 ng/ml. A persistent and otherwise unexplained increase in serum creatinine >30% would prompt an approximate 25% dose reduction of CSA, aiming for a corresponding 25% reduction in CSA trough level. If with this dose reduction the creatinine does not return to within 30% of baseline levels within 3 weeks, then a second dose reduction of approximately 25% with similar reduction in CSA trough level will be used. If the creatinine does not fall to baseline values with this second dose reduction, the drug will be discontinued. At the end of 12 months, Cyclosporine will be tapered by 1/3 of the maintenance dose monthly and hence discontinued after 3 months.
1880127|NCT01180062|Drug|Latanoprost|"Group 1 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 0.5µg Latanoprost.
Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
Duration of drug release is expected to be 3-6 months.
Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost."
1880128|NCT01180062|Drug|Arm 2|Group 2 will be given two, low dose Latanoprost SR inserts that contain a combined daily dose of 1.0µg Latanoprost.
1880129|NCT01180062|Drug|Latanoprost SR insert|Group 3 will be given a single, low dose Latanoprost SR insert that contains a daily dose of 2.0µg Latanoprost.
1880130|NCT01180075|Drug|tenofovir/emtricitabine/efavirenz (TDF/FTC/EFV)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
1880131|NCT01180075|Drug|tenofovir/emtricitabine (TDF/FTC)|Patients receiving this drug for clinical care at standard dosages will be enrolled.
1880132|NCT01180075|Drug|Atazanavir (ATV)|Patients receiving this drug for clinical care at 300mg with 100mg ritonavir daily will be enrolled.
1880133|NCT01180075|Drug|Ritonavir|Patients receiving this drug for clinical care at 100mg daily with 300mg atazanavir will be enrolled.
1880134|NCT01180075|Procedure|Phlebotomy|Multiple blood draws will be performed in the study, and vary depending on the group.
1880135|NCT01180088|Procedure|RIGHT HEPATECTOMY WITH CLASSIC APPROACH|The right portal branch and the right branch of the hepatic artery were identified, dissected and divided. Extraparenchymal ligation of pedicles for Sg4 was performed in case of extended right hepatectomy. The falciform and the right triangular ligaments were sectioned and the right liver up to the retrohepatic vena cava was totally mobilized by section and sutures of the accessory right hepatic veins. The right hepatic vein was controlled in an extrahepatic plane and encircled with a tape. At the end of parenchymal transection right hepatic vein was sectioned with endovascular stapler. The right bile duct and middle hepatic vein (in case of extended right hepatectomy) were divided intraparenchymally
1880136|NCT01180101|Behavioral|Diet and exercise|This group will follow a hypocaloric diet and supervised exercise training for 12 weeks.
1880137|NCT01180101|Procedure|Bariatric Surgery|Patients will undergo bariatric surgery
1880138|NCT01180114|Behavioral|Suubi-Maka ('Hope for Families')|Each child in the SUUBI-MAKA condition receive the usual care plus asset focused services, specifically: a matched Child Development Account (CDA); twelve 1-2 hour training sessions on career planning, setting short-term and long-term career goals, and how to save money; and monthly mentorship program with young adult peers (undergraduate students) on life options and how to avoid risk behaviors. In addition, participants receive a 2:1 match for their deposits into the account. Further, participants and their adult caregivers receive specific training on microenterprise development and specifically on how to start an income-generating project using up to 50% of the matched savings. The intervention is delivered over a period of 24 months.
1880139|NCT01180114|Other|Usual Care|Each child in the control condition receives the usual services for orphaned children (counseling, school lunches, and textbooks).
1880140|NCT01180127|Dietary Supplement|Flavanol containing food product|12 weeks, 2X/day, 20g serving
1880141|NCT01180127|Behavioral|Aerobic training|4X/week, 1 hour/session at 75% maximum HR
1880142|NCT01180127|Dietary Supplement|Food product lacking flavanol|20 g serving, 2X/day, food additive lacking flavonol
1880143|NCT01180127|Behavioral|Wait list control|12 week wait list control condition during which participants abstain from aerobic exercise
1880181|NCT01180413|Drug|Losartan|Up to 100 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
1880182|NCT01180426|Drug|CHR-2797|120mg once daily oral for 48 weeks
1880144|NCT01180140|Device|Seamguard|GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement is specifically engineered to reduce the incidence of perioperative leaks and bleeding in a variety of open and minimally invasive surgeries. Then, after six months, it is completely absorbed eliminating the risk of a prolonged inflammatory response.
1880145|NCT01180153|Drug|S-1 oxaliplatin|S-1 (20mg, 25mg); L-OHP (50 mg)
1880146|NCT01180166|Drug|nimotuzumab|200 milligram (mg) of nimotuzumab per week during radiation period
1880147|NCT01180179|Drug|Lansoprazole|30mg once daily
1880148|NCT01180179|Drug|Famotidine|40mg once daily
1880149|NCT01180192|Drug|oxygen|either 8 L/minute O2 via face mask for 2 hours
1880150|NCT01180205|Drug|Telmisartan|Telmisartan (80 mg ,Tablets, QD, p.o., 26 weeks)
1880151|NCT01180205|Drug|Amlodipine|Amlodpine 5 mg po 14 days, the forced - titration to 10 mg po for 24 weeks
1880152|NCT01180205|Drug|Olmesartan medoxomil|Olmesartan 40 mg po for 26 weeks
1880153|NCT01180205|Drug|Hydrochlorothiazide|HCT 12,5 mg po for 14 days, then 25 mg po for 24 weeks
1880154|NCT01180218|Procedure|complete revascularization|-Complete revascularization : one time primary percutaneous coronary intervention (PCI) of the culprit and nonculprit lesions in patient with ST elevateion myocardial infarction (STEMI) and multivessle disease
1880155|NCT01180218|Procedure|Culprit revasularization|Culprit revascularization : PCI of only the culprit lesion and staged nonculprit PCI at a later date in patients with ST-segment elevation myocardial infarction (STEMI) and multivessel disease.
1880156|NCT01180231|Drug|Moxonidine (Physiotens)|Subjects will be asked to take moxonidine, dosage to be determined prior to commencement by a medical doctor for 6 months duration.
1880157|NCT01180231|Other|Dietary intervention|Subjects will be asked to follow dietary plans designed by a qualified nutritionist for 6 months.
1880158|NCT01180244|Device|Noninvasive cortical electrical stimulation|Subjects will receive 22 sessions of the intervention protocol, twice per week for a total of 11 weeks. The signal stimulation used in this study utilizes amplitude modulation to shape a high frequency carrier signal, nominally greater than 10 kilohertz, into the form of one or more low frequency components, nominally less than 40 hertz. Exact protocol is set in software and is the same for all participants in the active treatment arm.
1880159|NCT01180244|Device|Sham treatment|Subjects in the placebo group will receive the exact same experience as those in the active treatment group. However, the device will not output any electrical stimulation signal.
1880160|NCT01180283|Drug|lodenafil carbonate|Dosage: lodenafil carbonate 80mg once a day. It should be taken between 6 and 2 hours before the sexual intercounter.
1880161|NCT01180296|Drug|oral micronized progesterone|400 mg oral micronized progesterone nightly from 16 to 34 weeks vs placebo
1880162|NCT01180296|Drug|Identical Placebo tablet|placebo taking nightly from 16 to 34 weeks
1880163|NCT01180322|Drug|Cytarabine|"Induction therapy:100 mg/m2/day by continuous intravenous (IV) infusion on days 1-7 (total dose 700 mg/m2)
Consolidation therapy:
Younger adults (18 to 65 years): 3 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 18 g/m2).
Elderly patients (>65 years): 1 g/m2/day by IV infusion over 3 hours every 12 hours on days 1, 2, and 3 (total dose 6 g/m2)."
1880164|NCT01180322|Drug|Idarubicin|"First induction therapy:
Arm A, C, D:
12 mg/m2/day by IV push on days 1,3,5 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 1+3.
Arm B:
12 mg/m2/day by IV push on days 6, 8 10 (total dose 36 mg/m2). For elderly (>65 yrs) patients only two doses of idarubicin are foreseen on days 6+8.
Second induction therapy:
Arm A, C, D:
12 mg/m2/day by IV push on days 1 and 3 (total dose 24 mg/m2; for all age groups)
Arm B:
12 mg/m2/day by IV push on days 6 and 8 (total dose 24 mg/m2; for all age groups)."
1880165|NCT01180322|Drug|Etoposide|"Induction therapy:
Arm A, C, D:
100 mg/m²/day by 1-hour IV infusion on days 1,2,3 (total dose 300 mg/m2). On days 1 and 3 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 1+3.
Arm B:
100 mg/m²/day by 1-hour IV infusion on days 6,7,8 (total dose 300 mg/m2). On days 6 and 8 start after idarubicin push. For elderly (>65 yrs) patients only two doses of etoposide are foreseen on days 6+8."
1880166|NCT01180322|Drug|Azacitidine|"Induction therapy:
Arm B and C:
100 mg/m2/day by subcutaneous (SC) injection or 15-minute IV infusion on day 1 to day 5 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.
Arm D:
100 mg/m2/day by SC injection or 15-minute IV infusion on days 4-8 (total dose 500 mg/m2). Azacitidine is always given prior to idarubicin and etoposide.
Maintenance therapy:
Arm B, C, D:
50 mg/m2/day by SC injection on days 1-5 (total dose 250 mg/m2) every 4 weeks. (Maintenance therapy is scheduled for a total duration of 2 years in patients with continuous CR)"
1880167|NCT01180322|Drug|Lenograstim|"Consolidation therapy:
subcutaneously daily beginning on day 10 until neutrophil count > 0.5 x 109/l."
1880168|NCT01180335|Drug|Chemotherapy|4 cycles FEC followed by 4 cycles docetaxel
1880169|NCT01180335|Drug|Genomic driven chemotherapy|High DLD30 receive 3 months weekly paclitaxel followed by 4 FEC, patients with high TOP2A receive 4FEC then 4 docetaxel, patients with low DLD30 and low TOP2A are treated with 6 cycles of docetaxel-capecitabine.
1880170|NCT01180348|Drug|Botulift|Application of 90 U of Botulift divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
1880171|NCT01180348|Drug|Botox|Application of 90 U of Botox divided in 3 applications on each side of the face in fifteen predetermined sites in three regions of the face (front, glabellar, periocular).
1880172|NCT01180374|Drug|Cannabidiol|Active Cannabidiol 5mg.
1880173|NCT01180374|Drug|Delta-9-THC|"Active Delta-9-THC (0.035mg/Kg) given intravenously over 20 minutes. The dose of THC that you may receive is a small dose and is roughly equivalent to smoking approximately one half to one whole marijuana cigarette, or joint."
1880174|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no CBD).
1880175|NCT01180374|Drug|Placebo|Placebo (about a quarter spoon of alcohol with no THC) given intravenously over 20 minutes.
1880176|NCT01180400|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
1880177|NCT01180400|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
1880178|NCT01180413|Drug|Amlodipine|5 mg per day for 6 months as add-on to original ongoing antihypertensive treatment
1880179|NCT01180413|Drug|Ramipril|5 mg per day for the first to weeks as add-on to original ongoing antihypertensive treatment. Then upward adjustment to 10 mg per day for 6 months if no intolerable side effects are experienced.
1880183|NCT01180439|Device|Adjustment of ventilator settings (device)|Decrease in pressure support, increase in respiratory back-up rate, increase in expiratory positive airway pressure (EPAP) to counteract effect of PEEPi, and adjustment of cycling (at higher percentage of peak inspiratory flow)
1880184|NCT01180452|Procedure|enteroscopy|endoscopic enteroscopy to do biopsies on jejunum
1880185|NCT01180465|Drug|LIPO-102|LIPO-102 High dose
1880186|NCT01180465|Drug|LIPO-102 Low|LIPO-102 Low dose
1880187|NCT01180465|Drug|LIPO-102, Placebo|Placebo
1880190|NCT01180491|Device|K101 nail solution|
1880191|NCT01180504|Radiation|intensity-modulated whole-abdominal radiotherapy|Consolidation intensity-modulated whole-abdominal radiotherapy using helical tomotherapy to a total dose of 30 Gy in 1.5 Gy fractions
1880192|NCT01180517|Procedure|Percutaneous coronary intervention (PCI)|balloon angioplasty
1880193|NCT01180517|Procedure|PCI|balloon angioplasty
1880194|NCT01180530|Device|NovoPen Echo®|Prescribed insulin treatment delivered by NovoPen Echo®
1880195|NCT01180543|Device|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
1880196|NCT01180543|Device|Placebo Patch|same as active patch
1880197|NCT01180556|Dietary Supplement|Probiotics|Daily oral supplementation for four weeks
1880198|NCT01180556|Dietary Supplement|Placebo|Placebo administration
1880199|NCT01180569|Drug|lenalidomide|"Patient enrollment FNA of palpable lymph node prior to escalation phase
Escalation phase of Lenalidomide:
Lenalidomide 5 mg daily PO x 14 days Lenalidomide 10 mg daily PO x 14 days Lenalidomide 15 mg daily PO x 14 days Week of rest FNA of palpable lymph node prior to treatment phase
Treatment phase of Lenalidomide:
15 mg daily PO days 1-21 out of a 28 day cycle Repeat x 6 cycles"
1880200|NCT01180582|Device|Triathlon Periapatite (PA)-coated Tibial Component|Triathlon Periapatite (PA)-coated Total Knee Arthroplasty Tibial Component for uncemented fixation
1880201|NCT01180595|Device|Trabecular Metal Modular Tibial Total Knee Component|The modular design of the Trabecular Metal Total Knee allows for increased options for physicians however, it is not clear how this modular feature will affect fixation since it may compromise some of the advantages of the original TM Monoblock tibial component.
1880202|NCT01180595|Device|Trabecular Metal Monoblock Tibial Total Knee Component|
1880203|NCT01180608|Other|MR Spectroscopy|"During each MR Spectroscopy session, we will measure at regions of interest (rACC, both thalami, dominant DLPC) the levels of the following biochemical substances:
gamma-aminobutyric acid (GABA)
glutamate (Glu)
glutamine (Gln)
N-acetylaspartate (NAA)
Choline-containing compounds (Cho)
Creatine plus phophocreatine (total creatine: Cr)
Myo-inositiol (Ins)
Choline (Cho)
Glucose (Glc)
Lactate (Lac)"
1880204|NCT01180621|Biological|Fluviral|0.25 mL Fluviral for children up to and including 35 months of age 0.50 mL Fluviral for children 36-59 months of age
1880205|NCT01180634|Drug|MP-376 (Levofloxacin solution for Inhalation)|240 mg of MP-376 administered BID for 28 days
1880206|NCT01180634|Drug|Placebo|same volume and frequency as study drug
1880207|NCT01180647|Drug|Extended-Release Naltrexone|380mg IM XR-NTX injection one week prior to release from jail; a second XR-NTX 380mg IM injection is offered 4 weeks later (monthly).
1880208|NCT01180647|Behavioral|Motivational Enhancement Counseling|The randomized control arm receives no medication treatment and is offered brief, two-session Motivational Enhancement counseling prior to release from jail.
1880209|NCT01180660|Drug|Lidocaine Infusion|1.5 mg/kg bolus followed by an infusion of 2 mg/kg/hr throughout the intra operative period
1880210|NCT01180660|Drug|Normal Saline|Saline bolus equal to that of lidocaine in addition to continuous infusion of normal saline during the intra operative period
1880211|NCT01180673|Behavioral|MINT-TLC|This intervention is based on established clinical practice guidelines for prevention and treatment of hypertension, which recommend weight loss (if overweight), limiting sodium and alcohol intake, regular physical activity, and eating a low-fat diet that is rich in fruit and vegetables. Seniors will attend weekly group classes conducted by trained research assistants for the first 12 weeks (intensive phase); followed by three individual motivational interview (MINT) sessions that will occur monthly over the next three months (extended phase); and finally each senior will receive three bi-monthly booster MINT sessions in the remaining six months (maintenance phase).
1880212|NCT01180673|Behavioral|Control Condition|"Seniors randomized to the control arm will receive a single individual brief advice session on therapeutic lifestyle changes recommended for blood pressure reduction. In addition, they will be given print versions of the NHLBI publications Your Guide to Lowering Blood Pressure; and Facts about the DASH Eating Plan. Sessions will be delivered by trained research assistants."
1880213|NCT01180686|Device|Activator IV single impulse instrument|This is a manually operated device that delivers a single thrust into the joint involved.
1880214|NCT01180686|Device|Multiple thrust Impulse adjusting instrument|A device used for delivering 12 thrusts to the involved joint of the lumbar spine.
1880215|NCT01180699|Biological|Influenza vaccine: Vaxigrip or Fluviral and Intanza|Patients will be randomized to receive either one intradermal dose of 0.1 mL or one intramuscular injection of 0.5 mL of the standard influenza vaccine in the deltoid muscle of the nondominant arm.
1880217|NCT01180725|Dietary Supplement|Dried Plum|
1880218|NCT01180725|Dietary Supplement|Metamucil|
1880219|NCT01180738|Behavioral|Body weight supported treadmill training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking on a treadmill using a body weight support system.
1880220|NCT01180738|Behavioral|Overground walking training|Training will include 10 sessions over a 2 week period, each session with 30 minutes of walking overground.
1880221|NCT01180751|Radiation|[18F]-Fluorodeoxyglucose|With each Positron Emission Tomography/Computed Tomography (PET/CT)scan an intravenous administration of radioactive glucose (FDG)is given. This is a weight dependent dosage.
1880222|NCT01180764|Drug|Lovaza (Omega-3 acid ethyl esters)|1g capsules, 4 capsules po daily
1880223|NCT01180764|Drug|Placebo|Placebo matching active lovaza, 1 g capsules, 4 capsules po daily
1880224|NCT01180777|Device|etafilcon A (A)|Daily wear contact lens
1880225|NCT01180777|Device|etafilcon A (B)|Daily wear contact lens
1880226|NCT01180777|Device|etafilcon A (C)|Daily wear contact lens
1880227|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|200 mg oral capsule once daily
1880228|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|400 mg oral capsule once daily
1880229|NCT01180790|Drug|ACH-0141625 (Sovaprevir)|800 mg oral capsule once daily
1880230|NCT01180790|Drug|Placebo|Powder in capsule once daily
1880231|NCT01180790|Drug|Pegylated Interferon alpha-2a|180 ug once a week by subcutaneous injection
1880232|NCT01180790|Drug|Ribavirin|400 mg or 600 mg (am) and 600 mg (pm) capsules taken orally twice daily
1880233|NCT01180803|Device|pulse oxygen supplementation devices|oxygen therapy delivered by systems using oxygen-saving valves
1880234|NCT01180803|Device|continuous oxygen|oxygen therapy delivered by continuous liquid oxygen devices
1880235|NCT01180816|Drug|Super-Selective Intraarterial Intracranial Infusion of Temozolomide|A single dose of Intraarterial Mannitol to open the blood brain barrier followed by Intra-arterial Temozolomide single dose (starting at 75mg/m2 and up to 250mg/m2)
1880236|NCT01180829|Behavioral|Personalized feedback text messages|A series of 12 text messages, each of which contains one personalized feedback item about the person's drinking.
1880237|NCT01180829|Behavioral|Consciousness raising text messages|A series of 12 text messages, each of which consists of an item designed to get the person to think about his or her drinking
1880238|NCT01180842|Other|Yoga treatment program|yoga program designed specifically for the patient with CF
1880239|NCT01180855|Drug|Placebo|Placebo pill nightly for 42 nights.
1880240|NCT01180855|Drug|Rozerem 8mg|Rozerem 8mg pill, nightly for 42 nights
1880241|NCT01180855|Other|Rozerem 8mg in combination with Multi Component Behavior Therapy|Rozerem 8mg pill nightly for 42 nights with 4 sessions and 2 telephone calls of Multi Component Behavior Therapy.
1880242|NCT01180894|Drug|Iron sucrose|100 mg IV TIW
1880243|NCT01180894|Drug|Placebo|
1880244|NCT01180933|Dietary Supplement|fish oil|400 mg of DHA and 150 mg of eicosapentaenoic acid per day
1880245|NCT01180933|Dietary Supplement|folate|400 µg per day
1880246|NCT01180933|Dietary Supplement|fish oil + folate|500 mg DHA, 150 mg eicosapentaenoic acid, 400 µg MTHF per day
1880247|NCT01180933|Dietary Supplement|placebo|only vitamins and minerals as recommended, but no fish oil or folate
1880248|NCT01180946|Dietary Supplement|ergocalciferol|ergocalciferol (a dietary form of vitamin D). 50,000 units by mouth once a week for 16 weeks.
1880249|NCT01180946|Other|placebo pill|placebo pill once weekly for 16 weeks. At the end of the study, subjects in this arm will receive vitamin D repletion
1880250|NCT01180959|Drug|Bevacizumab|10 mg/kg by vein once every 2 weeks on days 1 and 15 of each cycle. The first dose of bevacizumab will be given over about 90 minutes
1880251|NCT01180959|Drug|Erlotinib|150 mg by mouth once a day.
1880252|NCT01180985|Device|galyfilcon A prototype lens|silicone hydrogel contact lens
1880253|NCT01180985|Device|comfilcon A|silicone hydrogel contact lens
1880254|NCT01180998|Device|Senofilcon A Toric (AOfA)|Soft toric contact lenses for astigmatism
1880255|NCT01180998|Device|Etafilcon A Toric (1DAMfA)|Soft toric contact lenses for astigmatism
1880256|NCT01181011|Drug|amlodipine/telmisartan/combination|patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
1880257|NCT01181024|Drug|Placebo|matching RO5303253 placebo, administered as single dose (Parts A + B) or multiple dose (Part C)
1880258|NCT01181024|Drug|RO5303253|Cohorts receiving single ascending doses
1880259|NCT01181024|Drug|RO5303253|Single dose
1880260|NCT01181024|Drug|RO5303253|Multiple doses
1880261|NCT01181050|Drug|NNC0142-0002|A single dose of 4 mg NNC 0142-0000-0002/kg bodyweight. Administered subcutaneously (s.c., under the skin).
1880262|NCT01181050|Drug|placebo|A single dose of 4 mg NNC 0142-0000-0002 placebo/kg bodyweight. Administered subcutaneously (s.c., under the skin).
1880263|NCT01181063|Drug|Budesonide/formoterol 320/9 μg and 400/12 μg inhalers|Budesonide/formoterol 320/9 μg and 400/12 μg in different kind of inhalers and Symbicort Turbuhaler forte 320/9 μg. Ech subject will be randomly allocation to 4 of 5 products, a single dose administration of each product
1880265|NCT01181089|Biological|Placebo|
1880266|NCT01181089|Biological|Baminercept|
1880267|NCT01181102|Drug|edoxaban|
1880268|NCT01181102|Drug|enoxaparin sodium|
1880269|NCT01181115|Drug|Avonex|Interferon treatment for MS
1880270|NCT01181128|Drug|Factor VIII (rFVIIIFc)|
1880271|NCT01181128|Drug|Advate®|
1880272|NCT01181141|Drug|DU-176b (edoxaban)|
1880273|NCT01181141|Drug|Enoxaparin sodium 20mg|
1880276|NCT01181167|Drug|edoxaban|
1880277|NCT01181167|Drug|enoxaparin sodium|
1880278|NCT01181180|Dietary Supplement|water consumption|The effect of water consumption on postural stability of old adults (65 years old and over) will be measured using RCT study design
1880279|NCT01181193|Other|Surgery|Craniotomy with total or partial removal of the brain tumor
1880280|NCT01181193|Radiation|Radiotherapy to tumour bed and/or residual tumour|60 Gy in 30 fractions over 6 weeks
1880281|NCT01181193|Drug|Temozolomide|"75 mg/m2/day for entire period of radiotherapy
150-200 mg/m2/day for 5 days every 28 days, 6 cycles total"
1880393|NCT01173796|Procedure|catheter ablation|perimitral flutter ablation by blocking the mitral isthmus
1880282|NCT01181193|Drug|Vitamin D3|4000 IU started 1 week before commencing radiotherapy and discontinued immediately after completing last chemotherapy cycle
1880283|NCT01181206|Procedure|Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs|
1880284|NCT01181219|Procedure|CXL without epithelial removal|UV-radiation of a Riboflavin saturated cornea without prior epithelial removal
1880285|NCT01181219|Procedure|CXL with epithelial removal|UV-radiation of a Riboflavin saturated cornea after surgical epithelial removal has been performed
1880286|NCT01181232|Drug|Zolpidem MR|oral
1880287|NCT01181232|Drug|Zolpidem IR|oral
1880288|NCT01181245|Drug|FG-3019|3mg/kg IV, 10mg/kg IV, 15mg/kg IV, 25mg/kg, 35mg/kg IV, 45mg/kg IV - Biweekly, 35/17.5mg/kg, 45/22.5 mg/kg - Weekly
1880289|NCT01181258|Drug|Rituximab|375 mg/m^2 administered intravenously (IV) weekly * 4, (day -7, -1, +6, +13) pre-infusion with natural killer cells (NK)
1880290|NCT01181258|Biological|Interleukin-2|subcutaneously administered 9 million international units (IU) every other day * 6 doses over 2 weeks begin 1 to 24 hours after NK cell infusion. If weight < 45 kilograms, give IL-2 at 5 million units/m2 on same schedule.
1880291|NCT01181258|Biological|Natural killer cells|administered intravenously 1.5 to 8 * 10^7 cells/kg on Day 0 (day of NK cell infusion)
1880292|NCT01181258|Drug|Cyclophosphamide|60 mg/kg administered intravenously (IV) for 2 hours on day -5 after Fludarabine.
1880293|NCT01181258|Drug|Methylprednisolone|1 mg/kg on Days -2 through +9 as an intravenous (IV) infusion.
1880294|NCT01181258|Drug|Fludarabine|25 mg/m^2/day administered as a 1 hour IV infusion once a day for 5 doses (day -6 through day -2).
1880295|NCT01181271|Drug|Busulfan (conditioning for AUTO transplant)|0.8 mg/kg intravenous (IV) bolus every six hours (Q6H) on days -8,-7,-6,-5 (total of 14 doses). The total daily dose of busulfan will be 3.2 mg/kg on days -8,-7, and -6 and 1.6 mg/kg on day -5
1880296|NCT01181271|Drug|Etoposide (conditioning for AUTO transplant)|Etoposide 30 mg/kg IV bolus every day (QD) on day -4. The total daily dose of etoposide will be 30 mg/kg.
1880297|NCT01181271|Drug|Cyclophosphamide (conditioning for AUTO transplant)|Cyclophosphamide 60 mg/kg IV bolus QD on days -3 and -2. The total daily dose of cyclophosphamide will be 60 mg/kg.
1880298|NCT01181271|Drug|Mesna (prior to AUTO transplant)|Mesna 15 mg/kg IV bolus on days -3 and -2 infused over 15 minutes and given 15 minutes prior to cyclophosphamide administration. This is followed by Mesna given 15 mg/kg IV bolus three times daily (TID) on days -3 and -2 infused over 15 minutes at 3, 6, and 9 hours after completion of cyclophosphamide infusion. Total daily dose of Mesna should be equivalent to daily dose of cyclophosphamide. Lastly, Mesna will be given at 15 mg/kg IV bolus QD on day -1. This makes a total of 9 doses of Mesna
1880299|NCT01181271|Other|autologous (auto) peripheral blood stem cell transplantation|Infusion of autologous peripheral blood stem cells on Day 0.
1880300|NCT01181271|Drug|Neupogen|Neupogen 5 mcg/kg subcutaneous (SQ) daily starting on day +1 until absolute neutrophil count (ANC) is greater than or equal to 1000 per micro liter on two separate occasions or greater than 5000 per micro liter once
1880301|NCT01181271|Drug|Fludarabine (conditioning for ALLO Transplant)|Fludarabine 30 mg/m2/day will be administered as a bolus infusion over approximately 30 minutes for 4 days on days -5, -4, -3, -2.
1880302|NCT01181271|Drug|Busulfan (conditioning for ALLO Transplant)|Busulfan will be administered by IV infusion over approximately 3 hours on days -5, -4, -3, -2. The dose of busulfan will be 0.8 mg/kg/day
1880303|NCT01181271|Other|non-myeloablative allogeneic (allo) transplant|Donor peripheral blood stem cells (PBSC) will be infused intravenously beginning on Day 0. The minimum total CD34+ cell dose will be 2 x 10^6 CD34+cells/kg of recipient's actual body weight with a maximum dose of 8 x 10^6/kg of recipient's actual body weight
1880304|NCT01181271|Drug|Tacrolimus|Tacrolimus (FK506) will be given orally at a dose of 0.05 mg/kg orally (PO) twice a day (BID) starting day -3.
1880305|NCT01181271|Drug|Sirolimus|Sirolimus (rapamycin) will be given orally at a dose of 12 mg times one on day -3 and then the dose shall be 4 mg by mouth daily starting on day -2. The dose may then be adjusted according to serum levels at the discretion of the treating physician
1880306|NCT01181271|Drug|Methotrexate|Methotrexate will be administered once daily on days 1, 3, and 6 as an IV bolus over 15 minutes at a dose of 5 mg/m2
1880307|NCT01181297|Other|Extensively Hydrolyzed Formula with a Probiotic|
1880308|NCT01181297|Other|Extensively Hydrolyzed Formula without a Probiotic|
1880309|NCT01181310|Drug|A: Placebo to match Donepezil and MK-3134 + Placebo to match Scopolamine|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of placebo to match scopolamine SQ.
1880310|NCT01181310|Drug|B: Placebo to match Donepezil and MK-3134 + Scopolamine 0.5 mg|Single doses of placebo to match both donepezil and MK-3134 PO, plus a single dose of scopolamine 0.5 mg SQ.
1880311|NCT01181310|Drug|C: MK-3134 25 mg + Scopolamine 0.5 mg|A single dose of MK-3134 PO 25 mg, plus a single dose of scopolamine SQ 0.5 mg.
1880312|NCT01181310|Drug|D: Donepezil 10 mg + Scopolamine 0.5 mg|A single dose of donepezil 10 mg PO, plus a single dose of scopolamine 0.5 mg SQ.
1880313|NCT01181310|Drug|E: Combo: Donepezil 10 mg + MK-3134 25 mg + Scopolamine 0.5 mg|A combination of single doses of all active drugs: donepezil 10 mg and MK-3134 25 mg PO, plus scopolamine, SQ.
1880314|NCT01181323|Other|Placebo|0.2 ml of Intranasal placebo study product (using sucrose phosphate placebo filled sprayers), will be administered to maternal subjects.
1880315|NCT01181323|Biological|Cold-adapted live attenuated influenza virus vaccine, trivalent|Licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose LAIV (Flumist®) 0.1 ml administered to maternal subjects intranasally in each nostril for a total of 0.2 mL.
1880316|NCT01181323|Other|Placebo|0.5 ml of Sterile saline (0.9 percent Sodium Chloride for injection), administered IM to maternal subjects.
1880317|NCT01181323|Biological|Trivalent inactivated influenza vaccine|Preservative free, licensed product formulated for the 2011-2012 or 2012-2013 influenza season. Standard dose of TIV (Fluzone®) 0.5 ml administered to maternal subjects, IM in the deltoid.
1880318|NCT01181336|Biological|Influenza vaccine (FLU-v)|Comparison of different dosages of FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences). Administration: A single subcutaneous injection of (Low Dose / High Dose with adjuvant / water for injection)
1880319|NCT01181336|Biological|FLU-v Control|Adjuvant only or water for injection only Administration: a single subcutaneous injection
1880320|NCT01181349|Other|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug[s]) are not specified in the protocol.
1880321|NCT01181349|Other|Neuromuscular Blocking Agent (NMBA)|While neuromuscular blockade drug(s) are involved in this study prior to actual study initiation (this is an observational study), it should be noted that the identity, combination(s), and dosages of these drugs (also referred to as general anesthesia drug[s]) are not specified in the protocol.
1880322|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
1880323|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone, Agriflu and Fluarix do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber..
1880324|NCT01173211|Biological|Trivalent inactivated influenza vaccine|Three licensed 2010-2011 seasonal inactivated trivalent influenza vaccines. Single intramuscular 0.5 mL dose. Each vaccine is formulated to contain 45 micrograms (mcg) hemagglutinin (HA) per 0.5 mL dose. Thimerosal is a preservative used in some vaccines. Fluzone®, Agriflu® and Fluarix® do not contain thimerosal. For Fluarix, the tip cap and rubber plunger of the needleless prefilled syringes contain dry natural latex rubber.
1880325|NCT01173224|Drug|Placebo|Placebo: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
1880326|NCT01173224|Drug|DAS181|DAS181 F03: Cohort 1: 20mg DAS181 or placebo for 1 day (total dose of 20mg). Cohort 2: 20mg DAS181 or placebo for 10 consecutive days (total dose of 200mg). Cohort 3: 30mg DAS181 or placebo for 1 day (total dose of 30mg).
1880327|NCT01173237|Procedure|Use tracheal intubation for surfactant therapy|Surfactant endotracheal administration after tracheal intubation
1880328|NCT01173237|Procedure|Use of Proseal laryngeal mask airway for surfactant therapy|Surfactant use by proseal laryngeal mask airway
1880329|NCT01173250|Procedure|adding diverting ileostomy|
1880330|NCT01173250|Procedure|omitting diverting ileostomy|
1880331|NCT01173263|Other|BIS 70 maintained|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 70.
1880332|NCT01173263|Other|BIS level 50|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 50.
1880333|NCT01173263|Other|BIS 35|Each patient will receive propofol sedation by continuous infusion titrated to a BIS level of 35.
1880334|NCT01173276|Other|Sperm Washing with Intrauterine Insemination (IUI)|For semen samples, seminal fluid will be separated from sperm using a density gradient/swim-up separation technique. The purified sperm sample will be washed, and screened for HIV RNA using sensitive real-time RT-PCR. Samples with detectable traces of HIV RNA will not be used for insemination. Samples with no detectable traces of HIV RNA will be used for a standard intrauterine insemination of the female partner.
1880335|NCT01173289|Radiation|External Beam Radiotherapy|"Definition of target volume:
Gross tumor volume (GTV) = gross tumor defined with intravenous bolus contrast administration given CT scan
Clinical target volume (CTV) = GTV + included volumes of clinical and suspected subclinical involvement (draining lymph nodes)
Planning target volume (PTV) = CTV + 5-10 mm of lateral, craniocaudal, and anteroposterior margins.
Radiation dose and planning
Total dose 65 Gy for gross tumor, 62.4 Gy for microscopic involved area, 58.5 Gy for high risk lymph node area and 52 Gy for elective lymph node area in 26 fractions during 6 weeks
Dose prescription: 90% isodose volume of prescribed dose encompassed PTV
The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the esophagus, lung, contralateral normal thyroid, arytenoids, vocal cord and spinal cord, etc., was calculated."
1880337|NCT01173315|Dietary Supplement|vitamin and mineral supplementation|Group MV: Zinc sulfate and Magnesium oxide (providing 10 mg Zn and 125 mg Mg) and vitamin C (100 mg) and vitamin E (100 mg); Group MVB: both of the above mineral and vitamin supplements plus vitamin B1 (5 mg), vitamin B2 (5 mg), vitamin B6 (5 mg), biotin (50 µg), vitamin B12 (5 µg) and folic acid (0.5 mg); Group P: starch (placebo).
1880338|NCT01173328|Behavioral|Pursed-lip breathing|Pursed-lip breathing involves a nasal inspiration followed by expiratory blowing against partially closed lips, avoiding forceful exhalation.
1880339|NCT01173328|Behavioral|Normal Breathing|
1880340|NCT01173341|Other|Blood, Echocardiography, and Questionnaire Timepoints for Anthracycline abd Trastuzumab|"Blood Draw is 16 ml at Pre-treatment and 12ml every 6 weeks during therapy Questionnaire is every 6 weeks during therapy.
1 Echo during pre-treatment, 1 Echo after anthracycline/before Trastuzumab, 1 Echo 3 months, 6 months, 9 months and 12 months of Trastuzumab"
1880341|NCT01173341|Other|Blood, Echocardiography and Questionnaire for Trastuzumab|Echo at Pre-Treatment, 3 months, 6 months, 9 months and 12 months Blood Draw 16 ml at Pre-Treatment, 12 ml every 6 weeks during therapy Questionnaire at Pre-Treatment and every 6 weeks during therapy
1880342|NCT01173341|Other|Blood, Echocardiography and Questionnaire for Anthracycline Regimen|Echocardiogram at Pre-anthracycline, Completion of anthracycline and 1 year after anthracycline initiation Blood Draw 16 ml at Pre-anthracycline, 12 ml during anthracycline, completion of anthracycline and 1 year after anthracycline initiation Questionnaire during Pre-anthracycline, during anthracycline, completion of anthracycline and 1 year after anthracycline initiation
1880343|NCT01173354|Dietary Supplement|Free balanced amino acid mixture|7 g free amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 24% is leucine.
1880344|NCT01173354|Dietary Supplement|Free essential amino acid mixture|7 g free essential amino acids provided as a one time bolus, including 15 g carbohydrates. As part of the total amount of essential amino acids 40% is leucine.
1882929|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
1880345|NCT01173367|Other|Aggressive Fever Treatment|Patients assigned to the aggressive fever treatment protocol will receive acetaminophen 650 mg enterally every 6 hours for fever ≥ 38.3°C and external cooling will be initiated for temperatures ≥ 39.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 38.3°C and 39.5°C respectively.
1880346|NCT01173367|Other|Permissive Fever Treatment|Patients assigned to the permissive treatment strategy will not receive anti-pyretic therapy until the temperature reaches 40.0°C at which point they will receive acetaminophen 650mg every 6 hours. External cooling will be initiated for temperatures ≥ 40.5°C. Acetaminophen and external cooling will be discontinued once core temperature is less than 40.0°C and 40.5°C respectively.
1880347|NCT01173380|Other|Soy nuts|Oil roasted soy nuts with 101 milligrams of soy isoflavones per day for 4 weeks
1880348|NCT01173380|Other|Matched food|Control food (matched for calories and macronutrients) per day for 4 weeks
1880349|NCT01173393|Procedure|PARAMEDIC COOLING|"For patients randomised to paramedic cooling:
LMA/ Intubation and ventilation with 100% oxygen
Measure temperature using tympanic probe and record
Paramedic cooling using infusion of 20mL/kg cold fluid via IV during CPR
If temperature >34.5ºC, infuse further 10mL/kg stat
After ROSC, infuse further (max 2 litres) ice-cold saline
If shivering occurs post resuscitation and intubated, administer midazolam 2-5mg IV and pancuronium 8 mg."
1880350|NCT01173406|Behavioral|CPAP education|Standard CPAP education plus an session and one telephone follow up
1880351|NCT01173419|Device|VNUS RF ClosureFAST|VNUS® RF ClosureFAST is a minimally invasive varicose vein treatment procedure that uses radiofrequency energy (electricity) to heat, collapse and seal off the targeted blood vessels.
1880352|NCT01173419|Device|VenaCure EVLT NeverTouch|Endovenous Laser Treatment (EVLT) uses laser energy, which is a highly concentrated beam of light to treat varicose veins.
1880354|NCT01173471|Drug|AZD4017|tablet, oral, one tablet once daily, 28 days
1880355|NCT01173471|Drug|Placebo|matching placebo tablet, oral, one tablet once daily, 28 days
1880356|NCT01173471|Drug|AZD4017|tablet, oral 2 tablets twice daily, 28 days
1880357|NCT01173471|Drug|Placebo|matching placebo tablets, oral, 2 tablets twice daily, 28 days
1880358|NCT01173497|Drug|INIPARIB + irinotecan|21 day cycle
1880359|NCT01173510|Drug|Raltegravir plus Truvada|Raltegravir 400 mg twice daily plus tenofovir/emtricitabine (Truvada) one tablet once daily
1880360|NCT01173510|Drug|Atripla|Efavirenz/Emtricitabine/Tenofovir DF one tablet once daily
1880361|NCT01173523|Drug|STA-9090|
1880362|NCT01173536|Drug|GDC-0449|Oral repeating dose
1880363|NCT01173536|Drug|moxifloxacin|Oral single dose
1880364|NCT01173536|Drug|placebo|Oral repeating dose
1880365|NCT01173549|Drug|Canagliflozin/Placebo Placebo/Canagliflozin|Part 2: 240 mL water 20 min prior to the MMTT on Day 1 of Periods 1 and 2 in each treatment sequence (1 dose of canagliflozin in Period 1 followed by 1 dose of placebo in Period 2 and then crossover to 1 dose of placebo in Period 1 followed by 1 dose of canagliflozin in Period 2).
1880366|NCT01173549|Other|no intervention|Part 1: 240 mL water 10 minutes (min) prior to the start of the MMTT on Day 1 of Periods 1 and 2. Periods 1 and 2 will be separated by 7 to 21 days.
1880367|NCT01173562|Drug|Mebendazole|Type= exact number, unit= mg, number= 500, form= chewable tablet, route= oral use. One mebendazole 500-mg chewable tablet taken on Day 1.
1880368|NCT01173588|Other|yogurt added with bifidobacteria and soluble fiber (YBF)|Yogurt in YBF was added with 1.5 g inulin/100 g and ≥5 x 107 CFU of bifidobacterium/mL
1880369|NCT01173601|Drug|LY2216684|Taken by mouth once daily
1880370|NCT01173601|Drug|Placebo|Taken by mouth once daily for 11 weeks
1880371|NCT01173627|Drug|Test fentanyl citrate 400 mcg troche|Test fentanyl citrate 400 mcg troche administered as a single dose under fasted conditions
1880372|NCT01173627|Drug|Actiq 400 mcg|Actiq 400 mcg administered as a single dose under fasted conditions
1880376|NCT01173653|Other|Smoking Cessation|Randomly introducing patients to a Department of Health program to help them quit smoking.
1880377|NCT01173653|Other|Smoking Cessation|A simple intervention where ED patients who were motivated to quit smoking were put in direct phone contact with a trained smoking cessation counselor during their ED stay.
1880378|NCT01173666|Procedure|stenting angioplasty plus medical therapy|Patients will be treated by stenting angioplasty of renal artery plus medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according to clinical indications.
1880379|NCT01173666|Drug|Medical therapy|Patients will be treated by standard medical therapy. Medical therapy is based on antihypertensive, statin or antiplatelet drugs according with clinical indications.
1880380|NCT01173679|Drug|dasatinib|Taken orally once a day on days 1-14 of each 28-day cycle
1880381|NCT01173679|Drug|Rituximab|Given intravenously, 375 mg/m2 each cycle (dose split, given on Days 3+4 of cycle 1, variable after that).
1880382|NCT01173679|Drug|fludarabine|Given intravenously, 25 mg/m2/day, for 3 doses per cycle (Days 3-5 in cycle 1, Days 1-3 after that)
1880383|NCT01173692|Drug|Minocycline|100 mg twice daily (200 mg) by mouth , every day for 7 weeks starting first day of radiation therapy.
1880384|NCT01173692|Drug|Placebo|Twice daily by mouth, every day for 7 weeks starting at first day of radiation therapy.
1880385|NCT01173718|Device|GORE® ACUSEAL Vascular Graft|Surgical implantation of the GORE® ACUSEAL Vascular Graft for Hemodialysis per the Investigator's standard of practice.
1880386|NCT01173731|Drug|AFQ056|
1880387|NCT01173744|Device|Gamma-3 Nail|Gamma-3 Nail (stryker)
1880388|NCT01173744|Device|DHS|DHS (Zimmer)
1880389|NCT01173757|Drug|PF-04995274|Single dose of up to 5 mg PF-04995274, delivered in solution on study day 1
1880390|NCT01173770|Drug|ADC3680B|Escalating single doses ADC3680B or Placebo over 5 study periods
1880391|NCT01173770|Drug|ADC3680B|ADC3680B or Placebo for 7 days
1880392|NCT01173770|Drug|ADC3680B|Single doses ADC3680B over 2 study periods under fasted and fed conditions
1880394|NCT01173796|Procedure|catheter ablation|cardioversion and repeat isolation of pulmonary veins (PV) with ablation of additional triggers
1880395|NCT01173809|Drug|Amiodarone|Patient will continue taking Amiodarone before, during and after ablation (8 weeks post-ablation).
1880396|NCT01173809|Drug|Amiodarone|Amiodarone therapy will be stopped at least 5-months before ablation procedure and ablation will be performed off Amiodarone. Patients will not take Amiodarone during the blanking period (8 weeks post-ablation).
1880397|NCT01173822|Other|Ultrafiltration of residual blood|The inflow line to the hemoconcentrator was connected to the sideport of the arterial filter stopcock, allowing the residual blood in the CPB circuit to be processed through the hemoconcentrator. The outflow line from the hemoconcentrator was connected to a second three way stopcock located on the cardiotomy reservoir. Blood was circulated from the venous reservoir through the hemoconcentrator and returned to the venous reservoir until the desired hematocrit was achieved. The blood was then diverted to a transfer pack until all the blood from the venous reservoir, heat exchanger, and membrane oxygenator had been filtered and hemoconcentrated. This transfer pack was given to the anesthetist for reinfusion into the patient.
1880398|NCT01173835|Behavioral|Incentives for being tobacco free|Students who join the program will be entered into regularly scheduled drawings throughout the school year to earn incentives for being tobacco free.
1880399|NCT01173848|Drug|Ergocalciferol|1.25mg weekly for 12 weeks then once a month for 3 months. or 1.25 weekly for 4 weeks then once a month for 5 months. or 1.25 monthly for 6 months
1880400|NCT01173848|Drug|Cholecalciferol|1.25 weekly for 12 weeks then monthly for 3 months or 1.25 weekly for 4 weeks then monthly for 5 months or 1.25 monthly for 6 months
1880401|NCT01173861|Behavioral|Physical activity counseling|20-30 minutes of face-to-face physical activity counseling using motivational interviewing followed by 3 20 minute telephone counseling sessions.
1880402|NCT01173874|Drug|Cognitive Remediation|Cognitive remediation intervention will be administered in small group settings twice weekly for 30 sessions and will utilize computerized and verbal group training exercises to address basic skills such as auditory processing, attention, processing speed, and verbal working memory and learning, as well as intermediate and complex skills such as deductive reasoning, planning and sequencing, set shifting, and complex problem solving.
1880403|NCT01173887|Drug|VCAP/AMP/VECP(mLSG15)|VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
1880404|NCT01173887|Biological|KW-0761|VCAP/AMP/VECP(mLSG15) + KW-0761
1880405|NCT01173900|Biological|Gardasil® HPV vaccine|0.5 ml given at 0, 2, 6 months
1880406|NCT01173913|Drug|ModraDoc001 10mg capsules|Bi-daily administration. One cycle will last 7 days
1880407|NCT01173913|Drug|ModraDoc003 10mg tablets and ModraDoc004 10/50 mg|The patients will receive 40 mg docetaxel and 200 mg ritonavir once daily as different dosage forms (ModraDoc001 10 mg capsules, ModraDoc003 10 mg tablets and ModraDoc004 10/50 mg tablets). Patients continue in Week 4 with 80 mg docetaxel (as ModraDoc001 10 mg capsules) in combination with 100 mg ritonavir once daily in a weekly schedule until progressive disease or adverse events, which require dose modifications or discontinuation of therapy, are observed.
1880408|NCT01173913|Drug|ModraDoc006 10 mg tablet|Bi-daily administration. One cycle will last 7 days
1880409|NCT01173926|Drug|insulin degludec|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
1880410|NCT01173926|Drug|insulin degludec/insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
1880411|NCT01173926|Drug|insulin aspart|Each trial participant will receive one single dose of each trial product in varying order (NN5401, NN1250 and insulin aspart) on 3 separate dosing visits. The trial products will be administered subcutaneously (under the skin).
1880412|NCT01173939|Drug|Pravastatin|5 mg/day or 10 mg/day of pravastatin will be administered orally for 36 months, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of <120 mg/dL (JASGL 2007 target level) as quickly as possible. (Maximum dose increase of pravastatin: 20 mg/day)
1880413|NCT01173939|Drug|Rosuvastatin|5 mg/day or 10 mg/day of rosuvastatin will be administered orally for 36 months based on the LDL-C level of the subject, with a follow-up period of one month. If the target LDL-C level is not attained after one month of treatment, the steps will be taken to reduce the LDL-C to the target level of <70 mg/dL as quickly as possible. (Maximum dose increase to rosuvastatin: 20 mg/day)
1880414|NCT01173965|Device|MEA|Microwave endometrial ablation device
1880415|NCT01173965|Device|Novasure|Bipolar impedence control system
1880416|NCT01173978|Behavioral|Steroid hormone|Steroid hormone: 37,5 mg of prednisolone; High energy diet: 130 % of recommended daily energy intake; Relative physical inactivity: no exercise and at least 8 hours of rest/day
1880417|NCT01173978|Other|No intervention|
1880418|NCT01173991|Behavioral|Carbohydrate counting training|Carbohydrate counting was taught during 4-5 individual sessions with a dietician and a diabetologist.
1880419|NCT01174004|Drug|pimavanserin tartrate|pimavanserin tartrate, 40 mg, tablet, once daily by mouth for 6 weeks
1880420|NCT01174004|Drug|placebo|placebo, tablet, once daily by mouth for 6 weeks
1880421|NCT01174017|Radiation|Iodine 125 standard loose brachytherapy seeds|radioactivity 0.4 U per seed, prescribed dose 144 Gy
1880422|NCT01174017|Radiation|AnchorSeed Iodine 125 brachytherapy prostate implant|activity 0.4 U per seed, prescribed dose 144 Gy
1880423|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.5% QD
1880424|NCT01174030|Drug|Vehicle Gel|Vehicle Gel QD
1880425|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% QD
1880426|NCT01174030|Drug|CD07805/47 Gel|CD07805/47 Gel 0.18% BID
1880427|NCT01174030|Drug|Vehicle Gel|Vehicle Gel BID
1880428|NCT01174043|Drug|Erlotinib|Erlotinib will be administered orally at 150 mg once a day, continuously. Each cycle will be 28 days and there will be no break between the cycles.
1880429|NCT01174056|Drug|Zileuton|600 mg tablets po QID for 5 days prior to endotoxin, stopping 24 hours after endotoxin instillation
1880430|NCT01174056|Drug|Pioglitazone placebo|Lactose filled gelatin capsule, size 00, 1 tablet po bid x 2 weeks prior to endotoxin instillation until 24 hours after endotoxin.
1880431|NCT01174056|Drug|Zileuton placebo|Placebo tablets provided by manufacturer of Zyflo CR (Cornerstone Therapeutics), 2 tablets po bid x 5 days prior to endotoxin instillation until 24 hours after endotoxin.
1880432|NCT01174056|Drug|Pioglitazone|PPAR-gamma agonist
1880433|NCT01174069|Procedure|NOTES assisted laparoscopic cholecystectomy|Surgical removal of the gallbladder using endoscopic instruments.
1880434|NCT01174082|Biological|KLH Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to lymphocyte collection.
Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
1880435|NCT01174082|Biological|KLH-id Vaccine|"Donor: 0.5 cc subcutaneously, 3 times on weeks -8, -6 and -2 prior to donor lymphocyte collection.
Patient: 0.5 cc subcutaneously, 3 times immediately after infusion of donor cells (DLI), and again 4 and 8 weeks post DLI."
1880436|NCT01174082|Drug|GM-CSF|250 mcg/m2 subcutaneously daily for 4 days after each vaccine
1880437|NCT01174082|Procedure|Apheresis|Day 0 (day of lymphocyte collection) donors undergo a steady state pheresis to obtain lymphocytes.
1880438|NCT01174082|Procedure|Donor Lymphocyte Infusion (DLI)|Day 0, infusion to patient of collected donor cells.
1880446|NCT01174134|Other|Nutritional beverage|
1880447|NCT01174160|Drug|vernakalant hydrochloride|Patients will receive a 3 mg/kg infusion of vernakalant hydrochloride. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of 2 mg/kg vernakalant hydrochloride will be administered.
1880448|NCT01174160|Drug|Placebo to vernakalent hydrochloride|Patients will receive an infusion of placebo. If the patient is in atrial fibrillation (AF) or atrial flutter (AFL) 25 minutes after the start of the infusion, then a second infusion of placebo will be administered.
1880449|NCT01174173|Drug|Ranolazine|ranolazine 1000 mg PO BID for 3 months
1880450|NCT01174186|Drug|Adalimumab|Tumor Necrosis Factor (TNF) alpha inhibitor given 40 mg subcutaneously every other week except the first time where 80 mg is given
1880451|NCT01174199|Drug|vorinostat|Given orally
1880452|NCT01174199|Drug|temsirolimus|Given IV
1880453|NCT01174199|Other|laboratory biomarker analysis|Correlative study
1880454|NCT01174199|Procedure|positron emission tomography/computed tomography|PET scan
1880455|NCT01174212|Procedure|Prophylactic Antibiotics|Preoperative Antibiotics
1880456|NCT01174212|Procedure|Control Antibiotics|Antibiotics will be held until intraoperative cultures have been obtained.
1880457|NCT01174225|Device|Flexi T 380(+) IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
1880458|NCT01174225|Device|Nova T IUD|The intrauterine device is placed in the uterus immediately post-abortion. Participant is counseled that she may leave the device in for up to five years.
1880459|NCT01174238|Drug|Axitinib|5mg BID Axitinib Days 1-14 for dual therapy - 5mg BID QD for patients on monotherapy
1880460|NCT01174238|Drug|Carboplatin|Day 1 of each 21 day cycle in combination with paclitaxel if patients are in dual therapy phase
1880461|NCT01174238|Drug|Paclitaxel|Day 1 of each 21 Day cycle in combination with Carboplatin if patients on on dual therapy phase.
1880462|NCT01174264|Other|Pharmacological Study|Correlative studies
1880463|NCT01174264|Drug|Vismodegib|Given PO
1880464|NCT01174277|Other|Collection of blood sample|Participation involves collection of blood sample at baseline, 2, 4, 6 and 12 months regardless of whether or not patients continue on treatment.
1880465|NCT01174290|Drug|Haloperidol decanoate|"IV q6h.
Study drug will be continued until one of the following study withdrawal/termination criteria is met:
Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.
The patient is discharged from the ICU at Tufts MC.
10 days of study drug administration occurs.
The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
1880466|NCT01174290|Drug|Placebo|"D5W 0.2mL IV q6h
Study drug will be continued until one of the following study withdrawal/termination criteria is met:
Delirium (ICDSC ≥ 4) develops. The diagnosis of delirium will be confirmed in all instances by the Psychiatric Consultation Service, Division of Psychiatry, Tufts Medical Center using DSM-IV criteria.
The patient is discharged from the ICU at Tufts MC.
10 days of study drug administration occurs.
The subject experiences an adverse event potentially attributable to the study drug that is deemed, in the opinion of one of the physicians on the study team or the MICU team, to warrant discontinuation of therapy."
1880467|NCT01174303|Drug|insulin degludec/insulin aspart|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
1880468|NCT01174303|Drug|biphasic insulin aspart 30|Each subject will be randomly allocated to two single doses injected subcutaneously (under the skin) of insulin degludec/insulin aspart and biphasic insulin aspart 30 in random order.
1880507|NCT01174667|Procedure|Specific massage for fascial release|Patient will receive a 3 minute massage to reduce restrictions in the lumbodorsal fascia.
1880508|NCT01174667|Other|Quiet non-instructed rest for 3 minutes|Patient will lay quietly without any instructions on how to relax.
1880469|NCT01174316|Device|AutoVPAP™|Automatically titrated non-invasive ventilator, with target gross alveolar ventilation, end expiratory positive pressure, and back up respiratory rate determined by the clinician based on height and weight. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
1880470|NCT01174316|Device|VPAPIIIST-A™|Standard non-invasive ventilator, with inspiratory and expiratory positive pressure determined by the healthcare professional. The NIV must be used for as many hours as possible over the 24 hour period but breaks for meals, physiotherapy and bathroom are allowed.
1880471|NCT01174329|Device|"Automatic neuro-electrostimulation by Saliwell Crown"|"Continuous stimulation of the lingual nerve by Saliwell Crown"
1880472|NCT01174329|Device|"Patient-regulated neuro-electrostimulation by Saliwell Crown"|"On-demand stimulation of the lingual nerveby Saliwell Crown"
1880473|NCT01174355|Drug|ND0801|Confidential
1880474|NCT01174368|Biological|Cancer Macrobead placement in abdominal cavity|8 macrobeads per kilogram
1880475|NCT01174381|Behavioral|lifestyle modification|Lifestyle modification for six months
1880476|NCT01174394|Procedure|DCEAS (Hwato®/ Dongbang®)|Upon insertion of acupuncture needles, dense cranial electro-acupuncture stimulation (DCEAS), is directly delivered on a density of cranial acupoints (in general 6-8 pairs) located on the frontal, parietal, and temporal scalp areas.
1880477|NCT01174394|Procedure|Body electro-acupuncture (Hwato®/ Dongbang®)|Both study arms received body electroacupuncture on both sides of ipsilateral limb pairs: Hegu (LI4) and Quchi (LI11) , Zusanli (ST36) and Taichong (LR3). Electrical stimulation as DCEAS is applied.
1880478|NCT01174394|Procedure|n-CEA (Strietberger®)|Streitberger's non-invasive acupuncture needles were applied to serve as sham control at the same cranial acupoints and the same stimulation modality, except that the needles only adhere to the skin instead of insertion
1880479|NCT01174394|Drug|Fluoxetine|Subjects of both study arms received orally administered SSRIs for 4 weeks in an open manner. For those who were currently under antidepressant treatment, they would continue the existing treatment regimens. For those who were not medicated at the time of trial, fluoxetine (FLX) was given at an initiate dose of 10 mg/day and escalated to an optimal dose within one week, based on individual response, but the maximum dose was set at 40 mg/day.
1880480|NCT01174407|Other|cd 35, cd21, cd55|Blood drawing/ 10ml/ once- duration of 1 day of full examination of the patient
1880481|NCT01174420|Device|Use of ologen Collagen Matrix in trabeculectomy|After trabeculectomy, place ologen Collagen Matrix on the top of the scleral flap under the conjunctiva before suturing
1880482|NCT01174420|Drug|Use of Mitomycin-C in trabeculectomy|After creating a scleral flap, a sponge with Mitomycin-C (0.02%) is applied on the scleral surface for 3 minutes. Afterwards, Mitomycin-C was rinsed out with balanced salt solution.
1880483|NCT01174433|Device|Tryton|Percutaneous coronary intervention of a bifurcation lesion, with a Tryton bifurcation coronary stent for the side branch and a drug-eluting coronary stent for the main branch
1880484|NCT01174446|Biological|BAX 326|"Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX
Study Part 2: Open-label evaluation of prophylaxis and on-demand BAX326 only
Study Part 3: Open-label repeat of PK evaluation (repeat Study Part 1) with BAX326 only and same study participants as Study Part 1"
1880485|NCT01174446|Biological|BeneFIX|"Study Part 1: Pharmacokinetic (PK) Crossover with BAX326 and BeneFIX.
BeneFIX only used in Part 1 of this study.
Study Part 2 and 3 only utilized BAX326"
1880486|NCT01174472|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of the novel paclitaxel eluting balloons
1880487|NCT01174472|Device|Percutaneous Transluminal Angioplasty (PTA)|Angioplasty performed with the use of conventional angioplasty balloons
1880488|NCT01174485|Procedure|exercise|combined resistance and aerobic training
1880489|NCT01174498|Device|Cerbomed t-VNS® transcutaneous stimulation|Subjects experience a transcutaneous, electrical, vagal stimulation with the t-VNS device.
1880490|NCT01174498|Device|t-VNS Sham stimulation|t-VNS Sham stimulation
1880491|NCT01174511|Drug|A -1 Cool Cream,Vaselin ointment|A- 1 Cool Cream applied to flexural aspects of the upper and lower limb on the one site of patient and placebo (Vaseline ointment) applied to other site of the upper and lower limb in the itch patient. Applying the ointment will be a regular time, twice a day for 5 consecutive days
1880492|NCT01174524|Drug|gestoden 60 mcg|gestoden 60 mcg, once a day, administered in 24/4 regimen.
1880493|NCT01174524|Drug|ethinylestradiol 15 mcg|ethinylestradiol 15 mcg, once a day, administered in 24/4 regimen
1880494|NCT01174537|Biological|New Castle Disease Virus|Patients will receive IV 1*10^10 EID50 (50 percent Embryo Infectious Dose. One EID50 unit is the amount of virus that will infect 50 percent of inoculated eggs) on a daily basis for a minimum of 5 days a week until disease progression for a minimum duration of 1 year.
1880495|NCT01174550|Procedure|Coronary Angiography|Use of standard equipment for usual-care testing
1880496|NCT01174550|Procedure|Stress Echocardiogram|Use of standard equipment for usual-care testing
1880497|NCT01174550|Procedure|Nuclear Stress Test|Use of standard equipment for usual-care testing
1880498|NCT01174550|Procedure|Exercise Electrocardiogram|Use of standard equipment for usual-care testing
1880499|NCT01174563|Drug|erlotinib [Tarceva]|150 mg orally daily, with dose-reductions to 100 mg or 50 mg orally daily according to protocol
1880500|NCT01174576|Other|caffeinated and decaffeinated coffee|3 treatments on separate days, i.e. a standard breakfast with oral ingestion of 200 ml of either caffeinated coffee (3mg caffeine/kg body weight), decaffeinated coffee or water
1880501|NCT01174589|Other|Strength training|to compare if there is a difference between 6 or 12 weeks of physical strength training
1880502|NCT01174602|Behavioral|Exposure Therapy for AN (AN-EX/RP)|12 Sessions, 3 times per week. 90 minute sessions. Group therapy twice per week.
1880503|NCT01174602|Behavioral|Cognitive Remediation Therapy|12 Sessions, 3 times per week. 45 minute sessions. Group therapy twice per week.
1880504|NCT01174641|Other|trans-cranial magnetic stimulation|1 Hz trans-cranial magnetic stimulation will be applied for 20min at 60% motor threshold over the vertex
1880505|NCT01174641|Other|trans-cranial magnetic stimulation|trans-cranial magnetic stimulation will be applied at 1Hz for 20 min over the ipsilesional posterior parietal cortex of stroke patients with unilateral neglect
1880506|NCT01174654|Behavioral|Contingency management|A 12-week contingency management intervention
1880509|NCT01174680|Procedure|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
1880510|NCT01174693|Drug|Triflusal|Dose: 150mg or 300mg capsule, 300mg bid, Mode of administration: oral, Duration: from randomization to 31 December 2014
1880511|NCT01174693|Drug|Clopidogrel|Dose: 75mg tablet, 75mg once daily, Mode of administration: oral, Duration: from randomization to 31 December 2014
1880512|NCT01174706|Behavioral|Information prescriptions|One arm will receive usual care at discharge. The other three arms will receive practical assistance and/or an information prescription which will consist of written information from Medline Plus and access to a clinical informationist if subject has additional information needs.
1880513|NCT01174719|Drug|volume replacement|Hydroxyethylstarch up to 50mL/kg/24 hrs
1880514|NCT01174719|Drug|Humanalbumin 5%|Humanalbumin 5% up to 50 mL/kg/24 hours
1880515|NCT01174719|Drug|volume replacement|up 10 50mL/kg/24 hours
1880516|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, one inhalation
1880517|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 1 inhalation
1880518|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 120 mcg/inhalation, 2 inhalations
1880519|NCT01174732|Drug|albuterol inhalation powder|A006 albuterol inhalation powder, 180 mcg/inhalation, 2 inhalations
1880520|NCT01174732|Drug|Placebo|placebo, lactose inhalation carrier
1880521|NCT01174732|Drug|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 2 inhalations
1880522|NCT01174732|Drug|albuterol inhalation aerosol|albuterol inhalation aerosol, 90 mcg/inhalation, 4 inhalations
1880523|NCT01174784|Device|Chronic TOtAl OcclusioN CrossiNg with thE WildCat CatheTer|A Non-Randomized Study of the Avinger Wildcat™ used to Cross Chronic Total Occlusions in the Superficial Femoral and Popliteal Arteries
1880524|NCT01174810|Drug|Exenatide|Exenatide, 5 micrograms twice a day for 1 month and 10 micrograms twice a day for 11 months. Total duration of treatment 12 months
1880525|NCT01174823|Drug|bepotastine besilate ophthalmic solution|sterile ophthalmic solution
1880526|NCT01174823|Drug|placebo comparator ophthalmic solution|sterile ophthalmic solution
1880527|NCT01174836|Other|Educational session|Physicians will have a brief education session provided in powerpoint about the risks of CT
1880528|NCT01174849|Drug|Synflorix|The 10-valent vaccine contains 1 µg of purified capsular polysaccharide of pneumococcal serotypes 1, 5, 6B, 7F, 9V, 14, and 23F conjugated to protein D, 3 µg of serotype 4 conjugated to protein D, 3 µg of serotype 18C conjugated to tetanus toxoid and 3 µg of serotype 19F conjugated to diphtheria toxoid.
1880529|NCT01174849|Drug|Prevenar13|"The vaccine is a ready to use homogeneous white suspension for intramuscular injection, supplied as a pre-filled syringe.
Active ingredients
Each 0.5 mL dose contains:
2.2 μg of pneumococcal purified capsular polysaccharides for serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F and 23F 4.4 μg of pneumococcal purified capsular polysaccharides for serotype 6B. Each serotype is individually conjugated to non-toxic diphtheria CRM197 protein and adsorbed on aluminium phosphate (0.565 mg). CRM197 is a nontoxic variant of diphtheria toxin isolated from cultures of Corynebacterium diphtheriae strain C7 (β197) grown in a casamino acids and yeast extract-based medium."
1880530|NCT01174849|Drug|COMBO|COMBINATION SCHEDULE of vaccine 1 and vaccine 2: Synflorix (PHiD-CV) at 1,2,4 months then Prevenar13 (PCV13) at 6 months of age.
1880531|NCT01174888|Drug|midostaurin|Drug midostaurin, Given orally given twice daily days 1-14
1880532|NCT01174888|Drug|Bortezomib|Bortezomib given IV on days 1, 4, 8, and 11
1880533|NCT01174888|Drug|mitoxantrone hydrochloride|Patients receive mitoxantrone hydrochloride IV over 10 minutes
1880534|NCT01174888|Drug|etoposide|Patients receive etoposide IV over 1 hour
1880535|NCT01174888|Drug|cytarabine|Patients receive cytarabine IV over 6 hours on days 1-6
1880536|NCT01174914|Other|ARV's + Placebo|Patients continued ARV's plus a placebo nightly for 9 months
1880537|NCT01174914|Drug|Naltrexone|Naltrexone, Low-Dose (3mg) given once daily at bedtime for 9 months
1880538|NCT01174914|Drug|Naltrexone + ARV's|Patients were given standard ARV's plus Naltrexone (Low Dose) 3mg nightly.
1880539|NCT01174927|Drug|diacetylmorphine (DAM)|The heroin-dependent patients will administer either their individual dose of prescribed DAM dose or placebo (saline) through an indwelling intravenous line. Afterwards they will complete four experimental paradigms testing response inhibition, emotional processing and working memory while brain responses are measured with fMRI. Before and after the fMRI investigation cortisol samples, DAM blood levels, neurophysiological and psychological stress parameters, such as skin conductance, heart rate, anxiety, anger, and heroin craving will be measured.
1880540|NCT01174927|Other|Placebo|Saline
1880541|NCT01174940|Drug|extracorporeal photopheresis|"Patients will receive 2 ECP treatments prior to the commencement of the high dose chemotherapy and then for two consecutive days every two weeks starting from post engraftment (ANC > 500) up to day 90 (total of 10 treatments). This may be given as an outpatient procedure.
The dose of UVADEX® used to inoculate these cells will be calculated based on the treatment volume collected during the plasma/buffy coat collection process, using the following formula:
Treatment Volume in mL X 0.017 of UVADEX® (20 mcg/ml) required for administration into the recirculation bag = Amount of UVADEX® (in mLs) required for administration into the recirculation bag.
After the cells are inoculated with UVADEX®, the buffy coat/plasma suspension is irradiated with ultraviolet-A light and then re-infused back into the patient."
1880542|NCT01174953|Drug|finasteride|"Finasteride 5 mg once daily
Soy 4 capsules twice daily (160 mg total)"
1880543|NCT01174979|Drug|Caroverin|treatment with eardrops 2 times for 48 hours
1880544|NCT01174992|Biological|Evicel|EVICEL is a human plasma derived fibrin sealant
1880545|NCT01174992|Other|Sutures only|Standard of care
1880546|NCT01175018|Drug|Anakinra|Anakinra 100 mg s.c. daily for 14 days
1880547|NCT01175018|Drug|Placebo|0.67 ml of NaCl 0.9% solution given subcutaneously daily for 14 days
1880548|NCT01175031|Other|Manipulation of Positive Airway Pressure (PAP)|Positive airway pressure (PAP) will be manipulated throughout the night to induce breathing events. PAP will be set to the participant's prescribed pressure, increased until breathing events are induced , and then returned to the prescribed pressure. This cyclic pattern will continue throughout the night.
1880549|NCT01181362|Procedure|Endoscopy|All patients will meet the physician at the Head and Neck centre at PMH, where they will have a topical anesthetic (lidocaine endotracheal aerosol, 10 mg/dose) sprayed into both nostrils. After allowing 5-10 minutes to let the anesthetic take effect, they will have an endoscopy procedure using a flexible scope inserted through the nostrils. The procedure will first be performed while patients are sitting up. During the procedure, patients will be asked to rate their discomfort on a 10-point scale. The endoscope will then be removed. After a short rest (15 minutes), the endoscopy procedure will be repeated with patients lying down. They will again be asked to rate their level of discomfort. After another short rest for recovery, they will meet with the physician to discuss both endoscopic procedures and to complete a questionnaire on discomfort, tolerance and acceptability
1880550|NCT01181375|Other|Tumour Biopsies and Blood Sampling|Patients who consent to the tissue part of this study will have Biopsies taken for study purposes at the same time as their routine tumour biopsies . In addition,those who consent to the blood sampling part of the study will have their samples taken assess serum biomarkers of tumour oxygenation.
1880551|NCT01181388|Procedure|administration of tirofiban by thrombus aspiration catheter in infarct-related artery|a bolus of 10ug/kg tirofiban administration via thrombus aspiration catheter followed by 0.1ug/kg/min for 12 hours after PCI
1880552|NCT01181388|Procedure|administration of tirofiban by guide catheter|a bolus of 10ug/kg tirofiban administration via guide catheter followed by 0.1ug/kg/min for 12 hours after PCI
1880553|NCT01181401|Drug|TPF induction chemotherapy|Docetaxel 75 mg/m2 d 1 Cis-platinum 75 mg/m2 d 1 5-FU 750 mg/m2/d c.i. d 1-4 Cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
1880554|NCT01181401|Drug|TPF experimental|Docetaxel 40 mg/m2 d 1+8 Cis-platinum 40 mg/m2 d 1+8 5-FU 1500 mg/m2/24h c.i. d 1+8 every 21 day for 3 cycles 2. Antibody therapy with: cetuximab loading dose of 400 mg/m2 1 week prior to RTX, and 250 mg/m2 weekly x 6 concurrent to RTX
1880555|NCT01181401|Radiation|Standard Radiochemotherapy (HART)|Hyperfractionated accelerated radiotherapy with concurrent Cisplatin and 5-Fluorouracil chemotherapy
1880556|NCT01181414|Procedure|Atrio ventricular junction ablation with radio-frequency|Atrioventricular junction ablation by using radiofrequency energy.
1880557|NCT01181414|Drug|Beta blocker/digoxine/amiodarone|Ventricular rate control by using drug treatment.
1880558|NCT01181427|Drug|ABT-267|See arm description
1880559|NCT01181427|Drug|Placebo|See arms description
1880560|NCT01181427|Procedure|Blood Sample Collection|See arm description
1880561|NCT01181427|Drug|Cytochrome P450 inhibitor|See arm description
1880562|NCT01181440|Device|Dermagraft(R)|Weekly application of Dermagraft(R) with conventional care
1880563|NCT01181440|Other|Conventional care|Weekly application of conventional care
1880564|NCT01181453|Device|Dermagraft|Weekly application of Dermagraft(R) with standard care
1880565|NCT01181453|Other|Comparator|Weekly application of standard care
1880566|NCT01181466|Device|AeriSeal System|The AeriSeal System will be Administered at 3 to 4 Pulmonary Subsegments During a Single Treatment session.
1880569|NCT01181505|Drug|Tolterodine|
1880570|NCT01181531|Drug|Traditional Vitamin D Therapy|Traditional vitamin D therapy (eg, calcitriol, paricalcitol, alfacalcidol, doxercalciferol), to manage secondary hyperparathyroidism (SHPT) in this study will be administered according to strategies that have been used in clinical practice and that conform to current therapeutic recommendations and available clinical practice guidelines and product labeling.
1880571|NCT01181531|Drug|Cinacalcet|Subjects randomized to treatment with cinacalcet will receive an initial oral dose of 30 mg once daily. Doses will be titrated incrementally to 60, 90,120, and 180 mg per day based upon periodic measurements of serum calcium and plasma PTH levels. Cinacalcet is formulated as light green tablets in 30, 60, and 90 mg free-based equivalents. Tablets will be 30, 60, and 90 mg, graduated in size, smallest to largest. Combinations of these 3 fixed dosage formulations will be used to achieve the 120 and 180 mg daily doses.
1880572|NCT01181544|Procedure|Heparin dose titration|Patients will begin the study using their currently prescribed heparin doses - both bolus and constant infusion - for three treatments to establish a baseline and provide information on inter-treatment variability in dialyzer clotting. Subsequently, the bolus and infusion rates will be titrated either upward or downward based on the Robbins-Monro process and an evaluation of dialyzer clotting during the preceding treatment. Heparin doses will be adjusted for a total of 30 dialyses.
1880573|NCT01181570|Drug|Adalimumab|Patients receive adalimumab 80 mg followed by 40 mg at week 1 and 40 mg every other week (EOW) thereafter.
1880574|NCT01181570|Drug|Placebo|Patients will receive 2 injections of placebo at week 0, one injection at week 1 and one injection every other week (EOW) thereafter.
1880575|NCT01181583|Behavioral|Tailored Internet-delivered CBT|"This intervention contains 8-10 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
1880576|NCT01181583|Behavioral|Non-tailored Internet-delivered CBT|Specific text-based self-help for depression, which has previously been tested in three previous randomized trials. Anxiety symptoms will not be covered, but insomnia is included as a module together with advice on health.
1880577|NCT01181583|Behavioral|Online discussion group|Participants take part of an online discussion group which are monitored daily. New discussion topics on depression are introduced every week.
1880579|NCT01181609|Drug|bevacizumab [Avastin]|5 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks according to the chemotherapy regimen
1880580|NCT01181622|Drug|denufosol tetrasodium Inhalation Solution|60 mg by oral inhalation three times daily
1880581|NCT01181622|Drug|0.9% w/v sodium chloride solution|0.9% w/v sodium chloride solution by oral inhalation three times daily
1880582|NCT01181635|Behavioral|Psychotherapy|Standard psychotherapy for psychiatric disorders.
1880617|NCT01182389|Other|Conventional Therapy|Review of ICD programming to ensure that detection and therapy will occur appropriately
1880583|NCT01181648|Behavioral|questionnaire and semi-structured interviews|Survivors will be asked to complete a brief, self-administered, paper-based survey to assess quality of life, mental health and employment status following completion of therapy. Second, in a subset of 20 survivors of HPV+ oropharynx cancer, we will conduct in-depth, semi-structured, face-to-face interviews addressing the psychosocial impact of the HPV diagnosis. A follow up letter will be sent to participants who do not return their completed study questionnaires.
1880584|NCT01181661|Behavioral|Full Group Contingency|This group (n = 20) will earn vouchers based only on team (n = 4) performance. Only if all members of the team submit a negative sample (CO ≤ 4 ppm), will they each earn a voucher.
1880585|NCT01181661|Behavioral|Mixed Group Contingency|This group (n = 20) will earn vouchers based on both individual and team (n = 4) performance. If an individual submits a negative sample (CO ≤ 4 ppm), s/he will earn a voucher. Additionally, bonus vouchers will be earned if all team members submit negative samples.
1880586|NCT01181674|Drug|insulin glargine|sc injection
1880587|NCT01181674|Drug|metformin|oral administration
1880588|NCT01181674|Drug|acarbose|oral administration
1880589|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
1880590|NCT01181674|Drug|insulin glargine|sc injection
1880591|NCT01181674|Drug|metformin|oral administration
1880592|NCT01181674|Drug|acarbose|oral administration
1880593|NCT01181674|Behavioral|lifestyle therapy|diet and exercise
1880594|NCT01181674|Other|Standard glycemic care|as informed by the current clinical practice guidelines
1880595|NCT01182194|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
1880596|NCT01182194|Drug|YAZ®|3 mg/0.02 mg Tablets
1880597|NCT01182207|Drug|Drospirenone/Ethinyl Estradiol (Gianvi®)|3 mg/0.02 mg Tablets
1880598|NCT01182207|Drug|YAZ®|3 mg/0.02 mg Tablets
1880599|NCT01182233|Radiation|Total Skeletal Irradiation|Escalating doses of TSI starting at 200cGy (escalating up to 400cGy unless maximum tolerated dose is determined in lower dose level) in cohort 1 over 5 days followed by high dose melphalan and cytoprotection followed by autologous hematopoietic stem cell transplant
1880600|NCT01182246|Drug|AXP107-11|"The drug substance, AXP107-11, is a crystalline form of genistein, a substance shown in literature data to target pancreatic tumor cells and also the tumor microenvironment and thus sensitizes tumors to chemotherapy. AXP107-11 is formulated in a capsule containing 2x100 mg of active substance.
A maximum of four cohorts of three to six patients each will be treated with escalating dose levels of AXP107-11 alone (two weeks) and in combination with gemcitabine (one week).
AXP107-11 capsules will be ingested orally twice daily (morning and evening) each day of the treatment period. In phase Ib, AXP107-11 will be administered once daily on the first treatment day (morning), followed by twice daily administrations continuously throughout the treatment period. When a minimum of six patients have been treated and evaluated on the maintenance dose (phase 1b), additional patients will be included directly into phase IIa."
1880601|NCT01182272|Drug|sorafenib tosylate|
1880602|NCT01182272|Other|laboratory biomarker analysis|
1880603|NCT01182272|Procedure|neoadjuvant therapy|
1880604|NCT01182272|Procedure|therapeutic conventional surgery|
1880605|NCT01182285|Drug|Valproic Acid|"Week 1:
(Days 1-3): Valproic acid - 500 mg every evening (Day 4-7): Valproic acid - 500 mg twice daily (morning and evening) Weeks 2 through 10: Valproic acid 500 mg every morning and 1000 mg every evening"
1880606|NCT01182285|Drug|Liothyronine Sodium|Patients who exhibit an increased radioiodine uptake on Thyrogen scan post valproic acid therapy at week 10. Begin Cytomel for 4 weeks (25 micrograms twice a day)
1880607|NCT01182337|Drug|Intradiscal rhGDF-5|The API is recombinant human growth and differentiation factor-5 (rhGDF-5), a recombinant version of human GDF-5. GDF-5 is a member of the transforming growth factor-b (TGF-b) superfamily and the bone morphogenetic protein (BMP) subfamily, and is known to influence the growth and differentiation of various tissues, including the intervertebral disc. In vitro experiments have shown that rhGDF-5 can stimulate gene expression and synthesis of the extracellular matrix proteins type II collagen and aggrecan. In vivo experiments in rabbit models of disc degeneration have shown that intradiscal injections of rhGDF-5 can stimulate an increase in disc height and hydration.
1880608|NCT01182337|Drug|Vehicle control|Excipients in Intradiscal rhGDF-5, to include Trehalose, Glycine, HCl, and Water for Injection
1880609|NCT01182350|Drug|Bevacizumab|• Bevacizumab, 10 mg/kg IV, will be given at least three weeks from the biopsy and at least two weeks after start of the radiation therapy and then every 14 +/- 3 days concurrently with radiation therapy, during the interim period, and for up to 10 maintenance cycles.
1880610|NCT01182350|Drug|Erlotinib|• The erlotinib dose will be 85 mg/m2/day given continuously during irradiation. Patients will then continue erlotinib at 85 mg/m2/day beginning immediately after completion of radiation therapy through the interim period, and to complete 10 cycles of maintenance therapy
1880611|NCT01182350|Drug|Temozolomide|• The temozolomide dose will be 90 mg/m2/day given continuously during irradiation and then 200mg/m2/day for five days every 28 +/- 5 days to begin approximately 4 weeks after completion of the radiation therapy and to continue for 10 maintenance cycles.
1880612|NCT01182350|Radiation|Irradiation|All patients will receive local radiotherapy(for approximately 7 weeks) to consist of 59.4Gy delivered using conventional conformal or other standard treatment planning with adjuvant bevacizumab
1880613|NCT01182363|Behavioral|Project Solve Education|Problem solving education (PSE), a brief skills-building psychotherapeutic intervention that focuses on specific daily problems, and applies to these problems a structured approach to finding and evaluating solutions, is one such problem solving approach. Problem solving education differs from other problem solving interventions in that it can be conducted by a variety of health providers, who do not have specific training as mental health clinicians. Sessions are fairly brief (approximately 30 minutes in length) and positive, sustained effects have been achieved in 6-8 sessions. Problem solving education's success is based on premise that strong problem solving abilities promote a sense of control and self-efficacy and buffer the negative effects of life stressors.
1880614|NCT01182376|Drug|dronedarone|Dronedarone will be prescribed by the patient's team according to established guidelines.
1880615|NCT01182376|Drug|Placebo|Placebo will be administered by the patient's team according to established guidelines.
1880616|NCT01182389|Procedure|Robotic VT Ablation|Robotic VT Ablation
1880645|NCT01182636|Drug|Differin®|0.1% Topical Gel
1880618|NCT01182402|Device|Compliance monitoring with electronic device|Patients get all their unsupervised substitution medication doses in electronic monitoring devices during the study. Daily dose of the drug is possible to get from the device in given time points and in the meantime device is locked.
1880619|NCT01182415|Procedure|High-dose chemotherapy with autologous stem cell transplant|High-dose chemotherapy with rituximab, thiotepa, busulfan, and cyclosphosphamide followed by autologous stem cell transplant
1880620|NCT01182428|Device|XIENCE V®/ XIENCE PRIME™|Coronary artery placement of a XIENCE V®/ XIENCE PRIME™ Everolimus Eluting Stent System
1880621|NCT01182428|Device|CYPHER SELECT|XIENCE V® / XIENCE PRIME™ to CYPHER SELECT in female patients with de novo coronary artery lesions
1995125|NCT02844660|Biological|EpiCord|Weekly application of EpiCord and standard of care (moist wound therapy and offloading)
1995126|NCT02844660|Other|Standard of Care|moist wound therapy and offloading
1880624|NCT01182467|Radiation|PET-CT scan|PET-CT scan performed at baseline to determine SUV-max
1880625|NCT01182480|Behavioral|Patient Relationship Management (PRM) Program|"Patients will be contacted through SMS text messaging under the following circumstances:
7 days, 2 days, and 1 day before scheduled appointments. Messages will contain the date, time, and location where the appointment is scheduled. Patients will be prompted to respond with 'YES' if they are able to keep their appointment, and 'NO' if they need to reschedule. An acknowledgement of receipt will be sent in response to all patient-initiated messages.
3 days per week to request that patients respond with fasting blood sugar measurements. An acknowledgement of receipt will be sent in response to all patient-initiated messages."
1880626|NCT01182493|Device|Insulin Pump (Medtronic Minimed Paradigm® VEO)|The pump delivers insulin as specified by the patient
1880627|NCT01182506|Behavioral|Cogmed Working Memory Training Program|"Women will be randomized to one of two 5-week rehabilitation software training programs that train working memory called Cogmed Working Memory Training Program.
The training software will be provided to each participant. For each group, training occurs for 30 minutes a day, 5 days a week for 5 weeks. As part of the set-up, training data is uploaded to the internet at a minimum of every 3 days. This function allows the coach (in this case, the PI and RSA) to review the training. A weekly coach phone call is made to review the training results, answer questions, troubleshoot, and motivate the participant. Participants can load the software onto multiple computers to provide flexibility for them to do training at home, after work, when they are away from home."
1880628|NCT01182519|Behavioral|questionnaire, blood draw and urine sample|Patients will be asked to participate on a single day. After study registration they will be asked to complete the questionnaire. All participants will complete a questionnaire detailing tobacco and NSAID exposure, as well as detailing any other inflammatory conditions of the lung. Then the patient will give a single blood sample (up to 3 tubes) and a single urine sample.
1880629|NCT01182532|Other|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.
Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;
Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
1880630|NCT01182532|Drug|TCM Syndrome Differentiation and Treatment|"Lung-Spleen Damp-Heat Syndrome Symptoms: Fever, maculopapule and herpes on hand, foot and buttock; herpes on oral mucous membrane; redness in throat, salivation, tiredness, faint red tongue or reddish tongue, greasy fur, speedy pulse, red and purple fingerprint.
Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Lonicera japonica Thunb (Jin Yin Hua), Scutellaria baicalensis Georgi (Huang Qin), etc.
Dosage: Adjusting by age and weight of patients. Decoction.
Dampness-Heat Retention Syndrome Symptoms: High fever, dirty color of tetter, tiredness, oral ulcer, reddish tongue or deep red tongue, little saliva, yellow and greasy fur, fine and rapid pulse, deep purple fingerprint.
Formula: Forsythia suspensa (Thunb.) vahl.(Lian Qiao), Gardenia jasminoides Ellis (rough Zhi Zi), Scutellaria baicalensis Georgi (Huang Qin), etc.
Dosage: Adjusting by age and weight of patients. Decoction."
1880631|NCT01182532|Other|Western therapy plus TCM treatment|"Symptomatic treatment using the same treatment methods in western therapy group;
Syndrome differentiation and treatment adopting the same methods in TCM treatment group."
1880632|NCT01182545|Procedure|Ventilation|Mechanical ventilation was conducted in all the patients with a Datex-Ohmeda Aestiva/5 Smart Ventilator (Madison, WI) through a rebreathing circuit incorporating a CO2 absorber, a heat and moisture exchanger using volume-controlled mode with an inspiratory to expiratory ratio of 1:2.5, and positive end-expiratory pressure (PEEP) of 5 cm H2O. Plateau pressure was kept as low as possible with an upper limit of 30 cm H2O, and the absence of auto-PEEP was ensured by a drop of the expiratory flow to zero on the flow-time curve.
1880633|NCT01182558|Other|Hypothenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
1880634|NCT01182558|Other|Thenar muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
1880635|NCT01182558|Other|EDB muscle activation--maximum, voluntary, isometric|"Each subject will perform maximum, voluntary, isometric muscle activation (of the target muscle) for each of various durations (single brief muscle twitch, 2 seconds, 5 seconds, 10 seconds, and 20 seconds [two epochs of 10 seconds of muscle activation with 1-2 seconds of rest between the two epochs])."
1880636|NCT01182558|Other|Relaxation of muscle|The muscle on the opposite side will be maintained at rest.
1880637|NCT01182597|Drug|Pantoprazole (Pantoloc)|Pantoprazole (Pantoloc) 3.3mg/hr for 72hrs
1880638|NCT01182597|Drug|Lansoprazole (Takepron OD)|Lansoprazole (Takepron OD) 30mg q12h PO
1880639|NCT01182610|Drug|Panitumumab|Panitumumab 9mg/kg on Days 1, 22, and 43
1880640|NCT01182610|Drug|Paclitaxel|Paclitaxel 200mg/m2 on Days 1 and 22
1880641|NCT01182610|Drug|Carboplatin|Carboplatin AUC=6 on Days 1 and 22
1880642|NCT01182610|Drug|5FU|5FU 225mg/m2/day on Days 1-15 and 22-36
1880643|NCT01182623|Other|Observation of surface patterns of polyps|examination of the surface patterns of polyps using FICE and indigo carmine dye spray
1880644|NCT01182636|Drug|Adapalene|0.1% Topical Gel
1880647|NCT01182649|Device|coronary stent|coronary angioplasty with stent implantation
1880648|NCT01182649|Device|stent|coronary angioplasty with stent implantation
1880649|NCT01182662|Other|Human umbilical cord-derived MSCs and cyclosporin A|1.0E+6 MSC/kg, IV drop and repeat to apply in trimonthly for 2 cycle and cyclosporin A 5mg/kg po for 12 months
1880650|NCT01182662|Other|cyclosporin A|cyclosporin A 5mg/kg po for 12 months
1880651|NCT01182675|Drug|Transplant Conditioning with Mobilization Only|Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0 Transplant
1880652|NCT01182675|Drug|Transplant Conditioning with Mobilization and Alemtuzumab|Day -7: Alemtuzumab 0.3 mg test dose then 0.3 mg/kg IV; Day -6: Alemtuzumab 0.3 mg/kg IV; Day -5: Alemtuzumab 0.3 mg/kg IV; Day -4: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -3: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -2: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day -1: Filgrastim (G-CSF) 5 mcg/kg IV q12 hours; Day 0: Plerixafor 240 mcg/kg subcutaneous 9-12 hours prior to transplant; Day 0: Transplant
1880653|NCT01182701|Behavioral|Cognitive behavioral training|The behavioral training group will be involved six group sessions focusing on cognitive behavioral training for stress and mood management, cognitive restructuring, empowerment, values clarification, problem solving and decision making via a manualized program
1880654|NCT01182714|Procedure|immediate removal of in-dwelling catheter|
1880655|NCT01182714|Procedure|24 hours delayed removal of catheter|
1880656|NCT01182727|Drug|salsalate|Salsalate will be administered in 500 mg tablets. Salsalate will be administered in two divided doses of 2 grams in the morning and 2 grams in the evening. Salsalate will be administered for a total of 6 weeks. If a participant is not able to tolerate the target dose of 4 grams per day then 500 mg reductions will be made in a stepwise fashion until tolerated or a minimum dose of 2 grams per day is achieved.
1880657|NCT01182753|Radiation|carbon ion therapy|"Arm A (carbon ion therapy):
Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4 - 6 days a week, 15 fractions Total dose to the PTV1 - 60 Gy E ± 5%, further 4 - 6 fractions a 3 Gy E."
1880658|NCT01182753|Radiation|proton therapy|"Arm B (proton therapy):
Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4 - 6 days a week, 25 - 28 fractions Total dose to the PTV1 - 70 Gy E ± 5%, further 6 - 10 fractions a 2 Gy E."
1880659|NCT01182766|Drug|Topiramate with brief behavioral enhancement therapy|high-dose topiramate (up to 250 mg/day), or low-dose topiramate (up to 125 mg/day)
1880660|NCT01182766|Drug|Placebo with brief behavioral enhancement therapy|placebo
1880661|NCT01182779|Radiation|Carbon ion|"Arm A (carbon ion therapy):
Total dose to the PTV2 - 45 Gy E in 3 Gy E /d, 4-6 days a week, 15 fractions Total dose to the PTV1 - 63 Gy E ± 5%, further 5-7 fractions a 3 Gy E."
1880662|NCT01182779|Radiation|Protons|"Arm B (proton therapy):
Total dose to the PTV2 - 50 to 56 Gy E in 2 Gy E /d, 4-6 days a week, 28 fractions Total dose to the PTV1 - 72 Gy E ± 5%, further 6-9 fractions a 2 Gy E."
1880663|NCT01182792|Dietary Supplement|Vitamin C and E|1 month, 1g Vitamin C and 400 IE Vitamin E or Acute, 1g Vitamin C (in the offspring)
1880664|NCT01182792|Dietary Supplement|Placebo|1 month Placebo
1880665|NCT01182805|Device|Echocardiography system Ultra DCI Model 5000|Each subject will undergo scanning using the investigational echocardiography system (Ultra DCI Model 5000)to measure Diastolic Circumferential Strain Rate during Isovolumic Relaxation (DCSR-IVR) as novel measure of diastolic function.
1880666|NCT01182805|Device|Echocardiography machine GE Vivid E9|Each subject will undergo echocardiography using a conventional echocardiography machine to evaluate the early diastolic mitral annular velocity (E-prime) using tissue Doppler as a standard measure of diastolic function.
1880667|NCT01182805|Device|Diastolic function assessment|Each subject will undergo standard echocardiographic measure of the mitral inflow pattern and invasive catheter-derived measure of left ventricular end-diastolic pressure to determine their diastolic function. This evaluation will be used as the gold standard for this study.
1880668|NCT01182831|Procedure|percutaneous fluoro guided celiac plexus neurolysis|It is percutaneous injection of neurolytic agent in and around the celiac ganglion
1880669|NCT01182831|Procedure|EUS guided neurolysis|It is injection of neurolytic agent in and around the celiac ganglion using an echo endoscope.
1880670|NCT01182844|Dietary Supplement|Lactobacillus casei Shirota|3 bottles of Yakult(R) light per day
1880671|NCT01182870|Drug|choleclaciferol|800-6000 IU cholecalciferol per day
1880672|NCT01182883|Drug|IMC-A12|
1880673|NCT01182883|Drug|Temsirolimus|
1880674|NCT01182922|Behavioral|Invitation letter|Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
1880675|NCT01182948|Behavioral|Aerobic Training|The aerobic training group will exercise on cardiovascular training equipment. The workload will be gradually increased up to 60% of the reserve heart rate. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
1880676|NCT01182948|Behavioral|Resistance Training|The resistance training group will perform different exercises on weight machines and free weights to exercise upper and lower extremity muscles. Participants will perform 8-10 different exercises each session, alternating abdominal, upper and lower extremity exercises. Subjects will exercise 3 times per week for 60 min in the Fitness Centre of the Exercise and Sport Science School. Training will be carried out in small groups, under the supervision of personal trainers. During the study subjects will be instructed to follow an isocaloric diet.
1880677|NCT01182961|Other|gait training|subjects will walk on a treadmill while virtual obstacles will be displayed using a head mounted device
1880678|NCT01182961|Other|gait training 2|subjects will walk on a treadmill under a progressive intensive gait protocol
1880679|NCT01182961|Other|exercise group|standard of care exercise group to improve strength and balance
1880680|NCT01182974|Drug|paracetamol|1 gr of paracetamol PO/PZ/PR
1880681|NCT01182974|Drug|dypirone|1 gr PO/PZ/PR/IM
1880717|NCT01183234|Drug|Methylphenidate hydrochloride|one 60mg capsule, single oral dose
1880718|NCT01183247|Drug|Rapamycin|Add rapamycin de novo to tacrolimus and MMF
1880682|NCT01182987|Behavioral|Dementia Care Management|"The SCAN Memory Program is a care management program for cognitively-impaired SCAN members and for their informal/family caregivers. The program includes collaboration between SCAN Health Plan, partnering medical groups, and community organizations.
Program activities include: 1) telephonic-structured assessments with informal caregivers conducted by SCAN Memory Program care managers; 2) problem identification as a result of these assessments; and 3) pre-established protocols and procedures for problem resolution."
1880683|NCT01183000|Procedure|Closure of the peritoneum at cs|
1880684|NCT01183013|Drug|Pioglitazone 15 mg|Pioglitazone Capsules 15 mg once daily for 30 weeks followed by Pioglitazone Capsules 30 mg once daily for up to 54 weeks
1880685|NCT01183013|Drug|Pioglitazone 45 mg|Pioglitazone Capsules 30 mg once daily for 6 weeks followed by Pioglitazone Capsules 45 mg once daily for up to 78 weeks
1880686|NCT01183013|Drug|Pioglitazone 30 mg|Pioglitazone Capsules 30 mg once daily for up to 84 weeks
1880687|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 45 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg Tablets once daily for 6 weeks followed by Linagliptin 5mg low dose / Pioglitazone 45 mg FDC Tablets once daily for up to 78 weeks
1880688|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 30 mg FDC|Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 84 weeks
1880689|NCT01183013|Drug|Linagliptin 5mg|Linagliptin 5mg Tablets low dose once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
1880690|NCT01183013|Drug|Linagliptin 5mg / Pioglitazone 15 mg FDC|Linagliptin 5mg low dose / Pioglitazone 15 mg FDC Tablets once daily for 30 weeks followed by Linagliptin 5mg low dose / Pioglitazone 30 mg FDC Tablets once daily for up to 54 weeks
1880691|NCT01183039|Other|Training|20 sessions of training
1880692|NCT01183052|Other|Training|20 sessions of training
1880693|NCT01183065|Drug|Pralatrexate With Vitamin B12 and Folic Acid|Patients will be treated with 30 mg/m2 of pralatrexate intravenously once weekly for 3 weeks in a 4 week cycle with vitamin supplementation. Patients will take 1.0-1.25 mg oral folic acid on a daily basis. Folic acid should be initiated during the 10-day period preceding the first dose of pralatrexate and dosing will be continued during the full course of therapy and for 30 days after the last dose of pralatrexate. Patients will also receive a vitamin B12 (1 mg) intramuscular injection no more than 10 weeks prior to the first dose of pralatrexate and every 8-10 weeks thereafter. Subsequent vitamin B12 injections may be given the same day as treatment with pralatrexate.
1880694|NCT01183078|Procedure|free-hand|Free-hand technique utilizes x-rays to find screw holes.
1880695|NCT01183078|Procedure|Wand technique|Wand technique is utilized to find screw holes.
1880696|NCT01183091|Procedure|Ablation of atrial fibrillation|Ablation of atrial fibrillation
1880697|NCT01183104|Drug|Sitagliptin|Starting dose for sitagliptin is 50mg per day, can be increased up to 100mg (25-50mg; estimate glomerular filtration rate (eGFR) 30=< <50).
1880698|NCT01183104|Drug|Glimepiride|Starting dose for glimepiride is 0.5mg per day, can be increased up to 6.0mg
1880699|NCT01183117|Device|SM-01|SM-01 is a self-expandable, crush recoverable stent with a diameter larger than that of the arterial lumen. The stent is indicated for use in a vessel with a diameter 1 to 2 mm smaller than the nominal stent diameter. This stent will open to the diameter of the artery and will continue to apply expanding force on the artery.
1880700|NCT01183117|Device|PTA|balloon angioplasty
1880701|NCT01183130|Device|Compliance monitoring with electronic device|Electronic compliance monitoring with monitoring device (Pharma DDSi, Stora Enso) is used in control group (n=6) and device with mobile phone in intervention group (n=6). Patients in intervention group send every day the information of their medication intakes with the mobile phone to the clinic. This intervention is tested in pilot study (n=2-3) before the actual study begins.
1880705|NCT01183169|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
1880706|NCT01183169|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
1880707|NCT01183169|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
1880708|NCT01183169|Drug|Placebo|ALV placebo soft gel capsules administered orally
1880709|NCT01183182|Device|ActiSight Needle Guidance System|Three different groups of patients defined per lesion size
1880710|NCT01183208|Drug|Intervention A|A single dose of 3 mg will consist of 3 sprays of the 1 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
1880711|NCT01183208|Drug|Intervention B|A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
1880712|NCT01183208|Drug|Intervention C|A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
1880713|NCT01183208|Drug|Intervention D|A dose of placebo will consist of 3 sprays of the placebo spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
1880714|NCT01183208|Drug|Intervention E|A dose of placebo will consist of 15 sprays of the placebo spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
1880715|NCT01183221|Drug|Syntocinon|One dose of 24 IU (3 sprays/nostril)
1880719|NCT01183247|Drug|Everolimus|Add everolimus de novo to tacrolimus and MMF
1880720|NCT01183247|Drug|Prednisone|Add prednisone de novo to tacrolimus and MMF
1880723|NCT01183273|Procedure|Microlaparoscopic gastric bypass|microlaparoscopic gastric bypass will be performed using standard of care procedure.
1880724|NCT01183273|Procedure|Laparoscopic Surgery|laparoscopic gastric bypass will be performed using standard of care procedure.
1880725|NCT01183286|Behavioral|CFFONE|A password-protected, secure website, which can be accessed via a web capable cell phone. The website contains age appropriate medical and behavioral information, disease management tools and social networking features for adolescents and young people who have Cystic Fibrosis.
1880726|NCT01183286|Behavioral|CF website|A CF-related educational website which has some areas of CF information and services relevant to adolescents.
1880727|NCT01183299|Other|Dietary salt intake|
1880728|NCT01183312|Drug|Flumazenil|Sublingual flumazenil
1880729|NCT01183325|Device|Proceed Ventral Patch placement|Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
1880730|NCT01183351|Behavioral|Psychosocial intervention|Multidisciplinary Intervention for challenging behavior in patients with Dementia (MID) is developed in clinical practice in nursing homes as an answer to the need of a systematic and simple tool for the nursing home health workers to meet agitation. The model is based on the theoretical framework of cognitive behavioural therapy (CBT) where human behaviour is understood as always acting under the influence of biological, social and psychological factors. The systematic and structured approach of CBT to problem solving is central and is transformed in the model to meet the specific characteristics of challenging behaviour in dementia.
1880731|NCT01183364|Drug|STA-9090 (ganetespib) with Docetaxel|One treatment cycle will consist of weekly treatments for 2 weeks followed by a 1-week rest period. Treatment cycles will be repeated every 3 weeks. STA-9090 will be administered on Days 1 and 8 of each cycle and docetaxel will be administered on Day 1 of each cycle. Each agent will be administered as a separate 1-hour intravenous infusion.
1880732|NCT01183390|Drug|Anastrozole|1 mg Tablets
1880733|NCT01183390|Drug|Anastrozole|1 mg Tablets
1880734|NCT01183416|Drug|3F8 monoclonal antibody and 13-cis-Retinoic Acid|A cycle consists of treatment with 3F8 for 5 days. GMCSF is started 5 days in advance of each 3F8 cycle. The break between end of a cycle of 3F8/GM-CSF and start of next cycle is 2-to-4-weeks through 4 cycles; subsequent breaks are ~6-8 weeks. 13-cis-retinoic acid is started after cycle 2.
1880735|NCT01183429|Drug|3F8 and 13-cis-retinoic acid|3F8 is dosed at 80 mg/m2/day (cycles 1-2) or 20 mg/m2/day (cycles 3 and beyond) and infused iv over 30-90 minutes. 13-cis-retinoic acid is dosed at 160 mg/m2/day, divided into two doses, x14 days. If a dose is missed, it can be made up at the end of the cycle. It is not taken on same days as 3F8. *High-dose 3F8 will be administered only for patients enrolled on protocol from A(0) to A(7). Starting with A(8), patients receive standard dose (20mg/m2/day) during cycles 1 and 2.
1880736|NCT01183442|Drug|vitamin D|orally administered 2800 IU of vitamin D or placebo daily
1880737|NCT01183455|Drug|Aralast NP|Participants will receive IV infusions of Aralast NP (90mg/kg) once a week for 12 weeks.
1880738|NCT01183455|Drug|Placebo|Participants will receive IV infusions of placebo once a week for 12 weeks.
1880739|NCT01183468|Biological|Aralast NP 45 mg dose|- 45 mg/kg/week
1880740|NCT01183468|Biological|Aralast NP 90 mg dose|- 90 mg/kg/week
1880741|NCT01183468|Biological|Aralast NP 180 mg dose|- 180 mg/kg/week
1880742|NCT01183481|Drug|Aprepitant|Patients will be given a single dose of Aprepitant 125 mg on Day 0 (at least one hour before on the day of RT) followed by 80 mg of Aprepitant once daily in the mornings on Days 1 and 2 following the radiation treatment.
1880743|NCT01183481|Radiation|Palliative radiation therapy|Moderately emetogenic palliative radiation therapy (RT) will be administered to all patients on the study.
1880744|NCT01183481|Drug|Granisetron|Patients will be given a single dose of both Granisetron 2 mg orally on Day 0 (at least one hour before on the day of RT).
1880745|NCT01183494|Drug|FOLFIRI, Avastin, Irinotecan|Patients will be treated with the FOLFIRI regimen plus bevacizumab. Irinotecan will be administered at doses higher than the standard dose in patients with the UGT1A1*1/*1 and UGT1A1*1/*28 genotypes, while the doses of infusional 5-FU/LV and bevacizumab will remain unchanged.
1880746|NCT01183507|Behavioral|NIA intervention|The NIA physical activity intervention is of moderate intensity and will consist of aerobic, strength, flexibility, and balance training, with a target duration of 120 minutes per week.
1880747|NCT01183507|Behavioral|TSE|The TSE intervention is also of moderate intensity and target duration of 120 minutes per week and will consist of exercises that closely mimic functional tasks, such as vacuuming, stair ascent and descent, and lifting a weighted laundry basket.
1880748|NCT01183520|Dietary Supplement|Omega-3 fish oil provided by salmon|Eating 3 different amounts of provided salmon twice a week for four weeks
1880749|NCT01183533|Drug|Alteplase (iv t-PA)|0.9 mg/kg (maximum of 90 mg) IV t-PA will be administered with 10% bolus given over 1 minute, the rest given as an infusion over the remaining hour.
1880751|NCT01183572|Dietary Supplement|Multivitamins, Folic Acid, and Iron|Daily oral dose containing 2500 IU Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 2.6 mg Vitamin B12, 1.9 mg Vitamin B6, 18 mg Niacin, 70 mg Vitamin C, 14.9 IU Vitamin E, 30 mg elemental iron, 0.4 mg folic acid
1880752|NCT01183572|Dietary Supplement|Folic Acid and Iron|Daily oral dose of 30 mg elemental iron, 0.4 mg folic acid
1880753|NCT01183572|Dietary Supplement|Folic Acid|Daily oral dose of 0.4 mg folic acid
1880754|NCT01183585|Drug|RO4917838 and Rosuvastatin|multiple oral doses of RO4917838 and single oral dose of Rosuvastatin
1880755|NCT01183598|Drug|tocilizumab [RoActemra/Actemra]|maintenance dose
1880756|NCT01183611|Biological|Experimental recombinant hepatitis B vaccine, HBIG|Experimental 10mcg/0.5 ml recombinant hepatitis B vaccine and 200IU HBIG
1880757|NCT01183611|Biological|Active Comparator hepatitis B vaccine|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine，200IU HBIG
1880758|NCT01183611|Biological|Experimental recombinant hepatitis B vaccine|Experimental 10mcg/0.5 ml of recombinant hepatitis B vaccine
1880759|NCT01183611|Biological|Active Comparator recombinant hepatitis B vaccine.|Active Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
1880760|NCT01183611|Biological|Placebo Comparator recombinant hepatitis B vaccine|Placebo Comparator 10mcg/0.5 ml of recombinant hepatitis B vaccine.
1880761|NCT01183624|Other|Herbal Patch|1 herbal patch applied for approximately 8 hours per day for 14 days
1880762|NCT01183624|Other|Placebo Patch|Control patch with no herbal ingredients
1880763|NCT01183637|Device|Kensey Nash Corp. Cartilage Repair Device|To perform the Cartilage Repair Device implantation procedure, the surgeon first removes the damaged cartilage. Then, the surgeon creates a cylindrical hole in the bone below the area of damaged cartilage. The Cartilage Repair Device is then implanted into the hole so that the surface is level with the surrounding native cartilage. The Cartilage Repair Device will then absorb blood and bone marrow from the bone to begin the healing process.
1880764|NCT01183637|Procedure|Microfracture|To perform the microfracture technique, the surgeon will first remove the damaged cartilage. Then, the surgeon will make a number of small fractures in the bone below the area of damaged cartilage. The fractures cause the bone to bleed and a clot to form over the exposed bone. Over time, the clot forms a layer of fibrocartilage over the bone.
1880765|NCT01183650|Drug|Tadalafil|5 mg, administered orally, daily for 10 days
1880766|NCT01183663|Drug|Lenalidomide|Starting dose 10 mg by mouth daily for 21 days of a 28 day cycle.
1880767|NCT01183663|Drug|Bevacizumab|Starting dose: 5 mg/kg by vein every 2 weeks of a 28 day cycle.
1880768|NCT01183663|Drug|Sorafenib|Starting dose: 200 mg by mouth daily for 28 a day cycle.
1880769|NCT01183663|Drug|Temsirolimus|Starting dose: 15 mg by vein every week for a 28 day cycle.
1880770|NCT01183663|Drug|Lenalidomide|Starting dose: 5 mg by mouth daily for 14 days of a 21 day cycle.
1880771|NCT01183663|Drug|Oxaliplatin|Starting dose: 65 mg/m2 by vein on day 1 of a 21 day cycle.
1880772|NCT01183663|Drug|Leucovorin|400 mg/m2 by vein on day 1 of a 21 day cycle.
1880773|NCT01183663|Drug|5-fluorouracil|400 mg/m2 by vein through ambulatory pump on days 1-2 of a 21 day cycle.
1880774|NCT01183676|Drug|DEPAKOTE® Tablets, 500 MG|1 x 500 mg Tablet, under fed conditions
1880775|NCT01183676|Drug|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 x 500 mg Tablet, under fed conditions
1880776|NCT01183689|Behavioral|Self-regulation theory|Participants randomized to either of these two groups will be taught to self-weigh daily and report weights regularly. They will be reinforced for maintaining weight below randomization weight and taught that if weight exceeds randomization weight, they should reinstate either large or small changes.
1880777|NCT01183702|Procedure|LASIK surgery|Participants have received LASIK surgery and their eyes are healthy.
1880778|NCT01183702|Other|No Intervention|Participant has healthy eyes not altered by LASIK surgery.
1880779|NCT01183715|Drug|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
1880780|NCT01183715|Drug|PF-05161704 or placebo|PF-05161704 will be administered as an extemporaneously prepared suspension in the initially planned dose range of 1.5 mg to 300 mg. Correspondingly, placebo doses will be administered as suspension
1880781|NCT01183728|Other|Autologous bone marrow mesenchymal stem cells (MSV)|Bone marrow collection from patient, mesenchymal cells isolation and expansion under GMP conditions following the IBGM-Valladolid protocol (MSV). Autologous MSV implantation by articular injection.
1880782|NCT01183767|Drug|Epigallocatechin-Gallate|EGCG in a dosage of up to 10mg/kg body weight
1880783|NCT01183767|Drug|Placebo|
1880784|NCT01183780|Biological|Ramucirumab|8 milligrams / kilogram (mg/kg) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
1880785|NCT01183780|Biological|Placebo|Administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
1880786|NCT01183780|Drug|Irinotecan|180 milligrams/square meter (mg/m^2) administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
1880787|NCT01183780|Drug|Folinic Acid|400 mg/m^2 administered intravenously every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
1880788|NCT01183780|Drug|5-Fluorouracil|400 mg/m^2 bolus immediately followed by 2400 mg/m^2 continuous infusion every 2 weeks until disease progression, unacceptable toxicity, noncompliance or withdrawal of consent by the participant or investigator decision
1880789|NCT01183793|Radiation|Barium follow-through and MR-enterography|Assessment of the lack of difference between surgical and MR enterography small bowel length measurement with a comparison sample test
1880790|NCT01183806|Drug|Rivastigmine|All patients start on a 5-cm2 rivastigmine transdermal patch and their dose is progressively increased
1880791|NCT01183806|Other|Exercise training program|Exercise training program
1880792|NCT01183819|Behavioral|Space Fortress|Space Fortress sessions 3 times a week for 12 weeks
1880793|NCT01183819|Behavioral|Aerobic Exercise|Aerobic Exercise 4 times a week for 12 weeks
1880794|NCT01183819|Behavioral|Stretching|Stretching/Toning exercise 4 times a week for 12 weeks.
1880795|NCT01183819|Behavioral|Control Games|Control games session 3 times a week for 12 weeks
1880796|NCT01183845|Procedure|Colon Capsule Endoscopy|Ileocolonic endoscopy scheduled; then colon capsule endoscopy performed.
1880797|NCT01183858|Drug|Erlotinib [Tarceva]|Single daily oral dose
1880798|NCT01183871|Procedure|Monitoring of cerebral oxygenation|The internal jugular vein will be cannulated using ultrasound guidance in a cephalad direction, using the Seldinger J-shaped guidewire and it will be advanced only for 2-3 cm beyond the needle insertion site to avoid vascular injury to the jugular bulb. At which point the catheter is advanced until resistance is met at the jugular bulb, usually about 15 cm. The catheter is then pulled back 0.5-1.0 cm so that the catheter does not continue to abut the roof of the jugular bulb and to minimize the cephalad vascular impact with head movement, thereby reducing the risk of vascular injury. Skull x-ray will be used to confirm placement.
1880869|NCT01184391|Drug|DEPAKOTE® Tablets, 500 MG|1 x 500 mg tablet, under fasting conditions
1880799|NCT01183884|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid|"3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles .Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage.
Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20 mg/m2/day) for all cycles. The patients are in > or = to 2nd CR/VGPR and at high risk for additional relapse. Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started after cycle 2."
1880800|NCT01183897|Biological|3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic|"This phase II, open-label, single arm trial assesses the anti-NB activity of high-dose 3F8 (80 mg/m2/day), which is used in cycles 1-2, with return to standard 3F8 dosage (20 mg/m2/day) in subsequent cycles.Clinical results will be compared to those in the predecessor trials which used only the standard 3F8 dosage. Starting with A(6), patients no longer receive high-dose 3F8 but receive only standard dose 3F8 (20mg/m2/day) for all cycles The patients have primary refractory BM disease. Protocol treatment is through 24 months.
Real-time quantitative RT-PCR63-65 will be used to assess MRD in BM. 13-cis-retinoic acid is started no later than after cycle 4 (i.e., after response is scored), but sooner if CR is achieved after cycles 1, 2, or 3, or if early HAMA develops."
1880801|NCT01183910|Dietary Supplement|Citrus Bioflavanoid Blend|Pill Taken Twice a Day
1880802|NCT01183910|Dietary Supplement|Calcium Carbonate|Oral Tablet Taken Twice a Day
1880804|NCT01183936|Procedure|2-cm margin|Patients with CMM treated with a surgical safety margin of 2-cm in the surrounding skin and down to the fascia.
1880805|NCT01183936|Procedure|4-cm margin|Patients with CMM treated with a surgical safety margin of 4-cm in the surrounding skin and down to the fascia.
1880806|NCT01183949|Drug|AT7519M|"Part A: Nine patients will receive AT7519M as an intravenous infusion on days 1, 4, 8 and 11 of a three week cycle. The starting dose of AT7519M will be 21mg/m^2/dose and will be increased to 27mg/m^2/dose during subsequent cycles in the absence of AT7519M-related toxicities.
Part B: Amendment clarified there will be no further exploration of AT7519M as a monotherapy.
Part C: Amendment modified dose escalation to a conventional 3 + 3 design with a maximum total of 14 patients will be treated at the maximum tolerated dose."
1880807|NCT01183949|Drug|Bortezomib|Part C will treat between 3-26 patients with a combination of bortezomib and AT7519M in a dose escalation design. The starting doses for the dose escalation are bortezomib 1 mg/m2 and AT7519M 14 mg/m2.
1880808|NCT01183962|Dietary Supplement|Vitamin D|Vitamin D 3000 IU daily
1880809|NCT01183962|Other|No medication|No intervention
1880810|NCT01184001|Drug|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
1880811|NCT01184001|Drug|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
1880812|NCT01184001|Drug|Treatment B|Single dose of tasocitinib (CP-690,550) 10 mg under fasted conditions.
1880813|NCT01184001|Drug|Treatment A|Single dose of tasocitinib (CP-690,550) 10 mg under fed conditions.
1880814|NCT01184014|Drug|NPH insulin plus Complete Insulin Orders|NPH dosed per study-specific algorithm which incorporates total daily dosage of steroid to determine NPH dose. Complete insulin orders include background, meal-time and correction factor.
1880815|NCT01184014|Drug|Complete Insulin Orders|3-part insulin which includes background, meal-time and correction factor
1880816|NCT01184027|Behavioral|nutrition /swallowing counseling|general nutrition and swalling information
1880817|NCT01184027|Behavioral|G-tube/swallowing intervention|Patient will have active swallowing intervention with an SLP
1880818|NCT01184027|Behavioral|nutrition /swallowing intervention|Patient will have active (daily) nutrition and swallowing intervention based on patients individual needs.
1880819|NCT01184040|Behavioral|VIP CM|Participants will receive progressively increasing CM for walking 10,000 steps per day over 4 days prior to visit as verified by the pedometer.
1880820|NCT01184053|Drug|Arsenic trioxide|Arsenic trioxide - 0.25 mg/kg/day for 5 consecutive days, every 4 weeks.
1880823|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 12 months
1880824|NCT01184079|Biological|quadrivalent human papillomavirus vaccine|0.5 mL of quadrivalent HPV vaccine at enrollment, 2 months, and 6 months
1880825|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
1880826|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
1880827|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
1880828|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
1880829|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
1880830|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
1880831|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
1880832|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
1880833|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
1880834|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
1880870|NCT01184391|Drug|DIVALPROEX SODIUM DELAYED-RELEASE TABLETS, USP, 500 MG|1 X 500 mg Tablet, under fasting conditions.
1880835|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
1880836|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
1880837|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
1880838|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
1880839|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
1880840|NCT01184092|Drug|Treatment C|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg tablets (Phase 2B tablets).
1880841|NCT01184092|Drug|Treatment B|Single oral dose of 10 mg CP-690,550 -10 administered as two 5 mg immediate release filmcoated tablets (Phase 3 tablets).
1880842|NCT01184092|Drug|Treatment A|Single oral dose of 10 mg tasocitinib citrate (CP-690,550-10)administered as one 10 mg immediate release tablet (ICH -commercial image tablet).
1880843|NCT01184105|Drug|Intervention A|A single dose of 60 mg will consist of 6 sprays of the 10 mg strength spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
1880844|NCT01184105|Drug|Intervention B|A dose of placebo will consist of 6 sprays of the placebo spray applied topically to cervix (2 sprays) and vaginal fornices (4 sprays)
1880845|NCT01184118|Drug|FP 220 mcg 2 puffs BID|The design is a prospective 16-week open-label study of inhaled FP hydrofluoroalkane-propelled metered dose inhaler (HFA-MDI), 220 mcg, 4 puffs BID in 36 ICS naive asthma subjects. This is followed by a 4-week run-out period, including FP 220 mcg 2 puffs BID for 2 weeks, then either continue FP 220 mcg 2 puffs BID or discontinue FP (as tolerated), for the remaining two weeks, with subsequent transition to clinical care.
1880846|NCT01184131|Other|Mentor Training|Four 2 hour sessions of Mentor Training
1880847|NCT01184144|Drug|Pioglitazone|Pioglitazone, 30 mg, by mouth daily for 2 weeks
1880848|NCT01184157|Behavioral|Home screening|
1880849|NCT01184157|Behavioral|Clinic screening|
1880850|NCT01184170|Behavioral|overfeeding|Subjects will begin an 8-12 week high-calorie diet intervention. They will eat an additional 1000 kcal/day for two to three months, until a moderate, approximately 5% weight gain is achieved. The recommended dietary energy intake will be 1000 kcal/d more than the subject's baseline resting energy expenditure. An individualized diet plan will be developed for each subject by the study dietitian based on estimated energy requirements, and the subject's food preferences and dietary habits.
1880851|NCT01184183|Procedure|Comparing Accuseal Vs. Bovine Pericardial in CEA|"Accuseal patch - The Goretex Company has since designed a new patch, the Accuseal, which is marketed as decreasing the intra-operative time (i.e, having a short hemostasis time) without affecting the perioperative stroke rate.
Bovine Pericardial patch - The Bovine Pericardial patch has been used for nearly two decades, since the late 1990s. However, studies based on retrospective review of data in which patients received the Bovine Pericardial patch, reported the clinical outcomes post-operative stroke, death, time to hemostasis and recurrent restenosis."
1880854|NCT01184222|Device|great occipital nerve stimulation|"Active Comparator: Arm Active SENGO The patients will be hospitalised and managed by medication withdrawal and active GONS, surgically temporarily implanted.
Arm sham SENGO : The patients will be hospitalised and managed by medication withdrawal and sham GONS, surgically temporarily implanted."
1880855|NCT01184235|Drug|Pharmacological Intervention|This study will include those anticipating or receiving any pharmacological intervention
1880856|NCT01184248|Behavioral|Sound stimulation|Listening to sound stimuli at the lowest audible level.
1880857|NCT01184261|Behavioral|behavioral intervention|8 session behavioral intervention.
1880858|NCT01184274|Drug|SB939|"Dose Levels for Part A
-1 - 20mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
(starting dose) 25mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
- 35mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
- 45mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing
4+ - Previous level + 10mg/m2 - oral - Every other day three times/week1 for three consecutive weeks, followed by one week off-dosing"
1880859|NCT01184287|Drug|Ranpirnase|Cycles 3 and until patient progression, on days 1,8 and 15 in a 21 day cycle
1880860|NCT01184300|Genetic|Point-of-care genetic screening with subsequent prasugrel administration to CYP2C19*2 carriers|Patients found to carry the CYP2C19*2 allele will receive prasugrel 10 mg daily for 1 week. Non-carriers will receive clopidogrel 75 mg daily.
1880861|NCT01184313|Procedure|aortic valve surgery with CPB|elective aortic valve surgery with CPB
1880862|NCT01184326|Drug|pazopanib|Taken orally once daily
1880863|NCT01184326|Drug|everolimus|Taken orally once daily
1880864|NCT01184339|Device|MicroPhage S. aureus/MSSA/MRSA Blood Culture Test|"In vitro diagnostic for the Identification of S. aureus and determination of MSSA or MRSA from a positive blood culture.
Approximately 5 hour rapid test."
1880865|NCT01184352|Device|TriReme Medical, Inc. Glider(TM) PTCA Balloon Catheter|Percutaneous Coronary Interventions performed with the Glider PTCA Balloon Catheter
1880866|NCT01184365|Behavioral|Energy Management Program|The program content over the four sessions is structured as follows: Session 1 is an introduction to the group, important concepts, and upcoming session topics; Session 2 further elaborates on the concepts introduced in session 1 and encourages self-reflection; Session 3 is the peer to peer contact by phone or in person to assist with problems and share tips that really worked; and Session 4 concludes the program and serves to consolidate information learned.
1880867|NCT01184365|Behavioral|Energy Management Program|The goal of the EnMP-2 is to control for group effects
1880868|NCT01184378|Dietary Supplement|dairy lipids and soluble milk proteins|one month formula supplementation feces are collected during a 3 days period after 15 and 30 days of formula intake
1880871|NCT01184404|Drug|Bosentan|The treatment group receives a starting dose of 62.5 mg tablet bosentan twice daily for four weeks followed by 125 mg tablet of bosentan twice daily two weeks prior to and 12 weeks after surgery.
1880872|NCT01184417|Drug|10 mg/kg IV phenobarbital in 100 ml saline|10 mg/kg IV phenobarbital in 100 ml saline
1880873|NCT01184417|Drug|placebo|100 m l saline
1880874|NCT01184430|Device|Pulse contour cardiac output device|Goal directed volume therapy using stroke volume variation and cardiac output to guide volume therapy and inotropic support.
1880875|NCT01184443|Drug|Olanzapine|Dosing regimen is in keeping with clinical practice. Patients will typically start oral olanzapine at 2.5mg (rarely 1.25mg) daily for 1 to 2 weeks, and if tolerated and clinically indicated, are increased to 5.0mg daily. The majority of patients will remain on a maintenance dose of 5.0mg, but more agitated patients may take 7.5mg (rarely 10.0mg) daily. Patients will be tapered off as they approach/attain their ideal body weight.
1880876|NCT01184456|Dietary Supplement|GanedenBC30, GBI-30, PTA-6086|1 capsule per day containing 2 billion CFU of GanedenBC30, GBI-30, PTA-6086 for 90 days.
1880877|NCT01184456|Drug|Placebo|1 capsule per day for 90 days.
1880878|NCT01184482|Drug|cetuximab and lapatinib|"Cetuximab: 400 mg/m2 on Day 1 then 250 mg/m2 weekly
Lapatinib: Start once daily on Day 1. Dose escalating cohorts:
750 mg (3 tabs)
1000 mg (4 tabs)
1250 mg (5 tabs)"
1880879|NCT01184495|Drug|Epoetin Alfa-BioManguinhos|Subcutaneous administration of EPO-BioManguinhos
1880880|NCT01184495|Drug|Epoetin Alfa-BioSimilar|Subcutaneous administration of EPO-BioSimilar
1880881|NCT01184508|Drug|Placebo|Administered orally once daily, for 12 weeks
1880882|NCT01184508|Drug|LY2300559|300 mg administered orally once daily, for 12 weeks
1880883|NCT01184534|Behavioral|Video|5 minute multimedia presentation (video)
1880884|NCT01184534|Behavioral|Questionnaires|2 questionnaires pre and post procedure taking approximately 15 minutes each to complete.
1880885|NCT01184547|Behavioral|Quality of Life questionaires|To assess Return to work and quality of life
1880886|NCT01184560|Drug|Sibutramine|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.
Treatment period: The total dosing period is 12 weeks.
Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily
Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
1880887|NCT01184560|Drug|Orlistat|"○ Dosing standard Run-in period: All subjects would administer Sibutramine placebo 1 capsule (once daily) and Orlistat placebo 1 capsule (three times daily). The total dosing period is 2 weeks.
Treatment period: The total dosing period is 12 weeks.
Sibutramine monotherapy group: Sibutramine 1 capsule once daily + Orlistat placebo 1 capsule three times daily
Orlistat and Sibutramine combination group: Sibutramine 1 capsule once daily + Orlistat 1 capsule three times daily"
1880888|NCT01184586|Device|Intervention - ESWT Storz Duolith high energy|Three weekly sessions of extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,35-1,25mJ/mm2)
1880889|NCT01184586|Device|CONTROL SHAM-ESWT Storz Duolith [0.01mJ/mm2]|Three weekly sessions of sham extracorporeal shock wave (2000 impulses, 0,01mJ/mm2)
1880890|NCT01184599|Drug|aliskiren|150 mg/day p.o.
1880891|NCT01184612|Behavioral|Motivational Interviewing; MI|"MI is a communication style defined as a collaborative, person-centred form of guiding to elicit and strengthen motivation to change. The method is based on four principles: showing empathy; developing discrepancy between the subject's current behaviour and an alternate, more desired, behaviour; reinforcing self-efficacy; and rolling with resistance to change. Client arguments for change are elicited and reinforced in an atmosphere that is empathic, collaborative and supportive of autonomy. The choice to change and the responsibility for change remain with the client."
1880892|NCT01184625|Other|Physical Exercise|12 weeks of physical exercise.
1880893|NCT01184638|Drug|Sevoflurane|1-8% sevoflurane for maintaining the whole period of general anesthesia
1880894|NCT01184638|Drug|Propofol|1-4 mg/kg/h of propofol during the whole period of general anesthesia
1880895|NCT01184651|Behavioral|Questionnaires/Interviews|Girls answer questions about activities and interests, school, feelings about being a girl, stage of physical development, and family relationships during a home interview , provide saliva samples, and participate in phone interviews to answer questions about daily activities .
1880896|NCT01184651|Behavioral|Questionnaires/Interviews|Parents complete questionnaires about their daughter's activities, interests, and behaviors, educational goals, family demographics and relationships, grades, diagnosis and treatment of her CAH, their own activities, interests, and thoughts and feelings about being male or female. Parents answer questions during phone interviews about their daughters daily activities.
1880897|NCT01184664|Drug|Nicotine Patch|Varenicline + nicotine patch
1880898|NCT01184664|Drug|Placebo|Varenicline + placebo patch
1880899|NCT01184664|Drug|Varenicline|All participants will receive a standard dose of varenicline (12 weeks).
1880900|NCT01184677|Device|insertion of the ProSeal LMA (PLMA)|ProSeal LMA size 3 is inserted to the patients of Group size 3.
1880901|NCT01184677|Device|insertion of the PLMA|ProSeal LMA size 4 is inserted to the patients of Group size 4.
1880902|NCT01177852|Drug|diphenhydramine + dropropizine + pseudoephedrine|"Group 1: fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
Posology: The medicine treat will be as follows:
- Notuss® syrup Age: 2-5 years / Dosage: 5,0 mL Age: 6-12 years / Dosage: 10,0 ml"
1880903|NCT01177852|Drug|Dropropizine and fixed dose combination of pseudoephedrine hydrochloride + brompheniramine maleate (Dimetapp® elixir).|"Dropropizine:
Age: 2 - 3 years / Dosage: 5,0 ml Age: 4 - 12 years / Dosage: 10,0 ml
Pseudoephedrine hydrochloride + brompheniramine maleate:
Age: 2 - 3 years / Dosage: 2,5 ml Age: 4 - 6 years / Dosage: 5,0 ml Age: 7 - 9 years / Dosage: 7,5 ml Age: 10 - 12 years / Dosage: 10,0 ml"
1880904|NCT01177865|Other|informational intervention|
1880905|NCT01177865|Other|questionnaire administration|
1880906|NCT01177904|Other|Cease progsterone at 5|Cease administration of progsterone at first US at 5 weeks
1880907|NCT01177904|Other|control group: progesterone 8|Control group: progesterone until 8 weeks of pregnancy
1880908|NCT01177917|Other|Infant Formula|
1880909|NCT01177943|Drug|Atomoxetine|Administered orally, once.
1881104|NCT01186107|Device|Cypher stent|sirolimus-eluting stent
1880910|NCT01177956|Biological|Cetuximab|"The initial dose of cetuximab will be 400 milligram per square meter (mg/m^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m^2 as an IV infusion over 60 minutes.
Chemotherapy will be continued for up to a maximum of six 3-week cycles in the absence of progressive disease (PD) or unacceptable toxicity. All subjects will receive cetuximab treatment until the occurrence of PD or unacceptable toxicity to cetuximab."
1880911|NCT01177956|Drug|Cisplatin|Subjects will receive 75 mg/m^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle.
1880912|NCT01177956|Drug|5-Fluorouracil|Subjects will receive 750 mg/m^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 5 of each 3-week treatment cycle.
1880913|NCT01177969|Behavioral|Cognitive-Behavioral Therapy|The form of treatment will involve 16 weekly meetings of about 90 minutes each. Sessions involve both the child and parent and involve teaching youth how to cope with their anxiety through a variety of behavioral techniques.
1880914|NCT01177969|Behavioral|Wait-list|A wait-list essentially involves not receiving treatment for a specified period of time (in this case 16 weeks). No active treatment is provided; rather, the family 'waits'.
1880915|NCT01177982|Behavioral|Usual RBT (t-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social Club Job Club
1880916|NCT01177982|Behavioral|Reduced RBT (r-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
1880917|NCT01177982|Behavioral|Abbreviated RBT (a-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation
1880918|NCT01177982|Behavioral|Enhanced RBT (e-RBT)|Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job Club Recovery housing CAP housing admission Recovery sponsor
1880919|NCT01177982|Behavioral|Early compliant t-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social club Job club
1880920|NCT01177982|Behavioral|Early non-compliant t-RBT|t-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach Social club Job club e-RBT: Recovery housing CAP short term housing admission Recovery sponsor
1880921|NCT01177982|Behavioral|Early compliant r-RBT|a-RBT Individual therapy CBT skills modules Functional assessment Behavior contracts Behavior graphing Recreation r-RBT: Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach
1880922|NCT01177982|Behavioral|Early non-compliant r-RBT|r-RBT Individual therapy Skills modules Functional assessment Behavior contracts Behavior graphing Tangible rewards MI feedback Recreation Outreach t-RBT: Social Club Job Club
1880923|NCT01177995|Behavioral|Social Network Intervention|Social network leaders will communicate HIV prevention messages to members of their social networks.
1880924|NCT01178008|Procedure|Active acupuncture|Active acupuncture regimen consists of electroacupuncture stimulation on cranial and body acupoints which are empirical for treating depression in term of traditional Chinese medicine theory. It is done by a registered Chinese medicine practitioner with at least 3 years experience of providing acupuncture treatment. An electric-stimulator is connected to these needles to give an electric-stimulation in a continuous wave The needles will be left for 30 min and then removed. Acupuncture treatment will consist of two sessions per week for 4 consecutive weeks.
1880925|NCT01178008|Procedure|Placebo acupuncture|Streitberger's non-invasive acupuncture needles will be applied to serve as placebo control at the same acupoints and the same stimulation modality, except that the needles only affixed on the skin with adhesive tapes instead of insertion. Since all the points used are beyond patients' vision as they lay on bed, they could not visualize the acupuncture procedure. The acupuncturist, setting, treatment frequency, and duration of the treatment course are the same as the active acupuncture group.
1880926|NCT01178021|Drug|Chloroquine|Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2
1880927|NCT01178021|Drug|Chloroquine/Primaquine|Chloroquine 10 mg/kg on day 0 & 1 and 5mg/kg on day 2 Primaquine (if given) 0.25mg/kg/day for 14 days
1880928|NCT01178034|Genetic|Calculate warfarin dose using demographic/genetic algorithm|Age, body weight and genetic to calculate warfarin dosage
1880929|NCT01178047|Drug|Rasagiline|Rasagiline: 1 mg/d p.o. or Placebo one tablet p.o. once daily
1880930|NCT01178060|Other|Personalized Heart Attack and Stroke Risk|Personalized assessment of heart attack and stroke risk based on 10yr predictors with individual risk factors.
1880931|NCT01178060|Other|Standard Education|Patients received a general handout describing risk factors for heart attack and stroke.
1880932|NCT01178073|Drug|ambrisentan|ambrisentan (target dose: 10mg)
1880933|NCT01178073|Drug|tadalafil|tadalafil (target dose: 40mg)
1880934|NCT01178099|Drug|Prasugrel|Oral, daily for 12 days
1880935|NCT01178112|Drug|Trientine|Starting dose 750 mg by mouth four times a day, two times with meals and two times without meals for 28 days.
1880936|NCT01178112|Drug|Carboplatin|Starting dose area under curve (AUC) 4 by vein over two hours on day 1, and once every 28 days.
1880937|NCT01178112|Drug|Trientine MTD|Maximum tolerated dose found in MTD Dose Escalation Group; Carboplatin PK Group A, instead of starting on Day 1 of Cycle 1, starts taking trientine daily beginning on Day 2 of Cycle 1. Trientine PK Group B, 1500 mg of trientine is given once without food on Day 21 of Cycle 1 and once without food after the completion of carboplatin on Day 1 of Cycle 2.
1880938|NCT01178112|Drug|Carboplatin MTD|Maximum tolerated dose found in MTD Dose Escalation Group
1880939|NCT01178112|Other|PK Testing|Blood samples of 4 mL at following time points: 0, 30, 60 minutes, 2, 3, 4, 6, and 24 hours.
1880940|NCT01178125|Drug|DR-102|
1880941|NCT01178138|Drug|Prazosin|Prazosin or oral placebo given before methamphetamine or iv placebo to determine effects of prazosin on methamphetamine.
1880942|NCT01178151|Drug|Everolimus|10mg daily orally
1880943|NCT01178164|Genetic|Blood sampling for biological and genetic analysis|"Clinical examination
Blood sampling for biochemical enzymatic measures of alphagalactosidase A activity in males, and genetic analysis using direct sequencing of GLA in females."
1880944|NCT01178203|Drug|Placebo|Placebo
1881105|NCT01186120|Device|Biolimus A9-eluting stent|drug-eluting stent
1880945|NCT01178203|Drug|Tramadol|Tab, 100mg in 6, 12 and 24 hours after root canal treatment
1880946|NCT01178203|Drug|Novafen|325 mg in 6, 12 and 24 hours after root canal treatment
1880947|NCT01178203|Drug|Naproxen|Tab, 500 mg in 6, 12, and 24 hours after root canal treatment
1880948|NCT01178216|Biological|Rituxan|Rituximab (1gm) given on day# 15. Transplanted patients will receive an additional dose of Rituximab at 3M if DSA remains or 6M if denovo DSA present.
1880949|NCT01178229|Other|Physiotherapy|"The physiotherapeutic intervention was based on the Awareness through Movement technique. Ten sessions were planed. Each session lasted three hours.
The children of the experimental group and their parents were guided by two physiotherapist and the sessions took place in a room rounded by mirrors.
Each session developed as follows: presentation to the parents of the somatic awareness technique for each day; movements, games, motor tales and exercises performed by the children; in each session, a guide book with cartoons was given to the children and their parents to reinforce the exercises at home to keep a long-term result.
All the children assisted together to all the sessions and the instructions and instruments given to the children and their parents were the same for all of them."
1880950|NCT01178242|Procedure|Salivary Gland and Labial Mucous Membrane Transplantation|"Minor salivary glands (SG) will be obtain en block from the same donor site, at the inferior or superior labial mucous membrane, above the orbicularis oris muscle to correct lubrication. The thin split thickness graft of mucous membrane will be suture to the sclera with absorbable sutures"
1880951|NCT01178255|Drug|homeopathic q-potencies|individualised homeopathic medicines
1880952|NCT01178255|Drug|Placebo|placebo
1880953|NCT01178255|Other|homeopathic case history taking type I|one special homeopathic technique for case history taking
1880954|NCT01178255|Other|homeopathic case history type II|another type of homeopathic case history taking
1880955|NCT01178268|Device|XIENCE V EECSS|Patients who will receive this stent.
1880956|NCT01178268|Device|CYPHER SELECT PLUS SECSS|Patients who will receive this stent.
1880957|NCT01178281|Drug|Pomalidomide 0.5 mg|Pomalidomide 0.5 mg capsule taken by mouth once daily. Immunomodulatory agent with demonstrated efficacy in the treatment of subjects with RBC-transfusion-dependence associated with MNP-associated myelofibrosis.
1880958|NCT01178281|Drug|Placebo|Placebo Comparator to active drug
1880960|NCT01178307|Behavioral|Questionnaires|10 minutes to complete 3 questionnaires for development of MDASI-GIST
1880961|NCT01178307|Behavioral|Interview|Each interview will take approximately 30 minutes.
1880962|NCT01178307|Behavioral|MDASI-GIST Questionnaire|Every 4 weeks for one year
1880963|NCT01178320|Drug|Simvastatin, simvastatin plus extended-release niacin|Participants will be enrolled in this substudy only if they are candidates for the main AIM-HIGH study (NCT00120289). Participants will be randomly assigned to simvastatin or simvastatin plus niacin as a part of the main AIM-HIGH protocol, and adjustments in simvastatin and/or niacin doses will be made as per the protocol for the main AIM-HIGH study.
1880964|NCT01178346|Biological|NicVAX vaccine|NicVAX vaccine given 6 times over 6 months
1880965|NCT01178346|Biological|Placebo|Placebo vaccine given 6 times over 6 months
1880966|NCT01178359|Drug|nitrite|
1880967|NCT01178372|Drug|Lactulose|will receive 30-60 ml of lactulose in 2 or 3 divided doses so that patient passed 2-3 semisoft stools per day
1880968|NCT01178372|Drug|Probiotics(VSL#3)|will receive VSL#3 (110 billion CFU)three times a day
1880969|NCT01178385|Behavioral|Cognitive-behavioral therapy|Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
1880970|NCT01178385|Behavioral|Treatment as Usual|Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
1880972|NCT01178424|Behavioral|Mindfulness Based Cognitive Therapy|Mindfulness-Based Cognitive Therapy, a manualized, group skills training program (Segal et al., 2013) that is based on an integration of aspects of cognitive therapy for depression (Beck, 1979) with components of the mindfulness-based stress reduction program (Kabat-Zinn, 1990). Patients participate in 8 weekly sessions, each of which incorporates didactic and experiential learning, along with home practice of skills taught in the program.
1880973|NCT01178424|Behavioral|Cognitive Behaviour Therapy|CBT is an evidence based depression-specific psychotherapy that examines the relationship between thinking styles and the perpetuation of mood symptoms in major depression. Patients use thought records and activity scheduling, among other tools, to record and reappraise their thinking during situations where negative affect is present, both in session and for homework.
1880974|NCT01178437|Device|T-VNS® Stimulator cM02 (Transcutaneous Stimulation of the Vagus Nerve)|daily, transcutaneous, electrical stimulation of the vagus nerve by the t-VNS device for a period of 9 months
1880975|NCT01178450|Procedure|Subtotal parathyroidectomy|The procedure of choice is subtotal parathyroidectomy if the intraoperative biopsy confirms multiglandular disease and at least 3 glands are removed leaving a remanent of one normal gland
1880976|NCT01178450|Drug|Cinacalcet|Cinacalcet is initiated at a dose of 30 mg per day PO, adjusting the dose monthly (up to 90 mg per day PO) to achieve normocalcemia
1880977|NCT01178463|Other|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
1880978|NCT01178463|Other|Biospecimen staining|The sections will be incubated with rabbit anti GPR125 followed by Cy3-conjugated anti rabbit secondary antibodies.
1880979|NCT01178476|Device|Hyposafe Hypoglycaemia alarm device|An EEG based hypoglycemia alarm is tested against standard glucose measurement on the risk of severe hypoglycemia
1880980|NCT01178515|Other|Modification of the content of fat in milk|Comparison of three levels of fat content in cow´s milk
1880981|NCT01178515|Other|Modification of the content of cows milk|Comparison of three levels of fat content in cows' milk
1880982|NCT01178515|Other|Modification of the fat content of cows´ milk|Comparison of three levels of fat content in cow´milk
1880983|NCT01178528|Drug|ivabradine|7.5 mg bd
1880984|NCT01178528|Drug|"Drug:Carvedilol and Drug:Ivabradine"|up to 12.5/5 mg bd
1880985|NCT01178528|Drug|Carvedilol|25 mg bd
1880986|NCT01178554|Behavioral|psychotherapy|Usual Care therapists could use any treatment procedures they used regularly in their clinical practice.
1880987|NCT01178554|Behavioral|evidence-based treatment|Evidence-based treatment manuals were used for anxiety (Coping Cat Manual; Kendall, 1994; Kendall et al., 1994 ), depression (Primary and Secondary Control Enhancement Training; Weisz et al., 1997, 1998), and conduct problems (Defiant Children Manual; Barkley, 1997).
1880988|NCT01178554|Behavioral|modular evidence-based treatment|Therapists used the Modular Approach to Therapy for Children with Anxiety, Depression, or Conduct Problems (MATCH-ADC; Chorpita & Weisz, 2004)
1880989|NCT01178593|Other|Gut-focused hypnotherapy in group sessions|weekly session (45 min) of gut focused hypnotherapy (10 sessions within 12 weeks)
1880990|NCT01178632|Drug|Passiflora|01 tablet Passiflora p.o., b.i.d.
1880991|NCT01178632|Drug|Valeriana officinalis|Active Comparator group will receive 01 tablet of Valeriana officinalis, p.o., b.i.d.
1880992|NCT01178645|Drug|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
1880993|NCT01178658|Drug|Busulfan, etoposide, cytarabine, and melphalan|Busulfan 3.2 mg/kg/d for 2 days, etoposide 400 mg/m2/d for 2 days, cytarabine 1 g/m2 for 2 days, and melphalan 140 mg/m2 for 1 day
1880994|NCT01178671|Drug|Mirtazapine|Mirtazapine capsule, flexible dose of 15-45 mg/day for up to 24 weeks
1880995|NCT01178671|Drug|Sertraline|Sertraline tablet, flexible dose of 25-200mg/day for up to 24 weeks
1880996|NCT01178671|Other|Sugar pill|Sugar pill capsule, flexible dose of 1-3 per day, for up to 24 weeks
1880997|NCT01178697|Drug|Bevasizumab|Intravitreal, 1.25 mg, 3 times, one month apart.
1880998|NCT01178697|Drug|Triamcinolone Acetonide|Intravitreal, 2 mg, 2 times, two months apart.
1880999|NCT01178710|Drug|Simvastatin|20 mg per day, start at 5 days before surgery and continue for one year. For some congenital heart diseases which other drugs such as digoxin, antistone, furosemide were prescribed less than half year, simvastatin will be prescribed less than half year.
1881000|NCT01178723|Dietary Supplement|breakfast size|"The research group will receive instructions to eat a large breakfast, Dividing the total daily calories recommended to the patient to: breakfast - 1/8 of the total daily calories , lunch - 1/3 of the total daily calories and supper- 1/3 of the total daily calories.
(the rest of the calories will be snacks between the meals) In contrast, the control group that will receive instructions to eat a small breakfast.
Dividing the total daily calories recommended to the patient to: breakfast - 1/3 of the total daily calories , lunch - 1/4 of the total daily calories and supper- 1/4 of the total daily calories (the rest of the calories will snacks between the meals).
The instructions will be adapted to each patient individually"
1881001|NCT01178736|Procedure|Breast Cancer Screening and Diagnosis|Clinical Breast Examination and Sonography followed by Fine needle aspiration biopsy (FNAB) of screen positive cases.
1881002|NCT01178736|Procedure|Cervical Cancer Screening and Diagnosis|Visual Inspection with Acetic acid, PAP smear or Human Papilloma Virus DNA testing followed by Cryotherapy of screen positive cases.
1881003|NCT01178736|Procedure|Ovarian Cancer Screening and Diagnosis|Transvaginal sonogram and clinical evaluation in post menopausal women with symptoms suggestive of ovarian cancer.
1881004|NCT01178736|Procedure|Endometrial Cancer Screening and Diagnosis|Transvaginal sonographic assessment of the endometrial stripe in post menopausal women with abnormal bleeding.
1881005|NCT01178762|Drug|Azithromycin|Oral Azithromycin in the Treatment of Chlamydial Conjunctivitis
1881006|NCT01178775|Behavioral|walking|use a pedometer for records steps.
1881007|NCT01178788|Drug|17 alpha-hydroxy progesterone caproate|weekly injection of 17 P
1881008|NCT01178788|Drug|micronized Progesterone|daily administration of vaginal progesterone
1881009|NCT01178788|Procedure|Control|
1881010|NCT01178814|Drug|Revlimid (Lenalidomide)|The starting dose will be 10 mg days 1-28 with the first dose reduction going to 5 mg days 1-28 of a 28 day cycle. Therapy will cease if there is no response after 12 weeks.
1881011|NCT01178827|Drug|trospium chloride|trospium chloride (60mg) once daily for 10 days
1881012|NCT01178827|Drug|oxybutynin IR|oxybutynin IR (5 mg) three times daily for 2 days
1881013|NCT01178827|Drug|oxybutynin IR placebo|oxybutynin IR placebo three times daily for 2 days
1881014|NCT01178840|Device|WC then FC2|4 uses of WC followed by 4 uses of FC2
1881015|NCT01178840|Device|FC2 then WC|4 uses of WC followed by 4 uses of FC2
1881016|NCT01178853|Drug|Warfarin|Warfarin 5 mg once daily
1881017|NCT01178853|Drug|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)|Warfarin 5mg + Rosuvastatin 40 mg once daily (QD)
1881018|NCT01178853|Drug|Warfarin 5 mg + Pitavastatin 4mg once daily (QD)|Warfarin 5 mg + Pitavastatin 4mg
1881019|NCT01178879|Behavioral|Telehealth consultation|"The consultations are structured as outpatient sessions immediately after discharge. The content of the education deals with the regular treatment, prevention of exacerbation and how to live with the illness. The aim of the counseling is to increase the patient's empowerment and competence to take action. The patients have the consultations for 7 days followed by a telephone call. Each session is organized and individualised according to the patient's wishes and needs for education and counselling.
The equipment consists of a computer with web camera, microphone and measurement equipment. A button to contact to the nurse at the hospital, an alarm button and a volume button. The results are transferred to the hospital by a secure internet line."
1881020|NCT01184690|Procedure|Single-operator double-balloon endoscopy|Single-operator double-balloon endoscopy
1881021|NCT01184690|Procedure|dual-operator double-balloon endoscopy|dual-operator double-balloon endoscopy
1881022|NCT01184703|Other|Low GI food|Comparison of carbohydrates in diabetic patients
1881023|NCT01184716|Other|Vitamin D fortification|Bread and milk fortified with vitamin D3
1881024|NCT01184755|Behavioral|Relaxation|Participants are instructed to use the modified device (which paces the breath at a constant 13 breaths/minute) daily for 15 minutes (timing set automatically by device).
1881025|NCT01184755|Device|RESPeRate|
1881026|NCT01184781|Device|Comparison of capsule endoscopy Pillcam II™ versus colonoscopy|On the same patient, we compare both methods (video-colonoscopy vs capsule endoscopy)
1881027|NCT01184794|Drug|levobupivacaine|40 ml over 48 hours
1881028|NCT01184807|Drug|OPB-51602|OPB-51602 at a dose of 2, 5, 10, 20, 40, 60, 80, or 100 mg/day,will be orally administered to subjects once daily for 2 weeks in each cycle of treatment in Dose Escalation Stage.A 2-day treatment-free interval will occur on Days 2 and 3 for PK sampling. Study drug administration will resume on Day 4 and continue until Day 17 in cycle 1.In Expansion stage part 1, OPB-51602 will be administered at recommend dose (4mg) for 3 weeks per cycle 9 2 weeks treatment and 1 week washout). There is also 2-day treatment free interval between Day 1 and Day 4 for PK sampling in cycle 1.In Expansion stage part 2, subject dosing will be started on Day 1 without 2-day treatment free interval and continued until Day 28 at recommend dose (4mg) first in Cycle 1. The same subjects will be treated at MTD(5mg)from cycle 2 onwards for 4 weeks per cycle.
1881029|NCT01184820|Biological|BAY94-9027 + Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Single dose of Kogenate FS and 16 doses of BAY94-9027 given 2 times a week for 8 weeks. Both drugs to be given intravenously.
1881030|NCT01184820|Biological|BAY94-9027 + Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Single dose of Kogenate FS and 9 doses of BAY94-9027 given once a week for 8 weeks. Both drugs to be given intravenously.
1881031|NCT01184833|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|Patients treated with regular dose of Betaferon injections (250 micrograms subcutaneously every other day) under the routine practice setting.
1881032|NCT01184846|Biological|10% liquid formulation of human immunoglobulin|
1881033|NCT01184859|Drug|Desmopressin|Desmopressin oral lyophilisate melt tablet, in either the 10, 25, 50, or 100 μg dosage, for sublingual administration
1881034|NCT01184859|Drug|Placebo|Placebo melt tablet for sublingual administration
1881035|NCT01184872|Drug|Daptomycin|"Patients with bacteremia: Daptomycin 6 mg/Kg intravenous once daily for at least 5 days and up to 28 days.
Patients without bacteremia: Daptomycin 4 mg/Kg intravenous once daily for at least 5 days and up to 14 days."
1881036|NCT01184872|Drug|Vancomycin or Semi-Synthetic Penicillins (SSPs)|"Patients with bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 4 hours for at least 5 days and up to 28 days.
Patients without bacteremia: Vancomycin 1 g intravenous twice daily or Semi-Synthetic Penicillins 2 g intravenous every 6 hours for at least 5 days and up to 14 days."
1881037|NCT01184885|Drug|Hyper-CVAD|"Cycle A: Cyclophosphamide 300mg/m2 every 12 hours on days 3-5; Vincristine 2mg/day on days 6 and 13; Doxorubicin 50mg/m2 on day 6; Decadron 40mg/ day po on days 3-6 and 13-16; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.
Cycle B: Methotrexate 1000mg/m2 on day 3; Leucovorin 50mg every 6 hours starting 24 hours from the beginning of the MTX infusion until MTX levels are < 0.1 umol/L; Ara-C 3000mg/m2 every 12 hours on days 4 and 5; Methotrexate 12mg IT on day 4; Ara-C 100mg IT on day 9.
Rituximab (if given) will be 375 mg/m2 on Days 3 and 13 of Cycle A and on Days 4 and 9 of cycle B, for a total of 8 doses over the first 4 courses."
1881038|NCT01184885|Drug|Sirolimus|Sirolimus loading dose of 12mg on day 1 followed by a single daily dose of 4 mg/ day on days 2 through 7 (Cycle A) and on days 2 through 6 (Cycle B)
1881039|NCT01184898|Drug|Sirolimus|Sirolimus, by mouth, will be given as a 12mg loading dose followed by 8 daily doses of 4mg/day.
1881040|NCT01184898|Drug|Mitoxantrone|Mitoxantrone 8mg/m2/day IV
1881041|NCT01184898|Drug|Etoposide|100 mg/m2/day IV
1881042|NCT01184898|Drug|Cytarabine|1000mg/m2/day IV every 24 hours for 5 days
1881043|NCT01184911|Drug|Sulfadoxine-pyrimethamine|Sulfadoxine-pyrimethamine tablets, once
1881044|NCT01184924|Behavioral|Evaluation of the Arthritis Foundation Tai Chi Program|The primary goal of this study is to assess the effectiveness and feasibility of the arthritis foundation (AF) Tai Chi Program for People with Arthritis. Arthritis, the most prevalent chronic condition in the US and a leading cause of disability, is characterized by chronic pain and progressive impairment of joints and soft tissues. Promoting physical activity is a key public health strategy to addressing arthritis management, but more scientific data regarding effectiveness and feasibility are need to support the promotion of the AF Tai Chi Program as an exercise intervention for people with arthritis. Participants will be randomly assigned to the intervention or delayed control arm of the study.
1881045|NCT01184937|Behavioral|Patient education program|"All patients receive standard care. Experimental group receive a structured patient education program based in self-care theory and pedagogical theory, build upon the the principles of the Pro-Self education program. The intervention program consist of five weekly one-to-one sessions with a transplant nurse, lasting about 40-60 minutes, starting during the first week after discharge and lasting until 7 weeks post transplantation. Education content consists of two levels: general knowledge level and individual knowledge. Each session has a specific program. In addition, academic detailing is used to describe patient's knowledge levels and for tailoring the education to individual needs."
1881046|NCT01184950|Other|Trainer Curriculum|
1881047|NCT01184963|Dietary Supplement|High protein diet|High protein diet (30% protein, 40% carbohydrate, 30% lipid)
1881048|NCT01184963|Dietary Supplement|Normal protein diet|Normal protein diet (15% protein, 55% carbohydrate, 30% lipid
1881049|NCT01184976|Biological|VGX-3400|Plasmid DNA delivered via IM injection with electroporation
1881050|NCT01184989|Drug|Dabigatran etexilate|once daily approved dose by EMEA and Health Canada
1881051|NCT01185002|Other|PillCam® COLON 2 procedure using MgC boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take MgC boosts.
1881052|NCT01185002|Other|PillCam® COLON 2 procedure using Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take Suprep boosts
1881106|NCT01186120|Device|Everolimus-eluting stent|drug-eluting stent
1881053|NCT01185002|Other|PillCam® COLON 2 procedure using reduced dose of Suprep boosts|Subjects will be instructed to perform the colon preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. During the CE procedure the subjects will be required to take reduced dose of Suprep boosts
1881054|NCT01185015|Drug|Sigmart (nicorandil)|Sigmart will be administered for 2 weeks when the subject enters the secondary treatment period (Day 15 to approximately Day 28), at the dosage of 5 mg per oral tid in addition to the previous anti-anginal regimen.
1881055|NCT01185795|Dietary Supplement|Cardioviva™ yogurt|L. reuteri cardioviva in yogurt, twice per day (BID), 6 weeks
1881056|NCT01185795|Dietary Supplement|Placebo yogurt|yogurt, twice per day (BID), 6 weeks
1881057|NCT01185808|Biological|Vitamin D|Vitamin D 5000IU/day for 6 weeks
1881059|NCT01185834|Device|Lotrafilcon A upgrade soft contact lens|Silicone hydrogel contact lens approved for daily wear and extended wear up to 30 consecutive nights.
1881060|NCT01185847|Drug|RO5083945|intravenously, until disease progression
1881061|NCT01185847|Drug|cisplatin|standard treatment, up to 6 cycles
1881062|NCT01185847|Drug|gemcitabine|standard treatment, up to 6 cycles
1881063|NCT01185847|Drug|pemetrexed|standard treatment, up to 6 cycles
1881064|NCT01185860|Drug|danoprevir|oral doses
1881065|NCT01185860|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc once weekly
1881066|NCT01185860|Drug|placebo|oral doses
1881067|NCT01185860|Drug|ribavirin|1000-1200mg/day po
1881068|NCT01185860|Drug|ritonavir|oral doses
1881069|NCT01185873|Drug|danoprevir|Repeated oral doses
1881070|NCT01185873|Drug|ritonavir|Repeated oral doses
1881071|NCT01185886|Genetic|gene expression analysis|
1881072|NCT01185886|Genetic|mutation analysis|
1881073|NCT01185886|Genetic|polymorphism analysis|
1881074|NCT01185886|Other|biologic sample preservation procedure|
1881075|NCT01185886|Other|laboratory biomarker analysis|
1881076|NCT01185886|Other|pharmacogenomic studies|
1881077|NCT01185912|Procedure|Ventricle muscle tissue samples|
1881078|NCT01185925|Drug|Sildenafil|Sildenafil, 50 mg 3 times/day
1881079|NCT01185925|Drug|Placebo|Placebo
1881080|NCT01185938|Drug|Rosuvastatin|One oral single dose of rosuvastatin of 40 mg at admission and then 20 mg/day for 1 month.
1881081|NCT01185951|Drug|Polidocanol|Power-Doppler-guided extratendinous sclerosing therapy using Polidocanol 0.5% up to 2ml every 6-8 weeks
1881082|NCT01185951|Device|Focused extracorporeal shock wave therapy|Focused extracorporeal shock wave therapy using a STORZ Duolith machine 2000 Impulses 0.25mJ/mm2 every 6-8 weeks
1881083|NCT01185951|Drug|Topical NO|Topical nitroglycerine (Nitrolingualspray(R)) 2x2 hubs per day over 6 months daily on the painful tendon
1881084|NCT01185951|Behavioral|Painful eccentric training in Achilles tendinopathy|Painful eccentric training for Achilles tendinopathy on a stair single-stance with 6x15 repetitions per leg and day over at least 12 weeks
1881085|NCT01185951|Behavioral|Painful eccentric training for patella tendinopathy on 25° decline board|Painful eccentric training for patella tendinopathy on a 25° decline board single-stance with 6x15 repetitions per leg and day over at least 12 weeks
1881086|NCT01185951|Behavioral|Painful eccentric training for elbow tendinopathy using Thera-Band Flex-Bar|Painful eccentric training for elbow tendinopathy using a green coloured Thera-Band Flex-Bar with painful supination and pronation with 6x15 repetitions per day over at least 12 weeks
1881087|NCT01185964|Biological|Olaratumab|Olaratumab 15 mg/kg by intravenous transfusion (I.V.) on days 1+8 of a 21-day cycle
1881088|NCT01185964|Drug|doxorubicin|Doxorubicin 75 mg/m2 by intravenous injection on day 1 of the 21-day cycle.
1881089|NCT01185977|Drug|Fluoxetine|one-week single-blind PBO-lead-in phase, FLX 10 mg/d for 4 days then 20 mg/d of FLX thereafter
1881090|NCT01185977|Drug|Placebo|One pill of PBO for 4 days then two pills of PBO thereafter
1881091|NCT01186003|Drug|Detemir|Detemir 0.25 units per kg body weight given subcutaneously every 24 hours while patients are receiving intravenous (IV) standard insulin drip therapy
1881092|NCT01186016|Behavioral|Genetic Education Session|The intervention includes receiving education about genetics and smoking. The content is basic genetics and education about the multifactorial nature of smoking; research findings about genetic contributions to smoking, potential applications of this research for cessation treatment, and legal, ethical and social implications of future use of genotyping for cessation. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
1881093|NCT01186016|Behavioral|Nutrition Education Session|To control for an attention placebo effect, the control group will receive information about nutritional guidelines as established by the USDA and the FDA. The attention control group will be referred to as the Nutritional Education Session (NES) group. The content of NES sessions one and two are use of the USDA (MyPyramid) dietary and food safety guidelines. All participants also receive a 5-week standard cognitive-behavioral smoking cessation intervention with 6 weeks of OTC transdermal nicotine replacement therapy.
1881094|NCT01186029|Drug|aprepitant|Emend 40mg by mouth 30 minutes before procedure x 1
1881095|NCT01186042|Other|Observational|No intervention
1881096|NCT01186055|Behavioral|Smoking Cessation Counseling|Participants shall all receive 8 weeks (6 weeks) of group or individual counseling during their quit attempt.
1881097|NCT01186068|Drug|V-101|Cream QD
1881098|NCT01186068|Other|vehicle|Cream QD
1881099|NCT01186081|Radiation|Preoperative chemoradiotherapy|Preoperative chemoradiation with conventional radiotherapy (46 Gy in 23 fractions to the whole pelvis followed by a boost dose of 4 Gy in 2 fractions) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
1881100|NCT01186081|Radiation|Postoperative chemoradiotherapy|Postoperative radiotherapy with conventional radiation schedule (50 Gy in 25 fractions to the whole pelvis) and oral fluoropyrimidine (capecitabine 825 mg/m2 twice per day without weekend breaks during whole radiotherapy period)
1881101|NCT01186094|Device|Cypher|Sirolimus-eluting stent
1881102|NCT01186094|Device|Endeavor Resolute|Zotarolimus-eluting Stent
1881103|NCT01186107|Device|Endeavor Resolute stent|zotarolimus-eluting stent
1881107|NCT01186146|Drug|Aspirin monotherapy|stopping clopidogrel at 1 year after DES
1881108|NCT01186146|Drug|Aspirin,Clopidogrel|continue aspirin and clopidogrel 1year after DES
1881109|NCT01186159|Drug|Parecoxib Sodium|40 mg Parecoxib Sodium is give to the patients intravenously (diluted with 5 ml normal saline) at 30 minutes before surgery, 20 mg Parecoxib Sodium (diluted with 5 ml normal saline) at 8 hours,20 hours,32 hours,44 hours,56 hours after surgery respectively.
1881112|NCT01186185|Drug|Fludrocortisone|Fludrocortisone 0.2 mg by mouth daily for 30 days
1881113|NCT01186198|Device|MINI TREK RX 1.20 mm Coronary Dilatation Catheter|Enlarging coronary luminal diameter during percutaneous coronary intervention (PCI) procedures in subjects with ischemic heart disease due to stenotic lesions
1881114|NCT01186224|Drug|Plerixafor and G-CSF|"G-CSF will be given daily from day 1, which will usually be timed to fall toward the end of the working week. Plerixafor will commence on day 4 at as near to 10 PM as practicable, and also on day 5 and subsequent days (maximum of 4 total days) at a similar time of day if insufficient CD34+ cells have been collected. Stem cell harvesting will be carried out on day 5 and if necessary on days 6, 7 and 8, until the target yield of 4 x 106 CD34+ cells /kg recipient weight have been achieved.
The daily dose of G-CSF is 300 ug for patients up to and including 60kg in weight; 480 ug for patients over 60 kg but under 96 kg, and 600 ug for patients weighing 96 kg or more. This equates to a dose of at least 5 ug/kg (maximum 8 mg/kg) for all patients up to 120 kg. The daily dose of plerixafor is 240 ug/kg if the creatinine clearance is equal to or greater than 50mls/minute; if less than this then the dose is 160 ug/kg daily."
1881115|NCT01186237|Procedure|Early urinary catheter removal|All patients will have foley catheters removed between 0600 and midnight of post-operative day 3 (Day 0 being the day of operation).
1881116|NCT01186250|Drug|Pioglitazone|15mg pioglitazone taken daily for one month, 30mg pioglitazone taken daily for another month, 45mg pioglitazone taken daily for remaining ten months
1881117|NCT01186250|Drug|Placebo|placebo taken daily for one year
1881118|NCT01186263|Drug|MAA for diagnostic SPECT imaging|Intraarterial application of 5ml containing 500.000 particles with an activity of 150MBq.
1881119|NCT01186263|Drug|Diagnostic B20- SPECT imaging.|Intraarterial application of 5ml containing 150.000 particles with an activity of 150 MBq.
1881120|NCT01186276|Dietary Supplement|Fiber|Dietary fiber supplements to be consumed daily for 6 weeks.
1881121|NCT01186276|Dietary Supplement|Corn starch|Corn starch to be consumed daily for 6 weeks. This will serve as the control/placebo arm.
1881122|NCT01186289|Drug|atorvastatin|high dose atorvastatin therapy (80 mg/day) beginning 48 to 72-hours preoperatively and continuing until 6-weeks postoperatively
1881123|NCT01186302|Other|Type of provider|Different types of clinicians have different types of medical training. This study tested whether midlevel providers were as safe and effective in administering medical abortion as doctors. All types of providers underwent the same training in medical abortion and used the same medical abortion regimen.
1881124|NCT01186315|Behavioral|Prolonged Exposure Therapy|These treatments include repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories.
1881125|NCT01186315|Behavioral|Prolonged Exposure therapy + VR/ER|The therapy includes repeated exposure to intrusive trauma-related memories in a safe and structured manner designed to reduce emotional arousal and facilitate processing of trauma-related memories and adding in virtual reality (VR)-based exposure to cues for marijuana, cocaine, heroin, cigarette, and/or alcohol use & CER used outside treatment sessions in response to VR exposure (available 24 hours per day/7 days per week) to high-risk contexts for drug use
1881126|NCT01186328|Drug|EZN-3042|Dose will be assigned at study entry. To be given as a 2 hour intravenous infusion on days -5, -2, 8, 15, 22 and 29.
1881127|NCT01186328|Drug|Cytarabine|Given intrathecally on day -6 at the dose defined by age. Age 1-1.99 get 30 mg, age 2-2.99 get 50 mg, and age greater than or equal to 3 get 70 mg.
1881128|NCT01186328|Drug|Doxorubicin|60 mg/m2/day given intravenous infusion (IV) over 15 minutes on day 1.
1881129|NCT01186328|Drug|Prednisone|40 mg/m2/day divided twice or three times a day given orally on days 1 through 29.
1881130|NCT01186328|Drug|Vincristine|.5 mg/m2/day (maximum dose 2 mg) given intravenous push over 1 minute or infusion via mini-bag as per institutional policy on days 1, 8, 15 and 22.
1881131|NCT01186328|Drug|Pegaspargase|2500 IU/m2 intramuscular injection on days 2, 9, 16, 23.
1881132|NCT01186328|Drug|Methotrexate|"Given intrathecally to patients with central nervous system 1 and central nervous system 2 disease at the dose defined by age below on days 15 and 36.
Age 1-1.99 get 8 mg, age 2-2.99 get 10 mg, age 3-8.99 get 12 mg and greater than or equal to age 9 get 15 mg."
1881133|NCT01186354|Behavioral|Receiving results via genetic counselor|participants will receive genetic risk information for Type 2 diabetes from a board certified genetic counselor
1881134|NCT01186367|Behavioral|Linear Aerobic Training|The 130-180 minutes/week will be achieved via either 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes per/session (± 10 minutes).
1881135|NCT01186367|Behavioral|Nonlinear Aerobic Training|The 130-180 minutes/week will be achieved via 3 to 4 individual aerobic training sessions at approximately 10 to 50 minutes/ per session (+/- 10 minutes).
1881136|NCT01186367|Behavioral|Progressive Stretching|All sessions are required to be supervised. Duration of the stretching sessions is prescribed and implemented in accordance with standard stretching and flexibility training principles. This approach will be applied to guide each participant's prescribed stretching plan, with dose and scheduling modifications made by exercise physiologists, as required.
1881137|NCT01186367|Other|Cardiopulmonary exercise test (CPET)|
1881138|NCT01186367|Other|Blood draws|Complete blood count
1881139|NCT01186380|Device|PET-512MC|Transesophageal Transducer
1882930|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
1881140|NCT01186393|Behavioral|Control|Dietary manipulation in the free-living setting to include potatoes/potato products frequently in the diet (5-7 days / week). The control diet will be prescribed for weight maintenance.
1881141|NCT01186393|Behavioral|Low Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
1881142|NCT01186393|Behavioral|High Glycemic Index|Diets will be energy-restricted (~ 500 kcal deficit /d) for weight loss, will include consumption of 5-7 potatoes/week, and will focus on Low Glycemic Index foods.
1881143|NCT01186406|Drug|Gliadel|Patients will have 1-8 wafers of Gliadel inserted at the time of surgical resection.
1881144|NCT01186406|Radiation|Radiation Therapy|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy.
1881145|NCT01186406|Drug|Avastin|"Avastin (10 mg/kg) will be given every 14 days, and will begin a minimum of 42 days post-operatively.
Beginning two to three weeks after the last radiation therapy, but not greater than eight weeks, subjects will be treated with Avastin (10mg/m2) every 14 days."
1881146|NCT01186406|Drug|Temodar|At a minimum of four weeks, but not greater than eight weeks post-craniotomy, subjects will be treated with standard radiation therapy and daily Temodar (75mg/m2) for 6.5 weeks of the radiation. In addition, beginning 2-3 weeks after the last radiation therapy, but not greater than 8 weeks, patients will be treated with 5 day Temodar (200 mg/ m2).
1881147|NCT01186419|Drug|SPD602 (FBS0701, SSP-004184)|Oral FBS0701 taken one time daily for up to 96 weeks.
1881148|NCT01186432|Drug|PDS 1.0|
1881149|NCT01186445|Drug|morphine chlorhydrate|1mg of morphine chlorhydrate dilute in 3ml of saline solution, intracoronary injection, just before reperfusion
1881150|NCT01186445|Drug|saline solution|3 ml of saline solution , intracoronary injection during reperfusion
1881151|NCT01186458|Drug|Fludarabine|Fludarabine 25 mg/m2 IV over 30 minutes on days 1, 2, 4. Cycle = 28 days; maximum of 6 cycles of therapy.
1881152|NCT01186458|Drug|Velcade|Velcade (given after fludarabine)1.3 mg/m2 IV push over 3 to 5 seconds on days 1, 4, 8, 11. Cycle = 28 days; maximum of 6 cycles of therapy.
1881153|NCT01186458|Drug|Rituximab|Rituximab given after Velcade) 375 mg/m2 IV piggyback on day 1. Cycle = 28 days; maximum of 6 cycles of therapy.
1881154|NCT01186471|Other|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
1881155|NCT01186471|Other|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
1881156|NCT01186471|Drug|placebo|placebo - three times daily during each treatment period
1881158|NCT01186497|Drug|Rabeprazole sodium: Treatment E|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a tablet vehicle suspension (Treatment E) on Day 1.
1881159|NCT01186497|Drug|Rabeprazole sodium: Treatment C|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of applesauce (Treatment C) on Day 1.
1881160|NCT01186497|Drug|Rabeprazole sodium: Treatment D|The contents of 2 rabeprazole sprinkle capsules containing 10 mg rabeprazole sodium mixed with 5 mL (1 teaspoon) of formula milk (Treatment D) on Day 1.
1881161|NCT01186497|Drug|Rabeprazole sodium: Treatment A|The contents of 2 rabeprazole sprinkle capsules equivalent to 10 mg rabeprazole sodium mixed with a strawberry-flavored vehicle suspension (Treatment A) on Day 1.
1881162|NCT01186497|Drug|Rabeprazole sodium: Treatment B|The contents of 2 rabeprazole sodium sprinkle capsules equivalent to 10 mg rabeprazole sodium sprinkled on 1 tablespoon of plain yogurt (Treatment B) on Day 1.
1881163|NCT01186510|Procedure|lung perfusion|see literature of proceeding
1881164|NCT01186510|Procedure|no lung perfusion|see literature of proceeding
1881165|NCT01186523|Other|Long Term Energy Balance|To see if there is a variance in weight loss and energy balance between men and women with similar energy expenditure over an extended period of time.
1881166|NCT01186536|Dietary Supplement|Whey Protein supplement|40 g/day of whey protein will be consumed in 2 doses for 9 months (Study duration)
1881167|NCT01186536|Dietary Supplement|Soy Protein Supplement|40 g/day of soy protein will be consumed in 2 doses for 9 months (Study duration)
1881168|NCT01186536|Dietary Supplement|Carbohydrate supplement|40 g/day of maltodextrin will be consumed in 2 doses for 9 months (Study duration)
1881169|NCT01186549|Drug|Ephedrine 30microgram/kg|"Patients were randomly allocated to one of 5
groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
1881170|NCT01186549|Drug|lidocaine0.5mg/kg -ephedrine30 micrograms/kg|"Patients were randomly allocated to one of 5
groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
1881171|NCT01186549|Drug|ephedrine 70 microgram/kg|"Patients were randomly allocated to one of 5
groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
1881172|NCT01186549|Drug|lidocaine 0.5mg/kg|"Patients were randomly allocated to one of 5
groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
1881208|NCT01186835|Procedure|Combination Botulinum Toxin A and Hyaluronic Acid|One side of subject's face will randomly be assigned combination treatment.
1881209|NCT01186835|Procedure|Botulinum Toxin A|Other side of subjects face with receive Botulinum Toxin A treatment alone.
1881277|NCT01187459|Dietary Supplement|Vitamin D|50 ug/day Vitamin D, taken for 6 months.
1881173|NCT01186549|Drug|normal saline 2ml|"Patients were randomly allocated to one of 5
groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected"
1881174|NCT01186562|Drug|Sitagliptin|100 mg PO daily
1881175|NCT01186562|Drug|Placebo|Placebo
1881176|NCT01186575|Other|Text Message|Context-sensitive text messages are sent to men after undergoing circumcision
1881177|NCT01186588|Drug|Canagliflozin|One 300-mg dose of canagliflozin on Day 1
1881178|NCT01186601|Drug|PET tracer (BAY94-9392)|A radioactive dose of 300 MBq of the study drug with a total quantity of </= 0.1 mg will be administered as slow intravenous bolus injection over up to 60 seconds
1881179|NCT01186614|Device|Automated CPR|Automated CPR utilised by paramedics to facilitate CPR during transport to hospital
1881180|NCT01186614|Device|ECMO|Insertion of peripheral VA ECMO
1881181|NCT01186614|Procedure|Coronary angiography|Coronary angiography and intervention where necessary will be performed following ECMO insertion
1881182|NCT01186614|Procedure|Therapeutic Hypothermia|Paramedic initiated hypothermia with intravenous ice cold fluid and then continued for 24 hours (33 degrees)
1881183|NCT01186640|Drug|Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab|"I. First treatment phase: Chemoimmunotherapy A-FMC
Alemtuzumab:
Cycle 1+2:
10 mg s.c., days 1-3
Cycle 3+4:
CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13."
1881184|NCT01186640|Drug|Alemtuzumab|maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
1881187|NCT01186666|Device|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
1881188|NCT01186666|Device|Coronary intervention using IVUS-VH & FDG PET-MDCT|All the patients will undergo percutaneous coronary intervention of culprit vessels after imaging of the entire coronary tree (culprit and non-culprit lesions) using intravascular ultrasound with radiofrequency data analysis (IVUS-VH). Before discharge, fluorodeoxyglucose positron emission tomography combined with multidetector computed tomography (FDG PET-MDCT) of the carotid arteries and the thoracic aorta, along with MDCT coronary angiography, will be performed and a blood sample will be obtained for subsequent measurements of emerging or new biomarkers.
1881189|NCT01186679|Procedure|laminectomy|surgical laminectomy with glial scar resection
1881190|NCT01186679|Procedure|Intrathecal|direct into the CSF through lumbar puncture
1881192|NCT01186705|Drug|MK-2206|Patients will receive MK-2206 orally in a once weekly dose of 200mg. There will be no dose escalation. Patients will be treated until disease progression or unacceptable side effects.
1881193|NCT01186731|Drug|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 (IV)in vein on day 1 of each 21 day cycle , 6 cycles, until progression or unacceptable toxicity
1881194|NCT01186744|Drug|CP-690,550|10 mg of CP-690,550 oral BID or placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
1881195|NCT01186744|Drug|CP-690,550|10 mg oral BID
1881196|NCT01186744|Drug|CP-690,550|5 mg of CP-690,550 oral BID or Placebo oral BID, as appropriate based on treatment withdrawal/retreatment design
1881197|NCT01186744|Drug|CP-690,550|5 mg oral BID
1881198|NCT01186757|Drug|PF-03715455|PF-03715455 1.6 mg BID
1881199|NCT01186757|Drug|PF-03715455|PF-03715455 4mg BID
1881200|NCT01186757|Drug|PF-03715455|PF-03715455 10 mg BID
1881201|NCT01186757|Drug|Placebo|Placebo
1881202|NCT01186770|Drug|Methylnaltrexone bromide|oral tablets
1881203|NCT01186770|Drug|Oral Placebo|oral tablets
1881204|NCT01186783|Drug|ivabradine|"Patients in the ivabradine treatment arm receive an additional enteral preparation (orally, via nasogastric tube or percutaneous endoscopic gastrostomy-probe) of ivabradine for 4 days.
Day 1 and 2:
5,0 mg ivabradine b.i.d. if heart rate ≥60bpm (acute renal failure: ≥70bpm)
Day 3 and 4:
5,0 mg ivabradine b.i.d. if 60bpm≥heart rate<90bpm (acute renal failure: 70bpm≥heart rate <90bpm
7,5 mg ivabradine b.i.d. if heart rate ≥90bpm"
1881205|NCT01186796|Drug|Fulvestrant|"Secretagogue combinations are assigned in randomized double-blind order within-subject to include the following four conditions:
(i)L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by 5 mL bolus of NS at 1000 h; (ii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH and Ghrelin (both at dose of 0.3 mcg/kg bolus i.v.) at 1000 h; (iii) L-arginine (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by GHRH (0.3 μg/kg bolus i.v.) at 1000 h; (iv) L-arginine infusion (30 gm i.v. over 30 min from 0930 h to 1000 h) followed by Ghrelin (0.3 μg/kg bolus i.v.) at 1000 h.
**Ghrelin dosage is based on 70 kg subject.Total exposure of Ghrelin will be 42 mcg total dose for 2 subject visits (21 mcg per visit)."
1991432|NCT01112358|Drug|Follitropin alpha (r-FSH)|Recombinant-human follicle stimulating hormone (r-hFSH) was administered by s.c. route at a daily dose of 225-450 IU/day and then adjusted according to ovarian response as determined by ovarian ultrasound (US) and/or serum E2 levels. This was then followed by administration of GnRH antagonist. Administration of r-hFSH, GnRH antagonist, and r-hLH was stopped within 24 hours prior to r-hCG administration.
1881207|NCT01186822|Device|Lung Flute|Used twice daily
1881210|NCT01186848|Device|Combination treatment|The contralateral side received the combination of micro-focused ultrasound treatment and 1550nm-fractionated laser alternatively every 2 weeks for a total of 4 treatments with site-match control area of baseline striae on each side.
1881211|NCT01186848|Device|1550-nm erbium-doped fractionated laser|Each side of thigh (or abdomen) was randomized to receive 1550nm-fractionated laser treatment every 2 weeks for a total of 4 treatments on one side.
1881212|NCT01186861|Drug|OSI-906|Tablet administered with food and with up to 200 mL of water
1881213|NCT01186861|Drug|erlotinib|Tablet administered at least 2 hours after food with up to 200 mL of water
1881214|NCT01186861|Drug|placebo|Tablet administered at least 2 hours after food with up to 200 mL of water
1881215|NCT01186887|Drug|Celecoxib|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
1881216|NCT01186887|Drug|Placebo|The treatment group will receive 400 mg Celecoxib p.o. preoperatively and the control group will receive a placebo between 1 and 3 hours pre-op, when other standard medications are administered. The treatment group will receive 200 mg of Celecoxib orally twice per day post operatively, for a duration of 5 days based on dosing protocols shown to be well tolerated and effective in treating pain following ambulatory surgery. The control group will receive a 5 day supply of placebo pills. Both groups will receive standard post surgical narcotic prescription (Oxycodone IR 5 - 10 mg po qid prn and acetaminophen 325 - 650 mg PO qid prn
1881217|NCT01186900|Procedure|ultrasound-guided needle aspiration|one time drainage at time of randomization
1881218|NCT01186926|Device|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation (HGNS) System is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping, and off when the patient is awake.
1881219|NCT01186939|Drug|Azacitidine|Azacitidine was injected subcutaneously (SC) for 7 days. The 7-day dosing was repeated every 28 days with dose adjustments allowed. The initial dose during the primary study was 75mg/m^2/day.
1881220|NCT01186952|Behavioral|Caloric restriction|The caloric restriction diet will follow the Canadian Diabetes Association guidelines and be nutritionally balanced with a reduced total fat as well as saturated content.
1881221|NCT01186952|Behavioral|Diet intervention and structured exercise training program|Participants will follow the diet intervention previously described and a supervised physical activity program. The supervised exercise training sessions will take place three times a week for 4 months. Each session will last 1hour and will include aerobic exercise and resistance training. The aerobic training program will be treadmills intervals exercise at 50-70 % of heart rate reserve(HRR) the first month and 85-90% of HRR from the second to the fourth month. The resistance training programme will consist of two to three sets of 12 repetitions of the following exercises: leg press, chest press, lat pulldown, shoulder press, biceps curl, triceps extension.
1881222|NCT01186965|Behavioral|eHealth program in the Virtual Environment (VE) platform Second Life|determine the feasibility and acceptability of an eHealth program that provides diabetes education and self-management support.
1881223|NCT01186978|Radiation|Radiation Therapy|1.5-2 Gy per fraction to a total dose of 19.8-20 Gy with radiation given 5 days/week
1881224|NCT01186991|Drug|Onartuzumab|Onartuzumab will be administered as intravenous (IV) infusion at a dose of 10 milligrams per kilogram (mg/kg) on Day 1 and Day 15 of each 28-day cycle. The dose of onartuzumab will be based on the participant's weight at screening and will remain the same throughout the study.
1881225|NCT01186991|Drug|Bevacizumab|Bevacizumab will be administered as IV infusion at a dose of 10 mg/kg on Day 1 and Day 15 of each 28-day cycle. The dose of bevacizumab will be based on the participant's weight at screening and will remain the same throughout the study.
1881226|NCT01186991|Drug|Paclitaxel|Paclitaxel will be administered as IV infusion at a dose of 90 milligrams per meter-squared (mg/m^2) on Day 1, Day 8, and Day 15 of each 28-day cycle.
1881227|NCT01186991|Drug|Bevacizumab Placebo|Placebo matching to bevacizumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
1881228|NCT01186991|Drug|Onartuzumab Placebo|Placebo matching to onartuzumab will be administered as IV infusion on Day 1 and Day 15 of each 28-day cycle.
1881229|NCT01187017|Drug|Cyclophosphamide|60 mg/kg
1881230|NCT01187017|Drug|Fludarabine|125 mg/m squared
1881231|NCT01187043|Drug|Proellex|1 capsule 1x/day of 1 mg(ARM1), 3 mg(ARM2), 6 mg(ARM3), 9 mg(ARM4) or 12 mg(ARM5)
1881232|NCT01187056|Behavioral|Training programme|2 x 2 hours of training (workshops)
1881233|NCT01187069|Behavioral|Training course for practice nurses in autonomy support|An interactive course consisting of 4X4 hours education in autonomy support over a 6 months period. The main-components in the course are 1) communication skills, 2) introduction to patient work-sheets and 3) a quick up-to-date knowledge about treatment recommendations of type 2 diabetes. Furthermore, the nurses in the intervention-practices receive a half an hour support-visit 4-5 months after the end of the course.
1881234|NCT01187082|Behavioral|bladdertraining in groups|Cognitive training in groups of 4 patients at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
1881235|NCT01187082|Behavioral|bladdertraining individually|Cognitive training individually at hospital by a continence nurse in 3 sessions (1 hour)over a period of 1 month. Follow up after 1 month. During all 2 month the patient has selfinitiatied daily training with a pocket bladder schedule.
1881236|NCT01187095|Behavioral|Expressive writing|3 consecutive days of writing
1881237|NCT01187095|Behavioral|Active ctrl|Control
1881238|NCT01187108|Drug|N-acetylcysteine|NAC 600 mg oral once daily
1881239|NCT01187108|Drug|Acetazolamide|Acetazolamide 250 mg oral once daily
1881240|NCT01187108|Drug|Placebo pills|1 (or 2 in the placebo group) empty gel capsules
1882931|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
1881241|NCT01187134|Behavioral|Change Management|Hospitals have to create local change teams which are supported and trained by the study center. Local awareness of the staff is increased by PowerPoint presentations, posters, and brochures. The change teams receive monthly information about their quality indicator (duration until antimicrobial therapy). Anonymous comparison to other hospitals is possible (Benchmarking). Hospitals are visited three times a year to discuss progress of quality. In case of failure to improve, the change team is supported with specific tools for change management such as SWOT-analysis or resistance radar.
1881242|NCT01187147|Dietary Supplement|green tea extract|Green tea extract capsule, equivalent to 450 ml 2% Green tea containing 540mg EGCG/day
1881243|NCT01187160|Procedure|Transoral robotic surgery (TORS)|The da Vinci® Robotic Surgical System (Intuitive Surgical, Inc., Sunnyvale, CA) is a manual image-guided surgery system that is computer enhanced rather than computer guided robotic surgery in which the surgeon programs the computer to do the surgery and the robot does the surgery (also known as a milling device). Use of the da Vinci® Robotic Surgical System in the aforementioned configuration in fact facilitates an exact translation of the surgeons hand and finger movements at the console to precise and tremor-free movements of the arms and instruments.
1881244|NCT01187186|Drug|ASP1941|oral
1881250|NCT01187212|Drug|Capecitabine/Cisplatin + Sorafenib|Capecitabine 800 mg / m² po bid (D1-14) Cisplatin 60 mg / m² IV Day 1 Sorafenib 400 mg p.o. bid continuous dosing
1881251|NCT01187212|Drug|Capecitabine/Cisplatin|Capecitabine 1000 milligram (mg) / m² po bid (D1-14) Cisplatin 80 mg / m² IV Day 1
1881252|NCT01187225|Drug|Fibrinogen concentrate|In this arm, children (< 18 year-old)undergoing cardiac surgery with pump will receive fibrinogen concentrate (60 mg/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (< 1g/L) or TEG < 7 mm
1881253|NCT01187225|Drug|Cryoprecipitate|In this arm, children (< 18 year-old)undergoing cardiac surgery with pump will receive cryoprecipiate (10 ml/Kg) if they present clinically significant bleeding associated to low levels of fibrinogen (< 1g/L) or TEG < 7 mm
1881254|NCT01187238|Drug|cisplatin|in experimental arm, the eligibility patients will be received the same radiotherapy as radical radiotherapy alone group, and also will received concurrent chemotherapy with the regimen of cisplatin 40mg/m2, weekly,from week 1 to week 7
1881255|NCT01187264|Drug|Methotrexate|once weekly for a total duration of 12 weeks or earlier till patient achieves PASI 75
1881256|NCT01187277|Behavioral|conventional therapy|conventional therapy means: 50 min individual physiotherapy and 60 min individual occupational therapy per work day (5x per week)for four consecutive weeks
1881257|NCT01187277|Device|conventional plus robotic gait assisted therapy|individual physiotherapy +individual occupational therapy+ robotic gait assisted therapy
1881258|NCT01187290|Radiation|neoadjuvant chemoradiotherapy|Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
1881259|NCT01187303|Drug|Ofatumumab|300 mg/m2 d1 week 1 1000mg/m2 d1 week 2-8
1881260|NCT01187316|Device|Transcutaneous electrical nerve stimulation|Sensors were positioned on anterior temporal and masseter muscles bilaterally, and the stimulation was used for 20 minutes at 150 Hz and 100 µs of pulse width; intensity was adjusted individually.
1881261|NCT01187316|Other|Physiotherapy|Massage and stretching of the anterior temporal and masseter muscle were performed by an experienced professional for 20 minutes.
1881262|NCT01187329|Other|hyperinsulinemic normoglycemic clamp (HNC)|Prior to anesthetic induction, a baseline blood glucose value will be obtained, followed by an insulin infusion of 5 mU.Kg-1.min-1. When blood glucose is <110 mg/dL, a variable continuous infusion of glucose (dextrose 20%) supplemented with potassium (40 mEq/L) and phosphate (30 mmol/L) is administered to preserve normoglycemia (80-110 mg/dL). The glucose infusion is titrated to target glucose levels by checking blood glucose every 5 - 15 min with Accu-Check (Roche Diagnostics, Switzerland) glucose monitor. At sternal closure, insulin infusion is decreased to 1 mU/Kg/min. On admission to the ICU, insulin treatment follows the ICU protocol. The dextrose infusion is slowly weaned off over 2 - 4 hrs maintaining blood glucose > 80 mg/dL. Arterial blood glucose is measured every 30 - 60 min for 2 hrs, then, as stated in ICU protocol.
1881263|NCT01187329|Other|control group|Baseline arterial blood glucose will be obtained before anesthetic induction. Repeat measurements are performed every 30-90 min. Glucose >150 on CPB will receive insulin according to intraoperative protocol. After surgery, insulin is given according to ICU protocol. Target glucose < 180 mg/dL.
1881264|NCT01187355|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational multi-purpose disinfecting solution used by subjects as specified in use instructions provided for the care of study contact lenses, 30 days.
1881265|NCT01187355|Device|renu fresh Multi-Purpose Solution (MPS)|Commercially available multi-purpose solution used by subjects as indicated for care of study contact lenses, 30 days.
1881266|NCT01187355|Device|Contact lenses|Contact lenses per subject's habitual brand and power worn for 30 days on a daily wear basis.
1881267|NCT01187368|Device|EVAHEART Left Ventricular Assist System (LVAS)|continuous flow implantable left ventricular assist system (LVAS) for patients who are at risk of imminent death from severe left ventricular failure for use as a bridge-to-transplantation in candidates listed for cardiac transplant
1881268|NCT01187407|Drug|LY2216684|Taken by mouth once daily
1881269|NCT01187407|Drug|Placebo|Taken by mouth once daily
1881270|NCT01187433|Biological|Live, attenuated, recombinant dengue serotype 1 , 2, 3 , and 4 virus|0.5 mL, Subcutaneous (SC)
1881271|NCT01187433|Biological|NaCl 0.9%|0.5 mL, Subcutaneous
1881272|NCT01187433|Biological|Tetanus toxoid, reduced diphtheria toxoid, acellular pertussis vaccine adsorbed|0.5 mL, Intramuscular
1881273|NCT01187433|Biological|Meningococcal A+C vaccine|0.5 mL, Intramuscular
1881276|NCT01187459|Dietary Supplement|Vitamin D|10 ug/day Vitamin D, taken for 6 months.
1881278|NCT01187485|Drug|Androderm® 2.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
1881279|NCT01187485|Drug|Androderm® 5.0mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
1881280|NCT01187485|Drug|Androderm® 7.5mg|Subjects will be asked to replace the study drug patch every 24 hours at night following the written and verbal instructions you will receive. The study drug patch should be placed over a small amount of a steroid cream on the skin to reduce irritation.
1881281|NCT01187498|Behavioral|Behavioral training|Comprehensive behavioral training program using delayed voiding, urge suppression techniques, pelvic floor muscle training, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
1881282|NCT01187498|Drug|Oxybutynin chloride, extended-release|Individually titrated, extended-release oxybutynin chloride, initiated at 10 mg, fluid management handout, and monitoring with bladder diaries. Treatment is implemented by a nurse practitioner in 4 clinic visits over 8 weeks.
1881283|NCT01187511|Drug|GSK561679|Verucerfont is a corticotropin releasing hormone receptor 1 (CRF1) antagonist.
1881284|NCT01187511|Drug|Placebo|Placebo is an inactive tablet design to look exactly like GSK561679
1881285|NCT01187537|Procedure|Continuous Femoral Nerve Block|20mls of 0.25% Bupivacaine with 1/400,000 adrenaline (2.5mcg/ml) If catheter localized to < 1.0mA, 0.1mS with patella twitch, start Bupivacaine 0.125% 4ml/hr. If unable to get twitch through catheter in final location or twitch at current ≥ 1.0m/A, start Bupivacaine 0.125% 6ml/hr.
1881286|NCT01187550|Drug|Recombinant human growth hormone (r-hGH)|Recombinant human growth hormone (r-hGH) administered at dose of 0.033 milligram/kilogram (mg/kg) body weight (0.1 International Unit [IU]/kg body weight) per day by subcutaneous injection.
1881287|NCT01187576|Behavioral|Multi-professional team intervention with PAR, lifestyle brochure|Multi-professional team intervention with PAR, lifestyle brochure
1881288|NCT01187576|Behavioral|Ordinary recommendations on health behaviours, lifestyle brochure|Ordinary recommendations on health behaviours, lifestyle brochure
1881289|NCT01187589|Device|Pulsehaler|
1881290|NCT01187589|Drug|Nebulizer & Albuterol 0.5ml|Albuterol aerosolized by a nebulizer
1881291|NCT01187615|Drug|Regorafenib (BAY73-4506) - sequential / Cisplatin / Pemetrexed|In Part A of this trial, regorafenib will be administered in a sequential dosing with a seven day wash out period before the next infusion of pemetrexed and cisplatin. Regorafenib will be administered at a dose of 160 mg qd from Day 2 to Day 14 followed by a 7 days break. Pharmacokinetics of regorafenib will be assessed on Day 14 of Cycle 1 and Day 1 of Cycle 2.
1881292|NCT01187615|Drug|Regorafenib (BAY73-4506) - continuous / Cisplatin / Pemetrexed|In Part B of this trial, regorafenib will be administered continuously from Day 1 to Day 21. Only in Cycle 1, regorafenib dosing will start on Day 2 in order to assess the pharmacokinetics of pemetrexed and cisplatin without concomitant regorafenib dosing. Pharmacokinetics of regorafenib will be assessed on Day 21 of Cycle 1 and on Day 1 of Cycle 2.
1881293|NCT01187628|Drug|Fosrenol (Lanthanum Carbonate, BAY77-1931)|Daily dose: 750-2250mg/day,(270-750mg each 3 times a day) for 52 weeks.
1881294|NCT01187654|Biological|AC133|intra coronary injection of bone marrow derived AC133+ cells
1881295|NCT01187654|Biological|MNC|intra coronary injection of bone marrow derived MNC
1881296|NCT01187654|Biological|CONTROL|autologous serum injection
1881297|NCT01187680|Device|Spraygel|
1881298|NCT01187680|Device|Control|Good surgical technique, no adhesion barrier
1881299|NCT01187693|Other|shoe lift|shoe lift for balancing the heights of bilateral pelvis of participants with leg length discrepancy during standing
1881300|NCT01187719|Drug|phenytoin|phenytoin 184 mg (2 tablets of 92mg) OD at onset of labour and continue for seven days
1881301|NCT01187732|Device|Washing without water|The experimental intervention is 'washing without water' and consists of disposable washing cloths made of a mix of soft synthetic fibers, saturated with a no rinse, quickly vaporizing skin cleaning and caring lotion.
1881302|NCT01187745|Other|CT Scan followed by ultrasound|A limited U/S is performed after the CT scan which is ordered by the Emergency Department physician.
1881303|NCT01187758|Behavioral|Workshops and focus group meetings|Multifacet intervention that includes: Guideline preparation and implementation, preparing clinic campaign, improving knowledge about Ab resistance and diagnosis of respiratory infections
1881304|NCT01187771|Procedure|Laparoscopic Gastric Banding|Those randomized to surgery would meet with the bariatric surgeon and the dietitian during the 3 month weight management period and based on insurance requirements, would undergo LGB surgery after 3 months of weight management. PAP therapy would be utilized for the 3 week peri-operative period (1 week prior to 2 weeks post-operatively) given evidence that this might reduce peri-operative respiratory complications. Routine surgical follow-up will occur 2 weeks post-operatively and then every 4-6 weeks to assess weight loss trajectory and adjust the band as needed.
1881305|NCT01187771|Procedure|Continuous Positive Airway Pressure|Participants randomized to the CPAP arm will undergo a CPAP titration within 2 weeks of enrollment unless a split-night study was already performed as part of their diagnostic polysomnogram (PSG) providing a reliable CPAP therapeutic pressure. As soon as an appropriate pressure is identified, CPAP therapy will begin with routinely scheduled follow-up visits to maximize CPAP adherence. All participants will be offered a 12 month supervised weight loss program in addition to OSA-specific therapy.
1881306|NCT01187784|Behavioral|Coping Cat cognitive-behavioral therapy for anxious youth|Manualized, empirically supported CBT treatment for anxious youth
1881307|NCT01187797|Other|Emotional stimulation|Increase of the physical correlates of an emotion
1881308|NCT01187810|Drug|Fenretinide|925 mg/m2 IV continuous infusion X 5 days for 6 cycles. Dose escalation will occur on a 3X3 basis.
1881309|NCT01187810|Drug|Cytarabine|dosing depending on age - will be administed intrathecally for all CNS negative subjects on day 0 and 15 of course 1, then on day 8 of each remaining cycle for CNS negative AML. For CNS positive ALL, NHL, and AML, will be administered alone on day 0 for and in combination with methotrexate and hydrocortisone on day 8, 15, 22 of cycle 1 and repeated on day 8 of each remaining cycle
1882932|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-high dose once a day
1881310|NCT01187810|Drug|Methotrexate|Dose depends on subject age - for CNS positive patients, will be given in combination with cytarabine and hydrocortisone on days 8, 15, and 22 during course 1. For courses 2-6, will be administered intrathecally on day 8 for CNS negative ALL and NHL. For patients who are CNS positive, it will be given in combination with cytarabine and hydrocortisone on day 8 of courses 2-6.
1881311|NCT01187823|Device|Adaptive servo ventilation|Nocturnal use of Adaptive servo ventilation
1881312|NCT01187823|Device|Nocturnal oxygen|Nocturnal use of oxygen
1881313|NCT01187836|Drug|TRV120027|Dose range (starting at 0.1 mcg/kg/min) of TRV120027 administered for 14 hours.
1881314|NCT01187836|Drug|Placebo|Placebo administered for 14 hours.
1881315|NCT01187849|Drug|Metformin|Volunteers will be given Metformin or placebo for 1 month, once daily.
1881316|NCT01187849|Drug|Placebo|Volunteers will be given Metformin or placebo for 1 month, once daily
1881317|NCT01187862|Drug|caffeine, efavirenz, losartan, omeprazole, metoprolol, chlorzoxazone and midazolam|
1881318|NCT01187875|Dietary Supplement|Placebo- Fiber free control|Dextrin control administered in a muffin treatment.
1881319|NCT01187875|Dietary Supplement|Hi-maize resistant starch 9g|9g Hi-maize resistant starch administered in a muffin treatment.
1881320|NCT01187875|Dietary Supplement|Novalose 330 resistant starch 9g|9g Novalose 330 resistant starch administered in a muffin treatment.
1881321|NCT01187875|Dietary Supplement|4.5g Hi-maize resistant starch and 4.5g Novalose 330|4.5g Hi-maize and 4.5g Novalose 330 in a muffin treatment.
1881322|NCT01187888|Drug|Rasagiline|tablet once daily 1 mg 1 year
1881323|NCT01187888|Drug|Sugar pill|tablet once daily one year
1881324|NCT01187901|Drug|Erlotinib|Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
1881325|NCT01187901|Drug|Sulindac|Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
1881326|NCT01187901|Drug|Placebo A|Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
1881327|NCT01187901|Drug|Placebo B|Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
1881328|NCT01187927|Biological|Cervarix®|Administered according to the prescribing information in the locally approved label by the authorities.
1881329|NCT01187940|Behavioral|PEGASUS|PEGASUS - a psychoeducational group intervention with parallel parent and child sessions.
1881330|NCT01187953|Drug|Prograf (tacrolimus)|Administered per current product labeling
1881331|NCT01187953|Drug|LCP-Tacro|Tacrolimus, once-per-day The initial dose of 0.17 mg/kg will be administered orally in the morning (before noon) within 24 hours following transplantation. Subsequent doses will be adjusted according to whole blood tacrolimus trough levels.
1881335|NCT01187979|Behavioral|Cash incentives|Cash incentives paid to learners for reaching pre-determined milestones
1881336|NCT01187979|Behavioral|Life skills curriculum|Standard department of education lifeskills curriculum
1881337|NCT01187992|Drug|Atorvastatin|80 mg/day
1881338|NCT01188005|Device|n-CPAP|administration of continuous positive airway pressure through a nasal device
1881339|NCT01188005|Device|Oxygen supplementation|Oxygen supplementation (3L) through nasal spectacles
1881340|NCT01188005|Drug|Vitamin A, Vitamin C, Vitamin E, Allopurinol, N-Acetylcysteine|Vitamin A 50,000 IU, Vitamin C 1000 mg , Vitamin E 200 mg, Allopurinol 600 mg, N-Acetylcysteine 2 g. Duration is set for 60 days
1881341|NCT01188018|Behavioral|Brief Advice (BA)|Participants in this arm will receive a single session of brief advice. A counselor will briefly discuss the risks associated with smoking.
1881342|NCT01188018|Behavioral|Motivational Interviewing (MI)|Subjects will receive 4 counseling sessions (over 18 weeks) in which their thoughts about their smoking will be discussed. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone(weeks 6 and 18).
1881343|NCT01188018|Behavioral|Health Education (HE)|Subjects will receive 4 counseling sessions (over 18 weeks)in which they will receive educational information about the risks of smoking and the benefits of quitting. Two of these counseling sessions will be performed in person (weeks 0 and 12) and the remaining two will be over the phone (weeks 6 and 18).
1881344|NCT01188031|Drug|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under fasting conditions
1881345|NCT01188031|Drug|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products under fasting conditions
1881346|NCT01188057|Drug|ALPRAZOLAM ORALLY DISINTEGRATING TABLETS, 2.0 MG|A: Experimental Subjects received Purepac Pharmaceutical Co. formulated products under non-fasting conditions
1881347|NCT01188057|Drug|NIRAVAM TM 2 mg orally disintegrating tablets, single dose|B: Active comparator Subjects received Schwarz Pharma Inc. formulated products non-under fasting conditions
1881348|NCT01188070|Behavioral|Usual Care|Educational materials
1881349|NCT01188070|Behavioral|Psycho-education|Educational group sessions
1881350|NCT01188070|Behavioral|Psycho-education plus physical exercise|Psychoeducation intervention plus an individualized exercise program
1881351|NCT01188083|Dietary Supplement|Fructose Drink|Fructose Based beverage 8 oz
1881352|NCT01188083|Dietary Supplement|Glucose Drink|Glucose Based beverage 8 oz per drink x 3 per day x 4 weeks
1881353|NCT01188096|Drug|Poly ICLC|Children will receive poly-ICLC 20 mcg/kg twice weekly IM (using Monday/Wednesday schedule if possible). The first 2 doses will be administered in the clinic under supervision.
1881354|NCT01188109|Drug|Gemcitabine|"Standard of care chemotherapy and dosage
Dose - 1000 mg/m²
Schedule - Days 1 and 15; Q 28 days"
1881355|NCT01188109|Drug|Cisplatin|"Dose - 50 mg/m²
Schedule - Days 1 and 15; Q 28 days"
1881356|NCT01188122|Device|AnapnoGuard 100|Respiratory guard system during mechanical ventilation
1881357|NCT01188135|Behavioral|Interactive voice messaging or Interactive voice messaging + psycho ed materials|Interactive voice telephone messages reminder participants to continue to take their antidepressive medications
1881358|NCT01188148|Drug|Memantine|5 mg per day of memantine
1881359|NCT01188148|Drug|Placebo|
1881360|NCT01188161|Device|Rotating Chair|Subjects will be spun in rotating chair
1881361|NCT01188174|Drug|Clofarabine|The present protocol aims to test the strategy of an early Reduced Intensity Conditioning (RIC) allo-SCT; in combination with a sequential preparative regimen for allo-SCT (Clofarabine, Intermediate dose Ara-C chemotherapy, followed by RIC with Cyclophosphamide, IV Busulfan and ATG; and delayed prophylactic infusion of donor lymphocytes (DLI) will be able to improve the outcome of patients with primary treatment failure AML.
1881362|NCT01188187|Drug|Custirsen|
1881363|NCT01188187|Drug|Docetaxel|
1881364|NCT01188187|Drug|Prednisone|
1881365|NCT01188187|Drug|Dexamethasone|Dexamethasone 8 mg by mouth twice a day for 3 days beginning one day before docetaxel administration to reduce the incidence and severity of hypersensitivity reactions and fluid retention.
1881366|NCT01188200|Other|Experimental nutritional formula #M979|One two hundred and forty mL serving at test time, taken orally
1881367|NCT01188200|Other|Standard food|Standard meal prior to test time
1881368|NCT01188213|Dietary Supplement|Methylsulfonylmethane (MSM)|
1881369|NCT01188226|Device|Denture teeth|Denture teeth made of nano hybrid composite material
1881370|NCT01188252|Drug|Roniciclib (BAY1000394)|Oral administration twice daily in a 3 days on / 4 days off schedule. Starting dose will be 0.3 mg corresponding to approximately 0.005 mg/kg and dose will be escalated dependent on any dose limiting toxicities.
1881371|NCT01181700|Drug|Treatment A|PF-00241939 300 ug using inhaler A
1881372|NCT01181700|Drug|Treatment B|PF-00241939 300 ug using inhaler A
1881373|NCT01181700|Drug|Treatment C|PF-00241939 300 ug using inhaler A
1881374|NCT01181700|Drug|Treatment D|PF-00241939 300 ug using inhaler B
1881375|NCT01181700|Drug|Treatment E|PF-00241939 300 ug using inhaler B
1881376|NCT01181700|Drug|Treatment F|PF-00241939 300 ug using inhaler B
1881377|NCT01181700|Drug|Treatment G|PF-00241939 300 ug using inhaler B
1881378|NCT01181726|Drug|Estradiol/Norethindrone acetate|1 mg/0.5 mg Tablets
1881379|NCT01181726|Drug|Activella®|1 mg/0.5 mg Tablets
1881380|NCT01181765|Biological|Infliximab 5 mg/kg body weight infused over 2 hours|Subjects will receive IV Infusion of infliximab 5 mg/kg body weight at Week 0, Week 2, Week 6, Week 14 and Week 22 as per the approved Canadian product monograph of infliximab.
1881381|NCT01181791|Dietary Supplement|Lactobacillus reuteri|Lactobacillus reuteri DSM will be given at a dose of 1x108 colony forming units (CFU)/day
1881382|NCT01181791|Other|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present.
1881383|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
1881384|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
1881385|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
1881386|NCT01181804|Drug|boceprevir|Boceprevir (tablet or capsule) at 800 mg administered under either fed or fasted conditions.
1881387|NCT01181817|Other|fMRI and MRS|fMRI and MRS
1881388|NCT01181830|Drug|magnesium pidolate|administration of 8.1 mmol bid of magnesium pidolate
1881389|NCT01181830|Drug|placebo|administration of 8.1 mmol bid of placebo
1881390|NCT01181856|Biological|MVA 85A|Single injection of 1 x 108 pfu MVA85A
1881391|NCT01181869|Device|oxygen|oxygen therapy, ventilation for respiratory failure CPAP for sleep apnoea
1881392|NCT01181882|Dietary Supplement|Fish Oil and Aspirin|4 grams of fish oil each day for 28 days and 81 mg aspirin
1881393|NCT01181895|Drug|Vilanterol|Vilanterol inhalation powder inhaled orally once daily for 12 weeks
1881394|NCT01181895|Drug|Salmeterol Inhalation Powder|Salmeterol inhalation powder inhaled orally twice daily for 12 weeks
1881395|NCT01181895|Drug|Placebo Inhalation Powder NDPI|Placebo inhalation powder inhaled orally via Novel Dry Powder Inhaler
1881396|NCT01181895|Drug|Placebo Inhalation Powder Diskus|Placebo inhalation powder inhaled orally twice daily for 12 weeks
1881397|NCT01181908|Drug|single dose|Subjects will receive a single dose of GSK1144814 or placebo.
1881398|NCT01181921|Drug|Galantamine|Type= range, unit= mg, number= 8-24, form= capsule, route= oral use. The starting dose will be 8 mg/day for 4 weeks. Subsequently, the initial maintenance dose will be 16 mg/day for 4 weeks. Then, an increase to the maintenance dose of 24 mg/day should be considered on an individual basis after appropriate assessment.
1881399|NCT01181934|Other|A643 (nicotine)|2mg oromucosal nicotine spray- three times daily during each treatment period
1881400|NCT01181934|Drug|placebo|placebo - three times daily during each treatment period
1881401|NCT01181934|Other|A643 (nicotine)|1mg oromucosal nicotine spray- three times daily during each treatment period
1881402|NCT01181947|Device|TEVAR|Thoracic endovascular aneurysm repair
1881403|NCT01181960|Drug|Risperidone long acting injectable - New Starts|Patients who switch to Risperidone long acting injectable or receive an initial injection of Risperidone long acting injectable within the 30 days prior to enrollment will be eligible for inclusion in the Risperidone long acting injectable New Starts cohort.
1881404|NCT01181960|Drug|Risperidone long acting injectable - Continuous Users|Patients who have been on Risperidone long acting injectable for at least 6 months before baseline, with no gaps between injections of more than 30 days will be eligible for inclusion in the Risperidone long acting injectable Continuous Users cohort.
1881405|NCT01181960|Drug|Paliperidone Palmitate -New and Continuous Users|Patients newly initiating Paliperidone Palmitate or on Paliperidone Palmitate at the time of enrollment
1881406|NCT01181960|Drug|Other Antipsychotics - New Starts|Participants in the other antipsychotic cohort may be newly started on any oral or injectable antipsychotic other than Risperidone long acting injectable and Paliperidone Palmitate
1881407|NCT01181973|Drug|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
1881408|NCT01181973|Drug|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
1881409|NCT01181973|Drug|pegvisomant|Two 1-mL subcutaneous injections at 15 mg/mL each. Two 15-mg vials are supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
1881410|NCT01181973|Drug|pegvisomant|One 1-mL subcutaneous injection at 30 mg/mL. A 30-mg vial is supplied as lyophilized powder. Each vial should be reconstituted with 1 mL of Sterile Water for Injection (WFI).
1881411|NCT01181986|Drug|Exenatide SC|Exenatide 5-10 ug sc BID/10 days
1881412|NCT01181986|Drug|Exenatide IV|50 ng/min intravenously for 45 minutes on 2 out of 3 study visits separated by 5-10 days
1881413|NCT01181986|Drug|Placebo SC|Placebo sc BID/10days
1881414|NCT01181986|Drug|Exendin-9|Primed (6,000 pM/kg), continuous (600 pM/kg) intravenous infusion for 75 minutes on 1 out of 3 study visits.
1881415|NCT01181986|Drug|Placebo IV|Intravenous infusion for 45 minutes on 1 out of 3 visits
1881416|NCT01181999|Drug|rituximab|A dose of 375mg/m2 rituximab will be administered intravenously on day 1 of first to fourth R-CHOP chemotherapy and on day 1, 8, 15, 22 of each augmentation chemotherapy.
1881417|NCT01182012|Behavioral|Lifestyle counseling|Depending on the results of cardiovascular risk factor indexes, the treatment (including drugs, if needed) may be modified or adjusted. A nurse visit will be programmed to explain the lifestyle behaviour the patient should have.
1881418|NCT01182025|Other|Western therapy|"Symptomatic treatment: vitamin B, vitamin C, mouth care and skin care.
Adopting physical cooling therapy, including physical cooling paste or warm bathing, when patient's body temperature is lower than 38.5 degree Celsius;
Using Ibuprofen suspension when patient's temperature higher than 38.5 degree Celsius;"
1881419|NCT01182025|Drug|Xiyanping Injection|"Dosage for child medication:
5-10mg/kg/d (0.2-0.4ml/kg/d) in 5% Glucose solution, IV, with speed of 20-30 drops per minute, each day; or as directed by doctor."
1881420|NCT01182025|Drug|Xiyanping Injection with western medicine|"Symptomatic treatment using the same treatment methods in western therapy group;
Symptomatic treatment using the same treatment methods in Xiyanpin injection group."
1881421|NCT01182038|Device|BirthRite birthing seat|Randomization takes place on admission to the labor ward when the participants are in active labor.Participants in this arm were to sit on the seat for 20 minute periods.After these 20 minutes, the participant should stand and mobilize during two to three contractions, before resuming the birth seat position. If progress of the descent of the fetal head was obvious the participant was not asked to mobilize.
1881422|NCT01182051|Behavioral|CBT or relaxation training|8 weeks of CBT or relaxation training.
1881423|NCT01182077|Drug|ASP015K|Oral
1881424|NCT01182077|Drug|Midazolam|Oral
1881425|NCT01182090|Procedure|Colposacropexy|In open approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
1881426|NCT01182090|Procedure|Colposacropexy|In laparoscopic approach the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area of at least 3 x 5 cms where the mesh will be attached with four-five Polyglycolic 0 sutures. The procedure is repeated for the posterior vaginal wall, where the mesh will be attached with three-four Polyglycolic 0 sutures. The sacral promontory surface is prepared and 1 or 2 non-reabsorbable 0.0 sutures are placed into the sacral periosteum about 2 cm below the promontory. A sub-peritoneal tunnel is created through which meshes are passed avoiding traction to the sacrum. The peritoneum is closed over the meshes.
1881427|NCT01182116|Procedure|J Pouch|Comparing J pouch, side to end coloanal surgery
1881428|NCT01182129|Drug|Nicotine|Nicotine pouch, 2.2 mg, single dose, 30 minutes
1881429|NCT01182129|Drug|Nicotine|Chewing Gum, 4 mg, single dose, 30 minutes
1881430|NCT01182142|Drug|Capecitabine|1,250 mg/m2 orally twice a day, days 1-14
1881431|NCT01182155|Procedure|Exhaled Breath Sampling|Standard of care
1881432|NCT01182168|Drug|gemcitabine and split-dose cisplatin plus escalating doses of continuous Everolimus (RAD001)|Patients will receive gemcitabine IV and cisplatin IV on days 1 and 8. Everolimus orally will be administered continuously (one cycle = 21 days). Everolimus will be escalated at the following dose levels: 5mg every-other-day, 5mg daily, and 10mg daily. Patients will receive a total of 6 cycles of gemcitabine and cisplatin in combination with Everolimus unless disease progression or unacceptable toxicity occurs.
1881433|NCT01182181|Drug|Anastrozole (Teva Pharmaceuticals USA)|1 mg Tablets
1881434|NCT01182181|Drug|Anastrozole (Arimidex®)|1 mg Tablets
1881435|NCT01188265|Drug|Valproate|
1881436|NCT01188265|Drug|Dextromethorphan 60 mg per day|VPA plus dextromethorphan 60 mg per day
1881437|NCT01188265|Drug|Placebo|VPA plus placebo
1881438|NCT01188265|Drug|Dextromethorphan 30 mg|VPA & Dextromethorphan 30 mg per day
1881439|NCT01188278|Drug|Imatinib|Drug being observed but not provided
1881440|NCT01188304|Drug|aleglitazar|repeated daily doses
1881441|NCT01188304|Drug|aspirin|repeated daily doses
1881442|NCT01188304|Drug|placebo|repeated daily doses
1881443|NCT01188317|Drug|aleglitazar|repeated daily doses
1881444|NCT01188317|Drug|placebo|repeated daily doses
1881445|NCT01188317|Drug|ibuprofen|repeated daily doses
1881446|NCT01188330|Behavioral|WITH Comprehensive Geriatric assessment|"Each month after randomization, a nurse practitioner will systematically review the intervention plan.
In case of hospitalisation, the nurse will go and meet the patient and his care giver to check each point of the intervention plan. If an action has not been done, a new proposal will be made to the patient. If the patient is at home or in institution, the nurse practitioner will call the patient and /or his care giver for the same purpose"
1881447|NCT01188330|Behavioral|Conventional|no Comprehensive Geriatric assessment
1881448|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each; Subcutaneous (SC)
1881449|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, Subcutaneous (SC)
1881450|NCT01188343|Biological|Japanese encephalitis chimeric virus: Measles, mumps, and rubella live attenuated virus|0.5 mL each, subcutaneous (SC)
1881451|NCT01188369|Drug|levosimendan|Intravenous infusion, 0,1ug/kg/min, duration 4 hours prior to operation and until the end of operation.
1881452|NCT01188369|Drug|placebo drug|Intravenous infusion, colour identical to levosimendan
1881453|NCT01188382|Procedure|CSF dynamic investigation|
1881454|NCT01188408|Drug|Liposome Entrapped Docetaxel (LE-DT)|110 mg/m2 IV (in vein) on day 1 of each 21 day cycle, 6 cycles or until disease progression or unacceptable toxicity
1881455|NCT01188421|Drug|Buprenorphine/naloxone|up to 8/2 mg Sublingual (SL) per day
1881456|NCT01188421|Drug|Clonidine|up to 0.8 mg per day (oral)
1881457|NCT01188421|Drug|Tramadol ER|up to 600 mg per day
1881458|NCT01188434|Behavioral|ITSAN|integrated behavioral intervention for substance abuse, parenting skills, and basic needs
1881459|NCT01188434|Behavioral|Services as Usual|Services as usual referred by child welfare
1881460|NCT01188447|Procedure|Canadian C-Spine Rule|Paramedics will apply a validated decision rule (the Canadian C-spine Rule) to determine whether or not immobilization is required for trauma patients being transported to the emergency department.
1881463|NCT01188473|Other|NPPV plus standard of care|Patients in the NPPV group were fitted with a nasal mask with gel seals (Comfortgel Masks, Respironics) and placed on the BiPAP Machine (Vision Bipap, Respironics). To optimize patient cooperation, the mask was initially applied manually to the patient's face. After a short adaptation period, it was firmly applied on the face by head straps to minimize air leak without causing skin injury. Pressures were initially set low for comfort and acceptance while being placed on the machine. The inspiratory positive airway pressure (IPAP) was gradually increased to 8 cm H2O in order to achieve a tidal volume of 6-9 ml/kg and the end expiratory positive airway pressure (EPAP) to 5 cm H 2O. These settings remained unchanged throughout the study period.
1881464|NCT01188486|Procedure|Stereotactic Body Radiation Therapy (SBRT)|standard of care
1881465|NCT01188486|Drug|Iohexol|1 to 5 cc
1881466|NCT01188486|Radiation|Computed Tomography (CT)|For each patient, Chest CT scans will be obtained: 1 before and 2 after interstitial injection of water soluble contrast
1881467|NCT01188486|Device|Cyberknife|Linear accelerator for producing high energy x-rays for radiation therapy.
1881468|NCT01188486|Device|Trilogy|Linear accelerator for producing high energy x-rays for radiation therapy.
1881469|NCT01188486|Device|True Beam|Linear accelerator for producing high energy x-rays for radiation therapy.
1881470|NCT01188499|Drug|Birinapant|
1881471|NCT01188512|Biological|BPZE1|Individuals will be vaccinated once intranasally with the designated dose of BPZE1 Dose 2 x 0.1 mL (0.1 mL per nostril).
1881472|NCT01188512|Biological|Placebo|Individuals will get placebo once intranasally. Dose 2 x 0.1 mL (0.1 mL per nostril).
1881473|NCT01188525|Drug|10 parents drugs adminstration|A single and concomittant administration of 10 parent drugs will be performed: Acetaminophene, cafeine, dextrometorphan, digoxin, memantine,midazolam, omeprazole, repaglinide, rosuvastatine, tolbutamide.
1881474|NCT01188538|Drug|Epiduo gel|Once daily application on the face in the evening for 12 weeks
1881475|NCT01188538|Drug|BPO|Once daily application on the face in the evening for 12 weeks
1881476|NCT01188551|Drug|Dexmedetomidine|dexmedetomidine (1 µg/kg) will be administered intranasally
1881477|NCT01188551|Drug|Fentanyl|fentanyl (2 µg/kg) will be administered intranasally
1881478|NCT01188551|Drug|Midazolam|Sedative given pre-op.
1881479|NCT01188564|Drug|rhC1INH|One i.v. injection of rhC1INH at the dose of 50 U/kg, for patients up to 84 kg; one i.v. injection of rhC1INH at the dose of 4200U (2 vials) for patients of 84 kg body weight or greater.
1881480|NCT01188564|Drug|Placebo (Saline)|One i.v. injection of saline (NaCl 0.9% w/v), equivalent in volume to the active treatment
1881481|NCT01188577|Drug|Epinephrine Inhalation Aerosol, HFA|10 inhalations of epinephrine inhalation aerosol, 125 mcg/inhalation
1881482|NCT01188577|Drug|Epinephrine Inhalation Aerosol|Epinephrine Inhalation Aerosol, 220 mcg/ inhalation, 10 inhalations
1881483|NCT01188590|Device|TOSCA 500 monitor|transcutaneous ear lobe probe that monitors pulse rate, oxygen saturation and carbon dioxide levels
1881484|NCT01190254|Drug|asenapine 2.5 mg|asenapine 2.5 mg tablets for sublingual administration
1881485|NCT01190254|Drug|asenapine 5.0 mg|asenapine 5.0 mg tablets for sublingual administration
1881486|NCT01190254|Drug|placebo|asenapine-matched placebo tablets for sublingual administration
1881487|NCT01190267|Drug|asenapine|asenapine 2.5 mg or 5.0 mg sublingual tablets, administered BID
1881488|NCT01190280|Procedure|Cholecystectomy operation|Cholecystectomy after randomization
1881489|NCT01190293|Drug|Maraviroc|All patients (previously on an efavirenz-based therapy) will be administered maraviroc at 600mg twice-daily for 2 weeks.
1881490|NCT01190306|Device|The VEGA UV-A Illumination System|This is a portable electronic device designed to deliver a dose of UV-A light to the treatment area
1881491|NCT01190306|Drug|Riboflavin|Riboflavin is a solution that will be delivered to the treatment area
1881492|NCT01190319|Other|Strawberry Beverage|Beverage, daily for 8 weeks, 12g freeze-dried strawberry powder
1881493|NCT01190319|Other|Placebo|Placebo beverage, 8 weeks
1881494|NCT01190332|Procedure|endoscopic sphincterotomy by conventional method|
1881495|NCT01190332|Procedure|endoscopic sphincterotomy by rendezvous method|
1881496|NCT01190345|Drug|bevacizumab|Patients receive on day 1 of each cycle : bevacizumab 15 mg/kg (8 injections in total).
1881497|NCT01190345|Drug|no bevacizumab|no bevacizumab
1881498|NCT01190358|Dietary Supplement|Placebo|Sugar pill containing maltodextrin.
1881499|NCT01190358|Dietary Supplement|Grape seed extract|Meganatural Gold® contains 300mg of grape seed extract.
1881500|NCT01190371|Drug|Artesunate|Oral, once daily, 7-day regimen of artesunate 2mg/kg/day
1881501|NCT01190384|Other|Couscous plus fiber|Soup with added fiber to equal Bean soup. Subjects' serving size is isocaloric to the experimental Bean soup.
1881502|NCT01190384|Dietary Supplement|Grape seed extract|300 milligrams of grape seed extract in capsule form will be consumed with the low ORAC value soup.
1881503|NCT01190384|Other|Bean Soup|Experimental soup with a high fiber content and ORAC value. The ORAC value is the Oxygen Radical Absorbance Capacity (ORAC) score which is a measure of the antioxidant levels of food and is expressed as Trolox Equivalents. The antioxidants in the soup are derived from beans.
1881504|NCT01190397|Device|Warming goggles|
1881505|NCT01190397|Device|warm and moist compresses|
1881506|NCT01190410|Drug|certolizumab pegol|400 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 200 mg for subjects 20 to < 40 kg
1881507|NCT01190410|Drug|certolizumab pegol|200 mg administered subcutaneously every 4 weeks for subjects ≥ 40 kg or 100 mg for subjects 20 to < 40 kg
1881508|NCT01190423|Behavioral|Out-Patient Psychotherapy Treatment|Individual and Group Therapy Sessions
1881509|NCT01190436|Drug|Bisoprolol|Bisoprolol will be administered at an initial dose of 5 milligram (mg) once daily for 2 weeks. If the blood pressure would be greater than or equal to 130/80 mmHg after 2 weeks, then dose will be adjusted to 10 mg once daily. Total duration of study treatment will be 12 weeks.
1881510|NCT01190449|Biological|ofatumumab|Given IV
1881511|NCT01190462|Biological|cetuximab|
1881512|NCT01190462|Drug|simvastatin|
1881513|NCT01190462|Other|laboratory biomarker analysis|
1881514|NCT01190475|Drug|BGS649|
1881515|NCT01190475|Drug|BGS649|
1881516|NCT01190475|Drug|Placebo|
1881517|NCT01190488|Behavioral|End-of-Life / Advanced Care Decision Aid|Patients assigned to the control group will receive usual care which includes a discussion of knowledge about their medical condition as well as their goals of care. Typically, this discussion includes one physician and one advanced practice nurse however there are occasions such as weekends and during clinic time where the consult will have only one palliative care team member. This consultation typically includes a discussion of advanced directives using the five wishes document.
1881518|NCT01190488|Behavioral|Active Comparator|TAU
1881519|NCT01190501|Device|complier device|"The procedure of use of complier has to follow the recommendations for standardization of subject conditions.
Assessment of arterial distensibility: pulse wave velocity (PWV), aortic stiffness is assessed by PWV which is a classic index of arterial stiffness. A semi-automatic device is used to measure carotid-femoral PWV. The distance covered by the pulse wave is measured on the surface of the body and represented the distance between the 2 recording sites."
1881520|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fed condition
1881521|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fed condition
1881522|NCT01190514|Drug|desvenlafaxine succinate sustained release|Two tablets of 25 mg, single administration, under fast condition
1881523|NCT01190514|Drug|desvenlafaxine succinate sustained release|One tablet of 50 mg, single administration, under fast condition
1881524|NCT01190527|Radiation|FDG-PET|This study is designed to apply functional imaging, Fluorodeoxyglucose-Positron Emission Tomography (FDG-PET) before treatment and again during treatment to see if it helps predict how well the treatment works for the cancer. The standard of care for patients with stage III unresectable NSCLC is combined chemoradiotherapy. This study will seek to determine 2 year local-regional progression free survival in patients with non-small cell lung cancer (NSCLC) when an adaptive plan is applied based on repeat PET-CT imaging during the course of radiation therapy (during RT), and investigate if there is an improvement compared to those treated with conventional radiation therapy without field and/or dose modification. The investigators hypothesize that during-RT, PET-CT-based adaptive therapy will allow them to dose escalate in the majority of patients and meet the dose limits of normal structures, thus improving local tumor control without increasing toxicity.
1881525|NCT01190540|Behavioral|Training and supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 months. This training and supervision will support the proper utilization of newly learned clinical skills.
1881526|NCT01190540|Behavioral|Training and Supervision|On-Site-Support (OSS) service training will occur monthly for a period of 9 to 15 months. This training and supervision will support the proper utilization of newly learned clinical skills and continuous quality improvement of processes of care. For the control group, the OSS training will occur during phase 2, after a randomly assigned wait list control period.
1881527|NCT01190540|Behavioral|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
1881528|NCT01190540|Behavioral|Integrated Management of Infectious Disease (IMID)|The IMID is a 9-month training program that begins with a three-week course at the Infectious Diseases Institute (IDI) in Kampala Uganda. After the course participants engage in 12 weeks of distance learning followed by a one-week boost course at the IDI. Then the engage in 12 more weeks of distance learning and a final one-week boost course. This intervention is offered to two clinicians (clinical officers or registered nurses or midwives) at every OSS Phase 1 and OSS Phase 2 site.
1881529|NCT01190553|Drug|Amantadine|Initiation: IV amantadine 200mg/500ml * 1/d for 3 days Maintenance: IV amantadine 200mg/500ml once per 6 weeks for 6 months
1881530|NCT01190592|Other|Resistance Training with Milk Supplementation in Adolescents|"On resistance training days, the RT+ milk group will receive milk (280kcals) immediately following exercise and milk at another time during the day. The RT+ juice group will receive fruit juice immediately following resistance exercise and juice again another time during the day. The RT+ water group will receive water following resistance exercise and water at another time during the day.
On non training days, students in the RT+ milk group will receive milk. Students in the RT+ juice group will receive juice. The RT+ water group will receive water during the school day. On non-RT days, the total volume of milk, juice, or water will be split into two administration times during the school day."
1881531|NCT01190631|Device|Acrysof IQ (SN60WF) IOL|Acrysof IQ (SN60WF) intraocular lens implanted in the capsular bag of the eye during cataract surgery. The IOL is intended for the lifetime of the patient. Unilateral (one eye only) implantation is planned.
1881532|NCT01190644|Drug|ACE 011|35 mg subcutaneous (SC) dose on study Day 1, Day 43, Day 85
1881533|NCT01190657|Drug|Selbex|50mg/day, 3 times/day, for 14 days
1881534|NCT01190657|Drug|Selbex|50mg/day, 3 times/day, for 56 days
1881535|NCT01190670|Drug|Tacrolimus|Oral and Intravenous
1881536|NCT01190670|Drug|ASP015K|Oral
1881537|NCT01190683|Drug|Cholecalciferol|60,000 IU/week for ist eight weeks followed by 60,000 IU every 15 days for four months
1881538|NCT01190683|Drug|Calcium Carbonate|two tablets of calcium carbonate daily containing 1 gm of elemental calcium for six months
1881539|NCT01190683|Drug|cholecalciferol and calcium carbonate|60,000 IU of cholecalciferol for first eight weeks and then 60,000IU for next four months along with 1 gm of elemental calcium daily for six months
1881540|NCT01190683|Other|lactose placebo|similar number of granules and tablets as active group
1881541|NCT01190683|Other|lactose granules and tablets|one sachet every week for eight weeks followed by two sachets every month along with two lactose tablets daily
1881542|NCT01190696|Procedure|titanium elastic nailing|we inserted titanium nail in femoral fractures retrogradely
1881543|NCT01190696|Device|Hip spica casting|we applied cast for three weeks in patients with femoral shaft fracture
1881544|NCT01190709|Procedure|Dynamic Compression Plate|we made a longitudinal incision 1 cm lateral to the tibial crest, expose the fracture, and retract the muscles laterally. After determining the length of plate, we used bending instruments to contour the plate to the anatomy then threaded plate holders used to position the plate on the bone. After that we placed the drill guide at the edge of the dynamic compression unit (DCU) portion of the plate hole without applying pressure and tightening of the cortex screws results in dynamic compression. We verified the screw position with a guide wire before insertion and then inserted the locking screw.
1881545|NCT01190709|Procedure|Unreamed intramedullary nailing|we inserted the nail, without reaming, across the fracture site, with particular attention being paid to the prevention of over distraction and the achievement of cortical contact of the fracture ends. An upper diameter limit of 10 mm and a nail measuring at least 2 mm less than the diameter measured at the isthmus of the tibia on anteroposterior and lateral radiographs were stipulated.
1881546|NCT01190722|Drug|etoricoxib|120 mg once daily for the 1st 6 postoperative days
1881547|NCT01190722|Drug|Diclofenac|50 mg oral 3 times daily the 1st 6 postoperative days
1881548|NCT01190735|Drug|Caffeine alkaloid|"The following intervention will be provided for six consecutive weeks:
Week 1 (100 mg BID), Week 2 (200 mg BID), Week 3 (300 mg BID), Week 4 (400 mg BID), Week 5 and 6(500 mg BID). At the conclusion of the study, patients will decrease their dose by 100 mg BID every other day, until caffeine is stopped. This gradual reduction will be to prevent withdrawal symptoms. If a patient experiences a dose-limiting event, they will be terminated from the study, and will withdraw from the medication in the same manner. If dose-limiting events occur between visits, patients will be encouraged to decrease the caffeine dose back to the previously-tolerated dose until in-person assessment can be performed."
1881549|NCT01190748|Drug|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fasting conditions
1881550|NCT01190748|Drug|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fasting conditions
1881551|NCT01190761|Drug|Galantamine 4 mg Tablet, single dose|A: Experimental Subjects received Purepac Pharmaceutical, Company, U.S.A. formulated products under fed conditions
1881552|NCT01190761|Drug|Reminyl 4 mg Tablet, single dose|B: Active comparator Subjects received Janssen Pharmaceutica Products,U.S.A., formulated products under fed conditions
1881553|NCT01190774|Behavioral|Information to health provider without patient knowledge|The intervention consists of the assessment information from the MDAS questionnaire being given to the dentist via the receptionist without the knowledge of the patient
1881554|NCT01190774|Behavioral|dentist behaviour and patient expectancy|patient give information about their dental anxiety to the dentist
1881555|NCT01190787|Drug|velcade subcutaneous melphalan prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.
Melphalan will be given orally. Each cycle will be repeated every 28 days. Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
1881556|NCT01190787|Drug|velcade cyclophosphamide prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.
Cyclophosphamide will be given orally. Each cycle will be repeated every 28 days.
Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
1881557|NCT01190787|Drug|velcade prednisone|"INDUCTION Velcade will be given as subcutaneous (SC) injection. Each cycle will be repeated every 28 days.
Prednisone will be given orally.Each cycle will be repeated every 28 days. MAINTENANCE Velcade will be given a SC injection. Each cycle will be repeated every 28 days."
1881558|NCT01190813|Drug|Levodopa/Carbidopa|Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
1881559|NCT01190813|Drug|Placebo|Oral placebo tid
1881560|NCT01190813|Other|Patching|Two hours of daily patching
1881561|NCT01190826|Drug|ASM-024|Target dose of 10 mg ASM-024 administered once by inhalation
1881562|NCT01190826|Drug|ASM-024 100 mg|Target dose of 100 mg ASM-024 administered once by inhalation
1881563|NCT01190826|Drug|Placebo|Placebo administered once by inhalation
1881564|NCT01190839|Biological|Infliximab|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
1881565|NCT01190839|Drug|Placebo|Type=equal, unit=mg, number=5, form=intravenous infusion, route=intravenous use, once every 8 weeks
1881566|NCT01190852|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray
1881567|NCT01190852|Drug|Azelastine mono|REF = AZE mono Azelastine Hydrochloride nasal spray (= essentially combination product formulation without any FLU; US AZE mono formulation as used in pivotal studies)
1882933|NCT01193218|Drug|BI 10773|BI 10773 tablets high dose once a day
1881568|NCT01190852|Drug|Azelastine|COMP = Astelin® Nasal Spray = AZE mono Azelastine Hydrochloride nasal spray (= US marketed product)
1881569|NCT01190865|Biological|HP802-247|One dose of HP802-247 consisting off 260 mL containing keratinocytes and fibroblasts totaling 5.0 x 10.6 cells per mL, plus fibrin.
1881570|NCT01190878|Drug|ISV-303|0.075% of bromfenac in DuraSite dosed QD
1881571|NCT01190878|Drug|ISV-303|0.075% of bromfenac in DuraSite dosed BID
1881572|NCT01190878|Drug|DuraSite Vehicle|Vehicle dosed BID
1881573|NCT01190878|Drug|Xibrom™|0.09% bromfenac dosed BID
1881574|NCT01190891|Procedure|Manual Physical Therapy|Same as arm description
1881575|NCT01190891|Procedure|Corticosteroid Injection|Dose represents a glucocorticoid potency of 400 hydrocortisone equivalents/injection (mg).
1881576|NCT01190917|Behavioral|Cognitive Behavioral Therapy (CBT)|The CBT social skills curriculum is manualized and anchored in CBT strategies, such as problem identification, affective education, performance feedback, and weekly homework activities to facilitate generalization. The curriculum is a compilation of lessons targeting key social deficits in children with ASD, such as nonverbal communication, emotion recognition, and theory of mind. Structured teaching includes defining skills, breaking them down into simple, concrete steps, modeling the skill through role-play, and introducing a game or activity to practice the target skill. The approach to the parent group will be psychoeducational with a focus on reviewing target skills, rationale for teaching target skills, homework, progress or obstacles, and identifying strategies to promote generalization. Parent information handouts will be provided.
1881577|NCT01190917|Behavioral|Play Therapy|The social play group is manualized, led by a trained clinician and support staff, follows a specific routine, and contains a parent group component. Group leaders will follow participants' interests and suggestions for games. Group leaders utilize strategies such as reflective functioning statements on the child's behaviors to build emotion-focused play skills. The therapeutic setting incorporates play designed to encourage emotion-focused play including make-believe (dolls, houses), sensory (e.g. play-doh), and cooperative play (e.g. board games) toys. The approach to the parent group will be supportive rather than psychoeducational. Parents will set the agenda for discussion, facilitated by the group leader.
1881578|NCT01190930|Drug|Cyclophosphamide|Given IV
1881579|NCT01190930|Drug|Cytarabine|Given IT, IV, or SC
1881580|NCT01190930|Drug|Dexamethasone|Given orally (PO) or IV
1881581|NCT01190930|Drug|Doxorubicin Hydrochloride|Given IV
1881582|NCT01190930|Other|Laboratory Biomarker Analysis|Correlative studies
1881583|NCT01190930|Drug|Leucovorin Calcium|Given PO
1881584|NCT01190930|Drug|Mercaptopurine|Given PO
1881585|NCT01190930|Drug|Methotrexate|Given IT, PO, or IV
1881586|NCT01190930|Drug|Pegaspargase|Given IV
1881587|NCT01190930|Other|Quality-of-Life Assessment|Ancillary studies
1881588|NCT01190930|Other|Questionnaire Administration|Ancillary studies
1881589|NCT01190930|Drug|Thioguanine|Given PO
1881590|NCT01190930|Drug|Vincristine Sulfate|Given IV
1881598|NCT01190969|Dietary Supplement|Nutritional Supplement (Ensure Plus)|Subjects will be provided with 2 to 3 serves of Ensure Plus (complete nutritional beverages) and to be taken between meals
1881599|NCT01190982|Drug|LEP-ETU|275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.
1881600|NCT01190995|Drug|24% Sucrose|The enrolled neonates will be administered either a sterile solution of 24 % sucrose or double distilled water orally for a period of 7 days from enrollment. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
1881601|NCT01190995|Drug|Placebo|The patient will be enrolled into the study only after an informed written consent has been obtained from either of the parent/caregiver. At the beginning of each potentially painful procedure namely, venepuncture, venous and arterial cannulation, heel lance,orogastric tube insertion, suprapubic aspiration of urine and any other skin breaking procedure,0.5ml of solution marked with patients serial number will be administered by a prefilled syringe to the patient on the anterior aspect of the tongue , avoiding spillage , by the personnel carrying out the procedure
1881602|NCT01191008|Drug|Latanoprost-timolol maleate fixed combination ophthalmic solution|"Xalacom® Combination Eye Drops depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows. One drop should be applied to the affected eye(s) once daily."
1881603|NCT01191021|Drug|Propofol Anesthesia|Volunteers will undergo propofol anesthesia for 90 min.
1881604|NCT01191034|Drug|Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.|"The vaccine will be either the MAGE-3.A1 peptide, or the NA17.A2 peptide, or both,matching the patient's HLA type and the gene expression of his tumor. If both antigens are expressed, then the patient will receive both peptides.
This treatment will combine subcutaneous peritumoral injections of IL-2, IFN-α and GMCSF,as well as topical applications of imiquimod."
1881605|NCT01191060|Drug|Lenalidomide, Bortezomib|"Lenalidomide/Bortézomib/Dexamethasone cycles:
Number of cycles: 8 cycles for arm A
Cycle length
Dosage:
Lenalidomide: 25 mg/day on days 1-14 of each cycle
Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle
Maintenance phase (12 months):
Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
1881648|NCT01191411|Other|Mailed invitations for a colonoscopy|These patients will be mailed invitations to directly book a free colonoscopy, or to see a physician for free pre-operative screening at John Peter Smith Hospital.
1881676|NCT01191632|Radiation|one time radiation|"Radiation: one time Radiation with an intensity of
0.5 Gy Group A 2.0 Gy Group B 5 Gy Group C Beginning on a weekday 48 hours before surgery"
1881606|NCT01191060|Drug|Lenalidomide, Bortezomib|"Lenalidomide Bortezomib Dexamethasone cycles:
Number of cycles: 5 cycles for arm B
Cycle length
Dosage:
Lenalidomide: 25 mg/day on days 1-14 of each cycle
Bortézomib: 1.3 mg/m2 on days 1, 4, 8, and 11 for 1 cycle of each cycle
Maintenance phase (12 months):
Cycle length: 28 days Dosage: Lenalidomide: 10 mg/day continuously for 28 days during 3 months and if the participant tolerates 10 mg/day without complication, a dose increase to 15 mg/day will be allowed"
1881607|NCT01191073|Device|CAD/CAM fabricated RPD's|group receiving Computer-Aided Design/Computer-Aided Manufacturing (CAD/CAM)fabricated removable partial dentures (double blind)
1881608|NCT01191073|Device|traditional fabricated RPD's|group receiving traditional fabricated dentures (double blind)
1881609|NCT01191086|Drug|USL255|
1881610|NCT01191099|Device|Pimonidazol|0.5gm/m2 Pimonidazol i.v. 16-24 hours before prostatectomy
1881611|NCT01191112|Other|Peptide based enteral formula|Sole source nutrition as per HCP
1881612|NCT01191125|Other|medical food with AN777|Two(220 mL)servings every day for six months
1881613|NCT01191125|Other|oral nutritional formula|Two (220 mL) servings daily for six months
1881614|NCT01191138|Procedure|Infracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the infracolic compartment by bringing down the stomach below the mesocolon to the left of the middle colic artery
1881615|NCT01191138|Procedure|Supracolic gastrojejunal anastamosis|Following resection in whipples pancreaticoduodenectomy, the gastrojejunal anastamosis is done in the supracolic compartment.
1881616|NCT01191164|Procedure|Partial Breast Irradiation Utilizing Permanent Breast Seed Implant|"Target Volumes: The surgical cavity will be assessed with US & CT scans. The Clinical Target Volume (CTV) will encompass the surgical cavity plus 1 cm uniform expansion. The Planning Target Volume (PTV) will be the CTV plus 0.5 cm.
Dose Selection/Prescription: A minimal peripheral dose of 90 Gy (same as in the OCC study) will be prescribed to the PTV. This dose is chosen as biologically equivalent, over a 2 month period, to 50Gy in 25 fractions, for α/β of 2Gy54.
Implant Procedure and QA: This will be performed as an outpatient procedure under conscious sedation and local anesthesia, by a team with several years experience in brachytherapy and conscious sedation administration. The technique used in this pilot study will be based on the OCC technique. It is intended that two oncologists and one physicist will spend 2-3 days at the OCC to acquire detailed and firsthand knowledge of the technique and its implementation at that centre."
1881617|NCT01191177|Drug|Lovaza (omega-3-acid ethyl ester)|supplied as 1gram transparent soft-gelatin capsules filled with yellow oil, dosage is 1gram per kilogram of body weight per day, not exceeding 4grams per day until normalization of liver function test
1881618|NCT01191177|Dietary Supplement|Corn oil|1 gram per kilogram body weight per day, not exceeding 4 grams
1881619|NCT01191190|Drug|Ofatumumab/HDMP|"High dose methylprednisolone sodium succinate (HDMP) at 1gm/m2 daily as infusion for 3 consecutive days every cycle.
Ofatumumab 300mg administered Day1 of cycle 1 followed by 12 doses of 1000mg administered based on specific schedule.
Each patient will receive a maximum of 3 cycles (one cycle is 28 days)"
1881620|NCT01191203|Drug|Copper IUD|Copper IUD (CuT360)
1881621|NCT01191203|Drug|Depo Medroxyprogesterone acetate|DMPA 150 mg IM q 3 months
1881622|NCT01191216|Drug|1-methyl-d-tryptophan|
1881623|NCT01191216|Drug|docetaxel|
1881624|NCT01191216|Other|diagnostic laboratory biomarker analysis|
1881625|NCT01191216|Other|pharmacological study|
1881626|NCT01191229|Device|Tecnis one-piece MF IOL|25 patients to be implanted after cataract surgery
1881627|NCT01191229|Device|Crystalens AO|25 patients that are previously implanted
1881628|NCT01191255|Drug|ferric citrate, ca acetate, sevelamer carbonate, placebo|All intervention doses will be based on serum phosphorus levels and/or drug label requirements
1881629|NCT01191268|Drug|Insulin Glargine|
1881630|NCT01191268|Drug|LY2189265|
1881631|NCT01191268|Drug|Insulin Lispro|
1881632|NCT01191281|Behavioral|Diet/nutrition counsel+food aid|Patients enrolled in the experimental arm will receive dietary and nutritional assistance plus a food aid basket, specifically tailored to meet the nutritional needs of the target population.
1881633|NCT01191281|Other|Dietary/nutrition counsel|Patients enrolled in the active comparison arm will receive dietary and nutrition counseling designed to help them meet their nutrition needs, based on foods which are locally available, culturally acceptable and within their budget.
1881634|NCT01191294|Other|Simulation teaching session|Simulation-based, mastery learning educational intervention in visual screening for melanoma
1881635|NCT01191320|Drug|Placebo|Placebo capsule 1x daily for 3 months
1881636|NCT01191320|Drug|Androxal|Capsules 12.5 mg or 25 mg 1x daily for 3 months
1881639|NCT01191346|Other|3T MRI|3T MRI in addition to standard 1.5T MRI for treatment planning
1881640|NCT01191359|Biological|oral immunotherapy|orally applied specific immunotherapy
1881643|NCT01191385|Drug|Any treatment for unresectable HCC as chosen by the physician|Only those patient are allowed to be enrolled that receive any HCC treatment for unresectable HCC as chosen by the physician except sorafenib. During the course of the study, each treatment is allowed.
1881644|NCT01191398|Drug|Atropine (0.01mg/kg)|Atropine will be given at 0.01mg/kg with a minimum dosage of 0.1mg and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
1881645|NCT01191398|Drug|Glycopyrrolate (0.01mg/kg)|Glycopyrrolate will be given at 0.01mg/kg with no minimum dosage and a maximum dosage of 0.4mg. This medication will be given once by IV 30 minutes before the administration of Ketamine.
1881646|NCT01191398|Drug|Normal saline 0.9%|Normal Saline of 0.9% will be given at a volume of 2mL. This medication will be given once by IV 30 minutes before the administration of Ketamine
1881647|NCT01191411|Other|Mailed invitations for FIT test kits|Mailed invitations for the non-invasive immunochemical stool blood test will be the intervention compared to the standard care at John Peter Smith Hospital. Patients will be invited to complete a free home-based, non-invasive immunochemical stool blood test.
1881649|NCT01191411|Other|Visit Based Care|Visit based standard care at John Peter Smith Hospital. Patients will continue to see their regular physician and follow the physician's recommendations as they normally would.
1881650|NCT01191424|Drug|CHF1535 NEXT DPI|FIXED COMBINATION OF BECLOMETHASONE DIPROPIONATE 100µg PLUS FORMOTEROL FUMARATE 6 µg DRY POWDER INHALER
1881651|NCT01191424|Drug|BDP DPI and formoterol DPI|FREE COMBINATION OF LICENSED BECLOMETHASONE DPI AND FORMOTEROL DPI
1881652|NCT01191450|Drug|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg|Chlorthalidone 25 mg + amiloride hydrochloride 5 mg - one oral tablet a day in the morning during approximately 12 weeks
1881653|NCT01191450|Drug|Higroton® Laboratório Novartis|Chlortalidone 25mg - oral tablet a day in the morning during approximately 12 weeks
1881654|NCT01191463|Other|Mung Bean Meal|50g mung beans will be cooked to a curry with oil, spices and small amounts of vegetables.
1881655|NCT01191463|Other|Guava|A fresh Guava fruit will be provided raw (approx 100g fresh weight)
1881656|NCT01191476|Drug|Sevoflurane Inhalational Induction and Maintenance|Sevoflurane was administered at a concentration of 8% via vital capacity induction and sevoflurane 0.8-1.5 minimum alveolar concentration (MAC) with a rate of 1 L/min fresh gas flow for maintenance.
1881657|NCT01191476|Drug|Propofol Target Controlled Infusion for Induction and Maintenance|Propofol IV 4 ug/mL was administered with target controlled infusion (TCI) for induction and propofol 3 to 6 ug/mL was administered with TCI for maintenance.
1881658|NCT01191476|Drug|Propofol Target Controlled Infusion for Induction and Sevoflurane Inhalation for Maintenance|Propofol was administered as a bolus IV dose of 1.5 mg/kg for induction at a rate of 40 mg/10 seconds. During maintenance, a sevoflurane concentration of 0.8-1.5 minimal alveolar concentration (MAC) was administered at a rate of 1 L/min fresh gas flow.
1881659|NCT01191489|Device|High Flow Conditioned Oxygen Therapy in High Risk Patients|OptiFlow system (R) with nasal cannula.
1881660|NCT01191489|Device|Non-invasive mechanical ventilation|Bilevel pressure support through a facial mask
1881661|NCT01191489|Device|Conventional Oxygen Therapy|Conventional Oxygen Therapy with nasal cannula or Venturi facial mask.
1881662|NCT01191515|Device|Monofocal Intraocular Lenses|Monofocal Intraocular Lenses
1881663|NCT01191528|Device|capnostream 20, Oridian Medical 1987 ltd, Needham MA|"Oxygen blood saturation measured by a s sensor that reflects infrared light on oxygenated and deoxygenated arterial blood via a noninvasive, clip on digit sensor connected to a combination capnometer and pulse oximeter monitor.
End-tidal Carbon dioxide (EtCO2) is measured with a noninvasive nasal cannula sampling line which calculates the EtCO2 from exhaled air. Measurements recorded at 5 second intervals."
1881665|NCT01191554|Drug|Tranexamic Acid|High and low dosage. Loading dose followed by continuous infusion in operation.
1881666|NCT01191567|Procedure|VAC treatment|wound treatment with VAC-therapy
1881667|NCT01191567|Procedure|Conventional treatment|wound treatment with conventional treatment according to the hospitals local routines
1881668|NCT01191580|Behavioral|Interpersonal Psychotherapy|Interpersonal Psychotherapy will consist of twelve 50-minute sessions delivered within a period of 16 weeks. IPT is divided into three phases.
1881669|NCT01191580|Behavioral|Problem-Solving Therapy|Problem-Solving Therapy will also consist of 12 50-minute sessions. The goals of the PST are: 1) to assist patients to identify and link life situations related to the depression; 2) to increase the effectiveness of the patient's problem-solving attempts at coping with current problems based on an intervention carried out in a concrete, structured and, unambiguous manner.
1881670|NCT01191580|Behavioral|Brief Supportive Psychotherapy|"The treatment approach will follow the standard supportive therapy approaches used in depression and medical illness, as noted below.
Brief Supportive Psychotherapy has a biopsychosocial perspective, recognizing contributions of genetic predisposition and neuroendocrine factors (Novalis et al., 1993, p. 257-277). Its goals are to maximize patient function during crisis, to support the patient's judgment with the therapist's reasoning skills, and to engender hope for recovery. Primary techniques and practices include reality testing; being relatively accepting of existing defenses but attempting to restructure them when appropriate; and, using self-esteem enhancing measures."
1881671|NCT01191593|Procedure|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
1881672|NCT01191593|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
1881673|NCT01191606|Procedure|the change of ventilatory mode|One lung ventilation initiated with volume controlled ventilation(OLV-VCV) with an inspired oxygen fraction (FIO2) of 1.0, a tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to pressure controlled ventilation and the inspiratory pressure was adjusted to obtain the tidal volume 6 mL/kg. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
1881674|NCT01191606|Procedure|the change of ventilatory mode|One lung ventilation initiated with pressure controlled ventilation with an inspired oxygen fraction (FIO2) of 1.0, an inspiratory pressure provided the tidal volume 6 mL/kg based on PBW and respiratory rate to maintain PaCO2 between 35-45 mmHg. After 30 min, the ventilator was switched to VCV with a tidal volume 6 mL/kg based on PBW. No external positive end-expiratory pressure was applied throughout the entire study. Arterial PaO2, PaCO2, peak inspiratory pressure (Ppeak), mean inspiratory pressure (Pmean), plateau inspiratory pressure (Pplateau) were recorded at the end of each ventilaroty mode.
1881675|NCT01191619|Procedure|McIvor retractor|The Mclvor blade- guided technique (McIvor group) involved the following steps. The PLMA was lubricated on the posterior aspect of the deflated mask with a water-based lubricant. The McIvor blade was fully inserted beneath the tongue of the patients. The tongue was lifted gently with the McIvor blade and PLMA was introduced into a space between the McIvor blade and maxillary incisors holding the bite block of the PLMA. The PLMA was advanced into the hypopharynx until definite resistance was felt and McIvor blade was removed.
1881677|NCT01191632|Radiation|No Radiation|Control group with 0Gy
1881678|NCT01191645|Drug|naloxone|Injection fluid, solution 0,4 mg/kg Bolus infusion 6ug/kg at one occasion Continuous infusion 0,1 ug/kg/minute during 50 min
1881679|NCT01191645|Drug|remifentanil|Powder for injection/ infusion fluid solution, 2 mg Infusion TCI 1ng/kg 10 min ( 0,05 ug/kg/min) Infusion TCI 2ng/kg 10 min ( 0.10 ug/kg/min) Infusion TCI 3ng/kg 20 min ( 0,15 ug/kg/min)
1881680|NCT01191645|Drug|Sodium Chloride|Infusion fluid, solution 9 mg/ml ( hydrogenic solution )
1881681|NCT01191645|Drug|metoclopramide|Injection fluid, solution 5 mg/mg Iv injection 0,2 mg/kg at one occasion
1881682|NCT01191684|Other|laboratory biomarker analysis|Correlative studies
1881683|NCT01191684|Other|enzyme-linked immunosorbent assay|Correlative studies
1881684|NCT01191684|Other|flow cytometry|Correlative studies
1881685|NCT01191684|Other|immunoenzyme technique|Correlative studies
1881686|NCT01191684|Biological|modified vaccinia virus ankara vaccine expressing p53|Given SC
1881687|NCT01191697|Drug|bevacizumab|Given intravenously on day 1 of each cycle beginning cycle 2
1881688|NCT01191697|Drug|trastuzumab|Given intravenously on day 1 of each treatment cycle
1881689|NCT01191697|Drug|oxaliplatin|Given intravenously on day one of each cycle beginning cycle 2
1881690|NCT01191697|Drug|capecitabine|Taken orally on days 1-14 of each cycle beginning cycle 2
1881691|NCT01191710|Other|In vitro fertilization|In vitro fertilization procedure with gonadotropin induced follicular ovarian stimulation
1881692|NCT01191723|Drug|MAP0004|3.0mg orally inhaled MAP0004 administered in Treatment B as per protocol
1881693|NCT01191723|Drug|Inhaler Placebo|Placebo for Inhaler administered in Treatments A and C
1881694|NCT01191723|Drug|Moxifloxacin|400mg encapsulated tablet administered in Treatment A as per protocol
1881695|NCT01191723|Drug|Placebo Capsule|Placebo for Moxifloxacin administered in Treatment B and Treatment C
1881696|NCT01191736|Behavioral|No training, assessed within 60 mins|Subjects receive no training in resuscitation
1881697|NCT01191736|Behavioral|Ultra-brief video; assessed in 60 mins|Subjects receive an ultra-brief (90-second) video on hands-only CPR
1881698|NCT01191736|Behavioral|Brief video; assessed in 60 mins|Subjects receive a brief (5-minute) video on hands-only CPR
1881699|NCT01191736|Behavioral|Brief video + hands-on; ass'd in 60 mins|Subjects receive a brief (5-minute) video with hands-on manikin practice
1881700|NCT01191736|Behavioral|Ultra-brief video; assessed at 2 months|Subjects see ultra-brief video (90-seconds), are assessed two months later
1881701|NCT01191736|Behavioral|Brief video; assessed 2 months later|Subjects see brief video (5 minutes), are then assessed two months later
1881702|NCT01191736|Behavioral|Brief video + hands-on; ass'd 2 ms later|Subjects see brief (5-minute) video, receive hands-on training, and are assessed two months later
1881703|NCT01191749|Drug|Alemtuzumab|10 mg by vein over 2 hours on Days 1 to 10 of a 28 day cycle.
1881704|NCT01191762|Drug|sevelamer carbonate|2400 mg with each meal for 4 weeks
1881705|NCT01191762|Drug|placebo|3 tablets with each meal
1881706|NCT01191775|Drug|PNT2258|Patients will receive PNT2258 as an intravenous infusion once daily for 5 consecutive days (Days 1-5) of every 21-day cycle (3 weeks). The treatment cycle repeats every 3 weeks for up to 6 cycles in the absence of disease progression, unacceptable toxicity, or patient withdrawal from the study.
1881707|NCT01191788|Behavioral|Group Cognitive Behavioral Therapy|16 two hour sessions of group CBT
1881708|NCT01191788|Behavioral|Group CBT for Depression|16 of group CBT for depression delivered in 2 hour groups for up to 8 weeks by a trained substance abuse treatment counselor
1881709|NCT01191801|Drug|vosaroxin + cytarabine|"Vosaroxin days 1 and 4: 90 mg/m2 for induction 1; 70 mg/m2 for all other cycles
Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
1881710|NCT01191801|Drug|placebo + cytarabine|"Placebo days 1 and 4: volume matched to vosaroxin
Cytarabine 1 g/m2 daily on days 1-5 (IDAC)"
1881711|NCT01191814|Procedure|Metal stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a metal stent.
1881712|NCT01191814|Procedure|Plastic stent|Patients with pancreatic cancer causing bile duct obstruction will be treated by placement of a 10Fr plastic stent.
1881713|NCT01191840|Drug|Vancomycin|Duration
1881714|NCT01191840|Drug|Vancomycin|Duration
1881715|NCT01191866|Behavioral|psychosocial intervention|The interventions will include an art therapist, a social worker and volunteer work under the supervision of a diabetes nurse. These therapies will be given to selected patients based on individual needs. We will use existing questionnaires in order to identify problematic areas and quantify quality of life
1881716|NCT01191879|Other|Blood test|Blood test
1881717|NCT01191892|Drug|carboplatin|
1881718|NCT01191892|Drug|gemcitabine hydrochloride|
1881719|NCT01191892|Drug|vandetanib|
1881720|NCT01191892|Drug|Placebo|Placebo of vandetanib tablet
1881721|NCT01191905|Drug|high dose CRRT|clearance of 80 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
1881722|NCT01191905|Drug|Conventional dose CRRT|clearance of 40 mL/Kg/hr (1:1 balanced pre-dilution CVVHDF)
1881723|NCT01191918|Drug|Donepezil and Lithium|Donepezil dose will be started at 5mg/d and increased to 10 mg/d in 1 week.
1881724|NCT01191918|Drug|Placebo plus Lithium|
1881725|NCT01191944|Drug|pramipexole immediate release tablet|0.375mg-4.5mg(daily dose), three times a day
1881726|NCT01191944|Drug|pramipexole extended release tablet|0.375mg-4.5mg, once a day
1881727|NCT01191957|Drug|Busulphan plus Cyclophosphamide|"I.V. Bu (Busilvex), 12.8 mg/kg:
Day -9: 0.8 mg/kg/dose x 4 doses Day -8: 0.8 mg/kg/dose x 4 doses Day -7: 0.8 mg/kg/dose x 4 doses Day -6: 0.8 mg/kg/dose x 4 doses Day -5: Rest
Followed by:
Cyclophosphamide, 120 mg/kg iv:
Day -4: 60 mg/kg Day -3: 60 mg/kg"
1881728|NCT01191957|Drug|Busulphan plus Fludarabine|"I.V. Bu (Busilvex), 12.8 mg/kg:
Day -6: 0.8 mg/kg/dose x 4 doses Day -5: 0.8 mg/kg/dose x 4 doses Day -4: 0.8 mg/kg/dose x 4 doses Day -3: 0.8 mg/kg/dose x 4 doses plus:
Fludarabine, 4 x 40 mg/m² iv:
Day -6: 40 mg/m² Day -5: 40 mg/m² Day -4: 40 mg/m² Day -3: 40 mg/m²"
1881730|NCT01191996|Biological|MIS416|MIS416 intravenously every week
1881731|NCT01192009|Dietary Supplement|Leucine|7.2 g of leucine during 2 weeks
1881732|NCT01192009|Dietary Supplement|Placebo|7.2 g of alanine during 2 weeks
1881733|NCT01192022|Biological|TachoSil®|Intraoperative application as secondary hemostatic treatment
1881734|NCT01192022|Device|Surgicel® Original|Intraoperative application as secondary hemostatic treatment
1881737|NCT01192048|Other|Blood Sample Collection|Blood sample collection for direct sequencing, microarray, single nucleotide polymorphism, whole-genome array comparative genomic hybridization DNA analyses, and/or whole exome sequencing.
1881738|NCT01192074|Device|Ultrasound|Preprocedure ultrasound examination of the spine
1881739|NCT01192087|Drug|Cetuximab|cetuximab initial dose (7 days prior to RT treatment start): 400 mg/m² body surface cetuximab weekly doses (from RT treatment start throughout radiation treatment): 250 mg/m² body surface
1881743|NCT01192113|Drug|Mecobalamin IV Injection|Mecobalamin injection 0.5 mg/ ml administered as an intravenous (IV) injection 3 times a week for four weeks
1881744|NCT01192113|Drug|Mecobalamin IM injection|Mecobalamin injection 0.5 mg/ ml administered as an intramuscular (IM) injection 3 times a week for four weeks
1881745|NCT01192113|Drug|Mecobalamin IV or IM injection|Mecobalamin injection 0.5 mg/ ml administered as an IM or IV injection 3 times a week for four weeks
1881746|NCT01192126|Device|Bausch & Lomb new daily disposable|Test lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
1881747|NCT01192126|Device|Johnson & Johnson Acuvue Moist|Control lenses are to be worn for approximately one week. Lenses will be worn on a daily wear basis.
1881748|NCT01192139|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
1881749|NCT01192139|Drug|metformin XR|Tablets, Oral, 500 mg. once daily, Single dose
1881750|NCT01192139|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 500 mg), once daily, Single dose
1881751|NCT01192152|Drug|saxagliptin|Tablets, Oral, 5 mg, once daily, Single dose
1881752|NCT01192152|Drug|Glucophage XR|Tablets, Oral, 500 mg, once daily, Single dose
1881753|NCT01192152|Drug|saxagliptin + metformin XR (FDC tablet)|Tablet, Oral, (saxagliptin 5 mg)(metformin XR 1000 mg), once daily, 4 days
1881754|NCT01192165|Drug|Trametinib (GSK1120212)|Investigational small molecule targeted therapy (MEK1/2 inhibitor)
1881755|NCT01192165|Drug|Docetaxel|Chemotherapy
1881756|NCT01192165|Drug|Erlotinib|Small molecule targeted therapy (EGFR inhibitor)
1881757|NCT01192165|Drug|Pemetrexed|Chemotherapy
1881758|NCT01192165|Drug|Carboplatin|Chemotherapy
1881759|NCT01192165|Drug|nab-Paclitaxel|Chemotherapy
1881760|NCT01192165|Drug|Cisplatin|Chemotherapy
1881761|NCT01192178|Drug|FLOVENT™ DISKUS™ 100 mcg BID|FLOVENT™ DISKUS™ 100 mcg, one inhalation twice daily (BID) from the DISKUS device from randomization through the end of study (week 16).
1881762|NCT01192178|Drug|ADVAIR™ DISKUS™ 100/50 mcg BID|ADVAIR™ DISKUS™ 100/50 mcg is a combination product containing a 100 mcg fluticasone propionate and a 50 mcg salmeterol. One inhalation from the DISKUS device twice daily (BID) from randomization through end of study (week 16).
1881763|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
1881764|NCT01192191|Drug|Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg|Fluticasone furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
1881765|NCT01192204|Drug|10% FBR containing bioadhesive gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
1881766|NCT01192204|Drug|placebo gel|0.5 gm applied 4 times daily to the oral premalignant lesion site for a duration of 3 months
1881767|NCT01192217|Procedure|Modified thoracoscopic technique|Two-port thoracoscopic technique
1881768|NCT01192217|Procedure|Axillary mini-thoracotomy|Axillary mini-thoracotomy
1881769|NCT01192230|Drug|Endostatins|7.5mg/m2 qd *14d,q3w
1881770|NCT01192230|Drug|Docetaxel|75mg/m2 D1, q3w,4-6cycles
1881771|NCT01192243|Drug|Gefitinib|250mg qd po d3-16
1881772|NCT01192243|Drug|Pemetrexed|500mg/m2 venous infusion,D1,q3w
1881773|NCT01192243|Drug|Cisplatin or carboplatin|Cisplatin:75mg/m2, venous infusion,D1,q3w or Carboplatin: AUC 5, venous infusion, D1,q3w
1881774|NCT01192269|Dietary Supplement|DHA (docosahexaenoic acid)|1 x 950 mg capsules per day orally, each capsule providing ~520 mg of DHA as a triglyceride. The liquid fill contains DHASCO® oil, derived from the microalgae, Schizochytrium sp., high-oleic sunflower oil, natural mixed tocopherols, ascorbyl palmitate, and rosemary extract (flavouring). The gelatin shell contains glycerin, water, and colouring (carmel, carmine, turmeric).
1881775|NCT01192282|Procedure|Medical / Surgical Treatment|All participants received treatment based on the morphology and distributions of lesions. For the treatment with Trichloroacetic Acid (TCA), patients were advised to attend the clinic weekly until no visible lesions seen. For electrosurgery or laser, patients were given a date for admission a day prior to surgery. Post-operatively, she remained in the ward for at least five days.
1881778|NCT01192321|Device|Toric T3 - T9|Bilateral implantation of Alcon AcrySof Toric Intraocular Lens (IOL) models SN60T3 through SN60T9 following cataract removal.
1881779|NCT01192321|Device|Monofocal|Bilateral implantation of any monofocal Intraocular Lens (IOL) following cataract removal.
1881780|NCT01192360|Procedure|Phase contrast flow velocity mapping (PC)|An MRI is done using the phase contrast flow velocity mapping (PC)technique. Using PC, an imaging slice is prescribed perpendicular to the vessel's course. Within the pulmonary circulation, PC can quantify total pulmonary blood flow and the right / left distribution of the lung blood flow volume.
1881781|NCT01192360|Procedure|Dynamic contrast-enhanced magnetic resonance imaging|Dynamic contrast-enhanced magnetic resonance (DCE MR) perfusion imaging imaging is a non-invasive method to quantify regional pulmonary blood flow. A bolus of gadolinium-containing contrast medium is injected and its passage through the pulmonary circulation traced using a repetitive rapid three-dimensional (3D) T1 weighted angiography sequence.
1881782|NCT01192373|Other|Metabolic substrate modulation|for high circulation free fatty acids: Heparin (250IE/hour) + intralipid (20%, 62 ml/hour).
1881783|NCT01192373|Other|metabolic substrate modulation|low circulating free acids: hyperinsulinaemic euglycemic clamp (0,8 mUkg/min) with venous blood glucose at 4,5-6,5 mM.
1881784|NCT01192399|Biological|Eculizumab|Subjects were treated with open label Eculizumab and following the dose described in the arm/group description.
1881785|NCT01192412|Procedure|Intervention is blood pressure management approach|1) 'Less tight' control. The dBP treatment goal is 100 mmHg. For safety, if dBP is >105 mmHg, then antihypertensive medication must be started or increased in dose. For dBP <100 mmHg, antihypertensive therapy should be decreased in dose or stopped, as appropriate. The intervention will be applied until delivery.
1881786|NCT01192412|Procedure|Intervention is blood pressure management approach.|'Tight' control. The dBP treatment goal is 85 mmHg. For safety, if dBP is <80 mmHg, then antihypertensive medication must be decreased in dose or discontinued. If dBP is >85 mmHg, then antihypertensive therapy should be started or increased in dose. The intervention will be applied until delivery.
1881787|NCT01192438|Procedure|Laser-based thermotherapy|MRI-guided transperineal placement of a laser probe into the prostate
1881788|NCT01192464|Drug|autologous CAR.CD30 EBV specific-CTLs|Three dose levels will be evaluated. Using the modified continual reassessment method, cohorts of size two will be enrolled at each dose level. Each patient will receive one injection.
1881789|NCT01192477|Other|Ozone|All subjects will have a 3-hour exposure to clean air, a 3-hour exposure to clean air with lower ozone (0.1 ppm), and a 3-hour exposure to clean air with higher ozone (0.2 ppm). Exposures will take place at least 3 weeks apart. Order of exposure will be randomized for each subject.
1881790|NCT01192490|Drug|Lidocaine|5cc of 2% Lidocaine gel will be placed on the cervix and intra-cervically prior to placement of a Mirena
1881791|NCT01192490|Drug|Lubricant|KY Gel will be placed on the cervix and intra-cervically prior to placement of the Mirena
1881792|NCT01192503|Drug|rasagiline|1mg (2 tablets of 0.5mg) at bedtime taken by mouth for 12 weeks
1881793|NCT01192503|Drug|placebo (sugar pill)|1mg (2 tablets of 0.5mg) taken at bedtime by mouth for 12 weeks
1881794|NCT01192516|Behavioral|Tailored Activity Pacing|Therapeutic intervention will be based on a tailored approach using collected data on symptom and activity patterns of each participant.
1881795|NCT01192516|Behavioral|General Activity Pacing|Therapeutic intervention using generalized pacing instruction to manage symptoms
1881796|NCT01192529|Dietary Supplement|Supressi. T-Diet plus Range|"Supressi is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patients with neurodegenerative diseases and related malnutrition.
Experimental group patients will receive, 2 packs per day (Tetra brik aseptic)of 200 ml for 6 months."
1881797|NCT01192529|Dietary Supplement|High Protein. T-Diet plus Range|T-Diet plus High Protein is a complete high protein and moderated high energy oral nutrition supplement, indicated for the dietary management of patient with related malnutrition and with increased protein requirements.
1881798|NCT01192542|Device|galyfilcon A prototype lens|Prototype silicone hydrogel contact lens
1881799|NCT01192542|Device|enfilcon A lens|Marketed silicone hydrogel contact lens
1881800|NCT01192555|Biological|Neuroblastoma Vaccine (unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells)|"1x10^7cells/m2 each of unmodified SKNLP, with gene-modified SJNB-JF-IL2 and SJNB-JF-LTN neuroblastoma cells will be given by subcutaneous injection while suspended in Ringers solution with 5% HSA in a single syringe in a volume of up to 1 ml.
Vaccines will be given on day 0 of week 0 and then on day 0 (+ 72 hours) of weeks 2, 4, 6, 9, 12, 16, 20.
Cells will be administered as a subcutaneous injection over 1 minute using a 21-gauge needle. Procedural pain control methods may be used per institutional protocol."
1881801|NCT01192555|Drug|Cytoxan (Cyclophosphamide)|Metronomic oral cytoxan will start 72 hours prior to the first vaccination at a dose of 50 mg/m2/day. Cytoxan will be held on the day of vaccine administration and for the next 96 hours. After the first vaccine, patients will take 25 mg/m2/day as outlined on the roadmap.
1881803|NCT01192581|Drug|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 500mg
1881804|NCT01192581|Drug|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1000mg
1881805|NCT01192581|Drug|hydroxyethyl starch 130/0.4 and sodium chloride injection|routine treatment for brain hypoperfusion plus hydroxyethyl starch 130/0.4 and sodium chloride injection 1500mg
1881806|NCT01192594|Behavioral|Training in all modules including MAPP Recovery Model|50% of the case managers will complete all five modules: Disease state,psychopharmacology,symptom management, motivational interviewing and adherence, and the Milestones of Adjustment Post-Psychosis Recovery Model including the MAPP treatment guide.
1881807|NCT01192594|Behavioral|Training in all modules except MAPP Recovery Model|50% of the case managers in the study will complete only four training modules: Disease state, psychopharmacology, symptom management, and motivational interviewing and adherence. They will not complete the Milestones of Adjustment Post-Psychosis Recovery Model module.
1881808|NCT01192607|Device|Endoscopic treatment during root canal treatment|Endoscopic treatment during root canal treatment
1881809|NCT01192633|Drug|GVP|"Drug: gemcitabine, vincristine,cisplatin
cisplatin 25mg/m2，ivgtt，D1, 2, 3 gemcitabine 1000mg/m2，ivgtt，30'，D1, 8 vincristine 1.4mg/m2(less than 2 mg), iv, D1 repeat every 3 weeks"
1881810|NCT01192646|Behavioral|HBLSS|Home Based life saving skills training will be done in the intervention cluster while in the control group no training
1881811|NCT01192672|Behavioral|Expressive Writing|Subjects in the Intervention were instructed to write for 30-minute intervals for 4 consecutive days about their deepest thoughts and feelings related to their Irritable Bowel Syndrome.
1881812|NCT01192672|Behavioral|Control Writing|Subjects were asked to write about the actions they performed during the last 24 hours. They were asked not to write about their feelings or thoughts related to these actions.
1881813|NCT01192685|Procedure|Transcranial Magnetic Stimulation (TMS)|TMS will be administered to subjects 5 days a week-typically Monday through Friday, for 6 weeks.
1881814|NCT01192685|Device|near infrared spectroscopy (NIRS)|near infrared spectroscopy (NIRS) will be used to measure the blood flow in the brain
1881815|NCT01192698|Drug|IV interferon|IV interferon 5MU during anhepatic phase
1881816|NCT01192711|Device|Diabetes Interactive Diary (DID)|DID is both a CHO/insulin bolus calculator, an information technology and a telemedicine system based on the communication between health care professional (physician or dietitian) and patient by SMS messages.
1881817|NCT01192724|Drug|Cilostazol|100 mg BID, for 3 months
1881818|NCT01192724|Drug|Aspirin|Aspirin 100 mg QD, for 1 year
1881819|NCT01192724|Drug|Clopidogrel|Clopidogrel 75 mg QD, for 1 year
1881820|NCT01192750|Other|immunohistochemistry staining method|
1881821|NCT01192750|Other|laboratory biomarker analysis|
1881822|NCT01192750|Other|medical chart review|
1881823|NCT01185028|Drug|Nitazoxanide With Pegylated Interferon And Ribavirin|Nitazoxanide 500mg po bid for 4 wks followed by peg-IFN/Ribavirin/nitazoxanide for 48 weeks
1881824|NCT01185041|Dietary Supplement|Watermelon Extract|6 weeks of watermelon extract taken in two doses of 3g each per day (6g per day)containing L-citrulline/L-arginine (4/2 g)
1881825|NCT01185054|Other|½ strength apple juice|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another fluid can be used.
1881826|NCT01185054|Other|Pediatric Electrolyte|For each episode of diarrhea 10 ml/kg of fluid will be given and for each episode of vomiting 2 ml/kg will be given. If the child does not like the solution another electrolyte maintenance fluid can be used. Fluids containing non-physiological concentrations of glucose and electrolytes (carbonated drinks, sweetened fruit juices, water) will be discouraged.
1881827|NCT01185067|Drug|grape seed extract (MegaNatural BP, Polyphenolics, Inc.)|Subjects will be randomized in double-blind fashion to either grape seed extract (GSE) or maltodextrin placebo capsules for for 6 weeks. Patient will take 300 mg GSE/placebo twice a day for 6 weeks. Patient will have a 2 week washout period and then cross over to the opposite group for an additional 6 weeks.
1881828|NCT01185080|Drug|AZD8848|Nasal spray solution, intranasal, three times weekly for one month
1881829|NCT01185080|Drug|Placebo|Nasal spray solution, intranasal, three times weekly for one month
1881830|NCT01185080|Drug|AZD8848 and placebo|Nasal spray solution, intranasal, three times weekly for one month
1881831|NCT01185119|Drug|native glp-1 (7-36)|During hyperglycemic clamp and GLP-1 versus placebo infusion 10 men will be CNS-PET scanned
1881832|NCT01185132|Radiation|accelerated partial breast irradiation - 3D-conformal planning|38.5 Gy, 10 fractions over 5 days
1881833|NCT01185132|Radiation|accelerated partial breast irradiation - IMRT planning|38.5 Gy, 10 fractions over 5 days
1881834|NCT01185145|Radiation|Breast Brachytherapy with Mammosite RTS|Treatment will be performed using high dose rate brachytherapy, starting between 2-5 days of implant, 34 Gy at 1 cm in 3.4 Gy fractions BID for 5 treatment days with typical boost dose od 10 Gy given in 2 fractions at least 6 hours apart.
1881835|NCT01185145|Radiation|Intensity Modulated Radiotherapy|Accelerated Partial Breast Irradiation using intensity modulated radiotherapy, a novel planning and delivery technique for external beam radiation
1881836|NCT01185158|Drug|ZD1839 (IRESSA)|ZD1839: 250mg/day po or via g-tube Q 24 hours
1881837|NCT01185171|Drug|ZD 1839 500mg|"Optional Induction chemotherapy:
Carboplatin and paclitaxel combination will be administered for 2 cycles of 4 weeks duration each. Paclitaxel: 100 mg/m2 in 500 ml of dextrose 5% in water over 3hrs. Carboplatin: Start after completion of paclitaxel on Day 1 AUC 6 (creatinine clearance [CC] + 25). Administered in 100 ml of normal saline over 30min after completion of paclitaxel.
Resume chemotherapy C2 on D29. ZD1839: 500mg PO QD from D1 of C1 of chemoradiotherapy, uninterrupted until disease progression. Chemotherapy should be administered during all 5 weeks of radiotherapy. P.M.:Start hydroxyurea at 500 mg PO q 12hrs × 6 days. The first daily dose of hydroxyurea on Days 1 through 5 is given 2 hours prior to the first fraction of daily radiotherapy. P.M.:Start continuous infusion of 5-FU at 600 mg/m2/day × 5D. Days 1 through 5: Radiation therapy is administered twice daily at 150 cGy ZD1839 will be administered from day 1 to 14 of every chemoradiotherapy cycle."
1881838|NCT01185184|Drug|CP-690,550|Single doses separated by a minimum of 72 hour washout between treatments
1881839|NCT01185197|Drug|Myfortic plus low-dose steroid|Prednisolone: 0.25 mg/kg/day for 8 weeks then 0.15 mg/kg/day for 8 weeks then 0.1 mg/kg/day for 8 weeks then off Myfortic: 720 mg b.i.d. (540 mg b.i.d. if body weight less than 60 kg) for 24 weeks then off
1881840|NCT01185197|Drug|Prednisolone|1 mg/kg/day to be tapered over a period of 24 weeks at the discretion of the attending physician
1881841|NCT01185210|Dietary Supplement|Placebo|Subjects will receive placebo (mix of sugar and salt) 20 minutes before consuming fructose.
1881842|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 12.5 grams of alanine 20 minutes before consuming fructose.
1881843|NCT01185210|Dietary Supplement|Alanine|Subjects will receive 25 grams of alanine 20 minutes before consuming fructose.
1881844|NCT01185223|Drug|Valganciclovir|Valganciclovir 450mg tablet or Valganciclovir powder for oral solution 50mg/mL
1881845|NCT01185223|Drug|Ganciclovir|2x5mg/kg/d intravenous ganciclovir
1881848|NCT01185249|Procedure|Weigh subjects on a scale in the standing position|Subjects will stand on a scale in the mornings, and the evenings for 3 days while hospitalized.
1881849|NCT01185262|Drug|Lenalidomida and Rituximab|"Lenalidomide: Oral use. It will be administered from day 1 to 21 of 28 days cycles in a total of 6 cycles.
Rituximab, intravenous use. The dose will be administered at the standard (375 mg/m2 in the first cycle and 500 mg/m2 in successive cycles).
In the first cycle Rituximab will be administered in two divided doses:100mg/m2 total on day 1 and the rest up to 375mg/m2 on day 2.
If lenalidomide treatment starts on day 1, Rituximab will be administered, in this first cycle, on days -2 (100 mg/m2) and -1 (275 mg/m2).
In the second and subsequent cycles, 500 mg/m2 of Rituximab will be administered on day -1."
1881850|NCT01185275|Device|Alair system|Bronchial thermoplasty
1881851|NCT01185288|Biological|Adalimumab|Adalimumab in pre-filled syringes
1881852|NCT01185288|Drug|Methotrexate|Methotrexate capsule
1881853|NCT01185301|Biological|adalimumab|Pre-filled syringe every other week
1881854|NCT01185301|Drug|methotrexate|weekly oral capsule dosing
1881855|NCT01185314|Procedure|Testing for mutation status|EGFR mutation test
1881856|NCT01185327|Behavioral|Breastfeeding|Breastfeeding
1881857|NCT01185340|Drug|LY2216684|12 mg to 18 mg Administered orally, once daily for 11 weeks
1881858|NCT01185340|Drug|Placebo|Administered orally, once daily for 11 weeks
1881859|NCT01185353|Drug|LY3009104|Administered orally
1881860|NCT01185353|Drug|Placebo|Administered orally
1881861|NCT01185353|Drug|Methotrexate|Administered orally as background therapy
1881862|NCT01185366|Drug|Everolimus|10 mg by mouth once a day.
1881863|NCT01185366|Drug|Sunitinib|50 mg by mouth daily for 4 weeks on / 2 weeks off
1881864|NCT01185379|Dietary Supplement|Efalex active 50+|4 x 500 mg Efalax Active 50+, to be taken daily for 6 months.
1881865|NCT01185379|Dietary Supplement|DHA rich fish oil|4 x 500 mg DHA rich tuna oil to be taken daily for 6 months
1881866|NCT01185379|Dietary Supplement|Placebo|4 x 500 mg capsules to be taken daily for 6 months
1881867|NCT01185405|Other|Use of different strategy for voriconazole dosage adjustment|Patients will be randomly assigned into 2 groups: conventional adjustment group (CA group) and early adjustment group (EA group). Voriconazole plasma levels will be measured on day 1 (both peak and trough levels), day 3, day 5, day 10, and day 14 (all trough levels). For CA group patients, voriconazole dosage will be adjusted according to the trough levels of day 5 (steady-state level). Predefined dose adjustment protocol will be used (< 1 µg/ml: 50% increase, 1~5.5 µg/ml: no change, > 5.5 µg/ml: 50% decrease). For EA group patients, voriconazole dosage will be adjusted according to the each measurements of voriconazole levels from day 1. Adjusted dosage will be calculated using the NONMEN software.
1881868|NCT01185418|Drug|risperidone|
1881869|NCT01185418|Drug|aripiprazole|
1881870|NCT01185418|Drug|haloperidol|
1881871|NCT01185418|Drug|amisulpride|
1881872|NCT01185418|Drug|lactose|
1881873|NCT01185431|Dietary Supplement|Ficus carica (Fig paste)|Ficus carica paste 300g/day
1881874|NCT01185431|Dietary Supplement|Placebo (Placebo paste)|Placebo composition 300g/day
1881875|NCT01185444|Procedure|Hya-Joint|The Hya-Joint group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hya-Joint, derived from Streptococcus zooepidemicus and produced by a highly purified biologic fermentation process, molecular weight 650-1200 kDa),into the target knee.
1881876|NCT01185444|Procedure|Hyalgan|The control group received 3 weekly intraarticular injections of 2 ml sodium hyaluronate (Hyalgan, extracted from chicken combs, molecular weight 500-730kDa) into the knee joints.
1881877|NCT01185470|Device|Implantation of Morphine Sulfate delivering programmable pump|Patients with chronic pain responsive to intrathecal opioid analgesia as demonstrated in a morphine trial or patients with a previous successful intrathecal opioid therapy with an implantable pump will undergo implantation of pump for intrathecal delivery of Morphine Sulfate.
1881878|NCT01185509|Drug|trastuzumab|
1881879|NCT01185509|Drug|vinorelbine|
1881880|NCT01185535|Procedure|times of topical anesthesia for glottis|topical anesthesia with pressure nebulized 2% lidocaine for glottis either two times or three times or four times
1881881|NCT01185548|Drug|Tolbutamide|Administered orally
1881882|NCT01185548|Drug|Tasisulam|Administered intravenously
1881883|NCT01185561|Behavioral|Psychoeducational intervention|The intervention is group therapy for depression treatment based on cognitive behavioral therapy principles developed for women with type 2 diabetes. Specifically, the intervention comprises activities including (1) Education about how dysphoric symptoms (i.e., depressive symptoms, anxiety, and anger) affect glycemic control; (2) Recognition of dysphoric symptoms; and (3) Management of dysphoric symptoms using cognitive-behavioral skills.
1881884|NCT01185574|Dietary Supplement|Vitamin D supplementation|Vitamin D2 50,000 IU will be administered once a week for six months.
1881885|NCT01185600|Biological|Washed RBC|There is no pre-set dosage, frequency and duration for transfusion with washed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed washed RBC for the subject.
1881886|NCT01185600|Biological|Unwashed RBC|There is no pre-set dosage, frequency and duration for transfusion with unwashed RBC. It all depends on the conditions of patients during and after surgery. As circumstances arise, the physician will request needed unwashed RBC for the subject.
1881887|NCT01185613|Device|Therapy™ Cool Flex Ablation Catheter|"The device under evaluation is the 4mm Therapy™ Cool Flex Ablation Catheter. The Therapy™ Cool Flex catheter is a flexible tip, insulated, 7F catheter constructed of thermoplastic elastomer material and noble metal electrodes.
The following CE Mark devices will be used in conjunction with the Therapy™ Cool Flex Ablation Catheter
IBI-1500T11 Cardiac Ablation Generator (RF ablation generator) with software version 3.0 or higher.
Cool Point™ Irrigation Pump
Cool Point™ Tubing set
Data Logger"
1881888|NCT01185626|Other|SCP care|
1881889|NCT01185639|Radiation|stereotactic body radiation therapy|For lung, liver, axial skeleton, and adrenal tumors a dose of either 54 Gy in 3 fxs or 5000 cGy in 5 fx using SBRT techniques
1881890|NCT01185665|Device|TENS|Transcutaneous Electrical Nerve Stimulator
1881891|NCT01185665|Device|Sham-TENS|TENS without electrical output, from the outside not different from a normal TENS
1881892|NCT01185678|Drug|Qlaira or Yaz (BSP products defined as Combined Oral Contraceptive) and Cerazette or Azalia (competitor's products defined as Progestogen Only Pill)|One tablet per day, orally, 28 tablets per cycle, during three consecutive cycles.
1881893|NCT01185691|Device|Impella 2.5|Impella 2.5 implant in patients with acute decompensated heart failure
1881894|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 1 (Day 0 of stimulation period [S0]) until r-hCG day (at least 2 follicles >=17 mm)
1881895|NCT01185704|Drug|Cetrorelix acetate|Cetrotide® 0.25 mg will be administered subcutaneously once daily from Day 7 (Day 6 of stimulation period [S6]) until r-hCG day (at least 2 follicles >=19 mm)
1881896|NCT01185704|Drug|Recombinant Human Choriogonadotropin (r-hCG)|The r-hCG will be administered subcutaneously as a single dose of 250 microgram (mcg) on r-hCG day
1881897|NCT01185704|Drug|Recombinant human follicle stimulating hormone (r-hFSH)|Recombinant human follicle stimulating hormone (r-hFSH) will be administered subcutaneously at a dose between 75 and 187.5 international unit (IU) once daily from Day 2 (Day 1 of stimulation period [S1]) until r-hCG day
1881898|NCT01185730|Procedure|Right Heart Catheterization|all patients of the all centers will have Right Heart Catheterization at the diagnosis
1881899|NCT01185743|Drug|olanzapine|olanzapine 10mg od + placebo od
1881900|NCT01185743|Drug|ziprasidone|ziprasidone 40mg td
1881901|NCT01185743|Drug|placebo|placebo td
1881902|NCT01185756|Radiation|MIBG for diagnostic purpose|All patients will undergo the diagnostic test specific to the study.
1881903|NCT01185769|Dietary Supplement|Tocotrienol|500 mg of tocotrienol will be administered after consumption of high fat diet
1881904|NCT01185769|Dietary Supplement|Tocotrienol|500 mg of tocotrienol will be administered after consumption of low fat diet
1881905|NCT01185782|Drug|Gonalef® (Follitropin alfa)|Subcutaneous administration of follitropin alfa at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
1881906|NCT01185782|Drug|Purified pituitary gonadotropin (Fertinorm-P®)|Subcutaneous administration of purified pituitary gonadotropin at a dose of 75 IU/day was started on dosing Day 1 and the same daily dose was maintained for the first 7 days of the treatment period. Dose increment by 37.5 IU was permitted on dosing Day 8, Day 15 and Day 22 if the dosage increase criterion was met.
1881907|NCT01192763|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
1881908|NCT01192763|Other|laboratory biomarker analysis|Correlative studies
1881909|NCT01192763|Other|pharmacological study|Correlative studies
1881910|NCT01192763|Procedure|neoadjuvant therapy|
1881911|NCT01192763|Procedure|therapeutic conventional surgery|
1881912|NCT01192776|Procedure|Whole-body Cooling|Whole-body cooling using a Blanketrol II or III to reach either a target core temperature of 33.5°C or 32.0°C for a duration of either 72 hours or 120 hours.
1881913|NCT01192789|Drug|Amoxicillin|LHWs treat severe pneumonia with oral amoxicillin at 90 mg/kg/day.
1881914|NCT01192789|Other|Referral to Health facility|LHWs refer the severe pneumonia case to local health facility or private practitioner. In case of refused referral , treat the case with oral cotrimoxazole for 7 days.
1881915|NCT01192802|Drug|albendazole|1 tablet of 400 mg of albendazole per day for three consecutive days
1881916|NCT01192802|Drug|albendazole|single 1 tablet of 400 mg of albendazole
1881917|NCT01192802|Drug|albendazole|1 tablet of 400 mg of albendazole per day for two consecutive days
1881918|NCT01192815|Drug|erlotinib hydrochloride|Given orally or via gastronomy tube
1881919|NCT01192815|Radiation|intensity-modulated radiation therapy|IMRT will be given in 35 fractions over 7 weeks. The primary tumor and involved nodes (PTV70) will receive 2 Gy per fractions, intermediate-risk areas (PTV63) will receive 1.8 Gy per fractions, and subclinical disease sites (PTV56) will receive 1.6 Gy perfraction. The total doses will thus be 70 Gy, 63 Gy and 56 Gy, respectively.
1881920|NCT01192815|Other|pharmacogenomic studies|Optional correlative studies
1881921|NCT01192815|Other|gene expression analysis|Correlative studies
1881922|NCT01192815|Radiation|3-dimensional conformal radiation therapy|"The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions a week to 54 Gy in 27 fractions in 5.4 weeks. The boost volume covering gross tumor and clinically/radiologically involved nodes will receive boost irradiation for additional 16 Gy at 2.0 Gy. The primary tumor and clinically/radiologically-involved nodes will thus receive 70 Gy in 35 fractions over 7 weeks, and uninvolved upper neck nodes will receive an elective dose of 54 Gy in 5.4 weeks.
The uninvolved lower neck nodes will receive 2.0 Gy per fraction at 3-cm depth to a total dose of 50 Gy in 25 fractions in 5.0 weeks through a matching AP or AP/PA lower neck field."
1881923|NCT01192815|Other|biopsy|Optional correlative studies
1881924|NCT01192815|Other|pharmacological study|Optional correlative studies
1881925|NCT01192815|Other|laboratory biomarker analysis|Optional correlative studies
1881926|NCT01192815|Other|questionnaire administration|Optional ancillary studies
1881927|NCT01192815|Other|enzyme-linked immunosorbent assay|Optional correlative studies
1881928|NCT01192815|Other|polymorphism analysis|Optional correlative studies
1881929|NCT01192828|Drug|taurine|Take Taurine for 4 1/2 days, two doses per day
1881930|NCT01192841|Other|Physician uniform|Participants were given a clean uniform (scrubs) on the day of the study. They wore this for approximately 8 hours.
1881931|NCT01192854|Drug|Clevudine|Clevudine flexible dosages of 30 mg/day
1881932|NCT01192854|Drug|Adefovir|Adefovir flexible dosages of 10 mg/day
1881933|NCT01192867|Drug|Placebo|Placebo will be administered orally QD for 56 weeks
1881934|NCT01192867|Drug|RO4917838|RO4917838 will be administered orally at 20 or 10 mg QD for 56 weeks.
1881935|NCT01192867|Drug|Antipshychotics (Standard of Care)|Participants will continue to receive their stable antipshychotic as standard of care based on their prescription up to Week 56.
1881936|NCT01192880|Drug|Placebo|Participants will receive bitopertin matching placebo once daily for 56 weeks.
1881937|NCT01192880|Drug|Bitopertin|Participants will receive 10 mg or 20 mg of bitopertin.
1881938|NCT01192880|Drug|Antipsychotics|Participants will continue to receive their stable antipsychotic regiment throughout the study. Study protocol does not specify any particular antipsychotic drug and regimen.
1881939|NCT01192906|Drug|Placebo|Oral doses, once a day for 52 weeks
1881940|NCT01192906|Drug|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
1881941|NCT01192906|Drug|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
1881942|NCT01192932|Radiation|Chest CT scan|"Supine CT scan after full inspiration. Acquisition parameters: (Topogram 35 mA 120 kV 512 mm length)
90 quality ref mAs with care-dose ON
120 kV
Pitch 1.4
Rotation time 0.33 s
Acquired images 64 x 0.6 mm"
1881943|NCT01192971|Drug|Apatinib|apatinib p.o. once daily for 4 weeks
1881944|NCT01192984|Biological|KW-0761|Intravenously 8 times at 1-week intervals
1881945|NCT01192997|Biological|Menveo|Single dose Menveo (a MenACWY vaccine conjugated to CRM-197).
1881946|NCT01192997|Biological|MenACWY-TT|Single dose MenACWY-TT (MenACWY vaccine conjugated to Tetanus Toxoid, TT)
1881947|NCT01193010|Procedure|Computer-Assisted Surgical Planning|Using a CT reconstructing of affected distal radius and the normal contralateral limb, surgical guides for the osteotomy will be created to assist with surgical planning.
1881948|NCT01193010|Procedure|distal radius osteotomy|In this control group, the planning and surgical execution of the distal radius osteotomy will be performed as usual, without computer-assisted planning of the osteotomy.
1881949|NCT01193023|Other|Pressure Support|Ventilation under pressure support
1881950|NCT01193023|Device|NAVA|Ventilation under NAVA
1881951|NCT01193036|Behavioral|Part 1: Interview + Questionnaires|Questionnaires to be completed immediately after interview, which will take approximately 15 minutes.
1881952|NCT01193036|Behavioral|Part 2: Multiple Questionnaires|Questionnaires to be repeated about every 2 weeks for 1 year.
1881953|NCT01193049|Drug|Prednisone|Prednisone (25 mg) tablets as a single oral dose on Day 1 of each study period
1881954|NCT01193049|Drug|Placebo|Matching placebo tablets as a single oral dose on Day 1 of each study period
1881955|NCT01193062|Drug|PF-04995274|Subjects will be randomized to receive single oral doses of 0.1 mg, 10 mg, 15mg/ 40 mg PF-04995274 or a placebo
1881956|NCT01193062|Drug|PF-04995274|Doses for cohort 2 will be decided based on an Interim analysis of data from cohort 1. The highest dose to be used in Cohort 2 not to exceed 15mg
1881957|NCT01194180|Biological|BCG: 100 microlitres ~ 2-8 x 105 pfu|BCG vaccination at day C (challenge day) then punch biopsy at day C+14
1881958|NCT01194180|Biological|MVA85A: 1 x 108 pfu BCG: 100 microlitres ~ 2-8 x 105 pfu|MVA85A vaccination at day C-28 followed by BCG vaccination at day C (challenge day) then biopsy at day C+14
1881959|NCT01194193|Drug|AZD8055|Oral tablet, single dose on Day 1, followed by a 48 hour - 7 day washout and then either twice daily alternate days dosing from multiple dose day 1 onwards or twice daily dosing for 21 days from multiple dose day 1 onwards followed by 7 days no treatment. Cycles of 28 days.
1881960|NCT01194206|Radiation|stereotactic body radiation therapy|At least 3 gold standard Cyberknife fiducials will be placed in the liver w/in 6 cm of the tumor for image guidance during radiation therapy. At least 1 wk will elapse between fiducial placement and tx planning simulation to allow for fiducial settling and any migration.The full radiation tx will be given ideally in 3 consecutive days. In any case there must be a minimum of 24 hrs between fractions and all 3 fractions will be delivered w/in 14 days. The dose to at least 95% of the tumor will be 37.5 Gy total in 12.5 Gy fractions.
1881961|NCT01194219|Drug|Apremilast|
1881962|NCT01194219|Drug|Placebo|Identical matching placebo
1881963|NCT01194219|Drug|Topical treatments or phototherapy|At week 32, participants considered partial responders or non-responders had the option of adding topical therapies and/or phototherapy to their treatment regimen.
1881964|NCT01194232|Drug|Sildenafil|8 week course of Sildenafil administered at a dose of 1 mg / Kg three times a day with a maximum dose of 20 mg per dose.
1881965|NCT01194245|Drug|Insulin lispro|
1881966|NCT01194245|Drug|recombinant human hyaluronidase PH20|
1881967|NCT01194245|Drug|Insulin aspart|
1881968|NCT01194245|Drug|Insulin glulisine|
1881969|NCT01194245|Drug|Insulin glargine|
1881970|NCT01194258|Drug|Insulin lispro|
1881971|NCT01194258|Drug|Insulin aspart|
1881972|NCT01194258|Drug|Recombinant human hyaluronidase PH20|
1881973|NCT01194258|Drug|Insulin glulisine|
1881974|NCT01194258|Drug|Insulin glargine|
1881978|NCT01194284|Drug|Mifamurtide|Mifamurtide will be prescribed to patients with high-grade osteosarcoma as part of their treatment regimen within the context of prevailing standard oncology practice. The recommended dose of mifamurtide is 2 mg/m2. Mifamurtide will be administered for 36 weeks as adjuvant therapy following surgical resection.
1881979|NCT01194297|Biological|Live attenuated influenza vaccine|One dose of live attenuated influenza vaccine, according to routine immunization recommendations
1881980|NCT01194297|Biological|Inactivated influenza vaccine|One dose of inactivated influenza vaccine, according to routine immunization recommendations
1881981|NCT01194310|Procedure|phaco|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) alone
1881982|NCT01194310|Procedure|phaco-ELT|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus excimer laser trabeculotomy (ELT)
1881983|NCT01194310|Procedure|phaco-Trabectome|Standard clear cornea phacoemulsification plsu intraocular lens Implantation (phaco) plus Trabectome
1881984|NCT01194336|Drug|Huperzine A|dosage form: tablet dose frequency: once only
1881985|NCT01194336|Drug|Donepezil|dosage form: tablet dosage frequency: once only
1881986|NCT01194336|Drug|Galantamine|dosage form: tablet dosage frequency: once only
1881987|NCT01194336|Other|Placebo|dosage form: tablet dosage frequency: once only
1881988|NCT01194375|Drug|Low Strength IDP-107|Once a day for 16 weeks
1881989|NCT01194375|Drug|High Strength IDP-107|Once a day for 16 weeks
1881990|NCT01194375|Drug|Placebo|Once a day for 16 weeks
1882040|NCT01194700|Drug|Seretide 250/placebo via Synchro-Breathe|Seretide 250/placebo 8puffs via breath actuated Synchro-Breathe device
1882041|NCT01194713|Behavioral|Sleep deprivation|subjects will undergo one night of full sleep deprivation
1881991|NCT01194388|Device|MicroFx™ PGLA COILS|. This observational evaluation will evaluate early experience using the Axium™ MicroFx™ Detachable Coils as compared to published literature of coils with electrolytic, thermal or hydraulic detachment process or the Axium™ bare Detachable Coils arm obtained from previous evaluation conducted following the same protocol.
1881992|NCT01194414|Drug|tocilizumab SC|Tocilizumab supplied in a single-use pre-filled syringe, with a needle safety device, delivering 162 mg/0.9 mL solution for subcutaneous injection once a week.
1881993|NCT01194414|Drug|tocilizumab IV|Tocilizumab supplied in vials as a sterile solution for 8 mg/kg intravenous infusion every 4 weeks.
1881994|NCT01194414|Drug|placebo to tocilizumab SC|Placebo tocilizumab supplied as a single-use pre-filled syringe with a needle safety device, delivering 0.9 mL sodium chloride for subcutaneous injection once a week for 24 weeks in the double-blind period.
1881995|NCT01194414|Drug|placebo to tocilizumab IV|Placebo to tocilizumab supplied as a solution in 10 mL vials containing polysorbate 80 and sucrose in water for infusion every 4 weeks for a total of 24 weeks in the double-blind period.
1881996|NCT01194414|Drug|Disease-modifying antirheumatic drugs (DMARDs)|stable dose as prescribed
1881997|NCT01194427|Drug|Vorinostat and Tamoxifen|vorinostat 400 mg PO once daily and tamoxifen 20mg PO once daily for 14 days
1881998|NCT01194440|Drug|letrozole|Given orally
1881999|NCT01194440|Drug|zoledronic acid|Given IV
1882000|NCT01194453|Drug|cisplatin, dexamethasone,vitamin B12, folic acid|Patients received cisplatin 75mg/m2 plus pemetrexed 500 mg/m2 on day 1.Chemotherapy was repeated every 3 weeks for a maximum of six cycles.Patients received dexamethasone prophylaxis of 3.75mg orally twice per day on the day before, the day of, and the day after each day-1 treatment. patients received oral folic acid (1,000ug)daily and a vitamin B12 injection (1,000 ug) every 9 weeks, beginning 1 to 2 weeks before the first dose and continuing until 3 weeks after the last dose of study treatment
1882001|NCT01194453|Drug|cisplatin, gemcitabine|cisplatin 75mg/m2 on day 1 plus gemcitabine 1000 mg/m2 on days 1 and 8
1882002|NCT01194466|Device|Transcutaneous Electrical Nerve Stimulation (TENS)|Four adhesive electrodes (1.375in x 1.375in) will be placed bilaterally on the: 1) temporomandibular joint (1/3rd of distance between ear and nose); and 2) upper neck area (2cm from spine, i.e., Cervical 1 and 2).
1882003|NCT01194479|Drug|Formoterol|Formoterol inhaler, 12mcg capsules, 4 capsules for one administration
1882004|NCT01194479|Other|Placebo|Participants in both arms received placebo on 1 of the 2 visits.
1882005|NCT01194492|Radiation|Albumin transcapillary escape rate (125I-albumin)|Repeated measure by injection of 0.1 megabecquerel and 0.3 megabecquerel of 125-iodine labeled albumin before surgery and 2 days after surgery, respectively.
1882006|NCT01194505|Other|Sciatic, femoral, obturator nerve blocks|Ultrasound guided blocks with ropivacaine
1882007|NCT01194505|Other|Sciatic nerve block, posterior lumbar plexus block|Ultrasound and neurostimulator nerve blocks with ropivacaine
1882009|NCT01194531|Device|24 Chromosome Aneuploidy Screening with Parental Support|Preimplantation Genetic Screening (PGS)
1882010|NCT01194557|Device|Rapid diagnostic test|Diagnosis of malaria using rapid diagnostic test
1882011|NCT01194557|Drug|Lumartem|Presumptive treatment of malaria/fever
1991464|NCT01023958|Drug|BI 6727, IV infusion|phase II
1882014|NCT01194596|Behavioral|Smoking cessation advice|Brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine).
1882015|NCT01194596|Behavioral|Spirometry and smoking cessation advice|Intervention group: will be given a brief but structured smoking cessation advice (according to the standards of the Tobacco Study Group of the Catalan Society of Family Medicine) together with a detailed and structured discussion of the spirometric results.
1882016|NCT01194609|Biological|Immune cell|InnoLak two consecutive weeks every 3 weeks for 3 times
1882017|NCT01194609|Radiation|Low dose radiation|20cGy whole body radiation every three weeks for three times
1882018|NCT01194622|Drug|Azelastine, Fluticasone|TEST = MP29-02 = Combination product Azelastine Hydrochloride and Fluticasone Propionate nasal spray (= US formulation as used in pivotal studies)
1882019|NCT01194622|Drug|Fluticasone mono|REF = FLU mono Fluticasone Propionate nasal spray (= essentially combination product formulation without any AZE; US FLU mono formulation as used in pivotal studies)
1882020|NCT01194622|Drug|Fluticasone|COMP = Fluticasone Propionate Nasal Spray, Roxane Laboratories = FLU mono Fluticasone propionate nasal spray (= US marketed product)
1882021|NCT01194635|Genetic|fluorescence in situ hybridization|
1882022|NCT01194635|Genetic|gene expression analysis|
1882023|NCT01194635|Genetic|polymerase chain reaction|
1882024|NCT01194635|Genetic|protein analysis|
1882025|NCT01194635|Genetic|protein expression analysis|
1882026|NCT01194635|Other|enzyme-linked immunosorbent assay|
1882027|NCT01194635|Other|immunohistochemistry staining method|
1882028|NCT01194635|Other|laboratory biomarker analysis|
1882029|NCT01194648|Other|questionnaire administration|
1882030|NCT01194648|Procedure|assessment of therapy complications|
1882031|NCT01194648|Procedure|high-intensity focused ultrasound ablation|
1882032|NCT01194648|Procedure|multiparametric magnetic resonance imaging|
1882033|NCT01194648|Procedure|quality-of-life assessment|
1882034|NCT01194648|Procedure|transperineal prostate biopsy|
1882035|NCT01194648|Procedure|transrectal prostate biopsy|
1882036|NCT01194674|Drug|Microplasmin|Participants received an intravitreal injection of 125 µg in 100 µL of microplasmin at baseline.
1882037|NCT01194700|Drug|Seretide 250(8puffs) via Evohaler actuator|8 puffs of Seretide250/Placebo via Evohaler actuator
1882038|NCT01194700|Drug|Seretide 250 (8 puffs)/placebo via Volumatic spacer|8 puffs of Seretide 250/placebo via volumatic spacer
1882039|NCT01194700|Drug|Seretide 250/placebo 8 puffs via Aerochamber Plus spacer|Seretide 250/placebo 8 puffs via Aerochamber Plus
1991465|NCT01022853|Drug|BI 6727|intravenous each 21 days
1991466|NCT01022853|Drug|BIBF 1120|oral continuously
1882042|NCT01194765|Other|Distance-based Cognitive Behavioural Therapy|Participants will engage in cognitive behavioural therapy to treat high anxiety sensitivity. Treatment will be delivered over the telephone.
1882043|NCT01194778|Dietary Supplement|placebo|1 placebo sachet per day containing only sucrose during 12 weeks
1882044|NCT01194778|Dietary Supplement|vitamin K1|15 µg vitamin K1 per day during 12 weeks
1882045|NCT01194778|Dietary Supplement|vitamin K2|15 µg vitamin K2 per day during 12 weeks
1882046|NCT01194778|Dietary Supplement|vitamin K2|30 µg vitamin K2 per day during 12 weeks
1882047|NCT01194778|Dietary Supplement|vitamin K2|45 µg vitamin K2 per day during 12 weeks
1882048|NCT01194791|Drug|Lenalidomide|Lenalidomide 15 mg by mouth for 21 days followed by 7 days rest during 6 cycles
1882049|NCT01194791|Drug|Cyclophosphamide|Cyclophosphamide 300 mg/m2, on days 1 and 8 every 4 weeks during 6 cycles
1882050|NCT01194791|Drug|Dexamethasone|Oral dexamethasone 20 mg/day on days 1-4 and 9-12 given at 4-week intervals during 6 cycles
1882051|NCT01194804|Drug|Eculizumab|Each vial contains 30 mL of 10 mg/mL eculizumab; dose of 900 mg intravenous every 14 days.
1882052|NCT01194817|Device|High-Flexion Knee Replacement System using Cemented Fixation|
1882053|NCT01194817|Device|High-Flexion Knee Replacement System using Cementless Fixation|
1882054|NCT01194830|Drug|Linagliptin|Active drug 1 tablet PO QD
1882055|NCT01194830|Drug|Placebo|1 Tablet PO QD
1882056|NCT01194843|Drug|Ropivacaine|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
1882057|NCT01194843|Drug|Physiological serum|40 ml infiltration at the end of the hepatectomy and then continuous local infiltration of 8 ml per hour over the 4 days after the hepatectomy
1882058|NCT01194856|Drug|Atazanavir/ritonavir|300 mg orally once daily with Ritonavir 100mg orally once daily for 96 weeks
1882059|NCT01194856|Drug|Efavirenz|Maintain dosage - 600 mg orally QHS for 96 weeks
1882060|NCT01194869|Drug|Sorafenib|Sorafenib 400 mg twice daily throughout the study. Patients will receive this as a single-agent for the first four weeks, then in combination with cisplatin followed by paclitaxel.
1882061|NCT01194869|Drug|Cisplatin|75 mg/m² given IV
1882062|NCT01194869|Drug|Paclitaxel|175 mg/m² given IV
1882063|NCT01194882|Drug|HUMAN INSULIN (BIOSYNTHETIC)|Pharmaceutical form: solution for infusion Route of administration: Intraperitoneal use Dose regimen: 400 IU/ml
1882064|NCT01194882|Drug|Insuplant|"Pharmaceutical form:solution for infusion Route of administration: Intraperitoneal use
Dose regimen:"
1882065|NCT01194895|Other|protective ventilation|set tidal volume of 5ml/kg during one-lung ventilation
1882066|NCT01194895|Other|conventional ventilation|keep tidal volume at 8ml/kg during one-lung ventilation
1882067|NCT01194908|Drug|Decitabine, LBH589, Tamoxifen|"Dose level -1; Decitabine (IV)(D1-5): 5mg/m2; LBH589 (IV)(D1,8): 10mg/m2
Dose level 0; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 10mg/m2
Dose level +1; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 15mg/m2
Dose level +2; Decitabine (IV)(D1-5): 10mg/m2; LBH589 (IV)(D1,8): 20mg/m2
Dose level +3; Decitabine (IV)(D1-5): 15mg/m2; LBH589 (IV)(D1,8): 20mg/m2
Dose level +4; Decitabine (IV)(D1-5): 20mg/m2; LBH589 (IV)(D1,8): 20mg/m2"
1882068|NCT01194934|Drug|NOX-A12|4 mg/kg daily IV for 5 days
1882069|NCT01194934|Drug|NOX-A12|2 mg/kg daily IV for 5 days
1882070|NCT01194934|Drug|Filgrastim|5 µg/kg SC daily for 5 days
1882071|NCT01194934|Drug|NOX-A12 in combination with Filgrastim|Safe and efficacious dose regimen according to results of groups A and B
1882072|NCT01194947|Device|RCM imaging|RCM imaging will be performed using a commercially-available RCM (Vivascope 1500, Lucid Inc, Rochester, NY, USA) with 830-nm diode laser with emitting power less than 35 milliwatts
1882073|NCT01194960|Drug|Docetaxel|Subjects will receive 10 cycles of Docetaxel alone until toxicity or progression.
1882074|NCT01194960|Drug|TroVax + Docetaxel|Subjects will receive both TroVax plus 10 cycles of Docetaxel.
1882075|NCT01194973|Drug|Eculizumab|All patients received open-label eculizumab administered intravenously on the following dose schedule: Induction dose - 900 mg per week for four weeks and a dose of 1200 mg one week later; Maintenance dose - 1200 mg every two weeks. Patients who received plasma exchange or infusion during the eculizumab treatment period received a supplemental dose of 600 mg within one hour before plasma infusion or within one hour after the completion of each plasma exchange.
1882076|NCT01194986|Other|[11C]AZ12807110|Radioligand
1882077|NCT01194986|Drug|AZD5213|
1882078|NCT01194999|Device|Pubovaginal sling procedure|The procedure involves placing a band of sling material directly under the bladder neck (ie, proximal urethra) or mid-urethra, which acts as a physical support to prevent bladder neck and urethral descent during physical activity. The sling also may augment the resting urethral closure pressure with increases in intra-abdominal pressure.
1882079|NCT01195012|Behavioral|Helping HAND (Healthy Nutrition and Activity Directions)|6-month behavioral intervention targeting 5-8 year old children and their parents to improve the child's lifestyle behaviors to improve their weight status. The families met monthly with trained Health Advisors for individual sessions in the pediatric clinic with phone calls in between visits to check on progress.
1882080|NCT01195025|Drug|acetated Ringers|Infusion of Ringer acetate 20 ml/kg over 30 min
1882081|NCT01195025|Drug|colloid|Infusion of starch 10 ml/kg over 30 min
1882082|NCT01195025|Drug|colloid+acetated Ringer|Infusion of combined colloid+acetated Ringer; 10 ml/kg of starch was infused between 0 and 30 min, followed by 20 ml/kg of Ringers acetate between 105 and 135 min.
1882083|NCT01195025|Device|Non-invasive hemoglobin with pulse-oximeter (SpHb)|Non-invasive hemoglobin with pulse-oximeter (SpHb) was measured in all subjects, during all infusions.
1882084|NCT01195038|Biological|Recombinant Influenza HA Vaccine (H5N1)|one booster dose of 45 μg rHA derived from A/Indonesia/05/2005 strain
1882085|NCT01195051|Other|Electronic medication reconciliation|A new, computer-based application will be used to document and prescribe outpatient medications in the inpatient setting.
1882086|NCT01195077|Other|seaweed, spirulina, seaweed + spirulina|"Arm 1: Seaweed. Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Arm 2: Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Arm 3: Seaweed: (2.5 grams) plus Spirulina (2.5 grams). Ten capsules of .5 grams per capsule for a total of 10 grams per day.
Spirulina: Ten capsules of .5 grams per capsule for a total of 10 grams per day."
1882087|NCT01195090|Drug|Sitagliptin|add sitagliptin100mg/d to pre-study OADs
1882088|NCT01195090|Drug|pioglitazone|add pioglitazone 30mg/d to pre-study OADs
1882089|NCT01195103|Drug|Fospropofol disodium|10 mg/kg bolus
1882090|NCT01195103|Drug|Fospropofol disodium|6.5 mg/kg bolus
1882091|NCT01195103|Drug|Placebo + Midazolam|Placebo bolus plus midazolam. The dose of midazolam will be based on the patient's weight: 1 mg for patients <60 kg; 1.5 mg for patients ≥60 kg to <90 kg; or 2 mg for patients ≥90 kg
1882092|NCT01195103|Drug|Fentanyl|All patients will receive a single dose of IV fentanyl (approximately 1 μg/kg not to exceed: 50 μg for patients <60 kg; 75 μg for patients ≥90 kg) five minutes prior to the initial dose of sedative.
1882093|NCT01195116|Drug|Dexmedetomidine|1 mcg/kg/hour
1882094|NCT01195116|Drug|Normal Saline|1mcg/kg/hr
1882097|NCT01195155|Dietary Supplement|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
1882098|NCT01195181|Drug|peginterferon plus ribavirin|peginterferon alfa-2a at 180ug/week (preempt syringe, sc) or peginterferon alfa-2b at 1,5 ug/kg/week (standard dose) or at 1,0 ug/kg/week (lower dose)(preempt pen, sc) for 24 or 48 week in relation to HCV genotype plus ribavirin (capsules, po) at 15mg/kg/daily combination therapy.
1882099|NCT01195194|Drug|PRE-TRANSPLANT (PRE=before)|"All patients will start with Thymoglobulin 1 mg/kg before transplant followed by 0,5 mg/kg/d during the next 5 days (total accumulated 3,5 mg/kg).
Steroids will be administered at 0,25 mg/kg/d until month 3rd, followed by 0,1 mg/kg/d thereafter.
Mycophenolate Mofetil: Pre-transplant 2 grams iv. After transplantation 1g/12 hours, starting iv and changing to oral formulation as soon as patient starts with oral intake (targeting mycophenolic acid (MPA) C0h levels 2-5 µg/mL)."
1882100|NCT01195207|Biological|CNTO 3157 or placebo|0.003 mg/kg CNTO 3157 or placebo infusion
1882101|NCT01195207|Biological|CNTO 3157 or placebo|0.03 mg/kg CNTO 3157 or placebo infusion
1882102|NCT01195207|Biological|CNTO 3157 or placebo|10 mg/kg CNTO 3157 or placebo infusion
1882103|NCT01195207|Biological|CNTO 3157 or placebo|0.01 mg/kg CNTO 3157 or placebo infusion
1882104|NCT01195207|Biological|CNTO 3157 or placebo|1 mg/kg CNTO 3157 or placebo infusion
1882105|NCT01195207|Biological|CNTO 3157 or placebo|3 mg/kg CNTO 3157 or placebo infusion
1882106|NCT01195207|Biological|CNTO 3157 or placebo|0.3 mg/kg CNTO 3157 or placebo infusion
1882107|NCT01195207|Biological|CNTO 3157 or placebo|0.1 mg/kg CNTO 3157 or placebo infusion
1882108|NCT01195220|Behavioral|HIV testing|This is the current standard of care. It obtains consent for HIV vesting by a proven video, and provides rapid HIV testing on site. Informed consent video includes information about the test and its interpretation, as mandated by New York State Law. The the OraQuick ADVANCE® Rapid HIV- 1/2 Antibody Test
1882109|NCT01195220|Behavioral|STI/HIV-T|This intervention adds testing for GC and CT to HIV testing. The informed consent video will incorporate information for STIs to accompany information presented on HIV. GC and CT screening is conducted via a urine sample. The APTIMA Combo 2 Assay has been cleared by the Food and Drug Administration for sale in the US. It employs Gen-Probe's patented Transcription-Mediated Amplification (TMA) technology to detect CT and GC using urine specimens for both male and female patients. We will test urine for GC and CT at the ED visit using the hospital lab within the urban ED.
1882110|NCT01195220|Behavioral|STI/HIV-Plus|This intervention includes the combined STI/HIV testing, and adds the behavioral video that encourages safer sex and is targeted to the participants' stage of change. While patients wait for their HIV test result (20-30 minutes), patients will view these video vignettes.
1882111|NCT01195233|Drug|bioxtra|spray /mouth rinse
1882112|NCT01195246|Biological|HEPLISAV|Intramuscular (IM) injection on Day1
1882113|NCT01195246|Biological|Engerix-B|Intramuscular (IM) injection on Day 1
1882114|NCT01195246|Biological|Fendrix|Intramuscular (IM) injection on Day 1
1882115|NCT01195259|Drug|allocation of treatment with metformin or rosiglitazone|Subjects from ADOPT that are included in this meta-analysis were randomly allocated to receive metformin or rosiglitazone. Subjects from RECORD that are included in this meta-analysis were taking one of three sulfonylureas (glibenclamide, gliclazide or glimepiride) and were randomly allocated metformin or rosiglitazone to use as add-on treament to background sulfonylurea.
1882116|NCT01195272|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 52 weeks
1882117|NCT01195285|Procedure|Single-Incision Laparoscopic Surgery cholecystectomy|Laparoscopic Cholecystectomy
1882118|NCT01195285|Procedure|Traditional Laparoscopic Cholecystectomy (TLC)|Laparoscopic Cholecystectomy
1882119|NCT01195298|Drug|Capecitabine and Bevacizumab|"Drugs will be administered in 3-week cycles as follows:
Bevacizumab 15mg/kg via i.v. infusion on day 1
Capecitabine 1000 mg/m2 tablets twice-daily, on days 1 through 14."
1882120|NCT01195311|Drug|INCB024360|INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
1882121|NCT01195324|Drug|Canagliflozin/Warfarin|Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6 followed 14 days later by Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1
1882122|NCT01195324|Drug|Canagliflozin/Warfarin|Treatment B: Tablets, oral, warfarin 30 mg, single dose on Day 1 followed 14 days later by Treatment A: Tablets, oral, canagliflozin 300 mg, once daily for 12 days and canagliflozin 300 mg + warfarin 30 mg, single dose on Day 6
1882123|NCT01195337|Behavioral|PA Prescription Plan|Exercise program and instructions.
1882124|NCT01195337|Device|Pedometer|Step monitor for individual PA progress.
1882125|NCT01195337|Behavioral|Newsletters|4 Newsletters with topics based on PA progression phases of adoption and maintenance.
1882126|NCT01195363|Drug|quetiapine SR|quetiapine SR, dose range 200-600mg, each night QHS for 6mos
1882127|NCT01195363|Drug|quetiapine sr placebo|quetiapine sr placebo, dose range 200-600mg, each night QHS for 6mos
1882128|NCT01195376|Drug|BEZ235|
1882129|NCT01195389|Device|Resonator|Treatment group vs. Placebo group
1882168|NCT01195779|Biological|GSK Bio's influenza vaccine GSK2321138A|Intramuscular injections
1882169|NCT01195779|Biological|Fluarix™|Intramuscular injections
1882130|NCT01195402|Procedure|pulmonary outpatient rehabilitation|Subjects take part in once weekly training sessions of 60 min duration. Sessions take place in local physiotherapist practice and involve simple training devices (chairs, elastic bands, balls). In addition, subjects take part in a structured and validated educational program concerning COPD (COBRA) of 8 h duration. They are offered counselling regarding nutrition (2 h), psycho-social (2 h) and social (2 h) aspects.
1882131|NCT01195415|Drug|Gemcitabine Hydrochloride|Given IV
1882132|NCT01195415|Other|Laboratory Biomarker Analysis|Correlative studies
1882133|NCT01195415|Drug|Vismodegib|Given PO
1882134|NCT01195428|Drug|Simvastatin|Simvastatin 40 mg daily
1882135|NCT01195428|Drug|Placebo|Placebo
1882136|NCT01195454|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: Lantus solution for injection
Route of administration: subcutaneous"
1882137|NCT01195454|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: New insulin glargine formulation solution for injection
Route of administration: subcutaneous"
1882138|NCT01195467|Drug|Truvada/Raltegravir|All subjects currently on Atripla® will switch to Truvada/Raltegravir
1882139|NCT01195480|Genetic|donor-derived EBV-specific cytotoxic T-cells (EBV-CTL) transduced with the retroviral vector SFGalpha-CD19-CD3zeta|All patients will be treated at the same total dose level of 2 x 10^8/m2
1882140|NCT01195480|Biological|Irradiated donor-derived Lymphoblastoid Cell Line|"The initial cohort of 5 patients (regardless of arm of study) will be treated as described. If transduced CTL infusion is safe in this initial cohort and real-time DNA PCR studies demonstrate that transduced CTL are undetectable in > 50% of patients by 2 months post-infusion, the remaining 25 patients (in either arm of the study) will be treated as above but with an additional vaccination of CD19-zeta-transduced EBV-LCL infusion.
Vaccination will consist of 3 doses of 5 x 10^6 irradiated (70Gy) donor-derived EBV-lymphoblastoid cell line used to generate CTL and will be administered subcutaneously into the thigh (volume 0.3 ml) at day -2, week 4 and 8 post-transduced CTL infusion."
1882141|NCT01195493|Other|Essential Oils solution|(Essential oils solution, Listerine®, Johnson & Johnson) to use twice a day (2 x 20 ml) following daily mechanical oral hygiene practices
1882142|NCT01195493|Other|negative control solution|this solution would be used twice per day (2 x 20 ml) following daily home care.
1882144|NCT01195558|Other|Data collection on blindness and sleep problems|Data related to degree of vision impairment and sleep problems is collected through a phone or web survey
1882145|NCT01195571|Biological|cmv vaccine|dose escalation study of 4 towne-toledo chimera vaccines
1882146|NCT01195597|Device|E-Cigarette 7.2 mg nicotine|"Participants were given a free e-Cigarette kit containing two rechargeable batteries, a charger, and two atomizers and instructed on how to charge, activate and use the e-Cigarette. Key troubleshooting were addressed and phone numbers were supplied for both technical and medical assistance. A full 4-weeks supply of 7.2 mg nicotine cartridges (Original cartridges; Arbi Group Srl, Milano, Italy) was also provided and participants were trained on how to load them onto the e-Cigarette's atomizer"
1882148|NCT01195623|Procedure|preoperative duplex examination|
1882149|NCT01195623|Procedure|Preoperative duplex|
1882150|NCT01195636|Drug|XPF-002|Twice daily application of XPF-002 ointment which contains 8% of the XPF-002 active ingredient
1882151|NCT01195636|Drug|Placebo|Twice daily application of Placebo ointment
1882152|NCT01195649|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients under daily life treatment according to local drug information
1882153|NCT01195662|Drug|Dapagliflozin|Tablets, Oral, 10 mg, once daily, Up to 12 weeks
1882154|NCT01195662|Drug|Placebo matching Dapagliflozin|Tablets, Oral, 0 mg, once daily, Up to 12 weeks
1882155|NCT01195675|Drug|BI 10773 (low)|single oral dose
1882156|NCT01195675|Drug|Moxifloxacin|single oral dose
1882157|NCT01195675|Drug|BI 10773 Placebo|2 times single dose
1882158|NCT01195675|Drug|BI 10773 (high)|single oral dose
1882159|NCT01195688|Drug|BI 638683 or placebo|oral doses given to 6 subjects per dose group
1882160|NCT01195688|Drug|Placebo solution|oral doses given to 2 subjects per dose group
1882161|NCT01195714|Drug|Ofatumumab|solution for perfusion, 1000mg per cycle, 1 cycle every 3 weeks, total 6 cycles
1882162|NCT01195727|Drug|Apixaban|
1882163|NCT01195740|Behavioral|Attachment Based Family Therapy|ABFT has three phases. In phase one, treatment focuses on helping the adolescent identify past and present family conflicts that have strained the attachment bond and damaged trust. Adolescents and parents are taught new communication and affect regulation skills in preparation for reparative conversations in phase two. This phase of treatment involves adolescents and parents discussing these past and present conflicts using their new communication skills. The final phase of treatment focuses on promoting adolescent autonomy (i.e., improving school productivity, finding a job, etc.). For the suicidal/depressed adolescent, this can decrease isolation and increase exposure to positive experiences. To accomplish these goals, there are five ABFT treatment tasks. Each task may take one or several sessions. Youth randomized to this condition will receive approximately 14 weeks of ABFT. One orientation meeting will occur, whenever possible, on the inpatient unit prior to discharge.
1882164|NCT01195740|Behavioral|Enhanced Usual Care|"Belmont offers the Therapeutic Bridge Program, funded by the Pew Charitable Trusts, which helps adolescents make the transition from the hospital back to home, school and community behavioral health services. The program serves as a bridge between inpatient and outpatient care during the first 90 days after discharge, linking them to supportive services. Aftercare begins at the point of intake. Several discharge planning meetings are held with the adolescent and parents during the inpatient stay. The range of services are based on the patient and families' need, and may include meeting with school personnel , conducting home visits or making referrals to other community services agencies. The main objective is to secure outpatient mental health services for the patient. These services will be enhanced by the weekly research tracking, assessment and 24-hour crisis phone line which will call into a cell phone rotated among the licensed mental health professionals on the research team."
1882165|NCT01195753|Biological|HHLivC|multiple infusion of liver cells
1882166|NCT01195766|Drug|Ofatumumab|Ofatumumab in addition with ESHAP therapy
1882167|NCT01195779|Biological|GSK Bio's influenza vaccine GSK2584786A, different formulations|Intramuscular injections
1882172|NCT01195805|Drug|Spironolactone|1 tablet twice a day for 28 days
1882173|NCT01195805|Other|Placebo|1 tablet twice a day for 28 days
1882174|NCT01195805|Drug|Amiloride|1 tablet twice a day for 28 days
1882175|NCT01195818|Drug|RAS Inhibitors|Clinical trial testing the effect of RAS inhibitors (Ramipril or Irbesartan)on sickle cell disease patients wit hyperfiltration and albuminuria for a six month period followed by one month wash out period. Drug will be given after the first GFR measurement on a daily basis with a full dose given after the first month.
1882176|NCT01195831|Drug|Xamiol® gel|Once daily application
1882177|NCT01195831|Drug|Calcipotriol scalp solution|Twice daily application
1882178|NCT01195844|Biological|Rotavirus Vaccine|This is an observational study evaluating hospitalizations and the medical care for the treatment of diarrhea from rotavirus infection in children < 5 years of age; however, any rotavirus vaccines used in the children presenting with rotavirus-attributed diarrhea were evaluated, as well the prevalent rotavirus serotypes in this sample for future vaccine development.
1882179|NCT01195883|Drug|Crystalloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of LR will be given over a period of 5 minutes.
1882180|NCT01195883|Drug|Colloid|For goal directed volume management we use corrected aortic flow time (FTc) and stroke volume derived from esophageal Doppler as in previous studies. In case of hypovolemia, detected by esophageal Doppler monitoring (CardioQ, Deltex Medical Group PLC, Chichester, UK) according to a previously published algorithm, an additional fluid bolus of 250 ml of Hydroxyethylstarch 6% 130/0.4 (Voluven®Fresenius-Kabi, Bad Homburg, Germany) will be given over a period of 5 minutes.
1882181|NCT01195896|Device|New NPWT system|According clinical routine (Instruction for Use)
1882182|NCT01195922|Drug|Sirolimus|21 evaluable subjects will take rapamycin (sirolimus) orally once per day for 21 days. Before and after dosing tumor assessments to include: photographs, CT & amp; PET scans will be done for tumor measurement.
1882183|NCT01195948|Drug|B27PD|
1882184|NCT01195948|Drug|Placebo|Capsule with no active ingredients to mimic B27PD
1882185|NCT01195974|Drug|YASMIN|YASMIN for 21 days
1882186|NCT01195974|Drug|GSK2248761|200 mg GSK2248761 taken on Days 1 - 10 or Days 12 - 21
1882187|NCT01195974|Other|Placebo|Placebo taken on Days 1 - 10 or Days 12 - 21
1882188|NCT01196000|Procedure|conventional laparoscopic surgery|operation using conventional laparoscopic techniques
1882189|NCT01196000|Procedure|robotic-assisted laparoscopic surgery|operation that involves use of laparoscopic assistance with robotic assistance
1882190|NCT01196000|Procedure|quality-of-life assessment|Ancillary studies
1882191|NCT01196000|Other|questionnaire administration|Ancillary studies
1882192|NCT01196013|Drug|Clofarabine|Intravenous, 30 mg/m2, 52 mg/m2
1882193|NCT01196026|Biological|Fluarix™|One or two intramuscular injections
1882194|NCT01196026|Biological|Havrix™ Junior|Two intramuscular injections
1882195|NCT01196039|Drug|MEMP1972A|Intravenous repeating dose
1882196|NCT01196039|Drug|placebo|Intravenous repeating dose
1882197|NCT01196052|Drug|Trastuzumab emtansine|Trastuzumab emtansine was provided as a single-use lyophilized formulation in a glass vial.
1882198|NCT01196065|Drug|RO5313534|single oral dose
1882199|NCT01196065|Drug|memantine|multiple doses to steady state
1882200|NCT01196078|Drug|erlotinib [Tarceva]|150 mg, orally once a day for up to 6 cycles of 21 days each
1882201|NCT01196078|Drug|vinorelbine|60 mg/m2, orally on days 1 and 8 of cycle 1, 80 mg/m2 for the other cycles
1882202|NCT01196091|Drug|LY2127399|120 mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug.
1882203|NCT01196091|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose
1882204|NCT01196091|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
1882205|NCT01196104|Drug|Technosphere® Insulin Inhalation Powder|
1882206|NCT01196104|Drug|Insulin Aspart|Usual Care
1882207|NCT01196104|Drug|Insulin Glargine|
1882212|NCT01196169|Drug|Daptomycin|One dose of Daptomycin 6 mg/Kg iv, will be infused over 30 minutes. The infusion will start no longer than one hour prior to surgical incision of primary knee or hip prosthetic joint arthroplasty.
1882213|NCT01196169|Drug|Vancomycin|Two doses of vancomycin 15 mg/Kg iv, with a maximum of 2 grams with each dose be infused over 60-120 minutes according to the dose. The first dose infusion will start no longer than one hour (if ≤ one gram), or no longer than two hours (if > one gram) prior to surgical incision of primary knee or hip prosthetic joint arthroplasty. A second similar dose will be given 12 hours after the first dose unless the patient has a creatinine clearance of < 50 ml/min. Patients with creatinine clearance of < 50 ml/min will only receive one dose.
1882216|NCT01196208|Drug|brentuximab vedotin|Every 21 days by intravenous infusion (1.8 mg/kg)
1882217|NCT01196234|Drug|Paclitaxel/Carboplatin/Gefitinib|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)/daily gefitinib 250mg/day during day 2-15
1991481|NCT01012492|Drug|Abatacept|Participants will receive one of two standard myeloablative conditioning regimens for their stem cell transplant, and will receive an aGvHD prophylaxis regimen including cyclosporine, methotrexate, and abatacept.
1882218|NCT01196234|Drug|Paclitaxel/Carboplatin|paclitaxel (175mg/m2 on day 1)/carboplatin (AUC 5 on day 1)
1882219|NCT01196247|Drug|Drug will be recommended based on IHC/Fish, CGH and Pan-XenoBank|FDA approved drugs as indicated by molecular profiling
1882220|NCT01196260|Drug|Capecitabine and Oxaliplatin|Capecitabine and Oxaliplatin will be under the NSCLC guideline
1882221|NCT01196273|Other|Comprehensive non invasive cardiovascular examination|"The examination includes:
Anamnesis incl. admission form
Physical examination
Documentation of the medical therapy (incl. HAART)
Electrocardiogram
Transthoracic echocardiography
Exercise electrocardiogram
6 minute walk test
Blood collection
Questionnaire to quality of life and health economics"
1882222|NCT01196286|Behavioral|Multifamily Group Psychoeducation (MFG)|Participation in multifamily psychoeducation comprised of (i) three individual sessions with family and individual with psychosis, (ii) one psychoeducational workshop, and (iiI) twice monthly multifamily meetings to complete structured problem-solving activity
1882223|NCT01196286|Behavioral|Cognitive Remediation (CR)|Computer exercises designed to improve cognitive functioning (3hr/wk).
1882224|NCT01196312|Behavioral|Anxiety sensitivity therapy|ASTH consists of 6 sessions of individual treatment, each lasting approximately 75 minutes over 3 weeks. In general, each session consists of the following components1) psychoeducation regarding the anxiety response, with a focus on increasing awareness of the ways in which the patient interprets or evaluates that response 2) assistance in developing healthy emotion regulation strategies that can be used to increase acceptance and tolerance of the anxiety response (including associated catastrophic thoughts), as well as understanding the consequences associated with avoidance or control of anxiety 3) a minimum of 3 interoceptive exercises tailored to activate feared anxiety-related sensations and 4) daily homework assignments (i.e., daily anxiety monitoring and interoceptive exercises).
1882225|NCT01196338|Behavioral|Early weight-bearing and range of motion exercises|"0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;
At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed placed in orthosis, with instructions to be weightbearing as tolerated. Instructions for limited range of motion to be given;
At 2 weeks to 6 weeks: Weightbearing as tolerated in orthosis, follow range of motion instructions;
After 6 weeks: Instructions to continue weightbearing as tolerated, wean from orthosis."
1882226|NCT01196338|Behavioral|non-weight bearing, no range of motion|"0 weeks to 2 weeks: Posterior plaster slab or cast, non-weightbearing, crutches;
At 2 week visit to clinic: Posterior plaster slab or cast removed, staples/stitches removed, BK fibreglass cast or other orthosis applied, with instructions to continue non-weightbearing;
At 2 weeks to 6 weeks: Ankle remains immobile and non-weightbearing;
After 6 weeks: Begin weightbearing as tolerated. Instructions for limited range of motion to be given, and wean from orthosis."
1882227|NCT01196351|Other|Dietary Supplement: water with noncalorie sweetener|
1882228|NCT01196351|Other|Activity: With noncalorie sweetener or glucose|
1882229|NCT01196364|Other|Dietary Supplement: water with noncalorie sweetener|
1882230|NCT01196364|Other|Activity: With noncalorie sweetener or glucose|
1882231|NCT01196377|Drug|Albuterol|Nebulized albuterol
1882239|NCT01196403|Other|questionnaire administration|
1882240|NCT01196403|Procedure|quality-of-life assessment|
1882241|NCT01196403|Procedure|robot-assisted laparoscopic surgery|
1882242|NCT01196403|Procedure|therapeutic conventional surgery|
1882243|NCT01196403|Procedure|therapeutic laparoscopic surgery|
1882250|NCT01196429|Drug|Carboplatin|Given IV
1882251|NCT01196429|Drug|Docetaxel|Given IV
1882252|NCT01196429|Other|Laboratory Biomarker Analysis|Correlative studies
1882253|NCT01196429|Drug|Paclitaxel|Given IV
1882254|NCT01196429|Drug|Temsirolimus|Given IV
1882255|NCT01196442|Other|electrical stimulation pain therapy|Electrical stimulation pain therapy for 45 minutes on Day 1, then 30 minutes Days 2-10
1882256|NCT01196442|Other|questionnaire administration|Brief Pain Inventory questionnaire administration at baseline, weekly, then monthly for 3 months
1882257|NCT01196455|Drug|Capecitabine and Mitomycin C|"Capecitabine 1000 mg/m2 twice-daily, administered orally on day 1-14, every three weeks
Mitomycin C 8 mg/m2 i.v. bolus, on day 1, every three weeks"
1882258|NCT01196468|Other|HIV test (serological or salivary)|"An HIV test will be offered to all patients accessing the healthcare setting for care of the indicator condition"
1882259|NCT01196468|Other|Interview|Demographic data will be collected for each patient consenting to an HIV test. With informed written consent, additional data will be collected from patients via focussed interview. Data comprises: previous medical history, previous health seeking behaviours, previous HIV testing history, previous viral hepatitis testing/diagnosis history, and assessment of HIV acquisition risk factors
1882260|NCT01196481|Drug|Carvedilol+VSL#3|Tablet Carvedilol 6.25 mg BD & capsule VSL#3 1 TDS for 2 year
1882261|NCT01196481|Procedure|Endoscopic variceal ligation|In the Endoscopic Variceal Ligation arm, Endoscopic Variceal Ligation will be performed using multibander devices by senior fully trained endoscopists or under their direct supervision. Varices will be banded starting at the gastroesophageal junction moving proximally upward in a spiral fashion. Patients will undergo Endoscopic Variceal Ligation every 3-4 weeks until eradication. Eradication is defined as the absence of varices or presence of grade I esophageal varices. Following eradication, the interval for the next endoscopy will be every 3 months to look for recurrence of varices. Endoscopic Variceal Ligation sessions would be repeated for the recurrent varices if they are sufficiently large.
1882262|NCT01196494|Procedure|intraoperative colon lavage with primary anastomosis|Patients with obstructive left-sided colonic cancer in wich treatment in one stage procedure is intraoperative colon lavage with primary anastomosis to avoid Hartamnn´s Procedure
1882263|NCT01196507|Drug|Carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol or with a maximum of 12.5 BD.
1882264|NCT01196507|Drug|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 4 BD.
1882266|NCT01196546|Drug|vildagliptin/metformin|
1882267|NCT01196559|Drug|Vinorelbine and Gemcitabine|Gmcitabine 1000㎎/㎡ mix in normal saline 100ml iv for 30min andVinorelbine 25㎎/㎡ mix in normal saline 50 ml iv for 5-10min on D1 and 8 every 21 days cycle
1882268|NCT01196572|Procedure|Internal Urethrotomy|surgical incision of urethral stricture using endoscopic cold knife vs. endoscopic laser
1882269|NCT01196585|Procedure|CT-Guided pleural needle biopsy with Abrams' needle|Patients will be randomized into two groups: Group A: CT-guided Abrams' needle biopsy.
1882270|NCT01196585|Procedure|Ultrasonography guided cutting pleural needle biopsy|Patients will be randomized into two groups: Group B: Ultrasonography guided cutting-needle biopsy.
1882271|NCT01196598|Other|Exercises|"Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.
The control group receive only lifestyle advice.
Followed by three months of home training with appointments each two weeks with physiotherapist."
1882272|NCT01196611|Behavioral|Voice Amplification|Behavioral: Voice Amplification. Patients use VA over a course of 6 weeks Control group. No treatment over a course of 6 weeks.
1882273|NCT01196611|Behavioral|Function Voice Exercises|Function Voice Exercises Patients will receive 6 sessions of therapy over a course of 6 weeks, with one session per week.
1882274|NCT01196624|Device|rapid TMS, EXPOSURE TO TRAUMATIC STIMULI|RAPID TMS, EXPOSURE TO TRAUMATIC STIMULI
1882275|NCT01196624|Device|rapid TMS, EXPOSURE|apid TMS, EXPOSURE
1882276|NCT01196650|Drug|IN 10 003 formulation A|
1882277|NCT01196650|Drug|IN 10 003 formulation B|
1882278|NCT01196650|Drug|Placebo capsules|
1882279|NCT01196663|Device|Intraoperative temperature measurement by TMS thermometer|Measurements will be taken from the patient's body using a biocompatible patch that will transfer data to the receiving unit. The patch will be sterilized before each surgery.
1882280|NCT01196663|Device|Esophageal or urinary bladder temperature measurement|Standard temperature measurement as is being measured from patients during surgery today
1882281|NCT01196676|Drug|AZD4451|1 mg capsules, 5 mg capsules, and 25 mg capsules
1882282|NCT01196676|Drug|Placebo|1 mg capsules, 5 mg capsules, and 25 mg capsules
1882283|NCT01188603|Drug|flibanserin 100 mg dose every evening|all subjects receive flibanserin
1882284|NCT01188616|Behavioral|Telephone Linked Care-HEAT (TLC-HEAT)|A primary care intervention linked with Telephone Linked Care-HEAT (TLC-HEAT), and delivered through an electronic health record (EHR). The HEAT system will guide children in the early stages of overweight toward healthy weight management and assist the child's parent(s) and primary care provider (PCP) to support the child's efforts.
1882285|NCT01188629|Behavioral|Safety Training|IT intervention focuses on safety in the home.
1882286|NCT01188629|Behavioral|Personal Health Partner and Counseling (PHP+C)|The PHP intervention will have three primary functional areas: 1) pre-visit assessment and counseling; 2) EHR data exchange with clinician review; and 3) post-visit follow-up, re-assessment, and counseling.
1882287|NCT01188642|Behavioral|obesity lifestyle intervention|physical activity 5 times per week + nutrition education
1882288|NCT01188655|Drug|Enbrel|"The patients will be treated in accordance with the requirements of the labeling of Enbrel® in Austria. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
To record complete dosing information, initial dose will be documented at baseline and any change will be documented with date, dose and reason at the subsequent visits."
1882289|NCT01188668|Drug|Aripiprazole|Period 1-Aripiprazole 5mg on study day 1.
1882290|NCT01188668|Drug|Aripiprazole + desvenlafaxine succinate sustained release|Period 2-Desvenlafaxine SR 100mg on days 1-19 with coadministration of Aripiprazole 5mg on day 7.
1882291|NCT01188681|Drug|TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
1882292|NCT01188681|Drug|Bendamustine|Bendamustine at 70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
1882293|NCT01188681|Drug|15 mg/kg TRU-016 and bendamustine|TRU-016 at 15 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
1882294|NCT01188681|Drug|20 mg/kg TRU-016 and bendamustine|TRU-016 at 20 mg/kg, weekly by IV infusion x 2 cycles, then every 14 days x 4 cycles PLUS bendamustine (70 mg/m2 by IV infusion on Days 1 and 2 of every 28-day cycle, for 6 cycles
1882295|NCT01188694|Drug|Psychotherapy plus Methylene Blue, USP|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, 260 mg of methylene blue, USP will be given.
1882296|NCT01188694|Behavioral|Psychotherapy plus Placebo|This treatment involves daily visits with a therapist for 50 to 60 minutes for a total of six sessions. At the end of each session, capsules containing the placebo will be given.
1882297|NCT01188694|Behavioral|Delayed Psychotherapy|Individuals must wait approximately five to six weeks to start treatment. They will come in for two check-in appointments before starting treatment. Treatment will consist of ten twice-weekly psychotherapy sessions (90-120 min each session).
1882298|NCT01188707|Drug|Belinostat and Erlotinib|"The design of the first phase is a 3 +3 phase I trial. The Belinostat dose will start at 500 mg and will be increased with 250 mg until a maximum dose of 1500 mg, administered daily in 2/3 weeks. Each patient will at the same time receive 150 mg of Erlotinib daily continously.
When the patient is enrolled at one dose level, there will be no further dose escalation for that individual patient.
3 patients will be treated at each dose level."
1882299|NCT01188720|Behavioral|Physical activity|30 minutes of moderate to intense physical activity including strength training and cardiovascular activity.
1882300|NCT01188733|Drug|Long acting octreotide 10mg|Comparison of different doses
1882301|NCT01188733|Drug|Long acting Octreotide 30mg|Comparison of drug doses
1882302|NCT01188733|Drug|Saline|Comparison of drug doses
1882303|NCT01188746|Behavioral|McGill Quality of Life Questionnaire and the European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire|Participants will be interviewed twice (if they chose to participate in the qualitative portion) and complete instruments at three time points: 1) immediately prior to the procedure, 2)within seven days after the procedure, preferably prior to discharge, and 3) three weeks after their catheter placement.
1882304|NCT01188759|Drug|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing <50 kg:
Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.
For adolescents aged 12-17 years, excluding 12-14-year-olds weighing <50kg:
Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.
Voriconazole therapy is to be given for 6-12 weeks."
1882305|NCT01188759|Drug|Anidulafungin|"Anidulafungin 3 mg/kg IV load q24h x 24h (maximum 200 mg), then 1.5 mg/kg q24h (maximum 100 mg).
Anidulafungin therapy is to be given for 2-4 weeks in combination with voriconazole."
1882306|NCT01188759|Drug|Voriconazole|"For Children aged 2-11 years and adolescents aged 12-14 years weighing <50 kg:
Voriconazole 9 mg/kg IV load q12h x 24h, then 8 mg/kg IV q12h, with option to switch to oral voriconazole at 9 mg/kg q12h (maximum 350 mg) after 7 days.
For adolescents aged 12-17 years, excluding 12-14-year-olds weighing <50kg:
Voriconazole 6 mg/kg IV q12h x 24h, then 4 mg/kg IV q12h, with an option to switch to oral voriconazole at 200 mg q12h after 7 days.
Voriconazole therapy is to be given for 6-12 weeks."
1882307|NCT01188772|Drug|Sofosbuvir|Sofosbuvir tablets were administered orally once daily.
1882308|NCT01188772|Drug|Placebo to match sofosbuvir|Placebo tablets to match sofosbuvir were administered orally once daily.
1882309|NCT01188772|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection.
1882310|NCT01188772|Drug|RBV|Ribavirin (RBV) was administered as a tablet orally according to package insert dosing recommendations (Genotype 1: < 75kg = 1000 mg and ≥ 75 kg = 1200 mg; Genotype 2/3: 800 mg).
1882311|NCT01188785|Drug|siG12D LODER|"Phase 0 - subjects diagnosed with an operable adenocarcinoma of the pancreas will have 8 siG12D LODER placed in tumor. The siG12D LODER will be placed in the subject's tumor using an EUS biopsy needle.
Phase I - subjects diagnosed with locally non-operable advanced adenocarcinoma of the pancreas. These subjects will have one of three different siG12D LODERs dose levels placed in tumor - Either 1 siG12D LODER, 2 siG12D LODERs or 8 siG12D LODERs. The siG12D LODER/s will be placed in the subject's tumor using an EUS biopsy needle."
1882312|NCT01188798|Drug|Methotrexate|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
1882313|NCT01188798|Drug|Pentostatin|Participants will be randomized to receive either methotrexate (MTX) or pentostatin for graft-versus-host disease (GVHD) prophylaxis after receiving an allogeneic bone marrow transplant from an HLA-matched related or unrelated donor.
1882314|NCT01188811|Drug|lipoic acid|1200 mg taken by mouth daily starting on day one of the study and ending on the last day of study participation.
1882315|NCT01188811|Drug|Placebo|The placebo comparator will be taken by mouth daily starting on day one of the study and ending on the last day of study participation
1882316|NCT01188824|Drug|Cilostazol|100 mg, bid p.o.
1882317|NCT01188824|Other|placebo|1 tablet, bid
1882318|NCT01188837|Other|Full Kinetic Chain Manipulative Therapy|"Treatment will focus on restoring knee flexion and extension by lesser grades of mobilization and patellar mobilization along with careful high velocity low amplitude axial elongation of the knee joint.
Additionally, manipulative therapy will be applied where needed to the full kinetic chain using diversified techniques, such as HVLA manipulation or mobilization.
This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email."
1882319|NCT01188837|Other|Full Kinetic Chain Rehabilitation|"Rehabilitative therapy includes exercises, focused soft tissue treatment and stretch to the knee and the full kinetic chain where needed based upon functional assessment. Also included; patient advice, education and home exercise recommendations for managing their KOA.
This group will receive a total of 6 treatments over a 3 week period. Outcome measures will be taken at baseline, prior to the 4th treatment and at the one week follow-up. A 3 month follow-up will be done by mail, phone or email.
The rehabilitative therapy group will be required to attend the initial treatment/training, the 4th visit and 1 week follow-up. Treatments 2, 3, 5 and 6 are considered optional; they may be done at home"
1882320|NCT01188837|Other|Full Kinetic Chain Manipulative Therapy with Rehabilitation|"This arm is a combination of the manipulative therapy arm and the rehabilitative therapy arm.
This group receives 6 treatments over a 3 week period with a one week follow-up on site and a 3 month follow-up by mail, phone or email."
1882321|NCT01188850|Biological|VGX-3100|DNA plasmid delivered via IM injection + electroporation using CELLECTRA device
1882322|NCT01188863|Drug|300 mg LX4211 (150 mg tablets)|Single oral dose of two 150 mg tablets LX4211
1882323|NCT01188863|Drug|300 mg LX4211 (50 mg tablets)|Single oral dose of six 50 mg tablets LX4211
1882324|NCT01188863|Drug|300 mg LX4211 (liquid)|Single 30 mL dose of liquid oral solution LX4211 (10 mg/mL)
1882325|NCT01188876|Drug|carboplatin|Given intravenously on Day 1 of each 28-day cycle
1882326|NCT01188876|Drug|pralatrexate|Given intravenously on Day 1 and Day 15 of each 28-day cycle.
1882327|NCT01188889|Drug|RAD001|"Dosing schedule of RAD001 for the Phase I portion:
Regimen 1. 5.0 mg q72 hours (400 mg QD); Regimen 2. 5 mg q48 hours (400 mg QD); Regimen 3. 5.0 mg q day (400 mg QD); Regimen 4. 7.5 mg PO q day (400 mg QD."
1882328|NCT01188889|Drug|Imatinib|Imatinib will be given continuously at a fixed daily dose of 400 mg once daily.
1882329|NCT01188902|Dietary Supplement|walnut|walnut consumption 48 g/d
1882330|NCT01188915|Procedure|intensive screening|Each year, women will have breast cancer detection based on mammography, echography and RMI. Questionaries will also be completed.
1882331|NCT01188928|Drug|Calcipotriol plus betamethasone|Topical suspension once daily for up to 8 weeks.
1882332|NCT01188928|Drug|Betamethasone-17,21-dipropionate|Topical suspension once daily for up to 8 weeks.
1882333|NCT01188928|Drug|Calcipotriene|Topical suspension once daily for up to 8 weeks.
1882334|NCT01188928|Drug|Topical suspension vehicle|Topical suspension once daily for up to 8 weeks.
1882335|NCT01188941|Behavioral|Health System Navigator|Subjects will be enrolled prior to an HIV test. Following TB screening, HIV infected subjects will meet with the health systems navigator who will administer a brief strengths-based interview. During this interview the participant and navigator will identify barriers to HIV and/or TB care and the resources and strengths that will be most helpful in overcoming these barriers. The health system navigator will stay in contact with participants for the next 4 months using phone calls and SMS on a standardized schedule. During the phone contacts the health system navigator will assess where the participant is on the care pathway. If the participant has not completed a step in his/her HIV or TB care, the health system navigator will help the participant draw on strengths identified in the initial interview and overcome any obstacles hindering him/her from accessing care.
1882336|NCT01188954|Drug|doxycycline|50 ml/mg
1882337|NCT01188954|Other|No intervention|Normal Saline/Water
1882338|NCT01188967|Drug|GSK598809|Oral dose of 60 mg/day for a treatment period six weeks
1882339|NCT01188967|Drug|Placebo|Placebo
1882340|NCT01188993|Other|early septic shock|Each patient will be assessed by both the transpulmonary thermodilution and Transesophageal Echocardiography.
1882341|NCT01189006|Drug|Dextromethorphan|Add-On double-blind study treatment commenced at randomization for 11 weeks while patients were continuing open-label risperidone. Randomization was immediately preceded by a one week open-label Risperidone-Only Treatment period. Patients who were receiving antipsychotics medication(s) at screen other than risperidone alone was withdrawn from previous non-risperidone medication(s) and at the same time commenced risperidone in titrating doses over a week. This Antipsychotic Switch-Over Period occurred between Screen and Risperidone-Only Treatment period. Patients remained hospitalized for at least during the Risperidone-Only treatment Period and first week of Add-On treatment Period.
1882342|NCT01189019|Drug|ranibizumab|2mg intravitreal injection monthly
1882343|NCT01189019|Drug|ranibizumab|2mg monthly x 3 doses, then as needed based on recurrence of activity on OCT
1882344|NCT01189032|Drug|DE-089 ophthalmic solution|
1882345|NCT01189032|Drug|DE-089 ophthalmic solution|
1882346|NCT01189032|Drug|Placebo ophthalmic solution|
1882347|NCT01189045|Behavioral|Aerobic Exercise Program|The AEROBIC PROGRAM will be the Experimental arm of this trial. It will be a structured, progressive aerobic training program that will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
1882348|NCT01189045|Behavioral|Non-aerobic Exercise Program|The BALANCE AND FLEXIBILITY (non-aerobic) PROGRAM will be the Active Comparator arm of this trial. It will be comprised of upper and lower body stretching, or balance activities, yoga- or Tai Chi-style classes. This program will be 6 months in duration. Classes will be held 3 times / week, for 1 hour / session.
1960401|NCT03220009|Procedure|Conventional Surgery|Undergo surgery
1882351|NCT01189071|Drug|Darifenacin|an M3 selective anticholinergic medication. M3 muscarinic receptors are felt to be related to bladder and ureteral contractility. The ureteral and bladder spasms related to ureteral stents are felt to be due to inappropriate contractions. By using a selective M3 receptor, it is felt that there will be fewer side effects. Participants will be placed on the standard 15 mg oral daily dosage for 3 days prior to the stent being placed, day 3 being the am of the surgery.
1882352|NCT01189084|Biological|Observational|Measure anti-Amyloid-beta antibody in serum during 24-26 weeks extension period to 48 weeks (after first vaccine treatment).
1882353|NCT01189097|Drug|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period first and then will be categorized into the opioid free group. The subjects of the opioid using group will be assigned randomly into the following six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo.
1882354|NCT01189097|Drug|Dextromethorphan|Subjects who have not used opioid for at least one week before baseline evaluation will take one-week placebo for the wash-out period and then randomly assigned into six groups: 1) Methadone + DM 60mg; 2) Methadone + DM 120mg; 3) Methadone + Placebo; 4) Methadone + DM 60mg + motivation and cognitive behavior therapy; 5) Methadone + DM 120mg + motivation and cognitive behavior therapy; 6) Methadone + Placebo + motivation and cognitive behavior therapy. The opioid free group will be 1) DM 30mg; 2) DM 60 mg; 3) Placebo. If the subjects of the opioid free group suffer from relapses and begin to use heroin, they will receive methadone treatment. The dosage of methadone will be increased or decreased maximal 5 mg each time as necessary.
1882355|NCT01189110|Device|Auriculotherapy using TENS unit Stim Flex 400A|Although the mechanism of action of auriculotherapy is not well understood, the dominant scientific theory for how traditional acupuncture procedures works has suggested possible neurophysiologic and neurochemical pathways that may explain its effectiveness for treating specific disorders
1882356|NCT01189123|Biological|High dose influenza vaccine Sanofi-Pasteur|High dose influenza vaccine Sanofi-Pasteur at standard dosing intramuscular injection
1882357|NCT01189123|Biological|fluzone by sanofi pasteur|standard dose fluzone
1882438|NCT01189747|Biological|onabotulinumtoxinA|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line areas on Day 1
1960402|NCT03220009|Biological|Ipilimumab|Given IV
1960403|NCT03220009|Other|Laboratory Biomarker Analysis|Correlative studies
1960404|NCT03220009|Biological|Nivolumab|Given IV
1882358|NCT01189136|Device|PTNS Active Treatment|34 gauge needle inserted 3cm above the medial ankle, and cables are connected to the PTNS stimulator device. Stimulation is provided, per manufacturer directions, over a 30-minute treatment period.
1882359|NCT01189136|Other|Sham treatment|34 gauge needle inserted 3cm above the medial ankle, but nonconductive cables are connected, so that no electrical stimulation is applied, over a 30-minute treatment period
1882360|NCT01189149|Procedure|IV fluids|Infants will be allocated to IV fluids
1882361|NCT01189149|Procedure|Naso/oro gastric tube feedings|Infants will be allocated to naso/oro gastric tube feedings
1882362|NCT01189162|Device|NIMV with SLE ventilator vs HFNC via Vapotherm|Nasal respiratory support for RDS
1882363|NCT01189175|Drug|BI 113823 + Ketokonazole|5 days ketokonazole with single oral dose of BI 113823 on day 3
1882364|NCT01189175|Drug|BI 113823|single oral dose
1882365|NCT01189188|Procedure|Artery puncture with ultrasound guidance|Ultrasound device will be used to locate artery for puncture.
1882366|NCT01189188|Procedure|Artery puncture without ultrasound guidance|Blood drawn from radial artery according to conventional procedure, without ultrasound guidance.
1882367|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A1)
1882368|NCT01189201|Drug|BI 10773/linagliptin|medium single dose of BI 10773/linagliptin FDC (Formulation A3)
1882369|NCT01189201|Drug|BI 10773/linagliptin SID|medium single dose of mono components BI 10773/linagliptin
1882370|NCT01189201|Drug|BI 10773/linagliptin FDC|medium single dose of BI 10773/linagliptin FDC (Formulation A1) after high fat, high caloric meal
1882371|NCT01189214|Drug|Memantine|Add-on of memantine or placebo treatment will proceed in a double-blinded fashion for 12 weeks after adjusted methadone dose. During the study, we will evaluate treatment response and adverse effect from multiple dimensions to elucidate the therapeutic effect of add-on memantine on addictive behaviors. It will also explore the possible advantage of this treatment on social re-adaptation and psychopathogenesis of opioid dependence.
1882372|NCT01189227|Procedure|Postoperative chemotherapy|Patients undergo hepatic resection. Beginning 31-56 days after surgery, patients receive mFOLFOX6 or FOLFIRI chemotherapy IV on day 1 over 3 hours. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats every 2 weeks for 12 cycles.
1882373|NCT01189227|Procedure|Perioperative chemotherapy|Patients receive mFOLFOX6 or FOLFIRI chemotherapy IV over 3 hours on day 1. Patients receive an additional dose of fluorouracil over 46 hours using a portable pump. Treatment repeats for every 2 weeks for 6 cycles. Patients then undergo hepatic resection. Beginning 31-56 days after surgery, patients receive an additional 6 cycles of mFOLFOX6 or FOLFIRI chemotherapy.
1882374|NCT01189240|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
1882375|NCT01189240|Biological|bevacizumab|Given IV
1882376|NCT01189240|Other|laboratory biomarker analysis|Correlative studies
1882377|NCT01189240|Other|pharmacological study|Correlative studies
1882378|NCT01189253|Drug|doxorubicin hydrochloride|
1882379|NCT01189253|Drug|trabectedin|
1882380|NCT01189253|Other|laboratory biomarker analysis|
1882381|NCT01189253|Procedure|quality-of-life assessment|
1882386|NCT01189279|Drug|bimatoprost Formulation A|bimatoprost Formulation A applied topically to the scalp once daily on Day 1 and Days 4-17.
1882387|NCT01189279|Drug|bimatoprost Formulation B|bimatoprost Formulation B applied topically to the scalp once daily on Day 1 and Days 4-17.
1882388|NCT01189279|Drug|bimatoprost Formulation C|bimatoprost Formulation C applied topically to the scalp once daily on Day 1 and Days 4-17.
1882389|NCT01189292|Drug|Dexamethasone|8mg (2ml) of dexamethasone (Mephameson®) administered intravenously preoperatively before thyroid surgery
1882390|NCT01189292|Other|NaCl 0.9%|2ml of NaCl 0.9% administered intravenously preoperatively before thyroid surgery
1882391|NCT01189305|Behavioral|Behavioral Couples Therapy|Behavioral Couples Therapy
1882392|NCT01189305|Behavioral|Individual Drug Counseling|Individual Drug Counseling
1882393|NCT01189318|Drug|Quetiapine Fumarate Extended Release|Day 1 50mg, Day 2 50mg, Day 3 150mg, Day 4~28 50~150mg (increments and deduction of 50mg are allowed)
1882394|NCT01189331|Device|CT coronary angiography and computational fluid dynamics|Evaluate coronary blood flow dynamics by CT coronary angiography and computational fluid dynamics
1882395|NCT01189344|Drug|Levothyroxine|600 µg of oral levothyroxine(LT4. Blood samples were collected before and after LT4 administration
1882396|NCT01189370|Drug|sorafenib|"Dose Level:
400mg twice daily, continuous.
600mg twice daily, days 1-5 of each week.
800mg twice daily, days 1-5 of each week."
1882397|NCT01189383|Biological|IL15-DC Vaccine|Autologous dendritic cells manufactured with GM-CSF, IL15 and loaded with melanoma/HIV peptides and KLH; then activated with LPS and CD40 Ligand. Approximately 9 x 10^6 DCs will be injected (subcutaneously)total per vaccination visit. Patients will receive four vaccinations at weeks 0, 4, 8 and 12. At each scheduled vaccination the patient will receive a total of 3 injections, i.e., 3 mL injections at each of 3 anatomical locations.Injection sites are in upper and lower extremities. Subsequent DC injections will be rotated to different locations on the upper and lower extremities.
1882398|NCT01189396|Drug|A006|Albuterol DPI with 180 mcg Albuterol/inhalation
1882399|NCT01189396|Drug|Placebo DPI|Placebo DPI with 0 mcg Albuterol/inhalation
1882400|NCT01189396|Drug|Proventil-HFA|Albuterol MDI with 90 mcg Albuterol/inhalation
1882401|NCT01189409|Drug|PEG then Senna|Stepped bowel protocol with PEG for 3 weeks followed by senna for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
1882402|NCT01189409|Drug|Senna then PEG|Stepped bowel protocol with senna for 3 weeks followed by PEG for 3 weeks. Both active treatments accompanied by placebo of alternate (lactose powder).
1882403|NCT01189422|Drug|teplizumab or placebo|infusion or injection
1882439|NCT01189747|Drug|normal saline|Injected into bilateral Crow's Feet Line areas on Day 1
1882934|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
1882404|NCT01189435|Drug|erlotinib|After baseline evaluation, patients will initiate treatment with erlotinib 150 mg daily, or at maximum previous tolerated dose. Initial response assessment will be done during the fourth week of therapy, during the eighth week of therapy, and then every 8 weeks thereafter. Patients will continue on therapy until disease progression by RECIST.
1882405|NCT01189448|Drug|Pyrimethamine/Sulfadiazine|"Pyrimethamine + sulfadiazine group : Pyrimethamine 50 mg once daily orally and sulfadiazine 1g tid. orally, with supplemental folinic acid 50 mg once a week.
Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.
Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment can be stopped in order to reduce the risk of intolerance, providing that the mother receives at least 4 weeks of therapy."
1882406|NCT01189448|Drug|Spiramycine|"Spiramycin group : spiramycin 1g tid orally Follow-up includes clinical and biological tolerance, according to usual recommendations. Monthly fetal ultrasound is performed. Prenatal diagnosis with amniocentesis is offered after 18 weeks gestation, usually 4 weeks after the maternal infection.
Treatment is be stopped or changed in case of toxicity. If prenatal diagnosis shows fetal infection with T. gondii, management is to be determined by the clinicians with the patient. If the prenatal diagnosis is negative the treatment is continued according to usual procedures"
1882407|NCT01189461|Drug|pegaptanib sodium|Upon enrollment, all subjects will be treated in the study eye with pegaptanib sodium 0.3 mg at the investigators' discretion based on visual acuity assessment up to a maximum of 48 weeks. The minimum dosing interval between injections will be at least 6 weeks.
1882408|NCT01189474|Device|Blephasteam|Eye lid warming goggles
1882409|NCT01189487|Drug|ampicillin sodium/sulbactam sodium|ampicillin sodium/sulbactam sodium is administered 12g/day (3 g four times a day) intravenously for 3 to 14 days
1882410|NCT01189500|Drug|Tamoxifen|Period 1-Tamoxifen 40mg on study day 1.
1882411|NCT01189500|Drug|Tamoxifen and Desvenlafaxine Succinate Sustained Release|Period 2-Desvenlafaxine SR 100mg on days 1-28 with coadministration of Tamoxifen 40mg on day 7.
1882412|NCT01189513|Drug|SCH 900105|10 mg/kg by vein every week on days 1, 8 and 15 of a 30 day cycle.
1882413|NCT01189526|Drug|Ranibizumab|Ranibizumab 0.5mg Ranibizumab will be administered to patients as multiple intravitreal injections.
1882414|NCT01189526|Procedure|macular laser photocoagulation|Treatment may include both focal and grid therapy using the laser and contact lens of the investigator's choice.
1882415|NCT01189552|Behavioral|LETS ACT Behavioral Activation Treatment|LETS ACT is based on the empirically validated Behavioral Activation Treatment for Depression (BAT-D; Lejuez, Hopko, & Hopko, 2001). Treatment includes eight sessions over a four-week period and is provided in small group format, with each group consisting of 3-5 patients.
1882416|NCT01189552|Behavioral|Nondirective Therapy (NDT)|The purpose of Nondirective Therapy (NDT) is to provide group therapy interaction, allowing for the development of a close therapeutic relationship and a safe and accepting environment to facilitate change. NDT will be conducted as outlined by Crits-Cristoph (1997). That is, the therapist will create an accepting, nonjudgmental, empathic environment to continuously direct client attention to primary feelings, and to facilitate accepting of affective experience using supportive statements, reflective listening, and empathic communications. Patients will received NDT in a small group format (3-5 participants) and will meet over the course of 4 weeks.
1882417|NCT01189591|Device|Slow-wave deprivation|Using acoustic tones to suppress slow-wave sleep
1882418|NCT01189604|Drug|Placebo|Infusion of placebo, same infusion rates as for arm 2
1882419|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.17 mg/kg for 3 minutes followed by maintenance with 25 µg/kg/minute
1882420|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.33 mg/kg for 3 minutes followed by maintenance with 50 µg/kg/minute
1882421|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 3 minutes followed by maintenance with 75 µg/kg/minute
1882422|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.8 mg/kg for 3 minutes followed by maintenance with 120 µg/kg/minute
1882423|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 1 minutes followed by maintenance with 75 µg/kg/minute
1882424|NCT01189604|Drug|ICI35,868 (propofol)|Infusion of propofol: initiation with 0.5 mg/kg for 5 minutes followed by maintenance with 75 µg/kg/minute
1882425|NCT01189617|Device|Formula PD-F-7619|Off-White to Beige Lotion
1960405|NCT03220009|Other|Patient Observation|Undergo active surveillance
1960406|NCT03220009|Radiation|Radiation Therapy|Undergo RT
1882428|NCT01189669|Dietary Supplement|LC n-3 PUFA (fish oil) Supplement|4 x 1g LC n-3 PUFA (fish oil)supplement containing 1.9g EPA and DHA given daily for 6 weeks
1882429|NCT01189669|Dietary Supplement|Placebo (olive oil) supplement|4 x 1g olive oil capsules were given daily for 6 weeks
1882430|NCT01189682|Procedure|Tegaderm, Tegaderm HP, Tegaderm CHG|dressings on catheters
1882431|NCT01189695|Drug|Ritonavir-boosted lopinavir|Lopinavir/ritonavir 200/50 mg every 12 hours
1882432|NCT01189695|Drug|optimized background regimens (OBRs)|Optimized background regimens such as NRTIs, etravirine or raltegravir
1882433|NCT01189708|Device|Ultrapro® Mesh implantation|After the aortic procedure (aortic aneurysm repair) an Ultrapro absorbable mesh will be used for the wound closure of the abdominal wall using an onlay technique.
1882434|NCT01189708|Other|Standard wound closure|Abdominal closure will be performed with standard sutures without a mesh.
1882435|NCT01189721|Drug|propofol, sevoflurane|"Remifentanil will be infused intraoperatively at 0.2 ㎍/㎏/min (group1 and 2) group 1 (Active Comparator, sevoflurane)will be infused propofol intraoperatively.
group 2(Experimental, propofol) will be inhaled sevoflurane intraoperatively."
1882436|NCT01189734|Procedure|laparoscopic common bile duct exploration|
1882437|NCT01189734|Procedure|laparoscopic cholecystectomy and intraoperative endoscopic sphincterotomy|
1882440|NCT01189760|Biological|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
1882441|NCT01189760|Biological|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin Type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart
1882442|NCT01189760|Drug|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients will receive two treatments 4 months apart.
1882443|NCT01189773|Drug|ibuprofen and codeine|ibuprofen: 10 mg/kg (max = 600 mg), codeine: 1 mg/kg (max = 60 mg)
1882444|NCT01189786|Device|CliniMACS CD34 Reagent system|A special machine that separates out the donor cells that have been mixed with a special protein, CD34 antibody, that binds to the stem cells from the white blood cells.
1882445|NCT01189799|Behavioral|Motivational therapy|Twelve, 60 minute weekly structured manualized therapy sessions.
1882446|NCT01189799|Other|Dual Recovery Anonymous/Treatment as usual|Twelve 60 minute weekly sessions of peer led 12-step Dual Recovery Anonymous group.
1882447|NCT01189812|Drug|Lithium Carbonate|300 mg one time per day for 4 weeks
1882448|NCT01189812|Drug|Placebo|Take one time daily for 4 weeks
1882449|NCT01189812|Drug|Citalopram|All patients will be administered Citalopram 20 mg to to be taken once daily, by mouth for the duration of the double-blind treatment phase (4 weeks)
1882450|NCT01189825|Behavioral|Exercise|Moderate to intense cardiovascular exercise on a treadmill for 20 minutes
1882451|NCT01189851|Device|Intraoperative Radiotherapy|The Axxent eBx™ System utilizes a miniaturized high dose rate (HDR) X-ray source to apply radiation directly to the cancerous tumor bed and provides brachytherapy when the physician chooses to deliver intracavitary or interstitial radiation to the surgical margins following lumpectomy for breast cancer.
1882452|NCT01189864|Drug|Ciprofloxicin or Vigamox or other.|Ciprofloxicin or Vigamox or other to be used qid till epithelialized.
1882453|NCT01189864|Drug|Nonsteroidal (Acular, Acuvail, Voltaren Xibrom, etc)|Nonsteroidal (Acular, Voltaren Xibrom, etc) qid up to 5-10 days post-op
1882454|NCT01189864|Drug|Steroid (FML, Pred Forte, Flarex, etc.)|Steroid (FML, Pred Forte, Flarex, etc.) to be used qid to qd for 1-8 weeks.
1882455|NCT01189877|Procedure|Eppendorf hypoximeter|Patients consented to the protocol will proceed to their surgery date without any change in the standard preoperative period. After arriving in the operating room, the patient will undergo intravenous general anesthesia (or spinal/epidural anesthesia) by the anesthesiologist and will receive 40% oxygen. At this time, the principal investigator (along with the assistance of the operating surgeon and a member of the Department of Medical Physics) will use the Eppendorf hypoximeter to gather pO2 measurements. We anticipate that this will add no more than fifteen minutes to the planned procedure. Once the measurements are collected, the anesthesia will be adjusted as appropriate for the surgery and the procedure will continue as usual.
1882456|NCT01189890|Drug|sitagliptin phosphate|Sitagliptin tablets, orally, at a dose of 100 mg or 50 mg QD for 30 weeks. The dose level to be administered will depend on the participant's estimated glomerular filtration rate (eGFR), calculated at Visit 3 and may be adjusted as medically indicated during the study.
1882457|NCT01189890|Drug|Glimepiride|Glimepiride tablets, orally, starting at a dose of 1 mg QD, which may be gradually increased, as needed, to maximum dose of 6 mg QD for 30 weeks. The dose may also be decreased as medically indicated during the study.
1882458|NCT01189890|Drug|Placebo to Sitagliptin|Matching placebo tablets to sitagliptin to allow for blinding.
1882459|NCT01189890|Drug|Placebo to Glimepiride|Matching placebo tablets to glimepiride to allow for blinding.
1882460|NCT01189903|Drug|Regorafenib|
1882461|NCT01189916|Procedure|Endoscopically assisted Appendectomy Surgery|Using endoscopic instruments a small incision will be made in the rectum wall and the endoscope will be advanced into the insufflated peritoneal cavity. At least one laparoscopic trocars will be placed through the abdominal wall for laparoscopic instrument insertion to manipulate and cut tissue. The flexible endoscope will provide visualization of the surgical field and flexible endoscopic instruments may be used to augment surgical manipulation with the laparoscopic instruments. The appendix will be removed through the anus. Endoscopic clips, sutures or tissue anchors (TAS)will be used to close the rectal access site.
1882462|NCT01189929|Drug|Demcizumab|Up to 50 subjects will be enrolled at up to 8 centers in Australia, New Zealand, and Spain. Up to 28 days (4 weeks) prior to treatment you will undergo testing to determine your eligibility to take part in this study, and then if you are enrolled in the study you will receive intravenous (in the vein) infusions of the demcizumab administered once every 2 weeks, and gemcitabine and Abraxane® administered weekly for 3 weeks, out of every 4 weeks. After 9 weeks, you will undergo assessments to determine the status of your disease. If there is no evidence of progression of your disease or if your tumor is smaller, you will continue to receive one additional infusion of demcizumab, and you will continue to receive infusions of gemcitabine and Abraxane® once weekly for 3 consecutive weeks out of every 4 weeks until it has been shown that your cancer has progressed. You will undergo assessments every 8 weeks thereafter to determine the status of your disease.
1882463|NCT01189929|Drug|Abraxane®|Abraxane® which will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes once a week for 3 weeks in a row, followed by a week of rest.
1882464|NCT01189929|Drug|Gemcitabine|Gemcitabine will be administered intravenously over 30 minutes initially at a dose of 1000 mg/m2 once a week for 3 weeks in a row, followed by a week of rest. If you develop side effects during this time period, your physician may decide to hold or reduce the dose of gemcitabine.
1882465|NCT01189942|Drug|OMP-21M18|The first 6 participants will receive OMP21M18 2.5 mg/kg once every other week, the next 6 participants will receive 5 mg/kg once every other week, and the final 6 participants will receive 10 mg/kg once every other week. A Data Safety Monitoring Board (DSMB) will review the data for the 6 participants in each dose level after the last participant in that group has been treated for 56 days and decide whether it is safe to move up to the next highest dose level. After confirming the optimum dose, 14 additional participants will be treated at the highest dose level that the DSMB considers safe.
1882553|NCT01197950|Device|Manual Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour.
1882466|NCT01189955|Procedure|HS total thyroidectomy|In the HS group, using the new harmonic scalpel device Focus (Ethicon Endo Surgery, Cincinnati, OH, USA) was used for cutting and coagulation . For closure of and division of superior and inferior arteries and veins we set the instrument at a power 2 i.e. more coagulation. And when smaller vessels like capsule veins we set it to the level 5 i.e. more cutting The superior artery and vein was divided close to the gland to avoid damage to superior laryngeal nerve. And control of any bleeding from the bed using the active blade of harmonic. Finally we insert drain.
1882467|NCT01189955|Procedure|conventional total thyroidectomy|A prophylactic antibiotic in the form of a third-generation cephalosporin was administered 2 hours before the operation. The operation was performed with the patient in the supine position under general anesthesia with endotracheal intubation. A Kocher incision, was made at the lower neck crease two finger above suprasternal notch. In the conventional group, mono- and bipolar coagulation, as well as ligatures, were allowed.
1882468|NCT01189968|Drug|Demcizumab|The 6 subjects in the first cohort will receive demcizumab 5 mg/kg once every 3 weeks; the 6 subjects in the subsequent cohort will be treated with 10 mg/kg once every 3 weeks; and the 6 subjects in the final cohort will be treated with 15 mg/kg once every 3 weeks. A Data Safety Monitoring Board (DSMB) will review the data for the 6 subjects in each dose cohort after the last subject in that cohort has been on study for 56 days and then decide whether it is safe to escalate to the next highest dose cohort. Once the dose-escalation portion of the study has been completed, 14 additional subjects will be treated at the highest dose level that the DSMB deems as safe.
1882469|NCT01189981|Behavioral|Lifestyle counseling|One health conversation at baseline
1882470|NCT01189981|Behavioral|eHealth intervention|SMS based encouragements to intensive exercise
1882471|NCT01189994|Procedure|Acupuncture|Needling of acupoints, some of them receiving electrostimulation
1882472|NCT01189994|Behavioral|Orientation|Orientation sessions focusing in fibromyalgia
1882473|NCT01190007|Drug|Caduet|One Caduet tablet will be administered once daily after breakfast, in principle, for 52 weeks
1882476|NCT01190033|Device|Neurotome OFF|In this intervention the neurotome will be unconnected.
1882477|NCT01190033|Procedure|neurolysis|In this procedure the neurotome will be connected
1882478|NCT01190046|Behavioral|Resistance exercise training|Lower extremity resistance exercise training 3x/wk
1882479|NCT01190059|Drug|Ex vivo lung perfusion with Steen Solution™|The circuit is primed with 2,000cc Steen Solution™. At one hour of EVLP, 500 cc of circulated perfusate was removed and replenished with 500 cc of fresh perfusate. After that, 250 cc of perfusate was exchanged every hour.
1882480|NCT01190085|Drug|Ghrelin|A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
1882481|NCT01190085|Drug|Ghrelin|A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
1882482|NCT01190085|Drug|Saline solution|Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
1882483|NCT01190098|Drug|Lacosamide|"Subjects randomized to lacosamide according to the following schedule:
Treatment Phase Week Dose Week 1 LCM 50 mg bid Week 2 LCM 100 mg bid Week 3 LCM 150 mg bid Week 4 LCM 200 mg bid"
1882484|NCT01190098|Drug|Placebo|Placebo will be packaged identically to experimental drug and titrated according to the same schedule.
1882485|NCT01190111|Biological|Interleukin-7|20 µg/kg/week. 3 administrations, 1 per week (1 cycle) repeated cycles based on a CD4-guided response
1882486|NCT01190137|Dietary Supplement|Cholecalciferol (D3) or ergocalciferol (D2)|400 IU administered as 1 drop daily for 3 months
1882487|NCT01190150|Drug|tranexamic acid|Either one or two modified-immediate release tranexamic acid tablets (0.65 g each) taken orally, administered with 240 mL of water, as a single dose, at approximately 8 AM.
1882488|NCT01190163|Drug|Dinoprostone|
1882489|NCT01190163|Drug|Oxytocin|
1882493|NCT01190189|Biological|GSK580299 (Cervarix™)|3-dose schedule intramuscularly vaccination
1882496|NCT01190215|Biological|FluarixTM|One Intramuscular injection
1882497|NCT01190215|Biological|HavrixTM Junior (in subjects of 15 years old or below) or HavrixTM (in subjects above 15 years old)|Two Intramuscular injections
1960413|NCT03215030|Drug|TAK-573|TAK-573 intravenous infusion
1882501|NCT01190241|Drug|desatinib or sunitinib or erlotinib or everolimus or lapatinib or sorafenib|The drug will be selected based on ex vivo test on the tumor tissue. The patients will be treated with the selected drug until disease progression.
1882502|NCT01196689|Drug|AZD1981 100 mg twice daily for 61/2 days|100 mg tablets
1882503|NCT01196715|Drug|Darbepoetin alpha|Aranesp 500 mcg vials once every 2 weeks.
1882504|NCT01196715|Drug|Filgrastim|300 mcg vials twice a week, 3-4 days apart
1882505|NCT01196715|Procedure|Blood Red Cell Transfusion|Red cell transfusion support to achieve a predicted post-transfusion haemoglobin of 11.0 to 12.0 g/dl at a quantity and frequency such that the minimum haemoglobin is never below 8.0 g/dl or such that the patient is never excessively symptomatic, according to local transfusion guidelines/policy.
1882506|NCT01196728|Drug|CM3.1-AC100|SAD study with single ascending subcutaneous doses
1882507|NCT01196741|Drug|Paclitaxel|Paclitaxel 80 mg/m2 weekly for 6 weeks followed by a 2 week break (1 cycle), for 4 cycles initially (32 weeks). If there is evidence of on-going response after 4 cycles, 3 further cycles will be given, unless there is dose-limiting toxicity or the patient requests to discontinue treatment. If best response is stable disease after 4 cycles, treatment should be discontinued but may continue at the discretion of the Investigator.
1882508|NCT01196741|Drug|Saracatinib|Saracatinib 175 mg PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
1882509|NCT01196741|Drug|Matched placebo|Matched placebo PO once daily, to begin 1 week prior to commencement of chemotherapy, taken continuously until progression
1882510|NCT01196754|Other|sevoflurane|
1882511|NCT01196767|Drug|Ropivacaine (in one arm); catheterization (in both).|"Parallel study with two groups:
ropivacaine (2 mg.mL-1), at the rate of 4 mL.hr-1 through two subcutaneous catheters lateral to the sternum, both alimented by an elastomeric pump.
same protocol, with normal saline instead of ropivacaine."
1882513|NCT01196832|Procedure|blood sample|blood sample for fibrocytes analysis
1882514|NCT01196832|Procedure|Clinical and functional evaluation|Plethysmography, Carbon monoxide capacity of transfer , arterial gaz
1882515|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
1882516|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or Sham cPAP
1882517|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
1882518|NCT01196845|Device|cPAP|Patients are randomised in 2 arms : cPAP or sham cPAP
1882519|NCT01196871|Drug|AT1001|Capsules, single dose
1882520|NCT01196897|Device|WATCHMAN LAA Closure Technology (Gen 4.0)|Implantation of the WATCHMAN device into the left atrial appendage.
1882521|NCT01196910|Device|treatment by HLPFC coil|"DTMS treatment will be given for 3 weeks, 5 days a week. Before each DTMS treatment, neural network excitation practice will be done using AttenGo software (AttenGo, Herzlia, Israel).
Each treatment day: Follow-up to evaluate clinical side effects of treatment. Two additional meetings with DTMS treatment and follow-up will be held to evaluate the efficacy of treatment and side effects. The first will be four weeks after the end of the daily treatment phase; the second eight weeks after the end of the daily treatment phase."
1882522|NCT01196923|Device|Endoscopically Guided Ablation|Visually Guided Ablation using EAS-AC
1882523|NCT01196936|Drug|Tamoxifen Citrate|5 mg PO Daily
1882524|NCT01196936|Drug|Placebo|1 tablet daily
1882525|NCT01196936|Procedure|Digital mammography|Correlative studies
1882526|NCT01196936|Other|immunohistochemistry staining method|Correlative Studies
1882527|NCT01196936|Other|pharmacological study|Correlative Studies
1882528|NCT01196936|Other|laboratory biomarker analysis|Correlative Studies
1882529|NCT01196936|Genetic|protein expression analysis|correlative studies
1882530|NCT01196936|Other|pharmacogenomic studies|correlative studies
1882531|NCT01196936|Other|questionnaire administration|Ancillary studies
1882532|NCT01196936|Procedure|Fine needle aspiration|
1882533|NCT01196936|Other|Quality of Life Assessment|Ancillary Studies
1882534|NCT01196949|Other|Manipulative and Rehabilitative Therapy|Participants will receive 6 treatments over a 3 to 5 week time frame. A minimum of one day and maximum of 3 days between treatments. This group will receive high velocity low amplitude thrust to a minimum of 1 and maximum of 3 restricted segments within the mortise joint, subtalar joint and tarsal along with the same rehabilitation protocol as the other group.
1882535|NCT01196949|Other|Rehabilitative Therapy|Participants will receive education and training in the home exercises. This group is only required to attend the treatment facility for outcome measure readings and if they have any questions about the research protocol or check if they are performing their exercises correctly. A Theraband will be utilized for the peroneal muscle strengthening; 3 sets of 12 repetitions. Proprioception will be conducted on a Bosu Ball; 10 minutes per period. This protocol will be conducted everyday at home for the 5 week study. A diary will be required to record compliance and indicate how exercises should be performed.
1882536|NCT01196962|Device|Central venous catheter|Central venous catheter insertion to subclavian vein
1882537|NCT01196975|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose
1882538|NCT01196975|Biological|FluLavalTM-VB|Single intramuscular dose
1882539|NCT01196975|Biological|FluLavalTM-YB|Single intramuscular dose
1882540|NCT01196988|Biological|Influenza vaccine GSK2321138A|intramuscular injections
1882541|NCT01196988|Biological|FluarixTM|intramuscular injections
1882542|NCT01196988|Biological|Influenza vaccine GSK2604409A|intramuscular injections
1882543|NCT01197001|Drug|Amlodipine plus Losartan|Amlodipine/Losartan low dose
1882544|NCT01197001|Drug|Amlodipine, Losartan|Amlodipine, Losartan
1882545|NCT01197014|Drug|Amlodipine plus Losartan|Amlodipine/Losartan high dose
1882546|NCT01197014|Drug|Amlodipine, Losartan|Amlodipine, Losartan
1882547|NCT01197872|Other|Preimplantation Genetic Diagnosis|Genetic testing on embryos to identify embryos that are affected by a single gene disorder (e.g. cystic fibrosis, Tay-Sachs, sickle cell anemia).
1882548|NCT01197885|Drug|IMAB362|Cohort 1 repeated doses of 300 mg/m2 Cohort 2 repeated doses of 600 mg/m2 Cohort 3 doses to be determined, 600mg/m2 or less
1882549|NCT01197898|Biological|Collagenase Santyl Ointment|Topical daily application
1882554|NCT01197950|Device|Electro Acupuncture|The women will receive treatment on bilateral points, both distal points and local points and the needles will be manually stimulated to reach De Qi every ten minutes during one hour. Eight needles in the painful area (local points) will be connected to an electro-stimulator and stimulated with high frequency (80 Hz) square wave pulses (0.18-ms duration) with alternating polarity. The woman will adjust the intensity of the electrical stimulation to be just under pain threshold.
1882555|NCT01197963|Procedure|Sleeve Gastrectomy and Ileal transposition|Laparoscopic sleeve gastrectomy with ileal transposition
1882556|NCT01197963|Dietary Supplement|dietary and medical management|dietary and medical routine management patients are currently following with an endocrinologist.
1882557|NCT01197976|Device|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
1882558|NCT01197976|Device|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
1882559|NCT01197989|Device|TEPSO cloth|TEPSO stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
1882560|NCT01197989|Device|Standard cloth|Standard cotton stocks should be worn continuously for 4 weeks of the study and will be changed every 3 days without wearing again those already used (even after washing).
1882561|NCT01198002|Drug|LY2127399|Administered Subcutaneously
1882562|NCT01198002|Drug|Placebo every 2 weeks|Administered Subcutaneously
1882563|NCT01198002|Drug|Placebo every 4 weeks|Administered Subcutaneously
1882564|NCT01198028|Drug|Erlotinib|150 mg by mouth for 8 weeks.
1882565|NCT01198054|Drug|Lenalidomide|"Initial dose of oral lenalidomide is 10 mg/day for 28 days every 28 days, during 6 months.
In case of response on day 169, patient will follow a treatment extension phase. The dose of lenalidomide should be the same as the last dose for initial phase, until 24 months or progression disease"
1882566|NCT01198067|Drug|Pomalidomide|Starting dose level 1 mg by mouth on days 1-28 of a 28 day cycle.
1882567|NCT01198067|Drug|Pomalidomide|Starting dose level 1 mg by mouth on days 1-21 of a 28 day cycle.
1882568|NCT01198080|Biological|CD133+ cells|bone marrow derived CD133+ cells injection with core compression
1882569|NCT01198106|Drug|scopolamine|0.6 mg
1882570|NCT01198106|Drug|cinnarizine|50 mg
1882571|NCT01198119|Device|Location of the suspected lesions|"The suspected lesions will be located before the excision, during the surgery.
With traditional light
NBI technique The images will be recorded and compared"
1882572|NCT01198119|Procedure|Biopsy|In case of suspected lesions detected by the NBI technique, this area is biopsied
1882573|NCT01198119|Procedure|Lesion excision/Surgery|In case of positive biopsy, the suspected lesions is excised
1882575|NCT01198145|Drug|sulfasalazine|Given orally
1882576|NCT01198145|Other|placebo|Given orally
1882581|NCT01198171|Other|Laboratory Biomarker Analysis|Correlative studies
1882582|NCT01198171|Other|Study of Socioeconomic and Demographic Variables|
1882583|NCT01198184|Drug|temsirolimus|Given IV or PO
1882584|NCT01198184|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
1882585|NCT01198184|Other|laboratory biomarker analysis|Correlative studies
1882586|NCT01198184|Other|pharmacological study|Correlative studies
1882587|NCT01198197|Drug|NOP-1A|
1882588|NCT01198210|Drug|saline|local peritonsillar infiltration of 2 ml saline,
1882589|NCT01198210|Drug|Ketamine|local peritonsillar infiltration of ketamine (0.5 mg/kg)
1882590|NCT01198210|Drug|Dexamethasone|local peritonsillar infiltration dexamethasone (0.2 mg/kg))
1882591|NCT01198210|Drug|ketamine-dexamethasone|local peritonsillar infiltration combination of ketamine0.5mg/kg-dexamethason 0.2mg/kg
1882592|NCT01198223|Drug|garlic , nystatin|mouthwash
1882593|NCT01198236|Drug|Itraconazole|"Itraconazole will be administered intravenously 2×200 mg/d(200mg twice a day, with 12 hours interval, and should be completed in no less than 60 minutes each time) in the first two days of treatment as a loading dose, then 200mg/d intravenously (200mg once a day with 24 hours interval and completed in no less than 60 minutes) until the end of the at-risk period.
In transplant patients, the end of at-risk period is defined as a stable engraftment of 1*109/L neutrophil cells; in patients who have undergone chemotherapy, it is defined as the resolution of neutropenia (neutrophil cells> 0.5*109/L).
If needed, the patients will take itraconazole solution orally after intravenous administration."
1882594|NCT01198249|Drug|multiple dose, crossover study between single and concomitant administrations of amlodipine, losartan, and hydrochlorothiazide|amlodipine 10 mg for 9 days , losartan 100 mg for 9 days, hydrochlorothiazide (HCTZ) 25 mg for 9 days and combination of amlodipine 10 mg, losartan 100 mg and hydrochlorothiazide (HCTZ) 25 mg for 9 days, 4 way crossover study
1882595|NCT01198275|Drug|n-3 PUFAs|1.0 g of EPA (eicosapentaenoic acid) and DHA (docosahexaenoic acid) in the average ratio EPA/DHA of 0.19:1.5, one capsule twice a day
1882596|NCT01198275|Drug|Placebo|1.0 g of olive oil,one capsule twice a day
1882597|NCT01198275|Drug|RASS inhibitors and/or RAS blockers|Patients on ACE-Is or ARBs were continued on the same agent. In those who were not on therapy, an ACE-I or an ARB was started. In all patients, an effort was made to achieve the highest tolerated dose.
1882598|NCT01198275|Drug|Amiodarone|Patients on amiodarone were continued at a maintenance dose of 200 mg daily, whereas those who were not taking amiodarone were started at a dose of 400 mg daily for 1 week and then continued on a maintenance dose of 200 mg daily.
1882599|NCT01198288|Other|domiciliary rehabilitation|a respiratory rehabilitation programme at the patient home
1882600|NCT01198288|Other|Standard Care|As describe in the standard care arm
1882601|NCT01198314|Procedure|immunosuppression withdrawal|tapering off immunosuppressant
1882602|NCT01198314|Procedure|continue of taking immunosuppressant|maintain immunosuppression
1882603|NCT01198327|Drug|ranibizumab|Intravitreal ranibizumab, .5mg dose, PRN but not less than 21 days apart.
1882604|NCT01198327|Other|Peripheral Laser|Areas of nonperfusion identified on wide field angiograms will receive laser, if the patient is continuing to require ranibizumab injections.
1882605|NCT01198340|Procedure|PC-FNB with basal administration of local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block with 3 ml/h of basal dose, 5ml bolus by the patient, 60 minutes of lock out time.
1882606|NCT01198340|Procedure|PC-FNB without basal local anesthetics|Administration of 0.2% ropivacaine for femoral nerve block without basal dose, with 8 ml bolus by the patient, 60 minutes of lockout time.
1882607|NCT01198353|Drug|Ziprasidone|100% of the past antipsychotic dose will be maintained in week 1, using flexible dosing of 0-100% during next 3 weeks and then discontinued. Ziprasidone will be maintained with flexible dosing of 40-160mg/day during the study period.
1882608|NCT01198366|Biological|AERAS-402 1.5 x 10^10 vp|
1882609|NCT01198366|Biological|AERAS-402 3.0 x 10^10 vp|
1882610|NCT01198366|Biological|AERAS-402 1.0 x 10^11 vp|
1882611|NCT01198366|Biological|Placebo|
1882612|NCT01198379|Drug|aspirin|aspirin 100 mg qd for 3 years
1882613|NCT01198379|Drug|Placebo|
1882614|NCT01198392|Drug|s-1 plus cisplatin|S-1:80 mg/m2/day po twice daily on Day 1-21,cisplatin: 20mg/m2 iv on Day 1-4, repeat every 5 weeks. Number of Cycles: until progression or unacceptable toxicity develops.
1882615|NCT01198392|Drug|5-Fu plus cisplatin|"5-Fu 800 mg/m2/d CI 120h ,Cisplatin 20 mg/m2 as a 2 hour i.v. infusion(on day 1 to day 4 )repeat every 4 weeks.
Number of Cycles: until progression or unacceptable toxicity develops."
1882616|NCT01198405|Device|Enhanced external counterpulsation|Treatment of enhanced external counterpulsation (EECP) with a prespecified protocol on top of a guideline-driven standard medical therapy. EECP Protocol is defined as a standard session of a total of 36 hours of EECP treatment, given one hour per day, six days per week. The same session is thereafter repeated at least once every year.
1882617|NCT01198405|Drug|Guideline-driven standard medical therapy|Standard management, both pharmacological and non-pharmacological, given according to current practice guidelines at the discretion of clinicians
1882618|NCT01198418|Behavioral|Experimental|Internet-based intervention that assesses transmission risk and provides prevention messages
1882620|NCT01198444|Drug|EE/DRSP (Yasmin Product Family)|One tablet per day, orally, 21 tablets followed by 7 days, during three consecutive cycles.
1882621|NCT01198457|Drug|Clodronate (Bonefos, BAY94-8393)|Random group of patients in oncology clinic
1882622|NCT01198470|Device|TRIUMPH® Lumbar Artificial Disc|The TRIUMPH® Lumbar Artificial Disc is an articulating artificial disc inserted using a posterolateral approach to the lumbar spine.
1882623|NCT01198483|Procedure|Combined Micro- Surgery|Microincision Cataract Surgery combined with 23-gauge/25-gauge/27 gauge Vitrectomy
1882624|NCT01198483|Procedure|Combined Small-Surgery|Smallincision cataract surgery combined with 23 gauge vitrectomy
1882625|NCT01198496|Drug|Losartan, Losartan and HCTZ, Amlodipine , Spironolactone|<Study drugs and treatment steps> Step 1: Losartan 50 mg in principle (other ARB is usable) Step 2: Combination drug containing losartan 50 mg and hydrochlorothiazide 12.5 mg Step 3: Combination drug containing losartan 50mg and HCTZ 12.5mg + amlodipine 5 mg Step 4: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 5 mg Step 5: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg Step 6: Losartan 50 mg + combination drug containing losartan 50 mg and HCTZ 12.5 mg + amlodipine 10 mg + spironolactone 25 mg
1882626|NCT01198509|Drug|doxycycline|doxycycline - 100 mg twice per day, for 2 months
1882627|NCT01198509|Drug|vancomycin|vancomycin, 250 mg four times a day, for 2 weeks
1882628|NCT01198522|Drug|L19IL2 monoclonal antibody-cytokine fusion protein in combination with gemcitabine|"Part A) Patient cohorts will sequentially be assigned to 800 or 1,000 mg/m2 of gemcitabine. gemcitabine will be given in combination with a fixed dose of L19IL2. Part B) Patient cohorts will sequentially be assigned to 10, 15,22.5,30 or 37,5 MioIU IL2 equivalents of L19IL2. L19IL2 will be given in combination with gemcitabine at the dose recommended from Part A. Should the MTD of L19IL2 not be reached within the planned cohorts listed above, the dose of L19IL2 will be further increased following 7.5 MioIU increasing steps.
Induction treatment: Intravenous (i.v.) infusions of L19IL2 on days 1,3,5,22,24, 26,43,45,47, followed by i.v. infusions of gemcitabine on days 1,8,15,22,29,36,43. Maintenance treatment: Patients with objective tumor responses or stable disease will receive up to 4 cycles of maintenance treatment, starting on day 57: i.v. infusions of L19IL2 on days 1 (day 57), 8,15, followed by an i.v. infusion of gemcitabine. Treatment cycles will be repeated on day 29."
1882629|NCT01198535|Biological|Cetuximab|Given IV
1882630|NCT01198535|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1882631|NCT01198535|Other|Laboratory Biomarker Analysis|Correlative studies
1882632|NCT01198535|Other|Pharmacological Study|Correlative studies
1882633|NCT01198548|Drug|leucovorin calcium|Given IV
1882634|NCT01198548|Biological|bevacizumab|Given IV
1882635|NCT01198548|Dietary Supplement|cholecalciferol|Given PO
1882636|NCT01198548|Drug|fluorouracil|Given IV
1882637|NCT01198548|Drug|oxaliplatin|Given IV
1882638|NCT01198548|Other|pharmacological study|Correlative studies
1882639|NCT01198561|Device|repetitive Transcranial Magnetic Stimulation|10 times repetitive TMS, high frequency
1882640|NCT01198574|Dietary Supplement|Iron group|Ferrous fumarate, 60 mg, weekly dose
1882641|NCT01198574|Dietary Supplement|Vitamin A group|Retinol, weekly dose, 15,000 IU
1882642|NCT01198574|Dietary Supplement|Iron and vitamin A group|Ferrous fumarate, Retinol combination group, weekly dose
1882643|NCT01198574|Dietary Supplement|Placebo group|folic acid only as placebo group
1882645|NCT01198600|Device|Habitual contact lens|Hydrogel or silicone hydrogel contact lens per participant's habitual brand and prescription
1882646|NCT01198600|Device|Lotrafilcon B contact lens|Commercially marketed silicone hydrogel contact lens
1882647|NCT01198600|Device|Contact lens cleaning and disinfecting system (ClearCare)|Commercially marketed, hydrogen peroxide-based contact lens care system
1882648|NCT01198613|Biological|ToleroMune Ragweed|Intradermal injection 1 x8 administrations 2 weeks apart
1882649|NCT01198613|Biological|Placebo|Intradermal injection, 1x8 administrations 2 weeks apart
1882650|NCT01198626|Drug|JNJ-32729463|150 mg intravenous formulation administered twice daily for at least 72 hours, followed by 250 mg oral formulation administered twice daily for a total treatment time of 7 to 14 days
1882651|NCT01198626|Drug|moxifloxacin|400 mg intravenous formulation administered once daily for at least 72 hours, followed by 400 mg oral formulation administered once daily for a total treatment time of 7 to 14 days. To maintain the blind, subjects will receive one dose of moxifloxacin and one dose of placebo daily.
1882652|NCT01198626|Drug|JNJ-32729463 (Open-Label)|Subjects may receive JNJ-32729463 intravenous formulation up to 150 mg either BID or TID followed by 250 mg oral formulation BID for a total treatment time of 7 to 14 days.
1882653|NCT01198639|Device|manual administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|the anesthesiologists are instructed to maintain the BIS values between 40 and 60 throughout anesthesia using target controlled infusion method
1882654|NCT01198639|Device|closed-loop administration of iv anesthetics (propofol and remifentanil) using the Toolbox platform|an algorithm is used to maintain automatically the BIS values between 40 and 60
1882655|NCT01198665|Drug|RAD001 (Everolimus)|Phase I Level 1: RAD001 2.5 mg PO daily D1-14 + CHOP Level 2: RAD001 5 mg PO daily D1-14 + CHOP Level 3: RAD001 7.5 mg PO daily D1-14 + CHOP Level 4: RAD001 10 mg PO daily D1-14 + CHOP CHOP every 3 weeks D1 Cytoxan 750mg/m2 + D5W 100ml MIV over 1hr D1 Doxorubicin 50mg/m2 + D5W 100ml MIV over 30mins D1 Vincristine 1.4mg/m2 (max.2mg) IV push D1-D5 Prednisolone 100mg/d PO (40-30-30) Phase II Determined dosage of RAD001 + CHOP every 3 weeks
1882656|NCT01198678|Dietary Supplement|Boost Nutritional Supplement|Boost- Nutritional Supplement
1882657|NCT01198691|Device|Insorb absorbable staples|Patients will be randomized to receive either the standard metallic staples or the Insorb absorbable staples
1882658|NCT01198691|Device|Insorb|Patients will be randomized to receive either standard metallic staples or Insorb absorbable staples
1882659|NCT01198704|Other|search of factors predicting tumor recurrence|Morphological, chronological, anatomy-pathological and molecular search
1882660|NCT01198730|Drug|Acarbose|Acarbose 25 mg tid, titrate to 100 mg tid.
1882661|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects 9 to 17 years of age, single intramuscular dose.
1882662|NCT01198756|Biological|Fluarix™ VB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose.
1882663|NCT01198756|Biological|Fluarix™ YB|For subject 3 to 8 years of age, single intramuscular dose for primed subjects, two doses for unprimed subjects. For subjects of 9 to 17 years of age, single intramuscular dose
1882664|NCT01198756|Biological|Quadrivalent seasonal influenza vaccine GSK2282512A|Single intramuscular dose for primed subjects, two doses for unprimed subjects.
1882665|NCT01198769|Biological|Rotarix TM|Oral, 2 doses
1882666|NCT01198782|Other|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops)|Patients will dose 4 times daily for 4 months.
1882667|NCT01198795|Drug|Escitalopram|Patients who meet eligibility criteria will receive open-label escitalopram. 10-20mg oral administration (10mg tablets) once daily for 24-weeks with a 2-week downtaper period.
1882668|NCT01198821|Drug|Sodium bicarbonate (g/kg/day)|Dose Escalation - Level 1: 0.3, Level 2: 0.5, Level 3: 0/7, Level 4: 1.0
1882669|NCT01198821|Drug|Gemcitabine (mg/m²)|Dose Escalation - Level 1: 1000, Level 2: 1000, Level 3: 1000, Level 4: 1000
1882670|NCT01198834|Drug|MRX-7EAT|Application of up to two patches at the discretion of the investigator for up to 7 days.
1882671|NCT01198834|Drug|Placebo|Application of up to two patches at the discretion of the investigator for up to 7 days.
1882672|NCT01198834|Drug|Lidocaine|Application of up to two patches at the discretion of the investigator for up to 7 days.
1882673|NCT01198834|Drug|Etodolac|Application of up to two patches at the discretion of the investigator for up to 7 days.
1882674|NCT01198847|Behavioral|Dietary, physical activity and sleeping|The intervention in the present study will be delivered through sessions aiming at developing healthy lifestyle habits regarding physical activity, food intake and regular sleeping habits for parents and children. These sessions will be performed face to face by trained health care workers and carried out in the welfare centres with the parent/s. Children will not be approached directly in the present study. All families will meet with their coach/facilitator during at least 12 times (including start and final evaluation meeting) until the children reach 6 years of age (such as school age). However extra effort (as boosting sessions) will be made if growth records show an increased BMI (weight induced meetings). The parents are also encouraged to keep contact with their coach either by phone or e-mail as often as they feel needed.
1882676|NCT01198873|Drug|Dronedarone|"Film-coated tablet
Oral administration under fed conditions (during breakfast and dinner)"
1882677|NCT01198873|Drug|Placebo (for Dronedarone)|"film-coated tablet strictly identical in appearance
Oral administration under fed conditions (during breakfast and dinner)"
1882678|NCT01198886|Other|Successful Aging Program|Once per week discussion on lifestyle topics important to older adults. Classes conclude with a gentle upper body stretching routine.
1882679|NCT01198886|Other|Exercise-Nutrition Program|Targeted exercise program offered 3-days per week at the study participants place of residence (senior housing facility). Other means to encourage physical activity outside of these exercise classes will be available. A nutrient-rich protein carbohydrate experimental beverage will be taken following the exercise sessions.
1882680|NCT01198899|Other|blood sampling|Blood sampling will be used.
1882681|NCT01198912|Drug|placebo|during 56 days
1882682|NCT01198912|Drug|doxycycline 100 mg|during 56 days
1882683|NCT01198925|Drug|piperacillin continuous infusion|piperacillin continuous infusion
1882684|NCT01198925|Drug|piperacillin extended infusion|piperacillin extended infusion
1882685|NCT01198938|Other|Melatonin|Melatonin 5 mg sublingually given at 9 p.m. for 5 postoperative days or until discharge
1882686|NCT01198964|Procedure|Low-level cortical stimulation|A couple of electrodes will be stimulated (at a lower level than the stimulation used for standard care) over a period of 4-12 hours based on the signals defined by the motor or language task.
1882687|NCT01198977|Behavioral|Brief telephone-based counseling|Brief telephone-based counseling using Motivational Interviewing and physical activity goal setting and problem solving
1882688|NCT01198977|Other|Education counseling|Mailed informational video of exercise programs
1882689|NCT01198990|Behavioral|Group 1|Subjects will be randomized to the small change eating strategy, a physical activity goal and will receive the positive affect/self affirmation component.
1882690|NCT01198990|Behavioral|Group 2|Subjects will be randomized to the small change eating strategy and a physical activity goal.
1882691|NCT01199016|Procedure|Tympanocentesis|To be performed as needed on children presenting with acute otitis media
1882692|NCT01199016|Procedure|Nose/throat swab|To be performed at every study visit
1882693|NCT01199016|Biological|Observational|Observational Study Only
1882694|NCT01199029|Drug|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test(OGTT)
1882695|NCT01199029|Drug|PF-04308515|10 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test(OGTT)
1882696|NCT01199029|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
1882697|NCT01199029|Drug|PF-04308515|X mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
1882698|NCT01199029|Drug|PF-04308515|Y mg of Pf-04308515 extemporaneous oral solution predosed at selected time from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
1882699|NCT01199029|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
1882700|NCT01199029|Drug|Prednisone|20 mg (5 mg tablets) predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
1882701|NCT01199042|Device|BiPAP autoSV Advanced|The sleep apnea device will be set-up in automatic mode with the settings wide open for the entire night.
1882702|NCT01199055|Drug|CS-7017|Drug: CS-7017 from 0.25 mg bid to 0.50 mg bid for up to 4~6 cycles (1 cycle: 3 weeks)
1882703|NCT01199055|Drug|Carboplatin|Drug: Carboplatin IV, AUC of 6, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
1882704|NCT01199055|Drug|Paclitaxel|Drug: Paclitaxel IV, 200mg/m2, once every three weeks for up to 4~6 cycles (1 cycle: 3 weeks)
1882705|NCT01199068|Drug|CS-7017|CS-7017 from 0.25 mg to 0.50 mg twice a daily
1882706|NCT01199068|Drug|Erlotinib|Erlotinib 150 mg once daily
1882707|NCT01199081|Drug|Dronedarone|"Pharmaceutical form: tablet
Route of administration: oral (together with meal)
Dose regimen: 400 mg twice daily"
1882708|NCT01199107|Behavioral|Prolonged Exposure|75-90 minute weekly psychotherapy sessions x 12 weeks, focused on gradually confronting distressing trauma-related memories and reminders
1882709|NCT01199107|Behavioral|Exercise|30 minutes of moderate-intensity treadmill exercise prior to the Prolonged Exposure
1882710|NCT01199107|Behavioral|Wellness Intervention|30 minutes of wellness education prior to Prolonged Exposure
1882711|NCT01199120|Dietary Supplement|Omega 3|measure of efficacy of omega-3 fatty acids supplement on cognition and academic performance in children attending elementary school.
1882712|NCT01199133|Drug|Dpte and Dfar Allergen Extracts|300 IR, once a day, for one year.
1882713|NCT01199133|Drug|placebo|once a day, for one year.
1882714|NCT01199146|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg by mouth per day
1882715|NCT01199159|Drug|Misoprostol|400mcg misoprostol given sublingually 30 minutes before total abdominal hysterectomy
1882716|NCT01199159|Drug|Vitamin B 6|20mg vitamin B6 given sublingually 30 minutes before total abdominal hysterectomy
1882717|NCT01199172|Behavioral|voice hygiene|subjects will receive voice hygiene training
1882718|NCT01199172|Behavioral|VH + VP|subjects will be trained in voice hygiene and voice production training
1882721|NCT01199198|Drug|Tolvaptan|Starting dose 15 mg by mouth once a day for 14 days.
1882722|NCT01199198|Drug|Placebo|Placebo by mouth once a day for 14 days.
1882724|NCT01199224|Drug|veliparib|veliparib formulation A
1882725|NCT01199224|Drug|veliparib|veliparib formulation B
1882726|NCT01199224|Drug|veliparib|veliparib formulation C
1882727|NCT01199224|Drug|veliparib|veliparib formulation C
1882728|NCT01199237|Drug|Sevoflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
1882783|NCT01199562|Genetic|protein expression analysis|Correlative studies
1882729|NCT01199237|Drug|Desflurane|Protective airway reflexes will be tested, judged by subject's ability to swallow 20 mL water
1882730|NCT01199237|Drug|Rocuronium|
1882731|NCT01199237|Drug|Neostigmine|
1882732|NCT01199237|Drug|Glycopyrrolate|
1882733|NCT01199250|Other|Laboratory Biomarker Analysis|Correlative studies
1882734|NCT01199263|Other|Laboratory Biomarker Analysis|Correlative studies
1882735|NCT01199263|Drug|Paclitaxel|Given IV
1882736|NCT01199263|Biological|Wild-type Reovirus|Given IV
1882737|NCT01199276|Drug|Xenon|Group A: xenon 60% (55%-65%)(1 MAC) in oxygen (FiO2 = 0.35-0.45)
1882738|NCT01199276|Drug|Sevoflurane|Group B: sevoflurane 1.1-1.4%(1 MAC) in oxygen (FiO2 = 0.35-0.45) and Medical air
1882739|NCT01199289|Drug|AMG 827|210 mg AMG 827 SC
1882740|NCT01199289|Drug|Placebo|Placebo SC
1882741|NCT01199289|Drug|AMG 827|140 mg AMG 827 SC
1882742|NCT01199289|Drug|AMG 827|280 mg AMG 827 SC
1882743|NCT01199302|Drug|AMG 827|350 mg AMG 827 administered intraveneously at baseline, week 4, and every 4 weeks thereafter.
1882744|NCT01199315|Drug|AZD1446|oral capsule, Moderate Release
1882745|NCT01199315|Drug|Placebo|oral capsule
1882746|NCT01199328|Drug|Aspirin|81mg Tablet oral, once daily
1882747|NCT01199328|Drug|Esomeprazole|20 mg Tablet oral, once daily
1882748|NCT01199341|Drug|AZD1981|100 mg per oral, twice daily for 14 days
1882749|NCT01199341|Drug|Warfarin|10 x 2.5 mg per oral, once daily at day 1 and day 15
1882750|NCT01199341|Drug|AZD1981|4 x 100 mg per oral, twice daily for 14 days
1882751|NCT01199354|Procedure|Mastectomy, preservation of the skin envelope,followed by immediate reconstruction with autologous latissimus dorsi flap.|Mastectomy, preservation of the skin envelope, removal of the nipple-areolar complex and dissection of the axillary lymph nodes followed by immediate reconstruction with autologous latissimus dorsi flap with or without prosthesis.
1882752|NCT01199367|Drug|KW-2450 in combination with lapatinib and letrozole|Three subjects will be assigned to each of 4 sequential cohorts. Dose escalation may proceed once at least 3 subjects have completed 30 days of study treatment. Subjects who withdraw prior to completing Day 30 for reasons other than DLT will be replaced. If a DLT is observed, additional subjects may be enrolled so that up to 6 subjects are enrolled at that dose level.
1882753|NCT01199380|Behavioral|Standard Treatment|Participants will receive a standard, group smoking cessation treatment, based on the most recent clinical practice guideline for treating tobacco use from the U.S. Department of Health and Human Services. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period. Patients in ST will also keep a weekly written journal throughout treatment elaborating on observations about the day's events, their thoughts, feelings, and insights about their reactions to these events as a means to equate for time spent on daily activity monitoring in the BATS condition.
1882754|NCT01199380|Behavioral|Behavioral Activation Treatment for Smoking|BATS is focused on identifying life areas, values, and daily activities to help one live according to his or her values. Treatment will be delivered in 8, 60-minute group sessions over an 8-week period.
1882755|NCT01199380|Drug|Transdermal Nicotine Patch|8 weeks of the Transdermal Nicotine Patch Nicoderm CQ at 24 hour doses of 21, 14, and 7 mg respectively depending on participant's initial level of nicotine use. Nicotine patch dose will decrease at 2 or 4 week increments also specific to the participant's initial nicotine level.
1882756|NCT01199406|Drug|Levobupivacaine|0.125% levobupivacaine 80 mL (100 mg) intraoperative, 20 mL subcutaneously and 60 mL intraperitoneally
1882757|NCT01199419|Procedure|comparison of PCI vs. CABG in multivessel disease|invasive treatment of coronary artery disease
1882758|NCT01199432|Drug|5-FU（intravenous infusion）+epirubicin+cyclophosphamide|5-FU 200mg/m2 per day from day 1 to day 28 （Continuous intravenous infusion）; epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed
1882759|NCT01199432|Drug|5-FU（intravenous bolus）+epirubicin+cyclophosphamide|5-FU 500mg/m2 per day on day 1 and day 8（intravenous bolus）; epirubicin 65mg /m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
1882760|NCT01199432|Drug|epirubicin+cyclophosphamide|epirubicin 65mg/m2 per day on day 1 and day 8 and cyclophosphamide 500mg/m2 per day on day 1 and day 8 ; every 28 days as a cycle. Total four cycles is needed.
1882761|NCT01199445|Dietary Supplement|Triple fortified extruded tice (Fe, Zn and vitamin A)|Triple fortified extruded rice (Fe, Zn and vitamin A)will be mix at ratio of 1:50 with normal rice then give to children at school lunch meal for 60 days.
1882762|NCT01199458|Drug|alfentanil|20 mikrogr/kg
1882763|NCT01199458|Drug|saline|The amount of saline will be equal the amount (in ml) of the study-drug (alfentanil)in order to keep it blinded.
1882764|NCT01199484|Other|Cow's milk|
1882765|NCT01199497|Drug|Group 1|fixed dose combination of diphenhydramine + dropropizine + pseudoephedrine (Notuss® syrup).
1882766|NCT01199497|Drug|Group 2|placebo
1882767|NCT01199510|Other|FID 112903 (SYSTANE® ULTRA Lubricant Eye Drops) plus standard of care|Patients will dose 4 times daily for 30 days with FID 112903 and follow routine standard of care post-operatively
1882768|NCT01199510|Other|Standard of Care|Post Cataract Surgery Standard of Care
1882769|NCT01199523|Drug|Placebo|oral
1882770|NCT01199523|Drug|mirabegron|oral
1882771|NCT01199523|Drug|moxifloxacin|oral
1882772|NCT01199562|Procedure|infection prophylaxis and management|Undergo infection prophylaxis and management
1882773|NCT01199562|Other|laboratory biomarker analysis|Correlative studies
1882774|NCT01199562|Other|flow cytometry|Correlative studies
1882775|NCT01199562|Genetic|DNA analysis|Correlative studies
1882776|NCT01199562|Genetic|RNA analysis|Correlative studies
1882777|NCT01199562|Procedure|management of therapy complications|undergo infection prophylaxis and management
1882778|NCT01199562|Drug|ganciclovir|Given IV
1882779|NCT01199562|Drug|valganciclovir|Given orally
1882780|NCT01199562|Drug|foscarnet sodium|Given orally
1882781|NCT01199562|Procedure|antiviral therapy|undergo infection prophylaxis and management
1882782|NCT01199562|Genetic|polymerase chain reaction|Correlative studies
1882784|NCT01199575|Drug|Revlimid, rituximab|Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.
1882785|NCT01199575|Drug|Relapsed or refractory CLL. Lenalidomide and Rituximab|Drug:Lenalidomide and Rituximab Revlimid starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of Revlimid monotherapy, continued weekly throughout cycle 2, and then every monthly for subsequent cycles.Patients with residual disease, but without evidence of significant toxicity or progressive disease may stay on study for up to 6 additional cycles of single agent Revlimid. Each patient may receive up to a maximum of 13 cycles of treatment if no progressive disease or significant toxicity.
1882786|NCT01199588|Drug|Nexagon® Low Dose|Weekly, topical application of Nexagon® low dose used with compression dressings.
1882787|NCT01199588|Drug|Nexagon® High Dose|Weekly, topical application of Nexagon® high dose used with compression dressings.
1882788|NCT01199588|Drug|Nexagon® Vehicle|Weekly, topical application of Nexagon® Vehicle used with compression dressings.
1882789|NCT01199601|Behavioral|Concentrated postpartum counseling|Intrapartum testing and concentrated postpartum counseling for the female patient from a retrained provider focusing on correct breastfeeding practices, postpartum contraception, and infant vaccination.
1882790|NCT01199614|Drug|open-label PTH(1-84)|open label PTH(1-84) at either 25mcg every other day, 25mcg every day, 50mcg daily, 75mcg daily, or 100mcg daily
1882791|NCT01199627|Drug|A|"Group A: 1st dose 15mg/kg of TXA (tranexamic acid) in 100ml saline 0.9% after the completion of regional anesthesia, and before the start of surgery.
2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
1882792|NCT01199627|Drug|B|"Group B: 1st dose: 10mg/kg of TXA(tranexamic acid) in 100ml 0.9% saline after the completion of regional anesthesia, and before the start of surgery.
2nd dose: intravenous infusion over 10 minutes of 10mg/kg of TXA in 100ml saline 0.9% at three hours after the first administration."
1882793|NCT01199627|Drug|C|"Group C: 1st dose: intravenous infusion over 10 minutes in 100ml of 0.9% saline after the completion of regional anesthesia, and before the start of surgery.
2nd dose: intravenous infusion over 10 minutes in 100ml of saline 0.9% at three hours after the first administration."
1882794|NCT01199640|Drug|MLN1202|Patients received 5 intravenous (IV) infusions of the study drug. The first 3 infusions were administered at 15-day intervals, followed by 2 infusions at 30-day intervals. Patients were randomized to receive 1 of 2 doses of MLN1202 (4mg/kg or 8mg/kg).
1882795|NCT01199653|Procedure|Operative treatment|Fracture stabilization with stainless steel reconstruction plate and screws. After the operation arm is immobilized to a sling for three weeks. Pendulum movements are allowed immediately.
1882796|NCT01199653|Procedure|Non-operative treatment with arm immobilised to a sling|Arm is immobilised to a sling for three weeks. Pendulum movements are allowed immediately.
1882797|NCT01199666|Other|Text message|text message appointment and immunization reminders
1882798|NCT01199679|Procedure|Mucosectomy|Endoscopic mucosal resection in the upper GI tract.
1882799|NCT01199679|Procedure|Rubber Band Ligation|Endoscopically ligate esophageal varices at or above the gastroesophageal junction or to ligate internal hemorrhoids.
1882800|NCT01199705|Biological|Immune Globulin Subcutaneous (Human) (SCIG)|IgPro20 is a 20% (weight per volume [w/v]) liquid formulation of human SCIG. Subjects will receive weekly infusions of IgPro20 at a weekly dosage calculated based on previous IVIG treatment.
1882801|NCT01199718|Drug|CX-4945|CX-4945 capsules, administered orally,as escalating doses. Dose schedule: four times daily for 21 consecutive days every 28 days.
1882805|NCT01199744|Drug|zanamivir|zanamivir
1882806|NCT01199757|Drug|Fluticasone furoate|cohort of patients receiving fluticasone furate
1882807|NCT01199757|Drug|mometasone furoate|cohort receiving mometasone furoate
1882808|NCT01199757|Drug|fluticasone propionate|cohort of patients on fluticasone propionate
1882809|NCT01199770|Other|Control, small|control pasta, small portion
1882810|NCT01199770|Other|Experimental B, small|experimental pasta, small portion
1882811|NCT01199770|Other|Experimental pasta C, small|experimental pasta C, small portion
1882812|NCT01199770|Other|control, medium|control pasta, medium portion
1882813|NCT01199770|Other|experimental pasta B, medium|experimental pasta B, medium portion
1882814|NCT01199770|Other|experimental pasta C, medium|experimental pasta C, medium portion
1882815|NCT01199770|Other|NL|no pasta, water only
1882816|NCT01199783|Drug|Daptomycin|Infusion (6 mg/kg/bodyweight) once daily
1882817|NCT01199783|Drug|Vancomycin|vancomycin once daily (effective blood-plasma concentration of 15 mg/L)
1882818|NCT01199809|Drug|Placebo|multiple doses
1882819|NCT01199809|Drug|RO5310074|multiple ascending doses
1882820|NCT01199822|Biological|Olaratumab|Cohort 1 10 milligrams/kilogram (mg/kg) intravenously (IV) administered on Days 1 and 8, every 3 weeks; Cohort 2 20 mg/kg IV administered every 2 weeks; Cohort 3 15 mg/kg IV administered on Days 1 and 8, every 3 weeks
1882821|NCT01199835|Other|High Calcium intake from dairy products|High dietary intake of calcium from dairy products (~1200 mg/d)
1882822|NCT01199848|Dietary Supplement|Placebo|whole milk shake without strawberry powder served with the high fat/carbohydrate test meal
1882823|NCT01199848|Dietary Supplement|10G|whole milk shake with 10g strawberry powder served with the high fat/carbohydrate test meal
1882824|NCT01199848|Dietary Supplement|20G|whole milk shake with 20 strawberry powder served with the high fat/carbohydrate test meal
1882825|NCT01199848|Dietary Supplement|40G|whole milk shake with 40g strawberry powder served with the high fat/carbohydrate test meal
1882826|NCT01199848|Dietary Supplement|Placebonofiber|Placebo without Fiber
1882827|NCT01199861|Drug|Fingolimod|Fingolimod 0.5 mg capsules for oral administration.
1882828|NCT01199861|Drug|Placebo|Matching placebo capsules for oral administration.
1882829|NCT01199861|Biological|Seasonal influenza vaccine|Commercially available injectable influenza vaccine for the 2010/11 influenza season.
1882830|NCT01199861|Biological|Tetanus toxoid vaccine|Commercially available tetanus toxoid vaccine booster injection.
1882831|NCT01199874|Biological|Rotavirus vaccine|live attenuated oral rotavirus vaccine; lyophilized; 1 ml
1882832|NCT01199887|Drug|IW001|IW001, 0.1 mg, 0.5 mg, 1.0 mg PO daily for 24 weeks.
1882833|NCT01199900|Drug|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 8 hours prior to Oral Glucose Tolerance Test (OGTT)
1882834|NCT01199900|Drug|PF-04171327|25 mg extemporaneous preparation of oral solution predosed 12 hours prior to Oral Glucose Tolerance Test (OGTT)
1882835|NCT01199900|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
1882836|NCT01199900|Drug|PF-04171327|3 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
1882837|NCT01199900|Drug|PF-04171327|10 mg extemporaneous preparation of oral solution predosed at time selected from Part 1 prior to Oral Glucose Tolerance Test (OGTT)
1882838|NCT01199900|Drug|Prednisone|5 mg tablet predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
1882839|NCT01199900|Drug|Prednisone|5 mg tablets predosed at 8 hours prior to Oral Glucose Tolerance Test (OGTT)
1882840|NCT01199913|Other|The intervention will be Mini-Mental Status Examination (MMSE)|A questionnaire given to the study patient before and after the anesthetic at 1, 6 and 24 hours.
1882841|NCT01199926|Dietary Supplement|Vitamin D|4000 IU of vitamin D per day for 12 weeks.
1882842|NCT01199926|Drug|Placebo|Placebo (microcrystalline cellulose) ingestion each day for 12 weeks.
1882843|NCT01199939|Drug|Etravirine|400mg once daily orally for 48 weeks
1882844|NCT01199939|Drug|Ritonavir|100mg once daily orally for 48 weeks
1882845|NCT01199939|Drug|Darunavir|800mg once daily orally for 48 weeks
1882846|NCT01199952|Behavioral|Treatment group: receives counseling phone call intervention|Subjects in the treatment arm will receive a phone call from a health educator to assist with contraception, 3 to 4 weeks after enrollment.
1882847|NCT01199965|Drug|MAP0004|1.0mg MAP0004 via inhalation at Visit 2 or 3 as per protocol
1882848|NCT01199965|Drug|IV DHE|IV DHE administered at Visit 2 or 3 as per protocol
1882849|NCT01199978|Radiation|Fractionated proton radiation|Given daily for approximately 5.5 weeks
1882850|NCT01200004|Drug|Azacitidine|75 mg/m2 subcutaneous or by vein on days 1 - 5 of a 28 day cycle.
1882851|NCT01200004|Drug|Lenalidomide|Starting dose 10 mg by mouth daily on days 1-21 of a 28 day cycle, until maximum tolerated dose (MTD) reached. MTD used for combination and expansion groups.
1882852|NCT01200004|Drug|Grifola Frondosa|3 mg/kg by mouth twice a day on days 1 - 21 of a 28 day cycle.
1882853|NCT01200017|Biological|CD34+ enriched, T Cell Depleted donor stem cell product|stem cell transplant
1882856|NCT01200043|Other|fructose restriction diet|fruits and vegetables only
1882857|NCT01200056|Drug|Atorvastatin 10mg versus 40mg.|2 arms comparing atorvastatin 10mg daily for 6 months to atorvastatin 40mg daily for 6 months. The primary endpoint would be the 6 months VH-IVUS findings and clinical outcomes.
1882858|NCT01200069|Drug|Placebo infusion|Identically appearing placebo dose administered IV prior to ECT and subsequently on ECT treatments 2 and 3
1882859|NCT01200069|Drug|ibuprofen intravenous|IV ibuprofen 800mg/8ml given over 30 minutes prior to ECT and subsequently on ECT treatments 2 and 3
1882860|NCT01200108|Drug|Budesonide|
1882861|NCT01200108|Drug|Budesonide|
1882862|NCT01200108|Drug|Budesonide|
1882863|NCT01200121|Drug|Bevacizumab|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of 400 mg Bevacizumabafter paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
1882864|NCT01200121|Other|Placebo|Patients will receive paracentesis as needed for symptom con¬trol. In addition, patients will receive up to 4 intraperitoneal administrations of Placebo after paracentesis has been performed. During the 8-week treatment period, a minimum interval of 14 days will be kept between applications of the study medication.
1882865|NCT01200134|Other|18F-FMISO PET-scanning|Other: 18F-FMISO PET-scanning 18F-FMISO PET-scanning: 18F-FMISO PET-scanning will be performed at the same place following the same protocol as mentioned above. However, the 20-minutes period of PET images acquisition will start 120 minutes after the 18F-FMISO bolus injection (0.05 mCi/kg).
1882866|NCT01200147|Procedure|Biopsy|
1882867|NCT01200147|Procedure|Dilation|
1882868|NCT01200160|Drug|Niacin|
1882869|NCT01200173|Other|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
1882870|NCT01200173|Other|2-Non fermented dairy product (control)|
1882871|NCT01200186|Drug|EV/DNG (Qlaira, BAY86-5027)|At the discretion of the attending physician
1882872|NCT01200186|Drug|Progestin Only Pills|At the discretion of the attending physician
1882873|NCT01200212|Drug|Taxane, Avastin|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
1882874|NCT01200212|Drug|Taxane, Avastin, Xeloda|Taxane (Investigator can choose between Paclitaxel (80 mg/m2 weekly or Docetaxel 75 mg/m2 day 1 q 22) + Bevacizumab (15mg/kg) i.v. day 1 q 22 + Capecitabine 1800 mg/m2 day 1-14 q22 Given until progression, unacceptable toxicity, patient's request or withdrawal from study
1882875|NCT01200238|Drug|STA-9090|Given intravenously once week or twice a week for three weeks of a four week cycle
1882876|NCT01200251|Drug|Bimatoprost eyelash gel|Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
1882877|NCT01200264|Drug|apremilast|apremilast 10 mg tablets with dose titration to 30 mg BID for 169 days
1882878|NCT01200277|Procedure|percutaneous vertebroplasty|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. For the vertebroplasty procedure, 11-gauge or 13-gauge needles are passed into the central aspect of the target vertebra or vertebrae. Bone cement is prepared on the bench and injected under constant fluoroscopy into the vertebral body. Injection is stopped when the PMMA reaches to the posterior aspect of the vertebral body or leaks into an extraosseous space, such as the intervertebral disk or an epidural or paravertebral vein.
1882879|NCT01200277|Procedure|sham procedure|Using fluoroscopic guidance, the practitioner infiltrates the skin and subcutaneous tissues overlying the pedicle of the target vertebra or vertebrae with 1% lidocaine and infiltrates the periosteum of the pedicles with 0.25% bupivacaine (marcaine. During the sham intervention, verbal and physical cues, such as pressure on the patient's back, are given, and the methacrylate monomer is opened to simulate the odor associated with mixing of cement, but the needle is not placed and cement is not injected.
1882880|NCT01200290|Drug|LY2127399|120mg administered subcutaneously every 4 weeks for 20 weeks. A loading dose of 240 mg will be given as the first dose of the study medication
1882881|NCT01200303|Procedure|non-cathartic CTC|non-cathartic, CAD-assisted CT Colonography
1882882|NCT01200316|Procedure|Standard of Care|Post surgical patient to sit in a non-rocking chair for at least sixty minutes per day, and ambulating at least three times per day.
1882883|NCT01200316|Procedure|Rocking Chair Motion|Post surgical patient to rock in a rocking chair in 10-20 minute increments for at least sixty minutes per day, and ambulating at least three times per day.
1882884|NCT01200316|Behavioral|Questionnaire|Beginning on day of surgery till discharge (3-5 days)
1882885|NCT01200329|Drug|Gemcitabine|2775 mg/m2 by vein over about 3 hours on days -8 and -3.
1882886|NCT01200329|Drug|Busulfan|"32 mg/m2 test dose with PKs as outpatient and on day -10 as inpatient
AUC 4,000 by vein over about 3 hours on days -8 to -5."
1882887|NCT01200329|Drug|Melphalan|60 mg/m2 by vein over about 30 minutes on days -3 and -2.
1882888|NCT01200329|Procedure|Stem Cell Transplantation|Infusion of stem cells on Day 0.
1882889|NCT01200329|Drug|Palifermin|60 mg/kg by vein over 30 seconds daily, Days -12 to -10 and Days 0 to 2.
1882890|NCT01200342|Drug|Genasense|900 mg by vein over 1 hour on Days 1, 3, and 5 of a 21 day cycle.
1882891|NCT01200342|Drug|Paclitaxel|175 mg/m^2 by vein over 3 hours on Day 3 of a 21 day cycle following Genasense.
1882892|NCT01200342|Drug|Carboplatin|"Carboplatin starting dose in mg (AUC= 6) is administered over 30 minutes IV Piggyback (IVPB). Carboplatin will be dosed after Paclitaxel dose on Day 3 every 3 weeks.
The total dose of Carboplatin is calculated using a formula based upon a participant's glomerular filtration rate (GFR in mL/min) and Carboplatin target area under the concentration (AUC)."
1882895|NCT01200368|Biological|13-valent pneumococcal conjugate vaccine (13vPnC)|0.5 mL per dose, 4 doses
1882896|NCT01200368|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
1882897|NCT01200368|Biological|7-valent pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
1882898|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
1882899|NCT01200368|Biological|DTaP|0.5 mL per dose, 4 doses
1882900|NCT01193101|Drug|LCZ696|LCZ696
1882901|NCT01193101|Drug|Placebo|matching placebo to LCZ696
1882902|NCT01193114|Behavioral|Ecologically Based Treatment (EBT)|Substance abuse treatment (the Community Reinforcement Approach), case management and housing.
1882903|NCT01193114|Behavioral|Treatment as Usual (TAU)|Treatment/intervention as normally provided by community service agencies that service substance abusing homeless families.
1882904|NCT01193127|Drug|OMS302 Solution|
1882905|NCT01193127|Drug|OMS302 Mydriatic Solution|
1882906|NCT01193127|Drug|OMS302 Anti-inflammatory Solution|
1882907|NCT01193127|Drug|Balanced Salt Solution (BSS) Solution|
1882908|NCT01193140|Drug|veliparib|Dose orally twice daily for 7 days, consecutively, every cycle
1882909|NCT01193140|Drug|Temozolomide|Dose orally once daily for 5 days, consecutively, every cycle
1882910|NCT01193153|Drug|Placebo|monthly by i.m. injection for 15 months
1882911|NCT01193153|Drug|paliperidone palmitate|78, 117, 156, 234 mg (50, 75, 100, or 150 mg eq.) monthly by i.m. injection for 15 months
1882912|NCT01193166|Drug|paliperidone palmitate|78, 117, 156, or 234 mg monthly injection for 12 months
1882913|NCT01193166|Drug|risperidone|flexible dosing as prescribed by the study doctor for 12 months
1882914|NCT01193166|Drug|olanzapine|flexible dosing as prescribed by the study doctor for 12 months
1882915|NCT01193166|Drug|aripiprazole|flexible dosing as prescribed by the study doctor for 12 months
1882916|NCT01193166|Drug|haloperidole|flexible dosing as prescribed by the study doctor for 12 months
1882917|NCT01193166|Drug|quetiapine|flexible dosing as prescribed by the study doctor for 12 months
1882918|NCT01193166|Drug|perphenazine|flexible dosing as prescribed by the study doctor for 12 months
1882919|NCT01193166|Drug|paliperidone|flexible dosing as prescribed by the study doctor for 12 months
1882920|NCT01193179|Drug|OPC-262|Oral administration of tablets for 52 weeks
1882921|NCT01193192|Other|Neevo®|"A prenatal medical food - analogous to a prenatal vitamin but containing L-methylfolate in addition to folic acid"
1882922|NCT01193192|Other|Prenatal vitamins|for inclusion in the Control Group, prenatal vitamins must have contained ≤1mg folic acid, 27 - 35mg iron, and ≤12mcg vitamin B12.
1882923|NCT01193205|Behavioral|Skills Training|20 weeks of Dialectical Behaviour Therapy Skills Training
1882924|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
1882925|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
1882926|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
1882927|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
1882935|NCT01193218|Drug|Placebo (high dose)|Placebo tablets once a day
1882936|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
1882937|NCT01193218|Drug|Placebo (low dose)|Placebo tablets once a day
1882938|NCT01193218|Drug|BI 10773|BI 10773 tablets mid-low dose once a day
1882939|NCT01193218|Drug|Placebo (mid dose)|Placebo tablets once a day
1882940|NCT01193244|Drug|Orteronel|Orteronel will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
1882941|NCT01193244|Drug|Placebo|Placebo will be administered orally twice a day continuously throughout the study. Additionally, all patients will receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and a testosterone concentration of <50 ng/dL.
1882942|NCT01193244|Drug|Prednisone|Prednisone will be administered orally twice a day continuously throughout the study. Patients will also receive concomitant gonadotropin-releasing hormone (GnRH) analogue therapy unless they have previously undergone orchiectomy and have a testosterone concentration of <50 ng/dL.
1882945|NCT01193270|Drug|Vitamin E|A single intragastric dose of dl-α-tocopheryl acetate 50 IU/kg.
1882946|NCT01193270|Drug|Placebo|Sterile water in volume equal to that of the comparator drug
1882947|NCT01193283|Drug|Cyclophosphamide|30 my/kg for 4 days
1882948|NCT01193283|Drug|Cyclosporine|daily to a trough of 100 t0 200 ng/ml
1882949|NCT01193296|Drug|Vildagliptin|
1882950|NCT01193296|Drug|Sitagliptin|
1882951|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
1882952|NCT01193335|Biological|13-valent pneumococcal conjugate vaccine|13-valent pneumococcal conjugate vaccine will be administered at 2, 3, 4 and 12 months of age.
1882953|NCT01193348|Drug|Eculizumab|Fixed dosing is based on body weight cohorts. Adjustment of dose to accommodate patient growth is possible.
1882954|NCT01193361|Drug|BMS-791325|Tablets, Oral, 75 mg, twice daily, 4-48 weeks depending on response
1882955|NCT01193361|Drug|BMS-791325|Tablets, Oral, 150 mg, twice daily, 4-48 weeks depending on response
1882956|NCT01193361|Drug|Placebo|Tablets, Oral, 0 mg, twice daily, 4-48 weeks depending on response
1882957|NCT01193361|Drug|Peg-interferon alfa-2a|Syringe, Subcutaneous Injection, 180 µg, once weekly, 4-48 weeks depending on response
1882958|NCT01193361|Drug|Ribavirin|Tablets, Oral, 1000 or 1200 mg based on weight, twice daily, 4-48 weeks depending on response
1882959|NCT01193374|Behavioral|Clinician enhanced screening and counseling prompts|PDA based health risk screening for well child issues and obesity risks
1882960|NCT01193374|Behavioral|Tailored education and motivational materials|Specific tailoring for those interested in change vs not . Two newsletters over 3 mpn.
1882961|NCT01193374|Behavioral|basic educational brochure|Booklet by ADA sent x 1.
1882962|NCT01193387|Drug|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
1882963|NCT01193387|Drug|insulin degludec|Each subject will be allocated to 2 single doses of trial product on 2 separate visits: One injection with formulation 1 and and one injection with formulation 2). Injected subcutaneously (under the skin).
1882964|NCT01193400|Drug|Clofarabine|
1882965|NCT01193400|Drug|Cytarabine|
1882966|NCT01193426|Other|Ascite liquid puncture|Ascitic fluid obtained by paracentesis
1882967|NCT01193452|Drug|S-1, Leucovorin|"S-1 :
The initial dosage of S-1 is determined by the body surface area:
Surface area: 1.25-1.5 m2 : 50mg twice per day;upper than 1.5 m2 : 60mg twice per day
Leucovorin:
25mg twice per day po.
The treatment is given for one week,and no chemotherapy is given for the following one week."
1882968|NCT01193452|Drug|leucovorin, 5-fluorouracil|"leucovorin: 400mg/m2 intravenous infusion d1;
5-fluorouracil: 400mg/m2 intravenous push,d1; 2400mg/m2 continuous intravenous infusion for 46 hours
repeat every 2 weeks"
1882969|NCT01193465|Device|Datex Ohmeda excel anesthesia machine|maintain one of following fresh gas flow, 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda excel anesthesia machine after draping complete
1882970|NCT01193465|Device|Datex Ohmeda Avance anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Datex Ohmeda Avance anesthesia machine after draping complete
1882971|NCT01193465|Device|Drager Cato anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Cato anesthesia work-station after draping complete
1882972|NCT01193465|Device|Drager Primus anesthesia work-station|maintain one of following fresh gas flow, 0.5 or 1 or 4 L/min (nitrous oxide:oxygen =1:1) during 2 hour with using Drager Primus anesthesia work-station after draping complete
1882973|NCT01193478|Drug|GS-5885|tablet, oral, 3 mg once daily for 3 days
1882974|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
1882975|NCT01193478|Drug|GS-5885|tablet, oral, 10 mg once daily for 3 days
1882976|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
1882977|NCT01193478|Drug|GS-5885|tablet, oral, 30 mg once daily for 3 days
1882978|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
1882979|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
1882980|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
1882981|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
1882982|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
1882983|NCT01193478|Drug|GS-5885|tablet, oral, up to 90 mg once daily for 3 days
1882984|NCT01193478|Drug|Placebo|tablet, oral, once daily for 3 days
1882985|NCT01193491|Drug|IPI-493|Capsules, ascending dose, multiple schedules
1882986|NCT01193504|Drug|Pred Forte|Pred Forte BID for 4 weeks postop
1882987|NCT01193504|Drug|Lotemax|Lotemax BID for 4 weeks postop.
1882988|NCT01193517|Drug|Azacitidine|Starting dose level 75 mg/m2/day subcutaneously on Days 1-5 of a 21 day cycle.
1882989|NCT01193517|Drug|Capecitabine|1500 mg/m2/day by mouth twice daily in divided doses on Days 1-14 of a 21 day cycle.
1882990|NCT01193517|Drug|Oxaliplatin|Starting dose level 90 mg/m2 by vein on Day 2 of a 21 day cycle.
1882991|NCT01193517|Drug|Azacitidine MTD|Highest tolerable dose of combination azacitidine with CAPOX found in Phase I.
1882996|NCT01193543|Dietary Supplement|calanus oil|1 gram twice daily
1882997|NCT01193543|Dietary Supplement|olive oil|1 gram twice daily
1882998|NCT01193556|Device|PEAK PlasmaBlade TnA|The PEAK PlasmaBlade will be used for the tonsillectomy.
1882999|NCT01193556|Device|Traditional Electrosurgery with scalpel|Traditional electrosurgery for the tonsillectomy.
1883000|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
4 doses starting from 121 to < 212 days of age"
1883001|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
3 doses starting from 212 days to < 12 months of age"
1883002|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
2 doses starting from 12 months to < 24 months of age"
1883003|NCT01193582|Biological|Prevenar|"Dosage form: intramuscular injection Dosage: 0.5 ml
Frequency:
1 dose starting from 24 months to < 72 months of age"
1883004|NCT01193595|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:Solution for infusion
Route of administration: Intravenous"
1883005|NCT01193595|Drug|bevacizumab|"Pharmaceutical form:Solution for infusion
Route of administration: Intravenous"
1883006|NCT01193608|Drug|AAB-003 (PF-05236812)|0.5 mg/kg AAB-003, IV
1883007|NCT01193608|Drug|AAB-003 (PF-05236812)|1 mg/kg AAB-003, IV
1883008|NCT01193608|Drug|AAB-003 (PF-05236812)|2 mg/kg AAB-003, IV
1883009|NCT01193608|Drug|AAB-003 (PF-05236812)|4 mg/kg AAB-003, IV
1883010|NCT01193608|Drug|AAB-003 (PF-05236812)|8 mg/kg AAB-003, IV
1883011|NCT01193608|Other|Placebo|Placebo, IV
1883012|NCT01193621|Drug|haloperidol, PET|"Biodistribution study Intravenous 18F haloperidol(10 mCi) Dose injection two times before whole body PET scan
D2-receptor occupancy study Group Doses No. of subjects 1 0.5 mg 4 2 1 mg 4 3 3 mg 4
above doses will be administrated orally every 24 hours for 7 days."
1883013|NCT01193634|Device|VR 9250 / DR 9550 / CRT 9750|Active implantable defibrillators range
1883014|NCT01193660|Biological|Umbilical Cord Blood Infusion|The subjects will be undertaken allogeneic umbilical cord blood infusion (total nucleated cells > 3x10^7/kg) intravenously under non-myeloablative immunosuppression (maintaining blood level of cyclosporine as 100-200ng/mL for 1 month).
1883015|NCT01193660|Drug|Erythropoietin Injection|Erythropoietin will be given as the schedule of twice a week for 4 weeks with the dosage of 500 IU/kg for 2 times intravenously and 250 IU/kg subcutaneously for 6 times.
1883016|NCT01193660|Other|Active Rehabilitation|All subjects should participate in active rehabilitation. They received two physical and occupational therapy sessions per day. Post discharge, each participant continued to receive rehabilitation therapy at least 3 days per week for additional 5 months.
1883017|NCT01193660|Other|Placebo Umbilical Cord Blood|Placebo Umbilical Cord Blood will be given except the Experimental arm. Placebo Umbilical Cord Blood was made using peripheral blood. Participants and Investigators maintained as blind.
1883018|NCT01193660|Other|Placebo Erythropoietin|Placebo Erythropoietin containing Normal Saline
1883019|NCT01193686|Other|Peer Visitation|Trained Volunteers will visit OEF/OIF Veterans with Polytrauma Injuries to provide support.
1883020|NCT01193699|Drug|PEG-P-INF alpha-2b (P1101)|µg (starting with 50 µg), subcutaneously, 2-weekly administration
1883021|NCT01193712|Procedure|temporary left ventricular endocardial pacing|a temporary pacemaker lead will be introduced through the aortic valve to evaluate the effect of left ventricular endocardial pacing. Four different pacing sites (basal and apical septal, basal and apical lateral) will be investigated with measurement of LV dP/dtmax. Afterwards, the endocardial pacing lead will be removed.
1883022|NCT01193725|Behavioral|Prolonged Exposure Therapy (PE)|Prolonged exposure therapy will consist of 10 treatment sessions lasting 90 - 120 minutes each, with additional between-session homework assignments.
1883023|NCT01193725|Behavioral|Virtual Reality Exposure Therapy (VRET)|Virtual Reality Exposure Therapy will consist of 10 treatment sessions lasting 90 -120 minutes with additional between-session homework assignments.
1883024|NCT01193725|Behavioral|Waitlist|This group will refrain from psychotherapy until after the completion of the 5 weeks of study participation
1883025|NCT01193738|Procedure|osteopathic compression of Pterygopalatine node|osteopathic compression of Pterygopalatine node
1883026|NCT01193764|Dietary Supplement|100% cocoa powder|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
1883075|NCT01194011|Behavioral|questionnaire|This research tool was a written questionnaire, did not do invasive or the subjects are exposed to physical danger on the experiment, so now there is no harm in this research and test more than minimal risk.
1883076|NCT01194024|Other|Standard of Care|bronchoscopy with collection of bronchioalveolar lavage specimen, blood samples, High-Resolution spiral computed tomography(CT)
1883077|NCT01194037|Drug|recombinant variant of interferon-alpha 2b|SC, Weekly
1883078|NCT01194037|Drug|Peginterferon alfa-2a|SC Weekly
1883027|NCT01193764|Dietary Supplement|gelatin (Gelita)|A single-center, prospective, double blind, placebo controlled study will be conducted in which male subjects with very mild acne swallow capsules filled with either unsweetened 100% cocoa (Ghirardelli), hydrolyzed gelatin powder (Gelita), or a combination of the two, at baseline. The study team will fill the capsules with either 6 oz. of hydrolyzed gelatin, 6 oz. cocoa powder (Ghirardelli ©), or a 6 oz. combination of cocoa powder (Ghirardelli ©) and hydrolyzed gelatin, totaling 6oz using a capsule encapsulation sheet (holding 60 capsules that need to be filled each time). All subjects will ingest the same number of total capsules. Evaluations will be performed using clinical assessments 4 days and 7 days after baseline evaluations (+/- 1 days).
1883028|NCT01193777|Drug|L-Carnitine|4 gram bolus followed by 8 gram in 1 L NS infused over 12 hours.
1883029|NCT01193777|Drug|Normal Saline|Bolus followed by 1 L NS infusion over 12 hours.
1883030|NCT01193790|Procedure|Coblation channeling|"The combination of the energy and the fluid creates a plasma field containing highly ionized particles (coblation). The ionized particles have sufficient energy to break organic molecular bonds that can remove tissue selectively without excessive heat production and subsequent damage to the surrounding tissue. Treatment of the tonsillar crypts and tissue by coblation may decrease antigen and immune system interaction and inflammation."
1883031|NCT01193803|Procedure|Microbiological cultures and Molecular biology|"Biological/Vaccine: Microbiological cultures and Molecular Biology Bacteriological procedures: All solid specimens will be crushed using a mechanic apparatus. Direct examination and cultures will be performed according to the guidelines applied for osteoarticular infections. Cultures and subcultures will be incubated for 15 days to 3 months for Mycobacteria.
Molecular procedures: DNA extraction will be based on Boom's method (QIAGEN kit and EZ1 BioRobot). Detections of bacteria will be performed by amplification and sequencing of the 16S rRNA gene. Some specific detections as the detection of Staphylococcus sp. and Mycobacterium tuberculosis will be added to this protocol."
1883032|NCT01193816|Drug|loxapine|Each patient may receive a maximum dosage of 900mg of Loxapine per day (drinkable solution through gastric probe) or the same volume of placebo. 2 initial administrations of 150 mg followed by potential readministration of 100 mg of loxapine. Maximum duration of treatment will be 14 days.The dosage by day is defined by patients' clinical condition, assessed with RASS score.
1883033|NCT01193816|Drug|Placebo|Placebo
1883034|NCT01193842|Drug|Cyclophosphamide|Given IV
1883035|NCT01193842|Drug|Doxorubicin Hydrochloride|Given IV
1883036|NCT01193842|Drug|Etoposide|Given IV
1883037|NCT01193842|Other|Laboratory Biomarker Analysis|Correlative studies
1883038|NCT01193842|Other|Pharmacological Study|Correlative studies
1883039|NCT01193842|Drug|Prednisone|Given PO
1883040|NCT01193842|Biological|Rituximab|Given IV
1883041|NCT01193842|Drug|Vincristine Sulfate|Given IV
1883042|NCT01193842|Drug|Vorinostat|Given PO
1883043|NCT01193855|Drug|dutasteride|
1883044|NCT01193855|Drug|gadolinium-chelate|
1883045|NCT01193855|Other|active surveillance|
1883046|NCT01193855|Procedure|diffusion-weighted magnetic resonance imaging|
1883047|NCT01193855|Procedure|functional magnetic resonance imaging|
1883048|NCT01193855|Procedure|prostate biopsy|
1883049|NCT01193855|Procedure|ultrasound imaging|
1883050|NCT01193868|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
1883051|NCT01193868|Other|laboratory biomarker analysis|Correlative studies
1883052|NCT01193868|Other|pharmacological study|Correlative studies
1883053|NCT01193881|Drug|Erlotinib Hydrochloride|Given PO
1883054|NCT01193881|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1883055|NCT01193881|Other|Laboratory Biomarker Analysis|Correlative studies
1883056|NCT01193881|Other|Pharmacological Study|Correlative studies
1883057|NCT01193894|Other|Profermin|Medical Food (food for special medical purposes)
1883058|NCT01193894|Other|Fresubin|Medical food (food for special medical purposes)
1883059|NCT01193907|Biological|NVGH Vi-CRM197 12.5 mcg|1 dose of 0.5 mL
1883060|NCT01193907|Biological|NVGH Vi-CRM197 5.0 mcg|1 dose of 0.5 mL
1883061|NCT01193907|Biological|NVGH Vi-CRM197 1.25 mcg|1 dose of 0.5 mL
1883062|NCT01193907|Biological|Vi-polysaccharide vaccine|1 dose of 0.5 mL containing 25 mcg of Vi polysaccharide
1883063|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 20/20/20 μg|Subjects received two injections of 20/20/20 μg dose of Group B Streptococcus (GBS) Trivalent Vaccine with aluminum.
1883064|NCT01193920|Other|Saline solution|Subjects received two injection of saline solution.
1883065|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 0.5/0.5/0.5 μg|Subjects received one injection of 0.5/0.5/0.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
1883066|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 2.5/2.5/2.5 μg|Subjects received one injection of 2.5/2.5/2.5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
1883067|NCT01193920|Biological|Group B Streptococcus Trivalent Vaccine - 5/5/5 μg|Subjects received one injection of 5/5/5 μg dose of non adjuvanted Group B Streptococcus (GBS) Trivalent Vaccine.
1883068|NCT01193920|Other|saline solution|Subjects received one injection of saline solution.
1883069|NCT01193933|Drug|L-asparaginase|prolonged L-asparaginase application at 10.000 IU weekly in induction, once in two weeks in 14 weeks consolidation, twice a month in maintenance (total proposed dose 560.000 IU)
1883070|NCT01193946|Dietary Supplement|dietary control|Seven dietary protein levels will be tested randomly on the 7 testing days: 0.10, 0.30, 0.60, 0.90, 1.2, 1.5, and 1.8 g∙kg-1∙d-1.
1883071|NCT01193972|Other|Decision aid|Decision aid to assist patients in making a decision about smoking during the perioperative period
1883072|NCT01193985|Device|TIGR Matrix Surgical Mesh|Lichtenstein repair of inguinal hernia using TIGR Matrix Surgical Mesh
1883073|NCT01193998|Other|Treatment as per model probability|Patients randomized to the arm where the clinician is exposed to the model results should be treated as per the model probability (i.e. if the model probability suggests AHF the clinician should treat for AHF).
1883074|NCT01193998|Other|Treatment as per usual care|Patients randomized to the arm where the clinician is blinded to the model results will undergo diagnostic tests and receive treatment as per the clinician's judgment and usual care standards.
1883079|NCT01194063|Drug|Omega-3 fish oil lipid emulsion|daily intravenous administration of Omegaven fish oil emulsion
1883080|NCT01194076|Behavioral|5-day intensive treatment|Exposure Based Cognitive Behavioral Therapy administered in 10 appointments over 5 days with an added focus on training parents to be exposure coaches
1883081|NCT01194089|Drug|Nasal Nicotine Spray|Single 3 mg dose of nasal nicotine spray
1883082|NCT01194089|Drug|Nasal Normal Saline Spray|An isotonic solution of sodium chloride 0.65% in deionized water
1883083|NCT01194102|Behavioral|Community Based Exercise Program|Three supervised exercise sessions per week, including individual and group sessions aimed at strengthening, flexibility and cardiovascular exercise.
1883084|NCT01194102|Other|Living with Stroke Education program|Weekly 1 hour long education sessions on living with stroke, aimed at helping participants take better care of their health after a stroke.
1883085|NCT01194102|Other|YMCA membership|Participants have access to YMCA facilities along with up to 7 individual sessions with a fitness trainer.
1883086|NCT01194115|Drug|cephalexin & metronidazole|cephalexin at 500 mg per oral every 8 hours for a total of 6 doses
1883087|NCT01194115|Drug|placebo|placebo representing standard of care
1883088|NCT01194128|Behavioral|Psychoeducational Support|The intervention is comprised of three modules, each of which has multiple components. Module One provides basic education about the clinical aspects of frailty as well as the organization and operating procedures of long-term care facilities. Module Two focuses on advanced care planning, and Module Three is designed to improve the emotional well-being of family caregivers. The intervention will be delivered via 11 sessions lasting approximately 90 minutes each distributed over a six-month period. All family caregivers will begin with the Basic Knowledge Module. Modules Two and Three will be delivered in alternating sessions, based on caregiver need and preference, a strategy successfully used in the REACH intervention trial.
1883089|NCT01194128|Behavioral|Information only control group|"Participants in the control group will receive a portion of the standardized packet of written information that is also provided to the treatment group. The fact sheets are relevant to the placement of a family member into a nursing home and are linked to the content areas covered in the intervention. Documents in this packet include Caregiving and Depression, End of Life Decision Making, and Taking Care of You: Self-Care for Family Caregivers from the Family Caregiver Alliance; and Family Involvement in Nursing Home Care, Problem Solving, and Residents' Rights from the National Citizen's Coalition. Also provided will be a resource guide containing local contact information."
1883090|NCT01194141|Behavioral|Exercise training|aerobic exercise training, 45-60 minutes, 3x/week, 12 weeks (3-months)
1883091|NCT01194154|Drug|Methoxy polyethylene glycol-epoetin beta|Methoxy polyethylene glycol-epoetin beta 30 microgram (mcg) subcutaneous injection once monthly up to 24 months with sequential dose adjustments to 50 mcg or 75 mcg depending on change of hemoglobin values of more than 1.0 gram (g)/ deciliter (dL).
1883092|NCT01194154|Drug|Placebo|Placebo matching to Methoxy polyethylene glycol-epoetin beta subcutaneous injection once monthly up to 24 months.
1883093|NCT01194167|Drug|Eltrombopag|75 mg per day with possible dose escalation to 150 mg per day and 300 mg per day
1883094|NCT01200381|Other|Quarterly remote follow ups and remote monitoring|Quarterly remote follow ups and remote monitoring
1883095|NCT01200381|Other|Quarterly remote follow ups + additional phone calls and remote monitoring|Quarterly remote follow ups + additional phone calls and remote monitoring
1883096|NCT01200381|Other|Quarterly in clinic follow ups and remote monitoring|Quarterly in clinic follow ups and remote monitoring
1883097|NCT01200394|Drug|PF-00489791|Tablet, 20 mg once daily for 12 weeks
1883098|NCT01200394|Drug|Placebo|Tablet, placebo once daily for 12 weeks
1883099|NCT01200407|Drug|Amlodipine + Olmesartan medoxomil|start dose is 5/20 mg, which can then be uptitrated to 5/40 mg up to 10/40 mg if BP goal is not reached during the 4 week follow-up
1883100|NCT01200420|Drug|miravirsen|SC injection
1883101|NCT01200420|Drug|saline|SC injection
1883102|NCT01200433|Drug|dexmedetomidine|Patients assigned to dexmedetomidine will be given a mg/kg bolus over 10-20 minutes; subsequently, an infusion will be titrated to between 0.4-0.6 mcg/kg/hr to maintain an adequate level of sedation during the procedure.
1883103|NCT01200433|Drug|propofol|Patients assigned to propofol will be given an infusion dose of 50-75 µ/kg/min which will be titrated to the patient's response
1883104|NCT01200446|Dietary Supplement|Docosahexaenoic Acid|8 docosahexaenoic acid (4.0 grams) capsules per day for 3 weeks.
1883105|NCT01200446|Dietary Supplement|Placebo Docosahexaenoic Acid|8 placebo docosahexaenoic acid (corn and soy oil blend) capsules per day for 3 weeks.
1883106|NCT01200459|Behavioral|Social/mobile weight loss promotion intervention.|Social/mobile intervention for weight loss promotion, compared to control group.
1883107|NCT01200472|Drug|Apremilast|Apremilast is supplied as 10 mg capsules for oral administration. After a 7-day titration phase patients will receive 20 mg PO BID apremilast.
1883108|NCT01200472|Drug|Placebo|Placebo capsules identical to apremilast
1883111|NCT01200498|Drug|SB939|Starting dose 60 mg by mouth every other day, three times weekly for 3 weeks.
1883112|NCT01200511|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
1883113|NCT01200524|Drug|AZD2423|20 mg tablet
1883114|NCT01200524|Drug|AZD2423|50 mg tablet
1883115|NCT01200524|Drug|Placebo|Placebo
1883116|NCT01200537|Drug|Estradiol|This group of patients will receive estradiol patches prior to the IVF cycle.
1883117|NCT01200537|Drug|Oral Contraceptive Pills (OCP)|This group of patients will receive OCP's prior to the IVF cycle.
1883118|NCT01200563|Device|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
1883272|NCT01202695|Drug|Placebo|Placebo comparator
1883119|NCT01200563|Device|Vacuum Assisted Closure|Controlled negative pressure (vacuum) delivering negative (sub-atmospheric) pressure to the wound site applied by a tubing which decompresses a foam dressing, continuously or intermittently depending on wound type.
1883120|NCT01200563|Device|MIST Therapy and Negative Pressure Wound Therapy|MIST Therapy will be provided 3 times per week, NPWT will be provided according to the manufacturer's recommended guidelines.
1883121|NCT01200589|Biological|Ofatumumab|Four weekly doses of single agent ofatumumab (1000 mg), followed by ofatumumab (1000 mg) every two months for four additional doses.
1883122|NCT01200589|Biological|Rituximab|Four weekly doses of single agent rituximab (375 mg/m2), followed by rituximab (375 mg/m2) every two months for four additional doses.
1883123|NCT01200602|Drug|megestrol acetate|Given orally in doses of either 10 mg/kg once a day or 5 mg/kg twice a day
1883124|NCT01200602|Other|clinical observation|No treatment is given.
1883125|NCT01200615|Behavioral|Wording of the explenation on side-effects as part of the informed consent.|Subjects will hear different versions of the description of SSRI's side-effects and the nocebo effect.
1883126|NCT01200628|Behavioral|DEPITAC|heteroevaluation scale by a nurse during hospitalization
1883127|NCT01200641|Drug|Melatonin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6
mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
1883128|NCT01200641|Drug|Gabapentin|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6
mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
1883129|NCT01200641|Drug|placebo|"ninety patients scheduled for cataract surgery by phacoemulsification were randomly allocated to three study groups to receive melatonin 6
mg (Group M, n = 30) , gabapentin 600mg(GroupG, n = 30)or placebo(GroupP, n=30) orally 90 minutes before retrobulbar injection( for all of three groups)."
1883130|NCT01200654|Drug|Linezolid|Dosage of 600 mg discontinuous administration twice a day was about studies in safety volunteers
1883131|NCT01200693|Device|Sirolimus eluting stent|Implantation of Sirolimus eluting stent
1883132|NCT01200693|Device|Everolimus eluting stent|Implantation of Everolimus eluting stent
1883133|NCT01200693|Device|Zotarolimus eluting stent|Implantation of Zotarolimus eluting stent
1883134|NCT01200706|Drug|Amoxicillin|amoxicillin 50mg/kg/day given in two different administration schemes
1883135|NCT01201499|Drug|Intrathecal morphine|a single dose of intrathecal morphine (ITM, 4 µcg/kg, or ~0.1-0.3 mg morphine before induction of general anesthesia, followed by postoperative patient-controlled morphine analgesia (IV-PCA) for postoperative pain.
1883136|NCT01201499|Drug|Continuous IV remifentanil|a continuous infusion of IV remifentanil supported by a single bolus of IV morphine, 0.2 mg/kg at the end of surgery, followed by IV-PCA morphine.
1883137|NCT01201525|Procedure|Pulsed dye laser treatment|Part 1 of the surgical scar will be treated with 4 595nm Pulsed dye laser treatments.
1883138|NCT01201525|Procedure|Control|Part 2 of the surgical scar will serve as a within patient control.
1883139|NCT01201538|Drug|Nilotinib|
1883140|NCT01201551|Drug|Brimonidine|Week1, day2: 1 eyedrop/right eye Week2, day1: 1 eyedrop/left eye Week2, day2: 1 eyedrop/left eye
1883141|NCT01201551|Drug|Latanoprost|Week1, day1: 1 eyedrop/right eye Week1, day2: 1 eyedrop/right eye Week2, day2: 1 eyedrop/left eye
1883142|NCT01201551|Drug|Placebo|Week1, day1: 1 eyedrop/left eye Week1, day2: 2 eyedrops/left eye Week2, day1: 1 eyedrop/right eye Week2, day2: 2 eyedrops/right eye
1883143|NCT01201564|Procedure|intraperitoneal onlay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
1883144|NCT01201564|Procedure|sublay mesh repair|The IPOM technique provides mesh positioning directly into the abdominal cavity onto the defect under laparoscopic control while in sublay position the mesh is placed directly behind des rectus muscle after small incision close to the belly button.
1883145|NCT01201577|Dietary Supplement|Bifidobacterium longum BB536|2 capsules od
1883146|NCT01201577|Dietary Supplement|Active hexose correlated compound (AHCC)|One capsule tds
1883147|NCT01201577|Dietary Supplement|Bifidobacterium longum BB536 and Active hexose correlated compound (AHCC)|One capsule tds (prebiotic) and two capsules od (probiotic)
1883148|NCT01201577|Dietary Supplement|Corn starch placebo capsule|One capsule tds and two capsules od
1883149|NCT01201577|Drug|Azithromycin|250mg od
1883150|NCT01201590|Dietary Supplement|High Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks.
1883151|NCT01201590|Dietary Supplement|Low Flavanol Cocoa|cocoa consumed as a 24g dairy based cocoa drink mix, twice a day (mid-morning & early evening on an empty stomach), for 4 weeks.
1883152|NCT01201603|Dietary Supplement|orange juice|250ml of orange juice or a sugars matched orange drink
1883153|NCT01201616|Other|High Fat Low Carbohydrate Diet|55% total energy intake from fats, 17% from protein and 28% from carbohydrate
1883154|NCT01201616|Other|Low fat High Carbohydrate Diet|20% total energy intake from dietary fats, 17% from protein and 63% from carbohydrate
1883155|NCT01201629|Device|t DC stimulation|tDCS is a non-invasive, non-painful technique that modulates cortical excitability. tDCS can induce intracerebral current flow that is sufficiently large to achieve changes in cortical excitability. Thus, tDCS can be applied to humans non-invasively and painlessly to induce focal, lasting but reversible shifts of cortical excitability.
1883156|NCT01201629|Device|tDCStimulation|1 mA of tDCS will be delivered through surface electrodes (25-35 cm2) to the unaffected motor cortex for 30 min prior to a patient's scheduled OT. In the sham group patient will receive stimulation for 30 seconds only.
1883157|NCT01201642|Drug|Prednisolone|Prednisolone as 5 mg tablets will be given as a single dose of 40 mg daily for 10 days; the dose will then be reduced by 10 mg per 5 day, with a total treatment time of 20 days.
1883192|NCT01201967|Other|Collaborative care|Study care manager provides psychoeducation, therapy, and care coordination between patient, psychiatrist, and primary medical physicians.
1883158|NCT01201642|Device|acupuncture|The acupuncture points used were Dicang (ST4), Jiache (ST6), Yangbai (GB14), Xiaguan (ST7), Taiyang (EX-HN5), Quanliao (SI18) and Yifeng (TE17) on the affected side, and Hegu (LI4) bilaterally. For acute stages acupuncture, shallow puncturing is used at facial acupoints and routine puncturing is used at other acupoints. For resting stage acupuncture, penetrative needling is used from Dicang (ST4) to Jiache (ST6) and from Taiyang (EX-HN5) to Quanliao (SI18) 2-3 cun, and routine puncturing is used at other acupoints. Filiform needles (33 - 49.5 mm, 0.32 mm) will be used with moderate stimulation to get an acupuncture sensation, and the needles were retained for 30 minutes, once a day, five times a week, for a total period of four weeks.
1883159|NCT01201642|Other|other treatment|common medicine or other physical treatment which are different from those 5 Arms Previously.
1883160|NCT01201694|Drug|Surface-Controlled Water Soluble Curcumin|Starting dose 100 mg by mouth two times a day of a 28 day cycle.
1883161|NCT01201694|Drug|Surface-Controlled Water Soluble Curcumin MTD|Dose will be maximum tolerated dose (MTD) from Arm 1.
1883162|NCT01201707|Procedure|Angioplasty|In this procedure, a small catheter (tube) that is approximately the size of a piece of spaghetti is introduced into the vein that is narrowed based on the findings of the venogram. This catheter has a small balloon on it. That balloon is inflated across the narrowing within the vein with the goal of increasing the diameter of that vein and improving flow within that vein.
1883163|NCT01201707|Other|Observation|Patients in this arm will be diagnosed with CCSVI based on venography but will receive no intervention. They will be followed in the same manner as patients treated with angioplasty.
1883164|NCT01201720|Procedure|Plasma exchange with albumin|Realization of 6 plasma exchange with albumin in 11 days
1883165|NCT01201733|Other|Traditional Thai massage|The participants will receive a thirty minutes session of traditional Thai massage onto the scapular region
1883166|NCT01201733|Other|Ultrasound therapy and hot pack|
1883167|NCT01201746|Procedure|Delayed treatment|Scaling, Root Planing and oral hygiene instruction
1883168|NCT01201746|Procedure|Periodontal therapy|Scaling, root planning and oral hygiene instructions
1883169|NCT01201759|Drug|Salsalate 2grams twice a day for 30 days. Then Placebo for 30 days|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2
1883170|NCT01201759|Drug|Placebo twice a day for 30 days. Then Salsalate 2gr BID for 30 days.|Participants will undergo randomization to either 1 month of Salsalate (4.0 g/day) or placebo. An untreated wash-in (1 month) will precede treatment (1 month), and a washout cross-over period (1 month) will follow. After the wash-in month participants will receive either Salsalate or the placebo. The last month will test effects of drug-placebo not examined in month 2.
1883171|NCT01201772|Drug|Prasugrel|Prasugrel 10mg, 30mg, or 60mg
1883172|NCT01201785|Drug|Aspirin|After having been on aspirin 81mg/daily for at least one-week, patients switched their aspirin regimen on a weekly basis according to the following scheme: aspirin 81mg twice daily (bid) for one week; aspirin 162 mg once daily (od) for one week; aspirin 162 mg bid for one week; aspirin 325 mg od for one week. Pharmacodynamic assessments were made after each sequence (5 time-points). Afterward, patients resumed the dose of aspirin that they were on prior to entering the study.
1883173|NCT01201798|Drug|Difluprednate 0.05% ophthalmic emulsion|1 drop in study eye, 4 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
1883174|NCT01201798|Drug|Prednisolone acetate 1.0% ophthalmic suspension|1 drop in study eye, 8 times a day, for 14 days, followed by a 14-day tapering period dependent on the Investigator's determination of adequate response to treatment
1883175|NCT01201811|Drug|Azacitidine|Subjects will receive azacitidine 75 mg/m2/day SC for 7 days every 28 days for up to 6 cycles, unless they are discontinued from the treatment. In addition, subjects may receive best supportive care as needed, including antibiotics and transfusions, per Investigator discretion.
1883176|NCT01201824|Procedure|intracavitary ultrasound|intracavitary ultrasound done during surgical intervention
1883177|NCT01201837|Drug|Placebo|Weekly injection
1883178|NCT01201837|Drug|CER-001|Weekly injection
1883179|NCT01201850|Drug|Bevacizumab (Avastin®)|Once enrolled on study, patients will be treated with bevacizumab (10mg/kg) intravenously (i.v.) every 2 weeks for a total of 6 doses. An MRI will be done after the first cycle (3 doses/ 6weeks) and then again at the end of therapy.
1883182|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
1883183|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
1883184|NCT01201902|Biological|un-adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
1883185|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.25ml, Intramuscular on Day 0 and 21
1883186|NCT01201902|Biological|Adjuvanted influenza A(H1N1) vaccine|0.5ml, Intramuscular on Day 0 and 21
1883187|NCT01201915|Drug|Vismodegib|Vismodegib was supplied in gelatin capsules.
1883188|NCT01201928|Drug|Comparator administered in parent trial|Comparator arm may be different for each parent trial, consisting of some sort of usual care for diabetes
1883189|NCT01201928|Drug|Technosphere Insulin Inhalation Powder|Pulmonary delivered inhaled insulin formulation containing human insulin and Technosphere Inhalation Powder (administered in parent trial)
1883191|NCT01201954|Drug|sucrose|oral sucrose solution, 24%, 0,5 ml/kg, 2 minutes before start the suctioning sterile water, 0,5 ml/kg, 2 minutes before start the suctioning
1883193|NCT01201967|Other|Usual care|Patient's primary medical physician informed of mental health symptoms/diagnosis
1883194|NCT01202006|Other|Training of general practitioners in an uptitration protocol.|The general practitioners randomly allocated to the intervention group will be trained in the practical appliance of the Dutch GP's 'heart failure' guideline. They will receive detailed instructions on initiating diuretics with ACE-inhibitors and uptitration of ACE-inhibitors and beta-blockers.
1883195|NCT01202019|Other|Circuit Resistance Training (CRT)|CRT will occur 3 times per week for 26 weeks. Each session will last approximately 40-45 minutes and employ resistance training (weight lifting) and endurance activities (reciprocal arm exercise, Vita-Glide®, RehaMed International) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
1883196|NCT01202032|Drug|Association of Bevacizumab (BVC)+ Pazopanib (PZP)|"Treatment is administered in 28-day cycles, during which patients received BVC intravenously every 2 weeks and oral PZP once daily from days 1 to 28. For the first cycle, PZP is administered alone from days 1 to 14.
The starting dose for dose escalation is BVC at 7.5 mg/kg in combination with PZP 400 mg (level 1).
The therapy regimens for each dose level are respectively:
BVC 7.5 mg/kg + PZP 600 mg (level 2) BVC 10 mg/kg + PZP 600 mg (level 3) BVC 10 mg/kg + PZP 800 mg (level 4). Patients who experience grades 3 to 4 adverse events have dose adjustments to one or both drugs. Dose reductions affect in priority the administration of PZP. Doses reductions to PZP are made in 200-mg decrements and to BVC to 2.5-mg/kg decrements.
Patients with toxicities that warrant reductions at either PZP 400 mg or BVC 7.5 mg/kg are withdrawn from the study."
1883197|NCT01202058|Device|NEVO™ Sirolimus-eluting Coronary Stent System|"Design Original Protocol
Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the NEVO™ Sirolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting."
1883198|NCT01202058|Device|XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System)|Intervention will consist of percutaneous coronary intervention for treatment of a single or multiple coronary lesion(s) using standard coronary intervention techniques. Intervention in this arm will include treatment with the XIENCE V®/XIENCE PRIME™/PROMUS® Everolimus-eluting Coronary Stent System. Subjects assigned to the IVUS sub-study population will undergo intravascular ultrasound evaluation immediately post-stenting.
1883199|NCT01202071|Drug|Rabeprazole sodium, 5 mg Tablets|"Rabeprazole sodium Tablets, 5 mg administered for 5 days.
Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.
Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
1883200|NCT01202071|Drug|Rabeprazole sodium, 10 mg Tablets|"Rabeprazole sodium Tablets, 10 mg administered for 5 days.
Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.
Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
1883201|NCT01202071|Drug|Rabeprazole sodium, 20 mg Tablets|"Rabeprazole sodium Tablets, 20 mg administered for 5 days.
Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.
Day 2 to Day 4: participants received a single dose with 200 mL of water >= 2 hours after the completion of breakfast."
1883202|NCT01202071|Drug|Rabeprazole sodium, 40 mg Tablets (two 20 mg Tablets)|"Rabeprazole sodium Tablets, 40 mg (two 20 mg Tablets) administered for 5 days.
Day 1 and Day 5: participants received a single dose with 200 mL of water in the morning while fasting for 10 hours or longer.
Day 2 to Day 4: participants received a single dose with 200 mL of water, >=2 hours after the completion of breakfast."
1883203|NCT01202084|Drug|Formoterol/Fluticasone|
1883204|NCT01202084|Drug|Foraseq®|
1883205|NCT01202084|Drug|Fluticasone|
1883206|NCT01202097|Drug|Salmeterol/Fluticasone|
1883207|NCT01202097|Drug|Seretide|
1883208|NCT01202110|Drug|Propranolol|
1883209|NCT01202149|Device|Elidel (pimecrolimus cream, 1%) Hylatopic Plus Emollient Foam (non-medicated device)|
1883210|NCT01202162|Drug|Desflurane|Administratino of Desflurane
1883211|NCT01202162|Drug|Administration of Sevoflurane|Administration of Sevoflurane
1883212|NCT01202175|Drug|Nebivolol|Oral nebivolol 2.5-5mg once daily
1883213|NCT01202188|Drug|indacaterol and glycopyrronium (QVA149)|Capsules for inhalation delivered via SDDPI.
1883214|NCT01202188|Drug|glycopyrronium (NVA237)|Capsules for inhalation delivered via SDDPI.
1883215|NCT01202188|Drug|indacaterol (QAB149)|Capsules for inhalation delivered via SDDPI.
1883216|NCT01202188|Drug|tiotropium|Capsules for inhalation delivered via HandiHaler® device.
1883217|NCT01202188|Drug|placebo|Placebo to match capsules for inhalation delivered via SDDPI.
1883218|NCT01202201|Other|Database analysis|Review and collect data from database (electronic admission database or any other applicable database of the hospital)
1883219|NCT01202214|Drug|1440115|
1883220|NCT01202214|Drug|Placebo|matching placebo
1883221|NCT01202227|Drug|pregabalin|Pregabalin capsules taken twice a daily (150-600mg/day)
1883222|NCT01202240|Drug|Tasocitinib (CP-690,55) plus Ketoconazole|Period 1, Day 1: tasocitinib (CP-690,550) as a single oral 10 mg dose given as two 5 mg tablets Period 2, Days 1-2: ketoconazole as a daily single oral 400 mg (dose given as two 200 mg tablets Period 2, Day 3: ketoconazole as a single oral 400 mg dose given as two 200 mg tablets PLUS tasocitinib (CP-690,550) as a single oral 10 mg oral dose given as two 5 mg tablets Period 2, Day 4: No treatment (discharge)
1883223|NCT01202253|Drug|anidulafungin|A single 200 mg loading dose should be administered on Day 1, followed by 100 mg daily thereafter.
1883224|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
1883225|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
1883226|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
1883227|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner
1883270|NCT01202669|Other|No intervention planned, observational study only.|No intervention planned, observational study only.
1883228|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered twice daily for 14 days immediately after breakfast and dinner or once daily for 14 days immediately after breakfast
1883229|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
1883230|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
1883231|NCT01202266|Drug|PF-05161704 or Placebo|PF-05161704 and Placebo (3:1) oral dosing Suspensions administered once daily for 14 days immediately after breakfast
1883232|NCT01202279|Drug|Guaifenesin|1200 mg guaifenesin and 120 mg pseudoephedrine HCl bid for 7 days
1883233|NCT01202279|Device|Placebo|Placebo bid for 7 days
1883234|NCT01202292|Behavioral|Behavioral (e.g., Psychotherapy, Lifestyle Counseling)|Group motivational intervention consist in expert psychologist 32 monthly sessions (group intervention) on top of the diet plus exercise
1883235|NCT01202305|Procedure|Lymph node biopsy|Inguinal lymph node biopsy
1883237|NCT01202344|Other|Additional x-ray images|Approximately 3 additional x-ray images following angioplasty (within 1 hour)
1883238|NCT01202357|Behavioral|Community Case Management|Community case management for psychosis by designated key-worker according to specified protocol
1883239|NCT01202370|Drug|7-t-butyldimethylsilyl-10-hydroxycamptothecin|IV Over 1 hour Days 1, 4, 8, 12 & 15 of a 21 day cycle (7.5 mg/m^2).
1883240|NCT01202383|Behavioral|Household-based water treatment with NADCC tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
1883241|NCT01202383|Behavioral|Household-based water treatment with placebo tablets|Study participants will be supplied with tablets and encouraged to use them for treating their water daily
1883242|NCT01202409|Drug|Panitumumab|Starting Dose Level: 9 mg/kg by vein over 60 minutes on day 1 of a 14 day cycle.
1883243|NCT01202422|Drug|Pregabalin controlled release, 165 mg|Two tablets of 165 mg controlled release (administered concurrently) once daily for four days.
1883244|NCT01202422|Drug|Pregabalin controlled release, 330 mg|330 mg controlled release tablet administered once daily for four days.
1883245|NCT01202422|Drug|Pregabalin immediate release, 150 mg|150 mg immediate release capsules administered every 12 hours for four days
1883246|NCT01202435|Drug|Pregabalin controlled release, 82.5 mg|82.5 mg controlled release tablet administered once daily for four days.
1883247|NCT01202435|Drug|Pregabalin immediate release, 25 mg|25 mg immediate release capsules administered three times daily for four days
1883248|NCT01202448|Procedure|CSF analysis|The cerebrospinal fluid will be evaluated via lumbar puncture.
1883249|NCT01202461|Procedure|Triple therapy of vitrectomy, IVTA and grid/focal laser photocoagulation|"all pars plana vitrectomy were accompanied with removal of retinal Internal limiting membrane (ILM) around fovea in round fashion with a dimension of approximately 2 disc diameters.
IVTA was introduced at the end of surgery or on the next day (4mg in 0.1cc). Two weeks afterward, fluorescein angiography guided macular laser photocoagulation which consisted of direct photocoagulation on leaking microaneurysms and application of grid pattern laser was undertaken."
1883250|NCT01202474|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day
1883251|NCT01202474|Drug|INSULIN GLARGINE|Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values
1883252|NCT01202487|Drug|LET - Lidocaine Epinephrine Tetracaine|One time application of 3 cc of Lidocaine Epinephrine Tetracaine Solution at least 45 minutes prior to laceration repair
1883253|NCT01202500|Procedure|reducing treatment to 3 months|The treatment will be stopped after 3 months
1883254|NCT01202500|Procedure|registered length of treatment|The treatment procedure will follow the actual recommandation
1883255|NCT01202513|Drug|Bimatoprost 0.03% topical ophthalmic solution|
1883256|NCT01202552|Biological|seasonal influenza vaccine|receives a single intramuscular dose of 0.5 ml of trivalent influenza vaccine, containing at least 15 microgram of hemagglutinin antigen per strain
1883257|NCT01202552|Biological|seasonal influenza vaccine|receives two-site intradermal dose of 0.1 ml each, containing at least 3 microgram of hemagglutinin antigen per strain per site and group
1883258|NCT01202552|Biological|seasonal influenza vaccine|receives two-site intradermal dose of 0.2 ml each, containing at least 6 microgram of hemagglutinin antigen per strain per site
1883259|NCT01202578|Device|tympanostomy tube|tympanostomy tube delivery system
1883260|NCT01202591|Drug|AZD4547|Tablet oral twice daily
1883261|NCT01202591|Drug|Exemestane|Tablet oral once daily
1883262|NCT01202591|Drug|Placebo|Tablet oral twice daily
1883263|NCT01202591|Drug|Fulvestrant|A monthly intramuscular injection of a depot formulation with a loading dose 14 days after initial administration
1883264|NCT01202630|Dietary Supplement|Lactobacillus acidophilus CL1285® and Lactobacillus casei|2 capsules of Lactobacillus acidophilus CL1285® and Lactobacillus casei (50 billion cfu/capsule), consumed once daily for 60 days
1883265|NCT01202630|Dietary Supplement|Placebo|2 capsules of placebo (no live cells), consumed once daily for 60 days
1883266|NCT01202643|Drug|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
1883267|NCT01202643|Drug|Saline|One intrauterine saline infusions of 1 cc
1883268|NCT01202656|Drug|G-CSF|One infusion of G-CSF 300 units administered by intrauterine infusion
1883269|NCT01202656|Drug|Saline|intrauterine saline infusion 1 cc
1883271|NCT01202695|Drug|AVP-21D9|intravenously, single dose
1995263|NCT02814435|Other|Computerised contrast sensitivity function test|This test involves the patient identifying whether bars on a screen are horizontal or vertical. It is designed to measure contrast sensitivity.
1883273|NCT01202708|Device|On line hemofiafiltration|hemodiafiltration with the Gambro AK 200 ULTRA
1883274|NCT01202708|Device|On line hemodiafiltration|On line hemodiafiltration with the Gambro AK 200 ULTRA System
1883275|NCT01202721|Drug|Atenolol|Atenolol or matching placebo 25 mg up-titrated to 100 mg
1883276|NCT01202721|Drug|Telmisartan|Telmisartan or matching placebo 40 mg up-titrated to 80mg.
1883277|NCT01202734|Drug|Methylphenidate HCl|Period 1: One tablet, oral, 36 mg, once daily, single-dose on Day 1
1883278|NCT01202747|Device|LipiFlow System|In-office treatment for meibomian gland dysfunction
1883279|NCT01202760|Drug|LY2127399|Administered Subcutaneously
1883280|NCT01202760|Drug|Placebo every 4 weeks|Administered Subcutaneously
1883281|NCT01202760|Drug|Placebo every 2 weeks|Administered Subcutaneously
1883282|NCT01202773|Drug|LY2127399|Administered Subcutaneously
1883283|NCT01202773|Drug|Placebo every 4 weeks|Administered Subcutaneously
1883284|NCT01202773|Drug|Placebo every 2 weeks|Administered Subcutaneously
1883285|NCT01202799|Drug|2% w/w diclofenac sodium topical gel|2% w/w diclofenac sodium topical gel
1883286|NCT01202799|Drug|1.5% w/w diclofenac sodium topical solution|1.5% w/w diclofenac sodium topical solution
1883287|NCT01202799|Drug|75 mg diclofenac sodium delayed release tablet|75 mg diclofenac sodium delayed release tablet
1883288|NCT01202812|Dietary Supplement|Omega-3 Fatty Acids: Eicosapentaenoic Acid (EPA) and Docosahexaenoic Acid (DHA)|Eicosapentaenoic Acid (EPA)/Docosahexaenoic Acid (DHA) 30mg/kg (LOVAZA capsules) given by mouth daily for 6 months.
1883289|NCT01202812|Other|Placebo Capsules|Placebo capsules given by mouth daily for 6 months.
1883290|NCT01202825|Drug|TMC647055|One single dose as oral solution, doses from 100 mg up to a maximum of 3000 mg increasing in sessions I through VI.
1883291|NCT01202825|Drug|Placebo|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
1883292|NCT01202825|Drug|TMC647055|Oral solution given in session XIII, treatment arm 1 during 10 days at a dose of 1000 mg every 12 hours.
1883293|NCT01202825|Drug|TMC647055|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
1883294|NCT01202825|Drug|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
1883295|NCT01202825|Drug|TMC435|Oral capsule given in session XIII, in treatment arm 1 during 10 days and in treatment arm 2 during 6 days at a dose of 150 mg once daily.
1883296|NCT01202825|Drug|Placebo|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
1883297|NCT01202825|Drug|TMC647055|One single dose as oral solution, selected dose ranging between 100 and 3000 mg in session VII
1883298|NCT01202825|Drug|Placebo|In sessions VIII through X, oral solution given once daily, every 12 hours or every 8 hours on 6 consecutive days. Doses are based on outcome of previous sessions.
1883299|NCT01202825|Drug|TMC647055|Oral solution given in session XI every 12 hours, in session XII every 12 or 8 hours. Doses and regimen will be determined based on outcome of previous sessions.
1883300|NCT01202838|Device|Composite Implant|Subjects receiving composite implants
1883304|NCT01202877|Drug|5-azacytidine|Starting dose: 75 mg/m2/d subcutaneously (SQ) or by vein (IV) on days 1-7 of a 28 day cycle.
1883305|NCT01202877|Drug|PKC412|Starting dose: 50 mg by mouth twice daily for 14 days (days 8-21), of every 28 day cycle. Starting with cycle 2, PKC412 administered continuously (daily).
1883306|NCT01202890|Drug|Lenalidomide, Liposomal Doxorubicin, Bevacizumab|"At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course.
Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease."
1883307|NCT01202890|Drug|Revlimid, Doxil, Avastin|At the expansion phase: Revlimid 20 mg (days 1-21), Doxil 30 mg/m2 on Day 1 and Avastin 15 mg/kg on Day 1, every 3 weeks. If this regimen is not cumulatively tolerable, Avastin will be administered every other course. Patients will be received up to 6 cycles or disease progression, followed by Revlimid maintenance at 25 mg PO q Day for 3 weeks every 4 weeks in patients with stable disease.
1883308|NCT01202903|Drug|Omalizumab|The minimum dose of 0.016 mg/kg/IgE (IU/mL) omalizumab was administered every 4 weeks by subcutaneous injection.
1883309|NCT01202903|Drug|Placebo|The minimum dose of 0.016 mg/kg/IgE (IU/mL) placebo was administered every 4 weeks by subcutaneous injection.
1883310|NCT01202929|Procedure|High Resolution Manometry|High Resolution Manometry which uses 36 solid state sensors spaced at 1-cm intervals, positioned from the hypopharynx to the stomach.
1883311|NCT01202942|Other|Quest|Participants smoke Quest cigarettes level 1 for 10 days, level 2 for 10 days, level 3 for 10 days.
1883312|NCT01202955|Drug|Tolcapone|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
1883313|NCT01202955|Drug|Placebo|Day 1 100mg three times per day Day 2 - Day 7 200mg three times per day Day 8 200mg twice a day Day 9 200mg once a day Day 10 100mg once a day
1883314|NCT01202968|Procedure|Transcutaneous neuro-muscular electrical stimulation|Neuro-muscular electrical stimulation with two pairs of surface electrodes was applied to submental area. One paired electrodes to be placed horizontally was attached on the anterior half of area between mandible and hyoid bone. The other was affixed to posterior half of the same area far laterally. Bipolar electrical stimulation with pulse rate of 80-Hz, duration of 700 µs and intensity to evoke visible muscle contraction was performed for 60 minutes a day until one day before extubation.
1883846|NCT01208064|Drug|pazopanib hydrochloride|
1883847|NCT01208064|Other|laboratory biomarker analysis|
1883316|NCT01203007|Dietary Supplement|Tailored diet|Tailored diet according to demonstrated food sensitivity, 6 months
1883317|NCT01203007|Dietary Supplement|Low antigen content diet|Low-antigen content diet for one month
1883318|NCT01203020|Drug|Busulfan|Busulfex 130 mg/m2 intravenous piggy back (IVPB) for 4 days (Day -6 to -3) pharmacokinetic (PK) samples for Busulfex dose adjustment drawn on Day -6
1883319|NCT01203020|Drug|Fludarabine|Fludarabine 40 mg/m2 IVPB for 4 days (Day -6 to -3)
1883320|NCT01203046|Drug|Ertapenem|Ertapenem 1 gr endovenous 3 or 7 days
1883321|NCT01203072|Drug|DU-176b|DU-176b 5mg tablets oral, once daily for 2 weeks
1883322|NCT01203072|Drug|DU-176b|DU-176b 15mg tablets, oral once daily for 2 weeks
1883323|NCT01203072|Drug|DU-176b|DU-176b 30 mg tablets, oral, once daily for 2 weeks
1883324|NCT01203072|Drug|DU-176b|DU-176b 60 mg tablets, oral, once daily for 2 weeks
1883325|NCT01203072|Drug|Placebo|Matching placebo oral tablets, once daily for 2 weeks
1883326|NCT01203098|Drug|DU-176b 15mg|DU-176b 15 mg tablets oral, once daily for 2 weeks initiated within 6 to 24 hours after surgery.
1883327|NCT01203098|Drug|DU-176b 30mg|DU-176b 30 mg tablets, oral once daily for 2 weeks initiated within 6 to 24 hours after surgery.
1883328|NCT01203098|Drug|Enoxaparin sodium 20 mg (=2000IU)|Enoxaparin sodium 20 mg (=2000IU) / 0.2ml twice daily, subcutaneous injection for 2 weeks initiated within 24 to 36 hours after surgery.
1883329|NCT01203111|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day in the evening at bedtime
1883330|NCT01203111|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day, 0 to 15 minutes before the main meal
1883331|NCT01203124|Drug|AZD8848|The subjects are dosed with a range of intranasal doses of AZD8848 on 2, 3, 4 or 7 days of the 7 days treatment period. On the other days the subjects receive placebo.
1883332|NCT01203124|Drug|Placebo|Placebo
1883333|NCT01203150|Other|Exercise|CRT will occur 3 times per week for 26 weeks. Each training session will last approximately 40-45 minutes and employ resistance training (weight lifting) and high-speed, low intensity endurance activities (arm cranking) with interposed periods of incomplete recovery (i.e., heart rate not falling to baseline).
1883334|NCT01203176|Procedure|Hysteroscopic polypectomy|Hysteroscopy is a well established minimally invasive surgery method for diagnostic and intervention operations inside the uterine cavity. Using this method one can observe the endometrium and remove polyps.
1960422|NCT03211403|Drug|SHR4640|SHR4640 or placebo once daily for a week
1883337|NCT01203202|Drug|Clomipramine|15mg and 30mg on demand
1883338|NCT01203215|Behavioral|2 print based physical activity interventions|physical activity promotion
1883339|NCT01203228|Other|Reduced Intensity Conditioning|"Busilvex®:
6.4 mg/kg IBW i. v. day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)
or (if i.v.-application is not available)
Busulfan:
8.0 mg/kg BW p. o.: day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW
plus:
Fludarabine:
5 x 30 mg/m² BS i. v.: day -7: 30 mg/m² BS day -6: 30 mg/m² BS day -5: 30 mg/m² BS day -4: 30 mg/m² BS day -3: 30 mg/m² BS"
1883340|NCT01203228|Other|Myeloablative conditioning|"Busilvex®:
12.8 mg/kg IBW i. v.; day -9: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -8: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -7: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours) day -6: 0.8 mg/kg IBW x 4 (2 hour infusion every 6 hours)
or (if i.v.-application is not available):
Busulfan:
16.0 mg/kg BW p. o.; day -9: 4.0 mg/kg BW day -8: 4.0 mg/kg BW day -7: 4.0 mg/kg BW day -6: 4.0 mg/kg BW
plus:
Cyclophosphamide:
120 mg/kg BW i. v.; day -4: 60 mg/kg BW day -3: 60 mg/kg BW"
1883341|NCT01203241|Procedure|Pulmonary vein encircling|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum
1883342|NCT01203241|Procedure|Pulmonary vein encircling plus roof ablation|Pulmonary vein encircling by performing continuous radiofrequency lesions surrounding each ipsilateral pulmonary vein antrum plus creation of a radiofrequency line joining contralateral superior pulmonary veins throughout the left atrial roof.
1883343|NCT01203254|Drug|Colesevelam|Colesevelam 625 mg tablet; 3 times daily 2 tablets
1883344|NCT01203254|Drug|Placebo|Placebo tablet: 3 times daily 2 tablets
1883345|NCT01203267|Drug|Paclitaxel, Carboplatin|Paclitaxel 80 mg/m2, carboplatin AUC of 2 mg/min/ml, given on days 1, 8 and 15 of a 28-day cycle.
1883346|NCT01203280|Other|icing massage|The intervention, ice massage, was conducted by replacing a bag of crushed ice (100 cc) inside a moistened towel and lightly rubbed over lumbosacral region for 10 minutes. The moisture towel increased the intensity of the cooling sensation more than the dry wrappings
1883347|NCT01203293|Behavioral|Cognitive behavior based therapy|15-20 individual psychotherapy sessions
1883348|NCT01203293|Behavioral|Treatment as usual|Treatment as usual is an active comparator group in which patients are provided referrals to specialty mental health care services or can use any primary or specialty care services available to them in usual care.
1883349|NCT01203306|Drug|bevacizumab + octreotide LAR + capecitabine|long acting octreotide acetate at a dose of 20 or 30 mg administered intramuscularly every 4 weeks; Bevacizumab at a dose of 5 mg/kg every 2 weeks; orally capecitabine administered at a dose of 2000 mg/daily
1883350|NCT01203319|Biological|60mcg/1.0ml recombinant hepatitis B vaccine|to receive 60mcg/1.0ml recombinant HBV vaccines on day 0, 30 and 60
1883351|NCT01203319|Biological|30mcg/1.0ml recombinant hepatitis B vaccine|to receive 30mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60.
1883352|NCT01203319|Biological|10mcg/1.0ml recombinant hepatitis B vaccine|to receive 10mcg/1.0ml recombinant hepatitis B vaccines on day 0, 30 and 60
1960423|NCT03211351|Drug|Liposic|one eye of the participant recieved Lipoic
1960424|NCT03211351|Drug|Tears Naturale Forte|the other eye of the participant recieved Tears Naturale Forte
1960425|NCT03209154|Diagnostic Test|Therapeutic drug monitoring|Therapeutic drug monitoring will be performed.
1883353|NCT01203332|Behavioral|Effectiveness of different strategies in HIV testing and linkage to care|HIV testing Linkage to Care
1883354|NCT01203345|Drug|IVIG|The infants received their first dose of study drug within 24 hours of randomization.
1883355|NCT01203345|Drug|Placebo|An equal volume of 5 percent albumin solution
1883356|NCT01203358|Drug|Exosurf|Infants received up to four intratracheal doses of the surfactant.
1883357|NCT01203358|Drug|Survanta|Infants received up to four intratracheal doses of the surfactant.
1883358|NCT01203371|Drug|Naftopidil|0,25 mg (2weeks) and 0,50 mg (10 weeks)
1883359|NCT01203371|Drug|Tamsulosin|0,4 mg/day
1883360|NCT01203384|Drug|CHF5074 1x|oral tablet, 1x, once a day in the morning for 14 days
1883361|NCT01203384|Drug|CHF5074 2x|oral tablet, 2x, once a day in the morning for 14 days
1883362|NCT01203384|Drug|CHF5074 3x|oral tablet, 3x, once a day in the morning for 14 days
1883363|NCT01203384|Drug|Placebo|oral tablet, placebo, once a day in the morning for 14 days
1883364|NCT01203397|Drug|TOPIC MUCOPOLYSACCHARIDE POLYSULFATE 5MG/G|APLIED 4 TIMES/DAY AT LESION
1883365|NCT01203436|Procedure|Supplemental Oxygen Management|Supplemental arm with pulse oximetry targeted at 96% to 99% saturation, for at least 2 weeks, and until both eyes were at study endpoints.
1883366|NCT01203436|Procedure|Conventional Oxygen Management|Conventional oxygen arm with pulse oximetry targeted at 89% to 94% saturation.
1883367|NCT01203462|Other|Probiotic strain of Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. Minimum Bifidobacterium dose of 1E+10 cfu/serving.
1883368|NCT01203462|Other|No Bifidobacterium|4 ounces (113g) of yogurt per day, for 14 days. No bifidobacterium added.
1883369|NCT01203488|Drug|Vitamin A|5,000 IU (0.1 ml) was given on Mondays, Wednesdays, and Fridays for four weeks.
1883370|NCT01203488|Other|Sham Procedure|Control infants received a sham procedure rather than placebo injections.
1883371|NCT01203514|Drug|Erythropoietin|Infants received 400 U/kg Erythropoietin (Epo) 3 times weekly and a weekly intravenous infusion of 5 mg/kg iron dextran until they had an enteral intake of 60 mL/kg/d.
1883372|NCT01203514|Other|Sham Comparator|Infants in the placebo/control group received sham subcutaneous injections when intravenous access was not available.
1883373|NCT01203540|Drug|NAABAK eyedrops|
1883374|NCT01203540|Drug|Saline eyedrops|
1883375|NCT01203553|Procedure|Abdominal surgery|Intraoperative mesh implantation
1883376|NCT01203566|Procedure|LESS appendectomy|See under arms description
1883377|NCT01203566|Procedure|Conventional 3-port laparoscopic appendectomy|See under arms description
1883378|NCT01203592|Drug|Albuterol|4 mg twice daily by mouth for adults. The dose for children 6 to 12 years is 2 mg two or three times daily; the dose for children 2 to 6 years is 0.1 mg/kg/day (maximum 2 mg) three times daily.
1883379|NCT01203618|Drug|Farletuzumab|Farletuzumab initial loading dose 5.0 mg/kg intravenous followed by 2.5 mg/kg intravenous for all subsequent doses every 2 weeks for up to 12 months.
1883380|NCT01203631|Drug|NNC 0142-0000-0002|A single dose administered subcutaneously (s.c., under the skin)
1883381|NCT01203631|Drug|Placebo|A single dose administered subcutaneously (s.c., under the skin)
1883382|NCT01203644|Drug|SKY0402|Single dose of SKY0402 administered locally into the surgical wound.
1883383|NCT01203644|Drug|Bupivacaine HCl|Single dose of bupivacaine HCl (100 mg) administered locally into the surgical wound.
1883384|NCT01203657|Behavioral|Tai Chi|Tai Chi classes, 60 minutes, 2x week
1883385|NCT01203670|Dietary Supplement|Phytalgic|Volunteers have to take three soft capsules per day, one in the morning and two in the evening.
1883386|NCT01203683|Behavioral|Active computer-based training|8 sessions across 4 weeks.
1883387|NCT01203683|Behavioral|Inert computer training|8 sessions across 4 weeks.
1883388|NCT01203696|Drug|Amlodipine|For patient with suboptimal angina control: oral 2.5-10mg daily
1883389|NCT01203696|Drug|Amlodipine|For patient with suboptimal BP control: 2.5-10mg daily po
1883390|NCT01203709|Drug|low dose combination of MMF and Tac|mycophenolate mofetil 500mg BID + tacrolimus 2mg BID
1883391|NCT01203722|Other|Fludarabine, Cytoxan, TBI, Sirolimus + MMF|"Pre-transplantation:
Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV
Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV
Day -1: 200 cGy TBI administered in a single fraction
Post-Transplantation Immunosuppression Consisting of:
Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV
Day 5: Sirolimus loading dose 6 mg PO once
Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)
Day 6 thru Day 180: Sirolimus maintenance dose 2 mg PO QD with dose adjustments to maintain trough of 3 - 12 ng/mL"
1883392|NCT01203722|Other|Fludarabine, Cytoxan, TBI, Tacrolimus + MMF|"Pre-transplantation:
Day -6 through -2: Fludarabine 30 mg/m2/day (adjusted for renal function; maximum cumulative dose, 150 mg/m2) administered IV
Day -6 and -5: Cytoxan 14.5 mg/kg/day administered IV
Day -1: 200 cGy TBI administered in a single fraction
Post-Transplantation Immunosuppression Consisting of:
Day 3 and 4: High-dose Cytoxan 50mg/kg/day (adjusted according to IBW) administered IV
Day 5 thru Day 35: MMF 15 mg/kg PO TID (maximum daily dose 3 g/day)
Day 5 thru Day 180: Tacrolimus 1 mg administered IV QD"
1883393|NCT01203735|Drug|Valproic acid|800mg per day for entire period of RT
1883394|NCT01203748|Procedure|PVI + Lines ablation|Pulmonary vein antrum isolation with additional linear ablation (mitral line and roof line)
1883395|NCT01203748|Procedure|PVI|Pulmonary vein antrum isolation
1883396|NCT01203748|Procedure|PVI + CFE ablation|Pulmonary vein antrum isolation with additional complex fractionated electrogram ablation
1883397|NCT01203774|Drug|Glargine insulin|20-180 units per day
1883398|NCT01203787|Drug|Sorafenib Standard Dosing Regimen|Sorafenib 400 mg twice daily until wk 24 or end of treatment
1883399|NCT01203787|Drug|Sorafenib Ramp-Up Regimen|200 mg daily, Day 0-Day 13 200 mg twice daily, Day 14-Day 20 600 mg daily, Day 21-Day 27 400 mg twice daily, Day 28 until end of treatment400 mg twice daily
1883400|NCT01203813|Other|Electronic Decision Support|"Physicians randomized to the intervention will receive:
Electronic alerts during office visits for patients with chronic kidney disease
Opportunity to enroll their patients with chronic kidney disease in a self management support outreach program"
1883401|NCT01203826|Biological|Asfotase Alfa|
1883848|NCT01208064|Other|pharmacogenomic studies|
1883402|NCT01203839|Radiation|multiple beams utilizing either intensity-modulated or 3D-conformal techniques|A dose of 40 Gy will be delivered to the tumor bed plus 1.5-2 cm margin. Treatment will be delivered once daily, 5 days a week, for approximately 2 weeks. Radiation therapy will begin within a minimum of 4 weeks and a maximum of 3 months from definitive surgical procedure and 2-6 weeks after chemotherapy, if chemotherapy given first. Prior to radiation, patients will receive a lumpectomy with an assessment of axillary lymph node status (for invasive tumors only). Axillary assessment may be any combination of sentinel lymph node biopsy or axillary lymph node dissection.
1883403|NCT01203852|Drug|Metoprolol|"Metoprolol 50 mg twice daily titrated to 100 mg twice daily
Note: due to discontinuation of the manufacture of chlorthalidone 15 mg, effective Jan 1, 2013; the starting dose of chlorthalidone will be 25 mg 4 times per week (Mon, Wed, Thur, Sat) with subsequent titration to 25 mg daily."
1883404|NCT01203852|Drug|Chlorthalidone|Chlorthalidone 25 mg 4 times per week titrated to 25 mg daily
1883405|NCT01203878|Drug|Photodynamic therapy|Administered 4 weeks after completion of imiquimod therapy
1883406|NCT01203878|Drug|Imiquimod|Imiquimod 3.75% cream, up to 2 packets, applied topically daily for two 2-week cycles separated by a no-treatment interval of 2-weeks, followed observation
1883407|NCT01203917|Drug|Gefitinib|250mg tablet oral, once daily until objective disease progression is documented or until other discontinuation criterion is met
1883408|NCT01203930|Drug|Idelalisib|Idelalisib 150 mg tablets administered orally twice daily
1883409|NCT01203930|Drug|Rituximab|Rituximab 375 mg/m^2 administered intravenously once weekly x 8 weeks
1883410|NCT01197027|Behavioral|Standard counseling|Standard HIV counseling
1883411|NCT01197040|Drug|Prednisone|1 mg/kg/day for 4 weeks. Then, the dose will be progressively tapered if the remission will be achieved. For patients who exhibit incomplete remission at this time, high dose steroid will be continued for 4 weeks again before the tapering.
1883412|NCT01197040|Drug|acid mycophenolic (Myfortic)|patients will receive prednisone 0.5 mg/kg/day combined with mycophenolic acid (MyforticR) 1440 mg/day. The management of steroid therapy will be identical in both groups, while MyforticR will be continued for six months
1883413|NCT01197053|Biological|Epicutaneous Immunotherapy|100 mcg peanut proteins (active arm) applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
1883414|NCT01197053|Biological|placebo of peanut|placebo applied on the skin every 24 hrs for 6 months blinded, followed by 12 months open treatment for all patients in the active arm
1883415|NCT01197066|Drug|Certolizumab Pegol|Certolizumab Pegol 200mg
1883416|NCT01197079|Other|Survey|Self administered anonymous survey
1883417|NCT01197092|Dietary Supplement|Mitochondrial preparations|"Oral therapy with mitochondrial preparations based on recipes of Dr Kremer and the Tisso company:
ProEMSan (large intestinal symbionts with 31 strains of bacteria) Pro Basan (small intestinal symbionts) ProSirtusan (Polyphenol-mix and vitamins) ProVita D3 (Vitamin D3 supplement) ProOmega (Omega 3-fatty acid preparation) ProCarnitin (Carnitine-preparation) ProSango Vital (trace element preparation)"
1883418|NCT01197092|Dietary Supplement|Infusion therapy|Infusion therapy in the form of a complex mix: 500ml-solution with trace elements, amino acids and antioxidants.
1883419|NCT01197092|Device|Webermedical device|Intravenous-Blood-Laser-Therapy: the Webermedical device will be used
1883420|NCT01197092|Behavioral|Nutritional therapy|"Nutritional therapy based on IgG-blood results. Significant antibody-formation against foodstuffs will be ascertained (in foodstuffs evaluated through the BioMedicalScreen), will be taken out of the diet - the background being the additional lowering of risk potential of those antibodies causing the so called silent inflammation (sub-clinical inflammation) -ultimately an anti-inflammatory diet will be given in the protocol. The following have special focus: gluten, cow's milk, fish, meat, nuts."
1960426|NCT03209154|Device|Home blood pressure monitoring|Patients will perform home blood pressure monitoring at home.
1883422|NCT01197118|Radiation|sequence chemoradiotherapy|"Postoperative radiotherapy regimen: Therapy plan system was formulated by Computed tomographic (CT) simulation. Radiation was delivered with 15MV photons. Radiotherapy consisted of 4500 cGy of radiation at 180 cGy per day, five days per week for five weeks, to the tumor bed, to the margins of resection or the stoma, to the regional nodes. Protection of spinal cord, heart, liver and kidney should be considered.
Postoperative chemotherapy regimen: see arm 2"
1883423|NCT01197118|Drug|chemotherapy alone following radical resection|Postoperative chemotherapy regimen: The OLF regimen was administrated: Oxaliplatin, 130 mg/m2/day on day1, i.v. 2 h; fluorouracil, 425 mg/m2/day on day1~5, i.v.; leucovorin, 200 mg/m2/day on day 1~5, i.v.; every 21 days repeated, for 6 cycles.
1883424|NCT01197144|Drug|adalimumab|Subcutaneous, 40 mg every other week for 4 weeks
1883425|NCT01197144|Drug|Placebo|Subcutaneous, every other week for 4 weeks
1883426|NCT01197157|Drug|Placebo|Group A: comprises 100 CHC patients who will receive placebo twice daily with food for an average of 12 weeks as a part of monotherapy lead-in phase followed by triple therapy, nitazoxanide 500 mg twice daily plus peginterferon alfa-2a (once weekly), and weight-based ribavirin (1000-1200 mg daily) for 48 weeks.
1883427|NCT01197157|Drug|Nitazoxanide|• Group B: comprises 100 chronic hepatitis patients who will receive oral Nitazoxanide 500 mg twice daily with food for an average of 12 weeks followed by the standard of care treatment, peginterferon Alfa 2a once weekly and weight-based ribavirin 1000 or 1200 mg/day (based on body weight < 75 kg or ≥ 75 kg, respectively) in divided doses plus placebo twice daily for 48 weeks.
1883428|NCT01197170|Drug|Anastrozole|1 mg by mouth daily of a 28 day cycle.
1883429|NCT01197170|Drug|Bevacizumab|Starting dose 10 mg by vein on day 1 of a 21 day cycle.
1883430|NCT01197170|Drug|Everolimus|Starting dose 5 mg by mouth daily for a 28 day cycle.
1883431|NCT01197170|Drug|Sorafenib|Starting dose 200 mg by mouth twice a day of a 28 day cycle.
1883432|NCT01197170|Drug|Erlotinib|Starting dose 75 mg by mouth daily for a 28 day cycle.
1883433|NCT01197196|Behavioral|Behavioral Weight Loss Intervention|Participants assigned to this condition will receive an intensive group-based lifestyle program modeled after the DPP and Look AHEAD trials. Participants will attend 16 weekly sessions involving provision of behavioral goals and strategies to modify diet and exercise behaviors in order to achieve a weight loss of at least 7% of initial body weight.
1883521|NCT01204008|Procedure|conservative discectomy|a smaller incision with removal of the disc fragment with little invasion of the disc
1883434|NCT01197196|Other|Migraine Education|Participants assigned to this condition (Healthy Living for Migraine Relief [HLMR]) will receive basic education and didactic instruction in migraine headaches and treatments that are the standard of care. Participants will attend 4 months of weekly group lectures focused on 3 different major topic areas: 1) migraine symptomatology and pathophysiology, 2) standard abortive and preventive pharmacological treatment options, and 3) standard and alternative non-pharmacological treatment options.
1883435|NCT01197209|Biological|Ad-REIC/Dkk-3|REIC (Reduced Expression in Immortalized Cells) protein is down regulated in a variety of cancer cell lines including prostate tumors. The REIC gene is identical to the Dickkopf-3 (Dkk-3) gene that is a member of the Dickkopf gene family. Ad-REIC/Dkk-3 is designed as a viral vector that delivers a DNA plasmid capable of producing intracellular REIC protein. The expression plasmid includes the full-length human cDNA sequence for REIC. The adenovirus vector is a transport mechanism to infuse the REIC/Dkk-3 plasmid into the cell providing a temporary transfusion of REIC protein.
1883436|NCT01197222|Device|EndoClear Lens Cleaning Device|EndoClear Lens Cleaning Device is used during a laparoscopic abdominal surgery.
1883437|NCT01197235|Drug|darbepoetin-α|Infusion of darbepoetin-α 1.5 μg/kg will be performed 1 hour before angiography
1883438|NCT01197235|Drug|isotonic saline|Infusion of isotonic saline will be performed 1 hour before angiography
1883439|NCT01197248|Procedure|Cystocele plication|placement of sutures over the pubocervical fascia during the cystocele repair
1883440|NCT01197248|Procedure|No Plication|Avoid sutures over pubocervical fascia during cystocele plication
1883441|NCT01197261|Drug|Oxycodone naloxone prolonged release tablets|2 tablets/ day
1883442|NCT01197261|Drug|Placebo tablets|2 tablets/ day
1883443|NCT01197274|Device|Simple blood lancet|Skin prick testing with blood lancet and DuoTip is performed on the back of mite-sensitized person. Allergen(Der p)is placed in 1st and 2nd row whereas histamine is placed in 3rd row. Allergen and normal saline are placed alternately in 4th row. Block randomization were allocated subjects into 2 groups; Group1:blood lancet is performed in 1st row and DuoTip in 2nd row. Group2:DuoTip is performed in 1st row and blood lancet in 2nd row. Blood lancet is applied in 3rd and 4th row in all subjects. A technician performed device applications and another technician who is blinded to device performed all readings. Pain was assessed on a scale from 0 to 10 with 0 being no pain and 10 being the worst imaginable pain
1883444|NCT01197287|Drug|QAK423A|
1883445|NCT01197287|Drug|QAK423A|
1883446|NCT01197287|Drug|QAK423A|
1883448|NCT01197313|Other|Home-based exercise|
1883449|NCT01197326|Device|use of the MP5 EWS patient monitor|All patients on the study ward receive the same care in Groups 1 and 2. The only difference is the device used to collect the vital signs. In Group 2, the MP5 EWS spot check monitor (FDA approved and CE marked) is the vital signs collection device.
1883450|NCT01197339|Behavioral|resonant voice|A 4-hr resonant voice exercise will be prescribed to subjects following vocal loading.
1883451|NCT01197339|Behavioral|voice rest|A 4-hr voice rest will be prescribed to subjects following vocal loading.
1883452|NCT01197339|Behavioral|Breathy voice|A 4-hr breathy voice exercise will be prescribed to subjects following vocal loading.
1883453|NCT01197339|Behavioral|Relaxation exercise|A 4-hr relaxation exercise will be prescribed to subjects following vocal loading.
1883454|NCT01197339|Behavioral|Resonant voice and relaxation exercise|A 4-hr resonant voice and relaxation exercise will be prescribed to subjects following vocal loading.
1883455|NCT01197352|Behavioral|Motivational and Normative Feedback|Weekly feedback based on their frequency and degree of at-risk drinking behavior using normative, educational and motivational feedback
1883456|NCT01197352|Behavioral|Self-Awareness|Weekly queries to raise awareness and allow self-reflection about drinking habits
1883457|NCT01197365|Other|Infant formula with GOS, beta-palmitate, acidified milk|"Infant formula supplemented with functional ingredients (galacto-oligosaccharides, beta-palmitate, acidified milk.
Infant formula with functional ingredients is in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae"
1883458|NCT01197365|Other|Standard infant formula without functional ingredients|Standard infant formula, in compliance with Directive 2006/141/CE on infant formulae and follow-on formulae, without functional ingredients
1883459|NCT01197378|Drug|Cysteamine Bitartrate Delayed-release Capsules (RP103)|RP103 every 12H, supplied in 75 and 25mg capsules
1883460|NCT01197391|Biological|REGN728|2 Subcutaneous Cohorts (dose 1, 2)
1883461|NCT01197404|Behavioral|Affect Management|12-session group intervention including affect management training as well as sexual health skills training.
1883462|NCT01197404|Behavioral|General Health Promotion|12-session group intervention including health information on a variety of developmentally relevant health topics.
1883463|NCT01197417|Drug|Intravenous Magnesium Sulfate|40 mg/kg (max 2.4 grams), infused at a concentration of 40 mg/ml (1 ml/kg, max 60 ml), every 8 hours for a total of 6 doses
1883464|NCT01197417|Drug|Normal Saline Placebo|(1 ml/kg, max 60 ml), administered every 8 hours for a total of 6 doses
1883465|NCT01197430|Other|exercise training|
1883466|NCT01197443|Behavioral|Parent-only Group|Parent-only group will include the same skills and techniques to promote weight loss as given to the parent + child group, but the information will be delivered only to the parent. Parent group will be compared to the parent group of the parent + child treatment arm. The focus will be on implementing skills learned to assist the child in weight management. The treatment length is set for 12 weekly meetings and bi-monthly meetings during months 4 and 5. Each group session will be 60-min including weigh-ins. Group meetings focus on behavior change, weight loss, healthy eating and activity for the overweight child and parent.
1883467|NCT01197443|Behavioral|Parent + Child Group|The treatment for participants in the parent + child group will be administered in two separate groups, one for the parents and one for the child. Treatment will include the same skills and techniques to promote weight loss as given to the parent-only group, but the information will be delivered to both the parent and child. The treatment length, session schedule, treatment content and follow-up assessments are same as the parent-only group.
1883468|NCT01197469|Drug|Tadalafil|Tadalafil 10mg once daily for 3 months
1883469|NCT01197469|Drug|Placebo|
1883520|NCT01203995|Behavioral|Nutrition education and exercise training|Twice per week nutrition education and exercise class held either in-clinic or through vide-conference.
1883470|NCT01197495|Device|hyaluronic acid gel|Dosage per Investigator's discretion to obtain lip treatment gel; 1 touch-up treatment is allowed 14 to 30 days after initial treatment. Repeat treatment occurs at month 12. Subjects in the control group start with treatment at month 3. Maximum total volume per subject is 4.8 mL for initial and touch-up treatment combined.
1883471|NCT01197508|Drug|TC-5214|Twice daily for 8 weeks.
1883472|NCT01197508|Drug|Placebo|Twice daily for 8 weeks.
1883473|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily
1883474|NCT01197521|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
1883475|NCT01197521|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily
1883476|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily
1883477|NCT01197534|Drug|fostamatinib|fostamatinib 100 mg twice daily/ 150 mg once daily
1883478|NCT01197534|Drug|placebo, fostamatinib|Placebo for 24 weeks followed by fostamatinib 100 mg twice daily.
1883479|NCT01197547|Device|Genesys HTA|Genesys HTA Endometrial Ablation
1883480|NCT01197560|Drug|Lenalidomide|Lenalidomide 25 mg orally for 21/28 days until Diffuse Large B-Cell Lymphoma (DLBCL) progressive disease. For patients with Creatinine Clearance ≥ 30 mL/min but < 60 mL/min, lenalidomide 10 mg (max escalation is 15 mg).
1883481|NCT01197560|Drug|Gemcitabine|Suggested starting doses and regimens for Gemcitabine is 1,250 mg/m2 IV days 1, 8, 15 every 28 days for 6 Cycles or 1,000 mg/m2 IV days 1 and 15 every 28 days for 6 Cycles
1883482|NCT01197560|Drug|Oxaliplatin|Suggested starting dose and regimen for Oxaliplatin is 100 mg/m2 IV day 1 for 21 days for 6 Cycles
1883483|NCT01197560|Drug|Rituximab|Suggested starting dose for Rituximab is 375 mg/m2 IV days 1, 8, 15, 22 during Cycle 1, and if stable disease at Week 12, also on Day 1 of Cycles 4, 6, 8, and 10 (CD20+ patients only)
1883484|NCT01197560|Drug|Etoposide|"Suggested starting doses for Etoposide are:
100 mg/m2 IV days 1-5 every 28 days for 6 Cycles, or 100 mg/m2 IV days 1-3 every 28 days for 6 Cycles, or 50 mg/m2 oral days 1-21 every 28 days for 6 Cycles, or 50 mg/m2 oral days 1-14 every 28 days for 6 Cycles, or 50 mg/m2 oral days 1-10 every 28 days for 6 Cycles"
1883485|NCT01197573|Drug|rTPA Treatment|Ex-vivo treatment of DCD liver or kidney with rTPA (recombinant tissue plasminogen activator)prior to implantation
1883486|NCT01197612|Drug|pulmicort|applied to nasal packing after surgery
1883487|NCT01197625|Biological|Dendritic cell vaccine|Autologous Dendritic Cells Loaded With mRNA From Primary Prostate Cancer Tissue, hTERT and Survivin
1883488|NCT01197664|Drug|paricalcitol|Given PO
1883489|NCT01197664|Radiation|radiation therapy|Undergo radiotherapy
1883490|NCT01197664|Other|laboratory biomarker analysis|Correlative studies
1883491|NCT01197664|Drug|fluorouracil|Given PO
1883492|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily
1883493|NCT01197755|Drug|fostamatinib|fostamatinib 100 mg twice daily/150 mg once daily
1883494|NCT01197755|Drug|placebo|Placebo twice daily
1883495|NCT01197768|Behavioral|Nutrition Intervention|Participants randomized to the intervention group receive a comprehensive nutrition assessment and a in-home intervention with follow-up calls from a Registered Dietician who will addresses their risk for becoming under-nourished at multiple levels.
1883496|NCT01197781|Drug|FOSTAMATIN|Oral tablets - single dose
1883497|NCT01197781|Drug|Verapamil|Oral tablets - administered 3 times daily over 4 days
1883498|NCT01197794|Drug|AZD1981|AZD1981 twice daily
1883499|NCT01197794|Drug|AZD1981|AZD1981 once daily
1883500|NCT01197794|Drug|Placebo|Placebo to match AZD1981
1883501|NCT01197807|Procedure|Bulb Suctioning|Bulb suctioning of the mouth then the nose immediately following delivery
1883502|NCT01197807|Procedure|Wiping|Gentle wiping of mouth then nose with a soft cloth immediately following delivery
1883503|NCT01197820|Device|MRI|"Patients will have a regular hepatic or kidney MRI investigation; we will add our sequences on their initial protocol. At first, one thermometry sequence is performed before angular correction is achieved with the following parameters: FOV=300 mm, matrix=96*96, TE/TR=18/72 ms, 67 lines/TR, Sense factor=1.4, 5 slices (4 coronal et 1 sagittal), 30° Flip angle.
In order to determine the main direction of motion, a set of 200 images are acquired during motion with two interleaved orthogonal slices (one coronal and one sagittal) centered on the region of interest, with the read out direction aligned with the head-feet direction. True-fisp images are acquired during 40 seconds with the following parameters: FOV=400 mm, matrix=128*109, TE/TR=1.2/2.43 ms, 60° flip angle, and 6 mm slice thickness.
Then the tested software proposes an angular correction to minimize out of plane motion. For each set of orientations, MR thermometry is performed"
1883504|NCT01197833|Drug|endovenous ablation+polidocanol injectable microfoam 0.125%|All components except API
1883505|NCT01197833|Drug|Endovenous ablation+polidocanol injectable microfoam 1.0%|endovenous ablation to target vein, followed by injection of polidocanol injectable foam 1.0%
1883506|NCT01197833|Drug|Endovenous ablation+polidocanol injectable foam 2.0%|Endovenous ablation to target vein followed by injection of polidocanol injectable foam 2.0%
1883507|NCT01197846|Drug|Quetiapine|quetiapine 300 mg or 600 mg
1883508|NCT01197846|Drug|Placebo|Placebo
1883509|NCT01203943|Drug|CC-930|CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
1883510|NCT01203943|Other|Placebo|Placebo
1883511|NCT01203943|Drug|CC-930|CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
1883512|NCT01203943|Drug|CC-930|C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
1883513|NCT01203956|Device|SmartFlex|Device used with smartflex engaged.
1883514|NCT01203956|Device|Standard|
1883515|NCT01203969|Procedure|Single port laparoscopic surgery|laparoscopic surgery in which all the instrument was entered into the abdominal cavity through the single port in the umbilicus
1883516|NCT01203969|Procedure|Conventional laparoscopic surgery|laparoscopic surgery in which each of the instrument were entered into the abdominal cavity through the multiple port in multiple quadrants of abdomen
1883517|NCT01203982|Drug|Rosuvastatin|Rosuvastatin 5mg/day for one year
1883518|NCT01203982|Drug|Rosuvastatin|Rosuvastatin 40mg/day for one year
1883519|NCT01203995|Behavioral|Nutrition information|Brief nutrition education with take home reference materials and portion size tools
1883849|NCT01208064|Other|pharmacological study|
1883522|NCT01204008|Procedure|aggressive discectomy|a large open incision with aggressive removal of the disc fragments and curettage of the disc space
1883523|NCT01204021|Behavioral|Tai Chi Chih|12 weeks of weekly classes of Tai Chi Chih
1883524|NCT01204021|Behavioral|Stress Education Control|Weekly meetings, for 2 hours for 12 weeks discussing issues related to stress education.
1883525|NCT01204034|Drug|Inuvair|6 µg formoterol and 100 µg beclometasone dipropionate combination spray pMDI aerosol
1883526|NCT01204060|Other|Nasal allergen challenge|Subjects will receive a nasal spray containing an allergen to which they are allergic
1883527|NCT01204060|Other|Nasal placebo challenge|Subjects will receive a nasal spray with allergen diluent
1883528|NCT01204073|Drug|TAK-441|"TAK-441 will be administered as an oral tablet as follows:
Patients enrolled in the dose escalation cohorts will receive:
A single-dose administration on Day 1, followed by a 1-week washout period during which pharmacokinetics is assessed
Continuous daily dosing on Days 8 through 28 in Cycle 1
In subsequent cycles, continuous daily dosing over 21 days, repeated continuously
Patients enrolled in the expansion cohorts will receive continuous daily dosing on Days 1 through 21 of each 21-day cycle"
1883529|NCT01204086|Drug|Venlafaxine|The initial dose of venlafaxine was 37.5 mg once daily for 4 days titrated to 75 mg once daily, which could be increased by 75 mg in divided doses to a maximal daily dose of 225 mg.
1883530|NCT01204086|Drug|Fluoxetine|The initial dose of fluoxetine was 20 mg once daily, which could be increased by 20 mg in divided doses to a maximal daily dose of 80 mg.
1883531|NCT01204099|Drug|Docetaxel|
1883532|NCT01204099|Drug|PX-866|
1883533|NCT01204112|Drug|Tasocitinib (CP-690,550) plus Rifampin|Period 1, Day 1: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 1-7: Rifampin 600 mg (single oral dose) q24h Period 2, Day 8: Tasocitinib (CP-690,550) 30 mg (single oral dose) as six 5 mg tablets Period 2, Day 9: No treatment (discharge)
1883534|NCT01204125|Drug|paclitaxel|"Pharmaceutical form:solution for infusion
Route of administration: intravenous"
1883535|NCT01204125|Drug|Iniparib (SAR2405550 -BSI-201)|"Pharmaceutical form : solution for infusion
Route of administration :Intravenous"
1883536|NCT01204138|Drug|Apremilast|Apremilast 30mg BID
1883537|NCT01204138|Drug|Placebo|Placebo BID
1883538|NCT01204151|Behavioral|discrete-trial training|
1883539|NCT01204164|Drug|TG02 citrate|TG02 citrate capsules given orally.
1883540|NCT01204164|Drug|Carfilzomib|Carfilzomib per PI
1883541|NCT01204164|Drug|Dexamethasone|Dexamethasone (Oral or IV)
1883542|NCT01204177|Drug|BAY86-9766 MEK Inhibitor + Sorafenib|All patients who meet the entry criteria will receive BAY86-9766 50mg (2x20mg + 1x10mg capsules) twice daily in combination with sorafenib 800 mg (2x200 mg tablets bid). During the first 3 weeks they will receive a reduced dose of sorafenib: 600 mg / daily (1x200mg tablet in the morning + 2x200mg tablets in the evening) daily. This dose will be increased to the standard dose of 800 mg (400 mg bid) if no major side effects occur. Treatment until PD or until one of the withdrawal criteria for this study is met as described in the protocol (e.g. radiological progression or clinical progression)
1883543|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.55 mg ethinyl estradiol (EE) + 2.1 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
1883544|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.35 mg ethinyl estradiol (EE) + 0.67 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
1883545|NCT01204190|Drug|Gestodene/EE Patch (BAY86-5016)|0.275 mg ethiny estradiol (EE) + 1.05 mg gestodene (GSD) per patch; 3 treatment cycles; 21 days per treatment cycle, i.e. 3 x 7 days patch-wearing phase and a patch-free interval of 7 days
1883546|NCT01204203|Drug|Zometa|Zoledronic acid will be administered IV on the first day of a 21 day cycle at a concentration of 4 mg. The treatment will take about 30-60 minutes with the infusion lasting about 15 minutes.
1883547|NCT01204216|Biological|re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 month"
1883548|NCT01204216|Biological|Re-infusion of biotin labeled cells|"Subjects will participate in experiments involving re-infusion of biotin-labeled cells in which a small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate.
These experiments require a series of small, precisely timed post-infusion blood samples over a period of 4 months, with each subject undergoing the procedure twice separated by an interval of at least 8 months.
small volume (< 10 ml) of autologous, biotinylated erythrocytes will be re-infused to determine cell lifespan and in vivo HbA1c formation rate."
1883549|NCT01204216|Behavioral|Diabetes education/diabetes medication adjustment|Between the initial 3-4 month trial period and the second infusion of biotin labeled cells approximately 8 months later,subjects will receive diabetes education from a CDE. In addition,if needed, diabetes medications may be adjusted by the study endocrinologist to improve subject's glycemic control.
1883550|NCT01204229|Behavioral|Motivational and Cognitive Intervention for Drinkers (MCID)|Integrate social anxiety/ depression and drinking intervention
1883551|NCT01204229|Behavioral|Brief Motivational Intervention (BMI)|Integrate drinking intervention
1883552|NCT01204242|Drug|Placebo|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.
Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
1883553|NCT01204242|Drug|Lidocaine|"ALL subjects will receive lidocaine up to 1.5mg/kg IV (in the vein) as a rapid injection.
Then the continuous IV infusion of the study medication (containing lidocaine 8 mg/ml or placebo) will be started and will continue for up to two hours in the recovery room."
1883559|NCT01204268|Procedure|Sev-I group|Sevoflurane will be given before the cerebral artery clip as a preconditioning procedure for the coming ischemia-reperfusion injury.
1883560|NCT01204268|Procedure|Sevo continuous inhalation|Patients will receive the anesthesia with continuous inhalation of sevoflurane.
1883561|NCT01205776|Device|Percutaneous Coronary Intervention|Those patients receiving the XIENCE PRIME™ EECSS or XIENCE V® EECSS or XIENCE Xpedition™ EECSS or XIENCE PRO EECSS
1883562|NCT01205776|Procedure|CABG|Those patients receiving CABG
1883563|NCT01205802|Procedure|MHV reconstruction|MHV reconstruction with PTFE or homograft
1883564|NCT01205815|Other|Tissue and blood collection|Tissue will be obtained from a previous biopsy if available, or if unavailable, tissue will be collected from a scheduled biopsy. About3-4 teaspoons of blood will be collected.
1883565|NCT01205828|Drug|Temozolomide|Temozolomide 150 mg/m2/day PO Days 1-5 every 28 days
1883566|NCT01205828|Drug|ABT-888|ABT-888 40 mg BID PO Days 1-7 every 28 days
1883567|NCT01205841|Procedure|Ottawa Ankle and Foot Rules|As previously published
1883568|NCT01205841|Procedure|Buffalo Rule|As previously published
1883569|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + application of a tuning fork to the distal fibula and tibia|As previously published
1883570|NCT01205841|Procedure|Thompson Test|As previously published
1883571|NCT01205841|Procedure|Palpation of the fibula|Palpation of the fibula over its entire length.
1883572|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + palpation of the cuboid bone|As previously published
1883573|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + palpation over the deltoid ligament|As previously published
1883574|NCT01205841|Procedure|Malleolar Zone Algorithm|As previously published
1883575|NCT01205841|Procedure|Low Risk Exam|As previously published
1883576|NCT01205841|Procedure|Bernese Ankle Rules|As previously published
1883577|NCT01205841|Procedure|Ottawa Ankle and Foot Rules + swelling of the distal fibula|As previously published
1883578|NCT01205854|Device|Ultrasonography|Standardized ultrasonographic assessment of 32 joints, assessed for both grey scale synovitis and power doppler signal, at each visit. Dose escalations based on DAS response in combination with change in US score. All joints with US Power Doppler signal are targets for intra articular injections.
1883579|NCT01205867|Drug|AZD8848|Nasal spray solution, intranasal, single ascending doses, 1.4 - 60 μg
1883582|NCT01205893|Device|Neovasc Reducer|Implantation of the Reducer
1883583|NCT01205893|Device|Control|Control - No device implanted
1883584|NCT01205906|Behavioral|Internet-based guided self-help for tinnitus|Internet-based self-help for tinnitus: provided via Internet, duration of 10 weeks
1883585|NCT01205906|Behavioral|Cognitive-behavior group therapy for tinnitus|Cognitive-behavior group therapy for tinnitus: weekly group sessions of 90 minutes, duration of 10 weeks
1883586|NCT01205906|Other|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
1883587|NCT01205919|Behavioral|Internet-based guided self-help for tinnitus|Internet-based guided self-help for tinnitus: provided via Internet, duration of 10 weeks
1883588|NCT01205919|Other|Internet discussion forum|Tinnitus-specific internet discussion forum over 10 weeks (no therapeutic intervention)
1883589|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 5mg/day (5mg, once daily) for 34 to 35 days (±4 days)
1883590|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 7.5mg/day (7.5mg, once daily) for 34 to 35 days (±4 days)
1883591|NCT01205932|Drug|Rivaroxaban (BAY59-7939)|Daily dose: 10mg/day (10mg, once daily) for 34 to 35 days (±4 days)
1883592|NCT01205932|Drug|Enoxaparin|daily dose: 40mg/day (20mg each, twice daily) for 6 to 7 days (±2 days)
1883593|NCT01205958|Procedure|acupuncture|Over an three-week period, one group(n=15) gets western medicine treatment(drug medication); another group(n=15) gets oriental medicine treatment(individualized needling 2-3 times a week); the other group(n=15) gets western medicine plus oriental medicine treatment for 3 weeks
1883594|NCT01205971|Behavioral|Motivational Interviewing|Motivational interviewing is delivered by trained public housing residents, every 3 months for a total of 8 sessions over 24 months.
1883595|NCT01205971|Behavioral|Dental Preventive Services|Written oral health educational materials
1883596|NCT01205984|Drug|methylprednisolone|Patients enrolled in the study were given either oral amoxicillin/clavulanate (AMX/C) or metylprednisolone (MP) (group MP) or AMX/C and placebo (group P) twice daily using a random allocation chart based on a table of random numbers. Oral AMX/C was administered 45/6.4 mg/kg/d (maximum 2000/285 mg/d) for 30 days for both groups. Oral MP was administered for the first 15 days: 1 mg/kg/d (maximum 40 mg/d) for 10 days, 0.75 mg/kg/d for 2 days, 0.5 mg/kg/d for 2 days, and 0.25 mg/kg/d for 1 day. Placebo tablets contained lactose and were of same size and color as MP tablets.
1883597|NCT01205997|Drug|Fentanyl|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
1883598|NCT01205997|Drug|placebo(distilled water)|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
1883676|NCT01206530|Drug|5-fluorouracil|"Dose: 2,400mg/m2 Route: IV continuous infusion over 46 hours immediately following bolus injection.
Treatment Administration: Days 1-2"
1883677|NCT01206530|Drug|Bevacizumab|
1883850|NCT01208064|Procedure|quality-of-life assessment|
1883599|NCT01205997|Drug|magnesium sulphate|Ninety patients 20-60 yr old American Society of Anesthesiologists ( ASA) physical status I or II, scheduled for femur surgery under spinal anesthesia, were studied in a prospective, double-blinded, randomized way. The patients were randomly allocated to one of three groups of 30 each. The magnesium group (groupM) received bupivacaine 15mg combined with 0.5ml magnesium 10%,The fentanyl group (group F) received bupivacaine 15mg combined with0.5 ml fentanyl[25microgram] and The placebo group (group P) received bupivacaine 15mg combined with 0.5ml distilled water(intrathecally) for each three groups 5 minutes prior to surgery)
1883600|NCT01206010|Drug|Varenicline|Participants will increase varenicline dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard dose of 1.0 mg twice daily.
1883601|NCT01206010|Drug|Placebo|Participants will increase placebo dose by 0.5 mg twice daily every three days to a maximum of 2.5 mg twice daily. This increased dose will be continued for 3-weeks before being reduced to the standard varenicline dose of 1.0 mg twice daily.
1883602|NCT01206010|Drug|Varenicline|All participants will receive the standard dose of Varenicline (14 weeks): 0.5 mg once daily for days 1-3, 0.5 mg twice daily for days 4-7, and then a continuation dose of 1.0 mg twice daily. In addition to this participants will use an tailored varenicline/placebo dose up to maximum of 2.5 mg twice daily for 3 weeks.
1883603|NCT01206023|Other|NA-NOSE artificial olfactory system|NA-NOSE is an artificial olfactory system that is based on nanomaterials and connected with machine learning. NA-NOSE can diagnosis diseases or disorders based on volatile biomarkers that are emitted from exhaled breath, blood, or from clinical tissue.
1883604|NCT01206036|Drug|Docetaxel|DL 1: Docetaxel 60mg/m^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
1883605|NCT01206036|Drug|Temsirolimus|DL 1: Docetaxel 60mg/m^2, Temsirolimus 15mg. DL 2: Docetaxel 60mg/m^2, Temsirolimus 25mg. DL 3: Docetaxel 75mg/m^2, Temsirolimus 25mg. One cycle is defined as a 3 week period (21 days) where docetaxel is given on day 1, and temsirolimus on days 1, 8 and 15.
1883606|NCT01206049|Drug|Gemcitabine|1,000 mg/m2 on day 1 of a 2 weeks cycle
1883607|NCT01206049|Drug|Oxaliplatin|60 mg/m2 on day 1 of a 2 weeks cycle
1883608|NCT01206049|Drug|Capecitabine|1,000 mg/m2 x 2 daily on days 1-7 of a 2 weeks cycle
1883609|NCT01206049|Drug|Panitumumab|6 mg/kg on day 1 of a 2 weeks cycle
1883610|NCT01206049|Drug|Bevacizumab|10 mg/kg on day 1 of a 2 weeks cycle
1883613|NCT01206075|Drug|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with Mozobil alone will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
1883614|NCT01206075|Drug|Mozobil|Previously mobilized splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive low doses G-CSF subcutaneously (starting at 2.5µg/kg/day and adjusted to the degree of leukocytosis), and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses. Previously non-splenectomized patients who failed to yield sufficient numbers of cells with G-CSF in the previous study will receive G-CSF at 10µg/kg/day subcutaneously for 4-7 days, and Mozobil at 240µg/kg starting on the 4th or 5th day of G-CSF, followed by one to three leukaphereses.
1883615|NCT01206075|Drug|Mozobil|Up to sixteen patients (splenectomized and non-splenectomized) who were not previously mobilized will receive Mozobil at 240µg/kg for one to three days, followed by one to three leukaphereses.
1883616|NCT01206088|Drug|nilotinib|administration of nilotinib as 2nd line
1883617|NCT01206101|Drug|liraglutide|Dose escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide dose for 52 weeks. Injected subcutaneously(under the skin) once daily.
1883618|NCT01206101|Drug|placebo|Dose escalation escalation of liraglutide up to 1.2 to 1.8 mg before islet cell transplant until the planned number of transplanted subjects is complete or subject is transplanted. After islet cell transplant, subjects continue to receive the reached liraglutide placebo dose for 52 weeks. Injected subcutaneously (under the skin) once daily.
1883619|NCT01206114|Other|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
1883620|NCT01206114|Other|Follow-up|Questionnaires, interviews, nasal/oral and serum samples, register data
1883621|NCT01206127|Other|Postoperative positioning: Bed rest|Patients in this group should be lying down facing up 2 hours postoperatively
1883622|NCT01206127|Other|Postoperative positioning: Sitting up|Patients in this group should be sitting up in a chair 2 hours postoperative
1883623|NCT01206140|Other|Laboratory Biomarker Analysis|Correlative studies
1883624|NCT01206140|Drug|Selumetinib|Given PO
1883625|NCT01206140|Drug|Temsirolimus|Given IV
1883626|NCT01206153|Drug|metformin|
1883627|NCT01206166|Drug|Olimel (5.7%E / N9E)|OLIMEL(Amino Acids, Dextrose, Lipids, with / without Electrolytes) is indicated for parenteral nutrition for adults when oral or enteral nutrition is impossible, insufficient or contraindicated.
1883628|NCT01206179|Biological|cell injection|Injection of mesenchymal cells in fractured zone
1883629|NCT01206205|Drug|Lenalidomide, Bortezomib|"Induction:
3 cycles of 21 days of Dexamethasone : 40 mg/j, days 1, 8 et 14 Bortezomib (Velcade®) : 1,3 mg/m2/d, days 1, 4, 8, et 11 Lenalidomide (Revlimid®) :25 mg/d, days 1 to 14
Consolidation (2 months After ASCT):
2 cycles of 21 days of Lenalidomide (Revlimid®) 25 mg/j, days 1 à 14 Bortezomib (Velcade®) 1,3 mg/m2/d, days 1, 4, 8, et 11 Dexamethasone 40 mg/j, days 1, 8 et 14
Maintenance Phase:
3 to 8 weeks after consolidation. Cycle length: 28 days Lenalidomide (Revlimid®) 10 mg/d until 12 months"
1883630|NCT01206218|Drug|FLOT Regimen|FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
1883631|NCT01206218|Drug|FLO Regimen or FLOT Regimen|FLO Regimen: 5-fluorouracil, Oxaliplatin FLOT Regimen: 5-fluorouracil, Oxaliplatin, Docetaxel
1883632|NCT01206257|Drug|Iopromide (Ultravist, BAY86-4877)|Intravenous/intraarterial digital subtraction angiography (DSA); Generally doses of up to 1.5 g iodine per kg body weight are well tolerated.
1883633|NCT01206270|Drug|Testosterone undecanoate|Testosterone undecanoate 1000mg (in 4 ml of castor oil injections) at baseline (0-week), 6-week, 18-week, 30-week
1883634|NCT01206270|Drug|Castor Oil|4 ml of Castor Oil injected at baseline (0-week), 6-week, 18-week, 30-week.
1883635|NCT01206283|Procedure|Modified Lund concept|"After surgical evacuation of intracranial mass lesion and clipping of aneurysm the objectives were achieved:
Reduction of cerebral energy metabolism with fentanyl (2-5 µg/kg/h) and thiopenthal (0.5-3 mg/kg/h);
Maintenance of colloid osmotic pressure with administration of red cell and albumin/plasma transfusions to maintain Hb/s 125-140 g/L and Alb/s ≈40 g/L;
Reduction of capillary hydrostatic pressure with α2-agonist clonidine (0.4-0.8 µg/kg, 1 x 4-6 iv.) and maintaining normovolaemia;
Reduction of mean arterial pressure and neuroprotection with Nimodipine infusion 5 ml per hour for 21 days and Urapidil 200 mg /200 ml, 7-10 ml/h.
Control of ICP, which can be in majority of patients, kept at values below 15 mmHg."
1883636|NCT01206283|Procedure|Cerebral perfusion pressure-targeted therapy|"ICP monitoring using an external ventricular drain and CSF drainage as a first measure if ICP was increased (over 15-20 mmHg);
Maintenance of CPP over 70-80 mmHg (Triple 'H' therapy = 3L/24 hours including 1L of colloids - 5% albumin; drugs = dopamine, dobutamine);
No hyperventilation if ICP was under 20-25 mmHg and hyperventilation as a third measure if ICP was increased;
Osmotherapy (20% manitol, bolus 150-350 ml or 10% manitol, 50 ml/h for 10 hours and standard electrolytes [Na, Cl and K]);"
1883637|NCT01206296|Drug|Intraperitoneal Gemcitabine|"Standard pancreatic resection followed by heated intraoperative intraperitoneal gemcitabine 1000 mg/m2
Adjuvant intraperitoneal gemcitabine treatments (days 1, 8 and 15 of each 4-week cycle) for 6 cycles"
1883638|NCT01206322|Drug|Intranasal insulin|The acute effects of a single 40-IU dose of intranasal insulin
1883639|NCT01206322|Drug|Placebo|The acute effects of intranasal sterile saline.
1883640|NCT01206335|Drug|OHR/AVR118|OHR/AVR118 given subcutaneously at 4mL per day
1883641|NCT01206348|Drug|Minocycline, Clindamycin, Tretinoin, Benzoyl Peroxide|Solodyn 1 tablet, Q day Ziana Gel, topical Q am Triaz FC, topical Q night
1883642|NCT01206361|Drug|XALACOM|Xalacom eye drops
1883643|NCT01206361|Drug|Duotrav|Duotrav eye drops
1883644|NCT01206361|Drug|Ganfort|Ganfort eye drops
1883645|NCT01206387|Drug|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
1883646|NCT01206387|Drug|placebo comparator|Placebo administered to affected area twice a day for 28 days
1883647|NCT01206413|Dietary Supplement|Low glycemic index diet|
1883648|NCT01206413|Dietary Supplement|High glycemic index diet|
1883649|NCT01206413|Other|Home-based exercise intervention|
1883650|NCT01206413|Other|Non-exercisers|
1883651|NCT01206439|Drug|nebivolol|nebivolol 5 or 10 mg oral, daily
1883652|NCT01206452|Drug|Prednisone|60mg of oral prednisone 2 days before procedure, day of procedure, and 1 day after procedure
1883653|NCT01206452|Other|Placebo|60mg placebo pill given 2 days before procedure, day of procedure, and 1 day after procedure
1883654|NCT01206452|Procedure|Ablation Procedure|Atrial Fibrillation (AF) ablation
1883655|NCT01206465|Drug|pralatrexate|Given IV
1883656|NCT01206465|Drug|fluorouracil|Given IV
1883657|NCT01206465|Other|laboratory biomarker analysis|Correlative studies
1883658|NCT01206465|Genetic|DNA analysis|Correlative studies
1883659|NCT01206465|Other|high performance liquid chromatography|Correlative studies
1883660|NCT01206465|Genetic|polymerase chain reaction|Correlative studies
1883661|NCT01206465|Genetic|nucleic acid sequencing|Correlative studies
1883662|NCT01206465|Other|pharmacological study|Correlative studies
1883663|NCT01206465|Other|pharmacogenomic studies|Correlative studies
1883664|NCT01206465|Genetic|polymorphism analysis|Correlative studies
1883665|NCT01206478|Drug|Amitriptyline|Amitriptyline 1 mg/kg once daily at bedtime.
1883666|NCT01206478|Drug|Placebo|Placebo (looks like study drug but has no active ingredients) once daily at bedtime.
1883667|NCT01206478|Drug|Megestrol|At Visit 2, after participating in the study for ten weeks, children will receive a prescription for the appetite stimulant megestrol. The dose each child will receive depends on their age and weight. The dose of megestrol is 6 mg/kg divided into two doses per day.
1883668|NCT01206504|Biological|MGAWN1|Humanized monoclonal to West Nile virus. Dose=30mg/kg
1883669|NCT01206517|Drug|Asenapine 2.5 mg|Asenapine tablet, sublingually (SL), 2.5 mg b.i.d. on Days 1-6 and one 2.5 mg tablet, SL, on Day 7.
1883670|NCT01206517|Drug|Asenapine 5 mg|Asenapine tablet, SL, 5 mg b.i.d. on Days 1-6 and one 5 mg tablet, SL, on Day 7.
1883671|NCT01206517|Drug|Asenapine 10 mg|Asenapine tablets, SL, in a rising dose schedule to 10 mg b.i.d. (with a single 10 mg dose on final day). For Cohorts 3b, 3c and 3d, rising dose schedule begins with asenapine 5 mg b.i.d. on Day 1 and dosing occurs through Day 8. For Cohort 3a, rising dose schedule begins with asenapine 2.5 mg b.i.d. on Day 1 and dosing occurs through Day 12.
1883672|NCT01206530|Drug|Hydroxychloroquine|Dose:600 or 800 mg Route:PO daily Treatment Administration: Daily
1883673|NCT01206530|Drug|Oxaliplatin|Dose: 85mg/m2 Route: IV infusion over 2 hours Treatment Administration: Day 1
1883674|NCT01206530|Drug|Leucovorin|Dose: 400mg/m2 Route IV infusion over 2 hours Treatment Administration: Day 1
1883675|NCT01206530|Drug|5-fluorouracil|Dose: 400mg/m2 Route: IV bolus immediately following leucovorin Treatment Administration Day 1
1883678|NCT01206543|Other|Intraoperative imaging using 1.5T MRI|Intraoperative imaging and determination of degree of resection / complete tumor removal
1883679|NCT01206569|Drug|Long-acting tacrolimus (Advagraf, Astellas Pharma)|Long-acting tacrolimus (Advagraf, Astellas Pharma) will be started at single daily dose of 0.15-0.2 mg/kg/day for 6 months.
1883680|NCT01206582|Biological|Hemin|10 iv infusions for 8 weeks
1883681|NCT01206582|Biological|Albumin|10 iv infusions for 8 weeks
1883682|NCT01206595|Drug|SKY0402|Single dose of SKY0402 administered as a nerve block
1883683|NCT01206595|Drug|Bupivacaine HCl|Single dose of 125 mg administered as a nerve block
1883684|NCT01206608|Drug|SKY0402 + bupivacaine HCl|Low-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
1883685|NCT01206608|Drug|Mid-dose SKY0402 + bupivacaine HCl|Mid-dose SKY0402 administered locally into one breast pocket and 75 mg bupivacaine HCl administered locally into the other breast pocket
1883686|NCT01206634|Procedure|Regenerative injection therapy|Injections of 1cc of a 15% dextrose and 0.6% lidocaine solution free of adrenaline in each of eight administration sites in the collateral ligaments and a 5 cc injection of a 20% dextrose and 0.5% lidocaine without adrenaline solution inside the knee joint.
1883687|NCT01206634|Behavioral|Exercise|the exercise program consists of 4 strengthening exercises for which participants are asked to perform 3 sets of 10 repetitions daily
1883688|NCT01206647|Drug|Metformin and Saxagliptin|Metformin 500mg/daily titrated to 2000mg/d in 4 Weeks (continued for 20 weeks) Saxagliptin 5 mg daily over complete trial
1883689|NCT01206660|Drug|Desoximetasone Spray 0.25%|Desoximetasone topical spray 0.25% administered to affected area twice a day for 28 days
1883690|NCT01206660|Drug|placebo|Placebo administered to affected area twice a day for 28 days
1883691|NCT01206673|Other|Blood sampling|One blood sampling is required for the research
1883692|NCT01206686|Behavioral|Planning Prompt|Patients were prompted to write down a planned date (and in some cases time) for receiving a flu shot.
1883693|NCT01206686|Behavioral|Default Appointment|Patients were given a suggested date and time for receiving a flu shot.
1883694|NCT01206686|Behavioral|Control|Patients were provided with basic information (present in all conditions) about when and where they could receive a flu shot, but they were given no further treatment.
1883695|NCT01206699|Drug|corticoid (altim® 1.5 ml)|Active arm : anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with corticoid (altim® 1.5 ml)
1883696|NCT01206699|Drug|physiological solution (1.5 ml)|Control arm: anesthetic bloc (1 ml of lidocaïne 1%) immediately followed with physiological solution (1.5 ml)
1883697|NCT01206725|Other|Exercise|"Moderate Intensity Exercise Group (ME). Exercise equivalent to the current exercise guidelines. In total 210 minutes per week of continuous moderate intensity (70% HRmax) exercise. Home based training.
Aerobic interval training (AIT). Exercise equivalent to the current guidelines achieved through high-intensity interval training.The exercise starts with warming-up for 10-min at 70% of HRmax before performing 4x4min intervals at 90-95% of HRmax, with 3-min active recovery at 70% of HRmax between each interval, and a 5-min cool-down period, giving a total of 40-min."
1883698|NCT01206738|Behavioral|Persuasive communication|The persuasive intervention aimed to reinforce the GP's beliefs about the positive consequences of managing sore throat without prescribing antibiotics.
1883699|NCT01206738|Behavioral|Action plan|This intervention was an action plan, supporting the GP to deal with two difficult prescribing situations: 1) a distressed patient (or often distressed parent of a child patient) 2) a patient demanding an antibiotic
1883700|NCT01206738|Behavioral|General intervention|No additional information was provided; the general information was the information already available to GPs about antibiotic prescribing.
1883701|NCT01206751|Other|Chest imaging technique and case presentation|
1883702|NCT01206764|Drug|RAD001|
1883703|NCT01206777|Drug|Rituximab|Dose 2 of Rituximab IVPB will be started at a rate of 100 mg/hr for the first 15 minutes. If tolerated, the remainder of the bag will be infused over 45 minutes.
1883704|NCT01206790|Behavioral|NET|Narrative Exposure Therapy for traumatized survivors of organized violence
1883705|NCT01206803|Drug|Ovarian stimulation in a GnRH-antagonist protocol|Long-acting FSH 150µg & daily recombinant FSH 200 IU, GnRH-antagonist 0.25mg, 5,000-10,000 IU urinary hCG, triptorelin 0.2mg, vaginal progesterone
1883707|NCT01206829|Behavioral|8-session CBTcourse|Hearing impaired workers voluntarily sign up for an 8 session cognitive therapy course. The study has a waiting list control group design. Participants will be randomized assigned to either an experiment group that will be offered to start on an immediate course, or a control group that will be offered the same course 12 months later.
1883708|NCT01206829|Behavioral|8 session cognitive behavioral therapy|8 sessions cognitive behavioral therapy in group
1883709|NCT01206842|Other|Training in Affect Recognition|A 12-session social cognitive training programming covering emotion perception and social perception administered in a group setting to up to four participants with schizophrenia at the time
1883710|NCT01206855|Device|MIST Therapy|Low-frequency, non-contact ultrasound system delivering therapeutic ultrasound via a fine saline mist to the wound bed without direct contact of the device with the body.
1883711|NCT01206855|Other|Standard Postoperative Incision Care|Incision cleansing, topical creams, and dressing as needed
1883712|NCT01206868|Procedure|Fenestration|Fenestration of the peritoneum according to the length of the transplanted kidney
1883713|NCT01206868|Procedure|Control|Standard kidney transplantation
1883714|NCT01206881|Drug|pegylated liposomal doxorubicin|35 mg/m2, IV, day 1 every 21 days, 4 cycles
1883715|NCT01206894|Procedure|Transthoracic Ultrasound|1 transthoracic ultrasound will be performed the evening before the thoracic surgery
1883716|NCT01206907|Drug|oxymorphone IR|oxymorphone IR liquid
1883717|NCT01206946|Drug|Betamethasone|A single course of betamethasone (two doses of 12 mg/dose given at 24 hourly intervals)
1883718|NCT01206946|Other|Normal Saline|Two doses of 2ml of normal saline given at 24 hourly intervals
1883719|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 5mg/day (5mg, once daily) for 11 to 12 days (±2 days)
1883720|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 7.5mg/day (7.5mg, once daily) for 11 to 12 days (±2 days)
1883721|NCT01206972|Drug|Rivaroxaban (BAY59-7939)|daily dose: 10mg/day (10mg, once daily) for 11 to 12 days (±2 days)
1883722|NCT01206972|Drug|Enoxaparin|daily dose: 40mg/day (20mg, twice daily) for 10 to 11 days (±2 days)
1883723|NCT01206985|Other|Von Frey electronic|Change in pain threshold testing mechanical stimulation (von Frey electronic)
1883724|NCT01206998|Drug|Vaginal progesterone gel|Subjects will receive daily vaginal progesterone gel provided by Columbia laboratories (1.125g progesterone gel containing 90mg (8%) progesterone)
1883725|NCT01206998|Drug|Placebo vaginal gel|Subjects will receive daily placebo vaginal gel, made of an identical bioadhesive delivery system as the active drug
1883726|NCT01207011|Drug|Amrubicin hydrocloride|AMR was administered i.v. by 35mg/m2 at day 1, 2 and 3 followed by 3 week rest as 1 course.
1883727|NCT01207011|Drug|Docetaxel|DOC was administered i.v. by 60mg/m2 at day 1 followed by 3 week rest as 1 course.
1883728|NCT01207024|Other|knee MRI|knee MRI before surgery (inclusion) and one year after
1883729|NCT01207037|Procedure|blood samples and scintigraphy|at 3 months, 6 months, 12 months, 18 months and 24 months will allow a clinical evaluation and an additional sampling of blood of 5 mL at each visit Scintigraphy at 6 months and 18 months
1883730|NCT01207050|Drug|Ramelteon|8mg capsule taken within one half hour of bedtime each night over the three night study period.
1883731|NCT01207050|Dietary Supplement|Placebo|Control treatment
1883732|NCT01207063|Other|Radiotherapy and concurrent chemo-therapy|Radiotherapy and concurrent chemo-therapy
1883734|NCT01207089|Drug|AZD8329|AZD8329 Oral Solution 20mg/ml
1883735|NCT01207089|Drug|Placebo|Placebo AZD8329 Oral Solution
1883736|NCT01207102|Drug|Abraxane|Abraxane® 100 mg/m2 IV over 30 min days 1,8,15 every 28 days
1883737|NCT01207102|Drug|Carboplatin|area under curve(AUC)=2 over 15 minutes days 1,8,15 every 28 days
1883738|NCT01207115|Drug|ABT-652|ABT-652 capsules - twice daily for 8 weeks. The dose of ABT-652 will depend on the Arm
1883739|NCT01207115|Drug|Placebo|Placebo capsules - twice daily for 8 weeks
1883740|NCT01207115|Drug|Naproxen|Naproxen capsules - twice daily for 8 weeks
1883741|NCT01207128|Drug|Voriconazole, micafungin|Patients will receive either IV micafungin 100 mg or placebo equivalent daily. Intravenous (IV)Voriconazole will be administered at a loading dose of 6 mg/kg every 12 hours for the first 24 hours followed by a maintenance dose of 4 mg/kg every 12 hours. Patients may be switched to oral voriconazole 200 mg BID provided aspergillosis response is achieved and gastrointestinal functions are intact.
1883742|NCT01207180|Other|Phone call follow-up|A nurse will call the patient to counsel patients on their medications and following up with their primary care provider.
1883743|NCT01207180|Other|Satisfaction survey|Patients will be given a satisfaction survey.
1883744|NCT01207180|Other|Control group --- no intervention|Control group
1883745|NCT01207193|Biological|cell injection|injection of mesenchymal cells to bone cyst defect
1883746|NCT01207206|Drug|oral ketamine|"The group will be divided into two pain matched groups of 25 each. One group will receive Ketamine (K group) and the other placebo (P). Both the researchers and the patients will not know to which group they belong. Four days prior to the beginning of the research the patients will document, using an ad-hoc diary, in predetermined hours, four times a day the level (VAS) of pain, sedation and vomiting scores, and other side effects. Pain will be assessed using a Visual Analog Scale (VAS) (0-10).
The documentation will continue throughout the research period. The Ketamine or plaecebo will also be taken in a predetermined hours to avoid an effect of diurnal disruption on pain perception"
1883747|NCT01207219|Behavioral|Yoga therapy|3 sessions per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
1883748|NCT01207219|Behavioral|Aerobic exercise|3 session per week for 12 weeks, total 36 sessions. Each session lasts around one hour.
1883749|NCT01207232|Behavioral|Planning Prompt|A prompt to write down a planned date (or date and time) for getting a flu shot
1883750|NCT01207232|Behavioral|Control Condition|A basic reminder mailing prompted each subject to get their flu shot.
1883751|NCT01207245|Other|Tobramycin time of administration|Random allocation to time of day of administration of tobramycin
1883752|NCT01207258|Behavioral|Motivational Enhancement Therapy|20 minute manual-driven, optionally audio-recorded Motivational Enhancement Training intervention by a MI-trained therapist during their ED visit and a 10-15 minute phone booster at 7 to 10 days.
1883753|NCT01207271|Behavioral|Cognitive Therapy|16 sessions of cognitive therapy administered weekly by a community mental health therapist
1883754|NCT01207271|Behavioral|Supportive-Expressive Psychodynamic Therapy|16 sessions of supportive-expressive psychodynamic therapy administered weekly by a community mental health therapist
1883755|NCT01207284|Other|Physical Therapy|strengthening passive and active stretching balance training gait training
1883756|NCT01207297|Drug|Tacrolimus|"The calcineurin inhibitor is widely administered for organ transplantation，which establish the current method for lupus nephritis (LN).
20 patients with LN were self-assigned the therapy of TAC and prednisone for 12 months. The dosage was adjusted to achieve a whole blood TAC 12 h trough concentration."
1883757|NCT01207297|Drug|cyclophosphamide|20 patients with LN were self-assigned the protolcol of intravenous cyclophosphamide (750mg/m2 per month)/prednisone for six months followed by azathioprine(100mg/day)/prednisone for six months.
1883761|NCT01207323|Drug|MEHD7945A|MEHD7945A will be administered as specified in the individual arms.
1883991|NCT01208441|Procedure|breast biopsy|
1883762|NCT01207336|Device|combined transcranial direct current stimulation and electrical peripheral nerve stimulation|tDCS: 1,2 mA 13 minutes rEPNS (radial nerve): 5 Hz, 0,7 x MT
1883763|NCT01207349|Behavioral|Secondary prevention intervention trial|Close follow-up by nurses, exercise physiologist and dieteticians
1883764|NCT01207349|Behavioral|standard follow up|
1883765|NCT01207375|Behavioral|memory retraining exercises|Memory retraining exercises will be administered on a laptop computer twice a week for 5 weeks (10 training sessions).
1883766|NCT01207375|Behavioral|placebo control memory exercises|Placebo control memory exercises will be administered on a laptop computer twice a week for five weeks (10 placebo control sessions.
1883767|NCT01207388|Drug|Blinatumomab|Continuous intravenous infusion
1883768|NCT01207401|Drug|Lidocaine|1% Lidocaine
1883769|NCT01207414|Drug|iloperidone|Iloperidone tablets supplied at doses of 1 mg, 2 mg, 4 mg, 6 mg, 8 mg, 10 mg and 12 mg to achieve a target dose of 12-24 mg/day for 12 weeks.
1883770|NCT01207427|Drug|Placebo|
1883771|NCT01207427|Drug|ADL5945 0.1 mg|
1883772|NCT01207427|Drug|ADL5945 0.25 mg|
1883773|NCT01207440|Drug|Ponatinib|45 mg dose taken orally once daily
1883774|NCT01207453|Drug|Milnacipran|Milnacipran comes in 50 mg tablets and is taken orally. Participants will gradually be increased to a target dose of 50 mg twice daily.
1883775|NCT01207453|Drug|Placebo|
1883776|NCT01207466|Device|Nelfilcon A investigational contact lens|Investigational, soft contact lens for astigmatism worn on a daily disposable basis.
1883777|NCT01207466|Device|Nelfilcon A commercial contact lens|Commercially marketed, soft contact lens for astigmatism worn on a daily disposable basis.
1883778|NCT01207479|Device|VitalaTM|A 43 day study design has been selected in order to capture meaningful safety and performance data of the Vitala™ device when used with these moldable products.
1883779|NCT01207492|Drug|nilotinib|Taken orally twice daily
1883780|NCT01207505|Behavioral|Enhancing Emotion Regulation|12 week of group therapy 3 modules: 1) mindfulness, 2) emotion regulation, 3)distress tolerance
1883781|NCT01207518|Behavioral|Intervention Group|This group of healthcare organizations will be given the Guide, web-based tools and access to a Guide facilitator throughout the study.
1883782|NCT01207518|Behavioral|Control Group|This group will provide their immunization rates for the base and study years and will provide information on their campaign activities. No other intervention will be provided.
1883783|NCT01207544|Behavioral|Fitball exercise|Supervised fitball exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
1883784|NCT01207544|Behavioral|task-oriented motor training program|Task-oriented motor exercise program session (1 hour per session, 1 session per week, for 8 consecutive weeks), supplemented by daily home exercise program.
1883785|NCT01207557|Behavioral|Standard Education Only|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
1883786|NCT01207557|Behavioral|Standard Education Plus OIDA|50% of non-immunized personnel 4 weeks following start of campaign will be given standard education materials and tested on their confidence with their immunization decision
1883787|NCT01207570|Procedure|Endermotherapy|The subjects will receive a single session of endermotherapy applied to the gastrocnemius/soleus muscle on the more affected side for 5 minutes. The treatment will be conducted by a qualified physiotherapist.
1883788|NCT01207570|Procedure|Passive manual stretching|The subjects will receive a single session of passive manual stretching of the gastrocnemius/soleus muscle on the more affected side. The treatment will be given by a qualified physiotherapist.
1883789|NCT01207583|Other|Non-interventional observational study|Non-interventional observational study
1883790|NCT01207596|Drug|Hydromorphone|Oral hydromorphone extended release, once daily
1883791|NCT01207609|Procedure|Laparoscopic Gastric Plication|The procedure is performed laparoscopic. The greater curvature of the stomach is separated from the greater omentum using a harmonic scalpel starting approximately 3-5 cm from the pylorus and ending at the angle of His. As needed, adhesions to the posterior surface of the stomach may be transected. At least two rows stitches will be placed laparoscopically about the greater curvature of the stomach starting at or near the angle of His and ending in the antrum. A calibration tube or endoscope will be used to maintain a lumen during the procedure, ensuring one exists after the procedure.
1883792|NCT01207622|Drug|Atomoxetine|
1883793|NCT01207622|Drug|Placebo|
1883794|NCT01207635|Procedure|Ductal Lavage Fluid Collection|Procedure of inserting a small catheter into the ductal openings in the nipple and washing out cells from inside the duct.
1883795|NCT01207648|Drug|Rebif®|This is an retrospective cohort study in Pediatric participants including both children (aged less than 12 years) and adolescents (aged 12 to less than 18 years) who were exposed to Rebif® for treatment of demyelinating events (Dose regimen as per investigator's decision)
1883796|NCT01207661|Biological|Mesenchymal Injection|Intra Articular Injection of Mesenchymal cells to the knee joint
1883797|NCT01207674|Other|Summons of patients and filling questionnaire|The study is conducted at the same time by 7 French specialised centres. The recruitment period is comprised between April 2009 and September 2011.For the first stage of the study, an initial evaluation will be performed at the time of recruitment. It consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and half hour, and focused mainly on gambling trajectory and severity, and on psychiatric and addictive comorbidities. The evaluation is completed by a set of self-administered questionnaires focused on cognitive distortions, temperament and character, ADHD, etc.For the second stage of the study, the cohort will be re-evaluated each year, based on the same questionnaires that for initial evaluation. Each participant will be followed-up during 5 years. The study will thus end up in September 2016.
1883798|NCT01207687|Biological|bevacizumab|Given IV
1883799|NCT01207687|Other|laboratory biomarker analysis|Correlative studies
1883800|NCT01207687|Procedure|quality-of-life assessment|Ancillary studies
1883801|NCT01207700|Behavioral|CHW based intervention post ACS|CHW is trained and supervised to provide interventions that could improved adherence to post ACS care
1883805|NCT01207739|Drug|Doxycycline|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: oral Doxycycline 100 mg combined with a placebo b.i.d. for 12 weeks
1883806|NCT01207739|Drug|Clarithromycin and hydroxychloroquine|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: clarithromycin 500 mg combined with hydroxychloroquine 200 mg b.i.d. for 12 weeks
1883807|NCT01207739|Drug|Placebo|After open-label i.v. ceftriaxone 2000 mg qd via a peripheral i.v. catheter: 12 weeks' course of double placebo b.i.d.
1883810|NCT01207765|Drug|indium-111-ibritumomab tiuxetan|1.5mg of 111In Zevalin (containing 5 mCi of 111In) will be used for radioimaging. 111In Zevalin will be administered by a 10 minute slow IV push injection immediately following completion of the rituximab infusion. 111In Zevalin may be injected by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the drug infusion port and the patient. The line must be flushed with at least 10cc of normal saline after 111In Zevalin has been injected.
1883811|NCT01207765|Drug|90Y Zevalin|Each patient will receive a single therapeutic dose of 90Y Zevalin at a dose of 0.4 mCi/kg, capped at a maximum dose of 32 mCi. 90Y Zevalin will be administered intravenously as a slow IV push over 10 minutes. 90Y Zevalin may be directly infused by stopping the flow from the IV bag and injecting the radiolabeled antibody directly into the IV line. A 0.22 micron filter must be on line between the syringe and the infusion port. The line must be flushed with at least 10cc normal saline after 90Y Zevalin has been infused.
1883812|NCT01207791|Behavioral|screening|Brief screening to assess eligibility and collect minimal baseline data
1883813|NCT01207791|Behavioral|assessment|comprehensive substance use assessment
1883814|NCT01207791|Behavioral|referral|referral to treatment if indicated or requested
1883815|NCT01207791|Behavioral|Brief intervention|30-minute brief intervention session in ED
1883816|NCT01207791|Behavioral|booster sessions|two 15-minute booster counseling sessions conducted by telephone
1883817|NCT01207804|Device|ValenTx Endo Bypass System|Patient is implanted with device and followed for 12 weeks
1883818|NCT01207817|Other|Pupillometry|Pupillometry readings will be taken at low, intermediate and high ambient light
1883819|NCT01207830|Device|Endo Bypass System|Subject is implanted with the device for up to 3 years.
1883820|NCT01207843|Behavioral|Imaging|CT image validation and lesion measurement, as well as comparison of different CT phases
1883821|NCT01207856|Behavioral|specific cognitive rehabilitation|"Individual rehabilitation procedures will be focused on attention, executive functions, IPS and working memory. The program will be tailored to each patient cognitive status depending on the impairments identified during the initial assessment while maintaining a systematic work on attention and executive functions. A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed. Sessions will include varied exercises according to complexity and presentation modality, using computerized and paper-and-pencil tasks and metacognitive training. Work will be progressive, depending on the progresses achieved (increase complexity and intensity of the exercises according to success at the previous level of exercises)."
1883822|NCT01207856|Behavioral|non specific cognitive rehabilitation|A total of 50 sessions lasting one hour at a rate of 3 sessions per week for a total period of 4 months will be proposed by group composed to 5 patients
1883823|NCT01207856|Other|no intervention|no intervention
1883824|NCT01207869|Biological|ucMSCs|the ucMSCs suspension(3× 106 cells per kg of the patient's weight) will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
1883825|NCT01207869|Other|Normal saline|the same amount of ucMSCs suspension will be instilled through a 6 French end-hole catheter inserted into the infant's endotracheal tube
1883826|NCT01207895|Device|PET imaging with [18F]-FLT|Up to three [18F]-FLT PET scans; one before beginning treatment, one at week three of treatment, and one at week 11, after completion of treatment but prior to surgery.
1883827|NCT01207895|Drug|[18F]-fluorodeoxythymidine|[18F]-fluorodeoxythymidine is administered intravenously approximately 60 minutes prior to the start of PET image acquisition.
1883828|NCT01207908|Drug|IGF-1|IGF-1 will be administered once daily by subcutaneous injection every morning with breakfast. Duration 6 months.
1883829|NCT01207908|Other|Standard steroid treatment|Will complete all study related procedures and evaluations
1883830|NCT01207921|Drug|Lenalidomide|
1883831|NCT01207934|Dietary Supplement|placebo|saline placebo
1883832|NCT01207934|Drug|low-dose leptin|30mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
1883833|NCT01207934|Drug|high-dose leptin|80mg per day of recombinant methionyl human (r-met hu) leptin for fourteen days
1883834|NCT01207947|Drug|Vardenafil (Levitra, BAY38-9456)|Patients under daily life treatment receiving Levitra according to local drug information.
1883835|NCT01207960|Behavioral|Eye Movement Desensitization and Reprocessing (EMDR)|The intervention consists of three 90-minute sessions of individual psychotherapy. Sessions take place weekly according to a treatment manual.
1883836|NCT01207973|Drug|BI 113823|5 dose-groups of multiple oral doses of BI 113823
1883837|NCT01207986|Radiation|Low dose computed tomography (CT)|
1883838|NCT01207999|Procedure|Collection of cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus DNA testing.
1883839|NCT01207999|Other|Data collection|Questionnaire completion
1883841|NCT01208025|Other|Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)|3 Tesla Magnetic Resonance Imaging (MRI), Multidetector Computed Tomography (MDCT), Ultrasonography (US), Transcranial Doppler (TCD)
1883842|NCT01208038|Drug|Intrinsa Transdermal testosterone patch|300 microgram transdermal testosterone patch, applied twice weekly for 12 weeks
1883851|NCT01208090|Drug|ACT-128800|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
1883852|NCT01208090|Drug|Placebo|ACT-128800 (Dose 1 or Dose 2) or matching placebo administered orally once daily
1883853|NCT01208103|Drug|Capecitabine|750 mg/m2 by mouth twice a day beginning on day 1-14 of 21 day cycle.
1883854|NCT01208103|Drug|Oxaliplatin|130 mg/m2 by vein on day 1 over 2 hours of 21 day cycle.
1883855|NCT01208103|Drug|Bevacizumab|7.5 mg/kg by vein on day 1 over 90 minutes of 21 day cycle.
1883856|NCT01208116|Other|Cardiovascular events|"Coronary intervention
Infarction
Congestive heart failure
Stroke
Cardiac death"
1883857|NCT01208129|Drug|NAB001|nail lacquer, once daily, 52 weeks
1883858|NCT01208129|Drug|Placebo control|nail lacquer, once daily, 52 weeks
1883859|NCT01208142|Other|standard of care treatment|weekly standardized physical therapy and daily wear of an AFO
1883860|NCT01208142|Device|Ankle Flexion Dynasplint|Weekly standardized physical therapy, daily wear of an AFO and nightly wear of the ankle flexion Dynasplint
1883861|NCT01208155|Drug|Fostamatinib|Oral tablets, 50 mg x 2, single dose
1883862|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 1, single dose
1883863|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 2, single dose
1883864|NCT01208155|Drug|Fostamatinib|Oral tablets, 100 mg Batch 3, single dose
1883865|NCT01208168|Drug|NAB001|nail lacquer, once daily, 52 weeks
1883866|NCT01208168|Drug|Vehicle alone|nail lacquer, once daily, 52 weeks
1883867|NCT01208181|Drug|Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
1883868|NCT01208181|Drug|Etoricoxib 90 mg|One tablet orally once daily for 6 weeks.
1883869|NCT01208181|Drug|Placebo to Etoricoxib 60 mg|One tablet orally once daily for 6 weeks.
1883870|NCT01208181|Drug|Placebo to Etoricoxib 90 mg|One tablet orally once daily for 6 weeks
1883871|NCT01208194|Drug|MGN1703|solution, 60 mg, twice a week, until progression
1883872|NCT01208194|Drug|Placebo|solution, 60 mg, twice a week, until progression
1883873|NCT01208207|Drug|Part I - etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 6 weeks
1883874|NCT01208207|Drug|Part I - etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 6 weeks
1883875|NCT01208207|Drug|Part I- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 6 weeks
1883876|NCT01208207|Drug|Part I - Placebo to naproxen 500 mg|Placebo to naproxen 500 mg oral tablet twice daily for 6 weeks
1883877|NCT01208207|Drug|Part II- etoricoxib 60 mg|etoricoxib 60 mg oral tablet once daily for 20 weeks
1883878|NCT01208207|Drug|Part II- etoricoxib 90 mg|etoricoxib 90 mg oral tablet once daily for 20 weeks
1883879|NCT01208207|Drug|Part II- naproxen 1000 mg|naproxen 500 mg oral tablet twice daily for 20 weeks
1883880|NCT01208207|Drug|Part I - Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 6 weeks.
1883881|NCT01208207|Drug|Part I - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 6 weeks.
1883882|NCT01208207|Drug|Part II- Placebo to etoricoxib 60 mg|Placebo to etoricoxib 60 mg oral tablet once daily for 20 weeks.
1883883|NCT01208207|Drug|Part II - Placebo to etoricoxib 90 mg|Placebo to etoricoxib 90 mg oral tablet once daily for 20 weeks.
1883884|NCT01208207|Drug|Part II- Placebo to naproxen 500 mg|Placebo to naproxen 500 mg orally twice daily for 20 weeks.
1883885|NCT01208220|Device|Negative Pressure Wound Therapy|NPWT changed 3 times weekly
1883886|NCT01208220|Biological|Collagenase Ointment|Apply TIW
1883887|NCT01208233|Drug|PF-03049423|1 mg of PF-03049423 daily for 90 days
1883888|NCT01208233|Drug|PF-03049423|3 mg of PF-03049423 daily for 90 days
1883889|NCT01208233|Drug|PF-03049423|6 mg of PF-03049423 daily for 90 days
1883890|NCT01208233|Other|Placebo|Placebo of PF-03049423 daily for 90 days
1883891|NCT01200719|Device|transcranial alternating current stimulation (tACS)|Patients in the tACS group received a total of 15 sessions of brain stimulation. The sessions were conducted on weekdays (from Monday to Friday) for three consecutive weeks. Each session lasted 30 minutes. The alternating current stimulations were generated by a CVFT-MG201 machine. Stimulations were delivered by two U-shaped electrodes (approximately 7 cm2) fixed on the patient's left and right mastoid regions (anode or cathode varied depending on polarity of the alternating current). The frequencies (supra-slow waves: < 1 Hz; theta to gamma), levels of intensities (0 to 3mA), and density function (follows a bell-shaped curve; mean intensity ~ 2.1mA) of the current were delivered according to the manufacturer's pre-set random protocol.
1883892|NCT01200732|Drug|Tadalafil, placebo|20mg tablets, 2 tablets Once daily(i.e 40mg once daily) 20mg placebo 2 tablets once daily
1883893|NCT01200745|Drug|Capsaicin patch|Over an four-week period, the treatment group (n=30) uses capsaicin patch (100 mcg/3cc) at the tender point of neck for 12 hours a day; the control group (n=30) receives Hydrogel patch instead of capsaicin patch.
1883894|NCT01200758|Drug|Rituximab SC|First cycle of rituximab IV infusion (375 mg/m^2) + 7 cycles of rituximab SC (1400 mg; rituximab induction) in administered every 3 weeks. Participants achieving at least PR entered rituximab SC (1400 mg) maintenance therapy once every 8 weeks for 24 months.
1883895|NCT01200758|Drug|Rituximab IV|Eight cycles of rituximab IV infusion (375 mg/m^2; rituximab induction) administered every 3 weeks. Participants achieving at least PR during induction, entered rituximab IV maintenance therapy (375 mg/m^2) once every 8 weeks for 24 months.
1883896|NCT01200758|Drug|Cyclophosphamide|Eight cycles of cyclophosphamide (750 mg/m^2 IV) administered every 3 weeks.
1883897|NCT01200758|Drug|Doxorubicin|Eight cycles of doxorubicin (50 mg/m^2 IV) administered every 3 weeks.
1883898|NCT01200758|Drug|Vincristine|Eight cycles of doxorubicin (1.4 mg/m^2 IV) administered every 3 weeks.
1883899|NCT01200758|Drug|Prednisone/Prednisolone|Eight cycles of prednisone/prednisolone (100 mg/day or 40 mg/m^2/day IV/orally) administered Days 1 to 5 of every 21 days cycle.
1883900|NCT01200771|Procedure|TEP|Intravenous injection of glucose labeled Fluor 18. The patient remains fasted at least 6 hours before the start of the examination. The review lasted 1 hour, during wich the patient should not move.
1883901|NCT01200784|Drug|Nicotinamide|dosage
1883902|NCT01200797|Drug|SJG-136|Given IV
1883903|NCT01200797|Other|laboratory biomarker analysis|Correlative studies
1883904|NCT01200810|Other|placebo|Given orally
1883905|NCT01200810|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
1883906|NCT01200810|Drug|bicalutamide|Given orally
1883907|NCT01200849|Other|Enhanced Label|A prescription drug label that has simplified text, more white space and overall is more patient-friendly.
1883908|NCT01200862|Drug|Investigational new drug company code: BGS649|
1883909|NCT01200862|Drug|Placebo|
1883910|NCT01200875|Procedure|Ultrasound-guided platelet-rich-plasma (PRP) injection|One ultrasound-guided intratendinous or intramuscular PRP injection
1883911|NCT01200875|Procedure|Platelet-Rich Plasma (PRP)|One ultrasound-guided PRP injection
1883912|NCT01200901|Drug|Quetiapine|quetiapine XR 100 - 300 mg (flexible dosing)
1883913|NCT01200914|Device|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|The 'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface' will be deployed at the brachiocephalic stenosis.
1883914|NCT01200914|Procedure|PTA alone without use of the GORE VIABAHN|Subject will receive standard of care PTA alone at the brachiocephalic stenosis without deployment of the'GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface'
1883915|NCT01200927|Other|Physical therapy|Perceptual motor therapy, comparing twice weekly to once weekly home program
1883919|NCT01200992|Biological|EN3348|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
1883920|NCT01200992|Biological|Mitomycin C|Induction: 6 weekly instillations. Maintenance: Monthly instillations to Month 12
1883921|NCT01201005|Dietary Supplement|Hydroxycobalamin|Hydroxycobalamin 400 µg (Vitamin B12 depot, Nycomed Pharma ) is given as a single intramuscular injection
1883922|NCT01201005|Dietary Supplement|Sham injection|needle injection without any substance given
1883923|NCT01201018|Drug|Oshadi D, Oshadi R|Oral administration
1883924|NCT01201044|Drug|Gemcitabine, Nedaplatin, iV|Gemcitabine, Injection, 1000mg/m2, D1 & D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.
1883925|NCT01201044|Radiation|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
1883926|NCT01201044|Radiation|3DCRT|non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.
1883927|NCT01201044|Drug|Gemcitabine，Nedaplatin, BAI|"Drug: Gemcitabine, Nedaplatin, iV
Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI"
1883928|NCT01201057|Drug|0.5% SPL7013 Gel|Vaginal gel
1883929|NCT01201057|Drug|1.0% SPL7013 Gel|Vaginal gel
1883930|NCT01201057|Drug|3.0% SPL7013 Gel|Vaginal gel
1883931|NCT01201057|Other|Placebo Gel|Vaginal gel
1883933|NCT01201096|Radiation|177Lutetium|two cycles of 177Lutetium radioreceptor therapy within two month
1883934|NCT01201096|Procedure|Liver transplantation|about 9 month after finishing the receptor therapy liver transplantation takes place
1883935|NCT01201122|Drug|Mesalamine|"Dosing: The current standard of care for pediatric UC is 75mg/kg/day of mesalamine (Pentasa) and should be in multiplications of 500mg (half sachets).
Patients will be randomized in blocks of six stratified by weight groups: 15- <30 kg, 30-40kg, >40kg.
For body wt. 15- <20kg Arm: Once daily, 1000 mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 500mg (morning) and 500mg (evening).
For body wt: 20- <30 kg Arm: Once daily, 1500mg (morning) and Placebo (0.5 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 500mg (evening).
For Body wt. 30- <40 kg Arm: Once daily, 2000mg (morning) and Placebo (1 sachet) (evening). Arm: Twice daily, 1000mg (morning) and 1000mg (evening).
For body wt. ≥40 kg Arm: Once daily, 3000mg (morning) and Placebo (1.5 sachet) (evening). Arm: Twice daily, 1500mg (morning) and 1500mg (evening)."
1883936|NCT01201148|Device|tDCS (Eldith DC-Stimulator (CE certified))|For participants receiving intermittent tDCS or oscillating TES, one electrode will be placed over the left pF3 electrode site (overlying the left dorsolateral prefrontal cortex and identified on the scalp using an EEG cap based on the 10/20 system) and the other over the right temporal area.
1883937|NCT01201161|Drug|Ranibizumab|Intravitreal injection of ranibizumab 0.05 ml (0.5 mg) one week before pars plana vitrectomy
1883938|NCT01201161|Other|Sham injection|Simulation of intravitreal injection one week before pars plana vitrectomy
1883939|NCT01201174|Other|fermented papaya preparation (FPP)|Hemolysis will be assayed by suspending 3 ml of packed RBC in PBS or in the autologous plasma and overnight incubation in the presence of various concentrations of antioxidants such as fermented papaya preparation (FPP) at 37oC in humidified atmosphere of 5% CO2 in air (10). Following 5 min centrifugation at 800 rpm, the supernatants will collected for Hb determination by measuring the absorbance at 540 nm.
1883940|NCT01201187|Drug|YY-162|YY-162(Ginkgo extract 30mg+Ginseng extract 50mg) 1T/twice a day(bid) for 8weeks, po medication
1883941|NCT01201187|Drug|Placebo|Placebo 1T/twice a day(bid) for 8weeks, po medication
1883942|NCT01201213|Drug|local anaesthetic injection|Single bolus of drug for pain relief in early labour
1883943|NCT01201226|Other|Removal of half an ovary|Removal of half an ovary
1883944|NCT01201239|Drug|raltegravir|RAL 400 mg twice daily plus OBT (optimized background therapy) for 48 weeks
1883945|NCT01201252|Procedure|Stool sampling|Stool samples will be collected, tested and genotyped for the presence of rotavirus
1883946|NCT01201265|Drug|Bevacizumab|15 mg/kg iv every 3 weeks
1883947|NCT01201265|Drug|Carboplatin|to an AUC = 2, on days 1 and 8 of each 3-week cycle
1883948|NCT01201265|Drug|Gemcitabine|1000 mg/m2 iv on days 1 and 8 of each 3-week cycle
1883949|NCT01201278|Drug|Insulin|Nasal insulin at a dose estimated to be equivalent to 8 IU bioavailable insulin
1883950|NCT01201278|Drug|Insulin|Nasal insulin at a dose estimated to be equivalent to 16 IU bioavailable insulin
1883951|NCT01201278|Drug|Insulin LISPRO|Subcutaneous insulin lispro 8 U
1883952|NCT01201291|Other|Normobaric oxygen|Fraction of inspired oxygen
1883953|NCT01201304|Behavioral|Standard exposure|Three 60-second trials of hyperventilation, each followed by diaphragmatic breathing, cognitive reappraisal, and prolonged rest until body sensations have subsided.
1883992|NCT01208441|Other|diagnostic laboratory biomarker analysis|
1883954|NCT01201304|Behavioral|Enhanced exposure|Three 60-second trials of hyperventilation, each followed by a 15-second rest period and cognitive reappraisal.
1883955|NCT01201304|Behavioral|Intensive exposure|Minimum of eight 60-second hyperventilation trials, each followed by 15-second rest period and cognitive reappraisal. Trials continue until participants rate the probability that their most feared outcome will occur as less than 5% on a 0% to 100% scale.
1883956|NCT01201304|Behavioral|Expressive writing|Individuals randomized to the expressive writing control group will receive a rationale for why writing about emotional issues helps resolve the fear of body sensations. These participants will then be asked to spend the next 25 minutes writing about past emotional issues. Participant writings are confidential and will not be viewed by the experimenter.
1883957|NCT01201317|Drug|AZD2423|20 mg tablet
1883958|NCT01201317|Drug|AZD2423|150 mg tablet
1883959|NCT01201317|Drug|Placebo|Placebo
1883960|NCT01201343|Drug|Interferon beta-1a|
1883961|NCT01201356|Drug|FTY720|
1883962|NCT01201369|Device|Coronary Stent Cypher|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols.
1883963|NCT01201369|Device|Coronary stent Xience|The angioplasty will then be performed in a usual fashion in accordance with the operator's discretion and local protocols
1883964|NCT01201382|Behavioral|IPT-AST|A school-based group prevention program that includes 2 individual pre-group sessions, 8 weekly 90 minute group sessions, an individual mid-group session and 4 booster sessions
1883965|NCT01201382|Behavioral|Group Counseling|Usual group counseling as delivered by school counselors; 1 pre-group session, 1 mid-group session, 8 90-minute group sessions, 4 booster sessions
1883966|NCT01201434|Dietary Supplement|Bio-25 probiotic|2 tablets per day for 6 months
1883967|NCT01208259|Behavioral|Cognitive Behavioral Therapy (CBT)|
1883968|NCT01208259|Behavioral|Interpersonal Therapy (IPT)|
1883969|NCT01208272|Behavioral|Cognitive Behavioral Therapy (CBT)|
1883970|NCT01208272|Behavioral|Interpersonal Therapy (IPT)|
1883971|NCT01208285|Drug|VX-770|150 mg oral tablet
1883972|NCT01208298|Device|Cold Sore Patch|All eligible subjects received CSP-Night at Screening Visit 1. Subjects were instructed to initiate therapy within approximately 1 hour of onset of their first sign or symptom. Treatment was continued until the lesion healed, or for a maximum of 10 days. All subjects were expected to return to the study center for clinical assessments within 24 hours and 48 hours after initiating treatment, and every other day thereafter, with a final visit at Day 10 or at the time of completion/ discontinuation if before Day 10.
1883973|NCT01208324|Drug|estrogen patch|150 subjects will be enrolled in a double blind placebo controlled study where they will be randomized to receive either treatment with 17β-estradiol (Vivelle Dot® 0.10 - 0.15 mg/day) or a look-alike placebo patch for a total of approximately 8 weeks. There will be four fMRI test sequences: two test sequences one week apart prior to estrogen treatment (ET) or placebo treatment (PT), and two sequences one week apart following approximately 6-weeks of double-blind ET or PT. During each test day, all subjects will have their blood drawn at specific time intervals and undergo a battery of cognitive testing.While on the ET or PT treatment, all subjects will be instructed to change the patch every 3.5 days.
1883974|NCT01208324|Drug|Amino acids|31.5 mg of amino acids or 31.5 mg of lactose will be administered to subjects on each of their 4 test days. On 2 of the test days subjects will receive the active pills (amino acids) and on the other 2 test days subjects will receive the placebo pills (lactose).
1883975|NCT01208324|Drug|Placebo Patch|placebo
1883976|NCT01208324|Drug|Placebo pills|There are 4 test days in this study. Each test day will involve the ingestion of 70 capsules. During one of each pair of tests, the 70 capsules will contain 31.5 g of lactose (sham depletion), while during the other test they will contain a total of 31.5 g of amino acids.
1883977|NCT01208337|Drug|Alemtuzumab|Alemtuzumab is a monoclonal antibody directed against the CD52 antigen. A single dose of 0.3-0.4 mg/kg is given to enrolled subjects at the time of intestine transplantation, 30 minutes after premedication with acetaminophen, diphenhydramine and methylprednisolone
1883978|NCT01208350|Behavioral|No intervention|Monthly weigh-ins for 6 months without financial incentives associated with weight loss, and follow-up weigh-in at 9 months
1883979|NCT01208350|Behavioral|Group-based payout|Monthly weigh-ins for 6 months where five sequential participants, randomized to this condition, will be joined into virtual groups where individual rewards for weight loss are dependent on the weight loss of others in the group, with follow-up weigh in at 9 months
1883980|NCT01208350|Behavioral|Individual payout|Monthly weigh-ins for 6 months and if monthly goals are met, participants receive payout at the end of the month, with follow-up weigh-in at 9 months
1883981|NCT01208363|Dietary Supplement|Cowpea fortified with NaFeEDTA, in form of Toubani.|66g raw Cowpea fortified with 10 mg Fe as NaFeEDTA, in form of Toubani, a cowpea snack. Ther snack will be given to the participants 3 times per week, for six month integrated in the school feeding trial.
1883982|NCT01208376|Other|Fibroscan|Fibroscan and Serum Fibrose-marker
1883983|NCT01208389|Biological|AAV2-hRPE65v2|One time, subretinal administration of 1.5E11 vg AAV2-hRPE65v2 vector to the contralateral, previously uninjected eye.
1883984|NCT01208402|Drug|Esmolol|Infusion will be started at 50 mcg/kg/min for 4 minutes and titrated in increments of 50 mcg/kg/min up to a maximum of 300mcg/kg/min (maintenance dose) to maintain a heart rate between 60 and 80 beats per minute (bpm) while maintaining a minimum systolic blood pressure (SBP) of 95 mmHg during the length of surgery and up to 12 hours post-operatively.
1883985|NCT01208415|Device|Endovascular repair for aortoiliac or iliac aneurysms.|Implantation of the Zenith® Branch Endovascular Graft-Iliac Bifurcation, the Zenith® Connection Endovascular Covered Stent/ConnectSX™ and the Zenith® Flex AAA Endovascular Graft.
1883986|NCT01208428|Behavioral|Conventional cognitive behavioral therapy|Conventional cognitive behavioral therapy is a standard treatment for depression. There will be ten 50-minute sessions delivered.
1883987|NCT01208428|Behavioral|Religious cognitive behavioral therapy|Religious cognitive behavioral therapy is conventional cognitive behavioral therapy that includes consideration of the patient's religious beliefs in therapy. Subjects will receive ten 50-min sessions of therapy
1883988|NCT01208441|Drug|letrozole|
1883989|NCT01208441|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
1883990|NCT01208441|Procedure|therapeutic conventional surgery|
1883993|NCT01208441|Other|pharmacological study|
1883994|NCT01208454|Drug|Isotretinoin|Given PO
1883995|NCT01208454|Other|Laboratory Biomarker Analysis|Correlative studies
1883996|NCT01208454|Other|Pharmacological Study|Correlative studies
1883997|NCT01208454|Drug|Vorinostat|Given PO
1883998|NCT01208467|Other|Laboratory Biomarker Analysis|Correlative studies
1883999|NCT01208480|Drug|Avastin, docetaxel, carboplatin|Avastin, docetaxel, carboplatin
1884000|NCT01208493|Other|preterm infant formula with high protein levels|minimum 3 weeks feeding until hospital discharge
1884001|NCT01208493|Other|preterm standard infant formula|minimum 3 weeks feeding until hospital discharge
1884002|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects.
1884003|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 administered s.c. (under the skin) in healthy subjects.
1884004|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
1884005|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA. In addition a single dose of NNC0114-0000-0005 may be administered s.c. (under the skin) in healthy subjects based on safety data.
1884006|NCT01208506|Drug|NNC0114-0000-0005|A single dose of NNC0114-0000-0005 administered i.v. (into the vein) in healthy subjects. Based on safety data, a single dose of NNC0114-0000-0005 may be administered i.v. (into the vein) in subjects with RA.
1884007|NCT01208506|Drug|placebo|A single dose of NNC0114-0000-0005 placebo.
1884008|NCT01208558|Behavioral|Diet A|"Prudent diet without grains. Written advice and 17-20 group sessions. Subjects are advised to avoid cereal grains as much as possible. Apart from that, the recommendation is to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. In order to match carbohydrate intake between the intervention arms, a high intake of potatoes, root vegetables, fruit and other carbohydrate-rich foods is recommended.
Guideline: 200-400 g of potatoes, 300-500 g of root crops, 400-600 g of vegetables, 200-300 g of beans, peas and corn, and 600 g of fruit and berries per day."
1884009|NCT01208558|Behavioral|Diet B|Prudent diet with whole grains. Written advice and 17-20 group sessions. An exchange of regular cereal grains for whole grains is recommended. A daily intake of 7-8 portions of whole grain products is recommended, and a list of recommended cereal products (brands, names) is provided. Apart from that, the recommendation is identical to Diet A: to follow Nordic Nutrition Recommendations (NNR) for overweight people (www.slv.se; in Swedish), i.e. to eat much fruit, vegetables, fish, and to choose low-fat meat, and low-fat dairy products, and to avoid candy, ice cream, snacks, cakes, pastries, chocolate, potato chips, beer, soft drinks and juice. The goal is that carbohydrate intake, as a proportion of total energy intake, should not differ between the groups.
1884010|NCT01208558|Behavioral|Physiotherapy|Twelve physiotherapy-led, charged, 2-hour sessions of structured group training for increased cardiorespiratory fitness. A pedometer sold at the start. Physical activity on prescription (FaR) at the end.
1884011|NCT01208571|Other|"Booster session"|Motivational interview
1884012|NCT01208584|Other|fMRI, DTI|functional magnetic resonance imaging (fMRI), MR diffusion tensor imaging (DTI)
1884013|NCT01208662|Drug|Lenalidomide|"Oral, 25 mg/day, days 1-14 for 8 total cycles for Arm A. Oral, 25 mg/day, days 1-14 for 5 total cycles for Arm B.
Oral, 10-15 mg/day, daily for 12 months in maintenance for Arm A and Arm B."
1884014|NCT01208662|Drug|Bortezomib|IV, days 1, 4, 8 and 11 for 8 total cycles for Arm A. IV, days 1, 4, 8 and 11 for 5 total cycles for Arm B.
1884015|NCT01208662|Drug|Dexamethasone|"Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 8 total cycles for Arm A. Oral, days 1, 2, 4, 5, 8, 9, 11 and 12 for 5 total cycles for Arm B.
Dose of 20 mg/day for first 3 cycles. Dose of 10 mg/day for remaining cycles."
1884016|NCT01208662|Procedure|Autologous Stem Cell Transplant|Stem cell transplant
1884017|NCT01208688|Device|FES Therapy|Treatment group received functional electrical stimulation and control group received conventional occupational therapy.
1884018|NCT01208688|Device|FES Therapy|Subjects will be divided into one of two groups: a) subjects that will be trained with neuroprosthesis for grasping and b) the control group. The control group will be administered standard occupational therapies appropriate for recovery of grasping function in SCI subjects. In group a), neuroprosthesis for grasping will be used to train subjects to reach, grasp and manipulate various objects in the activities of daily living.
1884019|NCT01208688|Other|Conventional Occupational Therapy|The conventional therapy represents control activities against which FES therapy will be assessed. Conventional occupational therapy includes : a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach;b)task-specific repetitive functional training;c)strengthening and motor control training using resistance to available arm motion to increase strength; d)stretching exercises;e)electrical stimulation applied primarily for muscle strengthening (this is not FES); and f)activities of daily living including self care where the upper limb was used as an assist if appropriate; and caregiver training. Control and treatment group will have 3 sessions per week (business days only) for 13 to 16 weeks (40 treatment sessions in total). Each session will last 60 minutes.
1884020|NCT01208701|Drug|Atorvastatin|Zarator, 80 mg pr day for 5 days
1884021|NCT01208701|Drug|Unikalk|1 tablet Unikalk pr day for 5 days
1884022|NCT01208714|Drug|Optimal medical therapy|"Optimal medical therapy, including optimal antihypertensive therapy as defined by ESH/ESC Guidelines Mancia G. J Hypertens 2007; 25: 1105), antiplatelet and, if necessary, hypolipemic and hypoglycemic treatment.
All patients will receive antiplatelet treatment with the same dose of aspirin (100 mg o.d.) or ticlopidine (250 mg b.i.d) if intolerant ASA, or clopidogrel (75 mg o.d.), if intolerant to ASA and ticlopidine, throughout the study period. LDL-cholesterol will be lowered to below 100 mg/dl, homocysteine if elevated will be lowered and treatment for diabetes will be optimized (HbA1c < 6.5%)."
1884955|NCT01216137|Other|Exercise|Bicycle ergometry and stretching
1884023|NCT01208714|Procedure|revascularization|The patients randomized to this treatment will undergo digital scan angiography (DSA) and PTA with stenting of the renal artery. PTA will be performed at the ostium or at truncular level. Stenoses involving more distal arterial vessels will be recorded and considered for data analysis but will not be treated. The patients randomized to revascularization will continue on their antihypertensive drug regimen. The dose and number of drugs will be down-titrated with the aim of pursuing the target BP values.
1884024|NCT01208727|Procedure|postconditioning|Direct postconditioning (brief repeated cycle of 4 occlusion and desocclusion of the initially occluded culprit coronary artery) after primary direct stenting.
1884025|NCT01208740|Drug|Metformin|500 mg three times daily
1884026|NCT01208740|Drug|Placebo|1 pill three times daily
1884027|NCT01208753|Drug|GLPG0555|two different aqueous formulations
1884028|NCT01208753|Drug|GLPG0555 aqueous|multiple dose, aqueous formulation, 13 days, 100 mg/day once daily, maximum dose to be determined
1884029|NCT01208753|Drug|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
1884030|NCT01208766|Drug|Bortezomib, Melphalan, Prednisone (VMP)|"Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11,22,25,29,32
Melphalan _ 9 mg/m² _ p.o. _ days 1-4
Prednisone _ 60 mg/m² _ p.o. _ days 1-4"
1884031|NCT01208766|Drug|1 or 2 cycle(s) HDM (High Dose Melphalan)|"- Melphalan _ 100 mg/m² _ i.v. rapid infusion _ -3, -2*
*Patients with renal insufficiency 100 mg/m2 only at day -3
If a patient is randomized to receive 2 x HDM a second course of High Dose Melphalan may be administered between 2 and 3 months after the first course when the patient achieved at least PR."
1884032|NCT01208766|Drug|2 cycles of Bortezomib, Lenalidomide, Dexamethasone (VRD)|"Bortezomib _ 1.3 mg/m2 _ i.v. rapid infusion _ days 1,4,8,11
Lenalidomide _ 25 mg _ p.o. _ days 1-21
Dexamethasone _ 20 mg _ p.o. _ days 1,2,4,5,8,9,11,12"
1884033|NCT01208792|Procedure|skin biopsy|The biopsy site (usually the forearm) will be first cleaned, and then anesthetized with pain relieving (spray, cream, or injection). The skin is then sampled using a punch that takes a core (a small cylindrical fragment of tissue from the area of interest
1884034|NCT01208792|Other|Blood Sample|a blood sample will be collected
1884035|NCT01208805|Behavioral|Recording spinal cord evoked potentials|Recording spinal cord evoked potentials from patients suffering from intractable pain in whom epidural electrodes have already been implanted
1884036|NCT01208818|Drug|Cyclophosphamide + Bortezomib + Dexamethasone regimen|"Dosing regimen (21 day-cycle):
Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.
Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12.
Cyclophosphamide 900 mg/m2 on day 1, through a short I.V. infusion The regimen is given for 3 cycles in the absence of serious side-effect."
1884037|NCT01208818|Drug|Bortezomib +Dexamethasone regimen|"Dosing regimen (21 day-cycle):
Bortezomib 1.3 mg/m2 I.V. on days 1, 4, 8, and 11. An interval of at least 72 hours between each administration of bortezomib is required.
Dexamethasone 20 mg on days 1, 2, 4, 5, 8, 9, 11 and 12. The regimen is given for 3 cycles in the absence of serious side-effect."
1884038|NCT01208818|Device|HCO group|TheraliteTM dialyzer of 2.1 m2 in surface
1884039|NCT01208818|Device|conventional high-flux dialyzer|conventional high-flux dialyzer; polyacrylonitrile, polysulfone, or PMMA dialysers, with an ultrafiltration coefficient > 14 ml/min and ≥ 1.8 m2 in surface, are recommended.
1884040|NCT01208831|Drug|LDE225|
1884041|NCT01208870|Behavioral|Variety Group|The intervention will consist of our traditional family based weight control intervention with elements of reducing variety of high energy dense foods for the variety group.
1884042|NCT01208870|Behavioral|Nutrition Education Control|The intervention will consist of our traditional family based weight control intervention.
1884043|NCT01208883|Other|repetitive per-treatment [18F]FDG-PET for treatment adaptation|repetitive per-treatment [18F]FDG-PET for treatment adaptation
1884044|NCT01208896|Drug|Reduced_intensity conditioning|The conditioning regimen is composed of Fludarabine (30 mg/m2) and Cyclophosphamide (750 mg/m2), both administered intravenously at Days -5, -4, -3 with Day 0 being the day of transplantation. Rituximab will be administered intravenously at 375 mg/m2 at Day -13 and 1000 mg/m2 at Days -6, +1, +8. Tacrolimus and low-doses of methotrexate will be used for prophylaxis of GVHD.
1884045|NCT01208909|Procedure|diagnostic 5-ALA and MRI for tumor resection|diagnostic 5-ALA and MRI for tumor resection
1884046|NCT01208922|Drug|Rifamycin SV MMX|800 mg per day
1884047|NCT01208922|Drug|Ciprofloxacin|1 g per day
1884048|NCT01208935|Drug|Nicotine Patch|
1884049|NCT01208935|Drug|Nicotine Gum|
1884050|NCT01208948|Drug|1,2 dithiolane 3 valeric acid|600 mg alpha lipoic acid per day
1884051|NCT01208961|Drug|Epanova (4 g) and Lovaza (4 g)|Single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters, 4x1g capsules, taken with high-fat meals
1884052|NCT01208961|Drug|Lovaza (4 g) and Epanova (4 g)|Single dose of Lovaza (omega-3-acid ethyl esters), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Epanova (omefas), 4x1g capsules, taken with low-fat meals, 7 day washout followed by single dose of Lovaza (omega-3-acid ethyl esters,4x1g capsules, taken with high-fat meals, 7 day washout followed by single dose ofEpanova (omefas),4x1g capsules, taken with high-fat meals
1884053|NCT01208974|Procedure|Nipple-Sparing Mastectomy|Nipple-Sparing Mastectomy with Immediate Breast Reconstruction followed by Prophylactic Nipple-Areolar Complex Radiation
1884054|NCT01208974|Procedure|Immediate Breast Reconstruction|Immediate reconstruction of the breast will be performed (after Nipple-Sparing Mastectomy) by the plastic surgeon, type depend on surgeon's discretion and patient's desire.
1884055|NCT01208974|Procedure|Axillary surgery|At surgeon's discretion.
1884056|NCT01208974|Radiation|Prophylactic Nipple-Areolar Complex RT|Nipple-sparing Mastectomy with Immediate Breast Reconstruction followed by Prophylactic Nipple-Areolar Complex Radiation
1884057|NCT01208987|Other|Medication History was printed|
1884956|NCT01216800|Procedure|adjuvant therapy|
1884059|NCT01209013|Device|Medlight PDT Balloon|Medlight PDT Balloon will be used once to apply the laser light treatment
1884060|NCT01209013|Procedure|Endoscopy|Endoscopy will be performed to confirm eligibility, apply photodynamic therapy, assess esophageal condition and effectiveness of the therapy
1884061|NCT01209013|Procedure|Endoscopy with biopsy|Endoscopy with collection of esophageal tissue will be performed at screening to confirm eligibility and at Week 13 (final visit) to assess effectiveness
1884062|NCT01209013|Procedure|Electrocardiogram|Resting electrocardiogram will be performed at screening (unless one has been performed within 30 days prior to screening) to measure heart function
1884063|NCT01209013|Procedure|Chest x-ray|A chest X-ray will be performed at screening (unless one has been performed within 90 days prior to screening) to provide several pictures of the chest to rule out any lung abnormalities
1884064|NCT01209013|Procedure|Blood collection|Blood samples for laboratory tests will be taken to assess the overall condition
1884065|NCT01209013|Procedure|Tissue sample collection|Esophageal tissue samples will be collected before the porfimer sodium injection and on four separate occasions after the injection (22-26 hour-, 40-50 hour-, 96-120 hour-intervals, and 13 weeks) to measure concentrations of oligomers in a subgroup of 12 patients.
1884066|NCT01209026|Drug|Fluticasone furoate (200 mcg)/GW642444 (25mcg) combination|Novel dry powder inhaler
1884067|NCT01209026|Drug|Fluticasone furoate (400 mcg)/GW642444 (50mcg) combination|Novel dry powder inhaler
1884068|NCT01209026|Drug|Placebo Inhaler|Matching placebo Novel dry powder inhaler. Lactose monohydrate and magnesium stearate.
1884069|NCT01209026|Drug|Moxifloxacin 400mg|Film coated oral tablet
1884070|NCT01209026|Drug|Moxifloxacin placebo|Film coated oral tablet
1884071|NCT01209039|Drug|GSK1144814|Multiple daily doses of GSK1144814 for 28 days
1884072|NCT01209039|Drug|GSK1144814|Multiple daily doses of GSK1144814 for 14 days
1884073|NCT01209039|Drug|GSK1144814|Multiple daily doses of GSK1144814 for 7 days (or until steady state is reached)
1884074|NCT01209052|Drug|GSK1325756|Drug will be orally administered in varying amounts over varying time periods as detailed in the 'arms' section.
1884075|NCT01209052|Other|Placebo|Placebo will be orally administered to at least 4 subjects in each treatment period of each cohort. In each sequence in each cohort, all subjects will receive one dose of placebo.
1884076|NCT01209065|Drug|GSK1349572|GSK1349572 is an integrase inhibitor being developed for the treatment of human immunodeficiency virus -1 infection by ViiV Healthcare. This drug is experimental and has not been approved by the Food and Drug Administration (FDA).
1884077|NCT01209065|Drug|Fosamprenavir|Fosamprenavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
1884078|NCT01209065|Drug|Ritonavir|Ritonavir is a drug in the protease inhibitor class that is approved by the FDA for the treatment of HIV infection.
1884083|NCT01209104|Drug|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
1884084|NCT01209104|Drug|GSK1325756|100mg of a single oral dose of GSK1325756 administered as 2 x 50mg tablets
1884085|NCT01209117|Drug|GSK2248761 WBM Capsule|200 mg GSK2248761 WBM capsule (reference) 2 X100mg
1884086|NCT01209117|Drug|GSK2248761 WBM Tablet Formulation 1|GSK2248761 WBM Tablet 200mg manufacturing process 1
1884087|NCT01209117|Drug|GSK2248761 WBM Tablet Formulation 2|GSK2248761 WBM Tablet 200mg manufacturing process 2
1884088|NCT01209117|Drug|GSK2248761 WBM Tablet Formulation 3|GSK2248761 WBM Tablet 200mg manufacturing process 3
1884089|NCT01209117|Drug|GSK2248761 WBM Tablet|GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4
1884090|NCT01209130|Drug|DCDT2980S|Intravenous repeating dose
1884091|NCT01209130|Drug|rituximab|Intravenous repeating dose
1884092|NCT01209143|Drug|Vismodegib|Vismodegib was supplied in hard gelatin capsules.
1884093|NCT01209143|Drug|Rosiglitazone|Rosiglitazone was supplied in tablets.
1884094|NCT01209143|Drug|Norethindrone/ethinyl estradiol|Norethindrone/ethinyl estradiol was supplied in tablets.
1884095|NCT01209156|Drug|[18F] PBR111|Subjects will be injected with 5mCi (not to exceed a maximum of 5.5 mCi) of [18F]PBR111, followed by PET imaging.
1884096|NCT01209195|Drug|MM-121|increasing doses of MM-121 IV QW
1884097|NCT01209195|Drug|Paclitaxel|Paclitaxel - 80 mg/m2 IV QW
1884098|NCT01209208|Drug|Budesonide|9 mg per day
1884099|NCT01209208|Drug|Mesalamine|3 g per day
1884100|NCT01209208|Other|Placebo|0 g per day
1884101|NCT01209221|Drug|Placebo - MAD|Once or twice daily doses of matching placebo to RO5271983 for 14 days
1884102|NCT01209221|Drug|Placebo - SAD|Single dose of matching placebo to RO5271983 for up to 3 periods
1884103|NCT01209221|Drug|RO5271983 - MAD|Once or twice daily doses of RO5271983 for 14 days
1884104|NCT01209221|Drug|RO5271983 - SAD|Single dose of RO5271983 at each period (for up to 3 periods)
1884105|NCT01209234|Behavioral|Standard-of-Care Education|Patients randomized to standard education will receive a binder with MRSA educational materials which will include or be based upon CDC guidance for MRSA patients at home.
1884106|NCT01209234|Drug|MRSA Decolonization|Participants in this arm will be instructed to complete a decolonization regimen that will involve a 5-day application of nasal mupirocin, oral CHG rinse, and CHG body wash twice a month.
1884107|NCT01209247|Other|Nasal, rectal and pharyngeal swabs|Nasal, rectal and pharyngeal swabs were performed before, during, and one month after the end of FQ treatment.
1884108|NCT01209260|Device|Radiofrequency energy needle|Radiofrequency energy needle for transseptal access
1884109|NCT01209260|Device|Mechanical Needle|Mechanical needle for transseptal access
1884110|NCT01209286|Biological|Blinatumomab|Continuous intravenous infusion over four weeks per treatment cycle
1884111|NCT01209299|Genetic|DNA methylation analysis|
1884112|NCT01209299|Genetic|gene expression analysis|
1884113|NCT01209299|Other|laboratory biomarker analysis|
1884114|NCT01209312|Other|Bolus timing and dosing|We will be altering the timing and dosages of the prescribed meal bolus.
1884115|NCT01209325|Biological|quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine|
1884116|NCT01209325|Other|laboratory biomarker analysis|
1884117|NCT01209338|Behavioral|Health education|Health education about HPV infection, HPV vaccine and cervix cancer.
1884118|NCT01209351|Drug|Placebo|placebo
1884119|NCT01209351|Drug|teduglutide|teduglutide 4 mg
1884120|NCT01209364|Device|Durolane is a device, methylprednisolone in a drug|single intraarticular injection
1884121|NCT01209377|Behavioral|standard|EMDR treatment with bilateral stimulation via eye movement
1884122|NCT01209377|Behavioral|fixed|EMDR treatment with fixed eyes
1884123|NCT01209377|Behavioral|no focus|trauma exposure without external focus
1884124|NCT01209377|Procedure|EMDR|Eye Movement Desensitization and Reprocessing (EMDR)
1884125|NCT01209390|Device|Chondromimetic|"The Chondromimetic implant is intended to serve as a scaffold for cellular and tissue ingrowth in osteochrondral defect repair such as bone and/or cartilage.
The plug consists of a chondral layer with collagen and GAG and an osseus layer with collagen, GAG, and calcium phosphate."
1884126|NCT01209403|Drug|Glucose-infusion|Continuous iv infusion of glucose
1884127|NCT01209403|Drug|Glucose-insulin infusion|Continuous iv infusion of glucose and shortlasting
1884131|NCT01209429|Drug|GH hormone infusion|Norditropin 30 ng/kg/min
1884132|NCT01209429|Behavioral|42 hour fast|The participant will be fasting 42 hours prior to the start of the study day, drinking water is allowed
1884133|NCT01209429|Behavioral|12 hour fast|12 hour fast will be used as a control scenario to 42 hour fast
1884134|NCT01209442|Drug|Bevacizumab|Bevacizumab will be administered at 10 mg/kg on day 1 and day 15. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, patients will receive 6 cycles of Bevacizumab.
1884135|NCT01209442|Drug|Temozolomide|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx) and daily temozolomide at 75 mg/m2 qd concurrent with IMRT. Four to six weeks following completion of concurrent IMRT, TMZ and bevacizumab, temozolomide will be given at 150-200 mg/m2 qd on days 1-5 of each cycle.
1884136|NCT01209442|Radiation|RT (Radiation Therapy)|Patients will be treated with hypofractionated IMRT (60 Gy in 10 Fx)
1884137|NCT01209455|Drug|Chlorphenamine and Ranitidine|We intend to use chlorphenamine (H1 antagonist) and ranitidine (H2 antagonist).Assuming NAC causes vasodilatation with an increase in forearm blood flow, we propose to administer 5 mcg/min to ensure maximal H1 blockade. In the presence of increased forearm blood flow, we propose to administer 37.5 mcg/min.
1884138|NCT01209455|Drug|Paracetamol|Therapeutic IV administration of 1g paracetamol results in a plasma concentration of ~12 mg/l. To achieve a desired concentration of ~25 mg/l, in the presence of a forearm blood blow of 50 ml/min, we would intend to administer an IA infusion of 1.25 mg/min. To account for the presence of increased forearm blood flow, we propose to administer 4 mg/min IA paracetamol.
1884139|NCT01209455|Drug|Paracetamol|To achieve a local paracetamol concentration of ~200 mg/l, a concentration comparable to potentially hepatotoxic concentrations following paracetamol overdose, we propose to administer 30 mg/min paracetamol.
1884140|NCT01209468|Device|monobloc oral appliance|one piece oral appliance
1884141|NCT01209468|Device|twinblock oral appliance|two-piece oral appliance
1884142|NCT01209481|Behavioral|nutritional education group action|The educational group activities will consist of two-hour group dynamics and cooking workshops once a week and for five weeks.
1884143|NCT01209507|Other|Chemotherapy|This study is designed only to look at the prevalence of adrenal suppression during chemotherapy. If adrenal suppression is detected, treatment will be off-study at the treating physician's discretion.
1884144|NCT01209520|Drug|Cisplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
1884145|NCT01209520|Drug|Carboplatin|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
1884146|NCT01209520|Drug|Paclitaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
1884147|NCT01209520|Drug|Vidaza|Patient will receive 5-azacitidine at a dose of 75 mg/m2 intravenously daily on day 1-5 every 28 days for 6 cycles
1884148|NCT01209520|Procedure|Tumor Specimen for Methylation Analysis|Obtained from tissue of resected NSCLC tumor.
1884149|NCT01209520|Procedure|Blood Sample for Methylation Analysis|Pre-Surgery, Post-Surgery, Post-Vidaza Therapy and during follow-up.
1884150|NCT01209520|Drug|Vinorelbine|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
1884151|NCT01209520|Drug|Docetaxel|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
1884152|NCT01209520|Drug|Pemetrexed|Patients will receive a total of 4 cycles of adjuvant chemotherapy (each cycle given every 21 days). Conventional chemotherapy will be selected at discretion of the treating physicians except on those cases in which pathologic diagnosis indicates non squamous NSCLC.
1884153|NCT01209533|Drug|Iloprost|Inhaled iloprost 2.5 or 5 micrograms four times daily for 14 days
1884154|NCT01209546|Other|control group|In placebo patients were assessed and were not subjected to any respiratory physical therapy technique.
1884155|NCT01209546|Other|Flutter group|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP).
1884156|NCT01209546|Other|PEP group|Patients have done exercise sessions with Flutter® VRP1 without the steel ball inside, with the closure of so many holes as necessary to produce a positive expiratory pressure equivalent to pressure achieved by patients during the performance with the ball in the Flutter®VRP1 for 30 minutes daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (Flutter®VRP1).
1884157|NCT01209546|Other|Group Sham|Patients have done exercise sessions with Flutter ®VRP1 for 30 minutes without the ball inside daily in a randomized, crossover, with four weeks of treatment with a therapy, a week of wash-out followed by four more weeks with the other modality (PEP)
1884158|NCT01209572|Device|calorimetric chamber|Participants stayed 26h in a calorimetric chamber. They performed a series of physical activities such as walking on a treadmill at different speeds, writing, standing, standing-sitting, stepper , rest , sleeping and eating. They also performed a power test on an ergocycle at different speeds.
1884159|NCT01209572|Device|Free living conditions|Volunteers followed the protocol of doubly labeled water to evaluate their energy expenditure during 10 days in free living conditions. For this period, their heart rate, parameters of actimetry and other parameters were recorded.
1884160|NCT01209585|Other|Blood samples|Subjects will have visits on Days 1, 30 and 120.
1884161|NCT01209585|Other|Synovial fluid aspiration|Subjects will have visits on Days 1, 30, and 120.
1884162|NCT01209585|Other|Synovial tissue sample|Subjects will have visits on Days 1, 30, and 120.
1884166|NCT01209637|Behavioral|exercise training|exercise training min. 4 times a day for at least 30 min
1884167|NCT01209637|Behavioral|Intensive exercise training|Intensive exercise training for 4 times / day incl. interval training at 95% individual threshold
1884168|NCT01209650|Drug|BIBW 2992|tablets
1884169|NCT01209663|Other|Postoperative Intermediate Care|Comparison of postoperative Intermediate Care versus Ward Care.
1884170|NCT01209676|Drug|IMCgp100 injection|a monoclonal T cell receptor anti-CD3scFv fusion protein
1884171|NCT01209689|Drug|Tocilizumab|
1884172|NCT01209689|Drug|Placebo|
1884173|NCT01209702|Biological|tocilizumab|Administered intravenously (iv) every 4 weeks
1884174|NCT01209702|Drug|Placebo|Placebo to tocilizumab administered intravenously every 4 weeks
1884175|NCT01209715|Drug|Placebo|participants will be assigned to 3-weeks treatment of inhaled placebo twice a day
1884176|NCT01209715|Drug|Fluticasone /salmeterol|Participant will be assigned to a 3-weeks treatment with inhaled fluticasone/salmeterol or matching placebo
1884177|NCT01209728|Other|Placebo/ethanol (blinded)|Elderly participants, including primary insomnia patients and healthy subjects will be administered i.v. ethanol or placebo in a blinded manner
1884178|NCT01209741|Drug|telcagepant potassium|[INTERVENTION NAME: MK-0974 12MoRT] Single dose MK-0974 12MoRT (12 month aged MK-0974 capsules, stored at room temperature) 300 mg in one of three treatment periods
1884179|NCT01209741|Drug|MK-0974 5Mo5C|Single dose MK-0974 5Mo5C (5 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
1884180|NCT01209741|Drug|MK-0974 12Mo5C|Single dose MK-0974 12Mo5C (12 month aged MK-0974 capsules, stored at 5 Â°C) 300 mg in one of three treatment periods
1884181|NCT01209767|Device|cryolipolysis|During cryolipolysis, the system drew fat tissue into an applicator then exposed the extracted fat tissue to cold temperatures. The cold exposure caused fat cells to die, with the goal to decrease the raised areas of cellulite
1884182|NCT01209767|Procedure|Subcision|Subcision was performed by inserting a specially designed needle under the skin after local numbing medication is injected. The needle is moved in a repetitive motion parallel to the skin to separate the surface tissue from the deeper scar tissue with the goal to improve the dimpling caused by these tissues sticking together.
1884183|NCT01209767|Other|Control|
1884184|NCT01209780|Biological|TIV|Investigational egg-derived trivalent subunit influenza vaccine.
1884185|NCT01209780|Biological|TIVf|US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.
1884186|NCT01209780|Biological|Comparator TIV|US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children <4 years.
1884187|NCT01209793|Biological|REGN846|5 IV cohorts (Dose 1, 2, 3, 4, 5)
1884188|NCT01209806|Drug|simethicone|400 mg simethicone at 6pm night prior to colonoscopy 400 mg simethicone 4 hours before colonoscopy
1884189|NCT01209832|Drug|Tasisulam|Patient specific dose, administered intravenously, on day 1 of a 28 day cycle. Minimum of one (1) 28 day cycle. Patients may continue to receive tasisulam until disease progression or until discontinuation criteria are met.
1884190|NCT01209832|Drug|Midazolam|1.2mg, administered orally once prior to the initiation of tasisulam therapy and once on day 8 after initiation of tasisulam therapy
1884191|NCT01209845|Drug|ketamine|intravenous ketamine(0.2 mg/kg) over 1-2 minutes IV
1884192|NCT01209858|Drug|Perampanel and Microgynon-30|Part A: Microgynon-30 single oral dose on Day 1 Period 1 and Day 35 Period 2; perampanel oral daily dose starting at 4 mg per day Period 2 from Days 1 through 35 and titrated weekly.
1884193|NCT01209858|Drug|Perampanel and Microgynon-30|Part B: Perampanel single oral dose of 6 mg on Day 1 Period 1 and Day 21 Period 2; Microgynon-30 orally from Day 1 through Day 21 of Period 2.
1884227|NCT01210170|Drug|mometasone 400 mcg 30min|mometasone inhalation 30 min before albuetrol
1884194|NCT01209871|Biological|DNA Vaccine|Series of 3 autologous lymphoma immunoglobulin derived scFV-chemokine DNA vaccinations (Cohort 1 dose 500 μg; Cohort 2 dose 2500 μg) intramuscularly at 4-week intervals (+/- 3 business days) according to the following schedule: 0, 4, and 8 weeks.
1884195|NCT01209897|Behavioral|Smoking cessation booklet|
1884196|NCT01209910|Other|Water|Subjects in this arm will be able to drink water with some conditions.
1884198|NCT01209936|Device|D2O|All participants received deuterium oxide (D2O) and testing with the BC3 for the measurement of total body water.
1884199|NCT01209949|Drug|Adapalene 0.1% and Benzoyl Peroxide 2.5% gel|Apply adapalene BPO gel once daily in the evening for 12 weeks
1884200|NCT01209975|Procedure|Selective Laser Trabeculoplasty|Patient will have selective laser trabeculoplasty as the first treatment for glaucoma. This treatment will be dictated clinically, since we do not assign the interventions.
1884201|NCT01209988|Drug|tamsulosin 0.4mg|perioperative tamsulosin 0.4mg daily for three weeks
1884202|NCT01209988|Other|No medication|No medication
1884203|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 low dose
1884204|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
1884205|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
1884206|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
1884207|NCT01210001|Drug|Placebo|Placebo tablets matching BI 10773 high dose
1884208|NCT01210001|Drug|BI 10773|BI 10773 tablets once daily
1884209|NCT01210014|Drug|zinc sulphate 220mg/day in one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.
The clinical data were scored according to the size of lesions were scored subjectively.
the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
1884210|NCT01210014|Drug|placebo: one dosage|"patients with clinical signs and symptoms of RAS , in whom clinical diagnosis was accompanied with low level of zinc serum were selected for the study. Gender, age, medical history, symptoms, types and site, number, size, pain level, intervals, disease duration and form of treatment were recorded for all participants. Patients were randomly divided into two groups . The case group (n=7) received a single dose of zinc sulphate in the form of 220 mg capsules for 1 month ,while starch-containing placebo was administered with the same dosage and period in the control group.
The clinical data were scored according to the size of lesions were scored subjectively.
the symptomatology score was obtained using a visual analogue scale(VAS). All participants in both groups were examined up to 5 months in order to assess the effectiveness of the treatment. At the end of fifth month the serum zinc level was tested again."
1884211|NCT01210040|Dietary Supplement|Folic Acid|2.8mg
1884212|NCT01210040|Dietary Supplement|Folic Acid and Iron|60mg Iron and 2.8mg Folic Acid
1884213|NCT01210053|Drug|malate Given orally|Patients receive oral sunitinib malate 25 mg daily in the absence of disease progression or unacceptable toxicity.
1884214|NCT01210066|Drug|Fentanyl|IV fentanyl 1mcg/kg
1884215|NCT01210066|Other|Cold pressor test|Non-dominant arm submerged in ice water (0 degrees Celsius) until it is no longer tolerable but less than 5 minutes
1884216|NCT01210066|Other|Fentanyl plus cold pressor test|fentanyl IV 1mcg/kg fifteen minutes prior to cold pressor test (arm submerged in ice water until no longer tolerable but no longer than 5 minutes)
1884217|NCT01210079|Drug|Gabapentin;|Gabapentin titrated to daily dose of 2400mg PO over 1 week with established dose taken daily for 5 weeks.
1884218|NCT01210079|Drug|Placebo|Placebo titrated over 1 week with established dose taken daily for 5 weeks.
1884219|NCT01210118|Behavioral|Low intensity intervention|Control group participants received a face to face low intensity intervention which lasted 5 minutes and included brief advice and the provision of a leaflet on smoking and pregnancy. This leaflet summarized the main effects of smoking during pregnancy and gave clear short messages for encouraging smoking cessation by setting up a quit date.
1884220|NCT01210118|Behavioral|Higher intensity intervention|"Experimental group participants received a higher intensity intervention, which include: 30 minutes of individualized cognitive-behavioural counselling delivered by a trained health care professional and a self-help manual especially tailored for smoking cessation during pregnancy. Counseling was based at the 5 Αs (Ask,Advise, Asses, Assist, Arrange). In addition to counselling, a self help manual especially tailored for smoking cessation during pregnancy for Greek women was provided."
1884221|NCT01210131|Drug|[18F]HX4|Intravenous injection
1884222|NCT01210144|Drug|Gonal -f® [r-hFSH]|On Day 2 of the menstrual cycle, a pre-defined fixed dose of 150 International Units (IU) per day of recombinant human follicle stimulating hormone (r-hFSH) will be administered until follicles are recruited and developed.
1884223|NCT01210144|Drug|Ovitrelle® [r-hCG alfa]|Ovulation triggering will be performed using a single injection of 250 microgram (mcg) recombinant human chorionic gonadotropin (r-hCG) alfa as soon as follicles satisfy the criteria for follicular development, that is at least 3 follicles greater than (>) 16 millimeter (mm), and with estradiol (E2) > 1 microgram per liter (mcg/L) if gonadotropin releasing hormone (GnRH) agonist will be used.
1884224|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Agonist|To prevent premature ovulation in participants undergoing a controlled ovarian stimulation (COS), 0.1 milligram (mg) GnRH agonist daily will be given after endometrial biopsy, 7 days after the peak day of luteinizing hormone (Day LH + 7) as per summary of product characteristics (SmPC), in long agonist protocol.
1884225|NCT01210144|Drug|Gonadotropin-releasing hormone (GnRH) Antagonist|To prevent premature ovulation in participants undergoing a COS, 0.25 mg GnRH antagonist daily will be given from Day 6 of Gonal-f® stimulation treatment as per SmPC, in multi-dose antagonist protocol.
1884226|NCT01210170|Drug|placebo 30min|placebo inhalation 30min before albuterol
1884957|NCT01216800|Procedure|assessment of therapy complications|
1884228|NCT01210170|Drug|placebo comparator simultaneous|placebo inhalation simultaneous with albuterol
1884229|NCT01210170|Drug|mometasone simultaneous|400ug mometasone simultaneously with albuterol
1884230|NCT01210183|Drug|Dextrose intraarticularly administered|9 ml of 12.5% dextrose
1884231|NCT01210196|Procedure|MRI|Cardiac MRI after 12 and 24 months.
1884232|NCT01210209|Other|genome-wide association study|
1884234|NCT01210235|Behavioral|FLU-FIT Program|In the intervention, eligible patients aged 50-75 who come in for flu shots and are due for colorectal cancer screening will be offered FIT.
1884235|NCT01210248|Other|BLOOD COLLECTION|BLOOD SAMPLE WILL BE COLLECTED FOR 3 KINDS OF TESTS
1884236|NCT01210261|Device|Compumedics Somnilink SPAP - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carryover effect.
Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.
All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
1884237|NCT01210261|Device|Resmed Autoset S8 - Auto-titrating CPAP|"Subjects will undergo the auto-titrating CPAP treatments in the Monash Sleep Centre with the test and reference devices during two nights in random order. There will be an interval of at least seven days between the two treatments to eliminate the carry-over effect.
Full polysomnographic (PSG) recording will be conducted during both treatment nights. The recorded physiological signals during PSG will include signals identical to those used during the baseline diagnostic PSG. The patients fill KSS questionnaire immediately after the PSG study.
All PSG recordings (both treatment studies and the baseline diagnostic study) will be scored according to the AASM rules by the same sleep technician blinded to the presence and type of auto-titrating CPAP treatment."
1884238|NCT01210287|Drug|nucleoside analog reverse transcriptase inhibitor|tablets 100mg qd
1884239|NCT01210326|Procedure|extaction|TESE (testicular sperm extraction), which is actually a surgical biopsy of the testis; or TESA (testicular sperm aspiration), which is performed by sticking a needle in the testis and aspirating fluid and tissue with negative pressure
1884240|NCT01210326|Procedure|testicular sperm extraction|testicular sperm extraction
1884241|NCT01210326|Procedure|testicular sperm aspiration|testicular sperm aspiration
1884242|NCT01210339|Drug|Clopidogrel|Clopidogrel
1884243|NCT01210339|Drug|Esomeprazole/ASA|20 mg/81 mg once daily for five days (Day 5-9)
1884245|NCT01210365|Drug|Diurisa®|Furosemide 40 mg + amiloride chloride 10 mg.The patient will swallow onde tablet per day in whole form on an empty stomach with some liquid during 4 weeks.
1884246|NCT01210365|Drug|Lasix ®|One group of patients will receive furosemide 40mg .The patient will swallow the tablet in whole form on an empty stomach with some liquid.
1884247|NCT01210378|Drug|Nitroglycerin patch|Nitroglycerin patch
1884248|NCT01210391|Other|Extensively hydrolyzed whey infant formula|New hydrolyzed infant formula.
1884249|NCT01210391|Other|Extensively hydrolyzed casein infant formula|Commercially available infant formula.
1884250|NCT01210404|Drug|filibuvir|Filibuvir, 600mg bid administered along with methadone on days 2-11
1884251|NCT01210417|Other|Non invasive monitoring|Three-lead electrocardiogram (ECG), PPG oxymetry, non-invasive blood pressure (NIBP) are registered
1884252|NCT01210430|Drug|Losartan|Subjects will receive placebo or losartan for 4 weeks. Days 1-7, subjects will receive 12.5mg of Losartan or placebo. Days 7-14, subjects will receive 25mg of Losartan or placebo. Days 14-28, subjects will receive 50mg of Losartan or placebo.
1884253|NCT01210430|Drug|Ascorbic Acid (Vitamin C)|Subjects will receive 60mg/kg of Ascorbic Acid over 20 minutes followed by a maintenance infusion of 20mg/kg.
1884254|NCT01210430|Drug|Normal Saline|Subjects will receive 60mg/kg of normal saline over 20 minutes followed by a maintenance infusion of 20mg/kg of normal saline.
1884255|NCT01210443|Drug|Sitaxentan|sitaxentan sodium 100 mg
1884256|NCT01210456|Drug|Physiological Saline, N-Acetylcysteine and Sodium Bicarbonate|"All patients receive N-Acetylcysteine(NAC) and sodium chloride. NAC is given orally at a dose of 700mg twice daily, on the day before and on the day of administration of the contrast media, for a total of two days.
154mEq/L of sodium chloride is given intravenously. The initial intravenous bolus is 3ml/kg per hour for 1 hour immediately before contrast injection. And then, patients receive the same fluid at 1ml/kg per hour during the contrast exposure and for 6 hours after the procedure.
In addition, intervention arms receive sodium bicarbonate.1000mEq/L of sodium bicarbonate is given intravenously twice at a dose of 40ml immediately before the contrast exposure and immediately after the procedure."
1884257|NCT01210469|Other|Strengthening and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
1884258|NCT01210469|Other|Stretching and balance exercises|The group trained for 8 weeks, with sessions of about 60 minutes, twice a week.
1884259|NCT01210482|Drug|Temsirolimus|The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30~60 minutes. The dosage is to be appropriately reduced according to patients' status.
1884260|NCT01210495|Drug|Axitinib (AG-013736)|Axitinib [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
1884261|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
1884262|NCT01210495|Drug|Placebo|Placebo [tablet, 1 mg, 5 mg] will be given twice daily [BID] with continuous dosing; duration is approximately 3-6 months; starting dose is 5 mg BID
1884263|NCT01210495|Other|Best Supportive Care|BSC may include medications and supportive measures deemed necessary to palliate disease related symptoms and improve quality of life.
1884264|NCT01210521|Drug|Vitamin D|Vitamin D, (2000IU) will be administered orally, once a day, for one month.
1884265|NCT01210534|Other|No intervention|No intervention
1884271|NCT01210573|Device|adjustment of LVAD or pacemaker|"For patients without a device: Patients start at rest for 2 minutes and will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide.
For patients with a device: patients will be at rest and the adjustments of their device will be made by a study physician or device coordinator, done routinely in clinical practice. This will take up to 15 minutes and during this time; participants will wear a face mask and breathing parameters are recorded using the SHAPE-HF system (SHAPE Medical St. Paul, MN) that measures respiratory airflow and the constituent respiratory gases, oxygen and carbon dioxide."
1884272|NCT01210586|Behavioral|Part 2|Comparing smoking symptomatology by HRT and nicotine patch status using a 2x2 randomized design.
1884273|NCT01210599|Drug|Pamidronate|The study was a randomized, double blind, dose-escalation trial of IV pamidronate. Study participants were divided among four study phases. Each group received IV placebo or escalating doses of IV pamidronate of 30mg, 60mg, 90mg and 180mg.
1884275|NCT01210625|Dietary Supplement|Nutrabiotix|Fiber supplement: 9mg or 12mg
1884276|NCT01210625|Dietary Supplement|Psyllium|12g total per day (4 capsules containing 1 gram psyllium fiber 3 times a day)
1884277|NCT01210638|Drug|Oxymorphone|10 mg tablet
1884278|NCT01210651|Behavioral|Hatha Yoga Practice Group|The hatha yoga intervention was a sequence of classical yoga practices, comprised of breathing techniques, mindful body postures, and a final deep relaxation pose. The same sequence was used in all sessions. Yoga practices were broken down into component elements and taught progressively to each student in accordance with his or her ability. Participants were encouraged to remain within their range of motion or comfort. Accommodations were made for those with limitations in tolerance or flexibility for any exercise. Blocks, bolsters and other props were used to support participants in learning and holding yoga poses safely, particularly during back-bends or inverted poses. The intervention was delivered by a licensed, registered nurse, who was also a registered yoga teacher.
1884279|NCT01210651|Behavioral|Attention Control Education Group|The educational seminars taught to participants covered the history and philosophy of the main branches of yoga. Documentary films were used during the seminars to enhance lectures, and interactive dialogue was encouraged between instructor and participants. Seminars were designed to control for non-specific mood benefits of study participation, such as attention from instructors, peer interaction, time spent away from routine activities, and anticipation/interest related to mastering novel yoga-related information. Since participants would join the attention control group on a rolling basis, seminars were designed to function as stand-alone educational modules, rather than requiring presentation in a specific sequence. The instructor for the seminars was a registered yoga teacher.
1884280|NCT01210664|Biological|Ex vivo Expanded Human Autologous Polyclonal Regulatory T Cells|The researchers will multiply/expand the Tregs in the laboratory using anti-CD3/anti-CD28 coated beads plus IL-2. Then, the Tregs will be infused back into the patient in a single infusion. The first cohort will receive 0.05 x10^8 cells. The second cohort will receive 0.4 x10^8 cells. The third cohort will receive 3.2 x10^8 cells. The fourth cohort will receive 26 x10^8 cells.
1884281|NCT01210677|Drug|Prednisone|Prednisone 0.5 mg/Kg orally per day for 3 months
1884282|NCT01210716|Device|Therapeutic plasma exchange|Patients are randomized to either Therapeutic plasma exchange procedures on AMICUS or Spectra first. The second procedure (based on time interval determined by physician) will be completed on the other instrument.
1884283|NCT01210729|Device|Solitaire FR, ev3|Placement of the stent in the occluded vessel segment, withdrawal in its unfolded state.
1884284|NCT01210742|Device|Synvisc One|Single intra-articular injection of a 6 mL of Hylan G-F 20 at baseline
1884285|NCT01210742|Other|Routine management|Routine non-operative management for knee OA (NICE guidelines)
1884286|NCT01210755|Drug|Rivaroxaban, Dabigatran|Rivaroxaban: One dose of 20mg (2 tablets of 10mg) then Dabigatran: One dose of 150mg(2 capsules of 75mg) two weeks later
1884287|NCT01210755|Drug|Dabigatran; Rivaroxaban|Dabigatran: One dose of 150mg(2 capsules of 75mg) then Rivaroxaban: One dose of 20mg (2 tablets of 10mg)two weeks later
1884288|NCT01210768|Drug|Epirubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by epirubicin 90 mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 4 cycles in the EC arm.
1884289|NCT01210768|Drug|liposomal-doxorubicin+Cyclophosphamide|Cyclophosphamide 600 mg/m2 infusion followed by pegylated liposomal-doxorubicin 37.5mg/m2 infusion on Day 1 in each 21-day treatment cycle. Treatment will be repeated for 5 cycles in the LC arm.
1884290|NCT01210781|Procedure|deep brain stimulation (DBS)|deep brain stimulation (DBS) is in itself not part of this study but a clinical indication. The study aims at documenting DBS parameters and outcome
1884291|NCT01210807|Device|One-Piece Tecnis Multifocal IOL|One-piece Tecnis Multifocal IOL, Model ZMB00, implanted lens.
1884292|NCT01210807|Device|One-Piece Tecnis monofocal IOL, Model ZCB00|Control lens: One-Piece Tecnis monofocal IOL, Model, ZCB00, implanted lens.
1884293|NCT01210820|Device|iFS™ Femtosecond Laser System|intrastromal arcuate cuts made with iFS™ femtosecond laser
1884294|NCT01210833|Device|HandTutor System|Computerized system designed to evaluate and rehabilitate hand function. It is composed of a glove with special sensors detecting the movements of the wrist and the fingers, with a biofeedback software designed to evaluate and then to exercise the hand movements through supplying a variety of computer graphic patterns.
1884295|NCT01210846|Drug|tivozanib|1 x 1.5 mg capsule of tivozanib orally once daily for 21 days
1884296|NCT01210872|Other|questionnaire administration|
1884297|NCT01210872|Procedure|quality-of-life assessment|
1884298|NCT01210872|Procedure|standard follow-up care|
1884299|NCT01210885|Biological|Meningococcal Vaccine|MenABCWY combination vaccine containing four different rMenB formulations with MenACWY, intramuscular (IM) administration, vaccination at 0 and 2 months.
1884300|NCT01210898|Biological|Adjuvanted seasonal influenza vaccine|Full or half dose of adjuvanted seasonal influenza vaccine; Full or half dose of unadjuvanted seasonal influenza vaccine
1884301|NCT01210911|Drug|gemcitabine|Gemcitabine at a dose of 1000 mg/m2 (iv, 30 minutes) will be given weekly, for 3 weeks, followed by one week without gemcitabine
1884302|NCT01210911|Drug|erlotinib|Erlotinib will be administered at a daily dose of 100 mg at least one hour before or 2 hours after the ingestion of food
1884303|NCT01210911|Drug|metformin|Metformin will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
1884304|NCT01210911|Drug|placebo|Placebo will be administered at a dose of 500 mg twice daily for the first week. If tolerated well, the dose will be increased up to 1000 mg twice daily in the second week.
1884305|NCT01210937|Procedure|CEA and TCD monitoring|All patients will receive carotid endarterectomy. During the surgery, all of them will be monitored by TCD. Record the blood flow velocity and blood pressure on specified time.
1884306|NCT01210950|Biological|cell and RPR injection|mesenchymal cells and Plasma reach Protein are injected to the callus center
1884307|NCT01210963|Device|SENSIMED Triggerfish|Contact lens-based Sensor with recording system for continuous monitoring of IOP fluctuation
1884308|NCT01210976|Drug|levosimendan|12 mcg/kg/10min bolus and 24 hour infusion at a rate of 0.2 mcg/kg/min
1884309|NCT01210976|Drug|placebo|nacl 0.9% coloured with thiamin in same volume and time than levosimendan
1884310|NCT01210989|Drug|Phyllanthus urinaria|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance. At week 24, subjects receiving active Hepaguard will be randomized (1:1) to continue Hepaguard for another 24 weeks or stop treatment.
1884311|NCT01210989|Drug|Placebo|Subjects meeting the inclusion and exclusion criteria will be randomized (2:1) to receive oral Hepaguard 1 g three times daily or placebo of identical appearance.
1884312|NCT01211002|Radiation|radiotherapy combined with EP|Tumor vo lume is 60-66 Gy / 30-33f and the combination regimen is etoposide (50 mg/m2 day1-5, 29-33) and cisplatin (50 mg/m2 day1, 8, 29, 36) in the 1st, 4th weeks of radiotherapy for 2 courses.
1884313|NCT01211002|Drug|radiotherapy / EP combined with recombinant human endostatin|Anti-vascular targeting therapy The number of courses is 3 ~ 4 and each course last for 28 days. Recombinant human endostatin（Endostar）：15mg，d1-14, intravenous injection.
1884314|NCT01211028|Biological|Expanded autologous ASCs|Drug: Expanded autologous adipose-derived adult stroma/stem cells
1884315|NCT01211067|Procedure|Lichtenstein hernioplasty|"Mesh hernioplasty
Ultrapro mesh (Ethicon, Johnson & Johnson)"
1884316|NCT01211080|Drug|Propranolol|Propranolol 2mg/kg/day divided to three oral doses with or without concomitant physical therapy (cryotherapy, laser)
1884317|NCT01211093|Procedure|High frequency whole body vibration|1 single session (10 minutes) of whole body vibration therapy at 30 Hz
1884318|NCT01211093|Procedure|Low frequency whole body vibration|1 single session of whole body vibration therapy at 20 Hz
1884319|NCT01211093|Procedure|control|1 single session of standing on the vibration platform, with no vibration signals delivered.
1884320|NCT01211106|Behavioral|Prolonged Exposure|Although almost every form of psychotherapy has been advocated for PTSD, all evidence-based psychotherapies for PTSD are CBT programs that include variants of exposure therapy (Prolonged Exposure), cognitive therapy (CT), stress inoculation training (SIT), eye movement desensitization and reprocessing (EMDR), or combinations of these procedures. Exposure therapy involves helping PTSD sufferers to gradually confront distressing trauma-related memories and reminders to facilitate successful emotional processing of the trauma memory and reduction of associated distress. Most exposure therapy programs include both imaginable confrontation with the traumatic memories and in vivo exposure to trauma reminders.
1884321|NCT01211106|Behavioral|Motivational Enhancement Therapy|Motivational Interviewing (MI) is defined as a client-centered, directive method for enhancing intrinsic motivation to change by exploring and resolving ambivalence. MI is characterized by its spirit, which is defined as collaboration with the client, evocation of the client's own perceptions, goals, and values, and respect for the client's autonomy.
1884322|NCT01211119|Other|No PRF|Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
1884323|NCT01211132|Device|Cap - Transparent retractable extension device.|Attaching a Cap - Transparent retractable extension device.
1884324|NCT01211132|Device|Standard|Without attaching a transparent cap to the tip of colonoscope.
1884325|NCT01204281|Other|Mechanical ventilation mode (PAV+ vs. ACV)|Compare two ventilatory modes in the acute phase of illness
1884326|NCT01204294|Drug|Linagliptin|Linagliptin once daily
1884327|NCT01204294|Drug|Linagliptin|Linagliptin once daily
1884328|NCT01204294|Drug|Metformin|Metformin twice or three time per day
1884329|NCT01204294|Drug|Metformin|Metformin twice or three time per day
1884330|NCT01204294|Drug|Linagliptin|Linagliptin once daily
1884331|NCT01204294|Drug|Linagliptin|Linagliptin once daily
1884332|NCT01204294|Drug|Linagliptin|Linagliptin once daily
1884333|NCT01204307|Drug|Docetaxel/cisplatin|The treatment schedule comprises a maximum of six 3-week treatment cycles consisting of weekly docetaxel (30 mg/m2) and cisplatin (37.5 mg/m2) for 2 consecutive weeks followed by a 1-week treatment-free period. The patients will be assessed after each cycle and a final assessment will be done after three and six cycles.
1884334|NCT01204307|Drug|Pemetrexed/cisplatin|The patients are given pemetrexed (500 mg/m2 as a 10-min intravenous infusion) and cisplatin (75 mg/m2) on day 1 every 21 days. Dexamethasone (4 mg) is administered twice daily on the day before, the day of, and the day after each dose of pemetrexed. Oral folic acid supplementation (1000 mg) is administered daily, beginning approximately 2 weeks prior to the first dose of pemetrexed and continues until 3 weeks after treatment discontinuation. A 1000 mg vitamin B12 injection is administered intramuscularly approximately 1-2 weeks before the first dose of pemetrexed and is repeated approximately every 9 weeks until 3 weeks after therapy discontinuation.
1884335|NCT01204320|Procedure|Paclitaxel-coated Balloon|POBA
1884336|NCT01204320|Device|Paclitaxel-eluting Stent|Stenting
1884337|NCT01204333|Drug|Endovascular thrombolysis|Endovascular thrombolysis consists of local application of alteplase or urokinase within the thrombosed sinuses. Standard endovascular techniques to mechanically remove clot material, such as thrombosuction, are allowed, but not mandatory.
1884338|NCT01204333|Drug|Heparin|The patients randomized to standard care will receive (or continue) either intravenous adjusted dose unfractionated heparin (aPTT value kept within 1.5 to 2.5 times the normal value), or any type of body-weight adjusted low molecular weight heparin in therapeutic dose, according to local custom and international guidelines
1884339|NCT01204346|Other|MBT|The intervention consists of twice weekly individual MBT therapy, group therapy with an MBT focus and weekly MBFT, which is MBT for families. The treatment duration will be 6-8 weeks.
1884340|NCT01204346|Other|treatment as usual|less intensive and structured psychotherapeutic program
1884341|NCT01204359|Radiation|Iodine 131|iodine 131，185、370、555mBq，6 months
1884342|NCT01204372|Drug|Gemcitabine - Trastuzumab - Erlotinib|"Treatment will be administered until disease progression, patient's refusal, unacceptable toxicity or investigator's decision.
Gemcitabine: IV 1000 mg/m2 on D1, D8, D15, D22, D29, D36 and D43 followed by one week of rest. Subsequently on D1, D8 and D15 followed by one week of rest.
Trastuzumab: IV once a week; 4 mg/kg over 90 min. at D1, and 2 mg/kg over 30 min. for the subsequent infusions.
Erlotinib: oral route 100 mg/day from C1D1."
1884343|NCT01204385|Procedure|Sample collection|Middle ear fluid and urine
1884344|NCT01204398|Drug|telmisartan+amlodipine fixed dose combination|after 2 weeks placebo wash-out, patients will be administered Telmisartan 80mg/Amlodipine 5mg for 8 weeks.
1884345|NCT01204411|Drug|Artesunate-amodiaquine fixed-dose combination|"artesunate 25 mg / amodiaquine 67.5 mg: 1 tablet / day for 3 days for children with a weight of 5 kg to less than 9 kg;
artesunate 50 mg / amodiaquine 135 mg: 1 tablet / day for 3 days for children with a weight of 9 kg to less than 18 kg;
artesunate 100 mg / amodiaquine 270 mg: 1 tablet / day for 3 days for children with a weight of 18 kg to less than 36 kg;"
1884348|NCT01204437|Drug|Epirubicin, Cyclophosphamide|4 cycles of chemotherapy with epirubicin plus cyclophosphamide (EC) on day 1 q22
1884349|NCT01204437|Drug|Cyclophosphamide, Methotrexate, 5 FU|6 cycles CMF on days 1 and 8 q29 Cyclophosphamide (500mg/qm), Methotrexate (40 mg/qm), 5 FU (600mg/qm)
1884350|NCT01204437|Drug|Capecitabine, Nab-Paclitaxel|6 cycles of weekly nab-paclitaxel 100 mg/m2 on days 1, 8, 15 q22 with a week of rest every 6 weeks in combination with capecitabine 2000 mg/m2, days 1 - 14 orally, divided into 2 daily doses every 3 weeks for 6 cycles
1884351|NCT01204450|Drug|Temsirolimus|60-230mg/m2 weekly during each 28 day course, for up to 12 courses
1884352|NCT01204450|Drug|Valproic Acid|All patients will be given oral VPA (5 mg/kg, 3 times a day for each 28 day course, up to 12 courses
1884353|NCT01204476|Biological|Cixutumumab|Given IV
1884354|NCT01204476|Drug|Everolimus|Given PO
1884355|NCT01204476|Other|Laboratory Biomarker Analysis|Correlative studies
1884356|NCT01204476|Drug|Octreotide Acetate|Given IM
1884357|NCT01204476|Other|Pharmacological Study|Correlative studies
1884358|NCT01204489|Behavioral|Intensified dietary counseling at child wellfare clinics.|The intervention is completed by public health nurses who receive updating education in nutrition. A special training in a family-centred lifestyle counseling method in implemented. The nutrition intervention consists of tailored dietary counseling, information leaflets and self-evaluation card given to the families in the intervention arm. In the control clinics, public health nurses continue their usual dietary counseling.
1884359|NCT01204502|Biological|HSVTK retrovirally-transduced donor T lymphocytes|"HSVTK retrovirally-transduced donor T lymphocytes will be given at 1 month intervals, providing that there is no significant GVHD
dose 1 5x104 cells/kg
dose 2 5x105 cells/kg"
1884361|NCT01204554|Drug|Indocyanine green (ICG)|a water-soluble dye that binds to plasma proteins and remains in the intravascular space after intravenous injection.ICG has a normal plasma half life of 3-4 min. Dosage planned is 0 .5 mg/kg dose of ICG resolved in 5 % dextrose 2 mg /ml.
1884362|NCT01204567|Other|Aerobic training|Group-based Aerobic Interval Training twice a week in 12 weeks, based on the Ulleval model. The Norwegian Ulleval Model is a group-based aerobic interval training program which is widely used in Scandinavian hospitals for patients with coronary disease. It is designed to improve physical capacity, body awareness and emotional well-being.
1884363|NCT01204580|Drug|GLIMEPIRIDE + METFORMIN|Pharmaceutical form: film coated tablet Route of administration: oral Dose regimen: 1 tablet of 1/250 mg per day
1884364|NCT01204593|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: once a day at bedtime
1884365|NCT01204593|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: sub-cutaneous Dose regimen: three times a day, preferably just before the meal
1884405|NCT01204840|Drug|Growth Hormone|Subjects in this trial will use a 3.33mg vial (1 vial =10 IU) by daily subcutaneous injection. This will start on day 1 of the menstrual cycle preceding the stimulation phase of an IVF cycle, and will continue until the day of the human chorionic gonadotropin (hCG) trigger (approximately 5-6 weeks)
1884452|NCT01205178|Drug|Chloroquine|The current gold standard for radical cure of P. vivax malaria in many areas of the world is chloroquine (CQ); typically 600 mg day 1, 600 mg day 2, 300 mg day 3 for clearance of the acute parasitemia. After this Tafenoquine will be given and subject will be followed up.
1884958|NCT01216800|Procedure|quality-of-life assessment|
1884366|NCT01204606|Procedure|Arthroscopic rotator cuff repair with intraoperative periarticular injection|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4 or 5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repaired of rotator cuff tear was done with suture anchors.
Mixed MMA drugs(ropivacaine 300mg;40ml, morphine 10mg;1ml, cefotetan 1g; dilution to ropivacaine, epinephrine 0.3mg;0.3ml, total volume:41.3ml) and sodium hyaluronate 20mg;2ml were injected divisionally periarticular area; intra-articular(sodium hyaluronate 20ml;2ml + 10.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound.
Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
1884367|NCT01204606|Procedure|Arthroscopic rotator cuff repair with non-injection of MMA drugs|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4 or 5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repaired of rotator cuff tear was done with suture anchors.
43.3ml of saline was injected divisionally periarticular area; intra-articular(12.3ml); posterior joint capsule(10ml); subacromial space and around suprascapular nerve(11ml); anterior capsule(10ml).
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound.
Peripheral intravenous PCA(Patient Controlled Analgesia) was connected."
1884368|NCT01204619|Behavioral|Intensive training group|an extra structured patient centric training program on PD technique and diet according to the developed training curriculum
1884369|NCT01204658|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
1884370|NCT01204658|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
1884371|NCT01204658|Biological|Synflorix|Intramuscular injection
1884372|NCT01204658|Biological|Prevenar 13|Intramuscular injection
1884373|NCT01204658|Biological|Infanrix Hexa (DTPa-HBV-IPV/Hib)|Intramuscular injection
1884374|NCT01204671|Biological|Influenza vaccine GSK2321138A|One intramuscular injection
1884375|NCT01204671|Biological|FluarixTM|One intramuscular injection
1884376|NCT01204671|Biological|Influenza vaccine GSK2604409A|One intramuscular injection
1884380|NCT01204697|Drug|docetaxel|75 mg/m2 intravenously every 3 weeks for 4 cycles
1884381|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally, days 2-16 each 3-week cycle for 4 cycles; 150 mg/day orally thereafter
1884382|NCT01204697|Drug|erlotinib [Tarceva]|150 mg/day orally as monotherapy
1884385|NCT01204723|Drug|Placebo Aprepitant|Placebo Aprepitant 0 mg once daily for 5 days
1884386|NCT01204723|Drug|Active Aprepitant|Active Aprepitant 160 mg once daily for 5 days
1884387|NCT01204749|Drug|AMG 386|Weekly Intravenous (IV) AMG 386 15 mg/kg
1884388|NCT01204749|Drug|AMG 386 Placebo|Weekly Intravenous (IV) placebo 15 mg/kg
1884389|NCT01204749|Drug|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
1884390|NCT01204749|Drug|Paclitaxel|Paclitaxel 80 mg/m2 intravenous (IV) weekly (3 on/1 off)
1884391|NCT01204762|Drug|pegIFN|Syringe, Subcutaneous, 180 μg, Once Weekly, 48 weeks
1884392|NCT01204762|Drug|pegIFNα-2a|Syringe, Subcutaneous 180 μg, Once Weekly, 48 Weeks
1884393|NCT01204762|Drug|PegIFN lambda|Syringe, Subcutaneous, 180 µg, Once weekly, 48 weeks
1884394|NCT01204762|Drug|Entecavir|Tablet, Oral, 0.5 mg, Once daily, 12 weeks initial monotherapy followed by 48 weeks of combination therapy with PegIFN lambda
1884395|NCT01204775|Drug|Saxagliptin|Tablets, Oral, 2.5 mg or 5.0 mg (according to body weight category), Once Daily, 1-52 weeks
1884396|NCT01204775|Drug|Placebo (Saxagliptin)|Tablets, Oral, Once daily, 1-16 weeks
1884397|NCT01204775|Drug|Metformin IR|Tablets, Oral, 500 mg, Once Daily, 17-52 weeks
1884398|NCT01204775|Drug|Placebo (Metformin)|Tablets, Oral, Once daily, 1-16 weeks
1884399|NCT01204775|Drug|Metformin (Active Rescue)|Tablets, Oral, 500 mg, Titrated as needed, 2-52 weeks
1884400|NCT01204788|Procedure|Prophylactic White Cell Transfusion|Radiated white blood cell transfusions 2-3 times each week, or daily if infection develops
1884401|NCT01204788|Procedure|Therapeutic White Cell Transfusion|Radiated white blood cell transfusions daily only with infection (or persistent fever)
1884402|NCT01204801|Device|Focused Microwave Thermotherapy|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs + Thermotherapy. Thermotherapy at first 3 chemotherapy treatments for Anthracycline chemotherapy nominally every 21±7 days plus Standard of Care chemotherapy. (A targeted tumor temperature of 44ºC (plus or minus 1.5ºC) and a targeted thermal dose of 80 equivalent treatment minutes (plus or minus 20 treatment minutes)). In the event that the targeted minimum cumulative thermal dose of 180 equivalent treatment minutes is not achieved in the first three treatments, an optional fourth thermotherapy treatment may be administered in combination with the fourth course of Anthracycline and standard of care chemotherapy. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
1884403|NCT01204801|Drug|Chemotherapy (control)|Anthracycline Doxorubicin 60mg/m2 (or Epirubicin 100 mg/m2) + Standard of Care chemotherapy and drugs. Anthracycline chemotherapy nominally every 21±7 days. Standard of care (including breast imaging, drugs, and radiation) will be provided to all eligible subjects during and following the above study treatments.
1884404|NCT01204827|Device|13C Methacetin Breath Test (BreathID)|
1884449|NCT01205139|Drug|TMC435|150 mg capsule once daily for 11 days
1884406|NCT01204840|Drug|Patch protocol|"Group A (n=10; control group) will receive patch protocol: 100ug estrogen patch (Estradot), Gonadotropin releasing hormone (GnRH) antagonist (Cetrotide; 0.25mg/d), gonadotropin stimulation 412 IU recombinant follicle stimulating hormone (r-FSH; Gonal F) and 150 IU of recombinant luteinizing hormone (r-LH; Luveris). With 3 or more follicles at mean diameter equal to or greater than 17mm, urinary human chorionic gonadotropin (u-hCG) 10,000 IU self-injected to complete final maturation of oocytes. Egg retrieval will occur 36 hours after hCG injection. Eggs fertilized by standard IVF or intra-cytoplasmic sperm injection (ICSI) depending on semen parameters. Embryos cultured to day 2 and the best 2-4 will be transferred back under ultrasound guidance. Surplus embryos will be frozen as per clinic protocol. Luteal support: Endometrin 100mg vaginally three times daily, starting on the day of egg retrieval and continuing until menses or positive serum beta-hCG, then stopped."
1884407|NCT01204853|Drug|Sitaxentan|sitaxentan sodium 100 mg
1884408|NCT01204866|Biological|Valortim and selected Components|"Valortim (Lot #10-08-001, 25 mg/mL) will be filtered through a 0.22 µm syringe filter and diluted 1:1000, 1:100, 1:10, and 1:1 in saline.
Polysorbate 80 will be diluted in saline to the following concentrations: 0.06 mg/mL, 0.2 mg/mL, and 0.6 mg/mL.
Mannitol (30 mg/mL) will be diluted in saline to the following concentrations: 1:1000, 1:100, 1:10, and 1:1
Histamine (1 mg/mL), positive control
Saline (0.9%), negative control"
1884409|NCT01204866|Drug|Valortim and Selected Components|"• It is anticipated that up to 4 subjects that received Valortim in a previous study (#0036-08-05) will participate in Stage II of the study; two of these subjects experienced adverse events while being dosed with Valortim. Subjects will each be tested percutaneously with Valortim, polysorbate 80, mannitol, histamine, and saline.
Only one subject will be skin tested in a single day.
The appropriate dilution for Valortim, mannitol, and polysorbate 80 will be based on the results from Stage I of this study. As was done in Stage I, Valortim will be filtered through a 0.22 µm syringe filter. Histamine (1 mg/mL) and saline (0.9%) will be used as the positive and negative controls, respectively"
1884410|NCT01204879|Behavioral|Contingency Management|Participants earn the chance to win prizes for the targeted behavior.
1884411|NCT01204892|Procedure|TAP Block|Patient will received bilateral ultrasound-guided TAP block with total of 30 ml of ropivacaine 0.5% after induction of general anesthesia
1884412|NCT01204892|Procedure|Local infiltration|20 ml of Ropivacaine 0.5% will be injected at port sites after induction of general anesthesia. 7 ml each for 10 mm ports, 3 ml each of 5 mm ports
1884413|NCT01204905|Drug|Raltegravir and Maraviroc in combination|"Raltegravir 400 mg tablet twice a day, ~12 hours (10 to 14 hours) apart
Maraviroc 300 mg tablet twice a day, ~12 hours (10 to 14 hours) apart"
1884416|NCT01204957|Dietary Supplement|Seaweed and Soy Protein|5 g/d Seaweed for 6 wks, followed by 5 g/d Seaweed + Soy Protein for 1 wk
1884417|NCT01204957|Dietary Supplement|Placebo and Soy Protein|5 g/d Placebo for 6 wks, followed by 5 g/d Placebo + Soy Protein for 1 wk
1884418|NCT01204996|Drug|CNTO888+DOXIL®/ Caelyx® doxorubicin HCl liposome injection|10 mg/kg CNTO 888 every 2 weeks plus DOXIL®/Caelyx® (doxorubicin HCl liposome injection) 50 mg/m2 every 4 weeks
1884419|NCT01204996|Drug|CNTO888 + gemcitabine|15 mg/kg CNTO 888 every 3 weeks plus gemcitabine 1000 mg/m2 administered on Days 1 and 8 of the 3-week cycle
1884420|NCT01204996|Drug|CNTO888 + Paclitaxel and carboplatin|15 mg/kg CNTO 888 every 3 weeks plus paclitaxel 175 mg/m2 and carboplatin dosed to AUC 6 every 3 weeks
1884421|NCT01204996|Drug|CNTO888 + docetaxel|15 mg/kg CNTO 888 every 3 weeks plus docetaxel 75 mg/m2 every 3 weeks
1884422|NCT01205009|Drug|Ovitrelle|One dose of Ovitrelle 250 mcg
1884423|NCT01205022|Drug|irinotecan hydrochloride|Given IV
1884424|NCT01205022|Drug|leucovorin calcium|Given IV
1884425|NCT01205022|Drug|fluorouracil|Given IV
1884426|NCT01205022|Biological|bevacizumab|Given IV
1884427|NCT01205022|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
1884428|NCT01205022|Other|laboratory biomarker analysis|Correlative studies
1884429|NCT01205035|Drug|ranibizumab 2.0mg|Baseline monthly intravitreal injection of ranibizumab 2.0mg for 3 months followed by possible monthly injections up to 9 additional injections
1884430|NCT01205048|Device|Emervel Classic Lidocaine|20 mg/ml + 0.3% lidocaine
1884431|NCT01205048|Device|Juvederm® Ultra|24mg/ml
1884432|NCT01205061|Device|Emervel Deep Lidocaine|20 mg/ml + 0.3% lidocaine
1884433|NCT01205061|Device|Juvederm® Ultra Plus|24 mg/ml
1884434|NCT01205074|Device|13C Methacetin Breath Test|
1884435|NCT01205074|Dietary Supplement|Grape fruit juice|
1884436|NCT01205074|Drug|Non selective beta blocker - Propranolol|
1884437|NCT01205074|Dietary Supplement|Ethanol|
1884438|NCT01205087|Drug|OKT3|Oral anti-CD3 MAb will be administered at a dosage level of 0.2 or 1.0 or 5.0 mg per day for 30 days. Up of 9 patients will be treated at each dosage level, and up to additional 9 patients will receive placebo.
1884439|NCT01205100|Behavioral|Bio-feedback|By providing on-line electromyography information of muscle activity, patients will be able to control and actively correct their muscle activity during the 15 min treatment session. Each patients will attend 3 treatment sessions.
1884440|NCT01205100|Drug|Placebo|
1884441|NCT01205126|Drug|Hydromorphone HCl|Hydromorphone HCl will be administered in dose of 8, 16, 24, and 32 milligram (mg), once daily for 2 to 8 days of Titration phase and 28 days of Maintenance phase. Starting dose will be based on participant's previous daily opioid dose.
1884442|NCT01205126|Drug|Oxycodone HCl CR|Oxycodone HCl will be administered in dose of 10, 20, 30 and 40 mg, twice daily for 2 to 8 days of titration phase and 28 days of maintenance phase. Starting dose will be based on participant's previous daily opioids dose.
1884443|NCT01205126|Drug|Placebo|Placebo will be administered to the participants receiving hydromorphone HCl or oxycodone HCl CR along with the study treatment to maintain necessary blinding.
1884444|NCT01205139|Drug|TMC435|150 mg capsule once daily for 7 days
1884445|NCT01205139|Drug|TDF|300 mg tablet once daily for 7 days
1884446|NCT01205139|Drug|TMC435 + TDF|150 mg TMC435 capsule + 300 mg TDF tablet, once daily for 7 days
1884447|NCT01205139|Drug|TMC435 + TMC278|150 mg TMC435 capsule + 25 mg TMC278 tablet, once daily for 11 days
1884448|NCT01205139|Drug|TMC278|25 mg tablet once daily for 11 days
1884453|NCT01205178|Drug|Primaquine|Primaquine (PQ) is another 8 aminoquinoline drug available for Malaria treatment
1884454|NCT01205178|Drug|Tafenoquine|Once daily on Day 1 only. For Part B and C of this study Chloroquine will be given to treat Malaria
1884455|NCT01205191|Behavioral|Cell-phone supported CBT|Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications
1884456|NCT01205191|Behavioral|CBT with digital audio player support|Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.
1884457|NCT01205191|Behavioral|CBT|CBT for anxiety disorders
1884458|NCT01205204|Drug|Fentanyl|GROUP BF25 (CONTROL) In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 25 mcg of fentanyl, intrathecally.
1884459|NCT01205204|Drug|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5%with15 mcg of clonidine, intrathecally.
1884460|NCT01205204|Drug|Clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 30 mcg of clonidine, intrathecally.
1884461|NCT01205204|Drug|clonidine|In this group, patient will be given 2.0 mL of hyperbaric bupivacaine 0.5% with 60 mcg of clonidine, intrathecally.
1884462|NCT01205217|Drug|Lapatinib|Lapatinib 1000 mg orally once daily continuously
1884463|NCT01205217|Drug|Trastuzumab|Part II (Week 13-24) Trastuzumab 4 mg/kg IV load followed by 2 mg/kg IV Day 1 of each week
1884464|NCT01205217|Drug|Epirubicin|Part I (Week 1-12) Epirubicin 90 mg/m2 by IV infusion on Day 1 every 21 days
1884465|NCT01205217|Drug|Cyclophosphamide|Part I (Week 1-12) Cyclophosphamide 600 mg/m2 by IV infusion on Day 1 every 21 days
1884466|NCT01205217|Drug|Paclitaxel|Part II (Week 13-24) Paclitaxel 80 mg/m2 by IV infusion on Day 1 of each week
1884467|NCT01205230|Drug|pazopanib|Adenosine triphosphate (ATP)-competitive tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3, platelet derivative growth factor receptor (PDGFR)
1884468|NCT01205243|Drug|ZIAGEN®|Basically there is no treatment allocation. Subjects who would be administrated ZIAGEN® at their physician's discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
1884469|NCT01205256|Drug|methadone|0.25mg/kg IV of racemic methadone at the induction of anesthesia.
1884470|NCT01205269|Drug|AZD8683, 50 mcg|Dry powder for inhalation, single dose
1884471|NCT01205269|Drug|Placebo|Dry powder for inhalation, single dose
1884472|NCT01205269|Drug|AZD8683, 200 mcg|Dry powder for inhalation, single dose
1884475|NCT01205295|Other|Cognitive behavioural therapy|Cognitive behavioural therapy Psychologist Preoperative Efficacy of treatment
1884476|NCT01205308|Dietary Supplement|Vegetable oil based margarine with plant stanol ester enrichment|3 g plant stanols/ day
1884477|NCT01205321|Drug|Bombesin (68Ga) labeled (BAY86-7548)|Cancer patients, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, PET/CT
1884478|NCT01205321|Drug|Bombesin (68Ga) labeled (BAY86-7548)|Healthy volunteers, single intravenous bolus injection of 140 MBq BAY86-7548 on day one of the treatment period, whole body PET/CT for determination of effective dose, kinetics of BAY86-7548 in blood
1884479|NCT01205334|Biological|Autologous CMV-specific CTL|"CMV-specific T cells will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line with a minimum 20g cannula. The expected volume will be 1-50 cc.
At the discretion of the attending physician, subjects can receive repeat infusions of modified T cells at the same dose level as long as they do not have progressive disease (up to a maximum of 6 doses and the minimum interval between repeat infusions is 6 weeks). Infusion procedures and follow-up will be identical to those for the first infusion. Patients, who receive additional doses of CTLs will be monitored exactly like after the 1st CTL infusion."
1884480|NCT01205347|Drug|Simvastatin 80mg|Simvastatin 80mg once a day
1884481|NCT01205347|Drug|Simvastatin 10mg|Simvastatin 10mg once a day
1884482|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Three millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 15 minutes as automated boluses.
1884483|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Four millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 20 minutes.
1884484|NCT01205360|Drug|Bupivacaine-Fentanyl Mixture|Six millilitres of mixture of bupivacaine (0.125%) with fentanyl (2 µg/ml) injected through epidural catheter every 30 minutes.
1884485|NCT01205373|Drug|BI 671800|High dose oral drinking solution
1884486|NCT01205386|Device|1. CROSSER System|The Crosser system will be used to recanalize the chronic total occlusion in the SFA (superficial femoral artery). The IVUS (Intravascular Ultrasound Imaging) System will be used in the treated occlusion after the Crosser to generate real-time images of the artery.
1884487|NCT01205412|Procedure|Endocervical samples|Endocervical samples collection during routine gynaecological examinations
1884488|NCT01205425|Other|PCI on the basis of coronary angiography|Interventional cardiologist will be blinded to the images obtained by CT. The PCI procedure will be planned and performed solely on the basis of invasive coronary angiography
1884489|NCT01205425|Procedure|CT guided PCI|The results of the CT scan will be analysed by the interventional cardiologist that is to perform angiography and PCI. Based on this analysis preliminary procedural strategy is planned (stent diameters, decision on direct stenting vs. predilatation, decision on postdilation)
1884490|NCT01205438|Drug|LY2127399|120mg administered via subcutaneous injection for 52 weeks. 240 mg loading dose will be administered as the first dose of study drug
1884491|NCT01205438|Drug|Placebo every 2 weeks|Administered via subcutaneous injection for 52 weeks. A matching loading dose will also be administered at the first dose.
1884492|NCT01205438|Drug|Placebo every 4 weeks|Administered via subcutaneous injection for 52 weeks.
1884493|NCT01205451|Drug|Botulinum toxin type A|Botulinum toxin type A
1884494|NCT01205464|Drug|Doxycycline|Doxycycline, 100 mg, 2 capsules once daily, 24 hour time interval, 21 days.
1884495|NCT01205464|Drug|Placebo|Placebo, 100 mg, 2 capsules once daily, 24 hour dosage interval, 21 days.
1884496|NCT01205477|Drug|EXPERIMENTAL|Infiltration of 40 mg of methylprednisolone acetate plus 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
1884497|NCT01205477|Drug|PLACEBO|Infiltration of 1 mL of xylocaine and Diclofenac sodium 100 mg PO QD for 10 days
1884498|NCT01205490|Other|head positions and spinal manipulation|Each subject will then undergo a baseline MRI in a head neutral position (0 degrees rotation). They will then be placed in head rotation (45 degrees) to the non-dominant and undergo a MRI. Maximum rotation to the side with MRI will follow. Finally, each subject will receive an upper cervical rotary manipulation to the non-dominant side with MRI immediately after. A total of 4 test conditions will be evaluated (rest, 45 degree, maximal, post-manipulation). The manipulation will be performed by an experience practitioner on a bed just outside the MRI room in supine position. A controlled impulse load will be applied and the head/neck returned to neutral position. Prior to each maneuver, the subject will be queried on their comfort, condition and willingness to continue
1884499|NCT01205503|Drug|Mesna|Mesna: 360 mg/m2 in 50 mL normal saline (NS) either on cycle 2 or cycle 1, day 1. Infused over 15 minutes
1884500|NCT01205503|Drug|Saline|Saline (used as a placebo) infused over the same time as mesna intervention
1884501|NCT01205503|Drug|Doxorubicin|60mg/m2 given IV over 15 minutes after receiving mesna or saline. Can allow for premedications of Ondansetron 8 mg orally, dexamethasone 12 mg orally, Aprepitant 125 mg orally.
1884502|NCT01205503|Drug|Cyclophosphamide|600 mg/m2 IV over 30 minutes. Start 6 hours after doxorubicin started.
1884503|NCT01205516|Drug|Methadone|Patients in the methadone arm will be supplied with 2.5 mg tablets. The dose will consist of 1-12 tablets taken twice daily, every 12 hours (range 5-60 mg per 24 hours).
1884504|NCT01205516|Drug|Controlled Release Morphine|controlled release morphine supplied in 10 mg tablets, 1-12 tablets taken twice daily, every 12 hours (range 20-240 mg per 24 hours).
1884506|NCT01205542|Behavioral|Training|Training of scapular function with strengthening exercises using bodyweight and elastic resistance
1884507|NCT01205542|Behavioral|Reference|Health check and advice to continue ordinary physical activity
1884508|NCT01205555|Device|urine LH testing|"The study group will start urine LH (LHu) testing according to the mean diameter of the leading follicle on ultrasound as per :
13mm or less - Repeat ultrasound scan in 1-2 days 14-17mm - start urine LH testing the evening of the day of the scan 18mm or greater - do one LHu test in the afternoon of the day of the scan before HCG administration Once the patient has commenced LHu testing she will perform 2 tests per day. The tests will be performed at 7am and 7pm. LHu testing will continue until the time of HCG administration or positive uLH.If the LHu result is positive either in the morning or afternoon, the insemination will be the next morning without the administration of exogenous HCG.
If the patient has an inconclusive LHu result, a blood LH test will be taken. If the LH blood test is negative (<8 IU\L) she will continue testing LHu. If the LH blood test is positive (≥ 8 IU\L) the insemination will be the next day."
1884511|NCT01205581|Biological|Fluzone High Dose Vaccine|Two doses of Fluzone HD will be administered to children with leukemia, solid tumor, or HIV.
1884512|NCT01205581|Biological|Fluzone Standard Dose Vaccine|Two doses of Fluzone Standard Dose Vaccine will be administered to children with leukemia, solid tumor, or HIV.
1884513|NCT01205594|Device|ITPR|the ITPR will be inserted in the anesthesia circuit and activated to provide -10 mmHg ETP.
1884514|NCT01205607|Device|ITPR -5 mm Hg then -9 mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
1884515|NCT01205607|Device|ITPR -9 & then -5mm Hg|the ITPR will be inserted in the ventilator circuit and activated to provide either -5 mm Hg or -9 mm Hg endotracheal tube pressure (ETP) Each subject will have all measurements recorded at both -5 & -9 mm Hg
1884516|NCT01205620|Device|ITPR|• Upon incision of the pericardium the -9 mmHg ITPR device will be applied to the patient's endotracheal tube (in the ITPR randomized group).
1884517|NCT01205620|Other|No intervention|No intervention will be performed in the control group
1884518|NCT01205633|Procedure|venous angioplasty|catheter venous angioplasty via femoral vein approach
1884519|NCT01205646|Drug|zoledronate therapy|Zometa will be administered at a dose of 4mg IV over 15 minutes. A third PET scan will be obtained within 1-2 weeks after Zometa administration. Intravenous (through a vein in the arm) infusion every four weeks. Dose will be determined by kidney function.
1884520|NCT01205646|Device|PET Scan|2 scans [about 1-2 weeks apart] will be obtained over a period of 2 weeks pretherapy to confirm reproducibility.A third PET scan will be obtained within 1-2 weeks after Zometa administration.
1884521|NCT01205672|Drug|Metformin|850 mg by mouth once daily for at least 7 days, and up to 30 days before surgery.
1884522|NCT01205685|Drug|OSI-906|"In a pill form by mouth, twice a day (12 hours apart)
During the safety run portion of the study
Dose level 2 = 150 mg twice a day
Dose level 1 = 100 mg twice a day
Dose level -1 = 100 mg twice a day
Dose level -2 = 100 mg twice a day"
1884523|NCT01205685|Drug|Erlotinib|"During the safety run phase of the study:
Dose Level 2 = 100 mg/d
Dose Level 1 = 100 mg/d
Dose Level -1= 75 mg/d
Dose Level -2 = 50 mg/d"
1884524|NCT01205685|Drug|Letrozole|In a pill form, by mouth, once per day at 2.5 mg/d.
1884525|NCT01205685|Drug|Goserelin|For pre-menopausal patients only. Given as an injection once a month at 3.6 mg/month.
1884526|NCT01205698|Other|Nutritional drink|
1884527|NCT01205711|Drug|FOLFIRI regimen|
1884528|NCT01205711|Drug|fluorouracil|
1884529|NCT01205711|Drug|irinotecan hydrochloride|
1884530|NCT01205711|Drug|leucovorin calcium|
1884531|NCT01205711|Drug|zibotentan|
1884532|NCT01205711|Other|laboratory biomarker analysis|
1884533|NCT01205711|Other|pharmacogenomic studies|
1884534|NCT01205724|Drug|turoctocog alfa pegol|Single dose (low) administered intravenously (into the vein)
1884535|NCT01205724|Drug|turoctocog alfa pegol|Single dose (medium) administered intravenously (into the vein)
1884536|NCT01205724|Drug|turoctocog alfa pegol|Single dose (high) administered intravenously (into the vein)
1884537|NCT01205737|Biological|TL011|375 mg/m2 iv every 3 weeks for 8 cycles
1884538|NCT01205737|Biological|Rituximab|375 mg/m2 iv every 3 weeks for 8 cycles
1884539|NCT01205750|Other|Glucose clamp|450 min hyperinsulinemic euglycemic glucose clamp, 0,5 mU / kg lean body mass / min
1884540|NCT01211145|Drug|Placebo|Placebo nasal spray
1884541|NCT01211145|Drug|Zolmitriptan|0.5 mg nasal spray
1884542|NCT01211145|Drug|Zolmitriptan|2.5 mg nasal spray
1884543|NCT01211145|Drug|Zolmitriptan|5.0 mg nasal spray
1884544|NCT01211158|Drug|Ketofol|Syringes containing ketofol (mixed propofol-ketamine) will contain propofol 5mg/ml and ketamine 5 mg/ml. Patients will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication. Patients in the propofol-ketamine group will receive 0.375 mg/kg each of ketamine and propofol as an initial bolus and 0.188 mg/kg each of ketamine and propofol as necessary until reaching deep sedation (Ramsay score = 5 or greater).
1884545|NCT01211158|Drug|Propofol alone|Propofol-only syringes will contain propofol 10 mg/ml. Patients in each group will receive an initial intravenous dose of 0.075 millilitres per kilogram of pre-prepared medication (0.75 mg/kg). One minute after the initial dose of sedative, and every minute thereafter, the attending physician will assess the patient's level of sedation using the Ramsay Sedation Scale (RSS). If the attending physician determines the level of sedation to be inadequate (RSS<5), additional study drug will be administered at a dose of 0.0375 millilitres per kilogram (0.375 mg/kg) every minute until deep sedation is achieved (RSS=5 or greater).
1884546|NCT01211171|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
1884547|NCT01211184|Dietary Supplement|Water administration|patients undergo hip surgery after receiving 800 ml water by mouth in the morning before the surgery.
1884548|NCT01211184|Dietary Supplement|carbohydrate drink|800 ml carbohydrate drink by mouth the evening before surgery and 400 ml carbohydrate drink by mouth 2 hours before surgery
1884549|NCT01211184|Behavioral|Fasting.|The patient is fasting from midnight before the surgery.
1884550|NCT01211197|Drug|C: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet after a high fat, high caloric meal
1884551|NCT01211197|Drug|B: BI 10773 tablet and metformin tablet|BI 10773 and metformin single tablets, administered together in fasted state
1884552|NCT01211197|Drug|A: BI 10773 / metformin tablet|BI 10773 / metformin fixed dose combination tablet in fasted state
1884553|NCT01211210|Drug|fluorouracil|Drug: fluorouracil Given IV continuously Radiation: radiation therapy Given 5 days a week for 5-6 weeks
1884554|NCT01211210|Drug|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
1884555|NCT01211210|Drug|fluorouracil, oxaliplatin|Drug: fluorouracil Given IV continuously Drug: oxaliplatin Given IV
1884556|NCT01211223|Drug|Administration of Metronidazole plus Amoxicillin|Metronidazole plus Amoxicillin after, during and after root planning
1884557|NCT01211236|Other|application of wound dressing made of bio-bags (vitapads) containing maggots|
1884558|NCT01211236|Other|application of classical hydrogel/alginate wound dressing|
1884559|NCT01211249|Drug|GLPG0259 oral capsule|Two capsules, each containing 25 mg of GLPG0259 (i.e. 50 mg/day), to be given once daily; in case of adverse events the dose may be split over two administrations, or reduced to 25 mg/day (one single capsule)
1884560|NCT01211249|Drug|Placebo|Placebo capsules; two capsules to be taken in the morning, in case of adverse events the dose may be split over two administrations, or reduced to one single capsule
1884561|NCT01211249|Drug|GLPG0259 (Part B)|Capsule, dosage to be established based on results of Part A
1884562|NCT01211249|Drug|Placebo (Part B)|Capsules, dosage to be established after Part A, and matching GLPG0259 (Part B)
1884563|NCT01211262|Drug|IMCgp100|For each arm, the study will be divided into two parts: In part 1, dose escalation, the MTD or RP2D for each dosing regimen will be established. In part 2, dose expansion, a cohort of patients will be treated at the RP2D or MTD.
1884564|NCT01211275|Biological|axitinib|axitinib: 5 mg BID, day 2 until day 21 of each cycle; cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
1884565|NCT01211275|Drug|chemotherapy|cisplatin: 75 mg/m2 day 1, every 3 weeks; pemetrexed: 500 mg/m2 day 1, every 3 weeks.
1884566|NCT01211301|Behavioral|Food-based, Reduced Energy Diet Plan|Control participants will be provided with a 1000-kcal/d meal plan based on regular foods selected and procured by participants. Food lists, sample menus, and portion size references will be provided.
1884567|NCT01211301|Other|Medifast 5 & 1 Plan|Participants randomized to the Medifast group will enroll online in the Medifast 5 & 1 Plan. This plan consists of 5 portion-controlled, nutritionally-balanced Medifast Meals plus one Lean & Green Meal each day. Medifast Meals come in individual packets that are mixed with water and microwaved or refrigerated, and are available in a wide variety of foods and flavors. There are >70 Medifast Meal choices, and Medifast Meals may be used interchangeably, so any five Medifast Meals can be chosen for the 5 & 1 Plan. The Medifast 5 & 1 Plan provides approximately 800 to 1,000 kcal/d. The Lean & Green Meal consists of a lean meat plus salad and/or vegetables selected by the participant. Intervention participants will have online access to Medifast dietitians, Medifast trainers, a Medifast message board, and a Medifast chat room, allowing them to interact with others on the Medifast 5 & 1 Plan.
1884568|NCT01211314|Drug|Lercanidipine/enalapril fixed combination|Lercanidipine 10 mg + enalapril 20 mg, once a day, used as a fixed combination drug. Unique dose during the study
1884569|NCT01211327|Drug|Cyclosporine A|Cyclosporine 2% eye drops
1884570|NCT01211327|Drug|Dexamethasone|Dexamethasone 0,1% eye drops
1884571|NCT01211340|Behavioral|ACTIVE|Assessing Caregivers for Team Intervention via Video Encounters: this intervention uses video technology to bridge geographic distance to empower hospice caregivers to participate in plan of care meetings for their patient
1884572|NCT01211353|Behavioral|Personalized Drinking Feedback|Personalized feedback about one's drinking habits
1884573|NCT01211353|Behavioral|Education-Only|Educational information about alcohol use
1884574|NCT01211366|Other|Cell Saver RBCs|Use of cell saver RBCs to decrease the infusion of allogeneic PRBCs, crystalloid, and colloid in post-operative infants following CPB as needed for hemodynamic instability
1884575|NCT01211366|Other|Conventional volume infusion|Infusion of allogeneic PRBCs, crystalloid, and colloid as needed for hemodynamic instability
1884576|NCT01211379|Behavioral|FLU-FOBT Program|Primary care patients who came in for flu shots were assessed by nurses for colorectal cancer screening eligibility and offered FOBT if due.
1884577|NCT01211392|Other|magnetic resonance imaging|magnetic resonance imaging is compared to dual-energy computed tomography for the detection of bone marrow changes
1884578|NCT01211405|Drug|Low dose MDMA|30 mg MDMA administered p.o. once during each experimental session. Upon mutual agreement this maybe followed by a supplemental dose of 15 mg MDMA 1.5 to 2 hours later
1884579|NCT01211405|Drug|Medium dose MDMA|75 mg MDMA adminis5tered p.o. once at start of an experimental session. Upon mutual agreement, may be followed 1.5 to 2 hours later by a supplemental dose of 37.5 mg
1884580|NCT01211405|Drug|Full dose MDMA|125 mg MDMA administered p.o. at start of an experimental session. By mutual agreement, may be followed 1.5 to 2 hours later by a supplemental dose of 62.5 mg MDMA.
1884581|NCT01211405|Behavioral|Psychotherapy|Psychotherapy throughout main study
1884582|NCT01211418|Behavioral|Integrative Meditation|"Stage 1: Treatment Engagement and Detoxification. Use 6 breaths/minute as near resonant-frequency.
Stage 2: Recovery and transition by reducing craving and irritability. Wk 3: introduce 16-mins IM. Wk 4: RFB & IM as a coping tool. Wk 5: add guided imagery into IM. Wk 6: review and catch-up if miss any prior sections.
Stage 3: Revitalization and Relapse Prevention. Wk 7: customize guided imagery. Wk 8: introduce full version of IM. Wk 9: techniques of handling random thoughts during meditation and learn to separate thoughts from action. Wk 10: how to use IM techniques to handle different relapse triggers. Wk 11: different ways to integrate IM technique into daily life. Wk 12: review, feedback, and provide local sources for more meditation practice and study."
1884583|NCT01211418|Behavioral|Supportive Counseling|"NT is a procedure in which the therapist refrains from directing the client, but instead reflects back to the client what the latter has said. NT is chosen for this study to control for non-specific effects that show to contribute to outcome such as therapeutic alliance and therapist competency.
The protocol for the individualized NT will mirror the layout of IM therapy -12 weekly meetings, 30 minutes each. Subjects in NT group will be instructed to do Diaphragmatic Breathing (DB) exercise and will be given assigned homework (writing journal) and track progress. DB is incorporated into the NT as treatment providing non-specific effects associated with attention and homework completion."
1884584|NCT01211431|Drug|Reference|Intrathécale morphine is used for post-cesarean pain control
1884585|NCT01211431|Drug|Experimental|A solution including both ropivacain and diclofenac continuously delivered to the wound is used for post-cesarean pain control
1884586|NCT01211444|Device|HGNS Treatment|The Apnex Hypoglossal Nerve Stimulation System (HGNS) is an implanted medical device that is designed to prevent the tongue from blocking the airway during sleep. It is fully automatic and can be implanted during a simple surgical procedure. After it is implanted, the device is programmed to meet the unique needs of each patient. The device is on when the patient is sleeping and off when the patient is awake.
1884587|NCT01211457|Drug|sapacitabine and decitabine|decitabine will be administered in alternating cycles with sapacitabine
1884588|NCT01211470|Drug|Daptomycin|Active Comparator: Daptomycin.
1884589|NCT01211470|Drug|PMX-30063-investigational drug|Experimental: PMX-30063
1884590|NCT01213342|Dietary Supplement|Omega-3 Fatty Acid|"Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal). They will continue this regimen for 8 weeks. The total daily amount included in 4 soft gels includes:
EPA (Eicosapentaenoic Acid) 1300mg
DHA (Docosahexaenoic Acid) 900 mg
Other Omega-3's 360mg
Total Omega 3's 2560 mg"
1884591|NCT01213342|Dietary Supplement|Soybean Soft Gels|Each patient will be instructed to take 4 soft gel capsules per day (2 with the morning meal and 2 with the evening meal. The main ingredient in the placebos is soybean oil (95.6%).
1884592|NCT01213355|Drug|Placebo|Capsule, single dose, oral, 1 day
1884593|NCT01213355|Drug|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
1884594|NCT01213355|Drug|PF-05212377|5 mg, PF-05212377, capsule, single dose, 1 day
1884595|NCT01213355|Drug|Scopolamine|injectable subcutaneous formulation, single dose, 1 day
1884596|NCT01213355|Drug|PF-05212377|20 mg, capsule PF-05212377, single dose, 1 day
1884597|NCT01213355|Drug|scopolamine|injectable subcutaneous formulation, single dose, 1 day
1884598|NCT01213355|Drug|PF-05212377|60 mg PF-05212377, capsule, single dose, 1 day
1884599|NCT01213355|Drug|scopolamine|injectable sub cutaneous formulation, single dose, 1 day
1884600|NCT01213355|Drug|Donepezil|Tablet, 10mg, single dose, 1 day
1884601|NCT01213355|Drug|Scopolamine|injectable sub cutaneous formulation, single dose, 1 day
1884602|NCT01213368|Drug|DRONEDARONE (SR33589)|"Pharmaceutical form: tablets
Route of administration: oral"
1884603|NCT01213368|Drug|placebo|"Pharmaceutical form: tablets
Route of administration: oral"
1884604|NCT01213381|Drug|Iniparib (SAR240550 - BSI-201)|"Pharmaceutical form:sterile aqueous solution
Route of administration: intravenous"
1884605|NCT01213381|Drug|Gemcitabine|"Pharmaceutical form:sterile aqueous solution
Route of administration: intravenous"
1884606|NCT01213381|Drug|Carboplatin|"Pharmaceutical form:sterile aqueous solution
Route of administration: intravenous"
1884607|NCT01213394|Drug|mycophenolate mofetil|"Introduction of CellCept or increase in the dose of CellCept to a maximum of 2 g/day. In patients not already receiving CellCept, azathioprine (AZA), enteric-coated mycophenolate sodium (EC-MPS) or sirolimus (SRL) will be discontinued and replaced by CellCept in divided doses to a maximum of 2 g/day. CNI doses will be reduced to conform to the target trough levels in the low-dose CNI arms of the ELITE-Symphony study +/- steroid dose reduction. Any CNI dose change will require measurement of CNI trough levels at 7 days post dose change +/- 3 days.
Target CNI trough levels in the Symphony study:
Low-dose CsA: Initial oral dose of 1-2 mg/kg bid, to achieve a target trough level of 50-100 ng/mL.
Low-dose TAC: Initial oral dose of 0.1 mg/kg/day divided into two doses* with a target trough level of 3-7 ng/mL (*Advagraf may also be used at a dose of 0.1 mg/kg once daily with a target trough level of 3-7 ng/mL)"
1884642|NCT01213693|Drug|Salmeterol|Salmeterol 50 mcg 1 inhalation bid
1884608|NCT01213394|Other|standard immunosuppression|Current immunosuppressive therapy will be maintained throughout the study unless a change is required for safety reasons.
1884611|NCT01213420|Other|Nivea Cream for scar hydration|3 applications per day during 6 months
1884612|NCT01213420|Other|Aloë Vera FORMULA F-BC-096 for scar hydration|3 applications per day during 6 months.
1884613|NCT01213420|Other|Eucerin Calming cream for scar hydration|3 applications per day during 6 months
1884614|NCT01213420|Other|Aloë Vera with modified preservative for scar hydration|3 applications per day during 6 months
1884615|NCT01213433|Drug|Artesunate-Amodiaquine|Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
1884616|NCT01213446|Biological|Biostate|"PK component: Single bolus infusion of 80 IU VWF:RCo/kg administered intravenously on Day 1, and approximately Day 180 in Type 3 VWD subjects only.
Efficacy component: Repeated bolus doses over 12 months as required to manage VWD condition."
1884617|NCT01213459|Procedure|Cervical samples|Human papillomavirus detection and typing in cervical samples.
1884618|NCT01213459|Other|Data collection|Questionnaire completion
1884619|NCT01213472|Biological|GSK Biologicals' 2241658A Antigen-Specific Cancer Immunotherapeutic (ASCI)|Up to 24 intramuscular administrations
1884620|NCT01213498|Drug|Atorvastatin|Zarator, 80 mg pr. day for 5 days
1884621|NCT01213498|Drug|Unikalk|1 tablet Unikalk pr day for 5. days
1884622|NCT01213511|Procedure|Coronary artery bypass grafting with the use of minimal extracorporeal circulation|The MECC system (Maquet Cardiopulmonary, Hirlingen, Germany) consists of a pre-connected closed CPB circuit containing a RotaFlow centrifugal pump and a Quadrox D diffusion membrane oxygenator. A flow meter and a bubble sensor are integrated in the drive unit of the centrifugal pump. The system features a tip-to-tip heparin coating (Bioline Coating, Maquet Cardiopulmonary, Hirlingen, Germany). No arterial or venous line filters are included. Initial priming volume of the system is 500 mL, while using retrograde autologous priming (RAP) the circuit could be filled in with autologous blood, thus reducing hemodilution. Since no cardiotomy suction is used, shed blood is collected with a cell-saving device (Haemonetics Corp, Braintree, MA).
1884623|NCT01213511|Procedure|Coronary artery bypass grafting under conventional extracorporeal circulation|A standard open CPB circuit is used, consisting of uncoated PVC tubing, a hard-shell venous reservoir, a microporous membrane oxygenator (Dideco, Mirandola, Italy) and a roller pump (Stöckert S3, Munich, Germany). The circuit contains a 40 μm arterial line blood filter (Dideco, Mirandola, Italy) and it is primed with 1500 mL of a balanced crystalloid/colloid solution (1000 mL of Ringer's solution, 200 mL of mannitol 20%, and 300 mL of hydroxyethyl starch 6%). Cardiotomy as well as sump sucker are integrated to the circuit.
1960465|NCT03199885|Other|Laboratory Biomarker Analysis|Correlative studies
1960466|NCT03199885|Drug|Paclitaxel|Given IV
1960467|NCT03199885|Biological|Pembrolizumab|Given IV
1960468|NCT03199885|Biological|Pertuzumab|Given IV
1884628|NCT01213550|Drug|Chlorhexidine gluconate|
1884629|NCT01213550|Drug|Placebo mouthrinse|
1884630|NCT01213563|Drug|Actrapid insulin+Gloucose|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin+ Glucose is administered as per standard sliding scale (Appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring, post-operative patients can be divided in two broad categories.
1884631|NCT01213563|Drug|Actrapid insulin|On admission to hospital all pre-operative oral antidiabetic agents and insulin are stopped and glucose monitoring is carried out every four hours at the same time as routine observations. Actrapid insulin is administered as per standard sliding scales (appendix A). Just prior to discharge, total insulin administered over the previous 24 hour post-operative period is calculated. Based on the results of ward based glucose monitoring patients are discharged home on metformin 1000mg BID and/or the equivalent amount of Glargine insulin requirement in previous 24 hours prior to discharge.
1884632|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|400 mg orally given annually
1884633|NCT01213576|Drug|Albendazole and ivermectin|albendazole 800 mg and ivermectin 400mg orally given annually
1884634|NCT01213576|Drug|Albendazole 400mg and ivermectin 200mcg/kg|Albendazole 400mg and ivermectin 200mcg/kg given twice a year
1884635|NCT01213576|Drug|albendazole 800mg and ivermectin 400mcg/kg bi-annually|albendazole 800mg and ivermectin 400mcg/kg given twice a year
1884636|NCT01213615|Device|Valve replacement|Aortic valve replacement of Hancock II Ultra porcine bioprosthesis
1884637|NCT01213628|Device|humidified warmed CO2|Additional insufflation of humidified carbon dioxide (approx. 30ºC, approx. 80-100% relative humidity) via a simple humidifier (sterile water in plastic bottle) connected to a gas diffuser (Cardia Innovation AB) that is able to create a local atmosphere of 100% carbon dioxide (humidified) in the wound cavity.
1884638|NCT01213667|Drug|Ranibizumab|upload (three monthly injections), re-treatment as needed
1884639|NCT01213680|Drug|Monofer (iron isomaltoside 1000)|1000 mg iron isomaltoside administered as a infusion over 15 minutes
1884640|NCT01213680|Drug|Monofer|500 mg iron isomaltoside 1000 given as bolus injection over 2 minutes
1884641|NCT01213693|Drug|Salmeterol/Fluticasone combination|Salmeterol/Fluticasone 50/500 mcg 1 inhalation bid
1960469|NCT03199885|Biological|Trastuzumab|Given IV
1960471|NCT03199053|Drug|Dapagliflozin|Tablets, Oral, 5mg , Once daily Tablets, Oral, 10mg, Once daily
1960472|NCT03199053|Drug|Saxagliptin|Tablets, Oral, 2.5mg Once daily Tablets, Oral, 5mg, Once daily
1960473|NCT03199053|Drug|Placebo|Matching placebo to dapagliflozin 5mg and 10 mg/saxagliptin 2.5 mg and 5 mg, Tablets, oral, Once daily
1884643|NCT01213706|Device|Whole Body Periodic Acceleration (WBPA)|Subjects will undergo to the Whole Body Periodic Acceleration platform for treatment (shaking period) for 45 min.
1884644|NCT01213706|Device|Sham WBPA|The subjects will rest for 45 minutes in the Whole Body Periodic Acceleration (WBPA) platform without movement as a control challenge.
1884645|NCT01213719|Dietary Supplement|creatine|20g/d throughout 10 days
1884646|NCT01213719|Dietary Supplement|betaine|2g/d throughout 10 days
1884647|NCT01213719|Dietary Supplement|dextrose|dextrose (placebo), 20 g/d throughout 10 days
1884648|NCT01213719|Dietary Supplement|creatine plus betaine|creatine (20g/d) plus betaine (2g/d) throughout 10 days
1884649|NCT01213732|Other|Isolated inferior limb perfusion|Single Melphalan bolus perfused for 60 min after 30 min of L19TNFα bolus. Intra-arterial (IA) infusion via bolus at 39˚C to 40˚C (mild hyperthermia).
1884650|NCT01213745|Other|Intervention|
1884651|NCT01213745|Other|Attention|
1884652|NCT01213745|Other|Control|
1884654|NCT01213771|Procedure|Preoperative preparation 2010|Preoperative optimisation Supportive care LEAN in patient pathways
1884655|NCT01213784|Other|all antidiabetic drugs will be appliable|We expect all participants to be set on insulin during the intervention, however all types of insulin and other antidiabetics can be used goal: Hba1c lower than 7,5%
1884656|NCT01213810|Biological|Zostavax|Biological/Vaccine
1884657|NCT01213823|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
1884658|NCT01213823|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply
1884659|NCT01213836|Drug|Seroquel XR- quetiapine fumarate extended release|Seroquel XR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken once a day for 10-16 days.
1884660|NCT01213836|Drug|Seroquel IR - quetiapine fumarate|Seroquel IR dose 400-700 mg (in tablet form). The investigator established the dosing schedule for each patient depending on the patient's dose when entering the study. The patients continued on the same dose during the study as they had prior to enrolment. Dose taken twice a day for 10-16 days.
1884661|NCT01213836|Drug|Placebo matching Seroquel XR|Placebo matching Seroquel XR dose 400-700 mg (in tablet form). Dose taken once a day for 10-16 days.
1884662|NCT01213836|Drug|Placebo matching Seroquel IR|Placebo matching Seroquel IR dose 400-700 mg (in tablet form). Dose taken twice a day for 10-16 days.
1884663|NCT01213849|Drug|Fluticasone furoate 50 mcg (4 inhalations)|4 inhalations of 50 mcg strength
1884664|NCT01213849|Drug|Fluticasone furoate 100 mcg (4 inhalations)|4 inhalations of 100 mcg strength
1884665|NCT01213849|Drug|Fluticasone furoate 200 mcg (4 inhalations)|4 inhalations of 200 mcg strength
1884666|NCT01213849|Drug|Vilanterol 25 mcg (4 inhalations)|4 inhalations of 25 mcg strength
1884667|NCT01213862|Behavioral|Home Based Education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope, sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
1884668|NCT01213875|Behavioral|Home based education|There will provided education about what is heart failure, its causes, how to recognize signs and symptoms, monitoring of weight and blood pressure, the importance of compliance to treatment. Patients will be instructed about the medications; a guide to rest and exercise, sexual activity, vaccines, travel and diet will be provided. The involvement of the family will be encouraged; the contact with the team should be done when: patient observes an increase of 1 or 2 kg of weight in 2-3 days, worsening of dyspnea on effort, edema in legs / abdomen, worsening of cough, persistent vomiting, syncope,sputum with blood, fever, persistent tachycardia. In phone calls made between home visits, the compliance to treatment will be evaluated and reinforced.
1884669|NCT01213888|Drug|Trientine Hydrochloride|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10-day course of oral Trientine at 1500mg administered for 7-days prior to and 3 days after the PRP sessions.
1884670|NCT01213888|Drug|Oral placebo capsules|All participating subjects will all receive PRP (pan-retinal photocoagulation) according to present standards of care; however, subjects randomized the placebo group will be on a 10-day course of oral placebo capsules at 1500mg administered for 7-days prior to and 3 days after the PRP sessions
1884671|NCT01213901|Procedure|Lispro insulin|Each patient will receive 2 insulin injections in the abdomen: Once using a pinch method and once using a spread method.
1960474|NCT03199326|Other|Collaborative Care|CPS caseworkers will explain collaborative care to parents, ask parents to allow communication with an infant's primary care provider, and have willing parents sign a release allowing communication with the infant's provider during the investigation. Caseworkers will make at least two attempts to contact identified providers with parental consent. In the first week, caseworkers will contact the provider, identify the infant, and summarize the child maltreatment concerns. The caseworker will ask whether the provider recognizes any additional strengths or vulnerabilities for the infant. Prior to case closure, caseworkers will provide a summary of investigation findings, disposition, and service referrals including placement changes, safety planning, family preservation, and community resources, with a summary letter delivered to the provider after case closure.
1884674|NCT01213940|Behavioral|pre-bariatric weight loss program|standard 6 month physician directed pre-bariatric weight loss program
1884675|NCT01213940|Procedure|bariatric surgery|bariatric surgery for weight loss
1884676|NCT01213966|Drug|OZ439|po, single dose
1884677|NCT01213979|Drug|500 mg iron isomaltoside 1000|500 mg iron isomaltoside 1000 given as a bolus injection over 2 minutes
1884678|NCT01213979|Drug|1000 mg iron isomaltoside 1000|1000 mg iron isomaltoside 1000 given as a infusion over 15 minutes
1884679|NCT01213992|Drug|Iron isomaltoside 1000|Single dose of 500 mg administered as a bolus undiluted over 2 min.
1884680|NCT01213992|Drug|Iron isomaltoside 1000|Single dose of 1000 mg infused over 15 min. The infusion is diluted in 100mL 0,9% sodium chloride
1884681|NCT01214005|Behavioral|smoking abstinence|3 days of biologically-confirmed smoking abstinence
1884682|NCT01214018|Other|Questionnaires and interview|Questionnaires and interview
1884683|NCT01214031|Device|Confocal laser endomicroscopy (CLE)|Confocal laser endomicroscopy (CLE) is another novel imaging tool for enabling histopathologic diagnosis in vivo during endoscopy. Specially designed confocal endoscopes have the confocal laser microscope integrated to the distal tip of the conventional endoscope. This provide images at a cellular level that have been shown to have a high sensitivity, specificity and accuracy
1884684|NCT01214044|Drug|placebo/escitalopram|Subjects will first complete a one week, single-blind placebo lead in phase. Subjects will then receive escitalopram for 8 weeks. Subjects will receive 10 mg/day for the first 2 weeks of active treatment, and then 20 mg/day for the remaining 6 weeks of treatment. Medication will be dispensed on a weekly basis.
1884685|NCT01214057|Drug|Propofol and Remifentanyl|Anesthesia will be induced with lidocaine 0.5 mg kg, propofol infusion at 250 mcg/kg/min (to reduce visual bias of propofol infusion) and total volume infused will be adjusted for an induction dose of 2-3 mg/kg before bolus of muscle relaxant, rocuronium 0.5 mg kg in both SR and PR groups. Remifentanil infusion will be started at a rate of 0.4 mcg/kg/min 1-2 minutes before the propofol infusion and a 100 ml 0.9% normal saline bag will be used to blind surgeons in the sevoflurane group. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the propofol concentration within their range (100-150 mg ml for propofol) according to the anaesthesiologist's judgement and by surgeon request. If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.
1884686|NCT01214057|Drug|Sevoflurane and Remifentanyl|Sevoflurane 1-3% will be administered in group SR, and the infusion of propofol will be stopped. After intubation remifentanil infusion will be changed to 0.2 mcg/kg/min. The target mean arterial blood pressure (MAP) will be maintained at 70-80 mm Hg by adjusting the sevoflurane concentration within their range (between 1-3 vol% for sevoflurane) according to the anaesthesiologist's judgement and by surgeon request.If this failed, the remifentanil rate will be adjusted by 0.05 mg kg min.In order to limit the amount of fluids remifentanil wil be diluted at a concentration of 4 mg in 100 ml.
1884687|NCT01214070|Other|Vision Restoration Therapy|Therapy that enhances the neuronal plasticity of the visual system
1884688|NCT01214070|Behavioral|NVT Eye Scanning Therapy|Therapy that trains eye and head scanning into the blind hemianoptic visual field
1884689|NCT01214070|Behavioral|Eccentric Viewing Training|Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
1884690|NCT01214070|Behavioral|Sham|Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
1884691|NCT01214083|Drug|N-acetylcysteine + high-dose naltrexone (150 mg)|All subjects will be evaluated weekly for 12 weeks.
1884692|NCT01214083|Drug|High-dose naltrexone (150 mg) alone|All subjects will be evaluated weekly for 12 weeks.
1884693|NCT01214083|Drug|Low-dose naltrexone (50 mg) alone|All subjects will be evaluated weekly for 12 weeks.
1884694|NCT01214096|Drug|rhNRG-1|Subcutaneous Administration:0.6ug/kg/day for 10days
1884695|NCT01214096|Drug|rhNRG-1|Subcutaneous Administration 1.2ug/kg/day for 10 days
1884696|NCT01214096|Drug|rhNRG-1|Vein infusion:0.6ug/kg/day for 10 days
1884697|NCT01214096|Drug|placebo|Subcutaneous Administration:0.6 or 1.2ug/kg/day for 10days
1884698|NCT01214109|Drug|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
1884699|NCT01214109|Drug|pramipexole extended release|0.375mg once per day for 5 days (cross-over), 0.75mg once per day for 5 days (up-titration), 1.5mg once per day for 5 days (cross-over)
1884700|NCT01214109|Drug|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
1884701|NCT01214109|Drug|pramipexole immediate release|0.125mg three times a day for 5 days (crossover), 0.5mg three times a day for 5 days (cross over)
1884702|NCT01214122|Drug|AZD9668|60 mg orally twice daily for 11 days
1884703|NCT01214122|Drug|Warfarin|10 x 2.5 (25) mg orally once daily on day 1 and on day 14
1884704|NCT01214148|Device|ORSIRO - Drug Eluting Coronary Stent|The coronary stent is delivered to the intended implantation location by means of the fast-exchange delivery system and then expanded to its final diameter by dilating the balloon. It remains in the vessel as a permanent implant.
1884705|NCT01214161|Drug|2% lidocaine gel|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control group with an inert gel similar in appearance, color and consistency to the lidocaine gel.
Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
1884706|NCT01214161|Other|placebo|"Participants, after informed consent, will be randomized in a 1:1 ratio to the inert gel group or the intervention group. In the intervention group, after tenaculum placement, a Q-tip soaked in approximately 1mL of 2% lidocaine gel will be placed in the cervix up to the level of the internal cervical os. The Q-tip will be held there for 1 minute and then be removed. We will repeat the same procedure in the control/placebo group with an inert gel similar in appearance, color and consistency to the lidocaine gel.
Both the patient and the provider will be blinded to which gel was received. The research assistant will place the gel from its labeled tube into the unlabeled sterile tube in another room."
1884707|NCT01214174|Drug|IBI-10090|
1884708|NCT01214187|Drug|inhaled carbon monoxide|The intervention will be inhaled CO at 100-200 ppm administered two times weekly for two hours per dose to complete 12 weeks of treatment.
1884709|NCT01214187|Other|Oxygen|Room air oxygen concentrations will be administered as placebo
1884710|NCT01214200|Device|High Intensity Non Invasive Pos. Pressure|High Intensity Non Invasive Positive Pressure Ventilation (HINPPV) will be applied to hypercapnic chronic obstructive pulmonary disease (COPD) patients for a period of 3 months. The Respironics bilevel positive airway pressure (BiPAP) Synchrony device has a maximum inspiratory positive airway pressure (IPAP) setting of 30 cmH2O and will be used for all participants in the study. If it is determined through the titration study the participant requires an IPAP greater than 30 cmH2O, they will be placed on the Respironics Trilogy ventilator.
1884711|NCT01214200|Device|Bilevel positive airway pressure (BiPAP)|This is a single arm interventional study. All participants that meet eligibility criteria will receive high intensity non-invasive positive pressure ventilation(HINPPV). Participants will receive HINPPV via bilevel positive airway pressure (BiPAP) if they require an inspiratory positive airway pressure (IPAP) less than or equal to 30 cmH2O; or the Trilogy ventilator if they require an IPAP greater than 30 cmH2O.
1884712|NCT01214226|Drug|Pentoxifylline|400 mg prolonged-released tablets 3 time per day for 1 month.
1884713|NCT01214226|Drug|placebo|prolonged-release tablets 3 time per day for 1 month
1884714|NCT01214239|Drug|Placebo|once a day
1884715|NCT01214239|Drug|Linagliptin|once a day
1884716|NCT01214252|Device|Permacol Surgical Implant|Permacol Surgical Implant
1996656|NCT02424799|Drug|GSK2646264 0.5% topical cream|GSK2646264 0.5% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
1884718|NCT01214278|Drug|rTG|EPA+DHA as re-esterified triglycerides (rTGs) from fish-oil; uncoated capsules (4 per day); 2016 mg n3 fatty acids daily (1008 mg EPA and 672 mg DHA)
1884719|NCT01214278|Drug|GArTG|EPA+DHA as rTGs from fish-oil in gastric acid resistant (coated) capsules (GArTG); 4 capsules per day; 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
1884720|NCT01214278|Drug|EE|EPA+DHA as ethylesters (EE) from fish-oil uncoated capsules (4 per day); 2016 mg n-3 fatty acids (1008 mg EPA and 672 mg DHA)
1884721|NCT01214278|Drug|KPL|DHA+EPA as phospholipids from krill-oil, uncoated capsules (KPL); 7 capsules per day; 2100 mg n-3 fatty acids (1050 mg EPA and 630 mg DHA)
1884722|NCT01214291|Drug|Toremifene|Toremifene 80mg daily
1884723|NCT01214304|Other|Essential Lavender Oil|Aromatherapy with essential lavender oil will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The essential lavender oil and will be administered by fan diffuser.
1884724|NCT01214304|Other|Lavender Scent|Aromatherapy with a fake lavender scent (placebo) will be initiated 5 minutes prior to the procedure and continued until the conclusion of the procedure (patient dressed and ready to leave the room). The fake lavender scent will be administered by fan diffuser.
1884725|NCT01214317|Procedure|plasmapheresis|3 courses of plasmapheresis are performed before mitoxantrone injection in first 3 months to investigate the efficacy of plasmapheresis in comparison with the other arm that are only treated with mitoxantrone
1884726|NCT01214330|Device|Patient-Collected Cervical Pap Smear|Patient-Collected Cervical Papanicolaou Smear
1884727|NCT01214343|Drug|Sorafenib with Low-dose FP|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in a cycle. Cisplatin at the dose of 20 mg/m2 will be administered at day 1 and day8, and fluorouracil at the dose of 330 mg/m2 will be administered continuously at day 1-day 5, and day8-day12 via the implanted catheter system. A cycle is defined as 28 days.
1884728|NCT01214343|Drug|Sorafenib|Sorafenib will be administered orally at a dose of 400 mg bid for 28 days in each cycle.A cycle is defined as 28 days.
1884729|NCT01214356|Drug|Vitamin D3|Patients receive vitamin D 400 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
1884730|NCT01214356|Drug|Vitamin D3|Patients receive vitamin D 4000 IU/d with calcium carbonate (1000 mg) once per day for 15 months (3 month run in phase with 12 month follow up)
1884731|NCT01214369|Procedure|Type of Supplementary Injection|Patients will be selected from a group who were not anesthetized following 3.6 ml block injection. Half of the randomly selected patients will receive X-tip intraosseous injection and half will receive PDL injection as a supplementary for completing the anesthesia in selected hot mandibular molar teeth.
1884732|NCT01214382|Drug|Sertraline|Single dose sertraline 100 mg, tablet and solution
1884733|NCT01214395|Drug|5% tea tree oil nasal ointment|daily for 5 days then weekly for 6 months
1884734|NCT01214408|Drug|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
1884735|NCT01214408|Drug|Buffered pantoprazole|Buffered pantoprazole 40 mg QD
1884736|NCT01214421|Drug|Tolvaptan|Daily split-dose of tolvaptan titrated to the maximally tolerated dose. Starting daily tolvaptan dose of 45mg/15mg titrated to 60mg/30mg, then 90mg/30mg based on tolerability.
1884737|NCT01214434|Device|Promiseb Topical Cream|topical non steroidal cream, twice daily
1884738|NCT01214434|Other|Bland emollient|Eucerin cream twice daily
1884739|NCT01214447|Other|No intervention|Observational study - no intervention
1884740|NCT01214473|Other|Synbiotics|Lactobacillus plantarum with fructo-oligosaccharide
1884741|NCT01214473|Other|Maltodextrin|Only maltodextrin as placebo
1884743|NCT01214499|Procedure|Transmyocardial revascularization (TMR) with Holmium YAG laser|Transmyocardial revascularization (TMR) is a surgical procedure that uses a laser to create channels through the myocardial, so this laser stimulates local angiogenesis and provides blood in the ischemic area.
1884825|NCT01215175|Biological|Adults-Adjuvanted V114|V114 vaccine, aluminum-adjuvanted, in adults
1884826|NCT01215175|Biological|Adults-Prevnar™|Prevnar™ vaccine in adults
1996657|NCT02424799|Drug|GSK2646264 1% topical cream|GSK2646264 1% topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
1996658|NCT02424799|Drug|Placebo|Placebo topical cream is supplied as white-to-off-white aqueous cream stored in amber glass jars
1996659|NCT02424734|Drug|Ceftaroline Fosamil|Ceftaroline fosamil will be given at a dose of 6 mg/kg IV over 60 (± 10) minutes every 8 hours (q8h) (± 1 hour).
1996660|NCT02424734|Drug|Ampicillin|Ampicillin IV is required for the first 48 hours if the presence of an organism that requires treatment with ampicillin cannot be excluded. Will be given as per local standard of care.
1996661|NCT02424734|Drug|Aminoglycoside|Optional, will be given as per local standard of care.
1884744|NCT01214499|Procedure|Transmyocardial revascularization (TMR) with Holmium YAG laser plus the patient's own stem cells extracted from bone marrow.|The system called PHOENIXTM consists of a laser probe with Holmium:YAG energy capable of creating transmural channels in the myocardium. Surrounding this fibre 3 needles with side holes are arranged so that the implantation of stem cells is done on the edges of the channel and not on the channel itself. This device is capable of distributing stem cells in those channels created by the laser, carrying out both procedures simultaneously.
1884745|NCT01214512|Other|blood-sample based diagnostic assay|A blood sample will be used in a Western blot and ELISA assay to determine CD24 levels
1884746|NCT01214564|Drug|PEP005 (ingenol mebutate) Gel|0.05%
1884747|NCT01214577|Drug|PEP005 (ingenol mebutate) Gel|0.015%
1884748|NCT01214590|Device|VascuActive device|self treatment by the patient, for 4 weeks, 3 sessions per day, approximately 30 minutes per session
1884749|NCT01214603|Drug|LY2090314|Administered intravenously
1884750|NCT01214616|Drug|afatinib 20mg|patient to receive afatinib low dose po daily in combination with vinorelbine iv
1884751|NCT01214616|Drug|afatinib 40mg|patient to receive afatinib high dose po daily in combination with vinorelbine iv
1884752|NCT01214616|Drug|vinorelbine IV 25 or 20mg/m2|patient to receive standard dose vinorelbine once a week for four times per cycle
1960475|NCT03199092|Behavioral|RRT+sat|RRT is a child-friendly computerized reading training program designed for Italian students with DD aged 8-14 yrs. The main feature of this intervention is the integration of a traditional remediation approach (sublexical treatment) with rhythm processing. Therefore, all reading exercises are characterized by a rhythmic accompaniment with gradually increasing speed. For this study, RRT was delivered in combination with a specific auditory training involving several music games specifically designed for improving auditory processing abilities typically compromised in children with DD.
1960476|NCT03199092|Behavioral|Abilmente|'Abilmente' method is an intervention for DD that comprises several validated treatments resulting in a proposal tailored to meet individual needs and features.
1884759|NCT01214668|Drug|LY573636|"Individualized dose is dependent on patients height, weight, gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle.
Patients may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m2 of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met."
1884760|NCT01214668|Drug|Liposomal Doxorubicin|"40 mg/m2 on Day 1, given intravenously of each 28-day cycle
Patients may continue on study drug until disease progression, unacceptable toxicity, cumulative dose of 550 mg/m2 of liposomal doxorubicin or doxorubicin is reached, or other withdrawal criterion are met."
1884761|NCT01214681|Dietary Supplement|Maltodextrin and Amioca starch|12g Maltodextrin and 23g Amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
1884762|NCT01214681|Dietary Supplement|Hi-maize 260|23g Hi-maize 260 and 12g Maltodextrin daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
1884763|NCT01214681|Dietary Supplement|Polydextrose|12g polydextrose and 23g amioca starch daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
1884764|NCT01214681|Dietary Supplement|Hi-maize 260 and polydextrose|12g polydextrose and 23g Hi-maize 260 daily in divided doses for 50 days. Provided as a powder to be added to food or drink.
1884765|NCT01214694|Behavioral|Internet-based Interacting Together Everyday: Recovery After Childhood TBI (I-InTERACT)|Families in I-InTERACT will view 10 web-sessions (like chapters) and participate in 27 family meetings over the course of 24 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
1884766|NCT01214694|Behavioral|Internet-based-Interacting Together Everyday, Recovery after Childhood TBI Express (I-InTERACT Express)|Families in I-InTERACT Express will view 10 web-sessions (like chapters) and participate in 14 family meetings over the course of 7 weeks focusing on increasing positive parenting skills, reducing parenting stress, and improving child behavior problems. Meetings will be conducted in their home using a computer hook-up with a trained therapist.
1884767|NCT01214694|Behavioral|Internet Resources Comparison (IRC)|Families in the IRC group will receive computers, high speed internet access, and links to brain injury information and resources. The resources are available for families to access as often as they choose.
1884768|NCT01214707|Other|Exercise|Exercise during EMU stay
1884769|NCT01214720|Drug|bevacizumab [Avastin]|Intervenous repeating dose
1884770|NCT01214733|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks in combination with allowed DMARDs
1884771|NCT01214746|Drug|Placebo|1 tablet Unikalk 1 time pr day for 5 days
1884772|NCT01214746|Drug|Atorvastatin|Zarator, 80 mg pr day for 5 days
1884773|NCT01214759|Drug|Truvada|Tenofovir 200mg/emtricitabine 300mg once a day
1884774|NCT01214759|Drug|Raltegravir|Raltegravir 400mg twice a day
1884775|NCT01214772|Drug|heparin|5000 IU subcutaneously in the day of embryo transfer until 6 week after delivery
1884776|NCT01214785|Behavioral|Provision of household latrines|WaterAid and local NGO partners mobilize householders in target villages to construct and use latrines in accordance with the Government of India's Total Sanitation Campaign.
1884777|NCT01214811|Device|Mepilex Border Ag|Mepilex Border Ag may be left in place for up to seven days, depending on the condition.
1884778|NCT01214824|Device|FreeStyle Navigator Continuous Glucose Monitoring System|Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
1960482|NCT03196128|Other|Digital communication|Communicating with patients via email and text message.
1960483|NCT03196128|Other|Non digital|Communicating with patients via telephone and written appointment letters.
1996662|NCT02422576|Other|cinnamon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
1996663|NCT02422576|Other|lemon extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
1996664|NCT02422576|Other|lemon extract plus eucalyptus extract|acute exposure to natural ingredient during physiological parameters recording (deglutition or cortical activity)
1884785|NCT01214863|Device|T3|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T3
1884786|NCT01214863|Device|T4|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T4
1884787|NCT01214863|Device|T5|Implantation of the AcrySof Toric Intraocular Lens (IOL) Model SN60T5
1884788|NCT01214889|Biological|PENTAXIM™: DTacP IPV//PRP~T combined vaccine|0.5 mL, intramuscular
1884789|NCT01214889|Biological|TETRAXIM™: DTacP IPV combined vaccine and ActHIB™: PRP tetanus conjugate vaccine|0.5 mL of each vaccine; intramuscular
1884790|NCT01214902|Device|Constraint induced movement therapy (CIMT)|soft mitten worn on the non hemiplegic hand
1884791|NCT01214902|Behavioral|play|play which encourages the use of the hemiplegic hand
1884792|NCT01214915|Drug|Anagrelide Hydrochloride|Subjects will be started at 1.0 mg per day and titrated as necessary.
1884793|NCT01214928|Drug|Cholecalciferol|cholecalciferol 50,000 IU po once weekly for 12 weeks
1884794|NCT01214941|Drug|Placebo|The subjects will be given orally placebo twice a day for 5 days prior to the study.
1884795|NCT01214941|Drug|Ticlopidine|The subjects will be given orally ticlopidine 250mg twice a day for 5 days prior to the study.
1884796|NCT01214941|Drug|Ticlopidine and itraconazole|The subjects will be given orally ticlopidine 250mg twice a day and itraconazole 200mg as a single daily dose for 5 days prior to the study.
1884797|NCT01214954|Other|Supervised progressive resistance training|Resistance training 2 times/week initiated within the first week after total hip replacement. The training is supervised by physiotherapists and individually progressed.
1884798|NCT01214954|Other|Control group|Standard rehabilitation consisting of home-based exercises with 2 postoperative instructions by a physiotherapist.
1884799|NCT01214967|Behavioral|Problem Solving Education|psycho-educational intervention
1884800|NCT01214980|Device|MIST Therapy|Low-frequency, non-contact ultrasound therapy provided in conjunction with standard of care treatment on a daily basis for 5 days.
1884801|NCT01214980|Other|Standard of care|Standard of care provided per site-specific protocol
1884802|NCT01214993|Drug|GSK1349572|GSK1349572 is an experimental drug in the integrase inhibitor class of drugs to treat human immunodeficiency virus (HIV)
1884803|NCT01214993|Drug|Placebo|Placebo is a tablet with no drug in it.
1884804|NCT01214993|Drug|Iohexol Injection|Iohexol is an FDA approved radiologic contrast medium
1884805|NCT01214993|Drug|Para-aminohippurate infusion|Para-aminohippurate is an agent to measure effective renal plasma flow.
1884806|NCT01215019|Drug|Mannitol|20% Mannitol, 1-5 doses as needed to control ICP
1884807|NCT01215019|Drug|NaCl|3% sodium chloride injection, 1-5 doses, as needed to control ICP
1884808|NCT01215032|Drug|Metformin|Taken orally twice daily each 28-day cycle, for 12 cycles
1884809|NCT01215045|Device|AcrySof ReSTOR Aspheric +4|Implantation with the AcrySof ReSTOR Aspheric +4 Multifocal Intraocular Lens (IOL)
1884810|NCT01215071|Procedure|limited lymphadenectomy|Field 5 (Group external iliac rigt) Field 7 (Group external iliac left) Field 9 (obturatorical Group right) Field 11 (obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
1884811|NCT01215071|Procedure|extended lymphadenectomy|Field 1 (paracaval right) Field 2 (interaortocaval) Field 3 (paraaortal left) Field 4 (Group iliac artery right) Field 5 (Group external iliac rigt) Field 6 (Group iliac artery left) Field 7 (Group external iliac left) Field 8 (presacral) Field 9 (obturatorical Group right) Field 10 (deep obturatorical Group right) Field 11 (obturatorical Group left) Field 12 (deep obturatorical Group left) Field 13 (Group internal iliac right) Field 14 (Group internal iliac left)
1884812|NCT01215084|Drug|BIIB041 (Fampridine-PR)|A single 10mg dose tablet by mouth of fampridine prolonged-release (PR) for all participants
1884813|NCT01215097|Drug|Linagliptin|once a day
1884814|NCT01215097|Drug|placebo|once a day
1884815|NCT01215110|Drug|TMC207|
1884816|NCT01215110|Drug|Rifafour e-275 mg|
1884817|NCT01215123|Drug|Bevacizumab|Participants received bevacizumab according to routine clinical practice until disease progression, unacceptable toxicity or withdrawal, along with taxane-based chemotherapy or in combination with other chemotherapy as prescribed.
1884818|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
1884819|NCT01215136|Drug|Everolimus|10 mg PO daily (continuously, without scheduled treatment interruptions). The cycle length will last 28 days. Everolimus will be dispensed on Day 1 of each cycle by the study center personnel on an outpatient basis.
1884820|NCT01215136|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV as a 1 hour infusion on days 1, 8, and 15, of a 28-day cycle.
1884821|NCT01215149|Biological|Ad35-ENV vaccine|Recombinant adenovirus serotype 35 vector vaccine 5x10^10 vp, delivered IM
1884822|NCT01215149|Biological|Ad26.ENVA.01 vaccine|Recombinant adenovirus serotype 26 vector vaccine, 5x10^10 vp delivered IM
1884823|NCT01215149|Biological|Placebo Control|Colorless 10mm Tris/HCl buffer
1884824|NCT01215162|Radiation|Intra-operative radiation to tumor bed|IOERT is given to the tumor bed. Applicator selection should allow treatment of the tumor bed plus 1-2 cm margin. The surgical incision may need to be enlarged slightly to allow the placement of the appropriate applicator. The use of more than 1 treatment field is discouraged. In order to encompass the entire tumor bed in 1 treatment field, it may be necessary to suture the mammary parenchyma loosely so that the lateral margins of the tumor bed are brought into apposition. Electron energy used for the treatment. If the tumor bed can be flattened and encompassed by an applicator, 6 MeV electron is recommended. Use of bolus material may be considered to increase the surface dose. If the mammary parenchyma has been brought into apposition by sutures, a higher electron energy may be necessary to allow adequate dose coverage to a depth of 1.0-2.0 cm into the tumor bed. The dose of IOERT is 1000 cGy, prescribed to the 90% isodose line.
1996665|NCT02422576|Other|Thicken Up clear: TUC|
1884827|NCT01215175|Biological|Toddlers-Adjuvanted V114|V114 vaccine, aluminum-adjuvanted, in toddlers
1884828|NCT01215175|Biological|Toddlers-Non-adjuvanted V114|V114 vaccine, non-adjuvanted, in toddlers
1884829|NCT01215175|Biological|Toddlers-Prevnar™|Prevnar™ vaccine in toddlers
1884830|NCT01215188|Biological|V114 Aluminum-adjuvanted|Four intramuscular (IM) doses at 0.5 mL of aluminum-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age
1884831|NCT01215188|Biological|V114 Non-adjuvanted|Four IM doses at 0.5 mL of non-adjuvanted V114 pneumococcal conjugate vaccine at 2, 4, 6, and 12 to 15 months of age
1884832|NCT01215188|Biological|Prevnar 13™|Four 0.5 mL IM doses of Prevnar 13™ at 2, 4, 6, and 12 to 15 months of age
1884833|NCT01215201|Device|Diode Laser|Diode Laser is used in addition to the standard Scaling and root planing procedure.
1884834|NCT01215214|Drug|midazolam|midazolam: 3mg iv
1884835|NCT01215227|Drug|Preladenant|Daily for 40 weeks: 2, 5, or 10 mg preladenant tablet each morning; 2, 5, or 10 mg preladenant tablet each evening (approximately 8 hours after the morning dose)
1884836|NCT01215227|Drug|Rasagiline|Daily for 40 weeks: 1 mg rasagiline capsule each morning
1884837|NCT01215227|Drug|Placebo to preladenant|Placebo to match preladenant given daily for 40 weeks: placebo tablet each morning; placebo tablet each evening (approximately 8 hours after the morning dose)
1884838|NCT01215227|Drug|Placebo to rasagiline|Placebo to match rasagiline given daily for 40 weeks: placebo capsule each morning
1884839|NCT01215240|Device|Peritoneal dialysis|Prophylactic peritoneal dialysis
1884840|NCT01215253|Drug|Ranolazine|At enrollment, patients will be randomized to ranolazine or placebo. In the active drug arm each patient will be started on a 500 mg twice a day dose for one week with subsequent increase to 1000 mg twice a day at beginning of second week.
1884841|NCT01215266|Drug|Sorafenib|Day 3-21 2x2 800 mg(milligram) daily
1884842|NCT01215266|Drug|Placebo|Day 3-21 2x2 800 mg(milligram) daily
1884843|NCT01215279|Drug|AZD2423|100 mg oral treatment once daily for 28 days
1884844|NCT01215279|Drug|Placebo to AZD2423|Oral treatment once daily for 28 days
1884845|NCT01215292|Drug|Acyline|300 mcg/kg on Day 1
1884846|NCT01215292|Drug|Testosterone gel|5 gm of 1% T Gel applied transdermally for 10 days
1884847|NCT01215292|Drug|ketoconazole 400|400 mg PO daily, Days 3-10
1884848|NCT01215292|Drug|Ketoconazole 800|800 mg PO daily, Day 3-10
1884849|NCT01215292|Drug|Dutasteride|2.5 mg PO daily, Day 3-10
1884850|NCT01215292|Drug|Anastrozole|1 mg PO daily, Day 3-10
1884851|NCT01215292|Drug|Placebo ketoconazole|placebo to mimic ketoconazole
1996666|NCT02419560|Drug|ABT-199 and Ibrutinib Combination|Both are administered orally once daily.
1884853|NCT01215331|Drug|Insulin|Insulins most commonly used during pregnancy by our group are rapid acting insulins and long acting human insulins (long acting analogs are not authorized in pregnancy). An ultra-fast acting insulin will be started before a meal (1, 2 or 3 meals) at 4-6 IU (according to the weight) if the glycemic value 2 hours after this meal is ≥ 6.7 mmol/L in 50% of cases. It will be increased by 2 units every 2 days until obtaining the aimed objectives. Long acting insulin will be started at 4-6 units at bedtime if the glycemic value before breakfast is ≥ 5.3 mmol/L in 50% of cases, and it will be increased by 2 units every 2 days until reaching the objective. A combination of both insulins could be necessary (maximum of 4 injections per day).
1884854|NCT01215331|Drug|Metformin, glyburide and insulin|"Metformin (tablets of 500 mg) will be started at 250 mg/day x 1 day, and increased thereafter by 250 mg per day every 3 days until obtaining an adequate glycemic control. If metformin does not prove its effect at a dose of 750 mg, or if the side effects (mainly gastric) command to slow down or not to increase the posology, glyburide will be added.
Glyburide (tablets of 5 mg) will be started at a dose of 2.5 mg and will be increased by 2.5 mg every 3 days until obtaining an adequate glycemic control. The maximal dose in the study will bw 10 mg. It corresponds to the half of the maximal dose recommended in Canada.
Treatment failure is defined as glycemia above the Canadian Diabetes Association therapeutic objectives in spite of maximal doses or whether the doses can not be increased because of side effects. Insulin will be added to oral hypoglycemic agents."
1884855|NCT01215344|Drug|VELCADE|1.3 mg/m2 by IV on days 1, 4, 8, 11 of each cycle
1884856|NCT01215344|Drug|Lenalidomide|25 mg by mouth on days 1-4 of each cycle
1884857|NCT01215344|Drug|Dexamethasone|20 mg the day before and the day after receiving VELCADE
1884858|NCT01215344|Drug|DVT prophylaxis|At least one asprin 81 mg per day. Other option per physician's choice
1884859|NCT01215344|Drug|Bisphosphonates|Zoledronic acid by IB or pamidronate by IV can be used as per standard of care.
1884860|NCT01215344|Drug|Liposomal doxorubicin|30 mg/m2 on day 4 of each cycle
1884861|NCT01215344|Drug|Dexamethasone|40 mg by mouth on days 1-4, 8-11, and 15-18 of cycle 1 and days 1-4 on cycle 2-4
1884862|NCT01215357|Drug|Ecopipam|50mg tablets
1884863|NCT01215370|Other|High-fat shake with Pea protein|Shake containing 95 gram of fat, additive 30 gram pea protein
1884864|NCT01215370|Other|High-fat shake with Pea protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten protein hydrolysate
1884865|NCT01215370|Other|High-fat shake - Control|Shake containing 95 gram of fat, no protein additive
1884866|NCT01215370|Other|High-fat shake with Gluten protein|Shake containing 95 gram of fat, additive 30 gram gluten protein.
1884867|NCT01215370|Other|High-fat shake with Gluten protein hydrolysate|Shake containing 95 gram of fat, additive 30 gram gluten gluten hydrolysate
1884868|NCT01215396|Dietary Supplement|AminoVital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener.
1884869|NCT01215396|Dietary Supplement|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and an amino acid mixture (2.4g of AA as: leucine, isoleucine, valine, arginine and glutamine).
1884870|NCT01215396|Dietary Supplement|Amino Vital Amino Acid formulation|Contains minerals, vitamin C, flavour and sweetener and a double dose of the amino acid mixture (4.8 g of AA as: leucine, isoleucine, valine, arginine and glutamine).
1884871|NCT01215409|Drug|Vardenafil (Levitra, BAY38-9456)|5 mg or 10 mg or 20 mg of Vardenafil, orally when necessary for 2 months
1884872|NCT01215422|Procedure|timed intubation|timed intubation
1884953|NCT01216124|Drug|docetaxel oxaliplatin|"docetaxel 75mg/m2 D1 oxaliplatin 130mg/m2 D2
1 cycle=21 days DO*6"
1884873|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before breakfast. The trial has 3 treatment phases for both treatment arms
1884874|NCT01215435|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin) once daily, before dinner. The trial has 3 treatment phases for both treatment arms
1884875|NCT01215448|Dietary Supplement|Wheatgrass juice|110 CC daily od frozen wheatgrass juice in the intervention arm
1884876|NCT01215487|Procedure|Stem Cell and Mutational Assay|Laboratory blood testing
1884877|NCT01215500|Radiation|Hypofractionated RT|"RT to site of metastatic disease for three fractions separated by 3 to 8 days. Doses of radiation will increase as follows in order to determine the MTD in Gy:
For all sites the dose levels are as follows:
8 Gy/ fraction x 3 fractions = 24 Gy
10 Gy/fraction x 3 fractions = 30 Gy
12 Gy/fraction x 3 fractions = 36 Gy
14 Gy/fraction x 3 fractions = 42 Gy
16 Gy/fraction x 3 fractions = 48 Gy
18 Gy/fraction x 3 fractions = 52 Gy
20 Gy/fraction x 3 fractions = 60 Gy"
1884878|NCT01215513|Drug|Degarelix|
1884879|NCT01215539|Drug|panitumumab|Panitumumab will be administered by IV infusion on day 1 of each 3-week cycle prior to the administration of chemotherapy. The starting panitumumab dose is 9 mg/kg. Subjects with evidence of complete response, partial response or stable disease will continue to receive the combination of chemotherapy with panitumumab until disease progression, unacceptable toxicity or withdrawal of consent.
1884880|NCT01215552|Drug|HT-0712|A range of single oral dose levels will be explored, utilizing 5mg and 25mg strength capsules
1884881|NCT01215565|Drug|Sutent|Sunitinib 50mg/day (per os) for 6 cycles duration of one cycle = 6 weeks (4 weeks of treatment over 6 weeks)
1884882|NCT01215578|Drug|Sutent|sunitinib 37.5 mg/day (per os) for 6 months
1884883|NCT01215591|Procedure|Gradual weaning from Nasal CPAP in preterm neonates|Nasal CPAP for gradual wean group it was cycled off for 3 hours alternating with 3 hours on for first 48 hours, if successful the cycle was extended to 6 hours off and 3 hours on for the next 48 hours. If the baby tolerated this regime the prongs were removed and CPAP was kept off.
1884884|NCT01215617|Behavioral|Aerobic Interval training|Treadmill walking or running - 3 times per week for 3 months. The interval training session consists of 10 minutes warm up and continues with 4 x 4 minutes high intensity intervals at 90-95% of maximal heart rate. Training intensity will be supervised through the use of Polar pulse monitors and the BORG scale of subjective perceived exhaustion.
1884885|NCT01215617|Behavioral|Control|Standard medical treatment
1884886|NCT01215630|Behavioral|Aerobic Interval Training|One interval training session
1884887|NCT01215643|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
1884888|NCT01215643|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
1884889|NCT01215643|Drug|Ribavirin|RBV 400 mg (2 x 200 mg tablets) administered orally twice daily (BID)
1884890|NCT01215656|Dietary Supplement|Lactobacillus fermentum|
1884891|NCT01215656|Dietary Supplement|Follow on formula without probiotics|
1884892|NCT01215669|Biological|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
1884893|NCT01215669|Biological|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
1884894|NCT01215669|Biological|IDflu™: Split virion inactivated influenza vaccine|Single dose 0.1 mL, intradermal
1884895|NCT01215669|Biological|Vaxigrip®: Split virion inactivated influenza vaccine|Single dose 0.5 mL, intramuscular
1884896|NCT01215682|Dietary Supplement|vitamin D|2000 IU/day of vitamin D3 as a once-daily dose
1884897|NCT01215682|Dietary Supplement|placebo|sweetened water
1884898|NCT01215695|Device|aScope (Ambu Inc. 6740 Baymeadow Drive Glen Burnie, MD)|The aScope is a flexible, disposable plastic tracheoscope that incorporates a high-resolution video camera with an LED light at its flexible tip and has attached monitor.
1884899|NCT01215695|Device|Control|pre-formed stylet provided by the manufacturer of the GlideScope® video laryngoscope
1884900|NCT01215708|Drug|Tamsulosin|tamsulosin 0,4mg every night for 30 consecutive days
1884901|NCT01215721|Drug|Vesicare|5 mg daily
1884902|NCT01215734|Biological|High-Dose Trivalent Inactivated Influenza Vaccine (HD-TIV)|0.5 ml of HD-TIV on visit 1
1884903|NCT01215734|Biological|Standard Dose Trivalent Inactivated Flu Vaccine|Twenty adult hematopoetic stem cell transplant recipients will receive 0.5 ml standard dose trivalent influenza vaccine on visit 1.
1884904|NCT01215747|Drug|KIACTA (eprodisate disodium)|Orally 1 to 3 capsules (Kiacta 400 mg) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases.
1884905|NCT01215747|Drug|Placebo|Orally 1 to 3 capsules (placebo) twice daily and adjusted as per the Creatine Clearance (CrCl) level increases or decreases:
1884906|NCT01215760|Other|Training with a mirror|Early sensory reeducation group, started at the first week postoperatively, using specific guidelines using the mirror training and stimulation of the contralateral side. Initially, the stimulation will be unilateral and later bilateral, after the removal of the splint in 4 weeks.
1884907|NCT01215760|Other|No mirror therapy|The classical group iniciates after 16 weeks postoperatively and follow a standard home protocol for sensory reeducation without the mirror. It begins with recognition of textures and objects, and specific rehabilitation, if any associated injuries.
1884908|NCT01215773|Drug|Placebo|Matching to HEA 200 mg tablet, oral administration
1884909|NCT01215773|Drug|BI 671800|High dose oral administration
1884910|NCT01215773|Drug|BI 671800|Medium dose oral administration
1884911|NCT01215786|Drug|AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo)|One drop of AGN-207281 ophthalmic solutions (0.1% on Days 1-7 and 0.3% on Days 8-14) instilled to both eyes in the morning followed by one drop of AGN-207281 vehicle ophthalmic solution (placebo) instilled to both eyes in the evening for 13 days.
1884912|NCT01215786|Drug|timolol ophthalmic solution 0.5%|One drop of timolol ophthalmic solution 0.5% instilled to both eyes, in the morning for 14 days, and in the evening for 13 days
1884913|NCT01215786|Drug|AGN-207281 vehicle ophthalmic solution (Placebo)|One drop of AGN-207281 vehicle ophthalmic solution instilled to both eyes, in the morning for 14 days and in the evening for 13 days.
1884914|NCT01215799|Drug|Bafetinib|Bafetinib 240 mg bid
1884954|NCT01216137|Other|Exercise: Vestibular Rehabilitation|Balance and eye movement training
1884915|NCT01208649|Drug|Exenatide|Exenatide; 48 weeks 10 microg injection s.c., twice daily, before the morning and evening meal with a four week wash-in phase with 5 microg injection s.c.twice daily
1884916|NCT01215851|Drug|PA-824|200 mg tablet, once daily for 14 days
1884917|NCT01215851|Drug|Pyrazinamide|Dosed by Weight
1884918|NCT01215851|Drug|TMC207|TMC207 700 mg Day 1; 500mg Day 2; 400mg Days 3-14
1884919|NCT01215851|Drug|Rifafour|Rifafour e-275
1884920|NCT01215851|Drug|Moxifloxacin|moxifloxacin 400 mg
1884921|NCT01215864|Drug|TCD-717|"Patients will receive TCD-717 at the following dose levels:
2, 4, 7, 10, 14, 19, 25, 31, 39, 49 or 61 mg/m^2"
1884922|NCT01215877|Drug|Tesetaxel|"Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
In Cycle 1, a dose of 27 mg/m2 will be administered. In subsequent cycles,
the dose will be increased to 35 mg/m2 in Cycle 2 for subjects who did not have an ANC < 1,500/mm3, a platelet count < 100,000/mm3, or a Grade 3 (or higher grade) nonhematologic adverse event considered by the Investigator to be related to protocol therapy (excluding alopecia, nausea, and vomiting) in Cycle 1. The dose is not to exceed the dose of 35 mg/m2 in any cycle subsequent to Cycle 2.
for all other subjects, the dose administered in Cycle 1 (27 mg/m2) will be administered in all subsequent cycles."
1884923|NCT01215890|Drug|risedronate|
1884924|NCT01215890|Drug|placebo|
1884925|NCT01215903|Dietary Supplement|Fish gelatin and omega-3 polyunsaturated fatty acid|
1884926|NCT01215903|Dietary Supplement|Omega-3 polyunsaturated fatty acid|
1884927|NCT01215916|Drug|LY573636|"Individualized dose is dependent on patients height, weight, gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is completed once in a 28 day cycle.
Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion are met."
1884928|NCT01215916|Drug|Pemetrexed|"375-500 mg/m2, intravenous dosing is completed once each 28 day cycle.
Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion are met."
1884929|NCT01215929|Drug|Dextroamphetamine|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral d-amphetamine at a dose of 30 mg twice daily for 2 weeks.
1884930|NCT01215929|Drug|Placebo|Thirty treatment-seeking methamphetamine dependent volunteers will be admitted to a residential facility in this 4-week, double-blind, placebo-controlled, clinical trial and be inducted onto d-amphetamine during week 1 of the study. 15 Participants then will be randomized by severity of methamphetamine dependence, sex, amphetamine withdrawal questionnaire score and history of Attention Deficit Hyperactivity Disorder to receive oral placebo tablets twice daily for 2 week.
1884931|NCT01215942|Drug|LY2127399|Administered Subcutaneously
1884932|NCT01215955|Drug|Insulin lispro|Administered subcutaneously, up to three times daily for 24 weeks
1884933|NCT01215955|Drug|Glargine|Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
1884934|NCT01215968|Biological|LY2189265|1.5 mg administered subcutaneously
1884935|NCT01215968|Drug|Placebo|Administered subcutaneously
1884936|NCT01215981|Biological|Influenza vaccine|One dose of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
1884937|NCT01215981|Biological|Influenza vaccine|Two doses of inactivated hemagglutinins of influenza A (H1N1, H3N2) and influenza B
1884938|NCT01216007|Drug|propofol|In the TIVA group, IV access will be obtained as per BCCH routine, with caregiver present. 2% lidocaine 1 mg/kg will be administered via IV to prevent venous pain before induction of anaesthesia with propofol, as per BCCH standard. Induction of anaesthesia will be achieved with an IV bolus of propofol 5 mg/kg and remifentanil 2.5 mcg/kg. Anaesthesia will be maintained with an infusion of propofol 200-400 mcg/kg/min and remifentanil 0.1-0.2 mcg/kg/min. Once the subject is under general anaesthesia, the anaesthesiologist will place a second IV cannula, specifically for the collection of blood samples. This cannula will not be in the same limb as the propofol infusion.
1884939|NCT01216007|Drug|sevoflurane|In the volatile anaesthesia group, induction of anaesthesia will be achieved with inhalation of sevoflurane (5-8% in O2/air). Maintenance of anaesthesia will continue with a volatile agent of the anaesthesiologist's choice.
1884940|NCT01216020|Drug|cetuximab|"Cetuximab is given according to the standard mode of administration: loading dose : 400 mg/m2 one week before the start of radiotherapy (week -1), followed by a weekly dose of 250 mg/m2 during the weeks of the treatment with radiotherapy.
Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
1884941|NCT01216020|Drug|cisplatin (associated to radiotherapy)|"CDDP dose: 40 mg/mq in a single weekly 1-hour infusion preceded by adequate hydration, diuretics e antiemetic premedication.
Radiotherapy: Doses: Clinical sites of disease (T e N) : total dose of 70 Gy given with a fractional dose of 2 Gy/day; prophylactic nodal volume (N) : total dose of 50 Gy given with a fractional dose of 2 Gy/day ; Treatment technique: conformal 3D. Intensity modulated radiotherapy (IMRT), also with simultaneous boost (SIB), is allowed."
1884942|NCT01216033|Drug|111-In-ABY-025|Intravenous injection of the agent
1884943|NCT01216046|Drug|VX-809|capsule, taken once daily
1884944|NCT01216046|Drug|VX-770|tablet, taken once every 12 hours
1884945|NCT01216046|Drug|VX-809 placebo|capsule, taken once daily
1884946|NCT01216046|Drug|VX-770 placebo|tablet, taken once every 12 hours
1884947|NCT01216059|Procedure|Text message to cell phone|Subjects will receive a daily text message reminder about their treatment for atopic dermatitis during the 6 weeks of the study
1884948|NCT01216072|Drug|Fingolimod|0.5 mg/day oral capsule
1884949|NCT01216072|Drug|Standard MS DMTs|
1884950|NCT01216085|Drug|high-dose imatinib|Study patients will receive 400 mg twice daily oral administration in the morning and the evening.
1884951|NCT01216098|Behavioral|Doula support|A doula is a paraprofessional who provides continuous emotional and physical support to women and their families during the intrapartum period.
1884952|NCT01216111|Drug|Paclitaxel Cisplatin|"Paclitaxel 100 mg/m2 D1，8，15 Cisplatin AUC=2 D1，8，15
1 cycle = 28days
PC*6"
1884959|NCT01216800|Radiation|3-dimensional conformal radiation therapy|
1884960|NCT01216800|Radiation|intensity-modulated radiation therapy|
1884961|NCT01216813|Other|informational intervention|
1884962|NCT01216813|Procedure|assessment of therapy complications|
1884963|NCT01216813|Procedure|psychosocial assessment and care|
1884964|NCT01216826|Drug|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/dia, in 28 days cycles. Maximum dosis: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
1884965|NCT01216839|Drug|Everolimus|Everolimus will be administered every day, initial dose 5 mg/m²/day, in 28 days cycle. Maximum dose: 10 mg/day. The cycles will be repeated till progression disease or untolerable toxicity.
1884966|NCT01216852|Drug|Losartan Potassium|100 mg tablet
1884967|NCT01216865|Biological|umbilical cord mesenchymal stem cells|5*10/7 per ischemic limb
1884968|NCT01216865|Drug|Standard Therapy|Any thing directed to improve blood perfusion in the limb example.Heparin,Antiplatelet agents etc
1884969|NCT01216878|Drug|losartan potassium|100 mg tablet
1884970|NCT01216891|Behavioral|Multi-element, team-oriented treatment|Participants will receive treatment and services based on their needs coordinated by a small team that is led by a clinical coordinator. Services that are available to the participants include social skills training, medication treatment to address symptoms, education and employment advising, and substance use treatment.
1884971|NCT01216904|Drug|nicotine patch|7 mg patches to be worn for 16 hours per day
1884972|NCT01216904|Drug|placebo|placebo patch to be worn 16 hours per day
1884973|NCT01216930|Other|Observation|Observation
1884974|NCT01216943|Drug|bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) administered to each eye, twice daily for 12 weeks.
1884975|NCT01216956|Drug|Extended-release nicotinic acid versus placebo|Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
1884976|NCT01216982|Drug|Lovaza, omega-3 fatty acid ethyl ester|Three 1g capsules/day for three months; this corresponds to a total of 2520mg EPA+DHA/day
1884977|NCT01216982|Drug|Placebo, visually identical to Lovaza|Three 1g corn oil capsules/day for three months
1884978|NCT01216995|Biological|Dose A|ADRC Dose A
1884979|NCT01216995|Biological|Placebo|Placebo Comparator
1884980|NCT01217008|Biological|GRNOPC1|One injection of 2 million GRNOPC1 cells.
1884981|NCT01217021|Drug|[18F] MNI-558|Subjects will be injected with 5mCi, not to exceed >10% of 5mCI, of [18F]MNI-558, followed by PET imaging.
1884984|NCT01217047|Device|FES Cycling|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. Electrodes (pads that stick to the skin) will be placed on your skin on your legs and buttock. The pads will be connected to a stimulator box through a wire. We will then start the cycle motor and stimulate your leg and buttock muscles with electric current. This will cause your legs to cycle. You will do this for 1 hour.
1884985|NCT01217047|Device|Cycling without FES|You will be seated in your own wheelchair in front of the cycle. We will place your legs onto the cycle and secure them with straps. The cycle is configured to work without FES. We will then start the cycle motor. This will cause your legs to cycle. You will do this for 1 hour.
1884986|NCT01217047|Procedure|Lumbar puncture|The study includes 2 lumbar punctures: one at the beginning of the study and one at the end. During a lumbar puncture a small needle will be inserted into the lower back and a small amount of spinal fluid will be drained (about 1 tablespoon).
1884987|NCT01217047|Behavioral|Mood assessment|"If you do not already have an account, you will be signed up with Mood24/7 (http://www.mood247.com). This is a free service that texts your mobile phone daily asking you to rate your mood on a scale of 1 (low) through 10 (high). We will not monitor your entries during the study but only at the final visit when we will get a printout of the course of your mood during the study. After completion of the study we will assist you in removing us from your Mood24/7 account and we will no longer have access to your mood reports outside of the study period."
1884988|NCT01217060|Drug|Docetaxel|20 mg/m2 given by vein (IV) over 1 hour once a week for up to 5 1/2 weeks.
1884989|NCT01217060|Drug|5-FU|300 mg/m2 given by vein, continuously for 96 hours a week for about 5 1/2 weeks.
1884990|NCT01217060|Radiation|Radiotherapy|50.4 Gy (1.8G/Fx/day) for about 5 1/2 weeks, Monday through Friday.
1884991|NCT01217060|Procedure|Esophagectomy|Surgery to remove part of esophagus and nearby lymph nodes, approximately 8 to 10 weeks after completing chemoradiation.
1884992|NCT01217060|Drug|Dexamethasone|10 mg IV 30 minutes prior to weekly Docetaxel.
1884993|NCT01217073|Drug|Omarigliptin|Omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For omarigliptin 3 mg, participants received two omarigliptin 1.5 mg capsules.
1884994|NCT01217073|Drug|Placebo to omarigliptin|Matching placebo to omarigliptin 0.25, 1, 1.5, 10 or 25 mg oral capsule administered once weekly. For matching placebo to omarigliptin 3 mg, participants received two matching placebo to omarigliptin 1.5 mg capsules.
1884995|NCT01217073|Drug|Pioglitazone|Pioglitazone 15 mg oral tablet or capsule administered once daily
1884996|NCT01217073|Drug|Metformin|Metformin 500 mg oral tablet administered once or twice daily
1884997|NCT01217073|Drug|Placebo to metformin|Matching placebo to metformin oral tablet administered once daily
1884998|NCT01217086|Drug|Infliximab|Infliximab 3mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
1884999|NCT01217099|Drug|methylprednisolone|treatment patients were iv methylprednisolone pulse azithromycin for 5 days.
1885000|NCT01217099|Drug|azithromycin|control patients were iv azithromycin for 5 days.
1885001|NCT01217112|Drug|GWP42003|100 mg capsules, PO, BD, 91 days
1885002|NCT01217112|Drug|GWP42003|5 mg capsules, PO, BD, 91 days
1885003|NCT01217112|Drug|GWP42004|5 mg capsules, PO, BD, 91 days
1885004|NCT01217112|Drug|Placebo|0 mg capsules, QDS, PO, 91 days
1885005|NCT01217125|Drug|Sirolimus|plasma levels between 4 and 8
1960485|NCT03193580|Device|Anodal Conventional tDCS|tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
1885007|NCT01217151|Device|Hemodynamic monitoring|Hemodynamic monitoring based on the NICOM device
1885008|NCT01217151|Other|Usual treatment|Hemodynamic monitoring based on common practice
1885009|NCT01217164|Dietary Supplement|no intervention|received enteral diet with 4.5 g / kg / day of protein and 160cal/Kg/dia
1885010|NCT01217177|Drug|everolimus|
1960486|NCT03193580|Device|Anodal High Definition tDCS|HD-tDCS will be applied for 20 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
1960487|NCT03193580|Device|Sham tDCS|tDCS will be applied for 1 minutes at 1milliamp while participants are performing a fine motor task. The current will be set at 1milliamp, stimulation will be ramped up over 30 seconds and ramped down over 30 seconds.
1960488|NCT03194867|Drug|Isatuximab SAR650984|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1885014|NCT01217203|Drug|IPH2101 combined to lenalidomide|"Dose level 1 : 0.2 mg/kg IPH2101(with Lenalidomide 10 mg/day) Dose level 2 : 0.2 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 3 : 1 mg/kg IPH2101(with Lenalidomide 25 mg/day) Dose level 4 : 2 mg/kg IPH2101(with Lenalidomide 25 mg/day)
Extension cohort: 6 patients at the Maximum Tolerated Dose (MTD)"
1885015|NCT01217216|Behavioral|Group-based Intervention|compared effects of a group-based intervention on weight loss and physical activity.
1885016|NCT01217216|Behavioral|Telephone-based Intervention|compared telephone-based intervention to weight loss and physical activity.
1885017|NCT01217229|Drug|PLX3397|Capsules administered once or twice daily, continuous dosing. Subjects will begin with 900 mg/day, but should safety data allow in our PLX108-01 study, subject may dose at 1200 mg/day.
1885018|NCT01217268|Behavioral|Training in person centered care by supervision using video-conference|The investigators will use video-conference for supervising and training of staff members in nursing homes
1885020|NCT01217294|Procedure|ultrasound guided fascia iliaca block|Spinal anaesthesia with hyperbaric bupivacaine at a dose between 10 and 15mg as deemed appropriate by the anaesthetic doctor performing the spinal injection, no spinal morphine and ultrasound guided fascia iliaca plane block using 2mg/kg levobupivacaine diluted to a total of 40ml with sterile saline.
1885021|NCT01217294|Procedure|spinal morphine|Spinal anaesthesia with hyperbaric bupivacaine 10 - 15mg as deemed appropriate by the anaesthetists performing the spinal injection, and with the addition of intrathecal morphine 100 micrograms. Sham fascia iliaca plane injection with saline.
1960489|NCT03194867|Drug|REGN2810|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1885024|NCT01217320|Dietary Supplement|creatine|5g/d throughout 12 weeks
1885025|NCT01217320|Dietary Supplement|placebo (dextrose)|5g/d throughout 12 weeks
1885026|NCT01217333|Behavioral|In-person CP|CP is a structured interview in which a lay health worker prompts a patient to articulate questions and concerns about decision issues in preparation for a treatment discussion with a provider. The Consultation Planner (CPer) then completes and prints out a word-processed template, paraphrasing and summarizing the patient's questions and concerns. The patient takes away the printed Consultation Plan to serve as a visual aid and agenda during the meeting with the doctor. CPers are trained to avoid providing medical advice or information. Arrangements will be made for participants who do not have transportation to the CRCMC.
1885027|NCT01217333|Behavioral|Tele-CP|Participants in the Tele-CP arm will receive CP by telephone. Arrangements will be made for participants who do not have access to a telephone.
1885028|NCT01217346|Other|no intervention is involved in this study|no intervention is involved in this study
1885029|NCT01217359|Drug|Interferon Alfa-2b|Patients will receive a single dose of interferon followed by serial blood draws to assess cellular responses to interferon
1885030|NCT01217372|Dietary Supplement|Lemon supplementation|60 ml of lemon juice twice daily (an amount expected to provide 6 grams or 92 mEq of citric acid per day)
1885039|NCT01217398|Biological|bevacizumab|
1885040|NCT01217398|Drug|temozolomide|
1885041|NCT01217398|Genetic|polymorphism analysis|
1885042|NCT01217398|Other|pharmacogenomic studies|
1885043|NCT01217411|Drug|Gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
1885044|NCT01217411|Radiation|Whole-brain radiation therapy (WBRT)|Undergo WBRT
1885045|NCT01217411|Radiation|Stereotactic radiosurgery (SRS)|Undergo SRS
1885046|NCT01217411|Procedure|Cognitive assessment|Ancillary studies
1885047|NCT01217411|Other|Laboratory biomarker analysis|Correlative studies
1885048|NCT01217424|Other|questionnaire administration|
1885049|NCT01217424|Procedure|aromatherapy and essential oils|
1885050|NCT01217424|Procedure|management of therapy complications|
1885051|NCT01217424|Procedure|massage therapy|
1885052|NCT01217424|Procedure|psychosocial assessment and care|
1885053|NCT01217424|Procedure|reflexology procedure|
1885057|NCT01217450|Drug|selumetinib|Given orally
1885058|NCT01217450|Biological|cetuximab|Given IV
1885059|NCT01217450|Other|laboratory biomarker analysis|Correlative studies
1885060|NCT01217450|Other|pharmacological study|Correlative studies
1885061|NCT01217463|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
1885062|NCT01217476|Drug|Trafermin 0.01% spray|For ulcers with a maximum diameter (longest axis) of less or equal to 6 cm, the daily dose of trafermin 0.01% spray is 5 puffs (30 microgram) sprayed onto the wound surface. If the maximum diameter (longest axis) of the ulcer is >6 cm, the ulcer should be sprayed in two parts, i.e. 5 puffs (30 microgram) sprayed onto each half of the wound surface
1885064|NCT01217502|Behavioral|Self management program|Professional caregivers will be trained in offering a self management program to aged persons with a dual sensory impairment. Duration of the program: 6 months
1885065|NCT01217502|Behavioral|self management program|Learning and practicing skills necessary to carry on an active and emotionally satisfying life in the face of the dual sensory impairment
1885066|NCT01217515|Drug|Diltiazem hydrochloride 4% cream|3 times daily
1885067|NCT01217515|Drug|Diltiazem hydrochloride 2% cream|3 times daily
1885068|NCT01217515|Other|Placebo|3 times daily
1885069|NCT01217528|Device|device settings for group A|VT zone: 350ms VF zone: 280ms
1885070|NCT01217528|Device|Device settings for group B|VT zone: 320ms VF zone: 250ms
1885071|NCT01217541|Other|Education and Supervision|Implementation of Scales in the care of patients with dementia in nursing home units with focus on person-centred care. Supervision of caregivers on a regular basis.
1885072|NCT01217541|Other|Control|A control group of nursing home units that do not get any form of active intervention
1885073|NCT01217567|Procedure|Staples left, subcuticular suture right|Closure of the skin after cesarean section with staples on the left side of the wound and subcuticular suture on the right side.
1885074|NCT01217567|Procedure|Subcuticular suture left side and staples right|Closure of the skin after cesarean section with staples on the right side of the wound and subcuticular suture on the left side.
1885075|NCT01217580|Drug|0.5% ropivacaine|20ml each side of the hip of 0.5% ropivacaine into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
1885076|NCT01217580|Drug|0.9% sodium chloride|20ml each side of the hip of 0.9% sodium chloride into the transverse abdominis plane after patient is brought to the recovery area after elective cesarean delivery
1885077|NCT01217593|Procedure|ultrasound|Ultrasound guidance will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
1885078|NCT01217593|Procedure|predetermined distance|The predetermined distance technique will be used for paravertebral space localization when performing paravertebral blocks on females 25-85 having unilateral mastectomy.
1885079|NCT01217606|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for up to 12 months.
1885080|NCT01217606|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for up to 12 months.
1885081|NCT01217619|Drug|erlotinib|erlotinib 150mg/d continuously for 56 days
1885082|NCT01217632|Drug|FG-3019|FG-3019 at a dose of 15-45 mg/kg will be administered every 3 weeks by IV infusion in a total volume of at least 250 mL in normal saline.
1885083|NCT01217632|Drug|Placebo|Placebo will be administered every 3 weeks by intravenous (IV) infusion in a total volume of at least 250 mL in normal saline.
1885084|NCT01217632|Drug|Entecavir|
1885085|NCT01217645|Radiation|150 mg [14C] AZD6765|
1885086|NCT01217658|Behavioral|The Happiest Baby on The Block|"Those receiving the intervention will be trained in the infant soothing techniques outlined in The Happiest Baby on the Block."
1885087|NCT01217658|Behavioral|AAP Infant Colic counseling|Those receiving the control group allocation will be counseled using the American Academy of Pediatrics material for Infant Colic.
1885088|NCT01217671|Biological|Kamada AAT for inhalation|Alpha-1 Antitrypsin (AAT)
1885089|NCT01217671|Other|Placebo|Placebo
1885090|NCT01217697|Drug|Abiraterone Acetate|Abiraterone acetate, type=equal, unit=mg, number=250, form=tablet, route=oral use, 4 tablets once daily.
1885091|NCT01217697|Drug|Prednisone\Prednisolone|Participants will receive prednisone 5 mg twice daily as oral tablet OR prednisolone 5 mg (if prednisone is not available).
1885092|NCT01217710|Behavioral|Activity monitor/smartphone health coaching|Initial health coaching at enrollment will involve the collaborative creation of an action plan with personally relevant, specific actions for increasing physical activity. The short term goals will be rated for self-efficacy and modified to maximize likelihood of success. Health coaches will discuss important mediators of physical activity (e.g., self-efficacy, enjoyment, social support, problem-solving). Weekly coaching calls will involve discussion of progress toward goals and problem-solving of barriers utilizing a motivational interviewing approach. Motivational messages will also be developed and sent daily to participants via the smartphone. These messages will indicate the percentage of steps related to their daily goal.
1885233|NCT01218633|Drug|saline infusion|saline infused at 30ml/hour
1885093|NCT01217723|Biological|Anti-Thymocyte Globulin (Rabbit)|Thymoglobulin 0.5 mg/kg on Day -2 prior to the Transplant, 2.5 mg/kg on Day -1, and 2.5 mg/kg on the day of transplant.
1885094|NCT01217723|Other|Patients will receive a standard preparative regimen (i.e. one that does not contain Thymoglobulin)|The standard preparative regimen can be myeloablative or reduced intensity.
1885095|NCT01217736|Drug|aliskiren|single dose, tablet
1885096|NCT01217736|Drug|placebo|single dose, tablet
1885097|NCT01217736|Drug|VTP-27999|single dose, tablet
1885098|NCT01217749|Drug|PCI-32765|420 mg PO daily
1885099|NCT01217749|Drug|ofatumumab|per package insert as an IV infusion
1885100|NCT01217762|Device|IRay|Low voltage stereotactic radiotherapy system
1885101|NCT01217775|Drug|PH80|PH80 intranasal spray 800 nanograms
1885102|NCT01217775|Drug|Placebo intranasal spray|Placebo intranasal spray
1885104|NCT01217801|Drug|Ondansetron (ODFS)|Ondansetron Orally Dissolving Filmstrip Ondansetron (ODFS)
1885105|NCT01217801|Drug|Ondansetron (ODT)|Ondansetron Orally Disintegrating Tablet Ondanestron (ODT)
1885106|NCT01217814|Drug|Sarilumab|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1885107|NCT01217814|Drug|Placebo|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1885108|NCT01217814|Drug|Golimumab|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1885109|NCT01217814|Drug|methotrexate (MTX)|"Pharmaceutical form: tablet or solution for injection
Route of administration: Oral (tablet) or subcutaneous, intramuscular (solution)"
1885110|NCT01217814|Drug|Folic/folinic acid|"Pharmaceutical form: tablet
Route of administration: oral Folic/folinic acid continued according to local standard."
1885111|NCT01217827|Behavioral|Clinical Reminder|
1885112|NCT01217840|Drug|Drisdol (Ergocalciferol) Vitamin D2|Ergocalciferol 150,000 IU every 12 weeks for total of 24 weeks.
1885113|NCT01217840|Drug|Placebo|Placebo pill - 3 pills every 12 weeks for total of 24 weeks
1885114|NCT01217853|Device|SENSIMED Triggerfish|Contact lens-based device for continuous intraocular pressure monitoring
1885115|NCT01217866|Procedure|Laparoscopic assisted vaginal hysterectomy|Surgical removal of uterus vaginally
1885116|NCT01217879|Drug|Telmisartan (Kinzal/Pritor, BAY68-9291)|Patients treated with telmisartan tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
1885117|NCT01217892|Drug|dapagliflozin|2.5 mg tablet, taken orally, twice daily
1885118|NCT01217892|Drug|dapagliflozin|5 mg tablet taken orally, twice daily
1885119|NCT01217892|Drug|dapagliflozin|10 mg tablet taken orally, once daily
1885120|NCT01217892|Drug|metformin|>/= 1500 mg total daily dose, tablets taken orally, twice daily
1885121|NCT01217892|Drug|placebo|placebo
1885122|NCT01217905|Drug|AZD7687|Oral suspension
1885123|NCT01217918|Drug|1 mg|1 mg or placebo a material sparing tablet per day for 10 days
1885124|NCT01217918|Drug|5 mg|5 mg or placebo as material sparing tablet per day for 10 days
1885125|NCT01217918|Drug|10 mg|10 mg or placebo as a material sparing tablet per day for 10 days
1885126|NCT01217931|Drug|Pazopanib|800 mg by mouth once daily for 28 days. A cycle consists of 4 weeks.
1885127|NCT01217931|Drug|Bevacizumab|10 mg/kg by vein every two weeks. A cycle consists of 4 weeks.
1885128|NCT01217931|Drug|Everolimus|10 mg by mouth once daily. A cycle consists of 4 weeks.
1885129|NCT01217944|Drug|Ranibizumab|0.5 mg ranibizumab intravitreal injection
1885130|NCT01217944|Drug|Verteporfin PDT|Verteporfin (6 mg/m2) intravenous infusion
1885131|NCT01217944|Drug|Sham Ranibizumab|Empty vial to mimic the intravitreal injection
1885132|NCT01217944|Drug|Sham verteporfin PDT|Sham vPDT intravenous infusion of dextrose 5% solution followed by light application (PDT).
1885133|NCT01217957|Drug|Ixazomib|Ixazomib capsules
1885134|NCT01217957|Drug|Lenalidomide|Lenalidomide capsules
1885135|NCT01217957|Drug|Dexamethasone|Dexamethasone tablets
1885136|NCT01217970|Drug|Ibudilast|Ibudilast oral 20mg BID for 7 days
1885137|NCT01217970|Drug|Ibudilast|Ibudilast oral 50mg BID for 7 days
1885138|NCT01217970|Drug|Ibudilast|Placebo oral BID 7 days
1885139|NCT01217996|Behavioral|Computerized working memory training program (intervention)|A computer-based training program will be completed in the home. This program requires approximately 30 minutes every weekday for five weeks. The program software guides the child through eight rotating exercises each day, with increasing difficulty based on the child's level of performance. Exercises train both visuospatial and verbal WM using child-friendly activities. A research team member will serve as a coach who monitors weekly progress online and offers support through weekly phone calls with the study participants and their caregivers). Intervention participants will also partake in neuroimaging exams before and after the intervention
1885140|NCT01217996|Behavioral|Computerized working memory training program (control)|Participants randomized to the control group will not complete any intervention during the intervention time period and will not partake in neuroimaging exams. They will complete an immediate and six month post follow-up cognitive assessment. Following completion of these assessments, they will be provided the opportunity to complete the computer-based training program off study.
1885141|NCT01218009|Drug|Placebo Spiromax|Placebo as a dry-powder inhaled orally using the Spiromax inhaler. During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime.
1885142|NCT01218009|Drug|Albuterol Spiromax|"Albuterol as a dry-powder inhaled orally using the Spiromax inhaler. Each inhalation delivers 90 micrograms (mcg). During the 12-week double-blind period, participants take two (2) inhalations four times a day (QID) at approximately 7:00 AM, 12:00 PM, 5:00 PM, and bedtime for a total dose of 720 micrograms per day for those paricipants randomized to the Albuterol treatment arm.
The double-blind period is followed by a 40-week open-label period in which all study participants will take Albuterol Spiromax 90 micrograms (mcg)/inhalation as needed (PRN)."
1885234|NCT01218633|Drug|GLP-1-9,36 infusion|infused @ 1.2pmol/kg/min
1885144|NCT01218035|Drug|zoledronic acid|The patients in the active-treatment group will receive a single 5 mg dose of zoledronic acid intravenously just prior to release from the hospital (about 5th day post-surgery) as an adjunct therapy. The control group will receive a placebo (saline) infusion. All infusions will be given 100 ml in volume and infused over a period of 15 minutes with a pre- and post-infusion flush with normal saline.
1885145|NCT01218048|Drug|Cetuximab|Pre-Surgery: IV, 400 mg/m2 day 1 then 250 mg/m2 alone days 8 and 15; Post-surgery: IV, 250 mg/m2 weekly concurrent with RT
1885146|NCT01218048|Procedure|Surgery|Surgery for tumor
1885147|NCT01218048|Radiation|Post-surgical radiation|Radiation (2 Gy/d) to min of 60 Gy + max of 66 Gy post-surgery
1885148|NCT01218048|Drug|Cisplatin or carboplatin|Cisplatin 30 mg/m2 or carboplatin AUC 1.5-2/week weekly, Concurrent with radiotherapy
1885149|NCT01218061|Other|Pre-diabetes screening|The timing of the study is :- Screening of high metabolic risk patients based on a clinical score : Finnish Diabetes Risk Score ≥ 15- if Diabetes Risk Score ≥ 15 or if history of blood glucose between 1.10 and 1.26 g/l (impaired fasting glucose): measuring fasting glycaemia + HbA1C + lipids profile + creatinemia + liver enzymes- if fasting blood glucose between 1.10 and 1.26 g/l (=V0):* OGTT (oral glucose tolerance test) to identify subjects with impaired glucose tolerance (optional)* establishment of a serum bank to identify biomarkers (serum, genomic, proteomic) - to plan for 10 years annual follow-up (V1 to V10) with blood sample (fasting glycemia + HbA1C + lipids profile + creatinemia + liver enzymes + serum bank (not after V5)) Making a total of 11 visits (V0-V10) with 6 blood samples.
1885150|NCT01218074|Device|Aggregometry+Thromboelastography|Patients undergo standard thromboelastography and subsequent aggregometry to test effectiveness of residual antiaggregation drugs. Patients found to have altered value undergo optimization with desmopressin.
1885151|NCT01218074|Device|Thromboelastography Alone|Patients undergo standard of care Thromboelastography to evaluate overall coagulation performance.
1885152|NCT01218087|Device|Cranial cup device and Moldable positioner|The cranial cup device was used 12/24 hours (alternating with the moldable positioner device) and was evaluated for feasibility, safety and efficacy for preventing head shape deformity in hospitalized infants
1885153|NCT01218087|Device|Moldable positioner device|This moldable positioning device was used 24/24 hours as a comparison to the cranial cup device.
1885154|NCT01218100|Drug|nebivolol and lisinopril (free combination)|"nebivolol 5-mg and lisinopril 10-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 10-mg tablet)/QD/oral administration/up to 12 weeks
nebivolol 20-mg and lisinopril 40-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 10 weeks
nebivolol 5-mg and lisinopril 40-mg (nebivolol non-trade 5-mg tablet and overencapsulated lisinopril 40-mg tablet)/QD/oral administration/up to 6 weeks
nebivolol 20-mg and lisinopril 10-mg (nebivolol non-trade 20-mg tablet and overencapsulated lisinopril 10-mg tablet/QD/oral administration/up to 6 weeks"
1885155|NCT01218100|Drug|nebivolol monotherapy|"nebivolol 5-mg (non-trade 5-mg tablet)/QD/oral administration/up to 12 weeks
nebivolol 10-mg (non-trade 10-mg tablet/QD/oral administration/for 1-week down-titration period only)
nebivolol 20-mg (non-trade 20-mg tablet)/QD/oral administration/up to 10 weeks"
1885156|NCT01218100|Drug|lisinopril monotherapy|lisinopril 10-mg (overencapsulated 10-mg tablet)/QD/oral administration/up to 12 weeks lisinopril 40-mg (overencapsulated 40-mg tablet)/QD/oral administration/up to 10 weeks
1885157|NCT01218100|Drug|placebo|Placebo tablet, oral administration/QD/oral administration/up to 12 weeks Placebo capsule, oral administration/QD/oral administration/up to 12 weeks
1885162|NCT01218165|Dietary Supplement|Probiotic drink|This group receives a probiotic drink daily for 6 week.
1885163|NCT01218165|Other|Control Group|without intervention
1885164|NCT01218178|Drug|Sodium bicarbonate plus NAC|154 mEq/L sodium bicarbonate (infusion rate of 3 ml/Kg for 1 hour followed by 1 ml/Kg for 6 hours) plus NAC (1200 mg bid for 48 hours)
1885165|NCT01218178|Drug|Saline hydration plus NAC|0.9% saline (1 ml/Kg for 12 hours) plus NAC (1200 mg bid for 48 hours)
1885174|NCT01218217|Drug|SQ109|SQ109 150 mg tablet
1885175|NCT01218217|Drug|Rifampicin|Rifampicin 150 mg capsules
1885176|NCT01218230|Drug|Intravitreal Pegaptanib|Intravitreal pegaptanib, 0.3 mg, every 6 weeks for 3 injections and then PRN.
1885177|NCT01218243|Device|needle|For the acupoint group,needle on bilateral BL33 60-80mm with a 45°angle. A feeling of soreness and distension will be felt when needling into the 3rd posterior sacral foramina(S3).Needle with a 100-125 mm long needle without lifting, thrusting or rotating.An electric stimulator is put on.G6805-2 electric stimulator (produced by Shanghai Huayi Medical Instrument Co.Ltd), Sparse-dense wave,20Hz. Stop turning up the current intensity when patients could not stand. 5 times for the first two weeks and 3 times for the last two weeks, 30 min/time.The non-point group take the place 2 cun far from BL33 on the outside horizontally as the non-point and the manipulation methods are the same with those of the point group.
1885178|NCT01218256|Other|Physical exercise training|aerobic endurance training (cycle ergometer, 60-70% heart rate reserve) hypertrophy resistance training (2sets, 10-12 repetitions, 70% of the one-repetition maximum) endurance resistance training (2 sets, 25-30 repetitions, 40% of the one-repetition maximum)
1885179|NCT01218269|Device|nitinol u-clip|The U-clip is comprised of nitinol, an alloy of nickel and titanium.
1885180|NCT01218282|Behavioral|Home exercise training|20-30 min/day for at least 4 days/week
1885181|NCT01218282|Behavioral|NO Exercise Training|No intervention
1885182|NCT01218295|Device|Spirotiger®|training session :10 minutes twice a day X 4 weeks
1885235|NCT01218633|Drug|Exendin-9,39 at low dose|infused at 30pmol/kg/min
1885183|NCT01218308|Biological|FluLaval® Quadrivalent|One intramuscular dose for primed subjects. Two intramuscular doses for unprimed subjects.
1885184|NCT01218308|Biological|Havrix™|Two intramuscular doses for primed subjects. Three intramuscular doses for unprimed subjects.
1885185|NCT01218321|Biological|antiepileptic treatment|White blood cells from peripheral blood samples
1885186|NCT01218334|Device|12 Lead Glove|Comparison of EKG's derived from the 12 Lead Glove vs. the Gold Standard EKG machine
1885187|NCT01218347|Drug|Rosuvastatin|20 mg once daily for 21 days
1885188|NCT01218360|Drug|Physician standard-of-care|Participants will be treated according to their physician's routine practice and the respective Summary of Product Characteristics (SmPC).
1885189|NCT01218373|Device|HOMESWEETHOME Services|Monitoring and alarm handling services. eInclusion services. Domotic services. Daily scheduler. Navigation services. Cognitive training services. Non-technology based services.
1885190|NCT01218373|Device|No HOMESWEETHOME services installed|Normal care and healthcare without HOMESWEETHOME services.
1885191|NCT01218386|Drug|Estradiol valerate|"Experimental group: estradiol valerate (Progynova, 2x2mg per day, 2mg in the morning, 2mg in the evening), orally, during 6-10 consecutive days from day 25 of the cycle onwards.
Both groups:start rFSH (Puregon®) at a dose of 150 IU GnRH antagonist (Orgalutran®) initiation on D6 of the stimulation."
1885192|NCT01218399|Drug|Symbicort|
1885193|NCT01218412|Behavioral|Web-based Motivational Interviewing|Participants will engage in 4 sessions of web-based motivational interviewing over the course of 4 weeks.
1885194|NCT01218425|Drug|Methylphenidate 40 mg|Oral dose 40 mg
1885195|NCT01218425|Drug|Levodopa/carbidopa 125 mg|oral dose, 100 mg levodopa, 25 mg carbidopa in one capsule
1885196|NCT01218425|Drug|Domperidon 10 mg|Domperidon 10 mg
1885199|NCT01218451|Biological|Meningococcal group C polysaccharide conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
1885200|NCT01218451|Biological|Pneumococcal 13-valent conjugate vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
1885201|NCT01218451|Biological|Combined Diphtheria-Tetanus-acellular Pertussis (DTPa), Hepatitis B, Poliovirus and Haemophilus influenzae type b vaccine|0.5 mL dose, subcutaneous administration in right anterolateral thigh
1885202|NCT01218464|Drug|Conventional plus MSC treatment|Participants received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 12 weeks.
1885203|NCT01218464|Drug|Conventional plus pacebo treatment|Participants received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 12 weeks.
1885204|NCT01218477|Drug|Dasatinib|Oral tablets, 100-140 mg once daily, depending on cohort (100 mg for those with chronic myeloid leukemia [CML]-chronic phase; 140 mg for those with CML-advanced phase)
1885205|NCT01218477|Drug|BMS-833923|Oral capsules, 50-200 mg, depending on cohort (100 mg for those with CML-chronic phase; 140 mg for those with CML-advanced phase)
1885206|NCT01218490|Procedure|ovarian cancer surgery|
1885207|NCT01218503|Behavioral|CHOICES - obese|Standard group behavioral weight loss treatment
1885208|NCT01218516|Biological|Farletuzumab|"Combination Therapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, farletuzumab (7.5 mg/kg) will be administered intravenously on Week 1 of all additional cycles.
Monotherapy: Farletuzumab 7.5 mg/kg will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
1885209|NCT01218516|Other|Placebo|"Combination Therapy: Placebo will be administered intravenously on Cycle 1, Week 1 and Cycle 1, Week 2 (loading dose). Beginning on Cycle 2, Week 1, placebo will be administered IV on Week 1 of all additional cycles.
Monotherapy: Placebo will be administered intravenously on Week 1 of every 3-week cycle until disease progression."
1885210|NCT01218516|Drug|Carboplatin|Carboplatin will be administered intravenously to achieve area under the serum concentration-time curve of 5 to 6 mg/mL^min [AUC5-6]
1885211|NCT01218516|Drug|Paclitaxel|Paclitaxel 200 mg/m2 will be administered intravenously
1885212|NCT01218516|Drug|Pemetrexed|Pemetrexed 500 mg/m2 will be administered intravenously
1885213|NCT01218516|Drug|Cisplatin|Cisplatin 75 mg/m2 will be administered intravenously
1885214|NCT01218529|Drug|Lapatinib|Co-administration of lapatinib 1250mg once daily during the WBRT period (2 weeks)and then monotherapy with lapatinib 1500mg once daily for 4 weeks.
1885215|NCT01218542|Radiation|Volumetric modulated arc therapy|Using volumetric modulated arc therapy to give simultaneous infield boost to gross metastatic brain lesions during whole brain radiation therapy.
1885216|NCT01218555|Drug|Lenalidomide|Lenalidomide (10mg, 15mg, 20mg or 25mg) once daily by mouth, every day of each 28-day cycle.
1885217|NCT01218555|Drug|Everolimus|5mg or 10mg of everolimus administered once daily by mouth on a once daily continuous dosing schedule for 28 days.
1885218|NCT01218568|Drug|Rifaximin plus lactulose|Rifaximin 400 mg three times a day Lactulose 30-60 ml in two or three divided doses.
1885219|NCT01218568|Drug|Lactulose|Lactulose 30-60 ml in two or three divided doses.
1885220|NCT01218581|Drug|received oral letrozole (2.5 mg/day)and goserelin subcutaneosly (3.6 mg/month)|
1885221|NCT01218594|Drug|Endostatin|7.5mg/m2,iv gtt daily up to 7 days,beginning 1 week before radiotherapy,and repeat every 2 weeks
1885222|NCT01218607|Drug|Bosentan|Treatment will be initiated at a dose of 62.5 mg twice daily for 4 weeks and then increased to the maintenance dose of 125 mg twice daily for 12 weeks.
1885223|NCT01218607|Drug|Placebo|Placebo will be taken twice daily for 16 weeks
1885224|NCT01218620|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1885225|NCT01218620|Drug|Ketoconazole|Given PO
1885226|NCT01218620|Drug|Rifampin|Given PO
1885227|NCT01218620|Drug|Midazolam Hydrochloride|Given IV
1885228|NCT01218620|Drug|Omeprazole|Given PO
1885229|NCT01218620|Drug|Tolbutamide|Given PO
1885230|NCT01218620|Drug|Dextromethorphan Hydrobromide|Given PO
1885231|NCT01218620|Other|Pharmacological Study|Correlative studies
1885232|NCT01218620|Other|Laboratory Biomarker Analysis|Correlative studies
1885236|NCT01218633|Drug|Exendin-9,39 at high dose|infused @ 300pmol/kg/min
1885237|NCT01218646|Biological|Investigational Quadrivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
1885238|NCT01218646|Biological|Investigational Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
1885239|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
1885240|NCT01218646|Biological|Fluzone®: 2010-2011 Trivalent Inactivated Influenza Vaccine, No Preservative|0.5 mL, Intramuscular
1885241|NCT01218659|Drug|migalastat hydrochloride|oral AT1001 capsules and inactive reminder capsules taken every day
1885242|NCT01218659|Biological|agalsidase|intravenous infusion in accordance with the local approved product labeling
1885244|NCT01218685|Biological|Split inactivated A/California/7/2009 (H1N1) (NYMC X-179A) VIRUS|1 full dose of 15 micrograms, IM, for volunteers 9 years of age or older; children 6 months to 2 years of age, half of the dose,IM, with 21 days interval; children 3 years old up to 8 years old, 1 full dose, IM, twice, with 21 days interval.
1885248|NCT01218737|Drug|0.3% gatifloxacin and 1.0% prednisolone acetate association|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the association and another with placebo. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.
This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
1885249|NCT01218737|Drug|isolated 0.3% gatifloxacin and 1.0% prednisolone acetate|"Each patient will receive two medication bottles (eye drops) in a blinded fashion: one with the 0.3% gatifloxacin eye drops and another with 1.0% prednisolone acetate eye drops. The patient must instill 01 drop of each bottle in each operated eye, with a 5-minute interval between the instillations.
This procedure should be performed 4 times a day (QID) during the wake hours, from Day 0 (surgery day) until Day 15."
1885250|NCT01218750|Procedure|Triple therapy for diffuse diabetic macular edema|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. Peeling of the epimacular tissue and ILM is performed by grasping the flap of the ILM with an eckhardts forceps. Trypan Blue is used to stain the ILM. Peripheral laser endophotocoagulation is performed in cases of avascular areas based on FA, active neovascularization, peripheral retinoschisis or retinal breaks. All eyes have a 1,25 mg/0,05 ml bevacizumab injection into vitreous cavity and SF6 gas tamponade at the end of the procedure. Even of absence of cataract formation, a combined procedure is performed because of exactly peripheral vitreous shaving and prevention of cataract formation.
1885251|NCT01218789|Drug|tasimelteon|20 mg tasimelteon capsules, PO daily for 1 year
1885252|NCT01218802|Drug|Rosuvastatin 10 mg. daily for 96 weeks|Participants will take Rosuvastatin 10 mg. daily for 96 weeks.
1885253|NCT01218802|Drug|Placebo|participants will take a sugar pill daily for 96 weeks
1885254|NCT01218815|Procedure|IRA stenting in culprit lesion only|stenting
1885255|NCT01218815|Procedure|IRA stenting|Complete IRA revascularization
1885256|NCT01218828|Other|LVEDP -Based hydration strategy|
1885257|NCT01218828|Other|Standard hydration|
1885258|NCT01218841|Dietary Supplement|Fish oil lipid emulsion|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
1885259|NCT01218841|Dietary Supplement|MCT/LCT|0.2g of fat/kg of body weight/day for 3 days during 6 continuous hours in peripheral vein.
1885261|NCT01218867|Biological|Anti-VEGFR2 CAR CD8 plus PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
1885262|NCT01218867|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose in 5% water (D5W) with mesna 15 mg/kg/day X 2 days over 1 hr
1885263|NCT01218867|Biological|Aldesleukin|Aldesleukin (based on total body weight) will be administered at a dose of 720,000 IU/kg (Arms 1-7) or 72,000 IU/kg (Arms 8-11) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of the cell infusion and continuing for up to 5 days (maximum 15 doses)
1885264|NCT01218867|Drug|Fludarabine|Fludarabine 25 mg/m(2)/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days
1885265|NCT01218880|Drug|M2ES 7.5mg|M2ES Dosage：7.5mg/m2
1885266|NCT01218880|Drug|M2ES 15mg|M2ES Dosage：15mg/m2
1885267|NCT01218880|Drug|M2ES 30mg|M2ES Dosage：30mg/m2
1885268|NCT01218880|Drug|M2ES 45mg|M2ES Dosage：45mg/m2
1885269|NCT01218893|Drug|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
1885270|NCT01218893|Biological|Immunization|All groups will be immunised with mosquitobites. The number of infected mosquitoes differs per group, as clarified in group description.
1885271|NCT01218893|Biological|Plasmodium falciparum challenge|Exposure to the bites of 5 Plasmodium falciparum infected mosquitoes.
1960501|NCT03192553|Behavioral|Double Gloving Procedure|Participants will doff PPE using a double gloving procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
1960502|NCT03192553|Behavioral|Intensified Hand Hygiene Procedure|Participants will doff PPE using an intensified hand hygiene procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
1960503|NCT03192553|Behavioral|One Step Procedure|Participants will doff PPE using a one-step procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
1960504|NCT03192553|Behavioral|CDC Procedure|Participants will doff PPE using a CDC recommended procedure after coating with Glogerm fluorescent dye +/- staphylococcus epidermidis
1885272|NCT01218893|Drug|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
1885273|NCT01218932|Drug|A|Subjects in A group who receive regimen 1 of primaquine (PQ) on the first admission (visit 2) will receive regimen 2 of primaquine and chloroquine combination (PQ and CQ) on second admission (visit 3) after 1 week wash out period and will finish with regimen 3 of Chloroquine (CQ) on the third admission (visit 4) after 8 weeks wash out period.
1885274|NCT01218932|Drug|B|Subjects in B group who receive regimen 1 of primaquine ( PQ) will receive regimen 2 of chloroquine (CQ) on second admission (visit 3) after 1 week wash out period and regimen 3 of primaquine and chloroquine combination (PQ and CQ)on third admission( visit 4) with 8 week wash out period in between.
1885275|NCT01218945|Procedure|Cell Culture|Aim of this study is to isolate and cultivate fat-derived progenitor cells and differentiation into osteoblasts. Therefore, our research idea is to pre-engineer large synthetic bone grafts and study the vascularization process in vivo.
1885276|NCT01218958|Drug|Medisorb naltrexone 190 mg|Intramuscular (IM) injection once every 4 weeks for a total of 6 administrations.
1885277|NCT01218958|Drug|Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
1885278|NCT01218958|Drug|Placebo matching Medisorb naltrexone 190 mg|IM injection once every 4 weeks for a total of 6 administrations.
1885279|NCT01218958|Drug|Placebo matching Medisorb naltrexone 380 mg|IM injection once every 4 weeks for a total of 6 administrations.
1885280|NCT01218971|Drug|Medisorb naltrexone 190 mg|naltrexone for extended-release injectable suspension
1885281|NCT01218971|Drug|Medisorb naltrexone 380 mg|naltrexone for extended-release injectable suspension
1885282|NCT01218984|Drug|Medisorb naltrexone 75 mg|Single administration via intramuscular (IM) injection.
1885283|NCT01218984|Drug|Medisorb naltrexone 150 mg|Single administration via IM injection.
1885284|NCT01218984|Drug|Medisorb naltrexone 300 mg|Single administration via IM injection.
1885285|NCT01218984|Drug|Hydromorphone (10 mg/mL)|Increasing doses of 0, 3, 4.5, and 6 mg were administered at baseline (pre-study drug administration). After study drug administration, additional hydromorphone challenge sessions consisting of administering 0, 3, 4.5, and 6 mg were administered at 1-hr intervals at each of the postdose evaluation visits. In addition, at a randomly selected evaluation visit, subjects received four 0 mg (placebo) doses at 1-hour intervals.
1885286|NCT01218984|Drug|Naloxone Challenge and Oral Naltrexone Tolerability Testing|Administered according to the instructions provided by the respective manufacturer. Testing occurred at least 7 days after the baseline hydromorphone challenge and prior to study drug administration.
1885287|NCT01218997|Drug|Medisorb naltrexone 380 mg|Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
1885288|NCT01218997|Drug|Oral naltrexone 50 mg|Tablet taken orally once daily for up to 1 year
1885289|NCT01219010|Biological|Siltuximab|15mg/kg IV infusion every 3 weeks for 4 cycles. If applicable extended dosing of 15 mg/kg IV infusion every 4 weeks for up to 2 years.
1885290|NCT01219023|Drug|sildenafil citrate|Subjects will be given 2 types of topical creams, one containing 1% sildenafil and one containing placebo control. Subjects will be randomized to apply sildenafil cream to either the right or left hand/foot; placebo cream will be applied to the opposite hand/foot. The cream will be supplied to subjects with proper labeling to indicate right and left application assignment. Cream will be applied to each affected hand/foot two times per day.
1885291|NCT01219036|Drug|Budesonide (directly observed)|Budesonide 1600 micrograms daily directly observed for 7 days
1885292|NCT01219049|Drug|Tyrosine|1000 mg / day
1885293|NCT01219049|Drug|Tyrosine|2000 mg / day
1885294|NCT01219049|Drug|Placebo|Placebo daily
1885295|NCT01219062|Drug|morphine|periarticular infiltration with 0.25% Bupivacaine for 20 ml.
1885296|NCT01219062|Other|control|the patients will be received spinal anesthesia with 0.5% Isobaric Bupivacaine and postoperative pain control by intravenous (IV) Patient - control Analgesia (PCA)
1885297|NCT01219062|Drug|Bupivacaine|the patients will be received spinal anesthesia and periarticular tissue infiltration with 0.25% Bupivacaine and postoperative pain control by IV PCA
1885298|NCT01219075|Dietary Supplement|soy isoflavones|Given orally
1885299|NCT01219075|Other|placebo|Given orally
1885300|NCT01219075|Other|questionnaire administration|Ancillary studies
1885301|NCT01219075|Procedure|magnetic resonance imaging|Correlative studies
1885302|NCT01219075|Procedure|biopsy|Correlative studies
1885303|NCT01219075|Other|immunohistochemistry staining method|Correlative studies
1885304|NCT01219075|Other|laboratory biomarker analysis|Correlative studies
1885305|NCT01219075|Procedure|mammography|Correlative studies
1885306|NCT01219088|Drug|Bupivacaine, morphine|1.8-2.5 mL of 0.5% heavy bupivacaine for spinal anesthesia 20 mL of 0.25% bupivacaine for femoral nerve block 0.1 mg of intrathecal morphine 20 mL of 0.25% bupivacaine for periarticular infiltration
1885307|NCT01219101|Drug|clomiphene citrate with ethinyl esteradiol|Clomiphene citrate is used in combination of ethinyl estradiol (0.05 mg for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
1885308|NCT01219101|Drug|clomiphene citrate with plasebo|Clomiphene citrate is used in combination of placebo (for 5 days) for induction ovulation of polycystic ovary syndrome women undergoing intrauterine insemination
1885309|NCT01219127|Other|Derma-PACE|ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
1885310|NCT01219140|Dietary Supplement|2 POMx Capsules|2 POMx Capsules daily
1885311|NCT01219140|Dietary Supplement|2 placebo Capsules|2 placebo Capsules daily
1885312|NCT01219153|Drug|Extended high dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland) is administered starting on cycle day one for 8 consecutive days . The dose of letrozole is 5mg /day during the first 5 days of cycle and 2.5 mg/day during the subsequent 3 days .
Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 5 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.
GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
1885313|NCT01219153|Drug|Short low dose letrozole regimen /GnRH antagonist protocol|"Letrozole (Femara; Novertis pharma AG, Basle, Switzerland)2.5 mg /daily is administered for 5 consecutive days starting on cycle day 3.
Highly purified urinary FSH (HP-uFSH) (Fostimon, IBSA) 300 IU/day is started on cycle day 3 and is continued until and including the day of HCG administration. Starting from cycle day 8 , the dose of HP-uFSH is adjusted individually according to ovarian response which is monitored using transvaginal ultrasound and serum estradiol.
GnRH antagonist (cetrorelix acetate)(Cetrotide®) 0.25 mg S.C once daily is started when the leading follicle is 14 mm in mean diameter and is continued until and including the day of HCG administration ."
1885314|NCT01219166|Procedure|Laparoscopic Cholecystectomy|Laparoscopic Cholecystectomy
1885315|NCT01219179|Other|Sterile water feedings|"Control group- no intervention
Prophylactic group will receive sterile water feeds starting at 24 hours of life if/or when their serum sodium value is ≥ 145 mEq/L. The volume of sterile water is 10mls/Kg/day based on birth weight, given via continuous infusion feed.
The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L.
The hypernatremia group will receive sterile water feeds when their serum sodium value is ≥ 150 meq/L. The volume of sterile water is 10 mls/Kg/day based on birth weight,given via continuous infusion feed. The feeding will be stopped when the serum sodium value is ≤ 140 mEq/L."
1885316|NCT01219192|Drug|M2ES|M2ES IV D1,8,15,21 every 28 days a cycle
1885317|NCT01219192|Drug|M2ES|M2ES IV D1,8,15,21, every 28days a cyce.
1885318|NCT01219192|Drug|M2ES|M2ES 45mg IV D1,8,15,22 28days a cycle
1885319|NCT01219192|Drug|M2ES 60mg|M2ES 60mg IV D1,8,15,22 every 28days a cycle
1885320|NCT01219205|Procedure|intravitreal bevacizumab|Intravitreal injections of bevacizumab were performed under sterile conditions in the operating room. a 27-gauge needle was inserted through the corneal limbus to withdraw 0.05 ml of aqueous humor and soften the globe. Then, 1.25 mg (0.05 ㎖) of bevacizumab was injected into the vitreous in the superior temporal quadrant with a 30-gauge needle that was inserted into the eye 3.5 mm from the limbus. The postoperative medications included topical antibiotics.
1885321|NCT01219218|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
1885322|NCT01219231|Behavioral|Exercise|6 months of aerobic exercise
1885323|NCT01219244|Behavioral|caloric restriction|6 months of caloric restriction (15 %)
1885324|NCT01219244|Behavioral|omega-3 supplementation|6 months of omega-3 supplementation
1885325|NCT01219244|Behavioral|resveratrol supplementation|6 months of resveratrol supplementation
1885326|NCT01219244|Behavioral|Placebo|6 months of placebo intake
1885327|NCT01219244|Behavioral|2nd step: intervention + physical / cognitive training|most effective dietary intervention plus physical and cognitive training
1885328|NCT01219244|Behavioral|2nd step: intervention + control|most effective dietary intervention plus control
1885329|NCT01219257|Biological|Anti-TNF alpha therapy|All medical treatment will be standardizes following good medical practice
1885330|NCT01211483|Drug|U3-1287|Liquid 70 mg/mL. One intravenous infusion every 3 weeks Until cancer gets worse or unacceptable side effects of the drugs or withdrawal of consent.
1885331|NCT01211483|Drug|Erlotinib|Tablet 150 mg. Once daily Until cancer gets worse or unacceptable side effects of the drugs or withdrawal of consent
1885332|NCT01211496|Behavioral|High-speed power training|High speed resistance training, 3 sessions per week for 12 weeks
1885333|NCT01211496|Behavioral|Slow-speed strength training|Slow speed resistance training, 3 sessions per week for 12 weeks
1885334|NCT01211509|Drug|Montelukast|After diagnosis of fBOS every day an oral capsule with 10 mg montelukast of placebo
1885335|NCT01211522|Drug|Haloperidol|Haloperidol, up to 10mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 5mg/mL. Patient will only receive IV while in the ICU.
1885336|NCT01211522|Drug|Ziprasidone|Ziprasidone, up to 20mg q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes at concentrations of 10mg/mL. Patient will only receive IV while in the ICU.
1885337|NCT01211522|Drug|Placebo|Placebo, up to 10mL q12 hours, will be administered intravenously (IV) by bolus over up to 5 minutes. Patient will only receive IV while in the ICU.
1885338|NCT01211535|Device|OPTI-FREE RepleniSH multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, rinsing, conditioning, disinfecting, and storing study contact lenses on a daily wear basis for 14 days
1885339|NCT01211535|Device|ReNu Biotrue multipurpose solution|FDA-approved, multipurpose solution used as indicated for cleaning, disinfecting, daily protein removing, and storing study contact lenses on a daily wear basis for 14 days
1885340|NCT01211535|Device|Silicone hydrogel contact lenses|Silicone hydrogel contact lenses per subject's habitual brand and prescription worn on a daily wear basis for 14 days, with either OPTI-FREE RepleniSH or ReNu Biotrue used for contact lens care
1885341|NCT01211548|Other|contrast CTA of the CAP|CT coronary angiography results will be reported for all patients by adjudicators blinded to their inclusion in the study.
1885342|NCT01211561|Drug|Selenium, selenomethionine|Patients will receive one 200 ug pill of Selenomethionine
1885343|NCT01211561|Drug|placebo|Patients will be given one 200 ug placebo pill each day for 6 months
1885344|NCT01211574|Behavioral|peer coach|Participants will receive behavioral weight loss treatment and be coached by a peer between treatment visits.
1885345|NCT01211574|Behavioral|mentor|Participants will receive behavioral weight loss treatment and be coached by a mentor between treatment visits.
1885346|NCT01211574|Behavioral|Professional|Participants will receive behavioral weight loss treatment and be coached by a behavioral weight loss interventionist between treatment visits.
1885349|NCT01211600|Other|Staples|Interrupted Ethicon Staples
1885350|NCT01211600|Other|Suture|Subcuticular continuous suture (4-0 Monocryl Plus on PS2 needle or 4-0 Vicryl Plus on FS2 or PS2 needle)
1885351|NCT01211613|Procedure|Manual Manipulation|Doctor of chiropractic will apply manual high-velocity low-amplitude thrust to lumbar spine of research participants.
1885352|NCT01211613|Device|Mechanically-assisted manipulation|Doctor of chiropractic will use the Activator Instrument to apply a mechanically-assisted thrust to the lumbar spine of research participants.
1885353|NCT01211613|Other|Standard Medical Care|Patients will receive an examination with a physician who is board certified in physical medicine and rehabilitation. Treatment will consist of medical monitoring of the patient's condition over 4 weeks (baseline and 2 follow up exams) and a prescription for over-the-counter anti-inflammatory medications if indicated.
1885354|NCT01211626|Drug|ANA773|ANA773 Tosylate Capsule
1885355|NCT01211626|Drug|Placebo|Matching Placebo Capsule
1885356|NCT01211665|Drug|Methylprednisolone|In intravenous form (for a daily dose of 1 g/day on treatment days).
1885357|NCT01211665|Drug|Prednisolone|Oral prednisolone used as a taper, with suggested dosages starting at 80 mg and tapering to 5 mg.
1885358|NCT01211691|Drug|KB004, Monoclonal Antibody|
1885359|NCT01211704|Drug|Paliperidone Palmitate|NVEGA® SUSTENNA™ or placebo in equivalent ml doses according to the following schedule: Day 1: INVEGA® SUSTENNA™ 234mg vs. placebo injection (equivalent ml); Day 8 (week 1) INVEGA® SUSTENNA™ 156mg vs. placebo injection (equivalent ml); Day 36 (week 5): INVEGA® SUSTENNA™ 117 mg vs. placebo injection (equivalent ml) ( this latter dose could range from 39mg to 156mg according to tolerability and clinical symptoms of bipolar disorder). Treatment with INVEGA® SUSTENNA™ /Placebo will last 5 weeks.
1885360|NCT01211704|Drug|Placebo|Placebo in equivalent ml doses to experimental intervention (Paliperidone Palmitate)
1885361|NCT01211717|Dietary Supplement|Branched Chained Amino Acids|Two doses of the Branched Chained Amino Acid supplement will be taken. The first dose will be taken 35 minutes before the intended exercise, and the other dose will be taken right after completing the exercise. The amount of the Branched Chained Amino Acid supplement administered to the subjects in the experimental group will vary from one person to the other but a total dose of 1 gram of BCAA per kilogram of lean body mass will be used. This dose will be divided in half and administered at the two specified occasions. The ratio of isoleucine, leucine, and valine will be 1:2.5:1 respectively
1885362|NCT01211717|Other|Cellulose Placebo mix|The control group will also take 2 doses, 1 before the exercise, and the other after completing the exercise. This dose will be divided in half and administered at the two specified occasions.
1885363|NCT01211730|Drug|Insulin|Insulin initially as continuous infusion for first 24-48 hours followed by subcutaneous administration once subjects eating and out of intensive care unit.
1885364|NCT01211743|Other|Laparoscopic cholecystectomy|Standard 4 port laparoscopic cholecystectomy
1885365|NCT01211743|Other|Single incision laparoscopic cholecystectomy|One port placed through the umbilicus
1885366|NCT01211756|Drug|Oxytocin|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
1885367|NCT01211756|Drug|Placebo|20 IU BID for one week, followed by 40 IU BID for 3 weeks.
1885368|NCT01211769|Drug|Naltrexone|A pill of naltrexone chlorhydrate 50mg, associated to yellow liquid paraffin pills simulating borage seed and fish oil.
1885369|NCT01211769|Drug|PUFAs|Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs; associated to a pill with 50mg of talcum powder, identical to the pill of naltrexone.
1885370|NCT01211769|Drug|Placebo|A pill with 50mg of talcum powder, identical to the pill of naltrexone; associated to PUFAs Placebo pills (yellow liquid paraffin identical to the pills of borage seed and fish oil).
1885371|NCT01211769|Drug|Naltrexone + Placebo|A pill of naltrexone chlorhydrate 50mg, associated to Borage Oil (Borago officinalis L. Boraginaceae) - rich in omega 6 PUFA, dosage of 1 gram and Fish oil 1 gram - rich in omega 3 PUFAs.
1885372|NCT01211782|Drug|caprylic triglyceride|oral, 20 gm, daily x 6 months
1885373|NCT01211782|Drug|long-chain triglyceride|oral, 14 gm, daily x 6 months
1885374|NCT01211795|Drug|topical intraoral ketoprofen gel|20% ketoprofen oral gel is applied once daily by cotton swab to a branch of the trigeminal nerve on the maxillary gingival mucosa above the 2nd and 3rd molars. The swab is held in place for 2 minutes at the same time once daily.
1885375|NCT01211795|Other|Placebo Gel|An identical oral gel, without ketoprofen, or 'placebo gel' is applied using a cotton swab, once daily to a branch of the trigeminal nerve on the maxillary gingival mucosa. It is held in place for 2 minutes, once daily.
1885376|NCT01211808|Drug|BMS-914832|Tablets, Oral, 30 mg, once, 1 day
1885377|NCT01211808|Drug|Diltiazem|Tablets, Oral, 360 mg, once daily, 10 days
1885378|NCT01211821|Drug|metoprolol|Tablets, Oral, 200 mg, once, 1 day
1885379|NCT01211821|Drug|BMS-914392|Tablets, Oral, 60 mg, once daily, 7 days
1885380|NCT01211834|Drug|tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
1885381|NCT01211834|Drug|DMARDs|Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
1885382|NCT01211834|Drug|Placebo|intravenously over 1 hour infusion every 4weeks
1885383|NCT01211834|Drug|DMARDs|Methotrexate(MTX) and/or 1 DMARDs
1885384|NCT01211847|Drug|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 126 days
1885385|NCT01211847|Drug|Placebo|Placebo matching DCCR
1885386|NCT01211860|Drug|Diazoxide Choline Controlled-Release Tablet|DCCR 290 mg once a day for 10 days
1885387|NCT01211873|Drug|Dotarem (gadoterate meglumine)|0.1 mmol/kg by body weight, single IV injection
1885388|NCT01211873|Drug|Magnevist (gadopentetate dimeglumine)|0.1 mmol/kg by body weight, single IV injection
1885389|NCT01211912|Drug|Arm 1 (20 patients)|Acetaminophen 1000 mg by mouth once
1885390|NCT01211912|Drug|Arm 2 (34 patients)|Acetaminophen 1000 mg by mouth once
1885391|NCT01211925|Procedure|distal venous arterialisation|The investigators perform reverse revascularisation of the ischemic limb with arterial blood supply from patent in flow artery to the superficial dorsal venous arch.
1885392|NCT01211925|Drug|Aspirin|100 mg per day continuous
1885453|NCT01212627|Drug|Ridaforolimus|Ridaforolimus 20 Daily, 5 days each week, (Mon-Fri) on a 28 day cycle
1885393|NCT01211938|Radiation|single-fraction radiotherapy with concomitant 5FU and Hydrea|single-fraction radiotherapy with concomitant 5FU and Hydrea
1885394|NCT01211938|Radiation|hyperfractionated radiotherapy with concomitant Cetuximab|hyperfractionated radiotherapy with concomitant Cetuximab
1885395|NCT01211951|Drug|KCT-0809|
1885396|NCT01211951|Drug|KCT-0809|
1885397|NCT01211951|Drug|KCT-0809|
1885398|NCT01211951|Drug|Placebo|
1885399|NCT01211964|Drug|LEO 22811|Oral administration of solution and tablet.
1885400|NCT01211977|Drug|XOMA 052|
1885401|NCT01212094|Drug|Rituximab|
1885402|NCT01212094|Other|normal saline|normal saline
1885403|NCT01212107|Drug|LY2874455|"LY2874455 will be taken orally (capsules) once or twice daily for a minimum of (1) 28 day cycle.
Part A: dose escalation
2-200 mg, administered orally, once or twice daily for a minimum of one (1) 28 day cycle
Part B: dose confirmation
dose determined by Part A dose escalation, administered orally, once or twice daily for a minimum of one (1) 28 day cycle
Both parts: If patients are determined to be receiving benefit, study treatment may be continued for up to one (1) year (12 cycles of 28 days)"
1885404|NCT01212120|Biological|Genetic profiling of bacterial cultures|Genetic profiling of bacterial cultures harvested from both the nose and foot lesions of patients
1885405|NCT01212133|Drug|liraglutide|Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
1885406|NCT01212146|Dietary Supplement|Lactobacillus paracasei IMPC 2.1 LMGP22043|participants will complement their usual lifestyles and dietary intakes with probiotic artichokes, enriched with the probiotic strain Lactobacillus paracasei IMPC2.1 (LMGP22043). The product contains approximately 1.20 x 10^8 CFU of live probiotic cells of Lactobacillus paracasei IMPC 2.1 LMGP22043 per gramme, which resulted in a daily dose of about 2 x 10^10 CFU.
1885407|NCT01212146|Dietary Supplement|Ordinary artichokes|Probiotic artichokes will be tested against ordinary artichokes (probiotic free) of identical shape, texture, and appearance produced by the same manufacturer. Artichokes will be put in similar packages and there will be no way to distinguish between the two products.
1885408|NCT01212159|Device|Self Monitoring Lipid Analyzer|The device is similar to a glucometer- Utilizing a lancet a small amount of blood is collected in a capillary tube and placed on a hand held monitor that records lipid values.
1885409|NCT01212172|Device|Soprano/SHR|For the Soprano, the constant motion technique will be used with a fluence ranging between 6 J/cm2 and 10 J/cm2, 10 Hz, 20 ms pulse duration. The constant motion technique involves treating 100 cm2 areas with multiple passes until reaching the cumulative energy dose of 8 kJ. Thus, the hand piece is kept in constant motion to deliver continuous low fluence that will build up energy over time.
1885410|NCT01212172|Device|LightSheer|The LightSheer/Duet will be used with conventional single pass (stamping) of the handpiece using settings of single pulse fluence of up to 14 J/cm2 and low vacuum settings.
1885411|NCT01212185|Drug|intranasal oxytocin spray|6 insufflations (24 IU of oxytocin total) given twice daily for 3 days
1885412|NCT01212185|Other|intranasal spray without oxytocin|6 insufflations (0.1 metered dose/insufflation) twice daily
1885413|NCT01212211|Other|change in drug therapy|Change in drug therapy with the help of the opinion of pharmacologists : the physician would review the drug treatment of ten residents in coordination with the opinion of pharmacologists
1885414|NCT01212237|Procedure|fMRI Evaluation|Functional magnetic resonance imaging (fMRI) uses MR imaging to measure the tiny metabolic changes that take place in an active part of the brain. fMRIs are used for many reasons, for example, to determine precisely which part of the brain is handling critical functions such as thought, speech, movement and sensation, to help assess the effects of stroke, trauma or degenerative disease (such as Alzheimer's) on brain function, and to guide the planning of surgery and radiation therapy.
1885415|NCT01212250|Drug|carvedilol|Carvedilol will be administered orally at a start dose of 3.125 mg twice daily. After 1 week, this will increased if systolic blood pressure does not fall below 90 mm Hg. The patient will receive the maximum tolerated dose of carvedilol with a maximum of 6.25 BD.
1885416|NCT01212250|Drug|Placebo|The placebo tablets will be identical to the carvedilol tablets. First the patients will receive placebo in the dose of 1 BD. Then depending on his tolerance it will be increased to a maximum of 2 BD.
1885417|NCT01212263|Drug|Step-up HP u FSH|HP u FSH (Fostimone 75 IU ,IBSA Institut Biochimique SA-CH 6903 Lugano) in doses of 37.5 IU (half ampole) im /day statrted from second day of the cycle for 7 days ,then increased to 75 IU for another 7 days ,then to 112.5 IU (one and half ampoule) untilleading follicle mean diameter reaches 18 mm
1885418|NCT01212263|Drug|Clomiphine citrate plus low dose uFSH|Clomiphene citrate 50 mg tab oral tablets(Clomid 50 mg tablets Global Napi , Egypt) two tablets(100 mg) /day are started from the 2nd day of cycle for 5 days togeteher with 37.5 IU HP uFSH (Fostimone 75 IU IBSA)/day for 8 days and may be extended to 10-12 days until leading follicle diameter reaches 18 mm
1885419|NCT01212276|Drug|MORAb-028|Cohort 1: 0.1 mg/kg IV on study day 1 only Cohort 2: 0.2 mg/kg IV on study day 1 only Cohort 3: 0.5 mg/kg IV on study day 1 only Cohort 4: 1.0 mg/kg IV on study day 1 only
1885420|NCT01212302|Drug|Optimizing ASA and clopidogrel treatment|"ASA 100 mg, ASA 300 mg, ASA 500 mg
Clopidogrel 75 mg, Clopidogrel 150 mg, Ticlopidine 2x 250 mg, Prasugrel 10 mg. Intervention List:
In the case of clopidogrel low-response, the maintenance dose was doubled (repeated loading dose followed by 150 mg daily), and when still ineffective ticlopidine or prasugrel, if available and not contraindicated, were used. ASA low-responders were treated by increasing the dose to 300 mg in a first step or to 500 mg ASA when the first modification was not sufficient."
1885421|NCT01212315|Device|Triclosan coated sutures|Subcutaneous and cutaneous sutures coated with triclosan (Vicryl Plus / Monocryl Plus) are used to close the incisions after vein harvesting and sternotomy. All wounds are inspected before discharge from hospital and the patients are instructed to contact the study coordinator if any suspected infection occurs. In addition, all patients are controlled after thirty days by a nurse and contacted by telephone sixty days after surgery to assess postoperative infections by a predefined questionnaire. Infection symptoms are graded according to the Asepsis score and the CDC classification. Patient records including bacterial cultures and antibiotic treatment are collected for all patients with suspected infections.
1885452|NCT01212614|Procedure|MRI, non invasive 13C-breath test, 24h-intragastric / esophageal pH monitoring|MRI, non invasive 13C-breath test, 24h-intragastric/esophageal pH monitoring
1885454|NCT01212627|Drug|Ridaforolimus|
1885422|NCT01212328|Other|Care Coordinator + Decision Support Software|Care coordinator + Decision Support Software (Experimental Arm): The patients will receive integrated diabetes care management consisting of current diabetes management guidelines + Non-Physician care coordinator assistance + Electronic Health Records- Decision Support Software (EHR-DSS) (The software will generate diabetes management prompts for the treating physician and reminders for clinic visits for the intervention arm patients.)
1885423|NCT01212328|Other|Usual care|Usual care (Active Comparator Arm): Patients will continue with the usual diabetes care with no care coordinator assistance and no decision support software - management prompt.
1885424|NCT01212341|Biological|Allogeneic NK cells|
1885425|NCT01212354|Radiation|Radiotherapy|7 weeks Radiation dose escalation (5 x 2.3 Gy up to 80.5 Gy total dose)
1885428|NCT01212380|Drug|carfilzomib|Given IV infusion lasting 30 minutes. Will be administered IV at a specified dose in mg/m2 QDx2 weekly for 3 weeks (days 1, 2, 8, 9, 15, and 16). The first and second dose will always be administered at 20 mg/m2.
1885429|NCT01212380|Other|Cytokine Assessment|TNF-α,IFN-γ,IL-6,IL-8,IL-10,and IL-1β pre-dose, completion, 30 minutes, 2 hours, 6 hours, and approximately 24 hours from initiation of therapy on days 1 and 8 of treatment. These will be assessed utilizing standard ELISA or flow cytometry methodology. Other cytokines or soluble factors may be assessed that relate to drug toxicity or response. After 6 patients are examined in each group, the time points or number of cytokines examined may be changed to decrease time points examined. Cytokines will be examined by a multiplex flow cytometry assay or ELISA. Other cytokines, chemokines, or soluble factors may be assessed on residual material not used for these studies.
1885430|NCT01212380|Other|Pharmacodynamic Studies|Based upon our preliminary data changes occuring in vivo during carfilzomib treatment will be determined and if their occurrence correlates with both clinical response and development of cytokine release. These studies will be performed from CD19 selected CLL cells at screening, pre-treatment, 4 hours, and 24 hours post-therapy on days 1 and 8 of treatment; end of therapy evaluation, and at time of relapse (in responding patients). These studies will include assessment of NF-κB (p50/p65 binding; I-κB level, P-I-κB level, select target genes), p53 (p53 nuclear levels, p53 nuclear binding, and select target genes), p73, and ER stress response. Standard Western Blot, EMSA, RT-PCR will be done to complete these studies.
1885431|NCT01212380|Other|Proteosome Inhibition Assessment|Proteosome inhibition on CLL cells will be examined at screening, pre-treatment and post-treatment (immediately after completion of drug) days 1, pre-treatment day 2, day 3 (optional), day 5 (optional),pre and post-treatment days 8, pre and post-treatment days 9, day 10 (optional),day 12 (optional), and day 15 (optional).
1885432|NCT01212380|Other|Pharmacogenomic Studies|Germ line DNA from a buccal swab and bone marrow fibroblasts will be obtained at baseline screening for possible examination of SNP polymorphisms that may correlate with response and toxicity to carfilzomib therapy. Tumor DNA will be derived from samples obtained at baseline for the p53 mutational studies. SNPs related to drug metabolism, response, or toxicity to therapy, cytokine release, and tumor biology may be examined. Other SNPs may be used in the future. Given the potential for contamination in the recipient, recipient DNA from a buccal swab and/or saliva will be obtained at baseline screening for examination of SNP polymorphisms that may correlate with response, toxicity, and pharmacokinetics.
1885433|NCT01212393|Behavioral|reminders|In the intervention group, emergency departments will be provided with poster and pocket cards and, if possible, with a computer decision support system remembering venous thromboembolism prophylactic treatment.
1885434|NCT01212406|Drug|Vitamin D|Every month 100.000 units of vitamin D in syringe Exacta-Med Oral Dispenser during 2 years and re-evaluation after 3 years
1885435|NCT01212432|Drug|Daptomycin|Daptomycin kinetics in CRRT
1885436|NCT01212445|Drug|PEG 3350 laxative plus electrolytes (PEG + E)/Macrogol (Movicol®, BAY81-8430)|13.125 g of PEG 3350 powder with approximately 0.6 g of electrolytes
1885437|NCT01212458|Drug|Rufinamid|Effect of oral rufinamide and oxcarbazepine on nerve excitability, hyperalgesia, allodynia and flare reaction compared to placebo.
1885438|NCT01212471|Drug|Bromfenac Ophthalmic Solution A|sterile ophthalmic solution
1885439|NCT01212471|Drug|Bromfenac Ophthalmic Solution B|sterile ophthalmic solution
1885440|NCT01212471|Drug|Placebo Comparator|sterile ophthalmic solution
1885441|NCT01212484|Drug|Carbidopa|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
1885442|NCT01212484|Drug|Placebo|The trial will be divided into two consecutive, but independent parts. Phase 1, will address the safety and tolerability of carbidopa in patients with FD using an open-label dose titration phase followed by 4-weeks of open-label treatment. Phase 2, will address the efficacy of carbidopa for the treatment of nausea in patients with FD using a randomized, placebo controlled, double blind, 4-week cross over design.
1885443|NCT01212497|Behavioral|Mindfulness meditation coaching|Participants interact with virtual coach to obtain instruction in mindfulness meditation and coaching support.
1885444|NCT01212510|Other|Blood sampling|blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA
1885445|NCT01212523|Drug|propofol and isoflurane|both drugs administered at age-related dose and titrated to effect. maximum dose of propofol 15 mg/kg/hr, maximum dose of isoflurane 1.5 MAC
1885446|NCT01212536|Device|Airtraq laryngoscopy|laryngoscopy and intubation
1885447|NCT01212549|Procedure|Immunocryosurgery|2 weeks imiquimod, cryosurgery (open spray liquid nitrogen, 2 cycles, 15 secs each), 3 more weeks imiquimod
1885448|NCT01212549|Procedure|Cryoimmunotherapy|Cryosurgery(open spray liquid nitrogen, 2 cycles, 15 secs each), followed by 5 weeks imiquimod
1885449|NCT01212562|Procedure|Immunocryosurgery|Assessing the efficacy of cryosurgery during continued imiquimod application (immunocrysurgery) in the treatment of basal cell carcinoma of the skin
1885455|NCT01212653|Drug|Simponi|Golimumab 50mg monthly
1885456|NCT01212653|Other|0.9ml sodium chloride|0.9ml sodium chloride
1885457|NCT01212666|Procedure|Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
1885458|NCT01212666|Procedure|Saline|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
1885461|NCT01212692|Behavioral|mentally stimulating activities|The study will compare the effects of different methods of mental stimulation. The intervention involves 6 classroom-style educational sessions and 10 mental stimulation studies involving computerized memory tasks.
1885462|NCT01212705|Device|Adaptive servoventilation|Background expiratory positive airway pressure with some inspiratory pressure support when needed
1885463|NCT01212718|Drug|FUFA|2600/500 mg/m2 i.v. 24 h via port, 1 time weekly for six weeks, than have a break for 2 weeks (=8 weeks for 1 cycle)
1885464|NCT01212718|Drug|systemic chemotherapy|CPT-11, 80 mg/m2 for 90 minutes and 5 FU/FA 2000/500 mg/m2 iv. 24h via port; 1 time weekly for six weeks, than have a break for 2 weeks
1885465|NCT01212731|Radiation|Photon treatment plans|10 of the 30 subjects on Cohort 1 will receive photon treatment plans.
1885466|NCT01212731|Radiation|Proton Treatment Plans|20 subjects from Cohort 1 will receive proton treatment plans with malignancies involving the base of skull.
1885467|NCT01212731|Behavioral|Neurocognitive evaluation|Verbal and Visual memory; immediate attention, working memory, and processing speed; executive functions and affect and depression.
1885468|NCT01212731|Device|Advanced MRI imaging|Anatomic Imaging, Blood volume measurements, Diffusion Tensor Imaging, DTI Image Processing
1885469|NCT01212744|Drug|rAvPAL-PEG|0.06 mg/kg/day, 0.1 mg/kg/day, 0.2 mg/kg/day, 0.4 mg/kg/day, 0.6 mg/kg/day, 0.8 mg/kg/day
1885470|NCT01212757|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
1885471|NCT01212757|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
1885472|NCT01212757|Drug|Placebo + 20 mg Apremilast|Placebo + 20 mg Apremilast
1885473|NCT01212757|Drug|Placebo + 30 mg Apremilast|Placebo + 30 mg Apremilast
1885477|NCT01212783|Behavioral|In-Home Cognitive Behavioral Therapy|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and two monthly booster sessions provided after the 15th session.
1885478|NCT01212783|Behavioral|Present-Centered Therapy|Present-Centered Therapy is a supportive psychotherapy.
1885487|NCT01212835|Procedure|Sham Comparator: no ring|Open roux-en-Y gastric bypass not banded
1885488|NCT01212835|Procedure|RYGBP-RING|Vertical Roux-en-Y banded gastric bypass
1885491|NCT01212861|Device|Suprachoroidal Dissection Instrument (SDI)|The Suprachoroidal Dissection Instrument (SDI) is a manually operated, non-powered, re-usable ophthalmic surgical instrument. The SDI is designed to enter a surgically exposed Schlemm's canal and be advanced up to 90 degrees around the canal from the entry site.
1885492|NCT01212874|Drug|nitroglycerin|nitroglycerin administered as an infusion following a step up/step down protocol to treat hypertension in patients undergoing cardiac surgery.
1885493|NCT01212874|Drug|esmolol|esmolol will be administered by infusion following a step up / step down protocol to control hypertension.
1885494|NCT01212887|Biological|MFE23 scFv-expressing autologous anti-CEA MFEz T lymphocytes|
1885495|NCT01212887|Biological|aldesleukin|
1885496|NCT01212887|Drug|cyclophosphamide|
1885497|NCT01212887|Drug|fludarabine phosphate|
1885498|NCT01212887|Other|laboratory biomarker analysis|
1885499|NCT01212887|Other|pharmacological study|
1885502|NCT01212913|Drug|INSULIN GLARGINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
1885503|NCT01212913|Drug|INSULIN GLULISINE|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once daily
1885504|NCT01212913|Drug|Insulin aspart|Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: twice daily
1885505|NCT01212926|Device|Echographic analysis of myocardial deformation in 2D strain|
1885506|NCT01212952|Drug|pomalidomide|Given orally
1885507|NCT01212952|Drug|bortezomib|Given IV
1885508|NCT01212952|Drug|dexamethasone|Given orally
1885509|NCT01212952|Other|laboratory biomarker analysis|Optional correlative studies
1885510|NCT01212952|Other|gene expression analysis|Optional correlative studies
1885511|NCT01212965|Drug|Selenium|400 μg once a day for 6 months by mouth
1885590|NCT01221298|Drug|ABT-072|tablets
1885512|NCT01212978|Behavioral|Pedometer to Increase Physical Activity|The pedometer will be given to arms 2 and 3 (pedometer only and pedometer+software intervention) to help them guide their increase in physical activity.
1885513|NCT01212991|Drug|Enzalutamide|Participants received enzalutamide 160 mg, administered as four 40-mg capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
1885514|NCT01212991|Drug|Placebo|Participants received placebo, administered as four capsules, once per day by mouth. Study drug treatment continued until disease progression (evidence of radiographic progression, a skeletal-related event, or clinical progression) and the initiation of a cytotoxic chemotherapy or an investigational agent, unacceptable toxicity, or withdrawal.
1885515|NCT01213004|Procedure|respiration correlated CT scan|Thoracic malignancies (study group 1): Patients to be treated for gastro-esophageal junction (GEJ) malignancy undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation, which are used to correct patient position at treatment. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. In cases of GEJ malignancy, oral contrast is administered prior to the standard CT scan; this is done at the treating physician's discretion. The standard CT is used to design the radiation treatment plan, where as the RCCT is used to define a volume that encompasses the motion extent of the tumor with breathing and is transferred to the standard CT.
1885516|NCT01213004|Procedure|respiration correlated CT scan|Abdominal malignancies (study group 2): Patients undergo an implantation procedure of two or three radiopaque markers several days prior to treatment simulation. At treatment simulation, patients receive a standard CT scan followed by an RCCT scan. Intravenous contrast is administered prior to the standard CT; this is done at the treating physician's discretion.
1885517|NCT01213017|Drug|certolizumab pegol|400mg at week 0, 2 and 4, followed by 200 mg every two weeks for 52 weeks
1885518|NCT01213030|Drug|[F-18] FMISO|10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
1885519|NCT01213030|Drug|[F-18] HX4|10 mCi [F18] HX4 and 10 mCi [F-18] FMISO within 7 days of each other regardless of sequence
1885520|NCT01213043|Biological|Prolastin-C, 60 mg/kg|60 mg/kg weekly infusion of Prolastin-C for 8 weeks
1885521|NCT01213043|Biological|Prolastin-C, 120 mg/kg|120 mg/kg weekly infusion of Prolastin-C for 8 weeks
1885522|NCT01213056|Behavioral|Mindfulness Based Cognitive Therapy|Cognitive Behavioral (Active treatment condition)
1885523|NCT01213069|Other|Questionnaires|The subjects are asked to fill out a questionnaire on the personal and professional situations, organ donation legislation, what happens in everyday practice, their own experience with donating their own organs, and what position they take.
1885524|NCT01213082|Drug|24GyE proton and Anti-VEGF|24GyE proton beam will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
1885525|NCT01213082|Drug|16GyE and anti-VEGF|16GyE of Proton Beam Irradiation will be administered in 2 fractions 24 hrs apart 2 to 6 weeks after intravitreal anti-VEGF therapy
1885526|NCT01213082|Drug|Sham Irradiation and anti-VEGF|2 Sessions of Sham Proton Beam Irradiation 24 hrs apart administered 2 to 6 weeks after intravitreal anti-VEGF therapy
1885527|NCT01213095|Drug|rituximab|rituximab 375mg/m2, every 8 weeks, 12 times
1885528|NCT01213108|Behavioral|Örebro prevention program|6 presentations on alcohol-specific parenting practices to parents of 13-16 year olds youth
1885529|NCT01213108|Behavioral|Business as usual|Regular alcohol prevention activities and curricula in Swedish schools
1885530|NCT01213121|Drug|Quetiapine|oral tablet/25-600mg per day/once a day/six weeks
1885531|NCT01213147|Drug|clomiphene citrate|100 mg per day oral for 7 days
1885532|NCT01213147|Drug|buserelin|50 µg Subcutaneous twice a day from cycle day 2 of menstrual cycle
1885533|NCT01213160|Drug|AZD4547|film coated tablet, PO, twice daily
1885534|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|treatment with 47.5mg for two weeks, if tolerated and without Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3, the dosage will be titrated to 95mg and last for another 6 weeks
1885535|NCT01213173|Drug|Succinate Metoprolol (Betaloc ZOK®)|Treatment with 95mg for two weeks, and if tolerated and without bradycardia symptoms presented, Systolic blood pressure<100mmHg and heart rate <45 bpm according to 12-lead Electrocardiogram at Week 3，the dosage will be force titrated to 190mg and last for another 6 weeks
1885536|NCT01213186|Drug|high dose of MSC|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 1.5*10E6/kg for 48 weeks.
1885537|NCT01213186|Drug|low dose of MSC treatment|Taken i.v., at week 0, 4, 12, 24, 36 and 48, at a dose of 0.5*10E6/kg for 48 weeks.
1885538|NCT01213199|Drug|Adapalene|Adapalene Gel 0.3%
1885539|NCT01213212|Other|Caloric restriction|Caloric restriction.
1885540|NCT01213212|Other|No intervention|"Diet ad libitum"
1885541|NCT01213238|Drug|Oxaliplatin|140 mg/m2 by Hepatic Arterial Catheter (HAI) on day 1 of a 21 day cycle.
1885542|NCT01213238|Drug|Capecitabine|Starting dose of 500 mg/m2 by mouth twice daily, on days 1 - 14 of a 21 day cycle.
1885543|NCT01213238|Drug|Bevacizumab|10 mg/kg by vein on day 1 of a 21 day cycle.
1885544|NCT01213251|Device|Single Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular lead.
1885545|NCT01213251|Device|Dual Site Pacing|Subjects will be implanted with a CRT-D that delivers pacing via the Left Ventricular and Right Ventricular lead.
1885546|NCT01213264|Other|No neuromuscular blockade (NMB)-reversal agent used|Participants whose reversal from NMB is spontaneous (no reversal agent used)
1885547|NCT01213264|Drug|Sugammadex|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.
As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive the NMB-reversal agent sugammadex, administered according to the local clinical practice and drug product labeling."
1885591|NCT01221298|Drug|Ribavirin|tablets
1885592|NCT01221298|Drug|Ritonavir|capsules
1885593|NCT01221311|Device|Fully covered Metallic Stent|Covered Wallflex Biliary (TM)
1885548|NCT01213264|Drug|Other NMB-Reversal Agents Used in Routine Anesthesiology Practice|"Participants receive NMB-reversal agents at the discretion of the treating physician per label according to local guidelines, in accordance with routine anesthesiology practice.
As this is a prospective observational study designed to collect data as part of routine clinical practice, the protocol does not assign which reversal agents, if any, are to be used. This intervention is associated with a cohort that is intended to include participants who receive any NMB-reversal agent other than sugammadex, and represents multiple drugs whose use and administration may vary according to local clinical practice, product availability and product labeling."
1885549|NCT01213277|Other|Fast Glycator|The subjects enrolled in this study will have a fructosamine test and blood drawn to see whether they are fast glycators
1885550|NCT01213277|Other|Control|These patients will have their blood drawn to know what the normal glycation rate is in diabetic patients
1885551|NCT01213290|Device|EUS - FNA with stylet|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) with stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
1885552|NCT01213290|Device|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)|Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA)without stylet. Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) has become a useful tool in the diagnostic evaluation of gastrointestinal tract lesions as well as other accessible organ sites and has found a wide use in the management of various gastrointestinal and non-gastrointestinal lesions.
1885553|NCT01213316|Drug|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 48 or 144 weeks
1885554|NCT01213316|Drug|Raltegravir|Raltegravir, 400 mg, per oral (p.o.) twice daily (b.i.d.) for 96, 144, or 48 weeks
1885556|NCT01219309|Dietary Supplement|Omega 3/6 fatty acids|3 capsules bid orally
1885557|NCT01219309|Dietary Supplement|Placebo (olive oil)|3 capsules bid orally
1885560|NCT01219348|Biological|IDO peptide vaccination|Vaccination every second week
1885561|NCT01219400|Drug|Vildagliptin|Vildagliptin (50 mg BID) given for four weeks
1885562|NCT01219413|Drug|Aliskiren, Perindopril|Rasilez 300 mg Prestarium 10 mg
1885563|NCT01219426|Other|Filling of three questionnaires|The only intervention of the study was the completion of the three questionnaires, and of a mini-questionnaire assessing gender, age, and gambling activities.
1885564|NCT01219452|Biological|umbilical cord mesenchymal stem cells|Multiple intra muscular injection of mesenchymal stem cells derived from human umbilical cord.
1885565|NCT01219465|Biological|umbilical cord mesenchymal stem cells|Transfusion of the umbilical cord mesenchymal stem cells (2 x 107 cells) intravenously.
1885566|NCT01219517|Other|Polar body and embryo biopsy|2 polar bodies and all embryos will be biopsied prior to embryo transfer.
1885567|NCT01219543|Drug|AZD1480 Daily|Oral Dose, Capsule, Daily Dosing
1885568|NCT01219543|Drug|AZD1480 BID|Oral Dose, Capsule, BID Dosing
1885569|NCT01219556|Drug|Olmesartan plus hydrochlorothiazide (Xirtam H, BAY98-7105)|Oral Xirtam H tablets every 24 hours (Q24H) or as per prescribing information
1885570|NCT01219569|Drug|propofol|Propofol infusion 120 and 160 mcg/kg/min in random sequence during the operative procedure
1885571|NCT01219569|Drug|Sevoflurane|sevoflurane 1.5% and 2.5% end tidal in random sequence
1885572|NCT01219582|Drug|Glucobay M (Acarbose/Metformin, BAY81-9783)|Oral Glucobay-M 25 every 8 hours (Q8H) titrated to Glucobay-M 50 Q8H or as per investigators discretion.
1885573|NCT01219595|Other|Sweetened, dried cranberries|Women in Arm 1 will consume one serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for two weeks.
1885574|NCT01219595|Other|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
1885575|NCT01219595|Other|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for three separate, two-week periods. Each two week period will be separated by a two-week interval.
1885576|NCT01219595|Other|Sweetened, dried cranberries|1 serving (1/3 cup; 42 g) of sweetened, dried cranberries each day for one 4-week period.
1885577|NCT01219595|Other|Strawberry Fruit Pieces|1 serving (1/3 cup; 42 g) of strawberry fruit pieces each day for one 4-week period.
1885578|NCT01219595|Other|Observation|Subjects in the non-UTI susceptible group will have one visit where one vaginal and one rectal swab will be collected.
1885579|NCT01219608|Dietary Supplement|Glutamine 0.5 g/kg/day|Glutamine 0.5 g/kg/day
1885580|NCT01219608|Dietary Supplement|Glutamine 1 g/kg/day|Glutamine 1 g/kg/day
1885581|NCT01219608|Dietary Supplement|Enteral Nutrition|Ordinary Enteral Nutrition
1885582|NCT01221259|Drug|E2212|single ascending doses ranging from 10mg to 250mg
1885583|NCT01221259|Drug|placebo|a single dose of matching placebo
1885584|NCT01221272|Drug|Ranolazine|"One 500 mg tablet in the evening on Day 1 of the period
One 500 mg tablet, twice daily on Days 2-3 of the period
Two 500 mg tablets (1000 mg total), twice daily from Day 4 to the end of the period (Day 15 ± 2 days)"
1885585|NCT01221272|Drug|Placebo to match ranolazine|Placebo to match ranolazine administered in the same form and frequency as the active drug.
1885586|NCT01221272|Procedure|SPECT MPI|Gated single photon emission computed tomography (SPECT) myocardial perfusion imaging (MPI) to confirm the presence of reversible exercise-induced left ventricular perfusion defect size (PDS) performed within 12 weeks prior to baseline or at the baseline visit, and at the end-of-period 1 and end-of-period 2 visits.
1885587|NCT01221272|Behavioral|Exercise|Treadmill stress test
1885588|NCT01221285|Biological|German cockroach (Blattella germanica) allergenic extract|Participants received weekly escalating doses of glycerinated German cockroach allergenic extract administered via the subcutaneous route up to a Maximum Study Dose of 0.6 mL of extract at a concentration of 1:20 wt/vol.
1885589|NCT01221298|Drug|ABT-450|tablets
1885594|NCT01221311|Device|Plastic Stent|Patients randomized to the PS group will be treated using a standard algorithm. Specifically, the stricture will be dilated using a passage dilator and/or dilation balloon catheter, and one or two PS will be deployed depending on the baseline characteristics of the stricture as well as the diameter of the proximal and distal bile duct (standard of care). The endoscopist will sequentially dilate and upsize the cumulative stent diameter on ensuing ERCPs, until the stricture has been obliterated using clinical and fluoroscopic criteria.
1885595|NCT01221337|Other|heparin free haemodialysis|"Comparison of two haemodialyzers VIE 2,1 versus EVODIAL 2,2 in a strategy of heparin-free haemodialysis (HFH)."
1885596|NCT01221350|Dietary Supplement|Lipoic acid|Lipoic acid 600 mg dose (two 300 mg capsules) once daily in the morning. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed.
1885597|NCT01221350|Dietary Supplement|Placebo|Placebo (two capsules filled with 300 mg vehicle) once daily in the morning during 60 days. All patients continued their asthma treatments given by their primary care physician also they were allowed to use rescue medication on demand consisting in inhaled salbutamol. During basal and 8 weeks visits spirometry with bronchodilator challenge, sputum induction and quality of life questionnaires and asthma control test were performed
1885598|NCT01221363|Behavioral|Life style intervention|Reduction of sedentary behavior through theory-based individually tailored lifestyle intervention.
1885599|NCT01221376|Drug|Imatinib Mesylate|Patient will receive Imatinib Mesylate, continuous-use, 260 mg/m2/day dose, maximum allowed 400 mg, for 24 months.
1885600|NCT01221389|Drug|Human Plasma|Patients will receive either 2 units of AB+ plasma or 2 units of hydroxyethylated starch control solution once they are sent to the OR for emergency surgery to address etiology for hemorrhagic shock.
1885601|NCT01221402|Drug|extended-release niacin (Niaspan)|Patients will be randomized in a 1:1 ratio to receive extended-release niacin (1500 - 2000 mg per day) or matching placebo that contains 50 mg of crystalline niacin (enough to cause flushing but has no effect on lipid levels).
1885602|NCT01221428|Biological|Umbilical Cord Mesenchymal Stem Cells|Intravenous infusion of ex vivo cultured umbilical cord mesenchymal stem cells(2*10/7),one week later,conduct intervention operation to inject mesenchymal stem cells to mesenteric artery(1*10/7).
1885603|NCT01221441|Biological|TissueGene-C|Single intraarticular injection at 3 x 10e7 cells
1885604|NCT01221441|Drug|Normal Saline|Single intraarticular injection of normal saline as a placebo control
1885605|NCT01221454|Procedure|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
1885606|NCT01221454|Drug|Conserved therapy|Oral or intravenous administration
1885607|NCT01221467|Device|Overnight closed-loop|The closed-loop system is purpose-built and comprises a hand-held computer containing the algorithm and communicating with the CGM device and the insulin pump.
1885608|NCT01221493|Procedure|Cryo biopsy|Cryoprobe, Erbe Company
1885609|NCT01221506|Drug|Pazopanib|800 mg PO QD x 28 days
1885610|NCT01221506|Device|DCE-MRI and Quantitative Doppler Ultrasound|Contrast-enhanced MRI
1885611|NCT01221519|Drug|AZD1656|3 different formulations, A, B and C of AZD1656 assessed before food intake and formulation B also after food intake
1885612|NCT01221532|Behavioral|SHHE Peridischarge Intervention|"Support from Hospital to Home (SHHE) Peridischarge Intervention patients will receive Usual care plus
a visit with in-hospital registered nurse, who provides additional patient education, assesses patient's needs post-hospitalization, communicates with the medical team, and develops a personalized discharge plan;
two phone calls from a nurse practitioner(NP)/physician assistant (PA) after discharge, in which adherence to medications, treatment plan, and access to outpatient care, and other issues identified during the hospitalization will be explored;
the provision of a phone support line, on which an NP/PA will call patients back within 24 hours to answer questions and assist transition to outpatient care."
1885613|NCT01221545|Drug|AZD1656|3 escalating dose levels are planned. Administration of the escalating doses of AZD1656 will be based on review of available safety from the previous dose.
1885614|NCT01221545|Drug|Placebo|Placebo
1885615|NCT01221558|Dietary Supplement|lycopene|
1885616|NCT01221571|Drug|AFM 13|Cohort escalation then expansion phase design. Starting dose 0.01 mg/kg. 4 weekly drug administrations.
1885617|NCT01221597|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
1885618|NCT01221597|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
1885619|NCT01221610|Device|Passeo-18 Lux DRB|
1885620|NCT01221610|Device|Standard PTA (POBA)|
1885621|NCT01221623|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
1885622|NCT01221623|Biological|Placebo|2 injections separated by at least 24 hours but not more than 72 hours. At least 24 hours but not more than 72 hours after the 2nd injection of the treatment cycle, the investigator will model the plaque (ie, gradual, gentle stretching of the flaccid penis in the direction opposite to the curvature). Treatment may be repeated after 42 days (± 5 days) for up to 4 treatment cycles.
1885623|NCT01221636|Drug|Abatacept|Solution for injection, Intravenous, 750 mg, 1 day
1885624|NCT01221649|Device|ICD/CRT-D|BIOTRONIK ICD family Lumax 540 and its successors
1885625|NCT01221662|Drug|Siwu Tang|Siwu Tang 3 g bid(oral) continuously two weeks
1885626|NCT01221675|Drug|Antibody TF2|preciblage with an antibody
1885627|NCT01221675|Radiation|IMP-288-Lutetium|Internal Radiation
1885628|NCT01221675|Radiation|IMP-288-Indium|Imaging
1885629|NCT01221688|Procedure|Axillar Sentinel lymph node biopsy|Group 2 : Patients without proven axillary involved nodes will undergo SLNB and a complete axillary level I-II lymphadenectomy only in the case of detection failure or involved SLN and a SLNB alone in the others cases. Patients of this last group will be followed 5 years in order to evaluate the risk of axillary relapse without lymphadenectomy.
1885630|NCT01221688|Procedure|SLNB and complete level I-II axillary lymphadenectomy|group 1 : patients with proven involved axillary nodes will undergo SLNB and complete level I-II axillary lymphadenectomy.
1885632|NCT01221727|Drug|Denosumab|Eighteen (18) subjects will receive 1 fixed dose administration of denosumab.
1885633|NCT01221727|Drug|Midazolam|All subjects will receive two oral dose administrations of midazolam.
1885634|NCT01221740|Drug|Savella|"The patients will be titrated to the maintenance dose of 50 mg BID over a 7-day period, and will be on the medication for 10 weeks.
12.5 mg QD on day 1 12.5 mg BID on days 2 and 3 25 mg BID on days 4, 5, 6, and 7 50 mg BID beginning day 8"
1885635|NCT01221753|Drug|docetaxel|
1885636|NCT01221753|Drug|cisplatin|Given intravenously on day 1 of each cycle
1885637|NCT01221753|Drug|5-FU|
1885638|NCT01221753|Radiation|IMRT|
1885639|NCT01221753|Drug|cetuximab|
1885640|NCT01221753|Drug|carboplatin|
1885641|NCT01221779|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
1885642|NCT01221779|Behavioral|Intensive language therapy|2 weeks of daily computerized naming training, daily, 3 hours
1885645|NCT01221818|Drug|E6007|E6007 25mg single dose or matching placebo
1885646|NCT01221818|Drug|E6007|E6007 50mg single dose or matching placebo
1885647|NCT01221818|Drug|E6007|E6007 100mg single dose or matching placebo
1885648|NCT01221818|Drug|E6007|E6007 200mg single dose or matching placebo
1885649|NCT01221818|Drug|E6007|E6007 400mg single dose or matching placebo
1885650|NCT01221818|Drug|E6007|E6007 600 mg single dose or matching placebo
1885651|NCT01221831|Drug|estetrol, P 1 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:
Days 1-24: one estetrol tablet and one P1 tablet per day
Days 25-28: two placebo tablets per day"
1885652|NCT01221831|Drug|estetrol, P2 and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:
Days 1-24: one estetrol tablet and one P2 tablet per day
Days 25-28: two placebo tablets per day"
1885653|NCT01221831|Drug|Estradiol valerate, dienogest and placebo tablets|"6 treatment cycles each consisting of 28 days of oral administration as follows:
Days 1-26: one tablet of Estradiol valerate/dienogest per day
Days 26-28: one placebo tablet per day"
1885654|NCT01221844|Dietary Supplement|Lattoglobina (Grunenthal) containing bLf|One capsule of Lattoglobina contains 100 mg of bLf. Dosage: one capsule twice a day before meals. In twin pregnancy or in severe anemia the dosage is increased to 2 capsules twice a day before meals
1885655|NCT01221844|Drug|FerroGrad by Abbott|Dosage: one tablet/day containing 540 mg of ferrous sulfate during meals
1885657|NCT01221870|Drug|Tesetaxel once every 3 weeks|Tesetaxel capsules orally once every 21 days; duration of therapy not to exceed 12 months
1885658|NCT01221870|Drug|Tesetaxel once weekly|Tesetaxel capsules orally once every 7 days for 3 consecutive weeks in a 28-day cycle; duration of therapy not to exceed 12 months
1885659|NCT01221883|Drug|Diazepam|Single dose 10mg Diazepam tablet
1885660|NCT01221896|Procedure|C11-Choline PET/CT|
1885661|NCT01221909|Drug|Tranexamic acid|Single dose TA 500mg or placebo will be given in DCR surgery right after the first surgical incision.
1885662|NCT01221909|Drug|saline solution|5cc saline solution
1885663|NCT01221922|Device|RevLite Q-Switched Nd:YAG Laser|Laser treatment once every 2 weeks for a total of 10 treatments.
1885664|NCT01221935|Other|Pristiq first-line treatment charts|300 charts including patients initiated on Pristiq within the past 6 months as a first-line treatment
1885665|NCT01221935|Other|Pristiq second-line treatment charts|800 charts including patients initiated on Pristiq within the past 6 months as a second-line treatment (following first-line treatment with a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)).
1885666|NCT01221935|Other|SNRI or SSRI first-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs) (excluding Pristiq) within the past 6 months as a first-line treatment.
1885667|NCT01221935|Other|SNRI or SSRI second-line treatment charts|800 charts including patients initiated on a Serotonin Norepinephrine Reuptake Inhibitor (SNRI) or Selective Serotonin Reuptake Inhibitors (SSRIs)(excluding Pristiq) within the past 6 months as a second-line treatment (following the first-line treatment with a SNRI or SSRI).
1885668|NCT01221948|Device|Deep Brain Stimulation|Rechargeable Deep Brain Stimulation System
1885669|NCT01221961|Device|Masimo Radical-7|The Masimo device will be placed on one finger of the patient. To see whether or not the hemoglobin values recorded at the same time matches between the standard clinical practice (CSMC Lab and outside Lab) and the Masimo device
1885670|NCT01221974|Device|Essure Micro Insert|
1885671|NCT01221987|Procedure|Cervical sampling|Cervical biopsy or excision specimen testing for human papillomavirus deoxyribose nucleic acid types
1885672|NCT01221987|Other|Data collection|Questionnaire completion
1885756|NCT01222611|Drug|Fosamprenavir|HAART including fosamprenavir boosted with ritonavir
1885673|NCT01222000|Drug|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
1885674|NCT01222000|Drug|apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side|After inclusion, the localization of test area will be decided and the side to treat with VEREGEN 10% will be randomized. Patient will be seen every week for 4 weeks for clinical evaluation of assessment criteria by an independent assessor. According to the randomisation he will apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side. If there is an improvement of at least a test zone he will enter in the follow-up period for 8 weeks.
1885675|NCT01222013|Drug|Imatinib Mesylate|patient will receive Imatinib (Glivec®), 300 mg/m²/day, per oral, in conjunction with chemotherapy, maximum dose allowed 400 mg/dia.
1885676|NCT01222026|Drug|Strontium Ranelate + Ca/Vitamin-D|2g Strontium Ranelate once daily 1000mg Calcium 800 IE Vitamin D
1885677|NCT01222026|Drug|Placebo|Placebo 1000mg Calcium 800 IE Vitamin-D
1885678|NCT01222039|Other|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. Low dose: 1 x10e6 / Kg.
Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
1885679|NCT01222039|Other|Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue.|"Conventional treatment plus intravenous infusion of allogenic mesenchymal stem cells from adipose tissue. High dose: 3 x10e6/Kg.
Conventional treatment:Gradually descending dosage of prednisone and cyclosporin or tacrolimus for at least 46 weeks. Starting dose: 1 mg/Kg/24 h prednisone and 3 mg/Kg/12 h cyclosporin."
1885680|NCT01222052|Drug|5-Fluorouracil, Epirubicin, Cyclophosphamide, Docetaxel|"Arm A 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q3weeks followed by Docetaxel 100 mg/m² q3weeks
Arm B 5-FU 500mg/m2, Epirubicin 100mg/m2, Cyclophosphamide 500mg/m2 q6weeks"
1885681|NCT01222078|Biological|otelixizumab|Two treatment courses of otelixizumab given 6 months apart. Each treatment course will consist of 8 consecutive days of otelixizumab intravenous infusions (each given over 30 minutes).
1885684|NCT01222117|Biological|Plasmin|Plasmin prepared in 0.9% saline for injection
1885685|NCT01222117|Biological|Plasminogen Activator|Plasminogen activator used according to the Investigator's clinical judgment.
1885686|NCT01222117|Other|Placebo|Normal saline for injection at the same volume as the plasminogen activator.
1885687|NCT01222143|Drug|NOVE-HiDAC|"NOVE-HiDAC consists of mitoxantrone, etoposide, and modified high-dose cytarabine. During induction patients will receive mitoxantrone by IV on Days 6-10, etoposide by IV on Days 6-10 and cytarabine by IV on Days 11-12.
During consolidation patients will be receiving mitoxantrone by IV on Days 1-10 and cytarabine by IV on Days 6, 8 and 10."
1885688|NCT01222143|Drug|Nilotinib|"The dose of nilotinib will be determined according to a dose escalation design. There will be three dose levels used in the study.
During induction, nilotinib will be given orally on Days 1-12.
During consolidation, nilotinib will be given orally on Days 1-10."
1885689|NCT01222156|Procedure|Remote magnetic navigation|Remote magnetic navigation of electrophysiology catheters to target intracardiac anatomical sites at mapping-ablation procedures in patients with cardiac arrhythmias
1885690|NCT01222156|Device|Magnetecs Catheter Guidance Control and Imaging system|Magnetecs Catheter Guidance Control and Imaging (CGCI) system
1885691|NCT01222169|Drug|NaCl 0,9%|Propofol 3micrgr/ml (TCI plasma concentration) and NaCl 0,9% 2min. and 10min. application
1885692|NCT01222182|Drug|atorvastatin|All patients desired to change atorvastatin 10, 20mg to an equivalent that is covered by their prescription plan. This is accomplished by either pharmacists by MD/Pharmacist practice agreement or physicians in usual practice
1885693|NCT01222195|Drug|Lenalidomide|10 mg/day by mouth on days 1-21 of every 28 day cycle.
1885694|NCT01222195|Drug|Darbepoetin alfa|200 mcg subcutaneously every 2 weeks of a 28 cycle.
1885695|NCT01222208|Dietary Supplement|Oral Nutrition with dextrose and pressurized whey protein|Ten (10) subjects will be randomly assigned to receive an oral nutrition regimen comprised of 50% of their REE as dextrose and 20% of their REE as pressurized whey protein. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned oral nutrition regimen. To minimize fasting during the perioperative period all subjects will receive peripheral parenteral nutrition (PPN) at the time of surgical incision until the first postoperative day.
1885696|NCT01222208|Dietary Supplement|Peripheral Parenteral Nutrition|Ten (10) subjects will be randomly assigned to receive peripheral parenteral nutrition (PPN) regimen comprised of 50% of their REE as dextrose and 20% of their REE as amino acids. Subjects will undergo a six-hour stable isotope infusion protocol one day before surgery (to obtain baseline data) and on the first post-operative day. During both infusion protocols, subjects will be asked to carry out their assigned PPN regimen. To minimize fasting during the perioperative period all subjects will receive PPN at the time of surgical incision until the first postoperative day.
1885697|NCT01222221|Biological|glioblastoma multiforme multipeptide vaccine IMA950|
1885698|NCT01222221|Biological|sargramostim|
1885699|NCT01222221|Drug|temozolomide|
1885700|NCT01222221|Other|laboratory biomarker analysis|
1885701|NCT01222221|Other|pharmacological study|
1885702|NCT01222221|Procedure|adjuvant therapy|
1885703|NCT01222221|Radiation|radiation therapy|
1885704|NCT01222234|Drug|Cholecalciferol - CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
1885705|NCT01222234|Device|Calcitriol - CKD|Calcitriol 0.25 mcg once daily for 8 weeks
1885706|NCT01222234|Drug|Cholecalciferol - non-CKD|Cholecalciferol tablet 50,000 IU twice weekly for 8 weeks
1885757|NCT01222624|Drug|PankoMab-GEX™|
1885758|NCT01222637|Drug|CetuGEX™|
1885707|NCT01222247|Drug|Corticosteroid|"The active study drug, betamethasone, trade name Celestone Soluspan® manufactured by Schering Plough.
3 mg per ml betamethasone sodium phosphate 3 mg per milliliter betamethasone acetate The first dose of study drug medication will be administered at randomization as 2 ml injection; the next dose of 2 ml will be administered 24 hours later."
1885708|NCT01222260|Drug|Bendamustine|"Patients will start bendamustine at dose level 0 and according to CrCl on day 1 and 2 of each cycle:
CrCl ≥ 60 mL/min: 100 mg/m2 IV on day 1 and 2 of each cycle
CrCl 59 - 30 mL/min: 90 mg/m2 IV on day 1 and 2 of each cycle
Available to qualifying subjects is the option to dose escalate to dose level (+)1:
120 mg/m2 (if CrCl ≥ 60 mL/min at the time of inclusion into the study)
100 mg/m2 (if CrCl 59-30 mL/min at the time of inclusion into the study)"
1885709|NCT01222260|Drug|Dexamethasone|40 mg orally on days 1, 8, 15, 22 of each cycle
1885710|NCT01222273|Dietary Supplement|cholecalciferol (Vitamin D3)|4,000 IU of cholecalciferol (Vitamin D3) orally every day for six months
1885711|NCT01222286|Drug|IPH2101|0.2 mg/Kg or 2mg/Kg, every 4 weeks by intravenous route over 1 hour, for 6 or up to 12 cycles
1885712|NCT01222299|Drug|bepotastine besilate nasal product - low dose|sterile nasal product
1885713|NCT01222299|Drug|bepotastine besilate nasal product - medium dose|sterile nasal product
1885714|NCT01222299|Drug|bepotastine besilate nasal product - high dose|sterile nasal product
1885715|NCT01222299|Drug|placebo comparator nasal product|sterile nasal product
1885716|NCT01222312|Drug|Cisplatin|75 mg/m2, d1 every 3 weeks
1885717|NCT01222312|Drug|Oxaliplatin|85 mg/m², d1 every 2 weeks
1885718|NCT01222312|Drug|Docetaxel|75 mg/m2, d1 every 3 weeks
1885719|NCT01222312|Drug|Docetaxel|50mg/m2, d1 every 2 weeks
1885720|NCT01222325|Procedure|extracorporeal shockwave lithotripsy (SWL)|patients were submitted to one session SWL at a Dornier Compact Delta lithotripter under general anesthesia under supervision of an anesthesiologist and an urologist.
1885721|NCT01222338|Biological|V-5 immunitor|once per day dosing for 2 months
1885722|NCT01222351|Drug|BAY 94-9172 (Florbetaben)|Measure of brain amyloid load using BAY 94-9172 PET/CT
1885723|NCT01222364|Procedure|Standard Cord Clamping|Immediate clamping (<5 seconds) of the umbilical cord after delivery.
1885724|NCT01222364|Procedure|Delayed Cord Clamping|Clamping of the umbilical cord at 30-45 seconds after birth.
1885725|NCT01222377|Procedure|endoscopic surgery|Undergo endoscopic breast surgery
1885726|NCT01222377|Procedure|quality-of-life assessment|Ancillary studies
1885727|NCT01222390|Device|Contour Profile Tissue Expander|The Contour Profile Tissue Expander is a tissue expander with a greater height to width ratio than traditional tissue expanders. This increased ratio allows for greater lower pole expansion, thus creating a more natural looking, ptotic breast. Additionally, the suture tabs on the back of the expander hold the expander in place and prevent malposition and displacement.
1885728|NCT01222403|Biological|MF59-adjuvanted trivalent influenza subunit vaccine|
1885729|NCT01222416|Radiation|Radiopharmaceutical Administration [18F]-FDG|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi,route IV. Time interval between administration and scanning: 60 +/- 10minutes post-injection.
1885730|NCT01222416|Radiation|Radiopharmaceutical: [18F]-FLT|Adult dose: (0.15 mCi/kg ranging from 3 to 16 mCi), route = IV, Time interval between administration and scanning: 60 +/- 10minutes post-injection.
1885731|NCT01222429|Other|vegan diet|Intervention group participants will follow a low-fat vegan diet and will receive instruction on this diet through the course of the study
1885732|NCT01222429|Other|diet following ADA guidelines|participants will be given instruction on the ADA guidelines for diabetes, and will follow an individualized plan based on these guidelines
1885733|NCT01222442|Drug|AZD3199|Single dose, oral inhalation
1885734|NCT01222442|Drug|Moxifloxacin|Single dose, oral encapsulated tablet
1885735|NCT01222442|Other|Placebo comparator|Single dose, oral inhalation
1885736|NCT01222455|Drug|Fostamatinib|Oral tablets, single dose
1885737|NCT01222468|Drug|nabilone 0.5 mg|nabilone 0.5 mg tablets od titrated to a maximum daily dose of 3mg po over an 11-week phase
1885738|NCT01222468|Drug|placebo|placebo 0.5 mg po daily, dose titrated to a maximum daily dose of 3.0mg po over an 11-week phase
1885739|NCT01222494|Behavioral|Behavioral Weight Loss|This intervention is a family-based, behavioral weight loss program that has been employed in studies with overweight and obese children, as well as with children who have diabetes. For the proposed study, the program has been modified to fit the needs of disruptive and behaviorally disturbed youth and their families. The modified program includes 16 weeks of weekly visits with a study interventionist, and supplemental phone contacts as needed. Phone contacts will only replace in-person visits if absolutely necessary to achieve the visit.
1885740|NCT01222494|Behavioral|Diet and Exercise Education|Participants assigned to this arm will receive monthly medically validated, individualized diet and exercise education by a trained research professional.
1885741|NCT01222520|Drug|Telmisartan and amlodipine|Telmisartan 80 mg and amlodipine 5 mg once a daily
1885742|NCT01222520|Drug|Telmisartan|80 mg once a daily
1885743|NCT01222533|Drug|Tiotropium medium|Tiotropium inhalation solution medium dose
1885744|NCT01222533|Drug|Tiotropium low|Tiotropium inhalation solution low dose
1885745|NCT01222533|Drug|Tiotropium high|Tiotropium inhalation solution high dose
1885746|NCT01222533|Drug|Tiotropium 18mcg|Tiotropium inhalation powder 18mcg
1885747|NCT01222533|Drug|Tiotropium placebo|Placebo inhalation solution
1885748|NCT01222546|Drug|CH5132799|
1885749|NCT01222559|Drug|co.don chondrosphere®|co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes. The dose depends on the size of the defect, recommended dose is 10-70 spheroids/cm2 defect.
1885750|NCT01222559|Procedure|Microfracture|A procedure in which the subchondral bone is perforated to allow a bloodcloth to form new tissue.
1885751|NCT01222572|Radiation|Stereotactic boost|
1885752|NCT01222572|Radiation|Conventional RT|
1885753|NCT01222572|Drug|Etoposide|
1885754|NCT01222572|Drug|Cisplatin|
1885755|NCT01222585|Drug|Metronidazole|Metronidazole will be administered intravenously to premature infants as a 15 mg/kg loading dose followed by maintenance doses of 7.5 mg/kg every 12 hours for infants with >=14 postnatal days and every 24 hours for infants <14 postnatal days.
1885763|NCT01222663|Device|standard therapy|Standard therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate
1885764|NCT01222663|Device|hemoperfusion|Extracorporeal hemoperfusion with Toraymyxin PMX-20R and conventional medical therapy in the ICU including but not limited to: antibiotic therapy, nutrition, fluid challenge, vasopressors, hemodynamic monitoring, organ support in the ICU including mechanical ventilation, renal replacement therapy when appropriate.
1885765|NCT01222676|Drug|cisplatin|
1885766|NCT01222676|Drug|gemcitabine hydrochloride|
1885767|NCT01222676|Drug|sorafenib tosylate|
1885768|NCT01222676|Other|imaging biomarker analysis|
1885769|NCT01222676|Other|laboratory biomarker analysis|
1885770|NCT01222676|Procedure|computed tomography|
1885771|NCT01222676|Procedure|neoadjuvant therapy|
1885772|NCT01222676|Radiation|fludeoxyglucose F 18|
1885773|NCT01222689|Drug|erlotinib hydrochloride|Given PO
1885774|NCT01222689|Drug|selumetinib|Given PO
1885775|NCT01222689|Other|laboratory biomarker analysis|Correlative studies
1885776|NCT01222702|Drug|Cadazolid|Cadazolid, provided as powder (250 mg, 500 mg or 1000 mg) to be reconstituted as a suspension prior to oral administration
1885777|NCT01222702|Drug|Vancomycin|Vancomycin, provided as capsules (125 mg) for oral administration
1885778|NCT01222702|Drug|Placebo-matching cadazolid|Placebo of cadazolid powder for oral suspension
1885779|NCT01222702|Drug|Placebo-matching vancomycin|Placebo of vancomycin capsules
1885780|NCT01222715|Biological|Bevacizumab|Given IV
1885781|NCT01222715|Drug|Cyclophosphamide|Given IV
1885782|NCT01222715|Other|Laboratory Biomarker Analysis|Correlative studies
1885783|NCT01222715|Drug|Temsirolimus|Given IV
1885784|NCT01222715|Drug|Vinorelbine Tartrate|Given IV
1885787|NCT01222767|Drug|Zalypsis|Zalypsis is provided as a lyophilized powder for concentrate for solution for infusion in a strength of 2.5 mg/vial.
1885789|NCT01222806|Device|Repetitive Transcranial Magnetic Stimulation|
1885790|NCT01222819|Drug|filgrastim|5 mcg/kg (rounded to 300 mcg or 480 mcg)
1885791|NCT01222832|Drug|Bacitracin|Bacitracin soaked nasopore sponge
1885792|NCT01222845|Drug|Test meal|Porridge made from rolled, or pinhead oats providing 50 g of carbohydrate
1885793|NCT01222858|Behavioral|Diet and Activity Education|Education about behavioral modification of eating and activity habits for weight loss.
1885794|NCT01222858|Behavioral|Self-monitoring with Feedback|Participants self-monitor diet and activity behaviors, which are submitted via a website. Automated feedback on the self-monitoring record is provided to participants.
1960512|NCT03191539|Drug|Apremilast|30 mg twice a day during 52 weeks. In the first 6 days will be a dose escalation
1885797|NCT01222884|Drug|Monofer|Iron isomaltoside 1000 (Monofer®) administered as 500 mg intravenous single bolus injection over approximately 2 minutes
1885798|NCT01222884|Drug|Iron sucrose|Iron sucrose is administered undiluted in doses of 100mg at baseline, 200mg at week 2 and 200 mg at week 4 as fractionated IV bolus injections according to local Summary of Product Characteristics
1885799|NCT01222897|Drug|Valacyclovir hydrochloride|
1885800|NCT01222910|Drug|Valacyclovir hydrochloride|
1885801|NCT01222923|Drug|Risperidone|1 mg orally disintegrating tablets
1885802|NCT01222936|Drug|LBH581|25 mg/5 ml solution packaged in 6 ml type I glass vials and given as a 30 minutes infusion at the dose of 20 mg/m2 i.v., on day 1 and 8, every 21 days.
1885803|NCT01222949|Drug|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 3 Tablets a Day for body weight comprised between 36 and 75 kg, 4 tablets for body weight above 75 kg.
1885804|NCT01222962|Drug|Eurartesim|Tablet containing 40 mg of Dihydroartemisinin (DHA) and 320 mg of Piperaquine phosphate (PQP). 4 Tablets a Day for body weight above 75 kg.
1885805|NCT01222975|Drug|Risperidone|orally disintegrating tablets
1885806|NCT01222988|Dietary Supplement|Optifast Products|Optional Optifast products offered once every other week X 6 months; then monthly.
1885807|NCT01223001|Drug|Duloxetine|Duloxetine 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
1885808|NCT01223001|Drug|Sugar pill|Sugar pills 30 mg. PO daily to 120mg. PO daily for nine months in patients who have suffered a traumatic brain injury at least six months previously.
1885809|NCT01223014|Drug|AZD2423|AZD2423
1885810|NCT01223027|Drug|Dovitinib|Dovitinib is formulated as an oral gelatin capsule of 100 mg strength and was dosed on a flat scale of 500 mg on a 5 days on/2 days off dosing schedule. Medication labels complied withthe legal requirements of each country and were printed in the local language.
1885811|NCT01223027|Drug|Sorafenib|Sorafenib is formulated as a round, oral, biconvex, red film-coated tablet that contains 200 mg of sorafenib (tosylate). Sorafenib was administered twice daily without food at least 1 hour before or 2 hours after a meal. Sorafenib was supplied according to local practice.
1885812|NCT01223040|Other|SYSTANE® Balance Lubricant Eye Drops|Subjects will be dosed (bilaterally) in the office during each visit. Between visits 2 and 3, patients will dose 4 times per day for the 7 day period.
1885813|NCT01223053|Drug|Ketoprofen 10% cream|100 mg (10%) in 1 gram of topical cream applied three times per day for 7 days. Safety follow up on day 14.
1885814|NCT01223053|Drug|Placebo|Matching placebo cream containing identical constituents as the active comparator except for ketoprofen
1885815|NCT01223079|Drug|r-hFSH|r-hFSH dose to be determined by the patient's primary doctor and adjusted according to their response
1885816|NCT01223079|Drug|r-hFSH and r-hLH|Patients will begin r-hLH at 300IU/day when there are 2 follicles greater than or equal to 14mm.
1885817|NCT01223105|Procedure|slow freeze|Eggs will be placed in a cryo-protected solution and frozen slowly in a programable freezer
1885818|NCT01223105|Procedure|Vitrification|Eggs will be placed in a high concentration of cryo-protectant and frozen very quickly by plunging in liquid nitrogen
1885819|NCT01223118|Procedure|Vitrification and PGD|Half of the oocytes retrieved from each patient will undergo vitrification, immediate thaw and insemination. All embryos will undergo biopsy for PGD prior to transfer.
1885820|NCT01223131|Drug|Insulin glargine (HOE901)|"Pharmaceutical form:aqueous solution for injection
Route of administration: Subcutaneous"
1885821|NCT01223131|Drug|NPH insulin|"Pharmaceutical form:aqueous solution for injection
Route of administration: Subcutaneous"
1885822|NCT01223144|Behavioral|Iowa Gambling Task and Ekman facial recognition test|"Iowa Gambling Task: mean number of cards chosen from decks with low (A+B) and high gain (C+D).
Ekman facial recognition test: mean number of faces correctly recognized (60 images with 6 different expressions: happiness, sadness, fear, surprise, disgust and anger)."
1885823|NCT01223157|Biological|Biological data|Height, Weight, waist circumference and systolic and diastolic blood pressure will be measured in obese and normal subjects. Blood and saliva sampling will be performed after an overnight fast, one hour and just before the beginning of the lunch and one hour after the end of the lunch. This will allow a measurement of fasting glycaemia and insulin, fasting cholesterol and triglycerides, liver profile. Endocannabinoids will be measured both in plasma and saliva at each time point. Gut hormones (Ghrelin and PYY) will be measured before, just before and after lunch in plasma.
1885824|NCT01223170|Behavioral|Tailored content|Participants will have access to content tailored for Stage of Change, Regulatory Focus and Self-Efficacy.
1885825|NCT01223170|Behavioral|Generic Internet-based information|Access to a website with general information about Cardiovascular Disease and self-management, including diet, physical activity, smoking and medications.
1885826|NCT01223170|Behavioral|Discussion forum|Access to a discussion forum for Cardiovascular Disease Rehabilitation.
1885827|NCT01223170|Behavioral|Behavioral monitoring|Participants will be offered behavioral monitoring, based on data collected from online self-reports and from activity sensors built into mobile phones.
1885830|NCT01223196|Drug|Pioglitazone|This study will examine the effect of Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
1885831|NCT01223196|Drug|Placebo|Inactive placebo for comparison to Pioglitazone on tissue inhibitor of metalloproteinases (TIMP-3) and on TNF-alfa converting enzyme in the skeletal muscle of type 2 diabetic subjects.
1885832|NCT01223209|Drug|LTX-315|0.25-2.0 mg/ML, maximum 5 injections during 36 days.
1885833|NCT01223222|Drug|LTX-109|Topical administration. 3 times daily. 5 days.
1885834|NCT01223235|Biological|bevacizumab and the polyvalent vaccine-KLH conjugate + OPT-821|A maximum of 6 doses of the polyvalent-KLH vaccine and OPT-821 will be administered to each patient as per the schedule. Bevacizumab will be administered once every two weeks until week 11 and then once every three weeks according to the schedule. When the 6 vaccinations of the polyvalent-KLH vaccine +OPT821 are completed, patients may still continue to receive bevacizumab on the once every three week schedule.
1885835|NCT01223248|Radiation|IGIMRT using a single dose of 24 Gy|Pts in both the hypofractionated & single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI & DCE-MRI pretreatment for both arms & 1 hour after their initial treatment for single fraction pts, & within one hour of their initial & final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule & MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, & approximately 24 hours [MCPG2.3]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
1885836|NCT01223248|Radiation|IGIMRT 27 Gy in 3 fractions|Pts in both the hypofractionated & single dose arms will receive the same following standard procedures. The only difference between the arms is the dose delivered at each treatment. 20 MSKCC pts (10 per treatment arm) will be accrued to undergo baseline DW-MRI & DCE-MRI pretreatment for both arms & within 1 hour after their initial treatment for single fraction pts, & within one hour of their initial & final radiation treatment for the hypofractionated pts. Pts will be considered for this scan based on compliance to scan schedule & MRI availability for performing the scan within one hour of the planned IGRT. 24 MSKCC pts (12 per treatment arm) will be accrued for the blood collection (optional) up to 4 hours prior, 50-90 minutes after, & approximately 24 hours [MCPG2.3]after treatment for single fraction pts. For pts partaking in both sub-studies, the post-treatment blood collection may be done in a 50-120 minute window to account for scheduling conflicts with the research MRI.
1885837|NCT01223274|Device|CPAP/PEEP|Infants received 100% oxygen by facemask and continuous positive airway pressure (CPAP) or positive pressure ventilation (PPV) with positive end-expiratory pressure (PEEP), if the infant required PPV.
1885838|NCT01223274|Device|Standard management practices|Control infants were treated with 100% oxygen and no CPAP. When a control infant required PPV, no PEEP was used.
1885877|NCT01223703|Drug|n-3 PUFAs|1.0 g gelatin capsules containing 850 to 882 mg of EPA and DHA ethyl esters in the average ratio EPA/DHA of 0.9:1.5 The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study.
1885878|NCT01223703|Drug|Placebo|1.0 g gelatin capsules containing olive oil. The treatment dose was five capsules daily for the first month followed by two capsules daily for the rest of the study
1885963|NCT01216761|Drug|Chlorhexidine gluconate|2% chlorhexidine gluconate/70% isopropyl alcohol packaged in a single 1.5 ml Frepp applicators (Enturia, Leewood KS)
1885839|NCT01223313|Device|Woman's Condom|The Woman's Condom (WC) is an investigational device manufactured by Shanghai Dahua Medical Apparatus Corp., Ltd (Dahua). Dahua's quality management system complies with ISO9001:2000, ISO13485:2003, MDD93/42/EEC. The WC consists of a 0.03-mm-thick pliable plastic pouch that easily conforms to the shape of the vagina. It is 22.9 cm (± 0.3 cm)(9 inches ± 0.1 inch) long and has a flexible soft outer ring that is designed to hug the external genitalia. The foam shapes on the outside of the pouch cling lightly to vaginal walls, ensuring stability of the device. The insertion capsule is made from dissolvable polyvinyl alcohol (PVA) and is similar to the PVA used in C-Film (Apothecus Pharmaceutical Corporation, New York, NY). The WC is a non-lubricated device. It is supplied with water-soluble lubricant with a chemical composition similar to a commercially available lubricant used in previous studies of the WC. Women will receive instruction sheets on the use of the WC and lubricant.
1885840|NCT01223326|Drug|Acetylcysteine (NAC)|NAC 150 mg/Kg; and infusion of 50 mg/kg, from 30 minutes before the ischemia up to 60 minutes later to the reperfusion
1885841|NCT01223326|Drug|Saline|Na Cl 0.9% infusion
1885842|NCT01223339|Drug|Ertugliflozin|Dose escalation of 1, 5, and 25 mg Ertugliflozin administered in the fasted state
1885843|NCT01223339|Drug|Placebo|Placebo tablets to Ertugliflozin administered in the fasted state
1885844|NCT01223339|Drug|Ertugliflozin|Ertugliflozin 25 mg tablets administered once daily in the fed state for 7 days
1885845|NCT01223339|Drug|Placebo|Placebo tablets administered once daily in the fed state for 7 days
1885847|NCT01223365|Drug|Hydrocodone ER|Hydrocodone bitartrate extended-release tablets were administered at doses of 15, 30, 45, 60, and 90 mg orally every 12 hours. During the open-label titration period, doses were adjusted until a stable pain control was achieved. In general, the dose of hydrocodone extended release tablets could be adjusted for efficacy or tolerability, as necessary, at any time during the open-label treatment period; however, participants were required to visit the study center before increasing the dose of study drug.
1885848|NCT01223378|Drug|Experimental: BOL-303259-X|ophthalmic solution, various concentrations, once daily (QD) 28 days
1885849|NCT01223378|Drug|Latanoprost|0.005% ophthalmic solution, QD 28 days
1885850|NCT01223391|Other|Abdominal binder|External abdominal compression sequentially applied at 20 mmHg for 3 minutes, maximal tolerable level for 1.5 minutes and comfortable level for 2 minutes.
1885851|NCT01223391|Other|No abdominal binder|Standing without abdominal binder for 3 minutes
1885855|NCT01223430|Drug|Si-Ni-Tang/ Placebo of Si-Ni-Tang|The prescription is 2.25 grams four times a day ( 9 grams per day) for 7 days or till shock reversal( if shock reversal < 1 week). Shock reversal was defined as the discontinuation of norepinephrine or dopamine lasting for at least 24 hours.
1885856|NCT01223443|Device|Paclitaxel eluting stent|Patients are randomized to either stenting the moderate SVG lesion with the paclitaxel stent or standard medical treatment
1885857|NCT01223469|Device|Contact force assisted irrigated RF ablation|radiofrequency ablation of atrial fibrillation or SVT
1885858|NCT01223521|Device|Immediate intrauterine contraception|A Cu-IUD or LNG-IUS is inserted after abortion.
1885859|NCT01223534|Drug|Preventive treatment with Isoniazid.|If TST positive: participant will be treated with Isoniazid 300 mg/d, for 6 months.
1885860|NCT01223534|Drug|Preventive treatment with Isoniazid|If QFT-IT positive, Isoniazid 300 mg/d, for 6 months.
1885861|NCT01223547|Other|Education|Participants are taught the principles of carb counting
1885862|NCT01223547|Other|Education|Participants are taught the principles of carb counting and the use of the integrated glucose meter and bolus calculator.
1885863|NCT01223560|Drug|Insulin Aspart|Insulin bolus with and without carbohydrate intake.
1885864|NCT01223560|Other|Exercise|Exercise on tread mill
1885865|NCT01223560|Dietary Supplement|Carbohydrate|Carbohydrate intake
1885866|NCT01223612|Drug|Ranibizumab|Intravitreal injection of 0.5mg in 0.05ml. One injection at baseline, 4 and 8 weeks then four-weekly as required to 44 weeks.
1885867|NCT01223612|Procedure|Modified ETDRS laser|Argon laser therapy to the macula in accordance with the modified ETDRS protocol at baseline, 12, 24 and 36 weeks.
1885868|NCT01223625|Drug|Rosuvastatin 5mg/day|Rosuvastatin 5mg/day
1885869|NCT01223625|Drug|Rosuvastatin 40mg/day|Rosuvastatin 40mg/day
1885870|NCT01223638|Other|Audiometry|Audiometry
1885871|NCT01223651|Procedure|two step hyperinsulinaemic glucose clamp study.|Study participants will have their blood glucose stabilized between 5 - 6 mmol/L by the delivering of a controlled rate insulin/glucose infusion. Participants will have their blood glucose level reduced by conducting a controlled two step hyperinsulinaemic glucose clamp. The clamp procedure will take a total of 120 minutes and will reduce the blood glucose level to below 3 mmol/L. During this time blood tests will be obtained for analysis, physical observations recorded and cognitive function tests performed at regular intervals. Participants will have been fitted at least 12 hours prior to the intervention with 2 real time continuous glucose monitoring systems which will remain in place for the duration of the clamp procedure, however participants will be blinded to their glucose readings.
1885872|NCT01223664|Procedure|Allogenic bone marrow stem cells transplantation|30ml allogenic bone marrow stem cells were infused to patients using interventional method via portal vein or hepatic artery as well as conserved therapy
1885873|NCT01223664|Drug|Conserved therapy|Oral or intravenous administration
1885874|NCT01223677|Behavioral|Rumination Focused CBT|see arms
1885875|NCT01223690|Drug|Clarithromycin|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
1885876|NCT01223690|Drug|Dextrose 5%|1000 mg diluted into 250 ml of dextrose 5% administered intravenously within one hour of continuous infusion for four consecutive days
1885962|NCT01216761|Drug|Iodine tincture|Iodine tincture (2% iodine and 2% sodium iodide diluted in 50% ethanol) packaged in a single 0.67 mL Sepp applicator (Enturia, Leewood KS)
1885879|NCT01223716|Behavioral|Perceptual learning|Research participants will be asked to practice a visual discrimination task (e.g. position acuity, contrast sensitivity, stereoacuity etc) in our laboratory for a period of time (2 hrs/day, 5 days/week).
1885880|NCT01223716|Behavioral|Video Game|"Research participants will be asked to play off-the-shelf video games in our laboratory for a period of time (2 hrs/day, 5 days/week)."
1885881|NCT01223716|Behavioral|Crossover (Occlusion therapy + Video Game)|"Phase 1. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks).
Phase 2. Research participants will be required to cover the good eye during the day in order to push the brain to use the amblyopic eye (2 hrs/day, 5 days/week for 2-4 weeks)."
1885882|NCT01223729|Drug|Acetyl-L-Carnitine|2 g acetyl-L carnitine twice a day
1885883|NCT01223729|Other|placebo|placebo twice per day
1885884|NCT01223742|Dietary Supplement|ACETYL-L-CARNITINE|2 g acetylcarnitine taken orally twice a day.
1885885|NCT01223742|Drug|placebo|placebo twice per day
1885886|NCT01223755|Drug|Sirolimus|Patients will be given SRL for one year starting at the oral daily dose of 3 mg, with periodical whole blood level measurements. The daily dose will be adjusted to keep SRL concentration within 5-10 ng/ml. Drug levels will be assessed at day 7 after starting treatment and every two weeks for the first month. Subsequently SRL concentrations will be monitored at monthly intervals (or at least 5 days after drug dose adjustments) until the end of the treatment period.
1885887|NCT01223755|Drug|conventional therapy|Conventional treatment relates usually to the administration of antihypertensive drugs for patients with high blood pressure. Thus, for the present study, no major change in antihypertensive treatment should be introduced throughout the whole study period unless deemed clinically necessary (the reasons of the changes should be, however, clearly explained in the CRF). Only small changes in the doses of the ongoing treatments are recommended in order to maintain the same level of blood pressure control (target systolic/diastolic blood pressure <130/80 mmHg). This approach is aimed to minimize the confounding effect of any change in concomitant treatments on some efficacy variables (such as urinary protein excretion rate).
1885888|NCT01216163|Drug|Novel Ibuprofen|Single-dose of novel ibuprofen (equal to 400 mg ibuprofen)
1885889|NCT01216163|Drug|Acetaminophen|Single-dose of acetaminophen (1000mg)
1885890|NCT01216163|Drug|Placebo|Single-dose of placebo
1885891|NCT01216176|Drug|Anastrozole|
1885892|NCT01216176|Drug|AZD0530|
1885893|NCT01216176|Drug|Placebo|
1885894|NCT01216241|Drug|Daptomycin|8 MG/KG IV
1885895|NCT01216241|Other|Saline Placebo|50 ml normal saline once daily
1885896|NCT01216241|Drug|Daptomycin|8 mg/kg once daily
1885897|NCT01216254|Device|classic v high-frequency electrocoagulation|During the BCT with SLND the investigators would use two types of electrocoagulation. The steps of the operation would remain the same in both arms, nevertheless the tool used would vary.
1885898|NCT01216267|Drug|Lansoprazole|lansoprazole 30 mg HS x 7 days
1885899|NCT01216267|Drug|lansoprazole|lanzoprazole 30 mg HS for 7 days
1885903|NCT01216293|Drug|Dexlansoprazole|Dexlansoprazole 60 mg, capsules, orally, once daily for up to 26 weeks.
1885904|NCT01216293|Drug|Esomeprazole|Esomeprazole 40 mg, capsules, orally, once daily for up to 26 weeks.
1885905|NCT01216293|Drug|Placebo|Placebo-matching capsules, orally, once daily for up to 26 weeks.
1885906|NCT01216306|Behavioral|Television reduction curriculum|Students are taught the television reduction curriculum during the school day (15-30 minutes/day) 3-5 days/week over 7 weeks. Parents are invited to attend brief after-school meetings every other week to discuss reducing their children's television viewing.
1885907|NCT01216319|Device|Nipple reconstruction|Biodesign® Nipple Reconstruction Cylinder
1885910|NCT01216345|Drug|Cetuximab + Gemcitabine + Oxaliplatin|Cetuximab 500mg/m2, iv every two weeks Gemcitabine 1000mg/m2, iv every two weeks Oxaliplatin 100mg/m2, iv every two weeks
1885911|NCT01216371|Drug|Sunitinib|one-year adjuvant Treatment with Sunitinib, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break
1885912|NCT01216371|Drug|Placebo|one-year Treatment, schematic (4:2): 4 weeks (28) 50 mg(milligram) daily, 2 weeks (14) break,
1885913|NCT01216384|Drug|BI 671800|In the SRD part subjects will receive a single dose and in the MRD part subjects will receive a total of 14 doses.
1885914|NCT01216384|Drug|placebo|Subjects will receive according to the dose group matching number of placebo tablets
1885915|NCT01216397|Drug|Linagliptin/Metformin (standard batch)|Fixed dose combination tablet
1885916|NCT01216397|Drug|Linagliptin/Metformin (side batch)|Fixed dose combination tablet
1885917|NCT01216410|Drug|Metoclopramide|Prophylactic Metoclopramide 10 mg given before spinal together with prophylactic phenylephrine infusion
1885918|NCT01216410|Drug|Phenylephrine infusion|Prophylactic phenylephrine infusion after spinal and placebo antiemetics
1885919|NCT01216410|Drug|Combination Group|Metoclopramide and ondansetron prophylaxis with phenylephrine infusion
1885920|NCT01216436|Biological|Vaccination with RNA-transfected mature autologous DC|Dendritic cells (DC) will be administered at a dose of 20 million cells by intranodal injection under ultrasound guidance. Each subject will receive a total of six vaccinations at one week intervals
1960525|NCT03188549|Other|AniosGel 85 NPC|Hand hygiene formula
1886014|NCT01224717|Drug|Forsteo|
1886015|NCT01224730|Drug|perifosine|100 mg daily
1960526|NCT03188549|Other|Softa-Man (Braun)|Hand hygiene formula
1960527|NCT03188549|Other|Septol|alcohol-based hand rub
1885923|NCT01216475|Procedure|Femtosecond LASIK|LASIK consists of two steps: the first step involves the formation of a corneal flap and the second one is when the excimer ablation is performed in the corneal stromal bed. Femtosecond lasers (FL) have been widely used in LASIK surgery to fashion the corneal flap. The laser will cut a lamellar followed by a vertical corneal incision. We are able to produce a vertical cut since the Femtosecond laser can deliver laser pulses of 1 micron diameter at a preselected depth in the cornea, which then expands to 2 to 3 microns with the formation of a cavitation bubble. These pulses create micro-photodisruption of the corneal tissue by the formation of an expanding bubble of carbon dioxide and water, which in turn cleaves the tissue and creates a plane of separation. The flap is then removed to expose the stroma and the refractive treatment is done by the excimer laser over the denuded stroma.
1885924|NCT01216475|Procedure|Small incision lenticule extraction (SMILE)|Patient's eye will be centered and docked with the curved interface cone before application of suction fixation. First, the posterior surface of the refractive lenticule (spiral in), then the lenticule border is created. The anterior surface of the refractive lenticule (spiral out) is then formed which extended beyond the posterior lenticule diameter by 0.5mm to form the anterior flap and is followed by a rim cut. After the suction is released, a Siebel spatula is inserted under the flap near the hinge before the flap is seperated and reflected. The edge of the refractive lenticule is separated from the stromal bed with a sinsky hook and the posterior border of the lenticule gently separated with the Siebel spatula and removed through small incision.
1885925|NCT01216488|Drug|Xylocaine|40 ml or 25 ml of Xylocaine injection
1885926|NCT01216527|Procedure|Neo-adjuvant Chemoradiotherapy followed by Surgery|"Radiotherapy combined with concomitant chemotherapy:
Radiotherapy Program:External radiation with a total dose of 40.0Gy is given in 20 fractions of 2.0Gy,5 fractions a week.
neo-chemotherapy program: Vinorelbine 25mg/m2, IV (in the vein) on day 1 and day 8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle;or Cisplatin 25mg/m2,IV DRIP on day 1 to day 4 of each 21 day cycle.
Number of cycles:two
surgery:Mckeown Modification Surgery and total two-field lymphadenectomy"
1885927|NCT01216527|Procedure|surgery|two field lymphadenectomy
1885928|NCT01216553|Other|Oxygen Therapy|1 lt/min oxygen via nasal cannulae intermittently for 30 minuets 4 times daily for 7 days
1885930|NCT01216579|Other|mannitol (an airway challenge agent)|
1885931|NCT01216592|Other|COPD treatment|Patients, will be asked to continue their previous medication (GOLD guidelines) during the study. No interventional change in COPD treatment will be performed during the study.
1885932|NCT01216605|Drug|Syntocinon 24 IU|
1885933|NCT01216605|Drug|Placebo|
1885934|NCT01216618|Device|InsuPatch|the InsuPatchTM device includes a heating pad and electronics. The heating pad is attached to an existing insulin infusion set by a simple procedure.
1885935|NCT01216631|Drug|methylprednisolone|intra-articular injection of methylprednisolone (80mg given at baseline only)
1885936|NCT01216631|Drug|Infliximab|intra-articular injection of 100mg infliximab given at baseline only
1885937|NCT01216631|Drug|Infliximab|intravenous infliximab at a dose of 5mg/kg (as per patient weight) given at week 0, 2, 6 and 14
1885938|NCT01216644|Drug|5-Fluorouracil|2600 mg/m²d1 i.v. every 2 weeks
1885939|NCT01216644|Drug|Leucovorin|200 mg/m², d1, i.v., every 2 weeks
1885940|NCT01216644|Drug|Oxaliplatin|85 mg/m², d1, i.v., every 2 weeks
1885941|NCT01216644|Drug|Docetaxel|50mg/m2, d1, i.v., every 2 weeks
1885942|NCT01216644|Drug|Epirubicin|50 mg/m2, d1, i.v., every 3 weeks
1885943|NCT01216644|Drug|Cisplatin|60 mg/m², d1, i.v., every 3 weeks
1885944|NCT01216644|Drug|5-fluorouracil|200 mg/m², d1-d21, i.v., every 3 weeks
1885945|NCT01216657|Drug|Sunitinib|50 mg oral, daily, for 4 weeks, then 2 weeks without treatment, repeat at d43
1885946|NCT01216670|Behavioral|remote patient's management|scheduled remote CareLink data transmission
1885947|NCT01216683|Biological|rituximab|Given IV
1885948|NCT01216683|Drug|bendamustine hydrochloride|Given IV
1885949|NCT01216683|Drug|bortezomib|Given IV
1885950|NCT01216683|Drug|lenalidomide|Given orally
1885951|NCT01216696|Drug|ipilimumab|Eligible patients will receive 10 mg/kg ipilimumab every 3 weeks during a 10-week induction period, followed by a radiological assessment in week 12. Patients with clinical benefit will continue with an ipilimumab administration every 3 months starting at week 24 up to week 48 until the end of the study or until disease progression, toxicities requiring discontinuation , withdrawal of consent,pregnancy, death or lost to follow up whichever occurs first.
1885952|NCT01216709|Dietary Supplement|ferrous sulfate|6.3 mg iron from iron drops and 0.3 mg iron from infant formula with no added iron (0.5 mg iron/L) for 45 days
1885953|NCT01216709|Other|iron-fortified infant formula (12.4 mg iron/L)|6.6 mg iron from iron-fortified infant formula (12.4 mg iron/L) for 45 days
1885954|NCT01216709|Other|iron-fortified infant formula (2.3 mg iron/L)|1.2 mg iron from iron-fortified infant formula (2.3 mg iron/L) for 45 days
1885955|NCT01216722|Other|Resistance Strengthening Exercise Program|Home exercise Program. 3-4 days a week. 30 minutes a session. 12 weeks
1885956|NCT01216735|Drug|Fluticasone|220 ug twice a day for 3 weeks
1885957|NCT01216735|Drug|Placebo|Placebo for 3 weeks
1885958|NCT01216748|Other|quiet breathing|Subjects were instructed to breath normally at room air.
1885959|NCT01216748|Other|Hypocapnic Hyperventilation|hypocapnic hyperventilation, the subjects were instructed to breathe fast and deep until their end-tidal pCO2 fell to 30 mmHg, corresponding to a systemic pH increase of about 0.1 pH units.
1885960|NCT01216748|Other|Hypercapnic Hyperventilation|For hypercapnic hyperventilation, a modification of a previously described procedure (15). While monitoring SaO2 using pulse oximetry and end-tidal CO2 by mass-spectrometry on a breath by breath basis, CO2 was bled into the inspired air to achieve an end-tidal pCO2 of at least 55 mmHg
1885961|NCT01216748|Other|eucapnic hyperventilation|For eucapnic hyperventilation, the subjects were instructed to increase their ventilation to the highest level of ventilation recorded in the previous two hyperventilation maneuvers, while CO2 was bled into the inspired air to maintain end-tidal pCO2 at 40 mmHg.
1886056|NCT01225107|Drug|Inert Placebo Capsule|Inert substance, 3 times per day in capsule form
1885964|NCT01216761|Drug|Povidone iodine|10% povidone iodine aqueous solution packaged in a single 0.67 Sepp applicator (Enturia, Leewood KS)
1885965|NCT01216774|Other|Strength training|"Leg extension exercise:
Experimental: 60 repetitions at 20-25% of 1RM, 10-12 repetitions at 40% of 1RM Active Comparator: 10-12 repetitions at 80% of 1RM Placebo Comparator: 10-12 repetitions at 40% of 1RM"
1885966|NCT01216787|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|
1885967|NCT01216787|Other|pharmacological study|
1885968|NCT01216787|Procedure|therapeutic conventional surgery|
1885969|NCT01216787|Other|laboratory biomarker analysis|Correlative studies
1885970|NCT01223768|Drug|Acetyl-l-Carnitine|2g per day
1885971|NCT01223768|Drug|placebo|twice per day
1885972|NCT01223781|Behavioral|Biofeedback-based motor learning for PD|Prior to freezing episodes, auditory stimulation is triggered
1885973|NCT01223807|Other|Diaphragmatic breathing training|The training group will participate in a diaphragmatic breathing program which will consist of three 45-min sessions each week (12 sessions totally). The program training will be individualized and supervised by the same physiotherapist. In each session, the patients will be initially instructed to perform 3 series of 10 maximally inspirations, predominantly with abdominal motion, while reducing upper rib cage motion in a supine position.
1885974|NCT01223820|Drug|Capsaicin|5x nasal application in one day, 1 hour between each application
1885975|NCT01223859|Procedure|Interstitial soft palate surgery|Soft palate RF surgery in local anaesthesia
1885976|NCT01223872|Other|interview|"Standard Interview (2-15 years from last treatment)
Demographic data interview (pre-initial study interview)"
1885977|NCT01223872|Other|clinic visit and interview|"REACH Clinic Visit(initial or regular)
Post-REACH Clinic Interview (3mos from initial or regular clinic visit)
Demographic data interview(pre-initial study interview)"
1885978|NCT01223872|Other|interviews and clinic visit|"Pre-REACH Clinic Interview(2-15 yrs from last treatment)
REACH Clinic Visit(initial or regular)
Post-REACH Clinic Interview(1mo from initial clinic visit)
Post-REACH Clinic Interview(3mos from initial or regular clinic visit)
Demographic data interview(pre-initial study interview)"
1885979|NCT01223885|Dietary Supplement|Camel's milk|Patients with proved cow's milk allergy who have negative prick skin tests to came's milk will be administered gradually increased doses of pasteurized camel's milk at 30 minute intervals
1885980|NCT01223898|Drug|Tasigna|
1885981|NCT01223911|Drug|NNC 0151-0000-0000|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
1885982|NCT01223911|Drug|placebo|Multiple doses will be administered subcutaneously (under the skin), one dose once weekly during a three week period
1885983|NCT01223924|Other|placebo|placebo
1885984|NCT01223924|Drug|M2ES|M2ES IV 7.5mg-90mg
1885985|NCT01223937|Drug|Desmopressin|
1885986|NCT01223937|Drug|Placebo|
1885987|NCT01223976|Other|Tuberculin skin test and Quantiferon -TB Gold test|"TST A 2-TU dose of PPD will bevadministered by a certified technician using the Mantoux method and induration measured after 72 h.
QFT-G test The second-generation QuantiFeron® (QIFN) whole-blood IFN assay (Cellestis) will be performed and interpreted according to the manufacturer's instructions."
1885988|NCT01223989|Other|hypocaloric diet balanced + nutrition education + ruled physical activity|
1885989|NCT01224015|Drug|normal saline|Normal Saline injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
1885990|NCT01224015|Biological|onabotulinumtoxinA 44 U|44 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
1885991|NCT01224015|Biological|onabotulinumtoxinA 24 U|24 units onabotulinumtoxinA (botulinum toxin type A) total dose injected into bilateral Crow's Feet Line and Frown Line areas per treatment. Patients may receive up to 2 treatments during the study.
1885992|NCT01224028|Drug|Tacrolimus|oral
1885993|NCT01224028|Drug|Placebo|oral
1885994|NCT01224041|Drug|Tacrolimus|oral
1885995|NCT01224067|Drug|Quetiapine|Adjunctive quetiapine -Participant will receive up to 300 mg/day of quetiapine for 8 weeks.
1885996|NCT01224080|Device|Adiana placement|All patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
1885997|NCT01224093|Drug|Chemotherapy|as prescribed
1885998|NCT01224093|Drug|rituximab [MabThera/Rituxan]|as prescribed
1885999|NCT01224106|Drug|Gantenerumab|Participants will receive gantenerumab 105 or 225 mg SC injection q4w.
1886000|NCT01224106|Drug|Placebo|Participants will receive placebo SC injection q4w.
1886001|NCT01224626|Drug|Zyvox (linezolid)|Patients should be treated with Zyvox (linezolid) 600 mg every twelve hours.
1886002|NCT01224639|Biological|TDV - Low Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. Low dose contains: TDV-1: 8 x 10^3 PFU, TDV-2: 5 x 10^3 PFU, TDV-3: 1 x 10^4 PFU, and TDV-4: 2 x 10^5 PFU, total virus per dose 2.2 x 10^5 PFU
1886003|NCT01224639|Biological|TDV - High Dose|TDV is a tetravalent dengue vaccine comprised of four recombinant, live attenuated dengue virus strains: TDV-1, TDV-2, TDV-3 and TDV-4. High dose contains TDV-1: 2 x 10^4 PFU, TDV-2: 5 x 10^4 PFU, TDV-3: 1 x 10^5 PFU, and TDV-4: 3 x 10^5 PFU, total virus per dose : 4.7 x 10^5 PFU. TDV administered intradermally.
1886004|NCT01224639|Biological|Placebo|Phosphate Buffered Saline (PBS)
1886005|NCT01224652|Drug|Paclitaxel|Paclitaxel, 70 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1, 8 and 15 of a 28-day cycle
1886006|NCT01224652|Drug|Irinotecan|irinotecan 150 mg/m2 will be administered as an intravenous (IV) infusion over 1 hour on Days 1 and 15 of a 28-day cycle
1886007|NCT01224665|Procedure|therapeutic conventional surgery|Patients undergo radical cystectomy
1886008|NCT01224665|Procedure|therapeutic standard lymphadenectomy|Patients undergo standard pelvic lymphadenectomy.
1886009|NCT01224665|Procedure|therapeutic extended lymphadenectomy|Patients undergo extended pelvic lymphadenectomy
1886012|NCT01224717|Drug|PTH134|
1886013|NCT01224717|Drug|Placebo|
1886016|NCT01224743|Dietary Supplement|Blend 1|Blend 1 consists of a combination of Juice Plus+® Orchard (Fruit), Garden (Vegetable), and Vineyard (Berry) blends
1886017|NCT01224743|Dietary Supplement|Blend 2|Blend 2 consists of a combination of Juice Plus+® Orchard (Fruit) and Garden (Vegetable) blends
1886018|NCT01224743|Dietary Supplement|Placebo|Placebo capsules are provided by the study sponsor and are identical in appearance to active treatments to ensure blinding.
1886019|NCT01224756|Drug|Tinoridine HCl|Tinoridine HCl 50 mg, orally, 2 capsules three times daily for up to 4 days.
1886020|NCT01224756|Drug|Placebo|Tinoridine placebo-matching capsules, orally, 2 capsules three times daily for up to 4 days.
1886021|NCT01224769|Drug|bendamustine +/- rituximab|
1886022|NCT01224795|Drug|Peramivir|Adults (≥ 18 years): Peramivir 600 mg, administered intravenously. Adolescents (12 to < 18 years): Peramivir 10 mg/kg (not to exceed a maximum dose of 600 mg), administered intravenously.
1886023|NCT01224795|Drug|Placebo Comparator|Placebo Peramivir, administered intravenously.
1886024|NCT01224808|Biological|Biostate|Single bolus doses, administered intravenously. Frequency and dose will be determined by the Investigator based on the subjects clinical condition, previous VWF concentrate requirements, response to therapy, weight and reason for usage.
1886025|NCT01224821|Biological|Tositumomab (Anti-B1 Antibody) and Iodine-131 Tositumomab|Patients receive a dosimetric dose consisting of 450 milligrams (mg) of unlabeled tositumomab (TST, Anti-B1 Antibody) intravenously (IV) followed by 5 milliCurie (mCi) of Iodine I 131 TST IV. Serial whole body sodium iodide probe scintillation counts and whole body conjugate view gamma camera scans obtained approximately 1 hour after administration and then daily for the next 7 days were used to determine the radioactive clearance and the dose of iodine I 131 TST required to deliver a 75 centigray (cGy) therapeutic dose. The therapeutic dose was administered 7-14 days after the dosimetric dose and consisted of TST 450 mg and an activity of Iodine 131 calculated to deliver 75 cGy or 65 cGy of total body irradiation, depending on platelet count, and 35 mg TST.
1886026|NCT01224834|Drug|Sublingual tablet of ragweed pollen allergen extract|administered once a day over 10 days
1886027|NCT01224847|Drug|Tetracaine|1 gtt
1886028|NCT01224847|Drug|Cocaine|1 gtt
1886029|NCT01224847|Drug|Lidocaine|Lidocaine soaked pledget
1886030|NCT01224860|Drug|Telmisartan|One week 40 mg daily, followed by fifteen weeks treatment period with 80 mg daily.
1886031|NCT01224860|Drug|Losartan|One week 50 mg daily, followed by fifteen weeks treatment period with 100 mg daily.
1886032|NCT01224886|Behavioral|Physical activity|Supervised exercise intervention
1886033|NCT01224899|Procedure|Left cervico-thoracic sympathetic blockade|Left cervico-thoracic sympathetic blockade by videothoracoscopic clipping under general anesthesia and single-lumen orotracheal intubation in semi-sitting position.
1886034|NCT01224912|Behavioral|Cognitive Behavioral Treatment|The techniques used throughout the self-help manual are all effective in reducing insomnia: 1) Stimulus control: patients should only go to bed when sleepy, use the bed and bedroom for sleep (and sex) only, maintain a regular rising time, avoid daytime naps and get out of bed and go into another room when unable to fall asleep within 15-20 minutes (return only when sleepy). 2) progressive muscle relaxation. 3) sleep hygiene education (improving health and environmental factors that affect sleep). 3). Sleep restriction, whereby participants will stay only the time in bed that they sleep. 4) cognitive therapy to challenge and dispute incorrect and unhelpful thoughts about sleep (e.g. I must sleep at least 8 hours, otherwise I'll be a wreck tomorrow).
1886037|NCT01224951|Drug|Beclomethasone|400 microgram of beclomethasone will be given to the patients in arm 1. During the last 4 weeks, the patients will receive additional 400 microgram of Qvar.
1886038|NCT01224964|Drug|Montelukast|Montelukast, 10 mg
1886039|NCT01224964|Drug|long acting beta2 mimetic|ICS+long acting beta2 agonist: twice daily
1886040|NCT01224977|Drug|azithromycin|azithromycin 500 mg 3/week for 3 months
1886041|NCT01224990|Procedure|Whole body diffusion MRI|These studies will be performed on a 3Tesla (T) MR system (Achieva, Philips Medical Systems). A major advantage of 3T compared to 1.5 T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
1886042|NCT01225016|Drug|Definity contrast agent|Thyroid ultrasound using contrast agent
1886043|NCT01225029|Other|Amount of total fluids|Term neonates receive either total fluids of 60 mL/kg/day (standard) or 40 mL/kg/day (restricted) on day of life (DOL) 1. Preterm neonates receive total fluids of 80 mL/kg/day (standard) or 60 mL/kg/day (restricted) on DOL 1. Each group receives an extra 20 mL/kg/day daily until total fluids of 150 mL/kg/day are achieved.
1886044|NCT01225042|Dietary Supplement|probiotics|Freeze-dried powder, dose 10E9 CFU twice daily for 4 weeks
1886045|NCT01225042|Dietary Supplement|placebo|placebo consisting of carrier material powder of identical appearance
1886046|NCT01225055|Drug|Teriparatide|20 ug daily over 12 months
1886047|NCT01225055|Device|vibration|10 min/day for 12 months
1886048|NCT01225068|Drug|Milnacipran|Total of 100 mg (50 mg twice a day) for 6 weeks. Option to increase to 200 mg (100 mg twice a day) after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
1886049|NCT01225068|Drug|Placebo|2 matching pills per day for 6 weeks. Option to increase dose after two weeks of treatment. Includes gradual escalation and discontinuation for week 1 and after week 6.
1886050|NCT01225081|Drug|ASP1941|oral
1886051|NCT01225081|Drug|Placebo|oral
1886052|NCT01225081|Drug|Pioglitazone|oral
1886053|NCT01225094|Drug|curcumin|Patients will take the study medication (500 mg x 4 capsules, twice daily [BID]) for two days leading up to repair, totaling 4000 mg per day. They will take a dose (2000 mg) the morning of repair, at the same time as regular medications not held for surgery. While they are on call to the operating room, they will take another dose of 2000 mg and then another 2000 mg dose 6 hours after the repair. Final dose is administered the morning after repair.
1886054|NCT01225094|Other|placebo|The placebo will look, smell, taste, and in every way be identical to the active drug. Patients will take the study medication in the exact same manner as the curcumin regimen.
1886055|NCT01225107|Dietary Supplement|Cranberry Extract|500mg TID
1886057|NCT01225120|Other|Gait Training|12 sessions, 30 minutes of walking on treadmill with real time therapist directed feedback on gait kinematics.
1886058|NCT01225133|Other|Complex Ayurvedic Treatment|In the Āyurveda group treatment will be individualized according to the Āyurveda diagnosis and include manual treatments, massages, dietary advice, specific consideration of selected food items, nutritional supplements, āyurvedic lifestyle and yoga posture advice and daily self-applied knee massage.
1886059|NCT01225133|Other|Conventional Care|Patients in the conventional standard care group will receive conventional standard care for OA of the Knee which includes self care advice, pain medication and intensified physiotherapy and follows the current international guidelines for OA of the knee.
1886060|NCT01225146|Drug|ranibizumab|Ranibizumab is formulated as a sterile solution aseptically filled in a sterile 3-mL stoppered glass vial. Each vial contains 0.5 mL of 40 mg/mL (2.0-mg dose level) ranibizumab aqueous solution.
1886061|NCT01225159|Drug|TGC|TGC used hyperinsulinaemic normoglycaemic clamp with modified glucose-insulin-potassium to control blood sugar. The insulin (HumulinTM R, Lilly pharma, Germany) was diluted with normal saline to the concentration 1 IU. mL-1 and was infused continuously throughout the operations at a fixed rate of 0.3 IU. kg-1.h-1 but the maximal rate was 20 IU/ h. A separate mixture of glucose 25% (A.N.B Laboratories, Thailand) 50 mL, potassium chloride (Nida pharma, Thailand) 20 mEq and magnesium sulfate (Atlantic, Thailand) 2 gm was infused at 0.75 mL.kg-1.h-1 and was adjusted to maintain blood glucose levels 80-150 mg/dL.
1886062|NCT01225159|Drug|Conventional glycaemic control|Conventional glycaemic control aims to control blood sugar less than 250 mg%. Insulin was given bolusly if the blood sugar more than 250 mg%.
1886063|NCT01225172|Drug|BMS-754807|Tablet, Oral, 100 mg, Daily, Until disease progression or unacceptable toxicity
1886064|NCT01225172|Drug|letrozole|Tablets, Oral, 2.5 mg, Daily, Until disease progression or unacceptable toxicity
1886065|NCT01225198|Dietary Supplement|Multi-Vitamin/Mineral Supplement|A broad-spectrum vitamin/mineral supplement designed for children and adults with autism
1886066|NCT01225198|Other|Liquid Placebo|The placebo was formulated to look and taste like the intervention supplement. A small amount of beta-carotene was used for coloring. Natural cherry, citric acid, and a proprietary blend of natural flavors were used for flavoring to create a vitamin-like after-taste. Sucralose was used as a sweetener and the same preservatives were included (potassium sorbate, sodium benzoate).
1886067|NCT01225211|Drug|Lumacaftor|Tablet
1886068|NCT01225211|Drug|Ivacaftor|Tablet.
1886069|NCT01225211|Drug|Lumacaftor Placebo|Matching placebo tablet.
1886070|NCT01225211|Drug|Ivacaftor Placebo|Matching placebo tablet.
1886071|NCT01225224|Drug|ASP015K|oral
1886072|NCT01225224|Drug|Placebo|oral
1886073|NCT01225237|Drug|Ramosetron|oral
1886074|NCT01225237|Drug|Placebo|oral
1886075|NCT01225250|Device|Polydioxanone (PDS) plates|0.5 mm PDS Flexible Plate made of poly-p-dioxanone, an aliphatic polyester which is manufactured by polymerization of the monomer p-dioxanone. Polydioxanone is a resorbable material degraded by hydrolysis and has been successfully used for bone discontinuities and septal reconstruction.
1886076|NCT01225250|Procedure|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
1886077|NCT01225250|Procedure|Caudal septal extension graft performed through endonasal rhinoplasty|The caudal septal extension (CSE) graft is a common method used to alter tip projection, alar-columellar relationship, and nasolabial angle.5 However, it can be difficult to stabilize and straighten the CSE graft, especially when performed through an endonasal approach. Use of a polydioxanone plate would provide a scaffolding for the CSE graft and could allow for a technically easier and more predictable surgical procedure.
1886078|NCT01225263|Drug|Simvastatin|simvastatin, 20 mg, twice daily for 6 months
1886079|NCT01225263|Dietary Supplement|Vitamin D|Vitamin D3, 1000 IU, twice daily for 6 months
1886080|NCT01225263|Other|Placebo|Two placebo pills, taken twice daily for 6 months
1886081|NCT01225276|Drug|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam . The maintenance doses to be infused 7 times will be 2.0 g/kg every 21 (+/-4) days.
1886082|NCT01225276|Drug|Placebo|Loading dose at baseline (Week 0) in Placebo arm will be corresponding volume of an authorised 0.9% saline solution . The maintenance doses of the 0.9% saline solution to be infused 7 times will be given every 21 (+/-4) days.
1886083|NCT01225276|Drug|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 1.0 g/kg every 21 (+/-4) days.
1886084|NCT01225276|Drug|NewGam 10%|Loading dose at baseline (Week 0) will be 2.0 g/kg NewGam in all three NewGam treatment arms. The maintenance doses to be infused 7 times will be 0.4 g/kg every 21 (+/-4) days.
1886085|NCT01225289|Dietary Supplement|Vitamin A|25000 IU/day (one capsule per day) Vitamin A for 6 months
1886086|NCT01225289|Drug|Placebo|1 capsule per day for six months
1886087|NCT01225302|Drug|Linifanib|Low dose linifanib (once a day)
1886088|NCT01225302|Drug|Linifanib|High dose linifanib (once a day)
1886089|NCT01225302|Drug|Carboplatin|Given on Day 1 of every 21-day cycle
1886090|NCT01225302|Drug|Paclitaxel|Given on Day 1 of every 21-day cycle
1886091|NCT01225315|Drug|Placebo|matching placebo administered orally twice daily
1886092|NCT01225315|Drug|Salbutamol/albuterol|Salbutamol/albuterol (100 Ug/puff, metered dose inhaler [MDI])
1886093|NCT01225315|Drug|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) administered orally twice daily
1886094|NCT01225328|Behavioral|Behavioral activation/problem-solving (BA/PS)|Six weekly telephone sessions to train participant in BA/PS procedures
1886095|NCT01225341|Drug|onabotulinumtoxinA|Botox® is supplied in a 100 U vial and will be reconstituted with 3.3 mL of 0.9% Sodium Chloride Injection USP to yield a solution of 3 U per 0.1 mL. Study treatment will consist of an injection of Botox® (onabotulinumtoxinA) (3 U/ 0.1 mL) into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
1886135|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
1886096|NCT01225341|Other|Bacteriostatic normal saline|Study treatment will consist of an injection of bacteriostatic normal saline, into the orbicularis oris muscle (8 U, .27 mL in the upper and/or lower lip, depending on the site of recurrence) using a 30G needle.
1886097|NCT01225354|Drug|Calcium hydroxylapatite|Subjects will be treated to full correction at visit 1 and, if needed, a touch-up injection at 2 weeks.
1886098|NCT01225367|Device|ultrasound doppler monitoring|Regular noninvasive chest echo monitoring
1886099|NCT01225380|Drug|GS-9190|GS-9190 capsule, 20 mg BID, 16 or 24 weeks
1886100|NCT01225380|Drug|GS-9256|GS-9256 capsule, 150 mg BID, 16 or 24 weeks
1886101|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a, (solution for injection) 180 µg/week, up to 48 weeks
1886102|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), up to 48 weeks
1886103|NCT01225380|Drug|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
1886104|NCT01225380|Drug|GS-9256|GS-9256 capsule, 150 mg BID, 24 weeks
1886105|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, up to 48 weeks
1886106|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), up to 48 weeks
1886107|NCT01225380|Drug|GS-9190 placebo|placebo matching GS-9190 capsule BID, 24 weeks
1886108|NCT01225380|Drug|GS-9256 placebo|placebo matching GS-9256 capsule BID, 24 weeks
1886109|NCT01225380|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week, 48 weeks
1886110|NCT01225380|Drug|Copegus®|ribavirin 200 mg tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day >/= 75 kg) divided twice daily (BID), 48 weeks
1886111|NCT01225393|Drug|MLTA3698A|Subcutaneous repeating dose
1886112|NCT01225393|Drug|adalimumab|Subcutaneous repeating dose
1886113|NCT01225393|Drug|leflunomide|Stable dose if not on methotrexate
1886114|NCT01225393|Drug|methotrexate|Stable dose if not on leflunomide
1886115|NCT01225393|Drug|placebo|Subcutaneous repeating dose
1886116|NCT01225406|Drug|Tenofovir|
1886117|NCT01225419|Drug|Plerixafor, mozobil|Subcutaneous injection of 240 µg/kg of Plerixafor (Mozobil ®, Genzyme) at 8 am the day of the cytapheresis. Determination of CD34+ cells circulating in h0 then every hour of h3 to h11. Taking by cytapheresis from the 5th hour of the injection if the rate of CD34+ is upper or equal in 10.106/l. If the rate of CD34+ in the blood does not reach 10.106/l after the first injection of plerixafor or if the first cytapheresis does not allow the collection of at least 5.106/kg CD34+ cells, the patient will be considered in failure and a conventional mobilization by G-CSF will be programmed
1886118|NCT01225432|Other|Gait Training|12 sessions, 30 minutes of walking on a treadmill with real time therapist directed feedback on gait kinematics.
1886119|NCT01225445|Drug|Ramipril|2.5 mg daily
1886120|NCT01225458|Other|shorter tests|Geriatric evaluation with MMS, GDS and ADL scoring
1886121|NCT01225458|Other|initial complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : only at the first visit
1886122|NCT01225458|Other|follow-up complete geriatric tests|evaluation of cognitive functions, psychological functions, dependency in activities, vision, audition, mobility and nutritional status : every 6 month for 3 years
1886123|NCT01225471|Biological|CDCA1|CDCA1-A24-56 will be administered by subcutaneously injection once every week for 3 months thereafter once two weeks. This peptide conjugated with Montanide ISA 51 as an adjuvant.
1886124|NCT01225484|Procedure|Continuous femoral nerve block + periarticular infiltration|Initial bolus of ropivacaine 5mg/ml 30mls into the femoral-nerve-catheter preoperatively. Periarticular infiltration of ropivacaine 2mg/ml 150 mls intraoperatively. Continuous perineural infusion of ropivacaine 2mg/ml at a rate of 6 mls/hr postoperatively. Rate can be adjusted to achieve optimal pain control and avoid motor blockade.
1886125|NCT01225484|Procedure|Intraarticular and periarticular ropivacaine|Periarticular infiltration of 150 mls ropivacaine 2mg/ml intraoperatively, intraarticular injection of 40 mls ropivacaine 2 mg/ml at skin closure followed by infusion of ropivacaine 2 mg/ml at a rate of 4 mls/hr delivered by an intraarticular catheter until the morning of postoperative day 3.
1886126|NCT01225497|Procedure|Standard eccentric exercise|"Participants stand with the balls of their feet on a step. They rise up onto tip toes using both legs then transfer onto the affected leg, then slowly lower their heel below the level of the step keeping their weight-bearing limb fully straight (eccentric phase). This constitutes 1 repetition and is repeated for 3 x 15 reps.
The previous procedure is then carried out with the knee bent during the eccentric phase of loading for 3 x 15 reps.
All of the above is carried out twice a day as per Alfredsons protocol. Participants are encouraged as per Alfredsons procedure to continue into discomfort not severe pain."
1886127|NCT01225497|Procedure|Eccentric exercise-Experimental group|Eccentric exercise is performed the same as in the standard group. However participants in this group are encouraged to do the number of repetition they can manage so long as it is also to discomfort.
1886128|NCT01225510|Biological|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
1886129|NCT01225510|Biological|PF-04856884|PF-04856884 at a dose of 15 mg/kg/week
1886132|NCT01225536|Drug|ARQ 736|Subjects in this study will receive ARQ 736 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 900 mg/day (first cohort) and escalate until the recommended Phase 2 dose or maximum tolerated dose is determined. Cycles will be repeated in four-week (28-day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
1886133|NCT01225549|Drug|AZD5423|Suspension for nebulisation once daily 7 days
1886134|NCT01225549|Drug|Budesonide 200 microgram|Dry powder for inhalation twice daily 7 days
1991828|NCT00460512|Drug|Paliperidone ER|Paliperidone ER tablet in dose range of 3 to12 milligram (mg) per day was given orally for 6 months as per Investigator's discretion to participants who transitioned to Paliperidone ER from other oral antipsychotics due to lack of efficacy, lack of tolerability, lack of compliance or other reasons.
1886136|NCT01225549|Drug|Placebo|Solution for nebulisation once daily 7 days
1886137|NCT01225562|Drug|Ticagrelor 90 mg|Oral dose twice a day
1886138|NCT01225562|Drug|Ticagrelor 60 mg|Oral dose twice a day
1886139|NCT01225562|Drug|Ticagrelor Placebo|Oral dose twice a day
1886140|NCT01225575|Drug|co.don chondrosphere®|"co.don chondrosphere® are spheroids in suspension, developed from autologous chondrocytes.
The dose in group A is 3-7 spheroids/cm2 defect, in group B 10-30 spheroids/cm2 defect and in group C 40-70 spheroids/cm2 defect"
1886141|NCT01225601|Behavioral|Tabacco discontinuation|Tabacco discontinuation
1886142|NCT01225614|Device|Bilevel pressure ventilator|Nocturnal home ventilation
1886143|NCT01225627|Other|Coordinated discharge|In intervention group, a discharge coordinator contacts hospitalized patients the day after randomization. During hospitalization, discharge coordinator visits are scheduled according to patients' problems and home-care needs. At 48 hours after hospital discharge, a discharge coordinator calls patients by phone to check the process of adjustment to home environment and to inquire about additional needs patients might have. Thereafter, phone contacts are scheduled according to the patients' needs and 7-10 days after the hospital discharge a home visit is performed by discharge coordinator, respectively.
1886144|NCT01225627|Other|Control|Patients in control group will be managed by attending physician, primary care physician, and/or pneumologist in accordance with established clinical practice.
1886145|NCT01225640|Drug|PNU-100480|600 mg twice daily (BID) for 14 days
1886146|NCT01225640|Drug|PNU-100480|1200 mg once daily (QD) for 14 days
1886147|NCT01225640|Drug|RHZE|Combination tablet (RHZE) dosed by weight. Dosage strength per tablet is 150 mg Rifampicin (R)/75 mg Isoniazid (H)/400 mg Pyrazinamide (Z)/275 mg Ethambutol (E)
1886148|NCT01225653|Drug|Latanoprost|Topical application
1886149|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 30% of the cumulative weekly dose achieved with daily rhGH, Once weekly
1886150|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 45% of the cumulative weekly dose achieved with daily rhGH, Once weekly
1886151|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, Once weekly
1886152|NCT01225666|Drug|MOD-4023|liquid solution for subcutaneous injection - 100% of the cumulative weekly dose achieved with daily rhGH, every-other week (50% of the two-weekly cumulative dose)
1886153|NCT01225679|Device|positive airway pressure, Non-invasive mechanic ventilation|"Vpap: 16 cm H2O inspiratory and 8 cm H2O expiratory pressures, 20 irpm.
Mechanic ventilation: tidal volume of 850 ml; 16 irpm; inspiratory pressure of 40 mmHg; PEEP: 5 cm H2O."
1886154|NCT01225692|Behavioral|Head Injury Guideline|
1886155|NCT01225705|Drug|raltegravir|Patients will be randomized 1:1 to either the experimental or the active control arm
1886156|NCT01225705|Drug|Atazanavir/ritonavir|Patients will be randomized 1:1 to either the experimental or the active control arm
1886157|NCT01225731|Biological|tildrakizumab|SC administration of tildrakizumab at assigned dose
1886158|NCT01225731|Drug|Placebo|SC administration of Placebo
1886159|NCT01225744|Drug|Cetuximab|"Cetuximab will be prepared under Good Manufacturing practice (GMP) and supplied by Merck KGaA (Darmstadt, Germany) as a solution for intravenous infusion. It will be made up into 250ml with N/Saline.
Dose administered is 400mg/m2 and will be given on day 1 and day 15 of a 28 day cycle.Cetuximab will always be administered first, i.e. the cetuximab infusion should be completed one hour before any chemotherapy begins. The cetuximab dose must always be based on the body surface area(BSA). There is no restriction for cetuximab in patients with a BSA > 2 m2 ."
1886160|NCT01225744|Drug|Irinotecan|Dose is 180mg/m2 made up into 250ml with 5% dextrose or 0.9% saline. It will be administered as a short infusion over 60-90 minutes after a 60 minute gap left after cetuximab administration. Irinotecan is administered on day 1 of the 28 day cycle.
1886161|NCT01225744|Drug|Oxaliplatin|Dose is 100mg/m2 and will be made up into 250ml with 5% dextrose. It will be administered as a short infusion over 120 minutes after the 60 minute gap left after cetuximab administration. Oxaliplatin is administered on day 15 of the 28 day cycle.
1886162|NCT01225744|Drug|UFT|UFT dose is 250mg/m2 and is given in three divided doses with calcium folate 30mg p.o. tds on days 1-21 of the 28 day cycle. The highest dose of UFT should be given in the morning if the dose cannot be divided equally.
1886163|NCT01225757|Device|Echocardiogram|Echocardiography will be utilized during the procedure to guide fluid management.
1886164|NCT01225770|Dietary Supplement|green tea|Gargling three times daily for 90 days
1886166|NCT01225796|Drug|Sodium bicarbonate|Sodium bicarbonate 650mg by mouth three times daily for 6 months.
1886167|NCT01225822|Drug|Enoxaparin|Enoxaparin 40 mg s.c once a day for 5-10 days of treatment period
1886168|NCT01225822|Drug|BIBR 1048|50 mg b.i.d BIBR 1048 capsule twice a day for 5-10 days of treatment period
1886169|NCT01225822|Drug|BIBR 1048|150 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
1886170|NCT01225822|Drug|BIBR 1048|225 mg b.i.d BIBR 1048 capsule twice a day for 5-10 treatment period
1886171|NCT01225822|Drug|BIBR 1048|300 mg q.d BIBR 1048 capsule for 5-10 treatment period
1886172|NCT01225835|Drug|Menotrophin|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
1886173|NCT01225835|Drug|Follitrophin alpha|Starting on Day 2 or 3 of the menstrual cycle, 150 IU (up to 300 IU) by subcutaneous injection once per day in the morning for up to 12 days until human chorionic gonadotropin (hCG) criteria are met.
1886174|NCT01225835|Drug|Cetrorelix|Participants self-inject subcutaneously Cetrorelix in the morning at a daily dose of 0.25 mg/day from Day 5 of gonadotrophin administration on and continue throughout the period of gonadotrophin treatment up to day 12 as a maximum. The last dose of Cetrorelix is given on the day of ovulation induction.
1886175|NCT01225835|Drug|Choriongonadotropin|10,000 IU administered by the Investigator or designated personnel in the evening of the day on which the hCG criterion is met (no later than Day 13). The criterion for hCG administration is three follicles >+17 mm diameter as shown by pelvic ultrasound examination.
1886176|NCT01225835|Drug|Progesterone|Vaginal gel progesterone is used once daily at a dose of 90 mg for a period of 30 days starting on the day of oocyte retrieval (approximately Day 14).
1886177|NCT01225848|Drug|SU011248|blinded-SU011248 or Placebo given at 50 mg/day as single agent for 4 consecutive weeks followed by a 2-week rest period to form a complete cycle of 6 weeks. Suty drug will be orally self administered once daily without regard to meals beginning on Day 1 of the study.
1886178|NCT01225874|Drug|SC-PEG E. coli L-asparaginase|Given IM
1886179|NCT01225874|Drug|cytarabine|Given IT
1886180|NCT01225874|Drug|daunorubicin hydrochloride|Given IV
1886181|NCT01225874|Drug|dexamethasone|Given orally
1886182|NCT01225874|Drug|methotrexate|Given IT
1886183|NCT01225874|Drug|pegaspargase|Given IM
1886184|NCT01225874|Drug|prednisone|Given orally
1886185|NCT01225874|Drug|vincristine sulfate|Given IV
1886187|NCT01225913|Drug|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 80ug/formoterol 4.5ug, 2 inhalations bid X 20-60 days or fluticasone 100ug/salmeterol 50ug, 1 inhalation bid X 20-60 days
1886188|NCT01225913|Drug|budesonide/formoterol or fluticasone/salmeterol in all asthmatics|budesonide 160ug/formoterol 4.5ug, 2 inhalations bid or fluticasone 250ug/salmeterol 50ug, 1 inhalations bid
1886189|NCT01225926|Device|Toric T3 - T9|Commercially available, acrylic, multifocal IOL intended to provide visual correction over the lifetime of the cataract patient
1886190|NCT01225926|Device|IQ SN60WF|Commercially available, acrylic, monofocal IOL intended to provide visual correction over the lifetime of the cataract patient
1886191|NCT01225939|Drug|AZD8329|tablet
1886192|NCT01225939|Drug|AZD8329|Solution
1886193|NCT01225952|Device|Crystalens AO|Bausch & Lomb model silicone multi-piece accommodating IOL.
1886194|NCT01225952|Device|ReSTOR 3.0|An aspheric multifocal IOL (Alcon Laboratories) combines the functions of an apodized diffractive region and a refractive region.
1886195|NCT01225952|Device|AMO Tecnis Multifocal|The Tecnis Multifocal foldable hydrophobic acrylic IOL, Model ZMA00 (Abbott Medical Optics), is an ultraviolet light-absorbing posterior chamber IOL.
1886196|NCT01225965|Device|Ectoin Inhalation Solution|Once daily inhalation of Ectoin Inhalation Solution
1886197|NCT01225965|Device|Placebo|Once daily inhalation of Placebo Inhalation Solution
1886198|NCT01225978|Device|GeneInsight Clinic (GIC)|"GeneInsight Clinic (GIC) is a clinical interface tool that provides genetics IT support infrastructure designed to address key genetic data and knowledge management issues.
The GIC enables the delivery of patient specific alerts when new information is learned about a variant after it has been reported to a treating clinician. The prototype for this study shows multiple tests, Hypertrophic Cardiomyopathy test updates, hearing loss test updates and broad spectrum genotyping test updates. Our intention is to build this functionality in a scalable manner that will ultimately accommodate whole genome sequencing."
1886199|NCT01225991|Drug|Milnacipran|All subjects will be free of antidepressant medications or opiates, or any other medications used to treat pain for at least 2 weeks prior to initiation of dose titration. Patients will be allowed to escalate up to 100 mg a day: Day 1: 12.5 mg once a day; Days 2-3: 25 mg/day (12.5 mg twice daily); Days 4-7: 50 mg/day (25 mg twice daily); After Day 7: 100 mg/day (50 mg twice daily). The stable-dose phase will be a 10-week period during which patients will take medications at the final dose achieved (either 100 mg per day in divided doses, or the maximum tolerated dose of less than 100 mg per day).
1886200|NCT01226017|Other|Measuring oxytocin level in blood|Blood sampling and instruments measuring anxiety and stress
1886201|NCT01226030|Drug|M2ES 7.5mg|M2ES 7.5mg
1886202|NCT01226030|Drug|M2ES 15mg|M2ES 15mg
1886203|NCT01226030|Drug|M2ES 30mg|M2ES 30mg
1886204|NCT01226030|Drug|M2ES 60mg|M2ES 60mg
1886205|NCT01226043|Drug|Insulin Glargine|"Pharmaceutical form: solution for injection
Route of administration: subcutaneous"
1886206|NCT01226056|Drug|RAD001 in combination with sorafenib|"Phase I / Dose escalation: during the first cycle RAD001 (2.5-10 mg/day) will be administered alone, once a day, on days 1-14 to allow PK-profiling of the drug. From day 15 sorafenib administration (400-800 mg/day) twice a day will be added.
The cycle 1 will last 6 weeks, subsequent cycles will last 4 weeks (the 2 drugs administered in combination from day 1 to day 28).
Phase II: The drugs will be administered at the Recommended Dose and each treatment cycle will last 4 weeks."
1886207|NCT01226069|Drug|Glycerine Magnesium sulphate paste|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
1886208|NCT01226069|Drug|Mucopolysaccharide polysulphate|Dosage to apply adheres to the manufacturer's recommendation. Sufficient amount should cover the erythema size. Dose frequency is 12 hourly.
1886209|NCT01226069|Other|No application|No application
1886210|NCT01226082|Device|Transcranial Direct Current Stimulation|Patients will recieve tDCS in a 5-day period of treatment
1886211|NCT01226108|Device|Patch|One patch per day, Duration: three weeks, Administration: behind the ear
1886212|NCT01226121|Biological|Clostridial collagenase injectable|Finger manipulation performed 1, 2, or 4 days following collagenase injection
1886213|NCT01226134|Drug|Itopride,|Itopride,50 mg capsules,thrice a day,for Four weeks
1886214|NCT01226134|Drug|Placebo|placebo capsules,thrice a day for four weeks
1886215|NCT01226147|Drug|Tamibarotene|4mg/day for 24 weeks.
1886216|NCT01226160|Procedure|Postoperative face-down posturing|Postoperative face-down posturing for 10 days after surgery.
1886217|NCT01226160|Procedure|Postoperative non-posturing group|avoid a face-up position only for 10 days after surgery
1886218|NCT01226173|Device|Bio-Rad Platelia Dengue NS1 Ag test|The purpose of the study is to screen blood donors for the presence of dengue NS1 antigen at the ARC in Puerto Rico region using the Bio-Rad Platelia Dengue NS1 Ag test.
1886219|NCT01226186|Behavioral|Nurse dispensed oral morphine.|Nurse will dispense oral morphine on request from the patient.
1886220|NCT01226186|Behavioral|Patient self medication of oral morphine.|Patients will self medicate their oral morphine pain control solution following surgery.
1886221|NCT01226212|Dietary Supplement|Synbiotic (Synergy 1/B. longum)|Combination of a prebiotic Synergy 1 and a probiotic Bifidobacterium longum
1886222|NCT01226212|Dietary Supplement|Placebo|maltodextrose
1886223|NCT01226225|Behavioral|Aerobic interval training|Patients will enter a training program during which aerobic interval training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
1886224|NCT01226225|Behavioral|Moderate endurance training|Patients will enter a training program during which moderate endurance training is implemented. Three sessions per week, each lasting for 60 minutes. Total duration of the program: 3 months.
1886225|NCT01226238|Other|Online self-help|Provision of online self-help
1886226|NCT01226251|Device|In vitro chair side test|Colour evaluation of a strip
1886227|NCT01226264|Procedure|Diffusion weighted MRI (DW- MRI)|"An MRI examination (including diffusion-weighted sequences) belongs to the standard protocol for patients with cervical uterine cancer. The additional burden is therefore restricted to an extra MRI scan during and/or early after therapy.
MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.
During the examination, an intravenous and vaginal contrast medium will be administered. In most cases, patients do not experience any discomfort and the use of these contrast agents is part of the clinical routine."
1886228|NCT01226277|Drug|GDC-0917|Oral repeating dose
1886229|NCT01226290|Device|VizAblate System|VizAblate enables a minimally invasive procedure to visualize, target, and ablate uterine fibroids using intrauterine ultrasound and radiofrequency (RF) energy.
1886230|NCT01226303|Drug|ATRA|see the protocol
1886231|NCT01226303|Drug|ATRA + IDA|see the protocol
1886236|NCT01226329|Behavioral|Right Question Project - Mental Health (RQP-MH)|"The RQP-MH trainings each take approximately 45 minutes to complete and are delivered approximately three weeks apart. The manualized intervention uses a Question Formulation Technique (QFT) and a Framework for Active Decision-Making (FADM). The QFT consists of asking patients to generate and revise questions to obtain more informative answers from their providers. The FADM teaches participants to identify questions that will help them consider their role in a decision, the process of decision-making, and the reasons behind a decision. All intervention sessions will be taught by a bachelors-level Care Manager."
1886237|NCT01226329|Behavioral|Pamphlet|"Participants in this group receive a handout called Managing Your Mental Health (available in Spanish and English) that provides tips on how to manage mental health through the proper maintenance of physical health and stress."
1886238|NCT01226342|Device|Transcutaneous electrical muscle stimulation|On the first hospitalization day patients received lower extremity TCEMS. We used GymnaUniphy device (GymnaUniphy N.V., 2004, 3740 Bilzen, Belgium) with four surface patch electrodes applied over each lower extremity quadriceps muscle. Patients were in the supine position and were advised to relax during sessions. A prespecified program for lower extremity strength training in sessions of 25 minutes, twice a day (first training in the morning, second in the afternoon, with minimal time difference of 6 hours) was performed six days per week during the hospitalization.
1886239|NCT01226355|Device|stent|"NOYA CoCr Biodegradable Coating Sirolimus-Eluting Stent System is manufactured by Medfavour (Beijing) Medical Co., Ltd.
Firebird drug-eluting stents from MicroPort Medical (Shanghai) Co., Ltd."
1886240|NCT01226368|Other|Biological Sample collection|Cervix cells
1886241|NCT01226381|Drug|Von Frey electronic|This protocol is based on a study of the interaction setron / paracetamol at 4 different levels of plasma concentrations, by repeating the tests at set intervals, while concentrations of setrons down gradually (half-life of 8 to 10 am ) after a single administration. In addition, the interindividual variability of the effects of paracetamol will be studied, and linking with certain genetic polymorphisms reported by the subjects tested
1886242|NCT01226394|Procedure|laparotomy plus HIPEC|Laparotomy + HIPEC
1886243|NCT01226407|Drug|CG200745|Multiple administration (IV) over the cycles untile MTD/LTD
1886244|NCT01226420|Drug|Alefacept|Given intravenously Days 1 and 4 of Week 1, then subcutaneously once weekly for Weeks 2-12
1886245|NCT01226446|Drug|vitamin D|Vitamin D on top of the standard treatment
1886246|NCT01226459|Drug|5% Minoxidil Topical Foam|Dosage Form: 5% Minoxidil Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
1886247|NCT01226459|Drug|Vehicle Topical Foam|Dosage Form: Vehicle Topical Foam applied to the scalp; Dosage: half a cap, equivalent to 1 g of foam; Frequency: once every day; Duration: 24 weeks
1886248|NCT01226472|Biological|KW-0761|In the first treatment course KW-0761 will be administered i.v. once a week for four weeks, followed by a 2-week observation period. Subsequent treatment courses are permissible for subjects demonstrating a response or maintaining stable disease and will consist of an infusion of KW-0761 every other week.
1886250|NCT01226498|Procedure|Red blood Cells auto-transfusion|Withdrawal from 10 Healthy volunteers of one unit of red blood cells and auto-transfusion after 3 days for one arm of the study, after 40 days for the other. Participants are enrolled in both arms of the study.
1886251|NCT01226511|Drug|Duloxetine|Administered orally
1886252|NCT01226511|Drug|Placebo|Administered orally
1886335|NCT01219673|Drug|Minocycline|100 mg by mouth twice a day.
1886253|NCT01226524|Drug|Bu Zhong Yi Qi Tang, Zhi Xue Tang, Chuan xin lian kang yan pian mod, Tian Wang Bu xin Dan|A traditional Chinese Medicine (TCM) therapist will diagnose and prescribe the herbal remedies according to TCM principles from one of four formulations or any combination of the four formulation
1886254|NCT01226537|Drug|Taurine|500 mg taurine capsules twice per day for 6 months
1886255|NCT01226550|Procedure|cytoreductive surgery and HIPEC|"The most complete cytoreductive surgery possible (ideally macroscopically complete) followed by a closed-abdomen hyperthermic intraoperative peritoneal chemotherapy (HIPEC), using a closed circuit connected to the self-regulating Cavitherm machine (EEC certified). This perfusion apparatus records temperature, flow, and pressure for 90 minutes at real temperature (42-43°C).
The dialysate is made up of peritoneal dialysis fluid containing 0.7 mg/kg of MMC and increasing doses of irinotecan added to the dialysate the last 30 minutes of the HIPEC.
Potentiation of irinotecan using an intravenous FUFOL perfusion at least 1hour before HIPEC (1st dose level: 10 mg/m² of folinic acid, then 200 mg/m² of 5-FU; 2nd dose level: 20 mg/m² of folinic acid, then 400 mg/m² of 5-FU)."
1886256|NCT01226563|Device|Sodium Alginate and Calcium Gluconate|4 mL (+/- 0.2 mL)administered through intracoronary slow bolus injection over 15 to 30 seconds at least 2 days after PCI but within 5 days of onset of symptoms.
1886257|NCT01226563|Device|Saline Solution|4 mL (+/- 0.2 mL)slow bolus, intracoronary injection of saline solution will be administered over 15 to 30 seconds at least 2 days after percutaneous coronary intervention (PCI) but within 5 days of onset of symptoms.
1886258|NCT01226576|Device|MRgFUS Treatment|Local treatment of prostate cancer using Magnetic Resonance Imaging guided endorectally applied focused ultrasound energy
1886259|NCT01226589|Procedure|MRS|
1886260|NCT01226602|Drug|AZD6140|P2Y12 receptor antagonist
1886261|NCT01226602|Drug|Placebo|
1886264|NCT01226628|Biological|CNTO 2476|
1886265|NCT01226628|Procedure|iTrack Model 275 micro catheter|CNTO 2476 will be administered subretinally using the iTRACK microcatheter in participants with visual acuity impairment. During surgery, the portion of microcatheter distal to the flexible blue hub is inserted into the subretinal space via a peripheral scleral cutdown and choroidal fistula.
1886266|NCT01226641|Device|Telemedicine|CPAP treatment with telemedicine system
1886267|NCT01226641|Device|Standard care|Standard care, including CPAP
1886268|NCT01226654|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging EDSS
1886269|NCT01226667|Drug|Pregabalin|"Fixed dosing of pregabalin: Week 1: 75 mg bid. Weeks 2 - 8: 150 mg bid. Week 9 (Days 57-60 and Days 61-63): 75 mg bid.
Flexible dosing of pregabalin: Week 1: placebo in the AM and 75 mg nightly; Week 2: placebo in the AM and 150 mg nightly.; Week 3 placebo in the a.m., 225 mg nightly; Weeks 4 - 8 placebo in the a.m., 300 mg nightly. Week 9 (Days 57-60) placebo in the a.m,, 150 mg bid nightly and Days 61-63: placebo in the a.m., and 75 mg bid nightly."
1886270|NCT01226680|Drug|Tasocitinib|0.005% QD for 12 weeks
1886271|NCT01226680|Drug|Tasocitinib|0.003% QD for 12 weeks
1886272|NCT01226680|Drug|vehicle for Tasocitinib|vehicle QD for 12 weeks
1886273|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
1886274|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
1886275|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
1886276|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
1886277|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
1886278|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
1886279|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
1886280|NCT01226693|Drug|PH-797804 material sparing tablet|oral, 6mg, single dose
1886281|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
1886282|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
1886283|NCT01226693|Drug|PH-797804 Phase2b/3 with sodium lauryl sulphate|oral, 6mg, single dose
1886284|NCT01226693|Drug|PH-797804 Phase2b/3 without sodium lauryl sulphate|oral, 6mg, single dose
1886285|NCT01226706|Drug|Botulinum Toxins, Type A|Botulinum Toxins, Type A 100U injected into the detrusor at Day 1
1886286|NCT01226706|Drug|Placebos|Placebos injected into the detrusor at Day 1, followed by injection of botulinum toxin Type A 100U after 24 weeks has elapsed from previous treatment, if requested/qualified.
1886287|NCT01226719|Drug|Panitumumab|6 mg/kg, 60-90 minute IV infusion every 2 weeks
1886288|NCT01226719|Drug|Oxaliplatin|85 mg/m2, 2-hour IV infusion every 2 weeks
1886289|NCT01226719|Drug|Irinotecan|125 mg/m2, 1-hour IV infusion every 2 weeks
1886290|NCT01226719|Drug|Leucovorin|200 mg/m2, 2-hour IV infusion every 2 weeks
1886291|NCT01226719|Drug|5-Fluorouracil|3200 mg/m2 IV, 48-hour continuous infusion every two weeks
1886292|NCT01226732|Drug|Capecitabine|Taken orally twice daily on Days 1 through 14 of 21 day cycle.
1886293|NCT01226732|Drug|Hsp90 Inhibitor AUY 922|IV infusion over 60 minutes on Days 1, 8, and 15 of each 21 day cycle
1886294|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.15 milligram (mg) in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
1886295|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.10 mg in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
1886296|NCT01226745|Drug|ONO-4641|Subjects will be administered with ONO-4641 at a dose of 0.05 mg in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
1886297|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.15 mg in this extension study for a duration of 225 weeks.
1886298|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.10 mg in this extension study for a duration of 225 weeks.
1886299|NCT01226745|Drug|ONO-4641|Subjects will receive placebo in the core study will be administered with ONO-4641 0.05 mg in this extension study for a duration of 225 weeks.
1886300|NCT01226758|Biological|Influenza vaccine (FLU-v)|FLU-v (sterile lyophilised mixture of polypeptide T-cell epitope sequences) and adjuvant. Administered by single subcutaneous injection.
1886301|NCT01226758|Biological|Placebo (adjuvant only)|Single subcutaneous injection of adjuvant
1886302|NCT01226771|Drug|"Ribavirin loading dose given"|PEG-IFN α-2a 180 μg/week plus loading (≥26 mg/kg/day for 2 weeks followed by ≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 4 weeks of therapy) dosing of ribavirin and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
1886303|NCT01226771|Drug|"Priming dose of ribavirin given"|Standard-of-care dosing of ribavirin (≥13 mg/kg/day) without PEG-IFN for 4 weeks followed by 24-48 additional weeks of PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day) and concentration targeted (≥ 2.5 mg/L, i.e ≥ 10.25 μmol/L, as measured after 28 days after the initiation of ribavirin) dosing of ribavirin and response guided treatment duration (RVR 28 weeks, non-RVR 52 weeks, pEVR consider 76 weeks), follow-up period 24 weeks
1886304|NCT01226771|Drug|"Group C (Standard-of-Care)"|PEG-IFN α-2a 180 μg/week plus standard-of-care dosing of ribavirin (≥13 mg/kg/day without any measurement of ribavirin concentration) and response guided treatment duration (RVR 24 weeks, non-RVR 48 weeks, pEVR consider 72 weeks), follow-up period 24 weeks
1886305|NCT01226784|Behavioral|Physcial activity|Strenght training Relaxation exercise
1886306|NCT01226797|Drug|Placebo|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
1886307|NCT01226797|Drug|PF-04136309|Take 4 capsules twice daily 12 hours apart with water. Swallow whole.
1886308|NCT01226823|Drug|Ursodeoxycholic Acid|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
1886309|NCT01226823|Drug|Placebo|300 mg capsules 20 mg/kg body weight/day divided in three administrations per day from enrolment until delivery
1886310|NCT01226836|Other|LWWCOPD for Pulmonary Rehabilitation|As part of clinical care participants will attend a 6 week pulmonary rehabilitation programme consisting of supervised exercise and education sessions. The exercise component will be consistent with the usual pulmonary rehabilitation programme delivered at that site (BTS 2001, NICE 2004). The education sessions will be delivered using the revised LWWCOPD programme (1/week, approx. 30-45min). All health professionals will be provided with the health professionals' manual and supplementary posters for their respective education session. All participants will be provided with the revised LWWCOPD information booklet and an action plan for recognising and managing exacerbations.
1886311|NCT01226849|Drug|bortezomib, rituximab, ifosphamide, etoposide, carboplatin|Rituximab 375mg/m2 day 1 Etoposide 100mg/m2 day 1-3 Carboplatin AUC (5) max 800 days 2 Ifosfamide continuous infusion + Mesna 5/m2/24hr day2 Bortezomib 1.3mg/m2 days 1,4,8,11 G-CSF (SC) recommended
1886312|NCT01226875|Procedure|SWL: Shock Wave Lithotripsy Intervention|Shock wave lithotripsy (SWL) is the most common treatment modality for kidney stones. It is a safe and non-invasive treatment performed on patients under intravenous sedation (light anesthesia) on an out-patient basis, whereby shock waves are generated by a source external to the patient's body and are then propagated into the body and focused on a kidney stone. The unique quality of SWL is in its exploitation of shock wave focusing. The Storz lithotripter is an electromagnetic lithotripter with a unique design that allows for a dual focus system with the option of either a narrow (6x28 mm) or wide (9x50 mm) focal zone, depending on the clinical situation. This is the first lithotripter on the market to allow for two different focal zones for shock wave targeting.
1886313|NCT01226901|Drug|MK-4827|MK-4287, 150 mg or 300 mg capsule, orally, once daily in 21 day cycles.
1886314|NCT01226914|Drug|EVICEL|EVICEL
1886315|NCT01226927|Other|Automated intermittent bolus|Automated intermittent bolus delivery method of 0.2% ropivacaine at 5 mL every 30 minutes with a basal infusion of 0.1 mL/hr.
1886316|NCT01226953|Biological|Haemophilus influenzae type b (Hib) vaccine|Comparator study of two commercially available Haemophilus influenzae type b (Hib) vaccines
1886317|NCT01226966|Drug|liraglutide|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine.
1886318|NCT01226979|Radiation|High-dose endorectal brachytherapy|The investigational tool being evaluated is high-dose endorectal brachytherapy (HDRBT) which is an FDA approved method to administer endoluminal radiation for low rectal cancer.
1886319|NCT01226992|Drug|Vancomycin|"Oral Vancomycin:
Dose: 125 mg po qid x 2 weeks then 125 mg po bid x 1 week then 125 mg po od x 1 week then 125 mg po q every other day x 1 week then 125 mg po q every third day x 1 week then discontinue Route: oral"
1886320|NCT01226992|Biological|Fecal Transplant|Fecal slurry 50 grams stool in 500ml normal saline
1886321|NCT01227005|Biological|Transfusion of blood products|The intervention will be either a) administration of 1 unit of whole blood plus pooled products or b) administration of component therapy (red blood cells, plasma, platelets).
1886322|NCT01227018|Drug|STA-9090|Given IV
1886323|NCT01227018|Radiation|Radiologic imaging|radiologic modalities used to evaluate response to treatment
1886324|NCT01227018|Procedure|blood draw|Venous blood will be drawn from those patients who give consent. Serum will be used to look for biomarkers predictive of response
1886327|NCT01227057|Behavioral|Cognitive Rehabilitation and Exposure Therapy for Compulsive Hoarding|The intervention includes cognitive remediation for deficits in executive functioning and exposure therapy for discarding/acquiring.
1886328|NCT01227057|Behavioral|Case Management|Case management
1886329|NCT01227096|Device|Electrical acupuncture stimulation|electroacupuncture would be administered on the bilateral P6 acupoint after anesthesia induction, but prior to surgery.
1886330|NCT01219621|Procedure|Symphony Dual Chamber Rate Responsive Device|Echocardiography ANP/BNP measurements
1886331|NCT01219647|Behavioral|exercise|subjects will participate in one of two forms of exercise
1886332|NCT01219647|Behavioral|stretching|subjects will particiopate in supervised stretching as described in arm description.
1886333|NCT01219673|Other|Placebo|1 by mouth twice a day.
1886334|NCT01219673|Drug|Armodafinil|150 mg by mouth once a day.
1886336|NCT01219673|Drug|Bupropion|100 mg by mouth twice a day.
1886337|NCT01219686|Drug|escitalopram, pindolol|escitalopram p.o., once daily, day 1-2: 10mg, days 3-42: 20mg pindolol p.o., twice daily 7.5 mg days 1-14, once daily 7.5 mg days 15-17
1886338|NCT01219686|Drug|escitalopram|escitalopram p.o., once daily. days 1-2: 10 mg, days 3-4: 20 mg, days 5-42: 30 mg
1886339|NCT01219686|Drug|escitalopram|escitalopram 20 mg, p.o., once daily. Days 1-2: 10mg, days 3-42: 20 mg
1886340|NCT01219699|Drug|BYL719|BYL719 is an oral α-specific phosphatidylinositol-3-kinase (PI3K) inhibitor.
1886341|NCT01219699|Drug|Fulvestrant|"In adult patients with advanced solid malignancies whose tumors have an alteration (mutation or amplification) of the PIK3CA gene.
Fulvestrant is an estrogen receptor antagonist, administered by monthly intramuscular injection"
1886342|NCT01219712|Procedure|Colloids, dobutamin, levosimendan|": The main aim of goal-directed therapy is to achieve a normal oxygen delivery to the tissues i.e. DO2 500-600ml/min/m2.
Hb would be optimized to > 90 g/l
SaO2 > 96%
Stroke volume index (SVI) > 30
Heart rate should ideally be < 80
Stroke volume index (SVI) > 30 is achieved by repeated volume substitution in the form of 100-200 ml colloid. If, despite bolus doses of colloids, the SVI is < 30, one would have to use ionotropic drugs e.g. dobutamine or levosimendan, in order to achieve this goal"
1886343|NCT01219725|Behavioral|Exercise training|6 months of moderate intensity exercise training 3 times per week
1886344|NCT01219738|Drug|Budesonide 360ug|A single inhaled dose of 360ug budesonide from a DPI.
1886345|NCT01219738|Drug|Budesonide 720ug|A single inhaled dose of 720ug budesonide from a DPI.
1886346|NCT01219738|Drug|Budesonide 1440ug|A single dose of 1440ug of the budesonide from DPI.
1886347|NCT01219738|Drug|Budesonide720ug 4 times|720ug of budesonide will be inhaled by the subjects 4 times, separated by 30 minutes.
1886348|NCT01219738|Drug|Placebo|A single inhaled dose of placebo from a DPI.
1886349|NCT01219751|Drug|Sunitinib|Sunitinib 50 mg D1-D28 every 6 weeks
1886350|NCT01219764|Drug|Rabeprazole, metronidazole, Clarithromycin, Amoxicillin|"Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.
Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days."
1886351|NCT01219777|Drug|carboplatin|Carboplatin AUC 5.0 or 6.0 will be administered on day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
1886352|NCT01219777|Drug|Bevacizumab|Bevacizumab 15 mg/kg administered on Day 1 during cycle 1-3. Treatment cycle consists of 21 days duration.
1886353|NCT01219777|Drug|Paclitaxel|60-80 mg/m2 administered on Day 1, 8 & 15 during cycle 1-3. Treatment cycle consists of 21 days duration.
1886354|NCT01219790|Radiation|external radiotherapy|All patients receive a total dose of 27 Gy divided into 3 fractions of 9 Gy performed at least 48 hours apart each, for a treatment to J1, J3 and J5
1886355|NCT01219790|Drug|Acide zoledronic|The administration of zoledronic acid as defined under the Authorisation on the Market.
1886356|NCT01219803|Drug|High Dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,5 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
1886357|NCT01219803|Drug|Mild dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc,3 times thick of low dose GGQL Decoction, 150ml/bag, twice in a day
1886358|NCT01219803|Drug|Low dose GGQL Decoction|The drug was a kind of decoction extracted by Chinese herbs such as Huanglian etc, 150ml/bag, twice in a day
1886359|NCT01219803|Drug|Placebo|The placebo was a kind of decoction,which including 4.5% low dose GGQL Decoction to feel bitter taste as other drugs, 150ml/bag, twice in a day
1886360|NCT01219816|Drug|Epratuzumab|Combination of chemotherapy + Epratuzumab
1886361|NCT01219816|Drug|Epratuzumab|Vincristine + Dexamethasone + Epratuzumab
1886362|NCT01219842|Procedure|INVASIVE (INV) treatment|Modern endovascular and/or open revascularisation according to the TASC II recommendations.
1886363|NCT01219842|Other|Best medical treatment (BMT)|Antiplatelet therapy, cilostazol and non-supervised exercise training. Smoking cessation support. Lipid-lowering therapy, diabetes and hypertension treated according to current national guidelines.
1886364|NCT01219855|Drug|Cohort 1 CTAP101 Capsules- 60µg|60µg of CTAP101 capsules given once daily for 42 days.
1886365|NCT01219855|Drug|Cohort 1 CTAP101 Capsules - 90µg|90µg of CTAP101 capsules given once daily for 42 days.
1886366|NCT01219855|Drug|Cohort 1 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
1886367|NCT01219855|Drug|Cohort 2 CTAP101 Capsules - 30µg|30µg of CTAP101 capsules given once daily for 42 days.
1886368|NCT01219855|Drug|Cohort 2 Matching Sugar Capsule|Placebo capsules given once daily for 42 days.
1886369|NCT01219868|Behavioral|Physician-nurse team supervision|Physician-nurse team will supervise patient's flow in the ED
1886370|NCT01219881|Drug|Desflurane|5.4 to 7.4% desflurane
1886371|NCT01219881|Drug|Sevoflurane|1.4 to 2.5% Sevoflurane
1886372|NCT01219907|Biological|HER-2/neu peptide vaccine|Given intradermally
1886373|NCT01219907|Drug|cyclophosphamide|Given IV
1886374|NCT01219907|Biological|ex vivo-expanded HER2-specific T cells|Given IV
1886375|NCT01219907|Other|laboratory biomarker analysis|Correlative studies
1886376|NCT01219907|Other|flow cytometry|Correlative studies
1886377|NCT01219907|Other|immunoenzyme technique|Correlative studies
1886378|NCT01219920|Drug|FOLFIRI|Irinotecan 180 mg/sqm on day 1 Leucovorin 100 mg/sqm on day 1 and day 2 5-fluorouracil 400 mg/sqm bolus followed by 5-fluorouracil 600 mg/sqm 22-hour continuous infusion on day 1 and day 2 Repeated every 2 weeks
1886379|NCT01219920|Drug|FOLFOXIRI|Irinotecan 165 mg/sqm on day 1 Oxaliplatin 85 mg/sqm on day 1 Leucovorin 200 mg/sqm on day 1 5-fluorouracil 3200 mg/sqm 48-hour continuous infusion starting on day 1 Repeated every 2 weeks
1886380|NCT01219933|Drug|methylprednisolone|starting dose >/= 1 mg and </= 20 mg orally daily, according to dose-reduction schedule
1886381|NCT01219933|Drug|tocilizumab [RoActemra/Actemra]|background therapy: 8 mg/kg iv every 4 weeks
1886382|NCT01219959|Drug|Dianeal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose
1886383|NCT01219959|Drug|Dianeal, Extraneal, Nutrineal|Dianeal 1.5% dextrose, 2.5% dextrose, 4.25% dextrose, Nutrineal 1.1% Amino Acids, Extraneal 7.5% Icodextrin
1886384|NCT01219985|Other|standard and respiratory-gated PET acquisitions|"After fasting for at least 6 hours, normal glucose blood level was checked and each patient received an intravenous injection of 18F-FDG (5MBq/kg). After a 60-minute uptake phase in a quiet environment, patients underwent the PET/CT examination.
Whole-body PET/CT (Ungated session) The Ungated acquisition consisted in a whole-body, free-breathing CT followed by standard multistep PET, used as routine clinical practice in the department.
Respiratory-gated PET/CT (CT-based session) The CT-based method consisted in an additional single-step, 10-minute List Mode respiratory gated PET acquisition followed by an end-expiration breath-hold CT added to the end of the clinical protocol, with continuous respiratory signal recording during these examinations."
1886385|NCT01220011|Procedure|Fetoscopic laser surgery|Fetoscopic laser surgery
1886386|NCT01220024|Drug|Bupivacaine Collagen Sponge|Drug: Bupivacaine Collagen Sponge
1886387|NCT01220024|Drug|Placebo collagen Sponge|Drug: Placebo Collagen Sponge
1886388|NCT01220037|Behavioral|Adhere to a specific standardized diet for 4 days|24 h before the start of the intervention all subjects will adhere to a standardized diet for 4 days. Young subjects are randomly allocated to either a low protein diet, regular protein diet or high protein diet group. All elderly subjects will adhere to a regular protein diet comparable to the regular protein diet of the young subjects.
1886389|NCT01220050|Drug|Paricalcitol|Paricalcitol capsules 1- 2 mcg/day/pts for 26 weeks
1886390|NCT01220050|Drug|Standard therapy|Standard therapy for hyperparathyroidism for 26 weeks
1886391|NCT01220063|Radiation|RSHF|10 Gy for 4 times (total 40 Gy)
1886392|NCT01220063|Drug|irinotécan|40 mg/m² : Day 1 and day 8
1886393|NCT01220076|Drug|tamoxifen|
1886394|NCT01220089|Behavioral|Standard maintenance|Participants will receive written materials in months 7-18
1886395|NCT01220089|Behavioral|Intensified maintenance|Participants will continue with in-person counseling visits in months 7-18
1886396|NCT01220102|Drug|0.1% adapalene/ 2.5% benzoyl peroxide|topical application, once per day
1886397|NCT01220128|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2302024A|6 or 8 injections at 3 weeks apart, injected intramuscularly in the deltoid or lateral region of the thigh.
1886398|NCT01220128|Drug|Placebo|6 or 8 doses at 3 weeks apart of sucrose/mannitol-based formulation reconstituted with an oil-in-water emulsion, injected intramuscularly in the deltoid or lateral region of the thigh.
1886399|NCT01220128|Drug|Aromatase inhibitor|This treatment consisted of any aromatase inhibitor (e.g. letrozole or exemestane), administered intravenously in Cohort A Groups daily for either 18 (if 6 doses of WT1 ASCI/placebo) or 24 weeks (if 8 doses of WT1 ASCI/placebo).
1886400|NCT01220128|Drug|5-Fluorouracil|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses at 3 weeks apart, and for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
1886401|NCT01220128|Drug|Carboplatin AUC|Administered intravenously in Cohort C Groups in 6 doses at 3 weeks apart, on the same day as WT1 ASCI/placebo administration (Day 1 of each cycle).
1886402|NCT01220128|Drug|Cyclophosphamide|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses in Cohort C Groups and 6 doses 3 weeks apart in Cohorts A Placebo, B and D Groups, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
1886403|NCT01220128|Drug|Docetaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
1886404|NCT01220128|Drug|Doxorubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 6 doses 3 weeks apart (Cohort C patients with this schedule did not receive this treatment), while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
1886405|NCT01220128|Drug|Epirubicin|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: for the 6 WT1 ASCI-dose schedule 3 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
1886406|NCT01220128|Drug|Paclitaxel|Administered intravenously in Cohorts A Placebo, B, C and D/E Groups: only in the 8 WT1 ASCI-dose schedule patients received 4 at 3 weeks apart or 12 weekly doses. For Cohorts A Placebo, B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
1886407|NCT01220128|Drug|Trastuzumab|Administered intravenously in Cohort C Groups: for the 6 WT1 ASCI-dose schedule 3 or 6 doses 3 weeks apart, while for the 8 WT1 ASCI-dose schedule 4 doses at 3 weeks apart. For Cohort B and C Groups, the administration was on the same day as the administration of WT1 ASCI/placebo (Day 1 of each cycle). For Cohort D/E Groups, the administration was on Day 14 of each cycle.
1886408|NCT01220141|Drug|activated recombinant human factor VII|Administration of room temperature stable NovoSeven® (activated recombinant human factor VII) in dosages prescribed by the treating physician according to the product labelling text approved in his country.
1886409|NCT01220154|Drug|Paclitaxel|Cycle 1 Day 1, 8, 15 IV 60-80mg mg/m2 as a 1 hour infusion. For cycle 2-6 Day 1,8,15 IV 60-80 mg/m2 as 1 hour infusion. Repeat every 3 weeks times 5 cycles.
1886410|NCT01220154|Drug|Carboplatin|Intraperitoneal Day 1 cycles 1-6 AUC
1886411|NCT01220154|Drug|Bevacizumab|Bevacizumab 15 mg/kg intravenous infusion Day 1 cycles 2-6 Optional cycles 7-22 15 mg/kg intravenous infusion Day 1 every 21 days
1992313|NCT03322306|Genetic|Genechip screening kit|10 ml blood for genetic screening by specific genetic screening kit
1886414|NCT01220180|Drug|pregabalin (Lyrica)|Pregabalin treatment can be started with a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after 1 week. The maximum dosage of 600 mg per day may be achieved after an additional week.
1886415|NCT01220180|Drug|pregabalin (Lyrica)|"Peripheral neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 3 to 7 days, and if needed, to a maximum dose of 600 mg per day after an additional 7-day interval.
Central neuropathic pain: Pregabalin treatment can be started at a dose of 150 mg per day. Based on individual subject response and tolerability, the dosage may be increased to 300 mg per day after an interval of 1 week, and if needed, to a maximum dose of 600 mg per day after an additional 1 week interval. In case that tolerability could not be shown in the targeted daily dose, dose reduction may be considered."
1886416|NCT01220180|Drug|pregabalin (Lyrica)|The recommended dose of pregabalin for fibromyalgia is 300 to 450 mg/day. Dosing should begin at 75 mg two times a day (150 mg/day) and may be increased to 150 mg two times a day (300 mg/day) within 1 week based on efficacy and tolerability. Subjects who do not experience sufficient benefit with 300 mg/day may be further increased to 225 mg two times a day (450 mg/day). Treatment with doses above 450 mg/day is not recommended.
1886417|NCT01220206|Drug|Placebo|2 placebo capsules daily
1886418|NCT01220206|Drug|One POMx capsule daily|One POMx capsule, one placebo capsule daily
1886419|NCT01220206|Drug|2 POMx Capsules|2 POMx Capsules daily
1886420|NCT01220219|Drug|Pregabalin controlled release, 82.5 mg|Two tablets of 82.5 mg controlled release (administered concurrently) once daily for four days.
1886421|NCT01220219|Drug|Pregabalin controlled release, 165 mg|165 mg controlled release tablet administered once daily for four days.
1886422|NCT01220219|Drug|Pregabalin immediate release, 75mg|75 mg immediate release capsule administered every 12 hours for four days
1886423|NCT01220232|Drug|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 5 days
1886424|NCT01220232|Drug|Abacavir/Lamivudine|Abacavir/Lamivudine 600/300 mg QD for 10 days
1886425|NCT01220232|Drug|Lersivirine|Lersivirine 750 mg QD for 10 days
1886426|NCT01220245|Procedure|Heparin-bonded ePTFE endoluminal fem-pop bypass|Heparin-bonded ePTFE endoluminal femoropopliteal bypass versus surgical femoropopliteal bypass
1886427|NCT01220245|Procedure|Surgical femoro-popliteal bypass.|Surgical femoro-popliteal bypass.
1886428|NCT01220258|Drug|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
1886429|NCT01220271|Drug|LY2157299|Administered orally
1886430|NCT01220271|Drug|Radiation|Administered as approved
1886431|NCT01220271|Drug|Temozolomide|Administered orally
1886432|NCT01220284|Drug|Satraplatin in combo with vinorelbine|"Satraplatin (gelatin capsules) p.o. on days 1 to 5 (from 60 mg/m2 up to 80 mg/m2)
Vinorelbine (soft capsules) p.o. on days 1, 8 and 15 (from 60 mg/m2 up to 80 mg/m2) The treatment is repeated every 4 weeks."
1886433|NCT01220297|Drug|Sirolimus|"Immunosuppressant administered orally to:
Adults (age 14 and older), beginning on Day -3 with 12 mg loading dose, followed by 4 mg/day.
Children < 13 years or weighing 40 kg, beginning on Day -3 with 3 mg/m² loading dose, followed by 1 mg/ m², rounded to the nearest full milligram.
Daily dosage may be adjusted to maintain a target serum trough level of 3 to 12 ng/ml. Sirolimus dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months."
1886434|NCT01220297|Drug|Mycophenolate mofetil (MMF)|Immunosuppressant given intravenously (IV) at 15 mg/kg 3 times daily, starting on Day 0 ≥ 2 hr after the completion of the HSCT infusion. Dose of MMF will be based on actual body weight, but limited to 15 kg above ideal body weight. MMF dose tapering will begin at Day 100 in the absence of GvHD, with the goal of discontinuation by 6 months.
1886435|NCT01220297|Drug|Carmustine|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -6 at the lesser of 15 mg/kg or 550 mg/m².
1886436|NCT01220297|Drug|Etoposide|For Carmustine + Etoposide + Cyclophosphamide cohort, chemotherapy administered IV on Day -4 at 60 mg/kg
1886437|NCT01220297|Drug|Cyclophosphamide (Cyclo, CY)|"Cyclophosphamide is a chemotherapy agent.
For FTBI + Cyclophosphamide cohort, administered IV on Day -3 and -2 at 60 mg/kg.
For Carmustine + Etoposide + Cyclophosphamide cohort, administered IV on Day -2 at 100 mg/kg"
1886438|NCT01220297|Drug|FTBI|For FTBI + Cyclophosphamide cohort, administered as 1320 cGy delivered in 11 120 cGy fractions over 4 days starting on Day -7.
1886439|NCT01220310|Behavioral|Online diabetes workshop observation and learning sessions|We will, by self-administered pre- and post-intervention surveys, evaluate the effectiveness of the online diabetes workshop observations and learning sessions.
1886440|NCT01220323|Device|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
1886441|NCT01220323|Device|direct current stimulation|Patients will receive sham tDCS or real tDCS in a 5-day period of treatment in a randomized, sham controlled study. The participants will be divided to 2 groups of 50 each. One group will receive 5 days period of 20 min 2mA tDCS over the lt M1 and the other will receive sham stimulation. X week later the groups will switch to the other arm
1886442|NCT01220336|Behavioral|Health coaching by medical assistants in primary care|Patients with uncontrolled diabetes, hypertension, hyperlipidemia will receive health coaching by medical assistants working with primary care providers in the Teamlet Model [Bodenheimer 2007] for 12 months.
1886443|NCT01220349|Device|Echocardiographic 2D strain analysis|Conventional transthoracic echocardiography with acquisitions for strain analysis by speckle tracking (2D strain)
1886444|NCT01220362|Drug|Bupivacain 0.125%|Bupivacain 0.125%
1886445|NCT01220362|Drug|Bupivacain 0.125%/Fentanyl 2mcg/ml|Bupivacain 0.125%/Fentanyl 2mcg/ml
1886513|NCT01220882|Radiation|Radiographic skeletal age assessment|bone age assessment from the elbow lateral radiograph
1886928|NCT01230983|Drug|leucovorin calcium|Given IV
1886446|NCT01220375|Drug|Vinorelbine, G-CSF, & Plerixafor|Patients 1-10 receive 35 mg/m2 vinorelbine i.v. on day 1, G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
1886447|NCT01220375|Drug|Vinorelbine and Plerixafor|Patients 11-20 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No G-CSF will be administered. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
1886448|NCT01220375|Drug|G-CSF and Plerixafor|Patients 21-30 receive G-CSF divided in two daily doses from day 4 until collection of stem cells, and plerixafor as an i.v. application on day 8, at 08:00 AM, in the dose of 240 microg/kg b.w. No chemotherapy with vinorelbine will be gine on day 1. Stem cell collection is initiated 4 hours later (at 12:00 PM) at day 8, if at least 20 X 103 of CD34+ cells / ml peripheral blood are detected.
1886449|NCT01220375|Drug|Vinorelbine & Plerixafor on day when CD34 count is at least 15'000 CD34+ cells/ml of peripheral blood|Patients 31-40 receive 35 mg/m2 vinorelbine i.v. on day 1 and plerixafor as an i.v. application at 08:00 AM, on the first day on which the CD34 count has risen to at least 15'000 CD34+ cells/ml of peripheral blood. Stem cell collection is initiated 4 hours later (at 12:00 PM) on this day. No G-CSF will be administered.
1886450|NCT01220388|Dietary Supplement|L-lysine|L-lysine, 4,95 G at day : 0,55 G 3 times a day, orally, during meals
1886451|NCT01220388|Dietary Supplement|placebo|placebo, 3 times a day, orally, during meals
1886452|NCT01220401|Behavioral|exposure, relaxation, and rescription therapy|veterans reporting chronic nightmares at least once per week for the past month who consent to participate will attend four consecutive weekly sessions lasting approximately two hours each. Participants will log their sleep events and associated symptoms (i.e. PTSD, depression, etc.)
1886455|NCT01220440|Drug|Methylphenidate|Methylphenidate:10mg x 3 for one week
1886456|NCT01220440|Drug|Placebo|Placebo: 1 pill x 2 for one week, 2 pills x 2 for one week.
1886457|NCT01220440|Drug|Dextroamphetamine|Dextroamphetamine: 5mg x 2 for one week, 10mg x 2 for one week
1886458|NCT01220466|Device|STAR S4IR LASIK with iDesign Aberrometer|CustomVue LASIK targeted for emmetropia
1886459|NCT01220479|Behavioral|Exercise training program|"Exercise Diabetic and Healthy groups perform a similar training program including two exercise sessions per week, of 90 minutes each, during 9 months (excluding holidays) under supervision by physical education teachers and pediatricians. Sessions comprise various weight-bearing activities: rope skipping, jumping, ball games and gymnastics.
Control groups are relatively inactive."
1886460|NCT01220492|Drug|conventional plus MSC treatment|received conventional treatment and taken i.v., once per 4 week, at a dose of 0.5*10E6 MSC/kg body for 8 weeks.
1886461|NCT01220492|Drug|conventional plus placebo treatment|received conventional treatment and taken i.v., once per 4 week, at 50 ml saline for 8 weeks.
1886462|NCT01220505|Procedure|Surgery|All subjects will have spinal surgery between the levels of T1 and Ilium using the Polaris Deformity Spinal System
1886463|NCT01220518|Drug|Infliximab|Infliximab 5mg/kg is going to be administered for both arm as a 2-hour infusion per dose.
1886464|NCT01220531|Biological|Thymus Tissue for Transplantation|Potential thymus recipient subjects are screened for eligibility. Thymus tissue (unrelated donor), donor, & donor's mother screened for safety. Thymus transplantation is done under general anesthesia in the operating room. Thymus tissue is transplanted into the subject's quadriceps. Two to three months post-transplantation, if medically stable, the subject undergoes allograft biopsy. At the time of transplantation and biopsy, skin biopsy conducted. Subjects undergo laboratory testing for approximately one year post-transplantation. At year 2 post-transplantation, subjects are contacted for data collection.
1886465|NCT01220531|Procedure|Blood Draw|Biological Mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow for testing of T cell identity in the complete DiGeorge subjects. If blood is not obtainable, then a buccal swab may be done.
1886466|NCT01220531|Drug|Rabbit anti-thymocyte globulin|Three doses of 2 mg/kg IV prior to thymus transplantation. Each dose is given over 12 hours. RATGAM is usually given on days -5, -4, and -3 prior to thymus transplantation.
1886467|NCT01220531|Drug|Cyclosporine|Csa may be given every 8 to 12 hours orally or IV before and after thymus transplantation. The Csa dose is dependent on T cell numbers and the target CSA trough levels. Csa is weaned as per protocol.
1886468|NCT01220531|Drug|Tacrolimus|If unable to tolerate cyclosporine, then FK506 is given. FK506 may be given every 8 to 12 hours orally or IV before and after thymus transplantation. FK506 dose is dependent on T cell numbers and the target FK506 trough levels. FK506 is weaned as per protocol.
1886469|NCT01220531|Drug|Methylprednisolone or Prednisolone|Steroids IV or orally may be given before and/or after thymus transplantation. Administration and dosage depends on T cell numbers. Steroids are weaned as per protocol.
1886470|NCT01220531|Drug|Basiliximab|A single dose of Basiliximab 5 mg/kg IV may be given. Administration of Basiliximab depends on T cell numbers and T cell activation. A single dose of Basiliximab may be given after the administration of rabbit anti-thymocyte globulin and before thymus transplantation. If Basiliximab is not given before thymus transplantation, and, depending on the T cell numbers and T cell activation, a single dose of Basiliximab may be given 3 to 5 days after thymus transplantation.
1886471|NCT01220531|Drug|Mycophenolate mofetil|Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after thymus transplantation. If MMF is given, the dose is 15 mg/kg/dose every 8 hours IV or orally. MMF may be stopped at 35 days or continued for up to six months after thymus transplantation.
1886472|NCT01220544|Biological|Haploidentical transplantation with donor NK cells|Pat received a myeloablative conditioning regimen with 12 Gy total-body irradiation in six single doses from day -11 to day -9, thiotepa (5mg/kg/d) on days -8 and -7, fludarabine (40mg/m2/d) from day -6 to day -3, and OKT-3 (5mg/d) from day -5 to day +3. The stem cell graft was aimed to contain > 8 x 10e6 CD34+ cells/kg and < 5 x 10e4 CD3+ cells/kg. A minimum of 1 x 10e7 CD56+CD3- NK cells/kg will be transferred on days +2.
1886473|NCT01220557|Behavioral|PRIMAS|PRIMAS is a newly developed treatment and education programme for type 1 diabetic patients. It consists of 12 lessons (duration 90 minutes each), slides for diabetes educators and patient material
1886474|NCT01220557|Behavioral|DTTP|The German DTTP (Diabetes Teaching and Treatment Programme) - The German ZI Program - is an established treatment and education programme for intensified insulin treatment consisting of 12 lessons (90 minutes duration each). Flipchart for diabetes educators and patient material.
1886475|NCT01220570|Drug|Ridaforolimus + Dalotuzumab|Ridaforolimus (MK-8669) once daily for 5 consecutive days per week and Dalotuzumab (MK-0646) intravenously (IV) once weekly for 2 weeks
1886476|NCT01220570|Drug|Ridaforolimus|Ridaforolimus 40 mg (once daily for 5 consecutive days per week) for 2 weeks, 10 mg enteric-coated tablets
1886477|NCT01220570|Drug|Dalotuzumab|Dalotuzumab, intravenously (IV) at 10 mg/kg/week for 2 weeks
1886478|NCT01220583|Drug|cisplatin|Given IV
1886479|NCT01220583|Radiation|3-dimensional conformal radiation therapy|Undergo radiotherapy
1886480|NCT01220583|Radiation|intensity-modulated radiation therapy|Undergo radiotherapy
1886481|NCT01220596|Drug|Entecavir and Pegylated interferon α-2a Sequential Treatment Group|Entecavir/Baraclude(TM), 0.5mg, oral administration, once daily, for the first 12 weeks Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, from week 4 to 52 for 48 weeks
1886482|NCT01220596|Drug|Pegylated interferon α-2a Monotreatment Group|Pegylated interferon α-2a/Pegasys(TM), 180mcg, subcutaneous injection. once a week, for the first 48 weeks
1886483|NCT01220609|Drug|Ixabepilone|Given IV
1886484|NCT01220609|Other|Laboratory Biomarker Analysis|Correlative studies
1886485|NCT01220622|Drug|Nimodipine|Administration of nimodipine 30mg tid for 6 months
1886486|NCT01220622|Drug|Placebo|Administration of placebo 30mg tid for 6 months
1886487|NCT01220635|Behavioral|Positive Thoughts and Actions Program|Students in the skills group will attend a 12-session (50 minutes each), 12-week program with 4-6 other students. The skills group will take place at school during school hours. Parents in the skill group will be asked to participate in two parent group workshops to take place at their child's school or other participating middle school (2-hours each). In addition, the skill group leader will conduct two individual family meetings with the student and parent(50 minutes each).
1886488|NCT01220635|Behavioral|Individual Support Program|Students will be individually interviewed (60-90 minutes) at school to review areas of stress and support. The health professional conducting the interview will reinforce the student's strengths, and provide connections to sources of help from caring adults at home and at school. Parents will be called following the assessment to help the family locate appropriate resources if needed (e.g., tutoring resources, school counselor).
1886489|NCT01220648|Drug|Nilotinib, interferon-alfa|
1886490|NCT01220661|Drug|Cefotetan|preoperative one dose prophylactic antibiotic (2g iv, within 1 hour before skin incision)
1886491|NCT01220674|Other|cognitive testing|computer-based cognitive assessment
1886492|NCT01220687|Drug|iNO|Immediately after birth, subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
1886493|NCT01220687|Other|Nitrogen|Subjects will be randomized to receive iNO (20ppm) or nitrogen (placebo gas) with blended oxygen (starting with 0.3). Fraction of inspired oxygen will be adjusted by 0.1 increments every 15 seconds targeting pre-ductal oxygen saturation of 70-85% in the first 2 minutes of life, and then 85-93% until the end of the study period while requiring supplemental oxygen.
1886494|NCT01220700|Other|Triclosane|Triclosane coated suture material
1886495|NCT01220700|Other|Control|Ordinary suture material
1886496|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|1.5 atm abs oxygen equivalent of 75% oxygen (balance 25% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
1886497|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|2.0 atm abs oxygen equivalent of 100% oxygen (no nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
1886498|NCT01220713|Procedure|Hyperbaric Oxygen Therapy|sham--air equivalent of 10.5% oxygen (balance 89.5% nitrogen), 40 treatments of 60 minutes each during a time period of up to ten weeks.
1886501|NCT01220739|Device|Transcranial Laser Therapy|Transcranial laser therapy is administered with the NeuroThera® Laser System (NTS) in subjects diagnosed with acute ischemic stroke. A laser system is a medical instrument that concentrates energy light on an area. Laser treatment has been used to deliver intense light energy to aid in the healing of tissues and wounds. The transcranial laser treatment procedure consists of applying the NTS laser to twenty different sites on the skull for two minutes at each site.
1886502|NCT01220752|Radiation|carbon ion boost|8 fractions carbon ion (8 x 3 GyE C12) therapy followed by 25 fractions of IMRT corresponding to a total dose of approximately 74 GyE. Treatment duration is approximately 61/2-7 weeks
1886503|NCT01220765|Device|Capnography|In the capnography arm, respiratory monitoring is performed with pulse oximetry and capnography. If the capnogram indicates sub-optimal ventilation and/or apnea, denoted as a flat line on the capnometer for ≥ 15 seconds, a respiratory rate ≤ 6, or a end-tidal CO2 > 50 mmHg, medical staff will intervene by arousing the patient, performing chinlift or jawthrust, abandon from giving additional propofol, or provision of oxygen. The nurse qualified in sedation management will assess capnography him/ herself.
1886504|NCT01220778|Behavioral|Exercise|
1886505|NCT01220791|Other|In vitro fertilization treatment for infertility|IVF treatment
1886506|NCT01220817|Drug|3 POMx capsules|3 POMx capsules daily
1886507|NCT01220817|Drug|1 POMx capsule|1 POMx capsule daily
1886508|NCT01220830|Device|Cytotron|Exposure to RFQMR with Cytotron for 28 consecutive days for one hour daily.
1886509|NCT01220843|Drug|Placebo|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks
1886510|NCT01220843|Drug|Sevelamer carbonate|dosage : 2 tablets 3 times per day corresponding taken during meals during 12 weeks ( each tablet :800mg sevelamer carbonate
1886511|NCT01220856|Drug|Reparixin|Reparixin + immunosuppression
1886512|NCT01220869|Drug|Degarelix|Degarelix was given as subcutaneous (s.c.) injections with a 240 mg starting dose followed one month later by a 80 mg maintenance dose. The maintenance dosing was repeated for an additional 5 months (total treatment period was 168 days).
1886514|NCT01220895|Biological|CMV-specific T-cells, single infusion following single positive CMV PCR result|"Intravenous ganciclovir 5mg/kg twice daily
Oral valganciclovir 900mg twice daily
Intravenous foscarnet 90 mg/kg twice daily"
1886515|NCT01220908|Device|Lung Volume Reduction Coil (LVRC)|Implantation of Lung Volume Reduction Coil(s) (LVRC)
1886516|NCT01220908|Device|Coils|Lung Volume Reduction Coil(s)
1886517|NCT01220921|Procedure|Lumbar Discectomy|Microsurgical removal of disc that is compressing a nerve root
1886518|NCT01220921|Procedure|Single-level lumbar fusion|pedicle screws with arthrodesis as directed by surgeon. Fusion can be posterolateral, interbody, or both.
1886519|NCT01220947|Drug|Copegus|Copegus 1000 mg or 1200 mg po daily for 24 weeks.
1886520|NCT01220947|Drug|Danoprevir|Danoprevir 50 mg BID
1886521|NCT01220947|Drug|Danoprevir|Danoprevir 100 mg BID
1886522|NCT01220947|Drug|Danoprevir|Danoprevir 200 mg BID
1886523|NCT01220947|Drug|Pegasys|Pegasys 180 microgram sc qw
1886524|NCT01220947|Drug|Ritonavir|Ritonavir 100 mg
1886525|NCT01220960|Other|art therapy|Art therapy sessions, 2 hours in duration, 1 session/week, 8 continuous weeks of sessions. Each group will be limited to eight women as space is limited.
1992314|NCT03322293|Drug|Aminolevulinic Acid Topical 20% Topical Solution|PDT involves the topical application of aminolevulinic acid (ALA), or one of its derivatives, as a photosensitizing agent. Subjects will receive ALA in all treatment arms (A, B, and C).
1886529|NCT01220986|Procedure|Liver biopsy|0, 30, 60, 90 min post inflow-division
1886530|NCT01220999|Drug|111In-CS-1008, CS-1008|"CS-1008 will be given in 5 dose cohorts.
Weekly doses of CS-1008 are administered for 7 consecutive weeks in Cycle 1. On each dosing day, CS-1008 will be infused intravenously over approximately 30 minutes.
Cohort No.: Pts - Dose Day 1 - Day 8 - Day15,22,29 - Day 36 - Day 43
Cohort #1: 2-5 pts - 0.2 mg/kg - 6 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg
Cohort #2: 2-5 pts - 1 mg/kg - 6 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg
Cohort #3: 2-5 pts - 2 mg/kg - 6 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg
Cohort #4: 2-5 pts - 4 mg/kg - 4 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg
Cohort #5: 2-5 pts - 6 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg - 2 mg/kg
Day 1 and Day 36 doses will be trace labelled with Indium-111 (111In-CS-1008)
Additional treatment cycles in suitable patients with stable disease or better at the day 44-50 reassessment may continue be given as weekly infusions of CS-1008 at 2 mg/kg per week. Disease reassessment is planned after every second 4-week cycle."
1886531|NCT01221025|Drug|Parecoxib|The study group will receive first dose of intravenous (IV) injection of parecoxib sodium 40 mg (in a volume of 2 ml) 60 min before the anticipated end of surgery, followed 2 ml IV injection of parecoxib 40 mg will be occurred at 12, 24 and 36 h after the first dose of parecoxib.
1886532|NCT01221051|Procedure|active management of the third stage of labor|early cord clamping, administration of oxytocin 10 IU, controlled cord traction, uterine massage after placenta expulsion
1886533|NCT01221051|Procedure|expectant management of the third stage of labor|early cord clamping, administer saline solution 2 mL i.v,wait for signs of placenta detachment, encourage the woman to push ot placenta by her own effort, uterine massage after placenta expulsion
1886534|NCT01221064|Procedure|Early drainage removal|Drainage will be removed in postoperative day 1
1886535|NCT01221064|Procedure|Late drainage removal|Drains will be kept until daily drainage is 30ml and then removed
1886536|NCT01221077|Drug|OSI-906|As of 01 March 2013, OSI-906 is no longer being administered
1886537|NCT01221077|Drug|Erlotinib|Erlotinib administered orally
1886538|NCT01221077|Drug|Placebo|As of 01 March 2013, the matching placebo is no longer being administered
1886539|NCT01221090|Behavioral|PDA|Technological assistance
1886540|NCT01221090|Behavioral|CDSMP|6-week classes
1886541|NCT01221090|Behavioral|PDA/CDSMP|Combined technology and education
1886542|NCT01221103|Drug|Combination of dexamethasone, ofatumumab and bendamustine|"Ofatumumab (liquid concentrate for infusion in glass vials) infused iv on day 1 at 300 mg during the first cycle, followed by infusions of 1000 mg on day 1 of each subsequent cycle
Bendamustine (powder dissolved in sterile water) infused iv over 30-60 minutes at the dose of 120 mg/m2 (days 2,3 every 21 days) or 120 mg/m2(days 2,3 every 28) or 90 mg/m2 (days 2,3 every 28 days) depending on toxicity
Dexamethasone administered i.v. at 40 mg (days 1,2,3,4)"
1886543|NCT01221116|Drug|levosimendan|levosimendan 0.1 microgram/kg/min) for 24 hours
1886544|NCT01221129|Other|Acclimation|11 mg Zn/day as a controlled intake level
1886545|NCT01221129|Other|Dietary zinc depletion|< 1 mg Zn/day achieved by providing a liquified diet of defined nutrient content
1886546|NCT01221129|Other|Dietary zinc repletion|15 mg Zn/day as a daily supplement plus normal habitual diet without restriction
1886547|NCT01221142|Device|"Cincinnati Sub-Zero, Blanketrol III"|
1992315|NCT03322293|Device|BLU-U blue light phototherapy illuminator|Depending on the treatment arm, subjects will either receive BLU-U exposure or not. Treatment arms A and B have BLU-U exposure and treatment arm C does not.
1886549|NCT01221194|Behavioral|Standard therapy|Standard therapy consisting of education, regular foot care and protective shoes and insoles. The standard therapy group will use the stockings they normally wear.
1886550|NCT01221194|Device|PFC Stockings|A pressure and friction reducing stocking. The novelty of the PFC Sock stems from its innovative double layer structure and technological fibre composition. These simultaneously and significantly reduce both pressure and friction in a format that is practical for everyday wear with therapeutic shoes in high-risk cases.
1886551|NCT01221207|Device|Total Contact Cast|A total contact cast (TCC) is a special cast technique that is used to take the pressure and shear stress off the ulcer to assist in the healing.
1886552|NCT01221207|Device|Instant Total Contact Cast (ITCC)|The instant total contact cast (ITCC) is a technique that uses the removable cast walker, but secures it so it cannot be removed between clinic visits and evaluation by the subject or the physician.
1886591|NCT01227421|Drug|Nitazoxanide|Tablets, 300 mg (one 300 mg tablet + 1 placebo tablet) with food twice daily for 5 days
1886929|NCT01230983|Drug|mercaptopurine|Given orally
1992316|NCT03322280|Procedure|TACE combined with iodine-125 seeds implantation|Conventional TACE with lipiodol was performed. Then Iodine-125 seed implantation into PVTT is conducted 7-10 days after TACE when liver function tests demonstrated values comparable to those obtained before TACE.
1992317|NCT03322280|Procedure|TACE|Only conventional TACE with lipiodol and chemotherapy drugs was performed.
1886553|NCT01221207|Device|Removable Cast Walker (RCW)|The removable cast walker (RCW) is a commercial product that is similar to a cast. It is secured with Velcro straps around the foot and leg and it is also effective at removing the pressure and shear stress on the foot.
1886554|NCT01221220|Behavioral|Standard Packard Pediatric Weight Control Program|Six-month, family-based, group, behavioral weight control program
1886555|NCT01221220|Behavioral|Standard Packard Pediatric Weight Control Program plus Home-based advising on environmental changes|Six-month, family-based, group, behavioral weight control program plus Home-based Environmental strategies intervention
1886556|NCT01221233|Other|Neuromuscular Electrical Stimulation plus Lumbar Stabilization Exercises|
1886557|NCT01221233|Other|Lumbar Stabilization Exercises|
1886558|NCT01221246|Drug|GM602|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or placebo in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 12 moderate and 12 severe patients will receive GM602.
1886559|NCT01221246|Drug|Placebo Comparator|First 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 320 mg/dose of GM602 or Matching Placebo (Bacteriostatic Saline) for GM602 in a 2:1 ratio, then the next 9 moderate patients (either co-treated or not co-treated) will be randomized to receive 480 mg/dose of GM602 or placebo in a 2:1 ratio. Concurrently, 18 severe patients will be randomized in the same manner. Total 6 moderate and 6 severe patients will receive placebo.
1886560|NCT01227135|Drug|hydroxychloroquine|
1886561|NCT01227135|Drug|imatinib mesylate|
1886562|NCT01227135|Genetic|cytogenetic analysis|
1886563|NCT01227135|Genetic|polymerase chain reaction|
1886564|NCT01227135|Other|laboratory biomarker analysis|
1886565|NCT01227135|Other|pharmacological study|
1886566|NCT01227148|Other|Tightly glucose control|A continuous insulin infusion (50 IU of Actrapid HM) in 49.5 ml of 0.9 percent sodium chloride with the use of a pump was started when blood glucose level exceeded 140 mg/dl to maintain a blood glucose level of between 120 and 140 mg per deciliter. The dose of insulin was adjusted according to whole-blood glucose levels, measured at one-four-hour interval in arterial blood or arterial catheter was not available. The insulin dose was adjusted by a neuro-fuzzy method
1886567|NCT01227148|Other|Conventional glucose control|a continuous insulin infusion was delivered when the blood glucose level exceeded 200 mg/dl and insulin level was then adjusted to maintain a blood glucose level of between 180 and 200 mg per deciliter.
1886568|NCT01227174|Drug|Propofol|Procedural sedation will be achieved using propofol
1886570|NCT01227200|Drug|dypiron, tramadol|dypiron 4 ML, tramadol 50 mg flashtab
1886571|NCT01227226|Drug|Artificial tears|Instill one drop of artificial tears
1886572|NCT01227239|Drug|S-1|40mg/m2 orally twice a day (BID) for 5 days a week at 1st week, 2nd week, 4th week and 5th week.
1886573|NCT01227239|Drug|Oxaliplatin|40-60mg/m2/week intravenously on day 1, 8, 22 and 29.
1886574|NCT01227239|Radiation|Radiation|Total dose is 50.4Gy (1.8Gy X 28 fractions)
1886575|NCT01227252|Drug|LY2886721|5 mg up to 35 mg, administered orally as capsules, daily for 14 days
1886576|NCT01227252|Drug|Placebo|Administered orally as capsules, daily for 14 days
1886577|NCT01227265|Drug|Preladenant|Preladenant 2 mg or 5 mg oral tablet taken twice daily
1886578|NCT01227265|Drug|Placebo|Preladenant-matching placebo oral tablet taken twice daily
1886579|NCT01227278|Other|Placebo|Placebo matched to benralizumab (MEDI-563) injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
1886580|NCT01227278|Biological|Benralizumab 100 mg|Benralizumab (MEDI-563) 100 mg injection subcutaneously every 4 weeks for the first 3 doses and then every 8 weeks for the next 5 doses (Day 1, 29, 57, 113, 169, 225, 281 and 337).
1886581|NCT01227291|Drug|SYL040012|SYL040012 ophthalmic drops, daily single dose administration
1886582|NCT01227304|Device|PiCCO-parameter-guided volume challenge|Infusion of 7ml/kg crystalloid over 30 minutes, Performing transpulmonary thermodilutions after 0min, 15min and 30min. Recording of pulse contour cardiac index, heart rate and mean arterial pressure after 5, 10, 15, 20, 25 and 30min. Catecholamines are kept stable over the 30min period.
1886583|NCT01227317|Other|Prognostic value of Biomarkers|Mr pro ADM, Mr pro ANP, PCT, Copeptin and pro endothelin value to stratify the risk in SOB patients
1886584|NCT01227330|Behavioral|Medication adherence intervention|12-week behavioral feedback intervention to improve adherence to statin medication
1886585|NCT01227330|Behavioral|Attention-control|Health education visits that are unrelated to medications or cholesterol, provided on the same visit schedule as the intervention group
1886586|NCT01227356|Drug|imatinib and pegylated interferon|imatinib 400 mg p.o. daily pegylated interferon 50 ug s.c. weekly
1886587|NCT01227369|Other|OPSAT-Q|A linguistically validated Korean version of OPSAT-Q
1886588|NCT01227382|Procedure|ERCP with cholangiopancreatoscopy|Endoscopic Retrograde Cholangiopancreatography (ERCP)with cholangiopancreatoscopy and sampling of stricture with SpyBite biopsy forceps, cytology brush and RJ3biopsy forceps
1886589|NCT01227395|Drug|Azithromycin|"Inhibition of onset: Perorally administer 1200mg of azithromycin (potency) once a week to adults.
Treatment: Perorally administer 600mg of azithromycin (potency) once a day to adults."
1886590|NCT01227408|Drug|doxorubicin, paclitaxel poliglumex, capecitabine, cyclophosphamide, methotrexate|doxorubicin 20mg/m2 weekly x 12 wks, cyclophosphamide 50 mg PO qd x 12 wks, methotrexate 2.5 mg PO bid d1,2 wkly x 12. One week later paclitaxel poliglumex 135mg/m2 IV every 3 wks plus capecitabine 825 mg/m2 PO bid x 14days x 4 cycles
1886592|NCT01227421|Drug|Nitazoxanide|Tablets, 600 mg (two 300 mg tablets) with food twice daily for 5 days
1886593|NCT01227421|Drug|Placebo|Tablets, (2 tablets) twice daily with food for 5 days
1886594|NCT01227434|Drug|PD 0332991 (pre-surgery)|PD 0332991 for 7 days prior to an indicated, intended surgical resection for progression
1886595|NCT01227434|Drug|PD 0332991|PD 0332991 daily for 21 consecutive days followed by a 7 day break off therapy, repeating cycles
1886596|NCT01227434|Procedure|Resection as clinical care|Indicated, intended, surgical resection as clinical care
1886597|NCT01227460|Drug|Sitagliptin|pill/tablet form of 100mg each. will take one tablet a day throughout study
1886598|NCT01227460|Drug|Sugar Pill|100mg tablet once a day
1886599|NCT01228500|Device|PriMatrix|Dermal Repair Scaffold
1886600|NCT01228513|Drug|ZK245186|Daily topical application
1886601|NCT01228513|Drug|Placebo (vehicle without active ingredient)|Daily topical application
1886602|NCT01228526|Device|PriMatrix|
1886603|NCT01228539|Behavioral|TARGET (Trauma Affect Regulation)|TARGET teaches a skill sequence for affect regulation and social/interpersonal information processing.
1886604|NCT01228539|Behavioral|Prolonged Exposure|Cognitive behavior therapy with trauma memory exposure
1886605|NCT01228552|Drug|Topical, intra-oral ketoprofen gel|Ketoprofen gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
1886606|NCT01228552|Other|Placebo gel|Placebo gel will be applied, using a cotton applicator, to the gingival mucosa at the onset of migraine. A second application may be used at 20 minutes, if necessary.
1886607|NCT01228565|Other|Radiotherapy + Erbitux® + placebo|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; Placebo local application, once a day, every day during the radiotherapy
1886608|NCT01228565|Other|Radiotherapy+Erbitux+OTD70DERM|3D radiotherapy 70 Gy / 7 weeks (no IRMT); Erbitux once a week, 1 week before radiotherapy and during radiotherapy ; OTD70DERM local application, once a day, every day during the radiotherapy
1886609|NCT01228578|Dietary Supplement|Multivitamin supplements B,C and E|One daily recommended dietary allowance of multivitamins B,C and E or placebo taken daily for 18 months
1886610|NCT01228591|Device|Acuvue Advance Plus|Silicone hydrogel contact lens.
1886611|NCT01228591|Device|Acuvue Advance|Silicone hydrogel contact lens
1886612|NCT01228604|Drug|methylphenidate (Ritalin®)|The scheme provides for initial dose of 0.3 mg / kg / day, with an average dose of 1mg/kg/day. The increases will be made considering the presentation of the drug (10mg), which allows increments of 5mg or 10mg, which will be made in clinical review, as the clinical symptoms, including increasing the dose until there is more room for improvement or there is presence of significant adverse effects, all the patients with indication of treatment will be assessed before the use of medication, 15 days, 30 days, 3 and 6 months after the start,
1886613|NCT01228617|Drug|Nicotine|Following a 12-hour nicotine abstinence period, subjects receive a single 2 mg dose of their assigned nicotine replacement therapy in the morning of the treatment visit day
1886614|NCT01228617|Drug|Nicotine Gum|Following a 12-hour nicotine abstinence period, subjects will be instructed to chew the gum once every 2 seconds, for 30 minutes.
1886615|NCT01228630|Drug|Cloratadd-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
1886616|NCT01228630|Drug|Allegra-D|The patients receive one pill of treatment every 12 hours ( to get up and going to bed), of a glass of water.
1886617|NCT01228643|Biological|Pancreatic enzimes|- Norzyme ® (product testing) composition: 20.000USP lipase, 65.000USP of 65.000USP amylase and protease.
1886618|NCT01228643|Device|Creon ®|- Creon ® (reference product) composition: 25.000UI lipase, amylase 74.700UI 62.500UI and protease
1886619|NCT01228656|Drug|mometasone furoate + salicylic acid|Dermatologic ointment applied once a day.
1886620|NCT01228656|Drug|Mometasone furoate|Dermatologic ointment applied once a day
1886621|NCT01228669|Drug|NNC 0172-0000-2021|Single dose injected i.v. (into a vein). Each treatment dose is assessed for safety before escalating to next dose
1886622|NCT01228669|Drug|NNC 0172-0000-2021|Single dose injected s.c. (under the skin). Each treatment dose is assessed for safety before escalating to next dose.
1886623|NCT01228669|Drug|placebo|Single dose injected i.v. and s.c. Each treatment dose is assessed for safety before escalating to next dose.
1886624|NCT01228682|Drug|Tolvaptan|Samsca 15mg tablet; Samsca 30mg tablet Administration as per Samsca SmPC and medical judgement of treating physician.
1886625|NCT01228695|Other|sleep study|The polysomnography (PSG) (Alice 3 System; Healthdyne, Atlanta, GA) consisted of continuous polygraphic recording from surface leads for electroencephalography, electrooculography, electromyography, electrocardiography, thermistors for nasal and oral airflow, thoracic and abdominal impedance belts for respiratory effort, pulse oximeter for oxyhemoglobin level, tracheal microphone for snoring, and sensors for leg and sleep position
1886626|NCT01228708|Other|Active implementation of a guideline for chronic disease|"Smoking cessation courses Remuneration to GPs for the planned follow-up and joint home visits Action card and sputum colour advice Webpage on How to live with COPD and the support the health system can provide Database with patients with COPD Feed-back from health centre to GPs, when patients have finished courses Fax from hospital to GPs, when patients with COPD is discharged Routines to recall patients for follow-ups Team audit, evaluate and adjust the strategies every 3rd month Joint home visit with GP and community nurse when a patient with COPD is discharged to plan future care Practice staff do part of follow-ups and monitoring Practice supervision with consultant in lung diseases Podcast with advice from specialists Guideline for COPD"
1886627|NCT01228721|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
1990683|NCT01877915|Drug|Rivaroxaban|Each participant, randomly allocated to the rivaroxaban arm, will receive one 2.5 mg tablet of rivaroxaban orally (by mouth) twice daily (once in the morning and once in the evening at approximately the same time each day) until the global treatment end date (GTED) (defined as the date when 1200 primary efficacy outcome events have occurred). Rivaroxaban will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
1992318|NCT03322267|Drug|Pembrolizumab|Cisplatin (30 mg/m2, QW, 2 cycles) and radiotherapy (18 Gy/10 fractions) as adjuvant chemoradiotherapy, followed by pembrolizumab (200mg, Q3W, 18 cycles)
1886632|NCT01228747|Drug|Levetiracetam|Oral dose at flexible increase doses: 1000 mg/day or 2000 mg/day or 3000 mg/day, twice daily, 28 weeks
1886633|NCT01228747|Drug|Placebo|Matching oral placebo tablets twice daily for 28 weeks
1886634|NCT01228760|Drug|ASG-5ME|IV
1886635|NCT01228773|Behavioral|Tailored web-based care program (Health Navigation®)|When intervention group participate in the Web-based care program (Health Navigation®), they can receive various information which is related with the CRF. Web-based fatigue care program consists of 6 strategic areas (energy conservation, nutrition, exercise, sleep disturbance, pain, and distress); three areas (pain, exercise, sleep disturbance) are based on the transtheoretical model (TTM), and others (energy conservation, distress, nutrition) are based on psycho-education method or cognitive behavioral therapy. Cancer survivors who participate in the Web-based care program (Health Navigation®) will be received tailored EMS/SMS message that notify participants of the next program's news and the last program's issue.
1886636|NCT01228799|Procedure|trabeculectomy|trabeculectomy with mitomycin C 0.2mg/ml
1886637|NCT01228799|Procedure|Canaloplasty|Canaloplasty with implant of suture
1886638|NCT01228838|Drug|NGX-1998|Capsaicin topical liquid to be applied for 5 minutes one time only.
1886639|NCT01228838|Drug|Placebo Liquid|Placebo topical liquid to be applied for 5 minutes one time only.
1886640|NCT01228851|Other|Balance Training|Group balance training sessions three times a week for 8 weeks
1886641|NCT01228864|Procedure|quality of life|survey
1886642|NCT01228864|Procedure|Quality of life|
1886644|NCT01228890|Behavioral|CATCH-IT|"The CATCH-IT 2-R intervention has a motivational (3 PCP motivational interviews at time 0, 1.5 months and 12 months and 3 coaching phone calls at 2 and 4 weeks and 18 months) and an Internet component (with separate adolescent [14 modules] and parent [5 modules] programs). This revised and expanded intervention will include a comprehensive approach to reducing modifiable risk factors and enhancing resiliency factors associated with increased or decreased risk of depression, respectively, proposed by Spence and Reinecke.148 The revised CATCH-IT Tracker will monitor time in study and deploy elements of the intervention based on time since enrollment, including computer and human elements (e.g. calls, doctor visits)."
1886645|NCT01228890|Behavioral|AMPE|The AMPE components are similar to those employed in previous primary care based quality improvement/Chronic Care Model Interventions (patient education [psycho-education described below], provider training [described in Case Finding and Recruitment], active monitoring and referral [case management, discussed under assessments], physician and nurse education and routine contact with PCP [study design rationale]). This Internet site will focus on assisting parents and adolescents in early identification of need for treatment and will also target stigma and negative attitudes toward treatment of mental disorders we have previously identified as barriers to seeking and adhering to treatment.
1886646|NCT01228903|Drug|Allopurinol|Xanthine oxidase inhibitor- effective at lowering uric acid levels.
1886647|NCT01228903|Other|Placebo|Placebo tablets with no active ingredient
1886648|NCT01228916|Behavioral|Tobacco Cessation and Secondhand Smoke Reduction|Awareness raising and resources for cessation and secondhand smoke reduction
1886649|NCT01228929|Other|Environmental Chamber Condition Change Intervention|For condition change studies, the chamber will operate between 65 and 85 degrees F and 25% and 80% RH with air flow turned off or set to a maximum of 3-4 m/s. For this type of study, we will have the subject acclimate to a set of environmental conditions (approximately 20-30 minutes) and take a set of measurements. Then we will change the conditions (rate of change is 3 degrees F/hour and 3% RH/hour), have the subject acclimate to these conditions (later on the same day or on another day) and take another set of measurements. The expected study length is approximately two hours for a single visit. Subjects may be asked to return for additional visits to accommodate a variety of chamber conditions (temp, humidity, airflow) within the prescribed limits above.
1886650|NCT01228942|Device|COXEN analysis for chemotherapy prediction|Using the affymetrix genechip along with the COXEN algorithm the subject's treatment will be determined
1886651|NCT01228994|Drug|Baclofen 30 mg/day|Baclofen 30 mg/day for 8 weeks with 2 week induction and 2 week decrease
1886652|NCT01228994|Drug|placebo pill|placebo pill
1886653|NCT01228994|Drug|Baclofen 60 mg/day|baclofen 60 mg/day for 8 weeks with 2 week induction and 2 week decrease
1886654|NCT01229007|Biological|Biostate|1 dose of 50 IU FVIII/kg body weight of Biostate administered intravenously on Day 1 in the PK component, followed by the Efficacy component for continuation of Biostate therapy, as required for a minimum of 50 exposure days.
1886655|NCT01229020|Other|Observational study - no intervention|Observational study - no intervention. Patients underwent VRI recordings and routine V/Q scan.
1886656|NCT01229033|Procedure|Ablation|Ablation of atrial tachycardia
1886657|NCT01229033|Procedure|Cardioversion|Cardioversion of atrial tachycardia
1886658|NCT01229046|Drug|Ticarcillin-clavulanic acid|5 doses of IV ticarcillin-clavulanate infants < 14 days PNA will receive 75 mg/kg Q12 infants ≥ 14 days PNA will receive 75 mg/kg Q8
1886659|NCT01229059|Dietary Supplement|Lipovenös lipid infusion|Lipid enriched infusions will be applied for 2-6 hours.
1886660|NCT01229072|Biological|Heparin sodic|Heparin sodic 150UI/kg
1886661|NCT01229072|Biological|heparin liquemine|Heparin sodic 150UI/kg
1886662|NCT01229085|Drug|memotasone + salicylic acid|mometasone 0,1% + salicylic acid 5%.
1886663|NCT01229098|Drug|LEO 80185 (Xamiol® gel/Taclonex® Scalp topical suspension)|LEO 80185 (Taclonex® Scalp topical suspension/Xamiol® gel) Topical suspension applied once daily for up to 8 weeks
1886664|NCT01229111|Drug|cediranib maleate|Given PO
1886665|NCT01229111|Drug|oxaliplatin|Given IV
1886666|NCT01229111|Drug|leucovorin calcium|Given IV
1886667|NCT01229111|Drug|fluorouracil|Given IV
1886668|NCT01229124|Genetic|RNA analysis|
1886669|NCT01229124|Genetic|nucleic acid sequencing|
1886670|NCT01229124|Genetic|reverse transcriptase-polymerase chain reaction|
1886671|NCT01229124|Other|laboratory biomarker analysis|
1886672|NCT01229137|Device|SRD-1 conversion|
1886673|NCT01229150|Drug|AZD6244|For KRAS mutant patients randomized to the single agent arm, AZD6244 75 mg bid (twice a day).
1886674|NCT01229150|Drug|Erlotinib|For Wild-Type KRAS patients randomized to the single agent arm, Erlotinib 150 mg qd (every day)
1886675|NCT01229150|Drug|AZD6244 + Erlotinib|For KRAS mutant patients and Wild-Type KRAS patients randomized to the combination arm (arms are stratified based on KRAS mutational status), AZD6244 150 mg qd (every day) + erl (erlotinib) mg qd.
1886676|NCT01229163|Device|Automated Contingency Management (ACM) software|
1886677|NCT01229176|Biological|Vi-CRM197 vaccine|
1886678|NCT01229176|Biological|Vi Polysaccharide (PS) vaccine|
1886679|NCT01229176|Biological|Pneumococcal conjugate vaccine|
1886680|NCT01229189|Dietary Supplement|Vitamin D|Maternal dose of 4000 IU daily for 20 weeks Neonatal dose of 400 IU daily for 24 weeks
1886681|NCT01229189|Dietary Supplement|Placebo|Placebo will be supplemented to pregnant women and their neonates in the same pattern as in intervention group.
1886682|NCT01229202|Drug|Bevacizumab|single bevacizumab subtenon injection of 1.25 mg. at end of trabeculectomy surgery
1886683|NCT01229215|Drug|FCFD4514S|Repeating intravitreal injection
1886684|NCT01229215|Drug|sham|Repeating sham injection
1886685|NCT01229228|Drug|Naproxen Test|200-mg single dose
1886686|NCT01229228|Drug|Naproxen Test|400-mg (2 x 200-mg)
1886687|NCT01229228|Drug|Naprosyn|single dose
1886688|NCT01229228|Drug|Naprosyn|single dose
1886689|NCT01229228|Drug|Placebo|single dose
1886690|NCT01229241|Drug|local anesthetic|"postoperative 48h epidural continuous infusion,
ropivacaine 0,2% (250ml)+ sufentanil 0,75mcg/ml
levobupivacaine 0,125% (250ml)+ sufentanil 0,75mcg/ml"
1886691|NCT01229254|Drug|Amiodarone|Patients on Amiodarone
1886692|NCT01229254|Drug|Betrixaban 60 mg|Betrixaban 60 mg once a day with food on Day 0 through Day 25
1886693|NCT01229254|Drug|Betrixaban 90 mg|Betrixaban 90 mg once a day with food on Day 0 through Day 25
1886694|NCT01229254|Drug|Betrixaban 30 mg|Betrixaban 30 mg once a day with food on Day 0 through Day 25 with concomitant amiodarone treatment.
1886695|NCT01229267|Biological|V212|0.5-mL subcutaneous injection administered ~30days (60 to 5 days) prior to HCT. Doses 2 through 4 will be administered 30, 60 and 90 days post-HCT.
1886696|NCT01229267|Biological|Matching placebo|0.5-mL subcutaneous injection administered ~30days (60 to 5 days) prior to HCT. Doses 2 through 4 will be administered 30, 60 and 90 days post-HCT.
1886699|NCT01229293|Procedure|Articular Surface Replacement (ASR)|Articular surface replacement, DePuy, posterolateral approach used
1886700|NCT01229293|Procedure|Standard Total Hip Arthroplasty (THA)|Device: Biomet 28mm
1886701|NCT01229306|Procedure|Ablation|Ablation of atrial fibrillation
1886702|NCT01229319|Drug|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
1886703|NCT01229319|Drug|Cryotherapy alone to Left arm plus cryotherapy + imiquimod to Right arm|Cryotherapy alone to Left arm plus cryotherapy + imiquimod 3.75% daily x 2 weeks on and 2 weeks off and 2 weeks on to Right arm
1886704|NCT01229332|Drug|Saline|Continuous 24 h administration
1886705|NCT01229332|Drug|Carbidopa|Continuous 24 h administration
1886706|NCT01229345|Drug|Breakfast & exercise|1859 kJ breakfast vs fast, exercise at 60% maximum aerobic capacity to expend 1859 kJ.
1886707|NCT01229358|Other|Surgical dressing|Acticoat Absorbant™ vs standard dry gauze as the immediate post operative dressing
1886708|NCT01229371|Biological|Inflexal V influenza vaccine (CSL HA Antigen) 2010|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using CSL HA Antigen) 2010/2011, with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
1886709|NCT01229371|Biological|Inflexal V influenza vaccine (AdImmune HA antigen) 2010/2011|Inflexal V influenza vaccine (surface antigen, inactivated, virosome, using AdImmune HA antigen) 2010/2011 with intramuscular administration, containing per 0.5 mL dose: 15 μg HA antigen of A/California/7/2009 (H1N1)-like virus; 15 μg HA antigen of A/Perth/16/2009 (H3N2)-like virus; 15 μg HA antigen of B/Brisbane/60/2008-like virus
1886710|NCT01229384|Device|Positive Airway Pressure nebulization|Using a device approved in pediatrics to deliver nebulized treatments of albuterol and racemic epinephrine with positive pressure
1886711|NCT01229384|Device|Standard passive nebulization of respiratory medications|Patients will receive standard passively inhaled nebulized albuterol and racemic epinephrine.
1886712|NCT01229397|Biological|Inflexal V|vaccination with Inflexal V 0.25 mL administered twice, 4 weeks apart
1886713|NCT01229397|Biological|Inflexal V|Inflexal V 0.5 mL administrated once only
1886714|NCT01229410|Drug|400 µg Brimonidine Tartrate Implant|400 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
1886715|NCT01229410|Drug|200 µg Brimonidine Tartrate Implant|200 µg brimonidine tartrate implant in the study eye on Day 1 (2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy).
1886716|NCT01229423|Drug|bimatoprost 0.03%|One drop of bimatoprost 0.03% (LATISSE®) applied evenly to each upper eyelid in the evening. Treatment is once daily for up to 40 weeks.
1886717|NCT01229436|Drug|Xiapex|Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol
1886809|NCT01230073|Device|Follow-up by Home-Monitoring|Follow-up by Home-Monitoring
1886723|NCT01229462|Drug|brimonidine tartrate/timolol fixed combination ophthalmic solution|One drop of brimonidine tartrate/timolol fixed combination ophthalmic solution (Combigan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
1886724|NCT01229462|Drug|brimonidine tartrate ophthalmic solution|One drop of brimonidine tartrate ophthalmic solution (Alphagan®) administered to the affected eye(s) twice daily (morning and evening) for four weeks.
1886725|NCT01229462|Drug|timolol ophthalmic solution|One drop of timolol ophthalmic solution administered to the affected eye(s) twice daily (morning and evening) for four weeks.
1886726|NCT01229462|Other|fixed combination vehicle|Fixed combination vehicle administered to the affected eye(s) twice daily (morning and evening) for four weeks.
1886727|NCT01229475|Procedure|Ablation with stepwise approach|Stepwise approach for repeat AF ablation
1886728|NCT01229475|Procedure|Linear ablation|Linear ablation for AF ablation
1886729|NCT01229488|Device|Intervention|Project was withdrawn before starting. There were no interventions
1886730|NCT01229514|Other|fMRI|fMRI and a response inhibition task to examine activation patterns in the prefrontal cortex and caudate nucleus
1886731|NCT01229527|Drug|Remifentanil|Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.
1886732|NCT01229527|Drug|Remifentanil|Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.
1886733|NCT01229527|Drug|Meperidine|Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
1886734|NCT01229540|Genetic|genetic analyzer|
1886735|NCT01229553|Drug|decolonization|The decolonization protocol for the patients will consist of two-week course of cephalexin (100 mg/kg/day divided TID) or oral T/S (20 mg/kg/day divided BID), HBW every other day for 2 weeks, and mupirocin ointment into both nares BID for 2 weeks.
1886736|NCT01229566|Drug|AKR-963|3600mg/day in capsules of AKR-963, Placebo, or Active Comparator
1886737|NCT01229579|Drug|Zinc Sulfate|2.5 ml Zinc supplement syrup daily containing 10 mg of elemental zinc from day 14 to 18 weeks of age.
1886738|NCT01229579|Drug|Placebo|2.5 ml syrup daily with no elemental zinc from day 14 to 18 weeks of age.
1886739|NCT01229592|Drug|Ethanol|Every three day lock using Ethanol(70%)in all the lumen(1ml/per lumen) of the Catheter
1886740|NCT01229592|Drug|Heparine|Every three day lock using Heparin(Fibrilin TM) 3ml in all the lumen of the Catheter
1886741|NCT01229605|Drug|Cyclophosphamide and docetaxel|Cyclophosphamide and docetaxel every 3 weeks as neoadjuvant chemotherapy
1886742|NCT01229618|Drug|Hyperpolarized Pyruvate (13C) injection|single hyperpolarized pyruvate IV (intravenous) injection followed by MR imaging scans (MRI and MRSI)
1886743|NCT01229631|Dietary Supplement|Juice plus+|Subjects in active group will be supplemented with Juice plus+ capsules (3 in the morning and 3 in the evening, for 3 months)
1886744|NCT01229631|Dietary Supplement|Placebo non active capsules|Subjects will take non-active placebo capsules (3 in the morning and 3 in the evening, for 3 months)
1886745|NCT01229644|Drug|Crenolanib (CP-868,596)|Highly potent inhibitor of both PDGFR receptors alpha and beta
1886746|NCT01229670|Other|exercise|"1.exercise(Aerobic interval training (AIT)): training with 90% of VO2 peak and 40% of VO2 peak cycle for total 30 minutes exercise time
2.exercise(moderate continuous training (MCT)):training with 60% of VO2peak for 30 min"
1886747|NCT01229683|Procedure|Interscalene Nerve Block|Patients undergoing shoulder surgery will be given an Interscalene Nerve Block. The patients' strength and sensation in their hand and forearm will be tested to determine if the nerve block is affectively delivering anesthetic to the nerves that serve these areas.
1886748|NCT01229696|Procedure|Catheter Placed At Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed at the bifurcaton of the sciatic nerve and outcome measures will be tested.
1886749|NCT01229696|Procedure|Catheter Placed 5cm Above Bifurcation|Patients randomized to this group will receive a sciatic nerve block placed 5cm above the bifurcaton of the sciatic nerve and outcome measures will be tested.
1886750|NCT01229709|Behavioral|Mindfulness Based Tinnitus Reduction|The Mindfulness Based Tinnitus Reduction (MBTR) program will be held for two-and-a-half hours one evening per week over 8 consecutive weeks. Participants will also complete a day-long Sunday retreat between the 6th and 7th sessions. Each participant will take part in a 30-minute private interview with the course instructor prior to beginning the program.
1886751|NCT01229722|Device|Beeper|Beepers are handheld portable devices which can be attached to a belt. At regular intervals corresponding to the participant's preferred reminder time, they buzz for a few minutes or until the participant presses a button to stop the buzzing.
1886752|NCT01229722|Device|ARemind|ARemind will personalize reminder messages based on adherence levels and facilitate patient phone calls with social workers/adherence counselors when appropriate. It will also consist of a text-messaging or interactive voice response (IVR) or phone-based pill count remote adherence assessment module.
1886753|NCT01229735|Drug|Levetiracetam|250 mg and 500 mg levetiracetam tablet 1000 mg/day (500 mg bid) levetiracetam (maximum to 3000 mg/day) Duration: maximum 52 weeks
1886754|NCT01229735|Drug|Topiramate|25 mg and 100 mg topiramate tablet 100 mg/day(50 mg bid) topiramate (maximum to 400 mg/day) Duration: maximum 52 weeks
1886755|NCT01229748|Behavioral|Standard Care|Clients attend two 90-minute group sessions per week.Treatment lasts for three months.
1886756|NCT01229748|Behavioral|Multidimensional Family Therapy|Multidimensional Family Therapy is an outpatient family-based treatment for troubled youth (Liddle, 2002). Treatment duration is 3 months, sessions last 60-90 minutes, with an average of 2 sessions per week and additional extrafamilial work and phone contacts as needed.
1886757|NCT01229748|Behavioral|Family Motivational Interviewing Intervention|Youth and parents receive 2 FMII sessions in their homes within 72 hours of the ER incident, and youth will be linked with group treatment lasting 3 months.
1886758|NCT01229761|Drug|cotrimoxazole prophylaxis|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
1886807|NCT01230060|Device|enVista|One-piece hydrophobic acrylic intraocular lens (IOL) implanted following cataract extraction surgery. Patients to be followed for 120-180 days following surgery.
1886759|NCT01229761|Drug|cotrimoxazole placebo|100mg/20mg per day (or 2.5 mL of syrup from a 200mg/40mg per 5mL suspension) from 1-6 months, followed by 200mg/40mg per day (or 5 mL of syrup from a 200mg/40mg per 5 mL suspension) from 6 to 12 months
1886760|NCT01229761|Behavioral|exclusive breastfeeding until 6 months of age|Breastfeeding for 6 months, followed by formula feeding for 6 month. Breastfeeding infants will be prophylaxed with maternal highly active antiretroviral therapy (HAART) (if available) or with infant nevirapine.
1886761|NCT01229761|Behavioral|breastfeeding for 12 months|Breastfeeding infants will be prophylaxed with maternal HAART (if available) or with infant nevirapine.
1886762|NCT01229774|Drug|Etoricoxib|Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
1886763|NCT01229774|Drug|Diclofenac|Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
1886764|NCT01229800|Drug|Polyethylene glycol|Group 1 (split-dose PEG regimen; Colyte, Taejoon Pharmaceuticals, Seoul, Korea; 236g PEG, 22.74g Na2SO4, 6.74g NaHCO3, 5.86g NaCl, and 2.97g KCl) ingested 2 liters of PEG at 6 PM on the day before the procedure and the remaining 2 liters in the early morning at least 2 hours prior to the procedure. Patients were instructed to take PEG 250 ml every ten minutes. Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure.
1886765|NCT01229800|Drug|Sodium phosphate(NaP) solution|Group 2 (NaP regimen; Solin Oral, Korea Pharma., Seoul, Korea; 48g NaH2PO4 monosodium phosphate, 18g Na2HPO4 disodium phosphate) ingested 45ml NaP solution at 6 PM on the day before the procedure and remaining 45ml of NaP solution, separated temporally by minimum of 10 to 12 hours, at least 2 hours prior to the colonoscopy on the day of the procedure. Patients taking NaP solution were instructed to drink a minimum 1L of clear liquids during the evening on the day before the procedure and were encouraged to consume additional clear liquids.
1886766|NCT01229813|Drug|bevacizumab, erlotinib|bevacizumab 7.5 mg/kg body weight every third week, erlotinib 150 mg daily
1886767|NCT01229813|Drug|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week
1886768|NCT01229813|Drug|bevacizumab|bevacizumab 7.5 mg/kg body weight every third week.
1886769|NCT01229813|Drug|low dose capecitabine|capecitabine 500 mg twice daily
1886770|NCT01229826|Radiation|MR Elastography|MRE is performed at the end of the examination after the standard MRI protocol. A test vibration is first applied on the patient to familiarize the patient with the vibration. The MRE sequence is performed with either a body coil or a pelvic-array coil. The total acquisition time is split into four periods of suspended respiration of 16 seconds for acquisition of wave images at four phase offsets. To obtain a consistent position of the fibroid for each phase offset, patients are asked to quietly breath and remain still.
1886771|NCT01229839|Other|Embolization|embolization with lipiodol and polyvinyl alcohol particles (PVA)
1886772|NCT01229839|Other|Infusion of anticancer agent|infusion with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ) desolved in water
1886773|NCT01229839|Other|Infusion of mixture of anticancer agent and lipiodol|infusion of mixture of lipiodol and chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water
1886774|NCT01229852|Device|DSF-rTMS|Effective Transcranial Magnetic Stimulation
1886775|NCT01229865|Drug|VB-111|
1886776|NCT01229878|Dietary Supplement|Cholecalciferol (Vitamin D)|50,000 units of cholecalciferol or a placebo pill administered once a week for 6 months
1886777|NCT01229891|Dietary Supplement|plain yogurt drink|daily intake of two bottle of plain yogurt drink
1886778|NCT01229891|Dietary Supplement|vitamin D fortified yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D/250 mL
1886779|NCT01229891|Dietary Supplement|vitamin D-calcium yogurt drink|daily intake of two bottle of yogurt drink fortified with 500 IU vitamin D and 250 mg calcium/250 ml package
1886780|NCT01229904|Behavioral|music therapy with guitar lessons|The treatment is a 6 week music therapy intervention. Subjects receive 1 hour individual lesson and a 1 hour group session weekly for 6 weeks. they are given a guitar following completion of the study
1886781|NCT01229917|Other|Fruit juice with Lactobacillus rhamnosus GG, version 1|
1886782|NCT01229917|Other|Fruit juice with Lactobacillus rhamnosus GG, version 2|
1886783|NCT01229917|Other|Standard fruit juice|
1886784|NCT01229930|Drug|carboplatin|
1886785|NCT01229930|Drug|cediranib maleate|
1886786|NCT01229930|Drug|paclitaxel|
1886787|NCT01229930|Other|laboratory biomarker analysis|
1886788|NCT01229930|Other|pharmacological study|
1886789|NCT01229930|Procedure|quality-of-life assessment|
1886790|NCT01229943|Biological|Bevacizumab|Given IV
1886791|NCT01229943|Drug|Everolimus|Given PO
1886792|NCT01229943|Drug|Octreotide Acetate|Given IM
1886793|NCT01229956|Genetic|DNA methylation analysis|
1886794|NCT01229956|Genetic|gene expression analysis|
1886795|NCT01229956|Genetic|microarray analysis|
1886796|NCT01229956|Genetic|reverse transcriptase-polymerase chain reaction|
1886797|NCT01229956|Other|laboratory biomarker analysis|
1886798|NCT01229969|Other|Wii Fit Balance Games|Ski Slaloms and Table Tilt
1886799|NCT01229969|Other|NeuroCom EquiTest® System|Sensory Organization Test (SOT) and Limit of Stability (LOS).
1886800|NCT01229982|Drug|Latanoprost-PPDS|Punctal Plug
1886801|NCT01229995|Device|dental implants - zirconia abutmetns - prefabricated abutments|
1886802|NCT01230008|Radiation|no drugs|Adjuvant radiotherapy 3.5 G will be administered or not (control group) in patients with mediastinal lymphoma,treated with R-CHOP
1886803|NCT01230021|Drug|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg bodyweight
1886804|NCT01230034|Drug|Ramipril|pill, 5 and 10 mg/day, od, 24 weeks
1886805|NCT01230034|Drug|Imidapril|pill, 10 and 20 mg/day, od, 24 weeks
1886806|NCT01230047|Behavioral|Psychoeducational course|Psychoeducational course on mindfulness and lifestyle interventions for depression and anxiety
1886808|NCT01230073|Device|Home-Monitoring|Home-Monitoring
1886810|NCT01230086|Device|ICD Implantation without DFT testing|Implantation
1886811|NCT01230086|Device|Upper limit of vulnerability testing|Upper limit of vulnerability testing
1886812|NCT01230086|Device|T-wave shock with induction of ventricular fibrillation|Traditional safety margin testing for defibrillation threshold
1886813|NCT01230099|Behavioral|Supportive Information Team Group|A minimum of two protocolized, interdisciplinary, informational support meetings led by palliative care clinicians will be arranged with family members or other patient surrogates who participate in decision-making for individual chronically critically ill patients.
1886814|NCT01230125|Drug|Mapracorat|Instill study medication into study eye per dosing instructions for 14 days
1886815|NCT01230125|Drug|Vehicle|Instill study medication into the study eye per dosing instructions for 14 days
1886816|NCT01230138|Drug|Placebo|Placebo tablets
1886817|NCT01230138|Drug|FP187|High daily dose of 750mg administered as 250mg TID
1886818|NCT01230138|Drug|FP187|High daily dose of 750mg administered as 375mg BID
1886819|NCT01230138|Drug|FP187|Low daily dose of 500mg FP187 administered as 250mg BID
1886820|NCT01230138|Drug|FP187|Oral tablets, up to 3 times daily for 20 weeks.
1886821|NCT01230151|Device|GUIDE software, Version 0.1|The GUIDE software uses computer-based models to determine the spread of stimulation from DBS therapy into surrounding nuclei of the brain. The software models stimulation and is not used to program or communicate with the patient's implanted DBS System. The software was recently validated in a multi-center clinical study.
1886822|NCT01230151|Device|Clinically defined stimulation parameters|Stimulation parameters clinically determined prior to start of clinical study
1886823|NCT01230177|Drug|etanercept (genetical recombination)|10 to 25 mg of etanercept (genetical recombination) reconstituted in 1 mL of water for injection (JP) administered twice weekly as a subcutaneous injection or 25 to 50 mg of etanercept (genetical recombination) administered once weekly as a subcutaneous injection, are usually the recommended dose for adults.
1886824|NCT01230190|Dietary Supplement|Ecologic ® Panda II|"Probiotic strains: 3 Bifidobacteria, 3 Lactococci, 1*10^9 Colony Forming Units/g.
Composition: rice starch, maltodextrins, bacterial strains and mix of minerals."
1886825|NCT01230190|Dietary Supplement|placebo|rice starch, maltodextrins, and mix of minerals. The placebo mixture is similar in aspect, consistency and taste as Ecologic ® Panda II (intervention).
1886826|NCT01230203|Procedure|Computed tomography scan versus color duplex ultrasound|Computed tomography scan versus color duplex ultrasound
1886827|NCT01230216|Drug|control systolic blood pressure less than 120 mmHg|use losartan to control blood pressure
1886828|NCT01230216|Drug|control systolic blood pressure less than 140 mmHg|use losartan to control blood pressure
1886829|NCT01230229|Procedure|Stenting|The stent should be deployed percutaneously, appropriate stent(s) size selected based upon the angiogram. The diameter must be 1-2 mm larger than the vessel. Length is chosen to cover lesion with one stent if possible. The choice of brand will be made through random selection among those offering possibility to cover the lesion with one stent. If more than one stent is required, overlap between 0.5 and 1 cm is acceptable. Postdilatation must be performed with a PTA balloon shorter than the length and less than the diameter of the stent. An angiogram should be made to compare the pre- and post-implant minimum lumen diameters. The non-diseased artery diameters shall be measured and residual % stenosis calculated.
1886830|NCT01230229|Other|Best medical treatment|Patients randomised to conservative treatment will receive appropriate medication with target levels of cholesterol 4,5 mmol/l, LDL 2,5 mmol/l and blood pressure level of 130/80 mmHg in addition to instruction how to engage in an exercise program. Each patient will receive a 'step-meter' which has to be carried during all activity during the first month and then during one week before each follow up visit. Step-meter read-outs will be recorded during each follow up visit. Smokers will be actively advised to quit smoking.
1886831|NCT01230242|Device|Levonorgestrel Intrauterine Device|levonorgestrel intrauterine device insertion within ten minutes of placental delivery using a ring forceps insertion protocol
1886832|NCT01230255|Procedure|Percutaneous catheter drainage|Ultrasound guided insertion of a 14 French pigtail catheter to drain free intra-peritoneal fluid or blood and thereby reduce elevated intra-abdominal pressure
1886833|NCT01230268|Other|Mulberry fruit extract|1000 mg oral daily dose for 2 weeks
1886834|NCT01230281|Other|Black bean seed coat extract|1000 mg oral daily dose for 2 weeks
1886835|NCT01230307|Drug|Vitamin D3|Vitamin D supplementation will be an oral load of 100,000 IU then 2000 IU by mouth daily of vitamin D3 (cholecalciferol)for 6 months
1886836|NCT01230307|Drug|Placebo|A placebo loading dose will be given followed by 2 placebo tablets daily for 6 months.
1886837|NCT01230320|Procedure|Denture fabrication technique|"Sequence of procedures involved with the fabrication of conventional complete dentures. Examples of common procedures are:
the reproduction of denture-bearing tissues by means of impression techniques and casts;
the registration of maxillo-mandibular relations;
try-in of artificial teeth and carved denture bases."
1886838|NCT01230346|Other|questionnaire administration|Ancillary studies
1886839|NCT01230346|Other|survey administration|Ancillary studies
1886840|NCT01230346|Other|counseling intervention|Telephone intervention
1886841|NCT01230346|Other|educational intervention|Telephone intervention
1886842|NCT01230359|Dietary Supplement|Pyridoxine hydrochloride|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
1886843|NCT01230359|Other|Tang orange powder|2.5 grams per day for subjects weighing upto 27 kilos and 5 g per day for greater than 27 kgs for 12 weeks
1886844|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fasted (wet granulated tablet) for 21 days
1886845|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fed (wet granulated tablet) for 21 days
1886846|NCT01230385|Drug|Lersivirine|Lersivirine 750 mg QD fasted (wet granulated tablet) for 21 days
1886847|NCT01230385|Drug|Lersivirine|Lersivirine 750 mg QD fed (wet granulated tablet) for 21 days
1886848|NCT01230385|Drug|Lersivirine|Lersivirine 500 mg QD fasted (dry granulated tablet) for 21 days
1886849|NCT01230411|Other|saline placebo|250 cc of placebo administered IV
1886850|NCT01230411|Drug|Ibuprofen|800 mg ibuprofen in 250 cc saline administered IV
1886851|NCT01230424|Drug|Triamcinolone Acetonide|40 mg into the study knee joint every 12 weeks for a total of 8 injections.
1886852|NCT01230424|Drug|0.9% Sodium Chloride Injection as Placebo|Sodium chloride injection will be given into the study knee once every 12 weeks for a total of 8 injections.
1886853|NCT01230450|Procedure|sub-urethral tape (TVT-O)|Tension free vaginal tape vs. single incision sub-urethral tension free vaginal tape
1886854|NCT01230450|Other|stand standard mid-urethral sling (TVT-O)|
1886855|NCT01230463|Drug|Ketorolac Tromethamine|15 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
1886856|NCT01230463|Drug|Ketorolac Tromethamine|30 mg ketorolac IV as a bolus 30 minutes before closure of surgery.
1886857|NCT01230476|Drug|Cetuximab|Cetuximab loading dose of 400mg/m2, then weekly dose of 250mg/m2 for 12 doses; Neoadjuvant Cisplatin 75mg/m2 D1, 5FU 1000mg/m2 D2-5, for 2 cycles; Concurrent Cisplatin 30mg/m2 given with radiation 70Gy/35fraction/7weeks.
1886858|NCT01230489|Biological|MediHoney|In this group a Medihoney 2 x 2 will be used in place of the standard dry 2 x 2 currently used as the wound dressing. Also all indentations of the wound will be filled with Medi-Honey ointment prior to the application of the dressing.
1886859|NCT01230502|Drug|Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy|"Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy
Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.
Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.
Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples."
1886860|NCT01230502|Other|data and sample collection|"Group 2 : Donor specific regulation (DSR) + standard of care:
These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.
Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples"
1886861|NCT01230502|Other|data and sample collection|"Group 3 : Donor specific regulation (DSR) - standard of care:
These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months."
1886862|NCT01230515|Other|Individual patient interview, focus group and structured survey|
1886863|NCT01230515|Other|interview, focus group and structured survey|
1886864|NCT01230515|Other|interview, focus group and structured survey|
1886865|NCT01230515|Other|interview, focus group and structured survey|
1886866|NCT01230541|Drug|Placebo|Daily, oral tablet
1886867|NCT01230541|Drug|Udenafil|Daily tablet
1886868|NCT01230554|Device|Daily disposable cosmetic tint lens|Bausch & Lomb daily disposable cosmetic tint contact lens worn on a daily disposable basis for 1 week.
1886869|NCT01230580|Drug|Protease Inhibitor|Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
1886870|NCT01230580|Drug|Standard-of-care Antiretroviral therapy|Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
1992319|NCT03322254|Other|respiratory pathogen panel|lab testing for respiratory pathogens
1886874|NCT01230606|Other|discharge vs. overnight stay|At six hours post-PCI,patients will be randomized to be discharged immediately or to stay overnight in the hospital for observation and discharged the following day. Randomization will occur in a 1:1 ratio. Additionally, randomization will be performed stratified by study site.
1886875|NCT01230619|Drug|RV568|RV568 400 ug administered as nasal drops twice daily on Day 1, RV568 800 ug administered as nasal drops once daily on Day 2
1886876|NCT01230619|Drug|Placebo|Placebo administered as nasal drops twice daily on Day 1, Placebo administered as nasal drops once daily on Day 2
1886877|NCT01230632|Dietary Supplement|high fat overfeeding|Dietary Supplement:3 days overfeeding
1886878|NCT01230645|Drug|RV568|RV568 400 ug administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
1886879|NCT01230645|Drug|Placebo|Placebo administered as nasal drops twice daily for 10 days (Day -1 to Day 8)
1886880|NCT01230671|Other|Yoga|A 12 week yoga session will be offered to women with breast cancer.
1886882|NCT01230697|Drug|Sorafenib|Sorafenib 800mg/die oral
1886883|NCT01230710|Drug|Erlotinib|Erlotinib was supplied as tablets.
1886884|NCT01230723|Device|Everolimus-Eluting-Stent|due randomization everolimus-eluting-stent will be implanted
1886885|NCT01230723|Device|Zotarolimus-Eluting-Stent|due randomization zotarolimus-eluting-stent will be implanted
1886886|NCT01230736|Drug|Travoprost 0.004%/Timolol 0.5% Fixed Combination eye drops solution (Duotrav®)|One drop in study eye(s) once daily for 8 weeks
1886926|NCT01230983|Drug|dexrazoxane hydrochloride|Given IV
1886927|NCT01230983|Drug|doxorubicin hydrochloride|Given IV
1992320|NCT03322241|Other|overall wellness|Wellness lab testing
1992321|NCT03322228|Other|Music Therapy|Music therapy is tailored to subject preference. Examples are active music-making, supportive listening, and includes opportunities for legacy building to decrease caregiver distress and promote self-care.
1992322|NCT03322215|Drug|Palbociclib|75-125 mg capsule orally once daily for 21 consecutive Days followed by 7 Days of treatment.
1992323|NCT03322215|Drug|Fulvestrant|500 mg intramuscularly Days 1 and 15 of cycle 1, and then on Day 1 of each subsequent 28-days cycle.
1992324|NCT03322215|Drug|Capecitabine|Oral tablet 500 - 1,250 mg/m2 twice Daily, for 2 weeks followed by 1 week of rest.
1992325|NCT03322202|Behavioral|Motivational Interviewing|Motivational Interviewing is a communication style that is intended to give patients the tools to reach goals through their own desires and actions.
1886887|NCT01230749|Drug|JNJ-41443532|Participants will receive JNJ-41443532 tablet(s) orally in JNJ-41443532 250 mg arm (1 X 250 mg) and JNJ-41443532 1000 mg arm (4 X 250 mg) in morning and evening, for 28 days.
1886888|NCT01230749|Drug|Pioglitazone 30 mg|Participants will receive tablet pioglitazone 30 mg orally in morning for 28 days.
1886889|NCT01230749|Drug|Placebo|Participants will receive matching placebo tablets of JNJ-41443532 and/or matching placebo tablets of pioglitazone orally as per the assigned arms.
1886890|NCT01230762|Drug|dapoxetine|60 mg tablet once daily as needed (prn) (with a possible dose reduction to 30 mg once daily) for up to 9 months
1886891|NCT01230775|Drug|Anagrelide retard|"Week 1:
1x1 tablet/d of Anagrelide retard (1 tablet = 2mg; total dose = 2mg/d) will be administered in week 1.
Week 2 Anagrelide retard: Dosing will be titrated up according to response (platelet reduction) to 4 mg/day (=2x1 tablet) in week 2.
Week 3 - Week 4 Anagrelide retard In week 3 and 4, dose will either be increased or decreased to maintain platelets in the normal or close to normal range. The maximum dose is 4 tablets (=8mg Anagrelide) per day.
Maintenance Phase Anagrelide retard During maintenance phase (month 2 - month 12) doses of treatment are adjusted at the highest tolerated level which is able to maintain the platelet count within the normal range."
1886892|NCT01230775|Drug|Placebo|"Week 1:
x1 tablet/d of placebo will be administered in week 1.
Week 2
Placebo:
x1 tablet/d of placebo will be administered in week 2.
Week 3 - Week 4
Placebo:
In week 3 and week 4 the maximum dose is 4 tablets per day.
Placebo:
In order to guarantee blinding of subjects the number of placebo tablets to be taken by the subject will vary during maintenance period:
Month 2 - month 3: 2x1 tablet/d Month 3 - month 6: 3x1 tablet/d Month 6 - month 9: 4x1 tablet/d Month 9 - month 12: 4x1 tablet/"
1886893|NCT01230788|Drug|rituximab|375 mg/m2/dose on days 8, 15, 22, and 29 (diluted in NS to a final concentration of 1 mg/ml for ease of administration). (Premedicate with Acetaminophen 15 mg/kg po (max 650 mg) and Diphenhydramine 1 mg/kg IV/PO (max 50 mg)).
1886894|NCT01230801|Biological|BMN 701|GILT-tagged recombinant human GAA
1886895|NCT01230814|Drug|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate)|Neo-Penotran® Forte (active ingredient Metronidazole & Miconazole Nitrate), co-formulated vaginal suppositories containing metronidazole 750 mg with miconazole 200 mg and excipients (Witepsol S 55). Witepsol S 55 is a hard fat suppository base. Such bases consist mainly of triglyceride esters of the higher saturated fatty acids along with varying proportions of mono- and diglycerides. 117 subjects receive nightly for 5 consecutive night each month.
1886896|NCT01230814|Drug|Placebo|Placebo vaginal suppositories, identical in appearance to the active product; contains Witepsol S 55, Titanium Dioxide and D+C yellow #10 with no metronidazole or miconazole.117 subjects receive nightly for 5 consecutive nights each month.
1886897|NCT01230827|Drug|CNTO 148 (Golimumab)|Patients will receive subcutaneous (SC) (under the skin) injection of golimumab 30 mg per square meter every 4 weeks from Week 0 through Week 248.
1886898|NCT01230827|Drug|Placebo|Patients who have a clinical response to golimumab at Week 16 and are randomly allocated to placebo, will receive SC injection of placebo every 4 weeks from Week 16 through Week 48.
1886899|NCT01230827|Drug|Methotrexate|All patients will receive their fixed dose of commercial methotrexate (10 to 30 mg per square meter) weekly throughout the study duration.
1886900|NCT01230840|Dietary Supplement|wheat dextrin|5 grams of wheat dextrin baked in cookies will be taken 3 times a day for 2 weeks
1886901|NCT01230840|Dietary Supplement|placebo|cookies not containing wheat dextrin will be taken 3 times a day for 2 weeks
1886902|NCT01230853|Drug|Active Comparator: A|BAN2401 Single Dose Ascending Single intravenous infusions at sequentially ascending doses on Day 1 (dose levels: 0.1, 0.3, 1, 3, 10, and 15 mg/kg)
1886903|NCT01230853|Drug|Placebo Comparator B|Placebo Matching Placebo Infusion
1886904|NCT01230853|Drug|Active Comparator B|BAN2401 Multiple Dose Ascending Intravenous infusions once every 4 weeks at sequentially ascending doses (dose levels: 0.3, 1, 3, and 10 mg/kg)
1886905|NCT01230853|Drug|Placebo Comparator A|Placebo Matching Placebo Infusion
1886906|NCT01230866|Radiation|Proton Radiation Hypofractionation|Dose: 38 Gy(RBE); 7.6 GY(RBE) five days a week in 5 treatments over 1-2 weeks
1886907|NCT01230866|Radiation|Proton Radiation Standard Fractionation|Dose: 79.2 GY(RBE); 1.8 GY(RBE) five days a week in 44 treatments over 8.5-9 weeks
1886908|NCT01230879|Other|EFR and TDM|EFR : Pulmonary function test TDM : tomodensitometry
1886909|NCT01230892|Drug|Nebivolol|10 mg PO qday
1886910|NCT01230892|Drug|Atenolol|100 mg PO qday
1886911|NCT01230905|Radiation|PET scan and ultrasound|Nuclear rest/stress testing of the heart using N-13-ammonia paired with brachial artery ultrasound
1886912|NCT01230918|Radiation|99mTc-NC100692|"HCM and ACS subjects: 99mTc-NC100692 SPECT scan, CMR and echocardiography images will be obtained and compared.
Normal control: 99mTc-NC100692 SPECT scan, CMR and echocardiography imaging obtained for comparison with HCM and ACS images."
1886913|NCT01230931|Biological|Vitagel topical surgical hemostat|Vitagel is topical spray that results in coagulation. The components are as follows. Autogenous blood is drawn and centrifuged to produce a sample of platelets and growth factors. This is combined with a bovine thrombin and collagen solution. When the two are applied together, it produces the hemostatic effect.
1886914|NCT01230944|Procedure|Laparoscopic Nissen fundoplication|
1886915|NCT01230944|Procedure|Open Nissen fundoplication|
1886916|NCT01230957|Biological|Clostridium difficile toxoids A and B (Low-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
1886917|NCT01230957|Biological|Clostridium difficile toxoids A and B (Low-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
1886918|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
1886919|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose without adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 30
1886920|NCT01230957|Biological|Placebo: 0.9% normal saline|0.5 mL, Intramuscular on Days 0, 7, and 30
1886921|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 7, and 180
1886922|NCT01230957|Biological|Clostridium difficile toxoids A and B (high-dose with adjuvant)|0.5 mL, Intramuscular on Days 0, 30, and 180
1886923|NCT01230970|Drug|BN83495|40mg tablet oral daily administration from Day 1 to Day 14.
1886924|NCT01230983|Drug|asparaginase|Given IV
1886925|NCT01230983|Drug|cytarabine|Given IV
1886930|NCT01230983|Drug|methotrexate|Given IV
1886931|NCT01230983|Drug|prednisone|Given orally
1886932|NCT01230983|Drug|therapeutic hydrocortisone|Given IT
1886933|NCT01230983|Drug|vincristine sulfate|Given IV
1886934|NCT01230983|Radiation|radiation therapy|Radiation to cranium
1886935|NCT01224119|Device|Amplex|225 micrograms of B2A per cc of ceramic granules
1886936|NCT01224119|Procedure|Autograft bone|Bone is collected through a separate incision at the iliac crest or tibia.
1886937|NCT01224132|Drug|probiotic ® pur|daily, four types of probiotic bacteria ( Bifidobacterium bifidity, Lactobacillus acidophilus, Lactobacillus casei and Lactobacillus salivarium) 2 bags (two billion bacteria) (probiotic ® pur) for a total of 8 (eight) weeks
1886938|NCT01224145|Drug|4, 5x5cm bupivacaine collagen sponges|
1886939|NCT01224171|Drug|vedolizumab|Vedolizumab for intravenous infusion
1886940|NCT01224171|Other|Placebo|Placebo intravenous infusion
1886941|NCT01224184|Behavioral|Young Women's CoOp|Participants in this group will participate in three individual sessions and one group session of the young woman-focused intervention about HIV/STIs, pregnancy, alcohol and other drug use, violence, gangs and other issues. This intervention is an adaptation of the evidence-based Women's CoOp (PI: Dr. Wendee M. Wechsberg).
1886942|NCT01224184|Behavioral|Staying Healthy and Eating Well|Participants in this group will participate in three individual sessions and one group session of the nutrition intervention about healthy eating, physical activity and general wellness.
1886943|NCT01224197|Drug|TMC435|100 or 200 mg capsule, one single dose
1886944|NCT01224197|Drug|TMC435|100 or 200 mg capsule, once daily for 5 days
1886945|NCT01224210|Drug|Ambrisentan|Ambrisentan once-daily in the morning with or without food. The adult dose selected for this study will be 5 mg for the first 4 weeks. After the initial 4 weeks the dose will be increased to 10mg (available doses are 5, and 10 mg) based on tolerance safety. Subjects will remain on 10mg until they complete the study. Dose adjustments may be made based on side effects.
1886946|NCT01224236|Drug|Iron Supplement|2 mg/kg/day elemental iron as multivitamin with iron solution
1886947|NCT01224236|Drug|control|multivitamin solution without iron
1886948|NCT01224249|Dietary Supplement|Fish and shellfish|Intake of 1000 grams of fish and shellfish per week for six months.
1886949|NCT01224262|Biological|Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine)|A single vaccination of Fluzone alone
1886950|NCT01224262|Biological|LIQ001 (0.45mg)|A single vaccination of 0.45 mg LIQ001
1886951|NCT01224262|Biological|LIQ001 (1.8mg)|A single vaccination of 1.8 mg LIQ001
1886952|NCT01224275|Other|group based care|Midwives is randomized and allocated to group based antenatal care. The midwives have a manual for the model of care.
1886954|NCT01224301|Behavioral|School based flu vaccine: Low intensity|Interventions: Parents of children in Low Intensity Notification schools got less than 3 communications from schools describing influenza vaccine and the clinics, and consent forms sent home one.
1886955|NCT01224301|Behavioral|School based flu vaccine: High intensity|Interventions: Parents in high intensity schools have 3 or more communications from schools about influenza illness, influenza vaccine, and school based clinics.
1886956|NCT01224314|Other|Changing potassium concentration in dialysis fluids|The dialysis sessions was divided into 3 tertiles, casually modulating potassium concentration in the dialysate between the value normally used K and the two cut-off points K+1 and K-1 mmol/l
1886957|NCT01224327|Biological|umbilical cord Mesenchymal Stem Cells|Umbilical cord mesenchymal stem cells were infused to patients using interventional method via hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography,umbilical cord MSCs were infused slowly for 15-20minutes.
1886958|NCT01224327|Drug|Conserved therapy|Oral or intravenous administration
1886959|NCT01224340|Behavioral|lollipop|The lollipops varied in color and each color had its own flavor. The children chose between blue, green, red, orange or yellow lollipop colors. The children started to taste the lollipops approximately three to five minutes before the wound care and continued to do so during the whole session.
1886960|NCT01224340|Behavioral|serious games|The serious game chosen, Tux Racer, contented a penguin that collected fishes at the same time as it did slalom in a path.
1886961|NCT01224340|Other|control|The participants in the control group were offered standard care without any specific distraction techniques, except consolation by the acting staff.
1886962|NCT01224353|Drug|lipoic acid|Tablet, 600mg, for oral use, 30 min before breakfast, once daily for 6 weeks
1886963|NCT01224353|Other|Placebo|Tablet, placebo, 1-week single-blind placebo treatment then, 30 min before breakfast, once daily for 6 weeks
1886964|NCT01224366|Drug|Vildagliptin|
1886965|NCT01224366|Drug|Placebo|
1886966|NCT01224379|Device|Topping off system|"The intervention group will receive a topping off system (PLIF -posterior intervertebral fusion- connected with a flexible pedicle screw system above the fusion)."
1886967|NCT01224379|Device|monosegmental PLIF|The control group receives a monosegmental PLIF. This is the current standard therapy for many pathologies in the lumbar spine (e.g. Spondylolisthesis)
1886968|NCT01224392|Other|Chemoradiotherapy|Radiotherapy (23 x 2 Gy) + capecitabine 825mg/m2 p.o. twice daily, excluding weekends
1886969|NCT01224392|Radiation|Radiotherapy with boost|Radiotherapy (23 x 2 Gy), with a simultaneous integrated boost up to 55.2 Gy on the primary tumor
1886970|NCT01224405|Drug|Docetaxel + LH-RH analogues|"Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.
In patients randomised to arms A up to 10 cycles of docetaxel will be planned in association to maintenance of LH-RH analogues administration."
1886971|NCT01224405|Drug|Docetaxel|"Docetaxel will be administered at a dose of 75 mg/m2 per square meter as a 1-hour intravenous infusion on day 1 every 21 days in association to 5 mg of prednisone orally twice daily.
In patients randomised to arms B up to 10 cycles of docetaxel will be planned, in association to stopping LH-RH analogues."
1887007|NCT01231126|Drug|Misoprostol|Procedures were taken for induced labor delivery with misoprostol 25mcg, by vaginal rout. The pills were administered each 6 hours in a maximum number of six.
1886972|NCT01224405|Drug|Docetaxel|Patients randomised in the arms AB1 (intermittent docetaxel) will suspend treatment after at least 4 cycles if their PSA level will be reduced >50%. Docetaxel treatment will be resumed when the serum PSA will rise by >50% from the lowest PSA level recorded and will be >10 ng/mL or when there will be other evidence of disease progression. PSA progression must to be confirmed with a second assessment after 2 weeks before deciding to resume docetaxel administration.
1886973|NCT01224405|Drug|Continuous Docetaxel|Patients randomised in the arms AB2 (continuous docetaxel) will continue treatment up to ten cycles after even if their PSA level at 4 cycles will be reduced >50% or will reach a level <4 ng/mL.
1886974|NCT01224405|Drug|Continuous Docetaxel|Patients randomised in the arms AB1(intermittent docetaxel) will continue treatment up to ten cycles even if their PSA level after 4 cycles will be reduced >50% or will reach a level <4 ng/mL.
1886975|NCT01224418|Drug|Tacrolimus|oral
1886976|NCT01224431|Drug|jtip needleless lidocaine injection|All patients were administered the J-tip and randomized to either treatment with 1% lidocaine or an equivalent amount of sterile normal saline prior to lumbar puncture. Vital signs were recorded during the procedure. Facial expressions were video recorded
1886977|NCT01224444|Other|standard polypectomy snare|Electrocautery snare resection of sessile colonic polyps
1886978|NCT01224457|Drug|Phenobarbital|phenobarbital 20mg/kg iv infusion, after 24hours of loading, 2.5mg/kg bid daily
1886979|NCT01224470|Drug|Dexmedetomidine|Dexamedetomidine intravenous injection (1 ㎍/kg )
1886980|NCT01224496|Drug|Chinese herbal concoction twice a day for 6 months|Definition of each TCM syndrome is based on TCM theory. Formulation composition is based on each defined TCM syndrome with addition or removal of herbs as indicated by the patient's manifestation
1886981|NCT01224509|Drug|Mifepristone|Administration of 200 mg of mifepristone orally 48 hours prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
1886982|NCT01224509|Other|Non-treatment|Non-treatment prior to a cervical biopsy and evacuation by dilatation and curettage of the endometrial cavity
1992326|NCT03322189|Genetic|pharmacogenomic|Standard Operating Procedures on Pharmacogenomic testing and changes made to specific SOP
1886985|NCT01224535|Dietary Supplement|Maize and Amaranth|80g porridge per day, 5 days a week, for 16 weeks (4 months)
1886986|NCT01224548|Other|vegan instruction and food accessibility|weekly 1-hr instructions including vegan nutritional information and cooking instructions. vegan menu will be made available at the cafeteria
1886987|NCT01224548|Other|control|no intervention in until June 2011. The control group start vegan diet in July 2011.
1886988|NCT01224561|Behavioral|Lipid overnutrition|During 4 months, the daily caloric intake will be increased by about 70 g fat as butter 20 grams, 100 grams of cheese (Emmental) and 40 grams of almonds. This overnutrition corresponds to an excess of 760 kcal / day or 21,280 calories for the period and then taken to a theoretical 2.4 kg of fat (1 kg fat = 9000 kcal).
1886989|NCT01224587|Drug|D1000078|Oral, one single dose
1886990|NCT01224587|Drug|D1000082|Oral, one single dose
1886991|NCT01224587|Drug|D1000083|Oral, one single dose
1886992|NCT01224587|Drug|D1000085|Oral, one single dose
1886993|NCT01224600|Other|patients with newly diagnosed PAD (<1year)|patients with newly diagnosed PAD (<1year) symptomatic or asymptomatic, without any history of previous coronary nor cerebrovascular event, and with no previous investigation of the aorta and cervical arteries were eligible
1886994|NCT01224613|Biological|Intanza|0.1 mL of Intanza intradermally at visit # 1
1886995|NCT01224613|Biological|Intanza|0.1 mL of Intanza intradermally at visit #1
1886996|NCT01230996|Drug|Cisplatin|Each patient will also receive chemotherapy with a drug called cisplatin, which is given intravenously through a drip in the arm once a week during their 6 week radiotherapy treatment. Again this is standard treatment for any patient with cervix cancer.
1886997|NCT01230996|Radiation|Intensity-modulated radiation therapy|Patients in this trial will receive radiotherapy to the pelvic area with additional chemotherapy (chemoradiotherapy). This is the standard treatment for cervix cancer and will be almost identical to patients not taking part in this study. As patients in the study will be treated with IMRT, the total radiation dose will be slightly higher but without increasing the dose to normal tissue in the pelvis. This will mean the number of radiotherapy treatments that each patient receives in the study is between 27 and 30 compared with the usual 28. Each patient will undergo 6 weeks of radiotherapy treatment and must attend the radiotherapy department hospital once daily (Monday to Friday) over 6 weeks. Each treatment lasts for approximately 10 15 minutes. This is exactly the same as standard practice if patients were not participating in the trial.
1886998|NCT01230996|Procedure|Intracavitary brachytherapy|Intracavitary brachytherapy Intracavitary brachytherapy will be given towards the end of external beam radiotherapy usually weeks five and six. This is routine treatment and will be given according to local practice As is the convention patients will be reviewed weekly (more frequently if necessary) by their study doctor and will have weekly blood tests to measure full blood count and urea and electrolytes.
1886999|NCT01231009|Drug|Corticosteroids|Intravenous Dexamethasone, 8mg three times per day tapering down for 7 days Per os dexamethasone, 2mg per day tapering down for 7 days
1887000|NCT01231009|Other|Vestibular exercises|Vestibular exercises in order to enhance vestibulo-ocular reflex for 15 days under the suspicion of physiotherapist
1887001|NCT01231061|Radiation|SBRT|•24 Gy in 3 fractions to cover at least 90% of the defined target volume
1887002|NCT01231061|Radiation|Radiosurgery|16 Gy in 1 fraction to cover at least 90% of the defined target volume
1887003|NCT01231074|Drug|Metformin|Metformin dosing will be done as is typical in clinical practice. Doses will be titrated at 500mg daily for one week, to a maximum dose of 1000mg twice a day as tolerated by subject.
1887004|NCT01231100|Other|HCUE-guided care|Care directed by hand-carried ultrasound echocardiography
1887005|NCT01231113|Drug|artesunate-amodiaquine|The 452 pregnant women in this arm will receive artesunate-amodiaquine tablets(artesunate 4mg/kg and amodiaquine 10mg/kg in twelve hourly doses over 3 days
1887006|NCT01231113|Drug|Dihydroartemisinin-piperaquine|a fixed-dose combination to be administered to the other 452 pregnant women in this arm at an estimated total dosing of 6.75mg/kg dihydroartemisinin and 55mg/kg piperaquine over 3 days
1887008|NCT01231139|Drug|Paracetamol|Intravenous paracetamol, 1 gram (100mls), administered over 30 minutes (every 4 hours for 3 days).
1887009|NCT01231139|Drug|0.9% Sodium Chloride Schedule:|Identical placebo: 100mls saline given intravenous over 30 minutes (every 4 hours for 3 days)
1887010|NCT01231165|Drug|Amiloride|5mg/daily for 12th months
1887011|NCT01231165|Drug|Nitrates, clopidogrel, aspirin, statins|Comparative Efficacious Research
1887012|NCT01231178|Dietary Supplement|Alginate beverage|The dosage is 3x500ml daily
1887013|NCT01231178|Dietary Supplement|Control beverage|The dosage is 3x500ml daily
1887014|NCT01231191|Drug|Intravenous acetaminophen|Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.
1887015|NCT01231191|Drug|Intravenous placebo|Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
1887016|NCT01231204|Procedure|Placebo (normal saline) Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with normal saline. The normal saline infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
1887017|NCT01231204|Procedure|Ropivicaine 0.4% Continuous Infusion|Patients randomized to this group will receive an initial catheter placement using the standard Ultrasound-guided Technique. For the surgical procedure they will receive 15cc of 0.5%Ropivicaine. Following the surgical procedure they will receive a pain pump filled with 0.4%Ropivicaine. The 0.4%Ropivicaine infusion will continue for the 3 days following surgery. All patients will have access to other pain relievers for break-through pain. All patients will have the outcome measures assessed.
1887018|NCT01231217|Other|Green tea (Camellia sinensis)|Patients are recommended to drink at least 5 cups of green tea per day
1887019|NCT01231217|Other|Coffee|Patients are recommended to drink as much coffee as they tolerate.
1887020|NCT01231230|Drug|fluticasone|220- mcg once
1887021|NCT01231230|Drug|placebo inhalation|placebo inhalation once
1887022|NCT01231230|Drug|Salmeterol|50 mcg salmeterol once
1887023|NCT01231230|Drug|fluticasone/salmeterol|inhalation of 250 mcg of fluticasone combined with 50 mcg of salmeterol
1887025|NCT01231256|Behavioral|Preventive health consultation|A one hour preventive health consultation, based on completed baseline questionnaire, with one or two goal setting for a better life during the next year, with discussion and registration of resources, barriers, and time scheme. And a 3 month follow up consultation.
1887026|NCT01231269|Other|MRI|MRI scan without administration of contrast/without radiation
1887027|NCT01231282|Other|diffusion-weighted MRI|MRI scan without contrast administration and without radiation exposure
1887028|NCT01231308|Procedure|Roux-en-Y-Gastric Bypass|Standard laparoscopic gastric bypass. Preoperative preparation will include antibiotic prophylaxis given less than 60 minutes prior to making the first incision. Under general anesthesia with endotracheal intubation, a laparoscopic gastric bypass will be performed in the usual fashion.
1887029|NCT01231308|Behavioral|Intensive lifestyle modification and Optimal medical Therapy|Very low calorie diet consisting of 5 feedings: 2 liquid meal replacements, 2 low-calorie snacks, and 1 small meal of known caloric content. After 10% weight loss is achieved, the subjects will received individualized nutrition sessions beginning bi-weekly but extending time intervals as the weight loss progresses.
1887030|NCT01231321|Drug|adalimumab|Adalimumab 40 mg in 0.8 ml in pre-filled syringe for under the skin of the abdomen or the thigh injection every other week.
1887031|NCT01231334|Drug|Dapsone plus Adapalene|Dapsone (Aczone® Gel 5%) applied to entire face in the morning. Adapalene (Differin® 0.3% Gel)followed by Dapsone (Aczone® Gel 5%) applied to entire face in the evening. Daily treatment for 12 weeks.
1887032|NCT01231334|Drug|Clindamycin/benzoyl peroxide plus Adapalene|Clindamycin/benzoyl peroxide (Duac® Topical Gel)applied to entire face in the morning. Adapalene (Differin® 0.3% Gel) applied to entire face in the evening. Daily treatment for 12 weeks
1887033|NCT01233206|Drug|Metformin|Metformin pre-treatment and co-administration
1887034|NCT01233206|Drug|Placebo administration|Placebo pre-treatment and co-administration
1887035|NCT01233219|Drug|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.
At the exit of the operative compartment patients will have an continuous infusion for 48h with morphine chlorhydrate 0,02 mg/kg/h.
Moreover, a rescue dose therapy will be prescribed with ketoprofen 160 mg or ketorolac 30mg (in case of allergy acetaminophene 1g) if NRS<4 maximum x 3 daily.
Postoperative analgesic treatment is lasting 48h for each patient (between starting of the infusion (T0) and the following 48h)."
1887036|NCT01233232|Drug|Placebo|Oral dose bid
1887037|NCT01233232|Drug|AZD5069 50mg|Oral dose bid
1887038|NCT01233232|Drug|AZD5069 80mg|Oral dose bid
1887039|NCT01233245|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
1887040|NCT01233258|Biological|rFVIII (BAY81-8973) on demand|Participants received on-demand treatment with rFVIII (BAY81-8973) assayed by CS/EP (Chromogenic Substrate Assay per European Pharmacopoeia) for 6 months and by CS/ADJ (Chromogenic Substrate Assay/label adjusted to one-stage assay) for 6 months, sequence according to randomization
1887041|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis low-dose|Participants received low dose prophylaxis treatment at 20, 25 or 30 IU/kg twice per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
1887042|NCT01233258|Biological|rFVIII (BAY81-8973) prophylaxis high-dose|Participants received high dose prophylaxis treatment at 30, 35 or 40 IU/kg 3 times per week with rFVIII (BAY81-8973) assayed by CS/EP for 6 months and by CS/ADJ for 6 months, sequence according to randomization.
1888320|NCT01240538|Biological|wild-type reovirus|Given IV
1992327|NCT03322176|Other|Genetic testing|LYNCH genetic testing
1887043|NCT01233271|Device|Space TGC|Space TGC with incorporated eMPC algorithm to establish glycaemic control with a blood glucose target range of 80-150 mg/dL (4.4-8.3 mM)
1887044|NCT01233284|Drug|tiotropium bromide 2.5µg once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
1887045|NCT01233284|Drug|Tiotropium matching Placebo once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
1887046|NCT01233284|Drug|tiotropium bromide high dose once daily|Efficacy and safety comparison of 3 doses of inhaled tiotropium (1.25µg, 2.5µg and 5µg) versus placebo
1887047|NCT01233284|Drug|tiotropium bromide 1.25µg once daily|IMP
1887048|NCT01233297|Drug|Azithromycin|10 mg/kg peroral for 3 consecutive days
1887049|NCT01233297|Other|Placebo mixture|Placebo mixture containing no active substance.
1887050|NCT01233349|Device|Litramine|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
1887051|NCT01233349|Device|Placebo|2 tablets 3 times daily (oral consumption, 30 minutes after meal)
1887052|NCT01233362|Biological|Modified killed oral cholera vaccine at 14 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 14 days for individuals aged 1 year and above.
1887053|NCT01233362|Biological|Modified killed oral cholera vaccine at 28 day interval|The modified killed bivalent (O1 and O139)whole cell based oral cholera vaccine is administered orally in 2 liquid doses (without need of any buffer solution) 28 days for individuals aged 1 year and above; as an alternate schedule.
1887054|NCT01233375|Drug|CO-1.01|"1250 mg/m2/day administered on Days 1, 8, and 15 in 4-week treatment cycles.
Patients who have SD or better at the Week 8 assessment and who adequately tolerated the first 2 cycles of treatment may continue CO-1.01 at the same or an increased dose (1400 mg/m2) for Cycle 3 and subsequent cycles."
1887055|NCT01233388|Other|Text message surveillance|Text message surveillance for vaccine adverse events
1887056|NCT01233401|Other|Survey|Mothers and Other infant caregivers are surveyed at the end of the 2 week newborn well child visit about whether they chose to receive the Tdap vaccine at the pediatrician's office.
1887057|NCT01233414|Behavioral|Parent Training|The Parent Training program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute treatment sessions over a 24-week period. Topics covered in the program include reinforcement, teaching compliance, and functional communication. The treatment sessions employ direct instruction, review of video-taped examples, practice activities, behavior rehearsal with feedback, and role-playing to accomplish specific skill acquisition. Parents will be given specific homework assignments between sessions.
1887058|NCT01233414|Other|Psychoeducational Program|The Psychoeducational program will be delivered individually to the parents of study participants. Families will attend up to 13 90-minute informational sessions over a 24-week period. The program provides an overview on a variety of topics including the complexities of a PDD diagnosis, co-occurring medical conditions, relevant aspects of child development, use of medications, treatment options for challenging behavior, nutritional issues, and complementary and alternative treatments.
1887059|NCT01233440|Biological|Recombinant Coagulation Factor IX Albumin Fusion Protein|Single dose of 25, 50 or 75 IU/kg of rIX-FP, given as intravenous infusion
1887060|NCT01233440|Biological|Plasma derived FIX [pdFIX]|Single dose of 50 IU/kg of reference product, given as intravenous infusion
1887061|NCT01233453|Device|the everolimus eluting ® stent|stenting in coronary artery disease using the XIENCE-V®, XIENCE-Prime® or PROMUS® stent
1887062|NCT01233453|Device|the Biolimus A9 eluting NOBORI® stent|stenting in coronary artery disease using the Biolimus A9 eluting NOBORI® stent
1887063|NCT01233479|Drug|systemic chemotherapy|
1887064|NCT01233479|Other|laboratory biomarker analysis|
1887065|NCT01233479|Procedure|therapeutic surgical procedure|
1887066|NCT01233479|Radiation|radiation therapy|
1887067|NCT01233492|Drug|boron phenylalanine|
1887068|NCT01233492|Drug|mannitol|
1887069|NCT01233492|Other|biologic sample preservation procedure|
1887070|NCT01233492|Radiation|radiation therapy treatment planning/simulation|
1887071|NCT01233505|Drug|veliparib|Given PO
1887072|NCT01233505|Drug|capecitabine|Given PO
1887073|NCT01233505|Drug|oxaliplatin|Given IV
1887074|NCT01233505|Other|pharmacological study|Correlative studies
1887075|NCT01233505|Other|laboratory biomarker analysis|Correlative studies
1887076|NCT01233518|Device|FFR|Fractional flow reserve measured during cardiac catheterization
1887077|NCT01233531|Behavioral|monthly cash transfer payments for attending school|In the intervention, young women and their households will be randomized in 1:1 ratio to receive monthly cash transfer payments, conditional on the young woman attending school, or to the control arm. Young women will be recruited at the beginning of grades 8 through 11 in the first year of the study.
1887078|NCT01233531|Behavioral|B--No cash transfers|No monthly cash transfers
1887079|NCT01233544|Procedure|SBRT or RFA|Patients are allocated to one of the two arms in a 1:1 randomization
1887080|NCT01233570|Drug|Tacrolimus|Once daily application for 12 weeks followed by 4 weeks observation. Optional 36 week open label extension
1887081|NCT01233583|Drug|Dovobet, neotigason, etanercept, adalimumab. infliximab|Dovobet ointment 15g/day for 6 weeks Neotigason capsule 50mg per day (oral) for 6 weeks Enbrel 50mg twice weekly subcutaneous injection for 6 weeks Humira 80mg week 0, 40 mg week 1 then every other week therafter subcutaneous injection for 6 weeks Remicade 3 separate doses of 5mg/kg intavenous injection for 6 weeks
1887082|NCT01233596|Device|Canalicular intubation|Intubation through the inferior canaliculus performed under general anaeshesia. The tubes were removed 3-4 months after the tube placement.
1887085|NCT01233622|Drug|Vildagliptin|
1887086|NCT01233622|Drug|Placebo|
1887087|NCT01233635|Other|no drug|none, no drug
1887088|NCT01233635|Drug|start cozaar|start cozaar
1887089|NCT01233635|Drug|continue cozaar|continue cozaar
1887090|NCT01233648|Other|rate control via CRT-D and AVN ablation|rate control
1887091|NCT01233648|Other|rhythm control via pharmacologic, electrical or ablative therapies|rhythm control
1887092|NCT01233661|Other|short AVD pacing ; prior (stable) programming|short AVD pacing prior (stable) programming
1887093|NCT01233687|Drug|AMG 102 and erlotinib|"Dose Level -2 Dose level -1 Dose Level 0 AMG 102 5 mg/kg 7.5 mg/kg 15 mg/kg Erlotinib 150 mg 150 mg 150 mg
The first cohort of patients in the phase I portion will start at dose level 0 of AMG102."
1887094|NCT01233700|Behavioral|Motivational Interviewing|Standard motivational interviewing techniques will be applied to assist subjects to consider and work to resolve any remaining concerns, doubts, or ambivalence about their decision about donating an organ to someone else.
1887095|NCT01233700|Behavioral|Healthy Lifestyles Education|Educational information will be presented to subjects in didactic form on lifestyles issues of relevance to living donors.
1887096|NCT01233713|Procedure|Hartmann's operation|Hartmann's operation is the surgical resection of the rectosigmoid colon with closure of the rectal stump and end colostomy, followed by a stoma reversal operation.
1887097|NCT01233713|Procedure|Primary anastomosis|Primary anastomosis refers to a colonic resection with primary anastomosis and covering proximal ileostomy, followed by a stoma reversal operation.
1887098|NCT01233726|Dietary Supplement|T-Diet plus Diabet IR|Group 1 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
1887099|NCT01233726|Dietary Supplement|ISOSOURCE PROTEIN FIBRE|Group 2 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
1887100|NCT01233726|Dietary Supplement|GLUCERNA SELECT|Group 3 will receive, 25 kcal / kg • day for 28 days, via gastric or transpyloric.
1887101|NCT01233739|Drug|Chondroitin sulfate|Administration of 2 capsules of 400 mg of chondroitin sulfate orally.
1887102|NCT01233739|Drug|Placebo|Administration of 2 capsules of placebo orally.
1887103|NCT01233752|Drug|morphine chlorhydrate|"The drug will be administrated by a bolus 45 minutes before the end of the surgery, with the following modalities: bolus with morphine chlorhydrate 0.15 mg/kg ± 20%. Also acetaminophene 1g and ketoprofen 160 mg (ketorolac 30mg) will be administrated during the operation.
At the exit of the operative compartment patients will have an electronic pump (PCA) for 48h with morphine chlorhydrate to be used in boluses by 1 mg with a lock out of 5 mins, max dose 20 mg in 4 hours.
Moreover, ketoprofen will be prescribed 160 mg x 2 per day (ketorolac 30mg x 2) (in case of allergy acetaminophene 1g x 3 daily).
Postoperative analgesic treatment is lasting 48h for each patient (between starting of the PCA infusion (T0) and the following 48h)."
1887104|NCT01233778|Dietary Supplement|Canola Oil|60g Canola oil daily per 3000kcal diet provided in a supplemental shake
1887105|NCT01233778|Dietary Supplement|High Oleic Acid + DHA Canola Oil|60g high oleic acid canola oil + DHA daily per 3000kcal provided in a supplemental shake
1887106|NCT01233778|Dietary Supplement|High Oleic Acid Canola Oil|60g high oleic acid canola oil daily per 3000kcal provided in a supplemental shake
1887107|NCT01233778|Dietary Supplement|Flax Oil|36g flax oil + 24g safflower oil daily per 3000kcal provided in a supplemental shake
1887108|NCT01233778|Dietary Supplement|Safflower Oil|45g safflower oil + 15g corn oil daily per 3000kcal provided in a supplemental shake
1887111|NCT01233804|Other|Opting Out|Usual care is for pregnant women to sign a consent to get the influenza vaccine. The intervention is to offer a group of women the option to sign only when they refuse the influenza vaccine.
1887112|NCT01233817|Other|Progressive strength training|the systematic increase in resistance weights
1887113|NCT01233830|Drug|AZD2423|oral solution
1887114|NCT01233830|Drug|Placebo|oral solution
1887118|NCT01233856|Drug|Lovaza|2000mg daily.
1887119|NCT01233856|Dietary Supplement|Placebo (corn oil).|Placebo capsules consisting of corn oil
1887120|NCT01233869|Drug|Bosutinib|Once daily oral dose of 200 mg of bosutinib
1887121|NCT01233869|Drug|Bosutinib|Once daily oral dose of 400 mg of bosutinib transitioned to 200 mg/day
1887122|NCT01233869|Drug|Placebo|Once daily oral dose of placebo
1887123|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with normal renal function
1887124|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with mild renal impairment
1887125|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with moderate renal impairment
1887126|NCT01233882|Drug|Bosutinib|Single dose of 200 mg of bosutinib in subjects with severe renal impairment
1887127|NCT01233895|Drug|AVE1642|For Part 1, AVE1642 was administered on Day 1 and then every three weeks intra-venously with the dose escalation step starting at 3 mg/kg/infusion with a classical dose escalation schema of 3+3. For Part 2, AVE1642 was administered at doses ranging from 0.5 mg/kg to 12 mg/kg
1887128|NCT01233895|Drug|Velcade|For Part 2 ONLY, fixed dose of 1.3 mg/m² administered on Days 1, 4, 8, and 11.
1887129|NCT01233921|Biological|palifermin|Given IV
1887130|NCT01233921|Other|flow cytometry|Correlative studies
1887131|NCT01233921|Other|laboratory biomarker analysis|Correlative studies
1887132|NCT01233921|Other|pharmacological study|Correlative studies
1887133|NCT01233934|Drug|Dexchlorpheniramine 1% Gel|Small amount applied over the lesion twice a day for 7 days.
1887134|NCT01233934|Drug|Dexchlorpheniramine 1% Cream|Small amount applied over the lesion twice a day for 7 days.
1887135|NCT01233947|Drug|AFP464|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycle
1887136|NCT01233947|Drug|AFP464 + Faslodex|AFP464 administered as a 3-hour IV infusion on Days 1 and 8 of a 21-day cycles and faslodex administered per the package label
1887137|NCT01233960|Drug|adult human mesenchymal stem cells|PROCHYMAL will be administered IV in a total volume of 300 ml (200 million cells) at a rate of 4-6 ml/minute. Treatments will be administered on Days 42-45, Days 84-87, and Days 126-129 following first infusion in Protocol 603.
1887138|NCT01233973|Other|video decision aid|video
1887139|NCT01233999|Drug|botulinum toxin A|Botulinum toxin A will be injected into participants hand total 40units
1887140|NCT01234012|Biological|IMF-001|subcutaneous injection of fixed dose IMF-001 (100 or 200 mcg) every 2 weeks.
1887141|NCT01234025|Drug|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
1887142|NCT01234025|Drug|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
1887143|NCT01234025|Drug|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle.
1887144|NCT01234025|Drug|Prednisone|5 mg administered orally twice daily on days 1, 8, 15 and 22 of each cycle
1887145|NCT01234025|Drug|Docetaxel|75 mg/m2 administered as a 1-hour intravenous infusion on day 1 of each cycle
1887146|NCT01234038|Drug|ISIS EIF4E Rx|800 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
1887147|NCT01234038|Drug|ISIS EIF4E Rx|1000 mg ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8 and 15 of each 21 day cycle
1887148|NCT01234038|Drug|ISIS EIF4E Rx|(Dose identified in Part 1)ISIS EIF4E Rx administered as a 3-hour intravenous infusion on Days 1, 8, and 15 of each 21 day cycle
1887149|NCT01234038|Drug|Paclitaxel|200 mg/m2 administered as a 3-hour intravenous infusion on Day 1 of each 21 day cycle
1887150|NCT01234038|Drug|Carboplatin|AUC 6.0 mg/mL/min administered as a 1-hour intravenous infusion on Day 1 of each 21 day cycle
1887151|NCT01234051|Drug|Docetaxel, Oxaliplatin|"1. Treatment Schedule
1.1. Docetaxel schedule Docetaxel 35 mg/m2 is administered on day 1 and day 8 by intravenously in 100 mL of 5% dextrose solution over 30 minutes. Dexamethasone 8mg is intravenously administered before 30 minutes, and then orally 4mg every 12 hours over 48 hours. In the event of a hypersensitivity reaction, dimethidine maleate, epinephrine, and intravenous fluids will be required.
1.2. Oxaliplatin schedule Oxaliplatin 100 mg/m2 is given on day 1 by intravenous infusion in 500 mL of 5% dextrose solution over 120 minutes. Therapy will be repeated every 21 days."
1887152|NCT01234064|Device|Anti-Embolism Graduated Pressure Stockings (by BSN-Jobst)|Apply 2 to 4 hours prior to surgery. Patient will continue to wear stockings until post-op Day 10.
1887153|NCT01234064|Device|No Graduated Compression Stockings|No stockings will be applied.
1887154|NCT01234077|Device|CPC M1|CPC M1
1887155|NCT01234103|Behavioral|Preventing Helath Damaging Health Behaviors in Male and Female Army Recruits|Groups will be randomly assigned to the sexual/substance use prevention intervention or the comparative/control intervention focused on impro risk Involves 10 hours of didactic presentations, interactive group discussions, skills-building exercises, and topic specific videos to reduce participants' risk for and acquisition of STIs, unintended pregnancies and their associated sexual and substance use behaviors.
1887156|NCT01234116|Drug|emtricitabine/tenofovir disoproxil fumarate|Each health care worker will receive one of the Treatment Arms for 28 days.
1887157|NCT01234129|Drug|zoledronic acid|zoledronic acid, 4 mg,standard dose,at monthly interval, by 2 years
1887158|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (12.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
1887159|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (18.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
1887160|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
1887161|NCT01234142|Drug|varenicline free base patch|varenicline transdermal delivery system (24.0 mg payload [drug amount loaded in each patch]) will be applied to the skin once daily for 14 days
1887162|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery system will be applied to the skin once daily for 14 days
1887163|NCT01234142|Drug|varenicline free base patch|2 varenicline transdermal delivery systems (combined to achieve a maximum drug payload of 36 mg) will be applied to the skin, side by side once daily, for 14 days
1887164|NCT01234142|Drug|placebo patch|Matched placebo transdermal delivery systems will be applied to the skin, side by side, once daily for 14 days
1887165|NCT01234155|Behavioral|Exercise Training - Interval Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week. Sessions will consist of walking for 3 minutes at 70% VO2max followed by 3 minutes at 40% VO2max for up to 60 minutes/day.
1887166|NCT01234155|Behavioral|Exercise - Continuous Walking|Duration: 4 months. Exercise training sessions will be performed 3-5 days/week and will consist of walking for up to 60 minutes/day at 55% VO2max.
1887167|NCT01234181|Procedure|Hypoxia-stressed BMSCs transplantation to cure MI|Experimental group: intracoronary injection of 10^7 BMSCs Sham Comparator: inject the same volume saline
1887168|NCT01234194|Drug|rising remifentanil concentrations|remifentanil effect-compartment concentrations 0,1,2,3 ng/ml
1887169|NCT01234194|Drug|falling remifentanil concentrations|remifentanil effect-compartment concentrations 3, 2, 1, 0 ng/ml
1887170|NCT01234207|Device|Standard, non-free-form, non-customized PAL spectacles|Control spectacles include several different PAL brands as selected by patients in the UC Berkeley Optometry Clinic and purchased in the Eyewear Center; after successful fitting and purchase, potential subjects were recruited for the trial.
1887171|NCT01234207|Device|Individually customized free-form surfaced PAL spectacles|Test spectacles are Zeiss Individual, free-form surfaced, and customized using the iTerminal device to account for individual back vertex distance, wrap angle and pantoscopic tilt
1887172|NCT01234233|Procedure|duration of preoperative active warming|"duration of prewarming by forced air warming"
1887173|NCT01234259|Device|Venus Freeze (MP2 V2 System|Facial wrinkles and temporary cellulite and circumference reduction treatments
1887174|NCT01234272|Drug|morphine|ITM-IVPCA: intrathecal administration of 0.3 mg morphine before induction of general anesthesia and application of IVPCA (basal infusion: fentanyl 0.4mcg/kg/hr, bolus: 0.16mcg/kg of fentanyl with a lock out time of 15 min)
1887175|NCT01234272|Drug|Ropivacaine|PCEA: epidural administration of 5ml 0.2% ropivacaine before induction of general anesthesia and application of PCEA (basal infusion: 5ml 0.2% ropivacaine with fentanyl 0.4 mcg/kg/hr, bolus: 2ml 0.2% ropivacaine with fentanyl 0.16mcg/kg with a lockout time 15min)
1887306|NCT01235078|Device|EZ-IO|powered intraosseous vascular access system
1887176|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 40-50 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
1887177|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 50-60 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
1887178|NCT01234285|Drug|heparin|intravenous heparin titrated to an aPTT of 40-45 seconds starting between 300-500 units per hour and adjusted every 6 hours based on aPTT, starting within 24 hours of ICU admission up to 6 days.
1887179|NCT01234285|Drug|heparin|5000 units subcutaneously three times a day, starting within 24 hours of ICU admission up to 6 days.
1887180|NCT01234298|Drug|SPD489 Low-Dose|SPD489 20, 30, or 40 mg capsules taken once-daily for up to 26 weeks
1887181|NCT01234298|Drug|SPD489 High-Dose|SPD489 50, 60, or 70 mg capsules taken once-daily for up to 26 weeks
1887182|NCT01234298|Drug|Placebo|Placebo capsule taken once-daily for up to 26 weeks
1887183|NCT01234311|Drug|tasquinimod|Tasquinimod up to a maximum maintenance dose of 1 mg once daily, administrated orally (capsule)
1887184|NCT01234311|Drug|Placebo|
1887185|NCT01234324|Drug|Epirubicin, Cisplatin, Capecitabine, Panitumumab|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle; Panitumumab: 9 mg/kg bodyweight, administered IV by an infusion pump through a peripheral line or catheter over 60 min +-15 min on day 1 of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
1887186|NCT01234324|Drug|Epirubicin, Cisplatin, Capecitabine|Epirubicin: 50mg/m², administered as an intravenous bolus over 10min on day 1 of each 21 day cycle; Cisplatin: 60mg/m², administered as an intravenous infusion over 4h on day 1 of each 21 day cycle; Capecitabine: 625mg/m², administered orally twice daily on each day of each 21 day cycle. Number of Cycles: 3 neoadjuvant cycles and 3 adjuvant cycles until disease progression, withdrawal of consent or unacceptable toxicity develops.
1887187|NCT01234337|Drug|Sorafenib (Nexavar, BAY43-9006)|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Sorafenib was administered orally at a dose of 600 mg (200 mg in the morning, 400 mg in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and sorafenib dose to a total daily dose of 800 mg for that subject.
1887188|NCT01234337|Drug|Placebo|Capecitabine was administered orally at a dose of 1,000 mg/m^2 twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle. Placebo matching to sorafenib was administered orally, 3 tablets (1 tablet in the morning, 2 tablets in the evening) daily, continuously (that is, Days 1 to 21, inclusive). A treatment cycle consisted of 21 days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily and placebo dose to a total daily dose of 4 tablets (2 tablets twice daily) for that subject.
1887189|NCT01234337|Drug|Capecitabine|Capecitabine was administered orally at a dose of 1,000 milligram per square meter (mg/m^2) twice daily (12 hours apart) on Days 1 through 14 of each 21-day cycle.days. If tolerability criteria were met for a subject, capecitabine dose was escalated to 1,250 mg/m^2 twice daily,
1887190|NCT01234363|Device|Magnetic Resonance Elastography, and Supersonic Shear Imaging|Magnetic Resonance Elastography, and Supersonic Shear Imaging
1887191|NCT01234376|Device|Confocal laser endomicroscopy|Confocal laser endomicroscopy
1887192|NCT01234389|Device|Electrochemical H. pylori detection method|Determination of H. pylori infection.
1887193|NCT01234389|Device|IHC|Determination of H. pylori infection.
1887194|NCT01234389|Device|C13-urea breath test|Determination of H. pylori infection.
1887195|NCT01234389|Device|HUT|Determination of H. pylori infection.
1887196|NCT01234402|Biological|Ramucirumab DP|"10 mg/kg I.V.
Day 1 of every-21-day cycle"
1887197|NCT01234402|Biological|IMC-18F1|"12 mg/kg I.V.
Days 1 and 8 of every-21-day cycle"
1887198|NCT01234402|Drug|Capecitabine|"1000 mg/m2 orally
Twice a day for 14 days"
1887199|NCT01234415|Device|Rhinoplasty|Rhinoplasty is performed under general anaesthesia; the duration is 1 to 2 hours. The surgical approach for implantation of the biomaterial is external rhinoplasty. The incision is made at the columella (base of nose) and becomes internal for the scar to be as unobtrusive as possible. The septum skeleton is then destroyed in order to place the synthetic biomaterial. The biomaterial is remodelled in order to have a natural external aspect of the nose. The incision is closed and the wicks are put in place in the nose for 4 days. A cast and a sticker will be put in place after surgery to maintain properly the biomaterial.
1887200|NCT01234428|Procedure|Laparoscopic surgery|Gastric banding
1887201|NCT01234428|Procedure|gastric banding|laparoscopic gastric banding
1887202|NCT01234441|Dietary Supplement|Control|A placebo non-nutritive beverage will be administered before dialysis sessions 3 times per week.
1887203|NCT01234441|Dietary Supplement|Protein|A whey protein beverage will be administered before dialysis sessions 3 times per week.
1887204|NCT01234441|Behavioral|Protein + Exercise|A whey protein beverage will be administered before dialysis sessions 3 times per week. Patients will also exercise by stationary bicycle during dialysis sessions 3 times per week.
1887205|NCT01234454|Drug|Risperidone|6mg/day or highest dose tolerated for 8 weeks, following 4 weeks baseline treatment of Thiothixene
1887206|NCT01234454|Drug|Olanzapine|20mg/day for 8 weeks, following 4 weeks of baseline Thiothixene.
1887207|NCT01234467|Drug|Bendamustine|Dosage Form: Intravenous (60 minute infusion) Dosage: 120mg/m2 (ECOG = 0-2) or 90mg/m2 (ECOG = 3) Frequency: Day 1 and Day 2; Every 3 weeks of a 21 day cycle. Duration: 3-6 Cycles
1887208|NCT01234467|Drug|Rituximab|Dosage form: Intravenous Dosage: 375 mg/m2 Frequency: Day 1 of every 3 weeks of a 21 day Cycle Duration: 3-6 Cycles
1887209|NCT01234493|Procedure|fixation|Syndesmosis fixation with one 3.5mm fully threaded three cortical screw
1887210|NCT01234493|Procedure|no fixation|No syndesmosis fixation.
1887211|NCT01234506|Dietary Supplement|secoisolariciresinol diglucoside|SDG supplementation as a packet of 0.8g/day of BeneFlax containing 300 mg SDG for 24 weeks
1887212|NCT01234519|Drug|AEZS-108|128, 160, 210 or 267 mg/m2, 2-hour intravenous (IV) infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
1887213|NCT01234519|Drug|AEZS-108 at MTD|2-hour IV infusion, Day 1 of 21-day cycles , until toxicity or progression, up to 6 cycles
1887214|NCT01234532|Drug|entinostat|orally
1887215|NCT01234532|Drug|anastrozole|Given PO
1887216|NCT01234532|Other|diagnostic laboratory biomarker analysis|"Correlative studies will be performed utilizing tissue and blood. A baseline tumor biopsy is done prior to study entry or archival tissue from diagnosis may be used and a representative tumor sample is submitted at time of surgery.
Bloods are drawn for correlative sciences on day 1 and 15 of treatment prior to entinostat dosing and 30 mins post and again on day of surgery."
1887217|NCT01234532|Procedure|therapeutic conventional surgery|Lumpectomy or mastectomy will be performed follwoing day 29 of study therapy
1887218|NCT01234545|Drug|activated recombinant human factor VII|Prescription is done at the discretion of the prescribing physician as part of normal clinical routine
1887220|NCT01234584|Procedure|spk|implants using SPK Abutments
1887221|NCT01234584|Procedure|CPK Abutments|implants using CPK Abutments
1887222|NCT01234597|Drug|INSULIN GLARGINE (HOE901)|Pharmaceutical form: solution for injection Route of administration: subcutaneous
1887223|NCT01234597|Drug|INSULIN GLULISINE (HMR1964)|Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
1887224|NCT01234610|Behavioral|Supervised exercise training|Patients will be asked to attend three exercise sessions per week for 12 weeks. They will exercise in groups of up to four per session and they will be supervised by an experienced exercise physiologist. Each session will comprise 5 to 10 min warm-up period (involving very light aerobic exercise and a range of gentle movements), 30 min of light-to-moderate intensity aerobic exercise (cycle-ergometry and or treadmill-walking), and a 5 to 10 min cool-down period involving low-intensity aerobic exercise and gentle stretching. The intensity of the aerobic exercise will be individualised and will be progressed gradually (if appropriate) during the course of the study.
1887225|NCT01234610|Behavioral|Usual care control|Usual care, no active intervention
1887226|NCT01234623|Other|UCS eyedrops|1 ml UCS eyedrops/day topically applied 8 times/day 1 drop/eye for 28 days
1887227|NCT01234636|Dietary Supplement|Placebo oil|Placebo oil of 4g/day
1887228|NCT01234649|Drug|Metformin XR plus placebo|Metformin plus Placebo Metformin 500 mg qd 2 weeks 500 mg bid 2 weeks 500 mg am, 1000 mg pm- 2 weeks 1000 mg bid -98 weeks (end study) Placebo-start 1 injection SC QD step up to a max dose as tolerated
1887229|NCT01234649|Drug|Metformin XR plus liraglutide|Metformin XR-500 qd for 2 weeks, 500 mg bid 2 weeks; 500 mg am, 1000 mg pm- 2 weeks - 1000 bid final dose Liraglutide- start 0.6 mg SC QD step up to 1.2 mg to a max dose of 1.8 mg SC QD as tolerated during the 4-wk non-forced dose-escalation period ( maximum allowed dose of 1.8 mg SC QD)
1887230|NCT01234662|Procedure|SPA|Spinal anesthesia and opioids
1887231|NCT01234662|Procedure|CSE|CSE and epidural opioids
1887232|NCT01234662|Procedure|CSEPCEA|CSE and continuous epidural patient controlled analgesia using an epidural catheter for 24 hrs
1887233|NCT01234675|Drug|Milnacipran|Placebo twice daily then 50 mg milnacipran or matching
1887234|NCT01234675|Drug|Milnacipran|50 mg twice daily; then matching placebo twice daily
1887235|NCT01234688|Other|Exercise training|Patients included in the exercise group were submitted to intra-dialytic exercise training, 3 times per week for 12 weeks.
1887236|NCT01234701|Other|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
1887237|NCT01234701|Procedure|Liver resection|Hepatectomy with an intention to cure
1887238|NCT01234701|Other|Histopathology diagnosis of resected liver specimen|Histopathology diagnosis by expert pathologist.
1887239|NCT01234714|Other|Non-invasive Magnetic Resonance Imaging (MRI)|Conventional pre-operative MRI
1887240|NCT01234714|Procedure|Major liver resection|Hepatectomy of >= 3 liver segments
1887241|NCT01234740|Drug|bafetinib|Given orally
1887242|NCT01234740|Procedure|microdialysis|Catheter placed intracerebrally during debulking craniotomy or stereotactic biopsy
1887243|NCT01234740|Other|pharmacological study|Correlative studies
1887244|NCT01234740|Other|liquid chromatography|Correlative studies
1887245|NCT01234740|Other|mass spectrometry|Correlative studies
1887246|NCT01234740|Other|laboratory biomarker analysis|Correlative studies
1887247|NCT01234740|Genetic|protein expression analysis|Correlative studies
1887248|NCT01234740|Genetic|western blotting|Correlative studies
1887249|NCT01234740|Other|immunohistochemistry staining method|Correlative studies
1887250|NCT01234740|Procedure|therapeutic conventional surgery|debulking craniotomy
1887251|NCT01234753|Other|Physician and nurse consultation|Usual care by a visit to physician at the hospital out-patient clinic and computer-based and individual education and psychosocial support by a nurse-led session.
1887252|NCT01234766|Drug|Bendamustine|90mg/m2, IV - Days 1 and 2 of every cycle
1887253|NCT01234766|Drug|Rituximab|375mg/m2, IV - Cycle 1 only: Day -7 (+1 day) Day 1 of every cycle
1887254|NCT01234766|Radiation|Y-90 ibritumomab|0.4mCi/kg, IV - Within 4 hours of rituximab, give over 10 minutes
1887255|NCT01234779|Drug|bitopertin [RO4917838]|10 mg orally daily, 4 weeks
1887256|NCT01234779|Drug|bitopertin [RO4917838]|30 mg orally daily, 4 weeks
1887257|NCT01234779|Drug|olanzapine|15 mg orally daily, 4 weeks
1887258|NCT01234779|Drug|placebo|orally daily, 4 weeks
1887259|NCT01234792|Drug|6 mg Experimental nicotine gum|A single 6 mg dose of an experimental nicotine gum, with a 36-hour washout between visits
1887260|NCT01234792|Drug|4 mg Nicotine Gum/|A single 4 mg dose of Nicorette® gum, with a 36-hour washout between visits
1887261|NCT01234792|Drug|2 mg Nicotine Gum|A single 2 mg dose of Nicorette® gum, with a 36-hour washout between visits
1887262|NCT01234805|Procedure|yoga therapy|Participates in yoga classes and yoga at home
1887263|NCT01234805|Other|questionnaire administration|Ancillary studies
1887264|NCT01234805|Procedure|quality-of-life assessment|Ancillary studies
1887305|NCT01235065|Device|type of laryngoscope|Patients who require emergency rapid sequence intubation are randomized to intubation with either the direct laryngoscope or the video laryngoscope
1887265|NCT01234818|Device|Mirena (LNG-IUS)|General Name/Brand name: Mirena - Bayer ② Active ingredient: levonorgestrel 52mg ③ Description: Mirena is a hormone-releasing T-shaped intrauterine system. A removal thread is attached to a loop at the end of the vertical stem of the T-body.
1887268|NCT01234844|Behavioral|care of guinea pigs|twice weekly sessions of care with guinea pigs
1887269|NCT01234844|Behavioral|guinea pigs|"twice weekly pet therapy and twice weekly usual  occupational therapy"
1887270|NCT01234857|Drug|ridaforolimus + dalotuzumab|Ridaforolimus 20 mg once daily (QD) five days a week, with the possibility of escalation to 30 mg once daily (QD) after the first cycle and dalotuzumab intravenous infusion 10 mg/kg once weekly (QW). Treatment will continue until disease progression.
1887271|NCT01234857|Drug|exemestane|Exemestane 25 mg daily (QD). Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
1887272|NCT01234857|Drug|ridaforolimus|Ridaforolimus 40 mg QD five days a week. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval. Note: the Sponsor-recommended dose of ridaforolimus when administered as a single agent is 40 mg/day, but when given in combination with dalotuzumab, it is given at 30 mg/day.
1887273|NCT01234857|Drug|dalotuzumab|Dalotuzumab intravenous infusion 10 mg/kg QW. Treatment will continue until disease progression. Patients may cross-over to the combination therapy after disease progression at the discretion of the investigator with Sponsor approval.
1887274|NCT01234870|Drug|Gadolinium|
1887275|NCT01234870|Drug|Adenosine|
1887276|NCT01234883|Drug|multiple electrolyte solution|IV multiple electrolyte solution dosed as clinically indicated for rehydration
1887277|NCT01234883|Drug|saline|IV solutions dosed as clinically indicated for rehydration
1887278|NCT01234896|Drug|Nicotine Medicated Gum|Dosage Form: Gum; Dosage: 6 mg; Frequency: Once; Duration: 30 minutes
1887279|NCT01234896|Drug|4 mg Nicotine Gum|Dosage Form: Gum; Dosage: 4 mg; Frequency: Once; Duration: 30 minutes
1887280|NCT01234896|Drug|2 mg Nicotine Gum|Dosage Form: Gum; Dosage: 2 mg; Frequency: Once; Duration: 30 minutes
1887281|NCT01234896|Drug|4 mg Nicotine Lozenge|Dosage Form: Lozenge; Dosage: 4 mg; Frequency: Once; Duration: until dissolved
1887282|NCT01234922|Drug|lisinopril|Given orally
1887283|NCT01234922|Drug|losartan potassium|Given orally
1887284|NCT01234922|Other|laboratory biomarker analysis|Correlative studies
1887285|NCT01234922|Drug|benazepril hydrochloride|Given orally
1887286|NCT01234922|Drug|ramipril|Given orally
1887287|NCT01234935|Drug|dasatinib|Given orally
1887288|NCT01234935|Drug|gemcitabine hydrochloride|Given IV
1887289|NCT01234935|Other|laboratory biomarker analysis|Correlative studies
1887290|NCT01234935|Genetic|mutation analysis|Correlative studies
1887291|NCT01234935|Genetic|nucleic acid sequencing|Correlative studies
1887292|NCT01234935|Other|immunohistochemistry staining method|Correlative studies
1887293|NCT01234961|Behavioral|Redesigning Daily Occupations|The ReDO is a 16-week group-based programme, comprising three phases. Phase I covers five weeks and has a special focus on occupational self-analysis, while Phase II, also comprising five weeks, is concentrated around goal setting and strategies for accomplishing desired changes in the patterns of everyday activities. During these ten weeks the group meets twice a week and each session lasts for 2½ hrs. Phase III consists of work placement for six weeks, if possible in relation to the woman's ordinary work but otherwise at another relevant work place. During Phase III the group meets three times (weeks two, four and six) in order to monitor the group placement. The groups are led by two licensed occupational therapists specifically trained for the ReDO programme.
1887294|NCT01234961|Other|Care as usual|The CAU group gets follow-ups by an officer at the Social Insurance Office, including contacts with the employer, but the additional support varies largely, from receiving relevant medical care, if any, to physical therapy and to more comprehensive rehabilitation programmes.
1887295|NCT01234974|Drug|Pasireotide|Given as an intramuscular injection on day 1 every 28 days, 60 mg per dose
1887296|NCT01234974|Drug|Everolimus|given as an oral tablet every day on days 1-28, 10 mg per day
1887297|NCT01235000|Biological|2010-11 trivalent inactivated influenza vaccine|A single age-appropriate dose of 2010-11 trivalent inactivated influenza vaccine
1887298|NCT01235013|Drug|Maraviroc|150 mg of Maraviroc every 12 hours (300 mg daily) orally for 24 weeks
1887299|NCT01235026|Dietary Supplement|Synbiotic|"5g of the prebiotic Oligofructose + 1 g of the probiotic Bifidobacterium animalis subsp. lactis Bb12 (4x10^10 CFU/g), twice a day, for 6 weeks."
1887300|NCT01235026|Dietary Supplement|Placebo|6g of maltodextrin, twice a day for 6 weeks.
1887301|NCT01235039|Drug|VIAject®25|Two vial presentation for reconstitution and single dose of 12 IU subcutaneous injection and 25 IU/mL
1887302|NCT01235039|Drug|VIAject®7|One vial presentation and single dose of 12 U for subcutaneous injection and 100 IU/mL
1887303|NCT01235039|Drug|Insulin Lispro|One vial presentation and single dose of 12 IU for subcutaneous injection and 100 IU/mL
1887304|NCT01235052|Radiation|Positon Emission Tomography using 18F-FMISO|We will introduce a pretherapy [18F]-FMISO PET-CT in the treatment planning of patients suffering of head and neck cancer and eligible to a radical treatment with curative intent, consisting of conformational radiotherapy with or without chemotherapy or associated targeted therapy. [18F]-FMISO PET-CT results will not be taken into account for the patients' management. We will test different acquisition protocols and use a wild panel of quantification parameters issued from published studies and originals 'one developed by our team enable to describe [18F]-FMISO uptake. Patients will be followed clinically and para-clinically during two years after the end of the treatment according to the edited recommendations of these tumours type and grade to analyze outcome.
1887307|NCT01235091|Behavioral|NIDA Cooperative Agreement Standard Intervention plus HIV/STD testing|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment.
1887308|NCT01235091|Behavioral|Standard Intervention plus Well-Woman Exam|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to additionally receive a well-woman examination within seven days.
1887309|NCT01235091|Behavioral|Standard Intervention plus Well-Woman Exam and Peer-Delivered Intervention|At the end of Baseline Session I, HIV pre-test counseling, per the NIDA Cooperative Agreement, was delivered, along with education about STD prevention, and biological samples were collected to test for HIV, Hepatitis C, syphilis, chlamydia and gonorrhea. At Baseline Session II, HIV post-test counseling was conducted and women were given their random group assignment. This group was assigned to receive a well-woman exam within seven days along with four two-hour peer-delivered educational sessions, covering health and nutrition, stress and coping, substance abuse, and HIV/AIDS.
1887310|NCT01235104|Procedure|Total nephrectomy|Total nephrectomy
1887311|NCT01235117|Drug|azacitidine|
1887312|NCT01235117|Other|laboratory biomarker analysis|
1887313|NCT01235130|Drug|OMEGA-3|600mg, 2 caps, twice a day
1887314|NCT01235130|Drug|Placebo soybean oil|600mg, 2caps twice a day
1887315|NCT01235143|Drug|Desflurane|Desflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
1887316|NCT01235143|Drug|Sevoflurane|Sevoflurane (not more than 1 MAC) for maintenance of anesthesia in urologic surgery
1887317|NCT01235169|Device|Proximal Femoral Nail Antirotation(PFNA) with cement augmentation|
1887318|NCT01235195|Drug|sertraline hydrochloride|50 mg capsule, single-dose
1887319|NCT01235195|Drug|sertraline hydrochloride|50 mg tablet, single-dose
1887320|NCT01235208|Other|"The Dr. Fedon Lindbergs Vektcoach Treatment"|Diet and lifestyle treatment
1887321|NCT01235221|Drug|BIIB041 (Fampridine-SR)|10 mg twice a day (BID) sustained-release (SR) tablets by mouth for up to 27 months (in addition to treatment in previous studies) or until the product is commercially available, whichever comes first. Doses of study treatment must be spaced at least 12 hours apart.
1887322|NCT01235234|Drug|CF101|orally q12h
1887323|NCT01235247|Behavioral|reminders vs. no reminders|Intervention providers will receive clinical reminders as part of patient care, and control group providers will not receive the reminders
1887324|NCT01235260|Other|Becaplermin nonusers|A cohort of becaplermin nonusers (ie, patients who are not treated with becaplermin but are similar in characteristics to patients in the becaplermin user cohort)
1887325|NCT01235260|Drug|Becaplermin users|A cohort of becaplermin users (ie, patients with diabetes treated with becaplermin)
1887326|NCT01235273|Drug|Growth Hormone|growth hormone administration
1887327|NCT01235273|Other|Placebo|standard placebo
1887328|NCT01235286|Procedure|remote ischemic preconditioning|"A standardized location for microcirculatory assessment was determined on the left leg of each participant between the proximal and distal third of a drawn line between the anterior superior iliac spine and the lateral aspect of the Patella.
The healthy subjects had to rest before starting data assessment in a horizontal position for 15 minutes. The probe was taped on the left upper leg in a standardized manner after localizing the measuring point. A blood pressure cuff was applied on the contralateral upper arm. Baseline data was assessed over 5 minutes before starting remote ischemia. Three circles of a five minute ischemia were applied at the contralateral right upper arm at suprasystolic levels. Parameters of microcirculation were assessed continuously over time. Microcirculation during the reperfusion phase was ascertained over 10 minutes after first and second remote ischemia and 15 minutes after the third remote ischemia."
1887329|NCT01235325|Dietary Supplement|phylloquinone (vitamin K1)|1000 mcg phylloquinone (vitamin K1) once daily for 12 months
1887330|NCT01235325|Dietary Supplement|placebo|placebo oil capsule
1887331|NCT01235338|Drug|LDX + Venlafaxine XR|"Day 1-5 LDX 30mg
Day 6-10 LDX 50mg
Day 11-15 LDX 70mg
Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily
Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily
Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily
Day 31-34 Venlafaxine XR 150mg daily
Day 35-38 Venlafaxine XR 75mg daily."
1887332|NCT01235338|Drug|Venlafaxine XR + LDX|"Day 1-5 Venlafaxine XR 75mg
Day 6-10 Venlafaxine XR 150mg
Day 11-15 Venlafaxine XR 225mg
Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily
Day 21-25 Venlafaxine XR and LDX 50mg daily
Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily
Day 31-34 Venlafaxine XR 150mg
Day 35-38 Venlafaxine XR 75mg."
1887334|NCT01235364|Device|Foley catheter|The Foley catheter was placed with the digital method
1887335|NCT01235364|Device|Foley catheter|The Foley catheter was placed with a speculum
1887336|NCT01235377|Other|Favor one of two thiazides for new prescriptions & attempt target dose|Providers will be randomized to either Favor Chlorthalidone or Favor Hydrochlorothiazide for patients who are to be newly prescribed a thiazide for hypertension, whether the thiazide is 1st line or add-on therapy. Providers will have agreed to adhere to their assignment for patients for whom there is equipoise, but they are free to deviate if medically indicated for individual patients. There is no requirement to maintain the initial thiazide therapy; it is expected that the regimen may require adjustment over time. The cluster assignment is simply to favor a particular thiazide on initiation of thiazide therapy and attempt to reach the target dose.
1887337|NCT01235390|Dietary Supplement|Walnuts|The consumption of assigned walnuts once a day during 4 weeks
1887338|NCT01235403|Drug|Lacosamide|"Lacosamide : 50 mg tablets bid. Titration phase: (12 weeks) 100 mg/day: duration 1 to 3 weeks. Then uptitration to optimal therapeutic dose of 200 mg/day to 400 mg/day, in steps of 100 mg/day and a time period per step of 1 to 3 weeks.
Maintenance phase (12 weeks): Optimal therapeutic dose 200 mg/day to 400 mg/day.
Taper phase if needed: 3 to 4 weeks"
1887381|NCT01227512|Drug|tolvaptan|15 mg titrated to 30 mg then 60 mg once daily as oral tablet for up to 7 days based on response.
1887339|NCT01235416|Drug|AMG 706|In each of these 3 planned treatment cohorts, approximately 6 evaluable subjects will be treated with gemcitabine (1000-mg/m2 intravenously over 30 minutes, once weekly starting on day 1, week 1 of cycle 1) and erlotinib (100 mg orally once daily starting on day 1, week 1 of cycle 1)
1887340|NCT01235429|Behavioral|Partners in Care|Participants will be offered 12 group diabetes self-management educational lessons delivered by trained community health workers.
1887341|NCT01235429|Behavioral|Partners in Care|Diabetes self-management education
1887342|NCT01235442|Drug|1=Etanercept|50 mg SC bi-weekly for 12 weeks followed by 50 mg SC weekly for 12 weeks.
1887343|NCT01235442|Drug|2=Clobetasol propionate foam|0.05% clobetasol propionate foam applied topically twice daily during two up-to-2 week courses
1887344|NCT01235455|Drug|Interferon beta-1b (Betaseron, BAY86-5046)|250 µg, sub-cutaneously, on alternate days
1887345|NCT01235468|Biological|ex vivo expansion|ex-vivo expansion of cord blood for transplantation
1887346|NCT01235481|Device|Exercise DVD|Exercise DVD added to usual care during maintenance phase of pulmonary rehabilitation
1887347|NCT01235481|Behavioral|Usual Care|Usual care during maintenance phase post pulmonary rehabilitation
1887348|NCT01235494|Other|polarised 3 helium|1 inhalation (= 1 litre)
1887349|NCT01235507|Drug|methotrexate|stable dose as prescribed
1887350|NCT01235507|Drug|tocilizumab [RoActemra/Actemra]|8 m/kg (maximum 800 mg) intravenously every 4 weeks for a total of 6 infusions
1887351|NCT01235520|Drug|Placebo|Oral doses, once a day for 52 weeks
1887352|NCT01235520|Drug|RO4917838|Oral dose level 1, once a day for 52 weeks
1887353|NCT01235520|Drug|RO4917838|Oral dose level 2, once a day for 52 weeks
1887354|NCT01235533|Dietary Supplement|N-3 polyunsaturated fatty acids|Three capsules per day. Each capsule included 600mg eicosapentanoic acid (20:5n-3), 400 mg of docosahexanoic acid (22:6n-3), tertiary-butylhydroquinone 0.2 mg/g and tocopherols 2 mg/g.
1887355|NCT01235546|Drug|Azithromycin and standard of care|500 mg in 250 cc normal saline 1 time dose plus standard of care (cephazolin or clindamycin)
1887356|NCT01235546|Drug|Placebo and standard of care|250 cc normal saline, plus standard of care (cephazolin or clindamycin)
1887357|NCT01235559|Drug|Placebo|Oral doses, once a day for 52 weeks
1887358|NCT01235559|Drug|bitopertin [RO4917838] level 1|Oral dose level 1, once a day for 52 weeks
1887359|NCT01235559|Drug|bitopertin [RO4917838] level 2|Oral dose level 2, once a day for 52 weeks
1887360|NCT01235572|Procedure|standard follow-up care|Undergo early discharge and standard outpatient care
1887361|NCT01235572|Other|medical chart review|Undergo early discharge and standard outpatient care
1887362|NCT01235572|Procedure|quality-of-life assessment|Ancillary studies
1887363|NCT01235585|Drug|Placebo|Oral doses, once a day for 52 weeks
1887364|NCT01235585|Drug|bitopertin [RO4917838]|Oral dose level 1, once a day for 52 weeks
1887365|NCT01235585|Drug|bitopertin [RO4917838]|Oral dose level 2, once a day for 52 weeks
1887366|NCT01235598|Other|Placebo|Placebo provided for the first subcutaneous injection in single-use vials at Week 0 (2 vials required), then Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4 and 6, followed by Certolizumab Pegol (CZP) 200 mg every 2 weeks from Week 8 to Week 40
1887367|NCT01235598|Biological|Certolizumab Pegol (CZP) 200 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
1887368|NCT01235598|Biological|Certolizumab Pegol (CZP) 400 mg|Placebo, saline solution for subcutaneous injection at Week 0 followed by Certolizumab Pegol (CZP) 400 mg at Weeks 2, 4, and 6, then Certolizumab Pegol (CZP) 200 mg 2-weekly from Week 8 to Week 40
1887369|NCT01235624|Genetic|genetic analysis|
1887370|NCT01235637|Drug|Alfentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.
Dosage: 10μg/Kg, dilution: 1 ml = volume equivalent to 66μg or 10μg/kg = 1.43μg/kg fentanyl.
Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
1887371|NCT01235637|Drug|Sufentanil|"dosage form: injectable drug, opioid analgesic morphine, intravenous drug.
Dosage: intravenous drug to 0,15 µg/Kg : Blisters of 10 ml, box of 20. MERCK
Frequency and duration: 2 bolus injection before 2 tracheal suctions at 0 and 4 hours respectively."
1887372|NCT01235663|Behavioral|advisory support|regular advisory support to the prolong breast-feeding period
1887373|NCT01235676|Behavioral|diet|calorie restriction to reduce weight gain
1887374|NCT01235676|Behavioral|Exercise|Exercise to reduce weight gain
1887378|NCT01227473|Behavioral|Mindfulness-based diabetes prevention education group|The mindfulness-based diabetes prevention group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, this group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the mindfulness-based diabetes prevention group, the instruction will be enhanced with a modified mindfulness meditation training designed to support the behavioral-change programming.
1887379|NCT01227473|Behavioral|Conventional diabetes prevention education group|The conventional diabetes prevention education group meets for 2 ½ hours per week for eight weeks, with one 4-hour retreat between the 6th and 7th weeks, and monthly booster sessions for 6 months. During the 8-week interventions, the group receives a 30-minute health behavior presentation (based on the landmark Diabetes Prevention Program). In the conventional diabetes prevention group, the instruction will be enhanced with group exercises and discussions.
1887380|NCT01227486|Device|Ultrasound|Ultrasound scan just proximal to the suprasternal notch during intubation and ultrasound scan of both lungs during ventilation
1887433|NCT01227759|Drug|Placebo|Placebo containing no active ingredient
1887382|NCT01227512|Other|Fluid Restriction|"Placebo tablet once daily with prescribed daily fluid intake of 1500 mL, then intensifying to 2 lower volumes of fluid intake for up to 7 days based on response.
Since all particpants were blinded to treatment, titration to stricter fluid restriction followed the same algorithm as tolvaptan, increasing both the level of fluid restriction and increasing the placebo dose"
1887383|NCT01227525|Device|Vibraject|The VibraJect clips onto the barrel of a conventional and intraligamentary dental syringe (and some disposable syringes) and vibrates the needle at a high frequency while injections are administered.
1887384|NCT01227538|Other|Mixed meal stimulated urinary C peptide for the assessment of residual beta cell function|Study will be designed to assess stimulated urinary C-peptide in comparison to mixed-meal stimulated plasma C-peptide response in the same individual in 30 number of patients with Type 1 diabetes.
1887385|NCT01227551|Biological|Coxsackievirus A21 (CVA21)|CVA21 is a live oncolytic virus preparation derived from the non-genetically altered prototype Kuykendall strain of Coxsackievirus A21.
1887386|NCT01227564|Biological|ACC-001 3 μg/ QS-21 50 μg|ACC-001 3 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
1887387|NCT01227564|Biological|ACC-001 10 μg/ QS-21 50 μg|ACC-001 10 μg/ QS-21 50 μg IM on day 1, month 1, month 3, month 6, month 12, and month 18
1887388|NCT01227564|Other|Placebo- Phosphate buffered saline (PBS)|Phosphate buffered saline IM on day 1, month 1, month 3, month 6, month 12, and month 18
1887389|NCT01227577|Drug|Nilotinib|Nilotinib was supplied as 150 mg and 200 mg hard gelatin capsules.
1887390|NCT01227590|Drug|Kaletra (lopinavir/ritonavir), African Potato (hypoxis obtusa)|The baseline PK of LPV/r will be established after 14 days of taking LPV/r at a dose of 400/100 mg twice daily. This will be followed by a 7 day course of LPV/r and AP together. The AP dose to be administered will be 15 mg/kg/day of hypoxoside.
1887391|NCT01227603|Drug|Nifedipine-candesartan FDC (BAY 98-7106)|Single dose of 1 FDC tablet consisting of 60 mg nifedipine GITS and 32 mg candesartan
1887392|NCT01227603|Drug|Nifedipine GITS (Adalat LA, BAYA1040)|Single oral dose of 1 tablet of nifedipine GITS 60 mg
1887393|NCT01227603|Drug|Candesartan (Atacand)|Single oral dose of 32 mg (2 x 16 mg tablet) candesartan
1887394|NCT01227616|Drug|Ferumoxytol|IV Ferumoxytol
1887395|NCT01227616|Drug|Iron Sucrose|IV Iron Sucrose
1887396|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
1887397|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
1887398|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
1887399|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
1887400|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
1887401|NCT01227629|Drug|dabigatran with ASA|dose comparison in combination
1887402|NCT01227629|Drug|warfarin|comparator
1887403|NCT01227629|Drug|dabigatran without ASA|dose comparison
1887404|NCT01227629|Drug|dabigatran without ASA|dose comparison
1887405|NCT01227629|Drug|dabigatran without ASA|dose comparison
1887406|NCT01227642|Other|An ultrasound-based technique to identify prostate cancer|The technique uses current ultrasound equipment already in use for prostate brachytherapy guidance.By extracting and processing the radiofrequency signal obtained from the ultrasound transducer in ways not done to create the standard B-mode ultrasound image, areas of cancer can be identified and displayed overlying the standard B-mode ultrasound image. Comparing the results with this technique to the results of prostate biopsies demonstrates a high degree of accuracy with the area under the receiver-operator characteristic curve of 0.87, a result superior to any other imaging methods.
1887407|NCT01227642|Other|pre-implant transrectal ultrasound images and planning|an ultrasound-based technique to identify cancer-containing areas within the prostate.
1887408|NCT01227642|Other|ultrasound-based cancer-specific images|ultrasound-based cancer-specific images of the prostate prior to the brachytherapy and use them to direct the dosimetry planning
1887409|NCT01227655|Drug|BIA 9-1067|Capsules will be used.
1887410|NCT01227655|Drug|Placebo|comparator
1887411|NCT01227655|Drug|Levodopa|
1887412|NCT01227655|Drug|Carbidopa|DOPA decarboxylase inhibitor (DDCI)
1887413|NCT01227655|Drug|Benserazide|DOPA decarboxylase inhibitor
1887414|NCT01227668|Drug|Aripiprazole|Tablets, Oral, 2-15 mg, once daily, 13-42 weeks
1887415|NCT01227668|Drug|Placebo|Tablets, Oral, 0 mg, once daily, 16 weeks
1887416|NCT01227681|Drug|G-CSF|G-CSF(granulocyte-colony stimulating factor) is planned injected subcutaneously
1887417|NCT01227681|Drug|Placebo|Sodium Chloride (NaCl) 0.9 %
1887418|NCT01227694|Other|Autologous MSC knee implantation|"Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection."
1887419|NCT01227707|Drug|bevacizumab [Avastin]|5 mg/kg intravenously every 2 weeks, 4 cycles
1887420|NCT01227707|Drug|capecitabine [Xeloda]|825 mg/m2 twice daily orally, 38 days
1887421|NCT01227707|Radiation|Radiation therapy|Total dose of 45 Gy over 38 days
1887422|NCT01227707|Procedure|Mesorectal excision|6-8 weeks after completion of neoadjuvant treatment
1887423|NCT01227707|Drug|bevacizumab [Avastin]|Post-surgery adjuvant treatment at the discretion of the investigator: 5 mg/kg iv every 2 weeks for at least 6 months
1887424|NCT01227707|Drug|5-fluorouracil|Post-surgery adjuvant therapy: bolus of 400mg/m2 iv plus iv infusion of 600 mg/m2 on Days 1 and 2 of each 2-week cycle for 6 months
1887425|NCT01227707|Drug|leucovorin|Post-surgery adjuvant treatment: 100 mg/m2 iv on Days 1 and 2 of each 2-week cycle for 6 months
1887426|NCT01227720|Drug|Experimental Nicotine Replacement Therapy (NRT) 2 mg|2 mg Single-dose of new NRT product (NSL2L)
1887427|NCT01227720|Drug|Experimental Nicotine Replacement Therapy (NRT)|4 mg Single-dose of new NRT product
1887428|NCT01227720|Drug|Marketed Nicotine Lozenge|2 mg Single-dose of marketed lozenge
1887429|NCT01227720|Drug|Marketed Nicotine Lozenge|4 mg Single-dose of marketed lozenge
1887430|NCT01227733|Other|Breast Tumor Blocks|
1887431|NCT01227746|Procedure|Tumor biopsies|
1887432|NCT01227759|Drug|Drug containing the active ingredient|The topical application is performed once daily during a 12-day treatment.
1887434|NCT01227772|Biological|OTSGC-A24|OTSGC-A24 administered at 1 mg in weekly, 2-weekly, and 3-weekly cohorts.
1887435|NCT01227785|Device|INCEPTA ICD or CRT-D|
1887436|NCT01227798|Drug|Interferon alfacon-1|15 mcg at fill volume of 0.5mL
1887437|NCT01227798|Drug|Placebo|Normal Saline
1887440|NCT01227824|Drug|GSK1349572 (dolutegravir)|GSK1349572 50 mg taken once daily with or without food
1887441|NCT01227824|Drug|raltegravir|raltegravir 400mg taken twice daily
1887442|NCT01227824|Other|GSK1349572 Placebo|GSK1349572 placebo taken once daily
1887443|NCT01227824|Other|ABC/3TC|Abacavir/Lamivudine background therapy once daily
1887444|NCT01227824|Other|TDF/FTC|Tenofovir/emtricitabine background therapy once daily
1887445|NCT01227824|Other|raltegravir Placebo|raltegravir placebo taken twice daily
1887446|NCT01227837|Dietary Supplement|placebo|placebo given to patients
1887447|NCT01227837|Dietary Supplement|omga3|use of omega 3
1887448|NCT01227863|Drug|MAXINOM®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% polimixyn B...................................0,1%
1887449|NCT01227863|Drug|Maxitrol®|Dexamethasone...............................................0,1% Neomicyn......................................0,35% Polimixyn B...................................0,1%
1887450|NCT01227876|Drug|Ster|prednisolone 1% ophthalmic suspension
1887451|NCT01227876|Drug|Pred Fort|prednisolone 1% ophthalmic suspension
1887452|NCT01227889|Drug|GSK2118436|150 mg twice daily
1887453|NCT01227889|Drug|Dacarbazine (DTIC)|Intravenous (IV), 1000 mg/m2 every 3 weeks until initial progression
1887454|NCT01227902|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum).
1887455|NCT01227915|Drug|Tobracort|tobramycin 0.3% + dexamethasone 1%
1887456|NCT01227915|Drug|Tobradex|tobramycin 0.3% + dexamethasone 1%
1887457|NCT01227928|Drug|Pazopanib|Pazopanib 800 mg daily for 24 months
1887458|NCT01227928|Drug|Placebo comparator|Placebo 800 mg daily for 24 months
1887459|NCT01227941|Drug|MK-4827 + pegylated liposomal doxorubicin|Initial evaluation of a 16-day dosing schedule: A loading dose of MK-4827 will be administered orally on Days 1-2 of the cycle and a maintenance dose daily on Days 3-16. Pegylated liposomal doxorubicin 40 mg/m^2 will be administered intravenously on Day 3 of each cycle. The maintenance dose of MK-4827 will be escalated, until the maximum tolerated dose (MTD) is determined. If the maintenance dose is escalated above the loading dose, the loading dose will be escalated to a level equal to the maintenance dose, for the subsequent cycle. Other dosing schedules of MK-4827 may be explored, including 7-, 10-, 21- and 28-day schedules.
1887460|NCT01227941|Drug|MK-4827 + pegylated liposomal doxorubicin|MK-4827 will be administered according to one or two dose schedules as determined in Part A. Pegylated liposomal doxorubicin 40 mg/m^2 will be administered intravenously on Day 3 of the cycle.
1887461|NCT01227954|Radiation|intensity-modulated radiation therapy|30 Gy in 10 fractions to the whole brain using intensity-modulated radiation therapy excluding the hippocampal avoidance area. Bilateral hippocampal contours manually generated on the fused planning MRI CT image set by the treating physician according to protocol-specified contouring instructions. Hippocampal avoidance regions generated by three-dimensionally expanding the hippocampal contours by 5 mm.
1887462|NCT01227967|Drug|Amantadine, Ribavirin, Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg, three capsules of Ribavirin 200 mg for total of 600 mg, and one capsule of Amantadine 100 mg.
1887463|NCT01227967|Drug|Oseltamivir|Subjects were prescribed the medication twice daily for 5 days, and each dose consisted of one capsule of Oseltamivir 75 mg.
1887464|NCT01227980|Drug|Pexacerfont|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
1887465|NCT01227980|Drug|Placebo|300 mg, orally, once/day during week 1, 100 mg, orally, once/day during weeks 2 and 3.
1887466|NCT01227993|Drug|Finasteride|
1887467|NCT01228006|Dietary Supplement|NatusGerin|1 capsule, 2 times a day.
1887468|NCT01228006|Other|Placebo capsules|1 capsule, 2 times a day
1887469|NCT01228019|Drug|Niacin (+) laropiprant|Niacin (+) laropiprant (TREDAPTIVE) prescribed according to the current local label
1887470|NCT01228032|Other|Care team|The ICC will provide care for both the index cardiometabolic conditions and common acute and chronic comorbidities.
1887471|NCT01228045|Drug|Trastuzumab in Combination with TS-ONE and cisplatin|Subjects will receive treatment that combined TS-ONE, cisplatin and trastuzumab every 3 weeks in this study. This 3 weeks period of time is called a cycle. The cycle will be repeated until subject experience disease progression or unbearable toxicities or they choose to withdraw from the study. Each cycle is numbered in order.
1887472|NCT01228058|Procedure|RapidTEG test|The RapidTEG test will be done at the study time points (3, 6, 12, 24 hours and 4 addiitonal days).
1887473|NCT01228071|Drug|testosterone gel 2%|40 mg testosterone gel 2%
1887474|NCT01228084|Drug|Sulforaphane|Sulforaphane given 200μmol (total daily) orally in four 50μmol capsules taken once daily from Week 1 Day 1 to Week 20 Day 7. On days when clinic visits are required patient must wait to take that day's dose until instructed to do so in clinic.
1887475|NCT01228084|Other|Laboratory biomarker analysis|Correlative studies
1887476|NCT01228084|Other|Pharmacological study|Correlative studies
1887477|NCT01228110|Drug|Hydrocortison|
1887478|NCT01228110|Drug|Saline Solution|
1887479|NCT01228123|Other|RRT for acute kidney failure using the CVVH method|patients randomized to receive CVVH
1887480|NCT01228123|Other|RRT for acute kidney failure using the IHD (intermittent HD)|patients randomized to receive IHD
1887481|NCT01228136|Drug|Tranexamic Acid|10mg/Kg, IV (in the vein), first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
1887482|NCT01228136|Other|normal saline solution|normal saline solution in the same volume calculated as treatment (tranexamic acid 250mg/mL, 10mg/Kg), IV (in the vein) first dose 30 minutes before surgery, second dose 8 hours after first dose, third dose 8 hours after second dose
1887525|NCT01228383|Biological|human polyclonal rabies immune globulin (HRIG)|HRIG 20 IU/kg intramuscularly on Day 0.
1887483|NCT01228149|Drug|Trabeculectomy with preoperative Diamox/DexaEDO treatment|Filtrating glaucoma surgery, preoperative treatment with Diamox (acetazolamide) 28 day prior surgery. DexaEDO (dexamethasone) 7 days prior surgery
1887484|NCT01228149|Drug|Trabeculectomy with preoperative Cosopt S treatment|Filtrating glaucoma surgery, preoperative treatment with Cosopt S (dorzolamide/timolol) 28 day prior surgery.
1887485|NCT01228162|Procedure|effect of muscle relaxation on muscle trauma, control group without relaxation|effect of muscle relaxation on muscle trauma, control group without relaxation
1887486|NCT01228175|Drug|Placebo|25mg look alike riboflavin tablets to match active study medication.
1887487|NCT01228175|Drug|Varenicline|Days 1-3 - .5mg tablet 1xdaily Days 4-7 - .5mg tablet 2xdaily Days 8-84 - 1mg tablet 2xdaily
1887488|NCT01228188|Procedure|Inverted ILM Repositioning|Three port pars plana vitrectomy is performed by one surgeon (JR). Induction of PVD is initiated by active suction with the vitrectomy probe over the ONH and continued peripherally. First a 0.6-1.0mm piece of ILM surrounding the macular hole is removed. Then significant margin of ILM in macular hole circumference is released while staying connected at the base to the macularrhexis border. Excess of ILM is trimmed. Perfluorocarbon is administrated, stabilizing ILM flap and facilitating the flap repositioning. Trypan Blue is used to stain the ILM. ILM flap is pressed down over the macular hole. The procedure is ended by SF6 gas tamponade. Even in absence of cataract formation, a combined procedure is performed because of exact peripheral vitreous shaving and prevention of cataract formation.
1887489|NCT01228201|Behavioral|Moderate continuous training|Three training sessions per week in a total of 12 weeks
1887490|NCT01228201|Behavioral|Aerobic interval training|Three training sessions per week in a total of 12 weeks
1887491|NCT01228214|Drug|Placebo|Placebo 5mg/daily for 12 months
1887492|NCT01228214|Drug|amiloride|5mg/daily for 12 months
1887493|NCT01228227|Drug|ATORVASTATIN 80 mg|reload of Atorvastatin 80 mg before the procedure
1887494|NCT01228227|Drug|ROSUVASTATIN 40 mg|reload of rosuvastatin 40 mg before the procedure
1887495|NCT01228240|Drug|Metformin|
1887496|NCT01228253|Device|rTMS: repetitive transcranial magnetic stimulation|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day)
1887497|NCT01228253|Device|SHAM rTMS: repetitive transcranial magnetic stimulation is off|patients will be treated with rTMS at 10 Hz (D3 to D7 and D10-D14, 1 session / day with the stimulator on off
1887498|NCT01228266|Biological|autologous mesenchymal stem cells|A randomized double-blind, crossover study comparing treatment with autologous MSC vs. suspension media on patients with active MS
1887499|NCT01228279|Other|DIANEAL|"Weeks 1 to 6 (6 weeks):
CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night
CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 4-6 hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night
Weeks 7 to 18 (12 weeks):
*same regimen as weeks 1 to 6, for both CAPD and CCPD patients"
1887500|NCT01228279|Other|EXTRANEAL|"Weeks 1 to 6 (6 weeks):
CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of DIANEAL during the night
CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and three to seven 2-4-hour dwells of DIANEAL during the night
Weeks 7 to 18 (12 weeks):
CAPD (Continuous Ambulatory Peritoneal Dialysis)patients will receive three 4-6 hour dwells of DIANEAL during the day and one 8-10-hour dwell of EXTRANEAL during the night
CCPD (Continuous Cycler Peritoneal Dialysis)patients will receive one-two 8-12-hour dwells of DIANEAL during the day and one 8-12-hour dwell of EXTRANEAL during the night"
1887501|NCT01228292|Drug|Unfractionated heparin|dose 5-10 IU/kg/hrs adaptations of infusion rate upon APTT measurements during hemodialysis
1887502|NCT01228292|Drug|Citrasate|Citrasate is infused as a dialysate
1887503|NCT01228305|Other|Acetaminophen|Acetaminophen will be given at a standard dose of 15 mg/kg IV every 6 hours for children >=2 years of age, 12.5mg/kg IV every 6 hours for children 29 days to <2 years of age, and 7.5mg/kg IV every 6 hours for neonates up to 28 days old for a total of 4 doses, starting shortly after intubation in the OR and before the start of CPB.
1887504|NCT01228318|Drug|Zoledronic acid|"A single dose of reclast containing 5 mg/100 mL ready-to-infuse zoledronic acid solution administered over 15-30 minutes.
A single dose of placebo containing 220 mg mannitol and 24 mg sodium citrate in a 100 mL ready-to-infuse solution, administered over 15-30 minutes."
1887505|NCT01228331|Drug|Amsacrine|one block amsacrine together with etoposide and methylprednisolone for very high risk patients
1887506|NCT01228331|Drug|Clofarabine|one block clofarabine with Asparaginase for MRD positive patients after induction
1887507|NCT01228331|Drug|Cyclophosphamide|together wit MTX and ASP in consolidation and together with cytarabine and 6-TG in reinduction
1887508|NCT01228331|Drug|Cytarabine|part of different chemotherapy blocks in consolidation and reinduction
1887509|NCT01228331|Drug|Daunorubicin hydrochloride|part of induction and reinduction therapy
1887510|NCT01228331|Drug|Dexamethasone|part of reinduction therapy
1887511|NCT01228331|Drug|Doxorubicin hydrochloride|part of reinduction therapy
1887512|NCT01228331|Drug|Etoposide phosphate|part of different chemotherapy blocks
1887513|NCT01228331|Drug|Mercaptopurine|part of different chemotherapy blocks
1887514|NCT01228331|Drug|Methotrexate|part of different chemotherapy blocks
1887515|NCT01228331|Drug|Methylprednisolone|part of different chemotherapy blocks
1887516|NCT01228331|Drug|Pegaspargase|part of different chemotherapy blocks
1887517|NCT01228331|Drug|Thioguanine|part of different chemotherapy blocks
1887518|NCT01228331|Drug|Vincristine sulfate|part of intravenous chemotherapy
1887519|NCT01228331|Radiation|Whole-brain radiation therapy|patients with initial cns involvement receive cranial irradiation
1887520|NCT01228344|Other|Artemether-lumefantrine|
1887521|NCT01228357|Drug|SSRI treated group|Antidepressant administration of SSRI class for 12 weeks under therapeutic dose
1887522|NCT01228357|Drug|non-SSRI treated group|Antidepressant administration of non-SSRI class for 12 weeks under therapeutic dose
1887523|NCT01228370|Drug|silodosin|silodosin 8mg once a day for 12 weeks
1887524|NCT01228383|Biological|Rabies virus-specific monoclonal antibodies|CL184 20 IU/kg intramuscularly on Day 0.
1887526|NCT01228383|Biological|Placebo|Placebo intramuscularly on Day 0.
1887527|NCT01228383|Biological|Human diploid cell vaccine (HDCV)|Rabies vaccine (HDCV) given on Days 0, 3, 7, 14, and 28.
1887528|NCT01228383|Biological|Purified verocell rabies vaccine (PVRV)|Rabies vaccine (PVRV) given on Days 0, 3, 7, 14, and 28.
1887529|NCT01228396|Drug|Hyperimmune caprine serum against HIV lysate|1.0ml solution for subcutaneous injection (4.5mg total protein / ml) twice weekly for 4 weeks
1887530|NCT01228409|Drug|Acitretin 17.5 mg/day|lower dose of Acitretin to 17.5 mg/day from 25 mg/day in those experiencing retinoid-related side effects
1887531|NCT01228422|Biological|Interferon alpha 2a|3MUI
1887532|NCT01228435|Drug|IPI-504|Given intravenously twice weekly for 2 weeks followed by 10 day off treatment
1887533|NCT01228448|Procedure|PET scan|In-Room PET scan
1887534|NCT01228474|Other|Select the Number of embryos to transfer|Select the Number of embryos to transfer
1887535|NCT01235702|Behavioral|12-week lifestyle modification|
1887536|NCT01235715|Drug|Evicel fibrin sealant|Used for hemostasis to control bleeding. It has been shown to stop bleeding in 2 minutes or less. It is a combination of a biologic activated component containing human fibrinogen and topical thrombin functioning on wet, actively bleeding tissue.
1887537|NCT01235728|Drug|MK-0873 2% Cream|Approximately 3 to 5 mg of MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
1887538|NCT01235728|Drug|MK-0873 vehicle (placebo) Cream|Approximately 3 to 5 mg matching placebo to MK-0873 2% cream per cm^2 of body area in 2 divided applications per day for 28 days. The maximum area for one treatment will be approximately 5% of body surface area.
1887539|NCT01235728|Drug|Calcitriol Cream|Approximately 3 to 5 mg of Calcitriol 0.0003% (3 µg/g) per cm^2 of body area once daily for 28 days. The maximum area for one treatment will be approximately 5% of body surface area
1887540|NCT01235741|Drug|Pramlintide+Metreleptin|Group A: Subcutaneous Injection once a day (QD): Pramlintide 360 mcg+Metreleptin 5.0 mg for 1 week followed by Pramlintide 360 mcg+Metreleptin 5.0 mg twice a day (BID) for 15 weeks.
1887541|NCT01235741|Drug|Placebo|Group B: Subcutaneous Injection-twice a day (BID): Placebo equivalent volumes to active doses.
1887542|NCT01235754|Drug|transdermal testosterone gel 1%|300 mcg once daily transdermal testosterone gel 1%
1887543|NCT01235754|Drug|placebo gel|once daily transdermal placebo gel
1887544|NCT01235767|Other|Food|Animal-source food (ASF) supplement rich in iron, zinc, vitamin A, and vitamin B12 taken week-days at mid-morning separate from other food. Length of intervention is either from pre-pregnancy (time of registration to marry) to term or from 16 weeks gestation to term.
1887545|NCT01235793|Drug|Temozolomide|The DRBEAT regimen will be similar to RBEAM. Rituximab and Carmustine will be given Day -6. Etoposide and Cytarabine will be given on Days -5 to -2. Temozolomide will be given via divided doses over five days starting on Day -5 to Day -1. A dose escalation design, known as EWOC (Escalation with overdose control) will be used to determine the target dose of temozolomide for this study. The starting dose given over five days will begin at 250mg/m2 (cumulative total dose of 1250 mg/m2), as previous data indicates this to be a safe dose. Based on the reported Dose Limiting toxicities from the previous patients, the EWOC statistical modeling will be performed to determine the next dose level.
1887546|NCT01235806|Radiation|MRI|MRI of the scaphoid bone fracture suspicion
1887547|NCT01235819|Drug|Insulin|Exenatide Sitagliptin
1887548|NCT01235819|Drug|Sitagliptin|Sitagliptin 100 mg per day oral
1887549|NCT01235819|Drug|Exenatide|Exenatide 10 micrograms daily twice
1887550|NCT01235832|Other|Avocado Diet|The avocado diet will be designed to ensure that all subjects incorporate 1 avocado (~136g) per day into a moderate fat diet. Both the Lower-Fat diet and avocado diet will be matched for SFA and dietary cholesterol, but will differ in total fat, primarily MUFA as provided by the avocado. The moderate fat plus avocado diet will provide 34% of calories from total fat, 18% calories from MUFA, and 9% calories from PUFA.
1887551|NCT01235832|Other|Lower-Fat Diet|The Lower-Fat diet will provide ~24% of calories from fat and meet the SFA and cholesterol recommendations of a Step-II diet recommended by the National Heart, Lung, and Blood Association's National Cholesterol Education Program. SFA will provide 7% of calories, and cholesterol will be less than 200mg/day. Vegetables and fruits in the Lower-Fat diet will be selected from foods that are low in antioxidants.
1887552|NCT01235832|Other|Moderate Fat Diet|This diet is designed to be the control diet for the avocado diet and will have an identical fatty acid profile. MUFA-enriched food (fats) will be substituted for avocado. The substitution foods will not contain antioxidant or cholesterol-lowering components similar to those in avocado.
1887553|NCT01235845|Biological|Biological: DC activated CIK combined with DC|"Dendritic cells pulsed With tumor lysate were injected back into the patient intradermally close to a lymph node, DC vaccinations will be given every week for a total of four vaccinations.
DC activated CIK combined with IL-2 were injected intratumorally via an Ommaya reservoir every week for a total of two vaccinations."
1887554|NCT01235858|Procedure|wearing of sterile gowns|Anesthesiologists wearing sterile gown for epidural insertion
1887555|NCT01235858|Procedure|No gown|Anesthesiologists not wearing sterile gown for epidural insertion
1887556|NCT01235871|Drug|SB1578|JAK2 Inhibitor
1887557|NCT01235871|Drug|Placebo|Control arm
1887558|NCT01235884|Dietary Supplement|Lactobacillus reuteri|1000000000 CFU per day (5 drops) for 28 days
1887559|NCT01235884|Dietary Supplement|Placebo|5 drops daily for 28 days
1887560|NCT01235897|Drug|MK-2206|Different dose levels of MK-2206 will studied, and co-administered with paclitaxel and trastuzumab. MK-2206 will be given orally with a starting dose of 135 mg weekly
1887561|NCT01235897|Drug|Paclitaxel|80 mg/m2 weekly - paclitaxel
1887562|NCT01235897|Drug|Trastuzumab|2 mg/kg weekly after a 1-time loading dose of 4 mg/kg - trastuzumab
1887563|NCT01235910|Drug|Aliskiren|Aliskiren 75 mg once daily x 2 weeks, then aliskiren 150 mg once daily x 2 weeks, if blood pressure allows
1887564|NCT01235923|Drug|three times weekly Epo|Epo 400 units/kg administered subcutaneously three times per week for a total of 4 weeks
1887565|NCT01235923|Drug|weekly Epo|Epo 1,200 units/kg administered subcutaneously once a week for a total of 4 weeks
1887566|NCT01235936|Drug|AKB-6548|Different dose levels
1992328|NCT03322163|Other|Exposure is maternal iodine|The exposure is preconception maternal iodine status There is no intervention in this observational study
1887572|NCT01235962|Drug|pazopanib|Pazopanib 600 mg daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
1887573|NCT01235962|Drug|placebo|placebo matching pazopanib daily initial dose for 8-12 weeks, dose can be escalated to 800 mg daily based on safety evaluation.
1887574|NCT01235975|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
1887575|NCT01235975|Biological|MencevaxACWY TM|Subcutaneous injection
1887576|NCT01235988|Drug|Eltrombopag|Eltrombopag 50mg & standard of care
1887577|NCT01235988|Drug|Placebo|Placebo + standard of care
1887578|NCT01236001|Drug|Lacosamide|
1887579|NCT01236014|Drug|Eltrombopag|Eltrombopag & standard of care
1887580|NCT01236014|Drug|Romiplostim|Romiplostim & standard of care
1887581|NCT01236014|Drug|Placebo|Placebo & standard of care
1887582|NCT01236027|Other|no intervention|not applicable-no intervention
1887583|NCT01236222|Behavioral|Cycling to school|Regular cycling to school
1887584|NCT01236248|Behavioral|Prevention|9-session computerized cognitive behavioral program that young girls and their mothers interact with on a weekly basis in the privacy of their home. Girls and their mothers will watch and interact with 10 compact disc (CD) intervention sessions to learn skills to help girls avoid substance use.
1887585|NCT01236261|Other|Non intervention|Non interventional study
1887586|NCT01236287|Drug|Voclosporin|Subjects will receive voclosporin capsules, twice daily to maintain a trough level > 20 ng/mL.
1887587|NCT01236300|Device|Cellvizio needle-based Confocal Laser Endomicroscopy (nCLE) system|
1887588|NCT01236313|Procedure|TEE report|Information will be collected during cardiac surgery.
1887589|NCT01236326|Procedure|Laparoendoscopic single site donor nephrectomy|Patients randomized to this arm will undergo laparoendoscopic single site donor nephrectomy
1887590|NCT01236326|Procedure|Conventional laparoscopic donor nephrectomy|Patients randomized to this arm will undergo conventional laparoscopic donor nephrectomy
1887591|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis
1887592|NCT01236339|Procedure|LVP|Large Volume Paracentesis
1887593|NCT01236339|Device|TIPS procedure with the GORE® VIATORR® TIPS Endoprosthesis for subjects who failed LVP and crossed over to TIPS per protocol|
1887594|NCT01236352|Drug|BMS-911543|
1887595|NCT01236365|Drug|Atorvastatin|10 or 20 mg daily
1887596|NCT01236365|Drug|Atorvastatin Placebo|10 or 20 mg daily
1887597|NCT01236378|Drug|Sirolimus|Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
1887598|NCT01236391|Drug|PCI-32765|560 mg daily
1887599|NCT01236404|Drug|Single Subcutaneous Dose (Part A) of PB1023 or Placebo (0.9% NaCl)|
1887600|NCT01236404|Drug|Multiple (Four Weekly) Subcutaneous Injections (Part B) of PB1023 or Placebo (0.9% NaCl)|Once weekly injections for up to four weeks
1887601|NCT01236417|Behavioral|Exercising block|Exercising for 8 weeks using an elastic band
1887602|NCT01236430|Drug|Ezetimibe|Ezetimibe 10mg tablet given orally after an overnight fast (at least 10 hours).
1887603|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/10mg FDC|Ezetimibe/atorvastatin 10mg/10mg FDC tablet given orally after an overnight fast (at least 10 hours).
1887604|NCT01236430|Drug|Atorvastatin 10mg|Atorvastatin 10mg given orally after an overnight fast (at least 10 hours).
1887605|NCT01236430|Drug|Atorvastatin 80mg|Atorvastatin 80mg tablet given orally after an overnight fast (at least 10 hours).
1887606|NCT01236430|Drug|Ezetimibe/atorvastatin 10mg/80mg FDC|Ezetimibe/atorvastatin 10mg/80mg FDC tablet given orally after an overnight fast (at least 10 hours).
1887607|NCT01236443|Drug|HPPH|3 mg/m2 IV
1887608|NCT01236456|Drug|Cyclophosphamide|
1887609|NCT01236469|Procedure|Echocardiogram|A prospective follow-up Study Echocardiogram will be performed, as applicable, for those subjects who do not have echo data as of January 1, 2009.
1887610|NCT01236482|Drug|Oxytocin versus oxytocin-ergometrine|Group 1: Oxytocin 0.1 I.U./kg/hr (plain) Group 2: Oxytocin 0.1 I.U./kg/hr with ergometrine 2 mcg/kg/hr co-administered Infusion rates determined to achieve equipotential doses based on an earlier PKPD study
1887611|NCT01236495|Drug|spinal morphine 0.3 mg|spinal morphine 0.3 mg
1887612|NCT01236495|Drug|spinal morphine 0.2 mg|spinal morphine 0.2 mg
1887613|NCT01236508|Radiation|PET/CT imaging with F-18 fluorodeoxyglucose|Dose of 5 MBq/kg F-18-FDG given to fasting participant. Nuclear whole body imaging starting at 3 hours post-injection. The relation of the PET/CT image results and both the number of covert brain infarcts and the extent of white matter MRI hyperintensity will be investigated.
1887683|NCT01237054|Drug|18-FDG PET/CT|The 18F-FDG injection procedure will be injected and be followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. The injection site will be evaluated pre- and post administration for any reaction (e.g. bleeding, hematoma, redness, or infection). Whole body (vertex to toes) static PET/CT imaging will be performed beginning at 1-hour, and again at 2-hours post injection.
1887777|NCT01237951|Drug|Melphalan|60 mg/m^2 IV on Days -3 and -2 over 30 minutes on both days as an outpatient or inpatient.
1888321|NCT01240538|Drug|cyclophosphamide|Given PO
1887616|NCT01236534|Drug|Lubiprostone|24 mcg twice daily for 21 days.
1887617|NCT01236534|Drug|Placebo|matching placebo twice daily for 21 days.
1887625|NCT01236573|Drug|Fludarabine|Fludarabine 25 mg/m^2/day intravenous piggyback (IVPB) daily over 30 minutes for 5 days.
1887626|NCT01236573|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) over 1 hr.
1887627|NCT01236573|Biological|IL-12 transduced TIL|On day 0 (one to four days after the last dose of fludarabine), cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
1887628|NCT01236586|Drug|RO4929097|
1887629|NCT01236586|Drug|Dexamethasone|
1887630|NCT01236599|Other|Polyethylene for thermoregulation in the preterm infant|3 groups with 30 preterm infants (PI) each one: 1) PI under radiant warmer, drying, wrapped in sterile field preheated (traditional care), 2) PI under radiant warmer, wrapped in polyethylene bag after drying, with their naked face and access to umbilical catheters or venous access, and 3) PI under radiant warmer, without drying, wrapped in polyethylene bag, with their naked face and access to umbilical catheters or venous access. Body temperature (BT) and incubator temperature (IT) were measured every 15 minutes from birth until 120 minutes of extra uterine life.
1887631|NCT01236612|Drug|Chloroquine prophylaxis|The chloroquine dose used will be 300mg for the first two days, followed by 300mg per week, for 13 weeks.
1887632|NCT01236612|Biological|Immunization|Groups 1 and 2 will be immunized with 3 times 15 bites of Pf infected mosquitoes under chloroquine prophylaxis.
1887633|NCT01236612|Biological|Plasmodium falciparum Bloodstage challenge|Groups 1 and 3 will be challenged by intravenous administration of Plasmodium falciparum infected erythrocytes.
1887634|NCT01236612|Biological|Plasmodium falciparum mosquito challenge|Groups 2 and 4 will be challenged by the bites of 5 Plasmodium falciparum infected mosquitoes.
1887635|NCT01236612|Drug|Malarone treatment|When thick smear positive, of ar day 21 after challenge, all volunteers will be treated with malarone.
1887636|NCT01236625|Procedure|Adhesiolysis|Blunt or sharp dissection of adhesive tissue.
1887637|NCT01236638|Drug|Momelotinib|Patients will continue receiving the same doses as assigned during the CCL09101 protocol; up to 400 mg once per day (QD). CYT387 will be administered orally as a single daily dose (at least 20 and no more than 28 hours apart, preferably in a fasted state at least two hours before and one hour after a meal), except for patients on the twice daily (BID) dosing regime (150 mg BID).
1887638|NCT01236651|Drug|Meperidine|administer 100mg meperidine i.v during the 1st stage of labor and calculate the duration of this stage of labor
1887639|NCT01236651|Drug|Drotaverine|administer 40mg drotaverine i.v during the 1st stage of labor and calculate the duration of this stage of labor
1887640|NCT01236664|Behavioral|Memory training|The Memory at Work program is a 4-hour classroom-based workshop that is led by a professional trainer. The format of the program is experiential, with a heavy focus on discussion, self-discovery, and hands-on use of trained skills. Specific memory compensation techniques are trained. Training consists of an explanation of each technique (i.e., how and when to use it, the science behind the technique) and ample opportunities for hands-on use of the strategies.
1887641|NCT01236664|Behavioral|Control Workshop|The control workshop consists of a 4-hour program that will train techniques for successfully completing Sudoku, word, and logic puzzles. Like the experimental intervention, the control workshop will be engaging and challenging, and will involve a combination of individual and group activities.
1887642|NCT01236690|Drug|Cinobufacin injection|Cinobufacin by Perfusion of Hepatic Artery Combining the Arterial Embolotherapy
1887643|NCT01236716|Drug|Albumin paclitaxel plus carboplatin|Patients receive carboplatin AUC=5 q3w and nab-p 135 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
1887644|NCT01236716|Drug|Gemcitabine plus carboplatin|Patients receive carboplatin AUC=5 q3w and gemcitabine 1250 mg/m2 weekly for 2 weeks (on days 1 and 8 of a 21-day cycle), followed by a week of rest.
1887647|NCT01236755|Device|single-vision glasses|Daily wear of glasses to correct vision
1887648|NCT01236755|Device|ortho-k lenses|Nightly wear of lenses to correct vision in day time
1887649|NCT01236768|Drug|AG200-15|"Contraception; AG200-15 is applied and replaced every 7 days for 3 weeks, followed by a 1-week patch free period."
1887650|NCT01236768|Drug|Levora|One tablet of Levora will be taken each day for a 28 day cycle.
1887651|NCT01236781|Device|Screening Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
1887652|NCT01236781|Device|Diagnostic Tomosynthesis|Tomosynthesis imaging sets (limited tomosynthesis set and then a sequential read with the low-dose CC view added for the tomosynthesis plus set).
1887729|NCT01237522|Drug|Metformin|A single dose study with one tablet of metformin 500 mg, time frame 24 hours
1887778|NCT01237951|Procedure|Stem Cell Transplant|On Day 0, stem cells returned to body by vein over 30-60 minutes.
1989666|NCT02428192|Biological|Ipilimumab|Given IV
1989667|NCT02428192|Other|Laboratory Biomarker Analysis|Correlative studies
1887653|NCT01236794|Behavioral|Lifestyle Education Sessions and Youth Exercise Sessions|The intervention will include a ~1-2 hour weekly education session to address the following constructs: health awareness, healthy eating, physical activity, roles and responsibilities, self-esteem, self-efficacy, diabetes knowledge, communication, and peer / family relationships. In addition to the education classes youth will participate in 3 exercise sessions per week (~1-1.5 hrs) that will consist of individual and group physical activities to include both aerobic and resistance exercises. The exercise intensity will progressively increase over the 12-week intervention. Both the education and activity sessions will be delivered at the Lincoln Family YMCA.
1887654|NCT01236807|Procedure|MR perfusion guidance|Coronary revascularization guided by MR perfusion imaging
1887655|NCT01236807|Procedure|FFR guidance|Coronary revascularization guided by invasive angiography and FFR
1887656|NCT01236833|Drug|Lactated Ringer's Solution|2.5 ml per kg every 3 hours, via nasogastric tube, orogastric tube or orally, until the infant reaches 80 ml/kg/day of milk feeding or for a maximum of 14 days
1887657|NCT01236846|Dietary Supplement|Fortified Yogurt Drink|Daily intake of yogurt drink fortified (500 ml) with 1000IU vitamin D for 12 weeks
1887658|NCT01236846|Dietary Supplement|Plain Yogurt Drink|Daily intake of unfortified yogurt drink(500 ml)for 12 weeks
1887659|NCT01236859|Drug|Gabapentin|Neurontin®, Pfizer
1887660|NCT01236872|Dietary Supplement|Beetroot juice|250ml once of beetroot juice
1887661|NCT01236872|Dietary Supplement|Water|250ml once of low-nitrate mineral water
1887662|NCT01236885|Other|computer-assisted intervention|Undergo blood glucose management using Glucommander
1887663|NCT01236898|Drug|NPC-09|NPC-09 tablet NPC-09 contains 50mg or 100mg N-acetylneuraminic acid (anhydride)
1887664|NCT01236911|Other|Calcium Measurement|after moderate-severe TBI (less as 24 hrs)
1887665|NCT01236924|Other|Global postural reeducation|
1887666|NCT01236937|Device|Bellows-based breath hold device|"Bellows-Based breath hold monitoring system:
The bellows-based breath hold system (IBC, Mayo Clinic Medical Devices, USA) contains of 2 elements; one belt which is strapped around the thorax of the patient and a voltage controlled light unit with 8 lights. Belt stretch from respiratory motion is converted into voltage readings and displayed on the light unit giving biofeedback as different lights are activated depending on the dept of the respiration. Patients are instructed to keep respiration constant at a certain dept during the second the guide needle is inserted by controlling their breath with the help of the light unit. The patient is given a brief introduction to the system as to how the lights get turned on and off due to respiration motion before the biopsy is preformed."
1887667|NCT01236950|Drug|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indication
1887668|NCT01236950|Drug|Delmopinol mouthrinse|Commercial mouthrinse with manufacturer's use indication
1887669|NCT01236963|Drug|Essential oils mouthrinse|Commercial mouthrinse with manufacturer's use indications
1887670|NCT01236963|Device|Dental Floss|
1887671|NCT01236976|Device|Therastride Treadmill System|This device supports spinal cord injured patients to stand (suspended in a harness by an overhead pulley) on the specially designed treadmill for locomotor training. It has adjustable ergonomic seating for the therapists, a dedicated computer, surge protector, battery backup, custom software and controls, and a closed-loop feedback system. A therapist/assistant is positioned behind the participant to stabilise the pelvis and trunk, and to assist with appropriate weight shifting and hip rotation during the step cycle. Two additional therapists are seated in front of the participant to provide manual assistance for the lower limbs to facilitate knee extension during stance and knee flexion and toe clearance during swing, maintaining appropriate alignment of the limbs. A fourth person controls the treadmill. This system is being used in US universities and rehabilitation facilities throughout North America and is registered with the FDA (Regulation Number 890.5380).
1887672|NCT01236976|Device|FES-assisted cycling|This intervention will be provided using a RT300 cycle (Restorative Therapies, Baltimore MD). Surface electrodes will be applied to the quadriceps, gluteal, hamstrings and calf muscles according to a standardized protocol. The pedal cadence will be set to 15-50 rev•min-1. Stimulation intensity will be gradually increased to a maximum of 140 mA with a pulse width of 0.3ms and frequency of 35Hz (Eser et al. 2003; Fornusek & Davis, 2008). Participants will exercise at the maximal power output possible at their level of recovery. Participants will commence with 10 minutes of training and gradually build up to a period of 30 minutes. The frequency, power output at each minute, and training duration will be recorded at each training session.
1887673|NCT01236976|Other|Trunk and upper and lower limb exercises|This intervention will comprise assisted and/or resisted movements aimed at facilitating and strengthening voluntary muscle activity and improving movement quality. These may be provided in lying (e.g. supine, prone) and in weight-bearing positions (e.g. kneeling, standing). Task-specific practice of functional tasks, involving moving the upper body over and outside the base of support, will also be undertaken. Participants may also be given exercises in motor imagery, imagining movements of their body
1887674|NCT01236976|Other|Upper body strength and fitness program|This intervention is a circuit-based exercise program incorporating resistance and cardiovascular training.
1887675|NCT01236989|Procedure|anatomical liver resection|anatomical liver resection by means of IOUS-finger compression
1887676|NCT01236989|Procedure|Non-anatomical liver resection|non-anatomical liver resection
1887677|NCT01237015|Device|Infant Flow nasal CPAP|Infant Flow nasal CPAP 5 cm H2O
1887678|NCT01237028|Drug|Calcitriol|Calcitriol(1,25-dihydroxycholecalciferol, vitamin D3 analog)0.25 μg per day
1887681|NCT01237054|Drug|18-NaF PET|The patient will receive 5mCi of F-18 NaF IV (intravenous) bolus, followed by a ~20 ml saline (sodium chloride IV infusion 0.9% w/v) flush over a period of ~20 seconds. Serial dynamic imaging (2 minutes/bed position) will be obtained over a 1-hour period. The patient will be permitted an imaging break until a static PET/CT is performed beginning at 2-hours post F-18 NaF injection.
1887682|NCT01237054|Other|DCE-MRI|An FDA (Food and Drug Administration) approved gadolinium chelate (e.g. Magnevist, Berlex Laboratories, NJ, USA) will be administered intravenously at 3 cc/sec using an automated pump injector (Medrad, Pittsburgh, PA, USA).
1887776|NCT01237951|Drug|Busulfan|"32 mg/m2 test dose with PKs as outpatient before Day -12, or as an inpatient on Day -10.
Busulfan AUC 4,000 by vein on Days -8 to -5 as an outpatient or inpatient."
1887686|NCT01237080|Device|GlideScope|The GlideScope is an anatomically shaped, rigid, fibreoptic videolaryngoscope.
1887687|NCT01237080|Device|Fastrach|The Fastrach is an intubation laryngeal mask.
1887688|NCT01237106|Other|IVM|all patients in this pilot study will undergo IVM. IVM involves immature eggs being retrieved and matured in the laboratory.After maturation they are fertilized like is done in a typical IVF cycle.
1887689|NCT01237119|Drug|Liraglutide|1.8 mg once daily, subcutaneous injection
1887690|NCT01237119|Other|Liraglutide-placebo|1.8 mg once-daily, subcutaneous injection
1887691|NCT01237171|Radiation|Cesium-131 Brachytherapy Seed|85 Gray Dose
1887692|NCT01237197|Drug|Exenatide|Exenatide 5 micrograms (mcg) twice per day (BID) for one month; up-titrated to 10 mcg twice per day for remainder of study.
1887693|NCT01237197|Drug|Placebo|Participants were randomized to a placebo injection for the first three months, then given open-label Exenatide for the remaining three months (Initiated at 5 mcg, twice per day, delivered by subcutaneous injection. After 1 month, exenatide was uptitrated to 10 mcg, twice per day for the remaining 2 months of the drug treatment phase).
1887694|NCT01237223|Drug|Aliskiren/Amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg tablet
1887695|NCT01237223|Drug|Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg tablet
1887696|NCT01237223|Drug|Aliskiren 150 mg|Aliskiren 150 mg tablet
1887697|NCT01237223|Drug|Amlodipine 2.5 mg|Amlodipine 2.5 mg capsule
1887698|NCT01237223|Drug|Placebo of Aliskiren|Aliskiren placebo tablet
1887699|NCT01237223|Drug|Placebo of Amlodipine|Amlodipine placebo capsule
1887700|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/2.5 mg|Aliskiren/amlodipine 150/2.5 mg placebo tablet
1887701|NCT01237223|Drug|Placebo of Aliskiren/amlodipine 150/5 mg|Aliskiren/amlodipine 150/5 mg placebo tablet
1887702|NCT01237236|Drug|LEE011|
1887703|NCT01237249|Drug|Melphalan|
1887704|NCT01237249|Drug|Prednisone|
1887705|NCT01237249|Drug|Velcade|
1887706|NCT01237249|Drug|Revlimid|
1887707|NCT01237249|Drug|Dexamethasone|
1887708|NCT01237262|Drug|Adalimumab, etanercept, infliximab|"Adalimumab at a dose of 80 mg at week 0 (Baseline) and successively 40 mg every other week starting from week1 and up to week 15. Adalimumab will be administered as subcutaneous injection.
Etanercept at a dose of 50 mg every week, as subcutaneous injection. Infliximab at a dose of 5 mg/kg at week 0 (Baseline), then at week 2 and every 8 weeks."
1887709|NCT01237275|Drug|SSRI treated group|characterize in arm of a study (SSRI treated group)
1887710|NCT01237288|Drug|Z-521|
1887711|NCT01237301|Device|Continuous Glucose Monitoring (CGM)|Using CGM unblinded for 16 weeks versus fingersticks 4 to 7 times a day to evaluate which is more beneficial in type 2 diabetes.
1887712|NCT01237327|Drug|Megestrol acetate|Megestrol Acetate 160 mg oral tablets Qd
1887713|NCT01237327|Drug|exemestane (Aromasin)|exemestane (Aromasin) 25 mg oral tablets Qd
1887714|NCT01237340|Drug|Saizen®|Single dose of Saizen® (recombinant human growth hormone, r-hGH) solution for injection will be administered subcutaneously for 26 weeks. Dosage regimen will be in accordance with marketed formulation of Saizen® (freeze-dried formulation), based on locally approved product labeling.
1887715|NCT01237353|Dietary Supplement|betaine hydrochloride|betaine hydrochloride 1500mg po x 1 on day 5
1887716|NCT01237353|Drug|Rabeprazole|rabeprazole po daily x 5 days
1887717|NCT01237366|Behavioral|Resilient Affective Processing Therapy (RAPT)|Participants will be asked to complete 7 intervention sessions which include: 1) expressive writing exercises that focus on exploring thoughts and feelings surrounding a difficult life experience; and 2) stress management skills training to assist participants with managing any acute increases in distress that arise following the writing experience.
1887718|NCT01237392|Device|Contact ultrasonic debridement device|Cavitational ultrasound wound debridement device
1887719|NCT01237405|Drug|99mTc-EC20|Study participants underwent a one-time evaluation by FolateScan which entailed a single intravenous injection of 99mTc-EC20 (total volume of 1.0 to 2.0 ml administered over a period of 30 seconds with radioactive dose between 20 and 25 mCi). A total of three imaging scans were acquired: an early phase (at ~1 minute) SPECT/CT of both knees; a late phase (at ~60 minutes) SPECT/CT image of both knees; and a late phase (at ~80 minutes) planar image of the whole body was performed (anterior-posterior, and postero-anterior).
1887720|NCT01237431|Dietary Supplement|500ml water intake|subjects have to ingest 500ml water within 5 minutes after resting 30 minutes in supine position
1887721|NCT01237444|Drug|lopinavir/ritonavir plus one nucleoside|"ARM 1:
Lopinavir/ritonavir 200mg/50mg 2 tabs bid plus 3TC 150mg x1 tab bid"
1887722|NCT01237444|Drug|lopinavir /ritonavir plus two nucleosides|"ARM 2:
3TC 150mg x1 tab bid or FTC 200mg 1 capsule qd plus Lopinavir/ritonavir 200mg/50mg 2 tabs BID plus a second NRTI, selected at investigator's discretion, based on baseline genotype."
1887723|NCT01237457|Drug|177Lu-DOTATATE|Patients will receive 200mCi dose of 177Lu Dotatate
1989668|NCT02428192|Biological|Nivolumab|Given IV
1887727|NCT01237496|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
1887728|NCT01237509|Device|Hypo device|
1887730|NCT01237535|Drug|Luteal support with progesterone only|Luteal support with progesterone only (they will received vaginal P gel (Crinone 8% vaginal gel; Serono, Israel).Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
1887731|NCT01237535|Drug|Luteal support with estrogen + progesterone|Luteal support with estrogen + progesterone [(Crinone 8% vaginal gel; Serono, Israel) and Estrofem 4mg].Luteal support will begin after insemination and will be continued through the 12th week of gestation if the patient conceived.If no pregnancy will be achieved patients will undergo 3 treatment cycles preferably in the same treatment group.
1887732|NCT01237535|Procedure|Insemination without luteal support|Routine insemination procedure without luteal support
1887733|NCT01237548|Other|Smoking Narghile for 30 min|No Other intervention will be used
1887734|NCT01237561|Other|provider support tools plus spirometer|Patient Activation Tool, Provider Web-based decision support tool, academic detailing
1887735|NCT01237574|Other|Intervention according to the standard of care.|Every 6 months, patients will have clinical, biological and morphological evaluation according to the standard of care.
1887736|NCT01237587|Drug|Duloxetine|Administered orally
1887737|NCT01237587|Drug|Placebo|Administered orally
1887738|NCT01237600|Procedure|Cultivated limbal transplantation|Cultivated corneal epithelial stem cell transplantation. Autograft, Living related allograft, and Cadaveric allograft
1887739|NCT01237613|Device|Artelon|Artelon Tissue Reinforcement
1887740|NCT01237639|Other|Red blood cell Transfusion|Transfusion of Red blood cells to based on daily complete blood count
1887741|NCT01237665|Drug|IXO regimen|"IXO regimen is administered as following: irinotecan 160 mg/m2 i.v. (over 60-90 minutes) with oxaliplatin 100 mg/m2 i.v. (over 120 minutes) on day 1, followed by capecitabine 950 mg/m2 PO, b.i.d. on days 2-15, every 3 weeks.
Each cycle of IXO lasts 21 days, with the subsequent cycle to start on day 22."
1960549|NCT03184662|Other|HIPA|"inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach.
First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months"
1960550|NCT03184662|Other|Counseling PA|Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD
1887744|NCT01237691|Behavioral|HOPE supervision|HOPE entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). HOPE includes regular random drug testing.
1887745|NCT01237691|Behavioral|Parole-as-usual|Parolees are supervised under standard parole supervision practice in California.
1887746|NCT01237704|Behavioral|Traditional rehabilitation (TR)|TR rehabilitation will be scheduled three 45-minute sessions per week for 4 weeks with a total of 12 sessions that include Mendelsohn manoeuvre, Shaker's exercise, Effortful swallow and Masako manoeuvre.
1887747|NCT01237704|Behavioral|Transcutaneous electrical stimulation (ES)|Subjects will receive three 45-minute sessions per week for 4 weeks with a total of 12 sessions.
1887748|NCT01237730|Drug|cefuroxime|Use the cefuroxime as prophylaxis.
1887749|NCT01237730|Drug|Tailored antibiotic|Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
1887750|NCT01237743|Device|Transcatheter aortic valve implantation.|Transcatheter aortic valve implantation,femoral access.
1887751|NCT01237756|Device|measurement of left and right lung ventilation|Patients are ventilated after endotracheal tube placement and left and right lung ventilation if determined using electrical impedance tomography
1887754|NCT01237782|Drug|Denture soaking solution|Immersion of complete dentures in 200ml of a denture soaking solution for 20 minutes. Propolis solution: Spa Dent (Nissin Dental Products Inc., Kyoto, Japan).
1887755|NCT01237782|Drug|Saline solution|Immersion of complete dentures in 200ml of a placebo denture soaking solution for 20 minutes.
1887756|NCT01237795|Other|Dentifrice|Dentifrices (4 formulations) used as auxiliary agents for brushing complete dentures.
1887757|NCT01237808|Drug|Cytarabine|in all treatment cycles: Cytarabine 20 mg/day, s.c., bid, days 1-7; (total dose 280 mg).
1887758|NCT01237808|Drug|Etoposide|first treatment cycle Etoposide 50 mg/m²/day, continuously i.v., days 1-3; (total dose 150 mg/m2) treatment cycles 2 to 6 Etoposide 100 mg/day, p.o. or i.v. (over 1 hour), days 1-3; (total dose 300 mg).
1887759|NCT01237808|Drug|All-trans retinoic acid (ATRA)|in all treatment cycles: ATRA 45 mg/m²/day p.o., days 8-10, ATRA 15 mg/m²/day p.o., days 11-28, with or shortly after meals distributed on 3 doses per day.
1887762|NCT01237847|Behavioral|2 Family-based problem solving phone sessions|2 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
1887763|NCT01237847|Behavioral|4 Family-based problem solving phone intervention sessions|4 family-based problem solving phone sessions to address and ameliorate barriers to adherence.
1887764|NCT01237847|Behavioral|Wait list comparison group|Wait list comparison group to receive intervention at later point.
1887765|NCT01237860|Device|NESS L300 Plus System|The patients will receive the device for daily use of six (6) weeks.
1887766|NCT01237873|Drug|Ali/Amlo 150/2.5 mg|Aliskiren/Amlodipine 150/2.5 mg and 150/5.0 mg
1887770|NCT01237925|Drug|Dexchlorpheniramine 1% gel|Small amount applied over the lesion twice a day for 7 days
1887771|NCT01237925|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days
1887772|NCT01237938|Behavioral|Low Glycemic Diet|Changing to low glycemic diet
1887773|NCT01237951|Drug|Palifermin|"60 micrograms/kg infused as an IVP (by vein) over 15-30 seconds Days -12 to -10 and Days 0 to +2 as an outpatient.
60 micrograms/kg by vein on Days -13 to -11 and on Days 0, +1 and +2 as in inpatient."
1887774|NCT01237951|Drug|Dexamethasone|8 mg IV twice a day by vein over 15 minutes Days -9 through -2 as an outpatient or inpatient.
1887775|NCT01237951|Drug|Gemcitabine|1875 mg/m^2 IV (75 mg/ m2 bolus followed by 1800 mg/m^2 over 3 hours) on Day -8 and Day -3 as an outpatient or inpatient.
1887779|NCT01237951|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +5 and continuing until neutrophil recovery is documented.
1887780|NCT01237964|Drug|Xiaflex (FDA approved collagenase)|0.58mg of collagenase will be diluted in saline and injected in 3 points surrounding the limiting contracture
1887781|NCT01237977|Drug|Botulinum Toxin Type A(Meditoxin®)|single administration, Day 0, 20U
1887782|NCT01237977|Drug|Botulinum Toxin Type A(Botox®)|single administration, Day 0, 20U
1887783|NCT01238003|Other|Interpretation of blood test results|Interpretation of blood test results
1887784|NCT01238016|Device|experimental|
1887785|NCT01238029|Drug|Lapatinib and Capecitabine and Vinorelbine|Dose finding Study Lapatinib: 1000-1250 oral, once daily, days 1-21 Capecitabine: 1000 mg/sqm oral, bid, days 1-14 Vinorelbine 10-22,5 mg/sqm, i.v. Day 1 + 8
1887786|NCT01238042|Drug|HPPH|3mg/m2 or 4 mg/m2 at light doses of 150, 175 and 200 joules/cm
1887787|NCT01238055|Drug|Docetaxel + Sunitinib|"Docetaxel 60 mg/m2 iv, every 3 weeks
Sunitinib 37.5 mg qd daily, every 3 weeks"
1887788|NCT01238055|Drug|Docetaxel only|Docetaxel 60 mg/m2 iv
1887789|NCT01238068|Device|gamma nail stryker|for acute unstable pertrochantric fractures the subjects will be treated randomaly with either Gamma nail device Vs Dynamic hip screw
1887790|NCT01238094|Drug|Simvastatin|simvastatin 40 mg qd daily until disease progression
1887791|NCT01238107|Drug|MT-102|BETA BLOCKER
1887792|NCT01238120|Drug|Ibuprofen|200 mg BID and 8 hours apart
1887793|NCT01238120|Behavioral|Home-Based Exercise|A progressive walking and resistance band exercise program called Exercise for Cancer patient (EXCAP) for a 6 week period
1887794|NCT01238120|Drug|Placebo|200mg BID and 8 hours apart
1887795|NCT01238133|Drug|Carboplatin|Given IV
1887796|NCT01238133|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1887797|NCT01238133|Other|Laboratory Biomarker Analysis|Correlative studies
1887798|NCT01238133|Drug|Paclitaxel|Given IV
1887799|NCT01238133|Other|Pharmacological Study|Ancillary studies
1887800|NCT01238133|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1887801|NCT01238146|Drug|bendamustine hydrochloride|Given IV
1887802|NCT01238146|Drug|obatoclax mesylate|Given IV
1887803|NCT01238146|Biological|rituximab|Given IV
1887804|NCT01238159|Radiation|CCRT+MIDLE chemotherapy|Patients are planned to be treated with CCRT plus MIDLE chemotherapy
1887805|NCT01238172|Other|dietary education and counseling|
1887806|NCT01238172|Other|prostate cancer foundation booklet|
1887807|NCT01238185|Drug|acetylsalicylic acid|
1887808|NCT01238185|Genetic|gene expression analysis|
1887809|NCT01238185|Genetic|protein expression analysis|
1887810|NCT01238185|Other|laboratory biomarker analysis|
1887811|NCT01238185|Other|questionnaire administration|
1887812|NCT01238185|Procedure|biopsy|
1887813|NCT01238211|Drug|Cytarabine|Given IV
1887814|NCT01238211|Drug|Dasatinib|Given PO
1887815|NCT01238211|Drug|Daunorubicin Hydrochloride|Given IV
1887816|NCT01238211|Other|Laboratory Biomarker Analysis|Correlative studies
1887817|NCT01238224|Drug|Tadalafil|This is an acute study. Tadalafil 20 mg administered prior to a meal
1887818|NCT01238237|Drug|Superselective Intraarterial Cerebral Infusion of Cetuximab|Intraarterial Mannitol 25% 3-10 ml to open the blood brain barrier followed by Intraarterial Cetuximab single dose (starting at 100mg/m2 and escalating up to 500mg/m2)
1887819|NCT01238276|Drug|Cefazolin|Cefazolin is approved for clinical use for some bacterial infections. The standard routes of administration are Intramuscular (IM) and intravenous (IV). For this study, the route of administration will be delivered using the Silberg TPS, which delivers the cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The concentration delivered is one gram/100 ml saline. Cefazolin can safely be given IM at the much higher concentration of 1 gram/2.5 ml of saline. The maximum dose that may be administered is 3 grams in 300 ml, which is within the approved guidelines of a daily dose. The concentration of antibiotic will be the same; only the dose may vary depending on the size of the wound or area of induration. Each subject will receive only one treatment in this study.
1887820|NCT01238276|Device|Silberg Tissue Preparation System|The TPS is FDA cleared for the subcutaneous infusion and ultrasonic dispersion of tumescent fluid excluding the parenteral delivery of drugs. Under this study, the TPS is a device to deliver cefazolin by subcutaneous injection followed by external ultrasonic dispersion. The TPS consists of a medical grade peristaltic pump that is used to infuse antibiotic solution using a sterile blunt-tipped infusion cannula into a superficial subcutaneous plane. After the cannula has been removed, high frequency external ultrasound is delivered transcutaneously over the area of infusion in order to disperse the antibiotic solution. The power density is within the range allowed for physical therapy.
1887821|NCT01238289|Behavioral|Peer Education|Conduct peer education classes for 8 weeks and support groups monthly for a total of 10 months and evaluate effects on metabolic and behavior outcomes
1887822|NCT01238289|Behavioral|Control|This group continues with standard care at the community health center
1887823|NCT01238302|Procedure|Conventional arthroscopic rotator cuff repair|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4-5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repair of full thickness rotator cuff tear was done with suture anchors.
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound."
1887824|NCT01238302|Procedure|Arthroscopic rotator cuff repair with PRP|"Under general anesthesia, the patient was placed in the lazy lateral decubitus position on the operating table.
The surgical area was prepared and draped with Betadine.
Small stab incisions were made in the creation of 4-5 portals as needed.
A scope was explored via the arthroscopic portal into the GH joint & subacromial space.
Repair of full thickness rotator cuff tear was done with suture anchors.
After tying sutures of the medial row, PRP gels were applied on the repair site.
The lateral row was secured using suture anchors.
The skin was closed with Nylon or medical staples.
Sterile dressing was applied on surgical wound."
1887825|NCT01238315|Biological|HuCNS-SC|Surgery to implant human CNS stem cells
1888322|NCT01240538|Other|laboratory biomarker analysis|Correlative studies
1887826|NCT01238328|Drug|Conditioning regimen|"For sibling full match:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
For other related full match, sibling or other related with one antigen mismatch and umbilical cord blood:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
Antithymocyte globulin (ATG) rabbit (Thymoglobulin) 10 mg/kg or ATG horse (Atgam) 40 mg/kg
For haploidentical:
Busulfan 16 mg/kg >5year - 20 mg/kg <5year po
Cyclophosphamide 200 mg/kg iv
Fludarabine 160 mg/m^2"
1887827|NCT01238328|Drug|Graft-versus-host disease (GVHD) prophylaxis|"Cyclosporin A 1.5 mg/kg/day iv from -2, then 3 mg/kg/day iv (from +7 in peripheral blood stem cell transplant (PBSCT) and +11 in Bone marrow transplantation or Umbilical Cord Blood (UCB) transplantation) then 9 mg/kg/day po
10 mg/m^2 iv day +1 then 6 mg/m^ iv day +3 and +6 (Not for UCBT)"
1887828|NCT01238328|Procedure|Stem Cell Transplantation|"Patients undergoing Hematopoietic Stem Cell Transplantation from one of below source:
Sibling full match
Other related full match
Sibling or other related with 1 mismatch antigen
Cord Blood
Haploidentical"
1887829|NCT01238341|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|An Endoscopic Retrograde Cholangiopancreatography (ERCP) performed with an overtube in the evaluation of pancreatobiliary disease in patients with altered gastric anatomy
1887830|NCT01238354|Behavioral|With friend|
1887831|NCT01238354|Behavioral|Without friend|
1887832|NCT01238367|Drug|turoctocog alfa|Subjects will receive recombinant factor VIII (N8) at a dose of 50 +/- 5 IU/kg body weight. Intravenous administration as a single bolus injection.
1887833|NCT01238380|Other|patient care pathway|"Stage 1: Urinary c-peptide creatinine ratio (UCPCR); if positive progress to Stage 2.
Stage 2: Pancreatic auto-antibodies measurement (GAD65 & IA2); if negative progress to genetic testing.
Genetic testing for HNF1A, HNF4A, GCK. If positive, progress to Stage 3.
Stage 3: review and potential change of diabetes treatment. Monitor success via use of three standardised health and quality of life questionnaires and Hba1c pre-treatment change and at 1, 3, 6 and 12 months post-treatment change."
1887834|NCT01238393|Drug|intravitreal ranibizumab|monthly injections x3 +/- 2nd series of 3
1887835|NCT01238406|Device|MD-logic Artificial Pancreas (MDLAP)|Treatment with the closed loop MD-logic Artificial Pancreas(MDLAP)System
1887836|NCT01238406|Device|Standard treatment with insulin pump|Standard treatment with sensor augmented pump therapy
1887837|NCT01238419|Device|Physiotulle|Physiotulle is a non adherent dressing, composed of a polyester fabric impregnated with hydrocolloid particles (CMC) suspended in vaseline
1887838|NCT01238419|Device|URGOTUL|Urgotul is an non occlusive dressing comprising of a polyester mesh impregnated with hydrocolloid particles dispersed on a petroleum jelly matrix
1887839|NCT01238458|Drug|[18F]AV-45 PET amyloid binding imaging|"This study will recruit a total of 150 evaluable subjects (30 cognitively normal volunteers, and 60 MCI, and 60 AD, respectively) Each evaluable subject involved in this study must fulfill all the inclusion and exclusion criteria according the subject grouping.
Safety measurement will be evaluated by medical history, vital signs, physical examinations, laboratory examinations and collecting of adverse events."
1887840|NCT01238471|Drug|propranolol|2 mg per kg per day divided in 3 doses for 2-4 weeks
1887841|NCT01238471|Drug|sucrose 5%|2 ml per Kg per day divided in 3 doses for 2-4 weeks
1887842|NCT01238484|Other|Standard of care|shoe modification home stretching exercises
1887843|NCT01238484|Device|Dynasplint|shoe modification home stretching exercises Ankle Dorsiflexion Dynasplint
1887844|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for either transfemoral or transapical access and any of the 3 valve sizes (23, 26 or 29)
1887845|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transapical or transaortic access and any of the 3 valve sizes (23mm, 26mm or 29mm)
1887846|NCT01238497|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Patients eligible for transfemoral access and requiring a 29mm valve.
1887847|NCT01238510|Procedure|stent technique: Provisional fKBT|"Provisional use of fKBT only when SB flow is aggravated to TIMI0-2 after stenting for non-left main bifurcation.
Additional stenting for SB is recommended if residual stenosis (>50% in visual) or TIMI flow grade (<TIMI 3) was seen at SB after fKBT.
Stent type: Everolimus-eluting stent only"
1887848|NCT01238510|Procedure|stent technique: Routine fKBT|"Mandatory use of fKBT irrespective of SB flow after stenting for non-left main bifurcation. Additional stenting for SB is recommended if residual stenosis (>50% in visual) or TIMI flow grade (<TIMI 3) was seen at SB after fKBT.
Stent type: Everolimus-eluting stent only"
1887849|NCT01238523|Procedure|Long leg cast in full extension|Long leg cast in full extension with instructions to begin immediate weight bearing as tolerated on the injured extremity
1887850|NCT01238523|Procedure|Long leg cast with 45 degrees of flexion|Long leg cast with 45 degrees of flexion at the knee with instructions not to bear weight on the injured extremity
1887855|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 10mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
1887856|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 20mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
1888169|NCT01238848|Drug|Normal saline|3 cc nebulized normal saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
1887857|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 30mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
1887858|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 45mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir
1887859|NCT01238562|Drug|YPEG-Filgrastim|s.c, single dose of 60mcg/kg of YPEG-Filgrastim at 48hr of cycle 2, followed by daily s.c either 2.5 mcg/kg or 5 mcg/kg of filgrastim(TOPNEUTER) starting from 48hr of cycle 3 until WBC≥10,000 per cubic milliliter or ANC≥5,000 per cubic milliliter in two continuous daily tests after ANC nadir.
1887860|NCT01238575|Other|placebo|Administered for up to 8 weeks.
1887861|NCT01238575|Drug|extended-release guanfacine|1 mg tablets; flexible dosing up to 4 mg/day for up to 16 weeks
1887862|NCT01238588|Drug|Sevelamer Carbonate (Renvela)|Patients' will be given doses of Renvela equivalent to their prior dose of calcium based phosphate binders and the dose will be titrated as necessary to achieve phosphate levels recommended by KDOQI guidelines.
1887863|NCT01238614|Other|CHICA PSF plus JIT|
1887864|NCT01238614|Other|CHICA maternal depression PSF|
1887865|NCT01238614|Other|Control|
1887866|NCT01238627|Drug|Nicotine Sublingual Tablet Mint (NSTM)|A single dose of an experimental NSTM, with a 36-hour washout between visits
1887867|NCT01238627|Drug|Marketed Nicotine Tablet|A single dose of a marketed Nicotine Replacement Therapy (NRT), with a 36-hour washout between visits
1887868|NCT01238640|Drug|Code STD|"2 mg Single-dose of experimental nicotine product coded STD"
1887869|NCT01238640|Drug|Code STE|"2 mg Single-dose of experimental nicotine product coded STE"
1887870|NCT01238640|Drug|Nicorette Microtab|A comparative 2 mg Single-dose of marketed tablet
1887871|NCT01238679|Drug|PF-04958242 0.03 mg|0.03 mg dose tablet every 12 hours for 14 days
1887872|NCT01238679|Drug|PF-04958242 0.05 mg|PF-04958242 0.05 mg dose tablet every 24 hours for 14 days
1887873|NCT01238679|Drug|Placebo|Placebo tablet every 12 hours or every 24 hours for 14 days
1887874|NCT01238692|Drug|LBH589|Patients randomized to both arms will receive oral LBH589, once-a-day, at a dose of 30 mg/day, on a three times-a-week (Monday, Wednesday and Friday) schedule as part of a 3 week (21 day) treatment cycle. Day one of each cycle will be on a Monday.
1887875|NCT01238692|Drug|Rituximab|"Patients randomized to Arm B will receive IV rituximab at a dose of 375 mg/m2 in combination with oral LBH589. Rituximab should be administered on the same day as LBH589, after the patient has taken their LBH589 dose. The appropriate amount of solution should be withdrawn from the vial for the following calculation:
Volume (mL) = BSA (m2) × dose (375 mg/m2) / concentration of reconstituted solution ml/mL (100 mg/10 mL and/or 500 mg/50 mL)."
1887876|NCT01231347|Drug|AMG 479|AMG 479 12 mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
1887877|NCT01231347|Drug|Placebo|Placebo administered intravenously on days 1 and 15 of a 28 day cycle
1887878|NCT01231347|Drug|AMG 479|AMG 479 20mg/kg administered intravenously on days 1 and 15 of a 28 day cycle
1887879|NCT01231347|Drug|gemcitabine|gemcitabine 1000mg/m2 administered intravenously on days 1, 8 and 15 of a 28 day cycle
1887880|NCT01231360|Other|Exercise Training|Subjects randomized to exercise training will participate in a three-month treadmill exercise program in 1-hour training sessions three times per week as previously described. After a 5-minute warm-up period, exercise is initiated at a low workload of 2 mph at 0% grade. Subjects walk until moderate claudication severity develops, and then rest until the discomfort resolves, repeating until the total exercise period is completed. The intensity of the treadmill exercise is increased as tolerated by increasing walking speed by 0.5-1 mph and/or grade by 1-2%. Subjects are encouraged to continue the walking program at home for at least 30 minutes on two separate occasions each week.
1887881|NCT01231360|Other|Normal routine|Subjects randomized to the routine activity control group will be asked to keep a log of their daily activities and return to the Vascular Research Center at weeks 4, 8, and 12 at which time they will be asked to return their log and undergo repeat treadmill testing and complete the 6 minute walk test.
1887882|NCT01231373|Drug|polidocanol injectable foam, 0.125%|active placebo for blinding
1887883|NCT01231373|Drug|polidocanol injectable foam, 0.5%|0.5% polidocanol foam injection
1887884|NCT01231373|Drug|polidocanol injectable foam, 1.0%|1.0% polidocanol foam injection
1887885|NCT01231373|Drug|Vehicle|injection of vehicle comparator
1887886|NCT01231399|Drug|fluorouracil|Given IV
1887887|NCT01231399|Drug|leucovorin calcium|Given IV
1887888|NCT01231399|Drug|oxaliplatin|Given IV
1887889|NCT01231399|Drug|everolimus|Given orally
1887890|NCT01231399|Other|laboratory biomarker analysis|Correlative studies
1887891|NCT01231399|Other|immunohistochemistry staining method|Correlative studies
1887892|NCT01231399|Genetic|microarray analysis|Correlative studies
1887893|NCT01231412|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSCT
1887894|NCT01231412|Drug|Cyclosporine|Given PO or IV
1887895|NCT01231412|Drug|Fludarabine Phosphate|Given IV
1887896|NCT01231412|Drug|Mycophenolate Mofetil|Given PO
1887897|NCT01231412|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSCT
1887898|NCT01231412|Drug|Sirolimus|Given PO
1887899|NCT01231412|Radiation|Total-Body Irradiation|Undergo TBI
1887900|NCT01231438|Drug|Renvela|800mg t.i.d. over 2 weeks
1887901|NCT01231438|Drug|Etalpha|0.25ug o.d. for 2 weeks
1887902|NCT01231451|Drug|DMPA|All subjects will take DMPA
1887903|NCT01231464|Drug|fluticasone furoate nasal spray|fluticasone furoate nasal spray 110ug, once daily
1887904|NCT01231464|Drug|placebo|placebo
1888084|NCT01232686|Other|Online disease surveillance data access|In the intervention areas we will give the study participants online access to the Snow disease surveillance system. The system will provide data about the incidents of respiratory and gastrointestinal communicable diseases in the patient population.
1887907|NCT01231503|Biological|GSK Biological's Investigational Malaria Vaccine 257049|3 doses, intramuscular (IM) route, in left antero-lateral thigh, as follows: 1) RTS,S Neo-10-14 Group at less than (=<) 7 days, at 10 and 14 weeks (wks) of age; 2) RTS,S Neo-10-26 Group =< 7 days, at 10 and 26 wks of age; 3) RTS,S 6-10-14 Group at 6, 10 and 14 wks of age; 4) RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 5) Engerix-B Neo/RTS,S 6-10-26 Group at 6, 10 and 26 wks of age; 6) RTS,S 10-14-26 Group at 10, 14 and 26 wks of age; 7) RTS,S 14-26-9M Group at 14 and 26 wks of age and at 9 months of age
1887908|NCT01231503|Biological|Engerix™-B|1 dose, intramuscular route: left antero-lateral thigh at birth (=< 7 days of age)
1887909|NCT01231503|Biological|Tritanrix™ HepB Hib|3 doses, intramuscular route: right antero-lateral thigh at 6, 10 and 14 weeks of age
1887910|NCT01231503|Biological|BCG|1 dose, intradermal route, in shoulder at birth (=< 7 days of age)
1887911|NCT01231503|Biological|OPV|4 doses, orally, at birth (=< 7 days of age) and at 6, 10 and 14 weeks of age
1887912|NCT01231503|Biological|Rouvax|1 dose, intramuscular (IM) route, in left antero-lateral thigh, at 9 months of age
1887913|NCT01231516|Drug|GSK1349572|50mg once daily
1887914|NCT01231516|Drug|Raltegravir|400mg twice daily
1887915|NCT01231516|Drug|GSK1349572 Placebo|Inactive placebo tablet once daily
1887916|NCT01231516|Drug|Raltegravir Placebo|Inactive placebo tablet twice daily
1887917|NCT01231529|Drug|GSK1349572|All subjects will receive a single dose of GSK1349572 50 mg. GSK1349572 is an experimental drug in the integrase inhibitor class being developed for the treatment of HIV infection. GSK1349572 is not approved by the FDA.
1887918|NCT01231542|Drug|GSK1349572|GSK1349572 is an experimental drug for the treatment of HIV. GSK1349572 is in the integrase inhibitor class. It is not yet approved by the FDA.
1887919|NCT01231542|Drug|Rifampin|Rifampin is approved by the FDA for the treatment of tuberculosis.
1887920|NCT01231542|Drug|Rifabutin|Rifabutin is approved by the FDA for the treatment of tuberculosis.
1989683|NCT02422797|Drug|DTG 50 mg|Participants will take one oral tablet of 50 mg DTG daily administered concomitantly with RPV. Each DTG tablet will contain 52.62 mg dolutegravir sodium salt, which is equivalent to 50 mg dolutegravir free acid.
1989684|NCT02422797|Drug|RPV 25 mg|Participants will take one oral tablet of 25 mg RPV daily administered concomitantly with DTG along with a meal. Each RPV tablet will contain 27.5 mg of rilpivirine hydrochloride, which is equivalent to 25 mg of RPV.
1887924|NCT01231568|Drug|Regimen A|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
1887925|NCT01231568|Drug|Regimen B|Two gelatin capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, larger, non-micronized particles, equivalent to 150 mg free base), dosed fasted
1887926|NCT01231568|Drug|Regimen C|Two Hydroxy Propyl Methyl Cellulose (HPMC) capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed fasted
1887927|NCT01231568|Drug|Regimen D|Two HPMC capsules containing 75 mg GSK2118436A (dosed as the mesylate salt, micronized particles, equivalent to 150 mg free base), dosed with a high-fat meal
1887928|NCT01231581|Drug|GSK1120212|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
1887929|NCT01231581|Drug|Gemcitabine|Intravenous gemcitabine infused over 30 minutes weekly for 7 weeks followed by one week of rest from treatment. Subsequent cycles will consist of 1000 mg/m2 intravenous infusion over 30 minutes on days 1, 8, and 15 followed by 1 week of rest from treatment for each 28-day treatment period.
1887930|NCT01231581|Drug|Placebo|administered orally starting on day 1 followed by a continuous daily dosing of 2.0 mg
1887931|NCT01231594|Drug|GSK2118436|Study Drug
1887932|NCT01231594|Drug|GSK1120212|Study Drug
1887933|NCT01231594|Drug|Other approved anti-cancer agent|Study Drug
1887934|NCT01231607|Drug|1mg Finasteride active|1mg finasteride active, by mouth once daily
1887935|NCT01231607|Drug|0.02mg dutasteride|0.02mg dutasteride active, by mouth once daily
1887936|NCT01231607|Drug|0.1mg dutasteride|0.1mg dutasteride active, by mouth once daily
1887937|NCT01231607|Drug|0.5mg dutasteride|0.5mg dutasteride active, by mouth once daily
1887938|NCT01231607|Drug|Finasteride placebo|finasteride placebo, by mouth once daily
1887939|NCT01231607|Drug|Dutasteride placebo|dutasteride placebo, by mouth once daily
1989685|NCT02422797|Drug|CAR|CAR will include following combinations: 2 NRTIs + 1 INI, 2 NRTIs + 1 NNRTI, or 2 NRTIs + 1 PI.
1887946|NCT01231646|Other|No intervention|No intervention. This is a cross-sectional study.
1887947|NCT01231659|Drug|Everolimus + Letrozole|
1887948|NCT01231672|Biological|Routine biological analyses|Bilirubinemia (total and conjugated), hematology, hemogram, SOFA score
1887949|NCT01231685|Drug|Raltegravir|Subjects will maintain their nucleoside backbone and switch ritonavir-boosted protease inhibitor to Raltegravir 400 mg po BID for 48 weeks.
1887950|NCT01231685|Drug|Ritonavir-boosted protease inhibitor|Subjects will maintain their nucleoside backbone and remain on a ritonavir-boosted protease inhibitor at standard doses for for 48 weeks
1887951|NCT01231698|Drug|esmolol|Strict heart rate control: esmolol at any dose to maintain heart rate between 95 and 80 bpm.
1887952|NCT01231698|Other|control|standard treatment without strict heart rate control
1887993|NCT01231984|Device|8mm x 31G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are directed to use pinch-up when injecting in the abdomen or thigh with the 8mm PN, and no pinch-up at other injection sites.
1888085|NCT01232699|Behavioral|Internet Obesity Treatment|Participants will engage in self monitoring, will receive skills training to help cope with environmental triggers, and will receive nutrition advice.
1887953|NCT01231711|Behavioral|Vets Prevail|"The intervention has two primary components that are both delivered over the Internet:
The first component is a structured series of brief peer-to-peer instant messaging Chats structured around ensuring effective motivation, engagement, and completion. This component was modeled after Motivational Interviewing (MI) techniques. The peer-to-peer contact was provided by a master's level social worker, as well as by trained and certified combat veterans who completed the Vet-to-Vet counseling certificate program offered by the Depression and Bipolar Support Alliance (DBSA).
The second component consists of six 30-minute e-Learning Lessons using standard Cognitive Behavioral Therapy (CBT) approaches to reducing depressive and anxiety symptoms and strengthening coping skills."
1887954|NCT01231724|Device|Allstate Nasal Spray|Allstate Nasal Spray, two sprays (total 100 microliters) in each nostril.
1887955|NCT01231724|Device|Placebo Nasal Spray|2 sprays in each nostril
1887956|NCT01231737|Drug|prulifloxacin|Prulifloxacin 1 tablet/week for 12 weeks.
1887957|NCT01231750|Drug|Capsaicin|0.1% topical cream,4cm spread over 8cm x 15cm area on skin, one time, 45 minutes prior to exercise
1887958|NCT01231750|Other|Placebo cream|cream, 4cm spread over 8cm x 15cm area of skin
1887959|NCT01231763|Other|No intervention (not applicable)|No intervention (not applicable)
1887960|NCT01231776|Other|electronic acupuncture|applying a stimula on neiguang and shenmen through electronic acupuncture
1887961|NCT01231789|Procedure|RIPC|RIPC consisted of three 5-min cycles of right upper arm ischemia, which was induced by an automated cuff-inflator placed on the right upper arm and inflated to 200 mmHg, with an intervening 5 min of reperfusion during which the cuff was deflated
1887962|NCT01231789|Procedure|sham RIPC|Patients had a deflated cuff placed on the right upper arm for 30 min without any inflation procedure.
1887963|NCT01231802|Drug|Eniluracil|Eniluracil (40 mg) orally at 18:00 ± 1 hour (6:00 PM) on Days 1, 8, & 15
1887964|NCT01231802|Drug|5-Fluorouracil|5-FU (30 mg/m2) orally at 7:00 AM ± 1 hour on Days 2, 9, & 16
1887965|NCT01231802|Drug|Leucovorin|Leucovorin (30 mg) orally at 7:00 AM ± 2 hours on Days 2, 3, 9, 10, 16, & 17
1887966|NCT01231802|Drug|Capecitabine|Capecitabine (1000 mg/m2) twice daily (12 hr apart) for 14 consecutive days followed by 7 days off-treatment
1887967|NCT01231815|Radiation|15O-H2O PET -|Assessment of coronary reserve using PET
1887968|NCT01231815|Radiation|MRI|Assessment of coronary reserve using MRI
1887969|NCT01231828|Drug|L-carnitine|L-carnitine 4g per day (4 bottles of 10ml).
1887970|NCT01231828|Drug|Lactulose|Lactulose (30-60 ml per day)
1887971|NCT01231841|Drug|cyclosporine|Given orally
1887972|NCT01231841|Other|flow cytometry|Correlative studies
1887973|NCT01231841|Biological|anti-thymocyte globulin|Given IV
1887974|NCT01231854|Drug|Ciclosporin|In accordance with the current guideline concerning the use of ciclosporin in dermatology and the current guideline management of hand eczema the daily oral dosage of ciclosporin microemulsion is 2.7 to 4.0 mg/kg bodyweight (half of the total daily dosage will be administered in the morning and in the evening). To enable both body-weight adjusted treatment and double-blind treatment patients will be allocated to 2 different dosages depending on their body weight (50-74.9 kg: daily dosage 200 mg; 75-100 kg: daily dosage 300 mg).
1887975|NCT01231854|Drug|Alitretinoin|In accordance with the current guideline management of hand eczema alitretinoin will be administered orally in a constant daily dosage of 30 mg.
1887976|NCT01231880|Drug|Four monthly IPT with dihydroartemisinin Piperaquine (DP)|Given every 4 months (once a school term)
1887977|NCT01231880|Drug|Monthly IPT using DP|Given every month
1887978|NCT01231880|Drug|Placebo given every month|No active ingredient
1887979|NCT01231893|Procedure|olfactory mucosa ensheathing cell grafting, rehabilitation|In this group patients are planned to underwent a biopsy of their own olfactory mucosa for isolation and culture of olfactory ensheathing cells and olfactory fibroblasts. The suspension of these cells will be next transplanted into the focus of spinal cord injury. Before and after surgery the patients will undergo an intense neurorehabilitation program.
1887980|NCT01231893|Other|rehabilitation|In this group the patients will not undergo any surgical procedure. They will participate in the same rehabilitation protocol that is planned for the patients from the experimental group.
1887981|NCT01231906|Drug|vincristine sulfate|Given IV
1887982|NCT01231906|Drug|doxorubicin hydrochloride|Given IV
1887983|NCT01231906|Drug|cyclophosphamide|Given IV
1887984|NCT01231906|Drug|ifosfamide|Given IV
1887985|NCT01231906|Drug|etoposide|Given IV
1887986|NCT01231906|Drug|topotecan hydrochloride|Given IV
1887987|NCT01231906|Other|laboratory biomarker analysis|Correlative studies
1887988|NCT01231919|Drug|Akt inhibitor MK2206|Given PO
1887989|NCT01231919|Other|diagnostic laboratory biomarker analysis|Correlative studies
1887990|NCT01231919|Other|pharmacological study|Correlative studies
1887991|NCT01231958|Behavioral|The Heart Healthy Initiative for Hispanic Adults (HIP)|This randomized controlled pilot intervention study will include 150 Hispanic adults (45-75y) in the Greater Boston area. Participants will be randomized to either the intervention or control group after completing their baseline interview. The intervention group will receive 6 months of weekly group educational sessions, Zumba fitness classes and interactions with an embodied computer agent (ECA). The fitness classes and interactions with the ECA will continue for the second 6 months of the 1 year intervention. Intervention activities will occur at community centers in the greater Boston area. Control participants will receive standard of care for the first 6 months and will be offered the full intervention (weekly group educational sessions, Zumba fitness classes and interactions with the ECA) for the second 6 months of the study. Participants will complete an interview and blood draw at baseline, 6 months, and 12 months.
1887992|NCT01231984|Device|4 mm x 32G Pen Needle|During the 12 week study period, subjects use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. Subjects are advised to inject straight in when using the 4mm PN, with no pinch up.
1888038|NCT01232283|Drug|Apremilast|Apremilast 30mg by mouth (PO) twice a day (BID) for 32 weeks
1888039|NCT01232283|Drug|Placebo|Identically matching placebo by mouth BID for first 16 weeks. Placebo participants will be switched to receive apremilast 30 mg BID at Week 16-32.
1887994|NCT01231984|Device|12.7mm x 29G Pen Needle|During the 12 week study period, subjects will use this pen needle with their own pen device for all daily insulin injections they usually administered themselves with a pen device. Subjects follow their usual insulin regimen and there is no upper limit on total daily insulin dosage or number of injections. When using the 12.7mm PN, subjects are instructed to insert either at an angle of 45 degrees, or to pinch up and hold the pen device at a 90 degree angle (straight in).
1887995|NCT01231997|Drug|Udenafil|100mg Single Oral Dose of
1887996|NCT01232010|Drug|Mirodenafil|50mg Single Oral Dose of
1887997|NCT01232023|Drug|Indobufen|Single Oral Dose of
1887998|NCT01232036|Drug|Glucophage 500mg|Single Oral Dose of
1887999|NCT01232036|Drug|HL-018 500mg|Single Oral Dose of
1888000|NCT01232036|Other|No administration of Drug|
1888001|NCT01232049|Drug|Multiple Oral Dose of|Pitavastatin 4mg
1888002|NCT01232049|Drug|Multiple Oral Dose of|Valsartan 320mg
1888003|NCT01232075|Drug|Extended letrozole regimen|"Letrozole (Femara; Novartis pharma AG, Basle, Switzerland) 2.5mg /day is administered from cycle day 1 to 9 .
Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .
Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.
Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
1888004|NCT01232075|Drug|Clomiphene citrate regimen|"Clomiphene citrate(Clomid; Aventis pharma S.AE, Global Napi pharmaceuticals, Cairo, Egypt) 100 mg/day is administered from cycle day 3 to 7.
Human chorionic gonadotropin (Pregnyl; N.V. Organon, Oss, Holland) ( 10.000 IU/I.M ) is administered to trigger ovulation when at least one follicle measures more than 18mm in mean diameter .Intrauterine insemination is performed 36 - 40 hours after HCG injection .
Starting from cycle day 9 , ultrasound scans are repeated daily to monitor follicle growth . Serum estradiol and endometrial thickness are measured on the day of HCG administration.
Serum B-subunit HCG is measured 2 weeks after IUI to diagnose pregnancy ."
1888005|NCT01232101|Device|covered or uncovered stents|Patients are randomized to covered or uncovered stent. Stent patency is monitored and compared as well as complications, efficacy and technical success.
1888006|NCT01232127|Drug|Atazanavir|Capsule, oral, 300 mg, once daily, 10 days
1888007|NCT01232127|Drug|Atazanavir|Capsule, oral, 400 mg, once daily, 7 days
1888008|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 10 days
1888009|NCT01232127|Drug|Ritonavir|Capsule, oral, 100 mg, once daily, 7 days
1888010|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 10 days
1888011|NCT01232127|Drug|Tenofovir (TDF)|Capsule, oral, 300 mg, once daily, 7 days
1888012|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 10 days
1888013|NCT01232127|Drug|Nucleoside Reverse Transcriptase Inhibitor (NRTI)|Oral, 7 days
1888014|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 20 mg, twice daily, 7 days
1888015|NCT01232127|Drug|Famotidine (FAM)|Tablet, oral, 40 mg, twice daily, 7 days
1888016|NCT01232140|Other|CRP-guided antibiotic treatment|If CRP> 50 mg/l patients with AECOPD receive antibiotic treatment, whereas in those patients with CRP =< 50 mg/l antibiotic treatment are withheld. This will be compared to the regular antibiotic treatment that has been advised by the GOLD strategy
1888017|NCT01232153|Device|Non invasive ventilation|Non invasive ventilation
1888018|NCT01232166|Other|Auscultation|
1888019|NCT01232166|Other|Observation of symmetric chest movements|
1888020|NCT01232166|Other|Tube depth|
1888021|NCT01232166|Other|All three|
1888022|NCT01232179|Procedure|conventional prp|pan retinal photocoagulation
1888023|NCT01232179|Procedure|targeted prp|1200-1600 spot in far periphery retin, anterior equator
1888024|NCT01232192|Behavioral|antenatal model|"Antenatal model is consisted of integrated efforts to lower preterm delivery rate through early detection and bacterial vaginal infection treatment:
Midwife training
Pregnant women campaigning
Early detection with self pH detection
Treatment of bacterial vaginosis"
1888025|NCT01232205|Dietary Supplement|micronutrient antioxidant|Supplementation with milk enriched with vitamin and mineral, such as Cu, Zn, Mn, Fe, carotene, vitamin B6, B12, C, E, selenium, and calcium
1888026|NCT01232205|Dietary Supplement|Control|supplementation with milk
1888027|NCT01232218|Other|Standard education/exercises for hemiplegic shoulder pain|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with standard stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour.
1888028|NCT01232218|Other|Three dimensional Scapular-Humeral Mobilizations|Each participant will receive standard education for safe positioning and movement of the painful hemiplegic shoulder. Participants will also be provided with stretching and strengthening exercises by and experienced Occupational Therapist who will grade the level of exercise to suit their needs. Intervention will take place 3x/week for 1 hour. Participants in this group will receive an additional scapular humeral mobilization while simultaneously performing the standard stretching/strengthening exercise protocol.
1888029|NCT01232231|Drug|pharmacological decolonization treatment|Chlorhexidine gluconate 4% body scrub and 2% shampoo daily PLUS mupirocin 2%, fusidic acid 2%, or chlorhexidine gluconate 0.2% intranasally bid PLUS trimethoprim-sulfamethoxazole 160/800mg po bid or doxycycline 100mg po bid all for 7 days
1888030|NCT01232231|Behavioral|Education|No pharmacological decolonization treatment but given education regarding personal hygiene and environmental cleaning
1888031|NCT01232244|Other|GLP-1 infusion|1 pmol/kg/min
1888032|NCT01232244|Other|Glucagon infusion|3ng/kg/min
1888033|NCT01232244|Other|Oxyntomodulin infusion|3 pmol/kg/min
1888034|NCT01232244|Other|GLP-1 and glucagon infusion|1 pmol/kg/min 3 ng/kg/min
1888035|NCT01232244|Other|Placebo|NaCl 9 g/L infusion
1888036|NCT01232257|Drug|N-acetylcysteine|4 gifts of N-acetylcysteine 600 mg BID
1888037|NCT01232270|Drug|propofol|1.1 mcg/ml for initial effect site concentration during spinal anesthesia (The effect site concentration will be changed at each subject by Dixon's up-and-down method.)
1888040|NCT01232283|Other|Topical or Phototherapy Therapy|Topical therapies such as low-potency or weak corticosteroids or phototherapies such as light therapy are added for non-responders at Week 32, (< PASI-50) and added to their treatment regimen. The decision to add these treatments during this phase can only be made at the Week 32 visit.
1888041|NCT01232296|Drug|dovitinib|500 mg p.o. o.d. 5 days on/2 days off
1888042|NCT01232296|Drug|sorafenib|400 mg p.o. b.i.d.
1888043|NCT01232309|Dietary Supplement|Chitin-Glucan|3 x 500 mg capsules (tid) = 4.5 mg daily dose
1888044|NCT01232309|Dietary Supplement|Low Dose Chitin-Glucan|3 x 167 mg capsules (tid) = 1.5 g daily dose
1888045|NCT01232309|Dietary Supplement|Low Dose Chitin-Glucan + Olive Extract|3 x 167 mg capsules (tid) = 1.5 g daily dose (C-G) + 135 mg olive extract
1888046|NCT01232309|Dietary Supplement|Placebo|3 x 500 mg capsules (tid)
1888047|NCT01232374|Drug|Nimotuzumab|200mg (4 bottles), once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
1888048|NCT01232374|Drug|Placebo|4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)
1888049|NCT01232374|Drug|cisplatin|cisplatin 25 mg/m2/d, d1-3, once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13); 5-FU 600 mg/m2/d, d1-3, continuously infusion for 72 hrs,once every 4 weeks for 4 cycles (week 1, week 5, week 9 and week 13).
1888050|NCT01232374|Radiation|Radiotherapy|"A total dose of 61.2 Gy will be delivered in 34 fractions at 1.8 Gy/fraction, 5 fractions per week in 6.8 weeks.
Placebo: 4 bottles placebo, once a week for 7 weeks during irradiation (week 1, week 2, week 3, week 4, week 5, week 6 and week 7). After irradiation 200mg (4 bottles), once every 4 weeks for 2 cycles (week 9 and week 13)"
1888051|NCT01232400|Drug|Esmolol|"The initial esmolol infusion will be 50 mcg/kg/minute IV. This will be increased by 25 mcg/kg/minute every 15 minutes until one of the following situations is reached:
Heart rate less than 70 bpm.
Systolic blood pressure less than 120 mmHg
Maximum dose of esmolol of 200 mcg/kg/minute is reached."
1888052|NCT01232413|Drug|Placebo|Oral
1888053|NCT01232413|Drug|ASP1941|Oral
1888054|NCT01232413|Drug|Moxifloxacin|Oral
1888055|NCT01232426|Procedure|Biodegradable Meniscus Arrow®|Closed reduction of the Mallet fracture and fixation with 1 biodegradable meniscus Arrow®
1888056|NCT01232426|Device|Mallet splint|Conservative treatment of the Mallet fracture with the traditional Mallet splint.
1888057|NCT01232439|Drug|opioid receptor kappa antagonist|"Starting dose of 2 mg, administered orally, once.
The potential dose range for this study is 0.2 mg to 30 mg"
1888058|NCT01232452|Drug|Pemetrexed|Administered intravenously (IV)
1888059|NCT01232452|Drug|Cisplatin|Administered IV
1888060|NCT01232452|Drug|Cixutumumab|Administered IV
1888061|NCT01232478|Behavioral|Comprehensive Adherence Program (CAP)|The Comprehensive Adherence Program (CAP) consists of training in the CF My Way program (a validated problem-solving adherence promotion intervention).
1888062|NCT01232491|Drug|Insulin detemir|Individually adjusted insulin detemir subcutaneously (under the skin) once daily. Subjects continue their pre-trial metformin treatment.
1888063|NCT01232491|Dietary Supplement|Dietary regimen|Subjects receive dietary consultation by a dietician at six occasions during the trial.
1888064|NCT01232504|Drug|rhGM-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
1888065|NCT01232504|Drug|rhG-CSF+rhGM-CSF group|a combination of 2-3μg/kg/d rhGM-CSF and 2-3μg/kg/d rhG-CSF each after transplantation, started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
1888066|NCT01232504|Drug|rhG-CSF group|subcutaneous rhGM-CSF 5-7μg/kg/d , started on day 5 post-transplant and continued until recovery from neutropenia (absolute neutrophil count [ANC] > 1.5×10(9)/L for 2 consecutive days).
1888067|NCT01232543|Drug|Product 0405|Product 0405 will be administered topically, twice daily for 28 days.
1888072|NCT01232569|Drug|Tocilizumab 162 mg|Tocilizumab will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
1888073|NCT01232569|Drug|Placebo|Placebo will be supplied in a ready-to-use, single-use, pre-filled syringe. Patients and/or caregivers will be trained to administer the injection.
1888074|NCT01232582|Device|Exablate treatment|MR guided Focused Ultrasound treatment
1888075|NCT01232595|Drug|LFF571|
1888076|NCT01232595|Drug|Vancomycin (POC)|
1888077|NCT01232608|Behavioral|Exercise|12 months of exercise training
1888078|NCT01232621|Other|Physician Introduction of research personnel|Physicians will introduce Research Coordinators (RCs) by name and acknowledge patient eligibility to participate in a research study using a standardized script.
1888079|NCT01232647|Drug|Phylloquinone|1.0 mg daily of vitamin K1
1888080|NCT01232647|Drug|Menatetrenone (MK4)|Menatetrenone (MK4) 45 mg daily
1888081|NCT01232647|Drug|placebo|placebo vitamin K1 and placebo MK4 given daily for 18 months
1888082|NCT01232660|Drug|Hydroxychloroquine|Hydroxychloroquine 400mg once daily orally
1888083|NCT01232673|Procedure|BMAC application in Critical Limb Ischemia|Collection of 240ml from both illiac crests, followed by gradient density centrifugation, resulting in obtaining 40ml of BMAC (Bone-Marrow Aspiration Concentrate). BMAC is subsequently administered into the ischemic limb along calf vessels.
1888164|NCT01238822|Drug|placebo|Placebo
1888165|NCT01238822|Drug|Methylphenidate|36 mg methylphenidate
1992329|NCT03322150|Drug|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
1888086|NCT01232699|Behavioral|Internet Obesity Treatment with MI|In addition to weekly group meetings, self-monitoring through recording calorie and fat intake daily as well as exercise, participants will meet one-on-one with an MI counselor on-line in order to augment an individual's motivation to change behavior.
1888087|NCT01232699|Behavioral|Contingent MI|Participants will attend weekly behavioral internet meetings. They may or may not receive Motivational Interviewing depending on their class attendance.
1888088|NCT01232712|Biological|ImMucin, hGM-CSF|"Six biweekly Intradermal or subcutaneous injections of 100 micrograms ImMucin
After six injections, if response will not be observed, or if response will not be sufficient, Immucin dose will be escalated to 250 micrograms for six additional injections.
In addition, each immunization, hGM-CSF with a total dose of 250 microgram will be injected."
1888089|NCT01232725|Dietary Supplement|Donor Human Milk|Donor Human Milk, obtained from the Mother's Milk of Iowa, a HMBANA milk bank
1989694|NCT02417064|Drug|Esketamine|Participants will self-administer either 84 mg or 56 mg of esketamine, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
1888091|NCT01232751|Dietary Supplement|Isoflavone supplement|The participants will consume 2 times 2 supplements per day, which will lead to a daily dose of 114 mg. (HPLC analysis confirmed an aglycone isoflavone content of 28.41 mg per supplement)
1888092|NCT01232764|Other|Exposure to multi-disciplinary wound care team|"Phase 1: In Person Support (3 mths)
Advance Practice Nurses (APNs) affiliated with Enhanced Multi-Disciplinary visit LTC facilities on a weekly basis. The APN may communicate with other members of an EMDT via telephone or online.EMDTs will collectively teach and mentor LTC facility wound care teams throughout the study.
Phase 2: Remote Support (2-11 mths) In the second phase, EMDTs will support LTC facility staff remotely via telephone and online communication, visiting the facilities on an as needed basis only.
All PU treatment will be based on RNAO evidence-based guidelines (updated in 2007)contextualized to the LTC setting."
1888093|NCT01232777|Drug|Bevacizumab|A single dosage of: 0.625mg(0.025cc)or 0.75mg(0.03cc) will be given intravitreally.
1888094|NCT01232790|Dietary Supplement|N-Acetylcysteine|N-acetylcysteine 1200mg bid for 3 days
1888095|NCT01232790|Drug|Placebo|Placebo
1888096|NCT01232803|Drug|Tenofovir 1% gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
1888097|NCT01232803|Drug|2% N-9 gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
1888098|NCT01232803|Drug|HEC Placebo gel|Entire contents of an applicator will be inserted rectally, for a total of 8 doses.
1888099|NCT01232829|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given PO
1888100|NCT01232842|Genetic|cytogenetic analysis|
1888101|NCT01232842|Other|HUMARA assay|
1888102|NCT01232842|Other|fluorescence activated cell sorting|
1888103|NCT01232842|Other|laboratory biomarker analysis|
1888104|NCT01232855|Genetic|protein expression analysis|
1888105|NCT01232855|Genetic|western blotting|
1888106|NCT01232855|Other|flow cytometry|
1888107|NCT01232855|Other|laboratory biomarker analysis|
1989695|NCT02417064|Drug|Placebo|Participants will self-administer matching placebo, intranasally, twice per week for 4 weeks as a fixed dose regimen in Double-Blind Induction Phase.
1888109|NCT01232881|Procedure|Tumor Sample|Tumor sample submission can consist of a fresh frozen tissue sample or a formalin-fixed paraffin embedded tissue block.
1888110|NCT01232881|Procedure|Serum Sample|Serum is to be collected prior to the initiation of lonafarnib treatment and 28 days after the last dose of lonafarnib.
1888111|NCT01232894|Drug|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
1888112|NCT01232894|Drug|Long-acting beta2-agonist|Long-acting beta2-agonist (LABA) bronchodilator monotherapy via inhaler twice daily
1888113|NCT01232907|Drug|L-Carnitine|L-Carnitine, a pharmaceutical product, for the treatment of fatigue in persons with spinal cord injury will be used for this study. L-Carnitine is a nutrient normally obtained in the fat from meat. It promotes fatty acid oxidation of muscle, thereby promoting efficient energy production. Treatment with L-Carnitine has been shown to produce clinically significant improvement in fatigue in persons with multiple sclerosis (MS), cancer, and in aging populations. While the causes of fatigue in persons with SCI may be multifactorial, successful use of L-Carnitine in MS-related fatigue suggests it may have a role in SCI. Standard treatment will entail daily dosages of 1980 milligrams of L-Carnitine (three 330 mg tablets in the morning and three 330 mg tablets in the evening) for 4 weeks.
1888114|NCT01232920|Drug|Methotrexate|All methotrexate doses will be taken orally once per week in a divided dose (half in the morning, half in the evening), and should be taken with food. For the first two weeks, a loading dose of 15 mg/week orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 25 mg/week until the end of follow-up or until treatment failure due to intolerability, adverse events, or of lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 20 mg per week while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 15 mg per week.
1888115|NCT01232920|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be taken twice daily on an empty stomach. For the first two weeks, a loading dose of 500 mg/BID orally will be administered to assess tolerability. After two weeks, the dose will be ramped up to 1 g/BID until the end of follow-up or until treatment failure due to intolerability, adverse events, or lack of efficacy. If the study ophthalmologist decides to reduce the study treatment dose due to intolerability, the dose will be reduced to 750 mg/BID while maintaining masking. If side effects persist and the study ophthalmologist wishes to reduce the dose a second time, the dose will be reduced to 500 mg/BID.
1888116|NCT01232933|Device|VPS System|Use of the navigational VPS system during catheter placement
1888166|NCT01238822|Drug|Methylphenidate|54 mg methylphenidate
1888167|NCT01238835|Device|SAPIEN XT™ Transapical aortic valve replacement|Transcatheter aortic valve implantation via the transapical approach
1888168|NCT01238848|Drug|Hypertonic saline|3 cc nebulized hypertonic saline + albuterol 0.25 mg/kg/day, four times a day (QID), 5 days
1888323|NCT01240538|Other|pharmacological study|Correlative studies
1992330|NCT03322150|Drug|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
1888120|NCT01232959|Device|Transvaginal Cholecystectomy|A small incision is made in the vagina. An endoscope (flexible lighted camera tube) is inserted into the abdomen. An endoscope is normally used to examine your stomach or colon. A very small camera is placed in your abdomen at the belly button (5 mm, ¼ inch). This helps the surgeons to remove your gallbladder through the vagina. The procedure to separate your gallbladder from your body will be assisted by instruments placed through your abdomen and instruments placed in your vagina. The surgeon will remove the gallbladder by passing it though your vagina.
1888121|NCT01232972|Procedure|vitrification of oocytes|eggs will be preserved via vitrification the day they are retrieved from the participant
1888122|NCT01232985|Device|RD047-26|RD047-26 emollient gel
1888123|NCT01233024|Dietary Supplement|Control|Dinner bar fortified with 0g fiber; breakfast bar fortified with 0g dietary fiber.
1888124|NCT01233024|Dietary Supplement|Soluble corn fiber|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
1888125|NCT01233024|Dietary Supplement|Resistant starch|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
1888126|NCT01233024|Dietary Supplement|Fructooligosaccharide|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
1888127|NCT01233024|Dietary Supplement|Inulin|Dinner bar fortified with 12g fiber; breakfast bar fortified with 11g dietary fiber.
1888128|NCT01233050|Drug|2% Chlorhexidine Gluconate/70% Isopropyl Alcohol|Preoperative skin antisepsis preparation
1888129|NCT01233050|Drug|Iodine Povacrylex/74% Isopropyl Alcohol|preoperative skin antisepsis preparation
1888130|NCT01233063|Behavioral|Physical Activity and Diet Intervention via Alive2|Weekly email/web goal-setting intervention to improve physical activity and diet, with and without additional phone and mail support.
1888131|NCT01233076|Device|Nelfilcon A contact lens|Commercially marketed, spherical contact lens for daily wear, daily disposable use
1888132|NCT01233076|Device|Narafilcon B contact lens|Commercially marketed (US), spherical contact lens for daily wear, daily disposable use
1888133|NCT01233089|Device|Lotrafilcon B contact lens, investigational|Investigational silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly
1888134|NCT01233089|Device|Lotrafilcon B contact lens, commercial (AIR OPTIX AQUA)|Commercially available silicone hydrogel, spherical contact lens worn on a daily wear basis and replaced monthly.
1888135|NCT01233089|Device|Lotrafilcon B multifocal contact lens, commercial (AIR OPTIX AQUA MULTIFOCAL)|Commercially available silicone hydrogel, multifocal, contact lens worn on a daily wear basis and replaced monthly.
1888136|NCT01233089|Device|Contact lens care system (ClearCare)|Commercially available, hydrogen peroxide-based system for cleaning, disinfecting, and storing contact lenses
1888137|NCT01233102|Drug|Conserved Therapy|Conserved Therapy
1888138|NCT01233102|Procedure|Hepatic artery infusion or Intravenous infusion|Patients with liver cirrhosis will be randomly divided into three groups. Umbilical cord MSCs will be infused to patients using interventional method via hepatic artery for one group. The catheter will be inserted to proper hepatic artery. After the catheter placement confirmed by angiography, umbilical cord MSCs will be infused slowly in 20-30 minutes. Umbilical cord MSCs will be infused intravenously slowly for 30-60 minutes in the intravenous infusion group. The control group will receive conserved therapy.
1888139|NCT01233154|Dietary Supplement|probiotic|
1888140|NCT01233154|Dietary Supplement|probiotic|
1888141|NCT01233167|Drug|clopidogrel|clopidogrel 75 mg po per day for 12 months
1888142|NCT01233167|Drug|placebo|placebo 75mg po per day for 12 months
1888143|NCT01233167|Drug|clopidogrel and placebo|clopidogrel 50mg per day for 3 months,clopidogrel 25mg per day for 3 months,then placebo 75mg per day for 6 months
1888144|NCT01233180|Other|Gua Sha|Single Gua Sha treatment of the neck and shoulder region
1888145|NCT01233180|Device|Thermotherapy|Single use of a mud heat pad on the neck and shoulder region
1888146|NCT01233193|Behavioral|Health education, Home blood pressure monitoring|Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
1888147|NCT01238705|Drug|Felodipine add Irbesartan|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.
Irbesartan,150mg/day, Sanofi - Aventis Pharmaceutical company, Registration Number: H20080074."
1888148|NCT01238705|Drug|Felodipine add Metoprolol|"Felodipine Sustained Release Tablets,5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: H20030415.
Metoprolol Succinate,47.5mg/day,AstraZeneca Pharmaceutical Co.Ltd., Registration Number: J20050061."
1888151|NCT01238744|Dietary Supplement|Flaxseed drink|Drink containing flaxseed mucilage
1888152|NCT01238744|Dietary Supplement|Flaxseed drink|Drink containing flaxseed mucilage
1888153|NCT01238744|Dietary Supplement|Flaxseed tablet|Tablets containing flaxseed mucilage consumed with a control drink
1888154|NCT01238744|Dietary Supplement|Control drink|Control drink
1888155|NCT01238757|Other|Non-invasive Ventilation under Pressure Support|"Non-invasive Ventilation under Pressure Support:
15 min with initial settings, 5 min with ETS-%%, 5 min with ETS+10%, in random order"
1888156|NCT01238757|Other|Non-Invasive ventilation under NAVA|20 min session under non-invasive ventilation with NAVA
1888157|NCT01238770|Drug|Pazopanib|"Phase I Cyclophosphamid Pazopanib Dose level I 50 mg/day 400 mg/day Dose level II 50 mg/day 600 mg/day Dose level III 50 mg/day 800 mg/day
Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally
Phase II:
Cyclophosphamide 50 mg daily orally Pazopanib 400, 600 or 800 mg daily orally The dose for the phase II part of the trial will be based on the MTD of phase I."
1888158|NCT01238783|Drug|AL-15469A 0.5% and AL-6515 0.3% Ophthalmic Suspension|Topical ocular dosed 3 times per day for 3 days
1888159|NCT01238783|Drug|AL-15469A 0.5%|Topical ocular dosed 3 times per day for 3 days
1888160|NCT01238783|Drug|AL-6515 0.3%|Topical ocular dosed 3 times per day for 3 days
1888161|NCT01238783|Drug|Vehicle|Topical ocular dosed 3 times per day for 3 days
1888162|NCT01238796|Drug|telavancin|Intravenous
1888163|NCT01238822|Drug|Methylphenidate|18 mg methylphenidate
1888170|NCT01238861|Biological|Benralizumab 2 mg|EOS+ participants received single benralizumab 2 milligram (mg) injection followed by a single placebo injection subcutaneously.
1888171|NCT01238861|Biological|Benralizumab 20 mg|EOS+ participants received single benralizumab 20 mg injection followed by a single placebo injection subcutaneously.
1888172|NCT01238861|Biological|Benralizumab 100 mg|EOS+ and EOS- participants received two benralizumab 50 mg injections subcutaneously.
1888173|NCT01238861|Other|Placebo|EOS+ and EOS- participants received two placebo injections subcutaneously.
1888174|NCT01238874|Device|Cardiac Resynchronization Therapy|All market-approved Medtronic CRT-D and CRT-P devices will be used in this study. All eligible devices are commercially released and will be used within their intended use per device labeling. The study may include future market-approved devices as they become commercially available. All market-approved leads may be used in the study. Epicardial leads may be used in the study.
1888175|NCT01238887|Dietary Supplement|Microcrystalline Cellulose placebo pill|Participants will be given gelatin capsules containing the placebo (microcrystaline cellulose) and will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. This will equal 3000 mg/day of the placebo contents. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
1888176|NCT01238887|Dietary Supplement|Garcinia cambogia-derived hydroxycitric acid (2800 mg/day)|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 2,800 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
1888177|NCT01238887|Dietary Supplement|Garcinia Cambogia derived Hydroxycitric Acid|The hydroxycitric acid treatment is derived from garcinia cambogia and is provided by the company, Glykon Technologies. In this condition, participants will receive HCA at a dosage of 5,400 mg/day in the form of gelatin capsules. Participants will be instructed to consume four capsules three times daily (30 minutes before breakfast, lunch, and dinner) with a glass of water. Participants will be instructed to follow this dosing regimen throughout the six week treatment period.
1888178|NCT01238900|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)|Endoscopic Retrograde Cholangiopancreatography (ERCP) with placement of metal stent in the bile duct
1888179|NCT01238913|Procedure|Endoscopy|Endoscopic placement of an esophageal metal stent as per medical indication.
1888183|NCT01238939|Drug|NK012 and 5-FU|NK012 infusion on Day 1 of each 28 day cycle 5-FU continuous infusion on Days 1 and 15 of each 28 day cycle
1888184|NCT01238952|Drug|NK012 and carboplatin|NK012 and carboplatin via infusion once every 28 days
1888185|NCT01238965|Drug|panobinostat|Given orally
1888186|NCT01238965|Drug|fluorouracil|Given IV
1888187|NCT01238965|Drug|leucovorin calcium|Given IV
1888188|NCT01238965|Procedure|biopsy|Correlative studies
1888189|NCT01238965|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
1888190|NCT01238965|Genetic|western blotting|Correlative studies
1888191|NCT01238965|Other|laboratory biomarker analysis|Correlative studies
1888192|NCT01238965|Genetic|gene expression analysis|Correlative studies
1888193|NCT01238965|Genetic|RNA analysis|Correlative studies
1888194|NCT01238965|Genetic|polymorphism analysis|Correlative studies
1888195|NCT01238978|Drug|Vildagliptin|
1888196|NCT01238978|Drug|"Usual Care"|
1888197|NCT01238991|Biological|ACC-001|IM injection, dose of 3 micrograms, at Day 1, month 6, 12 and 18
1888198|NCT01238991|Biological|ACC-001|IM injection, dose of 10 micrograms, at Day 1, month 6, 12 and 18
1888199|NCT01238991|Biological|ACC-001|IM injection, dose of 30 micrograms, at Day 1, month 6, 12 and 18
1888200|NCT01239004|Drug|Placebo|6 tablets daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
1888201|NCT01239004|Drug|Colesevelam|6 tablets (3750 mg total) daily, with up to 2000 mg niacin and 325 mg aspirin daily, for 12 weeks
1888202|NCT01239017|Biological|REGN475|
1888203|NCT01239017|Other|Placebo|
1960563|NCT03180619|Drug|TAF|25 mg tablet administered orally once daily with food
1888205|NCT01239563|Drug|antithymocyte globulin|Thymoglobulin 1.5mg/kg, 4 doses Thymoglobulin 6mg/kg, single dose
1888206|NCT01239563|Drug|Basiliximab|Intravenous 20mg, day 0&4
1888207|NCT01239641|Procedure|High intensity focused ultrasound|The term 'high intensity focused ultrasound' means using ultrasound to causes coagulation necrosis to destroy the targeted tissue, in this case, uterine fibroids.
1888208|NCT01239654|Device|stent implantation|implantation of everolimus-eluting stent vs zotarolimus-eluting stent
1888209|NCT01239667|Other|Individual oriented planning of the rehabilitation program for patients with heart failure|Individual oriented rehabilitation plan in collaboration with the patient followed by measuring health related quality of life and self care behavior
1888210|NCT01239680|Drug|Glutamine|Intravenous 25 grams once over 6 hours
1888211|NCT01239680|Drug|Ringer's Lactate|Intravenous 1 liter once over 6 hours
1888212|NCT01239680|Drug|Placebo (for Glutamine)|Given Intravenously in 1 liter Lactated Ringer's
1888250|NCT01239888|Drug|Oxytocin and Tibolone|20 IU of intranasal oxytocin twice per day for 8 weeks, and 2.5mg oral tibolone for the 8 week trial
1888319|NCT01240525|Other|No DLI|Patients will not receive DLI as trial treatment
1888213|NCT01239693|Dietary Supplement|IFA|Women during pregnancy: 1 tablet of iron+ folate daily until delivery (60 mg iron + 400 ug folic acid) Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of calcium (200 mg), akin to placebo Children from 6 to 18 months of age: None
1888214|NCT01239693|Dietary Supplement|MMN|Women during pregnancy: 1 tablet of multiple micronutrients daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily tablet of multiple micronutrients Children from 6 to 18 months of age: None
1888215|NCT01239693|Dietary Supplement|LNS|Women during pregnancy: 1 sachet of LNS-P&L (20 g of LNS) daily until delivery Women during lactation (from delivery to 6 months post-partum): 1 daily sachet of LNS-P&L (20 g of LNS) Children from 6 to 18 months of age: 2 daily sachet of LNS-20gM (20 g of LNS)
1888216|NCT01239706|Drug|NTx 265|10,000IU of hCG, every other day for three doses followed by 4000IU once daily for three days of erythropoietin
1888217|NCT01239719|Drug|Dexamethasone + clemastine|Dexamethasone 0.5 mg clemastine fumarate: 01 tablet every 12 hours.
1888218|NCT01239719|Drug|Dexamethasone|Dexamethasone 0.5 mg: 01 tablet every 12 hours.
1888219|NCT01239732|Drug|Paclitaxel|175 mg/m^2 on Day 1 every 3 weeks or at a dose of 80 mg/m^2 every week for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
1888220|NCT01239732|Drug|Bevacizumab|15 mg/kg intravenously on Day 1 of every cycle for up to 36 cycles of 3 weeks each or until disease progression or unacceptable toxicity, whichever occurs first
1888221|NCT01239732|Drug|Carboplatin|AUC 5-6 mg/ml/min on Day 1 every 3 weeks for a minimum of 4 cycles and not more than 8 cycles or until disease progression or unacceptable toxicity, whichever occurs first
1888222|NCT01239745|Drug|Aromasin|Aromasin® one 25 mg tablet to be taken once daily
1888223|NCT01239758|Biological|ACE-031 (Extension of cohort 1 from core study, A031-03)|ACE-031 0.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
1888224|NCT01239758|Biological|ACE-031 (Extension of cohort 2 from core study, A031-03)|Up to 1.0 mg/kg subcutaneously once every 2 weeks for 24 weeks.
1888225|NCT01239758|Biological|ACE-031 (Extension of cohort 3 from core study, A031-03)|Up to 2.5 mg/kg subcutaneously once every 4 weeks for 24 weeks.
1888226|NCT01239771|Drug|TC-5214|Tablet 1, 2, or 4 mg of TC-5213 will be given twice daily for 4 days and once on the 5th day.
1888227|NCT01239771|Drug|Placebo|Two subjects in each cohort will be given placebo.
1888228|NCT01239784|Behavioral|Home-based neurodevelopmental rehabilitation programme|Participation in the study will require the parent and child to attend two assessment visits in addition to completing a series of parent and infant activities on a daily basis throughout the 10-week intervention period. The parent-led activities will include activities such as walking with the child, stacking blocks, rolling a ball to the child, hiding a toy under a blanket for the child to find, encouraging the child to kick a rattle while the child is lying on his/her back, or crawling or rolling in different directions.
1888229|NCT01239797|Drug|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
1888230|NCT01239797|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
1888231|NCT01239797|Drug|Dexamethasone (Oral)|"On weeks without Elotuzumab dosing: Tablets, Oral, 40mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug.
On weeks with Elotuzumab dosing: Tablets, Oral, 28 mg, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
1888232|NCT01239797|Drug|Dexamethasone (IV)|"On weeks without Elotuzumab dosing: Not Applicable (N/A)
On weeks with Elotuzumab dosing: Solution, Intravenous (IV), 8 mg, weekly, Repeat every 28 days until subject meets criteria for discontinuation of study drug"
1888233|NCT01239797|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, IV, 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
1888234|NCT01239810|Drug|Hyaluronic Acid|Intraarticular injection 2ml Na-Hyaluronate (HA; MW 1.2 x 106; Ostenil, TRB Chemedica) weekly for five weeks
1888235|NCT01239823|Other|Whole Body Vibration Training|The subjects will participate in a 12-week exercise program with two sessions (1/2 hour) per week.
1888236|NCT01239823|Other|Exercise without vibration|Participants will complete the same exercises without vibration twice a week for 12 weeks (1/2 hour sessions).
1888237|NCT01239836|Behavioral|Constructivist interactive workshop on urinary incontinence|A one hour interactive group workshop aimed at contradicting commonly held beliefs and maladaptive practices about incontinence. The interactive continence workshop was designed to create cognitive dissonance and challenge these beliefs and practices, as well as to promote more effective therapeutic strategies for correcting urine leakage.
1888238|NCT01239836|Behavioral|Evidence-based self-management tool|Participants will receive a customized evidence-based risk factor modification self-management tool targeting up to 6 risk factors and associated therapeutic strategies. The six risk factors are pelvic floor muscle weakness, consumption of caffeinated drinks, obesity, constipation, vision loss and smoking.
1888239|NCT01239836|Behavioral|General health lecture|Participants will attend a lecture on general women`s health issues that does not address urinary incontinence.
1888240|NCT01239849|Drug|Atorvastatin, 10mg, 20mg, 40mg|"If initial LDL cholesterol between 100~ 129mg/dl then starting dose of Atorvastatin is 10mg, 130~159 mg/dl is 20 mg, 160~220mg/dl is 40mg.
After 4weeks treatment, if LDL cholesterol is below 100mg/dl then continue starting dose and if not reach below 100mg/dl then titration double dose.
After 4 weeks treatment, recheck the LDL cholesterol"
1888241|NCT01239862|Other|Autologous cell transplantation|Intrabronchial Instillation Of Bone Marrow Derived Mononuclear Cells
1888242|NCT01239875|Biological|dendritic cell vaccine therapy|Given intratumorally
1888243|NCT01239875|Procedure|cryotherapy|Undergo cryoablation
1888244|NCT01239875|Biological|pneumococcal polyvalent vaccine|Given intramuscularly
1888245|NCT01239875|Other|laboratory biomarker analysis|Correlative studies
1888246|NCT01239875|Other|immunoenzyme technique|Correlative studies
1888247|NCT01239875|Other|immunohistochemistry staining method|Correlative studies
1888248|NCT01239875|Biological|autologous dendritic cell-tumor fusion vaccine|Given intradermally
1888249|NCT01239888|Drug|Oxytocin|20 IU of intranasal oxytocin twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
1888251|NCT01239888|Drug|Placebo|20 IU of intranasal placebo twice per day for 8 weeks, and a placebo (oral) for the 8 week trial
1888252|NCT01239927|Procedure|Primary sigmoid resection with end colostomy (Hartmann)|
1888253|NCT01239927|Procedure|Primary sigmoid resection and immediate anastomosis with diverting stoma (PRA)|
1888254|NCT01239940|Device|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
1888255|NCT01239940|Device|Coronary angioplasty using the Everolimus-eluting stent|Stent implantation
1888256|NCT01239953|Device|Coronary angioplasty using the paclitaxel-eluting balloon|Balloon angioplasty
1888257|NCT01239953|Device|Coronary angioplasty using the everolimus-eluting stent|Stent implantation
1888258|NCT01239966|Device|Combined ECCOR and RRT|Insertion of a membrane oxygenator (Hilite 2400 LT, Medos, Germany) within an hemofilter circuit (M150,PrismaFlex, Hospal); either upstream or downstream of the hemofilter.
1888259|NCT01239992|Drug|Niacin/ Laropiprant|1000/ 20 mg first 4 weeks, 2000/40 mg next 8 weeks; daily
1888260|NCT01240005|Biological|DCIK|Renal cell carcinoma patients were treated with three intravenous infusions of DC activated CIK cells at 1-day intervals. Clinical examinations of these patients were performed.
1888261|NCT01240018|Dietary Supplement|Probiotic|Parallel, randomized, controlled 2 arms study.
1888262|NCT01240031|Other|Individualised nutritional therapy|"Nutritional therapy as based on previous results of the project on patient meal experiences and preferences (note citations below) and comprising of:
Thorough sensory and nutrition assessment (questionnaire).
Nutrition plan adjusted daily according to the assessment.
Serving appetising, energy- and protein-dense meals, snacks and drinks."
1888263|NCT01240031|Other|Usual nutrition care|Nutritional therapy according to current practice and general nutrition advice.
1888264|NCT01240044|Procedure|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
1888265|NCT01240044|Procedure|Physical Therapy|In this group the newborns were first submitted to the mechanical vibrator applied over a diaper, on the chest of newborns for 5 min, as follows: 1min 1min right hemithorax and the left hemithorax, both previously, followed 30 seconds in the lateral aspect of each hemithorax; more than 1min in each hemithorax in the posterior region. The mechanical vibrator was performed subsequent to manual chest compression, using light hand pressure on the chest of newborns, respecting the compliance of the chest. The chest compression was applied for 2min 2min in the right hemithorax and left-sided chest, above, and 1 minute on each side, another 2 minutes on the back of each hemithorax, totaling 10 minutes of compression. Next to chest compression, mechanical vibration was applied for 5 min in the same topographical sequence described.
1888266|NCT01240057|Procedure|fetal endoluminal tracheal occlusion|percutaneous fetoscopy, positioning of endoluminal balloon at 27-30 weeks and whenever possible elective removal at 34 weeks
1888267|NCT01240057|Other|watchful waiting during pregnancy|pregnancy surveillance for fetal wellbeing, development of polyhydramnios and cervical shortening
1888268|NCT01240070|Other|Intensive care|Intensive multi-factorial treat-to-target intervention program designed according to international guidelines
1888269|NCT01240083|Device|Thetaburst Stimulation|Thetaburst stimulation: continuous TBS over the right DLPFC, followed by intermitted TBS over the left DLPFC, each with 50 Hz, together 1200 stimuli (80% motorthreshold)
1888270|NCT01240083|Device|High frequency rTMS|Experimental high frequency rTMS ( Alpine Biomed Mag Pro Option) : 1000 stimuli of 1 Hz over the right DLPFC (110% motor threshold)followed by 1000 stimuli of 10 Hz over the left DLPFC (110% motorthreshold)
1888271|NCT01240083|Device|Placebo Stimulation|Sham Stimulation (Sham coil):right DLPFC continuous TBS, followed by left DLPFC intermitted TBS each with 50 Hz, together 1200 Stimuli, 80% motorthreshold
1888272|NCT01240096|Drug|Mirtazapine|Mirtazapine 15 mg daily
1888273|NCT01240109|Drug|Remifentanil|"propofol group : propofol effect site-TCI 2-4mcg/ml + remifentanil effect site-TCI 2-4ng/ml
sevoflurane group: sevoflurane end-tidal concentration 0.5-1.0 MAC + remifentanil effect site-TCI 2-4ng/ml"
1888274|NCT01240122|Device|Biotrue MPS|Multi-purpose contact lens care solution
1888275|NCT01240122|Device|Investigational MPS|Multi-purpose contact lens care solution
1888276|NCT01240135|Device|FID 114675A multi-purpose disinfecting solution (MPDS)|Daily regimen, 14 days: Thoroughly wet and rub each side of study contact lens for 10 seconds, rinse each side of the lens for 10 seconds, and soak contact lens for at least 6 hours.
1888277|NCT01240135|Device|renu fresh Multi-Purpose Solution (MPS)|Daily regimen, 14 days: Wet study contact lens with 3 drops and rub each side of the lens for 20 seconds, rinse each side of the lens for 5 seconds, and soak contact lens for at least 4 hours.
1888278|NCT01240135|Device|Galyfilcon A contact lenses (Acuvue Advance)|A fresh pair of contact lenses matching subject's pre-study lenses, including parameters, dispensed at the beginning of each period for daily wear, minimum 8 hours per day, 14 days.
1888279|NCT01240148|Drug|AZD3161|Single dose, intradermal injection
1888280|NCT01240148|Drug|Lidocaine|Single dose, intradermal injection
1888281|NCT01240148|Drug|AZD3161 Placebo|
1888282|NCT01240161|Drug|FLT-PET/CT: (3'deoxy-3'-[(18)F] fluorothymidine) PET/CT|Each patient will have 0-3 or more FLT-PET brain scans.
1888283|NCT01240174|Behavioral|Demonstration of near zero antibiotic prescribing for patients with acute bronchitis|A controlled, continuously-monitored, implementation of an EHR-integrated diagnosis and treatment algorithm for acute bronchitis in a large, diverse primary care practice.
1888284|NCT01240187|Drug|perampanel|Single dose of 6 tablets 2 mg orally
1888285|NCT01240187|Drug|perampanel|Single dose of 1 tablet 12 mg orally
1888286|NCT01240200|Drug|Glargine|oral antidiabetic agents plus once daily insulin glargine via an insulin syringe
1888287|NCT01240200|Device|glargine via insulin pen|oral antidiabetic agents plus insulin glargine in a pre-filled pen
1888288|NCT01240213|Dietary Supplement|Vitamin D|2000 IU per day of Vitamin D
1888289|NCT01240213|Dietary Supplement|Placebo|1 Placebo per day
1888290|NCT01240226|Drug|GDC-0941|Oral repeating dose
1888291|NCT01240226|Drug|GDC-0941|Oral repeating dose
1888292|NCT01240226|Drug|ketoconazole|Oral repeating dose
1888293|NCT01240252|Drug|Human insulin|U100 Humulin at a rate of 80 mU/m^2 surface area per minute one time over 4 hours
1888294|NCT01240265|Dietary Supplement|Vitamin D3|150,000 IU orally given once
1888295|NCT01240265|Dietary Supplement|Vitamin D3|5000 IU given orally daily for 28 days
1888296|NCT01240291|Dietary Supplement|Dipeptiven|Intravenous alanyl-glutamine (0.5 g/kg body weight; i.e. 0.35 g L-glutamine / kg body weight; continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks.
1888297|NCT01240291|Dietary Supplement|normal saline|0.5 g/kg bod weight /day, continuous infusion (20-24 hr/day) via central venous access for a maximum duration of 3 weeks
1888298|NCT01240304|Drug|Gemcitabine|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
1888299|NCT01240304|Radiation|Radiation therapy|The course of preoperative treatment in this study will consist of an alternating combination of 6mg/M² of Gemcitabine for 24 hours and 7.0 Gy (radiation) of radiation therapy. The subject will undergo one of these therapies alternating daily for a total of 10 days then the subject will be allowed to rest for 4 weeks before undergoing restaging and surgery. After surgery, the subject will then undergo the conventional chemotherapy regimen consisting of 6 cycles (1 cycle = 28 days) of 1000mg/M² of Gemcitabine over a 30 minute infusion rate.
1888300|NCT01240304|Procedure|pancreaticoduodenectomy|Surgery will be planned 28 days (+/- 3 days) after the last dose of chemotherapy. The liver and pancreas will be examined by palpation and inspection. In the absence of metastases, tumor mobilization and surgical resection will be performed with standard surgical technique.
1888301|NCT01240330|Device|Pneumatic Compression therapy|Subject comparison analysis of femoral venous Peak Flow Velocity at rest and during compression therapy.
1888302|NCT01240356|Device|2-MHz transcranial Doppler ultrasound|2-hours of hands-free ultrasound will be insonated continuously. A brain MRI with gadolinium will be performed before and after the ultrasound.
1888303|NCT01240356|Device|2-MHz transcranial Doppler ultrasound insonation|2-hours of hands-free ultrasound delivered to in the intracranial vessels.
1888304|NCT01240382|Drug|3% DE-089 ophthalmic solution|
1888305|NCT01240382|Drug|0.1% sodium hyaluronate ophthalmic solution|
1888306|NCT01240395|Behavioral|Mindfulness-based Cognitive Therapy (MBCT)|"MBCT is partly based on the mindfulness-based stress reduction program (MBSR), developed by Jon Kabat-Zinn and colleagues, and partly on cognitive therapy for depression, the latter influence particularly expressed through the aspect of decentering, meaning not accepting the content of thoughts as facts and not identifying with the thought. The MBCT programme in this study includes 2½ hours of training once a week for 9 weeks. In addition, participants are encouraged to practice at home for up to 45 min per day, 6 days a week during the entire course."
1888307|NCT01240408|Drug|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) with food
1888308|NCT01240408|Drug|HOPE|10 mg lenvatinib (1x10 mg lenvatinib capsule) without food
1888309|NCT01240421|Drug|Eribulin Mesylate|At a dose of 1.4 mg/m2 as a 2 to 5 minute intravenous bolus on Days 1 and 8 of a 21-day cycle.
1888310|NCT01240434|Procedure|Trocar site closure|The study has 2 arms: one in which all the ST orifices are closed by suturing the external fascia of the abdominal wall with a number 1 monofilament absorbable suture (Polydioxanone) (Group A), and another in which all the orifices of the ST are left open, closing only the skin (Group B).
1888311|NCT01240447|Biological|racotumomab|Patients will receive best support treatment and vaccination with racotumomab. The vaccination schedule is as follows: 5 doses (1mg/mL each), subcutaneously, every 2 weeks (induction period) followed by monthly vaccinations until any criteria for discontinuation are met. If disease progression occurs and a second line therapy is indicated, the patient will only be able to continue in the study if the drug indicated is docetaxel. Vaccination will not be interrupted during docetaxel administration unless criteria for vaccine discontinuation are met.
1888312|NCT01240447|Other|Best support treatment|Patients will receive best support treatment as indicated by the investigator. In case a second line therapy is indicated, docetaxel is the only drug allowed to continue in the study.
1888313|NCT01240460|Drug|XL765 (SAR245409)|Supplied as 10-mg and/or 50-mg capsules
1888314|NCT01240460|Drug|XL147 (SAR245408)|Supplied as 100-mg, 150-mg and/or 200-mg tablets
1888315|NCT01240473|Drug|Randomized trial for treatment of kala azar in Bangladesh|dose of SAG 20 mg/kg body weight, with a maximum dose of 850 mg/day, for 28 days
1888316|NCT01240499|Other|Health-At-Every-Size (HAES)|"HAES group: 14 weekly sessions.
Focus on general well-being and positive ways of having a healthy and satisfying lifestyle. Supported by lectures, guided self-reflection, group discussions, as well as practical exercises, this intervention aims at enhancing awareness and knowledge about biological, psychological, and sociocultural aspects of body weight.
SS group: 14 weekly sessions.
The objective is to reproduce a structural social support provided by the group itself. Each participant offers their support to each other. Each theme discussed in the HAES group is repeated in the SS group but the health professionals in charge of the group (dietitian & psychologist) are not counselors (as in HAES group) but only facilitators.
Outcome measures: For all women under study."
1888317|NCT01240512|Drug|Cholecalciferol|Vitamin D3 (cholecalciferol) 200 IU and 2000 IU drops will be supplied by D Drops. It is supplied as a liquid containing 400 drops/bottle with a potency of 200 IU/drop or 2000 IU/drop. The contents of the label will be in accordance with all applicable regulatory requirements. The droppers are gravity-metered to deliver a consistent drop size (dosage). Two drops (either 200 IU or 2000 IU) of Vitamin D (cholecalciferol) is to be taken orally once-daily.
1888318|NCT01240525|Other|CD4 DLI|Patients will receive CD4 DLI between day 70 to 115 post transplant
1888324|NCT01240551|Drug|F-18 NaF|All participants will undergo a static F-18 NaF PET/CT imaging session at baseline, at 4-8 months, and at 10-14 months following enrollment (3 sessions over 1-year). Half of the participants (15 in each group) will undergo two baseline F-18 NaF PET/CT imaging sessions (within 14-days of each other) in order to evaluate the reproducibility of F-18 NaF PET imaging for a total of 4 sessions over a 1-year period.
1888325|NCT01240577|Drug|IPdR|
1888326|NCT01240590|Drug|Crolibulin|Phase I:Dose Level (DL) 1 - 13 mg/m(2) intravenous (IV),DL 2 - 13 mg/m(2) IV, DL 3 - 20 mg/m(2) IV. Phase II: 20 mg/m(2)
1888327|NCT01240590|Drug|Cisplatin|Phase I:Dose Level (DL) 1- 75 mg/m(2) intravenous (IV),DL 2 - 100 mg/m(2),DL 3 - 100 mg/m(2). Phase II: 100 mg/m(2)
1888328|NCT01240629|Other|laboratory biomarker analysis|Correlative study
1888329|NCT01240629|Other|questionnaire administration|Correlative study
1888330|NCT01240629|Drug|doxorubicin-GnRH agonist conjugate AEZS-108|Given IV
1888331|NCT01240642|Drug|ASA404|
1888332|NCT01240655|Drug|LCL161|
1888333|NCT01240655|Drug|Paclitaxel|
1888334|NCT01240681|Procedure|FLT PET and BOLD MRI scan|Eligible consenting patients with LABC receiving neoadjuvant chemotherapy (NA CT) will undergo FLT PET, BOLD MRI, and clinical examination of the involved breast including ipsilateral axillary and supraclavicular nodes to assess the treatment response to chemotherapy (CT). The imaging studies will be performed at baseline and after the first cycle of NA CT.
1888335|NCT01240694|Drug|Lupuzor|200 mcg
1888336|NCT01240707|Other|Fiberoptic bronchoscopy|Fiberoptic bronchoscopy performed to remove secretions and assess soot in central airways
1888337|NCT01240720|Drug|131I-F16SIP Radioimmunotherapy (RIT)|"Dosimetric evaluation with 131I-F16SIP or 124I-F16SIP will be performed to assess eligibility for Radioimmunotherapy.
Patients eligible for Radioimmunotherapy will receive 55.5 mCi/m2 as established in the Phase I part of the study. A single dose of 5 to 10 mg of 131I-F16SIP will be administered intravenously (I.V)."
1888338|NCT01240746|Biological|Licensed 2010-2011 Trivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
1888339|NCT01240746|Biological|Investigational Trivalent Influenza Vaccine with alternate B strain, No Preservative|0.25 mL (6 to 35 months) or 0.5 mL (3 to <9 years), Intramuscular
1888340|NCT01240746|Biological|Quadrivalent Influenza Vaccine, No Preservative|0.25 mL (6 to 35 months), or 0.5 mL(3 to <9 years), Intramuscular
1888341|NCT01240759|Drug|S-707106 dose 1|One S-707106 dose 1 tablet and 3 Placebo A tablets matching S-707106 dose 1- and dose 2 tablets and metformin
1888342|NCT01240759|Drug|S-707106 dose 2|One S-707106 dose 2 tablet and 3 Placebo A tablets matching S-707106 dose 1- and dose 2 tablets and metformin
1888343|NCT01240759|Drug|S-707106 dose 3|Four S-707106 dose 2 tablets and metformin
1888344|NCT01240759|Drug|Placebo|Four Placebo A tablets matching S-707106 dose 1- and dose 2 tablets and metformin
1888345|NCT01240772|Device|doppler-guided arterial ligation with mucopexy|doppler-guided arterial ligation with mucopexy
1888346|NCT01240772|Device|stapled haemorrhoidopexy according to Longo|stapled haemorrhoidopexy according to Longo
1888347|NCT01240785|Drug|metformin|metformin 1 g twice daily or maximum tolerated dose less than 2 g daily
1888348|NCT01240785|Drug|insulin|subcutaneous Neutral Protamine Hagedorn (NPH) insulin and/or rapid acting insulin analog adjusted according to plasma glucose values until delivery
1888349|NCT01240811|Drug|IUD placement|Volunteer subjects who are not at risk of pregnancy because they are either surgically sterilized or heterosexually abstinent will be enrolled into the control group (no intervention). All other volunteers will be seeking an IUD for contraception and will be randomized to LNG-IUD (Mirena) or Copper IUD (ParaGard).
1888350|NCT01240811|Drug|Levonorgestrel IUD|
1888351|NCT01240811|Drug|Copper T380A IUD|
1888352|NCT01240824|Drug|aminophylline|One of three escalating doses of aminophylline (3 mg/kg, 6 mg/kg and 9 mg/kg) administered intravesically
1888353|NCT01240837|Other|Arenga Pinnata Sugar|50 g palm sugar given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
1888354|NCT01240837|Other|Glucose|50 g glucose given orally 3 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
1888355|NCT01240837|Other|Sucrose|50 g sucrose given orally 1 time in 250 ml of water. Blood glucose measurements will then be taken at time points, 0, 15, 30, 45, 60, 90 and 120 minutes.
1888356|NCT01240850|Drug|Methotrexate+Prednisone|Methotrexate will be added at a dose of 0.3 mg/kg/week (maximum dose, 20 mg/week, orally) to a reduced-dose prednisone regimen
1888357|NCT01240850|Drug|Prednisone|
1888358|NCT01240863|Drug|Hydrocodone ER|"During the open-label, titration period, all participants were administered hydrocodone ER tablets at dosages of 15, 30, 45, 60, or 90 mg every 12 hours to identify a dosage deemed successful for managing their pain.
Hydrocodone ER was taken by participants randomized to the hydrocodone ER treatment arm during the double-blind treatment period at the dose level identified during the titration period.
Participants were instructed to take tablets with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
1888359|NCT01240863|Drug|Placebo|"Placebo matching the active drug dose identified during the titration period was taken by participants randomized to the placebo treatment arm during the double-blind treatment period.
Participants were instructed to take intervention with a glass of water on an empty stomach at least 1 hour before or 2 hours after eating."
1888360|NCT01240876|Drug|CEP-37247|0.5-, 1-, 3-, 6-, and 12-mg doses of CEP-37247 will be administered by the transforaminal epidural route.
1888361|NCT01240876|Drug|Placebo|Matching placebo vials will be filled with the buffered solution for CEP-37247.
1888366|NCT01240915|Drug|placebo|once every 7 days for 1- 3 doses
1888367|NCT01240915|Drug|MultiStem low dose|1-3 doses
1888368|NCT01240915|Drug|placebo|Single dose at week 8
1888369|NCT01240915|Drug|MultiStem low dose|Single dose at week 8
1888370|NCT01240915|Drug|placebo|Single dose Day 1
1888371|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
1888372|NCT01240915|Drug|placebo|Single dose at week 8
1888373|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
1888374|NCT01240915|Drug|placebo|Single dose Day 1
1888375|NCT01240915|Drug|MultiStem high dose|Single dose Day 1
1888376|NCT01240915|Drug|placebo|Single dose at week 8
1888377|NCT01240915|Drug|MultiStem high dose|Single dose at week 8
1888378|NCT01240928|Drug|MSK-2206|Level 1: MK-2206 135mg weekly
1888379|NCT01240928|Drug|Exemestane|Level 1: Exemestane - 25mg daily
1888380|NCT01240928|Drug|Goserelin|Level 1: Goserelin- 3.6mg monthly for pre-menopausal subjects only
1888381|NCT01240941|Drug|MK-2206|dose to be determined on the Phase 1b trial (listed under a separate NCT number)
1888382|NCT01240941|Drug|Exemestane|25 mg orally daily
1888383|NCT01240941|Drug|Goserelin|3.6 mg orally monthly
1888384|NCT01240954|Drug|OSIRIS|OSIRIS current practice
1888385|NCT01240954|Drug|OSIRIS other concentration 1|OSIRIS new concentration 1
1888386|NCT01240954|Drug|OSIRIS other concentration 2|OSIRIS new concentration 2
1888387|NCT01240967|Drug|TC-5214|Oral tablets, single dose
1888388|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.1 mg, once daily, 1 day
1888389|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
1888390|NCT01240980|Drug|BMS-903452|Suspension, Oral, 3.0 mg, once daily, 1 day
1888391|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
1888392|NCT01240980|Drug|BMS-903452|Suspension, Oral, 30 mg, once daily, 1 day
1888393|NCT01240980|Drug|BMS-903452|Suspension, Oral, 60 mg, once daily, 1 day
1888394|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
1888395|NCT01240980|Drug|Placebo|Solution, Oral, 0 mg, once daily, 1 day
1888396|NCT01240980|Drug|Placebo|Suspension, Oral, 0 mg, once daily, 1 day
1888397|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 10 mg, once daily, 1 day
1888398|NCT01240980|Drug|BMS-903452|Suspension using crystalline form, Oral, 60 mg, once daily, 1 day
1888399|NCT01240980|Drug|Placebo|Suspension using crystalline form, Oral, 0 mg, once daily, 1 day
1888400|NCT01240980|Drug|BMS-903452|Solution, Oral, 0.6 mg, once daily, 1 day
1888401|NCT01240980|Drug|BMS-903452|Suspension, Oral, 10 mg, once daily, 1 day
1888402|NCT01240980|Drug|BMS-903452|Suspension, Oral, 120 mg, once daily, 1 day
1888403|NCT01240993|Behavioral|Mothers and Toddlers Program|This intervention is a short-term attachment-based parenting therapy for substance using mothers of young children that emphasizes the development of the capacity for mentalizing.
1888404|NCT01240993|Behavioral|Parent Education|PE was developed to represent parent education and support that is typically available to mothers with substance use problems who are at high risk for neglecting their young children. Mothers enrolled in PEP will meet weekly for one hour with a PE counselor who will provide assistance in solving problems related to family basic needs and a choice of pamphlets on age-related parenting topics.
1888405|NCT01241006|Drug|Dexamethasone|Dexamethasone 12mg PO single dose x 1 Placebo 1 capsule PO for 4 days
1888406|NCT01241006|Drug|Prednisone|Prednisone 60mg PO q day for 5 days
1888407|NCT01241019|Drug|Topiramate in newborns with hypoxic ischemic encephalopathy treated with therapeutic hypothermia|TPM 10 mg/kg once a day will be administered with an orogastric tube as enteric-coated granules mixed with water on arrival in the NICU, when the cooling will be begun (T0), once a day for the first 3 days of life, for a total of 3 doses per patient.
1888408|NCT01241032|Drug|Udenafil|200mg Single Oral Dose of
1888409|NCT01241032|Dietary Supplement|Alcohol|Alcohol 39g / 240ml
1888410|NCT01241071|Other|myofascial treatment|myofascial release techniques of different muscles implicated in low back pain
1888411|NCT01241071|Other|Placebo|A manual sham intervention will be applied to different muscles implicated in low back pain
1888412|NCT01241084|Dietary Supplement|Antileukotrienes + Lactobacillus reuteri|Montelukast (5mg/die) + 1000000000 CFU per day (5 drops) for 2 months
1888413|NCT01241084|Dietary Supplement|Antileukotrienes + Placebo|Montelukast (5mg/die) + 5 drops of placebo daily for 2 months
1888414|NCT01241097|Drug|simvastatin, combined with simvastatin ezetimibe, placebo|simvastatin 80 mg per days or simvastatin 10 mg and ezetimibe 10 mg, over a period of eight weeks, treatment consisted of tablets identical, or placebo
1888415|NCT01241110|Drug|Ofloxacin group A, Azitromycin group B|Group A (treated by Ofloxacin 400 mg. + Metronidazole 500mg) and Group B (a single dose of oral Azitromicine 1gr + Metronidazole 500mg) for 10 days, were compared in terms of side effects and efficacy.
1888416|NCT01241110|Drug|azitromycin|azitromicin vs ofluxacin
1888417|NCT01241123|Procedure|Ambulation regimen|Assistance and encouragement for at least ambulation 3 times a day
1888418|NCT01241123|Drug|Sitz-Markers|radiopaque markers to subjectively follow the return of bowel function
1888419|NCT01241123|Radiation|Daily abdominal x-rays|daily abdominal x-rays for 7 days - to follow the radiopaque markers
1888420|NCT01241123|Device|pedometers|to record the amount of ambulation
1888421|NCT01241136|Procedure|open wide-excision pilonidal cystectomy|traditional open wide-excisional pilonidal cystectomy
1888422|NCT01241136|Procedure|minimal invasive pilonidal cystotomy|unroofing the cyst cavity and curettage the cyst
1888423|NCT01241149|Procedure|anti-reflux surgery|Anti-reflux surgery (Laparoscopic Nissen Fundoplication)
1888424|NCT01241162|Biological|Autologous dendritic cell vaccine with adjuvant|"Week 1:
Decitabine (DAC): 10 mg/m2/day IV (Mon-Fri)
Weeks 2 and 3:
Vaccine: 3-5 E6 peptide pulsed DC (Mon)
Hiltonol applied topically to vaccine site before and after vaccination"
1888425|NCT01241175|Drug|Magnesium Sulfate|
1888426|NCT01241175|Drug|normal saline|
1888427|NCT01241188|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
1888428|NCT01241188|Biological|2 TU Tuberculin PPD RT 23 SSI|The 2 TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
1888429|NCT01241201|Dietary Supplement|Priobiotic supplement VSL#3|four weeks, twice daily two sachets of VSL#3, a priobitics mixture
1888430|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 1, Dose 2, or Dose 3) or matching placebo administered orally twice daily
1888431|NCT01241214|Drug|ACT-129968|ACT-129968 (Dose 4) & matching placebo administered orally once daily
1888432|NCT01241214|Drug|Reference|Active matching reference administered once daily & matching placebo administered twice daily.
1888433|NCT01241240|Drug|bimatoprost/brimonidine tartrate/timolol ophthalmic solution (Triple Combination Therapy)|One drop of Triple Combination Therapy administered to each eye, twice daily for 12 weeks.
1888434|NCT01241240|Drug|Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution|One drop of Fixed Combination 0.2% brimonidine tartrate/0.5% timolol ophthalmic solution administered to each eye, twice daily for 12 weeks.
1888435|NCT01241253|Other|Whole cooked beans with rice meals|Three types of bean-and-rice meals all equal to 50 grams available CHO. Control treatment was 50 grams available CHO in the form of white rice alone.
1888436|NCT01241279|Device|Crystalens AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the Crystalens AO intraocular lens.
1888437|NCT01241279|Device|SoftPort LI61AO|Participants will undergo small incision cataract surgery (phacoemulsification). At the time of surgery, eligible participants will be implanted bilaterally with the SoftPort LI61AO intraocular lens.
1888438|NCT01241292|Biological|BMS-901608 (Elotuzumab) 10 mg|Injection, Intravenous, 10 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
1888439|NCT01241292|Biological|BMS-901608 (Elotuzumab) 20 mg|Injection, Intravenous, 20 mg/kg, Weekly at cycle 1 and 2, bi-weekly at cycle 3 and thereafter, Until disease progression or unacceptable toxicity became apparent
1960568|NCT03179228|Device|Prostate Embolization|Embolization of the prostate with acrylic polymer microspheres impregnated with porcine gelatin
1960569|NCT03177941|Other|Eviderma Smart Phone Teledermatology Application (Eviderma)|First-degree relatives download a mobile application onto their smart phone (n=150). This is the skin self-examination training intervention used in the original RCT (MoleScore). Participants will perform a Skin Self-Examination with partner assistance each month during the study. Participants will take a picture of one of their moles using their smart phone and upload to the application one image of a mole/freckle with a decision about their mole/freckle.
1888442|NCT01241331|Drug|BLI1100|BLI110 topical cream
1888443|NCT01241331|Drug|Vehicle cream|Vehicle topical cream
1888444|NCT01241344|Drug|CMX001|"Adults: 200mg CMX001 given as four 50mg tablets orally either QW OR BIW.
Peds: 4mg/kg (NTE a total single dose of 200mg) given using a 5 mg/mL liquid formulation taken orally either QW OR BIW"
1888445|NCT01241357|Device|Hepatic biomagnetic susceptibility measurement|Subjects will first have an ultrasound study to determine the location of the liver and measure the distance from skin surface to the liver. Subjects will then be examined with the high Tc susceptometer to determine the amount of iron in the liver. The entire procedure will usually take one-half hour or less.
1888446|NCT01241383|Drug|Bosentan|Bosentan 62.5mg bid x 4 weeks; up-titrated to 125mg bid x 20 weeks
1888447|NCT01241396|Other|Any MMY treatment|Any line of treatment for MMY
1888448|NCT01241409|Drug|Rabeprazole sodium: Treatment A|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
1888449|NCT01241409|Drug|Rabeprazole sodium: Treatment B|One single oral dose of 10 mg (2 x 5-mg capsules) rabeprazole Phase 3 sprinkle capsule granule formulation administered in fasted state. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
1888450|NCT01241409|Drug|Rabeprazole sodium: Treatment C|One single oral dose of 10 mg (1 x 10-mg capsule) rabeprazole to be-marketed sprinkle capsule granule formulation administered after consumption of a standardized high-fat high-caloric breakfast. After the capsules are opened, the granules will be sprinkled on applesauce (1 tablespoon).
1888451|NCT01241422|Drug|JNJ 40929837|On Day 1: participants will receive 2 tablets of 50 mg JNJ 40929837 in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 tablet of 50 mg JNJ 40929837 in the morning and 1 JNJ 40929837 50 mg tablet + 1 placebo capsule in the evening; and on Day 7: 1 tablet of 50 mg JNJ 40929837 in the morning.
1888452|NCT01241422|Drug|Placebo|On Day 1: participants will receive 2 placebo tablets in the morning and 1 placebo capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 placebo tablet + 1 placebo capsule in the evening; and on Day 7: 1 placebo tablet in the morning.
1888453|NCT01241422|Drug|Montelukast|On Day 1: participants will receive 2 placebo tablets in the morning and 1 montelukast capsule in the evening; from Days 2 to 6: they will receive 1 placebo tablet in the morning and 1 montelukast capsule + 1 placebo tablet in the evening; and on Day 7: 1 placebo tablet in the morning.
1888454|NCT01241435|Drug|LY2216684|Administered orally
1888455|NCT01241448|Drug|LY2409021|Administered Orally
1888456|NCT01241448|Drug|Placebo|Administered Orally
1960570|NCT03175796|Behavioral|Infant Mental Health-Home Visiting|Behavioral intervention aimed to increase parental competencies and promote mental health and sensitive caregiving.
1888458|NCT01241474|Dietary Supplement|EPAX 6000 (marine omega 3 EPA/DHA fatty acid concentrates|6 x 1g capsules per day of marine oil (contains 3g/d docosahexaenoic acid plus eicosapentaenoic acid) for a 9 month period
1888459|NCT01241474|Dietary Supplement|Maize (corn) oil|6 x 1g capsules per day for 9 months
1888460|NCT01241487|Drug|valsartan/amlodipine|160/10 mg
1888462|NCT01241513|Drug|NAC|NAC provided to determine if beneficial at altitude
1888463|NCT01241513|Drug|Placebo|Placebo
1888464|NCT01241526|Other|Disease Management|"Individual, group and phone education sessions
Telephone supporter follow-up
LTOT monitoring"
1888465|NCT01241526|Other|Usual site management|"Usual education as per site protocol
Usual follow-up as per site protocol
LTOT monitoring"
1888466|NCT01241539|Drug|Dabigatran etexilate|150 mg capsule
1888467|NCT01241539|Drug|Dabigatran etexilate|75 mg capsule
1888468|NCT01241539|Drug|Dabigatran etexilate|110 mg capsule
1888469|NCT01241552|Biological|MK-3415|A single IV infusion of MK-3415 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A)
1888470|NCT01241552|Biological|MK-6072|A single infusion of MK-6072 (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
1888471|NCT01241552|Biological|MK-3415A|A single IV infusion of MK-3415A (10 mg/kg of monoclonal antibody to Clostridium difficile Toxin A and 10mg/kg of monoclonal antibody to Clostridium difficile Toxin B)
1888472|NCT01241552|Biological|Placebo|A single IV infusion of normal saline (0.9% sodium chloride)
1888473|NCT01241552|Drug|SOC|Standard of care (SOC) for CDI will be prescribed for 10 to 14 days and can begin on the day of study drug infusion; but the first dose must have been administered prior to or within a few hours following study drug infusion. SOC is defined as the receipt of oral metranidazole, oral vancomycin, IV metronidazole concurrent with oral vancomycin, oral fidaxomicin, or oral fidaxomicin concurrent with IV metronidazole.
1888474|NCT01241565|Device|ENDO GIA™ Stapler with TRI-STAPLE™ Technology|All patients will have surgery with ENDO GIA™ Stapler with TRI-STAPLE™ Technology
1888475|NCT01241578|Behavioral|Lifestyle Counseling|Participants receive instructions for making healthy changes to their diet and physical activity habits.
1888476|NCT01241591|Drug|CP 690,550 5 mg|CP-690,550 5 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
1888477|NCT01241591|Drug|CP 690,550 10 mg|CP-690,550 10 mg orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks
1888478|NCT01241591|Biological|Etanercept 50 mg|Placebo orally dosed twice daily and etanercept 50 mg subcutaneously dosed twice weekly for 12 weeks
1888479|NCT01241591|Other|Placebo|Placebo orally dosed twice daily and placebo subcutaneously dosed twice weekly for 12 weeks.
1888480|NCT01241617|Device|Duet TRS|Endo GIA stapler with integrated Duet TRS
1888481|NCT01241617|Device|Endo GIA|Endo GIA stapler with Single Use Loading Units
1888482|NCT01241630|Procedure|Somatosensory reflex arch (Xiao Procedure)|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
1888483|NCT01241643|Drug|CYT107|repeated cycles of 3 injections of CYT107 at 20 µg/kg/week over 2 weeks, for a maximum of 4 cycles within 21 months and a maximum of 3 cycles within 12 months
1888484|NCT01241656|Behavioral|DESI for home viewing|Decision support intervention is a 31 minute DVD mailed to the patients in all of the experimental groups. The program explains the function and location of the prostate and the nature of prostate cancer, including its associated mortality. Next, the program describes the different tests that are used to detect prostate cancer including the digital rectal exam, prostate specific antigen (PSA) test and prostate biopsy.
1888485|NCT01241656|Behavioral|DESI for viewing at Shared Medical Appointment|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
1888486|NCT01241656|Behavioral|Option of SMA and DESI or DESI only|Shared medical appointment (SMA) sessions will be led by a mid-level provider. The sessions will begin with an introduction about the importance of making an informed decision about prostate cancer screening. The PSA decision support intervention will be shown and then, after the program, participants will be invited to ask questions or share their thoughts and feelings. At the end of the session, information on how to obtain a PSA screening test will be provided to participants. Men who decide in favor of a PSA test immediately following a SMA will be given a lab order which they can use to have the test performed.
1888487|NCT01241669|Drug|E5555|Drug: Oral E5555 400 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV.
1888488|NCT01241669|Drug|E5555|Drug: Oral E5555 100 mg/matching placebo, oral metformin 500 mg, iohexal 20 mL intravenous (IV), and para-aminohippuric acid (PAH) 7 mg/kg IV bolus.
1888489|NCT01241682|Biological|DC + CTX|3x 50x10e6 DC + cyclophosphamide
1888490|NCT01241695|Dietary Supplement|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
1888491|NCT01241695|Dietary Supplement|Oral nutritional supplement, food for special medical purposes|2 servings of 200 ml per day, treatment period: 12 weeks
1888492|NCT01241708|Drug|Bortezomib|Bortezomib 1.6mg/m2 on day -4 and day -1
1888493|NCT01241721|Device|Positron Emission Mammography (PEM)|Phase 1 of the study will involve imaging the breast with cancer up to 3 times over 2 hours using one half (1/2) of the standard dose of the radioactive tracer, F18FDG, for PEM imaging. If this reduced dose is equivalent to the standard dose then one quarter (1/4) dose will be tested to find the lowest effective radiation dose of tracer to see breast cancer. Phase 2 of the study will involve imaging of both breasts several times over a shorter duration using the lowest effective dose of tracer identified in the first part of the study. This will allow us to examine the reliability of PEM to identify a second unsuspected abnormality in either breast. Patients will be offered biopsy by ultrasound, MRI or PEM as clinically appropriate of lesions suspected of being cancer prior to final surgical planning.
1888494|NCT01241734|Drug|Revlimid|"Stage I:
Cohort 1: RICE + Lenalidomide 10mg days 1-7 Cohort 2: RICE + Lenalidomide 15mg days 1-7 Cohort 3: RICE + Lenalidomide 20mg days 1-7 Cohort 4: RICE + Lenalidomide 25mg days 1-7
Stage III:
Lenalidomide 25mg days 1-21 every 28 days"
1888495|NCT01241747|Behavioral|Walking Exercise|3 times per week for 3 months
1888496|NCT01241747|Behavioral|Control|Resistance training 3 times per week for 3 months
1888497|NCT01241760|Drug|Ribavirin|Ribavirin (RBV) 1000-1200 milligram (mg) per day (weight dependent) twice daily regimen oral tablets for 24 or 48 weeks depending on the patient's treatment response at week 4
1888498|NCT01241760|Drug|Telaprevir|1125 mg (3 oral tablets) twice a day (every 10-14 hours) for 12 weeks
1888499|NCT01241760|Drug|Pegylated interferon alfa-2a|180 microgram (µg) per week, subcutaneous injection, for 24 or 48 weeks Pegylated interferon alfa-2a 180 microgram (µg) per week subcutaneous injection for 24 or 48 weeks depending on the patient's treatment response at week 4
1888500|NCT01241760|Drug|Telaprevir|750 mg (2 oral tablets) every 8 hours for 12 weeks
1888501|NCT01241773|Drug|raltegravir|One 400 mg tablet twice daily for 7 days
1888502|NCT01241773|Drug|TMC435 + raltegravir|Two 75 mg TMC435 capsules once daily and one 400 mg raltegravir tablet for 7 days
1888503|NCT01241773|Drug|TMC435|Two 75 mg capsules once daily for 7 days
1888504|NCT01241773|Drug|TMC435 + efavirenz|Two 75 mg TMC435 capsules + one 600 mg TMC278 tablet, once daily for 14 days
1888505|NCT01241773|Drug|TMC435|Two 75 mg capsules once daily for 14 days
1888506|NCT01241773|Drug|efavirenz|One 600 mg tablet once daily for 14 days
1888509|NCT01241799|Procedure|Endoscopic ultrasound guided fine needle aspiration biopsy|22 gauge fine needle aspiration biopsy of the pancreatic mass with the stylet in. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the style out is then used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle masses done.
1888510|NCT01241799|Procedure|Stylet out FNA first, Stylet in FNA second|22 gauge FNA biopsy of pancreatic mass with the stylet out. Vacuum suction applied. 12 intra mass needle passes done. A new 22 gauge FNA biopsy needle with the stylet in is used to biopsy the pancreatic mass. Vacuum suction applied. 12 intra mass needle passes done.
1888513|NCT01241825|Other|Trident sugarless chewing gum.|Patients will be randomly divided into 2 groups, one subject group (these chew gum) and one control group (these do not chew gum). The subjects will have to chew Trident sugarless chewing gum for 20-30 minutes every 2 hours, all together 4 times at t=0 h, t=2, t=4 and t=6 h.
1888514|NCT01241825|Other|One control group (these do not chew gum).|The control group will not chew chewing gum while undergoing capsule endoscopy
1888515|NCT01241838|Device|Pacemaker|Routine postoperative temporary pacemaker Rate change of 65-80-95-110-125 beats/second in random order at day 3-4 after operation
1888516|NCT01241851|Behavioral|Aerobic exercise|
1888517|NCT01241851|Behavioral|Resistance exercise|
1888518|NCT01241864|Biological|Allogenic islet cells (human, U. Chicago)|Human allogenic islet cells. Immunosuppression varies but may include prograf, cellcept, sirolimus, prednisone. Dosage will vary per patient based on weight. Patients will receive immunosuppression medications while islet cells are functioning.
1888519|NCT01241864|Procedure|Intraportal infusion of islet cells|Intraportal infusion of islet cell through the portal vein in the liver.
1888520|NCT01241877|Dietary Supplement|astaxanthin|astaxanthin
1888521|NCT01241877|Dietary Supplement|placebo|placebo
1888522|NCT01241903|Drug|rosuvastatin|Patients (n = 54) presenting acute coronary syndrome/non-ST elevation myocardial infarction who present within 8 hours of symptom-onset will be randomized to two groups to receive rosuvastatin (40 mg oral dose) or placebo at the time of presentation, in addition to standard of care (aspirin, clopidogrel, low molecular weight heparin). Blood will be collected at baseline (time of enrollment, immediately prior to drug or placebo), at 6 - 8 hours, at 18 - 24 hours, and at 30 days for analysis of platelet - leukocyte co-aggregate formation, biomarkers of platelet - leukocyte interactions, and biomarkers of myocardial necrosis. Additional samples may be collected just after revascularization, in patients undergoing PCI. The group of patients treated with rosuvastatin will be maintained on rosuvastatin 20 mg daily and the group randomized to placebo will be given rosuvastatin (20 mg oral once daily) within 48 hoursof enrollment and after planned PCI, but before hospital discharge.
1888523|NCT01241903|Drug|placebo|frequency and duration
1888524|NCT01241916|Device|Static-Progressive Splint|Static progressive splinting is a well-established adjunct for restoring elbow motion. Such splints apply a static stress relaxation force to the elbow tissues, which is sequentially increased, as motion is achieved.
1888525|NCT01241916|Device|Dynamic Splint|Dynamic splints are a popular alternative, and apply a constant prolonged force to the tissues as additional motion is achieved.
1888526|NCT01241929|Behavioral|video decision aid|video of CPR
1888527|NCT01241942|Device|Steen Solution™|This solution is a buffered dextran and albumin-containing extracellular perfusate with an optimal colloid osmotic pressure developed specifically for extra-corporeal perfusion of lungs. After EVLP, lungs will be cooled in the circuit to room temperature, then flushed with cold Perfadex™ and taken to UNCH where they will have an ex-vivo CT scan. Lungs determined suitable will be offered to consented patients at UNC Hospitals based on Lung Allocation Score. Lungs not considered for transplantation may be subjected to different experiments but are not to be a part of this research study. In summary, lungs with good and stable function during EVLP with Steen Solution™ will be transplanted into recipients as per current clinical practice.
1888528|NCT01241942|Other|Conventional Lung Transplant|No experimental procedures will be carried out. Lungs from conventional brain-dead organ donors will be used for transplant.
1888529|NCT01241955|Behavioral|video decision aid|video of CPR
1888530|NCT01241968|Device|Cardiac Extracorporeal Shockwave Therapy generator (Cardiospec)|Energy Density - 0.09 mJ/mm2
1888531|NCT01241968|Device|Placebo|Placebo
1888532|NCT01241994|Other|AASD dialysis technique|
1888533|NCT01242007|Other|Supine spirometry|In addition to the current upright lung function evaluation we performed a supine spirometry
1888534|NCT01242020|Drug|Perflutren Lipid Microsphere Injectable Suspension|1.3 mL activated DEFINITY® diluted in 50 mL of preservative-free saline will be used
1888535|NCT01242033|Dietary Supplement|red raspberries|single serving of one, two or four cups red raspberries
1888536|NCT01242033|Dietary Supplement|bread controls|two slices white bread alone or with 200 mg vitamin C supplement
1888537|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2590066A|Intramuscular injection, two doses
1888538|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2592984A|Intramuscular injection, two doses
1888539|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2340274A|Intramuscular injection, two doses
1888540|NCT01236040|Biological|GSK Biologicals' investigational vaccine GSK2340273A|Intramuscular injection, two doses
1888541|NCT01236040|Other|Placebo|Intramuscular injection, two doses
1888542|NCT01236053|Drug|Gabapentin prescriptions|The exposure of interest is gabapentin use as defined by prescriptions recorded by the GPRD general practitioner (British National Formulry codes). Data on prescriptions for gabapentin will be extracted for each case and control from entry into the study cohort up to two years prior to the index date (the exposure window). A two year lagged exposure is incorporated to account for latency between cancer onset and GPRD diagnosis, and for protopathic bias (gabapentin prescription for initial pain symptoms of undiagnosed cancer). Gabapentin exposure will be parameterized as follows: (1) Ever versus never exposed; (2) Number of prescriptions; (3) Duration of exposure; and (4) Cumulative dose.
1888543|NCT01236066|Other|Database analysis|Existing computerised administrative databases from the Australian Institute of Health and Welfare (AIHW) will be reviewed to retrieve data on all-cause gastroenteritis/ rotavirus enteritis and bronchiolitis hospitalisations of children <5 years in all the states using Rotarix from 1998 to 2009. Data from Australian Childhood Immunisation Register (ACIR) post introduction of rotavirus vaccines in the National Immunisation Program (2007 to 2009) will also be used.
1888544|NCT01236079|Behavioral|Assisted referral & IVR|includes assistance in enrolling in outpatient cessation services, pharmacy orders for cessation medication, interactive voice recognition follow-up
1888545|NCT01236092|Other|conservative therapy - traction, vibration, exercise|10 weeks of therapy. 3 treatments per week the first 4 weeks and 2 treatments the final 6 weeks.
1888546|NCT01236105|Drug|LY2624803|Administered orally (po), once.
1888547|NCT01236105|Other|Activated Charcoal|Administered po
1888548|NCT01236118|Drug|LY2439821|Administered subcutaneously
1888549|NCT01236131|Other|no intervention|Not Applicable- no intervention
1888550|NCT01236144|Drug|Plerixafor|Fixed dose of Plerixafor (240mcg/kg) given by subcutaneous injection on each day of chemotherapy for up to 3 courses (depending on cohort). The three chemotherapy courses will be Daunorubicin/Clofarabine for courses 1&2 and Daunorubicin/Ara-C for course 3. Each course will last 5 days, and Plerixafor will be given for 5 days.
1888551|NCT01236144|Drug|AC220|Each cohort of patients will receive three courses of chemotherapy approximately 4 to 5 weeks apart which will comprise of Daunorubicin/Ara-C/Etoposide in Courses 1&2 and Daunorubicin/Ara-C in Course 3. Two days after the last day of each chemotherapy course, patients will receive AC220 orally for 7, 14 or 21 (depending on cohort) consecutive days. Depending on which cohort the patient enters, they will receive either 60mg, 90mg or 135mg of AC220 daily, with a provision to assess 40mg if necessary.
1888552|NCT01236144|Drug|Ganetespib|Patients will receive 3 treatments of ganetespib on days 1, 8 and 15 of each course where day 1 is the first day of the chemotherapy. The chemotherapy will be DAE/DAE/DA. Three courses of chemotherapy will be given each of which will be associated with 3 administrations of ganetespib.
1888553|NCT01236196|Behavioral|Telephone cognitive behavior therapy|Cognitive behavior therapy aimed at teaching pain coping skills was conducted by telephone (12 sessions over a 6-month period).
1888554|NCT01236196|Behavioral|Telephone pain education|Participants received information on the management of chronic pain during 12 telephone sessions conducted over a 6-month period).
1888555|NCT01236209|Other|Webpage|one arm having access to a webpage with information about coping with pain and relaxation exercises
1888556|NCT01236209|Other|Webpage and situation feedback|having access to the same web-page with information about coping with pain and relaxation relaxation and completing 3 diaries and receiving situational feedback for 4 weeks at home through a web enabled mobile phone.
1888557|NCT01242046|Dietary Supplement|Caffeine|400 mg of caffeine in tablet form
1888558|NCT01242046|Dietary Supplement|Placebo|Inert tablet
1888559|NCT01242059|Dietary Supplement|yellow pea protein|Served in a tomato soup
1888560|NCT01242059|Other|yellow pea fiber|Served in a tomato soup
1888561|NCT01242059|Dietary Supplement|Control|Served in a tomato soup
1888562|NCT01242072|Drug|palifosfamide-tris|Intravenous on days 1, 2 and 3 of each 21-day cycle for up to 4 cycles
1888563|NCT01242085|Procedure|trumatch group|these patient will have CT based customized knee instruments used for surgery
1888564|NCT01242085|Procedure|control group|these patients will have standard instrumentation used for for knee replacement
1888565|NCT01242098|Drug|Fixed dose combination salmeterol / fluticasone|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
1888566|NCT01242098|Drug|Fixed-dose combination beclometasone dipropionate / formoterol|Branded fixed-dose combination inhaled corticosteroid / long-acting beta2-agonist therapy
1888567|NCT01242111|Drug|BMN 110|Patients will receive an intravenous infusion of BMN110 at 2.0mg/kg/week, over a period of approximately 4 hours per infusion, for up to 240 weeks.
1888568|NCT01242124|Procedure|side-to-side stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive side-to-side stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
1888569|NCT01242124|Procedure|circular-stapled esophagogastric anastomosis|20 patients of distal esophageal cancer receive circular-stapled esophagogastric anastomosis in Ivor-Lewis oesophagectomy
1888604|NCT01243931|Drug|OCT-guided laser phototherapeutic keratectomy|Preoperative measurements from the OCT are used to assist the calculation in deciding the laser depth settings for removal of anterior corneal opacities and defects in the phototherapeutic PTK procedure. The surgeon uses the OCT data to plan a range of treatment parameters to remove most of the opacity while preserving at least 250 microns of residual corneal stroma.
1889200|NCT01248611|Drug|fentanyl|nasally, dose titrated to effect
1888570|NCT01242150|Device|NCPAP by helmet|The infant helmet (Castar Starmed© Mirandola, Italy) is secured to a soft collar that adheres to the child's neck and is connected to a high flow NCPAP circuit (high fresh gas flow >40 L/min to avoid carbon dioxide rebreathing). To facilitate tolerance up to a maximum of 2 boluses of midazolam 0.1 mg/kg i.v. can be administered eventually followed by an i.v. continuous infusion rate according to OPS scale. Once the interface is positioned, a baseline Continuous Positive Airway Pressure (CPAP) level is set at 4 cm H2O and then raised in increments of 2 cm H2O every 20 min up to a maximum of 10 cm H2O. FiO2 is set to achieve a SpO2 ≥ 92%. If intolerance persisted despite sedative administration, the alternate interface can be used before considering tracheal intubation. All patients are kept in semirecumbent position.
1888571|NCT01242150|Device|NCPAP by facial mask|The size of NCPAP full face or nasal masks are chosen to be more comfortable for the infants (Respironics, Murrysville). The masks are secured by head straps while avoiding a tight fit and air leaks. A protective hydrocolloid sheet was applied over the nasal bridge (DuoDERM, ConvaTec, Deeside, UK). After a short adaptation period, it is firmly applied on the face by a pediatric head cap (Respironics, Murrysville ) to minimize air leaks. The mask is then connected to the same circuit previously described for helmet NCPAP.
1888572|NCT01242176|Drug|BI 10773 XX (Trial Formulation 2)|one single dose tablet in the morning
1888573|NCT01242176|Drug|BI 10773 (Final Formulation)|one single film-coated tablet in the morning
1888574|NCT01242202|Drug|ASP1941|oral
1888575|NCT01242202|Drug|alpha glucosidase inhibitor|oral
1888576|NCT01242215|Device|ASP1941|oral
1888577|NCT01242215|Drug|Placebo|oral
1888578|NCT01242215|Drug|Sulfonylurea|oral
1888579|NCT01242228|Drug|ASP1941|oral
1888580|NCT01242228|Drug|DPP-4 inhibitor|oral
1888583|NCT01242254|Biological|Intravitreal injection of KH902|0.5 mg 2.0 mg once per 4 weeks during fixed dosing phase once as needed during extended treatment phase
1888584|NCT01242267|Drug|Thalidomide+Melphalan +Bortezomib+stem cell transplant|Five days prior to transplant, the patient starts thalidomide. Dose range will be from 400mg for 5 days, to 1000mg for 5 days. Thalidomide dose is increased after groups of 3 to 6 patients have been treated. 4days before the transplant and again on the day before the transplant the patient will be given bortezomib (VELCADE) intravenously at a dose of 1.6 mg/m2 (mg/m2 means that the dose will be calculated based on the patient's height and weight). 2 days before transplant the patient will be given melphalan 200 mg/m2 intravenously. Dexamethasone is given before the VELCADE and the melphalan.
1888585|NCT01242280|Device|Stent|Self-expandable esophageal stent (SX-Danis, Czesc Republic).
1888586|NCT01242280|Device|Tamponade|Sengstaken-Blakemore tube
1888587|NCT01242293|Other|0.9% Saline with glucose 5%|intravenous hydration at a rate of 125 ml per hour during labor
1888588|NCT01242293|Other|Ringer lactate|intravenous hydration at a rate of 250 ml per hour during labor
1888589|NCT01242293|Other|Ringer lactate - Controls|intravenous hydration at a rate of 125 ml per hour during labor
1888590|NCT01242306|Drug|intracoronary infusion of acetylcholine|Acetylcholine will be infused at a concentration of 140 microg/minute, over a period of 2 minutes, yielding estimated intracoronary concentrations of 10(-5)mol/L, with the assumption of a flow rate of 80mL/min). All infusions will be delivered at a constant rate using an infusion pump. Subsequently, in order to evaluate the endothelium-independent vasomotor response, 2mg of isosorbide dinitrate or bolus 250microg of nitroglycerine will be infused by intracoronary bolus in all subjects. The response to nitrate will be recorded 1 minute after the bolus. A 3-min period will be allowed to elapse between each drug infusion.
1888591|NCT01242319|Behavioral|HeartAge intervention|Computerized kiosk in waiting room with HeartAge risk calculator, PDA based decision support tool regarding hyperlipidemia management, website and tool box with coronary risk reduction tools for smoking cessation, diet and exercise, medication adherence
1888592|NCT01242332|Drug|Pregabalin|75 mg po 2 hrs before surgery
1888593|NCT01242345|Device|Capnography|Monitoring of the capnography curve for early detection of apnea
1888594|NCT01242358|Device|Capnography|Capnographic monitoring
1888595|NCT01242358|Device|Standard monitoring|Standard monitoring
1888596|NCT01242371|Dietary Supplement|Probiotic Supplement|Probiotic Supplement 1 tablet by mouth daily
1888597|NCT01242371|Dietary Supplement|Identical-appearing Placebo|Probiotic identical placebo 1 tablet by mouth daily
1888598|NCT01242384|Device|Device: Silicon ring (Arabin Pessary)|Placement of a silicon pessary in the vagina, around the cervix.
1888599|NCT01243892|Device|NuSpin|Device for administration of doses of somatropin.
1888600|NCT01243892|Drug|Somatropin|Somatropin using either NuSpin or Nutropin AQ Pen, as per standard dosing.
1888601|NCT01243905|Other|Family psychoeducational therapy plus TAU|Group psychoeducation every two weeks for eight weeks in addition to treatment as usual administered by physicians
1888602|NCT01243905|Other|Treatment as usual|Treatment as usual administered by physicians
1888603|NCT01243918|Other|Oxygen therapy delivery systems|T-60 (minutes) : clinical examination, blood gas, electrocardiogram; T0 / First oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T10 : blood gas; Between T0 and T60 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T60 / Second oxygen therapy delivery system: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2; T70 : blood gas; Between T60 and T120 (every 10 minutes): clinical examination, measurement of positive and expiratory pressure and FiO2; T120: clinical examination, blood gas, electrocardiogram, measurement of positive and expiratory pressure and FiO2
1888605|NCT01243944|Drug|ruxolitinib tablets|Starting dose of 10 mg BID with individualized dose titration ranging from 5 mg QD to 25 mg BID based on safety and efficacy
1889263|NCT01249040|Procedure|Physical therapy|
1888606|NCT01243944|Other|Best Available Therapy (BAT)|Best Available Therapy (BAT) will be selected by the Investigator for each subject. BAT may not include experimental agents (i.e. those not approved for the treatment of any indication) as well as a limited number of other selected drugs in accordance with the protocol-defined requirements.
1888607|NCT01243957|Drug|LY2216684|Administered orally
1888608|NCT01243957|Drug|Fluoxetine|Administered orally
1888609|NCT01243970|Drug|Phenylephrine|"Infusion dose 50 mcg / minute. On/off regimen in response to blood pressure (BP) readings every minute. Approximative 30 minutes treatment duration. Total dose 50 mcg - 1500 mcg *
* We will start the infusion after the spinal anaesthetic (see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 1500 mcg."
1888610|NCT01243970|Drug|Ephedrine|"Infusion dose 4mg / minute. On/off regimen in response to blood pressure readings every minute. Approximative 30 minutes treatment duration. Total dose 4 mg - 120 mg. *
* We will start the infusion after the spinal anaesthetic(see trial design), and while we will monitor cardiac output and BP (for 20 minutes) the surgeons will prep the patient (surgery not started yet). Birth should occur more or less 10-15 minutes after beginning surgery, so this is approximatively 30 minutes after spinal anaesthetic. It is very unlikely that the infusion will run continuously and exceed 120mg."
1888611|NCT01243983|Drug|LX211|"Subjects will be sequentially assigned to one of the following treatment arms in a 1:1 ratio:
Treatment Arm A: voclosporin 0.4 mg/kg p.o. b.i.d., not to exceed 40 mg p.o. b.i.d.
Treatment Arm B: placebo p.o. b.i.d.
Dosage Form:
• Soft gelatin capsule
Duration of treatment:
• 24 weeks"
1888612|NCT01243996|Drug|Ibuprofen|Treatment with high (20-10-10 mg/kg/day)or standard dose(10-5-5 mg/kg/day) ibuprofen
1888613|NCT01244009|Drug|MK-4827|MK-4827 will be administered daily as an oral formulation in continuous 21-day cycles.
1888614|NCT01244022|Procedure|colorectal cancer resection|Open radical resection of colorectal cancer, according to oncological principals, depending on the tumor site
1888615|NCT01244035|Drug|Treatment A|MK-8266 orally twice daily (1 mg in the morning and 0.3 mg 8 hours later) plus placebo to match Treatment B on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
1888616|NCT01244035|Drug|Treatment B|MK-8266 0.1 mg orally every 2 hours (total dose of 0.9 mg) plus placebo to match Treatment A on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
1888617|NCT01244035|Drug|Treatment C|Placebo to match MK-8266 Treatments A and B orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
1888618|NCT01244035|Drug|Treatment D|MK-8266 orally twice daily (1 mg in the morning and 0.4 mg 8 hours later) plus placebo to match Treatment E on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
1888619|NCT01244035|Drug|Treatment E|MK-8266 0.2 mg orally every 2 hours (total dose of 1.4 mg) plus placebo to match Treatment D on Days 1 through 3. On Day 4, single dose of 1 mg MK-8266.
1888620|NCT01244035|Drug|Treatment F|Placebo to match MK-8266 Treatments D and E orally daily on Days 1 through 3. On Day 4, single dose of placebo to match MK-8266.
1888621|NCT01244048|Dietary Supplement|n3 long chain polyunsaturated fatty acids|Group 1 (placebo) Group 2 (0.8 g n3 LC-PUFA/d in 125 g yoghurt) Group 3 (3 g n3 LC-PUFA/d in 200 g yoghurt)
1888622|NCT01244061|Drug|Varenicline|Varenicline 1mg twice daily
1888623|NCT01244061|Drug|Placebo|Matched placebo twice daily
1888624|NCT01244074|Behavioral|biofeedback training|
1888625|NCT01244100|Drug|PL2200 fasted|Fasted state
1888626|NCT01244100|Drug|PL2200 fed|Fed state
1888627|NCT01244113|Drug|propofol|optimization of propofol dose from 1.5 mg/kg to 2.5 mg/kg using Dixon's up and down method during MRI scanning
1888628|NCT01244126|Drug|Intranasal fentanyl|2mcg/kg fentanyl IN
1888629|NCT01244126|Drug|morphine IM|0.1 mg/kg morphine IM for postop pain
1888630|NCT01244126|Drug|IV morphine|0.1 mg/kg morphine IV
1888631|NCT01244139|Drug|BIIB033|IV infusion of 0.3, 1, 3, 10, 30, 60 or 100 mg/kg
1888632|NCT01244139|Drug|Placebo|IV infusion dummy drug
1888633|NCT01244152|Behavioral|Intensive diabetes self-management education|18 group classes led by a dietitian and peer supporters, and weekly telephone calls by peer supporters. Intervention focus was on diet and physical activity.
1888634|NCT01244152|Behavioral|Enhanced standard diabetes education|2 3-hour diabetes education classes taught by a health educator at a local clinic
1888635|NCT01244165|Device|Cytrix|
1888636|NCT01244165|Other|Other treatments for pelvic organ prolapse|Treatments for pelvic organ prolapse using other products (standard of care for treatment of pelvic organ prolapse)
1888637|NCT01244178|Drug|Insulin|Intravenous Hyperinsulinemic therapy
1888638|NCT01244178|Drug|Insulin|Standard Intravenous Insulin Therapy
1888639|NCT01244191|Drug|Tivantinib|Tivantinib 720 mg daily as 3 x 120 mg oral tablets given twice a day
1888640|NCT01244191|Drug|Placebo|Tivantinib Placebo tablets given twice a day
1888641|NCT01244191|Drug|Erlotinib|Erlotinib 150 mg oral tablets, given once a day
1888642|NCT01244204|Dietary Supplement|Vitamin D|Daily dose of 800IU of vitamin D
1888643|NCT01244204|Dietary Supplement|Placebo|Identically appearing capsules
1888644|NCT01244217|Drug|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water
Route of administration: oral"
1888645|NCT01244230|Drug|fexofenadine/Allegra (M016455)|"Pharmaceutical form:dry syrup formulation to be suspended in water
Route of administration: oral"
1888690|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
1888691|NCT01244620|Drug|sitaxsentan|sitaxsentan 100 mg QD for 6 days
1888692|NCT01244620|Drug|tadalafil|tadalafil 40 mg QD for 6 days
1888693|NCT01244620|Drug|sitaxsentan|sitaxentan 100 mg QD for 6 days
1888694|NCT01244620|Drug|sildenafil|sildenafil 20 mg TID for 6 days
1888695|NCT01244633|Drug|Ecopipam|50 or 100 mg tablets given once per day for eight weeks
1888696|NCT01244659|Drug|Tacrolimus from EMS|Tacrolimus initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
1889264|NCT01249040|Procedure|steroid intraarticular injection|
1888646|NCT01244243|Device|Hand & Wrist Assisting Robotic Device|Treatment occurs in 2 hour sessions, 4 times a week over 3 weeks. In each treatment session, you will sit in a chair and have your weak hand attached to a mechanical device (the robot), which will help you open and close your hand. During the treatment, different types of objects (with varying shapes, sizes, and weight) will be placed into your hand. You will be given a variety of instructions related to the grasping, feeling, or identifying of the object in your hand. Sometimes these instructions will be given from the investigator and sometimes from the computer. You will often be asked to grasp, or release, each of these objects as best you can. You will also be asked to concentrate on the object in your hand. An example of what you may be asked to do is to name the object. During other times, you will play games, using the robot to control game parts on the computer screen. At other times, you will move your hand so that the robot can measure your hand function.
1888647|NCT01244256|Drug|Clotrimazole + Gentamicin + Beclomethasone|Treatment with Clotrimazole + Gentamicin + Beclomethasone
1888648|NCT01244256|Drug|Clotrimazole + Gentamicin|Treatment with Clotrimazole + Gentamicin
1888649|NCT01244269|Drug|Methylphenidate|Methylphenidate 10mg tablets will be overencapsulated in gelatin capsules for blinding. Subjects will take 1 capsule three times daily for a total of 7 doses.
1888650|NCT01244269|Drug|Methylphenidate|Methylphenidate 20mg three times daily for a total of 7 doses.
1888651|NCT01244269|Drug|Placebo 10|Blind gelatin capsule three times daily for a total of 7 doses.
1888652|NCT01244269|Drug|Placebo 20|Blind gelatin capsule three times daily for a total of 7 doses
1888653|NCT01244282|Procedure|fMRI with sensory stimulation|BOLD fMRI study with sensory stimulation followed by fMRI in the presence of increasing concentrations of ferumoxytol (Feraheme™)
1888654|NCT01244295|Behavioral|Complicated Grief Treatment|Complicated Grief Treatment (CGT) is a targeted psychotherapy for complicated grief. The treatment integrates principles, strategies and techniques from interpersonal psychotherapy, trauma-focused cognitive behavioral treatment and motivational interviewing. Treatment includes 16 sessions provided weekly.
1888655|NCT01244295|Behavioral|Interpersonal Therapy|Standard form of interpersonal psychotherapy delivered for 16 sessions weekly.
1888658|NCT01244347|Drug|folic acid|
1888659|NCT01244347|Drug|folic acid|
1888660|NCT01244360|Dietary Supplement|resveratrol|Subject will take resveratrol supplement for 4 weeks, with optional additional 4 week treatment period.
1888661|NCT01244360|Other|Placebo Comparator: Sugar Pill|Subject will take placebo for daily for 4 weeks, with optional additional 4 week treatment period.
1888662|NCT01244399|Dietary Supplement|Inositol|
1888663|NCT01244425|Drug|Fibrin Sealant (FS) VH S/D 500 s-apr|Dosage form: spray application; dosage frequency: single application
1888664|NCT01244425|Other|Manual compression|Dosage form: surgical gauze swab; dosage frequency: single application
1888665|NCT01244438|Drug|FP-1039|FP-1039 will be administered at a dose up to 16 mg/kg intravenously over 30 minutes once a week.
1888668|NCT01244464|Biological|IMOVAX Polio™-Inactivated types 1, 2, and 3 poliovirus D vaccine|0.5 mL, at 2, 3, and 4 months; Intramuscular
1992333|NCT03322124|Drug|Octenidinedihydrochlorid|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
1888670|NCT01244490|Drug|Extended-release Guanfacine Hydrochloride|Tablet, once daily, optimised dose (1mg to 7mg based on age and weight), 6-week maintenance duration on optimised dose.
1888671|NCT01244490|Drug|Atomoxetine Hydrochloride|Capsule, once daily, optimised dose (10mg to 100mg based on weight), 8-9-weeks maintenance duration on optimised dose
1888672|NCT01244490|Drug|Placebo Comparator|Placebo
1888673|NCT01244503|Drug|Sodium Octanoate Breath Test|100 mg of 13-C labeled sodium octanoate (Octanoate for short) is to be dissolved in 1 cup of tap water and administered to subject after baseline breath collection is completed.
1888674|NCT01244516|Device|galyfilcon A, BC 8.30|galyfilcon A, BC 8.30 soft contact lens
1888675|NCT01244516|Device|lotrafilcon B, BC 8.60|lotrafilcon B, BC 8.60 soft contact lens
1888676|NCT01244516|Device|comfilcon A, BC 8.60|comfilcon A, BC 8.60 soft contact lens
1888677|NCT01244529|Device|galy A Plus|galyfilcon A Plus, BC: 8.3 or 8.7
1888678|NCT01244529|Device|seno A|senofilcon A, BC:8.4 or 8.8
1888679|NCT01244529|Device|galy A|galyfilcon A , BC: 8.3 or 8.7
1888680|NCT01244542|Other|unpleasant stimuli|
1888681|NCT01244555|Other|ultrasound|Twice weekly ultrasound sessions for 6 weeks
1888682|NCT01244555|Other|massage|Twice weekly massage sessions for 6 weeks
1888683|NCT01244568|Behavioral|Prostate cancer treatment DESI|DESI is a 50 minute program on treatment choices for prostate cancer that will be given out to the experimental group. The program explains several treatment options including surgery (radical prostatectomy), radiation therapy (external beam and/or brachytherapy), hormone therapy, and active surveillance and watchful waiting. The program's intended audience is men with early state prostate cancer who are trying to make a treatment decision.
1888684|NCT01244581|Drug|Amoxicillin-clavulanate|Amoxicillin-clavulanate 40 mg/kg/day in two daily doses for 7 days
1888685|NCT01244581|Drug|Placebo|Placebo mixture in two daily doses for 7 days
1888686|NCT01244594|Other|Cycling with functional electrical stimulation|Subjects will cycle with functional electrical stimulation for one hour, 3 times per week at Magee Rehab's outpatient center. Subjects will cycle for a total of 26 weeks (6 months).
1888687|NCT01244607|Drug|Placebo|single i.v. administration
1888688|NCT01244607|Drug|NI-0801|single i.v. administration
1888689|NCT01244620|Drug|sitaxentan|sitaxsentan 100 mg QD for 6 days
1992334|NCT03322124|Other|Placebo|Mouth rinsing of the oral cavity with Octenidinehydrochlorid vs.Placebo over a period of 5 days
1992335|NCT03322111|Diagnostic Test|measurement of the cyclofusion|Measurement of the maximal cyclofusion competence with a dynamic 3-D Random-Dot Landolt-C stimulus
1992336|NCT03322098|Drug|Atropine|Atropine injection (0.01 mg/kg, max 0.5 mg) 3 minutes before spinal anesthesia
1992337|NCT03322098|Drug|Glycopyrrolate|Glycopyrrolate (0.00 4mg/kg, max 0.2 mg) 3 minutes before spinal anesthesia
1888697|NCT01244659|Drug|Prograf|Prograf initial dose of 0.2 mg/kg/day Myfortic®: 720 to 1440 mg/day Steroids: methylprednisolone: first dose 500mg, 250 mg at first day and 125mg at second day, reducing to 30mg after third day post transplantation.
1888698|NCT01244672|Procedure|Ferguson|This is a modification of the Milligan-Morgan technique, whereby the incisions are totally or partially closed with absorbable running suture. A retractor is used to expose the hemorrhoidal tissue, which is then removed surgically. The remaining tissue is either sutured or is sealed through the coagulation effects of a surgical device.
1888699|NCT01244672|Procedure|THD|Transanal hemorrhoidal dearterialization will be performed using an endoscopic ultrasonic probe. Approximately 7-8 hemorrhoidal arteries will be ligated at 1, 3, 5, 7, 9, 11 o'clock position as previously described in the literature. The ligation will be performed using a vicryl suture. The ultrasonic probe locates the arterial signal.
1888701|NCT01244698|Drug|Cefadroxil discontinued early|All patients will receive 24 hours of IV Cefazolin (1g IV every 8 hr), as is universal practice for clean breast surgery. The interventional group will then discontinue antibiotics. Clindamycin IV 600mg every 6 hours for 24 hours will be used in penicillin allergic patients.
1888702|NCT01244698|Drug|Cefadroxil until drain removal|All patients will receive 24 hours of IV Cefazolin, as is universal practice for clean breast surgery. The control group will receive oral outpatient Cefadroxil (500mg 2 times a day) until the final drain is removed. This is the normal postoperative regimen. In case of significant penicillin allergy (defined as a history of urticaria or anaphylaxis associated with penicillin) patients will receive Clindamycin 600mg IV every 6 hours for 24 hours followed by clindamycin 300mg IV every 6 hours.
1888703|NCT01244711|Drug|quetiapine|Dosing will begin with Seroquel-XR 50 mg. at bedtime and will escalate weekly to Seroquel-XR 100mg., Seroquel-XR 200mg. and Seroquel-XR 300 mg depending on clinical response and side effects.
1888704|NCT01244724|Drug|Lexapro|Escitalopram will begin at 10mg. a day. Visits will occur biweekly for 12 weeks. Subjects with minimal or no response and minimal or no side effects after 4 weeks will have the dose increased to 20mg. a day. The maximum dose of escitalopram will not exceed the FDA-approved maximum dose of 20 mg per day.
1888705|NCT01244737|Drug|[18F] FLT|[18F] FLT, intravenous, at a dose of 0.15 mCi/kg once before a PET scan
1888706|NCT01244750|Other|Non-Interventional|Non-Interventional
1888707|NCT01244763|Drug|FG-4592|Different dose levels and schedules
1888708|NCT01244776|Device|acellular corneal matrix|Efficacy of acellular corneal matrix to restore stroma integrity and treat corneal ulcer after lamellar keratoplasty.
1888709|NCT01244789|Drug|carboplatin and paclitaxel|6 courses of iv 3-weekly chemotherapy Carboplatin AUC5 Paclitaxel 175mg/m2
1888710|NCT01244789|Other|observation|active observation
1888711|NCT01244815|Drug|asenapine|Asenapine tablets, administered sublingually twice daily at one of three dose levels (2.5 mg, 5.0 mg, or 10.0 mg)
1888712|NCT01244815|Drug|Placebo to match asenapine|Placebo tablets to match asenapine tablets, administered sublingually twice daily
1888713|NCT01244815|Drug|Rescue medication|For participants whose symptoms worsen or are not adequately controlled on assigned treatment, rescue medication may be administered during the trial in the following circumstances. For the control of agitation, anxiety, insomnia, restlessness, or akathisia and extrapyramidal symptoms (EPS) some benzodiazepines and EPS medications (i.e., anticholinergics) are allowed. Benadryl (diphenhydramine) and beta blockers are also permitted, provided that they are not taken within 8 hours of efficacy assessments.
1888714|NCT01244828|Drug|Asenapine|5 mg or 10 mg fast-dissolving sublingual tablets BID for up to 52 weeks
1888715|NCT01244841|Procedure|fast post MI care|All post MI investigations, treatment, start of medication, information are performed within 3 days after admittance.
1888716|NCT01244854|Behavioral|Life Goals Collaborative Care|LGCC consists of 1) 10 sessions focused on CVD risk reduction through behavioral change within the context of patients' psychiatric symptoms; 2) participant goal setting in diet and exercise; 3) customized ongoing motivational interviewing (MI)-based patient contacts with a health specialist for 6 months, in addition to 4) strategies to increase provider access and support for behavioral change and medical management.
1888717|NCT01244867|Biological|20 micrograms dose H5 VLP|2 doses given 21 days apart of 20 micrograms of H5 VLP vaccine mixed with Alhydrogel
1888718|NCT01244867|Biological|30 micrograms dose H5 VLP|2 doses given 21 days apart of 30 micrograms of H5 VLP vaccine mixed with Alhydrogel
1888719|NCT01244867|Biological|45 micrograms dose H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine mixed with Alhydrogel
1888720|NCT01244867|Biological|45 micrograms non-adjuvanted H5 VLP|2 doses given 21 days apart of 45 micrograms of H5 VLP vaccine
1888721|NCT01244867|Biological|Placebo|2 doses given 21 days apart of the placebo
1888722|NCT01244880|Other|Saline|Saline infusion for 56 minutes
1888723|NCT01244880|Drug|PF-02545920|PF-02545920 10 mg single dose
1888724|NCT01244880|Other|Ketamine|"Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
PF-02545920 10 mg tablet"
1888725|NCT01244880|Drug|PF-02545920|PF-02545920 10 mg tablet single dose
1888726|NCT01244880|Other|Saline|Saline infusion for 56 minutes
1888727|NCT01244880|Other|Placebo|Placebo tablet single dose
1888728|NCT01244880|Other|Ketamine|Ketamine 0.23 mg/kg bolus over one min; and 0.58 mg/kg/hour maintenance for 56 minutes
1888729|NCT01244880|Other|Placebo|Placebo tablet single dose
1888730|NCT01244893|Device|Acuvue Advance Plus prePQ|silicone hydrogel contact lens manufactured prior to equipment process qualification activities.
1888731|NCT01244893|Device|Acuvue Advance Plus postPQ|silicone hydrogel contact lens manufactured after equipment process qualification activities.
1888732|NCT01244906|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Patients will receive fludarabine, busulfan and cyclophosphamide as the conditioning regimen prior to an allo SCT. Patients will then receive 2 doses of cyclophosphamide post-transplant and utilize sirolimus and mycophenolate mofetil (in mismatched transplants) as GVHD prophylaxis.
1888733|NCT01244932|Drug|bupivacaine 0.5%|Patients will be given bupivacaine 0.5% in different doses (up-down study).
1889068|NCT01247688|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on day 0
1888734|NCT01244945|Dietary Supplement|L. reuteri DSM 17938|L. reuteri will be administered at 1x10^8 CFU dosage in form of tabs. In order to ensure colonization (run in), 4 tabs will be administered per os daily (4x10^8CFU/die) for 15 days. Then administration will continue with 2 tabs daily (2x10^8 CFU/die) for 90 days.
1888735|NCT01244945|Other|Placebo Group|Placebo tabs identical in form, taste and consistency to active tabs
1888736|NCT01244958|Biological|Rituximab|1000 mg Rituximab infusion
1888737|NCT01244958|Drug|Placebo|infusion of Sodium citrate, Polysorbate, Sodium chloride
1888738|NCT01244971|Drug|Acarbose|100mg, 3 times daily
1888739|NCT01244971|Behavioral|Exercise|Moderate combined exercise, 50 minutes 3 times per week
1888740|NCT01244971|Other|Exercise + Acarbose|See respective monotherapy description
1888741|NCT01244984|Drug|Fluticasone Furoate/GW642444 Inhalation Powder|Fluticasone Furoate/GW642444 inhalation powder inhaled orally once daily for 52 weeks
1888742|NCT01244984|Drug|Fluticasone Furoate Inhalation Powder|Fluticasone Furoate inhalation powder inhaled orally once daily for 52 weeks
1888743|NCT01244997|Procedure|Dental Implant|This is designed to compare the response of the crestal bone after implants are placed whether delayed or immediately after tooth extraction in the maxilla.
1888744|NCT01245010|Other|Water|Water and education will be provided
1888745|NCT01245010|Other|Education|Education
1888746|NCT01245023|Procedure|Laparoscopic adhesiolysis|Laparoscopic adhesiolysis and Sprayshield
1888747|NCT01245023|Procedure|Placebo-surgery|skin incisions without laparoscopy or related procedures
1888748|NCT01245036|Drug|Antituberculous therapy along with steroids|INH (300 mg/day) plus Rifampicin (450 mg/day if wt.<50 kg and 600 mg/day if wt. >50 kg) for six months Prednisolone 1 mg/kg/day for 6 weeks (maximum 80 mg) Prednisolone 0.75 mg/kg/day for 6 weeks (maximum 60 mg) Prednisolone 0.5 mg/kg/day for 3 months (maximum 40 mg) Prednisolone 0.25 mg/kg/day for 3 months (maximum 20 mg) Taper over the next three months Prednisolone 0.25 mg/kg EOD for 15 days Prednisolone 0.125 mg/kg EOD for 15 days Then taper by 5 mg every 15 days to complete one year
1888749|NCT01245049|Biological|Boostrix PolioTM|Single dose, intramuscular administration.
1888750|NCT01245049|Biological|RepevaxTM|Single dose, intramuscular administration.
1888751|NCT01245049|Biological|PriorixTM|Single dose, intramuscular or subcutaneous administration.
1888754|NCT01245075|Other|Deep brain stimulation|Deep brain stimulation on
1888755|NCT01245075|Other|Placebo|deep brain stimulation off
1888756|NCT01245088|Drug|chondroitin sulfate|400 mg orally three times daily for 8 weeks
1888757|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
1888758|NCT01245101|Drug|Raltegravir|Raltegravir 400 mg twice daily in addition to subject's antiretroviral therapy.
1888759|NCT01245127|Drug|Ilaris|"Canakinumab 150 mg (or 2 mg/kg for patients weighing <40kg) every 8 weeks over a 6 months treatment period (i.e., weeks 0, 8, 16 and 24).
At Day 7, patients who show an improvement, but not a clinical remission, will be given another 150 mg (or 2 mg/kg for patients weighing <40 kg) injection and continue at 300 mg (or 4 mg/kg for patients weighing <40 kg) every 8 weeks beginning at Week 8.
Patients who show no improvement of symptoms and signs of Schnitzler's syndrome will not receive any additional canakinumab dose and will be offered corticosteroid therapy. These patients will return for a follow-up visit 2 weeks later (Day 21) for safety reasons and will be discontinued from the trial.
If a patient flares twice during the study, physician may optionally change the dosing frequency to every 4 weeks."
1888760|NCT01245140|Drug|alitretinoin|to receive verum (20 patients)
1888761|NCT01245140|Drug|Placebo|to receive placebo (10 patients)
1888762|NCT01245153|Other|Rectal Balloon Training|Subjects in combined RBT and PFMT group are taught for foley catheter insertion technique. The catheter is inserted into the rectum until the lower end of the balloon is 1 cm inside from the anus. Then the balloon is blown with clean water starting at 10 cc. Then the volume is progress to 15 cc in 3rd week and 20 cc in 5th week
1888763|NCT01245153|Other|Pelvic floor muscle training (PFMT)|Standard pelvic floor muscle exercise (Pelvic floor muscle training;PFMT) is assigned for 6 weeks.
1888764|NCT01245166|Drug|Acarbose|Acarbose 50 mg, per orem, thrice daily
1888765|NCT01245166|Drug|Metformin/Acarbose|Metformin HCl 500 mg plus Acarbose 50 mg Tablets, per orem, thrice daily
1888766|NCT01245179|Drug|panobinostat|"Oral capsules taken Monday, Wednesday,Friday for 12 weeks:
I. 10mg 1 week on/3 weeks off, 10 mg/ 2 weeks on 2 weeks off, 10mg/continuous
II. 15mg 1 week on/3 weeks off, 15mg/ 2 weeks on 2 weeks off, 15mg/continuous
III. 20mg 1 week on/3 weeks off, 20mg/ 2 weeks on 2 weeks off, 20mg/continuous"
1888767|NCT01245205|Drug|Akt inhibitor MK2206|Given PO
1888768|NCT01245205|Drug|lapatinib ditosylate|Given PO
1888769|NCT01245205|Other|pharmacological study|Correlative studies
1888770|NCT01245205|Other|laboratory biomarker analysis|Correlative studies
1888771|NCT01245231|Genetic|protein expression analysis|
1888772|NCT01245231|Genetic|western blotting|
1888773|NCT01245231|Other|flow cytometry|
1888774|NCT01245231|Other|laboratory biomarker analysis|
1888775|NCT01245231|Other|medical chart review|
1888776|NCT01245244|Drug|Morphine|Morphine oral mixture
1888777|NCT01245244|Other|orange juice|orange juice
1888778|NCT01245270|Dietary Supplement|Bilberry capsule first, then control cap|"Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).
Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
1889111|NCT01247935|Other|Transcutaneous electrical stimulation|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
1888779|NCT01245270|Dietary Supplement|Control capsule first then bilberry cap|"Male subjects aged >40 and <70 years, with type 2 diabetes controlling their diabetes by diet alone closely matched for adiposity as determined by waist circumference (n=8).
Volunteers will be randomised double blinded into two groups (n=4 per group) and given a single capsule of either 0.47 grams of a bilberry extract (mirtoselect provided by Indena S.p.A (http://www.mirtoselect.info/) or a control capsule. Following a two week wash out period the volunteers will be asked to take a second single capsule of either of 0.47 grams of mirtoselect or a control capsule in a cross over study, the opposite of what they took the first time."
1888780|NCT01245283|Other|normal activities and clinical care|Subjects will continue to participate in their normal activities and clinical care during the four month study. Telephone contact will be made weekly to encourage adherence to the knee management guidelines
1888781|NCT01245283|Other|Concentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
1888782|NCT01245283|Other|Eccentric Focused Resistance Exercise|Two resistance exercise sessions per week; 1 set of 10-12 repetitions of each exercise will be completed - leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, and calf press.
1888783|NCT01245296|Procedure|Timing of clamping the umbilical cord|The time passed after delivery until that the midwife stops circulation in the umbilical cord with a clamp.
1888784|NCT01245309|Procedure|scratching|endometrial scratching before COH in IVF
1888785|NCT01245309|Procedure|A PLACEBO PROCEDURE|A PLACEBO PROCEDURE
1888786|NCT01245322|Drug|lactobacilli|women were given a seven days course of daily 2% vaginal clindamycin cream (Dalacin vaginal cream 2%, Pfizer Norway Ltd) together with oral clindamycin 300 mg BID for 7 days (Dalacin 300 mg, Pfizer Norway Ltd). Oral clindamycin treatment was also given to the patient's sexual partner.
1888789|NCT01245348|Genetic|SULT4A1-1 genetic test|SULT4A1-1 haplotype result (+/-)
1888790|NCT01245361|Drug|Infliximab|Infliximab 3 mg/kg wk 0,2,6
1888791|NCT01245361|Drug|sodium chloride|Group II : Placebo wk 0,2,6
1888792|NCT01245374|Device|Norditropin NordiFlex®|Daily administration by a subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice
1888793|NCT01245387|Drug|Pegaptanib|Dosage recommendations for MACUGEN took place on the basis of the approved Summary of Product Characteristics (SmPC) and were adjusted solely according to medical practice. MACUGEN® is available as pre-filled syringe containing 0.3 mg MACUGEN® in 90 µL injection solution for intravitreal injection. Macugen injections were documented to reflect the routine clinical practice. Follow-up visits were only carried out and documented if they took place as part of the standard medical treatment for the respective case and were necessary for medical and/or therapeutic reasons.
1888794|NCT01245400|Device|Z-Lig|ACL replacement
1888795|NCT01245400|Device|allograft|ACL replacement
1888796|NCT01245413|Device|SenSura|Adhesive to stoma bag
1888797|NCT01245413|Device|Athena|Adhesive to stoma bag
1888803|NCT01245439|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
1888804|NCT01245452|Drug|Tocilizumab|Tocilizumab (8 mg/kg monthly from week 0 to 20)
1888805|NCT01245452|Drug|Methotrexate|MTX at a dose ranging from 10 mg/week at baseline to 20 mg/week at week 8
1888806|NCT01245465|Other|Profermin|Medical Food (food for special medical purposes)
1888807|NCT01245491|Other|Vibration|Whole-body vibration, 17 Hz, 1.1ms-2
1888808|NCT01245504|Other|Assessed for socket fit|Subjects are clinically assessed during standing to see how well computer manufactured sockets fit
1888810|NCT01245530|Drug|Aricept|Aricept Comparator Intervention: Drug: Aricept 5~10 mg orally every day for 24weeks
1888811|NCT01245530|Drug|INM-176|INM-176: Experimental Intervention: Drug:INM-176 600~1200 mg orally every day for 24weeks
1888812|NCT01245543|Drug|AC480IV|AC480IV will be administered as an infusion using a dose escalation design.
1888813|NCT01245543|Drug|Docetaxel|Docetaxel will be administered intravenously, initially as monotherapy and subsequently in combination with docetaxel immediately following AC480IV administration.
1888814|NCT01245556|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg, Q 12 h daily, Continuously
1888815|NCT01245556|Drug|BMS-908662|Capsules, Oral, escalating doses starting at 25 mg Q 12 h daily for 3 weeks with 3 weeks interval for 4 cycles, then Q12 h daily for 3 weeks every 12 weeks, Continuously
1888816|NCT01245556|Drug|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 3 weeks for 6 weeks, then once every 12 weeks, Continuously
1888817|NCT01245556|Drug|Ipilimumab|Vial, IV, escalating doses starting at 3 mg/kg, Once every 6 weeks for 4 cycles, then once every 12 weeks, Continuously
1888818|NCT01245569|Drug|Foster® 100/6 µg/unit dose|"Foster® (beclomethasone dipropionate 100 µg plus formoterol 6 µg/unit dose), 2 inhalations b.i.d. (daily dose of BDP extrafine 400 µg plus FF 24 µg)."
1888819|NCT01245569|Drug|Seretide Accuhaler® 500/50 µg/actuation|Seretide® Accuhaler® (fluticasone 500 μg plus salmeterol 50 μg/actuation), 1 inhalation b.i.d. (daily dose of fluticasone 1000 μg plus salmeterol 100 μg).
1888820|NCT01245582|Drug|oxaliplatin (SR96669)|"Pharmaceutical form:injection
Route of administration: intravenous"
1888821|NCT01245582|Drug|capecitabine|"Pharmaceutical form:tablet
Route of administration: oral"
1888822|NCT01245582|Drug|sorafenib|"Pharmaceutical form:tablet
Route of administration: oral"
1888823|NCT01245595|Drug|Aminophylline|5 mg/kg IV bolus then 1.8 mg/kg IV Q6 hours
1888824|NCT01245595|Drug|Placebo|Normal Saline
1888826|NCT01245621|Behavioral|Later entry group|"Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert Information (COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and
Comprehensive Palliative Care Team Assessment & Management Plan."
1888827|NCT01245621|Behavioral|Early palliative care intervention|"Advanced Practice Palliative Care Nurse Interventionist instituting a phone-based: a) Charting Your Course (CYC)-Patient Curriculum (6-session manualized); b) Creativity Optimism Planning Expert information(COPE) Caregiver Curriculum (3 session manualized) and c) ongoing contact as determined by the Palliative Care Team assessment/plan; and
Comprehensive Palliative Care Team Assessment & Management Plan."
1888828|NCT01245634|Drug|Placebo|iv infusion every 4 weeks, 32 weeks
1888829|NCT01245634|Drug|RO4905417|20 mg/kg iv infusion every 4 weeks, 32 weeks
1888830|NCT01245647|Drug|Naltrexone, 50mg, once per day for 4 months|Naltrexone: Two thirds of the total study participants will receive the medication naltrexone. Each study participant will take a single pill once a day for 4 months.
1888831|NCT01245647|Other|Sugar pill, 50mg, once per day for 4 months|Placebo: One third of the participants will receive placebo pills that look the same as the active comparator but are really just inert pills. Each study participant will take a single pill once a day for 4 months.
1888832|NCT01245660|Drug|LAPATINIB|Lapatinib, 1250 mg per day, per os, during 3 weeks +/- 5 days.
1888833|NCT01245673|Biological|Prevnar- Pneumococcal Conjugate Vaccine (PCV)|On day +2 all patients will receive ~ 5 x 10e10 costimulated T-cells which have been primed in vivo with MAGE-A3/ Hiltonol® and PCV.
1888834|NCT01245673|Other|Activated/costimulated autologous T-cell|For all patients, the cells will be expanded ex vivo for up to 12 days and then prepared for infusion ~day 2 post-transplant. The target number of costimulated T-cells for infusion will be ~ 5 x 10e10 T-cells total in 100-500 mL total volume. On the designated infusion date, the T-cells will be harvested.
1888835|NCT01245673|Drug|Lenalidomide|At about day 100 post-transplant, after completion of post-transplant immunological assessments and myeloma restaging studies, patients will be eligible to receive low-dose lenalidomide for maintenance therapy (10 mg/day) until progression of myeloma or development of intolerance.
1888836|NCT01245673|Biological|MAGE-A3, Hiltonol® (Poly-ICLC)|After study enrollment, patients will receive both MAGE-A3/GM-CSF [+ coinjection of 2mg of Hiltonol®(Poly-ICLC)]
1888837|NCT01245686|Behavioral|Lifestyle and medication intervention|The Heart to Health Intervention combines and enhances two previously tested interventions to reduce CVD risk (a counselor-based intervention to improve lifestyle and a web-based intervention to improve medication adherence). The new lifestyle and medication adherence intervention (delivered alternately in a one-on-one counseling or web-format) includes a decision aid on heart disease risk and risk-reducing options, general education on lifestyle and medication adherence, tips for overcoming barriers to CHD risk reduction, and goal setting and specification of first steps.
1888840|NCT01245725|Drug|Tirofiban (Aggrastat)|"Tirofiban (Aggrastat) will be dosed as a 25mcg/kg i.v. bolus followed by a 0.15mcg/kg/min i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.
Patients will receive tirofiban (Aggrastat) on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
1888841|NCT01245725|Drug|Placebo|"Placebo will be dosed as an i.v. bolus followed by an i.v. infusion during a percutaneous coronary intervention plus two hours after the procedure.
Patients will receive placebo on a background of oral anti-platelet agent(s) and either unfractionated heparin (50U/kg and repeat dosing guided per guidelines) or bivalirudin as per local practice and physician discretion."
1888842|NCT01245751|Biological|Zoster Vaccine, Live|Single approximately 0.65-mL subcutaneous injection of Zoster Vaccine, Live on Day 1 of the study
1888843|NCT01245764|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)|
1888844|NCT01245764|Biological|Placebo|
1888845|NCT01245777|Drug|ferric carboxymaltose|20 women with Restless Legs Syndrome (RLS) and iron deficiency and/ or anaemia in the third trimester of pregnancy will receive intravenous Ferric carboxymaltose in one or two single doses.
1888846|NCT01245790|Drug|fostamatinib|Oral tablets, single dose
1888847|NCT01245803|Drug|additional rosuvastatin loading|additional rosuvastatin (10mg p.o.)is given at 18 hours and 4-6 hours before PCI
1888848|NCT01245803|Drug|placebo control|sugar pill is given 18-24hr and 4-6hr before PCI as control
1888849|NCT01245816|Drug|Eflornithine plus Sulindac|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Sulindac, 150 mg tablet, one tablet orally once a day
1888850|NCT01245816|Drug|Eflornithine plus Placebo|Eflornithine, 250 mg tablet, two tablets (500 mg) orally once a day; Placebo, one tablet orally once a day
1888851|NCT01245816|Drug|Sulindac plus Placebo|Sulindac, 150 mg tablet, one tablet orally once a day; Placebo, two tablets orally once a day
1888852|NCT01245829|Other|Swabbing of observation chart|The observation charts to be studied will be stored on the DMH critical care unit and all existing non-laminated white charts removed for the duration of the study period. The observation charts will thereafter be used in the normal way as defined by nursing practice; blue charts from patient admission (irrespective of time) and white charts for each 24 hour period thereafter commencing at 8 am. On placement and after 24 hours of use, a standardised section of the patient observation area will be swabbed by the data collection researcher. The standardised area is defined as the section of the chart that is most comprehensively completed during the patient episode and is therefore most likely to become contaminated through contact. Use of white charts only is required in order to standardise the length of time each chart is in place between the two points of swabbing (white charts present at 8 am have been in use for exactly 24 hours).
1888894|NCT01246219|Drug|1 year treatment with placebo followed by optional 3 years of GH treatment|1 year treatment with placebo followed by optional 3 years of GH treatment
1889312|NCT01249443|Other|pharmacological study|Correlative studies
1888853|NCT01245842|Other|Hand exercise program|Hand exercise program three times/week for 12 weeks. In total four group sessions, otherwise home based. Weekly telephone calls from experienced physiotherapist/occupational therapist addressing adjustments of the exercise program and encouragement of program adherence.
1888854|NCT01245855|Drug|lipo-PGE1|those in the PGE1 group received additional 20 micrograms/day of lipo-PGE1 intravenously, starting at least 24 hours before PCI and continuing for 5 days
1888855|NCT01245868|Drug|Lidocaine|
1888856|NCT01245868|Drug|bupivacaine|
1888857|NCT01245881|Device|Non-ablative fractional photothermolysis laser|"Wavelength: 1,550 nm;
Energy: 15 mJ/MTZ;
Total coverage: 20%;
Total density: 1,048 MTZs/cm2;
Density per pass: 131 MTZ/cm2;
Number of passes: 8."
1888858|NCT01245881|Other|broad-spectrum sunblock (SPF 50+)|
1888859|NCT01245894|Drug|Low-dose Rosuvastatin|Rosuvastatin 5mg/day for one year
1888860|NCT01245894|Drug|High-dose Rosuvastatin|Rosuvastatin 40mg/day for one year
1888861|NCT01245907|Behavioral|Applied relaxation|Applied relaxation given by Internet during 10 weeks as a number of text-documents, audio-files and e-mail mediated support from therapists
1888862|NCT01245920|Biological|DFDBA + Bio-Gide Membrane|For patients in the FDBA + membrane group, a layer 4 mm thick of cancellous allograft bone (Puros Cancellous, Zimmer Dental inc., Carlsbad, CA) will be placed over the buccal bone in the area of the implant. A resorbable collagen membrane (Bio-Gide, 13 x 25 mm, Osteohealth, Shirley, NY) will be trimmed to extend 5 mm beyond the implant borders and to cover the implant head. Following membrane placement over the bone graft, the gingival flaps will be closed and sutured with 4-0 Vicryl (Ethicon Inc., Sommerville, NJ) with passive tension flap closure.
1888863|NCT01245920|Other|Non-FDBA|Patients in the non-FDBA group will have gingival flaps closed with the same suturing technique.
1888864|NCT01245946|Procedure|Photodynamic therapy|Photodynamic therapy: 2 sessions separated by 2 weeks of TDF with topical ALA20% for 1.5 hrs, then irradiated with red light (Waldmann lamp) at a fluence of 37 J/cm2 for 7-9 minutes. From the sixth week will begin adapalene 0.1% gel until 12 weeks
1888865|NCT01245946|Drug|Conventional therapy|Conventional therapy: Topical adapalene gel 0.1% at night for 12 weeks plus doxycycline 100 mg / day for 6 weeks.
1888866|NCT01245959|Drug|Docetaxel, cisplatin and fluorouracil|Patients receive docetaxel (60mg/m2 on day 1), cisplatin (60mg/m2 on day 1) and fluorouracil (600mg/m2 on Days 1 to 5) every three weeks for three cycles before the radiotherapy.
1888867|NCT01245959|Radiation|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
1888868|NCT01245972|Procedure|PDL Treatment|Pulsed-dye laser (PDL) treatment at one of two settings.
1888869|NCT01245985|Radiation|carbon ion boost|patients receive induction chemotherapy with TPF for a maximum of 3 cycles followed by radioimmunotherapy with cetuximab as intensity-modulated radiotherapy (IMRT) plus carbon ion boost
1888870|NCT01245998|Drug|Dalteparin|dalteparin 5000 I.U./24 h s.c. for 6 weeks
1888871|NCT01245998|Drug|Dalteparin|dalteparin 15000 I.U./24 h s.c. for 6 weeks
1888872|NCT01246011|Drug|Argatroban and warfarin|Subjects with the presence of heparin PF4 antibodies without signs or symptoms of HIT post CABG will be randomized to receive argatroban and warfarin or no drug for one month.
1888873|NCT01246024|Device|ERG|scotopic and photopic ERG
1888874|NCT01246037|Drug|Bisoprolol|In the first 4 months of study, the dose of the drug will be gradually increased; the titration scheme is based on the 'farmacotherapeutisch kompas' and monitored according to the ACC/AHA/ESC guidelines. Up titration will be performed under the responsibilities of an experienced heart failure cardiologist and pulmonologist.
1888878|NCT01246063|Drug|carfilzomib|
1888879|NCT01246063|Drug|pegylated liposomal doxorubicin (PLD)|
1888880|NCT01246063|Drug|Dexamethasone|
1888881|NCT01246076|Drug|Lenalidomide|
1888882|NCT01246089|Drug|ranibizumab injection|Ranibizumab intravitreal injection of 0,5 mg ( 0.05mL)
1888884|NCT01246154|Other|EXERCISE TRAINING|EXERCISE TRAINING
1888885|NCT01246167|Device|Philos|"Conservative treatment versus Philos locking plate in 2 part fracture group.
Conservative treatment versus Philos locking plating versus Epoca prosthesis in MFF group."
1888886|NCT01246167|Device|Epoca|Conservative treatment versus Philos locking plate versus Epoca fracture prosthesis in MFF group
1888887|NCT01246167|Other|Control group|Conservative control group
1888888|NCT01246180|Drug|Diclofenac|diclofenac 5% vs placebo (topical application) cutaneous blood flow measurement using laser Doppler
1888889|NCT01246180|Drug|Amiloride|amiloride 1mM vs placebo (intradermal injection) cutaneous blood flow measurement using laser Doppler
1888890|NCT01246193|Drug|CKD-828(FDC)|Drug: Telmisartan 80mg + S-Amlodipine 2.5mg(FDC) Tablet, Oral, Once Daily
1888891|NCT01246193|Drug|Combination Therapy|"Drug: Telmisatan 80mg Tablet, Oral, Once Daily
Drug: S-Amlodipine 2.5mg Tablet, Oral, Once Daily"
1888892|NCT01246206|Drug|Tacrolimus and Thymoglobulin|"Intravenous Tacrolimus 0.03 mg/kg/d, beginning day -3, where day 0 is the day of stem cell infusion or transplant. Intravenous tacrolimus will be discontinued once the participant starts eating, and the drug will then be given orally at a dose of approximately 4 times the intravenous dose. Tacrolimus will be discontinued starting 100 days after transplant unless signs of acute and chronic GVHD develop or if severe toxicity occurs. Thymoglobulin will be given 0.5 mg/kg day-3, Thymoglobulin 1.5 mg/kg day -2, Thymoglobulin 2.5 mg/kg day -1. Thymoglobulin will be given intravenously over 6 hours."
1888893|NCT01246219|Drug|GH treatment (Genotropin)|4 years treatment with GH
1889313|NCT01249443|Drug|carboplatin|Given IV
1992922|NCT03275285|Drug|isatuximab SAR650984|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1992923|NCT03275285|Drug|carfilzomib|"Pharmaceutical form: solution for infusion
Route of administration: intravenous"
1992924|NCT03275285|Drug|dexamethasone|"Pharmaceutical form: tablets or solution for infusion
Route of administration: oral or intravenous"
1994076|NCT03072706|Device|Corin OPS™|The OPS Dynamic Hip Analysis is a computer software package used to generate simulations of a total joint replacement from patient imaging. The dynamic simulation is used for operative planning, including implant selection, sizing and placement; and to create custom instruments or delivery specifications referencing the patient's anatomy and bio-mechanics. The simulation can also be used for the post-operative evaluation of joint performance.
1888895|NCT01246232|Drug|Amisulpride|Clozapine augmentation with another second-generation antipsychotic, amisulpride (400mg amisulpride for the first 4 weeks, then the option of titrating up to 800mg amisulpride for the remaining 8 weeks).
1888896|NCT01246232|Drug|placebo|Clozapine augmentation with 1 capsule placebo for the first 4 weeks, then the option of titrating up to 2 capsules placebo for the remaining 8 weeks).
1888897|NCT01246258|Other|Vestibular evoked myogenic potentials (VEMPs)|Standard test of balance function
1888898|NCT01246258|Other|Utricular centrifugation test|Standard test of balance function
1888899|NCT01246284|Drug|Triamcinolone acetonide|Injections will be given within a 3 cm2 area of alopecia which will be divided into 4 quadrants. Three different concentrations of triamcinolone acetonide will be used: 2.5, 5, and 10 mg/ml. Each quadrant will receive injections with either triamcinolone acetonide 2.5 mg/ml, triamcinolone acetonide 5 mg/ml, triamcinolone acetonide 10 mg/ml, or normal saline as a control. Injection of 0.1 ml will be given intradermally using a 30 gauge half inch long needle attached to a 3 ml syringe. Each quadrant will receive approximately 7 injections per treatment session so the total dose of triamcinolone acetonide will be around 13 mg. Injections will be given vertically, with the beveled side of the needle directed to the opposite side and 2 mm away from the margin of the adjacent quadrant to avoid a diffusion effect. The treatment will be repeated every 4 to 6 weeks for a total of 6 treatment sessions.
1888900|NCT01246284|Other|Normal saline|
1888901|NCT01246297|Other|Pulmonary Rehabilitation|Twice weekly exercise classes with an education component. For 8 weeks.
1888902|NCT01246297|Other|Usual post operative care|Usual post operative care for post lung lobectomy patients for 8 weeks post discharge.
1888903|NCT01246310|Dietary Supplement|Inositol|
1888904|NCT01246310|Dietary Supplement|Placebo|
1888905|NCT01246323|Procedure|Spinal anesthesia with Fentanyl+ Morphine|Fentanyl 15 microgram Morphine 0.1-0.5 mg
1888907|NCT01246349|Behavioral|Motivational Interviewing (Treatment Group)|Motivational interviewing (MI) can be defined as a client-centered, directive method of therapy for enhancing intrinsic motivation to change by exploring and resolving ambivalence (Miller and Rollnick, 2002). MI manifests through specific strategies, such as reflective listening, summarization, shared decision making, and agenda setting.
1888908|NCT01246349|Behavioral|Social Skills Training (Control Group)|Within the social skills training framework, advice is given to clients and sessions are focused on assigning goals for clients to work towards without specific regard for their readiness to change. The intervention is aimed at finding appropriate ways to navigate typical social situations (e.g., how to negotiate with parents).
1888909|NCT01246362|Drug|Control|Given placebo
1888910|NCT01246362|Drug|Etoricoxib|Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
1888911|NCT01246375|Device|Dual energy X-ray absorptiometry|Device which measures bone density
1888912|NCT01239043|Biological|Menomune®: A, C, Y, W 135 Meningococcal Polysaccharide|0.5 mL, Subcutaneous
1888913|NCT01239043|Biological|Menactra®: Meningococcal (A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1888914|NCT01239056|Procedure|Endoscopy|Endoscopic drainage of a pancreatic pseudocyst using a metal stent per medical indication.
1994077|NCT03072706|Other|2D X-ray templating technology|Standard care where hip replacement is planned using 2D X-ray templating software
1888918|NCT01239082|Procedure|Colonoscopy|One time screening Colonoscopy to screen for colorectal cancer
1888919|NCT01239082|Procedure|FIT|Annual FIT testing
1888920|NCT01239095|Drug|Green Tea and Milk Thistle Supplements|Green Tea Extract: 3,200 mg per day Milk thistle extract with phosphatidylcholine: 2,700 mg per day
1888921|NCT01239108|Drug|SGI-1776|SGI-1776 will be administered orally at escalating dose levels ranging from 350 to 1600 mg/day based on the dose escalation levels of the ongoing, first-in-human study.
1888922|NCT01239121|Other|HIE-Enhanced Medication Reconciliation|Medication reconciliation enhanced by regional health information exchange, implemented by a pharmacist
1888923|NCT01239121|Other|Optimal Medication Reconciliation without HIE|Medication reconciliation implemented by a pharmacist without regional health information exchange
1888924|NCT01239134|Biological|TRX518|Humanized, Fc disabled, anti-human GITR (glucocorticoid-induced tumor necrosis factor receptor) monoclonal antibody
1888925|NCT01239147|Other|Diet rich in whole grain|Ready-to-eat breakfast cereals and other cereal products, rich in whole grain
1888926|NCT01239147|Other|Refined grain|Ready-to-eat breakfast cereals and other cereal products, low in whole grain
1888927|NCT01239160|Device|Flexitouch System|"A segmental, programmable, gradient pneumatic compression device. It consists of a controller and garment set. The garments are constructed of nylon and have 27-32 chambers, depending upon garment size. The pressure setting is variable between normal and increased. The device is intended to be used for 60 minutes per day"
1888928|NCT01239160|Device|Hydroven FPR|The FH is an intermittent sequential external pneumatic compression system. The garment contains 3 compression chambers. The pressure range of the compressor device is 30-100 mmHg. It is intended to be used for 60 minutes per day.
1888929|NCT01239173|Drug|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
1888930|NCT01239173|Drug|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
1888931|NCT01239173|Drug|AVLOCARDYL|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
1888932|NCT01239173|Drug|Placebo|A grip of 2 tablets of 20 mg each took 90 min before the emotional memory reactivation and the anatomical and functional exploration in fMRI
1888933|NCT01239186|Other|methylation analyses on spermatozoa from infertile men|microarray analysis(www.EPIGENOMICS.com)
1888934|NCT01239199|Other|Measure of the exhaled NO|The exhaled NO will be measure by chemiluminescence in current ventilation by an indirect method (off-line)
1888935|NCT01239212|Drug|levetiracetam|50 mg/kg single loading dose of IV levetiracetam
1888936|NCT01239225|Device|Abdominal ultra-sound|
1888937|NCT01239225|Procedure|Abdominal ultrasound|
1888938|NCT01239251|Other|GlowCap device|Participants will be provided with a device called the GlowCap for a period of 30 days. The device has visual and auditory cues to help patients remember to take their medication at the same time each day. The GlowCap will be programmed to glow when it is time for each patient to take her medication. The GlowCap will initially glow bright orange for the first hour from the time the patient is scheduled to take the medication. During the second hour, the GlowCap system will play music in addition to continuing to glow. If after 2 hours the patient still has not opened the medication bottle, she will receive a phone call reminding her to take her medication.
1888939|NCT01239277|Other|protein|20g protein
1888940|NCT01239277|Other|protein and carbohydrate|20g protein and 20g carbohydrate
1888941|NCT01239277|Other|protein and leucine|20g protein, 2.5g leucine
1888942|NCT01239303|Dietary Supplement|Citrulline|single dose
1888943|NCT01239303|Dietary Supplement|alanine|single dose
1888944|NCT01239316|Other|Laboratory Biomarker Analysis|Correlative studies
1888945|NCT01239316|Other|Pharmacological Study|Correlative studies
1888946|NCT01239316|Drug|Vismodegib|Given PO
1888947|NCT01239342|Drug|Akt Inhibitor MK2206|200 mg Given PO once weekly
1888948|NCT01239342|Drug|Everolimus|10 mg Given PO daily
1888949|NCT01239342|Other|Laboratory Biomarker Analysis|Optional correlative studies
1888950|NCT01239355|Drug|Akt Inhibitor MK2206|Given PO
1888951|NCT01239355|Other|Laboratory Biomarker Analysis|Correlative studies
1888955|NCT01239381|Radiation|Stereotactic body radiotherapy-proton|Dose will be determined by the size and location of the tumor(s); 2-3 treatments per week for two weeks
1888957|NCT01239407|Behavioral|Culturally focused psychiatric consultation|"The consultation is comprised of 3 visits:
1a. Psychiatric diagnostic interview, self-rated questionnaires (in-person consultation).
1b. Intervention focused on learning about depression and how to treat it using culturally relevant resources.
2. Follow-up visit two weeks later to go over patients' questions, homework if applicable, and patients' ability to meet the goals outlined in the first visit (in-person or phone visit).
3. 6-month follow up: 6 months after the initial consultation, patients are asked about mental health symptoms and mental health treatment they might be receiving (phone visit unless patient requests in-person)."
1888958|NCT01239446|Other|Not relevant (there is no intervention in the present study)|Not relevant (there is no intervention in the present study)
1888959|NCT01239459|Drug|Teriflunomide HMR1726|"Pharmaceutical form:film coated tablet
Route of administration: oral administration on Day 1 under fasted condition"
1888960|NCT01239459|Drug|Cholestyramine|"Pharmaceutical form:powder
Route of administration: oral administration 3 times per day on Day 54 and 55"
1888961|NCT01239472|Drug|everolimus|Kidney transplant patients with living donors starting with the use of tacrolimus, mycophenolate sodium and prednisone without induction, and converted for use of mycophenolate sodium, everolimus, and prednisone after 90 days of kidney transplantation.
1888962|NCT01239485|Drug|Irinotecan|"Chemotherapy: irinotecan, etoposide, and cytarabine daily for 5 days (on days 0, 1, 2, 3, & 4) -30 min: Atropin ivs 0 hour: irinotecan X mg/m2 in D5W 100 mL IV over 60 min 0 hour: etoposide 100 mg/m2 in x3 N/S mL IV over 60 min 12 hour: cytarabine 2,000 mg/m2 over 3 hr
*if age ≤ 3 yrs: calculate all drugs in kg base (30kg=1m2) Irinotecan dose is escalated by 25-30% in successive cohorts. The starting irinotecan dose (level 1) is 20 mg/m2/dose on days 0 to 4."
1888963|NCT01239498|Procedure|Injection of Saline + Lidocaine/Adrenaline|"All anaesthetic injections will consist of xylocaine 1% with 1:100,000 adrenaline and will be administered through a short 30 Gauge needle at a constant slow speed at multiple (6-7) sites along the upper lid by a single oculoplastic consultant.
The experimental eyelid will receive a saline-consisted injection 0.5cc prior to the administration of the anesthetic injection.
Injection of Saline + Lidocaine 1%"
1888964|NCT01239498|Procedure|Lidocaine/Adrenaline only|Injection of Lidocaine/Adrenaline only
1888965|NCT01239511|Drug|green tea polyphenols (STA-2)|2 capsules t.i.d., after meal
1888966|NCT01239524|Procedure|denervation of thoracodorsal nerve or saving the nerve|
1888967|NCT01239537|Drug|Seasonal Flu vaccine|1 dose of seasonal trivalent flu vaccine (Fluarix)
1888968|NCT01239550|Drug|Detemir|"Subjects randomized to insulin detemir treatment group will receive the basal insulin in a 3 mL. Flex Pen® containing 300 units of insulin. insulin detemir once daily administered with the evening meal (dinner) or at bedtime as add-on to their oral antihyperglycemia (see inclusion/exclusion criteria) meds throughout the 24 week treatment period. The goal of insulin therapy is to achieve near normoglycemia with a low rate of hypoglycaemic episodes.
Insulin injections will be given subcutaneously preferably in the thigh or abdomen."
1888969|NCT01246401|Drug|Extended-Release Naltrexone|Extended-Release Naltrexone (Vivitrol), once a month by IM injection, for a total of 6 months. Dosage is 380mg
1888970|NCT01246427|Drug|BRN01|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
1888971|NCT01246427|Drug|Placebo|2 tablets every morning and every evening during 8 to 10 weeks. Each patient will receive 1 set of 5 treatment boxes (60 tablets/box).
1888972|NCT01246440|Drug|Catumaxomab|Catumaxomab: 4 intraperitoneal infusions of catumaxomab over 11 days administered in a period of 3 hours through an intraperitoneal catheter with the following dosage: 1) 10 µg on Day 0. 2) 20 µg on Day 3. 3) 50 µg on Day 7. 4) 200 µg on Day 10.
1888973|NCT01246453|Drug|Intrapleurally Alteplase vs Intrapleurally Urokinase|Alteplase 10 mg and urokinase 100000 intrapleurally administered, once daily for three days and if necessary 6 days
1888974|NCT01246466|Device|Hybrid ablation procedure|AtriCure Bipolar System plus a catheter ablation
1888975|NCT01246479|Procedure|Blood draw|blood draw at Month 12, Month 24 and Month 36.
1889065|NCT01247688|Drug|Cytoxan|50 mg/kg/dose will be given IV on day -5,-4, -3, -2 over 1 hour. The total dose to be given over 4 days is 200 mg/kg.
1888976|NCT01246479|Biological|IC51 has given in the parent study IC51-322|No more vaccinations in IC51-324 since this a study for long-term follow-up on safety and immunogenicity after vaccinations in parent study IC51-322.
1888977|NCT01246492|Dietary Supplement|Artificial Sweeteners|A 400mL drink sweetened with 45g glucose and artificial sweetener will be consumed orally
1888978|NCT01246505|Device|CTO Crossing and Percutaneous transluminal angioplasty|Crossing of the CTO with the BridgePoint Medical System and subsequent treatment of the CTO via PTA (specific devices to be used for PTA at investigators' discretion)
1888979|NCT01246518|Drug|MOB015|Arm 1; MOB015 once a day for 3 months. Arm 2; MOB015 once a day for 9 months.
1888980|NCT01246557|Drug|Lenalidomide|"Lenalidomide - Revlimid®: an analogue of thalidomide, is an immunomodulator agent with anti-angiogenic properties. The chemical name is 3-(4 ́-aminoisoindoline-1 ́ona)-1- piperidine-2,6-dione.
REVLIMID® (lenalidomide) is available in capsules of 5 mg, 10 mg and 15 mg p.o.. Each capsule contains lenalidomide as active ingredient and the following non active ingredients: anhydrous lactose, microcrystalline cellulose, sodium croscarmellose and magnesium stearate."
1888981|NCT01246557|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/day (on days 1 to 4) for oral administration.
1888982|NCT01246570|Behavioral|Exercise training|The patients will meet for organized exercise training once monthly and also exercise testing every third month.
1888983|NCT01246570|Other|Control|The patients will receive the usual care provided by the hospitals and the community health services
1888984|NCT01246583|Drug|CP-690,550 Ointment 1|2% CP-690,550 Ointment 1 twice daily for 4 weeks
1888985|NCT01246583|Drug|Vehicle 1|Vehicle 1 twice daily for 4 weeks
1888986|NCT01246583|Drug|CP-690,550 Ointment 2|2% CP-690,550 Ointment 2 twice daily for 4 weeks
1888987|NCT01246583|Drug|Vehicle 2|Vehicle 2 twice daily for 4 weeks
1888988|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus,[1] thus helping to establish a periodontium that is free of disease.[2]
1888989|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
1888990|NCT01246596|Procedure|dental root planing|The objective of root planing, otherwise known as conventional periodontal therapy, non-surgical periodontal therapy, or dental prophylaxis is to remove or eliminate the etiologic agents which cause inflammation: dental plaque, its products and calculus, thus helping to establish a periodontium that is free of disease.
1888991|NCT01246622|Drug|cytarabine|Given IV
1888992|NCT01246622|Drug|lenalidomide|Given PO
1888993|NCT01246635|Device|Trufit CB (Cartilage Bone) Implant|Implantation of 5,7, 9, or 11 mm Trufit CB Implants for small cartilage lesions. A maximum of two Trufit CB plugs may be implanted.
1888994|NCT01246635|Procedure|Microfracture if the knee|Creation of small holes through subchondral bone with the goal of stimulating cartilage growth
1888995|NCT01246648|Procedure|Biopsy|dental extraction and gingival epithelial biopsy
1888996|NCT01246648|Procedure|biopsy|dental extraction and gingival epithelial biopsy
1888997|NCT01246648|Procedure|Biopsy|dental extraction and gingival epithelial biopsy
1888998|NCT01246687|Behavioral|e-Intervention|Dietary educational programme developed using Transtheoretical Model of Change and delivered via a website specific for Type 2 Diabetes patients.
1888999|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.
Group A received SAFEx for 12 weeks then received no treatment for 12 weeks."
1889000|NCT01246700|Other|Sensory Attention Focused Exercise (SAFEx)|"Consisted of 12 weeks for SAFEx intervention, 3 times a week for an hour each session. Participants complete dynamic balance activities and a variety of seated stretches and range of motion activities. Participants are cued to focus on sensation and proprioception of limbs.
Group B received no treatment for 12 weeks, then received SAFEx for 12 weeks."
1889001|NCT01246713|Drug|Acetaminophen liquid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
1889002|NCT01246713|Drug|Acetaminophen solid formulation|Subjects in this arm will receive a 15mg/kg dose of a solid acetaminophen formulation.
1889003|NCT01246726|Procedure|CT SCAN|Prior to radiotherapy + after radiotherapy completion
1889004|NCT01246726|Procedure|MRI scan|Prior to radiotherapy + after completion of radiotherapy
1889005|NCT01246726|Procedure|3D Ultrasound scan|Prior to radiotherapy + after completion of radiotherapy
1889006|NCT01247181|Other|Mobile phone text message|Weekly message with motivational content
1889007|NCT01247181|Other|Usual care|Usual care provided at clinic
1889008|NCT01247194|Drug|PPI-461|capsule, oral, once daily for 3 days
1889009|NCT01247194|Drug|Placebo|capsules, oral, once daily for 3 days
1889010|NCT01247207|Drug|Ataluren|Oral powder for suspension taken 3 times per day (10 mg/kg in the morning, 10 mg/kg at mid-day, and 20mg/kg in the evening).
1889011|NCT01247220|Drug|Ranibizumab|Intravitreal Ranibizumab 0.5 mg
1889012|NCT01247220|Procedure|Peripheral Laser|Angiography-directed peripheral laser
1889013|NCT01247233|Radiation|Whole Breast Irradiation + Boost or Hypofractionated irradiation|Whole Breast Irradiation 50Gy + Boost 16 Gy or Whole breast, either 40Gy in 15 fractions in 3 weeks or 42,5Gy in 16 fractions in 3 weeks
1889014|NCT01247233|Radiation|Accelerated partial breast irradiation|Tumor bed 40Gy in 10 fractions, 2 fractions of 4Gy per day in 5 to 7 days.
1889015|NCT01247246|Drug|SCV-07|clinical trial material; (placebo or SCV 07) at doses of 0 (placebo), 0.1, 0.3, and 1.0 mg/kg will be administered sc
1889016|NCT01247246|Drug|Placebo|Placebo
1889066|NCT01247688|Drug|Fludarabine|40mg/m2/day will be given IV over 1 hour on day -4, -3, -2
1889067|NCT01247688|Radiation|Total Body Irradiation (TBI)|1.75Gy/fraction will be given on day -9, -8, -7, -6
1889017|NCT01247259|Drug|Pangramin®|During a 4-week increasing-dose phase, the patients increased the daily dose from 1 to 5 drops of 1.6 STU/mL solution from day 1 to 10, 1 to 5 drops of 8 STU/mL solution from day 11 to 15, 1 to 5 drops of 40 STU/mL solution from day 16 to 20, 1 to 5 drops of 200 STU/mL solution from day 21 to 25, and 1 to 5 drops of 1000 STU/mL solution from day 26 to 30. After reaching the maintenance dose, 5 drops of 1000 STU/mL solution, the patients took the allergen three times per week during the maintenance phase.
1889018|NCT01247272|Drug|Fluoxetine Hydrochloride|90 mg Capsules
1889019|NCT01247272|Drug|PROZAC WEEKLY®|90 mg Capsules
1889020|NCT01247285|Drug|Fluoxetine Hydrochloride|90 mg Capsules
1889021|NCT01247285|Drug|PROZAC WEEKLY®|90 mg Capsules
1889022|NCT01247298|Combination Product|Stereotactic Body Radiation Therapy (SBRT)|This investigational study will evaluate the combination of TACE along with high dose SBRT. TACE has been used extensively in the palliative treatment of hepatocellular carcinoma (HCC). It will be performed by the Interventional Radiologist prior to radiation therapy.
1889023|NCT01247311|Dietary Supplement|Dietary supplement|Placebo given orally 3xweek for six months
1889024|NCT01247311|Dietary Supplement|Vitamin D|5000 IU vitamin D given orally 3xweek for six months
1889025|NCT01247311|Dietary Supplement|Vitamin D|0.5ug 1,25 vitamin D given orally 3xweek for six months
1889030|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine, cetuximab|Intrahepatic oxaliplatin
1889031|NCT01247337|Drug|Oxaliplatin, capecitabine, gemcitabine cetuximab|Oxaliplatin given intravenous
1994078|NCT03072862|Device|Commercial Nucleus Cochlear Implant Systems|Commercially available Nucleus Cochlear Implant Systems, including Data Logging functionality
1889034|NCT01247363|Drug|LY2608204|Administered orally.
1889035|NCT01247376|Device|Cooling and compression|Cooling and compression of the knee postoperatively with an Aircast device.
1889036|NCT01247389|Procedure|laparoscopic colectomy|Laparoscopic segmental colectomy with planned abdominal extraction site
1889037|NCT01247402|Device|drug eluting balloon angioplasty|3 microgram Paclitaxel/mm2 on balloon, 60s application
1889038|NCT01247402|Device|standard balloon angioplasty|standard balloon angioplasty
1889039|NCT01247428|Device|MiStent SES|The MiStent SES is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
1889040|NCT01247441|Other|Clinical data|
1889041|NCT01247454|Behavioral|academic detailing|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is turned off. Providers receive academic detailing.
1889042|NCT01247454|Behavioral|Electronic Health Record (EHR) prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease.
1889043|NCT01247454|Behavioral|EHR prompt and patient prompt|EHR message that encourages providers to consider ASA therapy for patients at high-risk for developing cardiovascular disease is replaced with a message asking providers to consider terminating aspirin in patients who do not have appropriate cardiovascular disease. And a brief information sheet is distributed to patients prior to their visit asking them to discuss ASA therapy for primary prevention with their provider.
1889044|NCT01247467|Other|Breast Tumor Blocks|
1889045|NCT01247493|Drug|induction chemotherapy (fludarabine, cytarabine, idarubicin)|fludarabine, cytarabine, idarubicin
1889046|NCT01247519|Other|Post-hospitalization care|Post-hospitalization care included telephone call contact for caring after discharge, for opening for question, and for health education.
1889047|NCT01247532|Behavioral|Mindfulness-Based Stress Reduction - Cancer-Related Fatigue|7 week 2 hour class
1889048|NCT01247545|Procedure|Remote ischaemic preconditioning|Blood pressure cuff placed on upper arm and inflated to 200mmHg for 5 minutes then deflated for 5 minutes - this cycle is repeated a total of 4 times.
1889049|NCT01247545|Procedure|Control|Control treatment (sham RIC) will consist of four 5-minute simulated inflations of a blood pressure cuff placed on the upper arm. The inflations will be separated by 5-minute periods when the blood pressure cuff will be deflated.
1889050|NCT01247558|Other|Metanx® (a medical food)|Patient cohort compliant on Metanx® BID therapy for >120 days
1889051|NCT01247558|Other|Not treated with Metanx®|Non-treated comparative cohort
1889052|NCT01247571|Drug|Pazopanib Hydrochloride|Given PO
1889053|NCT01247584|Genetic|DNA analysis|
1889054|NCT01247584|Genetic|mutation analysis|
1889055|NCT01247584|Genetic|polymerase chain reaction|
1889056|NCT01247584|Other|laboratory biomarker analysis|
1889057|NCT01247623|Biological|GV1001|
1889058|NCT01247636|Other|Balance- training and home-exercise|Balance-training admitted at the geriatric hospital Home-exercise or advice to be generally active
1889059|NCT01247636|Other|Balance-training and home-exercise|The aim of the intervention was to enhance health-related quality of life, self-efficacy and physical function through education and exercise. The education program consisted of information given both oral and in writing regarding the benefits of physical activity. The aim was to increase the participants knowledge about the benefits of physical activity and to stimulate them to integrate physical activity into their immediate environment during daily routines. They were given an exercise-log and were advised to write down all their daily activities and exercise. The exercise program were conducted 2 times per week for 45 min per session. The content of these sessions were balance training with main focus on balance-exercises considered essential for daily living.
1889060|NCT01247649|Device|Physical Logic Continuous Glucose Monitoring System|Patients will be monitored to assess continuous blood glucose levels using the study device (Physical Logic) and reference methods, during 2-3 clinic visits, lasting 6-8 hours each
1889061|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
1889062|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
1889063|NCT01247675|Drug|ACP-001 (TransCon hGH)|s.c., weekly injection
1889064|NCT01247675|Drug|Omnitrope|s.c., daily injection
1889069|NCT01247701|Drug|Busulfan|Busulfan dosing will be as follows: Patients < 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients > 12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses. It will be given on Days -9, -8, -7 and -6.
1889070|NCT01247701|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours. The total dose to be given over 4 days is 200 mg/kg.
1889071|NCT01247701|Drug|Fludarabine|Fludarabine 40 mg/m^2 will be given IV daily over 1 hour on Days -3, -2 and -1.
1889072|NCT01247701|Procedure|Cord Blood Stem Cell Infusion|The cord blood stem cells will be infused on Day 0.
1889073|NCT01247714|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
1889074|NCT01247714|Dietary Supplement|T-Diet plus Diabet NP|T-Diet plus Diabet NP is a complete balanced oral nutrition supplement, indicated for the dietary management of diabetic patients or hyperglycemia related malnutrition.
1889075|NCT01247714|Dietary Supplement|Glucerna|GLUCERNA 1.0 CAL is a reduced-carbohydrate, modified-fat, fiber-containing formula clinically shown to blunt blood-glucose response in patients with abnormal glucose tolerance.
1889076|NCT01247714|Dietary Supplement|Novasource|Complete high protein diet for diabetic patients and hyperglycemic
1889077|NCT01247740|Drug|NuTRIflex Lipid peri|parenteral nutrition
1889078|NCT01247740|Drug|compounded monobag|parenteral nutrition
1889079|NCT01247753|Behavioral|Walking group|Internet-mediated pedometer-based walking program with gradually increasing step count goals and feedback on step counts. Also includes nutritional coaching course consisting of 1 individual session with a dietician, 4 group sessions, and monthly follow-up. Oral glucose tolerance tests pre and post-intervention.
1889080|NCT01247779|Procedure|gynecologic surgery - standard coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
1889081|NCT01247779|Procedure|gynecologic surgery - robot assisted coelioscopy|lymphadenectomy; hysterectomy; nerve sparing; enlarged trachelectomy; omentectomy; appendicectomy; pelvectomy
1889082|NCT01247792|Behavioral|SOPs for decision-making and communication|Development and implementation of SOPs for timely and interdisciplinary EOL-decisionmaking and a communication strategy with relatives which addresses participants, set-up, time-points, and content
1889083|NCT01247805|Drug|sildenafil citrate|Single oral dose of 1 x 20 mg IR oral tablet.
1889084|NCT01247805|Drug|Sildenafil citrate|single oral dose of 2 x 10 mg sildenafil citrate IR oral tablet.
1889085|NCT01247805|Drug|sildenafil citrate|single oral dose of 2 mL of the 10 mg/mL sildenafil citrate POS (20 mg dose).
1889086|NCT01247818|Drug|PH-10 (0.002% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
1889087|NCT01247818|Drug|PH-10 (0.005% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
1889088|NCT01247818|Drug|PH-10 (0.01% Rose Bengal)|PH-10 will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
1889089|NCT01247818|Drug|Vehicle|PH-10 vehicle will be applied daily for 28 days to skin areas affected by mild to moderate psoriasis.
1889090|NCT01247831|Procedure|Selective Laser Trabeculoplasty|100 spots with an energy of 0,8 mJ are applied over 360° of the trabecular meshwork of glaucoma patients with a Q-switched 532 nm frequency doubled neodymium YAG Laser.
1889091|NCT01247844|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. The man must return to the clinic for device removal. To remove the device, the outer ring locking mechanism is broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
1889092|NCT01247857|Drug|Ropivacaine 30 mg|"Intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) before surgery and intraperitoneal nebulization of normal saline 3 ml after surgery.
Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
1889093|NCT01247857|Drug|Ropivacaine 30 mg|"intraperitoneal Nebulization of normal saline 3 ml before surgery and intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) after surgery.
Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports."
1889094|NCT01247857|Drug|Saline|Intraperitoneal nebulization of normal saline 3 ml before and after surgery. Nebulization was performed over 5-10 minutes using the Aeroneb Pro® device through the umbilical port during the insertion of the other ports, while postoperative nebulization was performed before the withdrawal of the ports.
1889095|NCT01247870|Drug|Metformin|Metformin 1 g twice daily for 28-35 days
1889096|NCT01247870|Drug|Placebo|Placebo
1889097|NCT01247883|Drug|PF-04634817|single dose, 20mg, tablet
1889098|NCT01247883|Drug|PF-04634817|single dose, 20mg, solution
1889099|NCT01247896|Drug|PF-05190457|Single Dose 2 mg
1889100|NCT01247896|Drug|PF-05190457|Single Dose 10 mg
1889101|NCT01247896|Drug|PF-05190457|Single Dose 30 mg
1889102|NCT01247896|Drug|PF-05190457|Single Dose 100 mg
1889103|NCT01247896|Drug|PF-05190457|Single Dose 300 mg
1889104|NCT01247896|Drug|PF-05190457|Single Dose 600 mg
1889105|NCT01247896|Drug|PF-05190457|Single Dose - to be determined with food
1889106|NCT01247896|Drug|PF-05190457|Single Dose - to be determined
1889107|NCT01247896|Drug|Placebo|Single Dose Placebo
1889108|NCT01247909|Drug|Ceftriaxone v penicillin and gentamicin|Ceftriaxone v the standard treatment of infant meningitis (penicillin and gentamicin). Ceftriaxone will be given at a dose of 80mg/kg once a day for at least 14 days.
1889109|NCT01247922|Drug|Erlotinib|continuous oral Erlotinib 85 mg/m^2 per day
1889110|NCT01247935|Other|Acupuncture|Electrostimulation at 5 Hz in GI4, ST36, MP6, MP9 starting 20 minutes before colonoscopy
1889112|NCT01247935|Other|Control|Patients are monitored for pain and discomfort
1889113|NCT01247948|Procedure|navigation assisted spine surgery|navigation assisted pedicle screw placement of spine surgery
1889114|NCT01247948|Procedure|traditional spine surgery|traditional spine surgery without navigation assist
1889115|NCT01247961|Drug|Dexamethasone acetate|10 mg intravenous given as single administration with optional repeat dose after 36 hours.
1889116|NCT01247961|Other|Placebo|Normal saline
1889117|NCT01247974|Device|CorMatrix ECM for Pericardial Closure|Circumferential closure of the pericardium following CABG surgery using the CorMatrix ECM for Pericardial Closure
1889118|NCT01247987|Procedure|Blastocyst cryopreservation|Embryos cryopreserved at the blastocyst stage
1889119|NCT01247987|Procedure|Bipronuclear oocyte cryopreservation|Bipronuclear oocyte cryopreservation.
1889120|NCT01248000|Procedure|FDG-PET|PET interpretation is based on a site-to-site comparison of FDG uptake both before and after chemotherapy (qualitative approach), according to the criteria defined by Cheson (2008)
1889121|NCT01248013|Behavioral|gut focused hypnotherapy|7 session hypnotherapy protocol designed for irritable bowel syndrome
1889122|NCT01248026|Other|Buttermilk|"Consumption of the 2 experimental periods
buttermilk (45 g/d)
placebo (45 g/d,)"
1889123|NCT01248052|Drug|LY2979165|administered orally
1889124|NCT01248052|Drug|Placebo|administered orally
1889125|NCT01248065|Drug|Vitamin D3|vitamin D (100,000 IU loading dose followed by 4,000 IU/day)
1889126|NCT01248065|Drug|Ciclesonide|Low dose inhaled corticosteroid (80 mcg/puff two puffs twice daily)
1889127|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered before skin incision
1889128|NCT01248078|Drug|Keflex|2g of i.v. cefazolin singleshot administered after umbilical cord clamping
1889129|NCT01248078|Drug|saline solution|100cc administered before skin incision
1889130|NCT01248091|Procedure|Nitroprusside Gel|10 cc nitroprusside gel
1889131|NCT01248091|Procedure|Placebo Gel|half of the subjects will receive nitroprusside gel for IUD insertion and the other half will receive a placebo gel.
1994114|NCT03065387|Drug|Trametinib|"Starting dose of Trametinib - Dose Escalation Phase: 1 mg by mouth daily for 5 days on and 2 days off in Cycle -1. Dose level -2 is 4 days on and 3 days off.
Starting dose of Trametinib - Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
1889134|NCT01248117|Drug|ranibizumab 2.0mg|Monthly, intravitreal injection 0.05ml
1889135|NCT01248130|Drug|Omega-3 Fatty Acid|Children with Autism Spectrum Disorders will be randomized to receive either 1500mg (3 capsules) omega-3 fatty acids or placebo. Each 500mg capsule contains 350mg EPA and 50mg DHA. Omega-3 fatty acids dosing will be on a forced titration schedule to 3 capsules per day. All subjects will start with 1 capsule per day with an increase to 3 capsules per day by week 2. Subjects will be maintained at 3 capsules per day thereafter until the end of the trial (completion/discontinuation). During the 12 weeks of the study period, participants will be evaluated at weekly intervals during the first three weeks of the trial (baseline, weeks 1-3) and tri-weekly thereafter till the end of the trial (weeks 6, 9 and 12). At each visit, measures of safety and effectiveness will be administered and subjects will be evaluated for response and side effects to the treatment. Study medications will be prescribed under double blind conditions.
1889136|NCT01248143|Dietary Supplement|Green tea|9 gram per day
1889137|NCT01248143|Dietary Supplement|FPP|2 sachets twice daily
1889138|NCT01248195|Drug|Amisulpride open label|4-week open label amisulpride treatment
1889139|NCT01248195|Drug|6-week amisulpride double blind treatment|6-week amisulpride double blind treatment
1889140|NCT01248195|Drug|6-week olanzapine double blind treatment|6-week olanzapine double blind treatment
1889141|NCT01248195|Drug|12-week clozapine open-label treatment|12-week clozapine open-label treatment
1889142|NCT01248195|Behavioral|Psychosocial intervention|Psychosocial intervention
1889143|NCT01248208|Biological|FluMist intranasal influenza vaccine|FluMist intranasal vaccine 0.2 mL will be given 0.1 mL in each nostril per manufacturer's instructions.
1889144|NCT01248208|Biological|"Intramuscular influenza injection (flu shot)"|"Subjects < 2 years or > 49 years or those with asthma symptoms or treatment within the past year will receive the intramuscular flu shot in a single injection.
Age 6-36 months: 0.25 mL IM x 1; Age >36 months: 0.5 mL IM x 1 Boosters: All children aged 6 months-8 years who receive a seasonal influenza vaccine for the first time should be administered 2 doses. Children aged 6 months-8 years who received a seasonal vaccine for the first time during 2009-2010 but who received only 1 dose should receive 2 doses, rather than 1, during 2010-2011. In addition, for the 2010-11 influenza season, children aged 6 months-8 years who did not receive at least 1 dose of an influenza A (H1N1) 2009 monovalent vaccine should receive 2 doses of a 2010-11 seasonal influenza vaccine, regardless of previous influenza vaccination history. For all children, the second dose of a recommended 2-dose series should be administered 4 or more weeks after the initial dose."
1889145|NCT01248221|Drug|[13C]-Spirulina platensis and 99mTc sulfur colloid|The subject will consume the test meal containing 13C-Spirulina and 99mTc sulfur colloid in no more than 10 minutes. Scintigraphic image acquisition will be obtained upon completion of the meal and at 15, 30, 45, 60, 90, 120, 150, 180, and 240 minute time points. Breath samples will be collected at baseline before the test meal is started and thereafter on the same time schedule as the scintigraphic procedure.
1889146|NCT01248234|Drug|propofol|Propofol 1mg/kg will be given once to put the patient to sleep for surgery.
1889147|NCT01248234|Drug|Etomidate|Etomidate 0.3mg/kg will be given once to put the patient to sleep for surgery.
1889148|NCT01248234|Drug|Propofol and Etomidate|Etomidate 0.2mg/kg plus Propofol 0.5mg/kg will be given once to put the patient to sleep for surgery.
1889149|NCT01248247|Drug|Erlotinib|150 mg by mouth each day of a 28 day cycle.
1889150|NCT01248247|Drug|AZD6244|100 mg by mouth daily of a 28 day cycle.
1889151|NCT01248247|Drug|MK-2206|100 mg by mouth every week of a 28 day cycle.
1889152|NCT01248247|Drug|Sorafenib|400 mg by mouth twice a day for a 28 day cycle.
1889153|NCT01248247|Drug|Erlotinib|150 mg by mouth daily of a 28 day cycle.
1889154|NCT01248247|Drug|MK-2206|135 mg by mouth every week of a 28 day cycle.
1889155|NCT01248260|Dietary Supplement|Folic Acid|4mg of higher strength folic acid once a day until delivery
1889197|NCT01248572|Device|Softec HD IOL|Posterior chamber intraocular lens intended for the replacement of the human crystalline lens following phacoemulsification cataract removal in adults over the age of 21.
1889156|NCT01248273|Biological|Globo-H-GM2-sTn-TF-Tn-KLH conjugate, plus the immunological adjuvant QS-21|The injection will be administered subcutaneously during weeks 1, 2, 3, 7 and 19, totaling five injections over the course of the study. Three dose levels are planned: 25 mcg, 50 mcg and 100 mcg. We plan to vaccinate six patients at each dose level unless 2 dose limiting toxicities are observed, and an expansion cohort of 6 patients will be enrolled at the highest dose level achieved.
1889157|NCT01248286|Other|Whole grain rice|Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study
1889158|NCT01248286|Other|Refined grain rice|Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
1889159|NCT01248299|Drug|FU-CDDP|"every 21 days:
Fluoro-uracil [800 mg/m2, day 1 to day 5]
CisPlatin [75 mg/m2, day 1 or day 2]"
1889160|NCT01248299|Drug|LV5FU2-CDDP|"every 14 days:
Elvorin [200 mg/m2, 2h IV, day 1 and day 2]
Fluoro-uracil [400 mg/m2 as a bolus, day 1 and day 2]
Fluoro-uracil [600 mg/m2, 22h continous infusion, day 1 and day 2]
CisPlatin [50 mg/m2, day 2]"
1889161|NCT01248299|Drug|FOLFOX|"every 14 days:
Oxaliplatin [85 mg/m2 by 2h infusion, day 1]
Fluoro-uracil [400 mg/m2 as a bolus, day 1 and day 2]
Fluoro-uracil [600 mg/m2, by 22h continous infusion, day 1 and day 2]
Elvorin [500 mg/m2, day 1 and day 2]"
1889162|NCT01248299|Drug|TPF|"every 21 days:
Docetaxel [30 mg/m2, day 1 and day 8]
CisPlatin [60 mg/m2, day 1]
Fluoro-uracil [200 mg/m2/day by continous infusion]
Or every 21 days:
Docetaxel [50 mg/m2, day 1]
CisPlatine [70 mg/m2, day 1]
Fluoro-uracile [700 mg/m2 /day, day 1 to day 5]"
1889163|NCT01248299|Other|Best Supportive Care|See European professionnal recommendations (ESMO 2009) Exemples : antalgic treatment, nutritional support, ...
1889164|NCT01248312|Device|Sentec monitoring device|Sentec monitor applied transcutaneously to forehead
1889165|NCT01248312|Device|sentec monitor|transcutaneous monitoring
1889166|NCT01248325|Drug|Luffa Operculate Nasal Solution 5mg/mL|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
1889167|NCT01248325|Drug|Saline Solution (NaCl 0,9%)|The treatment will start on the first visit in which subjects will be instructed to instill in the nasal passages, 3 drops of the product by morning and 3 drops of the product at night.
1889168|NCT01248338|Drug|metoprolol succinate|once daily 50 or 100 mg for one year
1889169|NCT01248338|Drug|Nebivolol|once daily 5 mg capsule for one year
1889170|NCT01248351|Other|autologous stored platelets|Administration of autologous stored platelets
1889171|NCT01248351|Other|administration of autologous stored platelets|administration of autologous stored platelets
1889172|NCT01248351|Biological|autologous stored platelets|transfusion of autologous stored platelets
1889173|NCT01248364|Drug|BI 10773|BI 10773 tablets once daily high dose
1889174|NCT01248377|Procedure|Skin tests and ELISPOT assay|Patch test and/or intradermal test will be performed in patients as well as cytokine secretions from PBMCs will be analyzed by ELISPOT assay
1889175|NCT01248390|Behavioral|Interactive metronome|A randomized, controlled investigation into the effects of IM training on a sample of boys with attention deficit disorder showed positive results. Compared to an active control treatment, IM training improved performance on a host of measures, including attention, motor control, language processing, reading, and parental reports of improvements in the regulation of aggressive behavior.16 It should be noted that these cognitive and behavioral functions are common symptom areas in individuals surviving TBI and are likely to be especially affected in cases of blast injury
1889176|NCT01248403|Drug|Paclitaxel|Paclitaxel 80 mg/m2 on day 1, day 8 and day 15 of every 28-day cycle.
1889177|NCT01248403|Drug|RAD001|RAD001 10mg (2 x5 mg tablets / day) d1-d28
1889181|NCT01248429|Biological|CPK dosage|CPK dosage during a blood sample realized at least one week after the begining of the treatment
1889182|NCT01248429|Other|Clinical exam|Examination of the patient for myalgia, cramps, medical history and concomitant medication
1889183|NCT01248442|Drug|Cholecalciferol|monthly dose of 140.000 IU of cholecalciferol orally, 3 times.
1889184|NCT01248442|Drug|Placebo|Matching Placebo
1889185|NCT01248455|Drug|(Anti-KIR)|Patients will receive anti-KIR(IPH2101) (1mg/kg) every other month for 6 cycles
1889186|NCT01248468|Drug|Aspirin, acetaminophen and caffeine|2 tablets each containing Aspirin (250mg), acetaminophen (250mg) and caffeine (65mg)
1889187|NCT01248468|Drug|Sumatriptan|100 mg Sumatriptan
1889188|NCT01248468|Drug|Placebo|placebo
1889189|NCT01248481|Drug|Acarbose (Glucobay, BAYG5421)|Adult female and male patients are scheduled to be treated with acarbose will be enrolled after the therapy decision has been made. Physicians should consult the full prescribing information for Glucobay® before enrolling patients and familiarize themselves with the safety information in the product package label.
1889190|NCT01248494|Drug|BEZ235|"Dose level 1: 400mg PO BID
Dose level -1: 400mg PO in AM and 200mg PO in PM
Dose level -2: 200mg PO BID"
1889191|NCT01248494|Drug|BKM 120|"Dose Level 1: BKM120, 100 mg PO daily
Dose level -1: BKM120, 80 mg PO daily
Dose Level -2: BKM120, 60 mg PO daily"
1889192|NCT01248494|Drug|Letrozole|All levels: 2.5mg/day PO
1889193|NCT01248494|Drug|BKM120|"Dose Level 1: BKM120, 100 mg PO from Mondays through Fridays, weekly
Dose level -1: BKM120, 80 mg PO from Mondays through Fridays, weekly
Dose Level -2: BKM120, 60 mg PO from Mondays through Fridays, weekly"
1889194|NCT01248520|Other|influenza and general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver. These messages will contain general health information as well as information regarding influenza and the importance of vaccination during pregnancy.
1889195|NCT01248520|Other|general health information|Subjects assigned to the influenza information group will receive health text messages from the time they enroll until they deliver.
1889196|NCT01248546|Procedure|Digital breast tomosynthesis|The participants included in the trial will have an additional radiation exposure for breast tomosynthesis
1889314|NCT01249443|Drug|paclitaxel|Given IV
1889201|NCT01248624|Behavioral|Early Palliative Care Referral|The intervention arm receives early referral to and follow-up by a symptom control and palliative care team at Princess Margaret Hospital.
1889202|NCT01248637|Drug|Pimonidazole hydrochloride|Pimonidazole is a 2-nitroimidazole that is selectively reduced and covalently binds to intracellular macromolecules in areas of hypoxia (by definition, p02 <= 10mm Hg) within normal and tumour tissue. Pimonidazole adducts can then be detected by immunolabelling techniques (microscopy, ELISA, flow cytometry etc). In this study, pimonidazole will be administered orally as a one time dose of 0.5gm/m2 24hrs prior to surgery. Since the drug has a half-life of approximately 5 hrs, this time-frame ensures low circulating levels at the time of surgery and therefore reduces the confounding effects of surgical hypoxia on tumour analysis.
1889203|NCT01248650|Drug|nalfurafine hydrochloride|
1889204|NCT01248663|Procedure|antecolic reconstruction|see study arm description
1889205|NCT01248663|Procedure|retrocolic reconstruction|see study arm description
1889206|NCT01248676|Other|Multi-language Online Patient Education Module in addition to standard Patient Teaching|"Patients are usually be given a 5-10 minute new patient teaching before their radiation therapy simulation and planning appointment and before their first radiation therapy treatment appointment. Patients will be asked to view an online patient education module before their radiation therapy simulation and planning appointment or before their first radiation therapy treatment appointment. Then patients will be asked to participate in an interview session and fill out a survey (attached). They will still receive new patient teaching from the therapists before their radiation therapy simulation and planning or radiation therapy treatment appointment."
1889207|NCT01248689|Other|concentration profile 1|"IOP will be measured under this order of sevoflurane concentrations:
7%, 5%, 2%, 0.5%"
1889208|NCT01248689|Other|concentration profile 2|"IOP will be measured under this order of sevoflurane concentrations:
7%, 2%, 5%, 0.5%"
1889209|NCT01248689|Other|concentration profile 3|"IOP will be measured under this order of sevoflurane concentrations:
7%, 0.5%, 5%, 2%"
1889210|NCT01248702|Other|Use of the ICD Critical Pathway|The critical pathway is a series of predetermined processes designed to assess a patient's eligibility for an ICD. The critical pathway will incorporate current evidence-based practice guidelines.
1889211|NCT01248715|Drug|oseltamivir|These patients will receive early (within 8-12 hours of admission, no later than 24 hours after admission) oseltamivir plus current, standard empiric antibacterial therapy based on national recommendations from the IDSA/ATS guidelines for management of hospitalized patients with CAP (2). Anti-influenza therapy will be given using oseltamivir at a dose of 75 mg twice daily. The oseltamivir dose will be adjusted in patients with renal insufficiency according to the package insert. Duration of antiviral therapy will be for a minimum of 5 days for patients with evidence of early clinical improvement and prolonged depending on clinical stability
1889212|NCT01248728|Dietary Supplement|Omega-3 Fatty Acids|Children will be administered 3.75ml of the liquid formulation of Nutra Sea HP (containing 1.5 gr of EPA+DHA). The starting dose will be 1.875ml (0.75 gr of EPA+DHA) and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
1889213|NCT01248728|Dietary Supplement|Placebo|Children will be administered 3.75ml of the liquid formulation of Placebo. The starting dose will be 1.875ml and the dose will be doubled on week 2. The parents may choose to give this as a single dose or split it to two doses if stomach upset occurs. This formulation is double distilled and has very little fishy taste, which will make it more palatable for children and will make creating a matching placebo a simpler process.
1889214|NCT01248741|Radiation|HDR prostate brachytherapy|"HDR prostate brachytherapy to be delivered in 2 fractions of 10 Gray as a boost combined with external beam radiotherapy"
1889215|NCT01248754|Procedure|Surgical neuronavigation with 18F-DOPA PET imaging|Subjects will undergo preoperative 18F-FDOPA PET imaging, which will be used in neuronavigation software to guide resection of their high-grade glioma. Postoperative 18F-FDOPA PET imaging will be obtained to determine the extent of resection.
1889216|NCT01248780|Drug|Golimumab|50 mg subcutaneous (SC) injection every 4 weeks for up to 48 weeks
1889217|NCT01248780|Drug|Placebo|Placebo SC injections at Weeks 0, 4, 8, 12, 16, and Week 20 followed by golimumab 50 mg SC injections at Week 24 and every 4 weeks thereafter up to Week 48.
1889218|NCT01248780|Drug|Methotrexate (MTX)|A stable dose of MTX (oral or injectable) will be administered to participants according to the local prescribing guidelines for up to 48 weeks.
1889219|NCT01248793|Drug|Placebo|Placebo subcutaneous (SC) injections at Weeks 0, 4, 8, 12, 16, and 20
1889220|NCT01248793|Drug|Golimumab|Golimumab 50 mg SC injection every 4 weeks for 48 weeks
1889221|NCT01248793|Drug|Golimumab (placebo group)|Golimumab with early escape at Week 16, 50 mg SC injections at Week 24 and every 4 weeks thereafter through Week 48
1889222|NCT01248806|Radiation|Low dose CT scan|A low dose CT scan of the lungs is performed after the inclusion of the patient in the study and if negative for active disease, a CT scan if performed once per year for whole period of follow-up
1889223|NCT01248819|Drug|Ropivacaine 60 mg|Nebulization grou received intraperitoneal instillation of saline 20 ml on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus intraperitoneal nebulization of ropivacaine 1% 3 ml (30 mg) the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum (total of 60 mg). The first ropivacaine nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
1889224|NCT01248819|Drug|Ropivacaine 100 mg|Instillation group received intraperitoneal instillation of ropivacaine 0.5%, 20 ml (100 mg) on the gall bladder after induction of pneumoperitoneum but before dissection of gall bladder plus and intraperitoneal nebulization of normal saline 3 ml before the start of gall bladder dissection and again at the end of surgery just before deflation of pneumoperitoneum. The first saline nebulization was performed over 5-6 minutes using the Aeroneb Pro® device through the umbilical port while the other ports were being inserted, while second nebulization was performed before the withdrawal of the ports
1889265|NCT01249079|Other|No intervention would be provided in this research|No intervention would be provided in this research,but need to draw blood
1889351|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 0, 2, 4 6, 8, and 10
1889225|NCT01248832|Behavioral|Telephone Counseling|"Telephone counseling is conducted in Mandarin, Cantonese, Korean, or Vietnamese by veteran counselors at the California Smokers' Helpline. The counseling protocol is similar to that used by the Helpline in previous efficacy studies for English and Spanish speakers. However, the counseling is modified to make it culturally appropriate for Asian language speakers by: capitalizing on first contact, proactively presenting the Helpline as a credible quit smoking program staffed by experts and avoiding the term counseling since it is associated with mental illness, and assuming a more authoritative role and directive counseling style, in keeping with subject expectations. Counseling is proactive so after the smoker calls in subsequent calls are made by the counselor, a process that reduces attrition. Counseling includes a 30-40 minute comprehensive pre-quit session plus up to 5 shorter follow-up calls (about 10 minutes) that are scheduled according to the probability of relapse."
1889226|NCT01248832|Behavioral|Self-Help Materials|All subjects (both in the telephone counseling group and the materials-only group) receive self-help materials in teh appropriate language. Materials were created in-house, are written in the appropriate language, and cover the essentials of the quitting process such as motivation, physiological and emotional responses to quitting, nicotine in the body, quitting aids, quitting strategies (including those that might be culturally specific such as acupuncture or herbs), setting a quit date, planning, relapse prevention, differentiating between slips and relapse, long-term maintenance, and developing the nonsmoker self-image.
1889227|NCT01248845|Other|Titration of various level of assistance|Exploration of the effects on diaphragmatic electrical activity (EMG) and on respiratory pattern of various level of assistance delivered by the ventilator in intubated spontaneously breathing patients in pressure support (PS) and in Neurally Adjusted Ventilatory Assist (NAVA) by step by step increasing of the level of assistance. Flow, airway pressure, transesophageal EMG signal and transcutaneous EMG signal will be recorded.
1889228|NCT01248858|Drug|GSK2126458 and GSK1120212|GSK2126458 and GSK1120212 are experimental treatments for patients with cancer.
1889229|NCT01248871|Drug|procedure:sevoflurane-remifentanil/sufentanil|Active Comparator
1889230|NCT01248871|Drug|volatile agent only during reperfusion|Active Comparator
1889231|NCT01248871|Drug|propofol-remifentanil/sufentanil|Active Comparator
1889232|NCT01248884|Biological|Infanrix hexa™|3 doses, intramuscular into left thigh
1889233|NCT01248884|Biological|Prevenar 13®|3 co-administered doses, intramuscular into right thigh
1889234|NCT01248884|Biological|GSK217744|3 doses, intramuscular into left thigh
1889235|NCT01248897|Other|This study is non-interventional study, so this section is not applicable.|This study is non-interventional study, so this section is not applicable.
1889236|NCT01248910|Behavioral|Alpine Skiing|
1889237|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating; Part 2: multiple dose, single schedule.
1889238|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care; Part 2: standard of care determined in Part 1.
1889239|NCT01248923|Drug|Dexamethasone, steroid; oral|Part 1: standard of care; Part 2: standard of care determined in Part 1.
1889240|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care; Part 2: standard of care.
1889241|NCT01248923|Drug|ARRY-520, KSP(Eg5) inhibitor; intravenous|Part 1: multiple dose, escalating
1889242|NCT01248923|Drug|Bortezomib, proteasome inhibitor; intravenous or subcutaneous|Part 1: standard of care
1889243|NCT01248923|Drug|Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous|Part 1: standard of care
1889244|NCT01248936|Drug|RO5185426|
1889245|NCT01248949|Drug|MEDI3617|Participants will receive MEDI3617 via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
1889246|NCT01248949|Drug|Bevacizumab|Participants will receive bevacizumab via IV infusion in each cycle until unacceptable toxicity, initiation of alternative anticancer treatment, documented disease progression, or other reasons.
1889247|NCT01248949|Drug|Paclitaxel|Participants will receive paclitaxel via IV infusion in each cycle until unacceptable toxicity, documented disease progression, or other reasons.
1889248|NCT01248949|Drug|Carboplatin|Participants will receive carboplatin via IV infusion in each cycle until unacceptable toxicity, documentation of disease progression, or other reasons.
1889249|NCT01248962|Drug|carboplatin|Carboplatin Standard 30-minute infusion. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg (or famotidine 20mg IV)IV and diphenhydramine 50mg IV before carboplatin infusion.
1889250|NCT01248962|Drug|carboplatin|Extended 3-hour infusion carboplatin. All patients will receive identical chemotherapy premedications including dexamethasone 20mg the night before and morning of infusion, montelukast 10mg once daily for three days prior to carboplatin infusion, and ranitidine 50mg IV (or famotidine 20mg IV) and diphenhydramine 50mg IV before carboplatin infusion.
1889257|NCT01248988|Other|Synflorix™ Data collection|Safety monitoring: recording of adverse events during using diary cards and recording of serious adverse events using the latest version of Korea's Post-Marketing Surveillance Serious Adverse Event Reporting Form.
1889258|NCT01249001|Drug|Oral Aprepitant|Subject will receive an oral suspension containing 125mg of Aprepitant
1889259|NCT01249001|Drug|Aprepitant|Subjects will receive a 125 mg Aprepitant capsule
1889260|NCT01249014|Device|warmed fluids|use of IV fluid warmer to warm fluid administered to patient
1889261|NCT01249014|Device|Fluid warmer and warming blanket|patients will have IV fluids warmed through a belmont fluid warmer and warming blanket used (forced air will be warmed) a bair hugger device
1889266|NCT01249092|Drug|Pentoxifylline|Patients will take 400mg of pentoxifylline three times daily for a total duration of 6 months.
1889267|NCT01249105|Drug|MK-2206|Taken orally once a week
1889268|NCT01249118|Drug|GDC-0973 IV Infusion|IV infusion.
1889269|NCT01249118|Drug|GDC-0973 Oral Capsules|Oral dose.
1889270|NCT01249131|Drug|Cobimetinib|Cobimetinib 20 mg will be given orally as tablet formulation in fasted or fed state, or as capsule formulation in fasted state.
1889271|NCT01249144|Device|Intraocular Lens (IOL)|Device for implantation in the capsular bag of the eye for visual correction of aphakia following cataract surgery.
1889272|NCT01249157|Device|Positron Emission Mammography (PEM) and Magnetic Resonance Imaging (MRI)|An additional 5 women will be enrolled at the beginning of the study for training purposes only and will not be included in the assessment of this study. Once the patient has had both breast MRI and PEM, the location of each site of potential breast cancer will be listed for each modality. The location of each abnormality on each imaging examination will be documented. Once the histopathologic evaluation has been performed, the pathology results will be compared to the imaging results for each modality. Furthermore, comparison of the performance of MRI and PEM will then be made with the pathological results as the truth. Comparison of the histology and biomarkers in each lesion detected by each modality will be done in order to determine if these factors affect detection by each modality.
1889273|NCT01249170|Behavioral|First year program|Information on group that underwent new educational program
1889274|NCT01249170|Other|Control comparison|Information from group that did not undergo new first year program
1889275|NCT01249183|Biological|Concomitant administration|1 dose (0.5 mL) of VAXIGRIP and 1 dose (0.5 mL) of REPEVAX in 2 separate injections sites (1 on each arm)
1889276|NCT01249183|Biological|Separate administration|1 dose (0.5 mL) of VAXIGRIP at Day 0 and 1 dose (0.5 mL) of REPEVAX 28 days later
1889277|NCT01249196|Drug|SK-PC-B70M|for dosage
1889278|NCT01249209|Device|lifestyle advice|
1889279|NCT01249222|Procedure|plasmapheresis|Plasmapheresis was done every 24-48 hours and continues up to five times. Blood samples were collected 30 minutes before and after each session of plasmapheresis to determine sequential changes in plasma levels of IL-1β, IL-6 and TNF-α. During each exchange session a volume of 25-30 ml/kg bodyweight of patient's plasma was exchanged with equal volume of 20% human albumin diluted with normal saline solution. Before and after plasmapheresis, prothrombin time, activated partial thromboplastin time (aPTT), platelet count and serum calcium level were checked. calcium gluconate 10% (10 ml) was administered even if patient had normal serum calcium in order to prevent hypocalcaemia due to administration of citrate. All drugs except for vasopressors were stopped during procedure.
1889280|NCT01249222|Other|plasmapheresis|plasmapheresis 5 times every 24-48 hours. the apheresis volume will be 30 ml/kg.
1889281|NCT01249235|Procedure|Patch or bandage contact lens|Patients will be given a patch or a bandage contact lens at the conclusion of pterygium excision surgery.
1889282|NCT01249248|Device|PD2i Analyzer|Analysis of heart rate variability from a standard digital ECG for 6-12 minutes
1889283|NCT01249261|Drug|Risedronate|5 mg/day
1889284|NCT01249261|Drug|Placebo/Risedronate|placebo years 1-5 followed by 5 mg risedronate years 6 & 7 and no drug year 8
1889285|NCT01249274|Drug|Progesterone|100mgs progesterone twice daily
1889286|NCT01249274|Other|Placebo|Matched placebo pills to be taken twice daily
1889287|NCT01249300|Other|No intervention|No intervention
1889288|NCT01249326|Other|bariatric surgery|This is a prospective longitudinal study of the effect of bariatric surgery on protein requirements and protein metabolism, and protein supplementation interest, appropriate to the digestive tract changes, for the mass and muscle function
1889289|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
1889290|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 1g, single dose. One pouch administered over 30 minutes.
1889291|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 0.5 g, single dose. One pouch administered over 30 minutes.
1889292|NCT01249339|Procedure|Buccal Administration of nicotine|Oral pouch 0.3 g, single dose. One pouch administered over 30 minutes.
1889293|NCT01249352|Drug|Nimotuzumab|200 mg, IV Weekly IV dose for up to 26 weeks.
1889294|NCT01249352|Drug|Cisplatin|75 mg/m2, IV dose on D1 of each chemotherapy cycle, for 4 cycles, always after nimotuzumab.
1889295|NCT01249352|Drug|Fluorouracil|1,000 mg/m2, IV dose in a 24-hour continuous infusion, from D1 to D4, every chemotherapy cycle, for 4 cycles.
1889296|NCT01249352|Radiation|Radiotherapy|Radiotherapy 50.4 Gy, fractions of 1.8 Gy/day
1889297|NCT01249365|Biological|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination
1889298|NCT01249378|Other|All subjects receive three sequences of a standard breakfast|"All subjects receive three sequences of a standard breakfast containing :
10 g non emulsified
or 40 g non emulsified
or 40 g finely emulsified of milk fat with stable isotope (13C triglyceride). The administration order is determined by randomized allocation. The wash-out period is three weeks. There are not diet or exercise interventions. Only, one week before and three days after, the subjects consume neither naturally enriched in 13C foods or pre/probiotics. In addition, three days before and three days after each test, the subjects receive dietary instructions"
1889299|NCT01249391|Device|Splinting|Gutter thermoplastic custom-made splint for nominated joint, to be worn at night-time for consecutive nights for 3 months
1889302|NCT01249417|Drug|Botulinum type A toxin (Dysport®)|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
1889303|NCT01249417|Drug|Placebo|I.M. injection on day 1 of a single treatment cycle.
1889304|NCT01249430|Drug|Azacitidine|Given IV
1889305|NCT01249430|Drug|Cytarabine|Given IV
1889306|NCT01249430|Drug|Etoposide Phosphate|Given IV
1889307|NCT01249430|Other|Laboratory Biomarker Analysis|Correlative studies
1889308|NCT01249430|Drug|Mitoxantrone Hydrochloride|Given IV
1889309|NCT01249430|Other|Pharmacological Study|Correlative studies
1889310|NCT01249443|Drug|vorinostat|Given PO
1889311|NCT01249443|Other|diagnostic laboratory biomarker analysis|Correlative studies
1889315|NCT01249469|Other|skin whitening cosmetic product|Product application: twice a day in the morning and before sleep for 8 weeks; from D1 to D55, but no application on D27 at night/ D28 in the morning and D55 at night/ D56 in the morning before visit. The product is applied on one side of the hand
1889316|NCT01249495|Procedure|Sharp debridement|After use of local anestetics a sharp currette is used to debride slough and nonviable tissue from the ulcer surface until a healthy tissue is seen.
1889317|NCT01249508|Other|nutrition label|
1889318|NCT01249521|Drug|AMG386 and bevacizumab|AMG386 10mg/kg qw iv Bevacizumab 7.5mg/kg q3w iv
1889319|NCT01249534|Other|gastroesophageal cancer surgery|gastroesophageal cancer surgery
1889320|NCT01249547|Drug|axitinib|starting dose of 5 mg twice daily for 4 consecutive weeks without interruption.
1889321|NCT01249573|Other|fascia therapy or transcutaneous fibrolysis|fascia therapy or transcutaneous fibrolysis as treatment for an acute ankle distortion
1889322|NCT01249586|Other|E-learning|A traditional class of blindness prevention plus an additional e-learning material. The e-learning material included a PDF article about blindness prevention. This material was e-mailed one week before the traditional class.
1889323|NCT01249599|Procedure|blood sample analysis|The aim of this prospective single-center study is to evaluate endothelial function, vascular compliance, oxidative stress parameters, quality of life and platelet adhesion in patients with apical ballooning syndrome and age-matched controls.
1889324|NCT01249612|Other|Thermotherapy|Knee joint icing
1889325|NCT01249612|Other|Thermotherapy|Elbow joint icing
1889326|NCT01249625|Device|N95 Respirator|Participants in this arm will be asked to wear an N95 respirator for the extent of the 12 week study period.
1889327|NCT01249625|Device|Medical/surgical mask|Participants in this arm will be asked to wear a medical/surgical mask for the extent of the 12 week study period.
1889328|NCT01249638|Drug|Capecitabine|Capecitabine:2 x 1250 mg/m2 day 1-14 followed by 1 week pause q day 21
1889329|NCT01249638|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1 q day 21
1889330|NCT01249638|Drug|Capecitabine|Capecitabine: 2 x 800mg/m2 day 1-14 followed by 1 week pause q day 21
1889331|NCT01249638|Drug|Irinotecan|Irinotecan: 200 mg/m2 day 1 , q day 21
1889332|NCT01249638|Drug|Bevacizumab|Bevacizumab: 7.5 mg/kg day 1, q day 21
1889333|NCT01249651|Drug|esomeprazole 40 mg|esomeprazole 40 mg once daily, 8 weeks
1889334|NCT01242397|Device|CRT pacing|The chronic effect of CRT pacing on the degree of MR in pts with severe-to-moderate or severe functional MR. The treatment being studied is CRT pacing therapy with standard of care LV lead placement. Patients will be randomized to CRT pacing ON vs. OFF and followed for a total of up to 8 months. This includes two 3-month crossover periods for each pacing modality (CRT ON and CRT OFF) and a 6-week washout period between these periods.
1889335|NCT01242410|Device|Silicon ring (Arabin Cervical Pessary)|Vaginal pessaries CE 0482 MED / CERT ISO 9003 /EN 46003
1889336|NCT01242423|Device|extracorporeal shockwave therapy|ESWT is administered as a one-off treatment on the wound surfaces within 24 hours of a 2nd degree burn trauma and immediately after an intraoperative skin graft excision procedure. A defocused sound head is orthogradely applied to the burn wound or the donor site. 100 impulses/cm² is administered at 20 seconds per cm². The defocused sound head is placed on the wound along with a sterile gel (Lavaseptgel®, Octenidingel®) and a sterile protection foil. The shockwaves deployed are not at an energy density that is painful. This single application of ESWT is followed by routine dressing using Mepitel® in combination with Polyhexanid/Octenidin®.
1889337|NCT01242436|Procedure|intravenous contrast administration|"The additional burden is restricted to a WB-DWI scan before and during therapy.
MRI is a technique based on magnetic fields and do not require the use of ionizing radiation. Because of the strong magnetic field, a few precautions should be taken. This means that all metal and magnetized objects must be removed from the patient before entering the MRI room. Patients with a pacemaker, a cardiac defibrillator or other implanted conductor/prosthesis are for this reason not eligible for the study.
During the examination, an intravenous will be administered. In most cases, patients do not experience any discomfort and the use of this contrast agent is part of the clinical routine."
1889338|NCT01242449|Drug|Trastuzumab|Initial dose 8 mg/kg i.v. Subsequently, 6 mg/kg i.v. at intervals of 3 weeks
1889339|NCT01242449|Drug|Vinorelbine|Initial dose 70 mg/m2 on days 1 and 8 (capsules) If well tolerated, subsequently 90 mg/m2 on days 1 and 8. Capsule on day 1 to be taken at the hospital, and on day 8 at home.
1889340|NCT01242462|Procedure|Conventional Pressure Controlled SIMV|Initial ventilatory settings per clinical physician's discretion-tcCO2 & Saturation (SAT) monitoring. Adjust vent setting approximately every 15min with a goal of: SAT 88-95%, tcCO2 45-55, pH greater than or equal to 7.25. Once goals reached, ventilatory strategy will crossed over to other intervention.
1889341|NCT01242462|Other|Mid-frequency Ventilation|Ventilatory parameters include: max possible rate between 61-150 breaths/min; Shortest inspiration time (Ti) and expiration time (Te), but completed inspiration and expiration on pulmonary graphics. Stepwise weaning of PIP by 1 cm H20 to maintain tcCO2 at baseline. If measured PEEP - delivered PEEP generated is >/= to 1cm H2O, PEEP is reduced to baseline value. Adjustments will be made to PIP, then rate for pH and CO2 changes; FiO2, then PIP for FiO2 changes. Target goal blood gas parameters (same as baseline) Saturations 88-95%; tcCO2 45-55 mmHG; pH >/= 7.25. Maximum period of 2 hours. When goals met, or 2 hours in period, reverted back to SIMV at baseline settings
1889342|NCT01242475|Biological|C-Tb|The C-Tb agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
1889343|NCT01242475|Biological|2 TU Tuberculin PPD RT 23 SSI|The 2TU Tuberculin PPD RT 23 SSI agent is administered by the Mantoux injection technique to each volunteer in the RIGHT or LEFT forearms according to a double blind randomisation scheme
1889344|NCT01242488|Biological|CDP6038|60 mg subcutaneously (sc) at Weeks 0, 2, 4 6, 8, and 10
1889345|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 2, 4 6, 8, and 10
1889346|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 2, 4 6, 8, and 10
1889347|NCT01242488|Biological|Tocilizumab (Actemra or RoActemra)|8 mg/kg intravenously (iv) at Weeks 0, 4 and 8
1889348|NCT01242488|Biological|CDP6038|60 mg sc at Weeks 0, 4 and 8
1889349|NCT01242488|Biological|CDP6038|240 mg sc at Weeks 0, 4 and 8
1889350|NCT01242488|Biological|CDP6038|120 mg sc at Weeks 0, 4 and 8
1890177|NCT01255813|Other|Control|No stimulation applied
1889352|NCT01242488|Other|Placebo sc|0.9% Sodium chloride for injection at Weeks 2, 6 and 10
1889353|NCT01242488|Other|Placebo iv|0.9% Sodium chloride for injection at Weeks 0, 4 and 8
1889356|NCT01242514|Drug|Fostamatinib|Fostamatinib 100mg twice daily
1889357|NCT01242514|Drug|Fostamatinib|Fostamatinib 150mg once daily
1889358|NCT01242514|Drug|Fostamatinib|Fostamatinib 100mg once daily
1889359|NCT01242527|Drug|placebo|4 capsules (1g) daily for 12 weeks
1889360|NCT01242527|Drug|omefas|2 capsules (1g) + 2 placebo daily for 12 weeks
1889361|NCT01242527|Drug|omefas|3 capsules (1g) + 1 placebo daily for 12 weeks
1889362|NCT01242527|Drug|omefas|4 capsules (1g)daily for 12 weeks
1889363|NCT01242566|Drug|Temozolomide|orally 150-200 mg/m2/day for 5 consecutive days every 4 week
1889364|NCT01242579|Drug|Maraviroc/Dapivirine Gel|Vaginal gel containing 2.5g - Maraviroc 0.1%, Dapivirine 0.05%
1889365|NCT01242579|Drug|Dapivirine Vaginal Gel|Dapivirine vaginal gel containing 2.5g
1889366|NCT01242579|Drug|Maraviroc Vaginal Gel|Maraviroc vaginal gel containing 2.5g
1889367|NCT01242579|Drug|Matching Placebo Gel|Matching placebo gel containing 2.5g
1889368|NCT01242592|Drug|Anti-Tuberculosis Treatment|
1889369|NCT01242605|Drug|selumetinib|The starting dose of selumetinib will depend on the cohort. The first dose of selumetinib to be studied will be 75 mg twice daily (bd). Selumetinib will be taken every day (continuously) either once or twice a day, depending on the dose. Treatment with selumetinib may continue until disease progression.
1889370|NCT01242605|Drug|gemcitabine|gemcitabine: taken in combination with cisplatin will be given at 1000 mg/m*2 in 250 - 500 ml 0.9% saline over 30 minutes by intravenous infusion on days 1, and 8 of each 21-day cycle for eight cycles in total
1889371|NCT01242605|Drug|cisplatin|cisplatin: 25 mg/m*2 in 1000 ml 0.9% saline given over 1 hour followed by 500mls 0.9% saline over 30 minutes followed by gemcitabine on days 1, and 8 of each 21-day cycle for eight cycles in total
1889372|NCT01242618|Biological|engineered nasal cartilage graft|implantation of engineered nasal cartilage grafts in the alar lobule
1889373|NCT01242631|Drug|Everolimus|Everolimus 10 mg orally per day.
1889374|NCT01242644|Device|pain pump containing ropivacaine|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100mL of ropivacaine (0.5%) administered at 4 mL/hour
1889375|NCT01242644|Device|saline pain pump with injectable medication|30mL of ropivacaine(0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected plus a pain pump containing 100-mL of normal saline administered at 4 mL/hour
1889376|NCT01242644|Drug|ropivacaine, ketorolac , morphine sulfate|30mL of ropivacaine (0.5%), 30mg of ketorolac and 8mg of morphine sulfate injected
1889377|NCT01242657|Behavioral|Physical Activity Module|"Participants were provided pedometers in order to track specific Step Goals, which were defined for male or female participants. In addition, each participant recorded other forms of physical activity in a Challenge Log."
1889378|NCT01242657|Behavioral|Not On Tobacco (N-O-T) Program|Not On Tobacco (N-O-T) Program, a proven teen smoking cessation program
1889379|NCT01242670|Biological|Ross River Virus Vaccine|Ross River Virus Vaccine (Formalin Treated, UV Inactivated, Vero Cell-Derived) with Aluminum Hydroxide Adjuvant
1889380|NCT01242683|Behavioral|Vivamos Activos Fair Oaks Program|"Comparison of Case-management vs. Case-management plus Home Visits vs. Usual Primary Care.
Case-management: Five 60 minute individual and 15 90 minute group sessions devoted to behavioral strategies to facilitate weight loss conducted by a health educator.
Home-visits: Seven home visits provided by a community health worker to provide life-style/environmental support for behavior change to facilitate weight loss.
Usual primary care: Usual care provided at health center that is available to participants in all three study arms."
1889381|NCT01242696|Procedure|Coronary artery stenting|Coronary artery stenting with drug eluting stents
1889382|NCT01242722|Device|CRT-D|Cardiac pacing via a pulse generator and implanted intracardiac leads
1889383|NCT01242735|Behavioral|Aerobic exercise|12-week moderate-intensity behavioral exercise intervention. Weekly sessions with an exercise physiologist who will also assign weekly exercise goals.
1889384|NCT01242735|Behavioral|Health and Wellness|12-week health and wellness education control. Weekly sessions about 12 different topics related to OCD, led by an OCD expert.
1889385|NCT01242748|Drug|Degarelix|The degarelix doses were administered by subcutaneous (s.c.) injections into the abdominal wall. In the main CS35 trial, a starting dose of 240 mg degarelix was administered on Day 0. One month later a maintenance dose of 480 mg was administered. This was repeated after 4, 7, and 10 months (ie a total of 5 administrations in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the degarelix treated participants continued to receive degarelix 480 mg s.c. treatment every three months.
1889386|NCT01242748|Drug|Goserelin acetate|The goserelin doses were administered by subcutaneous (s.c.) implants into the abdominal wall. In the main CS35 trial, an initial dose of 3.6 mg goserelin was administered on Day 0. One month later a subsequent dose of 10.8 mg was administered and this was repeated after 4, 7, and 10 months (ie a total of 5 implants in the main trial). In the CS35A extension trial, the participants received the same treatment as in the main trial ie the goserelin treated participants continued to receive goserelin acetate 10.8 mg s.c. implants every three months.
1889387|NCT01242774|Drug|Panobinostat|Oral administration of panobinostat given 3 times a week (administered on weeks 2 and 3 of a 4 week cycle) in combination with induction chemotherapy (idarubicin and cytarabine.
1889388|NCT01242787|Drug|LB80380|Optimal dose of LB80380, by oral for 48 weeks (optimal dose will be chosen early 2011 based on the results of LG-BVCL007 study)
1889389|NCT01242787|Drug|Entecavir 0.5 mg|Entecavir 0.5 mg, by oral for 48 weeks
1889390|NCT01242800|Procedure|palliative surgery|Undergo standard palliative surgery
1889391|NCT01242800|Procedure|therapeutic conventional surgery|Undergo early surgery
1889392|NCT01242800|Radiation|palliative radiation therapy|Undergo standard palliative radiotherapy
1889393|NCT01242800|Radiation|radiation therapy|Undergo radiotherapy
1889394|NCT01242813|Drug|ACZ885|
1889395|NCT01242826|Drug|biphasic insulin aspart 50|A single dose of 0.3 U/kg BIAsp 50 for subcutaneous (under the skin) injection
1889396|NCT01242839|Device|CACICOL20|CACICOL20 is a solution of dextran & poly(carboxymethylglucose sulphate)in physiological salt serum. CACICOL20 is presented in 0.33 mL strip. One drop is instilled at each application to impregnate cornea.
1889397|NCT01242839|Device|Placebo|It is the placebo of CACICOL20, containing dextran in physiological serum salt. It is presented, like CACICOL20, in a 0.33 mL strip. One drop is delivered at each application.
1889398|NCT01242852|Procedure|Office hysteroscopy (in combination with a 'Saline Infusion Sonography'(SIS))|Routine fertility work-up, added up with diagnostic tests. In 5 research centers the extra tests consist of SIS & hysteroscopy (HY). In the other research hospitals it consists of only a HY. The HY examination will be scheduled on Day 3-12 of a cycle. It will be performed in an outpatient setting with a vaginoscopic approach. A 5-mm diameter continuous flow hysteroscope and a 30º direction of view will be used. The uterus will be inspected methodically a endometrial biopsy obtained and the findings recorded into a standardized form. Intrauterine pathology is defined as septum, endometrial polyp, submucous myoma, adhesions & endometritis. These will be treated, using scissors, Versapoint, grasping forceps, polyp snare or antibiotics. In 5 of the research hospitals, 1 week prior to the HY, also a SIS will be performed. Via a catheter saline solution will be infused into the uterine cavity as distention media. The findings at the following sonography will be standardized recorded.
1889399|NCT01242865|Behavioral|Attention and Interpretation Therapy|"Participants will receive a copy of the book, Train Your Brain Engage Your Heart Transform Your Life along with three handouts summarizing the contents of the book."
1889400|NCT01242891|Device|EXCOR® Pediatric Ventricular Assist Device|Extracorporeal Ventricular Assist Device
1889401|NCT01242904|Drug|bimodal solution|200 mL of 30% glucose infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
1889402|NCT01242904|Drug|icodextrin|200 mL of icodextrin infused into the abdomen by the patient each morning for 6 weeks, added to the daytime dwell of approximately 2000 mL icodextrin that has been infused by the cycler
1889403|NCT01242917|Drug|CCX-354-C|200mg film-coated tablets once daily for 12 weeks + Methotrexate
1889404|NCT01242917|Drug|Placebo|Placebo film-coated tablets twice daily for 12 weeks + methotrexate
1889405|NCT01242917|Drug|CCX354-C|100mg film-coated tablets twice daily for 12 weeks + methotrexate
1889406|NCT01242930|Drug|Imetelstat (7.5 mg/kg)|Imetelstat 7.5 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
1889407|NCT01242930|Drug|lenalidomide standard of care|Patients who are receiving lenalidomide as maintenance therapy upon enrollment as part of their treatment regimen may remain on this therapy during trial participation, provided that they have received this treatment for a minimum of 3 months and demonstrate evidence of stabilization of their response.
1889408|NCT01242930|Drug|Imetelstat (9.4 mg/kg)|Imetelstat 9.4 mg/kg as a 2-hour intravenous infusion (± 10 minutes) on Days 1 and 8 of a 28-day cycle; the Day 8 dose will be omitted in patients with a prior history of bone marrow or stem cell transplant.
1889409|NCT01242943|Drug|131I-L19SIP Radioimmunotherapy (RIT)|"Dosimetric evaluation with 131I-L19SIP will be performed to assess eligibility for Radioimmunotherapy.
Phase I: Patients eligible for Radioimmunotherapy will receive escalating doses of therapeutic 131I-L19SIP administration (intravenously) at the following dosages (expressed in mCi/m2): 111, 139 and 167."
1889410|NCT01242956|Behavioral|verum group|video-based training after stroke
1889411|NCT01242956|Behavioral|Placebo group|non-video group
1889412|NCT01242982|Procedure|Closed reduction and fixation with 2 pins|Closed reduction and fixation with 2 antegrade intramedullary Kirschner wires. Cast for 2 weeks. Control after 2 and 5 weeks. Thereafter a control after 3,6 and 12 months
1889413|NCT01242982|Procedure|Reduction and Plaster of Paris|Closed reduction in local anesthesia and a Plaster of Paris for max. 3 weeks. Control after 1 and 3 weeks, thereafter control after 3,6 and 12 months
1889414|NCT01242995|Procedure|Endoscopic Retrograde Cholangiopancreatography (ERCP)with Cholangiopancreatoscopy using the thin scope|Endoscopic Retrograde Cholangiopancreatography (ERCP) with cholangiopancreatoscopy using the thin scope system.
1889415|NCT01243008|Drug|Application of SHB001|"Cohort 1: Application of SHB001 on the skin of right thigh
Cohort 2:
Application of SHB001 on the skin of right thigh
punch biopsies of treated skin areas"
1889416|NCT01243047|Drug|Chemotherapy|Erlotinib, Oxaliplatin, Capecitabine
1889417|NCT01243060|Drug|Almorexant|100mg
1889418|NCT01243060|Drug|Almorexant|200mg
1889419|NCT01243060|Drug|Zolpidem 10mg|10mg
1889420|NCT01243060|Drug|Placebo|One-time dose of Placebo
1889421|NCT01243073|Drug|Imetelstat|
1889422|NCT01243086|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
1889423|NCT01243086|Drug|OZURDEX|OZURDEX injection of 0.7mg dosage at months 0 with follow up for a total of 6 months.
1889424|NCT01243112|Drug|1% Lidocaine with Epinephrine (1:100,000)|0.2ml Intradermal injection once.
1889425|NCT01243112|Drug|0.25% Bupivacaine with Epinephrine (1:200,000)|0.2ml Intradermal injection once.
1889426|NCT01243112|Drug|0.5% Lidocaine, 0.125 Bupivacaine, and epi (1:150,000)|0.2ml Intradermal injection once.
1889427|NCT01243112|Drug|1% Lidocaine, 0.5% Bupivacaine, and epinephrine (1:150,000)|0.2ml Intradermal injection once.
1889428|NCT01243125|Drug|NVC-422, 0.2%|0.2% NVC-422 (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
1889429|NCT01243125|Drug|Sterile normal saline, 0.9%|Saline (sterile), 25 ml instilled and retained in catheter for 15 min, 2x/day; 8 treatments administered over a 26 day period
1889791|NCT01252836|Device|AWBAT-D|Application of AWBAT-D bioengineered device
1889435|NCT01243164|Other|Wheelchair Skills Training Program|The Wheelchair Skills Training Program will be administered in 2, 1 hour sessions.
1889438|NCT01243190|Drug|Ofatumumab|Loading first dose 300 mg by vein on Day 1 of Cycle 1; and full dose 1000 mg over 4 hours 1 time each week for 7 additional weekly doses (8 doses).
1889439|NCT01243203|Drug|Champix|Days 1 - 3: 0.5 mg once daily (1 table each day) Days 4 - 7: 0.5 mg twice daily (1 in the morning and 1 in the evening) Days 8 - 12 weeks 1.0 mg twice daily (1 in the morning and 1 in the evening)
1889440|NCT01243216|Device|Ultrasound|Ultrasound examination of the lumbar spine. The level of the lumbar interspace will be determined by the oblique/sagittal method. The transverse method will be used to determine the best lumbar interspace and the distance from the skin to the target (epidural space or intrathecal space)
1889441|NCT01243242|Drug|Metadoxine (MG01CI)|MG01CI 1400 mg, that will be taken daily by the patients for a duration of 6 weeks.
1889443|NCT01243281|Drug|PEG-IFN and entecavir|The patients will be randomized in approximately 1:1 ratio into one of 2 treatment regimens; to receive PEG-IFN alpha-2b (1.5 microgram/kg/week) plus entecavir (0.5 mg/day) or PEG-IFN alpha-2b (1.5 microgram/kg/week) alone for 48 weeks by using pre-generated randomization schedule.
1889444|NCT01243294|Device|SS|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
1889445|NCT01243294|Device|SenSura|New ostomy appliance (SS) is tested in 10 ± 2 days and the degree of leakage under the baseplate is measured and compared to SenSura.
1889446|NCT01243307|Drug|CT327 (or placebo) followed by placebo (or CT327)|"During treatment/testing period 1, subjects will apply 0.25 g CT327 (or placebo) to 4 test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications.
During treatment/testing period 2, subjects will apply 0.25 g placebo (or CT327) to 4 different test fields of skin (2 on their arms and 2 on their legs) twice daily, 12 hours apart for a total of 7 applications."
1889447|NCT01243320|Drug|10ppm Oral Silver Particle|Silver nanoparticles at 10ppm
1889448|NCT01243320|Drug|32ppm Oral Silver Particle|Silver nanoparticles at 32ppm
1889449|NCT01243333|Radiation|Multi-tracer PET exams|Initial scan will be done before starting the trial. The other two will be done about 25 to 32 days after the trial starts. Each of the 4 PET scans will be done with up to three of the tracers (FDG, FLT, and water) depending on the type of drug they are receiving and the tumor type. The timing of the PET scans will vary. Typically the first series of PET scans will be within a few days of each other but will be obtained within one week of each other. Similarly the follow-up series of PET scans at about 28 days will be within a few days of each other depending on scheduling issues but also within one week of each other.
1889450|NCT01243346|Drug|Crenolanib besylate (CP-868,596-26), Dose: 140mg BID|Highly potent inhibitor of both PDGFR receptors alpha and beta
1889451|NCT01243359|Drug|sunitinib malate|Given PO
1889452|NCT01243359|Biological|bevacizumab|Given IV
1889453|NCT01243359|Other|pharmacological study|Correlative studies
1889454|NCT01243359|Other|laboratory biomarker analysis|Correlative studies
1889455|NCT01243359|Other|fluorine F 18 fluorothymidine|Undergo FLT PET/CT
1889456|NCT01243359|Procedure|positron emission tomography|Undergo FLT PET/CT
1889457|NCT01243359|Procedure|computed tomography|Undergo FLT PET/CT
1889458|NCT01243372|Genetic|mutation analysis|
1889459|NCT01243372|Other|laboratory biomarker analysis|
1889461|NCT01243398|Procedure|quality-of-life assessment|
1889462|NCT01243411|Biological|AA4500|2 injections separated by at least 24 hours but not more than 72 hours, repeated after 42 days (± 5 days) for up to 4 treatment cycles (ie, total of up to 8 injections per subject)
1889463|NCT01243424|Drug|linagliptin|linagliptin tablets 5mg QD
1889464|NCT01243424|Drug|glimepiride|glimepiride over-encapsulated tablet 1-4 mg QD
1889465|NCT01243424|Drug|linagliptin placebo|linagliptin placebo
1889466|NCT01243424|Drug|glimepride placebo|glimepiride placebo
1889467|NCT01243437|Drug|ciprofloxacin|"For adults and children aged > 15 years: 500 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;
For children aged 8-15 years: 15 mg/kg (maximum 500 mg per dose) orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
1889468|NCT01243437|Drug|doxyxcycline|"For adults and children weighing 45 kg or more: 200 mg orally one time as an initial loading dose, followed by 100 mg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer;
For children weighing less than 45 kg: 4.4 mg/kg orally one time as an initial loading dose, followed by 2.2 mg/kg orally every 12 hours for 10 days or until the patient has been fever-free for 24 hours, whichever is longer."
1889469|NCT01243450|Drug|Tretinoin|Treatment of acne
1889470|NCT01243450|Drug|placebo|treatment of acne
1889471|NCT01243476|Drug|Lenalidomide|Treatment with Revlimid (lenalidomide), oral use, 5 mg daily during study treatment (104 weeks).
1889472|NCT01243476|Other|Placebo|Placebo, oral use, daily during study treatment (104 weeks)
1889473|NCT01243489|Other|compliance supporting measures|"Patients will be treated for a total of 12 months, 6 months without and 6 months with compliance supporting measures. Patient can choose between an information service Leben mit CML or the use of a daily diary"
1889474|NCT01243502|Drug|0.01% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 1000 μg/dm2.
1889475|NCT01243502|Drug|0.001% CT327 (or placebo)|Cream (10 g) was applied at an even thickness over a test area on the back of 10 x 10 cm to give an exposure of 100 μg/dm2.
1889476|NCT01243515|Device|Non-Invasive Central Venous Pressure monitor|An adhesive patch (connected to the Mespere NICVP monitor) is placed on the neck of the subject, to determine if the CVP values displayed by the device correlates with CVP values obtained by physical examination (standard clinical practice)
1889477|NCT01243515|Procedure|Physical examination of jugular vein|Physicians assess CVP using the jugular vein of the subject
1889478|NCT01243528|Other|Laboratory values|Laboratory values which represent nutritional status
1889479|NCT01243541|Procedure|cryotherapy|Patients wear an Elasto-Gel cold glove and sock
1889480|NCT01243541|Other|questionnaire administration|Ancillary studies
1889481|NCT01243541|Procedure|quality-of-life assessment|Ancillary studies
1889482|NCT01243541|Procedure|management of therapy complications|In this therapeutic study, cold therapy is administered with an Elasto-Gel cold glove and sock (study device) that will be worn on your right hand and foot or your left hand and foot. The study device is a glycerine-based gel cold pack shaped like a mitten or sock with a cloth-like fabric kept at a constant temperature. The study device is not known to cause any major adverse affects and it is considered of non-significant risk. If you choose to participate in this study, you will be asked to wear a glove and sock at each paclitaxel infusion (4 treatments total). We hope the use of this study device will prevent or significantly reduce the onset and potential severity of paclitaxel-induced peripheral neuropathy and nail problems.
1889483|NCT01243541|Procedure|assessment of therapy complications|Study Treatment Assessment You will be asked permission for pictures to be taken of only your hands and feet. This is to have a visual documentation of symptom development during your treatment. This will be done at all six time points before you begin chemotherapy that day.
1889484|NCT01243554|Behavioral|Exercise|Exercise training at the hospital
1889485|NCT01243567|Drug|bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution|Bimatoprost 0.03%/timolol 0.5% combination ophthalmic solution (GANfort®) administered to each eye requiring treatment, once daily in the evening for 3 months.
1889486|NCT01243567|Drug|latanoprost 0.005% ophthalmic solution|Latanoprost 0.005% ophthalmic solution (Xalatan®) administered to each eye requiring treatment, once daily in the evening for 3 months.
1889493|NCT01243619|Drug|3'-deoxy-3'-(18) F-fluorothymidine|Radio-tracer for tumor imaging
1889494|NCT01243632|Drug|Prolonged 6-hr infusion of gemcitabine|Gemcitabine 250 mg/m2 in prolonged 6 hr infusion on day 1 and 8, and cisplatin at 75 mg/m2 on day 2 of 3 week cycle, for 4-6 cycles
1889495|NCT01243645|Behavioral|biofeedback training|
1889496|NCT01243658|Drug|Oxytocin|Oxytocin
1889497|NCT01243671|Biological|Adalimumab|
1889498|NCT01243684|Device|DTI - Diffusor Tensor Imaging|Radiology intervention
1889499|NCT01243697|Drug|desogestrel|Tablets of 75 µg, once daily during 112 days
1889500|NCT01243710|Device|Taurolidine with heparin (500 units/ ml)|Central venous catheter will be locked (the designated volume required to fill the dead space) with taurolidine with heparin after each dialysis session. The control arm will be locked with heparin as is current practice.
1889501|NCT01243723|Drug|Eductyl suppository|One suppository every morning during 21 days
1889502|NCT01243723|Drug|Placebo suppository|One suppository every morning during 21 days
1889503|NCT01243736|Drug|Combination Prep|"combination bowel preparation, which consists of:
drinking 2-liters (8 cups) of polyethylene glycol starting at 7 p.m. the night prior to the capsule endoscopy test;
drinking a teaspoon of simethicone 20 minutes prior to the capsule endoscopy test;
drinking a teaspoon of metoclopramide 20 minutes prior to the capsule endoscopy test;
lying on your right side for 30 minutes following the swallowing of the capsule endoscope."
1889507|NCT01243775|Drug|Belotaxel|60 mg/m2 3 weekly (day 1)
1889508|NCT01243775|Drug|Belloxa|70 mg/m2 3 weekly (day 2)
1889509|NCT01243788|Drug|Salmeterol/Fluticasone Propionate|Salmeterol/Fluticasone 50/500ug twice daily Duration:12 weeks
1889510|NCT01243801|Drug|Ketamine|Intravenous ketamine 0.5mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h Epidural Ketamine 0.5 mg/kg(induction of anesthesia)and 0.25 mg/kg/h for 48h
1889511|NCT01243814|Device|hyaluronate intra-articular injection|joint injection in ankle with hyaluronate
1889512|NCT01243814|Device|placebo injection|joint injection with saline solution for placebo
1889513|NCT01243827|Drug|carvedilol|carvedilol is administered after randomization at a dose of 10 mg once daily, and if needed, titrated to 15 mg and to a maximum of 20 mg to achieve a clinic BP <140/90 mmHg.
1889693|NCT01251991|Other|Microcrystalline cellulose|Oral suspension, oral use, two daily dosages consisting of 5 grams each
1889514|NCT01243827|Drug|bisoprolol|bisoprolol is administered after randomization at a dose of 2.5 mg once daily, and if needed, titrated to 3.75 mg and to a maximum of 5.0 mg to achieve a clinic BP <140/90 mmHg.
1889515|NCT01243853|Dietary Supplement|Alpha-galactosidase|3 months intervention, daily 3 x 3 capsules alpha-galactosidase enzyme (400 GalU/capsule) or 3 x 3 capsules placebo
1889516|NCT01243866|Other|comprehensive dental treatment|Early treatment children were scheduled for comprehensive dental treatment over a 2-month period (from May to June 2007). All test children had their last dental treatment visit within the last 2 weeks of the second treatment month. The follow-up survey was scheduled for each child to be approximately 6-month after their dental last visit. This step was very important to make sure that all children were examined at exactly the same interval between end of treatment and when re-examined at the follow-up examination.
1889517|NCT01243866|Other|Only emergency dental treatment|Regular treatment did not receive any dental treatment in the period when the early children were treated unless they had toothache or dental infection. In that case they were treated for the pain but did not have comprehensive dental treatment
1889518|NCT01243879|Other|Starvation|60 hours of starvation (fasting) in the presence or absence of visual and odorous food cues
1889519|NCT01249664|Biological|VEGF Trap-Eye (BAY86-5321)|1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed
1889520|NCT01249664|Procedure|No Drug|Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea
1889521|NCT01249677|Drug|insulin glargine|14 patients with type 2 diabetes on previous metformin therapy were treated with insulin glargine, aimed to normalize fasting glycaemia.
1889522|NCT01249690|Drug|Bortezomib,Pirarubicin,Dexamethasone|Bortezomib:1.3mg/m2,on day 1,4,8 and 11 of each 28 day cycle; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
1889523|NCT01249690|Drug|Thalidomide,Pirarubicin,Dexamethasone|Thalidomide:200mg/d, everyday; Pirarubicin:10mg,on day 1 to 4 of each 28 day cycle; Dexamethasone:20mg,on day 1 to 4 and 8 to 11 of each 28 day cycle; Number of cycles: up to 8 cycles.
1889524|NCT01249716|Dietary Supplement|individual nutritional therapy|individual nutritional therapy provided by a registered dietician by means of three follow-up home visits
1889525|NCT01249742|Behavioral|Internet intervention|Our intervention, Sugarsquare, is a secured treatment environment only accessible by patients of the KDCN and members of the treatment team. Sugarsquare consists of two main sections. The first section is a semi-public setting on which adolescents can exchange experiences with their diabetes (care) through a forum and a real time chat-application. All patients and treatment team members can see all messages posted here. The second section consists of patients' individual pages with treatment overview and an application for private interaction with the treatment team. Patients can only access their own individual page; treatment team members can access pages of all patients. Sugarsquare is a secured webpage, accessible only through computers equipped with the right certificate (access device) and by using the appointed username-password combination.
1889526|NCT01249794|Procedure|non invasive ventilation|continuous positive airways pressure
1889527|NCT01249820|Drug|anidulafungin 200 mg q48h|Day 1-15: anidulafungin 200 mg q48h IV maintenance dose (8 dosages)
1889528|NCT01249820|Drug|anidulafungin 300 mg q72h|Day 1-13: anidulafungin 300 mg q72h IV maintenance dose (5 dosages)
1889529|NCT01249833|Drug|Oseltamivir|Oseltamivir 75mg BID for 5 days
1889530|NCT01249846|Drug|PerioChip ®|
1889531|NCT01249872|Drug|GROUP A : 0 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose 2 ml of normal saline, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
1889532|NCT01249872|Drug|GROUP B : 1 mg MORPHINE- 0.1% LEVOBUPIVACAINE|Patients receive intraoperatively(45 min before the estimated end of the surgery)an epidural bolus dose of 1mg of morphine.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
1889533|NCT01249872|Drug|GROUP C : 2 mg MORPHINE-0.1% LEVOBUPIVACAINE|Patients receive intraoperatively (45 min before the estimated end of the surgery) a bolus dose 2 mg of morphine, epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.1% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
1889534|NCT01249872|Drug|GROUP D : 0 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 2 ml of normal saline epidurally. Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
1889535|NCT01249872|Drug|GROUP E : 1 mg MORPHINE-0.2 % LEVOBUPIVACAINE|Patients receive intra-operatively (45 min before the estimated end of the surgery) a bolus dose of 1mg of morphine, epidurally.Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
1889536|NCT01249872|Drug|GROUP F : 2 mg MORPHINE- 0.2% LEVOBUPIVACAINE|Patients receive an epidural bolus dose of 2 mg of morphine intra-operatively (45 min before the estimated end of the surgery).Postoperatively, immediately after extubation, patients receive patient controlled epidural analgesia (PCEA) of 0.2% levobupivacaine (5ml, lockout interval 10min) combined with a continuous epidural infusion of morphine 0.2 mg/h.
1889537|NCT01249911|Dietary Supplement|Lreuteri|L. reuteri DSM 17938 will be given at a dose of 5 drops containing 1x108 colony-forming units (CFU) once time per day in an oil formulation delivered from a drop bottle. In the active study product, freeze-dried L. reuteri is suspended in a mixture of pharmaceutical grade medium chain triglycerides and sunflower oil together with pharmaceutical grade silicon dioxide to give the product the correct rheological properties.
1889538|NCT01249911|Other|Placebo|The placebo consists of an identical formulation except that the L. reuteri is not present
1889539|NCT01249924|Device|auto-titrated CPAP|Patients will be treated with auto-CPAP preoperatively for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
1889540|NCT01249924|Device|Control|Patients in this group will receive routine care, undergo sleep study on the third postoperative night and be monitored by a pulse oximeter for oxygen saturation level for 2-3 nights preoperatively and 5 nights postoperatively during their sleep.
1889541|NCT01249937|Drug|Ranibizumab|Intra-vitreal injections of 0.5mg/0.05 mL dosage, injected at months 0, 1, and 2. For those requiring additional injections, patients will receive monthly treatment up to a maximum of 6 months total.
1889542|NCT01249937|Drug|Triamcinolone Acetonide|Sub-tenon injection of 40mg/mL dosage at months 0 and 2 with follow up for a total of 6 months.
1889543|NCT01249950|Other|feasibility|feasibility
1889544|NCT01249963|Dietary Supplement|T-Diet plus Atémpero|T-Diet plus Atémpero is a complete normocaloric and normoproteic enteral nutrition product for the dietary management of patients with mild acute pancreatitis.
1889545|NCT01249963|Dietary Supplement|AlitraQ (Abbott)|AlitraQ is a nutritional product for patients with impaired gastrointestinal function.For oral or tube nutrition. Enriched with glutamine and arginine.
1889546|NCT01249976|Other|blood culture|blood culture
1889547|NCT01249989|Behavioral|Sequential MBC Condition|Participants in the sequential condition will increase F/V consumption and decrease Sed behavior (weeks 1-6), then increase physical activity (weeks 7-12). Smartphones are equipped with customized real-time goal thermometers that provide objective feedback on target behaviors (FV, Sed, and PA). At the start of prescription, the FV and Sed goal thermometers are activated. During week 1-2, participants will close 1/3 of the gap between their baseline behaviors and target behaviors. During week 3-4 they will close 2/3 of the gap, and in weeks 5-6 they will achieve 100% of their goals. Participants will maintain these goals for the remainder of the 12-week intervention. At week 7, a real-time PA goal thermometer wirelessly linked to accelerometers will be activated. Similarly, in weeks 7-8 participants will be asked to close 1/3 of the gap between their baseline PA and target, in week 9-10 they will close 2/3 of the gap, and finally they will reach 100% of their PA goal in weeks 11-12.
1889548|NCT01249989|Behavioral|Simultaneous MBC Condition|Simultaneous MBC condition will target FV+, Sed- and PA+ simultaneously. Participants in the simultaneous condition will wear their accelerometers and enter diet and sedentary activity 5 days/week. All 3 goal thermometers will be activated from the outset of prescription. The goal will be to close 1/3 of the gap between their FV, Sed, and PA statuses and the targets in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain target level behavior changes for FV, Sed and PA through week 12.
1889549|NCT01249989|Behavioral|Stress Management|Participants in the stress management control condition target stress, relaxation and sleep. This will serve as an attentional control condition. During the 12-week prescription period, participants will wear accelerometers, log hours slept, enter real-time information about their relaxation exercises and stress, and monitor 3 goal thermometers (sleep, relaxation, stress) to meet behavioral targets. Similarly, their goal is to close 1/3 of the gap between their baseline stress, sleep, and performance of relaxation exercises and the target criterion in weeks 1-2, close 2/3 of the gap in weeks 3-4, reach their targets in weeks 5-6, and then maintain these behavior changes through week 12.
1889550|NCT01251120|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks plus background DMARDs (including methotrexate)
1889551|NCT01251120|Drug|DMARD|Non-biologic DMARDs (including methotrexate) according to current best practice
1889552|NCT01251133|Biological|LBVH0101 (Hib vaccine)|0.5mL
1889553|NCT01251133|Biological|Hiberix™ Vaccine|0.5mL
1889554|NCT01251146|Drug|Bisoprolol|Bisoprolol will be administered at a dose of 5 milligram (mg) once daily for 2 weeks. If heart rate is less than or equal to 65 beats per minute (bpm), then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 7.5 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate is still greater than 65 bpm, then the dose will be further increased to 10 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
1889555|NCT01251146|Drug|Atenolol|Atenolol will be administered at a dose of 50 mg once daily for 2 weeks. If heart rate is less than or equal to 65 bpm, then the initial dose will be administered for another 2 weeks. If the heart rate remains greater than 65 bpm, then the dose will be further increased to 75 mg once daily for 2 weeks. After 2 weeks, if the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks. If the heart rate still greater than 65 bpm, then the dose will be further increased to 100 mg once daily for 2 weeks. After 2 weeks, If the heart rate is less than or equal to 65 bpm, the increased dose will be administered for another 2 weeks.
1889556|NCT01251159|Genetic|mutation analysis|
1889557|NCT01251159|Genetic|polymerase chain reaction|
1889558|NCT01251159|Other|immunologic technique|
1889559|NCT01251159|Other|laboratory biomarker analysis|
1889560|NCT01251172|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
1889561|NCT01251172|Drug|Gamma-Secretase Inhibitor RO4929097|Given orally
1889562|NCT01251172|Procedure|Hematopoietic Stem Cell Mobilization|Undergo standard mobilization
1889563|NCT01251172|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo in vitro treated autologous peripheral blood stem cell transplant
1889564|NCT01251172|Other|Laboratory Biomarker Analysis|Correlative studies
1889565|NCT01251172|Drug|Melphalan|Given IV
1889566|NCT01251185|Device|Cardiospec|Non-invasive, low-intensity extracoporeal shockwaves at energy density of 0.99 mJ/mm2. 9 treatment sessions, 20 minutes each, over a period of 9 weeks (3 sessions on weeks 1, 5 and 9).
1889567|NCT01251211|Drug|botulinum toxin type A|BTX A : 5 units/0.2 ml, maximum 300 units will be injected subcutaneous in the painful area ; this will be performed after randomization and within a minimum of 3 months interval depending on the duration of efficacy (maximum 6 months) Saline will be injected in the same volume in the painful area within the same frequency
1889568|NCT01251224|Other|Integrated Pest Management|The IPM intervention will include professional mouse abatement, two HEPA filters, targeted cleaning, education about IPM, and allergen-proof mattress and pillow encasements. The intervention will be delivered at baseline to the IPM Group, and then repeated if recurrent or persistent mouse infestation is present.
1889569|NCT01251224|Other|Education|This group will receive education about mouse IPM.
1889570|NCT01251237|Drug|NRL0706|Patients receive 1 litre of NRL0706 solution followed by 0.5 litre of clear liquid during the afternoon/evening prior to colonoscopy. Patients receive 1 litre of 0706 solution followed by 0.5 litre of clear liquid during the morning of colonoscopy.
1889571|NCT01251250|Other|laboratory biomarker analysis|Correlative studies
1889572|NCT01251250|Genetic|western blotting|Correlative studies
1889573|NCT01251250|Genetic|gene expression analysis|Correlative studies
1889574|NCT01251250|Other|pharmacological study|Correlative studies
1889575|NCT01251250|Other|flow cytometry|Correlative studies
1889576|NCT01251250|Genetic|fluorescence in situ hybridization|Correlative studies
1889577|NCT01251250|Biological|azadirachta indica|Given orally
1889578|NCT01251250|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
1889579|NCT01251263|Drug|Estradiol or Placebo|Estradiol 1mg twice daily or placebo starting on the last day of OC and continuing during the HFI (total of 9 doses).
1889580|NCT01251263|Drug|Estradiol or Placebo|Estradiol 1mg will be taken twice daily starting with the last day of pills and the 4 days of the HFI(total of 9 doses)
1889581|NCT01251276|Biological|Modified Process Hepatitis B Vaccine|Modified Process Hepatitis B Vaccine given IM (intramuscular) as a single 1.0 mL (10 mcg) challenge dose on Day 1 of the Challenge Dose Study
1889583|NCT01251315|Drug|Placebo low dose|This is a prospective randomized controlled pilot study, which will include twenty-four (24) healthy individuals.The first 12 subjects (low dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
1889584|NCT01251315|Drug|N Acetyl cysteine, 600mg (low dose)|The sub-group of four subjects (low dose) will be given a single dose of 600 mg of N-Acetyl Cysteine (NAC).
1889585|NCT01251315|Drug|Proimmune 200 (FT061452) 3000mg low dose|The sub-group of four subjects (low dose) will be given a single dose of Proimmune 200 (FT061452) 3000mg low dose'
1889586|NCT01251315|Drug|Placebo (high dose)|The second sub set of 12 subjects (high dose) will be randomized into three sub groups. The first group will be given a single dose of placebo.
1889587|NCT01251315|Drug|N Acetyl cysteine, 1200mg (high dose)|N Acetyl cysteine (high dose) N-Acetyl Cysteine(NAC)1200mg (high dose) given as a single dose.
1889588|NCT01251315|Drug|FT061452, 6000mg high dose|Proimmune 200(FT061452) high dose group given 6000 mg as a single dose.
1889589|NCT01251328|Procedure|General anaesthesia|general anaesthesia is performed according to the hospitals standard
1889590|NCT01251328|Procedure|Sedation|Sedation is performed according to the hospitals standard
1889591|NCT01251341|Behavioral|Cognitive-Based Compassion Training|Eight-week training in compassion meditation, using a protocol developed by Geshe Lobsang Negi, Ph.D. of Emory University
1889592|NCT01251341|Behavioral|Mindful Attention Training|Eight week training in mindful attention, using a protocol developed by B. Alan Wallace, Ph.D.
1889593|NCT01251341|Behavioral|Adult Health Education Curriculum|Eight week training in health and wellness, using a curriculum developed specifically for this study.
1889594|NCT01251354|Drug|BN83495|1 tablet of 40 mg, oral, daily until progression or death or unacceptable toxicity develops
1889596|NCT01251380|Drug|Botulinum type A toxin (Dysport®)|Intramuscular (IM) injection on day 1 of each treatment cycle.
1889597|NCT01251393|Drug|Biperiden|Thirty volunteers will take three pills of Biperiden (6mg/day) during two months.
1889598|NCT01251393|Drug|Placebo|Thirty volunteers will take three pills of Placebo (6mg/day) during two months.
1889599|NCT01251406|Drug|Placebo|Daily subcutaneous administration for 8 hours a day for 10 days
1889600|NCT01251406|Drug|rhNRG-1 Dose 1|Daily subcutaneous administration for 8 hours a day for 10 days
1889601|NCT01251406|Drug|rhNRG-1 Dose 2|Daily subcutaneous administration for 8 hours a day for 10 days
1889602|NCT01251419|Other|Social Proximity and Conversion to Generic Medications|At companies where employees are predominantly union members, we will compare the efficacy of a peer information intervention using a testimonial from a union identified employee to an intervention using a testimonial with no union identification, as well as to a no-testimonial intervention.
1889603|NCT01251458|Drug|Torisel|Torisel will be administered intravenously as an IV infusion over a 30-minute period in adult clinical studies.
1889604|NCT01251471|Drug|Escitalopram|10 mg/d; optional 20 mg/d after 2 weeks.
1889605|NCT01251484|Drug|BIBF1120|Tablet 200 mg twice daily until progression
1889606|NCT01251497|Behavioral|diabetes self-management education|
1889607|NCT01251523|Behavioral|PACE|The first intervention to be tested, Physician Asthma Care Education (PACE), is a rigorously evaluated intervention for physicians that has reached hundreds of clinicians across the U.S. and also has been implemented in the United Kingdom and Australia. The efficacy trial of PACE was supported by the National Heart, Lung and Blood Institute and the effectiveness trial by the Robert Wood Johnson Foundation. PACE is now widely available to clinicians, through, among other channels, the National Asthma Education and Prevention Program (NAEPP). It is designed to enhance physician communication, counseling and therapeutics for assisting the general population of children with asthma.
1889608|NCT01251523|Behavioral|PACE Plus|In the PACE PLUS intervention a cultural competence component will be added to the PACE curriculum. The cultural competence component uses mini-lecture, video demonstration (video to be developed as part of this proposal), case studies and self observation tools to present the principles of cultural competence derived from the study of the literature. The component integrates into the skills taught, specific content related to working with African American and Puerto Rican families where a child has asthma.
1889609|NCT01251536|Drug|Dose escalation of cetuximab|"Dose, frequency & treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)
Arm allocation at day 22:
Patients with skin toxicity grade 0 will follow an increasing dose schedule: on days 22 and 29 they will receive 350 mg/m2 and from day 36 onwards, 500 mg/m2 weekly"
1889694|NCT01252017|Drug|nilotinib|nilotinib (200mg/tab) 1 tab everyday
1960631|NCT03164616|Drug|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until disease progression or other discontinuation criteria
1889610|NCT01251536|Drug|Standard first line treatment with cetuximab + Folfiri|"Dose, frequency & treatment mode: 400 mg/m2 (loading at day 1) followed by 250 mg/m2 weekly (at day 8 and 15)
Arm allocation at day 22:
Patients with skin toxicity grade 1-4 or other significant toxicity who are not eligible for dose escalation will continue on the standard dose of cetuximab: 250 mg/m2 weekly."
1889611|NCT01251549|Device|ReWalk - a motorized exoskeleton suit|The subject will wear the ReWalk suit and have training sessions for walking with the device
1889612|NCT01251562|Drug|Sterile Compound c31510 for Injection|During the treatment period, subjects in each initial dose level cohort will have a single 4-hour IV infusion of C31510 at the assigned dose level of their particular cohort, three times per week for 26 days (on Day 1, 3, 5, 8, 10, 12, 15, 17, 19, 22, 24 and 26) followed by a 28-day follow up period that will be counted from the first dose given on Day 1. In the absence of unacceptable toxicity or disease progression during the treatment period, those subjects may receive similar 28-day repeat treatment cycles of 3 times per week for up to 1 year, at the discretion of the investigator.
1889621|NCT01251588|Biological|autologous cultured chondrocytes on porcine collagen membrane|Implantation received in the previous MACI00206 study
1889622|NCT01251588|Procedure|Microfracture|Arthroscopic Microfracture treatment received in the previous MACI00206 study
1889623|NCT01251601|Other|Pharmacokinetics|Up to three 12 hour PK sampling sessions, one in the second trimester, one in the third trimester and one post partum
1889624|NCT01251614|Biological|Adalimumab|Adalimumab by subcutaneous injection every other week (eow)
1889625|NCT01251614|Drug|Methotrexate|Methotrexate 0.1 mg/kg at Week 0 and up to 0.4 mg/kg per week (maximum dose of 25 mg/week) orally.
1889626|NCT01251614|Biological|Placebo to Adalimumab|A single subcutaneous loading dose at Week 0 followed by eow dosing beginning at Week 1.
1889627|NCT01251614|Drug|Placebo to Methotrexate|Orally once a week
1889628|NCT01251627|Drug|Decitabine|Decitabine will be administered at a dose of 20 mg/m2 infused over a 1 hour period once daily for 5 consecutive days. The totale amount per course is 100 mg/m2. Cycles will be administered every 4 weeks (1 cycle of 28 days).It is recommented that patients be treated for a minimum of 4 cycles.
1889629|NCT01251640|Drug|BAY86-9766+Gemcitabine|Phase I: 40 mg/day (20 mg twice daily), 60 mg/day (30 mg twice daily, 100 mg/day (50 mg bid) dependent on safety/tolerability Phase II: Recommended Phase II dose (RP2D) dependent on the results of the Phase I part of this study Route of administration: Oral, twice daily (bid) in combination with gemcitabine 1000 mg/m2 Intravenous infusion over 30 minutes weekly for seven out of eight weeks (Cycle 1); followed by 1000 mg/m2 Intravenous infusion over 30 minutes weekly for three out of four weeks (Cycle 2 and subsequent)
1889630|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
1889631|NCT01251653|Drug|Afatinib|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
1889632|NCT01251653|Drug|docetaxel|Maximum Tolerated Dose of Afatinib in combination with docetaxel
1889633|NCT01251653|Drug|gemcitabine|Maximum Tolerated Dose of Afatinib in combination with gemcitabine
1889634|NCT01251666|Other|Colonoscopy|Colonoscopy if at least one of the faecal occult blood tests is positive (blinded to each test result)
1889635|NCT01251679|Behavioral|Hand washing|hand washing education and material
1889636|NCT01251679|Device|Hand washing and surgical mask|hand washing education and material and paper surgical face masks
1889637|NCT01251692|Procedure|Surgery|The corneal epithelium was debrided, and laser ablation was performed to a depth of 5 micron with an ablation zone of 7 to 9 mm, using the Technolas 217C Plano Scan excimer laser.
1889638|NCT01251718|Drug|donepezil hydrochloride|Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
1889639|NCT01251731|Drug|E5501|Treatment Group 1: 10mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 40mg E5501 in Treatment Period 2, followed by a single dose of 80mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose reatment Period.
1889640|NCT01251731|Drug|E5501|Treatment Group 2: 40 mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 80mg E5501 in Treatment Period 2, followed by a single dose of 10mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
1889641|NCT01251731|Drug|E5501|Treatment Group 3: 80mg E5501 as a single dose in Treatment Period 1, followed by a single dose of 10mg E5501 in Treatment Period 2, followed by a single dose of 40mg E5501 in Treatment Period 3, followed by a selected dose for the Multiple Dose Treatment Period.
1889642|NCT01251731|Drug|E5501|Treatment Group 4: A single dose of matching placebo in each of the three Single Dose Treatment Periods and in the Multiple Dose Treatment Period
1960632|NCT03164616|Drug|Tremelimumab|IV infusions every 3 weeks for 12 weeks (4 cycles). An additional dose of tremelimumab will be administered in the week 16.
1960633|NCT03164616|Drug|Abraxane + carboplatin|Standard of care chemotherapy (squamous and non-squamous patients)
1960634|NCT03164616|Drug|Gemcitabine + cisplatin|Standard of care chemotherapy (squamous patients only)
1960635|NCT03164616|Drug|Gemcitabine + carboplatin|Standard of care chemotherapy (squamous patients only)
1960636|NCT03164616|Drug|Pemetrexed + carboplatin|Standard of care chemotherapy (non-squamous patients only)
1889695|NCT01252030|Device|physical activity monitors|physical activity monitors
1889696|NCT01252030|Other|No physical activity monitors|No physical activity monitors
1889697|NCT01252056|Drug|Probucol|250mg,Bid
1960637|NCT03164616|Drug|Pemetrexed + cisplatin|Standard of care chemotherapy (non-squamous patients only)
1889648|NCT01251757|Other|Interactive Voice Recognition (IVR) phone calls|"The IVR intervention consisted of automated phone calls designed to educate participants about their medications and to assist them in refilling their prescriptions. The calls fell into two basic types: simple refill reminders and tardy calls for those who were overdue for a refill. Calls occured monthly and were triggered by dispensing information in the electronic medical record (EMR). Call features included the ability to transfer individuals to Kaiser's automated prescription refill service as well as to care managers. Although the calls were triggered by and focused on use of ACE inhibitors, ARBs and statins, they also included reminders to use aspirin, which is known to also be effective for secondary prevention in this patient population."
1889649|NCT01251757|Other|Educational mailings and follow-up for nonadherence|Participants received bimonthly educational materials by mail. In addition, patients received mailed refill reminder letters and their providers were notified electronically if the patients failed to refill in response to the automated calls. The educational mailings included personalized health information such as the participant's cholesterol and blood pressure readings, as well as tools for improving adherence such as frequently asked questions (FAQs) about their medications, a pocket-sized calendar for tracking refills with pertinent phone numbers and web site information and space for them to write their medical record number and prescription numbers.
1889650|NCT01251770|Drug|0.45% NaCl/dextrose 5%|Subjects in this arm will receive 0.45% NaCl/dextrose 5% intravenous (IV) maintenance fluids.Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 body surface.
1889651|NCT01251770|Drug|0.3% NaCl/dextrose 5%|Drug: 0.3% NaCl/dextrose 5% IV maintenance fluids. Total daily fluid infusion equal to: 80 ml/kg/day for those weighing up to 10 kg, and 1500 ml/m^2 surface.
1889652|NCT01251783|Dietary Supplement|Infant Formula|Only Infant Formula without Lactobacillus, Metlin OR Metlos
1889653|NCT01251783|Dietary Supplement|Exclusively breast milk|Children non randomized which mothers decided to feed them with exclusively breast milk
1889654|NCT01251783|Dietary Supplement|Metlin+metlos+Lactobacillus GG|A prebiotic Agave Derivated Metlin+Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
1889655|NCT01251783|Dietary Supplement|Metlin + Lactobacillus GG|A prebiotic Agave Derivated Metlin (6g/L) + 0.3x107 UFC Lactobacillus GG
1889656|NCT01251783|Dietary Supplement|Metlos + lactobacillus GG|A prebiotic Agave Derivated Metlos (6g/L) + 0.3x107 UFC Lactobacillus GG
1889657|NCT01251783|Dietary Supplement|Lactobacillus GG|An Infant Formula added with 0.3x107 UFC Lactobacillus GG with no Metlin or Metlos
1889658|NCT01251796|Drug|ARQ 197 and Erlotinib|Orally twice daily administration of ARQ197 and orally once daily administration of erlotinib hydrochloride
1889659|NCT01251809|Drug|Oncaspar|2000 U/m2 BSA, single infusion
1889660|NCT01251809|Drug|PEG-rASNase|500, 1000 or 1500 U/m2 BSA single infusion
1889663|NCT01251835|Drug|Sitaxsentan alone|Days 1-5: Sitaxsentan tablet, 100 mg, q24 h (once a day)
1889664|NCT01251835|Drug|Sitaxsentan|Days 6-12: Sitaxsentan tablet, 100 mg, q24h (once a day)
1889665|NCT01251835|Drug|Rifampin|Days 6-12: Rifampin capsule, 600 mg, q24h (once a day)
1889666|NCT01251848|Drug|Sitaxentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days.
1889667|NCT01251848|Drug|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days (morning dose only on Day 5).
1889668|NCT01251848|Drug|Sitaxsentan|Sitaxsentan Tablet, 100 mg, q24h (once daily) for 5 days
1889669|NCT01251848|Drug|Ritonavir|Ritonavir Capsule, 100 mg, q12h (twice daily) for 5 days
1889683|NCT01251926|Drug|EZN-2208|
1889684|NCT01251926|Drug|Bevacizumab|
1889685|NCT01251939|Device|Near-infrared spectroscopy (NIRS)|Non-invasive monitoring device measures the quantity of reflected light photons as a function of two wavelengths, and determines the spectral absorption of the underlying tissue.
1889686|NCT01251952|Drug|Denileukin Diftitox (Ontak)|"After receiving their stem cell transplant on Day 0, participants will receive study agent via a 30 minute infusion. Participants will also receive a 30 minute infusion of study agent on Day 21.
Follow-up visits for clinical assessment, blood draws for routine clinical laboratory studies and for immuno-correlative studies will also take place on days 42, 90, 180 and 360."
1889688|NCT01251978|Drug|Ranibizumab 2 mg|intravitreal injections of ranibizumab once a month, times 3.
1889689|NCT01251978|Drug|0.5 mg Ranibizumab|6 intravitreal injections of 0.5 mg Ranibizumab every 2 weeks x 3 months.
1889690|NCT01251991|Drug|Psyllium husks|Oral suspension, oral use, two daily dosages consisting of 5 grams each
1889691|NCT01251991|Dietary Supplement|Isolated soy protein|Oral suspension, oral use, 30 grams once per day
1889692|NCT01251991|Dietary Supplement|Isolated whey protein|Oral suspension, oral use, 30 grams once per day
1889698|NCT01252056|Drug|Probucol and Cilostazol|50-100mg,Bid
1889699|NCT01252069|Drug|PGL4001, placebo, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of placebo (oral tablets) during 3 periods each ending with a drug free period until return of menses.
1889700|NCT01252069|Drug|PGL4001, progestin, drug free period|PGL4001 10mg once daily (oral tablets) for 3 months followed by a period of 10 days of progestin Norethisterone acetate 10mg once daily (oral tablets) during 3 periods each ending with a drug free period until return of menses.
1889701|NCT01252082|Procedure|Scaling and Rootplaning|All patients in the test group receive scaling and rootplaning under local anesthesia
1889703|NCT01252108|Drug|SQ109|300 mg SQ109 daily for 14 days
1889704|NCT01252121|Other|Systane Ultra Lubricant Eye Drops|One drop in study eye, one time, during office visit.
1889705|NCT01252121|Other|Hialid 0.1 Artificial Tears Eye Drops|One drop in study eye, one time, during office visit.
1889706|NCT01252121|Other|Unisol 4 Saline Solution|One drop in study eye, one time, during office visit.
1889707|NCT01252134|Device|Biotrue multipurpose solution|Contact lens care solution
1889708|NCT01252134|Device|Sauflon Synergi multipurpose solution|Contact lens care solution
1889709|NCT01252134|Device|OTE Elements multipurpose solution|Contact lens care solution
1889710|NCT01252134|Device|Silicone hydrogel contact lenses (Acuvue Advance)|Commercially marketed contact lenses
1889711|NCT01252147|Other|No treatment|No treatment (intervention) will be provided in this study
1889712|NCT01252160|Drug|QUTENZA|Cutaneous patch
1889713|NCT01252186|Drug|91-day Levonorgestrel Oral Contraceptive|91-day treatment consisting of 84 blue combination tablets containing 150 µg LNG/30 µg EE and 7 yellow tablets containing 10 µg EE.
1889714|NCT01252186|Drug|28-day Levonorgestrel Oral Contraceptive|21 combination tablets containing 150 µg LNG/30 µg EE.
1889715|NCT01252186|Drug|28-day Desogestrel Oral Contraceptive|21 combination tablets containing 150 µg DSG/30 µg EE.
1889716|NCT01252199|Drug|cαStx1/cαStx2|cαStx1/cαStx2 administered concomitantly at a dose of 1 mg/kg (low dose cohort) or 3 mg/kg (high dose cohort)per antibody over 1 hour + standard of care
1889717|NCT01252199|Drug|Placebo|Placebo administered over 1 hour + standard of care
1889718|NCT01252212|Behavioral|SMS medication adherence|SMS messages to cell phones.
1889719|NCT01252212|Behavioral|No SMS adherence reminder|In this arm, patients will be sent supportive lifestyle suggestions to their phone using SMS technology but will not be sent a reminder regarding their medication adherence.
1889720|NCT01252225|Drug|10 % Lidocaine|600 mg Nebulised Lidocaine ( 6 mls of 10 % Lidocaine) one-off dose
1889721|NCT01252225|Drug|10 % Lidocaine|100 mg Lidocaine ( 1 ml of 10 % Lidocaine) given as one-off throat spray.
1889722|NCT01252225|Drug|0.9% saline|6 mls of 0.9% saline nebulised followed by 1 ml of 0.9% saline as throat spray
1889723|NCT01252238|Drug|Aliskiren|Aliskiren 150 mg daily for 10 weeks, force titrated after initial 2 weeks.
1889724|NCT01252238|Drug|Valsartan and Aliskiren|Subject taking combination of valsartan and aliskiren.
1889725|NCT01252238|Drug|Amlodipine|Taking Amlodipine as prescribed by MD for management of high blood pressure.
1889726|NCT01252251|Drug|RAD001 (Everolimus) and Pasireotide (SOM230) LAR|Patients will be treated with SOM-230 (pasireotide) LAR 60mg IM once every 28 days and with RAD001 (Everolimus) 10mg PO daily. Each cycle is 28 days. An optional biopsy may be requested required after weeks of therapy. The biopsy may be performed between days 28 and 42.
1889727|NCT01252277|Drug|Lovaza™|4 capsules daily for 6 months
1889728|NCT01252290|Drug|Lovaza™|4 capsules daily for 6 months
1889729|NCT01252303|Behavioral|Nutrisystem|Nutrisystem meal replacements for 12 weeks
1889730|NCT01252316|Other|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. The subject's will undergo training in-hospital then they will be encouraged to take the kit home with them to practice CPR with their family members and friends.
1889731|NCT01252316|Other|Implementation of an In-Hospital CPR Training Model|UPHS Nurses and Volunteers will be trained in our in-hospital CPR Training Model using VSI Kits, and encouraged to implement the training program in their respective hospitals.
1889733|NCT01252342|Drug|Oxytocin|10 U intramyometrial oxytocin bolus immediately after cesarian delivery, and an infusion of 20 U/L of oxytocin at 500ml/hr.
1889734|NCT01252342|Drug|Saline|10U intramyometrial normal saline bolus immediately after cesarian delivery, and an infusion of 20U/L of oxytocin at 500ml/hr.
1889735|NCT01252355|Drug|Teriflunomide|"Film-coated tablet
Oral administration"
1889736|NCT01252355|Drug|Placebo (for teriflunomide)|"Film-coated tablet
Oral administration"
1889737|NCT01252355|Drug|Interferon-beta (IFN-beta)|"Any of the IFN-beta which are approved for marketed use in the country where the patient is enrolled.
Administration according to the package insert."
1889738|NCT01252368|Biological|hypertension|patients taking daily ACE inhibitors or sartanes
1889739|NCT01252381|Other|12 weeks Strength exercise training|Training 3 times a week, leg extensions and leg press
1889740|NCT01252407|Other|transcutaneous electrical nerve stimulation|Application of low frequency (10-Hz) and high frequency (100-Hz) TENS, in two different days
1889741|NCT01252420|Drug|Enoxaparin|1.5mg/kg daily for 2 weeks
1889742|NCT01252433|Other|Energy density feeding study|In a crossover study, children are served all foods 1 day a week for 3 weeks. Meal entrees will vary in energy density (100%, 85%, 75%).
1889743|NCT01252459|Radiation|Radiation Therapy|Experimental intervention (Arm A): High-precision re-irradiation (stereotactic fractionated radiation therapy (SFRT) and/or image guided radiation therapy, (IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on AA-PET: GTV = AA uptake on PET, clinical target volume (CTV) = GTV+3mm, PTV = CTV+2mm
1889744|NCT01252459|Radiation|Radiation Therapy|Control intervention (Arm B): High-precision re-irradiation (SFRT and/or IGRT), total dose 39 Gy, 3 Gy/d, 5x/ week. Target volume delineation based on T1Gd-MRI: GTV = contrast enhancement on T1Gd-MRI, CTV = GTV+3mm, PTV = CTV+2mm
1889745|NCT01252511|Procedure|RYGB for surgical treatment of severe obesity|Twenty severely obese patients who have been scheduled to receive long limb RYGB will be enrolled in the study. By randomization, 10 patients will have a biliopancreatic limb that includes 40 cm of jejunum and a Roux limb that contains 150 cm of jejunum. The other 10 patients will receive a biliopancreatic limb that contains 75 cm of jejunum and a Roux limb of 115 cm.
1889746|NCT01252524|Drug|Placebo|Placebo tablet po TID before each meal with 8 oz of water for 6 months
1889747|NCT01252524|Drug|Calcium polycarbophil|calcium polycarbophil 625 mg po TID before each meal with 8 oz water for 6 months
1889748|NCT01252550|Dietary Supplement|Activia® (125g/pot)|Activia® (125g/pot) - dairy product containing bacterial culture Acti Regularis®
1889749|NCT01252550|Dietary Supplement|Acidified non-fermented dairy product|Acidified non-fermented dairy product (125g/pot)
1889751|NCT01252589|Other|HRQOL questionnaire|
1889752|NCT01252615|Behavioral|patient only|education, behavioral strategies, psychological interventions
1889753|NCT01252615|Behavioral|patient and partner intervention|education, psychological support, behavioral strategies
1889754|NCT01252628|Drug|PX-866 (SCCHN)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
1889755|NCT01252628|Drug|Cetuximab (SCCHN)|Cetuximab administered weekly on a 21 day cycle, as standard of care in patients.
1889756|NCT01252628|Drug|PX-866 (CRC)|PX-866 administered at the MTD/RD in combination in patients administered weekly on a 21 day cycle.
1889757|NCT01252628|Drug|Cetuximab (CRC)|Cetuximab administered weekly on a 21 day cycle in patients, as standard of care.
1889758|NCT01252641|Biological|SB-728-T|Each infusion will be 5-30 billion modified CD4+ T-cells
1889759|NCT01252667|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
1889760|NCT01252667|Drug|Clofarabine|Given IV
1889761|NCT01252667|Drug|Cyclosporine|Given PO
1889762|NCT01252667|Other|Laboratory Biomarker Analysis|Correlative studies
1889763|NCT01252667|Drug|Mycophenolate Mofetil|Given PO
1889764|NCT01252667|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic hematopoietic PBSCT
1889765|NCT01252667|Other|Pharmacological Study|Optional correlative studies
1889766|NCT01252667|Radiation|Total-Body Irradiation|Undergo TBI
1889767|NCT01252680|Biological|Healive+Healive|Hepatitis A vaccine (Healive), 250 u per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
1889768|NCT01252680|Biological|Healive+Havrix|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Healive, followed by another dose of Havrix after 6 months
1889769|NCT01252680|Biological|Havrix+Havrix|Hepatitis A vaccine (Havrix), 720 ELU per dose per 0.5 millilitre. Vaccines will be administered two doses in the deltoid muscle of the arm 6 months apart
1889770|NCT01252680|Biological|Havrix+Healive|Two kinds of Hepatitis A vaccines, Healive(250 u per dose per 0.5 millilitre) and Havrix(720 ELU per dose per 0.5 millilitre). The first dose will be administered with Havrix, followed by another dose of Healive after 6 months
1889771|NCT01252693|Drug|Ozarelix|Ozarelix Loading dose of 130 mg SC at randomization will be followed by maintenance dosing of 65 mg SC at day 8, 28 and 56.
1889772|NCT01252693|Drug|Goserelin|Goserelin depot 3.6 mg at randomization will be followed by 3.6 mg SC on days 28 and 56.
1889773|NCT01252706|Behavioral|brief intervention|limit time giving information, motivation, empathy, responsibility, self control
1889774|NCT01252719|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
1889775|NCT01252719|Drug|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
1889776|NCT01252732|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
1889777|NCT01252732|Drug|IV Vancomycin|Intravenous oritavancin and IV placebo or IV vancomycin will be administered for a minimum of 7 days up to a maximum of 10 days.
1889778|NCT01252745|Drug|Testosterone|
1889779|NCT01252745|Drug|Testosterone|
1889780|NCT01252745|Drug|Testosterone|
1889781|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 1|
1889782|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 2|
1889783|NCT01252758|Drug|albuterol sufate DPI (TBS-7) dose 3|
1889784|NCT01252758|Other|Placebo|
1889785|NCT01252758|Drug|Albuterol|
1889786|NCT01252758|Drug|Albuterol|
1889787|NCT01252771|Other|PKM Algorithm|"The subject's serum calcium and phosphorus values will be input into PKM in order to determine the required PhosLo prescription. The prescription is determined as the number of gelcaps per day that must be taken by the subject.
If PKM determines the number of PhosLo gelcaps per day to be greater than or equal to the subject's current prescription, then PKM will calculate the current Ca++ and phosphate balance. Furthermore, the PKM algorithm will determine the additional number of PhosLo gelcaps needed to achieve neutral phosphate (P) balance with serum P reduced to 5.5 mg/dL.
The PKM algorithm also calculates the total P intake between dialyses and along with ePCR also calculates a Phosphorus/Protein Ratio (PPR). This ratio ranges from 8 to 14 in dialysis patients following a renal diet."
1889788|NCT01252797|Radiation|Stereotactic Radiosurgery|"Group A will start at dose level II: 15 Gy
Group B will start at dose level I: 12 Gy"
1889789|NCT01252810|Drug|GE-145|GE-145-320 mg I/mL as a single iv. administration. Comparator agent Isovue (iopamidol) 370 mg I/mL as a single iv. administration.
1889790|NCT01252823|Device|Implantation of ILR|Subcutaneous implantation of ILR under local anesthesia
1996747|NCT02390427|Drug|Taselisib|
1996748|NCT02390427|Drug|Trastuzumab emtansine|
1996749|NCT02390427|Drug|Pertuzumab|
1889792|NCT01252849|Device|iStent|Implantation of One iStent through a small temporal clear corneal incision.
1889793|NCT01252849|Device|iStent|Implantation of Two iStents through a small temporal clear corneal incision
1889794|NCT01252849|Device|iStent|Implantation of Three iStents through a small temperal clear corneal incision
1889795|NCT01252862|Device|iStent|Implantation of two iStents through a small temporal clear corneal incision
1889796|NCT01252875|Procedure|Target : 100 mg/dL (+/-10 mg/dL)|Statin +/- other lipid lowering therapy during 3 years, Target : LDL-C =100 mg/dL (+/-10 mg/dL), recording recurrent non fatal stroke, non fatal MI, and vascular death and others endpoints such as new onset diabetes, hemorrhagic strokes.
1889797|NCT01252875|Procedure|70 mg/dL|Statin +/-lipid lowering therapy during eight and a half years maximum, Target : LDL-C concentration of less than 70 mg/dL, recording recurrent of non fatal stroke, non fatal IM, and vascular death and others endpoints such as: new onset diabetes, hemorrhagic strokes.
1889798|NCT01252888|Device|iStents|Implantation of two iStents through a small temporal clear corneal incision
1889799|NCT01252914|Device|iStent Supra Stent|Implantation of one iStent Supra Stent through a small temporal clear corneal incision
1889800|NCT01252927|Other|ASIST|The gatekeeper training intervention group will receive the Applied Suicide Intervention Skills Training (ASIST) workshop in addition to training as usual. ASIST is a 2-day intensive, interactive and practice-dominated course aimed at enabling people to recognize risk and learn how to intervene immediately to prevent suicide.
1889801|NCT01252940|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily (QD)
1889802|NCT01252940|Drug|PI|Protease inhibitors (PIs) included amprenavir, atazanavir, darunavir, fosamprenavir, Kaletra (lopinavir/ritonavir, coformulated), ritonavir, and saquinavir. PIs were administered according to prescribing information.
1889803|NCT01252940|Drug|RTV|Ritonavir (RTV) was administered according to prescribing information.
1889804|NCT01252940|Drug|NRTIs|NRTIs included abacavir, emtricitabine, Combivir (lamivudine/zidovudine, coformulated), Epzicom (abacavir/lamivudine, coformulated), lamivudine, stavudine, tenofovir DF, Truvada® (emtricitabine/tenofovir DF, coformulated), and zidovudine. NRTIs were administered according to prescribing information.
1889805|NCT01252953|Drug|anacetrapib|tablet, 100mg daily
1889806|NCT01252953|Drug|placebo anacetrapib|tablet, 1 tablet daily
1889807|NCT01252966|Behavioral|Cognitive Training|The computerized cognitive training intervention is a 12-week standardized course of internet-based computerized cognitive exercises designed to enhance executive cognitive function.
1889808|NCT01252966|Behavioral|Control training|The computerized control training intervention is a 12-week standardized course of internet-based deep breathing exercises which does not contain the cognitive exercises designed to enhance executive cognitive function.
1889809|NCT01252979|Dietary Supplement|Medium-Chain Triglycerides|Subjects will take supplemental MCT oil 3 times a day for 6 months
1889810|NCT01252992|Genetic|Genetic analysis|"identification of candidates genes by a differential analysis of the whole transcriptome of the peripheral leucocytes of 20 PR+ patients and 20 RP- controls, at D0, D15, M2,;
Genetic association analysis: comparison of allelic distributions of SNPs (diallelic markers) within the candidate genes, between PR+ and PR- patients, in the whole cohort.
One supplementary ACD tube of 5 ml à D0, D15, M2, PR+, for RNA extraction."
1889811|NCT01252992|Radiation|Body scan (CERVICO THORACO ABDOMINAL) + Cranian IRM|at day 0, Month 2, paradoxical reaction, end of treatment, read by an independent radiologist
1889812|NCT01252992|Other|Immunologic analysis|For patients included until 20 PR+ : blood puncture of 4 ACD tubes of 10 ml, 1 EDTA tube of 7,5 ml et 1 heparinate lithium tube of 7,5ml at D0, D15, M2, and M6 and at the time of an potential RP+
1889813|NCT01252992|Other|QuantiferonTB Gold test|at M0, M2, M6 and in case of PR+.
1889814|NCT01253005|Behavioral|Nutritional intervention|This study will investigate the effects of particle size of different triglyceride emulsions as well as the dynamics of intragastric structure formation and breakdown of the emulsions on GI function, the kinetics of the endocrine and the satiation response in healthy volunteers.
1889815|NCT01253018|Behavioral|Robot Therapy|Robot assisted arm exercise for 60 minutes progressing each month through three robot modules: wrist, planar, and alternating sessions on the wrist and planar robot 3x/week for 12 weeks.
1889816|NCT01253018|Behavioral|Transition to Task Training|Robot therapy as described for 45 minutes and 15 minutes of task specific arm exercise using the hemiparetic arm 3x/week for 12 weeks.
1889817|NCT01253044|Behavioral|Acceptance and Commitment Therapy|Acceptance and Commitment Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
1889818|NCT01253044|Behavioral|Present Centered Therapy|Present Centered Therapy, delivered twelve 60-minute one-on-one treatment sessions over 6-10 weeks (additional weeks are permissible if needed).
1889819|NCT01253070|Drug|Daunorubicin Hydrochloride|Given IV
1889820|NCT01253070|Drug|Sorafenib Tosylate|Given PO
1889821|NCT01253070|Drug|Cytarabine|Given IV
1889822|NCT01253070|Procedure|Bone Marrow Aspiration|Undergo bone marrow aspirate
1889823|NCT01253070|Procedure|Biopsy|Undergo biopsy
1889824|NCT01253070|Other|Laboratory Biomarker Analysis|Correlative studies
1889825|NCT01253070|Other|Quality-of-Life Assessment|Ancillary studies
1889826|NCT01253070|Other|Questionnaire Administration|Ancillary studies
1889827|NCT01253083|Behavioral|mobility training with dynamic body weight support|
1889828|NCT01253096|Drug|Intratumoral injections of L19IL2|Patients will be treated with intratumoral injections of L19IL2 1-3 x weekly. The maximum cumulative dose per week is 20 MioIU. Treatment duration is up to 20 weeks.
1889829|NCT01253109|Device|SENSIMED Triggerfish|Contact lens-based device for continuous IOP monitoring
1889830|NCT01253122|Drug|TRx0037|
1889831|NCT01253135|Biological|Fibrin|Topical application of fibrinogen spray, followed by thrombin spray
1889832|NCT01253135|Other|White Petrolatum|Topical application
1889833|NCT01253148|Device|TheraSphere® Yttrium-90 (Y-90) Microspheres|Y-90 is incorporated into very tiny glass beads called microspheres and is injected into the liver through the blood vessels supplying the liver.
1889922|NCT01246986|Drug|Ramucirumab|Administered IV
1889834|NCT01253161|Drug|Pasireotide Long Acting Release (LAR)|Pasireotide will be administered as an intramuscular injection at the beginning of every cycle which is defined as 28 days (+/- 3 days). Study treatment should begin within 14 days following enrollment into the study and continue until disease progression, unacceptable toxicity, or withdrawal of consent.
1889835|NCT01253174|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin, BAY86-5131)|single oral administration of 1 coated tablet SH T470FA (Yasmin, film-coated tablets with ethinylestradiol (EE) as free steroid), containing 0.030 mg EE + 3 mg drospirenone (DRSP)
1889836|NCT01253174|Drug|EE 0.03mg/DRSP 3mg/L-5-MTHF Ca 0.451mg (EE30/DRSP/L-5-MTHF Ca)|single oral administration of 1 coated tablet SH T04532A (film-coated tablet with ethinylestradiol (EE) as clathtrate), containing 0.030 mg EE + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin
1889837|NCT01253174|Drug|L-5-MTHF Ca 0.451 mg (Metafolin)|single oral administration of 1 coated tablet SH T04532C, containing 0.451 mg Metafolin
1889838|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg (YAZ, BAY86-5300)|Treatment group A: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
1889839|NCT01253187|Drug|EE 0.02 mg/DRSP 3 mg/L-5-MTHF Ca 0.451 mg (EE20/DRSP/L-5-MTHF Ca)|Treatment group B: Single 1 film-coated tablet (Ethinylestradiol [EE] 0.02mg / Drospirenone [DRSP] 3mg / L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
1889840|NCT01253187|Drug|L-5-MTHF 0.451mg (Metafolin)|Treatment group C: Single 1 coated tablet (L-5-methyltetrahydrofolate [L-5-MTHF] 0.451mg) taken orally under fasting condition at intervals of at least one menstrual cycle.
1989696|NCT02417064|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
1996750|NCT02390427|Drug|Trastuzumab|
1889843|NCT01253213|Drug|BR55|One to two bolus (2nd bolus optional) of BR55 per patient
1889844|NCT01253226|Drug|LY2127399|Administered subcutaneously
1889845|NCT01253226|Drug|Placebo|Administered subcutaneously
1889846|NCT01253252|Radiation|[18F] Fluorodeoxyglucose PET Scan Imaging|"Positron Emission Tomography (PET) is a nuclear medicine imaging technique which produces a 3-dimensional image of functional processes in the body. The system detects pairs of gamma rays emitted indirectly by a positron-emitting radionuclide, which is introduced into the body on a biologically active molecule. Images of tracer concentration in 3-dimensional space are then reconstructed by computer analysis.
The biologically active molecule chosen for PET is 18-fluorodeoxyglucose. The concentrations of tracer imaged then give tissue metabolic activity, in terms of regional glucose uptake.
The dose of 18FDG that is recommended for adults in a standard exploration varies from 200 to 500 MBq according to the weight of the patient and the camera used. No allergic or other incident has been observed after several thousands of examinations."
1889847|NCT01253252|Radiation|CT scan|Computed tomography (CT) is a medical imaging method employing tomography created by computer processing. Digital geometry processing is used to generate the PET's three-dimensional space image.
1889848|NCT01253252|Biological|Blood sampling for biological investigations|A venous blood sample of a total of 30 ml for measurement of enzymes associated with the development of aneurysms (= biomarkers).
1889849|NCT01253265|Drug|LY2439821|Administered subcutaneously
1889850|NCT01253265|Drug|Placebo|Administered subcutaneously
1889851|NCT01253278|Drug|LY2393910|as capsules, administered orally once daily for two weeks
1889852|NCT01253278|Drug|Placebo|as capsules, administered orally once daily for two weeks
1889853|NCT01253291|Drug|LY2127399|Administered subcutaneously every 4 weeks for 48 weeks
1889854|NCT01253304|Drug|LY2189265|Subcutaneous (SC) injection
1889855|NCT01253317|Drug|rhIGF-1|1) Multiple ascending dose (MAD) period (4 weeks): Subjects will receive escalating twice-daily doses of IGF-1 over 4 weeks (40 µg/kg, 80 µg/kg, 120 µg/kg) and then continue treatment at 120 µg/kg BID for 20 weeks should they choose to enroll in the open-label extension period.
1889856|NCT01253330|Other|Text Message Reminders|During baseline (Participant 1st Arm) or Month 3 Visit (Comparison 1st Arm), the study staff member will demonstrate for the teen how to log-on to the calendar system and set up reminders. Teens will be able to set their own reminders and add other reminders in addition to those that are asthma related.
1889857|NCT01253356|Device|IABP|Insertion of intra-aortic balloon < or = 3 hours before noncardiac surgery and maintained > or = 12-24 hours after surgery
1889858|NCT01253369|Drug|Pazopanib|
1889859|NCT01253382|Biological|ecallantide|10 - 30mg subcutaneous injection.
1889860|NCT01253395|Behavioral|Strength training|Daily supervised strength training.
1889861|NCT01253395|Behavioral|Aerobic exercise|Daily supervised aerobic exercise.
1889862|NCT01253408|Drug|Dronabinol|Dronabinol is a synthetic delta-9-tetrahydrocannabinol, a nonselective cannabinoid agonist. Subjects will receive either 2.5 mg bid, or 5 mg bid, taken orally with water for 2 days.
1889863|NCT01253408|Drug|Placebo|Placebo will match study drug; taken orally with water twice per day for two days.
1996751|NCT02390427|Drug|Paclitaxel|
1889866|NCT01253434|Drug|E2022|E2022 Type A patch
1889867|NCT01253434|Drug|E2022|E2022 Type B patch
1889868|NCT01253434|Drug|E2022|E2022 Type C patch
1889869|NCT01253434|Drug|E2022|E2022 Type D patch
1889870|NCT01253434|Drug|E2022|E2022 Type E patch
1889871|NCT01253447|Drug|Akt inhibitor MK2206|200 mg orally (PO) once weekly. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.
1889872|NCT01253447|Other|laboratory biomarker analysis|Correlative studies
1889873|NCT01253460|Drug|Cyclophosphamide|250 mg/m2 by vein (IV) over 30 minutes, 2 hours following the dose of Sapacitabine on days 1, 2, and 3 of each 28 day course.
1889874|NCT01253460|Drug|Rituximab|375 mg/m2 by vein over 6 - 8 hours on day 3 of course 1 after cyclophosphamide, then at 500 mg/m2 on day 1, after cyclophosphamide for subsequent courses. Each course is 28 days.
1889875|NCT01253460|Drug|Sapacitabine|350 mg flat dose by mouth in the morning of days 1,2, and 3 of each 28 day course.
1890004|NCT01254383|Drug|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
1889876|NCT01253473|Drug|Budesonide|Inhaled budesonide twice daily plus inhaled ipratropium/albuterol combination four times daily and every 4 hours as needed
1889877|NCT01253473|Drug|budesonide/formoterol|Inhaled budesonide/formoterol (160/4.5 mcg Symbicort®) 2 puffs twice daily plus inhaled ipratropium/albuterol (Combivent®) 1 puff four times daily
1889878|NCT01253473|Drug|Ipratropium/albuterol|Inhaled ipratropium/albuterol combination 2 puffs four times daily
1889879|NCT01253486|Behavioral|Disease-related Expressive writing|Participants in the disease-related expressive writing condition write about their feelings about cardiac disease four times, for at least 20 minutes each time, during a two week period.
1889880|NCT01253486|Behavioral|Active Comparator: Traditional expressive writing|Participants in the traditional expressive writing condition write about their feelings about one or more stressful experiences they lived in the past, for at least 20 minutes each time, during a two week period
1889881|NCT01253486|Behavioral|Sham Comparator: Neutral writing|Participants in the neutral writing condition write about the facts about cardiac disease, for at least 20 minutes each time, during a two week period
1889882|NCT01253499|Drug|TRx0037|75mg and 100mg tablets used to create doses of 100mg and 175mg. Active placebo 2mg and blank placebo used as comparators.
1889883|NCT01253512|Drug|THR-18|A single 0.25 or 0.5 mg/kg of THR-18 in combination with tPA treatment.
1889884|NCT01253512|Drug|Placebo|Intravenous
1889885|NCT01253525|Biological|Ramucirumab (IMC-1121B )|8 milligrams/kilogram (mg/kg) intravenously on Days 1 and 15 of each 28-ay cycle
1889886|NCT01253525|Drug|Paclitaxel|80 milligram/square meter (mg/m2) intravenously Days 1, 8, and 15 of each 28 day cycle
1889887|NCT01253551|Drug|Treatment sequence AB|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
1889888|NCT01253551|Drug|Treatment sequence BA|Treatment A: telaprevir 750 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. Treatment B: raltegravir 400 mg twice a day on Days 1 to 10 and telaprevir 750 mg every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
1889889|NCT01253564|Drug|RO5185426|960 mg b.i.d. orally
1889890|NCT01253577|Device|Sinus Stent with drug coating|Sinus stent coated with 370 ug of the corticosteroid mometasone furoate
1889891|NCT01253577|Device|Non Coated Sinus Stent|Sinus stent (visually identical) without drug coating
1889892|NCT01253590|Behavioral|questionnaire about the use of ECG device|Patients will be fitted with a continuous ECG monitor and blood pressure device. Data on every heart beat, including episodes of atrial fibrillation, for 4-6 weeks of continuous monitoring will be collected and transmitted wirelessly. Based on this information and blood pressure readings performed by patients in their home setting, clinicians can adjust oral coagulant dosage. Participants will attend 2 follow-up outpatient visits at the MSKCC outpatient cardiology practice upon the cardiologist's recommendation. Upon completion of the study, 4-6 weeks, a questionnaire will be sent via mail, including a pre-paid envelope, to participants to assess feasibility, acceptance, and overall experience with remote cardiac monitoring.
1889893|NCT01253603|Drug|QAW039 capsules once daily for 28 days|
1889894|NCT01253603|Drug|Placebo to QAW039 capsules once daily for 28 days|
1889895|NCT01253603|Drug|Fluticasone propionate inhaler twice daily for 28 days|
1889896|NCT01246739|Procedure|Adrenalectomy|Adrenalectomy (open or laparoscopic)
1889897|NCT01246752|Biological|Human Stem Cell Transplantation|Human allogenic stem cells
1889898|NCT01246752|Drug|Consolidation chemotherapy, i.e. High-dose Cytarabine (HiDAC)|Consolidation chemotherapy, recommended regimen: HiDAC = 3 x 2g/sqm BID on days 1,3,5
1889899|NCT01246791|Drug|NPC-01|NPC-01, contains 1mg norethisterone and 0.02mg ethinyl estradiol will be administered orally under the fasting condition
1889900|NCT01246804|Drug|raltegravir single dose|single dose 400mg raltegravir
1889901|NCT01246804|Drug|ginkgo biloba multiple dose|15 days ginkgo biloba 120mg BID
1889902|NCT01246817|Drug|Temsirolimus|temsirolimus (standard schedule: 25 mg weekly, by 1-hour i.v. infusion)
1889903|NCT01246830|Radiation|Panoramic radiograph, Cephalometric radiograph|2D images that are used for orthodontic treatment planning
1889904|NCT01246830|Radiation|Cone-beam computed tomography (CBCT)|CBCT data will be used in 3D cephalometric analysis softwares
1889905|NCT01246882|Behavioral|Augmented activity feedback|Feedback about walking speed and amount of physical activity will be provided 3 times per week from data acquired from wireless sensors on each ankle.
1889906|NCT01246882|Behavioral|Speed-only feedback|Feedback about walking speed will be provided 3 times per week.
1889907|NCT01246908|Drug|Placebo|Placebo administered twice per day for six weeks.
1889908|NCT01246908|Drug|CX157 (TriRima)|One tablet administered twice per day (total daily dose of 250 mg) for six weeks.
1889909|NCT01246921|Drug|Fluticasone proprionate 0.05% cream|Fluticasone proprionate 0.05% cream . In each patient a representative target lesion will be selected which will be assessed by digital analysis. Patients will apply Fluticasone proprionate 0.05% cream once daily during the first 3 months. I nthe following 9 months FP will be applied in a scheme of 3 days per week
1889910|NCT01246934|Other|ASR METHOD|
1889911|NCT01246947|Procedure|Tricuspid valve repair|Randomized to receive Tricuspid valve repair using a rigid 3-dimensional annuloplasty ring using standard techniques, during Mitral surgery.
1889912|NCT01246947|Other|Mitral surgery alone|Randomized to Mitral surgery alone
1889913|NCT01246960|Biological|Ramucirumab|Administered intravenously
1889914|NCT01246960|Drug|Placebo|Administered intravenously
1889915|NCT01246960|Drug|Oxaliplatin|Administered intravenously
1889916|NCT01246960|Drug|Leucovorin|Administered intravenously
1889917|NCT01246960|Drug|5-Fluorouracil|Administered intravenously
1889918|NCT01246973|Drug|Curcumin|4 Curcumin C3 Complex 500mg capsules (2.0 g) taken orally 3 times/day throughout course of radiation treatments plus one week
1889919|NCT01246973|Drug|Placebo|4 placebo capsules taken orally 3 times/day throughout course of radiation treatments plus one week
1889920|NCT01246986|Drug|LY2157299|Administered orally
1889921|NCT01246986|Drug|Sorafenib|Administered orally
1889923|NCT01246999|Biological|Live attenuated Influenza vaccine|0.2 mL dose delivered through nasal spray, 0.1 ml in each nostril, 2 doses separated by 28 days
1889924|NCT01246999|Biological|Trivalent Influenza Vaccine|.25 mL given intramuscularly to children 24 to 36 months of age, 2 doses given 28 days apart, .5 mL given intramuscularly to children 37 months to 9 years of age, 2 doses given 28 day s apart.
1889925|NCT01246999|Biological|TIV followed by LAIV|TIV .25 mL given intramuscularly to children 24 to 36 months of age or .5 mL given intramuscularly to children 37 months to 9 years of age, followed by FluMist 0.2 mL delivered by nasal spray (.1 mL in each nostril)28 days later
1889926|NCT01246999|Biological|LAIV followed by TIV|LAIV .2 mL given through nasal spray (.1 mL in each nostril) Followed by TIV .25 mL given intramuscularly to children 24 to 25 months of age or .5 mL given intramuscularly to children 36 months to 9 years of age 28 days later
1889927|NCT01247012|Dietary Supplement|Omegaven|Omegaven 1g/kg/day until infant receiving full enteral feeds
1889928|NCT01247012|Dietary Supplement|Lipid minimization|"1g/kg/day daily until infant receiving full enteral feeds
IF conjugated bili rises above 100, crossover to Omegaven (1gram/kg/day)"
1889929|NCT01247025|Other|No intervention|This study will not contain a specific intervention
1889930|NCT01247038|Device|Metal on ceramic articulation|Metal on ceramic articulation against metal-on-metal articulation using the same Recap Acetabular cup
1889931|NCT01247038|Device|Metal-on-Metal|Metal on Metal articulation
1889932|NCT01247051|Procedure|Precoating|preoperative filling of heart lung machine with patients blood
1889933|NCT01247051|Procedure|Standard priming|preoperative filling of heart lung machine with colloids
1889934|NCT01247064|Drug|Nebulized 3% saline|4 mL of nebulized 3% saline once
1889935|NCT01247064|Drug|Nebulized 0.9% Normal Saline|4 mL of 0.9% nebulized normal saline once
1889936|NCT01247077|Other|selenium|200 ug selenium once daily
1889937|NCT01247077|Other|placebo|
1889938|NCT01247090|Drug|Vasopressin - Very Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.15 mU * 70 kg, or 10.5 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
1889939|NCT01247090|Drug|Vasopressin - Low Dose|Intradialytic vasopressin (AVP) infusion. The dose is calculated based upon the individual's weight in kilograms. A kilogram is equal to 2.2 pounds. For example, a person who weighs 70 kg (or 154 pounds) would receive a dose equal to 0.30 mU * 70 kg, or 21 mU of AVP per minute by infusion at their thrice-weekly dialysis treatments.
1889940|NCT01247090|Drug|Placebo Comparator|Participants in Group 3 will receive an equal volume of normal saline (placebo) infusion during their standard thrice-weekly dialysis treatments.
1889941|NCT01247103|Drug|AZD4316|Single oral doses of AZD4316 suspension in the fasted state. In one group in Part A, subjects will receive a second dose of AZD4316 in the fed state (within 30 min after receiving a high fat breakfast)
1889942|NCT01247103|Drug|AZD4316|Multiple oral doses of AZD4316 suspension. It's planned that doses will be administered in the fasted state, however, if in Part A it's shown that food increases absorption of AZD4316, then doses will be administered after a meal.
1889943|NCT01247103|Other|Placebo|Placebo to match AZD4316
1889944|NCT01247129|Procedure|Delay procedure of SIEA flap.|Ligating the deep inferior epigastric artery ipsilaterally to the planned raising of the SIEA flap 2 weeks prior to the reconstructive procedure.
1889945|NCT01247168|Drug|AZD2461|oral capsules, continuous dosing and intermittent dosing
1889946|NCT01253616|Device|vagus nerve stimulation (VNS)|Daily stimulation synchronized with tones at the study assigned dose (amplitude, frequency, on/off cycle and treatment period).
1889947|NCT01253629|Drug|AFQ056|AFQ056, was provided as hard gelatin capsules, 25mg and 100 mg oral dosage strengths, identical in appearance were used
1889948|NCT01253629|Drug|Placebo|Placebo medication identical in appearance to active medication was provided
1989697|NCT02417064|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated up to a dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
1889953|NCT01253655|Drug|PF-05212365|Single dose of up to 30 mg PF-05212365, delivered as 1 mg, 3 mg, and/or 5 mg on study day 1.
1889954|NCT01253668|Drug|Brivanib alaninate|Brivanib by mouth daily at a dose of 800mg.
1889955|NCT01253668|Genetic|Polymerase chain reaction|Undergo 1241-cG250 PET/CT imaging (correlative studies)
1889956|NCT01253668|Other|Iodine I 124 chimeric monoclonal antibody G250|Undergo 124I-cG250 PET/CT imaging (correlative studies)
1889957|NCT01253668|Procedure|Positron emission tomography/computed tomography|Undergo 1241-cG250 PET/CT imaging (correlative studies)
1889958|NCT01253668|Genetic|Protein expression analysis|Correlative studies
1889959|NCT01253668|Other|Immunohistochemistry|correlative studies
1889960|NCT01253681|Drug|AMG 386, paclitaxel and carboplatin|15 mg/Kg AMG 386 IV (intravenous) weekly plus paclitaxel and carboplatin IV Q3W for 18 weeks, followed by 15mg/Kg AMG 386 IV (intravenous) weekly alone for an additional 18 months.
1889961|NCT01253694|Drug|injection of 0.5 mg of Intravitreal Ranibizumab|Following the sterile technique, intravitreal injection of anti-VEGF is applied
1889962|NCT01253707|Drug|AMG 337|AMG 337 is a small molecule inhibitor of c-Met which is a receptor tyrosine kinase expressed on the surface of epithelial cells.
1889963|NCT01253720|Behavioral|PACE CALL/Fit4Life|"The Fit4Life E intervention will be designed to promote weight loss and subsequent weight loss maintenance through the adoption and maintenance of improved eating, physical activity and sedentary behaviors in at risk for overweight and overweight adolescent survivors of ALL and their parent/guardian. the Fit4Life intervention will incorporate elements of the Chronic Care Model, including frequent phone and mail interactions, an initial in-person encounter to provide encouragement and initial patient-tailored counseling for obesity management, family-centered skill development to achieve healthy behavioral modification via goal setting, self-monitoring, and problem solving.
The Fit4Life intervention includes:
Web-based weight loss program Text and Picture messages Counseling Calls Health Coach"
1890005|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
1889964|NCT01253733|Behavioral|MD2ME|The goals of the MD2Me intervention include increasing disease self-efficacy, disease knowledge, and the ability to control one's disease independently. The intervention includes an 8-week web program with weekly behavioral skills, topics on how to navigate the healthcare system, lifestyle tips, a Discussion Board, and text messages.
1889965|NCT01253759|Procedure|TTT + ICG-based PDT|
1889966|NCT01253798|Other|Group training|Each session lasts 50 minutes and consists of warm-up, mobility training, strength training, balance training and endurance training. Mobility training is conducted to increase range of motion in the operated hip, strength exercises are conducted to strengthen muscles around the operated hip, balance training are conducted to improve stability around the operated hip and endurance training are conducted to increase patients' physical capacity. This is in line with current guidelines for the exercise of osteoarthritis patients.
1889967|NCT01253811|Drug|catridecacog|Intravenous injection of a single dose of recombinant factor XIII, 35 IU/kg body weight every 4th week
1889968|NCT01253824|Drug|NPC-01|NPC-01 contains 1mg norethisterone and 0.02mg ethinyl estradiol
1889969|NCT01253824|Drug|IKH-01|IKH-01 contains 1mg norethisterone and 0.35mg ethinyl estradiol
1889970|NCT01253837|Drug|L19TNFa|"Phase I: Sequential assignment of Patient cohorts to one of six dose levels of L19TNFa: 1.3, 2.6, 5.2, 7.8, 10.4, 13.0 µg/kg.
Phase II: The Recommended Dose (RD) of 13.0 µg/kg of L19TNFα determined in Phase I.
Schedule: Infusions of L19TNFα on days 1, 3 and 5 of each 21-day cycle. Patients may remain on treatment for a maximum of six 21-day cycles."
1889971|NCT01253863|Other|exploration|exploration of wound for determining damaged tissue
1889972|NCT01253876|Dietary Supplement|soy milk, Caw's milk|
1889973|NCT01253889|Drug|Glucose 25% oral solution|0.5ml of 25% glucose (26-31 weeks gestational age group) or 1.0 ml of 25% glucose (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of 25% glucose in the 26-31 weeks gestational age group or 4ml of 25% glucose in the 32-42 weeks gestational age group.
1889974|NCT01253889|Other|Oral water|0.5ml of oral water (26-31 weeks gestational age group) or 1.0 ml of oral water (32-42 weeks gestational age group). This application can be repeated if necessary to a maximum of four times, adding up to max 2ml of oral water in the 26-31 weeks gestational age group or 4ml of oral water in the 32-42 weeks gestational age group.
1889975|NCT01253902|Drug|bimatoprost ophthalmic solution 0.01%|One drop of bimatoprost ophthalmic solution 0.01% administered to affected eye(s), once daily in the evening for 12 weeks.
1889976|NCT01253902|Drug|travoprost ophthalmic solution 0.004%|One drop of travoprost ophthalmic solution 0.004% administered to affected eye(s), once daily in the evening for 12 weeks.
1889977|NCT01253902|Drug|latanoprost ophthalmic solution 0.005%|One drop of latanoprost ophthalmic solution 0.005% administered to affected eye(s), once daily in the evening for 12 weeks.
1889978|NCT01253915|Drug|Nasal Carbon Dioxide|10 sec/nostril up to 4 times to treat one migraine
1889979|NCT01253915|Drug|Placebo|10 sec/nostril up to 4 times to treat a migraine
1889980|NCT01253928|Drug|Pioglitazone|45mg qd for 4 months
1889981|NCT01253941|Other|Mud bath Therapy|patients will be randomized to Mud bath Therapy ( 12 sessions) or no treatment
1996752|NCT02390232|Biological|liver biopsy|A small needle is inserted into the liver to collect a tissue sample
1889983|NCT01254266|Behavioral|inpatient hospitalization and follow up|An inpatient program and a 1-year weekly follow up that include multi-disciplinary interventions for weight reduction and maintenance.
1889984|NCT01254266|Behavioral|inpatient treatment and follow up|one month inpatient treatment followed by a year-long follow up on the inpatient unit.
1889985|NCT01254266|Procedure|bariatric surgery|bariatric surgery.
1889986|NCT01254266|Behavioral|inpatient treatment with follow up|1 month inpatient treatment followed by a year-long follow up on the inpatient unit.
1889987|NCT01254279|Drug|CABAZITAXEL|Pharmaceutical form: Concentrate For Solution For Infusion Route of administration: Intravenous
1889988|NCT01254292|Drug|Levonorgestrel IUD (LCS, BAY86-5028)|LCS12 insertion will occur at randomization visit (Visit 2). Duration of study treatment is 18 months with optional extension to 36 months for subjects in this group only.
1889989|NCT01254292|Drug|Yasmin (EE30/DRSP, BAY86-5131)|Combined oral contraceptive (COC; Yasmin; 0.03 mg ethinyl estradiol and 3 mg drospirenone); Subjects will start taking COC at / on the day of visit 2 and continue taking one pill / day without any breaks for the entire study duration of 18 months.
1889990|NCT01254305|Drug|Levomilnacipran ER|Drug: Levomilnacipran ER (40 -120 mg/day) Study drug is to be given orally, in capsule form, once daily for 8 weeks
1889991|NCT01254305|Drug|Paroxetine, Sertraline, Citalopram or Fluoxetine.|Paroxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Sertraline (50, 100, or 150 mg/day) to be given orally, in capsule form, once daily for 8 weeks, or Citalopram (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks or Fluoxetine (20, 40, or 60 mg/day) to be given orally, in capsule form, once daily for 8 weeks
1889992|NCT01254305|Drug|Placebo|Matching placebo capsules, oral administration, once daily dosing
1889993|NCT01254318|Other|Standard Care|Health-care interventions will be recorded; no additional procedures outside the standard of care will be required.
1889994|NCT01254331|Drug|tocilizumab [RoActemra]|tocilizumab 8 mg/kg intravenous infusion every 4 weeks for a total of 6 infusions
1889995|NCT01254344|Drug|ertapenem sodium|Ertapenem sodium 1 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
1889996|NCT01254344|Drug|ceftriaxone sodium|Ceftriaxone sodium 2 g administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
1889997|NCT01254344|Drug|placebo to metronidazole|Placebo (0.9% sodium chloride) administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
1889998|NCT01254344|Drug|metronidazole|Metronidazole 500 mg administered IV as a single dose over 30 minutes within 2 hours prior to the initial surgical incision
1889999|NCT01254357|Other|Questionnaire self report|Burn specific outcome measurement and global health measurement
1890000|NCT01254370|Drug|Latanoprost|0.005%
1890001|NCT01254370|Drug|Travatan Z|0.004%
1890002|NCT01254383|Drug|Sildenafil Tablet|Tablet, 50 mg, Single Dose
1890003|NCT01254383|Drug|Sildenafil ODT|Orally Disintegrating Tablet, 50 mg, Single Dose
1890006|NCT01254396|Drug|Sildenafil|Orally Disintegrating Tablet, 50 mg, Single Dose
1890007|NCT01254409|Biological|PRM-151|Intravenous PRM-151 administered over 30 minutes on study days 1, 3, 5, 8, and 15 at doses of 1.0, 5.0, or 10.0 mg/kg.
1890008|NCT01254409|Other|Placebo|Intravenous 0.9% normal saline administered over 30 minutes on study days 1, 3, 5, 8, and 15.
1890009|NCT01254422|Biological|Live, attenuated, recombinant dengue serotypes 1, 2, 3, and 4 virus|0.5 mL (at 0, 6, and 12 months), Subcutaneous
1890010|NCT01254422|Biological|Placebo: NaCl 0.9%|0.5 mL (at 0, 6, and 12 months), Subcutaneous
1890011|NCT01254435|Procedure|Colonoscopy|Recording of colonoscopic extubation
1890012|NCT01254448|Drug|TC-5619|Group 1: 25 mg TC-5619 administered once daily for 28 days. Group 2: 50-150 mg TC-5619 administered once daily for 10 days.
1890013|NCT01254448|Drug|Placebo|Group 1: matching placebo administered once daily for 28 days. Group 2: matching placebo administered once daily for 10 days.
1890014|NCT01254461|Drug|AZD1981|100 mg per oral, twice daily for 8 days
1890015|NCT01254461|Drug|AZD1981|4x100 mg per oral, twice daily for 8 days
1890016|NCT01254461|Drug|pravastatin|40 mg, once daily at Day 1, period A and Day 8, period B
1890017|NCT01254474|Device|Cardiac chambers mapping with MAP 4|
1890018|NCT01254513|Drug|Docetaxel every 3 weeks + Prednisone|"Docetaxel IV 60 mg/m²/d then IV 70 mg/m²/d for subsequent cycles every 3 weeks
Prednisone 10 mg/day continuously"
1890019|NCT01254513|Drug|Docetaxel weekly+ Prednisone|"Docetaxel weekly 35 mg/m²/day at day 1 and day 8 of each cycle (J1 = J21)
Prednisone 10 mg/day continuously"
1890020|NCT01254526|Drug|GDC-0980|Oral repeating dose
1890021|NCT01254526|Drug|bevacizumab|Intravenous repeating dose
1890022|NCT01254526|Drug|paclitaxel|Intravenous repeating dose
1890023|NCT01254539|Procedure|Laminectomy and bone marrow stem cells transplantation|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.
T3-T4 laminectomy and bone marrow ficoll separated mononuclear autologous cells intraspinal transplantation"
1890024|NCT01254539|Procedure|Intrathecal infusion of autologous bone marrow stem cells|"Autologous bone marrow cells collection under sedation. Sixty ml are obtained and processed through a ficoll gradient.
Patients were drawn 2 ml of cerebrospinal fluid and infused 2 ml (two 1 ml syringes) of Autologous Stem Cells."
1890025|NCT01254539|Procedure|Intrathecal infusion of placebo (saline solution).|Patients were infused 2 ml of saline solution
1890026|NCT01254552|Drug|Iobitridol|Xenetix 350
1890027|NCT01254565|Drug|Etelcalcetide|Administered intravenously (IV) at the end of hemodialysis
1890028|NCT01254565|Drug|Placebo|Administered intravenously at the end of hemodialysis
1890029|NCT01254578|Other|Laboratory Biomarker Analysis|Correlative studies
1890030|NCT01254578|Drug|Lenalidomide|Given orally
1890031|NCT01254578|Other|Pharmacological Study|Correlative studies
1890032|NCT01254591|Other|18F-fluoromisonidazole|
1890033|NCT01254591|Other|fluorescence angiography|
1890034|NCT01254591|Other|laboratory biomarker analysis|
1890035|NCT01254591|Procedure|infrared thermography|
1890036|NCT01254591|Procedure|magnetic resonance imaging|
1890037|NCT01254591|Procedure|therapeutic conventional surgery|
1890038|NCT01254591|Radiation|[18F]-ML-10|
1890039|NCT01254591|Radiation|fludeoxyglucose F 18|
1890040|NCT01254591|Radiation|rubidium Rb-82|
1890041|NCT01254604|Drug|Preservative-Free Tafluprost or vehicle|Preservative-free tafluprost (0.0015%) ophthalmic solution; Preservative-free vehicle ophthalmic solution (contains no active drug)
1890042|NCT01254604|Drug|Preservative-Free Timolol maleate|Preservative-free timolol maleate (0.5%) ophthalmic solution
1890043|NCT01254617|Biological|Cetuximab|Given IV
1890044|NCT01254617|Other|Laboratory Biomarker Analysis|Correlative studies
1890045|NCT01254617|Drug|Lenalidomide|Given PO
1890046|NCT01254630|Biological|V212|V212 viral antigen for HZ, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
1890047|NCT01254630|Biological|Placebo|Vaccine stabilizer for V212 with no virus antigen, 0.5 mL SC injection per dose, in a four dose regimen, approximately 30 days apart, preferably in the deltoid area of the arm, alternating arms for each dose.
1890048|NCT01254643|Biological|V503|V503 0.5 mL intramuscular injection at Day 1, Month 2, and Month 6
1890049|NCT01254656|Drug|lersivirine|Lersivirine 500 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
1890050|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
1890051|NCT01254656|Drug|efavirenz|Efavirenz 600 mg tablets PO taken once daily + tenofovir DF 300 mg/emtricitabine 200 mg tablets PO once daily
1890052|NCT01254656|Drug|lersivirine|Lersivirine 750 mg tablets PO taken once daily + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
1890053|NCT01254656|Drug|lersivirine|Lersivirine 1000 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules PO taken twice daily + 1 optimized NRTI
1890054|NCT01254656|Drug|etravirine|Etravirine 200 mg PO tablets + darunavir 600 mg tablets/ritonavir 100 mg tablets or capsules taken twice daily + 1 optimized NRTI
1890055|NCT01254669|Behavioral|BNI-brief Negotiated Interview|use of a cognitive behavioral intervention to improve uptake of HPV vaccine
1890056|NCT01254682|Device|Ostenil|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment). Add-on treatment with Ostenil after standard arthroscopic procedure. Application twice: first injection directly after arthroscopic procedure and second injection 3 weeks post arthroscopic.
1890057|NCT01254682|Procedure|Standard arthroscopic procedure|Standard arthroscopy (including intra-articular injection of 5 ml scandicain (0,5%), or 5 ml bupivacain plus 5 ml suprarenin in case of post-arthroscopic treatment) without add-on treatment.
1890058|NCT01254695|Device|Medtronic InterStim / InterStim II|Standard stimulation (Amplitude: sensory threshold, frequency 14 Hz, Pulsewidth 210 microsec.) will be compared wiht experimental setting 1,2,3,4
1890059|NCT01254708|Drug|Ambisome ®|liposomal amphotericin B
1890060|NCT01254708|Drug|Regular standard of care medication|Drug for this group is at the physician's discretion. Patients in this group receive the standard of care medication currently implemented at the Institution. Example would be voriconazole
1890061|NCT01254721|Drug|Quetiapine fumarate|eXtended Release(XR) 50mg, 200mg, 300mg and/or 400mg tablet, oral, once daily in the evening, from assignment to the end of the study.
1890062|NCT01254721|Drug|lithium|300mg tablet, oral
1890063|NCT01254734|Procedure|transoral robotic surgery|Undergo transoral robotic microsurgery
1890064|NCT01254734|Other|laboratory biomarker analysis|Correlative studies
1890065|NCT01254734|Procedure|quality-of-life assessment|Ancillary studies
1890066|NCT01254747|Device|Delefilcon A contact lens|Investigational silicone hydrogel, single vision contact lens for daily wear, daily disposable use
1890067|NCT01254747|Device|Lotrafilcon B contact lens (O2 OPTIX, AIR OPTIX)|Commercially marketed silicone hydrogel, single vision contact lens for daily wear, daily disposable use
1890068|NCT01254747|Device|Nelfilcon A contact lens (DAILIES AquaComfort Plus)|Commercially marketed hydrogel, single vision contact lens for daily wear, daily disposable use
1890069|NCT01254747|Device|Narafilcon A contact lens (1-DAY ACUVUE TRUEYE)|Commercially marketed (Europe) silicone hydrogel, single vision contact lens for daily wear, daily disposable use
1890070|NCT01254760|Device|Nelfilcon A multifocal contact lens, investigational|Investigational, soft, multifocal contact lens for daily wear, daily disposable use.
1890071|NCT01254760|Device|Nelfilcon A multifocal contact lens, commercial|Commercially marketed, soft, multifocal contact lens FDA-approved for daily wear, daily disposable use.
1890072|NCT01254773|Drug|Experimental Bapineuzumab|Bapineuzumab 2 mg, Bapineuzumab 7 mg, Bapineuzumab 20 mg, Placebo
1890073|NCT01254786|Procedure|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.
Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min
Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio <0.3 and R.R 60 breaths/min for further 30 min."
1890074|NCT01254786|Procedure|Non-dependent lung ventilation|"the dependent lung will be ventilated with conventional ventilation (OLV) a tidal volume of 6 mL/kg (predicted body weight), whereas FiO2, I: E ratio, PEEP, frequency, peak inspiratory pressures, and a flow of fresh gas will be maintained as during two-lung ventilation for 15 min.
Then, the non-dependent lung will be connected to a second identical ventilator, 15 min after OLV, using a FiO2 of 1.0, VT 3 mL/kg (predicted body weight), I: E ratio <0.3 and R.R 60 breaths/min for further 30 min.
Then the non-dependent lung will be allowed to deflate to a CPAP of 2 cm H2O, which will be connected to the flowmeter of an oxygen cylinder with a flow rate of 5 L/min and FiO2 of 1.0 for 30 min"
1890075|NCT01254799|Drug|Doxycycline|100 mg Doxycycline capsules twice daily for 5 days
1890076|NCT01254799|Drug|Placebo|Placebo capsules twice daily for 5 days
1890077|NCT01254825|Procedure|Adductor-Canal-Block, Ropivacain|Ultrasound-guided ACB; 30 mL Ropivacain 7,5 mg/mL. Single dose.
1890078|NCT01254825|Procedure|Adductor Canal Block, Placebo (saline)|Ultrasound-guided Adductor Canal Block; 30 mL Saline. Single dose.
1890079|NCT01254838|Biological|HLA-A02 restricted HIG2|
1890080|NCT01254851|Behavioral|goal-augmented post-operative care|Patients in the goal-augmented post-operative care group will be given a goal number of steps to take on each post-operative day following in-patient gynecologic surgery.
1890081|NCT01254864|Drug|Abiraterone Acetate|1000 mg by mouth each day of a 28 day cycle.
1890082|NCT01254864|Drug|Prednisone|5 mg by mouth twice daily of a 28 day cycle.
1890083|NCT01254864|Drug|Sunitinib|37.5 mg by mouth daily for two weeks followed by a week of rest in a 28 day cycle.
1890084|NCT01254864|Drug|Dasatinib|100 mg by mouth each day of a 28 day cycle.
1890085|NCT01254877|Drug|ondansetron|ondansetron 0.2 mg bid, oral preparation, 16 weeks
1890086|NCT01254877|Drug|placebo ondansetron|Matching placebo will be prepared using a colorless strawberry syrup, simple syrup and flat Schweppes tonic water.
1890087|NCT01254877|Drug|Ondansetron|Ondansetron 0.8 mg bid, oral preparation, 16 weeks duration
1890088|NCT01254890|Drug|Azacitidine|75 mg/m^2 subcutaneously (SQ) or by vein (IV) daily for 7 days per 28 day cycle.
1890089|NCT01254890|Drug|Sorafenib|Starting dose level 200 mg by mouth two times a day in a 28 day cycle. In Phase II, Sorafenib administered per MTD dose from Phase I. Drug doses separated by approximately 12 hours.
1890090|NCT01254903|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation treatment.
1989698|NCT02417064|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
1890093|NCT01254942|Other|B4 Clinic|Fracture Follow-Up Clinic plus Exercise Program
1890094|NCT01254942|Other|Usual Care|
1890095|NCT01254955|Biological|H1N1 vaccine Pandemrix|
1890096|NCT01254981|Procedure|Percutaneous coronary intervention (PCI)|Implantation of coronary stent
1890097|NCT01254994|Drug|entecavir|Patients in the ETV Group were prescribed 0.5 mg entecavir following oral fasting one time per day.
1890098|NCT01254994|Drug|Traditional comprehensive medical treatment|bed rest, sufficient energy and vitamins, reduced glutathione, prostaglandin E1, hepatocyte growth factor (HGF), plasma and albumin, maintenance of water and electrolyte balance, and prevention and treatment of complications, such as infections, hepatic encephalopathy, hemorrhage, hepatorenal syndrome and ascites.
1890099|NCT01255007|Other|MR imaging|Primovist enhanced MRI, Diffusion weighted MRI
1890100|NCT01255020|Drug|α-Keto Acid with restricted protein diet|"α-Keto Acid: The daily dose of compound α-Keto Acid is 100mg/kg/d. The total daily dose will be divided into three times a day.
Restricted Protein Diet: Diet contain protein 1.0g/kg/d"
1890256|NCT01256398|Drug|Leucovorin Calcium|Given IV or PO
1890257|NCT01256398|Drug|Melphalan|Given IV
1890101|NCT01255020|Drug|Placebo plus restricted protein diet|"placebo: The daily dose of placebo is 100mg/kg/d. The total daily dose will be divided into three times a day.
Diet contain protein 1.0 g/kg/d."
1890102|NCT01255033|Device|Monitoring of tissular oxygenation|"Equanox: cerebral oxygenation by spectroscopy, near-infrared through forehead and noninvasive devices
Inspectra: tissular oxygenation by spectroscopy, near-infrared through thenar and noninvasive device"
1890103|NCT01255046|Drug|Donepezil,|10mg/tab, 1 tab/day for 72 weeks
1890104|NCT01255046|Drug|STA-1|300mg/tab, 2 tab/tid for 72 weeks
1890105|NCT01255046|Drug|placebo|2 tab/tid for 72 weeks
1890106|NCT01255072|Procedure|Transcranial Magnetic Stimulation|20 Sham daily sessions:25 trains, 10seconds at 5Hz, train interval of 25 seconds (time off). Target: left dorsolateral prefrontal cortex.
1890107|NCT01255072|Procedure|Repetitive Transcranial Magnetic Stimulation|20 daily sessions: each one with 25 trains of 10seconds at 5Hz, train interval of 25 seconds (time off), pulse intensity corrected based on atrophy degree by a specific correction formule. Target: left dorsolateral prefrontal cortex.
1890108|NCT01255085|Dietary Supplement|yellow pea protein|Served in a tomato soup
1890109|NCT01255085|Dietary Supplement|yellow pea fiber|Served in a tomato soup
1890110|NCT01255085|Dietary Supplement|Control Tomato Soup|Served in a tomato soup
1890111|NCT01255137|Drug|Axitinib|5 mg tab orally twice a day with food every 28 days
1890112|NCT01255163|Drug|Exendin-4 (Exenatide)|
1890113|NCT01255176|Procedure|Thoracoabdominal rebalancing|In this group the infants received four handlings thoracoabdominal rebalancing, in order: 1) 5min support thoracoabdominal, in which the therapist leaned one hand on the lower chest and upper abdomen of the newborn, with some of its fingers on the ribs, pulling them gently down and keeping them in that position during inspiration, 2) more than 5 minutes of abdominal support, carried by hand in the lower abdomen of the newborn, applying light pressure during inspiration enough to be beaten by the diaphragm of the newborn and not to increase the use of accessory muscles of inspiration, 3) 5min support ileo-costal, by a slight manual pressure of the physiotherapist on the lateral chest and abdomen of the newborn, maintained throughout inspiration and 4) finally ran up 5min ginga thoracic maneuver slight manual pressure on the lower chest of newborns, directing the costal movement during expiration, now an then the other hemithorax.
1890114|NCT01255189|Device|Device: near infrared spectroscopy: INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
1890115|NCT01255189|Device|invos 5100|near infrared spectroscopy: invos 5100
1890116|NCT01255215|Drug|Inhaled Nitric Oxide|Form: Gas (inhalational) Dose: 80 ppm Dosing schedule: Continuous Treatment period: Maximum 72 hours (may be discontinued earlier if patient recovers and no longer tolerates face mask)
1890117|NCT01255228|Other|Low glycemic index diet|The study expect that long-term low GI diet intervention have beneficial effects on regulate body composition of obese women
1890118|NCT01255254|Procedure|Gingival scaling|Oral hygeine instruction and gingival scaling using hand and ultrsonic instruments.
1890119|NCT01255280|Behavioral|Behavioral Activation Therapy and Risk Reduction Counseling (BAT-RR)|This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
1890120|NCT01255280|Behavioral|Information, Motivation, Behavioral skills change approach to sexual risk reduction|The comparison condition will only receive the two IMB risk reduction sessions.
1890121|NCT01255293|Procedure|1000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 1000 centistoke silicone oil.
1890122|NCT01255293|Procedure|5000 centistoke silicone oil|Patients who are enrolled in the study and have been identified to have a complex retinal detachment requiring silicone oil tamponade may be randomly assigned to receive 5000 centistoke silicone oil
1890123|NCT01255306|Other|Optical coherence tomography|"Optical coherence tomography will be performed in all study patients following pars plans vitrectomy and silicone oil tamponade. A fellow eye of each patient will serve as a control. Each patient enrolled in a study will receive 4 measurements:
On 7th postoperative day
On 30th postoperative day
On 90th postoperative day
On 180th postoperative day"
1890124|NCT01255306|Drug|Local medical treatment of raised intraocular pressure|"In patients with raised intraocular pressure following medications will be employed in order to control the intraocular pressure:
Cosopt (dorzolamide hydrochloride-timolol maleate ophthalmic solution; b.i.d.) Ganfort (Bimatoprost, timolol maleate ophthalmic solution; once daily) Alphagan (Brimonidine ophthalmic solution; b.i.d.) In patients with intraocular pressure less than 27 mmHg Alphagan will be prescribed. In patients with intraocular pressure greater than 27 mmHg either Cosopt, or Ganfort will be prescribed under the discretion of treating physician. If intraocular pressure in patients treated with either Cosopt or Ganfort does not drop under 21 mmHg, Alphagan will be added."
1890125|NCT01255345|Other|Chronic pelvic pain|A physioterapeutic examination of abnormal muscular findings, i.e tonus, elasticitt and strength, in the pelvic area connected to female CPP.
1996753|NCT02390232|Biological|collection of stools|collection of stools
1890127|NCT01255371|Drug|Lopinavir|Evaluation of second line antiretroviral regimen including boosted lopinavir
1890128|NCT01255371|Drug|Atazanavir|Evaluation of second line antiretroviral regimen including boosted atazanavir
1890170|NCT01255761|Biological|Certolizumab Pegol (CZP)|"400 mg subcutaneous injection at Weeks 0, 2 and 4
200 mg subcutaneous injection every two weeks, Week 6 through Week 52"
1890171|NCT01255774|Drug|ranibizumab|An open-label, study of intravitreally administered ranibizumab
1890172|NCT01255787|Drug|Vortioxetine|Vortioxetine tablets
1890173|NCT01255787|Drug|Placebo|Vortioxetine placebo-matching tablets
1890174|NCT01255800|Drug|IPI-926 and Cetuximab|"Patients will receive Cetuximab IV every week.
Starting on Day 15 of the first cycle, Patients will take IPI-926by mouth every day."
1890175|NCT01255813|Device|Stimulation (Sub-perception)|Stimulation applied below the perception threshold
1890176|NCT01255813|Device|Stimulation (Full)|Stimulation applied above the perception threshold
1996754|NCT02390232|Biological|blood sample|collection of blood sample
1890129|NCT01255397|Procedure|Male Infertility Protocol|"Healthy women with a regular cycle between 28 and 35 days. For the man, an abnormal sperm exam.
Daily US examinations from day 8 of the menstrual cycle. Excluding weekends.
When the leading follicle is 14 mm she will be given 100 units puregon and orgalutran,once daily until the leading follicle is at least 16 mm at which point she will be given ovitrelle at 21:00.
35 hours after Ovitrelle at 8:00 the husband will present a sperm sample for analysis. A pelvic US will be done to the wife.
If the follicle has collapsed than IUI will be performed
It the total motile sperm count is above 5 million sperm/ml then IUI will be done
If the total motile sperm count is below 5 million and the follicle has not collapsed, proceed to oocyte aspiration and ICSI
6) ICSI and embryo transfer performed on the same day. 7) Luteal support: Endometrin 100 mg twice a day following IUI\ET until 6 weeks gestation Protocol can be repeated for up to 3 cycles per couple."
1890130|NCT01255410|Biological|10^6 PFU rHMPV-Pa vaccine|Single dose of 10^6 PFU rHMPV-Pa vaccine delivered intranasally
1890131|NCT01255410|Biological|10^5 PFU rHMPV-Pa vaccine|Single dose of 10^5 PFU rHMPV-Pa vaccine delivered intranasally
1890132|NCT01255410|Biological|Placebo Vaccine|Single dose of placebo vaccine delivered intranasally
1890133|NCT01255423|Drug|Diclofenac sodium topical gel 1%|Diclofenac sodium topical gel 1%, 4 times daily
1890134|NCT01255423|Drug|Placebo|Placebo, 4 times daily
1890135|NCT01255436|Other|SMS text reminders|Patients in the intervention arm will receive 2 text messages per week delivered via SMS on randomly chosen days and times during the 12-week study period. The aims of the messages are to remind patients to take their blood pressure medications daily, what the target blood pressure is, and the benefits of daily intake of anti-hypertensive medications.
1890136|NCT01255436|Other|Usual Care|Patients in the usual care arm will receive the care usually provided by their physicians. This consists of consultations, medical advice, and prescriptions for maintenance medications. They will not be sent any SMS text reminders from the study.
1890137|NCT01255449|Drug|albuterol|400 mcg by inhalation
1890138|NCT01255462|Biological|LFG316|
1890139|NCT01255462|Biological|LFG316|
1890140|NCT01255462|Biological|LFG316|
1890141|NCT01255462|Biological|LFG316|
1890142|NCT01255475|Drug|Hydralazine/amlodipine|Patients will receive drug therapy aimed to reducing blood pressure - first line drug will be hydralazine up to 100mg/day; if systolic blood pressure reduces less than 20% from baseline and remains over 100mmHg patients will further receive amlodipine up to 10mg/day
1890143|NCT01255475|Drug|Placebo|Patients will receive placebo
1996755|NCT02389933|Drug|LCZ696|immediate release film coated tablet in 50 mg, 100 mg, 200 mg, and 400 mg strengths for oral administration.
1890145|NCT01255501|Drug|NI-0701|
1890146|NCT01255501|Drug|Placebo|
1890147|NCT01255514|Drug|high dose dexamethsone|high dose dexamethasone : 40mg/day , D1-D4, D9-D12, IV or PO, repeat every 21days for 2cycles
1890148|NCT01255527|Drug|Bortezomib|Bortezomib i.v. 0.7, 1.0 and 1.3 mg/m²/day
1890149|NCT01255553|Radiation|Partial Breast Irradiation|Partial breast irradiation will be administered using a 3D conformal external beam RT technique. Two fractions of 38.5 Gy separated by at least 6 hours will be given on 5 treatment days over a period of 5 to 10 days.
1890150|NCT01255579|Drug|Salmeterol Fluticasone|salmeterol 50 mcg and fluticasone 250 mcg (diskus) b.i.d.
1890151|NCT01255579|Drug|formoterol - beclometasone|formoterol 12 mcg and beclometasone 200 mcg HFA (by MDI) b.i.d.
1890152|NCT01255592|Drug|AZD5069|Oral dose bid
1890153|NCT01255592|Drug|Placebo|Oral dose bid
1890154|NCT01255618|Device|INVOS 5100|Near-infrared range and has been used in newborn infants since 1985. Fibre-optic bundles or optodes are placed either on opposite sides of the tissue being interrogated (usually a limb or the head of a young baby) to measure transmitted light, or close together to measure reflected light. Light enters through one optode and a fraction of the photons is captured by a second optode and conveyed to the measuring device. NIRS uses a frequency band between 650 nm and 1000 nm and relies on three important phenomena: (1) human tissue is relatively transparent to light in the near-infrared region of the spectrum; (2) pigmented compounds known as chromophores absorb light as it passes through biological tissue; and (3) human tissues contain substances whose absorption spectra at near-infrared wavelengths are well defined and depend on their oxygenation status.
1890155|NCT01255631|Device|PEMF Device|"The PEMF device we will use in this study is FDA approved for adjunctive use in the palliative treatment of post-operative pain and edema in superficial soft tissue (510(k) number: K903675). There are no side effects to use of a PEMF device. In the treatment arm, the PEMF would be automatically delivered for 15 minutes every two hours for one month. The manufacturer (Ivivi Technologies, Inc., Northvale, NJ) has already designed a lightweight, disposable device that can be placed around the patient's arm and taped in place. The patient would keep the device in place for two weeks, when they return for a followup visit and receive a fresh device to wear for an additional two weeks."
1890156|NCT01255631|Device|Sham PEMF Device|Inactive PEMF device, delivers no PMF
1890157|NCT01255644|Drug|Valganciclovir|900 mg every 24 hours per os, day 1 through 90
1890158|NCT01255657|Drug|ABT-806|ABT-806 will be administered by intravenous infusion.
1890159|NCT01255670|Drug|penicillin and metronidazole in peritonsillar abscess|Peroral Penicillin: 1000 000 IU 3 times a day for 10 days Peroral metronidazole: 500 mg 3 times a day for 7 days
1890160|NCT01255683|Drug|oral corticosteroid taper|This is an observational study in which patients self-select oral steroid treatment for symptoms of CRS. Drug treatments are NOT assigned in this investigation.
1890161|NCT01255696|Biological|ALV003|
1890162|NCT01255696|Biological|ALV003 placebo|
1890163|NCT01255709|Drug|Arm T1: Primatene Mist HFA|epinephrine inhalation aerosol, 90 mcg/inhalation, 12 inhalations over 6 minutes
1890164|NCT01255709|Drug|Arm T2: Primatene Mist HFA|epinephrine inhalation aerosol, 100 mcg/inhalation, 12 inhalations over 6 minutes
1890165|NCT01255709|Drug|Arm C: Primatene Mist (epinephrine inhalation aerosol, USP)|epinephrine inhalation aerosol, 220 mcg/inhalation, 12 inhalations over 6 minutes
1890166|NCT01255722|Drug|iobitridol|single IV injection
1890167|NCT01255722|Drug|iopromide|Single IV injection
1890168|NCT01255722|Drug|iomeprol|Single IV injection
1890169|NCT01255748|Radiation|Proton Therapy, Photon Therapy, SRS, Brachytherapy|Outcomes Tracking
1890178|NCT01255826|Procedure|Resuscitation of preterm neonates by sustained lung inflation through T piece device followed by CPAP|After oropharyngeal and nasal suctioning, if there are no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, the following approach will be followed:Pressure-controlled (20 cm H2O) inflation will be sustained for 15 secs, using a neonatal mask and a T-piece ventilator (NeoPuff Infant Resuscitator; Fisher & Paykel).To avoid pressure leakage, we will use a neonatal mask of appropriate size which adequately cover both the mouth and nostrils of infants. This pressure controlled inflation will be followed by CPAP at 5 Cm H2O.This procedure will be repeated a second time with a pressure of 25 cm H2O for 15 secs if breathing remained insufficient and/or the heart rate is < 100 bpm and/or the infant is cyanotic. To be followed by CPAP at 6 Cm H2O.A third puff with a pressure of 30 cm H2O for 15 secs will be used after few seconds if inadequate heart rate and respiration was not reached. This will be followed by CPAP at 7 Cm H2O.
1890179|NCT01255826|Procedure|Resuscitation of preterm neonates by intermittent bag and mask ventilation using self inflating bag.|After oropharyngeal and nasal suctioning, if there is no signs of spontaneous breathing or breathing is insufficient and/or heart rate is below 100 bpm, intermittent mask and bag ventilation will be administrated at a rate 40-60 per minute using a self-inflating bag and mask with an oxygen reservoir.
1890180|NCT01255839|Device|Double Balloon|The Double Balloon Catheter was applied (Atad 5) with 80 ml NaCl installed intrauterine above the intern orificium and 80 ml below in cervix/vagina.
1890181|NCT01255839|Drug|Minprostin|The prostaglandin 2 minprostin (3mg) was applied vaginally
1890182|NCT01255852|Drug|atorvastatin|Patients in atorvastatin group will received 80 mg atorvastatin daily from 3 days before the index procedure to 12 months after the procedure.
1890183|NCT01255878|Device|occlusal stabilization splint|
1890184|NCT01255878|Drug|Gabapentine|100 mg(1 capsule)three times per day for two months
1890185|NCT01255891|Radiation|Androgen suppression plus radiation therapy|Adjuvant androgen suppression plus radiation therapy
1890186|NCT01255904|Drug|Chloral Hydrate|Oral chloral hydrate 50 mg/kg
1890187|NCT01255904|Drug|Dexmedetomidine|Intranasal dexmedetomidine 3 mcg/kg
1890188|NCT01255904|Other|Oral placebo|Oral saline administered
1890189|NCT01255904|Other|Intranasal placebo|Intranasal saline administered
1890190|NCT01255943|Behavioral|healthcare staff processes for infection prevention|Toyota lean and positive deviance discovery and action dialogues to facilitate process improvement
1890191|NCT01255956|Device|Rapamycin eluting stent implantation|Rapamycin eluting stent implantation for in-stent restenosis treatment
1890192|NCT01255956|Device|Paclitaxel eluting balloon catheter|Paclitaxel eluting balloon catheter for in-stent restenosis treatment
1890193|NCT01255969|Other|Exercise|Personalized exercise program
1890194|NCT01255995|Device|Capsular Tension Ring|Capsular Tension Ring
1890195|NCT01256008|Behavioral|CBT|The subjects will receive standardized CBT treatment regularly for 9 sessions(once per week in the first month and once half a month in the second and third months), and each session will last for about 60 minutes.The treatment includes three steps:Concept stage (the first and second sessions): establishment of therapeutic relationships with the subjects; Skills acquisition and repeat stage (the third session to the 8th session): clarification of sources of stress, patients' cognitive and behavioral response to stress. Application and complete price segment (the 9th session): return visit to test efficacy of psychological intervention.
1890196|NCT01256008|Behavioral|Clinical Management|"Clinical management is a clear contrast method of psychological therapy, which is a half-structured interview and lasting for 20-25 minutes each session. Clinical management will be assigned to both experimental group and controlled group in the first stage of intervention.
Following are major elements:
Talk to the subjects to find their main problems; introduce knowledge and medication knowledge about cancer and depression; subjects reporting use of drugs for cancer and depression and a variety of signs and symptoms of the reaction. Encourage patients to adhere to drug treatment and to comply with this research program; The operation of CBT and clinical management should be conducted by the same person as far as possible."
1890197|NCT01256021|Drug|Botulinum Toxin Type A|1 time, gastrocnemius muscles injection, dose of 4U/kg body weight in patients with hemiplegia, dose of 6U/kg body weight in patients with diplegia, Maximum dosage 200U
1890198|NCT01256034|Dietary Supplement|Oral IMPACT|oral supplementation for 5 days (1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
1890199|NCT01256047|Dietary Supplement|Oral IMPACT|oral supplement for 5 days(1L/day) before surgery of a formula enriched with arginine, omega-3 fatty acids, and RNA
1890200|NCT01256060|Drug|Intranasal Oxytocin|We are selecting morning and afternoon dosing to try to influence most hours where youth are in settings with increased potential for social interaction (school, after school). Medication will be administered by the parents before school and early afternoon. All patients will receive their first dose by the study physician to educate parents and themselves on proper administration and determine safety of first dose.
1890201|NCT01256073|Drug|IPH2101|IPH2101 fully human anti-KIR monoclonal antibody
1890202|NCT01256086|Drug|Formatris 24µg|12µg Formoterol Novolizer#1 + 12µg Formoterol Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
1890203|NCT01256086|Drug|Formatris 12µg|12µg Formoterol Novolizer#1 + Placebo Novolizer#2 + Placebo Aerolizer#1 + Placebo Aerolizer #2
1890204|NCT01256086|Drug|Foradil P 24µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + 12µg Formoterol Aerolizer #2
1890205|NCT01256086|Drug|Foradil P 12µg|Placebo Novolizer#1 + Placebo Novolizer#2 + 12µg Formoterol Aerolizer#1 + Placebo Aerolizer #2
1890206|NCT01256099|Behavioral|Therapist guided Internet-CBT for insomnia|An 8 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for insomnia
1890207|NCT01256099|Behavioral|Brief Internet-CBT for insomnia, without support|No support and less text, not including the CBT-methods that are presumed to be most effective to reduce Insomnia symptoms
1890208|NCT01256099|Behavioral|Therapist Guided Internet-CBT for depression|An 9 week long, structured self-help program with weekly reports to, and feedback from, a CBT therapist over the Internet. Includes traditional CBT-methods for depression. Information and methods regarding sleep difficulties removed
1890258|NCT01256398|Drug|Mercaptopurine|Given PO
1890259|NCT01256398|Drug|Methotrexate|Given IT, IV, or PO
1890210|NCT01256151|Drug|Alprazolam tablet|1 mg single dose of alprazolam conventional tablet
1890211|NCT01256151|Drug|Alprazolam sublingual|1 mg single dose of alprazolam sublingual tablet
1890212|NCT01256164|Device|Fibrocaps (fibrin sealant)|Fibrocaps powder (max dose 1.5g) should be applied directly to the bleeding site or to the Gelfoam and then applied to the bleeding site. Re-application of 1.5 g of Fibrocaps is allowed.
1890213|NCT01256164|Device|Gelfoam|An identified Target Bleeding Site (TBS) should be treated with application of Gelfoam followed by light manual pressure with a sterile gauze.
1890214|NCT01256177|Drug|Quetiapine Fumarate (SEROQUEL) Extended Release|Quetiapine fumarate extended release(XR) will be administered orally, once daily in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
1890215|NCT01256177|Drug|Placebo|Placebo matching quetiapine extended release(XR) 50 mg, 200 mg, and 300 mg tablets will be orally administered once daily, in the evening. The initial dose will be 50 mg. This dose will be adjusted on Day 2 to 100 mg, on Day 3 to 200 mg, and on Day 4 to 300 mg and after.
1890216|NCT01256190|Biological|Fibrocaps (fibrin sealant)|human thrombin and fibrinogen topical powder
1890217|NCT01256190|Device|Gelatin sponge|absorbable gelatin sponge for topical use
1890218|NCT01256203|Drug|Solar Protection Formula SPF® 60|Solar Protection Formula SPF® 60 (2 mg/cm²) will be topically applied on a randomly predetermined specific skin area on the back of each subject on four separate occasions over 3 months. The same skin area will never be exposed more than once to the sunscreen.
1890219|NCT01256203|Procedure|Photobiological testing|Photobiological testing will consist of exposing a small area of the sunscreen-protected and unprotected (control) skin areas to visible light on four separate occasions over 3 months. Light will be applied 30 minutes after application of the sunscreen. The same skin area will never be exposed more than once to light.
1890220|NCT01256216|Device|Total Knee Replacement with Vanguard Total Knee|Patients indicated for a total knee replacement utilizing the Vanguard Total Knee System.
1890221|NCT01256229|Device|cochlear implantation|This is the experimental therapy for deaf children with developmental delays, and the conventional therapy for deaf children without developmental delays.
1890222|NCT01256229|Device|hearing aids|This is the conventional therapy for deaf children with developmental delays.
1890223|NCT01256242|Device|Augment Rotator Cuff|rhPDGF-BB and bovine collagen matrix
1890224|NCT01256242|Procedure|Standard Suture Repair|standard suture repair
1890225|NCT01256268|Drug|Ridaforolimus|Phase 1A: Ridaforolimus 20-40 mg will be administered daily for 5 days per week (days 2-5, days 8-12, days 15-19) in the first cycle of therapy and for further cycles on days 1-5, days 8-12, days 15-19 throughout the remainder of therapy. On the day of coadministration of ridaforolimus with paclitaxel 175mg/m^2 IV and carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle, ridaforolimus will be dosed at the time of initiation of paclitaxel infusion. Phase 1B: as outlined in Treatment Arms.
1890226|NCT01256268|Drug|Paclitaxel|Phase 1A: Paclitaxel 175mg/m2 IV. Phase 1B: As outlined in Treatment Arms.
1890227|NCT01256268|Drug|carboplatin|Phase 1A: Carboplatin AUC 5-6mg/ml/min on day 1 of each 3 week cycle. Phase 1B: As outlined in Treatment Arms.
1890228|NCT01256281|Procedure|Femoral Nerve Block|Patients enrolled will receive ultrasound guided FNB in addition to standard care. If subjects are experiencing pain in both lower extremities, both extremities will be blocked; if subjects are experiencing pain in one lower extremity, only the affected extremity will be blocked.
1890229|NCT01256294|Drug|Generic Tacrolimus|Generic Sandoz tacrolimus supplied as capsules of 0.5 mg, 1 mg and 5 mg dose strengths.
1890230|NCT01256294|Drug|Branded Tacrolimus|Capsules supplied at dose strengths of 0.5 mg, 1 mg, and 5 mg.
1890231|NCT01256307|Other|training and educational program|8 weeks
1890232|NCT01256307|Other|educational program|8 weeks
1890233|NCT01256320|Other|Classic Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial classic eggs
1890234|NCT01256320|Other|Omega 3 Egg Group|consumption of 6 eggs/week (1 egg/day for 6 days with 1 day rest) of commercial Omega-3 eggs
1890235|NCT01256346|Device|Apparatuses|Each baby will have both pulse oximetry leads (Massimo Radical 7) and electrocardiography leads (3M™ Red Dot™ Neonatal Limb Band Monitoring Electrodes, Pre-wired) applied. The time required for each modality to register a heart rate will be compared.
1890238|NCT01256372|Drug|AP214|AP214
1890239|NCT01256372|Drug|Placebo|Placebo; intravenous infusion
1890240|NCT01256385|Biological|Cetuximab|Given IV
1890241|NCT01256385|Other|Laboratory Biomarker Analysis|Correlative studies
1890242|NCT01256385|Drug|Temsirolimus|Given IV
1890243|NCT01256398|Biological|Alemtuzumab|Given IV
1890244|NCT01256398|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo peripheral blood allogeneic HCT
1890245|NCT01256398|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo peripheral blood autologous HCT
1890246|NCT01256398|Drug|Cyclophosphamide|Given IV
1890247|NCT01256398|Drug|Cytarabine|Given IV
1890248|NCT01256398|Drug|Dasatinib|Given PO
1890249|NCT01256398|Drug|Daunorubicin Hydrochloride|Given IV
1890250|NCT01256398|Drug|Dexamethasone|Given PO or IV
1890251|NCT01256398|Drug|Etoposide Phosphate|Given IV
1890252|NCT01256398|Biological|Filgrastim|Given SC
1890253|NCT01256398|Drug|Fludarabine Phosphate|Given IV
1890254|NCT01256398|Procedure|In Vitro-Treated Peripheral Blood Stem Cell Transplantation|Undergo peripheral blood autologous or allogeneic HCT
1890255|NCT01256398|Other|Laboratory Biomarker Analysis|Correlative studies
1890260|NCT01256398|Biological|Pegfilgrastim|Given SC
1890261|NCT01256398|Other|Pharmacological Study|Correlative studies
1890262|NCT01256398|Drug|Tacrolimus|Given IV or PO
1890263|NCT01256398|Drug|Vincristine Sulfate|Given IV
1890264|NCT01256411|Drug|LCZ696|Participants received LCZ696 200 mg as the starting dose with optional down titration to 100 mg for tolerance and optional up titration to 400 mg for adequate blood pressure control.
1890265|NCT01256411|Drug|Amlodipine|Optional add-on of amlodipine (5-10 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
1890266|NCT01256411|Drug|Hydrochlorothiazide (HCTZ)|Optional add-on of hydrochlorothiazide (HCTZ) (12.5-25 mg) was allowed (as applicable per local country regulations) for adequate blood pressure control.
1890267|NCT01256424|Drug|HAL 5% with illumination|Treatment with a singe dose of 2g, HAL 5% ointment followed by photoactivation
1890268|NCT01256424|Drug|HAL 1% with illumination|Treatment with a singe dose of 2g, HAL 1% ointment followed by photoactivation
1890269|NCT01256424|Drug|HAL 0.2% with illumination|Treatment with a singe dose of 2g, HAL 0.2% ointment followed by photoactivation
1890270|NCT01256424|Drug|Placebo ointment without illumination|Treatment with a singe dose of 2g placebo ointment, no photoactivation
1890271|NCT01256437|Drug|Threolone ointment|ointment once daily for 1 month
1890272|NCT01256437|Drug|ointment Synthomycine|ointment once daily for 1 month
1890273|NCT01256437|Drug|Aqua cream|ointment once daily for 1 month
1890274|NCT01256450|Drug|Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
1890275|NCT01256450|Drug|Placebo|buccal soluble film; applied to the buccal mucosa twice daily
1890276|NCT01256463|Behavioral|HIV prevention intervention|
1890277|NCT01256476|Drug|pitavastatin|pitavastatin 4 mg once daily (QD)
1890278|NCT01256476|Drug|pravastatin|Pravastatin 40 mg once daily (QD)
1890279|NCT01256489|Drug|Infliximab|The drug will be administered intravenously every month for 110 weeks (duration of the study). The initial dose of infliximab will be 5mg/kg of body weight. The dose may be adjusted up to a maximal dosing of 10mg/kg depending upon disease activity, as judged by the investigators.
1890280|NCT01256502|Device|SERI® Surgical Scaffold|Breast reconstruction surgery
1890281|NCT01256515|Behavioral|Health Education|CDs, techniques, advice, and group training pertaining to a healthier lifestyle. Both groups will have this intervention, but the specific type of health education training will vary between groups.
1890282|NCT01256515|Behavioral|Health Education Training|8 weeks of group training regarding health education techniques.
1890283|NCT01256528|Procedure|Delayed Breast Reconstruction|Approximately 3 months after postmastectomy radiation therapy, the preserved, irradiated, and re-inflated breast skin will be used to perform the delayed breast reconstruction. During the stage 2 reconstruction, the implant or expander will be removed and the definitive reconstruction will be performed with the preserved breast skin utilizing a preference for autologous tissue or autologous tissue with an implant due to the potential for complications with implant-based reconstructions after radiation therapy (XRT).
1890284|NCT01256541|Drug|Kristalose|The dosing regimen of Kristalose will be nine 20-gram doses (one dose every 30 minutes for 4 straight hours) taken the evening before the colonoscopy procedure.
1890285|NCT01256554|Procedure|Stereotactic Radiosurgery (SSRS)|Target dose of 18 or 24 Gy to spine in single session of radiation.
1890286|NCT01256554|Behavioral|Questionnaires|Questionnaire completion about health symptoms and pain at baseline, 3 months, 6 months, 9 months, 12 months, 24 months, then every 6 months.
1890287|NCT01256567|Biological|Ramucirumab|Ramucirumab administered as an intravenous (I.V.) infusion at a dose of 10 milligrams per kilogram (mg/kg) every 3 weeks.
1890288|NCT01256567|Drug|Docetaxel|Docetaxel administered by intravenous (I.V.) infusion at a dose of 75 milligrams per square meter (mg/m^2) every 3 weeks.
1890289|NCT01256580|Drug|Bevacizumab (Avastin; Genentech, Inc.)|1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection
1890290|NCT01256580|Drug|Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy|Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone
1890291|NCT01256593|Drug|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
1890292|NCT01256619|Drug|Marvelon|The study was a clinical trial without any control group. Sixty one healthy women were included in the study. The participants had been referred to family planning clinics centers under the supervision of Tehran University of Medical Science. weight and blood pressure were measured for all participants at baseline, at the end of cycle 1, at end of cycle 2, at the end of cycle 3 and at the end of cycle 6. Blood pressure was measured on the right arm with the subject seated after 10 minutes of rest
1989699|NCT02417064|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
1890294|NCT01256645|Other|blood transfusion|application of single units of red blood cell transfusions
1890295|NCT01256658|Drug|COA566|COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.
1890297|NCT01256684|Drug|Placebo|Placebo vaginal suppository
1890298|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.25% (3.25 mg) DHEA; daily dosing with one suppository for 12 weeks.
1890299|NCT01256684|Drug|DHEA|Vaginal suppository containing 0.50% (6.5 mg) DHEA; daily dosing with one suppository for 12 weeks.
1890300|NCT01256697|Dietary Supplement|Alga Dunaliella Bardawil|9-cis Rich Powder
1890301|NCT01256697|Dietary Supplement|Alga Dunaliella Bardawill|9-cis Rich Powder
1890302|NCT01256697|Other|Sugar pill|Sugar pill
1890303|NCT01256710|Device|Implantation of the Trifecta Valve|Implantation of the bioprothesis valve, Trifecta Valve
1890304|NCT01250002|Drug|Placebo|Placebo will receive the same volume of saline infusion.
1890305|NCT01250002|Drug|Lidocaine|Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter
1890306|NCT01250041|Procedure|continuous femoral nerve block|ultrasound guided femoral nerve catheter insertion.
1890307|NCT01250041|Procedure|continuous saphenous nerve block|ultrasound guided saphenous nerve catheter insertion
1890308|NCT01250054|Device|Lotrafilcon B contact lens|Commercially marketed, silicone hydrogel, multifocal contact lens for daily wear use
1890309|NCT01250054|Device|Comfilcon A contact lens|Commercially marketed (Europe), silicone hydrogel, multifocal contact lens for daily wear use
1890310|NCT01250067|Procedure|Motor-related cortical potential (Procedure)|
1890311|NCT01250080|Dietary Supplement|Total Parenteral Nutrition with Glutamine|daily glutamine supplement of 0.35 g/kg weight as N2-L-Alanyl-L-Glutamine (0.5 g/kg/d - Dipeptiven Fresenius Kabi España) during five days.
1890312|NCT01250080|Other|Total Parenteral Nutrition without glutamine|The control group received a supplemental volume of the basic TPN solution to achieve an isocaloric an isonitrogenated formula with the study group.
1890313|NCT01250093|Device|acupuncture|
1890314|NCT01250106|Dietary Supplement|Lactobacillus reuteri|twice daily
1890315|NCT01250119|Drug|erlotinib [Tarceva]|150 mg daily, orally
1890316|NCT01250132|Other|Biological and behavioral explorations|"Blood dosages:
biochemistry
pituitary gland
somatotropic axis
corticotropic axis
gonadotropic axis
thyrotropic axis
antidiuretic axis
Questionnaires and scales (quality of life, Vineland Adaptive Behavior Scales (VABS)-II)"
1890317|NCT01250145|Drug|LY333334|Transdermal patch
1890318|NCT01250145|Drug|Placebo|Transdermal patch
1890319|NCT01250158|Device|Liver-PILP kit|"Device: Liver-PILP kit The Liver-PILP kit (three devices) is composed of percutaneous, disposable (single-use), catheter-based devices for targeted, isolated, organ specific (liver), drug delivery and perfusion with high dose drugs.
The Portal Vein Device (PVD): balloon catheter to occlude the portal vein and allow aspiration through a central lumen for portal veno-venous bypass.
The Hepatic Artery Device (HAD): balloon catheter to occlude arterial flow to the liver.
The Vena Cava Device (VCD): catheter based device to isolate and access hepatic outflow to vena cava by creating a closed chamber in vena cava at ostia of the hepatic veins while maintaining central vena cava blood flow from lower extremities to right atrium through reduced central lumen."
1890320|NCT01250171|Biological|Secukinumab 10 mg/kg|Secukinumab was prepared in a sterile water solution.
1890321|NCT01250171|Biological|Canakinumab 10 mg/kg|Canakinumab was prepared in a sterile water solution.
1890322|NCT01250171|Biological|Placebo|The placebo solution for infusion contained 5% glucose.
1890323|NCT01250184|Other|Physical therapy|Twelve sessions (3 per week)
1890324|NCT01250184|Drug|Lidocaine injection|blocking the Myofascial trigger point (MTP) with lidocaine injection, unique dose.
1890325|NCT01250184|Other|Lidocaine injection + physical therapy|blocking the Myofascial trigger point (MTP) with lidocaine injection plus a standarized therapeutic exercise program (twelve sessions, 3 per week)
1890326|NCT01250197|Drug|AR-12286|Ophthalmic Solution
1994115|NCT03063177|Procedure|Spinal manipulative therapy|A SMT will be delivered by contacting the transverse processes of T7 through our apparatus. Each participant will receive one SMT per session for 3 sessions.
1890330|NCT01250249|Biological|BCG Vaccine IP - Serum Institute of India|0.1 ml for adults and children aged 1 month and over 0.05 ml for infants under 1 month of age
1890331|NCT01250262|Other|normal medical care and follow up|physical activity/ nutrition guidelines will be provided and reviewed with the participant as part of standard care; telephone contact will be made weekly to encourage adherence to the health guidelines
1890332|NCT01250262|Other|Isolated Lumbar Resistance Exercise Program|lumbar extension, two set of 10-15 repetitions, once a week for two weeks; lumbar extension, one set of 10-15 repetitions, three times a week, week 3 to 4 months
1890333|NCT01250262|Other|Total Body Resistance Exercise Program|exercises: leg press, leg curl, leg extension, chest press, seated row, overhead press, triceps dip, biceps curl, calf press and abdominal curl, one set of 10-12 repetitions, three time per week, week one to 4 months
1890334|NCT01250275|Other|traditional canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from traditional canola oil.
1890335|NCT01250275|Other|high oleic canola oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high oleic canola oil.
1890336|NCT01250275|Other|soybean oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from soybean oil.
1890337|NCT01250275|Other|high linoleic safflower oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from high linoleic safflower oil.
1890338|NCT01250275|Other|coconut oil|Participants (10 healthy and 10 with peripheral arterial disease) will be asked to attend a total of 5 consecutive visits (with a minimum of 6 days between visits) in a fasting state where they will be randomly assigned one food item in the form of banana bread containing 50 gm fat from coconut oil.
1890339|NCT01250275|Other|traditional canola oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of food items prepared with traditional canola oil for eight weeks.
1890340|NCT01250275|Other|safflower oil|Participants with peripheral arterial disease (n=25) will be randomized to daily consumption of foods prepared with an oil mixture representing the typical western diet
1890474|NCT01256983|Behavioral|Wait-list intervention|10000 Lux for 30 Minutes according to sleep wake rhythm
1890341|NCT01250288|Other|Personal Health Management System|BHIX and LIPIX are offering novel personal health management system to members of its community. These community members, also referred to as consumers, will include patients & their designated proxies. BHIX's system will allow patients to perform various tasks, including, but not limited to, viewing medications, medical allergies and lab results. LIPIX's system is primarily a mechanism forc consumers/patients to communicate directly with their physician through a secure messaging portal. Healthcare providers of these patients, who are affiliated with BHIX, will also be able to view the data entered by consumers in this personal health management system through the RHIO's health information exchange. Thus, the intervention of a personal health management system is being offered to both groups, however in different forms.
1890342|NCT01250301|Other|De-nicotinised cigarettes + standard treatment|"Participants will receive de-nicotinised cigarettes to use as required for 2 weeks after their quit day. These cigarettes are intended to provide a replacement for the behavioural and sensory aspects of smoking without supplying nicotine.
Participants will also receive standard NHS Stop Smoking Service treatment. This is a combination of weekly behavioural support and medication (e.g. nicotine replacement therapy/varenicline)."
1890343|NCT01250301|Other|Standard Treatment|Participants will receive standard treatment from the NHS Stop Smoking Service.
1890344|NCT01250314|Other|Radiology|Spine radiography, densitometry, evaluation of bone architecture and micro-architecture (computed tomography of lumbar spine and hip and peripheral micro-scanner (XREME SCANCO) at tibia and wrist).
1890345|NCT01250314|Other|Biological, biochemical and genetic samples|"*Serum calcium and phosphore evaluation, bone remodeling markers, 25-hydroxyvitamin D level assessment: Blood samples plasma (5 ml):Creatin, calcemia, phosphoremia, alkaline phosphatase, bone alkaline phosphatase, osteocalcin, CTX, 25 hydroxyvitamin D and parathormone
Urinary samples :
Deoxy-pyridinoline, creatinuria Fasting morning urine on a sample Calciuria, creatinuria, cortisoluria Day urine on a sample
*Assessment of possible determinants of fractures in man
Blood samples plasma (5 ml):
Sexual Hormones: Estradiol, Testosterone, SHBG, LH, FSH
Homocysteine
IGF1
Extraction of DNA for a genetic polymorphism study:
Sample of 10 ml of blood on EDTA for DNA extraction.
Tested polymorphisms will be: LRP5, CYP19 (Aromatase), COL1A1 (Collagen I),MHTFR, IGF-1,VDR vitamin D receptor
Globally 20 ml of blood will be taken for each subject. Every biological sample for biochemical dosages and for genetic analysis will be preserved in an anonymous way."
1890349|NCT01250340|Drug|Aspirin|100 mg/day for 30 days
1890350|NCT01250340|Drug|Placebo|1 cp day for 30 days
1890351|NCT01250353|Procedure|pterygium surgery|pterygium was removed surgically
1890352|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once Daily, 7 Days
1890353|NCT01250366|Drug|INX-08189|Capsule, Oral, 25 mg, Once Daily, 7 days
1890354|NCT01250366|Drug|INX-08189|Capsules, Oral, 50 mg, Single Dose, 1 day
1890355|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once daily, 6 days
1890356|NCT01250366|Drug|INX-08189|Capsules, Oral, 50 mg, Once daily, 7 days
1890357|NCT01250366|Drug|INX-08189|Capsules, Oral, 9 mg, Once daily, 7 days
1890358|NCT01250366|Drug|INX-08189|Capsules, Oral, 100 mg, Once daily, 7 days
1890359|NCT01250366|Drug|Placebo matching with INX-08189|Capsules, Oral, 0 mg, Once daily, 7 days
1890360|NCT01250366|Drug|Ribavirin|Capsules, Oral, 1000 or 1200 mg daily (delivered in weight-adjusted am/pm divided dose), 7 days
1890361|NCT01250379|Drug|bevacizumab [Avastin]|10 mg/ kg iv every 2 weeks or 15 mg/kg iv every 3 weeks
1890362|NCT01250379|Drug|Chemotherapy|Standard chemotherapy (doublets not allowed)
1890363|NCT01250392|Behavioral|The Effect of Active Choice on Nurse Visit Participation|"The goal of this project is to see if active choice will increase an individual's likelihood of participating in a nurse visit.
The employees in our sample will schedule their nurse visit time slot via e-mail and a health service provider website. The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and given instructions for scheduling an appointment. The treatment group, the active choice only arm, will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening. The treatment group will also receive email reminders one week before their appointment."
1890364|NCT01250405|Drug|Cinacalcet|One sequence receives Cinacalcet 30mg /d for 7 days followed by placebo for 7 days
1890365|NCT01250405|Drug|Placebo|One sequence receives placebo for 7 days followed by Cinacalcet 30mg/d for 7 days
1890366|NCT01250418|Drug|Ketamine group|ketamine bolus of 0.25mg/kg followed by an infusion set at 1.5 mcg /kg/min.
1890367|NCT01250431|Behavioral|EFT (Emotional Freedom Techniques)|10 EFT sessions
1890369|NCT01250457|Drug|topical Timolol|topical Timolol 0.5% solution applied twice daily
1890370|NCT01250470|Other|Laboratory Biomarker Analysis|Correlative studies
1890371|NCT01250470|Drug|Montanide ISA-51/Survivin Peptide Vaccine|Given SC
1890372|NCT01250470|Biological|Sargramostim|Given SC
1890373|NCT01250483|Other|PSA measurement, uroflowmetry, IPSS, transrectal ultrasonography|
1990684|NCT01877915|Drug|Placebo|Each participant, randomly allocated to the placebo arm, will receive one matching placebo tablet orally twice daily (once in the morning and once in the evening at approximately the same time each day) until the GTED. Placebo will be given with standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician).
1890376|NCT01250509|Behavioral|Craving and Lifestyle Management through Mindfulness|A preliminary, novel intervention was developed drawing on components from Mindfulness-Based Stress Reduction (MBSR), Mindfulness-Based Cognitive Therapy (MBCT), and Mindfulness-Based Eating Awareness Training (MB-EAT). The intervention program consisted of nine 2.5-hour classes and one 7-hour silent day of guided meditation practice after class 6.
1890377|NCT01250535|Drug|Warfarin|10 mg, po, single dose on day 7
1890378|NCT01250535|Drug|Placebo|po, once a day, days 1 through 14
1890379|NCT01250535|Drug|Lovastatin|40 mg, po, once a day, days 1 through 14
1890382|NCT01250561|Drug|Gabapentin|gabapentin 300mg/day, titrated up weekly to max tolerated dose or 3600mg/day (whichever is lower), for 4-9 weeks
1890383|NCT01250561|Drug|Valacyclovir|valacyclovir 1000mg three-times daily x 7 days
1890384|NCT01250574|Other|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
1890385|NCT01250574|Other|CD64 and Procalcitonin|Blood tests taken before and regularly after surgery or other treatment.
1890386|NCT01250587|Drug|PDC31|This study involves the sequential administration of PDC31 to 4 cohorts of patients. The dose will be escalated in the absence of dose-limiting toxicities. PDC31 is to be administered as a 3-hour continuous infusion.
1890387|NCT01250600|Behavioral|Home exercise|Daily home exercise for 3 months
1890388|NCT01250652|Drug|Levocetirizine|20 mg levocetirizine for 5 days
1890389|NCT01250652|Drug|Levocetirizine plus Hydroxyzine|24 patient will receive 15 mg Levocetirizine plus 50 mg Hydroxyzine at bad time for 5 days
1890390|NCT01250691|Other|ward-type ICU|frequency of hospital acquired pneumonia in the ICU
1890391|NCT01250717|Drug|Docetaxel|Given by an IV infusion over 1 hour on day 2 of a three-week cycle
1890392|NCT01250717|Drug|Dexamethasone|Orally 12 hours and 1 hour before docetaxel and again 12 hours after docetaxel
1890393|NCT01250717|Drug|Estramustine|Taken orally three times a day for 5 days for the first part of every three week cycle
1890394|NCT01250717|Drug|Zoladex|Given subcutaneously for 4 doses every three months
1890395|NCT01250717|Drug|Casodex|Taken orally once a day for 6 months
1890396|NCT01250717|Procedure|Radical Prostatectomy|after the chemo and hormonal therapy all patients have a radiacal prostatectomy
1890397|NCT01250730|Drug|PF-02341066|Cohort 1: a 150 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 1 x 100 mg IRT.
1890398|NCT01250730|Drug|PF-02341066|Cohort 2: a 250 mg single dose of PF-02341066 administered as 1 x 50 mg IRT and 2 x 100 mg IRTs.
1890399|NCT01250730|Drug|PF-02341066|Cohort 3: a 400 mg single dose of PF-02341066 administered as 4 x 100 mg IRTs.
1890400|NCT01250743|Dietary Supplement|ascorbic acid (vitamin C)|intravenous vitamin C, 25 to 100 grams, once or twice a week, for five months
1890401|NCT01250756|Biological|7-pneumococcal conjugate vaccine (7vPnC)|0.5 mL per dose, 4 doses
1890402|NCT01250756|Biological|diphtheria, tetanus, and acellular pertussis vaccine (DTaP)|0.5 mL per dose, 4 doses
1890403|NCT01250756|Biological|DTaP|0.5 mL per dose, 4 doses
1890404|NCT01250769|Device|Manual Toothbrush|A standard size manual toothbrush to clean visible tooth surfaces
1890405|NCT01250769|Device|Interproximal Cleaning Device|An electronic device that combines water and air to clean between the teeth
1890406|NCT01250782|Drug|Glutamine|0.5 g/kg/day of dipeptide N (2)-L-Alanyl-L-Glutamine
1890407|NCT01250782|Drug|Physiological serum|100 mL of physiological serum indistinguishable from active comparator
1890408|NCT01250795|Biological|HAI-05 Influenza Vaccine|injection, vaccine, twice every 3 weeks
1890409|NCT01250795|Other|Saline|
1890410|NCT01250808|Drug|Bortezomib/Dexamethasone/Melphalan|"Induction therapy: The treatment will continue for 3-4 cycles and each cycle will be last 21 days.
Bortezomib 1.3mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.
Bortezomib 1.0mg/m2, twice weekly for two weeks (days 1, 4, 8, and 11) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle.
Bortezomib 1.6mg/m2, once weekly for two weeks (days 1, 8) of each cycle + Dexamethasone 20mg/m2, on days 1-4 of each cycle and on days 9-12 of the first and second cycles.
ASCT therapy:
Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for four times. Melphalan 200mg/m2 +Bortezomib 1.0mg/m2 for two times."
1890411|NCT01250821|Drug|Menopur|"The medication used in this study is the follicle-stimulating hormone highly purified human menopausal gonadotrophin (HP-HMG), Menopur, (Ferring a/s).
Stimulation with HP-hMG (Menopur) is started on day 2-5 of menstrual bleeding.The HP-hMG starting dose is calculated based on the nomogram predicting the threshold dose. The dose-range is from 75 IU/day to 187.5 IU/day."
1890412|NCT01250834|Drug|Atorvastatin|Administered orally.
1890413|NCT01250834|Biological|LY2189265|Administered subcutaneously.
1890414|NCT01250847|Drug|Quetiapine(Seroquel-XR) 50~800mg a day|The only ARMS subjects will be given 50~800mg Seroquel-XR once daily for total of 12 weeks.
1890415|NCT01250860|Other|Derotational manual therapy techniques in selected segments in spine|Derotational manual therapy techniques in selected segments of spine in preparation for the exercises according to the DoboMed method.
1890416|NCT01250860|Behavioral|Sham therapy|
1890417|NCT01250873|Drug|LY2216684|administered orally
1890418|NCT01250873|Drug|Sertraline|administered orally
1890419|NCT01250886|Drug|Lactated Ringer's solution|Lactated Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
1890420|NCT01250886|Drug|Normal saline solution|Normal saline solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
1890421|NCT01250886|Drug|Acetate Ringer's solution|Acetate Ringer's solution is administered. The volume of fluid administration is calculated by means of Holliday and Segar formula.
1890422|NCT01250899|Dietary Supplement|Vitamin D|50,000 IU vitamin D3 twice weekly for 5 weeks, followed by 2000 IU daily maintenance supplementation to complete 12 weeks. At the end of the 12-week period, 25(OH)D levels will be checked. If the subject is still deficient, he/she may undergo a second period of supplementation (at the discretion of their provider) to complete a total of 24 weeks. After 24 weeks, we anticipate all subjects will be kept on daily maintenance supplementation by their primary physicians.
1890423|NCT01250912|Drug|123I-metaiodobenzylguanidine|FDA Approved for use in Cancer patients. This use is Off Label. For the imaging study, an activity of 370 MBq (10 mCi) 123I-mIBG (GE Healthcare) will be administered intravenously, and a 10-minute planar image of the anterior thorax (128_128 matrix) will be acquired beginning 15 minutes after tracer injection.
1890424|NCT01250925|Drug|ReNu MultiPlus® MultiPurpose Solution|Contact lens care regimen
1890425|NCT01250925|Drug|OPTI-FREE® RepleniSH®|Contact Lens care regimen
1890426|NCT01250925|Drug|Clear Care®|Contact lens care regimen
1890514|NCT01258985|Behavioral|Physical Therapy|6 weeks of individualized Physical Therapy followed by 6 weeks of supervised Home Exercise
1890515|NCT01258998|Drug|Akt inhibitor MK2206|Given PO
1890427|NCT01250938|Behavioral|ESI - Community Outreach|This is an individualized caregiver-implemented intervention (ESI-CO) offered in 2 weekly sessions to teach caregivers how to embed strategies to support social communication skills within everyday routines, activities, and places for 3 months. Additionally, families receive 6 months (3 months during weekly home sessions and three months upon the completion of weekly home sessions) of resource support to identify local and community autism programs available for continued intervention and services.
1890428|NCT01250951|Drug|Deferasirox|
1890429|NCT01250964|Procedure|Lens insertion during cataract surgery|After cataract removal during cataract surgery, a lens needs to be injected into the eye. Both arms are routinely used but different methods for injecting the lens.
1890430|NCT01250977|Drug|Donepezil|5 mg donepezil HCL (Aricept) Participants will be instructed to take one 5 mg pill every night before going to bed with a glass of water for 28 days. In case participants experience difficulty they will be allowed to take the study medication in the morning.
1890431|NCT01250990|Drug|Niacin|Niacin taken orally for 12 weeks at the highest tolerated dose (up to 6 grams), and at least 2 grams daily and up to the maximum approved dose. Subjects will initiate therapy with Niaspan and will advance to Niacor as tolerated.
1890432|NCT01250990|Other|Placebo|Placebo
1890433|NCT01251003|Biological|Autologous cord blood|there is no minimum acceptable dose, and the maximum allowable dose will be 10x10(9)cells/kg given IV (in the vein), one time infusion
1890434|NCT01251029|Drug|N-acetylcysteine|1200 mg orally; 600mg i.v.
1890435|NCT01251029|Drug|Siran (N-acetylcysteine)|
1890436|NCT01251042|Device|Sangvia|The Sangvia® Blood Salvage System used to collect blood intra-operatively.
1890437|NCT01251055|Drug|GlyT-1 inhibitor-1|GlyT-1 inhibitor-1(500) 4# BID
1890438|NCT01251055|Drug|Placebo|starch
1890439|NCT01251068|Device|near infrared spectroscopy: invos 5100|duration:six hours
1890440|NCT01251068|Device|INVOS 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
1890441|NCT01251068|Device|near infrared spectroscopy device|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, we applied NIRS probes to the forehead and the lower extremity for cerebral (rSO2C) and peripheric (rSO2P) regional oxygen saturation measurements.
1890442|NCT01251081|Other|extra high volume hemofiltration|extra high volume hemofiltration (85 mL/kg/h, EHVHF)
1890443|NCT01251081|Other|high volume hemofiltration|high volume hemofiltration (50 mL/kg/h, HVHF)
1890444|NCT01251107|Drug|Bleomycin|10 mg/m2 IV day 8 during cycles 1 to 8
1890445|NCT01251107|Drug|Etoposide|200 mg/m2 iv on days 1 to 3 during cycles 1 to 4; 100 mg/m2 iv on days 1 to 3 during cycles 5 to 8
1890446|NCT01251107|Drug|Doxorubicin|35 mg/2 iv on day 1 during cycles 1 to 4; 25 mg/m2 iv on day 1 during cycles 5 to 8
1890447|NCT01251107|Drug|Cyclophosphamide|1250 mg/m2 iv on day 1 during cycles 1 to 4; 650 mg/m2 iv on day 1 during cycles 5 to 8
1890448|NCT01251107|Drug|Vincristine|1.4 mg/m2 iv (max 2 mg) on day 8 during cycles 1 to 8
1890449|NCT01251107|Drug|Procarbazine|100 mg/m2 po from day 1 to 7 during cycles 1 to 8
1890450|NCT01251107|Drug|Prednisone|40 mg/m2 po from day 1 to 14 during cycles 1 to 8
1890451|NCT01251107|Drug|Doxorubicin|25 mg/m2 iv on days 1 and 15 in each cycle
1890452|NCT01251107|Drug|Bleomycin|10 mg/m2 iv on days 1 and 15 in each cycle
1890453|NCT01251107|Drug|Vinblastine|6 mg/m2 iv on days 1 and 15 in each cycle
1890454|NCT01251107|Drug|Dacarbazine|375 mg/m2 iv on days 1 and 15 in each cycle
1890455|NCT01256736|Drug|Tocilizumab|intravenously at dose of 8mg/kg over 1 hour infusion every 4weeks
1890456|NCT01256736|Drug|DMARDs|DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)
1890457|NCT01256762|Drug|Imetelstat sodium|Imetelstat is administered at a dose of 300 mg/m2 on day one of a 21 day cycle.
1890458|NCT01256762|Drug|Bevacizumab|Bevacizumab is administered at 15 mg/kg on day one of a 21 day cycle
1890459|NCT01256762|Drug|Paclitaxel|Paclitaxel is administered at 90 mg/m2 on days one and eight of a 21 day cycle
1890460|NCT01256775|Drug|NCX-4016|NCX4016 800 mg b.i.d. for 6 months on top of aspirin 100 mg o.d.
1890461|NCT01256775|Drug|NCX4016 placebo|NCX4016 placebo b.i.d. for 6 months
1990685|NCT01877915|Other|Standard of care for heart failure and coronary artery disease|Each participant's standard of care for heart failure and coronary artery disease (as prescribed by the participant's managing physician) should be continued throughout the study.
1890464|NCT01256801|Biological|cytokine|interleukin 2 2 million unit every week
1890465|NCT01256814|Behavioral|SystemCHANGE-HIV|SystemCHANGE, is based on social ecological theory and focuses on redesigning the family environment and daily routines that are linked to health behavior. This framework emphasizes context and specifies that change is best accomplished by: identifying a measurable goal, examining the system processes surrounding attainment of that goal, listing several ideas that may improve the system, engaging in a series of experiments to test the best ideas to improve the process, implementing the most successful ideas based on data from the experiments, and monitoring the system to maintain the gains. The SystemCHANGE-HIV intervention works to help participants make small environmental changes made in family daily routines that will eventually construct an environment.
1890466|NCT01256853|Drug|MVA Vaccine|The starting dose will be 5 x 107 plaque forming units (pfu) given by intradermal vaccination. Cohorts of three patients will receive escalating doses of the vaccine (100%, 100%, 67% and 50%). The dose escalation scheme is 5 x 107 pfu, 1 x 108 pfu, 2 x 108 pfu, 3.3 x 108 pfu, 5 x 108pfu. This will be dependant on toxicity.
1890467|NCT01256866|Drug|Dexmedetomidine|
1890468|NCT01256866|Drug|Midazolam|
1890470|NCT01256892|Procedure|induction of labour|
1890471|NCT01256905|Drug|Armodafinil|Armodafinil 150 mg
1890472|NCT01256957|Device|HEPA filter|
1890473|NCT01256983|Behavioral|Bright Light Therapy|10000 Lux for 30 Minutes according to sleep wake rhythm
1890475|NCT01256996|Procedure|Air abrasion of the implant surface with a low abrasive powder|Test treatment will be performed using the low abrasive powder in a standard air-polishing unit, which will be set up according to the manufacturer's instructions. The unit will be set to a medium water and powder setting, and the powder chamber will be filled to the indicated maximum powder level before treatment to ensure reproducible treatment conditions. The jet will be directed to the periodontal pocket for 5 s per surface (vestibular, lingual, mesio and distal) for subgingival plaque removal.
1890476|NCT01257009|Drug|Atorvastatin|6 weeks treatment with atorvastatin and studying the effect of atorvastatin on sympathetic activity
1890477|NCT01257022|Behavioral|Familias Unidas|There will be 8 group sessions and 4 family visits. During the group sessions, the facilitator offers support for parents and gently corrects maladaptive interactions between parents and adolescents. During family visits, facilitators assist families in practicing skills and restructuring family interactions. The parent group sessions focus on parental investment in the adolescent's worlds (e.g., peer and school worlds), family communication, family support, behavior management/positive parenting, parental monitoring, adolescent substance use, and adolescent unsafe sex and HIV.
1890478|NCT01257035|Other|18F-FAZA-PET/CT|Contrast fluid injected prior to scan
1890479|NCT01257048|Drug|Formoterol Turbuhaler|9 microgram on visit 5 single dose
1890480|NCT01257048|Drug|Budesonide/Formoterol Turbuhaler|320/9 microgram twice daily during 8 weeks
1890481|NCT01257048|Drug|Formoterol Turbuhaler|9 microgram twice daily during 8 weeks
1890484|NCT01258777|Drug|400 mg golimumab or placebo|Single dose of 400 mg subcutaneously
1890485|NCT01258777|Drug|200 mg golimumab or placebo|Single dose of 200 mg subcutaneously
1890486|NCT01258790|Device|Sham Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Sham intervention uses a sham magnetic coil.
1890487|NCT01258790|Device|Active Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation (RTMS) is a relatively new technology that allows for targeted noninvasive stimulation of the brain. RTMS is currently FDA-cleared for the treatment of refractory depression. It is also used experimentally to treat seizures, spasticity, dystonia and other neuropsychiatric conditions. The Active intervention uses an active magnetic coil.
1890488|NCT01258803|Drug|Formoterol Fumarate DPI|Two inhalations of Formoterol Fumarate DPI 10 mcg administered as a single dose
1890489|NCT01258803|Drug|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) without spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
1890490|NCT01258803|Drug|Mometasone Furoate/Formoterol Fumarate MDI (ex-actuator) with spacer|Two inhalations of Mometasone Furoate/Formoterol Fumarate MDI 50/5 mcg administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
1890491|NCT01258803|Drug|Placebo MDI with spacer|Two inhalations of placebo MDI administered as a single dose with an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
1890492|NCT01258803|Drug|Placebo MDI without spacer|Two inhalations of placebo MDI administered as a single dose without an AeroChamber Plus® Flow-Vu® Anti-Static Valved Holding Chamber (spacer)
1890493|NCT01258803|Drug|Mometasone Furoate DPI|Two inhalations of MF DPI 100 mcg administered as a single dose once daily at night. Used as maintenance therapy during screening and in between single doses of study drug.
1890494|NCT01258816|Drug|Elacytarabine for infusion|Elacytarabine 2000 mg/m2/d will be administered as a continuous intravenous infusion (CIV) in a d 1-5 q3w schedule.
1890495|NCT01258829|Other|Non-invasive haemodynamic optimisation|Comparing the method of non-invasive haemodynamic
1890496|NCT01258829|Other|ECHO optimisation|Standard ECHO optimisation method
1890497|NCT01258842|Dietary Supplement|Bifidobacterium lactis HN019|B. lactis HN019 (5 billion cfu / day) sachet, consumed once per day for 12 weeks
1890498|NCT01258842|Dietary Supplement|Placebo|Placebo sachet, consumed once per day for 12 weeks
1890502|NCT01258868|Drug|Celebrex|400 mg PO BID for 7 days prior to cell administration and then on days 1 through 28 of each vaccine cycle.
1890503|NCT01258868|Biological|Tumor cell vaccine|A minimum of 1x10e7 and a maximum of 1x10e8 patient tumor cells that have been exposed to 1 mcM decitabine for 6 days, exposed to 100 Gy radiation and emulsified in 0.5 ml of the ISCOMATRIX adjuvant at a concentration of 180 ISCO units/mL administered IM every 4 weeks for 6 injections; if subject shows immune response, vaccine will be given every three months from months 9 - 24
1890504|NCT01258907|Drug|MLDL1278A|Single intravenous dose
1890505|NCT01258907|Drug|MLDL1278A|Repeating intravenous dose
1890506|NCT01258907|Drug|placebo|Repeating intravenous dose
1890507|NCT01258907|Drug|statin, stable dose|Repeating oral dose
1890508|NCT01258920|Drug|Paliperidone palmitate|Paliperidone palmitate will be administered im as an initial loading dose of 150 mg eq. on Day 1 and 100 mg eq. 1 week later in the deltoid muscle, and will be administered in a flexible dose range of 25 to 150 mg eq. at 4-week intervals from Week 5 for a total of 11 injections.
1890509|NCT01258933|Drug|Ofatumumab|300 mg Dose 1, then 1,000 mg weekly x 7, (treatment) then 1,000 mg every 2 months beginning on week 12
1890510|NCT01258959|Procedure|Ultrasound detection of local anesthetics spread|During the parabulbar injection the ultrasound operator experienced in ultrasound guided retrobulbar block will assess whether there is spread of local anaesthetic in the central cone just behind the sclera (yes or no). The anaesthesist performing the block will be blinded to the ultrasound visualized spread of local anaesthetic.
1994116|NCT03064022|Other|Growth|Some preterm infants grow at higher rates than others
1890513|NCT01258985|Behavioral|Tai Chi|12 weeks of Tai Chi
1890516|NCT01258998|Other|laboratory biomarker analysis|Correlative studies
1890517|NCT01259011|Behavioral|the SPIRIT intervention|the SPIRIT intervention (Sharing the Patient's Illness Representation to Increase Trust) to improve discussions about end-of-life care between patients and their surrogate decision makers
1890518|NCT01259024|Device|transarterial chemoembolization using a drug-eluting bead|Up to 2 vials of LC Beads will be administered. One 2 mL vial each of 300-500 and 500-700 um LC Beads with 37.5 mg/mL doxorubicin will be prepared and mixed with radiographic contrast. Under fluoroscopic control, the vial of 300-500 um vial will be infused, followed by the vial of 500-700 um LC Beads. If the artery does not reach stasis prior to administration of both vials, and there is residual antegrade flow in the feeding artery, it will be treated with bland embolization similar to chemoembolization.
1890520|NCT01259063|Drug|Everolimus and Intravesical Gemcitabine|Phase I: Everolimus will be adm as follows: Dose level 1: 5 mg every other day, Dose level 2: 5 mg daily, Dose level 3: 10 mg daily Phase II: Everolimus will be adm at 10 mg daily the dose determined in Phase I. Pts will receive a dose of 2000 mg of intravesical gemcitabine twice a week (72-96 +8 hours between doses) for 3 weeks for a total of 6 treatments in course 1. After 1 week of rest from intravesical gemcitabine, course 2 will be administered, provided the treating physician notes acceptable pt tolerance. The total number of intravesical instillations will be 12. There will be no dose modifications to gemcitabine; however, pts will be allowed to skip gemcitabine doses if needed, per the treating physician's discretion. Missed or skipped doses of gemcitabine will not be repeated. The pt will receive as many instillations as tolerable up to the maximum of 12 instillations.
1890521|NCT01259076|Procedure|magnetic resonance imaging|Undergo MRI at baseline and 1 year later.
1890522|NCT01259076|Procedure|digital mammography|Undergo digital mammography at baseline and 1 year later.
1890523|NCT01259076|Procedure|conventional surgery|Undergo gastric bypass surgery
1890524|NCT01259089|Drug|erlotinib hydrochloride|Given orally
1890525|NCT01259089|Drug|Hsp90 inhibitor AUY922|Given IV
1890526|NCT01259089|Other|laboratory biomarker analysis|Correlative studies
1890527|NCT01259089|Procedure|needle biopsy|Undergo image-guided needle biopsy (correlative studies)
1890528|NCT01259089|Genetic|mutation analysis|Correlative studies
1890529|NCT01259089|Other|pharmacological study|Correlative studies
1890530|NCT01259102|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
1890531|NCT01259115|Drug|Buprenorphine transdermal patch|Buprenorphine 10 mcg/hour patch applied transdermally for 7-day wear.
1890532|NCT01259115|Drug|Ketoconazole tablet|Ketoconazole 200 mg tablets taken orally twice daily.
1890533|NCT01259115|Drug|Placebo to match ketoconazole tablet|Placebo to match ketoconazole 200 mg tablets taken orally twice daily.
1890534|NCT01259128|Drug|SER120 Nasal Spray 500 ng/day|SER120 Level 1
1890535|NCT01259128|Drug|SER120 nasal spray 750 ng/day|SER120 (750 ng/day)
1890536|NCT01259141|Drug|Moxifloxacin|0.4 Qd for 7days
1890537|NCT01259141|Drug|Cephalosporins and azithromycin|cefuroxime 1.5 bid for 7 days plus azithromycin 0.5 qd for 7 days
1890538|NCT01259180|Procedure|acupuncture treatment|twice a week, 6 weeks, 12sessions penetrating skin with stailess steel acupuncture device(diameter: 0.25-0.3mm,legth: 30-70mm) points: BL 23,BL31,BL32, BL40, BL53, GB30, SP 6 bilaterally plus Ashi. with
1890539|NCT01259180|Procedure|Sham acupunture|twice a week, 6 weeks, 12 sessions not penetrating skin with dull acupuncture device(Park Sham device :Acuprime Co. Ltd, UK) point: 1~2inches away from real acupuncture point
1890540|NCT01259193|Drug|Sorafenib and Zoledronic Acid|Sorafenib ,tablet,400mg Bid ,until patient can not tolerance Zoledronic Acid ,powder for injection,4mg per 3 week for 1 year
1890541|NCT01259219|Drug|Mycobutin|"Indication and Usage:
Mycobutin capsules are indicated for the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV Infection.
Dosage and Directions for use:
Mycobutin cab be administred as a single daily dose, independent of meals. In all cases Mycobutin is to be administred in combination regimens.
Identification:
Red-brown, self locking, hard gelatin capsule, size 0, containing a violet powder."
1890542|NCT01259245|Other|Tai chi + PRP|The exercise content was totally identical to PRP group except 15 minutes of 5 Sun Style Tai Chi were substituted to 15 minutes of relaxation exercise
1890543|NCT01259245|Other|PRP|Formal pulmonary rehabilitation program consisted of overview of COPD management, aerobic exercises, breathing control exercises, Thera-Band strengthening exercises, safety precautions for physical training and goal setting
1890544|NCT01259258|Procedure|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
1890545|NCT01259258|Procedure|without dye varicocelectomy|40 controls in whom no mapping technique was adopted in the period between
1890546|NCT01259284|Drug|Atorvastatin|1 capsule by mouth every morning 5 days before surgery, and 9 days after surgery or until discharge.
1890547|NCT01259284|Dietary Supplement|Fish Oil Supplement|3 capsules by mouth in the morning and evening 5 days before surgery, and 9 days after surgery or until discharge.
1890548|NCT01259284|Other|Placebo|"Placebo group: 4 capsules by mouth every morning and 3 every evening for 5 days before surgery and 9 days after surgery or until discharge.
Atorvastatin group: 3 capsules by mouth every morning and evening, 5 days before surgery and 9 days after surgery or until discharge.
Fish Oil Supplement group: 1 capsule by mouth every morning 5 days before surgery and 9 days after surgery or until discharge."
1890549|NCT01259297|Drug|Aliskiren|Aliskiren 150/300 mg once daily
1890550|NCT01259297|Drug|Amlodipine|Amlodipine 5 mg
1890551|NCT01259297|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 12.5/25 mg
1890552|NCT01259297|Drug|Placebo for Aliskiren|Placebo for Aliskiren 300 mg
1890553|NCT01259297|Drug|Placebo for Amlodipine|Placebo for Amlodipine
1890554|NCT01259297|Drug|Placebo for Hydrochlorothiazide (HCTZ)|Placebo for HCTZ 12.5/25 mg
1890555|NCT01259323|Biological|REGN668|Dose 1: REGN668 or placebo
1890556|NCT01259323|Biological|REGN668|Dose 2: REGN668 or placebo
1890557|NCT01259323|Biological|REGN668|Dose 3: REGN668 or placebo
1890558|NCT01259336|Drug|Itraconazole|Tablet 200 mg twice daily for 6 months
1890559|NCT01259336|Drug|treatment in cavitary pulmonary aspergillosis|Anti-tussive, blood transfusion, surgical resection and bronchial artery embolisation(BAE)
1890560|NCT01259349|Procedure|one percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at one percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
1890561|NCT01259349|Procedure|40 percent ultrasound power in CMICS|Co-axial MICS shall be performed in cases allocated to this arm .The ultrasound power shall be kept at 40 percent during the surgery.A note of effective phacotime,volume of fluid aspirated and any intraoperative complications shall be made.
1890562|NCT01259362|Procedure|Transcranial Magnetic Stimulation|5 Hz, 120 % motor threshold, intertrain interval 20s, number of pulses in train 50.
1890563|NCT01259362|Procedure|Transcranial Magnetic Stimulation|Cocaine addicted will receive 20 sham TMSr
1890564|NCT01259375|Drug|Amrubicin|Synthetic 9-aminoanthracycline Patients will receive 40mg/m2/day intravenously
1890565|NCT01259388|Drug|Lithium Carbonate|Lithium carbonate is dosed at 150 or 300 mg daily, as tolerated by study subjects, for one year's time.
1890566|NCT01259401|Behavioral|Sleep Intervention Program|Sessions focused on: 1) sleep consolidation and sleep schedule optimization, 2) sleep hygiene education, 3) cognitive therapy, and 4) maintenance of sleep improvements and coping with future bouts of insomnia.
1890567|NCT01259401|Behavioral|Sleep Education control|During sessions, participants reviewed two educational brochures that focused on changes in sleep with age and sleep hygiene education.
1890568|NCT01259414|Other|Solvent with specific gravity less than lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in distilled water and emulsified lipiodol followed embolization with polyvinyl alcohol particles (PVA)
1890569|NCT01259414|Other|Solvent with specific gravity equivalent to lipiodol|TACE with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg)dissolved in water-soluble contrast medium and distilled water,then emulsified with lipiodol followed embolization with polyvinyl alcohol particles (PVA)
1890570|NCT01259427|Behavioral|Ending Self Stigma (ESS)|Ending Self Stigma (ESS) is a 9-session small-group (4-8 persons) course designed to help individuals with serious mental Illness (SMI) develop skills to effectively cope with stigma and minimize the internalization of stigmatizing beliefs and stereotypes. Sessions combine in-class lecture, discussion of relevance to group members' personal experiences, review and practice of strategies and skills, and group sharing, support, and problem-solving. Each session is designed to focus on a specific strategy for addressing self-stigma.
1890571|NCT01259427|Behavioral|Health and Wellness Group|The Health and Wellness group is a 9-session small-group (4-8 persons) course designed for individuals with serious mental illness (SMI). Each session focuses on discussion of specific health and wellness related issues and education on ways to better manage health related concerns (e.g., physical activity/exercise, nutrition, managing fatigue/sleep, tobacco and other substance use, etc).
1890572|NCT01259440|Behavioral|Video Teleconferencing Care|The core component of the VTC intervention is the frequent contact between patient and provider using a telemedicine system that allows for audio-visual communication.
1890573|NCT01259440|Behavioral|Usual Care|Consists of one week telephone call and one month clinic visit
1890574|NCT01259453|Biological|Vaccination to prevent hepatitis B virus infection|Standard dosing with Twinrix; comparison of standard and acceleration dosing schedule
1890575|NCT01259466|Drug|Nicotine patch|Transdermal Nicotine Replacement Therapy - 21 mg daily for 10 weeks
1890576|NCT01259479|Drug|Satraplatin|Orally, once daily for 5 days repeated every 28 days, dose-escalation
1890577|NCT01259492|Drug|Placebo|Placebo Comparator: Placebo
1890578|NCT01259492|Drug|Ritalin LA 20 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg.
1890579|NCT01259492|Drug|Ritalin LA 30 mg|Ritalin LA (a racemic mixture of d- and l-thre-Methylphenidate Hydrochloride (MPH), extended release hard capsules) taken orally once daily in doses of 60, or 80 mg.
1890580|NCT01259505|Biological|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1|CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides mixed with Montanide ISA 51 Patients will be vaccinated once a week until patients develop progressive disease or unacceptable toxicity. On each vaccination day, CDCA1，URLC10，KIF20A，DEPDC1 and MPHOSPH1 peptides (0.5, 1 or 2mg of each peptide) mixed with Montanide ISA 51 will be administered by subcutaneous injection.
1890581|NCT01259518|Drug|TRIN2755|In treatment schedule A (Group A), the planned starting dose to be investigated is 25 mg TriN 2755 given once followed by a recovery period of 4 weeks. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after infusion (end of Cycle 1) does not indicate relevant toxicity.
1890582|NCT01259518|Drug|TRIN2755|In treatment schedule B (Group B), the starting dose to be investigated is 800mg, given once every 7 days in a 4 week cycle. Subsequent patients can only be included on a new dose level when the safety review from all patients included at the preceding dose level(s) at Day 28 after the start of the first infusion (end of Cycle 1) does not indicate relevant toxicity.
1890583|NCT01259531|Drug|Silodosin|Silodosin will be administered during 12 weeks, 8 mg (4 mg x 2 cap) QD with morning meal.
1890584|NCT01259544|Drug|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of powder form dissolved in one cup of tap water prior to breath test
1890585|NCT01259544|Drug|benzoyl-L-tyrosyl-[1-13C]alanine (Bz-Tyr-Ala)|300 mg of 13 C di peptide in single dose powder form dissolved in one cup of tap water.
1890586|NCT01259557|Drug|Botulinum Toxin Type A|2 times, Intra-muscular injection, Maximum dosage total 60U
1890587|NCT01259570|Dietary Supplement|Group 1|Skimmilk enriched with VD encapsulated in CM
1890588|NCT01259570|Dietary Supplement|Group 2|VD will be dissolved in milkfat and homogenized into skimmilk
1890589|NCT01259570|Dietary Supplement|group 3|3% fat milk wherein the VD will be in CM
1890590|NCT01259570|Dietary Supplement|Group 4|Placebo: un-enriched skimmilk.
1890591|NCT01259583|Procedure|CO2|CO2 insufflation
1890592|NCT01259583|Procedure|Warm water|warm water irrigation
1890593|NCT01259596|Behavioral|cognitive behavioral therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
1890594|NCT01259596|Behavioral|nondirective supportive therapy|weekly individual psychotherapy by telephone for 12 weeks; 4 booster sessions
1890595|NCT01259609|Procedure|Pars Plana Vitrectomy|25-gauge three-port pars plana vitrectomy
1890596|NCT01259622|Drug|saline|intravenous infusion
1890597|NCT01259622|Drug|K201|intravenous infusion
1890598|NCT01259635|Device|Biofeedback auditory stimulation|Whenever freezing episodes occures, a metronom sound will be heard.
1890599|NCT01259648|Drug|0.5 µg/kg remifentanil|0.5 µg/kg remifentanil is used during induction in addition to the classic induction protocol
1890600|NCT01259648|Drug|1.0 µg/kg remifentanil|1.0 µg/kg remifentanil is added to the classic induction anesthesia protocol
1890601|NCT01259648|Drug|NaCl|an equivalent volume (1 ml for 10 kg of weight) of 0.9% isotonic NaCl is injected in addition to the classic anesthesia induction protocol
1890602|NCT01259661|Other|A longitudinal intervention|In our longitudinal intervention study, all eligible subjects will undergo a physical examination by a physician to rule out obvious secondary causes of hypertension and contraindications to exercise. Randomization will be performed by random member generation. The exercise participants will attend three sessions per week at the facility during the study period. Training intensity is initially set at heart rate equivalent to 60% and progress to 80% of each subject's maximal heart rate reserve for 30 min/day with a frequency of 3 days/wk. Facility-based exercise sessions will consist of treadmill walking.
1890603|NCT01259674|Device|AboMeg-B-09|Syrup: AboMeg-B-09 5ml to be taken 4 times a day during the entire study period
1890604|NCT01259674|Other|Placebo|Placebo syrup: 5ml to be taken 4 times a day during the entire study period
1890605|NCT01259687|Device|Non-invasive cardiac output monitoring|During the surgery the continuous monitoring of blood pressure by peripheral artery catheter and cardiac output by NICOM (non-invasive cardiac output monitoring) will be applied. In case of intraoperative hemodynamic changes (hypertension, hypotension) the patient will be treated according to the standard care by Phenylephrine, Nitroglycerine or Colloid fluid boluses. Cardiac output will be measured by NICOM just before and after each treatment of hemodynamic events that described above. Simultaneous records of ECG, arterial and plethysmographic waveforms will be made just before and after each event. Systolic blood pressure and PuTT will be measured OFFLINE from the recorded waveforms
1890606|NCT01259700|Behavioral|High-risk patient standardized management package|A primary-care based high cardiovascular risk management package delivered by village doctors
1890607|NCT01259700|Behavioral|Community based salt reduction program|A community-based salt reduction program delivered mainly by community health educators
1890608|NCT01259713|Drug|Liposomal amphotericin B|Ambisome 5 mg/kg twice weekly administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week during induction chemotherapy
1890609|NCT01259713|Drug|Placebo|Placebo to match liposomal amphotericin B administered by IV route over 2 hours twice weekly (each dose separated alternately by 2 and 3 days each week) during induction chemotherapy
1890610|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for seven days
1890611|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 7 days followed by placebo as oral liquid once daily for 7 days
1890612|NCT01259726|Other|Placebo|10 mL placebo once daily for 14 days
1890613|NCT01259726|Biological|VP20621|VP20621 as oral liquid once daily for 14 days
1890614|NCT01259739|Other|Cocoa|dissolved in water twice-daily intervention
1890615|NCT01259752|Device|compression stockings|compression stockings
1890616|NCT01259752|Other|standard non compressive stockings|standard non compressive stockings
1890617|NCT01259765|Drug|VHH batch 203027|The active product is 165 mg of VHH batch 203027 and 835 mg maltodextrin with 0.5% (w/w) caramel colour in 10 mL ORS. The osmolality (concentration of the osmotically active substances in the solution such as sugar molecules, salts etc. ) of this solution will be around 60 mOsmol/kg. The mixture of the 165 mg of VHH batch 203027 and 835 mg maltodextrin (0.5% (w/w) caramel colour will be provided per sachet.
1890618|NCT01259765|Drug|Placebo product|The Placebo treatment consisted of 1000 mg of maltodextrine with 5% (w/w) caramel colour in 10 mL ORS.
1890619|NCT01259791|Drug|Individual-specific statin causing myopathy|Individual-specific statin causing myopathy vs. placebo
1890620|NCT01259791|Drug|Placebo|Placebo
1890621|NCT01259804|Dietary Supplement|Peanut oral immunotherapy|Daily doses of peanut flour
1890622|NCT01259817|Drug|PEGASYS|Patient will start at 45 micrograms per week and gradually increase to 180 micrograms per week. Pegasys will be supplied in prefilled syringes and are to be given subcutaneously.
1890623|NCT01259817|Drug|Aspirin|81 or 100 mg daily.
1890624|NCT01259830|Drug|Arcoxia®120 mg|Arcoxia® over encapsulated 120 mg; Perioperatively 6 days 1 tablet (Arcoxia® 120 mg) for oral use
1890625|NCT01259830|Drug|P Tablet White Lichtenstein|P Tablet White Lichtenstein over encapsulated; Perioperatively 6 days 1 tablet for oral use
1890626|NCT01259856|Drug|PEGASYS|The subject will begin receiving the PEGASYS at a dose level of 45 micrograms weekly and gradually get increased to the maximum dose of 180 micrograms per week. The dose will be administered by prefilled syringes that will be injected subcutaneously. Subjects will receive therapy for up to 12 months.
1890627|NCT01259856|Drug|Hydroxyurea|Subjects will receive a 500mg tablet to be taken twice daily for up to 12 months of treatment.
1890628|NCT01259856|Drug|Aspirin|Subject will be asked to take 81 to 100mg per day for the 12 months of the study treatment.
1890629|NCT01259869|Drug|PX-866|1 cycle = 8 weeks on study PX-866 - 8mg PO Daily
1890630|NCT01259882|Drug|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
1890631|NCT01259882|Drug|PF-05089771|Subjects will receive single ascending doses of PF-05089771 or placebo to investigate the safety/tolerability and PK of PF-05089771. The PK of alternative formulations of PF-05089771 and the effect of food on PK may also be investigated.
1890632|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur. In addition the exploratory pharmacodynamics of PF-05089771 will be investigated using novel biomarkers.
1890633|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
1890634|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
1890635|NCT01259882|Drug|PF-05089771|Subjects will receive single doses of PF-05089771 or placebo in a fully randomized crossover design. The investigation of the safety/tolerability and PK of PF-05089771 will occur.
1890636|NCT01259908|Procedure|Laparoscopic vs open Ygraft|Patients with aorto-iliac occlusive disease TASC type D operated with either laparoscopic aortobifemoral bypass or open aortobifemoral bypass shall be compared.
1890637|NCT01259921|Behavioral|neurofeedback|Operant conditioning of the EEG provided by computer reinforcement.
1890638|NCT01259934|Drug|Interferon-alpha2b - 1 year|Induction: IFN-alpha2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alpha2b, 10 MU (flat dose), 3 days/week, SC, 12 months
1890639|NCT01259934|Drug|Interferon-alpha2b - 2 years|Induction: IFN-alfa2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks Maintenance: IFN-alfa2b, 10 MU (flat dose), 3 days/week, SC, 24 months
1890640|NCT01259947|Drug|Lippia alba (Mill.) N. E. Brown ethanolic extract|1-2 drops per kilogram per day, PO, twice a day
1890641|NCT01259973|Drug|Risperidone|1 single dose of 2.5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
1890642|NCT01259973|Drug|Placebo|1 single dose of 2.5mL physiological serum masked in 250 mL of peach juice, for 1 day. Oral administration.
1890643|NCT01259973|Drug|Haloperidol|1 single dose of 5mg masked in 250 mL of peach juice, for 1 day. Oral administration.
1890644|NCT01259986|Procedure|Laser treatment|Laser treatment of using 635 nm laser with a dose of 3.0 J/cm^2 to small area (2cm x 2cm) of vitiligo once to twice a week for a total of 12 weeks.
1890645|NCT01259999|Dietary Supplement|Calogen extra strawberry|A daily dose of 3 x 30 ml Calogen extra strawberry flavour will be distributed at the same time as the medicines i.e. at 8.00, 12.00 and 20.00.
1890646|NCT01260012|Dietary Supplement|Praziquantel+antioxidant suppl|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive antioxidant supplement on daily basis for a period of one year.
1890647|NCT01260012|Other|Praziquantel + placebo 2mths then antioxidant for 10 mths|Praziquantel therapy will be offered at the start, at six weeks and at 12 weeks from date of enrollment. Thereafter praziquantel therapy will be offered if subjects have demonestrable S. mansoni eggs on the subsequent six-monthly evaluations. In addition subjects will receive placebo as a supplement for two months which will be followed by antioxidant as a supplement for the rest of the year.
1890648|NCT01260012|Dietary Supplement|Praziquantel therapy and placebo as supplement|Praziquantel at day 0, 6-weeks and at 12 weeks from start of study. Thereafter praziquantel therapy will be offered if subjects have demonestrable s.mansoni eggs on six-monthly evaluation periods. Placebo will be given as a supplement for one year.
1890649|NCT01260012|Dietary Supplement|Praziquantel+antioxidant|Praziquantel treatment will be offered at time 0, six weeks and 12 weeks from the start. Antioxidant supplement will be offered on a daily basis for a period of one year
1890650|NCT01260025|Drug|PEDylated Recombinant Human Endostatin|The initial dose of PEDylated Recombinant Human Endostatin (M2ES) will be 7.5mg/m2.Dose Escalation to a next higher level will occur when 3 patients in the same dose level complete 28 days of continuous treatment without experiencing a dose-limiting toxicity.
1890651|NCT01260064|Procedure|Open appendectomy|The subjects will have traditional open appendectomy procedure.
1890652|NCT01260064|Procedure|Laparoscopic appendectomy with metal endoclips|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by metal endoclips.
1890653|NCT01260064|Procedure|Laparoscopic appendectomy with suture ligation|The subjects will have laparoscopic appendectomy in which the appendiceal stump is secured by intracorporeal suture ligation.
1890654|NCT01260090|Device|Vagus nerve stimulation;|"Name of the Device:
We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220).
FDA Facility Registration Number: 1644487"
1890655|NCT01260090|Device|No stimulation|Vagus nerve stimulation
1890656|NCT01260103|Drug|Temozolomide|Study subjects in a fasting state receive TMZ orally once a day for five consecutive days (days 1 through 5) at a starting dose of 200 mg/m2/day. Treatment cycles are repeated every 28 days following the first daily dose of TMZ from the previous cycle. In the absence of PD or unacceptable toxicity, subjects continue to receive TMZ for a maximum of 13 cycles.
1890657|NCT01260103|Drug|ANP Therapy|Escalating doses of ANP therapy are administered for 52 weeks. If the study subject has an OR or maintains SD, ANP therapy is continued.
1890658|NCT01260129|Drug|Silodosin|Silodosin 8 mg orally, once daily after morning meal
1890659|NCT01260129|Drug|Silodosin|Silodosin 4 mg orally, twice daily after morning and evening meal
1890660|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 6.5 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 0.65 mg/kg IV bolus, or propofol injectable emulsion 0.65 mg/kg IV bolus followed by fospropofol disodium 6.5 mg/kg IV bolus.
1890661|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 10.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.0 mg/kg IV bolus, or propofol injectable emulsion 1.0 mg/kg IV bolus followed by fospropofol disodium 10.0 mg/kg IV bolus.
1890662|NCT01260142|Drug|Fospropofol disodium, propofol|Two Treatment Periods: fospropofol disodium 15.0 mg/kg single intravenous (IV) bolus followed by propofol injectable emulsion 1.5 mg/kg IV bolus, or propofol injectable emulsion 1.5 mg/kg IV bolus followed by fospropofol disodium 15.0 mg/kg IV bolus.
1890663|NCT01260155|Drug|E5501|Treatment A: 40 mg new tablet formulation (1 tablet) under fasted conditions
1890664|NCT01260155|Drug|E5501|Treatment B: 20 mg old tablet formulation (2 tablets) under fasted conditions
1890665|NCT01260155|Drug|E5501|Treatment C: 40 mg new tablet formulation administered with food
1890666|NCT01260181|Drug|Erlotinib|Erlotinib 150 mg tablet will be given orally daily.
1890667|NCT01260194|Drug|trastuzumab [Herceptin]|Loading dose of 8 mg/kg on day 1, followed by 6 mg/kg intravenous infusion every 3 weeks until disease progression in combination with standard chemotherapy
1890668|NCT01260207|Other|IVR group|Patients in this arm will receive IVR follow-up telephone calls at 1,3,6,9 and 12 months post-discharge consisting of predetermined questions related to medication management, smoking cessation, diet, exercise and education as recommended by the ACC/AHA BPG for ACS. Upon completion of the IVR follow-up, all patients will be called by a member of the clinical research staff and asked to complete a follow-up survey.
1890669|NCT01260220|Procedure|Circumferential Antral Ablation|The goal is to complete ablation in all segments around the pulmonary veins until a circle of ablation lesions is created in the antrum with at least 30 seconds of ablation, 25W on the posterior surface, 30W on the anterior surface at each site, and change in the local electrogram. Entry and Exit block will be confirmed in each vein. The left superior pulmonary vein and left inferior pulmonary vein will be isolated with one circle, and the right superior and right inferior pulmonary veins will be isolated with one circle.
1890670|NCT01260220|Procedure|Segmental Antral ablation|If the patient is in atrial fibrillation, ablation will begin in the segment with the highest frequency signals in the pulmonary vein antrum. If the patient is in sinus rhythm, mapping and ablation will occur during coronary sinus pacing. Segments with the earliest signals in the Lasso catheter will be targeted, and reassessed after each ablation lesion. This will continue in a segmental fashion on the antrum until pulmonary vein isolation is achieved. Lasso should be moved between veins between lesions to assess the earliest electrogram. Entry and exit block will be confirmed at each vein.
1890671|NCT01260233|Other|Smoking cessation program|"Smoking cessation program includes:
brief smoking cessation counselling by preadmission nurse (less than 5 minutes)
smoking cessation brochures
referral to the Smokers' Helpline telephone advice line, run by the Canadian Cancer Society
free transdermal nicotine replacement therapy for 6 weeks Smokers of 10 cigarettes per day or more receive 4 weeks of nicoderm 21mg/day, 1 week of 14mg/day and 1 week of 7mg/day Smokers of less than 10 cigarettes per day receive 4 weeks of nicoderm 14mg/day and 2 weeks of 7mg/day"
1890672|NCT01260246|Drug|sitagliptin|pill, 100mg/daily for 6 months
1890673|NCT01260246|Drug|placebo|placebo match for 6 months
1890674|NCT01260259|Procedure|RIPC|RIPC will be elicited in the operating room (OR) after anesthesia induction and before start of surgery. After placement of an arterial line, a tourniquet will be placed over a lower extremity. It will be inflated to 15 mmHg above systolic blood pressure for 5 minutes, and then deflated for 5 minutes. This cycle of inflation-deflation will be repeated another 3 times before surgery.
1890675|NCT01260259|Procedure|Control|In OR, after induction of general anesthesia and arterial line placement, a deflated tourniquet will be placed over the lower extremity for 40 minutes.
1890676|NCT01260272|Other|Alternative Snack Comparator|Any prepackaged commercial snack is permitted as an alternative comparator snack, as long as it is 100 kcal/serving, does not contain raisins, does not contain solely fruits, and/or does not contain solely vegetables. Preferred comparator snack examples include: Keebler® Cheez-It® Crackers, Fudge Shoppe ® Grasshopper® Cookies, Fudge Shoppe ® Mini Fudge Stripes ™ Cookies, Nabisco Chips Ahoy! Baked Chocolate Chip Snacks, Honey Maid Cinnamon Roll Thin Crisps, Lorna Doone Baked Shortbread Cookie Crisps, Oreo Baked Chocolate Wafer Snacks, Pepperidge Farm® Goldfish® Baked Snack Crackers
1890677|NCT01260272|Other|Raisins|Raisins are dry grape fruits that may be eaten raw, or used in cooking, baking, and brewing. Raisins are mostly composed of carbohydrates (mostly fructose). They are also high in fiber and antioxidants, relatively high in potassium, and low in sodium.
1890678|NCT01260285|Drug|Vardenafil|10 mg PO once
1890679|NCT01260298|Device|MC1 Ultrasonic Device|Ultrasonic and zonal massage device.
1890680|NCT01260311|Drug|Fesoterodine|Any dose of Fesoterodine
1890681|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
1890682|NCT01260324|Other|No intervention given in this observational study|No intervention given in this observational study
1890683|NCT01260337|Behavioral|Portion controlled diet|Participants learn skills for changing nutritional and lifestyle habits and diabetes management follow a program that includes eating a pre-packaged, portion controlled meal for weight loss in addition to attending the behavior modification groups
1890684|NCT01260337|Other|Diabetes Support and Education|The DSE groups will consist of educational sessions offered for diabetes support and education which will include sessions on diet/nutrition, exercise, foot care and living with diabetes.
1890685|NCT01260350|Drug|SOF|Sofosbuvir (SOF) tablets administered orally once daily
1890686|NCT01260350|Drug|RBV|Ribavirin (RBV) capsules administered orally in a divided daily dose
1890687|NCT01260350|Drug|PEG|Peginterferon alfa-2a (PEG) administered via subcutaneous injection once weekly
1890688|NCT01260350|Drug|LDV|Ledipasvir (LDV) tablets administered orally once daily
1890689|NCT01260350|Drug|GS-9669|GS-9669 tablets administered orally once daily
1890690|NCT01260350|Drug|LDV/SOF|LDV/SOF fixed-dose combination (FDC) tablet administered once daily
1890691|NCT01260363|Procedure|Femoral nerve block|Femoral nerve block ultrasound guidet with ropivacaine 20ml 2.5mg/ml
1890692|NCT01260363|Procedure|Local infiltration analgesia|Local infiltration analgesia with ropivacaine 2.5mg/ml with epfinedrine 5mikrogram/ml. 20ml at harvest site and 20ml at incisionsites.
1890693|NCT01260376|Drug|Acipimox|Tablet Acipimox 250 mg administered 4 times previous to and during the investigation day
1890694|NCT01260389|Behavioral|control|usual pharmacist care
1890695|NCT01260389|Behavioral|pharmaceutical care intervention|Pharmaceutical care intervention, focused at improving inhalation technique and drug adherence in patients with Chronic Obstructive Pulmonary Disease (COPD).
1890696|NCT01260402|Device|Resynchronization using a transeptal approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via a transeptal puncture.
Devices used for procedure : Medtronic C304 or 6227DEF, Nykanen RF Wire, RADI PressureWire"
1890697|NCT01260402|Device|Resynchronization using a coronary sinus approach|"Cardiac resynchronization with one in the right ventricle and one in the left ventricle via the coronary sinus.
Devices used for procedure : RADI PressureWire, routine catheters chosen by operator"
1890698|NCT01260415|Drug|Panitumumab, Oxaliplatin, 5-FU|"Panitumumab 6 mg / kg, given over 60 minutes
Oxaliplatin 85 mg / m2 combined with leucovorin 400 mg / m2, given over 2 hours OR
Irinotecan 180 mg / m2 , given over 90 minutes, concurrent with leucovorin 400 mg / m2, given over 90 minutes
5FU 400 mg / m2, by bolus infusion
5FU 2400 mg / m2, given over 46 hours"
1891275|NCT01257594|Procedure|Cytoreductive Surgery|Standard procedure
1890699|NCT01260428|Device|threshold PEEP|Various set of pressures : 0, 5, 10 cm H20; pursed lips breathing
1890700|NCT01260441|Other|CPR Training using the Family and Friends CPR Anytime VSI Kit|Subjects will be trained using the American Heart Association's Family and Friends CPR Anytime Kit. Subjects will undergo training in-hospital and will be encouraged to take the kit home to share with their family members and friends.
1890701|NCT01260454|Drug|Qutenza (8% capsaicin)|We will place a Qutenza (8% capsaicin) patch onto an area of normal, anesthetized skin for 60 minutes. Within 28 days, subjects will place a new treprostinil infusion site into the area of Qutenza pre-treated skin.
1890702|NCT01260467|Drug|memantine|10 milligrams orally twice a day
1890703|NCT01260480|Other|[18F]-ML-10 in conjunction with PET imaging|Subjects will receive two to three intravenous (IV) doses of [18F]-ML-10. The dose for each [18F]-ML-10 dose will be 5.50 MBq/Kg or 0.15 mCi/Kg but will not exceed 500.00 MBq (13.50 mCi) per administration.
1890704|NCT01260493|Other|integrated health care chain|Geriatric assessment at ED, case manager with multiprofessional team in the community, support for informal caregivers
1890705|NCT01260506|Drug|VB-111|
1890706|NCT01260506|Drug|Bevacizumab|Upon progression, subjects will receive a combination therapy of VB-111 and standard of care bevacizumab
1890707|NCT01260519|Drug|Heparin|unfractionated heparin 2000 unites
1890708|NCT01260545|Drug|CA-18C3|2.5 mg/kg, 3.75 mg/kg IV (in the vein) on Day 1 of each 14 day cycle until the subject is no longer benefiting clinically or unacceptable toxicity occurs.
1890709|NCT01260558|Device|Sirolimus-Permanent-Polymer Eluting Stent|due randomization sirolimus-permanent-polymer eluting stent was implanted
1890710|NCT01260558|Device|Sirolimus-Polymer-free Eluting Stent|due randomization sirolimus-polymer-free eluting stent was implanted
1890711|NCT01260571|Drug|Benzoyl peroxide and sulfur|topical cream, 5% benzoyl peroxide and 2% sulfur Frequency once to day Duration 24 hours
1890712|NCT01260584|Drug|Prasugrel|One 10 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
1890713|NCT01260584|Drug|Clopidogrel|One 75 mg film-coated, oral tablet daily x 10 days. In addition, aspirin 81 mg to 325 mg daily will be taken.
1890714|NCT01260597|Behavioral|IVR intervention|If individuals report having any smoking in the previous 30 days, the IVR will deliver questions to identify barriers to quit line re-enrollment and motivational messages to promote the re-enrollment
1890715|NCT01260597|Behavioral|IVR control|If individuals report any smoking in the last 30 days the IVR will thank them for their time and the call will end
1890716|NCT01260610|Drug|Tenofovir|300 mg of Tenofovir daily
1890717|NCT01260610|Drug|Telbivudine|600 mg of Telbivudine daily
1890718|NCT01260610|Drug|Tenofovir plus Telbivudine|Tenofovir (300 mg daily) plus Telbivudine (600 mg daily)
1890719|NCT01260623|Drug|Prednisolone and prednisone|oral, or intravenous prednisone, prednisolone, given the first time for asthma exacerbation
1890720|NCT01260636|Drug|Gadobenate Dimeglumine|0.1 mmol/kg, single dose
1890721|NCT01260636|Drug|Gadopentetate Dimeglumine|Double dose of 0.2 mmol/kg
1890722|NCT01260649|Drug|ketamine|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
1890723|NCT01260649|Other|IV Saline|eligible patients will be randomly assigned to a double-blind administration of ketamine (0.5 mg/kg) or IV Saline, followed by the routine anesthetic agent and muscle relaxant. ECT will be administered as per standard of care
1890724|NCT01260649|Procedure|ECT|ECT will be administered as per standard of care
1890725|NCT01260649|Drug|Muscle Relaxant|All participant will receive routine course of muscle relaxant with ECT as per standard of care
1890726|NCT01260649|Drug|Anesthetic Agents|All participant will receive routine course of anesthetic agents with ECT as per standard of care
1890727|NCT01260662|Drug|Propofol|1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
1890728|NCT01260662|Drug|1:1 Propofol/Ketamine|Propofol and ketamine mixed 1:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
1890729|NCT01260662|Drug|4:1 Propofol/Ketamine|Propofol and ketamine mixed 4:1, given at 1 mg/kg IV bolus followed by 0.5 mg/kg every 3 minutes as need for sedation
1890730|NCT01260675|Drug|Buprenorphine HCl/Naloxone HCl|
1890731|NCT01260688|Drug|cediranib maleate|Given orally
1890732|NCT01260688|Drug|dasatinib|Given orally
1890733|NCT01260688|Procedure|assessment of therapy complications|Ancillary studies
1890734|NCT01260688|Other|laboratory biomarker analysis|Correlative studies
1890735|NCT01260701|Drug|Akt Inhibitor MK2206|Given PO
1890736|NCT01260714|Drug|Azacitidine|Given SC
1890737|NCT01260714|Drug|Etoposide|Given IV
1890738|NCT01260714|Other|Laboratory Biomarker Analysis|Correlative studies
1890739|NCT01260714|Drug|Mitoxantrone Hydrochloride|Given IV
1890740|NCT01260727|Biological|PENNVAX-G DNA Vaccine|PENNVAX-G DNA (HIV-1 env A, C, and D, and consensus gag plasmids) vaccine; 4 mg administered IM as a total volume of 1 mL
1890741|NCT01260727|Biological|MVA-CMDR Vaccine|MVA-CMDR live attenuated modified vaccinia ankara vector (HIV-1 CM235 env/CM240 gag/pol); 1 x 10^8 plaque-forming unit (pfu) administered IM by needle and syringe as a volume of 1 mL in either deltoid
1890742|NCT01260727|Biological|Placebo PENNVAX-G Vaccine|Sodium Chloride Injection USP, 0.9%
1890743|NCT01260727|Biological|Placebo MVA-CMDR Vaccine|Sodium Chloride Injection USP, 0.9%
1890744|NCT01260753|Drug|UR-63325|UR-63325
1890745|NCT01260753|Drug|Fluticasone propionate nasal spray|Fluticasone propionate nasal spray
1890746|NCT01260753|Drug|Placebo|Placebo to UR 63325 and fluticasone propionate nasal spray
1890747|NCT01260766|Device|Oplon Active Patch|Patches are placed over acne lesion overnight. Treatment is a single treatment.
1890748|NCT01260766|Device|Placebo Patch|same as active patch
1890749|NCT01260779|Drug|PV-10 (10% rose bengal disodium)|Intralesional injection for chemoablation of cutaneous or subcutaneous lesions
1890750|NCT01260792|Other|questionnaire|The teachers or the professors complete questionnaires on the child on their behavior in classes
1890751|NCT01260792|Other|Questionnaire|The parents complete a questionnaire on the behavior of their child and on their own behavior
1890752|NCT01260805|Drug|Reference Drug|Femiane® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
1890753|NCT01260805|Drug|Test Drug|Harmonet® Ethinylestradiol 0,02mg + Gestodene 0,075mg sugar coated tablets single dose
1890754|NCT01260818|Drug|Tranexamic Acid|1 g Tranexamic Acid mixed with 100ml saline are kept in wound for 2 hours before drainage is opened postoperatively
1890755|NCT01260818|Drug|normal saline|100ml saline is kept in wound for 2 hours before drainage is opened postoperatively
1890756|NCT01260831|Other|Implementation of Bedside Paediatric Early Warning System|The Bedside Paediatric Early Warning System (Bedside PEWS) is a documentation-based system of care that will replace existing documentation systems for vital signs in inpatient ward areas in hospitals randomized to implement Bedside-PEWS. Frontline staff education within each hospital will occur over a period of three months preceding a 5 week run-in implementation phase, which will be followed by hospital-wide implementation. The Bedside-PEWS documentation record will become the primary method of documentation for vital signs and related data.
1890757|NCT01260831|Other|Hospital Standard of Care|Hospitals randomized to standard care will continue with established methods of care. This will include the use of calling criteria and/or the expert model to identify children at risk. As in intervention hospitals, existing MET-RRT practices, established staffing and documentation practices will continue.
1890758|NCT01260844|Drug|briakinumab|single dose briakinumab and 2 doses of CYP substrates
1890759|NCT01260857|Drug|Aldazide|Aldazide 25 mg OD
1890760|NCT01260870|Device|Cotavance Paclitaxel Coated Balloon|DEB
1890761|NCT01260870|Device|Standard balloon angioplasty|POBA
1890762|NCT01260883|Drug|Ketorolac Tromethamine 1 mg/kg|Ketorolac Tromethamine 1 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling in for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
1890763|NCT01260883|Drug|Ketorolac Tromethamine 0.5 mg/kg|Ketorolac Tromethamine 0.5 mg/kg infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
1890764|NCT01260883|Drug|Placebo|Dextrose in water (D5W) infusion over 10 minutes intravenous (IV) infusion. Blood sampling for up to 12 hours after infusion for analysis of ketorolac concentrations and safety assessments.
1890765|NCT01260896|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
1890766|NCT01260896|Drug|Effexor® XR|150 mg Extended-Release Capsule
1890767|NCT01260909|Device|Real-time kV/MV Prostate Imaging|The kV images will be acquired using onboard kV X-Ray imaging system existing in the clinical linear accelerator (LINAC).
1890768|NCT01260922|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
1890769|NCT01260922|Drug|Aricept®|10 mg Orally Disintegrating Tablet
1890770|NCT01260935|Procedure|Laparoscopic Hill Repair|With the Hill repair, stitches are placed right where the esophagus and stomach meet and attached to muscle tissue that is fixed to the spine.
1890771|NCT01260935|Procedure|Laparoscopic Nissen Repair|With the Nissen repair, the upper part of the stomach is wrapped around the esophagus, with some anchoring of the wrap at several locations.
1890772|NCT01260948|Drug|Donepezil Hydrochloride|10 mg Orally Disintegrating Tablet
1890773|NCT01260948|Drug|Aricept®|10 mg Orally Disintegrating Tablet
1890774|NCT01260961|Dietary Supplement|Placebo|The volunteers will start on the 200 mg daily of the placebo and will not increase their dose during the study.
1890775|NCT01260961|Dietary Supplement|Docosahexanoic Acid|The volunteers will start on the 200 mg daily of the DHA capsule and will not increase their dose during the study.
1890776|NCT01260974|Drug|Caspofungin|50mg/dd for 21dd, starting within 24h from Liver Transplantation.
1890777|NCT01260987|Drug|Conventional photodynamic therapy|Photodynamic therapy using methyl-aminolevulinate and red light (37 J/cm2)
1890778|NCT01260987|Drug|Fractional CO2 laser assisted PDT|Pretreatment with fractional CO2 laser before methyl-aminolevulinate PDT
1890779|NCT01261000|Drug|Pegvisomant|Pegvisomant used as indicated
1890780|NCT01261039|Radiation|UV radiation|Subjects in both groups will be exposed to light in a solar bed for approximately 10 minutes (depending on Fitzpatrick skin type test) on the first day, but only one of the solar beds wields ultraviolet rays. The other has a filter, which filters out the ultraviolet rays.
1890781|NCT01261052|Device|The Fading Memory Proportional Derivative/Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.
The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
1890782|NCT01261052|Device|The Adaptive Proportional Derivative Algorithm|"The APD algorithm is based largely on a program that employs the Fading Memory Proportional Derivative (FMPD) insulin and glucagon infusion algorithm. The FMPD algorithm determines insulin and glucagon delivery rates based on proportional error, defined as the difference between the current glucose level and the target level, and the derivative error, defined as the rate of change of the glucose. The fading memory designation refers to weighting recent errors more heavily than remote errors.
The APD algorithm, like the FMPD algorithm, will determine insulin and glucagon infusion rates based on sensed glucose values and utilizes the derivative and proportional glucose error to determine delivery rates of insulin. However, the APD algorithm has a model predictive element which also leads to frequent measurement of tissue sensitivity to insulin."
1890783|NCT01261065|Drug|carvedilol|Patients with heart failure and LVEF < 35 % were treated with maximally tolerated dose of carvedilol for a period of six months. Target dose was 25 mg bid or 37.5 mg bid if patient's baseline weight > 80 kg.
1890784|NCT01261078|Drug|Placebo|intrathecal 8 mg of bupivacaine only
1890785|NCT01261078|Drug|epinephrine 25|intrathecal 8 mg of bupivacaine mixed with 25 mcg of epinephrine
1890786|NCT01261078|Drug|Epinephrine 50|intrathecal 8 mg of bupivacaine mixed with 50 mcg of epinephrine
1890787|NCT01261078|Drug|epinephrine 100|intrathecal 8 mg of bupivacaine mixed with 0.1 mg of epinephrine
1890788|NCT01261078|Drug|Epi 200|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
1890789|NCT01261091|Procedure|Early Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
1890790|NCT01261091|Procedure|Late Tracheostomy|Tracheostomy is performed as percutaneous dilatative tracheostomy by neurointensivists whenever possible. If anatomically or otherwise indicated, surgical tracheostomy is applied.
1890791|NCT01261117|Drug|oral ibuprofen|oral or iv ibuprofen in 10, 5 and 5 mg/kg/day with 24 hr intervals
1890792|NCT01261130|Biological|10 μg Na-GST-1/Alhydrogel|3 doses 10 μg Na-GST-1/Alhydrogel administered at 56 day intervals
1890793|NCT01261130|Biological|30 μg Na-GST-1/Alhydrogel|3 doses 30 μg Na-GST-1/Alhydrogel administered at 56 day intervals
1890794|NCT01261130|Biological|100 μg Na-GST-1/Alhydrogel|3 doses 100 μg Na-GST-1/Alhydrogel administered at 56 day intervals
1890795|NCT01261130|Biological|10 μg Na-GST-1/ Alhydrogel/GLA-AF|3 doses 10 μg Na-GST-1/ Alhydrogel/GLA-AF administered at 56 day intervals
1890796|NCT01261130|Biological|30 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 30 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
1890797|NCT01261130|Biological|100 μg Na-GST-1/Alhydrogel/GLA-AF|3 doses 100 μg Na-GST-1/Alhydrogel/GLA-AF administered at 56 day intervals
1890798|NCT01261130|Biological|Butang® hepatitis B vaccine|3 doses Butang® hepatitis B vaccine administered at 56 day intervals
1890799|NCT01261143|Drug|BK-C-0701|tablet, 8 weeks
1890800|NCT01261156|Drug|E5555 100 mg and diltiazem|E5555 single 100 mg oral dose in Treatment Period 1 Day 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
1890801|NCT01261156|Drug|E5555 300 mg and diltiazem|E5555 single 300 mg oral dose in Treatment Period 1 and in Treatment Period 2 Day 8. Diltiazem 360 mg orally each day for 14 days (Days 1-14) in Treatment Period 2.
1890802|NCT01261169|Drug|Myfortic|Myfortic in uveitis
1890803|NCT01261182|Other|In School Feeding|The intervention provides meals consisting of 1049 kcals of energy, 32.6 gm protein, and 24.9 gm fat per child per school day and meet at least two thirds of the child's daily vitamin and mineral requirements, including 99 percent of iron requirements. SFP delivers these nutrients in the form of a fortified corn-soy porridge around mid-morning and beans and maize meal or rice at lunch.
1890804|NCT01261182|Other|Take Home Rations|The rations provided in the intervention are equal in size and composition to the food received in the in-school feeding intervention, but are provided to households once per month.
1890805|NCT01253967|Procedure|Collection of stool samples|Stool samples will be tested for the presence of rotavirus and a subset of rotavirus positive samples will be genotyped.
1890806|NCT01253967|Other|Health economics questionnaire|For a subset of subjects, additional economic data will be gathered by completing a questionnaire
1890807|NCT01253980|Drug|Amoxicillin|Amoxicillin syrup 20-30mg/kg 8 hourly for 5 days
1890808|NCT01253980|Drug|Placebo|"Placebo suspension made of water, dextrose and glycerine with a similar taste and appearance to the active comparator.
Dose 20-30mg/kg 8 hourly for 5 days"
1890809|NCT01254006|Drug|forskolin, rutin and vitamins B1 and B2|
1890811|NCT01254045|Drug|placebo|intranasal placebo (48 international units)
1890812|NCT01254045|Drug|oxytocin 24IU|intranasal oxytocin (24 international units) and intranasal placebo (24 international units)
1890813|NCT01254045|Drug|oxytocin 48IU|intranasal oxytocin (48 international units)
1890814|NCT01254071|Drug|Dutasteride (0.5mg); Tamsulosin hydrochloride (0.2mg); fixed dose combination product of duatsteride (0.5mg) and tamsulosin hydrochloride (0.2mg)|In the first dosing session, twenty-two subjects of each cohort will receive the FDC capsule (dutasteride and tamsulosin hydrochloride (0.5mg/0.2mg) and the other 22 will receive commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg co-administered. Following a wash-out period of at least 28 days, those subjects who received the FDC capsule in session 1, will be co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg while those who were co-administered commercial capsules of dutasteride 0.5mg and commercial tablets of tamsulosin hydrochloride 0.2mg in session 1 will receive the FDC capsule in the second dosing session.
1890815|NCT01254084|Dietary Supplement|Gynostemma Pentaphyllum tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
1890816|NCT01254084|Dietary Supplement|Placebo tea|6g/day per oral, twice a day in 10 weeks, 30 minutes before breakfast and dinner
1890817|NCT01254097|Dietary Supplement|Probiotic|Probiotic capsule, 2 capsules twice daily
1890818|NCT01254123|Drug|Exenatide infusion|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the Exenatide group will immediately be treated be with Exenatide iv, 5ug bolus in 30 minutes, followed by a continuous Exenatide infusion of 20ug/ 24 hours.
Exenatide preparation: Byetta injection pens containing 1,2 ml (concentration 0,25 mg/ml; 60 doses of 5 μg) will be obtained. 3 doses (15 μg) will be diluted in 49 ml saline and 1 ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml containing 15 μg exenatide (or 300 ng exenatide / ml). A 50cc syringe will be placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
1890819|NCT01254123|Drug|Placebo infusion.|"On arrival to our cardiac care unit (CCU) and after informed consent patients will be randomized to Exenatide infusion or Placebo infusion. Patients in the placebo group will immediately be treated with placebo infusion.
Placebo preparation: 49ml saline and 1ml Human Serum Albumen (Cealb 200g/L, 10ml) to get a total of 50 ml will be placed in a 50cc syringe and placed in a pump system that is connected with a cannula in the patient's vein. The infusionrate will be 33,3 ml/hr for the first 30 minutes, followed by an infusion rate of 2,8 ml/hr for 72 hours. New 50cc syringes will be made every 8 hours."
1890888|NCT01264393|Behavioral|Shape Up Rhode Island + Online Weight Loss Program|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program
1891190|NCT01266720|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, 15.
1890820|NCT01254136|Drug|INCB007839 300mg BID|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
1890821|NCT01254136|Drug|Trastuzumab|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
1890822|NCT01254136|Drug|Vinorelbine|INCB007839 tablets (300 mg BID) in combination with trastuzumab and vinorelbine will be administered in an initial Cycle of 28 days and followed by continuous 21-day cycles subsequently. Trastuzumab will be administered in continuous 21-day cycles beginning on Day 8 of Cycle 1. Vinorelbine will be administered on a weekly schedule for a minimum of the first four cycles beginning on Cycle 1 Day 8. All drugs will be administered continuously as tolerated or until a protocol-defined stopping criteria is met.
1890823|NCT01254162|Drug|MTC896 Gel|0.75% w/w gel applied daily for 28 days to the forehead
1890824|NCT01254175|Biological|rHPIV3cp45 Vaccine|10^5 TCID^50 of rHPIV3cp45 vaccine, delivered as nose drops
1890825|NCT01254175|Biological|Placebo Vaccine|Placebo vaccine, delivered as nose drops
1890826|NCT01254188|Drug|Nilotinib|This was an open-label, single-arm, prospective, multi-center, Phase IIIb clinical study with nilotinib 300 mg bid treatment in newly diagnosed CML-CP patients not previously treated with imatinib therapy and diagnosed within 6 months of study entry. For patients insufficiently responding to nilotinib 300 mg bid, the dose may have been increased to 400 mg bid. Among patients with adverse events who had dose reduction, this study also allowed a possible re-escalation to 300 mg bid.
1890827|NCT01254214|Behavioral|tMBSR|MBSR is an 8-week program of mindfulness meditation and gentle Hatha yoga, taught in a class of up to 30 participants. The telephone-adapted MBSR program (tMBSR) begins with a 5 hour-day workshop to introduce the techniques, followed by 6 weekly 1 ½ hour group teleconferences with the teacher to discuss the class's experiences with meditation practice, and ends with a 5 hour retreat in week 8.
1890828|NCT01254214|Behavioral|Support group|The attention control consists of a support group emphasizing communication skills and selecting resources. It includes two 90 minute in-person workshops and 6 1-hour teleconference calls. An experienced facilitator emphasizes communication skills and group support.
1890829|NCT01254227|Drug|Deferasirox and Deferoxamine|
1890830|NCT01254240|Device|UVA / UVB phototherapy|UVA / UVB phototherapy
1890831|NCT01254240|Device|UVB phototherapy|UVB phototherapy
1890832|NCT01261234|Drug|Cilostazol or Non-Cilostazol|Cilostazol group administrate 100-200mg/day per oral, unrestricted use of other antiplatelet agents and concomitant drugs.
1890833|NCT01261247|Drug|panobinostat|Given orally
1890834|NCT01261247|Other|laboratory biomarker analysis|Correlative studies
1890835|NCT01261247|Genetic|western blotting|Correlative studies
1890836|NCT01261247|Genetic|DNA analysis|Correlative studies
1890837|NCT01261247|Other|flow cytometry|Correlative studies
1890838|NCT01261247|Other|pharmacological study|Correlative studies
1890839|NCT01261247|Other|immunohistochemistry staining method|Optional correlative studies
1890840|NCT01261260|Drug|Uridine|1 gram tablets BID for 7 days
1890841|NCT01261286|Drug|verapamil|
1890842|NCT01261299|Drug|Carbon-14-labeled carboplatin|Patients are eligible for this study if they have non-small cell lung cancer or bladder cancer and will receive cisplatin or carboplatin-based chemotherapy for the treatment of cancer. They will receive one microdose of C-14-carboplatin approximately 4 hours before scheduled biopsy/surgery. One blood draw and a few milligrams of leftover tumor tissue will be taken for analysis of carboplatin-DNA adduct levels. The dose of carboplatin will be about 1/100th the therapeutic dose.
1890843|NCT01261312|Drug|SGI-110|"SGI-110 subcutaneous injection administered on Days 1-5
SGI-110 subcutaneous injection administered on Days 1-5 and 8-12"
1890844|NCT01261312|Drug|SGI-110|"SGI-110 administered weekly on Days 1, 8 and 15
SGI-110 administered weekly on Days 1, 4, 8, 11, 15, and 18"
1890845|NCT01261325|Drug|Placebo|Daily oral dose of two equal intakes of placebo in a double-blinded way for the 12-week treatment period
1890846|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 100 mg/ day in a double-blinded way for the 12-week treatment period
1890847|NCT01261325|Drug|Brivaracetam|Daily oral dose of two equal intakes of Brivaracetam 200 mg/ day in a double-blinded way for the 12-week treatment period.
1890848|NCT01261325|Drug|Antiepileptic drugs with market authorization available per country|
1890850|NCT01261364|Behavioral|GeneSightRx|Multi-genetic pharmacogenomic panel
1890851|NCT01261364|Behavioral|Treatment as usual|Treatment as usual
1890852|NCT01261377|Device|Bi-level positive airway pressure (BPAP)|The level of BPAP will be titrated to treat OSA as well as hypoxemia and hypercapnia. The duration of therapy will be six months.
1890853|NCT01261377|Drug|Oxygen|Oxygen will be titrated to keep resting oxygen saturation (as measured by pulse oximeter) more than 88 percent. The duration of therapy will be six months.
1890854|NCT01261377|Device|CPAP|The level of CPAP will be titrated to treat OSA. The duration of therapy will be six months.
1890855|NCT01261390|Behavioral|Conservative Medical Therapy (CMT)|All participants will meet with a research assistant who will provide 30 minutes of instruction on sleep hygiene and healthy lifestyle guidelines. Each subject's sleep routine will be reviewed with the aim to identify appropriate bed and wake times that provide a consistent schedule and allow for at least 7 hours of time in bed per night. Habits that may impact sleep, such as alcohol consumption, tobacco use, and exercise close to bedtime will be reviewed with appropriate guidance on how to minimize sleep disrupting exposures. Subjects will be provided external nasal dilator strips (Breathe Right®) and advised on how to maximize sleep time in a non-supine position using bed elevation, wedge pillows and/or objects affixed to the back of their night clothes as appropriate.
1890856|NCT01261390|Device|Sham PAP (Sham)|In addition to receiving CMT, participants in this treatment arm will receive a sham PAP unit. Sham devices look like active PAP devices, however, the exhalation port is increased and an orifice-resistor is inserted between the pump and tubing, creating a marginal pressure. A heated humidifier will be provided with this device and PAP masks will be fit and provided following the same procedures as for the active-PAP arms.
1890857|NCT01261390|Device|Active PAP with RT Support (Active-Beh)|In addition to receiving CMT, participants will receive active-PAP and meet with a PAP-specialist . The CPAP specialist would meet with the participant in person throughout the course of the study (set-up, 1-week, 1-month, 3-month, 6-month, and 9-month). Using the available data from the PAP monitor, the PAP specialist will discuss PAP use, mask leaks, and residual AHI to assist with troubleshooting. Adjustments to equipment would be performed as needed to improve adherence. It is estimated that each in-person follow-up adherence visit with the PAP-specialist would last 30 minutes.
1890858|NCT01261390|Device|Active PAP with Behavioral Modification (Active+Beh)|In addition to receiving CMT and active-PAP, participants will meet with a behavioral interventionist in addition to PAP-specialist visits. Participants also would speak with the behavioral interventionist over the course of the study (set up, 1-week, 3-week, 1-month, 2-months, 3-months, 5-months and 8-months). The duration of the first 2 behavioral intervention sessions are estimated to be 1-hour long, with subsequent 30-minutes intervention sessions. The intervention will be based on social cognitive theory and feedback concerning adherence with targeted problem solving training.
1890859|NCT01261403|Biological|PDA001|Dose escalation study: Subjects will be assigned to 1 of 2 treatment groups (1 unit or 4 units vs. vehicle control) based on the order in which they enroll in the study. Intravenous infusion will be administered on days 0 and 7. Nonresponders will be unblinded after 12 weeks of study. Non- responders on vehicle control will be re-dosed with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart). Nonresponders taking active PDA001 will enter the safety follow-up portion of the study. Responders at 12 weeks will continue in the safety and efficacy follow-up portion of the study until 12 months of study. Responders will be treated for RA flare between 3-9 months of study with the active PDA001 dose assigned at baseline (2 infusions, 7 days apart).
1890860|NCT01261403|Drug|Vehicle Controlled Placebo|"Cohort Dose Level 1: 4 units vehicle controlled placebp infused on Day 0 and Day 7
Cohort Dose Level 2: 4 units vehicle controlled placebo infused on Day 0 and Day 7"
1890861|NCT01261416|Drug|levetiracetam|Patients will receive levetiracetam as needed for clinical and/or electrographic seizures. Need for levetiracetam will be determined by the clinical team and will NOT determined by the study protocol.
1890862|NCT01261429|Drug|Tasigna|"The study drug is nilotinib (Tasigna®). All patients will be administered with nilotinib 400 mg twice a day for one year. The patient will begin the treatment the day of inclusion.
The prescribed dose should be swallowed whole with a glass of water. Doses of 400 mg should be administered twice daily approximately 12 hours apart. Patients should not eat within two hours before and one hour after taking nilotinib and need to avoid foods such as grapefruit juice which may inhibit CYP3A4 enzymes."
1890863|NCT01261442|Procedure|Nerve Conduction Study (NCS)|An NCS will be performed on each patient to confirm or exclude DSPN. Following this, a systematic ultrasound examination of the posterior tibial nerve will be performed for all the patients.
1890864|NCT01261455|Procedure|Location of the autograft taken following pterygium excision|Following pterygium excision, a conjunctival autograft is taken from either the superior or inferior conjunctiva.
1890865|NCT01261468|Device|Active SCS|SCS IPG activated
1890866|NCT01261468|Device|Deactivated|SCS IPG deactivated
1890867|NCT01261481|Drug|Tolvaptan|Tolvaptan 15 mg administered once orally as an intact tablet.
1890868|NCT01261481|Drug|Tolvaptan|Tolvaptan 15 mg administered once via nasogastric tube.
1890869|NCT01261494|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg,oral administration,4 capsules per day before breakfast
1890870|NCT01261494|Drug|Placebo|hard gelatin capsules,oral administration,4 capsules per day before breakfast
1890871|NCT01261520|Behavioral|Culturally-tailored video|A 18 minute DVD made in Chinese language (i.e. Mandarin and Cantonese)
1890872|NCT01261533|Device|foldable capsular vitreous body(FCVB)|FCVB with silicone oil inside is tamponaded into the vitreous cavity
1890873|NCT01261546|Drug|Dexamethasone|"Dexamethasone 0,25mg/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present
Ranitidine 5 mg/kg IV, q.d. for 2 days
Amoxicillin/Clavulanic acid orally (80mg/kg/day) during 15 days."
1890874|NCT01261546|Drug|Placebo|"Normal saline 0,6 ml/kg, IV, q.i.d. for 2 days.
Cefotaxime 200 mg/kg, IV, q.d. until discharge criteria are present.
Ranitidine 5 mg/kg IV, q.d. for 2 days.
Amoxicillin- Clavulanic acid 80mg/kg p.o., q.d. during 15 days."
1890875|NCT01261559|Device|Chrysalis breast displacement device|Chrysalis is a cloth device secured with velcro and buckles around the upper abdomen and chest following manual cephalad breast displacement.
1890876|NCT01264328|Drug|Panitumumab + paclitaxel|Paclitaxel 80 mg/m2 may be infused, intravenously, over one hour every week. Panitumumab will be administered every 2 weeks at a dose of 6 mg/kg, using a non pyrogenic low protein binding filter with a 0.20-0.22-μm pore size intravenously over 1 hour ± 15 minutes. Panitumumab will be administered prior to paclitaxel.
1890877|NCT01264341|Drug|Bevacizumab|Bevacizumab 10mg/kg intravenous every 2 weeks until disease progression, unacceptable toxicity or consent withdrawal.
1890878|NCT01264341|Drug|Temsirolimus|Temsirolimus 25mg intravenous once weekly until disease progression, unacceptable toxicity or consent withdrawal.
1890879|NCT01264354|Drug|Clevudine 30mg|Clevudine 30mg
1890880|NCT01264354|Drug|Clevudine 20mg+Adefovir dipivoxil 10mg|Clevudine 20mg+ Adefovir 10mg
1890881|NCT01264354|Drug|Clevudine 20mg|Clevudine 20mg
1890882|NCT01264367|Drug|Clevudine|30mg,QD
1890883|NCT01264367|Drug|Clevudine + Peg-interferon|30mg, QD(for 24 weeks) + 180mcg,QW(for 24 weeks)
1890884|NCT01264380|Drug|RO5185426|Single oral dose, fasted
1890885|NCT01264380|Drug|RO5185426|Single oral dose, with high fat meal
1890886|NCT01264380|Drug|RO5185426|Continuous administration, orally twice daily
1890887|NCT01264393|Behavioral|Shape Up Rhode Island + Online Resources|Participants will receive Shape Up Rhode Island, which is a 12-week statewide physical activity and weight loss campaign in addition to online weight loss resources
1890959|NCT01264874|Drug|Vitamin D3 ( Colecalciferol)|100000 IU every 50 days for 3 years
1890889|NCT01264393|Behavioral|Shape Up Rhode Island + Online Weight Loss Program + Group sessions|Participants will receive Shape Up Rhode Island, a 12-week statewide physical activity and weight loss campaign in addition to an online weight loss program and the option of attending group sessions
1890890|NCT01264419|Device|Carotid angioplasty and stenting with Silk Road Embolic Protection System|Major Adverse Event (MAE) rate with reverse flow neuroprotection
1890891|NCT01264432|Other|Laboratory Biomarker Analysis|Correlative studies
1890892|NCT01264432|Other|Quality-of-Life Assessment|Ancillary studies
1890893|NCT01264432|Radiation|Radiation Therapy|Undergo LDFWAR
1890894|NCT01264432|Drug|Veliparib|Given PO
1890895|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 1|Receive at Months 0 and 1
1890896|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0 and 1
1890897|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Month 0
1890898|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 3 and 4
1890899|NCT01264445|Biological|Adjuvanted GSK investigational HIV vaccine formulation 2|Receive at Months 0, 1, and 4
1890900|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Month 4
1890901|NCT01264445|Biological|Ad35 investigational HIV vaccine|Receive at Months 0, 1, and 4
1890902|NCT01264445|Biological|Placebo (saline)|(Vaccine:Placebo=28:7) Groups A, B, C, and D will all have a placebo comparator component (7 volunteers will receive placebo in each group at the specified months.)
1890903|NCT01264471|Procedure|Skin biopsy|A small skin sample will be obtained from the patients arm which is approximately the size of the top of a thumbtack (a small circle no more than a 1/4 inch across)
1890904|NCT01264471|Procedure|Blood Collection|Approximately 45ml or 3 tablespoons for blood will be drawn from a vein in the patient's forearm.
1890905|NCT01264484|Device|Advantage Prosthetic Heart Valve|All patients eligible for this study are treated with an Advantage prosthetic heart valve
1890906|NCT01264497|Drug|TH9507|1 and 2 mg, sc daily for 12 weeks
1890907|NCT01264510|Other|audiological test battery|routine audiological measurements.
1890908|NCT01264523|Other|Chronologically scheduled snacking with 40-30-30 products|Short-term analysis of the effects of the substitution of the habitual breakfast, mid-morning and afternoon snack of type-2 diabetes patients by 40-30-30 products. Longitudinal 2-period study
1890909|NCT01264536|Dietary Supplement|lactoferrin|Infants will receive oral bovine lactoferrin (200 mg/Kg/day divided in three dosis) for 4 weeks. Lactoferrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum lactoferrin concentration will be 25mg/mL.
1890910|NCT01264536|Dietary Supplement|Maltodextrin|Infants will receive oral maltodextrin (200mg/Kg/day in three divided dosis) for 4 weeks. Maltodextrin will be dissolved in human milk or infant formula or in a 5% glucose solution. Each dose will be dissolved in a small volume so the maximum maltodextrin concentration will be 25mg/mL.
1890911|NCT01264549|Device|Procalcitonin assay - B.R.A.H.M.S PCT ultrasensitive Kryptor|The physician will be given access to a PCT value for Day 1 - 7. Depending on the PCT concentrations, the protocol recommends or discourages from the use of antibiotics
1890912|NCT01264575|Drug|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine|intrathecal bupivacaine 6 mg with 100 mcg of epinephrine
1890913|NCT01264575|Drug|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine|intrathecal bupivacaine 7 mg with 100 mcg of epinephrine
1890914|NCT01264575|Drug|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine|intrathecal bupivacaine 8 mg with 100 mcg of epinephrine
1890915|NCT01264575|Drug|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine|intrathecal bupivacaine 9 mg with 100 mcg of epinephrine
1890916|NCT01264575|Drug|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine|intrathecal bupivacaine 10 mg with 100 mcg of epinephrine
1890917|NCT01264575|Drug|intrathecal bupivacaine 11 mg with epinephrine 100 mcg|intrathecal bupivacaine 11 mg with epinephrine 100 mcg
1890918|NCT01264575|Drug|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine|intrathecal bupivacaine 6 mg with 200 mcg of epinephrine
1890919|NCT01264575|Drug|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine|intrathecal bupivacaine 7 mg with 200 mcg of epinephrine
1890920|NCT01264575|Drug|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine|intrathecal bupivacaine 8 mg with 200 mcg of epinephrine
1890921|NCT01264575|Drug|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine|intrathecal bupivacaine 9 mg with 200 mcg of epinephrine
1890922|NCT01264575|Drug|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine|intrathecal bupivacaine 10 mg with 200 mcg of epinephrine
1890923|NCT01264575|Drug|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine|intrathecal bupivacaine 11 mg with 200 mcg of epinephrine
1890924|NCT01264588|Other|Topical calcium glycerophosphate lotion|2g once daily for 6 weeks (post-op day 3 thru 42)
1890926|NCT01264614|Behavioral|Strengthening exercise|3 months of 3-5 times per week of low-intensity exercises using a chair and small weights
1890927|NCT01264627|Behavioral|Mindful Breathing (MB) Intervention|"The MB intervention is based off of the Mindfulness Based Stress Reduction Program developed by Jon Kabat-Zinn. Participants will be organized into cohorts of eight, and attend eight weekly MB sessions. Mindful breathing consists of closely following the breath, throughout inhalation and exhalation, sustaining moment-to-moment awareness on the breathing process, and passively observing thoughts, affective states, perceptions and events, from a non-evaluative, non-judgmental perspective. As attention wanders to concerns, thoughts, events or ideas, the participants will be instructed to acknowledge and accept these without evaluation and return the focus of attention back to breathing. Participants in MB will have their breathing rate and PetCO2 monitored during the eight training sessions with individual ambulatory breathing monitors."
1890960|NCT01264874|Other|placebo|For 3 years IU every 50 days
1890961|NCT01264887|Drug|Tapentadol Prolonged Release|Titration to achieve sufficient pain relief to continue with effective analgesia for as long as the participant tolerates and wishes to continue treatment.
1890962|NCT01264900|Behavioral|Psychotherapy|Twelve weekly 50-minute sessions of individual cognitive behavioral aggression treatment or supportive psychotherapy
1890928|NCT01264627|Behavioral|Usual Care (UC) Control Condition|"This control intervention is designed to account for the effects of nonspecific factors such as enrollment in a study to enhance health with the associated expectancy effects, staff attention, and measurement procedures including the monitoring of PetCO2 and BP, and completion of questionnaires. Participants who are randomly assigned to the Usual Care condition will receive care as usual for the management of their prehypertensive condition. UC participants will receive their usual care and have access to all Kaiser Permanente (KP) health education resources, such as KP's interactive healthcare guide, and online Healthy Lifestyle Programs. We will assess the extent to which participants in both MB and UC used these resources."
1890929|NCT01264640|Drug|Aspirin and Clopidogrel|Intake of 500 mg Aspirin on day 1. Intake of 600 mg Clopidogrel on day 28. Blood collection for the measurement of platelet inhibition, platelet counts and BDNF, TGF-beta, 5-HT concentrations in peripheral blood on day 1 (before intake of 500 mg Aspirin), day 2 (24 hours after intake of 500 mg Aspirin), day 28 (before intake of 600 mg Clopidogrel), day 29 (24 hours after intake of 600 mg Clopidogrel).
1890930|NCT01264653|Drug|adrenalin|adrenalin 0.01%
1890931|NCT01264666|Dietary Supplement|Chinese tea flavor liquor|60 mL of Chinese tea flavor liquor (45% alcohol content) is consumed with high-fat meal.
1890932|NCT01264666|Dietary Supplement|Chinese Meijiao liquor|
1890933|NCT01264666|Dietary Supplement|Water control|
1890935|NCT01264692|Drug|ACT-280778|10 mg once daily for 28 ± 2 days
1890936|NCT01264692|Drug|Placebo|Placebo oral capsules matching ACT-280778
1890937|NCT01264692|Drug|Amlodipine|10 mg once daily for 28 ± 2 days
1890938|NCT01264705|Drug|bavituximab and sorafenib|Bavituximab:0.3,1.0,and 3.0 mg/kg weekly Sorafenib: 400mg PO twice daily
1890940|NCT01264731|Biological|MELITAC 12.1|Vaccine regimen: The vaccines will be administered in two treatment cycles. During cycle one, three vaccines will be administered over a 3-week period on days 1, 8, and 15. During cycle two, three vaccines will be administered over a 9-week period on days 36, 57, 78. Participants in cohort 1 will receive MELITAC 12.1 (100 mcg each of the12-MP and 200 mcg of Peptide-tet) administered subcutaneously (1 ml) and intradermally (1 ml) in Montanide ISA-51 VG adjuvant at a single vaccination site.
1890941|NCT01264731|Drug|Imiquimod|Topical Imiquimod regimen: Beginning on day 1, patients in cohorts 1 and 2 will have one or more cutaneous melanoma metastases treated topically with 5% imiquimod cream, with a dose of 1 to 3 packets of imiquimod daily, (depending on the extent of cutaneous metastases). Each packet contains 250 mg of cream and may be used for a surface area of up to 20 cm2. The number of lesions that are treated will be dependent on the availability and size of the lesions. In addition, if available, at least two lesions will be followed without treatment with the plan that they will be excised at week 3 (day 22) and week 6 (day 43), respectively, as controls. Imiquimod will be applied daily for seven days each week for 12 weeks. One course of treatment will be three weeks in duration, with evaluation by a clinician after every treatment course.
1890942|NCT01264757|Behavioral|Physical Activity Educational Materials|A brochure was provided to participants about the health benefits of physical activity and physical activity recommendations
1890943|NCT01264757|Behavioral|Pedometer|A pedometer was provided to participants in addition to educational materials about the health benefits of physical activity.
1890944|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily and placebo injection once every two weeks
1890945|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 150mg once daily and placebo injection once every two weeks
1890946|NCT01264770|Drug|Fostamatinib and placebo injections|Fostamatinib 100mg twice daily / fostamatinib 100mg once daily and placebo injection once every two weeks.
1890947|NCT01264770|Drug|Adalimumab and placebo of fostamatinib|Adalimumab 40mg injection once every two weeks and placebo to fostamatinib twice daily.
1890948|NCT01264770|Drug|Placebo of fostamatinib, fostamatinib, and placebo injections|Placebo injection once every two weeks. Placebo to fostamatinib for six weeks, followed by fostamatinib 100mg twice daily (Group F) / fostamatinib 100mg twice daily then 150mg once daily (Group G).
1890949|NCT01264783|Drug|RNS60|RNS60 for intravenous administration
1890950|NCT01264783|Drug|Placebo|0.9% normal saline for injection
1890951|NCT01264796|Behavioral|culturally tailored diabetes education|lifestyle modification group education
1890952|NCT01264809|Behavioral|Specific consultation for physical activity counseling|Specific consultation
1890953|NCT01264809|Behavioral|Consultation for physical activity counseling|Specific consultation
1890954|NCT01264822|Drug|Rabeprazole Sodium|"The following 3 drugs are taken orally at the same time twice daily for 7 days: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and clarithromycin 200 mg.
The dose of clarithromycin may be properly increased as needed, although the upper limit is 400 mg twice daily.
If Helicobacter pylori eradication with proton pump inhibitor, amoxicillin, and clarithromycin fails, the following 3 drugs will be taken at the same time twice daily for 7 days as an alternative treatment for adults: rabeprazole sodium 10 mg, amoxicillin hydrate 750 mg, and metronidazole 250 mg."
1890955|NCT01264835|Device|Slotted Anoscope|SA411
1890956|NCT01264848|Procedure|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of internal jugular veins and/or azygous vein and/or brachiocephalic veins
1890957|NCT01264848|Procedure|balloon angioplasty and/or stenting|balloon angioplasty and/or stenting of extracranial vein draining the central nervous system, on condition that such outflow pathology has been confirmed using catheter venography
1890958|NCT01264861|Drug|Safinamide|"Safinamide 100 mg/day = two 50 mg tablets administered orally, once a day, in the morning, with or without food.
Safinamide 200 mg/day = four 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 150 mg = three 50 mg tablets administered orally, once a day, in the morning, with or without food.
Safinamide 300 mg/day = six 50 mg tablets administered orally, once a day, in the morning, with or without food; this will be preceded by a three day titration of 250 mg = five 50 mg tablets administered orally, once a day, in the morning, with or without food."
1890963|NCT01264913|Behavioral|sleep extension & circadian alignment|Both groups of workers will undergo a 1-week period of fixed bedtimes, light-dark cycles and mealtimes in the laboratory to pay the sleep debt and align the circadian system
1890964|NCT01264939|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
1890965|NCT01264939|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
1890966|NCT01264939|Drug|H1 antihistamine, H2 antihistamine, leukotriene receptor antagonist|Participants were required to maintain stable doses of their pre-randomization combination therapy with an H1 antihistamine and either an H2 blocker or leukotriene receptor antagonist, or all 3 drugs in combination, throughout the 24-week treatment period and 16-week follow-up period of the 40-week study.
1890967|NCT01264939|Drug|Diphenhydramine|Participants were provided with diphenhydramine 25 mg for itch relief on an as-needed basis, up to a maximum of 3 doses within 24 hours for the duration of the 40-week study.
1890968|NCT01264952|Procedure|Electrochemotherapy|"Treatment procedure: anesthesia, positioning of electrodes, intravenous in bolus administration of bleomycin (15 mg/m2), within 5-30 min after administration of bleomycin application of electric pulses (8 pulses, duration 100 microseconds, frequency 4 Hz with amplitude adequate to cover the whole treated lesion with electric field necessary for reversible plasma membrane permeabilization), removal of electrodes.
The maximum duration of procedure is 90 minutes."
1890969|NCT01264965|Drug|long acting oxycodone|10mg twice daily
1890970|NCT01264965|Drug|extra strength acetaminophen|1,000 mg twice daily
1890971|NCT01264978|Device|Repetitive magnetic stimulation of the quadriceps muscle|"During 8 weeks, 7-10 days after hospital release, patients will receive repetitive magnetic stimulation sessions, 15 minutes on each thigh, alternatively two and three days /week.
Coil location: centered on the union between upper and lower two thirds of the vastus lateralis.
Stimulation bursts at 10-7 HZ lasting 2 seconds, followed by 4 seconds rest. Intensity will be from 40 to 70% of maximal output, adjusting frequency so that the coil does not overheat, (more than 41ºC).
Coils are cooled down to 5ºC before sessions."
1890974|NCT01265004|Procedure|Stitches|Surgical treatment of a rupture of the achilles tendon, in which both end are fastened with a U-forming stitching
1890975|NCT01265004|Procedure|Fibrin-glue|Surgical treatment, in which both ends are glued together using a medical fibrin-containing glue
1890976|NCT01265004|Procedure|Stitches and Fibrin-glue|Surgical treatment, in which both ends of the ruptured tendon are fastened together with u-forming stitches as well as fibrin-glue
1890977|NCT01265017|Drug|Estradiol, medroxyprogesterone, hydrocortisone, GH|"Estradiol 1mg every 8 hours administered orally
Medroxyprogesterone 2.5 mg every 24 hours administered orally
Hydrocortisone 2.5 mg every morning, 1.25 mg every afternoon, and 1.25 mg at bedtime administered orally
Growth hormone 2 mg once a day administered by subcutaneous injection,"
1890978|NCT01265017|Drug|Matching placebo|matching placebo
1890979|NCT01265030|Drug|Sirolimus|"Loading dose of 12 milligrams/meter2; Per Os (PO), by mouth day 1 (Max dose 12 milligrams)
Starting 24 hours after the initial loading dose, patients will receive a dose of 4 milligrams/meter2 daily; Per Os (PO), by mouth days 2 through 28 (Max dose 4 milligram/day)"
1890980|NCT01265043|Other|Oral hygiene intervention|Oral health promotion intervention
1890981|NCT01265056|Drug|Gabapentin|"On Study day 1: 1200mg (single dose).
Study day 2,3: 300mg TID, 900mg daily.
Study day 4-7: 600mg TID 1800mg* daily.
Study day 8-11: 800mg TID 2400mg* daily [Optional increase to 2400 if pain scores are still 4 on NRS]
Study day 11: 1200mg TID 3600mg* daily [Optional increase to 3600 if pain scores are still >4 on NRS]
* May revert back to prior dose if adverse symptoms occur and are thought to be drug related. Up titration then will be preformed in 48 hours following deexcalation."
1890982|NCT01265056|Drug|Placebo|Sugar Pill is administered similar to the protocol used for the investigational drug.
1890983|NCT01265069|Drug|high dose dual therapy|rabeprazole 20mg qid,amoxicillin 750mg qid for 14days
1890984|NCT01265069|Drug|concomitant therapy|rabeprazole 20 mg,amoxicillin 1000 mg,metronidazole 500 mg,clarithromycin 500 mg, bid for 10 days
1890985|NCT01265108|Drug|Iron sucrose.|Volunteers will receive an intravenous infusion of 200 mg iron sucrose, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
1890986|NCT01265108|Drug|Normal saline|Volunteers will receive an intravenous infusion of 100 ml normal saline, before exposure to 8 hours of alveolar hypoxia. At the end of the exposure, pulmonary artery systolic pressure will be measured and volunteers will undertake an exercise test while breathing hypoxic gas.
1890987|NCT01265121|Device|Continuous positive air pressure device (CPAP)|After titrating the air pressure during a polysomnography test, a CPAP device will be applied to the patient, during the night, for three months.
1891030|NCT01265550|Drug|baclofen|"Baclofen will be prescribed in a dose of 5 mg three times a day (TID) with meals.
The dose of baclofen will be increased by 5 mg TID every week until a total dose of 20 mg TID has been achieved."
1890988|NCT01265121|Other|External nasal dilator adhesive|An external nasal dilator adhesive will be given to patients. They will be applied on the nose and will be used for three months aiming to serve as a placebo for snoring and sleep apnea.
1890989|NCT01265147|Drug|Cisplatin|40mg/m2/w
1890990|NCT01265147|Drug|Nedaplatin|40mg/m2/w
1890991|NCT01265173|Drug|Cefotaxime|3 g
1890992|NCT01265173|Drug|Ceftriaxone|2 g
1890993|NCT01265173|Drug|Ciprofloxacin|400 mg
1890994|NCT01265186|Device|Bispectral Index|The Bispectral-Index is continuously recorded for up to 72 hours in the group of ventilated newborns. Every 15 minutes, a value that was generated by averaging the BIS values of the last 15 minutes will be recorded (automatically calculated by the software of the readout device). The Bispectral-Index is continuously recorded for a minimum of 4 hours in the controls.
1890995|NCT01265186|Device|Amplitude-integrated EEG|A aEEG is recorded once daily for a minimum of four hours in the group of ventilated newborns. In Controls an aEEG is recorded once for a minimum of four hours.
1890996|NCT01265199|Drug|AT-406 in combination with daunorubicin and cytarabine|Oral AT-406 (capsule) given once daily on days 1-5 of induction therapy with daunorubicin 90 mg/m2 I.v. on days 1-3 and cytarabine 100 mg/m2 i.v. by continuous infusion on days 107 of induction therapy.
1890997|NCT01265251|Device|Computerized neuropsychological test|Computerized neuropsychological test battery.
1890998|NCT01265251|Other|Conventional neuropsychological test|Conventional neuropsychological test (paper and pen)
1890999|NCT01265264|Drug|ulodesine|Oral dose administered daily for 84 days.
1891000|NCT01265264|Drug|Placebo|Oral dose administered daily for 84 days.
1891001|NCT01265290|Device|repeated 24 hours ECG Holter monitoring|repeated 24 hours ECG Holter monitoring
1891002|NCT01265290|Device|Telemetric ECG monitoring|Telemetric ECG full disclosure monitoring with GSM technology
1891003|NCT01265303|Device|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
1891004|NCT01265316|Device|There is no intervention for this study.|There is no intervention for this study. The pre-NSR IDE for this study is simply a modification to allow for recording of data without intervention.
1891005|NCT01265329|Other|Negative selection|Sperm selection to continue the treatment with healthy sperm
1891006|NCT01265342|Drug|Beclomethasone|Beclomethasone nebulised suspension 400 micrograms twice a day for 10 days
1891007|NCT01265342|Drug|Placebo|Placebo nebulised suspension twice a day for 10 days
1891008|NCT01265355|Dietary Supplement|Anti-rotavirus protein|11mg ARP In 1 Gm Product Daily For 12 Months, given in orange juice
1891009|NCT01265355|Dietary Supplement|Maltodextrin|Maltodextrin 1 gm daily
1891010|NCT01265368|Biological|MGN1601|Genetically modified allogeneic (human) tumor cells for the expression of IL-7, GM-CSF, CD80 and CD154, in fixed combination with a DNA-based double stem loop immunomodulator (dSLIM)
1891011|NCT01265394|Drug|[18F] Flutemetamol|Flutemetamol (18F) Injection, 185 MBq/5 mCi, single intravenous injection.
1891012|NCT01265420|Biological|Injectable clostridial collagenase|Injection of 0.58mg clostridial collagenase into Dupuytren's cord, up to three injections
1891013|NCT01265433|Biological|WT-1-vaccine Montanide + GM-CSF|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self administered) subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
1891014|NCT01265433|Biological|Montanide adjuvant + GM-CSF (This arm is closed)|Patients will receive 6 injections over 12 weeks. Treatment will be administered on weeks 0, 2, 4, 6, 8, and 10. All patients will receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination. Patients may self administer the Sargramostim (GM-CSF) on day -2 if they have been appropriately instructed on SQ injection administration. Patients will be informed of the expected reactions such as irritation at the injection site. Patients will keep a logbook noting the time and placement of the injection. Patients will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide. It will be administered by a nurse (it may not be self-administered)subcutaneously to the same anatomical site as the GM-CSF. This site will be marked by the patient or treating healthcare professional by a permanent marker pen.
1891015|NCT01265446|Drug|Lidocaine 8mg + CPC 2mg|one single dose
1891016|NCT01265446|Drug|Lidocaine 1mg + CPC 2mg|one single dose
1891017|NCT01265459|Device|Durolane 3 ml, Durolane 4,5 ml, Durolane 6 ml|Durolane is an intraarticular hyaluronic acid preparation
1891018|NCT01265485|Drug|coated suppository|Dose escalating study
1891019|NCT01265498|Drug|obeticholic acid|25 mg daily for 72 weeks
1891020|NCT01265498|Drug|placebo|placebo capsule, 25 mg daily for 72 weeks
1891021|NCT01265511|Drug|Placebo|Oral tablets given bid for 28 days
1891022|NCT01265511|Drug|SCY-635|SCY-635 tablets, 300 mg bid for 28 days
1891023|NCT01265511|Drug|Pegasys|180 ug prefilled syringe given once per week for up to 48 weeks
1891024|NCT01265511|Drug|Copegus|tablets given bid for up to 48 weeks
1891025|NCT01265524|Drug|CLP|Oral administration
1891026|NCT01265524|Drug|Placebo|Oral administration
1891027|NCT01265537|Drug|Tacrolimus|"Low target tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx:
0-1 month, level 5-7; 1-3 months, level 4-5; and 3-6 months, level 3-4"
1891028|NCT01265537|Drug|Tacrolimus|"Standard dose of tacrolimus Advagraf (0.25mg/kg) orally once daily dosed as per manufacturer's recommendation to target trough levels as per Table 1
Table 1
Months post tx
0-1 month; level 8-12; 1-3 months, level 6-9; and 3-6 months, level 5-8."
1891029|NCT01265550|Device|Nissen fundoplication|laparoscopic antireflux surgery
1891031|NCT01265550|Drug|Desipramine|Dose of 25 mg at bedtime (HS) for 1 week, then 50 mg HS for 1 week, then 100 mg HS until the next quarterly visit.
1891032|NCT01265563|Drug|N-acetylcysteine placebo and silibin placebo|Dietary Supplement: N-acetylcysteine placebo excipient and silibin placebo orally twice daily for three months
1891033|NCT01265563|Drug|N-acetylcysteine active and silibin placebo|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin placebo orally twice a day for three months
1891034|NCT01265563|Drug|N-acetylcysteine placebo and silibin active|Dietary Supplement: silibin 480 mg orally twice daily and N-acetylcysteine placebo orally twice a day for three months
1891035|NCT01265563|Drug|N-acetylcysteine active and silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 480 mg orally twice daily for three months
1891036|NCT01265563|Drug|N-acetylcysteine active + high-dose silibin active|Dietary Supplement: N-acetylcysteine 600 mg orally twice daily and silibin 960 mg orally twice daily for three months
1891037|NCT01265576|Drug|Sorafenib|Participants will be on sorafenib at least 30 days before randomization into either the Treatment or Control Arms. Sorafenib will be administered according to the package insert unless contraindicated based on physician expertise.
1891038|NCT01265576|Drug|VT-122 (propranolol plus etodolac)|Participants randomized to the VT-122 regimen (sorafenib plus VT-122) will receive oral doses of propranolol and etodolac, which will be titrated over a period of 3 weeks until the participant reaches a maximum tolerated dose (MTD)[no higher than 60 mg propranolol, twice daily (BID)/300 mg etodolac, BID]. Once the individual MTD has been reached, participants will enter a Maintenance Treatment period, and will receive the VT-122 regimen (propranolol and etodolac, co administered orally) on a continuous BID dosing schedule for a maximum of twelve 4-week cycles.
1891039|NCT01265576|Drug|Placebo|Participants randomized to the Control Arm (sorafenib with placebo) will receive placebo for the same periods as participants randomized to the Treatment Arm. Participants in the Control Arm will undergo the same visits and mock dose escalation.
1891040|NCT01265589|Drug|surfactant|Intratracheal Surfactant Administration without Vitamin A for Newborn Respiratory Distress Syndrome
1891041|NCT01265589|Drug|surfactant+vitamin A|Intratracheal Surfactant Administration with Vitamin A for Newborn Respiratory Distress Syndrome
1891042|NCT01265602|Drug|LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
1891043|NCT01265602|Drug|LASW1510|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
1891044|NCT01265602|Drug|vehicle of LAS41007|Topical gel, to be applied twice daily (mornings and evenings), for up to 90 days. Generally 0.5 g gel (pea-sized amount of gel) per application will be sufficient to cover an overall area of 25 cm².
1891045|NCT01265615|Drug|Paricalcitol|paricalcitol group (6-8 μg daily per os - orally - without special diet)
1891046|NCT01265615|Drug|Calcitriol|calcitriol group (2-4 μg daily orally under with dietary restrictions of vitamin D)
1891047|NCT01265615|Drug|Cholecalciferol|cholecalciferol group (intake of cholecalciferol with recommended daily allowance equals 1200-2400 IU per day)
1891048|NCT01265615|Dietary Supplement|Supplemental|intake of cholecalciferol in food and multivitamins, less than 400-900 IU per day
1891049|NCT01265628|Procedure|perimetry|automated static perimetry with adapted GATE strategy
1891050|NCT01265641|Drug|AZD1981, 2000mg|Single oral dose, tablets
1891051|NCT01265641|Drug|AZD1981, 200mg|Single oral dose, tablets
1891052|NCT01265641|Drug|Moxifloxacin, 400mg|Single oral dose, capsule
1891053|NCT01265641|Drug|Placebo|Single oral dose, tablets
1891054|NCT01265667|Drug|CF101|orally q12h
1891055|NCT01265667|Drug|Placebo|orally q12h
1891056|NCT01265680|Drug|Erythropoietin|80.000 UI of Human Recombinant Erythropoietin and intravenous iron at time of arrival at the hospital.
1990690|NCT01873573|Procedure|Dilation|Dilation will be performed by either dilation balloons or over the wire polyvinyl dilators based upon the physician's discretion. Fluoroscopy may be used to aid in endoscopic dilation at the physician's discretion.
1994117|NCT03063762|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 840 milligrams (mg) prior to RO6874281 administration as an IV infusion on Days 1, 15, 29, and once in 2 weeks from Day 29 onwards.
1891059|NCT01265732|Drug|PF-04191834|single dose, 100mg, dispersion
1891060|NCT01265732|Drug|PF-04191834|single dose, 100mg, suspension
1891061|NCT01265732|Drug|PF-04191834|single dose, 300mg, suspension
1891062|NCT01265745|Drug|Normal Saline for Injection|Equivalent amounts to subjects weight, once over 120 minutes
1891063|NCT01265745|Biological|MDX1303|a sterile solution at a protein concentration of 25 mg/mL: 20 mM sodium citrate, 50 mM sodium chloride, 3.0% mannitol, 50 µM diethylenetriamine pentacetic acid and 0.06% polysorbate 80 at pH 6.5. A tubular, clear glass vial, filled with a 5 mL dose of colorless to pale yellow solution. The vial is sealed with a 20 mm stopper and white flip-off seal.
1891064|NCT01265758|Device|Prolonged telemetric Full Disclosure ECG recording.|Continuous Full Disclosure Telemetric ECG monitoring lasting 14 days
1891065|NCT01265771|Device|Prolonged telemetric Full Disclosure ECG recording.|Thirty days Telemetric Full Disclosure ECG monitoring; subsequently analyzed in the Event Holter monitoring mode
1891066|NCT01265771|Device|Repeated 24 hours ECG Holter monitoring|Repeated 24 hours ECG Holter monitoring
1891067|NCT01265784|Drug|TP-434|
1891068|NCT01265784|Drug|Ertapenem|
1891069|NCT01265784|Drug|Placebo|Administered IV to maintain the blind.
1891070|NCT01265797|Device|Cranial Electrostimulator|participant wears active cranial electrostimulation device for 20 minutes daily for 28 days
1891071|NCT01265797|Device|Sham Device|participant wears sham device for 20 minutes daily for 28 days
1891072|NCT01265810|Other|supersaturated calcium-phosphate rinse|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
1891073|NCT01265810|Other|sodium chloride 0.9 %|4 times daily, 2 minutes rinse with 30 ml solution during active rinse period (14 days)
1891074|NCT01265823|Biological|Adalimumab|Adalimumab was administered as follows: 80 mg at baseline, followed by 40 mg every other week (eow; starting at Week 1 until Week 15). The study drug was self-administered via subcutaneous (sc) injection.
1891229|NCT01257230|Drug|tiotropium Respimat high dose|IMP
1891075|NCT01265849|Biological|LI plus CIZ|LI 400IU (2.0mL total daily) 1.0 mL peritumoral, 1.0 mL perilymphatic 5x weekly x3 weeks administered in combination with cyclophosphamide indomethacin and zinc (CIZ) as adjuvant therapy prior to SOC, surgery followed by radiation or concurrent radiochemotherapy with cisplatin 100mg/m^2 intravenously to determine if LI plus CIZ affects the overall survival of subjects at median 3 years. Cyclophosphamide 300mg/m^2 is administered intravenously bolus 3 days prior to treatment with LI. Indomethacin 25mg capsules are administered orally beginning on day 1 of LI treatment up to 1 day prior to surgery. Multivitamin tablets or capsules with zinc (> or = to 15mg but not > 40mg) are administered orally beginning on day 1 of LI treatment up to 1 day prior to surgery.
1891076|NCT01265849|Other|Standard of Care (SOC)|Standard of care (SOC) for previously untreated squamous cell carcinoma of the head and neck is currently surgery followed by radiotherapy (60-70Gy in 30 to 35 fractions over 6 to 7 weeks) or for higher risk subjects (subjects determined at surgery to have positive surgical margins, 2 or more clinically positive nodes or extracapsular nodal spread) radiotherapy is combined with concurrent chemotherapy (cisplatin 100mg/m2 intravenously 1x weekly for 3 weeks on day 1 of weeks 1, 4 and 7 of radiotherapy
1891077|NCT01265849|Biological|LI + SOC|LI is administered 400 IU (2.0mL) 1/2 peritumorally and 1/2 perilymphatically 5 times a week for three weeks prior to SOC to determine the contribution of CIZ on LI activity.
1891078|NCT01265862|Procedure|Tracheal intubation through LMA-Fastrach®|Tracheal intubation through a supraglottic airway device (LMA-Fastrach®) using a GlideRite® endotracheal tube
1891079|NCT01265862|Procedure|Tracheal intubation through I-gel®|Tracheal intubation through a supraglottic airway device (I-gel®) using a GlideRite® endotracheal tube
1891080|NCT01265875|Drug|Human Secretin|Dose Escalation
1891081|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM
1891082|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 2 LPM
1891083|NCT01265888|Drug|Inhaled Nitric Oxide|Inhaled nitric oxide 80 ppm via nasal cannula at 1 LPM for 15 minutes followed by placebo washout of 15 minutes inhalation of medical grade air (or prescribed supplemental oxygen), and then inhaled nitric oxide 80 ppm via nasal cannula at 4 LPM
1891088|NCT01265914|Biological|FP-01.1|Ascending doses of FP-01.1 will be administered
1891089|NCT01265914|Biological|placebo|
1891090|NCT01265927|Drug|GRN163L in combination with trastuzumab|GRN163L will be administered in escalating dose cohorts on Day 1 of each 21-day cycle prior to trastuzumab infusion. Trastuzumab will be a administered day 1 of each 21-day cycle after GRN163L. There will be a 30 minute observation period between the end of the GRN163L infusion and the beginning of the trastuzumab infusion.
1891091|NCT01265940|Drug|Pazopanib as add-on to vinflunine|"Patients will receive vinflunine standard regimen (intravenous infusion every three weeks) as specified per drug label plus additional pazopanib as daily oral medication. Doses of pazopanib will be escalated in 200 mg/d steps during phase I up to a maximum of 800 mg/d.
In Phase II the patients will be given pazopanib + vinflunine at maximum tolerated dose."
1891092|NCT01265953|Drug|sulforaphane glucosinolate capsules|Four weeks sulforaphane (SFN) glucosinolate capsules: 250 mg of broccoli seed extract (30 mg sulforaphane glucosinolate), 8 capsules (4 capsules B.I.D.) daily
1891093|NCT01265953|Dietary Supplement|Gelatin capsule containing cellulose and magnesium stearate|Four weeks placebo: 8 capsules (4 capsules B.I.D.) daily
1891094|NCT01265979|Procedure|Whole body diffusion MRI|These studies will be performed on a 3 Tesla (T) MR system. A major advantage of 3T compared to 1.5T is the improved signal to noise ratio that allows whole-body studies to be faster and without application of external antennas, which greatly improves patient comfort.
1891095|NCT01266005|Drug|Clevudine|30mg,QD
1891096|NCT01266005|Drug|Entecavir|0.5mg QD
1891097|NCT01266018|Drug|ADI-PEG 20 (Arginine deiminase pegylated)|ADI-PEG 20 was administered intramuscularly (IM) at a fixed dose of 320 IU/m^2 (36.8 mg/m^2) once weekly for 4 weeks followed by a 1-week follow-up (1 cycle)
1891098|NCT01266031|Drug|vorinostat|Vorinostat 400mg/day will be administered on day 1 to 7 and day 15 to 21 orally on a 28 day cycle in the arm with combination of vorinostat and bevacizumab. Vorinostat will be administered orally. Vorinostat capsules should not be opened or crushed and must be administered whole.
1891099|NCT01266031|Drug|bevacizumab|Bevacizumab 10mg/kg will be administered on day 1 and 15 intravenously on a 28 day cycle in both arms.
1891100|NCT01266044|Procedure|Acupuncture - Group 1|Acupuncture at 14 points. The needles will remain in place for 20 minutes with each treatment.
1891101|NCT01266044|Procedure|Acupuncture - Group 2|Acupuncture needles placed at different points from Group 1. The needles will remain in place for 20 minutes with each treatment.
1891102|NCT01266044|Other|Standard Care|Standard oral care recommendations. Participants in all groups will receive the same recommendations.
1891103|NCT01266044|Other|Questionnaire|Baseline assessments will be completed within 7 days prior to starting radiotherapy, and patients will then complete the same assessments again at week 4 and 7 of radiotherapy and 3, 6, and 12 months after the end of radiotherapy.
1891104|NCT01266057|Drug|Hydroxychloroquine|Starting dose of 200 mg by mouth every day for a 21 day cycle.
1891105|NCT01266057|Drug|Sirolimus|Starting dose of 2 mg by mouth every day for a 21 day cycle.
1891106|NCT01266057|Drug|Vorinostat|Starting dose of 200 mg by mouth per day for a 21 day cycle.
1891107|NCT01266070|Drug|Dovitinib|500 mg (5 capsules) daily by mouth on Days 1-5, 8-12, 15-19, and 22-26 of each 28-day cycle (i.e. 5 days on, 2 days off schedule).
1891230|NCT01257243|Drug|Syrup of oxomemazine, guaifenesin and potassium iodate|5ml each 4 hours
1891108|NCT01266083|Biological|WT1 peptide vaccine|Six vaccinations of the WT1 peptide preparation (1.0 ml of emulsion) will be administered on weeks 0, 2, 4, 6, 8, and 10. All vaccinations will be administered subcutaneously with vaccination sites rotated among extremities. Patients who are clinically stable and have not had disease progression, may receive up to 6 more vaccinations administered appropriately every month.
1891110|NCT01266109|Behavioral|Contingency Management-Family Engagement (CM-FAM)|Evidence-based outpatient intervention for adolescent substance use
1891111|NCT01266109|Other|Usual Services (US)|Typical community-based substance abuse treatment services
1891112|NCT01266122|Behavioral|Behavioral intervention|The behavioral intervention will consist of 4 group sessions and 4 individual sessions over 3 months. The overall focus is on psychosocial concerns and HIV risk.
1891113|NCT01266135|Drug|QAX576|QAX576 10 mg/kg intravenous infusion
1891114|NCT01266135|Drug|Placebo|Placebo to QAX576 intravenous infusion
1891115|NCT01266148|Drug|Cyclosporine|Cyclosporine (CsA) control group target blood level: 150-350 ng/mL (month 1-3); 100-250 ng/mL (month 4-6); 60-200 ng/mL (month 7-12); everolimus group target blood level: 75-175 ng/mL (month 1-3)
1891116|NCT01266148|Drug|Mycophenolate mofetil|Mycophenolate mofetil (MMF) target dose for control group: 2000-3000 mg/day everolimus group target dose: 1500-2000 mg/day and 75-175 ng/mL after week 11
1891117|NCT01266148|Drug|Corticosteroids|Corticosteroids (CS) initiated at 0.2-0.5 mg/kg/day. Tapered to no less than 0.1 mg/kg at Month 3 for control and everolimus groups.
1891118|NCT01266148|Drug|Everolimus|Everolimus 0.75 mg twice a day as starting dose up to a target blood level: 3-6 ng/mL (7-11 weeks) and 6-10 ng/mL for remaining of study
1891119|NCT01266148|Drug|Anti Thymocyte Globulin|Induction therapy, Anti Thymocyte Globulin (ATG): 1-2 mg/kg/day during 3-5 days for control and everolimus groups after transplant surgery and prior to randomization.
1891124|NCT01266187|Procedure|adjuvant surgery + FOLFOX + cetuximab|surgery -> 4-8 weeks rest -> 24 weeks FOLFOX + cetuximab
1891125|NCT01266187|Procedure|perioperative/Folfox + cetuximab|"12 weeks FOLFOX + cetuximab -> 4 weeks rest -> surgery
-> 4-8 weeks rest -> 12 weeks FOLFOX + cetuximab"
1891126|NCT01266200|Procedure|Mantis|percutaneous minimal-invasive technique at the thoracal-lumbal junction with for cuts of about 3 cms
1891127|NCT01266200|Procedure|XIA|Treatment of the fracture with Xia and conventional operation technique
1891128|NCT01266213|Drug|Fulvestrant plus Goserelin|Fulvestrant s.c. plus Goserelin s.c.
1891129|NCT01266213|Drug|Anastrozole plus Goserelin|Anastrozole 1 mg p.o. plus Goserelin s.c.
1891130|NCT01266213|Drug|Goserelin|Goserelin s.c.
1891131|NCT01266226|Device|Autologous conditioned plasma|4mL autologous conditioned plasma application under the footprint following an arthroscopic repair of the rotator cuff.
1891132|NCT01266226|Device|Control group|4mL saline application under the footprint following an arthroscopic repair of the rotator cuff.
1891133|NCT01266239|Procedure|kissing balloon inflation|Kissing balloon inflation following the MV stenting
1891134|NCT01266239|Device|EES vs. SES|Rapid endothelialization after EES deployment has been reported compared to that after SES deployment.
1891135|NCT01266252|Drug|Dexmedetomidine|"Dexmedetomidine will be given maximal 72 hours. In case analgosedation is still needed after stop of the dexmedetomidine infusion, the treatment is switched to conventional analgosedation regimens.
Additional drugs are given to every inadequately sedated-painful patient (assessed by regular Comfort-neo and Numeric Rating Scale scoring). In case of oversedation or adverse drug events (hypotension, bradycardia), a downtitration (or stop) of the dexmedetomidine infusion is needed."
1891136|NCT01266265|Drug|inhaled prostacyclin|Tyvaso
1891137|NCT01266265|Drug|inhaled prostacyclin|As prescribed by the physician
1891138|NCT01266265|Drug|prostacyclin|As prescribed by the physician
1891139|NCT01266265|Drug|subcutaneous and intravenous prostacyclin|As prescribed by physician
1891140|NCT01266265|Drug|oral ERA|As prescribed by physician
1891141|NCT01266265|Drug|oral PDE5 inhibitors|As prescribed by physician
1891142|NCT01266278|Other|Dynamic ultrasound|Measurement of the size of the subacromial space with dynamic ultrasound.
1891143|NCT01266278|Other|FASTRAK|Measurements of the 3D-kinematics of the shoulder with FASTRAK. Sensors are placed on the skin of the shoulder with adhesive tape.
1891144|NCT01266278|Other|Assessment of shoulder posture by measuring|Assessment of shoulder posture by measuring several angles and distances.
1891145|NCT01266291|Drug|vigabatrin|Subjects will begin taking vigabatrin (Sabril) during the third month of the study. Upward titration will happen at a rate of 500mg per week until subjects reach their maximum tolerated dose, or 3g per day (whichever is lower). This dose may be decreased if needed under the supervision of the study doctor. Subjects who need to lower their dose or who stop taking Sabril will have their dosage decreased at a rate of 1 gm/week for one month under the supervision of the study doctor.
1891146|NCT01266317|Drug|Combined Plasma Exchange (PEX), Rituximab, and Corticosteroids|Standard Steroid Treatment, Plasma exchange will consist of 1.5x estimated plasma volume exchanges, Rituximab
1891147|NCT01266330|Dietary Supplement|Low Dairy|Less than 0.5 standard servings of dairy products per day
1891148|NCT01266330|Dietary Supplement|Adequate Dairy|3.5 standard servings of dairy foods per day
1891149|NCT01266369|Drug|masitinib|
1891189|NCT01266720|Biological|VEGFR1, VEGFR2|One mg of each peptide will be administered subctaneously on days 1, 8, 15 and 22
1994118|NCT03063762|Drug|Bevacizumab|Bevacizumab will be administered at a dose of 10 milligrams per kilogram (mg/kg) after the atezolizumab administration, and prior to RO6874281 administration as an IV infusion on Days 15, 29, and once in 2 weeks from Day 29 onwards.
1891150|NCT01266382|Device|AposTherapy|a biomechanical device including 2 hemispheric biomechanical elements attached to a platform in a form of a shoe. the biomechanical device is calibrated to each patient by a physiotherapist specialized with the treatment methodology. patient are instructed to walk indoor with the device. time of exercise is gradually increase
1891151|NCT01266434|Drug|Simvastatin|10 mg once daily for 8 weeks
1891152|NCT01266434|Drug|B1-6-12|1 tablet once daily for 8 weeks
1891153|NCT01266447|Biological|Filgrastim|Given SC
1891154|NCT01266447|Other|Laboratory Biomarker Analysis|Correlative studies
1891155|NCT01266447|Biological|Pegfilgrastim|Given SC
1891156|NCT01266447|Drug|Topotecan Hydrochloride|Given IV
1891157|NCT01266447|Drug|Veliparib|Given PO
1891158|NCT01266460|Biological|Attenuated Live Listeria Encoding HPV 16 E7 Vaccine ADXS11-001|Given IV
1891159|NCT01266460|Other|Laboratory Biomarker Analysis|Correlative studies
1891160|NCT01266473|Other|Physiotherapy|Physiotherapy for Airway Clearance
1891161|NCT01266486|Drug|Metformin|Extended release Metformin 1500mg once daily for 14-21 days
1891162|NCT01266499|Drug|Colistin (Polymyxin E) 100mg x 4/d|Colistin (Polymyxin E) 100mg x 4/d
1891163|NCT01266499|Drug|both medications|PO Garamycin 80mg x 4/d +PO Colistin (Polymyxin E) 100mg x 4/d
1891164|NCT01266499|Drug|will not receive PO treatment|will not receive PO treatment - will receive plecebo treatment
1891165|NCT01266499|Drug|PO Garamycin 80mg x 4/d|PO Garamycin 80mg x 4/d
1891166|NCT01266512|Drug|DOCETAXEL|Pharmaceutical form: docetaxel 20mg or 80 mg concentrate for solution for infusion Route of administration: intravenous
1891167|NCT01266512|Radiation|Intensity Modulated Radiotherapy (IMRT)|2 Gy per fraction
1891168|NCT01266512|Drug|CISPLATIN|Pharmaceutical form: solution for infusion Route of administration: intravenous
1891169|NCT01266525|Drug|SAR110894|"Pharmaceutical form: Capsule
Route of administration: Oral"
1891170|NCT01266525|Drug|placebo (for SAR110894)|"Pharmaceutical form: Capsule
Route of administration: Oral"
1891171|NCT01266525|Drug|Donepezil|5 mg or 10 mg once daily continued as taken before inclusion
1891172|NCT01266551|Device|car safety seat|The positions in the car safety seat and in supine 15 degrees anti-Trendelenburg are compared on the basis of a 20 hour pH monitoring.In one group the infants were first continuously positioned at 45 degrees elevation in a car safety seat (car safety seat type Maxi cosi Citi for infants from 0-13kg). During the next period the infants were kept in a supine 15 degrees anti-Trendelenburg position (hospital infant bed), and vice versa for the other group.
1891173|NCT01266590|Drug|LY2216684|Administered orally
1891174|NCT01266590|Drug|Digoxin|Administered orally
1891175|NCT01266603|Drug|HDIL-2|720,000 IU/kg by vein over an approximate 15 minute period every eight hours, for a maximum of 14 doses per cycle.
1891176|NCT01266603|Biological|recMAGE-A3 + AS15|300 μg plus 420 μg of CpG7909 (a part of the Adjuvant System AS15) by intermuscular injection within 24 hours from first dose of HDIL-2.
1891177|NCT01266616|Biological|Profectus HIV MAG pDNA vaccine|3,000 mcg admixture of two vaccine plasmids: ProfectusVax DNA Plasmid (HIV-1 gag/pol) and ProfectusVax DNA Plasmid (HIV-1 nef/tat/vif, env) at Weeks 0, 4, and 12
1891178|NCT01266616|Biological|IL-12|Administered at Weeks 0, 4, and 12
1891179|NCT01266616|Other|Placebo|Saline injections at Weeks 0, 4, and 12
1891180|NCT01266642|Radiation|Hypofractionated Whole Breast Irradiation|"42.56 Gy in 16 fractions delivered to the whole breast on consecutive treatment days.
Boost of 10 Gy in 4 fractions or 12.5 Gy in 5 fractions delivered on consecutive days beginning on treatment day following completion of whole breast irradiation."
1891181|NCT01266642|Radiation|Conventionally Fractionated Whole Breast Irradiation|"50 Gy in 25 fractions delivered to whole breast on consecutive treatment days.
Boost of 10 Gy in 5 fractions or 14 Gy in 7 fractions delivered on consecutive treatment days, beginning on treatment day following completion of whole breast irradiation."
1891182|NCT01266655|Drug|Baclofen|Baclofen will be administered orally for a maximum of 20 consecutive weeks. For the first 3 days, patients will receive baclofen in a dose of 5 milligrams t.i.d.; subsequently, the daily dose of baclofen will be increased to a maximum of 90 milligrams t.i.d. within 4 weeks. In case of intolerance, dosage can be decreased to a minimum of 10 mg t.i.d.. Patients will receive maximum tolerated dosage of baclofen for 12 weeks. Medication will then gradually be tapered over a maximum of 4 weeks.
1891183|NCT01266655|Drug|Placebo|Placebo
1891184|NCT01266681|Drug|amiodarone|"Visit One:. Once consent is given patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.
Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.
Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires
Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires
Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires
Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires
Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist."
1891185|NCT01266681|Drug|Dronedarone|"Visit One: patarticipants will be randomised into either group and instructed and prescribed the drug as appropriate.
Visit Two: Patients will attend for routine cardioversion. This is performed by an experienced CCU nurse as per normal protocol. Patients will also undergo an ECG, and fill in symptom and quality of life (QoL) questionnaires.
Visit Three: Patients will attend a routine outpatient appointment 6 weeks post cardioversion. They will undergo ECG and fill in symptom and QoL questionnaires
Visit Four: Participants will attend at 12 weeks for ECG, symptom and QoL questionnaires
Visit Five: Participants will attend at 24 weeks for ECG, symptom and QoL questionnaires
Visit Six: Participants will attend at 36 weeks for ECG, symptom and QoL questionnaires
Visit Seven: Participants will attend at 52 weeks for ECG, symptom and QoL questionnaires. Participants will then be followed up as per protocol by their consultant cardiologist."
1891186|NCT01266694|Drug|Colchicines|oral form, 1 mg, once a day during 14 days
1891187|NCT01266694|Drug|Placebo|oral form, placebo
1891188|NCT01266707|Biological|antiangiogenic paptide vaccine|for drugs include administration time frame
1891231|NCT01257243|Drug|Syrup of guaifenesin|5ml each 4 hours
1891191|NCT01266733|Behavioral|Interdisciplinary treatment|The Experimental Group received 6 weeks of interdisciplinary treatment of fibromyalgia combining coordinated psychological, medical, educational, and physiotherapeutic interventions delivered by a team that included a physician, a psychologist, and a physiotherapist.Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions. One session included 1 hour with the psychologist and 45 minutes of educational activities with the physician and psychologist, while the other session included 1 hour with the psychologist and 45 minutes with the physiotherapist.
1891192|NCT01266733|Behavioral|Interdisciplinary treatment of fibromyalgia|The Control Group received the usual standard of care, which included pharmacologic treatment with a tricyclic antidepressant (amitriptyline, maximum dose of 75 mg/24h), an analgesic (paracetamol, maximum dose of 4 grams/24h), and a non-opioid central analgesic (tramadol, maximum dose of 400 mg/24h). The Experimental Group (EG) received 6 weeks of interdisciplinary treatment combining coordinated PSYchological, Medical, Educational, and PHYsiotherapeutic interventions (PSYMEPHY) delivered by a team that included a physician, a psychologist, and a physiotherapist. Patients in the EG were divided into groups of 12 individuals. Each attended biweekly group sessions of 1 hour and 45 minutes, for a total of 12 sessions.
1891193|NCT01266746|Procedure|Vitreous surgery|Vitreous surgery is performed to treat the original disease not for the study.
1891194|NCT01266759|Drug|NuvaRing|For the first cycle, women inserted the ring between days 1 and 5 of the menstrual cycle. Treatment continued for three cycles. Each cycle consisted of 3 weeks of ring use followed by a 1 week ring-free period.
1891195|NCT01266759|Drug|Norethisterone Acetate tablets - 5mg|Norethisterone Acetate tablets 5 mg three times daily from day 5 to 26 of the cycle over three cycles. Male condom used for contraception during treatment
1891196|NCT01266772|Drug|Montelukast sodium.|Children with asthma treated with montelukast and budesonide.
1891197|NCT01266772|Drug|Placebo tablet and budesonide|Children with asthma treated with placebo tablet and budesonide.
1891198|NCT01266785|Drug|Infliximab|Patient will receive Infliximab infusions during Weeks 0, 2 and 6. Therefore, the duration of the Infliximab treatment will last 6 weeks.
1891199|NCT01257061|Drug|Group 1|Clemastine fumarate 1,0 mg/g + dexamethasone 0,5/g applied 2 times / day at lesion
1891200|NCT01257061|Drug|Group 2|Dexchlorpheniramine maleate 10 mg/g applied 2 times / day at lesion
1891201|NCT01257074|Drug|Acyclovir 50mg/g|Cream, dose 5 times daily during 5 days
1891202|NCT01257074|Drug|Penciclovir 10mg/g|Cream, dose 5 times daily during 5 days
1891203|NCT01257087|Drug|Insulin|All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
1891204|NCT01257113|Other|supervised exercise|This group will receive 10 classes of supervised exercise in the 6 weeks intervention. In this classes the patients will be with a physiotherapist that will adjust their home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
1891205|NCT01257113|Other|homebased exercises|This group will receive 1 class of supervised exercise at the beginning of the 6 weeks intervention. In this class the patients will be with a physiotherapist that will put together a home-exercise program and make sure they do the exercises in a good way. They will receive 4-6 exercises they shall do 3 times with 30 repetitions, 2 times every day. If necessary, they should also do stretching exercises
1891206|NCT01257126|Drug|diclofenac potassium|
1891207|NCT01257126|Drug|nimesulide|
1891208|NCT01257139|Procedure|Dual-agent therapy or docetaxel alone or best supportive care|"ARM B: (245 patients)
Treatment if the SGS screening test is negative:
non epidermoid tumor:
Carboplatin ® AUC 5 on D1 and Alimta ®(pemetrexed) 500 mg/m² D1, D1=D21 with vitamin B9 and B12 supplementation. Maximum of four 3-week cycles.
epidermoid tumor:
Carboplatin AUC 5 on D1 and Gemcitabin 1000 mg/m² on D1 and D8, D1=D21. Treatment if SGS screening test is positive (cf.table 1): Vulnerable subjects will receive: Taxotere ® (Docetaxel) 38 mg/m² on D1 and D8, D1=D21. Maximum of four 3-week cycles Fragile subjects are patients considered to be at a high risk of complications during chemotherapy; they will therefore receive best supportive care (BSC) with appropriate geriatric management."
1891209|NCT01257165|Drug|Zopiclone|Zopiclone pill 5 or 10 mg, given orally as a single dose.
1891210|NCT01257165|Drug|Ethanol|50 mg per 70 kg body weight, given orally as a single dose
1891211|NCT01257165|Drug|Placebo pill|Placebo pill identical to zopiclone pill, given orally as a single dose
1891212|NCT01257165|Drug|Placebo drink|Placebo drink, given orally as a single dose
1891213|NCT01257178|Drug|LY2624803|Administered orally
1891214|NCT01257191|Drug|Carbon Black|source: commercial
1891215|NCT01257191|Drug|Diesel Exhaust Particles|source: diesel engine
1891216|NCT01257191|Drug|Fine Concentrated Ambient Particles|source: concentrated ambient air
1891217|NCT01257191|Drug|Ultrafine Concentrated Ambient Particles|source: concentrated ambient air
1891218|NCT01257191|Drug|Saline|Saline solution
1891219|NCT01257204|Drug|Placebo|Tablets, oral, 0 mg, once daily, for 24 weeks
1891220|NCT01257204|Drug|Daclatasvir|Tablets, oral, 60 mg, once daily, for 12, 16, or 24 weeks
1891221|NCT01257204|Drug|Pegylated interferon alfa-2a|Solution for injection, subcutaneous injection, 180 µg/0.5 mL, once weekly, for 12, 16, or 24 weeks
1891222|NCT01257204|Drug|Ribavirin|Tablets, oral, 800 mg, twice daily, for 12, 16, or 24 weeks
1891223|NCT01257217|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL Model SN6AD1|Multifocal IOL implanted for long-term use over the lifetime of the cataract patient
1891224|NCT01257217|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL Model SND1TT|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
1891225|NCT01257217|Device|Acri.LISA® 366D IOL|Aspheric diffractive IOL with +3.75 D add power implanted for long-term use over the lifetime of the cataract patient
1891226|NCT01257217|Device|Acri.LISA® 466TD Toric IOL|Aspheric diffractive IOL with +3.75 D add power and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
1891227|NCT01257230|Drug|tiotropium Respimat low dose|IMP
1891228|NCT01257230|Drug|placebo Respimat|placebo representing comparator
1891232|NCT01257269|Other|Observation|No interventions planned: treatment of patients at the discretion of the treating/responsible physician
1891233|NCT01257295|Dietary Supplement|control: no fiber addition|liquid breakfast without addition of fiber
1891234|NCT01257295|Dietary Supplement|breakfast with low viscous, low gelling pectin|10g of low viscous, low gelling pectin dissolved in a liquid breakfast
1891235|NCT01257295|Dietary Supplement|high viscous, low gelling pectin|10g of high viscous, low gelling pectin dissolved in a liquid breakfast
1891236|NCT01257295|Dietary Supplement|low viscous, high gelling pectin|10g of low viscous, high gelling pectin dissolved in a liquid breakfast
1891237|NCT01257295|Dietary Supplement|high viscous, high gelling pectin|10g of high viscous, high gelling pectin dissolved in a liquid breakfast
1891238|NCT01257295|Dietary Supplement|pectin supplement|10g of high viscous, high gelling pectin provided as a dietary supplement, a liquid breakfast is served seperately
1891239|NCT01257334|Drug|BI 10773|patients with type 2 diabetes mellitus with insufficient glycaemic control despite treatment with metformin alone or metformin in combination with a sulfonylurea
1891240|NCT01257347|Behavioral|Disclosure of adherence report to clinician|During clinical visits with patients with uncontrolled hypertension, clinicians will be provided with a quantitative summary of their patients' electronically-monitored adherence to antihypertensive medications. The summary will be in the form of a report that fits onto one page and lists the percent of days patients correctly adhered to each of the monitored BP medications and the mean adherence to the whole regimen. Adherence data will be provided for the 7-days and 1-month prior to the clinic visit. The report will also show the number of days patients exceeded the recommended number of pill container openings. Clinicians in the intervention arm will get a brief training (<10 minutes) in the interpretation and use of the report at the time of enrollment.
1891241|NCT01257347|Device|MedSignals pillbox|(Non-experimental) Patients will be given an electronic pillbox. The device records the date and time when each compartment is opened. Adherence to each BP medication was calculated as the percent of doses taken as prescribed. Patients are informed that their adherence was recorded by the electronic pillbox and might be shared with their clinician depending on randomization.
1891242|NCT01257360|Drug|Panitumumab|Panitumumab 6 mg/kg BW will be administered IV every 2 weeks (q2w) on day -14, 1, 15, 29 (and 43, in case radiotherapy is still ongoing due to delays) of the radiotherapy.
1891243|NCT01257360|Radiation|Radiation of the pelvis|Radiation is applied at single doses of 1.8 Gy at the ICRU 50 reference point, once daily, five times a week, adding up to 28 fractions over almost 6 weeks and a total reference dose of 50.4 Gy.
1891244|NCT01257373|Device|Firebird 2 Cobalt-Chromium Alloyed Sirolimus-Eluting Stent|Firebird2 CoCr-alloyed sirolimus-eluting stent system is the 2nd generation of drug-eluting stent(DES). It was registered successfully on Jan. 16, 2009 in China. This stent is based with a CoCr alloyed metal platform. The length is from 13-33mm, the diameter is from 2.5mm-4.0mm.
1891245|NCT01257386|Drug|Asacol®|400mg tablets
1891246|NCT01257386|Drug|Mesalazine|400mg tablets
1891247|NCT01257399|Drug|Asacol®|400 mg tablets
1891248|NCT01257399|Drug|Mesalazine|400mg tablets
1891249|NCT01257412|Drug|Dapagliflozin|5mg Oral dose od
1891250|NCT01257412|Drug|Dapagliflozin|10 mg Oral dose od
1891251|NCT01257412|Drug|placebo|5/10 mg Oral dose od
1891252|NCT01257425|Drug|Triptorelin Pamoate (Pamorelin® LA 11.25 mg)|"Pamorelin® LA 11.25 mg administered as standard IM injection (= reference group) at Day 1 and Day 85.
Triptorelin Pamoate (Pamorelin® LA 11.25 mg) applied subcutaneously (s.c.) at Day 1 and Day 85."
1891253|NCT01257438|Device|Fluency Plus Endovascular Stent Graft|Treatment of in-stent restenosis
1891254|NCT01257438|Device|Percutaneous Transluminal Angioplasty only|Treatment of in-stent restenosis
1891255|NCT01257451|Drug|Vildagliptin|vildagliptin 50mg bid
1891256|NCT01257451|Drug|Placebo|Placebo 50mg bid
1891257|NCT01257464|Drug|Sitagliptin|100mg po one dose
1891258|NCT01257464|Drug|Placebo|Sugar pill po one dose
1891259|NCT01257490|Behavioral|counseling vs. advice|1 session of brief physician advice to quit smoking plus bupropion (12 weeks) compared to 4 sessions of intensive counseling plus bupropion (12 weeks)
1891260|NCT01257503|Drug|Hyland's Cold 'n Cough 4 kids|5 ml PO q4h prn cold symptoms
1891261|NCT01257503|Drug|placebo|liquid made to look like the active homeopathic remedy
1891262|NCT01257516|Drug|Pregabalin immediate release, 300 mg|300 mg immediate release capsule administered twice daily for four days
1891263|NCT01257516|Drug|Pregabalin controlled release, 330 mg|Two tablets of 330 mg (total dose of 660 mg) given concurrently once daily for four days
1891264|NCT01257529|Drug|Pregabalin controlled release, 330 mg, low-fat|A single oral dose of 330 mg controlled release tablet administered following a low-fat evening meal
1891265|NCT01257529|Drug|Pregabalin controlled release, 330 mg, medium-fat|A single oral dose of 330 mg controlled release tablet administered following a medium-fat evening meal
1891266|NCT01257529|Drug|Pregabalin controlled release, 330 mg, high-fat|A single oral dose of 330 mg controlled release tablet administered following a high-fat evening meal
1891267|NCT01257529|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered following a medium-fat evening meal
1994119|NCT03063762|Drug|RO6874281|RO6874281 will be administered as an IV infusion on Days 1, 8, 15, 22, and 29, and once in 2 weeks from Day 29 onwards. Starting dose of RO6874281 will be 5 mg, and will be increased subsequently.
1891270|NCT01257555|Device|Photopneumatic therapy|Use of intense pulsed light (photo) in combination with vacuum technology (pneumatic) to treat mild to moderate acne.
1891271|NCT01257568|Device|Rejuvenate Modular Hip|Rejuvenate Modular Hip
1891272|NCT01257581|Drug|creatine|creatine monohydrate powder
1891273|NCT01257581|Drug|tamoxifen|Tamoxifen citrate capsules
1891274|NCT01257594|Drug|erlotinib|"For patients with no cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg on days 1 of every 7 days. For patients with cytoreductive surgery planned, patients will receive single-agent erlotinib at a starting dose of 2000 mg day 1 of every 7 days (+/- 2 days). One pre-operative dose of 2000 mg erlotinib will be administered in an open-label, unblinded manner, administered in the hospital on call to the operating room."
1891276|NCT01257607|Drug|MIM-D3 Ophthalmic Solution|28 Days, BID
1891277|NCT01257620|Dietary Supplement|Probiotic|Bifidobacterium infantis, 2 capsules (2.0E+9 CFU/capsule) 3 times/day for a total of 1.2E+10 CFU/day for 21 days.
1891278|NCT01257633|Procedure|Transoral robot-assisted tumor resection using the da Vinci robot|Transoral robot-assisted tumor resection using the da Vinci robot
1891279|NCT01257646|Other|Gait analysis|A Gaitrite system, a goniometer, and EMG are used to record data while the patient walks 10 meters.
1891280|NCT01257659|Procedure|STARR rectocele repair|The STARR transanal stapling system is used to repair a rectocele.
1891281|NCT01257659|Procedure|Elevate mesh rectocele repair|A posterior Elevate mesh is placed transvaginally to repair a rectocele.
1891282|NCT01257672|Drug|Ondansetron|ondansetron syrup (0,15 mg/Kg of body weight)
1891283|NCT01257672|Drug|Domperidone|domperidone syrup (0,5 mg/Kg of body weight)
1891284|NCT01257672|Drug|placebo|placebo
1891285|NCT01257698|Drug|Dorzolamide 2%-timolol 0.5% topical eyedrops|Dorzolamide 2%-timolol 0.5%, 1 drop in operated eye twice daily until gas bubble completely resorbed. Patients randomized to this arm are instructed to use this drop in addition to standard post-operative eye drops.
1891286|NCT01257711|Procedure|Roux-en-Y or Billroth II|Roux-en-Y had fewer problems related to reflux of bile but a higher incidence of stasis in the Roux limb resulting in longer hospital stay. Some surgeon avoids doing Roux-en-Y is a triad of post operative symptoms including abdominal pain, vomiting and nausea called Roux-en-Y loop syndrome. Billroth II reconstruction is a simpler operation with only one anastomosis and faster operating time. This has implications while managing gastric cancer patients who may be malnourished and a simpler procedure may have lesser risk of complications and yield better outcomes. Billroth II has increased reflux associated problem like esophagitis and gastritis, risk of afferent loop and dumping syndrome. Long term nutritional outcomes are similar for both procedures.
1891287|NCT01257724|Other|SHARE (Synthesized HIV/AIDS Research Evidence)|"SHARE (Synthesized HIV/AIDS Research Evidence) consists of several components:
an online searchable database of HIV-relevant systematic reviews;
monthly email updates highlighting new reviews;
access to user-friendly summaries produced by us or by others (when available);
links to scientific abstracts;
peer relevance assessments, which involves periodic requests to complete a brief assessment of how useful the information in the newly added review is with the average score posted once an assessment is completed;
an interface for participants to leave comments in the records of systematic reviews in the database;
links to full-text articles (when publicly available); and
access to worksheets that help CBOs find and use research evidence"
1891288|NCT01257737|Drug|HPN-100|HPN-100 will be administered orally three times daily (TID) with meals. The maximum recommended dose of HPN-100 in subjects weighing less than 20 kg is 0.53 mL/kg/day (equivalent to 600 mg/kg/day of NaPBA), and is 11.48 mL/m2/day in heavier subjects (equivalent to 13g/m2/day of NaPBA). The maximum HPN-100 dose should be 17.4 mL/day, which is equivalent to 20 g/day of NaPBA.
1891290|NCT01257763|Device|Transdermal Microchannel Skin System|A member of the research staff will apply the study device to the subject's lateral forehead, temple and nasolabial area on randomly selected sides of the face, 3 times at each anatomical location, for a total of 9 applications. All subjects will also receive 9 adjacent applications to the central forehead, and they will self-administer 3 adjacent applications to the chin under instruction of study staff.
1891291|NCT01257763|Device|Sham device|The side not receiving application of the study device at each anatomical location will receive a comparable number of applications of a sham device.
1891292|NCT01257776|Drug|Autologous adipose derived mesenchymal stem cells|Intra-arterial administration through a selective cannulation of target common femoral artery
1891293|NCT01257789|Procedure|laparoscopic gastric bypass|laparoscopic gastric bypass
1891294|NCT01257802|Drug|depot leuprolide acetate 3.75 mg|Monthly depot leuprolide acetate 3.75 mg vs placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
1891295|NCT01257802|Drug|Placebo|Monthly placebo during cyclophosphamide administration. First dose of study drug given at least 10 days before following dose of cyclophosphamide if cyclophosphamide is given in biweekly or monthly boluses
1891296|NCT01257815|Drug|Ranibizumab|
1891297|NCT01257828|Drug|riluzole|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
1891298|NCT01257828|Drug|Placebo medication|50mg BID orally for 14 days prior to surgery and 28 days after the surgery
1891299|NCT01257841|Drug|Leptin administration|Leptin 0.05 mg/kg sc daily in divided doses (0800, 1400, 2000, and 0200h) for four days.
1891300|NCT01257841|Behavioral|Fasting|Complete fasting, save for water and multivitamin, for four days.
1891301|NCT01257867|Dietary Supplement|Lithia water|Oral intake of approximately 2 litres (2L) daily for 4 weeks
1891302|NCT01257867|Dietary Supplement|Natural spring water with negligible lithium levels|Oral intake of approximately 2 litres (2L) daily for 4 weeks
1891303|NCT01257893|Drug|Aspirin (acetylsalicylic acid)|Aspirin one 81 mg capsule per day for 10-14 consecutive days
1891304|NCT01257893|Drug|Placebo|1 placebo capsule identical in appearance and excipient to aspirin capsule per day for 10-14 consecutive days
1891305|NCT01257906|Drug|CLIND PHOSPHATE (1.2%) AND TRETINOIN (0.025%) TOPICAL GEL|Topical Gel applied in the evening for 84 days
1891306|NCT01257906|Drug|ZIANA®|Topical Gel applied in the evening for 84 days
1891307|NCT01257906|Drug|Vehicle Control|Topical Gel applied in the evening for 84 days.
1891308|NCT01257919|Drug|Azelaic Acid Foam|Dermal application of Azelaic Acid Foam
1891309|NCT01257919|Drug|Azelaic Acid Gel|Dermal application of Azelaic Acid Gel
1891310|NCT01257932|Device|Diffuse Optical Spectroscopy Imaging|Diffuse Optical Spectroscopy Imaging Breast Cancer Response to Neoadjuvant Chemotherapy
1891311|NCT01257945|Behavioral|Aerobic Exercise|
1891312|NCT01257945|Behavioral|Flexibility and Function exercise program|
1891313|NCT01257945|Behavioral|Home exercise program|
1891314|NCT01257958|Drug|19 nor vitamin d|
1891315|NCT01257984|Drug|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser supported by a reminder function
1891316|NCT01257984|Drug|BAY86-5300|0.02 mg EE as ß-CDC / 3 mg DRSP in a tablet form (1 tablet/day) for up to 120 days, followed by a 4-day tablet-free interval, administered with a dispenser without reminder support
1891317|NCT01257997|Biological|15N-Thymidine, 2H-Water|"Stable isotope 15N-thymidine, infused IV (15mg/hour) for 72 hours (phase 1 pilot).
Stable isotope 2H-water, ingested by mouth once per day for 3 days (phase 1 pilot) or 28 days (phase 2 pilot)."
1891318|NCT01258010|Drug|Tranexamic Acid|Bolus dose of 30 mg/kg of tranexamic acid followed by a continuous intravenous infusion of 16 mg/kg/h of tranexamic acid administered up to 6 hours after surgery.
1891319|NCT01258010|Drug|Placebo|Bolus dose of normal saline (NaCl 0.9%) of equivalent volume followed by a continuous intravenous infusion of NaCl 0.9% administered up to 6 hours after surgery.
1891320|NCT01258023|Biological|Fluad 1x|"15 µg antigen/strain:
A/California/07/2009 (H1N1) - like strain
A/Perth/16/2009 (H3N2) - like strain
B/Brisbane/60/2008- like strain MF59 adjuvant 9.75µg ai 0.5ml"
1891321|NCT01258036|Radiation|HRpQCT|High Resolution peripheral Quantitative Computerized tomography
1891322|NCT01258036|Biological|Sampling|Urine and blood samples
1891323|NCT01258036|Radiation|Bone absorptiometry|DXA at the lumbar spine, hip, radius and whole body
1891324|NCT01258049|Drug|Artemether Sublingual Spray|Artemether sublingual spray administered at 3 mg/kg (milligrams per kilogram) at specified timepoints
1891325|NCT01258049|Drug|Quinine|Quinine administered intravenously, 20 mg/kg loading dose followed by 10 mg/kg every eight hours
1891326|NCT01258062|Drug|GelVac™ nasal powder H5N1 influenza vaccine.|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
1891327|NCT01258062|Drug|Placebo|subjects will be randomized to either 30 µg of Inactivated H5N1 Influenza Vaccine Administered in GelVac™ Nasal Powder given as two doses of 15 μg in one nostril or placebo vaccine given as two doses administered in GelVac™ Nasal Powder in one nostril
1891328|NCT01258075|Drug|Welchol for oral suspension placebo proxy|placebo proxy for Welchol for oral suspension, 0.625 grams colesevelam hydrochloride
1891329|NCT01258075|Drug|Welchol for oral suspension|Welchol for oral suspension, 3.75 grams colesevelam hydrochloride
1891330|NCT01258088|Drug|AN2728 Ointment|5mg/cm2, BID
1891331|NCT01258088|Drug|AN2728 Vehicle|5mg/cm2 BID
1891332|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
1891333|NCT01258101|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 16 weeks
1891334|NCT01258101|Drug|ribavirin|800 mg orally daily
1891335|NCT01258101|Drug|ribavirin|400 mg orally daily
1891336|NCT01258114|Other|SPA treatment (ST)|"Drug: spa treatment soon after randomization :
Spa treatment of 18 days. Spa treatment : the most adapted to the concerned pathology and common to all of spa resorts (mineral water drinking, bath with automatic air (bubble bathing), mud body wrapping, manual massages, water exercises ;
nutritional counseling (french nutritional recommendations booklet) ;
caloric restriction and physical training on demand (non mandatory)."
1891337|NCT01258114|Other|Non SPA treatment (NST)|"Drug: General practitioner (GP) counselling After randomisation Verbal and/or written advice based on the French national guidelines for a healthy life style brochure (given to the patient by the GP at baseline)"
1891338|NCT01258140|Radiation|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
1891339|NCT01258140|Radiation|Computed tomography pulmonary angiography|CT pulmonary angiography using iodinated contrast agent
1891340|NCT01258153|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
1891341|NCT01258153|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
1891342|NCT01258153|Drug|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
1891343|NCT01258166|Procedure|Surgery or immobilization|
1891344|NCT01258179|Other|Analysis of PSP and PAP from venous blood samples|to analyse the peri-operative expression of pancreatic stone protein in surgical patients following major abdominal surgery
1891345|NCT01258192|Drug|albumin-bound paclitaxel plus cisplatin|neo-chemotherapy program:Albumin-bound paclitaxel:100 mg/m2, IV (in the vein) on days 1,8 of each 21 day cycle. Cisplatin 75mg/m2,IV DRIP on day 1 of each 21 day cycle.Number of Cycles: 2 cycles before operation.If it is effective ,2 cycles will be given in 6 weeks after radical resection.
1891346|NCT01258205|Drug|AMG 139|Four dose levels of AMG 139 administered as multiple doses IV or SC in healthy volunteers (Part A) and subjects with moderate-severe Crohn's disease (Part B).
1891347|NCT01258218|Device|Implantation of an Accent MRI device|Implantation of an Accent MRI device
1891348|NCT01258257|Procedure|Insertion of a lumbar drain|In patients in the LD group, after insertion of the drain CSF is drained slowly and steadily at a rate of approximately 5 ml per hour. This leads to a planned daily CSF drainage of about 120 ml per day via lumbar route. To facilitate accuracy of drainage, regular drainage control every other hour and stopping in case of unwarranted excess drainage is strongly recommended by the principal investigators. In case of neurological decline suspiciously related to the lumbar drainage, the drain is closed immediately and may be gradually restarted after 12 to 24 hours, after performing a CCT scan. The drain is planned to remain in place until the control angiography on day 7 to 10 after the initial hemorrhage.
1891349|NCT01258270|Procedure|Postop Dressing|The AQUACEL® Ag Surgical Dressing is a silver impregnated, waterproof, adhesive dressing that sticks to the skin around the wound and blocks bacteria from the outside.
1891350|NCT01258270|Procedure|Postop Dressing|A standard island dressing consists of adhesive tape and gauze.
1891351|NCT01258283|Other|Addional imaging|All patients will systematically have an 18F-FDG PET-CT (18F-fluorodeoxyglucose positron emission tomography/computed tomography) and a 123MIBG (Iodine 123 metaiodobenzylguanidine) scintigraphy
1891352|NCT01258296|Drug|Fentanyl|25 mcg/hr transdermal patch
1891353|NCT01258296|Drug|Inactive patch|placebo patch (no drug)
1891354|NCT01258309|Drug|olopatadine hydrochloride /ketorolac tromethamine fixed dose combination ophthalmic solution|One drop of olopatadine hydrochloride/ketorolac tromethamine fixed dose combination ophthalmic solution administered to each eye, twice daily for 21 days.
1891423|NCT01266811|Drug|Placebo, Velcade and dexamethasone|Siltuximab 11 mg/kg as 1 hour IV infusion on Day 1 of every cycle
1891355|NCT01258309|Drug|olopatadine hydrochloride 0.1% ophthalmic solution|One drop of olopatadine hydrochloride 0.1% ophthalmic solution administered to each eye, twice daily for 21 days.
1891357|NCT01258335|Dietary Supplement|Omega 3|Omega-3-fatty acids 4 gm oral daily (Total:840mg EPA/2520mg DHA) (1:3 ratio of EPA to DHA) ( 6 capsules fatty acids)
1891358|NCT01258335|Other|Olive Oil|ii. Placebo oral daily (6 softgel capsules, each contains 1100 mg olive oil)
1891359|NCT01258348|Drug|Drug: LY573636-sodium|"Patient specific dose based on height, weight and gender to target a specific exposure range, administered intravenously on day 4 of a 42 day (6 week) cycle.
Dose will be escalated to reach the maximum tolerated dose (MTD). A cohort of patients enrolled after MTD will receive albumin-tailored doses.
Patients may continue on treatment until clinical or objective disease progression."
1891360|NCT01258348|Drug|Sunitinib|37.5 mg, administered orally, daily for 42 days (6 weeks). Patients may continue on treatment until clinical or objective disease progression.
1891361|NCT01258361|Procedure|echocardiography|Echocardiography is performed for all patients
1891362|NCT01258374|Drug|Raltegravir|Raltegravir, 400 mg bid
1891363|NCT01258374|Drug|Darunavir|Darunavir, 800 mg QD + ritonavir 100 mg QD
1891364|NCT01258387|Drug|Glial growth factor 2/ Neuregulin 1β3|
1891365|NCT01258387|Other|Placebo|
1891366|NCT01258413|Procedure|Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by laparoscopic approach
1891367|NCT01258413|Procedure|Abdominal radical hysterectomy|uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by abdominal approach
1891368|NCT01258439|Drug|raltegravir plus truvada|raltegravir 400 mg tablet with truvada 300/200 mg tablet for 24 weeks
1891369|NCT01258439|Drug|Darunavir, ritonavir, tenofovir/emtricitabine (Truvada)|Darunavir two 400mg tablets with one ritonavir 100mg capsule once daily plus Tenofovir/emtricitabine (Truvada) one 300mg/200mg tablet once daily with food for 24 weeks
1891370|NCT01258452|Drug|CHF 5074|Drug is administered to subject in a fasting state
1891371|NCT01258452|Drug|CHF 5974|Drug is administered to subject after consumption of a high fat, high calorie meal
1891372|NCT01258465|Behavioral|Pivotal Response Training|Naturalistic behavioral protocol designed to teach vocal communication.
1891373|NCT01258465|Behavioral|Picture Exchange Communication System|Pictorially-based behavioral protocol designed to teach communication to nonverbal children via pictures icons.
1891374|NCT01258478|Other|Rehabilitation|Three weeks of outpatient, intensive physical rehabilitation before lung resection surgery.
1891375|NCT01258478|Other|Usual care|Usual care
1891376|NCT01258491|Drug|Nicotinic Acids|
1891377|NCT01258504|Drug|St. Johns Wort|"Administration of bosentan: 1 x 125 mg p.o. on days 1 and 20, 2 x 62.5 mg p.o. on day 2, 2 x 125 mg p.o. on days 3-19.
Administration of SJW: 3 x 300 mg daily p.o. on days 11-19 and 2 x 300 mg on day 20"
1891378|NCT01258517|Device|near infrared spectroscopy (INVOS 5100)|monitorization of cerebral oxygenation by INVOS 5100 during surfactant administration
1891379|NCT01258530|Drug|over-encapsulated oseltamivir|75 mg once
1891380|NCT01258530|Drug|oseltamivir|75 mg once
1891381|NCT01258543|Other|General Osteopathic Evaluation|2 general osteopathic evaluations of approximately 1 hour in duration done consecutively on the same day with a 15 minute break between evaluations
1891382|NCT01258556|Dietary Supplement|Yogurt supplemented with L. rhamnosus fiti|200 ml of L. rhamnosus fiti at 10*9 cfu/ml daily for 30 days.
1891383|NCT01258556|Dietary Supplement|Yogurt not supplemented with a probiotic strain.|200 ml yoghurt without L. rhamnosus fiti daily for 30 days.
1891384|NCT01258569|Drug|Entereg|Alvimopan (Entereg), an oral peripherally- acting mu-opioid receptor antagonist, is the first and only drug approved by the FDA to accelerate the time to upper and lower GI recovery in after partial large or small bowel resection surgery with primary anastomosis.
1891385|NCT01258569|Drug|Entereg|oral, 12 mg 30-300 min pre-op then BID up to 7 days (or 15 total doses)
1891386|NCT01258569|Drug|placebo|12 mg oral 30-300 min pre-op then BID up to 7 days (or 15 doses)
1891387|NCT01258582|Procedure|Oral HIV screening|Participants will undergo oral HIV screening and, if positive, further study visits for up to 6 months
1891388|NCT01258582|Procedure|Fingerstick HIV screening|Participants will undergo fingerstick HIV screening and, if positive, further study visits for up to 6 months
1891389|NCT01258595|Biological|High-Dose Trivalent Inactivated Influenza Vaccine|0.5 mL Intramuscular
1891390|NCT01258595|Biological|Trivalent Inactivated Influenza Vaccine|0.5 mL, Intramuscular
1891394|NCT01258621|Procedure|Laparoscopy|Laparoscopic distal pancreatectomy
1891395|NCT01258634|Drug|Dexrazoxane|"Preoperative Chemotherapy Courses 1, 2, 3, 4: 750mg/m2; IV over 15 minutes on day 1
Postoperative Chemotherapy for Good Responders Courses 1 and 2: 750mg/m2 IV over 15 minutes on Day 1
Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 750mg/m2 IV over 15 minutes on Day 1"
1891396|NCT01258634|Drug|Doxorubicin|"Preoperative Chemotherapy Courses 1 and 3: 75mg/m2; IV push day 1 Courses 2 and 4: 75mg/m2; IV push day 1, hour 0
Postoperative Chemotherapy for Good Responders Course 1: 75mg/m2; IV push day 1 Course 2: 75mg/m2; IV push day 1, hour 0
Postoperative Chemotherapy for Poor Responders Course 2: 75mg/m2; IV push day 1 Course 4: 75mg/m2; IV push day 1, hour 0"
1891424|NCT01266811|Biological|Siltuximab, Velcade and dexamethasone|Given in 21-day treatment cycles
1891425|NCT01266824|Drug|Proparacaine Hydrochloride Ophthalmic Solution|1 drop into each eye once prior to the first set of mydriatic (dilating) eye drops
1997324|NCT02125955|Dietary Supplement|Prebiotic fiber|Dissolved in water.
1997325|NCT02125955|Dietary Supplement|Placebo|Dissolved in water
1997326|NCT02123966|Drug|Sirolimus|
1891397|NCT01258634|Drug|Cisplatin|"Preoperative Chemotherapy Courses 1 and 3: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol
Postoperative Chemotherapy for Good Responders Courses 1 and 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol
Postoperative Chemotherapy for Poor Responders:
Course 2: 60mg/m2 daily x 2 days, in 1000 ml D5W NS + 10g/m2 mannitol"
1891398|NCT01258634|Drug|G-CSF|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000
Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000
Postoperative Chemotherapy for Poor Responders Courses 2, 4, and 5: 5mcg/Kg; IV/SQ starting 24 hours after chemotherapy until WBC >10,000"
1891399|NCT01258634|Drug|PEG-filgrastim|"Preoperative Chemotherapy Courses 1, 2, 3, and 4: 6mg; SQ starting 24 hours after chemotherapy
Postoperative Chemotherapy for Good Responders Courses 1, 2, and 3: 6mg; SQ starting 24 hours after chemotherapy
Postoperative Chemotherapy for Poor Responders Courses 2 and 4: 6mg; SQ starting 24 hours after chemotherapy"
1891400|NCT01258634|Drug|Etoposide|"Preoperative Chemotherapy Courses 2 and 4: 50mg/m2 on days 1, 2, 3, 4
Postoperative Chemotherapy for Good Responders Course 2: 50mg/m2 on days 1, 2, 3, 4 Course 3: 50mg/m2 on days, 1, 2, 3, 4 Hour 0-1
Postoperative Chemotherapy for Poor Responders Course 4: 50mg/m2 on days 1, 2, 3, 4 Course 5: 50mg/m2 on days 1, 2, 3, 4"
1891401|NCT01258634|Drug|Ifosfamide|"Preoperative Chemotherapy Courses 2 and 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4
Postoperative Chemotherapy for Good Responders Course 2: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 3: 3g/m2; IV over 1 hour Days 1, 2, 3, 4
Postoperative Chemotherapy for Poor Responders Course 4: 3g/m2; IV over 1 hour Days 1, 2, 3, 4 Course 5: 3g/m2; IV over 1 hour Days 1, 2, 3, 4"
1891402|NCT01258634|Drug|Mesna|"Preoperative Chemotherapy Courses 2 and 4: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)
Postoperative Chemotherapy for Good Responders Courses 2 and 3: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)
Postoperative Chemotherapy for Poor Responders Courses 4 and 5: 600mg/m2, 1st dose in bag with ifosfamide, 2nd dose IV over 3 hours immediately post ifosfamide infusion, Subsequent doses - hour 5, 8, 11, 14 (IV push)"
1891403|NCT01258634|Drug|Leucovorin|Postoperative Chemotherapy for Poor Responders Courses 1 and 3: 15 mg/m2/dose IV or PO every 6 hours, beginning 24 hours after start of methotrexate infusion and continuing until methotrexate level is <0.1 uM
1891404|NCT01258647|Dietary Supplement|caterpillar cereal|A 30 gram portion of a cereal containing one part dried, ground caterpillar, one part corn flour and small quantities of sugar and palm oil will be evaluated by the mothers and then fed daily for seven days to infants.
1891405|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg/Metafolin + folic acid placebo|Combination EE/DRSP/ Metafolin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP) + 0.451 mg Metafolin] given orally in a cyclic regimen for 24 weeks (6 cycles) in combination with folic acid placebo tablets (encapsulated). Each treatment cycle consisting of once daily hormone and Metafolin treatment for 21-days followed by once daily hormone free, Metafolin only regimen for 7 days. This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
1891406|NCT01258660|Drug|EE 0.03 mg/DRSP 3 mg (Yasmin) + folic acid|Yasmin [0.030 mg ethinylestradiol (EE) + 3 mg drospirenone (DRSP)] in combination with folic acid tablets 0.4 mg (encapsulated), given orally in a cyclic regimen for 24 weeks (6 cycles). Each treatment cycle providing once daily hormone and folic acid treatment for 21 days followed by once daily hormone free, folic acid only regimen for 7 days (encapsulated). This phase was followed by 20 weeks (5 cycles) folate elimination phase consisting of oral administration of Yasmin alone.
1891407|NCT01258673|Drug|Fimasartan/HCTZ combination|Fimasartan/HCTZ combination 60/12.5mg 120/12.5mg
1891408|NCT01258673|Drug|Fimasartan|Fimasartan 60mg, 120mg
1891409|NCT01258686|Drug|Silymarin|700mg thrice daily
1891410|NCT01258686|Drug|Placebo|Placebo 700mg thrice daily
1891411|NCT01258699|Drug|Thiocacid HR Tab 600mg|600mg for 1 day
1891412|NCT01258699|Drug|BK-C-0701 320mg|320mg for 1 day
1891413|NCT01258699|Drug|BK-C-0701 480mg|480mg for 1 day
1891414|NCT01258712|Drug|Tocilizumab + methotrexate(MTX)|Tocilizumab:8 mg/kg every4weeks,IV infusion methotrexate:10-20 mg/week
1891415|NCT01258712|Drug|Tocilizumab placebo + methotrexate(MTX)|Tocilizumab placebo:8 mg/kg every 4 weeks,IV infusion methotrexate:10-20 mg/week
1891416|NCT01258725|Procedure|amnioinfusion procedure|Single/serial amnioinfusions aimed at restoring amniotic fluid volume until a normal amount (AFI≥8cm).(Every pregnant women presenting with severe (AFI<5) idiopathic (with unknown origin) oligohydramnios is treated with amnioinfusion at our Dept.)
1891417|NCT01258738|Biological|etanercept|In Period 1, subjects will receive in a prefilled syringe with 1.0 ml (test article Etanercept (SC) once weekly . Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
1891418|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by their attending physician. The name and dose of this NSAID is the decision of the attending physician.
1891419|NCT01258738|Other|PLACEBO|In Period 1 will receive a prefilled syringe of Placebo for Etanercept Additionally they will continue to take the background non steroidal anti inflammatory drug(NSAID) in the tolerated dose agreed upon by the attending Physician.
1891420|NCT01258738|Drug|Background NSAID|Subject will continue to take a concomitant background non steroidal anti inflammatory drug(NSAID)as prescribed by attending physician (dose drug selection as tolerated and agreed upon by the attending Physician).
1891421|NCT01258751|Drug|PF-05212377|Single dose of up to 70 mg PF-05212377, delivered as .25 mg, 5 mg and/or 15 mg on study day 1
1891422|NCT01266798|Behavioral|Portal|"The portal was tailored to improve the lay public's' healthy skepticism, or in other words, critical and social literacy skills to assist patients in the decision-making process and for improving access to health information and participation. Illustrated by typical examples which can be found in the news and through patient stories, the portal provides an introduction to research methods, the underlying principles of science and critical assessment tools appropriate for a lay public.
A checklist for critical assessment of health information
Access to research databases for health information and an introduction to research methods and principles of science
A checklist to the consultation"
1891426|NCT01266837|Drug|Everolimus|10 mg p.o once daily
1891427|NCT01266850|Biological|Rotarix®|Each 1-mL dose of Rotarix® contains a suspension of at least 10^6 median Cell Culture Infective Dose (CCID50) of live, attenuated human G1P rotavirus after reconstitution. The lyophilized vaccine contains amino acids, dextran, Dulbecco's Modified Eagle Medium (DMEM), sorbitol, and sucrose. The liquid diluent contains calcium carbonate, sterile water, and xanthan. The diluent includes an antacid component (calcium carbonate) to protect the vaccine during passage through the acid environment of the stomach. Rotarix® contains no preservatives. Once reconstituted, the vaccine will appear white and turbid.
1891428|NCT01266850|Biological|RotaTeq®|2-mL ready-to-use oral solution of live reassortant rotaviruses, containing G1, G2, G3, G4, and P1A, which contains a minimum of 2.0 to 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IU per aggregate dose. The buffered stabilizer solution contains sucrose, sodium citrate, sodium phosphate monobasic monohydrate, sodium hydroxide, polysorbate 80, cell culture media, and trace amounts of fetal bovine serum. RotaTeq® contains no preservatives. RotaTeq® is a pale yellow clear liquid that may have a pink tint.
1891429|NCT01266863|Other|E test method|E test strips directly applied to BAL
1891430|NCT01266876|Drug|Alirocumab|Alirocumab two SC injections in the abdomen only.
1891431|NCT01266876|Drug|Placebo|Placebo two SC injections in the abdomen only.
1891432|NCT01266889|Device|device:INVOS 5100|Continuous wave NIRS is a method for measurement of cerebral oxygenation and haemodynamics. This method is non-invasive, continuous, and can also be used as bedside monitoring. With continuous wave NIRS only changes in concentration of oxyhaemoglobin (O2Hb) and deoxyhaemoglobin (HHb) can be measured, not the absolute level of these parameters. It has been shown that changes in concentration of HbD (O2Hb - HHb) reflect changes in CBF. So, continuous monitoring of changes in concentration of HbD can be used as an indicator of changes in CBF, but changes in CBV will also influence the HbD signal, as will changes in arterial O2 saturation (saO2) and changes in cerebral metabolic rate for oxygen.
1891433|NCT01266902|Drug|Rilpivirine|25 mg once daily
1891434|NCT01266928|Drug|vitamine C and E|Eligible and consenting women were randomly assigned to capsules containing a combination of 1,000 mg vitamin C (ascorbic acid) and 400 international units of vitamin E (RRR alpha tocopherol acetate)
1891435|NCT01266941|Drug|Inhaled FF 200mcg/GW642444M 25mcg|All subjects are scheduled to receive FF 200mcg/GW642444M 25mcg once daily for 7 days. The dose for subjects with severe hepatic impairment may be adjusted to FF 100mcg/GW642444M 12.5mcg after review of the PK and safety data from the moderate and healthy matched control subjects.
1891436|NCT01266954|Drug|GSK2141795|GSK2141795 is an oral, low nanomolar pan-AKT kinase inhibitor that demonstrates activity in hematologic and solid tumor cell lines. It also delays tumor growth in a dose dependent manner in solid tumor xenograft mouse models
1891437|NCT01266967|Drug|GSK2118436|Subjects in this study receive 150 mg of GSK2118436 twice daily and continue on treatment until disease progression, death, or unacceptable adverse event.
1891438|NCT01266980|Drug|Inhaled FF/ GW642444M (200/25mcg)|All subjects will be assigned to take FF/ GW642444M (200/25mcg) combination once daily for 7 days.
1891440|NCT01267006|Drug|GSK1325756|GSK1325756 will be available as white, film coated immediate release tablets with dose strengths of 50 mg, 100 mg and 200 mg. The tablets will be administered twice daily by oral route with 240 milliliters of water.
1891441|NCT01267006|Drug|Placebo tablet|Placebo will be available as white film coated GSK1325756 matching tablet which will be administered twice daily by oral route with 240 milliliters of water.
1891442|NCT01267019|Behavioral|social cognitive training with in vivo augmentation|24 sessions of social cognitive training plus 6 sessions of in vivo exercises
1891443|NCT01267019|Behavioral|social cognitive training|30 sessions of social cognitive training without in vivo exercises
1891444|NCT01267019|Behavioral|non-social skills training|30 sessions of skills training that has no specific social content
1891445|NCT01267032|Behavioral|Integrated Care|A PTSD-aware smoking cessation intervention developed by Miles McFall, PhD.
1891446|NCT01267032|Behavioral|Cognitive-Behavioral Treatment for Insomnia|A behavioral treatment aimed at improving sleep continuity and subjective sleep through stimulus control, sleep restriction, and attenuation of maladaptive sleep-related cognitions.
1891447|NCT01267032|Behavioral|Desensitization Treatment for Insomnia|A credible sham treatment for insomnia matching CBTI in treatment time, patient expectations, therapist expectations, etc.
1891448|NCT01267045|Behavioral|Mindfulness-based stress reduction|Mindfulness-Based Stress Reduction (MBSR) teaches mindfulness as a non-religious practice of self-observation and self-awareness. Kabat-Zinn developed MBSR in 1979 in response to a growing awareness that medical interventions were often inadequate at addressing chronic pain issues and restoring function and life satisfaction. He drew on his meditation and yoga training to develop this program as a complement to traditional medicine that could help patients live fully despite their chronic medical and psychiatric conditions. Through MBSR an individual's emphasis shifts from a preoccupation with what is wrong to a growing appreciation for what is right and what can be built upon.
1891449|NCT01267058|Biological|GSK Biologicals' combined diphtheria, tetanus, acellular pertussis vaccine|Intramuscular, single dose
1891450|NCT01267058|Biological|GSK Biologicals' acellular pertussis vaccine|Intramuscular, single dose
1891451|NCT01267058|Biological|Commonwealth Serum Laboratories' combined diphtheria and tetanus vaccine|Intramuscular, single dose
1891452|NCT01267071|Drug|A|GSK962040 (50 mg, SD, oral)
1891453|NCT01267071|Drug|B|14C GSK962040 (100 μg, SD, iv)
1891454|NCT01267084|Drug|Trabectedin|Patients will receive trabectedin 1.3 mg/m2 when given alone and 0.2mg/m2 when given with ketoconazole, intravenously (into a vein) for 3-hour.
1891455|NCT01267084|Drug|Ketoconazole|Patients will receive ketoconazole 1 X 200 mg tablet, two times a day, orally (by mouth)
1891456|NCT01267084|Drug|Dexamethasone or equivalent steroid|Patients will receive dexamethasone 20 mg or equivalent steroid intravenously, 30 minutes before trabectedin in each cycle.
1891487|NCT01267461|Other|Tissue sample from tumor|Endometrial cancer specimens will be obtained from patients operated and treated at the Gynecologic Oncology Unit at Meir Medical Center. Colon cancer specimens will be obtained from patients that underwent colonoscopy at the Gastrointestinal Department at Meir Medical Center.
1891539|NCT01267916|Device|RR 10 + 0|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 0
1891457|NCT01267097|Behavioral|Cognitive Behavioural Therapy (CBT)|Clinical research supports the use of CBT-based interventions in weight management for adults and children. However, the current study will advance the existing knowledge-base by combining CBT with the parents as agents of change approach for pediatric weight management. CBT is a theoretically-based therapy that focuses on the role that cognitive processes play in the maintenance of problem behaviours, mood states, and habits. CBT highlights the relationship between thoughts, feelings and actions, and utilizes techniques involving motivation, goal-setting, problem-solving, and knowledge/skill acquisition that can facilitate sustainable behaviour changes.
1891458|NCT01267097|Behavioral|Psycho-Education Program (PEP)|PEP is a knowledge-based intervention that is modelled after traditional nutrition and health education programs. Research has demonstrated that knowledge based programs can improve health behaviours and outcomes in overweight and obese populations. In relation to CBT, PEP is a more passive intervention and there is limited focus on active skill building. While PEP does not represent a true control group, its content and delivery are consistent with what many clinicians provide for weight management.
1891459|NCT01267110|Other|MI2 intervention arm|For persons who are randomized to the MI2 intervention arm, the HLK-BH program will guide participants through a series of questions to fully delineate step-by-step breast cancer screening intentions of participants the when, where and how of screening)and encourage follow through on these intentions.
1891460|NCT01267110|Other|Control|Each participant in the C intervention arm will receive the same brief one-on-one breast cancer screening education information delivered in person by a CHW as MI2 participants. In additional participants will go through the Healthy Living Kansas-Breast Health computerized screening and intervention program.
1891461|NCT01267123|Procedure|Trendelenburg position|The patient will be placed in the Trendelenburg position with a 15 degree angle of inclination
1891462|NCT01267123|Procedure|Standard care|The patient will be placed in the standard horizontal position
1891463|NCT01267266|Drug|saracatinib|Given orally
1891464|NCT01267266|Other|hydrocortisone/placebo|Given orally
1891465|NCT01267279|Drug|Zoledronic acid|Zoledronic acid per protocol
1891466|NCT01267292|Drug|Buspirone|[week 1: Buspirone 30 mg twice a day (9am and 6pm) on Monday through Sunday] [weeks 2-3: Buspirone 45 mg twice a day (9am and 6pm) on Monday through Sunday]
1891467|NCT01267292|Drug|Placebo for Buspirone|[week 1: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday] [weeks 2-3: Placebo for Buspirone twice a day (9am and 6pm) on Monday through Sunday]
1891468|NCT01267292|Drug|Methylphenidate|Methylphenidate serves as an acute stimulant challenge. [week 1: no Methylphenidate or Methylphenidate placebo] [week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
1891469|NCT01267292|Drug|Placebo for Methylphenidate|[week 1: no Methylphenidate or Methylphenidate placebo] [week 2: 0mg Methylphenidate (placebo for Methylphenidate) on Monday at 10am; Methylphenidate once a day (10am) on Wednesday and Friday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)] [week 3: Methylphenidate once a day (10am) on Monday and Wednesday, and on each of these 2 days the Methylphenidate dose will be different (15 mg, 30mg, 60 mg, or 0mg)]
1891470|NCT01267305|Drug|Fondaparinux|2.5mg IH qd(8AM) after operation
1891471|NCT01267305|Drug|Nadroparin Calcium|4100AxaIU IH qd(8AM) after operation
1891472|NCT01267305|Drug|Nadroparin Calcium|4100AxaIU IH q12h(8Am,8Pm) after operation
1891473|NCT01267331|Procedure|bone marrow mononuclear cells injection|Participants will receive direct intramyocardial injection of autologous bone marrow mononuclear cells during CABG.
1891474|NCT01267331|Procedure|placebo intramyocardial injection|Participants will receive between 10 and 15 placebo injections that consist of saline and 5% human serum albumin during CABG.
1891475|NCT01267344|Drug|gemcitabine, oxaliplatin|GEMOX (intravenous infusion of gemcitabine 800 mg/m2 at a fixed rate of 10 mg/m2/min followed by oxaliplatin 85 mg/m2 2-hour infusion, every 2 weeks
1891476|NCT01267344|Drug|cetuximab, gemcitabine, oxaliplatin|E-GEMOX: intravenous infusion of cetuximab (120 minutes for the 1st, 90 minutes for the 2nd and 60 minutes for all subsequent infusions) before GEMOX will be administered as above. All of the study medication will be administrated on day 1 every 2 weeks, which is regarded as one cycle.
1891477|NCT01267357|Other|no intervention|
1891478|NCT01267370|Dietary Supplement|Soy polysaccharide fiber|"Dietary Supplement: Soy polysaccharide fiber First, disimpaction was carried out with phosphate enemas for 1 to 3 days. After the children have been cleaned out, they received a soy polysaccharide fiber supplement (powder containing 70 g of fiber/100 g) or placebo (purified soy extract, with no fiber) for 6 weeks. Fiber and placebo were given as a standard dose for the different age groups (median of 0,57 g/kg/day) - 2 to 5 years, 10 g/day; 6 to 9 years, 15 g/day; and > 10 years, 20 g/day.
The child that had fecal impaction (a dilated rectum filled with a large amount of stool on rectal examination) during the follow-up was treated by administering phosphate enemas for 1 to 3 consecutive days.
Arms: Soy polysaccharide fiber, purified soy extract, with no fiber
Other Names:
Soy polysaccharide fiber (Pró-fibra®) Purified soy extract, with no fiber (Soyac®)"
1891479|NCT01267383|Drug|Sertraline|Sertraline Hydrochloride Tablets 100 mg
1891480|NCT01267396|Drug|Sertraline|Sertraline Hydrochloride Tablets 100 mg
1891481|NCT01267409|Other|STN stimulation|Manipulating emotional processing of PD patients by high and low frequency stimulation of their subthalamic area (through the 4 DBS contacts) after the surgery
1891482|NCT01267422|Drug|rAAV2-ND4|injection
1891483|NCT01267435|Procedure|Anterior cruciate ligament reconstruction|reconstruct the anterior cruciate ligament rupturing
1891484|NCT01267448|Drug|Glipizide XL|The control group will receive Glipizide XL (10mg orally) for a total duration of 12 weeks.
1891485|NCT01267448|Drug|Saxagliptin + Metformin XR|The intervention group will receive Saxagliptin 5 mg daily for a total duration of 12 weeks.
1891486|NCT01267448|Drug|Metformin XR|The intervention group will receive Metformin XR 1000 mg daily and will be automatically titrated weekly in 2 weeks to Metformin XR 2000 daily for a total duration of 12 weeks.
1891537|NCT01267903|Biological|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
1891488|NCT01267474|Other|Nutritional education|"A nutritional education program was carried out during seven months of one school year aiming to reduce added sugar in school meals by the school lunch cooks and in their own consumption.
All women in the intervention group participated in three sections about sugar consumption and one section on food labeling, as well as recipes competition of with reducing sugar.
Printed material and gifts, such as mugs, refrigerator magnets and small purses with the logo of the campaign were given to the participants.
All sections of education were delivered in the schools. The activities required 20 to 30 minutes and were facilitated by trained research assistants. Printed instructions and orientations on the facilitation process supported the assistants' efforts."
1891489|NCT01267474|Other|Control|The control group received only three one-hour general sessions on health issues.
1891490|NCT01267487|Drug|Heparin fixed doses|"Fixed doses of 400 units/ kg of patient's body weight before CPB to achieve an ACT > 480 sec. Supplemental doses of 50mg of heparin if ACT <480 sec during CPB.
Reversal doses of protamine in a 1:1 ratio (1mg of protamine for every mg of heparin administered), plus 0.8mg/kg of protamine at the end of the surgery."
1891491|NCT01267487|Drug|PO continuous infusion of Protamine|25mg/hour in IV continuous infusion during first 6 PO hours
1891492|NCT01267487|Drug|Heparin and protamine titration|"Titrated doses of heparin during CPB were manually calculated using Bull´s dose-response curve, which was based in periodic assessment of Activated-Coagulation Times (ACT)- baseline ACT, after 2mg/kg of heparin at cannulation and every 15 to 30 minutes during CPB.
Reversal doses of protamine were calculated as a 1:1 ratio of the actual estimated heparin concentration (in mg/kg) at the end of CPB, using the Bull´s dose response curve."
1891493|NCT01267500|Procedure|Non surgical therapy|patching or fusion exercises
1891494|NCT01267526|Device|Easypod™|Saizen (Somatotropin) administered by easypod™ as defined in SAIZEN® Canadian Product Monograph
1891495|NCT01267552|Procedure|Non drains will be placed during operation|Non drains will be placed during operation
1891496|NCT01267552|Procedure|Closed suction drainage|Closed suction drainage will be placed during operation
1891497|NCT01267565|Other|dosage of amylase|4 sets of aspirations on one day per inclusion in the intubated and ventilated patients group and 1 set of aspiration in the non intubated patients group
1891498|NCT01267578|Biological|vaccination|Biological/Vaccine: URLC10, CDCA1, and KOC1 peptides
1891499|NCT01267604|Drug|Recombinant FSH (rFSH)|225IU
1891500|NCT01267604|Dietary Supplement|rFSH + Inositol + Melatonin|225IU rFSH, 4g Inositol, 3mg Melatonin
1891501|NCT01267643|Drug|Alefacept|"Dose Escalation Schedule
Level -1 5 mg IV once weekly
Level 1 7.5 mg IV once weekly
Level 2 10 mg IV once weekly
Level 3 12.5 mg IV once weekly"
1891502|NCT01267669|Drug|Somatostatin|Emergency EVL plus Somatostatin (250 mcg/hr) infusion for 5 days
1891503|NCT01267669|Drug|Placebo|Emergency EVL plus placebo infusion for 5 days
1891504|NCT01267682|Behavioral|Cognitive Stimulation|Thirty minutes of cognitive stimulation delivered daily for thirty minutes.
1891505|NCT01267695|Drug|imatinib mesylate|Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.
1891506|NCT01267695|Procedure|conventional surgery|All the patients should receive elective surgery with R0 resection.
1891507|NCT01267721|Procedure|Blood sampling|Blood sampling at various time points. Additional 92 mL blood.
1891508|NCT01267734|Device|Everolimus-eluting coronary stenting system (EECSS, Promus Element)|Everolimus-eluting stent
1891509|NCT01267734|Device|Zotarolimus-eluting coronary stenting system (ZECSS, Endeavor Resolute)|Zotarolimus-eluting stent
1891510|NCT01267734|Drug|Triple anti-platelet therapy (TAT)|100mg Aspirin QD + 75mg Clopidogrel QD + 100mg Cilostazol BID for 1 month
1891511|NCT01267734|Drug|Double-dose clopidogrel anti-platelet therapy (DDAT)|100mg Aspirin QD + 150mg Clopidogrel QD for 1 month
1891512|NCT01267760|Device|Multipass hemodialysis|8-hour dialysis using a recycled dialysis bath of 25-30 l
1891513|NCT01267773|Behavioral|Integrated Treatment|
1891514|NCT01267786|Procedure|Liver surgery|hepatectomy
1891515|NCT01267812|Drug|bortezomib|Given SC or IV
1891516|NCT01267812|Biological|rituximab|Given IV
1891517|NCT01267812|Other|laboratory biomarker analysis|Correlative studies
1891518|NCT01267812|Other|immunohistochemistry staining method|Correlative studies
1891519|NCT01267812|Genetic|RNA analysis|Correlative studies
1891520|NCT01267812|Genetic|gene expression analysis|Correlative studies
1891521|NCT01267812|Genetic|DNA analysis|Correlative studies
1891522|NCT01267812|Other|pharmacological study|Correlative studies
1891523|NCT01267812|Other|pharmacogenomic studies|Correlative studies
1891524|NCT01267812|Other|Questionnaire Administration|
1891525|NCT01267825|Drug|CT-guided corticosteroid+ bupivicaine|CT-guided corticosteroid+ bupivicaine Also get standard medical care
1891526|NCT01267825|Drug|Standard medical care|Naproxen + Oxycodone/ Acetaminophen
1891527|NCT01267838|Procedure|PCI|PCI of bifurcation lesions with double stenting
1891531|NCT01267877|Other|read unfavorable article prior to answering questions|"article title: Taking a hit on healthcare- why that's women's work"
1891532|NCT01267877|Other|read favorable article prior to answering questions|"read A Backlash of Mistrust"
1891533|NCT01267903|Biological|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28,modern medicines
1891534|NCT01267903|Biological|vaccine against EV71 of 640U/0.5ml|inactivated vaccine(vero cell) against EV71 of 640U/0.5ml on day0,28
1891535|NCT01267903|Biological|vaccine against EV71 of 160U/0.5ml|inactivated vaccine(vero cell) against EV71 of 160U/0.5ml on 0,28 day
1891536|NCT01267903|Biological|vaccine against EV71 of 320U/0.5ml|inactivated vaccine(vero cell) against EV71 of 320U/0.5ml on day0,28
1891538|NCT01267916|Device|RR 6 + 0|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 0
1891540|NCT01267916|Device|RR 16 + 0|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 0
1891541|NCT01267916|Device|RR 6 + 5|Respiratory rate 6 Tidal volume 16.7 ml/kg external PEEP = 5
1891542|NCT01267916|Device|RR 10 + 5|Respiratory rate 10 Tidal volume 10 ml/kg external PEEP = 5
1891543|NCT01267916|Device|RR 16 + 5|Respiratory rate 16 Tidal volume 6.25 ml/kg external PEEP = 5
1891544|NCT01267929|Procedure|The mirror neurons stimulation based VCD program|The children receive the mirror neurons stimulation based VCD program and practice at home three times a day for six months.
1891545|NCT01267929|Procedure|The conventional physical therapy|The children were randomly assigned to receive the conventional physical therapy for six months. Both experimental and control groups were measured their motor functions with GMFM-66 by an independent pediatric physical therapist who was blinded for treatment allocation at entry, the second month and the sixth month.
1891546|NCT01267942|Drug|Enhancin|"Intravenous Enhancin at induction at a dose of 25 mg/kg amoxycillin equivalent.
Oral dose of the same at the same dosage for the active comparator arm."
1891547|NCT01267955|Other|Laboratory Biomarker Analysis|Correlative studies
1891548|NCT01267955|Other|Pharmacogenomic Study|Correlative studies
1891549|NCT01267955|Drug|Vismodegib|Given PO
1891550|NCT01267968|Drug|GSK2251052|1500 mg (dosing detailed in Arm description)
1891551|NCT01267981|Drug|Standard diet|"After the lunch the day before the exploration, drink only clear liquids and stop solid food.
From 10 pm, stay fasting, don't drink except the usual drugs taken with mouthful of water until the exploration by video-capsule endoscopy."
1891552|NCT01267981|Drug|Standard Diet + 500 ml of polyethyleneglycol|Apply the standard diet and drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
1891553|NCT01267981|Drug|Standard diet + 2 liters of polyethylene glycol the day before + 500ml of polyethylene glycol|apply the standard diet and drink 2 liters of polyethylene glycol between 19h and 21h the day before exploration. Then drink 500 ml of polyethylene glycol 30 minutes after the endoscopy video-capsule ingestion.
1891554|NCT01267994|Drug|Anakinra|100mg of anakinra administered by a subcutaneous injection for 84 consecutive days.
1891555|NCT01268020|Drug|[18F]-FMH3|Subjects will be injected with up to 5 mCi and not to exceed 5.5mCi (not >10% of 5 mCi limit) or 2 ug of [18F]-FMH3, whichever is greatest.
1891556|NCT01268033|Drug|Rituximab|two infusions - at the dose of 375 mg/m²- will be administered at one week of interval
1891557|NCT01268033|Drug|Placebo|two infusions - at the dose of 375 mg/m² - will be administrered at one week of interval
1960647|NCT03161327|Device|ABI using QuantaFlo™|"Perform Digital ABI:
Will be performed by the nurse/medical assistant with training to perform this test
The patient will be placed in the supine position, with the arms and legs at the same level as the heart, for a minimum of 5 minutes before measurement.
The optical sensor (similar to a pulse oximeter) will be placed sequentially in the fingers of the hands and feet: Right and left hand fingers and then right and left feet toes.
Usually each digit takes about 15 seconds to obtain a waveform
At the end of 60 seconds, an automated digital ABI will be generated.
Clinical course: If based on Screening questionnaire and digital ABI, I. Patient is diagnosed with PAD- the referring physician and patient will receive a phone call about the same. He/ she will then be advised any further testing/ referral to IR clinic.
II. There is no evidence of PAD- no further action will be taken. The patient will be informed of the same."
1891563|NCT01268085|Other|Radiation Alert|A radiation safety pop-up alert with a message about the dangers of cumulative ionizing radiation, the patient's cumulative CAT scan history, and the most recent imaging test from any modality of the same body part
1891564|NCT01268085|Other|Control|Control with no inverention
1891565|NCT01268098|Drug|NPSP558|All patients will inject NPSP558 25 or 50 µg SC QD into alternating thighs in the morning via a multidose injection pen device.
1891566|NCT01268111|Drug|Ergocalciferols|ERgocaclciferol 50,000 units weekly for 8 weeks
1891567|NCT01268111|Drug|Placebo|matching placebo
1891568|NCT01268124|Drug|HTC-867|
1891569|NCT01268137|Procedure|Deep Brain Stimulation|Surgical electrode implantation in the white matter adjacent to the Cg25 region and implantation of the DBS pulse generating device
1891570|NCT01268150|Drug|Eribulin mesylate|Eribulin mesylate 1.4 mg/m2 will be administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
1891571|NCT01268163|Drug|European Taxotere®|60-100 mg/m^2 IV
1891572|NCT01268163|Drug|American Taxotere®|60-100 mg/m^2 IV
1891573|NCT01268163|Drug|Hospira Docetaxel Injection|60-100 mg/m^2 IV
1891574|NCT01268176|Dietary Supplement|cholecalciferol|50,000 IU once per month for 3 months
1891575|NCT01268189|Device|Oxygen diffusing dressing|Oxygen diffusing dressing applied to study wound
1891576|NCT01268189|Device|Standard of care dressing|Xeroform control dressing applied to control wound
1891577|NCT01268202|Drug|Pravastatin|Pravastatin 40mg/day during 12 months
1891578|NCT01268215|Drug|Infasurf|Endotracheal instillation of Infasurf once per week for three weeks
1891579|NCT01268215|Drug|Pulmicort|Endotracheal instillation, once per week for three weeks
1891580|NCT01268215|Other|Sham|None instilled through the endotracheal tube
1891581|NCT01268267|Device|Ninja 2 Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter and an investigational sensor. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
1891612|NCT01268527|Drug|0.005% E6201|Topical 0.005% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
1891747|NCT01269411|Other|pharmacological study|Correlative studies
1891585|NCT01268293|Drug|E7080|This arm will be a dose-escalation evaluation of 9-18 subjects to investigate the tolerability and safety of E7080 up to 24 mg when administered orally on a once daily continuous dose schedule in cycles (4 weeks as 1 cycle). Administration of the study drug can continue until subjects meet discontinuation criteria such as disease progression, intolerable toxicity, and withdrawal of study consent.
1891586|NCT01268306|Device|B+L Biotrue MPS and B+L PureVision|Subjects use Bausch & Lomb (B+L) Biotrue MPS with B+L PureVision contact lenses
1891587|NCT01268319|Device|Embolic Protection Device (EPD)|"The embolic protection device consists of a protection wire, a delivery sheath, a retrieval sheath and various accessories (wire torque device, introducer, dilator tool). The wire of the EPD is used as a standard 0.014 steerable guide wire. The filter is designed for embolic debris capture while maintaining continuous blood flow. At the completion of the procedure, the filter and its contents are removed using the retrieval sheath and then removed from the patient."
1891588|NCT01268319|Device|Intracoronary Spectroscopy and Ultrasonic Evaluation|This intervention requires a near infrared imaging catheter equipped with an intravascular ultrasonic transducer be used to evaluate the coronary artery wall prior to treatment and after treatment. This system detects the lipid containing plaques that may be the source of embolic debris released during standard angioplasty and stent placement.
1891589|NCT01268319|Device|Angioplasty and Stent Implant|The target plaque will be treated with a pre-dilation with a standard angioplasty balloon sized to within 0.5mm of the diameter of the reference vessel diameter. The physician will then implant a coronary artery stent that is appropriately sized for the reference vessel diameter.
1891590|NCT01268332|Drug|Non-medicated Intravaginal Ring|Cured silicone elastomer composed of an elastomer base, normal propylorthosilicate, and titanium dioxide. The ring will not contain an active pharmaceutical ingredient.
1891591|NCT01268345|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being
1891592|NCT01268345|Device|blood glucose monitor|Blood glucose monitor is used to monitor the blood glucose level of the human-being.
1891593|NCT01268358|Drug|Lamazym|Lamazym, ERT, infusion weekly
1891594|NCT01268371|Device|Promus Element, Boston Scientific Corporation|Everolimus-eluting stent
1891595|NCT01268371|Device|Nobori, Terumo Corporation (Japan)|Biolimus-eluting stent with biodegradable polymer
1891596|NCT01268384|Drug|Gemcitabine plus Capecitabine|Gemcitabine 1,250 mg/m2 mixed with 0.9% saline 500 ml i.v. for 10 mg/m2/min on D1 and D8 Capecitabine 950 mg/m2 b.i.d. po from D1 to D14 every 21 days
1891597|NCT01268397|Procedure|open reduction and internal fixation with a volar plate|flexor carpi radialis approach, open reduction, fixed-angle volar plate, plaster cast 2 weeks at the surgeon's discretion
1891598|NCT01268397|Procedure|closed reduction and plaster treatment|closed reduction, below elbow plaster cast for 5 week
1891599|NCT01268423|Procedure|Percutaneous tracheostomy|Percutaneous tracheostomy within the first 4 days of mechanical ventilation.
1891600|NCT01268423|Procedure|Prolonged translaryngeal intubation|Prolonged endotracheal intubation, and reevaluation at day 10 to establish the requirement of percutaneous tracheostomy. If clinical condition determines that the patient needs a percutaneous tracheostomy, this will be performed between days 11 and 14.
1891601|NCT01268449|Radiation|Low dose laser|5mv laser with a wavelength of 650nm
1891602|NCT01268449|Radiation|Placebo|The act of radiating laser to the ear is done while the set is off.
1891603|NCT01268462|Other|Heliox+PEP|For the nebulization with heliox was used radioaerosol a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to the PEP. PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a flow of 11 l / min of heliox for the heliox group according to the protocol of Hess et al. When powered by heliox mixture, the flow was adjusted flowmeter suitable for this mixture.
1891604|NCT01268462|Other|Oxygen+PEP|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). This mask was attached to the patient's face to prevent leaks and maintain proper pressurization and better patient compliance to PEP (Figure 2). PEP was offered to 10 cm H2O through valve (Vital Signs, Totowa, NY) attached to the expiratory branch. The nebulizer was fed by a stream of 8 l / min oxygen.
1891605|NCT01268462|Other|Heliox|For the nebulization with heliox we used a noninvasive delivery system that consists of a nontoxic orofacial mask with two unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
1891606|NCT01268462|Other|Oxygen|For nebulization of radioaerosol with oxygen, we used a noninvasive delivery system that consists of a mask with two nontoxic orofacial unidirectional valves - inspiratory and expiratory branch - connected to the nebulizer for radioisotopes Venticis ® II Medical device, class II, CE 0459 (Ventibox / CIS Bio International, France). We used a PEP valve without resistance.
1891607|NCT01268488|Device|Ninja 2 Investigational Blood Glucose Meter|Untrained subjects with diabetes performed Blood Glucose(BG) tests from the subject's capillary blood obtained from fingerstick, palm, and forearm using the Ninja 2 investigational meter. All BG results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
1891608|NCT01268501|Device|Lotrafilcon B multifocal contact lens|Commercially marketed, silicone hydrogel, multifocal, soft contact lenses FDA-approved for up to 4 weeks recommended replacement schedule and up to 6 nights of extended (overnight) wear.
1891609|NCT01268527|Drug|0.03% E6201|Topical 0.03% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
1891610|NCT01268527|Drug|0.1% E6201|Topical 0.1% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
1891611|NCT01268527|Drug|0.2% E6201|Topical 0.2% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
1891658|NCT01268839|Drug|Efavirenz|600mg tablet once daily for 14 days
1891613|NCT01268527|Drug|0.01% E6201|Topical 0.01% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
1891614|NCT01268527|Drug|0.05% E6201|Topical 0.05% E6201 gel was applied once daily to individual specific regions of the psoriatic plaque.
1891615|NCT01268527|Other|Placebo - 0.03% gel vehicle|Topical 0.03% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
1891616|NCT01268527|Other|Placebo - 0.1% gel vehicle|Topical 0.1% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
1891617|NCT01268527|Other|Placebo - 0.2% gel vehicle|Topical 0.2% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
1891618|NCT01268527|Other|Placebo - 0.05% gel vehicle|Topical 0.005% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
1891619|NCT01268527|Other|Placebo - 0.01% gel vehicle|Topical 0.01% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
1891620|NCT01268527|Other|Placebo - 0.05% gel vehicle|Topical 0.05% gel vehicle (negative control) was applied once daily to individual specific regions of the psoriatic plaque.
1891621|NCT01268527|Drug|Calcipotriene|Topical 0.005% calcipotriene (positive control) was applied once daily to individual specific regions of the psoriatic plaque.
1891622|NCT01268540|Device|FY-60AD|Phacoemulsification cataract extraction followed by implantation of an aspheric non-toric intraocular lens: Model FY-60AD.
1891623|NCT01268540|Device|NHT15, NHT30, & NHT53|Phacoemulsification cataract extraction followed by implantation of an aspheric toric intraocular lens: Model NHT15, NHT30, or NHT53.
1891624|NCT01268553|Drug|Treprostinil|Transition to inhaled treprostinil
1891625|NCT01268566|Drug|MEDI-575|MEDI-575 as an IV infusion.
1891626|NCT01268579|Drug|ribavirin|The clinical intervention in this study is ribavirin therapy for approximately 14 days. Ribavirin 800 mg/day is administered in divided doses, 400 mg PO qAM and 400 mg PO qPM.
1891627|NCT01268592|Procedure|oocyte vitrification|freezing of the patient's retrieved oocytes via vitrification (rapid freezing)
1891628|NCT01268605|Procedure|Restoration with a dentin bonding agent (DBA)|Restoration with a dentin bonding agent (DBA) and hybrid resin-based composite: Use of a self-etch DBA Clearfil SE Bond followed by Herculite Ultra resin-based composite (Sybron/Kerr), comprising a state-of-the-art bonding and restoration system for cervical lesions.
1891629|NCT01268605|Procedure|Restoration with a resin modified glass ionomer liner (RMGI)|Restoration with a resin modified glass ionomer liner (RMGI) (Vitrebond LC, placed on the pulpal floor at a thickness of approximately 0.5 mm) followed by application of a two step self etch DBA and nanofilled resin based composite (RBC).
1891630|NCT01268618|Dietary Supplement|Probiotic|"2 capsules, 3x/day capsules of Healthy Trinity (retail label)/Trenev Trio (professional label), for a total daily dose of:
Lactobacillus acidophilus NAS, 30 billion CFU
Bifidobacterium bifidum Malyoth, 120 billion CFU
Lactobacillus delbrueckii subspecies bulgaricus LB-51, 30 billion CFU"
1891631|NCT01268618|Dietary Supplement|Placebo|2 capsules, 3x/day placebo capsules
1891632|NCT01268631|Drug|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks. The assessing person will contact patients by phone every week during the treatment period to receive the pain score for the last 24 hours, so we will have an indication of the effect among patients will discontinue medication. Patients will be asked to visit the clinic during the last week of treatment, for assessment of clinical pain (questionnaires) and pain modulation.
1891633|NCT01268631|Drug|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 4 weeks. Drug should not be taken with meals. Same protocol will be applied as for Duloxetine.
1891634|NCT01268644|Drug|Leptin|weight based sub-cutaneous injection twice daily of Leptin
1891635|NCT01268657|Behavioral|Education|Learning about anxiety
1891636|NCT01268657|Behavioral|Relaxation Training|Learning skills to reduce tension
1891637|NCT01268657|Behavioral|Cognitive Restructuring|Learning skills needed to cope better with distressing thoughts
1891638|NCT01268657|Behavioral|Behavioral Activation|Learning to initiate healthy activity
1891639|NCT01268657|Behavioral|Exposure|Coaching in how to confront avoided thoughts, situations, and people)
1891640|NCT01268670|Drug|Ibuprofen|Subjects will receive topical LET and oral ibuprofen.
1891641|NCT01268670|Drug|Oxycodone|Subjects will receive topical LET and oral oxycodone.
1891642|NCT01268670|Other|Placebo|Subjects will receive topical LET and oral placebo.
1891643|NCT01268683|Drug|RP-1127 (Glyburide for injection)|Bolus plus 72 hour IV infusion
1891644|NCT01268709|Drug|Doxepin|
1891645|NCT01268709|Drug|Nortriptyline|
1891646|NCT01268709|Drug|placebo|
1891647|NCT01268722|Device|Balloon angioplasty|This arm will include patients randomized to undergo the treatment of a chronic total occlusion of the femoropopliteal artery with the use of balloon angioplasty
1891648|NCT01268722|Device|Primary stenting|This arm will include patients randomized to undergo primary stenting of the femoropopliteal chronic total occlusion
1891649|NCT01268735|Drug|Lubricating eyedrops containing hydroxypropyl-guar|Eyedrops BID
1891652|NCT01268761|Drug|GnRH antagonist (Cetrorelix)|•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval
1891653|NCT01268761|Drug|Placebo (saline solution)|• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval
1891654|NCT01268787|Biological|EV71 vaccine|Two-vaccination 0.25ml or 0.5ml dose assigned to two groups.
1891655|NCT01268813|Other|Breath analysis and blood analysis|Exhaled breath and blood samples will be collected and further tested using Gas Chromatography-Mass Spectroscopy system.
1891656|NCT01268839|Drug|TMC278|25mg tablet once daily for 28 days
1891657|NCT01268839|Drug|TMC278|25mg tablet once daily for 14 days
1891659|NCT01268852|Device|Damon self ligating orthodontic bracket|Orthodontic treatment with Damon self ligating bracket
1891660|NCT01268852|Device|Insignia self ligating orthodontic bracket|Orthodontic treatment with Insignia self ligating bracket
1891661|NCT01268891|Drug|Placebo|Once daily; tablet; orally; 18 weeks
1891662|NCT01268891|Drug|Azilect®|1 mg daily; tablet; orally; 18 weeks
1891663|NCT01268904|Drug|Valproate|Intravenous valproate application to pediatric patients suffering from status epilepticus and acute repetitive seizures
1891664|NCT01268917|Drug|aspirin|aspirin 100mg daily until the surgery day
1891665|NCT01268917|Drug|aspirin|aspirin is stopped 5-7 days before operation
1891666|NCT01268930|Procedure|Bipolar electrocautery for ovarian hemostasis|after surgical excision of ovarian endometrioma with cyst wall, bipolar electrocoagulation is used to control of bleeding.
1891667|NCT01268930|Procedure|hemostatic matrix (FloSeal)|after surgical excision of ovarian endometrioma with cyst wall, hemostatic matrix is administered to the bed of cyst for 2-3 minutes to control of bleeding. Then, area is rinsed and hemostasis is checked.
1891668|NCT01268943|Drug|Capecitabine|oral pills, 1000mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
1891669|NCT01268943|Drug|Capecitabine|oral pills, 1200mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
1891670|NCT01268943|Drug|Capecitabine|oral pills, 1400mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
1891671|NCT01268943|Drug|Capecitabine|oral pills, 1500mg/m2/d, split in two times, d1-14, d22-35 combined with concurrent pelvic radiation.
1891672|NCT01268969|Procedure|KARYDAKIS GROUP|The technique consisted of a vertical eccentric elliptical incision carried down to the post sacral fascia, complete removal of unhealthy tissue with the normal tissue around the cyst and sinus tracts, mobilization of the medial wound edge by undercutting the adipose tissue at a depth of 1 cm, the advancement of the flap across the midline to the post sacral fascia and suturing of its edge to the lateral one
1891673|NCT01268969|Procedure|Lamberg flap technique|The area to be excised was mapped on the skin in a rhomboid form . The skin incision was deepened to the presacral fascia centrally and to the gluteal fascia laterally. After removing the specimen, the Limberg fasciocutaneous flap was prepared by extending the incision down to and through the right gluteus maximus fascia
1891674|NCT01268982|Procedure|socket preservation|sockets will be filled with DFDBA and covered with absorbable membrane. Primary coverage will be achieved by full thickness mucosal flap advancement over each socket
1891675|NCT01268995|Drug|Cyclosporine A|"Patients randomized into arm A will be switched from Tacrolimus to Cyclosporine A. Conversion will be done by a stop and go protocol. Patients will take their last dose Tacrolimus in the morning of the day of conversion and will start taking Cyclosporine A in the evening of the same day at a dose of 3mg/kg/d. The first measurement of Cyclosporine A trough levels will be performed 3 days after conversion and the dose will then be adjusted if necessary. Furthermore, treatment with NPH insulin once daily in the morning will be initiated."
1891676|NCT01268995|Drug|Tacrolimus|Patients in arm B will remain on their immunosuppressive therapy with Tacrolimus. Furthermore, treatment with NPH insulin once daily in the morning will be initiated.
1891677|NCT01269008|Device|Medtronic ePID 2.0|Closed loop system is an automated insulin delivery system based on body blood sugar. It consists of an Insulin pump, glucose sensor, and a device presently a laptop with all the algorithms.
1891678|NCT01269021|Drug|mycophenolate mofetil plus lower dose of Prednisone|MMF 1.0-1.5g/d*6mons Prednisone 0.4-0.6 mg/kg/d
1891679|NCT01269021|Drug|Prednisone in full dose|0.8-1mg/kg/d
1891680|NCT01269034|Drug|Exenatide|1.25 mcg before the boost sub-cutaneously.
1891681|NCT01269034|Drug|Rapid and long acting insulin|Depends on their Carbohydrate ratio and body needs
1891682|NCT01269034|Drug|long acting insulin + rapid acting + 1.25 mcg Exenatide|Depends on their body needs.
1990691|NCT01873573|Other|Triamcinolone Injection|Triamcinolone is a generic name of a long-acting synthetic corticosteroid and approved for sale in the United States by the U.S. Food and Drug Administration (FDA). After endoscopic dilation is performed, a total of 40-80 mg (physician preference) of triamcinolone (40 mg/ml) will be injected throughout the stricture under direct visualization.
1891686|NCT01269060|Procedure|Single Incision Laparoscopic Surgery|Single Incision Laparoscopic Sigmoidectomy
1891687|NCT01269086|Behavioral|Family Preventive Visit|Systematic assessment of health diseases or risk factors in the spouse and adolescent child.
1891688|NCT01269099|Drug|IV-PCA|IV-PCA (fentanyl 10 mcg/ml) Dose bolus-lock out time - basal = 1.5 ml - 15 min - 1.5 ml/hr
1891689|NCT01269099|Drug|Control|control group (No-PCA group)
1891690|NCT01269112|Device|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:
Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
1891691|NCT01269112|Device|citrate regional anticoagulation|"Patients randomly allocated to 2 treatment groups:
Treatment A: - Regional citrate-based anticoagulation with the Prismocitrate® 10/2 solution (GAMBRO) Treatment B: - Standard unfractionated heparin anticoagulation"
1891692|NCT01269125|Drug|Leuprolide|single injection of 3.75 leuprolide every 28 days, 3 dosages
1891693|NCT01269125|Procedure|IVF|Assisted Reproduction Technique.
1891694|NCT01269138|Drug|plasma derived Factor VII|Treatment of bleeding episodes,treatment during surgery and prophylaxis
1891695|NCT01269138|Drug|recombinant FVIIa|Treatment of bleeding episodes,treatment during surgery and prophylaxis
1891696|NCT01269138|Drug|Fresh Frozen Plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
1891697|NCT01269138|Drug|Activated Prothrombin Complex Concentrates|Treatment of bleeding episodes,treatment during surgery and prophylaxis
1891698|NCT01269138|Drug|Virus Inactivated plasma|Treatment of bleeding episodes,treatment during surgery and prophylaxis
1891699|NCT01269151|Drug|Lucentis (Ranibizumab)|Ranibizumab Short- and Log-term Effects on Retinal Function measured by Multifocal-ERG and Microperimetry
1891700|NCT01269164|Procedure|Surgical Procedure Composite Facial Transplant|Single Center Prospective Clinical Study to Document the Safety and Feasibility of the Surgical Procedure for Composite Facial Allograft Transplantation
1891746|NCT01269411|Procedure|therapeutic conventional surgery|Undergo surgery
1891701|NCT01269177|Device|Non invasive ventilation|"Indications for the use of NIV are at least one of the following:
Respiratory Rate ≥ 30 bpm
PaO2/FiO2 < 200
pH < 7.35 and PaCO2 > 45 mmH
Contraindications for the use of NIV are at least one of the following:
Coma
Hemodynamic instability / shock
Lack of compliance
Indications for endotracheal intubation (ETI) are at least one of the following:
Respiratory or cardiac arrest
Coma
Hemodynamic instability"
1891702|NCT01269190|Drug|Proflavine|Swabbing of inside mouth with cotton-tip applicator soaked in 0.01% proflavine hemisulfate, a fluorescent dye which glows green in the dark, placed on proposed evaluation sites for up to 30 seconds.
1891703|NCT01269190|Procedure|Imaging|Imaging of inside mouth with multi-spectral digital microscope (MDM), the Identafi 3000, or portable screening system (PS2 or PS2.1) done first prior to swab with normal white light and second post swabbing of mouth with Proflavine at high magnification with High-Resolution Microendoscope (HRME).
1891704|NCT01269190|Device|Widefield Multispectral Imaging Devices|Widefield multispectral imaging device used for imaging inside mouth: the Multi-spectral digital microscope (MDM) and/or the Identafi 3000 handheld system, and/or portable screening system (PS2 or PS2.1) both before and after Proflavine swabbing.
1891705|NCT01269190|Device|High-Resolution Microendoscope (HRME)|High-resolution optical system used for imaging of inside mouth post proflavine application.
1891706|NCT01269203|Drug|Curcumin|1000 mg per day
1891707|NCT01269203|Other|Placebo|Administered daily same as Curcumin.
1891708|NCT01269216|Drug|5-FU with leucovorin|5FU 400mg/m2/day with Leucovorin 20mg/m2/day IV on day 1 and day29
1891709|NCT01269216|Drug|TS-1 with Irinotecan|Irinotecan 40mg/m2/day IV on day 1,8,15,22 and 29 with TS-1 70mg/m2/day PO for 25 days
1891710|NCT01269229|Drug|folfox|FOLFOX: Day1- Oxaliplatin 85mg/m2, Leucovorin 200mg/m2, 5-FU 400mg/m2 IV bolus -> 2400mg/m2 46hrs continuous
1891711|NCT01269229|Radiation|short course Radiotherapy|After FOLFOX 4cycle, subject have short course RTx 5Gy at once this should be continuing for 5days so that subject should have 25Gy within 5days. Then, subjects have another 4 cycle of FOLFOX and evaluate cancer for resection.
1891712|NCT01269242|Drug|bindarit|300 mg bid, that is one 300 mg tablet twice a day for 6 months;
1891713|NCT01269242|Drug|bindarit|600 mg bid, that is two 300 mg tablets twice a day for 6 months
1891714|NCT01269242|Drug|placebo|bindarit-matching placebo tablets for 6 months.
1891715|NCT01269255|Drug|TS-1 with Cisplatin|"SP CCRT(= TS-1 with Cisplatin concurrent radiation therapy)
Step 1: Chemotherapy; TS-1/CDDP #2 cycles
Step 2: Chemoradiotherapy; CCRT with weekly TS-1/CDDP
Step 3: Surgery therapy"
1891716|NCT01269281|Drug|Sumatriptan|Sumatriptan Succinate Tablets 100 mg
1891717|NCT01269294|Drug|TMC435|2 capsules of 75 mg once daily for 7 days in Treatment A
1891718|NCT01269294|Drug|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment C
1891719|NCT01269294|Drug|TMC435|2 capsules of 75 mg and 2 capsules of 100 mg once daily for 7 days in Treatment B
1891720|NCT01269294|Drug|Placebo for TMC435|2 placebo capsules once daily for 7 days in Treatment A
1891721|NCT01269294|Drug|Moxifloxacin|1 tablet of 400 mg on Day 7 of Treatment C
1891722|NCT01269294|Drug|Placebo for moxifloxacin|1 placebo tablet on Day 7 of Treatments A, B and D
1891723|NCT01269294|Drug|Placebo for TMC435|4 placebo capsules once daily for 7 days in Treatment D
1891724|NCT01269307|Procedure|1:1 ketamine-propofol mixture sedation|"Prepare Ketamine and Propofol 10mg/cc of ketamine 10mg/cc of propofol mix 1:1 in 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus. Repeat dose 0.025 - 0.05 every 60-90 seconds as needed to reach and maintain target level of sedation.
May round to nearest 0.5-1 cc. Note - 1 cc = 5mg of propofol and 5mg of ketamine"
1891725|NCT01269307|Procedure|Propofol Sedation|"Prepare Propofol 10mg/cc of propofol 10 or 20 cc syringes Sedation Initial dose 0.05 cc / kg IV bolus over 30 seconds. Repeat dose 0.025 - 0.05 cc/kg every 30-60 seconds as needed to reach and maintain target level of sedation.
May round to nearest 0.5 cc Note - 1 cc = 10 mg of propofol"
1891726|NCT01269320|Drug|Femarelle|Study treatment will consist of Femarelle, two 530mg oral tablets (equivalent to 322 mg of DT56a and 108 mg of Linum Usitatissimum extract each) twice a day for 90 days
1891727|NCT01269333|Drug|omeprazole|omeprazole 20mg for 7 days
1891728|NCT01269333|Drug|fluvoxamine|fluvoxamine 50mg for 7 days
1891729|NCT01269333|Drug|placebo|placebo for 7 days
1891730|NCT01269346|Drug|Eribulin Mesylate|"Eribulin mesylate 1.4 mg/m2 administered as an intravenous (IV) infusion (over 2 to 5 minutes) on Days 1 and 8 of each 3-week cycle.
Trastuzumab 8 mg/kg will be administered as in IV infusion over a 90-minute period on Day 1 of Cycle 1. Thereafter, trastuzumab 6 mg/kg will be administered as an IV infusion over a 30-minute period on Day 1 of each subsequent cycle."
1891731|NCT01269359|Procedure|robotic assisted surgery|Robotic guidance: SpineAssist™ (Mazor Surgical Technologies, Caesarea, Israel), is a bone-mounted miniature robot. It is a semi-active system offering surgical tool guidance while leaving performance of the actual surgical operation, such as the drilling, in the surgeon's hands.
1891732|NCT01269372|Device|PillCam Colon 2|"Each subject will be required to follow a bowel preparation regimen and will undergo Capsule Endoscopy (CE).
Following capsule ingestion and depending on capsule progression through the digestive tract subjects will be required to take an additional volume of laxatives in order to enhance capsule propulsion and maintain adequate cleansing of the colon."
1891733|NCT01269372|Device|Colonoscopy|The colonoscopy procedure will be scheduled approximately 4-6 weeks after the CE procedure, and the colonoscopy bowel preparation will be the same as the bowel preparation for CE.
1891734|NCT01269385|Biological|alemtuzumab|Given subcutaneously
1891735|NCT01269385|Biological|rituximab|Given IV
1891736|NCT01269385|Drug|PGG beta-glucan|Given IV
1891737|NCT01269385|Other|flow cytometry|Correlative studies
1891738|NCT01269385|Other|laboratory biomarker analysis|Correlative studies
1891739|NCT01269385|Genetic|DNA analysis|Correlative studies
1891740|NCT01269385|Genetic|fluorescence in situ hybridization|Correlative studies
1891741|NCT01269385|Genetic|polymerase chain reaction|Correlative studies
1891742|NCT01269385|Genetic|polymorphism analysis|Correlative studies
1891743|NCT01269385|Genetic|mutation analysis|Correlative studies
1891744|NCT01269398|Device|GO-LIF and SpineAssist SYSTEMS|
1891745|NCT01269411|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
1891748|NCT01269411|Other|laboratory biomarker analysis|Correlative
1891749|NCT01269424|Biological|MGMTP140K-encoding retroviral vector|
1891750|NCT01269424|Drug|O6-benzylguanine|
1891751|NCT01269424|Drug|temozolomide|
1891752|NCT01269424|Other|laboratory biomarker analysis|
1891753|NCT01269424|Procedure|autologous hematopoietic stem cell transplantation|
1891754|NCT01269424|Procedure|in vitro-treated peripheral blood stem cell transplantation|
1891755|NCT01269424|Radiation|radiation therapy|
1891756|NCT01269437|Drug|Budesonide dry powder inhaler|200mcg per inhalation, twice daily, for 12 weeks
1891757|NCT01269450|Drug|micronized progesterone 200 mg (Utrogestan)|micronized progesterone 200 mg (Utrogestan, company) as an intra-vaginal tablet once daily
1891758|NCT01269450|Drug|placebo|placebo 200mg vaginal tablets
1997366|NCT02107105|Behavioral|Questionnaires|Questionnaires completed regarding participant's quality of life and utilities. Questionnaires completed before surgery for rectal cancer and at multiple time points after the completion of surgery.
1891761|NCT01269476|Drug|SNX-001|3.6, 7.2, or 10.8 mg single dose or t.i.w.
1891762|NCT01269476|Drug|Placebo|Same volumes and frequency as active.
1891763|NCT01269502|Device|"Temp Touch Diabetica Solutions inc."|Daily measurement of skin temperature on feet for one year
1891764|NCT01269502|Other|Inspection|Inspection of feet daily for one year
1891765|NCT01269515|Drug|Etoricoxib|90 mg QD
1891766|NCT01269528|Other|Methacholine Challenge Test (MCT)|MCT challenge with determination of methacholine concentration that causes a 20% decrease from baseline FEV1 (forced expiratory volume in the 1st second of expiration) - PC20-FEV1 - is a well-documented method of assessing bronchial hyper-reactivity (BHR) in both adults and children. Our group has shown that the determination of PC20 by spirometry is feasible in preschool children. MCT is considered safe in this age group and our group has extensive experience with no adverse events. In the current study MCT will be performed (for the first time) in premature babies born at 30-32 weeks of gestation during 2008-2009 when they reach the age of 3-4 years (2011 and 2012, respectively). The results of MCT of the two groups will be compared.
1891767|NCT01269528|Other|Monthly telephone contact|Monthly telephone contact with the parents/caregivers will be scheduled from enrollment until the final visit at age 3-4 years. Subject illnesses and other medical events occurring during the past month will be recorded at each monthly follow-up.
1891768|NCT01269528|Other|Visits to the study site|Visits to the study site will be conducted at 6-month intervals in which physicians will record intercurrent doctor visits, emergency visits, and hospitalizations for respiratory symptoms.
1891769|NCT01269528|Other|Blood Test|For assessing IgE levels, Eosinophils count and cytokines levels
1891770|NCT01269528|Other|Fractional exhaled nitric oxide|Participant blow tidal volume for determination of exhaled NO in Exhaled breath.
1891771|NCT01269541|Drug|Mupirocin|Topical in the nose 3 times daily for 5 days
1891772|NCT01269541|Drug|Rifampin+Clindamycine or Trimehoprimsulfa|Rifampicin 10 mg/kgx1xVII Clindamycine 300 mgx3 Trimethoprimsulfa 400mg/80mg 2x2
1891773|NCT01269567|Procedure|Laying and management of the drain (strictly randomized arm with drainage)|At the end of intervention, the surgeon will position an aspiration drain in order to permit a postoperative pelvic drainage. The drain will be positioned forward sacrum, behind anastomosis. The drain will be leaved in place between 3 and 5 days. The criteria of drain ablation are the absence of haemorrhagic liquid and/or un daily debit < 100ml. Nursing care will be daily with change of bottle for collect pelvic serosity, accounting of quantity of collected liquid and realization of a dried bandage through contact with penetration of the drain.
1891774|NCT01269567|Procedure|No pelvic drainage|no aspiration drain at the end of intervention
1891775|NCT01269593|Drug|PET Imaging using 124 IPUH71|A dose of up to 11.0 mCi (range: 4.0-11.0 mCi) of 124I-PUH71 will be administered intravenously with the patient at rest. 124I-PUH71 scans will be performed at immediately and/or 3-4 hours, 20-24 hours, and 40-80 hours after injection of the radiotracer. Optionally, in willing patients scans will be performed 160-200 hours (~7-8 days) after injection of the radiotracer. At each time-point, a 45-60 minute axial body image is acquired. Images will be acquired on a state-of-the-art PET-CT scanner. A low-dose CT will be obtained immediately-prior to PET imaging, at each time-point. A 30-45 minute scanning timeperiod is typical for clinical PET studies.
1891776|NCT01269606|Drug|insulin aspart|At the first treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. At the second treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
1891777|NCT01269606|Drug|insulin human|At the first treatment visit, a single dose of fast-acting insulin human at 0.2 IU/kg via IM (in the muscle) injection is administered.At the second treatment visit, a single dose of insulin aspart at 0.2 U/kg via IM (in the muscle) injection is administered. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
1891778|NCT01269606|Drug|insulin aspart|At the first treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. At the second treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment visits.
1891779|NCT01269606|Drug|insulin human|At the first treatment visit, fast-acting insulin human is intravenously infused for 24 minutes, with rate of 1.25 mIU/kg/min at constant phase. At the second treatment visit, insulin aspart is intravenously infused for 24 minutes, with rate of 1.25 mU/kg/min at constant phase. Subjects will resume their usual insulin treatment in the wash-out period of 4-28 days between treatment periods.
1891780|NCT01269619|Device|Dynamic back support|A dynamic back support which provides pressure on the lumbar without pressure on the abdomen
1891781|NCT01269619|Device|Static back support|A standard wrap-around sacro lumbar support
1891847|NCT01262365|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
1891848|NCT01262365|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles
1891849|NCT01262365|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
1891782|NCT01269632|Biological|blood sampling, specific biological exams and biobank and self administered questionnaires|"HIV INFECTION at inclusion and annually up to 06 years follow-up
clinical and therapeutic evaluation by physician
biological: blood sampling, specific biological exams and biobank
self administered questionnaires
In the physiopathological module: at inclusion and after 3 years follow up: OGTT, CT Scan, Dexa Scan, cardiovascular explorations (carotid intima media thickness, pulse wave velocity, transthoracic echocardiography)
HIV UNINFECTED at inclusion and after 3 years follow up
clinical evaluation by physician
biological: blood sampling, specific biological exams and biobank
self administered questionnaires"
1891783|NCT01269645|Behavioral|Clinical Trial educational materials|Usual care and (1) a 10-minute clinical trials educational video; and (2) a 12-page educational booklet to accompany the educational video. Content includes basic information about clinical trials and patient testimonials about the value and benefits of participating in clinical trials. The video also addresses common misperceptions about clinical trials using patient and physician testimonials. After watching the video, participants will be provided a copy of the video for home viewing, along with the educational booklet to be reviewed at home.
1891784|NCT01269658|Drug|Azithromycin ophthalmic solution, 1%|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
1891785|NCT01269658|Drug|Vehicle|1 drop twice daily (BID) for the first 2 days and then 1 drop once daily (QD) for the remainder of treatment period (approximately 28 days total)
1891786|NCT01269671|Drug|Melatonin, Peppermint Oil (mentharil), and Simethicone|Dosing will be dependent on patient's age during time of enrollment. Patients 8-12 years of age will receive Melatonin 3mg tab at night, Peppermint oil 1 capsule (0.2ml) 30-60 minutes prior to meal twice daily, and Simethicone 80mg tab 30-60 minutes prior to meal twice daily. Patients 13-18 years of age will receive Melatonin 3mg tab at night, Peppermint oil 2 capsules (0.4ml) 30-60 minutes prior to meal twice daily, and Simethicone tab 125mg 30-60 minutes prior to meal twice daily
1891787|NCT01269671|Other|Sugar pill|Patients in the placebo group will receive one placebo tab to be taken at night, one placebo capsule to be taken 30-60 minutes prior to meal twice daily, and one placebo tab to be taken 30-60 minutes prior to meal twice daily.
1891788|NCT01269684|Drug|Everolimus|Initial dose 1.5 mg b.i.d. Target blood trough level 4-10 ng/ml
1891789|NCT01269697|Dietary Supplement|Nutrof Total|2 capsules 2 times per day during 6 month
1891790|NCT01269697|Dietary Supplement|Placebo Nutrof total|2 capsules 2 times per day during 6 month
1891791|NCT01269723|Dietary Supplement|Broccoli sprout homogenate|Subjects will drink the broccoli shake homogenate
1891792|NCT01269723|Dietary Supplement|Alfalfa sprout homogenate|Subjects will drink the alfalfa sprout homogenate.
1891793|NCT01261858|Device|Kryptonite|osteoconductive biologic bone cement to be applied upon sternal closure
1891794|NCT01261884|Behavioral|Exercise support|Group B (exercise support) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, and a pedometer. This group will be asked to wear the pedometer for 7 consecutive days between Visits 1 and 2, and record daily activities.
1891795|NCT01261884|Behavioral|Exercise intervention|Group C (exercise intervention) will be given the ACOG pamphlet on exercise in pregnancy, a daily activity log, a pedometer, a resistance band, and a handout on specific exercises (type and frequency) to be performed. The study coordinator will demonstrate each exercise and then observe the participant perform each exercise to assure full understanding. In addition to wearing the pedometer for 7 days and completing the activity log, this group will also record compliance with the exercise regimen.
1891796|NCT01261897|Procedure|Adductor-Canal-Blockade with Ropivacaine|US-guided Adductor-Canal-Blockade with ropivacaine 7,5 mg/ml
1891797|NCT01261897|Procedure|Adductor-Canal-blockade with saline|US-guided Adductor-Canal-blockade with saline
1891798|NCT01261910|Behavioral|Intensive initial education|Participants will (1) view a video, brochure, and fact sheet regarding living kidney donation, and (2) discuss the videos and materials with a transplant educator, in-person.
1891799|NCT01261923|Drug|Alitretinoin|30 mg capsule of 9-cis-retinoic-acid (9-cis-RA)(Alitretinoin, Toctino®)
1891800|NCT01261949|Device|Combined frontal and temporal rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 1000 stimuli of 1Hz rTMS over the right DLPFC (110% motor threshold) followed by 1000 stimuli of 1 Hz rTMS over the left temporal cortex DLPFC (110% motor threshold)
1891801|NCT01261949|Device|Temporal low frequency rTMS|Experimental repetitive transcranial magnetic stimulation (Alpine Biomed Mag Pro Option): 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold)
1891802|NCT01261962|Dietary Supplement|zinc|zinc sulfate, 35 mg twice daily for 4 months
1891803|NCT01261962|Other|Placebo|Placebo, One capsule, twice daily for 4 months
1891804|NCT01261975|Procedure|Coaxial Micro-Incision Cataract Surgery|1.8 mm coaxial micro incision
1891805|NCT01261975|Procedure|Coaxial Small Incision Cataract Surgery|2.75 mm coaxial incision
1891806|NCT01261988|Device|VIPER|Comparison of ostomy systems
1891807|NCT01261988|Device|Esteem™ Cut to Fit One Piece Closed End Pouch|Comparison of ostomy systems
1891808|NCT01262001|Drug|FG-3019|15 mg/kg (Cohort 1 and Cohort 1-Extension) and 30 mg/kg (Cohort 2 and Cohort 2-EX) by infusion every 3 weeks for 45 weeks in the target population (first treatment year and first extended treatment year and every 3 weeks thereafter for three additional extended treatment years..
1891809|NCT01262014|Drug|Pazopanib|800 mg (2x400mg) pazopanib per day should be taken orally without food at least one hour before or two hours after a meal until disease progression, the development of unacceptable toxicity, noncompliance, withdrawal of consent by the patient, or investigator decision.
1891810|NCT01262027|Drug|Dovitinib|500 mg by mouth for 5 consecutive days, followed by a 2-day rest period (5 days on/2 days off schedule) for every 28 day cycle.
1891811|NCT01262040|Other|Narrow Band Imaging (NBI)|The intervention is visual assessment of the peritoneal or pleural surface with NBI followed by biopsy and photographic documentation of any abnormal lesions. Photograph or video of abnormality(ies) under white light and NBI.
1891850|NCT01262378|Procedure|abdominal plastic surgery|Surgery for ABDOMINAL SUBCUTANEOUS FAT
1891851|NCT01262391|Drug|solifenacin suspension|oral suspension
1891852|NCT01262417|Procedure|- use of resorbable membrane Seprafilm|use of resorbable membrane during the first surgery for the resection of hepatic metastases, 1 to 4 membranes should be used around the liver
1891812|NCT01262053|Other|Passive Intervention|When a user is about to place orders on a patient, a pop up alert will show the user the name, age, sex, room number and MR# of the patient who is currently activated. The point of the alert is to display identification information about the patient as a double check for the provider to make sure he is on the correct patient. This alert will only occur once at the onset of each order session (i.e. the provider will not be alerted for every single order, but if the provider leaves the order pad and then returns, the alert will reoccur).
1891813|NCT01262053|Other|Active Intervention|"The user will be required to enter the initials, age and sex of the activated patient prior to placing any orders. For example, for a patient named Donald Duck who is 76 years old and male, the user will be required to type dd76m to unlock the order pad. This step will NOT be required for every order, but WILL be required every time the user enters the order pad (i.e. if a user leaves the order pad and then returns, the system will require the initials, age and sex to be re-entered as above). This will be a forcing function."
1891814|NCT01262053|Other|Control|Parallel control with no intervention
1891815|NCT01262066|Behavioral|Lifeskills Workshop Intervention|Intervention participants attended 10 one-hour weekly group sessions. The content of the groups followed the LifeSkills Workshop manual and Video ( (Williams LifeSkills, Inc, Durham NC). The LifeSkills Workshop is a structured psycho-educational group intervention using workbooks and videotapes that draw on cognitive-behavioral techniques and stress reduction approaches.
1891816|NCT01262092|Drug|Buprenorphine|Induction onto buprenorphine to a stable dose of 12mg/day. Then induction onto either 0 or 1600mg of gabapentin. Once the maintenance dose of gabapentin is reached a 10-day buprenorphine detoxification will begin.
1891817|NCT01262105|Device|Air Barrier System Device|Device is deployed adjacent to the surgery site and activated so that the filtered air emits over the site.
1891818|NCT01262118|Drug|CP-690,550 (tasocitinib)|CP-690,550 (tasocitinib) dosed at 10 mg BID for 6 weeks in patients with active rheumatoid arthritis
1891819|NCT01262131|Device|magnetic therapy protocol A|Application of magnetic fields using the Resonator device Protocol A
1891820|NCT01262131|Device|magnetic therapy Protocol B|Application of magnetic fields using the Resonator device Protocol B
1891821|NCT01262131|Device|placebo therapy|Application of inactive magnetic fields using the Resonator device
1891822|NCT01262144|Radiation|Radiotherapy|Radiotherapy for cervical cancer
1891823|NCT01262157|Device|Extracorporeal Shockwave Therapy Generator (Vascuspec)|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
1891824|NCT01262157|Device|Low intensity shock wave therapy|Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
1891825|NCT01262170|Dietary Supplement|CigRx Lozenge|lozenge made of dietary supplements
1891826|NCT01262170|Other|Tobacco Lozenge|lozenge made of compressed cured tobacco extract
1891827|NCT01262183|Drug|CRT + Panitumumab|Day -7, day +15 and day +36: panitumumab 9.0 mg/kg i.v. Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
1891828|NCT01262183|Drug|Concurrent chemoradiation therapy without panitumumab|Day +1 to +39: radiation therapy 1.8 Gy fractions 5 times per week to a cumulative dose of 50.4 Gy Day +1 and +29: cisplatin 75 mg/m2 i.v. Day +1 to +4 and +29 to +32: 5-fluorouracil 1000 mg/m2 i.v.
1891829|NCT01262196|Drug|MP4OX|4.3 g/dL pegylated hemoglobin in balanced lactate-electrolyte solution
1891830|NCT01262196|Drug|Saline|Normal saline (0.9%) solution
1891831|NCT01262209|Device|portable CCTV|This is a small handheld mini screen intended to improve reading.
1891832|NCT01262209|Device|Telescopes, telemicroscopes and microscopes|These are either worn like glasses, or held in one's hand and are intended to improve distance vision (like details of a hockey game), intermediate vision (like reading a sign), or 'up-close' vision (like reading small print).
1891833|NCT01262209|Device|Absorptive filters|These are worn like glasses, and have tinted colour lenses. They are intended to improve contrast sensitivity, or being able to tell light from dark (like reading gray letters on a white background).
1891834|NCT01262222|Other|endothelial function testing|After obtaining informed consent, eligible patients will undergo endothelial function testing using the Endo-PAT 2000 (Itamar Medical) device. This PAT device applied to the finger tip will be used to measure change in blood flow in one arm at rest and after a 5 minute occlusion of the brachial artery with a blood pressure cuff. The other arm will serve as the patient's own control. After the cuff is deflated, blood flow normally increases in the arm for a period of time (flow mediated dilatation). In patients with abnormal endothelial function, this increase in blood flow is damped. The ratio of flow in the ischemic finger to the nonischemic finger (RH-PAT) will then be correlated with postoperative cardiac events.
1891835|NCT01262235|Drug|TKM-080301|Repeat dose IV infusion.
1891836|NCT01262261|Drug|Probuphine (buprenorphine implant)|Implantable formulation of buprenorphine made of buprenorphine HCl/ethylene vinyl acetate, considered a drug.
1891837|NCT01262274|Drug|Anastrozole|ANA is given 1mg daily for 24 weeks.
1891838|NCT01262274|Drug|Anastrozole plus tegafur-uracil|ANA is given 1mg daily for 24 weeks. UFT is given by 270mg/m2 twice a day for 24 weeks.
1891839|NCT01262287|Drug|Dutasteride|dutasteride 4 mg loading dose followed by 1 mg daily for 8-week treatment period
1891840|NCT01262287|Drug|Placebo|placebo capsules in same number as active drug, daily for 8-week treatment period
1891841|NCT01262300|Biological|Varicella Zoster Virus Vaccine (Zostavax)|Single 0.65 mL subcutaneous injection of the live, attenuated VZV zoster vaccine (Zostavax; Merck, Whitehouse Station, NJ).
1891842|NCT01262313|Behavioral|Lifestyle Counseling|"Participants in the intervention group will attend an 8-week group intervention discussing Healthy Creations lifestyle changes."
1891843|NCT01262326|Other|Calorie and Carbohydrate Restriction|Carbohydrate Restriction = <20 g/d of dietary carbohydrate intake Calorie Restriction = 1200 kcal/d for women and 1500 kcal/d for men
1891844|NCT01262339|Drug|BTX-A|100 units of BTX-A will be delivered subject's hand via iontophoresis and standard of care intradermal injection of 100 units BTX-A will be delivered to the contra-lateral hand
1891845|NCT01262352|Drug|Ivacaftor|150 mg tablet, oral use, twice daily every 12 hours (q12h)
1891846|NCT01262352|Drug|Placebo|Tablet, oral use, twice daily every 12 hours (q12h)
1891853|NCT01262417|Procedure|without resorbable barrier (seprafilm)|non use of resorbable membrane during the first surgery for the resection of hepatic metastases
1891854|NCT01262430|Procedure|OtisMed|OtisMed Custom-fit Shapematching Guides
1891855|NCT01262430|Procedure|Computer Assisted Surgery (CAS)|Stryker Navigation System
1891856|NCT01262443|Procedure|Radiofrequency Ablation|Radiofrequency ablation by a standard 4mm irrigated flexible tip catheter
1891857|NCT01262456|Drug|Desmopressin|
1891858|NCT01262456|Drug|Placebo|
1891859|NCT01262469|Drug|lapatinib + capecitabine|"For Lapatinib: 5 tablets of 250 mg each, once daily, until disease progression or unacceptable toxicity occurence.
For Capecitabine: 850 mg/m2 twice a day from day 1 to 14 of cycle 1 and 1000 mg/m2 twice a day from day 1 to 14 of the next cycles."
1891860|NCT01262482|Drug|Oxaliplatin|130 mg/m2, IV during 2 hours on day 1 of each 21 day cycle. Number of cycles: until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
1891861|NCT01262482|Drug|Sorafenib|400mg, orally, 2 times per day. Until progression, intolerance or unacceptable toxicity develops, or until patient or investigator decide to stop the treatment.
1891862|NCT01262495|Other|cryopreservation|cryopreservation of testicular tissue
1891863|NCT01262521|Dietary Supplement|Dietary nitrate|150 ml tab water with 150 umol/kg sodium-nitrate
1891864|NCT01262521|Dietary Supplement|Water|150 ml Chapelle mineral water
1891865|NCT01262534|Other|Clinical profile of patients|Comorbidities and associated type of treatments will be collected.
1891866|NCT01262534|Other|Patient Preferences about treatment|Patient Benefit Index (PBI), for treatment to record patient preferences regarding psoriasis treatment.
1891867|NCT01262534|Other|Quality of Life|The Quality of Life will be assessed by 2 questionnaires (SF-36 questionnaire, to analyze the overall quality of life of patients, and Dermatology Life Quality Index (DLQI), to analyze the quality of life of patients, in dermatological terms).
1891868|NCT01262547|Device|Dermabrasion-Micrografting|Several small pieces of skin, each measuring 1.75 mm in diameter will be harvested from a normal pigmented area using a commercially available suction blister device. This will be attached to a sterile elastomeric substrate and then placed on a recipient area prepared by epidermal dermabrasion (removal of the epidermis).
1891869|NCT01262547|Procedure|Dermabrasion|Only dermabrasion (removal of epidermis) alone will be done at baseline.
1891870|NCT01262560|Drug|Manuka honey in liquid form|Patients swallow 10 cc (approximately 2 level teaspoons) of liquid Manuka honey 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
1891871|NCT01262560|Drug|Manuka honey in lozenge form|Patients place 2 lozenges (the equivalent of 10 cc of liquid Manuka honey), one at a time, in the mouth, allowing each lozenge to dissolve on the tongue/in the mouth, swallowing the honey as it dissolves. Patients do this 4 times per day while awake over an approximately 12 hour period (e.g. 8 a.m., Noon, 4 p.m., and 8 p.m.) 7 days/week during concurrent chemotherapy and radiation treatment.
1891872|NCT01262560|Drug|Standard supportive care|"Patients receive standard supporting care for esophagitis-related pain as needed during concurrent chemotherapy and radiation treatment. The following regimen is recommended, but the local standard of care is permitted.
A compound containing viscous lidocaine and magnesium aluminum oxide (Maalox®);
Liquid or solid oxycodone, 5-10 mg, every 3 hours as needed."
1891873|NCT01262573|Procedure|Closure of vaginal cuff|Closure of the vaginal cuff
1891874|NCT01262586|Drug|Vildagliptin|
1891875|NCT01262586|Drug|Glimepiride|
1891876|NCT01262599|Device|Sham PEMF Device|Inactive device placed in the same manner as the active device; does not deliver pulsed electromagnetic fields
1891877|NCT01262599|Device|Ivivi Torino II PEMF Device|"The PEMF device to be employed in this study is FDA cleared for adjunctive use in the palliative treatment of postoperative pain and edema in superficial soft tissue (510(k) number: K903675). The PEMF device will be taped over the affected breast and abdomen. The PEMF signal will consist of a 2 msec burst of 27.12 MHz sinusoidal waves repeating at 2 bursts/sec. The device will automatically provide a 15 minute treatment every 2 hours. Supplied by Ivivi Health Sciences, LLC."
1891878|NCT01262612|Drug|immediate cediranib|cediranib 30 mg on day one; Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken
1891879|NCT01262612|Drug|Start cediranib after 28 days Best Supportive Care|patients in this group will start with cediranib after one month best supportive care. Special in this study is the possibility to decrease (to a minimum of 15 mg) or increase the dose (to a maximum of 30 mg oid) during the study to get an individualized optimal palliative treatment with cediranib. The patient will continue cediranib as long as a clinical benefit is experienced, independent of tumour evaluation. Each dose changes should be documented with clear reasoning and documentation of the approach taken.
1891880|NCT01262625|Device|CCTA|Complete diagnostic CCTA per protocol specifications.
1891881|NCT01262625|Device|SPECT MPI/ICA|Perform SPECT MPI per institutional standard practice; diagnostic ICA will be performed only as indicated per protocol.
1891882|NCT01262638|Drug|ETC-1002|ETC-1002 daily for 12 weeks
1891883|NCT01262638|Drug|Placebo|Placebo daily for 12 weeks
1891884|NCT01262651|Drug|Sativex®|
1891885|NCT01262651|Drug|Placebo (GA-0034)|
1891886|NCT01262664|Drug|Prohibitin-TP01|Starting dose of 0.03 mg/kg as an injection under the skin 1 time each day for 28 days.
1891993|NCT01263288|Dietary Supplement|cholecalciferol|Vitamin D3 tablet 1000 IU. Once daily by mouth for 4 months
1891894|NCT01262690|Drug|PF-05230901|Single ascending doses of PF-05230901 in separate cohorts of subjects; each cohort consists of 6 subjects treated with PF-05230901 and 3 subjects treated with placebo.
1891895|NCT01262690|Drug|PF-05230901|Single dose SC
1891896|NCT01262703|Device|ReZolve Stent|ReZolve Sirolimus-Eluting Bioresorbable Coronary Stent
1891897|NCT01262729|Procedure|therapeutical hypothermia|Patients after successful cardiopulmonary resuscitation will be treated in accordance to international guidelines (Guidelines 2005 on cardiopulmonary resuscitation. Resuscitation 2005; 67: S7-S23)
1891898|NCT01262729|Drug|Xenon Inhalation|Patients after successful cardiopulmonary resuscitation will be inhalated with 65-70% Xenon within 2 hours additional to therapeutical hypothermia
1891899|NCT01262742|Drug|Carbetocin|80mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
1891900|NCT01262742|Drug|Carbetocin|90mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
1891901|NCT01262742|Drug|Carbetocin|100mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
1891902|NCT01262742|Drug|Carbetocin|110mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
1891903|NCT01262742|Drug|Carbetocin|120mcg carbetocin, IV, over 1 minute following delivery of the fetal head.
1891904|NCT01262755|Behavioral|Structured Interview|Subjects underwent a structured interview using a laptop computer and answered over 200 standardized questions. All patient had their height, weight, and waist circumference measured.
1891905|NCT01262768|Behavioral|Portion Size Measurement Aids (PSMAs)|Subjects are randomly assigned to receive either 2D or 3D PSMAs to examine accuracy, acceptability and usefulness of the models. Both groups receive brief instructions on the use of the respective PSMAs, complete an accuracy estimation task, and are given the 2D or 3D PSMAs to take home with them to use for 2-4 weeks, after which the researchers telephone parents to complete a brief satisfaction and usefulness survey.
1891906|NCT01262794|Biological|CDP6038|100 mg/mL solution for injection, single dose
1891907|NCT01262794|Biological|Placebo|0.9% sodium chloride for injection Single-dose
1891908|NCT01262807|Other|Exercises|A specific set of standardized exercises will be taught to patients who are randomized to the intervention group. They will be instructed to do these exercises daily while in-cast. They will have an exercise log to track adherence.
1891909|NCT01262820|Drug|Pazopanib|Pazopanib, 800 mg by mouth daily each 21 day cycle
1891910|NCT01262846|Biological|Fluzone®|Fluzone® Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
1891911|NCT01262846|Biological|Fluzone®|Fluzone® High dose or Standard dose in a blinded manner as single-0.5mL injection intramuscularly into one of the subject's deltoid muscles.
1891912|NCT01262859|Drug|bevacizumab|Bevacizumab, 15 mg/kg IV over 30 minutes (if this infusion rate was well tolerated), every 3 weeks until completion of radiation The initial dose will be delivered over 90+/-15 minutes. If the first infusion is tolerated without infusion associated adverse events (fever and/or chills), the second infusion may be delivered over 60+/-10 minutes. If the 60 minute infusion is well tolerated, all subsequent infusions may be delivered over 30+/-10 minutes.
1891913|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (LD formulation 1)|Intramuscular injection
1891914|NCT01262872|Biological|Pneumococcal vaccine GSK 2189242A (HD formulation 2)|Intramuscular injection
1891915|NCT01262872|Biological|Synflorix™|Intramuscular injection
1891916|NCT01262872|Biological|Prevnar13™|Intramuscular injection
1891917|NCT01262872|Biological|Tritanrix™-HepB/Hib|Intramuscular injection
1891918|NCT01262872|Biological|Polio Sabin™|Orally
1891919|NCT01262872|Biological|M-Vac™|Intramuscular injection
1891920|NCT01262872|Biological|Stamaril™|Intramuscular injection
1891921|NCT01262885|Drug|GSK2251052|500 mg tablet, dose levels detailed in Arm description
1891922|NCT01262885|Drug|Placebo|matching placebo tablet
1997367|NCT02106897|Drug|BIIB059|See Arm Descriptions
1891927|NCT01262911|Drug|SRT2379|SRT2379 will be supplied as hard gelatin capsules, with each containing 250mg.
1891928|NCT01262911|Drug|Placebo|Matching placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
1891929|NCT01262924|Biological|GSK Biologicals' reduced-antigen-content diphtheria-tetanus-acellular pertussis vaccine|Intramuscular, single dose
1891930|NCT01262924|Biological|GSK Biologicals' reduced-antigen-content acellular pertussis vaccine|Intramuscular, single dose
1891931|NCT01262924|Biological|Tedivax-Adult™/ Td-Rix™|Intramuscular, single dose or 2 doses (in the annex phase)
1891932|NCT01262937|Device|Confocal Imaging|Confocal imaging performed of the digestive system with the use of confocal miniprobes such as the Gastroflex UHD and Cholangioflex miniprobes (Cellvizio, Mauna Kea, Paris, France)
1891933|NCT01262950|Other|portable motion detector|
1891934|NCT01262963|Drug|GSK2118436|A single oral dose of 95 mg of GSK2118436 containing approximately 80 µCi of radioactivity
1997368|NCT02106897|Drug|Placebo|See Arm Descriptions
1891937|NCT01262989|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
1891938|NCT01262989|Drug|Reference formulation|tamsulosin 0,4 mg (Boehringer Ingelheim)
1891994|NCT01263288|Dietary Supplement|Placebo|Microcrystalline cellulose tablet p.o.daily. (Same color, shape and size as vitamin D tablet)
1891995|NCT01263301|Device|carotid duplex|Carotid duplex in the differential diagnosis of subclavian steal syndrome due to Arteriovenous Hemodialysis access in the Ipsilateral arm
1891996|NCT01263314|Drug|MK-8266|Oral capsules, 0.1 mg potency
1891997|NCT01263314|Drug|Placebo|Oral placebo capsules to match MK-8266 capsules
1892046|NCT01263691|Biological|AV7909 Formulation 3|AV7909 Formulation 3
1891939|NCT01263002|Drug|clevudine, Adefovir|"Nucleoside-analogue naive patient : Clevudine 30mg qd
Assess the complete virological response(HBV DNA < 60 IU/ml) at 24 weeks: Only Clevudine 30mg qd
Assess not the complete virological response at 24 weeks : Add Adefovir 10mg qd
During medication of Clevudine, virological breakthrough : add adefovir 10mg qd
During treatment period, composite virological response : stop the medication and F/U for 2 years
Recurrence after stopping treatment(HBV DNA > 2,000IU/ml) retreat medication at composite virological response.
complete virological response: HBV DNA < 60 IU/ml
virological breakthrough : During antiviral treatment, HBV DNA increased from nadir to 1 log10IU/ml continuously."
1891940|NCT01263015|Drug|Dolutegravir|Dolutegravir (also known as GSK1349572) 50 mg taken once daily
1891941|NCT01263015|Drug|Atripla|Atripla once daily on an empty stomach
1891942|NCT01263015|Drug|Abacavir/Lamivudine|taken once daily; also known as EPZICOM
1891943|NCT01263015|Drug|Abacavir/Lamivudine Placebo|matching placebo taken once daily
1891944|NCT01263015|Drug|Dolutegravir placebo|matching placebo taken once daily
1891945|NCT01263015|Drug|Atripla placebo|matching placebo taken once daily on an empty stomach
1891946|NCT01263028|Drug|Ergocalciferol supplementation|Vitamin D in the form of ergocalciferol will be the drug utilized in the study. This medication is a Vitamin D analog and is normally used in the current study population to help augment those who are deficient in Vitamin D.
1891947|NCT01263041|Drug|Glutamine|enteral or via NG tube dose of 312mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
1891948|NCT01263041|Drug|l-arginine|enteral or via NG tube dose of 260mg/kg/day divided every 12 hours from starting feeding + usual care and medications up to 30 says post natal age
1891949|NCT01263054|Device|TransDiscal System|Surgical Procedure using the TransDiscal System to perform disc biacuplasty.
1891950|NCT01263054|Other|Medical Management|Standard medical management, physical therapy, and lifestyle changes.
1891951|NCT01263067|Behavioral|Lifespan Integration Therapy|LI treatment guides the client to imaginally visit past memories, and then leads her or him forward through time to the present using a concept referred to as the time line. Beginning with the individual's memories from the traumatic experience, the time line first follows memories from the days and weeks after the trauma, then season by season to the present, and is reviewed in ongoing sessions as increasing details of the traumatic event are uncovered.
1891952|NCT01263067|Behavioral|Lifespan Integration- Control|Participants selected for the control group will be treated 4 weeks following initial contact. Treatment is the same as for the Experimental Group.
1891953|NCT01263080|Drug|mirtazapine|mirtazapine 30mg QD
1891954|NCT01263080|Drug|folic acid placebo|folic acid placebo 1 tablet QD
1891955|NCT01263080|Drug|mirtazapine placebo|mirtazapine placebo 1 tablet QD
1891956|NCT01263080|Drug|folic acid|folic acid 0.4mg QD
1891957|NCT01263093|Drug|Clopidogrel|Administered orally
1891958|NCT01263093|Drug|LY2216684 + clopidogrel|Administered orally
1891959|NCT01263106|Drug|LY2216684|Administered orally
1891960|NCT01263106|Drug|Theophylline|administered orally
1891961|NCT01263119|Drug|Warfarin|administered orally
1891962|NCT01263119|Drug|LY2216684|administered orally
1891963|NCT01263132|Drug|F0434|F0434 will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2).
1891964|NCT01263132|Drug|Gabapentin|Gabapentin will be administered orally with an initial dosage of 3 capsules per day divided into 3 doses with a time interval of 8 hours between each dose. The subject will continue with this dosage for one week and afterwards, the initial dosage will be increased from 3 capsules per day divided into 3 doses with the same time interval between doses, until visit 3 (week 2)
1891965|NCT01263145|Drug|Akt Inhibitor MK2206|Given PO
1891966|NCT01263145|Other|Laboratory Biomarker Analysis|Correlative studies
1891967|NCT01263145|Drug|Paclitaxel|Given IV
1891968|NCT01263145|Other|Pharmacological Study|Correlative studies
1891969|NCT01263158|Other|Expectancy of standard oxytocin treatment|
1891970|NCT01263171|Drug|Leucovorin|
1891971|NCT01263171|Drug|fluorouracil|
1891972|NCT01263171|Drug|leucovorin calcium|
1891973|NCT01263171|Drug|oxaliplatin|
1891974|NCT01263171|Procedure|adjuvant therapy|
1891975|NCT01263171|Procedure|neoadjuvant therapy|
1891976|NCT01263171|Procedure|therapeutic conventional surgery|
1891977|NCT01263171|Radiation|radiation therapy|
1891978|NCT01263197|Drug|LY2216684|administered orally
1891979|NCT01263197|Drug|albuterol|administered orally
1891980|NCT01263197|Drug|propranolol|administered orally
1891981|NCT01263197|Drug|placebo for LY2216684|administered orally
1891982|NCT01263197|Drug|placebo for albuterol|administered orally
1891983|NCT01263197|Drug|placebo for propranolol|administered orally
1891984|NCT01263210|Biological|Prevenar|
1891985|NCT01263223|Drug|LY2216684|Administered orally
1891986|NCT01263223|Drug|Placebo|Administered orally
1891987|NCT01263236|Drug|LY2940094|Administered orally
1891988|NCT01263236|Drug|Placebo|Administered orally
1891989|NCT01263249|Procedure|Catheter Anterior to the Femoral Nerve|Extremity randomized to Anterior Placement will be given a peripheral nerve block with the catheter placed just anterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
1891990|NCT01263249|Procedure|Catheter Posterior to the Femoral Nerve|Extremity randomized to Posterior Placement will be given a peripheral nerve block with the catheter placed just posterior to the femoral nerve. 4cc of Ropivicaine will be administered continuously every hour by a pain pain pump and the outcome measures will be tested.
1891991|NCT01263275|Device|tDCS (Eldith DC-Stimulator (CE certified))|Each tDCS session lasting continuously for 20 minutes at 2 mA
1891992|NCT01263288|Dietary Supplement|cholecalciferol|Vitamin D3 tablet 400 IU. Once daily by mouth for 4 months
1892045|NCT01263691|Biological|AV7909 Formulation 2|AV7909 Formulation 2
1891998|NCT01263327|Biological|HPV 16/18|Participants would intramuscularly receive 90mcg of HPV 16/18 bivalent vaccine at 0, 1, 6 month for 3 doses.
1891999|NCT01263353|Drug|Pasireotide LAR followed by Pasireotide LAR + Everolimus|
1892000|NCT01263353|Drug|Everolimus followed by Pasireotide LAR + Everolimus|
1892001|NCT01263366|Drug|Norepinephrine|Approximately 1.6 or 4.6 mL of a 400 mM norepinephrine solution will be applied topically to a portion of the radiation treatment field prior to each radiation treatment (20-33 treatments)
1892002|NCT01263379|Genetic|LZRSE-Col7A1 Engineered Autologous Epidermal Sheets|"This trial will create a graft, which we call LEAES, of the patient's own skin that has been genetically engineered in our lab to express this missing protein."
1892003|NCT01263392|Device|Intermittent catheterization|Subjects will use each type of catheter for 6 months and will report weekly in a diary on urinary tract infections (UTIs), urine dip for haematuria & leukocytes, antibiotic use, and days missed school; and will answer a Satisfaction questionnaire at the end of each 6 month arm.
1892004|NCT01263418|Drug|Ofatumumab|Intravenous; Dosage: 1000mg; Frequency: one time per week; Duration: 8 weeks
1892005|NCT01263431|Procedure|Hemorrhoidectomy|Each of the main haemorrhoid is dissected and the apex is ligated and then cut, near to the dentate line
1892006|NCT01263431|Procedure|Hemorrhoidal dearterialization|A special instrument (THD, G.F., Medical Division, Correggio, Italy )with an incorporated Doppler probe is used to detected the six terminal branches of the superior rectal artery which are ligated above the dentate line, then a running suture is performed in order to obtain a mucopexy
1892007|NCT01263444|Drug|Brinzolamide 1% / timolol 0.5% Fixed Combination|
1892008|NCT01263444|Drug|Habitual prostaglandin monotherapy|Topical ocular therapy used daily as prescribed
1892009|NCT01263457|Device|Easypod|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod
1892010|NCT01263470|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 12 weeks
1892011|NCT01263470|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 12 weeks.
1892012|NCT01263470|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 12 weeks.
1892013|NCT01263470|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 12 weeks
1892014|NCT01263470|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
1892015|NCT01263470|Drug|Placebo|Placebo-matching tablets, orally, once or three times daily for up to 12 weeks.
1892016|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
1892017|NCT01263483|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
1892018|NCT01263483|Drug|Voglibose|Alogliptin placebo-matching tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 12 weeks.
1892019|NCT01263496|Drug|Alogliptin|Alogliptin 6.25 mg, tablets, orally, once daily for up to 40 weeks.
1892020|NCT01263496|Drug|Alogliptin|Alogliptin 12.5 mg, tablets, orally, once daily for up to 40 weeks.
1892021|NCT01263496|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily for up to 40 weeks.
1892022|NCT01263496|Drug|Alogliptin|Alogliptin 50 mg, tablets, orally, once daily for up to 40 weeks.
1892023|NCT01263496|Drug|Voglibose|Voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
1892024|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 12.5 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
1892025|NCT01263509|Drug|Alogliptin and voglibose|Alogliptin 25 mg, tablets, orally, once daily and voglibose 0.2 mg, tablets, orally, three times daily for up to 40 weeks.
1892026|NCT01263522|Other|different training programs|two different endurance programs and one strength endurance program
1892027|NCT01263522|Other|control condition|unchanged lifestyle
1892028|NCT01263535|Device|SENSIMED Triggerfish|Contact lens-based device for the continuous recording of IOP fluctuations, with a portable recording system
1892029|NCT01263548|Drug|lisdexamfetamine dimesylate|Dosage form: Capsules; Dosage strength: 30-70mg/day, flexible dosing; Duration: 4 weeks
1892030|NCT01263561|Procedure|ExPRESS shunt|ExPRESS miniature glaucoma drainage device
1892031|NCT01263561|Procedure|trabeculectomy|trabeculectomy filtering surgery
1892032|NCT01263574|Drug|70% ethanol|Administration of the lock solution will occur between cycles of parenteral nutrition. Lock solutions will be administered three days per week. The pre-measured volume of lock solution will then be injected into the catheter for 4 hours. Prior to the next instillation of medications into the catheter, the lock solution will be aspirated and discarded. Another 5mL flush of saline will then be instilled into the catheter prior to medication or parenteral nutrition administration. Volume of lock solution administered will be determined by catheter size.
1892033|NCT01263613|Procedure|tumor biopsy and blood draw|tumor biopsy and blood draw during and after chemotherapy
1892034|NCT01263639|Other|Orthopaedic Attending Biosketch Card|"The intervention group will receive an attending photo/biosketch card within 24 hours of admission while the control group will not. The biosketch card will include a picture of the attending orthopaedic surgeon with a brief synopsis of his or her: education background, specialty, surgical interests, research interests, and other interests including hobbies."
1892035|NCT01263639|Other|Standard of care - No biosketch card|Standard of care
1892036|NCT01263652|Drug|Diclofenac hydroxyethylpyrrolidine|IM/PO
1892037|NCT01263652|Drug|orphenadrine|IM/PO orphenadrine
1892038|NCT01263652|Drug|Tramadol|IM/PO tramadol
1892039|NCT01263652|Drug|Dipyrone|PO/IM Dipyrone
1892040|NCT01263665|Device|25 cm GORE® VIABAHN®|25 cm GORE® VIABAHN® Endoprosthesis with PROPATEN Bioactive Surface, possibly in conjunction with an additional overlapping VIABAHN® device (2.5, 5, 10, 15, or 25 cm lengths) based on the enrolled patient's lesion length (greater than or equal to 20 cm length).
1892041|NCT01263678|Behavioral|Coaching|Decision support coaching will be provided after the participant has viewed the decision aid
1892042|NCT01263678|Other|Usual Care|Patient views DA and completes post DA survey.
1892043|NCT01263691|Biological|BioThrax|BioThrax
1892044|NCT01263691|Biological|AV7909 Formulation 1|AV7909 Formulation 1
1892047|NCT01263691|Biological|AV7909 Formulation 4|AV7909 Formulation 4
1892048|NCT01263691|Drug|Control|Saline control
1892049|NCT01263704|Drug|cyclophosphamide|150 mg/m2 on Days 1-3 of each 28-day cycle, 6 cycles
1892050|NCT01263704|Drug|fludarabine|12.5 mg/m2 on Days 1-3 of every 28-day cycle, 6 cycles
1892051|NCT01263704|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 iv Day 0 of Cycle 1, 500 mg/m2 iv Day 1 of Cycles 2-6
1892054|NCT01263730|Behavioral|Tai Chi|Tai Chi training consists of a sequence of slow, soft, and graceful movements derived from the martial arts. It is considered as a moving form of yoga and meditation combined. Tai Chi has been considered as one form of oriental healing arts, like acupuncture, which fosters the circulation of this 'chi' or energy within the body.
1892055|NCT01263743|Behavioral|Relaxation Response|The Relaxation Response is a type of relaxation. The goal of the Relaxation Response is to consciously elicit a reaction opposite in direction to the stress response.
1892056|NCT01263743|Behavioral|Relaxation Response|Relaxation Response is a type of relaxation. This is a technique that elicits a state that is opposite to the stress response.
1892057|NCT01263769|Drug|Axitinib|Starting dose: 5 mg by mouth twice each day for 12 weeks.
1892058|NCT01263782|Drug|Carboplatin|AUC 6 by vein on day 1 of every 21 day cycle for 4 cycles.
1892059|NCT01263782|Drug|Pemetrexed|500 mg/m2 by vein on day 1 of each 21 day cycle.
1892060|NCT01263782|Drug|Bevacizumab|15 mg/kg by vein on day 1 of each 21 day cycle.
1892061|NCT01263782|Drug|Cixutumumab|20 mg/kg by vein on day 1 of each 21 day cycle.
1892062|NCT01263808|Drug|Indacaterol 150 µg|Once daily (QD) via single-dose dry powder inhaler (SDDPI)
1892063|NCT01263808|Drug|Indacaterol 300 µg|QD via SDDPI
1892064|NCT01263808|Drug|Indacaterol 600 µg|QD via SDDPI
1892065|NCT01263808|Drug|Placebo|QD via SDDPI
1892066|NCT01263808|Drug|Placebo/moxifloxacin|Placebo QD via SDDPI for 14 days, followed by a single dose of moxifloxacin 400 mg
1892067|NCT01263821|Procedure|Diffusion-weighted magnetic resonance imaging|Undergo diffusion-weighted MRI
1892068|NCT01263821|Procedure|Perfusion-weighted magnetic resonance imaging|Undergo perfusion-weighted magnetic resonance imaging
1892069|NCT01263821|Procedure|Functional magnetic resonance imaging|Undergo functional MRI
1892070|NCT01263821|Procedure|Magnetic resonance spectroscopic imaging|Undergo MR spectroscopic imaging
1892071|NCT01263821|Procedure|Therapeutic conventional surgery|Undergo maximal surgical resection
1892072|NCT01263821|Procedure|Quality-of-life assessment|Ancillary studies
1892073|NCT01263821|Procedure|Radiation therapy treatment planning/simulation|Undergo IMRT planning
1892074|NCT01263821|Procedure|Intensity-modulated radiation therapy|Undergo intensity-modulated radiation therapy
1892075|NCT01263821|Other|Questionnaire administration|Ancillary studies
1892076|NCT01263834|Drug|Bevacizumab|Bevacizumab injection of 1.25m/0.05 cc + Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
1892077|NCT01263834|Drug|Mitomycin C|Mitomycin C soaked cellulose dose 0.4 mg/ml with 3 minutes of application
1892078|NCT01263847|Dietary Supplement|Galactooligosaccharide|Zero, 5 or 10 g/day of galactooligosaccharide will be administered in two yogurt drinks containing about 300 mg total calcium each per day for three weeks. During a clinical visit following three weeks of consumption, zero, 2.5 or 5 g of galactooligosaccharide will be administered in the same yogurt with the addition of 15 mg Ca-44 (calcium chloride). Participants will be given one of the above yogurts at breakfast in addition to intravenously receiving 3.5 mg Ca-43 (calcium chloride) in 4 ml saline one hour after breakfast consumption.
1892079|NCT01263860|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 24 weeks
1892080|NCT01263860|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 24 weeks
1892081|NCT01263860|Drug|Peginterferon alfa2a|patients receive a dose of 180 µg of PEGASYS once a week for 48 weeks
1892082|NCT01263860|Drug|Ribavirin|patients receive a dose 800 to 1200 mg of ribavirin once a day(according to weight) for 48 weeks
1892083|NCT01263873|Device|Mallinckrodt (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
1892084|NCT01263873|Device|Parker Flex-Tip (ETT)|7.0 millimeter internal diameter for female 8.0 millimeter internal diameter for male
1892085|NCT01263886|Drug|ombrabulin (AVE8062)|"Pharmaceutical form:solution
Route of administration: intravenous"
1892086|NCT01263886|Drug|placebo|"Pharmaceutical form:solution
Route of administration: intravenous"
1892087|NCT01263899|Drug|SB1518|SB1518 taken orally daily for 28 consecutive days in a 28 day cycle.
1892088|NCT01263912|Dietary Supplement|Nutrition supplement containing Long Chain Polyunsaturated Fatty Acids (LCPUFA)|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
1892089|NCT01263912|Dietary Supplement|Nutrition supplement containing Long Chain Polyunsaturated Fatty Acids (LCPUFA)|Children 12-13 months old will be assigned at random to receive either a nutrition supplement containing LCPUFA or a placebo until 24 months-of-age
1892090|NCT01263925|Drug|Alprostadil (Prostaglandin E1)|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours.
4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of 3 ampoules (20 µg) of Prostaglandin E1 (total 60 µg) in 50 - 250 ml physiological saline solution over 2 hours."
1892091|NCT01263925|Drug|Pentoxifylline|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets.
4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) 600 mg Pentoxifylline tablets."
1892133|NCT01269762|Drug|LipoCol Forte|Single dose of one, two and four 600 mg red yeast rice capsules (LipoCol Forte) Multiple dose of 600 mg red yeast rice Capsules (LipoCol Forte)twice daily for 4.5 days
1892092|NCT01263925|Drug|Placebo to Pentoxifylline oral|"4-week Daily Treatment Period 1: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets.
4-week Interval Treatment Period 2: 4 weeks of 2 x daily (including weekends) matching Placebo to Pentoxifylline tablets."
1892093|NCT01263925|Drug|Placebo to Alprostadil (Prostaglandin E1) intravenous|"4-week Daily Treatment Period 1: 4 weeks of 1 x daily intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours.
4-week Interval Treatment Period 2: 4 weeks of 2 x weekly intravenous infusion of Placebo in 50 - 250 ml physiological saline solution over 2 hours."
1892094|NCT01263938|Drug|Atorvastatin|"For subjects on PI-based HAART therapy: 10mg/day X 2weeks followed by 20mg/day.
For subjects on non PI-based HAART therapy: 20mg/day X 2weeks followed by 40mg/day."
1892095|NCT01263951|Drug|Everolimus|One 5 mg. tablet daily.
1892096|NCT01263951|Drug|Sorafenib|200 mg. twice daily.
1892097|NCT01263964|Procedure|coronary angiogram|coronary angiogram
1892098|NCT01263977|Device|Picco- thermodilution catheter|Transpulmonary thermodilution and pulse contour analysis with arterial catheter Arterial access via femoral
1892099|NCT01263990|Device|NexFin|noninvasive finger cuff system
1892100|NCT01264003|Drug|sefazolin|In prophylaxis
1892101|NCT01264016|Device|Investigational Blood Glucose Monitoring System|Untrained subjects with diabetes performed Blood Glucose (BG) tests with subject's capillary fingerstick using the investigational Tradewind meter and investigational sensor. Study staff tested subject venous blood. All BG Results were compared to a reference laboratory glucose method. Subjects' success at performing basic tasks using only the User Guide were rated by study staff.
1892102|NCT01264029|Behavioral|Mindful Tai Chi Intervention|
1892103|NCT01264029|Behavioral|Mindfulness Meditation|
1892104|NCT01264029|Behavioral|Mall Walking|
1892105|NCT01264029|Behavioral|Weekly Discussion|
1892106|NCT01264042|Dietary Supplement|Ferrous Sulfate|60 mg with 200 mL water, single administration
1892107|NCT01264068|Drug|Finished Herbal Product such as Suan Tsao Jen Tang, Jia-Wey Shiau-Yau San|Take medicine every day 3 times, each time 4 grams.
1892108|NCT01264081|Drug|Lapatinib|500 mg PO (orally) twice a day for 28 days (1 cycle). Up to 27 cycles allowed if response seen.
1892109|NCT01264094|Drug|Clevudine|clevudine 30 mg qd
1892111|NCT01264133|Drug|Clevudine, Adefovir|Clevudine 30mg qd or Clevudine 30mg + Adefovir 10mg qd
1892112|NCT01264146|Procedure|HBOT|Open reduction and internal fixation of calcaneal fracture + hyperbaric oxygen therapy 20 postoperative days (one time, 90 minutes a day)
1892113|NCT01264146|Procedure|Placebo (Sham)|open reduction and internal fixation of calcaneal fracture + Placebo (Sham)
1892114|NCT01264159|Device|Lung impedence-guided therapy|
1892115|NCT01264159|Other|Usual treatment of patients with developing acute heart failure|
1892116|NCT01264172|Procedure|PCCP|PCCP: an minimal-invasive surgery technique, in wich a special plate is pushed in position and fixed through 2 small approaches only (about 2 cm long)
1892117|NCT01264172|Procedure|DHS|Conventional surgical treatment of proximal femur fracture including one longer approach from lateral
1892118|NCT01264172|Procedure|Osteosynthesis with nails|Osteosynthesis with nails is a minimal-invasive surgery technique for proximal femur fractures.
1892119|NCT01264198|Behavioral|Resistance Training|Supervised Resistance Training
1892120|NCT01264211|Drug|Diacerein|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
1892121|NCT01264211|Drug|Placebo|Week 0 to Week 4: Diacerein 50 mg daily for 4 weeks Week 4 to Week 24: Diacerein 100 mg daily for 20 weeks
1892122|NCT01264224|Drug|PAC-14028|tablets, oral administration, single/multiple dosing, dose escalation
1892123|NCT01264237|Drug|Etoricoxib|90mg Tablet QD at 10:00a.m.
1892124|NCT01264237|Drug|Placebo|One tablet QD at 10:00a.m.
1892125|NCT01264250|Drug|AZD2927|Single dose of AZD2927
1892126|NCT01264250|Drug|Placebo|Single dose of placebo
1892127|NCT01264289|Drug|Finasteride|Finasteride Tablets 5 mg
1892128|NCT01264302|Drug|Finasteride|Finasteride Tablets 5 mg
1892129|NCT01264315|Drug|Lenalidomide|"Lenalidomide will be started at 6 months post-allotransplant at 10 mg/day continuously in all patients:
absolute neutrophil count >1x109/L without growth factors
platelet count >75x109/L without transfusion support
calculated/measured creatinine clearance: ≥20mL/minute
total bilirubin <2 x the upper limit of normal
AST (SGOT) and ALT (SGPT) <2.5 x upper limit of normal
<1mg/kg/day of prednisone, and no more than 2 immunosuppressive drugs other than steroid to control GVHD
Treatment will be continued without interruption, unless not tolerated, until unacceptable adverse events or progressive disease occur. In case of disease progression occurring before the start of lenalidomide, the patient will be withdrawn from study and treated according to the center preference. Lenalidomide will be discontinued in patients achieving and maintaining molecular remission for 2 consecutive controls at least 6 weeks apart."
1892130|NCT01269736|Behavioral|Education|Online ECG monitoring education program and strategies to implement and sustain change for nurses
1892316|NCT01275443|Drug|300mg TMC278LA|300mg TMC278LA intramuscular injection
1892134|NCT01269775|Other|Teaching Methods|We carried out a randomized controlled trial comparing three methods of teaching. These three instructional methods consist of face to face lecture, interactive internet based teaching and computer based teaching (lecture synchronized with presentation) regarding medical students' knowledge achievement and satisfaction.
1892135|NCT01269788|Drug|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
1892136|NCT01269788|Drug|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
1892137|NCT01269788|Drug|placebo|oral , daily 30 mins before breakfast, for 6 weeks
1892138|NCT01269788|Drug|Omeprazole|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
1892139|NCT01269788|Drug|Fluoxetine|20 mg , oral , daily 30 mins before breakfast, for 6 weeks
1892140|NCT01269788|Drug|placebo|oral , daily 30 mins before breakfast, for 6 weeks
1892141|NCT01269801|Drug|onabotulinumtoxinA|"Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;
Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.
At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
1892142|NCT01269801|Drug|JUVÉDERM|"Group 1 will initially receive BOTOX® Cosmetic or VISTABEL® injections to the affected facial regions;
• Group 2 will initially receive JUVÉDERM® Ultra XC or JUVÉDERM® Ultra 2 (for moderate facial lines or folds) or JUVÉDERM® Ultra Plus XC or JUVÉDERM® Ultra 3 (for severe facial lines or folds) injections to the affected facial regions.
At 4 weeks,Group 1 patients who initially received BOTOX® Cosmetic or VISTABEL® treatment will be crossed over and receive JUVÉDERM® treatment, and Group 2 patients who initially received JUVÉDERM® treatment will be crossed over to receive BOTOX® Cosmetic or VISTABEL® treatment."
1892143|NCT01269814|Procedure|Gastroscopy|Gastroscopy
1892144|NCT01269827|Drug|Pentoxifylline|Over a period of 4 months, patients of the study group received one PTX tablet (400 mg) orally once a day (at dinner time)
1892145|NCT01269827|Drug|starch tablets|Over a period of 4 months, patients of the control group received one starch tablet orally once a day (at dinner time)
1892146|NCT01269853|Drug|Bevacizumab|"Experimental portion of this proposal:
This trial will have two experimental arms that will be open labeled and non-randomized.
ARM 1 (If the patient has multifocal disease or leptomeningeal disease)
Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until disease progression on MRI scan.
If progression occurs, repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression and wait 28 days and then restart Intravenous Bevacizumab (10mg/kg) every two weeks thereafter until progression on MRI scan.
Repeat Cycle"
1892147|NCT01269853|Drug|Bevacizumab|"ARM 2 (If the patient has no multifocal disease or leptomeningeal disease)
Day 0: Intraarterial Bevacizumab single dose (15mg/kg) after Mannitol to open the blood brain barrier Day 28: No biweekly IV Bevacizumab treatment
If MRI shows progression then repeat Intraarterial Bevacizumab single dose (15mg/kg) to area of progression Repeat Cycle"
1892148|NCT01269866|Drug|Cymbalta|Cymbalta 60 to 120 mg PO QD
1892149|NCT01269879|Device|Flexi-Bar vibration device only|daily vibration training 10min twice
1892150|NCT01269879|Device|Flexi-Bar + XCO-Trainer|"XCO-Trainer is a way to overload the cardiovascular system and the core muscles during running. An oscillating mass inside the XCO-Trainer is activated when the XCO is propelled forward and backward with force. The movement of the mass triggers a series of responses from the runners' body.
In addition Flexi-Bar vibration training as in the referred active comparator group"
1892151|NCT01269892|Dietary Supplement|lactose-free milk|a milk without lactose
1892152|NCT01269892|Dietary Supplement|conventional milk|a milk with lactose
1892153|NCT01269918|Drug|Remifentanil|Remifentanil 0.08-0.15MCG/KG/MIN INFUSION THROUGHOUT PROCEDURE BASED ON HEMODYNAMICS
1892154|NCT01269918|Drug|Dexmedetomidine|a loading dose of dexmedetomidine was given at 0.5 to 1 micrograms/kg ideal body weight over 15 minutes, followed by an infusion at 0.2 to 0.7 micrograms/kg/hour.
1892155|NCT01269931|Procedure|EBUS-TBNA|Endobronchial ultrasound with transbronchial needle aspiration (EBUS-TBNA) is a revolutionary diagnostic pulmonary procedure that allows visualization and safe, accurate biopsies of intra-thoracic structures during bronchoscopy. Patients enrolled in this study at the University of Calgary would have undergone this procedure regardless of being enrolled in this study. The purpose of the study was to prospectively compare the EBUS-TBNA performance of 2 groups of learners, performing EBUS-TBNA on patients, who had received to different methods of EBUS-TBNA training. Patients were randomly assigned to undergo bronchoscopy with a trainee from Group 1 or Group 2.
1892156|NCT01269970|Other|18-FDG-PET-CT|
1892158|NCT01269996|Drug|Janumet, Lantus|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.
Treatment groups:
Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.
Group 2 - Janumet followed by Lantus insulin injection."
1892159|NCT01269996|Drug|metformin, gliclazide, protaphane|"In this multicentre, randomized, open-label prospective study. Recruited patients will be randomized to one of the two treatment groups. Treatment efficacy and safety in terms of HbA1c control and hypoglycemic events will be evaluated.
Treatment groups:
Group 1 - Metformin followed by Sulfonylurea (Gliclazide) and supplementary intermediate-acting insulin (Protaphane) injection.
Group 2 - Janumet followed by Lantus insulin injection."
1892160|NCT01270022|Other|Implementation|
1892161|NCT01270022|Other|dissemination|
1892162|NCT01270035|Drug|Adalimumab|To increase the ADA dose from 40 mg eow to 80 mg eow
1892163|NCT01270048|Drug|mild-ex-gwarip|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
1892164|NCT01270048|Other|Placebo|three times a day, AC 30 min., 4 capsules taken each time (4capsules=2.5g), 8 weeks.
1892165|NCT01270061|Behavioral|HIV testing|HIV education and counseling from a trained Research Assistant and offering of a free rapid, oral HIV test.
1892166|NCT01270061|Behavioral|General Health Screen|A video will provide health education on diabetes, hypertension, and HIV. The video will then offer free blood pressure check, blood glucose measuring, and a free, rapid oral HIV test.
1892167|NCT01274182|Biological|GP2013|1000 mg
1892168|NCT01274182|Biological|rituximab|1000 mg
1892169|NCT01274195|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
1892170|NCT01274221|Drug|SPD489|1 capsule per day throughout the open-label treatment phase and for one week of the double-blind crossover phase
1892171|NCT01274221|Other|Placebo|1 capsule per day for one week of the double-blind crossover phase
1892172|NCT01274234|Device|COMBO Stent (OrbusNeich Medical, Fort Lauderdale, Florida)|The COMBO Stent is a hybrid version of the GENOUS Stent. Upon implantation to the coronary artery, the stent will deliver a drug (sirolimus) to the wall of the treated segment to suppress neointimal growth, in addition to the anti-CD34 antibody coating which will in theory attract circulatory endothelial progenitor cells to hasten endothelialization and promote healing of the stented segment, and thereby may reduce late stent thrombosis.
1892173|NCT01274247|Drug|Topical Benzocaine|Topical administration of a drop of benzocaine to the lingual frenulum
1892174|NCT01274260|Drug|methylprednisolone|Subjects in this group will receive a loading dose of methylprednisolone 2mg/kg followed by 1mg/kg/day of methylprednisolone infusion from day 1 to day 7; 0.5mg/kg/d from days 8 to 10, 0.25mg/kg/d on days 11 and 12, 0.125mg/kg/d on days 13 and 14. The study drug infusion will be discontinued after 14 days.
1892175|NCT01274260|Drug|Normal Saline (0.9%)|The placebo will be 0.9% (normal) saline and the active medication will be diluted in 0.9% (normal) saline.
1892176|NCT01274273|Drug|Interleukin-2|2.4 MIU/m2 s.c. two times daily, 5 days per week, weeks 1 and 2, every 28-day-cycle, for a maximum of 9 cycles (i.e.for a maximum of 9 months).
1892177|NCT01274273|Drug|Interferon Alfa-2b|IFN-alfa given as one priming-week of daily IFN 3.0 MIU, followed by up to 9 treatment cycles (i.e. for a maximum of 9 months) with IFN-alfa 3.0 MIU as a fixed dose s.c. once daily - 5 days per week.
1892178|NCT01274273|Drug|Bevacizumab|Bevacizumab doses of 10 mg per kilogram of body weight, given every two weeks i.v. until disease progression, unacceptable toxicity, withdrawal of consent or a maximum of 1 year following obtaining no evidence of disease (NED).
1892179|NCT01274299|Procedure|Digital camera picture|A digital camera will be used to take a 3D picture the face of each infant. Off line measurements of landmarks on the face will be marked and dimensions will be calculated using a special analysis software.
1892180|NCT01274312|Procedure|Xiao procedure|Cross over surgery. Proximal part of L5 Ventral root is anastomosed to distal part of ventral root of S2 or S3 producing a somato-sensory reflex arch
1892181|NCT01274325|Drug|Sereflo|Patients take sereflo (25/125) 2 puffs twice a day for 4 weeks
1892182|NCT01274325|Drug|Seretide|Patients will take Seretide (25/125) 2 puffs twice a day for 4 weeks
1892186|NCT01274351|Drug|Tasigna|
1892187|NCT01274364|Other|JADE|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will receive protocol-driven diabetes care using a web-based disease management program (JADE), delivered by a trio-team comprising of a trained doctor, nurse and physician assistant.
1892188|NCT01274364|Other|DIAMOND|Patients will receive comprehensive assessments at baseline and again after 12-months. In the interim between these two time points patients will be managed according to 'usual care' procedures.
1892189|NCT01274377|Biological|CMV Specific T Cell donor lymphocyte infusion|Donor Lymphocyte Infusion (DLI)
1892190|NCT01274403|Drug|Melphalan, Prednisone and Thalidomide|
1892191|NCT01274416|Behavioral|Acceptance and Commitment Therapy|The stated goal of this intervention is to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in flexible action.
1892192|NCT01274416|Behavioral|Parent Skills Training|Skills Training for parents that provides psychoeducation for eating disorder and skills in behavior management, self-regulation, and emotion regulation.
1892193|NCT01274429|Drug|Peanut flour|Peanut flour that is ingested daily and administered in gradually increasing amounts up to a maximum maintenance dose.
1892194|NCT01274442|Other|anamnesis|To update the anamnesis.
1892195|NCT01274442|Procedure|oral examination|A brief clinical oral examination will be performed.
1892196|NCT01274442|Procedure|Blood sample|A blood sample will be taken to identify relevant genetic polymorphisms.
1892197|NCT01274455|Genetic|Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes|Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
1892198|NCT01274481|Drug|Iloprost|patients inhale 20 mcg of Iloprost via nebulizer and, if oxygenation and blood pressure is maintained receive a second dose of 20 mcg of Iloprost 30 minutes later.
1892199|NCT01274507|Other|Medical tests|All participants will undergo medical tests and will be observed.
1892201|NCT01274533|Drug|Lenalidomide|25mg or 10mg (based on creatinine clearance) once daily for days 1-21 of a 28 day cycle
1892202|NCT01274546|Device|cruciate-retaining Foundation Knee system|subjects who received the cruciate-retaining Foundation Knee system greater than or equal to 10 years ago and still maintain the original device in their knee.
1892203|NCT01274559|Drug|Extended-release niacin/laropiprant (ERN/LRPT)|1 oral 1 g tablet of ERN/LRPT to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of ERN/LRPT to be taken together in the evening or at bedtime with food for the next 8 weeks. Each 1g tablet contains 1g ERN and 20 mg LRPT
1892204|NCT01274559|Drug|Placebo|1 oral 1 g tablet of placebo to be taken with food in the evening or at bedtime for the first 4 weeks of treatment; then 2 oral 1g tablets of placebo to be taken together in the evening or at bedtime with food for the next 8 weeks.
1892205|NCT01274585|Device|Posterior tibial nerve stimulation (PTNS)|Stimulation using PTNS device for 30 minutes weekly for 12 weeks
1892206|NCT01274585|Device|Posterior tibial nerve stimulation|Sham needle placement without active PTNS device for 30 minutes weekly for 12 weeks
1892207|NCT01274598|Biological|Lactobacillus Rhamnosus GG, ATCC 53103 (LGG)|1x10^10 CFU by mouth twice daily for 28 days
1892208|NCT01274611|Drug|Botulinum Toxin Type A|Botox will be injected into the underarm, targeting the sweat glands, to stop underarm sweating.
1892209|NCT01274611|Device|Suction-Curettage|The doctor will insert a suction tool into two small incisions in order to suction out the sweat-producing glands. It is similar to liposuction, but instead of suctioning out fat, the doctor suctions out the layer of the deep skin where the sweat glands are located to decrease underarm sweating.
1892210|NCT01274624|Biological|REOLYSIN®|1 hour intravenous infusion administered on Days 1, 2, 3, 4, and 5 every 4 weeks.
1892211|NCT01274624|Drug|Irinotecan|90-minute intravenous infusion on Day 1 every 2 weeks. Dose levels of 125 mg/m2, 150 mg/m2, 150 mg/m2, 180 mg/m2.
1892212|NCT01274624|Drug|Leucovorin|2-hour infusion of 400 mg/m2 on Day 1 every 2 weeks.
1892213|NCT01274624|Drug|Fluorouracil (5-FU)|400 mg/m2 intravenous bolus followed by 2400 mg/m2 as a continuous intravenous infusion over 46 hours administered on Day 1 every 2 weeks.
1892214|NCT01274624|Drug|Bevacizumab|30, 60 or 90 minute infusion on Day 1 every 2 weeks. Dose level 5 mg/kg.
1892215|NCT01274637|Drug|Dalteparin Sodium|5,000 IU/0.2ml (anti-Xa) administered once daily in prefilled glass syringes.
1892216|NCT01274650|Procedure|Indirect Calorimetry|Indirect Calorimetry
1892217|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
1892218|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
1892219|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
1892220|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
1892221|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
1892222|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule in the fasting state in the AM; correspondingly, one dose of a matched powder-in-capsule placebo will be administered in the fasting state in the AM.
1892223|NCT01274663|Drug|PF-05175157 or Placebo|One dose of PF-05175157 will be administered as a powder-in-capsule immediately after breakfast; correspondingly, one dose of a matched powder-in-capsule placebo will be administered immediately after breakfast.
1892224|NCT01274676|Device|carotid stenting with MOMA|The MOMA system is an endovascular catheter for proximal protection during carotid stenting. The system allows a concomitant balloon occlusion of both external and common carotid arteries leading to blood flow reversal within the internal carotid artery.
1892225|NCT01274676|Device|Carotid stenting with filter wire EZ|The filter wire EZ a distal protection system that is placed in he distal internal carotid artery before carotid stenting. The filter should entrap almost all the debries that are generated during endovascular procedure. At the end of the procedure the filter is retrieved throught a dedicated retrieval catheter.
1892226|NCT01274689|Other|individually tailored lead weight|patients were treated with an individually tailored lead weight to train M. orbicularis oculi during day time
1892227|NCT01274702|Other|Visual Reconstitutions Therapy|
1892228|NCT01274702|Other|Saccadic Eye Movement Training|
1892229|NCT01274715|Behavioral|Behavioral Health Coaching|Behavioral health coaching consisting of goal-setting, action planning, behavioral activation, and cognitive therapy is delivered by telephone over approximately 3 months.
1960674|NCT03152565|Drug|Avelumab|"Autologous Dendritic Cells vaccine: A dose of ADC at days 1, 14, 28, 42 and 56 (total of 5 doses), and thereafter every 6 months until disease progression (maximum of 6 additional doses) or unacceptable toxicity.
Avelumab will be administered intravenously at a dose of 10 mg per kilogram of body weight, every 14 days until disease progression or unacceptable toxicity."
1892233|NCT01274780|Drug|Darunavir / Ritonavir + Tenofovir / Emtricitabine|oral, 800/100 mg, qd + oral, 300/200 mg, qd
1892234|NCT01274780|Drug|Atazanavir / Ritonavir + Tenofovir / Emtricitabine|oral, 300/100 mg, qd + oral, 300/200 mg, qd
1892235|NCT01274793|Drug|Mosapride Citrate tablet|Orally administered 5 mg mosapride citrate tablet s three times a day for 4 continuous weeks if no severe adverse effects were found.
1892236|NCT01274793|Device|Low-dose acupuncture|In this low current intensity group, the current applied would be relatively weak,it was clearly perceived by the participants
1892237|NCT01274793|Device|High-dose acupuncture|In this group,the current was strong enough to reach the patients'tolerance threshold value.
1892238|NCT01274806|Other|Physical Therapy|Core Stability Exercise, Endurance training, recovery massage
1989825|NCT02359331|Procedure|H. pylori culture and antimicrobial susceptibility testing|"This intervention will be performed in 7 days tailored therapy group.
All the patients who enrolled in this arm, they will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. Amoxicillin, clarithromycin, metronidazo, tetracycline and moxifloxacin for the H. pylori isolates were examined by use of the serial two fold agar dilution method"
1892239|NCT01274819|Other|Dynamic Light|Dynamic Light Application (DLA) is a light application which exposes the subject in the room to a varying light intensity and light temperature during the day thus mimicking a natural daylight exposure.
1892240|NCT01274832|Device|Deep Brain Stimulation|Deep Brain Stimulation of STN in Parkinsonian patients
1892241|NCT01274845|Other|Heliox mechanical ventilation|Mechanical ventilation (MV) with air-oxygen at baseline, then 1 hour of heliox (helium-oxygen) MV and then return to MV with air-oxygen.
1892242|NCT01274884|Procedure|Tightrope fixation|Arthroscopic repair
1892243|NCT01274897|Biological|Novartis MenACWY-CRM|All subjects had blood drawn at Day 1 and Day 29.
1892244|NCT01274897|Biological|Saline Placebo|All subjects had blood drawn at Day 1 and Day 29.
1892245|NCT01274910|Dietary Supplement|EPAX 6000 EE 1000mg (0.6 gr DHA+EPA)|"Patient will receive Fish Oil capsules (EPAX 6000 EE) .
Treatment: 5 capsules per day"
1892246|NCT01274910|Dietary Supplement|Capsules (Placebo)|"Patient will receive capsules which not contain fish oil.
Treatment: 5 capsules per day"
1892247|NCT01274923|Device|"MEDISPEC treatment probe"|shock wave treatment
1892248|NCT01274936|Drug|Qishe Pill|Pill, 3.75 g, twice per day, four weeks
1892249|NCT01274936|Drug|Qishe Placebo|Pill, 3.75 g, twice per day, four weeks
1892250|NCT01274949|Device|LI-ESWT|Low intensity shock wave treatment - 12 sessions
1892251|NCT01274962|Drug|FOLFOX|"Oxaliplatin* 85 mg/m2 IV in 500 mL of D5W over 120 minutes
Folinic Acid (Leucovorin)* 400 mg/m2 IV in 250 ml D5W over 120 minutes
5-Fluorouracil (5-FU) 400 mg/m2 IV bolus, after Folinic Acid
5-Fluorouracil** 2400 mg/m2 IV over 46 h in D5W to a total volume of 92 mL by continuous infusion at 2 mL/hour.
Repeat every 14 days for 6 cycles in the arm A and to be completed with 6 cycles after surgery and 12 cycles in arm B.
If necessary the schedule may be modified +/- 3 days."
1892252|NCT01274962|Radiation|high dose rate endorectal brachytherapy|High dose rate endorectal brachytherapy, consisting in a total dose of 26 Gy in 4 daily fractions of 6.5 Gy.
1892253|NCT01274975|Other|Autologous Adipose Derived Mesenchymal Stem Cells|Intravenous infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 4 x 10e8 cells
1989826|NCT02359331|Drug|14 days empirical bismuth quadruple therapy (Proton pump inhibitor)|"Giving the 14 days PBMT regimen as 2nd rescue therapy
Proton pump inhibitor (PPI) regular dose b.i.d., tripotassium dicitrate bismuthate 300 mg q.i.d. (three tablets at 30 min before meals and one tablet at 2 hours after dinner), metronidazole 500 mg t.i.d., and tetracycline 500 mg q.i.d."
1989827|NCT02359331|Drug|Metronidazole|
1892256|NCT01275014|Drug|Dexamethasone|1 ml of 20mg/ml solution was applied once, following the arthrocentesis procedure of the TMJ
1892257|NCT01275014|Drug|Isotonic saline|1 ml of isotonic saline was applied once, following the arthrocentesis procedure of the TMJ
1892258|NCT01275027|Dietary Supplement|Nutralin|7 capsules taken 15 minutes before each of the three main meals of the day
1892259|NCT01275040|Other|Mobile screening; Health Education|Active screening for diabetes complications - neuropathy screening, retinopathy screening, blood and urine tests. Health education for both patients and health workers on diabetes. Active collaboration between primary and tertiary care in the public health system.
1892260|NCT01275040|Other|Health education|Health education given to both patients and healthcare workers. No mobile screening team will visit facilities and no interaction between primary and tertiary care will be evaluated.
1892262|NCT01275066|Drug|BMN 110 Weekly|BMN 110 Weekly: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours once a week.
1892263|NCT01275066|Drug|Placebo|Intravenous infusion of placebo solution at a volume equivalent to that needed for 2.0 mg/kg dose of BMN 110 administered over a period of approximately 4 hours once a week.
1892264|NCT01275066|Drug|BMN 110 Every Other Week|BMN 110 Every Other Week: Intravenous infusion of BMN 110 at a dose of 2.0 mg/kg administered over a period of approximately 4 hours every other week and infusions of placebo on alternating weeks.
1892265|NCT01275092|Device|CorPath robotic-assisted PCI|CorPath 200® robotic-assisted percutaneous coronary intervention
1892266|NCT01275105|Drug|Vehicle|one drop in each eye at designated visits
1892267|NCT01275105|Drug|Brimonidine Tartrate 0.01%|one drop in each eye at designated visits
1892268|NCT01275105|Drug|Brimonidine Tartrate 0.025%|one drop in each eye at designated visits
1892269|NCT01275105|Drug|Oxymetazoline HCl 0.025%|one drop in each eye at designated visits
1989828|NCT02359331|Drug|Tetracycline|
1892272|NCT01275131|Drug|Insulin aspart|
1892273|NCT01275131|Drug|Recombinant human hyaluronidase PH20 (rHuPH20)|
1892274|NCT01275144|Drug|LY2216684|Administered orally
1892275|NCT01275144|Drug|Placebo|Administered orally
1892276|NCT01275144|Drug|Lorazepam|Administered orally
1892277|NCT01275157|Drug|LY2452473|Administered orally as a liquid suspension
1892278|NCT01275170|Drug|MK-7655|125 mg intravenous (IV) over 30 minutes as a single dose
1892279|NCT01275170|Drug|imipenem + cilastatin|250 mg IV over 30 minutes as a single dose
1892280|NCT01275170|Drug|caffeine|caffeine caplet, single 200 mg dose, orally
1892281|NCT01275170|Drug|midazolam|midazolam hcl syrup, single 2.0 mg dose, orally
1892282|NCT01275170|Drug|omeprazole|omeprazole tablets, single 40 mg dose (as two 20 mg tablets), orally
1892283|NCT01275183|Drug|raltegravir and cisplatin|"Cisplatin, intravenous, 30 mg/m2, days 2 and 16, 1 to 2 hours
Raltegravir, oral,400 mg, twice per day, days 1 through 5 or days 15 to 19
Part 2 (optional): Docetaxel, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles
Part 2 (optional): Cisplatin, intravenous, 75 mg/M2, day 2, every 21 days, 3 to 6 cycles
Part 2: (optional): Raltegavir, oral, 400 mg, twice per day, days 1 through 5, 3 to 6 cycles"
1892284|NCT01275196|Drug|Nilotinib|
1892285|NCT01275196|Drug|Imatinib|
1892286|NCT01275209|Drug|HCD122|
1892287|NCT01275222|Drug|Everolimus|
1892288|NCT01275222|Drug|Imatinib|Glevec is the brand name for imatinib.
1892289|NCT01275248|Drug|Ondansetron|Oral tablets in 0.5mg or 0.75mg strength
1892290|NCT01275248|Drug|Placebo|Oral tablet to match the experimental interventions
1892291|NCT01275261|Behavioral|Nursing protocol to avoid Foley catheter placement|A specific nursing order protocol will be followed addressing urinary care to try to avoid the use of Foley catheters.
1893317|NCT01281111|Drug|ASA matching placebo|
1892292|NCT01275274|Drug|Retinoic acid|Patients will be started at half the recommended dose of retinoic acid for the treatment of acute promyelocytic leukemia (APL), i.e. 22.5mg/m2/day orally in two divided doses, to minimize the risk of adverse events. If there is no decrease in PR3/MPO gene expression to a fold change of < 2 by quantitative polymerase chain reaction(QT-PCR) technique for PR3 at the end of 4 weeks, the dose will be increased to 45 mg/m2/day in two divided doses for an additional 8 weeks. If the patient shows a decrease in PR3/MPO gene expression to < 2 at 4 weeks, the patient will remain on the same dose for the remainder of 12 weeks. All patients will be followed for a total of 12 months for safety evaluations and to assess changes in disease activity and the incidence of disease relapse.
1892293|NCT01275274|Drug|Standard of care|maintenance therapy with azathioprine or mycophenolate mofetil with or without small dose prednisone. Dose, frequency and duration depend on disease activity (partial or complete remission).
1892294|NCT01275287|Drug|Standard of care treatment|"induction : pulse methyl prednisolone (7 mg/kg/day x3) then prednisone 1 mg/kg/day (not to exceed 60 mg/day) for 4 weeks, then taper over the following 12 weeks. Cyclophosphamide starting at 0.75 gm/m2 IV (decreased to 0.5 gm/m^2 for patients > than 70 or with estimated Glomerular Filtration Rate (eGFR) < 20 ml/min) to be titrated up to 1 gm/m^2 depending on the 2 week white blood count (WBC) nadir > 3000 cell/μL. Subsequent cyclophosphamide will be given every 4 weeks for at least 2 more doses. Once complete remission for 2 months, patient may be switched from cyclophosphamide to maintenance therapy with azathioprine 1.5-2 mg/kg/day for 6-9 months (to a total of 12 months of therapy) .
For patients who cannot tolerate cyclophosphamide, or who have received it in large doses previously, another medication called rituximab may be used instead. However, if rituximab is indicated for the patient, he cannot participate in the study."
1892295|NCT01275287|Drug|eculizumab|In addition to conventional therapy, patients randomized to eculizumab will receive 600 mg by IV infusion over 35 minutes every 7 days for the first 4 weeks, then 900 mg by IV infusion for the fifth dose 7 days later (week 5), then 900 mg every 14 days thereafter, for a total of 9 doses (about 3 months of treatment). This dosing scheme is based on that used for the treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH). The length of treatment is shorter than for PNH, based on a desire to target the addition of eculizumab to the period of maximal disease activity, while limiting the risks of infectious complications in this first pilot study.
1989829|NCT02359331|Drug|tripotassium dicitrate bismuthate|
1989830|NCT02359331|Drug|7 days tailored therapy Proton Pump Inhibitor|
1989831|NCT02359331|Drug|Moxifloxacin|
1989832|NCT02359331|Drug|Amoxicillin|
1892301|NCT01275313|Device|Lightweight wheelchair|Seating and wheeled mobility assessment and fitting of a lightweight wheelchair
1892302|NCT01275313|Device|Skin Protection Cushion|Seating assessment and provision of a cushion meeting CMS code for Skin Protection wheelchair cushion
1892303|NCT01275339|Drug|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
1892304|NCT01275339|Drug|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until study completion (6 months). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills is not tolerated, then the dose will be decreased back to 1 pill daily.
1892305|NCT01275352|Drug|Eplerenone|Eplerenone 50 mg/day
1892306|NCT01275352|Drug|placebo|placebo
1892307|NCT01275365|Drug|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
1892308|NCT01275365|Drug|Testosterone enanthate|Testosterone enanthate 100 mg intramuscularly weekly
1892309|NCT01275378|Behavioral|Collaborative Care Plus|Traditional collaborative care + systematic addressing of ADHD comorbidities, parental mental health issues, and adherence to treatment plans
1892310|NCT01275378|Behavioral|Traditional Collaborative Care|Traditional collaborative care, in which care managers serve as intermediaries between primary care physicians and specialists
1892311|NCT01275391|Behavioral|Computer Screening, Brief Intervention, Referral toTreatment|A computerized screening for tobacco, alcohol and drug use accompanied by 10-15 pages of health information regarding the risks of tobacco, alcohol and drug use. This is followed by a brief conversation with the primary care provider regarding the health risks of tobacco, alcohol and drug use and a referral to treatment for those at high risk of substance use problems.
1892312|NCT01275404|Behavioral|Sexual Medicine Rehabilitation Program + nurse practitioner information phone calls|Baseline Assessment which is 90-minute patient focus group interviews. SMRP, provided to all participating patients, consists of the following steps: 1) An introductory visit with SMRP Director, Dr. Mulhall, to orient the patient to post-surgery erectile rehabilitation and assess the patient‟s success with PDE-5 inhibitors; 2) Penile injection training provided by a NP over two visits, with follow-up calls as necessary until injection method and dose are deemed correct; 3) Follow-up visits with Dr. Mulhall every 4 months to monitor progress with rehabilitation. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
1892313|NCT01275404|Behavioral|Sexual Medicine Rehabilitation Program + Acceptance and Commitment Therapy for Erectile Dysfunction|Baseline Assessment which is 90-minute patient focus group interviews. SMRP+ACT-ED will receive four individual ACT-ED counseling sessions (60 minutes each) over a period of approximately four months, and will also be followed up with questionnaires 4 and 8 months post baseline These sessions focus on the four core elements of ACT: values, acceptance, exposure, and commitment. Study assessments will be administered at baseline, at 4-8 months post baseline (follow up 1) and 4-8- months post follow up 1 (follow up 2).
1892314|NCT01275430|Device|Sherlock 3CG|Sherlock 3CG is indicated for central venous catheter guidance and positioning during catheter placement. The Sherlock 3CG provides real time catheter tip location information through the use of passive magnet and cardiac electrical signal detection.
1892315|NCT01275430|Other|Blind Placement|"PICCs will be placed blindly, without the use of any tip location/positioning device."
1892317|NCT01275443|Drug|150mg TMC278LA|150mg TMC278LA intramuscular injection
1892318|NCT01275443|Drug|1200mg TMC278LA|1200mg TMC278LA intramuscular injection
1892319|NCT01275443|Drug|600mg TMC278LA|600mg TMC278LA intramuscular injection
1892320|NCT01275456|Procedure|Exposure to house dust mite|0 SQE/qm for 4 hours 250 SQE/qm for 4 hours 500 SQE/qm for 4 hours 1000 SQE/qm for 4 hours
1892321|NCT01275469|Drug|GFT505 80mg|Hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast.
1892322|NCT01275469|Drug|Placebo|Hard gelatin capsules, oral administration, 4 capsules per day before breakfast.
1892323|NCT01275482|Procedure|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue. During the massage, we can caused isolated contractions from the fiber muscles containing the latent trigger points.
1892324|NCT01275482|Procedure|Transverse friction massage (TFM)|The TFM was describe of Cyriax as an effective method to treat soft tissues. It is a massage done always in perpendicular direction of damage tissue.
1892325|NCT01275495|Behavioral|Telephone Assessment and Skill-Building Kit (TASK II)|
1892326|NCT01275495|Behavioral|Information, Support, and Referral (ISR)|
1892327|NCT01275508|Drug|FITC-Adalimumab|The study product FITC-Adalimumab will be topically applied via a spray catheter to the intestinal mucosa of Crohn's disease patients during endomicroscopy of the gut. One mL of the diluted study product will be applied each time to overall four selected intestinal areas at a concentration of 20 μg/mL respectively (equivalent to 20 μg of FITC-Adalimumab per area). Total amount applied will be 80 μg FITC-Adalimumab per patient.
1892328|NCT01275521|Drug|BONT-A intra-prostatic injection|"• Intra prostatic injection of 200 IU of BONT-A (2 x 100 IU to dilute in 10 cc salted serum), divided into 4 injections, 2 in each prostate lobe for a volume intra injected 2.5 cc per site.
Interruption of the medical therapy 1 month after the injection;"
1892329|NCT01275521|Drug|Optimized medical BPH treatment|Optimization of the medical therapy according to recent guidelines
1892330|NCT01275547|Drug|s-ketamine & midazolam|s-ketamine 6 mg intranasal midazolam 0.75 mg intranasal
1892331|NCT01275547|Drug|Morphine PCA|2 mg Morphine i.v. all 12 minutes as a patient controlled system
1892332|NCT01275560|Drug|Metronidazole|Metronidazole,per os,500mg, 3 per day during 10 days
1892333|NCT01275560|Drug|CArbosylane|
1892334|NCT01275573|Device|Repetitive Transcranial Magnetic Stimulation|Repetitive Transcranial Magnetic Stimulation will be applied on the contralateral primary cortical motor on the painful side for the Parkinson's disease patients and on the left primary cortical motor for the healthy volunteer. The stimulation frequency will be 20 Hz during 26 min with an intensity stimulation equal of 95% of the motor threshold.
1892335|NCT01275586|Drug|Tasigna|Following enrollment each subject will initially receive Tasigna orally at 200 mg twice daily for two weeks. If tolerated, the dose will be increased to 300 mg twice daily after a minimum of two weeks and will be increase to a maximum dose of 400mg twice daily after an additional two weeks if tolerated.
1892336|NCT01275599|Drug|telaprevir|Two 375 mg tablets administered every 8 hours on Day 1 through Day 7, inclusive.
1892337|NCT01275599|Drug|buprenorphine/naloxone|Buprenorphine/naloxone sublingual tablets or films contain buprenorphine HCl and naloxone HCl dihydrate at a ratio of 4:1 buprenorphine:naloxone (ratio of free bases). In this study buprenorphine/naloxone will be dosed from Day -14 through Day 38, inclusive. From Day -14 through Day -1 all subjects will receive a maximum of 24 mg/6 mg of buprenorphine/naloxone. Subjects will not be permitted to change their dose during the telaprevir co-administration period (Day 1 through Day 7) unless warranted by the investigator's clinical judgment of subject safety. After Day 8, the dose of buprenorphine/naloxone may be adjusted if deemed necessary by the investigator.
1892338|NCT01275612|Biological|Mesenchymal stromal cell infusion|The first 3 patients will receive a single i.v infusion of donor ex-vivo expanded MSC (1 x 106 MSC/kg). If the efficacy outcome of cell treatment is negligible or partial and the procedure is safe, a second group of additional 3 patients will be enrolled. They will be given MSC i.v infusion at higher dose (2 x 106 MSC/kg).Should the therapeutic efficacy of this treatment again negligible or marginal, but still safe, a third group of 3 patients will be enrolled in the study. The dose of cells to be infused will be up-titrated to 5 x 106 MSC/kg.
1892339|NCT01275625|Drug|HIV therapy|Combivir one tablet BD with maraviroc 300mg BD for 48 weeks
1960677|NCT03153592|Procedure|Transpulmonary pressure driven ventilation strategy|Patients will receive volume controlled ventilation set with a tidal volume at 6-8 ml/kg of ideal body weight, an inspiratory transpulmonary pressure less than 20 cmH2O, and an expiratory transpulmonary pressure (PLexp) equal or greater than 0. At PLexp increasing from 0 up to 10 cmH2O, inspired fraction of oxygen would also be increased from 40% to 100%. Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and to ensure a physiological pH. Whenever the clinician will deem it appropriate, an alveolar recruitment maneuver as previously described
1892341|NCT01275651|Other|laboratory biomarker analysis|Correlative studies
1960678|NCT03153592|Procedure|Conventional ventilation strategy|13 patients will undergo volume controlled ventilation set with a tidal volume between 6-8 ml/kg of ideal body weight, positive end-expiratory pressure and fraction of inspired oxygen set to obtain a peripheral saturation in oxygen equal or greater than 94% and a plateau pressure <28 cmH2O Respiratory rate will be set to obtain an arterial partial pressure of carbon dioxide between 35 and 45 mmHg and in any case to ensure a physiological pH. In addition, whenever the clinician will deem it appropriate, an alveolar recruitment maneuver will be performed as previously described
1892350|NCT01275677|Drug|Cyclophosphamide|Given IV
1892351|NCT01275677|Drug|Docetaxel|Given IV
1892352|NCT01275677|Drug|Doxorubicin Hydrochloride|Given IV
1892353|NCT01275677|Other|Laboratory Biomarker Analysis|Correlative studies
1892354|NCT01275677|Drug|Paclitaxel|Given IV
1892355|NCT01275677|Other|Quality-of-Life Assessment|Ancillary studies
1892356|NCT01275677|Biological|Trastuzumab|Given IV
1892445|NCT01276353|Drug|E2020|Patients will take study medication orally, once daily, for 2 weeks according to a double-dummy design in the double blind phase: 23 mg donepezil sustained release (SR) concurrently with placebo identical in appearance to the 10 mg donepezil immediate release (IR) formulation
1893318|NCT01281124|Drug|Azacitidine|Given subcutaneously
1892357|NCT01275716|Behavioral|Impact of Coronary Images Used During Patient Education on Coronary Artery Disease and Subsequent Lifestyle Modifications|Subjects will be randomly assigned (like the flip of a coin) to a study group. One group will be given before and after treatment pictures of their affected heart arteries. The other group will not be shown these pictures. Both groups will still receive written and verbal information about living a heart healthy lifestyle and taking heart medications properly as part of their normal routine care.
1892358|NCT01275729|Drug|Furosemide|dose: 1 mg / kg (iv) if the patient is furosemide naive or 1.5 mg/kg (iv) if the patient is not furosemide naive
1892359|NCT01275742|Behavioral|Brief Cognitive Therapy Intervention|The intervention group will receive an individual, 30 minute, scripted cognitive therapy session. This intervention will be delivered by an Advanced Practice Registered Nurse or a trained research nurse. An iPad will guide the outline of the intervention. The nurse will discuss depression in heart disease and the connection between thoughts, emotions, and behaviors. The nurse will ask the patient to describe a recent stressful experience and discuss thoughts that the patient has been experiencing. Two techniques for challenging negative thinking will be introduced to the patient: thought stopping and affirmations. The nurse will ask the patient to practice these techniques at home. After the patient has practiced both techniques, the nurse will leave the patient with a booklet with the intervention. At 1-2 weeks, the nurse will administer a booster session over the phone. This session will last 10-15 minutes and will reinforce the techniques learned during the brief CT intervention.
1892360|NCT01275755|Drug|Placebo|
1892361|NCT01275755|Drug|ADL5945 0.25 mg|
1892362|NCT01275768|Procedure|Endoscopic radio-frequency ablation|Endobiliary radiofrequency catheter is 8Fr in diameter and can easily be passed over a 0.035 guide wire through the biopsy channel of a duodenoscope at the time of endoscopic retrograde cholangiography (ERC). Its use in the biliary system was heralded by animal experiments following which power settings of 7-10 Watts for 2 minutes were found to provide adequate ablation. The ablation results in charring of the tumor and this is expected to enhance the patency of SEMS
1892363|NCT01275781|Drug|[14C]-AZD9742|1000 mg intravenous over 2 hours
1892364|NCT01275807|Device|acupuncture|10 sessions of acupuncture
1892365|NCT01275807|Other|self care|physical exercice, diet, self help groups, psychological support
1892366|NCT01275820|Dietary Supplement|Nutralin|Food product to be taken 15 minutes prior to each of the three main meals of the day.
1892367|NCT01275833|Device|Cardiac resynchronization therapy-defibrillator|Device programming that modifies AV timing
1892368|NCT01275846|Device|Health Guide using AHA heart failure protocols and content|Participants in the study will receive the use of the Intel Health Guide, a telehealth device, with AHA customized heart failure protocols, response algorithms and educational content. Participants interact with the Intel Health Guide device, receiving immediate feedback when transmitting vitals measures and health question responses to a site monitored by their nurse case managers. Nurse case managers review and address concerns raised in vitals and/or question responses through standard care protocols established by their institution. Nurse case managers strive to enhance the participants quality of life, support continuity of care, facilitate provision of services in the appropriate setting to promote positive health outcomes.
1892369|NCT01275859|Drug|Letrozole, Lapatinib|Letrozole 2.5mg po qd+ Lapatinib 1500mg po qd for 18-21 wks
1892370|NCT01275872|Other|Guided Imagery and Progressive Muscle Relaxation|4 supervised sessions per patient for 4 weeks additional to daily unsupervised sessions
1892371|NCT01275885|Dietary Supplement|cholecalciferol (D3)|10µg (400 IU) orally daily for 10 weeks
1892372|NCT01275885|Dietary Supplement|cholecalciferol (D3)|30µg (1200 IU) orally daily for 10 weeks
1892373|NCT01275885|Dietary Supplement|cholecalciferol (D3)|40µg (1600 IU) orally daily for 10 weeks
1892374|NCT01275911|Drug|Esmolol|Induction of anesthesia: 1mg/Kg; Maintenance during surgery: 5-15 mcg/kg/min
1892375|NCT01275911|Drug|Remifentanil|At the induction of anesthesia: 1mcg/Kg; Maintenance during surgery: 0.025-0.25mcg/kg/min
1892376|NCT01275924|Device|Tightrope Syndesmosis Repair Kit|Tightrope Syndesmosis Repair Kit
1892377|NCT01275924|Device|Syndesmotic screw|Quadricortical syndesmotic screw
1892378|NCT01275937|Drug|Esomeprazole|Esomeprazole 40 mg IV daily is given for three days. Thereafter, the patients receive 40 mg Esomeprazole orally daily for two months.
1892379|NCT01275937|Drug|esomeprazole|esomeprazole 160 mg/day continuous infusion is given for three days. Thereafter, the patients receive 40 mg nexium orally daily for two months.
1892380|NCT01275950|Behavioral|Health Education|"Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the shop-owners.
Administering the questionnaire to objectively asses the impact of direct/ surrogate tobacco advertisements influencing student behavior and perception about tobacco and tobacco products.
Implementing the intervention programme designed for creating awareness about harmful effect of tobacco (smoked and smokeless forms) and the current regulation to the students through interactive sessions with students in their respective educational institute."
1892381|NCT01275976|Drug|C1-esterase inhibitor|C1-esterase inhibitor 200 U/kg infusion over 30 minutes, just before the start of the femur or pelvic fixation operation.
1892382|NCT01275976|Other|Saline 0.9%|Infusion, just before the start of the femur or pelvic fixation operation
1892383|NCT01275989|Other|Ear acupuncture|
1892384|NCT01276002|Procedure|pancreatic duct stenting|in case of a disrupted pancreatic duct, patients will undergo pancreatic duct stenting.
1892385|NCT01276015|Drug|Botulinum Toxin Type A|BoNT-A (Dysport, Ipsen) ,into the medial gastrocnemius (MG) and LG muscles unilaterally on the affected spastic hemiplegic side; dose mean± SE, 283.3± 24.7 U.. The mean dose/kg injected was 14.4± 0.8, range from 8.5 to 20 U/kg, diluted in 2.5 ml saline. frequency: once.
1892386|NCT01276028|Procedure|Acupuncture|"For the Acupuncture group: Women will be eligible to receive from 1 to 20 treatments over a six month period. These women will receive an initial evaluation by a acupuncturist and will be given a Traditional Chinese Medicine (TCM) diagnosis as well as a recommended treatment schedule which they can then negotiate.
Women in the waitlist group will not receive any acupuncture for 6 months. At the end of the 6 month period the participants will be allowed to begin the acupuncture treatments."
1892490|NCT01261637|Drug|Saline placebo|20ml saline
1892491|NCT01261637|Drug|Ropivicaine|0.25% ropivicaine (maximum 1.5mg/kg)
1892387|NCT01276041|Drug|pertuzumab in combination with trastuzumab and paclitaxel|The regimen will consist of paclitaxel (80 mg/m2) weekly + trastuzumab every 3 weeks (8 mg/kg loading dose → 6 mg/kg every 3 weeks) + pertuzumab every 3 weeks (840 mg as a loading dose → 420 mg), all given intravenously (IV). Patients may be given trastuzumab weekly in lieu of every 3 weeks (4 mg/kg loading dose → 2 mg/kg every 3 weeks). Patients will be on treatment until progression of disease.
1892388|NCT01276054|Radiation|technetium Tc 99m sulfur colloid|Given intradermally and periareolarly
1892389|NCT01276054|Drug|methylene blue|Given subcutaneously
1892390|NCT01276054|Drug|indocyanine green solution|Given subcutaneously
1892391|NCT01276054|Procedure|sentinel lymph node biopsy|Undergo sentinel lymph node biopsy
1892392|NCT01276054|Procedure|axillary lymph node biopsy|Undergo axillary lymph node biopsy
1892393|NCT01276054|Procedure|bioimpedance spectroscopy|Correlative studies
1892394|NCT01276054|Procedure|quality-of-life assessment|Ancillary studies
1892395|NCT01276054|Other|lymphedema management|Undergo axillary reverse mapping
1892396|NCT01276067|Drug|Donepezil|10 mg Tablet
1892397|NCT01276080|Drug|Donepezil|10 mg tablets
1892398|NCT01276093|Procedure|PVI ablation|Pulmonary Vein Ablation using RF.
1892399|NCT01276093|Drug|Amiodarone|Amiodarone tablets
1892400|NCT01276106|Drug|AC-201, 25mg|Capsule, 25mg BID
1892401|NCT01276106|Drug|AC-201, 50mg|Capsule, 50mg BID
1892402|NCT01276106|Drug|AC-201, 75mg|Capsule, 75mg BID
1892403|NCT01276106|Drug|Placebo|Placebo BID
1892404|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single infusion over 60 minutes
1892405|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single infusion over 120 minutes
1892406|NCT01276119|Biological|CDP6038|100 mg/mL solution for injection Single sc injection
1892407|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single infusion over 60 minutes
1892408|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single infusion over 120 minutes
1892409|NCT01276119|Other|Placebo|0.9% sodium chloride for injection Single sc injection
1892410|NCT01276158|Procedure|Ultrasound|Ultrasound used to place arterial line
1892411|NCT01276158|Procedure|Doppler|Doppler used to place arterial line
1892412|NCT01276171|Procedure|Ultrasound|Participants will place arterial line using ultrasound technique
1892413|NCT01276171|Procedure|Doppler|Participants will place arterial line using doppler technique
1892414|NCT01276171|Procedure|Palpation|Participants will place arterial line using Palpation technique
1892415|NCT01276184|Behavioral|SMS Text Message|Women in the SMS Text Message group that reschedule a vaccination visit will receive text message reminders one per day for each of the seven days prior to the rescheduled visit (or as many days as possible depending on when the rescheduled visit will take place - for example, if they call in and reschedule the visit to take place in 4 days, they will receive text messages for the 3 days prior to the rescheduled visit). Participants in both the Usual Care group and the SMS Text Message group will receive the standard reminder from the clinic for their re-scheduled appointment(s) (phone call, letter, etc, as appropriate).
1892416|NCT01276197|Other|Story-Telling DVD|DVD will contain both informational and story-telling components.
1892417|NCT01276197|Other|Non-Storytelling DVD|DVD will contain only informational component.
1892418|NCT01276210|Drug|sorafenib tosylate|Given PO
1892419|NCT01276210|Radiation|stereotactic radiosurgery|Undergo stereotactic radiosurgery
1892420|NCT01276210|Other|laboratory biomarker analysis|Correlative studies
1892421|NCT01276223|Drug|Difluprednate 0.05% ophthalmic emulsion|Topical ocular steroid
1892422|NCT01276223|Other|Difluprednate vehicle|Inactive ingredients used as Run-In and placebo comparator
1892423|NCT01276236|Drug|Maraviroc|"FDA Recommended dosing will be used in this study. Subjects on an efavirenz or etravirine-based regimen will be dosed at 600 mg orally, twice per day, for 96 weeks.
Subjects on a ritonavir-boosted protease inhibitor based regimen (except for tipranavir/ritonavir) will be dosed at 150 mg orally, twice per day, for 96 weeks.
Subjects that are on regimens that do not include etravirine, efavirenz, or ritonavir will be dosed at 300mg orally, twice per day, for 96 weeks. These doses are based on the recommendations from the company based on drug-drug interactions."
1892424|NCT01276249|Device|Fortevo Endograft|The Fortevo Endograft, Main Body and Iliac Lumen Delivery System are indicated for the endovascular treatments of patients with infrarenal abdominal aortic aneurysms or aortic-iliac aneurysms having suitable morphology for endovascular repair.
1892425|NCT01276262|Drug|fostamatinib|Oral tablets, repeated doses for 21 days (2 x 50mg BID)
1892426|NCT01276262|Drug|Microgynon® 30 (Oral contraceptive)|Oral tablets, repeated doses
1892427|NCT01276262|Drug|Placebo|Oral tablets BID, repeated doses for 21 days
1892428|NCT01276275|Drug|Risk of selected safety events|First time users of ticagrelor, clopidogrel and prasugrel, respectively
1892429|NCT01276288|Drug|BI 10773|multiple oral doses
1892430|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
1892431|NCT01276288|Drug|torasemide|multiple oral doses
1892432|NCT01276288|Drug|BI 10773|multiple oral doses
1892433|NCT01276288|Drug|torasemide|multiple oral doses
1892434|NCT01276288|Drug|BI 10773|multiple oral doses
1892435|NCT01276288|Drug|hydrochlorothiazide|multiple oral doses
1892436|NCT01276301|Drug|Verapamil|single dose verapamil
1892437|NCT01276301|Drug|BI 10773|single dose BI 10773
1892438|NCT01276301|Drug|BI 10773|single dose BI 10773
1892439|NCT01276314|Drug|anti-TNF a|25mg BIW, SC
1892440|NCT01276327|Drug|Linagliptin + Pioglitazone|Medium doses, oral administration
1892441|NCT01276327|Drug|Linagliptin + Pioglitazone|Medium doses, oral administration
1892442|NCT01276327|Drug|Linagliptin/Pioglitazone|Medium dose oral administration
1892443|NCT01276327|Drug|Linagliptin/Pioglitazone|Medium dose oral administration
1892444|NCT01276340|Device|KEAT stimulator|electrical stimulation with KEAT stimulator : 4 times per week during 2 months
1892492|NCT01261650|Device|transcranial direct current stimulation|
1892493|NCT01261650|Device|sham treatment|
1892446|NCT01276353|Drug|E2020|10 mg donepezil immediate release (IR) concurrently with placebo identical in appearance to the 23 mg donepezil sustained release (SR) formulation. All patients who complete the double blind phase will take 23 mg donepezil sustained release (SR) orally, once daily, for 52 weeks in the Open-label Extension phase.
1892447|NCT01276366|Other|breast feeding|Newborns who are assigned to group one, receive breastfeeding during the blood sample and thereby have skin-skin contact between mother and child.
1892448|NCT01276366|Other|supplemental breast milk|In group two, the newborns receive supplemental breast milk, lying in the arms of a nurse during the heel lance.
1892449|NCT01276366|Other|sucrose|In the third group, newborns receive sucrose 1ml 24% two minutes before procedure, followed by non-nutritive sucking. During the procedure the newborn lies in his cot.
1892453|NCT01276418|Device|CO2 laser|Ablation and coagulation of soft tissue
1892454|NCT01276431|Drug|Buprenorphine transdermal patch|
1892455|NCT01276444|Device|Swan-Ganz catheter|the data s=derived from PAC included pulmonary artery occlusion pressure etc
1892456|NCT01276444|Device|transpulmonary thermodilution + central venous saturation|Described in details above
1892457|NCT01276457|Drug|Everolimus 0.25 and 0.75 mg tablets|The dose of everolimus for each patient was adjusted to achieve the target everolimus blood level range. Everolimus blood trough level was measured 5 days after any dose adjustment to verify that the blood level was within the desired target level range.
1892458|NCT01276457|Drug|Cyclosporine very low dose (150-300 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
1892459|NCT01276457|Drug|Cyclosporine low dose (350-500 ng/mL) microemulsion|The dose of cyclosporine for each patient was adjusted to achieve the target cyclosporine blood level. Cyclosporine dose adjustments were based on drug blood level determined from whole blood samples taken 2 hours (± 10 min) after the morning dose.
1892460|NCT01276496|Drug|Cilengitide|Given IV
1892461|NCT01276496|Other|Laboratory Biomarker Analysis|Correlative studies
1892462|NCT01276496|Drug|Paclitaxel|Given IV
1892463|NCT01276496|Other|Pharmacological Study|Correlative studies
1892468|NCT01276522|Drug|Canakinumab|Monthly subcutaneous injection with 150mg Canakinumab for 6 months
1892469|NCT01276535|Device|Erchonia MLS + Erchonia THL|"The Erchonia® MLS is administered weekly for 6 continuous weeks at the test site by the study investigator.
The Erchonia THL is administered twice daily for 6 continuous weeks (42 days) at home by the subject.
Administration of the MLS and the THL occur simultaneously over the 6-week administration phase.
The intent is to evaluate the effectiveness of Erchonia MLS & Erchonia THL when administered together, and not to compare Erchonia MLS vs. Erchonia THL"
1892470|NCT01276548|Drug|Genexol®-PM 260mg/m2 plus Carboplatin 5 AUC|
1892471|NCT01276548|Drug|Genexol® 175mg/m2 plus Carboplatin 5 AUC|
1892472|NCT01276561|Procedure|Single Incision Splenectomy|Patients will undergo laparoscopic splenectomy through a single incision
1892473|NCT01276561|Procedure|Laparoscopic Splenectomy|Patients will undergo laparoscopic splenectomy with 4 ports, placement is surgeon dependent
1892474|NCT01276587|Drug|Vitamin D3|Oral vitamin D3 100,000 IU administered monthly for six months in children and adolescents with sickle cell disease
1892475|NCT01276600|Drug|Emtricitabine/tenofovir|200mg of emtricitabine 300mg of tenofovir
1892476|NCT01276613|Drug|Gemcitabine|Gemcitabine administered by the anesthesiologist as a dose of 1,000mg/m2 at a fixed dose rate of 10mg/m2/min.
1892477|NCT01276613|Drug|Losartan|50 mg by mouth daily for one week and 50 to 100 mg of Losartan by mouth daily for at least 1 week and at most 3 weeks prior to surgical resection.
1892478|NCT01276626|Dietary Supplement|Bifidobacterium longum|Powder containing Bifidobacterium longum in maltodextrin.
1892479|NCT01276626|Other|Maltodextrin|Powder containing only maltodextrin
1892484|NCT01261572|Drug|ASP3350|periodic injection
1892485|NCT01261598|Procedure|Positron Emission Tomography|Positron Emission Tomography
1892489|NCT01261624|Drug|Givinostat|1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
1997395|NCT02101697|Behavioral|HIV Stigma Reduction Intervention|"The HIV stigma reduction intervention consists of two computer-administered sessions and one group session.
Session 1. (approx. 60 min). Introduction of the concepts of stigma and discrimination, vulnerable populations and symbolic stigma delivered in an interactive tablet format, using games and videos.
Session 2. (approx. 60 min). Interactive activities to address HIV transmission myths and misconceptions and the importance of universal precautions.
Session 3. (approx 90 min). Patient interaction skills. In person interactive group session co-facilitated by PLHIV and staff focusing on skills building through role-plays and feedback.
Our previous research has found that these modules address factors identified as contributing to health professionals' stigma."
1997396|NCT02100891|Procedure|Allogeneic HCT|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
1892494|NCT01261663|Other|oral nutritional energy and protein enriched supplement (NOS)|
1892495|NCT01261676|Other|Implementation aids|An implementation strategy to improve outcome for women in labour will be developed depending on the outcome of the current care study and the barrier and facilitator analysis.The strategy will be executed and evaluated in a controlled before-and-after study in 12 hospitals (6 intervention, 6 control)
1892496|NCT01261689|Drug|Ropivacaine/ Sufentanil according to local hospital protocol|according to local hospital protocol
1892497|NCT01261689|Other|Care-as usual pain treatment|Pain treatment only on request of the women in labour. Treatment is given according to local hospital protocol.
1892498|NCT01261702|Drug|Placebo|Normal saline IV
1892499|NCT01261702|Drug|magnesium sulphate|The magnesium group (Group M, n=16) received 50 mg/kg of magnesium sulphate infusion in 10 minutes before induction and then 15 mg/kg/hr until the end of the surgery.
1892500|NCT01261715|Procedure|Dermabond- liquid skin adhesive|Dermabond- liquid skin adhesive
1892501|NCT01261728|Drug|Gemcitabine and Cisplatin|Patients will receive four cycles of GC administered every 21 days. Gemcitabine 1,000 mg/m2 and Cisplatin 35 mg/m2 will be administered intravenously on days 1 and 8. A total of four cycles of therapy will be administered at 21 day intervals followed by radical nephroureterectomy or distal ureterectomy.
1892502|NCT01261741|Drug|Memantine|Each subject will receive memantine 10mg tablets once daily
1892503|NCT01261741|Drug|Placebo|Each subject will receive matching placebo tablets once daily
1892504|NCT01261754|Radiation|99mTc MIP 1404|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1404
1892505|NCT01261754|Radiation|99mTc MIP 1405|Subjects will be administered a single 20 (± 3) mCi intravenous (IV) injection of 99mTc MIP 1405
1892506|NCT01261767|Drug|anti-IL-20|Anti-IL-20 in 100mg/vial for subcutaneous (under the skin) injection
1892507|NCT01261767|Drug|placebo|Placebo for subcutaneous (under the skin) injection
1960688|NCT03152006|Other|ACT|Coordinated, graduated transition which includes an early introduction to the adult clinician during the PAPA pre-transfer period, a peer-facilitated organized support group aimed at improving transition readiness and addressing critical psychosocial skills including self-efficacy and locus of control and a case management team including a patient advocate who coordinates the transfer between pediatric and adult care teams.
1892510|NCT01261793|Drug|Placebo|Placebo infusions delivered weekly for 4 weeks over four 12-week treatment cycles
1892511|NCT01261793|Drug|Epratuzumab|600 mg infusions delivered weekly for a total of 4 weeks (cumulative dose 2400 mg) over four 12- week treatment cycles
1892512|NCT01261793|Drug|Epratuzumab|1200 mg infusions delivered every other week for a total of 4 weeks (cumulative dose 2400 mg) over four 12-week treatment cycles and Placebo infusions delivered every other week for a total of 4 weeks over four 12-week treatment cycles.
1892513|NCT01261806|Behavioral|Attachment and Biobehavioral Catch-up|Enhances nurturance, following the lead, and calming behaviors
1892514|NCT01261806|Behavioral|Developmental Education for Families|Attention control: Enhances parents understanding of developmental milestones
1892515|NCT01261819|Device|cystoscopy|
1892516|NCT01261832|Drug|antiplatelet therapy|Dual antiplatelet therapy is defined as combination therapy with aspirin and clopidogrel and triple antiplatelet therapy is defined as combination therapy with aspirin,clopidogrel and cilostazol.
1892517|NCT01267136|Drug|Codeine with acetaminophen|Liquid codeine/acetaminophen (Capital® 5mL= 120mg acetaminophen/12 mg codeine) 0.72 mg/kg [=0.3 mL/kg] (max. 36 mg) PO Q6h, plus 0.72 mg/kg (max. 36 mg) PO Q3h pro re nata (PRN) (max. of 3 PRN doses/day)
1892518|NCT01267136|Drug|Tramadol suspension|Liquid tramadol 1.05 mg/kg [=0.3 mL/kg] (max. 52.5 mg) PO Q6h, plus 1.05 mg/kg (max. 52.5 mg) PO Q3h PRN (max. of 3 PRN doses/day).
1892519|NCT01267175|Device|X54 insulin pump with low suspend feature|Change from current insulin pump to new X54 pump
1892521|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL single dose (8 mL)
1892522|NCT01267201|Drug|methylprednisolone|powder for oral suspension 4 mg/mL singe dose (8 ml)
1892523|NCT01267201|Drug|methylprednisolone|tablet 32 mg single dose
1892524|NCT01267214|Drug|Sodium Hyaluronate (Hyalgan)|1% Sodium Hyaluronate in prefilled syringe
1892525|NCT01267214|Procedure|Osteotomy alone|no injection
1892526|NCT01267227|Drug|Pterostilbene 50 mg twice daily|Pterostilbene 50 mg twice by mouth daily for 6 to 8 weeks
1892527|NCT01267227|Drug|Placebo|Matching placebo by mouth twice daily for 6 to 8 weeks
1892528|NCT01267227|Drug|Grape Extract|Grape extract 100 mg twice daily for 6-8 weeks
1892529|NCT01267227|Drug|Pterostilbene 125 mg twice daily|Pterostilbene 125 mg twice daily for 6-8 weeks
1892530|NCT01267240|Drug|Capecitabine|Given PO
1892531|NCT01267240|Drug|Vorinostat|Given PO
1892532|NCT01267253|Drug|Brivanib Alaninate|Given PO
1892533|NCT01267253|Other|Laboratory Biomarker Analysis|Correlative studies
1892534|NCT01276652|Behavioral|Environmental modification|Environmental modification consists of nursing-related efforts to optimize daytime light exposure, to minimize nighttime light and noise exposure, and to batch nursing care at night.
1892535|NCT01276665|Procedure|restrictive intraoperative fluid substitution|to analyze the impact of a restrictive volume regimen using advanced balanced electrolyte solution (which is by far more restrictive than the published data) combined with noradrenaline. We include only radical cystectomy and so nearly exclude surgical bias
1892536|NCT01276665|Procedure|assessment of the pelvic venous pressure|A 20 G catheter will be introduced into a small collateral vein of the internal iliacal vein to monitor pelvic venous pressure
1892537|NCT01276691|Drug|81 mg enteric coated aspirin|81 mg enteric coated aspirin will be provided both as an acute dosage immediately prior to firefighting (1 hour pre-activity) and as a 14 day dosage prior to firefighting
1892538|NCT01276704|Drug|Placebo|The placebo contains same filler materials as commercially available Brevail® but without active SDG.
1892539|NCT01276704|Drug|secoisolariciresinol|1 capsule daily of secoisolariciresinol diglycoside (SDG)50mg
1892540|NCT01276717|Drug|Drug: Carfilzomib|Carfilzomib 30 minutes infusion daily for days 1, 2, 8, 9, 15, 16, Every 28 days. A maximum of 13 cycles will be administered.
1892541|NCT01276717|Drug|Vorinostat|Vorinostat by mouth twice daily on days 1, 2, 3, 8, 9, 10, 15, 16 and 17. Maximum 13 cycles.
1892542|NCT01276730|Drug|Interferon, Retinoic Acid and radiation|Interferon-α2b will be administered 3 times a week for four weeks at a dose of 3 x 106 IU subcutaneously concomitant with radiotherapy. The first dose will be administered on the day the subject starts radiotherapy; 13-cis-retinoic acid will be administered orally at a dose of 40 mg/day for 1 month starting from day 1 of radiotherapy; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions to both the study group and the control group. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
1892543|NCT01276730|Drug|Cisplatin and radiation|Weekly cisplatin will be administered concurrent with external beam radiation at a dose of 40mg/m2/week for 5 weeks; a total of 40 to 45 Gy whole pelvis irradiation will be delivered in conventional fractions. Additional parametrial dosages will be delivered to complete 55 Gy. This will be followed by two intracavitary applications of approximately 40-50 Gy, depending on the volume.
1892544|NCT01276756|Drug|Pegylated interferon alfa-2a|Pegylated interferon 160ug once weekly 48 weeks
1892545|NCT01276756|Drug|Nitazoxanide|Nitazoxanide 500mg twice daily 4 weeks lead-in followed by triple therapy 48 weeks
1892546|NCT01276756|Drug|Ribavirin|Ribavirin (> 75kg:1200 mg, <75kg:1000mg daily)48 weeks
1892547|NCT01276769|Drug|Paclitaxel plus carboplatin|"Paclitaxel 175 mg/m2 D1 i.v., carboplatin AUC=5 D2 i.v.
1 cycle = 21days 2-6cycles"
1892548|NCT01276769|Drug|Paclitaxel and epirubicin|"Paclitaxel 175 mg/m2 D3 i.v.,Epirubicin 75mg/m2 D1，2 i.v.
1 cycle = 21days
2-6cycles"
1892549|NCT01276782|Drug|Levothyroxine|It is FDA approved drug for thyroid disease
1892550|NCT01276795|Dietary Supplement|Oral Nutrition Support|The patients will sip the oral nutrition support (in the form of a drink) over the course of 4 hours within each 6 hour study. Each patient will be studied once before surgery and once after surgery.
1892551|NCT01276808|Procedure|Magnetic navigation PCI|Magnetically navigated angioplasty wire technique
1892552|NCT01276808|Procedure|Conventional PCI|Conventional manual angioplasty wire percutaneous coronary intervention
1892553|NCT01276821|Drug|L-Epinephrine and Normal Saline (0.9%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 0.9% Normal Saline
1892554|NCT01276821|Drug|L-Epinephrine and Hypertonic Saline (3%)|1.5ml of 1:1,000 L-Epinephrine and 4 ml of 3% Hypertonic Saline
1892555|NCT01276834|Drug|everolimus|comparison of everolimus-based and CNI-based immunosuppression
1892556|NCT01276847|Drug|Ustekinumab|Ustekinumab 45 mg per dose, administered subcutaneously for participants weighing ≤ 100 kg, and ustekinumab 90 mg per dose administered subcutaneously for participants weighing > 100 kg on Day 1, and Weeks 4 and 16
1892557|NCT01276847|Drug|Etanercept|Etanercept 50 mg twice weekly by self-administered subcutaneous injection for 12 weeks, then once weekly for 4 weeks
1892558|NCT01276860|Device|Psychomotor Vigilance Testing|The purpose of this study is to examine the use of psychomotor vigilance testing (PVT) as a tool in the diagnosis and prediction of pediatric obstructive sleep apnea. PVT simply involves responding to a light by pressing a button on a small handheld device. It is a simple measure of reaction time.
1892559|NCT01276873|Device|Tracheal aspiration close system|use of closed system in comparision to open system to tracheal aspiration of nweborns, analyzing pain and climical variations associated.
1892560|NCT01276886|Drug|antibiotic|
1892561|NCT01276886|Procedure|Colonic resection with or without stoma|
1892562|NCT01276899|Procedure|Needle core biopsies|"No investigational products will be administered to subjects as part of this translational research study.
A taxane-based regimen will be administered as per the standard of care at each treating institution. Tissue samples from primary tumors will be collected and banked before the start of chemotherapy, after chemotherapy and at the time of surgery. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
1892563|NCT01276899|Procedure|Needle core biopsies of metastatic lesion|"No investigational products will be administered to subjects as part of this translational research study.
Chemotherapy will be administered as per the standard of care at each treating institution. Tissue samples from metastatic tumors lesions will be collected and banked before the start of chemotherapy and at the time of progression. Additionally, blood samples will be drawn before treatment initiation (baseline) and at different time points during treatment and stored in the tissue biobank."
1892564|NCT01276912|Drug|Insulin glargine|Insulin glargine therapy with a dosage adjusted to get FBG ≤ 5.3mmol / L as the goal, accompanied with a lifestyle counseling.
1892565|NCT01276912|Behavioral|Lifestyle counseling|To give lifestyle guidance, specifically including low fat, low saturated fatty acids, rich in dietary fiber, salt restriction, limit alcohol diet plan to reduce the 5% to 10% of body weight, and to ensure a regular moderate physical activity at least 150 minutes per week.
1892566|NCT01276925|Drug|Ropivacaine|7,5 mg/ml. 10 ml for the femoral nerve, 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
1892567|NCT01276925|Drug|Ropivacaine|7,5 mg/ml. 10 ml for the anterior division of the obturator nerve, 5 ml for the lateral femoral cutaneous nerve.
1892568|NCT01276925|Device|Ultrasound|All nerve blockades will be performed with ultrasound guidance.
1892569|NCT01276925|Procedure|Peripheral nerve blockade|All patients will receive injections around the three nerves before surgery.
1892570|NCT01276925|Drug|Saline|Isotonic. 10 ml for the femoral nerve.
1892571|NCT01276925|Procedure|Total hip arthroplasty|All patients undergoes total hip arthroplasty.
1892572|NCT01276925|Drug|Bupivacaine|5 mg/ml. 3 ml for spinal anaesthesia.
1892573|NCT01276938|Radiation|21 Gy radiation|21 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
1892574|NCT01276938|Radiation|18 Gy radiation|18 Gy radiation using electrons produced with mobile linear accelerator (energies ranging from 4 to 10 MeV)
1892575|NCT01276951|Dietary Supplement|Delivery and return of chocolate|At baseline and then every 2 weeks, each participant will receive different grams of chocolate, according to the group to which he is assigned.
1892606|NCT01277965|Other|Rest|Patient will be in rest, basal insulin flow rate will not be change
1892607|NCT01277991|Drug|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
1892608|NCT01277991|Drug|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
1892576|NCT01276951|Procedure|Determination of blood pressure|Blood pressure will be determined at study entry, ninth and eighteenth week taking into account the protocols established in 2007 by the European Society of Cardiology and Hypertension. Because blood pressure has variations throughout the day and that measuring ambulatory health institutions can generate emotional changes that induce changes in this clinical setting, which for purposes of this study is the main outcome variable, there will be 24-hour monitoring of blood pressure at the beginning and end of the study.
1892577|NCT01276951|Procedure|Anthropometric Measurements|The study will be determined the body mass index (BMI) by the ratio of weight in kilograms over height in meters squared, for which anthropometric measurement will be made at first, ninth and the eighteenth week as follows: The weight will be taken with an electronic balance of 0.05 g sensitivity standing capacity of 150 kg. We will be rated based on BMI cut points given by WHO-PAHO (1993) and adopted by the Ministry of Health of Colombia (2000).
1892578|NCT01276951|Procedure|Food Anamnesis|With the aim of learning about the eating habits, it will be made based on a food intake recall the last 24 hours, taking into account that is not preceded by a special food day (sundays, holidays, celebrations). For more accurately calculate nutrient ingested food, modules will be used.
1892579|NCT01276951|Procedure|Samples: serological tests and culture of mononuclear cells|At admission and at the end of the study will be obtained after 12 hours of fasting, 8 mL of blood in a dry tube without anticoagulant and 30 mL of blood in heparin tubes, properly labeled with the code assigned to the participant. The sample will be used to determine the complete lipid profile (triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol and VLDL cholesterol), State of oxidation of low density lipoprotein (oxLDL) and mononuclear cell culture. The remaining serum was kept at -20°C for use if is required repeat any study.
1892580|NCT01276951|Procedure|Analysis of cytokine production|We will be used the supernatant of mononuclears cell culture to quantify the production of interleukin one beta, interleukin two, tumor necrosis factor alpha by ELISA with commercially available kits for this purpose.
1892581|NCT01276977|Drug|Zolmitriptan 5 mg Nasal Spray|Patients will treat 2 migraine attacks with zolmitriptan 5 mg nasal spray and 2 migraine attacks with eletriptan.
1892582|NCT01276977|Drug|Eletriptan 40 mg tablet|Patients will treat 2 migraine attacks with Eletriptan and 2 migraine attacks with zolmitriptan 5 mg nasal spray
1892583|NCT01277809|Behavioral|Interpersonal Interaction|Participants will receive stationary 1:1 interaction time with the same research personnel who conduct the third group walking session at each individual care facility in order to control for the interpersonal interaction likely to be involved in the walking program (Interpersonal Interaction Group; IIG). This group will receive the equivalent interpersonal interaction time with research personnel as those participating in the WPG group. This interaction time will occur with the participant stationary, rather than walking with the researcher.
1892584|NCT01277809|Behavioral|Walking Program|Participants will walk five times per week, supervised by a licensed physiotherapist. Subjects will in general gradually increase their daily supervised walking time as tolerated to a maximum of 30 minutes once per day. The distance and number of minutes walked each time will be recorded. Interpersonal interaction will occur during the walking sessions, and will be similar in quality and quantity to that during the Interpersonal Interaction Group.
1892585|NCT01277822|Drug|Losartan (+) amlodipine|One tablet containing 100 mg losartan potassium and 5 mg amlodipine camsylate, orally, once daily, for 8 weeks.
1892586|NCT01277822|Drug|Placebo to match losartan/amlodipine tablets|One tablet containing placebo, orally, once daily, for 8 weeks.
1892587|NCT01277822|Drug|Amlodipine camsylate|2 tablets each containing 5 mg amlodipine, orally, once daily, for 8 weeks.
1892588|NCT01277822|Drug|Placebo to match amlodipine|2 tablets containing placebo, orally, once daily, for 8 weeks.
1892589|NCT01277835|Drug|Lidocaine Infusion|Infusion of lidocaine 3mg/min or 2mg/min during surgery
1892590|NCT01277835|Drug|Placebo|Saline Infusion at same rate as experimental arm
1892591|NCT01277861|Drug|Fentanyl|FENTANYL PRETREATMENT DURING INDUCTION OF ANESTHESIA
1892592|NCT01277874|Device|Nasal CPAP|NCPAP is delivered via nasal prongs placed into infant's nares. It may be delivered via ventilator or by bubble.
1892593|NCT01277874|Device|Oscillatory NCPAP|Bird Industries pneumatic diaphragm is attached to NCPAP patient circuit to provide oscillations.
1892596|NCT01277900|Procedure|Laparoscopic Roux en Y gastric Bypass|Laparoscopic Roux-en-Y gastric bypass will be used as a standard procedure to treat type 2 diabetes mellitus
1892597|NCT01277913|Drug|Vitamin D3|1000 IU once daily for 12 months
1892598|NCT01277913|Drug|Vitamin D3|500 IU once daily for 12 months
1892599|NCT01277939|Behavioral|Therapeutic Education System (TES)|Therapeutic Education System (TES) is an interactive, computer-based, psychosocial treatment program. TES is theoretically grounded in evidence-based psychosocial treatments (Community Reinforcement Approach and Cognitive Behavioral Therapy).
1892600|NCT01277939|Behavioral|Standard Care|Psycho-educational and psycho-social approaches to substance use disorders (commonly offered in prison settings) delivered by counselors in group formats.
1892601|NCT01277952|Device|Deep Brain Stimulation|Brain pace maker, implanted in the brain
1892602|NCT01277965|Other|50%VO2maxTBR50|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 50%
1892603|NCT01277965|Other|50%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (50% VO2max),a temporary basal rate will be reduced by 80%
1892604|NCT01277965|Other|75%VO2max TBR80|The basal rate of the pump will be adjusted in accordance with the intensity of physical activity being performed for moderate physical activity (75% VO2max),a temporary basal rate will be reduced by 80%
1892605|NCT01277965|Other|75%VO2max TBR100|Turning off the pump (75%VO2max TBR100).However, in order to maintain the study blindfold, the pump will be switched off but not removed
1892609|NCT01277991|Drug|Treatment B|Single oral dose of 5 mg CP-690,550 administered as one 5 mg tablet (Phase 2B tablet)
1892610|NCT01277991|Drug|Treatment A|Single oral dose of 5 mg CP-690,550 administered as five 1 mg tablets (Phase 2B tablets)
1892611|NCT01278004|Drug|Ethosuximide|Drug will be dose escalated in order to reach maximum tolerated dose starting with 250mg.
1892612|NCT01278004|Drug|Placebo|Capsule
1892613|NCT01278017|Drug|ceftriaxone|ceftriaxone ,parenteral route, 50mg/kg/day divided twice
1892614|NCT01278030|Procedure|3D echo-guided LV lead placement|Information about left ventricular mechanical dyssynchrony and the location of the site of latest mechanical activation based on RT3DE will be available to the physician from the core lab analysis. This location will be used as the target for optimal LV lead placement.
1892615|NCT01278056|Drug|Exjade|Two dose escalating cohorts of oral administration in Phase I. Phase II: oral administration of the maximum tolerated dose.
1892616|NCT01278082|Drug|Budesonide|Alternating daily dosing with 2 x 3 mg budesonide capsules OD and 1 x 3 mg budesonide capsule OD every second day
1892617|NCT01278082|Drug|Placebo|Alternating daily dosing with 2 placebo capsules OD and 1 placebo capsule OD every second day.
1892618|NCT01278095|Drug|GLPG0555 solid dispersion|solid dispersion capsules, 50 mg, single dose
1892619|NCT01278095|Drug|GLPG0555 nanosuspension|Nanosuspension, 50 mg, single dose
1892620|NCT01278108|Drug|GLPG0778|single ascending doses, oral solution (10 to 800 mg/dose) and capsules (100 mg/dose)
1892621|NCT01278108|Drug|placebo|single dose, oral solution or capsule (matching corresponding study medication)
1892622|NCT01278108|Drug|GLPG0778|multiple dose, capsule, 7 days
1892623|NCT01278108|Drug|placebo|multiple dose, capsule, 7 days
1892624|NCT01278121|Dietary Supplement|Diet A|3 days, 6 meals a day
1892625|NCT01278121|Dietary Supplement|Diet B|10 days, 6 meals a day
1892626|NCT01278134|Drug|Copegus placebo|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
1892627|NCT01278134|Drug|RO5024048|1000 mg bid orally, up to 24 weeks
1892628|NCT01278134|Drug|danoprevir|100 mg bid orally, up to 24 weeks
1892629|NCT01278134|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly, 24 weeks
1892630|NCT01278134|Drug|ribavirin [Copegus]|1000 mg or 1200 mg daily orally in split doses (morning/evening), up to 24 weeks
1892631|NCT01278134|Drug|ritonavir|100 mg bid orally, up to 24 weeks
1892632|NCT01278147|Behavioral|fatigue education program|the carer will help the patient develop competences on the following points: how to evaluate the severity of the fatigue; learn to recognize symptoms or prodromes showing associated difficulties (anxiety, fear, depression); how to improve control of fatigue by setting up suitable strategies (management of periods of activity and rest, physical and/or intellectual exercises, dietary program, complementary therapy); learn to ask for and accept the help of close relations or carers.
1892633|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a dosage of 2/3 and 1/3 total daily dose before breakfast and before dinner, in combination with metformin.
1892634|NCT01278160|Drug|biphasic insulin aspart 30|Administered subcutaneously (under the skin), twice daily with a split dosage of 1/2 and 1/2 total daily dose before breakfast and before dinner, in combination with metformin.
1892635|NCT01278160|Drug|metformin|Tablets 500 mg administered orally with meals. Pre-trial dose and regimen unchanged
1892636|NCT01278173|Drug|Sabril|Sabril: 500 mg tablets, orally. Physicians will dose their patients according to guidance provided in the product label.
1892637|NCT01278186|Procedure|Balloon angioplasty|Coronary angioplasty using the paclitaxel-coated balloon catheter
1892638|NCT01278186|Procedure|Stent implantation|Coronary angioplasty using the paclitaxel-eluting stent
1892639|NCT01278199|Other|Medicals measures|"Rest in bed. Monitoring of respiratory frequency. Fixation of intravenous route. Administration of nasal oxygenotherapy in order to maintain SpO2 > 90%. Administration of antituberculosis treatment, in case with active pulmonary tuberculosis known at admission or diagnosed during the stay.
If necessary a bronchial wash out of will be realized by a bronchial fibroscopy with measures of use of cold serum, adrenalin xylocain or terlipressin.
The administration of antibiotherapy by general mode according to the clinician appreciation.
The administration of terlipressin according to the clinician appreciation. Against the cough treatment administration according to the clinician appreciation."
1892640|NCT01278199|Other|bronchial artery embolization|The bronchial artery embolization is practised within 48 hours which follow the hospital admission for non-severe acute hemoptysis.
1892641|NCT01278212|Radiation|accelerated hypofractionated radiotherapy (AHF-RT)|30 Gy in 5 fractions once a week for 5 weeks, followed by optional boost of 10-16 Gy
1892642|NCT01278225|Behavioral|EEG biofeedback (BF) Group|Group 1 will take part in a minimum of 2 neurofeedback training sessions each week for up to 10 weeks, for a total of up to 20 training sessions.
1892643|NCT01278225|Behavioral|Wait-List Control (WLC) Group|Group 2 will be placed on a wait-list, will continue to receive standard care, will not take part in the neurofeedback training, but will take part in the follow-up visits.
1892644|NCT01278225|Behavioral|Follow UP Questionnaires|After Group 1 completes neurofeedback training, both Groups to complete 10 questionnaires that were completed at baseline.
1892645|NCT01278238|Drug|Phenylephrine|Intravenous infusion Dosage 0,25 microgram/kg bodyweight as bolus, continuous infusion with 0,25 microgram/kg/min
1892646|NCT01278238|Device|Lower limb compression|Tight bandaging of lower extremity up to hips with compression bandages
1892647|NCT01278238|Other|Placebo|Neither phenylephrine nor lower limb bandaging
1892648|NCT01278251|Procedure|Distal Biceps Re-Insertion|
1892649|NCT01278264|Drug|Ropivacaine 0.25%, 0.5 ml/kg|Posterior approach for TAP: ultrasound guided bilateral needle insertion in the transversus abdominis plane, anterior to the quadratus lumborum muscle
1892650|NCT01278264|Drug|Ropivacaine 0.25%, 0.5 ml/kg|Subcostal approach for TAP: US guided needle insertion in the transversus abdominis plane, lateral to rectus sheet
1892651|NCT01278277|Dietary Supplement|Saffron supplementation|Saffron supplementation 20 mg
1892652|NCT01278277|Other|placebo|placebo supplementation
1892653|NCT01278290|Drug|Triptorelin acetate and Gonadorelin acetate|Triptorelin acetate aqueous 0.1 mg/m2 subcutaneous. Gonadorelin acetate 100 ug intravenous.
1892654|NCT01278290|Drug|Gonadorelin acetate and Triptorelin acetate|Gonadorelin acetate intravenous 100 ug. Triptorelin acetate 100 ug/m2.
1892655|NCT01278303|Device|Treatment of Aortic Wall Injury|A Cheatham covered platinum stent will be implanted in the Descending aorta to repair coarctation of the aorta in qualified patients.
1892656|NCT01278316|Behavioral|Control|Participants will be asked to perform computerized tasks that involve auditory and verbal performance one hour each day, five days per week for 8-10 weeks. Six tasks requiring auditory and verbal information will be presented.
1892657|NCT01278316|Behavioral|Cognitive Training|Participants will be asked to perform the Brain Fitness (PositScience) cognitive training tasks an hour each day, five days per week for 8-10 weeks. Six tasks manipulating auditory and verbal information will be presented, and stimuli from all tasks are presented auditorily. All tasks are designed to begin with the lowest level of difficulty required to attain 85% accuracy, and as performance improves, difficulty increases to maintain 85% accuracy, with difficulty decreasing if accuracy decreases.
1892658|NCT01278329|Other|"Garbh Sanskar audio cassette (Times Music Inc., Mumbai, India)"|Approximate playing time = 50 minutes. Mothers advised to listen to it once every day.
1892659|NCT01278342|Drug|Sandostatin LAR|40 mg intramuscular (i.m.) every 28 days for 3 months
1892660|NCT01278342|Drug|pegvisomant|Weekly doses of pegvisomant 70 mg subcutaneously (s.c.) for 4 months given with Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months
1892661|NCT01278342|Drug|cabergoline|"Weekly cabergoline for 4 months, with weekly doses of Sandostatin LAR 40 mg intramuscular (i.m.) every 28 days for 4 months. Cabergoline doses as follows:
st week: 0.25 mg twice a week (0.50 mg/week)
nd week: 0.50 mg/week twice a week (1 mg/week)
rd week: 0.50 mg four times a week (2 mg/week)
th week: 0.50 mg daily (3.5 mg/week) Subsequent 3 months: 0.50 mg daily (3.5 mg/week)"
1892662|NCT01278355|Device|Ear acupuncture|Ear acupuncture
1892663|NCT01278368|Procedure|Pancreatic resection after preoperative chemotherapy|Pancreatic resection after preoperative chemotherapy
1892664|NCT01278368|Procedure|Pancreatic resection|Pancreatic resection
1892665|NCT01278381|Procedure|Pancreaticoduodenectomy|Resection of pancreatic lesion
1892667|NCT01278407|Drug|Donepezil 5 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg
1892668|NCT01278407|Drug|Donepezil 10 mg|Donepezil tablets orally, once daily, uptitrated from 3 to 5 mg and then the dose was increased to 10 mg
1892669|NCT01278407|Drug|Donepezil matched placebo|
1892670|NCT01278420|Device|Tecnis MF|30 subjects will be implanted with the Tecnis MF
1892671|NCT01278420|Device|ReSTOR|30 subjects will be implanted with ReSTOR
1892672|NCT01278433|Biological|IMOVAX Polio™: Inactivated Poliomyelitis Vaccine|0.5 mL, Intramuscular
1892673|NCT01278446|Other|Extensively hydrolyzed, whey protein infant formula|New hydrolyzed formula
1892674|NCT01278446|Other|Extensively hydrolyzed, casein protein infant formula|Commercially available hydrolyzed infant formula
1892675|NCT01278459|Drug|Atorvastatin|4 week treatment, 20mg/day taken orally in tablet form
1892676|NCT01278472|Device|Single Port Cholecystectomy|Using transumbilical single port device: SILS Port
1892677|NCT01278472|Device|4 Port Cholecystectomy|using 4 separate skin incisions and 2 5mm and 2 12 mm conventional ports
1892678|NCT01278485|Drug|Sulphonylurea|SU administered according to usual practice.
1892679|NCT01278485|Drug|Metformn|Metformin administered according to usual practice.
1892682|NCT01278511|Other|Canadian C-Spine rule|Emergency medicine undergraduates will accompany prehospital emergency crews and apply the Canadian C-Spine rule, though cervical collar will be applicated per current protocol.
1892683|NCT01278537|Behavioral|Information|Booklet, motivational interviewing, brief advice
1892684|NCT01278563|Behavioral|Low glycemic index diet|dietitian interview and counselling for the low glycemic index diet group
1892685|NCT01278576|Drug|BOTOX-A®|200 units, single treatment only
1892686|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 5g|Liquid (80g) containing Plantago asiatica L. extract 5g
1892687|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 10g|Liquid (80g) containing Plantago asiatica L. extract 10g
1892688|NCT01278589|Dietary Supplement|Plantago asiatica L. extract 20g|Liquid (80g) containing Plantago asiatica L. extract 20g
1892689|NCT01278589|Dietary Supplement|Placebo|Liquid (80g) without Plantago asiatica L. extract
1892690|NCT01278602|Drug|R-ESHAP|Rituximab 375mg/m2 at day 0, Meththylprednisolone 500mg IV at days 1 to 5, Etoposide 40mg/m2 at days 1 to 4, Cisplatin 25mg/m2 at days 1 to 4, Cytarabine 2000mg/m2 at day 5. Frequence of cycles: every 3 weeks. Numbers of cycles: 3 cycles.
1892691|NCT01278615|Other|Laboratory Biomarker Analysis|Correlative studies
1892692|NCT01278615|Drug|Selumetinib|Given PO
1892693|NCT01278628|Other|exercise training|exercise class once a year
1892694|NCT01278641|Behavioral|Graded strength resistance training program|Graded strength resistance training, 75 minutes, twice a week for 12 weeks.
1892695|NCT01278641|Behavioral|Temperate pool exercise program|Temperate pool low intensive exercise, 50 minutes, twice a week for 12 weeks.
1892696|NCT01278654|Behavioral|Incentive to exercise|Participants who attain their walkstation goal will be entered into a draw every two weeks. We are testing the effect of different prizes on walkstation usage.
1892697|NCT01278680|Behavioral|Incentives for walkstation usage|The investigators are testing the effect of two different incentive schemes on people's usage of walkstations at work: either a personal incentive (in which people receive personal financial benefit for using the walkstations) vs. a charitable incentive (in which others receive financial benefit if a given individual uses the walkstation).
1892698|NCT01278693|Drug|L-carnitine|500 mg,twice daily, 16 weeks
1892699|NCT01278693|Drug|placebo|500 mg,twice daily, 16 weeks.
1892700|NCT01278706|Procedure|endometrial biopsy/ies|performing office endometrial biopsy with a disposable sterile catheter
1892701|NCT01278732|Other|no intervention performed|no intervention is performed
1892702|NCT01278745|Biological|Rituximab induction/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
1892703|NCT01278745|Drug|Rituximab placebo/conventional immunosuppression (tacrolimus, MMF, and steroid taper)|
1892704|NCT01278758|Drug|ASA404, DMXAA or DXAA|
1892705|NCT01278784|Device|0.05% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
1892706|NCT01278784|Device|0.1% Chitosan-N-Acetylcysteine eye drops|Subjects will be randomized to receive one drop of the medical device in either the right or left eye
1892707|NCT01278797|Drug|Telmisartan/Amlodipine Combination Tablet|Combination Tablet
1892708|NCT01278797|Drug|Amlodipine Monocomponent|Active Comparator
1892709|NCT01278810|Drug|Icaritin|50mg,100mg,200mg,300mg,400mg,500mg ascending-multiple oral dose, Qd, single dose and continuing dose 28 days, to assess the safety,tolerance and pharmacokinetics of icaritin
1892710|NCT01278823|Procedure|laparoscopic roux en y gastric bypass operation|roux en y gastric bypass operation
1892711|NCT01278823|Other|medical management|latest type 2 diabetes medications, lifestyle/behavior modification and dietary regimen
1892712|NCT01278836|Procedure|fasciocutaneous flap|flaps which include skin, subcutaneous tissue, and the underlying fascia.
1892713|NCT01278849|Drug|ASA404|
1892714|NCT01278862|Device|DVS veneer|CAD/CAM milled porcelain veneer for Lava crown
1892715|NCT01278888|Procedure|Anterolateral thoracotomy|Standard anterolateral thoracotomy
1892716|NCT01278888|Procedure|Posterolateral thoracotomy|Standard muscle sparing posterolateral thoracotomy
1892717|NCT01278888|Procedure|VATS|Standard video assisted thoracic surgery, no use of rib-spreader.
1892718|NCT01278888|Procedure|Anterolateral Thoracotomy|Standard anterolateral thoracotomy
1892719|NCT01278914|Biological|Dendritic Cells (DC) prostate|
1892720|NCT01278927|Behavioral|Exercise|Participants assigned to the Exercise arm will receive a packet of materials from the study interventionist, along with a brief personalized introduction to the home-based exercise intervention.
1892721|NCT01278927|Behavioral|Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (10 minute) standardized introduction to the self-administered intervention.
1892722|NCT01278927|Behavioral|Exercise and Stress Management|Participants will receive a packet of materials from the study interventionist, along with a brief (15 minute) personalized introduction to the interventions.
1892723|NCT01278927|Other|Standard Care|Patients randomized to standard care only will be informed of their assigned condition and receive the DVD.
1892724|NCT01278940|Biological|Dendritic Cells (DC) malignant melanoma|The patients were assigned to intradermal or intranodal DC vaccination
1892725|NCT01278940|Procedure|IL-2|IL-2 were administrated by intranodal injection
1892726|NCT01278953|Device|Catheter ablation for the treatment of paroxysmal atrial fibrillation|A pulmonary vein isolation procedure will be performed using radiofrequency ablation.
1892727|NCT01278966|Other|The Modified Atkins Diet|The Modified Atkins Diet; 10 g carbohydrate per day and a high fat intake
1892728|NCT01278979|Device|"Objective measurements of perineal tears with Peri-Rule"|"Four measurements will be used in this study.
Depth of tear, from the fourchette into the greatest depth of the perineal body.
Length of tear, from the fourchette to the apex of the vaginal tear.
Length of tear, from the fourchette along perineal skin towards the anus.
Length of the perineal body, from the fourchette to outer margin of anus."
1892729|NCT01278979|Other|Visual and digital assessment|Midwifes assessing perineal tears as standard procedure with visual and digital examination of the perineal tear.
1892730|NCT01278992|Dietary Supplement|Rhodiola rosea|1 capsule = 182 mg Rhodiola rosea extract standardized to 2.8% total rosavins. Take 2 capsules at start of wakeful period each day. Participants will self-determine need for second dose, of 1 capsule, within 4 hours of the initial dose.
1892731|NCT01279031|Device|Abbott WHITESTAR Signature System with Ellips Transversal Ultrasound|Comparison of vision after cataract surgery based on two different types of equipment.
1892732|NCT01279031|Device|Alcon Infiniti wiht the OZIL Torsional Handpiece|Comparision of vision after cataract surgery based on two different types of equipment.
1892733|NCT01279044|Behavioral|Adapted Personalized Cognitive Risk-reduction Counseling intervention (PCC)|The individualized, cognitive counseling intervention was designed to help participants address the self-justifications—beliefs, thoughts, and attitudes—that they employed in the setting of high-risk sexual behavior, in the company of an empathic counselor.
1892734|NCT01279044|Behavioral|Standard HIV testing with information only|Standard HIV testing with information only
1892735|NCT01279057|Drug|Fluticasone Furoate (Lek Pharmaceuticals ) Nasal Spray|110 mcg per day
1892736|NCT01279057|Drug|Fluticasone furoate (Veramyst®) nasal spray|110 mcg per day
1892737|NCT01279057|Drug|Placebo nasal spray|
1892738|NCT01279070|Behavioral|Repyflec cognitive remediation training|Comparison of 32 Repyflec group sessions among 32 leisure group sessions where we stimulated non-specific cognitive perform.
1892745|NCT01279096|Drug|Clofarabine|escalating doses of clofarabine starting from 20 mg/m2/day to 40 mg/m2/day from day 1 to day 5 used in association with etoposide, asparaginase, mitoxantrone and dexamethasone
1892746|NCT01279109|Behavioral|Social network building intervention|Group support and 12 weekly health education/skills building sessions during pregnancy
1892747|NCT01279109|Behavioral|Home visit|Three home visits during pregnancy focused on providing education on infant injury prevention
1892748|NCT01279122|Device|Nanoflex IOL|Patients who were implanted with the Nanoflex IOL
1892749|NCT01279135|Radiation|Conventional Radiation|Standard Pelvic Radiation 50 Gy/ 25 fractions over 5 weeks
1892750|NCT01279135|Radiation|Tomotherapy based IGRT|Patients in this arm will received Tomotherapy based Image Guided Intensity Modulated Radiotherapy to a dose of 50 Gy/25 fractions/5 weeks
1892865|NCT01280058|Biological|Wild-type Reovirus|Given IV
1892866|NCT01280071|Drug|aminophylline|
1892751|NCT01279174|Other|Conventional physiotherapy|Patients in this study group will attend physiotherapeutic exercise sessions of one hour three times a week for six weeks. The sessions consist of aerobic and muscle strengthening as well as coordination exercises. Patients will practice activities of daily living. The goals of these exercises are to improve joint stability, optimize knee and ankle proprioception, and advance neuromuscular innervation of the lower extremity and thereby suppress pathologic motion patterns. This should lead to optimized mobility, increased stability, and thus more endogenous analgesia of the affected joint
1892754|NCT01279200|Other|Midcycle ultrasound + hCG injection|Mid-cycle ultrasound with administration of hCG (single dose of standardized pre-filled injection, 250 mcg, at time of ultrasound) when appropriate.
1892755|NCT01279200|Other|Urinary LH kits|Subjects randomized to monitoring with LH kits at home will keep a monthly calendar documenting when LH testing begins, day LH surge occurs and day(s) of intercourse/insemination.
1892756|NCT01279213|Drug|paliperidone clozapine|dose 3 to 12 mg paliperidone ER daily during 12 weeks
1892757|NCT01279226|Device|Auralevée device|Single treatment with Auralevée device.
1892758|NCT01279252|Drug|metronidazole, clarithromycin, ciprofloxacin and lansoprazole|
1892759|NCT01279265|Dietary Supplement|Nutramigen with Enflora|Hypoallergenic formula with probiotic - Lactobacillus GG
1892760|NCT01279265|Dietary Supplement|Nutramigen A+|Hypoallergenic formula without lactobacillus
1892761|NCT01279278|Other|Co-signed letter|Patients receive a personalized letter co-signed by their general practitioner and the medical coordinator of ADECA.
1892762|NCT01279278|Other|Classical Letter|Patients receive classical letter signed by the coordinator doctor of ADECA
1892763|NCT01279291|Biological|KHK2866|Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
1892764|NCT01279291|Drug|Gemcitabine and Carboplatin|Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
1892765|NCT01279291|Drug|paclitaxel|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.
1892766|NCT01279291|Drug|pegylated liposomal doxorubicin|Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
1892767|NCT01279304|Radiation|radiation - no radiation see intervention description|after MRM in group 1 (low risk): no radiotherapy after BCT in group 1 (low risk): radiation treatment of the breast with boost (optional)
1892768|NCT01279304|Radiation|radiation: see intervention description|after BCT in group 2 (intermediate risk): radiation treatment of the breast with boost (optional) after MRM in group 2 (intermediate risk): radiation treatment of the thoracic wall If no full ALND is performed in group 2 (intermediate risk) add radiation treatment of level 1 and 2 of the axilla.
1892769|NCT01279304|Radiation|radiation: see intervention description|after MRM in group 3 (high risk): radiation treatment of the thoracic wall and supraclavicular nodes after BCT in group 3 (high risk): radiation treatment of the breast with boost (optional) and supraclavicular nodes If no full ALND is performed group 3 (high risk) add radiation treatment of level 1 and 2 of the axilla.
1892770|NCT01279317|Dietary Supplement|placebo co-ingestion|25 ml water co-ingested with a glucose-containing beverage
1892771|NCT01279317|Dietary Supplement|vinegar co-ingestion|25 ml vinegar (1 g acetic acid) co-ingested with a glucose-containing beverage
1892772|NCT01279330|Other|Co-signed Letter|Patients receive a personalized stimulus letter co-signed by their general practitioner and the medical coordinator of ADECA.
1892773|NCT01279330|Other|Control|No intervention (Patients receive by mail the materials needed for stool samples).
1892774|NCT01279343|Device|Foley bulb|This is a randomized trial comparing foley bulb with the use of misoprostol versus use of misoprostol alone for cervical ripening and labor induction.
1892775|NCT01279382|Behavioral|Hypnotherapy (HYP)|Hypnotherapy was given to a subgroup of patients as intervention in IBS treatment
1892776|NCT01279382|Behavioral|Relaxation training (RT)|RT was given to a subgroup of patients as intervention in IBS treatment
1892777|NCT01279382|Other|Care as usual (CON)|CON was given to a subgroup of patients as control intervention in IBS treatment
1892778|NCT01279408|Other|None: Questionnaire Study|Patients enrolled in this study will have standard treatment as per the discretion of their attending physician. The only additional requirement is that they would be asked is to complete questionnaires
1892779|NCT01279421|Behavioral|Social Network HIV Testing|Crack users will be recruited for HIV testing and receive 3 coupons to recruit other crack users for HIV testing.
1892780|NCT01279421|Behavioral|Peer Network Intervention|Peer leaders will recruit small networks of crack users and facilitate a three-day prevention intervention.
1892781|NCT01279434|Drug|Vitamin E plus Pentoxiphyllin|Both drugs will be administered daily Vit E (400 mg BD) and pentoxiphyllin (400 mg TDS) for 12 months
1892782|NCT01279434|Drug|Vitamin E|Vitamin E 400 mg BD daily for 12 months
1892783|NCT01279447|Drug|0.25% Bupivacaine|10cc, single dose, US guided injection
1892784|NCT01279447|Drug|Normal Saline|10cc, single dose, US guided injection
1892785|NCT01279473|Drug|Nilotinib|
1892786|NCT01279499|Drug|Sevoflurane|Intraoperatively Sevoflurane will be guided by a target end tidal concentration 1 - 2 MAC .Every rise of BP or HR > 15% of baseline will be followed by a bolus SEVO inhalation 8% MAC for 2 minutes
1892787|NCT01279499|Drug|Sevoflurane|Intraoperatively sevoflurane will be guided by a target BIS of 40 - 50. If a positive sympathetic response occured (an elevation of the HR and/or MAP greater than 15% above baseline) a bolus SEVO 8 MAC will be administered for 2 minutes.
1892788|NCT01279499|Drug|Propofol- Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW).General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (doses based on ideal body weight).
Every rise of BP or HR > 15% of baseline will be followed by a Remifentanyl bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remifentanyl from 0.1 to 1.0 μg/kg/min"
1892789|NCT01279499|Drug|Propofol, Remifentanyl|"Anaesthesia will be induced with a continuous IV Propofol infusion (21mg/kg TBW for 5 min, 12 mg/kg TBW for 10 min and then 6 mg/kg TBW), followed by an IV bolus of Remifentanyl (1 μg/kg IBW) and succinylcholine (1mg/kg IBW). General anesthesia will be maintained with continuous intravenous administration of Propofol at 150-300mcg/kg/min (ideal body weight).
The depth of anesthesia will be adjusted so as to accomplish a BIS score between 40 and 50 Every rise of BP or HR > 15% of baseline will be followed by a Remi bolus IV (1 μg/kg IBW) and increase in the continuous infusion rate of Remi from 0.1 to 1.0 μg/kg/min"
1892790|NCT01279512|Drug|Metformin|The metformin dose will be 500 mg/ day in the first week, 1000 mg/ day in the second week and 1500 mg/ day for the next 10 weeks.
1892791|NCT01279512|Drug|Acarbose|Acarbose group will be treated by acarbose (its dose will be 100 mg/day in the first week, 200 mg/ day in the second week and 300 mg/ day for the next 10 weeks).
1892792|NCT01279525|Device|multifactorial|individual advice, information leaflet, physical exercise workshop and home visits
1892793|NCT01279538|Drug|ASKP1240|Intravenous (IV) infusion
1892794|NCT01279538|Drug|Placebo|Intravenous (IV) infusion
1892795|NCT01279551|Drug|0.4% nitroglycerin ointment|Local endoanal application 2 times a day
1892796|NCT01279551|Drug|lidocaine cloridrato 2.5% ointment|Local endoanal application of lidocaine cloridrato 2.5% ointment 2 times a day
1892797|NCT01279564|Device|ETview TVT endotracheal tube|intubation
1892798|NCT01279564|Device|Endotracheal tube|Intubation
1892799|NCT01279577|Drug|Low dose TSO|Low dose TSO suspension
1892800|NCT01279577|Drug|Medium dose TSO|Medium dose TSO suspension
1892801|NCT01279577|Drug|High dose TSO|High dose TSO suspension
1892802|NCT01279577|Drug|Placebo|Placebo solution
1892803|NCT01279590|Drug|PPD10558|"PPD10558 40 mg capsule and matching placebo capsule twice a day for 4 weeks, then
PPD10558 80 mg (two 40 mg capsules) twice a day for 8 weeks"
1892804|NCT01279590|Drug|Atorvastatin|"Atorvastatin 40 mg capsule and matching placebo capsule in the morning and 2 placebo capsules in the evening for 4 weeks, then
Atorvastatin 80 mg (two 40 mg capsules) in the morning and 2 placebo capsules in the evening for 8 weeks"
1892805|NCT01279590|Drug|Placebo|2 placebo capsules twice daily for 12 weeks
1892806|NCT01279603|Drug|GO-203-2c|GO-203-2c Injection is a non-preserved, sterile, ready-to-use liquid dosage form provided in a glass vial with rubber closure and crimp seal. Injection will be added to the contents of an intravenous bag (of 0.9% NS, D5W or sterile water) to a final concentration of between 0.03 - 0.3 mg/ml (preferable in 100 mls or greater) and administered as a single agent intravenously over 60 minutes. A treatment cycle will consist of a daily IV dose administered for 21 consecutive days followed by a 7 day rest.
1892807|NCT01279616|Drug|Fludarabine monophosphate|180 mg/m2 over 6 days.
1892808|NCT01279616|Drug|Rituximab|375 mg/m2 on day -13 and day -3
1892809|NCT01279616|Drug|Busulfan|AUC 1000-1200 microM.mt
1892810|NCT01279616|Drug|ATG|2.5 mg/kg for 3 days
1892811|NCT01279616|Drug|Cyclophosphamide|50 mg/kg on day +3
1892812|NCT01279616|Drug|Mycophenolate mofetil|15 mg/kg q 8 hours
1892813|NCT01279616|Drug|Tacrolimus|0.03 mg/kg /d
1892814|NCT01279629|Drug|Each patient will receive a sample of the drug test (tazarotene 0.1%) and a control sample of the drug (calcipotriene 0.005%).|Apply the medication once daily, preferably at night, in quantities sufficient to cover only the lesions with a thin layer of the product (an average of 2 mg/cm2).Apply only in lesions of the right hemisphere.
1892815|NCT01279642|Device|ultrasound|Doppler vascular ultrasound guidance to PICC insertion in children -
1892816|NCT01279642|Other|traditional puncture|traditional approach of PICC insertion by visualization and inspection of insertion site
1892817|NCT01279655|Device|tDCS|20 min, 1mA, 8 weeks (5 days a week, 20 min a day)
1892818|NCT01279655|Behavioral|Bimanual Training|The training program consisted of a bimanual etch-a-sketch task. By rotating two wheels subjects have to match a line presented on the screen with the cursor. 8 weeks (5 days a week, 20 min a day)
1892819|NCT01279668|Drug|Montelukast|10mg tablets, once per day for 28 days.
1892820|NCT01279668|Drug|Placebo|tablets, once per day for 28 days.
1892826|NCT01279694|Drug|Carfilzomib|There are 9 cycle of 20mg/m²,Intravenous for J1, J2, J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the first cohort; or 20mg/m²,Intravenous for J1, J2, and 27 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle) for the second cohort for the last, third cohort 20mg/m²,Intravenous for J1, J2, and 36 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle)and the fourth cohort 20mg/m²,Intravenous for J1, J2, and 45 mg/m² for J8, J9, J22, J23, J29 and 30 days with 12 days rest (42 day cycle). .
1892827|NCT01279694|Drug|Melphalan|from 9 cycle: 9 mg/m²/day PO from day 1-4
1892828|NCT01279694|Drug|Prednisone|from 9 cycle: 60 mg/m²/day PO from day 1-4
1892832|NCT01279720|Biological|Intravenous infusion of transduced cells|Intravenous infusion of transduced cells
1892867|NCT01280110|Drug|Hydroxypropylmethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month
1892868|NCT01280110|Drug|Carboxymethylcellulose|22 patients will receive this lubricating drop 4 times a day for 1 month.
1893320|NCT01281124|Other|Pharmacological Study|Correlative studies
1892833|NCT01279733|Genetic|Microarray analysis|"Microarray performed on prenatal specimen:
Fluorescence in-situ hybridization (FISH) or other standardized tests such as qPCR or MLPA will be performed on the fetal sample to confirm abnormal MA findings of known and unknown clinical significance which are discordant with CC findings, including anomalies normally detected by karyotyping.
Microarray analysis of DNA from parental blood samples will be used to determine whether CNVs detected in a fetal sample are also present in a healthy parent, in which case no further evaluation will take place, moreover any finding in a fetus which is duplicated in a parental microarray is considered to be confirmed."
1892834|NCT01279746|Device|Ultrasound compression of femoral and popliteal veins|Bedside ultrasound compression of femoral and popliteal veins.
1892835|NCT01279785|Drug|123I-MIP-1072|Single IV dose
1892836|NCT01279798|Biological|Lucanix® (belagenpumatucel-L)|Subjects will receive up to 12 monthly (28-35 day interval) Lucanix injections at a dose of 2.5 × 10e7 cells per injection.
1892838|NCT01279824|Behavioral|swallowing therapy|Standardized behavioral swallowing intervention
1892839|NCT01279837|Behavioral|Pharyngocise|swallowing intervention by a speech language pathologist, consisting of the battery of isometric / isotonic exercises
1892840|NCT01279850|Drug|Pregabalin (Lyrica) capsule|"Lyrica® Capsules depending on the investigator prescription. Frequency and duration are according to Package Insert as follows. The usual adult dosage for oral use begins at 150 mg/day of pregabalin in twice daily, and should be gradually increased to 300 mg/day over 1 week or more and should be orally administered twice daily. Dosage should be adjusted, depending on age or symptoms. However, the daily maximum dose should not be beyond 600 mg, and should be orally administered twice daily."
1892841|NCT01279876|Drug|Melatonin|3mg oral, daily, one hour before sleep
1892842|NCT01279902|Drug|Rituximab plus CHOP Immunochemotherapy|The R-CHOP treatment will continue up to 3 cycles with interval of 21 days: Each cycle consists of rituximab 375mg/m2 (iv, on day 1), cyclophosphamide 750 mg/m2 (iv, on day 1), doxorubicin 50mg/m2 (iv, on day 1), vincristine 1.4mg/m2 (iv, on day 1), and prednisolone 100mg (po, on day 1-5).
1892843|NCT01279915|Drug|ASP0456|oral
1892844|NCT01279915|Drug|Placebo|oral
1892845|NCT01279928|Procedure|Video Nailfold Capillaroscopy|Single session of video Nailfold Capillaroscopy wit KKK technology
1892846|NCT01279928|Device|Ambulatory 24 hr Blood Pressure Monitoring|24 hr upper arm cuff measurement of Blood Pressure
1892847|NCT01279928|Procedure|Fundoscopy of eyes|examination of microvascular health of eye with the use of opthalmoscope
1892848|NCT01279928|Procedure|Laser Doppler Flowmetry|Examination of vascular flow
1892849|NCT01279941|Behavioral|Behavioral: Team-based intervention|The intervention involves a scripted peer-taught interactive curriculum, which is delivered as twelve, one-hour weekly sessions incorporated into a team's usual work time activities, with four follow-up booster sessions after twelve months.
1892850|NCT01279954|Drug|Abatacept|"Subjects will receive approximately 10 mg/kg rounded to the nearest 25 mg for the first 6 months of the trial. At 6 months subjects will then be randomized to receive either 5 mg/kg or 10 mg/kg.
Abatacept will be administered as a 30-minute intravenous infusion. Following the initial administration, abatacept will be given at 2 and 4 weeks after the first infusion and every 4 weeks thereafter for up to 2 years."
1989969|NCT02302716|Drug|LY2963016|Administered SC
1989970|NCT02302716|Drug|LANTUS®|Administered SC
1892854|NCT01279993|Procedure|Kerato refractive Surgery|This interventional case series was performed on 297 eyes of 150 patients who were candidates for PRK. Complete ophthalmic evaluations focusing on orthoptic examinations were performed before and 3 months after PRK.
1892855|NCT01280006|Other|Intermittent hypoxia|The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. On the testing day, the subjects will undergo an acute intermittent hypoxia testing before and six hours of hypoxic chamber exposure mimicking obstructive sleep apnea syndrome.
1892856|NCT01280006|Drug|Indomethacin|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.
Indomethacin: 50 mg, Oral, three times per day for five days."
1892857|NCT01280006|Drug|Celecoxib|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.
Celecoxib: 200 mg, Oral, two times per day for five days with a visually matching sequential placebo in between of two doses."
1892858|NCT01280006|Drug|Placebo|"The subjects will receive five days of drug intervention: either non-selective cyclooxygenase (Indomethacin) or selective cyclooxygenase-2 inhibition (Celecoxib) or placebo. Then they will be tested with an exposure of intermittent hypoxia.
Placebo: Oral, three times per day for five days."
1892859|NCT01280019|Procedure|alveolar recruitment manoeuvre|Increase of airway pressures in a stepwise manner from set peak inspiratory pressure/ positive end-expiratory pressure up to 40/15 mbar and back over 2 minutes.
1892860|NCT01280032|Radiation|intraoperative radiotherapy|intraoperative radiotherapy (8 Gy) during kyphoplasty for spinal metatsases
1892861|NCT01280045|Procedure|VAGINAL HYSTERECTOMY|GOSERELINE ACETATE 10.8 MG FOR THREE MONTHS; ANASTROZOL ACETATE FOR THREE MONTHS
1892862|NCT01280058|Drug|Carboplatin|Given IV
1892863|NCT01280058|Other|Laboratory Biomarker Analysis|Correlative studies
1892864|NCT01280058|Drug|Paclitaxel|Given IV
1989971|NCT02302716|Drug|Oral Antihyperglycemic Medication|Administered as per standard-of-care.
1892869|NCT01280123|Drug|Pioglitazone|"Oral capsules of Pioglitazone (15 mg capsules) either 15 mg/qd or 45 mg/qd
Subjects will titrate in a blinded fashion to 30 mg/day after 2 weeks and to 45 mg per day) 2 weeks later as tolerated."
1892870|NCT01280123|Drug|placebo|Placebo will contain microcrystalline cellulose. An over-encapsulation process will be conducted in accordance with Clinical Good Manufacturing Procedures (cGMP) regulations to create a dosage form for the active study drug that will be indistinguishable from the comparator (Placebo) capsule.
1892871|NCT01280136|Behavioral|It's Your Game Tech|An interactive web-based intervention for 8th grade students. This web-based intervention will be adapted from the computer-based component of an existing successful prevention program, It's Your Game…Keep it Real, (IYG) as well as include critical elements from the IYG classroom component. The web-based intervention will consist of 13 lessons and will tailor information to the individual's gender and to his/her intentions or behaviors related to sexual risk-taking. The program will address peer norms, attitudes, self-efficacy, refusal skills, and communication skills related to healthy relationships, dating, and sexual risk-taking behavior.
1892872|NCT01280149|Biological|substance P|injections of substance P and low dose allergen or placebo
1892873|NCT01280149|Biological|substance P injections|injections of substance P for 8 weeks
1892874|NCT01280162|Drug|Dihydroartemisinin piperaquine|40/320 mg tablets, 9 tablets total
1892875|NCT01280175|Procedure|charcoal block|
1892876|NCT01280175|Device|Aerochamber Plus spacer|
1892877|NCT01280175|Drug|pMDI standard actuator|
1892878|NCT01280188|Drug|Desmopressin Oral Melt|Oral melt formulation starts on Day 2. The target initial dose of the orally disintegrating tablet is 180µg/day (60µg taken 3 times a day) and adjusted to optimally stabilise the participant's condition.
1892879|NCT01280188|Drug|Desmopressin intranasal|Self-administered intranasal desmopressin throughout the pre-study observation period (Days -30 to Day 0) and on study Day 1
1989972|NCT02302157|Biological|AST-OPC1|One injection of 2 million or 10 million AST-OPC1 cells, or 2 injections of 10 million AST-OPC1 cells for a total of 20 million cells; cohort dependent
1892881|NCT01280214|Drug|Triamcinolone|Subconjunctival and peribulbar, 40 mg/ml, 3 monthly injection
1892882|NCT01280227|Behavioral|SiSom|SiSom is a symptom assessment tool designed to help the child report disease specific problems.The child also report the severity of their problems. After using the tool a report is printed and given to the clinician.
1892883|NCT01280240|Drug|Monofer(R)|Intravenous bolus injection given over app. 2 minutes only once
1892884|NCT01280266|Drug|Udenafil or Amlodipine|Amlodipine 10mg daily then Udenafil 100 mg daily OR Udenafil 100 mg daily then Amlodipine 10mg daily
1892885|NCT01270074|Drug|Azithromycin|azithromycin will be given as a liquid preparation at a dose of 10 mg/kg three times per week from three months of age until three years of age
1892886|NCT01270074|Drug|Placebo control|inert liquid preparation will be given three times per week from three months of age to three years of age
1892887|NCT01270087|Drug|Adalimumab|40 mg IV every 14 days
1892888|NCT01270100|Behavioral|Recovery management|
1892889|NCT01270113|Behavioral|contingency management|
1892890|NCT01270126|Device|Repetitive transorbital alternating current stimulation|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000µA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
1892891|NCT01270139|Procedure|Transplantation of nanoparticles|60 patients into nanogroup with the use of 60/15-70/40 nm silica-gold nanoparticles (NPs) transplanted by endoscopic cardiac surgery in the composition of bioengineered on-artery patch grown on the basis of biopolymeric scaffold and host circulating CD45-CD34-CD73+CD105+ progenitor cells
1892892|NCT01270139|Procedure|Transplantation of iron-bearing nanoparticles|60 - into ferro-magnetic group with 60/15-70/40 nm silica-gold iron-bearing NPs with delivery in hand of magnetic navigation system
1892893|NCT01270139|Device|Stenting|60 - in sirolimus-eluting stenting control
1892895|NCT01270165|Drug|telbivudine|600mg, oral daily over 12 months
1892896|NCT01270178|Drug|Entecavir|film coated tablets / 0.5mg / once daily / 3 years
1892897|NCT01270191|Drug|Exenatide|They will be treated with 5 mcg bid for 4 weeks and then 10 mcg bid for 12 weeks. They also visit every 2 weeks in the first 2 visits and then every month until 4 months.
1892898|NCT01270191|Drug|Humulin-N|The insulin dose will be initiated with 0.25 unit/Kg per day, and the two thirds of daily dose will be administrated before breakfast and the other will be administrated at bedtime. Insulin doses will be titrated every 3 days to achieve target fasting blood glucose values between 70 and 130 mg/dl.
1892899|NCT01270217|Behavioral|Brief motivational interview|The brief motivational interview is a non-confrontational, patient-centered discussion between a counselor (e.g., social worker, nurse, physician, or psychologist) and an at-risk individual during which the individual's motivation and confidence to change health-related behaviors are explored.
1892900|NCT01270230|Behavioral|Bruthas Project|The Bruthas Project HIV prevention intervention is a four-session, semi-structured individual risk reduction counseling program based on the Information-Motivation-Behavior (IMB) theoretical model. The counseling sessions are designed to complement standardized HIV-Counseling and Testing, and are delivered every 2-3 weeks over the course of 3 months. Each session lasts for approximately one hour, and is facilitated by a trained African American male counselor. The counselors engage with participants using open-ended questions and a non-judgmental, conversational style designed to elicit feedback on an individual's current level of HIV-related risk. The counselor then provides information and strengthens the participant's prevention skills.
1892982|NCT01271803|Drug|vemurafenib|Participants will receive vemurafenib 720 or 960 mg along with cobimetinib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
1892983|NCT01271829|Dietary Supplement|Avocado supplement|Calories from avocados replace calories of the control lunch
1892984|NCT01271829|Dietary Supplement|Avocado included|Calories from avocados will be added to calories from the control lunch
1892901|NCT01270230|Behavioral|Standard HIV Testing and Counseling|This arm represents those receiving the standard HIV testing and counseling. We ultimately settled on the standard-of-care comparison group because our primary research question is whether the implementation of the intervention cast against the backdrop of usual care, in this case, HIV testing and counseling as mandated by the CDC, is efficacious. Thus, participants randomized to the comparison group will receive the current standard intervention which involves HIV testing, pre- and post-test counseling, plus linkage to case management. Individuals who test HIV-positive will be referred to post-test services including counseling for treatment options, HIV-positive support groups, and harm reduction workshops.
1892902|NCT01270256|Drug|Budesonide|Pulmicort Respules at a dose of 0.25 mg. delivered intranasally via NasoNeb nebulizer once daily
1892903|NCT01270256|Drug|Placebo|Placebo delivered intranasally via NasoNeb nebulizer once daily
1892904|NCT01270269|Behavioral|Behavioral: Physical and functional rehabilitation|A multi-component program of physical rehabilitation interventions (without cognitive rehabilitation) will be delivered to patients beginning in the ICU and continue throughout the hospitalization.
1892905|NCT01270269|Behavioral|Behavioral: Cognitive, physical, & functional rehabilitation|A multi-component program of cognitive, physical, and functional rehabilitation interventions will be delivered to patients beginning in the ICU with continued cognitive rehabilitation in their home environments over a focused 12-week period.
1892906|NCT01270282|Drug|AM-101 0.81 mg/mL|
1892907|NCT01270282|Drug|Placebo|
1892908|NCT01270308|Drug|Lansoprazole|Lansoprazole DR Capsules 30 mg
1892909|NCT01270321|Drug|Everolimus|Everolimus 10 mg daily continuously (switch to 2-drug combination at progression if no intolerable toxicity)
1892910|NCT01270321|Drug|Pasireotide|Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
1892911|NCT01270321|Drug|Everolimus and Pasireotide|Everolimus 10 mg daily continuously together with Pasireotide 1200 mcg bid for 4 weeks followed by Pasireotide long acting release (LAR) 60 mg i.m. once every 4 weeks
1892912|NCT01270334|Other|PH meassurment|meassuring ph USING PROBE
1892913|NCT01270347|Drug|MP-376 (Levofloxacin Solution for Inhalation)|MP-376 (Aeroquin, Levofloxacin solution for Inhalation) 240 mg administered BID for 28-days treatment followed by 28 days off treatment
1892914|NCT01270347|Drug|TIS (Tobramycin Inhalation Solution)|Tobramycin Inhalation Solution administered BID over 3 consecutive cycles of 28-days treatment followed by 28 days off treatment
1892915|NCT01270360|Device|COLOHYBRITEST OR VALIHYBRITEST|Detection of human colon or rectal tumours by using a simplified molecular test based on either a combination of methylated DNA or protein marker(s) alone or considered together in biological fluids like blood, urine and stools
1892916|NCT01270373|Drug|FAC x 3 followed by Docetaxel x 3|5-Fluorouracil (500 mg/m2), Adriamycin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles; followed by Docetaxel 100 mg/m2 every 21 days, for 3 cycles
1892917|NCT01270373|Drug|Docetaxel x 3 followed by FAC x 3|Docetaxel 100 mg/m2 IV every 21 days, for 3 cycles; followed by 5-Fluorouracil (500 mg/m2), Adriamycin (50 mg/m2) and Cyclophosphamide (500 mg/m2) IV every 21 days, for 3 cycles
1892918|NCT01270386|Drug|apatinib|Apatinib 750 mg p.o. once daily
1892919|NCT01270386|Drug|placebo|placebo p.o. once daily
1892920|NCT01270412|Biological|Platelet Rich Plasma (Preparation Rich in Growth Factors)|intra articular injection 6ml
1892921|NCT01270412|Drug|Hyaluronic acid|Intra articular injections: 20 mg / 2 ml
1892922|NCT01270438|Drug|FOLFOX regimen|Given IV
1892923|NCT01270438|Drug|gamma-secretase/Notch signalling pathway inhibitor RO4929097|Given orally
1892924|NCT01270438|Biological|bevacizumab|Given IV
1892925|NCT01270438|Drug|oxaliplatin|Given IV
1892926|NCT01270438|Drug|leucovorin calcium|Given IV
1892927|NCT01270438|Drug|fluorouracil|Given IV
1892928|NCT01270451|Other|Lifestyle intervention to prevent weight regain|To study if subjects receiving extra guidance in diet and physical activity experience less weight gain compared to a control group.
1892929|NCT01270464|Drug|Reslizumab|3.0 mg/kg or 0.3 mg/kg doses administered intravenously (iv) by qualified site personnel once every 4 weeks, for a total of 4 doses.
1892930|NCT01270464|Drug|Placebo|Placebo administered by iv infusion by qualified study personnel every 4 weeks for a total of 4 doses.
1892931|NCT01270477|Other|Hyperbaric oxygen treatment|Hyperbaric oxygen treatment for 2,5 hours at maximum 14 meters (standard table in Norway).
1892932|NCT01270490|Drug|Interferon-gamma, Recombinant|Interferon 50 mcg/m2 to be administered three times per week during two weeks
1892933|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1892934|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1892935|NCT01270503|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular
1892936|NCT01270516|Drug|HMB, hydroxymethylbutyrate|Hydroxymethylbutyrate will be given as 1500 mg powder dissolved in 30 ml saline given enterally every 12 hours for 7 days
1892937|NCT01270516|Drug|EPA, eicosapentaenoic acid|EPA given as 1000 mg solution in saline (30 ml) administered enterally every 12 hours for 7 days
1892938|NCT01270516|Drug|Saline|Control
1892939|NCT01270529|Other|Increasing Physical activity|The subjects (CKD Stages 1-4, ESRD on Hemodialysis or Peritoneal Dialysis) will continue to wear the pedometer for 12 weeks during which time he or she will be asked to gradually increase steps walked per day above baseline physical activity. The patient will be called once a week in order to monitor progress, set new weekly step goals (usually 500-1000 steps/day greater than the previous week), and also to motivate the participant.
1892940|NCT01270542|Drug|Avastin (bevacizumab)|single 0.05 mL intravitreal injection of bevacizumab 1.25 mg
1892941|NCT01270542|Other|Sham injection|Subject's eyes will be anesthetized but no injection will be performed.
1892942|NCT01270555|Drug|Bupropion SR|100mg capsules Initial dosing 100mgSR every morning, to be titrated to 200mgSR twice daily maximum
1892946|NCT01270581|Other|High Flow Nasal Cannula|Humidified high flow nasal cannula (HFNC) has emerged as an alternative respiratory modality for late preterm newborns with respiratory distress. Like NCPAP, oxygen is delivered to the infant via nasal prongs and provides a continuous distending pressure. Unlike the nasal prongs for NCPAP (which fit tightly in the nares), the nasal cannula for HFNC have smaller, loose-fitting prong. With HFNC, positive airway pressure is achieved by high gas flow through the cannula into the external nares which provide resistance to expiration and facilitate inspiration. The distending pressure is determined by the size and structure of the nasal cannula, gas flow rate, and the neonate's airway anatomy 4,5,7.
1892947|NCT01270581|Other|Bubble Nasal CPAP|NCPAP provides continuous distending airway pressure during inspiration and expiration via nasal prongs; this has been shown to increase lung volume by increasing alveolar size, recruiting collapsed alveoli, and preventing atelectasis. Improved lung volumes decrease V/Q mismatch and improve the clinical course of neonates with RDS, and as such, early NCPAP use often avoids the need for intubation and mechanical ventilation. Newborns receiving bubble NCPAP will be placed on a PEEP 5cm H2O, and supplemental oxygen will be provided to maintain oxygen saturation between 88-93% (standard of care group) as is standard practice. The size of the nasal prongs used will be based on the subject's weight as per the manufacturer instructions.
1892948|NCT01270594|Behavioral|COPD Inhaler Counseling|The counseling will be performed via telephone by a pharmacist at the William S Middleton Memorial Veterans Hospital. The counseling will include education about inhaled COPD medication, inhaler technique review, reminder tools, and motivational interviewing.
1892949|NCT01270594|Behavioral|Usual Pharmacy Care|The usual care arm will receive standard care from the William S Middleton Memorial Veterans Hospital pharmacists.
1892950|NCT01270607|Procedure|Acupuncture|Treatment given twice per week for 4 weeks
1892951|NCT01270620|Drug|propofol|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
1892952|NCT01270620|Drug|Desflurane|comparison of the incidence in delirium and post-operative cognitive dysfunction from propofol and desflurane in patients under general anesthesia
1892953|NCT01270633|Device|PriMatrix|Following sharp debridement, application of PriMatrix dermal repair scaffold in conjunction with moist wound therapy
1892954|NCT01270633|Other|Standard of Care|Following sharp debridement, moist wound therapy
1892955|NCT01270646|Device|Invasive mapping with CARTO3 system and Non-Invasive mapping with CardioInsight Atlas EC Mapping system|"Day 1: CRT device is implanted under general anesthesia in a conventional fashion. The coronary sinus leads will be implanted guided by the acute hemodynamic response (+(dP/dt)max) using a RADI guide wire. After device implantation, a steerable mapping catheter will be inserted in the Left Ventricle (LV) cavity to build a tridimensional activation map of the LV. This map will be obtained with and without CRT. From these maps different parameters describing LV activation will be measured and compared between patients with and without CRT.
Day 5±2: A non-invasive map of the LV will be recorded with the CardioInsight ® system with and without CRT. The same parameters will be measured and compared with those obtained with invasive mapping."
1892956|NCT01271712|Drug|Regorafenib (Stivarga, BAY73-4506)|160 mg po once daily (od), 3 weeks on/1 week off. Route of administration: oral
1892957|NCT01271712|Drug|Placebo|once daily (od), 3 weeks on/1 week off. Route of administration: oral
1892958|NCT01271712|Drug|Best supportive care|Best supportive care includes any method to preserve the comfort and dignity of the patients, and excludes any disease-specific anti-neoplastic therapy such as any kinase inhibitor, chemotherapy, radiation therapy, or surgical intervention.
1892959|NCT01271725|Drug|Vinorelbine 25 mg/m2 weekly|Patients to additionally receive vinorelbine at a dose of 25 mg/m2 weekly on disease progression on afatinib monotherapy
1892960|NCT01271725|Drug|Afatinib 40mg once daily (OD)|Patient to receive afatinib monotherapy at a dose of 40 mg/d until progression of their disease
1892961|NCT01271725|Drug|Paclitaxel 80 mg/m2 weekly|Patients to additionally receive paclitaxel at a dose of 80 mg/m2 weekly on disease progression on afatinib monotherapy
1892962|NCT01271738|Procedure|Remove tumor only|No additional margins (tissue) removed at the initial surgery
1892963|NCT01271738|Procedure|Removal of tumor and tissue|5 additional margins (tissue) removed at the time of surgery
1892964|NCT01271751|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
1892965|NCT01271751|Drug|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
1892966|NCT01271764|Other|no drug|The role of G9a protein in patients with endometrial cancer
1892967|NCT01271777|Drug|GFT505 80mg|hard gelatin capsules dosed at 20mg, oral administration, 4 capsules per day before breakfast
1892968|NCT01271777|Drug|Placebo|hard gelatin capsules, oral administration, 4 capsules per day before breakfast
1892969|NCT01271790|Drug|Tegobuvir (GS-9190)|Tegobuvir (GS-9190) capsule, 30 mg BID
1892970|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg once daily (QD)
1892971|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
1892972|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
1892973|NCT01271790|Drug|GS-9451|GS-9451 tablet, 200 mg QD
1892974|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
1892975|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
1892976|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)
1892977|NCT01271790|Drug|Tegobuvir placebo|placebo matching Tegobuvir (GS-9190) capsule BID
1892978|NCT01271790|Drug|GS-9451 placebo|placebo matching GS-9451 tablet QD
1892979|NCT01271790|Biological|Pegasys®|peginterferon alfa-2a (solution for injection) 180 µg/week
1892980|NCT01271790|Drug|Copegus®|ribavirin tablet (weight based: 1000 mg/day <75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID); tablet
1892981|NCT01271803|Drug|Cobimetinib|Participants will receive cobimetinib 60 to 100 mg at any of the 3 dosing schedules with or without vemurafenib in cycles of 28 days each until disease progression, unacceptable toxicity, or any other discontinuation criteria are met.
1892985|NCT01271855|Drug|B&O suppository|B&O suppository 16.2mg/30mg per rectum immediately after delivery, then every 8 hours for 24 hours following delivery
1892986|NCT01271855|Other|Control Group|A vegetable oil suppository (placebo) per rectum immediately after delivery, then scheduled every 8-hours for the first 24 hours.
1892987|NCT01271868|Drug|Recombinant factor IX Product, IB1001|On-Demand or Prophylaxis
1892988|NCT01271881|Other|PTA alone without use of the GORE VIABAHN|PTA alone with no stent used
1892989|NCT01271881|Device|GORE VIABAHN® Endoprosthesis with Heparin Bioactive Surface|Covered stent produced by GORE VIABAHN
1892990|NCT01271894|Drug|Efavirenz|600 mg once daily; given as 3 x 200 mg once
1892991|NCT01271894|Drug|Efavirenz|400 mg once daily; given as 2 x 200 mg + 1 x placebo
1892992|NCT01271907|Drug|fludarabine|Fludarabine 25 mg/m^2 x 5 days
1892993|NCT01271907|Drug|cyclophosphamide|Cyclophosphamide 60 mg/kg intravenous (IV) x 2 days
1892994|NCT01271907|Drug|Drosophila-peptide pulsed Melanoma-reactive autologous CD8+ PBL|Up to 1x10e10 CTL-05 cells
1892995|NCT01271907|Drug|Aldesleukin|Aldesleukin 125,000 IU/kg/dose as a daily subcutaneous injection
1892996|NCT01271920|Drug|AUY922|
1892997|NCT01271920|Drug|Trastuzumab|
1893000|NCT01271946|Device|Diagnostic catheterization procedure|Intervention includes diagnostic catheterization procedure involving access through a 5F or 6F introducer in the femoral artery.
1893001|NCT01271972|Drug|nesvacumab (REGN910/ SAR307746)|
1893002|NCT01271985|Drug|PolyPill|A combination tablet containing Aspirin 81 mg, enalapril 5 mg (or valsartan 40 mg), atorvastatin 20 mg and hydrochlorothiazide 12.5 mg taken once daily
1893003|NCT01271985|Other|Minimal care|Health education pamphlet on reducing cardiovascular risk factors, direct education on reducing cardiovascular risk factors provided by the study physician and the Community Health Worker, biannual follow-up and BP measurement
1893004|NCT01271998|Drug|TR-701 FA|200 mg, oral, once daily for 3 days.
1893005|NCT01272011|Other|Intermittent Hypoxia|Individuals received exposure to intermittent hypoxia for 10 days, and placebo for 1-2 days.
1893006|NCT01272011|Other|Locomotor Training|Individuals received 10 days of locomotor training, intense walking training on a treadmill with body weight support. Manual assistance was provided at the legs to optimize stepping patterns.
1893007|NCT01272024|Behavioral|Symptom Education|Participants are given a Symptom Education Toolkit at baseline and at each visit thereafter (1 month and 3 month) are encouraged to use the Toolkit for symptoms they are experiencing. They are also encouraged to use resources available to them.
1893008|NCT01272024|Behavioral|Intervention|Participants are visited/contacted by an intervention nurse ten times over a 12-week period for the purpose of helping them to manage uncertainty and distress,to boost their problem-solving skills, and to transition to treatment.
1893016|NCT01272050|Radiation|radiation therapy|"RT in the standard arm A will be administered to a total dose of 64 Gy in 32 fractions of 2 Gy over 6.4 weeks. RT in the experimental arm B will be administered to a total dose of 70 Gy in 35 fractions of 2 Gy over 7 weeks.
Megavoltage equipments with nominal photon energies ≥ 6 MV are required. Rotational techniques such as Tomotherapy®, Rapidarc®, intensity-modulated arc technique (IMAT) and volumetric-modulated arc therapy (VMAT) will also be eligible. The patient will be treated in an isocentric setting and all fields will be applied for 5 days per week for the total RT duration."
1893017|NCT01272089|Drug|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%|Olopatadine Hydrochloride Ophthalmic Solution, 0.2%, one drop once a day for one week
1893018|NCT01272115|Behavioral|Integrative health care model|The integrative health care model with an empowerment approach will address the care that should be given collaboratively by the health team in cooperation with the active participation of women. The IHCM will be provided under the leadership of the nurse who will coordinate with the health team members, promote preventive care, and incorporate cognitive-behavioral strategies, such as individual and group counseling. The IHCM will be provided for three months to each woman, followed by a three-month follow-up. Each woman will receive: monthly individual counseling by nurse; eight weekly (90-minutes) group counseling sessions and 2-9 consultations with psychologist defined in accordance to women individual needs and characteristics.
1893019|NCT01272128|Drug|Interferon beta-1a|Interferon beta-1a will not be provided as a part of this study. Participants will receive Interferon beta-1a as prescribed by their treating physician prior to enrollment.
1893020|NCT01272141|Drug|Lapatinib and Everolimus|"Lapatinib: 1250 mg by mouth daily
Everolimus: 5mg by mouth daily"
1893021|NCT01272154|Other|Transcranial magnetic stimulation|Transcranial magnetic stimulation (PAS and rTMS)
1893022|NCT01272167|Behavioral|Long-term grapefruit juice consumption|The main goals of this project are (1) to characterize the effect of a long-term grapefruit juice consumption on both vascular and bone protections and (2) to assess the specific role of naringin, in these potential protective effects.
1893023|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + OMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus OMV.
1893024|NCT01272180|Biological|Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.|Two injections of Meningococcal (group B) multicomponent recombinant adsorbed vaccine plus OMV.
1893025|NCT01272180|Biological|Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.|One injection of saline solution placebo and one of Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate vaccine.
1893065|NCT01272427|Dietary Supplement|water and whey protein|0.75 g/kg body weight of whey protein added to water
1893066|NCT01272427|Dietary Supplement|water with noncaloric sweetener|0.15 g of sucralose added to water
1893026|NCT01272180|Biological|Meningococcal (groups A, C, W, Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine + qOMV.|Two injections of a combined vaccine formulation, Meningococcal (groups A, C, W, and Y) oligosaccharide diphtheria CRM-197 conjugate combined with meningococcal (group B) multicomponent recombinant vaccine plus a quarter dose of OMV.
1893027|NCT01272193|Drug|insulin degludec/insulin aspart|Injected subcutaneously (under the skin) once daily prior to the largest meal of the day as monotherapy or combined with no more than 2 oral anti-diabetic drugs (OADs).
1893028|NCT01272193|Drug|insulin glargine|Administered according to approved labelling either as monotherapy or combined with no more than 2 OADs.
1893029|NCT01272206|Drug|NNC 0128-0000-2011|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
1893030|NCT01272206|Drug|NNC 0128-0000-2021|Administered as one single i.v. (intravenous) injection, 100 mcg/kg
1893038|NCT01272245|Drug|Omacetaxine|1.25 mg/m2 subcutaneously (SQ) every 12 hours (+/- 3 hours) for 3 days (Days 1-3). Each cycle will be 4-7 weeks.
1893039|NCT01272245|Drug|Cytarabine|20 mg subcutaneously every 12 hours (+/- 3 hours) for 7 days (Days 1-7). Each cycle will be 4-7 weeks.
1893040|NCT01272258|Drug|PRO 140|SC injection
1893041|NCT01272258|Drug|Placebo|SC injection
1893042|NCT01272284|Device|Altis® Single Incision Sling System (SIS)|The Altis® SIS is a permanently implantable synthetic sling for females placed at the mid-urethra to provide a scaffold for tissue in-growth and support for stress urinary incontinence.
1893043|NCT01272297|Device|LI-ESWT|Low intensity shock wave treatment - 12 sessions
1893044|NCT01272310|Biological|Hydroxychloroquine (HCQ), Pegylated Interferon Alpha-2a (Peg-IFN alpha-2a) and Ribavirin|"HCQ will be taken daily as an oral tablet of 200 mg b.i.d. Pegylated Interferon Alpha-2a - (180 µg) will be administered as weekly subcutaneous (s.c.) injections of 0.5 ml.
Ribavirin - will be taken daily based on the patient body weight. If body weight is < 75 kg, the total daily dose of Copegus® is 1000 mg, administered as 400 mg (2 tablets of 200 mg, morning intake) and 600 mg (3 tablets of 200 mg, evening intake). If body weight is >= 75 kg, the total daily dose is 1200 mg administered as twice 600 mg (3 tablets of 200 mg per intake, morning and evening)."
1893045|NCT01272323|Biological|Placebo|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
1893046|NCT01272323|Biological|Cat-PAD Dose 1|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
1893047|NCT01272323|Biological|Cat-PAD Dose 2|No further medication to be administered in this study. Intervention refers to treatment received in Study CP005.
1893048|NCT01272336|Drug|Acute Intermittent Hypoxia (AIH)|Participants will breath intermittent low oxygen via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.09±0.02 (hypoxia) air for 15 minutes.Participants will receive treatment for up to seven visits.
1893049|NCT01272336|Other|SHAM-Intermittent Room Air|This is a sham intervention to the AIH intervention. Participants will breath intermittent room air via air generators. The generators will fill reservoir bags attached to a non-rebreathing face mask. Oxygen concentration will be continuously monitored to ensure delivery of FIO2=0.21±0.02 (normoxia). Participants will receive treatment for up to seven visits.
1893050|NCT01272349|Other|Acute intermittent hypoxia|30 minutes of intermittent breathing low oxygen followed by walking on a body-weight support treadmill
1893051|NCT01272349|Other|Room air|30 minutes of breathing room air followed by walking on a body-weight support treadmill
1893052|NCT01272362|Drug|Indacaterol|Indacaterol 150 µg once-daily via single-dose dry powder inhaler
1893053|NCT01272375|Drug|Treatment A|PF-04764793 250/50 using inhaler A
1893054|NCT01272375|Drug|Treatment B|PF-04764793 250/50 using inhaler A
1893055|NCT01272375|Drug|Treatment C|PF-04764793 250/50 using inhaler A
1893056|NCT01272375|Drug|Treatment D|PF-04764793 250/50 using inhaler A
1893057|NCT01272375|Drug|Treatment E|PF-04764793 250/50 using inhaler B
1893058|NCT01272375|Drug|Treatment F|PF-04764793 250/50 using inhaler B
1893059|NCT01272375|Drug|Treatment G|PF-04764793 250/50 using inhaler B
1893060|NCT01272388|Drug|Tadalafil|Active drug will be encapsulated to look identical to the placebo pill. Subjects will take a single oral dose of tadalafil once daily from the time of randomization until the surgical date (~4 weeks). Subjects will begin by taking 20 mg (1 pill) daily for 3 days before having the dose increased to 40 mg (2 pills) once daily. If the increase to 40mg daily is not tolerated, then the dose will be decreased back to 20mg daily.
1893061|NCT01272388|Drug|Placebo|The placebo pill will be encapsulated to look identical to the active drug pill. Subjects will take a single oral dose of placebo once daily from the time of randomization until the surgical date (~4 weeks). Subjects will begin by taking 1 pill daily for 3 days before having the dose increased to 2 pills once daily. If the increase to 2 pills daily is not tolerated, then the dose will be decreased back to 1 pill daily.
1893062|NCT01272414|Drug|Botulinum Toxin Type A|2-12 units in weekly 2u doses to effect
1893063|NCT01272414|Drug|Saline injection|Injection of 0.4cc 0.9% normal saline
1893064|NCT01272427|Dietary Supplement|water with glucose|0.75 g/kg body weight of glucose added to water
1893067|NCT01272466|Biological|peptides derived from antiapoptotic proteins|8 Vaccinations on day 2 and 9 in every bortezomib treatment series
1893068|NCT01272492|Other|Computer Use|Participants use the computer with the 5 modules on infant/toddler feeding/nutrition
1893069|NCT01272505|Procedure|converntional SILC|
1893070|NCT01272505|Procedure|Harmonic scalpel Single incision laparoscopic cholecystectomy|
1893071|NCT01272531|Drug|Mood stabilizer treatment|lithium or valproate
1893072|NCT01272557|Drug|Doxorubicin|Doxorubicin 60 mg/m2 i.v. on day 1 every 21 days Sorafenib 400 mg bid (oral) from day 3-19 every 21 days. Maximum accumulative dose of doxorubicin: 360 mg/m2 (thereafter sorafenib monotherapy continuously until progression or unacceptable toxicity).
1893073|NCT01272557|Drug|Sorafenib|Sorafenib 400 mg bid (oral) continuously
1893074|NCT01272583|Drug|Sitagliptin|100 mg once daily for six weeks
1893075|NCT01272583|Drug|Placebo|placebo, once daily for six weeks
1893076|NCT01272609|Drug|Timolol + LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ² if LCP of Candela © or 7 J / cm ² if LCP of Cynosure ©) spaced out of 1 month. Twice-daily applications on the zone treated by the LCP of timolol frost and will be begun that very evening by the first session and will be pursued 15j after the 3rd session of LCP. The maximum surface of treatment will be 100 cms ².
1893077|NCT01272609|Device|LCP|Three sessions of LCP in 595nm (diameter of spot 7mm; duration of shooting 1,5ms; Fluence 8 J / cm ²if LCP of Candela © or 7 J / cm ²if LCP of Cynosure © spaced out of 1 month.
1893078|NCT01272622|Radiation|Radiation|Immediate irradiation after incomplete resection (fractionated, percutaneous irradiation, 54 gy)
1893079|NCT01272622|Other|wait and watch|wait ans watch, MRI controls, irradiation at the time of progression of residual tumor
1893080|NCT01272635|Drug|Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
1893081|NCT01272635|Drug|Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
1893082|NCT01272635|Other|Placebo Azithromycin|Suspension, 12 mg/kg once daily for 5 days, maximum dose 500mg/day
1893083|NCT01272635|Drug|Placebo Prednisolone|Syrup, 1 mg/kg/dose twice daily for 5 days, maximum dose 60mg/day
1893084|NCT01272648|Behavioral|RePCa A|"Intervention patients receives two consultations with a specialist oncology nurse three and six month after ended radiotherapy. The focus are on what is important for the patients at the specific time. The patient can bring his spouse.
Furthermore the patients have two physiotherapy consultations with guidance in pelvic floor exercises and an individual home-program of pelvic and functional training exercises"
1893085|NCT01272661|Behavioral|Enhanced Curriculum|Brief health literacy focused modules on breastfeeding delivered in the home by Community Health Workers
1893086|NCT01272661|Behavioral|Enhanced Curriculum+Breastfeeding Doula|In the Doula Program, the Community Health Worker and mother will identify a support person (e.g. grandma, father, friend) who commits to learning about breastfeeding with the mother at home visits, and then helps her with breastfeeding postpartum.
1893087|NCT01272661|Behavioral|Enhanced Curriculum +Father Support|In the Father Support Program, mothers will give their partners father-friendly breastfeeding information and an invitation to a 3-week breastfeeding education group for fathers that includes a resource specialist or resource information for child support, re-entry and job services.
1893088|NCT01272674|Other|exercise training|4 weeks supervised physical exercise training
1893089|NCT01272700|Procedure|volume control|Volume controlled ventilation of tidal volume 10 ml/kg
1893090|NCT01272700|Procedure|pressure control|Pressure controlled ventilation for peak airway pressure to deliver tidal volume 10 ml/kg.
1893091|NCT01272713|Other|Oxygen therapy|"Pre-hospital supplemental oxygen administered via Hudson mask at a flow rate of 8L/min
In-hospital oxygen as per hospital protocol"
1893092|NCT01272713|Other|No oxygen therapy|No oxygen pre-hospital or in-hospital unless the oxygen saturation falls below 94% in which case oxygen will be administered via nasal cannulae (4L/min) or Hudson mask (8L/min) and titrated to achieve oxygen saturation of 94%.
1893093|NCT01272726|Behavioral|Education|Education on the genetics of ADHD and treatment options for ADHD
1893094|NCT01272739|Dietary Supplement|IHBG-10|500 mg of IHBG-10 taken 15 minutes prior to the three main meals of the day
1893095|NCT01272739|Dietary Supplement|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
1893096|NCT01272752|Dietary Supplement|IHBG-10|500 mg IHBG-10
1893097|NCT01272752|Dietary Supplement|Placebo|Placebo taken 15 minutes prior to the three main meals of the day
1893098|NCT01272765|Other|Placebo|Placebo
1893099|NCT01272765|Dietary Supplement|IHBG-10|500 mg IHBG-10
1893100|NCT01272778|Drug|Lorazepam|Oral capsule, 0.2 mg, single acute dose
1893101|NCT01272778|Drug|Lorazepam|oral capsule, 0.5 mg, single acute dose
1893102|NCT01272778|Drug|Lorazepam|oral capsule, 1.0 mg, single acute dose
1893103|NCT01272778|Drug|Lorazepam|oral capsule, 2.0 mg, single acute dose
1893104|NCT01272778|Drug|Placebo|oral capsule, single acute dose
1893105|NCT01272791|Biological|bavituximab|Patients who qualify for enrollment into the study will be randomized in a 1:1 ratio to receive study treatment of gemcitabine alone or gemcitabine with weekly 3 mg/kg bavituximab. Treatment for each patient will begin on Study Day 1. Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities. Patients randomized to receive bavituximab will be treated weekly beginning on Day 1 of each cycle. Study visits are scheduled to occur every 7 (± 2) days for bavituximab administration (for patients randomized to receive bavituximab); gemcitabine administration will occur every 7 (± 2) days for the first 3 weeks of each 4-week cycle
1893106|NCT01272791|Drug|Gemcitabine|Gemcitabine (1000 mg/m2) will be given on Days 1, 8 and 15 of each 28 day cycle (4 weeks) until disease progression or unacceptable toxicities
1893107|NCT01272804|Drug|PF-04937319|Subjects will be dosed with PF-04937319 for 14 days. The doses planned are 10, 30, 100 and 300 mg QD. All doses will be administered as tablets (10 and 100 mg strengths). In each Cohort, 9 patients will receive PF 04937319 and 3 will receive placebo. An additional cohort of 12 patients (9 active, 3 placebo) may be performed to explore a QD or BID dose. The dose for this additional cohort could be a dose already studied or a new dose that is within the exposure stopping criteria.
1893319|NCT01281124|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1893108|NCT01272804|Drug|Placebo|Placebo to match PF-04937319 will be provided. Subjects will be dosed for 14 days. In each cohort 9 subjects will receive PF-04937319 and 3 will receive placebo.
1893109|NCT01272817|Procedure|Nonmyeloablative Allogeneic Transplant|Cladribine 0.14 mg/kg/day for five days, melphalan 100 mg/m2 on one day
1893110|NCT01272817|Procedure|Nonmyeloablative Allogeneic Transplant|Total lymphoid irradiation 100cGy/day times 10 days (Monday through Friday)
1990692|NCT01873573|Procedure|Esophagogastroduodenoscopy (EGD)|EGD is a test to examine the lining of the esophagus (the tube that connects your throat to your stomach), stomach, and first part of the small intestine. It is done with a small camera (flexible endoscope) that is inserted down the throat.
1893113|NCT01272856|Drug|Abatacept|125 mg pre-filled syringe for sub-q injection weekly.
1893114|NCT01272869|Device|SenSura|The ostomy bag filter will be tested for a period of 14 days
1893115|NCT01272869|Device|Morfeus|The new ostomy bag filter will be tested for a period of 14 days
1893116|NCT01272882|Device|Electrical Impedance Tomography monitoring|Chest belt with 16 electrodes connected to the EIT device
1893117|NCT01272895|Device|Coronary Intervention (GENOUS stent)|GENOUS stent (Coronary Intervention)
1893118|NCT01272908|Drug|rituximab|1000 mg intravenously on Days 1 and 15
1893119|NCT01272921|Drug|Bupivacaine|Varying doses to determine the duration of analgesia
1893120|NCT01272921|Drug|Ropivacaine|Varying doses to determine the duration of analgesia
1893121|NCT01272934|Drug|Diclofenac Sodium|Topical gel 1%-4 times daily
1893122|NCT01272934|Other|Placebo|Topical gel-4 times daily
1893123|NCT01272947|Drug|Diclofenac sodium|Topical gel 1%- 4 times daily
1893124|NCT01272947|Other|Placebo|Topical gel - 4 times daily
1990694|NCT01872689|Drug|Lebrikizumab|Administered SC every 4 weeks
1893126|NCT01272973|Drug|semaglutide|Semaglutide (oral) administered once daily for 10 weeks.Individually adjusted dose investigated up to maximum level.
1893127|NCT01272973|Drug|placebo|Placebo (oral) administered once daily for 10 weeks.
1893128|NCT01272973|Drug|semaglutide|Administered s.c. (under the skin) once weekly for 10 weeks. Individually adjusted dose investigated up to maximum level.
1893129|NCT01272986|Device|ALOA IgG-Elisa|measurement of IgG Level in blood
1893130|NCT01272986|Device|ALOA IgG-AtheroAbzyme|measurement of IgG in blood
1990695|NCT01872689|Drug|Pirfenidone|Administered daily at the maximum tolerated dose
1893132|NCT01273025|Dietary Supplement|Lime powder regime|1 sachet of lime powder regimen with 200 ml of water
1893133|NCT01273038|Device|Morfeus|The new ostomy bag filter (called Morfeus) will be tested for a period of 14 days
1893134|NCT01273038|Device|SenSura|The CE marked ostomy bag filter will be tested for a period of 14 days
1893135|NCT01273051|Drug|Capecitabine|Capecitabine will be administered at a dose of 825 mg/m2 bid during radiotherapy treatment
1893136|NCT01273051|Radiation|radiotherapy|radiation 25x2 Gy
1893137|NCT01273051|Procedure|TME resection|All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation. Patients who do not respond or clinically have a T3 tumour either on visual measurements or post therapy MRI or endoanal ultrasound will be operated on with a TME resection 8 - 10 weeks after the last chemo radiation treatment.
1893138|NCT01273051|Procedure|TEM surgery|"All patients undergo a MRI of the pelvis and a rectoscopy and endorectal ultrasound 6 weeks after chemo radiation.Patients with a significant downsizing of the tumour (T0-T2) will be operated on by TEM surgery 8 -10 weeks after the last chemo radiation treatment.
After TEM surgery, pathological assessment will dictate further treatment. Conservative treatment with careful follow-up will be performed in patients with a complete resection of a ypT0-1 rectal tumour. Patients with lymphangio invasion, an incomplete resected ypT1 (<2 mm margin), an ypT2 or ypT3 tumour after TEM will subsequently undergo TME surgery to remove the rectum within 4 weeks."
1893139|NCT01273064|Drug|CTS-1027|Supplied in 30mg, 10mg, or 5mg tablets (depending on dose arm) taken twice daily for up to 48 weeks.
1893140|NCT01273064|Drug|pegylated interferon|180 micrograms in 0.5 ml of solution subcutaneously (SQ), delivered in single use syringes administered once per week, for up to 48 weeks.
1893141|NCT01273064|Drug|Ribavirin|200 mg capsules of ribavirn taken in two divided daily doses totaling 1000 mg (5 capsules) for patients weighing 75 kg or less, or 1200 mg (6 capsules) for patients weighing more than 75 kg
1893142|NCT01273064|Drug|Placebo|"Tablets identical in appearance to CTS-1027 containing inactive ingredients.
Placebo arm patients: Two tablets taken twice daily, for a total daily dose of four tablets.
30 mg CTS-1027 patients: One tablet taken twice daily, for a total daily dose of two tablets. One bottle of placebo is added to the 30mg kits in order to maintain the study blind (all patients recieve two-bottle kits of CTS-1027 and/or placebo)."
1893143|NCT01273090|Drug|imetelstat sodium|
1893144|NCT01273090|Other|laboratory biomarker analysis|
1893145|NCT01273090|Other|pharmacological study|
1893146|NCT01273103|Drug|200mg [14C]- GSK2248761|single oral suspension dose of [14C]- GSK2248761 200 mg
1893147|NCT01273116|Other|CWS in Hospital|"Every patient aged ≥70 years will be screened for frailty. (For) every frail patient:
will have a comprehensive (geriatric) assessment using an adapted version of the EasyCare instrument;
a geriatric consultation team will propose/recommend a tailored care and welfare plan, which will be updated at the moment of discharge;
will be discussed at least once in a multidisciplinary meeting;
a structured medication review will be carried out by a geriatrician;
is offered an activation programme by volunteers focusing on improvement of orientation, mobility, social activities or nutrition;
may receive a consult of a geriatrician, if judged necessary;
will receive extra attention on discharge arrangements.
Hospital staff will be educated, disease-specific guidelines will be adapted to frail older patients."
1893185|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
1990696|NCT01872689|Drug|Placebo|Administered SC every 4 weeks
1893150|NCT01273181|Biological|PG13-MAGE-A3 TCR9W11 (anti-MAGE-A3/12 TCR) Transduced Autologous Peripheral Blood Lymphocytes|
1893151|NCT01273181|Drug|Aldesleukin|720,000 IU/kg every 8 hours for a maximum of 15 doses
1893152|NCT01273181|Drug|Cyclophosphamide|60 mg/kg/day x 2 days intravenous (IV)over 1 hour.
1893153|NCT01273181|Drug|Fludarabine|25 mg/m^2/day intravenous piggy back (IVPB) daily over 30 minutes for 5 days.
1893155|NCT01273233|Biological|Inactivated Enterovirus Type 71 Vaccine|A Sinovac EV71 vaccine contains inactivated EV71 virus, aluminum hydroxide, sodium chloride, disodium hydrogen phosphate, sodium dihydrogen phosphate and injection water. The EV71 vaccine is supplied in one mono-dose vial containing 0.5 mL of viral suspension with EV71 virus antigen of 200U and 400U (Elisa unit)
1893156|NCT01273233|Other|Placebo|Placebo is suspension with a little ivory precipitation, composition of which is aluminum hydroxide diluents.
1893157|NCT01273246|Biological|100U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 100U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
1893158|NCT01273246|Biological|200U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 200U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
1893159|NCT01273246|Biological|400U inactivated Enterovirus Type 71 Vaccine|Inactivated Enterovirus Type 71 Vaccine, 400U per 0.5ml per dose. Vaccine will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
1893160|NCT01273246|Biological|Placebo|Placebo, all components of the trial vacccine except for the Enterovirus Type 71 virus antigen, 0.5ml per dose. Placebo will be administered as a single 0.5 mL intramuscular injection in the deltoid muscle of the arm
1893161|NCT01273259|Drug|DHEA Treatment|DHEA : 200 mg/day hard gelatine capsule
1893162|NCT01273259|Drug|DHEA Treatment|DHEA : 25 mg/day hard gelatine capsule
1893163|NCT01273272|Behavioral|Comprehensive, CBT-based, multi-component treatment|It includes eight modules: diagnosis and goal setting; psychoeducation; engagement in pleasant activities; cognitive restructuring; live review; training caregiver in behavior man-agement techniques; interventions for the caregiver; and couples counselling. It consists of 20 weekly sessions (plus appr. 5 single session with caregiver).
1893164|NCT01273272|Behavioral|Treatment as usual|Each patient/caregiver must receive at least three out of six interventions: (1) psychoeducation on dementia and treatment of dementia (oral and written); (2) appropriate medical treatment; (3) social counseling by specialized staff; (4) memory training in group setting; (5) self-help group for the patient; (6) self-help group for the caregiver.
1893165|NCT01273285|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|
1893166|NCT01273298|Drug|Bisoprolol|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
1893167|NCT01273298|Drug|Placebo|Patients will be assigned to bisoprolol per os or matching placebo per os daily for 14 days. Bisoprolol will be initiated at a dose of 2.5mg daily for the first two days then up-titrated to 5mg daily for two other days. And finally, bisoprolol will be up-titrated to 10mg daily for the remaining 10 days.
1893168|NCT01273324|Device|ADM Cup|ADM Cup
1893171|NCT01273350|Device|Carotid PTA and stenting|Percutaneous interventional treatment of carotid artery stenosis using XACT carotid artery stent and emboshield protection system with bivalirudin as the procedural anticoagulant
1893172|NCT01273376|Drug|RX-10100|Extended-release tablet, taken twice daily for 8 weeks
1893173|NCT01273389|Drug|CNTO 136|Type=exact number, unit=mg/kg, number=10, form=solution for injection, route=intravenous. CNTO 136 is administered once every 4 weeks from Week 0 to Week 24.
1893174|NCT01273389|Drug|Placebo|Form=solution for injection, route=intravenous. Placebo is administered once every 4 weeks from Week 0 to Week 24.
1893175|NCT01273402|Drug|TF2/IMP288|TF2 is administered 4 days prior to radiolabeled IMP288. Each are given weekly for 2 weeks.
1893176|NCT01273428|Drug|HP011-101|
1893177|NCT01273428|Device|HP-828-101|
1893178|NCT01273428|Other|Standard Care|
1893179|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 5 days: PPI and 1g amoxicillin every 12h. After dual therapy continue with a triple therapy for 5 days: PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
1893180|NCT01273441|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for ten days:PPI, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
1893181|NCT01273454|Drug|OROS Hydromorphone|8,16, 32 mg once a day for 4 weeks
1893182|NCT01273467|Drug|CNTO 0007 or placebo (Stage A)|a single IV infusion of a selected dose of CNTO 0007 or placebo administered IV within 1-5 days (depending on cohort) after stroke (first cohort of patients will receive the lowest dose of CNTO 0007 or placebo and each subsequent group will be administered a higher dose (to be determined)
1893183|NCT01273467|Drug|CNTO 0007 or placebo (Stage B)|a single IV infusion of the MTD of CNTO 0007 or placebo administered IV within a specified number of days after stroke
1893184|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
1893277|NCT01280500|Behavioral|electronic medical record|Decision Support, Asthma Action Plans, and Population Management Reporting (EAP)
1893186|NCT01273480|Drug|Sequence 1|Cycle 1: 2 rifampin 300 mg capsules 1x daily for 5 days followed by 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 followed 28 days later by cycle 2 trabectedin 1.3 mg/m2 i.v. on Day 1. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
1893187|NCT01273480|Drug|Sequence 2|Cycle 1: Trabectedin 1.3 mg/m2 i.v. on Day 1 followed by 2 rifampin 300 mg capsules once daily on Days 24-28 followed by Cycle 2, 2 rifampin capsules prior to trabectedin 1.3 mg/m2 i.v. on Day 1 of Cycle 2. Dexamethasone 20 mg i.v. administered prior to trabectedin in each cycle.
1893188|NCT01273493|Drug|Trabectedin|Trabectedin 0.58 or 1.3 mg/m^2 (or adjusted dose) i.v. will be administered on Day 1.
1893189|NCT01273493|Drug|Dexamethasone|Dexamethasone will be administered as 20 mg/m^2, 30 minutes prior to trabectedin.
1893190|NCT01273506|Drug|tapentadol (CG5503) ER 25-mg TRF|50 mg TRF single oral dose
1893191|NCT01273506|Drug|tapentadol (CG5503) ER 50-mg TRF|50 mg TRF single oral dose
1893192|NCT01273532|Drug|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
1893193|NCT01273532|Drug|tapentadol (CG5503) ER 50-mg TRF|100 mg TRF single oral dose
1893194|NCT01273545|Drug|PRILIGY (dapoxetine hydrochloride)|The study will observe characteristics of the patients to whom PRILIGY 30-mg and 60-mg tablets are prescribed in Germany by general practitioners and (separately) by urologists, and in Italy by urologists
1893195|NCT01273558|Drug|Canagliflozin|One 100 mg capsule taken orally (by mouth) on Days Days 1-8
1893196|NCT01273571|Drug|Canagliflozin/Metformin|Two 1000-mg tablets of metformin on Day 1 followed by one 300-mg tablet of canagliflozin once daily on Days 4 through 8, followed by two 1000-mg tablets of metformin and one 300-mg tablet of canagliflozin on Day 8.
1893197|NCT01273584|Drug|Metformin|Maximum dosage 500 mg 2 tablets 3 times a day (with each meal) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
1893198|NCT01273584|Drug|Placebo|Placebo maximum dosage 2 tablets 3 times a day ( with meals) start with 1 tablet twice a day and gradually titrate upwards to maximum dose
1893199|NCT01273610|Drug|Lapatinib|250 mg tablets
1893200|NCT01273610|Drug|Trastuzumab|Intravenous injection
1893201|NCT01273610|Other|laboratory biomarker analysis|
1893202|NCT01273610|Other|pharmacological study|
1893203|NCT01273623|Device|Jetstream Atherectomy System|to perform atherectomy on calcified lesions
1893204|NCT01273649|Device|cryotherapy|cryotherapy is given with other physical training
1893205|NCT01273662|Drug|AG-013736|All enrolled patients will receive axitinib, 5 mg orally twice daily with food, until objective disease progression, development of unacceptable toxicity, or voluntary discontinuation by the subjects.
1893206|NCT01273688|Behavioral|Eccentric training (Flex-Bar)|6x15 repetitions of supination and pronation daily over 12 weeks
1893207|NCT01273688|Device|EpiHit elbow brace|daily wearing of the EpiHit elbow brace
1893208|NCT01273701|Behavioral|Psychosocial intervention|"The treatment is one-year long and composed of 3 stages of psychosocial intervention. Subjects of TSTSU arms receive urine methamphetamine examinations at each visit, while subjects in OPD arm being tested at first/last visits and during stage changes.
-Stage 1, early intensive monitoring stage: The visit interval is 1 week. If the urine tests and self-report on methamphetamine use are negative for consecutive 4 visits, subjects can proceed to stage 2. (In OPD arm, the visit interval can be 2 weeks according to subjects' requirements.)
-Sage 2, late intensive monitoring stage: The visit interval is 2 week. If the urine tests and self-reports are straightly negative for 4 visits, subjects can proceed to stage 3. Whenever recent methamphetamine is detected, subjects should move back to stage 1.
-Stage 3, usual monitoring stage: The visit interval is 1 month until the end of treatment. Whenever recent methamphetamine is detected, subjects should move back to stage 1."
1893209|NCT01273701|Behavioral|Telephone reminding|Subjects in TSTSU-T group will receive addition telephone reminding one day before each visit. Each call will be no longer than five minutes. On the telephone, brief motivation enhancement may be conducted.
1893210|NCT01273714|Procedure|thyroid resection|bilateral subtotal versus total thyroidectomy
1893211|NCT01273727|Drug|Dexamethasone|intravitreal implant 0.7 mg 6 month duration
1893212|NCT01273727|Drug|dexamethasone|intravitreal implant 0.7 mg duration 6 months
1893213|NCT01273740|Procedure|External support|Bypass surgery with externally supported graft
1893214|NCT01273753|Other|Intradialytic exercise|Patients will exercise using a stationary foot pedal cycle for 20 minutes at the beginning of hemodialysis.
1893215|NCT01273766|Drug|deferasirox|Given orally
1893216|NCT01273766|Other|laboratory biomarker analysis|Correlative studies
1893217|NCT01273766|Other|enzyme-linked immunosorbent assay|Correlative studies
1893218|NCT01273779|Drug|Talactoferrin alfa|15 mL of an oral solution of 100mg/mL (1.5 g) given 3 times a day for up to 28 days or until discharge from the intensive care unit
1893219|NCT01273779|Drug|Placebo|15 mL of oral solution of placebo given 3 times a day for up to 28 days or until discharge from the intensive care unit
1893220|NCT01273805|Drug|Hydroxychloroquine|
1893221|NCT01273818|Drug|Gentamicin and cefazolin|80 mg topically, intra-operative,single dose and intravenous 1000 mg cefazolin 1 hour before operation
1893222|NCT01273818|Drug|Cefazolin|1000 mg cefazolin application intravenously 1 hour before operation
1893223|NCT01273818|Drug|Gentamicin|80 mg gentamicin application intraoperatively
1893224|NCT01273831|Drug|atracurium|atracurium, Drop,0.5 mg/kg, one time, one day
1893225|NCT01273831|Drug|cisatracurium|cisatracurium, drop,0.15mg/kg,one time, one day
1893226|NCT01273844|Drug|Bortezomib|Bortezomib
1893227|NCT01273857|Procedure|Autologous cardiac progenitor cell transplantation|Patients will receive 0.3 million / kg of autologous cardiac progenitor cells via intracoronary delivery 1 month after cardiac surgery. Follow-up visits 3 months to 1 year after cell injection will need to prospectively verify the clinical, laboratory, and safety-related data.
1893228|NCT01273857|Procedure|staged shunt procedure|Norwood-Glenn, Glenn, or Fontan procedure will be applied
1893229|NCT01273883|Dietary Supplement|Magnesium|Magnesium 532 mg a day
1893230|NCT01273883|Other|Placebo|matching form/dosage
1893313|NCT01281098|Drug|Intravitreous injection of pegaptanib|Intravitreous injection of pegaptanib
1893314|NCT01281111|Drug|Dimethyl Fumarate (BG00012)|
1893315|NCT01281111|Drug|Aspirin|
1893231|NCT01273896|Drug|STA-9090|All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.
1893232|NCT01273909|Procedure|Perforator Flap Breast Reconstruction|perforator flap breast reconstruction with or without vascularized lymph node transfer
1893233|NCT01273909|Procedure|Vascularized Lymph Node Transfer|perforator flap vascularized lymph node transfer with or without concomitant perforator flap breast reconstruction
1893234|NCT01273922|Biological|NDV-3 investigational vaccine|Two doses of vaccine 6 months apart or placebo(only one dose at Time 0) administered intramuscularly
1893235|NCT01273948|Drug|Bavituximab|"Bavituximab 3 mg/kg given by intravenous (IV) infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or
Bavituximab 0.3 mg/kg given by IV infusion once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal to 75 kg) divided into twice-daily doses, for 12 weeks or"
1893236|NCT01273948|Drug|Pegylated interferon (PEG-IFN)|Pegylated interferon (PEG-IFN) alpha-2a 180 micrograms given by subcutaneous (SC) injection once weekly, plus oral ribavirin 1000 mg (weight <75 kg) or 1200 mg (weight greater than or equal 75 kg) divided into twice-daily doses, for 12 weeks
1893237|NCT01273961|Device|AuraLevée treatment|A single treatment, on day 0, on each of no more than two treatment sites, using the AuraLevée device. Treatment sites are the face, abdomen, upper arm, thigh or neck.
1893238|NCT01273974|Biological|intradermal influenza vaccine|0.25ml ,intradermal
1893239|NCT01273974|Biological|intramuscular influenza vaccine|0.5ml,intramuscular
1893240|NCT01273987|Procedure|Neobladder posterior wall suspended with round ligament of uterus|Neobladder posterior wall suspended with round ligament of uterus after radical cystectomy in female with bladder cancer
1893241|NCT01274000|Drug|YM060|oral
1893242|NCT01274000|Drug|placebo|oral
1893244|NCT01274039|Drug|Acetazolamide for glaucoma patients to lower eye pressure|Acetazolamide tablets 3 times daily for 3 to 4 weeks
1893245|NCT01274052|Other|Meal test|Liquid meal test
1893246|NCT01274065|Genetic|Genetic analysis|The research team will review data following DNA sample analysis and identify variants in genes that result in impaired drug metabolism
1893247|NCT01274078|Biological|Blueberries|150 grams of frozen blueberries on the same day as exercise
1893248|NCT01274091|Other|PUFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: polyunsaturated fatty acid diet (PUFA) will have P/S ratio 1.0.
1893249|NCT01274091|Other|SAFA-diet|Diets will contain 30% of energy as fat, 18% as protein and 52% as carbohydrates: Saturated fatty acid diet (SAFA) will polyunsaturated/saturated (P/S) ratio of 0.3.
1893250|NCT01274104|Dietary Supplement|Vitamin D3|15,000 IU of Vitamin D3 every day for 14 days
1893251|NCT01274104|Other|Placebo|Placebo
1893253|NCT01274130|Drug|Metformin|Diavex 1000mg on Day1 and 750mg on Day2
1893254|NCT01274143|Behavioral|TeleCARE|Personalized telephone-delivered cancer risk assessment.
1893255|NCT01274143|Behavioral|Pamphlet intervention|Mailed pamphlet about familial colorectal cancer risk and screening.
1893256|NCT01274156|Device|"MEDISPEC treatment probe"|300 shocks in 5 different anatomical locations of the penis.
1893257|NCT01274156|Device|"MEDISPEC Sham Probe"|Sham probe applied same as treatment probe without energy
1893258|NCT01274156|Device|"MEDISPEC Low intensity shock waves"|Treatment parameters will be as follows: Intensity: 0.09 mj/mm2 ,300 shocks per site, on 5 penile anatomical sites. Total number of shock waves: 1500/ session Frequency of 120/min
1893259|NCT01274156|Device|Sham|Probe does not deliver energy but creates same noise and sensation of active probe
1893260|NCT01280279|Other|education for behavioral modification|a systematized 30-minutes education program for behavioral modification (SBMP) by watching videos and discussion with a specialized continence nurse practitioner.
1893261|NCT01280292|Drug|Eltroxin|Eltroxin dosage titration according to free T4 measurement every 3 months
1893262|NCT01280305|Drug|raloxifene|raloxifene 60 mg bid
1893263|NCT01280305|Drug|placebo|Placebo bid
1893264|NCT01280318|Procedure|head and neck surgery|Blood Sample of biomakers at 3 days, 5 weeks and 3 months after surgery.
1893265|NCT01280331|Drug|Q8003 (morphine sulfate and oxycodone hydrochloride)|Two Q8003 6 mg/4 mg IR Capsules q6h
1893266|NCT01280331|Drug|Morphine sulfate|Two morphine sulfate 12 mg IR capsules q6h
1893267|NCT01280331|Drug|Oxycodone HCl|Two oxycodone HCl 8 mg IR Capsules q6h
1893268|NCT01280344|Drug|Saline Solution for Injection|Intravenous (IV)
1893269|NCT01280344|Drug|Ipamorelin|Intravenous (IV)
1893270|NCT01280357|Device|Monica AN24 (K101081)|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
1893271|NCT01280357|Device|Philips 50XM|If not confident of Monica AN24 displayed data then remove Monica AN24 monitor and continue monitoring with Philips 50XM
1893272|NCT01280370|Procedure|Abdominal surgery|intraoperative mesh implantation
1893273|NCT01280383|Device|non-invasive neurally adjusted ventilatory assist|non-invasive neurally adjusted ventilatory assist in critically ill patients
1893276|NCT01280487|Drug|ZSTK474|Daily oral dosing for 21 days each cycle
1893316|NCT01281111|Drug|BG00012 matching placebo|
1990699|NCT01871545|Device|Magnetic Resonance Imaging|Magnetic Resonance Imaging is a radiation free non invasive technique using magnetic radiofrequency waves to image the body. In this study, the research team would like to investigate the possibility of providing functional information on aggressiveness, vascularity and oxygen uptake in liver cancer tumors.
1893278|NCT01280500|Other|Integrated Approach to Care|Patients within the IAC group will also receive their own copy of an asthma action plan to allow for some degree of self-management support. In addition, IAC practices receive assistance from a practice coach trained in practice redesign and rapid cycle process improvement.
1893279|NCT01280500|Other|usual care|No EMR
1893280|NCT01280500|Other|Shared Decision Making|The research team will develop the SDM intervention during the first 6 months of the study. The team will model this intervention on the randomized control trial performed by Dr. Sandra Wilson and colleagues within the Kaiser Permanente Clinics in California and Oregon
1893281|NCT01280500|Other|school based care|the research team will start an electronic data capture system linking school data and the clinical EMR (Cerner Power Chart) that will be implemented over the first year. Flow of data between schools and the hospital system will allow the children who have a regular source of care as well as those without a medical home to be treated with a unified asthma program by the school nurse and the hospital system.
1893282|NCT01280513|Dietary Supplement|High protein intake|30% of energy intake coming from proteins
1893283|NCT01280513|Dietary Supplement|Low Protein intake|9% of energy intake coming from proteins
1893284|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
1893285|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
1893286|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
1893287|NCT01280526|Drug|Romidepsin and CHOP|Romidepsin dose administered IV at day 1 and 8 or at day 1 without day 8 in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) administered every 3 weeks for 8 cycles in patients with T-cell lymphoma
1893288|NCT01280539|Device|Transcutaneous electrical nerve stimulation|3 weeks, 5 times a week, 60 minutes a day.
1893289|NCT01280552|Biological|ICT-107|Autologous dendritic cells pulsed with immunogenic antigens
1893290|NCT01280552|Biological|Placebo DC|Autologous dendritic cells (DC) that have not been pulsed with antigens
1893291|NCT01280565|Drug|masitinib|masitinib 7.5 mg/kg/day
1893292|NCT01280565|Drug|Dacarbazine|dacarbazine IV bolus at 1,000 mg/m2 once every three weeks
1893293|NCT01280578|Device|Transcatheter PFO Closure|Transcatheter PFO Closure
1893294|NCT01280591|Drug|Naproxen sodium 440 mg / DPH 50 mg (BAY98-7111)|Participants received two Naproxen sodium 220 mg / DPH (Diphenhydramine hydrochloride) 25 mg tablets orally, single dose
1893295|NCT01280591|Drug|Naproxen sodium 220 mg / DPH 50 mg (BAY98-7111)|Participants received one Naproxen sodium 220 mg / DPH 50 mg tablet and one matching placebo capsule orally, single dose
1893296|NCT01280591|Drug|Naproxen sodium 440 mg (BAYH6689)|Participants received two Naproxen sodium 220 mg tablets orally, single dose
1893297|NCT01280591|Drug|DPH 50 mg|Participants received two DPH (Diphenhydramine hydrochloride) 25mg tablets orally, single dose
1893298|NCT01280604|Drug|Fenofibrate 54mg|Subjects will receive fenofibrate 54mg daily.
1893301|NCT01280955|Drug|Plerixafor|Matched sibling or Dual Cord donor subjects will receive plerixafor at 240 ug/kg subcutaneously every other day beginning at day +2 after transplant until day +21 or engraftment occurs.
1893302|NCT01280968|Biological|NIC002 in Aluminum hydroxide (Alum)|Fifty-five subjects will receive 4 subcutaneous injections of 0.1 mg Nicotine-QB (NIC002) in Alum vaccine with a 4-week interval between injections.
1893303|NCT01280968|Biological|Placebo Vaccine - Aluminum hydroxide|Ten subjects will receive 4 subcutaneous injections of indistinguishable placebo (Alum alone) with a 4-week interval between injections.
1893304|NCT01280981|Drug|Tranexamic acid|Tranexamic acid at an oral dose of 1.3 g administered 3 times per day for up to 5 days (maximum of 15 doses) during menstruation for 9 menstrual periods.
1893305|NCT01280994|Drug|Xenon|"Each subject will receive up to but not exceeding 5 doses of hyperpolarized 129Xenon gas during any given imaging session. One of these doses is used for calibrating the MRI scanner and will contain 200 ml Xe, and 800ml N2. Xenon Doses used for image acquisition will contain up to 100% xenon at a volume up to 1 liter. Subjects will receive no more than 4 doses consisting of 100% xenon at 1 liter.
Xenon will be administered with at least a 10 minute interval between doses to ensure that there is no imaging or health effect from residual xenon"
1893306|NCT01281007|Drug|Famciclovir|Famciclovir 125 mg every 12 hours for 5 days
1893307|NCT01281007|Drug|Aciclovir|Aciclovir 200 mg every 4 hours fo 5 days
1893308|NCT01281033|Procedure|Manual Thrombectomy|In patients in the thrombus-aspiration group, this step is followed by the advancing of the 6-French Export Aspiration Catheter (Medtronic; crossing profile, 0.068 in.) into the target coronary segment during continuous aspiration.
1893309|NCT01281033|Procedure|AngioJet Rheolytic Thrombectomy (RT) System|The AngioJet Rheolytic Thrombectomy (RT) System consists of a drive unit console, disposable pump set, and disposable catheter. Thrombectomy is accomplished by the introduction of a pressurized high velocity saline stream through directed orifices in the catheter distal tip so that thrombus is entrained (Bernoulli effect), dissociated into small particles, and evacuated from the body through the catheter and associated tubing. The pump set consists of a high pressure pulsatile pump which is used to generate the flow necessary for the dissociation and evacuation of thrombus, an effluent bag for the collection and storage of thrombus debris, and associated tubing.
1893310|NCT01281059|Device|BreathID - Breath Test - 13C Octanoate|
1893311|NCT01281072|Other|vaccine|
1893312|NCT01281098|Procedure|Panretinal Photocoagulation (PRP)|Panretinal Photocoagulation (PRP)
1893321|NCT01281137|Genetic|polymorphism analysis|SNPs will be genotyped in whole blood samples taken at baseline.
1893322|NCT01281137|Other|laboratory biomarker analysis|Biomarkers will be assessed in blood and serum samples at different time points.
1893323|NCT01281137|Procedure|quality-of-life assessment|Quality of life will be assessed using the Breast Cancer Prevention Trial (BCPT) Symptom Scales and the IBCSG Trial 35-07 QL Form.
1893324|NCT01281150|Drug|Carboplatin|Given IV
1893325|NCT01281150|Other|Laboratory Biomarker Analysis|Correlative studies
1893326|NCT01281150|Drug|Paclitaxel|Given IV
1893327|NCT01281150|Other|Pharmacological Study|Correlative studies
1893328|NCT01281150|Drug|Veliparib|Given PO
1893329|NCT01281163|Drug|Akt Inhibitor MK2206|Given PO
1893330|NCT01281163|Other|Laboratory Biomarker Analysis|Correlative studies
1893331|NCT01281163|Drug|Lapatinib Ditosylate|Given PO
1893332|NCT01281163|Other|Pharmacogenomic Study|Correlative studies
1893333|NCT01281163|Other|Pharmacological Study|Correlative studies
1893334|NCT01281176|Drug|Carboplatin|Given IV
1893335|NCT01281176|Other|Laboratory Biomarker Analysis|Correlative studies
1893336|NCT01281176|Drug|Paclitaxel|Given IV
1893337|NCT01281176|Other|Pharmacological Study|Correlative studies
1893338|NCT01281176|Drug|Vorinostat|Given PO
1893339|NCT01281189|Drug|Dexpramipexole|Oral tablet 150mg twice daily for up to 18 months.
1893340|NCT01281189|Drug|Placebo|Oral tablet twice daily for up to 18 months.
1893341|NCT01281202|Drug|Vigabatrin|Tablets
1893342|NCT01281202|Drug|Matching Placebo|Tablets
1893343|NCT01281215|Behavioral|Education interventional|The patients will receive pharmaceutical education to know more about asthma, the importance of treatment compliance, the medications used to control the pathology, corrected patients' inhalation techniques and the medication care.
1893344|NCT01281228|Drug|exenatide|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests.
1893345|NCT01281228|Drug|exenatide + exendin (9-39)|The loading dose is 50 ng/min during 30 min, followed by a maintenance dose 20 ng/min for the rest of the tests. Exendin 9-39 will be infused intravenously at doses of 600 pM/kg • min.
1893346|NCT01281228|Drug|placebo|saline infusion
1893347|NCT01281254|Drug|AMG386 plus PLD|AMG 386 is a first in class investigational anti angiogenic drug that provides potent and selective inhibition of angiopoietins. AMG 386 is designed to inhibit angiogenesis by sequestering Ang1 and Ang2, thereby preventing their interaction with the Tie2 receptor. Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug. PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 15 mg/kg IV weekly (QW)
1893348|NCT01281254|Drug|Placebo plus PLD|"Pegylated Liposomal Doxorubicin (Doxil/Caelyx) is a preparation of doxorubicin in a liposome that contains surface-grafted segments of the hydrophilic polymer methoxypolyethylene glycol associated with prolonged pharmacokinetics of the free drug.
PLD 50 mg/m2 IV every 4 weeks (Q4W) and blinded AMG 386 placebo IV weekly (QW)"
1893349|NCT01281267|Procedure|Facial Allograft Transplantation|Facial allograft transplantation surgery is the transfer of face tissue from a deceased human donor to a patient with a severe facial deformity.
1893350|NCT01281306|Drug|LCZ696|LCZ696 was supplied as tablets in blister cards in 100 mg strengths.
1893351|NCT01281306|Drug|Valsartan|Valsartan was supplied as tablets in blister cards in 160 mg and 320 mg strengths.
1893352|NCT01281306|Drug|AHU377|AHU377 was supplied in tablets in blister cards in 50 mg and 100 mg strengths.
1893353|NCT01281306|Drug|Placebo|Placebo was supplied as tablets in blister cards.
1893354|NCT01281332|Device|Menopod|The mechanism of action of the device will not be revealed in advance.
1893355|NCT01281332|Device|Inactive device|
1893356|NCT01281358|Other|HOP-ON|A programme of activities which promote motor development
1893357|NCT01281358|Other|SMILES|Details are provided on ways for parents to interact with their premature infants
1893358|NCT01281384|Other|Advanced Imaging|
1893359|NCT01281384|Other|Standard Imaging|
1893360|NCT01281410|Procedure|Inspiratory Muscle Training|Inspiratory Muscle Training with Respifit (5 times per week)
1893361|NCT01281410|Other|inspiratory muscle training|Inspiratory muscle training with a device named Respifit for patients receiving a hematopoetic stem cell transplantation (till 30 days after their transplantation)
1893362|NCT01281436|Other|HeartSmartKids & Web-based Provider Training|The providers assigned to Group 2 will receive the web-based training described in the web-based training arm, plus the HeartSmartKids™ (HSK) system. HSK is a bilingual, HIT kiosk system with clinical decision support and tailored patient education.
1893363|NCT01281436|Other|Web-based Provider Training|The training will include information about implementing the recommendations of the AMA, the pediatric metabolic working group, and the HEATSM guidelines into their practice setting through the use of the chronic care model for childhood obesity. Training will include self-management support, decision support, delivery-system redesign, clinical information systems, practice self-assessment, and staff development on obtaining, assessing, documenting BMI and BP; counseling families on appropriate interventions; and quality improvement processes to evaluate the practice's performance strategies.
1893364|NCT01281462|Drug|Ceftaroline fosamil and NXL104 (q8h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 8 hours (q8h);
1893365|NCT01281462|Drug|Ceftaroline fosamil and NXL104 (q12h)|600 mg ceftaroline fosamil/600 mg NXL104 IV coadministered every 12 hours (q12h);
1893366|NCT01281462|Drug|Doripenem|500 mg doripenem IV q8h;
1893367|NCT01281462|Drug|Placebo|On CXL-MD-02, there were (3) treatment arms (meaning a subject could be randomized to 1 of 3 possible treatment regimens). Each treatment arm contained 1 or 2 placebo doses of IV saline in order to preserve the blind.
1893368|NCT01281475|Drug|Levodopa|"Levodopa/Carbidopa (4:1)
Dosages are based on levodopa.
Subjects randomized to the levodopa arm will receive a levodopa dose of 5 mg/kg/day in the first 2 weeks of the study, a levodopa dose of 10 mg/kg/day in the second 2 weeks of the study, and a levodopa dose of 15 mg/kg/day (up to a maximum of 800 mg per day) for the remaining duration of the study.
Levodopa/Carbidopa is a combined formulation that will be dispensed as capsules. It should be taken 3 times a day."
1893369|NCT01281475|Drug|Placebo Oral Capsule|The placebo contains excipients similar to those in the active drug, but it does not contain levodopa or carbidopa.
1893373|NCT01281501|Drug|Normal saline|10 ml of 0.9% sodium chloride solution
1893374|NCT01281501|Drug|Pantoprazole|80 mg of intravenous pantoprazole
1893375|NCT01281501|Drug|Oral antacid|30 ml of oral antacid (1.32 grams of aluminum hydroxide, 0.72 grams of magnesium hydroxide)
1893376|NCT01281501|Drug|Hyoscine butylbromide|20 mg of intravenous hyoscine butylbromide
1893377|NCT01281514|Drug|everolimus|Given PO
1893378|NCT01281514|Drug|carboplatin|Given IV
1893379|NCT01281514|Drug|pegylated liposomal doxorubicin hydrochloride|Given IV
1893380|NCT01281514|Other|laboratory biomarker analysis|Correlative studies
1893381|NCT01281527|Drug|Paliperidone Palmitate|50 - 150 mg eq. every 30 days
1893382|NCT01281540|Drug|Cisapride|one 10 mg tablet 4 times a day for 8 weeks
1893383|NCT01281540|Drug|Placebo|one placebo tablet 4 times a day for 8 weeks
1893384|NCT01281553|Drug|Placebo|Suspension identical in appearance to cisapride q.i.d. for 8 weeks.
1893385|NCT01281553|Drug|Cisapride|0.2 mg/kg suspension q.i.d.for 8 weeks.
1893386|NCT01281566|Drug|Placebo|liquid suspension identical in appearance to Cisapride 4 times a day (q.i.d.) for up to 42 days
1893387|NCT01281566|Drug|Cisapride|0.2 mg/kg liquid suspension 4 times a day (q.i.d.) for up to 42 days
1893388|NCT01281579|Drug|Canagliflozin 100 mg|Tablets, oral, 100-mg, once daily on Day 1 and on Days 4 through 9.
1893389|NCT01281579|Drug|Canagliflozin 50 mg|Tablets, oral, 50-mg, once daily on Day 1 and on Days 4 through 9.
1893390|NCT01281579|Drug|Canagliflozin 300 mg|Tablets, oral, 300-mg, once daily on Day 1 and on Days 4 through 9.
1893391|NCT01281592|Drug|LOR-253 HCl|LOR-253 HCl will be given in ascending doses starting from 20 mg/m2 until the maximum administered dose or appropriate target dose is reached. Patient will be treated on LOR-253 HCl for 2 cycles for the evaluation.
1893392|NCT01281605|Behavioral|Active titration algorithm|Patients in active titration algorithm group will contact with investigator by telephone weekly to self-adjust the insulin dose till they achieve the target of FPG(<110mg/dl).
1893393|NCT01281605|Behavioral|Usual titration algorithm|All patients will be instructed to self-measure fasting capillary blood glucose. The dose of insulin detemir will be adjusted based on the average of three consecutive FPG values. the daily insulin dose should be increased by 2 IU/day if the FPG>=110mg/dL, and by 4 IU/day if the FPG>=180 mg/dL without any intervening hypoglycemic episodes; or it should be decreased by 2 or 4 IU/day if the FPG < 70 mg/dL.
1893394|NCT01281618|Procedure|24 hour pH study and upper endoscopy (EGD)|All subjects enrolled will undergo 24 hour pH followed by EGD.
1893395|NCT01281631|Drug|NP001|Low dose of NP001
1893396|NCT01281631|Drug|NP001|High dose of NP001
1893397|NCT01281631|Drug|Placebo|normal saline
1893398|NCT01281644|Device|Diode Laser|810 nm diode laser
1893399|NCT01281657|Drug|fingolimod|
1893400|NCT01281670|Other|vibration|8 week vibration
1893401|NCT01281696|Drug|Bevacizumab, etoposide, cisplatin|Bevacizumab (15mg/kg) on D1, etoposide (70mg/m2) on D2-D4, cisplatin (70mg/m2) on D2; 21 days a cycle, for a maximum of 6 cycles
1893402|NCT01281696|Drug|Intrathecal methotrexate|Additional intrathecal methotrexate only given in patients with leptomeningeal metastasis
1893403|NCT01281748|Drug|intravenous methylprednisolone|methylprednisolone 0,5 mg/kg every 6 hours for 72 hours, 0,5 mg/kg every 12 hours on days 4 through 6, 0,5 mg/kg daily for day 7 through day 10
1893404|NCT01281748|Other|intravenous normal saline solution|50 ml of intravenous normal saline solution every 6 hours for 72 hours, 50 ml every 12 hours on days through 6, 50 ml daily for day 7 through day 10.
1893405|NCT01281761|Drug|cetuximab/irinotecan/simvastatin|D1 Cetuximab 500mg/m2 IV stepwise shortened infusion duration- [C1D1 over 120min, C2D1 over 90min,subsequent dose over 60min] D1 Irinotecan 150-180mg/m2 + Dextrose 5% 500ml IV [over 90min] D1-14 Simvastatin 80mg P.O(continuous, daily) every 2weeks
1893406|NCT01281774|Biological|CSL112|reconstituted high density lipoprotein
1893407|NCT01281774|Biological|Placebo|Normal saline (0.9%)
1893408|NCT01281787|Drug|Metoprolol|Metoprolol; 100 mg x 2 die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
1893409|NCT01281787|Drug|Losartan|Losartan; 50 mg die (tablets); started within 12 hours after surgery and continued for the duration of hospital stay
1893410|NCT01281800|Procedure|Gemcitabine in long infusion|"TREATMENT A:
Day 1: Pemetrexed 500 mg/m2 Cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: folic acid [Tifol 400 mg tbl (350-1000 mg), beginning 7 days before CT, every day, till 3 week after the KT], vitamin B-12 [OH-B12 i.m., beginning in 7 days before CT, than at 3. + 6. cycles of KT + 9. week after the KT], corticosteroids, hydration, antiemetic, LMW heparin as thromboprophylaxis.
In the absence of progression, 4 cycles of chemotherapy with pemetrexed and cisplatin will be given, followed by two additional cycles of pemetrexed as monotherapy.
TREATMENT B:
Days 1 and 8: gemcitabine 250 mg/m2 in 6 hours day 2: cisplatin 75 mg/m2 Cycle every 3 weeks. Supportive treatment: corticosteroids, hydration, antiemetics, LMW heparin as thromboprophylaxis.
In the absence of progression, 4 cycles of chemotherapy with gemcitabine and cisplatin will be given, followed by two additional cycles of gemcitabine alone as monotherapy."
1893411|NCT01281813|Drug|Darunavir|600 mg tablet, intake of 1 tablet twice a day in combination with ritonavir
1893412|NCT01281813|Drug|Ritonavir|100 mg capsule, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
1893413|NCT01281813|Drug|Darunavir|400 mg tablet, intake of 2 tablets once daily in combination with ritonavir
1893414|NCT01281813|Drug|Ritonavir|100 mg tablet, to be taken once or twice daily in combination with Darunavir and following the Darunavir dosing schedule
1893415|NCT01281813|Drug|Darunavir|375 mg tablet (made up of 2 x 150mg +1 x 75mg tablets), intake of 3 tablets twice a day in combination with Ritonavir
1893416|NCT01281813|Drug|Darunavir|Darunavir oral suspension (dose dependant on weight) in combination with Ritonavir
1893417|NCT01281813|Drug|Ritonavir|Ritonavir oral solution as 80 mg/mL (dose dependant on weight) in combination with Darunavir twice daily
1893418|NCT01281813|Drug|Ritonavir|Ritonavir powder for oral suspension prepared as 100 mg/10 mL (dose dependant on weight) in combination with Darunavir
1893419|NCT01281839|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
1893420|NCT01281839|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
1893421|NCT01281839|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
1893422|NCT01281839|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
1893423|NCT01281852|Drug|Cisplatin|Given IV
1893424|NCT01281852|Other|Laboratory Biomarker Analysis|Correlative studies
1893425|NCT01281852|Drug|Paclitaxel|Given IV
1893426|NCT01281852|Drug|Veliparib|Given PO
1893427|NCT01281865|Other|diagnostic laboratory biomarker analysis|Correlative studies
1893428|NCT01281865|Drug|everolimus|Given PO
1893429|NCT01281865|Drug|imatinib mesylate|Given PO
1893430|NCT01281878|Drug|Vitamin B 6|Oral solution of pyridoxal phosphate start with 5mg per kg body weight per day in two dosages over 6 weeks, increase stepwise by 5mg/kg body weight every 6 weeks up to 20 mg/kg body weight/d.
1893431|NCT01281891|Drug|LIA|Ropivacaine 0.2% Ketorolac 30 mg Adrenaline 0.1 mg/ml
1893432|NCT01281891|Drug|I/T morphine|Morphine special 0.1 mg injected intrathecally
1893433|NCT01281904|Behavioral|Relaxation Acupressure|Apply pressure on 9 relaxatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
1893434|NCT01281904|Behavioral|Stimulating Acupressure|Apply pressure on 10 excitatory acupressure points for 3 minutes each once daily for a 6 week period, followed by a 4 week wash-out period.
1893435|NCT01281917|Drug|Velcade|Velcade, 1.6 mg/m2 weekly (days 1, 8, 15, and 22)
1893436|NCT01281917|Drug|Temsirolimus|Temsirolimus 25mg IV weekly (days 1, 8, 15, 22, and 29)
1893437|NCT01281930|Procedure|Full packing into abscess cavity|After incision and drainage plain 1/4-1/2 inch gauze packing material is placed into the cavity to fill it
1893438|NCT01281930|Procedure|Wick placement into abscess cavity|After incision and drainage of the abscess a piece of plain gauze 1/4-1 inch packing material that is as wide as can be easily passed through the opening is placed into the cavity spanning one diameter of the cavity
1893439|NCT01281943|Drug|Temsirolimus 25mg and Pegylated liposomal doxorubicin 25mg/m2|"Temsirolimus 25mg IV on days 1, 8, 15 and 22 of each 28 day cycle
Pegylated liposomal doxorubicin 25mg/m2 IV on day 1 of each 28 day cycle"
1893443|NCT01282034|Procedure|Marrow stimulation - Drilling or Microfractures|"Subchondral drilling consists in penetration of the subchondral bone endplate and creation of holes, and it is mostly indicated for the treatment of osteochodral lesion.
Microfractures (MF), according to Steadman's technique, are one of the most used first-line treatment for cartilage injuries, and commonly considered safe and effective."
1893444|NCT01282034|Device|MaioRegen Surgery|MaioRegen® (is a bioceramic, multi-layered scaffold, in a single gradient structure, consisting of deantigenated Type I equine collagen and Magnesium enriched-Hydroxyapatite, able to mime the entire osteocartilaginous section. MaioRegen® is able to promote the tissue regeneration in case of severe and large chondral/osteochondral lesions.
1893445|NCT01282047|Drug|Lenalidomide|oral course, 25 mg, day 1 to 21, per month, 7 days of wash-out each month. Duration according to initial response: 24 weeks and 12 weeks more if complete remission, 24 weeks more if partial remission or stable disease and stop in case of progression.
1893446|NCT01282073|Drug|Mycophenolate mofetil, low dose steroid|"Mycophenolate Mofetil: Myconol capsule 250mg, Myconol 500 mg bid per day (less than 50kg), 750 ~ 1000 mg bid per day (more than 50kg)
Steroid: Methylprednisone 4mg tablet or Prednisolone 5mg tablet or Deflazacort 6mg tablet. Prednisolone dose: 0.15mg/kg up to a maximum dose of 15mg/day
Duration: 48 weeks"
1893447|NCT01282073|Drug|Cyclosporin, low dose steroid|"Cyclosporin: Implanta soft cap (cyclosporin microemulsion) 25mg/100mg, starting dose of 4mg/kg per day and titrate according to investigator's decision based on cyclosporin trough level (100±50 ng/ml)
Steroid: same dosage with active comparator goup
Duration: 48 weeks"
1893448|NCT01282138|Drug|Olopatadine hydrochloride, 0.1% ophthalmic solution (Patanol)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
1893449|NCT01282138|Other|Dextran 70 0.1%, hydroxypropyl methylcellulose 0.3% (Tears Naturale II)|One drop twice daily in each eye for 5 days, followed by an additional drop in each eye prior to allergen test.
1893452|NCT01282164|Procedure|Glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), cerebrovascular disease (CVD), seizure
1893453|NCT01282164|Procedure|glucagon stimulation test and insulin tolerance test|glucagon stimulation test using 1 mg (1.5 mg if weigh >90 kg) glucagon stimulation test using 0.03 mg/kg (maximum dose 3 mg) insulin tolerance test using 0.10-0.15 U/kg ACTH stimulation test in subjects with type 2 diabetes mellitus (T2DM), coronary artery disease (CAD), CVD (cerebrovascular disease), seizure
1893454|NCT01282190|Behavioral|Motivational interview|Motivational interview
1893455|NCT01282216|Biological|Hepatitis A|1440 ELISA units, or 1 mL, IM
1893456|NCT01282216|Biological|PCV 13|0.5 mL IM
1893457|NCT01282229|Device|LANAP|Laser Assisted New Attachment Procedure (LANAP protocol) using the FR Pulsed Nd:YAG laser
1893458|NCT01282242|Drug|IV rt-PA|open-label
1893459|NCT01282255|Drug|NNC109-0012|The subjects will receive 12 weekly doses of 3 mg/kg of NNC109-0012 administered subcutaneously (under the skin)
1893460|NCT01282255|Drug|placebo|The subjects will receive 12 weekly doses of 3 mg/kg of Placebo administered subcutaneously (under the skin)
1893461|NCT01282268|Drug|arbaclofen|orally disintegrating tablet
1893462|NCT01282268|Drug|placebo|orally disintegrating tablet
1893463|NCT01282294|Device|ETN PROtect|Expert Tibial Nail PROtect with Gentamicin coating
1893464|NCT01282307|Behavioral|Guided Self-Determination GSD|The method GSD consists of 21 worksheets designed to guide patient and mental health professionals through autonomy-supportive problem solving. The worksheets are filled in by the patient before and between conversations with their community nurse over 10 sessions, approximately 1 hour a session.
1893465|NCT01282320|Behavioral|Physical activity intervention program|Individually tailored exercise programme (combination of pilates and aerobe training) with one hour activity sessions two-three times per week in 16 weeks.
1893466|NCT01282333|Drug|gemcitabine hydrochloride|Given IV
1893467|NCT01282333|Drug|veliparib|Given orally
1893468|NCT01282333|Other|diagnostic laboratory biomarker analysis|Correlative studies
1893469|NCT01282333|Other|pharmacological study|Correlative studies
1893470|NCT01282333|Drug|cisplatin|Given IV
1893471|NCT01282346|Device|SOLX Gold Shunt|Single use implant
1893472|NCT01282359|Other|Clinical practice group|Clinical practice group will not receive any specific education
1893473|NCT01282359|Other|"Gold Standard educational group"|"Gold Standard educational group will receive a formal program of structured and individualized education"
1893474|NCT01282359|Other|Intervention group|Intervention group will take the limited educational asthma program which have three parts: basic information, establishment and revision of a small Action Plan (MiniPlan) and training and review of the inhalation skill of the prescribed device. Educators involved will attend a short workshop (6 h), where they will be trained in the program.
1893475|NCT01282385|Drug|Simvastatin|simvastatin 20 mg capsules, starting at doses of 20 mg / 24 hours, may increase to 40 mg according to clinical and laboratory tolerance
1893476|NCT01282385|Drug|placebo|placebo capsules with external characteristics similar to simvastatin administrated each 24 hours.
1893477|NCT01282398|Drug|Simvastatin|The experimental group will take 40 mg each 24 hours for at least two years.
1893478|NCT01282398|Drug|placebo|the control group wiil take placebo pills for at least two years.
1893479|NCT01282424|Drug|Idelalisib|Idelalisib 150 mg tablet administered orally twice daily
1893480|NCT01282437|Radiation|Prophylactic Cranial Irradiation|"18 fractions of 2Gy
12 fractions of 2.5Gy
10 fractions of 3 Gy"
1893481|NCT01282450|Radiation|Radiotherapy|Radiotherapy
1893482|NCT01282463|Drug|Docetaxel|Docetaxel: 75 mg/m2 on Day 1 of each 21-day cycle
1893483|NCT01282463|Biological|Ramucirumab DP|Ramucirumab (DP): 10 mg/kg I.V. on day 1 of each 21-day cycle
1893484|NCT01282463|Biological|IMC-18F1|12 mg/kg I.V. on day 1 and Day 8 of each 21-day cycle
1893485|NCT01282476|Drug|Panobinostat with Rituximab|Panobinostat 40 mg orally 3 x weekly Rituximab 375 mg/m^2 IV days 1,8,15,and 22 of cycle 1, and then on day 1 of subsequent cycles.
1893486|NCT01282502|Drug|Midostaurin|50 mg BID for 8 cycles
1893487|NCT01282515|Drug|clobetasolpropionate|continuously treatment
1893488|NCT01282515|Drug|hexaminolevulinate|one PDT treatment
1893489|NCT01282528|Biological|infliximab|3mg/kg, at week 0, 2, 6, 14, 22
1893490|NCT01282541|Drug|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transconjunctivally into the palpebral lobe of the lacrimal gland once
1893491|NCT01282541|Drug|Botulinum Toxin Type A|100 units/2ml 0.9% sodium chloride, 5 units delivered transcutaneously into the orbital lobe of the lacrimal gland once
1893492|NCT01282554|Device|electrostimulation program (Rehab 400)|"electrostimulation program (Rehab 400) : electrostimulation program during dialysis sessions for 3 months.
Electrostimulation modalities have been chosen to seek both slow and fast muscle fibers : 35 Hz ; impulsion time: 400 µsec ; on/ off : 7'' contraction / 8'' relaxation. Stimulated muscles are quadriceps. Electrostimulation time will be 30 minutes. Each patient will individually regulate work intensity, maximal intensity should be the maximal tolerable intensity.
Electrostimulation will be done 3 times per week. In case of asthenia or medical condition, electrostimulation can be delayed. The program will take place for 3 months."
1893493|NCT01282567|Other|Blood samples|The study will be proposed to four patients hospitalized in the Diabetes Unit for a glucidic fast test carried out during 24 hours (lunch, dinner and breakfast). Blood samples will be taken every 20 minutes during 6 hours and 40 minutes to measure plasma insulin concentration and blood glucose. T0 will correspond to the first modification of the insulin basal flow (in more or less) or to the first insulin bolus corrector, usually administered if capillary blood glucose reaches 1.8 g/l. The capillary blood glucose monitoring will be performed every two hours by the nurse.
1893494|NCT01282580|Dietary Supplement|Lovaza-Omega 3 fatty acid capsules|The study will require monthly visits at 0, 1, 2 and 3 months of study intervention. At each visit a fasting serum sample will be obtained, self-report diaries (adverse events, record of omega 3 supplement doses or fish servings taken/missed) will be collected, and pill count / labels from cans of fish will be recorded. Medications and supplements will be reviewed with participants at each monthly visit. At clinic visits at 0 and 3 months, a history and physical examination and breast adipose fine needle aspiration (FNA)will be performed.Omega 3 supplements will be dispensed in monthly amounts.
1893495|NCT01282580|Other|Dietary fish (canned salmon, albacore)|Participants randomized to dietary fish will be asked to incorporate fish in the form of canned albacore and salmon into their diets at four 6 oz servings per week for 3 months. Participants on the dietary fish arm of the study will receive recipes using canned salmon and/or albacore. Sufficient canned salmon/albacore will be available for subjects who wish to prepare a meal for the family/household. Dietary intake will be assessed via 3 day diet records (0 and 3 months) and food frequency questionnaires (0 and 3 months). Verbal and written instructions on how to keep diet records, with food measured or weighed, will be given.
1893524|NCT01282840|Drug|Tolterodine SR|Tolterodine SR 4 mg qd
1893525|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
1893526|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
1893527|NCT01282853|Procedure|endoscopic biopsy|endoscopic biopsy for rapid urease test
1893528|NCT01282866|Device|LightSheer Duet|LightSheer Duet HS handpiece
1893496|NCT01282593|Other|Impact of CD9 expression level on motility assays|"1) Assess of the impact of CD9 expression level on motility assays (migration and adhesion) We have initiated motility assays (fibronectin adhesion experiments and CXCL12 chemoattracted migration tests with modified Boyden chamber technique) using the CD9 positive TEL/AML1-positive cell line REH and the CD9 negative cell line RAJI (wild or transfected with CD9 cDNA). Data will be analyzed in combination with blocking antibodies and chemical antagonist according to the level of CD9 (transcript and protein) and of CXCR4. Protein quantifications will be performed by flow cytometry and Western Blot. Interactions will be explored by confocal microscopy and biological pathways by immunoblot.
Adhesion results will be validated on patient samples of B-ALL."
1893497|NCT01282593|Other|Post-transcriptional regulation of CD9|"2) Post-transcriptional regulation of CD9 in TEL/AML1-positive ALL To identify miRNAs that are potentially deregulated in TEL/AML1-positive acute lymphoblastic leukaemia and especially to screen for CD9 -targeted miRNAs, we will use a TaqMan ®MicroRNA Arrays approach allowing the simultaneous measurement of about 760 human miRNA.
Small RNA will be extracted from bone marrow samples of twenty childhood B-ALL to screen miRNAs which are differentially expressed between CD9-positive and CD9-negative ALL and further compared with miRNAs which were predicted to target CD9 in databases. Validation of the selection will be performed by single Q-PCR for selected miRNAs using a novel cohort of ten bone marrow samples."
1893498|NCT01282606|Drug|SI-6603|SI-6603 is administrated into the nucleus pulposus of an intervertebral disc.
1893499|NCT01282619|Drug|Huperzine A|Sustained-Release Tablet, 400µg once a day, 24 weeks
1893500|NCT01282619|Drug|huperzine A|Tablet, 200µg twice a day, 24 weeks
1893501|NCT01282619|Drug|Placebo|placebo orally twice a day
1893502|NCT01282632|Drug|Risperidone|Risperidone will commence at 0.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit of increasing the risperidone dose to a maximum of 3 mg/day based on subject response and tolerability (please see Titration Recommendations below).
1893503|NCT01282632|Drug|Olanzapine|Olanzapine will commence at 2.5 mg per day in a single daily dose given once in the evening. Clinicians will have the option, at each visit, of increasing the olanzapine dose to a maximum of 15 mg/day based on subject response and tolerability.
1893504|NCT01282645|Device|PSI in PEEK|A Patient Specific Implant made of Polyether Ether Ketone to repair a cranial defect
1893505|NCT01282671|Other|Breathing exercises|On the fourth postoperative day the patients are randomly assigned to a Treatment group continuing to perform deep breathing exercises for 2 months postoperatively and to a Control group who will perform no breathing exercises after the third postoperative day. Patient management is otherwise similar in the groups. The patients in the Deep breathing group will be instructed to perform breathing exercises (3 x 10 deep breaths) 5 times a day (document compliance) during the two postoperative months. A Positive expiratory pressure (PEP) device PEP ventil, System 22 (Rium Medical, Täby, Sweden) is used to create an expiratory resistance of +10 cm H2O.
1893506|NCT01282684|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in dosage strengths of 25 mg and 100 mg with matching placebo
1893507|NCT01282684|Drug|Placebo|Matching placebo for PLX5622.
1893508|NCT01282697|Drug|Combined administration of irinotecan and rapamycin|This phase I trial is a dose escalation study of irinotecan + rapamycin with a 3+3 statistical design.
1893509|NCT01282736|Behavioral|Integrative Response Therapy|A 10 session manualized version of IRT is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead IRT after undergoing IRT training with the PI.
1893510|NCT01282736|Behavioral|Cognitive Behavioral Therapy|A 10 session manualized version of CBT-GSH is employed . Each of the 10 group therapy sessions will be 60 minutes in length. Non-specialty trained Masters-level therapists will lead CBT-GSH after undergoing CBT-GSH training with the PI.
1893511|NCT01282749|Behavioral|SisterTalk Hartford|12-week group support and film-based healthy lifestyle education program, including information on healthy nutrition and food preparation, increasing activity and exercise, healthy lifestyle behavior modification, and supportive spiritual materials.
1893512|NCT01282749|Behavioral|Attention control video series|Participants received general film series on healthy lifestyles while waiting to participate in the experimental arm.
1893513|NCT01282762|Biological|HEPLISAV|"0.5 mL administered intramuscularly (IM) at Week 0, Week 4 and Week 24.
HEPLISAV booster injection = one dose of 0.5 mL volume when needed."
1893514|NCT01282762|Biological|Engerix-B|"2.0 mL administered intramuscularly (IM) at Week 0, Week 4, Week 8 and Week 24.
Engerix-B booster injection = one dose of 2.0 mL volume when needed"
1893515|NCT01282775|Behavioral|WEB + Environment|Participants receive weekly lessons via the Web along with additional tools for weight loss support
1893516|NCT01282775|Behavioral|WEB + Cash Incentive for Weight Loss|Participants are paid cash based on the percent weight lost at 3, 6, and 12 months.
1893517|NCT01282788|Dietary Supplement|Caterpillar Cereal|Infants will receive once-daily servings of caterpillar cereal (30 g from 6-12 months of ages and 45 g from 12-18 months of ages). Study food will be delivered to homes weekly by Community Coordinators, who will also observe feedings of the cereal during the home visit. Feedings will be observed 3x/week for the first 3 weeks after enrollment, then 1x/week until 18 months of age. Parents and other care providers will receive specific instructions about cereal preparation and general education about feeding practices, food preparation and hygiene. This information will be reinforced during weekly visits.
1893518|NCT01282801|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
1893519|NCT01282801|Drug|Effexor® XR|150 mg Extended-Release Capsule
1893520|NCT01282814|Drug|Venlafaxine Hydrochloride|150 mg Extended-Release Capsule
1893521|NCT01282814|Drug|Effexor® XR|150 mg Extended-Release Capsule
1893522|NCT01282827|Device|rtACS (verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) was applied with a multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
1893523|NCT01282827|Device|placebo stimulation|a clicking sound was presented and the same electrodes montage set-up was used during rtACS and placebo stimulation, except that placebo patients received no current (stimulator turned off).
1893529|NCT01282879|Drug|Itraconazole|200mg bid, oral solution, until a dose of prednisone was tapered to 10mg/day in case of prednisone alone therapy group, or until prednisone was stopped in case of CNIs plus prednisone, CNIs plus prednisone plus mycophenolate mofetil, or mycophenolate mofetil plus prednisone group, etc.
1893530|NCT01282892|Procedure|excess of visceral fat|excess of visceral fat
1893531|NCT01282892|Procedure|patients with NAFLD|patients with NAFLD
1893532|NCT01282918|Device|ICD implantation w/o DF test|ICD implantation without Defibrillation Test
1893533|NCT01282918|Device|ICD implantation with DF test|ICD implantation with DF test according to standardized procedure
1893534|NCT01282944|Behavioral|Financial Incentive|Lottery with an approximate 3 in 10 odds of earning $50 and an approximate 3 in 100 odds of earning $200.
1893535|NCT01282944|Behavioral|Peer Network|Subjects will be connected with 4 other participants in the same study arm to form a peer network of 5 individuals.
1893536|NCT01282957|Behavioral|Financial Incentive Group I|Lottery with 1 in 100 odds of $100 and 18 in 100 odds of $10. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
1893537|NCT01282957|Behavioral|Financial Incentive Group II|Lottery with 1 in 100 odds of $50 and 18 in 100 odds of $5. The intervention involves the daily lottery itself along with feedback via email or text messaging to participants about the lottery results and whether or not they were included based on device adherence.
1893538|NCT01282970|Drug|BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
1893539|NCT01282970|Drug|Placebo to BI 135585|oral doses given to approximately 5-6 parallel groups of 12 subjects (9 on active and 3 on placebo) over 14 days
1893540|NCT01282983|Dietary Supplement|Fiber|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) with 4grams of fiber in each pack.
1893541|NCT01282983|Dietary Supplement|Placebo|The study consists of 21 days consumption of Orange juice. The volunteers will be instructed to consume 200ml of juice twice a day (1 pack of 200ml at lunch and one at dinner) without fiber.
1893542|NCT01282996|Other|Abdominal surgery|to compare the influence of a lung protective ventilation with conventional ventilation on postoperative complications following major abdominal surgery
1893543|NCT01283009|Drug|Methylprednisolone|Methylprednisolone will be given in a double-blind fashion for 20 full days. The treatment course includes a bolus dose on the day of randomization, 7 days of full dose (40 mg/day), 7 days of half dose (20 mg/day), and 6 days of tapering doses (12 mg/day and 4 mg/day).
1893544|NCT01283022|Drug|MVI 200|Dose reservoir of 200 mcg of misoprostol in a hydrogel polymer vaginal insert within a retrieval system. The MVI 200 will be kept in place for up to 24 hours or will be removed earlier if one of the following occur: onset of active labor, intrapartum adverse event necessitating discontinuation of the study drug, other reasons including maternal request.
1893545|NCT01283035|Drug|Akt Inhibitor MK2206|Given PO
1893546|NCT01283035|Other|Laboratory Biomarker Analysis|Correlative studies
1893547|NCT01283048|Drug|BKM-120 Bevacizumab|BKM-120 60, 80, 100 mg PO QD Bevacizumab 10 mg/Kg every 2 weeks
1893548|NCT01283061|Drug|Zafirlukast|Zafirlukast tablets 20 mg
1893549|NCT01283100|Drug|GSK1349572|50mg once every 24 hours for 7 days
1893550|NCT01283100|Drug|GSK2248761|200 mg once every 24 hours for 7 days
1893551|NCT01283126|Procedure|euglycemic and hypoglycemic clamp|Subjects will undergo standard euglycemic and hypoglycemic clamps, and will have concurrent assessments of cognitive function and measurement of interstitial glucose concentrations.
1893552|NCT01283139|Biological|Sifalimumab 200 mg|Sifalimumab 200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
1893553|NCT01283139|Biological|Sifalimumab 600 mg|Sifalimumab 600 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
1893554|NCT01283139|Biological|Sifalimumab 1,200 mg|Sifalimumab 1,200 mg intravenously every 2 weeks for 4 weeks and then monthly for 44 weeks for a total of 14 doses.
1893555|NCT01283139|Other|Placebo|IV Placebo every 2 weeks for 4 weeks and then monthly for 44 weeks
1893556|NCT01283152|Drug|Polyethylene glycol 3350-electrolyte solution (GoLYTELY®)|If randomized to this arm, subjects will receive a 1 time dose of 1 gallon
1893557|NCT01283152|Drug|Lactulose|If randomized to this arm, subjects will receive 10-30 grams per standard of care
1893558|NCT01283165|Behavioral|Health education intervention|Health education was conducted in two ways. (1) Teachers were taught how to use the flip chart that contained health education material about parasites. The lessons were done during free periods as this intervention had not been formally fitted into the school syllabus. (2) The research team provided health education to school children. Focus group discussions were conducted by the research team with school children all assembled outside their classes. Health education leaflets were distributed to all school children at the school. Children were asked to share the health information with their friends and families.
1893559|NCT01283178|Radiation|intensity-modulated radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
1893560|NCT01283178|Drug|cisplatin|Given IV
1893561|NCT01283178|Radiation|image-guided adaptive radiation therapy|Undergo intensity-modulated image-guided adaptive radiotherapy
1893562|NCT01283178|Other|3'-deoxy-3'-[18F]fluorothymidine|Undergo FLT-PET scans for IMRT/IGART
1893563|NCT01283178|Procedure|positron emission tomography/computed tomography|Undergo FDG/FLT-PET scans for IMRT/IGARTT
1893564|NCT01283178|Radiation|fludeoxyglucose F 18|Undergo FDG-PET scans for IMRT/IGART
1893565|NCT01283191|Behavioral|Behavioral Incentives|Vouchers for complying with target behavior of treadmill walking
1893566|NCT01283191|Behavioral|Education Control|Education class
1893567|NCT01283204|Drug|SP|"<Every 3 weeks>
Day 1~14 : TS-1 80mg/m2/day (PO),
Day 1 : CDDP 60mg/m2/day IVF 2hours,
Day 15~21 : Rest."
1893568|NCT01283204|Drug|FL/Tax|"<Every q 3 weeks>
Day1 : Paclitaxel 175mg/m2 IVF for 2hours
Day1 : Leucovorin 20mg/m2 IVF for 1hour
Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
1893569|NCT01283204|Drug|FL/Doc|"<Every q 3 weeks>
Day1 : Docetaxel 75mg/m2 IVF for 1hour
Day1 : Leucovorin 20mg/m2 IVF for 1hour
Day1~3 : 5-FU 1000mg/m2 IVF for 24hours"
1894265|NCT01280695|Drug|MSDC-0602 250 mg|MSDC-0602 250 mg Capsules
1893570|NCT01283204|Drug|FOLFOX|<Every q 2 weeks> D1 : Oxaliplatin 100mg/m2 IVF for 2hours D1 : Leucovorin 20mg/m2 IVF for 1hour D1 : 5-FU 400mg/m2 IV bolus D1~2 : 5-FU 1200mg/m2 IVF for 24hours
1893571|NCT01283217|Drug|DS|Docetaxel with S-1. S-1: Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
1893572|NCT01283217|Drug|SP|S-1 with cisplatin. S-1 : Orally, within 30 minutes after ingestion of food. Docetaxel and Cisplatin: IV infusion.
1893573|NCT01283230|Device|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
1893574|NCT01283243|Device|Acoustic radiation force impulse imaging|Acoustic radiation force impulse (ARFI) imaging were measured 10 times in each patient.The region of interest was chosen in an area where the normal liver parenchyma was at least 6 cm thick and free of large blood vessels was chosen. A measurement depth of 2 cm below the liver capsule was chosen to standardize the examination.
1893575|NCT01283256|Drug|zonisamide|zonisamide 100mg tablets
1893576|NCT01283269|Behavioral|Memory Support System|Training in use of a memory notebook system
1893577|NCT01283269|Behavioral|Computer Training|Computer brain fitness training
1893578|NCT01283282|Drug|Clopidogrel|Clopidogrel 75 mg PO qday for 6 weeks
1893579|NCT01283282|Drug|Placebo|Placebo PO qday for 6 weeks
1893580|NCT01283308|Behavioral|Lifestyle Intervention|Intervention arm participants will attend 6 months of weekly classes where they will be taught the skills necessary to reach these goals. The curriculum for the classes is based on the DPP lesson plans. Social support will be provided by trained lay health educators and peer support groups. Participants who remain at highest risk of T2DM after four or more months in the program will be prescribed metformin in addition to continuing the lifestyle program. Metformin dosages will start at 500 mg per day, and, when appropriate, will increase to 1000 mg per day (given as 500 mg twice per day). This group will be comprised of individuals who have (1) Fasting plasma glucose values of 100 mg/dl or more and (2) elevated fasting HbA1c measures of 5.7% or more.
1893581|NCT01283308|Behavioral|Standard of Care|Participants randomized to the standard of care group will meet with a physician and a dietician, attend one class/awareness lecture on diabetes prevention through weight loss and diet change and one class on exercise, and receive handouts reinforcing what they learn in class and with the dietician, fitness consultant, and physician.
1893582|NCT01283321|Drug|Human fibrinogen concentrate|4 g IV once, within 30 minutes of ACT < 155 seconds, post CPB, with evidence of significant microvascular bleeding
1893583|NCT01283321|Other|apheresis platelets|A single apheresis platelet unit will be administered as an initial therapy within 30 minutes of ACT <155 seconds post CPB with evidence of significant microvascular bleeding.
1893584|NCT01283334|Drug|Carboplatin|Will be given as a 30 minutes intravenous (IV) infusion on days 1, 8, and 15 of each 28 day cycle. The starting dose of carboplatin will be area under the plasma-concentration time curve (AUC) = 2 mg/ml.min. Appropriate dose reductions will be done for toxicity for subsequent cycles.
1893585|NCT01283334|Drug|Cetuximab|Will be given on days 1, 8, 15 and 22 of each 29 day cycle. On week 1, a loading dose of 400 mg/m² will be given. From week 2 onwards, the dose of cetuximab will be 250 mg/m².
1893586|NCT01283334|Drug|RAD001|For phase I, dose escalation will be 2.5 mg, 5 mg, 7.5 mg or 10 mg given orally on a daily basis.
1893587|NCT01283347|Drug|18F-DTBZ|"During this study, subjects will receive a single i.v. administration of approximately 10 mCi 18F-FP-(+)-DTBZ immediately prior to imaging.
The proposed dose for this study is based on our phase I study. At the proposed human dose of 10 mCi, the whole body effective dose (ED) will be approximately 680 mrem. The estimated human ED is expected to be comparable to or below the range of other approved brain imaging agents, such as 18F-FDG"
1893588|NCT01283360|Other|HEC Placebo Gel|The HEC universal placebo gel for Stage 2 will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the HEC placebo gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators with HEC placebo gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of HEC gel.
1893589|NCT01283360|Drug|Tenofovir 1% Gel|Tenofovir 1% gel will be supplied by CONRAD (Arlington, VA, USA). Under direction from CONRAD, DPT Laboratories will manufacture the tenofovir 1% gel and analyze/release the gels under cGMP. DPT Laboratories will fill the applicators designed for vaginal use with tenofovir 1% gel to create pre-filled applicators and package each applicator and plunger in a wrapper. Each pre-filled applicator will contain and deliver a dose of approximately 4 mL of tenofovir 1% gel (equal to 4.4 g).
1893590|NCT01283373|Drug|DSTP3086S|DSTP3086S administered intravenously
1893591|NCT01283373|Drug|DSTP3086S|Escalating intravenous dose
1960715|NCT03145038|Drug|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fed|Vericiguat high-dose pediatric formulation (fed; American breakfast), 10 mg given as 20 x 0.5 mg mini tablets
1960716|NCT03145038|Drug|Vericiguat(BAY1021189, high-dose pediatric-formulation)_fasted|Vericiguat high-dose pediatric formulation (fasted),10 mg given as 20 x 0.5 mg mini tablets
1893596|NCT01283412|Drug|Placebo|Placebo (saline) iv. during the operation and stoped 30min before end of the surgery
1893597|NCT01283412|Drug|Dexmedetomidine|Dexmedetomidine 0.1~0.2ug/kg/h iv. during the operation, and stoped 30min before end of surgery
1893598|NCT01283425|Device|InsuPatch|Heaters for single use and a permanent control unit.
1893599|NCT01283438|Device|Barricaid|CE Marked Device
1893600|NCT01283438|Device|Standard of Care|Standard Limited discectomy
1893601|NCT01270659|Drug|Fentanyl|Fentanyl buccal tablet 100 mcg once
1893602|NCT01270659|Drug|Fentanyl|Fentanyl buccal tablet 200 mcg once
1893603|NCT01270659|Drug|Oxycodone/acetaminophen|Oxycodone/acetaminophen 5/325 mg once
1893604|NCT01270659|Drug|oxycodone/acetaminophen|Oxycodone/acetaminophen tablet 5/325 mg, 2 tablets one time
1893605|NCT01270672|Drug|3,4-Methylenedioxymethamphetamine|125 mg per os, single dose
1893606|NCT01270672|Drug|carvedilol|50 mg per os, single dose
1893607|NCT01270672|Drug|placebo|capsules identical to MDMA or carvedilol
1893608|NCT01270698|Drug|IMMU-130|IMMU-130 will be administered intravenously every 2 weeks for up to 6 months or longer.
1893609|NCT01270711|Drug|Study Drug|non interventional study - usage as per usual care
1893610|NCT01270724|Drug|Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx).|Two to four cycles of induction therapy with GemPOx followed by consolidation and ASCT.
1893611|NCT01270737|Dietary Supplement|Whole soy (soy flour)|40g soy flour per day for six months
1893612|NCT01270737|Dietary Supplement|daidzein|66mg daidzein per day for six months
1893613|NCT01270737|Dietary Supplement|milk powder|40g low-fat dry milk per day for six months
1893614|NCT01270750|Drug|BOSENTAN|TWICE DAILY PERORAL BOSENTAN, 125 MG DAILY DIVIDED IN TWO DOSES DURING THE FIRST MONTH AND 250 MG DAILY DIVIDED IN TWO DOSES SUBSEQUENTLY.
1893615|NCT01270763|Behavioral|Intensive lifestyle intervention|Lifestyle intervention focused on weight loss through diet and physical activity
1893616|NCT01270763|Behavioral|Diabetes support and education|Behavioral intervention focused on diabetes support and education
1893617|NCT01270776|Drug|2% aqueous chlorhexidine|A single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
1893618|NCT01270776|Drug|2% Chlorhexidine 70% isopropyl alcohol|single application of a swabstick impregnated with the antiseptic solution over the desired area. The imparted solution will be allowed to air dry with a minimum time of 30 seconds before intervention.
1893619|NCT01270789|Drug|Liraglutide|Liraglutide administered as once daily sc injection
1893620|NCT01270789|Drug|placebo|placebo administered as once daily sc injection
1893621|NCT01270802|Drug|Tenofovir/emtricitabine|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
1893622|NCT01270802|Drug|Tenofovir/emtricitabine/efavirenz|Continued therapy with tenofovir/emtricitabine/efavirenz
1893623|NCT01270802|Drug|Raltegravir|Efavirenz will be switched to raltegravir 400mg orally twice daily while continuing tenofovir/emtricitabine
1893624|NCT01270815|Drug|Pregabalin controlled release, 330 mg, 400 to 500 calories|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie medium-fat lunch
1893625|NCT01270815|Drug|Pregabalin controlled release, 330 mg, 600 to 750 calories|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie medium-fat lunch
1893626|NCT01270815|Drug|Pregabalin controlled release, 330 mg, 800 to 1000 calories|A single oral dose of 330 mg controlled release tablet administered following an 800 to 1000 calorie medium-fat lunch
1893627|NCT01270815|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered fasted
1893628|NCT01270828|Drug|Pregabalin|Tablets, 82.5 to 660mg, once per day. Duration: 19 weeks
1893629|NCT01270828|Drug|placebo|Placebo, 82.5 to 660mg, once per day. Duration: 13 weeks
1893630|NCT01270841|Drug|Placebo|Placebo capsule 1x daily for 3 months
1893631|NCT01270841|Drug|topical testosterone|testosterone gel applied 1x daily for 3 months
1893632|NCT01270841|Drug|Androxal|Capsule of either 12.5 mg or 25 mg Androxal, 1x daily for 3 months
1893633|NCT01270854|Other|Plasmalyte A|Intravenous fluid
1893634|NCT01270854|Other|Normal Saline|Intravenous fluid
1893635|NCT01270867|Device|Mechanical Thrombectomy|Each arm will use either Merci or Trevo as the primary Mechanical Thrombectomy device.
1893636|NCT01270880|Drug|Hsp90 inhibitor STA-9090|Given IV
1893637|NCT01270880|Other|laboratory biomarker analysis|Correlative studies
1893638|NCT01270880|Genetic|polymerase chain reaction|Correlative studies
1893639|NCT01270880|Other|enzyme-linked immunosorbent assay|Correlative studies
1893640|NCT01270880|Genetic|RNA analysis|Correlative studies
1893641|NCT01270880|Other|spectrophotometry|Correlative studies
1893642|NCT01270880|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
1893643|NCT01270880|Genetic|gene expression analysis|Correlative studies
1893644|NCT01270893|Drug|Nilotinib|400 mg by mouth twice a day for 7 days. Patients on Arm 2 will continue to receive Nilotinib until they have disease progression or are resectable.
1893645|NCT01270906|Drug|CHIR-258 (TKI258)|
1893646|NCT01270919|Device|BioDuct Meniscal Repair Device|"The BioDuct® Meniscal Repair Device is a small, cannulated, arthroscopically implanted, bioabsorbable conduit that has length sizes of 5, 7 and 9 mm. Based on the concept of trephination for treating meniscal tears in the red-white zone, the BioDuct® Meniscal Repair Device is designed to create a vascular access channel between the vascular-rich and cell-rich synovium and the meniscal tear. This channel allows for the flow of blood from the vascular to the avascular tissue to promote repair of the meniscus.
The BioDuct® Meniscal Repair Device is not used across meniscal tears, like other fixation devices. The BioDuct® Meniscal Repair Device is used in conjunction with suturing and helps provide vascular access, while the sutures help provide fixation. Based on the Inclusion Criteria of this protocol, there can be a maximum of three BioDuct® Meniscal Repair Devices utilized for the meniscal tear."
1893647|NCT01270932|Drug|Lenalidomide and Dexamethasone|Lenalidomide:Daily for 21 days of a 28 day cycle Dexamethasone:Days 1-4, 9-12, 17-20 for the first cycle and then weekly dexamethasone from cycles 2-4.
1893648|NCT01270945|Drug|CV-18C3|3.75mg/kg given IV for a period of 6 weeks, followed by subcutaneous administration
1893649|NCT01270945|Procedure|Standard of Care|
1893650|NCT01270958|Drug|Avamys aqueous nasal spray 110mcg|"At the visit 1, subjects who fulfill the inclusion criteria are eligible to be included in the group to self-administer intranasal treatment of fluticasone furoate aqueous nasal spray 110 mcg once daily for 6 week. The subjects are instructed to administer two sprays from the device into each nostril once daily every morning. Administration of the dose will be performed by alternately spraying one spray to each nostril followed by a second spray to each nostril. Subjects will not be permitted to take any anti-allergy or rhinitis medication during the screening or treatment period.
Throughout the study, subjects will document their study drug administration/compliance, any medical conditions experienced, and any concomitant medications taken."
1893651|NCT01270971|Drug|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
1893652|NCT01270971|Drug|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
1893653|NCT01270984|Drug|Luckyvec 400mg film coated tablet|•400mg/tablet, PO, 1 tablet once daily for Period I & II D1(crossover)
1893654|NCT01270984|Drug|Glivec 100mg film coated tablet|•100mg/tablet, PO, 4 tablets once daily for Period I & II D1(crossover)
1893655|NCT01270997|Biological|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
1893656|NCT01270997|Biological|Etanercept|Subcutaneous injection (SC) Etanercept 25mg twice a week for 48 weeks
1960717|NCT03145038|Drug|Vericiguat(BAY1021189, low-dose pediatric-formulation)_fed|Vericiguat low-dose pediatric-formulation (fed; American breakfast), 2.5 mg given as 25 x 0.1 mg mini tablets
1960718|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;American breakfast|10 mg IR tablet, intact (fed; American breakfast)
1893660|NCT01271023|Device|Control-to-Range Automated Insulin Management System|The devices that will be used in the Closed-Loop Control System are standardized across all study sites and include the DexCom Seven Plus Continuous Glucose Monitor (CGM), the OmniPod insulin pump, and the FreeStyle blood glucose meter. The Closed-Loop Control System will be used during all 3 admission visits.
1893661|NCT01271036|Device|Formula PD-F-7716|Apply a dime-size amount on each application site as instructed during the 1-week study period
1893662|NCT01271049|Other|Novel Food Product|Novel food product containing essential oil blend
1893663|NCT01271049|Other|Control Food Product|Control food product
1893664|NCT01271062|Procedure|gastric bypass surgery|
1893665|NCT01271062|Procedure|abdominal surgery|
1893666|NCT01271062|Behavioral|very low caloric diet|
1893667|NCT01271075|Drug|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
1893668|NCT01271075|Drug|Bilastine|Single dose, oral, 20 mg, 40 mg, 80 mg each for 7 days
1893669|NCT01271088|Drug|N-acetylcysteine|N-acetylcysteine 600 mg twice a day,one week after administration of antibiotics
1893670|NCT01271114|Drug|Hypertonic Saline and Terlipressin|Hypertonic saline 3% 7mL/Kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation more than 10%; Terlipressin infusion (dilution 1mg in 100mL) triggered by MAP below 70 mmHg for a goal MAP above 70 mmHg
1893671|NCT01271114|Drug|Normal saline and norepinephrine|Normal saline IV bolus 7mL/kg (with a maximum 500 mL)triggered by either Systolic Volume Variation or Pulse Pressure Variation above 10%; Norepinephrine drip (80 micrograms/mL) to keep MAP at least 70 mmHg
1893672|NCT01271127|Radiation|CT coronary angiography|patient will undergo one CT coronary angiography
1893673|NCT01271140|Drug|Insulin|Intravenous insulin clamp at a rate of 2 mlu/kg/hr. In adition a titrating dose of 20% dextrose aiming to a blood glucose level of 4 - 5.5 mmol/l.
1893674|NCT01271153|Drug|Dobutamine|Dobutamine at 5 mcg/kg/min will be administered for 2.5 hours each. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
1893675|NCT01271153|Drug|Placebo|A 5% dextrose solution will be administered for 2.5 hours. Measurements will be performed at baseline (within 30 minutes before starting the infusion) and repeated within the last 30 minutes of drug infusion.
1893676|NCT01271166|Drug|Imatinib, Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab|
1893677|NCT01271179|Procedure|sequential perfusion with ipv Ross solution and UW solution|Totally 6 L of ipv Ross solution were initially infused (aortic: portal=1:1), followed by 2 L of cold UW solution infusion (aortic: portal=1:1).
1893678|NCT01271179|Procedure|sole perfusion with UW solution|Totally 6 L of cold UW solution were infused (aortic: portal =1:1)
1893679|NCT01271192|Procedure|surgical resection and adjuvant therapy|"Postoperative:
Drug: fluorouracil Given IV continuously, Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks"
1893680|NCT01271192|Procedure|Neoadjuvant followed by operation|"Preoperative:
Drug: fluorouracil Given IV continuously,Irinotecan Given IV Radiation: radiation therapy Given 5 days a week for 5-6 weeks
Postoperative:
Drug: fluorouracil Given IV continuously,Irinotecan Given IV"
1893681|NCT01271218|Other|Diet|Participants followed isoenergetic low fat diets with higher protein (HP) or higher carbohydrate (HC) macronutrient content. Participants consumed 1,200 kcals/d for 1-week (Phase I) and 1,600 kcals/d for 9-weeks (Phase II) during a 10-week weight loss period. Participants in the HC diet consumed a diet containing 55% carbohydrate, 15% protein, and 30% fat. Subjects in the HP group consumed a diet containing 7% carbohydrate, 63% protein, and 30% fat during Phase I of the diet and 15% carbohydrate, 55% protein, and 30% fat during Phase II of the diet. The final 4-weeks of the diet (Phase III) served as a weight maintenance period in which participants consumed 2,600 kcals•d-1 consisting of 55% carbohydrate, 15% protein, and 30% fat and were instructed to follow their respective Phase I diet (1,200 kcals/d) for 2-days only if they gained 1.35 kg (3 lbs).
1893682|NCT01271218|Other|Exercise|All subjects participated in a supervised exercise program three days per week for 14-weeks. Each circuit-style workout consisted of 14 exercises (e.g. elbow flexion/extension, knee flexion/extension, shoulder press/lat pull, hip abductor/adductor, chest press/seated row, horizontal leg press, squat, abdominal crunch/back extension, pec deck, oblique, shoulder shrug/dip, hip extension, side bends and stepping). Participants performed as many repetitions in a 30-s time period. In a continuous, interval fashion, participants performed floor-based callisthenic (e.g. running/skipping in place, arm circles, etc.) exercises on recovery pads for a 30-s time period after each resistance exercise in an effort to maintain a consistent exercise heart rate that corresponded to 60% to 80% of their maximum heart rate.
1893683|NCT01271231|Drug|Scaling and root planing plus placebo|Single session of scaling and root planing using ultrasonic device. placebo tablets 500 mg, 1 tablet every 24 hours for 3 days
1893684|NCT01271231|Drug|Scaling and root planing plus azythromycin|Single session of scaling and root planing using ultrasonic device. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
1893685|NCT01271231|Drug|Prophylaxis plus azythromycin|Dental polishing using prophylaxis paste and rubber cups. Azythromycin tablets 500mg. 1 tablet every 24 hours for 3 days.
1893686|NCT01271244|Drug|Escitalopram|10-20mg daily for 12 weeks
1893687|NCT01271257|Drug|Misoprostol|20 microgram PO per hour for 8 doses or 80 microgram PO per 4 hours for 2 doses
1893688|NCT01271270|Drug|Palomid 529|
1893689|NCT01271283|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1893690|NCT01271283|Drug|Lenalidomide|Given orally
1893691|NCT01271296|Dietary Supplement|Liquorice|24 gram liquorice eq. to 150 mg glycyrrhizinic acid, taken orally, for three days.
1893692|NCT01271296|Dietary Supplement|Grapefruit Juice|200 ml pink grapefruit juice three times a day, taken orally, for three days.
1893693|NCT01271322|Radiation|neoadjuvant radiochemotherapy in metabolic non responders|Metabolic non-responders, with a SUV decrease of less than 35%, discontinue induction chemotherapy and proceed to an intensified radiochemotherapy treatment
1893694|NCT01271335|Biological|collagenase|Lyophilized powder / sterile dosage form for single local intravascular administration via the occluded coronary.
1960719|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,crushed)_fed;American breakfast|10 mg IR tablet, crushed (fed; American breakfast)
1893697|NCT01271361|Procedure|primary PCI with thrombectomy|thrombectomy is performed before implantation of a drug eluting stent
1893698|NCT01271361|Procedure|primary PCI without thrombectomy|no thrombectomy is performed before the implantation of a drug eluting stent
1893699|NCT01271374|Drug|amlodipine and olmesartan|Weeks 1-2: Azor® 5/20 Weeks 3-14: Azor® 10/40 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
1893700|NCT01271374|Drug|losartan and HCTZ|Weeks 1-2: Hyzaar® 50/12.5 Weeks 3-14: Hyzaar® 100/25 Weeks 15-18: Azor® 10/40+HCTZ 25 Weeks 19-20: Azor® 10/40+HCTZ 25 + spironolactone 25 once daily
1893701|NCT01271387|Drug|tasimelteon|20 mg tasimelteon capsules, PO single dose
1893702|NCT01271413|Behavioral|Computerized cognitively stimulating activities|The study will compare the effects of different methods of computerized mental stimulation. The intervention involves 25 sessions involving computerized cognitive tasks.
1893703|NCT01271439|Drug|Cetuximab|400mg/m2 intravenous infusion the week before radiotherapy, 250mg/m2 intravenous infusion weekly for 6 weeks during radiotherapy
1893704|NCT01271452|Biological|botulinum toxin type A|20 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
1893705|NCT01271452|Biological|botulinum toxin type A|30 units (total dose) botulinum toxin type A injected into glabellar region on Day 0
1893706|NCT01271465|Procedure|Kidney Biopsy|biopsy of transplant kidney
1893707|NCT01271478|Drug|captopril plus placebo|This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day
1893708|NCT01271478|Drug|telmisartan plus placebo|Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day
1893709|NCT01271478|Drug|Telmisartan plus Captopril|Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)
1893710|NCT01271478|Drug|Placebo|Patients in this group will receive 2 tablets of placebo (starch) twice a day.
1893711|NCT01271504|Drug|Sorafenib|Phase Ib: Cohort 1; 200 mg E7050 + 400 mg Sorafenib Cohort 2; 300 mg E7050 + 400 mg Sorafenib Cohort 3; 400 mg E7050 + Sorafenib
1893712|NCT01271504|Drug|Sorafenib|"E7050 given orally at 200, 300 or 400 mg once daily.
Sorafenib given orally, 400 mg twice daily."
1893713|NCT01271517|Drug|NPH insulin|Treatment twice daily with Insulatard plus Novorapid at meals. Doses adjusted according to bloodsugar
1893714|NCT01271517|Drug|Glargine|Treatment once daily with Lantus plus Novorapid at meals. Doses adjusted according to bloodsugars
1893715|NCT01271517|Drug|Detemir|Treatment twice daily with Levemir plus Novorapid at meals. Doses adjusted according to bloodsugars
1893716|NCT01271530|Other|Upper Limb Ergometry|Cardiovascular training will be performed using upper limb ergometers at home for 8 weeks. Each subject will receive an individually prescribed programme and will begin exercising for at least ten minutes per day three days per week. If an individual has difficulty exercising for 10 minutes continuously, the 10 minute session may be broken into 2-3 minute bursts of exercise, with one minute rests. Subjects will aim to increase exercise durations to 20 minutes per day five days per week and will exercise at moderate to high intensities.
1893717|NCT01271543|Device|Endotracheal Intubation|General anesthesia will be induced with fentanyl 1-2 mcg/kg, 2-3 mg/kg propofol and maintained with 50% air /50% oxygen and isoflurane. Neuromuscular blockade will be obtained with rocuronium 0.5 mg/kg. Laryngoscopy will be performed with Shikani optical stylet (SOS) (one size) or MacIntosh laryngoscope blade size 3 for women and size 4 for men. Endotracheal intubation will be performed with an endotracheal tube of internal diameter of 7.0 mm l for female patients and 8 mm for male in both groups. Noninvasive blood pressure and heart rate will be recorded preinduction, preintubation, and every min for the first 5 min after successful intubation. The patients will be questioned post-operatively about symptoms of a sore throat, hoarseness, dysphonia or dysphagia in the Post Anesthesia Care Unit and again 24 hours after surgery.
1893718|NCT01271556|Drug|Salmeterol|50 mcg MDI (inhalatory), once on days A and C at t=0,
1893719|NCT01271556|Procedure|saline infusion (0.9 per cent sodium chloride)|rapid 50-minute 750-ml 0.9% saline infusion 240 minutes after inhalatory treatment on day A and B
1893720|NCT01271556|Other|Placebo|placebo, inhalatory (MDI) once
1893721|NCT01271569|Drug|Fospropofol disodium|Fospropofol disodium： 0.5g
1893722|NCT01271582|Drug|Irinotecan, 5FU, leucovorin|FOLFIRI regimen every 2 weeks [irinotecan 150mg/m2 or 180mg/m2, leucovorin 20(200)mg/m2, 5FU 400 mg/m2 (bolus) or 2400 mg/m2 (46hour infusion)]
1893723|NCT01271595|Other|sham acupuncture|12 sessions of sham acupuncture over 8 weeks
1893724|NCT01271608|Device|needle exchange|Comparing the pain intensity on a numeric scale (0-10) with intramuscular and subcutaneous injection between a retractable fixed syringe needle and the technique involving needle exchange; Comparing bruise formation following administration of insulin subcutaneous injections between retractable fixed needle and the conventional technique.
1893725|NCT01271621|Device|Intubation|Endotracheal intubation
1893726|NCT01271647|Drug|Yin and Yang tonic granules|Yin and Yang tonic granules,18g per time,two times per day,six months
1893727|NCT01271647|Drug|placebo|granules,18g per time,two times per day,six months
1893728|NCT01271660|Drug|Pregabalin|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.
Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
1893777|NCT01277341|Drug|Bepotastine besilate proprietary formulation|nasal spray
1893778|NCT01277341|Drug|Bepotastine besilate proprietary formulation|nasal spray
1893729|NCT01271660|Drug|Placebo|"drug form : capsule, 75/150mg. Pregabalin will be provided to treatment arm subjects for 6-week Treatment period.
Treatment period : 75 mg twice daily during the first 1 week as titration + 150mg twice daily for 4 weeks as maintenance + 75mg twice a day as tapering"
1893730|NCT01271686|Drug|0.01% bimatoprost|0.01% bimatoprost once in the evening for 4 weeks
1893731|NCT01276990|Drug|BI 224436|Oral drinking solution
1893732|NCT01276990|Drug|BI 224436|Oral drinking solution
1893733|NCT01276990|Drug|BI 224436|Oral drinking solution
1893734|NCT01276990|Drug|BI 224436|Oral drinking solution
1893735|NCT01276990|Drug|BI 224436|Oral drinking solution
1893736|NCT01276990|Drug|BI 224436|Oral drinking solution
1893737|NCT01276990|Drug|BI 224436|Oral drinking solution
1893738|NCT01276990|Drug|BI 224436|Oral drinking solution
1893739|NCT01276990|Drug|BI 224436|Oral drinking solution
1893740|NCT01276990|Drug|Placebo|Oral drinking solution
1893741|NCT01277003|Device|Aculife Magnetic Wave Therapist|two therapeutic points, each for 15 minutes
1893742|NCT01277003|Device|TENS|tow therapeutic points, each for 15 minutes
1893743|NCT01277016|Drug|BMDex|"BMDex:
cycles 1 and 2 = MDex with bortezomib (B) at 1.3 mg/m2 i.v. on days 1, 4, 8 and 11 of a 28 day cycle, cycles 3 - 8 = MDex with bortezomib at 1.3 mg/m2 i.v. on days 1, 8, 15 and 22 of a 35 day cycle."
1893744|NCT01277029|Other|No drug|Psychopathology, personality traits of patients with lower urinary tract symptoms
1893745|NCT01277042|Biological|GSK580299 (CervarixTM)|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
1893746|NCT01277042|Biological|Engerix-BTM|3-dose schedule intramuscularly vaccination (Months 0, 1 and 6)
1893747|NCT01277068|Procedure|Surgical and medical procedures|this study want to compare the differential effect of the 3 bariatric surgery procedures on the production rates of the intestinal TRL: the adjustable gastric banding the sleeve gastrectomy the gastric bypass
1893748|NCT01277081|Drug|Paracetamol hot drink|Hot drink containing paracetamol
1893749|NCT01277081|Drug|Paracetamol tablets|Paracetamol tablets
1893750|NCT01277094|Drug|Placebo|Oral daily doses for 12 weeks
1893751|NCT01277094|Drug|RO5093151|Oral daily doses for 12 weeks
1893752|NCT01277107|Drug|Zaleplon AP formulation|Gastric retentive dual release Zaleplon
1893753|NCT01277107|Drug|Placebo capsule|Identical placebo capsule
1893754|NCT01277146|Drug|OMP-59R5|IV infusion
1893755|NCT01277159|Drug|A. Control Nerve Block. IV Dexamethasone (4 mg).|A. Control Nerve Block. IV Dexamethasone (4 mg).
1893756|NCT01277159|Drug|B. Nerve Block with Dexamethasone (4 mg). IV saline.|B. Nerve Block with Dexamethasone (4 mg). IV saline.
1893757|NCT01277159|Drug|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)|C. Control Nerve Block. IV Dexamethasone (4 mg). IV Buprenorphine (0.3 mg)
1893758|NCT01277159|Drug|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).|D. Nerve Block with Buprenorphine (0.3 mg). IV Dexamethasone (4 mg).
1893759|NCT01277159|Drug|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg).|E. Nerve Block with Dexamethasone (4 mg) / block Buprenorphine (0.3 mg). IV saline.
1893760|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
1893761|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
1893762|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 2 weeks for 6 cycles
1893763|NCT01277172|Biological|Rituximab|375 mg/m2 IV every 14 days for 6 cycles
1893764|NCT01277185|Dietary Supplement|Low Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a lower (600-1200 mg/d)level of calcium in the first camp followed by the opposite (higher calcium diet)regime in the second camp.
1893765|NCT01277185|Dietary Supplement|High Calcium Diet|The basal diet will contain 600 mg of Ca per day and constant sufficient amounts of all other nutrients. Additional Ca will be given unfortified beverages served three times per day. Teens will be randomized to a higher (1100-2300mg/d)level of calcium in the first camp followed by the opposite (lower calcium diet)regime in the second camp.
1893766|NCT01277211|Drug|ENG 120 µg + EE 15 µg intravaginal ring|13 cycles of ENG-EE (NuvaRing) vaginal ring use. Each cycle 28 days, with a 21-day active treatment period followed by 7-day ring-free period. One ring per cycle, each ring containing 11.7 mg ENG and 2.7 mg EE, and releasing on average 120 mcg/day of ENG and 15 mcg/day of EE.
1893767|NCT01277211|Drug|DRSP 3 mg + EE 30 µg|13 cycles of DRSP-EE tablet use. Each cycle 28 days, with a 21-day active treatment period followed by a 7-day tablet-free period. Participants received total of 21 tablets per cycle, each tablet contained 3 mg DRSP and 30 μg EE.
1893768|NCT01277224|Behavioral|Movi2 Program|In the Movi2 program we will perform a recreational physical activity intervention during one year that include standardized recreative and non competitive activities conducted by sports instructors. It consisted of two 90-min after school sessions per week on school days and one 150-minute session on Saturday morning.
1893769|NCT01277237|Drug|Omacor|Active comparator: omacor 4g/day
1893770|NCT01277237|Drug|lactose tablet|placebo: lactose tablet 4g/day
1893771|NCT01277250|Behavioral|Web-based smoking cessation program|"Web-based smoking cessation program that includes a transition coach to hospitalized patients who will assist them in quitting as they are discharged from the hospital. Intervention arm participants will have access to a tailored web-based intervention that will include e-messages and activities that are tailored to their recent hospital stay."
1893772|NCT01277263|Device|Diffuse Optical Spectroscopy Imaging|Monitoring Breast Cancer during chemo therapy
1893773|NCT01277276|Device|Diffuse optical spectroscopy and Near infrared spectroscopy|Diffuse optical spectroscopy and Near infrared spectroscopy are non-invasive methods measure tissue hemodynamics in real time, direct quantitative information and insights treatment-associated toxicity.
1893774|NCT01277289|Drug|Dexamethasone|500 mg/20 ml encapsulated in erythrocytes, every month for 12 months
1893775|NCT01277302|Drug|Ranibizumab|Liquid ranibizumab (10 mg/ml) was supplied in a sterile solution in single-use vials.
1893776|NCT01277315|Drug|Anakinra|Open Safety and Tolerability study to evaluate a subcutaneous application 100 mg of Anakinra in combination with Riluzol in Amyotrophic Lateral Sclerosis.
1894266|NCT01280695|Drug|MSDC-0602 250 mg|MSDC-0602 500 mg Capsules
1893779|NCT01277341|Drug|Bepotastine besilate proprietary formulation|nasal spray
1893780|NCT01277341|Drug|Placebo comparator|nasal spray
1893781|NCT01277354|Behavioral|Cognitive Processing Therapy|"CPT utilizes a combination of a) exposure therapy aimed at extinguishing fear and distress induced by memories and external cues associated with the trauma, and b) cognitive behavioral techniques that address faulty thinking patterns developed to promote a sense of control over possible future traumas, but that instead perpetuate PTSD symptoms. In CPT, exposure to the traumatic memory occurs through writing and reading for periods of time determined by the client and is confined to the week of the 4th and 5th sessions. These sessions are otherwise used to identify stuck-points, i.e., distorted interpretations regarding the trauma and unrealistic beliefs regarding self and others."
1893782|NCT01277354|Behavioral|Waitlist Placebo|Behavioral ratings are conducted by a blind rater.
1893783|NCT01277367|Behavioral|Discovery Vitality base program|The existing Discovery Vitality health promotion base program, which offers points for various levels of physical activity.
1893784|NCT01277367|Behavioral|Communication|Participants will be sent regular communications by Discovery Vitality -equivalent to the level of communications in the other incentive groups - which will provide information and tips about ways of accumulating Vitality points on the existing programme (concerning fitness-related activities, in particular).
1893785|NCT01277367|Behavioral|Charitable Incentive|Members will be asked to nominate a charity, from a selection of charities, which will benefit financially (Discovery Vitality will make a direct payment to a nominated charity) based on their (member's) level of participation in points-earning physical activity. Individuals will receive one of four possible payouts, corresponding to their level of engagement, for their selected charity (amounts given below). In addition, members will be sent regular updates of activities by their nominated charities (This will be operationalised and facilitated by Vitality- and as such, no direct mailing from nominated charity will take place, to maintain confidentiality.)
1893786|NCT01277367|Behavioral|Prize Draw Incentive|Members will be entered into a prize draw for a monthly cash-prize if they achieve physical activity targets. Four lottery payouts, corresponding to their levels of engagement, will be made on a monthly basis. All members will be sent information regarding the winnings of those that are drawn (unlinked to personal identifiers, but to motivate).
1893787|NCT01277367|Behavioral|Direct Payment|Members will receive a direct payment (in the form of gift voucher) of one of four possible amounts depending on the level of participation in fitness-related activities equivalent in expected value to the payouts in arms 3 and 4.
1893788|NCT01277367|Behavioral|Free Choice|Members will be asked to choose one of the three aforementioned incentive options on enrollment to the study.
1893789|NCT01277406|Drug|4SC-201(Resminostat)|oral administration
1893790|NCT01277406|Drug|FOLFIRI|i.v. administration
1893791|NCT01277432|Other|Psychiatrist Interview|"Patients will receive a face-to-face interview by a trained clinician or psychiatrist using the following instruments:
MINI
SSI-28 (somatization)"
1893792|NCT01277432|Other|Depression screening - control|"All study participants will undergo;
a comprehensive diabetes assessment by completing a full set of questionnaires and clinical assessments, using the JADE e-portal
a detailed psychological and behavioral assessments using validated questionnaires
several specialist questionnaires on depression, self care and quality of life"
1893793|NCT01277445|Dietary Supplement|Prebiotic|Inulin-fructan 15mg/day for 28days
1893794|NCT01277445|Dietary Supplement|Prebiotic|Daily consumption of 15g inulin-fructan for 28 days
1893795|NCT01277471|Behavioral|Meal frequency (6 meals vs. 2 meals/day)|6 meals/day for 12 weeks followed by 2 meals/day for 12 weeks at the same caloric restriction (-500 kcal/day)
1893796|NCT01277471|Behavioral|6 meals/day followed by 2 meals/day|2 meals/day for the first 12 weeks followed by 6 meals/day for additional 12 weeks at the same caloric restriction (-500 kcal/day)
1893797|NCT01277484|Drug|Decitabine|"1. Dose finding study (cycle 1-cycle4)
Indicated dose for 5 consecutive days every 28 days
Cohort 1: 5mg/m2 of decitabine
Cohort 2 and 3:Dose escalation up to 15mg/m2 using a mechanism-based pharmacokinetic / pharmacodynamic model"
1893798|NCT01277497|Drug|Sevelamer carbonate|Sevelamer carbonate 1,600 mg three times daily with meals
1893799|NCT01277497|Drug|Calcium acetate|Calcium acetate 1,334 mg three times daily with meals for 12 weeks
1893800|NCT01277510|Drug|cinacalcet capsule|Cinacalcet was prepared for oral administration as both capsules for sprinkling and film coated tablets for swallowing.
1893801|NCT01277510|Drug|placebo|Placebo tablets and capsules for sprinkling identical to active treatment.
1893802|NCT01277510|Drug|Standard of Care|All participants, regardless of treatment assignment, will receive standard of care with vitamin D sterols (calcitriol and its analogs), as prescribed by the treating physician.
1893803|NCT01277523|Drug|tiotropium high dose|2 actuations once daily
1893804|NCT01277523|Drug|placebo|2 actuations once daily
1893805|NCT01277523|Drug|tiotropium low dose|2 actuations once daily
1893806|NCT01277549|Device|Mononuclear cell collection.|Each donor will undergo one apheresis procedure to collect mononuclear cells from their peripheral blood.
1893807|NCT01277575|Device|rtACS stimulation (Verum condition)|Repetitive, transorbital alternating current stimulation (rtACS) is applied with multi-channel device generating weak current pulses in predetermined firing bursts of 2 to 9 pulses. The amplitude of each current pulse is below 1000 microA. Current intensity is individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation
1893808|NCT01277575|Device|placebo condition|A clicking sound is presented and the same electrode montage set-up is used during rtASC- and Placebo-stimulation, except that placebo patients received no current (stimulator turned off).
1893809|NCT01277601|Drug|TDF|TDF 300 mg tablets administered orally once daily
1893810|NCT01277601|Drug|Peg-IFN|Peg-IFN 180 µg administered via subcutaneous injection once weekly
1893811|NCT01277614|Behavioral|Therapeutic lifestyle|This is a 6-month intervention in which participants with 2r more MS components are randomly assigned to intervention or control group. Intervention comprise individual diet counseling, an exercise plan and monthly lifestyle workshops. Controls receive printed material on healthy eating and lifestyle modification.
1893812|NCT01277627|Drug|Nevirapine|nevirapine: 400 mg a day.
1893813|NCT01277627|Drug|efavirenz, protease inhibitors|efavirenz: 600 mg a day
1893814|NCT01277640|Drug|dapivirine|"dosage form: gel 0.05%
dosage: 2.5g
frequency: once daily
duration: 7 days"
1893815|NCT01277640|Drug|matched placebo|"dosage form: gel, no api
dosage: 2.5g
frequency: once daily
duration: 7 days"
1893816|NCT01277640|Drug|universal placebo|"dosage form: gel, HEC-based
dosage: 2.5g
frequency: once daily
duration: 7 days"
1893817|NCT01277653|Device|tumor maker interval shortly|tumor maker interval every 3 month
1893818|NCT01277666|Drug|GSK1605786A|500 mg twice daily, administered orally for 12 weeks
1893819|NCT01277666|Drug|GSK1605786A|500 mg once daily, administered orally for 12 weeks
1893820|NCT01277666|Drug|Placebo|Placebo capsules, administered orally for 12 weeks
1893821|NCT01277679|Procedure|MRI|MRI of lungs to measure lung water content before and after passive leg raising (PLR)
1893822|NCT01277692|Drug|GSK2336805 10mg|single dose once daily
1893823|NCT01277692|Drug|GSK2336805 30mg|single dose once daily
1893824|NCT01277692|Drug|GSK2236805 100mg|single dose once daily
1893825|NCT01277692|Drug|GSK2236805 200mg|single dose once daily
1893826|NCT01277692|Drug|GSK2236805 10mg|repeat dose once daily for 7 days
1893827|NCT01277692|Drug|GSK2236805 dose to be determined up to 100mg|repeat dose once daily for 7 days
1893828|NCT01277692|Drug|GSK2236805 5mg|single dose in HCV infected patients
1893829|NCT01277692|Drug|GSK2236805 30mg|single dose in HCV infected patients
1893830|NCT01277692|Drug|GSK2236805 100mg|single dose in HCV infected patients
1893831|NCT01277705|Biological|GSK Biologicals' reduced antigen diphtheria and tetanus toxoids and acellular pertussis- inactivated poliovirus vaccine|Intramuscular, single
1893832|NCT01277705|Biological|Boostrix™|Intramuscular, single dose
1893833|NCT01277705|Biological|GSK Biologicals' IPV vaccine|Intramuscular, single dose
1893834|NCT01277705|Biological|Revaxis®|Intramuscular, single dose
1893835|NCT01277718|Drug|Cobimetinib|One 20-mg tablet of cobimetinib will be administered orally with 240 mL room temperature water after at least an 8-hour fast or approximately 30 minutes after starting the standardized FDA high-fat meal.
1893836|NCT01277718|Drug|Rabeprazole|Rabeprazole 20 mg will be administered orally once daily for 4 days starting on Day -4 and on Day 1 of the treatment period.
1893837|NCT01277731|Drug|Methylprednisolone|Run-in period: dexamethasone 10-20mg q day iv during chemotherapy Treatment period: methylprednisolone 60-125mg iv during chemotherapy
1893838|NCT01277744|Procedure|Hyperthermic Peritoneal Perfusion (HIPEC)|HIPEC, technique for combining hyperthermia and chemotherapeutic agents delivered intraoperatively to the peritoneal and retroperitoneal surface via a recirculating perfusion circuit, performed after cytoreductive surgery and lysis of adhesions.
1893839|NCT01277744|Drug|Cisplatin|100 mg/M2 per perfusion catheter. The perfusion is continued for 90 minutes after adding the cisplatin.
1893840|NCT01277757|Drug|Akt Inhibitor MK2206|Given orally (PO) weekly, starting (dose 0) at 200 mg
1893841|NCT01277757|Other|Laboratory Biomarker Analysis|Correlative studies
1893842|NCT01277757|Other|Pharmacological Study|Correlative studies
1893849|NCT01277796|Device|Heat pack conduction-heat therapy|Hand warmer heat pack with reliable (and monitored) temperature (50-52 degrees Celsius) will be applied to lesion borders for 3 minutes (fractionated to 90 second intervals or less) every day, for 7 consecutive days.
1893850|NCT01283451|Behavioral|Muscle contraction|Participants will perform a 30-60 second exercise designed to cause a temporary decrease in muscle oxygenation of a specific muscle group.
1893851|NCT01283464|Drug|Retinol|1.0% cream
1893852|NCT01283464|Drug|Tretinoin|0.02% cream
1893853|NCT01283477|Device|ACUPUNCTURE AT LI11|ACUPUNCTURE AT LI11 FOR 30 MINUTES PRIOR TO INTRATHECAL MORPHINE & LEFT IN PLACE FOR 30 MINUTES
1893854|NCT01283477|Device|SHAM ACUPUNCTURE|SHAM ACUPUNCTURE AT A POINT 2 CM LATERAL TO LI11 30 MINUTES PRIOR TO INTRATHECAL MORPHINE & LEFT IN PLACE FOR 30 MINUTES
1893855|NCT01283490|Device|DASD Group|Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
1893856|NCT01283490|Device|Sonic Vibration (SV)|Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
1893857|NCT01283503|Drug|BKM120|
1893858|NCT01283516|Drug|LDK378|LDK378 is a selective and a potent inhibitor of anaplastic lymphoma kinase (ALK) activity, is a capsule and is administered orally.
1893859|NCT01283542|Drug|Pasireotide LAR|
1893860|NCT01283555|Drug|Tenofovir|Delivered using prefilled and user-filled applicator
1893861|NCT01283581|Drug|Delafloxacin|300mg IV every 12 hours for 5-14 days
1893862|NCT01283581|Drug|Linezolid|600mg IV every 12 hours for 5-14 days
1893863|NCT01283581|Drug|Vancomycin|15mg/kg, up to 1250 mg, IV every 12 hours for 5-14 days
1893864|NCT01283594|Drug|Tozadenant (SYN115) 60 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
Total daily doses include 60 mg BID."
1893865|NCT01283594|Drug|Placebo|White-coated, modified-oval placebo tablets.
1893866|NCT01283594|Drug|Levodopa (L-dopa)|One intravenous infusion of L-dopa to reach approximately 600 ng/ ml plasma concentration.
1893867|NCT01283594|Drug|Tozadenant (SYN115) 120 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
Total daily doses include 120 mg BID."
1893868|NCT01283594|Drug|Tozadenant (SYN115) 180 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
Total daily doses include 180 mg BID."
1893869|NCT01283594|Drug|Tozadenant (SYN115) 240 mg BID|"Tozadenant tablets, white-coated, modified-oval tablets manufactured in 60 mg dosage strengths.
Total daily doses include 240 mg BID."
1893870|NCT01283607|Behavioral|Digicoach|Digicoach is an e-health cognitive behavioral therapy with 4-12 weekly sessions especially developed for IVF women. Digicoach is facilitated by an e-therapist. The investment for the weekly home work assignments is about one and a half hour. Digicoach consist of different modules (e.g. stress reduction, acceptance). Digicoach starts before the hormonal down regulation as the start of the IVF procedure and ends three weeks after the pregnancy test.
1893871|NCT01283620|Behavioral|modified constraint induced movement therapy (mCIMT)|The intervention group will receive usual care plus mCIMT. mCIMT consists of two components delivered in parallel: three 30 min therapy sessions/week focusing on progressively more difficult tasks performed with the arm/hand, and five hours/weekday of restraint of the unaffected upper limb. Each 30 min therapy session consists of using the affected upper limb in practicing 4-5 functionally relevant tasks.
1893872|NCT01283620|Other|Usual and Customary Care|Patients in this arm will receive usual care dose-matched to the experimental care group. Usual care will consist of occupational and physiotherapy intervention focused on affected upper limb range of motion (i.e., active range of motion incorporated into functional tasks such as reaching), strengthening (i.e., upper limb resisted exercise), manual dexterity exercises (i.e., grasp and release, stacking cones), and general aerobic conditioning (i.e., recumbent stepper, treadmill).
1893873|NCT01283633|Device|Neuromodulation|Neuromodulation as directed via remote presence robotic and experienced clinician for those with neuromodulation systems implanted to treat movement disorders and chronic pain
1893874|NCT01283646|Drug|Apevitin BC|3.5 to 5 ml 3 times a daily
1893875|NCT01283646|Drug|Vitamin B Complex + Vitamin C|3.5 to 5 ml 3 times a daily
1893876|NCT01283659|Other|Standard Imaging|
1893877|NCT01283659|Other|Advanced Imaging|
1893878|NCT01283672|Other|Controlled diet with whole grain barley, whole grain oats, or low grain diet|Participants will consume a standardized diet for 3 days prior to the treatment intervention meal. Meals will be prepared using traditional American foods with a macronutrient composition representative of a typical American diet. Participants will be instructed to eat all foods and only foods provided to them, with the exception of water, coffee, tea, and diet soda.
1893879|NCT01283685|Other|breathing helium-hyperoxia|40% O2, 60% He
1893880|NCT01283685|Other|breathing supplemental oxygen|oxygen (4 L/min) provided by nasal cannula
1893881|NCT01283698|Drug|Experimental: LAS 41004 dosage 1|dosage 1, once daily
1893882|NCT01283698|Drug|Experimental: LAS 41004 dosage 2|LAS 41004 dosage 2, once daily
1893883|NCT01283698|Drug|Experimental: LAS 41004 dosage 3|dosage 3, once daily
1893884|NCT01283698|Drug|Placebo Comparator: placebo|once daily
1893885|NCT01283698|Drug|Reference|Active Comparator,once daily
1893887|NCT01283724|Drug|Dienogest (Visanne, BAY86-5258)|Subjects received Dienogest tablet orally at a dosage of 2 mg once daily over a period of 52 weeks.
1893888|NCT01283737|Device|DBX Putty|OCD of the knee will be treated with DBX Putty
1893889|NCT01283737|Procedure|Mosaicplasty|Mosaicplasty procedure performed to treat OCD of the knee
1893890|NCT01283750|Behavioral|care coordination|dementia-related care coordination
1893891|NCT01283763|Drug|Topical Imiquimod|16 weeks
1893892|NCT01283763|Procedure|Conization|Large loop excision of the transformation zone
1893893|NCT01283776|Drug|Cyclophosphamide|100 mg/kg total dose, infused on day +3 and +3 after allogeneic stem cell transplantation
1893894|NCT01286766|Drug|DCS (docetaxel with cisplatin with TS-1)|"S-1: 70 mg/m2 #2 bid PO, D1-14
Docetaxel 30 mg/m2 IVF (for 1 hr) D1 and D8
Cisplatin 30 mg/m2 IVF (for 2 hrs, without hydration) D1 and D8, repeated by 3 weeks."
1893895|NCT01286766|Drug|DCF (docetaxel with cisplatin with 5-FU)|"5-FU: 1,000 mg/m2 CI, D1-3
Docetaxel 60 mg/m2 IVF (for 1 hr) D1 followed by
Cisplatin 60 mg/m2 IVF (for 2 hrs, with hydration) D1, repeated by 3 weeks.
Intercycle or intracycle dose modification is indicated if ≥G3 hematologic toxicity (except anemia) or ≥G3 non-hematologic toxicity (except alopecia)
treatment is repeated until 4 cycles"
1893897|NCT01286805|Procedure|Lumbar Plexus Blockade|The lumbar plexus block will be dosed with 30 milliliters of 0.25% bupivacaine with 1:200,000 epinephrine
1893898|NCT01286805|Procedure|Control|The control group will receive only a combined spinal-epidural.
1893899|NCT01286818|Biological|Ramucirumab (IMC-1121B)|Ramucirumab (IMC-1121B): Intravenous (IV) infusions, 8 milligrams per kilogram (mg/kg) every 2 weeks
1893900|NCT01286818|Drug|Irinotecan|IV Infusion, 180 milligrams per square meter (mg/m²) every 2 weeks
1893901|NCT01286818|Drug|levofolinate|IV infusion, 200 mg/m² every 2 weeks
1893902|NCT01286818|Drug|5-Fluorouracil (5-FU)|400 mg/m² bolus followed by a 2400 mg/m² continuous infusion, every 2 weeks
1893903|NCT01286831|Drug|[14C]GW642444|Single 200μg dose of [14C]GW642444 given on Day 1.
1893904|NCT01286844|Drug|GSK2190915A 5mg|Oral powder for dispersion in water
1893905|NCT01286844|Drug|GSK2190915A 10mg|Oral powder for dispersion in water
1893906|NCT01286844|Drug|GSK2190915A 25mg|Oral powder for dispersion in water
1893907|NCT01286844|Drug|GSK2190915A 50mg|Oral powder for dispersion in water
1893908|NCT01286844|Drug|GSK2190915A 100mg|Oral powder for dispersion in water
1893909|NCT01286857|Device|External Suction Interface and a Silicon Film|Evaluate the function of a new silicon cover film and an on-top suction device to be used in a NPWT system in the treatment of acute and chronic wounds.
1893947|NCT01287117|Drug|Omalizumab|Omalizumab was supplied as a lyophilized, sterile powder in a single-use vial.
1893948|NCT01287117|Drug|Placebo|Placebo was supplied as a lyophilized, sterile powder in a single-use vial without study drug.
1894046|NCT01287832|Drug|Vancomycin|Vancomycin dosed to achieve a trough of 15-20 microgram/mL.
1894047|NCT01287832|Drug|Daptomycin|
1893910|NCT01286870|Device|Mentor Becker 25 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
The Becker 25 Expander/Breast Implant has a silicone gel volume of approximately 25% and saline volume of approximately 75%. The Becker Expander/Breast Implant is available in sizes 150 - 800cc."
1893911|NCT01286870|Device|Mentor Becker 50 Expander/Breast Implant|"The breast implant is comprised of the Becker implant and the injection dome/fill tube and has a low bleed, gel-filled outer lumen and an adjustable saline-fillable inner lumen. The inner lumen can be gradually filled with saline over an extended period of time via the fill tube by injecting saline through the injection dome. Once expanded to the desired volume, the fill tube and injection dome are removed through a small incision under local anesthetic, and the prosthesis remains in position as a breast implant.
The Becker 50 Expander/Breast Implant has a 50% gel volume and a 50% saline volume, so a 400cc implant would nominally have 200cc of saline and 200cc of silicone. The Becker 50 Expander/Breast Implant is available in sizes from 300 to 700cc."
1893912|NCT01286896|Drug|Sunitinib|"Patients will start treatment with a continuous once-daily dose of 37.5 mg sunitinib. After 22 days the first dose modification will be performed based on the total trough levels (TTL) combined for sunitinib plus SU12662 as measured by dried blood spot (DBS) analyses taken at day 15 ± 1day. A second dose modification will be performed after 36 days (7 days after the first dose adjustment) based on the TTL taken at day 29 ± 1day. One treatment cycle is defined as 28 days.
After 8 weeks a third analyses for TTL will be performed without further consequences for sunitinib dosing. Patients will be evaluated by CT- or MRI-scans for the response to therapy at week 8, and thereafter every 12 weeks. One blood sample will be harvested for pharmacogenetic analyses."
1893913|NCT01286909|Dietary Supplement|LaFlavon|two tablets of LaFlavon (two x 3.5mg lycopene/25 mg soy isoflavone) daily for three months
1893914|NCT01286922|Other|Behavioral: exercise|"Specific Aim: We will identify, recruit, assess, and randomly assign 42 sedentary, overweight-obese individuals who are at risk for pre-diabetes to an AER or INT training group in order to test the hypothesis:
• Individuals randomized to INT will have greater improvements in insulin sensitivity than individuals assigned to traditional AER.
Secondary Aim: We will measure maximal cardiorespiratory fitness (VO2max/peak) in order to test the hypothesis:
• Individuals randomized to the INT group will have a greater improvement in VO2max/peak than individuals in traditional AER group."
1960720|NCT03145038|Drug|Vericiguat(BAY1021189,10 mg IR film-coated tablets,intact)_fed;Continental breakfast|10 mg IR tablet, intact (fed; Continental breakfast)
1893918|NCT01286948|Drug|Levonorgestrel (LNG) gel (Levogel) and oral LNG (Plan B)|"This is a randomized study with a cross-over design comparing two single dose treatment sequences of either Levogel (LNG vaginal gel 0.750 mg/4g) or oral LNG (1.5mg).
All women with a leading follicle diameter of ≥18 mm will be randomized to treatment with a single intra-vaginal application of LNG gel or oral LNG. After a washout cycle, the women will be crossed over to receive the other treatment and the study procedures will be repeated."
1893919|NCT01286961|Drug|bowel preparation using split dose of polyethylene glycol|polyethylene glycol, split dose(2L/2L), each dose for 1-2hours
1893920|NCT01286974|Drug|[14C]linifanib|[14C]linifanib, single administration, oral liquid
1893921|NCT01286974|Drug|ABT-869, linifanib|linifanib once a day (QD), oral tablet
1893922|NCT01286987|Drug|Talazoparib|Oral capsule with multiple dosage forms given once daily
1893930|NCT01287039|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
1893931|NCT01287039|Drug|Placebo|Matching placebo (20 mM sodium acetate, 7% sucrose), administered intravenously (iv) once every 4 weeks over 52 weeks, for a total of 13 doses administered. Each patient received a specific volume of placebo to match the volume of reslizumab on the basis of the patient's body weight.
1893932|NCT01287052|Drug|Nitrous Oxide|Once consent is obtained, the research assistant will notify the charge RN and MD of the patient's study participation. The patient will then be placed in a treatment room and nitrous oxide will be administered per the existing protocol. Each participant will be given nitrous oxide until he/she reports a pain score of zero or up to fifteen minutes. Study subjects will be asked to rate their pain on a scale of 0-10 before the treatment and after the treatment, the time duration of administering nitrous oxide will be recorded. In addition, the pain scores at 30, 60, 90, and 120 minutes post baseline measurement will be collected in order to evaluate the sustained effect of nitrous oxide in treating acute migraine pain. Someone from the study will also make a follow-up phone call 24 - 48 hours to see if pain relief persisted.
1893933|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) AM|Inhalation powder
1893934|NCT01287065|Drug|FF(100mcg)/Vilanterol(25mcg) PM|Inhalation powder
1893935|NCT01287065|Drug|Placebo AM|Inhalation powder
1893936|NCT01287065|Drug|Placebo PM|Inhalation powder
1893938|NCT01287091|Drug|GDC-0980|Oral tablet dose
1893939|NCT01287091|Drug|GDC-0980|Oral capsule dose
1893940|NCT01287091|Drug|GDC-0980|Oral tablet dose in fed state
1893941|NCT01287091|Drug|GDC-0980|Oral repeating dose in fasting state
1893942|NCT01287091|Drug|GDC-0980|Oral repeating dose in fed state
1893943|NCT01287091|Drug|GDC-0980|Oral tablet in a fasting state
1893944|NCT01287091|Drug|rabeprazole|Oral repeating dose
1894267|NCT01280695|Drug|Pioglitazone|Pioglitazone 45 mg Capsules
1893951|NCT01287182|Drug|Ateronon|Ateronon daily for 3 months
1893952|NCT01287195|Drug|Oral OKT3|1 mg or 2 mg Oral OKT3 will be given orally to participants once daily for 30 days
1893953|NCT01287195|Drug|Omeprazole|20 mg Omeprazole will be given orally to participants once daily for 30 days
1893954|NCT01287208|Device|Activity monitor|The activity monitor is an accelerometer that records steps, distance, calories, and sleep
1893955|NCT01287208|Device|Activity device|Accelerometer that has all the steps, distance, calories, and sleep data blinded to the study subject
1893956|NCT01287221|Drug|Rifampicin|300 mg, 2 times daily
1893957|NCT01287221|Drug|placebo|placebo
1893958|NCT01287234|Other|Echocardiogram/SonR|All patients will have an echocardiograph and SonR sensor readings
1893959|NCT01287247|Biological|Xeomin®|Xeomin® (incobotulinumtoxinA) at a dose determined by the physician based upon his/her clinical experience with botulinum toxin.
1893960|NCT01287260|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg twice daily (BID)
1893961|NCT01287260|Drug|Nifedipine (Adalat, BAYA1040)|BAYA1040_Nifedipine 40mg once daily (OD)
1893962|NCT01287286|Dietary Supplement|AC-Can|Antrodia cinnamomea compounds of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
1893963|NCT01287286|Dietary Supplement|placebo|Placebo of 15 milliliters liquid per pack, oral post meal, twice in a day for 30 days
1893964|NCT01287299|Other|Low Glycemic Load diet|Pregnant women were counseled to consume a diet with a glycemic load per 1000 kcal of less than 55.
1893965|NCT01287299|Other|Low Fat Diet|Pregnant women were counseled to consume diets providing less than 25% of the energy as fat.
1893966|NCT01287312|Procedure|Endoscopic repair of recurrent TEF by trichloroacetic acid aplications|
1893967|NCT01287325|Drug|DNK333 100 mg twice daily|
1893968|NCT01287325|Drug|Placebo|
1893969|NCT01287338|Drug|Olopatadine|low dose
1893970|NCT01287338|Drug|Olopatadine|high dose
1893971|NCT01287351|Drug|extra-fine hydrofluoroalkane beclometasone dipropionate|
1893972|NCT01287351|Drug|Fluticasone propionate|
1893973|NCT01287364|Drug|ciclesonide hydrofluoroalkane (HFA) nasal aerosol|ciclesonide hydrofluoroalkane (HFA) nasal aerosol 80 μg once daily for one week.
1893974|NCT01287364|Drug|mometasone nasal inhalation|mometasone nasal inhalation 200 μg once daily for one week
1893975|NCT01287377|Behavioral|Telephone Counseling|Telephone counseling has several distinguishing features, namely proactive follow up counseling calls, a manualized protocol, and relapse-sensitive scheduling. The follow-up call schedule includes a reminder call if the quit date is more than one week out, a call within 24 hours of the quit attempt, another call 4-7 days after the quit date, and another call 10-14 days after the quit date.
1893976|NCT01287377|Drug|Nicotine Patches|"Subjects are randomized into one of these pharmacotherapy interventions: direct mailing of active patches with a message to start using it on their quit date, direct mailing of active patches with a message to start using it right away, or usual care patches in which no patches are sent directly (although clients may still get them through their usual channels).
For those in the usual care condition, patches will not be mailed directly to them; however, we will facilitate their use by providing a certificate that can be used by the State Medicaid program and some other insurance companies to obtain free patches. For those in the active condition, we will mail 2 weeks of patches directly to their home. All subjects will receive a 2 week starter kit with fourteen 21mg patches."
1893977|NCT01287390|Procedure|video fluoroscopy|video fluoroscopy of swallowing function at baseline, 6 months and 12 months follow-up
1893978|NCT01287390|Procedure|extra imaging|For tumor response, 2 extra CT or Fludeoxyglucose (18F)-Positron Emission Tomography (PET)/Computed Tomography (CT), and/or Magnetic Resonance Imaging (MRI) will be performed.
1893979|NCT01287390|Other|scoring acute toxicity|Acute toxicity scoring, based on Common Toxicity criteria (CTC) version 2.
1893980|NCT01287390|Other|scoring of late toxicity|Scoring of late toxicity with the 'late effects in normal tissues subjective, objective, management and analytic'(LENT-SOMA) scale.
1893981|NCT01287390|Other|scoring quality of life (QOL)|Quality of life is scored with the Quality of Life Questionnaire of the 'European Organisation for Research and Treatment of Cancer' (EORTC QOL-C30) and the Head and Neck Cancer Specific Quality of Life Questionnaire (QLQ-H&N 35).
1893982|NCT01287403|Other|Refined wheat flour|A treated cereal flour mixed with milk.
1893983|NCT01287403|Other|Esterase wholegrain wheat flour|A treated cereal flour mixed with milk.
1893984|NCT01287403|Other|Wholegrain wheat flour|A treated cereal flour mixed with milk.
1893985|NCT01287403|Other|Liquid whole grain wheat flour|A treated cereal flour mixed with milk.
1893986|NCT01287403|Other|Wholegrain barley flour|A treated cereal flour mixed with milk.
1893987|NCT01287403|Other|Liquid wholegrain barley flour|A treated cereal flour mixed with milk.
1893988|NCT01287416|Behavioral|Applied Suicide Intervention Skills Training|Applied Suicide Intervention Skills Training (ASIST) is a 2-day, 14 hour suicide intervention skills training workshop.
1893989|NCT01287416|Behavioral|Resilience Retreat|The Resilience Retreat is a 2-day, 14 hour session
1893990|NCT01287429|Other|lung and pleural ultrasound|After the initial diagnostic work-out (medical history, physical examination, EKG, arterious blood gas), the emergency physician will classify dyspnoea in cardiogenic or respiratory dyspnoea and write it down in a specific form (clinical form). Immediately after this, lung and pleural ultrasound will be performed: the physician will describe it and evaluate the etiology again (integrated evaluation form). Then a chest X-ray evaluation will be performed for each patient.
1893991|NCT01287442|Procedure|Trabeculectomy|A scleral flap is created. The aqueous humor is so guided under the conjunctiva to lower IOP.
1893992|NCT01287455|Drug|"Vitamin D3 as BABY D3"|drops, 70 drops (= 14000 units), once weekly for 6 weeks
1893993|NCT01287455|Other|placebo|drops, 70 placebo drops, once weekly for 6 weeks
1893994|NCT01287481|Behavioral|Stress and Emotions|Focus on emotions, writing about stress, assertiveness training, role playing new ways to handle relationships, and sharing feelings and experiences with others.
1893995|NCT01287481|Behavioral|Thoughts and Behaviors|Focus on cognitive and behavioral skills, such as relaxation, increasing pleasant activities, pacing, and changing ways of thinking.
1893996|NCT01287481|Behavioral|Brain and Body|Focus on the empowering patients by providing the latest scientific information about fibromyalgia, including causes, the role of the nervous system, and various treatments.
1893997|NCT01287494|Drug|Sertraline|dosage form: Capsule dosage: 50-200mg/d frequency: once per day duration: 16 weeks
1893998|NCT01287507|Dietary Supplement|Lactoferrin (bovine origin)|Bovine lactoferrin 200 mg/daily, given with either human milk or preterm formula
1893999|NCT01287520|Drug|LY2090314|Administered intravenously
1894000|NCT01287520|Drug|pemetrexed|Administered intravenously
1894001|NCT01287520|Drug|Carboplatin|Administered intravenously
1894002|NCT01287533|Drug|Ibandronate|monthly dosage of ibandronate 150mg
1894003|NCT01287533|Drug|Placebo|monthly dosage of placebo
1894004|NCT01287546|Drug|LY2875358|Part A Dose escalation of LY2875358 administered intravenously (IV), Day 1 and 15 every 28 days for at least two cycles.
1894005|NCT01287546|Drug|LY2875358 + erlotinib|Part A2 Dose escalation of LY2875358 administered IV, on Day 1 and 15 every 28 days for at least two cycles in combination with daily erlotinib dosing (150 mg) taken orally (PO).
1894006|NCT01287546|Drug|LY2875358 at Part A highest dose|Part B (Dose Exploration): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles.
1894007|NCT01287546|Drug|LY2875358 at Part A highest dose + trametinib|Part B (in combination with trametinib): LY2875358 at Part A highest dose administered IV, on Day 1 and 15 every 28 days for at least two cycles, in combination with trametinib at 2 mg orally once daily
1894008|NCT01287585|Drug|ADI-PEG 20 (arginine deiminase formulated with polyethylene glycol)|18 mg/m2, weekly, intramuscular, until disease progression or toxicity.
1894009|NCT01287585|Drug|Placebo|weekly, intramuscular, until disease progression or toxicity.
1894015|NCT01287611|Procedure|Purse string closure technique|Uterine Kerr incision will be closed with purse string suture
1894016|NCT01287611|Procedure|Continuously locked closure technique|Uterine Kerr incision will be closed with continuously locked suturing
1894017|NCT01287624|Drug|Gemcitabine,cisplatin|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Cisplatin 75 mg/m2, IV drip 120 minutes, D1
1894018|NCT01287624|Drug|Gemcitabine, Paclitaxel|Gemcitabine 1250 mg/m2, IV drip 30 minutes, D1, D8 Paclitaxel 175 mg/m2, IV, 3h,D1
1894019|NCT01287637|Procedure|Early reversal of temporary ileostomy|Temporary ileostomy is reversed 8-13 days after the primary surgery
1894020|NCT01287637|Procedure|Standard reversal of temporary ileostomy|Patients in the control group will have the ileostomy reversed according to standard treatment, which is 12-26 weeks after primary operation
1894021|NCT01287663|Drug|Permethrin impregnated|
1894022|NCT01287663|Drug|no Permethrin impregnated|
1894023|NCT01287689|Other|Immunoglobulin G (IgG)|Not applicable. All interventions are at the discretion of the investigator. All marketed IgG formulations can be documented.
1894024|NCT01287702|Dietary Supplement|Delayed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
1894025|NCT01287702|Dietary Supplement|Dealyed feeding|patients with acute bleeding varices arrested by EVL, will receive feeding 48 hours after EVL
1894026|NCT01287702|Dietary Supplement|Early feeding|patients receiving EVL will receive liquid diet since 4 hours after arresting of variceal bleedingpatients with acute bleeding varices arrested by EVL
1894027|NCT01287715|Drug|etanercept|Discontinuation of etanercept (half of the dosis for 3 months and discontinuation thereafter)
1894028|NCT01287715|Drug|etanercept|Continuation of etanercept for another 9 months, and, if still meeting the eligibility criteria, discontinuation of etanercept thereafter.
1894029|NCT01287728|Drug|Treatment BY METROMIDAZOLE|Abnormal vaginal flora (a Nugent score of 4-10 or 3 Amsel criteria) will be treated with 2g of oral metronidazole
1894030|NCT01287741|Drug|Rituximab|Rituximab at a dose of 375 mg/m^2, administered by intravenous (IV) infusion on Day 1 of each 21-day cycle for 8 cycles.
1894031|NCT01287741|Drug|Obinutuzumab|Obinutuzumab 1000 mg IV infusion, administered on Day 1 of each 21-day cycle for 8 cycles. During Cycle 1, obinutuzumab was also infused on Days 8 and 15.
1894032|NCT01287741|Drug|Cyclophosphamide|Cyclophosphamide 750 milligrams per square metre (mg/m^2), administered intravenously (IV) on Day 1 of each 21-day cycle.
1894033|NCT01287741|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV, administered on Day 1 of each 21-day cycle.
1894034|NCT01287741|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV, administered on Day 1 of each 21-day cycle.
1894035|NCT01287741|Drug|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone), administered orally on Days 1-5 of each 21-day cycle.
1894036|NCT01287754|Drug|erlotinib [Tarceva]|150 mg daily orally
1894037|NCT01287767|Behavioral|A multidimensional support program|Counseling, education and problem-solving in support group, ad hoc counseling
1894038|NCT01287780|Device|Collagen-gentamicin sponge|A 10 by 10 cm sponge consisting of 280 mg collagen and 130 mg gentamicin.Two sponges are inserted during hemiarthroplasty surgery, one in the joint and one underneath the fascia at the time of surgical closure.
1894039|NCT01287793|Drug|tigecycline|intravenous, 200 mg, single dose
1894040|NCT01287793|Drug|tigecycline|intravenous, 50 mg, single dose
1894041|NCT01287793|Drug|moxifloxacin|oral tablet, 400 mg, single dose
1894042|NCT01287793|Drug|100 mL 0.9% Sodium Chloride intravenous|intravenous fluid, 100 mL, single dose
1894043|NCT01287793|Drug|placebo|0.9% Sodium Chloride intravenous 100mL, single dose
1894044|NCT01287806|Drug|ulinastatin|Resolved 4 vials of drugs in 100ml physiological saline solution,intravenously infused for 1-2h,tid,for continuous 10days
1894045|NCT01287806|Drug|blank group|standard treatment
1894048|NCT01287845|Drug|BAY1075553|Cancer patients, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
1894049|NCT01287845|Drug|BAY1075553|Healthy volunteers for dosimetry, single intravenous bolus injection of 300 MBq BAY1075553 over 60 seconds on the treatment day 1
1894050|NCT01287858|Drug|AC430|Healthy volunteers will either receive AC430 or placebo.
1894051|NCT01287884|Other|Venous Blood Gas|patients who have been identified by the treating physician as needing an ABG will receive an VBG is they consent to take part in the study
1894052|NCT01287897|Drug|PF-04236921 SC injection|Placebo delivered SC, 2 doses separated by 4 weeks
1894053|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 1 delivered SC, 2 doses separated by 4 weeks
1894054|NCT01287897|Drug|PF-04236921 SC injection|Drug dose level 2 delivered SC, 2 doses separated by 4 weeks
1894055|NCT01287910|Other|Cardiac MRI|Cardiac MRI within 30 days prior to TMR procedure and 6 months after TMR procedure.
1894056|NCT01287936|Biological|SB623|SB623, a modified stem-cell product, will be administered at 3 dose levels. Each patient in one of three groups will be given a dose of 2.5, 5.0, or 10 million cells once. Each group will be completed before going to the next higher-dose group.
1894057|NCT01287949|Biological|Diphtheria, tetanus, polio and pertussis vaccination|1 dose of REPEVAX (0.5 mL) at Day 0, 1 dose of REVAXIS (0.5 mL) 1 month later and 1 dose of REVAXIS 6 month later
1894058|NCT01287962|Drug|apatinib|750 mg，po，QD； 28 days every cycle
1894059|NCT01287962|Drug|placebo|po，QD； 28 days every cycle
1894060|NCT01287975|Other|Occupational Therapy|"Use of conventional manual facilitation and function-based training used in conventional occupational therapy training for post-stroke upper limb weakness.
Training is modelled along the neurodevelopmental techniques and will include stretching, tone management, weight bearing exercises, movement facilitation, selfcare training, arm ergometry by arm bicycles and grip strength training.
Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively."
1894061|NCT01287975|Device|BCI Haptic Knob|BCI based robotic rehabilitation works by detecting the motor intent of the user from electroencephalogram signals to drive the robotic rehabilitation via Haptic Knob. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
1894062|NCT01287975|Device|Haptic Knob|Haptic Knob is an upper limb robot designed for use in robotic-assisted rehabilitation of the stroke wrist and hand. Training intensity is 1.5 hours for 3 times a week for 6 weeks consecutively.
1894063|NCT01287988|Drug|ocriplasmin|Subjects were exposed to a single intravitreal injection of 125µg of ocriplasmin in a previous phase III study TG-MV-006 or TG-MV-007
1894064|NCT01287988|Drug|placebo|Subjects were exposed to a single intravitreal injection of placebo in a previous phase III study TG-MV-006 or TG-MV-007
1894065|NCT01288001|Drug|Ostenil plus|2% Sodium Hyaluronate plus Mannitol injection
1894066|NCT01288027|Biological|Alglucosidase Alfa|Alglucosidase alfa intravenous infusion 20 milligram per kilogram (mg/kg) every other week for 24 weeks.
1894067|NCT01288040|Behavioral|Split Belt treadmill|A split belt treadmill is like a typical treadmill that is seen in the gym, except that this treadmill has two belts that move instead of just one. One leg goes on one belt and the other leg uses the other belt. The belt speeds can be set to get at the same speed, making this treadmill similar to any regular treadmill, but, belt speeds can also be set so that one belt moves a little faster than the other. The belts are never set at a running or jogging speed, only a self-paced walking speed regardless of whether the belts are both going the same speed or both going slightly different speeds.
1894069|NCT01288066|Procedure|Hemiarthroplasty|Patients are treated with hemi shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
1894070|NCT01288066|Procedure|Total arthroplasty|Patients are treated with total shoulder arthroplasty with CE marked medical devices of the Epoca system. This procedure is a standard treatment for patients with a degenerative shoulder disease.
1894071|NCT01288079|Drug|TC-5214|Tablet, oral, twice daily for 8 weeks
1894072|NCT01288079|Drug|Duloxetine|Capsule, oral, once daily
1894073|NCT01288079|Drug|Placebo|Tablet, oral, twice daily for 8 weeks
1894074|NCT01288092|Drug|BEZ235|
1894075|NCT01288105|Device|Optical coherence tomography|Optical coherence tomography will be performed to determine the stent strut coverage. Patients in whom >95% of stent struts are covered will not receive perioperative bridging with a glycoprotein IIb/IIIa inhibitors, whereas those with <95% stent strut coverage will receive perioperative bridging.
1894076|NCT01288131|Drug|Cyclosporine combine with mycophenolate mofetil|Cyclosporine 100 mg BID and mycophenolate mofetil 750 mg BID for 24 weeks
1894077|NCT01288131|Drug|Cyclophosphamide + pred|Cyclophosphamide 100 mg QD combine with prednisolon 1.0 mg/kg/day
1894078|NCT01288144|Other|Quality improvement initiative|In intervention clinics, the LMR will use the existing reminder function to alert providers that a patient has a probable history of gestational diabetes. The provider will then have the opportunity to clarify the subject's history and order appropriate screening testing. Providers will also have access to online reference material regarding GDM follow-up screening and lifestyle interventions.
1894079|NCT01288157|Drug|Golimumab|Single dose of 100 mg subcutaneously
1894080|NCT01288157|Drug|Golimumab|Single dose of 50 mg subcutaneously
1894081|NCT01288170|Drug|Nebcinal Tobi|
1894082|NCT01288170|Drug|Tobi Nebcinal|
1894085|NCT01288196|Drug|Placebo IV|A single 30-minute IV infusion of placebo
1894086|NCT01288196|Drug|CNTO 6785 1 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 1 mg/kg
1894087|NCT01288196|Drug|CNTO 6785 3 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 3 mg/kg
1894088|NCT01288196|Drug|CNTO 6785 10 mg/kg IV|A single 30-minute IV infusion of CNTO 6785 10 mg/kg
1894089|NCT01288196|Drug|CNTO 6785 SC|A single SC dose of CNTO 6785 (3 mg/kg) administered in up to 3 SC injections
1894090|NCT01288196|Drug|Placebo SC|A single SC dose of placebo administered in up to 3 SC injections
1894091|NCT01288209|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 or 24 weeks.
1894092|NCT01288209|Drug|Peginterferon alfa-2a (PegIFNα-2a )|PegIFNα-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks.
1894093|NCT01288209|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
1894094|NCT01288222|Biological|KIR genotype|KIR genotype from unrelated donor.
1894095|NCT01288222|Biological|Unrelated donor transplant|hematopoietic cell transplant performed per each center's guidelines
1894097|NCT01288248|Device|Airway laryngeal mask classic|"This group includes patients with the randomization process are assigned to use Classic laryngeal mask as a method to secure the airway after induction of anesthesia, which will be maintained during surgery and removed the patient asleep once you are done the surgical procedure to determine the presence or absence of laryngospasm.
The laryngeal mask mark to be used will laryngeal Mask Device ® which comes in different sizes and sterilized in ethylene oxide. The size of the Classic laryngeal mask is used according to the weight assigned"
1894098|NCT01288248|Device|endotracheal tube|"This group includes patients with the randomization process are allocated to use endotracheal tube method for securing the airway after induction of anesthesia, which will be maintained during surgery and removed in the awake patient when you finish the surgical procedure to determine the presence or absence of laryngospasm.
The marks of the endotracheal tube will be one of the following: Kendall Curity ®, Well Lead Medical ®, Meditec ®, which are not reusable. The size of the endotracheal tube be allocated according to age."
1894099|NCT01288261|Drug|paclitaxel|Given IV
1894100|NCT01288261|Biological|bavituximab|Given IV
1894101|NCT01288261|Other|laboratory biomarker analysis|Correlative studies
1894102|NCT01288261|Other|pharmacological study|Correlative study
1894103|NCT01288274|Other|Community Based administration of DMPA|Injectable contraceptive administered by clinic based health extension worker or community based reproductive health agent using same protocol to test equivalence of community based distribution to facility based distribution
1894104|NCT01288300|Behavioral|Picture good health/Imaginate una buena salud|Diabetes education, self-empowerment training, exercise, patient navigator
1894105|NCT01288300|Behavioral|Diabetes lecture|Diabetes self-management lecture
1894106|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive 30gr/day rapeseed oil. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
1894107|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive diet associating 30gr/day of rapeseed oil and n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
1894108|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women will receive with 30gr/day n-3 margarine. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
1894109|NCT01288313|Dietary Supplement|nutritional intervention|Each diet will last 30 days. During the first period of 15 days, the mothers will receive mediterranean diet based on olive oil. Then, lactating women receive 30gr/day olive oil (standard group. Human milk will be collected during the first breastfeeding of the day (10 ml) at three times : Days 0 corresponding to the usual diet , at day 15 after the Mediterranean diet and at day 30, after the study diet.
1894110|NCT01288326|Drug|liraglutide|Liraglutide will be prescribed and titrated (individually adjusted) by the treating physician.
1894111|NCT01288339|Drug|Panitumumab + FOLFOX (DP)|Panitumumab and FOLFOX will be administered to patients with DP once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
1894112|NCT01288339|Drug|Panitumumab + FOLFOX (no-DP)|Panitumumab and FOLFOX will be administered to patients with no-DP (MMP7+/p-IGF-IR-, MMP7-/p-IGF-IR+ or MMP7-/p-IGF-IR) once every 14 days until 6 months of treatment or until disease progression (PD) or unacceptable toxicity. If patients have not progressed after 6 months of treatment with panitumumab and FOLFOX they will continue with panitumumab monotherapy until disease progression.
1894113|NCT01288352|Other|early standardised rhythm control|"Patients in the early therapy group will be treated following the same therapeutic recommendations of the ESC guidelines as the usual care group. In addition, rhythm control therapy will be initiated early with the aim of preventing recurrence and delaying or preventing progression of AF.
Early-onset rhythm control therapy can consist of:
Optimal antiarrhythmic drug therapy
Catheter ablation with the aim of pulmonary vein isolation (PVI),
Antiarrhythmic drug therapy and catheter ablation may be combined and supplemented by early cardioversion in patients with persistent AF.
All individual treatment decisions will be taken by the treating study physician considering the labelling of the procedures and drugs and patient preferences."
1894114|NCT01288365|Behavioral|Exercise training|Exercise training program for 3 months (two times a week).
1894115|NCT01288378|Drug|caspofungin acetate|intravenous route, at a 70 mg loading dose on day 1 of antifungal therapy, followed by 50 mg once a day thereafter.
1894650|NCT01292291|Other|study of socioeconomic and demographic variables|
1894116|NCT01288391|Drug|NNC 0128-0000-2011|Single dose of 100 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
1894117|NCT01288391|Drug|NNC 0128-0000-2011|Single dose of 200 mcg/kg NNC128-0000-2011 administered i.v. (intravenously)
1894118|NCT01288404|Drug|Fluorometholone|topical 0.1% fluorometholone eye drops 4 times daily for 4 weeks
1894119|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 1.25 mg/0.05mL
1894120|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 2.5 mg/0.1mL
1894121|NCT01288404|Drug|Bevacizumab|subconjunctival bevacizumab 3.75 mg/0.15mL
1894122|NCT01288417|Drug|boceprevir|10 days of boceprevir 800mg TID
1894123|NCT01288417|Drug|raltegravir|raltegravir 400mg single dose
1894124|NCT01288430|Drug|DS-2248|Oral capsules, of various strengths (1, 5 , 20 ,or 50 milligrams), once daily during 21-day cycles, until unacceptable treatment-related toxicity or tumor progression are observed.
1894125|NCT01288443|Drug|Alirocumab|Two SC injections in the abdomen only.
1894126|NCT01288443|Drug|Placebo (for alirocumab)|Two subcutaneous (SC) injections in the abdomen only.
1894127|NCT01288443|Drug|Atorvastatin|Orally once daily at a stable dose of 10 mg, 20 mg, or 40 mg as background therapy.
1894128|NCT01288469|Drug|Alirocumab|One subcutaneous (SC) injection in the abdomen only.
1894129|NCT01288469|Drug|Placebo (for alirocumab)|One SC injection in the abdomen only.
1894130|NCT01288469|Drug|Atorvastatin|Over-encapsulated tablet orally once daily in the evening with dinner.
1894131|NCT01288469|Drug|Placebo (for atorvastatin)|One over-encapsulated tablet of placebo for atorvastatin orally once daily in the evening with dinner.
1894132|NCT01288482|Device|AeroEclipse II breath-actuated nebulizer|The AeroEclipse II (Trudell Medicinal International, London, ON, Canada) is a breath-actuated nebulizer that allows for the creation of aerosol only in response to the patient's inspiratory flow, resulting in virtually no drug loss to the environment and providing a safer healthcare and patient environment by significantly reducing second-hand drug exposure and the possibility for transmission of viral airborne pathogens.
1894133|NCT01288482|Device|English-Wright continuous-mode nebulizer|The English-Wright is a continuous-mode nebulizer, designed to operate continuously with tidal breathing, producing an aerosol which is lost to the environment possibly posing a hazard to any fellow-patients, family members, or health-care workers in the vicinity. It is the only device recommended by the American Thoracic Society guidelines that is available on the market and it has recently been discontinued. For these reasons it is necessary to review the use of other nebulizers and validate their performance.
1894134|NCT01288495|Dietary Supplement|supplemental L-alanine|Subjects will consume l-alanine prior to eating fructose-containing foods.
1894135|NCT01288495|Dietary Supplement|Metamucil|Subjects will consume the placebo prior to eating fructose-containing foods.
1894136|NCT01288508|Dietary Supplement|Supra Fiber|2 tablespoons of fiber taken with 8oz water taken twice a day for 30 days
1894137|NCT01288508|Dietary Supplement|Psyllium|1 tablespoon of fiber taken with 8 oz water twice a day for 30 days
1894141|NCT01288547|Dietary Supplement|theobromine|700 mg theobromine in gelatin capsules given one time only
1894142|NCT01288547|Dietary Supplement|Caffeine|120 mg caffeine in capsules given one time only
1894143|NCT01288547|Dietary Supplement|caffeine + theobromine|120 mg caffeine and 700 mg theobromine in capsules given one time only
1894144|NCT01288547|Dietary Supplement|placebo|cellulose in capsules given one time only
1894145|NCT01288560|Other|Advanced cardiac imaging|
1894146|NCT01288560|Other|Standard Cardiac Imaging|
1894147|NCT01288573|Drug|plerixafor|160 μg/kg subcutaneous (SC) injection
1894148|NCT01288573|Drug|plerixafor|240 μg/kg subcutaneous (SC) injection
1894149|NCT01288573|Drug|plerixafor|320 μg/kg subcutaneous (SC) injection
1894150|NCT01288586|Device|Scandinavian Total Ankle Replacement System (STAR Ankle)|Total Ankle Replacement
1894151|NCT01288599|Procedure|Laparoscopic surgery|Laparoscopic surgery where adnexectomy or cystectomy is performed.
1894152|NCT01288612|Device|Sedated Endoscopy|The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
1894153|NCT01288612|Device|Transnasal Endoscopy|Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
1894154|NCT01288625|Drug|Amifostine|500 mg sc, qod, 3 times per week
1894155|NCT01288625|Radiation|Amifostine|500mg rinsing wash, qod, 3 times per week
1894203|NCT01288989|Biological|IMC-3C5|Escalating doses of IMC-3C5 administered intravenously (i.v.), weekly or every other week
1894204|NCT01289015|Drug|NAFT-600 ( naftin 2 % gel )|Topical; applied once daily for two weeks
1894205|NCT01289015|Drug|Placebo|Topical; applied once daily for two weeks
1894206|NCT01289028|Drug|Nilotinib|
1894207|NCT01289041|Drug|BKM120|
1894158|NCT01288651|Drug|Ferricarboxymaltose|"Ferricarboxymaltose (Ferinject®, Vifor Pharma) is used for intravenous iron administration. This iron is administered in high dose iron infusion of 1000 mg iron (equals 20 ml Ferinject) in 250 ml saline in the vein (infusion site)within 2 hours. During infusion, patients will be observed and blood pressure and heart rate are monitored before and after administration.
Four weeks after iron administration, iron parameters are measured in the general practitioners setting. When iron parameters are still under normal values, a repeat infusion will be given of 500 mg iron (equals 10 ml Ferinject)."
1894159|NCT01288664|Drug|ADVAGRAF|Tacrolimus Sustained-release Capsules (ADVAGRAF) Started: 0.05-0.1mg/kg/d, one time per day, the blood level:5-10ng/ml in induction phase.
1894160|NCT01288677|Drug|TMC649128|Escalated doses
1894161|NCT01288690|Behavioral|Narrative Exposure Therapy|3, 1-1/2 hour sessions, individual, meeting weekly.
1894162|NCT01288716|Drug|Arbaclofen|
1894163|NCT01288729|Device|Sure-T Steel Infusion Set Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
1894164|NCT01288729|Device|Quick-Set Teflon Catheter|Participants will wear Quick-Set Teflon Catheter or Sure-T Steel Infusion Set Catheter for 2 weeks each during the active study time
1894165|NCT01288742|Drug|Rosuvastatin|One 10-mg tablet for 1 day (Trt C).
1894166|NCT01288742|Drug|Rosuvastatin|One 10-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt D.
1894167|NCT01288742|Drug|TMC435|One 150-mg capsule once daily for 7 days (Trts B and D).
1894168|NCT01288742|Drug|Digoxin|One 0.25-mg tablet together with 1 capsule of TMC435 (150 mg) on Day 7 of Trt B.
1894169|NCT01288742|Drug|Digoxin|One 0.25-mg tablet for 1 day (Trt A)
1894170|NCT01288755|Drug|TMC278|One 25 mg tablet, once daily, for 11 days (TrtA and C)
1894171|NCT01288755|Drug|Raltegravir|One 400 mg tablet, twice daily, for 4 days (Trt B) and for 11 days (TrtC)
1894172|NCT01288768|Procedure|Knee arthroscopy|Knee arthroscopy within 4 weeks.
1894173|NCT01288781|Drug|Acetazolamide|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
1894174|NCT01288781|Drug|Lactose monohydrate|During a forty eight hour hypoxic exposure (3777m), subjects will be given either acetazolamide or placebo at hours fifteen, twenty and thirty two.
1894175|NCT01288794|Drug|Diuretics plus human albumin|The patients will receive standard medical treatment plus albumin infusion at the dose of 40 g twice weekly for 2 weeks, and then 40 g weekly for the rest of the study (up to 24 months).
1894176|NCT01288794|Drug|Diuretics (standard medical treatment)|The patients will receive standard medical treatment (diuretics)
1894177|NCT01288807|Drug|Milnacipram|Titration to 200mg PO daily
1894178|NCT01288820|Drug|Dihydroartemisinin/piperaquine + primaquine|Dihydroartemisinin 2.25mg/kg and piperaquine 16-18mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
1894179|NCT01288820|Drug|Artesunate-amodiaquine + primaquine|Standard treatment with artesunate-amodiaquine plus primaquine, with artesunate 4mg/kg and amodiaquine 10mg/kg on day 0, 1, and 2 and primaquine 15 mg/kg form day 0-13.
1894181|NCT01288859|Other|free curcumin|free curcumin in bread, dosage 1g/100g, 200g/day per 1 day
1894182|NCT01288859|Other|encapsulated curcumin|encapsulated curcumin-enriched bread, 1g/100g bread, 200g bread/day
1894183|NCT01288859|Other|encapsulated curcumin + PQG|bread enriched with encapsulated curcumin plus piperine, quercetin and genistein, 1g/100g bread, 200g bread/day
1894184|NCT01288859|Other|free cocoa polyphenol|nut cream enriched with free cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
1894185|NCT01288859|Other|encapsulated cocoa polyphenols|nut cream enriched with encapsulated cocoa polyphenols, 1,5 g/100g cream, 100g/day per 1 day
1894186|NCT01288859|Other|control nut cream|nut cream, cocoa polyphenols 0g/100g cream, 100 g/day per 1 day
1894187|NCT01288872|Drug|Praziquantel|Praziquantel (PZQ), 60 mg/kg, administered orally in split dose (30 mg/kg each dose) separated by three hours.
1894188|NCT01288885|Drug|ASP1941|Oral
1894189|NCT01288885|Drug|Placebo|Oral
1894190|NCT01288898|Drug|ASP1941|Oral
1894191|NCT01288898|Drug|Placebo|Oral
1894192|NCT01288911|Drug|enzalutamide|capsules
1894193|NCT01288911|Drug|Bicalutamide|tablets
1894194|NCT01288924|Drug|Parecoxib|Parecoxib 40 mg intravenous before surgery and every 12 hours for two days.
1894195|NCT01288924|Other|Control|NSS 2 ml intravenous before surgery and every 12 hours for two days.
1894198|NCT01288950|Dietary Supplement|Vitamin D3 (cholecalciferol)|A single oral dose of 50,000 IU of vitamin D3 (cholecalciferol) will be given prior to Bacille-Calmette-Guerin (BCG) vaccination
1894199|NCT01288963|Drug|IL-2|Observation only
1894208|NCT01289054|Drug|Tasigna|
1894211|NCT01289080|Drug|OPC-34712|administered orally
1894212|NCT01289106|Biological|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1 and 6 months
1894213|NCT01289106|Biological|Hepavax-Gene|20 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
1894214|NCT01289106|Biological|Hepavax-Gene|40 μg of Hepavax-gene intramuscularly injections at deltoid region at 0,1,2 and 6 months
1894215|NCT01289119|Drug|Alogliptin|Alogliptin tablets
1894216|NCT01289119|Drug|Placebo to alogliptin|Alogliptin placebo-matching tablets.
1894217|NCT01289119|Drug|Metformin|Stable metformin dose
1894218|NCT01289119|Drug|Pioglitazone|Stable pioglitazone dose
1894219|NCT01289132|Drug|Placebo|Placebo-matching tablets, orally, once daily for up to 12 weeks.
1894220|NCT01289132|Drug|Azilsartan|Azilsartan 5 mg, tablets, orally, once daily for up to 12 weeks.
1894221|NCT01289132|Drug|Azilsartan|Azilsartan 10 mg, tablets, orally, once daily for up to 12 weeks.
1894222|NCT01289132|Drug|Azilsartan|Azilsartan 20 mg, tablets, orally, once daily for up to 12 weeks.
1894223|NCT01289132|Drug|Azilsartan|Azilsartan 40 mg, tablets, orally, once daily for up to 12 weeks.
1894224|NCT01289132|Drug|Azilsartan|Azilsartan 80 mg, tablets, orally, once daily for up to 12 weeks.
1894225|NCT01289132|Drug|Candesartan cilexetil|Candesartan cilexetil 8 mg, tablets, orally, once daily for 4 weeks; titrated to 12 mg, tablets, orally, once daily for up to 8 weeks.
1894226|NCT01289145|Behavioral|Motivational intervention|The motivational intervention promotes positive outcome expectancies on physical activity.
1894227|NCT01289145|Behavioral|Volitional intervention|The volitional intervention promotes the formulation of action plans for physical activity.
1894228|NCT01289145|Behavioral|Active Control|Participants receive a quiz on physical activity and sports.
1894229|NCT01289171|Drug|Glycolic acid|Those who met the study criteria commenced once daily use of 15% glycolic acid lotion to the face and/or dorsal hands, with an increase to twice daily application as tolerated after two weeks of use.
1894230|NCT01289197|Behavioral|Family Check Up|Families in the intervention condition will be contacted by the parent consultant following the T1 and T2 assessments and be invited to participate in the Family Check-Up (FCU). The FCU intervention involves at least three sessions in which we expect both mother and child to participate in. First is the in-home family assessment. The second session involves rapport-building via an initial interview with the caregiver(s), referred to as the Get-to-Know-You visit, or for families already enrolled in an ongoing study, a Check-Back-In visit. The third is a Feedback Session during which the results of the assessment and initial interview are discussed with the caregiver, with attention focused on the caregiver's and child's readiness to change and the delineation of specific change options.
1894231|NCT01289210|Drug|VTX-2337 plus radiotherapy|Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.
1894232|NCT01289223|Drug|Bendamustine IV|
1894233|NCT01289223|Other|Treatment of Physicians Choice|Defined as any cancer specific therapy or best supportive care. Treatment should be given according to the label and based upon local institutional medical practice and clinical judgement.
1894234|NCT01289236|Drug|milnacipran|1 tablet (50mg) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period
1894235|NCT01289236|Drug|Milnacipran|1 tablet (100mg) BID (twice daily, approximately 12 hours apart)for 12 weeks after appropriate titration period.
1894236|NCT01289236|Drug|Placebo|1 tablet (placebo) BID (twice daily, approximately 12 hours apart) for 12 weeks after appropriate titration period.
1894237|NCT01289262|Procedure|Purse string closure technique|Uterine incision will be closed with purse string closure technique.
1894238|NCT01289262|Procedure|Continuously locked closure technique|Uterine incision will be closed with continuously locked closure technique
1894239|NCT01280617|Drug|Thymoglobulin|Thymoglobulin 1.25mg/kg dose
1894240|NCT01280617|Drug|Thymoglobulin 0.75mg/kg dose|Thymoglobulin
1894241|NCT01280643|Drug|fluorouracil|Given IV
1894242|NCT01280643|Drug|leucovorin calcium|Given IV
1894243|NCT01280643|Drug|oxaliplatin|Given IV
1894244|NCT01280643|Drug|irinotecan hydrochloride|Given IV
1894245|NCT01280643|Biological|bevacizumab|Given IV
1894246|NCT01280643|Biological|cetuximab|Given IV
1894247|NCT01280643|Drug|capecitabine|Given PO
1894248|NCT01280643|Genetic|mutation analysis|Correlative studies
1894249|NCT01280643|Genetic|gene expression analysis|Correlative studies
1894250|NCT01280643|Other|laboratory biomarker analysis|Correlative studies
1894251|NCT01280643|Other|immunohistochemistry staining method|Correlative studies
1894252|NCT01280643|Genetic|nucleic acid sequencing|Correlative studies
1894253|NCT01280643|Genetic|protein expression analysis|Correlative studies
1894254|NCT01280643|Genetic|polymerase chain reaction|Correlative studies
1894255|NCT01280643|Genetic|DNA analysis|Correlative studies
1894256|NCT01280656|Drug|Conventional Interferon|Conventional interferon according to the standard of care and aligned with the local prescription instructions
1894257|NCT01280656|Drug|Peginterferon Alfa-2a|Peginterferon alfa-2a according to the standard of care and aligned with the local prescription instructions
1894258|NCT01280656|Drug|Peginterferon Alfa-2b|Peginterferon alfa-2b according to the standard of care and aligned with the local prescription instructions
1894259|NCT01280656|Drug|Ribavirin|Ribavirin according to the standard of care and aligned with the local prescription instructions
1894260|NCT01280669|Drug|Intravitreal injection 440mcg|Intravitreal injections of sirolimus 440mcg/20mcL at baseline and months 1, 2, 3, 4, and 5.
1894261|NCT01280669|Drug|Intravitreal injection of sirolimus 880mcg|Intravitreal injection of 880mcg/20mcL sirolimus at baseline and months 2 and 4.
1894263|NCT01280695|Drug|Placebo|Placebo Capsules
1894264|NCT01280695|Drug|MSDC-0602 100 mg|MSDC-0602 100 mg Capsules
1894268|NCT01280708|Other|Capture data|Capture and standardization of data of patients aged over 18 years received a kidney transplant or a simultaneous pancreas-kidney transplant from data sources will be performed by clinical research associates.The quality of data will be validated by cross annual audits. The statistical analysis will be made on a case by case according to clinical objectives.
1894269|NCT01280721|Drug|tolvaptan|Repeated oral administration twice daily (morning and evening) at one of three split dose-regimens 45mg/15mg, 60mg/30mg or 90mg/30mg.
1894270|NCT01280734|Drug|Circadin (R) 2 mg|One 2 mg tablet at 23:00
1894271|NCT01280734|Drug|Stilnox (R) 10 mg|One 10 mg encapsulated tablet at 23:00
1894272|NCT01280734|Drug|Placebo|One tablet or encapsulated tablet at 23:00
1894273|NCT01280747|Other|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
1894274|NCT01280747|Other|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
1894275|NCT01280747|Other|prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
1894276|NCT01280747|Other|no prior authorization|This is a naturalistic study. The physician will prescribe medication(s) as appropriate
1894277|NCT01280760|Other|Device: Neurally Adjusted Ventilatory Assistance|"Device: Neurally Adjusted Ventilatory Assistance
In ICU following extubation NIV was performed as follows:
facial mask with PSV/NIV mode to define settings for NAVA ventilation facial use with NAVA/NIV mode"
1894278|NCT01280773|Device|Neurally adjusted ventilatory assist|Neurally adjusted ventilatory assist (NAVA) was delivered by a SVi ventilator. NAVA utilizes EAdi, a reflection of the neural respiratory output to diaphragm, as its primary source to trigger and cycle-off assist in synchrony with neural inspiratory efforts.
1894279|NCT01280786|Drug|Elesclomol Sodium|Weekly intravenous administration of escalating doses of elesclomol sodium provided response is seen after the first 4 week cycle.
1894280|NCT01280799|Behavioral|Acceptance-based separated family treatment|Family treatment that combines Acceptance and Commitment Therapy (ACT) for the adolescent with Parent Skills Training for caregivers. The treatment package is designed to increase willingness to experience difficult thoughts, feelings, and bodily sensations in order to engage in effective behavior. To facilitate this, caregivers are provided with psychoeducation on eating disorders and skills in behavior management, self-regulation, and emotion regulation.
1894284|NCT01280838|Behavioral|Hombre Seguro|A theory-based intervention that uses principles of behavior change derived from Social Cognitive Theory (SCT), Cognitive Behavioral Therapy (CBT), Theory of Reasoned Action (TRA), and MI to increase clients' use of condoms with FSWs.
1894285|NCT01280838|Behavioral|Didactic attention-control condition|The didactic control condition is a modified version of the CDC's revised guidelines for HIV counseling, testing, and referral and materials from Mexico's National Center for AIDS Studies (CENSIDA). The one-session, 60-minute counseling intervention focuses on HIV and STI prevention, risk appraisal, and the development of a risk reduction plan.
1894286|NCT01280851|Procedure|Magnetic Resonance Imaging|1 hour of MRI exam will be performed in addition to the standard of care procedures, using low dose of gadolinium-based contrast (not investigational drug).
1894287|NCT01280877|Device|tACS|Transorbital alternating current stimulation (tACS) is applied with a multi-channel device with paraorbital montage of 4 stimulation electrodes generating weak current pulses in predetermined firing bursts of 8 to 14 pulses. The amplitude of each current pulse was below 1000 microA. Current intensity was individually adjusted according to how well patients perceived phosphenes, i.e. any sensation of flickering light in response to the rtACS stimulation.
1894288|NCT01280877|Device|Sham stimulation|tACS is applied with the same device with equal electrodes set-up procedures but only one of four channels actually delivers current. The current intensity of this channel is individually adjusted (preselected on the side of lesioned eye) according with patient able to clearly perceive single phosphenes or any skin irritation phenomena (like weak sense of needles or vibration) whenever a single pulse is applied. The amplitude of pulses is always below 1000 microA. Current pulses are given as 1 pulse per minute during 25-35 min of session time. Session duration is equal for verum and sham patients. The perception of the single pulses leaves sham patients at the impression that they might receive the verum intervention, but total number of pulses is less than 0,5% of verum tACS.
1894289|NCT01280890|Behavioral|Staff training using VIPS|Staff training using the VIPS framework
1894290|NCT01280890|Behavioral|Staff training using DCM|The staff will be supervised using Dementia Care Mapping
1894291|NCT01280890|Behavioral|Control group|Filmed traditional Lectures will be given to care staff
1894319|NCT01289457|Drug|Clofarabine|"Phase I: 15 mg/m2 by vein (IV) daily for 5 days of a 28 day cycle.
Phase II: Clofarabine (dose selected based on Phase I portion) by vein over approximately 1 hour daily for 5 days (days 1-5) for a 28 day cycle."
1894294|NCT01280916|Behavioral|Mindful Awareness in Body-oriented Therapy|8 weekly sessions of 1.5 hours each delivered to women in substance use disorder treatment
1894295|NCT01280929|Procedure|Panretinal Photocoagulation (PRP)|
1894296|NCT01280929|Drug|Intravitreous injection of ranibizumab|
1894300|NCT01289288|Behavioral|Mailed printed materials and in-office training|"Mailed printed materials including CRC physician guide, patient brochure, flip chart and a poster
Two sessions of in-office training with two standardized patients"
1894301|NCT01289301|Drug|mTOR inhibitor (everolimus)|calcineurin-inhibitor based immunosuppression will be switched to immunosuppression based on m-TOR inhibitor (everolimus trough level 3-7ng/mL)
1894302|NCT01289301|Drug|cyclosporine or tacrolimus|calcineurin inhibitor (cyclosporine or tacrolimus) will be continued (trough level 60-90ng/mL resp 3-7ng/mL)
1894303|NCT01289314|Procedure|TLH|Total laparoscopic hysterectomy (TLH)
1894304|NCT01289314|Procedure|Laparoscopic supracervical hysterectomy|Laparoscopic supracervical hysterectomy (LSH)
1894305|NCT01289327|Drug|Sedation with Propofol or Midazolam+Alfentanil for FFB|Sedation was started with intravenous injection of a bolus of 2-4 mg midazolam and 0.5 mg alfentanil or 20-50 mg propofol. It was maintained with intermittent boluses of 1-3 mg intravenous midazolam or 0.5 mg intravenous alfentanil, according to clinical judgment, or with boluses of 10-20 mg intravenous propofol, administered at short intervals (~2 minutes) or according to clinical judgment.
1894306|NCT01289353|Drug|Carboplatin|IV, weekly for 6 weeks, AUC of 2.0
1894307|NCT01289353|Radiation|3D-RT or IMRT|"From week 2 to week 4 in the 6-week Carboplatin treatment:
Whole Breast 3D-RT or IMRT at 2.7 Gy X 15 fractions (5 times/wk x 3 wks=40.50 Gy), then the second and third Friday, 3 Gy to the tumor bed only X 2 fractions, Total dose to tumor bed = 46.5 Gy"
1894308|NCT01289366|Device|Endocytoscopy|Patients with Crohn's disease and ulcerative colitis who underwent colonoscopy are prospectively included in this study. Methylene blue or toluidine blue is topically applied to enable EC (XEC-120-U, Olympus, Tokyo, Japan). Data are digitally saved and analyzed independently from each other by two gastroenterologists and one pathologist who are blinded to clinical and endoscopic data.
1894309|NCT01289379|Procedure|High Frequency Jet Ventilation|
1894310|NCT01289379|Procedure|HFJV|
1894311|NCT01289392|Device|Continuous Positive Airway Pressure (CPAP)|Previously determinated airway pressure: used for two months unassociated with physical exercise and used for four months associated with physical exercise
1894312|NCT01289392|Device|Oral Appliance (OA)|Anterior mandibular repositioner: used for two months unassociated with physical exercise and used for four months associated with physical exercise
1894313|NCT01289392|Behavioral|Physical Exercise|aerobic and resistance Physical exercise, three times a week, for four months
1894314|NCT01289405|Device|Continuous Positive Airway Pressure (CPAP)|mechanical splint to open airway during sleep, considered the gold standard treatment for patients with obstructive sleep apnea
1894315|NCT01289431|Drug|Mapracorat|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
1894316|NCT01289431|Drug|Vehicle|administered daily to each eye for 2 weeks following allergen challenge using a CAC model
1894317|NCT01289444|Behavioral|FAmily CEntered (FACE) ACP|Three-60 to 90 minute sessions scheduled one week apart: 1) To assess values, spiritual and other beliefs, and life experiences with illness and EOL care & when to initiate advance care planning. 2) To facilitate conversations and shared decision-making between the adolescent and guardian/surrogate about palliative care & prepare the surrogate to be able to fully represent the adolescent's wishes. 3) Which person the teen wants to make health care decisions for him/her; The kind of medical treatment the teen wants; How comfortable the teen wants to be; How the teen wants people to treat him/her; What teen wants loved ones to know; Any spiritual or religious concerns teens may have.
1894318|NCT01289444|Behavioral|Healthy Living Control|"Active Comparator: Three 60 to 90 minute sessions scheduled one week apart. 1. Developmental History. Goal: To take a non-medical developmental history. The RA-Control will conduct the session in a structured interview format. Administered with all medical questions removed to prevent any risk of contamination with the experimental condition. 2. Safety Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures counseling guides. Participants will be asked questions about seat belt use, etc. Safety information will be provided.
3. Nutrition Tips. Goal: To provide safety information using the American Academy of Pediatrics Bright Futures nutrition/counseling guides."
1894405|NCT01290575|Drug|BMS-820132|Capsule, Oral, 5 mg, twice daily, 14 day
1960774|NCT03125226|Device|Polyethylene Glycol Hydrogel|Given TracelT hydrogel via injection
1894320|NCT01289457|Drug|Idarubicin|10 mg/m2 by vein over approximately 30 minutes daily for 3 days (days 1-3) of a 28 day cycle.
1894321|NCT01289457|Drug|Cytarabine|1 g/m2 by vein over approximately 2 hours daily for 5 days (days 1-5) for a 28 day cycle.
1894322|NCT01289457|Drug|Fludarabine|30 mg/m2 by vein over approximately 30 minutes daily for 5 days (days 1-5).
1894323|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
1894324|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
1894325|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
1894326|NCT01289483|Drug|fospropofol|After the initial bolus dose of study drug is given, a maximum of two supplemental doses of fospropofol at 25% of the initial dose will be permitted. Fospropofol supplements will be administered every 4 min
1894327|NCT01289496|Drug|Peg-interferon alpha-2a, Ribavirin|"4 weeks RBV priming;
24 or 48 weeks of Pegasys+Ribavirin (RBV) Treatment (depending on genotype);
24 weeks Follow-Up
Patients will receive PEGASYS® 180 µg in 0.5 mL (prefilled syringes) administered sc once weekly. Specific guidelines for adjusting the dose of PEGASYS® are provided in the product monograph.All PEGASYS® administrations will be via the sc route using sterile technique.
Ribavirin 200 mg tablets"
1894328|NCT01289509|Drug|E5501|Lot P01010ZZA (test) single oral doses of 40 mg tablets.
1894329|NCT01289509|Drug|Drug: E5501|Lot P97001ZZB (reference) single oral doses of 40 mg tablets.
1894330|NCT01289522|Biological|cetuximab IV|"Cetuximab 400 mg/m² over 120 minutes on day 1 of cycle 1 only.
Cetuximab dose will be 250 mg/m² IV over 60 minutes weekly on subsequent administrations during the four cycles of chemotherapy.
Cetuximab dose will be 500mg/m2 IV every 2 weeks during the maintenance therapy.
Drug: Cisplatin IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles
Drug: Docetaxel IV : 75 mg/m2 intravenous every 3 weeks for 4 cycles
G-CSF support with lenograstim 150 microg./m2/day is delivered after each cycle of chemotherapy."
1894331|NCT01289522|Other|Biopsies|No intervention, only biopsy for translational project.
1894332|NCT01289535|Procedure|Blood sample|Blood sample of 7 ml
1894333|NCT01289548|Device|remote ischaemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of left lower limb ischaemia, which was induced by an automated cuff-inflator placed on the left lower limb and inflated to 300 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
1894334|NCT01289561|Drug|Alcohol + Caffeine Beverage|14 g alcohol per 180 ml total beverage combined with 60 mg caffeine per 180 ml total beverage. The alcohol and caffeine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
1894335|NCT01289561|Drug|Alcohol + Caffeine-placebo|14 g alcohol per 180 ml total beverage combined with 2.2 mg quinine per 180 ml total beverage. The alcohol and quinine will be mixed in a fruit punch beverage. Participants may self-administer as much beverage as they like with several constraints to assure safety (e.g., participants must stop drinking if their blood alcohol content is above .12 g/dl).
1894336|NCT01289574|Drug|ASC-J9|Cream for twice daily topical application to the face
1894337|NCT01289587|Behavioral|Physical activity intervention|36 sessions of physical activity offered at different frequencies
1894338|NCT01289600|Device|Mechanical ventilation|The mechanical ventilator is set to different ventilation modes as described in the individual arms.
1894339|NCT01290198|Drug|Microdialysis of fluconazole, vehicle and N(G)-nitro-L-arginine-methyl ester (L-NMMA)|At the first three visits, volunteers will receive fluconazole (650µmol/L and 6.5mmol/L) and vehicle (NaCl 0.9%), and at the fourth, these plus L-NMMA (10mmol/L), delivered by microdialysis in the forearm, with or without anesthesia. Then post-occlusive hyperemia and thermal hyperemia are performed.
1894340|NCT01290211|Drug|Maraviroc|maraviroc 300 mg BID x 5 days
1894341|NCT01290211|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 700/100 mg BID x 10 days
1894342|NCT01290211|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg BID + fosamprenavir/ritonavir 700/100 mg BID x 10 days
1894343|NCT01290211|Drug|Maraviroc|maraviroc 300 mg QD x 5 days
1894344|NCT01290211|Drug|Fosamprenavir/ritonavir|fosamprenavir/ritonavir 1400/100 mg QD x 10 days
1894345|NCT01290211|Drug|Maraviroc + Fosamprenavir/ritonavir|maraviroc 300 mg QD + fosamprenavir/ritonavir 1400/100 mg QD x 10 days
1894346|NCT01290224|Other|scrambler therapy|Undergo MC5-A therapy
1894347|NCT01290224|Procedure|sham intervention|Undergo sham procedure
1894348|NCT01290224|Other|questionnaire administration|Ancillary studies
1960775|NCT03124108|Drug|Elafibranor 80 mg|Two coated tablets daily for 12 weeks
1894350|NCT01290250|Other|Orange juice based beverage enriched in polyphenols|2 daily doses (250 ml each) during 3 months
1894351|NCT01290263|Drug|Amgen 386|"For Cohort A, AMG 386 will be administered intravenously at 30 mg/kg every week.
For Cohort B Phase I, AMG 386 will be administered intravenously at beginning at starting dose level of 15 mg/kg every week.
For Cohort B Phase II, AMG 386 will be administered intravenously at the maximum tolerated dose determined in the Phase I portion of the study every week."
1894352|NCT01290263|Drug|Bevacizumab|The dose of bevacizumab will be 10 mg/kg and will be administered intravenously every other week.
1894353|NCT01290276|Drug|Ond-PR1|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1)
1894354|NCT01290276|Drug|Ond-PR1 + MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 1 (Ond-PR1) plus 10 mg methylphenidate immediate release (Mph-IR)
1894355|NCT01290276|Drug|Ond-PR2|Single oral dose of 8 mg ondansetron pulsatile-release formulation 2 (Ond-PR2)
1894356|NCT01290276|Drug|Ond-PR2 +_ MPh-IR|Single oral dose of 8 mg of ondansetron pulsatile-release formulation 2 (Ond-PR2) plus 10 mg methylphenidate immediate release (Mph-IR)
1960776|NCT03124108|Drug|Elafibranor 120 mg|Two coated tablets daily for 12 weeks
1960777|NCT03124108|Drug|Placebo|Two coated tablets daily for 12 weeks
1894357|NCT01290289|Other|Epidura, CSE & IV|"Gp 1: received CSE analgesia: 25µg of fentanyl & a bolus dose of 10 ml of 0.5% lidocaine was injected epidurally. E top-ups of 5-10 ml of 0.5-0.8% lidocaine were then injected.
Gp 2: received CSE analgesia: 25µg of fentanyl & a bolus dose of 10 ml of 0.0625% bupivacaine was injected epidurally. E top-ups of 5-10 ml of 0.0625-0.25% bupivacaine were then injected.
Gp 3: received 50µg of E fentanyl analgesia & a bolus of 10 ml of 0.5% lidocaine was administered, followed by lidocaine E top-ups of 5-10 ml of 0.5-0.8%.
Gp 4: received analgesia: 50µg of E fentanyl & a bolus dose of 10 ml of 0.125% bupivacaine was administered, followed by E bupivacaine top-ups of 5-10 ml of 0.125-0.25%.
Gp 5: 50mg of IV pethidine was administered as loading dose, followed by 0.5 mg/kg."
1894358|NCT01290302|Drug|Luitpold Azacitidine|Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
1894359|NCT01290302|Drug|Vidaza®|Subcutaneous (SC) at a dose of 75 mg/m2 per day on days 1 and 2 of a treatment cycle
1960780|NCT03122392|Device|AMS 800|AMS 800 Artificial Urinary Sphincter
1894362|NCT01290328|Drug|Epoetin Alfa|150 units/kg/weekly
1894363|NCT01290341|Drug|NAFT-600 (naftin 2 % gel)|Topical; applied once daily for two weeks
1894364|NCT01290341|Drug|Placebo|Topical; applied once daily for two weeks.
1894365|NCT01290354|Drug|Lapatinib|Unlabelled, administered orally
1894366|NCT01290354|Drug|[11C] lapatinib|Radiolabelled, administered intravenously
1894367|NCT01290367|Biological|Single Dose MPCs Injection|Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
1894368|NCT01290367|Procedure|Single injection of saline solution|Intradiscal control injection with saline solution
1894369|NCT01290367|Procedure|Single injection of hyaluronic acid|Intradiscal control injection with hyaluronic acid
1894370|NCT01290367|Biological|Single Dose MPCs Injection|Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
1894371|NCT01290380|Drug|ASA404, DMXAA, DXAA|ASA404 (5,6-dimethylxantheone-4-acetic acid) DMXAA or DXAA
1894372|NCT01290393|Other|Data collection|Data collection from hard copy interview forms routinely used by the Organization of Teratology Information Specialists (OTIS).
1894373|NCT01290406|Drug|BEZ235|
1894374|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 1 + adjuvant / dose; Day 0 and Day 30
1894375|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 2 + adjuvant / dose; Day 0 and Day 30
1894376|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 3 + adjuvant / dose; Day 0 and Day 30
1894377|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 3 / dose; Day 0 and Day 30
1894378|NCT01290419|Biological|Placebo|Placebo; Day 0 and Day 30
1894379|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 4 / dose; Day 0 and Day 30
1894380|NCT01290419|Biological|RSV-F Particle Vaccine|Dose 4 + adjuvant / dose; Day 0 and Day 30
1894381|NCT01290432|Dietary Supplement|Inofolic Plus|Inofolic Plus contains folic acid and myoinositol and melatonin
1894385|NCT01290458|Dietary Supplement|Antioxidant vitamins|Oral supplementation with one tablet of 1 g of vitamin C (Lamberts Healthcare Ltd, UK) and one tablet of 400 IU of vitamin E (Lamberts Healthcare Ltd, UK)
1894386|NCT01290471|Drug|U3-1565|U3 1565 will be provided as a sterile, frozen solution. Each glass vial will contain 1.1 mL (1 mL extractable) of study medication with a concentration of 100 mg/mL. U3 1565 will be diluted in a final volume of 100 mL and administered by continuous IV infusion over 60 minutes. Infusion times can be extended to a maximum of 120 minutes for subjects unable to tolerate the 60 minute infusion.
1894387|NCT01290484|Drug|Sildenafil|Sildenafil oral tablet three times daily
1894388|NCT01290497|Drug|Hyaluronic acid 5 x 2.5 ml|5 intraarticular administration of Adant® 2.5ml with one week interval between administrations (standard treatment)
1894389|NCT01290497|Drug|Hyaluronic acid 1 x 5 ml|1 intraarticular administration of Adant® 5ml
1894390|NCT01290497|Drug|Hyaluronic acid 2 x 5 ml|2 intraarticular administration of Adant® 5ml with a two-week interval between administrations.
1894391|NCT01290510|Device|hyaluronic acid sodium salt|Two injections of 2 % (40 milligrams (mg) / 2 millilitres (ml)) hyaluronan in weekly interval.
1894392|NCT01290523|Device|Selective internal radiation therapy of the liver with Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 TheraSphere glass microspheres into the hepatic artery
1894393|NCT01290536|Device|Selective internal radiation therapy to the liver using Yttrium-90 glass microspheres (TheraSphere)|Administration of Yttrium-90 glass microspheres (TheraSphere) into the hepatic artery
1894394|NCT01290549|Drug|Polatuzumab Vedotin|Participants will receive escalating intravenous dose of polatuzumab vedotin.
1894395|NCT01290549|Drug|Rituximab|Rituximab will be administered by an IV infusion at 375 mg/m^2 body surface area dose q3w.
1894396|NCT01290562|Radiation|Stereotactic Body Radiotherapy (SBRT)|One or more high dose(s) of radiation to treat the tumour.
1894397|NCT01290575|Drug|Placebo|capsule, Oral, 0.0mg, twice daily, 14 day
1894398|NCT01290575|Drug|Placebo|Capsule, Oral, 0.0mg, once daily, 14 day
1894399|NCT01290575|Drug|BMS-820132|Capsule, Oral, 15mg, twice daily, 14 day
1894400|NCT01290575|Drug|BMS-820132|Capsule, Oral, 60mg, twice daily, 14 day
1894401|NCT01290575|Drug|BMS-820132|Capsule, oral, 150mg, twice daily, 14 day
1894402|NCT01290575|Drug|BMS-820132|Capsule, Oral, 300mg, twice daily, 14 day
1894403|NCT01290575|Drug|BMS-820132|Capsule, Oral, 450mg, twice daily, 14 day
1894404|NCT01290575|Drug|BMS-820132|Capsule, Oral, To be determined (TBD), once daily, 14 day
1960785|NCT03120325|Device|Vagal Nerve Stimulation|Patients will be giving themselves vagal nerve stimulation for four weeks at interval of two times a day for five minutes for four weeks. The impact of the intervention on gastroparesis symptoms will be measured by upper endoscopy biopsies, blood work, autonomic function tests, survey data, stool samples, urine sample, and saliva samples before after after the four weeks of stimulation treatment.
1894410|NCT01290614|Other|Pharmacist based QI program|Per a study protocol, the pharmacist will call each subject (who has not opted out) and discuss their CKD. In brief, the pharmacist will introduce themselves, ask the subject if they have time to discuss their medical care, inform the subject that they have CKD, briefly discuss CKD, ask the subject if they can come for labs, discuss hypertension management as appropriate, and answer any questions. In addition, for subjects with poorly controlled hypertension, the study pharmacist will arrange for a nutrition consult for a low sodium diet, a mainstay of hypertension management in patients with CKD. Finally, for patients with advanced CKD (GFR <30 mL/min per 1.73 m2) who are not seeing a nephrologist, the study pharmacist will arrange for a nephrology outpatient appointment to assess the need for placement of access for renal replacement therapy.
1894411|NCT01290614|Other|Usual Care|"Patients in the control arm will continue to receive usual care from their VA providers."
1894412|NCT01290627|Device|Subjects implanted with DePuy LCS PS RP TKA|Subjects implanted with DePuy Low Contact Stress (LCS) Poster Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
1894413|NCT01290627|Device|Subjects implanted with DePuy Sigma PS RP TKA|Subjects implanted with a DePuy Sigma Posterior Stabilizing (PS) Rotating Platform (RP) Total Knee Arthroplasty (TKA)
1894414|NCT01290640|Device|DePuy fixed-bearing Total Condylar III (TC3) TKA|
1894415|NCT01290640|Device|DePuy PFC Rotating Platform TC3 TKA|
1894416|NCT01290653|Other|Dry needling|Deep dry needling until achieving twitch response of the muscle
1894417|NCT01290653|Other|Strain-counterstrain technique|A manual technique to release tension of painful muscles.
1894418|NCT01290653|Other|Placebo manual technique|A placebo technique, consisting of manual contact of the therapist with the patient without any further therapeutic approach
1894419|NCT01290666|Device|Fistula Plug|Bioabsorbable fistula plug
1894420|NCT01290679|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 48 weeks
1894421|NCT01290679|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a or peginterferon alfa-2b and ribavirin for 24 or 48 weeks
1894422|NCT01290679|Drug|Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b)|One subcutaneous (under the skin) injection of PegIFNα-2a (containing 0.5 mL solution with 180 mcg PegIFNα-2a) OR PegIFNα-2b (0.5 mL from a pre-filled pen) once weekly for up to 48 weeks.
1894423|NCT01290679|Drug|Ribavirin (RBV)|200-mg tablets of ribavirin (Copegus or Rebetol) (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
1894425|NCT01290705|Behavioral|High exercise therapy|
1894426|NCT01290705|Behavioral|Low exercise therapy|
1894427|NCT01290718|Drug|capecitabine [Xeloda]|900mg/m2 bid po on days 1-14 of each 3-week cycle
1894428|NCT01290718|Drug|trastuzumab [Herceptin]|8mg/kg iv on day 1 of the first 3-week cycle, followed by 6mg/kg iv every 3 weeks
1894429|NCT01290731|Drug|TMC435|100-mg capsule once daily for 12 weeks
1894430|NCT01290731|Drug|Pegylated interferon (pegIFN alpha-2a)|180 mcg injected subcutaneously (by a syringe under the skin) once weekly for 12 to 36 weeks (or until Week 48).
1894431|NCT01290731|Drug|Ribavirin (RBV)|200-mg tablets (daily dose: 600-1000 mg) taken orally (by mouth) two times a day for 12 to 36 weeks (or until Week 48).
1894432|NCT01290744|Drug|Clofazimine|Clofazimine 100mg daily for 12 months after completion of MDT.
1894433|NCT01290744|Drug|Placebo|Daily for 12 months
1894434|NCT01290757|Drug|Dabigatran etexilate|150 mg Capsugel (T)
1894435|NCT01290757|Drug|Dabigatran etexilate|150 mg Qualicaps (R)
1894436|NCT01290770|Other|blood sample|blood sample at inclusion and 1 month after inclusion
1894437|NCT01290783|Drug|Irintoecan|"Irinotecan, 180 mg/m2 IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
Repeat every two weeks.
8 months of treatment."
1894438|NCT01290783|Drug|HA-Irinotecan solution for Infusion|"HA-Irinotecan (irinotecan 180 mg/m2), IV, over 90 minutes, day 1 (in patients > 75 years of age, the irinotecan dose in must be reduced to 150 mg/m2).
Leucovorin, 400 mg/m2, or levoleucovorin, 200 mg/m2, IV over 90 minutes with irinotecan.
5-FU, 400 mg/m2 IV bolus day 1, then 1200 mg/m2/day x 2 days (total 2400 mg/m2 over 46-48 hours) continuous infusion.
Repeat every two weeks
8 months of treatment."
1894439|NCT01290796|Device|Ajust Adjustable Single-Incision Sling|The Ajust™ Adjustable Single-Incision Sling is a minimally invasive suburethral sling indicated for the treatment of female SUI resulting from urethral hypermobility and/or intrinsic sphincter deficiency (ISD). The system consists of a unique adjustable polypropylene mesh sling with permanent, self-fixating, polypropylene anchors, an introducer, and a flexible stylet for securing the mesh sling after adjustment.
1894440|NCT01290822|Device|BiVP|Biventricular pacing
1894441|NCT01290822|Device|AAI Pacing|Atrial pacing
1894442|NCT01290835|Radiation|Stereotactic radiotherapy delivered by CyberKnife|Adjuvant radiotherapy will be delivered using CyberKnife radiotherapy using twice daily sessions for five days for a total of ten sessions.
1894443|NCT01290835|Radiation|stereotactic radiotherapy|
1894534|NCT01291433|Drug|Tocopherol acetate|Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
1894535|NCT01291433|Drug|Clodronic Acid|Clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
1894444|NCT01290848|Behavioral|Take TIME Health Campaign|"Provision of free, family-based events, at least twice per month, that offer opportunities for physical activity and/or healthy eating in a safe, tobacco-free environment.
Information dissemination, via project web site, media and other formats, on how to achieve a healthier lifestyle with the already hectic family schedules.
Adoption of guidelines by community organizations and the Township of Uxbridge that will reduce tobacco exposure, increase safety and promote physical activity and healthy eating for young children."
1894448|NCT01290887|Drug|Reslizumab|Reslizumab (3.0 mg/kg) administered intravenously by infusion every 28 days (±7 days), for approximately 24 months
1894449|NCT01290900|Drug|NXL104|IV Solution
1894450|NCT01290900|Drug|Ceftaroline|IV Solution
1894451|NCT01290900|Drug|Placebo Infusion|IV Saline
1894452|NCT01290900|Drug|Ceftazidime|IV Solution
1894453|NCT01290900|Drug|Moxifloxacin|Tablet (1)
1894454|NCT01290913|Drug|Omalizumab|Omalizumab is an antibody that helps decrease allergic responses in the body
1894455|NCT01290926|Drug|chemotherapy|sorafenib 600mg/day capecitabine 1250 mg/m²/day
1894456|NCT01290939|Biological|bevacizumab|
1894457|NCT01290939|Drug|lomustine|
1894458|NCT01290939|Genetic|DNA methylation analysis|
1894459|NCT01290939|Other|laboratory biomarker analysis|
1894460|NCT01290939|Procedure|cognitive assessment|
1894461|NCT01290939|Procedure|quality-of-life assessment|
1894462|NCT01290952|Procedure|Off-pump bypass surgery|is a method of performing a coronary bypass operation for the purpose of treating advanced coronary heart disease while the heart is still beating normally.
1894463|NCT01290952|Procedure|On-pump bypass surgery|is a technique that temporarily takes over the function of the heart and lungs during surgery, maintaining the circulation of blood and the oxygen content of the body.
1894464|NCT01290965|Drug|Placebo|Oral tablet given once or three times daily for 15 consecutive days
1894465|NCT01290965|Drug|SCY-635|oral capsule
1894466|NCT01290978|Drug|ChloraPrep|The application sites (subjects' backs) will be prepped with ChloraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
1894467|NCT01290978|Drug|DuraPrep|The application sites (subjects' backs) will be prepped with DuraPrep according to manufacturer's instruction. Samples of 3 surgical incise drapes will be applied to the prepped sites according to randomization schedule
1894468|NCT01290991|Device|Augment Bone Graft|Augment Bone Graft physically fills bone defects by providing a biocompatible scaffold for new bone formation.The material is comprised of a matrix of beta tricalcium phosphate and a highly purified recombinant human platelet-derived growth factor.
1894469|NCT01291004|Drug|Desogestrel/ethinyl estradiol and ethinyl estradiol|Desogestrel/ethinyl estradiol 0.15/0.02 mg and ethinyl estradiol 0.01 mg tablet
1894470|NCT01291004|Drug|28-day drospirenone oral contraceptive|Drospirenone/ethinyl estradiol 0.3/0.02 mg
1894471|NCT01291004|Drug|28-day levonorgestrel oral contraceptive|Levonorgestrel/ethinyl estradiol 0.1/0.02 mg
1894472|NCT01291017|Drug|PD0332991|PD0332991 125 mg PO days 1 - 21
1894473|NCT01291030|Dietary Supplement|magnesium supplementation|The supplementation starts with 450 mg of magnesium oxide daily, up to a maximum of 3 times 450 mg daily, while aiming at a serum magnesium level of > 1,9 mg/dl.
1894474|NCT01291043|Other|Shiatsu|8-week treatment with two Shiatsu sessions per week (50-minute duration)
1894475|NCT01291056|Other|Placebo|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
1894476|NCT01291056|Drug|Clomiphene|Each participant will take assigned medication (clomiphene citrate 50mg or placebo) on days 3-7 of her menstrual cycle.
1894477|NCT01291069|Drug|Tadalafil Citrate|If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.
1894478|NCT01291069|Drug|Sugar pill|If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days
1894479|NCT01291095|Drug|CISPLATIN|"IN CRT ARM:RADIATION ONE FRACTION PER DAY, ON FIVE CONSECUTIVE DAYS FROM MONDAY TO FRIDAY ALONG WITH INTRAVENOUS CISPLATIN 40mg/m2 WEEKLY FOR SEVEN DOSES.
IN AFRT ARM: PATIENTS WILL NOT RECEIVE ANY CHEMOTHERAPY WITH CISPLATIN"
1894480|NCT01291095|Radiation|EXTERNAL BEAM RADIOTHERAPY|Patients assigned to CRT arm will be given radiation one fraction per day, on five consecutive days from Monday to Friday along with intravenous cisplatin 40 mg/m2 weekly for seven doses (a minimum of 5weekly chemotherapy). Patients assigned to AFRT arm will undergo radiation similarly one fraction per day and then the sixth fraction will be given on another day (Saturday) or as an extra fraction on one of the first five days, but always allowing at least a 6-hour interval between fractions on same day. If any unintended interruption of the treatment occurs, this missing treatment will be given as soon as possible, preferably within a week, but not allowing more than 14 Gy to be given during any 7-day period.
1894481|NCT01291108|Drug|AGN-210669|AGN-210669 0.05% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
1894482|NCT01291108|Drug|bimatoprost|bimatoprost ophthalmic solution 0.03% applied as 1 drop in both eyes every evening during Month 1 or Month 2.
1894483|NCT01291108|Drug|bimatoprost vehicle|bimatoprost ophthalmic solution 0.03% vehicle applied as 1 drop in both eyes every evening during Month 2.
1894484|NCT01291121|Procedure|Intravitreal expansile gas and ranibizumab injection|Intravitreal expansile gas (0.3 cc C3F8) and 0.5mg ranibizumab at day 0 Additional 3 monthly loading injection of intravitreal ranibizumab Additional injection of ranibizumab as needed
1894485|NCT01291134|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
1894486|NCT01291147|Drug|Levobupivicaine|levobupivicaine 0.5% continous infusion for 48 hours
1894487|NCT01291147|Drug|0.9% Saline|0.9% saline continous infusion for 48 hours
1894536|NCT01291433|Drug|Tocopherol placebo|Placebo for Tocopherol alpha-acetate, 500 mg: 1 capsule twice a day (7d/7)
1894488|NCT01291160|Device|Epiflo|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
1894489|NCT01291160|Other|Moist Wound Therapy|During the Treatment Period, subjects will be administered EPIFLO (either working units or sham units per randomization schedule) in conjunction with standard wound therapy regimen consisting of aggressive debridement, wound cleansing, wound dressing, for a period of 12 weeks, or until the wound completely closes, whichever event occurs first.
1894490|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489-30mg capsules taken once daily for up to 11 weeks
1894491|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 50mg capsules taken once-daily for up to 11 weeks
1894492|NCT01291173|Drug|lisdexamfetamine dimesylate (SPD489)|SPD489 70mg capsule taken once-daily for up to 11 weeks
1894493|NCT01291173|Drug|Placebo|Placebo capsule taken once daily for up to 11 weeks
1894494|NCT01291186|Drug|BPV6NO|intrathecal bupivacaine 6 mg for BMI less than 27.5 kg/m2
1894495|NCT01291186|Drug|BPV7NO|intrathecal bupivacaine 7 mg for BMI less than 27.5 kg/m2
1894496|NCT01291186|Drug|BPV8NO|intrathecal bupivacaine 8 mg for BMI less than 27.5 kg/m2
1894497|NCT01291186|Drug|BPV9NO|intrathecal bupivacaine 9 mg for BMI less than 27.5 kg/m2
1894498|NCT01291186|Drug|BPV10NO|intrathecal bupivacaine 10 mg for BMI less than 27.5 kg/m2
1894499|NCT01291186|Drug|BPV11NO|intrathecal bupivacaine 11 mg for BMI less than 27.5 kg/m2
1894500|NCT01291186|Drug|BPV6O|intrathecal bupivacaine 6 mg for BMI over 27.5 kg/m2
1894501|NCT01291186|Drug|BPV7O|intrathecal bupivacaine 7 mg for BMI over 27.5 kg/m2
1894502|NCT01291186|Drug|BPV8O|intrathecal bupivacaine 8 mg for BMI over 27.5 kg/m2
1894503|NCT01291186|Drug|BPV9O|intrathecal bupivacaine 9 mg for BMI over 27.5 kg/m2
1894504|NCT01291186|Drug|BPV10O|intrathecal bupivacaine 10 mg for BMI over 27.5 kg/m2
1894505|NCT01291186|Drug|BPV11O|intrathecal bupivacaine 11 mg for BMI over 27.5 kg/m2
1894506|NCT01291199|Drug|vardenafil|10 mg p.o. bid for 6 weeks
1894507|NCT01291199|Drug|Placebo|Placebo p.o. 6 weeks bid
1894508|NCT01291212|Drug|Testosterone and FSHr-LHr|75U of LHr added to FSHr ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
1894509|NCT01291212|Drug|testosterone and FSHr alone|FSHr alone used in ovarian stimulation in IVF, when testosterone was used to improve the ovarian response
1894510|NCT01291225|Other|Playground renovation and development|Playgrounds in Chillicothe will be renovated based on priorities determined by audits.
1894511|NCT01291225|Behavioral|Educational campaign|Educational materials will be developed and distributed in Ross County.
1894512|NCT01291238|Behavioral|Healthier, Smarter, Happier|Increased physical activity and decreased sugar and fat intake during school hours
1894513|NCT01291277|Device|Endoscopic Variceal Ligation|Ligation of esophageal varices
1894514|NCT01291290|Procedure|Platelet|2 portions of platelets (one portion = pooled from 4 donors, 350ml) infused when diagnosed with rAAA and vascular surgeon accepts to receive the patient, infused before transportation.
1894515|NCT01291303|Procedure|Optimized ventilation|Patients, ventilated in pressure support mode, were ventilated with initial setting PEEP and pressure support of 4 and as maximum tolerated cmH2O, inspiratory and expiratory trigger of 5 L/min and 50% of peak inspiratory flow, with changes driven by the analysis of flow and pressure curves; with a FiO2 to reach a SpO2 level between 88 and 92%.
1894516|NCT01291303|Procedure|Standard ventilation|"Patients, ventilated in pressure support mode, were ventilated with standard setting of ventilation:
-same initial setting, same time at the bedside (15 minutes at the beginning of NIV, and 5 minutes at each patients' new evaluation) same physician that optimized ventilation mode, while the ventilator screen was obscured (numerical data were, however, always available)."
1894517|NCT01291316|Drug|Clonazepam|clonazepam, 1 mg, single oral dose
1894518|NCT01291316|Drug|Tolterodine|Tolterodine 1,37mg, single oral dose
1894519|NCT01291316|Drug|clobazam|clobazam 20 mg, single oral dose
1894520|NCT01291329|Genetic|intracoronary human umbilical WJ-MSC transfer|intracoronary infusion of WJ-MSCs or placebo medium into the infarct artery 4-7 days after successful reperfusion therapy.
1894521|NCT01291355|Other|Specific maternal position during the labor|"women allocated to intervention group will be invited to adopt a posture all fours type:support on the knees, torso tilted forward, back stretched for a minimum of 10 minutes. A cushion is placed between the legs of the woman to limit the cuts."
1894522|NCT01291381|Drug|Dermatophagoides pteronyssinus|Children undergoing subcutaneous immunotherapy were given Dermatophagoides pteronyssinus extract (Alutard SQ, ALK-Abello, Hørsholm, Denmark) according to a cluster protocol
1894523|NCT01291381|Drug|Pharmacotherapy|For patients randomized to non-SIT group, persistent rhinitis was managed with pharmacotherapy including intranasal steroids and oral antihistamines. Intranasal steroids were kept at the same dose during the study and antihistamines were used as required.
1894524|NCT01291394|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
1960800|NCT03114345|Other|Measurement of interface pressure|A capacitive pressure mapping device (XSensor) is set up on the patient air mattress bed. It records the interface pressure on the whole patient body with one frame every second during one hour. Then the file is saved and the pressure mapping device is removed from the patient hospital bedroom.
1894531|NCT01291420|Biological|autologous dendritic cell vaccination|4 biweekly intradermal DC injections of 10*10E6 DCs (500 µL) at 5 sites (100 µL/site) in the ventromedial regions of the upper arm approximately 5-10 cm of the regional lymph nodes
1894532|NCT01291433|Drug|Pentoxifylline placebo|Placebo for pentoxifylline 400 mg, 1 cp twice a day (7d/7)
1894533|NCT01291433|Drug|Pentoxifylline|Pentoxifylline 400 mg: 1 cp twice a day (7d/7)
1894537|NCT01291433|Drug|Clodronate placebo|Placebo for clodronate disodium (clodronic acid) 800 mg: 2 cp per day, 5d/7 (from monday to friday)
1894538|NCT01291446|Dietary Supplement|High flatulogenic diet|During 3-days subjects will consume a diet with high content of fermentable residues
1894539|NCT01291459|Drug|MVC/RAL/FTC/TDF followed by Maraviroc/Raltegravir|MVC/RAL/FTC/TDF 24W followed by MVC/RAL until W48.
1894540|NCT01291472|Drug|Ketorolac Tromethamine|After dilution (solution for injection, 10 mg/1ml) in 50-100 ml bag of normal saline drug will be administered by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.
1894541|NCT01291485|Behavioral|Life Steps for Medication Adherence|The intervention was adapted into an electronic version of the empirically supported Life Steps intervention for HIV medication adherence. Education about HIV and medication adherence, motivational interviewing, cognitive behavioral techniques, and problem-solving strategies to improve medication adherence and clinical outcomes in people living with HIV were also included in the intervention.
1894542|NCT01291498|Device|High Intensity Focused Ultrasound|One or two HIFU sessions
1894543|NCT01291511|Drug|Iloperidone|Iloperidone capsules/tablets will be administered orally using a bid schedule; the strengths used include 1, 2, 4, 6, 8, 10, and 12 mg.
1894544|NCT01291511|Drug|Placebo|Matching placebo capsules will be administered orally duins a bid schedule during the double-blind period.
1894545|NCT01291524|Drug|Pregabalin controlled release, 330 mg, 400 to 500 calorie|A single oral dose of 330 mg controlled release tablet administered following a 400 to 500 calorie evening meal
1894546|NCT01291524|Drug|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
1894547|NCT01291524|Drug|Pregabalin controlled release, 330 mg, bedtime|A single oral dose of 330 mg controlled release tablet administered at bedtime
1894548|NCT01291524|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
1894549|NCT01291537|Drug|Duodopa|
1894550|NCT01291537|Drug|best médical treatment|
1894551|NCT01291563|Drug|Moxifloxacin|1 capsule of moxifloxacin (400 mg/capsule) on Day 2
1894552|NCT01291563|Drug|TMC207|8 tablets of TMC207 (100 mg/tablet) on Day 1
1894553|NCT01291563|Drug|TMC207 placebo|8 tablets of TMC207 placebo on Day 1
1894554|NCT01291563|Drug|Moxifloxacin placebo|1 capsule of moxifloxacin placebo on Day 2
1894555|NCT01291576|Procedure|Rectal/colorectal segmental resection|Resection of the rectum +/- sigmoid colon involved by the deep infiltrating endometriosis
1894556|NCT01291576|Procedure|Rectal nodule excision|Either full thickness excision or rectal shaving
1894557|NCT01291589|Behavioral|Cognitive-behavioral therapy|Treatment will include elements from effective interventions for reducing risky sexual behaviors
1894558|NCT01291602|Drug|NXL104|IV Solution
1894559|NCT01291602|Drug|CAZ104|IV Solution
1894560|NCT01291602|Drug|Placebo|IV saline
1894561|NCT01291615|Drug|Gemcitabine|800mg/m2 - 1000mg/m2, day 1 every 3 weeks. day 1, 15 every 4 weeks. day 1, 8 every 3 weeks. day 1, 8, 15, every 4 weeks
1894562|NCT01291615|Drug|S-1|S-1 40mg/day - 120mg/day (depend on body surface area) day 1-14, every 3 weeks day 1-28, every 6 weeks.
1894563|NCT01291628|Device|socks containing copper-oxide fibers|The patients will use a sock which contains copper fibers. The socks are sold in the free market (different Pharma stores) for various purposes such as prevention of diabetic foot. It is a product of Cupron company EPA :84542-2, 84542-3 from April 30 2009.
1894564|NCT01291641|Drug|HMGCoA reductase inhibitor|"During the study period, HMGCoA reductase inhibitor is continuously administered to the patients.
Dosage regimen: following the package insert of each HMGCoA reductase inhibitor"
1894565|NCT01291641|Drug|HMGCoA reductase inhibitor + probucol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol is administered.
Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner)"
1894566|NCT01291641|Drug|HMGCA reductase inhibitor + probucol + cilostazol|"In addition to the continued HMGCoA reductase inhibitor treatment, probucol and cilostazol are administered.
Dosage regimen: probucol 250-mg tablet, oral administration twice daily with meal(breakfast and dinner) Cilostazol 100-mg tablet, twice daily by the oral route"
1894567|NCT01291654|Drug|Paracetamol|po Paracetamol 15 mg/kg every 6 hours x 3 days
1894568|NCT01291654|Drug|NSAID|IV indomethacin 2 mg/kg/dose for three doses at 12 hour intervals; or IV Ibuprofen 10 mg/kg infused over 15 minutes, followed by two doses of 5mg/kg each at 24 hour intervals (total of 3 doses).
1894569|NCT01291654|Drug|D5W|Since the paracetamol is given q 6 hours, in order to maintain blinding of the clinical staff, a placebo (D5W) must be given intermittently between the doses of NSAID such that each infant will receive drug every 6 hours.
1894570|NCT01291693|Behavioral|Personal Counseling|At three time-points, participants receive counseling by health professionals trained in Motivational Interviewing based counseling. To assure that both interventions do not differ in their content, individual manuals generated by a software program are used. Counseling will be face-to-face during the hospital stay, and by phone one and three months later.
1894571|NCT01291693|Behavioral|Computer-generated feedback letters|At three time points, participants receive feedback letters, tailored to the stages of change according to the TTM, and generated by a computer software program. The first letter is handed out during their hospital stay and includes normative feedback. One and three months later, participants receive ipsative feedback letters by mail.
1894572|NCT01291706|Device|Transcranial Doppler|Negative predictive value of transcranial doppler in patients with mild to moderate traumatic brain injury
1894573|NCT01291719|Device|glucose and insulin infusions|combined algorithm directed glucose and insulin infusion with 5 minute blood glucose measurements to direct glucose control; regular insulin and glucose are infused intravenously as adjusted by the algorithm without manual intervention in the group of diabetic individuals under study to adjust the glucose level to a target range of 80-180 mg/dl
1894574|NCT01291732|Drug|Matching placebo|single dose of matching placebo
1894575|NCT01291732|Drug|BI 135585 XX|single dose of low, medium or high dose of BI 135585 XX
1894606|NCT01292057|Drug|Placebo|Placebo to match active drug Aripiprazole for 8 days
1894651|NCT01292291|Procedure|diffusion-weighted magnetic resonance imaging|
1894576|NCT01291771|Procedure|Invasive FFR + CFR measurements are performed during coronary angiography using a pressure guide wire|The guide is placed in the distal segment of the coronary artery to measure instantaneously distal pressure and temperature with a tip sensor. Proximal pressure and temperature are being measured from the probe used to catheterize the coronary vessel and from the shaft of the guide. After basal measurement, intracoronary injection of 150µg of adenosine is performed to induce peripheral vasodilatation leading to hyperaemia in the vessel. Additional injection of 3mL 0.9% saline bolus at room temperature at the time of hyperaemia is performed to calculate CFR from transit mean time. FFR and CFR are being recorded at the time of hyperaemia. Subsequently IMR is being calculated from distal pressure and transit mean time. The measurements will be performed in the LAD, circumflex and right coronary arteries.
1894577|NCT01291784|Biological|monoclonal antibody to TGF-beta|starting dose of 1mg/kg intravenous over approximately 1 hour every 4 weeks for a total of 6 doses
1894578|NCT01291810|Biological|TNF Kinoid|TNF Kinoid
1894579|NCT01291810|Biological|WFI|WFI
1894580|NCT01291823|Drug|gefitinib|gefitinib 250mg/day
1894581|NCT01291823|Radiation|Thoracic radiotherapy|Thoracic radiotherapy 54-60Gy over 30 fraction
1894582|NCT01291849|Drug|Dixon up-and-down method|The target Ce of remifentanil was determined by the response of the previous patient using Dixon's up-and-down method. If the patients did not cough throughout peri-extubation period, the extubation was defined as a smooth emergence, and the predetermined concentration of remifentanil for the subsequent patient was decreased by 0.5 ng ml−1. Similarly, if the patient cough anytime around extubation it was considered as failed smooth emergence and the predetermined concentration was increased by 0.5 ng ml-1 for the next patient. The patients were enrolled until getting at least six cross-over pairs in Dixon sequential allocation method.
1894583|NCT01291862|Device|Watchpat 100|Watchpat 100 is a noninvasive portable sleep monitoring device which monitors peripheral arterial tone, pulse, oxygen saturation, snoring, and body position. Patient places one probe at his or her finger and another sensor at front of the chest and Watchpat 100 monitors the patient overnight.
1894584|NCT01291875|Procedure|non-surgical periodontal treatment|Patients in this group will receive a non surgical periodontal therapy: scaling and root planing of the root surfaces under local analgesia (depending on the severity in one session or two sessions within 2 days). Any tooth that from the baseline examination is defined as hopeless or irrationale to treat will be extracted. After to 2 months re-assessment presenting at least one periodontal site with pocket depth of 6 mm will have additional corrective periodontal therapy.
1894585|NCT01291875|Procedure|Supragingival biofilm control|Control group patients will receive a standard cycle of supra-gingival mechanical instrumentation and polishing in one appointment performed as appropriate by a single clinician using a combination of hand and machine driven (piezoelectric) instrumentation.
1960801|NCT03114345|Other|Measurement of micro-vascularization related parameters|A medical device called O2C, measuring micro-vascularization related parameters (oxygen saturation, hemoglobin quantity and blood flow) is used. The probe (= an optic fibre) is set up lightly on the patient skin or on a transparent adhesive for 1 minute. The median value of the local micro-vascularization parameters are saved on the O2C interface. The location of the measurement is chosen using the pressure mapping device to locate peak pressure area. Then the O2C is removed from the patient hospital bedroom.
1894588|NCT01291914|Drug|FX005|Single Ascending Dose (SAD) Phase Cohorts: 1, 10 or 45 mg intra-articular injection; Proof of Concept Phase: Maximum, well-tolerated dose intra-articular injection (determined during SAD Phase)
1894589|NCT01291914|Drug|Placebo 1 (Carrier)|Single intra-articular injection
1894590|NCT01291914|Drug|Placebo 2 (Diluent)|Single intra-articular injection
1894591|NCT01291927|Procedure|Pancreas-sparing duodenectomy|Pancreas-sparing duodenectomy for periampullary carcinoma is defined as resection of the descending segment of duodenum; resection of papilla of Vater; reimplantation of bile and pancreatic ducts and reconstruction of duodenum.The Japan Pancreatic Society (JPS) system for numbering of lymph node stations was adopted for accurate description of the surgery and pathological assessment.The standard lymph node groups removed as part of PSD were the anterior pancreatoduodenal groups (JPS LN17), the posterior pancreatoduodenal groups (JPS LN13), the dextroinferior nodes of the hepatoduodenal ligament node groups (JPS LN12), the infrapyloric node (JPS LN6), the nodes around the anterior aspect of the common hepatic artery (JPS LN8) and the nodes on the right side of the SMA (JPS LN14).
1894592|NCT01291927|Procedure|Pancreaticoduodenectomy|The surgical technique used for standard PD has been described before. Standard PD included clearance of all soft tissues and lymphatics immediately to the left of the superior mesenteric artery, as well as removal of the lymphoareolar tissue along the proximal hepatic artery.
1894593|NCT01291940|Other|Pediatric Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
1894594|NCT01291940|Other|Adult Moisturizer|Apply moisturizer for four weeks daily to only one arm. Do not apply moisturizer to the other arm.
1894595|NCT01291953|Procedure|Screening|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
1894596|NCT01291953|Procedure|Control|Determination of the arterial pulse and if it is arrhythmic, accomplishment of an ECG
1894597|NCT01291966|Behavioral|Motivational interview|
1894598|NCT01291979|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
1894599|NCT01291979|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
1894600|NCT01292005|Drug|Pentoxifylline|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
1894601|NCT01292005|Drug|Placebo|400 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. Subjects received up to a maximum of 9 doses.
1894602|NCT01292031|Drug|Colistin|Colistin 4.5 MU/iv plus Colistin 3 MU/iv./8 h. 30 minutes infusion
1894603|NCT01292031|Drug|Meropenem|Meropenem 2 g/iv/ 8 h. 30 minutes infusion
1894604|NCT01292044|Other|Elastography|A conventional thyroid echography performed before a the time of fine needle aspiration will include elastographic measurements for each node under study.
1894605|NCT01292057|Drug|Aripiprazole|Aripiprazole(up to 15 mg/day) for 8 days
1894607|NCT01292070|Biological|Intradermal Human Fcγ1-Fel d1 fusion protein|"Part A: 7 sequential 10-fold dose increments from 0.001 BAU/mL to 1,000 BAU/mL; An 8th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm.
Part B: 5 sequential 10-fold dose increments from 0.1 BAU/mL to 1,000 BAU/mL; An 6th dose of 10,000 BAU/mL might be given only if the 10 BAU/mL of CAT is the dose that elicits a bump or hive of >= to 10mm."
1894608|NCT01292070|Biological|Positive Control - standardized cat hair allergenic extract (CAT)|4 sequential 10-fold injections starting from 0.01 BAU/mL to 10 BAU/mL
1894609|NCT01292070|Biological|Positive Control - Histamine Prick|1.0 mg/mL
1894610|NCT01292070|Biological|Negative Control - Intradermal Diluent|Saline, Albumin with Phenol (HSA) sterile diluent
1894611|NCT01292083|Drug|azacitidine|Given IV
1894612|NCT01292083|Other|laboratory biomarker analysis|Correlative studies
1894613|NCT01292083|Other|immunohistochemistry staining method|Correlative studies
1894614|NCT01292083|Genetic|polymerase chain reaction|Correlative studies
1894615|NCT01292083|Genetic|western blotting|Correlative studies
1894616|NCT01292083|Genetic|nucleic acid sequencing|Correlative studies
1894617|NCT01292083|Procedure|therapeutic conventional surgery|Undergo definitive breast surgery
1894618|NCT01292096|Other|Provision of extra (care coordination and management) services|The pilot intervention begins at the patient's bedside in the hospital and continue after his/her discharge into the community, utilizing a flexible and intensive care management model with a multi-disciplinary team approach. Community Based Care Managers (CBCMs) overseen by a social worker, will connect patients to needed community services including housing for homeless patients, accompany patients to appointments and facilitate transportation to medical, benefits enrollment, and perform other services based in the hospital and community.
1894619|NCT01292109|Drug|sodium picosulphate|Sodium picosulphate (PICOPREP®) taken by participant prior to X-ray examination, endoscopy or surgery.
1894620|NCT01292122|Device|VCT-01|Application of bi-layered living cell-based product (VCT-01) to STSG donor site wound at Day 0
1894621|NCT01292135|Drug|PCI-32765|420 mg daily
1894622|NCT01292161|Drug|Silymarin|Tab 210 mg, 630 mg, daily, six months.
1894623|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 120 mg
1894624|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 240 mg
1894625|NCT01292174|Biological|ibalizumab (biologic/MAb) for SC Injection or placebo|ibalizumab or matching placebo administered by subcutaneous injection weekly at 480 mg
1894626|NCT01292187|Drug|Oral calcitonin at dinnertime|Oral calcitonin at dinnertime.
1894627|NCT01292187|Drug|Oral placebo at dinnertime|Oral placebo at dinnertime.
1894628|NCT01292187|Drug|Oral calcitonin at bedtime|Oral calcitonin at bedtime
1894629|NCT01292187|Drug|Oral placebo at bedtime|Oral placebo at bedtime
1894630|NCT01292200|Behavioral|watch DVD and small group discussion|Women in the small-group discussion mode will be called by their community educators to determine possible dates, times, and places for group meetings. The small group sessions will be conducted near the participants' homes. Each small-group will consist of 5-10 participants who will first view a 20-minute video together and then discuss the content of the video as well as their barriers to screening for about 30 minutes. A community educator and an RA at the study site will facilitate the discussion in Chinese languages according to a structured guide.
1894631|NCT01292200|Behavioral|watch DVD|Women in the single video mode will receive a cultural video along with an information sheet on local free and low-cost screening programs by mail.
1894632|NCT01292213|Procedure|Cough swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
1894633|NCT01292213|Procedure|Oropharyngeal swab|Samples will be tested to determine and characterise the bacteria that may be associated with chronic cough.
1894634|NCT01292213|Procedure|Nasopharyngeal swabs|Samples will be tested to determine and characterise the bacteria and viruses that may be associated with chronic cough.
1894635|NCT01292213|Procedure|Blood sample|Samples will be tested to determine and characterise the immunological markers that may be associated with chronic cough.
1894636|NCT01292213|Procedure|Bronchoscopy/ bronchoalveolar lavage samples|Samples will be tested to determine and characterise the bacteria, viruses and immunological markers that may be associated with chronic cough.
1894637|NCT01292213|Other|Data collection|Questionnaire completion.
1894638|NCT01292226|Drug|mycophenolate mofetil|1 g PO BID for 24 weeks
1894639|NCT01292226|Drug|antibody induction|According to manufacturer recommendation
1894640|NCT01292226|Drug|Cyclosporine|According to manufacturer recommendation
1894641|NCT01292226|Drug|corticosteroid|According to manufacturer recommendation
1894642|NCT01292239|Drug|Placebo|Placebo capsule taken by mouth once daily for 12 weeks
1894643|NCT01292239|Drug|TMC435|100-mg capsule taken by mouth once daily for 12 weeks
1894644|NCT01292239|Drug|Peginterferon alfa-2a (pegIFN alfa-2a)|PegIFN alfa-2a (PEGASYS) will be administered according to the manufacturer's prescribing information as 180 mcg once weekly injected subcutaneous (under the skin) for up to 24-48 weeks for patients randomized to TMC435 and for up to 48 weeks for patients randomized to placebo.
1894645|NCT01292239|Drug|Ribavirin (RBV)|RBV (COPEGUS) will be administered according to the manufacturer's prescribing information. If body weight is > 80 kg the total daily dose of RBV will be 1000 mg, taken by mouth as 400 mg (2 tablets of 200 mg) after breakfast and 600 mg (3 tablets of 200 mg) after supper. If body weight is > 60 kg to <=80 kg the total daily dose will be 800 mg, taken by mouth as 400 mg (2 tablets of 200 mg per intake) after breakfast and supper. If body weight is <=60 kg the total daily dose of RBV will be 600 mg, taken by mouth as 200 mg (1 tablet of 200 mg) after breakfast and 400 mg (2 tablets of 200 mg) after supper. Total duration of RBV will be 24-48 weeks.
1894646|NCT01292252|Biological|teriparatide|Teriparatide 20 ug subcutaneous injection daily for 12 weeks
1894647|NCT01292265|Biological|Certolizumab Pegol|Certolizumab Pegol (CZP) subcutaneous (sc) injections of 400 mg at Weeks 0, 2 and 4, followed by 200 mg at Weeks 6, 8 and 10.
1894648|NCT01292291|Other|biologic sample preservation procedure|
1894649|NCT01292291|Other|laboratory biomarker analysis|
1894652|NCT01292291|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1894653|NCT01292291|Procedure|multiparametric magnetic resonance imaging|
1894654|NCT01292291|Procedure|quality-of-life assessment|
1894655|NCT01292291|Procedure|transperineal prostate biopsy|
1894656|NCT01292291|Procedure|transrectal prostate biopsy|
1894657|NCT01292291|Procedure|ultrasound-guided prostate biopsy|
1894658|NCT01292304|Drug|Tolvaptan|Oral administration once daily Dosage will range from 15 mg to 30 mg
1894659|NCT01292317|Other|application of intravenous volume|weight based intravenous application of volume
1894660|NCT01292317|Other|oral fluid application|oral fluid application
1894661|NCT01292330|Procedure|nutritional support before operation|nutritional support before operation for more than 4 days
1894662|NCT01292343|Other|Colgate Total Toothpaste|Toothbrushing with Colgate Total Toothpaste
1894663|NCT01292343|Other|Colgate Regular Toothpaste|Toothbrushing with Colgate regular toothpaste
1894664|NCT01292356|Drug|cetuximab|
1894665|NCT01292382|Device|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 trains Duration of trains: 5 seconds Interval: 25 seconds Number of sessions: 10 sessions Duration of intervention: two consecutive weeks
1894666|NCT01292382|Device|Repetitive transcranial magnetic stimulation|Intensity: 110% of motor threshold Frequency: 10 Hz Number of trains: 40 Duration of trains: 5 seconds Interval inter trains: 25 seconds Number of pulses each session: 2.000 Total number of pulses: 20.000
1894667|NCT01292395|Other|Dietary Protein Intake|Protein intakes within the current recommendation
1894668|NCT01292408|Drug|Hydrochloroquine|800 mg per os once, and then 400 mg per day
1894669|NCT01292421|Biological|hepatitis B antigen peptide|Given PO
1894670|NCT01292421|Other|placebo|Given orally (PO)
1894671|NCT01292421|Other|immunoenzyme technique|Correlative studies
1894672|NCT01292434|Behavioral|Lunch is in the Bag behavioral intervention|Multi-component behavior-based activities, includes: parent handouts, teacher training, age-appropriate child classroom activities, parent/child activity stations
1894673|NCT01292447|Drug|2% lidocaine gel|120mg lidocaine x 1
1894674|NCT01292447|Drug|Placebo gel|Inert gel x 1
1894675|NCT01292460|Drug|Timolol/ FDC/ Placebo/ Tafluprost|"Prior timolol users: Timolol (administered at 08:00 and 20:00) or FDC of tafluprost and timolol (at 08:00) and Placebo eye drops (at 20:00).
Prior prostaglandin users: Tafluprost (administered at 08:00) or FDC of tafluprost and timolol (administered at 08:00)."
1894676|NCT01292473|Drug|Placebo|Placebo was supplied lyophilized in vials.
1894677|NCT01292473|Drug|Omalizumab|Omalizumab was supplied lyophilized in vials.
1894678|NCT01292486|Device|Spectra Optia Apheresis System|In this study, the safety and effectiveness of the new device will be assessed in two ways. First, MNC collections in growth-factor mobilized cancer patients will be evaluated to confirm that the Spectra Optia is able to collect stem cells. Second, following stem-cell collection and transplant, the number of days required for the collected hematopoetic stem cells to engraft/recover will be compared with historical COBE Spectra engraftment/recovery data.
1894679|NCT01292499|Behavioral|Psychotherapy|10 sessions (50 min)
1894680|NCT01292499|Behavioral|Psychoeducation|7 sessions + 7 phone calls
1894681|NCT01292499|Behavioral|Psychoeducation and psychotherapy|Psychoeducation + psychotherapy
1894682|NCT01292512|Other|Prognostic screening for complicated grief|Patients in the intervention group are prognostically screened for development of complicated grief to identify those in need of help.
1894683|NCT01292525|Drug|Tacrolimus|"A control group continued conventional therapy, Tacrolimus (Prograf®) (control group) and will be followed in parallel group withdrawal that will stop treatment with Tacrolimus (Prograf®)."
1894684|NCT01292525|Drug|Placebo|"Patients randomized to the withdrawalgroup will begin the protocol with their usual dose of Tacrolimus (Prograf®) (initial dose). The initial dose of tacrolimus (Prograf®) will be reduced by one third at visit 3 (day 0) and again a third visit 5 (J60). The complete withdrawal Tacrolimus (Prograf®) begins to visit 7 (J120). The withdrawal of Tacrolimus (Prograf®) will be obtained in four months. Monitoring of all patients lasted 17 months in total from the screening visit, which corresponds to 12 months after complete withdrawal of Tacrolimus (Prograf®) for patients in the withdrawal group."
1894685|NCT01292538|Device|Erchonia GLS|532 nm green diode low level laser light device
1894686|NCT01292538|Device|Placebo laser|Sham light output with no therapeutic benefit
1894687|NCT01292551|Drug|Bosentan|tablets Bosentan 62,5 mg x 2 daily for two weeks, then 125 mg x 2 daily for 12 weeks
1894688|NCT01292551|Drug|Placebo|Placebo tablets 2 x daily for 2 weeks, then change to different placebo tablets to match Bosentan group, 2 x daily for 12 weeks
1894689|NCT01292564|Device|Erchonia MLS|The Erchonia MLS emits 635 nm low level laser light.
1894690|NCT01292564|Device|Placebo Laser|The Placebo Laser looks identical to the Erchonia MLS Laser but emits no therapeutic light.
1894691|NCT01292577|Behavioral|CET/PT|CET/PT is an 18-month comprehensive small group approach for the remediation of cognitive deficit in schizophrenia consisting of individual sessions and 45 group training sessions in social cognition that are integrated with an affect regulation approach and 60 hours of computer assisted training in attention, memory, and problem solving skills.
1894692|NCT01292577|Behavioral|Treatment as Usual|The usual care individuals with schizophrenia that misuse substances receive in the community for their conditions.
1894693|NCT01292590|Other|High fat meal|40 grams saturated fat
1894694|NCT01292603|Drug|Cyclophosphamide|Days 1-3 or Days 1-5 of cycles 1-6
1894695|NCT01292603|Drug|Fludarabine|Days 1-3 or Days 1-5 of cycles 1-6
1894696|NCT01292603|Drug|rituximab [MabThera]|One cycle of intravenous MabThera, followed by 5 cycles of subcutaneous MabThera
1894697|NCT01292603|Drug|rituximab [MabThera]|After 4 cycles of intravenous MabThera without experiencing grade 3 or 4 infusion-related reactions. patients will receive 1 additional cycle of intravenous MabThera and 1 cycle of subcutaneous MabThera.
1894698|NCT01292603|Drug|rituximab [MabThera]|6 cycles of intravenous MabThera
1894699|NCT01292616|Drug|therapy with disease-modifying anti rheumatic drugs (DMARD)|DMARD drug and dosage is chosen by the treating physician without restriction by the study
1894700|NCT01292629|Device|iSert 251 intraocular lens|aphakic intraocular lens
1894701|NCT01292642|Behavioral|Cognitive Behavioral Therapy|individual CBT once weekly, 50 minutes, for 10 weeks
1894702|NCT01292642|Drug|Nicotine Replacement Therapy|"21 mg patch for 6 weeks, 14 mg patch for 2 weeks, then 7 mg patch for 2 weeks
14 m g patch for 8 weeks, then 7 mg patch for 2 weeks"
1894705|NCT01284296|Drug|Lidocaine digital block|One dose of lidocaine 2% injected locally into one finger (2 mls total)
1894706|NCT01284296|Device|Masimo SpHb continuous hemoglobin monitor|Masimo SpHb continuous hemoglobin monitor
1894707|NCT01284309|Drug|Mirabegron|oral
1894708|NCT01284309|Drug|Placebo|oral
1894709|NCT01284322|Drug|Fresolimumab|intravenous fresolimumab 1mg/kg, first 8 patients; 5 mg/kg following 8 patients
1894710|NCT01284335|Drug|Gemcitabine|1000 mg/m2 administered intravenously on Days 1 and 15 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criterion are met.
1894711|NCT01284335|Drug|Docetaxel|60 mg/m2 administered intravenously over 60 minutes on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criterion are met.
1894712|NCT01284335|Drug|Temozolomide|200 mg/m2 administered orally on days 1-5 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criterion are met.
1894713|NCT01284335|Drug|Cisplatin|75 mg/m2 administered intravenously on Day 1 of the 28-day cycle until disease progression, unacceptable toxicity or other discontinuation criterion are met.
1894714|NCT01284335|Drug|Erlotinib|150 mg administered orally days 1-28 of a 28 day cycle until disease progression, unacceptable toxicity or other discontinuation criterion are met.
1894715|NCT01284335|Drug|LY573636|Individualized dose is dependent on patients height, weight, gender and is adjusted to target a specific exposure range corrected for a patient's laboratory parameters. Intravenous dosing is done on Day 1 of a 28 day cycle. Patients may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion are met.
1894719|NCT01284361|Device|30 cm Intermittent Catheter|Randomized cross-over
1894720|NCT01284361|Device|40 cm Intermittent Catheter|randomized cross-over
1894721|NCT01284387|Biological|ACC-001 (vanutide cridificar)|Comparisons of 2 different doses of ACC-001 or placebo for 24 months
1894722|NCT01284400|Other|Home-based disease management|Symptom monitoring, comprehensive advice, and counseling at home by nurses, as well as telephone follow-up by nurses
1894724|NCT01284439|Drug|hydroxypropylmethylcellulose|TearA: QID to every 2 hous , 1-2 drops per each time , duration 1 month
1894725|NCT01284439|Drug|sodium hyaluronate|QID to every 2 hous, 1-2 drops per each time, duration 1 month
1894726|NCT01284452|Drug|Placebo|Normal saline 50 ml intravenous every 6 hours for 7 days
1894727|NCT01284452|Drug|Hydrocortisone|Hydrocortisone 50 mg intravenous every 6 hours for 7 days
1894728|NCT01284465|Behavioral|Education and patient liaison combination|Group education sessions with Patient liaison using ecological momentary assessment principles
1894729|NCT01284465|Behavioral|Control group|Group education sessions at baseline, 3 and 6 months
1894731|NCT01284491|Device|PEAK PlasmaBlade 4.0|The PEAK PlasmaBlade will be used for the entirety of the operation, including the skin incision.
1894732|NCT01284491|Device|Traditional Electrosurgery with scalpel|Scalpel will be used for the skin incision and traditional electrosurgery for the subcutaneous dissection.
1894735|NCT01284517|Drug|Lurasidone|Tablets 20-120 mg, PM dosing,daily for 6 weeks
1894736|NCT01284517|Drug|Placebo|Equivalent to Lurasidone dosing
1894737|NCT01284530|Drug|TPM XR|Equivalent TDD in XR form, QD, Day 1-14
1894738|NCT01284543|Device|Use of the Tan EndoGlide to insert donor graft|Using the Tan EndoGlide to insert donor graft into the eye
1894739|NCT01284543|Device|Busin Glide for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye
1894740|NCT01284556|Drug|Phenobarbital|tablet
1894741|NCT01284556|Drug|Placebo tablet|tablet
1894742|NCT01284569|Biological|ALX-0061|Intravenous administration, single dose (0.3-1-3-6-8 mg/kg) or multiple dose (Biologically effective dose, once every 4 weeks or once every 8 weeks, for 24 weeks)
1894743|NCT01284569|Biological|Placebo|Intravenous administration, single dose or multiple dose (once every 4 weeks or once every 8 weeks, for 12(/24) weeks; switch to ALX-0061 in weeks 13-24 if no response after first 12 weeks)
1894744|NCT01284582|Biological|ATH03|4 vaccinations
1894745|NCT01284595|Drug|[14C] AZD8931|Single 160 mg oral dose administered on Day 1
1894746|NCT01284621|Drug|BI 10773|medium dose, oral administration
1894747|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
1894748|NCT01284621|Drug|BI 10773|medium dose oral administration
1894749|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
1894750|NCT01284621|Drug|Ramipril|Low dose oral administration on day 1
1894751|NCT01284621|Drug|Ramipril|Medium dose oral administration on day 2-5
1894752|NCT01284634|Drug|Cannabidiol|1 x 100 mg CBD/placebo twice daily (200 mg daily)
1894753|NCT01284634|Drug|Cannabidiol|2 x 100 mg CBD/placebo twice daily (400 mg)
1894754|NCT01284634|Drug|Cannabidiol|4 x 100 mg CBD/placebo twice daily (800 mg daily)
1894755|NCT01284647|Drug|Teprenone capsule and placebo of sucralfate|Teprenone 1 capsule (50mg)+placebo of sucralfate 4tab, tid×8 weeks.
1894756|NCT01284647|Drug|Sucralfate and placebo of teprenone|Placebo of teprenone 1 capsule+ sucralfate 4 tab(1.0), tid×8 weeks
1894757|NCT01284660|Dietary Supplement|DHA|DHA ingested orally by heavy smokers
1894758|NCT01284660|Dietary Supplement|Oral ingestion of 5 placebo tablets|Oral ingestion of 5 tablets containing the following: gelatin,glycerine,water and soy oil made by the Solgar Pharmaceutical Co., Israel
1894759|NCT01284673|Other|in vitro characterization of the cord blood stem cell|The quantitative and qualitative, functional characterization will insist on cell populations which could potentially participate to neuronal regeneration. and assessment such characteristics in conditions of cryo-preservation, compared to fresh cell preparation
1894760|NCT01284686|Other|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
1894761|NCT01284686|Other|subthalamo-cortical loops stimulation in a one-sided and bipolar way|Record STN-cortex LFP coherence pattern and then stimulate STN (at 0, 5, 10, 15, 20, 25, 30 Hz) in newly implanted patients
1894762|NCT01284699|Procedure|Gamma Knife radiosurgery|For patients presenting a contraindications for anaesthesia or electrode implantation, operate their brain without opening the skull without infection or bleeding risk.
1894763|NCT01284712|Biological|blood sample|blood sample coming from therapeutic bleeding in hospital
1894764|NCT01284725|Drug|mycophenolate mofetil or azathioprine|
1894765|NCT01284725|Other|immunosuppressive treatment discontinuation|
1894766|NCT01284738|Other|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :
the dosages of MP carried out by the UMR 608 in Marseille,
the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat.
In vitro production of MP of transfused red blood cells origin will also be evaluated in erythrocytes concentrates during the storage of the units."
1894767|NCT01284738|Other|Physiopathology|"Three sequential biological evaluations will be performed for each patient and will consist in :
the dosages of MP carried out by the UMR 608 in Marseille,
the evaluation of the oxidative stress markers and of iron performed in the UMR 773 in Paris-Bichat."
1894768|NCT01284751|Other|MDI - self-rating inventory|MDI with 12 questions to be completed approximately 1 week before surgery
1894769|NCT01284764|Drug|Mosapride|Mosapride 10mg, one dosage, once evening of the day before the endoscopy
1894770|NCT01284777|Genetic|blood sample, thoracocentesis|20ml of blood only one thoracocentesis (the same that one for diagnostic)
1894771|NCT01284790|Device|Cochlear implants|
1894772|NCT01284803|Behavioral|an educational intervention|To elaborate an educational program for the management of depression in primary care
1894773|NCT01284816|Procedure|bariatric surgery|The bariatric surgery is a relevant treatment for severely obese patients those with metabolic complications, as it significantly reduces weight, hypertension and ameliorates glycemic control.
1894774|NCT01284829|Other|FDG-PET scan|
1894776|NCT01284855|Drug|Antivenom|Polyvalent antivenom directed against Indian spectacled cobra (N. naja), common Indian krait (B. caeruleus), saw-scaled viper (Echis carinatus) and Russell's viper.
1894777|NCT01284868|Drug|mirabegron|oral
1894778|NCT01284868|Drug|Bisoprolol|oral
1894779|NCT01284868|Drug|propranolol|oral
1894780|NCT01284868|Drug|placebo|oral
1894781|NCT01284881|Device|MRA|daily wear overnight
1894782|NCT01284894|Device|Conventional manometry|Conventional esophageal manometry
1894783|NCT01284894|Device|High resolution manometry|High resolution esophageal manometry
1894784|NCT01284907|Dietary Supplement|Vitamin D3 (Cholecalciferol)|Vit D3 ( Cholecalciferol) 1200 IU oral daily for 6 months
1894785|NCT01284907|Dietary Supplement|Placebo Drops|
1894786|NCT01284920|Drug|MDV3100|oral
1894787|NCT01284946|Drug|Exjade|Orodispersible Tablet, 10 mg/Kg/day ± 5 mg/Kg/day during 24 weeks Deferasirox should be taken daily 30 minutes before breakfast
1894788|NCT01284959|Drug|risperidone|risperidone 3mg, PO, 3 times
1894789|NCT01284959|Drug|paliperidone ER|paliperidone ER 6mg, PO,3 times
1894790|NCT01284959|Drug|placebo|lactose PO, 3times
1894791|NCT01285024|Device|Vitagel|Two 4.5mL Vitagel Surgical Hemostat Kits, used just prior to closing the capsule.
1894834|NCT01285375|Device|CDC solution|2 ml of CDC 12/mg/ml is added to 1 l of UW solution. 500 ml of of this solution is used for flushing the kidney allograft prior to transplantation
1895097|NCT01294306|Other|Pharmacological Study|Correlative studies
1894797|NCT01285050|Drug|Antiretroviral therapy (ART)|Peginterferon alfa-2b administered once as part of a pharmacokinetic study before and after anti-HIV medications. Peginterferon is used to produce a measurement but the intervention is the HIV medications which are specified as raltegravir, emtricitabline, and tenofovir disoproxil fumerate.
1894798|NCT01285050|Drug|raltegravir|raltegravir is an HIV medication given 400 mg twice daily by mouth
1894799|NCT01285050|Drug|Emtricitabine and tenofovir disoproxil fumarate|Emtricitabine and tenofovir disoproxil fumarate are HIV medications, combination pill, once per day by mouth
1894800|NCT01285063|Other|Multidisciplinary intervention: physical activity, dietary instructions and behavioral treatment.|"3 months intervention. Nutritious plan: includes 6 meetings of the child and his or her parents with a dietician from the center.
Physical activity: physical trainings of 60 minutes each will be held twice a week.
behavioral treatment: all the participants will take part it a 45 minutes meeting of movement therapy once a week. The goal of such meeting is to strengthen nutritious and physical activity habits and to assimilate positive change in the participants' lifestyle."
1894801|NCT01285076|Other|Other: Retrospective chart review; one participant encounter visit.|Participants will be selected based on medical record review in the office of their treating cardiologist, nephrologist, neurologist, or family practice doctor. Participants will have one encounter visit to fill out questionnaires and have a blood draw and recording of weight, blood pressure and waist circumference.
1894802|NCT01285089|Drug|activated recombinant human factor VII|Data collection of the use of activated recombinant human factor VII observed through real-world treatment practices
1894803|NCT01285102|Device|irinotecan-eluting beads|Patients will be treated with drug-eluting irinotecan beads per protocol at up to 100 mg per dose every 3 weeks. Patients will receive chemoembolization using LC Bead, loaded with irinotecan. The beads size range used in the study will be 100-300µm (nominal) with a dose of up to 100mg irinotecan per treatment. The beads will be mixed with a non-ionic contrast media in the vial immediately prior to use according to the instructions for use. Irinotecan will be loaded onto the beads not more than 2 hours prior to the procedure. The study goal will be to deliver the full dose of 100mg of irinotecan per treatment
1894804|NCT01285102|Procedure|hepatic artery embolization|Using a unilateral femoral approach, selective catheterization of the hepatic artery will be performed. Vascular access is obtained via the common femoral artery and a guide-wire advanced under fluoroscopic guidance. A microcatheter is then inserted over the guide-wire. The superior mesenteric artery is selected and an angiogram performed to identify any aberrant arterial anatomy and verify antegrade portal vein flow. The celiac axis is then selected and an angiogram completed. The catheter and guide-wire are used to select the proper hepatic artery and a limited angiogram performed to identify the branches of the hepatic artery. The right or left hepatic artery is selected distal to the cystic artery (if visualized), depending on the location of the lesions to be treated. The LC Bead, loaded with irinotecan will be delivered into the artery.
1894805|NCT01285115|Drug|Placebo|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
1894806|NCT01285115|Drug|KyungBangn-Gamisoyosan-x-gwarip|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
1894807|NCT01285115|Drug|KyungBangn Gamisoyosan|AC 30 min, three times a day each sack taken before or between meals, 7.67g for each sack, 8 weeks.
1894808|NCT01285141|Biological|CN54gp140 glycoprotein-hsp70 conjugate vaccine|CN54gp140-hsp70 conjugate vaccine administered intravaginally 3 times over a 12-week period
1894809|NCT01285167|Drug|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
1894810|NCT01285180|Drug|Daxas|500 microgram, oral, once daily as add-on therapy to existing therapy
1894811|NCT01285193|Behavioral|Breath control|A music CD with sound cues is used to guide the subject to breathe in a regular and slower rate. This is practiced for at least 15 minutes a day over 2 months.
1894813|NCT01285219|Drug|pegylated filgrastim and ﬁlgrastim|patients were administered pegylated filgrastim 100 ug/kg in cycle 1 and ﬁlgrastim 5 ug/kg/d in cycle 2
1894814|NCT01285219|Drug|ﬁlgrastim and pegylated filgrastim|patients received ﬁlgrastim 5 ug/kg/d in cycle 1 and pegylated filgrastim 100 ug/kg in cycle 2
1894815|NCT01285232|Drug|Anakinra|150 mg sc once daily during four weeks
1894816|NCT01285245|Drug|kineret|once daily 100 mg of kineret subcutaneously for 8 days
1894817|NCT01285258|Procedure|hysterectomy|excluding the uterus with saving ovaries
1894818|NCT01285271|Drug|Xenon|gaseous anesthetic, dosage: 50% (v/v) in 50% oxygen, continuous application before the start and after the end of extracorporal circulation
1894819|NCT01285271|Drug|Sevoflurane|inhalative anesthetic, dosage: 1.4% (v/v) in 50% oxygen/medical air , continuous application before the start and after the end of extracorporal circulation
1894820|NCT01285284|Other|Music|A previously defined list of songs will be administered by headphones to these patients.
1894821|NCT01285284|Other|No music|No music will be administered by the headphones connected to the MP3 device.
1894822|NCT01285297|Biological|Bone Marrow Aspirate Concentrate|Injection of up to 18 mL BMAC
1894826|NCT01285323|Drug|Reslizumab|Patients were administered intravenously over 15 to 30 minutes reslizumab at a dosage of 3.0 mg/kg at baseline and once every 4 weeks relative to baseline over 48 weeks for a total of 13 doses.
1894827|NCT01285323|Drug|Placebo|Matching placebo (acetate sucrose buffer), administered intravenously (iv) once every 4 weeks for a total of 13 doses.
1894832|NCT01285362|Drug|Fish Oil Supplementation|Group A will receive fish oil capsules, containing n3-Fatty Acids, at a dose of 4g/day. Each 1g capsule will contain 465mg of EPA and 375 mg of DHA.
1894833|NCT01285362|Drug|Placebo Supplementation|Group B will receive corn oil in the capsules at the same dose as Group A. The corn oil capsules will appear identical in size and color to the fish oil capsules.
1894835|NCT01285375|Device|UW-solution|500 ml of UW solution is used for flushing the kidney allograft prior to transplantation
1894836|NCT01285388|Drug|MB12066|MB12066 10mg, 100mg/tab. once oral dose MB12066 10, 30, 100, 150, 200mg
1894837|NCT01285401|Drug|VigantOL oil plus interferon beta-1a (Rebif)|VigantOL oil 6,670 International Units per day (IU/d) (167 microgram per day [mcg/day]), was administered orally for 4 weeks followed by 14,007 IU/d (350 mcg/d) administered orally for 44 weeks on top of Rebif 44mcg three times per week (tiw) administered subcutaneously.
1894838|NCT01285401|Drug|Placebo plus interferon beta-1a (Rebif)|Matching placebo daily, orally administered matched placebo for 48 weeks on top of Rebif 44 mcg tiw.
1894839|NCT01285401|Biological|Interferon beta-1a (Rebif®) alone|Rebif® 44 mcg tiw, sub-cutaneously alone.
1894840|NCT01285414|Drug|Verubulin|Verubulin, dose determined in Part A, i.v. once weekly, Temozolomide & Radiation Therapy
1894841|NCT01285414|Drug|Temozolomide & Radiation Therapy|Temozolomide & Radiation Therapy
1894842|NCT01285453|Drug|vadimezan|
1894843|NCT01285466|Drug|BEZ235 + paclitaxel|
1894844|NCT01285466|Drug|BKM120 + paclitaxel|
1894845|NCT01285466|Drug|BEZ235 + paclitaxel + trastuzumab|
1894846|NCT01285466|Drug|BKM120 + paclitaxel + trastuzumab|
1894847|NCT01285479|Drug|Fingolimod|
1894848|NCT01285492|Drug|QVA149|QVA149 (110 μg indacaterol / 50 μg glycopyrronium o.d.), delivered via Concept1
1894849|NCT01285492|Drug|Tiotropium|Tiotropium (18 μg o.d.), delivered via Handihaler®
1894850|NCT01285505|Drug|alprazolam commercial sublingual formulation|0.5 mg tablet, single dose
1894851|NCT01285505|Drug|alprazolam test sublingual tablet|0.5 mg tablet, single dose
1894852|NCT01285518|Drug|PF-05231023|0.5 mg QD IV x 1 day
1894853|NCT01285518|Drug|PF-05231023|1.5 mg QD IV x 1 day
1894854|NCT01285518|Drug|PF-05231023|5 mg QD IV x 1 day
1894855|NCT01285518|Drug|PF-05231023|15 mg QD IV x 1 day
1894856|NCT01285518|Drug|PF-05231023|50 mg QD IV x 1 day
1894857|NCT01285518|Drug|PF-05231023|100 mg QD IV x 1 day
1894858|NCT01285518|Drug|PF-05231023|200 mg QD IV x 1 day
1894859|NCT01285518|Other|Placebo|0.9% w/v sodium chloride injection, USP QD IVx 1 day
1894860|NCT01285531|Device|Compass Lumbar Puncture Enhanced|Participants randomly assigned to this group will receive a lumbar puncture using the Compass device.
1894861|NCT01285544|Drug|Atorvastatin (Lipinon)|treatment of dyslipidemia administration : PO, qod
1894862|NCT01285544|Drug|Atorvastatin (Lipitor)|treatment of dyslipidemia administration : PO, qod
1894863|NCT01285557|Drug|S-1 (Tegafur/Gimeracil/Oteracil) /cisplatin (investigational arm)|25 mg/m² body surface area (BSA) orally 2 times daily from Days 1 through 21 followed by a 7 day rest period, plus cisplatin 75 mg/m2 BSA on Day 1 each 28 day cycle Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles.
1894864|NCT01285557|Drug|Fluorouracil/cisplatin (control arm)|"5-FU: 800 mg/m2 BSA/24 hours by continuous intravenous infusion (CIV) from Days 1 through 5 plus cisplatin 80 mg/m2 BSA on Day 1 each 21 day cycle.
Number of Cycles: until progression or unacceptable toxicity develops. Treatment with cisplatin is limited to a maximum of 8 cycles."
1894865|NCT01285570|Drug|Ulimorelin Intravenously (IV)|480 microg/kg daily (QD)
1894866|NCT01285570|Drug|Ulimorelin Intravenously (IV)|160 microg/kg daily (QD)
1894867|NCT01285570|Drug|5% dextrose in water|Placebo
1894868|NCT01285583|Drug|TRO19622|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
1894869|NCT01285596|Drug|Mirabegron|oral
1894870|NCT01285609|Drug|Ipilimumab|
1894871|NCT01285609|Drug|Placebo|
1894872|NCT01285609|Drug|Paclitaxel|
1894873|NCT01285609|Drug|Carboplatin|
1894874|NCT01285635|Drug|AT-101|Pulse Dose: AT-101 dose of 40 mg b.i.d. on days 1-3 Metronomic Dose: AT-101, 20 mg daily, days 1-14
1894875|NCT01285635|Drug|Docetaxel|Docetaxel 75 mg/m2 on Cycle Day 1
1894876|NCT01285648|Procedure|Cpap|This study did not involved drugs. The Oxygenation index, Borg Scale, pain scale and the presence and duration of thoracic drainage was determined in the immediate postoperative (POi) period and in the first and second postoperative (PO1, PO2) days in 40 patients who underwent elective lung resection,in two groups of intervention: chest physiotherapy, and associate this with cpap
1894877|NCT01285661|Drug|Sodium warfarin|Patients with early vein recanalization, as shown by ultrasonography, and repeatedly negative D-dimer will have anticoagulation discontinued. They will be followed-up for up to 4 years after recruitment in order to assess the rate of recurrent symptomatic VTE. In all other patients anticoagulation will not be discontinued.
1894878|NCT01285674|Drug|Intra-tympanic Cisplatinum|Intra-tympanic injection (under local anesthesia) of 0.5cc Methylprednisolone 62.5mg/cc. One injection per ear before each of the 3 cisplatin treatments. After injection the patient will remain with the treated ear upwards for 20 minutes and will try to avoid swallowing as much as possible.
1894879|NCT01285687|Device|acupuncture|Sterile, disposable, FDA-approved acupuncture needles will be used. Acupuncture will be performed bilaterally. The needles will penetrate the skin to a depth of 5-10mm and will be kept in place for no more than 5 minutes. The acupuncture points will be: Li 4, Li 11, St 44, according to Chinese acupuncture mapping. Treatment will be repeated at least 3 times during the hospital stay. Treatment will start in the pediatrics department approximately two hours after discharge from the postoperative unit. The 2nd treatment will be given on the same evening, approximately 4-8 hours after the 1st treatment and the 3rd treatment will be given the following morning, approximately 12-18 hours after the 2nd treatment. Exact treatment times will be recorded in the patient's file.
1894881|NCT01285713|Drug|5% Dextrose (D5) in Normal Saline (NS)|D5NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg of NS
1894882|NCT01285713|Drug|Normal Saline (NS)|NS 10 cubic centimeter (cc)/kilogram (kg) to be followed by 30cc/kg NS
1894883|NCT01285726|Other|Non-interventional study|This is a purely non-interventional, observational study, where treatment decisions are completely guided by the discretion of the attending nephrologists.
1894884|NCT01285739|Other|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
1894885|NCT01285739|Other|WBC, biomarkers, TBA, chest X ray|The above cited parameters were recorded and investigated every six months; chest X ray when needed.
1894886|NCT01285752|Drug|AK106-001616|
1894887|NCT01285752|Drug|AK106-001616|
1894888|NCT01285752|Drug|Active comparator|
1894889|NCT01285765|Drug|RCHOP21|Prednisone-60 mg/m2: D1 D2 D3 D4 D5;Rituximab-375 mg/m2 : D1; Doxorubicin-50 mg/m2 D1;Cyclophosphamide-750 mg/m2:D1 Vincristine-1.4 mg/m2 :D1; G-CSF SC -5 microg/kg/day: D6 to D13
1894890|NCT01285778|Drug|panitumumab, mytomicin C, 5-FU, radiation|"Radiation therapy will be administered concurrent with chemotherapy and Panitumumab treatment. It will start the day 1 of the systemic treatment. That is, the first day of radiation therapy will be the day of the administration of the first dose of Panitumumab and Mitomycin C, as well as the first day of the first 96-hours course of 5-FU continuous infusion. On day 1, drugs and radiation will be administered in the following order:
First, Panitumumab. Panitumumab will be administered by IV infusion on day 1, and every 2 weeks during 8 weeks
Then Mitomycin C, 10mg/m2 on days 1 and 29
Then start the 5-FU continuous infusion, 1000mg/m2 on days 1-4 and 29-32
Finally, no less than 2 hours after the start of the 5-FU infusion, first dose of radiation therapy."
1894891|NCT01285804|Other|Cuffed ETT|Kimberly Clark
1894892|NCT01285804|Other|Uncuffed ETT|Kimberly Clark
1894893|NCT01285817|Drug|celecoxib, Vinblastine, Cyclophosphamide , methotrexate ,|
1894896|NCT01285843|Procedure|Anterior Minimally Invasive Approach (AMIS)|
1894897|NCT01285856|Other|hair and saliva samples|"Using a sample of hair, testing for and measurement of the principal drugs (opiates, cannabis, cocaine, amphetamines) and the specific marker of ethanol consumption, ethyl glucuronide, will be performed by chromatographic techniques (high-performance liquid chromatography and gas phase chromatography) together with detection by mass or tandem mass spectrometry. This non-invasive sampling is more informative than blood tests, as it gives a retrospective profile of an individual's consumption over several months.
Saliva sample, a method which gives similar results without the need for venous blood sampling."
1894898|NCT01285869|Other|Multidimensional intervention|The patient will be cited 2 months after hospital discharge for a geriatric evaluation carried out by a geriatric nurse and an internist with geriatric training. The duration of the first visit is 45-60 minutes. The visit consists of: 1. Assessment of the pneumonia resolution, co-morbidities, aspiration risk, risk of multiresistant infections, and the immunization, functional and cognitive status. 2. An individualized intervention plan. The patient and family or caregiver will receive an educational intervention, a written report with the planned intervention and an educational leaflet. Those patients who require further assessment or follow up of the intervention will receive 1 or 2 more visits and all the patients will be cited one year after the first visit.
1894899|NCT01285882|Other|Representations|"A pre-test with 5 medical persons and 5 persons without mucoviscidosis will be realized to adjust the tools and place of the interview.
To collect analyzable data for 30 patients, 40 patients will be included in the study. A conceptual card will be associated to a semi-structured interviews to gather information.Two subgroups will be considered in th a analysis :
1st sub-group : After the announcement of the transplant indication by the doctor and before the consultation in the transplant centre.
2nd subgroup : After the consultation in the transplant centre but before the inscription on the waiting list. The analysis of conceptual cards in these two subgroups will permit to study the differences between the representations of patients before and after the consultation in the transplant centre.
Realize a 2nd interview on the same principle with all patients, 1 year after their lung transplantation."
1894900|NCT01285908|Drug|Intravenous Norepinephrine Infusion|
1894901|NCT01285921|Other|vestibular test before and after hippocampal surgery|"Research of a spontaneous nystagmus with and without fixation(VIDEONYSTAGMOSCOPY) and segmentary deviations (Fukuda test)
HIT (testing semicircular canal function at high frequency).Results: Gain in %
VEMp (testing saccular function). Results: Amplitude in μV and latency in ms
ERI (testing lateral semicircular function at middle frequency). Results: Nystagmus during and after the rotations in frequency and slow phase velocity (SPV) in °/s
Caloric test (testing lateral semicircular function at low frequency). Results: Canal paresis in % and SPV in °/S"
1894902|NCT01285934|Biological|Autologous Hematopoietic Stem Cell Transplantation|All participants randomized to the transplant arm wil undergo Autologous Hematopoietic Stem Cell Transplantation
1894903|NCT01285934|Drug|intensive insulin therapy|The control arm will be either CSII via an insulin pump or intensive subcutaneous insulin therapy with multiple insulin injections (at least 4/day) utilizing a long acting background insulin and pre-meal rapid acting insulin.
1894904|NCT01285947|Device|Thermage|Radiofrequency Device - specific setting will be determined by the location and thickness of skin. Periorbital: 58-140 J/cm2 Midface: 81-124 J/cm2 Abdomen: 95-181 J/cm
1894905|NCT01285947|Other|Needle Application|30-gauge needle insertion into skin
1894906|NCT01285947|Device|VBeam Laser|Pulsed Dye Laser at the following settings: 7.5 J, 0.6ms, 10mm, DCD 30/20
1894907|NCT01285947|Device|Ulthera|"Ultrasound Device at the following settings:
Transducer Frequency Depth Image Depth DS 7-3.0 7 MHz 3.0mm 0-8mm DS 4-4.5 4 MHz 4.5mm 0-8mm DS 7-4.5 7 MHz 4.5mm 0-8mm"
1894908|NCT01285960|Device|ExAblate Treatment UF V2|Treatment with the ExAblate UF V2 system. Patients may have up to two ExAblate treatments within a two-week period.
1894909|NCT01285986|Procedure|Vein collar at the distal anastomosis|Vein collar interposed at the distal anastomosis or No vein collar interposed at the distal anastomosis
1894916|NCT01286025|Behavioral|video case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate
1894917|NCT01286025|Behavioral|Text case modality|Patients whose case histories are pathophysiologically illustrative will be recruited, and interviewed on video. Their stories will be edited and divided into sections, and combined with the patient's laboratory, imaging, and pathological reports when appropriate. The transcript of these video-recordings will form the basis of the text-based case presentation modality.
1894918|NCT01286038|Drug|Eltrombopag|In Stage 1 the best dose of eltrombopag will be found to take into Stage 2, which will treat 15 participants at this dose.
1894921|NCT01286064|Device|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
1894922|NCT01286064|Device|Optical Fluoroscopy|Lithium-heparin was added to the blood samples to prevent coagulation. The samples were then centrifuged and the plasma was removed without disturbing the buffy coat and the erythrocyte sediments. The separated changes in the enzyme associated with heme biosynthesis have been reported for peripheral mononuclear cells in patients with epithelial tumors and metastatic spread. plasma was stored at -20 °C until assayed. For fluorescence measurements, analytical grade acetone was added to plasma in a 1:1 ratio by volume and the mixture was centrifuged. The clear supernatant was placed in a quartz cuvette of 1 cm path length for further analysis. Fluorescence analysis of blood plasma was performed by means of a spectrofluorometer (Model F-3000, Hitachi, Ltd., Tokyo, Japan).
1894923|NCT01286077|Drug|bortezomib|Each cycle will consist of 5 weeks treatment. Subjects in the treatment group will receive: Velcade® 1.6 mg/m2 as an intravenous bolus injection on Days 1, 8, 15, and 22 of each cycle followed by a 13-day rest period (Days 23 to 35) Cycle will be repeated on Day 36. Subjects in the treatment group will receive up to 4 treatment cycles, unless they experience either unacceptable toxicity or if the subject requests to withdraw from the study.
1894924|NCT01286090|Drug|Cisapride|One 10-mg tablet taken orally 4 times a day for up to 8 weeks.
1894925|NCT01286090|Drug|Placebo|One tablet taken orally 4 times a day for up to 8 weeks.
1894926|NCT01286103|Drug|Canagliflozin 300 mg once daily and 150 mg twice daily|Treatment A (one 300-mg tablet once daily for 5 days) followed 10 days later by Treatment B (one 50-mg and one 100-mg tablet twice daily for 5 days) or Treatment B followed by Treatment A.
1894927|NCT01286103|Drug|Canagliflozin 100 mg once daily and 50 mg twice daily|Treatment C (one 100-mg tablet once daily for 5 days) followed 10 days later by Treatment D (one 50-mg tablet twice daily for 5 days) or Treatment D followed by Treatment C.
1894928|NCT01286116|Device|Parachute Implant|Mechanical ventricular partitioning
1894929|NCT01286129|Procedure|Nasal allergen challenge|Allergen sprayed into nostrils. Allergen used will be house dust mite or cat allergen. Allergens will be given in increasing ten-fold dilutions until a positive response occurs.
1894930|NCT01286168|Device|Sodium hypochlorite (Dakin's Solution)|10 ml of 0.125% sodium hypochlorite (Dakin's solution) irrigation to the drainage bulb two times a day
1894931|NCT01286168|Device|Chlorhexidine gluconate disk|Apply one chlorhexidine disk to the intervention drain site(s) and change every three days
1894932|NCT01286168|Procedure|Control|Standard drain care will be performed twice a day or three times if bulb is full and needs to be emptied. Standard drain care consists of stripping the tubing, emptying the drainage bulb, recording the volume of fluid, and cleaning the drain site with a cotton swab dipped in rubbing alcohol. The drain exit will be covered with a dry sterile gauze dressing and changed after each episode of drain care.
1894933|NCT01286168|Device|Occlusive Adhesive Dressing|A chlorhexidine gluconate disk (BioPatch) covered by an occlusive adhesive dressing (Tegaderm) will be applied to the intervention drain sites and changed every three days.
1894934|NCT01286181|Behavioral|Twice daily practice of device-guided slow breathing.|Participants are asked to use the slow-breathing device for 20 minutes twice daily, for 8 weeks. Participants receive weekly telephone calls to monitor device use and are encouraged to use pursed-lips when following the breathing tones of the device while exhaling.
1894935|NCT01286194|Drug|Rabeprazole sodium|Rabeprazole sodium 10 mg orally every day for 14 days
1894936|NCT01286207|Drug|Rizatriptan 5 mg|Rizatriptan 5 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
1894937|NCT01286207|Drug|Rizatriptan 10 mg|Rizatriptan 10 mg orally once for treatment of index migraine attack, followed by two additional doses within 24 hours of the initial dose for migraine recurrence(s)
1894938|NCT01286207|Drug|Standard Care|Active standard care
1894939|NCT01286220|Other|Dilute bleach baths|Patients in the intervention group will be instructed to bathe in a dilute bleach bath twice weekly for 10 minutes.
1894940|NCT01286220|Other|Water|Patients in the placebo group will be instructed to bathe in plain water twice weekly for 10 minutes.
1894941|NCT01286233|Drug|Metformin|
1894942|NCT01286233|Drug|Placebo|
1894943|NCT01286246|Drug|Vaginal progesterone|Capsules of 200mg micronised progesterone suspended in sunflower oil. One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
1894944|NCT01286246|Drug|Placebo|Capsules of placebo (sunflower oil). One capsule inserted vaginally per day from time of randomisation to gestational age 35(+6)weeks or delivery (if sooner).
1894945|NCT01286259|Drug|Disulfiram|Open label 500mg disulfiram per day by mouth for 14 days
1894952|NCT01286298|Procedure|Laser gingivectomy|Gingivectomy by diode laser
1894953|NCT01286298|Procedure|Laser gingivectomy|Diode laser gingivectomy for gingival enlargement
1894954|NCT01286311|Behavioral|Direct-to-patient tailored cardiovascular risk message system|Patient informational mailings
1894955|NCT01286324|Dietary Supplement|Chamomile High Grade Extract|three tablets each (equivalent to 7.5 g of dried herb) p.o. twice daily for 28 days
1894956|NCT01286324|Drug|Placebo Tablet|
1894957|NCT01286337|Procedure|bipolar vessel sealing|
1894958|NCT01286337|Procedure|control|
1894959|NCT01286350|Behavioral|FL3X: Flexible Lifestyle Empowering Change|The FL3X Adaptive Intervention is designed to increase adherence to T1D self-management including medical management (blood sugar testing and insulin dosing), diet, and physical activity. FL3X relies on MI, and problem-solving skills training (PSST) as the basis for the counseling strategy, and creates a coherent integration across three key components of 1) behavior family systems therapy focused on family communications and teamwork; 2) individualized diabetes education in response to knowledge gaps relevant to behavioral goal attainment; and 3) use of currently available communications technology to support behavioral goal attainment through participant-defined reminders and motivational boosters, and/or peer support.
1894960|NCT01286376|Dietary Supplement|Symbiotic Lactofos|Lactobacillus Paracasei Lactobacillus Rhamnosus Lactobacillus Acidophilus Bifidobacterium lactis 12g/day
1894961|NCT01286376|Dietary Supplement|Maltodextrin|Maltodextrin
1894962|NCT01286389|Other|medical care|Conventional medical care, geriatric consultations at least 6 times in 12 months, short lifestyle counseling (exercise+healthy diet)
1894963|NCT01286389|Behavioral|caloric restriction|Nutritional guidance: through at least 2 individual assistance and group sessions, lasting 1 hour, weekly for 4 months, and biweekly for 2 months and monthly thereafter (26-28 meetings/1year).The diet plan will recommend a deficit from 500 to 750 kcal/day in order to promote loss of about 0.5kg/week, containing 1g/kg of protein per day (minimum 1200kcal/day), high in fiber, vegetables and whole foods. The goal of weight loss will be 10% of initial weight. Group activities consist of lectures on nutrition education, food composition and its importance to health, food preparation techniques, self-monitoring weight, eating behavior and count calories.
1894964|NCT01286402|Drug|Bupropion SR|"150mg, taken orally, taken daily for the 1st 3 days
300mg, taken orally, taken daily for the rest of the 8 weeks of drug treatment"
1894965|NCT01286402|Other|Placebo|-Avicel PH 302, Emcocel 50M, Cab-O-Sil M5P, Magnesium Stearate (appearance, taste, and dosing instructions were identical to the bupropion group), i.e., 1 pill orally, taken daily for the 1st 3 days; 2 pills, taken orally, taken daily for the rest of the 8 weeks of drug treatment
1894966|NCT01286415|Behavioral|Group Cognitive Processing Therapy-Cognitive Only|Cognitive Processing Therapy (CPT) is an evidence-based form of Cognitive Behavioral Therapy (CBT) used to treat PTSD. CPT is a 12-session manualized program that focuses on challenging beliefs and assumptions related to the trauma, oneself, and the world. Sessions will be conducted twice weekly for six weeks; each session is 90 minutes.
1894967|NCT01286415|Behavioral|Group Present Centered Therapy|Present Centered Therapy (PCT) is a supportive group intervention typically used within the Department of Veterans Affairs (VA) healthcare systems to address problems of veterans with PTSD (Rosen, et al., 2004). PCT focuses on problem-solving current difficulties that may be related to past traumatic events, but does not address specific memories or cognitions about the trauma. Sessions will be conducted twice weekly for 6 weeks; sessions are 90 minutes.
1894968|NCT01286441|Drug|10% EISO|During the Treatment Period, subjects will apply study medication (10% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
1894969|NCT01286441|Drug|Placebo|During the Treatment Period, subjects will apply placebo to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
1894970|NCT01286441|Drug|20% EISO|During the Treatment Period, subjects will apply study medication (20% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
1894971|NCT01286441|Drug|30% EISO|During the Treatment Period, subjects will apply study medication (30% EISO) to all warts in the treatment area for 12 weeks and will then be followed for an additional 12 weeks. Subjects achieving complete resolution will continue to apply the study medication for the entire 12-week treatment period. During the Follow-up Period, subjects will be followed by telephone every 4 weeks for 12 weeks.
1894972|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
1894973|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
1894974|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
1894975|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
1894976|NCT01286454|Drug|fesoterodine|single dose of tablet
1894977|NCT01286454|Drug|fesoterodine|single dose of beads in capsule
1894978|NCT01286467|Drug|PF-04449913|Escalating dose of PF-04449913 administered as tablets PO QD in 28-day cycles
1894979|NCT01286480|Behavioral|Clinic-based Educational Intervention|This will involve a 60 minute interaction between the teen and an advanced practice nurse (APN) in the cardiology clinic. A MyHealth passport will be created covering the name of the teen's cardiac condition, previous cardiac interventions, and name and purpose of the teen's medications. Potential late cardiac complications and contact names and location of local adult CHD cardiologists will also be reviewed. Three scenarios regarding adolescent risk taking behaviors (written in the 3rd person) will be presented to the teen who will be asked what advice he/she would offer to the teen in each of those scenarios. The teen will be given a study email address and encouraged to contact the APN by email or text messaging with follow-up questions. If no contact is initiated after 1 week, the APN will email or text (based on preference) the youth, to discuss additional questions.
1894980|NCT01286493|Biological|rabies vaccines on day 0 and 3|All subjects would receive conventional intramuscular booster rabies vaccination on day 0 and 3. Their blood would be drawn for rabies neutralizing antibody on day 0,7,14,30,90,180,360
1894981|NCT01286558|Drug|40 mg telmisartan|once daily
1894982|NCT01286558|Drug|5 mg amlodipine|once daily
1894983|NCT01286558|Drug|5 mg amlodipine|once daily
1894984|NCT01286558|Drug|80 mg telmisartan|once daily
1894985|NCT01286571|Drug|BI 135585|one oral single dose per subject
1894986|NCT01286571|Drug|BI 135585|one oral single dose per subject
1894987|NCT01286584|Drug|varenicline|one 0.5mg varenicline capsule on first 3 days one 0.5mg varenicline capsule, twice daily for 4 days one 1.0mg varenicline capsule, twice daily until end of treatment (12weeks of medication
1894988|NCT01286584|Drug|placebo|lactose filler in capsules identical to the varenicline capsules one 0.5mg capsule for 3 days one 0.5mg capsule twice daily for 4 days one 1.0mg capsule twice daily until end of treatment (12weeks of medication)
1894989|NCT01286597|Dietary Supplement|dietary restriction|restrict intake of lactose
1894990|NCT01286610|Device|ProMedVi Vibrosphere|vibration therapy
1894991|NCT01286610|Device|schwa-medico MUSKELaktiv|Electrical muscle stimulation
1894992|NCT01286610|Device|Galileo Home Plus (ICU)|vibration therapy
1894993|NCT01286636|Other|computer model|Diagnosis of Sleep apnea and treatment guidance will rely on a computer model prediction.
1894994|NCT01286636|Other|Polysomnogram|Diagnosis of sleep apnea will rely on polysomnogram
1894995|NCT01286649|Other|Human autologous hair follicle cells|Human autologous hair follicle cells suspended in cell medium
1894996|NCT01286649|Other|Cell medium|Cell medium
1894997|NCT01286675|Drug|Eltrombopag|oral eltrombopag, 50 mg, 100 mg, 150 mg, days 2-15
1894998|NCT01286688|Drug|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
1894999|NCT01286701|Drug|Terbinafine Hydrochloride Tablets, 250 mg|Terbinafine Hydrochloride Tablets, 250 mg of Dr. Reddy's Laboratories Limited.
1895000|NCT01286714|Device|CLIP OST|
1895001|NCT01286727|Drug|BB3|intravenous drug
1895002|NCT01286740|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (tenofovir DF; TDF) 300 mg single-tablet regimen (STR) administered orally with a meal once daily
1895003|NCT01286753|Drug|Vemurafenib|Vemurafenib 960 mg orally twice daily.
1895004|NCT01292668|Drug|methyl-5-aminolevulinate hydrochloride cream|Applied topically
1895005|NCT01292668|Drug|photodynamic therapy|Undergo light-emitting diode photodynamic therapy
1895006|NCT01292668|Procedure|laser therapy|Undergo laser light photodynamic therapy
1895007|NCT01292681|Other|Multi-modality imaging|Week -2-0 FDG-PET-CT,1H MRS, DCE-MRI, DWI Week 1 1H MRS, DCE-MRI, DWI, 19F MRS, FDG-PET-CT Week 9 FDG-PET-CT
1895008|NCT01292694|Drug|Losartan|Oral, single-dose, 50 mg tablet
1895009|NCT01292694|Drug|Captopril|Oral, single-dose, 50 mg tablet
1895010|NCT01292694|Drug|Placebo|Oral, single administration, gelatin capsule filled with microcrystalline cellulose
1895011|NCT01292707|Behavioral|Control|Standard national training
1895012|NCT01292707|Behavioral|HW|Prescribing staff in the intervention facilities will receive the same package of nationally-approved training in RDT use as will be provided to prescribers in control facilities. Following this, prescribers in the intervention facilities will be invited to participate in 3 small group training modules delivered in an interactive style lasting approximately 11/2 hours, with one session repeated between the 6th and 7th month of the trial
1895013|NCT01292707|Behavioral|HWC|The health worker-community arm will receive the same intervention as the health workers arm but with the addition of an intervention aimed at patients. This will consist of community sensitisation, clinic posters and providing a leaflet to each RDT-tested patient or caretaker giving details of the test and the corresponding treatment provided.
1895014|NCT01292720|Drug|Cholecalciferol|Cholecalciferol 90,000 IU followed by weekly 24,000 IU for 24 weeks of vitamin D3 (total dose: 666,000 IU)
1895015|NCT01292720|Drug|Placebo|Placebo in matching volumes
1895016|NCT01292733|Other|Laboratory Tumor Marker Analysis|Performed every 6 months, these blood samples will be drawn to measure the concentration of CA125 tumor marker. Remaining samples will be stored in a specimen repository for use in future research for ovarian and breast cancer tumor markers.
1895017|NCT01292733|Other|Transvaginal Ultrasound|Performed annually, these pelvic ultrasounds will be used used to look for 1) enlargement of one or both ovaries or 2) suspicious or indeterminate morphometric parameters, determined by the presence of intracystic papillations, and/or mural nodularity.
1895018|NCT01292733|Other|Health Status Questionnaire|Performed every 6 months, these questionnaires will ask about your health and medical history, environmental exposures, and family history.
1895019|NCT01292746|Device|Erchonia MLS|The Erchonia MLS administers 4 diodes of 10 milliwatts (mW) 635 nanometers (nm) red light to the scalp area for 18 minutes, 2 times each week for 12 consecutive weeks for a total of 24 treatments.
1895020|NCT01292772|Procedure|contract-enhanced MRI|Patients will have contrast-enhanced MRI of the breasts.
1895021|NCT01292772|Radiation|Unilateral Adjuvant Radiation Therapy|The study group will consist breasts receiving post-operative radiation, and the control group will consist of the patient's breasts on the non-radiated side. In this way, patients will act as their own control.
1895090|NCT01294293|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1895091|NCT01294293|Other|Pharmacological Study|Correlative studies
1895022|NCT01292785|Drug|Hormones|"FtM will receive
1000mg testosterone undecanoate every 12 weeks (Nebido® 4ml i.m.), or alternatively 50mg testosterone transdermally (Testogel® 5g-bag per day) and
if menstruation still occurs, additionally either lynestrenol Orgametril® (2-3 tablets/day) or in some cases 0.075mg desogestrel (Cerazette®, 1 tablet/day).
MtF will receive
50mg cyproterone acetate daily (Androcur®)
estradiol 100µg transdermal therapeutic system (TTS) twice a week (Estradot®, Estramon®), especially if subjects age is > 40 years, or p.o. estradiol 2x2mg (Estrofem®) if subjects age is < 40 years; alternatively estradiol 0,75-1,5mg (1-2 hubs) transdermally (Estrogel-Gel®) and
2,5mg alpha-5-reductase-inhibitor every 2nd day (Finasterid Actavis/ Arcana/ Aurobindo®) in case of extensive hair loss."
1895023|NCT01292798|Drug|Ranibizumab|0.05ml of 0.5mg or 2.0mg ranibizumab injected intravitreally
1895024|NCT01292811|Device|Functional Electrical Stimulation (Compex Motion Stimulator)|Functional electrical Stimulation:Parameters of stimulation: 1) balanced, biphasic, current regulated electrical pulses; 2) pulse amplitude from 8 to 50 mA (typical values 17-26 mA); 3) pulse width from250 to 300 μs; and 4) pulse frequency from 20 to 70 Hz (typical value 25 to 40 Hz).
1895025|NCT01292811|Other|Conventional Occupational therapy|"The Control group will receive conventional occupational therapy pertaining to hand function [15].
The conventional therapy represents control activities against which the FES therapy will be assessed. The conventional occupational therapy includes: a) muscle facilitation exercises emphasizing the neurodevelopmental treatment approach; b) task-specific, repetitive functional training; c) strengthening and motor control training using resistance to available arm motion to increase strength; d) stretching exercises; e) electrical stimulation applied primarily for muscle strengthening (this is not FES but TENS application); f) activities of daily living including self-care where the upper limb was used as an assist if appropriate; and g) caregiver training."
1895026|NCT01292824|Drug|ITX 5061|ITX 5061 (150mg) pre-transplant, immediately post-transplant and daily thereafter for 1 week.
1895027|NCT01292837|Drug|Levetiracetam|The initial dose is 20 mg/kg/day or 1000 mg/day, divided into two equal dose for the first two weeks, followed by 40 mg/kg/day or 2000 mg/day for two weeks. After reaching 60 mg/kg/day or 3000 mg/day, treatment will continue for 20 weeks.
1895028|NCT01292863|Other|Active Comparator: Conventional peritoneal dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
1895029|NCT01292863|Other|Experimental: Novel biocompatible dialysis solution|Daily dialysis solution to be used for 3 months in crossover fashion.
1895030|NCT01292876|Device|Extracellular Matrix|Extracellular Matrix
1895031|NCT01292902|Other|inspiratory muscle exercise|To conduct the exercise to the inspiratory muscles was used for IMT Threshold ® device (Threshold Inspiratory Muscle Trainer, HealthScan Products Inc., Cedar Grove, New Jersey) is one of the most used for training of inspiratory muscles in patients with several pathologies such as ICC.Threshold ® has been engaged in the patient's mouth by a mouthpiece, with the nose occluded by a nose clip. The exercise time was 3 minutes. During this period, participants were encouraged to only breathe through the mouth and maintain a respiratory rate between 12 and 16ipm. The exercise would be stopped if HR increased more than 20% and / or SpO2 < 88%.
1895032|NCT01292902|Other|inspiratory muscle exercise|Equal to the group with chronic heart failure.
1895033|NCT01292928|Device|Stent implantation|Stent implantation during the index procedure.
1895034|NCT01292941|Device|Intermittent catheterisation|Speedicath, Intermittent catheterisation
1895035|NCT01292941|Device|NonCE marked intermittent catheter/red|Paris, Intermittent catheterisation
1895036|NCT01292941|Device|NonCE marked intermittent catheter/green|Paris, Intermittent catheter
1895037|NCT01292941|Device|NonCE marked intermittent catheter/blue|Paris, Intermittent catheter
1895038|NCT01292954|Dietary Supplement|Blueberries|low dose: 31.4 g of freeze dried blueberry reconstituted in water medium dose: 57 g of freeze dried blueberry reconstituted in water high dose: 80 g of freeze dried blueberry reconstituted in water Placebo: sugars and vitamin c match control in water Frequency:1 single time Total Duration: 3 days study over 3 weeks period
1895039|NCT01292967|Dietary Supplement|Low flavanol chocolate|48 mg of total flavanols from cocoa
1895040|NCT01292967|Dietary Supplement|High-flavanol with sugar|high-flavanol containing 251 mg cocoa flavanols
1895041|NCT01292967|Dietary Supplement|High flavanol Maltitol|high-flavanol containing 266 mg cocoa flavanols
1895042|NCT01292980|Device|AFT bed|All identified patients will receive a AFT bed for a maximum of 21 days or until discharge
1895043|NCT01292993|Drug|400 mg LX4211|400 mg of LX4211 given as a solid oral dose form
1895044|NCT01292993|Drug|1000 mg metformin|1000 mg metformin given as a solid oral dose form
1895045|NCT01293773|Device|Taxus Element stent|paclitaxel-eluting stent
1895046|NCT01293773|Device|Integrity Resolute stent|ABT 578-eluting stent
1895047|NCT01293773|Device|Xience Prime stent|Everolimus-eluting stent
1895048|NCT01293799|Behavioral|Follow-up of PD patients´ theoretical and practical skills|Testing of patients knowledge and retraining if needed
1895049|NCT01293812|Drug|88% sucrose po solution|"88% sucrose solution (Syrup B.P.) The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a 88% sucrose solution or a color, consistency- and odor-matched placebo in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
1895050|NCT01293812|Drug|placebo po|"The pharmacy will provide 2 syringes labeled sucrose study calculated to provide a 2 ml dose of a solution or a color, consistency- and odor-matched placebo to the sucrose solution in identical packagings (2 syringes per patient in the case the dose needs to be repeated)."
1895051|NCT01293825|Drug|ziprasidone|"Patients will identify which psychotropic they currently receive that causes the most weight-gain concern. For individuals on multiple drugs, one drug must be identified as the offending agent. Study psychiatrist will switch the offending agent to ziprasidone. Participants will be switched to ziprasidone per package insert. Patients will be maintained on ziprasidone for 12 weeks (active part of study). After the active part of the study they will return to the care of their normal clinical provider who will determine whether they will continue on ziprasidone."
1895092|NCT01294293|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
1895093|NCT01294293|Drug|Paclitaxel|Given IV
1895094|NCT01294306|Drug|Akt Inhibitor MK2206|Given PO
1895095|NCT01294306|Drug|Erlotinib Hydrochloride|Given PO
1895096|NCT01294306|Other|Laboratory Biomarker Analysis|Correlative studies
1895052|NCT01293838|Drug|Cipralex®|"Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:
10 mg tablets: 28
20 mg tablets: 84
Total for 30 participants:
10 mg tablets: 840
20 mg tablets: 2520
Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:
*20 mg tablets: 84
Total for continuation study for all participants (assuming a 60% response rate, N=18):
*20 mg tablets: 1512"
1895053|NCT01293877|Procedure|Laparoscopy surgery for morbid obesity|The intervention will compare the 2 restrictive procedures one sleeve gastrectomy and gastric plication/
1895054|NCT01293903|Drug|Qiliqiangxin capsule|Qiliqiangxin capsule is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
1895055|NCT01293903|Drug|Placebo|Placebo, similar in color and taste to Qiliqiangxin capsule, is administrated based on the standard heart failure treatment in China. Dosage: 1.2g/times. Frequency: 3 times/day. Duration: The whole study period.
1895056|NCT01293916|Other|Spica casting|single versus double leg spica casting
1895057|NCT01293942|Drug|irinotecan, capecitabine, oxaliplatin (IXO) and bevacizumab|IXO plus bevacizumab regimen is given every 3 weeks (Q3W), in the following order: Bevacizumab (A): 7.5 mg/kg via IV infusion, day 1 Oxaliplatin (O): 100 mg/m2 via 2-hour IV infusion, day 1 Irinotecan (I): 160 mg/m2 via 1-hour IV infusion, day 1 Capecitabine (X): 950 mg/m2 twice daily PO, days 2 - 15
1895058|NCT01293955|Drug|JOINS 200mg|1 tablet at each time, 3 times a day
1895059|NCT01293955|Drug|Placebo|placebo of Joins 200mg
1895060|NCT01293968|Drug|Ibuprofen, Diphenhydramine and Aluminium MgS|3 times daily for 3 days
1895061|NCT01293968|Drug|Diphenhydramine and Aluminium MgS|3 times daily for 3 days
1895062|NCT01293981|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft.
1895063|NCT01294007|Biological|PureGen Osteoprogenitor Cell Allograft|PureGen Osteoprogenitor Cell Allograft with posterior transpedicular fixation.
1895064|NCT01294007|Procedure|Autograft bone|Iliac Crest and Local Autograft Bone
1895066|NCT01294033|Other|Fractional inspired oxygen (FiO2) 0.21|
1895067|NCT01294033|Other|Fractional inspired oxygen 0.28|Supplemental oxygen
1895068|NCT01294046|Device|Deep Brain Stimulation of SPG for Migraine|Deep Brain Stimulation of SPG for Migraine
1895069|NCT01294059|Drug|Milnacipran|50 mg BID Oral x 6 Weeks
1895070|NCT01294072|Dietary Supplement|curcumin|tablets-3.6 gram (gm) taken daily for 7 days - 15 subjects
1895071|NCT01294072|Dietary Supplement|Curcumin conjugated with plant exosomes|tablets-taken daily for 7 days - 15 subjects
1895072|NCT01294072|Other|No intervention|no treatment
1895073|NCT01294098|Drug|Marcaine|0.75 cc/kg of 1/4% Marcaine
1895074|NCT01294111|Behavioral|Tai Chi training|Three groups with 15 participants each will complete a 60 minutes tai chi training programme twice-weekly for 16 weeks. The programme is worked out by an expert in Chinese traditional medicine to suit elderly people with chronic heart failure, and the classes are led by experienced leaders.
1895075|NCT01294137|Device|ventilatory polygraphy|
1895076|NCT01294150|Device|UroLift System|The NeoTract UroLift System is a medical device approved for sale in the United States, European Union, and several other countries (see www.urolift.com). It was developed for the treatment of lower urinary tract symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). During the procedure, an implant is delivered into the prostatic lobe obstructing the urethra and restricting urine flow. The distal end of the device is used to compress the lobe then the implant is delivered to retain the lobe in position, thereby increasing the urethral opening and reducing the fluid obstruction through the prostatic urethra.
1895077|NCT01294150|Other|Cystoscopy|The Control Group will undergo cystoscopy.
1895078|NCT01294163|Drug|Xenon|Inhaled xenon, maximal inspired concentration of 65%.
1895079|NCT01294163|Drug|Sevoflurane|Inhaled sevoflurane, maximal inspired concentration of 1.8%.
1895080|NCT01294163|Drug|Propofol|Hourly dose of 2-4 mg/kg
1895081|NCT01294176|Drug|Lipoic Acid|Lipoic acid will be administered orally, in two 600mg capsules, for a total 1200mg dose. The dose will be administered daily for a 6-week treatment period.
1895082|NCT01294202|Drug|AT13387 and Imatinib|"In part 1 pts will receive AT13387 in combination with imatinib. Up to 5 possible dose levels of AT13387 could be evaluated in combination with imatinib 400 mg daily: 120 mg/m2, 150 mg/m2, 180 mg/m2, 220 mg/m2 and 260 mg/m2. AT13387 IV (in the vein) on day 1, 8 and 15 of each 28 day cycle, until progression or unacceptable toxicity develops, in order to establish the recommended phase II combination dose, which will be used in part 2 and/or part 3 of the study.
In part 2 an additional 6-9pts will be treated.
In part 3, provided that sufficient evidence of anti-tumour effect was observed in part 2 (disease stabilisation or reduction in tumour dimensions by RECIST), then an additional 12pts will be treated with AT13387 in combination with imatinib. Alternatively, if combination treatment is found to have excellent efficacy the randomised phase of the study may start so that 12 pts receive AT13387 on its own (monotherapy) and 12 pts receive AT13387 in combination with imatinib."
1895083|NCT01294215|Drug|Nifedipine (Adalat, BAYA1040)|Nifedipine (Adalat, BAYA1040) 40mg twice a day (BID)
1895085|NCT01294254|Drug|Oleogel-S10|Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
1895086|NCT01294254|Procedure|Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site|wound is covered conventionally by applying one half of the Mepilex cut
1895088|NCT01294280|Other|Laboratory Biomarker Analysis|Correlative studies
1895089|NCT01294293|Drug|TLR8 Agonist VTX-2337|Given SC
1960824|NCT03108781|Drug|Lavender Oil|Lavender Oil twice a day; one month on the face and one month on the legs
1960825|NCT03108781|Drug|sunflower oil|placebo twice a day (sunflower oil); one month on the face and on month on the legs
1895102|NCT01294358|Drug|Gemcitabine|
1895103|NCT01294384|Drug|carboxymethylcellulose sodium based New Eye Drop Formulation 1|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 1 in each eye at least twice daily for 90 days.
1895104|NCT01294384|Drug|carboxymethylcellulose sodium based New Eye Drop Formulation 2|1 to 2 drops of carboxymethylcellulose sodium based New Eye Drop Formulation 2 in each eye at least twice daily for 90 days.
1895105|NCT01294384|Drug|carboxymethylcellulose sodium based Eye Drops|1 to 2 drops of carboxymethylcellulose sodium based Eye Drops (Refresh Tears®) in each eye at least twice daily for 90 days.
1895106|NCT01294397|Drug|Etanercept|Administered by subcutaneous injection once a week
1895107|NCT01294397|Drug|Denosumab|Administered by subcutaneous injection
1895108|NCT01294410|Drug|Placebo|Normal Saline, Intravenous, 0mg, Once a week for the first two weeks and every other week thereafter, 7 Weeks
1895109|NCT01294410|Drug|Placebo|Normal Saline, Intravenous, 0 mg, Every other week, Up to 757 days
1895110|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 15 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
1895111|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 25 mg/kg, Once a week for the first two weeks and every other week thereafter, 7 weeks
1895112|NCT01294410|Drug|Anti-IP-10 Antibody|Solution for IV administration, Intravenous, 5 mg/kg, Every other week, Up to 757 days
1895113|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 10 mg/kg, Every other week, Up to 757 days
1895114|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 20 mg/kg, Every other week, Up to 757 days
1895115|NCT01294410|Drug|Anti-IP-10 Antibody|Intravenous, Solution for IV administration, 15 mg/kg or optimal dose, Every other week. Open
1895116|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 5mg/matching placebo for Dapagliflozin 10mg oral dose
1895117|NCT01294423|Drug|Dapagliflozin|Dapagliflozin 10mg/matching placebo for Dapagliflozin 5mg oral dose
1895118|NCT01294423|Drug|Placebo|Matching placebo for Dapagliflozin 5mg/10mg oral dose
1895119|NCT01294436|Drug|Dapagliflozin|Oral Dose 5 or 10 mg
1895120|NCT01294449|Device|MADIT-CRT ICD|Patients that were randomized to the the implantable cardioverter defibrillator (ICD) device for the study.
1895121|NCT01294449|Device|MADIT-CRT CRT-D|Patients that were randomized to the the cardiac resynchronization therapy with defibrillation (CRT-D) device for the study.
1895122|NCT01294462|Drug|Ticagrelor|90 mg, oral dose twice daily
1895123|NCT01294462|Drug|Clopidogrel|75 mg, oral dose once daily
1895124|NCT01294462|Drug|Acetylsalicylic acid ASA|Low Dose ASA
1895125|NCT01294475|Behavioral|Planned Activities Training|Mothers will be provided a parenting intervention, Planned Activities Training (PAT). Some of the mothers will receive the PAT intervention enhanced with a cell phone.
1895126|NCT01294488|Behavioral|Parent-Child Interaction Therapy|Therapists receive training in Parent-Child Interaction Therapy (PCIT) and receive supervision in their implementation of PCIT skills via phone consultation and polycommunication technology, each for 6 months.
1895127|NCT01294501|Other|Medication administration educational module|The Research Assistant (RA) will enter the subject's language (English or Spanish), the type of medicine (tablet/capsule, liquid, or ointment) from the antibiotic prescription, and the frequency (once a day, twice a day, three times a day, four times a day) from the antibiotic prescription into the web-based educational module on medication administration so that a tailored module will be setup for the subject. The subject will then view the educational interactive module. After the subject is done with the module, the RA will administer a verbal post-test. The post-test will include questions on medication administration as well as questions on fever assessment and management.
1895128|NCT01294527|Device|Wireless cardiac stimulator implant to pace the left ventricle for CRT|Transvascular endocardial implantation of wireless pacing Electrode and subcutaneous implantation of Implantable Pulse Generator
1895129|NCT01294540|Drug|Drug: E2609|E2609 orally at varying ascending doses
1895130|NCT01294540|Drug|Placebo|Matching Placebo
1895131|NCT01294553|Drug|Administration of rosiglitazone/metformin|Subjects who are administered rosiglitazone/metformin at least once
1895132|NCT01294566|Drug|GSK1322888|1 mg, 5 mg or 25 mg capsule
1895133|NCT01294566|Drug|Placebo|matching placebo capsules
1895134|NCT01294579|Biological|Ofatumumab|"1000 mg intravenous (IV) on day 1 of each cycle (cycles 1-6) for induction phase
1000 mg IV every 2 months for 2 years"
1895135|NCT01294579|Drug|Bendamustine|90 mg/m2 on day 1 (after the ofatumumab infusion) and day 2 of each cycle (cycles 1-6)
1895136|NCT01294592|Drug|Dutasteride plus tamsulosin|Take 1 capsule daily
1895137|NCT01294592|Drug|tamsulosin|Take 1 capsule daily when escalation criteria met
1895138|NCT01294605|Biological|Boostrix™ (dTpa)|Intramuscular, 3 doses
1895139|NCT01294605|Biological|GSK Biologicals' reduced-antigen-content combined diphtheria, tetanus, acellular pertussis and inactivated polio vaccine (dTpa-IPV; BoostrixTM)|Intramuscular, single dose
1895140|NCT01294605|Biological|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 2 doses
1895141|NCT01294605|Biological|Ditanrix™ Adult, TedivaxTM (Td)|Intramuscular, 3 doses
1895142|NCT01294618|Drug|Nilotinib,Novartis,300 mg twice a day +Pegylated interferon 2a,Roche, 45 microg weekly starting Month 2-Month 12 or beyond according to investigator choice.|Combination of both treatments active by different means on the leukemic cells, in order to enhance the response rates of CP CML patients since diagnosis.
1895143|NCT01294631|Drug|Canagliflozin 300 mg once daily and HCTZ 25 mg once daily|"Period 1: canagliflozin tablets, oral, 300 mg, once daily on Days 1 to 7 followed 14 days later by Period 2.
Period 2: HCTZ tablets, oral, 25 mg, once daily for Days 1 to 28 followed by canagliflozin tablets, oral, 300 mg, once daily taken with HCTZ tablets, oral 25 mg, once daily on Days 29 to 35.."
1895144|NCT01294644|Drug|Deoxycholic acid injection|
1895145|NCT01294644|Drug|Placebo|Phosphate buffered saline placebo for injection
1895146|NCT01294657|Behavioral|Health Education|Counseling, referrals to available resources and self-help materials on Day 1, at 6 and 12 month visits, along with surveys at 6 and 12 months.
1895147|NCT01294657|Behavioral|MAPS|12 counseling phone calls over 1 year, lasting about 20-30 minutes.
1895148|NCT01294670|Drug|Vorinostat and Etoposide|Patients will be assessed in 3-week cycles. Escalating doses of vorinostat will be administered orally on a daily x 4 schedule in combination with a fixed dose of etoposide. Etoposide will be administered intravenously daily x 3 days. Cohorts of 3-6 patients will be treated with vorinostat and etoposide. In the phase II component, patients will be treated at the RP2D established in the Phase I component of the study, which was found to be 270 mg/m2/dose of Vorinostat and 100 mg/m2/dose of Etoposide.
1895149|NCT01294683|Drug|Simvastatin|
1895150|NCT01294683|Drug|Extended Release (ER) niacin/laropiprant/simvastatin (N/LRPT/SIM)|
1895151|NCT01294683|Drug|Extended Release (ER) niacin/laropiprant (N/LRPT)|
1895152|NCT01294683|Drug|Placebo|
1895153|NCT01294696|Drug|Standard of care for treatment of osteoarthritis (OA) of knee(s)|All participants will be treated according to standard medical guidelines or usual clinical practice standards of the investigating physician.
1895154|NCT01294709|Drug|telcagepant|
1895155|NCT01294709|Drug|Placebo to telcagepant|
1895156|NCT01294735|Drug|MK-4827|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
1895157|NCT01294735|Drug|Temozolomide|MK-4827 in combination with temozolomide utilizing a number of doses and schedules for both drugs will be explored to determine a preliminary MTD. The preliminary MTD will then be confirmed in participants with melanoma and glioblastoma multiforme.
1895158|NCT01294748|Device|MiStent DES|The MiStent is a device/drug combination comprised of two components; a stent and a drug product (sirolimus within an absorbable polymer coating).
1895159|NCT01294748|Device|Endeavor DES|The Endeavor is a device/drug combination comprised of two components; a stent and a drug product (everolimus within a durable polymer coating).
1895160|NCT01294761|Drug|Raltegravir, Darunavir/r|"An arm to change the regimen to: raltegravir and darunavir/ritonavir
Prezista naive 2 tabs PC QD, Norvir soft-capsule 1 cap PC QD and Isentress 1 tab BID or Prezista 2 tabs PC BID and Norvir soft-capsule 1 cap PC BID, and Isentress 1 tab BID
from: Kaletra 4 tabs QD and Truvada 1 tab QD or Kaletra 4 tabs QD, Viread 1 tab QD, Epivir300mg 1 tab (or Epivir 150mg 2 tabs) QD"
1895161|NCT01294774|Drug|KRP203 - 1.2mg|
1895162|NCT01294774|Drug|Placebo to KRP203 - 1.2 mg|
1895163|NCT01294787|Drug|indacaterol and glycopyrronium bromide (QVA149)|
1895164|NCT01294787|Drug|placebo|
1895165|NCT01294787|Drug|tiotropium|
1895166|NCT01294800|Drug|Preladenant|2, 5, or 10 mg tablets taken orally twice daily (BID)
1895167|NCT01294800|Drug|Placebo tablet to match Preladenant|tablets taken orally BID
1895168|NCT01294813|Device|Electrical Impedance Tomography (EIT)|EIT measurements of 1-2 minutes are performed in patients who routinely undergo bronchoscopy (during 1.5 hours) before, directly after and 10, 30, 60 minutes after bronchoscopy. Therefore the rubber belt including 16 integrated electrographic electrodes is placed around the patient´s chest and connected with an EIT device. EIT data are generated by application of a small alternating current of 5mA and 50kHz and are stored and analyzed offline on a personal computer. Pseudonomyzed EIT data are evaluated descriptively.
1895169|NCT01294826|Drug|AUY922|Weekly intravenous infusion on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression. A minimum of 3 patients will be enrolled into each cohort. The anticipated dose escalation sequence of AUY922 is 40, 55, and 70 mg/m2 will be used.
1895170|NCT01294826|Drug|Cetuximab|Cetuximab will be administered after each AUY922 infusion, intravenously on Day 1, 8, 15 and 22 of each 28 day cycle until unacceptable toxicity develops or disease progression.
1895171|NCT01294839|Device|Right ventricular lead location|RV leads in RVOTs group will be located in right ventricular outflow tract septum, RV leads in the other two group will be implanted in right ventricular apex, for the last RVOTs and RVA groups, the accumulated ventricular pacrouping percentage should be over 80% by adjusting AV delays.
1895172|NCT01294852|Other|surfactant prophylaxis|Premature infants born before 28 weeks' gestation and infants born at 29 to 30 weeks' gestation who did not receive antenatal steroid were randomized before delivery to receive either immediate bolus or post-resuscitation surfactant prophylaxis at 15 minutes after birth. Those infants who were randomized to immediate bolus surfactant were intubated as rapidly as possible after birth, were administered 100 mg/kg surfactant (Curosurf[Chiesi, Farmaceutici, Parma, Italy]), and received standard resuscitation measures as indicated. Those infants who were randomized to post-resuscitation surfactant received standard resuscitation measures first, were intubated electively at 15 minutes after birth and received 100 mg/kg surfactant (Curosurf[Chiesi, Farmaceutici, Parma, Italy]).
1895173|NCT01294878|Drug|omalizumab|The omalizumab dose has been calculated on the basis of body weight and basal levels of total serum IgE. Treatment was administered subcutaneously every 2 or 4 weeks (according to the calculated total dose) for a total of 48 weeks. Each vial contained 150 mg of the active compound, therefore the number of injections for each administration varied between 1 and 3, depending on the total dose used.
1895174|NCT01294891|Other|Imaging|Contrast ultrasound perfusion imaging and complete echocardiography
1895175|NCT01294917|Device|Multi-purpose disinfecting solution|For the cleaning, rinsing, and storage of soft contact lenses.
1895176|NCT01294917|Device|Clear Care|Peroxide-based regimen for cleaning and disinfecting soft contact lenses.
1895177|NCT01294917|Device|Opti-Free RepleniSH|Multi-purpose disinfecting solution for the cleaning, rinsing and storing of soft contact lenses.
1895178|NCT01294930|Other|Urine density|measurement of urine color, density and plethysmographic variability index before and during surgery.
1895179|NCT01294943|Device|Tongue cleaner|Use of the tongue cleaner (TePe ®) to remove the tongue biofilm in patients on mechanical ventilation.
1895180|NCT01294956|Other|Lubricant Eye Drop|1 drop in each eye, four times a day for 42 days
1895181|NCT01294956|Other|Refresh Liquigel|1 drop in each eye, four times a day for 42 days
1895182|NCT01294969|Drug|AL-4943A|Once daily topical ocular allergy medication used for 7 days
1895183|NCT01294982|Drug|AOBO-001|AOBO-001 400 mg Oral Capsules (1.6 g dose) twice daily
1895184|NCT01294982|Drug|AOBO-001|AOBO-001 400 mg Oral Capsules (3.2 g dose) twice daily
1895185|NCT01294982|Drug|Placebo|Placebo Oral Capsules twice daily
1895186|NCT01294995|Dietary Supplement|Tea-flavor Liquor|30 mL of Tea-flavor Liquor(45% alcohol content)
1895187|NCT01294995|Dietary Supplement|Guizhou Meijiao Liquor|30 mL of Guizhou Meijiao Liquor (45% alcohol content)
1895188|NCT01295034|Dietary Supplement|conventional vitamin D treatment|Subjects in Protocol A (the conventional/active placebo arm) will receive 50,000 IU/wk of vitamin D2 for 8 wk followed by 1000 IU/d of vitamin D3 for 48 wk.
1895189|NCT01295034|Drug|tiered/titrated vitamin D dosing|Subjects in Protocol B will receive 2000-4000 IU/d of vitamin D3, depending on the basal 25(OH)D level, with dose titration, as necessary, based on the slope of the initial response, for a total duration of treatment of 12 mo.
1895190|NCT01295047|Drug|Atenolol|
1895191|NCT01295047|Drug|VERAPAMIL|240 MG SR
1895192|NCT01295047|Drug|Perindopril|4 MG
1895193|NCT01295060|Drug|Octreotide|84 mg Octreotide Implant
1895194|NCT01295073|Drug|Trientine Hydrochloride|"Arm A's therapeutic intervention is the use of Trientine Hydrochloride for 10 days in the perioperative period.
All participating subjects will all receive cataract surgery according to present standards of care; however, subjects randomized the intervention group (trientine hydrochloride) will be on a 10 day course of oral Trientine at 1500mg administered for 7 days prior to and 3 days after surgery."
1895195|NCT01295073|Other|For Arm B there is no therapeutic intervention other than standard of care, which is cataract surgery.|see above
1895196|NCT01295086|Drug|Docetaxel|42, 51 or 60 mg/m² day 1 every 3. week
1895197|NCT01295086|Drug|Oxaliplatin|100 mg/m² day 1 every 3. week
1895198|NCT01295086|Drug|Capecitabine|1250 mg/² continuously
1895199|NCT01295086|Drug|Trastuzumab|Trastuzumab 8 mg/kg day 1, cycle 1. Following cycles 6 mg/kg every 3. week
1895200|NCT01295099|Drug|5- fluorouracil|5mg of 5FU injected per 1cm square, at 6 week intervals for 30 weeks = 6 sessions
1895201|NCT01295099|Radiation|radiotherapy|after complete excision of keloid they have a single session of radiotherapy
1895202|NCT01295099|Drug|Triamcinolone|TAC 10mg in 1ml injected intralesional
1895205|NCT01295125|Device|XenMATRIX mesh|Use of XenMATRIX mesh in the repair of contaminated ventral hernia repair
1895206|NCT01295125|Procedure|Open abdominal ventral hernia repair|Abdominal ventral hernia repair with native tissue
1895207|NCT01295138|Drug|Lactulose|Lactulose liquid. 15mls twice daily
1895208|NCT01295151|Drug|Etanercept|"Etanercept will be administered at a dose of 50mg by subcutaneous injection per week for a total of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.
The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
1895209|NCT01295151|Drug|Abatacept|"Abatacept will be administered at a dose determined by body weight:
Body Weight (kg) Dose (mg) < 60kg = 500 mg
> or equal to 60kg and < or equal to 100kg = 750 mg > 100 kg = 1000mg
The intravenous infusions will be administered in clinic on days 1, 15, 29 and every 28 days thereafter for a minimum of 24 weeks. Further treatment will be prescribed at the discretion of the treating clinician."
1895210|NCT01295151|Biological|Rituximab|"Rituximab will be given at a dose of 1000mg; 2 intravenous infusions will be administered at days 0 (week 0) and 15 (week 2).
In line with standard practice, a patient who loses an initial response with a DAS28 increase of at least 0.6 may receive a further cycle of rituximab at the discretion of the treating clinician.
Prior to receiving rituximab, intravenous methylprednisolone 100mg will also be given."
1895211|NCT01295151|Drug|Adalimumab|"Adalimumab will be given at a dose of 40mg by subcutaneous injection every two weeks for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.
The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
1895212|NCT01295151|Drug|Certolizumab Pegol|"Certolizumab Pegol will be given at a dose of 400mg by subcutaneous injection at weeks 0, 2, 4and then at a dose of 200mg every two weeks thereafter for a minimum of 12 weeks. Further treatment will be prescribed at the discretion of the treating clinician.
The patient will be taught how to administer the subcutaneous injection and injections will be monitored by the hospital until the patient is proficient with the technique."
1895213|NCT01295151|Drug|Infliximab|"Infliximab will be given at a dose of 3mg/kg per intravenous infusion in clinic.
The intravenous infusions will be administered at week 0, 2, 6 and then 8-weekly thereafter for a minimum of 12 weeks.
Further treatment will be prescribed at the discretion of the treating clinician."
1895214|NCT01295151|Drug|Golimumab|"Golimumab will be given at a dose of 50mg by subcutaneous injection every 4 weeks for a minimum of 24 weeks.
Further treatment will be prescribed in line with the study protocol and following week 48, at the discretion of the treating clinician.
The participant will be taught how to administer the subcutaneous injection and injections will be monitored according to local arrangements until the participant is proficient with the technique according to local practice."
1895215|NCT01295164|Device|classic aberrometer and aberrometer AOVIS-1|"Measurement of aberrations in early stages (1 and 2) of keratoconus as compared aberrometer AOVIS-1 with a classic aberrometer."
1895216|NCT01295164|Device|Aberrometer AOVIS-I|Measurement of aberrations in high stages (3 and 4) of keratoconus. Objective characterization of the optical quality of the patient eye by application of wave-front sensing technology in late stage keratoconus The complete procedure in one patient takes less than 5 minutes in only one consultation and is completely non invasive. The optical measurements only involve the use of low power infrared laser
1895217|NCT01295177|Drug|topic cream insulin|Intervention: Placebo cream versus insulin cream. Patients with wounds for more than 3 months without infection. These patients were treated with placebo cream or insulin cream. The placebo or insulin were used for 8 weeks.
1895218|NCT01295203|Behavioral|website assess|The internet intervention group were given assess to the intervention website which included a personal page with tailored physical activity advice and a personal profile together with Recommendations and general training programs.
1895370|NCT01283997|Other|Placebo|One pill by mouth on Day 1. Staring on Day 2, 2 times a day (every 12 hours) by mouth for 10 weeks.
1895371|NCT01283997|Drug|Minocycline|200 mg by mouth for 1 dose, then 100 mg by mouth every 12 hours for 10 weeks.
1960828|NCT03107780|Other|Laboratory Biomarker Analysis|Correlative studies
1960829|NCT03107780|Drug|MDM2 Inhibitor AMG-232|Given PO
1895219|NCT01295216|Behavioral|Mobile technology to promote lifestyle modification|Effects of an intervention using mobile health (mHealth) technology, including short message services (SMS) and one-to-one telephone calls, to promote lifestyle modification focused on reducing blood pressure among participants
1895220|NCT01295229|Procedure|laparoscopic Roux-en-Y gastric bypass (RYGB) procedure|The laparoscopic Roux-en-Y gastric bypass (RYGB) procedure is the most commonly performed bariatric procedure in the United States. Patients randomized to the surgical arm will undergo a standard laparoscopic proximal RYGB, as commonly practiced by GH surgeons, using a 90-cm alimentary limb, 50-cm biliopancreatic limb, antecolic/antegastric approach, and totally stapled technique.
1895221|NCT01295229|Behavioral|Lifestyle Intervention|The lifestyle intervention includes behavior-modification skills counseling combined with training in diet and exercise change. The focus of the exercise intervention is a gradual increase in brisk walking or other activities of similar moderate aerobic intensity. The exercise prescription will consist of at least 45 minutes of exercise, 5 days per week for 12 months. The diet intervention will be conducted by a research dietician with training in behavior modification, with supervision by Dr. Foster-Schubert. In week 1 the dietician will meet for a 60-minute individual session with participants at the FHCRC Prevention Center. Over the next 23 weeks the dietician will conduct one 30-minute group session per week.
1895222|NCT01295268|Other|Emu Oil|Subjects will apply a specified amount of emu oil daily to area.
1895223|NCT01295268|Other|Inert oil|A specified amount of inert oil will be applied daily to area.
1895224|NCT01295281|Device|LoFric POBE 2.0|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
1895225|NCT01295281|Device|LoFric PVC|To be used at least twice daily, during 7 days. Treatment period 1 and 2 last 7 days, respectively.
1895226|NCT01295294|Drug|Tranexamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
1895227|NCT01295294|Drug|Mefenamic acid|500 mg 3 times daily per oral during bleeding/spotting episodes
1895228|NCT01295294|Drug|Placebo|3 times daily per oral during bleeding/spotting episodes
1895229|NCT01295294|Drug|Mirena (Levonorgestrel IUS, BAY86-5028)|In vitro release rate 20 microgram/24 hours. Intrauterine system
1895230|NCT01295307|Drug|Clofarabine|Induction and consolidation therapy / conditioning therapy with Clofarabine
1895231|NCT01295320|Procedure|Blood sample|Blood sample will be collected at Month 48, Month 60 and Month 72
1895232|NCT01295333|Drug|the early prophylactic introduction of low dose of LT4 (50 µg/d) at 15 days post-ablation|
1895233|NCT01295333|Drug|The initiation of LT4 as soon as the first biological signs of hypothyroidism.|
1895234|NCT01295346|Other|Head CT scan and blood draw|
1895235|NCT01295359|Other|Ground Walking Program|The patients will walk on a corridor, for 40min, once a day. The speed will be controlled through a metronome, that will be programed to a frequency of steps/min determinated as 80% of the mean frequency of steps performed in six minutes walk test of that day. The 40min will be divided in 3min of walk and 2min of rest, totalizing 24min of exercise and 16min of rest. Furthermore, these patients, in sitting position, will receive orientation to do calm and slow inspirations and expirations, associated with pursed lips expiration. They will try to maintain its Respiratory Rate in 6bpm, during four minutes.
1895236|NCT01295372|Drug|Zicronapine|7.5 mg/day; orally
1895237|NCT01295372|Drug|Risperidone|5 mg/day; orally
1895238|NCT01295385|Other|NUCLEAR MAGNETIC RESONANCE IMAGING|"Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow at rest and after cold pressor test in a population of healthy volunteers."
1895239|NCT01295385|Other|NUCLEAR MAGNETIC RESONANCE IMAGING|Techniques of nuclear magnetic resonance offer interesting perspectives in this context, and particularly to quantify the myocardial blood flow will be obtained by estimating myocardial blood flow at the venous coronary sinus site. This allows us to quantify a possible endothelial dysfunction in a reproducible way. No MRI study in diabetic patients has ever been led until now with this technique and to estimate the metabolic and structural abnormalities in this population.
1895240|NCT01295398|Device|nebulisations|
1895241|NCT01295411|Device|Magnetic Resonance Imaging|
1895242|NCT01295411|Other|EVALUATION NEUROPSYCHOLOGICAL|
1895243|NCT01295424|Other|No intervention|Observational study, no interventions
1895244|NCT01295437|Device|Vypro II mesh|partly absorbable mesh
1895245|NCT01295437|Device|Premilene LP|lightweight mesh
1895246|NCT01295437|Device|Premilene mesh|A conventional polypropylene mesh (82 g/m2)
1895247|NCT01295450|Drug|Apevinat BC|"Apevinat BC presents in its formula the cyproheptadine hydrochloride (0,800 mg), tiamin hydrochloride(0,120 mg), Riboflavin sodium phosphate (0,200 mg), nicotinamide (1,334 mg, piridoxin hydrochloride (0,134 mg), ascorbic acid (4,334 mg).
Administer the recommended dosage for children 7 to 14, preferably one hour before meals: 5 ml three times daily."
1895248|NCT01295450|Drug|Vitamin Complex|A vitamin complex contains: B1, B2, B3, B3 and C vitamins. Administer the recommended dosage preferably one hour before meals: 5 ml three times daily.
1895249|NCT01295463|Other|questionnaire administration|
1895250|NCT01295463|Other|study of socioeconomic and demographic variables|
1895251|NCT01295463|Procedure|assessment of therapy complications|
1895252|NCT01295463|Procedure|fertility assessment and management|
1895253|NCT01295463|Procedure|psychosocial assessment and care|
1895254|NCT01295463|Procedure|quality-of-life assessment|
1895255|NCT01295476|Genetic|gene expression analysis|
1895256|NCT01295476|Genetic|microarray analysis|
1895257|NCT01295476|Other|laboratory biomarker analysis|
1895258|NCT01295489|Other|Laboratory Biomarker Analysis|Correlative studies
1895259|NCT01295502|Drug|Carboplatin|Given IV
1895260|NCT01295502|Drug|Cisplatin|Given IV
1895261|NCT01295502|Radiation|External Beam Radiation Therapy|Undergo EBRT
1895262|NCT01295502|Radiation|Internal Radiation Therapy|Undergo brachytherapy
1895263|NCT01295502|Drug|Paclitaxel|Given IV
1960830|NCT03107780|Other|Pharmacological Study|Correlative studies
1895372|NCT01284010|Genetic|DNA analysis|
1960831|NCT03107780|Radiation|Radiation Therapy|Undergo radiation therapy
1895266|NCT01295554|Other|NCE MRA and CE MRA|"Each patient will receive on the same day:
NCE MRA
CE MRA usually performed in the clinical routine
After each MRA examination, the CE images will be interpreted by a radiologist and the report transmitted to the prescriber within the usual delay. The radiologists in charge of this interpretation will not be involved in the evaluation of NCE images nor in the comparison between CE and NCE images."
1895267|NCT01295567|Drug|Dipyridamole|prior to CABG surgery 3 day treatment with dipyridamole 200mg SR twice daily
1895268|NCT01295567|Drug|placebo|prior to CABG surgery 3 day treatment with placebo capsules twice daily
1895269|NCT01295580|Device|Hyaluronic acid, stabilized|Hyaluronic acid
1895270|NCT01295580|Device|Hyaluronic acid|Hyaluronic acid
1895271|NCT01295593|Drug|valproic acid and 2-chlorodeoxyadenosine|VPA : daily, oral, starting dose 10mg/kg/day total dose, taken in 2 separate administrations of around 5 mg/kg/day each, for a maximum of 6 months CdA : 5.6 mg/m²/day IV during 3 days, every 28 days, for a maximum of 4 cycles
1895274|NCT01295632|Drug|ridaforolimus|10 mg enteric-coated tablets, orally, starting dose 2 tablets and escalating to 4 tablets each day for 5 days per week.
1895275|NCT01295632|Drug|MK-0752|300 mg capsule, orally, 6 capsules per dose, once each week.
1895276|NCT01295632|Drug|MK-2206|Tablets (5 mg, 25 mg, and 200 mg) to equal starting dose of 90 mg and escalating to 200 mg per dose, orally, once each week.
1895277|NCT01295645|Drug|Cidofovir|0.5 mg/kg by vein (IV) 3 times a week for 4 weeks.
1895278|NCT01295645|Other|No Cidofovir|Standard of Care: Pharmacologic management of pain, spasms, and urinary urgency with medications, hyper-hydration, or continuous bladder irrigation.
1895280|NCT01295684|Other|Cranberry juice|base diet supplemented with two 8 ounce servings of low calorie cranberry juice per day
1895281|NCT01295684|Other|Placebo|base diet supplemented with two 8 ounce servings of a color and flavor matched placebo beverage
1895282|NCT01295697|Drug|EZN-2208|Experimental
1895283|NCT01295710|Biological|US-ATG-F|20 mg/kg body weight per day, diluted in 250 mL normal saline, IV infusion over 6-12 hours 3 days prior to transplantation
1895284|NCT01295710|Biological|Placebo|250 mL normal saline, IV infusion over 6-12 hours 3 days prior to transplantation
1895285|NCT01295723|Radiation|Hypofractionated Whole Breast Radiation Therapy|"Hypofractionated Whole Breast Radiation Therapy must start within 14-56 days postoperatively (week 2-8 post-op)
Single reference dose per fraction: 2.7 Gy (ICRU)
Number of fractions: 15
Number of fractions per week: 5
Regular Radiation Therapy breaks: Weekend/ Holidays (not exceeding 7 days break)
Total dose: 50.5 Gy (40.5 WBRT + 10 Gy boost) Radiation: Intraoperative Electron Radiation Therapy"
1895286|NCT01295723|Radiation|Intraoperative Electron Radiation Therapy|Intraoperative Electron Radiation Therapy (IOERT) is delivered after completion of the lumpectomy and sentinel node procedure. IOERT is performed on mobile or fixed linac with variable electron energies in the range of 4-12 MeV
1895287|NCT01295736|Drug|Sildenafil|Sildenafil 20 mg TID per os during 90 days
1895288|NCT01295736|Drug|placebo|Placebo pills TID per os during 90 days
1895289|NCT01295749|Device|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
1895290|NCT01295749|Device|laryngeal tube ventilation and continuous chest compression|Comparison of no flow time between two strategies in out of hospital cardiac arrest
1895291|NCT01295762|Other|Immunological analyses|Immunological analyses will be done on blood, bone marrow and tumor samples, at diagnosis, and during the treatment of children diagnosed for neuroblastoma (up to 3 time points). These types of samples are routinely done during conventional neuroblastoma treatment.
1895292|NCT01295775|Drug|sulodexide|"A (SULODEXIDE GROUP):
50 mg a day by oral route (1+1 capsules/day) for 360 days
B (PLACEBO GROUP):
Sulodexide placebo at the same schedule dosage and for the same lengths of time as group A."
1895293|NCT01295788|Device|Simultaneous RT-CGM and Pump Initiation|Subjects in this group will start using RT-CGM at the same time as they initiate insulin pump therapy.
1895294|NCT01295788|Device|Delayed Initiation of RT-CGM|Subjects in this group will start using RT-CGM 6 months after initiation of insulin pump therapy.
1895295|NCT01295814|Drug|Adalimumab|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
1895296|NCT01295814|Other|inactive drug|80 mg loading dose given subcutaneously followed by 40 mg dose given subcutaneously every two weeks over a twelve week period
1895297|NCT01295827|Drug|Pembrolizumab 1 mg/kg|IV infusion over 30 minutes on Day 1 of each cycle, at dose of 1 mg/kg
1895298|NCT01295827|Drug|Pembrolizumab 3 mg/kg|IV infusion over 30 minutes on Day 1 of each cycle, at dose of 3 mg/kg
1895299|NCT01295827|Drug|Pembrolizumab 10 mg/kg|IV infusion over 30 minutes on Day 1 of each cycle (every 2 or 3 weeks depending on study arm) at a dose of 10 mg/kg.
1895300|NCT01295827|Drug|Pembrolizumab MEL|IV infusion over 30 minutes on Day 1 of each cycle
1895301|NCT01295827|Drug|Pembrolizumab NSCLC|IV infusion over 30 minutes on Day 1 of each cycle
1895302|NCT01295827|Drug|Pembrolizumab MEL Low Dose|IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
1895303|NCT01295827|Drug|Pembrolizumab MEL High Dose|IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
1895304|NCT01295827|Drug|Pembrolizumab NSCLC Low Dose|IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
1895305|NCT01295827|Drug|Pembrolizumab NSCLC High Dose|IV infusion over 30 minutes every 2 or 3 weeks at dose determined during dose escalation
1895306|NCT01295827|Drug|Pembrolizumab NSCLC Medium Dose|IV infusion over 30 minutes every 3 weeks at dose determined during dose escalation
1895307|NCT01295827|Drug|Pembrolizumab NSCLC 200 mg|IV infusion over 30 minutes every 3 weeks
1895308|NCT01295840|Device|Cardiac Resynchronization Therapy Defibrillator|Cardiac Resynchronization Therapy Defibrillator
1895373|NCT01284010|Genetic|fluorescence in situ hybridization|
1895374|NCT01284010|Genetic|gene expression analysis|
1895375|NCT01284010|Genetic|microarray analysis|
1895309|NCT01295853|Procedure|t3 sympathicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
1895310|NCT01295853|Procedure|t4 symapthicotomy|The sympathetic chain was identified at the level of the crossing of the third or fourth costal heads after dissection of the parietal pleura and completely divided about 1 cm wide at the upper margin of the rib. With assistance of anaesthesia team we reinflate the lung totally in sequence with removal of the trocars. The same procedure was performed on the opposite side and ablation of the sympathetic chain overlying the rib was performed bilaterally. At the end of surgery, a postoperative chest x-ray was routinely taken to rule out pneumothorax or hemothorax.
1895311|NCT01295866|Device|nasal nitric oxide|
1895312|NCT01295879|Drug|Ergocalciferol|Ergocalciferol 50,000 IU's orally per week, for 8 weeks
1895313|NCT01295892|Drug|Estrogen|transdermal 17-β-estradiol 1mg/day during three months
1895314|NCT01295905|Device|delefilcon A contact lens|Investigational silicone hydrogel, single vision soft contact lens
1895315|NCT01295905|Device|narafilcon B contact lens|Commercially marketed silicone hydrogel, single vision soft contact lens
1895316|NCT01295918|Dietary Supplement|L reuteri in children on antibiotics|Each patient will be assigned to receive either a probiotic supplement containing 1 x 10 8 CFU Lactobacillus reuteri DSM 17938 in the form of one chewable tablet once per day (BioGaia AB, Stockholm, Sweden) or placebo, identical in taste and appearance. The probiotic or placebo will be taken 2 hours after lunch each day, during the entire period of antibiotic treatment and for an additional 7 days.
1895317|NCT01295931|Drug|Indocyanine Green (IC-Green)|5 intradermal injections, 25 µg IC-Green in 0.1 mL of saline, in locations on the extremity (i.e. arm or leg) correlating with the tumor draining nodal basin to begin. Corresponding injections performed on the contralateral limbs.
1895318|NCT01295931|Procedure|Imaging|Nonradioactive optical imaging with indocyanine green as a fluorescent contrast agent prior to sentinel lymph node biopsy or lymph node surgery.
1895321|NCT01295957|Behavioral|reminiscence therapy|24 bi-weekly sessions of reminiscence therapy, lasting one hour each one, over a period of 12 weeks. The latter refers to the use of images, sentences or memorabilia which help to focus on specific segments of the life history of an individual, and stimulates the emergence of affect-laden personal recalls, which are later verbalized in the context of guided conversations12. The term story life is intended to highlight samples of meaningful events of the subject's life rather than a historically structured biography13. Three main variables contributed to reminiscing: individuality, evaluation and structure.
1895322|NCT01295957|Behavioral|comparison group|The control group was administered counseling and informal social contacts in bi-weekly sessions of one hour, common subjects addressed by comparison group were social security incomes, diets, family visits.
1895323|NCT01295957|Other|control|advise and informal counseling
1895324|NCT01295970|Procedure|Surgery|Prior to surgery, patients will have placement of scalp fiducials and undergo a contrast enhanced MRI scan. Once the patient is anesthetized or sedated, the head will be secured with a head frame and scalp fiducials will be registered to the stereotactic neuronavigation system. The tumor will then be resected and the patient will be taken to the recovery unit.
1895325|NCT01295970|Procedure|Stereotactic Radiosurgery|This will be delivered using Gamma Knife technology. Patients randomized to this arm will be fitted with a stereotactic head-frame for stereotactic localization of brain metastases.
1895326|NCT01296009|Drug|Traditional Chinese medicine(Zhuyun Recipe)|The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
1895327|NCT01296022|Device|Implantation of subcutaneous ICD|Implantation of subcutaneous ICD
1895328|NCT01296022|Device|Implantation of transvenous ICD|Implantation of transvenous ICD
1895329|NCT01296035|Biological|Panitumumab|Panitumumab 2.5 mg/kg on D1, D8, D15, and D22 and Gemcitabine 800 mg/m2 on D1, D8, and D15 of each 28 day cycle.
1895330|NCT01296048|Device|Comparison test|Scaleman Body Fat Scales, FS-148BW1, accuracy: ±0.1kg and range: 0-180kg.
1895332|NCT01296087|Drug|TC-6987|TC-6987 50 mg capsule given once daily on Days 1 to 28
1895333|NCT01296087|Drug|Placebo|Matching placebo capsule given once daily on Days 1 to 28
1895334|NCT01296100|Behavioral|Lifestyle intervention (nutrition)|The 200 study participants of this arm will first receive 6 months of Nutritional counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
1895335|NCT01296100|Behavioral|Lifestyle intervention (physical activity)|The 200 study participants of this arm will first receive 6 months of physical activity counseling and thereafter combined nutrition/physical activity counseling during 18 month. The counseling sessions consists of monthly group seminars (10 participants/group) and totally 6 individual visits with a nutritionist and 6 visits with a physical activity expert.
1895336|NCT01296113|Drug|Chemotherapy|"Pemetrexed + Carboplatin
On D1 of a 21-day cycle:
Pemetrexed 500 mg/m² IV in 10 minutes followed 30 minutes later by:
Carboplatin AUC 5 in 30 minutes in 100 ml sterile water or 5% glucose or physiological serum. The carboplatin dose will be calculated by the Calvert formula with a target AUC of 5 mg/mL.min as follows:
Carboplatin dose in mg = 5 x (GFR + 25) GFR is estimated according to the MDRD equation for creatinine clearance
• 4 cycles total"
1895337|NCT01296139|Drug|Ferumoxytol|All subjects will undergo pre-injection, 24, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) MRI consisting of T1 weighted (W), T2W and T2*W MRI in a 3 Tesla magnet. Additionally, all subjects will undergo pre-injection, 24 hours, 48 hours post-Ferumoxytol injection (dose of 7.5mg/kg Fe) ultrasound.
1895338|NCT01296152|Drug|depo-medroxyprogesterone acetate|At study entry/ Day 0, participants will receive Depo-medroxyprogesterone (DMPA) 150mg administered intramuscularly (IM) as a single-dose.
1895339|NCT01296165|Behavioral|Analysing the behaviours of travellers while visiting India|For analyses surrounding the risks for acquisition comparisons between those who acquire ESBLs and those who do not, will be made using Stata version 9.0 (Stata Corp, College Station, TX). Differences in proportions among categorical data will be assessed using Fisher's exact test for pair-wise comparisons. Student T-test or Mann-Whitney U tests will be used for comparing means and medians. For all statistical comparisons a p-value <0.05 will be deemed to represent statistical significance.
1895344|NCT01296204|Drug|BB4 antibody-Iodine 131|Injection of an antibody after labelling with Iodine 131
1895345|NCT01296217|Procedure|lymph nod detection|
1895346|NCT01296230|Procedure|Hormone and semen measurements before varicocelectomy|Before surgery we will measure sex-hormone levels and semen parameters. This will be repeated after the varicocelectomy to record any changes.
1895347|NCT01296243|Drug|Tesetaxel|Tesetaxel capsules will be administered orally once every 21 days until progression, as defined by Prostate Cancer Working Group 2 (PCWG2) criteria. The duration of protocol therapy will not exceed 12 months. Treatment will be initiated at a dose of 27 mg/m2; dose escalation to a maximum of 35 mg/m2 is allowed in Cycle 2 depending on tolerability.
1895348|NCT01296256|Drug|Bendamustine-EAM|Bendamustine 200 mg/m2 starting dose on day -7 and -6 Etoposide 200 mg/m2 from day -5 to day -2 Ara-C 400 mg/m2 from day -5 to day -2 Melphalan 140 mg/m2 on day -1
1895349|NCT01283789|Drug|Lapatinib and RAD-001|"Lapatinib will be taken orally as a once-daily dose of 1250 mg (five 250 mg tablets) continuously from study day 1 until progression of disease. Patients will take the tablet at bedtime, at the same time each day, in a fasting state.
Everolimus will be taken orally as a once-daily dose of 5 mg (one 5 mg tablet) from study day 1 until progression of disease. Patients will take the tablet at the same time each morning."
1895350|NCT01283802|Procedure|INTRAOPERATIVE CHOLANGIO-ULTRASOUND|"Techniques are as follows:
Direct ultrasound exploration without any contrast agents.
IOCUS injection into the bile duct of a mixture of air and saline (2 parts water and 1 part air);
IOCUS injection of an air bolus into the bile duct."
1895351|NCT01283815|Procedure|Laparoscopic appendectomy|Laparoscopic appendectomy and laparoscopic drainage of the abscess. If appendectomy is not possible due to technical difficulties only laparoscopic drainage is performed. Patients are treated with the same antimicrobial therapy as the control group (intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day).
1895352|NCT01283815|Procedure|Conservative management with percutaneous drainage|Patients are treated with intravenous Cefuroxime 1,5 g x 3 per day plus Metronidazole 500 mg x 3 per day. If the abscess is at least 3 cm in diameter percutaneous ultrasound guided drainage is performed.
1895353|NCT01283841|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
1895354|NCT01283854|Behavioral|Supervised home-based exercise|"Each participant randomised to the exercise group will be required to participate in three 60-minute exercise sessions each week, starting at 14 weeks gestation, for a total of 14 weeks (i.e. to be completed by 28 weeks of gestation). All exercise sessions will be home-based and fully supervised by an experienced exercise physiologist. The exercise program will be implemented in accordance with the American College of Sports Medicine and the American College of Obstetrics and Gynecology guidelines. All sessions will be conducted on a stationary cycle ergometer.
Heart rate will be measured continuously during exercise to ensure that the exercise intensity is maintained as prescribed. In addition, blood pressure and rate of perceived exertion will be monitored at 10-min intervals. Perceived exertion will not be allowed to exceed a rating of 14 (i.e. somewhat hard)."
1895355|NCT01283867|Drug|Mycophenolate Mofetil|Mycophenolate Mofetil 500 mg tablets
1895356|NCT01283893|Procedure|Laparoscopic distal gastrectomy with D2 lymphadenectomy|The commonly practice laparoscopic surgery for gastric cancer involves a partial omentectomy+D1+b lymphadenectomy which includes the dissection of Lymph node stations 1, 3, 4, 5, 6, 7, 8a, 9; however, when performing a D2 lymph node dissection, a total omentectomy plus LN1, 3, 4, 5, 6, 7, 8a, 9, 12a retrieval will be completed. The same total omentectomy+D2 lymphadenectomy will also be performed by the open method.
1895357|NCT01283906|Device|MuGard|Mucoadhesive Oral Wound Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day
1895358|NCT01283906|Device|Control Rinse|Aqueous Control Rinse. 5 mL oral rinse is used to cover the entire oral cavity every 3 hours (while awake) for up to a maximum of 6 doses per day.
1895359|NCT01283919|Drug|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
1895360|NCT01283932|Drug|Pantoprazole Sodium|Pantoprazole Sodium DR Tablets 40 mg
1895361|NCT01283945|Drug|Lucitanib|"Oral administration, once daily (qd), in fasting conditions.
Dose escalation - continuous schedule
Dose expansion - continuous or intermittent dosing schedules (i.e. 5 days on/2days off or 21 days on/7 days off)
Dosage form: hard gelatin capsules for oral administration (2.5, 5, 10, 30 and 50 mg strengths)"
1895362|NCT01283971|Drug|tocilizumab [RoActemra/Actemra]|Tocilizumab 8 mg/kg IV every 4 weeks for 24 weeks.
1895363|NCT01283971|Drug|adalimumab|Adalimumab 40 mg SC every 2 weeks.
1895364|NCT01283971|Drug|placebo to tocilizumab|Placebo to tocilizumab IV every 4 weeks for 24 weeks.
1895365|NCT01283971|Drug|placebo to adalimumab|Placebo to adalimumab SC every 2 weeks for 24 weeks.
1895366|NCT01283971|Drug|methotrexate|Methotrexate 10-25 mg weekly.
1895367|NCT01283971|Drug|folate|Folate at least 5 mg weekly.
1895368|NCT01283984|Drug|AZD2115|Single dose, oral inhalation (nebuliser solution)
1895369|NCT01283984|Drug|Placebo|Single dose, oral inhalation (nebuliser solution)
1895376|NCT01284010|Genetic|mutation analysis|
1895377|NCT01284010|Genetic|polymerase chain reaction|
1895378|NCT01284010|Other|laboratory biomarker analysis|
1895379|NCT01284023|Other|Shaving|Male patients will have the leg hair under each sensor site shaved, using an electric razor, and near infrared spectroscopy monitored for an additional 15 minutes
1895380|NCT01284036|Drug|PF-05230905|Single dose subcutaneous or intravenous (IV) administration of PF-05230905 or placebo
1895381|NCT01284049|Drug|Intralipid 20%®|Administration of Intralipid 20%® at a dose ranging between 0.5 and 1 g/kg/infusion during 12 weeks.
1895382|NCT01284049|Drug|OMEGAVEN 10%®|OMEGAVEN 10%® will be used as the sole lipid supplement at a dose of 0.5 to 1.0 g/kg/Infusion with a maximum dose per infusion of 40 grams, in view of formulation constraints during 12 weeks.
1895383|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
1895384|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 400 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
1895385|NCT01284062|Biological|Anrukinzumab|200 mg sterile liquid vial, dose level 600 mg administered intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12 Note: dosing in the 600 mg arm will be delayed until the safety of the 200 mg and 400 mg arms has been reviewed.
1895386|NCT01284062|Other|placebo|200 mg liquid sterile vial, administered at matching dose level 200 mg, 400 mg or 600 mg intravenously, one-hour infusion on Day 1, Week 2, 4, 8, and 12
1895387|NCT01284075|Behavioral|Guided imagery and music therapy|Participants will undergo a standardized regimen of peri-operative guided imagery and music therapy guided by CDs (compact disc). The peri-operative regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
1895388|NCT01284075|Behavioral|White Noise|Control group (WN) will listen to a CD with white noise. Participants' regimen will include: listening to the CD while in the pre-operative holding area, listening to the CD during the procedure; listening to the CD after the procedure beginning on the evening of post-operative day (POD)#0 and continuing twice a day until POD#3.
1895389|NCT01284075|Other|No intervention|Control group (CP) will have no intervention at all and will follow our current peri-operative procedures.
1895390|NCT01284088|Device|PrePex™ device for adult male circumcision|The PrePex™ device is designed to enable bloodless male circumcision procedure with no anesthesia and no sutures.
1895391|NCT01284088|Procedure|Surgical circumcision|The penis will be surgically circumcised according to one of the WHO recommended circumcision methods as described in the Manual for Male Circumcision under Local Anaesthesia Version 2.5C January 2008
1895392|NCT01284101|Device|Use of the Tan Endoglide to insert the donor graft|Using the Tan Endoglide to insert the donor graft into the eye
1895393|NCT01284101|Device|Forceps for delivery of the donor graft|Use of the forceps for delivery of the donor graft into the eye.
1895394|NCT01284114|Drug|Aliskiren|150mg/day for all as initial dose, 300mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
1895395|NCT01284140|Behavioral|Sleep and circadian rhythm promotion|This multifaceted intervention will attempt to enhance sleep and circadian rhythmicity through improved scheduling of nursing procedures, enforcement of a day/night routine, increased light exposure during the day, and decreased light and sound exposure during the night. Supplemental bright lights and eyeshades and noise cancelling headphones may also be employed.
1895396|NCT01284140|Behavioral|Usual care|Usual care.
1895397|NCT01284166|Drug|dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution|1 drop of Triple Combination Therapy (dorzolamide hydrochloride 2.0%/brimonidine tartrate 0.2%/timolol 0.5% ophthalmic solution) administered to each eye, twice daily for 12 weeks.
1895398|NCT01284179|Behavioral|Home Hypnotherapy|Each session contains the following elements: (1) trance induction consisting of narrowing the focus of attention and eye-closure, (2) trance deepening through imagery, guided dissociation from the here-and-now and graded suggestions of change in mental state, (3) vivid guided imagery that engages all the senses and implies improved health, well-being and a sense of strength and personal power, (4) therapeutic suggestions and imagery, both direct and indirect, for enhanced chest comfort, overall physical comfort and mental well-being and immunity to discomfort, that is suggested will last beyond termination of the session and become more noticeable and permanent over time, and (5) trance termination through direct suggestions and counting.
1895399|NCT01284179|Behavioral|Educational|Educational recordings regarding FCP and FGIDs.
1895400|NCT01284192|Drug|ASP3026|Tablet
1895401|NCT01284205|Biological|Mycobacterial Cell-Wall DNA Complex|8 mg/50 mL (sterile WFI) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
1895402|NCT01284205|Biological|Bacillus Calmette-Guerin|mg/50 mL (sterile saline) Intravesical Administration; one weekly instillation per week for 6 week Induction Phase; three weekly instillations per month at Months 3, 6, 12, 18, and 24 followed by Maintenance Phase.
1895403|NCT01284231|Drug|MEDI-565|MEDI-565 will be administered by IV infusion
1895404|NCT01284231|Drug|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
1895405|NCT01284231|Drug|MEDI-565|20 subjects with selected gastrointestinal tumor type to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
1895406|NCT01284231|Drug|MEDI-565|20 Subjects with refractory Gastroesophageal cancer to receive MEDI-565 at the maximum tolerated dose or optimum biologic dose by IV infusion over 3 hours per day for 5 consecutive days every 28 days.
1895439|NCT01289834|Device|Hi-Fatigue Bone Cement|"Hi-Fatigue bone cement is a new development of Aap Biomaterials, GmbH & Co that has not yet been tested in the clinical setting. Hi-Fatigue has a medium to low viscosity. Laboratory tests confirm Hi-Fatigue bone cement to have properties equivalent to or better than the golden standard bone cement Palacos. Hi-Fatigue is to be used without pre-chilling. When mixed at a room temperature of 21°C Hi-Fatigue has a low initial viscosity improving mixing and theoretically reducing the porosity of the cured cement."
1895407|NCT01284244|Device|Uresta pessary|Participants randomized to the Uresta group will be fitted with device before immediately before performing the pad test. The Uresta pessary is made of medical grade rubber that has been extensively tested for safety. It is bell-shaped, with a narrow tip that allows for easy insertion into the vagina in a similar fashion to a tampon. The device can be easily inserted, and removed by a patient for use when needed. The Uresta comes in 3 sizes. Fitting starts with insertion of the smallest size. If urine leakage continues with valsalva or a cough stress test, it can be replaced by one size larger, until leakage is stopped. If the device prevents the patient from being able to void or is uncomfortable due to its size, the smaller size is replaced. Following the pad test, the participant will be given the opportunity to keep the device for continued use, or remove it if desired.
1895408|NCT01284244|Device|Silastic ring|The silastic ring is a plastic flexible ring similar to that used to administer vaginal estrogen (Estring). It is well tolerated and would not contain any medications. Immediately before performing the pad test, it would be placed high in the vagina, away from the urethra. It would be removed immediately after the pad test. Draping will conceal from the patient which device was inserted.
1895409|NCT01284270|Other|Cardiac MRI|Cardiac MRI
1895410|NCT01289626|Drug|lanthanum carbonate|FOSRENOL® will be administered orally in a dose of 1500- 3750 mg daily in divided doses with meals. Dose escalation will be utilized to a target dose of 3750 mg daily or as designated by clinician over a 4-week period from start of study. The drug will be administered for 12 weeks.
1895411|NCT01289626|Drug|Lanthanum for calciphylaxis|Lanthanum use in calciphylaxis
1895412|NCT01289639|Drug|fenofibrate|micronized fenofibrate 200 mg 1 po qd
1895413|NCT01289639|Drug|pioglitazone|pioglitazone 30 mg po qd
1895414|NCT01289639|Drug|placebo|placebo 1 capsule po qd
1895415|NCT01289665|Procedure|Lubricating gel used during speculum insertion.|Examiner will use 0.5 mL of sterile lubricating gel to lubricate standard-sized plastic speculum during clinically indicated vaginal speculum examination. Patients will mark visual analog scale immediately following insertion.
1895416|NCT01289665|Procedure|Water used during speculum examination.|Patients will under vaginal speculum examination using 3 mL of water as a lubricant and will mark a visual analog scale immediately after speculum insertion.
1895417|NCT01289678|Drug|Interleukin-2|Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days
1895418|NCT01289691|Other|One Lung Ventilation|Patients in this group will be ventilated with a mixture of air and oxygen during one lung ventilation.
1895419|NCT01289691|Other|One Lung Ventilation|Patients in this group will be ventilated with only oxygen during one lung ventilation.
1895420|NCT01289704|Other|TreSPE|"treadmill: 5'warm up, 20'aerobic exercise (gradually incremented to 30', from session to session, if possible), 5'warm down, controlling hearth rate, blood pressure and SaO2.
Respiratory Physiotherapy: positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training, for the other 10'.
Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors digitorum longus and brevis, both at the bed and in a static position.
Proprioceptive and postural kinesitherapy according to the Perfetti method.
Balance Exercising consists of exercises carried on by basculating bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handbar preventing falls."
1895421|NCT01289704|Other|SPE|"Respiratory Physiotherapy for 20', consisting of Positive Expiratory Pressure (PEP) bottle for 10' (in various postures), and postural training according to the Mèzières technique, for the other 10'.
Stretching for 20', of the triceps surae, tibialis posterior, extensor and flexors longus and brevis, both at the bed and in a static position.
Proprioceptive and postural kinesitherapy according to the neurocognitive method.
Balance Exercising consists of exercises carried on by moving bars with improving difficulties in the instruments utilized and in the tasks with therapist supervision and near a handlebar preventing falls."
1895422|NCT01289730|Drug|Etanercept|Etanercept 25 mg subcutaneously twice a week
1895423|NCT01289743|Drug|Etanercept|Etanercept 25 mg subcutaneously twice a week
1895424|NCT01289756|Drug|Clomiphene|clomiphene once 100 mg oral
1895425|NCT01289756|Drug|clomiphene and paroxetine|clomiphene 100mg and paroxetine 3x40mg
1895426|NCT01289756|Drug|clomiphene and clarithromycin|clomiphene 100mg and clarithromycin 9x500mg
1895429|NCT01289782|Drug|Placebo|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 48 weeks
1895430|NCT01289782|Drug|TMC435|150 mg capsule once daily for 12 weeks in addition to PegIFN alpha-2a and RBV for 24 or 48 weeks
1895431|NCT01289782|Drug|Peginterferon alpha-2a (PegIFN alpha-2a)|One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
1895432|NCT01289782|Drug|Ribavirin (RBV)|200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
1895433|NCT01289808|Drug|Glucose 25%|1ml of glucose 25% once
1895434|NCT01289808|Drug|Glucose 25%|1ml glucose once per os
1895435|NCT01289821|Drug|Regorafenib (Stivarga, BAY73-4506)|Subjects will receive regorafenib 160 mg od on days 4 to 10 and days 18 to 24 as four 40 mg coprecipitate tablets. In case of administration as a single agent during the study, regorafenib will be administered 160 mg od for 3 weeks on/1 week off. Each cycle consists of 28 days.
1895436|NCT01289821|Drug|Oxaliplatin|On day 1 and day 15 of each cycle, participants will receive 85 mg/m^2 oxaliplatin as a 2 hour i.v. infusion.
1895437|NCT01289821|Drug|Folinic acid|On day 1 and day 15 of each cycle, participants will receive folinic acid (either 400 mg/m^2 D/L-folinic acid or 200 mg/m^2 L-folinic acid) as a 2 hour i.v. infusion.
1895438|NCT01289821|Drug|5-FU (mFOLFOX6)|Participants will receive a 400 mg/m^2 5 FU i.v. bolus injection immediately followed by a 2400 mg/m^2 5 FU 46 hour i.v. infusion.
1895494|NCT01290068|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
1895495|NCT01290068|Device|Monofocal IOL|Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
1895440|NCT01289834|Device|Palacos Bone Cement|"Palacos Bone Cement has been used for 48 years and has a good reputation as the gold standard among bone cements (3). It is a high-viscosity cement with rapid application that makes it advantageous for use in orthopedic joint surgery. Palacos cement was developed in order to allow hand mixing of monomers and polymers in a dish in the operating room. Air pollution with toxic monomers in the operating room was a problem that was primarily solved by exhaust ventilation, later supplemented with vacuum mixing"
1895441|NCT01289847|Biological|Gammaplex|GAMMAPLEX 5g/100 mL, dose is 300-800 mg/kg/infusion every 21 or 28 days, intravenously. The total duration of treatment with GAMMAPLEX will be 12 months with a 3 month follow-up.
1895442|NCT01289860|Dietary Supplement|Flavonoids|475g of anthocyanidins in 300ml of blueberry drink.
1895443|NCT01289860|Dietary Supplement|Control|29g powder: sugars (glucose, sucrose, fructose), vitamin C and citric acid.
1895444|NCT01289886|Drug|BR-A-657|20, 60, 120, 240, 360, 480mg or placebo tablet
1895445|NCT01289899|Drug|BR-A-657|120, 360mg or placebo 7days
1895447|NCT01289925|Dietary Supplement|Selenium|200 micrograms of selenium (in the form of selenium methionine) in tablet form taken orally daily for 8 weeks. Capsule molds with inert coating.
1895448|NCT01289925|Other|Sugar Pill Placebo|Placebo supplements in the same capsule mold as selenium and coated with the same inert coating. 1 tablet daily for 8 weeks.
1895449|NCT01289938|Drug|Diphenhydramine|Diphenhydramine 50 mg oral once
1895450|NCT01289938|Drug|Metoclopramide|10 mg i.v. metoclopramide once
1895451|NCT01289951|Drug|Raltegravir 400 mg/12hours|
1895452|NCT01289951|Drug|Raltegravir 400 mg/12hours|
1895453|NCT01289964|Procedure|Dry Cupping or fire cupping|5 dry cupping treatments, application twice a week, non standardised procedure
1895454|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
1895455|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
1895456|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
1895457|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
1895458|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
1895459|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
1895460|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
1895461|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
1895462|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
1895463|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
1895464|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
1895465|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
1895466|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
1895467|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
1895468|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
1895469|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
1895470|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
1895471|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
1895472|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
1895473|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
1895474|NCT01289990|Drug|Placebo|Placebo matching Sitagliptin
1895475|NCT01289990|Drug|Sitagliptin 100mg|Sitagliptin once daily
1895476|NCT01289990|Drug|BI 10773|BI 10773 tablets once daily
1895477|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
1895478|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
1895479|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
1895480|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
1895481|NCT01289990|Drug|Placebo|Placebo matching BI 10773 low dose
1895482|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
1895483|NCT01289990|Drug|Placebo|Placebo matching BI 10773 high dose
1895484|NCT01290003|Drug|Piperacillin-Tazobactam and Amikacin|Inj Piperacillin-Tazobactam 50 mg/Kg/dose 12 hourly IV X 3 days (6 doses) Inj Amikacin 15 mg/kg/dose 24 hourly IV X 3 days (3 doses)
1895485|NCT01290016|Behavioral|2 servings dairy + exercise|Subjects in this group will receive family based counseling to maintain the intake of 2 servings of dairy per day and also receive instruction on how to improve their physical activity.
1895486|NCT01290016|Behavioral|4 servings dairy + exercise|Subjects in this group will receive family based counseling to increase intake of dairy to 4 servings per day and also receive instruction on how to improve their physical activity.
1895487|NCT01290016|Behavioral|Control|The group will receive information during the study about diet and exercise but will not receive the intervention until 6 months into the study protocol.
1895488|NCT01290029|Drug|Cinacalcet|Single, oral dose of 0.25 mg/kg cinacalcet
1895489|NCT01290042|Drug|AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
1895490|NCT01290042|Other|Placebo for AMG 181|Four escalating dose levels of AMG 181 administered as multiple doses of AMG 181 in healthy subjects, in subjects with active ulcerative colitis, and in subjects with active Crohn's disease.
1895491|NCT01290055|Biological|Yellow fever vaccine|Group 1: All participants will receive the yellow fever vaccine and will be asked to drink deuterium labeled water and will undergo serial blood draws over 1 year.
1895492|NCT01290055|Biological|Yellow fever vaccine and D20 water|Eligible participants will receive the yellow fever vaccine and will drink D20 water
1895493|NCT01290068|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal IOL|Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient
1895496|NCT01290081|Other|Case management approach in referral to health care services|Case management intervention aimed at increasing TB screening and treatment entry among injecting drug users referred from a methadone drug treatment program
1895497|NCT01290094|Drug|ibandronate [Bonviva/Boniva]|3 mg intravenously every 3 months
1895498|NCT01290107|Genetic|DNA analysis|
1895499|NCT01290107|Genetic|gene rearrangement analysis|
1895500|NCT01290107|Genetic|microarray analysis|
1895501|NCT01290107|Genetic|polymerase chain reaction|
1895502|NCT01290107|Other|immunological diagnostic method|
1895503|NCT01290107|Other|laboratory biomarker analysis|
1895504|NCT01290120|Drug|Chemotherapy-Rituximab combination|Short cycles of high-dose and conventional chemotherapy in combination with rituximab, followed by local radiotherapy in the case of initial mediastinal or central nervous system (CNS) involvement or a residual tumor after chemotherapy. Used drugs are rituximab,cyclophosphamide, prednisone, dexamethasone, vincristine, methotrexate, iphosphamide, teniposide, etoposide, dexamethasone, cytarabine,adriamycin, vincristine, vindesine.
1895505|NCT01290133|Drug|GW597599|Single dose IV infusion
1895506|NCT01290133|Drug|Placebo|Single dose IV infusion
1895507|NCT01290146|Drug|Diuretics|Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h
1895508|NCT01290146|Drug|Levosimendan|"Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.
Starting doses will be based on baseline SBP levels
SBP ≥ 85-99mmHg: 0.05 mcg/kg/min
SBP ≥100 mmHg: 0.1 mcg/kg/min"
1895509|NCT01290159|Other|heat tolerance test (HTT)|An exercise-heat test,which consists of 120 min exposure to walking on a treadmill (5km/h; 2% grade) under conditions of 40oC and 50% rh.
1895510|NCT01290172|Drug|Administration of Somatostatin|"6 mg will be diluted in saline in a 60 cc syringe to be infused over 24 h (250 mcg/h). The treatment will be started during the hepatectomy phase, after 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.
5 cc will be injected in 2 minutes as a single bolus of 500 mcg. Somatostatin will be given a second time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h(infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 g LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued for 5 days."
1895511|NCT01290172|Drug|Administration of placebo|"The placebo treatment will be started during the hepatectomy phase, after the 1st measurement of native arterial and portal flow and pressure and given a clinically significant portal hypertension (CSPH) with a hepatic venous pressure gradient (HVPG) >= 10 mmHg.
5 cc of the 60 cc solution will be injected in 2 minutes as a single bolus of 500 mcg. The placebo will be given a 2nd time at the beginning of the warm ischemia time as a continuous infusion of 250 mcg/h (infusion rate 2,5 cc/h). This will allow the time needed for reaching a stable plasma concentration at reperfusion and minimizing risks of secondary effects. After portal revascularization of the liver graft, a new measurement of portal flow and pressure will be performed. Provided a portal vein flow (PVF) >= 90 ml/min * 100 gram LW, the remaining 55 cc will be infused for the following 22 h. 6 mg per day of continuous infusion will be continued everyday to complete 5 days of therapy."
1895512|NCT01290185|Device|Placement of different catheters for continuous nerve block|Placement different catheters adjacent to the femoral
1895513|NCT01296269|Drug|Oxytocin|one-time intranasal administration, 24 International Units, 5 puffs for each nostril
1895514|NCT01296269|Drug|Arginine Vasopressin|one-time intranasal administration, 20 International Units, 5 puffs in each nostril
1895515|NCT01296269|Drug|placebo|contains all the ingredients as in the oxytocin and vasopressin conditions, save for the active ingredient, one time intranasal administration, 5 puffs in each nostril
1895516|NCT01296282|Device|Medronics CRT Optivol Impedance Measurement|Pacemaker
1895517|NCT01296282|Device|External Thoracic Impedance Measurement|
1895518|NCT01296295|Behavioral|Lifestyle counseling and spirometry|The patients of the intervention group will be given a brief structured smoking cessation advice by their primary care physician combined with a detailed and structured discussion of the spirometry results.
1895519|NCT01296295|Behavioral|Smoking cessation advice|Brief smoking cessation advice
1895520|NCT01296308|Other|inpatient integrative treatment|two weeks inpatient integrative therapy: conventional medicine, traditional European and Chinese medicine (TCM), mind-body medicine, physical therapy, lifestyle modification program: nutrition advices, stress management, exercise training
1895523|NCT01296334|Drug|morphine LO|intravenous infusion, 10 mg, once, 4 hours
1895524|NCT01296334|Drug|Morphine Hi|intravenous infusion, 20 mg, once, 4 hours
1895525|NCT01296334|Drug|Buprenorphine LO|intravenous infusion, 0.3 mg, once, 4 hours
1895526|NCT01296334|Drug|Buprenorphine Hi|intravenous infusion, 0.6 mg, once, 4 hours
1895527|NCT01296334|Other|saline|intravenous infusion, 0.9% saline, once, 4 hours
1895528|NCT01296347|Drug|Ketamine|Intravenous infusion of ketamine starting 10 minutes prior to surgery and running for 96 hours, which will be administered at a rate of 0.1mg/kg/hour. A loading dose of 0.1mg/kg will be administered prior to the start of the infusion
1895529|NCT01296360|Biological|IXIARO|0.25 ml i.m. (milliliter, intramuscular)
1895530|NCT01296360|Biological|IXIARO|0.5 ml i.m. (milliliter, intramuscular)
1895531|NCT01296386|Biological|IC84|IC84, a recombinant fusion protein consisting of truncated Clostridium difficile (C. difficile) Toxin A and Toxin B, which will be administered at two different doses: 75 and 200 µg without or with Al(OH)3, respectively, intramuscular (i.m.) injection, four vaccinations on Day 0, 7, 28 and 56.
1895532|NCT01296412|Drug|sitagliptin|100 mg tablet, orally, once daily.
1895533|NCT01296412|Drug|liraglutide|0.6 mg by subcutaneous (pen) injection, once daily, on Days 1-7; up-titrated on Day 8 to 1.2 mg daily. At Week 12, dose may be increased to 1.8 mg once daily for participants who did not meet protocol-specified glycemic goals.
1895534|NCT01296412|Drug|glimepiride|starting dose of 1 mg tablet (up-titrated as needed), once daily, as needed, after Week 12.
1895535|NCT01296412|Drug|metformin|metformin tablets at a dose of ≥1500 mg per day
1895536|NCT01296425|Device|Easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by Easypod™
1895537|NCT01296438|Drug|Faster-acting insulin aspart|Single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin)
1895538|NCT01296438|Drug|insulin aspart|Single dose of 0.2 U/kg body weight insulin aspart injected subcutaneously (under the skin) followed by single dose of 0.2 U/kg body weight faster-acting insulin aspart injected subcutaneously (under the skin)
1895539|NCT01296451|Biological|MVA-NSmut|Genetic vaccine against Hepatitis C virus infection
1895540|NCT01296451|Biological|AdCh3NSmut|genetic vaccine against Hepatitis virus infection
1895541|NCT01296451|Biological|AdCh3NSmut1|genetic vaccine against Hepatitis virus infection
1895542|NCT01296464|Drug|Carbidopa|Capsules
1895543|NCT01296490|Other|Stress test|Stress test while running on a treadmill until exhaustion for 8-12 minutes. Blood will be drawn before, 5 minutes after and an hour after the test.
1895544|NCT01296503|Drug|Thalidomide plus dexamethasone|"D+60 after ASCT: randomization in two arms of maintenance: Arm A (dexamethasone alone 40 mg/day for 4 days every 28 days) and Arm B (dexamethasone plus thalidomide 200 mg by mouth daily) for 12 months or until disease progression.
The dose of thalidomide could be reduced if the patient experienced grade 2 or higher adverse events. In this case, thalidomide was discontinued and re-challenged at a lower dose after resolution of the adverse event."
1895545|NCT01296503|Drug|Dexamethasone|dexamethasone alone 40 mg/day for 4 days every 28 days
1895546|NCT01296516|Behavioral|Non-intervention group|A pedometer and written material on a healthy lifestyle.
1895547|NCT01296516|Behavioral|Face to face|Motivational meetings held once per week; Behavioral sessions weill be led by a trained interventionist.
1895548|NCT01296516|Behavioral|Telehelath Group|Participants will speak to Trestletree personnel once a week via phone.
1895549|NCT01296555|Drug|Fulvestrant|Participants will receive fulvestrant 500 milligrams (mg) via intramuscular injection (as per package insert or Summary of Product Characteristics [SmPC]) on Days 1 and 15 of Cycle 1, then on Day 1 of each subsequent cycle, until disease progression (Cycle length: 28 days).
1895550|NCT01296555|Drug|GDC-0032|Participants will receive GDC-0032 at escalating (Phase I, Stage 1) or fixed (Phase II and Phase I, Stage 2) doses until disease progression. Cycle 1 may be 35 days in length to allow for a 7-day washout following the initial dose; thereafter, GDC-0032 will be administered orally once daily in 28-day cycles.
1895551|NCT01296555|Drug|Letrozole|Participants will receive letrozole 2.5 mg orally (as per Package Insert or SmPC) once daily in 28-day cycles until disease progression.
1895552|NCT01296555|Drug|Midazolam|Participants will receive midazolam 5 mg (as per Package Insert or SmPC) in hydrochloride syrup on Days 1 and 16 of Cycle 1.
1895553|NCT01296568|Drug|LY2603618|Administered intravenously
1895554|NCT01296568|Drug|Pemetrexed|Administered intravenously
1895555|NCT01296568|Drug|Gemcitabine|Administered intravenously
1895556|NCT01296581|Drug|X-82|Dose escalation starting at 20 mg, oral once or twice a day, 28 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
1895557|NCT01296594|Other|Usual Care|Usual Care
1895558|NCT01296594|Behavioral|Contingency Management|This intervention consists of congratulatory messages or reminders about adherence, and participants will earn vouchers each time medication ingestion occurs at the appropriate time, along with bonuses for sustained adherence.
1895559|NCT01299558|Drug|fluticasone furoate//GW642444|Single inhaled dose of FF (800mcg)/GW642444M (100mcg) Inhalation Powder administered in the morning
1895560|NCT01299558|Drug|fluticasone furoate|Single IV dose of FF (250mcg)
1895561|NCT01299558|Drug|GW642444|Single IV dose of GW642444 (55mcg)
1895562|NCT01299571|Drug|Dutasteride|Basically there is no treatment allocation. Subjects who would be administered of dutasteride at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
1895563|NCT01299584|Drug|Remifentanil|Basically there is no treatment allocation. Subjects who would be administered of remifentanil at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
1895564|NCT01299597|Drug|Atorvastatin|20mg single dose given alone and coadministered with SB649868 on day 8 and 12 of the 14-day repeat dose period.
1895565|NCT01299597|Drug|Simvastatin|10mg single dose given alone and coadministered with SB649868 on day 12 and 14 of the 14-day repeat dose period.
1895566|NCT01299597|Drug|SB649868|20mg daily given for 14 days.
1895571|NCT01299623|Behavioral|Comparison of evidential versus non-evidential education on women's breast cancer prevention behaviors|Participants will be randomized to either the evidential or non-evidential group. Both groups will receive primarily the same information, except one group will receive information that is more tailored to African American women, while participants in the other group will receive general information about breast cancer prevention.
1895572|NCT01299636|Drug|PM060184|PM060184 administered intravenously (i.v.) over 10 minutes at a starting dose of 4 mg/m2/day on three consecutive days q2w (on Days 1-3 and 15-17) every 28 days.
1895573|NCT01299662|Drug|Poly ICLC|One 1.6 mg subcutaneous injection of the study drug, poly ICLC in the upper arm.
1895574|NCT01299701|Drug|ASA404|(5,6-dimethylxanthenone-4-acetic acid) DMXAA or DXAA
1895575|NCT01299727|Biological|rhHNS-10 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
1895576|NCT01299727|Biological|rhHNS-45 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
1895577|NCT01299727|Biological|rhHNS-90 mg|Once per month via an Intrathecal Drug Delivery Device (IDDD) for a maximum of 8 years
1895578|NCT01299740|Behavioral|Participation in DBT Skills Group|Participation of 20 group meetings lasting an hour and a half for the children, and 15 group meetings lasting an hour and a half for the parents.
1895579|NCT01299740|Other|Control Group|Treatment as usual
1895580|NCT01299753|Drug|placebo|identically packed placebo
1895581|NCT01299753|Drug|propranolol|20-40 mg q6-8h
1895582|NCT01299766|Behavioral|Behavioral Activation (BA)|BA is a manual-based, behavioral treatment that helps people increase activity levels through goal setting, activity scheduling, graded task assignment, identifying avoidant behaviors, and rating one's sense of accomplishment.
1895583|NCT01299766|Behavioral|Supportive Therapy (ST)|ST is a person-centered psychotherapy in which interventionists create a comfortable, non-judgmental environment by demonstrating genuineness, empathy, and acceptance of subjects without imposing any judgments on their decisions.
1895584|NCT01299779|Drug|PEG-SD|"PEG-SD
Bisacodyl: two 5-mg tablets at 3 pm day prior
1L sports drink* (labeled #1) with PEG-3350 119 gram bottle (labeled #1) at 6 pm night prior
1L SD* (labeled #2) with PEG-3350 119 gram bottle (labeled #2) starting 4 hrs prior to colonoscopy
Same flavor, non-red Gatorade® for all patients."
1895585|NCT01299779|Drug|PEG-ELS|"1L + 500 cc clear liquids at 6 pm night prior
1L + 500 cc clear liquids starting 4 hours prior to colonoscopy"
1895586|NCT01299792|Other|sonographic measurement of bladder wall thickness|measurement of bladder wall thickness by ultrasound at different filling states of the bladder during urodynamic investigation
1895587|NCT01299805|Drug|Vortioxetine|Encapsulated tablet
1895588|NCT01299805|Drug|Placebo|Vortioxetine placebo-matching capsules.
1895589|NCT01299831|Behavioral|72 hour fast|The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
1895590|NCT01299831|Behavioral|control, 12 hour fast|The 12 hour fast will be used as a basic metabolic control
1895591|NCT01299831|Drug|Growth hormone|Genotropin bolus(0,005 mg/kg over 20 min.) will be administered at the beginning of the study day after a 12 hour fast.
1895592|NCT01299831|Drug|Olbetam|"The participants will be fasting 72 hours prior to the start of the study day, drinking water is allowed.
During the last 12 hours of fasting and the study day lipolysis will be inhibited with one tablet of olbetam 250 mg every 4 hours."
1895593|NCT01299844|Behavioral|Diabetes Peer Counseling|16 Home visits from a bilingual/bicultural diabetes peer counselor.
1895594|NCT01299857|Drug|Rituximab|375mg/m2
1960848|NCT03098238|Biological|Biological sample|Biological sampling of two citrate tubes (18 ml) during a normal blood
1895598|NCT01299896|Other|Coordinated Care|CTQ coordinators will contact the participants for various information sessions about the participant's smoking. These participants will also receive our Connecting to Quit newsletter quarterly.
1895599|NCT01299896|Other|Usual Care|Standard therapy to help participants with smoking cessation.
1895600|NCT01299909|Behavioral|Integrated Training for Smokers|8 classes in smoking cessation strategies, 2 weeks of nicotine patches, and access to the Freedom From Smoking online program
1895601|NCT01299909|Behavioral|Mindfulness Training for Smokers|8 classes of training in mindfulness meditation, 2 weeks of nicotine patches, and access to the MTS website.
1895602|NCT01299909|Behavioral|Quitline|Telephone-based smoking cessation treatment via the Wisconsin Tobacco Quit Line (WTQL) consisting of 2 weeks of nicotine patches, self-help materials, an interactive website, and unlimited follow-up calls to the WTQL at no cost.
1895603|NCT01299922|Drug|cyclosporine +mycophenolic acid+prednison|Cyclosporine for 26 weeks Prednisone+mycophenolic acid 106 weeks
1895604|NCT01299922|Drug|Mycophenolic Acid + prednison|Mycophenolic Acid + prednison for 106 weeks
1895605|NCT01299935|Behavioral|Transcendental Meditation|The Transcendental Meditation program is the principal mind-body approach of Maharishi Ayurveda, originating from the ancient Vedic tradition and introduced 50 years ago by Vedic scholar and teacher Maharishi Mahesh Yogi. The Transcendental Meditation technique is described as a simple and natural procedure that is practiced 20 minutes twice a day while sitting comfortably with the eyes closed. Practice of the Transcendental Meditation technique does not require any changes in personal beliefs, philosophy or lifestyle. During the practice a unique state of restful alertness is gained. Acute and chronic physiological effects have been documented. The course is taught by instructors certified by Maharishi Foundation - USA.
1895606|NCT01299935|Behavioral|Health Education|health education is taught in a clinical setting using standard AHA recommendations for proper diet, exercise and control of substance usage but without a stress management component.
1895607|NCT01299948|Drug|Prednisolone|5 mg prednisolone orally per day
1895608|NCT01299961|Drug|abatacept|125 mg once a week up to 12 months.
1895609|NCT01299974|Other|Parents and Residents in Session|Family Faculty members agreed to participate in meetings with pediatric residents who agree to participate. Standardized meetings include discussions of the following: 1. Impact of hospitalization on the behavior and development of each participating parent's child. 2. Effective communication with a parent 3. How to gain trust 4. The family meeting: who participates, the agenda 5. Troubleshooting: how to deal with difficult situations (the parents will present a few instances, from their own experience, which they think might be challenging to the clinicians who treated their children). Other core components will be added (or existing ones deleted) based on participants' feedback. The meeting will be attended by two residents, a family council member, and a senior faculty who will serve as monitor. Following the meeting, the residents will have an opportunity to ask questions and offer comments about the experience in a dedicated feedback interview with a senior faculty member.
1895610|NCT01299987|Radiation|intraoperative radiotherapy|intraoperative single dose radiotherapy (20 Gy)
1895611|NCT01300000|Other|Human Milk|ad lib
1895612|NCT01300000|Other|Investigational infant formula|ad lib
1895613|NCT01300000|Other|Milk based standard infant formula|ad lib
1895614|NCT01300013|Drug|Placebo|48-hour infusion of placebo
1895615|NCT01300013|Drug|Omecamtiv mecarbil|48-hour infusion of omecamtiv mecarbil; dose strength will depend on cohort assignment.
1895616|NCT01300026|Drug|AMG 319|AMG 319 is a highly selective, orally bioavailable and potent small molecule inhibitor of PI3Kδ.
1895617|NCT01300052|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 12 weeks
1895618|NCT01300052|Drug|Ointment Vehicle|Ointment Vehicle, applied twice daily for 12 weeks
1895619|NCT01300078|Drug|MF101|MF101 10 g/day MF101 15 g/day
1895620|NCT01300104|Behavioral|Exercise|"Prescriptions: Vigorous exercise (average 65-70% of maximal oxygen consumption) minimum 3 times 45 minutes per week according to customized endurance training programs.
Restrictions: None."
1895621|NCT01300104|Behavioral|Whole grain rye|Prescriptions: Minimum 170-180g of whole grain rye intake per day. Restrictions: None.
1895622|NCT01300104|Behavioral|Recommendations|Recommendations on a health-promoting, energy restricted diet according to Danish Nutrition Recommendations and encouraged to walk at least 10,000 steps every day.
1895623|NCT01300130|Dietary Supplement|low docosahexaenoic acid formula|
1895624|NCT01300130|Dietary Supplement|medium docosahexaenoic acid formula|
1895625|NCT01300130|Dietary Supplement|high docosahexaenoic acid formula|
1895626|NCT01300130|Dietary Supplement|breast milk|a non randomized group of breast milk fed infants was included
1895627|NCT01300143|Other|TACE|Control arm will be treated by 2 or 3 cures of TACE DC beads at week 0, 8 and 16 (if required)
1895628|NCT01300143|Other|TACE+ RTC|Experimental group will be treated by one cure of TACE DC Beads at week 0 then, within two weeks, by external conformational radiotherapy in 18 sessions
1895629|NCT01300156|Drug|Oxaliplatin-based chemotherapy (ESHAOx)|"Etoposide 40 mg/m2, D1-4
Methylprednisolone 500mg, D1-5
Cytarabine 2 g/m2, D5
Oxaliplatin 130 mg/m2, D1"
1895630|NCT01300169|Behavioral|The Collaborative Assessment and Management of Suicidality|"Intensive outpatient, suicide-focused, psychotherapy designed to target and treat the drivers of suicidal ideation and behaviors."
1895631|NCT01300169|Behavioral|Enhanced Care as Usual|This is just standard outpatient mental health care that is routinely provided in the study site outpatient clinic
1895632|NCT01300182|Other|Whole body vibration therapy|The WBVT will be carried out in a vibration plates operated in vertical direction. The frequency of that vibration can be adjusted step of 5Hz with vibration frequency ranges from 20Hz to 60Hz. The amplitude can be set as 4mm.
1895633|NCT01300182|Other|Control|Conventional post-operative physical therapy exercises and rehabilitation.
1895634|NCT01300208|Drug|CC-11050|Cohort 1: 50 milligrams twice per day for 4 weeks Cohort 2: 100 milligrams twice per day for 8 weeks Cohort 3: 200 milligrams twice per day for 12 week
1895635|NCT01300208|Other|Placebo|
1895636|NCT01300234|Drug|Tenofovir disoproxil fumarate (TDF) tablets|white, almond-shaped, film-coated tablets containing 300mg of TDF
1895637|NCT01300234|Drug|Adefovir dipivoxil (ADV) tablets|white to off-white, round, biconvex tablets containing 10mg of ADV
1895638|NCT01300247|Drug|Fludarabine|Participants will receive 6 cycles (each 28-day cycle) of fludarabine at dose of 25 mg/m^2 IV, on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
1895639|NCT01300247|Drug|Obinutuzumab|Participants will receive 6 cycles (each 28-day cycle) of obinutuzumab at dose of 1000 mg IV infusion, on Days 1, 8 and 15 of Cycle 1 and Day 1 of Cycles 2-6.
1895640|NCT01300247|Drug|Bendamustine|Participants will receive 6 cycles (each 28-day cycle) of bendamustine at dose of 90 mg/m^2 IV, on Days 2 and 3 of Cycle 1 and Days 1 and 2 of Cycles 2-6.
1895641|NCT01300247|Drug|Cyclophosphamide|Participants will receive 6 cycles (each 28-day cycle) of cyclophosphamide at dose of 250 mg/m^2 IV on Days 2, 3 and 4 of Cycle 1 and Days 1, 2 and 3 of Cycles 2-6.
1895642|NCT01300260|Biological|LY2189265|Administered subcutaneously
1895643|NCT01300260|Drug|Placebo|Administered subcutaneously
1895644|NCT01300260|Drug|Insulin|Administered intravenously
1895645|NCT01300260|Drug|Glucose|Administered intravenously
1895646|NCT01300260|Drug|Glucagon|Administered intravenously
1895647|NCT01300273|Dietary Supplement|Compound α-Ketoacid Tablet|30 patients will be treated with a LPD containing 0.6g protein/kg BW per day and 120-125 kJ/kg BW per day and supplemented with keto-amino acids (Ketosteril®, Fresenius Kabi) at a dosage of 100 mg/kg BW per day.
1895648|NCT01300286|Drug|RiaSTAP|One time dose of 70 mg/kg will be administered intravenously.
1895649|NCT01300299|Radiation|Stereotactic Body Radiation Therapy|12 Gray (Gy) x 4 fractions (48 Gy) will be delivered to peripherally located tumors (> 2 cm in all directions around the proximal bronchial tree and centrally located tumors (within <2 centimeters (cm) of proximal bronchial tree). Treatment should be given on consecutive days. There will be 4 or 5 treatments.
1895650|NCT01300312|Drug|Eperisone hydrochloride and Diclofenac sodium|Fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given 3 times a day after meals for 7 to 10 days
1895651|NCT01300312|Drug|Eperisone hydrochloride|eperisone hydrochloride 50 mg as tablet formulation to be given 3 times daily after meals for 7 to 10 days
1895652|NCT01300325|Other|3% hypertonic saline solution|Patients receive every 6 hours the nebulized 0.9% saline (Placebo comparator) (group I) or the 3% hypertonic saline solution group II) in addition to aerosolized epinephrine (1.5 mg) and to the conventional treatment (oxygen, fluids).
1895653|NCT01300338|Device|Blood pressure monitor with telemetry|Blood pressure monitor for home use with readings uploaded to a web server viewable by the diabetes care manager
1895654|NCT01300338|Device|Home blood pressure monitor without telemetry|Self monitor of blood pressure without telemetry
1895655|NCT01300351|Drug|Fulvestrant|Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
1895656|NCT01300351|Drug|Placebo|Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
1895659|NCT01300377|Drug|Bupivacaine / Lidocaine|5cc 1% Lidocaine solution mixed with 5 cc 0.25% Bupivacaine solution administered locally to the surgical site at time of the surgical procedure. Administered once only.
1895660|NCT01300377|Drug|Lidocaine|10 cc 1% solution administered locally to the surgical site at time of surgical procedure. Administered once only.
1895661|NCT01300403|Other|Flutter valve|Flutter valve is a physiotherapy device commonly used for the treatment of pulmonary hypersecretive conditions. The patients is taught to exhale through the device, producing positive expiratory pressure and flow oscillations. In this study the intervention took 15 minutes. During this period the patients were free to cough.
1895662|NCT01300403|Other|expiration with the glottis open in lateral posture (ELTGOL)|This technique is a maneuver of slow expiration with the glottis open, with the subject in lateral posture. The patients performed three sets of 10 repetitions in left and right lateral decubitus.
1895663|NCT01300403|Other|Control|Patients were instructed to stay comfortably seated during 15 minutes. After this period they were stimulated to cough during a five minutes period.
1895664|NCT01300429|Genetic|obtain tissue specimens|One core biopsy specimen will be placed in formalin and processed for cytogenetic and FISH analyses as well as DNA for ALK sequencing. The second core biopsy specimen will be immediately frozen in liquid nitrogen and stored in a -80 degree freezer for research specimen. Collection will be performed on-site at the time of the procedure.
1895665|NCT01300442|Other|TEDS in COPD patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
1895666|NCT01300442|Other|TEDS in healthy patients|For the TEDS (transcutaneous electrical diaphragmatic stimulation) the electrical current is pulsed, biphasic and symmetric, with the following parameters: frequency of 30 Hertz; 0.4ms phase width, rise time of 0.7 seconds; respiratory rate of 14 rpm; intensity is the minimum necessary to obtain diaphragm muscle contraction. Four silicone-carbon electrodes (3x5cm) were placed on the skin with gel and micropore tape. Two electrodes were located on each side of the thorax, specifically in the 3rd intercostal space near the xyphoid region and in the 7th intercostal space, on the mid-axillary line. Each session had duration of approximately 30 minutes and the subjects were instructed to co-ordinate breathing with the pulsing of the electrical current.
1895667|NCT01300455|Drug|Suvorexant|40 mg tablets, orally once daily for 4 consecutive days in the evening
1895668|NCT01300455|Drug|Matching Placebo|Placebo tablets, orally once daily for 4 consecutive days in the evening
1895669|NCT01300468|Drug|PHA-848125AC|
1895670|NCT01300520|Device|Target Tape|Comparing procedures using Target Tape against procedures not using Target Tape
1895671|NCT01300533|Drug|BIND-014|
1895672|NCT01300546|Drug|Sumatriptan/Naproxen Sodium|Each tablet of Treximet for oral administration contains Sumatriptan 85mg / Naproxen Sodium 500mg. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
1895673|NCT01300546|Drug|Naproxen Sodium|Each tablet of Naproxen Sodium for oral administration is provided in 500mg tablet. Study medication is to be administered within 1 hour of migraine onset on 14 or fewer days per month in the Treatment Period.
1895674|NCT01300559|Device|Tissuelink device|Tissuelink device plus Unipolar electrocautery
1895675|NCT01300572|Procedure|Allogeneic Bone Marrow Transplantation|Undergo allogeneic bone marrow transplant
1895676|NCT01300572|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic PBSC or bone marrow transplant
1895677|NCT01300572|Drug|Cyclosporine|Given PO or IV
1895678|NCT01300572|Drug|Fludarabine Phosphate|Given IV
1895679|NCT01300572|Biological|Indium In 111 Anti-CD45 Monoclonal Antibody BC8|Given IV (dosimetric dose)
1895680|NCT01300572|Other|Laboratory Biomarker Analysis|Correlative studies
1895681|NCT01300572|Drug|Mycophenolate Mofetil|Given PO or IV
1895682|NCT01300572|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic PBSC transplant
1895683|NCT01300572|Other|Pharmacological Study|Correlative studies
1895684|NCT01300572|Radiation|Total-Body Irradiation|Undergo TBI
1895685|NCT01300572|Radiation|Yttrium Y 90 Anti-CD45 Monoclonal Antibody BC8|Given via central line (therapeutic dose)
1895686|NCT01300585|Other|MRI|Patients who qualify for the study and consent to be included will undergo placement of areola and nipple markers that will be held in place with tape for the duration of the ordered MRI study. The markers consist of latex-free plastic tubing filled with vegetable based hydrogenated oil that is solid at room temperature. This creates a fat density marker that will define the areola but does not interfere with or create artifact onto the underlying tissue. The marker can be placed by the investigator or available MRI technician instructed in marker placement. The patient will then undergo the MRI. The patients participation in the study will end with the MRI.
1895687|NCT01300598|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intra-articular infusion of Autologous Adipose Derived Mesenchymal Stem Cells. Dose : 1x10e7 cells/3mL,5x10e7 cells/3mL, 1x10e8 cells/3mL
1895690|NCT01300624|Behavioral|Verb Network Strengthening Treatment|Treatment to improve word retrieval in sentences and discourse for persons with aphasia due to stroke.
1895693|NCT01300650|Drug|Anakinra|Anakinra 100 mg subcutaneous injection daily
1895717|NCT01300910|Procedure|Male circumcision|A conventional surgical procedure will be performed, per WHO recommendations, involving: drawing a line to mark the amount of foreskin to be cut; cutting off the foreskin; hemostasis; and wound closure with sutures.
1895718|NCT01300923|Drug|Acamprosate|
1895694|NCT01300676|Drug|Tualang honey|"This was a randomized, prospective, clinical study to evaluate the effect of Tualang honey in comparison with HRT. Subjects will be confined to healthy postmenopausal women who were naturally menopause for more than one year. The study period was four months. A total of 79 patients were recruited.
Group 1: Subjects receiving 20 g/day of Tualang honey. The honey used was from a single batch honey supplied by Federal Agricultural Marketing Authorities (FAMA), Malaysia, evaporated by FAMA to achieve a water content of about 20%, submitted to Sterile Gamma company at Shah Alam, Selangor for sterilization at 25 kGy and packed in 20 g sachet in collaboration with School of Pharmaceutical Sciences laboratory.
Group 2: Subjects receiving hormonal replacement therapy (Femoston®), also known as Femo conti 1/5 (contain 1 mg Estradiol valerate and 5 mg Dydrogesterone) supplied by Solvay Pharma Malaysia."
1895695|NCT01300715|Procedure|lumbar medial branch radiofrequency neurotomy|the classic tunnel vision technique versus the alternative technique
1895696|NCT01300728|Drug|NewGam 10% IVIG|"Subjects will be randomized to receive either an infusion of IVIG at 0.4 g/kg or every 14 days for two months for a total of five infusions.
Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio. Twenty-five subjects will receive IVIG and 25 subjects will receive placebo."
1895697|NCT01300728|Other|Placebo|Subjects will be randomized to receive either an infusion of 0.9% saline solution (placebo) every 14 days for two months for a total of five infusions. Fifty subjects will be enrolled and randomized in a 1:1 IVIG 2.0 g/kg: placebo ratio.
1895698|NCT01300741|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
1895699|NCT01300741|Device|Galyfilcon A contact lens (ACUVUE® ADVANCE® Plus)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
1895700|NCT01300741|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
1895701|NCT01300754|Procedure|Dextrose Injection|12.5 Dextrose in 1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
1895702|NCT01300754|Procedure|Lidocaine Injection|1% Lidocaine injected monthly for 3 months with a 27 gauge needle on painful areas of the tibial tuberosity, under the patellar tendon.
1895703|NCT01300754|Other|Usual Care|Therapist supervised exercises that are standard of care for Osgood-Schatter Disease as well as relative rest and gradual resumption of pain-limited sport.
1895704|NCT01300767|Device|Lotrafilcon B contact lens (AIR OPTIX® AQUA)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
1895705|NCT01300767|Device|Balafilcon A contact lens (PureVision® 2)|Silicone hydrogel, single vision contact lens worn in one eye in a daily wear modality for approximately 5 days or more per week, at least 10 hours per day, for up to 4 weeks.
1895706|NCT01300767|Device|Contact lens solution (Clear Care®)|Hydrogen peroxide-based system used for cleaning, disinfection and overnight storage of the study contact lenses.
1895707|NCT01300780|Drug|Etoricoxib|Group 2 - experimental Etoricoxib will receive two doses of selective anti-inflammatory to enzyme cyclooxygenase 2 (COX-2) (Etoricoxib 60 mg) given once every 24 hours;
1895708|NCT01300780|Other|Placebo|Group 1 - Control Group will receive two doses of placebo tablet administered a every 8 hours,
1895709|NCT01300793|Drug|Velcade (bortezomib), rituximab, ifosfamide, carboplatin, etoposide|Rituximab, 375 mg/m2, IV on day 1 Etoposide, 100 mg/m2, IV on days 2 to 4 Carboplatin, AUC 5 (using the Calvert Formula), IV on day 3 Ifosfamide, 5 g/m2 with Mesna 5 g/m2, CIV over 24 hours beginning D. 3 Bortezomib,1.0mg/m2 starting cohort. Based upon a satisfactory safety profile, additional pts. will be enrolled into the 1.3, 1.5 and 1.7mg/m2 cohorts given IVP over 3 sec. d. 1, 4, 8 & 11 q. 28 days.
1895710|NCT01300819|Other|Placebo|"Placebo patches of 2, 4, 6 & 8 mg / 24 hours Daily application of Placebo patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose was 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.
Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
1895711|NCT01300819|Drug|Rotigotine|"Rotigotine patches of 2, 4, 6, and 8 mg / 24 hours
Once daily application of Rotigotine patches starting at 2 mg / 24 hours (early Parkinson's Disease (PD) patients) or 4 mg / 24 hours (advanced PD patients). Dose was up-titrated in weekly increments of 2 mg / 24 hours until optimal or maximal dose was reached. Maximal dose is 8 mg / 24 hours for early PD patients and 16 mg / 24 hours for advanced PD patients.
Optimal or maximal dose was maintained for 12 weeks followed by a de-escalation by 2 mg / 24 hours every other day."
1895712|NCT01300832|Procedure|Duplex scan of lower extremities|Lower extremities will be duplex scanned pre and post-operatively
1895713|NCT01300845|Procedure|Humidification|From randomization, oxygen therapy is humidified
1895714|NCT01300845|Procedure|No Humidification|oxygen therapy is never humidified
1895715|NCT01300858|Drug|EGEN-001-301|Patients will be treated with EGEN-001 intra-peritoneally (IP) once every week for 12 weeks and then once every two weeks until disease progression or intolerable toxicity, but for no more than one year. Patients who develop progressive metastases will receive standard chemotherapy concomitant with EGEN-001. Hence, the initial EGEN-001 treatment period will be without chemotherapy. The standard chemotherapy regimen will be FOLFOX or FOLFIRI administered every 2-3 weeks. Patient with progressive disease a second time will be taken off-study. Those who remain progression-free will receive EGEN-001 for up to one year.
1895716|NCT01300910|Device|Shang Ring|The Shang Ring is a sterile device consisting of two concentric medical grade plastic rings: an inner ring with a silicone band and an outer, hinged ring. The inner ring fits inside the outer ring which will lock when snapped together. The Shang Ring comes in multiple sizes. The appropriate size is determined through use of a measuring strip. To ensure that men cannot remove the device prematurely, the locking mechanism must be broken open using a tool that is similar to a scalpel handle. Then, a pair of special scissors, specifically designed for this purpose, is used to remove the inner ring after healing
1895724|NCT01300975|Drug|pentavalent antimony|3 intralesional injections of antimony at D1, D3 and D7
1895725|NCT01300975|Procedure|cryotherapy|Frozing of lesions with liquid nitrogen ad D1 and D14
1895726|NCT01300975|Drug|placebo cream|topical emollient crean 3 times a day during 21 days
1895727|NCT01300988|Drug|Aprepitant|Aprepitant (Emend®) 375 mg daily for 14 days
1895728|NCT01300988|Drug|Aprepitant placebo|Aprepitant(Emend®) placebo for 14 days
1895731|NCT01301027|Drug|Pioglitazone|15mg/day pioglitazone for 2 weeks, then 30mg/day pioglitazone for the remaining 24 weeks
1895732|NCT01301027|Drug|Placebo|1 pill a day for 26 weeks
1895733|NCT01301040|Drug|epirubicin, cyclophosphamide, docetaxel|"Treatment arm 1: EC - epirubicin (100mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles.
Treatment Arm 2: TC - docetaxel (75mg/m2 IV) and cyclophosphamide (600mg/m2 IV) every 3 weeks for 4 cycles."
1895736|NCT01301066|Drug|Pitavastatin|Pitavastatin 4 mg QD
1895737|NCT01301066|Drug|Pravastatin|Pravastatin 40 mg QD
1895738|NCT01301079|Drug|Ketamine|Patients in group ketamine was administrated ketamine (5mcg/kg/min) during the surgery.
1895739|NCT01301079|Drug|Saline|Patients in group N (placebo) was administrated saline during surgery.
1895740|NCT01301092|Biological|LY2189265|administered intravenous, subcutaneous or intramuscular
1895741|NCT01301105|Behavioral|Mindfulness Based Stress Reduction (MBSR)|8 week class in stress reduction through instruction in mindfulness related techniques.
1895742|NCT01301105|Behavioral|Health Enhancement Program (HEP)|8-week intervention designed to be structurally equivalent to MBSR but without a mindfulness component. Consists of nutrition, functional movement, physical activity, and music therapy.
1895743|NCT01301131|Other|Probiotics|80 ml of fermented dairy product containing L. casei shirota via nasogastric tube once daily and 80 ml of fermented dairy product containing L. casei shirota oral rinse once daily
1895744|NCT01301131|Other|control|usual oral care
1895745|NCT01301157|Drug|M518101|Proper quantity twice a day
1895746|NCT01301157|Drug|placebo|Proper quantity twice a day
1895747|NCT01301157|Drug|Dovonex|Proper quantity twice a day
1895748|NCT01301170|Procedure|dry needling|The needling will take place bilaterally at both the suboccipital region and the paravertebral muscles between C4 and T4. The needling will take place with the patient in the prone position. Following all needle placement, they will rotated clockwise till the point that tension on the needle is felt by the therapist. This will create more tension between the needle and tissue fibers, after which the needles were removed.
1895749|NCT01301183|Drug|RhIGF-1 with transdermal 17-beta estradiol|"RhIGF-1 will be started at a dose of 30mcg/k/dose twice daily, and will be titrated up or down in 25% dose increments to maintain IGF-1 levels in the upper half of the normal range.
Estradiol will be delivered transdermally using a 100 mcg patch (Vivelle Dot) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D."
1895750|NCT01301183|Drug|Placebo and transdermal 17-beta estradiol|Placebo injections will be administered twice daily. Estradiol will be delivered transdermally using a patch (100 mcg) changed twice weekly. Subjects will receive cyclic micronized progesterone (Prometrium) 100 mg daily for the first 10 days of each month. All subjects will receive supplemental calcium and vitamin D.
1895751|NCT01301196|Behavioral|Educational workshop|3h attendance at educational workshop plus self-monitoring
1895752|NCT01301222|Drug|Inj. Octreotide|100 mcg subcutaneously for 5 days
1895753|NCT01301248|Other|Chemoradiation plus Cetuximab|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2)concurrently with weekly cetuximab 250mg/m2 (following initial loading dose of 400mg/m2 a week before radiotherapy initiation)
1895754|NCT01301248|Other|Chemoradiation|Radiotherapy 65-70 Gy (1.8 Gy fractionation) Chemotherapy delivered weekly (cisplatin; 40mg/m2
1895755|NCT01301261|Drug|sugammadex|Sugammadex 2 mg/kg when a two count of train of four appears
1895756|NCT01301261|Drug|Sugammadex 4 mg/kg|Sugammadex 4 mg/kg are given when a posttetanic count 1-3 appears
1895757|NCT01301261|Drug|Sugammadex 16mg/kg|Sugammadex 16 mg/kg three minutes after the injection of cis-atracurium
1895758|NCT01301274|Drug|hypotonic|0.45% NaCl/5% dextrose IV maintenance fluids
1895759|NCT01301274|Drug|isotonic|0.9% NaCl/5% dextrose IV maintenance fluids
1895760|NCT01301287|Drug|Chlorella|
1895762|NCT01301313|Drug|Levosimendan|Levosimendan 2.5 mg / ml ampoules. The drug will be administrated in continuous intravenous perfusion in a single dose of 0.1 - 0.2 micrograms/ kg / min for 24 hours.
1895763|NCT01301313|Drug|Conventional intensified inotropic treatment|Increasing the dose and / or the number of inotropes (dopamine and / or dobutamine and / or milrinone and / or adrenaline)
1895764|NCT01301326|Device|subthreshold and threshold laser treatment|subthreshold laser treatment
1895765|NCT01301326|Device|Threshold laser treatment|threshold laser treatment
1895766|NCT01301352|Other|Route of feeding (nasogastric vs. nasojejunal)|Safety and efficacy of feeding nasogastrically vs. nasojejunally while receiving noninvasive positive pressure ventilation
1895767|NCT01301378|Procedure|Molteno 3 glaucoma drainage shunt|Patients needing glaucoma drainage surgery
1895768|NCT01301391|Drug|Milciclib Maleate|"150 mg/day once daily, for 7 consecutive days (days 1 to 7) followed by 7 days of rest (days 8 to 14) in a 2-week cycle.
Number of cycles: until disease progression or unacceptable toxicity."
1895769|NCT01301404|Dietary Supplement|10% carbohydrate drink|In the study group, 10% carbohydrate drink 400 ml will be given between 18-24 hr the night before surgery and another 400 ml will be drunk at 6-7 hr in the morning of surgery.
1895770|NCT01301417|Device|ColonRing™|Creation of a circular Compression Anastomosis
1895771|NCT01301430|Drug|H-1PV|H-1PV administered at three increasing doses either intratumorally or intravenously and then 10 days after the first administration intracerebrally (into the walls of tumor resection cavity).
1895772|NCT01301443|Drug|Subretinally injected RetinoStat|Single subretinal injections, with increasing doses. 9 patients with 3 patients at each dose followed, by 12 patients at maximum tolerated dose.
1895786|NCT01301469|Drug|6% HES 130/0.42 in plasma adapted Ringer's solution|60 g/l hydroxyethyl starch 130 dissolved in plasma adapted Ringer's solution (balanced solution)
1895787|NCT01301469|Drug|6% HES 130/0.4 in a saline solution|60 g/l Hydroxyethyl starch (HES) with a mean molecular weight of 130 kDalton which is dissolved in a saline solution
1895788|NCT01301482|Device|Ear Acupuncture|Ear acupuncture utilizes up to 10 needles (see figure 6). If at any point the subject decides not to continue with the placing of the needles, the acupuncture will cease and the number of points will be documented. The ear Acupuncture points on the right ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero. The ear Acupuncture points on the left ear include Cingulate gyrus, thalamus, omega 2, shen-men, point zero (see figures 1-5).
1895789|NCT01301495|Device|HANAROSTENT TM covered Esophageal Stent|HANAROSTENT covered Esophageal Stent for maintaining esophageal luminal patency in esophageal strictures caused by intrinsic and or extrinsic malignant tumors only and occlusion of concurrent esophageal fistula
1895790|NCT01301508|Drug|AN2728 ointment, 2%|AN2728 ointment, 2%, applied twice daily for 6 weeks
1895791|NCT01301508|Drug|AN2898 ointment, 1%|AN2898 ointment, 1%, applied twice daily for 6 weeks
1895792|NCT01301508|Drug|AN2898 ointment vehicle|AN2898 ointment vehicle applied twice daily for 6 weeks
1895793|NCT01301508|Drug|AN2728 ointment vehicle|AN2728 ointment vehicle applied twice daily for 6 weeks
1895794|NCT01301521|Drug|water-soluble cinnamon extract (Cinnulin PF)|Will take (by mouth) 1 gelatin capsule that contains 1 gram water-soluble cinnamon extract (Cinnulin PF) once a day for 12 months plus standard of care aggressive lifestyle therapy
1895795|NCT01301560|Radiation|Radiosurgery|Gamma knife surgery for asymptomatic oligo-metastasis to brain from NSCLC
1895796|NCT01301560|Radiation|Observation|No local treatment
1895797|NCT01301573|Biological|rAAV-GAD|
1895798|NCT01301586|Drug|Doxycycline and S-equol|Oral doxycycline and s-equol twice a day
1895799|NCT01301586|Drug|Doxycycline|ORAL DOXYCYCLINE TWICE A DAY
1895800|NCT01301599|Drug|combination therapy|alpha blocker and 5-alpha-reductase inhibitor medication
1895801|NCT01301599|Drug|alpha blocker monotherapy|alpha blocker monotherapy group
1895802|NCT01301599|Drug|5 alpha reductase inhibitor monotherapy|5 alpha reductase inhibitor monotherapy
1895803|NCT01301612|Drug|Nimotuzumab|Nimotuzumab, 200 mg, IV, Weekly doses for 14 weeks
1895804|NCT01301612|Drug|Cisplatin|Cisplatin, 40 mg/m2, IV, Weekly doses for 6 weeks
1895805|NCT01301612|Radiation|Brachytherapy|"Brachytherapy: 40 Gy at spot A(low dose rate, Intracavitary, 1 or 2 separate fractions for 1 to 3 weeks.
Brachytherapy: 28 Gy at spot A (high dose rate), Intracavitary 4 fractions of 7.0 Gy once or twice a week."
1895806|NCT01301612|Drug|Cisplatin|Cisplatin, 40 mg/m2, IV. Weekly doses for 6 weeks
1895807|NCT01301612|Radiation|Radiation Therapy|"Pelvic radiation therapy: 45 Gy, External, Fractions of 1.8 Gy per day, 5 days a week.
Dose boosts: 15 Gy ± 5%, External, Daily fractions of 1.8 Gy or 2 Gy per day, 5 days a week.
Brachytherapy 40 Gy at spot A(low dose rate.) Intracavitary 1 or 2 separate fractions for 1 to 3 weeks.
28 Gy at spot A (high dose rate, Intracavitary, 4 fractions of 7.0 Gy once or twice a week"
1895809|NCT01301651|Behavioral|balance training|30 minute each time, 2 times per week for 6 weeks.
1895810|NCT01301664|Other|total knee / hip replacement|Human cartilage tissues were harvested from osteoarthritic patient during total knee arthroplasty surgery.
1895811|NCT01301677|Drug|Hydrocortisone|Hydrocortisone liquid formulation
1895812|NCT01301677|Drug|2PX+|strontium chloride hexahydrate in a penetration enhancing vehicle
1895813|NCT01301677|Drug|2PX-|strontium chloride hexahydrate without a penetration enhancing vehicle
1895814|NCT01301703|Biological|Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine, Adsorbed)|a single 0.5-mL intramuscular injection into the deltoid muscle of the upper arm
1895815|NCT01301716|Drug|GDC-0980|Oral escalating dose
1895816|NCT01301716|Drug|bevacizumab|Intravenous repeating dose
1895817|NCT01301716|Drug|carboplatin|Intravenous repeating dose
1895818|NCT01301716|Drug|cisplatin|intravenous repeating dose
1895819|NCT01301716|Drug|paclitaxel|Intravenous repeating dose
1895820|NCT01301716|Drug|pemetrexed|intravenous repeating dose
1895821|NCT01301729|Drug|Docetaxel|100 mg/m2 iv every 3 weeks, 6 cycles (18 weeks)
1895822|NCT01301729|Drug|Paclitaxel|90 mg/kg iv (+/-10%) every 3 weeks for 6 3-week cycles (18 weeks)
1895823|NCT01301729|Drug|Trastuzumab|4 mg/kg iv loading dose on Day 1, 2 mg/kg iv on Day 8 and weekly thereafter
1895824|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
1895825|NCT01301742|Drug|Gemfibrozil|Gemfibrozil 600 mg bid for 5 days
1895826|NCT01301742|Drug|BI 10773|1 tablet single dose BI 10773 in the morning
1895827|NCT01301755|Procedure|Lung aspiration|direct lung tissue Aspergillus galactomannan antigen detection from aspirate by ultrasound-guided fine needle aspiration
1895828|NCT01301768|Other|Group Education|Group educational workshops about dietary habits in the first trimester because it is when organogenesis occurs and therefore when the iodine deficiency in the mother is an important risk in the development of the fetal central nervous system.
1895829|NCT01301781|Drug|BLI801|BLI801 laxative - oral solution
1895830|NCT01301781|Drug|Placebo|BLI801 placebo - oral solution
1895831|NCT01301794|Dietary Supplement|Omega 3 fatty acid (Lovaza)|Lovaza is an FDA approved omega 3 fatty acid taken as 4 grams a day (two one gram formulations twice a day).
1895832|NCT01301807|Drug|Carfilzomib|"Phase I starting dose 20 mg/m^2 by vein over 30 minutes on days 1, 2, 8, 9, 15, and 16 of a 28 day cycle.
Phase Ib starting dose will be the maximum recommended dose from Phase I."
1895833|NCT01301807|Drug|Panobinostat|"Phase I starting dose 15 mg by mouth three times a week for first two weeks every 28 days.
Phase Ib group starting dose will be the maximum recommended dose from Phase I"
1895834|NCT01301807|Drug|Dexamethasone|40 mg on days 1, 8, 15, and 21.
1895835|NCT01301820|Drug|azacitidine|azacitidine sc 75 mg/m²/d (d1- d7)
1895836|NCT01301820|Drug|Lenalidomide|lenalidomide 10mg/d (d1- d21)
1895837|NCT01301833|Drug|teneligliptin|
1895838|NCT01301833|Drug|glinide|
1895839|NCT01301833|Drug|biguanide|
1895840|NCT01301833|Drug|alpha-glucosidase inhibitor|
1895841|NCT01301859|Behavioral|TIP|Treatment visits as usual with MD
1895842|NCT01301872|Other|check biomarker :RAGE|We will check RAGE for all patients who have ARDS included in our study
1895843|NCT01301898|Drug|GC1111_0.5mg/kg|
1895844|NCT01301898|Drug|GC1111_1.0mg/kg|
1895845|NCT01301898|Drug|Elaprase_0.5mg/kg|
1895846|NCT01301911|Drug|Cipatinib|Cipatinib either at 200, 400, 800, 1200, 1400, 1600 or 1800 mg, p.o. once daily
1895847|NCT01301924|Drug|Meglumine antimoniate|"Meglumine antimoniate is stored and ministered under actual conditions employed by health services in Brazil. Each patient will be included in one of the treatment groups with meglumine antimoniate IM:
High dose: 20 days of 20 mg/kg/day antimoniate meglumine. Low dose: 30 days of 5 mg/kg/day antimoniate meglumine."
1895848|NCT01301937|Drug|Meglumine antimoniate|"Meglumine antimoniate (Aventis, São Paulo, Brazil) is stored and ministered under actual conditions employed by the health services in Brazil. Each patient will be included in one of two treatment groups with meglumine antimoniate IM:
High continuous dose: 20 mg/kg/day for 30 continuous days.
Low continuous dose 5 mg/kg/day for up to 120 continuous days.
There will be no cross-over between the groups for the purpose of this study. The data from those patients who require permanent discontinuation of a scheme will be assessed in the group that were randomized, ie, by intention to treat
Arms: High continuous dose, Low continuous dose"
1895849|NCT01301950|Other|Custom Patient Instrumentation|TruMatch® Personalized Solutions is the brand name of DePuy Orthopaedics, Inc. custom patient instrumentation (CPI). TruMatch™ is a pair of custom-made cutting blocks that allow distal femoral and proximal tibial cuts to be made according to a predefined surgical plan. The inner surface of the femoral block is manufactured to match the geometry of the patient's distal femur. The inner surface of the tibial block is manufactured to match the patient's proximal tibia. The geometric data is obtained from a CT scan and a preoperative plan approved by the surgeon
1895850|NCT01301950|Other|Conventional Instruments|Total Knee Arthroplasty implanted using conventional instruments (non-CPI) and surgical technique.
1895851|NCT01301963|Drug|plerixafor|Given SC
1895852|NCT01301963|Biological|filgrastim|Given SC
1895853|NCT01301989|Behavioral|Sleep Counselor Intervention|Families in the sleep counselor arm of the study will receive 3 scheduled home visits by a trained sleep counselor during the first 3 months following enrollment. Two optional home visits may be scheduled to help families encountering ongoing barriers to improving their child's sleep. The intervention will be provided by trained, bilingual, culturally competent sleep counselors, who will assess home sleep conditions, work with the family to teach them how to improve sleep hygiene and the sleep environment, provide equipment as needed to improve the sleep environment (e.g. nightlight, inflatable bed, window shade, etc.) and guide the family to begin setting goals and making decisions to initiate and sustain behavioral and environmental changes to improve sleep.
1895854|NCT01301989|Other|Sleep Education Control|"The control group will receive a low intensity intervention that provides information about sleep and the benefits of adequate sleep. We will give parents the National Sleep Foundation's handout, Information about Children's Sleep for Parents and Teachers"
1895855|NCT01302002|Drug|Metformin Pre-Surgery|500 mg tablet, taken twice a day for 3 weeks
1895856|NCT01302015|Biological|RNL-Vascostem®|
1895857|NCT01302028|Drug|ASP1941|Oral
1895858|NCT01302041|Drug|Enzalutamide|Oral
1895859|NCT01293006|Drug|suvorexant|one tablet (30 or 40 mg suvorexant depending on participant age: 40 mg for participants <65 years of age and 30 mg for participants ≥65 years of age), orally, once daily, for 4 consecutive days
1895860|NCT01293006|Drug|Placebo|one tablet matching suvorexant, orally, once daily, for 4 consecutive days
1895861|NCT01293019|Procedure|Osteopathic treatment|Real treatment of osteopathy
1895862|NCT01293019|Procedure|Sham Placebo|Sham treatment of osteopathy
1895863|NCT01293019|Procedure|Usual care|Classical treatment of pain in cystic fibrosis patients
1895864|NCT01293032|Procedure|Neoadjuvant Therapy|Undergo neoadjuvant therapy
1895865|NCT01293032|Procedure|Therapeutic Conventional Surgery|Undergo therapeutic conventional surgery
1895866|NCT01293032|Other|Laboratory Biomarker Analysis|Correlative studies
1895867|NCT01293032|Genetic|Gene Expression Analysis|"Undergo Oncotype Dx gene expression profiling. The Oncotype DX gene expression profiling system will be used to calculate a Recurrence Score (RS)."
1895868|NCT01293032|Drug|Systemic Chemotherapy|Undergo chemotherapy
1895869|NCT01293032|Drug|Tamoxifen Citrate|Undergo hormonal therapy
1895870|NCT01293032|Drug|Aromatase Inhibition Therapy|Undergo hormonal therapy
1895871|NCT01293045|Dietary Supplement|hydrolyzed collagen|10g/day at breakfast during 90 days
1895872|NCT01293045|Dietary Supplement|wheat protein|10g/day at breakfast during 90 days
1895873|NCT01293058|Drug|Intranasal naloxone|spray naloxone, 0.4 mg/ each 4 minutes till increasing patient level of consciousness
1895874|NCT01293058|Drug|Intravenous|Amp naloxone, 0.4 mg / each 4 minutes till increasing patient level of consciousness
1895875|NCT01293071|Other|Antibiotic rotation|Rotation of antibiotic classes as specific preferred antibiotic class to be used for empiric treatment of ICU acquired infections.
1895876|NCT01293084|Drug|0.12% saline|5mL of 0.12% saline inhaled once over 20 minutes
1895877|NCT01293084|Drug|7% saline|5mL 7% saline inhaled once over 20 minutes
1895878|NCT01293097|Drug|Atorvastatin|Atorvastatin 80mg/d ×2d before PCI. After PCI, atorvastatin 40mg/d until 30 days later, and then followed by usual care
1895879|NCT01293097|Drug|Statin|Usual care, but statin dose should not be higher than that described in exclusion criteria
1895880|NCT01293123|Drug|Raltegravir|raltegravir 400 mg PO twice daily
1895881|NCT01293123|Drug|Efavirenz|efavirenz 600 mg PO once daily
1895882|NCT01293136|Procedure|Femoral nerve block|Ropivacaine
1895883|NCT01293136|Drug|Intravenous opioids|Whatever opioids prescribed
1895884|NCT01293149|Drug|Ropivacaine|ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
1895885|NCT01293149|Drug|Clonidine|clonidine 1 mcg/kg AND ropivacaine 0.2% 0.5 ml/kg (max 20 ml)
1895886|NCT01293162|Drug|Armolipid Prev|Ortosiphon 300 mg/die, CoQ10 15 mg/die, Berberine 500 mg/die, red yeast 60 mg/die, policosanol 10 mg/die, Folic acid 200 mg/die
1895887|NCT01293175|Dietary Supplement|Whole grains|Subjects will consume whole grains at dose of 80 g/die, for two months
1895891|NCT01293227|Procedure|Surgical treatment of distal radius fractures|Surgical repair of distal radius fracture using either intramedullary locked nail or volar locked plate
1895892|NCT01293240|Device|lotrafilcon B contact lens|Commercially marketed, silicone hydrogel contact lens worn bilaterally on a daily wear basis for up to 30 days with a two week and four week evaluation visit.
1895893|NCT01293253|Behavioral|Stair walking|Participants of the stair group is encouraged to use the stairs for 10 minutes a day at the workplace. Participants of the control group receive a health examination before and after the intervention period, and are advised to stay active
1895894|NCT01293266|Drug|Propofol|Anesthesia is switched from sevoflurane to propofol after obtaining a baseline blood gas analysis.
1895895|NCT01293292|Drug|Teriparatide|Teriparatide (Forsteo) 20 mcg subcutaneous injection once daily. Duration 104 weeks.
1895896|NCT01293305|Drug|Chondroitin sulfate + Glucosamine sulfate|1 capsule three times daily, preferably in the same period
1895897|NCT01293305|Drug|Chondroitin sulfate + Glucosamine sulfate|1 sachet per day of the drug dissolved in a beaker with 200 mL water.
1895898|NCT01293318|Other|No intervention|No intervention
1895899|NCT01293344|Other|Controlled nutritional intervention based on the Mediterranean diet|Men are assigned to a 4 weeks isocaloric controlled nutritional intervention based on the Mediterranean diet (MedDiet) in which all foods and drinks are provided. The respective percentages of kcal derived from lipids, carbohydrates, protein and alcohol are respectively of 32%, 48%, 15% and 5%. Habitual energy intake of each participant is established by averaging energy requirements estimated by a validated food-frequency questionnaire (FFQ) and energy needs as determined by the Harris-Benedict formula. Body weight is measured on weekdays and total energy provided is revised if necessary for minimizing body weight fluctuations. This intervention period is preceded by a 4 weeks uncontrolled run-in period based on the Canada's Food Guide.
1895900|NCT01293344|Other|Controlled nutritional intervention based on the Mediterranean diet|Women are assigned to the same intervention than men in order to compare men and women metabolic response to the MedDiet.
1895901|NCT01293357|Drug|LEO 90105|Ointment
1895902|NCT01293383|Drug|LEO 90105|Ointment
1895903|NCT01293396|Drug|Insulin Aspart|Patients received insulin aspart before breakfast and before lunch.
1895904|NCT01293396|Drug|Insulin Aspart 30|Patients received biphasic insulin aspart 30 before breakfast and before lunch.
1895905|NCT01293396|Drug|Insulin Aspart 70|Patients received biphasic insulin aspart 70 before breakfast and before lunch.
1895906|NCT01293409|Other|Transcranial Brain-Targeted Bright Light Treatment|Transcranial Brain-Targeted Bright Light Treatment via Ear Canals
1895907|NCT01293422|Drug|Rifampicin|Rifampicin 600 mg daily for a week
1895908|NCT01293448|Device|Cryoballoon Ablation|"Device: CryoBalloon Ablation System(TM) C2 Therapeutics Inc. received FDA market clearance for the CryoBalloon Ablation System on September 29, 2010. The System is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications. (K101825)"
1895909|NCT01293461|Drug|CBX129801|Subcutaneous injection
1895910|NCT01293461|Drug|Placebo|Subcutaneous injection
1895911|NCT01293474|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the choroidal thickness with Spectralis® SD-OCT
1895912|NCT01293487|Biological|RN564|Intravenous, single dose with experimental dose
1895913|NCT01293500|Procedure|Goal-directed Therapeutic Protocol|A 10 month period of data collection for transport patients with SIRS (Systemic Inflammatory Response Syndrome) will be followed by training and institution of a goal-directed resuscitation protocol. A second 10 month data collection period will then commence. Groups will be compared with respect to outcome measures at the end of the study. All subjects will be monitored with NIRS cerebral and somatic oximetry.
1895914|NCT01293513|Other|Gradual anti-HIV treatment interruption|Gradual interruption of anti-HIV treatment: the interruption initially for a week, up to six weeks' interruption, and continuing anti-HIV treatment for two weeks between successive interruptions
1895915|NCT01293526|Device|Control|Patients who respond will have leads will be placed using standard procedures.
1895916|NCT01293526|Device|Experimental|Patients who respond will have their leads placed based on study measurements.
1895917|NCT01293526|Device|Experimental 2|Patients who respond will have their leads placed based on standard lead placement.
1895918|NCT01293539|Drug|Melphalan hydrochloride|"Drug administered intra-arterially (injection in the artery).
Standard dose:
2.5mg (3-6 month old) 3.0 mg (6-12 month old) 4.0 mg (1-3 year old) 5.0 mg (>3 years old)
Dose modification: decrease standard dose by 25% if there are signs of toxicity. Increase the dose by 25% if there is inadequate tumor response.
Frequency: 2 treatment cycles at 3-4 week intervals, with a third treatment cycle administered if the tumor requires it.
Dose not to exceed 0.5mg/kg, per treatment cycle."
1895919|NCT01293552|Biological|ANT-1207|single dose application
1895920|NCT01293552|Biological|Vehicle|
1895921|NCT01293578|Other|Diabetes Medication Choice Cards|Clinician uses the Diabetes Medication Choice Cards to inform and engage patient in discussing the issues they find relevant in choosing a new diabetes medication.
1895922|NCT01293591|Other|Control|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine.
1895923|NCT01293591|Other|Garlic treatment|Subjects will consume a garlic-free diet for 10 days. On day 11, subjects will consume 270 kcal white bread with 15 g margarine and 5 g crushed garlic.
1895924|NCT01293604|Other|Daily ingestion of whole grain barley and oats|Subjects will be randomly assigned to one of three treatments: 1) a control diet containing 0.7 daily servings of whole grain, 2) a diet containing at least 4 daily servings of whole grain barley or 3) a diet containing at least 4 servings of whole grain oats. After 6 weeks, risk factors of cardiovascular disease will be assessed after a 12 hr fast. During the seventh week, risk factors of cardiovascular disease will be assessed in the postprandial state.
1895925|NCT01293617|Other|Blackberries|300 g blackberries daily for 5 days
1895926|NCT01293617|Other|Gelatin|300 g gelatin per day for 5 days
1895927|NCT01293630|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:solution
Route of administration: intravenous"
1895928|NCT01293630|Drug|Paclitaxel|"Pharmaceutical form:solution
Route of administration: intravenous"
1895929|NCT01293630|Drug|Carboplatin|"Pharmaceutical form:solution
Route of administration: intravenous"
1895930|NCT01293643|Drug|100 mg clindamycin /800 mg ketoconazole vaginal ovule|1 vaginal ovule for 3 consecutive days
1895931|NCT01293643|Drug|100 mg tetracycline hydrochloride /50 mg amphotericin B cream|1 applicator (4 g) full of cream intravaginally for 7 to 10 days
1895932|NCT01293656|Other|No intervention.|There is no study intervention. Participants will be treated locally per site standards.
1895933|NCT01293669|Drug|TC-6987|TC-6987-23 (TC-6987 HCl) as experimental treatment: 20 mg loading dose (2 capsules) on Day 1 and 10 mg (1 capsule) on Days 2 to 28 (dose expressed as free base). Each dose will be given once daily.
1895934|NCT01293669|Drug|Placebo|Matching placebo: Mode of administration: p.o. (microcrystalline cellulose in capsule) given once daily.
1895935|NCT01293682|Drug|Calcitriol|In pill form, 45 micrograms once a week for 12 weeks
1895936|NCT01293695|Behavioral|Hypnosis|Hypnosis relaxation in five weekly sessions
1895937|NCT01293695|Other|Structured attention|Meets with therapist for five weekly sessions and receives structured attention/supportive counseling, but receives no hypnotic relaxation therapy
1895938|NCT01293721|Device|Low-magnitude high - frequency vibration treatment|stand on a vibration platform at 35Hz, 0.3g, 20mins/day and 7 days/week
1895939|NCT01293734|Other|warming lung and relieving asthmatic granule and Securing origin and warming lung emplastrum|warming lung and relieving asthmatic granule:once 1 bag, 3 times a day. Securing origin and warming lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
1895940|NCT01293734|Other|clearing lung and relieving asthmatic granule and securing origin and clearing lung emplastrum|clearing lung and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and clearing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
1895941|NCT01293734|Other|securing origin and relieving asthmatic granule and securing origin and nourishing lung emplastrum|securing origin and relieving asthmatic granule: once 1 bag, 3 times a day. securing origin and nourishing lung emplastrum: paste on acupuncture point and take the emplastrum down after 3 hours, once a day
1895942|NCT01293734|Drug|Theophylline Sustained-release Tablets and budesonide suspension|Theophylline Sustained-release Tablets 0.2g a time, twice a day. budesonide suspension for inhalation 100ug, twice a day
1895943|NCT01293747|Drug|Estradiol + Progesterone|Estradiol 1 mg and progesterone 20 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
1895944|NCT01293747|Drug|Estradiol + Progesterone|Estradiol 0.5 mg and progesterone 15 mg microspheres injectable aqueous suspension, intramuscular monthly injection for a total of 4 doses.
1895945|NCT01293760|Other|Immediate insertion|Insertion of Copper T 380A immediately after c-section delivery of baby and placenta
1895946|NCT01293760|Other|6 weeks interval insertion|Insertion of Copper T 380A 6 weeks after c-section delivery of baby and placenta
1895947|NCT01302054|Drug|Fesoterodine 8 mg|Fesoterodine sustained release tablets once every morning at 4 mg dose for first week, followed by 11 weeks at 8 mg strength.
1895948|NCT01302054|Drug|Placebo|Matching placebo for fesoterodine 4 and 8 mg for a total of 12 weeks.
1895949|NCT01302067|Drug|Fesoterodine 8mg|Oral, 1 tablet per day, 12 weeks duration, 8mg/day
1895950|NCT01302067|Drug|Fesoterodine 4mg|Oral, 1 tablet per day, 12 weeks duration, 4mg/day
1895951|NCT01302067|Drug|Placebo|Oral, 1 tablet per day, 12 weeks duration
1997397|NCT02100891|Drug|Donor NK Cell Infusion|Patients will undergo HLA-haploidentical bone marrow transplant preceded by reduced-intensity chemotherapy and radiation therapy, followed by donor NK cells on day +7 after transplant.
1895954|NCT01302093|Drug|Racecadotril Film-Coated Tablet (FCT)|A single 100 mg dose of an experimental Racecadotril FCT administered orally with 240 ml of water, with a 7- day washout between visits
1895955|NCT01302093|Drug|Racecadotril Capsule|A single 100 mg dose of a marketed Racecadotril capsule administered orally with 240 ml of water, with a 7-day washout between visits
1895956|NCT01302106|Drug|Clofarabine plus low dose Ara-C|Clofarabine 10 mg/m2 by a 1-hr i.v infusion, once daily, from day 1 to 5. Ara-C 10 mg/m2, subcutaneously, twice a day (q12 hrs), from day 1 to 15. Clofarabine will be given 4 hours before the 2nd dose of Ara-C.
1895957|NCT01302119|Drug|AN2690 Topical Solution, 5%|AN2690 Topical Solution, 5%, applied once daily for 48 weeks
1895958|NCT01302119|Drug|Solution Vehicle|AN2690 Topical Solution, Vehicle, applied once daily for 48 weeks
1895959|NCT01302132|Drug|ASP1941|Oral solution
1895960|NCT01302145|Drug|ASP1941|Tablet
1895961|NCT01302145|Drug|Metformin|Tablet
1895962|NCT01302145|Drug|Placebo|Tablet
1895963|NCT01302158|Drug|ASP1941|oral
1895964|NCT01302158|Drug|Glimepiride|oral
1895965|NCT01302171|Drug|granulocyte colony stimulating factor (GCSF)|10mcg/kg per day 5 days
1895966|NCT01302171|Procedure|bone marrow mononuclear cells|intra coronary injection of stem cells or placebo
1895967|NCT01302184|Device|Lokomat®|"Patients of the experimental group were trained at 50% of BWS for 15 minutes and 30% of BWS for 15 minutes on the Lokomat®. Treadmill speed was initiated at 1.5km/h and increased to 3.0km/h by increments of 0.5km/h as tolerated.
A physical therapist supervised the treatment, adjusting treadmill speed and BWS.
Treatment was performed for 3 days/week, for 4 weeks"
1895968|NCT01302184|Device|Treadmill|"Patients of the control group had 30 minutes of treadmill gait training. After having calculated the speed during 6MWT, the patient was trained on a treadmill (RHC770CE - RAM Medical srl). They were trained using 80% of the maximum speed that the patient reached during the test for the first week, 90% for the second week, 100% for the third and fourth week.
A Physical Therapist provided auditory cueing and direct, continuous feed-back to the patient.
Treatment was performed for 3 days/week, for 4 weeks."
1895969|NCT01302197|Other|No intervention|longitudinal follow-up after stroke
1895970|NCT01302210|Drug|Decolonization|5 day regimen of mupirocin calcium 2% twice daily to the nares and any open wound plus bath or shower with 4% chlorhexidine used as a liquid soap
1895971|NCT01302236|Drug|Eplerenone|50mg/day for all as initial dose, 100mg/day for the patients that still show hypertension(above 140/90mmHg)after one month 150mg treatment,oral,on 6 months
1895972|NCT01302249|Drug|Latanoprost 0.005%|q.d.
1895973|NCT01302249|Drug|AR-12286 Ophthalmic Solution 0.5%|
1895974|NCT01302249|Drug|Timolol maleate ophthalmic solution 0.5%|
1895975|NCT01302275|Drug|Oxcarbazepine|Oxcarbazepine capsules 300 mg is gradually increased from 300 mg/day to 2400 mg/day Placebo capsules increase from 1/day to 8/day
1895976|NCT01302288|Procedure|Per oral endolumenal myotomy|patient cohort having flexible endoscopic submucosal esophageal partial myotomy
1895977|NCT01302301|Procedure|Per oral endolumenal myotomy|flexible endoscopic submucosal esophageal partial myotomy
1895978|NCT01302314|Behavioral|Goal management training (GMT)|Fourteen hours of GMT during a time period of three months.
1895979|NCT01302327|Drug|Exenatide|Exenatide
1895980|NCT01302340|Drug|Delta-THC|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
1895981|NCT01302340|Drug|placebo|Active treatment consists of THC in tablet form. Patients receive 0.75 mg THC twice daily during the first three treatment blocks (period A) and 1.5 mg THC twice daily during the latter three treatment blocks (period B). Placebo treatment consists of two tablets daily and is matched to the active treatment for taste, color and size. Study medication will be administered at 10 a.m. and 4 p.m., by the primary caregiver. These time points are chosen because NPS often occur later on the day, when fatigue and external signals build up to the stress and result in NPS. The order of administration of THC and placebo (1:1) will be determined by randomization per block: THC followed by placebo or placebo followed by THC.
1895982|NCT01302340|Drug|Delta-THC|In case either 2 times daily 1 tablet 0,75mg or 2 times daily 1 tablet 1.5mg Delta-THC appeared to be efficacious for a particular patient, this patient can continue the effective dose of delta-THC in an open label extension phase during 6 months.
1895983|NCT01302353|Drug|Emulsified Isoflurane|
1895984|NCT01302366|Drug|TBL12|
1895985|NCT01302379|Drug|Metformin|Week 1: 500 mg at dinner time Weeks 2-4: 1000 mg at dinner time Weeks 5+: 500 mg in morning; 1000 mg at dinner time
1895986|NCT01302379|Drug|Placebo|Week 1: 1 pill at dinner time Weeks 2-4: 2 pills at dinner time Weeks 5+: 1 pill in morning; 2 pills at dinner time
1895987|NCT01302379|Behavioral|Lifestyle intervention|Telephone-based lifestyle intervention (dietary change and physical activity) for weight loss.
1895988|NCT01302379|Behavioral|Standard printed dietary guidelines|Set of standard health education materials provided to participants at single time point (immediately after randomization)
1895989|NCT01302691|Drug|losartan potassium + hydrochlorothiazide + amlodipine besylate (MK-0954E)|One tablet, containing 50 mg losartan potassium, 12.5 mg hydrochlorothiazide, and 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
1895990|NCT01302691|Drug|Losartan potassium|One tablet, containing 50 mg losartan potassium, orally, once daily, for 8 weeks.
1895991|NCT01302691|Drug|Amlodipine besylate|One capsule, containing 5 mg amlodipine besylate, orally, once daily, for 8 weeks.
1895992|NCT01302691|Drug|Placebo to MK-0954E|One tablet, containing placebo, orally, once daily, for 8 weeks.
1895993|NCT01302691|Drug|Placebo to losartan potassium|One tablet, containing placebo, orally, once daily, for 8 weeks.
1895994|NCT01302691|Drug|Placebo to amlodipine besylate|One capsule, containing placebo, orally, once daily, for 8 weeks.
1895995|NCT01302717|Device|LV pacing|The left ventricular lead are positioned preferentially at the posterolateral or lateral venous branches of the coronary sinus.
1895996|NCT01302717|Device|RV pacing|The right ventricular lead are positioned at the right ventricular apex.
1895997|NCT01302743|Drug|Group 1: Metformin|Group 1: Will receive oral extended-release Metformin 1000 mg once a day for 90 days
1895998|NCT01302743|Dietary Supplement|Group 2: Cinnamon Bark|Group 2: Will receive Cinnamon Bark 1000 mg once a day for 90 days
1895999|NCT01302743|Dietary Supplement|Group 3: Cinnulin PF|Group 3: Will receive Cinnulin PF 500 mg once a day for 90 days.
1896000|NCT01302756|Other|Placebo|Group 1: Placebo plus standard of care pre-natal vitamins (which include 1 milligram of folic acid) a day for the duration of pregnancy
1896001|NCT01302756|Dietary Supplement|Folic Acid|Group 2: 4-milligrams of folic acid a day for the duration of pregnancy plus standard of care pre-natal vitamins (which include 1 milligram of folic acid)
1896002|NCT01302769|Device|Standard treatment plus ear acupuncture|Standard treatment plus ear acupuncture
1896003|NCT01302795|Drug|Canakinumab|Monoclonal antibody inhibiting interleukin 1 beta
1896008|NCT01302821|Biological|Adenovirus-p53 transduced dendritic cell vaccine|The Ad.p53 DC vaccine will be injected intradermally (through the skin) into four separate sites. The patient's vaccine will be the same dose throughout the study.
1896009|NCT01302821|Drug|1-methyl-D-tryptophan|Each treatment cycle is comprised of 21 days. The treatment is continuous with no breaks in between cycles. Patients would not be allowed to take any tryptophan containing supplements while participating on this study.
1896010|NCT01302821|Radiation|Carbon C 11 alpha-methyltryptophan|The experimental examination for this research is the administration by a needle in a vein of Tryptophan labeled with a radioactive tracer (a substance is believed to enhance imaging for easier detection and measurement), Carbon 11, when when the patient has not eaten for five hours. A standard PET/CT scanner is then used to create images of the tracer a few minutes later.
1896011|NCT01302834|Biological|cetuximab|Given IV
1896012|NCT01302834|Drug|cisplatin|Given IV
1896013|NCT01302847|Drug|Dolutegravir (DTG) film-coated tablets|"Stage I: Initial starting dose of DTG tablet(s) at approximately 1 mg/kg, to be taken orally once or twice daily.
Stage II: Stage I-approved dose of DTG to be taken orally once or twice daily."
1896014|NCT01302847|Drug|DTG granules for suspension|"Stage I: DTG granules for suspension, to be taken orally once or twice daily. Dose will vary for each participant.
Stage II: Stage I-approved dose of DTG to be taken orally once or twice daily. (Note: Cohort IIB will not be included in Stage II of the study)."
1896015|NCT01302847|Drug|DTG dispersible tablets|"Stage I: DTG dispersible tablets, to be taken orally once or twice daily. Dose will vary for each participant.
Stage II: Stage I-approved dose of DTG to be taken orally once or twice daily."
1896016|NCT01302860|Drug|ACZ885|
1896017|NCT01302873|Drug|BGG492A|
1896018|NCT01302873|Drug|BGG492A|
1896019|NCT01302886|Drug|BHQ880|
1896020|NCT01302899|Drug|Aliskiren|Aliskiren 150 mg (Tablet)
1896021|NCT01302899|Drug|Placebo to Aliskiren|Aliskiren 150 mg Matching Placebo (Tablet)
1896022|NCT01302899|Drug|Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule)
1896023|NCT01302899|Drug|Placebo to Hydrochlorothiazide (HCTZ)|HCTZ 25mg (Capsule) Matching Placebo
1896024|NCT01302899|Drug|Ramipril|Ramipril 10mg (Tablet)
1896025|NCT01302912|Procedure|Lymphoma-Biopsy|Patients after biopsy of orbital lymphoma
1896026|NCT01302925|Drug|PEP005 Gel|PEP005 Gel 0.05% for 2 consecutive days
1896027|NCT01302925|Drug|PEP005 Gel|PEP005 Gel 0.015% for 3 consecutive days
1896028|NCT01302938|Drug|Tolterodine ER|One 4 mg capsule will be taken with water every day with or without food. It should be swallowed whole without chewing.
1896029|NCT01302938|Drug|Placebo|A placebo of Tolterodine ER 4 mg will be taken with water every day with or without food. It should be swallowed whole without chewing.
1896030|NCT01302951|Drug|Moxifloxacin 400 mg|The patients receive MXF 400 mg as one hour intravenous infusion at randomized timed intervals prior to liver resection.
1896031|NCT01302964|Drug|Placebo|Subjects randomized to placebo will receive placebo for duration of the study
1896032|NCT01302964|Drug|Mirtazapine|Subjects will receive 7.5 mg daily at the start of the trial. The dose will be increased by 7.5 mg weekly for subject weighing less than 5 50kg and up to 15 mg weekly for subjects weighing more than 50kg depending upon efficacy and tolerability.
1896033|NCT01302964|Drug|Mirtazapine|Subjects will receive 7.5 mg of mirtazapine daily initially. The dose will be increased by 7.5 mg for subjects weighing less than 50kg and up to 15 mg per week for subjects weighing more than 50kg. depending upon efficacy and tolerability.
1896035|NCT01302990|Biological|Dose given at Day 0|Dose given by intramuscular administration (0.5 mL)
1896036|NCT01303003|Drug|Dexamethasone|40 cc. 0.125% bupivicaine + 0.5cc. dexamethasone (2mg.) per side.
1896037|NCT01303003|Procedure|TAP block|Bilateral TAP block of 40cc. of 0.125% bupivicaine + 0.5cc. sterile saline per side
1896038|NCT01303016|Dietary Supplement|Chispuditos|Daily dose per child is 1 heaping Tablespoon of Chispuditos (using the appropriate measuring spoon provided to each participant), 1 teaspoon of sugar if desired (using appropriate measuring spoon provided to each participant), mixed with 8 ounces of water or milk. The mixture is stirred over a heat source (fire or stove) until the mixture boils for 8 minutes.
1896039|NCT01303029|Drug|Gemcitabine+erlotinib|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
1896040|NCT01303029|Drug|Gemcitabine+erlotinib+capecitabine|Gemcitabine 1000mg/m2 over 30 minutes on days 1, 8, 15. Capecitabine will be administered orally 1.660 mg/m2 day from day 1 to day 21. Erlotinib will be administered orally at a dose of 100 mg daily from day 1 to day 28, repeated every 4 weeks .
1896041|NCT01303042|Drug|Insulin lispro mix 50/50|Insulin lispro mix 50/50 t.i.d : six months
1896042|NCT01303055|Drug|Alogliptin|Alogliptin 25 mg, tablets, orally, once daily : two years
1896043|NCT01303055|Drug|Metformin 750 mg|"Metformin 750 mg, tablets, orally, thrice daily: two years
The dose increase is possible up to its maximum, 2250 mg, so that HbA1c is maintained below 6.9 %."
1896044|NCT01303068|Device|13C urea breath test Kit|20 and 50 mg, 13C urea breath test: urea nebulizer solution to detect Pseudomonas
1896045|NCT01303081|Behavioral|Individual Rewards|If participants quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, they will receive a monetary award from the study investigators.
1896046|NCT01303081|Behavioral|Fixed Deposits|Participants will have to deposit a certain monetary amount of their own money as an incentive to quit smoking. If they quit smoking by their target quit date, and that is confirmed by cotinine/anabasine tests, participants will receive their deposit back. If participants do not quit, their money will be used to support future research studies designed to help people stop smoking.
1896047|NCT01303081|Behavioral|Chosen Deposits|Participants will choose their deposit amount (XX = chosen deposit); this same amount will be returned upon success (that is, quit smoking by the target quit date, and having this confirmed by cotinine/anabasine tests). If participants do not quit, their money will be used to support future research studies designed to help people stop smoking. The default deposit will be set to a certain monetary amount for consistency with other arms, and participants can increase or decrease this amount until they reach the amount they want to deposit.
1896048|NCT01303081|Behavioral|Competitive Deposits (Pari-Mutuel)|"Groups (or cohorts) of 6 smokers each will be formed on a rolling basis, linking individuals with target quit dates (day 0's) near each other. Participants will deposit a certain monetary amount (Y) in an account, and the payout for quitting on this arm will be Y x 6/Q , where Q is the number of quits in the cohort. Again, success will be confirmed by cotinine or anabasine tests, and if participants do not quit, their money will be used to support future research studies designed to help people stop smoking."
1896049|NCT01303081|Behavioral|Usual Care|Participants will receive reimbursements for completing the surveys that are part of the Way To Quit program and for submitting saliva or urine samples at 14 days and 3 months (among those eligible).
1896050|NCT01303094|Drug|Trabectedin|Trabectedin will be administered without drug holiday in Arm A until unacceptable toxicity, progressive disease or patient decision. The treatment beyond disease progression and in case of intolerance will be decided according to investigator discretion. In case of progression after drug discontinuation by patient decision, a re-challenge of Trabectedin is possible.
1896051|NCT01303094|Other|Drug: holiday|A drug-holiday will start after the 6th cycle until disease progression, and then Trabectedin will be re-challenged. Trabectedin will be administered until unacceptable toxicity, second evidence of progressive disease or patient decision.
1896052|NCT01303107|Drug|Bupivacaine|single dose of 15 mg by a slow injection rate of 1 mL/s
1896053|NCT01303120|Drug|Femoral Nerve Block|Preoperative Bupivacaine 0.5%, perineurally as single shot
1896054|NCT01303120|Drug|Combined nerve blocks|Preoperative Bupivacaine 0.5%, perineurally as single shot
1896055|NCT01303120|Drug|Patient-controlled analgesia|Patient controlled analgesia with morphine
1896056|NCT01303146|Drug|rhARSA|intravenous infusion 100U/kg every other week for 18 months
1896057|NCT01303159|Device|Endoscopic bipolar radiofrequency probe (ENDOHPB)|EndoHPB (EMcision Ltd, UK) is a single use sterile device for use at ERCP or PTC. It is a 8F (2.6mm) catheter with a 1.8m working length, that is designed to be inserted into the target duct of the hepatic, biliary or pancreatic system over a guide wire. The device is compatible with endoscopes that have a working channel of 3.2mm or greater. It comprises of a coaxial over the wire (OTW) catheter with 2 ring electrodes spaced 8mm apart at its distal end. The distal electrode is 5mm from the leading edge of the catheter. The two electrodes at the distal end of EndoHPB are designed to produce a heating zone length of approximately 25 mm.
1896058|NCT01303172|Biological|IMM-101|"IMM-101 is a suspension of heat-killed whole cell M. obuense in borate-buffered saline.
A single 0.1 mL intradermal injection of IMM-101 (10 mg/mL)will be administered every 2 weeks for the first 3 doses followed by a rest of 4 weeks then every 2 weeks for the next 3 doses followed by every 4 weeks thereafter.
Chemotherapy plus IMM-101 will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles of gemcitabine."
1896059|NCT01303172|Drug|Gemcitabine|"Gemcitabine will be administered intravenously at 1000 mg/m2 over 30 minutes once weekly for 3 consecutive weeks out of every 4 weeks.
Chemotherapy will be offered until intolerable toxicity or withdrawal from the study up to a maximum of 12 cycles (i.e. approximately 48 weeks).
Dosage reduction with each cycle or within each cycle may be applied based upon the grade of Gemcitabine-related toxicity experienced by the patient using centre's standard protocol."
1896060|NCT01303198|Device|APAP - Therapy|automatic positive pressure therapy
1896061|NCT01303224|Drug|Ibodutant|Oral tablet, low dose, once daily, for 8 weeks
1896062|NCT01303224|Drug|Ibodutant|Oral tablet, intermediate dose, once daily, for 8 weeks
1896063|NCT01303224|Drug|Ibodutant|Oral tablet, high dose, once daily, for 8 weeks
1896064|NCT01303224|Drug|Placebo|Oral tablet, (identical in appearance and weight to Ibodutant tablets), once daily, for 8 weeks
1896065|NCT01303237|Drug|Cetuximab + RT|Cetuximab initial dose 400 mg/m² on week 1; Cetuximab maintenance dose 250 mg/m² continued for 7 weeks plus concomitant RT
1896066|NCT01303250|Drug|balanced 6% hydroxyethylstarch 130/0.4|Fluid administration and optimization based on cardiac output findings during surgery.
1896067|NCT01303250|Drug|balanced crystalloid|Fluid administration and optimization based on cardiac output findings during surgery.
1896068|NCT01303263|Behavioral|Educational Intervention|45-minute teaching session on healthcare costs, in which each resident reviewed an itemized hospital bill for a patient he/she had cared for, followed by an open-ended discussion about reducing unnecessary costs.
1896069|NCT01303289|Dietary Supplement|T-Diet plus Standard|T-Diet plus Standard is a complete balanced protein and energy oral nutrition supplement, indicated for the dietary management of patients with related malnutrition.
1896070|NCT01303289|Dietary Supplement|Jevity|JEVITY is a diet for tube-fed patients in the medium to long term, to varying degrees of malnutrition with gastrointestinal disorders.
1896071|NCT01303302|Device|Tantalus System|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes
1896072|NCT01303302|Device|TANTALUS system|The TANTALUS System is an active implantable device, generating Gastric contractility modulation (GCM) stimulation for the treatmnet of type 2 diabetes. In the sham comparator the device is off.
1896073|NCT01303315|Device|TANTALUS System|An Active Implantable Pulse Generator Medical Device for the treatment of Obesity and Diabetes Type 2 and Obesity
1896074|NCT01303328|Drug|C1|Local application of the experimental gel or placebo gel.
1896075|NCT01303341|Other|Laboratory Biomarker Analysis|Correlative studies
1896076|NCT01303341|Other|Pharmacological Study|Correlative studies
1896077|NCT01303341|Drug|Riluzole|Given PO
1896078|NCT01303341|Drug|Sorafenib Tosylate|Given PO
1896079|NCT01303354|Procedure|Lumbar Transforaminal Epidural Steroid Injection|
1896080|NCT01303380|Drug|Canakinumab|
1896081|NCT01303406|Drug|Idebenone|All PROTI patients randomised to idebenone treatment will receive high dose idebenone. This is defined according to body weight. In patients weighing 45 kg or less, it is 1350 mg/day (3 x 150 mg tablets three times per day with meals). In patients weighing more than 45 kg, it is 2250 mg/day (5 x 150 mg tablets three times per day with meals).
1896082|NCT01303406|Drug|Placebo|
1896083|NCT01303419|Device|CE-BMRI|Contrast-enhanced breast imaging using Magnetic Resonance
1896084|NCT01303419|Device|DE-CEDM|Breast imaging using Dual-energy, contrast-enhanced digital mammography
1896085|NCT01303432|Dietary Supplement|Yogurt supplemented with Mobilee|One yogurt (125mL) per day including 80mg of Mobilee
1896086|NCT01303432|Dietary Supplement|Yogurt|One yogurt (125mL) per day
1896087|NCT01303445|Drug|Aggrenox alone|Aggrenox 1 capsule twice daily for 7 days
1896088|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
1896089|NCT01303445|Drug|Aggrenox and omeprazole|Aggrenox 1 capsule twice daily and omeprazole 80mg once daily for 7 days
1896090|NCT01303445|Drug|Omeprazole alone|omeprazole 80 once daily for 7 days
1896091|NCT01303458|Behavioral|Basic Needs Surveillance (BNS) protocol|The BNS intervention will consist of 4 components: 1) WE CARE survey which mothers will fill out in the waiting room prior to their child's WCC visits; 2) Family Resource book containing 1-page information sheets on resources, that providers will have access to in exam rooms; 3) a Community Resource Coordinator who will assist families link to available resources, and update providers; 4) Training Session which will provide a 1 hr overview of the intervention to providers
1896092|NCT01303471|Drug|opioid (remifentanyl)|Infusion of remifentanyl (opioid) will be started at different levels for each group of the randomized study : 0 ng/ml (group 0), 1 ng/ml (group 1), 3 ng/ml (group 3) or 4 ng/ml (group 4)
1896093|NCT01303484|Dietary Supplement|Bi2muno® GOS|5.5g/day for 10 weeks
1896094|NCT01303484|Dietary Supplement|Maltodextrin|5.5g daily for 10 weeks
1896095|NCT01303497|Drug|Paclitaxel|Day 1, 8 and 15 : Paclitaxel 90 mg/m², IV over 1h, during 6 cycles (1 cycle = 28 days)
1896096|NCT01303497|Drug|Bevacizumab|"Bevacizumab until progression or inacceptable toxicity :
During the cycles of chemotherapy : Day 1 and D15 : 10 mg/kg,IV
After 6 cycles of chemotherapy : 15 mg/kg, IV"
1896097|NCT01303510|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2008-2009 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Florida/4/2006-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
1896098|NCT01303536|Drug|Ondansetron|obsessive compulsive patients resistant to selective serotonin reuptake inhibitor therapy, in addition to their continued stable dose of FDA approved selective serotonin reuptake inhibitors, received oral ondansetron 0.25 mg in two daily administrations (0.5 mg daily) for 2 weeks. Subsequently, the dose was titrated to 0.5 mg in two daily administrations (1 mg/day total) for another 10 weeks. ondansetron was discontinued and the patients were followed for an additional 4 week with biweekly
1896099|NCT01303549|Drug|Anidulafungin|Anidulafungin once a day for 14 days: initial dose 200 mg/day IV administered in 180 minutes. Following doses 100 mg/day IV administered in 90 minutes.
1896100|NCT01303549|Drug|Liposomal amphotericin B|Liposomal amphotericin B once a day for 14 days: 3 mg/kg/day. IV administration during 60 minutes.
1896101|NCT01303562|Other|Whole grain oats and barley|One time dose of 48 g whole grain flour in 2 small muffins (24 g flour per muffin) per intervention
1896102|NCT01303575|Behavioral|HIV, STI and Pregnancy Prevention Curriculum|"A complete internet-based, It's Your Game...Keep It Real Intervention Program"
1896103|NCT01303575|Behavioral|Control Curricula|A computer-based, science education program that does not contain elements of sexual health education
1896104|NCT01303588|Behavioral|Yoga|24 group training sessions Yoga, 2 training sessions per week, 45 min duration , over 3 months
1896105|NCT01303588|Behavioral|Qigong|12 group training sessions Qigong, 1 training per week, 90 min duration , over 3 months
1896106|NCT01303601|Drug|olanzapine|"Tablet The initial dose of olanzapine was 5mg daily and raised to 10 mg/day. After week 1, flexible dosing was allowed based on symptom response, up to 20 mg daily, as tolerated.
daily 6 weeks"
1896107|NCT01303601|Drug|Starch|
1896108|NCT01303614|Drug|Lidocaine-Prilocaine cream|Implementation of 3 cm of lidocaine-prilocaine in the endocervical canal, 10 minutes before the intervention with a syringe without needle 5ml. Application, with a swab of the anesthetic cream ectocervix level.
1896109|NCT01303614|Drug|placebo|3 cm of gel application for the transmission of ultrasound into the endocervical canal 10 minutes before surgery, with a 5 ml syringe without needle. Application, with a swab in gel ectocervix.
1896110|NCT01303627|Drug|remifentanil|1-4 ng/mL i.v. infusion during the surgery, maintenance dosage till LMA removal is 1.5 ng/mL.
1896111|NCT01303640|Device|Biolimus-eluting stent|Biolimus-eluting stent
1896112|NCT01303640|Device|Everolimus-eluting stent|Everolimus-eluting stent
1896113|NCT01303653|Procedure|endoscopic closure of gastrointestinal fistulas and perforations|novel endoscopic tissue closure devices will be used for endoscopic closure of gastrointestinal fistulas or perforations
1896114|NCT01303666|Procedure|Intra-articular CSI|After full aseptic preparation, 40 mg triamcinolone acetonide and 2 ml 1% lignocaine were injected into the joint cavity using the medial patello-femoral approach via a 21-gauge needle.
1896192|NCT01304212|Drug|ropivacaine,morphine chloride,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
1896235|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|TIV 2010/2011 influenza vaccine Intramuscular: 15 mcg TIV 2010/2011 vaccine x 1: Control
1896115|NCT01303666|Procedure|TI of the knee|"This was done as a day case procedure under local anaesthetic. The medial patello-femoral approach was used. After full aseptic preparation, the skin and soft tissues were infiltrated with 5e10 ml of 1% lignocaine. The joint was then instilled with a further 10 ml of 1% lignocaine.
After an initial puncture using a scalpel, a 3.2 mm diameter wrist arthroscope was advanced into the joint cavity. Up to 1 l of 0.9% normal saline was then irrigated through the joint: saline was run into the joint until fully distended and then allowed to flow out of the joint in a cyclical method until the aspirated fluid runs clear for at least three successive cycles."
1896116|NCT01303679|Drug|Paclitaxel|IV, 80mg/m² at d1, d8, d15
1896117|NCT01303679|Drug|Bevacizumab|IV, 10 mg/kg at d1, d15 or IV, 15 mg/kg every 3 weeks
1896118|NCT01303679|Drug|Exemestane|daily 25 mg (1 pill) oral intake
1896119|NCT01303705|Drug|Anti-OX40|Anti-OX40 will be administered intravenously at 0.4 mg/kg on days 4, 6 and 8 of the study. The total anti-OX40 dose will be reconstituted in 100 ml 0.9% saline and infused over no more than 60 minutes intravenously. A single-use non-pyrogenic durapore membrane low protein binding filter (e.g.: Braun 1.2 micron air eliminating filter or equivalent) shall be used to filter the study product in the line between infusion bag and patient.
1896120|NCT01303705|Radiation|Radiation|8.0 Gy in 1 fraction to a maximum of three bone metastatic deposits will be administered on Day 4 of treatment. Imaging such as bone scan, MRI, CT scan, or radiograph must identify the target lesion as consistent with metastatic disease. Any bone lesion that is inducing pain or where there may be a clinical concern for potential pathological fracture will be selected over asymptomatic lesions.
1896121|NCT01303705|Drug|Cyclophosphamide|CTX will be administered on day 1 (Friday only) at a dose determined by cohort assignment. The drug should be diluted per institutional standards. An added dose of IV fluids may help prevent bladder toxicity. In this protocol, CTX will be administered intravenously over 30 - 60 minutes.
1896122|NCT01303718|Device|CardioFit® System|Vagal nerve stimulation with the CardioFit® system
1896123|NCT01303718|Other|Standard of Care|Usual care for LV dysfunction and heart failure (no CardioFit System implant)
1896124|NCT01303731|Drug|Bupivacaine and Fentanyl|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 7.5 mg (1.5 ml) diluted in 0.75ml of patient's CSF (0.25 ml)with addition of Fentanyl 12.5 mcg (total 2.5 ml)
1896125|NCT01303731|Drug|Bupivacaine|Spinal anesthesia with Marcaine Spinal 0.5% Heavy 12.5 mg (2.5 ml)
1896126|NCT01303744|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 12 weeks
1896127|NCT01303744|Drug|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 8 weeks
1896128|NCT01303744|Drug|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 4 weeks
1896129|NCT01303744|Drug|Placebo|oral tablet, once a day in the morning for 12 weeks
1896130|NCT01303757|Behavioral|Dietary counselling|
1896131|NCT01303770|Behavioral|Self-management cognitive rehabilitation group intervention|8-week cognitive rehabilitation program facilitated by an occupational therapist. Program goals include increased knowledge of cognitive impairments in multiple sclerosis, increased self-efficacy to manage cognitive changes and increased use of cognitive compensatory strategies.
1896132|NCT01303770|Behavioral|Control intervention|8-week group program that is not specifically directed to management of cognitive impairments.
1896133|NCT01303783|Drug|Candesartan cilexetil (Atacand), 4 mg|4 mg of candesartan as capsule
1896134|NCT01303783|Drug|Candesartan cilexetil (Atacand), 8 mg|8 mg candesartan as capsule
1896135|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 20 mg|20 mg nifedipine as tablet
1896136|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 30 mg|30 mg nifedipine as tablet
1896137|NCT01303783|Drug|Nifedipine GITS (Adalat, BAYA1040), 60 mg|60 mg nifedipine as tablet
1896138|NCT01303783|Drug|Placebo|3 different placebo tablets corresponding nifedipine doses and 1 placebo capsule corresponding to candesartan doses
1896139|NCT01303783|Drug|Candesartan cilexetil (Atacand), 16 mg|16 mg of candesartan as capsule
1896140|NCT01303783|Drug|Candesartan cilexetil (Atacand), 32 mg|32 mg of candesartan as capsule
1896141|NCT01303796|Drug|Sapacitabine and decitabine|Sapacitabine administered in alternating cycles with decitabine
1896142|NCT01303796|Drug|Decitabine|Decitabine alone
1896143|NCT01303809|Other|Enhanced Recovery After Surgey for Sleeve Gastrectomy|"Intraoperative:
Pre-op carbohydrate loading
No pre-op GIK while NBM
Pre-medication
Dexamethasone 4mg as antiemetic, IV Paracetamol (first dose) Parecoxib 40mg
Ondansetron regularly for first 48 hours and Cyclizine, Droperidol or Scopaderm as rescue antiemetics
Fluid restriction
Standardised method of anaesthesia
Give 40ml 0.5% bupivacaine with adrenaline administered prior to placement of laparoscopic port sites
10ml 0.75% ropivacaine diluted to 50ml with 0.9% normal saline solution administered to surgical site prior to procedure
Postoperative:
Rescue PCA for up to 12 hours. Oxynorm 5mg for rescue pain. Oxycontin 20mg bd/prn postoperatively
Maintenance IV fluids (60ml/hr plasmalyte to be stopped 0800 day 1 post op). Clear oral fluids 2 hours post op. Bariatric free oral fluids morning of day 1
Post operative oxygenation
Incentive spirometry
Drains (e.g. IDC) removed in recovery
Full mobilisation 4-8 hours post op)
Early Follow up"
1896144|NCT01303822|Behavioral|Mindfulness-based day-care clinic group program|11 weeks of mindfulness-based day-care clinic group program. 6 hours per week.
1896145|NCT01303835|Drug|LDN|Randomized patients received 4.5 mg low dose naltrexone (LDN) to be taken every night before bed.
1896146|NCT01303835|Drug|Placebo|Randomized patients received placebo to be taken every night before bed.
1896147|NCT01303848|Other|Blood Sampling|Blood Sampling over 24 hours
1896148|NCT01303861|Drug|Varenicline|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive varenicline at a dose of 0.5 mg once per day followed by 0.5 mg twice a day for the remaining 4 days of that week. Subsequently, the dose will be 1 mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
1896149|NCT01303861|Drug|Bupropion|For the first 3 days after being switched from nicotine patches (occurring at one week before the target quit date), smokers in this group will receive bupropion at a dose of 150mg once per day. Subsequently, the dose will be 150mg twice per day, and will remain at that dose for the remainder of the 12 weeks.
1896150|NCT01303861|Drug|Nicotine patches|"Nicotine Replacement Therapy Groups:
For smokers with high baseline carbon monoxide (CO): 42 mg/24 h for 2 weeks before the quit date and 3 weeks after the quit date, 21 mg/24 h for 4 weeks, 14 mg/24 h for 2 weeks, and 7 mg/24 h for 2 weeks; or
For smokers with low baseline CO: 21 mg/24 h for 2 weeks before the quit date and 7 weeks after the quit date, 14 mg/24 h for 2 weeks, and 7 mg/ 24 h for 2 weeks.
Varenicline and varenicline in combination with bupropion groups:
For smokers with high baseline CO: 42 mg/24 h for 1 week
For smokers with low baseline CO: 21 mg/24 h for 1 week"
1896151|NCT01303861|Drug|Nicotine Inhaler|Nicotine inhaler to use as needed after quit date
1896152|NCT01303874|Drug|Etanercept (ETN)|ETN 50 mg subcutaneous (SC) injections once weekly and MTX orally once weekly.
1896153|NCT01303874|Drug|Placebo|ETN-matching placebo SC injections once weekly and MTX orally once weekly.
1896154|NCT01303887|Drug|Rituximab|Rituximab 375mg/m2 IV day 1,repeated every 21 days for 8 cycles. All patients who have achieved a CR or PR to induction therapy will receive rituximab maintenance (375mg/m2 every 2 months for 2 years).
1896155|NCT01303887|Drug|Cyclophosphamide|Cyclophosphamide 250mg/m2 PO day 1-3, repeated every 21 days for 4 (R-FC) or 8 cycles (R-CVP)
1896156|NCT01303887|Drug|Vincristine|Vincristine 1.4mg/m2 IV day 1,repeated every 21 days for 8 cycles.
1896157|NCT01303887|Drug|Prednisolone|Prednisolone 40mg/m2 PO day 1-5, repeated every 21 days for 8 cycles.
1896158|NCT01303887|Drug|Fludarabine|Fludarabine 40mg/m2 PO day 1-3,repeated every 21 days for 4 cycles
1896159|NCT01303926|Drug|cisplatin pemetrexed|Cisplatin 75 mg / m2 d1 with Pemetrexed 500 mg / m2 d1 every 3 weeks for 6 cycles followed (in responding or stable patients) by Pemetrexed 500 mg / m2 every 3 weeks, until progression or unacceptable toxicity
1896160|NCT01303926|Drug|carboplatin paclitaxel bevacizumab|Carboplatin AUC 6 d1 plus Paclitaxel 200 mg/m2 d1 and Bevacizumab 15 mg/kg every 3 weeks for 6 cycles followed in stable or responding patients by Bevacizumab 15 mg/kg every 3 weeks, until progression or unacceptable toxicity
1896161|NCT01303952|Drug|Eculizumab|Weekly treatment with eculizumab (600 mg) via IV infusion for 4 doses followed the next week by eculizumab (900 mg) IV infusion and maintenance treatment with Eculizumab (900 mg) via IV infusion every other week for 21 weeks
1896162|NCT01303965|Drug|Sirolimus|Start on Day -3 and continue for 1 year
1896163|NCT01303965|Drug|Tacrolimus|Start on Day -3 and begin tapering on Day +100 until Day +180.
1896164|NCT01303965|Drug|Lenalidomide|Start between Day +30 and +120 and continue for 1 year.
1896165|NCT01303978|Drug|APD421|Single dose
1896166|NCT01303991|Other|Hexvix PDT with Karl Storz T-Light|
1896167|NCT01304004|Other|Satiety|"Intervention Description: Consumption of the 2 drinkable yogurts separated by 4 weeks:
Experimental drinkable yogurt enriched in proteins and fibres
Placebo drinkable yogurt (isocaloric and isovolumetric)"
1896168|NCT01304017|Other|Virtual Reality|The VR-therapy will include the playing of various virtual reality or video-games which encourages the use of the extremities while sitting and standing
1896169|NCT01304017|Other|Traditional Therapy|The traditional therapy will include exercise for balance and walking and for the upper extremity using traditional therapeutic tools such as balls, weights, chairs, bands, steps, etc.
1896170|NCT01304030|Behavioral|Empathy Training Modules|The Empathy Training Modules utilize translational research in emotion expression basic science, physiology of emotions, decoding facial expressions and self-regulation skills as pertaining to management of medical and surgical patients.
1896171|NCT01304030|Behavioral|Residency Training as usual|Residents will receive their typical didactic and clinical education
1896172|NCT01304043|Drug|chemotherapies protocols|Cisplatine 20 mg/m² IV Etoposide 100 mg/m² IV Bléomycine 30 mg IV
1896173|NCT01304056|Device|Ventilatory therapy|
1896174|NCT01304069|Drug|Placebo|The subjects will be given orally placebo twice a day for 7 days prior to the study.
1896175|NCT01304069|Drug|Selecoxib|The subjects will be given orally selecoxib 200mg twice a day for 7 days prior to the study.
1896176|NCT01304069|Drug|Etoricoxib|The subjects will be given orally etoricoxib 120mg once a day for 7 days prior to the study.
1896177|NCT01304082|Drug|Lidocaine|1 ml subcutaneous injection of 0.9% lidocaine, given once
1896178|NCT01304082|Drug|normal saline|1 ml subcutaneous injection 0.9% sodium chloride, given once
1896179|NCT01304082|Drug|alkalinized lidocaine|1 ml subcutaneous injection of 0.9% lidocaine and 0.84% sodium bicarbonate
1896180|NCT01304095|Drug|Ranolazine|Patients in the ranolazine arm would start with 500 mg po BID of ranolazine and be force titrated to 1gm po BID after 2 weeks. Down-titration would only be allowed for side effects. This would be on top of all standard medical therapy.
1896181|NCT01304108|Other|VTE-P Tollgate|Add VTE-P tollgate order set that requires a decision regarding VTE-P for every patient admitted or transferred in our hospital system
1896182|NCT01304108|Other|BLAZE Pop up|Develop and deploy a rules-based popup that reminds prescribers interfacing with the orders system when a patient does not have an active VTE-P plan.
1896183|NCT01304108|Other|Usual Care|No addition to the baseline system for care
1896184|NCT01304121|Device|Bioactive glass (SP53P4)|Commercial resorbable bone graft substitute (Vioxid Ltd)
1896185|NCT01304134|Drug|Oxycodone|dosage:10mg/l dosage form:injection frequency:via PCA pump, background rate:0.5ml/h, 2ml/time duration:48 hours
1896186|NCT01304134|Drug|Morphine|dosage: 10mg/ml dosage form: injection frequency: via PCA pump, background rate: 0.5ml/h, 2ml/times duration: 48 hours
1896187|NCT01304147|Drug|Ketamine|A single dose of intranasal ketamine up to 50 mg
1896188|NCT01304147|Drug|placebo|Single dose of saline intranasal
1896189|NCT01304160|Radiation|stereotactic body radiotherapy|30Gray in 5 fractions
1896190|NCT01304186|Behavioral|Tailored Information|The intervention comprises a computer-based application designed to provide individually-tailored information to participants in an interactive fashion.
1896191|NCT01304212|Drug|several drugs: morphine chloride,ropivacaine,epinephrine,ketorolac|This technique is performed intraoperatively with a 100 ml solution containing: 225 mg of ropivacaine 1% (22.5 ml) + 5 mg of morphine chloride 0.1% (5ml) + 30 mg of epinephrine 1:1000 (0.3 ml ) + ketorolac 30mg (1ml) +71 ml of 0.9% saline
1896234|NCT01304537|Drug|Alpha-1 Antitrypsin 80mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
1896648|NCT01305291|Dietary Supplement|digestion-resistant maltodextrin|
1896193|NCT01304212|Drug|ropivacaine|The lock is held before starting the operation, viewing with ultrasound and confirmed the femoral nerve with nerve stimulation at an intensity of 0.5 mA and a frequency of 2 Hz Pajunk 50mm needle, patellar flexion. It be administered 30ml of ropivacaine 0.75% (225mg)
1896194|NCT01304212|Drug|morphine ,ketorolac|ultrasound-assisted femoral nerve block is performed and leaks intraoperatively with a 100 ml solution containing: 5 mg of morphine to 0.1% (5ml) +30 mg of ketorolac (1 ml) +96 ml of 0.9% saline.
1896195|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 100ms pulse duration, moderate intensity burns, in a single-shot fashion
1896196|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, moderate intensity burns, in a multiple-shot fashion
1896197|NCT01304225|Procedure|Panretinal photocoagulation|Panretinal photocoagulation utilizing 20ms pulse duration, barely visible intensity burns, in a multiple-shot fashion
1896198|NCT01304238|Drug|lepirudin|lepirudin
1896199|NCT01304238|Drug|danaparoid|danaparoid
1896200|NCT01304238|Drug|argatroban|argatroban
1896201|NCT01304238|Drug|fondaparinux|fondaparinux
1896202|NCT01304251|Other|Short-term fasting|Short-term fasting, i.e. 24 hours before and 24 hours after administration of chemotherapy
1896203|NCT01304251|Other|Healthy nutrition|Eating according to the current guidelines for healthy nutrition as from 24 hours before until 24 hours after the beginning of administration of chemotherapy. Dietary instructions will be given by a dietician and actual food intake will be recorded in a journal.
1896204|NCT01304264|Device|Color Doppler Imaging|Color Doppler imaging (CDI) system for measurements of blood flow in the ophthalmic (OA), central retinal (CRA), and nasal (NPCA) and temporal (TPCA) posterior ciliary arteries. In each vessel, peak systolic velocity (PSV) and end diastolic velocity (EDV) were determined, and Pourcelot's resistive index will be calculated (RI = (PSV-EDV)/PSV).
1896205|NCT01304277|Biological|agalsidase alfa|
1896206|NCT01304290|Other|Hyperinsulinemic/normoglycemic clamp|"Dextrose/insulin therapy will start. Dextrose and insulin are given using the so-called normoglycemic, hyperinsulinemic clamp. Plasma insulin concentration will be increased by a 2ìU/kg/min continuous infusion of insulin. Dextrose will be infused at the rate required to maintain normoglycemia (4-6 mmol/l) until cross clamping of the aorta. The dextrose/insulin therapy will be maintained for a time period of minimum 6 hours."
1896207|NCT01304303|Drug|SPARC1023 I|IV administration
1896208|NCT01304303|Drug|SPARC1023 II|IV administration
1896209|NCT01304316|Drug|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%|Tetracaine HCl 3% and Oxymetazoline HCl 0.05%
1896210|NCT01304329|Drug|BI 10773|Medium dose oral administration
1896211|NCT01304329|Drug|simvastatin|Medium dose oral administration
1896212|NCT01304329|Drug|simvastatin|Medium dose oral administration
1896213|NCT01304329|Drug|BI 10773|Medium dose oral administration
1896214|NCT01304342|Drug|Remifentanil|1 microgram/kg/h, continuous infusion, 5 min before and during the ERCP
1896215|NCT01304342|Drug|Fentanyl|Intranasal fentanyl 200 micrograms 5 min before the ERCP
1896216|NCT01304342|Drug|Normal saline|Normal saline intravenously and intranasally
1896217|NCT01304368|Procedure|Thermotherapy|Patients are instructed to heat a moor mud filled heat pad (beinio®therm, bb med. product GmbH, Kalkar (Kehrum), Germany) to a hot, but tolerable temperature and to apply it over the painful area once a day for 20 minutes during a period of 14 days. Patients are instructed to continue their usual medication - including analgesic drugs - and physiotherapy (massages and exercise) during the study period.
1896218|NCT01304381|Other|Integrated care|Intervention Multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers, in a shared structured person-centred and identity-promoting care during 6 months
1896219|NCT01304381|Other|Integrated care|One group with 31 participants is offered a multidisciplinary approach and collaboration between specialist palliative and heart failure caregivers in a shared structured person-centred care at home. Assessment of need, length of visits and phone calls are planned to be adapted for each patient. After 6 months (+ - two weeks) the patients will be transferred to usual care provider following an established individual care plan.
1896220|NCT01304394|Drug|Ped3CB|The Ped3CB is a ready to use, triple-chamber bag containing a sterile, nonpyrogenic combination of amino acids (Primene®, Baxter) with electrolytes, glucose, and lipids (ClinOleic®, Baxter) in separate compartments for intravenous (IV) PN. The dosage, frequency and duration is dependent on patient's weight, age, clinical status as well as addition energy or protein given enterally/orally.
1896221|NCT01304420|Device|Ultrasonography|Scanning 5 joints bilaterally with an ultrasound scanner
1896222|NCT01304433|Drug|Venofundin 6% / Tetraspan 6%|Venofundin 6% / Tetraspan 6%
1896223|NCT01304446|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
1896224|NCT01304472|Drug|Prasugrel|Prasugrel 10mg per day
1896225|NCT01304472|Drug|Clopidogrel|Clopidogrel 150mg per day
1896226|NCT01304485|Drug|Sodium Acetate C11|PET Imaging with Sodium Acetate C11
1896227|NCT01304498|Biological|V503|9-valent HPV [Types 6, 11, 16, 18, 31, 33, 45, 52, and 58] L1 virus-like particle vaccine
1896228|NCT01304498|Biological|GARDASIL|Quadrivalent HPV [Types 6, 11, 16, and 18] L1 virus-like particle vaccine
1896229|NCT01304511|Drug|Orgalutran|
1896230|NCT01304524|Biological|VGX 3100|1ml of VGX-3100 delivered IM followed by electroporation at Day 0, Week 4 and Week 12.
1896231|NCT01304524|Biological|Placebo|1ml of placebo delivered IM followed by electroporation at Day 0, week 4 and week 12.
1896232|NCT01304537|Drug|Alpha-1 Antitrypsin 40mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
1896233|NCT01304537|Drug|Alpha-1 Antitrypsin 60mg (AAT, Glassia®)|Each study group will undergo 3 treatment periods:12 weeks, 8 weeks and 4 weeks.
1896236|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|Low dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
1896237|NCT01304563|Biological|TIV 2010/2011 influenza vaccine|Higher lower dose TIV 2010/2011 influenza vaccine delivered via intradermal injection x 1: Experimental
1896238|NCT01304563|Biological|INT|Low dose TIV 2010/2011 influenza vaccine delivered via a short needle intradermal device x 1: Experimental
1896239|NCT01304576|Behavioral|Neuropsychological testing|Experimental test about orientation agnosia and standard neuropsychological tests.
1896240|NCT01304576|Other|MRI|Cerebral MRI
1896241|NCT01304589|Drug|Milnacipran|6-week titration period starting at 12.5mg daily and moving up to 200mg daily (or maximum tolerated dose)for 12 weeks - total treatment period is 18 weeks
1896242|NCT01304602|Drug|Irinotecan|IV over 90 minutes on day 1 of each cycle (every 2 weeks) at the cohort assigned dose level
1896243|NCT01304602|Drug|BKM120|BKM120, oral, daily starting with cycle 1/day 2 at the cohort defined dose level
1896244|NCT01304615|Behavioral|Decrease Energy Density of the Diet|Participants will be given goals to help guide their food choices to decrease the energy density of the overall diet. The goals are to eat 10 or more foods with an ED less than 1.0 and 2 or less foods with an ED of great than 3.0 each day and to reduce portion sizes.
1896245|NCT01304615|Behavioral|Increase Steps per Day|Participants will increase their steps per day by at least 3,000 steps per day above their baseline levels.
1896246|NCT01304615|Behavioral|Consumption of Self-made Meals|Participants will have the goal of increasing the number of self-prepared meals that they consume to 10 or more lunch and dinner meals each week.
1896247|NCT01304628|Drug|PL-3994|subcutaneous PL-3994, single dose, 4 escalating dose groups
1896248|NCT01304641|Other|Atorvastatin Initiators|Retrospective database analysis no intervention performed.
1896249|NCT01304641|Other|Simvastatin Initiators|Retrospective database analysis no intervention performed.
1896250|NCT01304693|Biological|ESBA1008 solution|Administered as a single intravitreal injection (Dose A, Dose B, Dose C, Dose D)
1896251|NCT01304693|Biological|Ranibizumab 0.5 mg|Administered as a single intravitreal injection
1896252|NCT01304706|Drug|Fluocinolone Acetonide|0.2 μg/day
1896253|NCT01304719|Behavioral|Computer Assisted Healthy Families America Home Visitation|Computer modules added to home visitation protocol for Healthy Families America
1896254|NCT01304719|Behavioral|Healthy Families America Home Visitation|Healthy Families America Home Visitation Treatment as Usual
1896255|NCT01304745|Behavioral|Physical training in group|Physical training in group, 6-9 participants, two times av week (1.5 hours) over a period of 16 weeks, focusing on strength and endurance training including body awareness and relaxation.
1896256|NCT01304745|Behavioral|Educational and counseling in group|Educational and counseling groups with 6-9 participants, with seven group meetings 2.5 hours over a period of seven weeks. Each session starts with a (20 minutes) lecture were one out of seven different topics are presented (Fatigue, sexuality, coping and coping strategies, etc).
1896257|NCT01304758|Device|ExAblate Transcranial MRgFUS System|Treatment with the ExAblate Transcranial MRgFUS System.
1896258|NCT01304771|Biological|Synbiotic AKSB|AKSB is a novel synbiotic that contains a probiotic bacterium (Enterococcus faecium, microencapsulated SF68 or Ventrux ME 30), a probiotic yeast (Saccharomyces cerevisiae, Lynside® Pro-Lay 1), and a prebiotic (fructo-oligosaccharide [FOS], NutraFlora®).
1896259|NCT01304784|Drug|Cisplatin, Capecitabine, Trastuzumab and MM-111|Conventional chemotherapy
1896260|NCT01304784|Drug|Lapatinib +/- Trastuzumab and MM-111|Conventional chemotherapy
1896261|NCT01304784|Drug|Paclitaxel, Trastuzumab and MM-111|Conventional chemotherapy
1896262|NCT01304784|Drug|Lapatinib, trastuzumab, paclitaxel, and MM-111|Conventional chemo
1896263|NCT01304784|Drug|Docetaxel, trastuzumab and MM-111|Conventional chemotherapy
1896264|NCT01304797|Drug|MM-302 Monotherapy|Escalating doses of MM-302 as a single agent
1896265|NCT01304797|Drug|MM-302 in combination with trastuzumab|Escalating MM-302 at an every 4 week dosing schedule, while the dose of trastuzumab is fixed at an every 2 week dosing schedule
1896266|NCT01304797|Drug|MM-302 in combination with trastuzumab q3w|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab is fixed at an every 3 week dosing schedule
1896267|NCT01304797|Drug|MM-302 in combination with trastuzumab and cyclophosphamide|Escalating MM-302 at an every 3 week dosing schedule, while the dose of trastuzumab and cyclophosphamide is fixed at an every 3 week dosing schedule
1896268|NCT01304810|Biological|NicVAX vaccine|Prior treatment with NicVAX in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
1896269|NCT01304810|Biological|Placebo|Prior treatment with Placebo in Nabi-4514 or Nabi-4515. No intervention in Nabi-4522.
1896270|NCT01304823|Dietary Supplement|lactisole|flavoring agent/sweet taste antagonist
1896271|NCT01304823|Other|mixed liquid meal|Ensure Plus
1896272|NCT01304836|Drug|Advagraf|oral
1896273|NCT01304836|Drug|Mycophenolate Mofetil|oral
1896274|NCT01304836|Drug|Simulect|IV
1896275|NCT01304836|Drug|Corticosteroids|IV & oral
1896276|NCT01304849|Drug|Escalated BEACOPP|"Escalated BEACOPP chemotherapy will be delivered for those patients who are interim PET CT positive after 2 cycles of ABVD chemotherapy. The patients will receive 2-4 cycles of Escalated BEACOPP once in 3 weeks. The cycles will be delivered as follows:
Bleomycin 10mg/m2 IV in day 8, Etoposide 200mg/m2 Day 1 to Day 3, Adriamycin 35mg/m2 on Day 1 IV, Cyclophosphamide 1200mg/m2 on Day 1 IV, Vincristine 1.4mg/m2 on Day 8 IV, Cap Procarbazine 100mg/m2 Day 1 to Day 7 PO, T Prednisolone 40mg D1-D7 of a 21 day cycle. With Inj Mesna 400mg/m2 0, 4 and 8 hours on the day of Cyclophosphamide Inj G-CSF will be started routinely from Day 9 till recovery of Absolute neutrophil counts ≥5000/cmm or Total WBC counts≥ 8000/cmm"
1896277|NCT01304862|Behavioral|eSMART-MH intervention|Involves simulated interactions between participants and the virtual health care providers (avatars).
1896278|NCT01304862|Behavioral|Educational videos about healthy living|20 minute screen-based educational videos on topics about healthy living--nutrition, physical activity, and sleep hygiene.
1896303|NCT01305057|Other|Pyridoxine tri-isopalmitate|2% dosage, oil-in-water emulsion, twice a day, 28 days
1896304|NCT01305070|Device|Admiral Xtreme|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
1897426|NCT01312025|Procedure|conventional laparoscopic cholecystectomy|
1896279|NCT01304888|Other|Cash + nutrition education|Cash transfer of 150 Mexican pesos (equivalent to approximately 14 USD at the time) per month. The size of the cash transfer and the amount of food was the same for all households, i.e. no adjustments for family size or composition were made. Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
1896280|NCT01304888|Other|Food basket + nutrition education|Monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were required to attend nutrition and health education sessions and had to participate in program related logistic activities in order to receive the benefits. These program conditionalities, however, were not strictly enforced.
1896281|NCT01304888|Other|Food basket w/o nutrition education|A monthly food basket with a cost to the program of 150 pesos. The amount of food was the same for all households, i.e. no adjustments for family size or composition were made. The basket contained a number of staple and basic food products and powdered whole milk (Liconsa), which is fortified with Zn, Fe, Vitamin C, and folate. The composition of the food basket conformed to the Mexican norm for food aid programs (NOM-169-SSA1-1998). Households received the transfer once every 2 mo. Beneficiary households were not required to attend nutrition and health education sessions.
1896282|NCT01304888|Other|Control|No benefits were provided
1896283|NCT01304901|Drug|montelukast 4 mg granule|Children had received single dose of 4 mg oral montelukast after first dose of nebulized salbutamol and systemic glucocorticoids.
1896284|NCT01304901|Drug|Montelukast placebo granüle|Children had received single dose of oral placebo montelukast granule after first dose of nebulized salbutamol and systemic glucocorticoids.
1896285|NCT01304927|Drug|Cholecalciferol and calcium|Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
1896286|NCT01304927|Other|Placebo|microcrystalline cellulose maltodextrin Arachidis oil
1896287|NCT01304953|Drug|Group P+P|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.
Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
1896288|NCT01304953|Drug|Group P+T|"In this arm, anaesthesia was maintained with propofol and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely propofol was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.
Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
1896289|NCT01304953|Drug|Group S+P|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.
Patients in this arms received saline placebo i.v. after the induction of anaesthesia."
1896290|NCT01304953|Drug|Group S+T|"In this arm, anesthesia was maintained by sevoflurane and remifentanil (0.1 μg kg-1 min-1), and primary anaesthetic namely sevoflurane was titrated to maintain intraoperative BIS values between 45 and 55. If the patient did not respond to increases in the level of primary anaesthetic, additional doses of remifentanil up to 0.2 μg kg-1 min-1 were permitted to provide a more cardio-stable anaesthesia.
Patients in this arms received tropisetron 2 mg i.v. after the induction of anaesthesia."
1896291|NCT01304966|Procedure|biopsy|excisional biopsy
1896292|NCT01304979|Procedure|Acupuncture therapies|Acupuncture therapies combined in treatment: application of ear seeds; acupuncture; and acupuncture with gua sha treatment designed to relieve pain and facilitate recovery.
1896293|NCT01304979|Procedure|Control|Indirect therapies that mimic direct therapy intervention
1896294|NCT01304992|Dietary Supplement|Protein drink - low dosage|The subjects will consume 500 mL of a protein drink containing 25 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
1896295|NCT01304992|Dietary Supplement|Protein drink - high dosage|The subjects will consume 500 mL of a protein drink containing 40 g protein (lupin protein or reference protein) per day over eight weeks each. After a one-week run-in period, each volunteer has to pass both protein-periods in different order with a four-week wash out period in between.
1896296|NCT01305018|Dietary Supplement|BCAA|7 g of leucine + 3,5 g of isoleucine + 3,5 g of valine per day during 9 days
1896297|NCT01305018|Dietary Supplement|Leucine|7 g of leucine + 7 g of alanine per day during 9 days
1896298|NCT01305018|Dietary Supplement|Placebo|14 g of alanine per day during 9 days
1896299|NCT01305031|Other|Resuscitation|Use of inspiratory fraction of oxygen needed to achieve oxygen saturation in the preset limits 85-92%
1896300|NCT01305031|Other|100% oxygen|Use of 100% oxygen needed to achieve oxygen saturation in the preset limits 85-92%
1896301|NCT01305044|Behavioral|Tai Chi Chih|Tai Chi Chih (TCC), a westernized and manualized form of the ancient TC Chuan, consists of a series of 20 simple, repetitive, non-strenuous movements that involve no physical contact and emphasize a soft, flowing continuity of motion. This form of meditation through movement consists of a standardized protocol that emphasizes slow, fluid, continuous forms that integrate mental concentration, awareness, balance, shifting of body weight, gentle movement, imagery, muscle relaxation and breathing control. TCC was developed for use with elderly persons.
1896302|NCT01305044|Behavioral|Health Education Classes|The Health Education classes serve as an attention control group, are led by gerontology specialists, physicians, and other health professionals, and focus on topics that are relevant to elderly cancer survivors.
1896305|NCT01305070|Device|In.Pact Admiral|For balloon angioplasty of in-stent restenosis in the superficial femoral artery
1896306|NCT01305083|Drug|Udenafil|Placebo-control
1896307|NCT01305083|Drug|Placebo|Placebo
1896308|NCT01305096|Other|Yoga intervention|6 weeks of yoga postures, once a week for 60 minutes in a group session with a yoga teacher.
1896309|NCT01305109|Biological|ORV 116E|Oral Rotavirus Vaccine 116E (ORV 116E), 10^5.0 FFU of Bharat Biotech International Limited, 3 doses of 0.5mL at 4 week intervals
1896310|NCT01305109|Biological|Placebo|3 doses of 0.5 mL at 4 week intervals
1896311|NCT01305122|Behavioral|neurocognitive tests|"inclusion
1 year
3 years
5 years"
1896312|NCT01305135|Drug|azacitidine and idarubicin|azacitidine:100mg, 75mg/m²/d, during 7days every 28 days (D1-D7). Idarubicin: 5mg/ml, 5mg/m²/d (palier1) or 10mg/m²/d (palier2), D8
1896313|NCT01305148|Device|Warfarin GenoSTAT Test|Use of genetic information from the GenoSTAT test to determine the warfarin dose
1896314|NCT01296607|Drug|Urocortin 2|"Protocol 4a: Onset/Offset protocol: (Visits 1 or 3)
Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 in the presence of a saline washout between each dose.
Urocortin 2 will be infused at 3.6, 12, 36 and 120 pmol/min (15, 50, 150 and 498 nanograms/min) to achieve estimated end-organ concentrations of 0.6, 2, 6 and 20 micrograms/L respectively.
Protocol 4b: Reproducibility protocol (Visit 2 or 4)
Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 2 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of urocortin 2 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
1896315|NCT01296607|Drug|Urocortin 3|"Protocol 4a: Onset/ Offset protocol: (Visit 1 or 3)
Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive incremental doses of Urocortin 2 or Urocortin 3 in the presence of a saline washout between each dose.
Urocortin 3 will be infused at 1200, 3600, 12000 and 36000 pmol/min (5, 15, 50 and 150 micrograms/min) to achieve estimated end organ concentrations of 199, 600, 2000 and 6000 micrograms/L respectively.
Protocol 4b: Reproducibility protocol (Visit 2 or 4)
Following a 20-minute period of saline infusion for equilibration of the set-up, subjects will receive ascending doses of urocortin 3 in the absence of saline washout between each dose. This protocol aims to assess the reproducibility of the vasodilatory effect of 3 on repeated dosing. The doses used for this protocol will be identical to Protocol a."
1896316|NCT01296620|Drug|Ulimorelin Intravenously (IV)|160 µg/kg daily (QD)
1896317|NCT01296620|Drug|Ulimorelin Invtravenously (IV)|480 µg/kg daily (QD)
1896318|NCT01296620|Drug|5% dextrose in water|Placebo
1896319|NCT01296633|Behavioral|Medtable|Nurse works with patient to reconcile EMR-based medication list and load list into Medtable. Nurse uses Medtable with patient to develop plans for taking medications. Patient completes Medtable columns to identify when routine activities are performed during the day. Nurse discusses medications with patient: what the medication is called, used for, etc. Nurse and patient jointly develop the schedule by choosing times to take each medication. These times are entered into corresponding cells of the Medtable. Nurse corrects any mistakes (e.g., times that would conflict with dose spacing requirements). Nurse asks patient to review to ensure patient understands key facts and that drug interactions or other restrictions are addressed, using collaborative inquiry, teach-back, and teach-to-goal strategies. Patient takes home a hardcopy of the Medtable schedule to guide adherence. An updated e-copy is integrated with patient's record in the EMR.
1896320|NCT01296646|Drug|Naltrexone|50 mg oral naltrexone once/day
1896321|NCT01296646|Behavioral|Brenda Therapy Sessions|participants will meet with a trained therapist for nine 30-minute BRENDA therapy sessions Medical monitoring will also be conducted by study physicians and will consist of review of vital signs, concomitant medication use, and general inquiries into side effects.
1896322|NCT01296646|Drug|Placebo|An inactive pill to control for non-pharmacological responses.
1896323|NCT01296659|Drug|ridaforolimus|Ridaforolimus administered orally 5 days per week in combination with standard chemotherapy
1896324|NCT01296672|Drug|Finasteride|Finasteride 5mg every day by mouth for 3 months
1896325|NCT01296672|Drug|Placebo|Placebo every day by mouth for 3 months
1896326|NCT01296698|Drug|Placebo|Dosage Form: Oral NRT; Dose: 0 mg; Frequency: up to 4 times per hour; Duration: 12 weeks
1896327|NCT01296698|Drug|Nicotine|Dosage Form: Oral NRT; Dose: 1 mg;Frequency: up to four times per hour; Duration:12 weeks
1896329|NCT01296724|Other|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various Intravesical pressure measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
1896330|NCT01296724|Other|Measure of intravesical pressure|For the installation of the urinary catheter, a valve connected to a pressure head is intercalated between the probe and the collecting bag. Various IVP measurements will be conducted after injection of 0 ml/kg, 0.5 ml/kg, 1 ml/kg, 1.5 ml/kg, 2 ml/kg, 2.5 ml/kg 3 ml/kg, 3.5 ml/kg and 4 ml/kg of physiological saline.
1896331|NCT01296750|Other|Early Physiotherapy start|Physiotherapy starting at one day post op
1896332|NCT01297049|Behavioral|Cognitive behavior therapy (CBT)|All patients will receive standard care (reassurance, education, physiotherapy, and necessary medication). Complementary to this standard care, the participants will be required to closely monitor their blood glucose levels, weight, eating behavior and daily activities, and to relay this information to the nurse specialist trained in treating somatic patients with CBT. The nurse will then suggest appropriate treatment decisions, the patients will receive situational feedback based on the electronic diary during 3 months (daily during 4 weeks intensive treatment and weekly during 2 months as a complement).
1896333|NCT01297062|Drug|Exenatide|IV Exenatide (therapeutic and supratherapeutic concentrations)
1896334|NCT01297062|Drug|Moxifloxacin|Oral Moxifloxacin (400 mg)
1896335|NCT01297062|Drug|Placebo comparator|IV Placebo (matching volume of placebo)
1896378|NCT01297452|Drug|BKM120 (days 1 - 28, ) plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 28, per dose escalation scheme) plus paclitaxel (80 mg/m2 intravenously, days 1, 8 and 15) + carboplatin (AUC 5 intravenously, day 1) on a 28-day cycle.
1896336|NCT01297075|Behavioral|Outreach visits|The 16 facilitators in the project attend an educational programme designed to provide them with the necessary skills and tools for the task. The facilitators visit general practice clinics from March 2011 until the end of 2012. Each clinic is offered three visits. The facilitator is to act as a change agent who motivates and helps the clinic team in the process of defining common goals, and choosing the appropriate means for achieving them.
1896337|NCT01297088|Drug|BAY86-9596|One single dose administration of a diagnostic agent
1896338|NCT01297101|Drug|Erlotinib|150mg/qd, on day 15-28 of each 28 day cycle.
1896340|NCT01297140|Behavioral|questioning|Patients will be screened by questioning them and their caregiver and from the results of the clinical examination and the biological and neuroradiological tests habitually carried out in cases of dementia and following accepted procedures.
1896341|NCT01297153|Device|Intraocular Lens (Acrysof IOL)|IOL fixation, material and size are important determinants of immediate and long-term outcome. In-the-bag fixation is the most preferred site of IOL implantation.
1896342|NCT01297153|Device|No IOL|No IOL will be implanted in these eyes
1896343|NCT01297166|Drug|LEO 27989 ointment|once daily application, 3weeks
1896344|NCT01297166|Drug|Calcipotriol plus LEO 27989 ointment|once daily application, 3weeks
1896345|NCT01297166|Drug|Calcipotriol ointment|once daily application, 3weeks
1896346|NCT01297166|Drug|Vehicle ointment|once daily application, 3weeks
1896347|NCT01297179|Drug|Mirabegron|Oral
1896348|NCT01297179|Drug|Minidril|Oral
1896349|NCT01297179|Drug|Placebo|Oral
1896350|NCT01297192|Drug|solifenacin succinate|Oral
1896351|NCT01297192|Drug|mirabegron|Oral
1896352|NCT01297205|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|Dose A - 10 million cells per kg Dose B - 20 million cells per kg Single intratracheal administration
1896353|NCT01297218|Biological|Human Umbilical Cord Blood Derived-Mesenchymal Stem Cells|DOSE A - 250,000 cells per 5 uL per 1 entry site, 3 million cells per brain DOSE B - 500,000 cells per 5 uL per 1 entry site, 6 million cells per brain
1896354|NCT01297231|Other|MRI|"Baseline Breast-MRI within 1 year before starting tamoxifen (allows for surgery, chemotherapy and radiation before the start of tamoxifen).
During Tamoxifen Treatment:
Blood will be drawn for CYP2D6 genotype testing. Analysis of samples will be performed internally at MSKCC.
Follow-up breast MRI after 9-12 months of tamoxifen therapy. In patients whom further breast MRI screening and/or follow-up is clinically indicated, follow-up breast MRIs may be performed within 3 months (before or after) the 2, 3, and 4 year time points during tamoxifen treatment. All breast MRIs will be performed using the same technique.
Follow-up for all patients during and after tamoxifen should include routine standard clinical assessment and imaging such as mammography and breast MRI when clinically indicated."
1896355|NCT01297244|Drug|Tivozanib|Subjects will receive 1.5 mg tivozanib once daily beginning on Day 1 for 3 weeks followed by 1 week off treatment. One cycle will be defined as 4 weeks of treatment. Cycles will be repeated every 4 weeks.
1896356|NCT01297257|Device|Stent implantation|Single arm, open label stent implantation
1896357|NCT01297270|Drug|BI201335|QD BI 201335
1896358|NCT01297270|Drug|PegIFN/RBV|
1896359|NCT01297270|Drug|BI201335|QD (once daily) BI 201335
1896360|NCT01297270|Drug|Placebo|
1896361|NCT01297283|Other|LECG first|Measurement of the pacing threshold with the support of a leadless ECG
1896362|NCT01297283|Other|Programmer ECG first|Pacing threshold measurements are done with the support of the programmer ECG
1896363|NCT01297309|Drug|NPSP558|All patients will inject NPSP558 individual titration of 25, 50, 75 or 100 μg SC QD into alternating thighs in the morning via a multidose injection pen device.
1896364|NCT01297322|Other|Manual compression|Standard of Care
1896365|NCT01297322|Device|Cardiva VASCADE™ Vascular Closure System|Investigational Hemostatic Vascular Closure System
1896366|NCT01297335|Drug|clonidine|Intrathecal Clonidine
1896367|NCT01297348|Drug|90ug levonorgestrel / 20 ug ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
1896368|NCT01297348|Drug|Oral Contraceptives containing 20 ug of ethinyl estradiol|This is a non-interventional observational database study, thus no interventions are offered to patients in the study.
1896369|NCT01297361|Other|Blood Sample|Blood sampling for diagnosis of vitamins deficiencies
1896370|NCT01297374|Behavioral|physical activities, dietician counseling and behavioral changes|One arm receive an schedule for physical activities. One arm receive a diet prescription. One arm receive general guidance on diet, physical activity and behavioral changes
1896371|NCT01297387|Other|PTA BPG procedure,|Surgery PTA or BPG Procedure, according usual local clinical practice
1896372|NCT01297400|Drug|MEBO Wound Ointment (MEBO)|Topical application twice a day
1896373|NCT01297400|Procedure|Standard practice for partial thickness burns|Daily application of collagenase ointment with polysporin powder and covered with gauze dressings
1896374|NCT01297413|Biological|Allogeneic adult mesenchymal bone marrow stem cells|Patients will receive intravenously one dose of 0.5-1.5 million cells per kg of allogeneic adult mesenchymal bone marrow stem cells
1896375|NCT01297439|Procedure|suctioning of fetal nose and mouth during delivery|"Normal delivery without pushing maneuver: either an expectative attitude or a suctioning of fetal nose and mouth during delivery, since the crowning of the head (appearance of the fetal scalp at the introitus between pushes)."
1896376|NCT01297439|Procedure|Pushing maneuver|"The pushing maneuver is performed gently on the fetal head since the crowning of the head (appearance of the fetal scalp at the introitus between pushes), during one uterine contraction, aiming to facilitate the anterior shoulder to slip off behind the symphysis pubis, reducing thus the risk of shoulder dystocia."
1896377|NCT01297452|Drug|BKM120 days 1 - 21 plus paclitaxel + carboplatin|Patients will receive oral daily BKM120 (days 1 - 21, per dose escalation scheme) plus paclitaxel (175 mg/m2 intravenously, day 1) + carboplatin (AUC 5 intravenously, day 1)on a 21-day cycle. Pegfilgrastim (6 mg/subcutaneously) will be administered on day 2 of each cycle.
1896453|NCT01297959|Drug|Saline solution|8 mL of Placebo topically twice to surgical wound site (just after incision without penetration of the peritoneal fascia and just prior to skin closure).
1896379|NCT01297452|Drug|BKM120 (days 1-21) + paclitaxel (day 1) + carboplatin (day 1)|BKM120 100 mg (days 1 - 21, per dose escalation scheme) plus paclitaxel (200 mg/m2 intravenously, day 1) + carboplatin (AUC 6 intravenously, day 1) on a 21-day cycle. After enrollment to Groups 1 and 2 has been completed and all patients in Group 1 and 2 have completed the DLT monitoring period, up to 6 additional patients will be enrolled in this EXPANSION COHORT.A
1896380|NCT01297452|Drug|BKM120, Paclitaxel + Carboplatin|BKM120 100 mg per oral, days 1 - 21 Paclitaxel (175 mg/m2) intravenously on Day 1 Carboplatin (AUC 5) intravenously on Day 1 EXPANSION COHORT B
1896381|NCT01297465|Drug|Gonal-f®|Gonal-f® (follitropin alfa) 300 International Unit (IU) will be administered subcutaneously once daily from stimulation day 1 (S1) to stimulation day 5 (S5).
1896382|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously starting from S6 until recombinant human chorionic gonadotropin (r-hCG) administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted based upon the participant's ovarian response and according to the site's standard practice.
1896383|NCT01297465|Drug|Pergoveris®|Pergoveris® (follitropin alfa and lutropin alfa) 300 IU will be administered subcutaneously once daily from S1 until r-hCG administration day (at least 1 follicles >= 18 mm). The dose of Pergoveris® was adjusted starting from S6 based upon the participant's ovarian response and according to the site's standard practice.
1896384|NCT01297465|Drug|Recombinant human chorionic gonadotropin (r-hCG)|250 microgram of r-hCG will be administered once subcutaneously on r-hCG day (at least 1 follicles >= 18 mm).
1896385|NCT01297491|Drug|BKM120|Buparlisib was supplied as 10mg or 50mg capsules. It was administered on a continuous once daily dosing schedule at a dose of 100 mg. The patient was dosed on a flat scale of mg/day and not adjusted to body weight or body surface area.
1896386|NCT01297517|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
1896387|NCT01297517|Drug|Brinzolamide ophthalmic suspension, 1%|
1896388|NCT01297517|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
1896389|NCT01297530|Drug|BAY87-2243|Oral administration once daily in a continuous schedule. Starting dose will be 5 mg and dose will be escalated dependent on any dose limiting toxicities.
1896390|NCT01297543|Biological|human myeloid progenitor cells|Single intravenous injection/infusion
1896391|NCT01297543|Drug|G-CSF|Background therapy
1896392|NCT01297556|Behavioral|Cognitive Behavior Therapy(CBT)|Cognitive Behavior Therapy(CBT) for 6 weeks.
1896393|NCT01297569|Drug|Ranibizumab|
1896394|NCT01297582|Drug|ONO-6950|1mg, 3mg, 10mg, 30mg,100mg,300mg,1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
1896395|NCT01297582|Drug|ONO-6950|1mg, 3mg, 10mg, 30mg, 100mg, 300mg, 1000mg at a single dose; 30mg, 100mg and 300mg for food effect study
1896396|NCT01297595|Drug|crizotinib|Each subject will receive 250 mg single oral doses of oral liquid formulation and formulated capsule of crizotinib separated by at least 14 days.
1896397|NCT01297608|Drug|caoted suppository|coated suppository with active drug
1896398|NCT01297608|Drug|coated suppository|coated suppository with placebo
1896399|NCT01297621|Procedure|reduction mammaplasty|conventional reduction mammaplasty
1896400|NCT01297621|Other|control|follow up, questionnaire responses
1896401|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 1 unit. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 1 unit. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 1 unit. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
1896402|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 2 Units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 2 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 2 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
1896403|NCT01297634|Drug|Botulinum Toxin Type-A (day 0)|"Botulinum Toxin Type-A 3 units. Dilution:1U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 3 units. Dilution: 0,5U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle.
Botulinum Toxin Type-A 3 units. Dilution: 0,25U/0,01ml (with saline solution). will be injected in the left and right belly to the Frontal Muscle."
1896404|NCT01297647|Procedure|urodynamic examination|"Standard urodynamic investigation according to the ICS standard, Good urodynamic practice.Following insertion of 8 F transurethral catheter, retrograde filling of the bladder (20 mL/min) with body warm saline.
Current recording of pabd. , pves and pdet., subsequently pressure flow study. Additionally imaging with fluoroscopy to detect possible vesico ureteral renal reflux."
1896405|NCT01297660|Other|Video-urodynamic examination|
1896406|NCT01297673|Procedure|video-urodynamic examination|Assessment of bladder function during video urodynamic determine of incidence degree and localization of vesico ureteral reflux based on the result of video urodynamics
1896407|NCT01297686|Other|Karaoke Exercise|lateral side step movement involving crossing one foot over the next for 5 sets of 15 cross-overs in each direction
1896408|NCT01297686|Other|Balance walking exercise|Walking along a straight line on the ground, for 5 sets of 30 strides
1896409|NCT01297686|Other|Forefoot extension exercise|The subject stands feet shoulder width apart with one foot ahead of the other and then contracting only calf muscles of the back leg, lifts the heel of the back leg until the metatarsophalangeal joint of that foot is maximally extended. The subject is instructed to concentrate on maintaining balance on the back leg over the first and second metatarsophalangeal joints throughout movement for 5 sets of 15 repetitions.
1896410|NCT01297686|Other|Standing one-legged balance exercise:|This exercise is performed initially with eyes open, then with mastery exhibited by being able to hold balance and not touch the ground with contralateral leg performed with eyes closed, then on an unstable surface with and without eyes open for 1 minute.
1896411|NCT01297686|Other|Ankle inversion/eversion exercise|The foot is placed sideways at the edge of a step. After stabilizing the remainder of the foot and leg, the ankle is inverted and everted to the limits of the range for 3 sets of 15 repetitions.
1896907|NCT01307956|Procedure|therapeutic conventional surgery|Undergo surgical resection
1896412|NCT01297686|Other|Gastrocnemius and soleus stretching|This stretch is performed while standing in a neutral position and the knee extended the foot is placed on top of a ramp or phone-book elevating the forefoot on the rearfoot (talocrural dorsiflexion) and held for 3 sets of 30 seconds each. Next the foot is again placed on top of a phone-book with the knee flexed approximately 15-20 degrees and held for 3 sets of 30 seconds each.
1896413|NCT01297686|Other|Tissue-specific plantar fascia self massage|This deep massage is performed in a sitting position the right foot is crossed over the left while one hand passively extends the right forefoot. The left hand then applies light to moderate pressure in 3-5 second intervals along the length of the medial longitudinal arch. Same procedure is then repeated for the left foot.
1896414|NCT01297686|Drug|Dexamethasone|"A 22-gauge, 1.5 needle and 3 cm syringe filled with 1ml of dexamethasone mixed with 0.5ml of 1% lidocaine. Prior to injection, the skin will be sterilized with povidone-iodine. The needle is inserted 2-3 cm anteromedial to the focal point of pain in the inferior heel near the calcaneal tuberosity and moved toward the tenderest area."
1896415|NCT01297699|Drug|Tocilizumab (RoActemra®)|Single intravenous infusion of tocilizumab (8 mg/kg); every 4 weeks during 16 weeks.
1896416|NCT01297699|Drug|Sterile 0.9% Sodium Chloride|Single intravenous dip infusion of a sterile 0.9% sodium chloride, every four weeks during 16 weeks.
1896417|NCT01297712|Device|Latest generation colonoscopy as diagnostic instrument|this endoscope is used as compared to an older generations cope (classic line) currently in use
1896418|NCT01297725|Procedure|Blunt right, sharp left|Blunt fascial entry on the right side of the midline and sharp fascial entry on the left side of the midline.
1896419|NCT01297725|Procedure|Blunt left, sharp right|Blunt fascial entry on the left side of the midline and sharp fascial entry on the right side of the midline.
1896420|NCT01297738|Other|Meal size increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® with their meals, which results in an increase in meal size.
1896421|NCT01297738|Other|Meal size increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages with their meals, which results in an increase in meal size.
1896422|NCT01297738|Other|Meal frequency increase with HFHS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming a high-fat, high-sugar liquid medical food supplement (Nutridrink®). Subjects consume the Nutridrink® 3 times a day in between meals, which results in an increase in meal frequency.
1896423|NCT01297738|Other|Meal frequency increase with HS|On top of a healthy, eucaloric diet, study subjects consume a 40% calory surplus by consuming commercially available sugar-sweetened beverages. Subjects consume these sugar-sweetened beverages 3 times a day in between meals, which results in an increase in meal frequency.
1896424|NCT01297764|Drug|Vorinostat, Lenalidomide, Carfilzomib, Dexamethasone|"Dose Escalation Schema Cohort Carfilzomib (mg/m2) Lenalidomide (mg) Vorinostat (mg) Dexamethasone (mg)
15 15 300 40
20 15 300 40
20 25 300 40
20/27* 25 300 40
20/27* 25 400 40"
1896425|NCT01297777|Drug|Imatinib Mesylate|"In patients without B or C findings and without biological progression: 300 mg/24 h p.o during one year or until progression/unacceptable toxicity.
In patients with B or C findings or biological progression: 300 mg/24 h p.o for two weeks and then 400 mg/24 h p.o for a total of one year of therapy, or until progression/unacceptable toxicity."
1896426|NCT01297790|Other|Cough Challenge Tests|Inhalational cough challenge tests with capsaicin, bradykinin, Citric acid and prostaglandin E2
1896427|NCT01297790|Other|ambulatory cough recording|Cough recording with a portable device to capture cough sounds
1896428|NCT01297790|Other|Cough questionnaires|Questionnaires designed to study cough. These include Leicester cough questionnaire, cough visual analogue score and cough quality of life questionnaire.
1896429|NCT01297803|Drug|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before &after scleral flap dissection
1896430|NCT01297803|Drug|Mitomycin_c|0.02%.1,2,3,minutes match randomized in to two groups(before &after scleral flap dissection
1896431|NCT01297816|Drug|placebo|100mg,BD, fo three month
1896432|NCT01297816|Drug|Minocycline|100mg
1896433|NCT01297829|Drug|Intravenous Ibuprofen|800 mg IV ibuprofen 30 minutes preoperatively
1896434|NCT01297829|Other|IV Placebo|IV normal saline
1896435|NCT01297842|Drug|Ertapenem|Ertapenem 1 gram per day for 7 to 14 days
1896436|NCT01297842|Drug|Meropenem or Imipenem|Meropenem or Imipenem 0.5 to 1 gram 3 to 4 times per day for 7 to 14 days
1896437|NCT01297855|Drug|Colistin|Colistimethate Sodium dose 2.5-5mg/kg/day
1896438|NCT01297855|Drug|Colistin plus Rifampicin|Colistin 2.5 to 5 mg/ Kg/ day Rifampin 10 mg/ Kg/ day
1896439|NCT01297868|Other|exercise|
1896440|NCT01297894|Drug|colistin|Colistimethate sodium 2.5-5mg/kg of colistin base
1896441|NCT01297894|Drug|colistin plus fosfomycin|colitimethate sodium 2.5-5mg/kg iv plus fosfomycin 2gm iv every 12 hours
1896442|NCT01297907|Other|Methacholine Challenge Test|Methacholine challenge test to evaluate airway hyperreactivity
1896443|NCT01297907|Other|Fractional Exhaled NO (FENO)|Fractional Exhaled NO to evaluate eosinophilic inflammation
1896444|NCT01297907|Other|Blood Test|Blood Tests (Eosinophil Count)
1896445|NCT01297907|Other|PCDAI|Clinical Evaluation for Pediatric Crohn's Disease Activity Index (PCDAI)
1896446|NCT01297920|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
1896447|NCT01297920|Drug|Brinzolamide ophthalmic suspension, 1%|
1896448|NCT01297920|Drug|Brimonidine tartrate ophthalmic solution, 0.2%|
1896449|NCT01297933|Drug|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
1896450|NCT01297946|Device|Conventional continuous subcutaneous insulin infusion therapy|
1896451|NCT01297946|Device|Dual-hormone closed-loop|
1896452|NCT01297959|Drug|E-101 Solution 300 GU/ml|8 mL of E-101 Solution at a pMPO concentration of 300 GU/ml applied topically twice to surgical wound site (just after incision without penetration of the rectus fascia or linea alba and just prior to skin closure after closure of rectus fascia or linea alba).
1896908|NCT01307956|Other|laboratory biomarker analysis|Correlative studies
1896454|NCT01297972|Biological|Intravenous bone marrow mesenchymal stem cells infusion|After standard immunosuppressive therapy with rabbit antithymocyte globulin 3,5 mg/Kg/day during 5 days, allogeneic unrelated bone marrow derived mesenchymal stem cells will be infused intravenously. Oral cyclosporine 5 mg/Kg/day (with dose correction weekly to keep serum cyclosporine level between 150-250 mg/dl) up to 6 months will be added.
1896455|NCT01297985|Behavioral|BRIDGES Peer-Led Education|The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses.
1896456|NCT01297998|Drug|gemcitabine , cisplatin|Dose of gemcitabine and cisplatin and treatment schedule
1896457|NCT01298011|Drug|Gemcitabine and Abraxane|3 treatments for gemcitabine and abraxane every 28-days for 3 months, prior to surgery.
1896458|NCT01298024|Other|Early Neuromuscular Exercise|30 patients are randomized to early neuromuscular exercise (n=15) or treatment as usual, i.e., late exercise (n=15). Both groups are given an orthosis and are instructed to wear this for eight weeks. The experimental group starts with a structured exercise program one week after the diagnosis. The patients attend one training session/week during eight weeks, guided by a physical therapist. The level of training is progressed during this time. The patients in the control group (treatment as usual) are given exercise instructions and information at one occasion; 2 weeks after diagnosis. Both groups are followed up, by a blinded assessor, with valid and reliable self-reported and physical function outcomes at 1, 4, 8 and 16 weeks after injury.
1896459|NCT01298050|Procedure|ECMO|Insertion of peripheral Veno-Arterious ECMO, subsequent therapeutic hypothermia
1896460|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
1896461|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
1896462|NCT01298063|Drug|Afatinib|1 tablet, once qd in the morning
1896463|NCT01298076|Drug|bevacizumab|Anti-VEGF drug for intravitreal injection
1896464|NCT01298076|Drug|dexamethasone|Slow-release steroid formulation for intravitreal injection
1896465|NCT01298089|Device|Carriazo Pendular microkeratome|
1896466|NCT01298102|Biological|Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)|intramuscular injection of 1 dose vaccine
1896467|NCT01298128|Drug|NuvaRing|NuvaRIng 21 days for IVF pre-treatment.
1896468|NCT01298128|Drug|marvelon|marvelon 21 daily
1896469|NCT01298141|Biological|agalsidase alfa|"Cohort 1: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes every other week (EOW)
Cohort 2: 0.2 mg/kg body weight administered as an intravenous (IV) infusion over 40 minutes weekly"
1896470|NCT01298154|Other|Dietary intervention|Dietary treatments with beverages
1896471|NCT01298167|Device|Cyanoacrylate tissue glue versus Fast absorbing gut|All wounds will be closed using a linear, bilayered closure method, where the buried intradermal absorbing suture (5-0, Polysorb) will be placed along the length of the incision, consistent with standard surgical procedure. Only patients with wounds with a length of 3cm or greater will be enrolled. Each wound will be measured, and the length divided in half. Half of the surgical wound will be randomly selected (by coin toss) for epidermal reapproximation with cyanoacrylate, whereas the other half will be repaired with 6-0 fast absorbing gut suture in standard running fashion.
1896472|NCT01298180|Drug|Growth hormone (Genotonorm® or Omnitrope®)|drug : the treatment will be begun in progressive dose by beginning by ¼ of the dose the first week, then ½ of the dose the second week, then 3/4 of the dose the third week and total dose the fourth week.
1896473|NCT01298180|Procedure|DEXA, blood tests, H.G.P.O, osseous age.|"SPW, GHD, SPW-B :
blood tests : centralized dosage H.G.P.O : adjusted to children's age."
1896474|NCT01298180|Procedure|biopsy|Biopsy : Cutaneous and fat tissue biopsy.
1896475|NCT01298193|Drug|Aprepitant|Efficacy phase (second cycle)
1896476|NCT01298219|Drug|Lubiprostone|24 mcg capsules twice daily (BID)
1896477|NCT01298219|Drug|Placebo|0 mcg capsules twice daily (BID)
1896478|NCT01298232|Other|Cardiophonogram|Using data from cardiophonogram, the EMAT and S3 intensity, to guided clinical therapy for acute heart failure
1896479|NCT01298258|Drug|Aliskiren|Aliskiren 150mg
1896480|NCT01298271|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
1896481|NCT01298284|Drug|propranolol|Starting from 20 mg daily, titrated weekly to decrease heart rate more than 25 % of baseline, administrated during the whole study period
1896482|NCT01298297|Drug|Buprenorphine|0.4 mg, SL (sublingual) Buprenorphine PLUS 5 ml Placebo IV (in the vein)
1896483|NCT01298297|Drug|Morphine|Placebo SL PLUS 5 ml Morphine sulfate (1mg/ml) IV
1896484|NCT01298310|Drug|Xylocaine|1 mg/mL solution for injection
1896485|NCT01298310|Drug|Xylocaine|10 mg/mL solution for injection
1896486|NCT01298310|Drug|Placebo|solution for injection
1896487|NCT01298323|Behavioral|Patient outreach|Patients will be contacted at week 1 and then every 2 weeks until completion of 52 weeks to detect/treat AEs sooner
1896488|NCT01298323|Drug|Vandetanib|Treatment 300mg vandetanib opel label.
1896489|NCT01298336|Drug|Clarithromycin|500 mg twice a day seven days a week
1896490|NCT01298336|Drug|Moxifloxacin|400 mg per day seven days a week
1896491|NCT01298362|Drug|Aromatase Inhibitors|
1896492|NCT01298362|Drug|Chemotherapy|
1896493|NCT01298388|Other|medical chart review|
1896494|NCT01298388|Other|questionnaire administration|
1896495|NCT01298388|Other|study of socioeconomic and demographic variables|
1896496|NCT01298401|Biological|ganitumab|
1896497|NCT01298401|Drug|capecitabine|
1896498|NCT01298401|Drug|gemcitabine hydrochloride|
1896499|NCT01298401|Radiation|3-dimensional conformal radiation therapy|
1896500|NCT01298414|Genetic|RNA analysis|
1896501|NCT01298414|Other|laboratory biomarker analysis|
1896502|NCT01298466|Drug|Pregabalin|The investigator will administer pregabalin in a flexible dose-escalation regimen as follows: 150 mg per night for 1 week, 300 mg per day for 1 week, 450 mg per day for 1 week, then 600 mg per day through to the end of the study. Patients may change the dose of medication based on individual response and tolerability as determined by the investigator.
1896503|NCT01298479|Other|Uniject|single use container
1896504|NCT01298492|Drug|PF-00547659|75 mg SC once monthly for 72 weeks. Subjects may escalate to 225 mg or de-escalate to 22.5 mg one time.
1896505|NCT01298505|Drug|PF-03654764 2.5mg plus fexofenadine 60mg|PF-03654764 2.5mg plus fexofenadine 60mg twice daily for 7 days
1896506|NCT01298505|Drug|PF-03654764 5mg plus fexofenadine 60mg|PF-03654764 5mg plus fexofenadine 60mg twice daily for 7 days
1896507|NCT01298505|Drug|placebo|placebo given twice daily for 7 days
1896508|NCT01298518|Drug|PF-04620110|5 mg of PF-04620110 given once daily
1896509|NCT01298518|Drug|PF-04620110|2.5 mg of PF-04620110 given twice daily
1896510|NCT01298518|Drug|Placebo|Matching placebo giving for 4 weeks
1896511|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 16 weeks.
1896512|NCT01298531|Drug|etanercept|etanercept 50 mg subcutaneous (SC) injections once weekly for 8 weeks following the prior 8 weeks of placebo.
1896513|NCT01298531|Drug|placebo|placebo subcutaneous (SC) injections once weekly for 8 weeks.
1896514|NCT01298544|Procedure|Blood draw|One 5mL blood draw for immunogenicity at least 3 years post completion of clinical study 0887X-101518.
1896515|NCT01298570|Drug|Regorafenib (BAY 73-4506)|Regorafenib, 160 mg, PO, daily, per 7 day cycle
1896516|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
1896517|NCT01298570|Drug|Placebo|Placebo, oral administration, Days 4-10 and Days 18-24 of 28 day cycle +
1896518|NCT01298570|Drug|FOLFIRI|FOLFIRI (Irinotecan,180 mg/m2 IV over 90 minutes; 5-Fluorouracil l400 mg/m2 IV bolus followed by 2400 mg/m2 IV over 46 hours; Leucovorin 200-400c mg/m2 IV over 2 hours) Day 1 and Day 15 of each 28 day cycle.
1896519|NCT01298583|Behavioral|ankle tracking training|one group will use the ankle for tracking, the other group will use the ankle for simple movement
1896520|NCT01298596|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|LEEP procedure uses a low-voltage electrified wire loop to cut out diseased part of cervix
1896521|NCT01298596|Procedure|Cryotherapy|Cryotherapy procedure involves using a cryoprobe and carbon dioxide or nitrous oxide gas to freeze the diseased part of the cervix
1896522|NCT01298609|Device|Occipital Stimulation|Occipital Nerve Stimulation will be used in each study arm using the Eon Mini neuromodulation system
1896523|NCT01298635|Procedure|combined phacotrabeculectomy|trabeculectomy plus phacoemulsification with intraocular lens implantation
1896524|NCT01298635|Procedure|trabeculectomy|
1896525|NCT01298661|Other|Six-minute Step Test|The patients underwent a test where they need to step up and down a 20cm test during six minutes.
1896526|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00013%|Cumulative daily dose is below the travoprost ophthalmic solution, 0.004% once daily dose
1896527|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00033%|Cumulative daily dose equals the travoprost ophthalmic solution, 0.004% once daily dose
1896528|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.001%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
1896529|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.00267%|Cumulative daily dose is above the travoprost ophthalmic solution, 0.004% once daily dose
1896530|NCT01298687|Drug|Travoprost Ophthalmic Solution, 0.004%|
1896531|NCT01298687|Drug|Travoprost Vehicle|Inactive ingredients used as an active comparator
1896532|NCT01298700|Drug|bimatoprost 0.01% ophthalmic solution|One drop of bimatoprost 0.01% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
1896533|NCT01298700|Drug|bimatoprost 0.03% ophthalmic solution|One drop of bimatoprost 0.03% ophthalmic solution instilled to each eye, once daily in the evening for 2 years.
1896534|NCT01298713|Drug|Tamoxifen|20mg daily (1 cap) until unbearable toxicity or progression
1896535|NCT01298713|Drug|Everolimus|10mg daily (2 caps of 5mg) until unbearable toxicity or progression
1896536|NCT01298726|Other|PHARMACEUTICAL CARE|The pharmaceutical care program was characterized by face to face monthly visits to collect information, register information, prepare plan of care for every health problem; identification of drug therapy problems, communication to prescribers the drug therapy problems identified and education of participants to resolve the drug therapy problems.
1896537|NCT01298726|Other|HEALTH USUAL CARE|Usual care as defined in health consultations with doctors, nutritionists and nurses, access to laboratory tests and essential medicines
1896538|NCT01298752|Drug|Mapracorat|Mapracorat ophthalmic suspension 3%, one drop in post-operative study eye once daily (QD) for 2 weeks.
1896539|NCT01298752|Drug|Vehicle|Vehicle of mapracorat ophthalmic suspension, one drop in post-operative study eye once daily (QD) for 2 weeks.
1896540|NCT01298765|Drug|BEMA Buprenorphine|buccal soluble film; applied to the buccal mucosa twice daily
1896541|NCT01298778|Drug|Duramorph 150|Duramorph 150 mcg x 1 dose spinally + placebo capsules 2 PO q 6 hrs first 24 hrs postop x 4 doses
1896542|NCT01298778|Drug|Acetaminophen|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
1896543|NCT01298778|Drug|Duramorph 300|Duramorph 300 mcg spinally + acetaminophen 1 GM q 6 hrs first 24 hrs postop x 4 doses
1896544|NCT01298791|Behavioral|Sitting|Providers will sit during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain seated while communicating with the patient and caregiver.
1896545|NCT01298791|Behavioral|Standing|Providers will stand during inpatient family-centered walk rounds throughout the communication during rounds. The participating members of the care team (attending physician, resident and medical student) will remain standing while communicating with the patient and caregiver.
1896546|NCT01298804|Behavioral|Problem Solving Education and Activated Referral to Care|"The intervention represents an integrated identification and intervention system based on the evidence-based construct of screening, brief intervention, and referral to treatment (SBIRT). Within the comprehensive case management services of Head Start, eligible women will be randomized to receive either usual care or the Head Start-based intervention. In our intervention, mothers at risk for depression will receive a problem-solving intervention; depression symptom monitoring; and an Activated referral to more definitive services for those who have worsening symptoms over time."
1897427|NCT01312025|Procedure|modified laparoscopic cholecystectomy|
1896547|NCT01298817|Dietary Supplement|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). The soy used in Medifast products is Solae SUPRO® water-washed soy protein isolate. Depending on seasonal variations, soy MR products contain approximately 1.5-3.0 milligrams of soy isoflavones for every 1 gram of soy protein. Thus, participants in the soy treatment arm will consume at least 28 g/soy protein and 42-108 mg/isoflavones per day.
1896548|NCT01298817|Dietary Supplement|Medifast meal replacement products|A total of 4 meal replacement (MR)products per participant per day will be used. Approximately 2/3rd of the Medifast® MR product line is soy protein-based (i.e. at least 7 g of total protein coming from soy) with the remaining 1/3rd of items deriving total protein content from animal sources (whey and egg). This group will receive the non soy supplements.
1896549|NCT01298830|Drug|GLP-1 CellBeads|GLP-1 CellBeads are alginate microcapsules containing allogenic mesenchymal cells, transfected to secrete Glucagon like peptide-1. By implantation into brain tissue cavity after surgical evacuation of the hematoma, a volume of 500μl GLP-1 CellBeads which equals approximately 2330 GLP-1 CellBeads resulting in a total number of approximately 7.8 million cells is administered to the patient. The cells are removed by second surgery after a 14 days treatment period.
1896550|NCT01298843|Drug|Ceftaroline fosamil|Single dose of 15 mg/kg (up to 600 mg) by intravenous infusion
1896551|NCT01298856|Procedure|hydrotherapy|hydrotherapy and ankle taping and land-based
1896553|NCT01298882|Drug|Diacerein|
1896554|NCT01298882|Other|Placebo|
1896555|NCT01298908|Procedure|Operative treatment|In operative treatment the great saphenous vein will be removed after flush ligation by femoral vein and stripping of the trunk.
1896556|NCT01298908|Procedure|Laser ablation|In intravenous laser treatment a thin laser fiber is inserted through a tiny distal entry point. The probe is guided into place using ultrasound and the procedure is performed under local tumescence anesthesia. Laser energy is delivered to seal the faulty vein.
1896557|NCT01298908|Procedure|Foam sclerotherapy|Ultrasound guided foam sclerotherapy involves an injection of foam (sodium tetradecyl sulfate mixed with air according to the Thessari method) directly into the venous trunk under ultrasound control.
1896558|NCT01298921|Drug|Oxygen|A demand valve delivers oxygen to the user as soon as they try to inhale from an attached mask or mouth tube. As the user starts to inhale, the slight drop in pressure within the mouth piece or mask lifts a valve and starts the oxygen flow. If the user inhales more deeply, more oxygen will flow in response to the increased demand, hence the name demand valve. Unlike a constant flow O2 regulator, a demand valve has no flow meter or flow rate controls, but it is capable of delivering O2 from 0 to 160 liters per minute (LPM). When using a demand valve, O2 dosage is controlled by respiration rate
1896559|NCT01298921|Drug|Oxygen|100 percent continuous oxygen given via a non-rebreather facemask at 7 to 15 liters per minute for 20 minutes
1896561|NCT01298947|Device|Laser Atherectomy (Spectranetics CE marked peripheral laser atherectomy catheters (including Turbo Elite®), Turbo-Booster® and Turbo Tandem™ Systems|comparing the use of a Paclitaxel-eluting angioplasty balloon (PTX PTA) with initial photoablation to the use of PTX PTA alone in the treatment of instent lesions in femoropopliteal arteries
1896562|NCT01298960|Drug|Somatropin|0.1 IU/Kg/day from day one of stimulation until rHCG triggering
1896563|NCT01298973|Drug|Viscoat|One group will receive Viscoat for incision closure
1896564|NCT01298973|Drug|Saline|One group will receive Saline to irrigate the wound
1896565|NCT01298986|Procedure|Pulmonary vein isolation ablation procedure for atrial fibrillation|The catheters will be introduced to the right atrium using the femoral vein as an access. Following a trans-septal puncture, ablation catheters will be placed in the left atrium under appropriate imaging and anticoagulation conditions (Standard of care). Following the positioning of the ablation catheters in the left heart cavity ablation to achieve PVI and left atrial isthmus line are going to be performed. Following the appropriate protocol of mapping and AF induction the right sided isthmus is going to be ablated to achieve a flutter line ablation as well. Following the procedure and following the appropriate standard of care protocols, the catheter are going to be retrieved and the procedure will be concluded. The left atrial appendage will be managed surgically. All ablation lines will be placed according to their current standard of practice using radiofrequency ablation technology and based on CARTO mapping.
1896566|NCT01298986|Procedure|Hybrid procedure for ablation of atrial fibrillation|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
1896567|NCT01298986|Procedure|The Cox Maze Procedure for Ablation of Atrial Fibrillation|A 7-cm incision is placed and the chest is entered through the 4th or 5th intercostal space. The femoral artery and femoral vein are cannulated. The pericardium is opened. Cardiopulmonary bypass is instituted. The right sided lesions are applied using 3 purse-strings that are placed over the right atrial free wall. The right and left atrial lesions are done using cryoablation using either nitrous oxide or Argon. Next the left atrium is entered through a standard atriotomy placed in the interatrial groove. The base of the left atrial appendage is cryoablated and connected to the left upper pulmonary vein. All four pulmonary veins are then encircled using multiple application of cryo. An endocardial cryolesion is then placed posteriorly down to the level of the mid-mitral valve annulus and an epicardial cryolesion is placed on the coronary sinus directly across the atrial wall from the endocardial lesion. The left atrial appendage is then surgically managed.
1896568|NCT01298986|Procedure|Hybrid Procedure for Left Atrium >5 cm but < 6.1 cm|The endoscope will be passed though a small port in the right thoracic cavity to the beating heart. The pericardium will be opened, the coronary sinus transected. The ablation catheters will pass underneath the SVC and IVC establishing access to the transverse and oblique sinuses. A box lesion will be epicardially placed around the pulmonary veins using cryothermia. An additional lesion line will be placed from the box lesion to the left atrial appendage. The ablation catheter will be left in place to guide the EP physicians in placing the right and left atrial flutter lines using radiofrequency. Electromagnetic mapping using a CARTO system and measuring for conduction block of the pulmonary veins will be conducted by the EP's. A second small port will then placed in the left thoracic cavity and the pericardium on the left side will be opened and the left atrial appendage will be ablated with the use of a clip placed around the left atrial appendage and tightened.
1896569|NCT01298999|Drug|YF476|25 mg: one capsule to be taken by mouth once daily for 12 weeks.
1896570|NCT01298999|Drug|Placebo|Matching placebo: one capsule to be taken by mouth once daily for 12 weeks.
1896571|NCT01299012|Drug|Liraglutide|Liraglutide s/c 0.6mg once daily.
1896572|NCT01299025|Other|Training using Nintendo Wii Fit|Training 2 times per week, 30 minutes, for 6 weeks.
1896574|NCT01299051|Behavioral|Steps to Health|"Steps to Health (STH): The STH curriculum is a 12-month educational program targeting obese employees for healthy lifestyle changes for weight loss. The program includes:
Face-to-face visit with counselor during Month 1 to set specific health goals.
Telephone counseling at 6 and 12 months, coupled with biometric feedback sessions.
Monthly generic health education materials sent via e-mail.
Incentives (up to 1,000 STH dollars [$100]) to take part in the program assessments."
1896575|NCT01299051|Behavioral|Steps to Health Plus!|"The STH+ intervention is an intensive 12-month behavioral intervention targeting obese employees. It is stage-based and works with the participant at his/her level of readiness to change using counseling based on motivational interviewing. STH+ includes:
Face-to-face visit with counselor at Month 1
Meeting with exercise physiologist in Month 2
Monthly counseling sessions (in-person in Months 3, 6, 9 and 12, others via telephone)
Meeting with exercise physiologist during Month 5
Quarterly biometric feedback (Months 3, 6, 9, and 12)
Incentives (up to 1,000 STH dollars [$100]) to take part in the program assessments."
1896576|NCT01299090|Device|Pelleve Wrinkle Treatment System - includes the Pelleve Handpiece and S5 generator|two treatments spaced 30 days apart
1896577|NCT01299103|Device|Pelleve Wrinkle Treatment System|comparison of single vs. double and triple treatment with the Pelleve Wrinkle Treatment System
1896578|NCT01299116|Drug|DMPA|Injectable contraceptive, containing 150 mg depot medroxyprogesterone acetate (DMPA) and marketed in the US as Depo-Provera® or containing 104 mg DMPA and marketed as Depo-SubQ Provera 104®.
1896579|NCT01299116|Drug|oral contraceptives|Oral contraceptives (any variety of formulations are permitted)
1896580|NCT01299116|Drug|Implanon®|Subdermal contraceptive implant, marketed in the US as Implanon® or Nexplanon® (containing 68 mg of etonogestrel)
1896581|NCT01299116|Drug|ParaGard®|Intrauterine device marketed in the US as ParaGard® (a T-shaped plastic device containing 380mm2 of copper surface)
1896582|NCT01299116|Drug|Mirena®|Intrauterine system, marketed in the US as Mirena® (containing 52 mg of levonorgestrel)
1896583|NCT01299142|Drug|FGI-101-1A6|anti-TSG101 human monoclonal antibody, single dose
1896584|NCT01299155|Device|ReSTOR +3|Bilateral implantation of an Alcon AcrySof ReSTOR +3 Intraocular Lens (IOL) Model SN6AD1 following cataract extraction.
1896585|NCT01299155|Device|LENTIS MPlus|Bilateral implantation of a LENTIS MPlus Intraocular Lens (IOL) following cataract extraction.
1896586|NCT01299181|Drug|Atorvastatin|80mg once daily orally
1896587|NCT01299194|Drug|ATORVASTATIN|80mg once daily for 3 months
1896588|NCT01299220|Drug|Acitretin|Acitretin 10 mg by mouth daily
1896589|NCT01299233|Device|Spectralis® SD-OCT, Heidelberg Engineering GmbH, H|Measurement of the peripapillar nerve fiber layer with different settings of ART
1896590|NCT01299246|Procedure|Michigan Neuropathy Screening Instrument|Peripheral neurological assessment was carried out using MNSI. The diabetes nurse educators assessed five parameters on both feet and counted the total points, ranging from 0 to10: (1) Appearance of feet; if abnormal, then inspection of lower limbs for deformities was carried out; (2) Identification of foot ulceration; (3) Vibration perception of the big toe; (4) Ankle reflexes; (5) touch-pressure sensation test with a 10 g Semmes-Weinstein monofilament.
1896591|NCT01299259|Behavioral|Text Message Reminders|Patients in the intervention group will receive text messages on their cell phones following discharge from the emergency department reminding them to make an appointment with their primary care provider. Text messages will be sent daily for 4 days after discharge from the ED.
1896592|NCT01299272|Drug|LY2216684|Administered orally
1896593|NCT01299272|Drug|Placebo|Administered orally
1896594|NCT01299285|Drug|LY3009104|Administered orally
1896595|NCT01299298|Drug|mipomersen|50 mg (cohort A), 100mg (cohort B) or 200mg (cohort C) subcutaneous (SC) single dose of study drug
1896596|NCT01299298|Drug|placebo|50 mg (cohort A), 100mg (cohort B), or 200mg (cohort C) subcutaneous (SC) single dose of study drug
1896597|NCT01299311|Behavioral|NEAT|4 days of everyday activities, including 4 hours of walking, 8 hours of sitting, 2 hours of standing, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
1896598|NCT01299311|Behavioral|Exercise|4 days of activity program, including 1 hour biking (exercise), 13 hours of sitting, 2 hours of everyday activities and 8 hours of sleeping or laying down per day
1896599|NCT01299324|Device|BMAC infusion|Infusion of 60 mL of Bone Marrow Aspirate Concentrate
1896600|NCT01299337|Drug|T3|Given each day of ECT treatment 25 mg for the first 5 days increasing to 50 mg for the duration of treatment.
1896601|NCT01299350|Other|Nt-proBNP guided discharge|Every patient will receive the drug treatment indicated in the guidelines of the European Society of Cardiology. Patients will be discharged the third day if NT-proBNP levels drops >30% compared to admission values. If such a reduction is not achieved, then the pharmacological treatment will be increased and NT-proBNP will be measured the following days until reaching the 30% reduction. The cutoff point of 30% reduction in NTproBNP was chosen based on previous studies
1896646|NCT01305278|Other|Use of Nintendo Wii Balance Gaming system|Use of Nintendo Wii Balance Gaming system
1896602|NCT01299363|Behavioral|Dilator use|Women randomized to vaginal dilators will be given instructions to perform exercises with vaginal dilators from postoperative weeks 4 to 8
1896603|NCT01299376|Drug|L50/H12.5/A5|
1896604|NCT01299376|Drug|L50/H12.5|
1896605|NCT01299376|Drug|Placebo to L50/H12.5/A5|
1896606|NCT01299376|Drug|Placebo to L50/H12.5|
1896607|NCT01299389|Drug|Paliperidone palmitate|Paliperidone palmitate will be given intramuscularly as an initial loading dose of 150 milligram (mg) equivalents (eq.) on Day 1 and 100 mg eq. on Day 8, followed by 75 mg eq. on Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
1896608|NCT01299389|Drug|Placebo|Matching Placebo will be given intramuscularly (Injection of a drug into a muscle) on Day 1, Day 8, Day 36 and Day 64. Participants who complete double-blind period or discontinued early from double-blind period will have follow-up visits during post-observational period at Weeks 4, 8 and 12 after the last injection in the double-blind period. Participants will not receive any study drug during post-observational period.
1896609|NCT01299402|Dietary Supplement|Soulera Herbal Blend|This a powder blend of various reputed adaptogenic herbs. The dosage will be one 8.6 gram powder sachet daily.
1896610|NCT01299402|Dietary Supplement|Placebo|The placebo will be a similar tasting and looking powder blend as the Soulera Herbal Blend. The dosage will be 8.6 grams per sachet daily.
1896611|NCT01299415|Drug|Vadimezan™|
1896612|NCT01299428|Device|INVOS 5100|INVOS 5100 IS AN EQUIPMENT THAT MEASURED CEREBRAL OXYGENATION WITH NEAR INFRARED SPECTROPHOTOMETRY METHOD.
1896613|NCT01299441|Device|ECOM ETT|Intubation with ECOM endotracheal tube (ETT)
1896614|NCT01299454|Drug|OPC-34712|All groups will receive a single oral 2-mg OPC-34712 dose on Day 1 with 240 mL room temperature still water. Subjects will be administered the OPC-34712 dose in the fasted state (at least 8 hours of fasting) and no food will be allowed for 4 hours postdose. Water will be restricted as part of the dosing procedure from 1 hour prior to dosing and 2 hours post-dose.
1896615|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
1896616|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 1.396 mg twice a day for up to 12 days. Last dose given 8 hrs before allergen challenge
1896617|NCT01299467|Drug|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
1896618|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
1896619|NCT01299467|Drug|Active (PF-03526299)|Capsules for inhalation, 4.188 mg twice a day for up to 12 days. Last dose given 8hrs before allergen challenge
1896620|NCT01299467|Drug|Placebo|Capsules for inhalation, Placebo, twice a day for up to 13 days. Last dose given 0.5 hrs before allergen challenge
1896621|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, 2 and 5, saline at visit 3
1896622|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, 3, and 5, saline at visit 2
1896623|NCT01299480|Biological|Vaccine|rLP2086 vaccine at visits 1, and 5, saline at visits 2 and 3
1896624|NCT01299480|Biological|Vaccine|rLP2086 at visits 1 and 3, saline at visits 2 and 5
1896625|NCT01299480|Biological|Vaccine|rLP2086 at visits 3 and 5, saline at visits 1 and 2
1896626|NCT01299493|Other|Systems-level intervention to promote colon cancer screening|Intervention practices will receive access to, and assistance in implementing, evidence-based strategies for increasing colorectal cancer screening rates.
1896627|NCT01299519|Behavioral|Weight Maintenance|Subjects in the weight maintenance arm will maintain a steady body weight (plus or minus 2% of initial body weight) for six months.
1896628|NCT01299519|Behavioral|Weight Loss|Half of the subjects in the weight loss arm will lose 5% of their weight through a low-calorie diet, and half will also lose 10% and 15% body weight.
1896629|NCT01299532|Device|Macrolane VRF30|Device: Macrolane VRF30 (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast. Re-injection of a maximum of 120 ml/breast in a subgroup of subjects.
1896630|NCT01305161|Other|Blood simple|Single Blood simple at Day 1
1896631|NCT01305174|Device|PROTEGE GPS stent vs. VISI-PRO stent|Visi-Pro balloon expandable stent vs. PROTEGE GPS selfexpanding nitinol stent to treat stenosis or occlusion of common and external iliac artery disease
1896632|NCT01305187|Device|Hyaluronic Acid Filler|The dosage is individualized depending on the depth of the NLF. The goal is to achieve optimal correction of both NLF with single implantations of Belotero® Basic and Juvéderm® Ultra 3 respectively. Each subject will be injected with Belotero® Basic and Lidocaine containing Juvéderm® Ultra 3 according to a split-face design. The allocation of fillers to the side of the face will be randomized. The randomization method is block-wise with a ratio 1:1 to the groups Belotero® Basic left and Juvéderm® Ultra 3 right, Belotero® Basic right and Juvéderm® Ultra 3 left.
1896633|NCT01305200|Drug|supersaturated calcium phosphate rinse|Mouth rinse
1896634|NCT01305200|Other|placebo|Mouth rinse
1896635|NCT01305200|Other|questionnaire administration|Ancillary studies
1896636|NCT01305200|Procedure|quality-of-life assessment|Ancillary studies
1896640|NCT01305226|Drug|THR-100|THR-100: 15 mg double-bolus (15mg/15ml), separated by 30 minutes (total 30 mg)
1896641|NCT01305226|Drug|Streptokinase|Streptokinase: Standard regimen (1.5 million IU) is made up in 150 ml of physiological saline or glucose solution and administered intravenously over a period of 60 minutes.
1896642|NCT01305239|Drug|Aromasin|Aromasin 25 mg daily.
1896643|NCT01305252|Drug|treprostinil inhalations|Treprostinil inhalation QID starting at 3 breaths per inhalation & gradually increasing to 9 breaths. Each breath provides approximately 6mcg of treprostinil.
1896644|NCT01305252|Drug|tadalafil|tadalafil 20mg QD PO increasing to 40mg QD as tolerated
1896645|NCT01305265|Device|cuff manometer|endotracheal tube cuff will be inflated to 22-26 cm H20 using cuff manometer
1896647|NCT01305291|Other|placebo|
1896649|NCT01305304|Other|repeated long term endurance exercise|competitive running at a national level during a period of at least 5 years (i.e. approximately 50km per week over more than 10 years)
1896650|NCT01305304|Other|Other|No history of endurance sports activity
1896651|NCT01305317|Drug|Lipitor|Atorvastatin 20mg daily for 6 months
1896652|NCT01305343|Procedure|Routinely performed surgical correction of spinal deformity|Routinely performed surgical correction of spinal deformity
1896653|NCT01305356|Device|Augment(tm) Injectable Bone Graft|Implantation of up to 9cc of Augment(tm) Injectable Bone Graft
1896654|NCT01305356|Procedure|Autologous bone graft|Implantation of up to 9cc of autologous bone graft
1896655|NCT01305369|Drug|Prasugrel|"Patients will be blindly and randomly allocated to treatment A (prasugrel 10 mg daily) or B (placebo) for 15 days. After a 15-day wash-out period, patients who had initially been allocated to treatment A will be allocated to treatment B, and vice versa."
1896656|NCT01305395|Drug|Sirolimus|Will initiate sirolimus within 6 months of heart transplant
1896657|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by angiogram
1896658|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
1896659|NCT01305395|Drug|Sirolimus|Will start sirolimus after they develop CAV by angiogram
1896660|NCT01305395|Drug|Sirolimus|Will start sirolimus after CAV has been diagnosed by intravascular ultrasound
1896661|NCT01305408|Drug|Armodafinil|Armodafinil tablets, taken orally, once daily in the morning
1896662|NCT01305408|Drug|Placebo|Matching placebo tablets, taken orally, once daily in the morning
1896663|NCT01305421|Procedure|grip test|Muscle strength measurement by hand-held dynamometer
1896664|NCT01305434|Dietary Supplement|Mulberry leaf extract effect on post prandial blood glucose|"Mulberry leaf extract (400 mg, Mulberry Zuccarin, New Nordic) or placebo will be administered with meals to type 2 diabetics. Half the patients will receive mulberry leaf extract for the first two weeks and half will receive placebo. Following a one week wash out period, the interventions will be reversed for another 2 weeks, followed by a final wash out period. Subjects will keep diaries of food, exercise, daily fasting glucose, and at least one 2 hour pc glucose per day for the 6 weeks of the trial.
Baseline renal function blood work and urine, liver function blood work, hemoglobin A1C, weight, and blood pressure will be done. These will be repeated at the end of each subject's 6 weeks in the trial. In addition, blood pressure will be checked with the distribution of the each 2 week batch of medications."
1896665|NCT01305447|Behavioral|Exercise Behaviour Maintenance|Following the termination of the 14 week exercise aided smoking cessation program, trained exercise facilitators will deliver 15 minute biweekly (for the first month), monthly (for the next 2 months), and then bimonthly (for last 8 months) phone calls to remind the participants of the self-regulatory skills they learned during group discussion.
1896666|NCT01305447|Behavioral|Smoking Relapse prevention booklets|Participants will be given Brandon et al. (2000, 2004) smoking relapse prevention booklets following exercise program.
1896667|NCT01305447|Behavioral|Contact control|No treatment, but equal contact time as the other intervention arms. Topics of women's health, unrelated to exercise will be discussed in group-mediated sessions(control).
1896668|NCT01305460|Drug|Azacitidine|"Treatment will consist of azacitidine 75mg/m2/d for 5 days every 14 days for 4 cycles.
Patients achieving CR or PR will be then treated with 4 cycles of azacitidine 75mg/m2/d for 5 days every 21 days followed by cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 9 and beyond), to be continued until progression/relapse or toxicity arises.
Patients not obtaining CR or PR after the initial 4 cycles of azacitidine-14 will continue to receive azacitidine 75mg/m2/d for 5 days every 14 days for 4 additional cycles (cycles 5 to 8). If they achieve CR, PR or HI after 8 cycles, they will then be treated with azacitidine 75mg/m2/d for 5 days every 21 days (cycles 9 to 12) and subsequently cycles of azacitidine 75mg/m2/d for 7 days administered every 28 days (cycles 13 and beyond) until progression/relapse or toxicity arises.
Patients not obtaining CR, PR or HI after 8 cycles of azacitidine-14 will go off-study."
1896669|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
1896670|NCT01306214|Drug|Placebo|Placebo matching BI 10773 low dose
1896671|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
1896672|NCT01306214|Drug|Placebo|Placebo matching BI 10773 high dose
1896673|NCT01306214|Drug|BI 10773|BI 10773 low dose once daily
1896674|NCT01306214|Drug|BI 10773|BI 10773 high dose once daily
1896675|NCT01306227|Drug|L-Thyroxine|Treatment with L-Thyroxine:7,5 µg/kg/day. Oral treatment (one drop =5µg) in the morning, once a day.
1896676|NCT01306227|Drug|water|Oral treatment with water. Equal number of drop of water as compared with the treatment arm (according to the body weight of the newborn) in the morning, once a day.
1896677|NCT01306240|Procedure|Surfactant instillation|Intra-tracheal poractant alpha instillation after tracheal intubation
1896678|NCT01306240|Procedure|nCPAP|Nasal Continous Positive Airways Pressure (nCPAP). Positive End Expiratory Pressure (PEEP) is set between 4 to 6 cm H2O. FiO2 is adjusted for a target post-ductus arteriosus SpO2 between 92% and 96%.
1896679|NCT01306253|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoides) of a single dose of 0.5 mL on Day 1"
1896680|NCT01306266|Drug|Rizatriptan|initial treatment with Maxalt-MLT 10 mg followed by treatment with placebo. Drug is to be taken at onset of a moderate or severe headache
1896681|NCT01306266|Drug|Placebo|Initial treatment with placebo followed by treatment with Maxalt-MLT 10 mg at onset of a moderate or severe headache.
1896682|NCT01306292|Drug|SonoVue|dose of 4.8 mL administered intravenously one time
1896683|NCT01306292|Drug|Placebo|Placebo is normal saline 0.9% for injection used as the comparator administered at 4.8 mL (same dose as SonoVue)
1896684|NCT01306305|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements ofr the 2010-2011 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/California/7/2009 (H1N1)-like virus
15 µg HA antigen of A/Perth/16/2009 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Day 1"
1897428|NCT01312038|Drug|Simethicone|single 125 mg chewable tablet
1896685|NCT01306318|Drug|eperisone hydrochloride plus diclofenac sodium capsule|Single dose of fixed dose capsule formulation of eperisone hydrochloride 50 mg plus diclofenac sodium 50 mg to be given in healthy volunteers in fasting conditions
1896686|NCT01306318|Drug|eperisone hydrochloride tablet and diclofenac sodium tablet|Single dose of eperisone hydrochloride 50 mg as tablet formulation and diclofenac sodium 50 mg as tablet formulation to be given in healthy volunteers in fasting conditions
1896687|NCT01306331|Drug|Conceptrol|• Conceptrol® Vaginal Gel, which contains 100 mg (4% concentration) of nonoxynol-9 (N-9) in 2.5 mL volume of gel.
1896688|NCT01306331|Drug|Amphora|• Amphora™ gel, which will be delivered in 5 mL doses, is a clear, water-based, petroleum-free gel.
1896689|NCT01306357|Drug|Somatropin|4 mg or 10 mg delivered by needle-free device
1896690|NCT01306370|Drug|Tranexamic Acid|"Two dosage during the surgical intervention: the first dosage 15-30' before the leg ischemia and the second dosage at 60 -90' after the first dosage.
Each dosage: 2 ampoules of 500mg/5 mL/ampoule"
1896691|NCT01306370|Drug|Fibrin glue|Topical administration, before to close the surgical wound. Dosage: 2 mL.
1896692|NCT01306370|Biological|Fibrin glue|Topical administration, before to close the surgical wound.
1896693|NCT01306370|Other|Habitual haemostasis|The surgical habitual haemostasis.
1896694|NCT01306383|Other|SODIS Bottle|SODIS Bottles used by SODIS group to treat their drinking water
1896695|NCT01306396|Behavioral|dietary intervention mainly focusing on fructose reduction|Based on the daily fructose intake assessed at the beginning of the study, children participating in the intervention group are advised to reduce their daily fructose intake by 50%. In the first study year, every three months and in the second study year, every six months, nutritional counseling is repeated in small groups in which parents and children are separately trained.
1896696|NCT01306409|Drug|cera, darbepoetin, epoetin-beta|Epoetin once/ 2wk, cera once/ month, darbepoetin once/ 2wk
1896697|NCT01306409|Drug|ESA|Sequential application of three different ESA
1896698|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE(1110 mg) formulated yogurt drink, twice-daily, 65 minutes before breakfast and dinner, for 15 days
1896699|NCT01306422|Other|Placebo yogurt drink|Placebo product (yogurt drink matching the H.g.PE extract formulated yogurt drink in nutritional composition and taste. Placebo is consumed twice-daily, 65 minutes before breakfast and dinner for 15 days.
1896700|NCT01306422|Other|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and lunch
1896701|NCT01306422|Other|Placebo yogurt drink|Placebo product, twice-daily for two days, 65 minutes before breakfast and dinner
1896702|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and lunch
1896703|NCT01306422|Other|Hoodia gordonii purified extract (H.g.PE)|H.g.PE formulated product (1110 mg), twice-daily for two days, 65 minutes before breakfast and dinner
1896704|NCT01306435|Other|Laser|3-week treatment with three Laser sessions per week
1896705|NCT01306435|Other|Placebo Laser|3-week treatment with three Placebo Laser sessions per week
1896706|NCT01306448|Device|Vibrant capsule|vibrating capsule
1896707|NCT01306461|Drug|Timolol and Tafluprost|"Preservative-free Timolol eye drops administered twice daily concomitantly with preservative-free Tafluprost eye drops administered once daily
Treatment period 6 months"
1896708|NCT01306461|Drug|Fixed Dose Combination of tafluprost and timolol|"Preservative-free Fixed Dose Combination of tafluprost and timolol eye drops administered once daily.
For masking purposes also: vehicle for timolol administered twice daily
Treatment period 6 months"
1896709|NCT01306487|Procedure|Vitrectomy|Macular hole surgery
1896710|NCT01306500|Procedure|Gastric lavage|8 Fr feeding tube was inserted orally with length equal to distance from the bridge of the nose to the earlobe and from the earlobe to a point halfway between the xiphoid process and the umbilicus. 20ml normal saline was used for gastric lavage. It was ensured that entire amount of normal saline used was removed from stomach.
1896711|NCT01306513|Biological|autologous bone marrow derived mesenchymal stromal cells|Intravenous administration of autologous bone marrow-derived mesenchymal stromal cells.
1896712|NCT01306539|Procedure|Stimulation of the subthalamic nucleus|Stimulation is delivered to the subthalamic nucleus at experimentally prescribed settings.
1896713|NCT01306552|Behavioral|Student-Intervention only group|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) during 7th grade.
The parcours takes approximately 3 hours to complete. The parcours consists of 7 interactive stations where a class of students learns about differences between smokers and non-smokers in terms of health status such as atherosclerosis prevalence, loss of smell or lung capacity and aging. Students also learn about the toxic ingredients in cigarettes. Each station includes a quiz to complete by each group of students. At the end of the parcours, a moderator will announce which group of students accumulated the most points. For more information on the contents of the parcours see http://www.karuna-prevents.de/index.php."
1896714|NCT01306552|Behavioral|Multi-component Intervention|"One visit to the smoking prevention parcours offered by KARUNA e.V. (Rauchst Du noch oder lebst Du schon?) + one parent night with information about smoking prevention and one informational letter by mail"
1896715|NCT01306552|Behavioral|Control Group|"One visit to the Nutrition and Physical Activity Parcours offered by KARUNA e.V. (Kinderleicht gesund zu leben).
(same set up as the smoking prevention parcours with topics around healthy nutrition and promotion of physical activity)"
1896716|NCT01306565|Drug|Low dose Atorvastatin|80mg atorvastatin followed by two 20mg daily atorvastatin
1896717|NCT01306565|Drug|High dose atorvastatin|80mg daily atorvastatin for 72 hours
1896718|NCT01306578|Drug|IVIG|Intravenous Immune Globulin at a dose 0f 0.4 g/kg/day for 5 consecutive days
1896719|NCT01306578|Procedure|Plasma Exchange|Five sessions of plasma exchange, single plasma volume each, for 5 consecutive days
1896720|NCT01306591|Drug|Bevacizumab 1|Bevacizumab, 1.25mg/0.05ml, every 6 weeks, 42weeks
1896721|NCT01306591|Drug|Bevacizumab|Bevacizumab, 1.25mg/0.05ml, 0week(baseline), 6week, 12week, 24week, 36week
1896722|NCT01306617|Drug|ABT-450|tablets
1896723|NCT01306617|Drug|ABT-333|tablets
1896724|NCT01306617|Drug|ribavirin|tablets
1896725|NCT01306617|Drug|ritonavir|capsules
1896909|NCT01307956|Other|high performance liquid chromatography|Correlative studies
1896726|NCT01306630|Drug|tivozanib (AV-951) and capecitabine (Xeloda®)|Tivozanib 1.0 mg or 1.5 mg oral once daily for 2 weeks followed by 1 week off. Capecitabine 825 mg/m2, 1000 mg/m2, or 1250 mg/m2, oral twice daily for 2 weeks followed by 1 week off. 1 cycle= 3 weeks. Cycles will be repeated in the absence of disease progression or unacceptable toxicity.
1896727|NCT01306643|Drug|Idelalisib|Tablet(s) administered orally twice daily
1896728|NCT01306656|Drug|10,000 IU Vitamin D3|"Month 1: 20,000 IU vitamin D3 once a week
Months 2-6: 10,000 IU vitamin D3 once a week"
1896729|NCT01306656|Other|Placebo|"Month 1: Placebo once a week
Months 2-6: Placebo once a week"
1896730|NCT01306656|Dietary Supplement|Vitamin D|Daily multivitamin with 400 IU vitamin D.
1896731|NCT01306669|Biological|Trivalent influenza vaccine|single dose of 0.5ml of Trivalent influenza vaccine for season will be administered into deltoid muscle of non-dominant arm
1896732|NCT01306669|Biological|Normal saline|Single dose of 0.5ml of normal saline will be administered into deltoid muscle of non-dominant arm
1896733|NCT01306682|Biological|Trivalent influenza vaccine|0.5 ml of trivalent influenza vaccine administered into deltoid muscle of non dominant arm
1896734|NCT01306682|Biological|Normal saline|0.5ml normal saline administered into deltoid muscle of non dominant arm
1896735|NCT01306695|Behavioral|New York University Caregiver Intervention (NYUCI)|"The NYU Caregiver Intervention (NYUCI) has substantial evidence of efficacy. This intervention is unique in its emphasis on family support and in providing ongoing availability of the counselor. While the NYUCI is being implemented in several communities, its effectiveness in the Hispanic community of Northern Manhattan has not been tested. The first component of the intervention consists of two individual and four family counseling sessions that include relatives suggested by the caregiver. The second component of the intervention is participation in a support group to provide the caregiver with continuous emotional support and education. The third component of the treatment is ad hoc counseling the continuous availability of counselors to caregivers and families to help them deal with crises and with the changing nature and severity of their relatives' symptoms over the course of the disease."
1896736|NCT01306695|Other|Community Health Worker (CHW) Case Management|The CHW intervention will consist of 2 visits in month 1, followed by monthly visits until month 6. The main role of the CHW will be to provide access to existing education and referral resources about dementia and caregiving. In addition, CHW will assess other health and social issues and provide information on existing resources on Northern Manhattan. The CHW will carry a blackberry or iPhone type device with real time access to email, text, the internet, and telephone. Thus, the CHW will be able to provide participants with real time information from pertinent websites such as CUMC, Alianza, and the NY chapter of the Alzheimer's Association. CHW will also provide participants with their phone number and email address for ad-hoc contacts.
1896737|NCT01306708|Drug|amitriptyline|Nerve suprascapular blockade with local anaesthetic agent (novabupivacaine 0.25%, 10 ml, once per week) + oral tricyclic antidepressant (amitriptyline 25 mg, twice per day, for 14 days);
1896738|NCT01306721|Drug|fexofenadine HCL (M016455)|Pharmaceutical form:tablet Route of administration: oral
1896739|NCT01306721|Drug|pseudoephedrine|"Pharmaceutical form:tablet
Route of administration: oral"
1896740|NCT01306721|Drug|fexofenadine HCL matching placebo|"Pharmaceutical form:tablet
Route of administration: oral"
1896741|NCT01306721|Drug|pseudoephedrine matching placebo|"Pharmaceutical form:tablet
Route of administration: oral"
1896742|NCT01306747|Behavioral|The Stanford Chronic Pain Self-Management Programme|The Stanford CPSMP is a patient education program consisting of six 2½ hour weekly sessions. Two trained instructors teach a group of 8-16 persons about managing pain.
1896743|NCT01306760|Drug|Ketamine|Ketamine used as the anaesthetic during ECT.
1896744|NCT01306760|Drug|Propofol|The standard anaesthetic used for ECT.
1896745|NCT01306773|Drug|H1N1 convalescent plasma and oseltamivir|Oseltamivir 75mg bid orally during ICU hospitalization + 500mL convalescent plasma containing >= 1:160 of neutralizing antibody to Pandemic influenza A H1N1
1896746|NCT01306773|Drug|Oral Oseltamivir alone|Oral Oseltamivir 75mg bid during ICU hospitalization
1896747|NCT01306786|Drug|Quadruple therapy|"First line: 5 days esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.
Cross over second line for those who failed first line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d"
1896748|NCT01306786|Drug|Triple therapy|First line: 7 days esomeprazole 20mg b.d., amoxicillin 1g b.d. and clarithromycin 500mg b.d Second line cross over if failed first line: 7 days quadruple therapy: esomeprazole 20mg b.d., bismuth subcitrate 120mg q.i.d., tetracycline 250mg q.i.d. and metronidazole 250mg q.i.d.)
1896749|NCT01306838|Dietary Supplement|MicroLipid and fish oil|Infants in treatment arm will receive the same nutrition support as control group before they tolerate enteral feeding at 20 ml/kg/day. Then they will receive study oils when feeds reach 30 ml/kg/day.
1896750|NCT01306838|Other|Routine care|Routine care
1896751|NCT01306851|Drug|Fibrin glue|In the intervention group, 5 or 10 ml of fibrin glue are applied in the anastomotic line.
1896752|NCT01306864|Device|Hemospray Kit|Hemostasis of Arterial GI Bleeding
1896753|NCT01306877|Device|EEA Hemorrhoid and Prolapse Stapling Set|Surgical device
1896754|NCT01306877|Device|Endosurgery Proximate PPH03 Stapling Set|Surgical device
1896755|NCT01306890|Biological|sipuleucel-T|Each dose of sipuleucel-T contains a minimum of 50 million autologous CD54+ cells activated with PAP-GM-CSF. The recommended course of therapy for sipuleucel-T is 3 complete doses, given at approximately 2-week intervals.
1896756|NCT01306903|Device|MECC|Minimized extracorporeal circulation
1896757|NCT01306903|Device|MOPS|Modified and optimized perfusion system Frankfurt
1896758|NCT01306903|Device|Super MOPS|Super modified and optimized perfusion system Frankfurt
1896759|NCT01306929|Drug|pridopidine|45mg bid
1896760|NCT01306942|Drug|dasatinib plus trastuzumab plus paclitaxel|Eligible patients will be enrolled and treated with 4-week cycles of trastuzumab 2 mg/kg IV weekly (following a loading dose of 4 mg/kg in cycle 1) and paclitaxel 80 mg/m2 weekly x 3 weeks followed by a rest period of 7 days. Dasatinib will be administered orally in two dose levels 100 and 140 mg QD (a -1 dose level is included just in case dose de-escalation is needed). Treatment will be repeated on Day 1 of a 28-day cycle until radiographic or symptomatic progression or unacceptable toxicity occurs. Only in the phase I, the first cycle will last 38 days.
1896910|NCT01307956|Genetic|DNA analysis|Correlative studies
1896761|NCT01306955|Drug|methylorednisolone|intravenous infusion of 1000 mg methylprednisolone in 100cc D/w 5% on 3 consecutive days at beginning of treatment
1896762|NCT01306955|Other|dextrose water 5%|intravenous infusion of 100cc D/w 5% on 3 consecutive days at beginning of treatment
1896763|NCT01306968|Drug|hyperbaric oxygen|"The chamber will be compressed with air to 1.5 atm abs. Once the chamber is compressed to 1.5 atm abs, the subjects will don a hood and breathe 100% oxygen. Hoods will be supplied with oxygen with flows of at least 30 liters per minute and overboard dumping of excess gas. Each subject will complete 40 sessions.
The duration of the hyperbaric oxygen exposures will be 60 minutes (±2 minutes), timed from when the chamber hatch or door closes, and ending when the chamber hatch or door opens (door-to-door time equals 60 minutes). The total intervention exposure time is 50 minutes (±2 minutes). The interval to compress to the intervention pressure (1.5 atm abs) and will be 5 minutes (±1 minute). The interval to decompress from the study pressure will be 5 minutes (±1 minute)."
1896764|NCT01306968|Other|sham hyperbaric air|A pressure of 1.2 atm abs will provide an equivalent inhaled oxygen concentration of 25%. The duration of the sham exposures will be 60 minutes (±2 minutes). Each subject will complete 40 sessions.
1896765|NCT01306981|Drug|Ranibizumab|Intravitreal injection of ranibizumab, 0.5mg in 0.05ml
1896766|NCT01306981|Drug|Saline|Subconjunctival injection of 0.05ml saline 0.9% w/v
1896767|NCT01306994|Other|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination and exercise test by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest and during exercise.
1896768|NCT01306994|Procedure|Physiological Stress Test|During exercise, heart and lung function are monitored for changes caused by exercise, which increases the body's need for oxygen and puts extra demands on the heart. In this study, testing is done using a cycle ergometer and conducted according to the standardised exponential exercise protocol (STEEP).
1896769|NCT01306994|Other|Functional Enquiry Form|Evaluated before clinical examination, it is a checklist of medical problems.
1896770|NCT01306994|Other|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
1896771|NCT01306994|Other|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination (minus breasts, genitalia, or rectum).
1896772|NCT01306994|Other|Observational Gait Analysis|Completed during the clinical examination by researchers, it is a structured approach to evaluation of a person's walking.
1896773|NCT01306994|Other|Mental Health Interview|Completed during the clinical examination by the researchers, it is a general evaluation of mental health status.
1896774|NCT01307007|Drug|Ferric Carboxymaltose (FCM)|15 mg/kg up to a maximum of 1000 mg intravenous diluted in 250 cc normal saline solution administered over 15 minutes on Day 0
1896775|NCT01307007|Drug|Iron Dextran Injection|Test dose of 25 mg administered over 5 minutes, if no reaction occurs then the remainder of the dose (15 mg/kg or 1000 mg including the test dose) will be administered as per investigator. The infusion must be given only when resuscitative techniques for the treatment of anaphylactic reactions are readily available.
1896776|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol low dose, oral film-coated table, once
1896777|NCT01307020|Drug|Dexketoprofen Trometamol|Dexketoprofen Trometamol high dose, oral film-coated table, once
1896778|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride low dose, oral film-coated table, once
1896779|NCT01307020|Drug|Tramadol Hydrochloride|Tramadol Hydrochloride high dose, oral film-coated table, once
1896780|NCT01307020|Drug|Ibuprofen|Ibuprofen 400 mg, oral film-coated table, once
1896781|NCT01307020|Drug|Placebo|Placebo, oral film-coated table, once
1896782|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl low dose, oral film-coated table, once
1896783|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS low dose - TRAM.HCl high dose, oral film-coated table, once
1896784|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl low dose, oral film-coated tablet, once
1896785|NCT01307020|Drug|Dexketoprofen Trometamol + Tramadol Hydrochloride|DKP-TRIS high dose - TRAM.HCl high dose, oral film-coated tablet, once
1896786|NCT01307033|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
1896787|NCT01307033|Drug|MK-954H|Tablet containing losartan potassium (50 mg) and hydrochlorothiazide (12.5 mg), once daily
1896788|NCT01307033|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
1896789|NCT01307033|Drug|Placebo to MK-954H|Placebo tablet to match MK-954H, once daily
1896790|NCT01307046|Drug|MK-0954A|Tablet containing losartan potassium (100 mg) and hydrochlorothiazide (12.5 mg), once daily
1896791|NCT01307046|Drug|Losartan|Tablet containing losartan potassium (100 mg), once daily
1896792|NCT01307046|Drug|Placebo to MK-0954A|Placebo tablet to match MK-0954A, once daily
1896793|NCT01307046|Drug|Placebo to losartan 100 mg|Placebo tablet to match losartan 100 mg, once daily
1896794|NCT01307046|Drug|Placebo to losartan 50 mg|Placebo tablet to match losartan 50 mg, once daily
1896795|NCT01307059|Device|easypod™|Saizen (Somatotropin) as per Summary of Product Characteristics administered by easypod™
1896796|NCT01307072|Procedure|Vitrectomy|Vitrectomy. Diabetic retinopathy
1896797|NCT01307085|Procedure|remote ischemic preconditioning|Remote ischaemic preconditioning consisted of three 5-min cycles of right upper limb ischaemia, induced by an automated cuff-inflator placed on the upper arm and inflated to 200 mm Hg, with an intervening 5 min of reperfusion during which the cuff was deflated.
1896798|NCT01307098|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose A of SBC-102 (sebelipase alfa)
1896799|NCT01307098|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose B of SBC-102 (sebelipase alfa)
1896800|NCT01307098|Drug|SBC-102 (sebelipase alfa)|Weekly IV infusions Dose C of SBC-102 (sebelipase alfa)
1896801|NCT01307111|Drug|Misoprostol|400 micrograms inserted buccally or vaginally, per the participants desire prior to the IUD insertion.
1896802|NCT01307111|Drug|Placebo|Pills which are identical to the study drug in appearance, taste, and smell.
1896911|NCT01307956|Genetic|polymorphism analysis|Correlative studies
1896803|NCT01307124|Drug|kaletra|"The study participants will receive Lopinavir/ritonavir heat-stable tablet (100/25 mg or 200/50 mg) q 12 hour plus NRTIs. The other NRTIs is depend on physician discretion.
Arm 1:LPV/r Standard dose Arm 2:Low dose BW 25-35 kg 300/75 mg 200/50 mg BW >35-50 kg 400/100 mg 300/75 mg"
1896804|NCT01307137|Behavioral|Peer-led intervention|"An expert patient in the peer-led intervention will provide effective support for patients and families to accelerate adoption of CER for diabetes prevention and management in the elderly. This will lead to better self-efficacy and clinical outcomes.
Those veterans enrolled in the MOVE! and HARC programs that have showed success in management of weight and Diabetes will be offered to become peer-leaders.
Weight management success is defined as a loss of at least 5% of the weight since enrollment
Diabetes management will be defined as adequate control of HbA1c and/ or blood pressure and lipids.
The potentials peer-leaders will have a pre-assessment test to evaluate diabetes prevention and management knowledge and motivation and support skills."
1896805|NCT01307137|Behavioral|Telehealth Intervention|Participants in the TAP group will receive mobile phones that will be programmed to monitor specific clinical parameters and promote adoption of CER on prevention and management of diabetes, with protocols developed in part based on the input from the focus groups. These devices display messages, tips, reminders and questions regarding healthy lifestyle and clinical parameters of diabetes, which will be developed using best practice guidelines. Participants will be asked to respond to the questions daily if they can. Also they are asked to provide their daily weight, blood pressure, and glucose levels (the later only for patients with diabetes).
1896806|NCT01307176|Behavioral|Home exercise program|The home exercise program uses standard physical therapy exercises that have never been rigorously tested for people with cerebellar ataxia. These include sitting balance exercises (e.g. sitting on a peanut-shaped exercise ball and moving arms or legs), standing balance exercises (e.g. weight shifting, moving arms and legs), and walking exercises (e.g. walking heel-to-toe). The exercises are in a progression, going from less to more challenging. Though the exercises are standard, they are the intervention that we are testing and we will consider them experimental.
1896807|NCT01307189|Drug|Tiotropium|Tiotropium diskus inhalation powder, 18ug, once daily
1896808|NCT01307189|Drug|Placebo|Placebo diskus inhalation powder, once daily
1896809|NCT01307202|Drug|Gabapentin|600mg of Gabapentin will be given orally preoperatively and 200mg for 3 times a day after surgery for 3 days
1896810|NCT01307202|Drug|Placebo|Placebo will match the the gabapentin pill and will be given orally.
1896811|NCT01307215|Drug|Ropivacaine|20mLs of 0.5%
1896812|NCT01307215|Drug|Ropivacaine|30mLs of 0.33%
1896813|NCT01307215|Drug|Ropivacaine|40mLs of 0.25%
1896814|NCT01307228|Other|Health Systems Evidence|Health Systems Evidence (HSE) contains over 1400 research syntheses about governance, financial and delivery arrangements within health systems and about implementation strategies relevant to health systems. The syntheses have been: 1) categorized by topic, type of synthesis, and type of question addressed; 2) coded by the last year in which searches for studies were conducted and by the countries in which included studies were conducted; 3) rated for quality; and 4) linked to publicly available user-friendly summaries, scientific abstracts, and full-text reviews. We identified systematic reviews in HSE that are not accessible to study participants and developed a mechanism to reimburse publishers for full-text downloads of these reviews.
1896815|NCT01307254|Procedure|blood analysis|A single venous blood test will be taken - 4 tubes (hematology, clotting, chemistry, sedimentation rate)
1896819|NCT01307280|Behavioral|RCT1|the bookHEALTH manual and eHEALTH tools, the basic Internet component of the intervention
1896820|NCT01307280|Behavioral|RCT2|bookHEALTH and an interactive version of eHEALTH that provided tailored computerized feedback whenever participants submitted weekly assessments
1896821|NCT01307280|Behavioral|RCT3|bookHEALTH, the interactive version of eHEALTH, and telephonic coaching support provided by trained health lifestyle coaches every 2 weeks alternating between a telephone call (typically 15 to 20 minutes) and a personalized e-mail. The coaches used motivational interviewing, helped participants solve problems, and reinforced their successes.
1896822|NCT01307293|Behavioral|Cognitive behavior therapy|6 or 12 sessions of cognitive behavior therapy.
1896823|NCT01307306|Drug|Humulin R|Humulin R (U-100) will be given i.v. The dose given will be adjusted in order to achieve a blood glucose level of 130-140 mg/dl.
1896824|NCT01307306|Drug|Metformin|Metformin 850 mg q. 8 hours will be given to decrease blood glucose to 130-140 mg/dl.
1896825|NCT01307319|Drug|BDP HFA|BDP (beclomethasone dipropionate) HFA (hydrofluoroalkane) nasal aerosol administered as a single actuation in each nostril daily for the 15 day treatment period. Each actuation contains either 40 or 80 mcg for a total daily dose of either 80 or 160 mcg depending upon the assigned treatment arm.
1896826|NCT01307319|Drug|Placebo nasal aerosol|Placebo formulated as a nasal aerosol spray and administered as a single actuation in each nostril daily for the 15 day treatment period.
1896827|NCT01307332|Drug|MabCampath-1h|Drug:10 mg/mL alemtuzumab intravenous infusion. Form: Sterile, clear, colorless solution. Dosage: 2 cycles. Month 0 dosed over 5 consecutive days; month 12 dosed over 3 consecutive days.
1896828|NCT01307345|Behavioral|contingency management for abstinence|For each breath sample submitted that reads below the cut point, participants will receive a voucher that can be exchanged for a check or gift card. Amounts earned will increase for each consecutive negative sample submitted, up to a maximum amount.
1896829|NCT01307358|Device|Sonicare Interproximal (IP) Cleaning Prototype|Sonicare Interproximal (IP) Cleaning Prototype used to clean between the teeth 1 time a day in combination with brushing.
1896830|NCT01307384|Device|Continuum(R) Metal on Polyethylene Acetabular System|Used in primary hip arthroplasty
1896832|NCT01307423|Drug|Apremilast 20mg|Apremilast 20mg twice daily, orally
1896833|NCT01307423|Drug|Apremilast 30mg|Apremilast 30mg twice daily, orally
1896834|NCT01307423|Drug|Placebo|Placebo
1896835|NCT01307436|Biological|Epaxal|0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)
1896912|NCT01307956|Other|pharmacological study|Correlative studies
1896836|NCT01307436|Biological|Havrix 720|0.5ml Havrix 720: at least 720 EU hepatitis A antigen adsorbed onto aluminium hydroxide
1896837|NCT01307449|Biological|PNEUMOVAX and PREVNAR|Give either 1 dose of PNEUMOVAX or PREVNAR to all participants
1896838|NCT01307449|Biological|Pneumovax or Prevnar|Receipt of one vaccination at D0
1896839|NCT01307462|Drug|fluticasone propionate|Given inhaled PO
1896840|NCT01307462|Drug|montelukast sodium|Given PO
1896841|NCT01307462|Drug|azithromycin|Given PO
1896842|NCT01307475|Other|PTSD Checklist-Specific|Completed by patients before clinical examination; it is a 17-item survey listing of symptoms of posttraumatic stress disorder.
1896843|NCT01307475|Other|Modified Flanagan Quality of Life Scale|Completed by patients before clinical examination; it is a 16-item survey designed for use in persons with chronic illness.
1896844|NCT01307475|Other|Center for Epidemiologic Studies Depression Scale|Completed by patients before clinical examination; it is a 20-item survey that asks about depressive feelings and behaviours in the past week.
1896845|NCT01307475|Other|Functional Enquiry Form|Completed by patients before clinical examination; it is a checklist of medical problems.
1896846|NCT01307475|Other|Strength, Joint ROM, Girth and Length Measurements|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of muscles, joints, arms, thighs, and legs.
1896847|NCT01307475|Other|Study Physical Examination|Completed during the clinical examination by the researchers, it is a structured approach to a full physical examination, minus breasts, genitalia or rectum.
1896848|NCT01307475|Other|PTSD, Depression, and FSS-Focused Examination|Completed during the clinical examination by the researchers, it is a structured approach to evaluation of symptoms, signs, and perceptions that may be related to FSS, PTSS, or depressive problems.
1896849|NCT01307475|Other|Freeman-Sheldon Specific Quality of Life Survey|Completed after data analysis from the existing surveys and clinical examination, it will be a specific quality of life survey developed and tested during the study; it will take into consideration individual's total health outcome.
1896850|NCT01307475|Other|Lactate, Glucose, and Adenosine Triphosphate Blood Levels|Completed during the clinical examination by the researchers, lactate, glucose, and free and total adenosine triphosphate blood levels are determined at rest.
1896851|NCT01307488|Drug|Ritonavir boosted Atazanavir + Lamivudine|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for the first 4 weeks and then they will receive ATV/RTV 300/100 mg QD (once daily) and 3TC 300 mg QD for another 92 weeks. Treatment should be taken orally with a light meal at the same time each day.
1896852|NCT01307488|Drug|Ritonavir boosted Atazanavir + 2 NRTIs|ATV/RTV 300/100 mg QD + 2 optimized NRTIs for 96 weeks. Treatment should be taken orally with a light meal at the same time each day.
1896853|NCT01307501|Device|Cryoablation|All patients will receive cryoablation of up to 5 metastatic lung tumors bilaterally.
1896854|NCT01307527|Drug|Riboflavin|0.1%, applied every 5 minutes for 60 minutes
1896855|NCT01307527|Device|Kera-X|3 mW/cm2, to the central 7.5 mm of the cornea, for 30 minutes
1896856|NCT01307540|Device|phototherapy|low level light therapy, broad band light wavelengths.
1896857|NCT01307553|Device|Pericardium Covered Stent|Percutaneous implantation of pericardium covered stent
1896858|NCT01307566|Device|Continuous Positive Airway Pressure CPAP|CPAP treatment
1896859|NCT01307579|Drug|caspofungin acetate|Given IV
1896860|NCT01307579|Drug|fluconazole|Given IV or PO
1896861|NCT01307579|Other|laboratory biomarker analysis|Correlative studies
1896862|NCT01307592|Biological|rituximab|
1896863|NCT01307592|Drug|gemcitabine hydrochloride|
1896864|NCT01307592|Drug|lenalidomide|
1896865|NCT01307592|Drug|oxaliplatin|
1896866|NCT01307605|Biological|Rituximab|Rituximab (MabThera®) will be administered for a maximum of 8 infusions at weeks 1, 2, 3, 4 and again at weeks 12, 13, 14, 15 if the first restaging at week 10 (+/- 1 week) shows a partial response with at least more than 25% reduction in sum of product of diameters
1896867|NCT01307605|Drug|lenalidomide|Lenalidomide will be administered as 15 mg flat dose daily, starting 14 days before first and stopping 14 days after last rituximab administration.
1896868|NCT01307618|Biological|NA17.A2 Peptide Vaccine|Given SC or ID
1896869|NCT01307618|Biological|Recombinant MAGE-3.1 Antigen|Given SC or ID
1896870|NCT01307618|Biological|Recombinant Interleukin-12|Given SC or ID
1896871|NCT01307618|Biological|MART-1 Antigen|Given SC or ID
1896872|NCT01307618|Other|Laboratory Biomarker Analysis|Correlative studies
1896873|NCT01307631|Drug|Akt Inhibitor MK2206|Given PO
1896874|NCT01307631|Other|Laboratory Biomarker Analysis|Correlative studies
1896875|NCT01307644|Behavioral|Experimental: Web-based only (WO) weight intervention|The WO intervention included evidence-based lifestyle modification for healthy eating and activity, with self-monitoring and goal setting, and messages based on constructs from the Health Promotion Model across 3 phases. The intent of the phases was to deliver more intensive intervention during Phase 1, transitioning to less intensive intervention during phase 2, to providing support for self managed weight maintenance during Phase 3.
1896876|NCT01307644|Behavioral|Experimental: WO plus peer-led discussion board (WD)|Includes WO intervention plus asynchronous discussion board managed by peer leader, whose identity is masked. The peer leader who posted theme-based messages, called primers, that were consistent with WO themes across phases.
1896877|NCT01307644|Behavioral|Experimental: WO & professional email counseling (WE)|Includes WO intervention plus professional email counseling provided by a registered dietitian whose identity is masked. The email counselor is responsible for reviewing eating, activity, weight logs, and goals on the web-site and send e-mail feedback, in addition to responding to email questions. The e-mail process will follow the 5A's Model for Behavioral Counseling (assess, advise, agree, assist, and arrange) that was adapted for this study.
1896878|NCT01307657|Other|high fat meal|Clopidogrel 600 mg loading dose at 8 am and high-fat meal at 12 pm
1896879|NCT01307683|Behavioral|Mindful Moms|"8 weekly 2-hour sessions, 2 booster telephone sessions, and 1 postpartum booster session"
1896913|NCT01307956|Other|pharmacogenomic studies|Correlative studies
1896914|NCT01307969|Drug|Ropivacaine|1,8 mL of the local anesthetic formulations were injected at the apex of the maxillary right canine.
1897429|NCT01312038|Drug|Placebo|chewable calcium tablet
1896880|NCT01307722|Other|left atrial distensibility-guiding prescription of heart failure drugs|This study is a prospective, observational, and open label investigation. The guide group will be followed 1 time per 2 week at first 3 months, then 1 time per month later, and then 1 time per 3 months. Each time, the guide group should receive echocardiography, including the measurement of LA distensibility. LA distensibility-guided therapy is enabled in 2 ways. Prescriptions should be adjusted according to overall left ventricular filling pressure estimated by LA distensibility. The specified treatments after adjustment by the current LA distensibility are also allowed. Investigators individually adjust medications for each patient according to the ranges of LA distensibility. The specified therapy is based on 5 LA distensibility ranges (very low, low, optimal, high, and very high). Each range is associated with a prescription for medication dosing, sodium and fluid intake, or activity level.
1896881|NCT01307748|Other|aroma|Comparison of known stress reducing aroma to placebo aromas without stress-reducing effects
1896882|NCT01307787|Other|experimental Fit-program|Participants in the intervention group followed an eight week multi-disciplinary group rehabilitation program, consisting of a physical exercise part and an educational component. The physical exercise part consisted of a muscle exercise circuit and bicycle training,sport and aqua jogging. The educational part consisted of a weekly sixty minutes session. A multi-disciplinary group of healthcare professionals gave specialist orientated informational advice about how to handle the consequences of RA. Special attention was paid to ensure adjusting the level of each patients activity level to the participants' actual energy level. Further information was given about body sensations, sports, food and energy, pain, fatigue, emotional changes, sleeping disturbance and daily routine.
1896883|NCT01307787|Other|no intervention|waiting list control group with no intervention
1896884|NCT01307800|Drug|LY2140023|Administered orally
1896885|NCT01307800|Drug|Placebo|Administered orally
1896886|NCT01307813|Device|Overstitch Endoscopic Suturing System|"Assess the safety and effectiveness of the Apollo endoscopic suturing device (Overstitch) and cinching device for placement of sutures and surgical knots in a segment of colon under laparoscopic or open visualization of the operative area.
Patients will already require resection of segments of colon for treatment of benign or malignant disease and this will therefore be a treat and resect model"
1896887|NCT01307826|Other|massage|"session - 20 minutes.
Before the massage, palpable evaluation of the selected anatomical structures was carried out - to determine which tissues have the greatest sensitivity and which motor organs show increased tension (by pressing the attachment). In all the examined patients, pain of the following muscle attachments were shown:
latissimus muscle of the back
major pectoral muscle
supraspinous and infraspinous muscles
teres minor muscle
serratus anterior muscle
deltoid muscle The decision which muscles and fascias have to be massaged was made on the basis of the performed evaluation. In most cases the above mentioned tissues (together with other motor system organs which are structurally linked to it) were massaged to relax them.
A palpable evaluation of the previously examined points was again performed during the final part, with particular attention paid to painful muscles, in order to analyze the effectiveness of the performed relaxation."
1896888|NCT01307826|Other|massage|classical massage (Swedish massage)
1896889|NCT01307839|Drug|5% lidocaine patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours.
1896890|NCT01307839|Drug|placebo patch|Research intervention: After consent has been given, either an active 5% lidocaine patch or an inactive placebo patch will be placed on the lumbar spine of the patient. Both patches appear identical to the physician. The team will then wait for the patient to request an epidural due to labor pain, a minimum of 30 minutes from patch placement and a maximum of 12 hours
1896891|NCT01307852|Device|Plastic Scintillation Detectors|Radiation detectors attached to rectal balloon for each CT scan done during each radiation treatment. Treatment delivery Monday through Friday for 7 weeks.
1896893|NCT01307878|Drug|chemotherapy ± targeted therapy|FOLFOX 6 ± targeted therapy
1896896|NCT01307904|Other|Glucose|Each healthy and Diabetic volunteers received 50 grams of glucose
1896897|NCT01307904|Other|Dates|Each healthy and diabetic volunteers received 50 grams equivalent of carbohydrates of each of the five selected dates, on five separate days.
1896898|NCT01307917|Dietary Supplement|flavonoids|for 14 days, one dose two times per day, subjects will ingest a flavonoid-rich capsule containing 500 mg flavonoids or a placebo capsule made, stored, and dispensed by TTUHSC Pharmacy, with a similar look and taste.
1896900|NCT01307943|Other|Mindfulness-based stress reduction program|Eight MBSR sessions of 2 hrs/week to be held during regular class time plus one 3-hour retreat
1896901|NCT01307943|Other|Usual care|The site provides family centered treatment where adolescents take part in therapy from Sunday evening until Friday afternoon. In addition to a structured day and evening schedule, standard treatment includes: Daily group therapy; ii) Medications; iii) Schooling by Edmonton Public School Board teachers; iv) Physical education and recreation; and v) Weekly Multiple Family Therapy.
1896902|NCT01307956|Biological|panitumumab|Given IV
1896903|NCT01307956|Drug|oxaliplatin|Given IV
1896904|NCT01307956|Drug|leucovorin calcium|Given IV
1896905|NCT01307956|Drug|fluorouracil|Given IV
1896906|NCT01307956|Radiation|radiation therapy|Undergo radiation therapy
1896915|NCT01307982|Procedure|Fundoplication|During fundoplication surgery, the upper curve of the stomach (the fundus) is wrapped around the esophagus and sewn into place so that the lower portion of the esophagus passes through a small tunnel of stomach muscle. This surgery strengthens the valve between the esophagus and stomach (lower esophageal sphincter), which stops acid from backing up into the esophagus as easily.
1896916|NCT01307982|Procedure|Gastrojejunal (GJ) feeding tube|Gastrojejunal (GJ) tube placement is an image guided technique in which a special soft feeding catheter is placed through an existing hole in the stomach (gastrostomy) into the small bowel (jejunum).
1896919|NCT01308021|Biological|gpASIT+TM|entero-coated capsules containing 400µg of gpASIT+TM, daily , 28 days
1896920|NCT01308021|Biological|gpASIT+TM|entero-coated capsules containing 800 µg of gpASIT+TM, daily, 28 days
1896921|NCT01308021|Biological|Placebo|Placebo entero-coated capsules
1896922|NCT01308034|Drug|sunitinib|"All patients will be treated with sunitinib (3 dose level) once a day (in the morning) for 6 weeks in association with radiotherapy.Radiotherapy will be realised 1-4h after taking sunitinib.
Dose level 1 : 12.5 mg once daily Dose level 2 : 25 mg once daily Dose level 3 : 50 mg once daily. Authorization to include a patient in the upper step will be given only if the deadline of 14 weeks after the start of treatment of last patient included were strictly respected and depending of number of DLT occuring."
1896923|NCT01308047|Drug|Bupivacaine|single dose of 15mg by a slow injection rate of 1 ml/s
1896924|NCT01308060|Drug|Botulinum Toxin Type A|During part A, Azzalure will be adminitered at Baseline 60 Spey unit at canthal lines and compared with placebo.
1896925|NCT01308073|Device|Hemodialysis with EMIC 2 filters|Patients with indication for routine continuous hemodialysis due to acute renal insufficiency
1896926|NCT01308086|Drug|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 & 2, q2w, for 12 cycles
1896927|NCT01308086|Drug|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 & 2, q2w, for 12 cycles
1896928|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 12 cycles
1896929|NCT01308086|Drug|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 8 cycles
1896930|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 8 cycles
1896931|NCT01308086|Drug|5-Fluorouracil|5-FU 400mg/m2 Bolus and then 22 hours 5-FU 600mg/m2 IV, days 1 & 2, q2w, for 6 cycles
1896932|NCT01308086|Drug|Leucovorin|Leucovorin 200mg/m2 IV in 2 hours, days 1 & 2, q2w, for 6 cycles
1896933|NCT01308086|Drug|Capecitabine|Capecitabine 1000 mg/m2 X 2 ,days 1-14, q2w, for 4 cycles
1896934|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 130 mg/m2 in 2 hours IV, day 1, q2w, for 4 cycles
1896935|NCT01308086|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 in 2 hours IV, day 1, q2w, for 6 cycles
1896936|NCT01308099|Device|Blood Pressure and Blood Flow|"A blood pressure cuff will be placed on one arm and small probes on one finger on both hands. The probes also measure blood pressure. After 10 minutes, the arm blood pressure cuff will be inflated. The cuff will stay inflated for 5 minutes, then the air will be let out. A cuff will be place above the left calf and the left knee. The subject will lie quietly for 9 minutes, then blood pressure and calf blood flow will be measured for one minute. the lower leg cuff will be inflated after 1 minute, then the cuff will be deflated. The blood pressure and forearm blood flow will be recorded. Next, the cuff on the upper leg will be inflated for 5 minutes then, it will be released and the measurements of blood pressure and calf blood flow will be repeated.
The study lasts about 2 hours."
1896937|NCT01308112|Dietary Supplement|iron|Daily supplementation with iron (60 mg) as ferrous sulphate
1896938|NCT01308125|Procedure|PICSO|"Baseline (hemodynamic) measurement
Intra coronary
Blood sampling
LAD occlusion: for 3 min or until pain with and without PICSO
Break recovery: the patient can recover from pain for 3 min
CFIp: by a ComboWire advanced in the center lumen of an occlusion balloon.
PICSO: start automatically and continued for 10 min.
PCI/PICSO: concomitantly for the whole duration of the PCI intervention.
24h Follow up: additional blood samples every 6 hours (4 times)
30 days follow up."
1896939|NCT01308138|Behavioral|Exercise training|exercise training
1896940|NCT01308138|Procedure|remote ischemic preconditioning|remote ischemic preconditioning
1896941|NCT01308151|Other|Other|No interventions other than the culturally adapted manualised cognitive behavioral therapy
1896942|NCT01308164|Device|MD Logic Pump Advisor|Insulin pump setting (i.e basal plan, correction factor, carbohydrate ratio and insulin activity time)will be adjusted using the MD-LOgic Pump Advisor
1896943|NCT01308177|Drug|Ecabet|comparison between PPI+ ES (lanston 30mg bid+ ES 1g/1.5g/pkg bid) and PPI+placebo (lanston 30mg bid)for 28 days
1896944|NCT01308190|Drug|Capecitabine (Xeloda)|Capecitabine 825 mg/m2 every 12 hours orally on days of radiotherapy
1896945|NCT01308190|Radiation|50.4 Gy|Radiotherapy was administered in daily fractions of 1.8 Gy 5 days a week according to standard schema. The total dose is 45 Gy plus a boost of 5.4 Gy to the tumor area
1896946|NCT01308190|Procedure|Transanal Endoscopic Microsurgery|6-8 weeks after Chemoradiotherapy
1896947|NCT01308190|Procedure|Total Mesorectal Excision|Standard surgical treatment of T2 , T3s, N0, M0 rectal cancer. Early after diagnosis
1896948|NCT01308203|Drug|Extended release niacin/laropiprant|Randomized patient will received 1 tablet of 1g ERN/20 mg LRPT for the first 4 weeks of treatment. At week 4 (± 2 days)the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 tablets of 1 g ERN/20 mg LRPT that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to placebo.
1896949|NCT01308203|Drug|placebo|Randomized patient will received 1 oral 1 g tablet of placebo for the first 4 weeks of treatment. At week 4 (± 2 days), after randomization the patient will be assessed in the outpatient clinic. Patients with good tolerance to the study medication will receive 2 oral 1 g tablets of placebo that should be taken together for the next 8 weeks. At week 12 (± 2 days), patients will be assessed in the outpatient clinic patients and will be crossed over to active medication.
1896950|NCT01308216|Procedure|low level laser therapy procedure|Transcranial low level laser therapy by automatic scanning noncontact over both cerebral hemispheres.
1896951|NCT01308229|Device|Nile PAX® paclitaxel-eluting coronary stent|Implantation of a Nile PAX bifurcation dedicated drug-eluting stent in coronary arteries to treat stenosis lesions
1896952|NCT01308242|Drug|Sevelamer Carbonate|Sevelamer 800 mg by mouth three times daily with meals for 3 months
1896953|NCT01308255|Drug|Infliximab|"Prior to week 26
Infliximab 3mg/kg standard regime (weeks 0, 2, 6, 14, 22)
Methotrexate commencing at 10mg weekly, progressing to 20mg by week 6.
Folic acid 5 mg daily except the day methotrexate is taken
Patients will be unblinded at week 26 and then treated pragmatically guided by disease activity"
1896954|NCT01308255|Drug|Methylprednisolone|Steroid
1896955|NCT01308255|Drug|Methotrexate|All patients enrolled are commenced on oral methotrexate 10mg once a week The methotrexate dose should be increased to 15 mg at the week 2 visit. The methotrexate should be increased to 20mg at the week 6 visit.
1896956|NCT01308255|Dietary Supplement|Folic acid|All patients enrolled are commenced on oral folic acid 5mg daily, except the day methotrexate is taken, and the study infusions.
1896957|NCT01308268|Drug|Ivermectin + Albendazole|Ivermectin: 200µg/kg, single dose, PO + Albendazole 200 (children between 12 and 23 months) or 400 mg (>= 2 years old) single dose, PO
1896958|NCT01308281|Procedure|PCI with IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
1896959|NCT01308281|Procedure|PCI without IVUS guidance|Patients will be randomized in a two-by-two factorial manner according to the use of IVUS guidance (IVUS guidance vs. no IVUS guidance) for the PCI and the duration of dual anti-platelet therapy (100 mg/day aspirin and 75mg/day clopidogrel for 6 months vs. 12 months) after PCI. Each randomization of the enrolled subjects will be done 1:1.
1896960|NCT01308294|Biological|2 vaccine injections in 1 limb|All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in the same limb at about 5 cm distance from each other.
1896961|NCT01308294|Biological|2 vaccine injections in different limbs|All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A and MAGE-A3-DP4 peptides with IMP321/LAG-3 ± Montanide.The content of each syringe is injected s.c. in different limbs.
1896962|NCT01308294|Biological|2 vaccine injections in different limbs, the vaccine does not contain the MHC class II peptide MAGE-A3-DP4|All participants receive the vaccine separated in 2 syringes with syringe 1 containing NA-17, MAGE-3.A2 and NY-ESO-1 peptides with IMP321/LAG3 ± Montanide, and syringe 2 containing Melan-A peptide with IMP321/LAG-3 ± Montanide. The content of each syringe is injected s.c. in different limbs.
1896963|NCT01308307|Device|photorefraction|photorefraction is a name of device.
1896964|NCT01308320|Drug|fentanyl citrate|According to the enrolled group, certain dose of fentanyl is intravenously administered by bolus just after sevoflurane discontinuation.
1896965|NCT01308320|Drug|saline|According to the enrolled group, certain dose of saline is intravenously administered by bolus just after sevoflurane discontinuation.
1896966|NCT01308346|Device|Bioabsorbable Vascular Solutions Everolimus Eluting Coronary Stent System (BVS EECSS)|Bioabsorbable Everolimus Eluting Coronary Stent
1896967|NCT01308346|Device|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)
1896968|NCT01308359|Drug|IV glucose 5%|500 ml glucose 5% within 30 minutes
1896969|NCT01308359|Drug|saline|saline
1896970|NCT01308385|Other|Conditioned pain modulation|When evaluating conditioned pain modulation, pressure pain threshold in the musculus quadriceps femoris act as test stimulus and 2 minutes cold pressor test (stirred ice and water) acts as the conditioning stimulus. The difference between pain thresholds before and after the cold pressor test is defined as the effect of CPM.
1896971|NCT01308411|Other|50% step down reduction in inhaled corticosteroid dose|All participants will have their inhaled corticosteroid dose reduced by 50%
1896972|NCT01308424|Drug|BTL TML HSV|Sublingual micro-dosing for 7 days
1896973|NCT01308424|Drug|Matching placebo|sublingual dosing for 7 days
1896974|NCT01308437|Biological|Wosulin (N or 70/30 with R)|Basal bolus conventional Insulin viz. Wosulin (N or 70/30 with R) to be injected subcutaneously.
1896975|NCT01308437|Biological|Novolin® (N or 70/30 with R)|Basal bolus conventional Insulin viz. Novolin® (N or 70/30 with R) to be injected subcutaneously.
1896976|NCT01308463|Device|Discovery elbow minimally constrained|patient participating in the Discovery Elbow Multi-center study
1896977|NCT01308476|Procedure|SMS reminder|daily SMS in the SMS group to remind of treatment with tiotropium
1896978|NCT01308476|Procedure|control group|no daily SMS to remind of treatment with tiotropium
1896979|NCT01308489|Procedure|therapeutic conventional surgery|Undergo posterior spinal tumor resection
1896980|NCT01308489|Procedure|therapeutic conventional surgery|Undergo anterior and posterior spinal tumor resection
1896981|NCT01308489|Procedure|quality-of-life assessment|Ancillary studies
1896982|NCT01308502|Device|Dx-pH probe|Dx-pH probe with 24 hour recording
1896983|NCT01308515|Device|Vanguard Knee System with AS Bearing|FDA cleared Tibial bearing that stabilizes the knee with an anterior lip, and is used with FDA cleared Vanguard CR (Cruciate Retaining) Femoral Component.
1896984|NCT01308515|Device|Vanguard Knee System with PS Bearing|FDA cleared Tibial bearing that stabilizes the knee with a post that articulates with the FDA cleared Vanguard PS(Posterior Stabilizing) Femoral Component.
1896985|NCT01308528|Drug|Sodium enoxaparin|40 mg/mL
1896986|NCT01308528|Drug|Sodium Enoxaparin clexane|clexane 40 mg/ 0,4 mL
1896987|NCT01308541|Drug|arm 1|"Bolus Dose: two bolus doses of 15.0 mg/kg (first dose) and 8.0 mg/kg (second dose), 40 minutes apart.
Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour."
1897430|NCT01305499|Drug|Entinostat days 3, 10|Given orally on days 3, 10
1896988|NCT01308541|Drug|LUSEDRA|Mode of administration: intravenous (IV).Continuous Infusion Dose: Total dose of 42.0 mg/kg administered over 3 hours at an infusion rate of 0.40 mg/kg/min for 1 hour, followed by 0.20 mg/kg/min for 1 hour, followed by 0.10 mg/kg/min for 1 hour.
1896989|NCT01308541|Drug|Propofol (arm 3)|Mode of administration: intravenous (IV). A loading dose administered at a constant infusion rate of 0.20 mg/kg/min (0.50 mL/kg/min) for 10 minutes, followed by a constant-rate 2-hour infusion at 0.10 mg/kg/min; total dose infused over 130 minutes is 14.0 mg/kg.
1896990|NCT01308554|Drug|Placebo: sterile normal saline|Bilateral TAP block using 20 ml of normal sterile saline per block.
1896991|NCT01308554|Drug|Marcaine|Study group will receive a bilateral TAP block using 20 ml of 0,25% Marcain on each side.
1896995|NCT01308580|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form: Concentrate and solvent for solution for infusion
Route of administration: Intravenous"
1896996|NCT01308580|Drug|Prednisone (or Prednisolone)|"Pharmaceutical form: Tablet
Route of administration: Oral"
1896997|NCT01308593|Device|Juvederm XC|Filler
1896998|NCT01308593|Drug|Botox|26 units dosed one time
1896999|NCT01308606|Drug|TMC435 HPMC capsule|Single intake of one 150-mg capsule without food
1897000|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after high-fat breakfast
1897001|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule without food
1897002|NCT01308606|Drug|TMC435 HPMC or gelatin capsule|Single intake of one 150-mg capsule after standardized breakfast
1897003|NCT01308606|Drug|TMC435 gelatin capsule|Single intake of one 150-mg capsule without food
1897004|NCT01308619|Drug|Doxycycline|doxycycline 40 mg (30 mg immediate release / 10 mg delayed release beads) Capsules, oral, one capsule daily in the morning
1897005|NCT01308619|Other|Placebo|Placebo, oral, one capsule daily in the morning
1897006|NCT01308632|Drug|Temozolamide, irinotecan|"Phase I trial:
TMZ will be administered in a fixed schedule as follows:
TMZ 50 mg/m2/day divided in three daily doses (approx. 17 mg/m2/8 hours) on days 1-7, 9-21, and 23-28.
100 mg/m2 in a morning single dose on days 8 and 22
CPT-11 starting dose:
100 mg/m2 on days 8 and 22, administered 3 to 6 hours after TMZ. (Level 1)
One cycle = 28 days
CPT-11 will be escalated in successive cohorts of 3 patients as follows: 115, 130, 145, 160 mg/m2 ."
1897007|NCT01308645|Drug|SB injection|Infusion SB injection of 21.87 ml/m^2, IV route, 24 times for 4 months
1897008|NCT01308658|Drug|Darunavir (DRV)|2x400-mg DRV tablet or 800-mg tablet
1897009|NCT01308658|Drug|ritonavir|on Day 3
1897010|NCT01308671|Drug|Varenicline|Varenicline will be administrated 0.5 mg Qd for 3 days,0.5 mg Bid for 4 days, and then 1 mg Bid for 14 days
1897011|NCT01308671|Behavioral|Counseling and psychosocial support|Blank group will receive the same counseling and psychosocial support as varenicline group
1897012|NCT01308684|Drug|RO5323441 + bevacizumab [Avastin]|Dose-Finding part: RO5323441 intravenous escalating doses once every two weeks; Efficacy-Finding part: established dose from the Dose-Finding part; Avastin: 10 mg/kg intravenously once every two weeks
1897013|NCT01308684|Drug|bevacizumab [Avastin]|Efficacy-Finding part: 10 mg/kg intravenously once every two weeks
1897014|NCT01308697|Procedure|Operative fixation of flail chest|Plate fixation
1897015|NCT01308697|Other|Non Operative management|Non Operative treatment of Flail Chest
1897016|NCT01296763|Drug|Irinotecan|Irinotecan 70 mg/m2 IV, Days 1 and 8
1897017|NCT01296763|Drug|Cisplatin|Cisplatin 25 mg/m2 IV, Days 1 and 8
1897018|NCT01296763|Drug|Olaparib (for levels 1 and 5)|Olaparib 100 mg bid oral, Days 1 and 8
1897019|NCT01296763|Drug|Olaparib (for dose level 2)|Olaparib 100mg bid oral, Day 1-3, Day 8-10
1897020|NCT01296763|Drug|Mitomycin-C|Mitomycin 5 mg/m2 IV, Day 1
1897021|NCT01296776|Other|wellness control group.|Light physical exercise and relaxation program once a week in blocks of 10 weeks with breaks of 10 weeks between the blocks. The low-intensity, low-volume program was designed to avoid impact on our endpoints.
1897022|NCT01296776|Device|whole-body electromyostimulation|3 sessions of 18 min/14 (1,5 x week)days over 12 months. 10 low-intensity/low amplitude exercises with electromyostimulation equipment with 85 Hz with periods of 6 sec of current and 4 sec of rest.
1897023|NCT01296789|Other|Tissue perfusion guided protocol|A tissue perfusion guided protocol is used to guide hemodynamic therapy
1897024|NCT01296789|Other|Usual Care|Usual Care
1897025|NCT01296802|Drug|dexfenfluramine|oral, 40 mg to 60 mg, single application as a challenge
1897026|NCT01296815|Drug|Bevacizumab|Intralesional bevacizumab, dosis of 5mg/cm2, injections every 2 weeks, total number of injections: 3
1897027|NCT01296841|Device|Collaborative Imaging|Hardware and software communication tools to provide clinical care from a distance.
1897028|NCT01296854|Other|Spa therapy|3 weeks of spa therapy
1897029|NCT01296893|Behavioral|Exercise|150 minutes/week of aerobic exercise at 60-70% of heart rate reserve (individualized based on baseline VO2 peak test). The intervention is 24 weeks with an exercise progression to reach the full exercise prescription by week 8. Participants are required to attend two 45 minute supervised sessions per week and complete two additional 30 minute sessions independently at home.
1897030|NCT01296906|Behavioral|Recall conducted by private practices|All practices in these counties will receive training on practice-based R/R using the Colorado Immunization Information System (CIIS or immunization registry). Practices will receive a recommended schedule for conducting recall in 19-35 month children and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone informational systems) in order to assess the effect of these additional interventions.
1897096|NCT01308801|Device|placebo rTMS+ rehabilitation exercise|14 week program of placebo repetitive transcranial magnetic stimulation associated with rehabilitation exercise
1897031|NCT01296906|Behavioral|Recall conducted centrally by local health department|A centralized recall of children 19-35 months will be conducted through local health departments. CIIS will identify a cohort of 19-35 month olds with an who are in need of an immunization and will coordinate up to 3 mailers to children who are not current for recommended immunizations.
1897032|NCT01296932|Drug|BI 836826|Monotherapy with BI 836826 at escalating dose levels administered as an intravenous infusion.
1897033|NCT01296945|Other|Kiosk|Touchscreen computer containing three educational modules in Spanish on infant/toddler juice intake, milk, and solid/foods
1897034|NCT01296945|Other|paper|Participants will receive a paper handout with nutrition educational information.
1897035|NCT01296945|Other|Kiosk PLUS paper|Individuals will use the 3 computer modules on a touchscreen and receive the information on a paper handout.
1897036|NCT01296945|Other|Kiosk PLUS web|Participants will utilize the 3 modules on the touchscreen computer and be given a piece of paper that includes information on how to see this information again on the internet. Participants will be asked to view the modules on the web.
1897037|NCT01296958|Drug|Niclosamide|Single oral dose of niclosamide determined by weight (dose: 11 to 34kg receive 1 gram, 35 to 50kg receive 1.5 grams, over 50kg receive 2 grams)
1897038|NCT01296958|Behavioral|Community education campaign|Education about prevention of Taenia solium infection provided in a single short (20 minute) interaction with the participant. Education was verbal with visual aids.
1897039|NCT01296971|Drug|peginterferon alfa-2a [Pegasys]|180 mcg sc weekly
1897040|NCT01296971|Drug|ribavirin [Copegus]|1'000/1'200 mg daily orally, 24 - 72 weeks
1897041|NCT01296971|Drug|ribavirin [Copegus]|800 mg daily orally, 16 - 48 weeks
1897042|NCT01296997|Dietary Supplement|calcium phosphate|the subjects consumed for 3 weeks a bread enriched with 1 g pentacalcium phosphate per day
1897043|NCT01296997|Other|placebo|the subjects consumed a bread without pentacalcium phosphate
1897044|NCT01297010|Drug|Dexamethasone and ondasetron|Patients will receive ondansetron (0.1 mg / kg dose of 4mg cap) associated with dexamethasone (0.15 mg / kg dose of 5mg ceiling) or dexamethasone (0.15 mg / kg) or placebo
1897045|NCT01297010|Drug|Dexamethasone|Children were randomized to this group ni initiate proceedings with a 10ml syringe containing dexamethasone (0.15 mg / kg dose of 5mg ceiling)
1897046|NCT01297023|Dietary Supplement|calcium phosphate|20 subjects consume for 8 weeks a bread enriched with calcium phosphate [1g calcium/d]
1897047|NCT01297023|Dietary Supplement|vitamin d|20 subjects consume for 8 weeks a bread with vitamin d3 [10µg/d]
1897048|NCT01297023|Dietary Supplement|calcium phosphate and vitamin d|20 subjects consume for 8 weeks a bread enriched with calcium phosphate [1g calcium/d] and vitamin d3 (10µg/d]
1897049|NCT01297023|Other|placebo|All participants consume two weeks before intervention a bread without calcium an vitamin d.
1897050|NCT01297036|Drug|Donepezil, ODT 10 mg|Test- Donepezil Hydrochloride 10 mg Tablet single dose
1897051|NCT01297036|Drug|Donepezil, 10 mg tablet|Reference: Donepezil Hydrochloride 10 mg Tablet
1897052|NCT01302392|Drug|Carfilzomib|20mg/m² IV on Days 1 and 2 of Cycle 1, escalating to 27 mg/m² IV on Days 8,9,15,and 16 of Cycle 1 and continuing on Days 1,2,8,9,15,and 16 of Cycles 2 through Cycle 9. Cycles 10 and beyond will receive 27 mg/m² IV on Days 1,2,15, and 16 (alternatively, the investigator could choose to continue the dosing frequency on the original dosing days [Days 1, 2, 8, 9, 15, 16] for individual subjects).
1897053|NCT01302392|Drug|Best Supportive Care|"Corticosteroid (either prednisolone 30 mg orally (PO) every other day, dexamethasone 6 mg PO every other day, or other equivalent corticosteroid).
Optional cyclophosphamide 50 mg PO once daily may be given at the Investigator's discretion (maximum of 1400 mg per 28-day cycle)."
1897054|NCT01302405|Drug|PRI-724|Dose escalation
1897055|NCT01302418|Device|artus Influenza A/B RT-PCR Test|The investigational assay, used for detecting the presence of Influenza A/B.
1897056|NCT01302431|Other|Manualised nurse-led telephone support|The manualised nurse-led telephone support intervention is designed to provide proactive support and enable caregivers of people with multiple sclerosis manage problems encountered with caregiving
1897057|NCT01302444|Drug|Tadalafil|Tadalafil 40mg for 12 weeks
1897058|NCT01302444|Drug|Placebo|Placebo for 12 weeks
1897059|NCT01302470|Procedure|Primary epicardial placement of left ventricular lead|Epicardial leads will be placed on the left ventricle in the area of the most dyssynchrony . the leads will be attached to a Medtronic Cardiac resynchronization/ AICD/ device
1897060|NCT01302470|Procedure|Transvenous placement of left ventricular lead|Conventional placement of left ventricular leads performed in the electrophysiology department.
1897061|NCT01302483|Drug|3% tetracaine HCL with 0.05% oxymetazoline HCL|1 sham injection along with 3 sprays of Kovacaine Nasal Spray in each nostril; a 4-minute interval between every set of sprays. The total dose of 3% tetracaine HCL with 0.05% oxymetazoline HCL was 18 mg/0.3 mg.
1897062|NCT01302483|Drug|Lidocaine Injection|Each subject received both an injection along with 3 sprays of isotonic saline sham in each nostril; a 4-minute interval between every set of sprays.
1897063|NCT01302496|Biological|TriMix-DC and ipilimumab|Patients will receive 5 administrations of autologous TriMix-DC, administrations 2, 3, 4 and 5 will be preceded by ipilimumab (a CTLA-4 blocking monoclonal antibody, at a dose of 10 mg/kg). Patients who are free from progression according to the irRC will be offered ipilimumab maintenance administrations of ipilimumab (10mg/kg q12wks).
1897064|NCT01302509|Dietary Supplement|industrialized oral supplementation (IOS) and tube feeding regimen (TFR) with Nutren|The oral and tube supplement offered was Nutren Jr® (for patients aged 1 - 9 years) or Nutren 1.0- Nestlé Clinical Nutrition-Brazil (for those aged 10 years or over). This supplement was a whole powder formulation that presented a macro composition of 52% carbohydrates, 12% proteins and 36% lipids. Its vitamins were A, D, E, K, B complex, biotin and choline; its trace elements were iron, copper, zinc, manganese, selenium, chromium and molybdenum; its macroelements were potassium, calcium, sodium, chlorine, iodine, magnesium and phosphorus; and it contained taurine and L-carnitine presenting 1.0 kcal/ml.
1897065|NCT01302522|Behavioral|Mental practice|All patients in the study will be administered a regimen of locomotor therapy (rehabilitative therapy working on walking). Half of the patients will also be administered a regimen in which they mentally rehearse the exercises that they have just physically performed.
1897202|NCT01309945|Drug|Placebo matching with Duloxetine|Tablet, Oral, 0.0 mg, once daily (QD), 8 weeks
1897066|NCT01302535|Other|Yoga group with supervision (trainer)|The Yoga-with-trainer group will meet once a week (60 minutes) to practice yoga with a yoga instructor. The participants will be encouraged to practice yoga between the yoga classes at home for 30 minutes a day.
1897067|NCT01302535|Other|Yoga at home|The participants in the Yoga-at-home group will get a private doctor appointment (20 minutes) where they get instructions for two yoga exercises which they are encouraged to perform at home 15 minutes a day.
1897068|NCT01302548|Device|IRRISEPT|Device containing sterile water and chlorhexidine gluconate (CHG)
1897069|NCT01302548|Procedure|Usual Care|The usual care method will either be the saline irrigation or incision and drainage depending on the physicians discretion.
1897070|NCT01302561|Dietary Supplement|Sucrose|5 g of sucrose twice daily for 24 weeks
1897071|NCT01302561|Dietary Supplement|Galactooligosaccharide|2.5 g galactooligosaccharide plus 2.5 g sucrose twice daily for 24 weeks
1897072|NCT01302574|Dietary Supplement|lactisole|Lactisole-liquid meal: Lactisole (450 ppm) will be mixed with a liquid meal. Liquid meal only: The comparator will be the liquid meal alone.
1897073|NCT01302587|Drug|Albuterol|Albuterol MDI with integrated dose counter. Each participant will use 2 oral inhalations of 90 micrograms each of albuterol twice a day for the length of the study.
1897074|NCT01302600|Drug|Olesoxime|Liquid suspension formulation, 100 mg/ml at a dose of 10 mg/kg will be administered once a day with food at dinner
1897075|NCT01302600|Drug|Placebo|0.1ml/kg once a day with food at dinner.
1897076|NCT01302613|Drug|Capecitabine|Capecitabine will be delivered concurrently with the radiation therapy, at a dose of 1650 mg/m2 divided in even BID doses. It will only be taken on the days of radiation treatment (Monday-Friday, except for holidays). The A.M. dose of the capecitabine must be taken at least one hour prior to the radiation treatment.
1897077|NCT01302613|Drug|5-FU|5-FU 400 mg/m2, iv bolus on day 1 followed by 2400 mg/m2 iv over 46 hours of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
1897078|NCT01302613|Drug|Leucovorin|Leucovorin 400 mg/m2, IV, over 2 hours before 5-FU on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
1897079|NCT01302613|Drug|Oxaliplatin|Oxaliplatin 85mg/m2 IV on day 1 of each cycle. A cycle is delivered every two weeks. Three cycles will be given prior to the surgery. Five additional cycles will be given after surgery.
1897080|NCT01302613|Radiation|radiation|"28-30 fractions of radiation, given once a day, five days per week (Monday-Friday, except for holidays). The prescribed fraction dose is 180 cGy; the total radiation dose is thus 5040-5400 cGy. The primary treatment fields will be treated with 25 fractions of 180 cGy/fraction with a boost of 3-5 fractions of 180 cGy subsequently delivered."
1897081|NCT01302613|Procedure|total mesorectal excision|Optimal surgical technique involving use of total mesorectal excision (TME) is mandated. The type of surgery, either low anterior resection with sparing of the sphincter mechanism or sphincter-eliminating abdominoperineal resection (APR), will be at the discretion of the attending surgeon.
1897082|NCT01302639|Dietary Supplement|Comparison of different combinations of polyphenols with respect to effects on fat oxidation|EGCG, resveratol and genistein
1897083|NCT01308710|Dietary Supplement|Omega-3 fatty acid (Eicosapentaenoic acid)|1.0 grams daily for 6 weeks
1897084|NCT01308723|Drug|RO5323441|escalating doses iv
1897085|NCT01308723|Drug|RO5323441|iv every 2 weeks
1897086|NCT01308723|Drug|sorafenib|400 mg orally twice daily to once every other day
1897087|NCT01308736|Drug|Varenicline|Participants randomized to receive varenicline will follow the Pfizer recommended dosing schedule (0.5 mg QD on days 1-3, 0.5 mg BID on days 4-7, and 1 mg BID thereafter.
1897088|NCT01308736|Drug|Placebo pill|Participants randomized to receive placebo pill will follow the same dosing schedule as those randomized to receive varenicline (1 pill labelled 0.5 mg on days 1-3, pills labelled 0.5 mg BID on days 4-7, and pills labelled 1 mg BID thereafter.
1897089|NCT01308749|Drug|Oxytocin|"Subjects will use the Syntocinon® Nasal Spray (oxytocin) twice daily for 8 weeks if they are randomized to that arm in the Randomized Phase. All subjects will use the Syntocinon® Nasal Spray twice daily for 8 weeks in the Open Label Phase.
Subjects ages 3-10 years old will be titrated up to a maximum dose of 24 International units (IU). Subjects ages 11-17 years old will be titrated up to a maximum dose of 32IU."
1897090|NCT01308749|Drug|Placebo|Placebo Nasal Spray
1897091|NCT01308762|Biological|Heat killed whole cell M. obuense (IMM-101) 0.1 mg|"Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
Dose levels to be administered are 0.1 mg, 0.5 mg and 1.0 mg."
1897092|NCT01308762|Biological|Heat-killed whole cell M.obuense (IMM-101) 0.5 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
1897093|NCT01308762|Biological|Heat killed whole cell M.obuense (IMM-101) 1.0 mg|Each patient will receive an intradermal placebo injection of borate buffered saline solution (day -3) to provide an intra patient placebo control. Patients who were willing and able to proceed with the study will receive an intradermal injection of a single dose level of IMM 101 on three subsequent occasions. Doses of IMM 101 were administered over a 4 week period on days 0, 14 and 28.
1897094|NCT01308775|Behavioral|SIS.NET, Routine Follow-up|"SIS.NET - One or two oncology related clinic visits per year (as recommended by the American Society of Clinical Oncology breast cancer follow up guidelines (18)), with additional access to oncology care driven by ongoing review of patient's self reported symptoms through web-based questionnaires.
Routine follow up care with appointment frequency determined by the treating medical oncologist or oncology/breast surgeon. Patients complete the same web-based symptom questionnaires within 30 days of a scheduled clinic visit but the results are not reviewed until their clinic visit."
1897095|NCT01308801|Device|active rTMS + rehabilitation exercise|14 weeks program of active repetitive transcranial magnetic stimulation associated with rehabilitation exercise
1897097|NCT01308814|Drug|Estradiol|Transdermal 17β-estradiol (100 ug/day) for 12 months, administered as patches to be worn continuously and replaced once a week. Also, every 2 months, oral micronized progesterone (200 mg/day x 12 days) will be administered.
1897098|NCT01308814|Drug|Placebo|Placebo patches for 12 months, to be worn continuously and replaced once a week. Also, placebo pills will be administered for 12 days every 2 months.
1897099|NCT01308827|Procedure|Blood culture|A baseline blood culture will be obtained in all participants
1897100|NCT01308827|Procedure|Other cultures per Clinical routine practice|Cultures from other sterile sites will be obtained per routine clinical practice
1897101|NCT01308840|Drug|Panitumumab|Day 1 and 15 = 6 mg/kg IV
1897102|NCT01308840|Drug|oxaliplatin|Days 1 and 15 = 85mg/m2 IV
1897103|NCT01308840|Drug|gemcitabine|Days 1 and 15 = 1000 mg/m2 IV
1897104|NCT01308853|Device|NASHA BE|Device: NASHA BE (stabilized hyaluronic acid of non-animal origin) Treatment: Initial injection of a maximum of 120 ml/breast.
1897105|NCT01308866|Behavioral|Share decision tool|
1897106|NCT01308879|Behavioral|Contextualized Feedback Systems (CFS)tm|After clinical questionnaires are entered, an automated feedback report is available online weekly to clinicians (and supervisors) in the experimental group. The report shows current mental health status of youths, alerts, and trends over time. Reports also show some clinical data on youths' caregivers.
1897107|NCT01308892|Dietary Supplement|High flavanol chocolate|chocolate high in flavanols
1897108|NCT01308892|Dietary Supplement|Low flavanol chocolate|chocolate low in flavanols
1897109|NCT01308892|Dietary Supplement|High fat challenge|Milkshake with 95g fat
1897110|NCT01308905|Device|FLT-PET|PET scan will be conducted at diagnosis, at the end of the first cycle of treatment and prior to the surgical procedure (resection).
1897111|NCT01308944|Drug|Propranolol|
1897112|NCT01308957|Dietary Supplement|Omega-3 fatty acids|4 grams per day for 24 weeks
1897113|NCT01308957|Dietary Supplement|corn oil|4 grams per day for 24 weeks
1897114|NCT01308970|Behavioral|Stress Management Group 1|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
1897115|NCT01308970|Behavioral|Stress Management Group 2|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
1897116|NCT01308970|Behavioral|Stress Management Group 3|Subjects will attend individual stress management sessions once weekly for 8 weeks and will be instructed to listen to a health education CD for 20 minutes every day for the duration of the study.
1897118|NCT01308996|Device|INFUSE® Bone Graft|Implantation of INFUSE® Bone Graft [recombinant human Bone Morphogenetic Protein-2 (rhBMP-2)] and absorbable collagen sponge (ACS) carrier at 1.50 mg/cc with space maintenance device
1897119|NCT01308996|Procedure|Autogenous bone graft from tibia or iliac crest|Implantation of autogenous bone graft from iliac crest or tibia with titanium mesh space maintenance device
1897120|NCT01309009|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
1897121|NCT01309009|Drug|Placebo matching Nepadutant oral solution|Oral administration once daily for 7 days
1897122|NCT01309009|Drug|Nepadutant oral solution|Oral administration once daily for 7 days
1897123|NCT01309022|Drug|Sirolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
1897124|NCT01309022|Drug|Tacrolimus|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
1897125|NCT01309022|Drug|Mycophenolate mofetil|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
1897126|NCT01309022|Drug|Mycophenolic acid|Obtained by prescription and given at doses used in ClinicalTrials.gov record NCT00014911.
1897127|NCT01309035|Procedure|Total Knee Arthroplasty|Surgery for OA knee pains
1897128|NCT01309555|Device|easypod™|Saizen (Somatropin) as per Summary of Product Characteristics administered by easypod™
1897129|NCT01309581|Drug|Ketamine|Ketamine 1-2 mg/kg IV as indicated for ECT
1897130|NCT01309581|Drug|Methohexital|Methohexital 1 mg/kg IV as indicated for ECT
1897131|NCT01309594|Procedure|Hematopoietic stem cell transplantation|Harvest and apheresis of bone marrow cells from HIV infected patients with cirrhosis under general anesthesia, using bone marrow collection system and transplanting the patients' hematopoietic stem cells back to the patients
1897132|NCT01309607|Drug|paclitaxel/carboplatin/lapatinib|"Drug doses for the neoadjuvant regimen:
Paclitaxel 80mg/m2, day 1, 8, 15 of a 21-day cycle
Carboplatin AUC of 2, day 1, 8 of a 21-day cycle
Lapatinib 750mg daily continuously"
1897133|NCT01309620|Dietary Supplement|Zinc gluconate|Zinc gluconate (GNC, USA), 100 mg twice daily
1897134|NCT01309620|Dietary Supplement|Placebo|Placebo, Twice Daily
1897135|NCT01309633|Drug|12.5mg sunitinib with Cisplatin and Gemcitabine|"1) Arm A
Day -6 to Day 0 (total 7 days):
Sunitinib 12.5mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 12.5mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
1897136|NCT01309633|Drug|25mg Sunitinib alternating with Cisplatin and Gemcitabine|"Arm B
Day -6 to Day 0 (total 7 days):
Sunitinib 25mg daily Cycles 1 and 2 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2 Day 15 to Day 21: Sunitinib 25mg daily Cycle 3 - Day 1: IV Gemcitabine 1000mg/m2 + IV Cisplatin 75mg/m2 Day 8: IV Gemcitabine 1000mg/m2"
1897137|NCT01309646|Biological|Infanrix™-IPV+Hib|Intramuscular, 3 doses
1897138|NCT01309646|Biological|Infanrix™ IPV|Intramuscular, 3 doses
1897139|NCT01309646|Biological|Hiberix™|Intramuscular, 3 doses
1897140|NCT01309646|Biological|Synflorix™|Intramuscular, 3 doses
1897141|NCT01309646|Biological|Rotarix™|Oral, 2 doses
1897142|NCT01309659|Drug|iron sucrose|Patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
1897143|NCT01309659|Drug|iron sucrose|Following 12 weeks of observation patients will receive intravenous iron sucrose preparation at a dose of 200 mg per week through a peripheral intravenous catheter.
1897431|NCT01305499|Drug|5AC|
1897144|NCT01309672|Drug|abiraterone acetate|1,000 mg, oral (on an empty stomach at least 2 hours after or 1 hour before eating); taken daily
1897145|NCT01309672|Drug|Prednisone|5 mg, oral, 5 mg twice daily
1897146|NCT01309685|Drug|Varenicline|
1897147|NCT01309698|Drug|Vildagliptin (LAF237)|
1897148|NCT01309698|Drug|Voglibose|
1897149|NCT01309698|Drug|Vildagliptin and Voglibose|
1897150|NCT01309724|Other|USCOM-guided fluid administration|Patients in the intervention group underwent hemodynamic measurements with the ultrasound cardiac output monitor. Based on these measurements, patients were guided through a fluid resuscitation protocol.
1897155|NCT01309750|Radiation|Small Bowel Transit Study|Patients that are enrolled and consented in the study will be given 300ml of water containing 5 millicurie (mCi) of technetium-99m (Tc-99m) diethylenetriamine pentaacetate (DTPA). This nuclear tracer/water mix will either be drank orally or placed down a nasogastric tube to begin the study. The patient will have to have nothing else to eat or drink for the duration of the study. The patients will have a nuclear scan performed at 2, 4, and 6 hours after ingestion of the nuclear tracer.
1897156|NCT01309763|Biological|AFFITOPE AD03|s.c. injection
1897157|NCT01309763|Biological|AFFITOPE AD03 + Alum|s.c. injection
1897158|NCT01309776|Drug|Tianeptine|week1 : 25mg/day q.d., week2: 37.5mg/day b.i.d. (12.5mg 1T, 12.5mg 2T
1897159|NCT01309776|Drug|Escitalopram|week1 : 5mg/day q.d., week2: 10mg/day q.d.
1897160|NCT01309789|Drug|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-2 and if response, Cycles 9-16)
1897161|NCT01309789|Drug|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 3-8)
1897162|NCT01309789|Drug|brentuximab vedotin|1.2-1.8 mg/kg IV every 3 weeks (Cycles 1-6 and if response, Cycles 7-16)
1897163|NCT01309789|Drug|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 3-8)
1897164|NCT01309789|Drug|cyclophosphamide|750 mg/m2 IV every 3 weeks (Cycles 1-6)
1897165|NCT01309789|Drug|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 3-8)
1897166|NCT01309789|Drug|doxorubicin|50 mg/m2 IV every 3 weeks (Cycles 1-6)
1897167|NCT01309789|Drug|prednisone|100 mg daily PO on Days 1-5 every 3 weeks (Cycles 1-6)
1897168|NCT01309789|Drug|vincristine|1.4 mg/m2 IV every 3 weeks (Cycles 3-8)
1897169|NCT01309802|Drug|onabotulinum toxin type-A|up to 4 injections per hand dosage per injection: 100 units diluted in 2.0 mL normal saline; dosing will not exceed 360 units in a 3 month interval frequency: no less than 28 days between injections duration: during Study Year 1
1897170|NCT01309828|Drug|Azilsartan medoxomil and chlorthalidone|Fixed-dose combination tablets.
1897171|NCT01309828|Drug|Olmesartan medoxomil and hydrochlorothiazide|Fixed-dose combination tablets.
1897172|NCT01309841|Drug|NKTR-118|12.5 mg oral tablet once daily
1897173|NCT01309841|Drug|NKTR-118|25 mg oral tablet once daily
1897174|NCT01309841|Drug|Placebo|Oral tablet once daily
1897175|NCT01309854|Drug|fostamatinib|oral tablets, 100mg (2 X 50mg) twice daily for 8 days
1897176|NCT01309854|Drug|pioglitazone|oral tablets, 30mg single dose per period
1897177|NCT01309880|Device|Test lens|Investigational silicone hydrogel contact lens worn on a daily wear basis
1897178|NCT01309880|Device|Air Optix Aqua|Air Optix Aqua contact lens worn on a daily wear basis
1897179|NCT01309893|Device|Investigational Lens|Lenses worn on a daily wear basis for one week
1897180|NCT01309893|Device|Air Optix Aqua lens|Lenses worn on a daily wear basis for one week
1897181|NCT01309919|Device|IUD|Placement of the IUD after delivery (vaginal or cesarean birth), either immediately (within 10 minutes of placental delivery) or delayed (within 48 hours of delivery). Subjects will also keep a bleeding diary for three months postpartum.
1897182|NCT01309919|Other|Diary|Subjects will keep a bleeding diary for three months
1897183|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 or 48 weeks depending on response
1897184|NCT01309932|Drug|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 24 weeks
1897185|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 48 weeks
1897186|NCT01309932|Drug|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 24 weeks
1897187|NCT01309932|Biological|Pegylated Interferon Alfa-2a (pegIFNα-2a)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 48 weeks
1897188|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 24 weeks
1897189|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 24 weeks
1897190|NCT01309932|Biological|Pegylated Interferon Lambda (pegIFNλ)|Solution, Subcutaneous, 180 μg/mL, Once weekly, 16 weeks
1897191|NCT01309932|Drug|Ribavirin (RBV)|Tablets, Oral, 1000 or 1200 mg based on weight, Twice daily, 16 weeks
1897192|NCT01309932|Drug|BMS-790052 (NS5A Inhibitor)|Tablets, Oral, 60 mg, Once daily, 16 weeks
1897193|NCT01309932|Drug|BMS-650032 (NS3 Protease Inhibitor)|Tablets, Oral, 200 mg, Twice daily, 16 weeks
1897194|NCT01309932|Drug|Placebo (PBO) for BMS-650032 (Placebo for NS3 Protease Inhibitor)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
1897195|NCT01309932|Drug|Placebo (PBO) for BMS-790052 (Placebo for NS5A Inhibitor)|Tablets, Oral, 0 mg, Once daily, 24 weeks
1897196|NCT01309932|Drug|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 24 weeks
1897197|NCT01309932|Drug|Placebo for Ribavirin (RBV)|Tablets, Oral, 0 mg, Twice daily, 16 weeks
1897198|NCT01309945|Drug|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 8 weeks
1897199|NCT01309945|Drug|Placebo matching with BMS-820836|Tablet, Oral, 0.0 mg, once daily (QD), 14 weeks
1897200|NCT01309945|Drug|BMS-820836|Tablet, Oral, 0.5-2.0 mg, once daily (QD), 6 weeks
1897201|NCT01309945|Drug|Duloxetine|Capsule, Oral, 30-60 mg/day, once daily (QD), 6 weeks
1897203|NCT01309984|Drug|Lusedra|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
1897204|NCT01309984|Drug|Propofol|Pretreatment Phase - approximately 3 hours (Baseline) • Treatment Phase - approximately 8 days (includes Treatment, Discharge [up to 24 hours], and Follow-up Telephone Call on Day 8 post-dose after Discharge)
1897205|NCT01309997|Drug|imatinib mesylate|Given PO
1897206|NCT01309997|Biological|rituximab|Given IV
1897207|NCT01310010|Drug|dasatinib|Treatment with 100 mg QD of dasatinib (Sprycel®) administered orally as continuous daily dosing (CDD).
1989980|NCT02293902|Drug|sarilumab SAR153191 (REGN88)|
1897209|NCT01310049|Drug|LEO 32731|"Part 1 and 2: Oral single dose of oral solution or capsule
Part 3: Twice daily dose of oral solution or capsule for 7 days"
1897210|NCT01310075|Device|Alloderm|6 x 12 cm piece or 6 x 16 cm piece is trimmed into a semicircle and sewn into the inframammary fold using vicryl. The smooth side is placed against the implant.
1897211|NCT01310075|Device|Surgimend|10 x 15 cm piece of fenestrated material is sewn to the fold, curved side along the fold, using vicryl suture.
1897212|NCT01310088|Behavioral|Lifestyle intervention|Treatment protocol. The Children's Obesity Clinic Department of Paediatrics Holbaek Hospital, University of Copenhagen Denmark
1897213|NCT01310101|Drug|ofatumumab plus dexamethasone|"Dose and schedule
Cycle 1:
Ofatumumab: 300 mg as an i.v. infusion on day 1 of the cycle; Ofatumumab: 2000 mg as an i.v. infusion on days 8, 15, 22; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18
Cycles 2 to 6 (cycles every 28 days):
Ofatumumab: 1000 mg i.v. infusion on day 1, 8, 15 and 22 of the cycle; Dexamethasone: 40 mg/day p.o., days 1-4 and 15-18"
1897214|NCT01310114|Biological|Human Placenta-Derived Cells PDA001- (cenplacel-L)|240 mL of intravenous infusion
1897215|NCT01310114|Drug|Placebo|Thawed placebo
1897216|NCT01310127|Drug|Bromfenac|bromfenac 0.9% QD starting 3 days prior to cataract surgery, on the day of surgery and for up to 45 days after surgery
1897217|NCT01310127|Drug|Nepafenac|nepafenac ophthalmic suspension 0.1% TID dosed 3 days prior to cataract surgery, on the day of surgery, and for up to 45 days after surgery
1897218|NCT01310153|Procedure|prone positioning|
1897219|NCT01310166|Drug|Fingolimod|
1897220|NCT01310179|Genetic|Ad/PNP and fludarabine monophosphate|Subjects in the first 3 cohorts will receive 3x10e11 VP for 3 injections and escalating dose levels of F-araAMP (15, 45, and 75 mg/m2 in each sequential cohort) daily for 3 days. The fourth cohort will receive 3x10e12 for 3 injections and 75 mg/m2 fludarabine daily for 3 days.
1897221|NCT01310192|Device|Fluourine-18 Fluoromethylcholine PET/CT Imaging|Single-dose Study
1897222|NCT01310205|Drug|SCV-07|This is an extension of ongoing study SCI-SCV-HCV-P2-001. Subjects will be invited to participate in this extension study if they complete treatment in study SCI-SCV-HCV-P2-001 and are eligible for retreatment with peg-IFN and RBV
1897223|NCT01310218|Other|extended postoperative dressing|2 weeks of bulky dressing
1897224|NCT01310218|Other|short postoperative dressing|2 days bulky dressing followed by bandaid
1897225|NCT01310231|Drug|Metformin|"metformin 850 mg bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
Number of cycles: Until progression or unacceptable toxicity develops."
1897226|NCT01310231|Drug|Placebo|"Placebo bid in addition to standard chemotherapy (containing anthracyclines, platinum, taxanes or capecitabine; first or second line).
Number of cycles: until progression or unacceptable toxicity develops."
1897227|NCT01310244|Drug|Belinostat, Carboplatin, Paclitaxel|Up to 6 cycles of combination therapy of belinostat plus carboplatin (AUC 6) and paclitaxel 200 mg/m2. Initial dose of belinostat will be 1000mg/m2 for MTD dose escalation evaluation.
1897228|NCT01310257|Other|Questionnaires|Patients will be given questionnaires relevant to their condition to complete. In Study 2 and a sub-study of Study 1, patients will be invited to take part in Quantitative Sensory Testing.
1897229|NCT01310270|Dietary Supplement|Pro-Omega|Pro-Omega, 4.4gm/day x 1 month
1897230|NCT01310270|Dietary Supplement|Omega 3 Fatty Acid|4.4 gm/day for 1 month
1897231|NCT01310283|Other|xylitol mints and fluoride varnish|Subjects in the intervention group will receive additional diet, oral hygiene handouts, more frequent professional fluoride application, and xylitol mints based on their caries risk levels.
1897234|NCT01310309|Device|Coronary artery placement of a drug-eluting stent|Coronary artery placement of a drug-eluting stent (XIENCE V® EECSS)
1897235|NCT01310322|Drug|AZD5423|solution for injection, administered as intravenous infusion Corr to total dose of 250µg AZD5423
1897236|NCT01310322|Drug|AZD5423|nebuliser suspension, inhaled via Spira, corr to approximately 300 µg lung deposited dose AZD5423
1897237|NCT01310322|Drug|AZD5423|nebuliser suspension, inhaled via I-neb, corr to approximately 300 µg lung deposited dose AZD5423
1897238|NCT01310322|Drug|AZD5423|nebuliser suspension to be administered orally, corr to a total dose of 1200 µg AZD5423
1897239|NCT01310335|Device|whole-body vibration (WBV)|All cases will be trained on a whole-body vibration (WBV) platform (Power Plate) 5 times a week for one week period.
1897240|NCT01310348|Device|whole-body vibration (WBV)|The whole-body vibration (WBV) training group will be trained on a WBV platform (Power Plate) 5 times a week for 4 weeks period. Training volume and training intensity will be low at the beginning but progressed slowly according to the overload principle. The training volume will be increased systematically over the 4-week training period. The training intensity will be increased by increasing the amplitude (2-4 mm) and the frequency (40 Hz) of the vibration.
1897241|NCT01310348|Device|WBV (Sham stimulation)|Sham stimulus will be performed by WBV platform 5 times a week for a 4 weeks period.
1897242|NCT01310361|Drug|Amoxicillin|
1897279|NCT01310738|Drug|amphotericin B deoxycholate|1mg/kg/d, I.V. for 14 consecutive days.
1897280|NCT01310738|Drug|Liposomal amphotericin B|3mg/kg/d, I.V. for 7 consecutive days.
1897281|NCT01310738|Drug|Liposomal amphotericin B|10mg/kg/d, I.V. single dose.
1897494|NCT01306032|Drug|Cyclophosphamide|
1897243|NCT01310361|Drug|Intramuscular Benzathin Penicillin G|It is mentioned underlined in page 10 in research. (Once the throat swab was taken and cultured on plate at the place where the child was examined, hygiene teacher was trained about how to prepare the oral amoxicillin suspension and how to give it to the child. 750 milligrams of amoxicillin was thereafter given to the patient and in order not to infect other school children, the patient was sent home. The following morning, the patient would come to school and was given the second dose of amoxicillin by the hygiene teacher. All oral drugs were bought from a creditable company. In the injection group, 600000 units of penicillin was administered to children who weigh less than 27 kilograms and 1200000 units of penicillin was administered to children who weigh more. After 48 hours, patients were examined again when the result of first culture was ready)
1897244|NCT01310387|Behavioral|Active pain management|Active pain management will be provided by specialized pain nurse, such as telephone counseling for toxicity control and opioid dose modification.
1897245|NCT01310400|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:
15 µg hemagglutinin (HA) antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.5 mL on Days 0 and 28"
1897246|NCT01310400|Biological|Inflexal V|"Inflexal V influenza vaccine, formulated for the WHO requirements of the 2009-2010 season, containing per 0.5 mL dose:
15 µg HA antigen of A/Brisbane/59/2007 (H1N1)-like virus
15 µg HA antigen of A/Brisbane/10/2007 (H3N2)-like virus
15 µg HA antigen of B/Brisbane/60/2008-like virus
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
1897247|NCT01310400|Biological|Agrippal|"Agrippal influenza vaccine
Dose: intramuscular administration (M. deltoideus) of a single dose of 0.25 mL on Days 0 and 28"
1897248|NCT01310413|Biological|Influenza A (H5N1) Virus monovalent vaccine|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
1897249|NCT01310413|Biological|Saline placebo|All subjects will receive 2 doses administered as an intramuscular (IM) injection.
1897250|NCT01310426|Other|3D transperineal Ultrasound|3D transperineal Ultrasound after vaginal delivery
1897251|NCT01310452|Drug|insulin detemir|insulin detemir once daily with metformin
1897252|NCT01310452|Drug|neutral protamine insulin|neutral protamine insulin once daily with metformin
1897253|NCT01310465|Drug|zoledronic acid|zoledronic acid, 5mg(100ml), intravenous, one time at three days postoperatively
1897254|NCT01310465|Drug|sodium chloride|sodium chloride, 100ml, intravenous, one time at three days postoperatively
1897255|NCT01310478|Drug|recombinant human endostatin (Endostat)|mFOLFOX6:Oxaliplatin 85 mg/m2 d1 Leucovorin 400 mg/m2 d1+5-FU 400 mg/m2 bolus d1+5-FU 2.4 CIV 46h Endostar 7.5mg/m2/d～45mg/m2/d continous intravenous d4～d14
1897256|NCT01310491|Behavioral|Health coaching|Telephone based health coaching supported by tele-monitoring.
1897257|NCT01310504|Procedure|SonoSite Ultrasound|Will be moulaged to resemble a peritoneal dialysis patient. Paramedics will scan the abdomen and determine it there's fluid within.
1897258|NCT01310504|Procedure|SonoSite Ultrasound|Paramedics will scan the abdomen and determine it there's fluid within.
1897259|NCT01310530|Radiation|Proton Beam Radiotherapy|Daily proton beam radiotherapy is delivered to the site of the breast tumor in ten treatment sessions over two week as an outpatient.
1897260|NCT01310543|Behavioral|Teens and Toddlers|The T&T intervention aims to prevent teenage pregnancy and promote sexual health by providing young women at risk of teenage pregnancy with regular and direct contact with a toddler and combines this with 12 modules of group-based personal-development sessions involving communication skills, anger management, discussion of positive sexual health and relationships, culminating in an accredited National Award in Interpersonal Skills. One-to-one life coaching is also provided. The intervention consists of 20 weekly afternoon sessions run in nurseries near to the secondary schools from which participating young women are recruited.
1897261|NCT01310556|Other|ogtt for patients with coronary artery disease|75 g OGTT
1897262|NCT01310582|Drug|Desflurane|
1897263|NCT01310582|Drug|Sevoflurane|
1897264|NCT01310595|Procedure|Manual mobilization on cervical spine|Manual mobilization provided on selected cervical spine in patients with chronic mechanical neck apin
1897265|NCT01310595|Procedure|Infra-red therapy with self exercise pamphlet|Infra-red radiation therapy on cervical spine with self exercise pamphlet given to patients with chronic mechanical neck pain.
1897266|NCT01310608|Other|A-View|Pre-operative imaging of the thoracic aorta with A-View technique
1897267|NCT01310621|Drug|Bovine surfactant|"Dose of diluted surfactant : 20ml/kg
Type :Bovine surfactant
Phospholipid concentration: 5 mg/ml
Number of lavages to be given: 2 (10ml/kg each)"
1897268|NCT01310634|Behavioral|Comprehensive intervention|Parents of hospitalized neonates received comprehensive intervention program,including parent educational-behavioral intervention program, effective doctor/nurse parent communication,regularly visit the neonatal ward and care the hospitalized neonates under the guidance of a doctor.
1960885|NCT03086642|Drug|Talimogene laherparepvec|"T-Vec will be administered by intratumoral injection into pancreatic tumors accessible endoscopically with ultrasound guidance (at least one pancreatic lesion must be injected during each treatment).
On day 1 of week 1 the first dose of talimogene laherparepvec will be up to 4.0 mL of 10^6 PFU/mL. The second injection up to 4.0 mL of 10^6, 10^7, or 10^8 PFU/mL should be administered no sooner than day 1 of week 4 but should not be delayed more than 7 days after the scheduled time point. The maximum volume of T-Vec administered at any one time is 4.0 mL for any individual lesion."
1897272|NCT01310673|Drug|Allopurinol|"Allopurinol 300mg po QD for 30 days.
Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
1897273|NCT01310673|Drug|Placebo|"Placebo tablet QD for 10 days, followed by delayed allopurinol 300mg po QD days 11-30.
Indomethacin 50mg TID for 10 days. Colchicine 0.6mg po Bid or QD, as tolerated for 90 days."
1897274|NCT01310699|Device|Olympus Colonoscope CFHQ190AL|Technically improved colonoscope with close focus high definition narrow band imaging.
1897275|NCT01310712|Drug|Oxybutynin|5 mg every 12 hours for 6 weeks
1897276|NCT01310712|Drug|placebo|placebo twice a day for 42 days.
1897278|NCT01310738|Drug|Antimoniate of N-methylglucamine|Antimoniate of N-methyl glucamine 20mg/kg/d of pentavalent antimonial, I.V. for 20 consecutive days.
1897282|NCT01310738|Drug|Antimoniate of N-methylglucamine|20mg/kg/d of pentavalent antimonial I.V. for 10 days
1897283|NCT01310751|Drug|iloprost nebuliser solusion|50 ng/kg/min inhalation for 10 minutes, q2h for 2 days
1897284|NCT01310751|Drug|distilled water|2 ml per session
1897285|NCT01310764|Procedure|Trabeculectomy|Both groups underwent trabeculectomy ,but in active group bevacizumab was used and in sham group mitomycin c was used during the surgery.
1897286|NCT01310777|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension|
1897287|NCT01310777|Drug|Brinzolamide 1% ophthalmic suspension|
1897288|NCT01310777|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
1897290|NCT01310803|Drug|VALSTAR - Maintenance Therapy|Treatment phase - 10 monthly intravesical installations starting 10 to 12 weeks after the beginning of induction. Follow-up phase
1897291|NCT01310803|Other|No Maintenance treatment ( Standard of Care)|Subjects randomized to No Maintenance (Standard of Care) will not receive any additional intravesical therapy
1897292|NCT01310816|Drug|IPI-926|Oral
1897293|NCT01310816|Drug|Placebo Arm|oral placebo
1897294|NCT01310829|Behavioral|Questionnaires|Questionnaires completed before and after viewing virtual reality scenes, taking about 30 minutes to complete.
1897295|NCT01310829|Behavioral|Physiological Measurements|Small sensors applied to skin will measure heart rate and sweat amounts while participants view a virtual reality scene.
1897296|NCT01310829|Behavioral|Virtual Reality Scene Viewing|Prototype virtual reality application that demonstrates a provider-patient communication scenario commonly encountered in genetic counseling for hereditary cancers.
1897297|NCT01310842|Behavioral|Questionnaires|Questionnaires completed at each study visit, taking 60-90 minutes, in addition to 4 Smart Phone initiated assessments per day during waking hours, taking about 5-10 minutes.
1897298|NCT01310842|Drug|Nicotine Patch Therapy|4 weeks of nicotine patch therapy
1897299|NCT01310842|Behavioral|Counseling Sessions|5 or 7 in person counseling sessions on smoking cessation: Baseline, Week 0/Quit Date (1 week following the baseline visit), Week 1, Week 2, Week 3 for Pilot Group and additional sessions Week 12 and Week 26 for other group.
1897300|NCT01310855|Drug|cediranib maleate|
1897301|NCT01310855|Drug|gefitinib|
1897302|NCT01310855|Drug|Placebo|
1897303|NCT01310868|Drug|5-ALA|5-ALA is used to generate tumour specific fluorescence as an aid to surgical resection of GBM, prior to the insertion of Gliadel wafers
1897304|NCT01310868|Drug|Gliadel wafers|The implantation of Carmustine Wafers (Gliadel) delivers carmustine- (3-bis 2-chloroethyl 1-1-nitrosourea (BCNU)) directly into the surgical cavity created after tumour resection.
1897305|NCT01310868|Radiation|Radiotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|60Gy in 30 fractions (2Gy per fraction given once daily, five days per week (Monday-Friday) over 6 weeks. Radiotherapy delivered to gross tumour volume with 2-3cm margin. Standard treatment following neurosurgery for glioblastoma
1897306|NCT01310868|Drug|Concomitant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|temozolomide given alongside the radiotherapy at 75mg/m2 daily from the first day of radiotherapy, until the last day of radiotherapy, but for no longer than 49 days. Standard treatment following neurosurgery for glioblastoma
1897307|NCT01310868|Drug|Adjuvant chemotherapy as normal based on standard clinical protocols determined by the neuro-oncologist|Following a 4 week break after contomitant chemo/RT, temozolomide given 150-200mg/m2 TMZ 5/28 days for 6 cycles (dosage increase to 200mg/m2 on second and subsequent cycles dependent on haematological toxicity. Sites should follow local guidelines if different.). TMZ to be given on 5 consecutive days followed by 23 days with no TMZ, per cycle. Standard treatment following neurosurgery and concomitant chemo/RT for glioblastoma
1897308|NCT01310881|Drug|NSI-189 Phosphate|Once daily oral administration
1897309|NCT01310894|Drug|TOOKAD® Soluble|TOOKAD® Soluble-VTP procedure will consist of an IntraVenous (IV) administration to patients using a 753nm laser light at a fixed power of 150mW/cm and a fixed energy at 200J/cm delivered through transperineal interstitial optical fibers. The needles are positioned in the prostate under ultra sound image guidance
1897310|NCT01310920|Other|observation|genotyping
1897311|NCT01310946|Other|Database|Database
1897312|NCT01310959|Other|Database|Database
1897313|NCT01310972|Other|Registry|Registry
1897314|NCT01310985|Drug|Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)|Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
1897315|NCT01310998|Behavioral|High intensity exercise|4x4 intervals
1897316|NCT01311011|Procedure|SCT|SCT
1897319|NCT01311037|Other|GnRh Analogue and Aromatase Inhibitor|GnRh Analogue and Aromatase Inhibitor
1897320|NCT01311050|Drug|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab|Capecitabine (Xeloda), Oxaliplatin, Irinotecan, Bevacizumab
1897321|NCT01311076|Drug|TAK-329|TAK-329 50 mg, tablets, orally, single dose, one day.
1897322|NCT01311076|Drug|TAK-329|TAK-329 200 mg, tablets, orally, single dose, one day.
1897323|NCT01311076|Drug|Insulin|Insulin 0.2 U/kg, subcutaneous injection, single dose, one day.
1989981|NCT02293902|Other|placebo|
1989982|NCT02293902|Drug|methotrexate|
1989983|NCT02293902|Drug|folic acid|
1897324|NCT01311076|Drug|Placebo|TAK-329 placebo-matching tablets, orally, single dose, one day.
1897325|NCT01311102|Drug|Lidocaine|1.33 cc 2% liquid lidocaine
1897326|NCT01311102|Drug|Normal Saline|1.33cc normal saline
1897327|NCT01311115|Behavioral|Group commitment contract|"Each participant is required to deposit at least 50 baht at enrollment. A deposit collector visits each participant on a weekly basis and collects additional deposits on a voluntary basis. All deposits are returned only if the smoker quits successfully within three months.
The project gives a matching contribution of 150 baht for the initial deposit of at least 50 baht. All participants in the treatment group are further randomized to a one-month group and a three-month group. The one-month group receives an additional 150 baht of project funds if they deposit 100 baht of their money within one month of enrollment. The three-month group receives 150 baht for depositing 100 baht within three months of enrollment.
Each participant is paired with another study participant. If both quit, each receives a cash bonus of 1,200 baht. At enrollment, pairs receive brief counseling on ways to support each other during the quit attempt."
1897328|NCT01311115|Behavioral|Smoking cessation education and counseling|Participants receive educational pamphlets on reasons to quit smoking and strategies for quitting smoking. They also receive one-time, group counseling on quitting smoking from a nurse trained in smoking cessation counseling.
1897329|NCT01311128|Device|T-line hemodynamic monitoring device (placement and use)|The T-line device will be placed over the contralateral (from the radial artery catheter) radial artery at the distal wrist. To attach the device, a single-use sterile sensor is placed over the radial artery and the device then gently clamped around the wrist to incorporate the sensor. After a ten-minute stabilization period, data will be recorded every ten minutes during the first two hours of surgery, or until the patient is placed on cardiopulmonary bypass. The T-line device will then be removed. This intervention will be repeated, for a second two-hour period, in the ICU postoperatively.
1897330|NCT01311141|Drug|doripenem|doripenem once i.v.500mg
1897331|NCT01311167|Drug|Dexamethasone|Daily administration of 2 mg of dexamethasone for 4 days
1897332|NCT01311167|Drug|Placebo|Daily administration of 2 mg of placebo for 4 days
1897333|NCT01311180|Drug|Sensoril®|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
1897334|NCT01311180|Drug|Placebo|Start with 250 mg po QAM for 7 days and then 250 mg po bid for 7 weeks
1897335|NCT01311193|Other|light therapy|early morning exposures to bright light, 8000lux for 40min, daily during 3 weeks
1897336|NCT01311206|Other|partial blood flow restriction|Partial Blood Flow Restriction (PBFR) Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side, while receiving PBFR in each exercising limb. The padded belts (65 mm in width and 650 mm in length) of the Kaatsu Master™ PBFR device (Sato Sports Plaza, Tokyo, Japan) will be applied to the proximal thigh as near to the hip joint as is comfortable. Before training each leg, subjects will be seated in a chair where an initial belt pressure of 37-40 mmHg will be applied. The belt then will be iteratively pressurized for 30 seconds and then relaxed for 10 seconds in increments of 20 mmHg from 100 mmHg to the final pressure of 160 mmHg. During exercise, the cuff pressure will be continuously controlled and monitored by the PBFR apparatus
1897337|NCT01311206|Other|Low intensity exercise without partial blood flow restriction|Low-Intensity Exercise: using the Biodex 3 Dynamometer in isotonic mode at 10% (first 3 weeks), 15% (following 3 weeks) and 20% (final 3 weeks) of their 1RM for each side in each exercising limb without partial blood flow restriction.
1897338|NCT01311219|Other|Non-operative Treatment|A figure-of-8 brace will be applied to afflicted extremity in clinic. The patient will be instructed on proper application of the brace and asked to continue wearing the brace for 2 to 6 weeks, depending on the patient's level of comfort.
1897339|NCT01311219|Procedure|Operative Treatment-Plate Fixation|Plate fixation of the clavicle fracture will be performed utilizing a 3.5-mm dynamic compression plate.
1897340|NCT01311219|Procedure|Operative Treatment-Intramedullary Pinning|Clavicle fracture will be repaired through intramedullary pinning using The Rockwood Clavicle Pin (DePuy Orthopaedics, Warsaw, IN).
1897341|NCT01311245|Behavioral|Stage-tailored intervention|Based on the Trans-Theoretical Model of intentional behavior change (TTM). According to their stage of change, participants received two computer generated feedback letters on their risky drinking, stage of change, processes of change, self-efficacy, and decisional balance. The first letter included normative feedback (interpersonal comparison with other individuals in the same stage), and was sent out by mail after baseline. The second letter included normative and ipsative feedback (intrapersonal comparisons: baseline vs. 3 months later), and was sent out by mail three months later.
1897342|NCT01311245|Behavioral|Non-stage-tailored Intervention|Based on the Theory of Planned Behavior (TPB). Participants received two computer generated feedback letters on their risky drinking, beliefs (behavioral, normative, control), attitude, subjective norm, perceived behavioral control, intention, and they were asked to fill in a where-when-how to change plan. The first letter included normative feedback (interpersonal comparison with other women/ men), and was sent out by mail after baseline. The second letter included normative and ipsative feedback, and was sent out by mail three months later.
1897343|NCT01311271|Device|repetitive transcranial magnetic stimulation (rTMS)|"1 Hz frequency, 15 minutes, intensity of 90% resting motor threshold, with one session a day,
Real: unaffected M1 hotspot
Sham: coil perpendicular to scalp"
1897344|NCT01311284|Device|Macintosh laryngoscope, Airtraq NT, Mcgrath laryngoscope|Each participant will use the Macintosh laryngoscope (blade No. 3), laryngoscope Airtraq NT and Mcgrath Laryngoscope under conditions of normal and difficult airway in different simulated scenarios.
1897345|NCT01311284|Device|Macintosh laryngoscope|intubate with the macintosh laryngoscope
1897346|NCT01311284|Device|McGrath|Intubate with McGrath device
1897347|NCT01311284|Device|Airtraq Nasotracheal|intubate with Airtraq Nasotracheal
1897348|NCT01311310|Other|RIPC (remote ischemic preconditioning)|RIPC will be performed by four 5-min cycles of lower limb ischemia and 5 in reperfusion using blood-pressure cuff inflated to a pressure 15 mmHg greater than the systolic arterial pressure measured via arterial line.
1897349|NCT01311323|Procedure|PCI|Percutaneous Coronary Intervention
1897350|NCT01311323|Procedure|CABG|Coronary Artery Bypass Graft
1897351|NCT01311336|Drug|Loratadine|loratadine 10 mg capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
1897352|NCT01311336|Drug|placebo|placebo capsule orally once daily for 7 days beginning the day of administration of pegfilgrastim
1897353|NCT01311362|Drug|St. Johns wort|"Administration of ambrisentan: 5 mg p.o. q.d. on day 1 and days 3-20
Administration of SJW: 300 mg p.o. three times a day (t.i.d.) on days 11-20"
1897354|NCT01311375|Dietary Supplement|w3 supplement in SCI|"supplements(Mor DHA and Ca 500 mg -D200 micro g )( will be given in this group"
1897355|NCT01311375|Other|placebo|placebo+ capsule CA-D
1897356|NCT01311401|Other|NONE intervention|NONE intervention
1897357|NCT01311414|Drug|cafedrine/theodrenaline, urapidil|Increasing blood pressure using cafedrine/theodrenalin and decreasing blood pressure using urapidil during carotid endarterectomy.
1897358|NCT01311427|Behavioral|8-form Yang-style Tai chi|This study tested a modified 8-form Yang-style Tai chi program in subjects with fibromyalgia. Participants met in a small group two times weekly for 60 minutes over 12 weeks.
1897359|NCT01311427|Behavioral|Group education|Standard group education was delivered to participants in a small group format twice weekly for 60 minutes over 12 weeks.
1897360|NCT01311440|Other|Modified Atkins diet treatment|Eat a diet containing 16 grams of carbohydrates per day, maximize on fat. Assure sufficient intake of micronutrients.
1897362|NCT01311479|Procedure|Osteopathic Manipulation Therapy|"Subjects will then be treated based on the objective findings of the examination. Since the structural exam includes the whole body, other structural abnormalities will likely be identified and possible require treatment to aid in treatment of SIJ. Subjects will also be taught stretching routines in order to aid in treatment of the dysfunction.
Our control group will receive the same structural exam, and focused examination. Their treatment will involve massage, in an area not associated with the musculature of the SIJ. This will serve to identify a possible placebo effect, associated with simply providing a healing touch without focused treatment."
1897363|NCT01311492|Behavioral|Healthy Lifestyle Program|"The healthy lifestyle program includes upper body stretching and educational workshops. The purpose of this group is to control for general levels of staff and participant time and attention, in addition to general secular and seasonal effects that could influence the outcomes of interest. The rational for this placebo exercise activity is that it helps foster adherence to this arm of the study and increases the perceived benefit of the healthy lifestyle program to the participants without directly affecting the study outcomes."
1897364|NCT01311492|Behavioral|Physical Activity Intervention|The physical activity intervention consists of a general weekly physical activity goal of 150 minutes. This is consistent with the public health message from the Surgeon General's report that moderate physical activity should be performed for 30 minutes on most if not all days of the week (150-210 total minutes). This goal is approached in a progressive manner over the course of the trial.
1897365|NCT01311505|Drug|Myrin© 2 (Rifampicin + Isoniazid)|Two (2) fixed-dose combination tablets each containing Rifampicin 150 mg and Isoniazid 75 mg
1897366|NCT01311505|Drug|Rimactane® (Rifampicin)|One (1) capsule of Rifampicin 300 mg
1897367|NCT01311518|Drug|Drug: Placebo|Injectable administration by slow intravenous bolus, 0.00% Thymosin Beta 4 daily for 3 days then weekly for 4 consecutive weeks
1897368|NCT01311518|Drug|Drug: Injectable Thymosin beta 4|Injectable administration of Thymosin Beta 4 by intravenous bolus at 1200 mg, or 450 mg daily for 3 days then weekly for 4 consecutive weeks
1897369|NCT01311531|Procedure|Open reduction and fixation with TriMed fragment-specific system|Anatomical reduction, achieved by the open technique.
1897370|NCT01311531|Procedure|Open reduction and fixation with TriMed volar locking plate|Anatomical reduction, achieved by the open technique.
1897371|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
1897372|NCT01311557|Biological|Adacel®: Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Adsorbed|0.5 mL, Intramuscular
1897373|NCT01311570|Drug|Buprenorphine|"In the first 2 weeks all subjects will enter into a dose titration phase, starting with minimum dosage of 1mg/day Buprenorphine gradually increasing to 4-8 mg/day according to tolerance and clinical benefit.
From week 3 to week 8, all subjects are prescribed Buprenorphine sublingually, OID in a stable dosage according to the decision of the treating physician."
1897374|NCT01311583|Behavioral|Teach Back method of patient discharge teaching|Trained nurses will provide Teach Back to the intervention group. Appendix D lists the four questions that will be used in this study to confirm the patient's understanding. The nurses' training will focus on the concepts of Teach Back, provide coaching and guidance on how to use it as well as review the principles of conducting research. Role play will be a feature in the education sessions to improve the nurses' comfort level
1897375|NCT01311596|Other|Icons|Clinic- patients first shown picture icons of the steps of taking vital signs Lab - patients first shown picture icons of the steps of a blood draw procedure
1897376|NCT01311609|Other|Systane|Systane Lubricant Eye Drops [1-2 Drops in each eye four times daily (QID)]
1897377|NCT01311622|Drug|warfarin|2 single 25 mg doses of Warfarin (5 x 5 mg tablets) administered 14 days apart
1897378|NCT01311622|Drug|fostamatinib|2 x 50 mg Fostamatinib tablets (100 mg) twice daily for 13 days
1897379|NCT01311635|Drug|AZD1981, current small-particle tablet|3x100 mg per oral, single dose in fasted state
1897380|NCT01311635|Drug|AZD1981, new small-particle tablet|3x100 mg per oral, single dose
1897381|NCT01311635|Drug|AZD1981, new large-particle table|3x100 mg per oral, single dose in fasted state
1897383|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
1897384|NCT01311661|Drug|Olodaterol low daily dose twice daily|Inhaled Olodaterol medium daily dose administered as low dose twice daily
1897385|NCT01311661|Drug|Olodaterol medium daily dose twice daily|Inhaled Olodaterol high daily dose administered as medium dose twice daily
1897386|NCT01311661|Drug|Placebo twice daily|Inhaled Placebo of Olodaterol twice daily
1897387|NCT01311661|Drug|Olodaterol high daily dose once daily and placebo|Inhaled Olodaterol high daily dose administered as one full dose once daily and placebo once daily
1897388|NCT01311661|Drug|Olodaterol medium daily dose once daily and placebo|Inhaled Olodaterol medium daily dose administered as one full dose once daily and placebo once daily
1897389|NCT01311674|Biological|hepatitis B vaccine|Primary vaccination series 20 ug/1.0 mL at baseline, month 1, month 6; followed by booster vaccinations 20 ug/1.0 mL
1897390|NCT01311674|Biological|hepatitis B vaccine|Primary vaccination series 40 ug/2.0 mL at baseline, month 1, month 2, month 6; followed by booster vaccinations 20 ug/1.0 mL
1897393|NCT01311700|Drug|Injectable (i.v.) metoprolol tartrate (up to 15 mg).|"Patients are randomized to active intervention (early metoprolol initiation strategy) or no treatment (delayed metoprolol initiation strategy).
Patients randomized to early metoprolol initiation strategy receive up to three 5mg i.v. dosages (2 minutes apart) before reperfusion.
Patients randomized to delayed metoprolol initiation strategy receive no active treatment before reperfusion.
Patients in both groups receive oral metoprolol tartrate treatment (25-100mg/12h), starting 12-24 hr post-reperfusion."
1897394|NCT01311713|Drug|CEP-9722|CEP-9722 is administered daily or twice-daily for six 28-day cycles. Dose escalation will proceed until the MTD is identified.
1897395|NCT01311713|Drug|CEP-9722|CEP-9722 is administered daily or twice-daily for six 28-day cycles. Patients will be administered CEP-9722 at the MTD identified in Part 1.
1897396|NCT01311739|Drug|Cyanocobalamin|
1897397|NCT01311752|Procedure|surgical management of high grade lesions|"Clinical, pathological and biological, data at diagnosis and during follow-up will be collected.
Surgical sample will be collected to study human papillomavirus related genital pathology."
1897398|NCT01311765|Other|Duration of antibiotic therapy limited to 8 days|Initiation of adequate empiric antibiotics for postoperative peritonitis within 24 hours after surgery and up to 8 days. At randomisation performed on day 8, the patients assigned to the 8-day group (short-course group) stop their treatment
1897399|NCT01311778|Drug|Cannabidiol|"Subjects in Arm CBD 400 mg will receive 400 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl.
Subjects in Arm CBD 800 mg will receive 800 mg of Cannabidiol in two test sessions along with 0.5 mcg/kg and 1mcg/kg of fentanyl."
1897400|NCT01311778|Drug|Fentanyl|All subjects will receive 0.5 mcg/kg and 1mcg/kg of Fentanyl (test session 1 and test session 2)
1897401|NCT01311791|Device|Algisyl-LVR|Algisyl-LVR™ device (implants) administered during a surgical procedure
1897402|NCT01311791|Drug|Standard medical therapy|as defined per protocol
1897403|NCT01311804|Procedure|parecoxib sodium|periarticular parecoxib sodium injection will be given during total knee arthroplasty
1897404|NCT01311804|Procedure|parecoxib sodium|intravenous parecoxib sodium during total knee arthroplasty
1897405|NCT01311817|Biological|BMB72 (actA/plcB-deleted Listeria monocytogenes expressing influenza A nucleoprotein)|1mL liquid contained in an adhesive skin patch
1897406|NCT01311830|Behavioral|Telephone Counseling|
1897407|NCT01311830|Behavioral|Written Materials|
1897408|NCT01311856|Behavioral|Standard Arm (mail/telephone)|Participants will receive print materials on diet and exercise, telephone counseling calls (3 weekly calls, 2 semi-weekly calls, 4 monthly calls; 15-30 minutes in length), and customized mailed progress reports every 6 weeks to adhere to diet and exercise recommendations.
1897409|NCT01311856|Behavioral|Internet Arm|Participants will access print information online. Participants will also participate in a discussion forum facilitated by the intervention staff, have the opportunity to email questions directly to the intervention staff, and receive progress reports every 6 weeks by email.
1897410|NCT01311856|Behavioral|Surveys and Questionnaires|9 online surveys to be completed before intervention sessions. After 14 weeks on study, questionnaires will be mailed for completion at home and mailed back to the study staff.
1897411|NCT01311856|Behavioral|Exercise and Diet|15 minutes of strength exercise every other day, >30 minutes of walking or other moderate-intensity exercise on 5 or more days of the week. Diet recommendations for both groups.
1897412|NCT01311869|Dietary Supplement|EGCG ( Green Tea extract)|A randomized double-blind placebo-controlled clinical trial will be conducted with 80 women of reproductive age,the 80 women will be allocated into two groups, 40 each. Each group will be given one of two interventions: The first is 2 capsules of (EGCG which is green tea extract, taken orally with food on daily basis for 6 months, each capsule contain 326.25 mg decaffeinated EGCG,The second group will receive matched (color, taste and texture) placebo for a period of 6 months.
1897413|NCT01311869|Dietary Supplement|Brown rice pills|40 subjects will receive 800 mg EGCG orally daily for 6 months, the other 40 subject will receive brown rice pills for the same duration.
1897414|NCT01311882|Drug|MK-4305 40 mg|4 x 10 mg MK-4305 tablets
1897415|NCT01311882|Drug|MK-4305 20 mg|2 x 10 mg MK-4305 tablets
1897416|NCT01311882|Drug|Zopiclone|1 x 7.5 mg Zopiclone tablet
1897417|NCT01311882|Drug|Grossly Matching Placebo for Zopiclone|Grossly Matching Placebo for Zopiclone
1897418|NCT01311882|Drug|Matching Placebo for MK-4305|Matching Placebo for MK-4305
1897419|NCT01311895|Drug|H2O|2 mg IV hydromorphone
1897420|NCT01311895|Drug|1+1|"1mg I hydromorphone followed by an optional 1 mg IV hydromorphone 15 minutes later if the patient answers yes to the question, Do you want more pain medication?"
1897421|NCT01311908|Procedure|Methods of gastrojejunostomy reconstruction|Roux-en-Y reconstruction in pancreaticoduodenectomy
1897422|NCT01311947|Drug|Peginterferon alfa-2a|Peginterferon alfa-2a at 180 ug weekly for 24 weeks
1897423|NCT01311960|Drug|bevacizumab eye drop 0.05%|bevacizumab eye drop 0.05% will apply 4 times a day for 3 months
1897424|NCT01311960|Drug|normal saline 0.9%|normal saline eye drop 0.9% will apply 4 times a day for 3 months.
1897425|NCT01312012|Drug|antiviral therapy|100-120 pregnant women seropositive for both HBeAg and HBsAg and with hepatitis B viral DNA level > 10 8 copies/mL. Among them, 55-65 pregnant women will receive TDF therapy 300 mg once daily, starting from the gestational age 30-32 (the 3rd trimester) until 4 weeks after delivery of the neonate under informed consent. The total treatment duration will be 3-4 months. Another 45-55 pregnant women with the same serum HBAg and HBsAg and HBV DNA status will be enrolled as the control group with no TDF therapy ( An open-labeled study)
1897432|NCT01305499|Drug|Entinostat days 10,17|Given orally on days 10, 17
1897433|NCT01305512|Drug|SPARC1028|SPARC1028 administration as 30-minute intravenous infusion once a week for 3 weeks, followed by 1 week of rest
1897434|NCT01305525|Device|St. Jude Medical Spinal Cord Stimulation Systems|Spinal cord stimulation
1897435|NCT01305538|Drug|BMS-954561|
1897436|NCT01305538|Drug|BMS-954561|
1897437|NCT01305538|Drug|Placebo|
1897438|NCT01305551|Drug|Saxagliptin|Tablet, Oral, 5 mg, once on Day 1 only
1897439|NCT01305551|Drug|Metformin XR|Tablet, Oral, 500 mg, once on Day 1 only
1897440|NCT01305551|Drug|Saxagliptin/Metformin XR FDC|Tablet, Oral, 5/500 mg, once on Day 1 only
1897441|NCT01305564|Device|Denali inferior vena cava filter|The Denali inferior vena cava filter is a mechanical filtration device consisting of two levels of filtration (upper arms, lower legs), a retrieval hook to allow for retrieval using a standard snare, cranial and caudal anchors, and penetration limiters. The Denali filter is made from a laser cut nitinol tube.
1897442|NCT01305577|Drug|Deoxycholic acid injection|
1897443|NCT01305577|Drug|Placebo|Phosphate buffered saline placebo for injection
1897444|NCT01305590|Other|Survey to Understand Medication Adherence among HIV Patients|"We want to better understand how this particular population would react to commitment devices designed to increase medication adherence. We will survey participants to see if they would prefer more commitment, in the form of a Take-Medication-Get-Paid plan; less commitment, in the form of an Attend-Clinic-Get-Paid plan; or if they would prefer to designate their own levels of commitment."
1897445|NCT01305603|Drug|Bupivacaine|On both sides of the abdomen 30 ml of bupivacaine 2.5 mg/ml will be injected. This is a total of 60 ml of bupivacaine 2.5 mg/ml.
1897446|NCT01305603|Procedure|Injection|Injection under ultrasound-guidance
1897447|NCT01305616|Procedure|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light (380-500 nanometer)
1897448|NCT01305616|Procedure|Phacoemulsification with yellow-tinted intraocular lens|Phacoemulsification is a kind of cataract surgery using ultrasound machine. Yellow-tinted intraocular lens are a sort of lens with the ability to filter blue and ultraviolet spectrum of light.
1897449|NCT01305629|Behavioral|Spiritual Self-Schema Therapy|"The Spiritual Self Schema therapy (3S+) intervention will consist of a series of 12 one hour-long sessions delivered individually to participants over a four-month period. The 3S+ approach combines cognitive and behavioral therapy techniques with elements of non-theistic Buddhist philosophy to increase motivation for treatment adherence, alcohol and/or substance use reduction or abstinence and the prevention or reduction of HIV risk behaviors. 3S+ draws from self-regulation theory, self-schema theory, and self-discrepancy theory to assist participants in defining and perceiving their addict self, when their addict self is active, and its resulting negative affect state. 3S+ remediates the addict schema by proposing the construction of an alternate and competing schema: the spiritual self. This spiritual self schema is compatible with HIV self-care, alcohol and drug use reduction or abstinence, adherence to treatment, and a compassionate life."
1897450|NCT01305642|Dietary Supplement|Individualized fortification of breast milk|"Lactose, fat and protein content will be measured prior to breast milk fortification.
Subsequently, breast milk for preterm infants will individually fortified adjusted by using data from milk analysis."
1897451|NCT01305655|Drug|Glucarpidase|Patients treated with Glucarpidase if the 24 hour levels of MTX is >250 µM, 36 hour levels >30 µM or 42 hours levels >10 µM together with a reduced kidney function will be compared with patients in just below the tricking values.
1897452|NCT01305681|Device|LoFric® catheters during clean intermittent catheterization|LoFric® catheters during clean intermittent catheterization
1897453|NCT01305694|Biological|bone marrow derived mesenchymal stem cells|Intravenous administration of up to 6x10^5 MSCs per kg,qw,for 4 weeks
1897454|NCT01305707|Device|C-ECT|"C-ECT will be administered through a Thrymatron System IV device (Somatics, LLC, ISO 13485:2003). Electrode placement will be bilateral and energy administered during consolidation treatment will be same used in the acute episode. C-ECT will be given weekly for the first month, fortnightly for the following two months and monthly during the next 6 months. A total of 14 C-ECT sessions will be given over 9 months of treatment.
Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Drugs will be obtained as usually from the National Health System and will be prescribed according to data sheet and it will have a duration of 15 months."
1897455|NCT01305707|Drug|PHARMACOTHERAPY|Pharmacotherapy will remain unchanged since the acute episode to the end of the study. Psychotropics will be obtained as usually from the National Health System and will be prescribed according to data sheet and will have a 15 month duration.
1897456|NCT01305720|Device|near infrared spectroscopy: invos 5100|NIRS device used in this study, the optical field includes a volume of tissue approximately 2 cm deep to the surface probe with a 4-mm source-detector distance, and thus, organ-specific monitoring is feasible in small patients. With informed consent, the investigators applied NIRS probes to the forehead and abdomen for cerebral (rSO2C) and abdominal (rSO2P) regional oxygen saturation measurements.
1897459|NCT01305746|Drug|A-623|High dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
1897460|NCT01305746|Drug|A-623|Low dose given subcutaneously once a week until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
1897461|NCT01305746|Drug|A-623|High dose given subcutaneously once every 4 weeks until A623 is approved for clinical use in SLE or the Sponsor discontinues the study
1897462|NCT01305772|Drug|Panitumumab|Single dose Panitumumab 9mg/kg IV (in the vein) prior to definitive therapy (surgery or radiation therapy). Two additional doses of panitumumab 9mg/kg IV may be given at weeks 1 & 4 of RT alone or weeks 1 & 4 of cisplatin/RT if they tolerated first dose of panitumumab.
1897463|NCT01305772|Procedure|Surgery|Second biopsy was taken from surgical resection tissue (when possible obtained pre and post panitumumab biopsies from the same site).
1897464|NCT01305772|Procedure|Radiation Therapy|Radiation therapy was initiated within 8 weeks after surgery, or as soon as possible.
1897465|NCT01305798|Other|Scheduling and Active Choice for Biometric Participation|The control group will be informed via e-mail of the window of dates during which they can take part in the on-site screening and will be given instructions for scheduling an appointment. The active choice and default option arm will be informed via e-mail of a preselected time and date for their screening, which we will have generated randomly. This group will be asked to accept the default time, schedule a different time, defer the scheduling decision, or decline to receive a screening by clicking the appropriate option in the email. The active choice only arm will be given the same information as the control group, but they will also be asked to make an appointment immediately, defer the scheduling decision, or decline to receive a screening.
1897466|NCT01305811|Device|Acupuncture|Sterile insertive needles are applied by licensed, experienced practitioners.
1897467|NCT01305824|Drug|PRT-201|PRT-201 10 micrograms administered at the time of AVF creation.
1897468|NCT01305824|Drug|Placebo|Placebo administered at the time of AVF creation.
1897469|NCT01305824|Drug|PRT-201|PRT-201 30 micrograms administered at the time of AVF creation.
1897470|NCT01305837|Drug|methylprednisolone|500 mg of methylprednisolone taken in 3 days every month
1897471|NCT01305850|Drug|placebo|Patients in the control group will administer antihypertensive agents, except angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone. Dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
1897472|NCT01305850|Drug|Aliskiren|Patients with hypertension will take fixed-dose 150 mg aliskiren per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blocker and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
1897473|NCT01305850|Drug|Aliskiren plus Losartan|Patients with hypertension will take fixed-dose 150 mg aliskiren + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
1897474|NCT01305850|Drug|Enalapril plus Losartan|Patients with hypertension will take fixed-dose 20 mg enalapril + 50 mg losartan per day. Antihypertensive agents other than angiotensin converting enzyme inhibitors, angiotensin receptor blockers and spironolactone will be allowed and dosages are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
1897477|NCT01305876|Behavioral|yoga intervention|yoga session 2 x week over 3-1/2 months
1897478|NCT01305889|Behavioral|problem solving therapy|12 weeks of weekly 45 minute sessions of problem solving therapy
1897479|NCT01305889|Drug|Sertraline|12 weeks of sertraline; 25 mg for one week, 50 mg for 3 weeks; then 100 mg/day for 4 weeks; then 150 mg/day for 4 weeks based on tolerability and response
1897480|NCT01305902|Behavioral|contingency management|Participants assigned to the experimental group will earn chances to win prizes if they have walked the recommended number of steps.
1897481|NCT01305915|Behavioral|Getting Back on Track|The intervention, entitled Getting Back on Track, is two hours in duration and delivered by a multidisciplinary team representing nursing, radiation therapy, social work, rehabilitation services, and nutrition from the Breast Cancer Clinic at Princess Margaret Hospital. Relying on the content of the Getting Back on Track booklet, clinical experience and the principles of adult education, this team developed scripts for each component of the class.
1897482|NCT01305928|Other|Warm Hand-off|"Warm Hand-Off
Staff brief intervention and warm hand-off (5 min):
Assess withdrawal, need for medication change
Describe warm hand-off process
Provide 2-page flyer
Perform call, leave room
Notify patients' nurse patient is talking to quitline
Quitline session (20 min):
Collect minimum data set
Explore thoughts/feelings toward quitting
Provide medication education
Build plan to stay quit
Schedule next call
Staff check-back (5 min):
Ask patient how session went
Ask if patient requests cessation medication script on discharge"
1897483|NCT01305928|Other|Fax|"Fax
Staff standard in-patient session: (30 minutes):
Assess withdrawal, need for medication change
Conduct assessment of smoking history, interest in quitting
Explore relevance, risks, rewards, and roadblocks (4Rs) related to smoking and quitting
Provide 2-page flyer
Provide medication education
Build plan to stay quit
Describe fax-referral process
Ask if patient requests cessation medication script on discharge"
1897487|NCT01305967|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, Intravenous route, 16times for 2.5 months
1897488|NCT01305980|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, IV route, 24times for 4 months
1897489|NCT01305993|Drug|SB injection|Infusion SBinjection of 21.87ml/m^2, IV route, 24times for 4 months
1897490|NCT01306006|Biological|Providing measles vaccine for all children 9-35 months who have not yet received a routine measles vaccine|Normal measles vaccines licensed for distribution through the national EPI program
1897493|NCT01306032|Drug|ABT-888|PARP enzymes are critical for maintaining genomic stability by regulating a variety of DNA repair mechanisms. Individuals with deleterious mutations in the BRCA1 or BRCA2 tumor suppressor genes have an increased risk of developing breast and ovarian cancers due to impaired or defective DNA damage repair; these individuals have an increased susceptibility to DNA-damaging agents and PARP inhibitors. Inhibition of PARP inhibits the repair of DNA damage caused by alkylating agents such as cyclophosphamide. Metronomic cyclophosphamide has demonstrated efficacy in several tumor types. The PARP inhibitor ABT-888 has been shown to potentiate the action of cyclophosphamide in xenograft models. This combination is well tolerated in a Phase I study and showing promising activity.
1897503|NCT01306097|Drug|Zinc Supplement|10mg daily for under 1 years old children and 20mg daily for above 1 years old children
1897504|NCT01306123|Drug|Nascobal nasal spray (cyanocobalamin, USP)|Single intranasal administration
1897505|NCT01306123|Drug|Vitamin B12-ratiopharm N, injection solution|One single intramuscular administration
1897506|NCT01306136|Behavioral|Prolonged Exposure|15 psychotherapy sessions focused on helping clients overcome avoidance behaviors and emotionally process trauma-related memories
1897507|NCT01306136|Behavioral|Usual care|Per usual care, patients are referred to a mental health provider within the health care setting.
1897508|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose
1897509|NCT01306162|Drug|Dabigatran etexilate|150 mg as single dose
1897510|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg plus dronedarone 400 mg as single dose (staggered administration)
1897511|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid
1897512|NCT01306162|Drug|Dabigatran etexilate plus dronedarone|dabigatran etexilate 150 mg single dose plus dronedarone 400 mg bid (staggered administration)
1897513|NCT01306175|Drug|Digoxin plus BI 10773|Digoxin 0.5 mg as single dose, BI 10773 medium dose once daily
1897514|NCT01306175|Drug|Digoxin|Digoxin 0.5 mg as single dose
1897515|NCT01306188|Biological|Breast cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.
For each patient, the following analyses is performed:
The analysis of TCR and BCR repertoire diversity,
The phenotypic analysis of immune subpopulations,
The analysis of the global lymphopenia or subpopulations T,
The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
1897516|NCT01306188|Biological|Lung cancer cohort|"Blood samples must be made within 48 hours after the inclusion of the patient. Patients are treated according to the standards of the centre where they are supported. No follow-up is provided in this study.
For each patient, the following analyses is performed:
The analysis of TCR and BCR repertoire diversity,
The phenotypic analysis of immune subpopulations,
The analysis of the global lymphopenia or subpopulations T,
The analyses by multiplex assay of a large panel of plasma cytokines and chemokines."
1897517|NCT01312064|Drug|rituximab and everolimus|rituximab (375mg/m2) induction and subsequently everolimus-based immunosuppressive therapy. Everolimus initial dose: 1 mg bid within 24 hrs after reperfusion, adjusted to a target trough blood level of 6-10 ng/ml for the first 6 months after transplantation.
1897518|NCT01312064|Drug|thymoglobulin and tacrolimus|thymoglobulin induction and tacrolimus-based immunosuppressive therapy. thymoglobulin dose: 1.0mg/kg/d for 3 days daily dose of tacrolimus: 0.15 mg/kg/d given in two doses starting within 24 hours after transplantation
1897519|NCT01312077|Drug|Levobupivacaine|peri- and intraarticular surgical site infiltration before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight with epinephrine made up to a volume of 1.5ml/kg with saline. A catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. An elastomeric pump will deliver a continuous infusion of levobupivacaine 0.25% at 4ml/hr commencing 6 hours postoperatively and continuing for 24 hours.
1897520|NCT01312077|Drug|Intrathecal morphine|intrathecal morphine bolus 200 micrograms
1897521|NCT01312090|Biological|Whole body cryotherapy|Cryotherapy: The whole-cody cryotherapy device (Univers Cryo-Combi;Oy MJG Univers Ab, Helsinki, Finland) consists of 3 chambers set at different temperatures. The first 2 chambers are meant for precooling (−30°Cand−60°C), and the patient remains in these for a very short time. The third chamber temperature reaches -110°C, and the patient remains inside for 3-4 minutes wearing a bathing suit or trunks, acral parts covered.
1897522|NCT01312090|Behavioral|counseling and behavioral therapy for weight loss|Weight loss intervention with Very Low Calory Diet (VLCD, 500-1000 kcal / d + dietary supplements) and group and individual treatment (eating, physical activity counseling and behavioural therapy).
1897523|NCT01312103|Behavioral|Internet-based safety decision aid|"Participants will log into the the intervention website at baseline, 3 months, 6 months, and 12 months post baseline and receive:
Setting of priorities for safety; a sliding bar allows participants to establish priorities by making pairwise comparisons of importance between factors.
Danger Assessment; asks women to report on well-established risk factors for repeat violence and lethal IPV. A weighted scoring algorithm provides participants with their validated level of danger.
Personalized action plan. Based on a participant's answers to the previous sections, a list of safety strategies with links to resources will be presented to her. The participant is given the option to print her results and the personalized plan."
1897524|NCT01312103|Behavioral|Usual Care Safety Plan|"Participants will log into a control website at baseline, 3 months, 6 months and 12 months post baseline. Website will include the usual services provided to IPV survivors looking for safety planning resources on the internet. Participants will receive:
Danger Assessment, will see risk factors associated with lethal violence, but will not receive a score or feedback.
A brief emergency safety plan with links to national and state domestic violence resources as well as a suicide resource."
1897525|NCT01312116|Behavioral|iCBT|Internet-delivered cognitive behavior therapy, 8 weeks
1897526|NCT01312116|Behavioral|iPDT|Internet-delivered psychodynamic therapy, 8 weeks
1897527|NCT01312129|Drug|Sulfasalazine|500mg capsules of Sulfasalazine x 3 doses 12 hours apart.
1897528|NCT01312129|Drug|Placebo|Placebo capsule x 3 doses 12 hours apart
1897529|NCT01312155|Other|Intubation|Intubation, endotracheal
1897530|NCT01312168|Device|Therapeutic CPAP|CPAP ventilator, optimal pressure decided by CPAP manual titration, daily use at sleep, six months
1897531|NCT01312168|Device|Subtherapeutic CPAP|Subtherapeutic CPAP ventilator, pressure <3 cmH2O, daily use at sleep, six months
1897532|NCT01312181|Behavioral|HealthCall and Motivational Interviewing|A basic behavioral intervention used in the 3 arms including the Motivational Interview (MI), the two components of HealthCall (IVR, personalized feedback) and the advice+DVD educational control arm.
1897533|NCT01312181|Behavioral|Motivational Interviewing (MI)|A basic behavioral intervention used in the 3 arms including the Motivational Interview (MI), the two components of HealthCall (IVR, personalized feedback) and the advice+DVD educational control arm.
1897534|NCT01312181|Behavioral|HIV/AIDS health education|A basic behavioral intervention used in the 3 arms including the Motivational Interview (MI), the two components of HealthCall (IVR, personalized feedback) and the advice+DVD educational control arm.
1897535|NCT01312194|Procedure|Root canal therapy in one visit|Patient was anesthetized with local anesthetic solutions, and the caries was removed. The tooth was isolated with rubber dam and access to pulp chamber was completed. Cleaning and shaping preparation was achieved with manual and rotatory endodontic instruments.The ideal working length was determined by an electronic apex locator and periapical radiography. Irrigation was performed with 5.25%NaOCl solution. The smear layer was removed by 10% citric acid. The cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
1897536|NCT01312194|Procedure|Root Canal Therapy in two-vist|The treatment protocol was the same as described for one visit group. In the first visit, after cleaning, shaping and smear layer removal, the root canals were medicated with a calcium hydroxide paste and sterile distilled water (1:1) and the pulp chamber was sealed with a minimum 3mm thickness temporary filling restoration. After 10-12 days, during the second visit, the medication was removed, and the cases were obturated with guta-percha cones using a lateral compaction filling technique as well as zinc oxide-eugenol-based root canal sealer. The teeth filled with a light-cured resin.
1897537|NCT01312233|Other|Medical Care|Participants allocated to all three treatment groups receive medical care over a 12‐week period. Medical treatments are standard therapies for back pain. Medical and osteopathic physicians follow clinical practice guideline recommendations for back pain: focused history and physical exam; limited diagnostic imaging; self‐management education; maintaining physical activity as tolerated and local heat/cold application; pharmacotherapy with analgesics and anti‐inflammatory agents. Participants not responding to treatment may receive additional therapies such as physical therapy or specialist referral.
1897538|NCT01312233|Other|Dual Care|Participants allocated to Dual Care receive medical care as described plus chiropractic care over a 12‐week period. Chiropractic care includes standard therapies for back pain. A doctor of chiropractic determines the therapeutic approach based upon a participant's clinical presentation. Treatments may include spinal or extremity joint manipulation, such as: high velocity‐low amplitude or low velocity‐variable amplitude maneuvers; mechanical device assisted adjustments; or passive mobilization. Recommendations for exercise, lifestyle modifications, or other therapies may be provided.
1897539|NCT01312233|Other|Shared Care|Participants allocated to Shared Care receive co‐managed medical care from a medical or osteopathic doctor and chiropractic care from a doctor of chiropractic over a 12-week period. The medical and chiropractic treatments are standard therapies for back pain, as described under Medical Care and Dual Care.
1897540|NCT01312246|Device|EnSeal Device|measurement of bursting pressure of colonic vessels after using the EnSeal Device
1897541|NCT01312259|Other|"Changing the Interstim parameter of '' Frequency in patients with Interstitial Cystitis"|Subjects will be randomized into one of two groups. Group One will be programmed to receive 14 Hz as their frequency, while the other group (Group 2) will receive 40 Hz as their frequency for the first ninety days after surgical implantation. After three months each patient will come in to the office to have their InterStim frequency changed to the opposite frequency. After each patient has had three months to evaluate each of the two frequencies, the next step is to allow the patient to decide which setting they thought best controlled their respective symptoms. The InterStim was then programed to whichever frequency the patient chose, and this would remain for three to six months.
1897542|NCT01312272|Drug|Oxytocin|Oxytocin 40 units/ml nasal spray: use 5 sprays per nostril (40 IU total) one time
1897543|NCT01312272|Drug|Inactive placebo nasal spray|A placebo nasal spray will be prepared identically to the oxytocin nasal spray except lacking oxytocin. Its ingredients are mannitol, glycerin, and preserved water. It will be administered at 5 sprays to each nostril, one time.
1897544|NCT01312285|Device|Resonator device|low level magnetic fields
1897545|NCT01312298|Procedure|General anesthesia|Patients will receive general anesthesia using propofol 10 mg/ml and remifentanil 50 ug/ml
1897546|NCT01312298|Procedure|Regional anesthesia|Patients will receive intrathecal anesthesia
1897547|NCT01312311|Drug|Docetaxel, Cisplatin|Docetaxel 35mg/m2 D1 & D8 Cisplatin 70mg/m2 D1
1897548|NCT01312324|Drug|neoadjuvant docetaxel/cisplatin|3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks
1897549|NCT01312337|Drug|salvage iressa|Iressa 250mg per day until progression
1897550|NCT01312350|Drug|neoadjuvant docetaxel/cisplatin/fluorouracil|2 cycles of neoadjuvant Docetaxel/cisplatin/5-fluorouracil therapy followed by CCRT Neoadjuvant chemotherapy (docetaxel 75mg/m2 D1, cisplatin 75mg/m2 D1, 5-fluoruracil 759mg/m2/day, D1-4, every 3 weeks) CCRT protocol is same with that of control arm.
1897551|NCT01312350|Drug|No treatment before definitive CCRT|concurrent chemoradiation therapy radiation: 70Gy/35fractions chemotherapy: cisplatin single 100mg/m2/day D1, D22, D43
1897552|NCT01312363|Drug|Rivastigmine patch|Rivastigmine patch (5-10cm2, daily, 24hr)
1897553|NCT01312376|Biological|OC-DC vaccine|All subjects will receive a dose of 5-10 million cells of OC-DC intradermally
1897554|NCT01312376|Drug|Bevacizumab|Patients will start receiving Bevacizumab at 15 mg/kg starting Day 30 and every 4 weeks thereafter until end of study.
1897555|NCT01312376|Drug|cyclophosphamide 300 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous cyclophosphamide for 300 mg/m2/d for 3 days.
1897556|NCT01312376|Drug|fludarabine 30 mg/m2/d for 3 days|All subjects will receive a single course of outpatient lympho-depleting chemotherapy with intravenous fludarabine 30 mg/m2/d for 3 days
1897557|NCT01312376|Drug|ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells|All subjects will receive a single intravenous infusion of ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T-cells at the starting dose of 10-15 x 109 (10-15 billion) T-cells with escalating doses in cohort 2 and 3.
1897558|NCT01312389|Biological|OC-L/Montanide ISA 51 VG|All subjects will receive OC-L/Montanide ISA 51 VG) on day 0, 14,28,42 and 56 with a +/- 5 day window. The vaccine will be divided in two or more intradermal/subcutaneous injections in the groin areas bilaterally.
1897559|NCT01312389|Biological|Ampligen|All subjects will receive intravenous Ampligen (200mg given by IV infusion 60 +- minutes) 3 times starting 2-3 days after each vaccine administration. Each of the 3 Ampligen (200 mg) infusions will be separated by 2-3 days.
1897560|NCT01312389|Biological|Prevnar|A vaccine against Pneumococcus pneumoniae will be given intramuscularly on Day 0 and 14 as positive control of immune responsiveness.
1897561|NCT01313585|Drug|Initiation of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
1897562|NCT01313585|Drug|Initiation of beclometasone via the Easibreathe device plus salbutamol via and MDI device|
1897563|NCT01313585|Drug|Increase of beclometasone via the Easibreathe device plus salbutamol via the Easibreathe device|
1897564|NCT01313585|Drug|Increase of beclometasone via the Easibreathe device plus salbutamol via an MDI|
1897565|NCT01313598|Drug|GLPG0187|continuous IV infusion
1897566|NCT01313611|Drug|Rituximab + bendamustine|Induction phase: rituximab and bendamustine on Day 1, Bendamustine on Day 2, Rituximab on Day 8, Rituximab on Day 15, Rituximab on Day 22, bendamustine on Day 29, Bendamustine on Day 30
1897567|NCT01313624|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
1897568|NCT01313624|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
1960899|NCT03076814|Drug|Tadalafil|
1960900|NCT03076814|Other|Placebo|
1897573|NCT01313650|Drug|62.5/25mcg|GSK573719/GW64244
1897574|NCT01313650|Drug|62.5mcg|GSK573719
1897575|NCT01313650|Drug|25mcg|GW642444
1897576|NCT01313650|Drug|Placebo|Placebo
1897577|NCT01313663|Drug|pazopanib|oral agent, administered at 800 mg daily (400 mg tablets x 2). Dose can be reduced, interrupted or discontinued due to adverse events or intolerance
1897578|NCT01313663|Drug|pemetrexed|pemetrexed IV 500 mg/m2 once every 3 weeks
1897583|NCT01313689|Drug|Ofatumumab|Ofatumumab IV, initial dose 300 mg, followed 1 week later with 2000 mg once weekly for 7 weeks, followed 4 weeks later by one infusion of 2000 mg every 4 weeks for 4 infusions, for a total of 12 infusions over 24 weeks. After 24 weeks of ofatumumab treatment, patients who have achieved at least stable disease or better, and whom the investigator would deem appropriate for the therapy to continue, would undergo a second randomisation (2:1) to either 1) an additional ofatumumab dose regimen of 2000 mg once every 4 weeks for up to an additional 24 weeks, or 2) no further therapy (i.e. observation only).
1897584|NCT01313689|Drug|Physicians' Choice|Non-ofatumumab containing regimen as per physicians' choice for up to 6 months. Permitted therapies include treatments approved for CLL, and well established standards of care for CLL.
1897585|NCT01313702|Drug|polipillV1|polipill version 1: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, atenolol 50mg
1897586|NCT01313702|Drug|polipillV2|Polipill version 2: aspirin 75mg, simvastatin 40mg, lisinopril 10mg, hydrochlorothiazide 12.5mg.
1897587|NCT01313702|Drug|usual care|the drugs used in clinical practice, defined by physician
1897588|NCT01313715|Biological|160U /0.5ml|inactivated vaccine(vero cell) against EV71 of 160U /0.5ml, two doses, one month interval
1897589|NCT01313715|Biological|320U /0.5ml|inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, one month interval
1897590|NCT01313715|Biological|640U /0.5ml|inactivated vaccine(vero cell) against EV71 of 640U /0.5ml, two doses, one month interval
1897591|NCT01313715|Biological|0/0.5ml placebo|0/0.5ml placebo, two doses, one month interval
1897592|NCT01313728|Drug|Dapsone plus Tretinoin Gel|Dapsone gel, followed by tretinoin gel one hour later, applied once daily to the assigned side of the face for 2 weeks
1897593|NCT01313728|Drug|Tretinoin Gel|Tretinoin gel applied once daily to the assigned side of the face for 2 weeks
1897594|NCT01313741|Device|Shoulder arthroplasty with anchor peg glenoid|Shoulder arthroplasty with anchor peg glenoid
1897595|NCT01313754|Procedure|Vicryl Suture|Vicryl suture material will be placed on the patients left sided incision.
1897596|NCT01313754|Procedure|Dermabond|Dermabond skin glue will be placed on the patients left sided incision.
1897599|NCT01313780|Drug|Oxycodone/Naloxone|Dose and administration : Upto 40mg B.I.D per daily.
1897600|NCT01313780|Drug|Oxycodone(single compound)|Dose and administration : Upto 40mg B.I.D per daily.
1897601|NCT01313793|Drug|Treatment A-B|Subjects to receive 3 X 15 mg tablets of the clinical formulation in first period then 1 x 45 mg tablet of the commericializable formulation in 2nd period.
1897602|NCT01313793|Drug|Treatment B-A|Subjects to receive 1 x 45 mg tablet of the commericializable formulation in first period then 3X 15 mg tablets of the clinical formulation in 2nd period.
1897603|NCT01313806|Device|Resonator|Treatment group vs. Placebo group
1897604|NCT01313806|Device|Placebo|Inactive Resonator Device
1897606|NCT01313832|Other|remote ischemic preconditioning (RIPC)|RIPC will be performed by 5-min cycles of lower limb ischemia reperfusion using blood pressure cuff
1897607|NCT01313845|Drug|amantadine sulfate|infusion of amantadine sulfate 100mg/500ml/bottle over 3 hours twice a day
1897608|NCT01313845|Drug|0.9% sodium chloride|infusion of normal saline 500ml/bottle over 3 hours twice a day
1897609|NCT01313858|Drug|Simponi®|
1897610|NCT01313858|Drug|Methotrexate|Given concomitantly with Simponi®
1897611|NCT01313884|Drug|Irinotecan|50 mg/m2/day x 5 days
1897612|NCT01313884|Drug|Vincristine|2 mg/m2 (capped at 2mg total do)
1897613|NCT01313884|Drug|Temozolomide|100 mg/m2/day x 5 days
1897614|NCT01313884|Drug|Doxorubicin|75 mg/m2
1897615|NCT01313884|Drug|Cytoxan|1200 mg/m2
1897616|NCT01313884|Drug|Pegfilgrastim|6 mg
1897617|NCT01313884|Drug|Mesna|240 mg/m2 in 50 ml NS
1897618|NCT01313897|Drug|Bortezomib|bortezomib to be given days -9, -6, and -2 at 1.0mg/m2, i.v.
1897619|NCT01313910|Dietary Supplement|Immunolin®|Immunolin® 500 mg capsules to be taken 5 capsules twice daily for eight weeks
1897620|NCT01313923|Drug|Sirolimus (formerly known as Rapamycin)|For low to moderate immunologic risk, the loading dose is 6mg immediately after transplantation, followed by 2mg PO Qday in conjunction with cyclosporine and corticosteroids. After 2-4 months, cyclosporine should be discontinued over 4-8 weeks while titrating sirolimus drug concentrations within the target-range with whole blood trough concentrations every 1-2 weeks. Monitoring is needed because cyclosporine inhibits the metabolism of sirolimus, and discontinuation of cyclosporine can lead to lower levels of sirolimus. In high immunologic risk patients, the loading dose is 15mg after transplantation, followed by 5mg PO Qday in conjunction with cyclosporine and corticosteroids for 12 months. A whole blood trough level is recommended between days 5 and 7 with adjustment to the daily dose.
1897621|NCT01313936|Drug|Metaiodobenzylguanidine (MIBG)|Chemotherapy will be given over 5 days for each course, with a single dose of 131I-MIBG on the second day of irinotecan. A total course will be defined as 42 days, or longer if hematopoietic recovery to eligibility criteria occurs after day 42.
1897622|NCT01313949|Other|Training program|These diabetes patients will undergo a 32-hour 'Train the trainer' program (4 workshops, 8-hours each) led by health care experts in nutrition, physical activity, psychology and neuro-linguistic program [NLP] trainer to ensure the adequacy of knowledge and skills of these mentors.
1897623|NCT01313962|Drug|Flufirvitide-3 0.05 mg single dose|Nasal Spray
1897624|NCT01313962|Drug|Flufirvitide-3, 0.1 mg single dose|Nasal spray
1897625|NCT01313962|Drug|Flufirvitide-3, 0.2 mg single dose|nasal spray
1897626|NCT01313962|Drug|Flufirvitide-3, 0.4 mg single dose|Nasal spray
1897627|NCT01313962|Other|Placebo|Nasal spray
1897628|NCT01313988|Dietary Supplement|Plant sterols and fish oil|4 weeks intervention, 3 times daily
1897629|NCT01313988|Dietary Supplement|Plant sterols|4 weeks intervention, 3 times daily
1897630|NCT01313988|Dietary Supplement|Placebo|4 weeks, 3 times daily
1897631|NCT01314001|Drug|Varenicline|Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
1897632|NCT01314001|Drug|Placebo|"Day 1-3: 0.5mg once daily orally Day 4-7: 0.5mg twice daily orally Day 8-84: 1.0mg twice daily orally
Week 1 - 6: 21mg placebo patch Week 7 - 8: 14mg placebo patch Week 9 - 11: 7mg placebo patch"
1897633|NCT01314001|Drug|Transdermal Nicotine|Week 1-6: 21mg nicotine patch Week 7-8: 14mg nicotine patch Week 9-11: 7mg nicotine patch
1897634|NCT01314014|Drug|Imexon|Amplimexon will be administered daily on Days 1-5 of 21-day treatment cycles as an intravenous infusion over a time course of 60 minutes. Subjects will receive 17 cycles of therapy for a total of one year on treatment. The Amplimexon starting dose for each subject in this study is 1000 mg/m² on each treatment day. Dose may be reduced by 25% for toxicity; after 2 dose reductions, subjects must be withdrawn from treatment.
1897635|NCT01314027|Drug|Neoadjuvant Chemotherapy with gemcitabine/oxaliplatin|"Patients with resectable cytologically proven adenocarinoma of the pancreatic head are randomized to arm A or B.
Patients randomized to arm A receive an 8-week neoadjuvant chemotherapy with gemcitabine/oxaliplatin. Thereafter, surgery is performed if the restaging does not reveal a contraindication. Finally, all patients receive adjuvant gemcitabine for six months."
1897636|NCT01314027|Drug|adjuvant chemotherapy with gemcitabine|Patients randomized to arm B undergo surgery and receive the same adjuvant treatment as in arm A.
1897637|NCT01314040|Other|Run in diet|Fully controlled dietary period during 9 days. Participants will receive approximately 15 en% of protein. The amount of protein intake from dairy, meat, and grain will be equal to each other
1897638|NCT01314040|Other|High meat protein diet|Fully controlled diet during 7 days. Participants will consume 18 en% protein, mainly from meat.
1897639|NCT01314040|Other|High dairy protein diet|Fully controlled dietary intervention during 7 days. Participants will consume 20 en% protein. Mainly from dairy
1897640|NCT01314040|Other|High grain protein diet|Fully controlled dietary intervention for 7 days. Participants will consume 20 en% of protein. Mainly from grain
1897641|NCT01314066|Drug|Bevacizumab|Patients receiving drug will receive it as a single dose. Treatment will be given as 90-minute IV infusion. The patient will either receive Bevacizumab at 5 mg/kg OR Bevacizumab at 10 mg/kg.
1897642|NCT01314066|Drug|Placebo|Patients assigned to placebo-control group will receive a single dose of saline solution as a 90 minute IV infusion
1897643|NCT01314092|Biological|Autologous cultured adipose derived stem cells(low dose group)|low dose group: 1x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
1897644|NCT01314092|Biological|Autologous cultured adipose derived stem cells(high dose group)|high dose group: 2x10e7 cells/mL At 6 weeks after first stem cell injection, fistula closing was assessed. If it is not completely closed, second injection would be applied in 2 weeks. Additional dosage would be doubled to first dosage.
1897645|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
1897646|NCT01314105|Drug|BIBF 1120+ PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
1897647|NCT01314105|Drug|BIBF 1120 + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF1120 twice daily along with standard therapy of PLD + carboplatin
1897692|NCT01314508|Drug|Increlex|Increlex therapy will begin at 40 micrograms/kg/day twice a day. The dose will be escalated by 20 mcg twice a day every other week up to 100mcg/kg/week.
1897693|NCT01314560|Other|Blood sample|Blood sample
1897649|NCT01314131|Behavioral|Stimulation group|"Patients living in nursing home can be enrolled in the study by giving their verbal consent. The trial lasts two weeks for each patients and it will be performed in three parts :
a cognitive and behaviour assessment : MMSE, BREF, NPI, IA
an interest questionnaire for patients. It contains 40 questions about activities.
the intervention : patients will be propose 5 activities. 4 of them are activities that patients are interested in. Each activity have to last 15 minutes and the stimulation is measured by a scale named Observational Measurement of Engagement ."
1897650|NCT01314144|Drug|Bupivacaine|intraoperative wound soakage with 20ml of 0.5% bupivacaine with epinephrine and continuous infusion of 4ml/hr of 0.2% bupivacaine for 48 hours postoperatively
1897651|NCT01314157|Other|Isostretching|12 interventions (two times per week) for 45 minutes
1897652|NCT01314170|Device|Susanna Implant|device
1897653|NCT01314183|Other|Exercise|The program starts with a 10 minute aerobic exercise warm-up (treadmill walking or stationary cycling). Subjects then perform a series of strengthening, stretching, and neuromuscular control activities which are core exercises for the program and mandatory. In addition to the above core exercises, therapists have the option to select additional optional exercise activities, based on the initial examination findings. These exercises will address strength or flexibility in the hip, and ankle if impairments are identified in the initial examination.
1897654|NCT01314183|Other|manual therapy|The manual therapy (MT)techniques are maneuvers that are applied with manual force from the treating therapist. The MT techniques will include a series of accessory motion techniques, manual stretching , and soft tissue manipulation (deep massage to muscles and connective tissues associated with knee function). Core techniques include anterior-posterior and posterior-anterior tibiofemoral translations, superior-inferior and medial-lateral patellofemoral mobilizations, knee flexion and extension mobilizations that may be combined with varus-valgus stresses,medial-lateral tibial rotations, manual stretching of the quadriceps, rectus femoris, hamstring, and gastrocnemius muscles, and soft tissue manipulations of the quadriceps, peri-patellar tissues, hamstring, hip adductors, and gastroc-soleus muscle groups. There are optional MT techniques for the hip, and foot and ankle joints that can be selected by the therapist based on initial examination findings.
1897655|NCT01314196|Other|therapeutic exercises|therapeutic exercises for the shoulder and scapula stabilizers using bat without charge, training and isometric exercises commuting to the cuff muscles, without producing subacromial impaction.
1897656|NCT01314196|Other|biceps resistance training and therapeutic exercises|The biceps resistance training based on calculations of maximum resistance (MR), being conduct in three series 10 reps with 50% of MR in the first series of training and 75% of MR in the second series, with 2 minutes between each and therapeutic exercises for the shoulder and scapula stabilizers.
1897657|NCT01314209|Drug|Dexmedetomidine|Dexmedetomidine 0.7 microg/kg/h 12-hour intravenous infusion
1897658|NCT01314222|Drug|BMS-954561|
1897659|NCT01314222|Drug|Pregabalin|
1897660|NCT01314222|Drug|Placebo matching BMS-954561|
1897661|NCT01314222|Drug|Placebo matching Pregabalin|
1897662|NCT01314248|Device|each child will receive both the LMA and ILA|each child will receive both the size 2 LMA and size 1.5 ILA
1897663|NCT01314261|Drug|ABT-267|5 mg or 25 mg tablets
1897664|NCT01314261|Drug|Pegylated interferon (pegIFN)|Syringe, 180 µg/0.5 mL for subcutaneous injections administered weekly
1897665|NCT01314261|Drug|Ribavirin (RBV)|200 mg tablet dosed at 1000 or 1200 mg daily divided twice a day
1897666|NCT01314261|Other|Placebo for ABT-267|Participants received matching placebo tablet at each dose level for ABT-267.
1897667|NCT01314274|Drug|Bevacizumab|100mg intranasal submucosal bevacizumab in 10ml
1897668|NCT01314274|Drug|NaCl|10ml of 0.9% NaCl intranasal submucosal
1897669|NCT01314300|Drug|Lidocaine|Lidocaine 5% plaster
1897676|NCT01314339|Drug|Desloratadine|Desloratadine Tablets, 5 mg
1897677|NCT01314352|Drug|Desloratadine|Desloratadine Tablets, 5 mg
1897678|NCT01314378|Behavioral|Mindfulness Training|Eight session intensive behavioral training program for smokers
1897679|NCT01314378|Behavioral|Cognitive-Behavioral Therapy|Eight session intensive behavioral intervention for smokers
1897680|NCT01314391|Genetic|mutation analysis|
1897681|NCT01314391|Genetic|polymerase chain reaction|
1897682|NCT01314391|Other|laboratory biomarker analysis|
1897683|NCT01314417|Drug|Methotrexate|400 μg/100 μL monthly injections for the first 3 months, then as needed per the treatment criteria
1897684|NCT01314443|Other|Nicotine Replacement Therapy (NRT)|Participants will quit smoking with nicotine patches
1897685|NCT01314443|Dietary Supplement|Gamma-Tocopherol|Participants will take gamma-tocopherol (500 mg/d) supplements for 7 days
1897686|NCT01314443|Other|Placebo|Participants will take placebo for 7 days
1897687|NCT01314443|Behavioral|Smoking cessation|Participants will quit smoking without any pharmacological aids
1897688|NCT01314456|Device|NaviGo|Video recording of a normal TRUS guided prostate biopsy with additional 2 , non invasive,electromagnetic sensors attached to the TRUS probe and the patient's back,- to allow for a 3D modeling of the prostate.
1897689|NCT01314482|Drug|Minocycline|200mg bd for 3 days before surgery
1897690|NCT01314495|Drug|Abatacept|Abatacept will be administrated as a 30 minute intravenous infusion.
1897691|NCT01314495|Drug|Inactive infusion|Placebo will be administered as a 30 minute intravenous infusion.
1897735|NCT01314885|Drug|Placebo for PH-797804|Single Dose, Oral, Placebo for PH-797804
1897694|NCT01314573|Behavioral|Sprint interval exercise|3 session per week of exercise on a exercise cycle ergometer. Each session involves 30s of maximal exercise followed by 4.5 min of easy cycling at 10W. This is repeated 4 times at each exercise session.
1897695|NCT01314573|Behavioral|Maximal continuous exercise|3 sessions per week of an exercise intervention involving maximal cycling until the participant has completed an amount of work equivalent to a sprint interval training session. This exercise lasts between 3 and 3.5 minutes.
1897696|NCT01314586|Dietary Supplement|secoisolariciresinol diglucoside-containing extract of flaxseed|0, 150 or 300 mg/day as 2 pills taken at breakfast and dinner, dietary counseling to comply with NCEP Step I diet
1897697|NCT01314599|Drug|PM01183 1 mg Powder for concentrate for solution for infusion and PM01183 4 mg Powder for concentrate for solution for infusion|"PM01183 Drug Product will be provided as a lyophilized powder for concentrate for solution for infusion with a strength of 1.0 mg/vial and 4.0 mg/vial.
Before use, the vials will be reconstituted with 2 ml or 8 ml of sterile water for injection to give a solution containing 0.5 mg/ml of PM01183."
1897698|NCT01314612|Behavioral|Cognitive-Behavioral Insomnia and Nightmare Group|Group based cognitive-behavioral therapy meeting weekly for 90 minutes over the course of 9 weeks. Utilizes stimulus control, sleep scheduling, and progressive muscle relaxation to address symptoms of insomnia. Imagery rehearsal and rescripting are used to address nightmare symptoms.
1897699|NCT01314638|Other|Workshop balances|one workshop per week for 20 weeks. Evaluation before and after.
1897700|NCT01314651|Behavioral|Stimulus Control and Sleep Restriction|5 instructions in stimulus control and individually-tailored sleep restriction
1897701|NCT01314651|Behavioral|Lifestyle Modification|5 instructions in changing general lifestyle habits (maintaining consistent liquid intake, range of motion exercises, eating a serving of protein in the morning, etc.)
1897702|NCT01314677|Procedure|positron emission tomography/computed tomography (PET/CT)|Undergo FDG PET/CT
1897703|NCT01314677|Radiation|fludeoxyglucose F 18|Undergo FDG PET/CT
1897704|NCT01314690|Other|Caloric transition|6 week low calorie diet followed by 6 week stabilization period
1897705|NCT01314703|Drug|ChloraPrep One-Step|10.5 ml applicator preoperative skin preparation
1897706|NCT01314703|Drug|70% isopropyl alcohol|10.5 ml applicator
1897707|NCT01314716|Drug|AZLI|AZLI 75 mg reconstituted with diluent and administered via nebulizer three times daily
1897708|NCT01314716|Drug|Placebo|Placebo to match AZLI administered via nebulizer three times daily
1897709|NCT01314729|Device|Fiber-reinforced-composite retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment
1897710|NCT01314729|Device|Composite-wire retainer|this type of retainer is placed on the lingual surface of teeth from canine to canine just before the completion of orthodontic treatment to prevent treatment relapse
1897711|NCT01314742|Other|Biotene OralBalance® gel|Biotene OralBalance® gel is dispensed as 42gm, patient specific tube from hospital's Central Pharmacy. One pea-size oral application every 4 hours, or at touch time, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
1897712|NCT01314742|Other|Sterile Water moisten cotton tipped applicator|One oral care application will be performed every 4 hours, or at touch times, to gums and tongue, as long as the subject remains mechanically ventilated for the duration of hospitalization.
1897713|NCT01314755|Dietary Supplement|IMPACT|IMPACT (Nestlé Healthcare Nutrition, Minnetonka, MN, USA) an `immune-enhancing` feed which contains supplemental L-arginine (1.25 78 g/L), dietary nucleotides (1.2 g/L) and omega-3 fatty acids in the form of 79 eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (EPA/DHA 1.7 g/L) 80 as its active ingredients.
1897714|NCT01314755|Dietary Supplement|An iso-caloric, iso-nitrogenous control feed|
1897715|NCT01314768|Behavioral|Brief intervention|Structured behavioural Brief intervention given by trained GPs
1897716|NCT01314768|Other|Business as usual|GPs to treat patient as they have until now based on best established practice
1897717|NCT01314768|Other|Screening and outcome evaluation only|No additional intervention
1897718|NCT01314768|Other|Screening and outcome evaluation only|No additional intervention
1897719|NCT01314781|Drug|solifenacin|solifenacin 5mg tablet once daily
1897720|NCT01314781|Procedure|PFMT and WBVT|pelvic floor muscle and whole body vibration training once a week
1897721|NCT01314820|Other|normal saline injection|20 cc normal saline injection into knee joint
1897722|NCT01314820|Other|sham injection|no saline injection
1897723|NCT01314833|Drug|Docetaxel Cyclophosphamide|"Docetaxel 75 mg/m² D1 Cyclophosphamide600 mg/m² D1
1 cycle = 21 days
TC*6"
1897724|NCT01314833|Drug|Cyclophosphamide Fluorouracil Epirubicin Docetaxel|"1st -3rd Cycle: Fluorouracil 500 mg/m² D1 Epirubicin 100 mg/m² D1 Cyclophosphamide 500 mg/m² D1
1 cycle = 21 days 4th-6th Cycle: Docetaxel 100mg/m² D1
1 cycle = 21 days CEF*3-T*3"
1897725|NCT01314833|Drug|Epirubicin Cyclophosphamide Paclitaxel|"1st -4th Cycle: Epirubicin 90 mg/m² D1 Cyclophosphamide 600 mg/m² D1
1 cycle = 21 days 5th-8th Cycle: Paclitaxel 80mg/m² D1，8，15
1 cycle = 21 days EC*4-P*4"
1897726|NCT01314859|Drug|Nifedipine|"Oral Treatment with Nifedipine capsules (10mg)
Initial dose: 20 mg of nifedipine (2 capsules of 10 mg).
Maintenance Dose: 20 mg of nifedipine (2 capsules of 10 mg) every 6 hours.
Maximum Duration of the treatment: 48 hours."
1897727|NCT01314859|Drug|Atosiban|"Intravenously Treatment with Atosiban (7.5mg/ml)
Initial Dose: IV bolus injection during 1 minute + Intravenous infusion 7.5 mg/ml during 3 hours.
Maintenance: Maintenance intravenous infusion 7.5 mg/ml at least 18 hours to a maximum of 45 hours.
Maximum Duration of the treatment: 48 hours."
1897728|NCT01314872|Drug|Vibegron|Participants received vibegron oral tablets at dosages of 3 mg, 15 mg, 50 mg, or 100 mg depending on their vibegron arm assignment, taken orally each morning.
1897729|NCT01314872|Drug|Tolterodine ER|Participants received one tolterodine ER 4 mg capsule, taken orally once a day.
1897730|NCT01314872|Drug|Placebo matching vibegron|Participants received placebo matching vibegron tablets, taken orally each morning.
1897731|NCT01314872|Drug|Placebo matching tolterodine ER|Participants received placebo matching tolterodine ER capsule, taken orally each morning.
1897732|NCT01314885|Drug|PF-03715455|20mg, Inhaled, single dose
1897733|NCT01314885|Drug|PH-797804|30mg, Oral, single dose
1897734|NCT01314885|Drug|Placebo for PF-03715455|Single dose, inhaled, Placebo for PF-03715455
1897736|NCT01314898|Drug|3 mg PF-03882845|3 mg PF-03882845, single oral dose
1897737|NCT01314898|Drug|10 mg PF-03882845|10 mg PF-03882845, single oral dose
1897738|NCT01314898|Drug|30 mg PF-03882845|30 mg PF-03882845, single oral dose
1897739|NCT01314898|Drug|100 mg PF-03882845|100 mg PF-03882845, single oral dose
1897740|NCT01314898|Drug|Spironolactone|100 mg spironolactone, single oral dose
1897743|NCT01314924|Dietary Supplement|Dark chocolate|70% cocoa
1897744|NCT01314937|Drug|Mebendazole|Single-dose 500 mg mebendazole tablet
1897745|NCT01314937|Other|Usual care|Routine child health interventions (e.g. age-specific immunizations, supplementations, etc.)
1897746|NCT01314950|Behavioral|Home based occupational therapy|"An occupational therapist (OT) will deliver the home-based intervention. There are three cycles of intervention over two years, with each cycle delivering eight 60-90 minute home sessions. Cycle one takes place over 16 weeks, cycle two over 32 weeks, and cycle three over one year. Telephone calls take place in intervening weeks, with additional phone calls allowed to assist with problem solving and interval problems. At minimum, the OT will perform an assessment at the beginning of each cycle in order to tailor the home based component for individual dyads at each cycle. The OT will collaborate with the patients and caregivers to develop client centered goals with homework each week in order to encourage carryover of strategies, home environmental modifications, or home exercise programs."
1897747|NCT01314950|Behavioral|Best practices primary care|Collaborative care is provided by an advanced practice nurse working in collaborations with a family caregiver, the primary care physician, and geriatric medicine specialists. Caregivers complete a formal assessment of problematic behaviors to assess current symptoms and stressors, and the care manager makes recommendations based on these results and using standardized protocols. Protocols focus first on non-pharmacologic interventions. If these interventions fail, the care manager collaborates with the primary care physician and/or specialists to institute protocol-based drug therapy or other strategies. Patients and caregivers are also offered access to support groups.
1897748|NCT01314963|Device|Handheld Gamma Camera|Hand-held, portable, intraoperative gamma camera
1897749|NCT01314976|Drug|Metronidazole|"Metronidazole, oral suspension, 40mg/ml.
1 treatment period of 40mg/kg/day for 10 days, 3 daily dosages. Administered by parents."
1897750|NCT01314976|Drug|Placebo|"Placebo.
1 treatment period of 1ml/kg/day for 10 days, 3 daily dosages. Administered by parents.
Placebo formulation is identical to Flagyl® (Metronidazole), oral suspension from Sanofi-Aventis."
1897751|NCT01314989|Drug|Cyproheptadine|0,25mg/kg/day orally in 2 doses per day (2mg/5 ml)for 1 month
1897752|NCT01314989|Drug|Sugar pill|liquid placebo
1897753|NCT01315002|Drug|Transdermal nicotine patch|7mg transdermal nicotine patch (non-smoking subjects) 14mg transdermal nicotine patch (smoking subjects)
1897754|NCT01315002|Drug|Placebo patch|Placebo patch
1897755|NCT01315015|Other|Contrast enhanced breast MRI|Gadolinium contrast is administered as a bolus with a standard dose of 0.1 mL/kg followed by a saline flush of 30 mL.
1897756|NCT01315028|Other|Cognitive Interpersonal Therapy|Cognitive Interpersonal Therapy in Early Bipolar Disorder: Individuals will receive up to six months of individual CIT-BP. CBT will emphasise assessment, engagement and formulation; normalizing and compassionate understanding; specific cognitive and behavioural strategies; self-management and social rhythm regulation; affect regulation, and staying well (Gumley & Schwannauer, 2006).
1897757|NCT01315028|Other|Treatment As Usual|The comparison group is treatment as usual (TAU). This will comprise of the individuals normal psychiatric care and will vary with individual and locality and is therefore not specified.
1897758|NCT01315041|Drug|Capsicum frutescens fruits, homeopathic medicine|5 drops, PO, 3 times a day, during 16 weeks
1897759|NCT01315041|Drug|Inert alcoholic solution|5 drops, PO, 3 times a day, during 16 weeks
1897760|NCT01315054|Behavioral|MMT provider dosage training|Training on methadone dosing provided to health care providers working in methadone maintenance clinics
1897761|NCT01315054|Behavioral|targeted counseling|targeted counseling provided to methadone maintenance clinic attendees
1897762|NCT01315054|Other|national guidelines|Provided a hard copy of the existing national guidelines for methadone dosing
1897763|NCT01315093|Drug|Heparin, Low-Molecular-Weight|Heparin from start till hcg test
1897764|NCT01315093|Drug|no heparin|
1897765|NCT01315106|Device|Magnetic Resonance Image Scanner|Magnetic Resonance Imaging; 1.5 Tesla or 3 Tesla MRI scanner
1897766|NCT01315119|Procedure|SPY Intra-Operative Angiography|Calculated per patient
1897768|NCT01315145|Procedure|Percutaneous Lumbar Decompression|The percutaneous procedure is performed under fluoroscopic guidance to effect a lumbar decompression with minimal surrounding tissue and bone disruption. The mild® Device Kit is utilized to access, capture and remove bone and tissue.
1897769|NCT01315145|Drug|Epidural Steroid Injection|Injection of epidural steroids into the lumbar spine
1897770|NCT01315158|Drug|Propofol Alone|"Recommended Propofol doses before considering crossover:
Induction: 2-2.5 mg/kg
Maintenance: 0.1-0.2 mg/kg/min"
1897771|NCT01315158|Drug|Propofol+Benzo/Opioids|"Recommended Versed:
a. Prior to intubation
patient is < 50 kg = 1 mg Versed
patient is 50-75 kg = 1.5 mg Versed
patient is > 75 kg = 2 mg Versed
Recommended Fentanyl
Prior to intubation = 0.5 ug/kg
Total procedural dose = 1 ug/kg"
1897772|NCT01315171|Dietary Supplement|Medium chain triglycerides|4 tablespoons/day for 2 weeks
1897773|NCT01315184|Behavioral|Recovery Line Support System|"Full time access (24 hours/7 days per week) to an automated, telephone-based, interactive, voice response (IVR)system for 4 weeks.
The program was developed based on a behavioral theory of substance abuse, and comprises four components: 1) self-assessment 2) learning about skills , 3) activities for current help and skills training, and 4) Feedback."
1897774|NCT01315197|Other|Massage|Massage Anmá: 7-8 sessions, twice per week, kneading and pressure points on the bladder meridian
1897775|NCT01315210|Drug|D-Ribose Powder|5 g TID for 12 Weeks
1897776|NCT01315210|Dietary Supplement|Placebo Powder|5 g TID for 12 Weeks
1897777|NCT01315223|Other|Lung impedence-guided treatment|One hundred fifty patients with CHF will be treated according to common practice and values of lung impedance
1897778|NCT01315236|Drug|Liposomal amikacin for inhalation (LAI)|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 84 days in the double-blind, randomized portion of the study.
Subjects can continue with 84 additional days of dosing in the open label extension."
1897779|NCT01315236|Drug|placebo|"Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time is the same as for Arikayce.
Placebo will be administered for 84 days only during the double-blind, randomized portion of the study."
1897780|NCT01315249|Drug|indacaterol and glycopyrronium (QVA149)|QVA149 capsules delivered via dry powder inhaler (SDDPI), once daily.
1897781|NCT01315249|Drug|Placebo to fluticasone/salmeterol|Placebo to fluticasone/salmeterol delivered via Accuhaler® device, twice daily.
1897782|NCT01315249|Drug|fluticasone/salmeterol|Fluticasone/salmeterol dry inhalation powder delivered via Accuhaler® device, twice daily.
1897783|NCT01315249|Drug|Placebo to indacaterol and glycopyrronium (QVA149)|Placebo to QVA149 delivered via dry powder inhaler (SDDPI), once daily
1897784|NCT01315262|Drug|Sildenafil|1:1 Viagra 100 mg daily (taken either at bedtime - if sexual intercourse is not expected - or 1 hour prior to sexual intercourse, no more than one 100 mg dose of sildenafil per day) vs. Viagra 100mg OD (i.e. one hour prior to sexual intercourse)
1897785|NCT01315275|Drug|Ranibizumab|
1897786|NCT01315288|Other|One of 6 video presentation by one of 4 presenters|
1897787|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated one week after starting rifampicin based short course anti tuberculosis treatment.
1897788|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated four weeks after starting rifampicin based short course anti tuberculosis treatment
1897789|NCT01315301|Other|Comparison of different treatment strategies|600 mg efavirenz based HAART initiated eight weeks after starting rifampicin based short course anti tuberculosis treatment.
1897790|NCT01315314|Drug|Balance, Fresenius Medical Care, Germany|low glucose degradation product (GDP)-containing peritoneal dialysis fluid (PDF)
1897791|NCT01315327|Drug|Omega-3 Fatty Acids|Omega-3 fatty acids (derived from fish oil)
1897792|NCT01315327|Drug|Olive oil|Placebo
1897793|NCT01315340|Procedure|Ocular rigidity, outflow facility and intraocular pressure measurement|The measurement procedure includes cannulation of the anterior chamber of the eye, under sterile conditions. Infusion of the eye with microvolumes of a saline solution is performed, followed by manometric measurement of intraocular pressure, in order to quantify ocular rigidity. Outflow facility is estimated from recordings of intraocular pressure after the infusion is stopped.
1897794|NCT01315353|Procedure|cervical cryotherapy|Participants will undergo cervical cryotherapy within 7 days after study entry. The cryotherapy consists of two 3-minute freezes separated by 5 minutes of thawing.
1897795|NCT01315353|Procedure|Loop Electrosurgical Excision Procedure (LEEP)|Participants found to have CIN2+ by biopsy at any point during the study will be offered LEEP, an electro-surgical procedure used to treat high-grade cervical dysplasia.
1897796|NCT01315366|Dietary Supplement|Euro D and Ci-CalD|Ci-Cal D (1000mg/day) and vitamin D (500IU/day) daily, plus a supplement of vitamin D3 (20,000 IU/wk) for one year.
1897797|NCT01315366|Dietary Supplement|Euro D, Ci-CalD|Ci-Cal D(1000mg/day) and vitamin D (500IU/day) Ci-CalD daily, plus a weekly placebo Euro D supplement for one year.
1897798|NCT01315379|Behavioral|Prolonged Exposure Therapy|This intervention comprises 12-18 sessions of cognitive behavior therapy for PTSD with the components (a) Psychological education, (b) in vivo exposure (c) prolonged imaginal exposure, (d) cognitive restructuring (e) summary and relapse prevention.
1897799|NCT01315392|Procedure|delayed closure|wounds packed open with normal saline wet to dry gauze dressings and were returned to the operating room 36 to 72 hours after initial procedure for a second debridement and definitive closure.
1897800|NCT01315392|Procedure|immediate wound closure|traumatic and surgical wounds closed at the initial surgical intervention
1897801|NCT01315405|Behavioral|Emotional facial expression recognition tests|"20 patients with an Idiopathic Parkinson's disease
+ 20 paired healthy volunteers (on sex, age, and education)
After inclusion, patients are evaluated two times: they are studied without medication (MED OFF) and with medication (STIM ON) in a randomized order. The 2 evaluations should be spaced out 15 days to one month (J0 and J+15d)
Healthy subjects have only one visit J0 (inclusion and emotional facial expression recognition tests are made at the same time)"
1897802|NCT01315418|Other|1-Fermented dairy product containing the probiotic Lactobacillus casei DN-114 001 (Actimel®)|
1897803|NCT01315418|Other|2-Non fermented dairy product (control)|
1897804|NCT01315431|Drug|Tesetaxel plus capecitabine|"Study medication, which will include tesetaxel capsules and capecitabine tablets, will be administered orally for two 21-day cycles. In each cycle, tesetaxel will be administered at a dose of 27 mg/m2 on Day 1, and capecitabine will be administered in Cohort 1 at a dose of 2000 mg/m2/day and in Cohort 2 at a dose of 1750 mg/m2/day (in 2 equally divided doses) on Day 1 through Day 14.
At the conclusion of Cycle 2, patients who, in the opinion of the investigator, appear to have benefitted from protocol therapy may receive up to 6 additional cycles under a separate protocol."
1897805|NCT01315444|Drug|Stop PPI gradually|
1897806|NCT01315444|Drug|Stop PPI gradually|
1897807|NCT01315470|Drug|neupogen administration for women with recurrent IVF failure|neupogen 300 mcg - twice
1897836|NCT01315847|Drug|[11C]MK-4232|Single intravenous doses of ~300 MBq [11C]MK-4232 administered as a 5 minute infusion (Part I - Baseline, Period 1 and 2; Part III - Period 1 Baseline and Period 1, and Period 2 Baseline and Period 2)
1897837|NCT01315860|Other|Postural Analysis|Measure the subject's weight, sway rate and shift of center of gravity on a postural scale for 15 seconds. Measure lumbosacral angle with an inclinometer.
1897997|NCT01318720|Other|Manual Therapy|Thrust manipulation is a type of manual therapy that clinicians apply using a high-velocity, low-amplitude thrust directed at a joint(s)
1897808|NCT01315483|Other|Weight Loss Dietary Pattern|Diet-physical activity program creating a weekly negative energy balance equivalent to 3500 kcal. Intervention groups receive PA protocol promoting the Physical Activity Guidelines and translated in step recommendations, but one of two diets with divergent dietary patterns (opposing fat and CHO content) that do not overlap >+5% in CHO and fat content. Macronutrient values reflect a 'pattern' or ratio within (LC 3:2 ratio for F:CHO; HC 1:4 ratio for F:CHO ) and between diets (LC:HC 3:1 for fat; LC:HC 1:2 for CHO). Six-week meal plans for five calorie levels available and incorporate educational material, supporting program components (e.g. self monitoring tools) and core competencies reinforcing weight loss behaviors in order to promote high levels of dietary adherence.
1897809|NCT01315496|Drug|Immunoglobulin G|Immunoglobulin 1.5-2g/Kg/3days
1897810|NCT01315522|Device|ComVi stent|Endoscopic insertion of ComVi stent
1897811|NCT01315522|Device|Uncovered SEMS|Endoscopic insertion of uncovered SEMS
1897812|NCT01315561|Other|acupuncture, injection|MSAT and intramuscular injections of diclofenac(NSAID)
1897813|NCT01315574|Drug|Travoprost|One drop Travatan Z (0.004% ophthalmic solution) in affected eye once daily.
1897814|NCT01315574|Drug|Latanoprost|One drop Xalatan (0.005% ophthalmic solution) in affected eye once daily.
1897815|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation (Magstim rapid2 )|"3 pulses at 50Hz repeated each 200 ms for 2 seconds
80% MT
20 days treatment"
1897816|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation (Magstim rapid2)|LDLPFC 110% MT 15 Hz 20 days
1897817|NCT01315587|Device|repetitive Transcranial Magnetic Stimulation(Magstim rapid2)|Placebo treatment: Sham coil
1897818|NCT01315626|Other|Primary Care Educational event|The purpose of this study is to assess the accuracy of primary care physicians in diagnosing BE and evaluate the impact of an educational intervention targeting those primary care physicians and providing instruction in the recognition and treatment of BE. The hope is that a better understanding of the disease will result in more accurate diagnoses and ultimately in more appropriate care for these patients. In addition to better care for patients, earlier recognition of bronchiectasis may result in a decrease in health care costs.
1897819|NCT01315639|Biological|biomarkers, MRI and CSF|MRI at Day 0 and month 24 (or conversion) Biomarkers at Day 0 et month 24 (or conversion) CSF at D0
1897820|NCT01315652|Behavioral|Comorbidities treatment|" Comorbidities treatment:Number of actions initiated in order to treat or prevent Rheumatoid Arthritis comorbidities during the 6 months follow-up"
1897821|NCT01315652|Behavioral|Auto-DAS|"Auto-DASNumber of patients with a modification in their treatment between baseline and 6 months visits"
1897822|NCT01315665|Dietary Supplement|Broccoli sprouts|Subjects (both healthy volunteers and subjects with cystic fibrosis) will consume 100 gm of raw broccoli sprouts once daily for 5 consecutive days.
1897823|NCT01315678|Drug|Liposomal amikacin for inhalation (Arikayce) using the PARI Investigational eFlow® Nebulizer.|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
1897824|NCT01315678|Drug|Tobramycin inhalation solution using a PARI LC® Plus nebulizer.|"300 mg tobramycin inhalation solution is administered twice a day using a PARI LC® Plus nebulizer.
Nebulization time is approximately 20 minutes for each administration.
Tobramycin inhalation solution will be administered for 3 cycles where each cycle consists of 28 days on-treatment followed by 28 days off-treatment"
1897825|NCT01315691|Drug|Liposomal amikacin for inhalation|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered for 28 days followed by 56 days off treatment."
1897826|NCT01315691|Drug|Placebo for liposomal amikacin for inhalation|"Placebo is provided as a sterile aqueous lipid dispersion for inhalation via nebulization.
Administration procedures, volume and administration time are the same as for Arikace™.
Placebo will be administered for 28 days."
1897827|NCT01315704|Drug|Drug intervention|before-after interventional (anti-dementia drugs and/or vitamin D) study
1897828|NCT01315730|Device|Tactile Stimulation|See Arms
1897829|NCT01315743|Behavioral|Team COOL|1) a classroom-based experiential curriculum that incorporated school, family and community-linked activities to promote physical activity, healthy eating and limited television viewing, 2) environmental modifications of food and beverage offerings and physical activity opportunities at school and 3) a teacher-guided, youth-directed health advisory council to promote and support physical activity, healthy eating and limited television viewing.
1897830|NCT01315756|Device|Use of Few Touch Application (FTA)|"The users will receive a Smartphone with the diabetes diary application (the Few Touch application), a self-help tool that consists of five main elements accessible to the user. The five elements are the food habits registration, blood glucose data management system, physical activity registration, personal goals setting and general information. While blood glucose data is automatically transferred to the phone from the blood glucose meter when the user has performed a measurement, activity data and food habits have to be entered manually by the user."
1897831|NCT01315756|Device|Use of FTA and health counseling based on TTM and CBT|The users will additionally receive health counseling based on TTM and CBT by a diabetes nurse with individualized feedback via SMS from the diabetes nurse which is based on the patient's initiative (via SMS). In addition, the diabetes nurse will call the patients three times during this period and discuss progress. Both the SMS-messages and the calls will be based on CBT according to the TTM-level. The intervention allows information to be given both in an individualized and tailored manner for each particular patient by the nurse, but also in a general way via SMS. The patients need to understand the relationship between areas such as glucose levels, diet, exercises and medicine, in the context of their own lifestyle needs.
1897832|NCT01315795|Drug|Lanreotide Autogel 90 mg and 120 mg|administration of lanreotide sc every 4 weeks (28 days)
1897833|NCT01315821|Drug|Saccharomyces boulardii|5 million units/day for 3 months
1897834|NCT01315821|Drug|Placebo|Placebo for 3 months
1897835|NCT01315847|Drug|telcagepant|Single oral doses of telcagepant 1120 mg (Part I - Period 1) and 140 mg (Part I - Period 2; Part III - Period 1 and 2)
1897840|NCT01315886|Drug|SL fentanyl|SL fentanyl will be administered during 7- 15 BTcP episodes during a maximum period of 21 days, following a baseline period with standard BTcP treatment. The start dose of SL fentanyl is selected individually according to a standardized conversion ratio. The maximum start dose is limited to 400 μg. For a single BTcP episode no more than two (2) tablets or a maximum dose of 800 μg should be given.
1897841|NCT01315899|Drug|ORM-12471 30mg|Given as a single dose once during the crossover study as per Williams design
1897842|NCT01315899|Drug|ORM-12471|Given as a single dose once during the study as per Williams crossover design
1897843|NCT01315899|Drug|placebo|Given once as a single dose during the study as per Williams crossover design
1897844|NCT01315912|Drug|Letrozole|2.5 mg /day for 5 days
1897845|NCT01315938|Drug|Abatacept|abatacept will be given as intravenous infusions at time 0 then after, 2, 4, 8, 12, 16 and 20 weeks.
1897846|NCT01315938|Drug|Abatacept|Subjects will be treated with abatacept for 6 months and receive a total of up to 7 doses (intravenous infusions) the infusions will be given with the following intervals: at time 0 then after, 2, 4, 8, 12, 16 and 20 weeks.
1897847|NCT01315951|Biological|Petroleum Jelly|Every patient will be instructed to wet the affected area, blot dry, and then apply petroleum jelly to the area before bedtime. This regimen is to be followed every other night until symptoms diminish. The patient should follow-up at one week, two weeks, and four weeks after treatment begins to see the outcome.
1897848|NCT01315964|Dietary Supplement|plant stanol ester|3 gr of plant stanol esters per day in a margarine product as part of daily diet for a period of 6 months
1897849|NCT01315977|Dietary Supplement|Green tea|Each subject will take either green tea (2%w/v), or water, twice a day for twelve weeks, then wash out for twelve weeks and swap onto the other treatment (either green tea of water) for another twelve weeks in addition to their normal food and beverage intake
1897850|NCT01315990|Drug|FOLFIRI + Cetuximab|"Cetuximab (Erbitux® )- Cetuximab is a recombinant IgG1 chimeric monoclonal antibody directed against human epidermal growth factor receptor (EGFR).
FOLFIRI regimen
Administration Schedule:
Cetuximab at a initial dose 400 mg/sqm (first week), then 250 mg/sqm on day 1 and 8 Background Chemotherapy (every two weeks)
Irinotecan 180 mg/m² iv , 90 min on day 1
Folic acid (racemic) 400 mg/m², 120 min on day 1
5-FU 400 mg/m² bolus on day 1
5-FU 2400 mg/m² iv over 46 h on day 1 to 2"
1897851|NCT01316003|Other|Optical coherence tomography|Optical coherence tomography
1897852|NCT01316016|Dietary Supplement|Rose hip|40 g of rose hip powder daily for 6 weeks.
1897853|NCT01316029|Procedure|Okada Purifying Therapy|Each participant received a single session of Okada Purifying Therapy lasting 30 minutes or longer, administered by a voluntary certified practitioner.
1897854|NCT01316042|Drug|sugar pill|2 pills per day for 12 months
1897855|NCT01316042|Drug|Metformin, glucophage|2 212.5mg pills/day for 12 months
1897856|NCT01316055|Drug|Dalfampridine-ER|2 days of single dose 7.5 mg, 4 days of bid dosing, and a 3 day follow-up
1897857|NCT01316068|Drug|intravenous use of sulodexide followed by oral use|Patients will be given sulodexide 1200 LSU per day intravenously for 2 weeks,then receive 1000 LSU per day orally for 50 weeks.
1897858|NCT01316068|Drug|use of sulodexide orally only|Patients receive 1000 LSU per day orally for 52 weeks
1897859|NCT01316081|Dietary Supplement|Vitamin C Vitamin E Selenvital all from Burgerstein Vitamine|"Vitamin C: 500mg Vitamin E: 400 I.U. Selenium: 50mcg
Placebo Supplements: identical appearing tablets"
1897860|NCT01309048|Device|Philips MR-guided HIFU system|HIFU is the use of focused ultrasound energy to penetrate through soft tissue and causes localized high temperatures (55°C to 70°C) for a few seconds within the target producing well defined regions of protein and nerve denaturation, irreversible cell damage, and coagulative necrosis.
1897861|NCT01309061|Procedure|Autologous Adipose Tissue derived MSCs Transplantation|Intramuscular infusion of Autologous Adipose Tissue derived MSCs with autologous microlipoinjection. Dose: 1x10e7 cells/500ul/lipoinjection 20ml
1897862|NCT01309074|Drug|Pregabalin-Lyrica|Pregabalin in a dose up to 300mg/day in BID dosing.
1897863|NCT01309074|Drug|Sertraline|Sertraline in a dose up to 200mg/day in BID dosing.
1897864|NCT01309100|Device|Investigational Lens|Bausch & Lomb investigational silicone hydrogel lens on a daily wear basis for 1 week.
1897865|NCT01309100|Device|Acuvue Oasys Lens|Johnson & Johnson Acuvue Oasys contact lens on a daily wear basis for 1 week.
1897866|NCT01309100|Device|Air Optix Aqua Lens|Ciba Vision Air Optix Aqua contact lens on a daily wear basis for 1 week.
1897868|NCT01309126|Biological|Imprime PGG + cetuximab|Imprime PGG: 4 mg/kg and will be administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36) preceding the administration of cetuximab Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
1897869|NCT01309126|Drug|Cetuximab|Cetuximab: initial dose will be 400 mg/m2 on Cycle 1/Day 1 and subsequent doses will be 250 mg/m2, administered weekly in each cycle (Weeks 1-6/Days 1, 8, 15, 22, 29, and 36)
1897870|NCT01309139|Drug|Tiotropium|Medium dose of oral inhalation
1897871|NCT01309139|Drug|Tiotropium|Medium dose of oral inhalation
1897872|NCT01309139|Drug|BI 54903|Medium dose of oral inhalation
1897873|NCT01309139|Drug|BI 54903|Medium dose of oral inhalation
1897909|NCT01309438|Drug|Rivaroxaban (normal renal function)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2
1898080|NCT01319526|Genetic|RNA analysis|
1960908|NCT03068858|Diagnostic Test|real-time feedback of SYNTAX score category|
1897876|NCT01309178|Drug|Amitriptyline|2 x 12,5 mg capsules for oral use in the first two weeks, the higher dose of 50 mg (2 x 25 mg) will be adapted after 2 weeks of treatment.
1897877|NCT01309178|Drug|Mannite|Mannit capsules daily in two doses (2 x 12,5 mg). After 2 weeks of treatment the higher dose of 50 mg (2 x 25 mg) will be given
1897878|NCT01309191|Drug|Minoxidil|Over the counter Rogaine, twice a day for 8 weeks
1897879|NCT01309191|Other|Placebo|
1897880|NCT01309204|Drug|Brinzolamide 1%/brimonidine tartrate 0.2% fixed combination ophthalmic suspension|
1897881|NCT01309204|Drug|Vehicle|Inactive ingredients used as a placebo for masking purposes
1897882|NCT01309204|Drug|Brinzolamide 1% ophthalmic suspension|
1897883|NCT01309204|Drug|Brimonidine tartrate 0.2% ophthalmic solution|
1897884|NCT01309217|Behavioral|Tobacco Tactics Intervention|"At the intervention sites the research nurse will teach the Tobacco Tactics Intervention to nurses. For nurses, the Cessation Toolkit includes: 1) 1 CEU contact hour for training; 2) PowerPoint presentation on behavioral and pharmaceutical interventions; 3) pocket card Helping Smokers Quit: A Guide for Clinicians developed by U.S. Department of Health and Human Services, Public Health Service; 4) behavioral and pharmaceutical protocols; and 5) computerized template for nurse documentation. For patients, the Cessation Toolkit includes: 1) brochure; 2) videotape; 3); and 4) pharmaceuticals."
1897885|NCT01309217|Other|Usual Care|The comparison group will receive usual care in accordance to how the hospital responds to current Joint Commission on Accreditation of Healthcare Organization's (JC) standards. JC standards require that a patient with a smoking history receives at least one of the following: advice to stop smoking, brochures or handouts on smoking cessation, a smoking cessation aid such as nicotine patch, gum, nasal spray, inhaler, lozenge, or bupropion SR, viewed a smoking cessation video.
1897886|NCT01309230|Biological|Vigil™|intradermal autologous Vigil™ (1.0 x 10^7 cells/injection; maximum of 12 vaccinations)
1897887|NCT01309243|Drug|FTC/RPV/TDF|Emtricitabine (FTC) 200 mg/rilpivirine (RPV) 25 mg/tenofovir disoproxil fumarate (TDF) 300 mg single-tablet regimen administered orally once daily with a meal
1897888|NCT01309243|Drug|EFV/FTC/TDF|Efavirenz (EFV) 600 mg/FTC 200 mg/TDF 300 mg single-tablet regimen administered orally once daily on an empty stomach, preferably at bedtime
1897889|NCT01309308|Procedure|sweeping the membranes|The cervical length will be measured and the patient will be examined to determine the Bishop score. Later the the membranes will be swept.
1897890|NCT01309308|Other|No sweeping group|Cervical length will be measured by transvaginal USG and the patient will be examined to determine the Bishop score.
1897891|NCT01309321|Behavioral|Perinatal Handwashing Promotion|Pregnancy may serve as a unique opportunity to improve maternal handwashing behavior more deeply and sustainably than a handwashing promotion intervention at a different time. Primiparous women will receive an intensive handwashing promotion program delivered at 3 in-home visits between one month prenatal and 1 week post natal. The program will promote handwashing benefits, provide hardware to reduce barriers to handwashing, and educate mothers about the critical times for handwashing. Mothers will also receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
1897892|NCT01309321|Behavioral|Neonatal Health Promotion|Mothers will receive an essential neonatal care package with information on clean delivery, hypothermia prevention, breastfeeding counseling, umbilical cord care, and identification of neonatal danger signs.
1897893|NCT01309334|Procedure|PET scan|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
1897894|NCT01309334|Procedure|MRI|Performed at diagnosis, after 3 cycles of induction therapy, and at completion of therapy
1897895|NCT01309360|Drug|midazolam|Prior to performing the regional anesthesia the investigators administered midazolam as a premedication by mouth (3,75-7,5mg) or intravenously (2-3mg).
1897896|NCT01309360|Drug|prilocaine 1%|40 outpatients : 40ml prilocaine 1% were administered for axillary plexus block
1897897|NCT01309360|Drug|prilocaine 1%|40 outpatients : 30ml prilocaine 1% were administered for axillary plexus block
1897898|NCT01309360|Drug|prilocaine 1%|40 outpatients : 20ml prilocaine 1% were administered for axillary plexus block
1897899|NCT01309373|Other|Patient assessment|2 scales will be used to assesss the remission of schizophrenia (APA scale and PSRS scale). The BPRS scale will be used to assess the clinical integration of patients.
1897900|NCT01309386|Drug|Tapentadol ER|Tapentadol ER 100 to 400 milligram (mg) orally daily for 8 weeks (maximum up to 500 mg daily), as per Investigator's discretion.
1897901|NCT01309386|Drug|Morphine SR|Morphine SR 30 to 120 mg orally daily for 8 weeks (maximum up to 140 mg daily), as per Investigator's discretion.
1897904|NCT01309412|Drug|Siltuximab|5.5 or 11.0 mg/kg by intravenous infusion over 1 hour on Day 1 of each 21-day cycle until progression
1897905|NCT01309425|Drug|tapentadol (CG5503) ER two 100-mg TRF|200mg TRF single oral dose
1897906|NCT01309425|Drug|tapentadol (CG5503) ER 50-mg TRF|50mg TRF single oral dose
1897907|NCT01309425|Drug|tapentadol (CG5503) ER 25-mg TRF|25mg TRF single oral dose
1897908|NCT01309425|Drug|tapentadol (CG5503) ER 100-mg TRF|100mg TRF single oral dose
1897996|NCT01318694|Drug|ALV Placebo|ALV placebo soft gel capsules administered orally
1960911|NCT03067623|Drug|PRP|PRP intrauterine infusion
1960912|NCT03067623|Device|Tomcat catheter|PRP intrauterine infusion by means Tomcat catheter
1897910|NCT01309438|Drug|Rivaroxaban (mild and moderate renal impairment)|One 10 mg tablet of rivaroxaban taken orally (by mouth) on Day 1 of Treatment Period 1; One 5 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 2; One 10 mg tablet of rivaroxaban taken orally on Day 5 of Treatment Period 3
1897911|NCT01309438|Drug|Erythromycin (normal renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Period 2
1897912|NCT01309438|Drug|Erythromycin (mild and moderate renal function)|One 500 mg tablet taken orally (by mouth) three times daily on Days 1 to 6 of Treatment Periods 2 and 3
1897913|NCT01309451|Drug|Bevacizumab|intravitreal, 1.25mg., monthly
1897914|NCT01309451|Drug|dexamethasone intravitreal implant|0.7mg, intravitreal every 4 months
1897915|NCT01309477|Drug|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, then adjusting the dose to maintain the blood level 5-10ng/ml in the induction treatment .
1897916|NCT01309490|Drug|Ribavirin|Dose Level: 1 1400 mg po BID Dose Level: 2 1800 mg po BID Dose Level: 3 2200 mg po BID Dose Level: 4 2600 mg po BID Dose Level: 5 3000 mg po BID
1897917|NCT01309516|Behavioral|Complex Intervention|This 12 session Multimodal Psychosocial Intervention will include a supportive component, an educational component, psychosocial component and a parenting programme.
1897918|NCT01309542|Drug|Desvenlafaxine Succinate|Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months
1897919|NCT01316094|Drug|ASP1941|oral
1897920|NCT01316094|Drug|placebo|oral
1897921|NCT01316107|Drug|ASP1941|oral
1897922|NCT01316107|Drug|nateglinide|oral
1897923|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
1897924|NCT01316120|Other|Compare different self-obtained specimen for HPV identification|Instructions will be given to the patients by a research nurse and ICF will be obtained. For specimen collection, participants will be instructed to wash their hands before the procedure. Each participant will receive a package containing a specimen collection kit. Recommendations will be to hold the swab by the end of the handle, to insert the swab into the vagina avoiding contact with the external genitalia, rotate 1 round and to replace the swab in a plastic sleeve (v-DRY) or in a tube containing specimen transport medium (v-STM),.
1897925|NCT01316133|Drug|tacrolimus|oral
1897926|NCT01316146|Drug|CAR.CD30 T cells|"Three dose levels will be evaluated:
Group One, 2x10^7 cells/m^2
Group Two, 1x10^8 cells/m^2
Group Three, 2x10^8 cells/m^2;
Cell Administration: CAR+ ATL will be given by intravenous injection over 1-10 minutes through either a peripheral or a central line. The expected volume will be 1-50cc."
1897927|NCT01316172|Behavioral|5 Cs|education on consultation
1897928|NCT01316185|Drug|EBP921|Patients randomized to receive low or high dose. All dosing of EBP921 should be taken with food.
1897929|NCT01316198|Dietary Supplement|Verum|10 subjects consume for 4 weeks a beverage containing 10 mg lutein and 3 mg zeaxanthin per day
1897930|NCT01316198|Dietary Supplement|Placebo|10 subjects consume for 4 weeks a placebo beverage without any lutein and zeaxanthin
1897931|NCT01316211|Device|Implantation of coflex™ after surgical decompression|The device will be implanted after surgical decompression in patients with spinal stenosis.
1897932|NCT01316211|Procedure|Surgical decompression|Surgical decompression in patients with spinal stenosis without stabilization by an additional implant
1897933|NCT01316237|Drug|GS-6620|GS-6620 tablet, 50 mg QD
1897934|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD
1897935|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD
1897936|NCT01316237|Drug|GS-6620|GS-6620 tablet, 100 mg QD, Fasted
1897937|NCT01316237|Drug|GS-6620|GS-6620 tablet, 300 mg QD, Fasted
1897938|NCT01316237|Drug|GS-6620|GS-6620 tablet, 900 mg QD, Fasted
1897939|NCT01316237|Drug|GS-6620 tablet, 450 mg BID|GS-6620 tablet, 450 mg BID
1897940|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900mg , BID
1897941|NCT01316237|Drug|GS-6620 tablet|GS-6620 tablet, 900 mg
1897942|NCT01316250|Drug|Nilotinib|Nilotinib 300 mg orally twice per day for 12 months followed by imatinib mesylate at a dose of 400 mg orally daily
1897943|NCT01316263|Biological|Olaratumab|Administered IV
1897944|NCT01316276|Drug|Liposomal amikacin for inhalation|"Liposomal amikacin for inhalation is provided as a sterile aqueous liposomal dispersion for inhalation via nebulization.
590 mg of liposomal amikacin for inhalation is administered once daily using the PARI Investigational eFlow® Nebulizer.
Administration time is approximately 13 minutes.
Liposomal amikacin for inhalation will be administered in two consecutive extension periods, each consisting of 6 cycles for a total of 12 cycles. Each cycle consists of 28 days on-treatment followed by 28 days off-treatment."
1897945|NCT01316302|Drug|Pristiq|Flexible dose, 50-100mg QD, for 12 weeks.
1897946|NCT01316302|Drug|Placebo|Matching placebo, taken QD for 12 weeks.
1897947|NCT01316315|Drug|Active|A 5 mg single dose given intravenously via syringe pump over 1 minute.
1897948|NCT01316315|Drug|Placebo|Same as active
1897949|NCT01316341|Drug|BI10773|patient to receive a tablet containing high dose BI10773 p.o. plus one placebo
1897950|NCT01316341|Drug|Placebo|patient to receive two placebos
1897951|NCT01316341|Drug|Placebo|patient to receive two placebos
1897952|NCT01316341|Drug|Placebo|patient to receive two placebos
1897953|NCT01316341|Drug|BI10773|patient to receive a tablet containing low dose BI10773 p.o. plus one placebo
1897954|NCT01316354|Other|Bread types|Bread with 50 g available carbohydrate
1897955|NCT01316367|Behavioral|PRECEDE HPE model|"The model considers the influence of the following three factors on health-related behavior:
Predisposing: factors influencing the patient's motivation to undertake the behavior to be analyzed or encouraged.
Facilitators: factors influencing the level of easiness or difficulty the patient and his/her family have in undertaking a given behavior.
Reinforcing: factors arising after the patient has undertaken the behavior, and which reward or punish it."
1897956|NCT01316367|Behavioral|CHPE|The CHPE model was defined according to the recommendations of the Spanish Ministry of Health National Conference on Diabetes Mellitus, which was complemented by criteria for good care of the Madrid Primary Healthcare Service for the promotion of healthy lifestyles among adults (2004-2007). The model is based on the following aspects: self-monitoring of glycaemic control, physical exercise, diet, weight management, and times of the day when the patient was most vulnerable to overeating, and given improved understanding of the relative effects of certain food choices on blood glucose control, medication adherence and smoking cessation.
1897957|NCT01316380|Drug|placebo|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
1897958|NCT01316380|Drug|tiotropium 2.5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
1897959|NCT01316380|Drug|tiotropium 5 mcg|To evaluate efficacy and safety of 2.5 and 5 mcg tiotropium versus placebo delivered via Respimat inhaler
1897960|NCT01316393|Other|XER2020|mucoprotective product
1897961|NCT01316406|Drug|ATH008|The subject will be incorporated in the study and randomised to ATH008 cream 3% or 8% or ATH008 cream placebo
1897962|NCT01316419|Drug|Telmisartan|Telmisartan 40mg or 80mg
1897963|NCT01316419|Drug|amlodipine|amlodipine 5mg or 10mg
1897964|NCT01318460|Drug|Levosimendan infusion|Prophylactic 24h infusion of levosimendan at a dose of 0.1 mg/kg/min
1897965|NCT01318460|Drug|Placebo infusion|Twenty-four hour administration of placebo
1897966|NCT01318473|Device|ActiSight™ Needle Guidance System|ActiSight™ Needle Guidance System is comprised of several sub-system components: a computer, a disposable ActiSensor optical sensor, and the disposable ActiSticker, which provides a reference for the insertion of the tool and for the camera.
1897967|NCT01318486|Other|Heparin free dialysis technique|Saline flushes or predilution
1897968|NCT01318486|Device|Evodial|Evodial dialyer
1897969|NCT01318499|Drug|Nepafenac Ophthalmic Suspension, 0.3%|Nepafenac Ophthalmic Suspension, 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
1897970|NCT01318499|Drug|Nepafenac Ophthalmic Suspension, 0.1%|Nepafenac Ophthalmic Suspension, 0.1%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
1897971|NCT01318499|Other|Nepafenac Vehicle 0.3%|Nepafenac Vehicle 0.3%, one drop in affected eye once daily, for 16 days. An additional drop was administered between 30-120 minutes prior to surgery.
1897972|NCT01318525|Drug|ALF-5755|10 mg (25 ml) given in slow intravenous infusion over 10 minutes with an automatic syringe
1897973|NCT01318525|Drug|Saline solution (0.9% NaCl)|25 ml given in slow intravenous infusion over 10 minutes with an automatic syringe
1897974|NCT01318538|Behavioral|The Women's Recovery Group|The Women's Recovery Group (WRG) is a manual-based group therapy for women heterogeneous with respect to their substance use disorder, co-occurring psychiatric disorders, trauma history, age, and stage of life. The WRG is a 12-session, structured relapse-prevention group therapy that utilizes a cognitive behavioral approach and includes gender-specific content and single-gender group composition. Individual session content was derived from research on gender-specific substance use disorder antecedents, consequences, and treatment outcomes. The overall goals of the treatment are to (1) promote abstinence from all substances including alcohol; (2) improve understanding of specific aspects of SUDs, recovery, and relapse that are relevant to women, and (3) help participants with skills and strategies useful in preventing relapse and promoting recovery.
1897975|NCT01318538|Behavioral|Group Drug Counseling|Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances including alcohol; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
1897976|NCT01318551|Drug|BAY85-3934|single dose, 20 mg
1897977|NCT01318551|Drug|BAY85-3934|single dose, 40 mg (optional)
1897978|NCT01318551|Drug|BAY85-3934|single dose, 80 mg (optional)
1897979|NCT01318564|Drug|Metformin|500 - 1000 mg by mouth twice a day with either via a MEMS device pill bottle (medication event monitoring system) or by unit-dosing (blister packaging) with attached Med-ic device (electronic compliance monitoring for blistered medication).
1897980|NCT01318564|Behavioral|Questionnaires|Completion on Day 1 and after Month 3. Each questionnaire to take about 30 minutes to complete.
1897981|NCT01318590|Drug|Bupivacaine & Triamcinolone Acetonide|EUS procedure with injection of 10 ml Bupivacaine 0.5% and 40 mg of Triamcinolone in the celiac plexus after administration of intravenous (IV) antibioprophylaxis
1897982|NCT01318590|Other|No intervention except EUS procedure|EUS procedure without any drug injection
1897983|NCT01318616|Other|Strength training of the hip adductors|Adductor strength training
1897984|NCT01318642|Drug|Gemcitabine|Gemcitabine on days 1, 8, and 15, followed by placebo on days 1 and 15 of every 28 day cycle.
1897985|NCT01318642|Drug|AMG 479|Gemcitabine on days 1, 8, and 15, followed by AMG 479 20 mg/kg on days 1 and 15 of every 28 day cycle.
1897986|NCT01318642|Drug|Placebo|Gemcitabine on Days 1, 8, and 15 followed by Placebo 20 mg/kg on days 1 and 15 of every 28 day cycle
1897987|NCT01318655|Drug|NKTR-118|Tablet, Oral, Once daily
1897988|NCT01318655|Drug|Placebo|Tablet, Oral, Once daily
1897989|NCT01318668|Biological|vaccination with Nicvax|5 vaccinations of NicVax 400ug (1 ml) over a 18 week period or matching placebo.
1897990|NCT01318681|Drug|cetirizine 10 mg|cetirizine 10 mg over encapsulated
1897991|NCT01318681|Drug|fluticasone furoate|nasal spray 25ug per dose
1897992|NCT01318681|Drug|placebo|a placebo nasal spray and placebo capsule are available for double dummy treatment
1897993|NCT01318694|Drug|Alisporivir|ALV 200 mg soft gel capsules administered orally
1897994|NCT01318694|Drug|Peginterferon alfa-2a|PEG 180 μg administered via subcutaneous (s.c.) injection once weekly
1897995|NCT01318694|Drug|Ribavirin|RBV 200 mg tablets (weight-based dose: < 75 mg = 1000 mg/day; ≥ 75 kg = 1200 mg/day) administered orally in a divided daily dose
1897998|NCT01318733|Drug|CD07805/47 gel 0.5%|In this open-label study, all subjects will receive treatment with CD07805/47 gel 0.5% applied once daily, for up to 12 months.
1897999|NCT01318746|Procedure|Blood withdrawal|blood withdrawal every 2 hours during 24 hours
1898000|NCT01318772|Device|Radiography and Fluoroscopy Imaging System|"KALARE (DREX-KL80) is a new high resolution digital system designed for digital spot imaging, with the primary goal to address R/F and DSA clinical applications and produce images in a digital format.
The system includes a new digital camera and a new image processor."
1898001|NCT01318785|Other|Compression Armsleeves|"Type: Compression Class II (according to RAL)
The study is designed in a way, that per product after a one weak resting (preparing) cycle a 2 weeks wearing period will follow. Herewith the whole duration of the study is 6 weeks per patient."
1898002|NCT01318811|Drug|Dilute unfractionated heparin|Patients in the dilute heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started. Heparin will be delivered as a solution of 2 units/mL and the infusion will be prepared with 2,000 units of heparin in 1,000 mL of 0.9% NaCl and delivered intravenously proximal to the dialysis filter.
1898003|NCT01318811|Drug|Standard concentration unfractionated heparin|Patients in the standard heparin arm will receive a systemic loading dose of heparin of 15 units per kilogram of weight by rapid intravenous bolus. Then a maintenance rate of heparin of 7.5 U/Kg per hour will be started and delivered in a standard concentration intravenously proximal to the dialysis filter via a syringe. The concentration of heparin used will be 1,000 units of heparin per 1 mL of 0.9% NaCl.
1898004|NCT01318824|Procedure|Nasal Intermittent Positive Pressure Ventilation (NIPPV)|The Control group receiving Nasal Intermittent Positive Pressure Ventilation (NIPPV) treatment
1898005|NCT01318824|Procedure|Bi-Level Positive Airway Pressure (BIPAP)|BiPAP group receive Bi-Level Positive Airway Pressure (BIPAP) treatment
1898006|NCT01318837|Drug|solifenacin|oral
1898007|NCT01318850|Behavioral|Cognitive Remediation Therapy|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes paper and pencil tasks. The main technique utilized is the scaffolding (to provide strategies when the patient cannot carry out the task and to withdraw him when he is yet able of doing it alone) in a context of learning without errors.
1898008|NCT01318850|Behavioral|Psychoeducation|The program has a duration of 40 sessions (one hour of duration), with two sessions for week during four months. It is carried out individually and utilizes teaching information and coping skills and neuropsychological issues are not addressed.
1898009|NCT01318850|Other|Healthy controls|No intervention
1898010|NCT01318889|Drug|Dexpanthenol|5% dexpanthenol Mouth wash , three times a day, 10 cc each time
1898011|NCT01318902|Drug|MLN9708|Patients will receive escalating doses of MLN9708 orally on Days 1, 8 and 15 of a 28-day cycle. If there is no hematologic response after completion of 3 cycles, dexamethasone will be added on Days 1 to 4 of every cycle beginning with Cycle 4. If there is no hematologic response after the completion of 6 cycles, patients will discontinue therapy.
1898012|NCT01318915|Drug|ATG|1.5 mg/kg IV infusion on day of transplant, and 3 additional on days 2 through 7 after transplant.
1898013|NCT01318915|Drug|Rituximab|375 mg/m^2 IV infusion on day -6 before transplant and on day 1 after transplant.
1898014|NCT01318915|Drug|Tacrolimus|Taken orally. Tacrolimus dose adjusted to maintain target blood levels of 6-10 ng/mL.
1898015|NCT01318915|Drug|Sirolimus|Taken orally. Initial dose, 2 mg daily on day 10 post-transplant, subsequently adjusted to achieve trough levels of 8-12 ng/mL through week 56. Sirolimus withdrawal will be initiated between week 56 and week 88 in eligible participants.
1898016|NCT01318915|Drug|MMF|1 g twice daily on days 0 through 12
1960914|NCT03066427|Drug|Sunitinib|Sunitinib 50 mg/d
1898018|NCT01318941|Drug|Ranibizumab|
1898019|NCT01318941|Other|Ranibizumab|
1898020|NCT01318954|Biological|Allergen immunotherapy|
1898021|NCT01318967|Drug|Furosemide|Renal blood flow is measured after the administration of 20 mg of furosemide during MRI scan only.
1898022|NCT01318967|Other|Placebo|
1898023|NCT01318980|Drug|GSK2190915 100mg milled tablet|Taken orally
1898024|NCT01318980|Drug|[14C] radiolabelled GSK2190915 solution|Microtracer solution
1898025|NCT01318980|Drug|GSK2190915 100mg milled tablet administered to the proximal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
1898026|NCT01318980|Drug|GSK2190915 100mg milled tablet administered to the distal small bowel.|Ground half of a 200mg tablet. Administered via Enterion capsule.
1898027|NCT01318980|Drug|GSK2190915 100mg enteric-coated tablet.|Taken orally
1898028|NCT01318993|Drug|GSK1605786A|500 milligrams twice daily
1898029|NCT01319006|Drug|GSK1278863A|100mg (x90=13um), oral tablet, single-dose with 7 day wash-out
1898030|NCT01319006|Drug|GSK1278863A|100mg (x90=29um), oral tablet, single-dose with 7 day wash-out
1898031|NCT01319006|Drug|GSK1278863A|100mg (x90=41um), oral tablet, single-dose with 7 day wash-out
1960915|NCT03064152|Device|Rotational Thromboelastometry|ROTEM is a point-of-care coagulation assay.
1898035|NCT01319032|Other|Extraction of whole blood|Extraction of DNA from whole blood
1898036|NCT01319045|Drug|Iloprost|Aerosolized iloprost, 5 mcg/dose x 6 doses daily for 3 months
1898037|NCT01319058|Procedure|Tonsillectomy, laser tonsillotomy, debrider tonsillotomy|Each arm will be treated by one of the three methods in addition to adenoidectomy
1898038|NCT01319071|Other|Blood sample|Extraction of blood sample from top-level athletes
1898039|NCT01319097|Other|Sorbion Sachet S|Dressing is indicated for moderately to heavily exuding wounds.
1898040|NCT01319110|Drug|Coenzyme Q10|Patients will receive CoQ10 200mg three times per day for 7 days, until return to baseline neurologic status, or until death/discharge (whichever comes first). CoQ10 will be given through pre-existing NG or OG tube, and mixed with 20 ml of chocolate Ensure so as to blind investigators and staff.
1898041|NCT01319110|Dietary Supplement|Placebo|Patients will be given Chocolate Ensure via NG/ OG 3x daily as a placebo.
1898043|NCT01319162|Other|Weight reduction regimen|The dietary intervention begins with a 12-weeks VLCD/LCD period. The diet comprise of 3 to 5 portions liquid diet with a daily energy intake of 450-800 kcal. In addition, patients will be encouraged to drink 1,5-2L daily of non-caloric beverages (<6 kcal/100 ml). All patients will have scheduled nurse visits at week 0 (baseline), 2, 5, 8, and 12. At these visits general well-being and body weight will be monitored. The patient will also be given support and counselling to enhance compliance to the VLCD/LCD diet.
1898044|NCT01319175|Other|Hip flexion strength training|
1898045|NCT01319188|Drug|0.5 mg of ranibizumab|Intravitreous ranibizumab (0.5 mg, injections at four week intervals for six months followed by further treatment at three month intervals with total duration of treatment until 24 months).
1898046|NCT01319188|Procedure|0.5 mg of ranibizumab + photodynamic therapy|Photodynamic treatment with ranibizumab for predominantly classic type neovascular age related macular degeneration.
1898047|NCT01319188|Other|Sham injection|Sham treatment for occult or minimally classic type neovascular age related macular degeneration.
1898048|NCT01319214|Drug|Inderal|Inderal vs. placebo will be administered with or without cocaine cues
1898049|NCT01319227|Procedure|Hip replacement|Hip arthroplasty with uncemented components
1898050|NCT01319240|Drug|insulin degludec|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
1898051|NCT01319240|Drug|insulin degludec/liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
1898052|NCT01319240|Drug|liraglutide|Subjects will be randomised to one out of six possible treatment sequences. Single dose, administered subcutaneously (under the skin) on three separate dosing visits.
1898053|NCT01319266|Drug|Hydrocodone Bitartrate extended-release tablet|Hydrocodone bitartrate extended-release oral tablet will be administered at a dose of 45 mg and dosed one time on Day 1. Subjects will also be dosed with naltrexone hydrochloride to block opioid effects.
1898054|NCT01319279|Drug|Hydrocodone bitartrate extended-release tablet|15 mg (single dose)
1898055|NCT01319305|Device|FinESS Sinus Treatment|balloon sinuplasty
1898056|NCT01319318|Procedure|Pars Plana Vitrectomy|Pars plana vitrectomy performed in study eye on Day 0.
1898057|NCT01319331|Drug|Alpha 1-Antitrypsin (AAT, Aralast NP)|Eligible subjects will be treated once a week for 8 weeks (8 total treatments).
1898058|NCT01319344|Drug|Eplerenone|25 mg o.d. per os
1898059|NCT01319357|Drug|Saxagliptin|orally 5 mg/d for 6 weeks
1898060|NCT01319357|Drug|Placebo|orally for 6 weeks
1898061|NCT01319370|Drug|Minoxidil|1 g of 5% Minoxidil topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
1898062|NCT01319370|Drug|vehicle of 5% Minoxidil topical foam|1 g of vehicle topical foam twice daily over 24 weeks in double-blinded phase and further 80 weeks in open-label-phase
1898063|NCT01319383|Drug|Vorinostat|Vorinostat (VOR) 400mg will be given as single doses by mouth. Participants eligible to advance in study will have opportunity to receive more than one dose of VOR. Each participant will only take one dose of VOR in a 24 hour period. Repeat doses will be administered at least 24 hours apart, with option for dosing at intervals up to 96 hour
1898064|NCT01319409|Procedure|Anatomic Double-Bundle ACL Reconstruction|Surgical reconstruction of the posterolateral (PL) and anteromedial (AM) bundles of the ACL using an autograft quadriceps tendon with a bone block that is split into 2 free arms to recreate the AM and PL bundles. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The free ends of the graft are be placed in 2 separate tunnels located in the centers of the tibial insertions for the PL and AM bundles. The PL bundle is fixed with the knee in full extension and the AM bundle is fixed with the knee at 45 degrees of flexion.
1898065|NCT01319409|Procedure|Anatomic Single-Bundle ACL Reconstruction|Surgical reconstruction of the ACL using a single autograft quadriceps tendon with a bone block. The free end of the graft is not split. The bone block is placed in a single femoral tunnel located in the center of the femoral ACL insertion site. The single free end of the graft is placed in a single tibial tunnel located in the center of the tibial ACL insertion site. The graft is fixed with the knee in 10 to 20 degrees of flexion.
1898066|NCT01319422|Drug|Pomalidomide|Comparison of different dosages and schedules of drug
1898067|NCT01319435|Procedure|Collection of biological samples|"Sparse blood samples (n=2 or 3 depending on weight) will be drawn on day 1 and day 5- 7 (or last day of treatment if the course is completed before day 7).
Monitoring of adverse events DNA for pharmacogenetics (scavenged clinical samples or buccal) CSF (if required clinically) Faeces"
1898068|NCT01319448|Drug|Proguanil|Proguanil tablets, 1.5mg/kg/day
1898069|NCT01319448|Drug|mefloquine plus artesunate|This treatment is given once a day for 3 days. Patients weighing 5-8 kg receive one paediatric tablet per day, those weighing 9-17 kg two paediatric tablets, those weighing 18-29 kg one adult tablet and those weighing 30 kg and two adult tablets.
1898070|NCT01319448|Drug|Sulfadoxine-pyrimethamine plus amodiaquine|amodiaquine plus sulfadoxine-pyrimethamine supervised at each bimonthly clinic visit (amodiaquine 10mg/kg per day for three days and sulfadoxine-pyrimethamine (25/1.25 mg/kg) on the first day).
1898071|NCT01319461|Device|Hyalgan|Patients will receive intraarticular injection of 20mg /2ml /syringe Hyalgan® once a week for 5 consecutive weeks.
1898072|NCT01319461|Device|sterile normal saline|Patients will receive intraarticular injection of sterile normal saline once a week for 5 consecutive weeks.
1898073|NCT01319474|Other|Whole-leg compression ultrasound|Duplex ultrasound assessment of the venous system of the leg(s) suspected of deep vein thrombosis. Assessment occurs from the most proximal assessable portion of the common femoral vein (usually at the inguinal ligament) to the level of the malleolus.
1898074|NCT01319487|Drug|2304 Eye Drops High Dose|2304 Eye Drops High Dose self-administered in the study eye during the treatment period
1898075|NCT01319487|Drug|2304 Eye Drops Low Dose|2304 Eye Drops Low Dose self-administered in the study eye during the treatment period
1898076|NCT01319487|Drug|Placebo Eye Drops|Placebo Eye Drops self-administered in the study eye during the treatment period
1898077|NCT01319513|Other|whey protein bolus|single dose of 25 g whey protein
1898078|NCT01319513|Other|whey protein pulses|10 2.5 g pulses of whey protein
1898079|NCT01319526|Genetic|DNA analysis|
1898081|NCT01319526|Other|laboratory biomarker analysis|
1898082|NCT01319539|Drug|Akt Inhibitor MK2206|Given PO
1898083|NCT01319539|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1898084|NCT01319539|Other|Pharmacological Study|Correlative studies
1898085|NCT01319539|Other|Laboratory Biomarker Analysis|Correlative studies
1898086|NCT01319552|Procedure|Fresh transfusion|1 unit autologous transfusion of red blood cells stored for 3-7 days under standard conditions
1898087|NCT01319552|Procedure|Old transfusion|1 unit autologous transfusion of red blood cells stored for 40-42 days under standard conditions
1898093|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum 15 minutes Post meal: Begin chewing 45 minutes post meal
1898094|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum 30 minutes Post meal: Begin chewing 30 minutes post meal
1898095|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum for 45 minutes Post meal: Begin chewing gum 15 minutes post meal
1898096|NCT01319578|Other|K2CG chewing gum|Fasting: Chew gum for 60 minutes Post meal: Being chewing gum 5 minutes post meal
1898097|NCT01319604|Device|SENSIMED Triggerfish|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
1898098|NCT01319604|Device|Tonometer|Tonometric assessment of IOP
1898099|NCT01319617|Device|SENSIMED Triggerfish|Soft contact lens-based device intended for continuous recording of relative changes in IOP
1898100|NCT01319630|Device|Sidestream Dark Field (SDF)|"SDF will be applied to the sublingual microvascular network with a 5X objective providing a 167X magnification.
After the removal of saliva and other secretions using gauze, the device will be gently applied (without any pressure) on the lateral side of the tongue, in an area approximately 1.5-4 cm from the tip of the tongue. Five sequences of 20 secs each from different adjacent areas will be recorded using a computer and a video card and stored under a random number for later analysis. This will be done at baseline and then 1 hour after Fluid bolus."
1898101|NCT01319630|Device|Near Infrared Spectroscopy (NIRS)|Tissue oxygen saturation (StO2) will be measured by a tissue spectrometer, a noninvasive tool, which uses reflectance mode probes to measure scattering light reflected at some distance from where the light is transmitted into the tissue. The NIRS probe will be placed on the skin of the thenar eminence and a sphygmomanometer cuff will be wrapped around the arm over the brachial artery. After a 3-min period to stabilize the NIRS signal, arterial inflow will be stopped (VOT) by inflating the cuff to 50 mmHg above the systolic arterial pressure. After 3 min of ischemia, cuff pressure will be released, and StO2 recorded continuously for another 3 min period (reperfusion period=Reactive Hyperemia).This will be done at baseline and then 1 hour after fluid bolus.
1898102|NCT01319643|Drug|Oxygen|The lowest inspiratory fraction of oxygen between 21 and 100% in as a short time as possible to maintain SpO2 between 94 and 98% or PaO2 between 70 and 100 mmHg.
1898103|NCT01319656|Behavioral|Support, management, educational, counselling, follow-up|The project offers a range of activities (educational, counselling, follow-up) by several professionals. The varied range of services is spread out over six months and may include individual or group meetings with professionals. Informational documents and follow-up tools are provided to patients based on their condition, to facilitate the acquisition and maintenance of knowledge, self-management, and changes in risk behaviour.
1898104|NCT01319669|Drug|recombinant human thrombopoietin|Recombinant human thrombopoietin injection in 15000U/ml/amp.
1898105|NCT01319682|Drug|Intravenous lidocaine injection|Patients in Group I (intravenous lidocaine injection group) received an intravenous bolus injection of 1.5 mg/kg lidocaine followed by a continuous lidocaine infusion of 2 mg/kg/hr.
1898106|NCT01319682|Drug|Intravenous normal saline injection|The patients in Group C (placebo control group) received normal saline intravenous injection
1898107|NCT01319695|Drug|corifollitropin alfa|100 microg for a group of women weighing <or=60 kg and 150 microg for a group of women weighing >60 kg
1898108|NCT01319695|Drug|recombinant follicle stimulating hormone (FSH)|150-300 IU of the drug daily from day 2 of the menstrual cycle until more than 2 follicles are >18mm
1898109|NCT01319708|Procedure|mild ovarian stimulation|100-150 mg of clomiphene citrate from day 2 till day 6 of the cycle and 150 mg of gonadotrophins as soon as 1 follicle is more than 14mm together with 1 fixed dose of GnRH antagonist until egg recovery
1898110|NCT01319708|Procedure|conventional ovarian stimulation|300-450 IU of FSH starting by day 2 of menstrual cycle together with a fixed dose of GnRH antagonist starting by day 6 till egg recovery, or same doses with GnRH agonist long protocol
1898111|NCT01319721|Procedure|MMC|Intraoperative 0.2mg/ml mitomycin C (0.02%) for 3 minutes will be applied topically after extensive excision of recurrent pterygium.
1898112|NCT01319721|Procedure|LCAG|Limbal conjunctival autograft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
1898113|NCT01319721|Procedure|AMG|Amniotic membrane graft transplantation will be applied to closure of conjunctival defect after extensive excision of recurrent pterygium.
1898114|NCT01319734|Dietary Supplement|Vitamin C|Vitamin C supplementation 500mg
1898115|NCT01319734|Drug|glyburide|this group receiving glyburide 5 mg alone
1898116|NCT01319747|Procedure|PVI|For catheter ablation, we used irrigated 4mm RF-ablation catheters, at a maximum power of 30-35Watt, an irrigation rate of 20 mL/min. PV isolation was performed by wide circumferential ablation, encircling all ipsilateral PVs.
1898117|NCT01319747|Procedure|VATS-PVI|A bilateral video-assisted thoracoscopic (VATS) pulmonary vein isolation and left atrial appendage (LAA) excision is performed under general anaesthesia and double-lumen endotracheal ventilation.
1898120|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A|One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
1898121|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
1898122|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
1898123|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%|One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
1898124|NCT01319773|Drug|cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B|One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
1898125|NCT01319786|Other|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)|Two portions of fruit and vegetables per day (excluding berries and dark chocolate)
1898126|NCT01319786|Other|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.|Six portions of fruit and vegetables per day (one of which must be berries) and 50g dark chocolate.
1898127|NCT01319799|Other|Open heart surgery|TCD count of microembolic signals during surgical aortic valve replacement
1898128|NCT01319812|Device|Astron Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting the iliac artery.
1898129|NCT01319812|Device|Pulsar Stents|Implantation of self-expanding, bare-metal, nitinol stents for treatment of peripheral artery disease affecting superficial femoral or proximal popliteal arteries.
1898130|NCT01319825|Drug|milnacipran|100 mg and 200 mg orally daily for a total of 4 months including a one month titration period.
1898131|NCT01319838|Drug|Isotretinoin|>12 kg: 160 mg/m2/day, given PO, divided BID <=12 kg: 5.33 mg/kg/day, given PO, dividied BID doses given days 1-14 of 28 day cycle for 24 consecutive cycles
1898132|NCT01319851|Drug|Alefacept|0.25 mg/kg IV on day -40 and day -39 0.5 mg/kg IV on days -33, -26, -19 and -12 Alefacept was diluted in sterile water (2 ml total volume) and administered via i.v. push followed by a normal saline flush per package insert.
1898133|NCT01319864|Drug|Plerixafor Dose Escalation|"Plerixafor dose escalation Dose Level -1 = 3 mg/m2/dose Dose Level 1 = 6 mg/m2/dose Dose Level 2 = 9 mg/m2/dose Dose Level 3 = 12 mg/m2/dose Dose Level 4 = 15 mg/m2/dose
Doses administered 4 hours prior to chemotherapy, then at the same approximate time of day on subsequent days, through the end of that cycle of chemotherapy."
1898134|NCT01319890|Procedure|Patients will be divided in two groups- those having right colectomy by standard laparoscopy and those having Single Incision Laparoscopic Surgery (SILS)|Patients will be divided into 2 arms- those with right colon tumors treated by conventional laparoscopic right colectomy and those having a Single Incision Laparoscopic Surgery (SILS)
1898135|NCT01319903|Biological|CaCP29, a humanized monoclonal antibody|CaCP29 or placebo single i.v. infusion in ascending doses in healthy human males
1898136|NCT01319916|Drug|ATX-101|ATX-101 2mg/cm2
1898137|NCT01319929|Drug|LY2828360|Administered orally
1898138|NCT01319929|Drug|Placebo|Administered orally
1898139|NCT01319942|Other|Radiotherapy combined with sorafenib|Radiotherapy: 46 Gy to 60 Gy prescribed to involved hepatic tumor Sorafenib: 2 tablet of sorafenib (200mg) twice daily (totally 800mg per day)
1898140|NCT01319955|Biological|Trivalent inactivated influenza vaccine|Two doses of 0.25 ml vaccine delivered IM at least 4 weeks apart.
1898141|NCT01319968|Drug|Estriol 0.1% vaginal cream|Patients with both vulvovaginal atrophy (according to cytologic criteria) and dyspareunia will apply 0.5 ml of the cream (0.5 mg) to the vulvar vestibule once daily for one month and will return for check-up visit. In case both atrophy and dyspareunia will resolve, treatment with the cream will be continued 3 times a week.
1898142|NCT01319981|Drug|Rituximab|In CD20-positive patients, 375 mg/m2 by vein on day 1 and 8 for Courses 1 and 3; and day 1 and 8 of Courses 2 and 4.
1898143|NCT01319981|Drug|Imatinib|600 mg by mouth daily days 1-14 for course 1 and continuously on all other courses for patients who are Philadelphia chromosome positive (Ph+).
1898144|NCT01319981|Drug|Cyclophosphamide|300 mg/m2 by vein over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) for courses 1, 3, 5, 7
1898145|NCT01319981|Drug|Doxorubicin|50 mg/m2 by vein over 24 hours on day 4 after last dose of Cyclophosphamide for courses 1, 3, 5, 7
1898146|NCT01319981|Drug|Mesna|600 mg/m2 by vein continuous infusion daily for 24 hours days 1-3 for courses 1, 3, 5, 7
1898147|NCT01319981|Drug|VSLI|2.0 mg/m2 by vein on day 1 and day 8 for courses 1, 3, 5, 7
1898148|NCT01319981|Drug|Solu-Medrol|40 mg by vein every 12 hours for 6 doses days 1-3 for courses 2, 4, 6, 8.
1898149|NCT01319981|Drug|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 beginning after the completion of rituximab for Courses 2, 4, 6, and 8.
1898150|NCT01319981|Drug|Ara-C|3 gm/m2 by vein over 2 hours every 12 hours for 4 doses on days 2, 3 for Courses 2, 4, 6, and 8.
1898151|NCT01319981|Drug|G-CSF|10 µg/kg/day (rounded) given subcutaneously until neutrophil recovery to 1 x 10^9/L or higher can be substituted or can be added if neutrophils have not recovered to 1 x 10^9/L by day 21.
1898152|NCT01319981|Drug|Pegfilgrastim|6 mg/kg (rounded) within 72 hrs after completion of chemotherapy.
1898153|NCT01319981|Drug|Dexamethasone|40 mg by vein or by mouth daily days 1-4 and days 11-14 for courses 1, 3, 5, 7
1898156|NCT01320007|Drug|Preset increase in frusemide dose|"All patients in Group 1 will have the Optivol function and alerts switched on. Optivol levels will be downloaded monthly via the Medtronic Carelink Network (for those patients who have it) or during pacemaker follow up appointments.
If the Optivol alarm goes off, all patients will be requested to contact a member of the research team by phone and those with rising Optivol (irrespective of the presence or absence of heart failure symptoms) will be requested to increase the dose of diuretic that they are on by 50% for 1 week then revert to their usual dose after 7 days. A routine renal function check will be performed at the end of the week."
1898157|NCT01320007|Other|No intervention|The Optivol data for these patients will be downloaded periodically (at each scheduled device check) and recorded but will not be available at follow up in the heart failure clinic.. These patients will act as controls for group 1 patients. They will undergo baseline investigations and then will undergo routine heart failure treatment and follow-up in the heart failure clinic. These will include a routine clinical evaluation, body weight and blood analysis as per the heart failure clinic protocol. Medications will be reviewed and changed according to clinical needs.
1898158|NCT01320020|Drug|catumaxomab|Inter patient dose escalation 2 µg, 4 µg, 7 µg, 10 µg, 14 µg and 19 µg qwk corresponding to dose increments of 100%, 75%, 43%, 40% and 36% respectively of the previous dose
1898159|NCT01320033|Drug|CD2475/101 40 mg Tablets|CD2475/101 40 mg Tablets once a day for 16 weeks
1898160|NCT01320033|Drug|Doxycycline 100 mg Capsules|Doxycycline 100 mg Capsules once a day for 16 weeks
1898161|NCT01320033|Drug|Placebo Tablet, and Placebo Capsule|Matching Placebo Tablet, Matching Placebo Capsule once a day for 16 weeks
1898162|NCT01320046|Other|Questionnaires, gynecological exam , vaginal smear, and measurement of urine leakage|"Patients will undergo the following evaluation:
Questionnaires- age, medical background, BMI, UI characteristics , usage of pads, other hygiene practices,hormonal therapy, presence of allergic tendency and history etc.
Medical history.
Gynecological exam including bladder/rectum/uterine prolapse, vaginal atrophy, discharge, findings of VCD (as part of the usual evaluation in the clinic).
Vaginal smear: this will be used for vaginal pH measurement and for wet mount, which will assess estrogen deficiency, yeast infection and other inflammatory conditions. Vaginal smears are done as part of the usual evaluation in the clinic.
Evaluation of the severity of urinary incontinence will be done by collection and weighting of pads during 24 hours."
1898163|NCT01320059|Drug|18F-PEG6-IPQA|Radioactive injection (PET imaging agent) given by vein before PET scans.
1898164|NCT01320059|Procedure|Positron emission tomography (PET)|3 PET scans performed after injection and positioning CT. Imaging should take about 3 hours.
1898165|NCT01320085|Drug|MEK162|
1898166|NCT01320098|Behavioral|Home-Based Parenting Program|"The Home-Based Parenting Program aims to improve impulsive and oppositional behaviors in 3 and 4 year-olds. The program involves 8 home visits with a therapist. The visits focus on the skills listed below as a means of improving your child's behavior.
Helping you set developmentally appropriate goals for your child. One way we do this is by focusing on situations that occur naturally in your home. Another way is by having you engage in activities with your child that focus on improving attention and the ability to delay.
Increasing the quality and quantity of positive interactions between you and your child
Changing the way you respond to your child's inappropriate behaviors so as to reduce the frequency of negative interactions.
Improving your parenting skills. This program also includes between-session homework tasks so that you can practice the skills you have learned throughout the week."
1898167|NCT01320098|Behavioral|Clinic-Based Parenting Program|"The Clinic-Based Parenting Program aims to improve ADHD symptoms by reducing noncompliance, which is common in children with ADHD. Parents learn how to help their child attend to and comply with requests and directions so as to improve compliance and attention.
The program involves 8 clinic visits with a therapist. Parents learn various parenting skills to help improve their child's behaviors.
Parents learn techniques and skills to promote positive interactions with their child, including:
Increasing the positive attention you give to your child.
Reducing the inappropriate use of commands, questions and criticisms.
Appropriate use of praise and physical attention (e.g., hugs) as rewards.
Actively ignoring minor, inappropriate behaviors. Parents also learn how to: increase compliance via clear instruction; respond to compliant and noncompliant behaviors; and create and use clear rules about appropriate and inappropriate child behaviors."
1898168|NCT01320098|Behavioral|Wait-List Control Group|If your child is randomized to the 8-week Wait-List group, you and your child will be asked to attend 2 assessment visits -1 screening/baseline visit and one 8 weeks later. These assessment visits will take place at our clinic. After completing the second assessment, you will receive your choice of either the home-based or clinic-based parenting program.
1898169|NCT01320111|Drug|Paclitaxel and Sorafenib|"intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
AND
pills (200mg), cycle 1: 400 mg / day cycle 2: 600 mg / day from cycle 3: 800 mg / day"
1898170|NCT01320111|Drug|Paclitaxel|intravenous solution, 80 mg/sqm, 3 times per cycle, with one cycle = 28 d and application at days 1, 8 and 15
1898171|NCT01320137|Procedure|Blood withdrawal|Blood sampling
1898172|NCT01320163|Device|i-gel airway (Intersurgical Ltd., Wokingham, England)|supra-glottic airway device
1898173|NCT01320163|Device|Laryngeal Mask Airway|supra-glottic airway device
1898176|NCT01320189|Dietary Supplement|Differences in protein content of meals|Differences in protein content (energy percent) of meals
1898177|NCT01320202|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
1898178|NCT01320202|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
1898179|NCT01320215|Procedure|Robot-assisted promontofixation|Sacrohysteropexy with robotic assistance (da Vinci robot)
1898180|NCT01320215|Procedure|Non-robot assisted promontofixation|Laparoscopic sacrohysteropexy, without robot assistance
1898181|NCT01320228|Dietary Supplement|Control|Alli treatment plus placebo (rice flour)
1898523|NCT01323088|Other|Control|Standard care control (no exercise)
1898182|NCT01320228|Dietary Supplement|Capolac|Alli treatment plus Capolac supplement (1200 Ca/d from Capolac)
1898183|NCT01320228|Dietary Supplement|Flax fiber|Alli treatment plus flaxseed fibers (5 g/d of dietary fibers from flaxseed)
1898184|NCT01320228|Dietary Supplement|Capolac+Flax fiber|Allit treatment plus Capolac (1200 mg Ca/d from Capolac) and Flax fiber (5 g dietary fiber from flaxseed)
1898185|NCT01320241|Device|self-expandable 125I radioactive seeds-loaded-stent|Patients undergo placement of a self-expandable 125I radioactive seeds-loaded-stent on day 1.
1898186|NCT01320241|Device|self-expandable biliary nitinol alloys stent|Patients undergo placement of a conventional self-expandable biliary nitinol alloys stent on day 1.
1898189|NCT01320267|Procedure|Single port laparoscopic right hemicolectomy|above procedure using Roticulating instruments (from Covidien)
1898190|NCT01320280|Drug|BIBW 2992 (Afatinib)|50 mg BIBW 2992 (Afatinib) tablets daily continuously
1898191|NCT01320293|Drug|Adalimumab 40 MG/0.8 ML Subcutaneous Solution [HUMIRA]|40mg subcutaneously, every other week for 6 months
1898192|NCT01320319|Other|Placebo|Capsule form, 960 mg to be taken three times a day.
1898193|NCT01320319|Dietary Supplement|Experimental: Nutritional Supplementation with EPA|Capsule form, EPA, 960mg to be taken three times a day.
1898194|NCT01320332|Drug|ASP3291|Oral tablets
1898195|NCT01320332|Drug|Placebo|Oral tablets
1898196|NCT01320345|Drug|Fenofibrate|Oral Fenofibrate 145mg given once daily for 12 months.
1898197|NCT01320345|Drug|Inert lactose placebo|Oral matching inert lactose placebo given once daily for 12 months.
1898198|NCT01320358|Drug|ECMPS-IEM|ECMPS-IEM
1898199|NCT01320384|Other|O2 conventional|standard low flow therapy
1898200|NCT01320384|Device|O2-HFN : high flow nasal oxygen therapy|The patient will receive high flow nasal of humidified oxygen, set between 30 to 50 l/min. The inspired fraction of oxygen (FiO2) will be adjusted in order to obtain a SpO2 >92%.
1898201|NCT01320384|Device|O2-HFN/NPPV : association of high flow nasal oxygen therapy and non invasive positive pressure ventilation|The patient will receive successively in a day NPPV and O2-HFN. The NPPV will be applied with an airway humidification achieved by using a heated humidifier and a facial mask adapted to the morphology of the patient. The settings will be adjusted as follow : an inspiratory pressure between 6 to 14 cmH2O, in order to obtain a tidal volume between 7 to 10 ml/kg of predicted weight, a positive expiratory pressure between 0 to 10 cmH2O in order to obtain a SpO2 >92% with the minimal FiO2.
1898202|NCT01320397|Drug|Rostafuroxin|6 microgram capsules
1898203|NCT01320397|Drug|Rostafuroxin|50 micrograms capsules
1898204|NCT01320397|Drug|Rostafuroxin|500 micrograms capsules
1898205|NCT01320397|Drug|Losartan|Losartan 50 mg once a day
1898206|NCT01320410|Drug|ISM®|
1898207|NCT01320423|Procedure|Surgical Trial|Surgical Trial in Lobar Intracerebral Haemorrhage
1898208|NCT01320436|Dietary Supplement|Curcumin|3 capsules (820 mg containig 500 mg curcumin each) twice daily.
1898209|NCT01320436|Drug|5-aminosalicylic acid|The dosage of 5ASA medication will be the maximum dosage given in this group of patients according to clinical guidelines (4gr' per os + topical 1gr mesalamine
1898210|NCT01320449|Drug|recombinant human erythropoietin|rHuEpo (5000 IU)is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-10.
1898211|NCT01320449|Behavioral|Training|For ten weeks participants will receive supervised endurance training on a bike three times a week. Physical effect will be examined with VO2-max tests before during and after the training period.
1898212|NCT01320449|Other|Placebo|placebo (saline) is administered using a small syringe under the skin every other day for the first 2 weeks, on 3 consecutive days during week 3, and once a week from week 4-12.
1898213|NCT01320462|Drug|Smoking cessation counselling group|The smoking-cessation program has three components; structured preoperative counseling, pharmacotherapy with varenicline for three months, and referral to the quit line (Smokers' Helpline) for proactive telephone counseling and follow up
1898214|NCT01320462|Other|Control group:|Interventions in the control group will be a brief advice regarding smoking cessation and provision of the quit line's information.
1898215|NCT01320475|Drug|Sufentanil|Epidural infusion of levobupivacaine (1,25 mg/ml) and sufentanil(1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of saline (placebo for ketamine)
1898216|NCT01320475|Drug|Ketamine|Epidural infusion of levobupivacaine (1,25 mg/ml) and saline (1 ml = 50 µg diluted in the 200 ml bag of levobupivacaine) IV infusion of ketamine (2 µg/kg/minute) Up to the third postoperative day (6 PM)
1898217|NCT01320501|Drug|Erlotinib|All patients will receive: TarcevaTM 150mg/day PO.
1898218|NCT01320514|Drug|Fibrin Sealant (Artiss)|
1898219|NCT01320527|Dietary Supplement|Nutriceutical formulation|Two pills that collectively contain: folic acid (400µg), Vitamin B12 (6µg), Vitamin E (as alpha-tocopherol; 30 IU), S-adenosylmethionine (SAM; 400mg), N-acetyl cysteine (NAC; 600mg) and Acetyl-L-carnitine (ALCAR; 500mg). Taken once daily for duration of study (1 year).
1898220|NCT01320527|Other|Placebo|A mixture of 6 vitamins and nutriceuticals
1898221|NCT01320553|Drug|SPARC1102 I|SPARC1102 I will be administered in both eyes
1898222|NCT01320553|Drug|SPARC1102 II|SPARC1102 II will be administered in both eyes
1898223|NCT01320553|Drug|SPARC1102 III|SPARC1102 III will be administered in both eyes
1898224|NCT01320553|Drug|Vehicle|Vehicle will be administered in both eyes
1898225|NCT01320566|Device|AeriSeal System|Not applicable. Follow-Up study only.
1898226|NCT01320579|Drug|Cis-UCA 2.5% emulsion cream|2.5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
1898227|NCT01320579|Drug|Cis-UCA 5% emulsion cream|5% cis-UCA in emulsion cream base twice daily, amount of a fingertip per one hand (i.e. palm + thumb + fingers) area, applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area)
1898228|NCT01320579|Drug|Placebo for cis-UCA emulsion cream|The placebo for cis-UCA product (emulsion cream base) twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area on of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
1898229|NCT01320579|Drug|Protopic® 0.1% ointment|0.1% Protopic® twice daily, amount of a fingertip per one hand area applied topically as a thin layer on the affected skin area of approximate size of maximally three hand areas for up to 28 days (one fingertip per one hand area).
1898230|NCT01320592|Drug|PD0332991|
1898231|NCT01320592|Drug|Paclitaxel|
1898232|NCT01320605|Biological|Weekly wound spray with components 1 and 2 of the compound HP802-247|Weekly spray with HP802-247
1898233|NCT01320657|Device|Conventional orthodontic bracket, passive self-ligating brackets and active self-ligating bracket|"Subjects randomized to treatment with one of three fixed orthodontic appliances: Damon Q, InOvation C and Ovation brackets. A pre-determined archwire sequence will be used involving round nickel titanium, rectangular nickel titanium progressing to 0.019 X 0.025 inch stainless steel; specific archwire sequences and appointment intervals will be based on the manufacturer's guidelines. All erupted teeth will have attachments placed from the outset.
Treated for a minimum of 8 months with the 0.019 X 0.025 inch stainless steel archwire in place for at least 8 weeks."
1898234|NCT01320683|Drug|oxaliplatin|Given IV
1898235|NCT01320683|Drug|leucovorin calcium|Given IV
1898236|NCT01320683|Drug|fluorouracil|Given IV
1898237|NCT01320683|Biological|bevacizumab|Given IV
1898238|NCT01320683|Radiation|yttrium Y 90 DOTA anti-CEA monoclonal antibody M5A|Given IV
1898239|NCT01320683|Other|laboratory biomarker analysis|Correlative studies
1898240|NCT01320683|Other|pharmacological study|Correlative studies
1898241|NCT01320683|Drug|irinotecan hydrochloride|Given IV
1898242|NCT01320696|Biological|Reverse Genetic (RG) reassortant A/H9N2 influenza vaccine|Two intramuscular vaccinations; 5 dose groups: 3.75 µg, 7.5 µg, 15 µg, 30 µg or 45 µg HA antigen (strain A/H9N2/chicken/Hong Kong/G9/97; non-adjuvanted formulation
1898243|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 20 mg piroxicam (i.e., 1 piroxicam capsule + 3 placebo capsule)
1898244|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 40 mg piroxicam (i.e., 2 piroxicam capsules + 2 placebo capsule)
1898245|NCT01320709|Drug|Placebo|Single dose of placebo (i.e., 4 placebo capsules)
1898246|NCT01320709|Drug|Piroxicam ( BAYl1902)|Single dose of 80 mg piroxicam (i.e., 4 piroxicam capsules)
1898247|NCT01320722|Drug|Vitamin D ergocalciferol|50,000 unit soft gel capsule once per week for 8 weeks
1898248|NCT01320722|Drug|Probenecid|500 mg tablet once per day for 4 weeks, then either 500 mg tablet once per day for 4 weeks or 1000 mg once per day for 4 weeks (8 weeks total)
1898249|NCT01320722|Drug|Allopurinol|300 mg tablet once per day for 4 weeks then either 300 mg once per day or 600 mg once per day for 4 weeks (8 weeks total)
1898250|NCT01320722|Drug|Placebo|Placebo soft gel once per week for 8 weeks
1898251|NCT01320722|Drug|Placebo|Placebo tablet once per day for 4 weeks then twice per day for 4 weeks (eight weeks total)
1898252|NCT01320748|Behavioral|Dual Processing|A 10-week, 20-session program, which meets two times per week for 2 hours each time. It is a psychosocial intervention that combines a visual processing (structured drawing activities to engage in sensory-based cue exposure) and a verbal processing component (structured cognitive-behavioral therapy). The treatment focuses on sensory-based emotional expression and cognitive reappraisal and containment strategies that facilitate emotional regulation around a patient's drug and alcohol use experiences.
1898253|NCT01320748|Behavioral|Relapse Prevention|The program's standard care outpatient program is a Relapse Prevention 10-week, 20-session, psychosocial intervention program, which meets two times per week for 2 hours each time. This RP program is based on Gorski's Relapse Prevention model and is a primarily didactic approach.
1898254|NCT01320761|Drug|ATX-101-BA-free|ATX-101-BA-free
1898255|NCT01320761|Drug|ATX-101-BA|ATX-101-BA
1898256|NCT01320774|Drug|Daivobet® Gel|Once daily on areas with plaque psoriasis, treatment duration up to 8 weeks for body skin areas except scalp (scalp up to 4 weeks), treatment may be repeated under medical surveillance.
1898257|NCT01320787|Drug|18F-fluoroacetate|18F-fluoroacetate injection as a single intravenous bolus with a maximum volume of 4 mL followed by a saline flush of 20 to 50 mL.
1898258|NCT01320800|Behavioral|Skills for Academic and Social Success|12-week cognitive-behavioral, school-based group intervention
1898259|NCT01320800|Behavioral|Skills for Life|SFL is the Skills for Life Protocol delivered by school counselors.
1898260|NCT01320813|Procedure|Robot-assisted thyroidectomy|Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
1898261|NCT01320813|Procedure|Open thyroidectomy|Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
1898262|NCT01320826|Procedure|colonoscopy|Data pertaining to all colonoscopies performed by a APC-Endo study physician over a two month period will be collected.
1898263|NCT01320852|Other|PET Scan|All patients will have a PET scan as part of their pre-transplant assessment
1898264|NCT01320878|Drug|iloprost nebuliser solution|iloprost 30 ng/kg/min inhalation for 10 minutes,q4h in day time and q6h at night for 2 days
1898265|NCT01320878|Drug|iloprost nebuliser solution|iloprost 50 ng/kg/min inhalation for 10 minutes, q4h in day time and q6h at night for 2 days
1898266|NCT01320878|Drug|distilled water|distilled water 2 ml per session
1898267|NCT01320891|Behavioral|balanced solutions|during the general anaesthesia until 8 o'clock of the day after the operation the subject will receive only balanced fluids that means balanced crystalloid and colloids dissolved in balanced solution. 12 ml /Kg/h during operation time. ratio 3:1 between crystalloid and colloid.
1898268|NCT01320891|Behavioral|not balanced|during the operation time until the 8 o'clock of the day after the operation, the subjects will receive only normal saline and colloid dissolved in normal saline.
1898307|NCT01312623|Other|Remote ischemic preconditioning|Remote ischemic preconditioning at the left leg.
1898308|NCT01312636|Drug|activated recombinant human factor VII|Data will be collected at the baseline visit and approximately once a year until end of study.
1898309|NCT01312649|Behavioral|Experimental psychology methods (computer tests)|
1898729|NCT01324518|Drug|ORM-12741|200mg twice a day
1898269|NCT01320904|Procedure|NMES|"We used a electrical stimulation device with a 2500-Hz carrier frequency. We used four channels in the synchronous mode, with surface electrodes that were simultaneously fixed at the motor points of the quadriceps and hamstrings. Initially, a warm-up protocol that was five minutes long was used at a stimulation frequency of 40 Hz to activate the slow fibers. These fibers activated with a four-second-contraction time (on), a four-second-stimulus rise time, a four-second-stimulation decay time and a 12-second relaxation time (off).
We then increased the frequency to 70 Hz to activate the fast fibers for an additional 10 minutes using the parameters described above, and finally, the frequency was increase to 150 Hz for 10 minutes to achieve maximal muscle potentiation."
1898270|NCT01320904|Procedure|Closed Kinetic Chain|During the stimulation period, i.e., the on time, the patient remained in a mini-squat position at thirty degrees and returned to zero degrees during the decay period. During the electrical stimulation off period, the patient spontaneously performed another mini-squat at 30 degrees without electrical stimulation. The patients in the CKC + NMES placebo group simulated the same work applied to the NMES group. Notably, this group was also connected to the electrodes, but the equipment was set at a stimulus intensity of zero.
1898271|NCT01320917|Device|Levonorgestrel releasing device|LNG-IUD device releases levonorgestrel in circulation
1898272|NCT01320917|Device|Cu-IUD insertion|The action of a Cu-IUD does not release any hormonal compound
1898273|NCT01320930|Behavioral|Pulmonary rehabilitation|
1898274|NCT01320930|Behavioral|conventional care|
1898277|NCT01312415|Drug|Levobupivacaine|Patients will receive peri- and intraarticular surgical site infiltration to the knee during surgery and before wound closure with a solution of levobupivacaine 0.5% 2mg/kg body weight (maximum 200mg levobupivacaine will be used if the patient's weight exceeds 100kg) plus 0.5mg epinephrine made up to 100ml with saline. An intra-articular catheter will be placed by the surgeon before closure under the sterile surgical conditions and this will be left in situ in the wound. The patient will receive one further injection of 15ml of levobupivacaine 0.5% solution at 8am on the morning of the first postoperative day after which the catheter will be removed.
1898278|NCT01312415|Drug|Intrathecal morphine|Patients will receive spinal anaesthesia with intrathecal bupivacaine 0.5% (17.5 mg if greater than 70 kg and 15 mg if less than 70 kg) and preservative-free morphine (0.3 mg).
1898279|NCT01312428|Device|Pelvic Alignment Level (PAL) Instrument|Pelvic Alignment Level Instrument Used
1898280|NCT01312428|Device|No Pelvic Alignment Level (PAL) Instrument|No Pelvic Alignment Level Instrument Used
1898281|NCT01312441|Drug|Ergocalciferol|Ergocalciferol capsules 50,000 IU once weekly for 6 months
1898282|NCT01312441|Drug|Placebo|Placebo by mouth once weekly for 6 months
1898283|NCT01312454|Drug|AL-59412C injectable solution|Concentration 1 and Concentration 2
1898284|NCT01312454|Drug|Travoprost injectable solution|
1898285|NCT01312454|Drug|AL-59412C Vehicle|Inactive ingredients used as placebo
1898286|NCT01312467|Drug|metformin hydrochloride|Given PO
1898287|NCT01312467|Other|pharmacological study|Correlative studies
1898288|NCT01312467|Other|laboratory biomarker analysis|Correlative studies
1898289|NCT01312480|Other|5A's Model|"The smoking cessation intervention is based on the 5A's model, which includes the following elements:
Ask if the patient smokes.
Advise every patient to quit.
Assess readiness to quit.
Assist in quitting and finding services.
Arrange for cessation services and follow-up."
1898290|NCT01312480|Other|Media Use Assessment|The media use assessment (control condition) is based in part on the American Academy of Pediatrics policy statement on children and media, published in the November 2010 issue of Pediatrics. This assessment includes suggested questions on how much media per day is used and whether or not the adolescent has a television or Internet access in his/her bedroom. The adolescent will complete a one-page Media Use assessment form for this purpose, which will set the stage for relevant anticipatory guidance.
1898291|NCT01312493|Drug|Panitumumab|Weekly panitumumab intravenously at a dosage of 2.5 mg/kg started one week prior to RT until RT is completed. No more than 8 treatments.
1898292|NCT01312493|Radiation|Intensity Modulated Radiation Therapy|The dose per fraction will be 2 Gy per day. Thus, the total number of fractions will be 35. Five days a week for 7 weeks.
1898293|NCT01312519|Device|OnControl Bone Marrow Biopsy and Aspiration System|Battery powered device used for insertion of a single lumen catheter into the intraosseous space of the adult iliac crest for the purpose of aspiration and core biopsy collection.
1898294|NCT01312519|Device|Manual bone marrow sampling device|Hollow needle with a t-shaped handle that is pushed into the bone for the purpose of collecting bone marrow aspiration and core biopsy samples.
1898295|NCT01312532|Device|fixed-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson & Johnson, Leeds, UK
1898296|NCT01312532|Device|mobile-bearing (P.F.C.® Sigma)|P.F.C.® Sigma, DePuy, Johnson & Johnson, Leeds, UK
1898297|NCT01312545|Device|3DP|intervention involving local made implant with different fabricating technique-3-dimensional printing (3DP) technique.
1898298|NCT01312545|Device|Medpor|commercial porous polyethylene
1898299|NCT01312558|Behavioral|Prudent diet group|
1898300|NCT01312558|Behavioral|Mediterranean diet group|
1898301|NCT01312571|Behavioral|Internet-based cognitive behavioural therapy (iCBT)|The Internet-based cognitive behavioural therapy (iCBT) consists of our structured self-help program lasting a total of nine active treatment weeks. This treatment program has been well evaluated and involved in several research projects.
1898302|NCT01312571|Behavioral|Internet-based computerized attention training|The Internet-based computerized attention training program lasting a total of four active treatment weeks. The treatment is consist of two training sessions per week, about 10 minutes long.
1898303|NCT01312584|Dietary Supplement|Processed High-flavanol|
1898304|NCT01312597|Other|Fruit juice beverage|500ml fruit juice beverage, single dose per visit
1898305|NCT01312610|Dietary Supplement|High flavanone orange juice|High flavonone orange juice drink.
1898306|NCT01312610|Dietary Supplement|Control orange juice|Orange beverage, low flavanone content, matched for total carbohydrate content, individual sugar profile, vitamin C
1898310|NCT01312675|Device|S.A.F.E.BT|Five (5) S.A.F.E.BT treatments within a 7 day treatment period.
1898311|NCT01312688|Other|Early Goal Directed Hemodynamic Therapy in Sepsis|Early Goal Directed Hemodynamic Therapy according to the SSC guidelines
1898312|NCT01312714|Drug|Cholecalciferol|3 tablets of 1000 IU daily for 26 weeks
1898313|NCT01312714|Drug|Placebo|3 tablets of 1000 IU daily for 26 weeks
1898314|NCT01312727|Other|Blood and urine sample collections|phenotype and genotype analysis, biological analysis
1898315|NCT01312740|Other|LC-P-LGI diet|a hypocaloric diet low in lipids (25%) which is compensated by proteins (35%) with no change in carbohydrate content.
1898316|NCT01312740|Other|LC-CONV|4-week CONV period consisted in the subjects' consumption of 1200 Kcal/ day (25% protein, 31% lipids, 44% carbohydrates).
1898317|NCT01312766|Drug|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
1898318|NCT01312766|Drug|Menotropins|Daily administration, SC, starting dose 150 IU or 225 IU depending on patient age.
1898319|NCT01312779|Device|Implantation of CEP Magna Mitral Model 7000TFX|Heart valve surgery: CEP Magna Mitral Model 7000 TFX
1898320|NCT01312792|Other|Amoxycilline, Cephradine followed by follow up on day 3|Modified IMCI Guideline for treating severe phnemonia will be implemented in the arm 1. The Modified IMCI guideline denotes that all severe pneumonia cases with only chest indrawing and no other danger signs will be treated at the first level health facilities with first line oral antibiotics followed by follow-up on 3rd day. On 3rd day the patient will be reassessed and if the condition improves the first line antiobiotic will be continued and if deteriorates or remain unchange second line antibiotic will be used. The patient will be further asked to come on day 3 for reassessment.
1898321|NCT01312792|Other|Injectable ampicillin followed by urgent referral|Existing IMCI guideline denotes all severe pneumonia cases will be referred to the 1st level referral facilities after giving first dose of injectable antibiotics
1898322|NCT01312805|Other|CHICA Asthma Module|This module was added to CHICA to help diagnose and manage asthma
1898323|NCT01312805|Other|CHICA Control|This is CHICA without the asthma module, and was used as a control
1898324|NCT01312818|Drug|Bortezomib|1.3 mg/m^2 by intravenous pyelogram (IVP) over 3-5 seconds on days 1, 4, 8 and 11.
1898325|NCT01312818|Drug|Vorinostat|180 mg/m^2 (max dose 400mg) by mouth (PO) divided twice a day (BID) on days 1-14
1898326|NCT01312818|Drug|Dexamethasone|6 mg/m^2 by mouth (PO) divided twice a day (BID) on days 4-15.
1898327|NCT01312818|Drug|Methotrexate|Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
1898328|NCT01312818|Drug|Imatinib mesylate|"For Ph+ acute lymphoblastic leukemia (ALL) patients only:
Imatinib Mesylate is allowable at 340 mg/m2 PO once a day (rounded to the nearest 100 mg) for age ≤18 years and 400 mg for >18 years on Days 1-16."
1898329|NCT01312831|Other|Vitamin B12 (cyanocobalamin)|
1898330|NCT01312844|Drug|Scopolamine|Those receiving active drug will receive scopolamine 4mcg/kg IV with each treatment, until completion of ECT
1898331|NCT01312857|Drug|panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.
All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization to panitumumab 6 mg/kg day 15 and 29 Each cycle repeats every 36 days for a total of 6 cycles"
1898332|NCT01312857|Drug|Randomization to No Panitumumab|"All patients receive HAI FUDR (0.12 mg/kg/day X kg X pump volume) / pump flow rate and Dexamethasone flat dose of 25 mg on days 1.
All patients receive CPT-11 (150 mg/m2 IV over 30 min to an hour), Leucovorin (400 mg/m2 IV, over 30 min to an hour) and 5FU (1000 mg/m2/day continuous infusion over two days) on days 15 and 29 Randomization (to no panitumumab) Each cycle repeats every 36 days for a total of 6 cycles"
1898333|NCT01312870|Dietary Supplement|Ensure, Abbott Nutrition|Enteral feeding Ensure, Abbott Nutrition 400 ml per day for seven postoperative days
1898334|NCT01312870|Other|standard hospital diet|standard hospital diet
1898335|NCT01312883|Behavioral|Behavioral education intervention|One education session with a social worker while at the hospital, provision of an educational pamphlet and summary sheet for partner, a needs assessment by the social worker 2 weeks after hospital discharge, and additional patient education and reinforcement of self-management skills, as needed
1898342|NCT01312935|Drug|PMX-60056|investigational drug
1898343|NCT01312948|Device|Prototype mask (known as Pixi)|This is a prototype mask to be used with continuous positive airway pressure (CPAP) or non-invasive ventilation (NIV) therapy. The mask attaches to the face, covering the nose, and is kept in place with headgear. Therapy is delivered through the mask via a tube which attaches to the CPAP or NIV device.
1898344|NCT01312961|Drug|Dupilumab|Solution for injection, one subcutaneous injection.
1898345|NCT01312961|Drug|Placebo (for Dupilumab)|Solution for injection, one subcutaneous injection.
1898346|NCT01312961|Drug|Fluticasone/Salmeterol combination therapy|Oral inhalation twice daily.
1898347|NCT01312961|Drug|Fluticasone monotherapy|Oral inhalation twice daily.
1898348|NCT01312961|Drug|Albuterol|Oral inhalation as needed.
1898349|NCT01312961|Drug|Levalbuterol|Oral inhalation as needed.
1898350|NCT01312987|Dietary Supplement|Lipid-based nutritional supplement|"After gradual introduction of the lipid-based nutritional supplement, daily dose per child is as follows:
3 teaspoons 3 x day for children younger than 12 months 4.5 teaspoons 3 x day for children older than 12 months"
1898351|NCT01313000|Procedure|Autologous fat transfer|Autologous fat transfer from abdomen to upper arms
1898352|NCT01313013|Behavioral|question prompt sheet|
1898353|NCT01313026|Procedure|Percutaneous nerve evaluation|Implantation of a nerve stimulator to stimulate the sacral nerve plexus
1898354|NCT01313039|Drug|AZ6244|AZD6244 75 mg (3 x 25mg capsules) orally twice per day on Days 1 - 15
1898355|NCT01313052|Behavioral|Forensic Assertive Community Treatment (FACT)|Individuals in this arm will receive the services of an Assertive Community Treatment team and close supervision of a judge trained in the FACT model.
1898356|NCT01313052|Behavioral|Enhanced Treatment as Usual|Individuals in this arm of the study will receive an expedited appointment at a clinic specializing in the treatment of psychotic disorders. These individuals will receive the services of a therapist, psychiatrist, and case manager.
1898357|NCT01313065|Drug|VX15/2503|Dose escalation will begin at low doses and will gradually increase in each future cohort. The current trial design provides for 7 study cohorts with a 20 mg/kg expansion phase.
1898358|NCT01313078|Drug|Pegylated L-Asparaginase|Pegaspargase 2000 IU/m^2 intramuscular or intravenously every 2 weeks
1898359|NCT01313104|Procedure|colposcopy|Undergo colposcopy
1898360|NCT01313104|Other|cervical Papanicolaou test|Undergo cervical Pap smear
1898361|NCT01313104|Procedure|screening method|Undergo anal Pap smear
1898362|NCT01313104|Procedure|screening method|Undergo high resolution anoscopy
1898363|NCT01313117|Drug|Alpha lipoic acid|The baseline dose is 100 mg three times daily for four months. Dose escalation will occur until a maximum tolerated dose is found.
1898364|NCT01313143|Drug|AOP200704|Comparison of AOP200704 with Esmolol
1898365|NCT01313143|Drug|Esmolol hydrochloride, infusion|Comparison of AOP200704 with Esmolol
1898366|NCT01313169|Other|EMR Reminder|EMR reminders displayed
1898367|NCT01313169|Other|EMR Reminder + Panel management|EMR Reminder + Panel management
1898368|NCT01313182|Drug|mupirocin calcium ointment, 2%|"Approximately one-half of the ointment from the single-use tube should be applied into 1 nostril and the other half into the other nostril twice daily (morning and evening) for 5 days.
After application, the nostrils should be closed by pressing together and releasing the sides of the nose repetitively for approximately 1 minute. This will spread the ointment throughout the nares."
1898369|NCT01313182|Drug|Povidone-iodine solution 5% w/w (0.5% available iodine) Patient Preoperative Skin Preparation|The solution is applied to for 30 seconds to each nostril twice for a total of 2 minutes. The solution is applied by rotating the applicator around the circumference of the nostril for 15 seconds and then rotating the applicator in the anterior nares for 15 seconds.
1898370|NCT01313208|Drug|etanercept|Administered by subcutaneous injection once weekly.
1898371|NCT01313208|Drug|Placebo|Placebo subcutaneous injection
1898372|NCT01313208|Drug|DMARD Therapy|Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine
1898373|NCT01313221|Biological|etanercept|Administered by subcutaneous injection
1898374|NCT01313221|Drug|Topical agents|"Topical agents prescribed at the discretion of the Principal Investigator and were are limited to the following:
hydrocortisone 2.5%
betamethasone valerate 0.1%
betamethasone dipropionate 0.05%
clobetasol 0.05%
calcitriol
calcipotriol plus betamethsone dipropionate 0.05%"
1898375|NCT01313234|Behavioral|Education|Theory based education and systematic daily assessment
1898376|NCT01313247|Drug|paracetamol|1000 mg 4 times daily
1898377|NCT01313247|Drug|placebo tablets|Placebo pills eqv paracetamol are given 2 tablets 4 times daily instead of paracetamol
1898378|NCT01313273|Drug|Lanreotide, non steroidal anti androgens and LHRH-a|"Lanreotide 120 mg. Injection every 28 days, to be administered till progression or for a maximum of 24 months.
Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression."
1898379|NCT01313273|Drug|Non steroidal anti androgens and LHRH-a|Non steroidal anti androgens (e.g. bicalutamide 50 mg/day to be administered till progression) plus LHRH-a (e.g. triptorelin 3.75 mg/month till progression
1898380|NCT01313286|Drug|LY2608204 Reference|Administered orally
1898381|NCT01313286|Drug|LY2608204 Test|Administered orally.
1898382|NCT01313299|Drug|Botulinum type A toxin (Dysport®)|500 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
1898383|NCT01313299|Drug|Botulinum type A toxin (Dysport®)|1000 U, I.M. (in the muscle) injection on day 1 of a single treatment cycle.
1898384|NCT01313299|Drug|Placebo|I.M. (in the muscle) injection on day 1 of a single treatment cycle.
1898385|NCT01313312|Drug|Dysport®|"Dysport® was supplied to the study centres in vials containing 500 U of botulinum toxin type A (BTX-A). Depending on the dose administered up to 3 vials were required for the injection.
Each vial was reconstituted with sodium chloride for injection (0.9%). A total volume of 5.0 mL of the reconstituted product was injected for Dysport® 500 U and 1000 U, and 7.5 mL was injected for Dysport® 1500 U."
1898386|NCT01313325|Other|Hippotherapy|Children will receive treatment by a licensed physical therapist using hippotherapy as the treatment strategy. This includes sitting on a horse who's movement is controlled by a horse leader, with the PT directing the movements required of the horse, as well as supplying supplemental cues to the participant. Alternative positions (such as sitting backward and sideways) may also be used during the treatment session.
1898387|NCT01313364|Device|"25G x 1 Needle Autoinjector"|All subjects will self-administer 4 IM injections using single-use autoinjectors.
1898388|NCT01313377|Drug|gemcitabine hydrochloride|
1898389|NCT01313377|Drug|oxaliplatin|
1898390|NCT01313377|Other|clinical observation|
1898391|NCT01313377|Procedure|adjuvant therapy|
1898392|NCT01313377|Procedure|quality-of-life assessment|
1898393|NCT01313390|Drug|docetaxel|
1898394|NCT01313390|Drug|everolimus|
1898395|NCT01313390|Other|laboratory biomarker analysis|
1898396|NCT01313390|Other|pharmacological study|
1898397|NCT01313403|Other|Antidepressant (SSRI)|
1898398|NCT01313416|Biological|CT-011|3mg/kg, intravenous (IV) day 1 of each cycle over 2 hours.
1898399|NCT01313416|Drug|Gemcitabine|1000mg/m^2 intravenous (IV) over 30 minutes on days 8, 15, and 22 of each cycle.
1898524|NCT01323088|Other|Resistance Exercise|Supervised resistance exercise using stack weight equipments.
1898403|NCT01313468|Behavioral|1 x 4 minute interval|1 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate
1898404|NCT01313468|Behavioral|4 x 4 minutes Intervals|4 x 4 minutes of high intensity intervals at 90-95% of maximal heart rate separated by 3 minutes of active brakes in between at 70% of maximal heart rate.
1898405|NCT01313468|Behavioral|Moderate continuous Training|47 minutes of Moderate continuous Training
1898406|NCT01313481|Behavioral|Group exercise|Otago exercise performed in groups of 4-8 patients, 2 times a week over 12 weeks
1898407|NCT01313481|Behavioral|Home exercise|Otago exercise performed as home exercise 3 times a weeks over 12 weeks. Individually tailored physical balance and muscle strength exercise
1898408|NCT01313494|Drug|Roflumilast|Roflumilast tablets
1898409|NCT01313494|Drug|Placebo|Placebo tablets
1898410|NCT01313494|Drug|Salbutamol|Salbutamol (given by MDI and spacer) used as rescue medication on an ass needed basis throughout the trial, and was used for post-bronchodilator spirometry tests at all study visits.
1898411|NCT01313507|Biological|NewGam|The initial dose and dosing interval for each participant was the dose and dosing interval the participant received at the end of the NGAM-01 study. The dose of NewGam, solvent/detergent treated human normal immunoglobulin 10%, remained the same throughout the study, as long as the minimum trough level of serum immunoglobulin G (IgG) was above 5 g/L. If the serum IgG trough level dropped to 5 g/L or less, the dose was to be adjusted at the investigator's discretion. NewGam was supplied as a solution for infusion.
1898412|NCT01313520|Drug|Infliximab|3 mg/kg of Infliximab at Weeks 0, 2, 6, 14 via intravenous infusion
1898413|NCT01313520|Drug|Placebo|250 mL of 0.9% sodium chloride at Weeks 0, 2, 6, 14 via intravenous infusion
1898414|NCT01313533|Drug|Polyarginine|Vein soak treated with polyarginine
1898415|NCT01313533|Drug|Vein soak treated with Lactated Ringers Solution|Vein soak
1898416|NCT01313546|Other|Stimulation of quariceps muscle|stimulation of quadriceps muscle through the stimulating catheter
1898420|NCT01313572|Drug|Apadenoson SPECT-MPI|Apadenoson single bolus IV injection 100 or 150 ug
1898421|NCT01313572|Drug|Adenosine SPECT-MPI|Single IV infusion for 6 minutes at a rate of 140 µg/kg body weight per minute
1898422|NCT01320943|Drug|TDF|Tenofovir disoproxil fumarate (TDF) 300 mg tablet administered orally once daily
1898423|NCT01320943|Other|Stop TDF|Participants will stop TDF therapy
1898424|NCT01320956|Behavioral|Pre operative nurse consultation and Hypnosis|Pre operative nurse consultation with pain management nurse, the day before surgery and 5 to 10 minutes of hypnosis, just before anesthesia, with trained nurse.
1898425|NCT01320956|Other|Pre operative nurse consultation|Pre operative nurse consultation with pain management nurse. Usual care and anesthesia
1898426|NCT01320969|Behavioral|Mindfulness-Based Stress Reduction course|an eight-week mindfulness-based stress reduction course
1898427|NCT01320982|Drug|minocycline|minocycline 100 mg/bid
1898428|NCT01320982|Drug|pramipexole|pramipexole 0.125, 0.25, 0.5 and 0.75 mg/bid
1898429|NCT01320982|Drug|acetylsalicylic acid|acetylsalicylic acid 500mg/ bid
1898430|NCT01320982|Drug|placebo|placebo bid
1898431|NCT01320995|Procedure|Perineal ultrasound|Perineal ultrasound is performed after delivery in order to better detect sphincter lesions.
1898432|NCT01321008|Radiation|Radiation|50.4 to 54 Gy delivered 5 days a week for 28 to 30 treatments.
1898433|NCT01321008|Drug|Cyclophosphamide|750 mg/m2 by vein over 1 hour on Day 1 of a 21 day cycle.
1898434|NCT01321008|Drug|Doxorubicin|50 mg/m2 by vein over 15 minutes on Day 1 of a 21 day cycle.
1898435|NCT01321008|Drug|Vincristine|1.4 mg/m2 (max dose 2 mg) by vein over 15 minutes on Day 1 of a 21 day cycle.
1898436|NCT01321008|Drug|Prednisone|100 mg by mouth daily on Days 1-5 of a 21 day cycle.
1898437|NCT01321021|Drug|Losartan, Diphenhydramine, Placebo|placebo controlled crossover study with two arms: Losartan 40mg, Diphenhydramine 40mg
1898438|NCT01321034|Drug|Niacin/Laropiprant|1g/20 mg day of Niacin/Laropiprant for 4-weeks followed by 8 additional weeks of 2 g/40 mg day.
1898441|NCT01321060|Procedure|Aspiration|
1898442|NCT01321060|Procedure|Catheter drainage|
1898443|NCT01321060|Drug|Conservative treatment|Including antibiotics,somatostatin, proton pump inhibitors and sufficient fluid resuscitation
1898444|NCT01321073|Device|Model 10642 Implantable Intravascular Catheter|This clinical study consists of the Model 10642 Implantable Intravascular Catheter used in combination with the SynchroMed II Implantable Infusion System (Model 8637) to deliver Remodulin Injection. This study will focus on the safety of delivery of Remodulin Injection in the treatment of patients with PAH who meet the approved Remodulin Injection indication, using the approved formulation, and approved intravenous route of administration.
1898445|NCT01321086|Behavioral|Motivational Interviewing|9 sessions of MI from baseline to six months
1898446|NCT01321086|Behavioral|PACE|9 sessions of PACE delivered from baseline to six months
1898447|NCT01321099|Other|NaFeEDTA|Labeled iron as FeSO4 or NaFeEDTA added to a test meal
1898448|NCT01321099|Other|Phytase|Labeled iron as FeSO4 added to a test meal with or without phytase and with or without vitamin C
1898449|NCT01321099|Other|Vitamin C|Labeled iron as FeSO4 added to a test meal with or without vitamin C
1898519|NCT01323049|Procedure|Positive pressure extubation|Positive pressure extubation will be used for patients waking up from general anesthesia
1898520|NCT01323049|Procedure|Aspiration/suction extubation|Aspiration/suction extubation will be used for patients waking up from general anesthesia
1898450|NCT01321112|Drug|conversion from CNI to MMF|After screening procedure mycophenolate mofetil will be started (week -4) at a dose of 500 mg twice a day for two weeks and then (week -2) increased to 1000 mg twice a day and CNI will be reduced at the 50% of the initial dose. After two weeks (week 0) CNI will be completely discontinued (complete IS conversion). The investigators will follow up patients every 4 weeks up to 48 weeks after the complete IS conversion.
1898451|NCT01321125|Biological|Bacterial culture of the prepared skin's areas|Cultures were taken with a scrub-cup of 5cm2 of internal area pressed over the skin previously prepared, then it was added a 3mL of culture broth (C/E neutralizing broth (D/E Neutralizing Broth, DIFCO TM) containing a neutralizing agent and a detergent agent (1% solution tween-80) as washing solution. The skin was scrub with a sterile rubber policeman for 2 minutes, and the procedure was conducted once again. Both aliquots were gathered together in a sterile tube, and a sample of 50mL was spread in a plate containing a neutralizing agar (D/E neutralizing Agar, DIFCO TM) and incubated at 35°C for 72 hrs. After incubation, the colonies were counted.
1898452|NCT01321125|Other|Preparing skin's areas to be tested|Two antiseptics (2% chlorhexidine gluconate in 70% isopropyl alcohol and 10% sodium hypochlorite) and two controls were tested as skin antiseptics. The intervention consisted of preparing four skin's areas with the antiseptic or the control, two in each arm of the volunteer. These ones were approximately 25cm2 on the forearm for each antiseptic or control. The antiseptic or control were applied in an outward circular motion using a swab that was soaked with the solution. The solution was kept on the skin for 60 seconds before the bacterial culture was conducted. Every volunteer were studied in three separate occasions, alternating the four areas in every subsequent test, so every area was studied with each control or antiseptic.
1898453|NCT01321125|Biological|Antiseptic substantivity|Three antiseptics will be tested: 2% chlorhexidine gluconate in 70% isopropyl alcohol, 10% sodium hypochlorite and 10% povidone-iodine, each one will be applied on the surface of one fingertip each, and will be allow to dry for 60 seconds, then the remaining antiseptic on the skin will be wash out with distilled water. The evaluated zones will be dried with sterile gauze, and then will be covered with sterile gauze for two hours. After this period, each finger will be placed for 30 seconds on an agar plate, which will be inoculated whit an ATCC E. coli. The plate will be incubated at 35ºC for 72 hrs. After incubation, a blinded technician will report the presence or absence of bacterial growth
1898454|NCT01321138|Procedure|Femoral nerve block|The femoral nerve block will be performed with ultrasound 30 minutes before the intervention
1898455|NCT01321138|Procedure|PCA morphine|Postoperative analgesia with self-administration iv morphine
1898456|NCT01321151|Dietary Supplement|Resveratrol|The dose of resveratrol is 500 mg. The route of administration is oral, once-a-day for 30 days after injury.
1898457|NCT01321151|Dietary Supplement|Placebo|The placebo is a sugar pill. The route of administration is oral, once-a-day for 30 days after injury.
1898458|NCT01321164|Device|Full Body UV Therapy System UV 7002 plus fumaric acid esters|"Combination therapy of narrow band type B ultraviolet (UVB) therapy plus fumaric acid esters therapy.
Narrow band UVB therapy: 3 times a week for 6 weeks; Fumaric acid esters therapy: Capsules, schema therapy, 1 to 3 times a day for 6 months"
1898459|NCT01321164|Drug|Fumaric acid esters|Monotherapy, Capsules, schema therapy, 1 to 3 times a day, 6 months
1898460|NCT01321177|Behavioral|Integrated Treatment|"Integrated program of treatments and services delivered by a coordinated team of providers that includes:
education about schizophrenia and its treatment for the participants and their family members
medication for symptoms and preventing relapse that uses a computerized decision support system
strategies for managing the illness and building personal resilience
help getting back to school or work using a supported employment/education model"
1898461|NCT01321177|Behavioral|Community Care|"Standard mental health treatments and services offered at the local agency that may include :
medication for symptoms and preventing relapse
psychosocial therapy which may include a range of behavioral treatments and supportive services
Case management"
1898462|NCT01321255|Drug|FDC|FDC includes a combination of 100 mg aspirin, 40 mg simvastatin, and 2.5;5;10 mg Ramipril
1898463|NCT01321255|Drug|Separately drugs, simvastatin, aspirin and ramipril|Aspirin 100 mg once a day Ramipril 2.5; 5; 10 mg once a day Simvastatin 40 mg once a day
1898464|NCT01321268|Dietary Supplement|dietary supplement for cellulite (PUFA, resveratrol, lycopene, beta carotene, lutein)|oral, twice daily in morning and evening for 6 months
1898465|NCT01321268|Dietary Supplement|Viatmin E|oral, twice daily in morning and evening for 6 months
1898466|NCT01322594|Biological|MEDI2338|MEDI2338 single intravenous (IV) dose (lowest dose)
1898467|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
1898468|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
1898469|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (next highest dose)
1898470|NCT01322594|Biological|MEDI2338|MEDI2338 single IV dose (highest dose)
1898471|NCT01322594|Other|Placebo|Placebo single IV dose
1898472|NCT01322607|Behavioral|High-intensity Treadmill Exercise|High-intensity treadmill walking program
1898473|NCT01322607|Behavioral|Low-intensity Lifestyle Intervention|A low-intensity lifestyle intervention targeted towards group exercises incorporating balance, coordination, and strength.
1898474|NCT01322620|Other|No treatment given|No treatment given. Participants are to complete a questionnarie in the study.
1898475|NCT01322633|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
1898476|NCT01322633|Other|Does not apply|This is a non-interventional study, therefore the intervention type / name do not apply.
1898477|NCT01322646|Device|CarChipPro|On board driving monitor
1898478|NCT01322646|Behavioral|Driver's Education|10 Session License to Learn Program.
1898479|NCT01322646|Behavioral|STEER Program|8-session behavioral parent training and teen social skills/communication training program
1898480|NCT01322646|Other|Driving Simulator Practice|Practice Driving on a driving simulator
1898481|NCT01322659|Device|Helmet|Weaning from mechanical ventilation with noninvasive positive pressure ventilation delivered by means of the helmet
1898482|NCT01322659|Device|Endotracheal tube|Weaning from mechanical ventilation with invasive mechanical ventilation delivered by means of the endotracheal tube
1898521|NCT01323062|Drug|Bavituximab|Administered 3 mg/kg weekly
1898522|NCT01323075|Procedure|Truncal block|Patients will have a truncal block during hand or wrist surgery.
1898483|NCT01322698|Biological|Tests for candidiasis|Tests include (1) anti-candida antibody ELISA kit; (2) candida antigen ELISA kit; (3) detection of circulating Candida DNA via SYBR Breen qPCR Master mix; (4) colonization index based on mycological examination of five out of the following: urine, oral swab, bronchial aspirate, anal swab, swab of a central venous line, gastric liquid.
1898484|NCT01322711|Drug|Atorvastatin|Atorvastatin 40 mg day
1898485|NCT01322711|Drug|Placebo|Diet
1898486|NCT01322724|Procedure|Warm vs Cool water|Body vs Room temperature water used during insertion of colonoscopy
1898487|NCT01322737|Procedure|Tissue Access and Resection System|This feasibility trial will assess the effectiveness of SuMO System to create a submucosal pocket and resect the overlying mucosa in excised human colonic or gastric tissue
1898488|NCT01322776|Drug|Combination of Bortezomib, Fludarabine and Cyclophosphamide|bortezomib 1.3mg/m^2 i.v. on days 1, 4, 8 and 11 of each 28-day cycle fludarabine 25mg/m^2 i.v. on days 1~3 of each 28-day cycle cyclophosphamide i.v. on days 1~2 of each 28-day cycle
1898489|NCT01322789|Biological|Intravenous Mesenchymal stem cell infusion|Four consecutive intravenous infusions 1 week apart followed by 4 consecutive infusions 1 month apart
1898490|NCT01322802|Biological|pUMVC3-hIGFBP-2 multi-epitope plasmid DNA vaccine|Given ID
1898491|NCT01322802|Other|laboratory biomarker analysis|Correlative studies
1898492|NCT01322815|Drug|chemotherapy and GI-4000|"Standard chemotherapy and bevacizumab 40YU GI-4000 prior to initiation of chemotherapy and then intercycle 7 days after each chemotherapy cycle for up to 8 cycles.
maintenance of GI-4000 injection and bevacizumab every 2 weeks"
1898493|NCT01322815|Drug|GI-4000|40 YU GI-4000 every 2 weeks Bevacizumab every 2 weeks
1898494|NCT01322828|Procedure|Distal bicep tendon reconstruction|Randomized to either a single incision technique or a double incision technique.
1898495|NCT01322841|Other|CHICA Diagnosis Module|The CHICA module helped to screen and diagnose patients with tuberculosis or iron deficiency anemia
1898496|NCT01322841|Other|CHICA Placebo|This was CHICA without the screening module
1898497|NCT01322854|Radiation|IMRT with an simultaneous integrated boost|IMRT in 28 fractions delivering 50.4 Gy to the whole breast and 64.4 Gy to the tumor-bed
1898498|NCT01322867|Drug|alprazolam tablet|0,25 mg oral tablets given once
1898499|NCT01322867|Drug|alprazolam oral solution|0,75 mg/ml Oral Solution (Drops) given once
1898500|NCT01322880|Behavioral|Discussion sessions|Those selected were invited to attend a 6 session course on household decision-making with their spouses. Topics included budgeting, household financial management, and negotiation skills
1898501|NCT01322880|Behavioral|Village Savings and Loans Associations|The approach developed by CARE International develops Village Savings and Loan Associations (VSLAs). A VSLA is a self-selected group of people who pool their money into a fund from which members can borrow. The money is paid back with interest, causing the fund to grow. The regular savings contributions to the Association are deposited with an end date in mind for distribution of all or part of the total funds (including interest earnings) to the individual members, usually on the basis of a formula that links payout to the amount saved. This lump sum distribution provides a large amount of money that members can then use as they want, without restriction.
1898502|NCT01322906|Other|Group 1|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(2×105/Kg, once a week, 4 times).
1898503|NCT01322906|Other|Group 2|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(1×106/Kg, once a week, 4 times).
1898504|NCT01322906|Other|Group 3|Thirty of the enrolled patients were assigned to Group B to receive comprehensive treatment, as well as allogeneic bone marrow mesenchymal stem cells transplantation by peripheral vein(5×106/Kg, once a week, 4 times).
1898505|NCT01322919|Procedure|Supracor|"All patients will undergo LASIK treatment on their non-dominant eye with a new laser software algorithm designed to treat both the distance and near vision components.
The developed software algorithm uses the subjective refraction of the eye to create a treatment for the distance vision correction. This part of the treatment does not show any difference to a regular LASIK treatment for ametropic cases.
In addition to the treatment for the distance vision a central ablation component will be added to address the near vision."
1898506|NCT01322958|Device|Pelvic Ultrasound|Pelvic ultrasound performed by the emergency physician
1898507|NCT01322971|Drug|Metronidazole|Metronidazole 500mg orally twice daily for seven days
1898508|NCT01322971|Drug|Placebo|Placebo will be administered orally twice daily for seven days
1898509|NCT01322984|Behavioral|Pictures|The participants will be exposed to pictures of faces and non-facial stimuli presented on a PC screen.
1898510|NCT01322984|Behavioral|Startle eliciting noise|Startle will be elicited by 95 dB noise, presented at different times after picture onset.
1898511|NCT01322997|Device|Myomo e100 Robot and repetitive task specific training|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include about 1/2 an hour of use of a robot that targets arm function and assists with the movement of the affected arm, and about 1/2 an hour of repetitive task specific training (TRP) using the affected arm.
1898512|NCT01322997|Behavioral|Repetitive task specific training (RTP) targeting the affected arm|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. This therapy will include consist of repetitive task specific training (RTP) using the affected arm, in which patients use the arm to relearn valued movements using their arms.
1898513|NCT01322997|Device|Myomo e100 neurorobotic brace|Subjects in this group will be administered about an hour/day of therapy targeting the affected arm. Subjects will use a robot that targets arm function and assists with the movement of the affected arm.
1898514|NCT01323010|Drug|Albuterol - Experimental|The Experimental group will receive higher doses of albuterol in the first hour: 900 mcg (up to 15 kg), 1200 mcg (> 15 to 20 kg), 1500 mcg (> 20 to 25 kg) and 1800 mcg (> 25 kg).
1898515|NCT01323010|Drug|Albuterol - Control|The Control group will receive the following doses of albuterol in the first hour 600 mcg (up to 25 kg) or 1200 mcg (> 25 kg)
1898516|NCT01323023|Behavioral|varies by project|
1898517|NCT01323036|Dietary Supplement|Krill oil|Krill oil:Total omega-3 fatty acids: 560-660 mg and Astaxanthin: 1800 µg
1898518|NCT01323036|Dietary Supplement|Fish Oil|Fish oil: Total omega-3 fatty acids: 560-660 mg
1898525|NCT01323088|Other|Aerobic exercise|Supervised aerobic exercise using treadmills, bikes, and ellipticals
1898526|NCT01323101|Drug|Doxycycline|Doxycycline 40mg, 100mg, 200mg tablet once daily, or no drug for 28 days.
1898527|NCT01323101|Other|No doxycycline|
1898528|NCT01323114|Procedure|Laparoscopic duodenal exclusion|Laparoscopically-performed Roux-en Y intestinal bypass of the duodenum and proximal jejunum; stomach remains normal size and proximal division performed just distal to pylorus.
1898529|NCT01323114|Other|Conventional Medical Treatment|Standard of care medical treatment for type 2 diabetes to include medications and dietary management under the monitoring of the study endocrinologist.
1898530|NCT01323127|Procedure|Sagital xrays|5 xrays will be taken: (1) Upright standing position; (2) Upright, straight chair position; (3) Slouching, straight chair position; (4) Upright, ergonomic chair position; (5) Slouching, ergonomic chair position.
1898531|NCT01323140|Drug|testosterone matrix transdermal system|
1898532|NCT01323153|Drug|dalcetrapib|Oral doses of 600 mg once daily for 20 weeks
1898533|NCT01323153|Drug|placebo|Oral doses of matching placebo to dalcetrapib once daily for 20 weeks
1898534|NCT01323166|Procedure|Excision of the levator muscle|Cylindrical perineal excision including the levator muscle
1898535|NCT01323192|Drug|JNS001|Participants will receive JNS001 (18 mg, 36 mg, 54 mg or 72 mg per day) orally once daily for 8 weeks.
1898536|NCT01323192|Drug|Placebo|Participants will receive matching placebo orally once daily for 8 weeks.
1898537|NCT01323205|Drug|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg according to tolerability dose range increased stepwise from 50 mg to 150 mg capsule by mouth orally. Capsule (s) taken twice daily with a meal for 12 weeks.
1898538|NCT01323205|Drug|JNJ-40411813|JNJ-40411813 starting dose from 50 to 150 mg as an add-on therapy. Dose is increased step-wise from 50 mg to 150 mg. Capsule(s) taken by mouth twice daily with a meal for 10 weeks.
1898539|NCT01323205|Drug|Placebo|Placebo capsule (s) orally twice daily with a meal for 4 weeks.
1898540|NCT01323205|Drug|Antipsychotic medication|Regular antipsychotic medications (Risperidone, Olanzapine, Clozapine, Amisulpride, Quetiapine, Paliperidone, Aripiprazole, Haloperidol, Levomepromazine, Zuclopenthixol Hydrochloride, Clotiapine, Pipamperone Hydrochloride, Benperidol, Flupentixol, Fluphenazine Decanoate, Melperone Hydrochloride, or Chlorpromazine Hydrochloride) will be continued in Part B.
1898541|NCT01323218|Drug|25 OH vitamin D|After written informed consent, patients will be randomized to receive a single dose of oral vitamin D (400 000 UI) or placebo. Subjects will undergo medical screening before randomisation into placebo or active group. Follow-up measurements will be performed at the beginning (day 0) and after 32 days of vitamin D supplementation: clinical examination, biological check up and sleep parameter evaluation. Patients will be instructed to stop using continuous positive airway pressure device for two nights before nocturnal sleep studies
1898542|NCT01323231|Behavioral|XY-Zone|"The XY-Zone works to empower students to decrease risk factors and increase protective factors through three linear treatment steps. The first step is driven by guiding principles known as the five R's: respect, responsibility, relationship, role modeling, and reaching out. Through these principles, the participant explores healthy psychosocial behaviors and thoughts in a structured 10 session group setting. The leadership step builds upon the guiding principles and employs activities exploring true leadership through 10 sessions. During the leadership step, participants organize and carry out a service learning projects in their community. The third and final step is ambassador. Those in the ambassador step become a mentor to those in step one and are expected to explore the principles of leadership and the five R's, and determine their personal relevance to their lives as young men (Allen, 2009, p. i)."
1898543|NCT01323244|Drug|TMC435|Type=exact number, unit=mg, number=150, form=capsule, route=oral use, once daily for 12 weeks in addition to peginterferon alfa-2a peginterferon and ribavirin for 24 or 48 weeks
1898544|NCT01323257|Drug|erythromycin|500 mg tablets three times a day for 6 days + 1 morning dose for 7th day (Trt B)
1898545|NCT01323257|Drug|Ritonavir|100 mg tablet once daily for 7 days (Trt E, F)
1898546|NCT01323257|Drug|TMC435|150 mg capsule once daily for 7 days (Trt A, C, D)
1898547|NCT01323257|Drug|Darunavir|2 x 400 mg tablet once daily for 7 days (Trt E, F)
1898548|NCT01323257|Drug|TMC435|50 mg capsule once daily for 7 days (Trt F)
1898549|NCT01323257|Drug|erythromycin|500 mg tablets three times a day for 7 days (Trt C)
1898550|NCT01323270|Biological|rLP2086|0.5 mL dose, given at 0, 2 and 6 months.
1898551|NCT01323270|Biological|Repevax|0.5 mL dose, given at 0 months.
1898552|NCT01323270|Biological|Saline|0.5 mL dose, given at 0, 2 and 6 months.
1898553|NCT01323270|Biological|Repevax|0.5 mL dose, given at 0 months.
1898554|NCT01323283|Dietary Supplement|Omega-3|This group will receive capsules containing omega-3, omega-6 and vitamin E. The dosage is six capsules per day containing a total of 558 mg of eico-pentaenoic acid (EPA), 174 mg of docosahexaeonic acid (DHA), 60 mg of gamma-linolenic acid (GLA) and 9,6 mg vitamin E in natural form (alfa-tocopherol), gelatine, glycerol. Participants will be instructed to eat three capsules each morning and evening.
1898555|NCT01323283|Dietary Supplement|Placebo|This group will receive capsules containing rape seed oil. Participants will be instructed to eat three capsules each morning and evening.
1898556|NCT01323296|Other|Ferumoxytol|One dose of intravenous ferumoxytol (4 mgFe/kg body weight at a rate of up to 1 mL/sec)
1898557|NCT01323309|Behavioral|Individual Meaning-Centered Psychotherapy (IMCP)|IMCP is based on the principles of Viktor Frankl's Logotherapy, and is designed to help patients with advanced cancer sustain or enhance a sense of meaning, peace and purpose in their lives even as they approach the end of life. IMCP is structured as a 7-session (1-hour weekly sessions) individual intervention that utilizes a mixture of didactics, discussion and experiential exercises that focus around particular themes related to meaning and advanced cancer. In addition we will be asking patients in the IMCP arm to complete an optional weekly session rating survey
1898590|NCT01323569|Drug|Sativex|Sativex dose level 1: 10.8 mg THC/10 mg CBD (4 sprays) + 12 placebo sprays + 4 placebo capsules.
1898591|NCT01323569|Drug|Sativex|Sativex dose level 2: 21.6 mg THC/20 mg CBD (8 sprays) + 8 placebo sprays + 4 placebo capsules
1898592|NCT01323569|Drug|Sativex|Sativex dose level 3: 43.2 mg THC/40 mg CBD (16 sprays) + 4 placebo capsules
1898593|NCT01323569|Drug|Placebo|16 placebo sprays and 4 placebo capsules
1898730|NCT01324518|Drug|Placebo for ORM-12741|Placebo twice a day
1898558|NCT01323309|Behavioral|standard Individual Supportive Psychotherapy (ISP)|The ISP intervention utilized as the comparison treatment condition in this study, is adapted from the Supportive Group Psychotherapy manualized intervention developed by David Payne (1997) and adapted by Drs. Kissane, Breitbart and colleagues into the ISP manualized intervention. This intervention is a 7-session individual supportive psychotherapy utilizing an approach to supportive psychotherapy based on models described by Rogers. The essential components of supportive psychotherapy are integrated into this manualized intervention, including: reassurance, explanation, guidance, suggestion, encouragement, affecting changes in patient's environment, and permission for catharsis.
1898559|NCT01323309|Behavioral|enhanced usual care (EUC)|"We are therefore including what we refer to as an enhanced usual care arm to this randomized controlled trial to address the ethical issues raised by utilizing a usual care condition in a vulnerable advanced cancer population. Participants will receive feedback about their level of distress (based on the DT administered at screening) and given appropriate targeted referrals based on levels of distress and problem areas endorsed. Participants will be given a letter with a list of appropriate referrals."
1898560|NCT01323335|Drug|IV Uric Acid|
1898561|NCT01323335|Drug|IV Rasburicase|
1898562|NCT01323348|Behavioral|Diabetes Education|"The intervention will consist of the following at enrollment and at each follow-up visit (but no more frequently than once every 12 weeks):
Measurement of HbA1c in office with immediate feedback
Measurement of blood pressure with immediate feedback
Assessment of retinopathy risk with immediate feedback
Personalized risk assessment reports based on current HbA1c
Brief assessment of patient understanding of key issues with immediate feedback
Supplemental diabetes management educational materials (provided at baseline only)
Feedback to primary care provider
Email reminder to study participants with email access of individualized risk assessment findings"
1898563|NCT01323361|Procedure|Laparoscopic ventral hernia repair|Patients operated with laparoscopic repair of ventral or incisional hernia
1898564|NCT01323374|Drug|Droxidopa|Oral, 200mg, 400mg or 600mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
1898565|NCT01323374|Drug|Carbidopa|Oral, 25mg, or 50mg TID, duration includes up to a 1 week blinded titration period followed by an 8 week treatment period.
1898566|NCT01323374|Drug|Droxidopa/carbidopa|Oral, 200mg/25mg, 400mg/25mg, 600mg/25mg, 200mg/50mg, 400mg/50mg, or 600mg/50mg TID. Duration includes up to a 1 week titration period followed by an 8 week treatment period.
1898567|NCT01323374|Drug|Placebo|Oral, placebo TID
1898569|NCT01323400|Drug|Pazopanib|Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.
1898570|NCT01323400|Other|Best supportive care|"Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed).
Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency."
1898571|NCT01323426|Procedure|Periurethral injection|Periurethral injection of autologous muscle fibers
1898572|NCT01323439|Device|Axium™ MicroFX™ PGLA COILS|Axium™ MicroFX™ PGLA COILS to treat aneurysms
1898573|NCT01323452|Drug|Entecavir|once daily
1898574|NCT01323465|Drug|Sativex and rifampicin|Single dose of 4 sprays Sativex on Day 1, Rifampicin 2 x 300 mg capsules on Days 2-10, Sativex dose of 4 sprays and rifampicin 2 x 300 mg capsules on Day 11.
1898575|NCT01323465|Drug|Sativex and rifampicin|Rifampicin 2 x 300 mg capsules on Days 1-9, Sativex x 4 sprays and rifampicin 2 x 300 mg capsules on Day 10, Single dose of Sativex 4 sprays on Day 18.
1898576|NCT01323465|Drug|Sativex and ketoconazole|Single dose of 4 sprays Sativex on Day 1, ketoconazole 2 x 200 mg tablets on Days 2-5, Sativex x 4 sprays and ketoconazole 2 x 200mg on Day 6.
1898577|NCT01323465|Drug|Sativex and ketoconazole|Ketoconazole 2 x 200 mg tablets on Days 1-4, Sativex x 4 sprays and ketoconazole 2 x 200 mg tablets on Day 5, Single dose of 4 sprays Sativex on Day 9.
1898578|NCT01323465|Drug|Sativex and omeprazole|Single dose of 4 sprays of Sativex on Day 1 Omeprazole 2 x 20 mg on Days 2-6. Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 9.
1898579|NCT01323465|Drug|Sativex and omeprazole|Omeprazole 2 x 20 mg on Days 1-5, Sativex x 4 sprays and omeprazole 2 x 20 mg on Day 6, Single dose of 4 sprays Sativex on Day 9.
1898580|NCT01323478|Drug|Vortioxetine (Lu AA21004)|15 or 20 mg/day; tablets; orally
1898581|NCT01323491|Drug|Nicotine replacement therapy|Nicorette® TX tape 10mg, 15mg, 25mg Nicorette® microtab 2mg Nicorette® inhaler 10mg Nicorette® chewing gum 2 mg, 4mg freshfruit, freshmint, mint, whitemint
1898582|NCT01323504|Other|Music|Patient are listen music during their local care
1898583|NCT01323504|Other|no music|There are no music during the local care
1898584|NCT01323517|Drug|Ipilimumab, Melphalan and Dactinomycin|Isolated limb infusion ((ILI) with Melphalan and Dactinomycin- MSKCC operating room. Ipilimumab- IV administration in outpatient chemotherapy clinic. Induction therapy with Ipilimumab will start 1-3 weeks after ILI in the standard dose of 10mg/kg every 3 weeks for a total of 4 doses. Patients will then receive chronic therapy every 3 months. Patients will be followed every 3 months for 2 years.
1898585|NCT01323530|Drug|Eribulin mesylate administration as a 2 to 5 min IV infusion at on Day 1|Oral capecitabine 1000 mg/m2 bid on Days 1-14 (21-day cycles). If MTD is not observed at dose level 3 the dose of capecitabine might be escalated to 1250 mg/m2 bid on Days 1-14(21-day cycles) depending on the toxicities observed and/or PK data when available. Eribulin as a 2 to 5 minute IV bolus or infusion in two different schedules and at three different dose levels.
1898586|NCT01323530|Drug|Eribulin mesylate administration as a 2 to 5 min IV infusion on Day 1 and Day 8|Oral capecitabine 1000 mg/m2 bid on Days 1-14 (21-day cycles). If MTD is not observed at dose level 3 the dose of capecitabine might be escalated to 1250 mg/m2 bid on Days 1-14(21-day cycles) depending on the toxicities observed and/or PK data when available. Eribulin as a 2 to 5 minute IV bolus or infusion in two different schedules and at three different dose levels.
1898587|NCT01323543|Device|Elaspine™|Implantation of device
1898588|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure with interoceptive exposure during in vivo exposure
1898589|NCT01323556|Behavioral|Cognitive Behavioural Therapy (CBT)|12 sessions of CBT including psychoeducation, behavioral analyses, interoceptive exposure and in-vivo exposure without additional fear augmenting strategies
1898594|NCT01323569|Drug|Marinol|Marinol dose level 1: 20 mg THC (2 marinol capsules) + 2 placebo capsules + 16 placebo sprays
1898595|NCT01323569|Drug|Marinol|Marinol dose level 2: 40 mg THC (4 marinol capsules) + 16 placebo sprays
1898596|NCT01323582|Drug|Erythromycin|200mg/5ml elixir administered orally three times a day half an hour prior to meals.
1898597|NCT01323582|Drug|Azithromycin|The dose of Azithromycin given was determined based on the following study on 10 healthy subjects. In random order, each of ten healthy subjects underwent OBT studies following administration of AZI, at doses of 50mg, 100mg, and 133mg. The T½ and Tlag was then compared for the three doses by a randomized block analysis using Analysis of Variance followed by Tukey's multiple comparison. Results: The T½ for each of the respective doses of AZI (50mg, 100mg, and 133mg) was 129 ± 27, 128 ± 31, and 128 ± 16 minutes (p = 0.98). This data suggested that AZI at doses of 50mg, 100mg and 133 mg have fairly similar activity in its effects on gastric emptying in healthy subjects. Based on this analysis , we decided to use a dose of 50 mg/5 ml for administered TID prior to meals.
1898598|NCT01323595|Drug|Celecoxib|Celecoxib 200mg PO BID x 6 days
1898599|NCT01323595|Drug|Sugar Pill|Sugar pill PO BID x 6 days
1898600|NCT01323608|Drug|Vitamin D3|Vitamin D3 will be given at the equivalent of the following doses: 400, 1000, and 2000 IU/day.
1898601|NCT01323608|Drug|Placebo|Placebo
1898602|NCT01323621|Drug|Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg|inhalation powder
1898603|NCT01323621|Drug|Fluticasone Propionate 250mcg / salmeterol 50mcg|inhalation powder
1898604|NCT01323621|Drug|Double-dummy placebo|inhalation powder
1898605|NCT01323621|Drug|Salbutamol as needed|inhalation powder
1898606|NCT01323634|Drug|Fluticasone Furoate 100mcg / GW642444 (vilanterol) 25mcg|inhalation powder
1898607|NCT01323634|Drug|Fluticasone Propionate 250mcg/ salmeterol 50mcg|inhalation powder
1898608|NCT01323647|Biological|PoliorixTM|Single dose, intramuscular administration
1898609|NCT01323647|Biological|Infanrix+Hib|Single dose, intramuscular injection. Part of the local standard of care. No outcome measures associated.
1898610|NCT01323660|Drug|GSK573719/GW642444 125/25|125mcg/ 25mcg QID (Once daily , inhaled)
1898611|NCT01323660|Drug|GSK573719/GW642444 62.5/25|62.5mcg/25mcg QID
1898612|NCT01323660|Drug|GSK573719 125|125mcg QID
1898613|NCT01323660|Drug|GSK573719 62.5|62.5mcg QID
1898614|NCT01323660|Drug|GW642444 25|25mcg QID
1898615|NCT01323660|Device|placebo|Comparator QID
1898616|NCT01323673|Drug|clobetasol propionate 0.05%|2 times a day, 14 total days study treatment
1898617|NCT01323673|Drug|Vehicle / Placebo|2 times a day, 14 total days of study treatment
1898618|NCT01323686|Other|Imaging guided optimal LV lead placement|"LV lead placement guided by cardiac imaging using echocardiography, single-photon emission computed tomography, and CT to target a cardiac vein at the site of latest mechanical activation without scar tissue.
Visualization of cardiac venous anatomy is performed using cardiac CT if not contraindicated by depressed renal function (estimated glomerular filtration rate <30 ml/min) or allergy to contrast media. In that case, a coronary venogram is used."
1898619|NCT01323699|Behavioral|Cognitive Behavioral Therapy|A modified version of existing Cognitive Behavioral Treatment and Self-management manuals.
1898620|NCT01323712|Dietary Supplement|Vitamin D Cholecalciferol|Cholecalciferol 100,000 Units 6 doses; 0,4,8,12,24,42 weeks
1898621|NCT01323725|Behavioral|Team-based financial incentives|Team-based financial incentives for smoking cessation at 6 month post-quit date.
1898622|NCT01323738|Behavioral|Psychoeducation|Psychoeducation group on stress and how it relates to alcohol use, 4 sessions a 45 minutes
1898623|NCT01323751|Drug|ACY-1215|Liquid oral dose on Days 1-5 and 8-12 of 21-day treatment cycle
1898624|NCT01323764|Device|ShuntCheck test|Non-invasive, thermal dilution test for CSF shunt flow compared to radionuclide shunt patency testing
1898625|NCT01323777|Device|AcrySof® IQ ReSTOR® +3.0 D Multifocal Toric IOL|Multifocal IOL with extended secondary focal point and astigmatism correction implanted for long-term use over the lifetime of the cataract patient
1898626|NCT01323790|Drug|NKTR-118|12.5 mg oral tablet once daily
1898627|NCT01323790|Drug|NKTR-118|25 mg oral tablet once daily
1898628|NCT01323790|Drug|Placebo|Placebo to NKTR-118
1898629|NCT01323816|Other|Medically directed care|There is no research directed care. Patients are treated as medically indicated.
1898630|NCT01323829|Other|EMG Guidance of Injection|The use of the EMG guidance is the experimental part of the study. We will perform EMG Needle testing in order to pin-point the best location for the patients Botox injections.
1898631|NCT01323842|Procedure|EDTU|bedside ultrasound imaging by the treating emergency physician
1898632|NCT01323855|Drug|Preladenant|After an overnight fast, a single 5 mg dose, (1 x 5 mg tablet) was administered orally
1898633|NCT01323881|Device|Intermittent theta burst stimulation|Intermittent theta burst stimulation with 1200 pulses or sham stimulation over the ipsilesional M1 hand region for 10 daily sessions in 2 weeks.
1898634|NCT01323907|Drug|Omegaven IV lipid emulsion|For infants meeting inclusion criteria and whose guardians consent to participation, Omegaven will be initiated at the dose of 0.5gram/kg/day and is infused over 24 hours for 1-2 days and then advanced to 1 gram/kg/day. Omegaven will be infused intravenously through a central or peripheral catheter alone or in conjunction with parenteral nutrition.
1898635|NCT01323920|Drug|Bortezomib|Bortezomib 1.3 mg/m^2 IV
1898636|NCT01323920|Drug|Tacrolimus|Tacrolimus 0.05 mg/kg PO bid
1898637|NCT01323920|Drug|Methotrexate|Methotrexate 15 mg/m^2 IV
1898638|NCT01323933|Drug|AB0024|Comparison of different dosages of drug
1898640|NCT01323959|Biological|BoostrixTM Polio|Single dose, intramuscular administration.
1898641|NCT01323972|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine (257049)|4 different lots of the candidate malaria vaccine (257049) representative of either commercial (manufacturing) process or pilot plant process
1898642|NCT01323985|Drug|GSK2315698|5mg-400mg IV (in the vein) single dose over 1-4 hours
1898643|NCT01323985|Drug|GSK2315698|IV (in the vein) single dose over 24 hours, in two sessions
1898644|NCT01323998|Drug|5ARI|Dutasteride or Finasteride
1898645|NCT01323998|Drug|AB|Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
1898646|NCT01324011|Behavioral|Adult diabetes family-based weight loss intervention|Participants assigned to the experimental group will begin the 2o-week weight loss intervention, while delayed intervention controls will wait until the end of this period to begin their program. The weight loss intervention includes 20 weekly group-based sessions facilitated by a registered dietitian. Each group session will last about 120 minutes and include: weight check, group sharing and problem-solving, discussion of a weight control topics (nutrition, physical activity, or behavior change), physical activity and/or taste-testing. Ten sessions will include a brief component, focused on improving family relationships for better diabetes self-care. The study weight loss goal is ≥10 pounds (minimum rate-0.5 lb/week; maximum-2 lbs/week). While the control group waits, they will receive 1 newsletter with study updates and general health or diabetes information. The delayed intervention includes 6 sessions (4 weekly + 2 bi-weekly) following the same format as the experimental group.
1898647|NCT01324024|Drug|Lisdexamfetamine|In a counterbalanced fashion, participants would receive titrated doses of LDX 20 to 60 mg/d for 4 weeks followed by a 2-week washout and then crossed over to the placebo tablets for another 4 weeks. All women will start with LDX 20 mg/d and then be titrated to 40 mg/d after 1 week and 60 mg/d after 2 weeks (as tolerated).
1898648|NCT01324024|Drug|Placebo|In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
1898649|NCT01324037|Other|diagnostic algorithm|diagnostic algorithm consisting of a clinical decision rule, D-dimer and (serial) ultrasonography
1898650|NCT01324050|Behavioral|Internet-delivered psychodynamic therapy for depression|This intervention contains 9 text-based self-help modules. These modules contain material inspired by psychoanalytic theory about identifying reoccurring patterns in life among other things. In addition to the self-help modules, 10-15 minutes of therapist contact is given every week. In total, the intervention will last for 10 weeks.
1898651|NCT01324050|Behavioral|Internet-delivered therapist support|This intervention contains 1 text-based self-help module, which is mainly based on information on depression. In addition to this text, the participants in this group gets 10-15 minutes of therapist contact every week. In the conversation with the therapist, the participant informs the therapist about the activities during the week. This intervention is considered to be a form of support. In total, the intervention will last for 10 weeks.
1898652|NCT01324063|Biological|sargramostim|
1898653|NCT01324063|Drug|amsacrine|
1898654|NCT01324063|Drug|cytarabine|
1898655|NCT01324063|Drug|daunorubicin hydrochloride|
1898656|NCT01324063|Procedure|quality-of-life assessment|
1898657|NCT01324076|Drug|doxorubicin-eluting beads|
1898658|NCT01324076|Drug|sorafenib tosylate|
1898659|NCT01324076|Other|laboratory biomarker analysis|
1898660|NCT01324076|Other|pharmacogenomic studies|
1898661|NCT01324076|Other|pharmacological study|
1898662|NCT01324076|Procedure|quality-of-life assessment|
1898663|NCT01324089|Dietary Supplement|Resveratrol|Resveratrol 2.5 grams
1898664|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose
1898665|NCT01324089|Dietary Supplement|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose|Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
1898666|NCT01324102|Behavioral|Yoga therapy|For the second aim of the study, individuals will complete an 8 week yoga intervention in a non-randomized trial to establish safe procedures for yoga for an older post colorectal cancer veteran population.
1898667|NCT01324115|Drug|NG-nitro-L-arginine|
1898668|NCT01324115|Other|laboratory biomarker analysis|
1898669|NCT01324115|Other|pharmacological study|
1898670|NCT01324115|Procedure|computed tomography|
1898671|NCT01324115|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1898672|NCT01324128|Drug|PA21 (2.5 g tablet containing 500 mg iron)|Dose range of 5.0 g/day (2 tablets/day) to 15.0 g/day (6 tablets/day).
1898673|NCT01324128|Drug|Sevelamer carbonate|Dose range of 2.4 g/day (3 tablets/day) to 14.4 g/day (18 tablets/day)
1898674|NCT01324128|Drug|PA21-1 (1.25 g tablet containing 250 mg iron)|Low dose comparator (1.25 g/day)
1898675|NCT01324141|Drug|Tempol|Tempol gel will be applied to the bilateral groins and the gluteal cleft, avoiding a 3 cm radius from the anal verge, immediately prior to each fraction of RT.
1898676|NCT01324141|Drug|5-Fluorouracil|5-FU will be delivered as 1000mg/m2/day as 96 hour continuous infusion beginning on day 1 and 29.
1898677|NCT01324141|Drug|Mitomycin-C|MMC will be delivered at a dose of 10mg/m2 on days 1 and 29
1898678|NCT01324141|Procedure|Radiation Therapy|RT will be delivered to a total dose of 50-54 Gy based on tumor characteristics.
1898679|NCT01324180|Drug|Metformin|Will be dosed orally BID as per dose level of subject as defined in dose escalation schema. Both liquid and tablet forms are allowed and can be chosen based on convenience. Metformin will be continued throughout the cycle until Day 28 or until the patient is removed from study (e.g. to pursue new lines of therapy such as transplant), whichever occurs sooner.
1898680|NCT01324180|Drug|Vincristine|1.5 mg/m^2/dose IV push (maximum single dose 2 mg) on days 2, 9, 16 and 23
1898681|NCT01324180|Drug|Dexamethasone|"10 mg/m^2/day divided BID
Take dexamethasone by mouth days 2-15"
1898682|NCT01324180|Drug|PEG-asparaginase|"2500 IU's/m^2/day
Intramuscular injection (IM) or intravenous infusion per institutional standard on days 3, 9, 16 and 23
If the patient develops an allergic reaction to PEG while being treated on this protocol, eliminate all future doses of PEG and substitute Erwinia if not intolerant of Erwinia and has no history of pancreatitis.
Patients will receive Erwinase® 25,000 IU/m^2 x 6 doses intramuscularly (IM) on a Monday/Wednesday/Friday schedule as a replacement for each scheduled dose of PEG-asparaginase on the original protocol."
1898683|NCT01324180|Drug|Doxorubicin|60 mg/m^2/day IV over 15 minutes on day 2
1898684|NCT01324180|Drug|Intrathecal chemotherapy|"IT cytarabine given intrathecally to all patients on day 1 of each cycle. Dose defined by age. May be given with staging lumbar puncture before enrollment, but must be within 72 hours of starting therapy. If not done at study entry or before, may be done on Day 2 prior to doxorubicin administration.
30 mg for patients age 1-1.99
50 mg for patients age 2-2.99
70 mg for patients greater than 3 years of age IT methotrexate given Intrathecally to all patients who are CNS negative at study entry on day 16 at the dose defined by age."
1898728|NCT01324518|Drug|ORM-12741|60mg twice a day
1898685|NCT01324193|Dietary Supplement|Pomegranate extracts|a 1000mg capsule of a purified pomegranate polyphenol supplement (POMx™, POM Wonderful, Inc. Los Angeles, CA)7 days a week for 12 months.
1898686|NCT01324219|Behavioral|Staff|Your participation will involve participating in video recordings of nursing care for a participating resident for 2-hour periods on 8 to 10 days. Communication training will be provided to staff in participating nursing homes during paid work hours regardless of their participation in the video recordings. The nursing home you work in may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
1898687|NCT01324219|Behavioral|Resident|Your participation will involve participating in video recordings of nursing care for 2-hour periods on 8 to 10. Communication training will be provided to staff in participating facilities during paid work hours regardless of their participation in the video recordings. Your nursing home may be randomly selected to receive the communication training at the start of the study or after a 3-month delay.
1898688|NCT01324232|Drug|AVP-923|AVP-923 capsules administered twice-a-day, over a 12 week period
1898689|NCT01324245|Drug|Fenoldopam|Intravenous infusion at 0.5 mics/Kg/min for three hours
1898690|NCT01324258|Drug|GSK1120212|Part1 and Part2
1898691|NCT01324258|Drug|Gemcitabine|Part2
1898692|NCT01324271|Device|Acclarent Tympanostomy Tube Delivery system (TTDS)|placement of tympanostomy tube under local anesthesia
1898693|NCT01324284|Drug|Lubiprostone|Lubiprostone is a chloride channel activator approved by the Food and Drug Administration for the treatment of chronic constipation. A randomized, double-blind, parallel-group, placebo-controlled study evaluating the effect of lubiprostone on gastric function showed slowed gastric emptying and increased small bowel and colonic transit time. Peak plasma concentration was shown to be around 1.14 hours, with a majority of the drug excreted in the urine within 48 hours.
1898694|NCT01324297|Other|skin test|four patches of 2 x 3cm thin blotting paper will be soaked with an equivalent amount (0.1 mL) of aqueous methyl nicotinate in four different concentrations: 0.1, 0.01, 0.001, 0.0001 M. The four patches will then be applied at the same time to the inner forearm for 60 seconds.
1898695|NCT01324310|Drug|Romidepsin|Romidepsin 8 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
1898696|NCT01324310|Drug|Ketoconazole|Ketoconazole 400 mg oral once daily on Days 4-8
1898697|NCT01324323|Drug|Romidepsin|14 mg/m^2 intravenous infused over 4 hours on Day 1 and Day 8.
1898698|NCT01324323|Drug|Rifampin|600 mg oral once daily on Days 4-8
1898699|NCT01324336|Drug|6-Mercaptopurine|75 mg/m2/dose/day
1898700|NCT01324349|Device|Veriset Hemostatic Patch|Topical hemostat
1898701|NCT01324349|Device|Fibrin Sealant (TachoSil®)|Topical hemostat
1898702|NCT01324362|Drug|Placebo|Twice daily dosing
1898703|NCT01324362|Drug|Placebo|Twice daily dosing
1898704|NCT01324362|Drug|FP 100mcg|Twice daily dosing
1898705|NCT01324362|Drug|FP 250mcg|Twice daily dosing
1898706|NCT01324362|Drug|FP 500mcg|Twice daily dosing
1898707|NCT01324362|Drug|FSC 100/50mcg|Twice daily dosing
1898708|NCT01324362|Drug|FSC 250/50mcg|Twice daily dosing
1898709|NCT01324362|Drug|FSC500/50mcg|Twice daily dosing
1898710|NCT01324375|Device|heat pain test (Modular Sensory Analyzer, Somedic AB, Horby, Sweden).|pain during heat test preoperatively
1898711|NCT01324388|Biological|LY2189265|Administered subcutaneously
1898712|NCT01324388|Drug|Metoprolol|Administered orally
1898713|NCT01324388|Drug|Lisinopril|Administered orally
1898714|NCT01324388|Drug|Placebo|Administered subcutaneously
1898715|NCT01324401|Drug|Peanut flour OIT|Patients will receive daily escalating dosages (Peanut flour OIT) as determined in the modified rush phase as stated in the protocol. The dosage will be escalated until a daily dose of 4000 mg is reached. A Double-blind, placebo-controlled food challenge will then consist of two challenges performed on the same day. One challenge will consist of 7 doses of peanut given every 10-20 minutes in increasing amounts up to a total of 10 grams of whole peanut (5 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
1898716|NCT01324427|Behavioral|virtual medical visit|"At the pre-set time, the Mobile Telehealth Cart will be set up in the exam room or the clinic office, and a connection with the doctor will be made through their computer. The telemedicine visit will be conducted at the same time as the regular clinic visit. During the visit, the nurse will evaluate the physical symptoms, vital signs, past medical history, present medical history, and any side effects from the autologous or allogeneic transplant. The nurse will place a digital stethoscope on the chest to listen to the heart and lungs. The virtual medical visit will take about 25 minutes. At the end of the Virtual Medical Visit, the patient will evaluate the event using a survey to assess the acceptance of the virtual visit. The surveys will be written and should take around 15 minutes to complete. The answers provided will be shared with the MD and nurses after the patient has completed all their virtual medical visits."
1898717|NCT01324440|Biological|V710 (30 µg) with MAA|Single 0.5-mL injection (30-µg) of V710 with MAA, intramuscularly
1898718|NCT01324440|Biological|V710 (30 µg) without MAA|Single 0.5-mL injection (30-µg) dose of V710 without MAA, intramuscularly
1898719|NCT01324453|Procedure|Post Conditioning + Primary PCI|Four, 30-second PTCA balloon occlusions followed by 30-seconds of reperfusion over a total of 4 minutes, in addition to Percutaneous Coronary Intervention as clinically indicated.
1898720|NCT01324453|Procedure|Standard Primary PCI|Routine Percutaneous Coronary Intervention as clinically indicated.
1898721|NCT01324466|Drug|NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
1898722|NCT01324466|Drug|Vehicle|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
1898724|NCT01324492|Drug|RAD001|
1898725|NCT01324505|Drug|semaglutide|Semaglutide will be administered once weekly by s.c. (under the skin) injections in the abdomen. A total of 13 doses of semaglutide will be administered according to a predefined dosing scheme
1898726|NCT01324505|Drug|placebo|Placebo semaglutide will be administered once for securing eligibility of subjects (willingness and ability to self inject) at the screening visit.
1898727|NCT01324505|Drug|Microgyn®|Microgyn® will be given as once daily oral dosing in two periods, each of 8 days' duration. One tablet contains levonorgestrel 0.15 mg and ethinylestradiol 0.03 mg.
1898731|NCT01324531|Procedure|Bankart repair and remplissage|Bankart repair may be completed before or after remplissage. While maintaining camera in anterior-superior portal drill guide and anchor cannula is placed through the posterior portal into remplissage site. Anchor cannula with obturator is passed through infraspinatus tendon and posterior capsule via pre-existing portal, and first anchor is placed in inferior aspect of Hill-Sachs lesion.Once anchor is inserted, penetrating grasper is passed through tendon and posterior capsule, 1 cm inferior to the initial portal entry site, to grasp and pull 1 suture limb.Second anchor is placed in superior aspect of Hill-Sachs lesion and grasper penetrator is used in same fashion to pass 1 suture limb 1 cm superior to initial portal entry site. The inferior suture is tied first with knots remaining extraarticular in the subdeltoid space. The superior suture is tied to complete remplissage.
1898732|NCT01324531|Procedure|Bankart repair|Bankart repair based on surgeon's preference
1898733|NCT01324544|Drug|Buprenorphine IV|Buprenorphine IV administered via patient-controlled analgesia (PCA) pump for at least 24 hours and up to 72 hours.
1898734|NCT01324557|Procedure|CSII and MDI|The aims of this study are to assess the potential efficacy and safety of insulin pump(MiniMed Paradigm® REAL-Time Revel™ Insulin Pump) to improve glycemic control in conjunction with continuous glucose monitoring (CGMS) for diabetic CAPD Patients.
1898735|NCT01324570|Drug|Buprenorphine transdermal system|Buprenorphine transdermal system 2.5 mcg/h, 5 mcg/h, 10 mcg/h or 20 mcg/h applied transdermally for 7-day wear.
1898736|NCT01324583|Drug|Cabazitaxel (XRP6258)|"Pharmaceutical form:solution
Route of administration: intravenous"
1898737|NCT01324583|Drug|prednisolone|"Pharmaceutical form:tablet
Route of administration: oral"
1898738|NCT01324596|Drug|Intravenous|Chemoimmunotheraphy
1898739|NCT01324596|Drug|Bortezomib|Chemoimmunotheraphy
1898740|NCT01324622|Device|Laminoplasty|Utilizing the ARCH Fixation System (Study device)
1898741|NCT01324622|Procedure|laminectomy|standard procedure
1898742|NCT01324635|Drug|Panobinostat|Given PO
1898743|NCT01324635|Radiation|Stereotactic body radiation therapy|Undergo SBRT
1898744|NCT01324635|Procedure|Quality-of-life assessment|Ancillary studies
1898745|NCT01324635|Radiation|Stereotactic radiosurgery|Undergo stereotactic radiosurgery
1898746|NCT01324648|Behavioral|Telephone-supported self-help and GP treatment as usual|"Participants' use of the BB self-help materials will be supported by three to five telephone coaching sessions that occur approximately every 2-3 weeks. Total contact time will be approximately 2 hours (2 hour total contact time will be considered brief in our study). Participants will also continue to receive whatever current treatment their general practitioner is providing."
1898747|NCT01324648|Behavioral|Unsupported self-help and GP treatment as usual|This treatment was chosen as a control for the telephone coaching component of the BB program. Participants will be sent a package containing the BB self-help materials and along with instructions on how to utilize these materials. Participants will use the materials on their own and at their own pace. Participants will also continue to receive whatever current treatment their general practitioner is providing.
1898748|NCT01324648|Other|General practitioner treatment as usual|This group will receive treatment as usual - whereby the clinic staff will inform the participant's GP of their PHQ-9 score. They will also be informed that their GP will be contacted that they are taking part in the research and that their GP will continue to support them with their depression as usual.
1898749|NCT01324661|Behavioral|Ostracism|Participants would received the ball of a computerized ball-tossing game once or twice in the beginning and then never again for the duration of the game.
1898750|NCT01324674|Other|Bach´s Flower Remedy|The subjects will have 4 drops 4 times per day, for approximately 8 months.
1898751|NCT01324674|Other|Placebo group|The subjects will have a solution non-drug type, 4 drops 4 times per day, for approximately 8 months
1898752|NCT01324687|Other|Telemedicine care|Availability of telemedicine
1898755|NCT01324739|Drug|human BNP-32|3pmol/kg/min infusion
1898756|NCT01324752|Drug|PA21 and Losartan with Food|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
1898757|NCT01324752|Drug|No PA21; Losartan with food|The maximum dose of Losartan will be 100 mg/day.
1898758|NCT01324752|Drug|PA21 with food and Losartan 2 hours later|The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Losartan will be 100 mg/day.
1898759|NCT01324765|Behavioral|TARGET|12-session group therapy twice weekly 6 weeks
1898760|NCT01324765|Behavioral|SGT|12 sessions supportive group therapy twice weekly 6 weeks
1898761|NCT01324778|Device|OsseoSpeed TX|OsseoSpeedTM TX implants of lengths 6-17 mm
1898762|NCT01324778|Device|OsseoSpeed|OsseoSpeedTM implants of lengths 6-17 mm
1898763|NCT01324791|Procedure|anti-reflux surgery|
1898764|NCT01324817|Device|Kai Spot (v 2.1)|The Kai Spot (v 2.1) provides a measurement of respiratory rate at a single point in time for neonates, pediatrics, and adults.
1898765|NCT01324817|Device|Kai Continuous (v 1.0)|The Kai Continuous (v 1.0) provides a continuous monitor, measurement, and display of the respiratory rate, respiratory patterns, depth of breath, history/events and respiratory activity of a subject for neonates, pediatrics, and adults.
1898766|NCT01324830|Drug|day 1 to day 5|low to high dose
1898767|NCT01324830|Drug|day 1 to day 14|low to high dose
1898768|NCT01324843|Drug|EMLA Cream|
1898769|NCT01324843|Drug|Aveeno Daily Moist|
1898770|NCT01324843|Device|Derma Vax|
1898771|NCT01324843|Procedure|Intradermal Electroporation|
1898772|NCT01324843|Procedure|Visual Analogue Scale|
1898773|NCT01324843|Procedure|Present Pain Intensity|
1898774|NCT01324843|Procedure|McGill Pain Questionnaire|
1898775|NCT01324843|Procedure|Skin Assessment|
1898845|NCT01316861|Drug|Bayer Acarbose|Bayer Acarbose 50 mg 3 times a day
1898846|NCT01316874|Drug|Valrubicin, 800 mg|Investigator will be responsible for regulating the use of concomitant medications (systemic and/or topical anticholinergic therapy or topical anesthesia) and other medications.
1898847|NCT01316887|Drug|125/25 mcg once-daily GSK573719/GW642444|GSK573719/GW642444
1898848|NCT01316887|Drug|125mcg once-daily GSK573719|GSK573719
1898776|NCT01324856|Procedure|Pancreatico gastro anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico gasto teremino-lateral anastomosis will be performed. The anastomosis will be done with posterior wall of the stomach. Pancreas will be mobilized at least 5 cm, two tobaco stiches will be applied on posterior wall of the stomach and hole of 2 cm will be done in the middle. Anterior wall of the stomach will be opened, for easier placement of the pancreas in to the stomach cavity. Pancreas will be entered in the stomach trough , tobacco stitches tided and just 2 or 3 stitches will be applied on the stomach mucosa and pancreatic capsule. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
1898777|NCT01324856|Procedure|Pancreaticojejuno anastomosis|After the pylorus preserving cephalic pancreaticoduodenectomy, pancreatico jejuno termino lateral duct to mucosa anastomosis will be performed. After that classic hepatico jejuno and antecolic duodeno jejuno anatomosis will ber performed.
1898778|NCT01324869|Biological|KH902|Intravitreal injection of 0.5mg/eye/time KH902
1898779|NCT01324882|Device|Colonoscopy with Olympus Technically Improved Colonoscope|The standard colonoscopy will be performed using the Olympus Technically Improved Colonoscope.
1898780|NCT01324882|Device|Control with standard colonoscope Olympus CF-H180|Standard colonoscopy using the adult scope, Olympus CF-H180.
1898781|NCT01324908|Procedure|extracorporeal photopheresis|Undergo ECP
1898782|NCT01324908|Other|laboratory biomarker analysis|Correlative studies
1898783|NCT01324921|Other|No breakfast/beverage only|12 fluid ounces made up of one of some combination of the following: decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
1898784|NCT01324921|Other|Breakfast|1 serving of unflavored instant oatmeal and 12 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
1898785|NCT01324921|Other|10004RF|1 serving (8 fluid ounces) of the experimental beverage and 4 fluid ounces made up of one of some combination of the following:decaffeinated coffee, decaffeinated tea or water, with non-nutritive sweetener
1898786|NCT01324934|Drug|ATG-Fresenius S|"Dosage: Single high-dose of 9 mg/kg pre-operatively, followed by 3 mg/kg/d at day +2 and +4. ATG-Fresenius treatment at Days 0, +2, and +4 is mandatory.
(In case of persisting DGF, the treatment is left to the discretion of the investigator. Treatment options include the continuation of ATG-Fresenius treatment with 3 mg/kg/d at Day +6 and if deemed necessary also at Day +8 - but without corticosteroids)."
1898787|NCT01324947|Drug|pomalidomide|Oral pomalidomide 4 mg on Days 1-21 of 28-day cycle until progressive disease (PD) or unacceptable toxicity
1898788|NCT01324960|Drug|Ceplene®, IL-2, Azacitidine|Azacitidine: 75 mg/m2 subcutaneously daily for 7 days every 4 weeks. Ceplene® / IL2: Patients will receive Ceplene at 0.5 mg subcutaneous twice daily and human recombinant IL-2 at 16 400 U/kg subcutaneous twice daily during 15 days for up to 10 cycles, on days 8 to 21 of AZA cycles.
1898789|NCT01324960|Drug|Azacitidine|Azacitidine 75 mg/m2 subcutaneously daily for 7 days every 4 weeks
1898790|NCT01324973|Behavioral|eWellness|A weight management program that includes computerized delivery of evidence-based education regarding diet and physical activity, and peer coaching.
1898791|NCT01324986|Procedure|Laparoscopic anti-reflux surgery|
1898792|NCT01324999|Drug|Tadalafil|20mg/day for one month then 40mg/day for additional 4 months
1898793|NCT01325012|Procedure|Subgluteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the subgluteal location 1-3 cm caudad to the inferior border of the gluteus maximus muscle. After catheter placement, outcome measures will be assessed.
1898794|NCT01325012|Procedure|Popliteal Sciatic Nerve Block|Patients randomized to this group will receive a sciatic nerve block with the catheter tip insertion at the popliteal location 1-3 cm cephalad to the sciatic bifurcation. After Catheter placement outcome measures will be assessed.
1898795|NCT01325025|Other|High-field MRI (3 Teslas)|"anatomical location
conventional anatomical sequence T1, T2, FLAIR
diffusion tensor sequence (21 directions)
high angular resolution diffusion (HARDI) sequence
field map
reflexology T1, T2
spectroscopic imaging sequence"
1898796|NCT01325025|Other|High-field MRI (3 Teslas)|"anatomical location
conventional anatomical sequence T1, T2, FLAIR
diffusion tensor sequence (21 directions)
high angular resolution diffusion (HARDI) sequence
field map
reflexology T1, T2
spectroscopic imaging sequence"
1898797|NCT01316432|Drug|Cenderitide|Cenderitide is a novel rationally designed chimeric natriuretic peptide to be administered in this trial as either a subcutaneous injection or infusion.
1898798|NCT01316432|Other|Placebo|Placebo will be administered as a 24-hour SQ infusion
1898799|NCT01316445|Drug|nasal Midazolam|Intranasal and buccal administration of the standard IV formulation of midazolam (5mg/mL), administered via a metered dose sprayer at 0.1mL/spray (i.e. 0.5mg/spray). Administration will be via three sprays in each nostril (for nasal) or three sprays between the cheek and the gum per side (for buccal).
1898800|NCT01316458|Drug|STI571 (Glivec®)|
1898801|NCT01316471|Behavioral|Online Behavioral Intervention|The online behavioral intervention is travel-themed and participants visit 8 destinations (1 per week) designed to take 30 min each to complete. The destinations serve as an online analog for the weekly sessions used when delivering behavioral interventions face-to-face. The 8 child destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) relaxation and distraction skills, 4) school, 5) cognitive skills, 6) sleep hygiene and lifestyle, 7) staying active, and 8) relapse prevention. The eight parent destinations include: 1) education about chronic pain, 2) recognizing stress and negative emotions, 3) operant strategies I, 4) operant strategies II, 5) modeling, 6) sleep hygiene and lifestyle, 7) communication, and 8) relapse prevention.
1898802|NCT01316471|Other|Education: Online Patient Education|The purpose of the online patient education group is to control for time, attention, and computer usage. Children and parents will be provided with access to a modified version of the study website that will provide links to information from publicly available educational websites about pediatric chronic pain management. Children and parents will log onto the web program weekly at the same interval as the Online Behavioral Intervention group. Children and parents will be asked to view 3 links each week and then report a few details pertaining to the content of what they viewed.
1898849|NCT01316887|Drug|Placebo once-daily|inactive
1898850|NCT01316900|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
1898851|NCT01316900|Drug|GSK573719/GW642444 62.5/25|62.5/26 mcg once-daily
1898852|NCT01316900|Drug|GW642444|25 mcg once-daily
1898803|NCT01316497|Procedure|Remote ischemic preconditioning (RIPC)|RIPC was performed by applying a blood pressure cuff around the child's leg. The cuff was inflated to 40 mmHg above the systolic pressure in 4 cycles of 5 minutes. Every cycle of ischemia was followed by 5 minutes of reperfusion. The first RIPC cycle started after anesthesia induction when invasive arterial blood pressure was monitored. Appropriate cuff size was used choosing between four sizes. For reproducibility RIPC was performed on the right leg with only a few exceptions, when the leg was used for invasive catheters.
1898804|NCT01316497|Procedure|Control|The cuff was applied on the leg without inflation in the control group.
1898807|NCT01316523|Drug|Rituximab|Rituximab 375 mg/m2/wk x 4 weeks, to begin Day 15 of cycle 1. After 4 cycles of therapy if patient does not respond to treatment, the patient will receive a second course of Rituximab.
1898808|NCT01316523|Drug|Lenalidomide|Lenalidomide will be taken at 20 mg daily, days 1-21 of a 28 day cycle, to be continued until the disease progresses, there are too many side effects, or after twelve cycles if the patient responds to treatment.
1898809|NCT01316536|Other|provide headphones with music playing|Participants will be provided with music through headphones
1898810|NCT01316536|Other|Sounds|recorded ICU sounds will be provided to participants through headphones
1898811|NCT01316575|Device|nCPAP|The experimental group will receive nasal CPAP at 10cmH20 for one hour in the Post Anesthetic Care Unit.
1898812|NCT01316575|Device|Low Flow Oxygen|The control group will receive standard therapy of low flow oxygen via simple mask at 8 litres per minute.
1898813|NCT01316588|Other|Plastic adesive drape|Plastic adhesive drape intraoperatively on patients skin around the surgical wound on the chest and bare skin on the leg
1898814|NCT01316588|Other|Microbial Sealant|Microbial sealant intraoperatively on patients skin around the surgical wound on the leg and bare skin on the chest
1898815|NCT01316601|Drug|QAX567|
1898816|NCT01316614|Device|FNA with and without a stylet|If the patient agrees to enrollment in the study, the initial stage of the EUS exam will be performed in the usual manner. If a solid lesion that requires FNA is identified, an envelope will be opened which contains a computer generated randomization sequence for all passes. These sequences will be generated by a web-based program at http://www.randomizer.org/form.htm. Passes will be made based on the randomization, either with or without a stylet. Six passes (three with a stylet and three without a stylet) will be performed on solid lesions and four passes (two with and two without a stylet) will be performed on lymph nodes. Additional passes will be made at the discretion of the endosonographer as clinically indicated but will not be included in the data.
1898817|NCT01316627|Behavioral|Crooked Mirror Externalization Therapy|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
1898818|NCT01316627|Behavioral|Mirror Retraining Method|After subjects complete the pre-treatment assessments, the study therapist will meet with participants to design their treatment program. Treatment will be conducted every day for 15 days, Monday through Friday, for 90-minute sessions. In addition, as a part of therapy, subjects will complete homework assignments daily. Intensive CBT for BDD is done in the form of Exposure and Response Prevention (ERP) with either the mirror retraining method or the crooked mirror externalization therapy. This involves prolonged and repeated exposures to images of the perceived defects, and prevention of ritualistic behavior (e.g., camouflaging with cosmetics, skin-picking, etc.).
1898819|NCT01316653|Behavioral|GROW Healthier|Group sessions that meet once weekly for 3 months (intensive phase) with choice of phone call session as preferred by participant, phone call coaching monthly for 9 months (maintenance phase), and monthly cues to action to use one's built environment for healthy activities for 24 months (sustainability phase)
1898820|NCT01316653|Behavioral|GROW Smarter|Group sessions that meet six times over the course of three years with quarterly newsletters.
1898821|NCT01316692|Other|laboratory biomarker identification and analysis|Correlative studies
1898822|NCT01316692|Procedure|biopsy|Correlative studies
1898823|NCT01316692|Other|immunohistochemistry/tissue microarrays|Correlative studies
1898824|NCT01316692|Genetic|TdT-mediated dUTP nick end labeling assay|Correlative studies
1898825|NCT01316692|Other|mass spectrometry|Correlative studies
1898826|NCT01316718|Drug|Mesalazine|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
1898827|NCT01316718|Drug|Placebo|2g oral granules, once a day for 1 week, then 2g oral granules, twice a day for 11 weeks
1898828|NCT01316731|Other|Single legged exercise|A single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. The non-exercising leg will serve as control for the exercising leg.
1898829|NCT01316744|Drug|ketamine hydrochloride|
1898830|NCT01316744|Other|pharmacogenomic studies|
1898831|NCT01316744|Other|questionnaire administration|
1898832|NCT01316744|Procedure|assessment of therapy complications|
1898833|NCT01316744|Procedure|quality-of-life assessment|
1898834|NCT01316757|Biological|cetuximab|Given IV
1898835|NCT01316757|Drug|paclitaxel|Given IV
1898836|NCT01316757|Drug|carboplatin|Given IV
1898837|NCT01316757|Drug|erlotinib hydrochloride|Given PO
1898838|NCT01316757|Other|laboratory biomarker analysis|Correlative studies
1898841|NCT01316809|Drug|AZD8055|Patients will start at 120 mg once daily
1898842|NCT01316822|Drug|ARRY-382, cFMS inhibitor; oral|multiple dose, escalating
1898843|NCT01316848|Drug|tivozanib|tivozanib 1.5 mg capsule, 2 discrete single doses separated by 6-weeks
1898844|NCT01316861|Drug|EMS Acarbose|EMS Acarbose 50 mg 3 times a day
1898853|NCT01316900|Drug|tiotropium bromide|18 mcg once-daily
1898854|NCT01316913|Drug|GSK573719/GW642444 125/25|125/25 mcg once-daily
1898855|NCT01316913|Drug|GSK573719/GW642444 62.5/25|62.5/25 mcg once-daily
1898856|NCT01316913|Drug|GSK573719|125 mcg once-daily
1898857|NCT01316913|Drug|tiotropium bromide|18 mcg once-daily
1898858|NCT01316926|Drug|Test formulation|Paroxetine Hydrochloride 25 miligrams (mg) tablet with controlled release (Paxil CR) manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
1898859|NCT01316926|Drug|Reference formulation|Paroxetine Hydrochloride 25 mg tablets with controlled release (Paxil CR) manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
1898860|NCT01316939|Drug|GSK1605786A|GSK1605786A 500 milligrams once daily
1898861|NCT01316939|Drug|Placebo|Placebo
1898862|NCT01316939|Drug|GSK1605786A|GSK1605786A 500 milligrams twice daily
1898863|NCT01316952|Drug|Carvedilol immediate release only|All dosages of carvedilol immediate release
1898864|NCT01316952|Drug|Carvedilol extended release only|All dosages of carvedilol extended release
1898865|NCT01316952|Drug|Long acting β-blockers|All dosages of LA propranolol and SA metoprolol
1898866|NCT01316952|Drug|Other α1/β-adrenergic antagonists|i.e., labetalol. All dosages. Excluding carvedilol immediate release and carvedilol extended release.
1898867|NCT01316952|Drug|Short acting Non-selective β-blockers and short acting β1-Selective agents|All dosages of short acting non-selective β-Blockers (Carteolol, Levobunolol, Metipranolol, Nadolol, Penbutolol, Pindolol, Sotalol, Timolol) and short acting β1-Selective agents (Acebutolol, Atenolol, Betaxolol, Bisoprolol, Nebivolol)
1898868|NCT01316952|Other|No β-blocker|No β-blocker within the month prior to the index date
1898869|NCT01316965|Behavioral|Multifaceted prevention program HELP(Hospital Elder Life Program)|"A. Structured geriatric consultation will be performed by geriatricians of the MGT(Mobile Geriatric Teams) before surgery, including clinical examination and geriatric assessment
B. All members of medical and nursing staffs will attend a two hours training session performed by the MGTs and HELP(Hospital Elder Life Program) will be implemented in the surgical wards
C. On a quarterly basis, all members of medical and nursing staffs and MGTs will gathered to analyze medical records of patients having experienced a postoperative delirium."
1898870|NCT01316978|Drug|Ibuprofen|A single 2 x 100 mg dose of an experimental Ibuprofen Fast Melt Orodispersible Tablet administered orally, with a 7-day washout between visits
1898871|NCT01316978|Drug|Ibuprofen|A single 200 mg Nurofen Meltlets Orodispersible Tablet administered orally, with a 7-day washout between visits
1898872|NCT01316978|Drug|Ibuprofen|A single 2 x 100 mg dose of Junior Strength Motrin Chewable Tablet administered orally, with a 7-day washout between visits
1898873|NCT01316991|Dietary Supplement|Chewing Gum|chewing gum will be provided
1898874|NCT01316991|Dietary Supplement|No Gum|no chewing gum will be provided
1898875|NCT01317004|Drug|Fingolimod|0.5 mg/day oral capsule
1898876|NCT01317004|Drug|Standard MS DMT|Interferon beta 1a or interferon beta 1b or Glatiramer Acetate
1898877|NCT01317017|Drug|Actimmune|"All subjects will receive one intradermal injections of 0.25ml of IFN-g (Actimmune TM 100 micrograms/0.5ml), in normal appearing skin of both normal volunteers and psoriasis patients.
Blood will be taken at baseline and day 1. A skin biopsy (6mm punch) will be taken at the injection site 24 hours later.
Patients will return at one to two weeks for suture removal.
Clinical assessments done at every visit.
Patients will also be evaluated at each visit for any adverse events."
1960932|NCT03062657|Device|PRESTIGE LP™ Cervical Disc|The PRESTIGE LP™ Cervical Disc is an artificial cervical disc comprising of two low-profile metal plates that interface through a ball and trough mechanism, permitting segmental spinal motion. The PRESTIGE LP™ Cervical Disc was approved by the Food and Drug Administration (FDA) to be used at a single and two contiguous levels.
1898881|NCT01317069|Drug|Fluorouracil implant|Before the abdomen was closed, fluorouracil implant 1000mg was sprayed evenly on the surface of tumor resection area, and some of the drugs were put into mesenteric root based on the location
1898882|NCT01317082|Device|Acupressure|P 6 Pressure Point
1898884|NCT01317108|Drug|CMF Chemotherapy|
1898885|NCT01317134|Device|EndoPAT measurement|EndoPAT (Itamar Medical Ltd, Ceasarea, Isreal) quantifies the endothelium-mediated changes in vascular tone, elicited by a 5-minute occlusion of the brachial artery (using a standard blood pressure cuff). When the cuff is released, the surge of blood flow causes an endothelium-dependent Flow Mediated Dilatation (FMD). The dilatation, manifested as Reactive Hyperemia, is captured by EndoPAT as an increase in the PAT Signal amplitude. A post-occlusion to pre-occlusion ratio is calculated by the EndoPAT software, providing the EndoPAT index. EndoPAT is FDA-cleared and CE-marked.
1898886|NCT01317134|Biological|Blood Test|It is hypothesized that L-arginine/NO-metabolites are altered in pulmonary hypertension depending on disease severity. Moreover, polymorphisms in L-arginine/NO-metabolism modifying factors may influence disease severity. Analysis will be performed following established/published protocols after isolation from whole blood.
1898887|NCT01317147|Procedure|Roux-en-Y gastric bypass (RYGBP)|
1898888|NCT01317160|Device|Intermittent pneumatic compression (IPC)|6 hours IPC, daily, applied to both calves during two weeks post-operatively. The VenaFlow Elite system (Aircast, Vista, California) uses calf cuffs containing two overlapping air chambers located posteriorly on the leg. As the device cycles, the distal chamber inflates to 52 mm Hg over half a second. During the last 0.2 second of this period, the proximal chamber inflates and reaches 45 mm Hg. After six seconds of inflation the cuff deflates, and the cycle is repeated every minute.
1898889|NCT01317199|Drug|Muscadine Plus Grape Skin Extract|"Phase I: Dose escalation starts at 500mg pills given by mouth once daily for 28 days per cycle
Phase II: to be determined after maximum tolerated dose in Phase I is established"
1898890|NCT01317212|Drug|Peritumoural carboplatin administration.|Peritumoural carboplatin administration by convection-enhanced delivery (CED) through 4 implanted intracranial catheters. Infusions conducted weekly for 4 consecutive weeks.
1898933|NCT01317550|Drug|Minocycline|100 mg by mouth twice a day for a 10 week cycle.
1898891|NCT01317225|Drug|17 α hydroxyprogesterone caproate|250mg intramuscular (gluteal muscles) biweekly from enrollment until delivery.
1898892|NCT01317225|Drug|Placebo|250 mg intramuscular (gluteal muscles)biweekly from enrollment until delivery.
1898893|NCT01317238|Drug|smallpox vaccine CJ-50300|Conventional CJ-50300 2.5 x 100000 pfu/dose vaccination
1898894|NCT01317251|Other|Dietary intervention (without dairy products)|Control diet without dairy products
1898895|NCT01317251|Other|Dietary intervention (high milk content)|Diet with a high content of milk (~1200 mg Ca/d from milk)
1898896|NCT01317251|Other|Dietary intervention (high cheese content)|Diet with a high content of cheese (~1200 mg Ca/d from cheese)
1898897|NCT01317264|Other|no β-glucan|daily consumption of non-β-glucan containing milk drinks together with the 3 main meals for 21 days
1898898|NCT01317264|Other|oat β-glucan|daily consumption of 5g of oat β-glucan in the form of milk drinks with the 3 main meals for 21 days
1898899|NCT01317264|Other|barley β-glucan|"daily consumption of 5g β-glucan extracted from the barley-mutant mother Bomi in the form of milk drinks with the 3 main meals for 21 days"
1898900|NCT01317264|Other|mutant-barley β-glucan|"daily consumption of 5g β-glucan extracted from the high β-glucan barely mutant lys. 5.f in the form of milk drinks with the 3 main meals for 21 days"
1898901|NCT01317277|Behavioral|individualized Texting for Adherence Building (iTAB)|Intervention is designed to send automated text messages to HIV+ persons who are current methamphetamine (METH+) users. Text messages are personalized, automated, real-time text messages. The iTAB intervention is designed to improve adherence to ART medications among HIV+/METH+ persons above and beyond an active comparator group.
1898902|NCT01317277|Behavioral|Psychoeducation|Participants will also receive daily text messages to evaluate mood and methamphetamine use, but these messages will not remind participants about medication adherence.
1898903|NCT01317290|Dietary Supplement|n-3 PUFA free olive oil|negative control
1898904|NCT01317290|Dietary Supplement|linseed oil|
1898905|NCT01317303|Procedure|cTBS-PAS25|40 seconds of continuous Theta-burst stimulation, followed by PAS25 which refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after
1898906|NCT01317303|Procedure|cTBS-iTBS|40 seconds of continuous Theta-burst stimulation, followed by 190 seconds of intermittent Theta-burst stimulation
1898907|NCT01317303|Procedure|PAS25|PAS25 refers to the intervention 'paired-associative stimulation' with peripheral ulnar nerve stimulation followed by TMS to the motor cortex 25 ms after.
1898908|NCT01317303|Procedure|iTBS|190 seconds of intermittent theta-burst stimulation
1898909|NCT01317329|Other|Clinically prescribed CPAP therapy|CPAP as prescribed by attending physician
1898910|NCT01317342|Device|Hypothermic oxygenated perfusion (HOPE)|Application of HOPE for 1 hour, perfusion rate 150-300 ml/min, pressure controlled, perfusion pressure < 3 mm Hg, perfusion route portal vein, recirculating system, perfusion volume 2 L, perfusate Institute George Lopez solution (IGL-1), perfusate temperature 4-6 °C, perfusate oxygenation 150-200 mm Hg
1898911|NCT01317368|Drug|Naropine|"20 mL of 0,75% Naropin is deposited on each side (40 mL in total) in the TAP.
At the same time 40 mL of saline 0,9% will be deposited subcutaneously as wound infiltration.
Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
1898912|NCT01317368|Drug|Naropine|"20 mL Saline 0,9% is deposited on each side (40 mL in total) in the TAP.
At the same time 40 mL Ropivacaine 0,75% will be deposited subcutaneously as wound infiltration.
Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
1898913|NCT01317368|Other|Placebo|"20 mL 0,9% Saline is deposited on each side (40 mL in total) in the TAP.
At the same time 40 mL Saline 0,9% will be given as wound infiltration.
Both procedures is carried out at the end of the surgery while the patient is still anaesthetized and only this once."
1898914|NCT01317381|Procedure|Observational|Blood draw
1898915|NCT01317420|Drug|BI 836845|Intravenous infusion once every three weeks
1898916|NCT01317433|Drug|Doxycycline|Doxycycline 100 mg daily per os to start 7 days before Cetuximab for 6 weeks.
1898917|NCT01317433|Drug|Cetuximab|500 mg/m² IV infusion of 60 minutes every 15 days
1898918|NCT01317446|Drug|amine fluoride/stannous fluoride|10 ml qd, oral, topical, 6 months duration
1898919|NCT01317459|Behavioral|Guided self-determination|Group counselling
1898921|NCT01317485|Procedure|Laparoscopic lavage and drainage|"[CLOSED] The abdominal cavity is irrigated with six litres of warm saline in all four quadrants. At the end of the procedure a Douglas drain is inserted via the right lateral port.
***This part of the study was closed in 2013 on advice of the data and safety monitoring board due to safety issues"
1898922|NCT01317485|Procedure|Sigmoidectomy with primary anastomosis|[OPEN] Sigmoidectomy is done according to the guidelines of the American Society of Colon and Rectal Surgeons. The distal transsection margin has to be on the proximal rectum, the proximal margin is determined by the absence of wall thickening due to diverticulitis. The type of anastomosis is done according to the preference of the operating surgeon. A loop ileostomy can be fashioned in order to ensure faecal deviation to the discretion of the surgeon.
1898923|NCT01317485|Procedure|Sigmoidectomy with end-colostomy|[OPEN] This is a two-stage procedure with the intention to close the colostomy in a second stage. During the primary surgery, only the perforated diseased part must be resected. There is no need of having the distal transsection line on the proximal rectum.
1898924|NCT01317498|Other|Standard Care|CD4, liver function and CBC every 6 months
1898925|NCT01317498|Other|Virological Monitoring|Viral Load test every 6 months
1898926|NCT01317511|Dietary Supplement|Protein|Protein drink
1898927|NCT01317524|Dietary Supplement|Homogenized milk|900 mL homogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
1898928|NCT01317524|Dietary Supplement|Unhomogenized milk|900 mL unhomogenized milk 2 slices of bread with marmalade 2 pieces of crisp bread
1898929|NCT01317524|Dietary Supplement|Skimmed Milk|900 mL skimmed milk 44 g of salted butter 2 slices of bread 2 pieces of crisp bread
1898930|NCT01317537|Other|Electronic personal health record|
1898931|NCT01317550|Drug|Armodafinil|150 mg by mouth once a day for a 10 week cycle.
1898932|NCT01317550|Other|Placebo|Capsules taken by mouth once a day for a 10 week cycle.
1898934|NCT01317550|Behavioral|Questionnaires|Completion of symptom questionnaire before chemoradiation, then once a week during Weeks 1-16, takes up to 5 minutes to complete.
1898935|NCT01317563|Dietary Supplement|Vitamins A, E, C & Selenium|daily dose = Vitamin A 10000 IU (beta carotene), Vitamin E 400 IU, Vitamin C 1200mg, and Selenium 300mcg.
1898936|NCT01317563|Dietary Supplement|Placebo|total daily dose = 1200mg whey protein, 800mg microcrystalline cellulose
1898937|NCT01317576|Behavioral|Exercise intervention|Subjects will be training for 12 week, 3 times a week. Two times a week they will perform a 30 minutes bicycle training. Once a week they will perform a 30 minutes resistance training.
1898938|NCT01317589|Drug|fentanyl|"T = 0
start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur
breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day
T=1
1 week
if necessary increase dose strong opioid with 50%
T=2 3 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%
T=3 5 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%
T = 4 9 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%"
1898939|NCT01317589|Drug|methadone|"T = 0
start methadone 2 x 2,5 mg or fentanyl patch 12 μg/uur
breakthrough medication: 50 µg fentanyl nose spray or fentanyl stick 400 µg till 6x/day
T=1
1 week
if necessary increase dose strong opioid with 50%
T=2 3 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%
T=3 5 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%
T = 4 9 weeks
if necessary increase dose strong opioid with 50%
if necessary decrease dose strong opioid with 30%"
1898940|NCT01317615|Drug|RAD001|Participants started RAD001 treatment with a dose of 5 mg/day once daily. A dose decrease to 5 mg every other day was allowed if tolerability issues arose.
1898941|NCT01317615|Drug|Paclitaxel|Paclitaxel was started at doses of 175 mg/m². Dose reductions of Paclitaxel to 135 mg/m2 was permitted if tolerability issues arose.
1898942|NCT01317615|Drug|Carboplatin|Carboplatin was started at doses of Area under the Curve 5 (AUC 5). Dose reductions of carboplatin to AUC 4 was permitted if tolerability issues arose.
1898943|NCT01317628|Behavioral|Tobacco smoke reduction trial intervention program|Both the parents and children will receive 8 times intervention program weekly in first session. The telephone counseling will reduce the child's tobacco smoke exposure every weekly in second session. The interventionist and child jointly select behavioral goals for reducing tobacco smoke exposure for the child to work toward. The goals will be formalized as a written smoke exposure reduction plan for any of four specific behaviors, as relevant to that family: (a) smoking cessation for the child, (b) making the child's primary home smoke-free, (c) making non-home locations smoke-free.
1898944|NCT01317641|Drug|ODM-201|ODM-201 administered orally daily
1898945|NCT01317654|Other|Observation|Collection of mortality data at 5 years post trial
1898946|NCT01317667|Biological|RVEc|
1898947|NCT01317680|Device|Omnispec model ED1000|Device: Extracorporeal Shockwave Therapy Generator (Omnispec model ED1000) Gel is spread around the penis and on the Shock Wave applicator and Treatment (12 sessions in total) of 300 shocks per site, on 5 penile anatomical sites.
1898948|NCT01317680|Device|Sham control|We use the same probe that induces the same sensation on the penis and the same noise yet no energy
1898949|NCT01317693|Device|Low intensity shock waves|1500 shocks, Energy Density - 0.09 mJ/mm2
1898950|NCT01317706|Other|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
1898951|NCT01317719|Procedure|Distal Biceps Re-Insertion Surgery|Surgical Repair of the Distal Biceps Tendon
1898952|NCT01317732|Device|MOTIONPOD (TM) measures|It is a study with a single arm. The MOTIONPOD TM measures are compared with simultaneous estimations obtained with the criteria measure (indirect calorimeter) and with existing activity monitors (heart rate monitor POLAR; different accelerometers - rT3 et Actigraph GT3X-, Actiheart, Sensewear Pro2 Armband) After physical fitness evaluation, different activity monitors are set up and the subjects perform a series of standardised activity tasks of different intensities, and well as a 30-min free activity period. Physical activity energy expenditure is measured at the end of each task using a metabolic gas analyser
1898953|NCT01317745|Other|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided be sanofi pasteur
1898954|NCT01317745|Drug|MF59 Adjuvant|Adjuvant/diluent manufactured by Novartis
1898955|NCT01317745|Biological|H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, , administered at 3.75, 7.5, or 15mcg, with either MF59 adjuvant or PBS.
1898956|NCT01317758|Drug|AS03 Adjuvant|Adjuvant/diluent manufactured by GlaxoSmithKline (GSK)
1898957|NCT01317758|Other|Phosphate Buffered Saline (PBS) diluent|Placebo/diluent provided by sanofi pasteur
1898958|NCT01317758|Biological|Sanofi H5N1 Antigen|Subvirion inactivated monovalent influenza A/H5N1 (Hemagglutinin (HA) of A/Indonesia/05/2005) virus vaccine manufactured by sanofi pasteur, at 2 doses levels 21 days apart, administered at 3.75, 7.5, or 15mcg, with either AS03 adjuvant or PBS.
1898959|NCT01317771|Procedure|Open proximal biceps tendon tenodesis with an EndoButton|Surgical fixation for bicipital pathology
1898964|NCT01317797|Drug|namilumab (MT203)|administered three times, subcutaneous in the abdomen
1898965|NCT01317797|Drug|Placebo|administered three times, subcutaneous in the abdomen
1898966|NCT01317823|Other|Assessment of cervical status|Assessment of cervical status based on Bishop score versus sonographically measured cervical length
1898967|NCT01317849|Drug|Folic Acid|0.8mg
1898968|NCT01317849|Drug|Vitamin B6|10mg
1898969|NCT01317849|Drug|Vitamin B12|500ug
1898970|NCT01317849|Drug|placebo|0.8 mg
1898971|NCT01317849|Drug|placebo|10mg
1898972|NCT01317849|Drug|placebo|500ug
1898973|NCT01317862|Device|Transcervical foley catheter, Prostaglandins|16 French foley catheter 10mg dinoprostone vaginal insert
1898974|NCT01317875|Drug|Ruxolitinib|"Starting dose of ruxolitinib for cohort 1 in dose escalation phase - 5mg twice a day (BID)
Doses will be increased a total of approximately 5mg for successive dosing cohorts based on baseline platelet count"
1898975|NCT01317888|Drug|MAB-425 radiolabeled with I-125|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
1898976|NCT01317901|Drug|TRU-016|100 mg TRU-016 lyophilized solution for infusion at 10 or 20 mg/kg (or 6 mg/kg, if necessary) on Days 1 and 15 of each 28 day cycle
1898977|NCT01317901|Drug|Bendamustine|Bendamustine by IV administration on Days 1 and 2 of each 28 day cycle.
1898978|NCT01317901|Drug|Rituximab|Rituximab by IV administration at 375 mg/m^2 on Day 2 of each 28 day cycle.
1898979|NCT01317914|Other|Dietary instruction|Subjects subsequently diagnosed with celiac disease will have gluten-free diet instructions given by registered dietitian experienced in the gluten-free diet. Subjects will have follow-up in 3 months time from initial instruction to verify compliance.
1898980|NCT01317927|Drug|Belinostat, Warfarin|1000 mg/m2 injection infusion given in a 30 min period plus Warfarin 5mg PO
1898982|NCT01317953|Dietary Supplement|epigallocatechin gallate|"Starting dose green tea catechin extract EGCG 400 mg twice a day (BID) of EGCG (400 mg caps BID), second escalated dose 800 mg BID of EGCG (2x400 mg caps BID), third escalated dose 1200 mg BID of EGCG (3x400 mg),fourth escalated dose 1600 mg BID of EGCG (4x400 mg),and fifth escalated dose 2000 mg BID of EGCG (5x400 mg),"
1898983|NCT01317966|Drug|rhIL-11|Recombinant Human Interleukin-11 (rhIL-11) Combinating Low-dose Rituximab
1898984|NCT01317992|Drug|Ibudilast|Ibudilast 4 x 10 mg capsules, orally, twice daily for 8 weeks.
1898985|NCT01317992|Drug|Placebo|Placebo 4 capsules, orally, twice daily for 8 weeks.
1898986|NCT01318005|Drug|Oral Contraceptive: Ortho-Novum® 1/35|Oral Contraceptive: Ortho-Novum® 1/35, pill, 2-3 mos, daily.
1898987|NCT01318005|Drug|Oral Contraceptive: Ovcon® 35|Oral Contraceptive: Ovcon® 35, pill, 2-3 mos, daily.
1898988|NCT01318005|Drug|Oral Contraceptive: Microgestin Fe® 1/20|Oral Contraceptive: Microgestin Fe® 1/20, pill, 2-3 mos, daily.
1898989|NCT01318031|Drug|Period 1|Subjects will receive a single 45 mg dose of PF-00299804 on Day 1 of Period 1.
1898990|NCT01318031|Drug|Period 2|Subjects will receive a single 30 mg tablet of paroxetine once daily for 3 days (Days 1 to 3). Then, subjects will be co-administered a 45 mg single dose of PF-00299804 plus a single dose of 30 mg paroxetine on Day 4. Single 30 mg doses of paroxetine will be administered once daily for 6 days (Days 5-10).
1898991|NCT01318044|Drug|Propofol and Thiopental|"An initial bolus of 0.5 mg/kg of propofol will be administered over 1 minute. Supplementary boluses of propofol will be added until the UMSS score 3 are achieved.
An initial bolus of 2 mg/kg of thiopental will be administered over 1 minute. Supplementary boluses of thiopental will be added until the UMSS score 3 are achieved"
1898992|NCT01318070|Drug|Alogliptin and pioglitazone|Alogliptin 12.5mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
1898993|NCT01318070|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
1898994|NCT01318070|Drug|Pioglitazone|Pioglitazone 15 or 30 mg, tablets orally once daily for up 12 weeks.
1898995|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
1898996|NCT01318083|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily for up 12 weeks.
1898997|NCT01318083|Drug|Glimepiride|Glimepiride 1, 2, 3 or 4 mg, tablets, orally, once or twice daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
1898998|NCT01318096|Drug|raltegravir and tenofovir and lamivudine|raltegravir 400mg BID and tenofovir 300mg qd and lamivudine 300mg gd for 48 weeks
1898999|NCT01318096|Drug|efavirenz+tenofovir+lamivudine|efavirenz 600mg QN +tenofovir 300mg qd +lamivudine 300mg qd for 48 weeks
1899000|NCT01318109|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
1899001|NCT01318109|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 250 mg, tablets, orally, twice or three times daily for up 12 weeks.
1899002|NCT01318109|Drug|Metformin|Metformin 250 mg, tablets, orally, twice or three times daily and alogliptin placebo-matching tablets, orally, once daily for up 12 weeks.
1899003|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 12.5 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
1899004|NCT01318122|Drug|Alogliptin and pioglitazone|Alogliptin 25 mg, tablets, orally, once daily and Pioglitazone 15 mg or 30 mg, tablets, orally, once daily for up to 40 weeks.
1899005|NCT01318135|Drug|Alogliptin and glimepiride|Alogliptin 12.5 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
1899006|NCT01318135|Drug|Alogliptin and glimepiride|Alogliptin 25 mg, tablets, orally, once daily and sulfonylurea 1, 2, 3, 4, 5 or 6 mg, tablets, orally, once or twice daily for up to 52 weeks.
1899007|NCT01318135|Drug|Alogliptin and metformin|Alogliptin 12.5 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
1899008|NCT01318135|Drug|Alogliptin and metformin|Alogliptin 25 mg, tablets, orally, once daily and metformin 500 mg, tablets, orally, twice daily or metformin 750 mg, tablets, orally, three times daily for up to 52 weeks.
1899009|NCT01318148|Drug|caspofungin|Intermittent intravenous application of caspofungin
1899010|NCT01318161|Drug|Ropivacaine + opioid epidurally|Epidural analgesia with local anesthetic + opioid
1899011|NCT01318161|Drug|Morphine|Morphine via PCA pump
1899012|NCT01318187|Drug|paracetamol|1 gr
1989996|NCT02282462|Other|Reg Pressure|Regulated Suction using the Thopaz+ digital chest drainage device
1899013|NCT01318187|Drug|morphine|0.1mg/kg intravenous in 100 ml serum physiologic
1899014|NCT01318187|Drug|Paracetamol|1 gr intravenous
1899015|NCT01318187|Drug|Paracetamol|intravenous 1 gr
1899016|NCT01318187|Drug|Morphine|0.1 mg/kg intravenous
1899017|NCT01318200|Procedure|Transarterial Chemoembolization|Transarterial Chemoembolization will be given within 12 weeks and up to 3 staged procedures, depending on the architecture of the tumor vasculature.
1899018|NCT01318200|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) or 36 Gy(12 Gy in 3 fractions). Tumors should receive the higher dose unless normal tissue constraints cannot be met.
1989997|NCT02282462|Other|Unreg Pressure|Unregulated Suction using a traditional system (multi-chambered system e.g. Pleur-Evac, Atrium-Maquet or similar device as is routine at each institution)
1989998|NCT02282462|Other|Active Suction (Dig)|Thopaz+ digital chest drainage device set at -20cmH2O at the patient
1899021|NCT01318239|Procedure|DCE MRI|"MRI and blood test(VEGFR2 signaling assay) will be undergoing at three time points in the patients with Avastin chemotherapy; at baseline (pretreatment), 3 days after Avastin alone treatment, 3 days after Avastin combined chemotherapy (about 10 days after initial Avastin alone treatment).
MRI and blood test(VEGFR2 signaling assay) will be undergoing at two time points in the patients who will get chemotherapy without antiangiogenic agent; at baseline (pretreatment), 3 days after chemotherapy."
1899022|NCT01318252|Drug|AL-54478 0.005%|
1899023|NCT01318252|Drug|Latanoprost 0.005%|
1899024|NCT01318252|Drug|AL-54478 Vehicle|Inactive ingredients used as a placebo comparator
1899025|NCT01318265|Drug|Regorafenib (BAY73-4506); Regorafenib (BAY73-4506) plus ketoconazole|Treatment 1: A single 160 mg dose of BAY73-4506. Treatment 2: Ketoconazole 400 mg once daily from Day -4 to Day 3. A single 160 mg dose of BAY73-4506 on Day 1.
1899026|NCT01318278|Drug|Dopamine|dopamine at low/medium/and high dose (5, 10, 15, and 20 mcg/kg/min) given IV as a continuous infusion, titrated up for efficacy
1899027|NCT01318278|Drug|Arginine Vasopressin|vasopressin at low/medium/and high dose (0.01, 0.02, 0.03, or 0.04 units/kg/hr) given IV as a continuous infusion, titrated up for efficacy
1899028|NCT01318291|Behavioral|CCRI Group|Cognitive Coping and Relaxation Intervention (CCRI) Cognitive Coping and Relaxation Intervention (CCRI) group who will receive a packet of relaxation and stress management suggestions
1899029|NCT01318291|Behavioral|Control|Medical treatment alone
1899030|NCT01318304|Other|Vaginal lavage specimen|Collection of 3cc of saline used in the vagina to collect innate immunity markers
1899031|NCT01318317|Procedure|peripheral blood stem cell transplantation (PBSCT)|Undergo autologous PBSCT
1899032|NCT01318317|Biological|filgrastim|Given IV
1899033|NCT01318317|Genetic|polymerase chain reaction|Correlative studies
1899034|NCT01318317|Biological|rituximab|Given IV
1899035|NCT01318317|Biological|genetically engineered lymphocyte therapy|Receive ex vivo expanded autologous central memory (TCM)-enriched CD8+ T cells expressing CD19-specific chimeric antigen receptor (CAR)
1899036|NCT01318317|Other|laboratory biomarker analysis|Correlative studies
1899037|NCT01318317|Drug|plerixafor|Given IV
1899038|NCT01318317|Procedure|autologous hematopoietic stem cell transplantation|Undergo autologous PBSCT
1899039|NCT01318330|Drug|Homeo-GH|Bone Marraw derived Clonal Mesenchymal Stem Cell (cMSC)
1899040|NCT01318356|Behavioral|Cognitive behavioral therapy|CBT will consist of a protocolized intervention of 12 sessions during a period of 24 weeks. It starts with goal setting and psycho-education on the possible role of cognitions and behavior in maintaining the fatigue. The maintaining factors will subsequently be addressed (regulation of sleep-wake cycle, gradual increasing activity, reformulating fatigue related cognitions).
1899041|NCT01318356|Drug|Doxycycline|Antibiotic therapy will consist of doxycycline once daily 200 mg (in 1 capsule) for 24 weeks. Patients will be monitored 4, 8, 16 and 26 weeks after start for side effects (rash, liver enzymes). Antibiotics will be stopped in case of side effects or pregnancy.
1899042|NCT01318356|Drug|Placebo|Patients in the placebo group will receive once daily 1 placebo capsule identical in appearance to the doxycycline for 24 weeks and have the same visits and monitoring for side effects as the patients randomized to doxycycline (Patients will be monitored 4, 8, 16 and 26 weeks)
1899043|NCT01318369|Drug|Namisol|Single dose delta-9-tetrahydrocannabinol
1899044|NCT01318369|Drug|Diazepam|Diazepam single dose 5mg in subgroup non-opioid users and 10 mg in subgroup opioid users.
1899045|NCT01318382|Device|TOF-Watch SX® Monitoring of NMB|Participants will have the extent of NMB monitored by a TOF-Watch SX®.
1899046|NCT01318395|Drug|Aliskiren|orally 150 mg/d for 1 week, then orally 300 mg/d for 7 weeks
1899047|NCT01318395|Drug|Placebo|orally once per day
1899048|NCT01318408|Drug|Levetiracetam|Titration of Keppra will start at 250 mg by mouth twice daily for three days. Then 500 mg by mouth twice daily for three days. Then 750 mg by mouth twice daily for the duration of the study, or for as long as treatment is necessary. This titration schedule is subject to change based on subject's tolerability.
1899049|NCT01318421|Drug|ELND002|
1899050|NCT01318434|Drug|EB-1010 25mg BID|capsule once daily
1899051|NCT01318434|Drug|SSRI Active|Active Comparator
1899052|NCT01318434|Drug|EB-1010 50mg BID|Experimental Active
1899053|NCT01318434|Drug|Placebo|Placebo comparator
1899054|NCT01318447|Radiation|CyberKnife SBRT|Dose is 45 Gy (15 Gy in 3 fractions) and delivered over 5 to 10 days.
1899055|NCT01325038|Procedure|Isometric exercise|Isometric exercise several times/week for three months
1899056|NCT01325051|Drug|Raltegravir|400 mg tablets by mouth BID from Day 1 - Day 7 after enrollment visit
1899057|NCT01325077|Other|model of health care service|Conventional model(C): Nurses give fixed-dose analgesic according to surgeons' prescription Study model(S): Nurses give initial-dose analgesic according to surgeons' prescription. In case of inadequate pain relief, another half of initial dose will be given twice at 15-min interval and acute pain service will be consulted if there is still pain.
1899058|NCT01325090|Drug|BOTOX|A syringe of 1 ml contain 25 Allergan units.
1899059|NCT01325090|Other|PLACEBO|The pharmacist will fill syringes in tuberculins of 1 ml with injectable solution of sodium chloride of 0,9 %.
1989999|NCT02282462|Other|Active Suction (Trad)|Pleur-Evac, Atrium-Maquet or similar set at -20cmH2O at the device.
1899060|NCT01325103|Procedure|Stem Cell Transplantation|All patients will undergo autologous bone marrow stem cell transplantation into the lesion area.
1899061|NCT01325116|Behavioral|Educational Reminder|Personalized letters sent via post to the patient and their family physician at one, five, eight, and eleven months after their angiogram, sent on behalf of the interventional cardiologist. The patient letter provides a review of the role of each of the cardiac medications and urges long-term adherence. The language in the patient letter is simplified to a grade 6 level; this letter was tested for understanding and acceptability amongst a series of Cardiology patients.At the same time, close examination of data from Ontario indicated large stepwise declines in adherence at 30 and 60 days post-STEMI. To address this, patients will be provided an additional postcard type reminder two months post-STEMI.
1899062|NCT01325168|Drug|syntocinon nasal spray|nasal oxytocin - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
1899063|NCT01325168|Drug|placebo nasal spray|nasal placebo - 24 IU, 3 inhalations of 4IU to each nostril (45 sec waiting between the inhalations)
1899064|NCT01325181|Drug|Verteporfin|a 6mg/m2 infusion of verteporfin(Visudyne; Novartis)over 10 minutes followed by laser delivery
1899065|NCT01325181|Drug|ranibizumab|Consecutive intravitreal injection of ranibizumab(Lucentis®, Novartis) 0.5mg/0.05ml for the first 3 months
1899066|NCT01325194|Drug|liposomal cytarabine|50 mg intrathecally three times
1899067|NCT01325207|Radiation|Trastuzumab|Trastuzumab will be administered twice per week for 4 weeks, then once per week for 4 weeks, and then every 2 weeks
1899068|NCT01325220|Drug|arbaclofen|5 mg bid
1899069|NCT01325220|Drug|arbaclofen|10 mg bid
1899070|NCT01325220|Drug|arbaclofen|10 mg tid
1899071|NCT01325220|Drug|Placebo|tid
1899072|NCT01325233|Drug|PG2|Powder for Injection, 500 mg PG2/500 ml normal saline, tiw, 2 weeks
1899073|NCT01325233|Drug|Placebo|500 ml normal saline, tiw, 2 weeks
1899074|NCT01325259|Other|neuropsychologic assessment|Mini Mental Status Examination, Mattis dementia rating scale, Geriatric Depression Scale, Edinburgh Inventory, DO 80, 12 irregular words dictation, RL-RI16, DMS 48, Rey complex figure, Stroop test, span right and reverse, praxis, ESR words, ESR drawings, Trail Making Test A and B, code test from WAIS III, Hayling inhibition test, fluences, NPI
1899075|NCT01325259|Radiation|[18F]AV-45 PET|intravenous injection of 4 MBq/kg of [18F]AV-45
1899076|NCT01325259|Radiation|18-FDG PET|intravenous injection of 100 to 120 MBq of FDG
1899077|NCT01325259|Other|MRI|Magnetic Resonance Imaging
1899078|NCT01325285|Device|RespirAct|"Participants will breathe through a mask connected to a sequential rebreathing circuit and gas blender. The following seven gas stages will be targeted for about 10 minutes each:
Baseline, measured in eye A (PETCO2=38mmHg and PETO2=100mmHg)
10% hypercapnic increase, measured in eye A (PETCO2=42mmHg and PETO2=100mmHg)
20% hypercapnic increase, measured in eye A (PETCO2=46mmHg and PETO2=100mmHg)
Baseline, measured in both eyes (PETCO2=38mmHg and PETO2=100mmHg)
250% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=250mmHg)
500% hyperoxic increase, measured in eye B (PETCO2=38mmHg and PETO2=500mmHg)
Baseline, measured in eye B (PETCO2=38mmHg and PETO2=100mmHg)"
1899079|NCT01325298|Device|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
1899080|NCT01325298|Drug|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
1899081|NCT01325298|Device|UV-X Light|UV-X 365 nm wavelength light source is applied to the cornea with continued application of riboflavin 0.1%
1899082|NCT01325298|Drug|Riboflavin|Riboflavin 0.1% is applied to the cornea every 2 minutes for 14 minutes prior to and also during UV-X Light treatment.
1899083|NCT01325311|Drug|Cholecalciferol|Given PO
1899084|NCT01325311|Drug|Genistein|Given PO
1899085|NCT01325311|Other|Laboratory Biomarker Analysis|Correlative studies
1899086|NCT01325311|Other|Pharmacological Study|Correlative studies
1899087|NCT01325311|Other|Placebo|Given PO
1899088|NCT01325324|Device|measurement of intraocular pressure|Intraocular pressure will be measured with the following devices (each 2 times)at the first and only study visit
1899089|NCT01325337|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
1899090|NCT01325337|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
1899091|NCT01325337|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
1899092|NCT01325337|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
1899093|NCT01325337|Drug|minoxidil 5% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
1899094|NCT01325350|Drug|bimatoprost Formulation A|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
1899095|NCT01325350|Drug|bimatoprost Formulation B|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
1899096|NCT01325350|Drug|bimatoprost Formulation C|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
1899097|NCT01325350|Drug|bimatoprost vehicle solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, once daily for 6 months.
1899098|NCT01325350|Drug|minoxidil 2% solution|Approximately one mL dose applied evenly onto pre-specified area on scalp, twice daily for 6 months.
1899099|NCT01325363|Device|Magnetoencephalograph (MEG)|Brain imaging device that records the magnetic fields in the brain.
1899100|NCT01325714|Behavioral|PAVeD Intervention|In the PAVeD Intervention, the caregiver will receive six to eight 45-minute visits to teach caregiver about pain and memory problems. The person with dementia will also be able to learn from these visits. These visits will take place over three months.
1899101|NCT01325714|Behavioral|Enhanced Usual Care|"In Enhanced Usual Care, the caregiver will receive information in the mail about memory problems and pain; and the caregiver will receive eight short telephone calls to check on how the person with dementia is doing.
Primary Care providers will be notified through electronic medical records about any significant behavioral problems or pain."
1899102|NCT01325727|Other|Brief computerized feedback|Brief computerized feedback
1899103|NCT01325727|Other|Resources only (control)|Participants randomized to the control group will discuss the option of quitting smoking, along with an information sheet, highlighting resources available to assist participants with smoking cessation, such as the Virginia Quitline (1-800 QUIT NOW) and nicotine replacement therapy.
1899104|NCT01325740|Drug|STX107|STX107 10 mg single dose po capsule, STX107 30 mg single dose po capsule, Placebo single po capsule
1899105|NCT01325753|Procedure|cryotherapy|Undergo CT-guided CA
1899106|NCT01325753|Procedure|quality-of-life assessment|Ancillary studies
1899107|NCT01325766|Other|Yoga|Yoga 2 sessions per week for 8 weeks
1899108|NCT01325779|Drug|heparin|subcutaneous heparin 5000 units every 8 hours
1899109|NCT01325779|Drug|enoxaparin|subcutaneous enoxaparin 40 milligrams every 24 hours
1899110|NCT01325792|Device|GORE® BIO-A® Tissue Reinforcement|Retrorectus or intraperitoneal placement of device to reinforce the midline fascial closure after single-staged open complex ventral incisional hernia repair of primary or recurrent anterior abdominal wall hernia.
1899111|NCT01325805|Behavioral|Structured Weight Loss Program|Those patients randomized to the structured weight loss group will have a formal evaluation and counseling a medical endocrinologist specializing in weight management. The structured weight loss program will consist of meeting with a dietician who will guide them on following a hypocaloric diet with a calorie deficit of 750kcal/day. The weight loss goal will be to lose 1-1.5 pounds/week. The participants will receive teaching utilizing the American Diabetes Association Exchange Lists and will receive sample meal plans. In addition, participants will be seen by the dietitian once a week for a month, then every 2 weeks for 2 months, then once per month for 3 months. Patients randomized to the study group will continue in the structured weight loss program for 6 months.
1899112|NCT01325805|Behavioral|Routine Weight Loss Counseling|Participants randomized to the routine weight loss counseling group will receive the ACOG Patient Education pamphlets on obesity.
1899113|NCT01325818|Drug|pravastatin, rosuvastatin|"Active Comparator Intervention: Drug: pravastatin 10mg/day or 20mg/day
Active Comparator Intervention: Drug: rosuvastatin 20mg/day"
1899114|NCT01325831|Device|repetitive transcranial magnetic stimulation(rTMS)|10-day course of 10 Hz rTMS on left dorsolateral prefrontal cortex of the subjects.
1899115|NCT01325831|Device|Sham repetitive transcranial magnetic stimulation(rTMS)|Sham repetitive transcranial magnetic stimulation(rTMS)
1899116|NCT01325844|Procedure|Epidural anesthesia|0.5% ropivacaine infusion via epidural catheter at 5ml/hr during general anesthesia
1899117|NCT01325857|Procedure|Bilateral superficial cervical plexus block|Bilateral superficial cervical plexus block with 0.525% ropivacaine 20ml
1899118|NCT01325857|Procedure|placebo|Procedure: Bilateral superficial cervical plexus block with normal saline 20ml
1899119|NCT01325857|Procedure|Control group|Procedure: Local anesthetic infiltration at incision site with 0.525% ropivacaine 20ml
1899120|NCT01325870|Device|ACD-CPR|
1899121|NCT01325870|Device|ITPR|standard CPR with use of the CirQlator intrathoracic pressure regulator (ITPR)
1899122|NCT01325870|Procedure|S-CPR|standard manual CPR
1899123|NCT01325870|Device|Impedance Threshold Device (ITD)|
1899124|NCT01325896|Drug|PEG-Intron sc injection|"This program is only open to patients with multiple myeloma who have achieved a complete or partial response after a myelosuppressive chemotherapy regimen followed by autologous stem cell infusion of peripheral blood transplant (PBSCT) as treatment intensification. These patients will be treated with PEG-Intron as maintenance therapy, to be permitted during the same concomitant administration of corticosteroids and / or bisphosphonates.
PEG-Intron: 35 mcg per week by subcutaneous injection to progression or recurrence of the disease, or for 5 years maximum.
Patients were administered PEG-Intron to a uniform dose of 15 mg initial week for 2 weeks. If this dose is tolerated, it would be gradually increased to 25 mg and then to 35 mg every 2 weeks, assuming that there is no toxicity of grade 3 or worse."
1899125|NCT01325909|Behavioral|Exercise programme|
1899126|NCT01325922|Procedure|DFT Testing with a 50/50% tilt|
1899127|NCT01325935|Drug|Clopidogrel|DAPT using aspirin 81 mg/day (minimal dose) and clopidogrel 75 mg/day should be conducted for 3 months (+ 30 days) after stenting.
1899128|NCT01325961|Radiation|Intensity-Modulated Radiation Therapy|
1899129|NCT01325987|Dietary Supplement|Vitamin D2|Subjects with vitamin D deficiency (serum 25(OH)D <20ng/ml) will receive an 8 week of vitamin D treatment (50,000 IU oral vitamin D2/once per week) vs. placebo. All subjects will continue their existing hypoglycemic regimen.
1899130|NCT01325987|Other|Sugar pill|"group: vitamin D2 50000 IU weekly once for 8 weeks
nd group: placebo weekly once for 8 weeks"
1899131|NCT01326000|Drug|FOLFIRI|standard iv chemotherapy
1899132|NCT01326000|Drug|RO5083945|1400 mg iv on Day 1 and Day 8, and every 2 weeks thereafter
1899133|NCT01326000|Drug|cetuximab|400 mg/m2 iv on Day 1, followed by 250 mg/m2 iv every week
1899134|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted.
1899135|NCT01326026|Drug|insulin degludec|Injected subcutaneously (under the skin) once daily. Dose individually adjusted in a stepwise manner.
1899136|NCT01326039|Drug|bupivacaine|perineural bupivacaine 5 mg/ml 20 ml
1899137|NCT01326039|Drug|saline|perineural isotonic saline 20 ml
1899138|NCT01326052|Procedure|Inferior Mesenteric Artery Preservation|Performing left hemicolectomy the IMA was preserved ligating close to the colonic wall the sigmoids arteries.
1899139|NCT01326052|Procedure|Inferior Mesenteric Artery Ligation|Performing left hemicolectomy the IMA is ligated and sectioned after the origin of left colic artery
1899140|NCT01326078|Drug|propofol|3 - 4 mg/kg IV, adjustment dose if necessary
1899141|NCT01326091|Other|Hyperlordotic Positioning|Hyperlordotic positioning will be achieved through pelvic pads positioned low on iliac crest to maximize lumbar hyperlordosis and increased hip flexion with as many pillows as tolerated at thighs and knees to allow for increased sacral slope. Regular position will involve the pelvic pads at above or iliac crest and without extra pillows at thighs and legs.
1899144|NCT01326117|Drug|tadalafil|7 days of Cialis for Daily Use (5mg)
1899219|NCT01326702|Drug|Bendamustine Hydrochloride|Given IV
1899145|NCT01326130|Behavioral|Chronic care management 1-6|1- an interdisciplinary team in an education center working with primary care physicians and offering to referred patients a pre-determined sequence of clinical interventions over a 2-year-period; 2- a program supporting primary care physicians (continuing education, documentation and clinical guidelines, referral system to second line of care); 3- networking between actors insuring clinical information transfer required for efficient patient management.
1899146|NCT01326143|Device|ORM Narval MRD|
1899147|NCT01326156|Device|Knee arthroplasty|Comparison of patellofemoral arthroplasty versus conventional total knee arthroplasty in cases of isolated patellofemoral osteoarthritis.
1899148|NCT01326169|Behavioral|Brief intervention|Telephone-delivered counseling
1899149|NCT01326169|Behavioral|Standard care|No intervention
1899150|NCT01326182|Behavioral|MAADRE|Group-based intervention combining asthma education and CBT for depressive symptoms
1899151|NCT01326182|Behavioral|MAAS|Group-based intervention including asthma education and education regarding general child health
1899152|NCT01326195|Behavioral|Cognitive-Behavioral Dating Violence and HIV Prevention Group|Six, two-hour weekly sessions and one 2-hour booster session 6 weeks later with adolescent females
1899153|NCT01326195|Behavioral|Psycho-educational Dating Violence and HIV prevention group|Knowledge based intervention matched for time and attention to skills arm
1899154|NCT01326208|Procedure|PEEP titration|PEEP is set according to the following protocols, respectively, in a randomized order: ARDSnet table, Open Lung strategy, guided by EIT
1899155|NCT01326221|Drug|tenofovir + emtricitabine|tenofovir 300mg + emtricitabine 200mg x one dose
1899156|NCT01326234|Behavioral|Personalized Feedback|The interactive program will provide assessment and personalized feedback on the participants' level of nicotine dependence, daily cigarette consumption, money spent on cigarettes, behavioral consequences of smoking, individual medical consequences of smoking, and family members' medical consequences of secondhand smoke.
1899157|NCT01326234|Behavioral|Treatment as Usual|Practitioners are able to provide normal care with regard to smoking; participants will complete the Treatment Fidelity Questionnaire to assess whether any smoking cessation interventions occurred
1899158|NCT01326247|Other|thermal waters nasal irrigation|"The first group (group 1) has practiced crenotherapy with hyper-mineral chloride sodium water aerosol by nasal adapter for 15 days per month, for three consecutive months, at thermal spa services of Lacco Ameno, while the control group (group 2) was treated, in the same period, daily, by a micronized nasal douche with 0.9% NaCl (isotonic) solution."
1899159|NCT01326273|Procedure|Lymphopheresis|Lymphopheresis
1899160|NCT01326273|Procedure|CMV specific lymphocyte infusion|CMV specific lymphocyte infusion
1899161|NCT01326273|Procedure|Peripheral blood for CMV DNA PCR|Peripheral blood for CMV DNA PCR
1899162|NCT01326273|Procedure|Haematology/Blood chemistry|Haematology/Blood chemistry analysis, Collection of blood for ancillary laboratory tests.
1899163|NCT01326299|Other|Carbohydrate placebo|dissolve in water and consume with meal
1899164|NCT01326299|Other|Nutritional ingredient|Dissolve in water and consume with meals
1899165|NCT01326299|Other|#1 Nutritional ingredient +Fiber|Dissolve in water and consume with meal
1899166|NCT01326299|Other|#2 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
1899167|NCT01326299|Other|#3 Nutritional ingredient + Fiber|Dissolve in water and consume with meal
1899168|NCT01326312|Drug|GTx-758|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
1899169|NCT01326312|Drug|Lupron Depot|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
1899170|NCT01326312|Drug|GTx-758|comparison of different dosages of GTx-758 with leuprolide acetate for depot suspension
1899171|NCT01326325|Drug|Ketamine|Drip continues of ketamine in intravenous injection included posology enters 0,5mg/kg /day and 2mg/kg/day during 4 days
1899172|NCT01326325|Drug|NaCl|Drip continues of NaCl 0,9% in intravenous injection during 4 days
1899173|NCT01326338|Drug|Nitazoxanide|Nitazoxanide Oral Suspension 100 mg/5 ml for patients aged 1-3 years twice daily for 3 days or Nitazoxanide Oral Suspension 200 mg/10 ml for patients aged 4-11 years twice daily for 3 days
1899174|NCT01326351|Procedure|Regenerative injection therapy|Injection of 10cc of a 15% dextrose and 0.6% lidocaine solution free of epinephrine in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade (injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
1899175|NCT01326351|Procedure|Dry needle injection|Injection of dry needle in one injection site (lateral infiltration of the plantar fascia). This injection will be performed following posterior tibial nerve blockade(injection of 10cc of 1% lidocaine and 0.25% bupivacaine solution free of epinephrine behind the posterior tibial artery). The intervention will be administered every three weeks until symptoms are alleviated for a maximum of 5 injection sessions. Furthermore, patients must perform an at-home exercise program 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
1899176|NCT01326351|Behavioral|Exercise|At-home exercise program that patients must perform 3 times a week for a total of 12 weeks. The exercise program consists of 3 stretching exercises, 1 muscle release exercise and 1 strengthening exercise.
1899177|NCT01326364|Procedure|Stereotactic body radiotherapy|Standard of Care
1899178|NCT01326364|Drug|Iodixanol|IV, calculated per patient
1899179|NCT01326364|Drug|Iohexol|IV, Calculated per patient
1899180|NCT01326390|Device|dTA/dBA C-arm fluoroscopy system with Dyna CT|C-arm CT of the liver; state-of-the-art flat panel detector on a ceiling or floor mounted C-arm gantry
1899181|NCT01326390|Procedure|DSA arteriogram- hepatic arteries|Standard of care
1899182|NCT01326390|Procedure|CO2 aortogram|Standard of care
1899216|NCT01326676|Drug|Usual medication|Participants in the 'Usual Care' arm will continue to take the separate, individual medications prescribed by their usual doctor, e.g. aspirin, blood pressure lowering drugs, statins.
1899183|NCT01326403|Drug|Tranexamic acid|"GROUP A - receive IV Tranexamic acid 1 gram upon diagnosis and consent in the emergency room. A second 1 gram in a slow drip during the next 8 hours.
GROUP B - IV Tranexamic acid 1 gram five minutes before skin incision and a second 1 gram in a slow drip during the next 8 hours.
Group C - A control group will only receive placebo in the emergency room and in the OR."
1899184|NCT01326416|Dietary Supplement|L-Leucine and L-arginine|Specific nutritional supplementation for six months by 30g per day of a mixture of amino acids (21 g L-Leucine and 9 g of L-arginine), to be distributed during each of the 3 main meals.
1899185|NCT01326416|Other|Physical Reconditioning by a trainer|Physical reconditioning sessions begin with a warm-up for five minutes for the type of effort made, and then correspond to a sporting course composed of elements of strength training and / or aerobic exercises and will be completed by a return to simple stretching and general advice on managing their physical life. The duration of each session will be 45 minutes at the beginning of the protocol and then gradually increased over time to achieve 1:30 of total physical activity at the end of protocol.
1899186|NCT01326442|Other|low glycemic diet|a low glycemic diet, calorie restricted with exercise sessions 3 times per week
1899187|NCT01326442|Dietary Supplement|vitamin D omega-3|2000 IU vitamin D3 plus 1.8 g EPA + DHA per day for 16 weeks.
1990000|NCT02282462|Other|Passive Drainage (Dig)|"Thopaz+ digital chest drainage device set at -8cmH2O at the patient (physiologic)"
1899191|NCT01326468|Drug|Temsirolimus|All patients will receive temsirolimus. The dose of temsirolimus in this study will range from 15-25 mg depending on the dose level. Temsirolimus will be infused over a 30-60 minute period once a week for the duration of radiation therapy.
1899192|NCT01326468|Drug|Cetuximab|"All patients will receive cetuximab. An initial loading dose of cetuximab 400 mg/m2, intravenously over 120 minutes at least 4 days before radiation therapy but no more than 7 days before the start of radiation therapy.
Thereafter, cetuximab will be infused at 250 mg/m2 dose over 60 minutes weekly for the duration of radiation therapy."
1899193|NCT01326468|Drug|Cisplatin|All patients in Cohort A will receive cisplatin. The dose will be 20 mg/m2 or 30 mg/m2 depending upon the dose level.
1899194|NCT01326468|Device|Radiation Therapy|Patients will be treated on a linear accelerator fitted with multi-leaf collimators with 1.6-2.3 Gy fractions delivered daily 5 days per week over 4-7 weeks to a cumulative dose of 66 Gy. A variance of +/- 10% in this nominal prescription dose is allowable and will depend on the extent of residual disease, at the discretion of the attending radiation oncologist.
1899195|NCT01326481|Drug|TRC105|IV
1899196|NCT01326494|Drug|Arm 1 Oral Cortico Steroids|"Prednisolone: 1 mg / kg per day course of dose for 5 days up to child's weight of 20 kgs.
Dexamethasone: 0.3mg/kg per dose for 3 days (minimum weight 20 kgs )"
1899197|NCT01326507|Biological|Dosage de l'h-FABP|Dosage de l'h-FABP
1899198|NCT01326520|Dietary Supplement|milk phospholipid|The patients will consume daily 250 mL of a dairy product, which is enriched with 3 g of milk phospholipids.
1899199|NCT01326520|Dietary Supplement|diary product|The patients will consume daily 250 mL of a common dairy product.
1899200|NCT01326533|Drug|hydroxychloroquine|Thirteen weeks of oral hydroxychloroquine (400 mg/day) provided as capsules
1899201|NCT01326533|Other|Placebo|Thirteen weeks of oral placebo provided as capsules
1899202|NCT01326546|Drug|Therapeutic HBV vaccine, entecavir|Therapeutic HBV vaccine :900ug,per time,intramuscular injection; Entecavir:0.5mg,per day,oral intake.
1899203|NCT01326546|Drug|Empty liposome, entecavir|Empty liposome: 900ug,per time,intramuscular injection; Entecavir:0.5mg,per day,oral intake.
1899204|NCT01326559|Drug|Docetaxel, Cisplatin, 5-FU and Cetuximab|"Induction phase (Weeks 1-9):
Drug Docetaxel Docetaxel 75 mg/m2 IV, D1 every 3 weeks for 3 cycles
Drug Cisplatin Cisplatin 75 mg/m2 IV, D1 every 3 weeks for 3 cycles
Drug Fluorouracil Fluorouracil 750 mg/m2 IV, D1-4 every 3 weeks for 3 cycles
Concurrent phase (weeks 10-16):
Drug Docetaxel Docetaxel 15 mg/m2 IV, D1 weekly for 7 weeks (Weeks 10-16)
Drug Cetuximab Cetuximab 400 mg m2 IV, D1 initial dose, then 250 mg/m2 weekly for 7 week (Weeks 10-16)
IMRT (60 Gy to GTV or biological dose equivalent): 2 Gy/fraction/day, D1-5 per week, for 6 weeks (Weeks 11-16)"
1899205|NCT01326585|Drug|Dexamethasone Sodium Phosphate Injection|8mg (2cc of 4mg/mL solution), IV solution, 1-time dose during surgery
1899206|NCT01326585|Drug|Saline Injection|2cc of 0.9% normal saline, IV injection, 1-time dose during surgery
1899207|NCT01326598|Device|V-Go™|Use of Insulin Delivery Device, V-Go, and the effect on A1C for T2DM patients in five categories of baseline oral antidiabetes drug (OAD) use with or without insulin.
1899208|NCT01326611|Drug|Clarithromycin|
1899209|NCT01326611|Drug|Dextrose|
1899210|NCT01326624|Device|wearable defibrillator (LifeVest)|LifeVest wearable defibrillator for unattended treatment of sudden cardiac arrest due to ventricular tachycardia or ventricular fibrillation
1899211|NCT01326637|Other|Patient Overview Document|"The Intervention has two components:
Pre-visit care coordination:
5-7 days prior to a study patient's appointment with the doctor, the doctor's nurse/MA will call the study patient and collect pertinent clinical information using a data collection form we call a Patient Overview Document or POD. The purpose of the POD is to comprehensively inform the doctor about the patient before the doctor enters the exam room.
The nurse/MA will ensure that lab results, consultant reports, ER reports, imaging studies, etc., needed by the physician during the patient's visit, are available to the doctor in their usual place.
Team Meeting:
On the day of the patient's appointment, prior to the beginning of the clinic session, the nurse/MA and doctor will jointly review the POD."
1899212|NCT01326650|Drug|Vitamin D|daily oral vitamin D supplement of 100 micrograms for three years
1899213|NCT01326650|Drug|placebo|daily oral placebo supplement for three years
1899214|NCT01326663|Drug|Medication Trial|
1899215|NCT01326676|Drug|Polypill: Red Heart Pill|"The polypill will be taken once/day in the form of a hard capsule, to be taken orally. There are two versions of the polypill (Red Heart Pill):
Version 1 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Atenolol 50mg; Version 2 contains aspirin 75mg, simvastatin 40mg, Lisinopril 10mg and Hydrochlorothiazide 12.5mg.
Red Heart Pill Version 1 and Red Heart Pill Version 2. In general, participants with a history of coronary heart disease will be given version 1, and those with a history of stroke or cerebrovascular disease will be given version 2."
1899217|NCT01326689|Drug|KW-2246|Rescue medication at an optimal dose, which is determined by dose titration
1899218|NCT01326689|Drug|Placebo|
1899220|NCT01326702|Other|Pharmacological Study|Correlative studies
1899221|NCT01326702|Biological|Rituximab|Given IV
1899222|NCT01326702|Drug|Veliparib|Given PO
1899224|NCT01326754|Drug|Artemether-lumefantrine combination|Dispersible formulation of artemether-lumefantrine at a dose of 2/12 mg/kg body weight of artemether and lumefantrine, respectively, per dose, given twice a day for 3 days
1899225|NCT01326754|Drug|Artesunate-amodiaquine combination|Co-formulated artesunate-amodiaquine at a dose of 4 mg/kg/day artesunate and 10 mg/kg/day amodiaquine once a day for 3 days
1899226|NCT01326754|Drug|Dihydroartemisinin-piperaquine|Co-formulated dihydroartemisinin-piperaquine at a dose of 4 mg/kg/day dihydroartemisinin and 18 mg/kg/day piperaquine once a day for 3 days
1899227|NCT01326767|Drug|Paclitaxel dosing according to SmPC|Paclitaxel i.V. Up to 6 cycles Dosing according to SmPC
1899228|NCT01326767|Drug|Individualized pharmacokinetically driven paclitaxel dosing|Paclitaxel i.V. Up to 6 cycles Dosing based on patient age, gender, severity of neutropenia and Paclitaxel plasma concentration
1990001|NCT02282462|Other|Passive Drainage (Trad)|"Pleur-Evac, Atrium-Maquet or similar set by gravity (water-seal')"
1990002|NCT02281994|Device|Pulsed Electromagnetic Feld (PEMF) Orthofix Cervical-Stim Model 2205OD|Active devices emit PEMF signal; control devices do not emit PEMF signal.
1899233|NCT01326793|Other|Skype Consultation|One-hour Skype consultation with MA-licensed psychiatrist and a written summary of findings.
1899234|NCT01326806|Behavioral|Families Talking Together|The intervention will take place in a primary health care clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. A mother of the adolescent will meet with an interventionist for approximately 30 minutes while her child is being examined by a physician. During this time, the intervention will be delivered to the mother. At the conclusion of the session, the mother will be given reference materials to take home and tasks to perform to facilitate discussions about sex with her adolescent. There will be three follow-up booster sessions administered through phone calls to increase completion probabilities of the tasks. The target behavior is sexual activity in adolescents.
1899235|NCT01326806|Behavioral|Active Control on Hygiene & Nutrition|The active control group will take place in a primary health care clinic and will be coordinated through allied health professionals when physicians see youth for their annual physical examination. The mother of the adolescent will meet with a social work interventionist for approximately 30 minutes while her child is being examined by a physician. During this time, the active control on hygiene and nutrition will be delivered to the mother.
1899236|NCT01326832|Device|Primoris|Total hip arthroplasty with the new Primoris femoral component
1899237|NCT01326845|Drug|Deferasirox|
1899238|NCT01326858|Drug|Olopatadine hydrochloride ophthalmic solution, 0.7%|Treatment A
1899239|NCT01326858|Drug|Olopatadine hydrochloride ophthalmic solution vehicle|Treatment B, inactive ingredients used as placebo
1899240|NCT01326858|Drug|Ketotifen fumarate ophthalmic solution, 0.025%|Treatment C
1899241|NCT01326871|Drug|Cisplatin|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 1 of each course (if given)
1899242|NCT01326871|Drug|Gemcitabine|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II); on day 1 and 8 of each course
1899243|NCT01326871|Biological|ALT-801|Intravenous infusion; 3 initial treatment courses and an additional 3 maintenance courses for responders (maintenance revised for Phase II): on day 3, 5, 8, and 12 of each course
1899244|NCT01326884|Device|ZLP|ZLP Graft
1899245|NCT01326897|Behavioral|Healthy Homes/Healthy Families|"Participants in the intervention group will work with coaches to make their homes more supportive of healthy eating and physical activity. Each intervention participant will receive a tailored home environment profile, and will select from a menu of healthy actions to make changes in their home. The intervention will be delivered over the course of 5 months, with 3 home visits, 4 coaching calls, and 4 support mailings."
1899246|NCT01326897|Behavioral|Health Education|Study participants in this group will receive health education materials by mail (3 times over the course of 5 months).
1899247|NCT01326910|Drug|Colloidal Oatmeal|Topical cream applied twice daily (or as needed)
1899248|NCT01326910|Device|Topical Cream|Topical cream applied twice daily (or as needed)
1899249|NCT01326923|Drug|Cetuximab|Single arm phase II study of chemotherapy
1899250|NCT01326936|Behavioral|Online education|A brief (2-hour) interactive online training program in substance abuse (SU) management using virtual patient (VP) technology. Each learner will take one of two similar online programs involving five VPs that represent the range of SU management issues that commonly arise in clinical practice.
1899251|NCT01326949|Procedure|Transjugular intrahepatic portosystemic shunt (TIPS)|Transjugular intrahepatic portosystemic shunt(TIPS)- TIPS was performed in a conventional fashion or in combination of percutaneous transhepatic or transsplenic approach. Postoperatively, intravenous heparin (8,000-12,000 u/d) for five days, warfarin for six months were given.
1899252|NCT01326949|Procedure|ET+NSBB|"ET-Esophageal varices was treated by endoscopic variceal ligation (EVL). EVL was repeated at intervals of 1-2 weeks until the varices were obliterated or reduced to grade-I size.
NSBB-Propranolol started at a dose of 20mg twice a day. The dose is adjusted to the maximal tolerated doses to heart rate (HR) of 55 bpm or to decrease the HR 25% from baseline.
AT-A continuously intravenous infusion of unfractionated heparin followed by oral warfarin is employed. Initially, heparin is administered intravenously for 5 days. Subsequently, oral warfarin is prescribed at the dosage of 2.5 mg/d for 6 months or until complete portal vein recanalization and adjusted to maintain the INR at a target of 2.5 (range 2.0-3.0)."
1899253|NCT01326962|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg (max. 800 mg) iv every 4 weeks, 6 infusions
1899254|NCT01326988|Procedure|Real-time ultrasound guided spinal anesthesia|The neuraxial US scan will be performed with the patient in the sitting or lateral position with the hip and knees slightly flexed using full aseptic technique. The spinal needle will be inserted in real-time under direct ultrasound guidance to administer the spinal anesthetic.
1899255|NCT01327014|Drug|XueZhiKang (XZK), a botanic product with multiple components|4 capsules of study drug twice a day for 12 weeks.
1899256|NCT01327014|Drug|Placebo|4 capsules twice a day for 12 weeks.
1899257|NCT01327027|Drug|Vasopressin|Vasopressin will be dissolved in sterile saline and intranasally delivered in one of 2 doses to each subject (20IU, 40IU)
1899258|NCT01327027|Drug|Placebo|Sterile saline will be delivered intranasally on a second test day, in counterbalanced order with vasopressin administration.
1899259|NCT01327040|Other|light exposure|12-hour light exposure of approximately 200 lux
1899260|NCT01327053|Drug|LDE225|LDE225 was administered orally, on a continuous once daily dosing schedule and was supplied as 200 mg hard gelatin capsules in bottles. Every 4 weeks on the day of study visit, patients received a prescription of an adequate drug supply for self-administration at home. The 800 mg dose patients received 4 capsules of LDE225 and 200 mg dose arm patients received 1 LDE225 capsule + 3 placebo capsules.
1899261|NCT01327066|Drug|Droxidopa|600 mg, single oral dose
1899262|NCT01327066|Drug|Droxidopa|2000 mg, single oral dose
1899263|NCT01327066|Drug|Moxifloxacin|400 mg, single oral dose
1899264|NCT01327066|Drug|Placebo|Placebo matching Droxidopa or Moxifloxacin
1899265|NCT01327079|Drug|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.
Administration of inulin:
Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
1899266|NCT01327079|Drug|Methadone|"If the infant has been treated with morphine than substitute for that one study dose 0.1 mg morphine with 0.1 mg methadone, whereas if the infant has been treated with fentanyl substitute for that one study dose 1 μg fentanyl with 0.1 mg methadone.
Administration of inulin:
Inulin will be administered as a glucose 10%-inulin solution containing 25 gr. inulin/L, at an infusion rate of 0.6 mL/kg/h. After 24 h, the inulin clearance will be calculated."
1899267|NCT01327092|Other|Injury Intervention Group|The hazards identified in the home will be reviewed with the parent and the proposed interventions will be presented. Intervention options are designed and prioritized so that the most passive and durable interventions are recommended first (e.g. self-closing, self-locking stair gate) and progressively less 'passive' and less durable options last (e.g. area gate, pressure mounted gate, or refusal of intervention).
1899268|NCT01327105|Device|TVU|Use of transvaginal ultrasound to determine location of micro-insert
1899269|NCT01327118|Drug|Prostaglandin F2alpha|intravenous injection
1899270|NCT01327118|Drug|Isoton sodium chloride|intravenous injection
1899271|NCT01327144|Drug|Famciclovir|Famciclovir 500 mg- 1 tablet each 12 hours for 7 days
1899272|NCT01327144|Drug|Aciclovir|Aciclovir 400 mg- 02 tablets each 4 hours for 7 days
1899275|NCT01327170|Procedure|Subthreshold diode micropulse laser|
1899276|NCT01327183|Procedure|Percutaneous Coronary Intervention (PCI)|at least 1 hour and up to 24 hours after completion of drug infusion
1899277|NCT01327183|Drug|RO4905417|5 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
1899278|NCT01327183|Drug|RO4905417|20 mg/kg iv infusion, completed at least 1 hour and up to 24 hours before PCI
1899279|NCT01327183|Drug|placebo|iv infusion, completed at least 1 hour and up to 24 hours before PCI
1899280|NCT01327222|Drug|Bevacizumab|1.25 mg intravitreal bevacizumab
1899281|NCT01327235|Drug|Endostar|intrapleural injection 45 mg; intraperitoneal injection 60 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
1899282|NCT01327235|Drug|Cisplatin|cisplatin 40 mg, q3d ×3(d1、d4、d7), 3 times as one cycle, at most 2 cycles
1899283|NCT01327261|Drug|Levodopa + benserazide|Single oral dose of either Experimental or Active Comparator. Levodopa 200 mg/benserazide 50 mg tablets,with 200 mL of water.
1899285|NCT01327300|Drug|Mesalamine|Apriso is a 5-ASA drug with Intellicor ™ extended-release delivery technology. A 1.5 gram dosage of Apriso (equaling four 375 mg capsules) once a day will be administered orally for a period of 12 weeks followed by a 3 week wash out prior to crossing over to the placebo arm.
1899286|NCT01327300|Other|Placebo|4 capsules (.375 gm sugar pill capsules) administered orally once a day. This group will receive the placebo for 12 weeks then a wash out for 3 weeks prior to crossing over to the drug arm.
1899287|NCT01327313|Biological|EMD525797|Subjects will receive 250 milligram (mg) of EMD525797 intravenously every 2 weeks, until progressive disease (PD), unacceptable toxicity or withdrawal of consent.
1899288|NCT01327313|Biological|EMD525797|Subjects will receive 500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
1899289|NCT01327313|Biological|EMD525797|Subjects will receive 1000 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity or withdrawal of consent.
1899527|NCT01322269|Drug|HQK-1001|HQK-1001 tablets, once daily for daily 26 weeks
1899290|NCT01327313|Biological|EMD525797|Subjects will receive 1500 mg of EMD525797 intravenously every 2 weeks, until PD or unacceptable toxicity, or withdrawal of consent.
1899291|NCT01327326|Drug|Naltrexone|Oral, 50 mg, 1 Time Dose
1899292|NCT01327326|Drug|Placebo|Oral, 1 Time Dose
1899293|NCT01327339|Drug|Ropinirole|Basically there is no treatment allocation. Subjects who would be administered of ropinirole at their physician's direction will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
1899294|NCT01327352|Drug|Oshadi D|oral administration
1899295|NCT01327365|Procedure|trans-radial PCI (TRI)|TRI performed using the sheathless guiding approach
1899296|NCT01327365|Procedure|trans-radial PCI (TRI)|TRI performed using a conventional guiding approach
1899297|NCT01327391|Procedure|On line Hemodiafiltration|3 sessions/week; 3-4 hours per session
1899298|NCT01327391|Procedure|Hemodialysis|3 sessions/week; 3-4 hours per session; high flux dialyzers
1899299|NCT01327430|Dietary Supplement|Milk phospholipid|During day 1 until 10 the subjects were supplemented with daily 3 g milk phospholipids, during the day 11 and 20 the supplementation was increased to daily 6 g, and during the day 21 and 30 the subjects received daily 6 g milk phospholipids and 2 g of plant sterols.
1899300|NCT01327443|Behavioral|Weight loss|Nutritional counseling
1899301|NCT01327443|Behavioral|Exercise|Under direct supervision
1899302|NCT01327456|Behavioral|Self-Management Intervention|patients will participate in a 1-on-1 interactive intervention, delivered by a trained research assistant targeting self-management skills (e.g. inhaler use, use of an action plan), smoking cessation, and exercise/pulmonary rehabilitation. All participants will return 2-4 weeks after the intervention for a follow-up assessment of inhaler technique use, COPD-related knowledge, and time spent in self-management.
1899303|NCT01327469|Drug|Albendazole, 2 x 400mg|Albendazole 2 x 400mg
1899304|NCT01327469|Drug|Albendazole 400mg|Albendazole 400mg
1899305|NCT01327469|Drug|Mebendazole 500mg|Mebendazole 500mg
1899306|NCT01327469|Drug|Mebendazole 2 x 500mg|Mebendazole 2 x 500mg
1899307|NCT01327469|Drug|Pyrantel-oxantel + mebendazole|Pyrantel-oxantel + mebendazole
1899308|NCT01327482|Drug|Raltegravir|Dosage: 400mg/PO (by mouth) Frequency: Twice daily Duration: During course of menstrual cycle (28 days)
1899309|NCT01327495|Other|placebo acyline|Placebo acyline subcutaneous injection every 2 weeks
1899310|NCT01327495|Other|placebo gel|daily placebo testosterone gel applied transdermally x 12 weeks
1899311|NCT01327495|Drug|Testosterone 1% gel 1.25 g|testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
1899312|NCT01327495|Drug|Testosterone 1% gel 2.5 g|Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
1899313|NCT01327495|Drug|Testosterone 1% gel 5.0 g|Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
1899314|NCT01327495|Drug|testosterone 1% gel 10 g|Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
1899315|NCT01327495|Drug|testosterone 1% gel 15 g|Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
1899316|NCT01327495|Drug|Acyline|300 ug/kg subcutaneous injection every 2 weeks
1899317|NCT01327508|Device|TRIGEN SURESHOT Distal Targeting Instrumentation.|image-guided localization system
1899318|NCT01327508|Other|Free-hand technique|Free-hand technique utilizes x-rays to find screw holes.
1899319|NCT01327521|Device|CyberKnife|Standard of Care
1899320|NCT01327521|Procedure|TACE|Standard of Care
1899321|NCT01327521|Drug|CT Contrast|Standard of Care
1899322|NCT01327521|Drug|doxorubicin|Standard of Care
1899323|NCT01327521|Drug|Epirubicin|Standard of Care
1899324|NCT01327521|Drug|5-fluorouracil|Standard of Care
1899325|NCT01327521|Drug|Mitomycin C|Standard of Care
1899326|NCT01327521|Drug|Gemcitabine|Standard of Care
1899327|NCT01327521|Drug|Cisplatin|Standard of Care
1899328|NCT01327521|Device|SMANCS|Standard of Care
1899329|NCT01327534|Drug|Prasugrel|treatment with a 60 mg loading dose prasugrel, followed by a maintenance dose of 10 mg for 30 days
1899330|NCT01327534|Drug|Clopidogrel|treatment with a 600 mg loading dose clopidogrel, followed by a maintenance dose of 75 mg for 30 days
1899331|NCT01327547|Drug|Maraviroc|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
1899332|NCT01327547|Drug|Placebo|150mg, 300mg or 600mg twice daily x 144 weeks; dosing dependent on components of the current suppressive anti-HIV therapy
1899334|NCT01327586|Behavioral|ATM|Weekly counseling focused on improving money management, abstaining from cocaine,and minimizing unprotected sex
1899335|NCT01327586|Behavioral|Individual Drug Counseling|Standard individualized drug counseling, modified from that described by Woody and colleagues
1899336|NCT01327599|Drug|Travoprost 0.004%+Timolol 0.5% ophthalmic solution|Fixed dose combination topical ocular agent preserved with polyquaternium-1 (POLYQUAD)
1899337|NCT01327612|Drug|FOLFOX6|Oxaliplatin: 100mg/m2, IV in 500mL of D5W over 120 minutes on Day 1 Leucovorin: 400mg/m2, IV diluted in D5W over 120 minutes (concurrently with oxaliplatin) on Day 1 Fluorouracil: 400 mg/m2, IV bolus, after leucovorin, on Day 1 Fluorouracil: 2400mg/m2, CIV over 46 hours (single dose) start on Day 1 Cycle frequency: repeat every 14 days until disease progression or unacceptable toxicity
1899338|NCT01327612|Biological|Conatumumab|Conatumumab is an investigational, fully human monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR-5.
1899339|NCT01327612|Biological|Conatumumab|Conatumumab is an investigational, fully human, monoclonal antibody that binds with TNF-related apoptosis-inducing ligand, DR5.
1899340|NCT01327612|Biological|Ganitumab|Ganitumab is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
1899341|NCT01327612|Biological|Bevacizumab|Recombinant humanized monoclonal antibody targeted against vascular endothelial growth factor (VEGF); angiogenesis inhibitor.
1899342|NCT01327612|Biological|Ganitumab|Ganitumab is an investigational, fully human, monoclonal antibody that binds with Insulin-like growth factor receptor type 1.
1899343|NCT01327625|Drug|azithromycin + N-acetylcystein + inhaled corticosteroid|"Azithromycin 500mg qd x 1 week --> 250mg qod x 6 months
N-acetylcystein 200mg tid x 6 months
Fluticasone 250mcg puff x2/day x 6 months"
1899344|NCT01327638|Drug|etoricoxib|Patients with SpA/AS who took etoricoxib
1899345|NCT01327638|Drug|Other COX-2 inhibitor|Patients with SpA/AS who took other COX-2 inhibitors
1899346|NCT01327638|Drug|nsNSAIDs|Patients with SpA/AS who took nsNSAIDs
1899347|NCT01327651|Drug|Daily dosing|A fixed-dose combination of emtricitabine and tenofovir disoproxil fumarate.
1899348|NCT01327651|Drug|Time-driven dosing|TDF/FTC twice weekly with a post-exposure dose
1899349|NCT01327651|Drug|Event-driven dosing|TDF/FTC as needed with a post exposure dose
1899350|NCT01327664|Biological|AIN457|
1899351|NCT01327677|Drug|Fentanyl|25-50 mcg every 20 minutes
1899352|NCT01327677|Drug|Fentanyl|20mcg/demand dose with an 8 minute lock out
1899353|NCT01327690|Behavioral|CBT (Cognitive Behavior Therapy)|CBT group therapy sessions
1899354|NCT01327690|Behavioral|EFT (Emotional Freedom Techniques)|Group therapy sessions using EFT
1899355|NCT01327703|Drug|Panzytrat® 25,000|Panzytrat® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 European Pharmacopoeia (Ph.Eur.) units lipase/kilogram (kg) body weight/day in either first treatment period or second treatment period.
1899356|NCT01327703|Drug|Kreon® 25,000|Kreon® 25,000 capsule will be given orally daily at a stabilized dose, as per investigator's discretion, for 14 days. Stabilized dose for a participant will be the optimal dose determined during a qualification phase that precedes the first treatment period and will be based upon the participant's usual lipase and lipid intake. Total dose will not exceed 10,000 Ph.Eur. units lipase/kg body weight/day in either first treatment period or second treatment period.
1899357|NCT01327729|Drug|pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg|YPEG-IFN α-2a 180mcg dose form: subcutaneous dosage : 180 mcg frequency every week or ten days or 2 weeks according to the group
1899358|NCT01327742|Device|Relay Thoracic Stent-Graft|Device implant
1899359|NCT01327755|Dietary Supplement|Selenium|Selenium yeast containing selenomethionine 200 mcg per day for 2 years
1899360|NCT01327755|Other|Placebo|Same number of pills, frequency, and duration as selenium intervention.
1899361|NCT01327768|Procedure|Olfactory ensheathing cells|Recruited patients should be received the endoscopic surgery for picking the olfactory mucosa 1 to 2 months before transplantation. The OECs will be cultured and expanded under the rule of GTP. Finally, we will transplant the OECs (about 2 to 8 X 10´6 cells in saline) into the peri-infarcted area of the brain for old stroke ischemic patients.
1899366|NCT01327794|Genetic|polymorphism analysis|
1899367|NCT01327794|Other|immunologic technique|
1899368|NCT01327794|Other|laboratory biomarker analysis|
1899369|NCT01327794|Other|medical chart review|
1899370|NCT01327846|Drug|Canakinumab|
1899371|NCT01327846|Drug|Placebo|
1899372|NCT01327859|Drug|Prior Donepezil 5mg|Received 5 mg donepezil once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
1899373|NCT01327859|Drug|Prior Donzepezil 10mg|Received 10 mg donepezil once daily during the preceding double-blind study, E2020-G000-316 . Received open-label 5 or 10 mg donepezil during the present study.
1899374|NCT01327859|Drug|Prior Placebo|Received placebo once daily during the preceding double-blind study, E2020-G000-316. Received open-label 5 or 10 mg donepezil during the present study.
1899375|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fasted condition
1899376|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01008ZZA in the fed condition
1899377|NCT01327872|Drug|E5501 40mg 2 x 20-mg tablets, orally, fasted|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fasted condition
1899378|NCT01327872|Drug|E5501 40 mg 2 x 20-mg tablets, orally, with food|single 40 mg dose (2 x 20-mg tablets) of Lot P01009ZZA in the fed condition
1899379|NCT01327885|Drug|Eribulin mesylate 1.4 mg/m^2 intravenous|Administration of eribulin mesylate at a dose of 1.4 mg/m^2 as an intravenous (IV) bolus infusion over 2-5 minutes on Days 1 and 8 of every cycle, where the duration of each cycle is 21 days.
1899380|NCT01327885|Drug|Dacarbazine of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 IV|Administration of dacarbazine at a dose of 850 mg/m^2, or 1,000 mg/m^2, or 1,200 mg/m^2 selected by the Principal Investigator [PI] or designee according to the subject's clinical status as an IV infusion over 15-30 minutes on Day 1 of every cycle, where the duration of each cycle is 21 days.
1899381|NCT01327898|Behavioral|empowerment theory-based small group discussion|four small group discussion sessions followed by one individual counseling session
1899382|NCT01327898|Behavioral|individual resilience counseling|one individual resilience counseling session
1899383|NCT01327911|Biological|NT-501 implant|Ciliary neurotrophic factor (CNTF) implant
1899384|NCT01327924|Drug|Norditropin NordiFlex®|Daily administration by subcutaneous injection (under the skin). Starting dose and frequency will be determined by the physician as part of normal clinical practice.
1899385|NCT01327937|Device|Apligraf|Apligraf group - Applied at Day 0, Weeks 1-4 (maximum of 5 applications) Also cross-over at Week 4 for Control NPTH group - Apligraf applied at Week 4, Weeks 5-8 (maximum of 5 applications)
1899386|NCT01327937|Other|Standard of Care Dressing Group|Standard dressing regimen - Foam dressing (eg, Mepilex) and 4 layered compression system (eg, Profore)
1899387|NCT01327963|Device|Transoral Incisionless Fundoplication (EsophyX)|Transoral incisionless esophago-gastric fundoplication performed using the EsophyX system with SerosaFuse fasteners (EndoGastric Solutions, Inc., Redmond, WA, USA) and following the standardized TIF2 protocol.
1899388|NCT01327976|Device|vBloc (Active Device)|Active device will deliver vBloc Therapy
1899389|NCT01327976|Device|Sham (Non-active Device)|Functional non-active control device will deliver no vBloc Therapy
1899390|NCT01327989|Device|Solitaire™ FR device|Mechanical Thrombectomy
1899394|NCT01328028|Other|Testing of archived cervical cancer tissue samples|Cervical samples will be tested for histopathology diagnosis and human papillomavirus deoxyribonucleic acid testing.
1899395|NCT01328028|Other|Data collection|Log sheet
1899396|NCT01328041|Drug|dolutegravir|50 mg twice daily
1899397|NCT01328054|Drug|lapatinib|lapatinib commercial tablet, 2000mg, will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
1899398|NCT01328054|Drug|placebo matching lapatinib|placebo matching lapatinib will be given as three separate doses (8 tablets/dose) given 12 hours apart over a 2 day period
1899399|NCT01328067|Device|Exablate 2100|MRgFUS
1899400|NCT01328067|Procedure|Myomectomy|Non-Hysteroscopic Myomectomy
1899401|NCT01328080|Radiation|Targeted UV-B|Daavlin Lumera phototherapy device (290-320 nm), dosed by patients' individual minimal erythema dose (MED)
1899402|NCT01328093|Drug|LY2140023|Administered orally
1899403|NCT01328093|Drug|Aripiprazole|Administered orally
1899404|NCT01328106|Drug|GSK1120212|Repeating oral dose
1899405|NCT01328119|Other|4-hour HD, 4-hour HDF, 8-hour HD and 8-hour HDF|Prevalent conventional HD (CHD) patients (dialysing 3 days a week during 4 hours per dialysis session) will undergo, in random order, a mid-week 4-hour HD session, a mid-week 4-hour HDF session, a mid-week 8-hour HD session, and a mid-week 8-hour HDF session with a 2-week interval between every session to assess the influence of treatment duration and of convection on the removal of uremic toxins and on the haemodynamic responses and autonomic nervous regulation. In between the study dialysis sessions these patients will receive routine CHD treatments.
1899406|NCT01328132|Drug|Saline|100 ml of saline will be given in addition to the standard of care every 8 hours for 24 hours.
1899407|NCT01328132|Drug|25% albumin|100 ml of 25% albumin will be given in addition to the standard of care every 8 hours for 24 hours
1899408|NCT01328145|Drug|Acetylsalicylic acid|500 mg /day
1899409|NCT01328171|Drug|FOLFOXIRI + Panitumumab|irinotecan 150 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3000 mg/m² cont. inf. + panitumumab, iv, 6 mg/kg BW all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
1899410|NCT01328171|Drug|FOLFOXIRI|irinotecan 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 3200 mg/m² cont. inf. all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
1899411|NCT01328184|Drug|levonorgestrel|multiple doses
1899412|NCT01328184|Drug|levonorgestrel|multiple doses
1899413|NCT01328184|Drug|Ethinylestradiol|multiple doses
1899414|NCT01328184|Drug|Microgynon + BI 10773|multiple doses BI 10773
1899415|NCT01328184|Drug|Ethinylestradiol|multiple doses
1899416|NCT01328197|Device|Treovance Abdominal Aortic Stent-Graft with Navitel Delivery System|Stent-graft implant
1899417|NCT01328210|Procedure|blood letting|blood letting twice within 4 weeks. First blood removal baseline with 400ml of venous blood and second blood removal with 300-400ml according to serum ferritin levels.
1899418|NCT01321281|Dietary Supplement|AquaCal|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.
The daily dose of 4 capsules of AquaCal provide 800mg calcium, (the EU RDA for calcium) and 74 mgs Magnesium (EU RDA 375mg)."
1899419|NCT01321281|Dietary Supplement|AquaPT|"AquaCal and AquaPT are produced by Marigot Ltd according to EU and FDA requirements.
The daily dose of 4 capsules of AquaPT provides 720mg calcium, 200mgs green tea (polyphenols) and 50 mgs pine bark extract."
1899420|NCT01321294|Procedure|laparoscopic anti-reflux surgery|
1899422|NCT01321333|Biological|HuCNS-SC cells|single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord
1899423|NCT01321346|Drug|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week given on a Monday, Wednesday, Friday schedule, every week. One course is 28 days (4 weeks). Patients will get 2 courses and may receive up to 8 courses total.
1899424|NCT01321346|Drug|Cytarabine|"All patients will receive 70 mg of intrathecal cytarabine on day 0 of course 1. The day 0 dose must be given at least 24 hours prior to initiation of panobinostat. Omit the day 0 dose of intrathecal cytarabine if the patient received intrathecal therapy within 72 hours of treatment.
All patients will receive 70 mg of intrathecal cytarabine on day 29 of course 1-8 in conjunction with their disease evaluation."
1899425|NCT01321346|Drug|Panobinostat|Dose will be assigned at study entry. Patients will take panobinostat orally 3 times a week on a Monday, Wednesday, Friday schedule, every other week. Once course is 28 days (4 weeks). Patients will get 2 course and may receive up to 8 courses of therapy.
1899426|NCT01321359|Drug|Vehicle versus NB-001|Topical, 5 times daily until investigator assessment of healing or a maximum of 4 days
1899427|NCT01321385|Other|laboratory biomarker analysis|
1899428|NCT01321385|Other|study of socioeconomic and demographic variables|
1899429|NCT01321398|Other|Esophageal Pressure Monitoring|An esophageal pressure monitor will be placed through the mouth into the esophagus by a study physician. Placement will be confirmed by a bedside chest X-ray. Once placement has been confirmed all air will be evacuated from the balloon by syringe. One ml of air will then be injected to partially inflate the esophageal balloon. Pleural pressure measurements will be recorded after 1 minute without spontaneous breathing or patient care related movement. This measurement will be repeated at 30 minutes and at 60 minutes after the first measurement. Trans-pulmonary pressure is calculated as the difference between esophageal pressure and mouth pressure. Once the measurements have been recorded, the catheter will be removed.
1899491|NCT01321957|Drug|Oxaliplatin, 5FU/LV, Bevacizumab|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
1899430|NCT01321411|Other|Near Infrared Spectroscopy|"Healthy Volunteers:
Study #1 (Abnormal Pulmonary Resistance) subjects will breathe through a Starling resistor simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV.
Study #2 (Abnormal Pulmonary Compliance) subjects will breathe while wearing a chest binder simulating abnormal pulmonary resistance. WOB and RMBF will be measured during resting breathing, as well as at 25%, 50% and 75% of MVV."
1899431|NCT01321411|Other|Near Infrared Spectroscopy|"Clinical Volunteers:
Study #3 (Abnormal Pulmonary Resistance) subjects recovering from COPD exacerbations will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB.
Study #4 (Abnormal Pulmonary Compliance) subjects recovering from ARDS will breathe through their ventilator circuit. PAV support will be altered to change the subjects' WOB. WOB and RMBF will be measured during resting breathing, as well as at 75%, 125% and 150% of baseline WOB."
1899432|NCT01321437|Procedure|therapeutic conventional surgery|Undergo surgery
1899433|NCT01321437|Other|laboratory biomarker analysis|Correlative studies
1899434|NCT01321437|Drug|Axitinib|Axitinib will be administered 5 mg orally twice each day (BID) continuously. Dose adjustments will be based on adverse events.
1899435|NCT01321437|Other|pharmacological study|Correlative studies
1899436|NCT01321463|Drug|PH-797804|6 mg oral tablet once daily for 12 weeks
1899437|NCT01321463|Drug|Placebo|Placebo oral tablet once daily for 12 weeks
1899438|NCT01321489|Drug|Sildenafil Citrate 20mg Tablet Sublingual|Administer one tablet of Sildenafil Citrate 20 mg sublingually 10 minutes before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
1899439|NCT01321489|Drug|Viagra ® 50mg tablet Coated|Administer one tablet of Viagra ® 50mg tablet Coated orally 1 hour before intercourse. It is recommended that the administration of just one tablet a day. The patient will receive six tablets of the medication.
1899440|NCT01321502|Drug|famciclovir|500 mg tablet
1899441|NCT01321515|Drug|famciclovir|500 mg tablet
1899442|NCT01321541|Drug|Pixantrone + Rituximab|Pixantrone + Rituximab: Rituximab 375 mg/m2 IV on day 1 and pixantrone 50 mg/m2 (equivalent to 85mg/m2 pixantrone dimaleate)IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
1899443|NCT01321541|Drug|Gemcitabine + Rituximab|Gemcitabine + Rituximab: Rituximab 375 mg/m2 IV on day 1 and gemcitabine 1000 mg/m2 IV on days 1, 8, and 15. Regimen is given in 28-day cycles. Up to 6 cycles may be administered.
1899444|NCT01321554|Drug|Lenvatinib|Lenvatinib 24 mg (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
1899445|NCT01321554|Drug|Placebo|Matching placebo (two 10-mg and one 4-mg lenvatinib matched capsules) taken orally once daily, continuously.
1899446|NCT01321554|Drug|Lenvatinib|"Lenvatinib 20 mg (two 10-mg capsules) taken orally once daily, continuously. Dose interruptions or reductions were allowed for subjects who experienced treatment-related toxicity.
The dose of lenvatinib during the OOL Lenvatinib Treatment Period was 24 mg once daily from 03 Oct 2011 until 15 Feb 2013. The dose was lowered at the request of the Data Monitoring Committee to 20 mg on 16 Feb 2013. Thus, more subjects were treated with 24 mg starting dose and the treatment duration was longer for these participants than those whose starting dose was 20 mg."
1899447|NCT01321567|Drug|rabeprazole sodium|Doses of 10 mg or 20 mg twice daily may be administered orally to reflux esophagitis patients for a further 8 weeks when proton pump inhibitor treatment is ineffective. However, a dose of 20 mg twice daily should only be administered to patients with severe mucosa injury.
1899448|NCT01321580|Device|Masimo Pronto 7|non invasive hemoglobin determination by the Masimo Pronto 7 versus laboratory hemoglobin measurement
1899451|NCT01321619|Drug|Daflon|Drug B (Daflon): Administered one tablet two times daily (oral), the main meals (breakfast and dinner)for 30 days.
1899452|NCT01321619|Drug|Varicell placebo|Drug C (Varicell placebo) : Administered one tablet three times a day,(oral), the main meals (breakfast, lunch and dinner)for 30 days.
1899453|NCT01321632|Drug|Zingiber officinalis|To start with subjects will be prescribed Zingiber officinalis in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
1899454|NCT01321645|Drug|Azadirachta Indica|To start with subjects will be prescribed Azadirachta Indica in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.
1899455|NCT01321658|Other|Geriatric intervention|A comprehensive geriatric assessment (CGA), focusing on co-morbidity, medication, cognitive status, depression, nutritional status and physical status is performed. The intervention is individualized according to the results of the CGA.
1899456|NCT01321671|Drug|Pregabalin controlled release, 330 mg, 600- 750 calorie|A single oral dose of 330 mg controlled release tablet administered following a 600 to 750 calorie evening meal
1899457|NCT01321671|Drug|Pregabalin controlled release, 330 mg, fasted|A single oral dose of 330 mg controlled release tablet administered fasted in the evening
1899458|NCT01321671|Drug|Pregabalin immediate release, 300 mg|A single oral dose of 300 mg immediate release capsule administered in the evening
1899459|NCT01321684|Other|lateral decubitus position with full spinal flexion|The patients maintained the lateral decubitus position with the hips and back fully flexed for 15 minutes.
1899460|NCT01321684|Other|lateral decubitus position without spinal flexion|the patients are allowed to straighten their flexed hips and back to obtain the normal lordotic curvature of spinal column
1899461|NCT01321697|Procedure|Routine Leg edema and groin dissection|The investigators will be documenting and reporting the variations in leg lymphatic drainage sentinel lymph node biopsy with inguinal-femoral lymph node dissection.
1899526|NCT01322256|Biological|Bloodwork|CRP and procalcitonin are measured in the pre-inclusion work up.
1900192|NCT01334918|Drug|regadenoson|Administered by intravenous bolus.
1899462|NCT01321710|Behavioral|Sleep hygiene|"This intervention consists of behavioral strategies for minimizing maternal arousal and sleep disturbance as a result of night-time infant care. Key components include: infant proximity, low lighting, and noise attenuation.
It is administered to women during their last month of pregnancy."
1899463|NCT01321710|Behavioral|Dietary information|This intervention consists of dietary information aimed at improving postpartum sleep. The recommendations include avoiding alcohol, caffeine, and heavy meals before bed, as well as eating healthy foods.
1899464|NCT01321710|Drug|Acetaminophen|51-90mg depending on infant weight (12.5mg per kg infant weight). Administered 30 minutes prior to immunization and q4-6h for a total of 5 doses.
1899465|NCT01321723|Drug|PTH analog|A recombinant 1-31 amino acid fragment of PTH.
1899466|NCT01321723|Drug|Placebo|
1899467|NCT01321723|Drug|Forsteo (Teriparatide)|A recombinant 1-34 amino acid fragment of PTH.
1899468|NCT01321736|Dietary Supplement|dietary fiber|mixture of fiber sources added to liquid nutrition product
1899469|NCT01321749|Procedure|Remote ischemic preconditioning (RIPC)|The detail of RIPC included five cycles of bilateral upper limbs 5/5 min. of ischemia and reperfusion alternation. Limb ischemia was induced by inflating tourniquets to 200 mmHg. This process was placed on both arms every day.
1899470|NCT01321775|Drug|Bevacizumab,Trastuzumab,Paclitaxel,Cyclophosphamide,Myocet|"Neo-adjuvant doses (12 weeks):
Bevacizumab: 15mg/Kg every 3 weeks Trastuzumab: 4 mg/Kg (First dose) - 2mg/Kg every week. Paclitaxel: 80mg/m2 every week.
Adjuvant doses:
Trastuzumab: 8mg/Kg(first dose)- 6mg/Kg every 3 weeks (At least 9 months) Cyclophosphamide: 600mg/m2 every 3 weeks (9 months) Doxorubicin Liposomal: 50mg/m2 every 3 weeks (3 months)"
1899471|NCT01321788|Drug|TINZAPARIN|Eligible women following cesarean section will randomly receive once-daily injections of study drug (4,500 IU tinzaparin sodium within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
1899472|NCT01321788|Drug|PLACEBO|Eligible women following cesarean section will receive a once-daily injections of placebo within 12 to 24 hours postpartum and continued for two (2) weeks postpartum.
1899473|NCT01321801|Drug|Pregabalin|Preoperative administration of pregabalin 600mg
1899474|NCT01321801|Drug|placebo|Preoperative administration of a matching placebo
1899475|NCT01321814|Behavioral|Cognitive behavioural therapy|6 sessions by licensed psychologist, including psychoeducation, exposure therapy, applied relaxation and behavioral activation.
1899476|NCT01321827|Drug|Glucocorticoids|Prednisolone 0.5 mg/kg/day for 4 weeks; 0.25 mg/kg/day for 4 weeks; 0.125 mg/kg/day for 4 weeks. Then taper by 5 mg every 2 weeks and discontinue. Patients will also receive inhaled formoterol/fluticasone (6/125 mcg) as needed as per the SMART approach for control of asthma
1899477|NCT01321827|Drug|Itraconazole|Itraconazole 200 mg BD for 6 months along with inhaled formoterol/fluticasone (6/125 mcg) 2 puffs twice daily by MDI and as needed as per the SMART approach
1899478|NCT01321840|Procedure|Specific Autoregulation Therapy (SART)|Complex intervention involving acupuncture and hypnotherapeutic techniques after an extensive diagnosis using chinese medical concepts. Patients will receive a maximum of 10 treatments, which are delivered weekly.
1899479|NCT01321853|Other|MD2 machine and nurse care coordination|MD2 machine filled at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
1899480|NCT01321853|Other|Medplanner and Nurse Care Coordination|Medications are dispensed via a medplanner filled by a nurse at least every 2 weeks and subjects monitored for changes in condition. Additional visits made as needed. Care is coordinated with other providers such as the primary care physician and pharmacist.
1899481|NCT01321866|Procedure|Cutting balloon angioplasty|Angioplasty of fistula stenosis using a cutting balloon
1899482|NCT01321866|Procedure|Angioplasty|Angioplasty of fistula stenosis using a non-cutting balloon
1899483|NCT01321879|Drug|Telavancin|10 mg/kg by vein once daily for patients with a creatinine clearance of more than 50 ml/min, and a dose of 7.5 mg/kg once daily for patients with a creatinine clearance of 30-50 ml/min.
1899484|NCT01321905|Dietary Supplement|Supplementation with vitamin D2/D3|"Patients younger than 16 years of age are administered 35,000 IU ergo-/chole-calciferol per week divided into doses 5000 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring. The intervention time is 3 months, followed by 2-months wash-out period when patients do not take any more extra vitamin D but they are still monitored.
Patients 16 or more years of age are administered 50,000 IU ergo-/chole-calciferol per week divided into doses 7150 IU per day as a starting dose that is further adjusted by serum 25-hydroxy vitamin D concentration monitoring."
1899485|NCT01321918|Other|Case Controls|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised on a route of vascular development place in the context of medical practice.Clinical data will be indicated in the CRF and the computerized database. In the event an eligible patient has not been included during his support by an emergency ambulance service but, after successful resuscitation, he has been hospitalised in a cardiology department, its inclusion may be realised during the hospitalization by a physician investigator of the study. A blood sample of 10 ml of 2 EDTA tubes will be realised on a route of vascular development in the context of routine care.
1899486|NCT01321918|Other|Control subjects|A blood sample of 10 ml (2 x 5 ml) on two EDTA tubes will be realised and clinical data will be indicated in the CRF and the computerized database.
1899487|NCT01321931|Drug|Nicotine|6 mg experimental Nicotine Replacement Therapy (NRT)
1899488|NCT01321931|Drug|Nicotine|4 mg marketed Nicotine Fruit Gum (NFG)
1899489|NCT01321931|Drug|Nicotine|4 mg marketed nicotine mint lozenge (NIQ)
1899490|NCT01321944|Other|Direct to Smoker Outreach Program|"Intervention group participants will be sent 3 letters at monthly intervals signed by the participant's PCP, encouraging the smoker to quit, and offering a free telephone consultation by Partners' Tobacco Treatment Coordinator (TTC). Participants can respond to the treatment offer by calling or emailing the TTC, who will provide a 15-minute consultation following the 5A strategy recommended by the US Public Health Service's clinical guideline and help smokers access treatment by (1) offering a free 4-week supply of 21mg nicotine patches sent by secure mailing to their home (refillable once for a total of 8 weeks), (2) helping smokers obtain prescriptions from their PCP for other FDA-approved smoking cessation medication, (3) using a fax-referral system to facilitate connection to free multi-session counseling from the Massachusetts Smokers Quitline, and (4) referring to local in-person counseling programs."
1899492|NCT01321957|Drug|5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan|bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
1899493|NCT01321970|Procedure|Stress ultrasound|Qualitative interpretation of the left ventricular wall motion abnormalities is performed in real time in the resting phase and during pharmacological stress. The translation of quantitative data is then performed for each of the 17 segments on a bulls-eye pattern identical to that of scintigraphy.
1899494|NCT01321970|Procedure|Scintigraphy|Image acquisition is synchronized to the electrocardiogram. The tomographic sections are represented in the 3 directions of space, the analysis is also done on the classical representation in 17 segments. (Typically used in ultrasound perfusion scintigraphy or PET).
1899495|NCT01321970|Procedure|Coronary angiography|"Performed in interventional cardiology setting using a guide introduced through the radial or femoral artery. The injection of iodine allows opacification of coronary arteries and their visualization by fluoroscopy. The qualitative interpretation of the data is translated in terms of percentage of stenosis of the coronary artery. It is thus considered that the stenosis is significant at over 70% obstruction of the lumenal diameter. This interpretation is made for each of the three main coronary arteries and their tributaries:
Right coronary (proximal, middle and distal) and collateral (inter ventricular posterior ventricular posterior retro)
Inter ventricular anterior (proximal, middle and distal) and its tributaries (diagonal and septal)
Circumflex (proximal, middle and distal) and collateral (first and second marginal)"
1899496|NCT01321983|Other|Inspiratory muscular training - IMT|
1899497|NCT01321996|Procedure|68Ga-DOTA-NOC PET/CT|procedure: PET/CT scan with 68Ga-DOTA-NOC
1899498|NCT01322009|Drug|Probenecid and N-acetyl cysteine|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days or to receive placebos.
1899499|NCT01322009|Drug|Placebo|After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
1899500|NCT01322022|Behavioral|ParentTraining|5 sessions of individual parent training
1899501|NCT01322022|Other|Parent Education|Parent Education to control for time and attention
1899502|NCT01322048|Drug|IV Propranolol and Per Tube Clonidine|1 mg IV q6h Propranolol and 0.1 mg Per Tube Clonidine, both for 7 days
1899503|NCT01322048|Drug|Placebo|Placebo IV q6h and Per Tube q12, both for 7 days
1899504|NCT01322061|Drug|Ascorbic Acid|Effervescent,1000mg/tablet, 2000 mg dissolved in 50ml water, the drug will be given once, one hour prior to surgery
1899505|NCT01322087|Dietary Supplement|Nutritional intervention|"The study was a 12 weeks intervention trial with inclusion of 40 patients at nutritional risk, according to the NRS-2002 system.
All included patients received nutritional counseling and information about the new food concept by a clinical dietician.
Recording of the dietary intake was carried out on a daily basis over a period of 3 to 7 days, with nutritional registration forms filled in by the nurse and/or the patient."
1899506|NCT01322100|Device|The Electroporation System|The Electroporation System comprises of 3 parts: 1.Switch Box, 2. Driver, 3. Brain Probe
1899507|NCT01322100|Drug|Bleomycin|Bleomycin dosage for i.v. use is 15.000 IU/m2, and is administered 10-30 minutes before the electric pulses. Bleomycin dosage for intratumoral use is either 2.000 IU, 4.000 IU, or 6.000 IU per 3 ml, and 20 % of the calculated tumor volume is injected.
1899508|NCT01322126|Device|ultrasound probe|we will compare two technique of neuraxial anesthesia;one group will be passed neuraxial anesthesia with the intervention the ultrasound and the other group without the intervention of the ultrasound.
1899509|NCT01322139|Drug|Placebo spray and oral moxifloxacin placebo|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
1899510|NCT01322139|Drug|Sativex spray and oral moxifloxacin placebo|8 Sativex sprays (4 sprays twice daily every 12 hours) + 16 or 28 placebo sprays (8 or 14 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
1899511|NCT01322139|Drug|Sativex spray and oral moxifloxacin placebo|24 or 36 Sativex sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin placebo on Day 5.
1899512|NCT01322139|Drug|Placebo spray and moxifloxacin|24 or 36 placebo sprays (12 or 18 sprays twice daily every 12 hours) for 5 days and single oral moxifloxacin 400 mg tablet on Day 5.
1899513|NCT01322152|Drug|irinotecan, capecitabine|Irinotecan: 90 mg/m2, d1, iv gtt; Capecitabine: 1200mg/m2 Bid, d1-5, po; The regimen is repeated every 7 days.
1899514|NCT01322178|Drug|Cetuximab; mFOLFOX6|"Cetuximab (Erbitux): 500 mg/m2 iv gtt, D1
Oxaliplatin: 85 mg/m2 iv gtt over 2 hours, D1; leucovorin: 400 mg/m2 iv gtt , D1; 5-FU: 400 mg/m2 iv, 2400 mg/m2 civ46h
repeated every two weeks for 4.5 months(9 cycles)"
1899515|NCT01322191|Drug|Morphine|A single dose of morphine 0.1 mg/kg infused by syringe pump over 10 minutes; urine and blood sample frozen at -80 degrees Celsius
1899516|NCT01322204|Drug|Codeine|One single oral dose of 1 mg/kg of codeine
1899517|NCT01322230|Other|Control|Multimedia Control
1899518|NCT01322230|Other|WISEMD Original|Current WISEMD
1899519|NCT01322230|Other|Social Networking|Social networking feature
1899520|NCT01322230|Other|Social Networking plus Emotional Design|social networking features plus user interface enhancements
1899521|NCT01322243|Other|Dietary manipulation|Participants are maintained in a fasted (only noncaloric beverages) or fed (isocaloric weight-maintenance diet) state for two days.
1899522|NCT01322256|Procedure|Bone scintigraphy|Bone scintigraphy of the affected area
1899523|NCT01322256|Procedure|Leukoscan|Scintigraphy with labeled neutrophils
1899524|NCT01322256|Procedure|PET / CT|PET / CT of the affected area
1899525|NCT01322256|Procedure|Bone biopsy|A bone biopsy is performed during pre-inclusion work up.
1899528|NCT01322282|Drug|Cetirizine|A single 10 mg dose of an experimental Cetirizine Orodispersible Tablet (ODT), with a 7-day washout period between visits
1899529|NCT01322282|Drug|Cetirizine|A single 10 mg dose of a marketed Cetirizine Film-Coated Tablet (FCT), with a 7-day washout period between visits
1899530|NCT01322308|Drug|pioglitazone|30 mg tablet QD (taken once daily)
1899531|NCT01322308|Drug|placebo|tablet taken once a day
1899532|NCT01322321|Drug|ACZ885|
1899533|NCT01322321|Drug|Placebo|
1899534|NCT01322334|Behavioral|Singing exercises|A 3 month self-guided treatment based on a specially designed 3CD box set, which patient performed every day ('Singing for Snorers': UK)
1899535|NCT01322347|Drug|Soluble Ferric Pyrophosphate (SFP)|Patients to receive 11 micrograms (µg) of iron/ deciliter (dL) of dialysate during dialysis 3 or 4 times/week for up to 18 months.
1899536|NCT01322347|Device|Standard dialysate|Patients to receive standard dialysate (no iron) during dialysis 3 or 4 times/week.
1899537|NCT01322360|Drug|Morphine Sulfate|
1899538|NCT01322386|Drug|Vancomycin|Oral 50mg/Kg per day up to maximum of 1500 mg a day for three months.
1899539|NCT01322399|Procedure|Structural Integration|"Structural Integration (SI) is an alternative method of manual therapy and somato-sensory training that purports to improve biomechanical functioning of the body as a whole rather than to focus on the treatment of specific symptoms. SI therapists employ both manipulation and somatosensory education. SI is delivered in a series of ten treatments, referred to as the Ten Series, each of approximately one hour in duration. The Ten Series protocol includes manipulation of all major joints and anatomical segments. Each of the ten sessions aims to achieve a different set of biomechanical changes, which are regarded as contributing to the progressive approximation of specific ideals of posture and movement."
1899540|NCT01322399|Procedure|Usual care|Usual care in this study consists of the treatment regimen provided for chronic low back pain at Spaulding Medford Rehabilitation clinic, which may include pain medication, exercise and physical therapy. Frequency of treatment averages twice weekly, duration ranges from 3 to 7 weeks
1899541|NCT01322438|Drug|Regorafenib (BAY73-4506) + rifampin|Drug: BAY73-4506 A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 1 as four 40 mg tablets. Drug: BAY73-4506 and rifampin 600 mg once a day doses of rifampin will be orally administered after overnight fasting from Day 15 to Day 23. A single 160-mg dose of BAY73-4506 will be administered in the fasted state on Day 21 as four 40 mg tablets.
1899542|NCT01322451|Drug|GLPG0259 fumarate|single oral dose, two capsules each containing 25 mg of GLPG0259 fumarate
1899543|NCT01322451|Drug|GLPG0259 free base|single oral dose, GLPG0259, 50 mg solid formulation
1899544|NCT01322464|Drug|Sativex|4 sprays Sativex in fasted state on Day 1. 4 sprays Sativex in fed state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
1899545|NCT01322464|Drug|Sativex|4 sprays Sativex in fed state on Day 1. 4 sprays Sativex in fasted state on Day 4. 4 sprays Sativex daily in fasted state Days 5-13.
1899546|NCT01322464|Drug|Sativex|2 sprays Sativex daily in fasted state Days 4-13.
1899547|NCT01322464|Drug|Sativex|8 sprays Sativex daily in fasted state Days 4-13.
1899548|NCT01322477|Other|F18-FDG PET/CT|
1899549|NCT01322490|Biological|PROSTVAC-V|
1899550|NCT01322490|Biological|PROSTVAC-F|
1899551|NCT01322490|Drug|GM-CSF|
1899552|NCT01322490|Other|GM-CSF Placebo|
1899553|NCT01322490|Biological|Placebo|PROSTVAC V/F Placebo
1899554|NCT01322503|Biological|Norovirus|Norovirus challenge pool administered to each subject
1899555|NCT01328223|Radiation|sorafenib and radiotherapy for hepatocellular carcinoma|Concurrent and maintenance sorafenib 400mg twice daily
1899556|NCT01328236|Drug|Bortezomib|"INDUCTION THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
MAINTENANCE THERAPY: 1.3 mg/m2, IV (in the vein) on day 1， 4， 8， 11 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
1899557|NCT01328236|Drug|Liposome doxorubicin|INDUCTION THERAPY: 30 mg/m2, IV (in the vein) on day 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
1899558|NCT01328236|Drug|Dexamethasone|"INDUCTION THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 6 Cycles: until progression or unacceptable toxicity develops.
MAINTENANCE THERAPY: 40 mg/d, IV (in the vein) on day 1- 4 of each 28 day cycle. 4 Cycles: interval between every two cycles for 6 months, until progression or unacceptable toxicity develops."
1899559|NCT01328249|Drug|eribulin mesylate|Dose dense doxorubicin and cyclophosphamide for 4 cycles during the first 8 weeks followed by eribulin mesylate 1.4mg/m2 for 4 cycles during the next 12 weeks
1899560|NCT01328262|Other|Red blood cells (RBCs)|The subjects receive an amount of RBCs that has been calculated from their BSA.
1899561|NCT01328262|Other|Red blood cells|The subjects in this group receive the prescribed number of redd blood cell units.
1899562|NCT01328275|Drug|standard regimens according to the Thai Ministry of Public Health national guidelines|Participants may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
1899563|NCT01328288|Drug|standard ART according to the Thai Ministry of Public Health national guidelines|Patients may receive any of the standard regimens. These regimens are recommended in the Thai Ministry of Public Health National guidelines for the treatment of HIV in children. Change of treatment will be according to the treating physicians.
1899564|NCT01328301|Other|Experimental|For SDT training, subjects received short intervals of locomotion training with a treadmill. After walking for 30s, the subjects were given two minutes of rest. If they completed the first walking trial safely and without stumbling, the belt speed was increased by 10% on the next trial. However, if a subject failed to complete the first trial, the belt speed was decreased by 10% on the next trial. The speed of the treadmill was adjusted in each subsequent trial according to the same principle. Subjects usually completed 7-8 walking trials in one session. The belt speed was increased by a maximum of five increments within one training session.
1899565|NCT01328301|Other|Speed-stable treadmill training|Subjects in the control group walked on the treadmill with the belt speed adjusted according to their fastest over-ground gait speed. There was no adjustment of the belt speed throughout the 30-minute steady-speed treadmill training session.
1899566|NCT01328340|Other|High-speed power training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 12 to 14 repetitions at 40% of maximal strength
1899567|NCT01328340|Other|Slow-speed strength training|exercised 3 times per week for 12 weeks. Each training session will consist of 3 sets of 8 to 10 repetitions at 80% of maximal strength
1899568|NCT01328353|Other|telehealth plus aprn triage|aprn using either telephone or telephone plus video conferencing will provide triage for CCHCN
1899569|NCT01328379|Drug|Dalfampridine-ER 5mg|5mg, twice daily
1899570|NCT01328379|Drug|Dalfampridine-ER 10mg|10mg, twice daily
1899571|NCT01328379|Other|Placebo|placebo, twice daily
1899572|NCT01328392|Drug|Dexlansoprazole|30mg a day, 3 months
1899573|NCT01328405|Device|Laryngeal Mask Airway (LMA)|Comparison of airway seal pressure, airway morbidity bronchoscopic view obtained between two different laryngeal mask airways.
1899574|NCT01328418|Procedure|Lengthening over nail|External fixator is used to lengthen either the femur or the tibia over an intramedullary nail
1899575|NCT01328431|Other|Brief Intervention with NRT Initiation|Brief Negotiated Interview is a manual-guided therapy designed for the ED setting. The purpose is to assist subjects to change some aspect of their smoking and to decide to start nicotine replacement therapy while in the ED. It combines techniques from motivational interviewing and stages of change. a 6-week supply of nicotine replacement therapy is given in the form of patches and gum and subjects are encouraged to use both concurrently. Patches come in 21 mg, 14 mg, and 7 mg doses and the dosage is determined based on how many cigarettes per day a subject is smoking. All subjects receive 400 pieces of 2 mg nicotine gum. All subjects complete a referral form for the state's Smokers' Quitline which is then faxed directly to the Quitline's vendor.
1899582|NCT01328457|Drug|Paromomycin sulfate|Paromomycin IM Injection, 11 mg/kg as the base, intramuscular, once a day on 21 consecutive days (or no more than 22 days if one injection is missed during the treatment period).
1899583|NCT01328470|Drug|Clopidogrel, cilostazol|Patients with CKD received clopidogrel (75 mg/day)for 14 days Patients with CKD received clopidogrel (150 mg/day)for 14 days Patients with CKD received clopidogrel (75 mg/day)and cilostazol (100 mg twice daily)for 14 days 75mg clopidogrel in patients with normal kidney function for 14 days
1899584|NCT01328483|Procedure|Intrapartum Oropharyngeal Suctioning|After delivery of the head, the infant's mouth and nose were suctioned. Nose was suctioned after the mouth and throat. Oropharyngeal suctioning was performed using a 10 french suction catheter with suction pressure of 100mm Hg or De Lee's suction trap in event of electricity failure or non availability of suction machine
1899585|NCT01328496|Drug|Preparative Regimen|"Fludarabine (75 mg/m2), fractionated total body irradiation (TBI) (12.0 Gy), and cyclophosphamide (120mg/kg) with mesna. Fludarabine will be given once a day at 25 mg/m2 for three days on day -10 to day -8, TBI will be given twice a day at 150 cGy for four days on day -7 to day -4, and cyclophosphamide will be given once a day for at 60mg/kg for two days on day -3 and day -2.
Post-transplantation immunosuppression with cyclosporine and MMF will begin on day -3. Cord Blood infusion will occur on day 0 and G-CSF will start on day +1."
1899586|NCT01328522|Drug|SAR153191 (REGN88)|"Pharmaceutical form:solution
Route of administration: subcutaneous"
1899587|NCT01328535|Drug|temozolomide|Given PO
1899588|NCT01328535|Other|flow cytometry|Correlative studies
1899589|NCT01328535|Other|staining method|Correlative studies
1899590|NCT01328535|Procedure|biopsy|Optional correlative studies
1899591|NCT01328535|Other|laboratory biomarker analysis|Correlative studies
1899592|NCT01328548|Drug|Zostavax|
1899593|NCT01328574|Drug|TRC105|15 mg/kg intravenously
1899594|NCT01329185|Drug|Valganciclovir|Valganciclovir 450mg twice a day for 14 days prior to transplant date
1899595|NCT01329185|Drug|Placebo|1 capsule twice a day for 14 days prior to transplant date
1899596|NCT01329198|Device|NeuroPace RNS® (responsive neurostimulation) System Deep Brain Stimulator|"There will be a one month post-operative period during which stimulation is not turned on.
One month post-implant, subjects will be randomized one to one in a blinded fashion to receive active or sham stimulation.
By Day 60, all subjects will be programmed to receive active stimulation. Physiological data will be collected for Specific Aim 2 of the study.
Both the sham and the active groups (3 subjects in each group) will undergo identical programming procedures at 30 and 60 days."
1899597|NCT01329224|Other|Measurement of platelet anti-aggregation|Whole blood impedance platelet aggregometry was performed with the Multiplate analyzer (Dynabyte, Munich, Germany) to test the response to ASA with arachidonic acid as the trigger.
1899598|NCT01329237|Other|dynamic physical exercise and OCT imaging|supine dynamic physical exercise during coronary angiography and optical coherence tomography OCT imaging of the coronary stent
1899599|NCT01329250|Drug|Moxifloxacin|Patients will start on a standard dose of MFX 400 mg once daily. After 8 days the dose will be increased to 600 mg once daily and on the 15th day of treatment, the dose of MFX will be escalated to 800 mg. In patients who have been treated with rifampicin (RIF) in the past three weeks prior to start of MFX treatment an additional washout period of 3 weeks to reduce the rifampicin induced enzymatic activity will precede the dose escalation.
1899600|NCT01329263|Other|Menthol to non-menthol|Switch from smoking menthol to non-menthol cigarettes.
1899601|NCT01329276|Drug|Symbicort® forte Turbohaler®|320 µg budesonide / 9 µg formoterol fumarate dihydrate
1899602|NCT01329289|Drug|SOM230|60 mg intramuscularly (IM) on day 1 of each 28 day cycle
1899603|NCT01329289|Drug|Bortezomib|1.3 mg/m2 intravenously (IV) on days 1, 4, 8, and 11 of each cycle. Bortezomib will be infused by IV push.
1899604|NCT01329289|Drug|Dexamethasone|20 mg orally on day of and day after bortezomib (Days 1, 2, 4, 5, 8, 9, 11, 12).
1899642|NCT01329640|Device|Drug: Paclitaxel; trastuzumab; doxorrubicin; cyclophosphamide|"Paclitaxel 100mg/m2 once a week for 8 weeks concomitant to trastuzumab 4mg/kg dose attack after 2mg/kg once a week for 8 weeks followed by;
Doxorrubicin 24mg/m2 once a week concomitantly with oral cyclophosphamide 100mg/day (flat dose) concomitantly with trastuzumab 2mg/kg for 9 weeks"
1899605|NCT01329302|Procedure|Direct aspiration needle Echo tip® Cook® single Lumen and Follicular flushing with double lumen needle Echo tip® Cook® Double Lumen Aspiration|In addition to direct aspiration of the follicular fluid all follicles are flushed with flushing solution, 20CC of flushing medium( Flushing Medium MediCultâ France) is provided for all the procedure and flushing medium is collected separately from direct fluid
1899606|NCT01329315|Behavioral|BMI-T|Brief Motivational Intervention (BMI-T): social worker/therapist-delivered intervention (25-minute tailored structured module).
1899607|NCT01329315|Behavioral|BMI-C|Computer-delivered intervention (BMI-C): computerized tailored 25-minute intervention.
1899608|NCT01329328|Device|vibrating platform (Bioplate RF)|whole body vibration exercise with multiple positions, with or without localized delivery of heating radiofrequency
1899609|NCT01329341|Other|Service Dogs|Service dogs will be trained to help Veterans with PTSD
1899611|NCT01329367|Behavioral|Control group|"Subjects will receive Nutritional education together with weight management counselling for overweight and obesity.
-10 weekly personal interviews with a registered nutritionist for body weight control."
1899612|NCT01329367|Behavioral|Protein group|"Participants will receive Nutritional education and personalised structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of legumes and fish (protein rich diets).
-10 weekly personal interviews with a registered nutritionist for body weight control."
1899613|NCT01329367|Behavioral|Antioxidant group|"Participants will receive Nutritional education and personalized structured meal plan with a calorie restricted diet (20-40% of the subject's energy expenditure at baseline) according to obesity degree, encouraging high consumption of fruits and vegetables (antioxidant rich diets).
-10 weekly personal interviews with a registered nutritionist for body weight control."
1899614|NCT01329393|Behavioral|Benefits Management|Money-management intervention consisting of brief advice on budgeting, assessment of ability to follow a budget, and assessment of need for a representative payee.
1899615|NCT01329393|Behavioral|Illness Management and Recovery|Recovery Oriented Training in Biopsychosocial Model of Stress and How to Cope with Stress
1899616|NCT01329406|Drug|Milnacipran|1 tablet (100mg) by mouth twice daily for 28 days
1899617|NCT01329406|Drug|Placebo|1 tablet by mouth twice daily for 28 days
1899618|NCT01329419|Drug|adefovir dipivoxil|Basically there is no treatment allocation. Subjects who would be administered of adefovir at their physicians' discretion will be enrolled. Dosage regimen will be recommended according to the prescribing information. Subjects will be enrolled consecutively.
1899619|NCT01329432|Procedure|Take care|In TAKE CARE procedure all premature infants who suffered from respiratory distress syndrome (RDS) received 100 mg/kg of porcine surfactant preparation via an intratracheal catheter during spontaneous breathing.
1899620|NCT01329432|Procedure|InSurE|infants treated with InSurE procedure were intubated and ventilated to receive surfactant and placed on nCPAP rapidly after surfactant administration.
1899621|NCT01329445|Other|DeNovo NT, Natural Tissue Graft|DeNovo NT Natural Tissue Graft of 1 or 2 lesions up to 5 cm squared in area.
1899622|NCT01329484|Behavioral|Reminiscence therapy|Personalized reminiscence therapy using a computerized system
1899623|NCT01329484|Behavioral|Cognitive training|Cognitive training using a computerized system
1899624|NCT01329484|Other|No treatment|Participants in the control group will receive neither of the 2 experimental interventions or any other similar interventions.
1899625|NCT01329497|Other|systemic dietary instruction|systemic dietary instruction based on continuous quality improvement (CQI) team-oriented approach
1899626|NCT01329510|Device|One-night polysomnographic recordings|One-night polysomnographic recordings before and during methylphenidate treatment.
1899627|NCT01329549|Drug|BIBF 1120 (high) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
1899628|NCT01329549|Drug|BIBF 1120 (medium) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
1899629|NCT01329549|Drug|BIBF 1120 (low) + PLD 30 mg/m2 + CBDCA AUC5 mg/mL*min|BIBF 1120 twice daily along with standard therapy of PLD + CBDCA
1899630|NCT01329562|Drug|Treximet|Tablet for oral administration contains sumatriptan 85mg / naproxen sodium 500mg.
1899631|NCT01329562|Drug|Placebo|A placebo tablet matching Treximet for oral administration.
1899632|NCT01329588|Drug|Monthly antibiotic|Azithromycin 1g per os once at months 1, 4 and 7 Ciprofloxacin 500 mg per os once at months 2, 3, 5, 6, 8 and 9
1899633|NCT01329588|Drug|Monthly placebo|Azithromycin placebo (sugar pill) per os once at months 1, 4 and 7 Ciprofloxacin placebo (sugar pill) per os once at months 2, 3, 5, 6, 8 and 9
1899634|NCT01329601|Behavioral|StaCog, stage specific cognitive Intervention|StaCog intervention to improve cognitive performance and activities of daily living in AD and MCI
1899635|NCT01329601|Behavioral|booklet based training|Home based training of episodic memory using paper-pencil exercizes
1899636|NCT01329614|Behavioral|Cue Extinction Training|Repeated exposure to cigarette cues while receiving Nicotine Replacement Therapy.
1899637|NCT01329614|Drug|Nicotine Replacement Therapy|Study doctor applies a nicotine patch to the participant's shoulder blade. The patch dose is blinded by placement of a Bandaid over the patch itself.
1899638|NCT01329614|Behavioral|Cue Extinction Therapy|Participant is repeatedly exposed to cigarette cues without being allowed to partake in nicotine use.
1899639|NCT01329614|Behavioral|Progressive Muscle Relaxation|Participant relaxes muscles in her body, lead through the process using guided imagery and breathing techniques.
1899640|NCT01329627|Drug|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:
Paclitaxel 100 mg/m2 once a week for 8 weeks followed by;
Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
1899641|NCT01329627|Drug|Paclitaxel/doxorubicin/cyclophosphamide|"Metronomic chemotherapy as described below:
Paclitaxel 100 mg/m2 once a week for 8 weeks followed by; Doxorubicin 24 mg/m2 once a week concomitant to oral cyclophosphamide 100 mg/day (fix dose) for 9 weeks."
1899643|NCT01329653|Behavioral|aerobic training|12 weeks of aerobic training, 4X/week
1899644|NCT01329653|Behavioral|Wait list|wait list control condition
1899645|NCT01329666|Dietary Supplement|Placebo|Subjects will receive placebo vitamin D3, 1 pill weekly for 12 weeks.
1899646|NCT01329666|Dietary Supplement|Vitamin D3|"Baseline:
50,000 IU/week for 8 weeks
Week 8:
Subjects with D3 less than 30 ng/ml: 50,000 IU/week for 4 weeks.
Subjects with D3 25-OHD at or above 30 ng/ml: 50,000 IU/every 2 weeks for 4 weeks."
1899647|NCT01329679|Dietary Supplement|5 Hour Energy|5 Hour Energy, 2oz twice daily for 7 days
1899648|NCT01329679|Drug|Placebo|Water, lime juice and cherry flavoring
1899649|NCT01329692|Behavioral|Lifestyle counseling|Weeks 1 and 2 consist primarily of a review of current dietary habits with initiation of a food journal; a basic review of macronutrients and metabolism; and the beginning of a weekly exercise regimen. Weeks 3, 4, & 5 introduces counseling, with specific emphasis on emotional aspects of eating and behavioral modification strategies. Week 6 focuses on the metabolic impact of exercise, and includes an exercise session with a personal trainer. Week 7 incorporates a question and answer session with a sharing of discoveries, as well as an option for additional individual follow-up as needed. During this period, patients will also be given access to an interactive web-based tool providing additional emphasis on the aforementioned components and clinician follow-up.
1899650|NCT01329705|Device|Ankle Dorsiflexion Dynasplint|"Dynamic splinting utilizes the protocols of Low-Load Prolonged Stretch (LLPS) with calibrated adjustable tension to increase Total End Range Time (TERT)to reduce contracture. The Dynasplint or Experimental group will add this therapy to their standard of care regimen"
1899651|NCT01329705|Other|Standard of care|"Patients will begin a 12 week course of physical therapy with once-weekly therapy appointment, focusing on:
range of motion stretching of the Achilles tendon, hamstrings, hip flexors and any other tight musculature
strengthening of tibialis anterior to allow dorsiflexion in swing phase of gait as well as strengthening of other weak musculature
gait training to improve heel strike and toe off, stride length, and gait progression
sensory, proprioceptive training in foot position and degree of plantarflexion or dorsiflexion
no electric stimulation (e-stim) will be utilized"
1899652|NCT01329718|Other|Blood Sample|Blood sample collection
1899653|NCT01329731|Drug|elmex® gelée|1.25% fluoride (elmex® gelée) Dosage: Weekly brushing with 0.5g of respective gel Route: Intraoral topical
1899654|NCT01329731|Drug|negative control (placebo)|0% fluoride (negative control) Dosage: Weekly brushing with 0.5g Route: Intraoral topical
1899655|NCT01329744|Drug|mecasermin|a subcutaneous injection twice a day
1899656|NCT01329744|Drug|Placebo control|Subcutaneous injection given twice per day of placebo compound, for 24 weeks
1899657|NCT01329757|Drug|GH|Administration of a subcutaneously injected daily dose of GH (0.4mg)for 1 year
1899658|NCT01329757|Drug|Placebo|Administration of a subcutaneously injected daily dose of placebo for 1 year
1899659|NCT01329770|Dietary Supplement|Ascorbic Acid (Vitamin C) and Alpha-tocopherol (Vitamin E)|"Vitamin E (D-alpha-Tocopherol) 10 mg/kg/day (with a maximum of 600mg/day)
Vitamin C (L-Ascorbic Acid) 10 mg/kg/day (with a maximum of 800mg/day) For 12 weeks"
1899660|NCT01329770|Dietary Supplement|Placebo|Two daily dose of placebo, administered at breakfast and dinner for 12 weeks
1899661|NCT01329783|Other|maraviroc|No intervention is distributed during this trial.
1899662|NCT01329796|Drug|Lignocaine|Intrauterine flushing, pertubation, three treatments given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
1899663|NCT01329796|Drug|Ringers Solution|Intrauterine flushing, pertubation, given preovulatory at cycle day 6-12 in three sequential menstrual cycles.
1899664|NCT01329809|Drug|Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)|intratumoral or intravenous dosage: 10e9 pfu Intravenous: administered over 60 minutes Intratumoral: direct injection into a single liver lesion
1899665|NCT01329822|Behavioral|Caloric restriction|Caloric restriction
1899666|NCT01329835|Behavioral|Lifestyle counseling|4 prenatal sessions based on principles of motivational interviewing and positive reinforcement
1899667|NCT01329835|Other|brochure|brochure given after randomization
1899668|NCT01329861|Behavioral|Guided Internet-based cognitive behavioural treatment|Eight weeks internet-based cognitive behavioural treatment. Treatment consisted of education, cognitive skills acquisition, behavioural rehearsal, generalization and maintenance.
1899669|NCT01329874|Procedure|Type of block injection|Patients will be selected from a group with acute irreversible pulpitis in mandibular molars. Half of the patients randomly selected for receiving gow gates block injection and half will receive traditional inferior block injection by 3.6 ml Lidocaine plus epinephrine.Teeth with no response to anesthetizing will be randomly divided into two group of either buccal or lingual infiltration.
1899670|NCT01329887|Drug|ketanserin|ketanserin administration is started and increase, guided by the effect on sublingual MFI, dosage is 0,03mg/kg/hr
1899671|NCT01329900|Drug|Ofatumumab|1000 mg by vein on Day 1 and 2000 mg by vein on Day 8
1899672|NCT01329900|Drug|Ifosfamide|3.33 gm/m2 by vein on Days 2, 3, and 4 continuously.
1899673|NCT01329900|Drug|Etoposide|150 mg/m2 by vein over 2 hours every 12 hours Days 2, 3, and 4 for 6 doses.
1899674|NCT01329900|Drug|Mesna|"2 gm/m2 by vein over 1 hour on Day 2 (given before Ifosfamide starts)
2.66 gm/m2/day by vein continuous infusion given over 24 hours daily for 3 days starting on Day 2 (together with Ifosfamide)
After Ifosfamide/Mesna, 2 gm/m2 by vein given over 12 hours for one dose."
1899675|NCT01329900|Drug|G-CSF|6 mcg/kg subcutaneously twice a day on day 6 (rounded off to the nearest vial) until completion of apheresis.
1899676|NCT01329900|Procedure|Stem Cell Collection|Blood stem cells will be collected when blood counts have returned to normal (about 10-16 days after chemotherapy). Stem cell collection takes about 4 hours each time.
1899677|NCT01329913|Drug|MK-6325|Two 100 mg capsules, orally, once per day for 7 days
1899678|NCT01329913|Drug|Placebo to MK-6325|Two 100 mg capsules, orally, once per day for 7 days
1899679|NCT01329913|Drug|MK-6325|Four 100 mg capsules, orally, once per day for 7 days
1899680|NCT01329913|Drug|Placebo to MK-6325|Four 100 mg capsules, orally, once per day for 7 days
1899681|NCT01329913|Drug|MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
1899682|NCT01329913|Drug|Placebo to MK-6325|Eight 100 mg capsules, orally, once per day for 7 days
1900565|NCT01337414|Behavioral|Standard of Care|
1899683|NCT01329926|Procedure|Harvesting of neural stem cells|During neurosurgical procedures, tissue samples are obtained along trajectory of implanted electrodes or removal of stimulators previously implanted.
1899684|NCT01329939|Drug|Montelukast|Age-dependent dose, nightly, 24 weeks
1899685|NCT01329939|Drug|Placebo|Age-dependent dose, nightly, 24 weeks
1899686|NCT01329939|Drug|Montelukast|Age-dependent dose, nightly, 24 weeks
1899687|NCT01329939|Drug|Placebo|Age-dependent dose, nightly, 24 weeks
1899688|NCT01329965|Drug|LPS (reference endotoxin, E. coli O113:H10:K:neg, manufactured under GMP)|LPS or placebo (saline—salt water) will be injected (at approximately 7:30 am) in this catheter by a trained GCRC staff member involved with this study. Participants will not be told if they have received the drug or placebo. The LPS is a sterile solution of protein-free endotoxin which will be injected at a dose of 0.6 ng/kg body weight. Blood samples will be collected from a venous catheter for the first 12 hours and by venipuncture thereafter. Subjects will be continuously monitored by trained nursing staff for blood pressure (q 15 minutes) and body temperature (q 30 minutes), and the study will have physician oversight.
1899689|NCT01329978|Drug|Sofosbuvir|Sofosbuvir (SOF) administered as a 400 mg tablet orally once daily
1899690|NCT01329978|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1899691|NCT01329978|Drug|PEG|Pegylated interferon alfa-2a (PEG) 180 μg administered once weekly by subcutaneous injection
1899692|NCT01329991|Drug|PLX5622|PLX5622 drug substance is an achiral,small molecule Fms kinase inhibitor. The drug product is available in capsule form, to be taken orally, in a dosage strength of 100 mg with matching placebo
1899693|NCT01329991|Drug|Placebo|Matching placebo for PLX5622
1899694|NCT01330017|Drug|Phenylephrine HCl|10-mg immediate-release tablets, orally, up to 4 tablets per dose every 4 hours, for 7 days
1899695|NCT01330017|Drug|Placebo|Placebo tablets, orally, up to five tablets per dose every 4 hours, for 7 days
1899696|NCT01330017|Drug|Loratadine|10-mg tablets, orally, once per day at a dose not to exceed 10 mg in a 24-hour period.
1899697|NCT01330030|Drug|Selegiline|6mg/24 hrs for 8 weeks
1899698|NCT01330030|Other|matching placebo|placebo/24hrs for 8 weeks
1899699|NCT01330043|Drug|Bupropion|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
1899700|NCT01330043|Drug|Nicotine patch|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
1899701|NCT01330043|Drug|Varenicline|Both groups received the same pharmacotherapy per protocol. During open label treatment, all received CBT and bupropion and NRT patch. At week 10 those who continued to smoke were switched to varenicline through week 26. At week 10 those who are abstinent and reported low levels of craving and low levels of depression symptoms were withdrawn from study medications. Those who were abstinent but reported difficulty with craving or depression symptoms remained on bupropion and NRT through week 26. Medication was not available after week 26.
1899702|NCT01330056|Procedure|FOPS|"Functional organ preservation (FOPS) as a first-line treatment modality
Postoperative RT or CRT may be included for the patients of this group."
1899703|NCT01330056|Radiation|CRT|"Concurrent chemoradiotherapy as a first-line treatment modality
Salvage surgery may be applied for the patients with persistent or recurrent cancers after RT or CRT"
1899707|NCT01330095|Dietary Supplement|Administration of Bifidobacterium bifidum|Administration of Bifidobacterium bifidum to very low birth weight infants
1899708|NCT01330108|Drug|ambrisentan|ambrisentan 2.5mg, 5mg, & 10mg. Daily dosage.
1899709|NCT01330121|Other|Pharmacist Counseling|"Pharmacist Counseling includes but is not limited to:
Reviewing and explaining their medications (dosing, side effects, route) Reviewing symptoms and complications of hyper and hypoglycemia Defining glycemic & non-glycemic goal levels Explaining the importance of compliance with medications & appointments Educating on the basics of nutrition and physical activity"
1899712|NCT01330173|Drug|Vismodegib|Given PO
1899713|NCT01330173|Other|Pharmacological Study|Correlative studies
1899714|NCT01330173|Other|Laboratory Biomarker Analysis|Correlative studies
1899715|NCT01330186|Other|FMISO-PET, FDG-PET-CT and Magnetic Resonance Imaging (MRI)|This study involves 6 imaging sessions. One FMISO-PET before radiation therapy, one FDG-PET-CT before radiation therapy and one FDG-PET-CT during radiation therapy and tree Magnetic Resonance imaging (MRI) sessions with one session before radiation therapy, one session during radiation therapy and one sessions post radiation.
1899716|NCT01330199|Other|Pharmacokinetic Sampling|Blood plasma, Rectal, Cervical, and Vaginal Tissues and Secretions
1899717|NCT01330238|Drug|Zoledronic acid vs. placebo|Single infusion of zoledronic acid or placebo
1899718|NCT01330290|Drug|Neupro®|Neupro patches were prescribed by the treating physician according to the Summary of the Product Characteristics. Patients with idiopathic Parkinson's Disease (iPD) were treated for at least 1 month with a combination of Levodopa (L-DOPA) or other oral iPD medication and Neupro by the time the questionnaire was completed.
1899719|NCT01330303|Drug|Reference formulation|SECOTEX® (tamsulosin hydrochloride) 0,4 mg (Boehringer Ingelheim)
1899720|NCT01330303|Drug|Test formulation|tamsulosin hydrochloride 0,4 mg (Synthon BV)
1899721|NCT01330316|Drug|BI 201335|BI 201335 for 24 weeks
1899722|NCT01330316|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
1899723|NCT01330329|Behavioral|Standard behavioral treatment|Participants receive a standard behavioral weight loss program similar to that used in other large trials such as Look AHEAD and the Diabetes Prevention Program. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors.
1899724|NCT01330329|Behavioral|SBT + technology system (SBT+FIT)|Participants will receive a standard behavioral weight loss program and will also be asked to use the Body Media FIT system as part of their weight loss intervention. Individuals will come to weekly group meetings for 6-months and will be instructed to reduce caloric intake, increase physical activity, and self-monitor their weight, eating, and exercise behaviors. Participants in this group will also wear an armband that measures energy expenditure and they will log their food intake on the internet.
1899725|NCT01330355|Drug|Besivance|Besifloxacin hydrochloride 0.6% ophthalmic suspension, one drop instilled into infected eye, three times daily (TID) for 7 days
1899726|NCT01330355|Drug|Gatifloxacin|Gatifloxacin 0.3% ophthalmic solution one drop instilled into infected eye, TID for 7 days
1899727|NCT01330381|Drug|prucalopride|"prucalopride
subjects with weight ≤50kg: 0.04 mg/kg once daily as oral solution of 0.4 mg/ml
subjects with weight >50 kg: prucalopride 2 mg tablet once daily"
1899728|NCT01330381|Drug|Placebo|Matching oral solution or oral tablets given once daily
1899729|NCT01330381|Drug|PEG 4000|
1899730|NCT01330394|Device|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS, 5 x 7 cm2, 1 mA, during 10 min) will be applied over the left dorsolateral prefrontal cortex once a week for 5 consecutive weeks.
1899731|NCT01330407|Procedure|cryopreserved skin allografts.|
1899732|NCT01330407|Procedure|Cultured Epidermal Autografts|
1899733|NCT01330420|Behavioral|Relaxation Response Resiliency Program for Depression|"The program combines lecture, skills training, symptom monitoring, and group sharing aimed at preparing patients to take active roles in managing their own health. Elements of the program include:
Elicitation of the relaxation response through techniques such as diaphragmatic breathing and mindfulness.
Examination and reversal of negative thought patterns.
Physical movement, including stretching and yoga.
Healthy eating and other positive lifestyle behaviors.
Goal setting."
1899734|NCT01330433|Device|CoSeal Surgical Spray Group|"A patient randomized to the CoSeal treatment group will have CoSeal Surgical Spray applied at the end of their first staged procedure.
The dose regimen is as follows:
Patients weighing < 3kg will receive 1ml of CoSeal
Patients weighing 3-10kg will receive 1-2ml of CoSeal
Patients weighing >10kg will receive 2-4ml of CoSeal"
1899735|NCT01330446|Drug|Armodafinil|50 mg the first 3 days, 100 mg the next 4 days, and 150 mg for the remaining treatment period.
1899736|NCT01330446|Other|Placebo|1 by mouth every morning for a 28 day cycle.
1899737|NCT01330446|Behavioral|Questionnaires|Series of questionnaires completed at different time points before, during, and at study completion.
1899738|NCT01330459|Drug|Hydrocodone/acetaminophen|Administration of 2 tablets 5/325mg hydrocodone/acetaminophen 45-90 minutes prior to procedure.
1899739|NCT01330459|Drug|Placebo|Administration of 2 tablets methylcellulose (placebo) 45-90 minutes prior to procedure.
1899740|NCT01330472|Drug|Xanax XR tablets 3 mg (sourced from Caugus)|Tablets, 3 mg, single dose
1899741|NCT01330472|Drug|Xanax XR tablets 3 mg (sourced from Barceloneta)|Tablets, 3 mg, single dose
1899742|NCT01330485|Behavioral|ART|The ART is a transdiagnostic, group-based intervention that has been developed to explicitly target emotion regulation skills (e.g., the abilities to be aware of, understand, accept, tolerate and modify negative emotions).
1899743|NCT01330485|Behavioral|CFT-C|The CFT-C is an active treatment condition designed to control for unspecific effects of psychotherapeutic interventions.
1899744|NCT01330485|Behavioral|i-CBT-D (individual cognitive therapy for depression)|Individual cognitive therapy for depression (iCBT-D) will cover a 4-month period with 16 (weekly) sessions (à 50 minutes) in total. Treatment will follow a manualized protocol that is based upon procedures developed by Hautzinger (2003) and that includes: (1) psychoeducation on depression, introducing the CBT-based treatment rationale; (2) behavioral activation; (3) cognitive restructuring, training of social skills, stress reduction and relapse prevention.
1899745|NCT01330524|Drug|Avastin and Triamcinolone|1.25 mg Avastin and 2mg Triamcinolone will be injected trough vitreal
1899746|NCT01330524|Other|placebo|2mg placebo
1899747|NCT01330550|Dietary Supplement|High fiber sugar free biscuit|Dosage form:Biscuit, Dosage:1.94gram fiber/slice, Frequency:9 slices/meal;3 times/day. Duration:8 weeks
1899748|NCT01330563|Drug|CKD-501, Ketoconazole|Subjects received single 0.5mg doses of CKD-501 alone in one period and, in the other period, Ketoconazole 200 mg twice daily for 5 day with the CKD-501 dose also co-administered with Ketoconazole on day 5.
1899749|NCT01330576|Procedure|cooling blanket/mattress|Therapeutic controlled hypothermia (33.5C) using cooling blanket/mattress
1899750|NCT01330576|Procedure|Standard treatment of care at normothermia|Standard treatment of care in 33.5C for 48 hours
1899751|NCT01330589|Drug|Placebo|Non-active placebo for 7 days: PO/TID
1899752|NCT01330589|Drug|St. Johns Wort|For 7 days: 300mg PO/TID
1899753|NCT01330602|Behavioral|IMPRESS intervention|"The key elements of the IMPRESS intervention include:
Promoting a healthy lifestyle
Supporting lifestyle and risk modification
Encouraging active self-management of risk and chronic disease
Improving coordination of care
Pharmacological therapy"
1899754|NCT01330615|Drug|EMLA|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
1899755|NCT01330615|Drug|Placebo|The cream is applied as a thick layer to the wart and to the surrounding 1 to 2 mm and left on for 60 minutes under occlusion of Tegaderm dressing. The cream is then removed, and liquid cryotherapy applied using cryospray.
1899756|NCT01330628|Device|Turbo Elite Laser and Turbo Tandem Laser Guide Catheters|application of laser energy to remove blockage followed by standard balloon angioplasty
1899757|NCT01330628|Procedure|Balloon angioplasty|standard balloon catheters for PTA
1899758|NCT01330641|Procedure|Injection of Subacromial Bursa|Injection of steroid and anesthetic to relieve pain
1899759|NCT01330654|Drug|metoprolol|50mg PO BID starting two weeks prior to surgery. Patients will be reevaluated one week prior to surgery. If their pulse is above 70, the dose will be increased to 100mg BID. If the HR is 50-70, the dose will not be changed. If the pulse is below 50, the dose will be decreased to 25mg. This dose will be continued for thirty days after operation.
1899760|NCT01330667|Dietary Supplement|Nutramigen Infant Formula|Investigators will advise to supplement with 10cc's of extensively hydrolyzed formula immediately following each breastfeeding until TSB declines.
1899761|NCT01330680|Dietary Supplement|Coffee|40 mL dose of a decaffeinated preparation spiked with the addition of caffeine, at a dose of 3 mg/kg
1899762|NCT01330680|Dietary Supplement|Decaffeinated coffee|40 mL dose of decaffeinated coffee
1899763|NCT01330693|Drug|Atomoxetine|Atomoxetine is FDA-approved for the treatment of ADHD symptoms in children. Single dose of 0.5 mg/kg at baseline visit. Then dose adjusted in an open-label design afterwards.
1899764|NCT01330693|Drug|Sugar Pill|In-active sugar pill randomly assigned at baseline visit
1899766|NCT01330719|Procedure|Diseased periodontal treatment|"Treatment includes scaling and root planing with systemic antibiotics, Amoxicillin 500 mg and Metronidazole 250 mg tid 7 days. At certain intervals after the scaling and root planing, your gums will be reevaluated. You will receive further surgical gum therapy only if your gums haven't shown improvement after first treatment on the reevaluation appointments. If surgery is needed, a bone substituting material may be necessary to fill the spaces where bone has been destroyed by the disease. Extraction of teeth might also be part of gum treatment if the disease is very severe. Re-treatment with antibiotics also may be necessary depending on the response after treatment. You are usually re-examined and receive additional cleanings every 3 to 6 months to ensure the disease does not come back."
1899767|NCT01330719|Procedure|Conventional periodontal treatment|Scaling and gum measurement will be taken to compare to the treated group.- If it is determined that you do not have this disease, a conventional cleaning is done, usually every 6 months. This is all part of normal clinical care.
1899768|NCT01330745|Other|sublingual microcirculatory evaluation|TNF, ICAM, syndecan-1, heparan sulfate
1899769|NCT01330758|Drug|AZD8931|40 mg AZD8931 wet granulation tablet formulation
1899770|NCT01330758|Drug|AZD8931|40 mg AZD8931 roller compacted tablet formulation
1899771|NCT01330771|Drug|hMG-HP/r-FSH|
1899772|NCT01330784|Drug|hMG-HP|
1899773|NCT01330810|Drug|curcumin|standardized curcumin supplements containing curcumin, demethoxycurcumin and bisdemethoxycurcumin
1899774|NCT01330823|Dietary Supplement|L-Carnitine|L-Carnitine, 4g/day, orally (Juice)
1899775|NCT01330823|Dietary Supplement|Placebo|tartaric acid same dose like L-Carnitine as placebo
1899776|NCT01330849|Behavioral|ADHD Toolkit|For children allocated to the active intervention arm, teachers are trained to apply the ADHD Toolkit. Teacher will use the behaviour modification tool for 3 months. They are trained to select target behaviours causing impairment for the child and will apply a systematic approach of increased intensity of monitoring and feedback for the behaviour, including training of appropriate behaviour.
1899777|NCT01330849|Other|Waiting List Control group|Children in the control group will receive no specific intervention, but are promised that their teachers will apply the schoolkit for them after the study.
1899778|NCT01330875|Other|survey|no intervention. Only questionnaire after lumbar infiltration with steroids - effects on pain reduction
1899779|NCT01330901|Drug|Ustekinumab|Ustekinumab 90 mg given subcutaneously at weeks 0, 4, and 16
1899780|NCT01330927|Drug|VA106483|"Once daily oral dose of placebo for 2 nights
Once daily oral dose of 0.5 mg VA106483 for 2 nights
Once daily oral dose of 1 mg VA106483 for 2 nights
Once daily oral dose of 2 mg VA106483 for 2 nights
Once daily oral dose of 4 mg VA106483 for 2 nights
Placebo: as above"
1899781|NCT01330940|Dietary Supplement|Orange soda|32 ounces per day
1899784|NCT01330966|Drug|pazopanib|Pazopanib 800 mg orally once daily will be started on Cycle 1 Day 1 and will be administered continuously for a 28-day cycle.
1899785|NCT01330979|Drug|AR-12286 0.5% Ophthalmic Solution|Ophthalmic Solution
1899786|NCT01330992|Other|Ocular light or darkness exposure|Ocular light or darkness exposure
1899787|NCT01331005|Drug|nepafenac 0.1% drops|One drop three times per day for one year
1899788|NCT01331005|Other|Nepafenac Vehicle|Placebo
1899789|NCT01331018|Procedure|Bone Marrow Aspiration|Undergo bone marrow harvest
1899790|NCT01331018|Biological|Filgrastim|Given SC
1899791|NCT01331018|Biological|Genetically Engineered Hematopoietic Stem Progenitor Cells|Undergo infusion of genetically modified hematopoietic progenitor cell therapy
1899792|NCT01331018|Other|Laboratory Biomarker Analysis|Correlative studies
1899793|NCT01331018|Drug|Methylprednisolone|Given IV
1899794|NCT01331018|Drug|Plerixafor|Given SC
1899795|NCT01331018|Drug|Prednisone|Given PO
1899796|NCT01331018|Procedure|Leukapheresis|Undergo leukapheresis
1899797|NCT01331044|Dietary Supplement|Plumpy Nut|to RUTF will receive commercially available RUTF (Plumpy nut) in a total of 200 kcal/kg.day in a sequential manner (Plumpy nut will be offered ~ 125 kcal/kg in 1st 24 hours, ~ 150 kcal/kg in 2nd 24 hours, then~200k cal/kg by the third day).
1899798|NCT01331044|Dietary Supplement|Khichuri and Halwa|"Day 1: Milk suji, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day 125kcal/kg.day
Day 2: Milk suji, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day & khichuri 10gm/kg; 2 feed per day 150kcal/kg.day
Day 3: Milk suji 100, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 2 feed per day & khichuri 10gm/kg; 2 feed per day 175kcal/kg.day
Day 4: Milk suji 100, 10ml/kg/ feed for 11 feed & halwa 10gm/kg; 3 feed per day & khichuri 10gm/kg; 3 feed per day 200kcal/kg.day
Day 5 onward: Milk suji 100, 10ml/kg/ feed 6 hourly (4 feed per day) & halwa 20gm/kg; 3 feed per day & khichuri 20gm/kg; 3 feed per day 200kcal/kg.day"
1899799|NCT01331057|Other|NEEL test|An assessment for children in French with items extracted from the NEEL test
1900763|NCT01332552|Drug|placebo|Repeat dose, once daily for 3 days
1899800|NCT01331057|Other|ELAL test|An assessment of mother tongue with the ELAL of AVICENNE
1899801|NCT01331057|Other|Interview|For parents of children include in the study: A semi -structured interview
1899802|NCT01331070|Other|cerebral fMRI|the central breathing control with cerebral fMRI in COPD patients
1899803|NCT01331070|Other|cerebral fMRI|the central breathing control with cerebral fMRI in Accepts Healthy Volunteers
1899804|NCT01331083|Drug|PX-866|PX-866: 8mg orally taken daily
1899805|NCT01331109|Drug|Milnacipran|maximum tolerated dose (50, 75, or 100 mg/day tablets); for 52 weeks.
1899806|NCT01331122|Drug|droxidopa|Oral, 100, 200, 300, 400, 500, or 600 mg TID, duration includes two crossover periods of up to a 2 week titration period followed by a 4 week treatment period,with a washout between crossover periods.
1899807|NCT01331135|Drug|sirolimus|daily administration of sirolimus in oral form starting at a dose of 1 mg/m2 and increasing to a possible 3 mg/m2.
1899808|NCT01331148|Drug|Vitamin D|10,000 IU/caplet, patients receiving 240,000 IU to 600,000 IU cumulative Vitamin D dose based on weight.
1899809|NCT01331148|Other|Placebo|placebo with daily calcium/Vitamin D soft chews
1960951|NCT03051516|Other|Laboratory Biomarker Analysis|Correlative studies
1899811|NCT01331174|Device|Pulsed short wave|The treatment was performed with 2 devices named Diatermed II (Carci, São Paulo, SP, Brazil), previously calibrated, carrying frequency of 27.12MHz, peak power of 250W, and pulse duration of 400µs. All these parameters are predetermined in the device according to the manufacturer. We used the maximum power provided by the machine in a pulsed form with a pulse frequency of 145Hz, resulting in a mean power of 14.5W.
1899812|NCT01331187|Procedure|Pocket-size ultrasonography|Routinely adding a ultrasound examination of the heart, pleura, great abdominal vessels, liver/gall bladder and kidneys at patients admittance to hospital
1899813|NCT01331187|Other|Usual care|No intervention, except for usual care (goal-directed diagnostics)
1899814|NCT01331213|Drug|Pregabalin|FDA approved medication (capsules) at 200mg dose.
1899815|NCT01331213|Drug|Placebo|Placebo capsules
1899816|NCT01331226|Behavioral|telephone counseling 3 sessions|3 sessions of telephone counseling
1899817|NCT01331226|Behavioral|telephone counseling 1 session|1 session of telephone counseling
1899818|NCT01331226|Behavioral|written materials only|written materials only
1899820|NCT01331252|Other|semi-recumbent|Patient rests in a semi-recumbent body position
1899821|NCT01331252|Other|supine|Patient rests in a supine position
1899822|NCT01331278|Procedure|Total Knee Arthroplasty with Custom Cutting Blocks|Subjects randomized to this study group will undergo TKA with patient specific custom cutting blocks generated by pre-op MRI and a Biomet Vanguard knee implant
1899823|NCT01331278|Procedure|Total Knee Arthroplasty via Computer Assisted Surgery|Subjects randomized to this study group will receive TKA via computer assisted surgery and a Biomet Vanguard knee implant
1899824|NCT01331291|Drug|bosutinib|Taken orally
1899825|NCT01331304|Drug|Lithium|600-900mg per day over 6 months
1899826|NCT01331304|Drug|Quetiapine|100-800mg a day over 6 months
1899827|NCT01331317|Drug|Paricalcitol|capsule, 1-2 micrograms daily for 90 days
1960952|NCT03051516|Other|Placebo|Given IM
1960953|NCT03051516|Other|Questionnaire Administration|Ancillary studies
1899830|NCT01331343|Device|Guardian RT Telemetered Glucose Monitoring System|
1899831|NCT01331356|Drug|Botox|One injection of botulinum toxin type A in the ganglion Impar in patients with chronic proctalgia
1899832|NCT01331369|Behavioral|Intensification of Care|Usual provided care plus social-psychological intervention: 6 consultation with doctors and 9 with community health workers, both oriented by protocol.
1899833|NCT01331369|Other|Usual Care|Usual care provided (medical and/or nurse consultation and medicines)
1960954|NCT03051516|Biological|Recombinant Human Papillomavirus Nonavalent Vaccine|Given IM
1899836|NCT01331395|Other|Traditional Chinese Medicine|Active arm will receive Acupuncture with their IVF cycle.
1899838|NCT01331421|Drug|exemestane|25 mg tablet
1899839|NCT01331434|Drug|exemestane|25 mg tablet
1899840|NCT01331447|Drug|exemestane|25 mg tablet
1899841|NCT01331460|Behavioral|RBT|"Intervention for Injection Drug Using Women:
Incorporates elements of Reinforcement-Based Treatment and Women's Health CoOp to help prevent drug abuse (and promote drug abstinence) and lower risk of Human Immunodeficiency Virus, violence, and high-risk sexual behaviors."
1899842|NCT01331460|Other|Case-Management|"Standard Intervention:
Incorporates standard practice elements like accessing resources, service linkage, monitoring the success of patient-service linkages, and advocating for the patient to help her meet her needs"
1899843|NCT01331473|Procedure|Carotid Artery Stenting with Proximal Protection|Carotid artery angioplasty and stenting with proximal embolic protection provided by the GORE Neuro Protection System
1899844|NCT01331473|Procedure|Carotid Artery Stenting without Protection|Carotid artery angioplasty and stenting without cerebral embolic protection
1899845|NCT01331486|Dietary Supplement|Hawthorn|Hawthorn standardized extract liquid capsule
1899846|NCT01331486|Dietary Supplement|Placebo capsule|Matched placebo liquid capsule
1902016|NCT01342016|Drug|tacrolimus placebo|oral
1899849|NCT01331525|Biological|Ipilimumab|This trial will investigate the addition of the anti-CTLA4 antibody ipilimumab to conventional carboplatin and etoposide chemotherapy in extensive stage small cell lung cancer.
1899850|NCT01331564|Behavioral|electronic intervention during pregnancy and postpartum|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy and to follow a healthy lifestyle postpartum to minimize postpartum weight retention
1899851|NCT01331564|Behavioral|electronic intervention during pregnancy|Electronically-mediated behavioral interventions to encourage women to gain an appropriate amount of weight during pregnancy.
1899852|NCT01331564|Behavioral|Control|Control women will receive non-weight related content during both time periods at the project website.
1899853|NCT01331577|Behavioral|Cognitive Behavioural Training|Two day seminar
1899854|NCT01331577|Behavioral|Integrative Kinesiology Intervention|Two day seminar
1899855|NCT01331590|Drug|G-CSF|
1899856|NCT01331590|Drug|Ifosfamide|
1899857|NCT01331590|Drug|Etoposide|
1899858|NCT01331590|Drug|Dexamethasone|
1899859|NCT01331590|Drug|Mesna|
1899860|NCT01331616|Drug|Bevacizumab (Avastin)|Dosage is: 10 mg/kg every 2 weeks as monotherapy or in combination (unlabeled) with irinotecan. Patients will also receive Radiotherapy prior to beginning chemotherapy.
1899861|NCT01331629|Other|ART-THERAPIE|8 sessions of art therapy during radiotherapy
1899862|NCT01331655|Drug|EE20/DRSP (BAY86-5300)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP (1 tablet/day); up to 120-day treatment period followed by a 4-day tablet-free interval
1899863|NCT01331655|Drug|EE20/DRSP/L-5-MTHF (BAY98-7071)|Day 1-120: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium (1 tablet/day) up to 120-day treatment period followed by a 4-day tablet-free interval
1899864|NCT01331655|Drug|EE20/DRSP/L-5-MTHF (BAY98-7071) + L-5-MTHF (BAY86-7660)|Day 1-24: 0.02 mg EE as ß-CDC / 3 mg DRSP / 0.451 mg levomefolate calcium per tablet (1 tablet/day) Day 25-28: tablets with 0.451 mg levomefolate calcium (1 tablet/day)
1899865|NCT01331681|Biological|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks (2Q4).
1899866|NCT01331681|Biological|VEGF Trap-Eye (BAY86-5321)|Participants received 2mg Intravitreal aflibercept injection (IAI) (EYLEA, VEGF Trap-Eye, BAY86-5321) every 4 weeks for 5 visits followed by injections every 8 weeks (2Q8).
1899867|NCT01331681|Procedure|Macular Laser Photocoagulation (Control)|Participants received laser treatment at baseline and as needed at visits at which laser retreatment criteria were met, but no more frequently than every 12 weeks.
1899868|NCT01331694|Drug|fluticasone/salmeterol combination (FSC) 250/50mcg|patients initiating treatment with fluticasone/salmeterol combination (FSC) 250/50mcg
1899869|NCT01331694|Drug|tiotropium|patients initiating treatment with tiotropium
1899870|NCT01331694|Drug|ipratropium bromide alone or in fixed dose combination with albuterol|patients initiating treatment with ipratropium/albuterol
1899871|NCT01325376|Behavioral|Technology assisted health behavior|Web-based interactive program using an hpod sensor that tracks physical activity as well as biometric parameters into the iWell server and is transmitted to the internet site via the users PC. Also serves as a social networking site.
1899872|NCT01325376|Behavioral|Self directed|Receives support and encouragement with minimal contact. Receives printed lifestyle guidelines with diet and physical activity recommendations.
1899873|NCT01325389|Dietary Supplement|Myo-Mel|
1899874|NCT01325389|Dietary Supplement|Placebo|
1899875|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 40 and 50 ug.
1899876|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose around 20 ug.
1899877|NCT01325402|Other|[18Fluor]AZD4694|Low mass dose below 5ug. High mass dose will be the Maximum Detective Mass established in the previous panels.
1899878|NCT01325415|Drug|NKTR-118|25 mg tablet
1899879|NCT01325415|Drug|moxifloxacin|400 mg tablet
1899880|NCT01325415|Drug|Placebo|tablet
1899881|NCT01325428|Drug|Afatinib once daily (OD)|Patient to receive afatinib monotherapy until progression of their disease
1899882|NCT01325428|Drug|Vinorelbine Weekly|Patients additionally receive vinorelbine weekly on disease progression on afatinib monotherapy
1899885|NCT01325454|Device|pleural pigtail drainage|With the guidance of chest US, 50 ml of pleural fluid was collected using a standard thoracentesis technique immediately or within 24 hr after hospitalization. When pleural effusion was multi-loculated, the fluid was aspirated from the largest loculus. Routine analyses of pleural fluid for total leukocytes, cell differentials of leukocytes, pH value, and levels of protein, glucose and LDH were performed in addition to cytological and microbiologic examination of pleural fluid.The rest of pleural fluid samples were mixed with 3.8 % sodium citrate in a 9:1 ratio of pleural fluid to citrate. The sodium citrate-mixed pleural fluid specimens were immersed in ice immediately and then centrifuged at 2,500 g for 10 minutes. The cell-free supernatants of pleural fluid were frozen at -70℃ immediately after centrifuge for later measurements. The commercially available enzyme-linked immunosorbent assay kits were used to measure the effusion levels of VEGF, IL-8 , tPA and PAI-1.
1899886|NCT01325480|Device|Cardiac Pacing|
1899887|NCT01325493|Drug|Ketamine|ketamine 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
1899888|NCT01325493|Drug|Normal Saline|Normal saline given 0.5mg/kg intravenous (IV) load followed by an intraoperative continuous infusion at 0.25mg/kg/h and a postoperative infusion at 0.1mg/kg/h
1899890|NCT01325519|Other|video decision aid|video
1899891|NCT01325532|Device|Active CES|CES current
1899892|NCT01325532|Device|Sham CES|Sham CES (device off) for 20-minutes each day 5 days/week for 3 weeks.
1899893|NCT01325545|Other|Mobile cardiac rhythm monitoring|Continuous ambulatory cardiac rhythm monitoring using the CardioNet MCOT device
1899927|NCT01331837|Drug|Etanercept|Participants will receive 50 mg etanercept subcutaneously weekly until switch to another RA therapy or up to 4.9 years.
1899928|NCT01331837|Drug|Tocilizumab|Participants will receive 8 mg/kg tocilizumab IV every 4 weeks until switch to another RA therapy or up to 4.9 years.
1899894|NCT01325558|Biological|ALT-836 in combination with gemcitabine|Study participants will receive up to four courses of a 28-day biochemotherapy with the study drug (ALT-836) and gemcitabine. Each treatment course consists of five doses of ALT-836 (on Day 1, 4, 8, 15 and 22) and three doses of gemcitabine (Day 1, 8 and 15). Participants with persistent responses will receive additional two cycles, three doses each, of standard of care gemcitabine therapy.
1899895|NCT01325571|Drug|Tacrolimus capsule|oral
1899896|NCT01325571|Drug|Placebo|oral
1899897|NCT01325584|Drug|Omegaven|initial dose of 0.1 g/kg body weight (1ml/kg) and increased to 0.2 g/kg body weight (2ml/kg) on day 2 or 3 of treatment. The infusion rate will not exceed 0.5mL Omegaven/kg body weight/hr (corresponding to 0.05g fish oil/kg/hr). Patients will receive the initial infusion of PN containing Omegaven at Midwestern Regional Medical Center (MRMC) in the infusion center to observe for adverse reactions. Patients will continue to receive infusions at MRMC for the first 2 to 3 days of dosing. After tolerance is established, patients will receive treatment at home. All study patients will have a Screening Visit; Day 1, Day 2 and Day 3 visits; and weekly visits for one month.
1899898|NCT01325597|Other|Combined training|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks. The IMT will also be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure.
1899899|NCT01325597|Other|Electrical stimulation|FES will be applied at 15 Hz, 0.4 ms pulse width, 10-s contraction time, 50-s resting time and maximum tolerable intensity, 3 sessions per week, for 12 weeks
1899900|NCT01325597|Other|Inspiratory muscle training|IMT will be performed for 12 weeks, 5 sessions per week, with an intensity of 30% of maximal inspiratory pressure
1899901|NCT01325597|Other|Control group|No intervention
1899902|NCT01325610|Dietary Supplement|cholecalciferol|a weekly dose of 20,000 IU of vitamin D3 will be given orally for 12 weeks.
1899903|NCT01325623|Device|Model 106 VNS Therapy System|The VNS Therapy System is an adjunctive therapy for the treatment of epilepsy. VNS Therapy is available as a scheduled stimulation, this is cyclic stimulation between programmable On- and Off- times (e.g., a 30-second burst every 5 minutes). VNS Therapy is also available as on-demand stimulation, that is, when a magnet is introduced briefly over the implanted device (Magnet Mode). The AspireSR VNS Therapy System includes a new feature, Automatic Magnet Mode or AutoStim. In addition to Normal Mode and Magnet Mode, AspireSR uses a Seizure Detection Algorithm to identify a potential seizure onset based on associated heart rate increases known as ictal tachycardia. The purpose is to deliver stimulation at or near the onset of a seizure.
1899904|NCT01325636|Other|Cell therapy|"Injection of specific T cell by intravenous way with a posology of 1000 to 5000 CD3 IFN γ+ / kg.
A second injection could be made at day 21"
1899905|NCT01325649|Procedure|total mesorectal excision / long course radiochemotherapy|long course 5-FU based radiochemotherapy before total mesorectal excision
1899906|NCT01325649|Radiation|long course 5-FU bases radiochemotherapy|
1899907|NCT01325675|Behavioral|Interval training|Aerobic interval training will be performed with 4 times of 4 minutes intervals at an intensity of 90-95% of maximum heart rate and active pauses of 3 minutes between intervals. 3 times a week for 12 weeks.
1899908|NCT01325688|Drug|PEP005 (ingenol mebutate) Gel, 0.05%|PEP005 (ingenol mebutate) Gel, 0.05% for up to three consecutive days
1899909|NCT01325688|Device|Aluminium disk|
1899910|NCT01325688|Device|OpSite(TM) disk|
1899911|NCT01325701|Drug|ibrutinib|ibrutinib is an inhibitor of BTK
1899912|NCT01331707|Device|Resolute Integrity (Zotarolimus-eluting stent)|Third generation drug-eluting stent
1899913|NCT01331707|Device|Promus Element (Everolimus-eluting stent)|Third generation drug-eluting stent
1899914|NCT01331720|Drug|hMG-HP|
1899915|NCT01331733|Drug|hMG-HP|
1899916|NCT01331733|Drug|hMG + GnRH antagonist|
1899917|NCT01331746|Drug|APD515|20 mg oromucosal-oral administration qds for 7 days
1899918|NCT01331746|Drug|Placebo|qds for 7 days
1899920|NCT01331772|Other|Control arm|Dietetic follow-up only
1899921|NCT01331772|Other|Intervention arm|Dietetic follow up + adapted physical activity
1899922|NCT01331785|Drug|Midodrine|Midodrine 2.5 mg to 10 mg three times a day to increase systolic BP above 100 mmHgor by 10 mmHg
1899923|NCT01331798|Device|Cohera TissuGlu Surgical Adhesive|TissuGlu device used prior to closing of the flap in the abdominoplasty procedure.
1899924|NCT01331798|Procedure|Control- Standard of care|Control Arm- no TissuGlu device used. Standard abdominoplasty procedure followed.
1899925|NCT01331811|Other|Development of a diagnosis algorithm|"At entry in the study, HIV infected children with suspected tuberculosis will undergo a complete evaluation including:
interview on anamnesis
clinical examination
evaluation of HIV infection stage
hematology and biochemistry tests
CD4 count
HIV viral load
IGRA
chest radiograph
Abdominal ultrasonograph to detect abdominal lymphadenopathy
Tuberculin skin test
gastric aspirates, sputum and string tests according to the age of children
nasopharyngeal aspirate
stool sample
lymph node fine needle aspirate or other specimen collection if applicable
Diagnosis and treatment of all participating children will be done according to national guidelines. The children will be followed-up for 6 months until the end of their anti-TB treatment. For the analysis of data and the validation of the algorithm, children will be randomized into 2 groups. Data from Group I will be used to develop the algorithm; data from Group II will be used to validate it."
1899926|NCT01331824|Drug|Amrubicin|Patients will receive 35 mg/m2/day of amrubicin intravenously for 3 consecutive days as the initial dose starting on Day 1 of a 21-day cycle for up to 6 cycles
1899929|NCT01331850|Drug|Copegus|1000 mg or 1200 mg daily oral doses for 24 weeks
1960965|NCT03048058|Behavioral|Internet survey|Weekly internet survey asking subjects about the condition and how often they have used the prescribed brimonidine gel.
1960966|NCT03048058|Drug|Brimonidine gel|All subjects will use Brimonidine gel to rosacea once daily
1899930|NCT01331850|Drug|Copegus|1000 mg or 1200 mg daily oral doses for 48 weeks
1899931|NCT01331850|Drug|Pegasys|180 microgram subcutaneously once weekly for 24 weeks
1899932|NCT01331850|Drug|Pegasys|180 microgram subcutaneously once weekly for 48 weeks
1899933|NCT01331850|Drug|RO5024048|1000 mg oral doses twice a day for 24 weeks
1899934|NCT01331850|Drug|danoprevir|100 mg oral doses twice a day for 24 weeks
1899935|NCT01331850|Drug|ritonavir|100 mg oral doses twice a day for 24 weeks
1899936|NCT01331863|Procedure|Airway and/or pulmonary Vessels Transplantation|Use of a stent-supported aortic allograft to prevent pneumonectomy in lung cancer SURGERY
1899937|NCT01331876|Behavioral|Cognitive and behavioral Therapy|15 CBT sessions with a psychologist expert in OCD treatment
1899938|NCT01331902|Other|Maximal Hyperemia with Adenosine Followed by Nicorandil|Firstly FFR was measured with intravenous adenosine infusion (140 μg•min−1•kg−1) via femoral vein or antecubital vein. Secondly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively). Lastly with intracoronary nicorandil bolus injection (1mg followed by 2mg).
1899939|NCT01331902|Other|Maximal Hyperemia with Nicorandil Followed by Adenosine|Firstly FFR was measured with intracoronary nicorandil bolus injection (1mg followed by 2mg). Secondly with intravenous adenosine infusion (140 μg•min−1•kg−1) via femoral vein or antecubital vein. Lastly with intracoronary adenosine bolus injection (80μg, 40μg to LCA and RCA, respectively).
1899940|NCT01331915|Biological|Theravac|"Three groups with three doses (50 - 150 - 250 mcg), four times every three weeks.
Injection: intradermally and subcutaneously."
1899941|NCT01331928|Drug|Capecitabine (Xeloda, Roche), Oxaliplatin (Sanofi-Aventis), Docetaxel (Sanofi-Aventis)|capecitabine orally 1000 mg/m2 twice daily, day1 to day 10, every 2 weeks plus oxaliplatin 85mg/m2 (2hrs IV infusion)on day1, every 2 weeks for 6 cycles, then shift to docetaxel 30 mg/m2(over 30-minute intravenous infusion) on day 1 and day 8 plus oral capecitabine 825 mg/m2 twice daily on day 1 to 14, every 3 weeks for 4 cycles.
1899942|NCT01331941|Drug|AMG 386 + Paclitaxel|15 mg/kg IV (in the vein) of AMG 386 weekly + 80 mg/m^2 IV (in the vein) 3 weeks on/1 week off, optional beginning week 6 until progression, unacceptable toxicity, or withdrawal of consent.
1899943|NCT01331941|Drug|AMG 386|15 mg/kg IV (in the vein) weekly beginning week 1 day 1 until progression, unacceptable toxicity, or withdrawal of consent.
1899944|NCT01331954|Device|Ultrasonic ablation device|One or two HIFU procedures
1899945|NCT01331967|Drug|Pioglitazone|Pioglitazone 15-30mg, once daily for 9 months
1899946|NCT01331980|Device|Peripheral quantitative computed tomography (pQCT)|A pQCT scan of the non-dominant radius at the 4% and 65% sites will be conducted at a single study visit
1899947|NCT01331980|Device|Dual X-ray absorptiometry (DXA)|A total body DXA scan will be conducted at a single study visit
1899948|NCT01331993|Drug|VIMOVO (AstraZeneca)|VIMOVO (AstraZeneca) 500 mg naproxen/20 mg esomeprazole
1899949|NCT01331993|Drug|VIMOVO (Patheon)|VIMOVO (Patheon) 500 mg naproxen/20 mg esomeprazole
1899950|NCT01331993|Drug|Marketed enteric-coated naproxen formulation|Marketed enteric-coated naproxen formulation (manufactured by Roche) 500 mg tablet
1899951|NCT01332006|Procedure|Intrabone injection|All adults patients with hematological malignancies, lacking a HLA matched donor fulfilling the inclusion criteria, will undergo to intrabone HSC infusion of CB.
1899952|NCT01332006|Biological|Intra-bone cord blood hematopoietic stem cell transplantation|
1899953|NCT01332006|Biological|Intra-bone cord blood hematopoietic stem cell transplantation|Intra-bone injection of CB hematopoietic SCs after conditioning regimen
1899954|NCT01332019|Drug|peginterferon beta-1a|Administered as specified in the treatment arm
1899955|NCT01332032|Behavioral|Reminder Letter|A letter sent to women reminding them that they are coming due or overdue for a mammogram. It contains a reminder that their doctor recommends mammography screening every 1-2 years; urges them to call a special number to a study scheduler to get assistance scheduling a mammogram and is signed electronically by their primary care provider. For women in the reminder letter only arm, who did not complete a mammogram within 12 months of the first reminder, a booster intervention (I.E. reminder letter) will be sent. The letter requests that a woman call in to schedule a mammogram, and reminds her that her PCP recommends she get one. Booster letters will be sent up to three times at annual intervals for those failing to get a mammogram
1899956|NCT01332032|Behavioral|Reminder Call|A reminder letter (as in the 1st group) is sent. If a woman does not call in to schedule a letter, 2 weeks later, a study scheduler will call her, remind her she is coming or is overdue, remind her that her PCP recommends screening every 1-2 years and offers to schedule a mammogram for her. For women in the reminder letter arm who did not complete a mammogram within 12 months of the first reminder, a booster intervention ( I.E.a reminder letter will be sent requesting that they call in to schedule a mammogram. The letter reminds her that her PCP recommends she get a mammogram. Those who do not respond within 7 days, will receive a scheduler call) will be repeated as necessary for up to 3 times.
1899957|NCT01332032|Behavioral|Counselor Call|Reminder letter s as above is sent. If subject does not call in to schedule within 2 weeks, second letter is sent with mammography educational booklet. Second letter reiterates reminder that PCP recommends screening. Has number to call to schedule. If subject does not schedule within 2 weeks, counselor will call. Protocol script includes tailored barriers counseling, correction of misinformation and motivational interviewing techniques. For those who did not complete a mammogram within 12 months of the first reminder, a booster intervention will be repeated annually for up to 3 times as necessary.Booster is reminder letter with pamphlet stressing the 4 reasons why women need regular mammograms.
1899958|NCT01333020|Other|cross-linking of an emulsion drink|This study will assess whether a subtle change in food structure (cross-linking of interfacial protein) can alter gastric emptying rate.
1899959|NCT01333033|Drug|Oxaliplatin|Given IV
1899960|NCT01333033|Drug|Leucovorin Calcium|Given IV
1899961|NCT01333033|Drug|Fluorouracil|Given IV
1899962|NCT01333033|Drug|Carboplatin|Given IV
1899963|NCT01333033|Drug|Paclitaxel|Given IV
1899964|NCT01333033|Procedure|Positron Emission Tomography|Undergo PET/CT scan
1899965|NCT01333033|Procedure|Computed Tomography|Undergo PET/CT scan
1899966|NCT01333033|Radiation|Radiation Therapy|Undergo RT
1900031|NCT01333527|Procedure|Sling|Patients will use the sling for 6 weeks, as per usual care
1900032|NCT01333540|Drug|TD-1211|Escalating doses
1899967|NCT01333046|Biological|Antigen-Escalation Stage|"Antigen-Escalation Stage
Each patient will receive 2 injections at the same dose (5 x 10^6 cells/m2), 28 days apart, according to the following schedules:
Schedule One:
Day 0: PRAME-specific T cells
Day 28: PRAME- and SSX-specific T cells
Schedule Two:
Day 0: PRAME- and SSX-specific T cells
Day 28: PRAME/SSX/MAGE-specific T cells
Schedule Three:
Day 0: PRAME/SSX/MAGE-specific T cells
Day 28: PRAME/SSX/MAGE/NY-ESO specific T cells
Schedule Four:
Day 0: PRAME/SSX/MAGE/NY-ESO specific T cells
Day 28: PRAME/SSX/MAGE/NY-ESO/Survivin-specific T cells"
1899968|NCT01333046|Biological|Dose-Escalation Stage|"Dose-Escalation Stage
Three different dosing schedules will be evaluated. Each patient will receive 2 injections at the same dose, 14 days apart, according to the following dosing schedules:
DL1: Day 0 and Day 14: 5 x 10^6 cells/m^2
DL2: Day 0 and Day 14: 1 x 10^7 cells/m^2
DL3: Day 0 and Day 14: 2 x 10^7 cells/m^2"
1899969|NCT01333046|Biological|5-azacytidine and multiTAA T cells Stage|"Up to 15 patients will be treated with 3 cycles of 5-aza at a dose of 75 mg/m2 I.V. administered for 5 days/cycle followed, within 28 days of the last 5-aza dose, by two infusions (on Day 0 and Day 14) of multi-TAA specific CTLs at a fixed dose of 1x10^7 cells/m2. If drug-related myelosuppression occurs 5-aza dosing will be modified, according to the following:
ANC >1,000 or Platelets >50,000 (or any other grade I AE attributable to 5-aza)
Adjustment: None
ANC 500-1000 or Platelets 25,000-50,000 (or any other grade II-III AE attributable to 5-aza)
Adjustment: 50% dose reduction
ANC <500 or any episode of febrile neutropenia or platelets <25,000 or any episode of bleeding attributed to thrombocytopenia (or any other grade IV or higher AE attributable to 5-aza)
Adjustment: Discontinue drug, can proceed with CTL infusion if eligible within 28 days of last 5-aza infusion"
1899970|NCT01333046|Biological|Pediatric multiTAA T cells Stage|Patients < 18 years old will receive two infusions (on Day 0 and Day 14) of multi-TAA specific T cells at a fixed dose of 1x10^7 cells/m2. We will enroll and infuse at least 5 adolescents on the pediatric arm before opening to all patients.
1899971|NCT01333059|Drug|Midazolam/Fentanyl|Sedative Control
1899972|NCT01333059|Drug|Sedative Intervention|Intervention arm - Fentanyl and Midazolam will be replaced with placebo
1899973|NCT01333072|Drug|Aripiprazole|The starting dosage will be 2.0 mg/day. The dosage will be allowed to increase to 5.0 mg/day on day 4 and can be increased thereafter as judged clinically appropriate until the maximum dosage of 15 mg/day. The dosage will only be increased in 5.0 mg intervals. No dosage adjustments will be allowed for either drug after 4 weeks.
1899974|NCT01333072|Drug|Risperidone|Children weighing 20-45 kg will receive an initial dose of 0.5 mg daily that will be increased to twice daily on day 4 (morning and bedtime). The dosage will be gradually increased in 0.5 mg increments to a maximum dose of 2.5 mg per day (1.0 mg in the morning and 1.5 mg at bedtime) by the fourth treatment week. A slightly accelerated dosage will be allowed for children who weigh more than 45 kg for a maximum dosage of 3.5 mg /day (McCracken et al 2002).
1899975|NCT01333085|Drug|carboplatin|
1899976|NCT01333085|Drug|RAD001|
1899977|NCT01333085|Drug|paclitaxel|
1899978|NCT01333098|Drug|Mifepristone|300mg per day, by mouth, for 21-28 days
1899979|NCT01333111|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
1899980|NCT01333111|Drug|nonacog beta pegol|One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience
1899981|NCT01333111|Drug|nonacog beta pegol|Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode
1899982|NCT01333124|Radiation|chemoradiotherapy with Gemcitabine|All patients will receive gemcitabine 400 mg/m2 as an intravenous 30-min infusion on day 1, 8, 15, 22, and 29 with radiotherapy.After 4-6 week from end date of chemoradiotherapy, patients undergo preoperative evaluation including CT, PET, CA19-9, CEA. If the patient is feasible for resection on this evaluation, the surgery is performed in 1 to 2 weeks. After surgery, patients will receive gemcitabine 1000 mg/m2 as an intravenous 30-min infusion on day 1, 8, and 15 for every 28 days. Subjects will be treated for at least 1 cycle and to a maximum of four cycles of adjuvant chemotherapy unless there is documented relapse, unacceptable adverse events or withdrawal of consent.
1899983|NCT01333124|Radiation|Radiation: chemoradiotherapy with Gemcitabine|Radiation: chemoradiotherapy with Gemcitabine
1899984|NCT01333137|Drug|Gemcitabine and Carboplatin|Gemcitabine 1000 mg/m2/day on Days 1 & 8 and carboplatin at AUC 2 on Days 1 and 8 every 21 days.
1899985|NCT01333137|Drug|P276-00 along with Gemcitabine and carboplatin|In phase I run in period, P276 00 will be administered at starting dose of 100 mg/m2/day (and higher if tolerated) in 200 mL of 5% dextrose as an iv infusion over 30 minutes, on Days 1 to 5, along with gemcitabine 1000 mg/m2/day and carboplatin at AUC 2 on Days 1 & 8 every 21 days. In Phase 2 component, P276-00 will be administered at recommended phase II dose of P276-00 in combination with standard dose of gemcitabine and carboplatin.
1899986|NCT01333150|Drug|Propranololhydrochlorid|One single dose of Propranolol tablet of 40 mg randomized in one of the two sessions
1899987|NCT01333150|Drug|Placebo|One single dose of placebo
1899988|NCT01333163|Biological|Human GLP-1 (7-36) amide|2 hour IV infusion, 1,5pmol/min/kg.
1899989|NCT01333163|Biological|Isotone NaCl|2 hours IV infusion.
1899990|NCT01333176|Procedure|"Point-of-care finger-poke HbA1c determination."|"All volunteers receive finger-poke HbA1c test. Result: If < 6: Offered a requisition to have gold standard testing for diabetes screening. If 6-6.5: Given requisition for FBG, HbA1c and OGTT. If A1c result >6.5: Counseled that they may have diabetes. Given requisition as above.
Estimates about how many have undiagnosed diabetes will be calculated.
Did the clients who were counseled to do so get follow-up blood tests?
Were all the formal diagnostic tests performed?
Did the formal tests correlate to the POC HbA1c test or was there significant discrepancy? Thus is this new test for diagnosing diabetes confirmed as a valid test for screening in First Nation Communities in Canada?
Did the family physicians find this useful?"
1899991|NCT01333176|Procedure|HbA1c blood test|All candidates will have a HbA1c blood test (Finger poke)
1899992|NCT01333176|Procedure|HbA1c finger poke test|All study candidates will have the same HbA1c test performed
1899993|NCT01333176|Procedure|Blood test|HbA1c blood test
1899994|NCT01333176|Procedure|Blood test|HbA1c finger poke blood test
1900033|NCT01333540|Drug|Placebo|Placebo once daily
1900034|NCT01333553|Device|Image-guided remove Port Wine Stain|Image-guided surgery remove Port Wine Stain
1899995|NCT01333189|Other|Weight-bearing biofeedback exercise|"Patients in the experimental group completed the same standard of care rehabilitation program as the control group. Thus, the experimental intervention was in addition to the standard intervention.
Upon discharge to home, patients in the RELOAD group began the weight bearing (WB) biofeedback phase of the study. Patients participated in two 30-minute training sessions/week with a physical therapist for a total of 6 weeks, focusing on promoting WB symmetry using a progressive series of activities adapted to video games."
1899996|NCT01333189|Other|Standard of care exercise|Standard inpatient rehabilitation began on post-operative day 1 and lasted for an average of 3.2 days. After hospital discharge, two weeks of home rehabilitation (6 visits) were provided by physical therapists. Patients progressed to outpatient rehabilitation, consisting of 4 weeks of treatment. As such, 6 weeks of rehabilitation following hospital discharge was implemented for both groups.
1899998|NCT01333228|Other|Autologous bone marrow-derived endothelial progenitor cells|Intraarterial administration (hepatic artery) of autologous bone marrow-derived endothelial progenitor cells
1900000|NCT01333254|Procedure|Intermittent urinary catheterisation|Patients randomised to the I group will urinate either in a toilet or in a bedpan or a diaper when needed. Bladder scan control will be performed on these patients at least every four hour. If the patient is unable to urinate and bladder scan indicates ≥ 450 ml urine in the bladder, the patient will be intermittent catheterised.
1900001|NCT01333267|Drug|Parathyroid Hormone-related Protein (1-36)|PTHrP (1-36) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
1900002|NCT01333267|Drug|parathyroid hormone (1-34)|PTH (1-34) intravenously at 2 picomoles (pmols)/kg/hr for one week; doses will be increased by 2 picomoles (pmols)/kg/hr in subsequent subjects.
1900003|NCT01333267|Drug|PTH (1-34) and PTHrP (1-36)|This is a dose escalation study to determine the maximum tolerable dose of Parathyroid Hormone-related Protein, PTHrP, or Parathyroid Hormone, PTH, that can be given safely over one week in healthy African-American volunteers. The investigators plan to infuse low doses of intravenous PTHrP or PTH to determine if it leads to a sustained and progressive suppression of bone formation as occurs in humoral hypercalcemia of malignancy (HHM) or an increase in bone formation as occurs in hyperparathyroidism (HPT). Additionally, the investigators will assess the direct influence of PTHrP and PTH on vitamin D metabolism, markers of bone turnover, and fractional excretion of calcium.
1900004|NCT01333280|Behavioral|Double Trouble in Recovery|DTR is a 12 Step-based fellowship for individuals with co-occurring problems of substance abuse and mental illness
1900005|NCT01333280|Behavioral|Treatment as usual|Receive usual treatment at the programs
1900006|NCT01333293|Drug|injections|subcutaneous injections
1900007|NCT01333306|Procedure|Transcranial direct current stimulation (tDCS)|
1900008|NCT01333332|Drug|Capecitabine|Capecitabine
1900009|NCT01333332|Radiation|Standard Dose Acclerated Fraction Radiotherapy|Standard dose accelerated fraction radiotherapy
1900010|NCT01333358|Drug|Alemtuzumab|Alemtuzumab 12mg given intravenously each day for five days and again twelve months later for an additional three days
1900011|NCT01333371|Procedure|Surgical Repair of Distal Radius Fracture|2 surgical methods to treat Distal Radius Fracture
1900012|NCT01333397|Drug|Botulinum type A toxin (Dysport RU)|I.M. (in the muscle) injection on day 1 (single treatment cycle)
1900013|NCT01333397|Drug|Botulinum type A toxin (Azzalure)|I.M. on day 1 (single treatment cycle)
1900014|NCT01333397|Drug|Placebo|I.M. on day 1 (single treatment cycle)
1900015|NCT01333410|Drug|tacrolimus ointment|2 applications per days for 6 months
1900016|NCT01333410|Drug|Mometasone furoate|2 applications per day for 6 months
1900017|NCT01333423|Drug|Liposomal Doxorubicin|40 mg by vein administered over 2 -3 hours on Day 4 of a 28 day cycle.
1900018|NCT01333423|Drug|Seliciclib|Starting dose 200 mg by mouth twice daily on Days 1 - 3 of a 28 day cycle.
1900019|NCT01333436|Other|Test Meal|During Visit 2, a test meal will be supplied by the Sponsor of approximately 944 kcal (57% fat, 31% carbohydrate, and 12% protein), and postprandial blood draws will be done at 1, 2, 3, 4, and 6 hours after the meal.
1900020|NCT01333449|Drug|Decitabine|20mg/m^2 infusion one hour per day, for 5days,every 28days,total 2-6cycles.
1900021|NCT01333462|Biological|NB-1008|NB-1008 is composed of Fluzone containing 4 micrograms (mcg) or 10 micrograms of strain-specific hemagglutinin (HA) and 5%, 10%, 15%, or 20% W805EC adjuvant.
1900022|NCT01333462|Other|Control|The controls include PBS placebo control as well as Fluzone IN and IM active controls.
1900023|NCT01333475|Drug|MK-2206 + AZD6244|MK-2206 and AZD6244 hydrogen sulfate are selective inhibitors of human AKT and MEK, respectively, with preclinical and clinical anti-tumor activity as single agents and in combination with a variety of drugs. Combination treatment in mouse cancer models harboring mutations in both the PI3K and RAS pathways was more potent compared to either agent used alone, and resulted in substantial tumor inhibition, including tumor regression.
1900024|NCT01333488|Device|Arctic Sun|Core Body Temperature will be lowered using an Arctic Sun device to 34C. Bladder probe will monitor core temperature.
1900025|NCT01333488|Drug|Magnesium Sulfate|IVI drug levels of Magnesium Sulfate targeted to plasma levels of magnesium of 2.5-3.5 mEq/Liter.(1.25-1.75mmol/L; or 3.04 - 4.26mg/dL)for 72 hours.
1900026|NCT01333501|Drug|Fingolimod|0.5 mg in capsules for oral administration once daily
1900027|NCT01333501|Drug|Interferon beta 1b|250 μg injected s.c. every other day
1900028|NCT01333514|Drug|aspart|Subjects will received aspart insulin subcutaneously based on the amount of carbohydrates consumed based on the formula 0.1 units/kg X (grams of carbohydrate eaten/75 grams carbohydrate)
1900029|NCT01333514|Drug|aspart|0.1 units/kg of Aspart insulin will be given subcutaneously TID with meals if a subject eats 50% or more of their meal-tray
1900030|NCT01333527|Procedure|No Sling|Early range of motion
1960971|NCT03048344|Drug|ORH-2014|ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
1900035|NCT01333566|Behavioral|Intervention Group|The study will include one week baseline phase, 6-week intervention phase, and a 3-month follow-up evaluation. Subjects in the intervention group will go through three training sessions during the baseline phase, weekly group exercise sessions once per week and daily home exercises two times each day during the intervention phase, and a follow-up evaluation in three months after the intervention phase.
1900036|NCT01333566|Behavioral|Placebo Comparator: Control Group|Subjects in the control group will be monitored during the baseline and intervention phase without participating in the interventional exercise. At the end of intervention phase, the subjects will have the option to stop their participation or switch to the intervention group.
1900037|NCT01333579|Other|Repetitive transcranial magnetic stimulation|Repetitive transcranial magnetic stimulation, frequency of 1Hz, once a day for ten days.
1900038|NCT01333592|Drug|KAD-1229|
1900039|NCT01333605|Drug|IGEV|Ifosfamide 1200 mg/m2 at days 1-4, Mesna 400 mg 0,4,8h at days 1-4, Gemcitabine 800 mg/m2 at day 1 and day 4, Vinorelbine 20 mg/m2 at day 1, Prednisone 100 mg at days 1-4. Frequency of cycles: every 3 weeks. Numbers of cycles: 4 cycles.
1900040|NCT01333618|Device|curving introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark) The amplitude of introducer curvature was 5°-15° less than the angle between the inferior vena cave axis and the approached iliac vein axis and the distance between the vertex of the curved angle and the hook of the filter was 2-4cm less than the distance between the level of the renal vein confluence and the furcation of inferior vena cave.
1900041|NCT01333618|Device|straight introducer Günther Tulip Filter|The Günther Tulip filter (Vena Cava MReye Filter Set; William Cook Europe, Bjaeverskov, Denmark)
1900042|NCT01333631|Drug|Valproic acid|Valproic acid given concurrent with chemoradiotherapy for patients with pancreatic cancer
1900043|NCT01333670|Device|Prontosan wound irrigation solution|"cleansing wound bed at change with Prontosan Wound Irrigation solution (syringe 20-30 ml, needle 19-20 G)
positioning of sterile gauze dressing impregnated with Prontosan Wound Irrigation solution on the wound for 10 minutes
dressing with Prontosan Wound Irrigation solution"
1900044|NCT01333670|Drug|Isotonic solution (saline or lactated ringer)|"cleansing wound bed at change with isotonic solution (syringe 20-30 ml, needle 19-20 G)
positioning of sterile gauze dressing impregnated with isotonic solution on the wound for 10 minutes
dressing with isotonic solution"
1900045|NCT01333696|Drug|Pemetrexed|Pemetrexed 500 mg/m2 at day 1. Frequence of cycles: every 3 weeks
1900046|NCT01333709|Drug|Induction trichemotherapy - FOLFIRINOX regimen|A short (4 cycles) and intensive trichemotherapy combinig irinotecan 180 mg/m2, oxaliplatin 85 mg/m2, elvorin 200 mg/m2, 5-Fu (bolus 400 mg/m2, followed by a 46-hour continuous infusion 2,400 mg/m2) will be delivered for 8 weeks (D1=D15).
1900047|NCT01333709|Other|Early tumor response evaluation by MRI volumetry|Two weeks after the CT completion, the tumor volume will be measured by MRI with specific software which automatically borders the tumor so as to determine the early tumor response. A centralized reassessment of all MRI exams will be systematically performed by two radiologists of the coordinator center.
1900048|NCT01333709|Radiation|Radiochemotherapy Cap 50|RCT Cap 50 will combine radiotherapy at a dose of 50 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 5 weeks / 44 Gy in mini pelvis, and boost 6 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake).
1900049|NCT01333709|Radiation|Radiochemotherapy Cap 60|RCT Cap 60 will combine radiotherapy at a dose of 60 Gy by either conventional 3D or IMRT (2 Gy per fraction, 5 fractions per week during 6 weeks / 44 Gy in mini pelvis, and boost 16 Gy on reduced peritumoral volume) with concomitant oral capecitabine at 1600 mg/m2 per day delivered the days of RT treatment (2 daily intake)
1900050|NCT01333709|Procedure|Radical proctectomy with total mesorectal excision|The proctectomy can be performed by laparoscopic surgery or conventional laparotomy.
1900051|NCT01333722|Drug|Hydrocodone/Acetaminophen Extended Release|
1900052|NCT01333722|Drug|Placebo|Placebo tablet
1900053|NCT01333748|Genetic|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
1900054|NCT01333748|Genetic|blood collection|blood collection for research quantification of allelic expression in the gene BRCA1.
1960972|NCT03048344|Drug|Trisenox|Trisenox will be administered IV at 0.15 mg/kg over 2 hours.
1900056|NCT01333774|Drug|Glucobay (Acarbose, BAYG5421)|Patients treated with acarbose tablets under the real-life setting. Dosing regimen customised to the needs of each participating patient according to the investigators assessment
1900057|NCT01333787|Dietary Supplement|Dietary Fiber Mixture|"During the four weeks the patients received fiber mixtures (intervention) or maltodextrine as the placebo. The fiber mixture was composed of six different types of fibers: 10.5% fructooligosaccharides, 12.5% inulin, 24% Arabic gum, 9% resistant starch, 33% Soya polysaccharide e 12% cellulose.
The dose was defined in accordance with the child's body weight: 6.3 grams of fiber supplement, which corresponds to 4.8 g of fiber, or placebo(1 table spoon) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing up to 18 kg; 12.6 grams of fiber supplement, which corresponds to 9.6 g of fiber, or placebo (2 table spoons) twice per day, diluted in 200 mL of a milky chocolate drink for children weighing more than 18 Kg."
1900058|NCT01333800|Drug|Beclomethasone|200 to 400 mcg per day for 6 months
1900059|NCT01333800|Drug|Ciclesonide|80 to 160 mcg per day for 6 months
1900060|NCT01333813|Biological|Engerix-B™ Kinder|Intramuscular, single dose
1900061|NCT01333826|Behavioral|Zomba Cash Transfer Program|Cash transfers were provided monthly to a randomly selected sample of school aged girls. Amounts were also varied in both treatment arms.
1900062|NCT01333839|Other|exercise training|endurance exercise training: 40 min of exercise at 65% of VO2peak, 3 days/week
1900063|NCT01333852|Drug|metformin up to 2500mg/d|metformin up to 2500mg/d
1900064|NCT01333852|Drug|paclitaxel 175mg/m² q21d|paclitaxel 175mg/m² q21d
1900065|NCT01333852|Drug|placebo|placebo
1902017|NCT01342016|Drug|leflunomide tablet|oral
1960973|NCT03048344|Drug|ORH-2014|ORH-2014 capsule orally, at recommended dose from part 1.
1960974|NCT03048344|Drug|ORH-2014|ORH-2014 capsule at recommended dose orally.
1900066|NCT01333865|Drug|Memantine|"Memantine (Namenda®) was approved by the U.S. Food and Drug Administration in 2003 and by the European Agency for the Evaluation of Medical Products in 2002 for the treatment of moderate to severe Alzheimer's disease. Evidence from available treatment trials of memantine in ASD and non-ASD populations of youth and adults strongly suggest that memantine could be an effective agent for the treatment of adults with ASD.
During the 12 weeks of study duration, subjects will be evaluated at weekly intervals for the first 4 weeks and thereafter every 3 weeks. Memantine will be administered in divided dose twice a day in the morning and evening. Titration of study medication will be guided by a forced titration schedule with an option for slower titration or holding at lower dose per clinician judgment. Safety, effectiveness, response and side effects will be evaluated."
1900067|NCT01333878|Biological|Subcutaneous Abatacept|Subcutaneous Abatacept 125 mg once weekly for 6 months
1900068|NCT01333891|Drug|Phenylephrine|Neosynephrine®, Winthrop Breon Laboratories New York, NY, USA 0, 0.5, 1 and 2 μg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
1900069|NCT01333891|Drug|Sodium-Nitroprusside|Nipruss®, Sanol-Schwarz, Monheim, Germany 0, 0.5, 1 and 2 µg/kg/min, each infusion step for 5 minutes, total infusion period of 20 minutes
1900070|NCT01333891|Device|Suction Cup|experimental stepwise increase of intraocular pressure while measurement of choroidal thickness suction force of 25, 50, 75, and 100 mmH
1900071|NCT01333891|Device|Goldmann applanation tonometer|intraocular pressure measurements
1900072|NCT01333891|Device|1060nm Optical coherence tomography|Optical coherence tomography is a widely used non-invasive method to image the retina and choroid. Using a 1060nm light source coupled to a commercially available OCT system (Heidelberg Engineering, Heidelberg, Germany) allows for the measurement of choroidal thickness
1900073|NCT01333904|Drug|PUR118|inhaled
1900074|NCT01333917|Drug|Curcumin C3 tablet|4 grams Curcumin C3 tablet daily x30 days
1900075|NCT01333930|Other|Active O2|oxygenised table water containing at least 20 mg O2 per 500 ml (15-fold higher content in comparison to placebo), further excipients: natural mineral water: carbonic acid, oxygen, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulfate, hydrocarbonate (according to the summary of analysis)
1900076|NCT01333930|Other|Adelholzener Mineralwasser|natural mineral water containing the following ingredients: carbonic acid, sodium, potassium, magnesium, calcium, fluoride, chloride, nitrate, sulphate, hydrocarbonate (according to the summary of analysis)
1900079|NCT01333956|Drug|Pregabalin 50mg|Patients will receive 50mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
1900080|NCT01333956|Drug|Pregabalin 100mg|Patients will receive 100mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
1900081|NCT01333956|Drug|Pregabalin 150mg|Patients will receive 150mg of pregabalin per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
1900082|NCT01333956|Drug|Placebo|Patients will receive placebo drug with no active ingredients per dose. 2 capsules will be taken pre-operatively. One capsule twice a day until end of POD14 and one capsule at bedtime POD15, POD16.
1900083|NCT01333969|Procedure|Ischemic Preconditioning|In the study group, the patients' operative limb will be preconditioned by inflating the tourniquet for 5 minutes, followed by deflation and a 5-minute reperfusion period. Subsequently, the tourniquet will be inflated for the entire length of the operation (before skin incision to after insertion of the final components). In the control group, the tourniquet will be used for the entire length of the operation without a preconditioning phase.
1900084|NCT01333982|Other|Amoxycillin, Gentamicin|If referral fails, community management of neonatal sepsis according to clinical algorithm.
1900085|NCT01333982|Other|Counselling|counselling of management of neonatal sepsis in the community according to clinical algorithm.
1900086|NCT01333995|Behavioral|Peer counseling on infant feeding|Peer counseling intervention group will recieve nutrition education on initiation of breastfeeding within one hour of delivery, continuation of exclusive breastfeeding until six months, and timely introduction of safe, nutritionally adequate complementary feeding after six months.
1900087|NCT01334008|Biological|Blood sampling|30ml of patient peripherical blood will be collected
1900088|NCT01334021|Procedure|Tumor Biopsy|The amount of tumor collected for this study will be about the size of the tip of a pencil.
1900089|NCT01334021|Other|Breast Cancer Registry|For 5 years, the study staff will review medical records to see how patients are responding to any breast cancer therapies received.
1900090|NCT01334034|Drug|NNC 0123-0000-0338|Subjects will be randomised to receive a single dose of NNC 0123-0000-0338 (tablet), at 7 escalating dose levels. Progression to next dose level will be based on a safety evaluation.
1900091|NCT01334034|Drug|placebo|Subjects will receive a single dose of placebo (tablet), as a comparator to NNC 0123-0000-0338 at all dose levels. Placebo dose remains the same at all dose levels.
1900092|NCT01334034|Drug|insulin glargine|As an open label active comparator, a single dose of insulin glargine will be administered subcutaneously (under the skin), at all dose levels. Insulin glargine dose remains the same at all dose levels.
1900093|NCT01334047|Biological|DC-006 vaccine|Vaccine is administered every 4 weeks during the first year. Only patients that show immunological response will continue vaccination every months during the 2nd and 3rd year.
1900133|NCT01334346|Other|Nike Free 3.0|Partial minimalist shoe with partially elevated heel, but with increased mid-sole flexibility.
1900134|NCT01334346|Other|Vibram Five Fingers Shoe|Full minimalist shoe. Virtually no mid-sole, therefore no heel elevation or forefoot rockering. A proxy for a barefoot running condition.
1960983|NCT03044834|Other|PPB|Global current care
1900094|NCT01334060|Biological|p.DOM-WT1-37 DNA Vaccine and p.DOM-WT1-126 DNA Vaccine|p.DOM-WT1-37: 1mg/dose/vaccine p.DOM-WT1-126: 1mg/dose/vaccine The DNA vaccine will be administered 6 times at 4 weekly intervals. Responders (Immunological but without molecular progression) may continue vaccination 3 monthly to maximum of 24 months. The vaccines will be injected intramuscularly (im) followed by electroporation (EP) into separate locations.
1900095|NCT01334073|Drug|Axitinib plus everolimus|Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
1900096|NCT01334086|Drug|Aprepitant|Oral aprepitant will be given to the participant on Days 1-5 of standard induction treatment. A dose of 125 mg will be given on Day 1 and 80 mg will be given on Days 2-5.
1900097|NCT01334099|Biological|CP-675,206|Intravenous infusion for one cycle (further cycles permitted as per medical assessment). Patient assigned dose of 3mg/kg, 6mg/kg, 10mg/kg, or 15mg/kg.
1900098|NCT01334099|Radiation|External local radiation therapy|One cycle of 2000cGy administered locally to one site over 5 days.
1900099|NCT01334112|Drug|Axitinib (AG-013736)|5mg, oral, twice daily, continuous dosing. A dosing cycle is defined as 4 weeks. Treatment may continue until disease progression/relapse
1900100|NCT01334125|Drug|Metformin|Metformin 1000 mg once daily by mouth for 9 months
1900101|NCT01334125|Drug|Placebo|2 capsules once daily by mouth for 9 months
1900102|NCT01334138|Other|A 4-week diet, low in sodium.|"Study subjects receive personal advice to decrease sodium consumption and will change his diet for 28 days.
Follow up is performed by measuring blood pressure, a 24-hour urine sample collection, diaries and questionnaires."
1900103|NCT01334151|Drug|Insulin LISPRO|Single doses of: 0.15 U/kg
1900104|NCT01334151|Drug|recombinant human insulin|Single doses of: 0.15 U/kg
1900105|NCT01334164|Behavioral|Recovery Management Checkups|Women assigned to the RMC condition met with a linkage manager after each research interview. When a woman reported substance use, HIV risk behavior or illegal activity, the linkage manager used motivational interviewing to: provide feedback regarding her current substance use, HIV risk behavior or illegal activity, discuss barriers that prevented her from stopping each activity and ways of avoiding them in the future, and assess and discuss her level of motivation for change. Linkage managers also scheduled treatment appointments, accompanied the women to treatment intake and stayed through the process and implemented an Engagement and Retention Protocol designed to improve retention rates. For women who refused the treatment option, the linkage manager and participant agreed upon an Alternative Action plan, which included various behaviors the woman had agreed to engage in to reduce or stop her substance use, HIV risk, or her participation in illegal activity.
1900106|NCT01334164|Other|Outcome Monitoring|Outcome monitoring only, however participates are still able (and do) enter treatment on their own
1900107|NCT01334177|Drug|TLR8 agonist VTX-2337|Given SC
1900108|NCT01334177|Biological|cetuximab|Given IV
1900109|NCT01334177|Other|laboratory biomarker analysis|Correlative studies
1900110|NCT01334177|Other|pharmacogenomic studies|Correlative studies
1900111|NCT01334203|Drug|Ranolazine|"Subjects will be randomized to either ranolazine 500 mg twice daily up-titrated on Day 4 to 1000 mg administered orally twice a day or matching placebo for the 12 week treatment period.
Subjects receiving diltiazem or verapamil as their concomitant antianginal medication will receive ranolazine 500 mg or placebo administered orally twice a day."
1900112|NCT01334216|Other|CHICA Smoking Cessation Module|The CHICA module helped to screen parents for smoking and assist them in quitting.
1900113|NCT01334216|Other|CHICA Placebo|This was CHICA without the study module.
1900114|NCT01334229|Drug|Sitagliptin|Sitagliptin 100 mg/d for 6 weeks
1900115|NCT01334229|Drug|Placebo|Placebo for 6 weeks
1900116|NCT01334242|Drug|Schedule A|Dosing 1 hour before breakfast
1900117|NCT01334242|Drug|Schedule B|Dosing 0.5 hour before breakfast
1900118|NCT01334242|Drug|Schedule C|Dosing immediately before breakfast
1900119|NCT01334242|Drug|Schedule D|Dosing immediately before lunch
1900120|NCT01334242|Drug|Schedule E|Split dose, dosing 1 hour before breakfast and dinner
1900121|NCT01334255|Drug|iSONEP (sonepcizumab/LT1009)|Up to 3 doses of iSONEP given monthly will be administered as intravitreous injections in the ophthalmologist's office.
1900124|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top), 7 times (total of 210 ml for study) at the indicated time points: 1) enrollment, 2) anticipated midpoint of desensitization, 3) prior to transplant, 4) three months post-transplant, 5) six months post-transplant, 6) 12 months post-transplant, and 7) 24 months post-transplant.
1900125|NCT01334281|Procedure|Blood Draw|Three tubes of blood will be drawn (three 10ml-green top) twice (60 ml total for study), 8-12 weeks apart. Can be drawn during clinic visit or separate standard of care dialysis visit.
1900126|NCT01334294|Device|ForeseeHome|The ForeseeHomeTM device, was designed to identify central and paracentral irregularities (vision abnormalities) in the visual field, most commonly associated with exudative macular degeneration.
1900127|NCT01334307|Device|Lung Volume Reduction Coil (LVRC) (PneumRx)|Lung Volume Reduction Coil (LVRC)
1900128|NCT01334307|Device|Control|Standard of Care
1900129|NCT01334320|Procedure|elective neck dissection|patient underwent elective neck dissection as initial treatment, along with the excision of the primary tumor
1900130|NCT01334333|Drug|Tacrolimus - Prograf® twice daily formulation|twice daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
1900131|NCT01334333|Drug|Tacrolimus - Advagraf® once daily formulation|once daily, dosage will be as determined by best treatment for each participant, duration of study period will be 4 months for each participant
1900132|NCT01334346|Other|Nike Pegasus|Conventional neutral supportive running footwear. Non minimalist.
1902018|NCT01342016|Drug|leflunomide placebo|oral
1900135|NCT01334359|Behavioral|Physical Activity|9-month afterschool program designed to increase physical activity and aerobic fitness.
1900136|NCT01334372|Behavioral|CAMS|First, as discussed above, suicidality is the focus of treatment rather than one of many symptoms being treated. Second is the emphasis on patient and therapist collaborating on treatment rather than the therapist dictating how therapy progresses. Beyond those two basic tenets, each therapist is free to utilize their current clinical skills to conduct psychotherapy.
1900137|NCT01334398|Behavioral|Health & Wellness|"The specific content of the intervention was adapted from four existing evidence-based interventions: (1) Healthy Lifestyles for People with Disabilities, (2) Promoting Wellness for Women with MS, (3) Living Well with Disability, and (4) Social Skills and TBI: A Workbook for Group Treatment."
1900138|NCT01334424|Drug|propofol|2-2.5 mg/kg for induction plus or not plus 2 mg/kg.h for maintenance
1900139|NCT01334450|Device|TMS , H2-coil|Trans cranial magnetic stimulation with H2-coil
1900140|NCT01334489|Device|Arabin Cervical Pessary|"The Arabin cervical pessary, which is CE-certified for preventing SPB (CE 0482 / EN ISO 13485: 2003 annex III of the council directive 93/42 EEC).
It is a vaginal device which is used to treat pregnant women for preventing spontaneous preterm birth. This device can be easily placed around the uterine cervix without pain."
1900141|NCT01334502|Biological|rituximab|PO
1900142|NCT01334502|Drug|cyclophosphamide|IV
1900143|NCT01334502|Drug|doxorubicin hydrochloride|IV
1900144|NCT01334502|Drug|everolimus|PO
1900145|NCT01334502|Drug|prednisone|PO
1900146|NCT01334502|Drug|vincristine sulfate|IV
1900147|NCT01334515|Biological|hu14.18-IL2 fusion protein|Given IV
1900148|NCT01334515|Drug|isotretinoin|Given PO
1900149|NCT01334515|Biological|sargramostim|Given SC
1900150|NCT01334515|Other|laboratory biomarker analysis|Correlative studies
1900151|NCT01334541|Behavioral|SAFE VET|"All SAFE VET EDs provide a standardized intervention that is specifically adapted for use in the ED to mitigate suicide risk. Given that the SAFE VET intervention was developed for use in a busy ED setting, the length of the intervention is approximately 45 minutes. The SAFE VET intervention is administered by a clinical provider who has been specifically trained and consists of:
Risk Assessment
Safety Planning Intervention: Developed by Stanley and Brown (2008), Safety Planning Intervention consists of a hierarchically-arranged list of coping strategies identified for use during a subsequent suicidal crisis.
Clinical Follow-Up Protocol"
1900152|NCT01334554|Drug|Sildenafil|20 mg three times a day.
1900153|NCT01334554|Drug|Placebo|No active drug
1900154|NCT01334567|Drug|Tenofovir DF|Provision of tenofovir disoproxil fumarate (tenofovir DF) 300 mg tablets, as prescribed by study investigators
1900155|NCT01334580|Behavioral|Cognitive-Behavioral Therapy for Pain and Opioid Dependence|CBT is provided by skilled psychologists in weekly sessions for 12 weeks and focuses on reducing illicit drug use and increasing pain management.
1900156|NCT01334580|Behavioral|Methadone Drug Counseling|Methadone Drug Counseling (MDC)is provided by skilled drug counselors over a 12-week period. The primary goal of MDC is cessation of illicit drugs.
1900157|NCT01334606|Device|4 mm x 32G pen needle (Nano)|The pen needle will be used to administer all pen-based diabetes medications. When using the 4mm Nano pen needle, subjects are directed to hold the pen device at a 90 degree angle and perform the injection with no pinch-up.
1900158|NCT01334606|Device|8mm x 31G pen needle (Short)|The pen needle will be used to administer all pen-based diabetes medications. When using the 8mm Short pen needle, subjects are directed to use the pinch-up technique for injections in the abdomen and thigh, and no pinch-up at other injection sites. Subjects are to hold the pen device at a 90 degree angle.
1900159|NCT01334619|Procedure|appropriate volume of 0.5% ropivacaine|initial concentration: 30 ml, subsequently varied at a ratio of 1: 1.2 for each consecutive patient according to the response of the previous patient, until 5 up-and-down cycles completed.
1900160|NCT01334632|Procedure|Continuous interscalene block|The continuous interscalene block will be performed with ultrasound 30 minutes before the intervention.
1900161|NCT01334632|Procedure|PCA morphine|Postoperative with iv self-administration of morphine
1900162|NCT01334645|Other|Copeptin|"Patients with hyponatremia < 135 mmol/L or troponin > 1 μg/L are released study.
Blood sampling are taken for Troponine T, myoglobin, creatin kinase and copeptine analysis and 18-lead ECG was performed after 2, 4, 6 and 12 h.
Copeptin and myoglobin are measured at the end of the patients inclusion, after to be centrifugrd end frozen at -80°C at each time point.
The treatment of patients is not modified by the study. At 90 days, clinicals and paraclinicals events are collected"
1900163|NCT01334658|Procedure|Phacoemulsification cataract surgery|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.
All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
1900164|NCT01334658|Drug|Glucose-bicarbonate-Ringer Lactate (GBRL)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.
All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
1900188|NCT01334866|Procedure|Minimally invasive coronary artery bypass graft surgery|The MICS CABG procedure can bridge the gap between percutaneous coronary intervention (PCI) and standard sternotomy. The key components are direct vision, creating anastomoses with traditional instruments and proximal aortic location.
1900189|NCT01334879|Drug|ranibizumab 2.0 mg|Intravitreal ranibizumab (2.0 mg)
1900190|NCT01334892|Drug|Cyclosporine Inhalation Solution|Cyclosporin for inhalation twice daily
1900191|NCT01334905|Drug|YM178|oral
1900165|NCT01334658|Drug|Balanced Salt Solution (BSS®)|"A group received BSS ® (ALCON LABORATORIES, INC.) and another group received glucose-bicarbonate-Ringer Lactate (GBRL) [500 cc. Ringer Lactate (GLICOLABOR, Pharmaceutical LTD.) enriched with 1.5 ml of glucose in water (25%) and 08 ml of sodium bicarbonate (8.4%)] as a solution for irrigation during surgery.
All surgeries were performed by single surgeon (HON), using the standard surgical technique quick-chop. Immediately before surgery, solutions for irrigation [BSS ® (ALCON LABORATORIES, INC..) and glucose-bicarbonate-Ringer Lactate (GBRL)] were brought to the operating table in a temperature of 22 degrees Celsius. The microcoaxial Phacoemulsification was performed under a phaco Legacy Series 20000 (ALCON LABORATORIES, INC..)."
1900166|NCT01334671|Drug|Atorvastatin|Group 1:80mg before PCI and 40mg per day after PCI for one month then 20mg per day until the end of the trial Group 2:40mg per day after PCI for one month then 20mg per day until the end of the trial Group 3:20mg per day after PCI until the end of the trial
1900167|NCT01334684|Drug|Metformin|Metformin, pills, 850 mg three times a day for three months
1900168|NCT01334697|Drug|recombinant human cardiotrophin-1|Single dose intravenous administration
1900169|NCT01334697|Other|Placebo|Single dose intravenous administration
1900170|NCT01334710|Drug|Sorafenib and OSI-906|Sorafenib - 400 mg twice daily OSI-906 - 150 mg twice daily
1900171|NCT01334723|Drug|Adherent with 5-alpha-reductase inhibitor (5ARI) therapy|Patient with BPH who are adherent to 5ARI therapy (Adherence will be calculated using a medication possession ratio (MPR); 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
1900172|NCT01334723|Drug|Non-adherent to 5ARI therapy|Patients with BPH non-adherent to 5ARI therapy (Adherence will be calculated using a MPR; 3 MPR threshold values of 70%, 75%, and 80% will be evaluated.)
1900173|NCT01334736|Behavioral|Usual care|After participants have completed the data collection portion of the SHIELD visit, the research assistant will provide the participant with an informational flyer regarding the risks of tobacco smoking and benefits of tobacco cessation. The participant will be provided the phone number for the Tobacco Quit Line in Maryland as well as a list of local tobacco cessation programs. Any questions will be answered by the research assistant. If the participant inquires about nicotine replacement therapy, they will be advised to contact their primary care provider to discuss potential therapeutic options. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
1900174|NCT01334736|Behavioral|Lung age|For individuals randomized to spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be verbally informed of spirometric results. It will be explained that lung function normally reduces with age and that smoking can damage lung as if they were aging more rapidly than normal using visual depictions. Their lung function estimates based on their chronological age and lung age will be provided. They will be informed that smoking cessation would slow the aging of their lungs. After questions are answered, the participant will receive a written report that includes enumeration of their lung age and chronological age. At initial and follow-up visits, the research assistant will provide the participant with the same informational flyer and Tobacco Quit Line in Maryland as the usual care intervention.
1900175|NCT01334736|Behavioral|Contingency Management|For individuals randomized to CM, after completion of data collection, it will be explained to the participant that they will receive monetary compensation for biological confirmation of tobacco cessation. At each visit, exhaled carbon monoxide levels will be checked. If the subject has a negative CO level, they will be compensated. If a participant has a CO consistent with recent tobacco use, (s)he will receive the payment for attending the visit, but no additional payment at that visit. Spirometry results will be verbally disclosed to participants describing their lung function as a percent of predicted value. A handout with these results will be given to participants. At each follow-up visit, after obtaining CO and questionnaire data, spirometry results will be reviewed and participants will be offered the informational flyer and quit line number.
1900176|NCT01334736|Behavioral|Lung age + Contingency Management|For individuals randomized to the combined contingency management + spirometric lung age intervention, after completion of data collection, CO level and acceptable spirometry, the participant will be described the process of contingency management as outlined above. Following this, the research assistant will then describe lung age to the participant as described above. At the end of this process, the participant will then receive the informational flyer, quit line and local tobacco cessation program information similar to the usual care intervention. At each follow-up visit, after obtaining CO level and questionnaire outcomes, appropriate CM payment, review of participant's baseline lung age and informational flyer will occur.
1900177|NCT01334762|Drug|Letrozole/IUI|Patients received 5 mg letrozole daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
1900178|NCT01334762|Drug|CC/IUI|Patients received 100 mg lCC daily for 5 days. A single insemination was performed 32-36 hours after hCG (10,000 IU, IM). Patients underwent up to four cycles of treatment.
1900179|NCT01334775|Procedure|Open anterior inguinal hernia repair|Placement of a surgical mesh in open anterior inguinal hernia repair.
1900180|NCT01334788|Other|sleep deprivation|Sleep restriction
1900181|NCT01334788|Other|Normal sleep|These are subjects who are randomized to sleep normally.
1900182|NCT01334801|Procedure|Blood Draw|"Two tubes of blood (about five tablespoons) will be drawn for research purposes, and these will be analyzed for the following tests:
BNP (Brain Natriuretic Peptide)
(PFA) Platelet Function Analyzer 100
von Willebrand Factor (vWF) antigen
(vWF) multimers
(vWF) *activity by latex aggregation
Plasma stored for development of new testing approaches"
1900183|NCT01334814|Device|Deep Brain Stimulation (Model 7438 Therapy Controller)|Deep brain stimulation (DBS) is a surgical procedure used to treat a variety of disabling neurological symptoms
1900184|NCT01334840|Dietary Supplement|Bicarbonated mineral water|"Volunteers fasted overnight consumed:
0.5 L of the bicarbonated mineral water without meal or, 0.5 L of the bicarbonated mineral water with meal"
1900185|NCT01334840|Dietary Supplement|Mineral water low in mineral content (control)|"Volunteers fasted overnight consumed:
0.5 L of the control water without meal or, 0.5 L of the control water with meal"
1900186|NCT01334853|Other|No drug will be used|Biomarker
1900187|NCT01334853|Other|No drug will be used|Biomarker
1900193|NCT01334918|Radiation|technetium Tc99m sestamibi /technetium Tc99m tetrafosmin|Administered by intravenous infusion
1900194|NCT01334918|Radiation|Contrast|Administered by intravenous infusion.
1900195|NCT01334918|Procedure|Single Photon Emission Computed Tomography|
1900196|NCT01334918|Procedure|Multidetector Computed Tomography|
1900197|NCT01334931|Radiation|Large field of view arm|Patients will be allocated in the large field of view arm. Coronary angiography will be performed with large field of view lens (25 cm)
1900198|NCT01334931|Radiation|Medium field of view|Patients will be allocated in the medium field of view arm. Coronary angiography will be performed with medium field of view lens (20 cm)
1900199|NCT01334944|Drug|Intravenous ibuprofen|400 mg or 800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
1900200|NCT01334957|Drug|Intravenous ibuprofen|800 mg intravenous ibuprofen administered intravenously over 5-10 minutes
1900201|NCT01334983|Behavioral|REST|Instruction in an individualized rapid easy strength training (isotonic with therabands) and pedometer-based walking programs.
1900202|NCT01335009|Biological|MORAb-004 (monoclonal antibody)|Subjects will receive one cycle of treatment with MORAb-004, administered intravenously, on Days 1, 8, 15, and 22 (4 administrations per cycle). Additional cycles will continue without interruption until disease progression occurs.
1900203|NCT01335022|Behavioral|lecture|6 lectures on cardiovascular disease covering obesity, diet & exercise, smoking cessation, coronary artery disease, hypertension, heart failure, diabetes, peripheral vascular disease, and stroke.
1900204|NCT01335035|Drug|deferasirox|
1900205|NCT01335048|Drug|atorvastatin and clopidogrel|Atorvastatin 80 mg daily + clopidogrel 150 mg daily
1900206|NCT01335048|Drug|Clopidogrel|Clopidogrel 150 mg daily
1900207|NCT01335061|Biological|Nonacog alfa|Period 1: During on-demand period, dosing at the discretion of investigator.
1900208|NCT01335061|Biological|Nonacog alfa|Period 2: During the prophylaxis period, 100 IU/kg once weekly
1900209|NCT01335074|Drug|Temsirolimus + Sorafenib|200mg bid Sorafenib + 15, 20 or 25 mg Temsirolimus
1900210|NCT01335087|Other|Standard care|Patients with conservative treatment: (Group 2). This group will also be instructed in hygienic-dietary measures, standard care of cardiovascular risk factors and sleep hygiene counselling.
1900211|NCT01335087|Device|continuous positive airway pressure|Patients with CPAP treatment (Group 1): CPAP pressure titration will be performed by automated equipment before discharge. It will follow the methodology described by our group (Mass et al. Alternative Methods of titrating continuous positive airway pressure: a large multicentre study. American Journal of Respiratory and Critical Care Medicine (2004) vol. 170 (11) pp. 1218-1224). This group will also be instructed in hygienic-dietary measures recommended for all patients, standard care of cardiovascular risk factors and sleep hygiene counselling.
1900212|NCT01335126|Other|Emulsion type artificial tear|2 types of artificial tears
1900213|NCT01335139|Biological|Sublingual immunotherapy (SLIT)|Participants randomized to receive sublingual allergen tablet immunotherapy with placebo injections.
1900214|NCT01335139|Biological|Subcutaneous immunotherapy (SCIT)|Participants randomized to receive subcutaneous injection immunotherapy with placebo tablets. Subcutaneous immunotherapy was included as a positive control.
1900215|NCT01335139|Other|Placebo|Participants randomized to double-placebo tablets and injections. This group was included as a negative control.
1900216|NCT01335152|Behavioral|Coping with Breast Cancer web-based workbook|10 chapter web-based workbook that teaches stress management, cognitive behavioral coping skills and relaxation training.
1900217|NCT01335165|Drug|ALXN1102|Single Ascending Dose IV
1900218|NCT01335165|Drug|ALXN1103|Single Ascending Dose IV or SC
1900219|NCT01335178|Behavioral|Intervention|The intervention consisted of the following elements: (a) Three motivational interviews, scheduled for baseline, one month, and three months; (b) Feedback on air quality in the home (PM2.5 was measured using a Sidepak and/or a Dylos monitoring device, and air nicotine was measured using passive air nicotine dosimeters); (c) Feedback on child's exposure via hair nicotine; (d) a website designed especially for the project [parents.org.il];and (e) various self-help materials, including a booklet, a magnet about TSE, and air fresheners.
1900220|NCT01335191|Biological|TUTI-16 (1.0 mg)|Two subcutaneous injections of TUTI-16 (1.0 mg) at Day 0 and Week 3.
1900221|NCT01335191|Other|Placebo|Two subcutaneous injections of Placebo at Day 0 and Week 3.
1900222|NCT01335204|Drug|Cabazitaxel plus bavituximab|Cabazitaxel (25 mg/m2) will be administered IV on Day 1 of each 21-day treatment cycle, and bavituximab (3 mg/kg) will be administered as an IV infusion on a weekly basis (Cycle 1 Day 2, all other cycles Day 1; day 8; day 15) for 8 cycles.
1900223|NCT01335217|Procedure|Transcutaneous Electrical Nerve Stimulator (TENS)|External trigeminal nerve stimulation (TNS) as an adjunctive treatment for adults with major depressive disorder (MDD) co- occurring with posttraumatic stress disorder (PTSD) when added onto antidepressant medications
1900224|NCT01335243|Procedure|The Transforaminal Lumbar Interbody Fusion (TLIF) surgery|The TLIF surgery use a per-operating artificial substitute specific biomaterial: autologous osteoblasts punctured on iliac crest and put on a collagen support waxed with tri-calcium phosphate (which is osteoconductive) to perform a intervertebral body fusion.
1900225|NCT01335256|Drug|BAY1000394|BAY1000394 will be administered orally twice a day (bid) in a 4 week on / 2 week off schedule.
1900226|NCT01335269|Drug|BI 853520|BI 853520 once daily in a dose escalation schedule
1900227|NCT01335295|Drug|Flavocoxid|Flavocoxid capsules TTD 500 mg/die or 1000 mg/die for 1 year
1900228|NCT01335308|Behavioral|Standard Care|Practitioners will receive 2 hour obesity lecture and ½ day protocol training. Families recruited are given parent education materials. Outcomes will be collected at 1 year and 2 years after enrollment
1900229|NCT01335308|Behavioral|Moderate Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner. Outcomes will be collected at 1 year and 2 years after enrollment
1900230|NCT01335308|Behavioral|Higher Dose Motivational Interviewing|Practitioners receive 2 days of Motivational Interviewing and Behavioral Therapy Training and ½ day protocol training. Families recruited receive 4 x MI visits with the pediatric practitioner and 6 x visits (in phone or in person) with a Registered Dietitian, also trained in Motivational Interviewing. Outcomes will be collected at 1 year and 2 years after enrollment
1900231|NCT01335321|Drug|Hylan GF-20 alone|A intraarticular injection of 6ml of Hylan GF-20 (Synvisc)
1900232|NCT01335321|Drug|Triamcinolone|A Intraarticular injection of 6ml of Hylan GF-20 (Synvisc) + 1ml of triamcinolone (Triancil)
1900233|NCT01335334|Drug|bismuth subcitrate potassium, metronidazole,tetracycline hydrochloride and omeprazole|Pylera capsule contains bismuth subcitrate potassium, 140 mg (q.i.d.), metronidazole, 125mg (q.i.d.), tetracycline hydrochloride, 125mg (q.i.d.). Generic omeprazole (20mg, b.i.d) tablets
1900234|NCT01335347|Biological|ND1.1|adenovirus with the dsRNA adjuvant, dried and put into capsules
1900235|NCT01335347|Biological|Placebo control|Capsules of the same size and shape as experimental groups
1900236|NCT01335360|Drug|Nevirapine|200mg twice daily of nevirapine
1900237|NCT01335373|Drug|Metronidazole/Miconazole (Neo-Penotran Forte, BAY86-5276)|Patients older than 18 years with previously taken decision of their gynecologist to prescribe Neo-Penotran Forte according to registered indications, and microbiological tests were performed.
1900238|NCT01335386|Drug|KLYX|
1900239|NCT01335386|Drug|Glycerine|
1900247|NCT01335412|Biological|Japanese Encephalitis Virus vaccine, inactivated, adsorbed|2 x 6mcg / 0.5mL intramuscular injection, Day 0 and 28 (Primary series) or 1x 6mcg / 0.5mL intramuscular injection (Booster)
1900248|NCT01335438|Device|Cementless (Nexgen)|Cementless fixation of Nexgen CR TKR
1900249|NCT01335438|Device|Cemented (Nexgen)|Cemented fixation of Nexgen CR TKR
1900250|NCT01335451|Drug|AZD5213|Four increasing doses for young and two increasing doses for elderly subjects. Subject will receive single dose of AZD5213 oral solution (Day 1) and then start the once daily repeated doses from Day 3 to 12 for 10 days
1900251|NCT01335451|Drug|Placebo|Placebo solution, single dose (Day 1) and repeated dose from Day 3 to 12 for 10 days
1900252|NCT01335464|Drug|placebo|placebo matching BIBF1120, BID
1900253|NCT01335464|Drug|BIBF 1120|BIBF1120 BID (twice daily)
1900254|NCT01335477|Drug|placebo|placebo matching BIBF 1120 BID
1900255|NCT01335477|Drug|BIBF 1120|BIBF 1120 BID (twice daily)
1900257|NCT01328626|Drug|ABT-199|Arm A (Cohorts 1-8) and Arm B (Cohort 1-6): Subjects in dose escalation phase will receive 1 dose of ABT-199, followed by 6 days off drug, followed by continuous once daily dosing with ABT-199. Arm B (Cohorts 7+): Subjects in dose escalation phase will receive continuous once daily dosing with ABT-199. Arm A and Arm B: Subjects in expanded safety cohort will receive continuous once daily dosing with ABT-199.
1900258|NCT01328639|Other|TeamCare Depression Intervention|The TeamCare-PCN intervention involves a registered nurse Care Manager (CM), who coordinates collaborative team management for patients with diabetes and depression. The goal of the intervention is to reduce depressive symptoms, achieve targets for cardio-metabolic measures and improve lifestyle behaviours. The intervention includes three phases: (1) managing depression and improving depressive symptoms, (2) managing diabetes and controlling blood glucose, blood pressure and cholesterol, and (3) improving lifestyle behaviours such as healthy eating, physical activity and smoking cessation.
1900259|NCT01328639|Other|Usual diabetes and depression care|Usual care of diabetes and depression involves providing care by the family physician based on usual standards of care and available clinical practice guidelines. Usual care does not involve additional active support from the Care Manager.
1900260|NCT01328652|Drug|dexlansoprazole|dexlansoprazole 60 mg once daily for 3 months
1900261|NCT01328665|Other|Expressive Writing|Writing intervention for cognitive appraisal of stressor.
1900262|NCT01328717|Device|Contour Link Investigational Blood Glucose Monitoring System|Subjects with diabetes and study staff each performed Blood Glucose tests from the subject's capillary blood obtained from fingerstick using the Contour Link investigational meter.
1900263|NCT01328730|Device|Firebird 2 SES|The FIREBIRD2™ Rapamycin-Eluting CoCr Coronary Stent is the second generation DES of MicroPort, which based on the new cobalt chromium alloy stent platform. It uses polyolefin polymer, which makes the coating property very remarkable.
1900264|NCT01328730|Device|Cypher SES|The Cypher SES is based on the 316L platform with Controlled-release, nonresorbable, elastomeric polymer coating.
1900265|NCT01328743|Behavioral|Brief alcohol intervention|3 sessions of individual face-to-face counseling at baseline, 3 and 6 months. Sessions are motivationally focused including discussion of pros and cons of drinking and feedback on health and its relation to heavy drinking
1900266|NCT01328756|Drug|Lisdexamfetamine dimesylate|Optimized dose of either 30, 50 or 70 mg capsule administered once daily for 2 years
1900267|NCT01328769|Drug|Febuxostat|
1900268|NCT01328769|Drug|Placebo|
1900269|NCT01328782|Drug|Oxycodone with Acetaminophen|0.1- 0.15 mg/kg (oxycodone) every 4-6 hours as needed. Pills: 325 mg acetaminophen: 5 mg oxycodone per tablet. Liquid: 325 mg acetaminophen:5 mg oxycodone per 5 mL.
1900384|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 30 μg|120 adults were assigned to receive 1 dose of 30μg split-virion, non-adjuvanted H1N1 vaccine.
1902019|NCT01342016|Drug|prednisone|oral
1900270|NCT01328782|Drug|Bupivacaine 0.25%|"Up to 4 ml at 0.25 % given to .. In toxic doses can lead to irregular heart beat, patients aged 4-7 (dose will be irregular heart rate and cardiac arrest. (This no greater than 0.71 mg/kg)
Up to 5 ml at 0.25 % by volume solution will be given to patients aged 8-12 (dose will be no greater than 0.63 mg/kg)
All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
1900271|NCT01328782|Drug|Ropivacaine 0.20%|"Up to 4 ml at 0.20 % given to patients aged 4-7 (dose will be no greater than 0.57 mg/kg)
Up to 5 ml at 0.20 % by volume solution will be given to patients aged 8-1(dose will be no greater than 0.50 mg/kg)
All doses given will be significantly less then maximum allowable dose of 2.5- 3.0 mg/kg"
1900272|NCT01328795|Other|cardiogoniometry|In the course of the project a cardiogoniometry will be carried out during the ambulant or residential hospitalization before the coronary angiography.
1900273|NCT01328808|Drug|Acetaminophen/APAP|"In preterm and term neonates with a GA of 28 weeks or more a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute.
In preterm and term neonates with a GA of less than 28 weeks a 15 mg/kg dose of APAP will be given every 8 hrs by an intravenous infusion over 30-minute"
1900274|NCT01328821|Drug|CTP-499|600 mg, 1200 mg, 1800 mg and 2400 mg
1900275|NCT01328821|Drug|CTP-499|400 mg immediate release capsule
1900276|NCT01328834|Drug|Tacrolimus Sustained-release Capsules (ADVAGRAF)|Started: 0.05-0.1mg/kg/d, one time per day, the blood level 5-10ng/ml in the induction treatment.
1900277|NCT01328860|Biological|bone marrow progenitor cells (BMPC) autologous transplantation|Not more than 5ml/kg bone marrow will be collected under anesthesia; after the bone marrow has been processed, about 6-8 hours after bone marrow aspiration, subjects will receive the cells via intra-venous (in the vein) infusion and will be monitored for 24 hours for any adverse events.
1900278|NCT01328873|Other|Microbiological analysis|Bronchoalveolar lavage (BAL) with subsequent testing for pathogens
1900279|NCT01328886|Drug|Omalizumab|omalizumab lyophilized 150 mg injection
1900280|NCT01328899|Device|Lung Volume Reduction Coil (LVRC) (PneumRx's)|Lung Volume Reduction Coil
1900281|NCT01328912|Other|Remote ischemic preconditioning stimulus|The intervention will consist of 3 cycles of 5 minutes of upper limb ischemia. The RIPC stimulus will be performed using a blood pressure cuff placed on the upper arm inflated above systemic pressure to 200 mmHg for 5 minutes, then deflated for 5 minutes. Ischemia will be assured with the use of a saturation probe on the digit of the involved arm.
1900282|NCT01328912|Other|control|These patients are randomized to placebo, thus they will no undergo the RIPC stimulus.
1900283|NCT01328925|Drug|Nitazoxanide|"Nitazoxanide Oral Suspension dose based on age:
Age <12 months- 7.5 mg/kg by mouth twice daily for 3 days; Age 12-47 months- 100 mg/5 ml by mouth twice daily for 3 days; Age 48-72 months- 200 mg/10 ml by mouth twice daily for 3 days"
1900284|NCT01328938|Biological|GCPGC 3.6mg|Stage I:Single blinded
1900285|NCT01328938|Biological|GCPGC 6mg|Stage I: Single blinded;
1900286|NCT01328938|Biological|Neulasta (pegfilgrastim) 6mg|Stage II: Active comparator, double blinded
1900287|NCT01328938|Biological|GCPGC 6mg|Experimental: Stage II
1900288|NCT01328951|Drug|Placebo|Placebo will be administered PO once daily as first-line maintenance until disease progression, death, or unacceptable toxicity.
1900289|NCT01328951|Drug|Erlotinib|Erlotinib will be administered as 150 mg PO once daily until disease progression, death, or unacceptable toxicity, as first-line maintenance or as second-line therapy for those who progress while receiving placebo.
1900290|NCT01328951|Drug|Second-Line Chemotherapy|Participants who progress on first-line maintenance erlotinib may receive an approved second-line therapy (but not EGFR targeted therapies) until disease progression, death, or unacceptable toxicity. The selected chemotherapy will be non-investigational and chosen at the discretion of the Investigator.
1900291|NCT01328964|Drug|Fluticasone propionate|fluticasone propionate 44 mcg
1900292|NCT01328964|Drug|Budesonide|budesonide
1900293|NCT01328964|Drug|Montelukast|montelukast
1900294|NCT01328977|Behavioral|education|teaching
1900295|NCT01328990|Drug|sulfadoxine-pyrimethamine plus amodiaquine|one dose of sulfadoxine-pyrimethamine 25/1.25 mg/kg plus three daily doses of amodiaquine, 10 mg/kg/day
1900296|NCT01329016|Drug|Glyburide|Women with GDM who require treatment will be given glyburide 2.5 mg. Medication will be given at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
1900297|NCT01329016|Drug|Metformin|Women with GDM requiring treatment will be given metformin 500 mg. Medication will be administered at least twice daily and equal doses will be given for each dosing time for the 3 days prior to the pharmacokinetic study day.
1900298|NCT01329016|Drug|Glyburide-Metformin combination|Women with GDM requiring treatment will be given glyburide 2.5 mg with metformin 500 mg. Medications will be administered at least twice daily and equal doses will be given for each dosing time 3 days prior to the pharmacokinetic study day.
1900299|NCT01329029|Drug|Roflumilast|500 µg, once daily
1900300|NCT01329029|Drug|Placebo|once daily
1960984|NCT03043872|Drug|Durvalumab|IV infusions every 3 weeks for 12 weeks (4 cycles) and every 4 weeks thereafter until PD or other discontinuation criteria.
1900302|NCT01329068|Behavioral|individual consult|regular individual consultations
1900303|NCT01329068|Behavioral|group medical consult|group medical consult
1900304|NCT01329081|Other|Postoperative rehabilitation after fast-track TKA|Six weeks of strength training combined with patient education
1900305|NCT01329081|Other|Postoperative rehabilitation after fast-track TKA|Six to eight weeks of supervised home training
1900306|NCT01329107|Behavioral|Multimodal Intervention|"Patients in the intervention group will be taught to manage their new urinary diversion BEFORE operation. Traing kit will be provided so they can train the procedure forehanded. Second they will get a personally physical training program to optimize the total body function before operation. Nutritional status will be meassured and appropriate advices will be given BEFORE operation.
After operation the intervention group will be mobilised in a fast speed compared to standard care."
1900307|NCT01329120|Procedure|Minimally invasive repair of pectus excavatum|Minimally invasive surgical technique basically consisting of inserting one or more convex steel bars under the sternum through small bilateral incisions in the thoracic wall
1900308|NCT01329120|Procedure|Open surgical repair of pectus carinatum|Open surgical removal the affected cartilages bilaterally and the excess cartilage over the sternum
1900309|NCT01329133|Procedure|Deep Brain Stimulation (DBS)|In a first time: Implantation of DBS electrodes, stereotactically, in each hemisphere into the targeted brain structure under local anesthesia. In a second time (next week): installation of the deep brain neurostimulator and connection to the electrodes implanted under general anesthesia. And one month later: beginning of the stimulation.
1900310|NCT01329172|Other|polyunsaturated fatty acids n-3|polyunsaturated fatty acids n-3 1 gram per day during two months
1900311|NCT01329172|Other|placebo|sun flower oil with Poly Unsaturated Fatty Acid 1g/day
1900312|NCT01335490|Other|Cook stoves, either Biolite wood stove, or liquified petroleum gas stove plus fuel|The cooking stoves will reduce air emissions significantly in the home, resulting in improved infant health. It will be given to the mother in the second or third trimester.
1900313|NCT01335503|Dietary Supplement|AN-PEP|Endoprotease enzyme (AN-PEP)
1900314|NCT01335516|Other|Glypressin (terlipressin)|Study drug (without placebo)
1900315|NCT01335529|Drug|Boceprevir, Peg-interferon alfa 2b and Ribavirin|"Screen period from Week-8
Standard treatment from day 0 to week 4 (W4)
Three-drug-regimen (Boceprevir introduction) from W4 to W8
HCV RNA determination at W8 determines treatment group and participation duration:
If undetectable HCV RNA at W8, it is a complete virological response: 3 drug-regimen is continued until W48, then there is a follow-up period up to W72 and SVR analysis,
If HCV RNA ≤ 1000IU/mL at W8, it is an incomplete virological response. The 3-drug-regimen is continued until W72, when another analysis is done."
1900316|NCT01335542|Procedure|Peri-Articular Injection|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), dexamethasone (6mg) Anesthetic:: Combined Spinal-Epidural with 0.5% bupivacaine. IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Postoperative pain management: hydromorphone/bupivacaine PCEA (4/4/10/20, initially). Meloxicam (7.5 or 15mg), Oxycodone/Acetaminophen (5/325 3hr PRN)
1900317|NCT01335542|Procedure|Epidural Pathway (PCEA+FNB)|Pre-operative anesthesia/analgesia: meloxicam (7.5 or 15mg), extended release oxycodone (10mg or 20mg), dexamethasone (6mg), clonidine patch (100 mcg/24 hr) Anesthetic: Spinal with 0.5% bupivacaine, IV sedation with midazolam, propofol Antiemetic: 20mg famotidine, 4mg ondansetron Post-operative analgesia:Prilosec (20mg), Meloxicam (7.5mg or 15 mg PO), extended release oxycodone (10mg or 20mg), Oxycodone (5mg q 3 hr PRN), Acetaminophen (1000mg), ketorolac 15mg IV
1900318|NCT01335568|Procedure|Hepatocyte Matrix Implant|Open surgical procedure with biopsy of liver tissue and pancreatic tissue for proceeding in institutional GMP laboratory. Implantation of autologous hepatocytes and islet cells on scaffolds into the small bowel mesentery. Usually 10 to 20 implants are used.
1900319|NCT01335581|Device|Q-Switched Nd:YAG Laser (RevLite)|Laser treatment added to a microdermabrasion and topical lightening agent regimen
1900320|NCT01335594|Procedure|clinical, endoscopical and manometric evaluation|clinical evaluation: questionnaire endoscopical analysis manometry
1900321|NCT01335607|Drug|Samatasvir tablet|Two samatasvir (IDX184) 50 mg tablets (100 mg single oral dose)
1900322|NCT01335607|Drug|Samatasvir capsule|Two samatasvir (IDX184) 50 mg capsules (100 mg single oral dose)
1900323|NCT01335620|Drug|Raltegravir|400 mg twice daily
1900324|NCT01335646|Procedure|Lumbar Microdiscectomy|lumbar discectomy within 1 month of randomization
1900325|NCT01335646|Other|Physiotherapy, Epidural injections, Education, Pain Medications, Anti-inflammatories|Physiotherapy following standardized protocol Epidurals - Depomedrol 80 mg plus 10cc of 0.35% Lidocaine Education to occur at each visit Medications may include: NSAIDS; Acetaminophen with codeine or oxycodone or tramadol; Amitriptyline or Neurontin or Pregabalin
1900326|NCT01335659|Device|Fractional flow reserve|Fractional flow reserve measured by pressure wire
1900327|NCT01335659|Device|IVUS|"intravascular ultrasound
:IVUS was performed in a standard fashion using an automated motorized pullback system (0.5mm/s) with commercially available imaging catheter"
1900328|NCT01335685|Drug|IXAZOMIB|
1900329|NCT01335685|Drug|Melphalan 9 mg/m2|
1900330|NCT01335685|Drug|Melphalan 6 mg/m2|
1900331|NCT01335685|Drug|Prednisone|60 mg/m2
1900332|NCT01335698|Drug|Atazanavir Sulphate|
1900333|NCT01335698|Drug|Ritonavir|
1900334|NCT01335711|Drug|ChronVac-C + SOC|"IMP: I.m. administration of 500 μg plasmid DNA vaccine CHRONVAC-C (solution for injection) administered i.m. in combination with electroporation using MedPulser® DDS on 2 occasions with 4 weeks in between followed by standard of care (SOC) initiation after 14 - 42 days.
SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of < 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)"
1900335|NCT01335711|Drug|SOC|SOC: Peg-IFN-α-2a (180 μg per week) and Ribavirin (1000 mg/day for subjects with a BW of < 75 kg and 1200 mg/day for subjects with a BW of > 75 kg)
1900336|NCT01335724|Drug|Diclofenac diethylamine 1.16% gel|Diclofenac diethylamine 1.16% gel
1900337|NCT01335724|Drug|Placebo gel|Placebo gel
1900338|NCT01335737|Behavioral|aerobic training|12 weeks of aerobic training, 4 times/week
1900339|NCT01335737|Behavioral|Wait list|wait list control condition
1900340|NCT01335750|Other|Multipurpose Solution #1|B&L Renu Fresh Multipurpose Solution
1900341|NCT01335750|Other|Multipurpose Solution #2|Optifree Replenish Multipurpose Solution
1900342|NCT01335750|Other|Mutlipurpose Solution #3|Ciba ClearCare Multipurpose Solution
1900343|NCT01335750|Other|Multipurpose Solution #4|Saline Solution
1900344|NCT01335763|Drug|Insulin glargine|10 units at bedtime of insulin glargine will be prescribed to the patients who has HbA1c levels of 7.5-11%. Insulin glargine dose is going to be titrated by increments of 1 unit daily by the patient to achieve a morning fasting glucose of <=5.5mmol/L
1900345|NCT01335776|Behavioral|Mindfulness-Based Stress Reduction|This intervention is provided over the course of eight, weekly, 90 minute sessions, plus one 6 hour silent retreat.
1900346|NCT01335776|Behavioral|Cognitive Behavior Therapy|This treatment is delivered to small groups over the course of 8 weekly, 90 minute sessions
1900347|NCT01335789|Drug|Oxytocin|40 IUs
1900348|NCT01335789|Drug|Saline|40 IUs
1900349|NCT01335893|Drug|Indocyanine Green|Dose will be diluted in saline solution. This will be a single dose given before the surgery intravenously.
1900385|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 45 μg|120 adults were assigned to receive 1 dose of 45μg split-virion, non-adjuvanted H1N1 vaccine.
1900386|NCT01336166|Biological|Placebo control|120 adults were assigned to receive 1 dose of placebo.
1900350|NCT01335906|Other|Information|The experimental information consists of receiving verbal and written evidence-based information about the benefits and risks of mammography screening program. The standard information consists of receiving the information that public institutions provide to the women invited to the screening program.
1900351|NCT01335932|Drug|IV Ganciclovir|For first 5 days, dosing of intravenous ganciclovir is 10 mg/kg daily, given as 5 mg/kg every 12 hours (adjusted for renal function). After first 5 days (up to 28 days) IV ganciclovir 5 mg/kg QD ( adjusted for renal function). A minimum interval of 6 hours is required between the first and second dose.
1900352|NCT01335932|Drug|Placebo|"For first 5 days, dosing of intravenous placebo is daily, given every 12 hours. After first 5 days (up to 28 days), IV placebo QD. A minimum interval of 6 hours is required between the first and second dose.
The placebo is an IV solution that does not contain any active medications."
1900353|NCT01335945|Procedure|Cryoablation|All subjects will receive cryoablation of the celiac plexus with Galil Medical cryoablation systems and needles under imaging guidance.
1900354|NCT01335958|Drug|DMUC5754A|Escalating intravenous dose
1900355|NCT01335971|Drug|Sulforaphane 25|25 micromoles (4.4 mg) sulforaphane daily by mouth
1900356|NCT01335971|Dietary Supplement|Sulforaphane 150|150 micromoles (26.6 mg) sulforaphane daily by mouth
1900357|NCT01335971|Other|Placebo|Microcrystalline cellulose once daily by mouth
1900358|NCT01335984|Procedure|Telemonitoring|"The subjects who are assigned in the Telemonitoring group will be provided Blood Pressure monitor, body composition analyzer, and remote monitoring device.
The subjects who are assigned in the Telemonitoring group should visit the site once per every 2 months (8 weeks), and they should measure their blood pressure using a provided blood pressure monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood pressure and body composition, the subjects should make the transmission terminals of remote monitoring device situate near transmission terminal of Smart Care PC and transmit measured information through Smart Care PC into a centralized server of Smart Care Center."
1900359|NCT01335984|Procedure|Telemonitoring & Telemedicine|"The subjects who are assigned in the Telemonitoring & Telemedicine group should perform the same remote monitoring procedures as the subjects in the Telemonitoring group.
Since the remote visit substitute for a face to face visit, subjects should reserve the time for remote visit in each clinical trial center. A primary doctor or remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring device and then issue electronic prescriptions."
1900360|NCT01335984|Other|control group|"- The subjects who are assigned in the control group will be provided blood Pressure Monitor (Self BP measuring).
The subjects who are assigned in the control group should perform the same blood pressure measurement (2 times a day) same as the test group during the study, and measured results should be recorded in a diary of self blood pressure measurement. In addition, the subjects should visit the site once per every two months (8 weeks)."
1900361|NCT01335997|Drug|ER niacin/laropiprant (ERN/LRPT)|ER niacin 1 g/laropiprant 20 mg oral tablet taken once daily
1900362|NCT01335997|Drug|ER niacin/laropiprant/simvastatin (ERN/LRPT/SIM)|ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet taken once daily
1900363|NCT01335997|Drug|Simvastatin (SIM)|Simvastatin 10 mg oral tablet taken once daily
1900364|NCT01335997|Drug|Placebo Run-In|Placebo matches both ER niacin 1 g/laropiprant 20 mg oral tablet and ER niacin 1 g/laropiprant 20 mg/simvastatin 10 mg oral tablet; placebo is taken once daily
1900365|NCT01335997|Drug|SIM-matching placebo|Placebo for simvastatin 10 mg oral tablet taken once daily
1900366|NCT01336010|Drug|Peginterferon alfa-2a|PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
1900367|NCT01336010|Drug|Ribavirin|Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing <75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
1900368|NCT01336023|Drug|insulin degludec/liraglutide|Insulin degludec/liraglutide treatment will be initiated and titrated (individually adjusted) twice weekly according to the mean self measured plasma glucose (SMPG) (fasting). Insulin degludec/liraglutide is injected subcutaneously (under the skin) once daily.
1900369|NCT01336023|Drug|insulin degludec|Insulin degludec treatment will be initiated with 10 U and titrated (individually adjusted) twice weekly according to the mean SMPG (fasting). Insulin degludec is injected subcutaneously (under the skin) once daily.
1900370|NCT01336023|Drug|liraglutide|Liraglutide will be started with 0.6 mg and subsequent 0.6 mg weekly dose escalation to 1.8 mg. Liraglutide dose of 1.8 mg/day will be continued for the remaining part of the trial. Liraglutide is injected subcutaneously (under the skin) once daily.
1900371|NCT01336049|Drug|Nimotuzumab|Nimotuzumab 200mg/week
1900372|NCT01336062|Drug|Nanoparticle Albumin-Bound Paclitaxel|this study evaluate 3 dose level of nab-paclitaxel:100 mg /m2;125 mg /m2;80 mg /m2;
1900373|NCT01336075|Procedure|Percutaneous radiofrequency catheter ablation|Percutaneous radiofrequency catheter ablation around the rights and lefts pulmonary veins, with complete circumferential ablation.
1900374|NCT01336075|Procedure|Mini invasive thoracoscopic radiofrequency ablation|Video-assisted thoracoscopic approach for electrical isolation of the pulmonary veins bilaterally and left atrial appendage excision or exclusion.
1900375|NCT01336088|Drug|ADX48621|oral administration
1900376|NCT01336088|Drug|Placebo|oral administration
1900377|NCT01336101|Device|EPIC™ Self-Expanding Nitinol Vascular Stent|SFA/Popliteal Artery stenting
1900378|NCT01336127|Behavioral|Occupational Therapy|Patients in the experimental group will receive 10 weeks (maximum 16 hours) occupational therapy according to a treatment protocol, which is based on the Dutch evidence based guideline for occupational therapy in Parkinson's Disease and refined for this study.
1900379|NCT01336140|Drug|Aminophylline|75 mg of intravenous aminophylline
1900380|NCT01336140|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
1900381|NCT01336153|Drug|MLC601|group A (100 patients; NeuroAid 400mg, 4 capsules 3 times daily) or for 3 month
1900382|NCT01336153|Drug|Placebo|group B (50 patients; placebo, 4 capsules 3 times daily) for 3 months
1900383|NCT01336166|Biological|split-virion, non-adjuvanted H1N1 vaccine of 15 μg|120 adults were assigned to receive 1 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.
1900387|NCT01336179|Procedure|Salvadora persica|twice daily use, two minutes interval
1900388|NCT01336179|Procedure|Toothbrush|Twice daily use two minutes interval
1900389|NCT01336192|Drug|Gemcitabine|Gemcitabine 1250mg/m^2 Day 1 and 8, 28 days per cycle until PD
1900390|NCT01336192|Drug|Best supportive care|Best supportive care
1900391|NCT01336205|Drug|NKTR-118|25 mg oral tablet once daily
1900392|NCT01336205|Drug|Usual care|As prescribed by the investigator
1900393|NCT01336218|Drug|fostamatinib|oral tablets, 150mg (3 X 50mg) single dose per period
1900394|NCT01336218|Drug|rifampicin|oral tablets, 600mg (2 X 300mg) 8 doses over 8 days
1900395|NCT01336244|Drug|GLPG0778|capsules containing 50 or 100 mg of GLPG0778
1900396|NCT01336244|Drug|placebo|multiple dose, aqueous formulation, 13 days days, matching ascending dose schedule
1900397|NCT01336257|Other|SEBASTIAN Clinical Decision Support System (CDSS)|SEBASTIAN is an example of a clinical decision support technology that supports the latest, service-based architectural approach to CDSS implementation. Developed at Duke University, SEBASTIAN is a clinical decision support Web service whose interface is now the basis of the HL7 Decision Support Service draft standard SEBASTIAN places a standardized interface in front of clinical decision support knowledge modules and makes only limited demands on how relevant patient data are collected or on how decision support inferences are communicated to end-users
1900398|NCT01336270|Other|biological collection|to collect some human cell samples in melanoma
1900399|NCT01336283|Other|Endurance training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
1900400|NCT01336283|Other|Strength training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
1900401|NCT01336283|Other|Combined training|compare the efficacy of endurance, strength, and the combination of strength and endurance exercise training in patients with COPD.
1900402|NCT01336296|Drug|mycophenolic acid|Comparing mycophenolic acid 720mg orally twice daily starting 2 weeks prior to transplant to mycophenolic acid 720mg orally twice daily starting day of transplant.
1900403|NCT01336309|Behavioral|Yoga Research Tool|We will be collecting data from a literature search, focus groups, cognitive interviews, and an online survey to build a measure for yoga researchers.
1900404|NCT01336322|Drug|Metformin|Metformin 850 mg bid
1900405|NCT01336322|Drug|Sitagliptin|Sitagliptin 100 mg qd
1900406|NCT01336322|Drug|Sitagliptin + Metfomin|Sitagliptin 100 mg qd + Metformin 850 mg bid
1900407|NCT01336335|Device|CPAP|CPAP
1900408|NCT01336348|Drug|Prasugrel|60 mg loading dose given orally at presentation
1900409|NCT01336348|Drug|Tirofiban|Tirofiban will be given at high bolus dose only of bolus followed by 2 H infusion in a randomized manner (1:1 ratio).
1900410|NCT01336361|Other|Survey|A one-time paper survey was mailed to subjects, along with a cover letter, explanation of the research study, and contact and informed consent information. A reminder postcard was sent to subjects approximately one week later, encouraging return of the completed survey.
1900411|NCT01336387|Drug|retinoid 9cUAB30|Given PO
1900412|NCT01336387|Other|placebo|Given PO
1900413|NCT01336387|Other|pharmacological study|Correlative studies
1900414|NCT01336387|Other|laboratory biomarker analysis|Correlative studies
1900415|NCT01336387|Other|cancer prevention|Disease prevention
1900416|NCT01336400|Other|single cell haplotyping|We aim to collect single blastomeres from spare IVF embryos of 30 couples to optimize and test methods for single cell haplotyping. We aim to collect 20 and 10 couples coming to the fertility centre for FISH- or PCR-based PGD respectively. In both groups, at least 5 different indications for PGD will be collected. Per couple, we will perform 10 SNP-arrays: 2 for the couple donating the embryo, 4 for family members (often parents of the couple) and 4 for blastomeres since we aim to pick 2 cells from 2 embryos per couple. For five couples, 2 blastomeres of all available embryos will be aspirated to validate and optimize the phasing methods. Finally, for some embryos, all blastomeres will be picked to be able to prove the reproducibility of single cell haplotyping.
1960985|NCT03043872|Drug|Tremelimumab|IV infusions every 3 weeks for 12 weeks(4 cycles). An additional dose of tremelimumab will be administered in the week 16.
1960986|NCT03043872|Drug|Carboplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
1900419|NCT01336439|Drug|Botulinum toxin type A (Meditoxin®)|"In this study, the botulinum toxin type A (Meditoxin®)was supplied as a freeze-dried powder of 200U, and was reconstituted with 4ml of sterile saline to a concentration of 5U/0.1ml.
After pre-injection polysomnography, botulinum toxin type A was injected into each side bilaterally using a 1ml-syringe with a 29-gauge, and a 1/2-inch needle. The M group had an injection in masseter muscle. The MT group had an injection in masseter and temporal muscle. A total of 25U of botulinum toxin type A was injected into each site.
After 4 weeks, the subjects had a post-injection polysomnography."
1900420|NCT01336452|Radiation|DCE MRI|DCE (dynamic contrast enhanced) MRI will be obtained just before CCRTx and immediately after finishing CCRTx with 0.1mmol/kg of MR contrast media; CEUS will be obtained just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx with 2.4 mL of SonoVue. Blood sampling for biomarker analysis will be performed just before CCRTx, immediately after finishing CCRTx, and 1 month after CCRTx (20mL)
1900421|NCT01336465|Drug|placebo|Repeating subcutaneous injection
1900422|NCT01336465|Drug|rhuMAb Beta7|Repeating subcutaneous injection
1900423|NCT01336478|Procedure|Infusion of donor derived ex-vivo selected NK cells to patients after transplant|Infusion of donor derived ex-vivo selected NK cells to patients after transplant
1900424|NCT01336478|Procedure|Haematology / Blood chemistry sampling|Haematology / Blood chemistry sampling, collection of blood for ancillary lab research
1900425|NCT01336530|Drug|oxetacaine, aluminium and magnesium hydroxide|20mg/10ml oxetacaine, 196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
1900426|NCT01336530|Drug|oxetacaine|20mg/10ml oxetacaine. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
1900427|NCT01336530|Drug|magnesium and aluminium hydroxide|196mg/10ml magnesium hydroxide, 582mg/10ml aluminium hydroxide. Suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
1900428|NCT01336530|Other|Vehicle|Placebo suspension for oral intake 3-6 times per day for a maximum of 11 weeks.
1900429|NCT01336543|Drug|Chemotherapy following concurrent Chemoradiotherapy|"NSCLC (Non-Small Cell Lung Cancer)
PE (Cisplatin 50mg/m2 on days 1,8,29,36 Etoposide 80mg/m2 days 1-3 and 29-31)
Radiation 59.4 Gy with 2 cycles of PE
(Non-squamous histology) Pemetrexed consolidation 500mg/m2 every 21 days for 4 cycles
(Squamous histology) Gemcitabine consolidation 1000mg/m2 days 1,8, every 21 days for 4 cycles"
1900430|NCT01336556|Procedure|Oral appliance|Anterior mandibular repositioner: used for two months
1900431|NCT01336569|Drug|Travoprost 0.004%/timolol maleate 0.5% fixed combination|
1900432|NCT01336582|Drug|taxotere|70 mg/m2 for age of ≥ 65
1900433|NCT01336595|Device|Zirconium (Zirconium Genesis II)|Oxidized Zirconium femoral component of Genesis II TKR system is used.
1900434|NCT01336595|Device|Cobalt-Chrome (Cobalt Chrome Genesis II)|Cobalt Chrome Femoral Component of Genesis II TKR system is used
1900435|NCT01336608|Drug|Fluticasone Furoate/Vilanterol|Inhaled corticosteroid/long acting beta-agonist
1900436|NCT01336608|Drug|Vilanterol|Inhaled long acting beta-agonist
1900437|NCT01336608|Drug|Placebo|Placebo
1900438|NCT01336621|Drug|Retigabine IR|Flexible dose between 300 mg/day (minimum) and 1200 mg/day (maximum)
1960987|NCT03043872|Drug|Cisplatin|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
1960988|NCT03043872|Drug|Etoposide|up to 4 cycles every 3 weeks in Arm 1 and 2, up to 6 cycles every 3 weeks in Arm 3
1900441|NCT01336647|Drug|Group A - Low-Dose Ha44 0.37% w/w|Low Dose Ha44 Gel applied to scalp and hair for 10 minutes
1900442|NCT01336647|Drug|Group B - High Dose Ha44 Gel 0.74% w/w|High Dose Ha44 Gel applied to scalp and hair for 10 minutes
1900443|NCT01336647|Drug|Group C - Placebo|Placebo- vehicle Ha44 Gel without active ingredient applied to scalp and hair for 10 minutes
1900444|NCT01336660|Biological|Equine F(ab')2 antivenom|A single dose of 4 vials of Equine F(ab')2 antivenom will be administered intravenously over 10 minute
1900445|NCT01336660|Other|Intensive care support plus placebo|Intensive care support as needed plus placebo
1900446|NCT01336686|Drug|Arhalofenate|Arhalofenate 400 mg once daily for 4 weeks
1900447|NCT01336686|Drug|Arhalofenate|Arhalofenate 600 mg once daily for 4 weeks
1900448|NCT01336686|Drug|Placebo comparator|Matching placebo once daily for 4 weeks
1900449|NCT01336686|Drug|Colchicine|0.6 mg colchicine daily for flare prophylaxis
1900450|NCT01336699|Biological|WRSs2|WRSs2 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
1900451|NCT01336699|Biological|WRSs3|WRSs3 is a live, attenuated Shigella sonnei vaccine product, given orally at five escalating doses from 1x10^3 colony-forming units (cfu) to 1x10^7 cfu.
1900452|NCT01336699|Other|Placebo|Placebo comparator: 1 or 1.5 ml of sterile normal saline 0.9% added to 30 mL of 0.9% sterile normal saline, given orally.
1900453|NCT01336712|Procedure|Peripheral Blood Stem Cell Transplant|"Total Body Irradiation 1200cGy (150cGy given in 8 fractions twice a day six hours apart on days -4, -3, -2 and -1.
Fludarabine 30 mg/m^2 given once a day for 3 days on days -7, -6 and -5 Cyclophosphamide 50mg/kg given one a day on days +3 and +4"
1900454|NCT01336725|Behavioral|Teaching life style changes|Single group: Teaching, group sessions, physical activity
1900455|NCT01336725|Other|Active participation|Obesity group attend 10 group sessions,are informed about and discuss needed life style changes such as weight loss and participate in physical activity and cooking.
1900456|NCT01336725|Other|Teaching|Morbid obesity group attend 40 hours of group sessions
1900457|NCT01336738|Drug|Placebo|Tablets (n=6), 0 mg, once daily for 84 days
1900458|NCT01336738|Drug|150 mg PF-04991532|Tablets (n=1), 150 mg + tablets (n=5), 0 mg, all once daily for 84 days
1900459|NCT01336738|Drug|450 mg PF-04991532|Tablets (n=3), 150 mg + tablets (n=3), 0 mg, all once daily for 84 days
1900460|NCT01336738|Drug|750 mg PF-04991532|Tablets (n=5), 150 mg + tablets (n=1), 0 mg, all once daily for 84 days
1900461|NCT01336738|Drug|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=5), 0 mg, all once daily for 84 days
1900462|NCT01336751|Drug|Insulin glargine|solution for subcutaneous injection
1900463|NCT01336751|Drug|75% insulin lispro protamine suspension and 25 % insulin lispro injection|suspension for subcutaneous injection
1900464|NCT01336764|Behavioral|Cognitive reappraisal and breathing retraining|They will be induced to rapidly achieve reduced autonomic arousal through use of a graphics-rich biofeedback procedure and simultaneously engage in the generation and rehearsal of cognitive reappraisal scripts under the coaching of project therapist also in the vehicle.
1900465|NCT01336764|Behavioral|Control|Unguided listening to radio/music.
1900466|NCT01336803|Drug|Feraheme|5 mg Fe/kg iv
1900467|NCT01336803|Procedure|MR Scan|Standard of Care
1900468|NCT01336816|Other|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
1900469|NCT01336816|Other|Placebo Wintergreen|Placebo Wintergreen lozenge containing no tobacco, nicotine, or silver salt, administered orally as a single dose.
1900470|NCT01336829|Drug|ETR/telaprevir|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
1900471|NCT01336829|Drug|TMC278/telaprevir|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
1900472|NCT01336829|Drug|telaprevir/ETR|Treatment A: ETR 200 mg twice a day from Day 1 to Day 10 + a single dose in the morning on Day 11. Treatment B: telaprevir 750 mg every 8 hours from Day 1 to Day 17 + 2 doses (morning and afternoon) on Day 18, and ETR 200 mg twice a day from Day 8 to Day 17 + a single dose in the morning on Day 18.
1900473|NCT01336829|Drug|telaprevir/TMC278|Treatment C: TMC278 25 mg once day from Day 1 to Day 11. Treatment D: telaprevir 750 mg every 8 hours from Day 1 to Day 18, and TMC278 25 mg once daily from Day 8 to Day 18.
1900563|NCT01337401|Drug|Placebo|30mg, once daily, oral until 24 weeks or disease progression if sooner
1900564|NCT01337414|Behavioral|VMS diary booklet|
1900474|NCT01336842|Drug|Panobinostat, Cisplatin, Pemetrexed|"Drug: Panobinostat Oral (by mouth) once daily every Monday, Wednesday, and Friday for the first two weeks of each three week cycle (as per dose escalation schedule (dose levels 1 and 2: AUC 5; dose levels 3 and 4: AUC 6). Number of cycles: 6 maximum.
Drug: Cisplatin IV (in the vein) on day 1 of a 21-day cycle Number of cycles: 6 maximum. Drug: Pemetrexed IV (in the vein) on day 1 of a 21-day cycle Other: Correlative studies Biomarker Analysis: blood collected pre-study and Cycles 2-6, Day 1."
1900475|NCT01336881|Genetic|RNA analysis|
1900476|NCT01336881|Genetic|gene expression analysis|
1900477|NCT01336881|Genetic|microarray analysis|
1900478|NCT01336881|Genetic|nucleic acid sequencing|
1900479|NCT01336881|Other|diagnostic laboratory biomarker analysis|
1900480|NCT01336894|Procedure|therapeutic conventional surgery|Undergo surgery
1900481|NCT01336894|Radiation|iodine I 125|Undergo seed implant radiotherapy
1900482|NCT01336894|Radiation|stereotactic body radiation therapy|Undergo radiotherapy
1900483|NCT01336920|Drug|carfilzomib|Given IV
1900484|NCT01336933|Drug|prednisone|Given PO
1900485|NCT01336933|Drug|cyclophosphamide|Given IV
1900486|NCT01336933|Drug|etoposide|Given PO or IV
1900487|NCT01336933|Drug|vincristine sulfate|Given IV
1900488|NCT01336933|Drug|pralatrexate|Given IV
1900489|NCT01336933|Other|laboratory biomarker analysis|Correlative studies
1900490|NCT01336933|Genetic|comparative genomic hybridization|Correlative studies
1900491|NCT01336933|Genetic|gene expression analysis|Correlative studies
1900492|NCT01336933|Genetic|nucleic acid sequencing|Correlative studies
1900493|NCT01336933|Genetic|mutation analysis|Correlative studies
1900494|NCT01336933|Other|immunohistochemistry staining method|Correlative studies
1900495|NCT01336933|Genetic|microarray analysis|Correlative studies
1900496|NCT01336933|Genetic|RNA analysis|Correlative studies
1900497|NCT01336946|Behavioral|Psycho educational and behavioural group sessions|10 psycho educational and behavioural group sessions on topics like the Food Triangle, healthy eating, the importance of physical activity, healthy eating on a limited budget, implementing physical activity into the daily life, the influence of advertisements...
1900498|NCT01336946|Behavioral|Walking session|A weekly supervised walking session (30 minutes) in a 10-week period.
1900502|NCT01336972|Drug|Tolvaptan|Tolvaptan was supplied as 15 and 30 mg tablets.
1900503|NCT01336985|Drug|Irinotecan|
1900504|NCT01336985|Procedure|Chemoembolization|
1900505|NCT01336985|Device|Drug-Eluting Beads|
1900506|NCT01336985|Procedure|Biopsy|
1900507|NCT01336998|Dietary Supplement|arginine|oral L-arginine supplementation 261mg/kg/day (1,5mmol/kg/day), one dose daily ,from the 3rd day of life until the 28th day of life
1900508|NCT01337011|Other|autologous CD133pos stem cell application|The study aims to show efficacy of both intra-myocardial autologous CD133pos bone marrow cell application as well as intra-coronary CD133pos cell application in patients with symptomatic ischemic heart disease. In addition, efficacy between the two delivery routes will be compared.
1900509|NCT01337037|Device|VATS lobectomy using modified equipments|"the procedure of this group is the same with standard VATS lobectomy group.the VATS surgical equipments used in the group are designed according to the experience of chinese lobectomy surgery. All the patent applications of the surgical equipments are granted. proprietor of the patents is Jun Wang, head of Department of Thoracic surgery of people's hospital, peking university.
Details of the modified equipments: Lobectomy Equipments Pack (Manufacturer B.J.ZH.F.Panther Medical Equipment Co.,Ltd.) consists of 8 basic surgical equipments, which are crafoord dissecting and ligature forcep, Yankauer suction tube, mixter dissecting and ligature forceps(long),mixter dissecting and ligature forceps(short), atraumatic-grip aorta-aneurysma clamp with toothing De Bakey, De Bakey atraumatic-grip vascular forcep, Bozemann tite grip needle holder, Winter placenta and ovum forcep."
1900510|NCT01337037|Procedure|VATS lobectomy using less staples|VATS lobectomy with at most 4 staples used, aimed at reduced hospital cost.This procedure is similar with the standard VATS lobectomy procedure without staples limits. The lobar vessels and bronchus are stapled. However, the interlobar fissures should be deal with electronic cautery, harmonic scalpel,or suturing.
1900511|NCT01337037|Procedure|Standard VATS lobectomy|VATS lobectomy without new equipments and limitation of staples, same with the current procedure of VATS lobectomy performed in thoracic departments of Peking university people's hospital and the Collaborators. All procedures were conducted under general anesthesia with double lumen intubation. The thoracoscope was introduced through 7th or 8th intercostals space on the mid-axillaries line. The 4 cm long utility incision was made on the 4th or 5th intercostals space anterior axillary's line without rib-spreading. A third retraction incision located on the 7th or 8th intercostals space sub-scapular line. The surgeon stands on the ventral side of patient using an electrocautery hook and a suction device through the utility incision. Anatomic lobectomy was performed with systemic mediastinal lymph node dissection for lung cancer patients.
1900512|NCT01337037|Procedure|Open lobectomy|standard lobectomy procedure by thoracotomy approach
1900513|NCT01337050|Drug|PF-03446962|PF 03446962 given by a 1 hour IV infusion. Each patient will initially receive the first dose on Cycle 1 Day 1 with a 28 day observation period. Cycle 2 will start on Day 29. The dosing interval will be 14 days for Cycle 2 and subsequent cycles.
1900514|NCT01337063|Other|Mentored medication reconciliation quality improvement|"Based on expert recommendations from a recent conference on medication reconciliation sponsored by the Society of Hospital Medicine and funded by AHRQ, investigators will engage a steering committee and conduct a second conference to operationalize these recommendations into a set of best practice guidelines, standards, and tools to be adapted by each of 6 participating sites. After training mentors and developing data collection tools, a mentored quality improvement project will be conducted for 21 months, in which each site works to improve medication reconciliation using the toolkit and with mentorship in the form of two site visits and monthly phone calls."
1900515|NCT01337076|Device|cochlear implant|Cochlear implant surgery
1900516|NCT01337089|Drug|Sativex®|Sativex® oromucosal spray administered orally with a spray into cheek
1900517|NCT01337102|Procedure|Physician Receives QoL results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician receives the print out of the results.
1900518|NCT01337102|Procedure|Physician Does not receive the results|Patient completes the Lung Cancer QoL scale on the Palm held computer device and the Physician does not receive the print out of the results.
1900519|NCT01337115|Procedure|SNB plus CFNB|A single shot sciatic nerve block (SNB) is performed with 25 ml of 0.2% ropivacaine before surgery in addition to an isolated continuous femoral nerve block (CFNB) in the control group
1900520|NCT01337115|Procedure|CFNB|A continuous femoral nerve block is performed for peri-operative analgesia and a bolus of 30 ml of ropivacaine 0.375% is injected before induction of general anesthesia and surgery starts. An infusion of 8ml/h of ropivacaine 0.2% is started in post anesthesia care unit (PACU) and maintained for 48h
1900521|NCT01337128|Procedure|Carotid endarterectomy (CEA)|Carotid endarterectomy (CEA) will be performed on the patients
1900522|NCT01337128|Procedure|Carotid stenting (CAS)|Carotid Stenting (CAS) will be performed on these patients.
1900523|NCT01337128|Procedure|Neurocognitive functions|Neurocognitive functions will be measured pre-operatively and after 3 weeks, 6 months and 1 year.
1900524|NCT01337128|Procedure|Levels of biomarkers|Levels of biomarkers (Protein S100B) will be examined pre- , peri- and post-operatively after 2 hours, 6 hours and 24 hours.
1900525|NCT01337128|Procedure|Detection of peri-operative embolization|A Transcranial Doppler Ultrasonography will be used to detect peri-operative embolization.
1900526|NCT01337128|Procedure|Validation results|On a subgroup of 20 patients a MRI-scan will be done pre- and post-operatively after 48 hours and 3 weeks.
1900527|NCT01337141|Other|Control|7 face-to-face visits.
1900528|NCT01337141|Device|Telecare system|5 telematic visits and 2 face-to-face visits.
1900529|NCT01337154|Drug|Tamibarotene|Tablet, 6 mg/m2, oral, divided into twice a day dosing.
1900530|NCT01337154|Drug|Placebo|Tablets, orally, daily
1900531|NCT01337167|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 4, and 6 months of age
1900532|NCT01337167|Biological|DAPTACEL™|DAPTACEL™ 0.5 mL intramuscular injection at 15 months of age
1900533|NCT01337167|Biological|PedvaxHIB™|PedvaxHIB™ 0.5 mL intramuscular injection at 15 months of age
1900534|NCT01337167|Biological|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
1900535|NCT01337167|Biological|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
1900536|NCT01337167|Biological|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 2, 4, and 6 months of age
1900537|NCT01337167|Biological|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
1900538|NCT01337167|Biological|ActHIB™|ActHIB™ 0.5 mL intramuscular injection at 15 months of age
1900539|NCT01337193|Other|Pelvic floor exercises with biofeedback|Exercises will be performed with assistance of biofeedback cueing
1900540|NCT01337193|Other|Pelvic floor muscle exercises|Exercises will b performed with verbal cueing of investigator.
1900541|NCT01337206|Device|Stenting with ELLA Biodegradable stent|Treating benign esophageal lesions with the placement of a degradable stent
1900542|NCT01337206|Procedure|Standard Dilations|Treating benign esophageal lesions with standard dilation therapy
1900543|NCT01337219|Drug|Tobramycin|
1900544|NCT01337232|Behavioral|Complex sentence treatment protocol|Treatment: listening, speaking, reading, and writing activities that teach three types of complex sentences. Individual sessions are 40 minutes in length, delivered by or under the supervision of a certified, trained speech-language pathologist.
1900545|NCT01337245|Drug|Snake (Micrurus) North American immune F(ab')2 Equine|5 vials of study drug reconstituted and diluted to 250 mL Normal Saline and administered intravenously.
1900546|NCT01337258|Drug|Dutasteride|dutasteride 0.5mg daily.
1900547|NCT01337258|Drug|Placebo|Men taking placebo daily
1900548|NCT01337271|Procedure|SBT- PSV|An Spontaneous breathing trial for 30 minutes on pressure support ventilation, which is a commonly used strategy to evaluate readiness for extubation
1900549|NCT01337271|Procedure|SBT - NAVA|An spontaneous breathing trial (SBT) on the ventilatory mode NAVA, with ventilatory support titrated to be similar to the support provided during an SBT on pressure support mode (PSV). NAVA captures the electrical activity of the diaphragm with an esophageal-gastric catheter, and uses the electrical signal to deliver inspiratory pressure proportional to the intensity of patient effort, as well as to trigger and cycle assisted mechanical breaths.
1900550|NCT01337297|Device|transcranial Direct Current Stimulation|transcranial Direct Current Stimulation (tDCS) will be applied by electrodes (5 x 7 cm2), with intensity of 2 mA, during 20 min, with cathode over the left dorsolateral prefrontal cortex (F3 site) and anode placed in the contralateral dorsolateral prefrontal cortex (F4 site).
1900551|NCT01337310|Drug|Tesetaxel|The starting dose for the first 3 patients treated will be 24 mg/m2. In the absence of dose-limiting toxicity, the dose will be increased by 3 mg/m2 for the next group of 3 patients treated. Interpatient dose escalation will continue in this manner to 27 and 31 mg/m2 until the maximum tolerated dose or the maximum dose allowed per protocol (31 mg/m2) is reached and 6 patients are treated at this dose.
1900552|NCT01337323|Drug|Fluticasone furoate nasal spray|fluticasone furorate intranasal steroid spray
1900553|NCT01337336|Drug|fluticasone propionate/salmeterol xinafoate|combination fluticasone priopionate and salmeterol xinafoate 250/50mcg
1900554|NCT01337336|Drug|Anticholinergics|tiotropium; ipratropium alone; or ipratropium + albuterol
1900555|NCT01337349|Drug|Placebo|Sugar Pill 400mg taken orally three times a day for 6 months
1900556|NCT01337349|Drug|Pentoxifylline|Pentoxifylline 400mg taken orally Three times a day for 6 months
1900557|NCT01337362|Procedure|Insulin clamp|Patients will be exposed to low bloodsugar
1900558|NCT01337375|Drug|peginterferon alfa 2a [Pegasys]|sc weekly
1900559|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv weekly
1900560|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|sc twice weekly
1900561|NCT01337375|Drug|peginterferon alfa-2a [Pegasys]|iv twice weekly
1900562|NCT01337401|Drug|Cediranib|30mg once daily, oral until disease progression
1900566|NCT01337427|Drug|BIIB017|BIIB017 is supplied as a liquid in pre-filled syringes to deliver 0.5 mL of 0.25 mg/mL (125 mcg dose) of 20 kDa mPEG-O-2-methylpropionaldehyde-modified human IFN β-1a in 20 mM acetic acid/sodium acetate buffer pH 4.8, 150 mM arginine hydrochloride, and 0.005% Polysorbate 20.
1900567|NCT01337440|Drug|UDCA|"Sitagliptin: 50 mg, po, qd for 12 weeks, then UDCA add-on therapy for additional 12 weeks.
UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
1900568|NCT01337440|Drug|Sitagliptin|"UDCA for 12 weeks, then Sitagliptin add-on therapy for additional 12 weeks.
UDCA dosage: dosing from 600 mg for initial 4 weeks. Then, if there is no adverse effect, UDCA is escalated to 900 mg, po, tid."
1900569|NCT01337466|Radiation|[124I]FIAU|This is a single dose study of 2 mCi [124I]FIAU in healthy volunteers or subjects with prosthetic joint infection of the knee or hip who will undergo serial PET-CT scanning.
1900570|NCT01337492|Drug|Nexavar|400 mg of Sorafenib
1900571|NCT01337505|Drug|INNO-206|INNO-206 at dosages of 230, 350, and 450 mg/m2 (doxorubicin equivalents of 165, 260, and 325 mg/m2) will be administered as a 30 minute IVI on Day 1 of each cycle.
1900572|NCT01337518|Drug|EZN-4176|EZN-4176 can be administered as a weekly one-hour i.v. infusion; weekly for 3 weeks followed by a 1 week rest; or 1 out of 2 weeks (every other week)
1900573|NCT01337531|Drug|Gonal-F, Fostimon|dosage form
1900574|NCT01337531|Drug|Gonal-F, Fostimon|injection, daily, 10-15 days
1900575|NCT01337544|Other|HAPLOIDENTICAL IL-15 STIMULATED NK CELLS|ONE MEGADOSE 30 DAYS AFTER TRANSPLANTATION (DOSE WILL DEPEND ON PATIENT BODY WEIGHT)
1900576|NCT01337557|Drug|Bepotastine|1.5% bid
1900577|NCT01337570|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
1900578|NCT01337570|Other|Placebo|Vaginal Ring containing no drug substance
1900579|NCT01337570|Drug|Dapivirine|
1900580|NCT01337583|Other|Dapivirine|Vaginal ring containing 25mg dapivirine; one ring inserted every 28 days for at least 15 months
1900581|NCT01337583|Other|Placebo|Vaginal Ring containing no drug substance
1900582|NCT01337583|Drug|Dapivirine|
1900583|NCT01337596|Drug|LY2951742|Administered subcutaneously
1900584|NCT01337596|Drug|Placebo|Administered subcutaneously
1900585|NCT01337609|Drug|Ganeden BC30|2 billion CFU per capsule; One pill daily for 60 days
1900586|NCT01337609|Other|Placebo (sugar pill)|1 pill daily for 60 days
1900587|NCT01337609|Other|Ganeden BC30, Placebo (sugar pill)|Ganeden BC30 (2 billion CFU per capsule), One capsule daily for 30 days Sugar Pill (placebo), One capsule daily for 30 days
1900588|NCT01337622|Procedure|No check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on clinical examination of the abdomen and gastric aspirates containing blood or significant vomiting.
1900589|NCT01337622|Procedure|Routine check of gastric residuals for early enteral feeding advancement|Discontinuation of gastric feeding and its advancement will be based on current practice of clinical examination of the abdomen and checking residual before every feed. Volume and color of gastric residual will be considered according to the current guideline.
1900590|NCT01337635|Drug|Vitamin D|Ergocalciferol 300,000 IU single oral dose Cholecalciferol 400 IU orally every day for 6 weeks
1900591|NCT01337674|Drug|MK-4618|Once daily oral dose of MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
1900592|NCT01337674|Drug|Placebo for MK-4618|Once daily oral dose of placebo for MK-4618 100 mg (two 50 mg tablets) on Days 1 through 7
1900593|NCT01337674|Drug|Metoprolol|Previously prescribed daily dose of open-label metoprolol for the duration of the study
1900594|NCT01337674|Drug|Amlodipine|Previously prescribed daily dose of open-label amlodipine for the duration of the study
1900599|NCT01337713|Other|Swedish Massage|Swedish massage, 45 minutes, 2 x per week for 6 weeks
1900600|NCT01337713|Other|Light Touch|Light touch, 45 minutes, 2 x week for 6 weeks
1900601|NCT01337726|Behavioral|Combined Psychotherapy and Illness Management|Participants will have 10 weekly visits with a study clinician at their home and by phone. They will focus on their self care and illness management as well as how to manage their mood/cope emotionally. Follow up assessments will occur at 26 and 52 weeks.
1900602|NCT01337726|Behavioral|Illness Management Only|Participants in this group will have 10 weekly sessions with a study clinician at home and by phone. They will focus only on how they manage their illness. Follow up assessments will occur at 26 and 52 weeks.
1900603|NCT01337739|Drug|Placebo Comparator|Placebo administration (.9 normal saline sterile)
1900604|NCT01337739|Drug|Active Comparator|Administration of Dexmedetomidine
1900605|NCT01337752|Drug|BHQ880|
1900606|NCT01337752|Drug|BHQ990|
1900607|NCT01337765|Drug|BEZ235 + MEK162|
1900608|NCT01337778|Behavioral|Primary care for Daughters-in-Law|Primary care for DILs will be offered based on national and international standards and include access to critical support services for women who have experienced GBV.A comprehensive health examination for MILs will include a gynecological exam and screening for diabetes and hypertension, along with appropriate information, prescriptions, and/or referrals. We will routinely offer GBV-related resources, such as information, counseling, and referrals to all participants. Referrals will be documented using a Referral Care Form and reviewed on a routine basis to ensure that appropriate care is being provided and to detect any potential study-related risks.
1900633|NCT01337973|Behavioral|MI-CBT+CC|Acute phase MI-CBT intervention plus a subsequent 12-week phone based continuing care counseling intervention
1900634|NCT01337973|Behavioral|E-TAU|Enhanced Treatment as Usual
1900764|NCT01332552|Drug|GSK2485852 420 mg|Repeat dose, twice daily for 3 days
1900609|NCT01337778|Behavioral|The Dil Mil Intervention|The Dil Mil intervention will be implemented during the second and third trimesters of the DILs' pregnancy. It consists of 2 half-day group sessions with DILs, 5 half-day group sessions with MILs, and one joint half-day session with DILs and MILs. The sessions are based on participatory learning and action principles and use stories, role-play, and discussion to enhance participants' knowledge, skills, and social support. Participants are encouraged to critically analyze their relationships and to develop and implement responses appropriate to their families and communities. The DIL-MIL joint session ends in a short celebration (based on a traditional ritual) in which MILs bless their DILs, and the MIL sessions culminate in a ceremony in which MILs' position in the family and community is recognized and celebrated. MILs draw up a family health action plan and take a pledge to reduce GBV and protect and promote their family's health.
1900610|NCT01337791|Drug|Telbivudine treatment|Two arms in this study, One is Telbivudine 600 mg by mouth daily from late pregnancy to 28 weeks of post partum. Another arm is clinical observation only without telbivudine treatment
1900611|NCT01337804|Drug|omeprazole/sodium bicarbonate|Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension
1900612|NCT01337804|Drug|omeprazole magnesium|Single 40 mg capsule of omeprazole given orally
1900613|NCT01337817|Other|Ariva Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
1900614|NCT01337817|Other|Ariva Wintergreen|Comparator product, a compressed dissolvable smokeless tobacco lozenge containing 2 mg nicotine administered orally as a single dose.
1900615|NCT01337830|Other|Ariva® Silver Wintergreen|Study product containing 6 mg silver salt and 2 mg nicotine per dissolvable lozenge, administered orally as a single dose.
1900616|NCT01337830|Other|Silver Wintergreen|Comparator product containing 6 mg silver salt and no tobacco (i.e., no nicotine), administered orally as a single dose.
1900617|NCT01337843|Other|Wellness Workbook|A web-based cognitive behavioral pain management intervention to help individuals with chronic low back pain (CLBP) learn adaptive coping and pain management skills, increase physical activity and manage stress. This is a 10 week intervention. Participants use one chapter of the workbook each week. Each chapter takes approximately 1.5 hours to complete.
1900618|NCT01337843|Other|Pain Management Print Materials|Print materials comparable to the content within Wellness Workbook
1900619|NCT01337856|Other|Hand hygiene protocol|Comparison of efficacy of 3 hand hygiene protocols
1960990|NCT03043222|Device|UroLift as artifical device for prostatic urethral lift.|UroLift as artifical device for prostatic urethral lift. The PUL treatment is a minimally invasive approach to treating an enlarged prostate, or BPH, that lifts or holds the enlarged prostate tissue using clips so that it is out of the way so it no longer blocks the urethra. There is no cutting, heating or removal of prostate tissue.
1960991|NCT03043222|Device|Embospheres Microspheres as embolic agents for prostate artery embolization|Embospheres Microspheres as embolic agents for prostate artery embolization Arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery to the prostate gland.Small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the enlarged prostate. The prostate is then expected to shrink , thus relieving urinary symptoms related to prostate enlargement.There is no cutting or removal of prostate tissue.Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
1900622|NCT01337882|Other|Forearm venous occlusion plethysmography study|Forearm venous occlusion plethysmography to measure forearm blood flow during unilateral intrabrachial infusion of endothelium-dependent (bradykinin [100, 300 & 1000 pmol/min]; acetylcholine [5, 10 & 20 µg/min]) and -independent [sodium nitroprusside [2, 4 & 8 µg/min]; verapamil [10, 30 & 100 µg/min]) vasodilators. Each drug to be infused for 6 mins at each dose in increasing concentrations. 0.9% sodium chloride will be infused for 20 min between each individual drug to allow washout.
1900623|NCT01337895|Other|Low dairy|No more than 1 serving per day
1900624|NCT01337895|Other|High dairy|4 or more servings per day
1900625|NCT01337921|Dietary Supplement|Multi-strain Probiotic|Multi-strain Synbiotic: 1.5 billion CFU of Lactobacillus acidophilus, Bifidobacterium bifidum,and Bifidobacterium lactis WITH galacto-oligosaccharide(GOS)/fructo-oligosaccharide (FOS) combination at 1g/dL (0.9g/dL GOS/ 0.1g/dL FOS)
1900626|NCT01337934|Drug|Lactated Ringer|Lactated Ringer
1900627|NCT01337934|Drug|Albumin|Albumin 4%
1900628|NCT01337947|Drug|Definity microbubbles|Definity microbubbles are used as a contrast agent to image blood flow in skeletal muscle
1900629|NCT01337960|Behavioral|Seated Robot Training (SRT)|Participants at least 6 mos. post-stroke will use the ankle robot in a seated visuo-motor training paradigm. They will train on the robot 3x weekly for 6-weeks (18 sessions) by playing videogames with the paretic ankle. They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
1900630|NCT01337960|Behavioral|Treadmill Locomotor-based Training (TMR)|Treadmill training with ankle robot group. Participants at least 6 mos. post-stroke will wear the ankle robot during treadmill locomotor training. They will walk on a treadmill with the ankle robot adjusted to promote paretic ankle engagement during 3 x weekly training sessions over 6 weeks (18 sessions). They will be evaluated on outcomes at baseline, post-6 weeks training, and again after a 6-week retention period with no training.
1900631|NCT01337960|Behavioral|Treadmill Only (TMO)|Treadmill only group. This group will consist of participants at least 6 mos. post-stroke who engage in treadmill training 3x weekly for 6 weeks without robotic support. They will be volunteers from another treadmill training study and evaluated on outcomes at baseline and post-6 weeks training. They will not receive retention testing at 12 weeks because they will be continuing with regular treadmill training beyond the 6-week period.
1900632|NCT01337973|Behavioral|MI-CBT|Six individual psychotherapy sessions during the acute substance use disorder treatment phase integrating motivational interviewing and cognitive behavioral approaches
1900708|NCT01332227|Drug|Ritonavir (heat-stable)|Tablets, Oral, 100 mg, Once daily, 48 weeks
1960993|NCT03041454|Other|Novel systematic review format|A 2-page summary of systematic review content that has been designed in collaboration with policy makers and health care managers.
1900637|NCT01337999|Other|blood draws|5 blood draws during ovulatory menstrual cycles in premenopausal women
1900638|NCT01338012|Biological|sipuleucel-T|Sipuleucel-T is an autologous cellular product consisting of antigen presenting cells (APCs) activated with PA2024, a recombinant fusion protein composed of prostatic acid phosphatase (PAP), linked to granulocyte-macrophage colony-stimulating factor (GM-CSF).
1900639|NCT01338025|Drug|HAART regimen|The study participant continued their non-suppressive HAART regimen as prescribed by their primary provider.
1900640|NCT01338025|Drug|3TC or FTC monotherapy|The study participant was assigned to either 3TC or FTC monotherapy (the choice of 3TC or FTC was left to the provider.
1900641|NCT01338051|Biological|Gardasil|"Gardasil will be administered to 10-13 year old daughters and granddaughters of study participants according to manufacturers recommended schedule of administration. Gardasil is supplied as 0.5-mL suspension for intramuscular injection at the following schedule: 0, 2 months, 6 months.
DOSAGE FORMS AND STRENGTHS • 0.5-mL suspension for injection as a single-dose vial and prefilled syringe."
1900642|NCT01338077|Drug|Sodium alginate|oral suspension, 50 mg/ml, 20 ml three times daily, 4 weeks
1900643|NCT01338077|Drug|Omeprazole|20 mg capsule, 1 capsule once daily, 4 weeks
1900644|NCT01338090|Drug|89Zr-bevacizumab|Intravenous injection 120 MBq
1900645|NCT01338090|Drug|Everolimus|Oral use, 10 mg per day
1900646|NCT01338103|Drug|Rituximab|intravenous (IV) Rituximab 1 gramX2, every (q) 2 weeks.
1900647|NCT01338116|Other|antibiotic treatment of by TREAT/PCR|Management by TREAT/PCR. The data available at the time of patient recruitment will be entered into TREAT. TREAT will provide advice for the empirical antibiotic treatment and unless the caring physician can justify a deviation from this recommendation, TREAT's recommendation will be implemented (yes or no antibiotic treatment and type of antibiotic). TREAT will also recommend whether a blood sample for PCR should be obtained. Blood will be collected aseptically and the test will be performed once daily between 1000AM-1700PM (results available daily at 1700 PM). PCR results and a PCR-revised TREAT recommendation will be reported to the patient's physician in charge and treatment will be revised accordingly. On day 2, when results of blood cultures and other cultures become available TREAT will be re-consulted and will issue a new recommendation based on the full microbiological investigation (negative and positive results).
1900648|NCT01338129|Dietary Supplement|vitamin c|1000 mg of vitamin c for 45 days
1900649|NCT01338129|Drug|placebo|placebo pills
1900650|NCT01338142|Other|CCC|"600 mg (2 capsules of 300 mg) for oral use of 480 mg CCC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca and 120 mg of inactive filler, sucrose.
1.5 mg of 42Ca labeled CaCl2 through IV injection"
1900651|NCT01338142|Other|ACC|600 mg (2 capsules of 300 mg) for oral use containing 600 mg ACC (192 mg elemental calcium) intrinsically labeled with 15 mg 44Ca 1.5 mg of 42Ca labeled CaCl2 through IV injection
1900652|NCT01338298|Drug|Aripiprazole|Aripiprazole dosing will begin at 5 mg/day once daily and increased to 10mg by mouth once daily at the end of week 2 and then increased to 15 mg/day once daily at the end of week 8 in women who have not yet regained their menstrual period. If a woman gets her menstrual period on the 5 or 10 mg dose she will remain on this dose for the study.
1900653|NCT01338298|Drug|Placebo|The placebo will be sucrose filled capsules that are identical to the active medication. It is double blind so no one will know if the capsule is placebo or aripiprazole.
1900654|NCT01338311|Drug|salbutamol|200mcg twice daily for a total of 7 doses
1900655|NCT01338311|Drug|Placebo|200mcg twice a day for a total of 7 doses (3.5 days).
1900656|NCT01338324|Drug|Simvastatin|Simvastatin 20 mg single dose on day 1
1900657|NCT01338337|Drug|Azacitidine|Azacitidine 75 mg/m2, for 5 days of each 20 day cycle. Transfusional support will be applied for symptomatic anaemia using clinical discretion and chelation therapy when ferritin is ≥ 1000 μgr/ml with the chelating agents allowed
1900658|NCT01338350|Drug|AZD5423|Inhalation, suspension
1900659|NCT01338350|Drug|Placebo|Inhalation, solution
1900660|NCT01338376|Behavioral|Structured Education|"All of the educators who are responsible for the intensive group will be trained with the standard contents before the study kick-off.
Educator Activities: insulin injection, SMBG instruction, self-learned manuals, periodic assessment for subjects, subject counseling, self-care education (healthy eating, exercise, weight control), prevention and treatment of hypoglycemia complication education ,newsletter delivered by SMS
Physician Activity: frequent insulin titration"
1900661|NCT01338376|Behavioral|Conventional Diabetes Education|"The activities of the educators who are responsible for conventional group are identical with their routine clinical practice.
Educator Activities: insulin injection, SMBG instruction, healthy eating , prevention and treatment of hypoglycemia
Physician Activity: less frequent insulin titration"
1900662|NCT01338376|Drug|Scilin®M30|Subjects will be treated with Scilin®M30 twice daily
1900663|NCT01338389|Dietary Supplement|CITICOLINE|"Oral administration of CITICOLINE:
Form: Powder for solution Dosage: 800mg per day duration: 5 years"
1900664|NCT01338389|Dietary Supplement|PLACEBO|"Oral administration of placebo:
Form: Powder for solution duration: 5 years"
1900665|NCT01338402|Device|Lotrafilcon B contact lens|Silicone hydrogel contact lens
1900666|NCT01338402|Device|Lotrafilcon B contact lens with color|Silicone hydrogel contact lens with color
1900667|NCT01338402|Device|Phemfilcon A contact lens with color|Hydrogel contact lens with color
1900709|NCT01332227|Drug|Raltegravir|Tablets, Oral, 400 mg, Twice daily, 48 weeks
1900710|NCT01332227|Drug|Tenofovir/Emtricitabine|Tablets, Oral, 300/200 mg, Once daily, 48 weeks
1900711|NCT01332240|Procedure|Endoscopic ultrasonography|in order to stage the mediastinum
1900712|NCT01332253|Drug|Intravenous ibuprofen|Participants will receive a single 10mg/kg dose of intravenous ibuprofen diluted in normal saline at the induction of anesthesia.
1900765|NCT01332552|Drug|GSK2485852 420 mg|Repeat dose, TIDfor 3 days
1900670|NCT01338428|Behavioral|Enhanced AAA Sexual Assault Resistance Education|Resistance Program: 4x3-hour units. Unit 1 (Assess) accurate assessment of sexual assault risk. Provides: empirically-based information on situational and (male) behavioural danger cues; practice identifying risk and counteracting it. Unit 2 'Acknowledge[ment]' of risk when present. Includes: women's sexual rights; emotional barriers; tactics used by coercive men; practice. Unit 3 (Act) includes: assessing whether or not an escape is possible; research evidence on the effectiveness of resistance strategies; physical self-defense training. Unit 4 applies content to longer term relationships covering: comfort talking about sexuality, identification of sexual values, practices beyond intercourse, and articulation of relationship goals.
1900671|NCT01338428|Behavioral|Brochure|Current 'standard of care' at Canadian universities. Invitation to take and read brochures on sexual assault selected from those available on their Canadian university campus. All sites' brochures include general information on sexual assault and 'date-rape' drugs and post-rape legal and medical advice. The research assistant (RA) will ask the participants to take brochures, read them over, and to ask any questions they may have. Questions will be answered in a group setting and the participant will take home any brochures that she selected. Interaction between participants and the RA on the topic will be limited to 10-15 minutes and will be audio recorded for verification.
1900672|NCT01338441|Drug|Erythromycin|4mg/Kg, IV during 20 min once
1900673|NCT01338441|Drug|Placebo|4mg/Kg, IV during 20 min once
1900674|NCT01338454|Drug|transamin|TA was administered intravenously over a 5 min period at delivery of the anterior shoulder
1900675|NCT01338467|Device|EYEOP device|Cyclocoagulation using High Intensity Focused Ultrasound with EYEOP device
1900676|NCT01338480|Other|video|The videos will be developed and contain information on the procedure, risks, benefits, and alternatives of the surgery. The knowledge measure instrument will also be developed.
1900677|NCT01338493|Procedure|lumbar spinal arthroplasty + Maverick™|All patients will be subjected to a lumbar spinal arthroplasty. The anterior lumbar spine is approached through either a transperitoneal or retroperitoneal exposure. A complete anterior discectomy is performed and the Maverick™ Artificial Disc System is inserted to replace the damaged lumbar intervertebral disc.
1900678|NCT01338506|Behavioral|Concurrent Treatment with Prolonged Exposure (COPE)|12 weeks of concurrent prolonged exposure treatment for PTSD combined with cognitive behavioral therapy for substance use disorders (alcohol or drugs).
1900679|NCT01338532|Other|A 12 week supervised exercise program and patient education|"The exercise protocol included exercises from former studies on comparable patient populations. The intensity of the strength- and flexibility exercises meets the American College of Sports Medicine's (ACSM) recommendations for developing and maintaining muscular fitness in adults. Patients was required to exercise for approximately 60 minutes, to-three days a week for 12 weeks. Patient's attendance to the exercise program (compliance) was registered.
All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time."
1900680|NCT01338532|Other|Patient education|All patients included in the study participated in a patient education program which included two individual and three small-group sessions lasting one hour each time.
1900681|NCT01332045|Procedure|continuous saphenous nerve block|Postoperative intermittent boluses of 15 Ml Ropivacaine 7,5 mg/Ml every 12 hours for three days
1900682|NCT01332045|Procedure|Saline boluses in nerve catheter|A nerve catheter will be placed in the adductor canal using saline instead of Ropivacaine for intermittent boluses.
1900683|NCT01332058|Behavioral|Motivational Interviewing|8 possible weeks of motivational interviewing sessions
1900684|NCT01332071|Drug|Rosiglitazone Maleate + Metformin 2 miligrams (mg) + 500 mg|Avandamet reference product
1900685|NCT01332071|Drug|Rosiglitazone Maleate + Metformin 4 miligrams (mg) + 1000 mg|Avandamet test product
1900686|NCT01332084|Other|HA wheat cereals|HA wheat cereals used in SOTI test and as part of desensitization plan
1900690|NCT01332110|Device|Knee abduction moment-reducing footwear|Patients in each study group will be asked to run using their assigned footwear at least 3 times per week (minimum 15 km per week) for six weeks. Each patient will document their perceived knee pain each week throughout the six week intervention.
1900691|NCT01332123|Device|Alignment perturbations|Increased foot plantar flexion, increased foot dorsal flexion, increased foot supination, increased foot pronation (always 2 degrees from the neutral position)
1900692|NCT01332149|Drug|Pregabalin|"Subjects in the pregabalin group will start treatment with pregabalin capsule 150 mg/day for 1 week, then their dose will be increased to 300mg/day. After 1-week titration period, dose must be stable during study, no dose adjustment is permitted, and subject who cannot tolerate 300 mg/day pregabalin will be withdrawn.
At the completion of the dose maintenance phase subjects will taper off study medication over a 1-week period. 300 mg/ day subjects will taper to 150 mg/ day."
1900693|NCT01332149|Drug|Placebo matched with pregabalin|Subject will take placebo matched with pregabalin twice a day.
1900694|NCT01332162|Device|Biventricular pacing|All patients will be pacing during two years
1900695|NCT01332162|Device|No Pacing|No Pacing during the first year. In the second year all patients will be pacing
1900696|NCT01332175|Device|Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
1900697|NCT01332175|Device|Placebo-Provent®|Nightly use of Provent® versus Placebo-Provent® versus CPAP
1900698|NCT01332175|Procedure|CPAP|Nightly use of Provent® versus Placebo-Provent® versus CPAP
1900699|NCT01332188|Drug|AC-170 0.05%|1 drop in each eye at 3 separate times during a 21 day period
1900700|NCT01332188|Drug|AC-170 0.1%|1 drop in each eye at 3 separate times during a 21 day period
1900701|NCT01332188|Drug|AC-170 0.24%|1 drop in each eye at 3 separate times during a 21 day period
1900702|NCT01332188|Drug|AC-170 0%|1 drop in each eye at 3 separate times during a 21 day period
1900703|NCT01332201|Drug|Advagraf|oral
1900704|NCT01332201|Drug|Prograf|oral
1900705|NCT01332214|Drug|AZD2820|Subcutaneous Injection in abdomen or Thigh
1900706|NCT01332214|Drug|Placebo|Subcutaneous Injection in abdomen or Thigh
1900707|NCT01332227|Drug|Atazanavir|Capsules, Oral, 300mg, Once daily, 48 weeks
1900762|NCT01332552|Drug|placebo|single dose
1900713|NCT01332253|Other|Normal Saline|Participants will receive a comparable weight based volume of normal saline as a placebo comparator at the induction of anesthesia.
1900714|NCT01332266|Drug|E7050|E7050 given orally at 200, 300, or 400 mg once daily.
1900715|NCT01332266|Drug|Cetuximab|Cetuximab is given at an initial dose of 400 mg/m2 given as a 2-hour intravenous (IV) infusion on Day 1 of Cycle 1, followed by a dose of 250 mg/m2 given as a 1-hour IV infusion on Day 8, Day 15, and Day 22 of Cycle 1, and Day 1, Day 8, Day 15, and Day 22 of each subsequent cycle.
1900716|NCT01332279|Drug|everolimus|Given PO
1900717|NCT01332279|Drug|erlotinib hydrochloride|Given PO
1900718|NCT01332279|Procedure|biopsy|Correlative studies
1900719|NCT01332279|Other|laboratory biomarker analysis|Correlative studies
1900720|NCT01332279|Other|immunohistochemistry staining method|Correlative studies
1900721|NCT01332279|Genetic|polyacrylamide gel electrophoresis|Correlative studies
1900722|NCT01332279|Other|pharmacological study|Correlative studies
1900723|NCT01332279|Radiation|external beam radiation therapy|Undergo EBRT
1900724|NCT01332279|Genetic|microarray analysis|Correlative studies
1900725|NCT01332292|Drug|Fluticasone furoate|Novel dry powder inhaler: 100µg per blister One blister strip containing fluticasone furoate micronised drug blended with lactose and a second blister strip containing lactose and magnesium stearate.
1900726|NCT01332292|Drug|Matching placebo|Novel dry powder inhaler: One blister strip containing lactose and a second blister strip containing lactose and magnesium stearate.
1900727|NCT01332305|Drug|GEn (XP13512/GSK1838262)|Double-Blind Treatment Phase: 600 mg GEn (XP13512) orally, once daily for 3 days followed by 600 or 1200 mg on days 4-6, followed by 600 or 1200 or 1800 mg on days 7-9, followed by 600 or 1200 or 1800 or 2400 mg on days 10-84. Double-Blind Taper Phase: 600 or 1200 or 1800 mg GEn (XP13512) orally, once daily on days 85-86, followed by 600 mg or 1200 mg on days 87-88, followed by 600 mg on days 89-91
1900728|NCT01332305|Drug|Placebo|Placebo orally once daily
1900729|NCT01332318|Drug|XP13512|XP13512 once daily for 16 days
1900730|NCT01332318|Drug|Diphenhydramine|one 50 mg dose of diphenhydramine (DPH) on day 16
1900731|NCT01332318|Drug|Placebo|XP13512 placebo once daily for 16 days
1900732|NCT01332331|Drug|Ambrisentan - low dose|body weight 20 to 35 kg - 2.5 mg; body weight 35 kg and over - 5.0 mg
1900733|NCT01332331|Drug|Ambrisentan - high dose|body weight 20 to 35 kg - 5.0 mg; body weight 35 to 50 kg - 7.5 mg; body weight 50 kg and over - 10.0 mg
1900734|NCT01332344|Drug|Fluticasone propionate/salmeterol combination|Asthma subjects newly prescribed fluticasone propionate/salmeterol combination
1900735|NCT01332344|Drug|Inhaled corticosteroids|asthma subjects newly prescribed inhaled corticosteroids in clinical practice
1900736|NCT01332357|Drug|Fluticasone propionate/salmeterol combination ED MD|Receipt of fluticasone propionate/salmeterol combination from the ED physician
1900737|NCT01332357|Drug|Fluticasone propionate/salmeterol combination OP MD|Receipt of fluticasone propionate/salmeterol combination from the OP physician
1900738|NCT01332370|Drug|Rosiglitazone + Metformin|At least 180 days of continuous therapy with RSG+MET after the first Rx for RSG
1900739|NCT01332370|Drug|Sitagliptin + Metformin|At least 180 days of continuous therapy with STG+MET after the first Rx for STG
1900740|NCT01332383|Drug|Naratriptan|
1900741|NCT01332396|Drug|Lapatinib|
1900742|NCT01332409|Drug|Salmeterol and Fluticasone|Administered according to the prescribing information in the locally approved label by the authorities.
1900743|NCT01332422|Drug|Salmeterol and Fluticasone|Collection of safety data
1900744|NCT01332435|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride AB: Doxazosin, Tamsulosin, Terazosin, or Alfuzosin
1900745|NCT01332448|Drug|Orlistat 120|Orlistat 120mg tid
1900746|NCT01332448|Drug|Orlistat 60|Orlistat 60mg tid
1900747|NCT01332461|Drug|fluticasone propionate/salmeterol xinafoate combination|Patients filling a prescription for fluticasone/salmeterol combination as index drug
1900748|NCT01332461|Drug|Other maintenance Treatments (OMT)|OMT group includes tiotropium, ipratropium alone or in combination with albuterol, inhaled steroids, long acting beta agonists
1900749|NCT01332474|Drug|BOTOX|BOTOX
1900750|NCT01332487|Drug|5ARI + AB|5ARI: Dutasteride or Finasteride and any AB: Doxazosin, Prazosin, Tamsulosin, Terazosin or Alfuzosin
1900751|NCT01332500|Drug|Sumatriptan/Naproxen combination|Sumatriptan and Naproxen Sodium
1900752|NCT01332500|Drug|other oral triptans|almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, sumatriptan, zolmitriptan
1900753|NCT01332513|Drug|Investigational Medicinal Product (MR1)|Ezogabine MR1 at a dose strength of 300 mg will be orally administered with approximately 250 milliliter (mL) of water to group A subjects during the bioavailability phase. For the food effect phase subjects in group G will be orally administered MR1 tablets at a dose strength of 600 mg.
1900754|NCT01332513|Drug|Investigational Medicinal Product (MR2)|Ezogabine MR2 at a dose strength of 300 mg will be orally administered to group B subjects with approximately 250 mL of water during the bioavailability phase. For the food effect phase subjects in group H will be orally administered MR2 tablets at a dose strength of 600 mg.
1900755|NCT01332513|Drug|Investigational Medicinal Product (MR3)|Ezogabine MR3 will be orally administered with approximately 250 mL of water to group C subjects during the bioavailability phase. For the food effect phase subjects in group I will be orally administered MR3 tablets at a dose strength of 600 mg.
1900756|NCT01332513|Drug|Investigational Medicinal Product (MR4)|Ezogabine MR4 will be orally administered with approximately 250 mL of water to group D subjects during the bioavailability phase. For the food effect phase subjects in group J will be orally administered MR4 tablets at a dose strength of 600 mg.
1900757|NCT01332513|Drug|Investigational Medicinal Product (MR5)|Ezogabine MR5 will be orally administered with approximately 250 mL of water to group E subjects during the bioavailability phase. For the food effect phase subjects in group K will be orally administered MR5 tablets at a dose strength of 600 mg.
1900758|NCT01332513|Drug|Investigational Medicinal Product (IR)|Ezogabine IR at dose strengths of 50 mg and 200 mg will be orally administered with approximately 250 mL of water.
1900759|NCT01332539|Other|no intervention|non-interventional study
1900760|NCT01332552|Drug|GSK2485852 70 mg|single dose
1900761|NCT01332552|Drug|GSK2485852 420 mg|single dose
1900766|NCT01332552|Drug|GSK2485852 630 mg|Repeat dose, twice daily for 3 days
1900767|NCT01332552|Drug|GSK2485852 70 mg + Ritonavir 100mg|single dose, day 1
1900768|NCT01332552|Drug|GSK2485852 210 mg + Ritonavir 100mg|single dose, day 1
1900769|NCT01332552|Drug|GSK2485852 210 mg +Ritonavir 100mg|single dose daily for 3 days
1900770|NCT01332565|Drug|GSK1349572|50mg tablet
1900771|NCT01332578|Drug|Paracetamol|Present in both test and active comparator
1900772|NCT01332578|Drug|Phenylephrine|Test product
1900773|NCT01332578|Drug|Ascorbic Acid|Test product
1900774|NCT01332591|Procedure|Percutaneous coronary intervention|"PCI of significant stenoses of non-infarct coronary arteries"
1900775|NCT01332604|Drug|GDC-0980|Oral escalating dose
1900776|NCT01332604|Drug|bevacizumab|Intravenous repeating dose
1900777|NCT01332604|Drug|capecitabine|Oral repeating dose
1900778|NCT01332604|Drug|mFOLFOX6|Intravenous repeating dose
1900779|NCT01332617|Drug|Simvastatin,Zoledronic Acid,Bortezomib,Bendamustine,Methylprednisolone.|"Simvastatin 80 mg PO daily starting day -2 through day 10.
Zoledronic acid 4 mg IV over 15 minutes on day 1 and then monthly
Bortezomib 1.3 mg/m2/day IV bolus on days 3,6 and 10.
Bendamustine 100 mg/m2/day IV over 30 minute infusion on days 3 and 10.
Methylprednisolone 1g/m2 IV over 30 minutes on days 1 and 8."
1900780|NCT01332630|Drug|TPI 287|"Starting dose Phase I: 160 mg/m2 by vein over 60 minutes on Days 1, 8, and 15 of every 28 day cycle.
Starting Dose Phase II: Maximum tolerated dose from Phase I."
1900781|NCT01332630|Drug|Dexamethasone|6 mg by mouth at 12 hours and 6 hours prior to treatment. As alternative and based on the treating physician discretion, dexamethasone 10 mg by vein may be given 30-60 minutes prior to treatment with TPI 287.
1900782|NCT01332630|Drug|Benadryl|12.5-25 mg intravenous (IV) push 30-60 minutes prior
1900783|NCT01332630|Drug|Ranitidine|As H2 blocker 1mg/kg IV 30-60 minutes prior
1900784|NCT01332643|Genetic|Preimplantation Genetic Diagnosis|All embryos in the test group reaching blastocyst stage will undergo embryo biopsy of 3-10 trophectoderm cells. The cells will be analyzed by array CGH to detect the presence or not of chromosome abnormalities. The embryos will be vitrified and those classified by array CGH as normal, thawed for replacement.
1900785|NCT01332656|Drug|Ombrabulin (AVE8062)|"Pharmaceutical form:solution
Route of administration: intravenous"
1900786|NCT01332656|Drug|Placebo|"Pharmaceutical form:solution
Route of administration: intravenous"
1900787|NCT01332656|Drug|Paclitaxel|"Pharmaceutical form:solution
Route of administration: intravenous"
1900788|NCT01332656|Drug|Carboplatin|"Pharmaceutical form:solution
Route of administration: intravenous"
1900789|NCT01332669|Procedure|DebDox TACE|HCC patients will receive chemoembolization (TACE) using DC beads containing Doxorubicin. The objective is to give 2 vials of DC Bead (2ml per vial) loaded with 70-75mg of Doxorubicin per vial (Each vial contain 2ml of DC Bead, thus doxorubicin concentration will be of 35-37.5mg per ml of DC Beads)
1900790|NCT01332682|Behavioral|Nutrition Counseling|Patients will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
1900791|NCT01332682|Behavioral|Resistance Training and Nutrition Counseling|Patient will meet with an exercise specialist once per week for the first 6 weeks. Patient will receive guidance in a safe and appropriate exercise regimen based on specific medical history and preference. An exercise specialist will telephone weekly for consultation and support once per week for the final 6 weeks. Also, patient will meet once per week with dietitian for the first 6 weeks in 60 minute sessions. Dietitian will telephone each patient weekly for the final 6 weeks of counseling and support.
1900792|NCT01332695|Drug|ST101|tablets for oral administration
1900793|NCT01332695|Drug|Placebo|placebo to match
1900794|NCT01332708|Behavioral|high complex carbohydrates diet given in a diet group|diet groups that meet every week for eight weeks or more.
1900795|NCT01332721|Drug|TRC105 and Bevacizumab|Escalating doses of i.v. TRC105 will be administered weekly beginning with 3 mg/kg in combination with 15 mg/kg bevacizumab given every 3 weeks. Patients will receive TRC105 treatment on Days 1, 8, and 15 and bevacizumab treatment on Day 1 of each 21-day cycle.
1900796|NCT01332734|Drug|Magnesium Sulfate|2 gram in 1 hour
1900797|NCT01332747|Drug|safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.
to be given in a dosage of 5 gms twice daily"
1900798|NCT01332747|Drug|compressed tablet of safoof e muhazzil|"drug is composed of 5 herbal(Carum Carvi,Trachyspermum copticum,Foeniculum Vulgare,Origanum Vulgare,Ruta Graveolens) 1 animal origin (Lac)and 1 mineral origin (Borax) ingredients.
compressed into tablets of 1 gm each+ binders qs. dose is 5 tablets twice daily"
1900799|NCT01332747|Drug|Atorvastatin|atorvastatin 10 mgs once daily
1900800|NCT01332760|Other|narrow diameter heavy dental tool|8mm diameter, heavy periodontal tool made from steel
1900801|NCT01332760|Other|large diameter light weight tool|Periodontal tools (4-8) provided to dental practitioners to use for all dental scaling or cleaning. This tool handle diameter is 11 mm diameter and it is made from lightweight Delrin.
1900802|NCT01332773|Procedure|Artery first procedure|early identification of SMA to evaluate infiltration
1900803|NCT01332773|Procedure|No artery first procedure|conventional exposure and preparation (Kocher's manoeuvre) before transection of pancreatic parenchyma
1900804|NCT01332786|Drug|Tigecycline|"Dosage Form: one-hour intravenous infusion Dosage levels, frequency, duration: (3-week cycles)
Level 1: 50 mg daily x 10 doses; 1 week rest
Level 2: 100 mg daily x 10 doses; 1 week rest
Level 3: 150 mg daily x 10 doses; 1 week rest
Level 4: 200 mg daily x 10 doses 1 week rest
Level 5: 250 mg daily x 10 doses; 1 week rest
Level 6: 300 mg daily x 10 doses; 1 week rest
Level 7: 350 mg daily x 10 doses; 1 week rest"
1900805|NCT01332799|Drug|allopurinol or placebo|Daily active drug (allopurinol administered orally) to be compared to daily placebo (sugar pill) administered orally for 3 years.
1900806|NCT01332812|Drug|Dexamethasone|a dose of 8 mg of dexamethasone will be administered intravenously before induction of general anesthesia
1900807|NCT01332812|Other|control group|General anesthesia, without additional interventions
1900808|NCT01332825|Other|saline nasal irrigation|subjects irrigate with nasal saline daily for one week
1961001|NCT03038672|Other|Laboratory Biomarker Analysis|Correlative studies
1961002|NCT03038672|Biological|Nivolumab|Given IV
1961003|NCT03038672|Drug|Varlilumab|Given IV
1991026|NCT01600105|Drug|Perfusion MRI|1) Assess the role of a new FDA approved blood pool gadolinium contrast agent (gadofosveset trisodium, Ablavar, Lantheus) for the measurement of liver MR Perfusion, compared to extra-cellular contrast agents.
1900813|NCT01332864|Procedure|Osteopathic Manipulative Treatment (OMT)|O OMT applied to areas of somatic dysfunction other than the head region.
1900814|NCT01332864|Procedure|Light touch|Light touch applied to head region for 10 minutes with patient supine at rest.
1900815|NCT01332877|Behavioral|Enriched breakfast|high carbohydrate, high protein breakfast supplying 600 kcal as 50k% carbohydrate, 20% protein, 30% fat
1900816|NCT01332877|Behavioral|Control breakfast|Control breakfast providing 300 kcal, 13% carbohydrate, 40% protein, 48% fat
1900817|NCT01332890|Other|Sequence 1|Period1(A) Period2(B) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
1900818|NCT01332890|Other|Sequence 2|Period1(C) Period2(A) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
1900819|NCT01332890|Other|Sequence 3|Period1(B) Period2(C) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
1900820|NCT01332890|Other|Sequence 4|Period1(C) Period2(B) Period3(A) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
1900821|NCT01332890|Other|Sequence 5|Period1(B) Period2(A) Period3(C) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
1900822|NCT01332890|Other|Sequence 6|Period1(A) Period2(C) Period3(B) A : Revaprazan 200mg/Day (multiple dose for 7days) B : Itopride 50mg/Day (multiple dose for 7days) C : Revaprazan 200mg plus Itopride 50mg(multiple dose for 7days)
1900823|NCT01332903|Drug|[14C] AZD5069|Single 120 mg oral dose administered on Day 1
1900824|NCT01332916|Procedure|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
1900825|NCT01332916|Procedure|cognitive tests and cerebral IRM|cognitive tests and cerebral IRM
1900826|NCT01332929|Drug|Bevacizumab|"5, 10 or 15 mg/kg, IV, on day 1, 15 and 29 plus radiation therapy of the whole brain.
For level 0,1 and 2, a total dose of 30 Gy will be administered in 15 fractions of 2 Gy, from D15 to D33 with 5 fractions a week.
For level 3,a total dose of 30 Gy will be administered in 10 fractions of 3 Gy, from D15 to D26 with 5 fractions a week."
1900827|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of placebo tablet matched to the molidustat dose (BAY85-3934) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
1900828|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 5 mg of molidustat IR tablet on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
1900829|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 10 mg of molidustat ( 2x 5mg IR tablets) on Day 1 followed by a washout day and once daily multipledose over 12 days (from Day 3 to Day 14).
1900830|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 25 mg of molidustat (1 x 20 mg IR tablet and 1 x 5 mg IR tablet) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
1900831|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 50 mg) of molidustat (2 x 20 mg IR tablets and 2 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
1900832|NCT01332942|Drug|BAY85-3934|Subjects received an oral single dose of 75 mg of molidustat (3 x 20 mg IR tablets and 3 x 5 mg IR tablets) on Day 1 followed by a washout day and once daily multiple-dose over 12 days (from Day 3 to Day 14).
1900833|NCT01332955|Drug|Telaprevir|"Drug : telaprevir, Tablet, Oral, 750 mg, q8h, 12 weeks if associated with atazanavir or raltegravir
Drug : telaprevir, Tablet, Oral, 1125 mg, q8h, 12 weeks if associated with efavirenz"
1900834|NCT01332955|Biological|pegIFN alfa-2a|Subcutaneous injection, 180 μg, once weekly, 48 weeks or 72 weeks
1900835|NCT01332955|Drug|Ribavirin|(weight-based dose) Tablet, Oral, 1000 mg for subjects weighing below 75 kg or 1200 mg for subjects weighing equal or over75 kg, once daily, 48 weeks or 72 weeks
1900836|NCT01332968|Drug|Obinutuzumab|Obinutuzumab 1000 milligrams (mg) intravenous (IV) infusion will be administered on Day 1, 8, and 15 of Cycle 1 and then on Day 1 of each subsequent cycle during induction period and obinutuzumab 1000 mg IV infusion every 2 months during maintenance period.
1900837|NCT01332968|Drug|Cyclophosphamide|Cyclophosphamide 750 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
1900838|NCT01332968|Drug|Doxorubicin|Doxorubicin 50 mg/m^2 IV will be administered on Day 1 of each cycle during induction period.
1900839|NCT01332968|Drug|Vincristine|Vincristine 1.4 mg/m^2 (maximum 2 mg) IV will be administered on Day 1 of each cycle during induction period.
1900840|NCT01332968|Drug|Prednisone|Prednisone 100 mg (or equivalent prednisolone or methylprednisolone) will be administered orally on Days 1-5 of each cycle during induction period.
1900841|NCT01332968|Drug|Bendamustine|Bendamustine 90 mg/m^2 IV infusion will be administered on Days 1 and 2 of each cycle during induction period.
1900842|NCT01332968|Drug|Rituximab|Rituximab 375 milligrams per square meter (mg/m^2) IV infusion will be administered on Day 1 of each cycle during induction period and rituximab 375 mg/m^2 every 2 months during maintenance period.
1900843|NCT01332994|Drug|rituximab [MabThera/Rituxan]|1 g intravenously at Week 16 and 18
1900844|NCT01332994|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks for 12 weeks.
1900845|NCT01332994|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg intravenously every 4 weeks from Week 16 to Week 28
1900846|NCT01338558|Drug|bevacizumab [Avastin]|5 mg/kg iv on Day 1 of each 2-week cycle until disease progression, unacceptable toxicity or withdrawal of consent
1900847|NCT01338558|Drug|cetuximab|400 mg /m2 iv on Day 1, followed by 250 mg/m2 every week until disease progression, unacceptable toxicity or withdrawal of consent
1901009|NCT01340079|Behavioral|virtual world|health education using virtual world Second Life
1900848|NCT01338558|Drug|mFOLFOX6|Standard mFOLFOX6 chemotherapy, 2-week cycles until disease progression, unacceptable toxicity or withdrawal of consent
1900849|NCT01338584|Behavioral|Pelvic floor muscle training 3 weeks before radical prostatectomy|Participants in the intervention group need to attend the nurse-led clinic 6 times for practising pelvic floor muscle preoperatively instead of starting the exercise one day before surgery (usual management).
1900850|NCT01338584|Behavioral|Intensive preoperative pelvic floor muscle training|Patient started to learn pelvic floor muscle 3 weeks before surgery
1900851|NCT01338597|Procedure|endoscopic thyroidectomy|endoscopic thyroidectomy via the breast approach. the difference between two arms is in the subcutaneous dissection area.
1900852|NCT01338610|Biological|ESBA105 ophthalmic solution|
1900853|NCT01338610|Other|ESBA105 vehicle|Inactive ingredients used as Run-In and placebo comparator
1900854|NCT01338623|Drug|Tansulosine|capsule 0,4 mg
1900855|NCT01338636|Drug|Ambrisentan|5 mg orally every day for 4 weeks. At Week 4, if ambrisentan 5 mg was tolerated, the dose was increased to 10 mg every day for the remainder of the 24-week period.
1900856|NCT01338649|Device|Bright Light Treatment (Sun Ray Sunbox SB-558)|Bright Light Treatment (Sun Ray Sunbox SB-558) using light intensity of 10,000 lux, administered during two 1 hour periods during the day.
1900857|NCT01338649|Device|Dim red light (Sun Ray Sunbox SB-558)|Dim red light box administered during two 1 hour periods during the day using
1900858|NCT01338675|Drug|Busulfan|First dose: busulfan (120 mg/m2 ivs once daily) (if age<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
1900859|NCT01338701|Procedure|Traditional Chinese Acupuncture (TCA)|An acupuncturist will examine and evaluate subjects before inserting thin, sterile stainless steel needles at specific points on their body. Patients will receive 10 treatments over a 6 week period.
1900860|NCT01338701|Procedure|Auricular (Ear) Acupuncture|An acupuncturist will insert sterile stainless steel needles and an ASP ear needle into various points in subject's outer ear. The ASP is a shorter needle that will stay in the participant's ear for a few days. Patients will receive 10 treatments over a 6 week period.
1900861|NCT01338701|Other|Usual Care|Subjects do not receive acupuncture during the 6 week study time period. Instead, they continue to receive medical care for headaches and other symptoms. They can elect to receive up to 10 ear acupuncture treatments between the 6- and 12-week assessments.
1900862|NCT01338714|Other|Compound Herbal Formula (RHD-1)|100 ml/per day
1900863|NCT01338714|Other|dilute RHD-1|100 ml/per day
1900864|NCT01338727|Behavioral|Breastfeeding Peer Counseling|3 Prenatal visits, daily in-hospital visits, 11 postpartum home visits.
1900865|NCT01338740|Drug|Adalimumab and Infliximab|Patients with moderately to severely active Crohn's disease with primary non-response or loss of response to Adalimumab switch to Infliximab.
1900866|NCT01338753|Other|Bevacizumab, docetaxel and doxorubicin followed by surgery|"The dosage form is Parenteral Injection (I/V) for all study drugs. Bevacizumab 15mg/kg in a single dose on day 1. Then 3 weeks later begin the cycles. On the day 1 of the cycle the patient receives Bevacizumab 15mg/kg, docetaxel 60mg/m2 and doxorubicin 50mg/m2.
The cycles have a frequency of one every three weeks, and the protocol defines 4 cycles in total.
The surgical procedure will be done 4-6 weeks after completion of chemotherapy."
1900867|NCT01338766|Procedure|Decompression using the iO-Flex® system|Decompression using the iO-Flex® system
1900868|NCT01338792|Drug|oxaliplatin|Given IV
1900869|NCT01338792|Drug|pemetrexed disodium|Given IV
1900870|NCT01338792|Other|questionnaire administration|Ancillary studies
1900871|NCT01338792|Other|laboratory biomarker analysis|Correlative studies
1900872|NCT01338792|Genetic|reverse transcriptase-polymerase chain reaction|Correlative studies
1900873|NCT01338792|Genetic|polymorphism analysis|Correlative studies
1900874|NCT01338805|Drug|BGG492|
1900875|NCT01338818|Drug|Ritalin LA (methylphenidate hydrochloride extended release)|Ritalin LA 20 mg or 30 mg (a racemic mixture of d- and l-thre-Methylphenidate Hydrocloride (MPH), Extended release hard capsules) taken orally once daily in doses of 40, 60, or 80 mg. For 40mg dose patients took (2) Ritalin LA 20mg daily, for 60mg patients took (2) Ritalin LA 30mg daily and for 80mg patients took (2) Ritalin LA 30mg daily + (1) Ritalin LA 20mg daily for their optimal dose.
1900876|NCT01338831|Drug|LFA102|
1900877|NCT01338844|Dietary Supplement|Myo-inositol|
1900878|NCT01338844|Dietary Supplement|D-chito-Inositol|
1900879|NCT01338857|Drug|Sorafenib (Nexavar)|"Sorafenib (in tablet form) will be administered orally BID (approximately every 12 hours). Grapefruit juice is not allowed while taking sorafenib. A cycle of therapy is considered to be 28 days and there is no interruption between cycles. Patients may receive up to a total of 12 cycles provided that no off-protocol or off-study criteria are met.
Children/adolescents (< 18 years of age, non-NF1): 200 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 400 mg PO twice daily
Adults (greater than or equal to 18 years of age, non-NF1): 400 mg PO twice daily
NF1 patients (regardless of age): 80 mg/m2/dose PO twice daily (rounded to the nearest 50 mg increment as per Section 4.1) to a maximum of 150 mg PO twice daily"
1900880|NCT01338870|Drug|Placebo|Tablets (n=4), 0 mg twice daily for 84 days
1900881|NCT01338870|Drug|25 mg PF-04991532|Tablets (n=1), 25 mg strength + tablets (n=3) 0 mg twice daily for 84 days
1900882|NCT01338870|Drug|75 mg PF-04991532|Tablets (n=3), 25 mg strength + tablets (n=1) 0 mg twice daily for 84 days
1900883|NCT01338870|Drug|150 mg PF-04991532|Tablets (n=1), 150 mg strength + tablets (n=3) 0 mg twice daily for 84 days
1900884|NCT01338870|Drug|300 mg PF-04991532|Tablets (n=2), 150 mg strength + tablets (n=2) 0 mg twice daily for 84 days
1900885|NCT01338870|Drug|Sitagliptin 100 mg|Tablets (n=1), 100 mg strength + tablets (n=3) 0 mg once daily in the morning for 84 days; and tablets (n=4) 0 mg once daily in the evening for 84 days.
1900886|NCT01339182|Drug|Pegylated-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-Somatropin, 10mcg/kg.
1900887|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 30mcg/kg.
1901010|NCT01340079|Behavioral|face to face|health education delivered in face to face groups
1900888|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 60mcg/kg.
1900889|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 120mcg/kg.
1900890|NCT01339182|Drug|YPEG-Somatropin|Daily s.c, randomized with Saizen, 0.1IU/kg or 0.15IU/kg for the first week, followed by one week wash-out, and then s.c, single dose of pegylated-somatropin, 200mcg/kg.
1900891|NCT01339195|Behavioral|French adaptation of NINDS-Canadian Stroke Network battery|"clinical: post-stroke neurological follow-up assessment
neuropsychological: comprising the NINDS-Canadian Stroke Network neuropsychological battery
MRI"
1900892|NCT01339208|Other|Telemedicine diabetes intervention|3 month duration telemedicine consultation and diabetes education
1900893|NCT01339221|Procedure|Stool samples|Stool samples collected and checked for the presence of rotavirus
1900894|NCT01339234|Other|Body-weight supported treadmill training|Patients will undergo training using the Woodway Loco-system which consists of a treadmill with an overhead pulley system connected to a support harness. BWSTT allows patients with limited mobility to safely walk upright on a treadmill with a portion of their body weight counter balanced. Three trainers will be required to assist with the BWSTT program. Two trainers will be positioned at the lower limbs to manually guide the participant through a proper gait motion and provided lower limb control. A third trainer will stand behind the participant to provide trunk support and assist with weight shifting.
1900895|NCT01339247|Drug|Paxil CR 25 mg manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico|Paroxetine Hydrochloride 25 miligrams(mg) tablet with controlled release (Paxil CR), once a day, manufactured by SmithKline Beecham (Cork) Limited - Cidra - Puerto Rico (reference formulation)
1900896|NCT01339247|Drug|Paxil CR 25 mg manufactured by GlaxoSmithKline Inc. - Mississauga - Canada|Paroxetine Hydrochloride 25 mg tablet with controlled release (Paxil CR), once a day, manufactured by GlaxoSmithKline Inc. - Mississauga - Canada (test formulation)
1900897|NCT01339260|Drug|Netupitant and Palonosetron|
1900898|NCT01339260|Drug|Palonosetron|
1900899|NCT01339260|Drug|Dexamethasone|
1900900|NCT01339273|Procedure|Ultrasound guided Transversus Abdominis Plane (TAP) bock|Ultrasound guided TAP bock with Bupivacaine 0.25% 20ml per side or to a maximum 1mg/kg per side and the skin puncture will be covered with a small plaster
1900901|NCT01339273|Procedure|Local anaesthetic infiltration of laparoscopic port sites|Laparoscopic port sites and specimen extraction site will be infiltrated with a total of 40 mls 0.25% bupivacaine subcutaneously at the end of the procedure in the control group and plasters will be stuck on either side approximately where a skin puncture for tap block would be made.
1900902|NCT01339286|Drug|atomoxetine|Atomoxetine will be titrated to optimal dose, beginning with 0.5mg/kg.d, then increasing to 1.2mg/kg.d in two weeks and maintaining for 4 weeks. If the optimal dose does not achieved, the dose can be increased further to 1.4mg/kg.d and maintained for 4 weeks.
1900903|NCT01339299|Drug|recombinant luteinizing hormone (r-LH)|administration of r-LH 150 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
1900904|NCT01339299|Drug|recombinant human chorionic gonadotropin (r-hCG)|administration of r-hCG 25 IU/day subcutaneously , from S1 to r-hCG administration day (treatment day 10 to 14)
1900905|NCT01339312|Biological|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
1900906|NCT01339312|Biological|Purified inactivated rabies vaccine, serum free|0.5 mL, Intramuscular
1900907|NCT01339312|Biological|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
1900908|NCT01339312|Biological|Purified Vero Rabies Vaccine|0.5 mL, Intramuscular
1900909|NCT01339325|Procedure|Cholecystectomy|"Standard laparoscopic cholecystectomy The first cannula is inserted with an open laparoscopy technique. LCs are performed with either HF or US energized dissection, standard or fundus-first gallbladder dissection, closure of the artery by ligature/clip or US, closure of cystic duct by ligature/clip.
Laparo-endoscopic single site cholecystectomy
The TriPort device is inserted at the navel site through a 15 to 25 mm incision with an open laparoscopy technique. Two working instruments are inserted (one grasper and one energised device) through the TriPort. A further 1.8 or 3 mm instrument inserted through the larger gel valve, parallel to a 5 mm dissecting instrument, is used in some cases to enhance exposure. Gallbladder dissection is accomplished either after preparation of the cystic duct and artery or with a fundus-first technique, by means of HF electrosurgery or US shears.The cystic artery is divided between clips or by US scissors. The duct is divided between clips."
1900910|NCT01339338|Procedure|warming the contrast media|warm the contrast media with 37℃ water-bathing
1900911|NCT01339351|Behavioral|Therapeutic Group by Teleconference|10 sessions
1900912|NCT01339364|Other|Didactic Lecture|2 sessions of didactic lecture with PowerPoint presentations each delivered by a special lecturer. whole education period lasts 3 hours.
1900913|NCT01339364|Other|Interactive Lecture|2 sessions of brief interactive lectures followed by case discussion sections.
1900914|NCT01339364|Other|Lecture plus Small Group Education|A 1.5 hours session of didactic lecture followed by a session of small group education with 3 simulated patients.
1900915|NCT01339377|Device|AO-1000|Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.
1900916|NCT01339390|Behavioral|MOVE OUT|The MOVE OUT intervention builds on the high quality information provided by the nationally-developed MOVE program by adding 1) peer support; 2) convenient local access to educational sessions, which allows the material to be delivered in smaller, more easily retained aliquots; 3) convenient local exercise opportunities; and 4) open-ended availability of both education and exercise support.
1900917|NCT01339390|Behavioral|MOVE!|"As part of routine care at the ZVAMC, all patients who are eligible for the present study are identified by a clinical reminder. This reminder prompts the PCP to determine if the person would benefit from a weight loss program, and to refer them to MOVE if they and the patient agree that it would be beneficial. The MOVE program in Milwaukee can be tailored by the patient and PCP, but includes dietitian assessment, education, weekly weigh-ins, follow-up classes, and exercise programs."
1900918|NCT01339403|Other|non-interventional trial|No study specific intervention, non-interventional trial
1900919|NCT01339403|Other|non-interventional trial|No study specific intervention, non-interventional trial
1900920|NCT01339429|Device|simplified negative pressure wound therapy device (Wound Pump device)|A non-powered negative pressure device utilizing a bellows attached to a specialized dressing via drainage tube to promote healing of open wounds.
1900921|NCT01339442|Drug|BKM120|
1900922|NCT01339442|Drug|Fulvestrant|
1900923|NCT01339442|Procedure|biopsy|Correlative studies
1900925|NCT01339468|Drug|Advagraf|oral
1900926|NCT01339468|Drug|Prograf|oral
1900927|NCT01339468|Drug|Prograf|intravenous
1900928|NCT01339481|Drug|abatacept|Intravenous Infusion
1900929|NCT01339494|Dietary Supplement|Arginine and citrulline supplementations|Arginine or citrulline will be given orally at dose of 10 grams per meter square body surface area per day divided every 4 hours.
1900930|NCT01339520|Behavioral|Scorecard|Points were assigned for blood pressure, HbA1c level, LDL-cholesterol level, aspirin use and exercise level.
1900931|NCT01339520|Behavioral|Control|Standard of care for diabetes subjects
1900932|NCT01339533|Device|Mechanical Ventilation|Patients who experience problems breathing and require assistance in breathing are placed on a machine that delivers air to the lungs through a tube through the vocal cords. This study is testing 3 protocols for that machine.
1900935|NCT01339572|Drug|Plerixafor|"240 mcg/kg/day based on ideal body weight will be given for the following conditions:
Pre-apheresis peripheral blood CD34+ count <20 cells/μL on day 5.
Estimated CD34+ cell collection is < 25% of target cell dose after 1 day of apheresis.
Estimated CD34+ cell collection is < 50% of target cell dose after 2 days of apheresis."
1900936|NCT01339572|Drug|Filgrastim|"All patients will receive filgrastim starting 4 days prior to apheresis (D1-4 mobilization). The dose and schedule of filgrastim will based upon the risk category of the patient:
Standard risk: 5 μg/kg SQ BID.
High risk: 10 μg/kg SQ BID."
1900937|NCT01339585|Device|Transcranial direct current stimulation (tDCS)|Eldith Direct Current Stimulator (NeuroConn GmbH, Germany)
1900938|NCT01339598|Device|Transcranial direct current stimulation (Eldith DC Stimulator)|Eldith DC Stimulator (NeuroConn GmbH, Germany)
1900939|NCT01339611|Behavioral|Educational program|Individual orientation (slides) during hospitalization period and telephone follow-up after discharge
1900940|NCT01339624|Drug|FENTANYL|FENTANYL CITRATE, NASAL, 3 GAMMA/KG
1900941|NCT01339624|Drug|Ketorolac Tromethamine AND morphine|morphine 5 MG diluted in saline solution 100 ml followed by 2-ml ampoule of ketorolac 30 MG in saline solution 100 ml was infused:
1900943|NCT01339663|Drug|cyclophosphamide|Given IV
1900944|NCT01339663|Biological|aldesleukin|Given SC
1900945|NCT01339663|Biological|autologous tumor cell vaccine|Receive T-APC via IV
1900946|NCT01339663|Other|laboratory biomarker analysis|Correlative studies
1900947|NCT01339663|Other|immunologic technique|Correlative studies
1900948|NCT01339663|Other|immunohistochemistry staining method|Correlative studies
1900949|NCT01339663|Genetic|polymerase chain reaction|Correlative studies
1900950|NCT01339663|Biological|therapeutic autologous lymphocytes|Receive adoptively transferred CD8+ antigen-specific T cell clones via IV
1900951|NCT01339676|Drug|Colecalciferol|Once weekly treatment with peroral colecalciferol capsules (Dekristol®, Swiss-Caps, Switzerland) containing 20 mg of colecalciferol corresponding to 20000 IU or 0.5 mg of vitamin D
1900952|NCT01339676|Drug|Placebo capsules|Identically appearing once weekly peroral placebo capsules
1900953|NCT01339689|Drug|Ganaxolone|200-600 mg bid, capsules, up to 12 weeks
1900954|NCT01339689|Drug|Placebo|capsules, bid, up to 12 weeks
1900955|NCT01339702|Other|The National Prehospital TBI Management Guidelines|"In the post-implementation (after) cohort, implementation of the entire bundle of the TBI treatment guidelines with special emphasis on prevention and treatment of hypotension (IV crystalloids), prevention and treatment of hypoxia (pre-oxygenation with high-flow O2 via non-rebreather mask, bag-valve-mask, extraglottic airways/intubation when basic maneuvers have failed), and prevention of hyperventilation (in intubated patients) and prevention/treatment of hypoventilation (in all patients)."
1900956|NCT01339715|Procedure|acupuncture and far-infrared ray|During experimental phase,inserting the needle of acupuncture into CV12 acupoint or using far-infrared ray to illuminate on CV12 20 minutes.
1900957|NCT01339728|Procedure|far-infrared ray|The duration of far-infrared ray is 20 minutes.
1900958|NCT01339741|Dietary Supplement|Vitamin D3|Vitamin D3, oral supplement, 12 weeks
1900959|NCT01339741|Drug|Placebo|Placebo, oral route, 12 weeks
1900960|NCT01339754|Drug|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks
1900961|NCT01339754|Drug|trabectedin|1.3 mg/mq as a 3 hour continuous infusion every three weeks until progression
1900962|NCT01339780|Radiation|BS, SPECT/CT, PET/CT, MRI|Planar bone scintigraphy (BS), single photon emission computed tomography combined with low-dose computed tomography (SPECT/CT), 18F-fluoride positron emission tomography computed tomography (PET/CT) and magnetic resonance imaging (MRI) will be performed to all patients.
1900963|NCT01339806|Behavioral|Cognitive Rehab|APT-III, Other standard individual and group interventions.
1900964|NCT01339806|Behavioral|Brainworks|POSIT
1900965|NCT01339806|Behavioral|Informational Handout/Provider Visits|Provider based visits every three weeks and informational handout given to patient in regulation with current standard of care procedures.
1900966|NCT01339819|Drug|Dabigatran|Patients assigned to this group will receive Dabigatran
1900967|NCT01339819|Drug|Phenprocoumon|Patients assigned to this group will receive Phenprocoumon
1901056|NCT01340547|Drug|Normal Saline|0.9% Normal Saline 250 ml IV infusion on Cycle 1 Day -1
1900972|NCT01339871|Drug|Pazopanib|Starting dose 400 mg orally daily of 28 day cycle.
1900973|NCT01339871|Drug|Vorinostat|Starting dose 100 mg orally daily of 28 day cycle.
1900974|NCT01339884|Drug|Resveratrol|Resveratrol 1g daily (500mg twice daily) for 12 weeks Resveratrol 5 daily (2.5g twice daily) for 12 weeks
1900975|NCT01339897|Drug|5 mg/N6022|Intravenous formulation, given at doses of 5 mg once each day over 7 days.
1900976|NCT01339897|Drug|Placebo|Same administration procedures as active
1900977|NCT01339897|Drug|10mg/N6022|Intravenous formulation given at doses of 10 mg once each day over 7 days.
1900978|NCT01339897|Drug|20mg/N6022|Intravenous formulation given at doses of 20 mg once each day over 7 days.
1900979|NCT01339910|Drug|Fludarabine and Busulfan|"(Flu/Bu)
Fludarabine: 30 mg/m^2/day on Days -6 to -2 (total dose of 150 mg/m^2)
Busulfan: 4 mg/kg/day PO or 3.2 mg/kg/day (total dose of 8 mg/kg or 6.4 mg/kg, respectively) on Days -5 to -4"
1900980|NCT01339910|Drug|Fludarabine and Melphalan|"(Flu/Mel)
Fludarabine: 30 mg/m^2/day on Days -5 to -2 (total dose of 120 mg/m^2)
Melphalan: 140 mg/m^2 on Day -2"
1900981|NCT01339910|Drug|Busulfan and Fludarabine|"(Bu/Flu)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or mg/m^2/day with Bu Css 900±100 ng/mL (total dose of 16 mg/kg, 12.8 mg/kg or 520 mg/m^2, respectively) on Days -5 to -2
Fludarabine: 30 mg/m^2/day on Days -5 to -2: Flu (total dose of 120 mg/m^2)"
1900982|NCT01339910|Drug|Busulfan and Cyclophosphamide|"(Bu/Cy)
Busulfan: 4 mg/kg/day PO, 3.2 mg/kg/day IV or 130 mg/m^2/day with Bu Css 900 ± 100 ng/mL (total dose of 16 mg/kg or 12.8 mg/kg or 520 mg/m^2, respectively) on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
1900983|NCT01339910|Drug|Cyclophosphamide and Total Body Irradiation|"(Cy/TBI)
TBI: 1200-1420 cGy on Days -7 to -4
Cyclophosphamide: 60 mg/kg/day on Days -3 to -2 (total dose of 120 mg/kg)"
1900984|NCT01339923|Biological|rMenB + OMV NZ vaccine|3 doses (2.5, 3.5, 5 months if age) plus booster (11 months of age)
1900985|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (3.5, 5 months of age) plus booster (11 months of age)
1900986|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses (6, 8 months of age) plus booster (11 months of age)
1900987|NCT01339923|Biological|rMenB + OMV NZ vaccine|2 doses 2 months apart
1900988|NCT01339923|Biological|Meningococcal C oligosaccharide conjugated vaccine|Schedule 3, 5, 7, 12, Meningococcal C oligosaccharide conjugated vaccine
1900989|NCT01339923|Biological|Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.|Schedule 3, 5, 7, 12 Pneumococcal polysaccharide conjugate vaccine, 10 valent adsorbed.
1900990|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 3, 5, 12 rMenB + OMV vaccine
1900991|NCT01339923|Biological|rMenB + OMV NZ vaccine|Schedule 13,15 rMenB + OMV vaccine
1900992|NCT01339936|Device|Carboxymethylcellulose sodium, glycerin and polysorbate 80|1 drop in each eye three times a day for a period of 30 (± 4) days
1900993|NCT01339949|Device|IRay|low voltage external beam radiosurgery
1900994|NCT01339949|Device|IRay|low voltage external beam radiosurgery
1900995|NCT01339962|Other|Non-interventional|Non-interventional (retrospective chart reviews)
1900996|NCT01339975|Biological|Biological sample|"2 blood samples of 10mL + one urine sample
on pre-operative d-1/d, post-operative d1 and d5(+/-2),
one month post-operative,
at the end of the study in the absence of disease progression or at the date of recurrence or progression if the case arises."
1900997|NCT01339975|Biological|Biological sample|"2 blood samples of 10mL + one urine sample
before starting the therapy
at first therapeutic evaluation (2 or 3 months depending on the treatment chosen)
at the end of the study or at the date of disease progression."
1900998|NCT01339988|Drug|Busulfan/Cyclophosphamide|"Conditioning regimen:
Cyclophosphamide 50mg/kg/day for 4 days + Busulfan 0.8-1.0mg/kg/day for 4 days."
1900999|NCT01340001|Procedure|Electrical stimulation of the nucleus basalis of Meynert|Differents parameters will be assessed.
1901000|NCT01340014|Drug|Brinzolamide 1.0% + Timolol 0.5% ophthalmic suspension|
1901001|NCT01340014|Drug|Dorzolamide 2.0% + Timolol 0.5% ophthalmic solution|
1901002|NCT01340027|Drug|Mirabegron|oral
1901003|NCT01340027|Drug|Solifenacin succinate|oral
1901004|NCT01340027|Drug|Placebo|oral
1901005|NCT01340040|Drug|MEDI-573|MEDI-573 will be administrated once 7 days in Cohort 1 and 2, and once every 21 days in Cohort 3 as a IV infusion as part of a 21-day treatment cycle.
1901006|NCT01340053|Drug|RDX5791|Capsule, QD
1901007|NCT01340066|Drug|UISH001|sublingual dosing, 1 drop 3 times a day
1901008|NCT01340066|Drug|matching placebo|sublingual dosing,1 drop 3 times a day
1901011|NCT01340092|Other|Family Navigator|"Families in the intervention group will receive approximately six sessions with a Family Navigator. The Family Navigator will:
Help family identify key issues they need to address to get their child autism-specific services
Help family address barriers to obtaining these services and strategize approaches to overcome them."
1901012|NCT01340105|Procedure|Microwave ablation|Use of microwave energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
1901013|NCT01340105|Procedure|Radiofrequency ablation|Use of radiofrequency energy to ablate hepatocellular carcinoma. It can be employed by percutaneous, open surgery or laparoscopic means.
1901014|NCT01340118|Drug|Budesonide|once daily inhalation with 400 µg budesonide (dry powder)during 6 weeks
1901015|NCT01340131|Drug|CKD-828|Drug: Telmisartan 40mg + S-Amlodipine 5mg(FDC) Tablet, Oral, Once Daily
1901016|NCT01340131|Drug|Combination Therapy|"Drug: Telmisartan 40mg Tablet, Oral, Once Daily
Drug: S-amlodipine 5mg Tablet, Oral, Once Daily"
1901017|NCT01340157|Drug|Fexinidazole|Single oral dose of 1200mg fexinidazole consisting of 2 tablets dosed at 600mg per tablet.
1901018|NCT01340170|Device|OsseoSpeed TX|OsseoSpeed TX dental implants, 6-17 mm
1901019|NCT01340183|Drug|AZD5099|IV Dose
1901020|NCT01340183|Drug|Placebo|IV Dose
1901021|NCT01340196|Drug|tenofovir/BI 201335|tenofovir medium dose once daily (qd) for first 15 days; BI 201335 medium dose twice daily (bid) on days 8 through 22 with last dose on morning of day 22
1901022|NCT01340209|Drug|Tiotropium Respimat|Tiotropium high dose once daily delivered with Respimat inhaler
1901023|NCT01340209|Drug|Placebo Respimat|Tiotropium placebo once daily delivered with Respimat inhaler
1901024|NCT01340209|Drug|Tiotropium Respimat|Tiotropium low dose once daily delivered with Respimat inhaler
1901025|NCT01340222|Biological|biological samples|4 blood sampling will be made at J0, J2, J4, J6 befor delivery and 1 blood sampling 3 days after delivery
1901026|NCT01340235|Drug|Oral erythromycin|Severe Dowling Meara EBS patients from 6 months to 8 years old
1901027|NCT01340248|Drug|Dilatrend 64mg capsule|"Dilatrend 64mg capsule during fasting + Dilatrend 64mg capsule after high fat diet
Dilatrend 64mg capsule after high fat diet + Dilatrend 64mg capsule during fasting"
1901028|NCT01340261|Behavioral|Questionnaires|Questionnaires are completed at admission, discharge, 1-month, 6 month, and yearly follow-up.
1901029|NCT01340274|Behavioral|CRAFT treatment|Clients will receive 12 sessions of CRAFT delivered over a 12 week period. There will be 1 session per week.
1901030|NCT01340274|Behavioral|Treatment as Usual|Clients will receive Treatment as Usual delivered over 12 session. There will be 1 session per week.
1901031|NCT01340287|Dietary Supplement|1- plain low-fat dairy fermented product (drinkable) enriched with plant sterols-esters (1,6g /day equivalent as free sterols).|1 = Intervention 1 (1 test product/day)
1901032|NCT01340287|Dietary Supplement|2- plain low-fat dairy fermented product (drinkable) without plant sterols-esters|2 = Intervention 2 (1 control product/day)
1901036|NCT01340326|Drug|high dose of valsartan|comparison of different dosages of drug
1901037|NCT01340326|Drug|usual dose of valsartan|comparison of different dosages of drug
1901040|NCT01340365|Behavioral|Tai Chi Exercise|Practicing Tai Chi exercise 4 times a week for 6 months - twice in a classroom and twice independently
1901041|NCT01340365|Behavioral|Tai Chi|Usual care, individuals attend testing sessions for 6 months with testing at times 0, 3, and 6 months. Individuals in Usual Care receive 3 months of Tai Chi at the study end.
1901042|NCT01340391|Device|Omnicast|dorsal splint 2-5 weeks
1901043|NCT01340404|Procedure|Stem cell transplantation|Stem cell transplantation
1901044|NCT01340404|Procedure|Transfusion program|Transfusion program
1901045|NCT01340417|Other|Measurements of melatonin levels in urine, blood, milk.|Measurements of melatonin levels in urine, blood, milk.
1901046|NCT01340430|Drug|Trastuzumab|neoadjuvant FEC (fluorouracil, epirubicin, cyclophosphamide) followed by weekly paclitaxel and concomitant trastuzumab
1901047|NCT01340456|Drug|Rifampicin treatment|induction of CYP3A4 with one of three rifampicin doses (10, 20, 100 mg QD)
1901048|NCT01340469|Biological|probiotics|Daily enteral probiotic supplementation (live Lactobacillus acidophilus and Bifidobacterium infantis) at a dose of 2.5 x 108 CFU of each strain once a day.The supplementation was started on the first day of enteral feeding and continued for at least 28 days or until discharge. The study drug was in liquid form and mixed with breast milk or formula before given to the infants. The preparation was made on a daily basis by one person who was not involved in the care of the infants.
1901049|NCT01340482|Drug|KRN23|Subjects will receive escalating doses of KRN23 administered by SC injections every 28-days (up to 4 doses) based on a dosing algorithm and discretion of the investigator and sponsor.
1901050|NCT01340495|Radiation|Proton Radiation|45-50.4 Gy(RBE) to the chest wall and 45-50.5 Gy(RBE) once daily, 5 days per week, for approximately 5 1/2 weeks
1901051|NCT01340508|Radiation|Intensity Modulated Radiotherapy|Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions
1901052|NCT01340521|Drug|Clomiphene Citrate|0, 25, 50 or 100 milligrams daily. Will be taken orally days five through nine of the menstrual cycle.
1901053|NCT01340534|Device|Supplemental oxygen 80% FIO2|Use of oxygen 80% FIO2 during surgery and 2 hours after the procedure. For this purpose an oxygen mask with reservoir will be used (to guarantee the supply of 80% oxygen during and after surgery)
1901054|NCT01340534|Procedure|Use of air (no oxygen during surgery)|No use of oxygen during surgery or in the 2 hours after the procedure.
1901055|NCT01340547|Drug|palifosfamide-tris|palifosfamide-tris IV infusion of 150 mg/m2 on Days 1, 2 and 3 every three weeks (21 day cycle)
1901057|NCT01340560|Procedure|Endometrial biopsy|Endometrial biopsy was performed with biopsy catheter
1901058|NCT01340573|Drug|PegIntron Pen|Peginterferon alfa-2b, 1.5 microgram/kg each week, administered subcutaneously.
1901059|NCT01340573|Drug|Ribavirin|Dose is based on body weight. Each tablet of ribavirin is 200mg, and given by oral administration. Participants with body weight of <65 kg were administered 800 mg of ribavirin daily, body weight of 65 kg-85 kg received 1000 mg daily, and participants with a body weight of >85 kg received 1200 mg of ribavirin daily.
1901060|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Once, 4 days
1901061|NCT01340586|Drug|Apixaban|Tablets, Oral, 5 mg, Twice, 15 days
1901062|NCT01340599|Dietary Supplement|defined green tea catechin extract|Given PO
1901063|NCT01340599|Other|placebo|Given PO
1901064|NCT01340599|Other|immunohistochemistry staining method|Correlative studies
1901065|NCT01340599|Other|immunoenzyme technique|Correlative studies
1901066|NCT01340599|Other|questionnaire administration|Ancillary studies
1901067|NCT01340599|Procedure|therapeutic conventional surgery|Undergo radical prostatectomy
1901068|NCT01340599|Other|high performance liquid chromatography|Correlative studies
1901069|NCT01340599|Other|mass spectrometry|Correlative studies
1901070|NCT01340612|Device|endovascular coiling with any type of currently approved coil (first or second generation)|Standard procedure for endovascular coiling.Coils may be bare Platinum coils or any so-called second generation coils such as but not restricted to Hydrocoil or Cerecyte
1901071|NCT01340612|Device|endovascular stenting with or without coiling. The stent may be any of the currently approved stents for intracranial aneurysms.|Standard procedure for stenting. Addition of coils to the stent is left to the judgment of the treating physician
1901072|NCT01340625|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/35 mcg Chewable Tablets
1901073|NCT01340625|Drug|Ovcon® 35 Fe|0.4 mg/35 mcg Chewable Tablets
1901074|NCT01340638|Device|cookgas mask|This group will be assigned to use cookgas mask
1901075|NCT01340638|Device|LMA mask|LMA mask
1901076|NCT01340651|Drug|Ruxolitinib|Ruxolitinib was supplied as SR and IR formulated tablets.
1901077|NCT01340664|Drug|Canagliflozin 50 mg|One canagliflozin 50-mg capsule taken orally twice daily with a meal for 18 weeks
1901078|NCT01340664|Drug|Placebo|1 placebo capsule taken orally twice daily with a meal for 18 weeks
1901079|NCT01340664|Drug|Canagliflozin 150 mg|1 canagliflozin 150-mg capsule taken orally twice daily with a meal for 18 weeks
1901080|NCT01340664|Drug|Metformin|The patient's stable daily dose of Metformin background therapy should be continued throughout the study.
1901081|NCT01340677|Drug|Canagliflozin, 50 mg|Type=1, unit=mg, number=50, form=tablet, route=oral use.Tablet is taken once without food during 1 of 3 treatment periods.
1901082|NCT01340677|Drug|Canagliflozin, 300 mg|Type=1, unit=mg, number=300, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
1901083|NCT01340677|Drug|Canagliflozin, 100 mg|Type=1, unit=mg, number=100, form=tablet, route=oral use. Tablet is taken once without food during 1 of 3 treatment periods.
1901084|NCT01340690|Dietary Supplement|ω-3 fatty acids suspension|2 bags of Esprico(R) suspension given orally once daily in the morning for 84 days
1901085|NCT01340690|Dietary Supplement|placebo suspension|suspension to mimic verum Esprico (R) suspension. 2 bags of Esprico(R) placebo suspension given orally once daily in the morning for 84 days
1901086|NCT01340703|Procedure|vitrectomy without laser or gas tamponade|vitrectomy without laser or gas tamponade
1901087|NCT01340716|Other|Tai Chi Chuan exercise|patients in this group held three weekly classes of 60 minutes during 12 weeks of Tai Chi Chuan, Yang style. The exercises will be mild to moderate (HR 60 to 75% of HR Max). Slow movements combined with exercises and maintained using your own body weight.
1901088|NCT01340716|Other|stretching exercise|patients in this group held weekly classes of two stretching for 12 weeks.
1901089|NCT01340729|Drug|TPI 287|Starting dose of 125 mg/m2 IV via a central venous catheter (CVC) or a peripherally inserted central catheter (PICC) line over 60 minutes (+/- 10 minutes) on Days 1, 8, and 15 (+/- 2 days) of each 28 day (+/- 3 days) study cycle. The 4-week schedule composes one cycle.
1901090|NCT01340742|Procedure|Remote Ischemic Pre-conditioning|Cuff placed on arm. Three 5- minute cycles of blood pressure cuff inflation: cuff is inflated to 200 mm Hg for 5 minutes followed by a 5-minute deflation (reperfusion.)
1901091|NCT01340742|Procedure|Control|Cuff placed on arm uninflated for 30 minutes.
1901092|NCT01340755|Procedure|Transanal endoscopic surgery|Laparoscopy-assisted transanal endoscopic rectosigmoid resection
1901093|NCT01340768|Drug|Sitagliptin|One 100 mg tablet taken orally once daily
1901094|NCT01340768|Drug|Sulfonylurea|Participant continued pre-study sulfonylurea therapy (dose as prescribed by the physician). Pre-study sulfonylurea therapy consisted of either glibenclamide, glimepiride or gliclazide.
1901095|NCT01340768|Drug|Metformin|Participants receiving metformin at enrollment, continued pre-study doses of metformin. If necessary, the physician could either discontinue or adjust the dose of metformin during Ramadan.
1901096|NCT01340781|Procedure|Polysomnogram|An attended polysomnogram will be conducted in the subjects room during an in patient hospital stay
1901097|NCT01340794|Other|Laboratory Biomarker Analysis|Correlative studies
1901098|NCT01340794|Drug|Pazopanib Hydrochloride|Given PO
1901099|NCT01340807|Other|Specialized Functional Prosthetic Training|Each subject receives specialized functional prosthetic training
1901100|NCT01340820|Drug|AERAS-422|rBCG
1901101|NCT01340820|Drug|BCG Tice|1-8 x 10^5 CFU
1901102|NCT01340833|Drug|GSK2118436|Two capsules each containing 75 mg GSK2118436, followed by a single IV dose of 50 ug (no more than 7.4 kBq or 200 nCi) [14C]GSK2118436, starting 1.75 hours after the oral dose
1901103|NCT01340846|Drug|Warfarin|Warfarin dosed at 15mg on Day 1 and Day 22
1901104|NCT01340846|Drug|Ketoconazole|Ketoconazole dosed at 400mg daily on Days 19 through 22
1901105|NCT01340846|Drug|Gemfibrozil|Gemfibrozil dosed at 600mg twice daily on Days 19 through 22
1901106|NCT01340846|Drug|GSK2118436 150mg|GSK2118436 dosed at 150mg twice daily
1901107|NCT01340846|Drug|GSK2118436 75mg|GSK2118436 dosed at 75mg twice daily
1901277|NCT01342094|Drug|Timolol ophthalmic solution 0.5%|
1901108|NCT01340859|Behavioral|Post Admission Cognitive Therapy (PACT)|Individual psychotherapy; 60-90 minutes sessions; 6 sessions over preferably 3 days of inpatient stay
1901111|NCT01340885|Drug|Strattera|10-30 mg b.i.d. for 6 weeks
1901112|NCT01340885|Drug|Exelon|1.5-4.5 mg b.i.d. for 6 weeks
1901113|NCT01340885|Other|Placebo|2-6 pills for 6 weeks
1901119|NCT01340937|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) (from one of three lots) 0.5 mL intramuscular injection at 2, 4, and 6 months of age.
1901120|NCT01340937|Biological|PENTACEL™|PENTACEL™ 0.5 mL intramuscular injection at 15 months of age in the V419 groups and at 2, 4, 6, and 15 months of age in the control group
1901121|NCT01340937|Biological|Prevnar 13™|Prevnar 13™ 0.5 mL intramuscular injection at 2, 4, 6, and 15 months of age
1901122|NCT01340937|Biological|RotaTeq™|RotaTeq™ 2 mL oral dose at 2, 4, and 6 months of age
1901123|NCT01340937|Biological|Recombivax HB vaccine|Recombivax HB vaccine 0.5 mL intramuscular injection at 2 and 6 months of age
1901124|NCT01340950|Drug|zidovudine-lamivudine-nevirapine|96 weeks of zidovudine 300 mg orally twice daily, lamivudine 300 mg orally daily, nevirapine 200 mg orally daily for the first 14 days then 200 mg orally twice daily
1901125|NCT01340950|Drug|tenofovir-lamivudine-efavirenz|96 weeks of tenofovir disoproxil fumarate 300 mg orally daily, lamivudine 300 mg orally daily, efavirenz 600 mg orally daily
1901126|NCT01340976|Drug|LY2787106|Administered intravenously (IV).
1901127|NCT01340976|Dietary Supplement|Iron Supplementation|Administered orally.
1901128|NCT01340989|Procedure|alteration of the insufflation gas|addition of 4% oxygen
1901129|NCT01340989|Procedure|full conditioning|"addition of 4% oxygen + 10% nitrous oxide to the peritoneum
humidification
set temperature of 32°C"
1901130|NCT01340989|Procedure|standard pneumoperitoneum|no intervention besides the use of CO2
1901131|NCT01341002|Procedure|Transfusion|Red Blood Cells (RBC) Transfusion if SCVO2 < 70% and guidelines
1901132|NCT01341002|Procedure|Transfusion|transfusion based on guidelines
1901133|NCT01341015|Other|Ultrasound|Single interventional group - patients agree to an ultrasound of potential ankle fracture, to be compared to standard of care xray.
1901134|NCT01341028|Procedure|Roux-en-Y gastric bypass (LRYGBP)|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass
1901135|NCT01341028|Procedure|LRYGBP+gastric fundus resection|Twelve patients underwent laparoscopic Roux-en-Y gastric bypass and gastric fundus resection
1901136|NCT01341041|Biological|chlorine dioxide|one time wash with 50ppm CD solution
1901137|NCT01341041|Biological|saline|one time wash with 50-100 cc normal saline
1901138|NCT01341054|Other|mouthwash with Chamomilla|The Chamomile recutita mouthwash was administered two times daily for 30 days. 10 mL of this solution was swished around in the mouth for approximately one minute and then expectorated.
1901139|NCT01341054|Other|Standard oral care protocol|The standard protocol at the unit, which comprises mouthwash with chlorhexidine 0,12% twice a day; oral hygiene teaching, recommended at least three times per day and always after meals. For brushing, brushes with extra-soft bristles and non-abrasive toothpaste are used. In case the toothbrush cannot be used due to gingival or oral mucosa bleeding, gauze is used to replace it.
1901140|NCT01341080|Drug|Varenicline|Varenicline 1mg twice daily for eight weeks after a one week dose escalation period.
1901141|NCT01341080|Drug|Sugar pill|1mg twice daily for eight weeks after a one week dose escalation phase.
1901142|NCT01341093|Behavioral|educational program+telephone follow up|Patients will participate in the educational program with telephone follow-up, the education program will initiate in preoperative period and will continue for six months.
1901143|NCT01341093|Behavioral|Usual care|Patients will receive orientations about the surgery and the rehabilitation by health professionals, especially in the discharge. And will have return for evaluation scheduled by health professionals.
1901144|NCT01341106|Drug|Treatment with entecavir(Baraclude®)|Patient will be daily treated with 1 tablet of entecavir per oral
1901145|NCT01341132|Procedure|MRI Scan of the Liver enhanced with Eovist|10mL of gadoxetate disodium administered intravenously while being scanned via the MRI. Images will be attained on a 5, 10 and 20 minute delay. Expected scan time is 45 minutes total
1901146|NCT01341145|Behavioral|Aerobic Exercise|12-week moderate-intensity aerobic exercise program designed in accordance with the recommended guidelines established by the American College of Sports Medicine
1901147|NCT01341145|Behavioral|Relaxation|12-week progressive muscle relaxation program (active control)
1901148|NCT01341158|Drug|human interferon-α|Neoadjuvant treatment: Multiferon is given as flat dosages (3 - 9 - 18 MIU) 5 days per week, subcutaneously for 4 weeks
1901149|NCT01341184|Drug|Rifabutin|Rifabutin 300 mg orally on days 20-41
1901150|NCT01341184|Drug|Rifampin|Rifampin 600 mg orally on days 20-41
1901151|NCT01341184|Drug|TMC207|TMC207 400 mg orally on days 1 and 29
1901152|NCT01341197|Other|Fecal immunochemical test, guaiac fecal occult-blood test, and Helicobacter pylori stool antigen test|
1901153|NCT01341236|Other|different nutrional regimen|compare bolus versus intermittent nutrition
1901154|NCT01341236|Other|comparison of different feeding regimens|compare intermittent versus bolus nutrition
1901155|NCT01341249|Drug|Experimental DW224aa|DW224aa tablet, single dose
1901156|NCT01341249|Drug|Experimental DW224a|DW224a capsule, single dose
1901157|NCT01341262|Drug|Thalidomide|"INDUCTION THERAPY: 100 mg/d on days 1-14, 200 mg/d on days 15-120 (in case of delay of HD-CTX , Thalidomide will be continued until the day before Cyclophosphamide as priming therapy for PBSC collection)
AFTER PBSC COLLECTION: 200 mg/d from day after last PBSC collection until the day before first course of MEL-200
AFTER FIRST TRANSPLANTATION: 200 mg/d from recovery of hematopoiesis until the day before the second course of MEL-200"
1901158|NCT01341262|Drug|Dexamethasone|"INDUCTION THERAPY: 40 mg/d days 1-4, 9-12 and 17-20 (cycles 1 and 3, 30 days each); 40 mg/d days 1-4 (cycles 2 and 4, 30 days each)
AFTER PBSC COLLECTION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide)
AFTER FIRST TRANSPLANTATION: 40 mg/d days 1-4 (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
1901159|NCT01341262|Drug|Zoledronic acid|"INDUCTION THERAPY: 4 mg i.v. once a cycle for 4 cycles (30 days each)
AFTER PBSC COLLECTION: 4 mg i.v. once (the same day of resumption of Thalidomide)
AFTER FIRST TRANSPLANTATION: 4 mg i.v. once a cycle (starting the same day of resumption of Thalidomide) for 3 cycles (30 days each)"
1901160|NCT01341262|Drug|Cyclophosphamide|Cyclophosphamide 7 g/sqm + G-CSF 5 mcg/Kg from the day +6 for stem cell mobilisation
1901161|NCT01341262|Drug|Melphalan|Melphalan 200 mg/sqm on day -1 for first and second ASCT
1901162|NCT01341275|Biological|hepatitis B vaccine|10 ug dose, one-time administration
1901163|NCT01341275|Biological|hepatitis B vaccine|20 ug dose, one-time administration
1901164|NCT01341288|Device|EUCLIDIAN Robot|EUCLIDIAN (Endo-Uro Computed Lattice for Intratumoral Delivery, Implantation, Ablation with Nanosensing) system for placement of radioactive seeds in the prostate
1901172|NCT01341340|Device|Everolimus Eluting BVS|Patients receiving the Everolimus Eluting Bioresorbable Vascular Scaffold System (BVS)
1901173|NCT01341353|Procedure|catheter ablation|circumferential pulmonary vein isolation complex fractionated atrial electrograms ablation circumferential pulmonary vein isolation combined left atrial roof ablation circumferential pulmonary vein isolation combined left atrial isthmus ablation circumferential pulmonary vein isolation combined left atrial roof and isthmus ablation circumferential pulmonary vein isolation combined complex fractionated atrial electrograms ablation
1901174|NCT01341353|Drug|Digaoxin,amiodarone,β receptor antagonist, Calcium Antagonists|
1901175|NCT01341366|Other|Fast-track perioperative program|Preoperative counseling, no preoperative fasting, short-acting anesthetics, continuous infiltration of wound with local anesthetic agent, non-opioid pain management, the use of chewing gum, and early postoperative feeding and mobilization
1901176|NCT01341366|Other|Traditional perioperative program|Preoperative fasting, standard anesthetic management with no intraoperative fluid restriction, opioid pain management, no chewing gum, feeding/mobilization according to attending surgeon
1901177|NCT01341379|Drug|N-carbamylglutamate|N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses
1901178|NCT01341392|Drug|CKD-501|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
1901179|NCT01341392|Drug|amlodiopine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
1901180|NCT01341392|Drug|CKD-501 amlodipine|Subjects received CKD-501 0.5mg once daily for 10 days. Subjects received amlodipine 10mg once daily for 10 days. Subjects received CKD-501 0.5mg and amlodipine 10mg for 10 days.
1901184|NCT01341418|Procedure|Suprapatellar approach|Suprapatellar surgical approach will be used for intramedullary nailing of tibial fractures. Arthroscopic photos will be obtained before and after nail insertion. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
1901185|NCT01341418|Procedure|Infrapatellar approach|The Infrapatellar surgical approach will be used for intramedullary nailing of tibial fractures. No arthroscopic examination for this intervention. Postoperative radiographs, outcome questionnaires and an MRI will be performed over ther course of one-year follow-up.
1901186|NCT01341431|Drug|bee venom|12 monthly injections of 100 micrograms(in 1 milliliter of NaCl 0.9%) of bee venom s.c.
1901187|NCT01341444|Device|Prevena Incision Management System|It is intended to manage the environment of surgical incisions that continue to drain following sutured or stapled closure by maintaining a closed environment and removing exudate via the application of negative pressure wound therapy (NPWT).
1901188|NCT01341444|Other|Standard of Care for Surgical Incisions|Sterile 4X4 Non-Penetrable barrier
1901189|NCT01341457|Drug|LY2603618|Administered intravenously
1901190|NCT01341457|Drug|Gemcitabine|Administered intravenously
1901191|NCT01341470|Drug|LY2495655|administered intravenously or subcutaneously
1901192|NCT01341470|Drug|Placebo|administered intravenously or subcutaneously
1901193|NCT01341496|Biological|Epigenetically Modified Autologous Tumor|5x 10^7 autologous tumor cells emulsified in 0.5 mL ISCOMATRIX adjuvant will be administered IM every 4 weeks for 6 months
1901194|NCT01341496|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each 4 week treatment cycle
1901195|NCT01341496|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each 4 week vaccine cycle.
1901196|NCT01341509|Procedure|Flexor Hallucis Longus Tendon transfer|The flexor hallucis longus tendon was transferred during surgery for insertional achilles tendinopathy
1901197|NCT01341509|Procedure|Transfer of the Flexor Hallucis Longus Tendon|The Flexor Hallucis Longus Tendon was transferred during surgery for insertional achilles tendinopathy
1901278|NCT01342094|Drug|Placebo ophthalmic solution|
1901198|NCT01341509|Procedure|No transfer of Flexor Hallucis Longus tendon|There was no transfer of the Flexor Hallucis Longus tendon in surgery for insertional achilles tendinopathy
1901199|NCT01341522|Procedure|MRI exam|MRI exam
1901200|NCT01341522|Procedure|control|waiting room
1901201|NCT01341535|Radiation|Adaptive dose-painting-by-numbers|Adaptive dose escalation by dose-painting-by-numbers.
1901202|NCT01341535|Radiation|standard intensity-modulated radiotherapy (IMRT)|Standard radiotherapy for head and neck cancer.
1901203|NCT01341548|Drug|Civamide nasal solution 0.01%|20ug/dose, BID for 7 days 0.1 ml to each nostril
1901204|NCT01341574|Procedure|Prism adaptation with optical shift of 10 degrees.|Prism adaptation with optical shift of 10 degrees.
1901205|NCT01341574|Procedure|Prism adaptation optical shift of 0 degrees.|Prism adaptation with optical shift of 0 degrees.
1901206|NCT01341587|Device|Telcare Blood Glucose Meter (BGM)|Cellular enabled glucometer
1901207|NCT01341600|Drug|Clopidogrel|Over a 6 week period participants will be given: 75 mg of clopidogrel for 8 days, at least 1 week washout, 150 mg of clopidogrel for eight days, at least 1 week washout, 300 mg of clopidogrel for eight days.
1901208|NCT01341600|Drug|Omeprazole/Clopidogrel|After a washout of at least 1 week, participants will have the option to participate in a final intervention in which they will be given 75 mg of clopidogrel together with 20 mg of omeprazole daily for eight days.
1901209|NCT01341613|Dietary Supplement|Cardioviva™ supplement capsule|Twice per day (BID), 9 weeks
1901210|NCT01341613|Dietary Supplement|Placebo capsule|Twice per day (BID), 9 weeks
1901211|NCT01341626|Behavioral|Treatment Foster Care (TFCO)|Youth placed individually in well-trained and supervised foster homes. Basic components: (a) daily telephone contact with TFCO parents; (b) weekly foster parent group meetings focused on supervision, training in parenting practices, and support; (c) an individualized behavior management program implemented daily in the home by foster parent; (d) individualized skills training for the youth; (e) family therapy for aftercare family focused on parent management strategies; (f) close monitoring of school attendance, performance, and homework completion; (g) case management to coordinate TFCO, family, peer, and school settings; (h) 24-hour on-call staff availability to TFCO and biological parents; and (i) psychiatric consultation. Services typically last approximately 6 months.
1901212|NCT01341626|Behavioral|Group Care|Group Care is the usual service for youth placed in out-of-home care for chronic delinquency in Oregon. These programs represented typical services for girls being referred to out-of-home care by the juvenile justice system and had 2-51 youth in residence (M = 21) and 1-50 staff members (Mdn = 2); most also had onsite schooling. Although the programs differed somewhat in theoretical orientations, 86% reported that they endorsed a specific treatment model, of which the primary philosophy was a behavioral (70%), eclectic (26%), or family-style therapeutic approach (4%). Services typically last approximately 6 months.
1901213|NCT01341639|Biological|V419|V419 (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Outer Membrane Protein Complex], and Hepatitis B [Recombinant] Vaccine) 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age
1901214|NCT01341639|Biological|INFANRIX hexa|INFANRIX™ hexa 0.5 mL intramuscular injection at 2, 3, 4, and 12 months of age.
1901215|NCT01341639|Biological|RotaTeq|RotaTeq 2 mL oral dose at 2, 3, and 4 months of age
1901216|NCT01341639|Biological|Prevenar 13|Prevenar 13 0.5 mL intramuscular injection at 2, 3, 4,and 13 months of age
1901217|NCT01341639|Biological|ProQuad|ProQuad™ 0.5 mL subcutaneous injection at 12 and 13 months of age
1901219|NCT01335841|Device|Navigation station coupled with a 3D fluoroscopy|After randomization, patients will be operated with the conventional method either with navigation station. In the conventional method, the orthopedic surgeon based on anatomical criteria to establish its implants. It uses an image intensifier in 2D mode to monitor the implementation of the implants. In computer assisted surgery, the surgeon uses a navigation station that allows real-time flow instruments to guide its implementation of the implants. It uses an image intensifier in 3D mode on the one hand to achieve a first series of image that will be used for navigation and also to monitor the implementation of the implants.
1901220|NCT01335854|Behavioral|Web-based Access to CPAP Data|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the study, and then as frequently as they choose after the first week.
1901221|NCT01335854|Behavioral|Web-based Access to CPAP Data with Financial Incentive|Participants will have web-based access to their CPAP usage for each 24 hours of treatment. They will be asked to view this data each day during the first week of the the study, and then as frequently as they choose after the first week. There will be a payment of $30 during the first week for each day a participant uses CPAP for more than 4 hours the previous night and logs on to the website.
1901222|NCT01335867|Drug|Vigabatrin|Vigabatrin escalated to 3 grams daily for 8 weeks
1901223|NCT01335867|Drug|Placebo|Placebo pills
1901224|NCT01335880|Behavioral|Coupons for use within the next week|Participants who attend an exercise class will receive a coupon for a free exercise class to be used within the next week.
1901225|NCT01335880|Behavioral|Coupons for use within the next 3 months|Participants who attend an exercise class will receive a coupon to attend an exercise class for free within the next 3 months.
1901226|NCT01341652|Biological|pTVG-HP|pTVG-HP (100 µg) with rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
1901227|NCT01341652|Biological|rhGM-CSF|rhGM-CSF (208 µg) administered intradermally (i.d.) biweekly for 6 total doses, then every 3 months to complete a 2-year treatment period
1901228|NCT01341678|Drug|Lanthanum Carbonate|Diet will be supplemented with 1000mg at each meal
1901229|NCT01341678|Dietary Supplement|NeutraPhos|Diet will be supplemented with NeutraPhos
1901230|NCT01341678|Other|Diet Only|Diet containing 1500mg of phosphorus
1901231|NCT01341691|Other|chewing gum|single piece of chewing gum containing specified amount of chitosan with or without extender chewed twice daily for 14 days
1901335|NCT01342523|Other|Lozenge - nicotine mini-lozenges|2-week starter pack of nicotine mini-lozenges
1901525|NCT01343836|Other|Autologous Tenocyte Implantation|Intratendinous ATI (autologous tenocyte injection) with eccentric exercises
1901232|NCT01341704|Biological|MSP3-LSP/AlOH|"30 µg of test vaccine MSP3-LSP/AlOH, administered by subcutaneous route according to the following schedule:- Primary administration: Three doses administered at 4 weeks interval: D0, D28 (± 2 days), D56 (± 4 days)
Secondary administration (Boost):
Year 1: One dose 3 months after the third dose Year 2: Two doses, given exactly one year after the date corresponding to the third dose and the first boost given during Year 1"
1901233|NCT01341704|Biological|Verorab Vaccine|The Verorab rabies vaccine will be given as control for the primary series of the experimental vaccine. It consists of inactivated rabies virus produced in vero cells (Wistar Rabies PM/W138 1503-3M (inactivated). Manufacturer SANOFI PASTEUR SA. Presentation is 0.5 ml per dose in a pre-filled syringe.
1901234|NCT01341704|Other|0.9% NaCl/Normal Saline|0.5 ml per dose; to be given as control for the secondary/booster doses of experimental vaccine
1901235|NCT01341717|Drug|Sitagliptin|100 mg once daily for 6 months
1901236|NCT01341717|Drug|Glimepiride|1 mg/2 mg/3 mg once daily
1901237|NCT01341717|Drug|Metformin|>=1000 mg twice daily
1901238|NCT01341717|Drug|Insulin|TDD > 10 IU once/twice daily
1901239|NCT01341730|Drug|Atorvastatin 20mg|20 mg QD for 3 months
1901240|NCT01341730|Drug|Atorvastatin 20 mg + Pioglitazone 30 mg|atorvastatin 20 mg plus pioglitazone 30 mg QD for 3 months
1901241|NCT01341743|Drug|Entecavir|patients will receive oral entecavir 1mg, daily for 104 weeks.
1901242|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 1mg daily and adefovir 10mg daily for 104 weeks
1901243|NCT01341743|Drug|Entecavir, Adefovir|patients in this arm will receive oral entecavir 0.5mg daily and adefovir 10mg daily for 104 weeks
1901244|NCT01341756|Radiation|Palliative Radiotherapy|Palliative Radiotherapy to a total dose of 36Gy in 12 fractions
1901245|NCT01341769|Other|Dietary Intervention|
1901246|NCT01341769|Other|Dietary Intervention|
1901247|NCT01341769|Other|Dietary Intervention|
1901248|NCT01341769|Other|Dietary Intervention|
1901249|NCT01341782|Drug|paricalcitol|
1901250|NCT01341782|Drug|maxacalcitol|
1901251|NCT01341782|Drug|paricalcitol placebo|
1901252|NCT01341782|Drug|maxacalcitol placebo|
1901253|NCT01341808|Biological|Epaxal Berna (virosomal hepatitis A vaccine)|standard 0.5 mL dose of Epaxal Berna (virosomal hepatitis A vaccine) given at Day 0, Month 6.
1901254|NCT01341834|Drug|LBH589 and RAD001|Dose escalation of LBH589 tablets (5 and 10 mg) and RAD001 tablets (2.5, 5 mg and 10mg)
1901255|NCT01341847|Procedure|water method colonoscopy|This technique allow only water infusion (air pump is turned off) through the adaptor on the biopsy channel of colonoscope during insertion since the scope is inserted into the anus until reach the cecum.
1901256|NCT01341847|Procedure|air method colonoscopy|This technique only use usual air insufflation technique during colonoscope insertion and shortening maneuvers.
1901257|NCT01341873|Other|educational intervention|Undergo APN FCI
1901258|NCT01341873|Other|psychosocial support for caregiver|Undergo APN FCI
1901259|NCT01341873|Procedure|quality-of-life assessment|Ancillary studies
1901260|NCT01341873|Other|questionnaire administration|Ancillary studies
1901261|NCT01341886|Drug|Metformin|in case group metformin is added to levothyroxine and levothyroxine is decreased by 30% .in control group levothyroxine is reduced by 30% and no metformin is added to the regimen.
1901262|NCT01341899|Procedure|immunosuppression and stem cell transplantation|Hematopoietic stem cells were mobilized with cyclophosphamide (CY, 2.0 g/m2) and granulocyte colonystimulating factor (10 μg/kg per day) and then collected from peripheral blood by leukapheresis and cryopreserved. The cells were infused after conditioning with CY (200 mg/kg) and rabbit antithymocyte globulin (4.5 mg/kg).
1901263|NCT01341912|Biological|Human-cl rhFVIII|Human-cl rhFVIII is administered intravenously on demand for bleeding episodes and prophylactically in case of surgery. The dosage depends on the severity of the bleeding episodes and the surgery.
1901264|NCT01341925|Drug|Omega-3 Supplementation|The Ω3 group will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3) two times daily for a total daily dose of 2000 mg Ω3 (1400 mg EPA: 200 mg DHA; 400 other Ω3). The placebo group will receive two capsules two times daily matched for odor and appearance with the active intervention.
1901265|NCT01341925|Behavioral|Psychoeducational Psychotherapy (PEP)|Therapy sessions occur twice a week for up to 24 sessions of manualized treatment. The importance of separating symptoms from the individual is emphasized. The family is offered support, validation, and recognition for their own difficult experiences in living with the child's mood disorder. Family members are taught that patients are particularly vulnerable to stress and tension; thus, therapists work with families to reduce the level of stress and tension in their homes. Improvement of communication, problem solving and coping strategies can lead to restoration of hope for recovery and decrease family dysfunction. Goals include strengthening the parent-child bond and helping children and parents feel competent to manage depression now and in future recurrences.
1901266|NCT01341925|Other|Placebo|The placebo group will receive active monitoring (no IF-PEP) and two capsules two times daily matched for odor and appearance with the active intervention.
1901267|NCT01341938|Drug|Commit® nicotine lozenges (4 mg).|Participants will be provided with instructions on the proper use of the lozenge and instructed to use the lozenge any time they have a craving or urge to use ST or tobacco. Dosing: weeks 1-6 one lozenge every 1-2 hours/16 per day, weeks 7-9 one lozenge every 2-4 hours/8 per day, weeks 10-12 one lozenge every 4-8 hours/4 per day.
1901268|NCT01341938|Behavioral|Phone Counseling|Three phone counseling sessions to assist in cessation from use of all tobacco.
1901269|NCT01341938|Behavioral|Self-help materials|"Participants receive the Enough Snuff video and printed guide providing strategies for tobacco cessation."
1901270|NCT01341951|Drug|Granulocyte colony stimulating factor|300 I.U twice daily for 5 days
1901271|NCT01341964|Drug|Clopidogrel|600mg (2 pills)
1901272|NCT01341964|Drug|Aspirin|325mg (1 pill)
1901273|NCT01341964|Drug|Aspirin|81mg (1 pill)
1901274|NCT01341977|Device|Alcon MPDS|Multi-Purpose Solution intended for use with silicone hydrogel and soft contact lenses
1901275|NCT01341977|Device|ReNu Fresh MPS|ReNu Fresh MPS is a marketed product indicated for cleaning, removing protein deposits, rinsing, disinfecting and storage of soft contact lenses.
1901276|NCT01342094|Drug|DE-111 ophthalmic solution|
1901279|NCT01342107|Device|FID 114675A multi-purpose disinfecting solution (MPDS)|Investigational multi-purpose disinfecting solution intended for use as a cleaning, reconditioning, rinsing, disinfecting, and storage solution for silicone hydrogel and soft contact lenses.
1901280|NCT01342107|Device|Soft contact lens|Soft hydrogel or silicone hydrogel contact lens matching subject's pre-study lens, including parameters, worn 16 hours on day of dispense.
1901281|NCT01342107|Device|Blister pack solution|Commercially approved storage solution as found in the contact lens blister pack.
1901282|NCT01342146|Drug|pegylated Somatropin|0.1 mg/kg/wk once a week for 25 weeks
1901283|NCT01342146|Drug|pegylated Somatropin|0.2 mg/kg/wk once a week for 25 weeks
1901284|NCT01342146|Drug|Jintropin AQ|0.25 mg/kg/wk, once a day for 25 weeks
1901285|NCT01342159|Procedure|Intravitreal injection|Intravitreal Injections were done under sterile conditions with topical anesthesia and insertion of a lid speculum. For the bevacizumab group, 1.25 mg (0.05 cc) bevacizumab (Avastin, made for F. Hoffmann-La Roche Ltd Basel, Switzerland by Genentech Inc., San Francisco, CA, USA) was injected intravitreally with a 30-gauge needle through the superotemporal quadrant. For the bevacizumab with triamcinolone group, in addition to intravitreal bevacizumab, 2 mg(0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally through the inferotemporal quadrant. For triamcinolone group, 2 mg (0.05 cc) triamcinolone acetonide (Triamhexal, Hexal AG,Holzkirchen, Germany) was injected intravitreally.
1901286|NCT01342172|Drug|Lenalidomide|"Patients will receive gemcitabine 1000 mg/m2 IV on days 1 + 8 and cisplatin 70 mg/m2 IV on day 1 of each 21 day cycle. Lenalidomide will be given orally on days 1-14 and the dose will be escalated in successive cohorts during the phase Ib portion to define the recommended phase II dose. Patients will continue gemcitabine, cisplatin, plus lenalidomide for up to 6 cycles, in the absence of disease progression or prohibitive toxicity. After completion of 6 cycles of therapy, patients who have achieved at least stable disease will proceed with maintenance lenalidomide given orally on days 1-21 of each 28-day cycle. Treatment will continue, in the absence of prohibitive toxicity, until the time of disease progression."
1901287|NCT01342185|Device|medical ozone therapy with tianyi|Medical ozone therapy with instrument made in China Patients in this arm will receive autohemotherapy. First month: ozone concentration: 20µg ~40µg /ml;The second month: 30µg/ml × 100ml oxygen- ozone gas × 100 ml blood;The third month: 20µg/ml × 100ml oxygen- ozone gas× 100 ml blood.
1901288|NCT01342185|Device|medical ozone therapy with humares|Medical ozone therapy with instrument made in Germany Patients in this group will receive autohemotherapy treatment, regime as ArmⅠ.
1901289|NCT01342185|Drug|Diammonium glycyrrhizinate Capsules|Drug: Diammonium glycyrrhizinate Capsules Patients in this group will receive oral Diammonium glycyrrhizinate Capsules 150mg, three times a day for 12 weeks.
1901290|NCT01342198|Drug|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
1901291|NCT01342198|Drug|Pregabalin controlled release, 330 mg|A single oral dose of 330 mg controlled release tablet
1901292|NCT01342198|Drug|erythromycin|A total of three doses of 500 mg erythromycin ethylsuccinate tablets administered six hours apart beginning approximately 1 hour prior to pregabalin CR
1901298|NCT01342224|Biological|tadalafil and vaccination|Participants receive a 4-week course of vaccination with telomerase vaccine and GM-CSF by injection, along with a cycle of gemcitabine chemotherapy (IV). This is followed by radiation and gemcitabine given twice weekly then by another dose of vaccine. Four weeks after completion of chemotherapy and radiation, participants able to have surgical treatment will have surgery followed by vaccination and chemotherapy. Participants with stable or responsive disease that cannot be treated by surgery will have vaccination and chemotherapy with 2 cycles of telomerase vaccine with GM-CSF along with gemcitabine. Participants with unresectable and progressive disease after administration of vaccine, chemotherapy and radiation treatment may transition to vaccination and chemotherapy treatment.
1901299|NCT01342237|Drug|HDCT 1(TTC), HDCT2(MEC)|"TTC Topotecan (2 mg/m2 once daily i.v. on days -8, -7, -6, -5, -4) Thiotepa (300 mg/m2 once daily i.v on days -8, -7, -6) Carboplatin (500 mg/m2 once daily i.v on days -5, -4, -3) (max. 700 mg/day)
MEC Melphalan (140 mg/m2 once daily i.v on day -7, 70 mg/m2 once daily i.v on day -6) Etoposide (200 mg/m2 once daily i.v on days -8, -6) Carboplatin (350 mg/m2 once daily i.v on days -8, -7, -6, -5)"
1901300|NCT01342250|Biological|conventional therapy plus low dose hUC-MSCs treatment|patients will receive the conventional therapy plus low dose hUC-MSCs treatment
1901301|NCT01342250|Biological|conventional therapy plus medium dose hUC-MSCs treatment|patients will receive conventional therapy plus medium dose hUC-MSCs treatment
1901302|NCT01342250|Biological|conventional therapy plus high dose hUC-MSCs treatment|patients will receive conventional therapy plus high dose hUC-MSCs treatment
1901303|NCT01342263|Behavioral|iCDM|The iCDM intervention will be managed by a nurse with experience in chronic disease management who will review patient data, communicate with the patients, implement the Treatment Algorithms and interact with the patients' PCP. Patients will also be able to interact with a dietitian and exercise specialist to support them in their disease management. These personnel will have formal training in principles of the Transtheoretical Model of Change and Social Cognitive Theory.
1901332|NCT01342510|Drug|Control|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
1901333|NCT01342510|Drug|Lidocaine/Magnesium|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
1901334|NCT01342523|Other|CIS - telephone cessation quitline counseling|Up to 5 total tobacco cessation counseling calls
1901405|NCT01342965|Drug|Erlotinib|Erlotinib was supplied as tablets.
1901304|NCT01342276|Behavioral|vHFC|Common practice for managing HF patients attending urban-based, specialized HF clinics is to have them weigh themselves daily and report any dramatic fluctuations and/or increasing symptoms to their clinic. We have transformed this model to the vHFC website such that each day, participants will logon to the vHFC and enter their weight and answer six questions regarding their current symptoms. An alert will be generated if the participant enters data outside of the desired parameters, does not enter their data for three consecutive days, or enters a comment in the text box for the vHFC nurse to view. If an alert is generated, following participant data entry, the participant is presented with a pop up window to inform them that the vHFC nurse will contact them within 24 hours. The nurse will contact the participant by telephone to discuss the alert generated and provide counselling.
1901305|NCT01342289|Procedure|Bone Marrow Transplant|Preparative regimen consists of Fludarabine - 30 mg/m2/day , Cytoxan - 14.5 mg/kg/day , and Total Body Irradiation administered in a single fraction , with posttransplantation high-dose Cytoxan - 50 mg/kg IV, Mycophenolate mofetil - 15 mg/kg PO TID, and tacrolimus- starting dose is 1 mg IV QD.
1901306|NCT01342302|Behavioral|Psychosocial Intervention for Couples|Intervention delivered on line
1901307|NCT01342315|Drug|33525|Daily dosing
1901308|NCT01342315|Drug|Placebo|Daily dosing
1901309|NCT01342328|Other|Normal saline infusion|Normal saline infusion
1901310|NCT01342328|Drug|Dexmedetomidine|"Infusion of Dexmedetomidine will be administrated during the overnight sleep study. An initial target concentration of 0.25 ng/ml will be selected. After 5 min, the sedative point will be assessed and the concentration will be adjusted stepwise by increments and decrements of 0.05 ng/ml. This process will be repeated until the target sedative state is achieved. Using the Richmond Agitation Sedation Scale (RASS) infusion rates, using known pharmacokinetic parameters will be adjusted to achieve equivalent levels of sedation (RASS -3) for both DEX and propofol sessions.
We aim to achieve an RASS of -3 so that the subjects are moderately sedated. This state of sedation will be maintained for 3-4 hours."
1901311|NCT01342328|Drug|Propofol|"For propofol, an initial concentration of 0.75 ng/ml will be targeted. Depending on the score achieved, the infusion rate will be increased or decreased every 5 min by 0.2 ng/ml until the target sedative state is achieved.
Note that the target sedative state (RASS score of -3) is the same for both DEX and propofol sessions, with the investigator being unaware of which drug is being administered. To ensure the investigator is not aware of the type of drug being administered, all drug delivery systems will be covered.
Intravenous drug delivery will be continued throughout the scanning period for 3-4 hours to maintain equivalent levels of sedation for both DEX and propofol."
1901312|NCT01342341|Drug|Parafon Forte|"Drug: Parafon Forte administered at study visit
Other: Placebo administered at study visit"
1901313|NCT01342354|Radiation|Stereotactic Radiation|Escalating Doses of SBRT in periods of three doses over 10 days
1901314|NCT01342367|Drug|Bicalutamide|Bicalutamide 50 mg orally daily with either dutasteride or finasteride for 2 months. After two months of treatment bicalutamide with either dutasteride or finasteride will be taken along with radiation. After completion of radiation, bicalutamide will be stopped.
1901315|NCT01342367|Drug|Dutasteride|Dutasteride 0.5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment dutasteride and bicalutamide will be taken along with radiation. After completion of radiation, dutasteride will be taken alone for two years.
1901316|NCT01342367|Drug|Finasteride|Finasteride 5 mg orally will be taken daily with bicalutamide for 2 months. After two months of treatment finasteride and bicalutamide will be taken along with radiation. After completion of radiation, finasteride will be taken alone for two years.
1901317|NCT01342367|Radiation|Radiation|7-8 weeks of radiation with bicalutamide and either dutasteride or finasteride.
1901318|NCT01342432|Other|General exercise only|exercises for stretch and strength of paraspinal and abdominal muscles
1901319|NCT01342432|Other|Balance reeducation plus general exercise|patients perform balance reeducation exercises in addition to general exercises for stretch and strength of back and abdominal muscles
1901320|NCT01342445|Drug|lisdexamfetamine dimesylate|30-mg, 50-mg, 70-mg administered for one week in context of double-blind, placebo-controlled crossover design
1901321|NCT01342445|Drug|Placebo|
1901322|NCT01342458|Other|Flexible footwear|The patients of the Intervention Group (IG) will be use over 6 month a flexible and non-heeled footwear (Moleca; Calçados Beira Rio S.A., Novo Hamburgo, Rio Grande do Sul, Brazil) is a women's flexible flat walking shoe, without heels, with an anti-slip rubber sole, 5-mm thin, with a 3 mm internal wedge of ethylene vinyl acetate, made out of dubbed canvas. It had a mean weight of 172 ± 19.6 g, ranging from 142 to 193 g depending upon the size.
1901323|NCT01342471|Behavioral|TV commercial stepping|"Participants were instructed to stand and briskly step in place, or briskly walk continuously around the room/house for the duration of each commercial break during at least 90 min of TV programming on at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
1901324|NCT01342471|Behavioral|30-min walk|"Participants were instructed to use brisk walking (at least 30 min/day in bouts of at least 10 min) at least 5 days/week. Both conditions will receive an ankle mounted Omron pedometer, so they were able to track their steps each day. Participants were not given instructions concerning diet modification or modifying TV viewing time during a 6 month behavioral physical activity intervention"
1901325|NCT01342484|Drug|placebo|comparison of different dosages of drug (low vs high) vs placebo
1901326|NCT01342484|Drug|BI1356 low dose|comparison of different dosages of drug (low vs high) vs placebo
1901327|NCT01342484|Drug|BI1356 high dose|comparison of different dosages of drug (low vs high) vs placebo
1901328|NCT01342497|Drug|isoniazide|Tablets, dosing 3 times daily, 12 weeks
1901329|NCT01342497|Drug|placebo|tablets, dosing 3 times daily, 12 weeks
1901330|NCT01342510|Drug|Magnesium Sulfate|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
1901331|NCT01342510|Drug|Lidocaine|We propose studying Lidocaine 50 mg in a 10 cc syringe, Magnesium sulfate 0.25 g (2 mOsmol) in a 10 cc syringe, 0.9% saline in a 10 cc syringe, Lidocaine 50 mg and 0.25 g (2 mOsmol) magnesium sulfate in a 10 cc syringe for pretreatment of propofol related pain on injection.
1901336|NCT01342523|Other|Emails - Brief smoking prevention messages|Brief email messages that could be accessed by any computer or mobile device that allowed email receipt
1901337|NCT01342523|Other|Full website - standard smokefree.gov website content|Over 50 web pages of resources for quitting smoking, including interactive features and referral links
1901338|NCT01342523|Other|Lite website - lite version of smokefree.gov|Reduced version of the smokefree.gov website developed for the research; reduced number of web pages and external links (considered a placebo intervention)
1901339|NCT01342523|Other|Full mailed booklet - NCI's detailed 36-page quit guide|NCI's Clearing the Air brochure for preparing to quit, quitting and preventing relapse
1901340|NCT01342523|Other|brief mailed booklet - smaller version of NCI's booklet|12-page booklet developed by the investigators for the research (considered to be placebo intervention)
1901341|NCT01342536|Behavioral|Coping with Depression Course (CWD) and Oh Happy Day Class (OHDC)|"The OHDC is a culturally adapted, cognitive behavioral group counseling intervention. The OHDC is theoretically grounded in social learning theory and an Afrocentric paradigm (Nguzo Saba). It uses a social support group and psychoeducation format so participants learn skills to help them in coping and reducing symptoms of depression. The OHDC is offered over 13 weeks with 2-hour sessions in a clinical setting.
The CWD, an evidence-based cognitive behavioral depression intervention. The CWD is offered over 8 weeks with 2-hour sessions in a clinical.
Arms: lifestyle counseling (OHDC), lifestyle counseling (CWD)"
1901342|NCT01342549|Drug|Valproate|250mg per day 30 minutes after a meal. Dosages will be increase as tolerated to a maximum recommended dosage of 60 mg per kg per day. Usual dosage is between 1250mg to 2000mg per day
1901343|NCT01342549|Drug|Naltrexone|25mg per day, taken by mouth for 7 days, then 50mg per day
1901344|NCT01342562|Drug|spinal anesthesia|0.4% bupivacaine(normal saline 0.3ml with dexmedetomidine 3 mcg)
1901345|NCT01342562|Drug|spinal anesthesia|0.4% bupivacaine(normal saline 0.3 ml with 0.5% bupivacaine 1.2 ml)
1901346|NCT01342575|Procedure|Intra-operative exposure maneuvers|"Feet compression maneuver: Taking feet from the ankles, gentle pressure will be applied toward the cranium and maintained for 1 minute. X-rays and IONM will be performed
Arm traction maneuver: Holding two strips around the wrists and using a dynamometer adjusted to 8 kg per side, sustained traction will be maintained for 1 minute. X-rays and IONM will be performed.
Shoulder taping maneuver: Both shoulders will be pulled caudally with adhesive tape adjusted for a tension of 8 kg on each side. X-rays and IONM will be performed
Arm traction plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed
Shoulder taping plus feet compression maneuvers: Simultaneous combination of both maneuvers as described before. X-rays and IONM will be performed"
1901348|NCT01342601|Device|ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)|Comparison of ANS01 and AAT01 with placebo
1901349|NCT01342601|Device|Placebo products|Nasal Spray and Eye drops without Ectoin
1901350|NCT01342614|Drug|Fosinopril|Fosinopril group received fosinopril, 10mg, once per day.
1901351|NCT01342614|Drug|Metformin|Metformin group was treated with metformin hydrochloride, 500mg, three times per day
1901352|NCT01342627|Drug|Sorafenib|"Sorafenib will be orally administered at a daily dose of 400 mg taken twice daily without food, at least one hour before or two hours after eating. Four weeks of treatments will be considered as a cycle. Each patient enrolled in the study will received medications for topical therapy. Dermatological medications will be provided free.
In case of toxicities, dose reduction/interruption is permitted according to the protocol.
In case of disease progression Sorafenib administration will be discontinued."
1901353|NCT01342640|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Recommended starting dose 1.2 micrograms/kg subcutaneously every 4 weeks (depending on patient's weight). Dose adjustment may be required in the event of inadequate or excessive treatment response.
1901354|NCT01342653|Other|Intraperitoneal and systemic chemotherapy plus maximum cytoreduction plus HIPEC|see Design
1901355|NCT01342666|Dietary Supplement|Tomato consumption|Daily consumption of 300g of uncooked roma tomatoes during one month.
1901356|NCT01342666|Dietary Supplement|Cucumber consumption|Daily consumption of 300g of cucumber.
1901357|NCT01342679|Drug|dasatinib|100mg QD
1901358|NCT01342692|Drug|Azacitidine|6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks The first course will be started on day 1 regardless of the blood count. Subsequent courses will be scheduled every 4 weeks
1901359|NCT01342692|Drug|Azacitidine associated with Valproic acid|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Valproic Acid (Depakine-Chrono®) (VPA) will be administered concomitantly for a minimum of 6 cycles.
- In patients aged 60 years or less: VPA (25 mg/kg twice a day i.e. 50 mg/kg/d) administered orally, daily for 7 days (days 1-7)
- In patients older than 60 years: VPA (17.5 mg/kg twice a day i.e. 35 mg/Kg/d) administered orally daily for 7 days (days 1-7)"
1901360|NCT01342692|Drug|Azacitidine associated with Lenalidomide|"6 cycles of Azacitidine 75 mg/m2 subcutaneously daily for 7 days, every 4 weeks Lenalidomide (Revlimid®) will be administered once daily orally as continuous schedule started on day 1 of Azacitidine.
Patients will receive Lenalidomide 10 mg/d, during 14 days (D1 to D14)"
1901361|NCT01342692|Drug|Azacitidine associated with Idarubicine|Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above. Idarubicin (Zavedos®) as the reconstituted solution, will be administered slowly by the intravenous route over 60 minutes at 10 mg/m²of body-surface area on day 8 of Azacitidine or day 10 if azacitidine was administered according to (5-2-2 regimen)
1901362|NCT01342705|Procedure|phlebotomy|Procedure: Phlebotomy of 4 ml / kg to obtain (1 phlebotomy every 14 days) and maintain (1 phlebotomy every 3 months) a serum ferritin below 50 µg / l.
1901406|NCT01342965|Drug|Chemotherapy|Cisplatin and gemcitabine were locally sourced with commercial products.
1901407|NCT01342991|Procedure|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy
This procedure will be performed under local anaesthetic with sedation as a day case
The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.
Pre-operative local anaesthesia will be given"
1901363|NCT01342718|Dietary Supplement|Herbal extract granule and probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal)
The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (2 hours after morning and evening meal)"
1901364|NCT01342718|Dietary Supplement|Herbal extract granule and placebo probiotics|"The herbal extract granule, Gwakhyangjeonggisan granule, consists of 11 herbs. Ingredients: Agastachis, Perillae Folium, Angelicae Radix, Arecae Pericarpium, Hoelen, Magnoliae officinalis Cortex, Atractylis Rhizoma, Aurantii nobilis Percarpium, Pinelliae Rhizoma, Platycodi Radix, Glychrrhizae Radix. Dosage and frequency: 1 pack (3g), 3 packs per day (2 hours after morning, afternoon and evening meal).
Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
1901365|NCT01342718|Dietary Supplement|Placebo herbal extract granule and probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).
The probiotics, Duolac7S, consist of 7 bacteria. Ingredients: Lactobacillus acidophilus, L. plantarum, L. rhamnosus, Bifidobacterium breve, B. lactis, B. longum, Streptococcus thermophilus. Dosage and frequency: 1 capsule (5✕1,000,000,000 bacteria/capsule [7✕100,000,000 viable cells/strain]), 2 capsules per day (2 hours after morning and evening meal)"
1901366|NCT01342718|Dietary Supplement|Placebo herbal extract granule and placebo probiotics|"The Gwakhyangjeonggisan placebo has the same form, color and flavor as experimental intervention (Gwakhyangjeonggisan). The dosage, frequency and duration is also the same as experimental intervention (Gwakhyangjeonggisan).
Duolac7S placebo has the same form, color and flavor as experimental intervention (Duolac7S). The dosage, frequency and duration is also the same as experimental intervention (Duolac7S)."
1901367|NCT01342731|Drug|Tigecycline|100 mg of tigecycline intravenous infusion for 30 minutes followed by 50 mg every 12 hours for 7 to 14 days.
1901368|NCT01342744|Drug|Metformin|Metformin(850 mg) 1tab oral twice aday
1901369|NCT01342744|Drug|Placebo|Placebo 1 tab oral twice a day
1901370|NCT01342757|Drug|vorinostat|Given orally
1901371|NCT01342757|Drug|temozolomide|Given orally
1901372|NCT01342757|Procedure|magnetic resonance spectroscopic imaging|Undergo MRI
1901373|NCT01342757|Other|survey administration|Ancillary studies
1901374|NCT01342770|Other|Laboratory Biomarker Analysis|Correlative studies
1901375|NCT01342770|Drug|Pioglitazone Hydrochloride|Given PO
1901376|NCT01342770|Other|Quality-of-Life Assessment|Ancillary studies
1901377|NCT01342783|Genetic|DNA analysis|
1901378|NCT01342783|Genetic|RNA analysis|
1901379|NCT01342783|Genetic|mutation analysis|
1901380|NCT01342783|Genetic|nucleic acid sequencing|
1901381|NCT01342783|Other|laboratory biomarker analysis|
1901382|NCT01342796|Biological|MF59C.1-adjuvanted subunit influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
1901383|NCT01342796|Biological|Sub unit, Inactivated, Influenza vaccine|2 x 0.25 ml doses administered intramuscularly in the deltoid muscle of (preferably) the non dominant arm
1901384|NCT01342809|Behavioral|Follow up|Follow up, consultations with general practitioner, written guidelines, supervision.
1901385|NCT01342822|Device|Angioplasty (PROMUS Element™, and Xience™ Prime stent)|Patients with symptomatic ischemic heart disease due to stenotic lesions amenable to percutaneous treatment with a drug eluting stent in a consecutive unselected patient population, provided that the proposed research use of the product is consistent with the approved (labeled) uses of such product and with the reimbursed indications (in countries where reimbursement procedure applies, eg France) and does not violate any other applicable law, regulation or ethical directive/code.
1901386|NCT01342835|Drug|Propofol|The induction dose of propofol is 3-5 mg/kg-1 (mean induction dose: 4 mg/kg-1) follow by propofol infusion (12 mg/kg/h-1 for the first 10 min of general anesthesia, 9 mg/kg/h-1 for another 10 min, and 6 mg/kg/h-1 thereafter; mean maintenance dose: 9 mg/kg/h-1) and a 50:50 mixture of N2O and O2.
1901387|NCT01342861|Dietary Supplement|Addition of protein (milky food in the breakfast)|The main purpose of this study is to evaluate the efficacy of additional protein (adding milky food to the breakfast) in order to deliver an optimized protein and energy intake of 15.75 g and 559 Kcal, respectively.
1901388|NCT01342874|Dietary Supplement|Inositol|inositol exposure in early GDM
1901389|NCT01342887|Drug|cyclosporine|Given IV
1901390|NCT01342887|Drug|pravastatin sodium|Given PO
1901391|NCT01342887|Drug|mitoxantrone hydrochloride|Given IV
1901392|NCT01342887|Drug|etoposide|Given IV
1901393|NCT01342887|Procedure|bone marrow aspiration|Correlative studies
1901394|NCT01342900|Device|connected to the InSpectra Monitor|
1901395|NCT01342913|Drug|Fluticasone Furoate 100mcg/Vilanterol 25mcg|Inhalation Powder
1901396|NCT01342913|Drug|Fluticaosne Propionate 500mcg/Salmeterol 50mcg|Inhalation Powder
1901397|NCT01342926|Drug|GSK933776|GSK933776
1901398|NCT01342926|Drug|Placebo|Placebo
1901399|NCT01342939|Other|Oral Glucose Tolerance Test (OGTT)|50g waterfree glucose dissolved in 300ml water consumed over 5 min.
1901400|NCT01342939|Other|iso glycaemic intravenous (iv) glucose infusion (IIGI)|20% glucose
1901401|NCT01342939|Dietary Supplement|Meal test|Energy drink, 350ml (525 kcal: 65 g carbohydrates, 20 g fat and 21 g protein)
1901402|NCT01342939|Other|Sitagliptin|Healthy control subject are given an acute dosage of 100mg the evening before the experimental day, and the same morning in order to increase levels of endogen incretin hormones
1901403|NCT01342939|Other|Incretin effect on sulphonyl urea treatment|Subject with MODY who are treated with sulphonyl urea are investigated without medication break prior to examination.
1901404|NCT01342952|Drug|Ambrisentan|open label, flexible dosing from 2.5 to 10 mg (not to exceed 10 mg/kg) per day
1901408|NCT01342991|Procedure|Laser Haemorrhoidectomy|"The intervention comprises laser haemorrhoidectomy
This procedure will be performed under local anaesthetic with sedation as a day case
The haemorrhoids are excised using sharp dissection (over a clamp) and the cut edges are sealed using CO2 laser.
Pre-operative local anaesthesia will be given"
1901409|NCT01343004|Drug|Placebo|Placebo 0 mcg subcutaneous daily
1901410|NCT01343004|Drug|BA058 80 mcg|BA058 80 mcg subcutaneous daily
1901411|NCT01343004|Drug|teriparatide|teriparatide 20 mcg subcutaneous daily
1901412|NCT01343017|Other|Ventilatory pattern|In group one, increased tidal volume with a adjusted apparatus dead space volume (IVT), In group two, normal tidal volume with a PEEP to 10 cmH2O applied(NVT). PETCO2 will be adjusted to maintain at 4.5 kPa, in both groups. When PETCO2 values were stable at 4.5 kPa, sevoflurane administration will be started with a vaporiser set to 3%. After 5 minutes the fresh gas flow will be adjusted to 1.0 L/min with an unchanged vaporiser setting throughout the anaesthesia period.
1901414|NCT01343056|Behavioral|Office Staff Support|The intervention includes the Office staff of primary care practices trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
1901415|NCT01343056|Behavioral|Peer Support|Community peers trained to provide diabetes support for behavioral goal setting were tasked to follow up with patients via phone following completion of diabetes self-management education.
1901416|NCT01343056|Behavioral|Usual Care Support|Diabetes educators provided patient follow up for behavioral goal setting support according to traditional clinical guidelines following completion of diabetes self-management.
1901417|NCT01343056|Behavioral|Educator Support|Diabetes educators provided patient follow up for behavioral goal setting support that was problem-focused and patient centered.
1901418|NCT01343069|Procedure|implementation surgical checklist|a checklist according to the suggestions raised by the WHO is implementated
1901419|NCT01343082|Drug|DE-111 ophthalmic solution|
1901422|NCT01343121|Other|sample collection|Blood samples will be collected on days 1, 8, 15 and 22. They will be taken 30 minutes and 2 hours post Gemcitabine infusion.
1901423|NCT01343121|Other|sample collection|Urine will be collected on days 1, 8, 15 and 22. They will be taken pre gemcitabine and 2 hours post Gemcitabine
1901424|NCT01343121|Other|Sample Collection|Quality of Life (QOL) questionnaires given to the patient at each visit
1901425|NCT01343134|Device|Measure the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg), and microperimetry (OPKO Instruments)|Measure the thickness of the outer retina by spectral domain optical coherence tomography (HRA Spectralis; Heidelberg)and perform central microperimetry using new OPKO Instruments OCT.
1901426|NCT01343147|Other|Microwave diathermy|Deep tissue heating via microwave diathermy
1901427|NCT01343147|Other|Superficial hyperthermia|Superficial heating via hot pack application
1901428|NCT01343160|Device|GORE® VIABIL® Biliary Endoprosthesis|Deployment of GORE® VIABIL® Biliary Endoprosthesis to the area of stricture
1901429|NCT01343173|Drug|Imatinib stop|To stop imatinib after inclusion.
1901430|NCT01343186|Drug|Peginterferon alfa|s,c, 45mcg of Ypeginterferon alfa-2a
1901431|NCT01343186|Drug|Peginterferon alfa 2a|s,c, 90mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
1901432|NCT01343186|Drug|Peginterferon alfa-2a|s,c, 180mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
1901433|NCT01343186|Drug|Peginterferon alfa-2a|s,c, 270mcg of Ypeginterferon alfa-2a or 180mcg of Pegasys.
1901434|NCT01343212|Other|stiffness measurement using ARFI|Stiffness measurement will be performed for HCC using ARFI technique.
1901435|NCT01343225|Drug|atripla|once a day
1901436|NCT01343225|Drug|darunavir ritonavir raltegravir|as directed
1901437|NCT01343238|Behavioral|Diet|12 week diet behavior modification
1901438|NCT01343238|Behavioral|Exercise|12 week exercise behavioral intervention
1901439|NCT01343238|Behavioral|Diet and Exercise|12 week diet and exercise behavioral modification intervention
1901440|NCT01343277|Drug|Trabectedin|Type=exactly number, unit=mg/m2, number=1.5, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
1901441|NCT01343277|Drug|Dacarbazine|Type=exactly number, unit=g/m2, number=1, form=intravenous infusion, route=intravenous use. Once every 3 weeks until disease progression or signs of toxicity.
1901442|NCT01343290|Drug|Canagliflozin|Type = 1, unit = mg, number = 300, form = tablet, route = oral use. Single tablet taken with or without a meal during 2 treatment periods
1901443|NCT01343303|Drug|Placebo|Placebo tablet/capsule every 12 hours for 21 days
1901444|NCT01343303|Drug|JNJ-39439335|2 x 25 mg tablets once daily for 21 days
1901445|NCT01343303|Drug|Naproxen|500 mg capsule every 12 hours for 21 days
1901446|NCT01343303|Drug|JNJ-39439335|2 x 5 mg tablets once daily for 21 days
1901447|NCT01343316|Device|Transpyloric feeding tubes (Nasogastric Tube (NG tube), Tiger2, Syncro BlueTube)|To determine the benefits of utilizing one type of transpyloric tube over another.
1901448|NCT01343329|Drug|Esmolol|The Esmolol arm is defined as a 48-hour intravenous infusion of esmolol (Brevibloc 20mg/ml), which will be started on enrollment. The infusion rate will begin at 50 micrograms/kg/min and be adjusted to achieve heart rates between 80 and 100 beats/min with standard dosing regimens used in our Neuro intensive care unit. The infusion will be started at a rate of 0.05 milligrams/kg/min (50 micrograms/kg/min) for 5 minutes. After the 5 minutes of initial infusion, maintenance infusion may be continued at 0.05 mg/kg/min or increased stepwise (e.g. 0.1 mg/kg/min, 0.15 mg/kg/min to a maximum of 0.2 mg/kg/min) with each step being maintained for 4 or more minutes until the target heart rate is achieved.
1901481|NCT01343641|Drug|MK-0677|The oral agent MK-677 is spiropiperidine, Merck L-163 191, GH secretagogue ghrelin mimetic which increases GH and IGF-I secretion, fat free mass and energy expenditure76-79. It is produced by Merck & Co, Inc.
1901449|NCT01343329|Drug|Propranolol|The comparison arm will be comprised of oral propranolol, starting with 20mg PO every 6 hours prn (as needed) to reduce heart rate into target range. If 20mg is ineffective, the dose will be doubled at each dosing interval until an adequate dose is found, not to exceed 120mg four times daily. (ex: 20mg, 40mg, 80mg, 120mg)
1901450|NCT01343342|Dietary Supplement|n-3 PUFA supplementation|3g per day of n-3 PUFA supplementation (1.9g EPA, 1.1g DHA). 5 capsules per day (1g fish oil each, 5g of fish oil/day)
1901451|NCT01343355|Drug|Tamibarotene|Oral administration of tamibarotene 2 mg daily over a period of 12 weeks, then 4mg daily for another 12 weeks.
1901452|NCT01343368|Drug|Leuprolide|Long-acting leuprolide 11.25 mg intramuscularly (IM) pre-transplant (HCT) and 3 months post-HCT PLUS Short-acting leuprolide 0.2 mg subcutaneously (SQ) daily for 14 days
1901453|NCT01343368|Biological|hematopoietic cell transplant|Conventional bone marrow transplant regimen.
1901454|NCT01343368|Biological|reduced intensity allogeneic HCT|A reduced-intensity conditioning transplant is a bone marrow or cord blood transplant (also called a BMT) that uses less intense treatment to prepare for transplant than a standard transplant does. While a standard transplant uses the pre-transplant treatment to destroy most of the disease cells, a reduced-intensity transplant relies on the donor's immune cells to fight disease.
1901455|NCT01343381|Drug|Hepalean Heparin|400 units per kilogram bolus prior to initiation of CPB
1901456|NCT01343381|Drug|PPC Heparin|400 unit per kilogram bolus prior to initiation of CPB
1901457|NCT01343394|Biological|Autologous Human Umbilical Cord Blood|6 million cells/kg will be administered intravenously at one treatment time point.
1901458|NCT01343407|Drug|MK-1029 10 mg|Six capsules once daily for 5 days
1901459|NCT01343407|Drug|MK-1029 100 mg|Five capsules once daily for 5 days
1901460|NCT01343407|Drug|Placebo for MK-1029 10 mg|Six capsules once daily for 5 days
1901461|NCT01343407|Drug|Placebo for MK-1029 100 mg|Five capsules once daily for 5 days
1901462|NCT01343420|Biological|Dog Hair Extract, ALK-Abelló, Inc.|ALK-Abelló dog epithelial 1:10w/v glycerin
1901463|NCT01343459|Radiation|HIOB|"IOERT single shot as a boost followed by hypofractionated WBRT (HIOB)
IOERT is performed on mobile or fixed linacs
Reference dose: 11 Gy specified as maximum dose, with a minimum target volume dose of 90% encompassing the PTV (i.e. 10 Gy).
WBRT
must start within day 36- 56 postoperatively (week 6 - 8 p.o.) in case of adjuvant hormonal treatment (or no further tumor specific medication)
In case of adjuvant chemotherapy, a time - gap between IOERT and WBRT up to 9 months is allowed.
Single reference dose per fraction: 2,7 Gy (ICRU)
Number of fractions: 15, Number of fractions per week: 5
Total WBRT dose: 40,5 Gy"
1901464|NCT01343472|Behavioral|WISP supervision|WISP entails a warning session (Orientation Hearing) where the rules of parole are laid out and parolees are told that any violation of stated parole conditions will be sanctioned with a brief jail term (typically a few days in jail). WISP includes regular random drug testing.
1901465|NCT01343472|Behavioral|Parole-as-usual|Parolees are supervised under standard parole supervision practice in Washington State.
1901466|NCT01343485|Behavioral|Computer reminder system|Intervention sites will receive computer kiosk with study specific software to assist in reminding study participants to return for HPV vaccine series
1901467|NCT01343498|Drug|BEZ235|BEZ235 will be given on a dose-escalation design, beginning at 200 mg BID (SDS sachet) in 3 patients and progressing to 400 mg, 600 mg, and 800 mg respectively based on tolerability.
1901468|NCT01343511|Biological|human cord blood mononuclear cells|Participants will be given rehabilitation therapy plus hCB-MNCs transplantation.
1901469|NCT01343511|Biological|human cord blood mononuclear cells and human umbilical cord mesenchymal stem cells|Participants will be given rehabilitation therapy plus and hCB-MNCs and hUC-MSCs transplantation.
1901470|NCT01343537|Other|Neuro Monitoring|Neuro monitoring from day 4 to day 14 post subarachnoid hemorrhage for cerebral vasospasm
1901471|NCT01343550|Other|creativity group|This is a creativity group intervention. There will be 4 groups. Each group has one session per week. Each session is a duration of two hours.
1901472|NCT01343563|Procedure|Trigeminal Nerve Stimulation|External trigeminal nerve stimulation (TNS) as an adjunctive treatment added onto antidepressant medications.
1901473|NCT01343576|Dietary Supplement|milk fat|45 g milk fat per day in 4 weeks
1901474|NCT01343589|Dietary Supplement|milk fat|39 g milk fat per day in 12 weeks
1901475|NCT01343602|Behavioral|mod. Constraint-Induced Movement Therapy|"Therapists of the intervention group are trained in CIMT at home. During an initial home visit the therapist determines together with the patient an individually tailored home training program focussing on everyday practice and instructs the non-professional coach. For four weeks the patients will perform 2 hours of daily training at home together with an instructed non-professional coach (e.g. family member) applying shaping techniques (i.e. 20 consecutive days). Patients are supposed to wear a resting hand splint for the entire treatment period for 4 to 6 hours daily. During the four weeks the therapist will provide 5 weekly visits at the patients' home to instruct and supervise the training."
1901476|NCT01343602|Other|Therapy as usual|Therapy as usual consists of the therapy, which is usually provided by the occupational or physical therapist. Therapy will be applied at the patients home or at the therapists' practice.
1901477|NCT01343615|Procedure|carotid stenting|A group of patients will be operated by endovascular technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects.
1901478|NCT01343615|Procedure|carotid endarterectomy|A group of patients will be operated by open technique. Then will be analyzed and compared with the other group in relation to clinical and radiological criteria, emphasizing the cognitive aspects
1901479|NCT01343628|Drug|Placebo Comparator|16 NET SNP rs 11648486 CC and CT individuals will receive placebo and then after one week washout period, receive atomoxetine. Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5
1901480|NCT01343628|Drug|Active Comparator: Atomoxetine, Placebo|16 NET SNP rs 11648486 CC and CT individuals will receive atomoxetine and then after one week washout period, receive placebo.Medications will be given as 2 capsules 1x day for 5 days; active atomoxetine groups will receive 40 mg for 3 days, followed by 80 or 120mg (.91-1.4 mg/kg) on days 4 and 5.
1901482|NCT01343641|Drug|Placebo|Inactive Pill used as a comparator
1901526|NCT01343836|Other|Saline|Intratendinous saline injection with eccentric exercises
1901483|NCT01343654|Behavioral|Text messaging plus EMA|Personalized, tailored text messaging to prompt medication adherence, with EMA random queries about nonadherence and drug use, and two-way messaging for participants to report critical events
1901484|NCT01343654|Behavioral|Treatment as usual|usual care in one of the three participating ID clinics, along with usual care (if any) in the community for problematic drug and alcohol use
1901485|NCT01343667|Device|Gore Flow Reversal System|Embolic protection by the GORE Flow Reversal System during carotid artery angioplasty and stenting
1901486|NCT01343667|Device|Gore Embolic Filter|Embolic protection by the GORE Embolic Filter during carotid artery angioplasty and stenting
1901487|NCT01343680|Drug|Heparin|5ml 10 units/ml IV heparin 3 times per week
1901488|NCT01343680|Drug|Normal saline|10ml normal saline IV weekly
1901489|NCT01343706|Drug|Placebo|Solution for oral administration
1901490|NCT01343706|Drug|Placebo .|Immediate release solid oral dosage
1901491|NCT01343706|Drug|BI 409306|Immediate release solid oral dosage medium
1901492|NCT01343706|Drug|BI 409306|Immediate release solid oral dosage low
1901493|NCT01343706|Drug|BI 409306|Immediate release solid oral dosage high
1901494|NCT01343706|Drug|BI 409306|low dose solution for oral administration
1901495|NCT01343706|Drug|BI 409306|low dose solution for oral administration
1901496|NCT01343706|Drug|BI 409306|medium dose solution for oral administration
1901497|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
1901498|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
1901499|NCT01343719|Drug|BI 661051|medium dose solution for oral administration
1901500|NCT01343719|Drug|BI 661051|low dose solution for oral administration
1901501|NCT01343719|Drug|BI 661051|low dose solution for oral administration
1901502|NCT01343719|Drug|BI 661051|low dose solution for oral administration
1901503|NCT01343719|Drug|BI 661051|high dose solution for oral administration
1901504|NCT01343719|Drug|BI 661051|high dose solution for oral administration
1901505|NCT01343719|Drug|BI 661051|low dose tablet
1901506|NCT01343719|Drug|Placebo|solution for administration
1901507|NCT01343719|Drug|BI 661051|medium dose tablet
1901508|NCT01343732|Device|Deep TMS|deep transcranial magnetic stimulation
1901509|NCT01343745|Drug|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 4 inhalations bid (total daily dose 800 µg BDP + 48 µg formoterol)
1901510|NCT01343745|Drug|BDP/formoterol|pressurised metered dose inhaler, BDP + Formoterol 100/6 µg, 1 inhalation bid (total daily dose 200 µg BDP + 12 µg formoterol)
1901511|NCT01343745|Drug|Placebo|pressurised metered dose inhaler
1901512|NCT01343758|Other|5% dextrose in normal saline|Subjects will be randomized to receive a intravenous fluid bolus of 5% dextrose in normal saline or normal saline
1901513|NCT01343771|Drug|DHEA (Prasterone) + ERT (Aviane)|Micronized oral DHEA in a dose of 50 mg daily + ERT (0.3 mg Premarin, 1 tablet daily for 3 months, follow by Alesse, 20 mcg ethinyl estradiol + 0.1 mg levonorgestrel for 9 months)
1901514|NCT01343771|Other|Placebo|A placebo tablet will be developed by the Children's Hospital Pharmacy. Both treatments (DHEA+ERT and placebo) will be administered in a gelatin capsule.
1901515|NCT01343784|Other|Urinary voiding assessment after midurethral sling|Both groups will undergo voiding trial in the similar manner. The decision to discharge based on an objective measure (voided amount) versus based on the subjective measure (force of stream self assessment).
1901516|NCT01343797|Other|Glycemic and insulinemic index tests of a fruit fructose syrup and a fruit fructo-oligosaccharid syrup|One test with 65,5g of fruit (apple) extract sugar syrup with high fructose content in 250mL of water One test with 108,2g of peach purified sugar syrup with high fructo-oligosaccharid content in 250mL of water Three tests with the reference : 50g of anhydrous glucose in 250mL of water
1901517|NCT01343810|Behavioral|Mindfulness Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
1901518|NCT01343810|Behavioral|Mindfulness-Based Stress Reduction (MBSR)|The MBSR program consists of 8 weekly classes that last for 2.5 hours each and a commitment to daily meditation practice for the duration of the course. Classes include didactic instruction on mindfulness and its relationship to stress and health, guided meditation practices, and group discussion. Mindfulness meditation practices include awareness of breathing, awareness of emotions, body scan, mindful hatha yoga, mindful walking, mindful eating, mindful listening, and lovingkindness (metta). Participants are expected to practice formal meditation outside of class for 20-45 min per day, 6 days per week. In addition, participants are encouraged apply mindfulness to everyday activities like eating, communicating with others, and hobbies. Written materials and audio CDs with guided meditations and yoga are provided. The course also includes one full day (7-hours) of meditation on a Saturday following the 6th week of class.
1901519|NCT01343823|Drug|ecallantide 60 mg|Administered as two 3 mL SC injections, each containing 30 mg ecallantide
1901520|NCT01343823|Drug|ecallantide 30 mg|Administered as one 3 mL SC injection containing 30 mg ecallantide
1901521|NCT01343823|Drug|ecallantide 10 mg|Administered as one 3 mL SC injection containing 10 mg ecallantide.
1901522|NCT01343823|Drug|placebo|Administered as two SC 3 mL injections
1901523|NCT01343823|Drug|placebo match for 30 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 30 mg ecallantide arm.
1901524|NCT01343823|Drug|placebo match for 10 mg ecallantide arm|One 3 mL SC injection of matching placebo given to subjects randomized to the 10 mg ecallantide arm.
1901527|NCT01343862|Drug|D-cycloserine|single dose of D-cycloserine given 48-72 hours after moderate traumatic brain injury
1901528|NCT01343862|Drug|placebo|A sugar pill will be given to those patients randomized to the control group at 48-72 hours after moderate brain injury
1901529|NCT01343875|Procedure|tear of the distal tendon in the biceps muscle|
1901530|NCT01343888|Drug|PegIFN/RBV|PegIFN/RBV for 48 weeks
1901531|NCT01343888|Drug|BI 201335|BI 201335 once daily high dose
1901532|NCT01343888|Drug|BI 201335|BI 201335 once daily low dose
1901533|NCT01343888|Drug|Placebo|
1901534|NCT01343901|Drug|Bevacizumab|Participants with mCRC and having exclusively liver or liver and lung metastases who were receiving bevacizumab as part of first line treatment for potentially resectable liver metastases as per treating physician's discretion will be observed. All concomitant medications as used in routine clinical practice are allowed.
1901535|NCT01343927|Behavioral|Weekly yoga classes|Manualized 12-week Hatha yoga intervention developed specifically for chronic low back pain in adult populations; classes meet once each week at community-based locations.
1901536|NCT01343927|Behavioral|Individual physical therapy treatment|12 weeks of fifteen individual physical therapy sessions divided as follows: Week 1 intake appointment; weeks 2-4 two appointments per week; weeks 5-12 one appointment per week.
1901537|NCT01343927|Behavioral|Education|"Participants given The Back Pain Helpbook and periodic newsletters addressing back pain and self care."
1901538|NCT01343940|Behavioral|Project dulce|"Participating families are assigned to a legal/developmental specialist who joins health care team during well-child visits and home visits. The specialist (a Dulce family partner) supports parent around child development issues, addresses unmet basic needs (e.g., housing, utilities, food, etc.), and makes referral to existing agencies and services. Specialist meets with family during all routine well-child visits scheduled in primary care between birth and 6 months (1-mo, 2-mo, 4-mo, 6-mo). Parent may meet with specialist before or after scheduled appointment, and may request a home visit. Specialist will be available by phone for consultation."
1901539|NCT01343940|Behavioral|Safety intervention|Participating family is assigned a safety specialist. Meeting with the safety specialist will occur before or after a routine well-child visit or at a separately agreed upon time. The specialist will discuss infant injury risks associated with transportation and sleep. The specialist will provide safety equipment (car seat and pack-and-play) and instruct the parent in their proper use.
1901540|NCT01343953|Procedure|Cord Blood Transplantation|One or 2 cord blood units containing alone or both together more than 4x107 frozen nucleated cells/Kg with no more than 2 out of 6 HLA mismatches between them and with the patients for acquired Severe Aplastic Anemia
1901541|NCT01343966|Drug|MABT5102A|Repeating subcutaneous injection
1901542|NCT01343966|Drug|MABT5102A|Repeating intravenous infusion
1901543|NCT01343966|Drug|placebo|Repeating subcutaneous injection
1901544|NCT01343966|Drug|placebo|Repeating intravenous infusion
1901545|NCT01343992|Behavioral|Bed rest|Patients will rest in bed ten minutes after the embryo transfer.
1901546|NCT01343992|Behavioral|No bedrest|Patients will not rest in bed after the embryo transfer.
1901547|NCT01344005|Other|caregiver-related intervention or procedure|
1901548|NCT01344005|Other|questionnaire administration|
1901549|NCT01344005|Procedure|quality-of-life assessment|
1901550|NCT01344005|Procedure|radiography|
1901551|NCT01344018|Procedure|therapeutic conventional surgery|
1901552|NCT01344018|Radiation|3-dimensional conformal radiation therapy|
1901557|NCT01344044|Device|BCI|24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
1901558|NCT01344057|Biological|Seasonal Influenza Vaccine|This phase II is performed as a multicenter study in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: until day 22) .
1901559|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational innovator formulation
1901560|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation a
1901561|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation b
1901562|NCT01344070|Drug|one of the 15 drugs listed below|single, oral, immediate-release, non-combinational generic formulation c
1901565|NCT01344122|Other|KPI training only|See comparison arm description.
1901566|NCT01344122|Other|KPI plus OLI|See experimental arm description.
1901567|NCT01344135|Dietary Supplement|Dietary supplementation|"Phase A, Rehabilitation (4 months): 3 nutritional supplements daily
Phase B, Maintenance (8 months): nutritional supplementation on advice (1 supplement daily)
Phase C, Follow-up (3 months): no supplementation"
1901568|NCT01344135|Dietary Supplement|Placebo supplement|"Phase A, Rehabilitation (4 months): 3 placebo nutritional supplements daily
Phase B, Maintenance (8 months): No supplementation
Phase C, Follow-up (3 months): No supplementation"
1901569|NCT01344135|Behavioral|Nutritional counselling|"Phase A, Rehabilitation (4 months): No counselling
Phase B, Maintenance (8 months): Nutritional counselling (4x)
Phase C, Follow-up (3 months): No counselling
Aim:
Optimising dietary intake to physical activity pattern and energy expenditure.
Minimize deterioration of dietary intake during acute exacerbations.
Optimize dietary lipid profile with respect to total fat intake; trans fatty acids and proportion of poly-unsaturated fatty acids to modulate cardiovascular risk and muscle fatty acid metabolism.
Increasing adherence/compliance by addressing issues like taste fatigue, gastro-intestinal symptoms, individual preferences and lifestyle."
1901599|NCT01344421|Procedure|Minimally invasive approach for Periacetabular osteotomy|A peri-acetabular osteotomy is a surgery performed to correct the dysplastic acetabulum and reduce joint contact pressures and early osteoarthritis.
1901600|NCT01344447|Drug|Gadobutrol (Gadovist, BAY86-4875)|A single bolus injection of approx. 0.1mmol/kg
1901570|NCT01344135|Behavioral|Feedback on physical activity level|"Phase A, Rehabilitation (4 months): No exercise counselling
Phase B, Maintenance (8 months): Exercise counselling (2x)
Phase C, Follow-up (3 months): No exercise counselling
Aim:
Integration of exercise behaviour into daily routine
Improvement of self-regulation skills (e.g. self-monitoring, goal setting, action planning)
Increasing adherence/compliance by addressing issues like coping with difficult situation, individual preferences and lifestyle"
1901571|NCT01344148|Drug|INH RIF Rifb PZA EMB AZT 3TC D4T EFV|The first cohort study is the patients begin HAART after anti-TB therapy 2 weeks,and the second cohort is after 8 weeks begin HAART. Anti-TB therapy program is 2HREZ-4HRifb. And the first line of HAART plan is AZT+3TC+EFV and the second line plan is D4T+3TC+EFV.If begin with HAART and the RIF will change to Rifb.
1901572|NCT01344161|Dietary Supplement|Placebo|dosage form:lactose dosage: 25 micrograms frequency: every day duration: 12weeks
1901573|NCT01344161|Dietary Supplement|vitamin D|dosage form:cholecalciferol dosage: 25 micrograms (1000 International Unit) frequency: every day duration: 12weeks
1901574|NCT01344174|Drug|5 days dexamethasone therapy|dexamethasone 10mg, intravenously, po daily for the first 5 days
1901575|NCT01344187|Drug|riboflavin solution|0.12% riboflavin ophthalmic solution
1901576|NCT01344187|Drug|placebo solution|0.0% riboflavin ophthalmic solution
1901577|NCT01344187|Device|KXL System|30 mW/cm2
1901578|NCT01344200|Drug|Celecoxib|"All patients, on day of first scheduled LP, will receive celecoxib suspension 10 mg/kg by mouth 180 mins before their scheduled LP. Prior to beginning the second cycle of chemotherapy the patients will be randomly allocated to either of 2 cohorts (CSF dose timing cohort versus dose escalation cohort). The CSF dose timing cohort patients will be assigned to receive celecoxib 10 mg/kg at a predetermined time (60 mins, 120 mins, 300 mins and 900 mins before LP+/- BM) and they will rotate in chronological order for four chemotherapy cycles to complete the remaining time points of interest. The dose escalation cohort patients, at the beginning of each cycle of chemotherapy, will be administered either 6 or 14 mg/kg celecoxib 180 mins before LP for a total of 4 chemotherapy cycles.
Approximately 8-12 hours after the first dose, each patient will be required to ingest a second dose of celecoxib suspension (one half of the premedication dose) with food."
1901579|NCT01344213|Drug|Pregabalin|Oral single-dose of pregabalin (150 mg) and placebo (P) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
1901580|NCT01344213|Drug|Celecoxib|Oral single-dose of celecoxib (400 mg) and placebo(C)1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
1901581|NCT01344213|Drug|Pregabalin with celecoxib|Oral single-dose of pregabalin (150 mg) and celecoxib (400 mg) (PC) 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg.
1901582|NCT01344213|Drug|Placebo|Oral single dose of placebo 2 capsules 1-2 hours before starting spinal anesthesia with intrathecal morphine 0.2 mg
1901585|NCT01344252|Drug|Lidocaine|We will made anesthesia with topical lidocaine and compared with subtenon anesthesia
1901586|NCT01344278|Behavioral|Lifestyle Counseling|A lifestyle curriculum of individualized telephone counseling calls, augmented with e-mails and an interactive study Web site.
1901587|NCT01344291|Drug|Curcumin|Curcumin is prescribed to new cases of hyperprolactinoma
1901588|NCT01344304|Drug|Aprepitant / Fosaprepitant|"Aprepitant:
125 mg PO on day 1 80 mg PO on days 2 to 3
Fosaprepitant:
150 mg IV on day 1"
1901589|NCT01344343|Other|Accelerated surgical hip fracture repair|Accelerated hip fracture surgery defined as arrival in the operation room within 6 hours of diagnosis of a hip fracture requiring surgery
1901590|NCT01344356|Radiation|stereotactic body radiotherapy|14-16 Gy / 1 fraction OR 18-21 Gy / 3 fractions (6-7 Gy per fraction)OR 25-45 Gy / 5 fractions (5-9 Gy per fraction)
1901591|NCT01344356|Radiation|Stereotactic body radiotherapy|8-12 Gy / 1 fraction OR 12-18 Gy / 3 fractions (4-6 Gy per fraction) OR 35-45 Gy / 5 fractions (7-9 Gy per fraction)
1901592|NCT01344369|Drug|Norethindrone/Ethinyl Estradiol|0.4 mg/0.035 mg Chewable Tablets
1901593|NCT01344369|Drug|FEMCON® Fe|0.4 mg/0.035 mg Chewable Tablets
1901594|NCT01344382|Behavioral|Community Reinforcement and Family Training|The philosophy of Community Reinforcement and Family Training (CRAFT) is that drug abuse is caused by multiple biological and environmental factors, many of which are beyond the parents' control. However, because parents have an important relationship with their child, they may able to influence his or her behavior. CRAFT for parents (CRAFT-P) will teach the parent new ways to interact with their child. Sessions will be designed to build the parents' motivation to comply with the training, conduct a functional analysis of their child's drug use pattern, train methods of behavior management and communication skills, enrich the parent's life and to suggest and motivate treatment entry.
1901595|NCT01344382|Behavioral|Al-Anon Facilitation|Al-Anon Facilitation (ANF) parallels the Twelve Step Facilitation intervention developed by Nowinski et al. (1992) for Project MATCH. The content focuses on introducing parents to Alanon or Naranon's purpose and philosophy, educating about 12-step concepts, the fellowship community, denial and enabling, acceptance, caring detachment, and surrendering to a higher power. The trainer's role is to help the parent to gain insight into the ways they interact with their child and to educate and encourage the parent to become actively involved in a 12-step community and to take advantage of its many offerings.
1901596|NCT01344395|Drug|ropivacaine and ketorolac|The RK-group receives four intra-articular injections via catheter with a total volume of 40 ml (380 mg ropivacaine and 60 mg ketorolac) combined with 4 intravenous injections of saline during 24 hours postoperatively
1901597|NCT01344395|Drug|Ketorolac|The K-group receives four intra-articular injections via catheter with a total volume of 40 ml saline combined with 4 intravenous injections of ketorolac (total 60 mg) during 24 hours postoperatively
1901598|NCT01344408|Procedure|Computer-training|"The computer-training program Move IT To Improve IT is a exercise program which is installed and used on a Apple Imac in the patients home to support vestibular rehabilitation"
1901601|NCT01344460|Drug|Gadobutrol (Gadovist, BAY86-4875)|a single bolus injection of approx. 0.1mmol/kg
1901602|NCT01344473|Device|Tooth Mousse creme (Casein Phosphopeptide)(RECALDENT)|TM is a water based creme containing RECALDENT. RECALDENT consists of CPP-AP: Casein Phosphopeptide - Amorphous Calcium Phosphate.
1901603|NCT01344486|Procedure|full conditioning|addition of 4% oxygen + 10% nitrous oxide to the pneumoperitoneum + humidification + temperature regulation at 32°C
1901604|NCT01344486|Procedure|standard pneumoperitoneum|100% carbon dioxide used for the pneumoperitoenum
1901605|NCT01344499|Procedure|Carbon dioxide|standard pneumoperitoneum with 100% CO2
1901606|NCT01344499|Procedure|full conditioning|Pneumoperitoneum with CO2 + 4% of oxygen + 10% nitrous oxide + 100% RH + T° 32°C
1901607|NCT01344499|Drug|Adept|instillation of 1 liter of fluid at the end of laparoscopy
1901608|NCT01344499|Drug|Ringer Lactate|instillation of 1 liter of fluid at the end of laparoscopy
1901609|NCT01344512|Drug|Ceftazidime|Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.
1901610|NCT01344512|Drug|Ciprofloxacin|Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.
1901611|NCT01344512|Drug|Voriconazole|Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.
1901612|NCT01344525|Procedure|Laparoscopic gastric sleeve|Laparoscopic gastric sleeve
1901613|NCT01344525|Procedure|Gastric Banding|Gastric Banding
1901614|NCT01344525|Procedure|Multidisciplinary lifstyle intervention|Multidisciplinary lifstyle intervention (OPTIFAST®52-program)
1901615|NCT01344525|Procedure|Roux-en-Y Bypass|Roux-en-Y Bypass
1901616|NCT01344538|Drug|Ginger Root Extract (Pure Encapsulations)|2.0 g per day (10:1 extract)
1901617|NCT01344538|Dietary Supplement|Placebo Capsule|2.0 g per day
1901618|NCT01344551|Dietary Supplement|Cocoa Drink|High Flavanol (495mg) Low Flavanol (23mg) Matched for macro and micro nutrients
1901619|NCT01344564|Drug|Degarelix acetate, Leuprolide acetate|Degarelix acetate, 1 mo depot for 3 months Leuprolide acetate, 3 mo depot once
1901620|NCT01338883|Drug|Cenicriviroc 100 mg|100 mg CVC plus Truvada
1901621|NCT01338883|Drug|Cenicriviroc 200 mg + Truvada|200 mg CVC plus Truvada
1901622|NCT01338883|Drug|Sustiva + Truvada|Sustiva plus Truvada
1901623|NCT01338896|Drug|Rotigotine transdermal patch|8 mg/24 h, transdermal patch 8 mg/24 h, 2 days
1901624|NCT01338909|Drug|Prasugrel|Prasugrel 60mg immediate loading dose (Day 0)followed by 10mg/day starting from Day 1 until Day 5
1901625|NCT01338909|Drug|Clopidogrel|Clopidogrel 150mg/d starting from Day 1
1901626|NCT01338922|Other|Insulin Pump Therapy|Continuous subcutaneous insulin infusion therapy
1901627|NCT01338922|Other|Multiple daily injection therapy (usual care)|Multiple daily injection therapy
1901628|NCT01338935|Drug|CW 002|"For Cohort 1, subjects receive a single bolus of 0.02 mg/kg CW 002 (i.v.) and neuromuscular function will be allowed to recover spontaneously for at least 5 half-lives.
For Cohort 2, an estimated ED50 bolus dose of CW 002 (approximately 0.03 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.
For Cohort 3, an estimated ED 75 bolus dose of CW 002 (approximately 0.04 mg/kg) will be given i.v. followed by a second bolus of the same dosage *.
For Cohort IV, an estimated ED 90 bolus dose of CW 002 (approximately 0.06 mg/kg) will be given i.v. followed by a second bolus of the same dosage*.
*For Cohorts 2-4, a second bolus dose will be administered following a minimum of 5 half-lives of CW002 (based on PK data from Cohort 1)."
1901629|NCT01338935|Drug|CW 002|"Subjects receive an initial ascending bolus dose of CW 002 injection, and a second bolus followed by a continuous infusion initiated at the point of 25% recovery of twitch response. Infusion rate will be adjusted to maintain 97%- 99% suppression of twitch, but to avoid complete neuromuscular block. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.
Cohort 5- subject receives 2.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 30 min infusion of 2-10 mcg/kg/min of CW 002
Cohort 6 - subject receives 3.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 60 min infusion of 2-10 mcg/kg/min of CW 002
Cohort 7 - subject receives 4.0x ED95 dose of CW 002, followed by 1.5x ED95 dose and 90 min infusion of 2-10 mcg/kg/min of CW 002
Bolus doses of ED95 are determined in Part I of the study."
1901630|NCT01338935|Drug|CW 002|"In Part III, safety, intubation efficacy, and PK will be evaluated in 2 cohorts (Cohorts 8 and 9) of 6 subjects each, who will undergo endotracheal intubation at 60 or 90 seconds after a bolus dose of CW002 injection at 3 to 4 times the ED95. For the first 3 subjects of each cohort, CW 002 will be allowed to recover spontaneously. For the second 3 subjects, reversal will be performed at the appearance of 1st twitch using 0.05 mg/kg neostigmine and 0.01 mg/kg glycopyrrolate.
Cohort 8 - subject receives 3.0x ED95 dose of CW 002, and intubation attempt is made 90 seconds post-bolus.
Cohort 9 - subject receives 4.0x ED95 dose of CW 002, and intubation attempt is made 60 seconds post-bolus."
1901631|NCT01338948|Procedure|preoperative 3D-CT reconstruction|Robotic Surgery with CT reconstruction images using Tile-pro program.
1901632|NCT01338961|Procedure|Hypothermic CPB|Patients will be cooled to 31-32oC (nasopharyngeal) after the beginning of CPB. Rewarming will begin 10-15 min before release of aortic cross-clamp. The gradient between heat-exchanger and nasopharynx during rewarming will be maintained at 3oC. The rewarming will be stopped at 36,5oC
1901633|NCT01338974|Genetic|gene expression analysis|
1901634|NCT01338974|Genetic|proteomic profiling|
1901635|NCT01338974|Other|flow cytometry|
1901636|NCT01338974|Other|laboratory biomarker analysis|
1901644|NCT01339000|Drug|Glycosylated Recombinant Human Interleukin-7|Interleukin-7 (CYT 107) 20 microgram/kg / dose, by intramuscular (IM) injection
1901645|NCT01339000|Biological|Diphtheria/Tetanus Vaccine|Diphtheria/Tetanus Vaccine will be administered according to the random schedule per protocol.
1901646|NCT01339000|Biological|Polio Vaccine|Polio Vaccine will be administered according to the randomized schedule per protocol.
1901647|NCT01339000|Biological|Pneumococcal Vaccine|Pneumococcal Vaccine will be administered according to the randomization schedule per protocol.
1901648|NCT01339000|Biological|Hepatitis A Vaccine|Hepatitis A Vaccine will be administered according to the randomization schedule per protocol.
1901649|NCT01339000|Biological|Hepatitis B Vaccine|Hepatitis B vaccine will be administered according to the randomization schedule per protocol.
1901650|NCT01339013|Device|Anesthetic Conserving Device (AnaConDa )|Standard HME was replaced by AnaConDa. AnaConDa has charcoal filter, HME does not.
1901651|NCT01339026|Drug|Prasugrel|Day 1 loading 60mg Day 2 to 7 10mg o.d. Day 8 to 30 days 10mg od
1901652|NCT01339026|Drug|Plavix|Clopidogrel (Plavix) Day 1 Loading 600mg Day 2 to 7 day: 150mg o.d. Day 8 to 30 days: 75mg o.d.
1901653|NCT01339039|Drug|Plerixafor|Given subcutaneously once a day for 3 weeks followed by 1 week off (standard 3x3 design); MTD determined in Part 1 will be used as dose in Part 2.
1901654|NCT01339039|Drug|Plerixafor|Given subcutaneously once daily; MTD determined in Part 1 will be used as dose in Part 3.
1901655|NCT01339039|Drug|Bevacizumab|Given intravenously on days 1 and 15 (10 mg/kg) of each 28-day cycle
1901656|NCT01339039|Drug|Plerixafor|Daily administration for 5-9 days prior to surgery
1901657|NCT01339039|Procedure|Surgery|After receiving 5-9 days of Plerixafor (AMD3100) monotherapy, patients proceed to surgery. After recovering from surgery, patients will proceed to 28-day post-surgical cycles of therapy (Plerixafor at the MTD established in Part 1, 21 days on / 7 days off; bevacizumab 10 mg/kg on days 1 & 15).
1901658|NCT01339052|Drug|BKM120|
1901659|NCT01339052|Procedure|Surgery|Surgery
1901660|NCT01339065|Drug|Ketamine|determining the effect of low dose sub anesthetic doze of ketamine and placaebo on post operative patients
1901661|NCT01339078|Procedure|Plastic stenting|The patients receive plastic stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 3 months, for a total duration of 1 year.
1901662|NCT01339078|Procedure|Kaffes stenting|The patients receive Kaffes stenting after ortothopic liver transplantation with a choledocho-choledochal anastomosis, presenting with an anastomotic stricture. These patients will receive change of the stent every 6 months, for a total duration of 1 year.
1901663|NCT01339091|Drug|Dalbavancin|IV Dalbavancin 1000 mg on Day 1 and 500 mg on Day 8
1901664|NCT01339091|Drug|Vancomycin / Linezolid|IV Vancomycin (1 gram Q 12 hours or 15mg/Kg Q 12 hours) with optional switch to oral linezolid (600 mg Q12 hours). Total duration of therapy is 10-14 days.
1901665|NCT01339104|Drug|Regorafenib (Stivarga, BAY73-4506)|All subjects will receive regorafenib administered from Day 1 -21 at a dose of 160 mg od (4 x 40 mg tablets) followed by a 7 days break in repeating cycles of 28 days. The drug is to be taken in the morning with approximately 240 mL of water after having a low fat breakfast. Holter ECGs with triplicate measurements will automatically be obtained at specified timepoints over 24 hours on days -1 and Cycle 1, Day 21. PK samples will be drawn on Cycle 1, Day 21. PK timepoints are time-matched with Holter ECG timepoints. 24 hour urine will be collected beginning on Cycle 1, Day 21. MUGA scans will be done at screening, Cycle 2 Day 21 (after 42 doses of BAY73-4506), then every 3 cycles starting in Cycle 5, and at end of treatment.
1901666|NCT01339117|Other|Low fermentable substrate diet|Diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols.
1901667|NCT01339117|Other|High fermentable substrate diet|Diet high in fermentable oligosaccharides, disaccharides, monosaccharides and polyols
1901668|NCT01339130|Behavioral|Computerized tests and Electrophysiological measurements|"Computerized tests: used to evaluate the empathy The participant observes a computer screen on which appears different types of images or words that can evoke an emotion. The participant responds by pressing the screen with his finger. This is a choice between several answers and respond as quickly as possible.
Electrophysiological measurements: provide a measure of autonomic response to emotional stimuli: galvanic response (GSR) and electromyographic activity (EMG) of facial muscles (corrugator supercilii and zygomatic major).
Neuropsychological assessment includes an assessment of intellectual efficiency, perceptual and visual-constructive abilities, memory, executive and an assessment of behavior and mood from questionnaires."
1901669|NCT01339143|Drug|Galvus (vildagliptin)|50mg BID, PO, for 16 weeks
1901670|NCT01339143|Drug|pioglitazone|15mg, QD, PO, 16 weeks
1901671|NCT01339156|Drug|P3914|"Part A:
The subjects will be fasted overnight for at least 10 hrs.The drug will be administered orally to each subject in sitting posture.
Part B:
Dosing will start on Day 1. Each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).
The investigational product will be administered orally to each subject with 240 mL of water.
Part C:
Dosing will take place on Day 1 of each study period. Each subject will receive a single oral dose.
For administration of P3914 tablets subjects will be required to fast for 10 hrs prior to dosing.
Part D:
Patients will be fasted for at least 4-6 hrs. The investigational product will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
1901672|NCT01339156|Drug|Placebo|"Part A:
The subjects will be fasted overnight for at least 10 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture.
Part B:
Dosing will start on Day 1. It is planned that each subject will receive the investigational product under fasting conditions for 14 days (Days 1 to 14).
The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject with 240 mL of water.
Part D:
Patients will be fasted for at least 4-6 hrs. The investigational product (allocated as per the randomisation schedule) will be administered orally to each subject in sitting posture on day 1 within 6 hrs of first administration of anesthesia (day of dental surgery)."
1901713|NCT01344876|Drug|OPB-51602|once daily during the treatment period
1901674|NCT01344590|Other|Normal Saline|Standard saline procedure will be utilized.
1901675|NCT01344590|Other|Ethanol 70% pharmaceutical grade|70% pharmaceutical grade ethanol will be instilled in the line in a volume calculated to fill the lumen and the hub.
1901676|NCT01344616|Behavioral|lifestyle support|computer-based lifestyle improvement support and clinician support
1901677|NCT01344629|Drug|Telmisartan/Amlodipin FDC|Telmisartan80mg/Amlodipin5mg FDC
1901678|NCT01344629|Drug|Telmisartan|Telmisartan 80 mg tablet
1901679|NCT01344629|Drug|Amlodipin|Amlodipin 5mg tablet
1901680|NCT01344655|Drug|Atimos®|Formoterol 12 μg pMDI
1901681|NCT01344655|Drug|Serevent™|Salmeterol 25 µg pMDI
1901682|NCT01344655|Drug|Placebo|placebo
1901683|NCT01344668|Other|Enhanced Diabetes Education|Provide enhanced diabetes education
1901684|NCT01344668|Other|Standard Diabetes Education|Provide Standard Diabetes Education
1901685|NCT01344681|Drug|Micafungin sodium|"Treatment period (active treatment): an average 14 days
Dosage:
- Study Drug: Micafungin sodium (mycamine ® injections 50mg/vial) 2 vials (100mg / day)
Administration Method:
Study Drug: 3-5 days after fever begins. Infusion one time a day (one hour). Termination of treatment after maintaining fever for three days or the recovery of neutrophils with no fever."
1901686|NCT01344681|Drug|Itraconazole|"Treatment period (active treatment): an average 14 days
Dosage:
- Active Comparator: Itraconazole (Sporanox ® injection) 200 mg 2 times(400mg / day)
Administration Method:
Active Comparator: 200 mg two times(400 mg) a day, total of 4 times for 2 days and then one times (200 mg) a day for 12 days. Termination of treatment after keeping fever for three days or the recovery of neutrophils with no fever."
1901687|NCT01344694|Other|patient with liver fat|30 patient with liver fat
1901688|NCT01344694|Other|pts. with excess of visceral fat|pts. with excess of visceral fat
1901689|NCT01344694|Other|control|30 control subjects
1901690|NCT01344707|Drug|4SC-202|oral administration dose escalation twice daily (bid)or three times a day (tid) continuous dosing for 21 days per cycle
1901691|NCT01344720|Drug|etoricoxib|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.
Group 1 non-responders will receive an increase in monotherapy from etoricoxib 30mg to eterocoxib 60mg/die."
1901692|NCT01344720|Drug|oxycodone|"At visit 2 eligible patients will then receive Etoricoxib 30mg for 2 weeks. Patients who achieve a clinically meaningful improvement in pain at the end of this period (defined as a ≥30% improvement in BPI avg daily pain intensity), will continue therapy up to week 5 (visit 4), if they become non-responders between week 4-5, they can be tapered off meds and then discontinued from the study. Patients who do not achieve a clinically meaningful improvement will be considered non-responders and will be randomized to receive either titration of their monotherapy or combination treatment.
Group 2 non-responders will receive in addition to etoricoxib 30mg/day a dose of oxycodone CR 5mg q12hr (dose of 5mg tablet is available in Italy)."
1901693|NCT01344759|Drug|Dexmedetomidine|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of dexmedetomidine 1 mcg/kg will be administered over 10 minutes followed by a continuous infusion of dexmedetomidine at rate of 1 mcg/kg/h using a syringe pump.
1901694|NCT01344759|Drug|Propofol|Once an IV is in place, atropine 10 mcg/kg will be given. Loading dose of propofol 2 mg/kg will be administered over 2 minutes followed by a continuous infusion of propofol at rate of 100 mcg/kg/minute using a syringe pump.
1901695|NCT01344772|Procedure|Internal fixation|Two cannulated screws are placed under x-ray guidance
1901696|NCT01344772|Procedure|Total hip arthroplasty|A total hip arthroplasty is performed through a standard posterior approach
1901697|NCT01344785|Procedure|Intramedullary nailing|All patients will be treated with Intramedullary nailing
1901698|NCT01344798|Biological|AAV1-gamma-sarcoglycan vector injection|single intramuscular injection into carpi radialis muscle under open procedure
1901699|NCT01344811|Procedure|Telemonitoring|The Telemonitoring group will be provided the Smartphone, body composition analyzer and pedometer. They should visit the site once per every 3 months (12 weeks), and measure their body composition during study period. After measurement of body composition, the subjects should make transmit measured information through Smartphone into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote body composition and activity monitoring and individual obesity case management
1901700|NCT01344811|Other|control group|The control group will receive a weighting scale and pedometer. They should perform the same weight measurement (minimum three times a week) like the intervention group during the study, and measured results should be recorded in a diary of self body weight and the number of steps. In addition, the subjects should visit the site once per every three months (12 weeks).
1901705|NCT01344837|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1901706|NCT01344837|Other|Immunohistochemistry Staining Method|Correlative studies
1901707|NCT01344837|Other|Medical Chart Review|Correlative studies
1901708|NCT01344837|Genetic|Microarray Analysis|Correlative studies
1901709|NCT01344837|Other|Study of Socioeconomic and Demographic Variables|Correlative studies
1901710|NCT01344837|Genetic|Western Blotting|Correlative studies
1901711|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a single-use injection device on Day 1
1901712|NCT01344863|Drug|trastuzumab [Herceptin]|600 mg subcutaneously using a handheld syringe on Day 1
1901714|NCT01344902|Drug|hexaminolevulinate HCl|200mg hexaminolevulinate HCl capsule 6 hours before colonoscopy
1901715|NCT01344915|Procedure|Locked knee brace|
1901716|NCT01344915|Procedure|Locked knee brace|
1901717|NCT01345227|Procedure|Intra bone marrow islet infusion|A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
1901718|NCT01345240|Biological|GlaxoSmithKline (GSK) Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|Children enrolled in 9 groups will receive 3 doses of the candidate malaria vaccine (Lot 1, 2 and 3) by intramuscular injection.
1901719|NCT01345240|Biological|Engerix-B™ vaccine|Children enrolled in 2 groups will receive 4 doses of Engerix-B™ vaccine by intramuscular injection. Children enrolled in all other groups will receive one dose of Engerix-B vaccine by intramuscular injection.
1901720|NCT01345240|Biological|Infanrix/Hib™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Infanrix/Hib™ vaccine by intramuscular injection
1901721|NCT01345240|Biological|Polio Sabin™ vaccine|Children enrolled in all 11 groups will receive 3 doses of Polio Sabin™ by intramuscular injection.
1901722|NCT01345240|Biological|Rotarix™ vaccine|Children enrolled in all 11 groups will receive 2 doses of oral Rotarix™ vaccine.
1901723|NCT01345240|Biological|Synflorix™ vaccine|Children enrolled in all 11 groups will receive 4 doses of Synflorix™ vaccine by intramuscular injection.
1901724|NCT01345240|Biological|Measles vaccine|Children enrolled in all 11 groups will receive 1 dose of measles vaccine by intramuscular injection.
1901725|NCT01345240|Biological|Yellow fever vaccine|Children enrolled in all 11 groups will receive 1 dose of yellow fever vaccine by intramuscular injection.
1961034|NCT03030547|Device|SenseWear activity monitor|Individuals will wear SenseWear activity monitors on right triceps muscle for 5 days. The data stored on the device will be recorded in computer using the software. Individuals will be given information of the resulting data (total number of steps, total energy expenditure, the number of daily steps and energy expenditure, physical activity duration in different intensity).
1901728|NCT01345266|Procedure|Inhalation Profiling|All subects recieve Inhaltion Profiling there are no interventions.
1901729|NCT01345279|Drug|cisplatin|50 mg/m2 IV cisplatin on day 1 and then every 3 weeks for 6 courses
1901730|NCT01345279|Drug|topotecan|topotecan 0.75 mg/m2 on days 1, 2, and 3. The regimen was repeated every 3 weeks for 6 courses
1901731|NCT01345279|Drug|paclitaxel|135 mg/m2 paclitaxel on day 1 and then every 3 weeks for 6 courses
1901732|NCT01345292|Device|Mouthwash|Rinse with 10 ml of the assigned mouthwash for 60 seconds after you brush in your usual manner twice daily for one minute using at least a one-inch strip of the assigned toothpaste
1901733|NCT01345292|Drug|Potassium nitrate toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
1901734|NCT01345292|Drug|Sodium fluoride toothpaste|Brush in your usual manner twice daily for at least one minute using at least a one-inch strip of the assigned toothpaste
1901735|NCT01345318|Biological|PF-04236921|Subjects entering this study will be given a 50 mg SC dose at baseline and then every 8 weeks through Week 40.
1901736|NCT01345318|Biological|PF-04236921|Dose escalation to 100 mg SC every 8 weeks will be allowed for subjects who have either not responded at Week 8 or have relapsed during the study.
1901737|NCT01345331|Behavioral|Real stimulation VS Sham|Ear stimulation at specific points should work by stimulating a nerve called the vagus nerve. Previous research has shown that stimulating this nerve can help patients feel less pain. During any testing session, participants may receive either the real ear stimulation or a sham (placebo) treatment. The sham treatment will use the same equipment as the real treatment, but will not deliver any real stimulation to the ear. We use placebo/sham procedures in research to make sure that the study results are related to the study procedure, and not to other reasons.
1901738|NCT01345344|Behavioral|Cognitive Behavioral Therapy|Practicing certain strategies such as relaxation and changing negative thoughts about pain.
1901739|NCT01345344|Behavioral|Education|Giving participants information about pain and how to change perceptions of pain.
1901740|NCT01345357|Drug|CEP-9722|CEP-9722 will be administered orally from day 2 through day 7 of each cycle beginning with cycle 2. The starting dose will be 150 mg twice daily. Following cycle 2, the dose will either be decreased to 150 mg daily or increased to 200 mg twice daily in a cohort of 3 to 4 new patients. Subsequent cycles will increase the dose by 100 mg twice daily in cohorts of 3 to 4 patients (with criteria to expand to 6 patients) to a maximum of 400 mg twice daily. Patients must receive CEP-9722 to remain in the study. Once treatment with CEP-9722 is discontinued, patients will withdraw from the study.
1901741|NCT01345357|Drug|Gemcitabine|Gemcitabine will be administered at 1250 mg/m^2 intravenously on day 1 and day 8 of each 21-day cycle. Dosage reduction may be applied on day 8 (within a cycle) or on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
1901742|NCT01345357|Drug|Cisplatin|Cisplatin will be administered at 75 mg/m^2 intravenously on day 1 of each cycle, after the infusion of gemcitabine. Dosage reduction may be applied on day 1 of the next cycle based upon the grade of toxicity experienced by the patient.
1901743|NCT01345370|Drug|Temozolomide|According to sites procedures
1901744|NCT01345370|Radiation|Radiation Therapy|According to sites procedures
1901745|NCT01345383|Procedure|bronchoscopy|Routine bronchoscopy under local anesthesia (lidocain). Duration: +/- 10 min
1901746|NCT01345396|Behavioral|Health education about asthma|Three face-to-face appointments (<20, 36 weeks of gestation and 12 weeks after the baby birth). Topics: What is asthma? What influence the course of asthma? How to monitor it? How to manage it?
1901747|NCT01345422|Other|Wii Balance Board|Participant will undergo Nintendo Wii Balance Board training for two months , five days a week for 30 minutes
1901808|NCT01345851|Radiation|stereotactic body radiation therapy|Undergo hypofractionated RT
1901809|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
1901748|NCT01345435|Procedure|Telemonitoring group|The Telemonitoring group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should visit the site once per every 2 months (8 weeks), and measure their blood glucose using a provided blood glucose monitor twice a day during study period (once after first morning urination and once before going to bed). After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management
1901749|NCT01345435|Procedure|Telemonitoring & Telemedicine|The Telemonitoring & Telemedicine group will be provided blood glucose meter, body composition analyzer, and remote monitoring PC. They should measure their blood glucose using a provided blood glucose monitor twice a day during the study period. After measurement of blood glucose and body composition, the subjects should make transmit measured information through Smart Care PC into a centralized server of Smart Care Center. At Smart care Center, care manager will provide remote blood glucose monitoring and individual diabetes case management. A remote medical doctor should provide medical consultation to the subjects through videotelephony using the remote monitoring PC and then issue electronic prescriptions.
1901750|NCT01345435|Other|SMBG|The subjects who are assigned in the control group will be provided blood glucose Monitor. The subjects who are assigned in the control group should perform the same blood glucose measurement same as the test group during the study, and measured results should be recorded in a diary of self blood glucose measurement. In addition, the subjects should visit the site once per every two months (8 weeks).
1901751|NCT01345448|Drug|Brimonidine|0.1% Brimonidine Lotion, dosed once.
1901752|NCT01345448|Drug|Placebo Lotion|Placebo Lotion dosed once.
1901753|NCT01345461|Device|transcutaneous electrical muscle stimulation, (model DS7A, Digitimer, Welwyn, Garden City, Hertfordshire, UK)|two constant current high voltage stimulators delivered ten single stimuli twitches with biphasic square pulses at widths of 300 μs. A train generator was then switched on, triggering the delivery a 35 Hz current in bouts of 3 seconds periods separated by 1-second pause for a total of 40 tetanic contractions. In immediate succession to the tetanic contractions a second series of ten single twitch stimuli ended the protocol.
1901754|NCT01345474|Drug|D-methionine, oral liquid suspension|Two daily doses of up to 100mg/kg/day of D-met for 18 days
1901755|NCT01345474|Other|Placebo Comparator|Equal volume placebo.
1901756|NCT01345487|Other|Vegetable Protein|Vegetable protein in the form of fava beans/split peas
1901757|NCT01345487|Other|Animal protein|Protein in the form of minced pork/beef
1901758|NCT01345500|Other|Higher Carbohydrate, Lower Fat Diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower fat, higher carbohydrate diet provides 60% energy from carbohydrate, 20% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
1901759|NCT01345500|Other|Lower carbohydrate, Higher fat diet|Study participants will receive prepackaged prepared foods as needed to achieve a meal plan, free-of-charge for a 12-month period. The lower carbohydrate, higher fat diet provides 45% energy from carbohydrate, 35% energy from fat, and 20% energy from protein. The diet falls within the range of current dietary recommendations.
1901760|NCT01345500|Other|Individualized Counseling|Participants assigned to the usual care group will be provided consultation with a research staff dietetics professional, who will provide publicly available print material that describes dietary and physical activity guidelines to promote weight loss and maintenance, at baseline (after randomization) and again at 6 months.
1901761|NCT01345513|Other|Sample Collection for Genome-Wide Sequencing|Collection of archival tumor tissue, fresh tumor biopsy, blood sample, and pleural effusion (if available)or ascites (if available)
1901762|NCT01345526|Device|Reconval K1 Cream|
1901763|NCT01345526|Device|Reconval Cream|
1901764|NCT01345539|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size, the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, adrenal, and liver sites were being treated, both lung sites could be treated Monday, Wednesday, and Friday, the liver on Tuesday, Thursday and the following Tuesday, and the adrenal on Monday, Wednesday, Friday of the second week.
1901765|NCT01345552|Radiation|Stereotactic Radiosurgery (SRS)|Dose and fractionation will be dependent on the lesion location and lesion size and is up to the exact fractionation and dose is at the discretion of the treating physician. A minimum of 48 hours must be used in between SRS treatments at each site. Note that patients can have SRS everyday or multiple SRS sessions in one day as long as the minimum time for each treatment site is met. For example, if two lung lesions, brain, adrenal, and liver sites were being treated both lung sites could be treated Monday, Wednesday, and Friday and the adrenal, liver and brain lesions treated Tuesday, Thursday
1901766|NCT01345565|Drug|human hepatocytes|"The intrahepatic site for liver cell transplantation has been associated with the best engraftment and function based on animal experiments. Several approaches for access to the portal vein will be considered. The technique used will be determined based on what is considered best for the child based on risk/benefit at the time.
We propose to attempt to infuse approximately 5-10% of the hepatic mass in order to provide improved hepatic function. Since we do not yet know from our experience so far the correct number of cells to transplant in order to improve function, we will continue to infuse hepatocytes as donors become available until the patient improves to the point where they are no longer meet the criteria for organ transplantation. The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant."
1901810|NCT01345864|Drug|Scopolamine + Donepezil 5 mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 5 mg tablet orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
1901811|NCT01345864|Drug|Scopolamine + Donepezil 10mg + PF-04995274 Placebo|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil 10 mg (2 x 5 mg tablets) orally x 1 dose on Day 1 PF-04995274 matching placebo oral liquid x 1 dose on Day 1
1901812|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 0.25 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 0.25 mg oral liquid x 1 dose on Day 1
1901767|NCT01345578|Drug|human hepatocyte transplantation|"Transplantation of hepatocytes into the liver will be through the portal vein. The portal vein will be accessed transhepatically, by umbilical vein, or surgically by a peripheral mesenteric vein.
The subject will be evaluated de novo and if they are a candidate for orthotopic liver transplantation they will receive the transplant. Even if the subject receives the hepatocyte transplant and it does not work, they will be evaluated for orthotopic liver transplantation as if they never received the hepatocyte transplant.
If at 6 months we see an improvement in disease, we will recommend a re-transplantation with a goal of complete correction of disease and until the subject is no longer required to be a candidate for organ transplantation. Subjects will be re-evaluated every 6 months for re-transplantation. Subjects will remain on the waiting list for organ transplantation. Further radiation therapy will not be needed prior to re-transplantation."
1901768|NCT01345578|Radiation|Preparative Radiation Therapy|Just prior to the hepatocyte transplant, a portion of the right hepatic lobe comprising between 35-50% of the entire liver volume will be irradiated to a dose of 7.5-10 Gy in a single fraction using a linear accelerator-based stereotactic radiosurgery system with intensity-modulated radiation therapy planning (IMRT).
1901769|NCT01345591|Procedure|Fat Grafting|
1901770|NCT01345604|Procedure|transcruciate injection of 20cc of normal saline|Group 2 (control group) will receive a transcruciate injection of 20cc of normal saline through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
1901771|NCT01345604|Procedure|transcruciate injection of 20 cc of 0.5% Ropivacaine|Group 1 (study group) will receive a transcruciate injection of 20 cc of 0.5% Ropivacaine through the posterior cruciate ligament during the procedure (in addition to a subarachnoid block and femoral nerve block pre-operatively).
1901772|NCT01345630|Drug|Maraviroc|Maraviroc tablet 150 mg once daily for 96 weeks.
1901773|NCT01345630|Drug|Emtricitabine/tenofovir|Emtricitabine/tenofovir tablet 200/300 mg once daily for 96 weeks.
1901774|NCT01345630|Drug|darunavir/ritonavir 800/100 mg|darunavir/ritonavir 800/100 mg
1901775|NCT01345630|Drug|placebo for emtricitabine/tenofovir|placebo for emtricitabine/tenofovir
1901776|NCT01345630|Drug|placebo for maraviroc|placebo for maraviroc
1901777|NCT01345643|Other|Maintenance of hemoglobin level not less than 10g/dL|The patient's hemoglobin level is maintained not less than 10g/dL perioperatively.
1901778|NCT01345643|Other|Transfusion trigger based on WCPTS|Determination of whether a patient needs red blood cell transfusion or which hemoglobin level should be maintained is based on WCPTS
1901779|NCT01345656|Drug|BAY94-8862|Two 1.25 mg BAY94-8862 and 2 placebo tablets for duration of 4 weeks
1901780|NCT01345656|Drug|BAY94-8862|Four 1.25 mg BAY94-8862 tablets for duration of 4 weeks
1901781|NCT01345656|Drug|BAY94-8862|One 10 mg BAY94-8862 tablet for duration of 4 weeks
1901782|NCT01345656|Drug|BAY94-8862|Part B only: Four 1.25 mg BAY94-8862 tablets in the morning and four tablets in the evening for duration of 4 weeks
1901783|NCT01345656|Drug|Placebo|Placebo tablets for duration of 4 weeks
1901784|NCT01345656|Drug|Spironolactone|Part B only: 25 mg spironolactone once daily with up-titration to 50 mg once daily starting at day 15, if serum potassium is less or equal to 4.8 mmol/L, for duration of 4 weeks
1901787|NCT01345682|Drug|Afatinib|Once daily
1901788|NCT01345682|Drug|Methotrexate|Weekly
1901789|NCT01345708|Drug|prednisone, low dose rituximab|"Patients with warm AIHA will receive:
Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28), and prednisone 1 mg/kg/die p.o. days from day +1 to day +30, followed by tapering (10 mg/week until 0.5/mg/kg/die, then 5 mg/week until stop)
Patients with CHD will receive:
Rituximab 100 mg i.v.weekly (fixed dose irrespective of body surface area) for 4 consecutive weeks (days +7, +14, +21, +28)"
1901790|NCT01345721|Biological|MenACWY-CRM|
1901791|NCT01345734|Drug|liraglutide|Liraglutide will be prescribed and titrated by the treating physician and will be self-administered by the subject s.c. (under the skin) once daily. Study participants being treated with GLP-1 (Glucagon-Like Peptide 1)agonists or DDP-4-inhibitors (Dipeptidyl-peptidase 4 ) should stop treatment when initiating liraglutide treatment.
1901792|NCT01345747|Device|laryngeal tube (VBM Medizintechnik, Sulz, Germany)|laryngeal tube suction number 3 and 4
1901793|NCT01345773|Procedure|Gastric surgery|Patients receiving gastric cancer surgery will be prospectively observed for the development of venous thromboembolism
1901794|NCT01345786|Drug|Commercial NOMAC-E2|1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination commercial tablet orally in the morning on Day 1 for all periods
1901795|NCT01345786|Drug|"Phase 3 NOMAC-E2 Batch A"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch A) orally in the morning on Day 1 for all periods"
1901796|NCT01345786|Drug|"Phase 3 NOMAC-E2 Batch B"|"1 x 2.5 mg NOMAC/1.5 mg E2 fixed dose combination tablet from the Phase 3 clinical trial program (Batch B) orally in the morning on Day 1 for all periods"
1901797|NCT01345799|Drug|TRK-170|
1901798|NCT01345799|Drug|Placebo|
1901799|NCT01345812|Drug|HP-HMG|100 - 300 IU for stimulation of women in ART treatment
1901800|NCT01345812|Drug|recombinant FSH|100 -300 IU for stimulation of women in ART treatment
1901801|NCT01345825|Other|Resistance training|Week 1: 2 sets x 12 repetitions at 12 RM Week 2: 3 sets of 12 repetitions with 12 RM Week 3: 3 sets of 10 repetitions with 10 RM Week 4-5: 3 sets of 10 repetitions with 10 RM Week 6: 3 sets of 8 repetitions with 8 RM Week 7: 4 sets of 8 repetitions with 8 RM Week 8: 4 sets of 8 repetitions with 8 RM
1901802|NCT01345838|Procedure|labrum|Two years follow-up after PAO, to find any differences among patients with and without known acetabular labral tears
1901803|NCT01345851|Radiation|hypofractionated radiation therapy|Undergo image-guided hypofractionated Radiation Therapy over 35 minutes 5 days a week for 2 weeks
1901804|NCT01345851|Other|laboratory biomarker analysis|Correlative studies
1901805|NCT01345851|Radiation|image-guided radiation therapy|Undergo 5 fractions of image-guided hypofractionated Radiation Therapy boost.
1901806|NCT01345851|Drug|carboplatin|The maximal chemotherapy treatment dose for carboplatin during the 3 week radiation therapy is AUC 2.
1901807|NCT01345851|Drug|paclitaxel|The maximal chemotherapy treatment dose for paclitaxel during the 3 week radiation therapy is 45mg/m2.
1901813|NCT01345864|Drug|Scopolamine + Donepezil Placebo + PF-04995274 15 mg|Scopolamine 0.5 mg subcutaneously x 1 dose on Day 1 Donepezil-matching placebo tablet x 1 dose on Day 1 PF-04995274 15 mg oral liquid x 1 dose on day 1
1901814|NCT01345877|Procedure|first degree cutaneous burn injury|application of thermode (5 x 2.5 cm) to lower leg temperature 47.0 C, 420 s
1901815|NCT01345890|Procedure|electrical stimulation|sub motor threshold stimulation of mylohyoid muscles
1901816|NCT01345903|Procedure|therapeutic conventional surgery|Undergo robotic-assisted surgery
1901817|NCT01345916|Drug|CHF 1535 100/6 NEXT DPI® 2 months|CHF 1535 100/6 NEXT DPI® 2 months
1901818|NCT01345916|Drug|CHF 1535 100/6 pMDI 2 months|CHF 1535 100/6 pMDI 2 months
1901819|NCT01345916|Drug|BDP DPI 2 months|BDP DPI 2 months
1901820|NCT01345929|Drug|CXA-201|CXA-201 IV infusion (1500mg q8) for 7 days
1901821|NCT01345929|Drug|Levofloxacin|Levofloxacin IV infusion (750mg qd) for 7 days
1901822|NCT01345942|Drug|RO5428029|Single oral dose
1901823|NCT01345968|Drug|Ferinject 50 mg/ml|iv administration of max. 50 ml (Dilution: 20 ml in 30 ml NaCl 0.9%) in 30 minutes
1901824|NCT01345968|Drug|NaCl 0.9%|iv administration of max. 50 ml in 30 minutes
1901825|NCT01345981|Drug|Lidocaine|dosage 20 mg and 40 mg
1901826|NCT01345994|Procedure|electro-acupuncture|acupuncture stimulation with electricity
1901827|NCT01346007|Biological|7-valent pneumococcal conjugate vaccine|A 0,5 ml dose of 7-valent pneumococcal conjugate vaccine in both arms A 0,5 ml anamnestic dose of 7-valent pneumococcal conjugate vaccine in subjects with idiopathic nephrotic syndrome 12 months after priming
1901828|NCT01346059|Drug|Vancomycin|Vancomycin solution will be instilled through the colonic catheter every 6 hours. 250cc of solution will be used each time. The solution is 2 grams vancomycin mixed in 1 liter normal saline.
1901829|NCT01346059|Drug|Saline|Saline, used as a placebo, will be instilled through the colonic catheter. Every 6 hours, 250cc of saline will be used.
1901830|NCT01346072|Drug|tolvaptan|oral, 30 mg, single dose, one time administration
1901831|NCT01346085|Drug|CNI free immunosuppression|Immunosuppression consisted of: (i) pre-Tx rapamycin treatment (0.1 mg/kg/day) for at least 30 days; (ii) induction therapy with ATG (1.5 mg/kg/day for 4 days starting at day -1) and a steroid bolus (methyl-prednisolone 500 mg, day -1) plus low dose steroids (prednisone, 10 mg/day) and interleukin-1 (IL-1) receptor antagonist (100 mg/day) for 2 weeks (with ATG and steroid bolus administered only prior to the 1st islet infusion; (iii) maintenance with rapamycin (0.1 mg/kg/day) plus mycophenolate mofetil (2 g/day).
1901832|NCT01346098|Procedure|Pancreaticoduodenectomy with pancreatic anastomosis|Standard lymphadenectomy, end-to-side two-layer pancreaticojejunostomy and duodenojejunostomy will be performed. If the pylorus is preserved, so will be the right gastric artery, unless the artery is damaged or hindering adequate gastric mobilization. No prokinetic agent will be administered routinely, but IV metoclopramide will given on demand (10 mg , three times daily). Prophylaxis will consist of octreotide (0,1 mg three times daily from day 0 to 7), low molecular weight heparin and a single dose of antibiotic (cefazolin 2 g). Early postoperative analgesia will be achieved by epidural or, when contraindicated, patient-controlled analgesia
1901833|NCT01346098|Procedure|Total pancreatectomy with islet autotransplantation|If the patient will be assigned to this group, the surgeon will complete the pancreatectomy preserving the spleen. The body and tail of the pancreas will be sent to the islet isolation facility. Islets will be isolated and purified according to the automated method described by Ricordi. The resulting islet tissue will be suspended in a cold isotonic saline solution and infused into the portal vein during the next 24h.
1901834|NCT01346124|Radiation|High Dose Intensity Modulated Proton Radiation|Radiation given once a day Monday-Friday
1901836|NCT01346163|Drug|PF 03654746|All participants will receive 3 weeks of PF-03654746 and 3 weeks of placebo. PF-03654746 and placebo will be administered in a flexible titration regimen, beginning with 0.5 mg/d. If 0.5 mg/d is well tolerated, the dose will be increased to 1.0 mg/d after 5 days. If 1.0 mg/d is not well tolerated, the dose will be decreased to 0.5 mg/d, with the goal of achieving a stable dose of PF-03654746 within the first two weeks of dosing and avoiding further dose changes during the final week of dosing.
1901837|NCT01346163|Other|Placebo|Placebo will be used as a comparator to the active arm.
1901838|NCT01346176|Other|Advance Directive Forms|Consenting subjects will be randomly assigned to one of 3 study arms. Subjects will receive a different AD form based on which arm they have been randomly assigned. Once a completed AD form is received, a debriefing session will be held to alert patients to exactly how the 3 ADs used in the study differ. Once patients are fully informed about the variations in the ADs, they will have an opportunity to change their AD selections prior to finalizing them as a part of their medical record. A final satisfaction interview will take place with a research associate who will contact patients via telephone to administer a satisfaction questionnaire.
1901840|NCT01346215|Biological|heparin sodium|5000 UI/mL
1901841|NCT01346215|Biological|heparin sodium|5000 UI/mL
1901842|NCT01346228|Behavioral|Panic Control Treatment (PCT)|2 Day treatment for Panic Disorder
1901843|NCT01346241|Behavioral|Intensive Panic Control Treatment (IPCT)|A manualized treatment that consists of psychoeducation about panic disorder
1901844|NCT01346254|Drug|Vildagliptin|50mg tablets once daily 20 min before breakfast for 3 months
1901845|NCT01346254|Drug|Pioglitazone|30mg tablets once daily 20 min before breakfast for 3 months
1901846|NCT01346254|Behavioral|Life-Style Modification|All study participants were counselled regarding life-style modification including regular exercise, weight loss and diet.
1901849|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
1901850|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
1901851|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Measles, Mumps, Rubella + Varicella Virus|0.5 mL, Intramuscular (DTap-IPV); Subcutaneous (M-M-R®II and VARIVAX®)
1901852|NCT01346293|Biological|Diphtheria and Tetanus Toxoids and Acellular Pertussis + Poliovirus + MMR + Varicella Virus|0.5 mL, Intramuscular (IM) DAPTACEL®; Subcutaneous (SC) MMR®II and VARIVAX®; IM or SC IPOL®
1901853|NCT01346306|Device|Eldith Company - direct current stimulator|Direct current stimulation montage 1.
1901854|NCT01346306|Device|Eldith Company - direct current stimulator|Direct current stimulation montage 2.
1901855|NCT01346319|Drug|ABT-SLV361|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
1901856|NCT01346319|Drug|placebo|For dose groups 1, 2 and 3 medication is taken 1 time per day the first day followed by 2 times per day for 14 days. For dose groups 4 and 5, medication is taken 1 time per day for the first day followed by 2 times per day for 28 days.
1901857|NCT01346332|Device|Iontophoresis System with Headset|Iontophoresis of an anesthesia solution to the tympanic membrane using the Acclarent Iontophoresis System with Headset
1901858|NCT01346358|Biological|IMC-CS4|
1901860|NCT01346384|Device|laryngeal tube (VBM Medizintechnik)|laryngeal tube number 4
1901861|NCT01346397|Drug|cyclosporine or tacrolimus|after alemtuzumab, cyclosporine or tacrolimus was administered
1901862|NCT01346410|Radiation|Stereotactic Body Radiotherapy|Suggested fractionation is 20-25 Gy / 1 fraction OR 30-36 Gy / 3 fractions (10-12 Gy per fraction) OR 40-45 Gy / 5 fractions (8-9 Gy per fraction)
1901863|NCT01346423|Behavioral|Interdisciplinary intervention|Interdisciplinary collaboration deals with tasks often complex which require different skills to make a wide assessment.In this study the treatment team consists of a physician, a physiotherapist and a social service worker. The main goal for the team is to make a survey of the patient's situation, in which the biomedical tradition to make a diagnosis is replaced by a disability diagnosis, with systematically identification of barriers for return to work. The conclusion of the team will be followed by a targeted rehabilitation plan. Factors assessed to be the major cause of the reduced function at work will have priority in the following rehabilitation process. One of the team members will be responsible for the further process to follow the plan to help the patient back to work, in cooperation with the patient, the workplace, the general practitioner, and NAV.
1901864|NCT01346423|Behavioral|Control Group, Brief Intervention|The brief intervention is a standardized intervention and the essential features are interview and examination by a specialist in physical medicine and rehabilitation. Patients will be given time to express their concerns and problems in daily activities. The examination is thorough with detailed feedback on findings and normal functions, and clear and consistent explanations on pain and defense mechanisms. Somatic findings will be explained.Unless pathological findings, the patient will be encouraged to physical activity.
1901865|NCT01346436|Procedure|Minimally invasive rectopexy|Use of a minimally invasive approach (robotic or laparoscopy) to perform a rectopexy
1901866|NCT01346449|Behavioral|Provide menu with visual cue and calorie information|Menu to be provided prior to placing the food order.
1901867|NCT01346449|Behavioral|Provide menu with visual cue but no calorie information|Menu to be provided prior to placing the food order.
1901868|NCT01346449|Behavioral|Provide menu with no visual cue but with calorie information|Menu to be provided prior to placing the food order.
1901869|NCT01346449|Behavioral|Provide menu with no visual cue and no calorie information|Menu to be provided prior to placing the food order.
1901870|NCT01346462|Behavioral|Patient-Centered Transition Intervention|Community Health Workers will act as PaCT Partners for uninsured/Medicaid patients who are being discharged from the Hospital of the University of Pennsylvania and Presbyterian Hospital. PaCT Partners will help patients to overcome the challenges of transition, including arranging primary care provider (PCP) follow-up, filling medication prescriptions and obtaining referrals to community-based social services.
1901871|NCT01346475|Drug|valacyclovir|1000 mg orally three times daily for 5 weeks
1901872|NCT01346475|Drug|Valacyclovir|500 mg orally once daily for 5 weeks
1901873|NCT01346514|Behavioral|Intensive Addiction/Housing Case Management|AHCM provided: 1) support in obtaining/maintaining housing through education about resources, coordination with VA and community housing program providers, assistance in establishing housing program eligibility, and problem-solving around threats to housing stability; 2) support for SUD and related issues that affect housing status through treatment engagement/re-engagement, referrals for needed services (e.g. psychiatric, medical, vocational), and addressing substance use issues proactively; 3) promotion of residential stability through Life Skills Training, which was designed to improve key skills (room and self-care, money management, and community participation).
1901874|NCT01346514|Behavioral|Housing Support Group|The HSG focused on gaining support from fellow study participants and learning from those who successfully obtained housing. Group facilitators provided education about housing resources and assistance with housing-related issues.
1901875|NCT01346540|Drug|BIBF 1120|VEGF inhibitor
1901876|NCT01346540|Drug|Placebo|BIBF 1120 placebo
1901877|NCT01346553|Device|ESVV device|wearing the ESVV device for 6 hours
1901878|NCT01346566|Device|Cionni Modified Capsule Tension Ring|Cionni ring was used to fixate the capsular bag to the sclera and IOL was implanted in-the-bag
1901879|NCT01346579|Other|laboratory biomarker analysis|Correlative sciences
1901880|NCT01346592|Biological|Trivalent split influenza vaccine (TIV)|
1901881|NCT01346592|Biological|MF59-adjuvanted trivalent influenza vaccine (aTIV)|
1901882|NCT01346592|Biological|Licensed comparator trivalent split influenza vaccine (comparator TIV)|
1901883|NCT01346631|Other|paleolithic diet|The diet consists of unlimited quantities of meat and fish, fruits and vegetables, eggs, nuts and water. Foods to be avoided include grains, wheat products, legumes, soy, potatoes and corn, rice, legumes, processed meats, soft drinks, dairy products and sugar. Allowed in moderation include coffee, alcohol,cooking oil, honey, salt, dried fruit.
1901884|NCT01346644|Other|Infant formula|Powder infant formula
1901885|NCT01346644|Other|Infant formula|Powder infant formula
1901886|NCT01346657|Drug|Nifidipine & LipoCol|The effect of LipoCol Forte® capsules on the pharmacokinetics of nifedipine after administering single-dose combination in healthy subjects.
1901887|NCT01346670|Drug|LipoCol and Mevacor|To evaluate the relative bioavailability of lovastatin and its ß-hydroxy acid of 600 mg LipoCol Forte® Capsules compared to that of one 20 mg Mevacor® Tablet after single oral administration in healthy subjects using a 2x2 crossover design.
1901888|NCT01346683|Device|OsseoSpeed TX|OsseoSpeed TX implants of lengths 8-17 mm
1901889|NCT01346696|Device|OsseoSpeed™ TX implants|OsseoSpeed™ TX implants of length 6 mm
1901890|NCT01346722|Other|Diet-ZnBfR|zinc biofortified rice-based diet
1901891|NCT01346722|Other|Diet- CR|conventional rice-based diet
1901892|NCT01346722|Other|Diet-ZnBfR|zinc biofortified rice-based diet
1901893|NCT01346722|Other|CR + Zn|conventional rice-based diet plus zinc fortificant (Diet-CR+Z).
1901894|NCT01346735|Other|No intervention|
1901895|NCT01346748|Drug|statin|Sinvastatin 80 mg per day - 21 days versus placebo
1901896|NCT01346761|Behavioral|Telephone Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor over the telephone. Counseling sessions will be audiotaped for quality control of intervention.
1901897|NCT01346761|Behavioral|In-Person Genetic Counseling|Participants will complete a pre-test session and a test results disclosure session (if tested) with a licensed, board-certified genetic counselor in person. Counseling sessions will be audiotaped for quality control of intervention.
1901898|NCT01346774|Drug|Cranberry powder capsules|2 cranberry powder capsules twice a day
1901899|NCT01346774|Drug|Placebo powder capsules|2 placebo capsules twice a day
1901900|NCT01346787|Drug|CARFILZOMIB, CYCLOPHOSPHAMIDE, DEXAMETHASONE|Patients will start induction treatment with Cyclophosphamide given orally at the dose of 300 mg/m2 on days 1, 8, 15. Low dose Dexamethasone will be given orally at the dose of 40 mg on days 1, 8, 15, 22 or 20 mg on days 1-2, 8-9,15-16, 22-23. Carfilzomib = 20 mg/m2 IV once daily on days 1, 2, of cycle 1 only followed by 36 mg/ m2 days 8, 9, 15, 16 in cycle 1, then for all subsequent doses 36 mg/ m2 IV once daily on days 1, 2, 8, 9, 15, 16, followed by 13-day rest period (day 17 through 28). Each cycle will be repeated every 28 days for a total of 9 courses. MANTEINANCE PERIOD At the end of induction phase (9 courses), maintenance phase with Carfilzomib alone IV at 36 mg/ m2 IV on days 1, 2, 15, 16 will start, until progression or intolerance. For patients who show evidence of progression during maintenance phase, the frequency of Carfilzomib can be increased to days 1, 2, 8, 9, 15, 16 at the discretion of the investigator, or the patient may be removed from the study
1901901|NCT01346800|Drug|Prasugrel|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4
1901902|NCT01346800|Drug|Ritonavir|Assessment of prasugrel metabolic ratio and phenotyping of CYP2B6/2C9/2C19/3A4 in presence of ritonavir
1901903|NCT01346826|Drug|Standard 2 hours-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.
After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7."
1901904|NCT01346826|Drug|Accelerated 1 hour-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.
After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7."
1901905|NCT01346826|Drug|Accelerated 30 minutes-infusion|"Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.
After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5."
1901906|NCT01346839|Behavioral|Contact Intervention|The intervention will include activities such as electronic communication and surveillance that facilitate the care of patients experiencing delays. A trained chart reviewer will conduct chart reviews on trigger-positive patients to confirm they are at risk for care delays and this will be followed by an electronic and/or verbal communication to the provider. The intervention will be compared to usual care at both sites.
1901907|NCT01346852|Drug|Asthma treatment with an asthma-related medication and at least one asthma controller medication|participants with an asthma diagnosis who also had at least one dispensing event of an asthma-related medication and had at least one asthma controller medication (inhaled corticosteroids containing inhalers, methylxanthines, leukotriene receptor antagonists, cromolyn sodium) or albuterol.
1901908|NCT01346865|Drug|Cilostazol|Cilostazol 100mg bid
1901909|NCT01346865|Drug|Placebo|Placebo 1tablet bid
1901910|NCT01346917|Drug|Lidocaine|Lidocaine 1mg/kg(loading dose, just before skin incision) and lidocaine(in normal saline, total 240cc) 1mg/kg/hr with ketorolac 90mg for 24hrs.
1901911|NCT01346917|Drug|Normal saline|Normal saline 5cc(loading dose, just before skin incision) and normal saline 240cc with ketorolac 90mg for 24hrs.
1901912|NCT01346930|Drug|Macitentan|10 mg, tablet, once daily
1901913|NCT01346943|Device|Altura Medical Abdominal Aortic Aneurysm Stent-Graft|Altura Medical AAA Stent Graft System
1901914|NCT01346969|Drug|EXC 001|Single-dose administered by injection four different times
1901915|NCT01346969|Drug|EXC 001|Single reduced dose compared to Group 1 administered by injection at the same four time periods as Group 1
1901916|NCT01346969|Drug|EXC 001|Single reduced dose compared to Groups 1 and 2 administered by injection at the same four time periods as Groups 1 and 2
1901917|NCT01346969|Drug|EXC 001|Same sinlge dose as Group 1 administered by injection at the same four time periods as Groups 1, 2, and 3
1901918|NCT01346982|Drug|Silimarine|darunavir/ritonavir 600/100 mg + silimarine (150 mg every 8 hours)
1901919|NCT01346995|Other|Experimental knee pain|Injection of 1 ml hypertonic saline (5.8%) into the infrapatellar fat pad
1901920|NCT01346995|Other|Non-painful control injections|Injection of isotonic saline into the infrapatellar fat pad
1901921|NCT01347008|Drug|Sildenafil citrate|Oral sildenafil citratre, 50mg b.i.d., 8 weeks
1901922|NCT01347008|Drug|Placebo (Sugar pill)|Placebo pills similar to sildenafil citrate pills, b.i.d for 8 weeks
1901966|NCT01347307|Radiation|SBRT for Vertebral/Paraspinal Metastases|12-16 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
1901923|NCT01347021|Procedure|sacrospinous colpopexy versus high uterosacral colpopexy|Women with uterine prolapse grade III or IV were randomly allocated to the sacrospinous colpopexy or high uterosacral colpopexy with vaginal hysterectomy.Before the surgery P-Qol questionnaire were completed and urogynecological examination include de POP-Q system was done. All patients underwent clinical check-ups 1, 6 and 12 months postoperatively. Each check-up included clinical examination and questionnaire.
1901924|NCT01347034|Procedure|External Beam Radiation Therapy (RT)|"Day 1: Start external beam RT, 25 fractions from days 1-33 administered Monday through Friday only (no conventional external beam RT on days 6, 7, 13, 14, 20, 21, 27, or 28
Days 57-70: Surgery will occur 3-5 weeks after the final dose of external beam RT.
Day 78-91: First post-operative visit
Days 91-365: Clinical follow-up
Beyond day 365, follow-up will be conducted using the standard of care approach applicable to these patients for the determination of disease recurrence, progression and survival."
1901925|NCT01347034|Biological|Autologous Dendritic Cells|"Prior to each injection on Arm B, patients may receive prophylactic doses of a first generation cephalosporin antibiotic per physician discretion.
Following each DC injection, Arm B patients will assess procedure-associated pain on a scale of 0-10. The next Monday following each DC injection, the patient will be called and questioned about such procedure associated toxicities."
1901926|NCT01347060|Drug|fluticasone propionate/salmeterol xinafoate combination|Fluticasone propionate/salmeterol xinafoate combination for asthma, all doses (100mcg/50mcg, 250 mcg/50mcg and 500 mcg/50mcg)
1901927|NCT01347060|Drug|inhaled corticosteroids|Inhaled corticosteroids: beclomethasone dipropionte, mometasone, fluticasone propionate, budesonide, and flunisolide
1901928|NCT01347073|Drug|HPN-100|HPN-100 is a pro-drug of PAA that combines with glutamine to provide an alternative vehicle for waste nitrogen elimination. It is a liquid with minimal taste and odor. Approximately three teaspoons of HPN-100 (~17.4 mL) delivers an equivalent amount as PBA that 40 tablets of NaPBA.
1901929|NCT01347086|Drug|Matching placebo (low dose)|single dose of matching placebo
1901930|NCT01347086|Drug|BI 207127 NA (medium dose)|Single does of BI 207127 NA
1901931|NCT01347086|Drug|BI 207127 NA (low dose)|single dose of BI 207127 NA
1901932|NCT01347086|Drug|Matching placebo (medium dose)|Single dose of matching placebo
1901933|NCT01347086|Drug|BI 207127 NA (high dose)|Single dose of BI 207127 NA
1901934|NCT01347086|Drug|Matching placebo (high dose)|Single dose of matching placebo
1901935|NCT01347099|Behavioral|Internet-based cognitive behavior therapy|Internet-delivered CBT. Contact with therapist thru an e-mail system. 10 weeks
1901936|NCT01347099|Behavioral|Support therapy on Internet|Internet-delivered support therapy. Contact with therapist thru an e-mail system. 10 weeks
1901937|NCT01347112|Drug|Varenicline|varenicline 1.0 mg dose, twice daily for 12 weeks
1901938|NCT01347112|Drug|placebo|sugar pill twice daily for 12 weeks
1901939|NCT01347125|Device|ImCardia Device|The device operates by harnessing energy expended by the left ventricle (LV) during Systole and returning it to the heart during Diastole thereby making it available to augment diastolic performance
1901940|NCT01347138|Other|case management|confirmation of hospital visit date, checking the adverse effect and treatment compliance
1901941|NCT01347151|Device|The glidescope video laryngoscopy|
1901942|NCT01347151|Device|The Pentax airwayscope|
1901943|NCT01347164|Behavioral|RISE life coaching intervention|6 2-hour sessions
1901944|NCT01347164|Behavioral|HIV Counseling|Standard one-hour HIV counseling session
1901945|NCT01347177|Procedure|Zirconia-based adhesive bridge|Zirconia-based adhesive bridge will be used to replace the missing tooth/teeth.
1901946|NCT01347177|Procedure|Metal-based adhesive bridge|The metal-based adhesive bridge will be used to replace the missing tooth/teeth.
1901947|NCT01347190|Biological|CR002 Liquid API|A single nominal dose of CR002 (three different dose groups) will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
1901948|NCT01347190|Biological|Placebo|A single nominal dose of Placebo will be inhaled as an aerosol mist produced by an I-neb Adaptive Aerosol Delivery (AAD) System.
1901949|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation A = 16 hr release formulation)
1901950|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation A = 16 hr release formulation)
1901951|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 100 mg (Formulation B = 20 hr release formulation)
1901952|NCT01347203|Drug|DPOC-4088|A single oral dose of DPOC-4088 prolonged release tablet 200 mg (Formulation B = 20 hr release formulation)
1901953|NCT01347229|Device|SENSIMED Triggerfish®|Soft contact lens-based device for the continuous monitoring of IOP fluctuations
1901954|NCT01347242|Genetic|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
1901955|NCT01347255|Drug|LEO90100 cutaneous spray, ointment|once daily application, 4 weeks
1901956|NCT01347255|Drug|LEO 90100 cutaneous spray, ointment, vehicle with betamethasone dipropionate|once daily application, 4 weeks
1901957|NCT01347255|Drug|LEO 90100 cutaneous spray, ointment, vehicle|once daily application, 4 weeks
1901958|NCT01347255|Drug|Daivobet® ointment|once daily application, 4 weeks
1901959|NCT01347268|Procedure|GnRH antagonist|GnRH antagonist administration and continued low dose r-FSH 75 IU
1901960|NCT01347268|Procedure|withdrawing GnRH agonists|withdrawing GnRH agonists and continued low dose r-FSH 75 IU
1901961|NCT01347281|Procedure|Injection of [18F]HX4|"Injection of [18F]HX4 before treatment (baseline) and after radiotherapy with 20 +/-4 Gy:
[18F]HX4 PET scans; 444 MBq (12 mCi) [18F]HX4 administrated via a bolus IV injection. Image acquisition: static scan at 240 min p.i.
Venous blood sampling: before injection of [18F]HX4 (blood hypoxia markers) Follow-up (3 months after treatment): [18F]FDG PET in treatment position"
1901962|NCT01347294|Drug|Bleomycin|Intralesional
1901963|NCT01347294|Drug|Fibrovein|Intralesional
1901964|NCT01347294|Drug|Bleomycin + Fibrovein|Intralesional
1901965|NCT01347307|Radiation|SBRT for Benign Extradural Spine Tumors|14-25 Gy / 1 fraction OR 21-27 Gy / 3 fractions (7-9 Gy per fraction) OR 25-30 Gy / 5 fractions (5-6 Gy per fraction)
1901967|NCT01347320|Other|Preoperative MRI|Preoperative staging
1901968|NCT01347333|Radiation|Stereotactic body radiosurgery|36-60 Gy / 3 fractions (12-20 Gy per fraction) OR 45-50 Gy / 5 fractions (9-10 Gy per fraction)
1901969|NCT01347333|Radiation|Stereotactic Body Radiotherapy|26-30 Gy / 1 fraction OR 36-45 Gy / 3 fractions (12-15 Gy per fraction) OR 40-50 Gy / 5 fractions (8-10 Gy per fraction)
1901970|NCT01347346|Genetic|Autologous CD34 positive cells transduced with a lentiviral vector containing human WAS gene|transplantation of patient's autologous CD34+ cells transduced with lentiviral vector containing human WAS gene
1901971|NCT01347359|Behavioral|One-on-one peer support|The peer support intervention will take the form of a one-on-one peer mentoring program, using a mutually agreed upon method of communication between each pair of peer mentor and EIA participant (either by telephone or face-to-face meeting at a neutral public location). The research team will pair trained peer mentors and individuals with EIA as closely as possible based on such characteristics as sex, age, working status, and specific disease/type of IA. Peer mentors will be responsible to initiate and maintain contact with individuals with EIA. Individuals with EIA and peer mentors will be asked to have contact once a week for 30 minutes during the 12-week study period. Meetings/ interactions will not be prescribed; rather they will be defined by the individual with EIA. Peer mentors will provide support based on the needs of the individual they are mentoring. As such the nature of each interaction is likely to vary among pairs and from one interaction to the next.
1901972|NCT01347359|Behavioral|Standard of care|"Standard of care is at the discretion of the treating rheumatologist. In addition to information and patient education about the underlying disease process provided at the time of diagnosis, it may include referral to allied health professionals (e.g., physiotherapist, occupational therapist, podiatrist, social worker). This may be via referral to The Arthritis Society or directly to individual practitioners. In addition, it may include referral to voluntary support programs in the community (e.g., Arthritis Self-Management Program)."
1901973|NCT01347372|Behavioral|Peer Mentor Training|Peer mentors will complete a training program (up to 20 hours) during which they will be evaluated. This face-to-face training applies an interactive format, with a combination of lectures, question/answer sessions, and experiential learning (e.g. role-playing, simulations) and practice sessions.
1901974|NCT01347385|Procedure|Laparoscopic myomectomy with unidirectional barbed suture|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using unidirectional barbed suture material (V-Loc 180TM, CovidienTM). For patients randomized to the barbed suture arm of the trial, any secondary fibroid that is greater than 5cm intra-operatively (as measured by a laparoscopic measurement instrument) will also be closed with barbed suture material. The cut-off of 5cm will be used, since it is generally above this size when uterine defects need to be closed in multiple layers, making the barbed suture potentially useful. Any other secondary fibroids less than 5cm will be closed with traditional extracorporeal suturing in both arms of the trial, since these can usually be closed in one layer.
1901975|NCT01347385|Procedure|Traditional suture material|Patients will be randomized to repair of the uterine defect during laparoscopic myomectomy using traditional extracorporeal suturing using absorbable monofilament suture material.
1901976|NCT01347398|Procedure|PSG|Sleep study made by PSG (polysomnography)
1901977|NCT01347398|Procedure|MicroMESAM system|Sleep study made by MicroMESAM system
1901978|NCT01347411|Procedure|CPAP|Treatment with CPAP
1901979|NCT01347424|Drug|Paclitaxel , carboplatin, endostatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w endostatin：7.5 mg/m2 iv 3－4h， d1～15，q3w
1901980|NCT01347424|Drug|Paclitaxel and Carboplatin|PTX：175mg/m2，D1, q3w CBP：AUC5，D1, q3w
1901981|NCT01347437|Behavioral|Positive STEPS|This intervention is given to patients in the experimental condition only. The Positive STEPS intervention-developed by our team—is based on general principles of cognitive-behavioral therapy as well as more specific principles of motivational interviewing32,33 and problem solving therapy. Informational, problem solving, and cognitive-behavioral STEPS are targeted over 5, in-person, intervention sessions with a PhD-level counselor. The intervention will also include a series of short videos related to the topics that the Positive STEPS intervention covers with participants. Participants in the experimental condition can also choose to receive text messages sent to their cell phone to remind them to take their medication.
1901982|NCT01347450|Dietary Supplement|Cocoa powder berverage, dark chocolate bar|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
1901983|NCT01347450|Dietary Supplement|Placebo|Sugar drink containing 30 g of cocoa powder and 50 g of a 65% dark chocolate, and the control group received 30 g of placebo drink containing 0 g of cocoa powder. Each drink was prepared by using 300 ml of water and 30 g of sugar, also were consumed twice each day: with breakfast and afternoon meal. during 7-d after the intervention started.
1901984|NCT01347463|Procedure|SCM triangle - ipsilateral nipple|draws the tract of the IJV using the SCM triangle head and the ipsilateral nipple
1901985|NCT01347515|Other|olive oil|"Each volunteer will be given, in random order, a single dose of 30 ml on a base of 80 g bread, of the following functional olive oils (FOO): FOO750 ppm, FOO500 ppm, which are enriched with two different amounts of broad-spectrum phenolic compounds from the virgin FOO250 ppm; all prepared at the Universitat de Lleida.
Post-ingestion the volunteers will rest for 8h in a comfortable warm room. During the run-in period of 2 weeks prior the first postprandial study and 1 week between each FOO treatment period, all subjects will undergo a 2-day pre-treatment wash-out period of a phenol-free diet (saturated fatty acids in the diet will be 10-13% of energy in an isocaloric diet). Volunteers will avoid non-essential physical activity during the 3 days prior to the treatment day."
1901986|NCT01347528|Behavioral|Medication Adherence Support System (MASS)|The intervention consists of the use of an electronic Medication Adherence Monitor for a 6-month period as well as 2 visits to the heart failure outpatient clinic of the TweeSteden hospital (usual care). This monitor (a) dispenses all prescribed medication in the right dosage at the specified time, (b) reminds patients to take their medications through an alarm, sms or voicemail service and records adherence, and (c) sends critical data about non-adherence to the heart failure nurse, via a web application (CarebyWeb). The Medication Adherence Monitor is provided to the patient by the hospital pharmacy, including an instruction how to use the device. After the intervention patients return to usual care only. We expect a training effect, with continued improved adherence in the intervention group.
1901987|NCT01347541|Behavioral|Cognitive Behavioral Therapy|Behavioral therapy includes standard cognitive behavioral therapy, with an emphasis on behavioral activation. Treatment is administered on the basis of the participants' individual needs and may continue for up to 12 months.
1901988|NCT01347541|Behavioral|Motivational Interviewing|Motivational interviewing is designed to address alcohol and drug use.
1901989|NCT01347541|Drug|FDA-Approved Anti-Anxiety Medications|Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline, paroxetine, buspirone, propranolol, trazodone, and any of the benzodiazepines. Participants may begin receiving medication immediately or anytime within the 12 months post-injury. Form, dosage, frequency, and duration depend on patient need, but all are prescribed in accordance with standards of care.
1901990|NCT01347541|Behavioral|Standard Care Control|Standard care control includes the usual treatment for injured trauma survivors
1901991|NCT01347554|Device|Everolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
1901992|NCT01347554|Device|Zotarolimus eluting stent|Comparison of the safety and efficacy between everolimus-eluting stent and zotarolimus-eluting stent resolute
1901993|NCT01347567|Other|Interventions with heart failure medications|Therapeutic interventions with heart failure medications per decision of treating physician for subjects in all study arms but using the different information available in each study arm.
1901994|NCT01347580|Drug|Ticagrelor|Oral Ticagrelor loading dose (180 mg) followed by matching placebo
1901995|NCT01347580|Drug|Placebo|Placebo followed by oral Ticagrelor loading dose (180 mg)
1901997|NCT01347619|Other|Toolkit only with Web Access to Online Version|NHs in this arm will receive a letter announcing the availability of an atypical antipsychotic toolkit within the facility and online at the Qualidigm website. The letter will be sent to the NH administrator, Director of Nursing, and Medical Director of each facility by Qualidigm. It will state that the toolkit is designed to provide NH staff, including prescribers, leadership, nursing staff, and patients' families with information about the use, risks and costs of atypical antipsychotics in the NH setting.
1901998|NCT01347619|Other|Toolkit, Periodic Audit/Feedback, Educational Messages|"Providing healthcare professionals with data about their performance (audit and feedback) may help improve their practice. It is more effective when clinicians previously agree to review their practice. We will use an adaptation of a Medicaid Utilization Report developed by AM Hamer. This report will show current atypical antipsychotic prescribing rates in the NH, with comparisons to state and national levels, and information regarding summary evidence for atypical antipsychotics from the AHRQ atypical antipsychotic CERSG. Reports will be sent to the NH administrator, Director of Nursing, and Medical Director of the facilities randomized to the moderate intensity arm on an every 4-month basis."
1901999|NCT01347619|Other|Items in Arm 2 plus Academic Detailing Program|This arm will receive the same information, toolkit, letters, and audit and feedback reports distributed to homes in the moderate-intensity arm. In addition, two visits to the NH will be scheduled by a pharmacist educator specially trained in the pharmacology of atypical antipsychotics, and communication techniques. Staff will be provided with up-to-date, unbiased information about antipsychotic use in NHs based on the AHRQ CER Review product adaptations. The educator will deliver targeted messages relevant to each stakeholder regarding roles in decision-making around the use atypical antipsychotic therapy in the NH setting. Each NH will receive up to two visits over the course of the 12-month intervention period.
1902000|NCT01347632|Drug|Metronidazole|All participants had BV at baseline. They all received metronidazole 500 mg po BID for 7 days
1902001|NCT01347645|Drug|FOLFIRI|Comparator dose and mode of administration The FOLFIRI regimen consists of irinotecan at 180 mg/m2 (IV infusion) on Day 1 of each 14-day cycle, leucovorin at 200 mg/m2 (400 mg/m2 if using d,l-racemic mixture of leucovorin) by IV infusion on Day 1 of each cycle, and 5-FU at 400 mg/m2 as an IV bolus injection followed by a total of 2400 mg/m2 by continuous IV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump (the use of an ambulatory pump is optional).
1902002|NCT01347645|Drug|E7820|"Test product: dose and mode of administration:
E7820 is administered orally in tablet form once daily, every day of each 14-day treatment cycle. For the Phase Ib portion, the doses will be 40 mg/day, 70 mg/day, and 100 mg/day, and for the Pase II portion, the dose will be the MTD in combination with Irinotecan, as determined during the Phase ib portion of the study.
The irinotecan regimen consists of an irinotecan dose of 180 mg/m2 by IV infusion once every 2 weeks (Day 1 of each 14-day cycle)."
1902003|NCT01347658|Dietary Supplement|Echinacea purpurea|Patients will take Echinacea purpurea (500 mg every 8 hours) during 14 days.
1902004|NCT01347671|Drug|GRT6005|25µg/day once daily
1902005|NCT01347671|Drug|GRT6005|75 µg/day once daily
1902006|NCT01347671|Drug|GRT6005|200 µg/day once daily
1902007|NCT01347671|Drug|Matching Placebo|Once daily
1902008|NCT01347684|Behavioral|Behavioral therapy, splint therapy and physical therapy|Includes patient education, use of a mouth guard, jaw muscle exercises and brief cognitive-behavioral intervention.
1902009|NCT01347684|Drug|Standard care using current drugs|Standard Drug therapy
1902010|NCT01347697|Procedure|Reconstruction with an acellular porcine collagen implant|Reconstruction of floor of lesser pelvis with an acellular porcine collagen implant after extended excision of rectum including levator muscles in advanced low rectal cancer.
1902011|NCT01347697|Procedure|Reconstruction with a gluteus maximus myocutaneous flap|Reconstruction of floor of lesser pelvis with an gluteus maximus myocutaneous flap after extended excision of rectum including levator muscles in advanced low rectal cancer.
1902012|NCT01341990|Device|FID 114675A Multi-Purpose Disinfecting Solution (MPDS)|Investigational solution intended for use as a cleaning, rinsing, reconditioning, disinfecting, and storage solution for silicone hydrogel and soft contact lenses
1902013|NCT01341990|Device|ReNu Fresh Lens Comfort Multi-Purpose Solution (MPS)|Commercially marketed prodouct indicated for cleaning, removing protein deposits, rinsing, disinfecting, and storing soft contact lenses
1902014|NCT01341990|Device|Silicone Hydrogel Contact Lenses|Commercially marketed silicone hydrogel contact lenses per habitual prescription for daily wear use, at least 8 hours/day. New pair dispensed at Day 0 (Baseline Visit) and at the conclusion of Day 1 (Visit 2).
1902015|NCT01342016|Drug|tacrolimus capsule|oral
1902022|NCT01342042|Biological|rExenatide-4|This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 [glucagon-like peptide-1] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.
1902023|NCT01342055|Drug|Apetrol ES|sequences of administered drugs
1902024|NCT01342081|Drug|DE-111 ophthalmic solution|
1902025|NCT01342081|Drug|Tafluprost ophthalmic solution 0.0015%|
1902026|NCT01342081|Drug|Concomitant use of tafluprost ophthalmic solution 0.0015% plus timolol ophthalmic solution 0.5%|
1902027|NCT01347710|Drug|Flurpiridaz F18|Injection of Flurpiridaz F18 for the purposes of PET myocardial profusion imaging (MPI) analysis
1902028|NCT01347710|Drug|99mTechnicium (sestamibi or tetrofosmin)|Injection of 99mTc sestamibi or tetrofosmin for the purposes of SPECT MPI analysis
1902029|NCT01347723|Other|scrambler therapy|Undergo scrambler therapy
1902030|NCT01347723|Other|questionnaire administration|Ancillary studies
1902031|NCT01347723|Procedure|management of therapy complications|Undergo scrambler therapy
1902032|NCT01347736|Other|scrambler therapy|Undergo scrambler therapy
1902033|NCT01347736|Other|questionnaire administration|Ancillary studies
1902034|NCT01347736|Procedure|dermatologic complications management/prevention|Undergo scrambler therapy
1902035|NCT01347749|Behavioral|Mindfulness & Compassion Meditation-based Exposure Therapy|A 16 week group psychotherapy intervention involving PTSD psychoeducation, breathing exercises and relaxation, and Mindfulness and Self-compassion meditation exercises in session and daily at home, and Mindfulness-based in vivo exposure exercises.
1902036|NCT01347749|Behavioral|Present Centered Therapy for PTSD|This 16 week, active group psychotherapy involves PTSD psychoeducation, supportive listening, and focusses on current stressors and PTSD symptoms.
1902037|NCT01347762|Drug|Nabilone|nabilone titrated to 1 mg by mouth twice daily
1902038|NCT01347762|Drug|Placebo|one placebo capsule by mouth twice daily
1902039|NCT01347775|Device|Inspiratory muscle training (URES HS730)|It will be set at 40% of the subjects baseline maximal inspiratory pressure and increased by 10% each week by an unblinded assistant. All subjects were trained with these devices for 8-10 breaths, 3 times a day, everyday for 6 weeks
1902040|NCT01347775|Device|Sham inspiratory muscle training (URES HS730)|Subjects in the control group underwent sham training, using the same device with the diaphragm removed, thus providing no resistance. They were not given frequency or duration but told to use the device when desired.
1902041|NCT01347788|Drug|cabozantinib|Cabozantinib PO QD
1902047|NCT01347814|Drug|Domperidone 10mg|10mg domperidone tablet 30 minutes before a test-meal.
1902048|NCT01347814|Drug|Placebo|Homeopathic (Sugar) pill-Placebo
1902049|NCT01344928|Behavioral|HIT exercise intervention|
1902050|NCT01344928|Behavioral|Aerobic exercise intervention|
1902051|NCT01344954|Drug|TB-402|Administered intravenously over 10 minutes
1902052|NCT01344954|Drug|Rivaroxaban|Administered orally as a capsule once a day for 35 days
1902053|NCT01344954|Drug|TB-402|Administered intravenously over 10 minutes
1902054|NCT01344967|Drug|Zoledronic acid|Zoledronic Acid at a dose of 4mg will be administered by intravenous infusion over 15 minutes in at least 100mls of saline
1902055|NCT01344980|Procedure|Stainless steel suture|Stainless steel suture material will be used (size 3-0) in an MGH repair technique
1902056|NCT01344980|Procedure|Polypropylene suture|Polypropylene suture (size 3-0) will be used in a double-locking loop repair technique
1902057|NCT01344980|Behavioral|Aggressive early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 4 weeks and ideally will be back at work at normal duties by 6 weeks. This rehabilitation uses more movement at a faster progression than other early active range of motion protocols.
1902058|NCT01344980|Behavioral|Early active range of motion rehabilitation|Patients undergoing this form of rehabilitation will have their splints discontinued at 6 weeks and ideally will be back at work at normal duties by 10-12 weeks. This rehabilitation uses less movement at a slower progression than the early AROM rehabilitation protocol specified in the experimental group
1902059|NCT01344993|Biological|MA09-hRPE|Cohort 1 50,000 cells Cohort 2 100,000 cells Cohort 2a Better Vision 100,000 cells Cohort 3 150,000 cells Cohort 4 200,000 cells
1902060|NCT01345006|Biological|MA09-hRPE|"Cohort 1 50,000 cells
Cohort 2 100,000 cells
Cohort 2a Better Vision 100,000 cells
Cohort 3 150,000 cells
Cohort 4 200,000 cells"
1902061|NCT01345019|Drug|Denosumab|Denosumab 120 mg SC
1902062|NCT01345019|Drug|Zoledronic acid|Zoledronic acid 4 mg (adjusted for renal function) IV over at least 15 minutes Q4W (n = 760)
1902063|NCT01345032|Other|Home visit|Patients and their homecare helper will receive visits from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the visits is follow up on the individual diet plan distributed at discharge and supply dietary advice.
1902064|NCT01345032|Other|Telephone consultation|Patients and their homecare helper will be contacted on telephone from a clinical dietician 1 week, 2 weeks and 4 weeks after discharge. The purpose of the telephone contact is follow up on the individual diet plan distributed at discharge and supply dietary advice.
1902065|NCT01345045|Drug|ABT-639|ABT-639 Twice Daily for six weeks.
1902066|NCT01345045|Drug|pregabalin|pregabalin starting dose twice daily for 1 week then titrated to maintenance dose twice daily for the remainder of the study.
1902067|NCT01345045|Drug|Placebo|Placebo twice daily for 6 weeks.
1902068|NCT01345058|Drug|lacosamide|"Lacosamide maximum of 200 mg/day, to be titrated as follows:
Week 1: 50 mg twice a day
Beginning Week 2: 100 mg twice a day."
1902069|NCT01345058|Drug|levetiracetam|Low dose ≤1500 mg/day, High dose >1500 mg/day
1902070|NCT01345084|Radiation|Radiation Therapy|66- 70 Gy External, Fractions of 2.0 Gy per day, 5 days a week
1902071|NCT01345084|Drug|Nimotuzumab|200 mg, IV, weekly doses during the radiation therapy until completing 6 months (Diluted into 250 mL of sodium chloride sterile solution 0.9% in intravenous infusion for 30 minutes).
1902072|NCT01345084|Drug|Cisplatin|75 mg/m2, IV, doses every 3 weeks (a total of three doses)
1902073|NCT01345097|Device|Total Hip Arthroplasty|Total Hip Arthroplasty
1902074|NCT01345123|Behavioral|Provision of condition specific shared decision making (SDM) aids only|Subjects are mailed decision aid digital video discs (DVDs) and pamphlets regarding lumbar back, hip osteoarthritis or knee osteoarthritis.
1902075|NCT01345123|Behavioral|Telephonic outreach and support by Health Coach|Subjects are direct dial attempted by Health Coaches up to three attempts. If contacted, Health Coaches tailor support around health matters of importance to the subjects and to help individuals become active participants in their treatment plans, and make more informed decisions in consort with their health care providers. The number of total contacts is determined by mutual agreement between the subject and the Health Coach. Health Coaches may provide additional educational materials and resources.
1902076|NCT01345136|Drug|RAD001, everolimus|Adults: 10 mg p.o. daily dose, age 16 - 17: 3.0 mg/m2 p.o. daily
1902077|NCT01345149|Behavioral|Diet + Exercise|"Diet: Intensive counselling about calorie restriction to reduce weight gain by dietician.
Exercise: Individual counselling"
1902078|NCT01345162|Drug|Ketorolac postoperative|Ketorolac 10mg 1cp x 3/die
1902079|NCT01345162|Drug|postoperative Patrol|acetaminophene 325mg+tramadol 37.5mg, 1cp x 3/die
1902080|NCT01345162|Drug|intraoperative analgesia|ketorolac 30 mg iv
1902081|NCT01345162|Drug|intraoperative analgesia|Tramadol 100 mg if Weight over 50 kg, 50 mg if weight below 50 kg
1902082|NCT01345175|Drug|Rifaximin|Pt will receive rifaximin 400mg bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
1902083|NCT01345175|Drug|Placebo|Pt will receive placebo bid for 4 weeks. Patients will at this stage on a volunteer basis be asked to submit stool samples and undertake a breath test. Patients will receive the respective treatment for four weeks. Following cessation of treatment all patients will be assessed using the BFI and respective patients will have repeat stool sampling and breath testing. Patients will then have these tests repeated 4 weeks later. This corresponds to 8 weeks after the start of the trial. For those patients not undertaking stool and breath testing, they will be reminded by phone, mail or email to fill out the BFI. Before and during the trial patients will be asked to fill out a weekly stool diary to evaluate trends on bowel function.
1902086|NCT01345201|Biological|OMP-18R5|IV infusion. Subjects with stable disease or a response at Day 56 will be allowed to continue until disease progression.
1902087|NCT01345214|Drug|ONO-7746|10mg, 20mg, 50mg, 100mg, 200mg and 300mg once-daily for 14 days
1961049|NCT03027258|Other|mHealth|"HBI participants who consent will be enrolled in this study and will have data collected from their community screening stored in a secure, web-based database. The stored data will be encrypted into a Quick Response code embedded in a smart card. A unique identification number and participant's blood group type will be on the outside of the card. There will be no names or any other identifiers. Each participating center will identify a dedicated delivery room staff that will be trained to read the contents of the card using the cell phone application as well as enter new data in the participant's profile. When a participant presents at delivery without the card, information can still be obtained from the secure, web-based database and confirmed using the participant's name, date of birth and cell phone number. This information is provided to the clinician to guide management of the infant."
1961052|NCT03026972|Biological|Placebo|The placebo drug contains 20μg mannitol and 10 millimole(mM) phosphate buffer(PB).Population I、Population II and Population III are coxal muscle injection of placebo.
1961053|NCT03026972|Biological|Low dose adjuvant|Population I、Population II and Population III are coxal muscle injection of low dose adjuvant.
1961054|NCT03026972|Biological|Middle dose adjuvant|Population II and Population III are coxal muscle injection of middle dose adjuvant.
1961055|NCT03026972|Biological|High dose adjuvant|Population II and Population III are coxal muscle injection of high dose adjuvant.
1907914|NCT02998671|Other|Placebo|
1961056|NCT03026972|Biological|Low dose vaccine|Population I、Population II and Population III are coxal muscle injection of low dose vaccine.
1961057|NCT03026972|Biological|Middle dose vaccine|Population II and Population III are coxal muscle injection of middle dose vaccine.
1961058|NCT03026972|Biological|High dose vaccine|Population II and Population III are coxal muscle injection of high dose vaccine .
1961059|NCT03026153|Behavioral|Control Group Oral Survey 1|Oral survey 1 will be administered as control intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-monthly injections
1961060|NCT03026153|Behavioral|Intervention Group Oral Survey 2|Oral Survey 2 will be administered as the intervention: patients will be asked how willing they would be to take an injectable medication to control their psoriasis which required once-daily injections, then surveyor would ask how willing they would be to take an injectable medication which required only once-monthly injections
1961073|NCT03022825|Drug|ALT-803|BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive treatment in the maintenance treatment period at Months 6, 9 and 12.
1961074|NCT03022825|Drug|BCG|BCG and ALT-803 will be mixed together (with saline) and administered via intravesical instillation weekly for 6 consecutive weeks (induction). After the first disease assessment, eligible patients will receive either a 3-week maintenance course or a 6-week re-induction course (second treatment period) at Month 3. Eligible patients will continue to receive treatment in the maintenance treatment period at Months 6, 9 and 12.
1961077|NCT03021109|Device|Measurement of inferior vena cava diameters with ultrasound|The patient is placed in the supine position. Curvilinear probe is used. Subxiphoid view is obtained. The IVC is visualized in the longitudinal plane as it enters the right atrium. The diameter of the IVC for calculation of the caval index is measured 2 cm from where it enters the right atrium
1961078|NCT03020771|Biological|KIRIM-KONGO-VAX|Crimean-Congo Hemorrhagic Fever Vaccine
1961079|NCT03020771|Other|Placebo|
1997401|NCT02093546|Procedure|Blood Draw and Biopsy|Participant undergoes tumor biopsy to check for biomarkers during screening and at Day 28. Blood drawn to test for biomarkers and CTCs between Day 3 and Day 5 and at Day 56.
1997402|NCT02090998|Procedure|SPG Block with 5% Lidocaine gel|cotten tipped applicators are with 5% lidocaine gel and placed in the nares to lye in the skin over the sphenopalitine ganglion. The applcator is use to saturate the spenopalitine ganglion with 5ml of 1% lidocaine local anesthesia
1997403|NCT02090998|Drug|Amitriptyline|The intervention will be Amitriptyline daily (starting with 10 mg) PO for 30 Days
1997404|NCT02091804|Behavioral|Immediate Group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
1997405|NCT02091804|Behavioral|Wait-List group|"The intervention consists of delivering the Promoting First Relationship (PFR) program. PFR comprises 10 sessions and lasts approximately 12 weeks. Each session lasts approximately 30 minutes, and begins with brief (~10 min) discussions and education on the target topic for that week . The remaining 20 minutes will alternate between video recording a structured interaction between the caregiver and child or viewing the previous session's recording and engaging in reflective discussion about successful caregiving strategies and child's response to caregiver behavior. Trained PFR specialists who are community members use the 5 consultation strategies, labeled Joining, Positive Feedback, Instructive Feedback, Reflective Questions and Comments, and Instruction with Handouts."
1997410|NCT02091440|Device|Implant of the HW005 Ventricular Assist System.|The HW005 Pump is in implantable centrifugal pump that was designed to provide flows up to 10 L/min. It is a small device which is both lightweight and simple to use.
1997411|NCT02091232|Biological|T Regulatory Cell Infusion|After blood is collected from the donor and recipient, the facility will sort out one particular kind of immune cell called a regulatory T cell which is strongly influenced by tolerance induction to minimize (suppress) responses to the donor cells. In this study, these regulatory T cells are the cells which will be given back to the recipient on Day 7 (+3 days) post-transplant.
1997412|NCT02088554|Device|Model 400 aortic valve bioprosthesis|
1997413|NCT02087956|Behavioral|Navigation|The navigator provides up to 4 months outreach and support to implement the personal care plan. Patients determine the preferred frequency and type of contact with the navigator. . At the end of the four months, the patient and navigator will review the personal care plan, and the navigator will work with the patient as to how she can continue progress through accessing other supports and resources as needed.
1997414|NCT02087956|Behavioral|Enhanced Screening and Referral|Patients assigned to ESR will be provided with a print-out of their Promote-W comprehensive health screening results. More specifically, they will receive a list of concerns they endorsed plus a resource list of locations where they can obtain assistance with those issues, which are largely free.
1997415|NCT02083913|Behavioral|Telehealth supervised exercise training|Endurance and strength training (3x/week during 12 weeks)
1997416|NCT02082249|Drug|ABT-SLV187|Dose levels will be individually optimized
1997417|NCT02082496|Drug|Liraglutide|S.c. liraglutide 3.0mg once daily
1997419|NCT02081248|Other|Consent Form Specific Format 1|The Consent Form Specific Format 1 is the 'Standard Consent'. The standard consent does not have the format of two-columns with changes in layout readability, organization of content, typography and use of plain language. Standard consents are already used by sites for the BMT CTN 0901, 1101, 1203, and 1301 clinical trials.
1997420|NCT02081248|Other|Consent Form Specific Format 2|The Consent Form Specific Format 2 is the 'Easy-to-Read Informed Consent'.The Easy-to-Read Informed Consent is two-columns with changes in layout readability, organization of content, typography and use of plain language.
1997421|NCT02079987|Behavioral|ED to home care transition|The Area Agency on Aging patient advocate's role is to build self-management capabilities for the patient and caregiver. During each contact, the patient advocate reviews the four components of the Care Transition Intervention: 1: Follow-up Medical Visit. 2: Knowledge of Red Flag Symptoms. 3: Medication Reconciliation. 4: The Personal Health Record (PHR). The patient advocate assists the patient use the PHR to document and maintain vital information and to communicate with providers.
1997422|NCT02079987|Other|Usual Care|Patients randomized to usual care will receive verbal and written discharge instructions from the treating emergency department physician and nurse as is the standard of care.
1997425|NCT02078713|Behavioral|Contraceptive Decision Support Tool|"The decision support tool:
Provides an educational session about different aspects of contraception
Elicits patient preferences about different aspects of contraception
Identifies potential contraindications to certain contraceptive methods
Allows the patient to view details about and compare available contraceptive methods
Suggests methods most appropriate based on the patient's preferences
Collects questions the patient may have for her provider
Generates a printout the patient can bring to her contraceptive counseling visit"
1961135|NCT03009786|Other|Measurement of salivary flow|A compress of about 0.95 g which is weighed and then placed under the tongue of the subject for 5 minutes. Once the time has elapsed, the compress is weighed, a simple subtraction determines the weight of saliva produced in 5 minutes
1961140|NCT03008746|Other|water used for oral wash|
1961141|NCT03008746|Other|sputum|
1961142|NCT03008746|Other|oral wash|
1961143|NCT03008460|Drug|Eziclen®/Izinova®|Oral solution taken the evening before the colonoscopy
1961144|NCT03008460|Drug|Klean-Prep®|Oral solution taken the evening before the colonoscopy
1961145|NCT03007108|Other|blood withdrawal|
1961148|NCT03007732|Drug|Pembrolizumab|200 mg IV every 21 days for up to 13 doses (Arms 1 and 2)
1961149|NCT03007732|Drug|SD-101|5 mg will be delivered to the dominant prostatic tumor lesion on Day 1 and Day 8 of Cycle 1 pembrolizumab, immediately preceding HDR brachytherapy (Arm 2)
1961150|NCT03007732|Radiation|High Dose Rate (HDR) Brachytherapy|13.5 Gy x 2 fractions (27 Gy total) delivered to the whole prostate gland via HDR brachytherapy on Day 1 and Day 8 of Cycle 1 pembrolizumab (Arms 1 and 2)
1961151|NCT03007732|Other|Combined Androgen Blockage (CAB)|Combined androgen blockade (CAB) will be given for 9 months, then off (Arms 1 and 2)
1961156|NCT03005964|Drug|AM001 Cream, 7.5%|Active Cream
1961157|NCT03005964|Drug|Vehicle Cream|Placebo
1961200|NCT02996032|Other|Vascular and Pulmonary Ultrasound|
1961206|NCT02994056|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily
1961207|NCT02994056|Drug|RBV|Tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)
1961213|NCT02991274|Procedure|genomic testing of T790M mutation|patients will need to have genomic testing of T790M mutation at hospital laboratories and in central laboratory.
1961217|NCT02989857|Drug|AG-120|
1961218|NCT02989857|Drug|AG-120 matched placebo|
1997431|NCT02076386|Drug|Dolutegravir|Prospective, non-interventional study of the use of doluetegravir as part of an antiretroviral combination therapy in routine daily practice in Germany. No drug will be provided. No study visits or procedures are mandated per protocol.
1997432|NCT02076243|Drug|nab-paclitaxel|nab-paclitaxel (abraxane) administered weekly (days 1,8, and 15 of 28 day cycle) to patients with unresectable locoregional or distantly metastatic cutaneous squamous cell carcinoma (SCC).
1997436|NCT02072824|Drug|Pregabalin Dose Level 1|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 7.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
1997437|NCT02072824|Drug|Pregabalin Dose Level 2|Pregabalin liquid dosed daily three times a day in equally divided doses escalated to 14.0 mg/kg/day beginning at Randomization through Taper Phase then tapered to 3.5 mg/kg/day during 1 week Taper Phase
1997438|NCT02072824|Drug|Placebo|Placebo Liquid dosed three times daily beginning at Randomization through Taper Phase
1997439|NCT02073760|Other|There is no intervention. The investigators are interviewing cardiac surgery staff with knowledge of infection prevention.|The investigators will conduct tape recorded interviews with hospital staff about infection prevention.
1997440|NCT02070549|Other|Laboratory Biomarker Analysis|Correlative studies
1997441|NCT02070549|Other|Pharmacogenomic Study|Correlative studies
1997442|NCT02070549|Other|Pharmacological Study|Correlative studies
1997443|NCT02070549|Drug|Trametinib|Given PO
1997446|NCT02065557|Biological|Adalimumab|Subcutaneous (SC) injection
1997447|NCT02065557|Other|Placebo|Placebo
1997450|NCT02062346|Drug|BQ123 or BQ123/788|
1997451|NCT02059980|Behavioral|Response inhibition training|This is a computerized video game that offers 40 training levels, which aims to enhance the individual's response inhibition performance
1997452|NCT02059980|Behavioral|Placebo Control Training|This placebo control training looks very similar to the response inhibition training program in its appearance. However, it does not offer any practice related to response inhibition capabilities.
1997454|NCT02058381|Drug|alpelisib (BYL719)|BYL 719 350 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 1 only).
1997455|NCT02058381|Drug|buparlisib (BKM120)|BKM120 100 mg will be administered orally once daily on a continuous dosing schedule starting on day 1 (Group 2 only)
1997459|NCT02056652|Device|Bioteque cup pessary|
1997460|NCT02056639|Device|Bioteque cup pessary|
1997461|NCT02056171|Drug|quetiapine|Patients who are diagnosed with delirium and assigned to the intervention arm will receive quetiapine.
1997462|NCT02056171|Other|Placebo|Patients who are diagnosed with delirium and assigned to the placebo arm will receive placebo.
1961231|NCT02983903|Procedure|transbronchial biopsy|
1961240|NCT02980133|Drug|Fp MDPI|
1961241|NCT02980133|Drug|FS MDPI|
1961242|NCT02980133|Drug|Placebo|
1961266|NCT02973685|Procedure|Hepatic arterial infusion chemotherapy|A standard hepatic artery catheter was introduced via the femoral artery percutaneously. Selective catheterization of the proper hepatic artery was performed using standard diagnostic catheters and fluoroscopic guidance. In the event of multiple arterial supply(including superior-mesenteric artery), the proportion of the liver supplied by each artery was estimated by the arteriogram. After optimal positioning of the catheter in dominant supplying artery to ensure minimal reflux, the catheter was fixed and connected with infusion tube. In the condition of multiple tumors on both left and right lobe, the gastroduodenal artery was embolized and the catheter was positioned in the hepatic proper artery for infusion. Folfox Protocol were infused through the fixed catheter sequentially.
1961267|NCT02973685|Procedure|Transarterial chemoembolization|Previous procedure was same with hepatic arterial infusion chemotherapy. After optimal positioning of the catheter, TACE Drug Protocol were injected.
1961268|NCT02973685|Drug|Folfox Protocol|oxaliplatin,leucovorin and 5-FU
1961269|NCT02973685|Drug|TACE Drug Protocol|lipiodol mixed with chemotherapy drugs(EADM , lobaplatin, and MMC) followed by polyvinyl alcohol particles (PVA)
1961275|NCT02971137|Behavioral|Smoking Cessation plus CBI|proactive tele-health intervention combining evidence-based smoking cessation counseling augmented with behavioral approaches for coping with pain
1961276|NCT02971137|Behavioral|Smoking Cessation Standard|standard telephone-based smoking cessation intervention
1961285|NCT02966314|Drug|Omalizumab|Omalizumab 300mg subcutaneous injection once monthly for 6 months. Total dose will be divided into two 150mg/1.2mL injections.
1961286|NCT02966314|Drug|Placebos|Placebo Group (Sodium Chloride 0.9%) two 1.2mL subcutaneous injections once monthly for 6 months.
1961296|NCT02962856|Drug|BAY987517|50 μl/cm*2 of each test product is applied to duplicate skin sites (approximately 2 x 2 cm each) on the lower or mid-back. (Formulation: Z43-078)
1961297|NCT02962856|Other|Untreated Skin|This site is patched without treatment as irradiated control
1961306|NCT02959138|Drug|GS-9876|Tablet administered orally
1961310|NCT02957539|Behavioral|Financial rewards|Veterans in the financial reward arm receive all of the services of the usual care arm, plus rewards that are earned in two ways: an assured portion, and a random portion. For the assured reward, they will receive compensation at the end of each month (defined as a four week period) that they are at or below their target weight. For the random portion, each week that a participant is at or below their target weight, the patient is entered into a drawing to win additional compensation. Over the first eight weeks the patient has a 1-in-8 chance of winning. Over the 17-32 week period, Veterans in this group will receive token incentives for tracking and reporting their weekly weights regardless of whether it was on target. Each week that the patient enters their weight into the portal, s/he will have a 1-in-8 chance to earn the token incentive, such as a t-shirt or movie ticket. The participant will receive reminder text messages.
1961311|NCT02957539|Behavioral|Non-Financial rewards|Procedures for the non-financial rewards arm are identical to procedures for the financial reward arm, except that the Veteran will earn points rather than cash. Each weekly random drawing will be for 20 points. Veterans will choose non-financial rewards associated with the number of points they earn.
1961312|NCT02956629|Drug|Uprifosbuvir|Participants take 3 tablets each containing 150 mg Uprifosbuvir q.d. by mouth.
1961313|NCT02956629|Drug|Ruzasvir|Participants take 3 capsules each containing 60 mg RZR q.d. by mouth.
1961314|NCT02956629|Drug|Ribavirin|RBV 200 mg capsules will be taken according to package instructions for a maximum of 16 weeks for any GT that meets virologic futility rules on Uprifosbuvir + RZR alone.
1961333|NCT02950064|Drug|BTP-114|"Part 1 (Escalation) IV treatment of BTP-114 in 21-day cycles. Doses will be increased in sequential cohorts until the maximum tolerated dose is determined which will lead to the recommended phase 2 dose
Part 2 (Expansion) 5 cohorts of patients will be treated at the RP2D of IV BTP-114 in 21-day cycles for the tumor types pancreatic cancer, castration-resistant prostate cancer, ovarian cancer, triple-negative breast cancer and deoxyribonucleic acid (DNA) repair mutation-positive advanced solid tumors."
1961334|NCT02949700|Drug|Metformin|Metformin will be administered orally twice daily during treatment with chemo-radiation for head and neck squamous cell carcinoma. This will occur 7 to 11 days prior to chemotherapy and radiation.
1997515|NCT02031536|Other|placebo|Given PO
1997516|NCT02031536|Other|laboratory biomarker analysis|Correlative studies
1997517|NCT02030249|Behavioral|Low calorie diet administered from 0 to 2 months|The 2-month low calorie diet is administered from the 0 months to the 2 months time point. It is designed to elicit a weight loss of 8% of initial body weight. Please see parent study for further intervention details: http://clinicaltrials.gov/ct2/show/NCT01777893?term=preview&rank=1
1997518|NCT02030249|Behavioral|High Protein / Low Glycaemic Index|Please see description of the Arm by the same name.
1997519|NCT02030249|Behavioral|Moderate Protein / High Glycaemic Index|Please see description of the Arm by the same name.
1997522|NCT02030015|Drug|miglustat|The Syner-G therapy regimen includes treating with orally-administered miglustat for the duration of the 60-month study.
1997523|NCT02030015|Other|Ketogenic Diet|The Syner-G therapy regimen includes switching the research subject to a full-time ketogenic diet for the 60-month duration of this study.
1997524|NCT02028221|Drug|Metformin|metformin 850 mg 1 tablet taken by mouth daily X 4 weeks, then metformin 850 mg 1 tablet taken twice daily for the duration of he intervention period.
1997525|NCT02028221|Drug|Placebo|1 tablet daily by mouth X 4 weeks, then 1 tablet twice daily by mouth for the remaining duration of the trial (12 months)
1997533|NCT02024789|Drug|Placebo|Orally twice daily, 26 weeks
1997534|NCT02024789|Drug|RG1662|120 mg (80 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
1997535|NCT02024789|Drug|RG1662|240 mg (160 mg for subjects 12 and 13 years of age) orally twice daily, 26 weeks
1997536|NCT02024581|Drug|10% East Indian sandalwood oil cream|A topical oil/water emulsion cream containing 10% East Indian sandalwood oil (EISO)
1997537|NCT02024581|Drug|Placebo Cream|A sandalwood-scented oil/water emulsion topical cream matching the appearance of the active comparator creams
1997541|NCT02019420|Drug|Tedizolid phosphate IV|Tedizolid phosphate IV 200 mg once daily
1997542|NCT02019420|Drug|Linezolid|Linezolid IV 600 mg twice daily
1997543|NCT02020356|Behavioral|Music therapy|"U sequence: the musical sequence lasts 20 minutes and is made up of several phases that progressively induce a relaxed state in the patient. The phase of maximum relaxation is followed by a stimulating phase."
1997544|NCT02020356|Behavioral|Placebo|Interview with an occupational activity (such as discussion of personal pictures or news) with the caregiver in charge of music therapy sessions with the same period.
1997545|NCT02019875|Drug|Rifampin|P450 inducer
1997546|NCT02019875|Drug|Clarithromycin|CYP3A4 and Pgp inhibitor in both intestine and liiver
1997547|NCT02019875|Other|Grapefruit Juice|CYP3A4 inhibitor in intestine
1997548|NCT02019875|Other|Placebo|
1997549|NCT02019472|Biological|adalimumab 40 mg|SC injections
1997550|NCT02019472|Biological|sirukumab 100 mg|SC injections
1997551|NCT02019472|Biological|sirukumab 50 mg|SC injections
1997552|NCT02019472|Drug|Placebo|SC injections
1997553|NCT02019290|Drug|Midazolam|Single oral doses will be given on Days 1 and 15, after an overnight fast.
1997554|NCT02019290|Drug|bitopertin|An oral dose will be given daily in the morning from Days 2-15. On Days 14 and 15, bitopertin will be given after an overnight fast; on Days 2-13, bitopertin will be given under fed conditions.
1997555|NCT02018822|Device|urethane dimethacrylate|
1997556|NCT02018822|Device|TPH3|
1997557|NCT02017795|Other|electronic asthma action plan (eAAP)|An electronic asthma action plan (eAAP) will be provided to intervention group
1997558|NCT02017795|Other|written asthma action plan (WAAP)|A written asthma action plan will be given to control group arm
1997559|NCT02016196|Drug|Rifaximin|6 rifaximin caps of 200 mg morning and night, 15 days before and 6 months after TIPS
1961352|NCT02942017|Drug|SAGE-547|
1961353|NCT02942017|Drug|Placebo|
1961354|NCT02942004|Drug|SAGE-547|
1961355|NCT02942004|Drug|Placebo|
1961357|NCT02937558|Drug|Glucagon|Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide
1961358|NCT02937558|Other|Placebo|Isotonic saline
1961363|NCT02935478|Device|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embosphere Microspheres beads) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry
1961369|NCT02934321|Dietary Supplement|Erythritol|Erythritol is a well tolerated, low calorie sugar alcohol that is becoming more widely used as a sugar substitute.
1961370|NCT02934321|Dietary Supplement|Aspartame|Aspartame is a well tolerated, commonly used artificial sweetener.
1961371|NCT02933554|Device|Embospheres Microspheres|Via a radial artery in the wrist or the femoral artery in the groin, arterial access will be obtained.Under live X-ray monitoring and using contrast, a catheter will be advanced into the artery of the stomach (left gastric artery). A CT scan will be performed on the X ray table to confirm the placement of catheter. Once this is confirmed small micro spherical particles (Embopheres Microspheres) will be injected though the catheter to occlude the artery and cut off blood supply to the stomach. Once the procedure is complete, in case of wrist access compression will be achieved with a band; in case of groin access a closure device will be used to plug the site of entry.
1961374|NCT02932826|Biological|Umbilical Cord Blood Regulatory T cells Therapy|Receive Treg infusion: 1~5*10^6/kg b.w. in 100ml NS
1961375|NCT02932826|Drug|Insulin|Treated according to routine clinical practice at the discretion of the treating physician
1961376|NCT02932813|Behavioral|THINK Program|Lessons and laboratory sessions will be 60 minutes, followed by physical activity sessions lasting 60 minutes. Laboratory activities include assessing heart rate, making healthy meals, learning portion sizes, brain challenges, and more. To improve physical activity participation, a wide selection of developmentally appropriate and multiculturally sensitive activities will be offered, such as sports, games, obstacle courses, and dance.
1961379|NCT02932280|Drug|Neratinib|Neratinib will be administered orally, or through existing gastrostomy feeding tube, once a day with food, preferably in the morning, continuously for 28-day cycles, with no rest between cycles. Dose will be scaled by body surface area (BSA).
1961385|NCT02928939|Other|drug-drug or drug-disease interaction|
1902366|NCT03305367|Dietary Supplement|Hydrolyzed pine nut oil|Randomized cros-over intervention of 3 OGGT with no oil, low dose or high dose.
1902367|NCT03305354|Behavioral|CBTI app intervention|Self-management guided use of a mobile app called the CBT-I Coach to teach sleep hygiene and enhance sleep
1902368|NCT03305354|Behavioral|Physical Activity intervention|Self-management guided motivation to increase physical activity by increasing daily step counts
1902371|NCT03305328|Device|Transcranial Alternating Current Stimulation|Transcranial Alternating Current Stimulation passes a weak, 2 mA sinusoidal current through the scalp to the cortex at a specified frequency. Previous evidence suggests this exogenous sinusoidal stimulation interacts with the endogenous, cortical sinusoidal oscillatory activity, resulting in modulations of cortical oscillations. The intervention is non-invasive and virtually painless with no lasting adverse side-effects.
1902372|NCT03305315|Other|Measurements of jaw movement|Jaw mobility will be measured during simple movements of the mouth (opening the mouth, side-to-side and backwards-and-forwards movement of the jaw). These movements will be measured using a specific apparatus, part of which will be placed on the head like a helmet with the other part placed in the mouth and stuck to the teeth using a dental adhesive. The part in the mouth is specifically designed for this purpose. Measurements using this apparatus will take around 30 minutes.
1902373|NCT03305315|Other|Measurement of natural electrical activity of facial muscles|Natural electrical activity of the facial muscles will be measured using electrodes placed on the skin.
1902374|NCT03305302|Procedure|Sample of cancerous epithelium from the tongue|Harvesting and culture of cancerous epithelium from the surgical piece
1902375|NCT03305289|Procedure|pulsed Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then pulsed radiofrequency will be applied for 10 patients for 10 mins
1902376|NCT03305289|Procedure|thermal Radiofrequency|sensory stimulation will be carried out at 50 Hz. The definitive position of the electrode will be verified by inducing paresthesia with sensory stimulation between 0.1-0.3 V in the affected painful area, then Thermal lesion will be applied for 10 patients for 2 cycles of 90 seconds
1902377|NCT03305263|Drug|Hydroxychloroquine|One tablet a day from inclusion until end of pregnancy or gestational age 28
1902378|NCT03305263|Drug|Hydroxychloroquine placebo|One tablet a day from inclusion until end of pregnancy or gestational age 28
1902379|NCT03305250|Device|Implantable Loop Recorder|An implantable loop recorder (ILR), also known as an insertable cardiac monitor, is a small device (smaller than a AAA battery) that is inserted under the skin on the front of the chest. The ILR is inserted using local anesthetic as an out-patient procedure and lasts approximately 30 minutes. The ILR captures a continuous ECG of your heart activity, which allows doctors to detect any abnormal heart rhythms at any point. If you have the ILR, you will have the device for 3 years, after which it will be removed under local anesthetic during an out-patient procedure, again lasting approximately 30 minutes. The ILR device is completely safe and shouldn't affect your day to day living.
1902380|NCT03305237|Other|Big Breakfast|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at breakfast (percent daily calories split between breakfast, lunch and dinner as 45-35-20%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
1902381|NCT03305237|Other|Big Dinner|Weight loss diet (Calories fed to measured RMR) with calories distributed predominantly at dinner (percent daily calories split between breakfast, lunch and dinner as 20-35-45%). The diet will be high protein (30% protein, 35% fat and 35% CHO) with all meals provided.
1902382|NCT03305224|Drug|Ra-223 in combination with enzalutamide|Ra-223 (55 kBq/kg i.v.) 6 injections at 4 weeks interval in combination with enzalutamide 160 mg per a day
1902383|NCT03305211|Other|sample|Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine.
1902384|NCT03305198|Biological|Capillary blood sampling from the earlobe|Sample at rest before the walking test Sample at rest 3 minutes after the end of the walking period
1997560|NCT02016196|Drug|placebo|6 placebo caps per day morning and night, during 15 days before TIPS and 6 months after TIPS
1902388|NCT03305159|Drug|Povidone-Iodine|Patients will receive povidone iodine for the surgical preparation of the vagina.
1902389|NCT03305159|Drug|4% Chlorhexidine Gluconate|Patients will receive 4% chlorhexidine gluconate for the surgical preparation of the vagina.
1902390|NCT03305146|Genetic|Molecular biology analysis of pancreatic intra-cyst fluid|"The EUS FNA will be performed according to the Francophone Club of Echo Endoscopy recommendations.
For molecular biology technique, the samples will be processed within the UMR_S910 unit. Nucleic acids will be extracted from the intra-cystic fluid or, for post-operative patients, from a resected specimen that will be collected into a tube containing a nucleic acid stabilization solution (Allprotect Tissue reagent, Qiagen).
The nucleic acids will be extracted and then sequenced. The sequencing technology chosen (HaloPlexHS, Agilent) allows a detection close to 1% in allelic frequency. This new technical approach that links high sensitivity and specificity is also suitable with degraded and/or low-volume ( <50ng) DNA."
1902391|NCT03305133|Other|Immunohistochemistry|The slides which allowed the large cell neuroendocrine carcinoma diagnosis will be re-read centrally.
1902392|NCT03305120|Other|pain VAS evaluation|each patient has to answer to a questionnaire about pain
1902393|NCT03305107|Other|Exercise and Chocolate Milk|High intensity interval exercise Chocolate Milk
1997561|NCT02015754|Drug|DEBIRI|Irinotecan hydrochloride is a semisynthetic derivative of camptothecin, an alkaloid extracted from the tree Camptotheca acuminata. Irinotecan hydrochloride trihydrate is a pale yellow to yellow crystalline powder, it is mixed in DC Beads and injected in the tumor.
1997562|NCT02015754|Device|LC Bead M1|The LC Bead M1, loaded with irinotecan (DEBIRI-M1) to treat patients with hepatic metastases from colorectal cancer.
1997563|NCT02015754|Procedure|TACE|TACE a minimally invasive procedure performed to restrict a tumor's blood supply.
1997564|NCT02015611|Dietary Supplement|Vitamin D|2,000 IU/ day of Vitamin D3
1997565|NCT02015611|Dietary Supplement|Placebo|Placebo
1997567|NCT02004704|Drug|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion
Route of administration: intravenous infusion"
1997568|NCT02002533|Behavioral|Brief Behavioral Therapy|Undergo BBT intervention
1902394|NCT03305107|Other|Exercise and Water|High intensity interval exercise Water
1902395|NCT03305107|Other|Sitting and Chocolate Milk|Sitting Chocolate Milk
1902396|NCT03305107|Other|Sitting and Water|Sitting Water
1902398|NCT03305081|Device|Levonorgestrel IUD, copper IUD, etonorgestrel implant|Long-acting reversible contraception
1902399|NCT03305068|Drug|Celecoxib|
1902400|NCT03305055|Drug|ketamine|Information included in arm descriptions
1902401|NCT03305055|Drug|Fentanyl|Information included in arm descriptions
1902402|NCT03305029|Drug|SCNT-hES-RPE Cells|Pars Plana Vitrectomy and Sub-retinal Transplantation of Human Somatic cell nuclear transfer Embryonic Stem Cell Derived Retinal Pigmented Epithelial(SCNT-hES-RPE) Cells in Patients with Advanced Dry Age-related Macular Degeneration
1902403|NCT03305016|Drug|TransCon hGH|Once weekly subcutaneous injection at a starting dose of 0.24 mg/kg/week
1902404|NCT03305003|Other|Spiral notebook|
1902405|NCT03305003|Other|Mobile application|
1902406|NCT03304990|Other|Patients with CA or suspected risk of CA or a family Hx|Patients with Family History of Cancer, (ii) Patients with Clinical and Environmental Risk Factors for Cancer, (iii) Patients with a Suspected or Confirmed Diagnosis of Cancer.
1902407|NCT03304977|Other|questionnaire via smartphone|questionnaire via smartphone
1902408|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment A: 14 oral doses of 100 mg FP-025 (n=6) or placebo (n=2) in 8 days.
1902409|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment B: 14 oral doses of 200 mg FP-025 (n=6) or placebo (n=2) in 8 days.
1902410|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment C: 14 oral doses of 400 mg FP-025 (n=6) or placebo (n=2) in 8 days.
1902411|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment D: single oral dose of 200 mg FP-025 under fasted conditions.
1902412|NCT03304964|Drug|FP-025 (MMP-12 inhibitor)|Treatment E: single oral dose of 200 mg FP-025 after intake of a high-fat, high-calorie breakfast (fed condition).
1902413|NCT03304951|Device|Sinopsys® Lacrimal Stent|The Sinopsys® Lacrimal Stent is indicated for use in creating a transcaruncular ethmoid access.
1902414|NCT03304938|Drug|Lavender Oil|The intervention group pour 3 drops of Lavender essential oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
1902415|NCT03304938|Drug|Placebos|The placebo group pour 3 drops of Almond oil on a cotton wool then smell it rhythmic and slowly for 5 minutes at bed time for 4 weeks
1902416|NCT03304925|Device|The ZELTIQ System|The CoolSculpting machine will be used to perform the treatments.
1902417|NCT03304912|Behavioral|PrEP Education and option to accept a PrEP prescription|Participants will receive educational information about PrEP, be offered a PrEP prescription, and those who choose to initiated PrEP will be monitored for side-effects and adherence at their follow-up visit. There is no group assignment within this study and WWID do not have to choose to initiate PrEP. Rather, the goal of this study is to understand factors that impact PrEP initiation (and engagement in the PrEP care continuum).
1902418|NCT03304899|Drug|RiaSTAP Injectable Product|"RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.
Dose (mg/kg body weight) =
([Target level (mg/dL) - measured level (mg/dL)])/(1.7 (mg/dL per mg/kg body weight))"
1902419|NCT03304873|Drug|Retapamulin|Retapamulin is a topical antibiotic ointment. The ingredients include retapamulin and white petrolatum as the vehicle. The composition is 10mg retapamulin per 1g of ointment (1%).
1902420|NCT03304873|Drug|Placebo Ointment|The placebo that will be used is triple-purified pharmaceutical-grade petrolatum.
1902421|NCT03304860|Other|Survey|Survey with 4-7 questions about each parents' demographics and CRC screening history. Depending on answers, provided a CRC screening document and asked to discuss screening with parents, followed by a brief survey in 4 months
1902424|NCT03304821|Drug|GM-CSF|Participants will self-administer 500 μg/day of GM-CSF, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of subcutaneous GM-CSF, three times per week for another 3 weeks and then will be followed for another 3 months.
1902425|NCT03304821|Drug|Placebo|Participants will self-administer 500 μg/day of a placebo, subcutaneously, three times per week (Monday, Wednesday, Friday) for three weeks. After three months the participants will receive a second administration of 500 μg/day of a placebo administered subcutaneously, three times per week for another 3 weeks and then will be followed for another 3 months.
1902428|NCT03304782|Other|Fitbit activity tracker|Wearable device that records the number of steps a person takes throughout the day
1902429|NCT03304769|Device|Virtual Reality|Virtual Reality Headset applied to the patient during placement of IV. Control is patient group without headset applied.
1902431|NCT03304743|Diagnostic Test|Dental panoramic radiograph|"If not performed within the previous 6 months at the Centre of Dentistry, an OPG will be performed during enrolment visit.
OPGs are routine low-dose x-rays that are often performed during dental check-ups, follow-ups or before dental treatments (e.g. extractions, implant placement, etc.), as they allow the evaluation of both bone and dental structures of both jaws, the sinus and temporo-mandibular joints."
1902432|NCT03304743|Diagnostic Test|DXA|"On Visit 2, a DXA scan of the hip and lumbar spine will be performed, with the Hologic QDR-4500 Acclaim densitometer owned by the University of Parma and located at the Centro Osteoporosi e malattie metaboliche scheletriche, if not already available from the previous 6 months.
DXA is a low-dose exam that allows the measurement of bone mineral density in relation to a T- score, and is considered the gold-standard for the diagnosis of osteoporosis.
Patients will be classified into healthy (T score -1), osteopenic (T score between -1 and -2.5) and osteoporotic (T score-2.5)."
1902433|NCT03304717|Drug|Tenofovir (TDF) and Emtricitabine (FTC)|"Tenofovir (TDF): a nucleotide reverse transcriptase inhibitor (NtRTI) an acyclic nucleotide analog of adenosine 5'-monophosphate. This is used in children as young as age 2.
Emtricitabine (FTC): a nucleoside reverse transcriptase inhibitor (NRTI), a synthetic analog of cytidine which binds at the active site of the reverse transcriptase."
1902434|NCT03304717|Other|Placebo|Placebo for Tenofovir and Placebo for Emtricitabine
1902435|NCT03304652|Drug|Zaleplon|Sleep Aid; 10mg; Oral; Single Use
1902436|NCT03304652|Other|Natural Sleep|Natural Sleep without medication
1902437|NCT03304639|Biological|Pembrolizumab|Given IV
1902438|NCT03304639|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1902439|NCT03304626|Drug|Budesonide 3Mg Capsule|Budesonide capsule in place of prednisone (standard of care)
1902440|NCT03304405|Diagnostic Test|Gait Analysis|All patients will undergo gait analysis using reflective surface markers placed at different locations on the head, trunk, upper and lower extremities, and pelvis. All patients will complete an analog pain scale, Oswestry, and SRS-22 questionnaires. These are health-related quality of life questionnaires that provide subjective assessment.
1902441|NCT03304600|Device|Active stimulation|Patients will receive a tDCS stimulation during 30 mn with an intensity of 2 milliampere (mA).
1902442|NCT03304600|Device|Sham stimulation|Patients will receive a Sham stimulation during 30 mn
1961408|NCT02924818|Other|Clinical assessment|
1902502|NCT03304028|Behavioral|Educationnal Intervention|After a first statistical analysis and interpretation (5 months), alert parameters for each patient are then fixed. An educational visit will be scheduled with patients and a personnalized action plan will be defined..
1961409|NCT02924818|Behavioral|questionnaires|
1961410|NCT02924818|Other|pulmonary function test|
1961411|NCT02924818|Biological|blood test|
1961412|NCT02924818|Biological|microbiology|
1961413|NCT02924818|Biological|histology|
1961414|NCT02924818|Other|imaging|
1997569|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo BBT intervention
1997570|NCT02002533|Other|Educational Intervention|Undergo HEAL
1997571|NCT02002533|Behavioral|Telephone-Based Intervention|Undergo HEAL
1997572|NCT02003365|Drug|FX006 10 mg|
1997573|NCT02003365|Drug|FX006 40 mg|
1997574|NCT02003365|Drug|TCA IR 40 mg|
1997600|NCT02001870|Procedure|In Vitro Fecundation (IVF)|In vivo fertilization will be performed according to the usual procedure of each Assisted Reproductive Technology (ART) center.
1997601|NCT02001870|Procedure|Intra Uterine Insemination (IUI)|Intra-uterine insemination will be performed according to the usual procedure of each ART center
1997602|NCT01998633|Biological|Hematopoietic Stem Cell Transplant|"NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.
Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10
Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4
Melphalan 140mg/m2 on Day -3
The GVHD prophylaxis will consist of the following:
Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.
Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)"
1961426|NCT02924285|Procedure|Procedure (Radiofrequency catheter ablation)|Radiofrequency catheter ablation
1961427|NCT02924285|Drug|Amiodarone|"Amiodarone, Verification of superiority of catheter ablation over amiodarone for treatment of PVCs in patients with structural heart disease as:
Antiarrhythmic Drug Amiodarone"
1902457|NCT03304574|Behavioral|Integrated personalized feedback|Integrated personalized feedback about self-reported risk behaviors will be generated and shown to participants as they complete their baseline health risk assessment using the CheckED Yourself app. The integrated personalized feedback is based on motivational feedback strategies such as normative feedback (comparison to peer behaviors and age-based health guidelines), increasing knowledge regarding potential consequences of behaviors, and providing practical tips for changing behavior.
1902458|NCT03304561|Other|traditional rehabilitation|traditional AC rehabilidation programe
1902459|NCT03304561|Other|Cross-over training|Cross-over training addition to the traditional rehabilidation
1902460|NCT03304548|Other|Telephone concept elicitation interview|All interview questions are designed to be very open-ended in order to ascertain subjects' preferences in an un-biased manner (as possible), with additional probes only being used when necessary to ensure all concepts of interest are covered. Subjects will be asked a series of broad, open-ended questions designed to encourage them to talk openly and as spontaneously as possible about their experience of taking oral treatment(s) for their PAH.
1902463|NCT03304509|Other|Telematic follow-up|Telematic follow-up by using a platform with videoconference
1902464|NCT03304496|Drug|Nitroglycerin 100 MCG/ML Injectable Solution|Previously described.
1902465|NCT03304496|Drug|Saline Solution|Previously described.
1902466|NCT03304483|Other|246-km running|Spartathlon 2017
1961428|NCT02923947|Drug|Osimertinib; AZD9291|80mg tablet dose to be taken orally - single dose in part A, daily dosing in Part B and continued access until progression or no longer receiving benefit
1902471|NCT03304444|Drug|Bupivacaine|bupivacaine hydrochloride used in TAP block
1902472|NCT03304444|Drug|liposomal bupivacaine|liposomal bupivacaine used in TAP block
1902473|NCT03304431|Drug|Orotracheal Lidocaine Oral Spray application|The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application
1902474|NCT03304418|Drug|Radium Ra 223 Dichloride|Radium Ra 223 dichloride will be delivered intravenously at 55 kBq/kg for a total of six cycles. 1 cycle= 28 days. The first cycle will commence at study enrollment, then cycles 2-6 will commence after the completion of radiotherapies at 4 week intervals
1902475|NCT03304418|Radiation|Radiation|"All external beam radiations oligometastatic sites will commence 1 to 2 weeks after administration of Cycle 1 of Radium-223. All subjects will receive Stereotactic body or hypofractionated radiation to sites of bone disease seen on imaging studies. Patients will have the primary tumor sites and 5 or fewer sites of bone-only metastasis treated with external beam radiation.
Any of the following regimens are considered ablative, acceptable and are biologically equivalent to 60Gy EQD2:
Single fraction: 16 Gy total at 16 Gy per fraction (SBRT)
Three fractions: 24 Gy total at 8 Gy per fraction (SBRT)
Five fractions: 30 Gy total at 6Gy per fraction (SBRT)
Six fractions: 32.4 Gy total at 5.4Gy per fraction (Hypofractionated)"
1902503|NCT03304028|Device|Connected Devices for 12 months|Each included patient will be re-equipped with CDs-spirometer, oxymeter, scale and watch during 12 months. If alerts occur, patients will be informed by email or SMS, with data transmission to the medical team who will not interfere. Patients should apply the shared action plan they learned. Quality of Life and Anxiety-Depression will be collected.
1902480|NCT03304379|Drug|Fasinumab|Solution for injection in pre-filled syringe
1902481|NCT03304379|Other|Diclofenac|NSAID active comparator (capsule)
1902482|NCT03304379|Other|Celecoxib|NSAID active comparator (capsule)
1902483|NCT03304379|Drug|Matching placebo|Fasinumab-matching placebo (solution for injection in pre-filled syringe); NSAID-matching placebo (capsule)
1902484|NCT03304366|Diagnostic Test|Pentacam (scheimpflug imaging)|Corneal changes including thickness, elevations....etc
1902487|NCT03304340|Device|functional electrical stimulation (FES)|Two dual-channel stimulators (MEDTRONIC Respond Select；Empi Inc) were connected with a program timer to form one stimulating unit for functional electrical stimulation (FES). FES was delivered with 0.3-ms pulses at 30 Hz, maximum tolerance intensity about 20 to 30 mA to cause visible muscle contraction.
1902488|NCT03304340|Device|transcutaneous nerve stimulation (TENS)|Transcutaneous nerve stimulation (TENS) stimulator (BioTENS, Skylark Device & Systems Co., Ltd,) was applied with 0.2 ms pulses, at 100 Hz in the constant mode within the subject'sensory level without muscle contraction, via (5 × 3.5 cm) electrodes attached to the motor points of quadriceps and tibialis anterior (TA) on the affected lower extremity.
1902489|NCT03304340|Other|standard rehabilitation (SR)|The standard rehabilitation (SR) program was a part of a regular intervention in stroke center. The activities of SR performed including neurodevelopment facilitation techniques, range of motion exercises and movement re-learning exercises etc.
1902490|NCT03304327|Behavioral|Mindfulness and Yoga Training|"Centering and Breathing- Practice begins by turning attention to the breath to help participants make the transition from the busy, doing, outward focus of daily life into the mindful, balanced, internal focus central to yoga practice.
Practices:Breath awareness, the relaxed abdominal breath. Posture Practice-Warm up with the range-of-motion sequence to take the major joints of the body through their full range of motion.This is done lying down with the head on the floor; the head can be supported by a small, folded towel if desired.
Practices: Knee-to-chest sequence, Arms and Shoulders, Gentle Spinal Twist, Apanasana.
Standing Poses for Strength and Balance, to enhance function and confidence. Practices: Mountain Pose, Flying Crane Sequence, Tree Pose, Warrior 2 and Side Angle.
Relaxation- Practice concludes with guided relaxation to quiet the mind and calm the body.
Practices: Seated Mountain Pose, even breath, extended exhalation,Yoga Nidra."
1902491|NCT03304314|Diagnostic Test|objective chromatic multifocal pupillometer|objective chromatic multifocal pupillometer (OCMP) enables objective and accurate measurement of pupillary responses to chromatic light at different wavelengths and light intensities and at different visual field locations.
1902493|NCT03303326|Behavioral|Immediate interview|A women's health interview that obtains information about physical, mental, and sexual health, particularly relatively private sexual health-related attitudes and experiences, as well as conflicts and stress related to sexuality.
1902495|NCT03304145|Other|The Carevive CPS|The Carevive Care Planning System (CPS) was developed to overcome challenges by providing an efficient, clinically integrated solution for both psychosocial and physical symptom distress screening and management through the delivery of personalized and evidence-based care plans at the point of care. The Carevive CPS simultaneously collects and aggregates discrete data for quality reporting and improvement.
1902496|NCT03304132|Other|Classification of Oral Microbiome Using 16S rRNA gene sequence-based approach|The sequence-based approach is selected because it classifies samples by considering the entire difference (genetic distance) in 16S rRNA gene sequences among samples analyzed, unbiased by artificial details such as taxonomies, sequence length, or even quality scores.
1902497|NCT03304132|Other|Classification of Oral Microbiome Using taxonomic approach|The taxonomic approach is a complement to the sequence-based approach in that it will further identify specific taxonomic groups or species that can explain the difference found by overall analyses.
1902501|NCT03304028|Device|Connected Devices for 3 months|Inclusion will be proposed at a follow-up visit by the child's or adult's referring doctor. A written informed consent form will be obtained. Quality of Life and Anxiety-Depression will be collected. Then, each included patient will be equipped with CDs-spirometer, oxymeter, scale and watch during 3 months for base-line.
1988473|NCT02823431|Drug|lidocaine gel|
1988474|NCT02823431|Other|Plain aqueous gel|
1902504|NCT03304028|Other|Interviews|At the end, semi-structured interviews will be completed to explore confidence on the CDs, impact on the doctor-patient relationship, change in the workload of medical team…etc.
1902505|NCT03304028|Behavioral|Refusal Questionnaires|Clinic staff will email all patients or parents (pediatric settings) to introduce the study. A qualitative interview with 10 patients who declined to participate in the study will be conducted to identify the reason of refusal
1902508|NCT03303729|Dietary Supplement|Meat Hydrolysate|25 grams of meat hydrolysate to maximally stimulate protein synthesis.
1902509|NCT03303729|Dietary Supplement|Cluster Dextrin|75 grams of Cluster Dextrin
1902510|NCT03303729|Dietary Supplement|Placebo|75 grams of Glucose
1902514|NCT03303586|Other|Compression Stockings|We will use knee length, ready-made compression stockings at a pressure of 20-30mmHg at the ankle and if a good fit cannot be obtained, custom-made stockings will be ordered. Patients will be measured for compression stockings by a certified fitter.
1902515|NCT03303586|Other|Control|Participants will not wearing compression stockings for two weeks.
1902520|NCT03303183|Device|Standard Impression technique|Silicone impression technique
1902521|NCT03303183|Device|Direct Ear Scanner|Direct Ear Scanner to scan the ear anatomy
1902522|NCT03303118|Other|Hypoxia|No drug or product will be used in this study. No medication will be give to the participants. No arm will be used for product administration.
1902526|NCT03302832|Other|Physical Therapy|Physical therapy includes both the in-person and home-based interventions prescribed for each individual participant in order to maximize overall patient outcomes including: ambulation, range of motion, strength, functional activities, pain, swelling, balance, patient safety, and other items within the scope of physical therapy practice.
1902527|NCT03302832|Other|In-home Exercise Equipment|The in-home exercise component of the study will supplement physical therapy services. This exercise equipment will be utilized daily for up to 90 minutes as guided by the healthcare team
1961475|NCT02908113|Behavioral|collection data|
1961476|NCT02908113|Behavioral|IRM|
1902617|NCT03292120|Other|measure of the SOFA score|The Sequential Organ Failure Assessment (SOFA) Score predicts ICU mortality based on lab results and clinical data.
1902543|NCT03301337|Dietary Supplement|Meat protein absorption|Meat protein absorption when digested together with a full meal.
1902544|NCT03301103|Biological|E. coli strain E1392-75-2A|After an overnight fast, subjects will be orally infected with a live, but attenuated, diarrheagenic E. coli (strain E1392-75-2A; collection NIZO food research; dose 1E10 CFU (at study day 14).
1902545|NCT03301103|Device|PTM202|PTM202 is a dietary formula containing a proprietary mixture of dried bovine colostrum and dried whole egg.
1961496|NCT02896855|Drug|Docetaxel|Docetaxel (75-mg/m^2) administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
1902563|NCT03300531|Biological|Ultrasound-guided pure platelet-rich-plasma (P-PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Pure platelet-rich plasma will be injected into the tendon.Once a week for three times.
1902564|NCT03300531|Biological|Ultrasound-guided platelet-rich-plasma (PRP) injection|Blood will be drawn, and tendon will be penetrated with dry needle under ultrasound guidance. Platelet-rich plasma will be injected into the tendon.Once a week for three times.
1902565|NCT03300531|Drug|Ultrasound-guided Compound betamethasone injection|Tendon will be penetrated with dry needle under ultrasound guidance. Compound betamethasone will be injected into the tendon.Once a week for three times.
1961497|NCT02896855|Drug|Pertuzumab|Pertuzumab (840-mg loading dose for Cycle 1, followed by 420 mg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
1961498|NCT02896855|Drug|Placebo|Placebo matched to pertuzumab administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
1961499|NCT02896855|Drug|Trastuzumab|Trastuzumab (8-mg/kg loading dose for Cycle 1, followed by 6 mg/kg for subsequent cycles) administered by IV infusion every 3 weeks until disease progression or unacceptable toxicity.
1961500|NCT02895997|Other|Travel Telehealth Delivery|Clinical Operations Room (COR) staff will travel to Sydney Australia to deliver telehealth to patients in Georgia United States. Upon arrival, participants will have eight nights and seven days free of clinical responsibilities. Thereafter, each participant will work four consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. The following week, participants will work three consecutive days of 12 hour shifts followed by four consecutive days with no clinical assignment. Upon return to the USA, participants will have a week free of clinical responsibilities.
1902570|NCT03300466|Device|GP0045|Hyaluronic acid gel
1902571|NCT03300466|Device|Comparator|Hyaluronic acid gel
1902573|NCT03299790|Other|high-intensity interval exercise training (HIIT)|This program includes 12 weeks of exercise training and is divided in 3 phases (phase 1: week 1-2, phase 2: week 3-6, phase 3: week 7-12).
1902574|NCT03299790|Other|moderate-intensity exercise training (MIT)|the exercise training program consists of 3 endurance exercise sessions per week (for 6 months). During each exercise training session, walking and cycling exercise is performed, for a total duration of 45 min (including 5 min of warming-up and cooling-down, at 65% of VO2peak.
1902581|NCT03298880|Device|Supine VM VAD|Valsalva strain delivered using VAD
1902582|NCT03298880|Device|Supine VAD manometer|supine Valsalva strain delivered using manometer
1902583|NCT03298880|Other|Modified VM VAD|modified VM using VAD
1902584|NCT03298880|Other|Modified VM Manonmeter|Postural modified position VM using manometer
1902586|NCT03298672|Drug|NDX-1017|Solution of NDX-1017 for subcutaneous injection
1902587|NCT03298672|Drug|Placebo|Placebo solution for subcutaneous injection
1902589|NCT03297476|Diagnostic Test|High-risk subtype detection panels|The designed detection technology were used to identify the high-risk patients cohort.
1902597|NCT03294239|Procedure|Transurethral extraction of bladder stone(s)|Patients will have transurethral approach for management of their bladder stones. Either pneumatic or Holmium:YAG laser will be used for stone distentegration. Stone basket and/or Elics current evacuation will be used to retrieve stone fragments. Urethral catheter will be applied for 48 hours.
1902598|NCT03294239|Procedure|percutaneous extraction of bladder stone(s)|Patients will have percutaneous approach for management of their bladder stones. After initial cystoscopy a Foley's urethral catheter will be fixed for continuous irrigation. Then, the bladder will be filled to capacity with normal saline. Access to the distended bladder will be obtained by 10-gauge needle in the midline 1-2 cm above the pubic bone. Once suitable placement is confirmed with return of fluid, a guide wire will be passed through the needle into the bladder. Dilatation will be done using 8-10 Fr coaxial dilators then single fascial dilator with placement of 16 Fr Amplatz sheath as a working tract. No ultrasonic or fluoroscopic guidance will be used. Stone basket will be used to extract the stone. If the stones were larger than the used sheath, disintegration will be performed with a pneumatic lithotrite. Primary skin closure of the suprapubic stab wound by one stitch will be done and the urethral catheter will remain for 48 hours.
1902603|NCT03293498|Biological|NanoFlu|Vaccine
1902604|NCT03293498|Biological|Fluzone HD - Day 0|Vaccine
1902605|NCT03293498|Biological|Fluzone HD - Day 21|Vaccine
1902606|NCT03293498|Other|Saline - Day 21|Placebo
1902609|NCT03292835|Device|LeiProtect®|Filmogenic dressing gel
1902610|NCT03291977|Drug|Fluorescéine Sodique Faure|Fluorescéine Sodique Faure given intravenously during the induction of the anesthesia, at the dose of 3mg/kg, diluted in 50mL of physiological serum, in 10 minutes.
1902611|NCT03291977|Procedure|White-light surgery|The surgery will be performed under classical conditions
1961521|NCT02888548|Procedure|botulinum toxins (Dysport°) alone|botulinum toxins (Dysport°) alone
1961522|NCT02888548|Procedure|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined|orthosis (Saebo Strech°) + botulinum toxins (Dysport°) combined
1961523|NCT02888015|Other|upper extremity exercise program|five exercises to improve upper extremity strength and endurance will be provided to patients, shoulder flexion, abduction/adduction, elbow flexion/extension, internal/external rotation
1961525|NCT02885714|Procedure|Placebo surgery and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated. Nothing is to be removed or excised and the use of any vapour or shaver device is not allowed. The presence of a full-thickness rotator cuff tear is verified. Altogether 3 to 5 small stab wounds are made in typical locations resembling locations of typical rotator cuff repair. The time spent in the operating theatre with patients in placebo group should resemble the time spent with patients in the active treatment group and hence give an impression of a rotator cuff repair.
1961526|NCT02885714|Procedure|Rotator cuff repair and supervised specific exercises|The patient is prepared for surgery as normal (plexus+general anesthesia or TIVA, with antibiotic prophylaxis). The arthroscope is introduced in the glenohumeral joint, and thereafter online randomization is performed. The joint space is evaluated and the presence of a full-thickness rotator cuff tear is verified. The cuff tear is repaired to its anatomic location using suture anchors according to surgeon preference. . A biceps tenotomy or tenodesis may be performed according to surgeon preference if the biceps tendon is noted to be frayed, unstable or inflamed. An additional acromioplasty may be performed according to surgeon preference.
1961549|NCT02879422|Genetic|genetic analysis|
1961556|NCT02876146|Drug|Benzimidazole|Withdrawal of benzimidazole after 4 years (non operable AE) or one year after surgery (curative hepatectomy)
1961559|NCT02874105|Other|Group C: physiotherapy protocol with Conventional physiotherapy.|
1902654|NCT03284905|Dietary Supplement|Probiotic supplement|Capsule containing freeze dried probiotic bacteria together with maize starch
1902655|NCT03284905|Dietary Supplement|Placebo supplement|Capsule containing maize starch
1902656|NCT03284372|Behavioral|Text Message Only|The intervention group (n=25, randomly selected from the base cohort) will receive informational and socially supportive text messages during a 10-week intervention. Investigators will deploy the intervention using the Way to Health platform, which automates outgoing messages and feedback. Many of the messages will be sent to all Intervention 1 participants, to assure consistency of the intervention. A subset will be tailored to address participants' specific allergies. At 10 unannounced check-ins, we will send text messages asking participants in the intervention and control groups if they are carrying their epinephrine.
1902657|NCT03284372|Behavioral|Text message + Incentive 1|Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=25) to receive text message reminders plus Incentive 1. At each of 10 unannounced check-ins, if unsuccessful in documenting epinephrine-carrying, participants will lose part of their incentive. The remainder of the Cohort (control) will receive text reminders.
1902658|NCT03284372|Behavioral|Text message + Incentive 2|Among base cohort members not exposed to the text message only intervention (#1), we will randomly select a new intervention group (n=25) to receive text message reminders plus Incentive 2 (at each of 10 check-in, successful participants will have a 2/5 chance of winning a small prize or a 2/25 chance of winning a bigger prize). The remainder of the Cohort (control) will receive text reminders.
1902659|NCT03283397|Drug|EK-12|10 mg metenkefalin acetate + 2 mg tridecactide acetate in 2 mL 0.9 % NaCl solution.
1902660|NCT03283397|Drug|INF beta-1a|Active substance is INF beta-1a, 44 mcg in 0.5 mL solution
1961560|NCT02874105|Other|Group S: physiotherapy protocol with Dynamic Humeral Centering.|
1902664|NCT03282214|Behavioral|Self-management energy conservation|"The experimental group will receive four sessions approximately every three weeks with the PI. These sessions will correspond to the cycles of chemotherapy they will receive, with the first two sessions being during cycle 1, and sessions 3 and 4 being during cycles 2 and 3 of chemotherapy, respectively. The women will be instructed on how to assess their activity patterns by making a list prioritizing their usual activities. The journal and priority list (a to do list) provide the basis for the second session. In this session, the participant will learn to create a plan for managing valued activities to minimize the amount of energy used, to report the fatigue experienced during and after an activity done in the journal and will learn strategies to manage fatigue and optimize activity. In the third session, the participant will evaluate and revise their individualized plan. In addition, the participant will be instructed to wear a pedometer to record objective physical activity."
1961566|NCT02873715|Behavioral|Enhanced Usual Care + Family-based|Enhanced Usual Care + Family based treatment as the invention to randomized participants. Family Based treatment utilizes behavior change techniques to target family-wide changes in diet and physical activity habits with the goal of promoting weight loss and subsequently healthy weight maintenance in all participants. Participants will have visits between 15 to 60 minutes as frequent as weekly and no longer than monthly over the two year study
1961567|NCT02873715|Behavioral|Enhanced Usual Care|Enhance usual care pediatricians provide their normal care for obesity treatments guided by the AAP Next Steps 5210.
1902668|NCT03280342|Drug|IR-TPM (Topamax)|XR-TPM (Trokendi XR)
1902669|NCT03280342|Drug|XR-TPM (Trokendi XR)|XR-TPM (Trokendi XR)
1902677|NCT03277729|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD20 CAR T cell IV
1902678|NCT03277729|Drug|Cyclophosphamide|Given IV
1902679|NCT03277729|Drug|Fludarabine|Given IV
1902680|NCT03277729|Other|Laboratory Biomarker Analysis|Correlative studies
1902681|NCT03277729|Procedure|Leukapheresis|Undergo leukapheresis
1902682|NCT03278548|Drug|Volulyte 6%|Solution for infusion
1902683|NCT03278548|Drug|Ionolyte|Solution for infusion
1902685|NCT03278067|Other|Enhanced vaccine safety surveillance|Routinely collected primary care data from up to ten general practices to support passive surveillance. Additionally, this passive surveillance will be enhanced by the use of a customized card-based ADR reporting system.
1961583|NCT02870907|Other|Observation|no post operative chemotherapy
1961584|NCT02870907|Drug|Etoposide|100 mg/m²/d, IV (in the vein) from D1 to D5.
1961585|NCT02870907|Drug|Vincristine|1, 5 mg/m²/d, IV at D1.
1961586|NCT02870907|Radiation|Orbital irradiation|45 Grays (Standard or external beam radiotherapy).
1961587|NCT02870907|Drug|Carboplatin|160 mg/m²/d, IV from D1 to D5.
1961588|NCT02870907|Drug|Vincristine|1,5 mg/m²/d, IV at D22 and D26
1961589|NCT02870907|Drug|Cyclophosphamide|300 mg/m²/d, IV from D22 to D26.
1961590|NCT02870907|Drug|Carboplatin|560 mg/m²/d, IV at D1.
1961591|NCT02870907|Drug|Etoposide|100 mg/m²/d, IV from D1 to D5
1961592|NCT02870907|Drug|Carboplatin|160 mg/m²/d,IV from D1 to D5
1961593|NCT02870907|Drug|Thiotepa|15 mg, intrathecal Thiotepa injection at D1.
1961594|NCT02870907|Drug|Vincristine|1,5 mg/m²/d), IV at D22
1961595|NCT02870907|Drug|Cyclophosphamide|1000 mg/m²/d, IV from D22 à D24.
1961596|NCT02870907|Procedure|Cytapheresis|Cytapheresis for peripheral blood stem cells collection after the primary or the secondary courses of Vincristine- Cyclophosphamid.
1961597|NCT02870907|Drug|Carboplatin|AUC : 7/d, IV from D-8 to D-6.
1961598|NCT02870907|Drug|Etoposide|250 mg/m²/d, IV from D -5 to D-3.
1961599|NCT02870907|Drug|Thiotepa|300 mg/m²/d, IV from D-5 to D-3.
1961600|NCT02870907|Procedure|Peripheral bood stem cell transplantation|at D0
1961607|NCT02867579|Behavioral|"evaluation of the child quality attachment (Strange situation)"|
1902713|NCT03277092|Device|VeinViewer®|Near-infrared (NIR) technology consists on light-emitting diodes placed underneath the hand, that makes vessels visible by projecting the processed image in a green light directly on to the puncture site
1902714|NCT03277092|Procedure|Usual care|The blood drawing is performed traditionally
1961621|NCT02862756|Other|diffusion-weighted MRI and clinical examination|
1961622|NCT02862743|Other|patients with metastatic melanoma|Blood sample to realize molecular characterization of melanoma
1961623|NCT02861937|Procedure|non surgical periodontal therapy|
1961654|NCT02856126|Procedure|Hepatic arterial infusion chemotherapy|
1961655|NCT02856126|Procedure|Transarterial chemoembolization|
1961656|NCT02856126|Drug|TACE regimen|infusion with lipiodol mixed with chemotherapy drugs (EADM 50mg, lobaplatin 50mg, and MMC 6mg ), and embolization with polyvinyl alcohol particles (PVA)
1902748|NCT03274063|Other|Supported self-management|Participants will be supplied with urate self-testing kits. Participants will have a mobile phone application installed which will prompt the participant to perform urate self-testing, enable the clinical research team to advise on escalation of urate lowering therapy, and collect quality of life data .
1902749|NCT03274063|Other|Usual care|Participants will have a mobile phone application installed which will allow the research team to collect quality of life data.
1961657|NCT02856126|Drug|HAIC Regimen|Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
1961658|NCT02856126|Drug|Oral Sorafenib|Oral Sorafenib, 400mg, Bid
1961659|NCT02854618|Other|additional blood sample|
1961660|NCT02852200|Other|SEGAm|
1961661|NCT02853292|Biological|urine collection|
1961662|NCT02853110|Radiation|Hypo-FLAME study|SBRT technique with 35 Gy in 5 weekly fractions and an additional simultaneously integrated focal boost to the tumor nodule(s) visible on MRI up to 50 Gy. In addition, patients will be asked to undergo 5 additional MRI scans (~15 min/scan) without contrast enhancement prior to each radiation session as well as blood sampling for translational research (radiogenomics) and Biobank purposes.
1961663|NCT02849496|Drug|Atezolizumab|Given IV
1961664|NCT02849496|Other|Laboratory Biomarker Analysis|Correlative studies
1961665|NCT02849496|Drug|Veliparib|Given PO
1961666|NCT02849886|Drug|T lymphocytes iCASP9 ΔCD19|Intravenous injection of the T lymphocytes armed with the iCASP9 suicide gene
1961667|NCT02849886|Drug|Dimerizer drug AP1903|"AP1903 drug will be administrated at a dose of 0.4 mg/kg by intravenous route in the two following cases:
Acute Grade ≥II or symptomatic Grade I GvHD justifying systemic immunosuppression therapy;
Grade ≥3 toxicity attributable to GMC."
1961668|NCT02847260|Drug|Remodulin|Treatment will be initiated whilst hospitalized at approximately 2.0 ng/kg/min with dose increments of 1- 2 ng/kg/min approximately every 12 hours according to clinical response and tolerability. Following subject discharge, the dose rate is increased by 1-2 ng/kg/min with dose increments separated by at least 24 hours. When a dose rate of 20 ng/kg/min is achieved dose increments can be increased at a rate of up to 4 ng/kg/min with dose increments separated by at least 24 hours depending on tolerability. The aim is to achieve a dose rate of at least 10, 20 and 30 ng/kg/min by the end of weeks 1, 4 and 12, respectively and a dose rate by the end of week 16 that achieves pre-defined treatment goals subject to clinical response and tolerability.
1961671|NCT02845934|Other|blood sample|additional sampling of blood (estimated volume 6 mL for each sampling) on day of suspicion of the mucormycosis and then twice a week up to a maximum of 8 weeks.
1961672|NCT02845739|Other|Kidney transplanted patients|
1961675|NCT02842320|Other|biological samples|bone marrow and blood
1902770|NCT03268954|Drug|Azacitidine|Azacitidine intravenous or subcutaneous formulation
1902771|NCT03268954|Drug|Pevonedistat|Pevonedistat intravenous infusion
1902773|NCT03267277|Drug|Sodium Thiosulfate|Sodium thiosulfate is a calcium chelator
1902777|NCT03263546|Behavioral|Internet-delivered cognitive behavioral therapy (ICBT)|"Participants will receive internet-delivered CBT with therapist support for 16 weeks. The treatment consists of 14 online chapters with interactive features as videos and illustrations. The treatment has the main focus on exposure with ritual prevention. The children and parents have regular contact with a personal assigned therapist via written text messages in the platform.
Participants that are classified as non-responders at 3 months follow-up will receive face-to-face CBT of up to 12 sessions over 12 weeks."
1902778|NCT03263546|Behavioral|Cognitive behavioral therapy (CBT)|"Participants in the gold standard group will receive 14 individual face-to-face CBT sessions over 16 weeks. The treatment is based on current evidence based recommendations for OCD, and focuses on exposure with ritual prevention.
Participants that are classified as non-responders at 3 months follow-up will receive additional face-to-face CBT of up to 12 sessions over 12 weeks."
1902780|NCT03261739|Biological|RYI-018|Anti-CB1 monoclonal antibody
1902781|NCT03261739|Biological|Placebo|Placebo
1902782|NCT03262259|Behavioral|GSDG multi-component intervention|Multi-component intervention, including screening and brief intervention, other evidence-based interventions, and novel or partially tested interventions that warrant further evaluation.
1902785|NCT03261115|Procedure|No topical anesthesia|Lack of use of topical anesthesia application prior to infiltration injection intra-orally
1961691|NCT02835170|Biological|Autologous immunoglobulin|Autologous immunoglobulin (IgG) aseptically purified from the autologous plasma will be administered to the patients by intramuscular injection, once a week for 7 weeks (total 8 injections).
1902792|NCT03260699|Device|OCSI Rehabilitator brace|Guardian Brace features the innovative Rehabilitator™ line of gait correcting, leg strengthening braces. Rehabilitator™ Knee Braces are clinically proven to reduce UNBRACED pain, strengthen the affected leg, and significantly improve function after only 90 days of brace wear.
1961692|NCT02835170|Other|Placebo|"Saline will be administered to the patients by intramuscular injection, once a week for 7weeks (total 8 injections).
(In addition, autologous immunoglobulin is colorless and odorless, injection volume is same between autologous immunoglobulin and saline)"
1961697|NCT02833324|Behavioral|Education regarding ambulation|The participants will be educated on the importance of postoperative ambulation during the recovery period.
1961698|NCT02833324|Behavioral|Ambulation reminder alarms|Participants in the intervention arm will receive 5 daily alarms to prompt them to ambulate. Alarms will be set to ring at 9am, 11am, 2pm, 5pm and 9pm. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
1961699|NCT02833324|Other|Fitbit|Participants who are postoperative for colorectal surgery, who have been cleared to ambulate during recover, will be equipped with an off-the-shelf Fitbit device (a wireless activity tracking device) which will record steps taken while the participant is hospitalized. The Fitbit will be worn from the day of surgery (postoperative day 0) through postoperative day 9 or hospital discharge, whichever occurs first.
1902801|NCT03256526|Drug|Placebo|0 mg
1902802|NCT03256526|Drug|PF-06835919 Low Dose|75 mg once daily
1902803|NCT03256526|Drug|PF-06835919 High Dose|300 mg once daily
1902804|NCT03257930|Drug|ethanol injection|inject ethanol in cystic thyroid nodule and follow up until complete recovery
1961711|NCT02829983|Drug|Clarithromycin|Use of 500mg of Clarithromycin twice a day for 3 days
1961712|NCT02829983|Drug|Placebo|Use of placebo tablets twice a day for 3 days.
1902818|NCT03254056|Procedure|Conventional technique|Conventional technique: In this group; S-retractors will be used to visualize the fascia and a single interrupted stitch will be placed using 0-vicryl suture.
1961713|NCT02829983|Other|One-stage full-mouth ultrasonic debridement (FMUD)|One session of Periodontal debridement using ultrasonic device.
1902819|NCT03254056|Procedure|Berci technique|Berci group: In this group; the fascial incision will be closed with the fascial closure device, (Berci Fascial Closure instrument) using 1 interrupted stitch with 0-vicryl suture.
1961732|NCT02826928|Biological|blood sample withdrawn|
1961733|NCT02826668|Other|Ultrasound|A baseline lumbar ultrasound in a standardized lateral position (by bed markings) will be performed with the midline and L3-L4 interspace marked, and estimated depth to the epidural space recorded. A second lateral lumbar ultrasound will be performed immediately prior to placement at the time of epidural request. The bed position will be standardized with lines drawn down the back, at the flexion of the knee, and heel of the foot. The sonographic measurements will include the midline, the L3-4 interspace, (both marked at the skin surface), and the measured depth to the ligamentum flavum (in centimeters).
1902823|NCT03252509|Procedure|Percutaneous radiologic gastrostomy|Percutaneous radiologic gastrostomy: Under conscious sedation and local analgesia, the ultrasound is performed to determine abdominal structures. The stomach is distended using room air through a nasogastric catheter or a 5 French (Fr) catheter. Gastropexy is performed under fluoroscopic guidance. The stomach is accessed using a 18 gauge (G) needle. Guidewire is advanced to the stomach. Progressive tract dilatations until the size of the gastrostomy tube is achieved. The catheter is advanced through the peel-away sheath. The catheter's balloon is inflated with 10ml of distilled water. Iodine contrast is injected to confirm position. After the procedure, the patient is observed for 3 hours. If there are no complications, the patient is discharged.
1902832|NCT03250039|Drug|PF-04965842|14C labeled PF-04965842
1902833|NCT03250039|Drug|Absolute Bioavailability|Oral dose of unlabeled PF-04965842 and an IV dose of 14C labeled PF- 04965842
1961742|NCT02824900|Device|Vibration stimuli to neck muscles|
1961743|NCT02824900|Device|Vibration stimuli to hand|
1961744|NCT02824900|Behavioral|conventional physiotherapy|
1902839|NCT03249259|Drug|Choline alfoscerate|Treatment duration is 6 months.
1902840|NCT03249259|Drug|Placebo|Treatment duration is 6 months.
1961747|NCT02825264|Device|STARflo Implant|All patients who have been implanted with STARflo implant from 2011 will be offered to participate to this data collection
1902844|NCT03248518|Behavioral|Usual Care|Information booklet on fatigue which represents usual care in almost all UK rheumatology centres
1902845|NCT03248518|Behavioral|Cognitive behavioural approach|A talking therapy which explicitly aims to replace unhelpful beliefs and behaviours through the application of patient-centred strategies and behavioural activities
1902846|NCT03248518|Behavioral|Personalised Exercise Programme|PEP is a graded exposure behaviour therapy which aims to gradually optimise patients levels of physical activity with view to modifying their altered perception of effort and ultimately reduce the severity and impact of fatigue.
1902847|NCT03248414|Dietary Supplement|Lactobacillus sakei|1 pack contained 5 x 109 cfu
1902848|NCT03248401|Drug|Cilostazol|Cilostazol 200 mg/day
1902849|NCT03248401|Drug|Aspirin|Aspirin 100 mg/day
1961748|NCT02824562|Behavioral|Behavioral intervention for chronic pain in HIV|
1902853|NCT03246126|Device|Valiant™Thoracoabdominal Stent Graft System|The Visceral Manifold System is comprised of the Thoracic Bifurcation and Visceral Manifold to treat a thoracoabdominal aortic aneurysm or TAAA. The experimental procedure to implant the stent graft will be done in an operating room and will last anywhere from four to eight hours, but may take longer.
1992370|NCT03321838|Behavioral|accommodative/vergence therapy|Accommodative/vergence therapy (60 minutes per visit, one time per week, 12-14 weeks) and home reinforcement (15 minutes each time, five times per week, 12-14 weeks) will be provided to patients of treatment group. These therapy includes accommodative, vergence and anti-suppression technique. No drug is used during the whole therapy process.
1992371|NCT03321825|Device|Belotero® Volume Lidocaine|Mode of application: subdermal injection
1992372|NCT03321812|Device|Acellular bone matrix scaffold|Acellular bone matrix scaffold is a tissue engineering acellular matrix scaffold with the closest biomechanics and structure of normal cartilage.
1992373|NCT03321812|Device|microfracture|Microfracture is the surgical option for conventional treatment of cartilage defects.
1992377|NCT03321773|Drug|triple therapy plus bismuth therapy|pantoprazole 40mg twice daily for 14 days, amoxicillin 1g twice daily for 14 days, clarithromycin 500mg twice daily for 14 days, bismuth subcitrate 240mg twice daily for 14 days.
1992378|NCT03321773|Drug|reverse hybrid therapy|(pantoprazole 40mg twice daily for 7 days, amoxicillin 1 g twice dailyfor 7 days, clarithromycin 500 mg twice daily for 7 days, and metronidazole 500 mg twice daily for 7 days) followed by (pantoprazole 40mg twice daily for 7 days and amoxicillin 1 g twice daily for 7 days)
1992379|NCT03321760|Radiation|Stereotactic Ablative Radiation Therapy (SABR)|SABR will be delivered to the primary disease and hilar (N1) node over 5 fractions.Reductions may be made to the hilar (N1) node according to a 3+3 design during the run-in period.
1992380|NCT03321747|Radiation|Stereotactic Ablative Body Radiation (SABR)|Treatments shall not be delivered more frequently than every other day.
1902858|NCT03245034|Behavioral|Auricular Acupuncture Therapy|"Acupuncture treatment will be the NADA protocol, a well-known and commonly used protocol that has previously been studied for stress relief in health care workers.In this protocol, 5, ½ needles are inserted in each auricle and retained while the group relaxes for 20 minutes. It will be conducted by two acupuncturists credentialed at NYU Lutheran (TK and AG)."
1902859|NCT03245840|Drug|Budesonide oral suspension|Budesonide oral suspension (BOS) 10 mL twice daily
1902860|NCT03245567|Other|PLM|Participants will take the PLM on the visual estimation of LVEF. They will also take a pretest, a post-test and a delayed test at 6 months.
1902861|NCT03245567|Other|Pre, post, delayed test|Participants will perform a pretest, a posttest and a delayed test at 6 months.
1902863|NCT03245229|Drug|ACT-132577|Capsule for oral administration
1902864|NCT03245229|Drug|Rosuvastatin|Tablet for oral administration
1961771|NCT02815761|Other|NO intervention, just observation|No intervention.
1902874|NCT03242824|Drug|Fluorine F 18 Fluorodopa|Contrast used in PET
1902875|NCT03242824|Radiation|Intensity-Modulated Radiation Therapy|Radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor
1902876|NCT03242824|Procedure|Positron Emission Tomography|imaging test
1902880|NCT03242200|Other|Mobile Health App|Mobile Health is a multi-featured app designed to enable participants to self-record and track their health and wellness. Participations will set up a profile and complete questionnaires. The app also records the amount of time and features of programs accessed.
1961787|NCT02804711|Biological|Low dosage of Staphylococcus aureus vaccine (15µg/0.6ml)|
1961788|NCT02804711|Biological|Middle dosage of Staphylococcus aureus vaccine (30µg/0.6ml)|
1902895|NCT03239223|Drug|ABI-1968|Topical ABI-1968 Cream or Placebo with 4 doses administered up to 4 Cohorts
1961789|NCT02804711|Biological|High dosage of Staphylococcus aureus vaccine (60µg/0.6ml)|
1961790|NCT02804711|Biological|Placebo|
1961824|NCT02790138|Drug|Vedolizumab|Vedolizumab IV infusion
1961825|NCT02790138|Drug|Ciprofloxacin|Ciprofloxacin Tablets
1902924|NCT03232814|Behavioral|Group-based walking|The walking prescription will be progressive in nature. The program will begin with participants walking for approximately 20 minutes in weeks 1-3. This will gradually increase to approximately 30 minutes in weeks 4-6. Finally, this will increase to 45-60 minutes in weeks 7-8. The program will promote walking at a moderate intensity as assessed by Borg's Rating of Perceived Exertion scale. Each session will be preceded by a brief warm-up and followed by a brief cool-down period.
1961826|NCT02790138|Drug|Vedolizumab Placebo|Vedolizumab placebo-matching IV infusion
1961829|NCT02788890|Procedure|Scaling without LA|The patient will undergo a supragingival scaling procedure without local anesthesia
1961830|NCT02788890|Procedure|Simple restoration under LA|The patient will undergo a simple dental restoration procedure under local anesthesia
1961831|NCT02788890|Procedure|Simple exodontia under LA|The patient will undergo a simple dental extraction procedure under local anesthesia
1902934|NCT03233048|Device|ORBERA™ Intragastric Balloon|The balloon will be inserted into the stomach and inflated, and will remain in place for 6 months, after which the device will be removed.
1902946|NCT03230318|Drug|ARQ 087|ARQ 087 will be orally administered at 300 mg once per day with or without food and is supplied as 100 mg capsules.
1902982|NCT03220737|Other|Placebo|Placebo control for this study is normal (0.9%) saline.
1992409|NCT03321500|Other|Silicone-based soft liner|gold standard for denture relining material
1902948|NCT03229083|Other|Carevive software|In this study, Carevive will deliver a link to subjects so that an online survey can be completed. The survey will occur weekly for the first 12 weeks of the study and will be spaced out to every other week thereafter. The questions will mostly focus on side effects from their cancer therapy, as well as a few questions about drug compliance and healthcare utilization. After completion of the survey, the subject will be given a care plan with at home self-management options for drug-related toxicities.
1961839|NCT02786485|Biological|BPX-501|T cells transduced with CaspaCIDe suicide gene
1961840|NCT02786485|Drug|Rimiducid|administered to treat GVHD
1961841|NCT02784444|Drug|MSDC-0602K|MSDC-0602K capsules
1961842|NCT02784444|Drug|Placebo|Placebo capsules
1961849|NCT02781064|Drug|Atorvastatin 20mg|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
1961850|NCT02781064|Drug|Placebo|Atorvastatin and matching placebo to be taken in a randomised order for 12 months
1902973|NCT03224559|Device|Transcranial Electrical Stimulation|Transcranial Electrical Stimulation
1902974|NCT03224234|Device|Insulclock with feedback|Daily information on a smartphone on insulin administration (time and dosing) as well as reminders in the event of missing doses.
1902975|NCT03224234|Device|Insulclock without feedback|Not feedback on insulin administration.
1961860|NCT02774616|Device|Ilivia ICD Family|pre-defined device programming, measurements and follow-up schedule
1961861|NCT02774616|Device|Plexa ICD lead|predefined follow-up schedule
1902981|NCT03220737|Biological|VAXCHORA (Cholera Vaccine, Live, Oral)|VAXCHORA (Cholera Vaccine, Live, Oral) is a live, attenuated bacterial vaccine suspension for oral administration containing the V. cholerae strain CVD 103-HgR.
1961862|NCT02774187|Drug|Sorafenib|administration of Sorafenib
1961863|NCT02774187|Procedure|Hepatic arterial infusion chemotherapy|administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
1961864|NCT02774187|Drug|Folfox Protocol|Oxaliplatin , fluorouracil, and leucovorin
1961865|NCT02775045|Other|Observation Period|8 week observational period
1902985|NCT03219502|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|"Ten rTMS sessions given over a 10 business day period.
Each rTMS session should take about 30 minutes to complete."
1902986|NCT03219502|Procedure|Sham Repetitive Transcranial Magnetic Stimulation (rTMS)|"Ten sham rTMS sessions given over a 10 business day period.
Each sham rTMS session should take about 30 minutes to complete."
1902987|NCT03219502|Procedure|Electroencephalogram (EEG)|"rTMS and Sham rTMS Groups: EEG performed at baseline, within 7 days after rTMS/shamrTMS, and at 1 month follow up visit.
Standard of Care Group: EEG performed at baseline and at 1 month follow up visit."
1902988|NCT03219502|Behavioral|Assessment Questionnaires|"Questionnaires completed about symptoms, how participant has been feeling, basic information, and participant's general quality of life at baseline, within 1 week after last rTMS session (if received), and again at 1 month follow up.
It should take about 25 minutes to complete them."
1902989|NCT03219502|Behavioral|Pain Questionnaires|At each rTMS/sham rTMS session, participant rates any pain or symptoms on a scale of 0-10 before the session, and again after the session is complete.
1961876|NCT02766543|Device|MRI-guided Transurethral Ultrasound Ablation|Magnetic resonance imaging-guided transurethral ultrasound ablation (MRI-TULSA) is a novel minimally-invasive procedure where the therapeutic endpoint is prostate ablation through thermal coagulation.
1961877|NCT02765347|Drug|Metformin|For arm 1, accept MDI or CSII plus metformin (initially starting dosage with 0.5g qd, then gradually increasing to 0.5g tid) for 24 weeks.
1961878|NCT02765347|Drug|Insulin|For arm 2, just accept insulin for 24 weeks
1903005|NCT03216486|Drug|BPS804|IV administration of BPS804 in 5% Dextrose solution
1903011|NCT03214081|Drug|Vonoprazan|Vonoprazan tablets
1990027|NCT02258464|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update)
1990028|NCT02258464|Drug|Placebo (saline)|Up to 6 cycles of saline injection
1990029|NCT02258464|Other|Background hormonal therapy|Prescribed by PI and is provided as long as patient can tolerate treatment. It must be prescribed as per local label in country participating.
1990036|NCT02255097|Biological|pembrolizumab|
1990037|NCT02253420|Drug|Copanlisib (BAY80-6946)|"Part 1 of Cycle 1 Cycle 1 Day 1: Single i.v. dose 12mg Cycle 1 Day 15: Single i.v. dose 12 mg Part 2 of Cycle 1 Cycle 1 Day 1: Single i.v. dose TBD (based on Part 1 data) Cycle 1 Day 15: Single i.v. dose TBD (based on part 1 data)
Part 1 & Part 2
Cycle 2 and subsequent cycles:
Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
1990038|NCT02253420|Drug|Itraconazole|Cycle 1 Day 12: 2 x 200 mg itraconazole oral (two doses, 12 hours apart) Cycle 1 Days 13-21: 200 mg itraconazole oral, once daily in the morning
1990039|NCT02253420|Drug|Rifampin|Cycle 1 Days 10 - 21: 600mg Rifampin oral, once daily in the morning
1990040|NCT02253420|Drug|Copanlisib (BAY80-6946)|"Cycle 1 Day 1: Single i.v. dose 60mg Cycle 1 Day 15: Single i.v. dose 60mg
Cycle 2 and subsequent cycles:
Day 1: Single i.v. dose of 60mg Day 8: Single i.v. dose of 60mg Day15: Single i.v. dose of 60mg"
1990049|NCT02246270|Drug|Intravesical Heparin|Heparin bladder instillation
1990050|NCT02246270|Other|Placebo|Intravesical saline
1903028|NCT03209713|Behavioral|HPV Vaccine Education|A one on one twenty-minute parental educational program providing facts about HPV, HPV-related cancers, and the HPV vaccine.
1903029|NCT03209713|Behavioral|Text Messaging Reminder|Participants will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after participating in the education session. These reminders will occur until uptake of the first dose of the vaccine is reported or for up to 12 weeks.
1903031|NCT03210311|Device|compression|a compression stocking is worn, a garment compression class 2, flat knitted
1961902|NCT02760316|Drug|AZD9567 10 mg|Oral suspension Multiple doses 5 days of treatment Once daily
1961903|NCT02760316|Drug|AZD9567 20 mg|Oral suspension Multiple doses 5 days of treatment Once daily
1961904|NCT02760316|Drug|AZD9567 40 mg|Oral suspension Multiple doses 5 days of treatment Once daily
1961905|NCT02760316|Drug|AZD9567 80 mg|Oral suspension Multiple doses 5 days of treatment Once daily
1961906|NCT02760316|Drug|Prednisolone 20 mg|Oral Multiple doses 5 days of treatment Once daily
1961907|NCT02760316|Drug|AZD9567 125 mg|Oral Multiple doses 5 days of treatment Once daily
1961908|NCT02760316|Drug|AZD9567 155 mg|Oral Multiple doses 5 days of treatment Once daily
1961909|NCT02760316|Drug|Prednisolone 5 mg|Oral Multiple doses 5 days of treatment Once daily
1961910|NCT02760316|Drug|Prednisolone 40 mg|Oral Multiple doses 5 days of treatment Once daily
1903058|NCT03202992|Drug|ABI-1968|Topical cream applied at Day 1 for the SAD portion and applied at Day 1, Day 8, Day 15, Day 22 and Day 29 for the MAD portion
1903065|NCT03201211|Biological|Blood sampling|A volume of approximately 20 mL of whole blood should be drawn from each subject, at each study visit, for antibody determination and assay validation/development.
1903066|NCT03201211|Biological|Formulation 1 : NTHi-Mcat high dose adjuvanted vaccine GSK3277513A|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1903067|NCT03201211|Biological|Formulation 2 : NTHi-Mcat low dose adjuvanted vaccine GSK3339036A|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1903068|NCT03201211|Drug|Placebo|2 doses, not administered as part of this study but administered at Day 0 and Day 60 during STEP 2 of NTHi Mcat-001 (201281 - NCT02547974) study, to subjects who were then enrolled in this study. Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1903069|NCT03198884|Drug|Darunavir 800 MG, Norvir 100 MG, Dolutegravir 50 MG|
1903072|NCT03198559|Drug|Disulfiram, (National Drug Code) NDC 0378-4141-01|This study will provide open label disulfiram. Participants will take 2 grams (4x500mg tablets) of disulfiram per day for a total of 28 days
1903073|NCT03198559|Drug|Vorinostat, NDC 00006-0568-40|This study will provide open label vorinostat. Participants will take 400mg (4x100mg capsules) of vorinostat per day on days 8, 9, 10 and days 22, 23, 24.
1903090|NCT03193645|Drug|Firmagon|Injection
1961930|NCT02751931|Drug|Mirabegron|Oral
1903097|NCT03192436|Device|Ultrasound|Low-intensity (Ispta < 720 mW/cm2, Isppa < 190 W/cm2) transcranial focused ultrasound
1903147|NCT03185013|Biological|VGX-3100|1 milliLiter (mL) VGX-3100 will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
1961949|NCT02745145|Drug|Abituzumab 1500 mg|Abituzumab 1500 mg, intravenous infusion over approximately 1 hour every 4 weeks with last administration is at the Week 100 visit (2 years). Close observation of the subject is recommended for a period of at least 1 hour after administration of abituzumab.
1961950|NCT02745145|Drug|Abituzumab 500 mg|Abituzumab 500 mg, intravenous infusion over approximately 1 hour every 4 weeks with last administration is at the Week 100 visit (2 years). Close observation of the subject is recommended for a period of at least 1 hour after administration of abituzumab.
1961951|NCT02745145|Drug|Placebo|Placebo, intravenous infusion over approximately 1 hour every 4 weeks with last administration is at the Week 100 visit (2 years). Close observation of the subject is recommended for a period of at least 1 hour after administration of placebo.
1903110|NCT03190200|Other|MRI|No intervention - observational trial using MRI
1903117|NCT03189914|Drug|RX-3117|RX-3117 will be administered orally in combination with Abraxane.
1903123|NCT03188042|Device|rtACS Stimulation|Electric current stimulation; rtACS is a non-invasive application of electric current to stimulate the retina to induce synaptic efficacy, in particular those cells that have some measure of dysfunction but are not dead, and oscillations of nearby neuronal ensembles.
1903124|NCT03188042|Device|Sham Intervention|A computer-controlled sham stimulation function for masking interventionist to study group. The device will be used to deliver a weak electric current stimulation protocol to participants via electrodes placed transorbitally, with one reference electrode positioned elsewhere.
1903127|NCT03188133|Other|behavioral task : emotional priming|emotional priming task on ambiguous visual stimuli
1903128|NCT03188094|Other|community health worker (CHW)-led health coaching for patients|Using a stepped-wedge design, investigators will implement the study in 25 NYC PCP sites enrolling 2,840 South Asian patients at- risk for T2DM.
1961980|NCT02737241|Procedure|Low power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 50W holmium laser energy.
1961981|NCT02737241|Procedure|High power Holmium laser enucleation of the prostate|HoLEP entails dissection of the whole median and lateral prostatic lobes off the surgical capsule via a retrograde approach starting at the apex. The enucleated lobes were pushed to the bladder followed by hemostasis of the prostate bed then intravesical morcellation of the enucleated adenoma. The procedure entails power setting of 100W holmium laser energy.
1961987|NCT02733133|Drug|Testagen® TDS Testosterone 5% HypoSpray®|Topically applied Testosterone Hormone Replacement Lotion
1903145|NCT03185806|Device|Puncture and drainage|The enrolled SAP patients are punctured under guidance of B ultrasound or CT scan, and prolonged drained by 8-F or 10-F pigtail tube
1961992|NCT02729961|Drug|Brentuximab Vedotin|Given IV
1961993|NCT02729961|Drug|Ceritinib|Given PO
1961994|NCT02729961|Other|Laboratory Biomarker Analysis|Correlative studies
1961995|NCT02729961|Other|Pharmacological Study|Correlative studies
1961996|NCT02730637|Other|Early nephrologist consultation|
1903148|NCT03185013|Biological|Placebo|1 mL of Placebo will be injected IM and delivered by EP using CELLECTRA™-5PSP on Day 0, Week 4 and Week 12.
1903149|NCT03185013|Device|Electroporation (EP)|Intramuscular injection followed by EP with the CELLECTRA™ 5PSP device.
1903156|NCT03183778|Drug|Patiromer|Patiromer is a drug used for the treatment of hyperkalemia, a condition that may lead to palpitations and arrhythmia.
1903157|NCT03183778|Dietary Supplement|Research Diet Menu|During the study, participants will be asked to consume only the foods provided in the research diet
1903160|NCT03183492|Biological|Havrix®|One challenge dose of Havrix® administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
1903164|NCT03182894|Drug|Epacadostat (INCB024360) in Combination with Pembrolizumab (MK-3475) and Azacitidine (VIDAZA)|Oral Epacadostat (INCB024360) (50, 100, or 300 mg twice per day,on days 1-21 of each cycle, every 21 days) in combination with Pembrolizumab (MK-3475) (200 mg IV on days 1 of each cycle, every 21 days) and Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)
1962014|NCT02721979|Drug|Apalutamide|Given PO
1962015|NCT02721979|Other|Laboratory Biomarker Analysis|Correlative studies
1962016|NCT02721979|Other|Quality-of-Life Assessment|Ancillary studies
1903172|NCT03180996|Device|Vascutek Fenestrated Anaconda™ Custom AAA Stent Graft System|Fenestrated Endovascular Aortic Repair (FEVAR)
1962027|NCT02716428|Drug|Faldaprevir|
1962028|NCT02716428|Drug|TD-6450|
1962029|NCT02716428|Drug|Ribavirin|
1962035|NCT02713815|Radiation|repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 24 weeks by Theta-burst stimulation (TBS), once a day for the first 8 weeks and twice a week for the last 16 weeks
1962036|NCT02713815|Radiation|sham repetitive transcranial magnetic stimulation (rTMS)|Stimulate the dorsomedial prefrontal cortex for 24 weeks by sham Theta-burst stimulation (TBS), once a day for the first 8 weeks and twice a week for the last 16 weeks, with the coil set at 90° against the skull
1962037|NCT02713815|Behavioral|motivational-cognitive psychotherapy|self-awareness training, social and moral strengthening, impulse control training , problem solving training , situational awareness training , HIV prevention, social skills training under the family atmosphere , family social skills training , interpersonal skills training, community interaction skills training , psychiatric symptoms of self-monitoring skills training
1962038|NCT02709369|Device|HIRREM|HIRREM is a noninvasive, closed-loop, allostatic, acoustic stimulation neuro-technology to facilitate recipient-unique relaxation, auto-calibration, and self-optimization of cortical neural oscillations by reflecting auditory tones in near real time. After an initial HIRREM assessment, evaluating patterns of brain electrical rhythms, subjects get a series of 90-120 minute HIRREM sessions, including 5 to 9 individualized protocols. A protocol is a combination of sensor montage and specific software design, during which dominant brain frequencies, recorded at high spectral resolutions, are translated to audible tones, and reflected back via earphones with as little as 8 milliseconds delay. Protocols are received sitting or reclining in a chair, some with eyes open, others eyes closed.
1903196|NCT03174197|Drug|Temozolomide|"Concurrent Phase Group: Temozolomide 75 mg/m2 capsules taken by mouth every day for 6 weeks.
Adjuvant Phase Group: Temozolomide 150 mg/m2 capsules taken by mouth on Days 1-5 every 28 days."
1903197|NCT03174197|Drug|Atezolizumab|"Concurrent Phase Group: Atezolizumab 840 mg given by vein on Day 1. If drug tolerated well, it may be given after that on Days 15, 29, and 42 (about every 2 weeks).
Adjuvant Phase Group: Atezolizumab 840 mg given by vein every 2 weeks for up to 12 cycles of therapy until there is evidence of disease progression."
1903198|NCT03174197|Radiation|Radiation Therapy|Radiation therapy administered using 1.8-2 Gy/fraction daily for 5 days/week for ~6 weeks for a total dose of up to 60 Gy.
1962063|NCT02702180|Drug|molgramostim|molgramostim nebuliser solution
1962064|NCT02702180|Drug|placebo|placebo nebuliser solution
1962065|NCT02701751|Other|Exercise session|A blood sample and fat biopsy will be obtained before and after the 60 minute moderate exercise session. There is no drug or device intervention in this study.
1903296|NCT03125902|Drug|Atezolizumab Placebo|Placebo matching to atezolizumab will be administered via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
1962073|NCT02698111|Drug|Donafenib|donafenib 200mg，bid
1903225|NCT03157609|Device|Thermometry|Within the same patient comparison of 2 thermometry methods: SpotOn skin sensor versus oesophageal temperature probe
1962081|NCT02691026|Drug|Pembrolizumab|
1903240|NCT03153982|Drug|Ruxolitinib|15 mg or 20 mg (three or four 5 mg tablets) PO BID
1903249|NCT03152149|Drug|Tiotropium & olodaterol|Spiolto Respimat (Tiotropium 2.5 micrograms,olodaterol 2.5 micrograms) 2 puffs once daily for 6 months
1903250|NCT03152149|Drug|fluticasone furoate & vilanterol|Relvar Ellipta (fluticasone furoate 92 micrograms, vilanterol 22 micrograms) 1 puff once per day for 6 months
1903253|NCT03152071|Procedure|Robot assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is robot assisted thoracic surgery
1903254|NCT03152071|Procedure|Video assited thoracic surgery|The lobectomy will be preformed in case of an operable lung cancer. The thoracic surgery technique used is video assisted thoracic surgery.
1903255|NCT03149718|Behavioral|Brief Intervention Medication Therapy Management|BI-MTM is designed to: (1) eliminate opioid medication misuse, (2) promote opioid regimen adherence, (3) connect participants with Patient Navigation to increase patient self-management activation for health conditions that increase risk for misuse (Patient Navigation is an evidence-based chronic care intervention), and (4) provide naloxone rescue training referrals.
1903375|NCT03088696|Other|stimulation|activation of the acupuncture point
1903256|NCT03149718|Behavioral|Standard Medication Counseling (SMC)|Standard Medication Counseling (SMC; n=23; i.e., treatment-as-usual condition). Standard Medication Counseling is the Centers for Medicaid and Medicare Services requirement for pharmacists in the US wherein pharmacy patients filling prescriptions receive information and opt-in counseling.
1903259|NCT03143556|Device|Magnetic stent|Patients who are undergoing renal transplant surgery for the treatment of end stage renal failure will be assigned to magnetic stent or routine stent using computer generated randomization method in the operating room. Those who receive magnetic stent would get their stent removal by magnetic device retrieval and not by routine cystoscopy.
1903260|NCT03142724|Drug|[18F]MNI-968|Healthy volunteers recruited for the study will undergo a single [18F]MNI-968 injections and PET scans.
1903264|NCT03136029|Dietary Supplement|Antioxidant|Daily consumption of over-the-counter vitamins (600mg alpha lipoic acid, 1000mg vitamin c, 600IU vitamin E)
1903265|NCT03136029|Dietary Supplement|Tetrahydrobiopterin (BH4)|Daily consumption of BH4 (10mg/kg)
1903266|NCT03136029|Other|Exercise training|Aerobic exercise training program (3x/week for 8 weeks, 1 hour per session)
1903271|NCT03135418|Device|Intervention|"Patients will use virtual reality device to play task oriented games like bowling, arrow shooting and home activity simulations which focuses upper extremity abduction, flexion and rotation movements. Each session will be a total of 45 minutes divided to 3 15 minute games. Sessions will held for 4 weeks each monday, wednesday and friday at same time for each patient.
In addition to the virtual reality treatment program conventional rehabilitation therapies including neurodevelopmental facilitation techniques, physiotherapy, and occupational therapy and, where necessary, speech therapy will be applied according to the needs of the patient."
1903272|NCT03135418|Device|Control|The control group will be included in the virtual reality program only focusing on visual scenes without upper extremity interaction. Bobath therapy, walking exercises, upper extremity active exercises, proprioceptive neuromuscular facial techniques will be applied to the control group for 4 weeks.
1903273|NCT03135210|Other|Open-Chain Leg Exercise|Individuals in the open-chain group will progress through standard mobility progression.
1903274|NCT03135210|Device|Closed-Chain Leg Exercise|Individuals in the closed-chain group will progress through standard mobility exercises with the addition of closed-chain leg exercises using the MOVEO platform.
1962111|NCT02677428|Behavioral|Remotely-Delivered Benefits Counseling|Veterans will complete three intervention modules online. For the first module, Veterans will be instructed on how to use the website and its purpose; will be asked about their perception of the relationship between disability benefits and work. An explanation of relationship between disability benefits and work will be provided. For the second module, Veterans' feelings and attitudes towards employment will be solicited. Motivational Interviewing exercises will be implemented; barriers to work including the disabling condition and consideration of treatment for disabling conditions will be reviewed. An action plan will be developed. For the third module, inquiries will be made regarding the Veteran's reaction to the service-connection decision; information will be provided on how to appeal the decision. Veterans will be asked to reconsider work and financial goals in light of service-connection award. Their action plan will be reviewed. Follow-up resources will be provided.
1962112|NCT02677428|Behavioral|Control|The control condition will involve referrals to VA websites and represents enhanced treatment-as-usual. A Veteran who completes a Compensation examination ordinarily has no further treatment or referral as part of the Compensation examination. The information about benefits-related websites controls for having information available about benefits and receiving encouragement to pursue that information. The control condition involves being urged to explore links to three VA websites with Compensation & Pension-related information: (a) the VBA website with links about VA disability compensation, (b) the VBA site with fact sheets about the different types of benefits available to Veterans, and (c) the VBA websites for the local C&P office where issues pertaining to an individual Veteran's specific application are addressed.
1962114|NCT02677168|Device|cNEP|continuous negative external pressure
1903286|NCT03127956|Drug|Olumacostat Glasaretil Gel|Olumacostat Glasaretil Gel
1903295|NCT03125902|Drug|Atezolizumab (MPDL3280A), an engineered anti-PDL1 antibody|Atezolizumab will be administered at a dose of 840 mg via IV infusion on Days 1 and 15 (± 3 days) of every 28-day cycle.
1903297|NCT03125902|Drug|Paclitaxel|Paclitaxel will be administered at a dose of 90 mg/m^2 via IV infusion on Days 1, 8, and 15 of every 28-day cycle.
1903303|NCT03118752|Behavioral|Collaborative Care|The CC intervention will use a novel three-pronged approach to these high-risk patients. Care managers will provide centralized care coordination and specific interventions targeting: (1) the psychiatric disorders, (2) cardiac health behaviors, and (3) the cardiac illness.
1962128|NCT02671695|Drug|Spirulina|Spirulina capsules (500 mg) in a dose of 250 mg/kg/day orally for 3 months
1962129|NCT02671695|Drug|Amlodipine|Amlodipine in a dose of 5 mg/day orally for 3 months
1903310|NCT03117231|Device|Active Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. During active stimulation, the current will be active for the full 20 minutes.
1903311|NCT03117231|Device|Sham Transcranial Direct Current Stimulation (tDCS)|Subjects will undergo 15 sessions of tDCS stimulation, 1x per day at 20 minutes per session, of up to 2mA. However, during sham stimulation (placebo) the current will not be active for the full 20 minutes
1903312|NCT03114800|Device|E-Scale|The E-Scale is comprised of a series of weight monitoring 'pods' and a set of software modules that facilitate data transfer and analysis.
1903313|NCT03115528|Behavioral|Estimation of Prognosis Questionnaire|Survey will examine two aspects of prognosis estimation: 1.) physician factors, 2.) prognosis estimation and contributing factors to patient prognosis. Survey will take approximately 5 minutes to complete.
1903319|NCT03111628|Drug|Omalizumab|omalizumab 300 mg every 4 weeks by subcutaneous injection
1962140|NCT02665754|Biological|ILIT with extract of causal allergen|0.5 ml of allergen extract from D. farinae, D. pteronyssinus, cat, and/or dog for allergen specific immunotherapy (Tyrosine S, Allergy Therapeutic, UK) will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
1962141|NCT02665754|Biological|ILIT with normal saline|0.5 ml of normal saline will be injected into inguinal lymph node through guidance by ultrasonography three times with 4-week interval.
1962142|NCT02665754|Drug|Rescue medication for allergic rhinitis|Subjects are requested to administer oral antihistamine (cetirizine) or nasal glucocorticosteroid (ciclesonide) as rescue medication for allergic rhinitis in accordance with severity and frequency of allergic rhinitis symptoms according to Allergic Rhinitis and its Impact on Asthma (ARIA) guideline.
1962148|NCT02660567|Procedure|Amr maneuver|sustained traction of the anterior and posterior lips of the cervix by ovum forceps downwards and anteriorly until maximum yield for about 90 seconds
1962149|NCT02660125|Procedure|Endometrial scratch injury|midluteal single endometrial strip will be taken using a Novak curett under general anasthesia to avoid discomfort and cramping and to proceed to cervical dilatation in case of forbidden cervix
1903376|NCT03088696|Other|no stimulation|no activation of the acupuncture point
1903377|NCT03087643|Other|Passive mobilization - PM|
1903341|NCT03111329|Other|No aspiration of gastric residuals|No assessment of gastric residuals will be performed prior to administering 3-hourly feeds with increasing amounts of the feeds given as per a predefined plan
1962168|NCT02656680|Behavioral|FB + Friends|Participants will receive a weight loss intervention. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet. Participants will be able to invite their friends who are also interested in losing weight.
1962169|NCT02656680|Behavioral|FB Only|Participants will receive a weight loss intervention. The intervention content will be structured to deliver in an online context. The online coaches will post daily content, respond to questions, address concerns, and encourage engagement. The weight loss intervention is based on the Diabetes Prevention Program (DPP), an evidence-based weight loss program focused on lifestyle changes. The goals for the intervention are 175 minutes of moderate physical activity per week and an overall weight loss of 7%. Each participant will get an individualized calorie goal that would facilitate a 1-2 lbs. weight loss weekly. Participants will also be encouraged to use an app such as MyFitnessPal to track daily diet.
1962172|NCT02656056|Other|Food: (Q-Can Plus fermented soybean beverage)|Fermented soybean beverage. Dose is 8 oz, twice daily.
1903351|NCT03105336|Biological|KTE-C19|A conditioning chemotherapy regiment of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells administered intravenously.
1903360|NCT03096574|Other|Questionnaire|The participants will be approached by a member of the study team and, following recruitment, participants will be asked to fill in a short paper or online questionnaire. Our estimated time for completion is 10 minutes, and this time will be stated at the start of the questionnaire. Having completed the questionnaire they will be free to leave without further follow up, and given the contact details of the investigators/research governance office whom they can contact if they have further questions or concerns.
1962182|NCT02651675|Biological|AAV directed hLDLR gene therapy|A novel adeno-associated viral (AAV) vector with human low-density lipoprotein receptor (hLDLR) gene
1903365|NCT03095287|Biological|Alphanate|Daily intravenous infusion of Alphanate 100 IU/kg/day
1903374|NCT03088215|Device|shock-waves|Application of shock-waves (radial and focused)
1903617|NCT02975700|Drug|PLX3397|
1962194|NCT02646618|Behavioral|Get Social|Online-delivered weight loss intervention
1962195|NCT02646618|Behavioral|Traditional|Group-delivered weight loss intervention
1962196|NCT02646618|Device|Smartphone|A smartphone is needed to use MyFitnessPal for all participants and to access Twitter for the Get Social participants
1903378|NCT03087162|Drug|Dexlansoprazole 60 mg once daily|Once daily dose dexlansoprazole(Dexlansoprazole(60) OD) in experimental arm and Twice daily dose dexlansoprazole(Dexlansoprazole(60) 1 BID) in active arm
1903379|NCT03086408|Device|THRIVE|active nasal oxygen delivery system
1903380|NCT03086408|Device|Endotracheal tube or Supraglottic airway|Plastic devices for mechanical ventilation
1903385|NCT03085394|Drug|tranexamic acid|Preoperative intravenous administration of 2 grams tranexamic acid in 10 ml saline
1903386|NCT03085394|Drug|Placebo|Preoperative intravenous administration of 10 ml saline
1903399|NCT03079401|Biological|MPC; rexlemestrocel-L|MPCs will be injected into the patient's myocardium during planned surgical procedures.
1903404|NCT03074331|Drug|SOF/VEL|Tablet(s) administered orally once daily
1903408|NCT03073486|Drug|Olumacostat Glasaretil Gel|Olumacostat Glasaretil Gel
1903409|NCT03073486|Other|Vehicle|Vehicle
1903412|NCT03071224|Drug|[18F] MNI-946|Subjects will undergo PET imaging using [18F]MNI-946, a PET radioligand for imaging tau.
1903413|NCT03071224|Drug|[18F]Florbetapir|Subjects with Alzheimer's disease will receive a [18F]florbetapir scan to compare distribution of tau in the brain compared to that of [18F]MNI-946.
1962228|NCT02630992|Drug|Amoxicillin-Clavulanate potassium|amoxicillin-clavulanate potassium (600 mg/21.5 mg/5 mL; 28:1) administered at 90/3.2 mg/kg in two divided doses for 10 days.
1962229|NCT02630966|Drug|Vedolizumab|Vedolizumab 300 mg IV
1962230|NCT02630966|Drug|Placebo|0.9% sodium chloride used as vedolizumab placebo-matching IV
1992410|NCT03321487|Device|Blood-Brain Barrier opening with MRgFUS|ExAblate Transcranial MR-guided Focused Ultrasound to temporarily open the Blood-Brain Barrier
1992411|NCT03321474|Procedure|modified gull wing preparation|"preparation is the inciso - proximal extension of porcelain laminates veneer margin more palatally.
The preparation finished at the gingival margin and extended towards the papilla to finish the interproximal elbow preparation."
1962240|NCT02623582|Biological|Autologous Anti-CD 123 CAR TCR/4-1BB-expressing T-lymphocytes|Given IV
1903434|NCT03057327|Behavioral|Improve awareness of checking moles|"Intervention:
Improve awareness Each of the eight changing rooms will have a large mirror that can be used to see the face and chest. Each room will be equipped with a poster, brochures and the SSE kit consisting of the laminated card with a ruler on one edge and the magnifying lens will be fastened to the wall on a cord.
Provide education The subject may chose to read the poster and a brochure. c) A woman research assistant will perform in-person exit interviews with participants to ascertain if women noticed the poster, and found the information relevant."
1903435|NCT03057327|Other|Comparator|Prior to placing the intervention materials into the changing rooms, 100 eligible subjects will be asked if they regularly check their moles for concerning features. If the response is yes, then they will be asked if they have found concerning moles and what they did next.
1962241|NCT02623582|Drug|Cyclophosphamide|Given IV
1903456|NCT03051438|Procedure|Subxiphoid uniportal VATS|Patients were placed in a supine position, and the operating table was manipulated as needed to elevate the appropriate side of the body for surgery. The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi.
1903457|NCT03051438|Procedure|Three-port VATS|The surgical procedures followed principles of pulmonary resections; in particular, similar to mediastinal lymphadenectomy for lung cancer, these procedures involved the individual dissection of veins, arteries and lobar bronchi
1903458|NCT03051165|Device|Hypoglossal Nerve Stimulation Treatment Withdrawal|After 90 days of hypoglossal nerve stimulation (HGNS), therapy will be discontinued for 30 days before being reactivated.
1992416|NCT03321435|Other|placenta previa patient|women had placenta previa either major or minor degree
1992417|NCT03321435|Other|normal women|those women had not placenta previa
1992418|NCT03321422|Other|No intervention Observational study|follow up of the function of the hip after lateral shelf acetabuloplasty by harris hip score and WOMAC score
1992419|NCT03321409|Diagnostic Test|The general population|After recruiting participants, collecting the baseline data, the SSS-Ch and PHQ-15 will be carried out. Then validating the reliability, validity of the SSS-Ch will be compared with the PHQ-15.
1992420|NCT03321409|Diagnostic Test|Patients with suspected CAD|In patients with suspected CAD, after recruiting participants, collecting the baseline data, the SSS-Ch and PHQ-15 will be carried out before undergo coronary angiography. Then the prevalence of somatic symptoms will be investigated.
1992421|NCT03321396|Device|sodium alginate mixed with calcium lactate|"The product is used in Endoscopic submucosal dissection which is accomplished by steps listed as follows: lesion marking, submucosal injection, mucosal incision, submucosal dissection, then en-bloc resection. It's a new submucosal injection regimen, sodium alginate mixed with calcium lactate, which turned to calcium-alginate gel, we called it as Gut Guarding Gel."
1992422|NCT03321370|Diagnostic Test|Continuous electrocorticography post severe traumatic brain injury requiring neurosurgical intervention|Continuous electrocorticography via subdural electrode strips for 1 to 3 weeks in the neuro intensive care unit following traumatic brain injury
1992423|NCT03321357|Diagnostic Test|five-repetition sit-to-stand test|"An armless chair with a hard seat was stabilised by placing it against a wall. Seated participants were asked to come forward on the chair seat until the feet were flat on the floor and to fold their upper limbs across the chest. Participants were then instructed to stand up all the way and sit down once without using the upper limbs. For those unable to complete the initial manoeuvre or who required assistance, the test was terminated. If successful on the initial sit to stand, participants were then asked to stand up all the way and sit down landing firmly, as fast as possible, five times without using the arms. Timing with a stopwatch was started on the command 'go' and stopped at the end of the completed fifth stand; the time taken was recorded as the participant's score.
(1) Jones et al."
1992424|NCT03321344|Device|Focused Ultrasound Thermal ablation|Focused Ultrasound Thermal ablation of the Medial Nerve Branch
1992425|NCT03321331|Combination Product|Lark (JITAI)|Lark works as a just-in-time adaptive intervention (JITAI), providing interactive counseling through a chat-style interface. The app prompts users to self-monitor, set goals, review them, provides feedback, and social support.
1992426|NCT03321331|Combination Product|MyFitnessPal (no JITAI)|MyFitnessPal (MFP) is a calorie counting app, which relies on user input for food tracking, but automatically tracks activity through the phone or through integrations with wearable devices. This app provides allows to set weight and caloric goals, review them and to receive feedback, but it has limited social support, a feature that is generally lacking in calorie-counting apps.
1992427|NCT03321318|Drug|AK-R215|Investigational product is prescribed to all ofrandomized subjects
1992428|NCT03321318|Drug|Bazedoxifene 20 mg|Investigational product is prescribed to all of randomized subjects
1992429|NCT03321318|Drug|Cholecalciferol 800IU|Investigational product is prescribed to all of randomized subjects
1992430|NCT03321292|Drug|L-arginine 1000 mg and Acetylesalicylic acid75mg|l-arginine 1000mg capsule will be given every 8 hours till delivery and acetylesalicylic acid75mg tablet once starting of diagnosis till birth.
1903460|NCT03049124|Behavioral|Exercise|Participants will engage in supervised exercise 3 times per week for 60-75 minutes/session for 12 weeks. Sessions will include a warm-up (aerobic activity less than < 60% of heart rate reserve), aerobic training (30 minutes of exercise at 60-75% of heart rate reserve, using cycle ergometers/treadmills), strength training (8 exercises; upper body, lower body, and core), and a cool-down (aerobic activity less than < 60% of heart rate reserve) component.
1903478|NCT03037346|Behavioral|Questionnaires|"Participants: 3 questionnaires completed at new patient visit that should take about 15 minutes to complete.
Questionnaires also completed 3 months later that should take about 17 minutes to complete.
Family/Caregiver: 7 questionnaires completed at new patient visit that should take about 8 minutes total to complete.
Another questionnaire completed 3 months later that should take about 2 minutes to complete."
1903479|NCT03037346|Behavioral|Surveys|Participants: 8 surveys completed at new patient visit that should take about 23 minutes total to complete.
1903480|NCT03035123|Behavioral|Therapeutic education|Interventional arm
1962271|NCT02616406|Device|GENEactiv|To wear a monitoring device for a period of time prior to surgery and post surgery
1903492|NCT03033732|Drug|Methadone|Methadone is a synthetic analgesic drug used as a substitute drug in the treatment of opioid use disorder. Methadone is administered via strict daily witnessed ingestion.
1903493|NCT03033732|Drug|Buprenorphine-Naloxone|Buprenorphine/Naloxone is an opioid agonist treatment used to treat opioid use disorder. Buprenorphine/Naloxone is administered via flexible take home dosing once the patient has reached stabilization as per physician discretion.
1903500|NCT03030066|Drug|DS-1001b|Generic not assigned
1903501|NCT03029143|Drug|Vedolizumab IV|Vedolizumab intravenous infusion
1903508|NCT03027375|Drug|Qishen Granules|The QSG are manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China), a company that has obtained Chinese Good Manufacturing Practice for Pharmaceutical Products certification. All the ingredients have been approved by the Chinese Ministry of Food and Drug Safety. 13.6 grams (dry weight) of granules consist of six herbs: Astragalus membranaceus (Fisch.) Bge. var. Mongolicus (Bge.) Hsiao (6g), Salvia miltiorrhiza Bge. (1.5g), Lonicera japonica Thunb. (2g), Scrophularia ningpoensis Hemsl. (2g), Aconitum carmichaeli Debx. (0.9g), and Glycyrrhiza uralensis Fisch. (1.2g).
1903509|NCT03027375|Drug|Placebo|The placebo is manufactured by Beijing tcmages Pharmaceutical Co., Ltd. (Beijing, China) as well, following the Specification for processing Chinese medicine in Beijing. The placebo granules are similar in appearance, taste, and scent to the Qishen granules.
1962278|NCT02611817|Drug|Vedolizumab SC 108|
1962279|NCT02611817|Drug|Placebo SC|
1962280|NCT02611817|Drug|Vedolizumab IV 300 mg|
1962281|NCT02609919|Drug|Gadoteric Acid|MRI Contrast Agent
1903517|NCT03022409|Drug|AZD6738|AZD6738 is 100 mg or 20 mg oral tablet
1903518|NCT03022409|Drug|Olaparib|green film-coated tablet containing 100 mg or 150 mg of Olaparib
1903529|NCT03016728|Behavioral|Physical Activity|Participants will receive a 12-week home-based physical activity program that has been individualized using their baseline assessment results. The program will be comprised of aerobic training (2 days/week) and resistance training (2 days/week). The aerobic training will be performed unsupervised. The resistance training will be performed under the supervision of a study team member (who will visit participants homes) for the first 6 weeks to ensure proper form and safety.
1903530|NCT03017534|Procedure|Spinal Manual Therapy|Supine thoracic spine sham manipulation located between the levels of T4-7; identical procedure as an active treatment intervention but without the delivery of a high velocity low amplitude thrust
1962295|NCT02602314|Drug|Imatinib|
1962296|NCT02602314|Drug|Nilotinib|
1903535|NCT03013777|Behavioral|8-week CBT Program|
1903545|NCT03005938|Procedure|Spinal manipulation|"Spinal manipulation (SM) is a therapeutic intervention performed on spinal articulations in which force is applied to the spine. The selected joint is moved to its end range of motion, followed by application of an rapid impulse or thrust to achieve a gapping of the target joint.
SM is performed by an orthopedic medical doctor certified in Manual Therapy. After manual evaluation, high-velocity low-amplitude SM is carried out in all regions of the spine, including thoracic adjustments in the prone position, lumbar manipulation in lateral recumbent position, and cervical manipulation in sitting position."
1903546|NCT03005938|Procedure|Imitation of the spinal manipulation|Imitation of the SM physically and visually resembles the act of SM. It comprises placing the patient in the same positions and performing the same movements as during SM but without applying the force in the end range of motion.
1962322|NCT02596022|Drug|CI-581a|a 50 minute infusion 24 hours prior to cocaine self-administration session
1962323|NCT02596022|Drug|CI-581b|a 50 minute infusion 24 hours prior to cocaine self-administration session
1962325|NCT02595879|Drug|Cisplatin|Given IV
1962326|NCT02595879|Radiation|External Beam Radiation Therapy|Undergo pelvic EBRT
1962327|NCT02595879|Radiation|High-Dose Rate Brachytherapy|Undergo HDR brachytherapy
1962328|NCT02595879|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1962329|NCT02595879|Radiation|Internal Radiation Therapy|Undergo LDR brachytherapy
1962330|NCT02595879|Other|Laboratory Biomarker Analysis|Correlative studies
1962331|NCT02595879|Other|Pharmacological Study|Correlative studies
1962332|NCT02595879|Drug|Triapine|Given IV and PO
1962353|NCT02591654|Drug|Pembrolizumab|Each patient will receive pembrolizumab 200mg administered as a 30 minute intravenous (IV) infusion every 3 weeks for an indefinite period.
1962354|NCT02591654|Drug|FLT PET|FLT PET/CT is increasingly being utilized as an early PD biomarker in cancer given the close association between FLT uptake and proliferative index.
1903589|NCT02989675|Drug|10% dextrose|Bolus of 10% dextrose 5mls/kg
1903601|NCT02979925|Device|Active Transcutaneous Magnetic Stimulation|Active transcutaneous magnetic stimulation (TMS) at the target site of nerve damage/injury.
1903602|NCT02979925|Device|Sham Transcutaneous Magnetic Stimulation|Sham TMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
1903608|NCT02977663|Other|Magnetic Resonance Imaging (MRI)|"Chest MRI during the MRI cerebral
2 tubes of blood taken during the medical visit"
1903632|NCT02967510|Drug|Estriol|
1903633|NCT02967510|Drug|Placebo|
1962408|NCT02571049|Drug|Strength A of DFN-11|
1962409|NCT02571049|Drug|Strength B of DFN-11|
1962415|NCT02567435|Drug|Cyclophosphamide|Given IV
1962416|NCT02567435|Biological|Dactinomycin|Given IV
1962417|NCT02567435|Drug|Irinotecan Hydrochloride|Given IV
1962418|NCT02567435|Other|Laboratory Biomarker Analysis|Correlative studies
1903650|NCT02961907|Procedure|PEPCI|"Both parents will receive:
consultation with a psychiatrist then psychologist follow-up if required, addiction specialist physician consultation then liaison nurse follow-up if required
endocrinologist consultation then dietitian follow-up if required
actiphysician consultation and follow-up if required This program will be added to the usual routine course Both parents will receive a 3 months personalized follow-up if required from the multi disciplinary consultation and before the first ART attempt."
1962419|NCT02567435|Other|Questionnaire Administration|Ancillary studies
1962420|NCT02567435|Radiation|Radiation Therapy|Undergo RT
1903653|NCT02961803|Drug|MD1003 100 mg capsule|
1903654|NCT02961803|Drug|Placebo|
1962421|NCT02567435|Drug|Temsirolimus|Given IV
1962422|NCT02567435|Drug|Vincristine Sulfate|Given IV
1903665|NCT02960217|Drug|UX007|UX007 is a liquid intended for oral (PO) administration.
1903666|NCT02960217|Drug|Placebo|Placebo
1903668|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
1903669|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
1903670|NCT02956837|Biological|RSV Vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
1903671|NCT02956837|Drug|Placebo (Formulation buffer S9b)|A single dose of placebo is administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm.
1903681|NCT02953054|Drug|DMTS|DMTS applied before surgery and worn for 72 hours
1903682|NCT02953054|Drug|Placebo|Matching patches that have no active drug applied before surgery and worn for 72 hours.
1903683|NCT02952885|Drug|Pegvisomant|Study medications will be prescribed as per clinical practice with PEGV being added, or optimally dosed, at the Month 0 visit. Subjects who are naïve to PEGV should start their daily injections at 10 mg / day if used as combination therapy or 20 mg / day if used as monotherapy. Maximum dosing should not exceed 40mg/day. Dosing of PEGV can be adjusted as per clinical judgement to meet the normalization of IGF-1 levels (<1.0 ULN) in increments of 5-10mg/day. In the event of a reduction in IGF-1 below the LLN, the dose of PEGV could be decreased by 5-10 mg/day.
1962447|NCT02562989|Drug|[18F]MK-6240|IV dose of ~185 MBq [18F]MK-6240
1962448|NCT02562989|Drug|[18F]MK-6240|IV dose of ~160 MBq [18F]MK-6240
1962458|NCT02556138|Device|ORBERA Intragastric Balloon|The ORBERA Intragastric Balloon will be placed in the stomach endoscopically through a catheter under conscious sedation. The procedure takes about 20 minutes to complete. The balloon will stay in place for 6 months and then it will be removed endoscopically.
1962459|NCT02556333|Drug|FTC/TAF|Tenofovir alafenamide (TAF) is an investigational oral prodrug of tenofovir. This trial will explore the safety and efficacy of TAF in a fixed combination with emtricitabine (FTC) (F/TAF, Gilead Sciences Inc.) as part of a salvage antiretroviral regimen for HIV-1-infected adults and adolescents (greater than or equal to 14 years) who experienced virologic failure.
1903704|NCT02941107|Drug|Rotarix (RV1)|Oral
1903705|NCT02941107|Drug|Placebo|Oral
1990072|NCT02238925|Drug|CPX-351|
1990083|NCT02229396|Drug|Exantide with Dapagliflozin|2 mg weekly suspension injection and 10 mg Dapagliflozin
1990084|NCT02229396|Drug|Exentide|2 mg
1990085|NCT02229396|Drug|Dapagliflozin|10 mg once daily Dapagliflozin
1990087|NCT02225990|Other|Experimental Group, Sub-Acute|For the sub-acute experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
1990088|NCT02225990|Other|Experimental Group, Chronic|For the chronic experimental group, the intervention schedule will be as follows: six months of individual therapy five times weekly (1 - 2.5 hours/session); 6 months of 'refresher' individual therapy twice monthly (1 - 2.5 hours/session) + group therapy up to three times weekly (1 hour/session); and 1 year of group therapy, up to three times weekly (1 hour/session) + 1 'refresher' individual therapy session every 3 months for a total study duration of 2 years.
1990089|NCT02225990|Other|Standard of Care, Sub-Acute|This group will receive standard of care stroke rehabilitation therapy.
1990090|NCT02225990|Other|Standard of Care, Chronic|This group will receive standard of care stroke rehabilitation therapy.
1990091|NCT02224573|Drug|GWP42003-P|
1903713|NCT02938377|Behavioral|Computerized Brief Intervention (CBI)|A video which emphasizes personal responsibility for change, uses empathy as a counseling style, and enhances self-efficacy. Depending on alcohol dependence level, four different CBI versions may be shown over two visits.
1903714|NCT02938377|Behavioral|CBT4CBT|9 computerized modules delivered at the participant's pace
1903715|NCT02938377|Drug|Recommendation and Counseling for Alcohol Pharmacotherapy|The APT algorithm will utilize the four FDA approved APTs for the treatment of alcohol use disorder. The treatment of the patient is part of routine care.
1903719|NCT02936037|Drug|MD1003 100mg capsule|
1903720|NCT02936037|Drug|PLACEBO|an inactive substance
1903742|NCT02935335|Drug|Menotrophin|
1903749|NCT02930902|Drug|Pembrolizumab|200 mg via 30 minute IV infusion once each cycle, Day 1 of 3 week cycle
1903750|NCT02930902|Drug|Paricalcitol|7 mcg/kg IV infusion over 15 minutes once weekly, Days 1, 8, 15 of each 3 week cycle
1903751|NCT02930902|Drug|Gemcitabine|1000 mg/m2 IV infusion once weekly for three out of 3 weeks, Days 1, 8, and 15 of planned one cycle
1903752|NCT02930902|Drug|Nab-paclitaxel|125 mg/m2 IV infusion once weekly for three out of 3 weeks, Days 1, 8, and 15 of planned one cycle
1903753|NCT02930902|Procedure|Surgical Resection|Surgery planned within 1 week and up to 4 weeks from last dose of Paricalcitol.
1903754|NCT02929186|Behavioral|Opt-In Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to elect to receive a home FIT kit or report prior screening.
1903755|NCT02929186|Behavioral|Opt-Out Outreach|Subjects will receive a communication (mail or electronic) describing the importance of colorectal cancer screening with the option to choose not to receive a home FIT kit or report prior screening. A FIT kit will otherwise be sent to the subject as a default.
1903767|NCT02926222|Drug|Regorafenib|Regorafenib is formulated as tablets of 40mg for oral administration.
1903768|NCT02926222|Drug|Lomustine|Lomustine is formulated as tablets of 40mg for oral administration.
1903769|NCT02927002|Device|Noninvasive brain stimulation|
1903772|NCT02926924|Device|Wound Vac|a therapeutic technique using a vacuum dressing to promote healing in acute or chronic wounds and enhance healing of first and second degree burns.
1903773|NCT02926924|Other|Standard Dressing|standard dressing with drain tube and bandage
1903776|NCT02924389|Drug|dolutegravir|Tivicay is a human immunodeficiency virus type 1 (HIV-1) integrase strand transfer inhibitor (INSTI) indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. 50 mg of Tivicay (dolutegravir) will be taken orally once a day in combination with Truvada.
1903777|NCT02924389|Drug|Triumeq|Triumeq is a fixed-dose combination drug for the treatment of HIV/AIDS. It is a combination of 600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine. Triumeq will be taken orally once daily.
1903778|NCT02924389|Drug|Truvada|Truvada is a combination of emtriva and viread, both nucleoside analog HIV-1 reverse transcriptase inhibitors. Truvada is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. One Truvada tablet (containing 200 mg/300 mg of emtricitabine and tenofovir disoproxil fumarate) will be taken orally once daily in combination with Tivicay (dolutegravir).
1962520|NCT02536339|Drug|Pertuzumab|Participants will receive 840 milligrams (mg) loading dose of pertuzumab, followed every 3 weeks thereafter by a dose of 420 mg via intravenous (IV) infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
1962521|NCT02536339|Drug|Trastuzumab|Participants will receive trastuzumab at a dose of 6 milligrams per kilogram (mg/kg) of body weight once weekly via IV infusion until disease progression, unacceptable toxicity, withdrawal of consent, or study termination.
1962524|NCT02535338|Drug|Erlotinib Hydrochloride|Given PO
1962525|NCT02535338|Other|Laboratory Biomarker Analysis|Correlative studies
1962526|NCT02535338|Drug|Onalespib Lactate|Given IV
1962527|NCT02535338|Other|Pharmacological Study|Correlative studies
1903803|NCT02921087|Device|Test Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
1903804|NCT02921087|Device|Control Daily Disposable Soft Contact Lenses|Worn daily for 7 +/- 2 days
1903806|NCT02919722|Behavioral|Music Therapy|The majority of each study session will be spent engaging in music therapy: playing live music with a music therapist with the help of an occupational therapist. At the beginning and end of each session subjects will complete 2 assessments.
1962549|NCT02528669|Device|RX Navigait|The RX Navigait is an accelerometer that tracks the number to steps taken, duration of walking, and time of walking. In addition, this device sends messages to patients regarding daily walking goals and walking reminders.
1962552|NCT02524639|Drug|Sirolimus|Subjects will receive 1 mg/m2/day orally for 6 weeks. Maintenance dose will be titrated up or down by 0.25-0.5 mg/m2/day every 4 days. Serum concentration will be checked on day 4 after initial therapy and 4 days after any dose adjustment. Levels will be checked at lease once a week during the duration of the study. Target serum concentration range is 5-10 ng/mL.
1903824|NCT02911623|Device|Shockwave Lithoplasty® System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
1903827|NCT02910063|Drug|Blinatumomab|Blinatumomab monotherapy
1903828|NCT02910063|Drug|Investigator's Choice Chemotherapy|Investigator's Choice Chemotherapy
1962561|NCT02520791|Biological|Anti-ICOS Monoclonal Antibody MEDI-570|Given IV
1962562|NCT02520791|Other|Laboratory Biomarker Analysis|Correlative studies
1962563|NCT02520791|Other|Pharmacological Study|Correlative studies
1962569|NCT02516722|Device|Therapeutic Intra-Vascular UltraSound (TIVUS™) System|"The TIVUS™ System generates high intensity, non-focused ultrasonic energy that is delivered through the wall of the pulmonary artery to achieve local nerve deactivation.
Denervation in the pulmonary arteries (PDN) would be performed during right heart catheterization. The PDN procedure would be attempted in the main, right and left pulmonary arteries, close to the main bifurcation."
1903860|NCT02899793|Drug|Pembrolizumab|Pembrolizumab 200 mg (fixed dose) IV every 3 weeks (+/- 3 days) until progression or adverse effects prohibit therapy
1962589|NCT02508532|Drug|BLU-285|
1903868|NCT02892903|Device|Routine Measurement of FFR|FFR measurement will be performed in all major vessels with normal (TIMI 3) flow. Occluded vessels and vessels with TIMI flow <3 will not be examined but will be 'awarded' an FFR value of 0.5
1962602|NCT02505945|Drug|Omeprazole|
1962603|NCT02505945|Device|LINX Reflux Management System|
1962606|NCT02503839|Drug|etoricoxib|cyclooxygenase-2 inhibitor. Anti-inflammatory
1962607|NCT02503839|Biological|H56:IC31|Therapeutic and prophylactic TB vaccine
1962615|NCT02499328|Drug|AZD9150|AZD9150
1962616|NCT02499328|Drug|MEDI4736|MEDI4736
1962617|NCT02499328|Drug|AZD5069|AZD5069
1962618|NCT02499328|Drug|tremelimumab (treme)|tremelimumab
1903885|NCT02883556|Drug|Pembrolizumab|200 mg, administered as intravenous (IV) infusion every 3 weeks up to 24 months or until progression or unacceptable toxicity develops.
1903886|NCT02882308|Drug|Olaparib|50/25 mg BD split x 5 days
1903887|NCT02882308|Drug|Cisplatin|60 mg/m^2 d1-d5
1903888|NCT02882308|Drug|Olaparib|300 mg BD x 21-28 days.
1962633|NCT02494999|Biological|13-valent pneumococcal conjugate vaccine|0.5ml vaccine produced by Beijing Minhai Biotechnology Co., Ltd.,three doses with 2 month interval, a booster dose 10 months after the first dose
1903904|NCT02874989|Drug|Dasatinib + Quercetin|
1962634|NCT02494999|Biological|Prevnar 13|0.5ml vaccine produced by Wyeth,three doses with 2 month interval, a booster dose 10 months after the first dose
1990120|NCT02203331|Drug|Placebo|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
1903920|NCT02866175|Drug|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects
1903921|NCT02866175|Drug|Clopidogrel|Clopidogrel 75 mg once-daily
1903922|NCT02866175|Drug|Prasugrel|prasugrel 5mg or 10 mg once-daily
1903923|NCT02866175|Drug|ticagrelor|ticagrelor 90 mg twice-daily
1904384|NCT02640729|Drug|Placebo|once daily, oral, matching tablets
1962636|NCT02490423|Other|Nudges Intervention|The intervention arm will employ standard cardiovascular clinical care plus the combination of the MoBe Maps Patient Activation Platform with the Intermountain Risk Score to personalize and deliver motivational nudges to each participant.
1962642|NCT02488382|Drug|Lonquek|Patients will be given a single fixed dose of Lonquek (Teva LTD), 12-mg subcutaneously.
1903936|NCT02860546|Drug|TAS-102|One Arm Only (of TAS 102 plus nivolumab)
1903937|NCT02860546|Drug|nivolumab|One Arm Only (of TAS 102 plus nivolumab)
1962643|NCT02488343|Behavioral|Behavioral Intervention|Three types of intervention will be used: a) Interventions aimed to dealing with cognitions and habits will be based on cognitive-behavioral therapy (CBT) principles. b) Interventions aimed to dealing with affective factors that interfere with adherence will be based on dynamic therapy, crisis intervention and supportive elements. c) In the case of condition-related or therapy related barriers to adherence, psycho-educational multidisciplinary interventions of 1-2 appointments will be offered. Education about injection techniques and about reasonable expectations from therapy, and from MS itself, are a key strategy to successfully maintaining adherence.
1962647|NCT02487459|Biological|BPX-501|T cells transduced with CaspaCIDe suicide gene
1962648|NCT02487459|Drug|AP1903|dimerizer drug administered to treat GVHD
1903944|NCT02856594|Drug|Dexmedetomidine|Dexmedetomidine
1903945|NCT02856594|Drug|Placebo|Placebo
1962655|NCT02483767|Drug|goserelin|Gonadotropin-Releasing Hormone Agonist
1962656|NCT02483767|Drug|standard chemotherapy|(Anthracyclines/cyclophosphamide) followed by paclitaxel or doxetaxel; doxetaxel/cyclophosphamide; doxetaxel or paclitaxel/Anthracyclines; fluorouraci/Anthracyclines/cyclophosphamide followed by doxetaxel or paclitaxel; doxetaxel/Anthracyclines/cyclophosphamide; Anthracyclines/cyclophosphamide;
1903961|NCT02847949|Biological|IGN002|IGN002 is a monoclonal antibody fusion protein
1903966|NCT02845596|Drug|cyclosporine|cyclosporine
1903967|NCT02845596|Procedure|Matched Unrelated Donor Hematopoietic Stem Cell Transplant|Matched Unrelated Donor (MUD) Hematopoietic Stem Cell Transplantation (HSCT)
1903968|NCT02845596|Drug|horse anti-thymocyte globulin (ATG)|horse anti-thymocyte globulin (ATG)
1903969|NCT02845596|Drug|rabbit anti-thymocyte globulin (ATG)|rabbit anti-thymocyte globulin (ATG)
1903970|NCT02845596|Drug|methotrexate|methotrexate
1903971|NCT02845596|Drug|fludarabine|fludarabine
1903972|NCT02845596|Drug|cyclophosphamide|cyclophosphamide
1903973|NCT02845596|Radiation|low-dose total body irradiation (TBI)|low-dose total body irradiation (TBI)
1903974|NCT02845596|Procedure|Immunosuppressive Therapy (IST)|Immunosuppressive Therapy (IST)
1903979|NCT02842463|Other|2 times : 6-minute stepper test with a rest of 20min between each test.|
1962670|NCT02478463|Drug|Cabotegravir tablet 30 mg once daily for 28 days.|GSK1265744B, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, Aquarius film-coating, white BP18237
1962671|NCT02478463|Drug|Cabotegravir injection 3 mL (200 mg/mL) IM given once on Day 1.|Cabotegravir will be supplied as sterile suspension for injection 200 mg/mL vial. Each vial appears as sterile white to slightly colored suspension containing 200 mg/mL of CAB for administration by intramuscular (intragluteal) injection and will be administered as 1 × 3 mL Injections (3 mL [600 mg] total) IM given once on Day 1 of injection phase
1962676|NCT02475135|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
1962677|NCT02475135|Drug|Elvitegravir /Cobicistat/Emtricitabine/Tenofovir alafenamide FDC|A tablet containing EVG 150 mg, COBI 150 mg, FTC 200 mg and TAF 10 mg as FDC will be administered.
1962678|NCT02475135|Drug|Darunavir|A tablet containing Darunavir (DRV) 800 mg will be administered.
1962679|NCT02475135|Drug|Emtricitabine/Tenofovir alafenamide (FTC/TAF)|A tablet containing Emtricitabine (FTC) 200 mg and Tenofovir alafenamide (TAF) 10 mg will be administered.
1962680|NCT02475135|Drug|Cobicistat|A tablet containing cobicistat (COBI) 150 mg will be administered.
1962681|NCT02475135|Other|High-fat Breakfast|High-fat breakfast will be administered.
1962682|NCT02475135|Other|Standardized Regular Breakfast|Standardized regular breakfast will administered.
1962683|NCT02474173|Other|Laboratory Biomarker Analysis|Correlative studies
1962684|NCT02474173|Drug|Onalespib|Given IV
1962685|NCT02474173|Drug|Paclitaxel|Given IV
1962686|NCT02474173|Other|Pharmacological Study|Correlative studies
1962691|NCT02472613|Device|acupuncture|"Patients will be treated at Renzhong（Du26）, Yintang（EX-HN3）、accupuncture Shangxing（DU23）penetrate to Baihui（DU20）,Sishencong（EX-HN1）; Neiguan（PC6）,Sibai（ST2）,Fengchi（GB20）and Sanyinjiao（SP6）in bilateral;Jianyu（LI15）,Quchi（LI11）,Shousanli（LI10）,Hegu（LI 4）, Fengshi (GB31),Xuehai（SP10） ,Zusanli（ST36）、Taichong（LR 3） of the hemiplegia side. There are another six groups of acupoints in bilateral. The acupuncturist will choose one group acupoints according to patients syndrome:Zhigou (SJ6),Qimen (LR14);Xingjian (LR2),Xiaxi(GB43);Fenglong (ST40),Lianquan(RN23);Tongli (HT5),Xinshu (BL15);Xinshu (BL15),Pishu(BL20);Shenshu (BL23),Taixi (KI3).
The acupoints are inserted at the depth of 20-30mm except Renzhong（Du26）, Sibai（ST2）, Sishencong（EX-HN1）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
1962692|NCT02472613|Drug|placebo|Placebo was given for 12 consecutive weeks.
1904038|NCT02816086|Other|Interdisciplinary collaboration structure|A pharmacist is integrated in the team surrounding the patient, working by the Integrated Medicines Management (IMM) model. The IMM-model consist of medication reconciliation, medication review, standardized medication reports and counseling patients about their medication at discharge. In addition a phone meeting between the primary care physician and the study pharmacist is added after discharge.
1904039|NCT02813824|Drug|Acetylsalicylic acid lysinate 300 mg|Daily dose during 4 years
1904040|NCT02813824|Drug|Placebo (for Aspirin 300)|Daily dose during 4 years
1904041|NCT02813824|Drug|Acetylsalicylic acid lysinate 100 mg|Daily dose during 4 years
1904042|NCT02813824|Drug|Placebo 100 (for Aspirin 100)|Daily dose during 4 years
1962693|NCT02472613|Device|sham-acupoint acupuncture|"Jianliao（SJ14）,Tianquan（PC2）,Xiabai (LU4),Xiaoluo (SJ12),Shouwuli (LI13),Sidu (SJ9),Huizong (SJ7),Wenliu (LI7),Zhouliao (LI12),Quze（PC3）,Kongzui（LI6）,Zhigou（SJ6）,Zhongzhu（SJ3）,Futu（ST32）,Jimen (SP11),Yinshi (ST33),Liangqiu（ST34）,Shangjuxu（ST37）,Xiajuxu（ST39）,Xiyangguan（GB33）,Ligou（LR5）,Pucan (BL61),Jinggu (BL64),Rangu (KI2),Ligou (LR5),Neiting （ST44） of the hemiplegia side.
• The acupoints are inserted at the depth of 20-30mm,except Pucan (BL61),Jinggu (BL64),Rangu (KI2) ,Neiting （ST44）are inserted at the depth of 5-10mm. The needles will be left for 30 minutes and then removed. Acupuncture treatment will consist of three sessions per week for 12 consecutive weeks."
1962694|NCT02472613|Drug|Fluoxetine|Fluoxetine was given at a dose of 20 mg/day for12 consecutive weeks.
1904051|NCT02806583|Other|structured support groups|Telephone-based Support Groups, information booklet and telephone-based preparatory meeting prior to the telephone-based support groups
1904064|NCT02801669|Drug|Du-176b|DU-176b orally administered at a dose of 15 mg once daily.
1904065|NCT02801669|Drug|placebo|Placebo orally administered once daily.
1904067|NCT02800915|Other|Service innovation with focus on interdisciplinary collaboration|The follow- up is performed via telemedicine to the patient in his or her own home, and in cooperation with the local health care workers.
1904068|NCT02800356|Procedure|Subthreshold 577 nm yellow wavelength laser photo-coagulator|"Subthreshold photocoagulation is a method in which the burn spots (treated areas) cannot be seen with biomicroscopy, on color fundus photograph, on Optical Coherence Tomography or Fluorescein Angiography when the subthreshold level is adequately set. Subthreshold photocoagulation can be considered to be truly minimally invasive or non-damaging photocoagulation. A term sometimes used is photo-thermal stimulation since the Retinal Pigment Epithelium (RPE) layer is heated and stimulated, but not destroyed.
The threshold level output power is set to obtain barely visible burn at approximately 200 mW to 250 mW using the titration mode, and irradiation is conducted after switching over to Endpoint Management."
1904069|NCT02800213|Device|Modified Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a modified Ambu Spur II bag valve mask with a supplemental external handle
1904070|NCT02800213|Device|Conventional Ambu Spur II bag valve mask|Subjects deliver breaths to manikin (IngMar RespiTrainer manikin model) a conventional Ambu Spur II bag valve mask
1904077|NCT02796781|Biological|Lung stem cells|
1904078|NCT02796599|Device|Non invasive ventilation during exercise with facial or nasal mask.|Every patients will achieve 3 constant work load test (CWLT) at 75% Wpic. The first CWLT will be realized without any ventilatory support. The 2 others CWLT will be achieved with non-invasive ventilation support using facial or nasal interface in a randomized order.
1904089|NCT02787356|Drug|TDS Lidocaine 5%; generic|TDS Lidocaine 5%; generic
1904090|NCT02787356|Drug|TDS Lidocaine 5%; RLD|TDS Lidocaine 5%; RLD
1904100|NCT02787187|Procedure|Pancreaticoduodenectomy with Standard lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction standard lymphadenectomy: No 5 6 8a 12b1 12b2 12c 13a 13b 14a 14b 17a 17b
1904101|NCT02787187|Procedure|Pancreaticoduodenectomy with Extended lymphadenectomy|Pancreaticoduodenectomy：child's digestive reconstruction extended lymphadenectomy: No8p 12a 12p 14c 14d 16
1904107|NCT02786875|Other|low Glycemic Index Mediterranean diet|All carbohydrate foods will be low GI choices (GI<70 on bread scale, e.g. legumes, pasta al dente, barley, oat, apples, oranges, berries, nuts) within a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
1904108|NCT02786875|Other|Mediterranean diet|General recommendations for a healthy Mediterranean diet (≥5 servings veg/fruit per day, ≤1 serving red meat+cold cuts/week, <7% SFA).
1904109|NCT02786875|Behavioral|Moderate physical activity|Brisk walk of at least 30min per day (or approximately 5000 steps) more than the habitual physical activity.
1904110|NCT02786875|Behavioral|Basic physical activity|General recommendations for physical activity
1904111|NCT02786875|Dietary Supplement|high level Vitamin D|Vitamin D supplement (cholecalciferol) up to 4000 IU/day to reach normal blood levels of 60-80 ng/ml of 25(OH)D.
1962748|NCT02461589|Drug|semaglutide|Administered subcutaneously ( s.c., under the skin) once daily.
1962749|NCT02461589|Drug|liraglutide|Administered subcutaneously ( s.c., under the skin) once daily. All subjects will follow a 4-week dose-escalation regimen.
1962750|NCT02461589|Drug|placebo|Administered subcutaneously ( s.c., under the skin) once daily.
1962751|NCT02461966|Other|Aflatoxin|Evaluation of Aflatoxin level
1962755|NCT02456636|Behavioral|Fee-for-Service Model|To be performed by participant's doctor or other healthcare professional in their doctor's office.
1962756|NCT02456636|Behavioral|Patient Centered Medical Home|To be performed by a registered dietitian, a nurse or other healthcare professional.
1962757|NCT02456636|Behavioral|Disease Management|To be preformed by obesity treatment specialists with relevant graduate training and experience with weight loss counseling
1962759|NCT02453620|Drug|Entinostat|Given PO
1962760|NCT02453620|Biological|Ipilimumab|Given IV
1962761|NCT02453620|Other|Laboratory Biomarker Analysis|Correlative studies
1962762|NCT02453620|Biological|Nivolumab|Given IV
1962763|NCT02453620|Other|Pharmacogenomic Study|Correlative studies
1962764|NCT02453620|Other|Pharmacological Study|Correlative studies
1962768|NCT02451735|Behavioral|Video and Booklet|Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.
1962769|NCT02451735|Behavioral|Factsheet|Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
1904112|NCT02786875|Dietary Supplement|normal level Vitamin D|Vitamin D (cholecalciferol) will be given only if vitamin D insufficiency is detected to bring blood levels up to normal ranges of 30ng/mL.
1962772|NCT02451137|Drug|INSULIN GLARGINE (U300)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1962773|NCT02451137|Drug|INSULIN GLARGINE (U100)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1962774|NCT02451137|Drug|Insulin detemir (Levemir)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1904125|NCT02783976|Drug|Sovaldi|Sovaldi 400 mg tablets administered orally once daily
1904131|NCT02779244|Procedure|Early Weight bearing + Cam Boot|Patients will be transitioned to weight bearing as tolerated in a cam boot.
1904132|NCT02779244|Procedure|Non-Weight Bearing + Cam Boot|Subject will be transitioned to non weight bearing cam boot, standard treatment.
1904145|NCT02769819|Device|Flexible fiberscope|"Characteristics of patients will be assessed before induction of general anesthesia
Glottic visualization will be evaluated by direct laryngoscopy.
The endotracheal tube will be loaded onto the scope after silicon spray lubrication
Intubation will be performed with the flexible fiberscope with the patient in supine position with head and neck in neutral position
With the tip of the fiberscope in satisfactory position, the endotracheal tube will be advanced into the trachea. The scope will then be removed.
Accurate positioning of the endotracheal tube will be confirmed by capnography and lung auscultation."
1904146|NCT02767154|Device|A colloid Dextran 40 solution for extracorporeal circulation|The oncotic pressure of the PrimECC solution is higher than that of a crystalloid Ringer-acetate/mannitol solution. It should maintain the plasma oncotic pressure during and after cardiopulmonary bypass (CPB). Subsequently, the leakage of fluids from the systemic circulation to the interstitial compartment during CPB can be reduced, and a higher plasma volume and a better fluid balance can be achieved.
1904147|NCT02767154|Device|Ringer-Acetate and Mannitol|Currently clinic standard for priming the CPB circuit.
1904152|NCT02763540|Procedure|Lung cryobiopsy|Transbronchial cryobiopsy
1904162|NCT02759380|Other|Phytoestrogen-rich foods|The patients will be given a package containing food with a high amount of phytoestrogens (≥100 mg isoflavonoids and ≥100 mg lignans) that are to be consumed daily. The food-package contains 30 grams of flaxseed, 25 grams of roasted soybeans and 50 grams of frozen green edamame beans to be consumed daily.
1904168|NCT02753426|Drug|Doxycycline|Doxycycline 20mg capsule by mouth, twice a day for 30 days.
1904169|NCT02753426|Drug|Placebo (for Doxycycline)|Inactive pill manufactured to mimic Doxycycline 20mg. Capsule by mouth, twice a for 30 days.
1904173|NCT02752347|Device|Surface EMG device|measuring the muscles activity using surface EMG device
1904185|NCT02748109|Behavioral|Vestibular Rehabilitation + audio biofeedback|Vestibular rehabilitation paired with audio biofeedback for balance control 2 times per week with a physical therapist for 6 weeks.
1904186|NCT02748109|Behavioral|Vestibular Rehabilitation|Standard vestibular rehabilitation 2 times per week with a physical therapist for 6 weeks.
1962827|NCT02428101|Genetic|polymorphism analysis|
1962828|NCT02427737|Behavioral|Comfort Talk® Training|Personnel of MRI units will be trained in advanced rapport skills, patient-centered and hypnoidal language, correct use of suggestions and skills of tension diffusion. This will entail 16 hrs class room work, additional on-site post training support, and access to a post-training support web module resulting in at least 20 hrs training.
1904191|NCT02743546|Drug|Duvortuxizumab|Duvortuxizumab will be administered at starting dose of 15 nanogram per kilogram (ng/kg) as an intravenous (IV) infusion during Part 1 (Dose Optimization) and at RP2D level determined in Part 1 during Part 2 (Dose Expansion). Participants will receive duvortuxizumab either with or without a priming dose. Participants who receive a priming dose will have infusions on Days 1, 8, and 22 of an initial 35-day cycle and then on Days 1 and 15 of 28-day cycles thereafter. Participants who do not receive a priming dose will have infusions on Days 1 and 15 of 28-day cycles.
1904192|NCT02743546|Drug|Ibrutinib|Ibrutinib will be administered at 560 milligram per day (mg/day) orally once daily during Part 1 (Dose Optimization) and at a dose of 420 mg/day (for participants with CLL) or 560 mg/day (for participants with DLBCL, FL, or MCL) during Part 2 (Dose Expansion). In Part 1, ibrutinib will be initiated on Day 1 of the initial treatment cycle. In Part 2, ibrutinib will be initiated on Day -7 prior to the initial treatment cycle.
1904193|NCT02743871|Biological|PF-06817024|Subjects will be given one dose of PF-06817024 intravenously
1904194|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 intravenously
1904195|NCT02743871|Biological|PF-06817024|Subjects will be given one dose of PF-06817024 subcutaneously
1904196|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given one dose of placebo for PF-06817024 subcutaneously
1904197|NCT02743871|Biological|PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
1904198|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given two doses of PF-06817024 intravenously
1904199|NCT02743871|Biological|PF-06817024|Subjects will be given 2 doses intravenously
1904200|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given 2 doses intravenously
1904201|NCT02743871|Biological|PF-06817024|Subjects will be given doses of PF-06817024 intravenously
1904202|NCT02743871|Other|Placebo for PF-06817024|Subjects will be given doses of Placebo intravenously
1904203|NCT02741180|Other|3D Imaging|"roadmapping of electrophysiology (EP) procedures"
1904204|NCT02741180|Other|Late Gadolinium Enhancement (LGE)|useful for delineating abnormal myocardium, including fibrotic regions that can serve as sources of arrhythmias.
1904205|NCT02739828|Biological|Adalimumab|Adalimumab
1904383|NCT02640729|Drug|Nelotanserin|once daily, oral, 20-mg tablets
1904216|NCT02732275|Drug|DS-3201b|
1904219|NCT02728336|Procedure|Cardiac MRI|
1962836|NCT02425462|Drug|Dienogest (Visanne, BAY86-5258)|Dienogest 2mg daily Oral dose
1962837|NCT02424357|Drug|5%povidone iodine ophthalmic solution|"At the conclusion of the surgery, all patients will receive a strip of ophthalmic ointment containing antibiotics and corticosteroids into the conjunctival fornix. The subjects will then be randomized (use computer program to generate random digit) into two groups:
Group 1: Patients will receive one drop of 5% povidone iodine instilled into the conjunctival fornix.
Group 2: Patients will not receive 5% povidone iodine into conjunctival fornix."
1904224|NCT02725268|Drug|Paclitaxel|Paclitaxel intravenous solution
1904225|NCT02725268|Drug|MLN0128|MLN0128 capsules
1904226|NCT02725268|Drug|MLN1117|MLN1117 capsules
1962840|NCT02423551|Other|MRE|MRE consumption
1904229|NCT02722798|Drug|KRN23|Doses may be titrated to achieve the target peak serum phosphorus range
1904235|NCT02717988|Drug|SKI-O-703 capsule|SKI-O-703 25 mg capsule or 200 mg capsule without excipient
1904236|NCT02717988|Drug|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose
1904258|NCT02712710|Device|functional knee brace|The functional knee brace for OA can decrease abnormal varus torque by external force.
1962866|NCT02413541|Procedure|Polymyxin-B Hemoperfusion|Endotoxin removal
1962867|NCT02413541|Procedure|Standard treatment|
1904274|NCT02708927|Other|Clinical evaluation|• Clinical assessment : Expanded Disability Status Scale (EDSS), ambulation test. Medications will be recorded.
1904275|NCT02708927|Other|Cognitive evaluation|• Neuropsychological, psychological, social and social cognitive evaluation
1904276|NCT02708186|Drug|Nelotanserin|once daily, oral, 20-mg tablets
1904277|NCT02708186|Drug|Placebo|once daily, oral, matching tablets
1904278|NCT02706353|Drug|APX005M|"Dose Escalation Phase Starting Dose Level of APX005M: 0.1 mg injected directly into 1-3 tumors every 3 weeks (Weeks 0, 3, 6, and 9) for up to 4 doses.
Dose Expansion Phase Starting Dose Level of APX005M: Maximum tolerated dose from Dose Escalation Phase."
1904279|NCT02706353|Drug|Pembrolizumab|Dose Escalation and Expansion Phase Dose of Pembrolizumab: 2 mg/kg by vein 1 time every 3 weeks (Weeks 0, 3, 6, 9, and 12). First dose of Pembrolizumab given 1-2 days before or after first dose of APX005M.
1904280|NCT02706873|Drug|ABT-494|Oral Tablet
1904281|NCT02706873|Drug|Methotrexate|Oral capsule
1904282|NCT02706873|Drug|ABT-494 matching placebo|Oral tablet
1904283|NCT02706873|Drug|Methotrexate matching placebo|Oral capsule
1904284|NCT02706405|Biological|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ Central Memory T-lymphocytes JCAR014|Given IV
1904285|NCT02706405|Drug|Cyclophosphamide|Given IV
1904286|NCT02706405|Biological|Durvalumab|Given IV
1904287|NCT02706405|Drug|Fludarabine Phosphate|Given IV
1904288|NCT02706405|Other|Laboratory Biomarker Analysis|Correlative studies
1904289|NCT02706405|Other|Pharmacological Study|Correlative studies
1904292|NCT02702232|Other|Ultrasonography|Ultrasonography is applied for normal subjects and patients with Parkinson's disease
1904299|NCT02695537|Drug|Epidiolex|In some patients additional titration by 5 mg/kg/day every 2 weeks up to 50 mg/kg/day may be instituted at the discretion of the PI upon discussion with the Co-PI
1904303|NCT02691156|Other|Bilirubin Binding Capacity|Laboratory assay of bilirubin binding capacity
1904304|NCT02691156|Other|End-tidal Carbon Monoxide|Noninvasive bedside test to measure exhaled end-tidal carbon monoxide levels for the detection of hemolysis
1904305|NCT02691156|Other|Carboxyhemoglobin|Laboratory assay of carboxyhemoglobin levels for the detection of hemolysis
1904306|NCT02691169|Drug|18F-DCFPyL|18F-DCFPyL is a sterile diagnostic radiopharmaceutical used for PET imaging.
1904307|NCT02690350|Drug|U3-1784|All doses of U3-1784 will be administered every 2 weeks (q2w) as a 250 mL IV infusion of 5% dextrose.
1962883|NCT02405442|Drug|GS-5745|GS-5745 administered via subcutaneous (SC) injection
1962884|NCT02405442|Drug|Placebo|Placebo to match GS-5745 administered via subcutaneous (SC) injection
1962888|NCT02399644|Behavioral|ACT|ACT is a type of Cognitive behavioral Therapy (CBT) that focuses on acceptance and mindfulness. The aim is to prevent avoidance and control of negative private events such as anxiety or pain. The treatment consists of 7 weekly group sessions, 2 hours a week. The participants are given homework between sessions.
1962889|NCT02399644|Other|Physical activity|Participants are going to perform a training programme including aerobic exercise as well as endurance and strength training for the neck, shoulders, low back, core and leg muscles. The training is group-based and supervised by a physiotherapist two times a week, one hour a time for eight weeks. Home exercises twice a week are also a part of the intervention. It is possible to individually adjust movements and intensity to the participants' capacity if needed.
1962890|NCT02398773|Procedure|Computed Tomography|Undergo PET/CT
1962891|NCT02398773|Drug|F-18 16 Alpha-Fluoroestradiol|Given IV
1962892|NCT02398773|Other|Laboratory Biomarker Analysis|Correlative studies
1962893|NCT02398773|Procedure|Positron Emission Tomography|Undergo PET/CT
1962894|NCT02398461|Drug|rHIgM22|Administered via IV infusion
1962895|NCT02398461|Drug|Placebo|
1904310|NCT02688413|Device|MindMotionPRO|The MindMotionPRO, a certified device for medical use, is a virtual reality based system to train upper limb activities in a game scenario. The participant will receive 5 exercises sessions with the MindMotionPRO per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
1904311|NCT02688413|Other|Self-Directed Prescribed Exercises|GRASP is an arm and hand exercise program for stroke patients, designed to supplement standard rehabilitation therapies. The participant will receive 5 GRASP exercises sessions per week over 4 weeks. This is done in addition to standard practice for upper limb rehabilitation which should be at least 30 min five times per week.
1962898|NCT02395497|Procedure|Penile Transplant|
1904315|NCT02687542|Drug|Placebo|Placebo
1904316|NCT02687542|Drug|PF-06649751 low dose (1 mg QD)|PF-06649751 low dose (1 mg QD)
1904317|NCT02687542|Drug|PF-06649751 middle dose 1 (3 mg QD)|PF-06649751 lower middle dose 1 (3 mg QD)
1904318|NCT02687542|Drug|PF-06649751 middle dose 2 (7 mg QD)|PF-06649751higher middle dose 2 (7 mg QD)
1904319|NCT02687542|Drug|PF-06649751 high dose (15 mg QD)|PF-06649751 high dose (15 mg QD)
1962899|NCT02395497|Biological|Monoclonal Antibody (Humanized Anti-CD52)|
1904321|NCT02683447|Other|CRM Simulation|Each participant will manage a PEA arrest scenario (pre-test) and then be debriefed on their CRM skills by a trained facilitator for 20 minutes. They will then manage another crisis scenario (PEA arrest with a different inciting event) as an immediate post-test. Three months afterwards participants will return to manage a third PEA arrest scenario, which will serve as a retention post-test.
1962900|NCT02395497|Drug|Tacrolimus|
1904340|NCT02675491|Drug|DS-6051b|Drug: DS-6051b 400 mg or 800 mg daily
1904342|NCT02670759|Drug|Continuous infusion of bupivacaine|The infusion of local anesthetics will be initiated using a conventional infusion pump and will be transferred on a portable elastomeric pump before discharge from the hospital if the patient is discharged the day after surgery or at the latest on the second morning following surgery. The infusion will continue on the portable pump for 30 hours.
1904343|NCT02670759|Drug|Single dose of bupivacaine|A single dose of bupivacaine will be administered at the end of surgery before skin closure.
1904344|NCT02669797|Behavioral|Family Meals Coaching|The experimental arm includes three incremental phases over 18 months. Phase I includes 12 bi-weekly in-home visits that last 90 mins. facilitated by a behavioral health and dietitian team. Meal quality and quantity will be targeted. The primary caregiver will also receive daily EMI messages about increasing meal quantity and quality via a smartphone, based on the stress level reported earlier in the day. Phase II visits will occur every 3 weeks over 6 months. Daily EMI prompts will continue and video feedback will be introduced. In between visits, families will video-record via an iPad at least 3 family dinner meals. Family meal coaches will watch the videos in between home visits to identify specific footage to show family members at the next in-home visit that highlights both positive and negative family interactions and diet quality patterns. During Phase III, parents will receive monthly booster phone calls for six months. The EMI and the video feedback will discontinue.
1904345|NCT02669797|Behavioral|Usual Care|The usual care condition will receive childhood obesity prevention messages (i.e., 5-2-1-0) from primary care providers and monthly newsletters focusing on general child health. All clinics in the study already use 5-2-1-0 messages for childhood obesity prevention. These are evidence-based messages (i.e., 5 fruits and vegetables/day; no more than 2 hours of screen time/day; at least 1 hour of physical activity/day; 0 sugar-sweetened beverages/day) that providers share with parents during well-child visits. The monthly newsletters will cover general child health issues, such as car seat safety, immunizations, etc.
1904356|NCT02664038|Behavioral|Cognitive Remediation Training|Up to 65 hours of computer based cognitive training of attention, verbal and visual memory, verbal and visual working memory, and executive functions
1904364|NCT02658669|Behavioral|Cognitive-Behavioral Therapy for Insomnia|Intervention includes strategies designed to improve sleep such as: sleep restriction, stimulus-control techniques, sleep hygiene education, and relaxation training.
1904365|NCT02658669|Behavioral|Sleep Education|Intervention includes sleep hygiene education and education regarding the impact of TBI on sleep.
1904366|NCT02655419|Drug|ATM-AVI|"Cohort 1:
(Creatinine clearance > 50 mL/min)6500mg ATM/1777mg AVI on day 1 followed by total daily dose of 6000mg ATM/1640mg AVI
Cohorts 2 and 3:
(Creatinine clearance > 50 mL/min) As above, or: 6500 mg ATM/2167 mg on Day 1 followed by a total daily dose of 6000 mg ATM/2000 m AVI
(Creatinine clearance 31 - 50 mL/min) 4250 mg ATM/1162 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/820 mg AVI, or:
4250 mg ATM/1417 mg AVI on Day 1 followed by total daily dose 3000 mg ATM/1000 mg AVI"
1904367|NCT02655419|Drug|Metronidazole|Metronidazole 500mg infused over 1 hour every 8 hours
1904368|NCT02653768|Behavioral|Stepped Exercise Program|"STEP 1: Participants have access to an internet-based exercise program for knee OA.
STEP 2: Participants have access to an internet-based exercise program for knee OA plus telephone support.
STEP 3: Participants have access to an internet-based exercise program for knee OA plus in-person physical therapy visit"
1904369|NCT02653768|Behavioral|Arthritis Education|The arthritis education intervention will include bi-weekly mailings of low-literacy educational materials on a comprehensive set of topics related to OA and its management, based on established treatment guidelines.
1904397|NCT02630472|Drug|Quinine Sulfate|Our plan is to first study quinine against saline to determine efficacy and safety. The vast majority of patients with rhinosinusitis utilize low pressure / high volume (240mls) sinonasal lavage to cleanse the sinonasal cavity. The patients will be exposed to a maximum of 12mls or 12.0 mg of quinine. In standard tonic water, quinine is 8.3mg/100mls and thus an 8oz glass of Canada Dry tonic water has 19.6mg of quinine. Thus, the maximum systemic exposure in our study (assuming ingestion of the total nasal administration) is less than drinking one glass of tonic water / day. To put this in context, the therapeutic range of quinine to treat malaria is 10mg/kg true ileal digestibility (TID) (2100mg for a 70kg individual) nearly 200 X the dose the investigators are proposing.
1904398|NCT02630472|Drug|Placebo|In order to blind the participants to which arm they have been randomized into, the placebo arm will contain saline solution spiked with 0.5 mg/ml sucrose octaacetate. This solution will produce a bitter flavor similar to the one produced by quinine. There is no evidence that sucrose octaacetate produces nitric oxide production in the sinonasal cavity, nor is there evidence that it has any side effects (it is used to wean babies off of pacifiers) so the investigators feel it is an effective and safe option for a placebo.
1904399|NCT02630953|Behavioral|Original Tailored Intervention|The intervention includes regular mailings: weekly in month 1, biweekly in months 2 and 3, monthly in months 4 to 6, and a maintenance dose. Mailings consist of; 1) Manuals matched to the participant's current level of motivational readiness to change, based on TTM 2) Individually tailored computerized expert system feedback reports based on the participant's answers to monthly questionnaires. The computer expert system draws from a bank of over 330 messages developed from previous studies that address different levels of psychosocial and environmental factors affecting PA. 3) PA tip sheets addressing PA barriers specifically identified by Latinas in our formative research (e.g., caregiving duties, neighborhood safety).
1904400|NCT02630953|Behavioral|Enhanced Tailored Intervention|Participants in the Enhanced Tailored arm will receive all the intervention components of the original tailored intervention, as well as: 1) additional print materials; 2) more in-depth tailored reports; and 3) text-messages. Self-monitoring was an important aspect in increasing PA in our previous trials however, participants were only asked to turn in the self-monitoring logs once a month. Based on the importance of self-monitoring and feedback from participants (R01NR011295; R01CA15994) that they wanted greater accountability and interactivity, we added a text-message component for self-monitoring.
1963047|NCT02371369|Drug|PLX3397 capsule|Each capsule of PLX3397 will contain 200 mg of PLX3397 HCl
1963048|NCT02371369|Drug|Placebo capsule matching PLX3397 capsule|Placebo capsule matching PLX3397 capsule
1904415|NCT02623361|Drug|Peripheral Nerve Block|Regional Anesthesia by Local Anesthetic Injection
1904416|NCT02623361|Drug|Sham Block|Sham Block by saline injection
1904417|NCT02620423|Biological|REOLYSIN®|4.5x10E10 TCID50 1 hour intravenous infusion, administered on Day 1 and 2 of a 21-day cycle
1904418|NCT02620423|Drug|Chemotherapy|Patients may be treated with one of three chemotherapy backbone regimens. The decision on the chemotherapy backbone is based on physician preference.This includes either: a) Gemcitabine or b) Irinotecan or c)Leucovorin followed by 5-fluorouracil
1904419|NCT02620423|Drug|Gemcitabine|1000 mg/m2 intravenous infusion over 30 minutes on Day 1 of a 21-day cycle or
1904420|NCT02620423|Drug|Irinotecan|125 mg/m2 intravenous infusion over 90 minutes on Day 1 of a 21-day cyle or
1904421|NCT02620423|Drug|Leucovorin|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
1904422|NCT02620423|Drug|5-fluorouracil|Leucovorin (LV) followed by 5-fluorouracil (5FU). LV 200 mg/m2 intravenous infusion over 2 hours on Day 1, 5FU 200 mg/m2 intravenous infusion bolus over 5-10 minutes on Day 1, followed by 5FU 1200 mg/m2 continuous intravenous infusion over 22 hours on Day 1 of a 21-day cycle
1904423|NCT02620423|Drug|Pembrolizumab|Pembrolizumab, 2 mg/kg intravenous infusion 30 minutes on Day 8 of a 21-day cycle
1904430|NCT02613273|Behavioral|Experimental: Arm 1 (Aerobic Exercise)|This periodized program consists of 3 aerobic exercise sessions per week comprised of two high-intensity interval training workouts and 1 continuous vigorous intensity workout.
1904431|NCT02613273|Behavioral|Experimental: Arm 2 (Resist. Exercise)|This periodized program consisting of 3 resistance exercise sessions per week comprised of high load/low volume, light load/high volume, and moderate load/moderate volume.
1904435|NCT02610088|Drug|Dapagliflozin|Dapagliflozin 10 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by > 0.4% at 12 week, rescue therapy (sitagliptin 100 mg) can be added at investigator's discretion.
1904436|NCT02610088|Drug|Gliclazide|Gliclazide MR 30 mg, orally once daily at any time of day with or without food. If HbA1c does not decrease by > 0.4% at 12 week, rescue therapy (gliclazide MR 30 mg) can be added at investigator's discretion.
1904437|NCT02610777|Drug|Azacitidine|Azacitidine intravenous or subcutaneous formulation.
1904438|NCT02610777|Drug|Pevonedistat|Pevonedistat intravenous infusion.
1904440|NCT02609815|Drug|gemigliptin/metformin|zemimet-SR 50/1000 mg x 1 tablet
1904441|NCT02609815|Drug|glimepiride/metformin|amaryl-Mex 1/500 mg x 2 tablets
1963068|NCT02362672|Drug|NKTR-181 BID tablets|NKTR-181 tablets 100-400 mg twice daily (BID)
1963069|NCT02362672|Drug|Placebo to match NKTR-181 BID tablets|Placebo to match NKTR-181 tablets 100-400 mg twice daily (BID)
1963074|NCT02359890|Device|THERMOCOOL® SMARTTOUCH® (RF ablation treatment)|Radiofrequency Ablation Treatment
1963075|NCT02359565|Procedure|Diffusion Tensor Imaging|Correlative studies
1963076|NCT02359565|Procedure|Diffusion Weighted Imaging|Correlative studies
1963077|NCT02359565|Procedure|Dynamic Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
1963078|NCT02359565|Procedure|Dynamic Susceptibility Contrast-Enhanced Magnetic Resonance Imaging|Correlative studies
1963079|NCT02359565|Other|Laboratory Biomarker Analysis|Correlative studies
1963080|NCT02359565|Procedure|Magnetic Resonance Spectroscopic Imaging|Correlative studies
1963081|NCT02359565|Biological|Pembrolizumab|Given IV
1963082|NCT02359565|Procedure|Perfusion Magnetic Resonance Imaging|Correlative studies
1990121|NCT02203331|Drug|Levonorgestrel|Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
1992431|NCT03321292|Drug|acetylsalicylic acid 75 mg|acetylsalicylic acid 75 mg will be given orally once daily for group B starting of diagnosis till birth.
1904458|NCT02600767|Drug|Artemether-lumefantrine combination|This is the sole arm in this study and it is the use of the standard combination therapy for treatment of P. falciparum malaria.
1963100|NCT02352363|Drug|CVT-301|
1963101|NCT02352363|Other|Observational cohort|
1963103|NCT02348723|Drug|Warfarin|Patients receiving Warfarin to keep INR between 2.0 - 3.0
1963104|NCT02348723|Drug|Dabigatran Etexilate 150mg|Patients receiving Dabigatran Etexilate 150mg BID
1904488|NCT02580305|Drug|SUVN-502|
1904489|NCT02580305|Drug|Placebo|
1963133|NCT02341950|Behavioral|SCI Hard|The game SCI Hard is designed to enhance self-management skills in individuals with spinal cord injury
1963136|NCT02340637|Behavioral|Coping Kids|The first half (10 sessions) of Coping Kids focuses on building skills that are common to both anxiety and depression. The children practice strategies to regulate their mood, learn problem-solving, and behavioral activation is used to break the cycle of withdrawal. The second half of Coping Kids (10 sessions) is focused on the youth's specific problem; for depressive symptoms, building a positive self-schema and behavioral activation; for anxiety problems, gradual exposure to fear-inducing situations. Cognitive restructuring directed at different maladaptive thoughts is also emphasized.
1963137|NCT02340637|Behavioral|TAU|Treatment as usual
1904497|NCT02578589|Procedure|Plica resection vs conservative treatment|Plica resection vs conservative treatment
1963149|NCT02338245|Drug|ASLAN001|ASLAN001 400mg BID
1963150|NCT02338245|Drug|Lapatinib|Lapatinib 1250mg QD
1963151|NCT02338245|Drug|Capecitabine|Capecitabine 1000mg/kg BID days 1-14 of a 21-day cycle
1904533|NCT02563717|Device|T-piece used for respiratory support (several manufacturers)|Infants will receive support by a standard T-piece resuscitator system (manufacturer not dictated in protocol). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
1963178|NCT02318108|Other|Mentored organizational change|Practices are given basic education related to population-based care and are supported by physician peer mentors and given feedback on performance.
1963179|NCT02318108|Other|Education only|Practices are given basic education related to population-based care and are given feedback on performance.
1904534|NCT02563717|Device|New system used for respiratory support|Infants will receive support by the new system (manufactured by Inspiration Healthcare, UK). Apart from the system used for respiratory support all patients will receive standard care (specified in management protocol)
1904535|NCT02563496|Drug|Tafenoquine|Tafenoquine tablet is supplied as film-coated tablet (150 mg) and fast-dispersing film coated tablet (50 mg)
1904536|NCT02563496|Drug|Chloroquine|Subjects will receive chloroquine according to local/national treatment guidelines
1904548|NCT02555358|Drug|docetaxel,0xaliplatin,capecitabine|docetaxel 60mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14; oxaliplatin 130mg/m2， ivgtt，2h，d1;q21d
1904549|NCT02555358|Drug|oxaliplatin,capecitabine|oxaliplatin 130mg/m2， ivgtt，2h，d1;capecitabine 1000mg/m2 po bid d1-14;q21d
1904567|NCT02551224|Other|Patient preference questionnaire|The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
1904888|NCT02352389|Other|Symptom checklist|Obtained on Day 0, 7, 14, 21 and 28.
1963224|NCT02305927|Dietary Supplement|Vitamin D3 (cholecalciferol)|Supplements containing 3,000 IU vitamin D3 taken orally once per day by the mother starting from the second trimester until 12 months postpartum
1963225|NCT02305927|Other|Placebo|Placebo supplements taken orally once per day by the mother starting from the second trimester until 12 months postpartum
1963226|NCT02304575|Other|Questionnaires|"Questionnaires:
For examinee: European Organization for Research and Treatment of Cancer quality of life questionnaire of 30 items and testicular cancer module of 26 items (EORTC QLQ-30 + QLQ-TC-26), Multidimensional Coping Inventory, The Meaning Test for cognitive function, cognitive orientation questionnaires.
For partner: Multidimensional Inventory of quality of life (QoL) for Adults, Multidimensional Coping Inventory."
1963227|NCT02304575|Other|Hormonal Function measurement|Plasma levels of: follicular stimulating hormone (FSH), luteinizing hormone (LH), thyroid-stimulating hormone (TSH), prolactin, free androgen index.
1963233|NCT02301351|Other|Graphic Warning Label|All packs provided will include FDA-approved graphic warning labels
1963234|NCT02301351|Other|Text Warning Label|All packs provided will include standard text warning labels
1963240|NCT02298075|Drug|Eltrombopag|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
1963241|NCT02298075|Drug|Romiplostin|Investigation of the impact of TPO-RAs on the achievement of sustained and persistent response after discontinuation in adult patients affected by pITP.
1963242|NCT02296125|Drug|AZD9291 80 mg/40 mg + placebo|"The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.
Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria."
1963243|NCT02296125|Drug|Placebo Erlotinib 150/100mg|The initial dose of Placebo Erlotinib 150 mg once daily can be reduced to Placebo 100 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
1963244|NCT02296125|Drug|Placebo Gefitinib 250 mg|The initial dose of Placebo Gefitinib 250 mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
1963245|NCT02296125|Drug|Erlotinib 150/100 mg|"The initial dose of Erlotinib 150mg once daily can be reduced to 10 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.
Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
1963246|NCT02296125|Drug|Gefitinib 250 mg|"The initial dose of Gefitinib 250mg once daily cannot be reduced. A cycle of treatment is defined as 21 days of once daily treatment.
Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Following objective disease progression according to RECIST 1.1, as per investigator assessment, patients who were randomized to Standard of Care arm may have the option to receive open-label AZD9291 (crossover to active AZD9291)."
1963247|NCT02296125|Drug|Placebo AZD9291 80 mg/ 40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to Placebo AZD9291 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment. Number of cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
1963248|NCT02296437|Other|Transcranial direct current stimulation combined with cognitive training|
1963249|NCT02295280|Drug|Metoclopramide|IV
1963250|NCT02295280|Drug|Diphenhydramine|iv
1904585|NCT02537028|Drug|MSC2364447C|Subjects will be administered with MSC2364447C 25 milligrams orally once daily for 4 weeks.
1904586|NCT02537028|Drug|MSC2364447C|Subjects will be administered with MSC2364447C 75 milligrams orally once daily for 4 weeks.
1904587|NCT02537028|Drug|Placebo|Subjects will be administered with placebo matching to MSC2364447C orally once daily for 4 weeks.
1904588|NCT02536859|Drug|insulin degludec|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
1904589|NCT02536859|Drug|insulin glargine|Dose levels will be 0.4 U/kg body weight. The trial products will be administered subcutaneously (s.c., under the skin) once daily.
1963251|NCT02295280|Drug|Codeine|PO
1904594|NCT02524158|Behavioral|Yoga Therapy for CLBP|Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
1904597|NCT02521038|Drug|Brilinta|90mg bid as a treatment for Acute coronary syndrome. Dose and Duration can be adjusted by the primary physician.
1904598|NCT02520479|Drug|P-CHOP|Two cycles of P-CHOP:cyclophosphamide, 750 mg/m2 day 1; vincristine,(maximal dose 2 mg),adriamycin , 50 mg/m2 day 1; dexamethasone,10mg days 1-8; Pegaspargase, 2500IU/m2 day 1 are given before radiotherapy
1904599|NCT02520479|Radiation|Radiotherapy|Radiotherapy was scheduled after 2 cycles of P-CHOPregimen. Involved field radiotherapy(IFRT) is delivered using 6-Million electron Volts linear accelerator using 3-dimensional conformable treatment planning. The IFRT dose was 56 grays (Gy) in 28 fractions.
1904600|NCT02520479|Drug|P-CHOP|"Two consolidation cycles of P-CHOP are given after radiotherapy"
1904601|NCT02520011|Drug|Alvocidib|
1904602|NCT02520011|Drug|Cytarabine|
1904603|NCT02520011|Drug|Mitoxantrone|
1904604|NCT02519270|Biological|IGN002|IGN002 is a monoclonal antibody fusion protein.
1963261|NCT02286466|Behavioral|Health Education Program|Participants in the control group will receive a health education program using a tablet computer identical to the intervention group. The content of this program is adapted from a health education intervention used as the control condition for a cognitive behavioral stress and affect management intervention in a NIH-funded randomized controlled trial of a quality of life intervention for patients with advanced prostate cancer (R21CA102761, PI: Penedo). The program consists of the same number of sessions as the intervention group and includes general information about health and well-being. Specifically, control participants will learn information about topics such as healthy eating, exercise, memory and cognition, and side effects in the context of a cancer diagnosis and treatment.
1963262|NCT02286466|Behavioral|CBT Mobile Application|The CBT intervention is brief, consisting of 6 modules lasting approximately 30 minutes each. Sessions focus on skills for relaxation, coping with cancer-related worries, as well as activity planning and pacing. Prior to starting the program, a trained research assistant will meet with participants in a private office setting to orient them to the software and instruct them on the use of the mobile tablet device. Once patients are comfortable with the functions and features of the mobile app, they will be encouraged to self-administer the intervention on their study-issued tablet at home and during their regularly scheduled oncology visits, for example while receiving chemotherapy infusion or waiting for a doctor's appointment or tests.
1904620|NCT02510469|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
1904625|NCT02509806|Drug|Apatinib|Apatinib Mesylate Tablets 500 mg qd p.o.
1904627|NCT02504671|Drug|GSK3196165|GSK3196165 is supplied as liquid and will be administered as SC injection.
1904628|NCT02504671|Drug|MTX|MTX will be supplied as capsule, tablet or liquid and will be administered orally or as SC injection.
1904629|NCT02504671|Drug|Folic acid|Folic acid will be supplied as capsule, tablet or liquid and will be administered orally.
1904630|NCT02504671|Drug|Placebo|Placebo is supplied as liquid as sterile 0.9% weight by volume (w/v) sodium chloride solution and will be administered as SC injection
1904631|NCT02504008|Drug|AXS-02 (oral zoledronate)|Once weekly for 6 weeks
1904632|NCT02504008|Drug|Placebo|Once weekly for 6 weeks
1904637|NCT02500043|Drug|TAS-102|35 mg/m2/dose of TAS-102 orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
1904638|NCT02500043|Drug|Placebo|35 mg/m2/dose of placebo orally, twice daily on days 1-5 and days 8-12 of each 28-day cycle.
1904639|NCT02500576|Drug|Cyclophosphamide|60 mg/kg/day by vein on Days -7 and -6.
1904640|NCT02500576|Drug|Mesna|60 mg/kg by vein on Days -7 and -6.
1904641|NCT02500576|Drug|Fludarabine|25 mg/m2 by vein on Days -5 to -1.
1904642|NCT02500576|Procedure|TIL (T-cells)|On day 0, TIL infused as an inpatient by vein approximately 15-60 minutes depending on the volume of cells infused. Up to 150 billion cells infused.
1904643|NCT02500576|Drug|IL-2|"High dose IL-2 Group: 720,000 IU/kg by vein every 8-16 hours for up to 15 doses starting 12-16 hours after T cell infusion on Day 1.
Low Dose IL-2 Group: 2 million IU/kg subcutaneously for 14 days starting 12-16 hours after T cell infusion on Day 1."
1904644|NCT02500576|Drug|MK-347|If participants develop stable or partially responding disease, up to 31 doses (2 years) of MK-3475, 200 mg by vein every 21 days.
1904645|NCT02500576|Behavioral|Questionnaires|Questionnaires completed at baseline, Day 63, then every 12 weeks.
1904646|NCT02500576|Behavioral|Phone Calls|After 2 years of pembrolizumab, phone calls made by study staff to participant every 3 months.
1990122|NCT02203331|Drug|Anastrozole + Levonorgestrel (BAY98-7196)|Anastrozole 300 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
1990123|NCT02203331|Drug|Anastrozole + Levonorgestrel (BAY98-7196)|Anastrozole 600 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
1990124|NCT02203331|Drug|Anastrozole + Levonorgestrel (BAY98-7196)|Anastrozole 1050 µg/d + Levonorgestrel 40 µg/d intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Placebo 3-months depot intramuscular injection
1990125|NCT02203331|Drug|Lupron / Leuprolide acetate|Placebo intravaginal ring (treatment for 84 days, 28 days wearing period for each ring) and Lupron / Leuprolide acetate 11.25 mg 3-months depot intramuscular injection
1990126|NCT02202421|Behavioral|Targeted Applied Behavior Analysis (T-ABA)|Participants will be enrolled in a five week Targeted Applied Behavior Analysis (T-ABA) parent therapy group. T-ABA parent groups will be 1.5 hours in length. Following the five weeks of parent group sessions, parents will participate in five weekly one-hour parent-therapist sessions in which a therapist will work one-on-one with the parent and their child. One treatment group (T-ABA Parent Group plus Individual Therapy) will also receive eight one-hour individual therapist-child applied behavior analysis therapy sessions concurrent with the parent group and parent-therapist sessions. The second treatment group (T-ABA Parent Training Only) will be offered eight one hour individual therapist-child applied behavior analysis sessions at the conclusion of the study if desired.
1990127|NCT02201329|Drug|Azacitidine|Azacitidine (subcutaneous)
1990128|NCT02201329|Drug|Volasertib|Volasertib escalating doses (intravenous)
1904761|NCT02436135|Drug|Idelalisib|Idelalisib tablets administered orally for 24 weeks
1904677|NCT02470936|Behavioral|Lifestyle intervention|Patients will have access to the lifestyle website and an activity monitor (e.g., Fitbit), receive texts, and be provided with individualized lifestyle recommendations.
1963305|NCT02276664|Behavioral|Self-Help (SHI)|The newly revised Stop Smoking for Good booklets.
1963306|NCT02276664|Behavioral|Usual Care (UC)|The existing Clearing the Air smoking-cessation manual published by the National Cancer Institute (NCI).
1963307|NCT02276599|Procedure|Volume expansion|Fluid bolus of 0.9% normal saline 10 mL/kg over 10 minutes
1963308|NCT02275260|Device|Cerebral Diffusion-Weighted Magnetic Resonance Imaging|Patients undergo a cerebral Diffusion-Weighted Magnetic Resonance Imaging (DW-MRI)
1963309|NCT02275260|Device|Transesophageal Echocardiography|Patients undergo a Transesophageal Echocardiography prior to the ablation itself
1963310|NCT02275260|Other|Paperbased neurocognitive testing|To assess the impact of PVI on the patient's neurocognitive status
1904724|NCT02455076|Drug|Exenatide|Exenatide is dispensed via a 1.2 mL prefilled pen with 250 mcg/mL solution for subcutaneous (s.c.) injection and will be administered twice daily starting at 5 mcg per dose, either in the abdomen, thigh or upper arm. Exenatide injections will be given within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart between doses). The exenatide dose will be increased to 10 mcg twice daily after 1 month based on clinical response.
1904725|NCT02455076|Drug|Glargine|"Glargine will be given once daily, at the same time of day. If the BG is between 140-200 mg/dL, the dose will be 0.2 units/kg/day; for BG levels 201-400 mg/dL, the dose will be 0.25 units/kg/day. The patients will be discharged on glargine once daily at 50% of the hospital dose.The total daily dose (TDD) of glargine is based on the patient's fasting BG levels for the last 2 days.
FBG >180 mg/dL, no hypoglycemia; glargine increased by 4 IU.
FBG >140 mg/dL, no hypoglycemia; glargine increased by 2 IU.
FBG 100-140 mg/dL, no hypoglycemia; no change in dosage.
FBG 70 - 99 mg/dl, decrease glargine by 4 IU or 10% of TDD.
FBG or RBG < 70 mg/dl, decrease glargine by 8 IU or 20% of TDD.
FBG or RBG < 40 mg/dl, decrease dose of glargine by 30%."
1904726|NCT02455076|Drug|Oral antidiabetic drugs|The dose of oral antidiabetic drugs will be adjusted based on the blood glucose levels.
1904727|NCT02455076|Drug|Rapid-acting insulin analogs|"If the BG levels are >140 mg/dL, rapid acting insulin analogs will be administered following the supplemental/sliding scale protocol. If a patient is able and expected to eat all or most of his/her meals, supplemental insulin will be administered before each meal and at bedtime following the usual dose of the sliding scale protocol. If a patient is not able to eat, supplemental insulin will be administered every 6 hours following the sensitive dose of the sliding scale. If the BG is 141-180 mg/dL, then 2,3 or 4 units of insulin will be given; for BG 181 - 220 mg/dL; the units of insulin will be 3, 4 or 6; for BG 221 - 260 mg/dL, the units of insulin will be 4,5 or 8; for BG 261 - 300 mg/dL, the units of insulin will be 5, 6 or 10; for BG 301 - 350, the insulin will be 6, 8 or 12 units; for BG 351 - 400 mg/dL, the units of insulin will be 7,10 or 14; for BG> 400 mg/dL, the insulin will be 8,12 or 16 units."
1904728|NCT02451774|Drug|Pentoxifylline Plus Chemotherapy|Pentoxifylline 10 to 20 milligrams per kilogram, daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
1904729|NCT02451774|Drug|Placebo Plus Chemotherapy|Placebo daily, for up to 32 days Chemotherapy: Prednisone 40 milligrams per square meter per day, orally, day 5-32. Vincristine 1.5 milligrams per square meter per week, intravenously, day 5, 12, 19, 26. Daunorubicin 25 milligrams per square meter per week, intravenously, days 5; 12. L-asparaginase 10,000 units for square meter, intramuscular, days 6, 8, 10, 12, 14, 16, 19, 21, 23. Cyclophosphamide 1000 milligrams per square meter per dose intravenously, day 26. Cytarabine 75 milligrams per square meter per dose intravenously, days 27-30, 34-37. 6-Mercaptopurine 60 milligrams per square meter per dose, orally, days 26-39, Mix: Methotrexate 8-12 milligrams, Hydrocortisone 16-24 milligrams and Cytarabine 24-36 milligrams, intrathecal, day 19.
1963338|NCT02260986|Drug|Dupilumab|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
1963339|NCT02260986|Drug|Placebo (for Dupilumab)|Subcutaneous injection in the different quadrants of the abdomen (avoiding navel and waist areas) and upper thighs
1963340|NCT02260986|Other|Topical Corticosteroid (TCS)|All participants were required to treatment with a (TCS) using a standardized regimen. It was recommended that participants use triamcinolone acetonide 0.1% cream or fluocinolone acetonide 0.025% ointment for medium potency, and hydrocortisone 1% cream for low potency.
1963345|NCT02258113|Device|Ocusweep|A novel reaction-time based visual field device.
1904756|NCT02439775|Device|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
1904757|NCT02439775|Procedure|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
1904759|NCT02439749|Device|Symplicity Spyral™ multi-electrode renal denervation system|After a renal angiography according to standard procedures, subjects remain blinded and are immediately treated with the renal denervation procedure after randomization.
1904760|NCT02439749|Procedure|Sham Procedure|After a renal angiography according to standard procedures, subjects remain blinded and remain on the catheterization lab table for at least 20 minutes prior to introducer sheath removal.
1904762|NCT02436135|Drug|Ruxolitinib|Ruxolitinib will be administered per standard of care according to package insert
1904764|NCT02432326|Drug|BBI608|The BBI608 starting dose is 240 mg twice daily (480 mg total daily). Dose will be decreased to 160 mg twice daily (320 mg total daily) at modification level 2 and 80 mg twice daily (160 mg total daily) at modification level 3. For BBI608 once daily dosing, doses at starting level and modification level 1 are 240 mg once daily, and 480 mg once daily at escalated levels. Dose will be decreased to 160 mg once daily at modification level 2 and 80 mg once daily at modification level 3.
1904765|NCT02432326|Drug|BBI503|The BBI503 starting dose is 200 mg once daily. Dose at modification level 1 to 3 will be 100 mg once daily.
1963353|NCT02254408|Drug|Presatovir|Presatovir 200 mg (4 × 50 mg tablets) administered orally or via nasogastric (NG) tube
1963354|NCT02254408|Drug|Placebo|Placebo to match presatovir administered orally or nasogastric tube
1963361|NCT02251990|Drug|Grazoprevir/Elbasvir|FDC tablet containing 100 mg of grazoprevir and 50 mg of elbasvir taken q.d. by mouth for 12 weeks.
1963362|NCT02251990|Drug|Placebo|Placebo tablet matching grazoprevir/elbasvir FDC tablet taken q.d. by mouth for 12 weeks.
1904780|NCT02424175|Biological|Fecal Microbiota Transplantation|
1904784|NCT02420756|Device|PET Scan|
1963369|NCT02244944|Drug|EZ-Urso combination therapy|Ursodiol 13-15 mg per kg per day combined with Ezetimibe (Zetia) 10 mg per day
1963373|NCT02242578|Device|1 Hz rTMS|About 1,000 stimulation pulses over 20 min
1963374|NCT02242578|Device|10 Hz rTMS|About 1,000 stimulation pulses over 20 min
1963375|NCT02243306|Drug|GSK1278863|Round, biconvex, white film coated tablet containing 5 mg GSK1278863.
1904793|NCT02415517|Behavioral|Cognitive training|"Cognitive training on computer. Six sessions with different tasks: Tiere merken & Räumlich visuelles Training (application BrainTwister) and Taskswitching (programmed with eprime)"
1904794|NCT02415517|Behavioral|Test of general knowledge|Training of general knowledge on computer. Six sessions with different topics.
1904801|NCT02409953|Other|Lying in a bath during 2 hours|
1904802|NCT02409953|Other|Lying in a bed during 2 hours|
1904803|NCT02408445|Drug|testosterone cypionate 200mg/ml|Subjects in this group will be randomized to receive testosterone cypionate 200 mg/ml to be given intramuscularly every 4 weeks for a total of 3 doses.
1904810|NCT02396043|Drug|induction|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.
Pegaspargase :3750U/m2 im on days 8,22"
1904811|NCT02396043|Drug|induction|Cyclophosphamide: 1000 mg/m2 iv on days 29, 57,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41, 45-48, 52-55,Mercaptopurine: 60 mg/m2 po on days 29-56
1904812|NCT02396043|Drug|protocol M|Methotrexate: 5 g/m2 d 8, 22, 36, 50;Mercaptopurine:25 mg/m2 1-56
1904813|NCT02396043|Drug|maintenance therapy|6-mercaptopurine , 50 mg/m 2 daily, and Methotrexate, 20 mg/m 2 once a week.The treatment lasted 2.0 years.Note that there were four additional doses of HD-MTX(5 g/m2 ) every 3 months during the maintenance phase
1904814|NCT02396043|Drug|reinduction|"Vincristine: 1.5 mg/m2 (max 2 mg) iv on days1, 8, 15, 22,Pirarubicin: 30 mg/m2 iv on days1, 8, 15, 22,Prednisone: 60 mg/m2 po on days 1-28.
Pegaspargase :3750U/m2 im on days 8"
1904815|NCT02396043|Drug|reinduction|Cyclophosphamide: 1000 mg/m2 iv on days 29,Cytarabine: 75 mg/m2 iv on days 31-34, 38-41,Mercaptopurine: 60 mg/m2 po on days 29-42
1904816|NCT02396043|Drug|Intrathecal (IT)|methotrexate (15 mg/m 2 ), cytarabine (40 mg/m 2 ) and dexamethasone (4 mg).induction :d1, 15, 29, 45 ;Protocol M:d1, 15, 29, 43;Reinduction:d31,38
1963399|NCT02233491|Behavioral|Active lifestyle intervention|Active intervention will comprise reviews by a renal dietician, with cognitive behaviour therapy, to provide additional support for lifestyle intervention.
1963400|NCT02233491|Other|Control|No additional support other than lifestyle advice by clinician
1904831|NCT02386137|Device|Contrast-enhancement ultrasound with Sonovue|
1963406|NCT02228967|Behavioral|SBIRT|"SBIRT is an opportunistic approach whereby patients are screened by Health Educators for their alcohol use, and then, taking advantage of a teachable moment, are delivered a brief, motivational intervention matched to their level of risk."
1963407|NCT02228330|Procedure|obturator nerve block|a uni-lateral obturator nerve block will be performed under ultrasound guidance- using 2% lidocaine for obtaining a short term block.
1904836|NCT02374593|Drug|Levothyroxine|Levothyroxine dose will be adjusted at the first clinic visit based on thyroid anatomy on ultrasound.
1904837|NCT02374593|Device|Ultrasound|
1963410|NCT02224560|Drug|GWP42003-P|
1904841|NCT02369341|Biological|Fluarix Tetra|One dose of the Fluarix™ Tetra vaccine was administered to all subjects on Day 0 (Visit 1) intramuscularly into the deltoid of the non-dominant arm.
1963411|NCT02224560|Drug|Placebo control|
1904884|NCT02352389|Other|Blood sample|Blood samples will be drawn and analyzed at Day 0, 7, 14, 21, and 28
1904885|NCT02352389|Other|Nasal swab|Obtained on Day 0, 7, 14, 21 and 28.
1904886|NCT02352389|Other|Oropharyngeal swab|Obtained on Day 0, 7, 14, 21 and 28.
1904859|NCT02359162|Drug|Gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
1904860|NCT02359162|Drug|Oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
1904861|NCT02359162|Drug|Pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
1904862|NCT02359162|Drug|Etoposide|50 mg/m 2 /day 24 h continuous infusion on days 1-4
1904863|NCT02359162|Drug|Vincristine|0.4 mg/m 2 /day 24 h continuous infusion on days 1-4
1904864|NCT02359162|Drug|Doxorubicin|10 mg/m 2 /day 24 h continuous infusion on days 1-4
1904865|NCT02359162|Drug|Cyclophosphamide|cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
1904866|NCT02359162|Drug|Prednisone|60 mg/m 2 /day 60 mg/m 2 /day on days 1-5
1904867|NCT02359162|Radiation|IMRT|IMRT is delivered using 6-8 MeV linear accelerator using intensity-modulated radiation treatment planning. The radiation dose is 50 grays (Gy) in 25 fractions.
1904870|NCT02356575|Other|Acupuncture|
1904871|NCT02356575|Other|Cognitive Behavior Therapy|
1904887|NCT02352389|Other|Stool sample|Obtained on Day 0, 7, 14, 21 and 28.
1990144|NCT02192424|Drug|Metformin alone|
1990145|NCT02192424|Drug|Metformin + Intermittent Insulin Therapy|
1990167|NCT02176837|Drug|Sodium Nitrite|Subjects will receive continuous intravenous infusion of study drug for 7 days at a dose of 64 nmol/min/kg. The infusion will begin shortly after angiographic demonstration of cerebral vasospasm and will be for 7 days unless side effects of the drug dictate stopping the infusion.
1963457|NCT02197715|Behavioral|Computer-adaptive SAFE|
1963458|NCT02197715|Behavioral|Face-to-face SAFE|
1904894|NCT02344485|Procedure|OMM treatment|OMM is a gentle hands-on treatment that helps to reduce myofascial restrictions and improve joint range of motion. In doing so, it can address the mechanical, neurologic, and respiratory functions of the body
1904895|NCT02343939|Drug|Entospletinib|Tablet(s) administered orally every 12 hours
1904896|NCT02343939|Drug|Daunorubicin|60 mg/m^2 administered intravenously daily on Days 1 to 3 of each 14-day induction cycle
1904897|NCT02343939|Drug|Cytarabine|100 mg/m^2 administered intravenously daily on Days 1 to 7 of each 14-day cycle
1904898|NCT02343939|Drug|Decitabine|20 mg/m^2 administered intravenously
1904899|NCT02343939|Drug|High dose Cytarabine|3 g/m^2 administered IV every 12 hours on Days 1, 3, and 5 (< 60 years of age) or 1 g/m^2 once daily on Days 1-5 (≥60 years of age) of each 28-day post-remission cycle
1904900|NCT02343939|Drug|Azacitidine|75 mg/m^2 administered intravenously or subcutaneously
1904901|NCT02343003|Device|Cooled Radiofrequency|Delivery of energy to ablate sensory nerves via cooled radiofrequency probe
1904902|NCT02343003|Drug|Corticosteroid injection|Delivery of corticosteroid into knee by injection with needle to reduce knee pain
1963459|NCT02197715|Behavioral|Usual Care|
1963460|NCT02197000|Dietary Supplement|DIM-Avail 100mg|DIM 100 mg*1 daily for 2 years
1904908|NCT02338921|Drug|Sitagliptin|"100mg qd per oral during 24months
compared with other treatment groups"
1904909|NCT02338921|Drug|Dapagliflozin|"10mg qd per oral during 24months
compared with other treatment groups"
1904910|NCT02338921|Drug|Lobeglitazone|"0.5mg qd per oral during 24months
compared with other treatment groups"
1904911|NCT02338921|Drug|Glimepirde|
1904912|NCT02338921|Drug|Metformin|
1963467|NCT02195518|Drug|Tenofovir disoproxil fumarate|Tenofovir disoproxil fumarate tablets supplied will be white, almond-shaped, film-coated tablets containing 300 mg of TDF. Each tablet contains the following inactive ingredients: microcrystalline cellulose, lactose monohydrate, pregelatinised starch, croscarmellose sodium, and magnesium stearate.
1904927|NCT02310633|Behavioral|Memory Strategy Training|This intervention involves intervention that teaches participants to use active encoding strategies to learn and remember new information. The intervention will be implemented using verbal and face-name paired associate learning.
1904928|NCT02310633|Behavioral|Errorless Learning|This intervention enhances consolidation of correct target information by preventing false recall of incorrect information during the acquisition phase. Participants are encouraged to recall target information only if they are sure it is correct, thus eliminating errors. The intervention will be implemented using verbal and face-name paired associate learning.
1904929|NCT02310633|Behavioral|Retrieval Practice|This intervention enhances retrieval of correct target information by actively practicing retrieval in the presence of a cue. The intervention will be implemented using verbal and face-name paired associate learning.
1904930|NCT02310399|Device|Nucleus ABI541 Auditory Brainstem Implant|Surgical implantation of the Nucleus ABI541 Auditory Brainstem Implant device
1963479|NCT02192333|Procedure|Management of Therapy Complications|Receive survivorship care
1904933|NCT02309541|Device|feedback canceller algorithm (Firmware)|The study consists of two phases. Phase 1: optimization of parameters of new feedback canceller algorithm. Phase 2: comparison of new and reference feedback canceller algorithms.
1963480|NCT02192333|Other|Quality-of-Life Assessment|Ancillary studies
1963481|NCT02192333|Other|Questionnaire Administration|Ancillary studies
1963482|NCT02192333|Behavioral|Telephone-Based Intervention|Receive phone-based booster intervention
1963494|NCT02185521|Other|patient assessmen|Patient clinician status assessment based on HII trend. The HII indicator combines existing data such as physiologic parameters (HR, BP), laboratory measurements (Albumin, HCT, Bicarbonate, WBC, BUN), and ADT information (age). HII will be displayed on charting workstation (WOW). Nurse's role will be to observe the value of HII while accessing WOW desktop (during regular charting), interpret HII value, and share this information to the physician when indicative of potential patient hemodynamic instability to trigger patient clinical status assessment. This intervention is associated with Experimental Study Arm: visible HII.
1963495|NCT02181842|Drug|Pioglitazone|Pioglitazone tablets
1904979|NCT02279030|Other|MIBG nuclear scan|To have scan to help define pathways for PVC ablations.
1963514|NCT02167204|Procedure|Computed Tomography|Undergo 18F-FLT PET/CT
1963515|NCT02167204|Radiation|Fluorothymidine F-18|Undergo 18F-FLT PET/CT
1963516|NCT02167204|Procedure|Positron Emission Tomography|Undergo 18F-FLT PET/CT
1904987|NCT02278133|Drug|WNT974|
1904988|NCT02278133|Drug|LGX818|
1904989|NCT02278133|Biological|Cetuximab|
1905002|NCT02266030|Drug|Cilostazol|Pletaal as an active drug
1905003|NCT02266030|Drug|Aspirin|Aspirin as an active comparator
1963538|NCT02160652|Procedure|Laparoscopic ureteral re-implantation.|Laparoscopic ureteral re-implantation for the treatment of malignant ureteral obstruction.
1905008|NCT02256436|Biological|pembrolizumab|IV infusion
1905009|NCT02256436|Drug|paclitaxel|IV infusion
1905010|NCT02256436|Drug|vinflunine|IV infusion
1905011|NCT02256436|Drug|docetaxel|IV infusion
1905013|NCT02251704|Procedure|Blood sampling|Capillary blood samples collected for determination of parasite prevalence at the time of survey.
1905014|NCT02251704|Procedure|Assessment of body temperature|Axillary body temperature of all subjects recorded by a digital thermometer at the time of survey.
1963541|NCT02160145|Drug|Tolvaptan (OPC-41061)|Tolvaptan tablets (15 or 30 mg) will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later.
1905017|NCT02249858|Procedure|Cranial Vault Hold|
1905018|NCT02249858|Procedure|Cervical HVLA|
1963542|NCT02160145|Drug|Placebo|Matching placebo tablets will be self-administered orally as split-dose regimens, once upon awakening and another approximately 8 to 9 hours later
1963543|NCT02159222|Procedure|Additional physical therapy|
1905023|NCT02249273|Other|Diagnostic approaches|General practitioners will register the diagnostic process in patients with a suspected urinary tract infection
1905025|NCT02245308|Drug|Nicotine Patches|Nicotine replacement therapy in the form of nicotine patches will be provided to ART group participants beginning on their smoking quit date. Nicotine patches may be provided to control group participants as part of usual care.
1905026|NCT02245308|Behavioral|mobile contingency management (mCM)|Mobile contingency management (mCM) is a behavioral intervention designed to provide positive reinforcement for remaining abstinent from smoking. In this intervention, participants are loaned a smart phone equipped with a videocamera and a carbon monoxide (CO) monitor. Participants are trained to upload videos of themselves taking CO readings. Any time a participant uploads a video recording that suggests abstinence (i.e., low CO reading), he/she will be provided a monetary reward.
1905027|NCT02245308|Behavioral|Smoking cessation counseling|Smoking cessation counseling is a cognitive-behavioral treatment designed to prepare participants for a quit attempt, and to address relapse when necessary.
1905028|NCT02245308|Drug|Nicotine rescue method|Nicotine replacement therapy in the form of nicotine gum or lozenges will be provided to ART group participants beginning on their smoking quit date. Nicotine gum or lozenges may be provided to control group participants as part of usual care.
1905029|NCT02245308|Drug|Bupropion|Bupropion SR may be prescribed to medically eligible ART group participants beginning one week prior to quit date. Bupropion may also be prescribed to control group participants as part of usual care.
1963548|NCT02155088|Drug|BYL719|Dose escalation beginning at 250 mg/day
1963549|NCT02155088|Drug|Gemcitabine|Dose escalation beginning at 800 mg/m^2
1963550|NCT02155088|Drug|(nab)-paclitaxel|125 mg/m^2 dose
1905039|NCT02234908|Behavioral|Contacts|Household contacts who come to the study clinic, present a referral card, and complete TB symptom screening will receive a shopping voucher of $5-10 value.
1905040|NCT02234908|Behavioral|Index|Index subjects will be entered in a prize lottery if any of their contacts complete TB symptom screening at the study clinic.
1905044|NCT02231723|Drug|BBI608|Administered continuously twice daily with doses separated by 12 hours
1905045|NCT02231723|Drug|Nab-paclitaxel|Nab-paclitaxel 125 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
1905046|NCT02231723|Drug|Gemcitabine|Gemcitabine 1000 mg/m^2 I.V. infusion on Days 1, 8, and 15 of every 28-day cycle
1905047|NCT02231723|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
1905048|NCT02231723|Drug|Leucovorin|Arm C, D: Leucovorin 400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
1905049|NCT02231723|Drug|Irinotecan|Arm B: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Irinotecan 165 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
1905050|NCT02231723|Drug|Fluorouracil|Arm B, D: Fluorouracil 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle, Arm C: Fluorouracil 400 mg/m^2 I.V. bolus followed by 2400 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
1905051|NCT02231723|Drug|MM-398|MM-398 70 mg/m^2 I.V. infusion on Days 1 and 15 of every 28-day cycle
1963570|NCT02151110|Biological|MEDI4920|CD40L antagonist
1963571|NCT02151110|Other|Placebo|0.9% saline for injection
1905061|NCT02227498|Device|Effect of Argus II on Functional Vision|To evaluate the safety and effectiveness of the Argus II Retinal Prosthesis in subjects with AMD.
1905065|NCT02225353|Drug|Progesterone Cervical Pessary|Progesterone Cervical Pessary: 6.3 g Progesterone Cervical Pessary: 7.7 g
1905066|NCT02225353|Drug|Progesterone 200 mg vaginal capsules|Progesterone 200 mg vaginal capsules daily
1963577|NCT02146430|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
1963578|NCT02146430|Drug|Pregabalin|Pregabalin 150 mg capsule for oral administration
1963579|NCT02146430|Drug|Placebo tablet|Placebo tablet (matching DS-5565) for oral administration
1963580|NCT02146430|Drug|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
1963583|NCT02137772|Drug|MK-8228|
1963584|NCT02137772|Drug|Placebo|
1905075|NCT02213003|Biological|Islet transplantation|Transplantation of at least 5000 islet equivalents/kg of body weight onto the Omentum.
1905080|NCT02205736|Other|Breast Health Education|Small group breast health educational sessions for Latino women in home setting.
1963602|NCT02119650|Drug|Ruxolitinib|5 mg tablets to be administered by mouth at dose selected from safety run-in phase (Ruxolitinib 15 mg twice daily (BID))
1963603|NCT02119650|Drug|Placebo|5 mg matching placebo tablets to be administered by mouth
1963604|NCT02119650|Drug|Pemetrexed|500 mg/m^2 administered as an intravenous infusion over 10 minutes
1963605|NCT02119650|Drug|Cisplatin|75 mg/m^2 infused over 2 hours beginning 30 ± 5 minutes after the end of the pemetrexed infusion
1963606|NCT02120079|Drug|Lotemax|
1963607|NCT02120079|Drug|Artificial Tears|
1905111|NCT02188186|Drug|Initial triple combination|Initial triple combination arm
1905112|NCT02188186|Drug|Conventional treatment|Conventioanl treament with dose escalation
1905115|NCT02182778|Drug|Gemcitabine/Cisplatin|Gemcitabine and cisplatin are infused on day1, 8. The cycle is repeated every 3 weeks.
1905116|NCT02182778|Drug|Gemcitabine/Cisplatin /S-1|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
1963644|NCT02108210|Drug|Anakinra|
1963645|NCT02108210|Drug|Placebo|
1905129|NCT02177812|Drug|GSK2879552|GSK2879552 capsules contain 0.25 mg, 0.5 mg, 2 mg or 5 mg of GSK2879552 as parent. The initial dosing regimen will be continuous oral daily dosing.
1905132|NCT02173171|Other|Information collection|Q3M Information collection
1905133|NCT02165813|Drug|Nitazoxanide|
1905134|NCT02165813|Drug|Placebo|
1905143|NCT02156778|Behavioral|Active Comparator: Extended Standard Care (Stroke Card)|"Standard Care plus
extended training with access to weekly educational lectures (education of patients and relatives), implementation of My Stroke Card containing (a) an adopted version of the 'post-stroke checklist' (ascertainment of post-stroke complications), (b) self-administered internet-based tools for risk factor monitoring and reinforcement of target level achievement, and (c) information and educational materials.
3-Mo outpatient appointment with standardized assessment of risk factors and screening for complications, health problems and residual deficits, estimation of the patient's demand for nursing services and support, guideline-conform secondary prevention with full achievement of target levels, assessment of patient adherence to drug prescriptions.
6-Mo and 9-Mo visits on the discretion of the study team in case of medical needs.
12-Mo clinical visit and outcome assessment."
1905144|NCT02156778|Behavioral|Active Comparator: Standard Care|"In-hospital training (education of patients, next of kin and caregivers on risk factor management and assessment, life style improvement, and compliance).
Complimentary provision of a book / information material dealing with patient and caregiver relevant aspects of stroke care.
Advise by a dietitian (general advise and individualized recommendations in patients with diabetes and obesity).
Standardized information materials (e.g. for OAK or NOAK therapy). Support for smoking cessation and weight reduction if necessary or requested. Detailed medical reports (doctor's letter for the general practitioner and patient) at discharge containing target levels for risk factor management.
AF detection at the Stroke Unit (1-5 day monitoring) and/or at the ward (24-hour ECG).
3-Mo telephone interview and 12-Mo clinical visit and outcome assessment."
1905174|NCT02130024|Drug|Ranibizumab|Patients will receive 0.5mg ranibizumab via intravitreal injection
1905175|NCT02130024|Drug|Aflibercept|Patients will receive 2.0mg aflibercept via intravitreal injection.
1905176|NCT02129998|Other|IVF/ICSI treatment|
1963701|NCT02087423|Drug|MEDI4736|MEDI4736 by intravenous infusion every two weeks. Treatment from Day 1 for a maximum of 12 months or study drug withdrawal if this occurs earlier.
1963702|NCT02088073|Drug|Zirconium silicate (acute phase)|Oral 10g three times a day with meals for 48 hours.
1963703|NCT02088073|Drug|Zirconium silicate (maintenance phase)|Oral doses (either 5g, 10g, or 15g) once daily with breakfast for 28 days.
1963704|NCT02088073|Other|Silicilate microcrystaline cellulose (maintenance phase)|Oral dose once daily with breakfast for 28 days.
1963709|NCT02075255|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks
1963710|NCT02075255|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 24 inclusive.
1963711|NCT02075255|Biological|Benralizumab|Benralizumab administered subcutaneously every 4 weeks for the first 3 dose and then every 8 weeks; matching placebo subcutaneously at the 4 week interim to maintain the blind.
1963712|NCT02071290|Device|Pneumatic tourniquet|"Four cycles of brief occlusion of bloodflow to the thigh (5 minutes) followed by reperfusion (5 minutes) using a pneumatic tourniquet
Remote Ischemic Conditioning"
1905188|NCT02120469|Drug|everolimus|Given PO
1905189|NCT02120469|Drug|eribulin mesylate|Given IV
1905190|NCT02120469|Other|pharmacological study|Correlative studies
1905191|NCT02120469|Other|laboratory biomarker analysis|Optional correlative studies
1905192|NCT02119468|Drug|ixazomib citrate|Given orally
1905193|NCT02119468|Drug|dexamethasone|Given orally
1905194|NCT02119468|Drug|pomalidomide|Given orally
1905195|NCT02119468|Other|laboratory biomarker analysis|Correlative studies
1963717|NCT02068495|Drug|Candesartan cilexetil/amlodipine|Candesartan cilexetil/amlodipine tablets
1963727|NCT02057185|Behavioral|Study questionnaire|Questionnaire based on work situation of enrolled patients.
1963728|NCT02057185|Behavioral|SF-36 Questionnaire|Version 1.6
1963729|NCT02053805|Other|PSA|PSA. Serum & plasma will be stored for future investigations
1963730|NCT02053805|Other|IPSS questionnaire|the validated International Prostate Symptom Score
1963731|NCT02053805|Other|DRE (Digital Rectal Examination )|physical examination for the prostate gland
1963732|NCT02053805|Other|urine flow and residual|The post void residual will be recorded by using ultrasound. Creatinine level will be checked.
1963733|NCT02053805|Procedure|a multiparametric prostate MRI|The MRI will be reported on a 5 point Likert Scale
1963734|NCT02053805|Procedure|trans-rectal ultra-sound guided prostate biopsy|12 core Trans-rectal prostatic biopsy for diagnostic purposes
1905216|NCT02106611|Other|Clinical Assessment|HL treatment will be determined by review of available medical records as archived at MSKCC. Recorded variables will include: (1) RT - field, fractional and cumulative dose, and duration; (2) chemotherapy - regimen, planned interval, dose per cycle, and cumulative dosages. Patients will also be asked to complete the FACT-LYM questionnaire and the FACIT Fatigue questionnaire.
1905217|NCT02106611|Procedure|Stress cardiac MRI|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
1905218|NCT02106611|Procedure|Stress echocardiogram|Both imaging tests will be performed within a 30 day interval, with the two modalities interpreted by dedicated study investigators blinded to the results of the other modality.
1905256|NCT02098629|Drug|Milrinone|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.
Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
1905257|NCT02098629|Drug|Esmolol|"Approximately 5 minutes before stent deployment, the patients in the milrinone+esmolol group start to receive continuous intravenous drug infusion for 10 minutes. Milrinone and esmolol (each in 10 ml volume) will be placed in two separate syringes being connected to their respective venous catheters.
Dosage of study drugs: Syringe #1 Milrinone 5 ug/kg/min Syringe #2 Esmolol 10 ug/kg/min"
1905258|NCT02098629|Drug|Saline Infusion|Approximately 5 minutes before stent deployment, the patients in the placebo group start to receive continuous intravenous saline infusion for 10 minutes. Two syringes containing saline (10 ml volume in each) will be connected to two separate venous catheters during the infusion
1963751|NCT02042014|Drug|QTI571|QTI571 200mg up to 400mg (depending on tolerability) taken orally, once a day.
1905276|NCT02079870|Drug|semaglutide|Solution for subcutaneous (s.c. - under the skin) injection. 0.25 mg semaglutide once weekly for four weeks, 0.5 mg semaglutide once weekly for four weeks followed by 1.0 mg semaglutide once weekly for five weeks
1905277|NCT02079870|Drug|placebo|Solution for subcutaneous (s.c. - under the skin) injection
1905280|NCT02075203|Biological|AERAS-404|The H4 antigen is a fusion protein created from two Mtb antigens: antigen Ag85B and TB10.4. Ag85B is also referred to as α-antigen and is a 30-kDa mycolyl transferase protein. TB10.4 is one of three members of the very similar ESAT-6 group of proteins found in Mtb culture supernatants. TB10.4 induces broad immune responses in T cells isolated from TB subjects compared to BCG-vaccinated donors and unvaccinated donors. IC31 is a combination of a leucine-rich peptide named KLK & a synthetic oligonucleotide named ODN1a. The optimal molar ratio of KLK to ODN1a in mice is 25:1. AERAS-404 & saline placebo trial arms will be double-blinded since BCG causes a recognizable local injection site reaction, the BCG revaccination trial arm will be unblinded.
1905281|NCT02075203|Drug|Placebo|Tris buffered saline (10mM Tris,pH 7.4, 150NM sodium chloride)
1905282|NCT02075203|Biological|Bacillus Calmette-Guérin (BCG)|BCG SSI Vaccine is registered in South Africa for prevention of TB in children and adults. BCG, an attenuated, live culture of the Bacillus Calmette-Guérin, was originally attenuated between 1906 and 1919 by serial passage of an M. bovis strain. The manufacturer Statens Serum Institut (SSI) in Copenhagen, Denmark derives this vaccine from the Danish BCG strain 1331. BCG SSI is supplied by the manufacturer in amber 10-dose vials containing 0.75 mg lyophilized SSI BCG. The BCG revaccination trial arm will be unblinded (open label).
1905449|NCT01916122|Procedure|PET/CT Imaging|
1963763|NCT02026297|Drug|Tranexamic Acid|1 gram IV over 10 minutes
1963764|NCT02026297|Drug|Placebo; Normal Saline|0.9% Normal Saline
1905286|NCT02073669|Procedure|Answering the study Questionnaire and blood sampling for Interferon gamma release assay (IGRA)|
1963782|NCT02015312|Drug|Epigallocatechin-3-gallate (EGCG)|"Pharmaceutical formulation: capsules
Dose:
400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
1963783|NCT02015312|Drug|Placebo|"Pharmaceutical formulation: capsules
Dose:
400 mg/d for 3 months; 800 mg/d for 3 months, 1200 mg/d for 6 months Route of administration: p.o. Treatment duration: 12 months"
1905293|NCT02064946|Dietary Supplement|vitamin D|50,000IU/week of vitamin D3
1905294|NCT02064946|Dietary Supplement|Placebo|
1963784|NCT02015481|Drug|Cabaletta|
1905301|NCT02058511|Drug|Anesthesia Premedication, Induction and Maintenance|"The enrolled patients receive standard of care general anesthesia for knee arthroscopy. No additional pharmacological interventions are performed in study participants.
The administered drugs, as outlined in the arms section, are midazolam, fentanyl, propofol, and sevoflurane. Study patients receive analgesic drugs as needed in the recovery room if they experience pain."
1905302|NCT02058511|Procedure|Pupillometry after administration of anesthetic drugs|"All study patients receive the standard of anesthetic care. Every time a anesthetic drug has been administered, changes in pupillary oscillations will be recorded.
Assessment of pupil size and movements by shining infrared light into the eye and measuring the reflection over a 20 s period
The administered drugs are:
Midazolam 1-2 mg iv, Fentanyl 1mcg/kg body weight, Propofol for anesthesia induction 2-2.5 mg/kg body weight, Sevoflurane as needed for maintenance of general anesthesia."
1963790|NCT02014558|Drug|Gilteritinib|tablet
1905304|NCT02049138|Drug|ABT-494|Capsule
1963791|NCT02014376|Drug|3% SD-101 dermal cream|applied topically once a day for 90 days
1963792|NCT02014376|Drug|6% SD-101 dermal cream|applied topically once a day for 90 days
1963793|NCT02014376|Drug|Vehicle (0% SD-101)|applied topically once a day for 90 days
1905312|NCT02042781|Drug|PG545|PG545 will be administered once weekly, as a one hour IV infusion. Patients will be treated until they exhibit disease progression, withdraw due to poor tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 250 mg anticipated.
1963798|NCT02008318|Drug|LY2157299|Administered orally
1963799|NCT02008318|Drug|Placebo|Administered orally
1963801|NCT02005614|Procedure|Gamma Knife Radiosurgery|"Treatment will be administered on an outpatient basis. No other treatment, investigational or commercial agents or therapies other than those described below may be administered with the intent to treat the patient's brain metastases.
Gamma knife radiosurgery is a one day out-patient procedure. Time from initiation of treatment (premedication and placement of a stereotactic frame) until end of treatment (completion of radiation delivery and removal of stereotactic frame) ranges from 3 to 16 hours."
1905318|NCT02033590|Device|Biodegradable (purified) surgical silk scaffold|
1905323|NCT02029157|Drug|ARQ197|
1905324|NCT02029157|Drug|Placebo|
1905327|NCT02024607|Drug|BBI608|
1905328|NCT02024607|Drug|Fluorouracil|
1905329|NCT02024607|Drug|Oxaliplatin|
1905330|NCT02024607|Drug|Leucovorin|
1905331|NCT02024607|Drug|Irinotecan|
1905332|NCT02024607|Drug|Bevacizumab|
1905333|NCT02024607|Drug|Capecitabine|
1905334|NCT02024607|Drug|Regorafenib|
1905344|NCT02012972|Behavioral|Referral for NCD care|Subjects in the NCD Risks group not already receiving care for the condition will be referred to a primary health clinic for care.
1963843|NCT01983761|Drug|Fludarabine, Clofarabine, Busulfan, ATG, TBI (Myeloablative)|
1963844|NCT01983761|Drug|Fludarabine, Melphalan, ATG (Reduced Intensity)|
1905377|NCT02001558|Drug|Microcyn|Microcyn is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with Microcyn twice daily for the earlier of total wound closure or Week 24
1905378|NCT02001558|Other|Sterile saline|Sterile saline is liberally sprayed on wound and permitted to remain on wound which will then be dressed with gauze that is moistened with sterile saline twice daily for the earlier of total wound closure or Week 24
1905379|NCT01999361|Drug|Myfortic|treatment with myfortic
1905623|NCT01717209|Drug|Nitric Oxide|inhaled nitric oxide
1905624|NCT01717209|Drug|Prostacyclin|inhaled prostacyclin
1905391|NCT01981044|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
1905401|NCT01973569|Drug|denosumab|denosumab administered subcutaneously
1905402|NCT01973569|Drug|placebo|placebo administered subcutaneously to match denosumab
1905403|NCT01972217|Drug|Olaparib|Olaparib bid
1905404|NCT01972217|Drug|Placebo|Placebo bid
1905405|NCT01972217|Drug|Abiraterone|Abiraterone 1000 mg
1905406|NCT01972217|Drug|Prednisone or prednisolone|Prednisone or prednisolone 5 mg bid will be co-administered with the abiraterone in this study.
1905414|NCT01953094|Procedure|Screening Anal Pap Smear - No High Resolution Anoscopy|
1905415|NCT01953094|Procedure|Screening Anal Pap Smear - With High Resolution Anoscopy|
1905446|NCT01917617|Drug|Gemcitabine , Cisplatin, Oral Rehydration Solution (ORS)|"Short hydration via oral rehydration solution (OS-1)
Cisplatin plus gemcitabine will be administered via infusion as follows; 500 ml of 0.9% saline including cisplatin (25 mg per square meter of body-surface area) over 1 hour followed by 250 ml of 0.9% saline including gemcitabine over 30 minutes. Before and after the infusion, each 500ml bottle of oral rehydration solution (OS-1) will be taken respectively."
1963881|NCT01959529|Drug|insulin degludec|Injected once daily subcutaneously (s.c., under the skin)
1963882|NCT01959529|Drug|insulin glargine|Injected once daily subcutaneously (s.c., under the skin)
1963887|NCT01952067|Procedure|line-to-line reaming and cementing technique|
1963888|NCT01952067|Procedure|standard over-reaming with 2 broach sizes|
1963894|NCT01948960|Drug|everolimus dose escalation|patients with an AUC below mean will have dose escalation of everolimus based on their AUC
1963911|NCT01942512|Device|Endovascular treatment of intracranial aneurysm|
1963912|NCT01940185|Device|LINX device|
1905444|NCT01919489|Drug|Liraglutide + OADs|Liraglutide subcutaneously daily
1905445|NCT01919489|Drug|Glargine + OADs|Glargine once daily subcutaneously
1905447|NCT01917617|Drug|Gemcitabine , Cisplatin|"Standard hydration via intravenous infusion
Cisplatin plus gemcitabine will be administered via usual infusion regimen by each hospital. In general, it is administered total 2 litters over 3 hours or more."
1905448|NCT01916122|Drug|Fluorestradiol (FES)|
1905450|NCT01914653|Device|Silk surgical mesh|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
1963939|NCT01920243|Behavioral|Health Mechanics Program|The intervention will consist of six modules that will address attitudes, self-monitoring, communication and organizational skills, problem solving skills and stress management as presented through the Health Mechanics program. These modules are designed to take place over 6 phone calls of approximately 45 minutes each. In order to provide flexibility for the participants, the quantity and duration of calls may vary depending on the extent that the participant completes the homework and the amount of time they need to learn the skill.
1905452|NCT01908829|Drug|mirabegron 25 mg|Mirabegron was supplied as the marketed formulation in the 25 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
1905453|NCT01908829|Drug|mirabegron 50 mg|Mirabegron was supplied as the marketed formulation in the 50 mg OCAS (Oral Controlled Absorption System) modified release tablets. Medication was taken orally with a glass of water, with or without food.
1905454|NCT01908829|Drug|solifenacin 5 mg|Solifenacin was provided as the marketed formulation in the 5 mg strength. Medication was taken orally with a glass of water, with or without food.
1905455|NCT01908829|Drug|solifenacin 10 mg|Solifenacin was provided as the marketed formulation in the 10 mg strength. Medication was taken orally with a glass of water, with or without food.
1905456|NCT01908829|Drug|mirabegron 25 mg matching placebo|Matching placebo of mirabegron OCAS 25 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
1905457|NCT01908829|Drug|mirabegron 50 mg matching placebo|Matching placebo of mirabegron OCAS 50 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
1905458|NCT01908829|Drug|solifenacin 5 mg matching placebo|Matching placebo of solifenacin succinate 5 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
1905459|NCT01908829|Drug|solifenacin 10 mg matching placebo|Matching placebo of solifenacin succinate 10 mg tablets was supplied. Medication was taken orally with a glass of water, with or without food.
1905460|NCT01900561|Behavioral|Interactive Voice Response Symptom Management|The Interactive Voice Response (IVR) system will provide automated telephone monitoring of PC survivor symptoms and goals for symptom reduction, based on a patient empowerment approach.
1905461|NCT01900561|Behavioral|Tailored Newsletters|Personally tailored newsletters will incorporate elements of CBT to improve survivors' identification with the material, confidence/self-efficacy in symptom management, and to reduce common cognitive distortions related to successful implementation of behavior change. Information collected during automated phone assessments will be used to construct tailored newsletters, which will be sent following each automated call.
1905462|NCT01898936|Procedure|Pretreatment with CO2 laser before photodynamic therapy|"The treatment will be a field treatment performed with a 30 W Lutronic carbondioxide laser; covering one of the symmetrical treatment areas allocated to fractional carbondioxide laser.
The laser settings will be as follows:
The fluence will initially be 10mJ/cm2 delivered with a 120 micron tip (producing 120 micron ablative columns) with 5% density. The fluence will be increased until the patient experiences pain (pain indicating penetration to dermis), and then reduced to maximum fluence without pain. Allocation to laser therapy is blinded for the future evaluator.
The PDT procedure includes application of Metvix cream on the skin on both symmetrical areas with a thickness of approximately 1 mm, plastic covering for 30 minutes before entering daylight for 2 hours."
1905463|NCT01898936|Device|Only photodynamic therapy|
1963943|NCT01916941|Drug|Prazosin|
1905468|NCT01896102|Genetic|Lenti-D Drug Product|Lenti-D Drug Product (autologous CD34+ cell-enriched population that contains cells transduced with Lenti-D lentiviral vector encoding human adrenoleukodystrophy protein, suspended in a cryopreservative solution) is administered intravenously. Lenti-D Drug Product is administered by IV infusion following myeloablative conditioning with busulfan and cyclophosphamide.
1963944|NCT01916941|Drug|Placebo|
1963947|NCT01913600|Device|Resolute Integrity Stent|Drug eluting stent (DES)
1963949|NCT01911819|Procedure|Sinus augmentation|
1963950|NCT01911819|Drug|Equimatrix|Equimatrix cancellous particle size 0.2-1mm approximately 2g (4cc)
1963951|NCT01911819|Drug|OSSIF-i sem|OSSIF-i sem Mineralized Cancellous Bone Allograft SP 0.25-1.0mm approximately 2cc x 2
1963952|NCT01911819|Drug|Bio-oss|Bio-oss small granules cancellous 0.25-1mm, approximately 2g (4cc)
1963953|NCT01909453|Drug|LGX818|LGX818- Orally 100 mg and 50 mg capsules
1963954|NCT01909453|Drug|MEK162|MEK162- Orally 15 mg tablets
1905480|NCT01884597|Drug|high-dose ranibizumab|20mg ranibizumab vials, 0.05ml injected intravitreally, monthly
1905481|NCT01884597|Drug|ranibizumab|3 mg ranibizumab, liquid, vials, 0.1ml injected intravitreally monthly
1963955|NCT01909453|Drug|vemurafenib|Tablets in bottles or blisters 240 mg
1905625|NCT01713387|Drug|Gemcitabine, S-1|Dose of gemcitabine and S-1 and treatment schedule
1905626|NCT01711541|Drug|Carboplatin|Given IV
1905490|NCT01868022|Drug|GSK3052230|A clear to opalescent, colorless to pale yellow solution for IV infusion once weekly (Day 1, Day 8, Day 15) in each 21-day cycle with unit dose strengths/dose level of 5, 10, 15, and 20 mg/kg supplied in a sterile 25 mL glass vial.
1905491|NCT01868022|Drug|paclitaxel|paclitaxel will be from commercial stock.
1905492|NCT01868022|Drug|carboplatin|carboplatin will be from commercial stock.
1905493|NCT01868022|Drug|docetaxel|docetaxel will be from commercial stock.
1905494|NCT01868022|Drug|pemetrexed|pemetrexed will be from commercial stock
1905495|NCT01868022|Drug|cisplatin|cisplatin will be from commercial stock
1905497|NCT01858987|Procedure|Stapler hepatectomy|Liver resection using vascular stapler for transection of the parenchyma
1905498|NCT01858987|Procedure|LigaSure hepatectomy|Liver resection using LigaSure for transection of the parenchyma
1905499|NCT01858987|Device|Ligasure|
1905500|NCT01858987|Other|vascular staple|
1963971|NCT01903486|Drug|Apo-Prednisone Cordorol, Detasone - Prednisone|Oral prednisone (study medication) at a dose of 40mg for 1 week, then 30mg for 1 week, then 20mg for 1 week, then 10mg for 1 week, and then stop the medication.
1963972|NCT01900444|Biological|IMOJEV®: Live Attenuated Japanese Encephalitis Chimeric Virus|0.5 mL, Subcutaneous
1905520|NCT01841281|Drug|L-Arginine|L-arginine tablets containing 1 g of elemental L-arginine (1204 mg of L-arginine HCL) developed by Jarrow Formulas in Los Angeles.
1905521|NCT01841281|Drug|Placebo|Matching placebo tablets do not contain L-arginine. Placebo tablets were manufactured by Jarrow Formulas and contain cellulose and other excipients.
1963981|NCT01894308|Drug|Testosterone|10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
1905527|NCT01840579|Biological|Pembrolizumab 2 mg/kg|Administered as an intravenous (IV) infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
1905528|NCT01840579|Biological|Pembrolizumab 10 mg/kg|Administered as an IV infusion on Day 1 of Cycle 1 (28 days), Cycle 2 (14 days), and Cycle 3 (14 days)
1905529|NCT01840579|Biological|Pembrolizumab 200 mg|Administered as an IV infusion on Day 1 of each 21-day cycle
1905530|NCT01840579|Drug|Cisplatin 75 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
1905531|NCT01840579|Drug|Pemetrexed 500 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
1905532|NCT01840579|Drug|Carboplatin AUC 5 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
1905533|NCT01840579|Drug|Carboplatin AUC 6 mg/mL/min|Administered as an IV infusion on Day 1 of each 21-day cycle
1905534|NCT01840579|Drug|Paclitaxel 200 mg/m^2|Administered as an IV infusion on Day 1 of each 21-day cycle
1905535|NCT01840579|Drug|Nab-paclitaxel 100 mg/m^2|Administered as an IV infusion on Days 1, 8, and 15 of each 21-day cycle
1905536|NCT01840579|Biological|Ipilimumab 1 mg/kg|Administered as an IV infusion on Day 1 of every other 21-day cycle (every 42 days)
1905537|NCT01840579|Drug|Etoposide 100 mg/m^2|Administered as an IV infusion on Days 1, 2, and 3 of each 21-day cycle
1905627|NCT01711541|Drug|Cisplatin|Given IV
1905628|NCT01711541|Drug|Fluorouracil|Given IV
1905629|NCT01711541|Drug|Hydroxyurea|Given PO
1905630|NCT01711541|Other|Laboratory Biomarker Analysis|Correlative studies
1905540|NCT01834963|Drug|Interferon Alfa、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil combined with systemic administration of Interferon-alpha
Interferon Alfa 5×10⁶International Unit(IU)/body subcutaneously 3 times a week for 4 weeks
Fluorouracil 300mg/m2, day1-5,8-12, every 6 weeks"
1905541|NCT01834963|Drug|Cisplatin、Fluorouracil|"Hepatic Arterial Infusion of 5-fluorouracil and Cisplatin (Low-dose FP)
Cisplatin 20mg/m2 ,day1,8,22,29, every 6 weeks
Fluorouracil 300mg/m2, day1-5,8-12,22-26,29-33, every 6 weeks"
1905563|NCT01821248|Drug|Gemcitabine, Cisplatin, S-1|"Preoperative chemotherapy (GCS) 3 cycles -FDG-PET- surgery
GCS therapy Gemcitabine 1000mg/m2/day1 Cisplatin 25mg/m2/day1 S-1 100mg/body/day1-7"
1905567|NCT01818401|Device|the prosthesis GMK ® without the ancillary MyKnee ® LBS|
1905568|NCT01818401|Device|Matched patient cutting blocks MyKnee ® LBS|
1905570|NCT01811316|Other|Probiotics|
1964024|NCT01864486|Device|Intelligent Retinal Implant System|
1964025|NCT01863914|Drug|Rosuvastatin|Arteriovenous fistula surgery was performed after 1-week treatment with placebo or Rosuvastatin (randomized, double blind). The intervention drug treatment continues for 3 more weeks after creation of AV fistula.
1905631|NCT01711541|Drug|Paclitaxel|Given IV
1905632|NCT01711541|Other|Placebo|Given PO
1905633|NCT01711541|Radiation|Radiation Therapy|Undergo radiation therapy
1905634|NCT01711541|Drug|Veliparib|Given PO
1905601|NCT01767506|Other|Surveillance and treatment with azithromycin of newcomer and traveler families|The intervention is a surveillance for newcomers and travelers in communities, and provision of azithromycin to them at the time of arrival, in advance of scheduled mass drug administration
1905602|NCT01767506|Other|Usual care|Scheduled mass drug administration (MDA) of azithromycin if trachoma infection level is greater than 1% or TF is 5% or more. Communities will have MDA stopped if infection is 1% or less, or TF is less than 5%. MDA will be reinstated if infection re-emerges to 6% or more.
1905603|NCT01760447|Drug|Sitagliptin + Metformin XR FDC|Sitagliptin + Metformin XR fixed-dose combination tablet (sitagliptin/metformin: 50/500 mg, 50/1000 mg) administered with a meal, preferably in the evening
1905604|NCT01760447|Drug|Placebo to Sitagliptin + Metformin XR|Matching placebo to Sitagliptin + Metformin XR fixed-dose combination tablet administered with a meal, preferably in the evening
1905605|NCT01760447|Drug|Metformin XR|Metformin XR tablet (500 mg, 1000 mg) administered with a meal, preferably in the evening
1905606|NCT01760447|Drug|Placebo to metformin XR|Matching placebo to metformin XR tablet administered with a meal, preferably in the evening
1905607|NCT01760447|Drug|Insulin glargine|The insulin regimen and dosing will be at the discretion of the investigator (based on locally accepted, national, or international guidelines for the indication and use of insulin glargine). When thresholds for rescue are met, participants who are not on background insulin will initiate insulin glargine.
1905608|NCT01760447|Biological|Background insulin|Participants who enter the study on background insulin will continue on the same dose and formulation of insulin throughout the study. When thresholds for rescue are met, participants who have entered the study on background insulin will uptitrate their background insulin dose.
1905614|NCT01752920|Drug|ARQ 087|Subjects in this study will receive ARQ 087 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 25 mg every other day (QOD) and will escalate until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
1905615|NCT01743365|Drug|Cisplatin-5FU-Afatinib|
1964049|NCT01860794|Drug|Mesencephalic Neuronal Precursor Cells|All the patients are continuously registered for this study. Data monitoring committee inspects the clinical results of first patient and decides whether the treatment for four subjects are appropriate to proceed. 5 subjects of each group are subject to inspection by Data monitoring committee after the end of tracking fifth patients.
1905618|NCT01740297|Drug|Talimogene laherparepvec|Talimogene laherparepvec administered by intratumoral injection on Day 1 of Week 1, Day 1 of Week 4, then every two weeks thereafter.
1905619|NCT01740297|Drug|Ipilimumab|Ipilimumab administered intravenously every 3 weeks for a total of 4 infusions.
1905643|NCT01693653|Drug|Tocilizumab|Intravenous infusions every 4 weeks for 3 doses.
1905644|NCT01688102|Dietary Supplement|Oral Vitamin D3|50,000 units orally, each week x8 weeks; supplemental doses of 50,000 units orally, each month thereafter as needed
1905645|NCT01688102|Radiation|Ultraviolet Light|16 treatments, 2-3 times weekly over 8 weeks; initial dose 45-75 seconds, whole-body exposure except face and groin, increasing by 10% as tolerated, to a maximum of 4.5 minutes
1905648|NCT01682044|Biological|pegfilgrastim|Given SC
1905649|NCT01682044|Biological|rituximab|Given IV
1905650|NCT01682044|Other|flow cytometry|Correlative studies
1905651|NCT01682044|Procedure|biopsy|Correlative studies
1905652|NCT01682044|Other|immunohistochemistry staining method|Correlative studies
1905653|NCT01682044|Genetic|western blotting|Correlative studies
1905654|NCT01680640|Dietary Supplement|Synbiotic|The synbiotic to be used is fructo-oligosachharide with a degree of polymerization < 10 at 4 g/twice a day (two sticks a day) plus Bifidobacterium animalis subsp. lactis BB-12 as minimum of 10 billion CFU/day (1 capsule a day).
1905655|NCT01680640|Dietary Supplement|Maltodextrin|
1964067|NCT01856049|Other|Collection of umbilical cord blood|Cord blood will be processed in the temperate state it was collected to produce a pure, stem cell product identifiable to patients with Hypoplastic Left Heart Syndrome, and will be stored at a frozen state for their potential, future use in a clinical trial.
1964068|NCT01855698|Other|Observation|
1905665|NCT01649830|Radiation|Radiotherapy|External beam radiation: 54.0 Gy in 27 - 30 fractions over 6 - 7 weeks.
1905666|NCT01649830|Drug|Temozolomide|dosed at 200 mg/m2 (150 mg/m2 for the first cycle) daily for 5 consecutive days, repeated every 28 days.
1905667|NCT01646177|Drug|Placebo|Administered SC
1905668|NCT01646177|Drug|50 mg etanercept|Administered SC
1905669|NCT01646177|Drug|80 mg ixekizumab|Administered SC
1905822|NCT01361724|Behavioral|Group Exercise Class|The participant will be in an exercise class for 3 days a week for 4 weeks.
1964085|NCT01849146|Other|Laboratory Biomarker Analysis|Correlative studies
1964086|NCT01849146|Other|Pharmacological Study|Correlative studies
1964087|NCT01849146|Radiation|Radiation Therapy|Undergo radiation therapy
1964088|NCT01849146|Drug|Temozolomide|Given PO
1964089|NCT01849146|Drug|WEE1 Inhibitor AZD1775|Given PO
1964098|NCT01838655|Drug|Nitisinone (NTBC)|
1905695|NCT01613833|Procedure|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
1905696|NCT01613833|Procedure|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
1905697|NCT01613833|Procedure|Blood Draw|Blood drawn for A2M levels to be assayed at Cytonics
1905698|NCT01613833|Procedure|Joint Aspirate Harvest|Joint aspirate harvested for A2M levels to be assayed at Cytonics
1964105|NCT01831232|Drug|pravastatin sodium|Given PO
1964106|NCT01831232|Drug|idarubicin|Given IV
1905702|NCT01603641|Biological|botulinum toxin Type A|Subjects will receive intramuscular injections of botulinum toxin Type A into the lower limb muscles and/or upper limb muscles at a minimum of 12 weeks apart for a maximum of 5 treatments. Treatment dosing will be according to investigator judgment not to exceed a maximum of 10 U per kg of body weight (10 U/kg) per treatment.
1964107|NCT01831232|Drug|cytarabine|Given IV
1964108|NCT01831232|Other|laboratory biomarker analysis|Correlative studies
1964109|NCT01830842|Drug|Nicotine polacrilex|nonsmokers will be measured following nicotine administration
1964110|NCT01830842|Drug|Placebo|nonsmokers will be measured following placebo administration
1964111|NCT01830842|Other|satiety|smokers will be measured in a smoking satiated condition
1964112|NCT01830842|Other|abstinence|smokers will be measured following 24-hours of smoking abstinence
1964113|NCT01829100|Behavioral|Group Behavioral Activation Therapy (GBAT)|GBAT consists of 15 weekly, hour-long sessions. The first five group sessions teach four core BA principles: (a) psychoeducation of anxiety and depression, (b) functional analysis and identifying the maintaining role of avoidance, (c) problem solving and approach-oriented decision-making, and (d) graded exposures and behavioral activation. The second five group sessions consist of graded exposures or engagement exercises, where group members take turns practicing skills in role plays and in vivo exposures. Each youth receives two individual meetings (30-45 minutes) after the second and fourth group sessions. The first individual meeting promotes engagement and motivation for the group; the second helps develop the youth's individual avoidance/challenge hierarchy.
1964116|NCT01823978|Biological|BPX-201 vaccine plus AP1903|The trial design consists of 3 cohorts of 6 patients each, receiving escalating doses of BPX-201 of 10 million (M), 20M and 40M cells, respectively. Dose escalation will occur according to a 3+3 design. Patients will receive administration of BPX-201 every other week for 6 cycles (1 cycle equals 2 weeks). Approximately 1.6 mL of BPX-201 will be administered as 8 intradermal injections (200μL each) at each treatment visit. On the day following each vaccination, a single 40 mg dose of the activating agent, AP1903, will be administered via intravenous (IV) infusion over 2 hours.
1905715|NCT01576055|Device|TIGRIS Vascular Stent|Implant
1905716|NCT01576055|Device|BARD LifeStent|Implant
1905734|NCT01554618|Drug|Exenatide Once Weekly|2 mg exenatide once weekly
1905735|NCT01554618|Drug|Placebo|Placebo
1964154|NCT01797809|Drug|EV/DNG (Qlaira, BAY86-5027)|Patients in daily life clinical practice tratment receiving Qlaira according to indication on the label.
1905747|NCT01522404|Drug|Atomoxetine|6 month, crossover, dose escalating (up to a maximum dose of 100 mg per day) of oral atomoxetine
1905748|NCT01522404|Drug|Placebo|At the six-month timepoint, subjects who were taking placebo during the first six months will be placed on active study medication.
1905749|NCT01516944|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80 mg/m2 D1-D14 q3wk and Oxaliplatin 130 mg/m2 D1 q3wk for six cycles postoperation
1905750|NCT01516944|Drug|Tegafur, Gimeracil and Oteracil Potassium Capsules；Oxaliplatin|Tegafur，Gimeracil and Oteracil Potassium Capsules 80mg/㎡ ,D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycles preoperation, Tegafur，Gimeracil and Oteracil Potassium Capsules ,80 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for six cycles postoperation
1905751|NCT01516944|Drug|Oxaliplatin; Capecitabine|Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/㎡ D1 q3wk for two cycle pre-operation, Capecitabine,2000 mg/㎡ D1-D14 q3wk and Oxaliplatin,130 mg/m2 D1 q3wk for six cycles postoperation
1905755|NCT01506609|Drug|Veliparib|Days 1 through 7 of 28-day cycle (in combination with Temozolomide) or Days 1 through 7 of 21-day cycle (in combination with Carboplatin and Paclitaxel).
1905756|NCT01506609|Drug|Temozolomide|Days 1 through 5 of 28-day cycle (in combination with veliparib).
1905757|NCT01506609|Drug|Carboplatin|Day 3 of 21-day cycle
1905758|NCT01506609|Drug|Paclitaxel|Day 3 of 21-day cycle.
1905759|NCT01506609|Drug|Placebo|Placebo comparator for Veliparib days 1 through 7 of 21-day cycle (in combination with carboplatin and/or paclitaxel).
1964163|NCT01790880|Behavioral|ORLA|Practice on ORLA (Oral Reading for Language in Aphasia), a computer-based virtual therapy system.
1964164|NCT01790880|Behavioral|ORLA + Writing|Treatment includes writing of sentences in combination with ORLA
1964169|NCT01788813|Drug|GSK2245035|Nasal spray solution, to be given intranasal, 80 ng/20 ng once weekly for 8 weeks
1964170|NCT01788813|Drug|Placebo|Nasal Spray Solution, to be given intranasal, once weekly for 8 weeks
1905766|NCT01465997|Drug|Lacosamide|50 and 100 mg tablets of Lacosamide given as 100 mg/day, 200 mg/day, 300 mg/day, 400 mg/day, 500 mg/day or 600 mg/day throughout the Treatment Period (Maximum 3.5 Years)
1905767|NCT01465997|Drug|Carbamazepine-Controlled Release (CBZ-CR)|200 mg tablets of Carbamazepine-CR given as 200 mg/day, 400 mg/day, 600 mg/day, 800 mg/day, 1000 mg/day or 1200 mg/day throughout the Treatment Period (Maximum 3.5 Years)
1905768|NCT01463527|Device|Nellcor NPB-70 Capnograph|Use of capnography as an additional monitor during sedation to detect hypoventilation and apnea prior to declines in pulse oximetry and clinical examination findings
1964176|NCT01783535|Drug|vincristine|Given via minibag/gravity flow.
1964177|NCT01783535|Drug|topotecan|Given IV over 30 minutes.
1964178|NCT01783535|Drug|filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until absolute neutrophil count (ANC) is >2,000/µL on one occasion after the expected nadir.
1964179|NCT01783535|Drug|PEG-filgrastim|Given subcutaneously 24-36 hours after chemotherapy for 7-10 days, until ANC is >2,000/µL on one occasion after the expected nadir.
1964180|NCT01783535|Drug|carboplatin|Given IV over 60 minutes. Given periocular (subtenon/subconjunctival).
1964181|NCT01783535|Other|focal therapy|Focal treatments will be administered at the discretion of the treating team to strata A, B and D. In select cases of very early stage retinoblastoma (Stratum A), participants may receive focal therapies only and chemotherapy will be held at the discretion of the treating team. If there is any evidence of progression or unsatisfactory results, the participant will begin chemotherapy as per Stratum A. For selected participants an effort will be made to perform sequential chemo-thermotherapy. In these cases, carboplatin will be administered one or two hours prior to thermotherapy.
1905779|NCT01439165|Biological|Tetanus Toxoid, Diphtheria Toxoid and Pertussis Vaccine|0.5 mL, Intramuscular
1905780|NCT01439165|Biological|Tetanus and Diphtheria Toxoids Adsorbed For Adult Use|0.5 mL, Intramuscular
1905781|NCT01434732|Procedure|Umbilical Cord Milking|UCM will be performed by the obstetric team by having the delivering obstetrician hold the infant below the mother's introitus at vaginal delivery or below the level of the incision at cesarean section and having the assistant (the second obstetrician) milk about 20 cm of umbilical cord over 2 seconds and repeating two additional times.
1905782|NCT01434732|Procedure|Immediate Cord Clamping|The umbilical cord will be clamped soon after birth without any milking of the umbilical cord.
1964182|NCT01783535|Drug|etoposide|Given IV. Participants who cannot tolerate etoposide may be given etoposide phosphate (Etopophos(R)).
1905784|NCT01434355|Other|laboratory biomarker analysis|Correlative studies
1905785|NCT01434355|Other|questionnaire administration|Ancillary studies
1964183|NCT01783535|Drug|cyclophosphamide|Given IV.
1964184|NCT01783535|Drug|MESNA|Given IV before CYCLO and at 3, 6 and 9 hours after CYCLO.
1905788|NCT01425086|Device|Embrace, PCM, warming blanket|"Infant will be placed on a blanket that encloses the Embrace device, The infant will be wrapped in this blanket to create a snug, comfortable and warm micro-environment."
1964185|NCT01783535|Drug|doxorubicin|Given IV on Day 1 of Cycles 2, 4 and 6 in Stratum C high-risk.
1964186|NCT01783535|Procedure|enucleation|Eye removal due to advanced disease in Strata C and D participants.
1964187|NCT01783535|Radiation|external beam radiation or proton beam radiation|EBRT or proton beam radiation will be administered to any eye in which the disease is considered to be not controllable with focal treatments alone, and in participants with enucleated eyes in which high risk of orbital and/or central nervous system disease is documented histologically (high-risk group with disease extension beyond the sclera or cornea, or beyond the cut end of the optic nerve). EBRT will be administered using standard techniques practices with the objective of limiting dose to normal tissues including the hypothalamic-pituitary unit, supratentorial brain, orbit, cochleae and contralateral eye when indicated. Participants will be evaluated on an individual basis to determine whether they might benefit from referral for proton therapy.
1905793|NCT01390948|Drug|Bevacizumab|10 milligrams per kilogram every 2 weeks during the study for up to 12 cycles, each cycle length of 28 days
1905794|NCT01390948|Radiation|Radiotherapy|Total dose of 54 Grey (Gy) units delivered in 30 daily fractions of 1.8 Gy over 6 weeks during the chemoradiation phase.
1905795|NCT01390948|Drug|Temozolomide (TMZ)|75 milligrams per square meter (mg/m^2) daily continuous starting concomitantly with the first radiation fraction and ending with the last radiation fraction for a maximum number of treatment days = 49 days. During the TMZ adjuvant treatment phase and for participants from YPC: TMZ (150 to 200 mg/m^2/day) x 12 cycles, 1st cycle 150 mg/m^2/days 1-5, escalated to 200 mg/m^2 on Days 1-5 from Cycle 2 onwards depending on the tolerance during the 1st cycle. Cycle length = 28 days.
1905796|NCT01383928|Drug|IXAZOMIB + Lenalidomide + Dexamethasone|"Ph 1: Patients will receive escalating doses of IXAZOMIB orally on Days 1,4,8&11; plus dexamethasone orally on Days 1,2,4,5,8,9,11&12 at 20mg in Cycles 1-8/10mg in Cycles 9-16 & lenalidomide 25mg orally on Days 1-14 of a 21-day cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients who have stable or responding disease will continue treatment in the maintenance therapy portion of the study.
Ph 2: Patients will receive IXAZOMIB orally at the maximum tolerated dose or recommended phase 2 dose on Days 1,4,8,11, plus dexamethasone orally on Days 1,2,4,5,8,9,11&12 at 20mg in Cycles 1-8/10mg in Cycles 9-16 and lenalidomide 25mg orally on Days 1-14 of a 21-day cycle. Treatment repeats every 21 days for up to 16 cycles in the absence of disease progression or unacceptable toxicity. Patients with stable or responding disease will continue treatment in the maintenance therapy portion of the study."
1905804|NCT01365169|Device|Smart phone|Answer questions sent by the phone . Some participants will video-record swallowing exercises or device usage.
1905805|NCT01365169|Device|Accelerometers|These devices are worn on a belt around the waist, and record activity.
1905806|NCT01365169|Device|Blood Pressure Monitor|This device is used at home to measure blood pressure and pulse rate.
1905807|NCT01365169|Other|Telephone Surveys|On days 1, 3, and 6 of each 5-day sensor usage period, study personnel will call participants to ascertain functionality, acceptability, and overall satisfaction regarding use of sensing devices.
1905808|NCT01365169|Other|Home Visit|For the first 10 patients enrolled in the trial, a home visit to be made on day 2, to ascertain if there were any problems related to home set-up.
1905809|NCT01365169|Device|Home Health Hub and Modem|These devices collect data from other home devices, and send this data (over the internet) to study researchers.
1905810|NCT01365169|Device|Carbon Monoxide (CO) Monitor|This device captures the CO level expelled in one breath.
1905811|NCT01365169|Device|Heat Rate Monitor|This device is worn on a chest strap, and measures heart rate.
1905812|NCT01365169|Device|Global Positioning System (GPS) Device|This device describes location on a map, but not location within a building.
1905813|NCT01365169|Other|Surveys|After training about each device, completion of a survey about that training.
1905814|NCT01365169|Device|Weight Scale|Weight scale will monitor weight.
1905815|NCT01365169|Device|Fitbit Monitor|Participants wear a Fitbit monitor on wrist all day and night starting from the day they receive the monitor (up to 4 weeks before surgery) until final study visit (3-7 months after surgery).
1905816|NCT01365169|Behavioral|At-Home Exercise Program|Participants participate in a walking program and strengthening exercise program at home guided by a rehabilitation specialist.
1905817|NCT01365169|Behavioral|Physical Fitness Tests|Participants strength checked using a hand-held grip test. Walking speed will be checked with a 6-minute walking test. Tests to check your balance, walking speed, and ability to stand from a seated position also performed. Tests to be done 3 times: (1) before surgery, (2) 4-7 weeks after surgery, and (3) 3-7 months after surgery.
1905818|NCT01365169|Behavioral|Questionnaires|"Questionnaires completed about physical ability, health, and quality-of-life 3 times: (1) before pancreatic surgery, (2) 4-7 weeks after surgery, and (3) 3-7 months after surgery. About 1 week after participant leaves the hospital for surgery, participant again completes the physical ability and quality-of-life questionnaires. Participant to re-take the quality-of-life questionnaire 7-10 days after each of the 4 time-points noted above. This will take about 7-10 minutes each time.
Participant completes a questionnaire about the usefulness of the devices used at home. Questionnaires completed 2 times: the first will be 1 week after starting using the weight scale and the second will be 3-7 months after surgery."
1905819|NCT01365169|Behavioral|Lean Body Mass Assessment|If computerized tomography (CT) scans are performed as part of routine medical care, the study staff will look at 3 of those scans to estimate participant's lean body mass. If available, the study staff will also look at CT scans at 3 time points: before surgery, at about 4-7 weeks after discharge from hospital for that surgery, and 3-7 months after surgery.
1905821|NCT01361724|Behavioral|Physical therapy|Physical therapy program for people with PD--one on one with a PT
1905823|NCT01361724|Behavioral|Home Program|The participant will meet one time with a physical therapist and will be given a home program--which is standard of care--to follow for 4 weeks.
1964198|NCT01769573|Biological|RG-HRV16|A suspension of the RG-HRV16 virus in Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin
1964199|NCT01769573|Drug|Placebo|The placebo to be used will be Minimal Essential Media (MEM, HyClone) containing 0.1% Human Serum Albumin. Placebo will be supplied in 2 ml borosilicate glass vials sealed with butyl stoppers containing 0.5 ml.
1964200|NCT01769209|Drug|bortezomib|Given SC
1964201|NCT01769209|Drug|doxorubicin hydrochloride|Given IV
1964202|NCT01769209|Drug|pegaspargase|Given IV or IM
1964203|NCT01769209|Drug|vincristine sulfate|Given IV
1964204|NCT01769209|Drug|dexamethasone|Given PO
1964205|NCT01769209|Drug|cytarabine|Given IT
1964206|NCT01769209|Drug|methotrexate|Given IT
1964211|NCT01767194|Biological|Dinutuximab|Given IV
1964212|NCT01767194|Drug|Irinotecan Hydrochloride|Given IV
1964213|NCT01767194|Other|Laboratory Biomarker Analysis|Optional correlative studies
1964214|NCT01767194|Biological|Sargramostim|Given SC or IV
1964215|NCT01767194|Drug|Temozolomide|Given PO
1964216|NCT01767194|Drug|Temsirolimus|Given IV
1905849|NCT01325441|Drug|BBI608|
1905850|NCT01325441|Drug|Paclitaxel|
1964224|NCT01762943|Drug|Leuprolide Acetate|All subjects will receive one IM injection (3.75 mg) each month for four months.
1964225|NCT01762943|Drug|Micronized estradiol|All participants will receive micronized estradiol daily for eight weeks. Estradiol will be started at a dose of 4 mg/day and increased progressively up to 10 mg/day.
1964226|NCT01762943|Drug|Progesterone|All subjects will receive micronized progesterone daily for eight weeks. Progesterone will be started at 400 mg/day and increased progressively up to 800 mg/day.
1964227|NCT01760915|Other|NC100182 Hyperpolarized 3He|Magnetic Resonance Imaging (MRI) will take place and include inhalation of hyperpolarized helium to construct an image of the lungs.
1964231|NCT01751412|Radiation|Proton Radiation|
1964233|NCT01749514|Drug|ACE-536|Subjects receive ACE-536 administered subcutaneously (SC) every 3 weeks for up to 5 cycles.
1964236|NCT01741363|Other|FIT(Eiken OC-Sensor) Two-day sampling|Collect two stool samples in two separate days
1964237|NCT01741363|Other|FIT(Eiken OC-Sensor) One-year interval|Screening with one-year interval
1905866|NCT01281956|Drug|PRX-00023|selective 5HT1A agonist or placebo
1964238|NCT01741363|Other|FIT(Eiken OC-Sensor) One-day sampling|One-day sampling
1964239|NCT01741363|Other|FIT(Eiken OC-Sensor) Two-year interval|Screening with two-year interval
1964240|NCT01741363|Other|HpSA (Firstep Helicobacter pylori Antigen Rapid Test)|HpSA for detection of upper gastrointestinal diseases; screen and treat for H. pylori infection. Upper endoscopy for H. pylori carriers. HPSA+FIT compared with FIT alone.
1905878|NCT01254929|Device|F-18 PET bone scan|Following the intravenous administration of approximately 10 mCi F-18, subjects will undergo an F-18 PET bone scan.
1905879|NCT01254929|Device|Tc-99m bone scan|Following the intravenous administration of approximately 30mCi Tc-99m MDP, subjects will undergo a traditional bone scan on a gamma camera.
1905880|NCT01252095|Drug|PG545|PG545 Lyophilized Powder for Subcutaneous Injection. Patients will be dosed once weekly until they exhibit disease progression, are discontinued for reasons of tolerability, or the study reaches its defined end-point. This study is a dose escalation study with doses of 25 mg to 500 mg planned.
1905881|NCT01244477|Behavioral|Group CPT-C|Participants will be randomly assigned to participate in CPT-C or a 12 week waitlist control group. Waitlist control subjects will participate in CPT-C after the 12 weeks.
1905882|NCT01243606|Behavioral|Single Diagnosis Treatment Protocol|SDPs include: Managing Social Anxiety: A CBT Approach; Mastery of Anxiety and Panic-IV; Mastery of Anxiety and Worry-II; and Obsessive-Compulsive Disorder: A CBT Approach
1905883|NCT01243606|Behavioral|Unified Protocol (UP)|The UP is designed to help patients learn how to confront and experience uncomfortable emotions and learn how to respond to their emotions in more adaptive ways. Individual treatment sessions will be conducted by experienced clinicians who will be trained in the administration of this protocol. A workbook will be provided to each patient as part of this manualized treatment. Treatment and session length of the UP will be matched to the SDPs for each principal diagnosis (see description above).
1905884|NCT01225887|Drug|Nintedanib|Given PO
1905907|NCT01190943|Genetic|DNA methylation analysis|
1905908|NCT01190943|Genetic|RNA analysis|
1905909|NCT01190943|Genetic|comparative genomic hybridization|
1905910|NCT01190943|Genetic|gene expression analysis|
1905911|NCT01190943|Genetic|microarray analysis|
1905912|NCT01190943|Genetic|mutation analysis|
1905913|NCT01190943|Other|laboratory biomarker analysis|
1905915|NCT01180049|Drug|temsirolimus|175mg IV once a week for first 3 weeks, followed by 75mg IV once a week until disease progression, provided that patient is tolerating treatment and getting clinical benefit
1905916|NCT01180049|Drug|temsirolimus|75mg IV once a week until until disease progression, provided that patient is tolerating treatment and getting clinical benefit
1905917|NCT01176604|Device|TheraSphere Treatment|Injection via arterial catheter of TheraSphere microspheres containing yttrium-90 (Y-90) to whole liver, lobar or segmental treatment delivered as a sequence of treatments using approximately 30 - 90 days apart.
1906182|NCT00132964|Device|Removable ankle brace|not required
1905924|NCT01148225|Drug|adalimumab|"This study is a Phase 3, open-label multicenter study designed to evaluate long-term safety and efficacy of adalimumab in adult subjects with non-infectious intermediate-, posterior-, or pan-uveitis who have either discontinued from study M10-877 or M10-880 for having met Treatment Failure criteria or have successfully completed study M10-877 or M10-880."
1905927|NCT01126840|Behavioral|Telephone Interview|The phone interview should take 30-45 minutes to complete.
1905928|NCT01126840|Behavioral|Questionnaire|Mailed questionnaire that contains questions about experiences living with colorectal cancer, take 45-60 minutes to complete.
1905929|NCT01117779|Device|Cryoablation|Cryoablation (freezing) with Galil Medical cryoablation systems and needles under imaging guidance
1905930|NCT01114542|Drug|insulin degludec|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
1905931|NCT01114542|Drug|insulin glargine|Subjects were randomised to one of three possible dose levels (low, middle or high) and to one of two treatment sequences. A treatment sequence consisted of 2 periods of each 13 days. One dose once daily. The trial products were administered subcutaneously (under the skin)
1905940|NCT01065974|Behavioral|Behavior Therapy|Weight loss using CBT and continued CBT during weight loss maintenance.
1905941|NCT01065974|Dietary Supplement|Meal Replacements|Weight loss using CBT and meal replacements.
1905942|NCT01065974|Behavioral|Nutritrol|To make widespread nutritional changes to participants personal food environments.
1905943|NCT01064921|Drug|vorinostat|The first vorinostat dose level is 100mg, and the second dose will be 200mg, third dose will be 300mg. If the first vorinostat dose level is found to be excessively toxic, the patient will be reduced to -1 dosing level then if still too toxic reduced again to dose level -2. Dose escalation of vorinostat will continue in increments of 100 mg (i.e., 200 mg on dosing days, 300 mg on dosing days). Vorinostat will be given 3 consecutive days per week (e.g. Monday, Tuesday, Wednesday).
1905944|NCT01064921|Drug|cisplatin|Given IV
1905945|NCT01064921|Radiation|radiation therapy|Standard chemoradiation therapy X 7 weeks (Days 7-56), concurrent with oral Vorinostat given three days per week (Mon, Tues, Wed)
1905946|NCT01064921|Procedure|Correlative Studies|Day 35, 2 weeks post radiation therapy completion optional tumor/normal muscosal biopsy and blood draw for correlative studies. At day 153 an optional tumor/normal tissue biopsy and blood draw for correlative studies.
1905949|NCT01060774|Drug|Lidocaine|Up to 5 capsules of 2% lidocaine with epinephrine as a reinforcement drug post-operatively
1905950|NCT01060774|Drug|Bupivacaine|Up to 5 capsules of 0.5% Bupivacaine with epinephrine given post-operatively.
1964276|NCT01705106|Drug|capecitabine|Given PO
1964277|NCT01705106|Drug|celecoxib|Given PO
1964278|NCT01705106|Other|pharmacological study|Correlative studies
1964279|NCT01705106|Other|laboratory biomarker analysis|Correlative studies
1964280|NCT01705106|Other|pharmacogenomic studies|Correlative studies
1905966|NCT01010217|Drug|Cyclophosphamide|50 mg/kg/day intravenous (IV) over 3 hours on Days 3 and 4.
1905967|NCT01010217|Drug|Fludarabine|40 mg/m^2 IV over 1 hour on Days -6, -5, -4, and -3.
1905968|NCT01010217|Drug|Melphalan|140 mg/m^2 IV (or 100 mg/m^2 with reduced intensity Regimen 2) over 30 minutes on Day -8.
1905969|NCT01010217|Drug|Mesna|10 mg/kg IV every 4 hours for a total of 10 doses starting just prior to first dose of Cyclophosphamide on Days 3 and 4.
1905970|NCT01010217|Drug|Rituximab|CD20+ lymphoid malignancies: 375 mg/m2 on Day -13 followed by 1000 mg/m2 on Day -6, +1, and +8.
1905971|NCT01010217|Procedure|Stem Cell Transplantation|Infusion of donor's stem cells by vein on Day 0, may last anywhere from 15 minutes to several hours.
1905972|NCT01010217|Drug|Thiotepa|5 mg/kg Regimen 1 (or 5 mg/kg with reduced intensity Regimen 2) IV over 4 hours on Day -7.
1905973|NCT01010217|Drug|Tacrolimus|0.015 mg/kg by vein or orally daily starting on Day +5 for 3 months
1905974|NCT01010217|Drug|Mycofenolate mofetil|15 mg/kg/dose orally three times a day starting on Day +5 to Day +100 or otherwise indicated
1905975|NCT01010217|Drug|G-CSF|5 mcg/kg/day subcutaneously starting Day 7 once a day daily until neutrophil recovery > 1000/mcl.
1905976|NCT01005277|Genetic|gene expression analysis|
1905977|NCT01005277|Genetic|microarray analysis|
1905978|NCT01005277|Genetic|polymorphism analysis|
1964291|NCT01696721|Other|No intervention|
1905990|NCT00989794|Device|GelrinC|Applied once during surgery
1905992|NCT00966446|Drug|Unsupervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member.
1905993|NCT00966446|Drug|Supervised Decolonization|Households will undergo decolonization for MRSA with Mupirocin nasal ointment and Hibiclens body wash. This means that the intervention includes applying Mupirocin ointment twice daily in each nostril for the first 7 days of study enrollment as well as using Hibliclens body wash twice total (on day 1 and day 7 of study enrollment) according to the instructions provided. Households are given detailed, written instructions and are asked to fill out logs tracking compliance for each household member. In addition, households are contacted by study stuff via phone or text messages to ensure complicane, to provide reminders to household members to perform the decolonization protocol as well as to answer any question/concerns household members may have.
1905994|NCT00961324|Drug|insulin degludec|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
1905995|NCT00961324|Drug|insulin glargine|The dose level will be 0.4 units per kg body weight injected subcutaneously (under the skin) once daily for 12 days
1905996|NCT00953225|Drug|vitamin D3|4,000 IU daily for one year
1905997|NCT00953225|Drug|Placebo daily for one year|Placebo
1964294|NCT01692730|Behavioral|Enhanced Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and some combination of novel interactive and social network features, including a variety of better-practice features recommended recent literature, and technologically advanced proactive features (e-mails, SMS texting, and social networking).
1964295|NCT01692730|Behavioral|Basic Web Assisted Tobacco Intervention|Subjects at community college campuses will be directed to a cessation website with current Public Health Service Guideline information and effective smoking cessation strategies, and with minimal interactive web-based features.
1906005|NCT00903409|Drug|Simvastatin + Lovaza® (omega-3-acid ethyl esters)|Open-label Simvastatin + Lovaza® (omega-3-acid ethyl esters) [formerly known as Omacor]
1906007|NCT00892775|Biological|Priorix-Tetra TM (combined measles-mumps-rubella-varicella vaccine)|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
1906008|NCT00892775|Biological|GSK Biologicals' 208136, new formulation|Vaccine will be administered subcutaneously in the left upper arm (deltoid region)
1906009|NCT00878709|Drug|neratinib|
1906010|NCT00878709|Other|placebo|
1964301|NCT01688843|Device|INGEVITY lead|
1906017|NCT00855140|Other|Acupuncture|Acupuncture, derived from the TCM literature, specific for insomnia
1906018|NCT00848744|Drug|Formulation A|Formulation A will be applied to the randomly-assigned single (left or right) side of the face twice daily.
1906019|NCT00848744|Drug|Formulation B|Formulation B will be applied to the randomly-assigned single (left or right) side of the face twice daily.
1906023|NCT00842153|Drug|Clobetasol propionate foam|Topical Clobetasol propionate foam
1906024|NCT00842153|Drug|Vehicle foam|Vehicle foam does not include the active drug.
1906025|NCT00833859|Drug|GTX (gemcitabine, docetaxel and capecitabine)|GTX: 21 day cycle x 2 Gemcitabine 750mg/m2 on days 4 and 11 Taxotere® (docetaxel) 30 mg/m2 on days 4 and 11 Xeloda® (capecitabine) 750 mg/m2 on days 1-14
1906026|NCT00833859|Radiation|stereotactic body radiation therapy|stereotactic body radiation therapy (SBRT) 25
1906037|NCT00793611|Behavioral|Behavioral therapy standard of care|controls will receive usual interventions for overactive bladder: voiding diary, bladder drills, pelvic floor exercises
1906038|NCT00793611|Other|hypnotherapy|Patients will receive 3 hypnotherapy sessions in addition to usual behavioral treatment of overactive bladder
1906039|NCT00785876|Other|LRAR Implementation|"Pre-LRAR - no changes in the usual procedures for the first 26 weeks except for flagging of all paediatric charts with ankle injuries, ED documentation which will not refer to the LRAR and phone follow up.
Post-LRAR: At 27 weeks, in addition to the aforementioned ED collection sheet and phone follow up, the implementation strategy for the LRAR rule and related management will be introduced at the intervention hospitals."
1964322|NCT01672944|Other|TBCCN-developed educational materials|Participants will be asked to view the educational materials developed by TBCCN, in either English or Spanish depending on the RCT in which they are enrolled. These materials include a DVD and a booklet that were developed to enhance community members' understanding and awareness of biospecimen collection and biobanking from healthy individuals.
1906052|NCT00730613|Biological|therapeutic autologous lymphocytes|Cycles of escalating cell dose infusions up to the target cell dose of 10(8)
1906053|NCT00730613|Genetic|gene expression analysis|At the time of excess pathology samples documenting response/relapse
1906054|NCT00730613|Other|laboratory biomarker analysis|CSF generated at the time of each T-cell dose
1964323|NCT01672944|Other|NCI-developed educational materials|"Participants will be asked to view the English biobanking educational Brochure entitled Providing your Tissue for Research: What you need to Know, or Spanish brochure entitled Lo que usted debe saber antes de dar sus tejidos para investigación médica."
1906057|NCT00720096|Drug|Liposomal Doxorubicin|Liposomal Doxorubicin 40 mg/m2 q 28 days
1906058|NCT00720096|Drug|Topotecan|"Topotecan (daily x 5 days of a 21 day cycle)
Per amendment #15: Topotecan (days 1, 8, 15 of a 28 day cycle)"
1906059|NCT00718328|Drug|Simvastatin 80 mg|Patients in study arm 1 will receive simvastatin 80 mg once daily for 14 days or until death or discharge.
1906060|NCT00718328|Drug|Placebo|Patients in study arm II will receive placebo once daily for 14 days or until death or discharge.
1964325|NCT01663272|Drug|CABOZANTINIB|Daily oral cabozantinib administered days -7 until disease progression, intolerable adverse event(s) or patient choice.
1906061|NCT00703092|Drug|Fiber-Stat|Liquid fiber supplement, 2 tablespoons twice daily.
1964326|NCT01663272|Drug|gemcitabine|Gemcitabine administered intravenously on days 1, 8, and 15 every 28 days.
1906068|NCT00676052|Drug|GSK233705 12.5mcg|Once daily via dry powder inhaler
1906069|NCT00676052|Drug|GSK233705 25mcg|once daily via dry powder inhaler
1906070|NCT00676052|Drug|GSK233705 50mcg|Once daily via dry powder inhaler
1906071|NCT00676052|Drug|GSK233705 100mcg|Once daily via dry powder inhaler
1906072|NCT00676052|Drug|GSK233705 200mcg|Once daily via dry powder inhaler
1906073|NCT00676052|Drug|Placebo|Once daily via dry powder imhaler
1906074|NCT00667823|Drug|Macitentan|Tablet, oral administration, 10 mg dose once daily
1964336|NCT01658228|Drug|Donepezil|Donepezil 5mg will be given for 6 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg per day is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
1964337|NCT01658228|Drug|Placebo|A placebo capsule will be given to randomized subjects for the starting at week 16 and continuing for the remainder of the study. This group will not receive donepezil as treatment.
1964338|NCT01658228|Drug|Citalopram|Citalopram tablet will be given to subjects during an 8 week flexible dosing open treatment. If subjects respond to citalopram treatment they will be randomized to add-on donepezil/placebo.
1906082|NCT00619983|Drug|donepezil|Group 1: Will receive donepezil 5mg once a day
1906083|NCT00619983|Drug|duloxetine|Group 2: Will receive duloxetine 30 mg twice a day
1906084|NCT00619983|Drug|donepezil 2.5 mg and duloxetine 30mg|Group 3: Will receive a combination of donepezil 2.5 mg and duloxetine 30mg
1906085|NCT00619983|Drug|placebo|Group 4: Will receive placebo pills
1906086|NCT00619983|Drug|gabapentin|Week 8: all subjects will have open label gabapentin added to their randomized study medication
1906087|NCT00610220|Device|Fiberglass short arm cast|Cast will be applied for a 4-week period
1906088|NCT00610220|Device|Prefabricated wrist splint|Splint will be applied for a 4-week period
1964339|NCT01658228|Drug|Venlafaxine|Venlafaxine tablet will be given to subjects during an 8 week flexible dosing open treatment if they did not respond to citalopram. If subjects respond to venlafaxine treatment they will be randomized to add-on donepezil/placebo.
1906092|NCT00598806|Drug|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
1906093|NCT00598806|Drug|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
1906094|NCT00598806|Procedure|TURBT|TransUrethral Resection of the Bladder Tumor
1906101|NCT00575159|Drug|GSK189075|investigational drug
1906102|NCT00575159|Drug|placebo|placebo comparator
1906110|NCT00501020|Drug|Rosiglitazone|
1906119|NCT00476190|Drug|Doxorubicin|Induction: Intravenously on days 4 and 5. Consolidation 1A: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously day 1 of each cycle.
1906120|NCT00476190|Drug|Cytarabine|Prophase: Intravenously on days 1-3. Induction: Intrathecal on days 15 or 18. Consolidation IB: Intravenously or subcutaneous on days 2-5 and 9-12. Consolidation IC: Intravenously every 12 hours starting on day 1 CNS Therapy: Intrathecal 4 times over 2 weeks. Consolidation II: Intrathecal once every 18 weeks Continuation: Intrathecal every 18 weeks
1906121|NCT00476190|Drug|Methotrexate|"Induction: Intravenously on day 6 and intrathecally on day 29 or 32. Consolidation IA: Intravenously on day 1 and intrathecally on Day 1 (prior to IV).
Consolidation IB: Intrathecally on day 1. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation: Intrathecally once every 18 weeks. Continuation: Intravenously weekly and intrathecally every 18 weeks."
1906122|NCT00476190|Drug|Vincristine|Induction: Intravenously on days 4, 11, 18, 25. Consolidation IA: Intravenously on day 1. CNS Therapy: Intravenously on day 1. Consolidation II: Intravenously on day 1 of each cycle.
1906123|NCT00476190|Drug|Cyclophosphamide|Consolidation IB: Intravenously on day 1
1906124|NCT00476190|Drug|Methylprednisone|Prophase: Intravenously on days 1-3
1906181|NCT00132964|Device|Below knee walking cast|Not required
1906125|NCT00476190|Drug|Hydrocortisone Sodium Succinate|Induction: Intrathecally on day 15 or 18. CNS Therapy: Intrathecally 4 times over 2 weeks. Consolidation II: Intrathecally once every 18 weeks. Continuation: Intrathecally every 18 weeks.
1906126|NCT00476190|Drug|Dexamethasone|Consolidation IC: Orally on days 1-5 twice per day. Consolidation II: Orally on days 1-5 of each cycle. Continuation: Orally on days 1-5 of each cycle.
1906127|NCT00476190|Drug|6-MP|Induction: Orally on days 3-43 or 33-46. Consolidation IA: orally on days 1-14. Consolidation IB: orally on days 1-14. CNS Therapy: Orally on days 1-14. Consolidation II: Orally on days 1-14. Continuation: Orally on days 1-14 of each cycle.
1906128|NCT00476190|Drug|PEG-Asparaginase|"Consolidation IC: Intravenously every 3 weeks, starting on day 8. CNS Therapy: Intravenously every 3 weeks, starting 3 weeks after the Consolidation IC dose.
Consolidation II: Intravenously every 3 weeks."
1906129|NCT00476190|Drug|Imatinib|Used for PH+ ALL subjects enrolled prior to May 1st 2011 only and is used continuously throughout every phase of treatment.
1906130|NCT00476190|Drug|Etoposide|Consolidation IC: intravenously on days 3, 4 and 5 of this cycle.
1906131|NCT00476190|Procedure|Radiation Therapy|Given during CNS Therapy either 8 or 10 daily treatments, on days 1-8 or 1-10, depending upon leukemia involvement in the CSF
1906132|NCT00476190|Drug|E. coli Asparaginase|Intramuscularly Day 7 of Induction.
1906135|NCT00475020|Drug|Busulfan|Test dose = 32 mg/m^2 by vein x 1 day; 100 mg/m^2 by vein daily over 3 hours x 4 days
1906136|NCT00475020|Drug|Fludarabine|40 mg/m^2 by vein daily over 1 hour x 4 days
1906137|NCT00475020|Drug|Thymoglobulin (ATG)|2.5 mg/kg by vein over 6 hours x 3 days if there is an unrelated or a mismatched donor
1906140|NCT00461591|Drug|Apaziquone|A single intravesical dose of Apaziquone 4mg in 40ml instilled into the bladder post-TURBT
1906141|NCT00461591|Drug|Placebo|A single intravesical dose of placebo instilled into the bladder post-TURBT
1906142|NCT00461591|Procedure|TURBT|TransUrethral Resection of the Bladder Tumor
1906146|NCT00436696|Genetic|gene mapping|
1906147|NCT00436696|Genetic|polymorphism analysis|
1906160|NCT00338338|Drug|Lacidipine 4 or 6 mg (oral)|
1906161|NCT00338338|Drug|Amlodipine 5 or 10 mg(oral)|
1906162|NCT00333723|Drug|Rosiglitazone|
1906171|NCT00306098|Drug|islets|Islet transplantation
1936123|NCT02475317|Drug|LUM001|
1936124|NCT02475317|Drug|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
1936129|NCT02474576|Procedure|Percutaneous aponeurotomy|The finger(s) with limited extension due to Dupuytrens disease and for which the patient desires treatment, will be treated by fine-needle percutaneous aponeurotomy under local anesthesia (outpatient procedure). This procedure is already routinely used in clinical practice ; our study aims at better describing the time-sustainability of its benefits.
1936130|NCT02474329|Other|Clinical assessment|During the 13 week follow-up, trained physiotherapists will perform a standardized clinical assessment, based on the PPMI protocol (www.ppmi-info.ors) for every included patient. This assessment will last for 60 minutes, and it will be done once.
1936131|NCT02474329|Device|Fox Insight self-monitoring android app and falls detector|Patients will be asked to wear a smartwatch and a pendant movement sensor, both with triaxial accelerometers, during day and night, for a period of 13 weeks. Additionally, a self-monitoring App on a Smartphone is used, where the patient reports when (s)he takes any PD medication. An additional, optional button allows the patient to report general feeling.
1936132|NCT02474290|Drug|Sorafenib|The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
1936135|NCT02474069|Drug|Secukinumab|
1936143|NCT02473614|Device|Music Glove|Participants will exercise at home using the music glove for 3 times a week for 3 weeks with a minimal of 3 hours per week.
1936144|NCT02473614|Other|Conventional Hand Exercise Program|Participants will exercise at home using the hand exercise program designed by an occupational therapist for 3 times a week for 3 weeks with a minimal of 3 hours per week.
1936145|NCT02473471|Device|Micro-osteoperforation|Three Micro-osteoperforation (MOPs) will be performed distal to canine by Mini screw. Before the application of the MOPs, Patient will be asked to wash their mouth twice by chorhexidine for 1 minute.
1936540|NCT02398448|Drug|Zyloprim® 300 mg|
1906197|NCT00067873|Behavioral|Diet|
1906198|NCT00067873|Behavioral|Aerobic exercise|
1906199|NCT00067873|Behavioral|Resistance exercise|
1906204|NCT00048204|Drug|GW597599B|
1906205|NCT00048204|Drug|paroxetine|
1906206|NCT00044460|Drug|rosiglitazone|
1906207|NCT00043914|Drug|lamotrigine|
1964374|NCT01624441|Drug|Dinaciclib|Given IV
1964375|NCT01624441|Drug|Epirubicin Hydrochloride|Given IV
1964376|NCT01624441|Other|Laboratory Biomarker Analysis|Correlative studies
1964390|NCT01613768|Drug|eribulin mesylate|Given IV
1988529|NCT02799420|Device|GastroFlex UHD, Cellvizio; Mauna Kea Technologies, Paris, France|The patients who enrolled the pCLE group will undergo endoscopic biopsy using pCLE. The cancerous lesion is observed using probe-based confocal laser endomicroscopy. The biopsy was done at the most suspicious parts of the cancerous lesion.
1988530|NCT02799420|Device|white light endoscopy (WLE)|The patients who enrolled this group will undergo endoscopic biopsy under standard white light endoscopy
1988541|NCT02795455|Behavioral|Interoceptive Exposure (IE)|Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
1988542|NCT02795455|Behavioral|Family Based Therapy-Weight Gain Control (FBT-WG)|Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.
1988543|NCT02795455|Dietary Supplement|meal replacement shake|
1988544|NCT02794571|Drug|Atezolizumab|Atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle in combination with MTIG7192A. Combination treatment may continue until disease progression or loss of clinical benefit.
1988545|NCT02794571|Drug|MTIG7192A|Several dose levels will be evaluated for MTIG7192A administered as a single agent and in combination with atezolizumab. MTIG7192A will be given via intravenous (IV) infusion on Day 1 of each 21-day cycle until disease progression or loss of clinical benefit. Those who discontinue treatment with single-agent MTIG7192A may receive combination treatment with MTIG7192A plus atezolizumab. Combination treatment may continue until disease progression or loss of clinical benefit.
1964396|NCT01609348|Drug|Placebo|Capsule matching active drug to be taken once a day for 12 weeks
1964397|NCT01609348|Drug|Venlafaxine|225 mg daily for 12 weeks
1964415|NCT01602016|Drug|Folinic Acid and placebo|Capsules of folinic acid and placebo will be administered in 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated for 10 weeks.
1964416|NCT01602016|Drug|Folinic Acid|capsules of folinic acis will be provided. The target dose will be 1mg/kg/day in two divided doses (0.5mg/kg/dose; 25mg/day maximum) for two weeks followed by 2 mg/kg/day with a maximum dose of 50mg/day provided the lower dose is well tolerated, for 10 weeks.
1964424|NCT01597037|Behavioral|Script training|90 minutes/day, 6 days a week; includes 3 weeks of training
1988572|NCT02783599|Drug|Olaratumab|Administered IV
1988573|NCT02783599|Drug|Doxorubicin|Administered IV
1988576|NCT02782104|Drug|Intranasal Esketamine|Open-Label Induction Phase: Participants will self-administer with esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 milligram [mg] or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants entering from studies ESKETINTRD3001 (NCT02417064), ESKETINTRD3002 (NCT02418585) or ESKETINTRD3006 (US sites only) will self-administer intranasal esketamine (same dose) once weekly. Participants entering from study ESKETINTRD3005 (NCT02422186) will self-administer Esketamine intranasally (28 mg in week 1; 28 or 56 mg in week 2; and 28, 56 or 84 mg in week 3 and 4) once weekly. After Week 4 (starting at Week 5), based on the Investigator's clinical judgment, the dose of esketamine for all participants can be adjusted based upon efficacy and tolerability.
1964436|NCT01590394|Device|Large plastic biliary stent|Stent placement for bile duct obstruction.
1964449|NCT01580293|Biological|BAY94-9027|Intravenous infusion of BAY94-9027
1939525|NCT01790594|Drug|methylprednisolone|
1964461|NCT01572844|Device|Fractional Carbon Dioxide (FCO2) Laser (Candela QuadraLase (TM))|At each treatment visit, a 2 X 2 cm (+/- 1 cm) area of the target calcinosis lesions will be treated with one pass of the Candela QuadraLase (TM) FCO2 laser. Patients will receive a total of 8-10 treatments over a 6 month period.
1964462|NCT01572844|Drug|Sodium thiosulfate|Following treatment with FCO2 laser, 4 ml of 5% Sodium Thiosulfate solution will be applied to the treatment site only. Subjects will receive a total of 8-10 treatments over a 6 month period.
1992432|NCT03321279|Behavioral|Social Incentive|Participants in the intervention arm will receive social incentives as part of the intervention. See arm descriptions for more detail.
1992433|NCT03321266|Device|Cook Biodesign® Fistula Plug|The Cook Biodesign® Fistula Plug is for implantation to reinforce soft tissue for repair of Anorectal fistulas.
1992434|NCT03321253|Device|Nd: YAG laser posterior capsulotomy|Nd: YAG laser posterior capsulotomy
1992435|NCT03321240|Procedure|visual and quantitative SEEG signal analysis|signal SEEG analysis
1992436|NCT03321240|Procedure|Resective epilepsy surgery procedure|Surgical removal of the epileptogenic brain area
1992439|NCT03321201|Procedure|Cauterization|To ensure the stability of the graft during cuttings, four sealing wraps will be installed, which will be removed after cauterisation is completed. Autograft and conjunctiva will be approximated by surgical forceps and will be cauterized using a bipolar cutter (Erbe ICC 50) with a force 1-3 / 20. Forceps will be released slowly to prevent elevation of the graft. The same procedure will be performed 10 times until graft is well firmed. Graft stability will be checked up with a sponge and additional cauterization will be preformed if needed.
1992440|NCT03321201|Procedure|Fibrin glue|Fiber adhesive (Tissel 1 mL kit4-iu) will be prepared according to manufacturer's instructions. Preparation time will be approximately 10-15 min per kit. Once mixed the fibrin glue is usable up to 4 h. For the purpose of the study preparation of the fibrin glue will be performed by a nurse.
1992441|NCT03321188|Procedure|HIPEC|HIPEC with cisplatin
1992442|NCT03321188|Drug|Carboplatin|Adjuvant IV chemotherapy
1992443|NCT03321188|Drug|Paclitaxel|Adjuvant IV chemotherapy
1992444|NCT03321175|Other|subcutaneous saline irrigation|200 cc saline irrigation
1992445|NCT03321162|Diagnostic Test|scan protocol|Scanning strategy is based on multiple scans. Essentially one CT scan of the patient (usually with a scan appliance). Another CT scan of the model or scan appliance may be required (double scan technique). Such a second CT scan can be replaced by optical scanning of the model and scan appliance (triple scan technique).
1992446|NCT03321149|Other|RiseTx|Participants were given access to the RiseTx application, as well as given a Jawbone, a wrist-worn device that can assess activity patterns throughout the day and provide sensory alerts to stand after prolonged sitting (i.e., ≥30 minutes of sedentary time). The intervention consisted of five phases following initial data collection that comprised of self-regulatory strategies to reduce sitting time and self-monitoring of step counts.
1992453|NCT03321123|Drug|MB-CART19.1|Miltenyi Biotec has established a semi-automated manufacturing process that can be made available to academic settings for systematic exploration of CAR strategies in advanced clinical studies. Closed-system operation, improved robustness, simplified work flows, and reduced labor intensity, while maintaining strict adherence to regulatory guidelines, allows for decentralized manufacturing. In this study, we will explore autologous 2nd generation CD19 CAR T cell products in patients with relapsed and refractory disease incurable with standard therapies.
1992454|NCT03321110|Other|Placebo|Placebo (dextrin)
1992455|NCT03321110|Dietary Supplement|Coenzyme Q10|150 mg or 300 mg
1992597|NCT03319823|Drug|Intensified Thiazide Treatment Group|At 4 weeks of therapy, individuals initially assigned to the Thiazide treatment group whose ambulatory blood pressure recheck showed a sleep systolic blood pressure >120 mm Hg, the investigators will intensify their blood pressure medications by adding on Telmisartan 40 mg and Amlodipine 5 mg. In two week intervals, labs and ambulatory blood pressure will be measured. If the systolic blood pressure >120, then the doses of Telmisartan and Amlodipine will be up-titrated until the sleep systolic blood pressure is <120.
1964493|NCT01549886|Drug|Zevalin Regimen|Day 1 - Rituximab 250 mg/m2 intravenous infusion. Day 8 - Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push
1964494|NCT01549886|Drug|Moxtezafin Gadolinium|"Day 1-4 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 1 only) by Day 1 Rituximab 250 mg/m2 intravenous infusion.
Day 8-11 Motexafin gadolinium 5 mg/kg intravenously once daily, followed in one hour (Day 8 only) by Day 8 Rituximab 250 mg/m2 intravenous infusion, followed 4 hours later by Y-90-Zevalin 0.4 mCi/kg 10-minute intravenous push (0.3 mCi/kg in patients with a platelet count in 100,000/μL to 149,000/μL."
1964501|NCT01529060|Drug|Phenylbutyrate|Dosage of phenylbutyrate powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day, the standard UCD dose studied in our preliminary studies, for 14 days.
1939864|NCT01729897|Drug|Fentanyl|
1964502|NCT01529060|Drug|Placebo powder|Dosage of inactive placebo powder will be 500 mg/kg/day in patients weighing less than 20kg and 10 g/m2/day in larger patients in four divided doses per day for 14 days. Subjects will receive the same amount of powder for each arm of the study.
1906352|NCT03307603|Radiation|yttrium-90 radioembolization|Yttrium-90 will be given as biocompatible resin-based microspheres and will be introduced to the tumor(s) on one side of the liver through a catheter placed in the right or left hepatic artery. The dose of radiation will be determined by a radiologist and will be based on body surface area and tumor burden.
1906353|NCT03307603|Drug|Phase Ib - nivolumab|240 mg intravenously
1906354|NCT03307603|Drug|Phase II - nivolumab|nivolumab will be administered as determined during the phase Ib portion of the study. Nivolumab will be administered on an every 2 week basis for a total of 48 weeks or until disease progression, unacceptable toxicity or discontinuation due to patient/physician preference.
1906362|NCT03307538|Radiation|Stereotactic body radiation therapy|15 fractions of 3-4,5 Gy (risk-adapted)
1906363|NCT03307512|Drug|inhaled human insulin|Dance 501 (Human Insulin Inhalation Solution and Inhaler) will be administered by inhalation
1906364|NCT03307512|Drug|Insulin Lispro (Humalog U-100)|Insulin Lispro (Humalog U-100) will be administered by subcutaneous injection
1906365|NCT03307499|Other|NeoPatch|NeoPatch as an adjunct to foot and ankle tendon revision/repair surgery
1906366|NCT03307473|Behavioral|E6BIKE|During 3 months in a the geographic area of Clermont-Ferrand (France), new e-bike buyers and renters are invited to take part in VELONAPS study before starting to use their e-bike
1906367|NCT03307460|Drug|68Ga-NOTA-AE105|PET/MRI scan
1906368|NCT03307447|Drug|Secukinumab|Secukinumab 300 mg subcutaneous injection
1906428|NCT03306927|Dietary Supplement|Split yellow pea chili|Chili containing split yellow peas
1906429|NCT03306927|Dietary Supplement|Rice chili|Chili containing long grain white rice
1906371|NCT03307421|Other|debriefing without instructor|"The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.
The sequence of scenarios for each binomial will also be determined by randomization."
1906372|NCT03307421|Other|debriefing with instructor|The randomization will focus on the allocation of the debriefing method: group without instructor versus group with instructor (AI). It will be stratified by center and performed before the first simulation session. The randomization will be carried out by the clinical methodology center of the Besançon University Hospital.
1906373|NCT03307408|Other|blood collection|Standard routine practice clinico-biological data will be collected
1906374|NCT03307382|Device|SpyGlass DS Cholangioscopy|SpyGlass DS Cholangioscopy includes a 10 French diameter single use digital cholangioscope and a light source with the digital sensor. During ERCP with cholangioscopic exam, the cholangioscope would be first inserted through the working channel of the duodenoscope and subsequently passed into the bile duct for direct visualization of the bile duct mucosa. The visual impression (VI) of the biliary stricture will be assessed. Tissue acquisition of the biliary stricture will be performed by cholangioscopy directed biopsy (CDBx), and conventional brush cytology with or without intraductal biopsy.
1906377|NCT03307278|Biological|House dust mite|As a stimulant to induce inflammasome activation
1906378|NCT03307265|Device|Personalized weighted jacket|Patients in this group will wear a jacket with weights (1,5 to 2% of the total body mass) strategically placed in order to correct their imbalance.
1906379|NCT03307265|Device|Control jacket|Patients in this group will wear a jacket with weights (200 grams maximum) evenly distributed.
1906380|NCT03307252|Drug|Digoxin|Tablet
1906381|NCT03307252|Drug|Furosemide|Oral solution
1906382|NCT03307252|Drug|Metformin|Oral solution
1906383|NCT03307252|Drug|Rosuvastatin|Film-coated tablet
1906384|NCT03307252|Drug|Verapamil|Film-coated tablet
1906385|NCT03307252|Drug|Rifampin|Film-coated tablet
1906386|NCT03307252|Drug|Cimetidine|Tablet
1906387|NCT03307252|Drug|Probenecid|Tablet
1906390|NCT03307226|Behavioral|Youth Development Accounts (YDA)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development Financial workshops on asset-building, saving and investing in Income Generating Activities (IGAs) Behavioral: Youth Development Accounts (YDA)
1906391|NCT03307226|Behavioral|YDA + Multiple Family Groups (MFG)|Youth Development Accounts (YDA) with 1:1 incentive match rate to be used for education and microenterprise development 12 Financial Management workshops on asset-building, saving and investing in Income Generating Activities (IGAs) 18 Multiple Family Groups sessions focused on strengthening family relationships and mental health
1906392|NCT03307213|Device|BioFreedom™ CoCr Biolimus A9™ stent|Stent implantation
1906393|NCT03307213|Device|BioFreedom™ SS Biolimus A9™ stent|Stent implantation
1906395|NCT03307174|Drug|Bupivacaine|
1906396|NCT03307174|Drug|Fentanyl|
1906397|NCT03307161|Other|osteopathic manual therapy|Investigators board certified in osteopathic manual therapy will use their hands in a non-invasive manner to improve dystonia symptoms
1906398|NCT03307148|Drug|ATRA|Administered orally on D1-15 of each 28 day cycle.
1906399|NCT03307148|Drug|Gemcitabine|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
1906400|NCT03307148|Drug|Nab-paclitaxel|Intravenous Infusion on D1,8 and 15 of each 28 day cycle.
1906401|NCT03307135|Device|Assessment with the MSPMI|Manually applied stretch with the MSPMI installed on the foot and shank at 3 different velocities on 2 positions (knee flexed and extended)
1906402|NCT03307122|Other|Routine Infant Formula 1|Routine infant formula with probiotic
1906403|NCT03307122|Other|Routine Infant Formula 2|Routine infant formula with probiotic and prebiotic
1964533|NCT01506219|Procedure|Geriatrician-performed CGC|Individual disease management and coping was provided using the holistic approach during the face-to-face counselling, where the actual problems, expectations and aims were defined in dialogue with the patient and/or relatives. Afterwards, targeted problem solving with focus on the potentially reversible causes of functional deterioration was established. Finally, medication adjustment was carried out with particular attention to drugs which may lead to iatrogenic functional deterioration, delirium, falls, and malnutrition. Furthermore, the intervention included intravenous antibiotics or blood transfusions (if indicated) conducted by the geriatrician at the rehabilitation units.
1964537|NCT01504737|Other|Aerobic Exercise Training|12 weeks of endurance training, 40 minutes, 3 times per week on ergometer bicycle.
1906404|NCT03307109|Other|Quality of life|Patients will complete two EQ-5D-5L and EQ-5D-3L quality of life questionnaires and will complete an analog visual scale during each of their follow-up visits to the Infectious and Tropical Diseases Department of Croix-Rousse hospital. No visits will be added to complete the questionnaires.
1906407|NCT03307083|Other|Check list FOR (Foundation for Oral Rehabilitation)|the surgeon uses this check list during the pre surgery consultation
1906408|NCT03307070|Behavioral|Cognitive Behavioral Therapy for individuals with TBI|Cognitive Behavioral Therapy for depression that has been adapted for a population who has experienced a moderate to severe Traumatic Brain Injury. This is a 12 week long treatment for depression with weekly visits that challenges negative thoughts and behaviors. This version has been specifically developed for the study to account for specific cognitive needs of individuals who have experienced a moderate to severe TBI.
1906409|NCT03307070|Other|Waitlist Control|Participants will be randomized to a waitlist. They will attend biweekly study sessions for 12 weeks to track progress, but will receive their treatment as usual.
1906413|NCT03307044|Procedure|Laser Therapy|Undergo fractional CO2 laser therapy
1906414|NCT03307044|Other|Questionnaire Administration|Ancillary studies
1906415|NCT03307031|Other|High Volume Group|Performed four weekly session, during 10 weeks with 45 to 55 minutes per session.
1906416|NCT03307031|Other|Low Volume Group|Performed only twice a week, during 10 weeks with 45 to 55 minutes per session.
1906417|NCT03307031|Other|Control Group|Did not exercise, during 10 weeks.
1906418|NCT03307018|Procedure|Postoperative systematic bronchial aspiration.|Postoperative flexible bronchoscopy and systematic bronchial aspiration.
1906419|NCT03307005|Drug|Zolpidem Tartrate|Zolpidem tartrate 5 mg capsule one per night taken for 7 nights
1906420|NCT03307005|Drug|Placebo oral capsule|Placebo capsule one per night taken for 7 nights
1906421|NCT03306992|Behavioral|Personalized Exercise Program|"The PEP intervention involves a combination of home-based exercise as well as in-patient exercise. The exercise modes will include basic transfer and calisthenics mobility, aerobic and resistance exercises and will be performed in various postures (supine, sitting, standing and walking) with variable challenges (level walking, bending, inclines, steps and squatting).
For patients randomized to the Intervention Group (Group 1), the PEP intervention will be personalized, implemented, and modified (based on the patients AM-PAC mobility stage) by a licensed physical therapist in face-to-face meetings (~30-40 minutes). An exercise education manual, specifically developed for this study, will be used by the physical therapist to educate the patients on all aspects of starting and maintaining the exercise intervention."
1906422|NCT03306979|Drug|N Acetylcysteine|Patients will be randomized to receive N Acetylcysteine (NAC) (four 600 mg capsules given as 2 capsules in the morning and 2 capsules in the evening). The initial NAC dosage will be 600mg/day (one 600mg capsule in the morning) for the first week, followed by 1,200 mg/day (one 600 mg capsule in the morning, one 600mg capsule in the evening) for the second week, followed by 1,800 mg/day (two 600mg capsules in the morning, one 600mg capsule in the evening) for third week, followed by 2,400mg/day (two 600mg capsules in the morning, two 600mg capsules in the evening) for the following 21 weeks.
1906423|NCT03306979|Other|Placebo oral capsule|Patients will receive four placebo capsules (lactose-based filler) given as 2 capsules in the morning and 2 capsules in the evening, which will be prepared to mimic the weight of the experimental capsules.
1906424|NCT03306966|Device|Endoscopic Linear Cutter Stapler (Fengh Medical)|The Endoscopic Linear Cutter Stapler and 45/60 mm reloads from Fengh Medical received CE-mark in September 2013 and is a class IIb device. It is used to staple and simultaneously divide tissue from the central line.
1964538|NCT01504737|Other|Physical Activity Recommendations|Written and verbal information on minimal level of physical activity recommended.
1906427|NCT03306927|Dietary Supplement|Whole yellow pea chili|Chili containing whole yellow peas
1939865|NCT01729897|Drug|Propofol|
1996847|NCT02345772|Drug|Trastuzumab (H, 8mg/kg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
1996848|NCT02345772|Drug|Pertuzumab (P, 840 mg|Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent cycles before and after surgery), pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery.
1996849|NCT02344576|Behavioral|DT LVAD Decision Support Intervention|Decision coaching and training of staff prior to intervention, to allow for additional decision support to patients and caregivers considering DT LVAD. Decision aid materials will be used with patients and caregivers.
1906436|NCT03306888|Other|Physical Activity Coaching|Physical activity coaching over 4 months
1906437|NCT03306875|Behavioral|Cognitive Training|Individuals will take part in a computer-based cognitive training program. The program is aimed at building attention, processing speed, memory, and executive function.
1906438|NCT03306862|Dietary Supplement|Whole yellow pea soup|Soup containing whole yellow peas
1906439|NCT03306862|Dietary Supplement|Split yellow pea soup|Soup containing split yellow peas
1906440|NCT03306862|Dietary Supplement|Potato soup|Soup containing potatoes
1906441|NCT03306836|Drug|Heparin Sodium|Infused with 5000 IU of Heparin Sodium
1906442|NCT03306836|Drug|Heparin Sodium|Infusion Heparin Sodium at a rate of 18 IU / kg.h
1906443|NCT03306810|Other|AG service|The AG service group is divided to two 200 patients groups: 1) with AGS 2) with AGS extended to first control in 3 months (AG- nurse may be contacted by phone). Patients are followed up up to 5 years.
1906444|NCT03306797|Other|STANDARD REHAB|"The rehabilitative standard intervention (Occupational Therapy) consists of 15 minutes of warm-up exercises plus a 20 minutes training with at least 6 exercises selected from:
wrist
ulnarization radialization
prono-supination
horizontal flexion-extension
vertical flexion-extension hand
grasping
pinching
extensors
interosseous shoulder-elbow
vertical flexion-extension
push forward"
1906445|NCT03306797|Device|SONICHAND|"The intervention is similar to the standard protocol (15 minutes of warm-up plus 20 minute of training) but involves the sonification of the exercises selected from the list. The Leap Motion Controller is managed with an ad-hoc developed application that is able to associate the movements with a 4 notes arpeggio or with a modulated texture.
With the first mode the movement produces and modulates an harmonic progression built on the consecutive grades of the major scale played as ascending and descending arpeggio with also a volume crescendo and decrescendo.
With the second mode, the movement modulates the volume and the low-pass cutoff frequency of a synthetic texture."
1906446|NCT03306784|Other|questionnaires|questionnaires, including RAPID3 and pain catastrophizing scales
1906447|NCT03306771|Diagnostic Test|Ultrasound Duplex|The two groups will have Ultrasound Duplex before bariatric surgery, and 6,12 and 24 months post surgery
1906448|NCT03306758|Drug|Sodium Bicarbonate|Sodium Bicarbonate was given 1g tid for one month
1906449|NCT03306745|Dietary Supplement|Profertil female|"For micronutrient ngredients please see details above. PROfertil ® female is approved in Austria by the Austrian Ministry of Health and has a Free Sales Certificate."
1906450|NCT03306745|Dietary Supplement|Folic acid 400 microgramm|Folic acid 400 microgramm
1906453|NCT03306719|Biological|Blood sampling|Serial blood sampling
1906454|NCT03306706|Dietary Supplement|Whole pea muffins|2 muffins containing whole peas
1906455|NCT03306706|Dietary Supplement|Split pea muffins|2 muffins containing split peas
1906456|NCT03306706|Dietary Supplement|Wheat muffins|2 muffins containing wheat
1906457|NCT03306238|Procedure|Open approach to port insertion|This involves the peritoneum being cut down, followed by the insertion of a blunt trocar under direct visualisation, gas insufflation, and insertion of the laparoscope
1906458|NCT03306238|Procedure|Closed approach to port insertion|This involves the insertion of a Veress needle (a needle equipped with a spring-loaded obturator) into the peritoneal cavity, followed by gas insufflation (act of blowing) and insertion of a trocar (a sharp, pointed instrument with a cannula used to enter the body cavity).
1906459|NCT03306680|Radiation|SBRT|Patients will be assigned to treatment doses using the TITE-CRM model.
1906460|NCT03306667|Drug|FYU-981|Oral single dosing
1906463|NCT03306615|Drug|Hyaluronidase|1200 units (8 vials) of HYLENEX recombinant, will be diluted with 8 ml of 0.9% Sodium Chloride Injection, USP - Preservative-Free, Diluent in a 1:1 ratio (total volume = 16 mL) and dispensed in two 10 ml syringes (8ml in each syringe) for intramuscular injection.
1906464|NCT03306615|Drug|Placebo|The placebo will consist of 16 ml of 0.9% Sodium Chloride Injection, USP - Preservative-Free, also dispensed in two 10 ml syringes for intramuscular injection. The label will include a statement that the product is limited to investigational use, and the original drug containers will be retained.
1906465|NCT03306602|Device|Filtek Bulk Fill Posterior Restorative|Filtek™ Bulk Fill Posterior Restorative is a one-step bulk placement solution for fast and easy posterior resin restorations.
1906466|NCT03306602|Device|Filtek Z350 XT|Filtek Z350XT is a material for incremental layered composite resin restorations
1906467|NCT03306589|Biological|Cantharidin|5 microliter (µL) of 0.2 percent Cantharidin solution (diluted in acetone) will be applied to all subjects on forearm by topical route.
1906468|NCT03306589|Biological|Lipopolysaccharide|0.5 to 4 ng/kg body weight of LPS formulated as suspension in normal saline will be administered to randomized subjects via intravenous (IV) route in dose-escalation manner.
1906469|NCT03306589|Biological|Granulocyte-Macrophage Colony-Stimulating Factor|5 to 15 µg/kg of GM-CSF will be administered to randomized subjects via subcutaneous (SC) route in the abdominal region in dose-escalation manner.
1996850|NCT02343718|Drug|Vinblastine|
1996851|NCT02343718|Drug|Temsirolimus|
1906470|NCT03306589|Drug|Saline Solution|0.9 percent sodium chloride will be administered via IV route to all subjects at a rate of 250 mL/hour for 4 hours prior to dosing with LPS and 8 hours after dosing with LPS.
1906474|NCT03306550|Drug|salvianolate injection|The main ingredient of salvianolate injection is salvianolic acid B(SAB) which is extracted from the root of red salvia. Red salvia is used in traditional Chinese Medicine. It could promote blood circulation to removing blood stasis,which is clinically effective in treatment for cardiovascular disease.
1906475|NCT03306550|Drug|Aspirin Tablet|Anti-platelet medicine treatment and Chinese traditional medicine (TCM) promoting blood circulation to removing blood stasis is widely used in treatment for cardiovascular disease.
1906476|NCT03306537|Device|RespiraSense Respiratory Rate Monitor|RespiraSense device will be attached at the same time as the capnograph (gold standard) and both will measure simultaneously for one hour
1906477|NCT03306524|Device|SIPPV_VG_0_08|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.08 seconds, inspiratory time of 0.40 seconds for 15 minutes
1906478|NCT03306524|Device|SIPPV_VG_0_16|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.16seconds, inspiratory time of 0.40 seconds for 15 minutes
1906479|NCT03306524|Device|SIPPV_VG_0_24|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.24 seconds, inspiratory time of 0.40 seconds for 15 minutes
1906480|NCT03306524|Device|SIPPV_VG_0_32|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.32 seconds, inspiratory time of 0.40 seconds for 15 minutes
1906481|NCT03306524|Device|SIPPV_VG_0_40|Mechanical ventilation using SIPPV-VG ventilator mode with a slope time of 0.40 seconds, inspiratory time of 0.40 seconds for 15 minutes
1906482|NCT03306524|Device|PSV_VG_0_08|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.08 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
1906483|NCT03306524|Device|PSV_VG_0_16|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.16 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
1906484|NCT03306524|Device|PSV_VG_0_24|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.24 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
1906485|NCT03306524|Device|PSV_VG_0_32|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.32 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
1906486|NCT03306524|Device|PSV_VG_0_40|Mechanical ventilation using PSV-VG ventilator mode with a slope time of 0.40 seconds, maximum inspiratory time of 0.60 seconds for 15 minutes
1906487|NCT03306511|Other|Repeated-sprint test|6x30-meter sprint interspersed with 90-s rest
1906488|NCT03306498|Drug|Aminoleban (8% amino acids infusion)|Each 1000ml of AMINOLEBAN contains: Aminoacetic acid - 9.0 g L-alanine -- 7.5 g L-arginine Hydrochloride (HCl) -- 7.3 g (L-arginine equivalent) -- (6.0 g) L-cysteine HCl monohydrate -- 0.4 g (L-cysteine equivalent) -- (0.3 g) L-histidine HCl monohydrate -- 3.2 g (L-histidine equivalent)-- (2.4 g) L-isoleucine -- 9.0 g L-leucine -- 11.0 g L-Lysine HCl -- 7.6 g (L-lysine equivalent) -- (6.1 g) L-methionine -- 1.0 g L-phenylalanine -- 1.0 g L-proline -- 8.0 g L-serine -- 5.0 g L-threonine -- 4.5 g L-tryptophan -- 0.7 g L-valine -- 8.4 g Water for injection q.s -- 1000 m
1906489|NCT03306485|Other|Correlating the number of reflux episodes detected on 1-h post prandial esophageal high resolution manometry combined and those detected on ambulatory 24-h pH-impedance monitoring performed on PPI|Esophageal high resolution impedance manometry (HRIM) consists of introducing a transnasal probe to record esophageal contractility (manometry), bolus transit (impedance) but also the occurrence of reflux episodes. Ambulatory 24-h pH-impedance monitoring consists of recording the occurrence of reflux episodes by introducing a transnasal catheter into the esophagus. After inserting the transnasal HRIM probe and the pH-impedance catheter, both HRIM and 24-h pH-impedance recordings are started. The patient is instructed to eat a meal that induces reflux symptoms (the patient brings his own meal). One hour the end of the meal, the HRIM probe is removed. The patient is discharged at home and the 24-h pH-impedance monitoring is continued. The patient is coming back 24-h after catheter insertion to stop the pH-impedance recording and remove the catheter.
1906490|NCT03306472|Drug|Megestrol Acetate 40 MG|Progesterone Agonist
1906491|NCT03306472|Drug|Megestrol Acetate 160 MG|Progesterone Agonist
1906492|NCT03306472|Drug|Letrozole|Aromatase Inhibitor
1906494|NCT03306446|Drug|Start adalimumab in monotherapy|Discontinuation of Adalimumab in patients who achieved deep remission
1906495|NCT03306433|Device|UDMA-K18 smooth surface sealant|The K18 as part of the UDMA polymer network (UDMA-K18) is hypothesized to prevent microbial attachment to the surface.
1906496|NCT03306420|Drug|MS201408-0005A|Subjects will receive MS201408-0005A in 28-day cycles until confirmed disease progression or unacceptable toxicity.
1906497|NCT03306420|Drug|MS201408-0005C|Subjects will receive MS201408-0005C in 28-day cycles until confirmed disease progression or unacceptable toxicity.
1906498|NCT03306420|Drug|MS201408-0005B|Subjects will receive MS201408-0005B in 28-day cycles until confirmed disease progression or unacceptable toxicity.
1906680|NCT03302520|Device|PEEK cage|PEEK cage
1996857|NCT02341989|Drug|Bleomycin Etoposide and Cisplatin|
1996858|NCT02341989|Drug|Carboplatin|
1996865|NCT02339506|Drug|Cosyntropin|Subjects will receive cosyntropin at 70 mcg/hr for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
1996866|NCT02339506|Drug|Placebo|Subjects will receive placebo (normal saline infusion) for two sessions of 2.5 hours each on day 2 of a three day admission to our research center.
1997603|NCT01997840|Drug|ACY-1215 (Ricolinostat) in combination with pomalidomide and dexamethasone|ACY-1215 (Ricolinostat) 160mg QD Days 1-21 with pomalidomide 4mg QD Days 1-21 and dexamethasone 40mg QD Days 1,8,15,22 of a 28-day cycle
1906499|NCT03306407|Other|Improved hand hygiene|The intervention group receives pre-travel advice with a special focus on improved hand hygiene including the use of hand gel sanitizer (Hartmann Sterillium) (bundle intervention)
1906500|NCT03306394|Drug|Trifluridine/Tipiracil hydrochloride (S95005)|
1906501|NCT03306381|Other|Dietary intervention|Elimination of certain products.
1906502|NCT03306368|Behavioral|Youth Opioid Recovery Support|"The components of the Youth Opioid Recovery Support intervention are:
XR-NTX, home delivery of XR-NTX, the family framework approach engages and empowers families, assertive continuing care incorporates outreach, home delivery of XR-NTX, contingency management."
1906503|NCT03306355|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
1906504|NCT03306355|Device|IOL implantation active comparator|Implantation of trifocal IOL POD F consisting of hydrophilic material
1906505|NCT03306342|Device|IOL implantation experimental|Implantation of trifocal IOL POD F GF consisting of hydrophobic material
1906506|NCT03306329|Drug|DNS-7801 (low-dose)|DNS-7801 (low-dose) tablets administered once daily.
1906507|NCT03306329|Drug|DNS-7801 (high dose)|DNS-7801 (high dose) tablets administered once daily.
1906508|NCT03306329|Drug|Placebo|Placebo tablets administered once daily
1906509|NCT03306316|Dietary Supplement|Prebiotic|Prebiotic experimental group
1906510|NCT03306316|Dietary Supplement|Dextrose Control|Dextrose Control
1906513|NCT03306264|Drug|ASTX727|ASTX727 is a tablet for oral administration, containing the fixed-dose combination of 100 mg cedazuridine (a cytidine deaminase inhibitor) and 35 mg decitabine, given by mouth Dailyx5 in 28-day cycles (in Cycle 1 or Cycle 2, then in Cycle 3 and beyond).
1906514|NCT03306264|Drug|Dacogen|Decitabine 20 mg/m^2 one-hour IV infusion Dailyx5 (in one 28-day cycle: either Cycle 1 or Cycle 2).
1906515|NCT03306693|Behavioral|Emotional skills|2-hour 3 group sessions
1906516|NCT03306693|Behavioral|Relaxation and talking group|2-hour 3 group sessions
1906517|NCT03305393|Device|Adaptiv CRT|Adaptiv CRT algorithm to be programmed to ON in CRT devices of study patients at 6 month follow-up visit
1906518|NCT03306212|Drug|Botulinum toxin A|
1906519|NCT03306212|Other|Occupational Therapy|
1906520|NCT03306212|Other|Intermittent serial casting|
1906521|NCT03306199|Device|Laser Atherectomy|The Turbo-Power is a laser atherectomy catheter designed for treatment of de novo or restenotic lesions in native infrainguinal arteries and for the treatment of femoropopliteal artery in-stent restenosis (ISR) in bare nitinol stents with adjunctive percutaneous transluminal angioplasty (PTA).
1906523|NCT03306173|Other|XXII Century, Inc. cigarettes|Research cigarette with either 0% or 25% filter ventilation. Menthol flavor will be available in both types.
1906525|NCT03306147|Behavioral|Pain education with follow up encounters|Patient pain review, counseling and education by pharmacists and physicians in follow up encounters
1906526|NCT03306134|Diagnostic Test|Dysphagia|"An overall assessment is going to be carry out by a multidisciplinary team during the visit.
Swallowing assessment is going to be performed during the visit. We are going to use: (i) the Eating Assessment Tool (EAT-10), which is a short 10-item, easy to use, self-administered questionnaire [4]. Although the EAT-10 is considered to be predominantly a questionnaire on FHS, some items on HR-QoL are also included. The sum score of this 10-item questionnaire ranges from 0 to 40, and (ii) the Sydney Swallowing Questionnaire (SSQ) to clinically assess the severity of the symptoms of dysphagia, if present.
All subjects are going to be submitted to the volume-viscosity swallow test (V- VST)"
1906528|NCT03306108|Device|NRT|NRTratio is based on each individual electrode's ECAP threshold and can identify the intracochlear electrode array position in perimodiolar electrodes. The NRT-ratio showed a good reliability for the determination of the intracochlear electrode array position compared to the radiologic control intraoperatively Calculation of the NRT-ratio is done by dividing the arithmetic average of the t-NRT values from the apical electrodes 16 to 18 divided by the arithmetic average of the basal t-NRT from electrodes 5 to 7. With a NRT-ratio above 1.05, a high chance of a scalar change was rather likely, and a NRT-ratio below 1.05 was associated with a high chance of an electrode array position within the scala tympani.
1906529|NCT03306095|Other|Early refeeding group|Food Intake by patient with in 4 hours i.e <4 hours after the EVL procedure
1906530|NCT03306095|Other|Delayed refeeding group|Food Intake by patient after 4 hours i.e > 4 hours after the EVL procedure
1906531|NCT03306082|Other|Image-Guided Cochlear Implant Programming|Post Cochlear Implant surgery, participant will receive traditional activation and programming per routine. IGCIP will be used to offer alternative programming of the implant.
1906532|NCT03306069|Other|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
1906533|NCT03306069|Other|HIIT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based high-intensity interval training (HIIT).
HIIT:
2 sessions per week
session 1: 2x4 min / session 2: 5x1 min, each at 85-95% HRmax
time-effort per week: ~30 min"
1906534|NCT03306069|Other|MIIT-HR|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of HRmax (MIIT-HR).
MIIT-HR:
2 sessions per week
session 1: 2x4 min / session 2: 5x1 min, each at 65-75% HRmax
time-effort per week: ~30 min"
1906535|NCT03306069|Other|MIIT-LT|"Procedures: Nutritional therapy (individualized, weightreducing nutritional therapy and counseling) during a study period of 12 weeks combined with supervised ergometer-based moderate-intensity interval training on the basis of lactate threshold (MIIT-LT).
MIIT-LT:
2 sessions per week
session 1: 2x4 min / session 2: 5x1 min, each at 105% LT
time-effort per week: ~30 min"
1906536|NCT03305380|Other|No interventions|As this is a patient registry, there are no interventions.
1906538|NCT03306030|Drug|Split dose of 4L PEG|All patients were given oral instruction for bowel preparation on the day of appointment and re-instruction through phone call on two days before scheduled colonoscopy. They were instructed to have a regular lunch and take only clear liquid or low-residual food for the dinner on the day before colonoscopy. The participants began to drink the first 2 L of PEG at 7:00-9 PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients took the remaining 2 L 4-6 hours before colonoscopy.
1906539|NCT03306030|Drug|Three times dose of 4L PEG|The same as mentioned above. The participants began to drink the first 1.5 L of PEG at 2:00 PM and the second 1.5L of PEG at 8:00PM on the day before colonoscopy at a rate of 250 mL every 15 minutes. On the day of the procedure, patients take the remaining 1.0 L 4-6 hours before colonoscopy.
1906540|NCT03306017|Other|Blood sampling|Three venous blood sampling before the left ventricular assist device implantation and 1 and 2 months after implantation in ambulatory patients.
1906541|NCT03306004|Other|Questionare|
1906542|NCT03305978|Device|Ultra low dose chest CT|An additional ultra low dose CT row is performed for every subject besides standard diagnostic low dose chest CT.
1906543|NCT03305978|Device|Low dose chest CT|standard diagnostic low dose chest CT
1906544|NCT03305965|Behavioral|Patient navigation|Consultations with a specifically trained oncology nurse (i.e. patient navigator), who assesses patients' needs for supportive cancer care, provides information on supportive cancer care, and guides patients through the supportive cancer care system. Consultations with the patient navigator take place at the start, halfway through, and at the end of treatment.
1906545|NCT03305952|Behavioral|CBCT|
1906546|NCT03305952|Other|TAU|
1906547|NCT03305939|Behavioral|Life style Intervention|"Month 1-3: Session 1 - Week 1: Group session Session 2-Week 3: Group session Session 3-Week 6: Group session+ Support strategies delivered remotely. Following this session, participants receive reminders of core messages, behaviours, and actions via SMS and phone calls.
Month 6- Session4: Week 26- Group session +Support strategies delivered remotely: Participants receive reminders of core messages, behaviours, and actions via SMS or voice messages and phone calls.
Month 7-12-2 Intensification Sessions (week 32 and week 44); Individual sessions: If participants are persistently overweight, or gain >2% of baseline weight.
Week 26 -48 onwards: Support strategies delivered remotely: Participants who lose desired weight continue to receive reminders of core messages, behaviours, and actions via SMS and voice messages.
Week 52 End of intervention evaluation: Individual visit: Participants provide feedback on different elements of the intervention."
1906548|NCT03305926|Other|Conventional CVR programme|Programme in a CVR centre involving 20 sessions of reconditioning to effort, 3 times per week for roughly 7 weeks, as well as 14 sessions of therapeutic education in groups.
1906549|NCT03305926|Other|Connected CVR programme|First week in the CVR centre with 3 sessions combining reconditioning to effort, individual interviews and targeted therapeutic education, so as to define the objectives and methods of the connected CVR at home for the 6 following weeks.
1906550|NCT03305926|Other|Follow-up visit M2|Effort test and evaluation at the end of the CVR programme
1906551|NCT03305926|Other|Follow-up vsit M8|Evaluation at 8 months following the CVR programme
1906552|NCT03305913|Drug|TAS 102|TAS-102 tablet
1906553|NCT03305913|Drug|Regorafenib|Regorafenib tablet
1906554|NCT03305900|Other|No Intervention|Cross-sectional study requiring a single serum sample
1906555|NCT03305887|Device|STRATAFIX™ Symmetric PDS™ Plus Knotless Tissue|This devices will be used in deep and intermediate layers of barbed suture group.
1906556|NCT03305887|Device|CR8 VICRYL® PLUS|This devices will be used in deep and intermediate layers of conventional suture group.
1906557|NCT03305887|Device|STRATAFIX Spiral PGA-PCL sutures|This devices will be used in intradermal layer of both barbed suture and conventional suture group.
1906558|NCT03305887|Device|DERMABOND™ Advance™ Skin Closure System|This devices will be used in skin layer of both barbed suture and conventional suture group.
1906559|NCT03305874|Other|Exposure to CBCIN risk score|The computer-based contrast induced nephropathy (CBCIN) risk score and associated standard hydration strategy will be displayed on a monitor in front of the treating interventional cardiologist during the entirety of the PCI case. Since this scoring system and hydration strategy are both available in the peer-reviewed literature, clinical use of these data and implementation of a CIN-avoidance strategy is not experimental; however, the display of these data to interventional cardiologists is experimental. Based on exposure to these data, the treating interventional cardiologist may use the information as clinically appropriate (i.e. it is not the basis for clinical decisions).
1906560|NCT03305861|Procedure|HoLEP|Holmium laser enucleation of prostate
1906561|NCT03305861|Procedure|ThuLEP|Thulium laser enucleation of prostate
1906562|NCT03305861|Procedure|Green LEP|Greenlight laser enucleation of prostate
1906681|NCT03302507|Procedure|BESS|Biportal endoscopic surgery
1906682|NCT03302507|Procedure|ULBD|Unilateral laminotomy bilateral decompression
1906563|NCT03305848|Drug|Nitrostat 0.4Mg Sublingual Tablet|Up to 3 administrations of 0.4mg sublingual nitroglycerin tablets, dissolved in 10mL tap water, given orally in a single swallow. Each administration is separated by at least 5 minutes, and only if systolic blood pressure > 100 mmHg.
1906568|NCT03305796|Radiation|Diffusion magnetic resonance imaging|Patients with suspected cholesteatoma will have diffusion magnetic resonance imaging
1906570|NCT03305757|Drug|Artiss|Application of ARTISS Glue to skin flaps after mastectomy
1906571|NCT03305757|Procedure|vicryl sutures|Flap fixation with vicryl sutures after mastectomy
1906572|NCT03305757|Procedure|Conventional|Conventional closure after mastectomy
1906573|NCT03305731|Behavioral|Activating Behavior for Lasting Engagement|Activating Behavior for Lasting Engagement (ABLE) is a behavioral intervention in which participants learn skills to schedule, self-monitor, and problem solve strategies to overcome barriers to engagement in meaningful daily life activities.
1906574|NCT03305718|Other|Meal sequence: 3C1A2B4D|Participants receive test meals in the sequence 3C1A2B4D
1906575|NCT03305718|Other|Meal sequence: 2A3D4C1B|Participants receive test meals in the sequence 2A3D4C1B
1906576|NCT03305718|Other|Meal sequence: 2D4B3A1C|Participants receive test meals in the sequence 2D4B3A1C
1906577|NCT03305718|Other|Meal sequence: 3B2C1D4A|Participants receive test meals in the sequence 3B2C1D4A
1906578|NCT03305718|Other|Meal sequence: 4C2B1A3D|Participants receive test meals in the sequence 4C2B1A3D
1906579|NCT03305718|Other|Meal sequence:1B4D3C2A|Participants receive test meals in the sequence 1B4D3C2A
1906580|NCT03305718|Other|Meal sequence:4A1C2D3B|Participants receive test meals in the sequence 4A1C2D3B
1906581|NCT03305718|Other|Meal sequence:1D3A4B2C|Participants receive test meals in the sequence 1D3A4B2C
1906582|NCT03305718|Other|Meal sequence: 4D3B2C1A|Participants receive test meals in the sequence 4D3B2C1A
1906583|NCT03305718|Other|Meal sequence: 3A4C1B2D|Participants receive test meals in the sequence 3A4C1B2D
1906584|NCT03305718|Other|Meal sequence: 1C2A3D4B|Participants receive test meals in the sequence 1C2A3D4B
1906585|NCT03305718|Other|Meal sequence: 2B1D4A3C|Participants receive test meals in the sequence 2B1D4A3C
1906588|NCT03305692|Diagnostic Test|Optimization of CRT Device|Use a body surface mapping system to quantify electrical dyssynchrony or echocardiography to quantify diastolic blood flow characteristics. Program the pacemaker to maximize the benefit of the modality the subject is randomized to.
1906589|NCT03305679|Procedure|Direct provisional technique|The method of implantation will be accomplished directly.
1906590|NCT03305679|Procedure|Indirect Provisional technique|The method of implantation will be accomplished indirectly.
1906591|NCT03305666|Drug|Liposomal bupivacaine injection|A single injection of liposomal bupivacaine is administered at the time of SSRF, directly to the fracture site via VATS
1906592|NCT03305666|Drug|Bupivacaine indwelling catheter|Bupivacaine indwelling OnQ pain pump catheter is placed in the subscapular space at the time of SSRF for continuous bupivacaine infusion post op
1906593|NCT03305653|Device|Esophageal String Test (EST)|The EST is a gelatin capsule filled with a 90cm nylon string. A trailing end of the string protrudes from one end of the capsule. This end is taped to the cheek and the capsule is swallowed. As the capsule travels to the small intestine, the string inside the capsule is dislodged, leaving a string that goes from the cheek to the small intestine. The capsule dislodges from the string and the string is left in place, in the mouth, esophagus, stomach and small intestine for an hour. During this time, the string rubs against the inside of the esophagus and collects eosinophil proteins. After one hour, the string is removed through the mouth and placed in preservative to save the eosinophil proteins.
1906594|NCT03305640|Procedure|acetabular fracture surgery|acetabular fracture surgery
1906595|NCT03305627|Other|Short PAP|Perioperative antibiotic prophylaxis for 24h
1906596|NCT03305627|Other|Extended PAP|Perioperative antibiotic prophylaxis for >48h
1906597|NCT03305614|Device|tDCS|C-tDCS during the first 20 minutes of aphasia therapy, at an intensity of 1mA or sham-tDCS at an intensity of 0mA
1906598|NCT03305614|Behavioral|Aphasia therapy|Based on linguistic tests, individualized aphasia therapy will be provided
1906599|NCT03305601|Other|application on smarthphone|application on smarthphone
1906600|NCT03305588|Device|Unframed Virtual Cone|The patient will undergo stereotactic radiosurgery. Radiosurgery is a single non-surgical radiation treatment and will be done as an outpatient procedure. High-energy radiation will be delivered to a small, precise area of the patient's brain using a linear accelerator. A face mask (unframed) will be placed over the patient's face to keep their head from moving during the procedure. During the procedure, the study doctor will confirm the exact location that needs to be treated using x-rays and optical imaging cameras. The face mask will hold the patient's head to prevent it from moving and to focus the x-rays and aim them on a small area in the thalamus of the patient's brain. For most patients, the actual time on the radiosurgery treatment machine is 30 to 60 minutes. The face mask will be removed after the treatment.
1906601|NCT03305575|Drug|Chloroprocaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.
During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
1906684|NCT03301688|Biological|JS001|To compare the different drug batch number with different process
1906685|NCT03301870|Drug|ATx201 Gel 2%|2% active gel
1906602|NCT03305575|Drug|Bupivacaine|"The patient will be randomly selected to receive either Chloroprocaine or Bupivacaine as the local medication for in spinal anesthesia, with a 50% chance to receive either drug.
During the cervical cerclage procedure and in the recovery room, the patient will be checked for motor block (the ability to move feet and legs) and for sensory block(the ability to feel) using a plastic tip, every 5 minutes in the first hour, and at 10 minutes intervals afterwards until the anesthesia wears off completely. The patient will also be asked to walk and urinate after the local anesthetic wears off to ensure complete resolution of local anesthesia."
1906606|NCT03305523|Device|Thermocautery|In the thermocautery method, a digital thermocautery device (Thermo-Med TM 802-B, Thermo Medical, Adana, Turkey) with 6 different temperature settings was used. Circumcision was performed in the same way as the surgical circumcision. Only cutting and bleeding intervention was done by using a thermocautery device. Cutting was performed by making the appropriate heat adjustment according to the age of the child and the thickness of the glans. Hemorrhage control was performed with a thermocautery device and then the skin-mucosa integrity was ensured by using a 5/0 absorbable suture
1906607|NCT03305510|Diagnostic Test|vitamin D is below 20ng/ml|
1906608|NCT03305497|Behavioral|Mobile Phone Application|110 persons will be equipped with a mobile phone application, trained in overdose prevention, and equipped with naloxone. The mobile phone app will allow persons witnessing an overdose to signal persons in the vicinity to respond with naloxone.
1906609|NCT03305484|Other|No intervention|No intervention, observation only
1906610|NCT03305471|Drug|DS-2330b PIB|DS-2330b as powder in bottle with stock solution (PIB)
1906611|NCT03305471|Drug|Placebo|Placebo matching stock solution in bottle
1906612|NCT03305471|Drug|Sevelamer|Sevelamer is a phosphate binder. It is used to decrease serum phosphate (Pi) level in people with chronic kidney disease who are on dialysis.
1906613|NCT03305471|Drug|DS-2330b Tablet|DS-2330b as tablet formulation
1906616|NCT03305445|Drug|Ipilimumab|Ipilimumab (1mg/kg)
1906617|NCT03305445|Drug|Nivolumab|Nivolumab (3mg/kg)
1906620|NCT03305419|Drug|GSK2982772 capsule|GSK2982772 will be available as size 00, white, opaque capsule containing white to almost white Solid (120 mg maximum fill per capsule). It will be administered orally with water to receive total dose of 120 mg, 240 mg or 360 mg per randomization.
1906621|NCT03305419|Drug|Placebo capsule|Placebo will be available as size 00, white, opaque capsule containing white to almost white Solid. It will be administered orally with water.
1906624|NCT03306056|Other|Control|Individualized, weight-reducing nutritional therapy and counseling, during a study period of 12 weeks
1906625|NCT03306056|Other|Standard Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with a standard strength training program:
5 strength training exercises (chest, upper/lower back, abdominals, legs)
3 sets per exercise
time-effort per session: ~90 min
2 training sessions per week
duration of exercise intervention: 12 weeks"
1906626|NCT03306056|Other|Low-volume Strength Training|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined a low-volume strength training program:
5 strength training exercises (chest, upper/lower back, abdominals, legs)
1 set per exercise
time-effort per session: ~20 min
2 training sessions per week
duration of exercise intervention: 12 weeks"
1906627|NCT03306056|Other|Whole-Body Electromyostimulation (WB-EMS)|"Procedures: Nutritional therapy (individualized, weight-reducing nutritional therapy and counseling) during a study period of 12 weeks combined with WB-EMS:
time-effort per session: ~20 min
duration of exercise intervention: 12 weeks"
1906628|NCT03304301|Behavioral|sunlight exposure|Participants will be encouraged to reduce time spent on bed and bedroom. We will also take participants outdoors and receiving sunlight exposure (if the UV index is over 8 according to the forecast of Center Weather Bureau, the participants will be asked to stay inside) five days a week for three months
1906629|NCT03305341|Drug|Etoposide Injection plus Methotrexate Injection|Experimental: Etoposide Intravenous plus Methotrexate Intravenous
1906630|NCT03305341|Drug|Etoposide Capsule plus Methotrexate Tablet|Etoposide Oral plus Methotrexate Oral
1906631|NCT03305172|Behavioral|Financial Incentive|Giving different structures of long term (36 weeks) financial incentives to increase physical activity
1906632|NCT03305094|Procedure|Blood pressure cuff inflation|Cuff pressure for ischemia sham is 20 mm Hg, ischemia is 200 mm Hg and reperfusion is 0 mm Hg
1906633|NCT03304834|Device|ECHOPULSE|Patient are treated with the HIFU device and the physician is doing a compressive bandage.
1906686|NCT03301870|Drug|ATx201 Gel 4%|4% active gel
1906634|NCT03304808|Device|Exercise Programme +device+ lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.
Four exercise:
Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .
Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.
Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating
Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
1906635|NCT03304808|Behavioral|Exercise Programme + lubricant|"A first line treatment for the PE of a new 7 weeks exercise programme to control male orgasm using a masturbation aid device in a variation of the classical stop-start technique first introduced by Semans in 1956.
Four exercise:
Exercise of Masturbation that intends to raise awareness of the ejaculatory response and identify the tension on the muscles of the genital area .
Star and Stop to identify the tension and try to reduce this tension, on the pelvic floor muscles pay special attention to the anal sphincter.
Delay the ejaculatory response on four different occasions, by loosening the tension in the genital area and relaxing the anal sphincter not stop masturbating
Practice the ability to delay ejaculation as in previous exercises, but this time performing hip movements similar to penetration not stop masturbating"
1906636|NCT03304288|Drug|Rituximab|Low-dose rituximab was used in combination with ATRA or as the monotherapy
1906637|NCT03304288|Drug|All-trans retinoic acid|ATRA was used in combination with low-dose rituximab
1906638|NCT03304587|Diagnostic Test|Polysomnography (PSG)|Sleep patterns will be measured by in-lab PSG following a standardized protocol. 10mm silver/silver chloride electroencephalogram (EEG) and electromyography (EMG) electrodes and 11mm silver/silver chloride electroculography (EOG) electrodes will be connected to a Nihon Kohden system, 912 model (Nihon Kohden, Irvine, CA). A standard sleep montage following the 10/20 procedure for electrode placement, left and right electrooculography referenced to the opposite mastoid and mentalis electromyography will be followed. Data will be visually scored by a polysomnographer blind to study conditions following the American Academy of Sleep Medicine (AASM) Manual.
1906639|NCT03304587|Diagnostic Test|Rectal thermistor 400 Series|Nocturnal core body temperature will be measured using a rectal thermistor 400 series manufactured by YSI (Yellow Springs, OH, USA) inserted up to a depth of 7 cm. and taped in place. The thermistor will be connected to a Model 4600 thermometer (YSI, Yellow Springs, OH, USA) that will be interfaced with the PSG via cabling. Core temperature readings will be continuously monitored and recorded every 5 minutes during the all-night sleep studies.
1906640|NCT03304587|Other|Bright blue-green light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
1906641|NCT03304587|Other|Dim red light|-The cap visor-mounted device controls the distance of the light exposure, and positions the light source above eye level to target on the lower retina for better effect
1906642|NCT03304587|Diagnostic Test|Digital foot candle datalogging light meter|"On 2 random days during the 2-week bright light treatment, ambient light will be recorded continuously during waking hours using a digital foot candle datalogging light meter (Extech Instruments, Waltham, MA) Model SDL400. The 7.1 x 2.9 x 1.0 light meter (12.21 oz) has the capacity to measure up to 10,000 footcandles (accuracy: ± 4% reading). The light-weight light sensor is approximately 2 inches in diameter and comes with a clip and strap that makes it comfortable to wear just below the neck."
1906643|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Cancer-Fatigue|8 items with a 5-point rating scale (1=not at all to 5 =very much) measuring fatigue experience and fatigue impact. Higher scores indicate worse fatigue. PROMIS-Fatigue was developed based on rigorous methodologies. The psychometric properties have been established across chronic illnesses including cancer.
1906644|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Sleep Disturbance|8 items with 5-point rating scales measuring overall sleep and sleep-related impairments. Higher scores indicate worse sleep disturbances. Validity was supported by moderate to high correlations with the existing scales, e.g. PSQI, Epworth Sleepiness Scale (ESS). The scores significantly differed participants with and without sleep disorders.
1906645|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Depression|8 items with 5-point rating scales (1=never to 5=always) measuring affective and cognitive manifestations of depressive mood. Higher scores indicate worse depression. In a sample of depressed outpatients, PROMIS-Depression showed greater reliability when compared to the CES-D and the Patient Health Questionnaire (PHQ-9). Convergent validity with the CES-D and PHQ-9 was supported by strong correlations, ranged 0.72 to 0.84
1906646|NCT03304587|Other|Patient-Reported Outcomes Measurement Information System (PROMIS)-Physical Function|8 items with 5-point rating scales measuring the individual's ability to complete daily activities. Higher scores indicate worse functioning. Validity was tested in 1,415 adults with diverse clinical conditions. The PROMIS Physical Function scores corresponded to the expected positive or negative changes in the individual's physical function.
1906647|NCT03304587|Other|Pittsburgh Sleep Quality Index (PSQI)|19 self-report items measuring sleep quality, latency, duration, efficiency, disturbance, medication use, and daytime dysfunction. Each item is rated on a 0-3 rating scale. The global PSQI score ranges 0-21, with higher scores indicating more severe sleep disturbance. A global PSQI score greater than 5 was found to have a sensitivity of 89.6% and a specificity of 86.5% in differentiating good and poor sleepers.
1906648|NCT03304587|Other|Center for Epidemiological Studies - Depression|20-item self-report instrument commonly used to measure depressive symptoms in cancer patients. Each item is rated on a 4-point rating scale (0=rarely or none of the time to 3=all of the time) describing the frequency of occurrence during the past week. Score can range from 0-60, with higher scores indicating more depressive symptoms.
1906649|NCT03304587|Other|Montreal Cognitive Assessment (MoCA)|The MoCA is highly sensitive for screening patient with mild cognitive impairment. The MoCA is a 30-point scale with 7 cognitive subtests: visuo-executive, naming, attention, language, abstraction, delayed recall, and orientation. It scores from 0 to 30, where higher scores indicate better cognition and a score below 26 indicates cognitive impairment. The MoCA is highly sensitive for screening patient with mild cognitive impairment.
1906687|NCT03301870|Drug|Positive Control|Sodium Lauryl Sulfate 0.05% (w/v), USP in sterile, distilled Water for Injection, USP
1906650|NCT03304587|Other|European Organization for Research and Treatment of Cancer-Quality of Life Questionnaire (EORTC QLQ-C30)|The EORTC QLQ-C30 consists of 30 items with a 4-point rating scale (1=not at all to 4=very much) measuring functioning, symptom intensity, and global health status/quality of life during the past week.
1906651|NCT03304587|Other|Daily Log|-A log where the participants will indicate date, wake time, sleep time answer 3 questions regarding the previous nights sleep (answers range from 1=not at all to 5=very much), have an area to indicate if naps occurred during the day, and 2 questions about fatigue & sleepiness (answers ranging from 0=no fatigue/sleepiness to 10=worst fatigue/sleepiness
1906652|NCT03304470|Drug|ATx201 2% Cream|Anhydrous Cream
1906653|NCT03304470|Drug|ATx201 Cream Vehicle|Anhydrous Cream
1906654|NCT03304457|Drug|Olanzapine|Olanzapine 10mg once daily orally for 6 weeks
1906655|NCT03304457|Drug|Lurasidone|Lurasidone 80mg once daily orally for 6 weeks
1906656|NCT03304392|Behavioral|Personalized ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support within one business day of client emails. Amount of contact will be personalized to patients' needs.
1906657|NCT03304392|Behavioral|Standard ICBT|An 8-week transdiagnostic internet-delivered cognitive behavioural therapy (ICBT) will be delivered to participants. All clients will receive support from registered social workers, psychologists or supervised graduate students, with experience delivering ICBT, with contact depending upon group allocation. In addition to the online program, therapists, registered social workers, psychologists or supervised graduate students, with experience delivering ICBT will provide support by email only once a week. Therapist will spend approximately 15 minutes per week/per client.
1906661|NCT03304158|Behavioral|FCHV visit|FCHVs will visit selected households 3 times a year for providing health promotion messages and measure the blood glucose
1906662|NCT03304067|Behavioral|Tueo Program|The asthma management solution utilizes devices (2 to attach on the child's bed and 1 for data transmission), which collect various metrics for a tailored smartphone application experience. The smartphone application provides access to view and interact w
1906663|NCT03304054|Drug|Amifampridine Phosphate|tablets equivalent to 10mg amifampridine, titrated to an efficacious and tolerable dose, 3 to 4 times a day
1906664|NCT03304054|Drug|Placebo Oral Tablet|tablets matching amifampridine phosphate, 3 to 4 times a day
1906665|NCT03303911|Drug|Cytisine|film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose
1906666|NCT03303859|Diagnostic Test|Bacterial vaginosis|
1906667|NCT03303625|Biological|Ad26.RSV.preF (1*10^11 vp)|Participants will receive two doses of 0.5 milliliter (mL) (1*10^11 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
1906668|NCT03303625|Biological|Ad26.RSV.preF (5*10^10 vp)|RSV seropositive participants will receive two doses of 0.25 mL (5*10^10 vp) via IM route on Day 1 and 29 of Ad26.RSV.preF.
1906669|NCT03303625|Drug|Placebo|Participants will receive either 0.5 mL (cohort 0) or 0.25 mL (cohort 1) of placebo via IM route on Day 1 and 29.
1906670|NCT03303573|Drug|recombinant human erythropoietin|Subcutaneous rhEPO injection
1906671|NCT03303287|Behavioral|School health education|School health education program in Pakistan(SHEPP): The health education program will be directed towards children, parents and teachers
1906672|NCT03302455|Behavioral|eCBTI|The short-term eCBTI contains a one-week core course: daily listening to the 5-minute sleep course, recording the sleep diary, and selectively listening to audios of eCBTI tools. In addition, individual customized sleep restriction and stimulation control treatments were provided according to the subject's previous 2-week sleep status.
1906673|NCT03302949|Dietary Supplement|Lacprodan® DI-8090|Whey protein concentrate. 100g powder contains 392 kcal (1646 kJ), hereof 80% protein.
1906674|NCT03302247|Biological|Nivolumab|Monoclonal antibody against non small cell lung cancer
1906675|NCT03302247|Drug|Nivolumab+Gemcitabine|Gemcitabine is added to the Nivolumab treatment
1906676|NCT03302728|Drug|Lenalidomide 15mg|At commencement of study : Lenalidomide will commence at 15 mg daily for days 1-14 of each cycle. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may vary from 5 mg -25 mg daily depending on dose escalation results and recommendation of safety committee
1906677|NCT03302728|Drug|Brentuximab Vedotin 1.8 mg/Kg|At commencement of study : Brentuximab vedotin 1.8mg/kg IV on day 1, repeated every 21 days. Maximum number of cycles = 16. This is a dose finding study so doses will be adjusted depending on toxicity assessment over the course of the study. Dose may be either 1.2 mg/Kg q21 days or 1.8 mg/kg q21 days depending on dose escalation results and recommendation of safety committee
1906679|NCT03302520|Device|NovoMax, BioAlpha Inc, Seong-nam, Korea|CaO-SiO2-P2O5-B2O3 glass ceramics spacer
1964553|NCT01485003|Biological|natalizumab|Natalizumab will not be provided as a part of this study. Participants will receive natalizumab as prescribed by their treating physician.
1906688|NCT03301870|Drug|Negative Control|Water for Injection, USP
1906689|NCT03301870|Drug|ATx201 Placebo|matching placebo gel
1906690|NCT03301818|Device|Vaginal tactile imager|Patients will undergo elasticity assessment with vaginal tactile imaging the be once before surgical repair and twice after during a 3 month interval.
1906691|NCT03300817|Other|Laboratory Biomarker Analysis|Correlative studies
1906692|NCT03300817|Biological|MUC1 Peptide-Poly-ICLC Vaccine|Given SC
1906693|NCT03301389|Other|Cardiac magnetic resonance imaging|The cardiac imaging protocol will include pre-contrast T1, post-contrast T1, and T2 mapping images acquired of the mid ventricle with the short axis plane for the analysis of native T1, T2, and extracellular volume (ECV) values of the myocardium. It will also include cine imaging covering the whole LV myocardium in the short axis plane for a functional analysis of the LV myocardium.
1906698|NCT03300570|Other|Laboratory Biomarker Analysis|Correlative studies
1906699|NCT03300570|Drug|Linaclotide Acetate|Given orally (PO)
1906700|NCT03300570|Other|Placebo|Given PO
1906701|NCT03300570|Other|Questionnaire Administration|"Undergo Was It Worth It questionnaire"
1906702|NCT03300557|Drug|Exemestane|Given PO
1906703|NCT03300557|Other|Laboratory Biomarker Analysis|Correlative studies
1906704|NCT03300544|Drug|Capecitabine|Given PO
1906705|NCT03300544|Drug|Fluorouracil|Given IV
1906706|NCT03300544|Other|Laboratory Biomarker Analysis|Correlative studies
1906707|NCT03300544|Drug|Oxaliplatin|Given IV
1906708|NCT03300544|Radiation|Radiation Therapy|Undergo chemoradiation
1906709|NCT03300544|Biological|Talimogene Laherparepvec|Given intralesionally
1906714|NCT03299322|Drug|Jia Wei Yang He Formula|This is an empirical traditional Chinese medicine compound used in the treatment of asthma for a long time
1906715|NCT03299322|Drug|Jia Wei Yang He Formula Placebo|Made from 1/20 doses which has certain taste, but no therapeutic effect
1906716|NCT03299751|Biological|Diagnostic performances of biomarkers combination|"A blood sample of 400µL will be drawn at inclusion, when neonatal sepsis is suspected, at the same time of a venipuncture prescribed for standard care.
The dosage of 11 biomarkers will be performed in a central laboratory."
1906717|NCT03300115|Drug|AC0010|After subjects prove eligible after screening and are enrolled, they are given AC0010 300 mg Bid (the two doses are advised to be administered at an interval of 12 hours), receive evaluation of safety indicators every 3 weeks, efficacy evaluation every 6 weeks until disease progression or intolerable toxicities or withdrawal from the trial. (If the investigator suspects disease progression, CT or MRI may be performed in advance; if the patient does not have disease progression, subsequent efficacy evaluation will proceed still according to the protocol).
1906718|NCT03298750|Procedure|Resection of ovarian tissue and mechanical stimulation|"he women will undergo a surgical laparoscopy during which one of the two technique will ensue.
One of the ovaries will be scratched ( 2 mm depth) with a knife. Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory.
A piece of one ovary will be resected (up to one third of the ovary's volume, without harming the other ovary.
The resected ovarian tissue will be transferred immediately to the laboratory where the cortex will be divided from the medulla and sliced to small pieces of 1-2 square millimeters.
These pieces will be transferred back to the operation room in order for them to be transplanted under the serosa layer of the remaining ovary.
Any bleeding would be stopped using a stiches or hemostatic mesh (diathermy will not be used).
Simultaneously, a piece of the ovary will be preserved for further histologic analysis and research in the laboratory."
1964557|NCT01475370|Drug|OCV-501|"Before the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the dose in the study 311-10-001.
After the recommended dose will be decided OCV-501 will be subcutaneously administered once a week at the recommended dose."
1906721|NCT03297333|Other|Resistance training|The resistance training group
1906722|NCT03297333|Other|Aerobic interval training|The aerobic interval training group
1906723|NCT03297528|Drug|donor lymphocyte infusion|Participants in study group receive chemotherapy and donor lymphocyte infusion based on the state of GvHD, even they have a negative result of MRD. If participants in study group have no GvHD, they will receive chemotherapy and donor lymphocyte infusion until they develop GvHD. If the participants in study group have GvHD, they will be observed. But, the participants in control group don't receive chemotherapy and donor lymphocyte infusion as long as they have a negative result of MRD, in despite of whether or not GvHD.
1906807|NCT03282370|Biological|JEVAX|JEVAX - VABIOTECH Vietnam Liquid form Subcutaneous injection 0.5ml/dose, 2 doses, 28-34 days interval
1906808|NCT03282370|Biological|JECEVAX|JECEVAX - VABIOTECH Vietnam Liquid form Composition: 0.5 BR209 Subcutaneous injection 0.5ml/dose, 2 doses, interval 28-34 days
1946617|NCT00287989|Drug|carboplatin|
1906724|NCT03295708|Dietary Supplement|fish oil capsule|N-3 PUFAs is a kind of essential fatty acid,however the formation is too slow. Studies show that intakes of N-3 PUFAs is associated with MDD.It have to be got from food like deep-sea fishes. EPA and DHA are crucial for the body.Although studies have shown that reduced N-3 PUFAs were correlated with MDD, and patients with an elevated rate of N-6 PUFAs /N-3 PUFAs or a low level of DHA may be at higher odds for suicide. Trials on whether N-3 PUFAs is effective in the treatment of MDD is still controversial, which might be affected by several factors, such as dose, duration etc.. Now there is no large-scale randomized controlled clinical trial in determining the effects of N-3 PUFAs add-on in treatment of MDD.
1906725|NCT03295708|Dietary Supplement|soybean oil capsule|placebo capsule
1906726|NCT03296735|Procedure|Ipsilateral tilt|The operation table will be tilted 20 degrees right laterally.
1906727|NCT03296735|Procedure|Contralateral tilt|The operation table will be tilted 20 degrees left laterally.
1906733|NCT03296592|Diagnostic Test|MRI with DBSI technology|The MRI will be done with diffusion basis spectrum imaging
1906734|NCT03294681|Device|Objective measures with CSEP|Objective measures to be conducted with Custom SoundTM EP 5 software and the CP900 series sound processor in CI532 and CI512 Cochlear Implant recipients
1964567|NCT01461785|Biological|Addition of PRP ( platelet rich plasma) to the lipograft|"27 ml blood will be drawn from the patient. The blood will be prepared according to the GPS System instructions (Biomet Biologics, LLC, Warsaw, Indiana USA). This desktop-size centrifuge has disposable cylinders to separate the different blood components (platelet rich plasma, PRP, platelet poor plasma, PPP, and red blood cells). The PRP is activated by adding calcium (15-volume % Ca2+ Sandoz®). creating activated Platelet Rich Plasma (aPRP).
The lipograft of Group A will be enriched with 3ml of autologous PRP"
1964568|NCT01461785|Procedure|Lipofilling of the midface|The Coleman technique for fat harvesting and injection is employed but refined by utilizing a smaller, custom-made cannula for harvesting (inner diameter, 1.3 mm). The abdomen and upper legs are donor sites. Approximately two to three times more fat is harvested than the estimated amount required for the procedure. Fat is centrifuged for three minutes at the maximum speed of 3000 revolutions per minute after which the oil layer (top) and serum/infiltrate layer (bottom) are drained away, preserving the preadipocyte-rich pellet. Fat injection is performed in 1-mm aliquots with a short, curved Coleman cannula. Between 13 and 23 mL of fat is injected into the deep subcutaneous plane of each side of the face, except for the lower lid/tear trough region (where the injection is performed in the supraperiosteal/submuscular plane) and the temporal area (where the level of injection was above the superficial fascia of the temporal muscle).
1906742|NCT03292939|Diagnostic Test|A complete Doppler ﬂow assessment of the maternal and fetal circulation|A complete Doppler ﬂow assessment of the maternal and fetal circulation was conducted by an independent investigator blinded to the treatment, 48 hours after receiving 400mg of vaginal progestrone .Voluson E8 (GE Healthcare, Zipf, Austria) ultrasound machine ,equipped with a 3.5-MHz curvilinear abdominal transducer with color imaging capabilities, was used in all cases.
1906743|NCT03291782|Drug|D-0120|oral, single dose
1906746|NCT03292250|Drug|BYL719|Patients will be instructed to take BYL719 orally at a dose of 100 mg with a glass of water once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
1906747|NCT03292250|Drug|Poziotinib|Patients will be instructed to take BYL719 orally at a dose of 12 mg once daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
1906748|NCT03292250|Drug|Nintedanib|Initial dose 200 mg twice per day orally according to study protocol.
1906749|NCT03292250|Drug|Abemaciclib|Patients will be instructed to take Abemaciclib orally at a dose of 200mg bid with a glass of water twice daily, in a fasting state or with a light fat-free meal, and as close as possible to the same time each day.
1906750|NCT03292250|Drug|Durvalumab,Tremelimumab|Durvalumab: 1.5g Q4W plusTremelimumab: 75mg Q4W up to 4cycle then Durvalumab 750mg Q2W, till PD or unacceptable toxicity.
1906751|NCT03290495|Drug|ketamine|ketamine hydrochloride 250microgram/ ml for iv injection after 30 minutes of stable isoflurane anesthesia
1906752|NCT03290495|Drug|saline|a similar volume of normal saline 0.9% for intravenous injection instead of ketamine will be given to the control group. this because the attending anesthesiologist will be blinded to the study drugs and aim according to the study proposal.
1906753|NCT03290963|Drug|Lithium|Lithium will be dosed in units (LI level > or = 0.4 milliequivalents (mEq)/L)
1906754|NCT03290963|Drug|Placebo|Placebo tablets, dosed in units
1906755|NCT03290963|Drug|Ketamine|All subjects will receive 3 IV ketamine infusions of 0.5mg/kg, over 100 min. over 7 days.
1906756|NCT03290937|Drug|Irinotecan|"Dose Escalation Starting Dose: 60 mg/m2 by vein on Days 1 and 15 of a 28 day cycle.
Dose Expansion Starting Dose: Maximum tolerated dose from Dose Escalation by vein on Days 1 and 15 of a 28 day cycle."
1906757|NCT03290937|Drug|PF-05082566|Dose Escalation and Dose Expansion: 100 mg by vein on Day 2 of a 28 day cycle.
1906758|NCT03290937|Drug|Cetuximab|Dose Escalation and Dose Expansion: 500 mg/m2 by vein on Days 1 and 15 of a 28 day cycle.
1906892|NCT03274076|Drug|Tofacitinib|Oral medication tofacitinib 5 mg twice a day for 24 weeks.
1906763|NCT03290378|Drug|Tramadol|IV; 25 mg or 50 mg, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
1906764|NCT03290378|Other|Placebo|IV; Placebo, given at Hours 0, 2, 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, and 44
1906765|NCT03290339|Procedure|hysterectomy|laparoscopic hysterectomy and vaginal hysterectomy
1906766|NCT03290209|Procedure|Laparoscopic D1 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D1 Lymphadenectomy will be performed in the experimental group.
1906767|NCT03290209|Procedure|Laparoscopic D2 Lymphadenectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case, laparoscopic D2 Lymphadenectomy will be performed in the comparator group.
1906772|NCT03288636|Drug|Danoprevir|Danoprevir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
1906773|NCT03288636|Drug|Ritonavir|Ritonavir tablet administered orally 100mg QD on day 7 and 13, 100mg BID on day 14-22, 100mg QD on day 23
1906774|NCT03288636|Drug|Ravidasvir|Ravidasvir tablet administered orally 200mg QD on day 1, 13 - 23
1906775|NCT03288636|Drug|Placebo|Placebo
1906776|NCT03288389|Dietary Supplement|NTFactor Lipids®|Membrane Lipid Replacement with NTFactor Lipids wafers
1906777|NCT03288389|Dietary Supplement|Placebo|Placebo wafers
1906778|NCT03287674|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg is administered i.v. on day -7 and day -6.
1906779|NCT03287674|Drug|Fludarabine|Fludarabine 25 mg/m2 is administered on day -5 to day -1.
1906780|NCT03287674|Biological|TIL infusion|The maximum number of expanded TILs are infused over 30-45 minutes on day 0.
1906781|NCT03287674|Drug|Interleukin-2|Interleukin-2 is administered as a daily low-dose subcutaneous injection of 2 MIU for a total of 14 days.
1906782|NCT03287674|Drug|Ipilimumab|One dose of Ipilimumab 3 mg/kg is administered 14 days prior to surgical removal of tumor tissue for TIL expansion.
1906783|NCT03287674|Drug|Nivolumab|Nivolumab 3 mg/kg is administered on day -2 before TIL infusion and every 2 weeks for a total of 4 doses.
1906791|NCT03285867|Procedure|TACE|transcatheter arterial chemoembolization
1906802|NCT03283059|Drug|Octohydroaminoacridine Succinate|Octohydroaminoacridine Succinate Tablet:4mg P.O. tid
1906803|NCT03283059|Drug|Aricept|Aricept 5mg/day, P.O.
1906804|NCT03283059|Drug|Placebos|Placebo Tablet: P.O. tid
1997604|NCT01997710|Device|all-ceramic inlay-retained RBFDP|Rehabilitation of tooth loss with an all-ceramic inlay-retained RBFDP
1997605|NCT01997710|Device|all-ceramic RBFDP|Rehabilitation of tooth loss with an all-ceramic RBFDP
1997606|NCT01997658|Drug|Methylprednisolone|Patients in Methylprednisolone arm will receive injection methylprednisolone 500 mg I/V over 15 to 20 minutes, single dose, 30 minutes before starting surgery.
1997607|NCT01997658|Drug|Placebo|Patients in the placebo group will receive standard perioperative care and surgery, without preoperative administration of methylprednisolone.
1997608|NCT01996488|Drug|Olanzapine Orally Disintegrating Tablets 5mg|
1997609|NCT01996943|Drug|Ethanol|6% volume/volume ethanol in 0.45% saline solution.
1997610|NCT01996943|Drug|Placebo|"The placebo with be 0.45% saline solution (half normal saline)."
1997611|NCT01994265|Drug|Warfarin|Warfarin once daily, at fast, targeting INR between 2 and 3
1997612|NCT01994265|Drug|Dabigatran|
1997613|NCT01992250|Device|Visica 2 Treatment System|Cryoablation
1997786|NCT01915810|Other|Walking Program|"Group 2 start a walking program 2 weeks before their quit day and finish it 2 weeks after their quit day. Participants walk about 150 minutes (about 2 ½ hours) a week.
Group 3 start a walking program on their quit day and finish it 4 weeks after their quit day. Participants walk about 150 minutes (about 2 ½ hours) a week."
1906809|NCT03280511|Drug|PIPAC|PIPAC is performed during a standard laparoscopy with a capnoperitoneum of 12 mmHg. During PIPAC, oxaliplatin 92 mg/m2 in 150 ml dextrose will be intraperitoneally nebulized at a rate of 0.5 ml/s with a maximum pressure of 200 PSI. The intraperitoneal air will be evacuated after 30 minutes of simple diffusion
1906812|NCT03280173|Drug|tafamidis|bioavailability study
1906822|NCT03279068|Other|Teaching and EFM Paper|Data will be collected for patients receiving EFM without pattern interpretation as the first phase of the study, as this is the current practice at Ayder Hospital. Then, the second phase will involve a week of teaching sessions regarding interpretation and management of EFM as per ACOG and FIGO guidelines. For the third phase of this study, paper will be provided for the use of EFM with pattern interpretation for all patients receiving EFM.
1906823|NCT03279874|Other|Interviews|Semi-structured one-on-one interviews
1906824|NCT03277755|Drug|AL-335 800 mg|Participants will receive AL-335 800 mg (2 tablets of 400 mg AL-335) single oral dose on Day 1 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
1906825|NCT03277755|Drug|ODV 25 mg|Participants will receive ODV 25 mg (1 tablet of 25 mg ODV) single oral dose on Day 8 of part 1 and in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
1906826|NCT03277755|Drug|SMV 75 mg|Participants will receive SMV 75 mg in combination as AL-335 + ODV + SMV once daily orally from Day 1 to 14 of part 2.
1906828|NCT03278366|Behavioral|Dancing|Participants in the intervention group will participate in daily dance activities with their teacher by following along with a video created by the dance researchers at Skidmore College. Teachers will be specifically asked to utilize the movement phrases just prior to administering any formal assessment activity within their classroom (tempo may be chosen at teacher's discretion). Furthermore, teachers may choose to utilize the dance phrases as 'brain breaks' at any point throughout their school day.
1906831|NCT03277651|Diagnostic Test|hemodynamics tests|Hemodynamics tests for intrahepatic blood flow by colour doppler ultrasound
1906832|NCT03276806|Behavioral|tobacco dependence/smoking cessation counseling|Standard of care tobacco dependence/smoking cessation counseling offered to all smokers at Boston Medical Center.
1906833|NCT03276806|Behavioral|SDM|SDM is three-fold to: 1) conduct a tailored discussion on tradeoffs of LDCT screening, consistent with CMS requirements for SDM using a decision aid; 2) directly connect interested patients to LDCT screening; 3) to empower and motivate patients to quit smoking within the LDCT screening context.
1906834|NCT03276806|Other|Decision Aid|The decision aid is a 4-page paper format with the following features: 1) LDCT screening harms and benefits information, written in plain language and using pictographs, easily understood by those with low health literacy; 2) prompts to clarify patient values and preferences and to stimulate discussion about trade-offs; 3) clear quit smoking messaging and resources (1-800-QUIT-NOW).
1906835|NCT03276806|Other|LDCT brochure|A informational brochure developed by the BMC screening program about low dose CT screening for lung cancer.
1906836|NCT03276728|Drug|AMG 986 IV Dose Level A or matching Placebo|Single dose Healthy Volunteers
1906837|NCT03276728|Drug|AMG 986 IV Dose Level B or matching Placebo|Single dose Healthy Volunteers
1906838|NCT03276728|Drug|AMG 986 IV Dose Level C or matching placebo|Single dose Healthy Volunteers
1906839|NCT03276728|Drug|AMG 986 IV Dose Level D or matching placebo|Single dose Healthy Volunteers
1906840|NCT03276728|Drug|AMG 986 IV Dose Level E or matching Placebo|Single dose Healthy Volunteers
1906841|NCT03276728|Drug|AMG 986 IV Dose Level F or matching Placebo|Multiple daily dose Healthy Volunteers
1906842|NCT03276728|Drug|AMG 986 IV Dose Level G or matching Placebo|Multiple daily dose Healthy Volunteers
1906843|NCT03276728|Drug|AMG 986 Oral Dose Level A or matching Placebo|Single dose Healthy Volunteer
1906844|NCT03276728|Drug|AMG 986 Oral Dose Level B or matching Placebo|Single dose Healthy Volunteer
1906845|NCT03276728|Drug|AMG 986 Oral Dose Level C or matching Placebo|Single dose Healthy Volunteer
1906846|NCT03276728|Drug|AMG 986 Oral Dose Level D or matching Placebo|Single dose Healthy Volunteers
1906847|NCT03276728|Drug|AMG 986 Oral Dose Level E or matching Placebo|Single dose Healthy Volunteers
1906848|NCT03276728|Drug|AMG 986 Oral Dose Level F or matching Placebo|Single dose Healthy Volunteers
1906849|NCT03276728|Drug|AMG 986 Oral Dose Level A or matching Placebo|Multiple daily dose Healthy Volunteers
1906850|NCT03276728|Drug|AMG 986 Oral Dose Level B or matching Placebo|Multiple daily dose Healthy Volunteers
1996943|NCT02311478|Device|T380A Intrauterine Copper Contraceptive|The T380A is intrauterine device (IUD) that used to prevent pregnancy. It is a soft, flexible T-shaped device made primarily of plastic and copper that is inserted into the uterus.
1996944|NCT02309944|Procedure|Standard Wound Closure|The standard surgical closure consists of closure of the fascia with a looped polydioxanone (PDS) suture in a running fashion either in with the use of a mass closure technique or a Smead Jones closure at the discretion of the operating surgeon, closure of the subcutaneous space if >2 cm deep, followed by staple or suture closure of the skin.
1906851|NCT03276728|Drug|AMG 986 Oral Dose Level C or matching Placebo|Multiple daily dose Healthy Volunteers
1906852|NCT03276728|Drug|AMG 986 Oral Dose Level D or matching Placebo|Multiple daily dose Healthy Volunteers
1906853|NCT03276728|Drug|AMG 986 Oral Dose Level E or matching Placebo|Multiple daily dose Healthy Volunteers
1906854|NCT03276728|Drug|AMG 986 Oral Dose Level F or matching Placebo|Multiple daily dose Healthy Volunteers
1906855|NCT03276728|Drug|AMG 986 Oral Dose Regimen or matching placebo - R|Multiple daily dose - Patients with heart failure and reduced ejection fraction
1906856|NCT03276728|Drug|AMG 986 Oral Dose Regimen or matching placebo - P|Multiple daily dose - Patients with heart failure and preserved ejection fraction
1997787|NCT01915810|Drug|Nicotine Patch|6-week supply of the nicotine patch given to participants. Patch dosage congruent with pre-quit smoking rate and will taper over time.
1997788|NCT01915810|Behavioral|Audio Recorded Focus Group|Participants take part in a final audio recorded focus group 8 weeks after quitting smoking.
1997789|NCT01914393|Drug|Lurasidone 20, 40, 60, 80 mg, flexibly dosed|Lurasidone 20, 40, 60, 80 mg once daily, flexibly dosed
1997790|NCT01914146|Other|Insulin|Initiation of insulin administration will be determined as part of standard of care by the subjects diabetologist in the VGH Diabetes Centre and not as part of participation in this study.
1906863|NCT03274609|Device|Pentax EBUS-J10 in combination with Hitachi Preirus Hi-vision system|The study will replace the current conventional standard TBB procedure (fluoroscopy and rEBUS guided bronchoscopy) in the endoscopy suite. Consecutive patients will be included on the MITeC hybrid operating room (needed to monitor patient safety and CT availability). All data will be prospectively collected. In case tissue biopsy is found to be malignant or benign, it will be termed representative. In case tissue biopsy is found to be non-representative (=blood, anatomical lung tissue, unreachable), conventional follow-up of CT guided TTNA, follow-up monitoring and/or surgical biopsy will serve as golden standard for obtaining tissue diagnosis. For verification of reaching the target lesion, another study parameter of interest, (cb)CT imaging will be performed for verification that instruments are within the nodule (per-procedurally available).
1906864|NCT03275597|Drug|Durvalumab|Durvalumab is an FDA-approved immunotherapy for cancer. Durvalumab is a human monoclonal antibody (mAb) of the immunoglobulin G (IgG) 1 kappa subclass that inhibits binding of PD-L1 and is being developed by AstraZeneca/MedImmune for use in the treatment of cancer.
1906865|NCT03275597|Drug|Tremelimumab|Tremelimumab is a monoclonal antibody against CTLA-4. It is an IgG 2 kappa isotype mAb directed against the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) also known as CD152 (cluster of differentiation 152). This is an immunomodulatory therapy (IMT) that is being developed by AstraZeneca for use in the treatment of cancer.
1906866|NCT03275597|Radiation|Stereotactic Body Radiotherapy|SBRT is a highly conformal approach to the delivery of radiation therapy, maximizing radiation dose to the tumor while minimizing dose to nearby normal tissues.
1906867|NCT03275493|Biological|Humanized CD19 CAR-T cells|Express a Second Generation 4-1BB:humanized CD19 CAR-T cells
1906868|NCT03275493|Biological|Humanized CD19 CAR-T cells with CRS suppression technology|Express a Second Generation 4-1BB:humanized CD19 CAR-T cells with CRS suppression technology
1997791|NCT01914146|Other|No Insulin|Study session will occur prior to initiation of insulin therapy.
1906884|NCT03274492|Drug|Polatuzumab Vedotin|Polatuzumab vedotin IV infusion will be administered as per the schedule specified in the respective arm.
1906885|NCT03274492|Drug|Rituximab|Rituximab IV infusion will be administered as per the schedule specified in the respective arm.
1906886|NCT03274492|Drug|Cyclophosphamide|Cyclophosphamide IV infusion will be administered as per the schedule specified in the respective arm.
1906887|NCT03274492|Drug|Doxorubicin|Doxorubicin IV infusion will be administered as per the schedule specified in the respective arm.
1906888|NCT03274492|Drug|Vincristine|Vincristine IV infusion will be administered as per the schedule specified in the respective arm.
1906889|NCT03274492|Drug|Vincristine Placebo|Placebo matching to vincristine will be administered as per the schedule specified in the respective arm.
1906890|NCT03274492|Drug|Prednisone|Prednisone PO will be administered as per the schedule specified in the respective arm.
1906891|NCT03274492|Drug|Polatuzumab vedotin Placebo|Placebo matching to polatuzumab vedotin will be administered as per the schedule specified in the respective arm.
1906893|NCT03274076|Drug|Placebo Oral Tablet|Oral Placebo 5 mg twice a day for 24 weeks
1906894|NCT03273400|Other|Lumbar Mobilisations|Please see arm (intervention) description
1906895|NCT03273309|Other|Vibratory Perineal Stimulus|Vibratory perineal stimulus will be applied in patients randomized to this group through an intravaginal probe which emits vibratory pulses, with the device fixed in the following parameters:on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
1906896|NCT03273309|Other|Transvaginal Electrical Stimulation|The transvaginal electrical stimulation will be applied in patients randomized to this group through an intravaginal probe which emits electrical pulses, with the device fixed in the following parameters: frequency = 50 Hz, pulse width = 300ms,on time = 8 seconds, off time = 16 seconds, total time = 20 minutes. The intervention time will be 6 weeks, with sessions held once a week.
1906897|NCT03271281|Drug|One injection of 68Ga-NODAGA-E[c(RGDyK)]2|One injection of 68Ga-NODAGA-E[c(RGDyK)]2
1906898|NCT03271281|Device|PET/CT|Following injection of 68Ga-NODAGA-E[c(RGDyK)]2 the patients will be subjected to whole body PET/CT
1964622|NCT01434303|Drug|Entinostat|Given PO
1964623|NCT01434303|Other|Laboratory Biomarker Analysis|Correlative studies
1964624|NCT01434303|Drug|Lapatinib Ditosylate|Given PO
1964625|NCT01434303|Biological|Trastuzumab|Given IV
1964626|NCT01434290|Radiation|hypofractionated radiation therapy|Given twice a week for 2½ weeks (36.25 fractions)
1997793|NCT01908101|Drug|Eribulin Mesylate|Given IV
1997794|NCT01908101|Other|Laboratory Biomarker Analysis|Correlative studies
1997795|NCT01905267|Behavioral|Rumination-Focused Cognitive Behavior Therapy|This intervention targets rumination and other maladaptive forms of emotion regulation such as suppression and avoidance and provides skills training in effective coping strategies. Mindfulness is a key component of this intervention as a strategy for disengaging from one's thoughts. Strategies from Dialectical Behavior Therapy (DBT), such as the use of effective interpersonal skills, are also included as methods for regulating strong emotion. Rumination-Focused Cognitive Behavior Therapy is a structured, manual based program designed to be delivered weekly over eight weeks. Sessions are 60-90 minutes in length.
1906911|NCT03270553|Drug|plazomicin|single intravenous dose
1906912|NCT03270553|Drug|metformin|single oral dose
1906913|NCT03270085|Drug|Colesevelam|Colesevelam (Welchol) is approved by the Food and Drug Administration (FDA) for the treatment of high blood cholesterol levels and to treat type 2 diabetes however, Colesevelam is not approved for the use proposed in this study and is considered investigational.
1906914|NCT03270085|Other|Placebo|A placebo looks exactly like the study drug, but it contains no active ingredient. This is used to learn if the effects seen in research participants are truly from the study drug.
1906915|NCT03269890|Procedure|Capsule and cutaneous blocks|7.5 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml for both blocks once before surgery per side
1906916|NCT03269890|Procedure|US-intermediate cervical plexus block|15 mL of 0.5% bupivacaine + Epinephrine 5 ug/ ml once before surgery per side.
1906917|NCT03269851|Radiation|computed tomography|ct will be done to detect radiological risk factors for neurological deficits after thoracolumbar fractures
1906918|NCT03268655|Dietary Supplement|Ginger extract|2000mg ginger extract daily for 6 weeks, plus 6 weeks washout
1997797|NCT01903564|Device|magnetocardiography|recording of magnetic heart activity
1997798|NCT01903564|Device|postnatal ECG|postnatal ECG
1997799|NCT01903564|Device|fetal echocardiography|fetal echocardiography
1997800|NCT01896999|Drug|Brentuximab Vedotin|Given IV
1997801|NCT01896999|Biological|Ipilimumab|Given IV
1906924|NCT03265886|Drug|Warm bupivacaine at (37°c)|Bupivacaine 0.5%, 30 mL, warmed to 37◦C for 20 minutes. The empty syringes and needles, in their packaging, will be held at the same temperature before initiating the block.
1906925|NCT03265886|Drug|Bupivacaine at operating room temperature (23°c)|Bupivacaine 0.5%, 30 ml held in crash shelf of the operating room temperature at 23◦C. The empty syringes and needles will be held in the same temperature before use.
1906926|NCT03263637|Drug|AZD4573|AZD4573 will be administered as a intravenous (IV) infusion.
1997802|NCT01896999|Other|Laboratory Biomarker Analysis|Correlative studies
1997803|NCT01896999|Biological|Nivolumab|Given IV
1906934|NCT03260868|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: Solution
Route of administration: Subcutaneous"
1906935|NCT03260868|Drug|Glulisine|"Pharmaceutical form: Solution
Route of administration: Subcutaneous"
1906936|NCT03260868|Drug|Aspart|"Pharmaceutical form: Solution
Route of administration: Subcutaneous"
1906937|NCT03260868|Drug|Lispro|"Pharmaceutical form: Solution
Route of administration: Subcutaneous"
1906938|NCT03260790|Biological|PCV13|Single 0.5 ml dose of PCV13 administered via intramuscular injection
1906939|NCT03260790|Biological|PPSV23|Single 0.5 ml dose of PPSV23 administered via intramuscularly or subcutaneously
1906940|NCT03258996|Procedure|Modified vestibular incision subperiosteal tunnel access|"Single vertical mucosal incision, mesial to the area to be treated, from which we began to lift a mucoperiosteal flap in a single plane.
With a micro-scalpel intrasulcular incisions are made extending to the base of the papillas.
Preparation of a tunnel in the same plane. Take a connective tissue graft on the same side of the palate. The connective graft is inserted through the vertical incision prepared with the aid of the suture.
All is stabilized by means of suspensory sutures of coronal traction on each point of contact.
Finally the vertical incision made is sutured."
1906941|NCT03258996|Procedure|Coronally advanced flap|"Oblique submarginal incisions in both interdental areas of each recession, which continue with the intrasulcular incision, one tooth extending on each side of the teeth to be treated.
A partial-total-partial thickness flap is elevated in the coronal-apical direction.
A vestibular mucosal dissection is performed to eliminate muscle tension. The remnant tissue of the anatomical interdental papillas is desepithelized. Take a CTG on the same side of the palate. The connective tissue graft is stabilized with resorbable suture over the recessions with suspensory sutures on the teeth.
Finally, suspensory sutures with non-resorbable sutures are also used to achieve an accurate adaptation of the vestibular flap over the exposed root and stabilize each surgical papilla over each desepithelized interdental area."
1906942|NCT03258762|Drug|Pyrimethamine|Pyrimethamine will be available as 25 mg tablets. Subjects will be orally administered two pyrimethamine tablets on Day 1 in a fasted condition with 240 mL of water.
1906943|NCT03258762|Drug|Calcium folinate|Calcium folinate will be available as 5 mg tablets. Subjects will be orally administered three calcium folinate tablets on Day 1 along with pyrimethamine followed by once daily administration of calcium folinate until Day 8. Each administration will be with 240 mL water.
1906948|NCT03257358|Drug|Fingolimod|Commercially available 0.5mg hard capsules, taken orally once per day
1906950|NCT03257163|Drug|Capecitabine|Given PO
1906951|NCT03257163|Other|Laboratory Biomarker Analysis|Correlative studies
1906952|NCT03257163|Biological|Pembrolizumab|Given IV
1906953|NCT03257163|Radiation|Radiation Therapy|Undergo radiation therapy
1906955|NCT03255941|Drug|DMPA|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use DMPA.
1906956|NCT03255941|Drug|Sayana Press|The safety and effectiveness of provision of injectable contraception will be compared between providers' screening and counseling for eligibility to use Sayana Press
1906965|NCT03254433|Behavioral|BAS+|The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: (1) ensure that not smoking is as reinforcing as smoking; and (2) prevent an over-reliance on food as a substitute reinforcer for smoking so that PCWG does not precipitate smoking relapse.
1906966|NCT03254433|Behavioral|SC|Overeating and weight gain are common concerns reported during smoking cessation treatment. Per convention, SC will address these concerns through standard recommendations to consume low-calorie snack foods, drink water, eat nutritious meals, and exercise, but will not include skills to shape the use of these suggestions.
1964644|NCT01406886|Behavioral|Eating rate|
1964645|NCT01404949|Drug|Tretinoin and Arsenic Trioxide|See Detailed Description
1964649|NCT01394627|Drug|Eplerenone|100mg x 2
1906975|NCT03250923|Drug|silver citrate complex and acemannan|Oral rinse solution with each dose containing 100μg silver citrate complex and 40mg acemannan
1906976|NCT03250871|Other|Support of patients during their surgery|"Support of patients is different. Patients in arm Placebo are supported by a nurse. Hypsnosis will be supervised by a nurse trained by the French Institute of Hypnosis."
1906977|NCT03249116|Other|animal-assisted intervention|Interaction with a therapy dog
1906978|NCT03249116|Other|active control|Interaction with a stuffed dog
1906979|NCT03249909|Device|Exufiber Ag +|Gelling Fiber Dressing with Ag
1906980|NCT03249909|Device|Exufiber|Gelling Fiber Dressing without Ag
1906981|NCT03249909|Device|Aquacel Ag Extra|Gelling Fiber Dressing with Ag
1906984|NCT03249571|Dietary Supplement|Flavonoid supplement|2-weeks ingestion of flavonoid supplement
1906985|NCT03249571|Dietary Supplement|Placebo|2-week ingestion of placebo supplement
1906991|NCT03248011|Other|Stretching|Lower extremity flexibility exercises will be performed
1906992|NCT03248011|Other|Strengthening|Eccentric hamstring strengthening exercises will be performed
1906993|NCT03248011|Other|Neuromuscular|Dynamic lower extremity balance and movement control exercises will be performed
1906994|NCT03248544|Drug|vitamin D|Fat-soluble vitamin D injection contain of 300,000 IU vitamin D that given via intramuscular injection
1906995|NCT03248544|Other|control|No intervention
1906998|NCT03246958|Drug|Nivolumab|Ipilimumab are types of immunotherapy Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
1906999|NCT03246958|Drug|Ipilimumab|Nivolumab are types of immunotherapy. Immunotherapy works by encouraging the body's own immune system to attack cancer cells.
1907000|NCT03246789|Behavioral|Engage-M|Engage is a stepped care psychotherapy based on what is known about how older adults respond to depression interventions. Stepped care is a model of treatment that starts with the minimum effective therapeutic techniques first, and then based on how well people respond to treatment, additional therapeutic techniques are added until people are recovered from their depression.
1907001|NCT03246789|Behavioral|Wellness in Mind and Body|An active intervention focusing on psychoeducation and de-stigmatization of health and mental health conditions. These sessions are commonly part of senior centers programs. W-MH will offer mental health referral to a clinic or primary care physician as part of senior center procedures for clients with positive PHQ-9s.
1964665|NCT01375699|Drug|Doxorubicin|As prescribed by treating provider.
1964666|NCT01375699|Drug|Sildenafil|Given PO, by mouth
1907007|NCT03245255|Drug|Sonazoid|Whenever a patient undergoes cardiac catheterization, which routinely includes intracardiac pressure monitoring using a pressure catheter, as part of their standard clinical care and agrees to participate in the study, we will acquire research data. With Sonazoid infusion, SHAPE algorithm will be initiated to determine optimum acoustic pressure. Then, at the optimum acoustic pressure, SHAPE specific data will be acquired from the cardiac chambers and aorta synchronously with the pressures recorded by the catheter (as a part of the patient's standard of care). After acquiring the ultrasound imaging data, the remainder of the heart catheterization will be completed by the attending cardiologist according to the patients' standard of care.
1907011|NCT03244462|Drug|BAY1834845|Single oral dose (IR [immediate release] tablets)
1907012|NCT03244462|Drug|BAY1834845|I.v. infusion of [13C6]-labeled BAY1834845
1907013|NCT03244462|Drug|Methotrexate|Single dose of commercially available MTX
1997848|NCT01865617|Biological|Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes|Given IV
1997849|NCT01865617|Other|Laboratory Biomarker Analysis|Correlative studies
1997850|NCT01866449|Drug|Cabazitaxel|
1997852|NCT01864629|Behavioral|Focused contraception counseling|This intervention will be provided to those randomized to the intervention group only. This counseling will follow a pre-written, structured script describing all contraceptive methods in rank order starting with most effective to least effective in preventing unplanned pregnancy.
1997853|NCT01864369|Behavioral|eCounseling + Usual Care|"This intervention will use film vignettes and interactive web pages. The e-counseling messages will promote: (i) validation of the subject's stage of readiness for behavior change, (ii) collaborative participation by means of subject-selected menus, (iii) reinforcement of change talk to resolve ambivalence, (iv) use of self-help information and e-tools for self-monitoring of targeted self-care behaviors, and (v) development of cognitive-behavioral skills to build and strengthen efficacy. Messages will be proactively sent to Controls according to the following schedule: weekly for months 1 to 4, bi-weekly for months 5 to 8, and monthly for months 9 to 12."
1997854|NCT01864096|Drug|Metformin|One month run-in of 850mg metformin once daily, followed by 850mg twice daily of metformin for 35 months. Total time is 36 months.
1997855|NCT01864096|Drug|Placebo|One month run-in of placebo tablet once daily, followed by twice daily for 35 months. Total time is 36 months.
1907023|NCT03242811|Diagnostic Test|MRI scan of knee, ankle and wrist|"At the day of the intervention, the subject is informed about the study by a nurse and provides written informed consent.
Girls must leave urine tests to rule out pregnancy. The questionnaire for the study is answered by the subject and weight and length are measured. The subject is asked to self-assess his/her puberty.
After detailed information on how a magnetic camera examination is carried out, an examination of five selected growth zones (knee joint, ankle joint including heel leg and wrist) is performed using 1.5 Tesla magnetic camera with dedicated cartilage sequence."
1907027|NCT03242083|Other|quality of life questionnaire|quality of life questionnaire
1907033|NCT03240848|Procedure|artificial intelligent clinic|Participants in group A assigned to artificial intelligent clinic to get the initial diagnosis after the eye examinations, including visual acuity, IOP, images of ocular anterior segment.
1907034|NCT03240848|Procedure|normal clinic|Participants in group B assigned to normal clinic to get the initial diagnosis after the eye examinations, including visual acuity, IOP, images of ocular anterior segment.
1907035|NCT03240848|Procedure|experts diagnose|After making the initial diagnosis, participants went to get the final definite diagnosis from experts with more than 10 years of clinical experience.
1907036|NCT03241225|Behavioral|EM/PROTECT|EM/PROTECT is a behavioral intervention for depressed elder mistreatment (EM) victims designed to work in synergy with EM mistreatment resolution services that provide safety planning, support services, and links to legal services
1907037|NCT03241225|Behavioral|EM/MH|EM/MH provides individuals experiencing elder mistreatment with support services from staff trained in linking elder mistreatment victims to community mental health services.
1907044|NCT03239340|Drug|Osimertinib|Osimertinib is an oral, potent, selective, irreversible inhibitor of both EGFR tyrosine kinase inhibitor sensitizing and resistance mutations in non-small cell lung cancer with a significant selectivity margin over wild type EGFR.
1964694|NCT01355406|Device|FlexStent® Femoropopliteal Self Expanding Stent System|Transcatheter over guidewire placement of an intravascular stent(s)
1964695|NCT01355380|Drug|Inhaled iloprost (Ventavis, BAYQ6256)|Patients treated with inhaled iloprost (Ventavis) 2.5 or 5 micrograms 6-9 times daily
1907049|NCT03237936|Drug|1mg/mL ciclosporin|IKERVIS® (1mg/ml ciclosporin) eye drops administered once daily following 3 months of treatment
1964702|NCT01352195|Behavioral|Forever Free Booklets|Randomized 3-arm design, with 660 smokers recruited into each condition. Assessments will occur at six-month intervals, through 30 months.
1907053|NCT03238638|Drug|Pembrolizumab|Both cohorts will receive pembrolizumab at a flat dose of 200mg every 3 weeks.
1907054|NCT03238638|Drug|epacadostat|Both cohorts will receive epacadostat. Patients in cohort 1 will take 300mg of epacadostat by mouth twice per day. Cohort 2 will take 300mg of epacadostat every 6 weeks.
1907055|NCT03238612|Drug|FFA, clarithromycin, oseltamivir|2-day course of triple combination of clarithromycin 500mg, flufenamic acid 200mg and oseltamivir 75mg twice daily followed by oseltamivir 75mg twice daily for 3 days
1907056|NCT03238612|Drug|Oseltamivir alone|2-day course of oseltamivir 75mg plus placebo capsules twice daily followed by oseltamivir 75mg twice daily for 3 days as control
1907057|NCT03238365|Biological|Nivolumab|Given IV
1907058|NCT03238365|Drug|Tadalafil|Given orally
1907059|NCT03238365|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1964706|NCT01344031|Drug|Akt Inhibitor MK2206|Given PO
1964707|NCT01344031|Drug|Anastrozole|Given PO
1964708|NCT01344031|Drug|Fulvestrant|Given IM
1907063|NCT03237052|Other|model|a model that has been established in advance.
1907064|NCT03237052|Other|non-model|real-world psychiatrist decision
1907069|NCT03235986|Drug|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part I)|Single ascending doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part I)
1907070|NCT03235986|Drug|nCPAP (nasal Continuous Positive Airway Pressure) + Nebulised Curosurf® (Part II)|Two doses of Curosurf® administered through nebulisation to neonates receiving nCPAP (Part II)
1907071|NCT03235986|Other|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part I)|Nasal continuous positive airway pressure alone
1907072|NCT03235986|Other|nCPAP (nasal Continuous Positive Airway Pressure) alone (Part II)|nasal continuous positive airway pressure alone
1907073|NCT03235349|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
1964709|NCT01344031|Other|Laboratory Biomarker Analysis|Correlative studies
1907078|NCT03234491|Device|DiAS|Diabetes Assistant (DiAS) hybrid closed loop system.
1907079|NCT03234491|Drug|Afrezza low dose|Afrezza inhaled insulin low dose.
1907080|NCT03234491|Drug|Afrezza high dose|Afrezza inhaled insulin high dose.
1907081|NCT03233126|Drug|KRN23|Subjects will receive subcutaneous injections of KRN23 every 2 weeks from Week 0 through Week 86
1907082|NCT03233230|Drug|Evobrutinib|Evobrutinib low dose will be administered orally for 24 weeks.
1907083|NCT03233230|Drug|Evobrutinib|Evobrutinib mid dose will be administered orally for 24 weeks.
1907084|NCT03233230|Drug|Evobrutinib|Evobrutinib high dose will be administered orally for 24 weeks.
1907085|NCT03233230|Drug|Placebo|Placebo matched to evobrutinib will be administered orally for 24 weeks.
1907086|NCT03233230|Drug|Methotrexate|Subjects will receive stable background therapy of methotrexate 7.5 to 25 mg/week (oral or parenteral) for >= 16 weeks.
1907089|NCT03231228|Drug|Cefazolin 1 g Infusion|1 g cefazolin infusion for pediatric surgical subjects weighing ≥25 to <60 kg
1907090|NCT03231228|Drug|Cefazolin 2 g Infusion|2 g cefazolin infusion for pediatric surgical subjects weighing at least 60 kg
1907093|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
1907094|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
1907095|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
1907096|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
1907097|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
1907098|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
1907099|NCT03230383|Drug|PF-06865571|Multiple ascending dose of PF-06865571 as extemporaneously prepared suspension for 14 consecutive days with total daily dose of 90mg, 300mg, 900mg, 1800mg, 3000mg and TBD.
1907100|NCT03230383|Drug|Placebo|Matching Placebo for PF-06865571 for each cohort.
1907101|NCT03230175|Biological|TTAX01|TTAX01 will be applied directly to the wound surface and retained with non-absorbable sutures. A single layer of the test article should cover the entire open surface of the wound. The material is to be applied once every 4 weeks unless the wound shows evidence of healing, in which case dosing is suspended; or, if the test article has been accidentally dislodged, it may be replaced at any time.
1907105|NCT03226808|Device|Vivacit-E Liner|All subjects enrolled will receive the Vivacit-E liner.
1907106|NCT03228303|Drug|Nilotinib 150 MG [Tasigna]|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
1907107|NCT03228303|Drug|Imatinib 400mg|Nilotinib vs imatinib in patients with newly diagnosed CML-CP
1907108|NCT03227185|Device|real anodal transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
1907109|NCT03227185|Device|sham transcranial direct current stimulation (tDCS)|The MR-compatible neuroConn DC-Stimulator MR (neuroCare Group, Ilmenau, Germany) will be used in the study.
1907110|NCT03227861|Drug|DRV 800 mg + COBI 150 mg + FTC 200 mg + TAF 10 mg FDC|Participants will receive oral tablet containing D 800 mg /C 150 mg /F 200 mg /TAF 10 mg FDC once daily within 24 hours of the screening/ baseline visit.
1907115|NCT03228134|Drug|Ke Chuan Liu Wei Granule|Traditional Chinese Medicine
1907116|NCT03228134|Drug|Yang He Ping Chuan Granule|Traditional Chinese Medicine
1907117|NCT03228134|Other|Ke Chuan Liu Wei Granule placebo|Placebo
1907118|NCT03228134|Other|Yang He Ping Chuan Granule placebo|Placebo
1907119|NCT03223506|Drug|Paracetamol|
1907121|NCT03225664|Drug|Trametinib|"Phase Ib: Trametinib + Pembrolizumab Group: Dose level 1: Trametinib 1.5 mg by mouth daily for 2 weeks lead‐in followed by Trametinib 10 days on, 11 days off. Dose level 2 : Trametinib 2 mg by mouth daily for 10 days on, 11 days off.
Phase II Group 2: Trametinib + Pembrolizumab: Starting dose of Trametinib is MTD from Phase Ib.
Phase II Group 3: Trametinib + Pembrolizumab: Starting dose of Trametinib is MTD from Phase Ib."
1907122|NCT03225664|Drug|Pembrolizumab|"Phase Ib: Trametinib + Pembrolizumab Group: Pembrolizumab administered at the fixed dose of 200 mg by vein every 3 weeks.
Phase II Group 1: Pembrolizumab: Pembrolizumab 200 mg given by vein every 3 weeks.
Phase II Group 2: Trametinib + Pembrolizumab: Pembrolizumab 200 mg by vein on Day 22 and every 3 weeks.
Phase II Group 3: Trametinib + Pembrolizumab: Pembrolizumab 200 mg by vein on Day 22 and every 3 weeks."
1907124|NCT03225547|Drug|Pembrolizumab|Pembrolizumab 200mg will be administered to all patients on day 1 of every 21 day cycle.
1907125|NCT03225547|Drug|Mifepristone|Mifepristone 300mg will be administered to all patients daily starting the week prior to pembrolizumab.
1907139|NCT03220191|Drug|Palbociclib|palbociclib tablet formulation
1907140|NCT03220191|Drug|Rabeprazole|rabeprazole as PPI
1907145|NCT03219008|Drug|Fluoxetine|Fluoxetine is one kind of selective serotonin reuptake inhibitor(SSRIs), whose effect is much better than other non-underload subtypes compared with underload subtypes.So patients would be treated with fluoxetine only.
1907146|NCT03219008|Combination Product|fluoxetine + cognitive-behavioral treatment（CBT）|the investigators would recommend fluoxetine to help to cure depressive disorder.And CBT is a very effective way for patients to alleviate or relieve clinical symptoms during episode stage.
1907147|NCT03219008|Drug|fluoxetine + Amfebutamone|Amfebutamone is one kind of SNRIs, and it shows much better therapy effect on patients with exhaustion /dizziness.So the investigators recommend these two drugs to help to cure patients with depressive disorder.
1907148|NCT03219008|Combination Product|physical treatment+fluoxetine+amfebutamone|the investigators recommend drug(fluoxetine and amfebutamone) and physical treatment as intervention.
1907149|NCT03219008|Drug|Fluvoxamine|Fluvoxamine could inhibit CYP1A2 and CYP2C19 and affect the metabolism of melatonin, and help to release symptoms of depressive disorder with sleep problems.
1907150|NCT03219008|Drug|Lithium+fluvoxamine|the investigators recommend lithium as a mood stabilizer and use fluvoxamine to affect the level of melatonin.
1907151|NCT03219008|Combination Product|fluvoxamine + lithium + physical therapy|the investigators recommend depressants and mood stabilizers as well as physical therapy to help to cure depressive disorder.
1907152|NCT03219008|Combination Product|Cognitive behavior treatment +fluvoxamine|the investigators recommend behavioral therapy as well as drugs.
1907153|NCT03219008|Drug|Mirtazapine/SNRIs|Mirtazapine is one kind of antagonist of a2 adrenergic receptors and could block 5-hydroxytryptamine2 and 5-hydroxytryptamine3,help to release symptoms like anxiety or somatization.Besides, SNRIs could also make similar effect on patients.Therefore, the investigators recommend mirtazapine/SNRIs to treat patients with depressive disorder.
1907154|NCT03219008|Combination Product|mirtazapine+ Cognitive behavior treatment|the investigators recommend CBT and mirtazapine as interventions.The dosage and frequency would depend on patients' severity of symptoms .
1907155|NCT03219008|Drug|mirtazapine + SNRIs|the investigator recommend mirtazapine and SNRIs to treat patients with major depressive disorder.
1907156|NCT03219008|Combination Product|mirtazapine + SNRIs + physical therapy|the investigators would manage to use drugs and physical treatment to help to release the symptoms of depressive disorder.
1907157|NCT03219008|Other|TAU(treat as usual)|patients in this group would receive therapy strategies according to their symptoms and preference.
1907162|NCT03215927|Drug|Abatacept|Abatacept 125mg subcutaneous weekly
1907163|NCT03215927|Other|Placebo|Placebo
1907164|NCT03215420|Diagnostic Test|MRI 3T|
1964761|NCT01305941|Drug|Everolimus|everolimus 5 mg PO daily as two 2.5-mg tablets
1964762|NCT01305941|Drug|Vinorelbine|vinorelbine 25 mg/m2 will be administered via IV infusion over 6-10 minutes weekly.
1964763|NCT01305941|Drug|Trastuzumab|2 mg/kg IV administered over 30 minutes weekly
1907167|NCT03213938|Device|Acupuncture|"For acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 75mm; size 0.30 × 40mm) will be used. Bilateral SP6, BL33, BL23, and BL35, were selected as acupoints protocol.
Acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
1907168|NCT03213938|Device|Sham acupuncture|"For sham acupuncture group, Hwato brand disposable acupuncture needles (size 0.30 × 25mm) will be used to insert vertically about 2-3 mm without manipulation into non-acupoints bilateral sham SP6, sham BL33, sham BL23, and sham BL35, which were located at different physical locations than SP6, BL23, BL 33, and BL35.
Sham acupuncture group consists of 20 sessions over an 8-week period after baseline, each for 30 minutes, and will be administered over 8 weeks (3 sessions in each of the first 4 weeks, and 2 sessions in each of the remaining 4 weeks)."
1907174|NCT03210337|Drug|A-101 Topical Solution|A-101 Topical Solution
1907175|NCT03210246|Drug|Vilaprisan (BAY 1002670)|Multiple doses of Vilaprisan for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
1907176|NCT03210246|Drug|Vilaprisan Placebo|Multiple doses of placebo for 3 cycles of 28 days each and 7 additional doses on the 7 days after cycle 3.
1907177|NCT03210246|Drug|Microgynon|Multiple doses of Microgynon for 3 cycles of 21 days each (day 1-21)
1907178|NCT03210246|Drug|Microgynon Placebo|For the treatment cycle 1-3, 7 doses of Microgynon placebo on Day 22-28 per cycle and after 3 treatment cycles 7 additional doses of Microgynon placebo on the 7 days after cycle 3 (day 84 - 91).
1907180|NCT03205618|Other|Non-Interventional|Non-Interventional
1964773|NCT01288638|Other|Pulse-based diet|The pulse based-diet will include meals prepared with dry peas, lentils, chickpeas, and beans. Two meals will be supplied daily for 16 weeks to those participants on the pulse-based diet program. Meals will contain approximately 90g dried peas, 225 g chickpeas or beans, or 150g lentils.
1964774|NCT01288638|Other|TLC diet|Grocery gift cards will be provided weekly for 16 weeks to those participants in the placebo group. Recipe booklet will be given to follow Therapeutic Lifestyle Changes (TLC) guidelines, recommended by National Cholesterol Education Program (NCEP) and will be based on lean-meats for the protein source. The recipes will exclude pulses.
1964775|NCT01288235|Radiation|Proton radiotherapy|5 days a week
1907197|NCT03206047|Drug|Atezolizumab|Given IV
1907198|NCT03206047|Biological|DEC-205/NY-ESO-1 Fusion Protein CDX-1401|Given SC
1907199|NCT03206047|Drug|Guadecitabine|Given SC
1907200|NCT03206047|Other|Laboratory Biomarker Analysis|Correlative studies
1907201|NCT03206047|Drug|Poly ICLC|Given SC
1907205|NCT03203564|Drug|Modufolin®|Thirty-three eligible and consenting subjects will be included in 3 cohorts, 11 subjects in each cohort, Within each cohort, subjects will be randomized to receive either placebo (3 subjects) or Modufolin® for injection, 100mg (8 subjects)
1907206|NCT03203473|Drug|Ipilimumab|YERVOY is thought to work with the body's immune system to increase the activity of T cells and cause the body to attack cancer cells
1907207|NCT03203473|Drug|Nivolumab|Nivolumab binds to and blocks the activation of PD-1, an Ig superfamily transmembrane protein, by its ligands programmed cell death ligand 1 (PD-L1), overexpressed on certain cancer cells, and programmed cell death ligand 2 (PD-L2), which is primarily expressed on APCs
1907208|NCT03203408|Device|OSTENIL PLUS|Injection into the joint cavity of the most painful knee
1907209|NCT03203408|Device|SYNVISC-ONE|Injection into the joint cavity of the most painful knee
1907218|NCT03198715|Drug|DS1040b|DS-1040b in solution for intravenous infusion
1907219|NCT03198715|Drug|Placebo|Saline solution for intravenous infusion
1907221|NCT03197922|Combination Product|MIE Treatment|"Appointments consist of a series of sitting routines (i.e., sits). Each sit consists of 10 min on the toilet, followed by 1 min of standing, then repeating the 10 min on the toilet 1 min off, for 30 cumulative minutes of sitting. The first sit occurs prior to the administration of any medication providing an opportunity for an independent continent bowel movement. If no continent bowel movement occurs, trained staff administer a dose of a liquid glycerin suppository, immediately followed by another sit to ensure any resulting bowel movement is continent. Glycerin suppositories are replaced by bisacodyl if 2 days pass without a continent bowel movement using the liquid glycerin suppository. Behavioral intervention consists of potent positive reinforcers when a continent bowel movement occurs. As independent continent bowel movements begin to occur, the need for the medical regimen diminishes, and is gradually faded out entirely."
1907228|NCT03197714|Drug|OPB-111077|"Two dose schemas will be employed:
Level 1: 200 mg daily
Level 2: 250 mg daily"
1907229|NCT03196531|Drug|Loratadine (Xisimin [Test Treatment])|Participants will receive 10 mg loratadine as Xisimin (test treatment) as per the treatment sequence.
1907230|NCT03196531|Drug|Loratadine (Clarityne [Reference Treatment])|Participants will receive 10 mg loratadine as Clarityne (reference treatment) as per the treatment sequence.
1964790|NCT01279187|Drug|Teriparatide|20ug per day,via subcutaneous injection, for 7 weeks
1964791|NCT01279187|Drug|Placebo|20ug per day, self administered injection, for 7 weeks
1907233|NCT03195699|Drug|C188-9|Dose level 1. 3.2 mg/kg/day administered in divided doses every 12 hours Dose level 2. 6.4 mg/kg/day administered in divided doses every 12 hours Dose level 3. 12.8 mg/kg/day administered in divided doses every 12 hours Dose level 4. 25.6 mg/kg/day administered in divided doses every 12 hours
1907237|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 1 bleeding episode(3/1 regimen).
1907238|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 2 treatment periods of 24 weeks, each separated by 2 bleeding episodes episodes(6/2 regimen).
1907239|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 4 treatment periods of 12 weeks, each separated by 2 bleeding episodesepisodes(3/2 regimen).
1907240|NCT03194646|Other|Standard of care|Standard of care as determined by the investigators (including watch and wait, symptomatic nonhormonal)
1907241|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 8 treatment periods of 12 weeks, each separated by 1 bleeding episode (3/1 regimen)
1907242|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 24 weeks, 4 treatment periods of 24 weeks, each separated by 2 bleeding episodes (6/2 regimen)
1907243|NCT03194646|Drug|Vilaprisan (BAY1002670)|2 mg of Vilaprisan once daily for 12 weeks, 6 treatment periods of 12 weeks, each separated by 2 bleeding episodes (3/2 regimen)
1907248|NCT03193164|Device|Neuromuscular Electrical Stimulation|The patient will be positioned on a headboard at 30° in the decubitus position with the limbs raised to 20°. The location of the electrical current will be cleared with trichotomy when necessary. Adhesive electrodes 90 x 50 mm will be positioned in the gastrocnemius. The stimulator device will be the Neurodyn II (Ibramed, Sao Paulo, Brazil) to provide symmetrical biphasic pulses of 50 Hz, 250 µsec pulse duration, 2 seconds on (1 second of time of rise and 1 second of time of decay), and 5 seconds of rest during 30 minutes at an intensity capable of generating visible contractions and articular motion.
1907249|NCT03193164|Other|Decubitus Position with the limbs raised to 20º|The patient position will be the same used for intervention protocol (headboard to 30°, decubitus position with the limbs raised to 20°) for 30 minutes, without NMES.
1964795|NCT01275053|Drug|leptin|0.01mg/kg
1907267|NCT03190889|Other|HOME|At home rehabilitation following ACL reconstructive surgery as described in the HOME arm.
1907268|NCT03190889|Other|TNMT|Standard of care, clinical rehabilitation following ACL reconstructive surgery with the addition of specified targeted neuromuscular training as described in the TNMT arm.
1907269|NCT03189745|Biological|MenACWY-TT|Single dose of MenACWY-TT given 10 years after first vaccine with either MenACWY-TT or Mencevax ACWY
1907272|NCT03190005|Drug|clopidogrel|routine Dual antiplatelet therapy after stent implantation, then check PRU(platelet reactivity unit)
1907273|NCT03190005|Drug|Placebos|no medication, healthy subjects.
1907274|NCT03189901|Drug|Regular management+Levosimendan|Patients are treated with regular management recommended in guidelines and levosimendan.
1907276|NCT03188978|Drug|Atorvastatin 40mg|one 40mg tablet daily for 8 weeks starting 2 weeks before the AVF creation.
1907277|NCT03188978|Other|Placebo|one tablet daily for 8 weeks starting 2 weeks before the AVF creation.
1907282|NCT03189394|Behavioral|PRIDE|A couples curriculum that is relationship-focused and in-person, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
1907283|NCT03189394|Behavioral|ePRIDE|A couples curriculum that is relationship-focused and online, aimed at helping to reduce the odds of a composite HIV risk variable among gay couples.
1907284|NCT03189394|Behavioral|Men's Health|A men's health curriculum that is individualized and in-person, aimed at helping participants to focus on gay men's health.
1907285|NCT03188003|Other|Exercise Movement Techniques based on mobilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
1907286|NCT03188003|Other|Exercise Movement Techniques based on stabilization|10 sessions will be held twice a week, with each session taking an average of 50 minutes.
1964809|NCT01271933|Drug|pregabalin|controlled release tablet; 165-495 mg/day; given once daily
1964810|NCT01271933|Drug|placebo|matching placebo tablet; given once daily
1964811|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
1907293|NCT03187340|Behavioral|Sleep education and relaxation 1|Sleep hygiene and relaxation training; Sleep education and relaxation 1
1907294|NCT03187340|Behavioral|Sleep education and relaxation 2|Modified sleep hygiene and relaxation training; Sleep education and relaxation 2
1907298|NCT03187184|Device|OneOme RightMed®|OneOme RightMed® currently tests for 22 genes that impact over 340 drugs used in multiple fields of medicine, including oncology. The drugs tested for by OneOme RightMed® were generated from practice guidelines and the FDA's guidelines for genotyping, and drugs with published, clinical evidence supporting genotyping. Testing is done using a prepackaged OneOme RightMed® kit to collect a buccal swab. OneOme RightMed® PGx test uses a DNA Genotek ORAcollect OC-100 buccal swab kit to extract DNA, which is then analyzed through polymerase chain reaction (PCR).
1907332|NCT03178942|Drug|Permethrin|Permethrin Cream 5%
1964812|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 11 days
1964813|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 330 mg, once per day (QD) for the remainder of the double-blind treatment phase (max is 12 weeks)
1964814|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for 7 days
1964815|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 82.5 mg, once per day (QD) for 3 days
1964816|NCT01262677|Drug|pregabalin|Controlled Release Tablets, 165 mg, once per day (QD) for the remainder of the up-titration and double-blind treatment and taper phases (max 14.5 weeks)
1964817|NCT01262677|Drug|placebo|matched to the active drug
1907314|NCT03183973|Biological|PRF|patients who will receive PRF suspension
1907315|NCT03183973|Biological|placebo group|patients who will receive Placebo
1907316|NCT03183739|Drug|ASP8062|ASP8062 will be administered orally.
1907317|NCT03183739|Drug|Placebo|Placebo will be administered orally.
1907322|NCT03182140|Drug|Kyleena|Kyleena - intrauterine delivery system containing 19.5 mg LNG
1964826|NCT01251874|Drug|Carboplatin|Given IV
1964827|NCT01251874|Other|Fluorothymidine F-18|Correlative studies
1964828|NCT01251874|Other|Laboratory Biomarker Analysis|Correlative studies
1964829|NCT01251874|Other|Pharmacological Study|Correlative studies
1907330|NCT03181243|Procedure|Madajet|The spermatic cord is firmly trapped between the middle finger, index finger and thumb of the left hand. The injector's sheath is placed over the spermatic cord with gentle pressure adjacent to the external inguinal ring. Depending upon the thickness of spermatic cord, three or four injections are consecutively administered around it, beginning from proximal to distal points.
1907331|NCT03181243|Procedure|Needle injection|The pubic tubercle is palpated on the side that is going to be blocked. The spermatic cord is then immobilised with the non-dominant hand between the thumb and index finger. Right after needle puncture with attached syringe and local anaesthetic solution is conducted at a point that is 1 cm inferior to and 1 cm medial to the pubic tubercle, pass the needle directly downward in a vertical fashion, which leads it into the spermatic cord. After a check-up (negative aspiration) for bleeding, approximately 3 mL of solution (Lidocaine 2%) is injected into the cord.
1964830|NCT01251874|Procedure|Positron Emission Tomography|Correlative studies
1964831|NCT01251874|Drug|Veliparib|Given PO
1964832|NCT01251367|Drug|Dysport|I.M. (intramuscular) injection on day 1 of each treatment cycle.
1964837|NCT01249404|Drug|Botulinum type A toxin (Dysport®)|I.M. injection on day 1 (single treatment cycle)
1964838|NCT01249404|Drug|Placebo|I.M. injection on day 1 (single treatment cycle)
1964840|NCT01245608|Drug|Polypill|Polypill taken once daily for 5 years. Each pill contains acetylsalicylic acid 81 mg, atorvastatin 20 mg, hydrochlorothiazide 12.5 mg, valsartan 40 mg
1907333|NCT03178942|Drug|Elimite 5% Cream|Elimite 5% Cream (Permethrin)
1907334|NCT03179267|Device|SNAP40|SNAP40 ambulatory monitoring device
1907335|NCT03179111|Procedure|Pneumoperitoneum Pressure|There will be two arms in this study. The participants recruited for this study are those who have been screened and planned for elective bariatric surgery.The pneumoperitoneum pressure will be adjusted to either 8-10mmHg or 12-15mmHg until a clear operating field is obtained by the surgeon. Low pneumoperitoneum pressure has been expected to give a clearer and better surgical view than standard pneumoperitoneum pressure. Participants under the low pressure group are expected to have lesser pain score on abdominal pain and shoulder tip pain as compared to participants in the standard pressure group.
1907336|NCT03179059|Diagnostic Test|Pregnancy test at Baseline|Among respondents who are randomly selected to receive a free home pregnancy test service, they will be offered the chance to take the test in the presence of the enumerator. Specifically, this would mean they would be given a cup to collect a sample of urine. The respondent would do so privately, then bring the cup back to the enumerator who would dip the home pregnancy tests and assist with interpreting the result. However, respondents can decline to take the test with the enumerator. Treatment assignment will be stratified by whether respondent use modern family planning at baseline.
1907337|NCT03179059|Diagnostic Test|Pregnancy test at follow up survey|We will provide a free pregnancy tests in the follow up survey, they are randomly selected from intervention #1 treatment group.
1907338|NCT03178552|Drug|Alectinib|Participants will receive 600 mg BID (Cohort A); 900, 1200, or 750 mg BID (Cohort B) or RP2D BID; orally until disease progression, unacceptable toxicity, withdrawal of consent or death.
1907339|NCT03178552|Drug|Atezolizumab|Participants will receive atezolizumab 1200 mg IV infusion Q21D.
1907340|NCT03178552|Drug|Pemetrexed|Participants will receive pemetrexed 500 mg/m^2 IV infusion on Day 1 Q21D.
1907341|NCT03178552|Drug|Cisplatin|Participants will receive cisplatin 75 mg/m^2 IV on Day 1 Q21D.
1907342|NCT03178552|Drug|Carboplatin|Participants will receive carboplatin of AUC 5 or 6 IV on Day 1 Q21D.
1907343|NCT03178552|Drug|Gemcitabine|Participants will receive gemcitabine 1000 or 1250 mg/m^2 on Days 1 and 8 of every cycle (1 Cycle=21 days).
1907344|NCT03178435|Other|Measures to prevent AKI among critically ill patients|"Meticulous optimization of the fluid balance
Avoidance of nephrotoxic medications where possible
Optimisation of the hemodynamic status
Avoidance of blood transfusion unless marked acute blood loss or symptomatic anemia
Optimization of the underlying medical condition
Seek expert renal advise when necessary"
1907345|NCT03177252|Drug|Lidocaine|-2% lidocaine will be given
1907346|NCT03177252|Drug|Sodium chloride|-Normal saline will be given
1907347|NCT03177252|Drug|Bupivacaine|-0.5% bupivacaine will be given
1907348|NCT03176719|Other|Venipuncture|"Full blood count and leukocyte differentiation.
Detection of malaria parasites and parasite differentiation to trophozoites, gametocytes and ringstages (XN-30)
Detection of anemia, thallasemia and sickle cell anemia (XN-20)
Ex-vivo stimulation of wholeblood with various stimuli. Read-out will be a spectrum of cytokines (ELISA)
Circulating cytokines and inflammatory markers (ELIZA)
DNA analysis to assess genetic variations determining pro- versus anti inflammatory response including mTOR, HK2, PFKP, GLS, and GLUD1/2.
pan-Salmonella PCR
Gametocyte PCR"
1907350|NCT03176277|Drug|ONO-7475|ONO-7475 tablets
1907352|NCT03174964|Drug|IVIg|Patients will take IVIg 1-2 days before IVF, another dose will be administered immediately after testing positive for human chorionic gonadotropin (hCG) and subsequent doses will be repeated interval of 4 weeks and will be repeated until the sixth month of pregnancy
1907353|NCT03174951|Drug|IVIg|Patients will take IVIg 1-2 days before IVF, another dose will be administered immediately after testing positive for human chorionic gonadotropin (hCG) and subsequent doses will be repeated interval of 4 weeks and will be repeated until the sixth month of pregnancy
1907358|NCT03174405|Drug|Avelumab|"All eligible patients will receive cetuximab and mFOLFOX6 combined avelumab from the second cycle onwards.
Cetuximab at a dose of 250 mg/m2 IV over 60 to 90 min (day 1 and 8) (first dose 400mg/m2) mFOLFOX6 (administration according to local standard) Oxaliplatin at a dose of 85 mg/m2 IV (day 1) 5-FU 400 mg/m2 IV bolus (day 1) LV at a dose of 400 mg/m2 iv (day 1) 5-FU at a dose of 2400 mg/m2 IV (day 1-3) Avelumab at a dose of 10mg/kg IV over 60 to 90 min (day 1 from cycle 2 onwards)"
1964853|NCT01231555|Drug|GSK2248761 100 mg once daily|1x100 mg capsule plus matching placebo
1964854|NCT01231555|Drug|GSK2248761 200 mg once daily|2x100 mg capsules
1964855|NCT01231555|Drug|Efavirenz 600 mg once daily|1x600mg tablet
1907366|NCT03172715|Procedure|Locking plate|Osteosynthesis
1907367|NCT03172715|Procedure|TKR|Total knee arthroplasty
1907368|NCT03172156|Genetic|ctDNA detection|To detect ctDNA in Patients With Stage I Non-small Cell Lung Cancer (NSCLC) Using Secondary Gene Sequencing (NGS)
1907380|NCT03171519|Behavioral|Exercise|The EXERCISE group will participate in an aerobic exercise program for 12 weeks, performed in intensity relative to 50% of reserve heart rate, on a treadmill.
1907381|NCT03171519|Behavioral|Acupuncture|The ACUPUNCTURE group will participate in an aerobic exercise program following the protocol of the EXERCISE group, plus acupuncture therapy once a week.
1907382|NCT03170609|Biological|Multivalent group B streptococcus vaccine|Various formulations at three dose levels
1907383|NCT03170609|Biological|Placebo|Saline Control
1907384|NCT03169985|Drug|Rosuvastatin 10 mg plus ezetimibe 10 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months by clinical judgement.
1907385|NCT03169985|Drug|Rosuvastatin 20 mg orally once a day|After the initial 12 months, randomized intervention will be stopped and then this arm will be received either usual dose rosuvastatin plus ezetimibe or high-dose rosuvastatin during the next 24 months based by clinical judgement.
1964892|NCT01194570|Drug|Ocrelizumab|Two IV infusions of 300 mg in each treatment cycle of double blind treatment period; two IV infusions of ocrelizumab 300 mg for Cycle 1 and single IV infusion of ocrelizumab 600 mg for subsequent cycles in OLE phase.
1964893|NCT01194570|Other|Placebo|Two IV infusions of placebo matched to ocrelizumab in each treatment cycle of double blind treatment period.
1964896|NCT01191333|Device|rTMS|Repetitive Transcranial Magnetic Stimulation
1907406|NCT03164785|Drug|Jinshuibao Capsule|1.98g t.i.d. p.o. for 6 months
1964897|NCT01191333|Device|Sham Device|Placebo Device that simulates active rTMS treatment
1907408|NCT03162224|Drug|MEDI0457|MEDI0457 Administration by IM injection followed by electroporation (EP) using CELLECTRA®5P device.
1907409|NCT03162224|Device|CELLECTRA®5P device (CELLECTRA 2000)|MEDI0457 Administration by IM injection followed by electroporation (EP) using CELLECTRA®5P device.
1907410|NCT03162224|Drug|Durvalumab|Durvalumab will be administered intravenously at a dose of 1500mg every 4 weeks.
1907411|NCT03163069|Combination Product|in-office bleaching with the conventional whitening dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the conventional whitening dentifrice.
1907412|NCT03163069|Combination Product|in-office bleaching with the whitening dentifrice containing blue covarine|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the whitening dentifrice containing blue covarine.
1907413|NCT03163069|Combination Product|in-office bleaching with the regular dentifrice|Participants will receive in-office tooth bleaching with 40% hydrogen peroxide (Opalescence Boost PF 40%) for the maxillary anterior teeth (2 sessions, with a 1-week interval). During the tooth bleaching procedure and 3 weeks after the procedure, the participants will be instructed to brush their teeth twice with the regular dentifrice.
1964900|NCT01181076|Dietary Supplement|Individualized Nutrition|The patients who are able to achieve oral nutrition requirement will receive a therapeutic diet using regular foods, which is lactose-reduced and energy-enriched. The naso-jejunal tube will be inserted during the first five days after transplantation. EN will be given when oral intake discontinue. EN with an additional PN will be given if the estimated requirements by the enteral route is lower than reference values.
1907542|NCT03113461|Device|CPAP|non-invasive positive airway pressure applied using an oronasal mask
1907448|NCT03153449|Device|ATTUNE Revision Knee System in Total Knee Arthroplasty|Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their anatomy is such that the use of revision components are required to perform primary total knee arthroplasty
1907449|NCT03153332|Other|surgical residents' comprehension of the hepatic anatomy|Surgical residents were assigned to three different groups to evaluate different modes of patients' data. Residents were ask to state the liver segment in which the tumor resided and make a minimal resection proposal, including the tumor, the safety margin (1cm) and the dependent liver tissue. Residents were recommended to proceed in a classic way by resecting the whole liver segment. The time spent by each resident was also recorded in order to assess the quickness of comprehension and information transfer of the three different modes of presentation.
1907450|NCT03153111|Drug|Macitentan|macitentan 10 mg; film-coated tablet; oral use
1907451|NCT03153111|Drug|Placebo|film-coated tablet (identical to the macitentan tablet); oral use
1907454|NCT03152188|Drug|FMT|Fifteen FMT Openbiome capsules administered at the same time
1907455|NCT03152188|Other|Placebo|Fifteen placebo capsules administered at the same time
1907456|NCT03150966|Drug|Nanocurcumin|Patients will take 80 mg nanocurcumin in the form of capsules daily during the 6 month study period
1907457|NCT03150966|Drug|Placebo|Patients will take placebo in the form of capsules daily during 6 months study period
1907460|NCT03145142|Procedure|Umbilical cord milking|At delivery, the umbilical cord is grasped, and blood is pushed toward the infant 4 times before it is clamped. The procedure infuses a placental transfusion of blood into the preterm infant and can be done in 15-20 seconds
1907461|NCT03145142|Procedure|Delayed Cord Clamping|At delivery, delayed cord clamping will be performed by having the delivering obstetrician delay clamping of the umbilical cord for at least 60 seconds.
1907470|NCT03140657|Drug|Nanocurcumin|Nanocurcumin capsules (the formulation of curcumin nanoparticles, Exirnanosina). Subjects randomized to Nanocurcumin Arm will receive 80 mg/day for 4 month
1907471|NCT03140657|Drug|Placebo|Subjects randomized to Placebo Arm will receive placebo in the form of capsules for 4 month
1907543|NCT03112330|Device|Plasma rich platelet injection|Plasma rich platelet injection with 26-gauge needle and 2cc syringe on inferior turbinate mucosa
1964945|NCT01147172|Device|Elevess|Injectable gel, 0.5mL or 1.0mL material supplied in a 1.0mL pre-filled sterile glass syringe with two 30 gauge needles
1907478|NCT03135041|Dietary Supplement|Fiber-containing dietary supplement|Effects of fiber-containing dietary supplement on weight loss during energy restriction
1907479|NCT03135041|Dietary Supplement|Placebo|Effects of placebo supplement on weight loss during energy restriction
1907480|NCT03135834|Biological|MenABCWY|N meningitidis group A, B, C, W, and Y vaccine
1907481|NCT03135834|Biological|Saline|Placebo
1907482|NCT03135834|Biological|rLP2086|Bivalent recombinant lipoprotein 2086 vaccine
1907483|NCT03135834|Biological|MenACWY-CRM|meningococcal group A, C, W-135, and Y conjugate vaccine
1907486|NCT03134573|Drug|Interferon beta-1b (Betaferon, BAY86-5046)|Solution for injection
1907487|NCT03134573|Device|Betaconnect auto-injector|Auto-injector for application of Betaferon solution which automatically covers injection related data
1907488|NCT03134573|Device|myBETAapp|Medical device which can be connected with Betaconnect auto-injector and displays injection related data to patients and offers tracking of patient reported data at the wellness- tracker
1907495|NCT03130751|Behavioral|Pocket Coach for AYA with Cancer|The Pocket Coach for AYA with Cancer is a psychosocial intervention to be delivered through a mobile platform. Intervention content is based on Mindfulness Based Stress Reduction (MBSR) and the Resilience in Illness Model [Dr. Joan E. Haase et al] and includes modules on relaxation, mindfulness, cognitions, and self-compassion.
1907496|NCT03128320|Drug|BAY1193397|Single dose of 1 mg BAY1193397 given in the fasted state
1907497|NCT03128320|Drug|BAY1193397|Single dose of 5 mg BAY1193397 given in the fasted state
1907498|NCT03128320|Drug|Placebo|Single dose of placebo given in the fasted state
1907499|NCT03128905|Drug|Colchicine opocalcium 1mg|"International non-proprietary name: Colchicine
Molecule owner: Mayoly-Spindler Laboratory, 1mg scored tablet for oral administration, authorized 03/02/1995.
Composition :
Active principle : Crystallized colchicine Excipients: Erythrosine aluminium lake, lactose, saccharose, magnesium stearate and povidone."
1907500|NCT03128905|Drug|Prednisone : Cortancyl 20mg|"International non-proprietary name: Prednisone
Molecule owner : SANOFI AVENTIS France 20 mg scored tablet for oral administration, authorized since 02/05/1990, generic drug available.
Composition :
Active principle : Prednisone Excipients: Maize starch, lactose, talc, magnesium stearate."
1907544|NCT03112330|Device|Saline nasal spray|two puffs of isotonic saline nasal spray twice daily
1964972|NCT01098071|Drug|mometasone furoate nasal spray|One spray (50 mcg per spray) in each nostril once daily (100 mcg daily) for 3 months
1907504|NCT03127189|Drug|Rilpivirine|Rilpivirine 25 mg immediate release oral solution.
1907505|NCT03127189|Drug|Rilpivirine Long-acting Parenteral Formulation|RPV LA 600 mg extended-release suspension for IM injection.
1964989|NCT01063114|Radiation|proton beam radiation|Given once a day, 5 days a week (Monday-Friday)
1964999|NCT01049516|Behavioral|Prolonged Exposure Therapy - Massed|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions occur 5 days/week for two weeks.
1965000|NCT01049516|Behavioral|Prolonged Exposure Therapy - Spaced|10 75-90 minute psychotherapy sessions, focused on gradually confronting distressing trauma-related memories and reminders. Sessions 1-3 occur in the first two weeks, Sessions 4-5 occur in Weeks 3-4, and Sessions 6-10 occur in Weeks 5-10.
1965001|NCT01049516|Behavioral|Minimal Contact Control|Participants receive minimal contact for 4 weeks after randomization and thereafter are offered PE-Spaced or PE-Massed, according to their preference. Participants receive 10-15 minute phone calls once per week by the study therapist or independent evaluator in order to monitor their status and to provide support as needed.
1907525|NCT03122548|Biological|CRS-207|via IV infusion
1907526|NCT03122548|Biological|Pembrolizumab|via IV infusion
1907527|NCT03122106|Biological|Personalized neoantigen DNA vaccine|-Personalized polyepitope inserts integrating the prioritized neoantigens and mesothelin epitopes will be designed and then synthesized and cloned into the pING parent vector
1907528|NCT03122106|Device|TDS-IM Electrode Array System|-Ichor Medical Systems
1907529|NCT03122106|Procedure|Peripheral blood draws|-Enrollment, mid adjuvant chemotherapy, end of chemotherapy, week 1, week 5, week 9, week 13, week 17, week 21, week 25, and week 77
1965002|NCT01049516|Behavioral|Present-Centered Therapy|10 75-90 minute psychotherapy sessions, focused on identifying and solving day-to-day problems as they are brought up by the participants
1907534|NCT03118570|Drug|BPS804|Intravenous infusion
1907535|NCT03118570|Drug|Placebo IV Infusion 5% Dextrose|Intravenous infusion
1907536|NCT03119558|Drug|18F‑Florbetaben (Neuraceq®) PET/MRI|Administration of 8.0 mCi 18F‑Florbetaben (Neuraceq®) IV followed by simultaneous acquisition PET emission and cardiac MRI sequence scan 45-60 minutes post-injection.
1907537|NCT03119012|Drug|Clopidogrel|75mg/day
1907538|NCT03119012|Drug|Ticagrelor|120mg/day
1907539|NCT03119012|Drug|Aspirin|100mg/day
1965007|NCT01033227|Drug|sodium nitrite injection, usp|Sodium nitrite injection, USP will be administered in blocks of six subjects (3 sodium nitrite and 3 no drug). A total of five dose levels are planned, pending safety starting. Drug will be given by continuous infusion infusion for 48 hours starting at 6 nmol/min/kg (10% of the maximal tolerated dose).
1907545|NCT03109886|Drug|Milciclib maleate|100 mg/day once daily, for 4 consecutive days a week in a 4-week cycle (4 days on/3 days off x q4 wks) for a total of 12 weeks (i.e. 3 cycles) unless patient refusal, consent withdrawal, Investigator's decision, unacceptable toxicity or death whichever occurs earlier. After the completion of three cycles, patients who, in the Investigator's judgment, are benefiting from treatment with milciclib, will resume treatment and will remain on study up to Day 180 from treatment start, unless withdrawal criteria are met earlier.
1907554|NCT03110120|Drug|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|Serratus plane block realized with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
1907555|NCT03110120|Drug|0.5% levobupivacaine injectable solution with 10 ml of physiological saline|local infiltration of the wound with a mixture of 10 ml of 0.5% levobupivacaine injectable solution with 10 ml of physiological saline
1907556|NCT03110120|Drug|0.5% levobupivacaine injectable solution with physiological saline|Serratus plane block realized with 20 ml of injectable solution of physiological saline
1907557|NCT03110120|Drug|0.5% levobupivacaine injectable solution with physiological saline|local infiltration of the wound with 20 ml of injectable solution of physiological saline
1907558|NCT03109964|Device|Bipolar coagulation forceps (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a bipolar coagulation device.
1907559|NCT03109964|Device|SURGIFLO hemostatic matrix (ETHICON inc.)|Hemostasis of the base of the ovarian cyst by utilization of a an absorbable gelatin based matrix known as SURGIFLO.
1965012|NCT01026532|Biological|Segmental Allergen Challenge|Segmental allergen challenge: Briefly, this procedure will be done during a bronchoscopy. Two airway tubes of the lung will have about 1 teaspoon of allergen put in it while the scope is wedged in an airway tube segment. The allergen will stimulate this portion of the airway tube to produce eosinophils. The scope will then be removed. The bronchoscopy will be repeated two days later to collect lung fluid and biopsy samples from the parts of the lung where the allergen solution was placed.
1965013|NCT01026298|Other|FDA-Approved Treatment|8 weeks of treatment with Continuous Positive Airway Pressure (CPAP)
1907563|NCT03109730|Drug|ABI-H0731|A novel HBV core protein allosteric modifier (CpAM) which is being developed as a potential therapeutic advance for CHB patients
1907564|NCT03109730|Drug|Placebo for ABI-H0731|Sugar pill manufactured to mimic the ABI-H0731 tablet
1907565|NCT03109730|Drug|Entecavir|An antiviral medication used in the treatment of hepatitis B virus infection
1907566|NCT03109730|Drug|Tenofovir Disoproxil Fumarate|An antiviral medication used in the treatment of hepatitis B virus infection
1907567|NCT03109730|Drug|Pegasys|Used to treat adults with chronic hepatitis B virus who show signs of liver damage
1907568|NCT03109080|Drug|Olaparib|five levels of dose, per os administration, twice daily each day
1907569|NCT03109080|Radiation|Radiation therapy|3D conformal radiotherapy or intensity-modulated radiotherapy (IMRT), Simultaneous Integrated Boost (SIB), postoperative radiotherapy
1907570|NCT03108937|Drug|Dexmedetomidine|Patients in the experimental group will receive Dexmedetomidine during surgery.
1907571|NCT03108937|Drug|saline|Patients in the control group will receive saline but not Dexmedetomidine during surgery.
1907572|NCT03107494|Device|Gala Airway Treatment System|The Gala Airway Treatment system is a device-based, energy delivery system that delivers high frequency short duration energy to the airway epithelium and sub-mucosal tissue layers. The energy is delivered via a proprietary catheter through the bronchoscope. In this study, 2 treatment sessions will be delivered 1 month apart. The right lung is treated at the first treatment session and the left lung is treated at the second treatment session. A third bronchoscopy will be performed 3 months following the second treatment session where treatment is not delivered but a cryo-biopsy will be taken from the airway sites that have been treated during the two previous bronchoscopic treatment session to evaluate the effect of the treatment on the airways producing excessive mucous. Subjects will be required to submit to several tests during the study including two CT scans (lung), respiratory function tests, exercise testing.
1907573|NCT03108885|Other|Blood and Tissue Collection|Blood DNA will be isolated from plasma. Tumor DNA will be purified with a kit and amplified regions of 10 genes discovered to by mutated in whole exome sequencing.
1907574|NCT03108625|Drug|Vortioxetine|Target dose is 10 mg/day; the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
1907575|NCT03108456|Device|Orbital Atherectomy|Vessel preparation with Orbital Atherectomy followed by balloon pre-dilatation
1907576|NCT03108456|Device|Balloon|Vessel preparation with conventional and/or specialty balloons
1907581|NCT03106831|Drug|Pituitrin infusion|To begin with 0.02 U/min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
1907582|NCT03106831|Drug|Norepinephrine infusion|To begin with 0.04 μg/kg.min to maintain mean arterial pressure(MAP) higher than 65 mmHg.
1907592|NCT03102320|Drug|Cisplatin|Cisplatin 25 mg/m2 IV administered on day 1 and day 8 of 21 day cycle, for up to maximum 6 cycles
1907593|NCT03102320|Drug|Gemcitabine|Gemcitabine 1000 mg/m2 IV administered on days 1 and 8 of a 21-day cycle
1907594|NCT03102320|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine 6.5mg/kg IV in monotherapy indications. For combination indications, the MTD determined in safety lead in phase will be administered
1907606|NCT03100747|Procedure|Bilamellar 3mm|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 3mm from the eyelid margin
1907607|NCT03100747|Procedure|Bilamellar 5m|Trichiasis surgery using the bilamellar tarsal rotation procedure with incision 5mm from the eyelid margin
1907608|NCT03100747|Procedure|Trabut 3mm|Trichiasis surgery using Trabut procedure with incision 3mm from the eyelid margin
1965044|NCT00989781|Radiation|3-D Ultrasound|One time pelvic ultrasound
1907611|NCT03097328|Drug|TAK-228|TAK-228 works to inhibit or interfere with cellular functions involved in cell growth and survival. TAK-228 specifically targets a type of protein that can make chemicals that trigger cell growth, including cancer cell growth
1907612|NCT03096301|Device|Low-intensity laser|Laser applications will be applied as initial treatment, with 2 sessions per week. A wave length of 780 nm, with an energy density of 25 J/cm2, a power of 50 mW and power density of 1.25 W/cm2, will be used for a duration of 20 seconds per point, resulting in a total energy of 1J per point. The laser will be applied at each point, using a conventional tip in contact with the skin, thus considering an area of 0.04 cm2
1907613|NCT03096301|Device|occlusal plates|"The group undergoing treatment with occlusal plates will be instructed to use the device during sleep, 8 hours per night, for a period of 12 months. The plates will be made following the principles established by Okenson (1998).
Participants will be molded with alginate to obtain models. In the upper model, a 2 mm acetate plate will be made, to be later replaced with acrylic resin (STRINI et al., 2009), and these plates will be adjusted in centric relation, to promote occlusal stability and disocclusion guide.
Weekly follow-up and adjustments will be performed during the evaluation period, until the completion of treatment"
1907614|NCT03096301|Device|Placebo|For the placebo group, all the measures described for the group 1 (LIL) will be adopted, however the laser equipment will remain switched off.
1965045|NCT00989781|Drug|recombinant human chorionic gonadotropin|Recombinant human chorionic gonadotropin will be given iv and blood samples obtained before and 24 hr afterwards
1965046|NCT00989781|Drug|Recombinant human follicle stimulating hormone|Recombinant human follicle stimulating hormone will be given iv and blood samples obtained before and 24 hr later.
1907617|NCT03095118|Drug|Daratumumab|Open-label
1907618|NCT03093402|Drug|JBT-101|Subjects will receive JBT-101 5 mg in the AM and placebo in the PM, Days 1-84
1907619|NCT03093402|Drug|Placebo|Subjects will receive JBT-101 5 mg in the AM and placebo in the PM, Days 1-84
1965047|NCT00989781|Drug|Adrenocorticotropin|Each subject will receive a 7 hr dose-response infusion of Adrenocorticotropin.
1965048|NCT00989781|Drug|Dexamethasone|Dexamethasone will be given prior to ACTH infusion test.
1965049|NCT00989781|Drug|Glucose|Each subject will undergo 3 oral glcuose tolerance tests.
1907624|NCT03090893|Drug|ATryn continuous infusion|replenish serum thrombin levels
1907629|NCT03086200|Behavioral|brief Motivational Interviewing|"All study participants will receive daily dosing text message reminders.
Participants randomized to the MI-b Intervention and who are persistently non-adherence based on negative or non-responses to iTAB will be sent automated high alert messages notifying the participant to take their study medication and respond to iTAB. Both the study coordinator and the MI counselor will also receive the high alert message. Participants will be contacted by the MI counselor for a phone MI-b session within 72 hours of a high alert message to discuss adherence. Participants who continue to be non-adherent despite receiving these messages will be switched to receive alert messages on a monthly schedule."
1907630|NCT03084835|Behavioral|Usual Care|Brief cessation counseling
1907631|NCT03084835|Behavioral|WEB+TXT|Access to Become an Ex website plus text messaging
1907632|NCT03084835|Behavioral|WEB+TXT+TTS|Access to Become an Ex website plus text messaging plus consult with a trained tobacco treatment specialist
1907636|NCT03084926|Drug|MP0274|Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons
1907637|NCT03083782|Drug|Apixaban alone|A single dose of 10 mg apixaban administered orally at 0H on Day 1.
1907638|NCT03083782|Drug|Cyclosporine|Once daily dose of 100 mg cyclosporine administered orally on Days 1 to 3.
1907639|NCT03083782|Drug|Tacrolimus|Once daily dose of 5 mg tacrolimus administered orally on Days 1 to 3.
1907640|NCT03083782|Drug|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following cyclosporine
1907641|NCT03083782|Drug|Apixaban|A single dose of 10 mg apixaban administered orally on Day 3 immediately following tacrolimus
1907642|NCT03083821|Drug|Baraclude|Specified dose on specified day
1907643|NCT03083236|Other|Standard PBI|Standard Parent Based Intervention (PBI)
1907644|NCT03083236|Other|Enhanced|Enhanced Parent Based Intervention (EPBI)
1965076|NCT00948922|Drug|Bortezomib|AUTOLOGOUS ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows Melphalan infusion). ALLOGENEIC ARM: Day -3 bortezomib (1.3 mg/m^2) as an intravenous push over 3 to 5 seconds (follows fludarabine and melphalan infusion).
1965077|NCT00948922|Drug|Melphalan|AUTOLOGOUS ARM: Day -4 and Day -3 Melphalan 100 mg/m^2/day IV over 30 minutes. ALLOGENEIC ARM: Day -4, Day -3 Melphalan 70 mg/m^2/day IV over 30 minutes.
1965078|NCT00948922|Procedure|Autologous Stem Cell Transplant|Autologous Stem Cell Transplant: Autologous Peripheral Blood Stem Cell Rescue. Day 0 Infusion of autologous stem cells.
1965079|NCT00948922|Drug|Fludarabine|Days -6,-5,-4,-3 Fludarabine 30 mg/m^2/day IV
1965080|NCT00948922|Procedure|Allogeneic Stem Cell Transplant|Allogeneic Stem Cell Transplant: Allogeneic Peripheral Blood Stem Cell Rescue. Day 0 Infusion of allogeneic peripheral blood stem cells.
1907660|NCT03074305|Device|PCI for in-bioresorbable scaffold stenosis|"In patients who have in-bioresorbable scaffold stenosis after bioresorbable scaffold implantation, PCI will performed according to the allocated arms
DEB strategy
DES strategy"
1907666|NCT03071250|Procedure|Total knee or Hip Arthroplasty|Patients who received either a total knee or hip arthroplasty will be identified
1907671|NCT03070119|Drug|BIIB067|Participants will receive a loading dose regimen followed by maintenance dosing.
1907678|NCT03068468|Biological|BIIB092|BIIB092 intravenous infusion on specified days
1907679|NCT03068468|Biological|Placebo|Placebo intravenous infusion on specified days
1907680|NCT03066830|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet
Route of administration: oral"
1907681|NCT03066830|Drug|placebo|"Pharmaceutical form: tablet
Route of administration: oral"
1907682|NCT03066830|Drug|Metformin|"Pharmaceutical form: tablet
Route of administration: oral"
1907683|NCT03066830|Drug|Sulfonylurea|"Pharmaceutical form: tablet
Route of administration: oral"
1907689|NCT03066609|Drug|Secukinumab 150 mg s.c.|150 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
1907690|NCT03066609|Drug|Secukinumab 300 mg s.c.|300 mg s.c. at randomization, Weeks 1, 2, 3, 4 and every 4 weeks till Week 48
1907691|NCT03066609|Drug|Placebo|Placebo 150 or 300 mg s.c at randomization, Weeks 1, 2, 3, 4, and 8. PASI responders at week 12 will continue to receive placebo till Week 48. PASI non-responders at Week 12 will receive Secukinumab 300mg at Weeks 12, 13, 14, 15, 16 and every 4 weeks till Week 48
1907694|NCT03064269|Biological|CD19 CAR-T cells|CNS leukemia is defined as unequivocal evidence of leukemic blasts in the cerebrospinal fluid by cytology or flow cytometry; cranial palsies or a nonhemorrhagic mass seen in cranial computed tomography or magnetic resonance imaging because of infiltration by leukemia cells
1907699|NCT03064126|Device|RANGER™ Paclitaxel Coated Balloon|"A procedure that utilizes a balloon coated with paclitaxel (drug) which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
1907700|NCT03064126|Drug|Paclitaxel|The RANGER™ Balloon is coated with the drug Paclitaxel.
1907701|NCT03064126|Procedure|Standard Balloon Angiplasty|"A procedure that utilizes an uncoated balloon which can open up a blocked blood vessel using a small, flexible plastic tube, or catheter, with a balloon at the end of it. When the tube is in place, it inflates to open the blood vessel, or artery, so that normal blood flow is restored. The tube is then removed. The blood vessels that will be treated in the RANGER II SFA study include the superficial femoral arteries and the proximal popliteal arteries."
1907702|NCT03060629|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5x10^10 virus particles (vp) as 0.5 milliliter (mL) via Intramuscular (IM) into the left deltoid on Months 0, 3, 6, and 12.
1907703|NCT03060629|Biological|Clade C gp140|Participants will receive Clade C gp140 (250 mcg) co-formulated with Aluminum phosphate adjuvant as 0.5 mL IM into the right deltoid on Months 6 and 12.
1907704|NCT03060629|Biological|Placebo|Participants will receive matching placebo.
1907705|NCT03060447|Drug|Vesatolimod|4 mg tablet administered orally once every 14 days
1907706|NCT03060447|Drug|Vesatolimod Placebo|Tablet administered orally once every 14 days
1907707|NCT03060447|Drug|ART|ART regimens administered in accordance with their Prescribing Information
1907708|NCT03058107|Dietary Supplement|Nutrition Therapy|At the time of diagnosis, patients will immediately be screened and started with Nutrition Therapy if assigned to group A. This regimen will stay in place for 6 weeks to 3 months, after which a switch will be made towards normal dietary counselling. Nutrition Therapy can be given orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status and aims at matching Caloric Intake with Resting Energy Expenditure. Moreover, a switch between these modalities is possible. Afterwards, standard dietary counselling will be given during the remainder of the study. Follow-up will last one year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
1907709|NCT03058107|Dietary Supplement|Control Therapy|At the time of diagnosis, patients will immediately be screened and started with standard dietary counselling for 1 year if assigned to group B. Dietary intervention can be orally, parenterally or via tube feeding (enteral nutrition), depending on the patient's status. Moreover, a switch between these modalities is possible. Follow-up will last 1 year. If 6 months after the last enrolment the study shows a large difference with the control group, the study will be stopped for ethical reasons.
1907713|NCT03056729|Drug|BIIB076|Administered as single intravenous (IV) infusion
1907714|NCT03056729|Drug|Placebo|Administered as single IV infusion
1907718|NCT03055884|Device|tDCS|active tDCS versus sham tDCS
1907719|NCT03055884|Behavioral|Verbal paired-associate learning task|with or without repeated retrieval practice
1965118|NCT00917618|Other|Exercise|Patients randomized to treatment arm attended 2-3 Spinning classes per week for 12 weeks.
1965119|NCT00917618|Other|Control|Patients randomized to the control arm were instructed not to change their baseline exercise programs
1907730|NCT03054077|Other|iPad with downloaded games|iPad with downloaded games will be given to children randomized to group 2 for use during their time in the peri-operative unit
1965125|NCT00903201|Drug|SB656933|20 mg
1965126|NCT00903201|Drug|SB656933|50mg
1965127|NCT00903201|Drug|Placebo|placebo
1907739|NCT03050879|Drug|Indocyanine Green Tracer|Laparoscopic gastrectomy with lymph node dissection for gastric cancer using Indocyanine Green Tracer
1965138|NCT00871845|Drug|Orlistat|Orlistat 60 mg capsules, three times daily, before meals) will be prescribed for a time frame starting 3 to 6 weeks prior to and during the 48 weeks of the standard anti-HCV therapy.
1965139|NCT00871845|Behavioral|Dietary and Lifestyle modification educational sessions|6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy.
1965142|NCT00859573|Drug|Modafinil|400 mg/day
1965143|NCT00859573|Drug|Placebo|inactive substance
1907750|NCT03047226|Other|next-generation sequencing|Use next-generation sequencing to test germline mutation and microsatellite instability.
1907751|NCT03047018|Behavioral|The Changing Health in Autism through Nutrition, Getting fit and Expanding variety (CHANGE) Program|The CHANGE program is a a six-month long intervention consisting of 16 sessions. The first 10 sessions occur weekly while the remaining 6 sessions occur bi-weekly. Sessions last about 1 hour each. Nutrition intervention focuses on decreasing excess calories from liquids and solids and creating a balanced meal plan. Physical activity intervention uses fading strategies to increase participation in exercise. Behavior strategies promote success with meeting goals. Problem-solving techniques address challenges to adherence with implementing the program in the home setting. The standardized protocols include educational handouts, clinic-based activities and assessment procedures, and caregiver-directed homework and data collection.
1907752|NCT03046849|Other|next-generation sequencing|Use next-generation sequencing to test germline mutation.
1965148|NCT00855413|Drug|Darunavir|800 mg orally once daily
1907756|NCT03045705|Behavioral|Routine pain management|Women that will be asked according to the routine management regarding pain management during labor, meaning frequent inquiries regarding the woman`s wishes to receive analgesia by the medical team.
1907757|NCT03045705|Behavioral|No inquiry regarding analgesia|women will not be asked about analgesia during labor by the medical team, but will be able to receive the modality of choice at the time of choice.
1965149|NCT00855413|Drug|Ritonavir|100 mg orally once daily
1965150|NCT00855413|Drug|Etravirine|200 mg orally twice daily, although patients may choose to take ETR 400 mg QD to have a simpler all QD regimen
1907760|NCT03044626|Drug|Radiotherapy|"Nivolumab 240 mg fixed dose (q2w). First dose followed by radiotherapy. Radiotherapy has to start at the latest 72 hours after nivolumab administration.
Radiotherapy: A metastatic site will be treated with a radiation dose of 4 Gy for a total of 5 courses during a two week time interval (total dose 20 Gy)"
1907761|NCT03044626|Drug|Nivolumab|Nivolumab 240 mg fixed dose (q2w)
1907766|NCT03044353|Drug|GSK2315698 (CPHPC)|20mg/hour, IV (in the vein) for up to 72hours followed by 60mg three times daily subcutaneous injection for 11 days. Number of cycles: up to 6. Dose level and frequency adjusted according to renal function
1907767|NCT03044353|Biological|GSK2398852 (anti-SAP mAb)|Up to 1200mg, IV divided over days 1 and 3. Number of cycles: up to 6. Dose level adjusted based on tolerability.
1907768|NCT03043716|Other|PAP therapy with telemonitoring|Patients will receive a prescription for PAP therapy in the course of their clinical Routine pathway and afterwards be asked to enrol in the registry. The will be asked if they are willing to use telemonitoring technology.
1907769|NCT03042117|Other|periodontal probing|A periodontal probe will be inserted between the tooth and the gum in the gingival sulcus and a measurement of the pocket depth will be measured by a trained dentist in all subjects
1907770|NCT03041259|Drug|Rejuveinix Low Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
1907771|NCT03041259|Drug|Rejuveinix High Dose|A intravenous administration of Rejuveinix after standard mechanical intervention of blocked peripheral artery
1965157|NCT00835328|Drug|exendin-(9-39)|exendin-(9-39) 1000-30000pmol/kg/min (0.2-6mg/kg/hr) Intravenous infusion over 9 hours
1965158|NCT00835328|Other|placebo|normal saline Intravenous infusion over 9 hours
1907777|NCT03039426|Drug|Bupivacaine|0.5% bupivacaine 20ml divided in two; 10 ml intraperitoneal infiltration and 10 ml subcutaneous infiltration
1907778|NCT03039426|Drug|Diclofenac|diclofenac 75 mg intramuscular, 2 hours postoperation
1965169|NCT00806429|Procedure|transvaginal appendectomy|patient undergoes transvaginal appendectomy
1965174|NCT00802438|Biological|mepolizumab|up to three monthly doses of 750mg i.v. mepolizumab
1907800|NCT03034213|Device|Gentrix™ Surgical Matrix (Treatment)|Gentrix™ Surgical Matrix will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
1907801|NCT03034213|Device|Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend (Control)|A biological or prosthetic mesh (Permacol, Parietex, Progrip, Strattice Perforated, or Surgimend) will be placed in the retrorectus space. The anterior midline fascia will be closed with long-acting absorbable suture either with a running or interrupted manner as per the surgeon's discretion.
1907802|NCT03034161|Device|Thermal imaging|Thermal imaging of the various stages of pressure ulcer will be analyzed to determine if a recognizable pattern of thermal distribution can be identified which can then be applied to identify patients at risk of developing pressure ulcers at an earlier stage in their hospital course.
1907808|NCT03032614|Drug|Carboplatin|Carboplatin is a second generation tetravalent organic platinum compound. Similar to cisplatin, carboplatin produces predominantly interstrand DNA crosslinks as opposed to DNA-protein crosslinks. Carboplatin is cell-cycle non-specific.
1907809|NCT03032614|Drug|Eribulin|Eribulin Mesylate is a synthetic halichondrin analog.
1965184|NCT00789776|Procedure|Allogeneic Bone Marrow Transplantation|Undergo donor bone marrow transplantation
1965185|NCT00789776|Drug|Cyclophosphamide|Given IV
1965186|NCT00789776|Drug|Fludarabine Phosphate|Given IV
1965187|NCT00789776|Other|Laboratory Biomarker Analysis|Correlative studies
1965188|NCT00789776|Drug|Mycophenolate Mofetil|Given PO
1965189|NCT00789776|Biological|Natural Killer Cell Therapy|Given IV
1965190|NCT00789776|Drug|Tacrolimus|Given IV or PO
1965191|NCT00789776|Radiation|Total-Body Irradiation|Undergo total-body irradiation
1997859|NCT01863290|Other|Primary care redesign|Connect individuals released from prison to primary care using trained, culturally competent primary care providers and community health workers (CHWs).
1997860|NCT01861665|Drug|Marcaine- 0.25%|Marcaine 0.25% administered pre-incision.
1997861|NCT01861665|Drug|Marcaine 0.25%.|Marcaine 0.25% administered post-incision.
1997862|NCT01860040|Drug|Cisplatin|Alkylating antineoplastic agent (Chemotherapy)
1997863|NCT01860040|Drug|Pemetrexed|Antimetabolite antineoplastic agent (Chemotherapy)
1997864|NCT01860040|Drug|Gemcitabine|Antimetabolite antineoplastic agent (Chemotherapy)
1997865|NCT01858194|Device|Renal sympathetic denervation|"The ablation catheter is placed within a long vascular sheath and advanced into the renal artery. The sheath is advanced over the catheter to engage the renal artery ostium and allow for contrast injection and visualization of the vessel during catheter manipulation.
After completion of the measurement, no more than six radiofrequency ablation lesions separated both longitudinally and rotationally (a spiral pattern, see figure) will be placed per renal artery. The power will be started at 10 W and titrated to a maximum 20 W, as deemed appropriate by the impedance drop (goal 10% drop). Each lesion should be between 30-120 seconds in duration (no more than 120 seconds per lesion)."
1997866|NCT01858194|Device|VT ablation alone|Placebo arm will receive standard VT ablation using current techniques
1907810|NCT03032614|Drug|Veliparib|Veliparib is a potent PARP inhibitor that delays the repair of DNA damage induced by chemotherapeutics.
1907813|NCT03032029|Device|Adaptive Servo-Ventilation|Bi-Level positive airway pressure with a targeted minute ventilation
1907820|NCT03029468|Behavioral|cognitive behavioral therapy|CBT teaches users how to recognize negative thoughts and emotions, use cognitive skills and problem-solving, and apply coping behaviors such as distraction, activity scheduling, and relaxation.
1907825|NCT03026088|Drug|Bisoprolol|Subjects will receive Bisoprolol at a dose of 1.25 milligram (mg) up to Weeks 3, and then it will be up-titrated to 2.5 mg up to Week 6 , 3.75 mg up to Week 10, 5 mg up to Week 14, 7.5 mg up to Week 18, and 10 mg up to Week 26.
1907836|NCT03020654|Other|Virtual environment with fast moving objects|A beach/park environment with graded moving objects, the individual will complete head and eye exercises.
1907837|NCT03020654|Other|Virtual environment with no movement|A beach/park environment with static objects, the individual will complete head and eye exercises.
1965211|NCT00765999|Drug|Linaclotide 300 micrograms|Oral, once daily each morning at least 30 minutes before breakfast for the duration of the study
1965214|NCT00746811|Drug|P-OM3|4 grams/day - 4 one gram capsules
1965215|NCT00746811|Drug|Placebo|4 grams/day - 4 one gram capsules
1965223|NCT00733980|Drug|GSK561679|GSK561679
1965224|NCT00733980|Other|Placebo|Placebo
1907860|NCT03013192|Other|Text message reminder|Patients will receive automated text message reminders regarding their physical therapy
1907868|NCT03010657|Other|Experimental intervention|Subjects will be asked to consume certain foods during chemotherapy treatment.
1907869|NCT03009227|Procedure|Colonic resection with D2 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D2 lymph node dissection
1907870|NCT03009227|Procedure|Colonic resection with D3 lymph node dissection|Appropriate to the tumor location colonic resection is performed with D3 lymph node dissection
1907871|NCT03008889|Drug|N-acetylcysteine|"Participants will start with taking 900mg of NAC once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events.
In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.
If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
1907872|NCT03008889|Drug|Placebo|"Participants will start with taking 900mg of the placebo once per day for one week (study days 1-7). At Day 7, parents (or primary caregiver) and subjects will return to the study site to review adverse events. The dosing for the placebo will increase in the same fashion as the active treatment.
In the absence of dose limiting adverse events attributable to the study drug, the dose will be gradually increased to 900 mg twice per day for study days 8-28.
If this dose is well-tolerated, the dose will be increased to 900 three times per day for study days 29-63."
1907873|NCT03007420|Drug|Occipital Nerve Block (ONB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive an ONB will receive the block with dexamethasone 2mg (steroid) each site with 3ml 1% lidocaine (local anesthetic), for a total of two sites.
1907911|NCT02999100|Drug|IV Oxytocin|Oxytocin will be supplied as solution for infusion in 1ml ampoule containing colourless and clear sterile solution to be administered as a 30-second IV bolus with unit dose strength 5 I.U./mL, or 10 I.U./mL.
1965245|NCT00702039|Other|No Music|No music will be played in patients in arm 2 of the study.
1965246|NCT00702039|Other|Music Therapy|Classical music being played during intravitreal injection.
1907874|NCT03007420|Drug|Cervical Medial Branch Block (CMBB) using lidocaine and dexamethosone|Patients enrolled in the study will be randomized to receive either an ONB or a CMBB. The assignment of the procedure will be randomized however neither the patients nor the investigator will be blinded to the procedure. Patients randomized to receive CMBB will receive the block with dexamethasone 1.5mg (steroid) each site with 2 ml 1% lidocaine (local anesthetic), for a total of three sites on each side.
1907875|NCT03008187|Drug|SEL24|"SEL24 taken orally once daily for 14 consecutive days over a 21-day treatment cycle.
Part 1 will commence with an accelerated dose escalation design. Part 2 will enroll patients at the recommended dose identified in Part 1."
1907881|NCT03005678|Drug|Denosumab|active treatment group
1907882|NCT03005678|Drug|Alendronate|comparator
1965261|NCT00658021|Drug|Placebo|Subcutaneous injection, twice a day
1965262|NCT00658021|Drug|Exenatide|Subcutaneous injection, 5 µg, twice a day
1965263|NCT00658021|Drug|Exenatide|Subcutaneous injection,10 µg, twice a day
1965264|NCT00658294|Other|Stop treatment|
1907903|NCT02999633|Drug|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
1907904|NCT02999633|Drug|dexamethasone|Pharmaceutical form:pills Route of administration: oral
1907905|NCT02999633|Drug|dexamethasone|Pharmaceutical form:solution Route of administration: intravenous
1907906|NCT02999633|Drug|acetaminophen|Pharmaceutical form:pills Route of administration: oral
1907907|NCT02999633|Drug|ranitidine|Pharmaceutical form:solution Route of administration: intravenous
1907908|NCT02999633|Drug|diphenhydramine|Pharmaceutical form:solution Route of administration: intravenous
1907909|NCT02999100|Drug|IH Oxytocin|Oxytocin will be supplied as colourless and clear hard capsule with powder blend for inhalation with unit dose strength 400 mcg and 200 mcg. It will be administered using ROTAHALER dry powder inhaler (DPI).
1907910|NCT02999100|Drug|IM Oxytocin|Oxytocin will be supplied for solution for infusion in 1ml ampoule containing colourless and clear sterile solution with unit dose strength 5 I.U./mL, or 10 I.U./mL for IM administration
1907912|NCT02999100|Device|ROTAHALER|ROTAHALER DPI device is a high airflow resistance capsule-based inhaler. It will be used to deliver IH oxytocin
1907913|NCT02998671|Biological|CJM112|
1965278|NCT00640224|Drug|rosiglitazone|4 mg daily for 6 months
1965279|NCT00640224|Drug|drospirenone/ethinyl estradiol|1 tab (3mg/30mcg) daily for 6 months
1907915|NCT02998554|Drug|SHP640|Instill 1 drop of SHP640 (0.1 percentage Dexamethasone and 0.6% povidone-iodine [PVP-I]) ophthalmic suspension in each eye 4 times daily (QID) (with a minimum of 2 hours between doses) for 7 days.
1907916|NCT02998554|Drug|Placebo|Instill 1 drop of placebo ophthalmic solution in each eye QID for 7 days.
1907920|NCT02997527|Device|Intraluminal Impedance|Esophageal impedance testing measures epithelial integrity as reflected through the ability of the mucosa to conduct electric current. Recently, a site specific endoscopically placed impedance probe has been developed that can measure esophageal mucosal impedance at any point of the esophagus.
1965284|NCT00625066|Other|biologic sample preservation procedure|
1965285|NCT00625066|Other|cytology specimen collection procedure|
1965286|NCT00625066|Other|medical chart review|
1965287|NCT00625066|Other|questionnaire administration|
1965288|NCT00625066|Other|survey administration|
1965289|NCT00625066|Procedure|biopsy|
1907928|NCT02996890|Biological|MV-ZIKA|MV-Zika vaccine
1907929|NCT02996890|Other|Placebo|physiological saline
1965290|NCT00625066|Procedure|evaluation of cancer risk factors|
1907931|NCT02993250|Drug|AL-335|Participants will receive AL-335 800 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
1907932|NCT02993250|Drug|Odalasvir (ODV)|Participants will receive ODV 25 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
1907933|NCT02993250|Drug|Simeprevir (SMV)|Participants will receive SMV 75 mg once daily for 8 weeks in cohort 1 and 12 weeks in cohort 2.
1907937|NCT02993406|Drug|Bempedoic acid 180 mg tablet|Patients take bempedoic acid 180 mg tablet orally once daily
1907938|NCT02993406|Drug|Matching placebo tablet|Patients take matching placebo tablet orally once daily
1965291|NCT00625066|Procedure|screening colonoscopy|
1965292|NCT00624013|Drug|sertraline|50 mg up to 100 mg daily for 6 months
1907947|NCT02991456|Drug|Rolapitant|single 180 mg dose by mouth
1907948|NCT02991456|Drug|Ondansetron|8 mg by mouth daily
1907955|NCT02989519|Drug|dydrogesterone|
1907956|NCT02989519|Drug|Micronized progesterone|
1965302|NCT00592592|Radiation|Proton Beam Radiation|Once per day, 5 days a week for a total of 4 to 6 weeks.
1965309|NCT00577512|Drug|DTPACE|"Dexamethasone 200 mg Intravenous Infusion Piggy-Back (IVPB) Days 1-7
Thalidomide 200 mg by mouth (PO) Days 1-7
Cisplatin 15mg/m2 Days 1-4 (modify for renal insufficiency)
Adriamycin 15 mg/m2 Days 1-4
Cyclophosphamide 600 mg/m2 Days 1-4
Etoposide 60 mg/m2 Days 1-4"
1965311|NCT00574080|Drug|Interim/Maintenance Dexamethasone|20 mg Days 1-4 every 3 weeks in the interim between treatment phases and during maintenance
1965312|NCT00574080|Drug|Induction/Consolidation Dexamethasone|40 mg Days 1-4
1965313|NCT00574080|Drug|Induction/Consolidation Cisplatin|10 mg/m2 by continuous infusion Days 1-4
1965314|NCT00574080|Drug|Induction/Consolidation Adriamycin|10 mg/m2 by continuous infusion Days 1-4
1965315|NCT00574080|Drug|InductionConsolidation Cyclophosphamide|400 mg/m2 by continuous infusion Days 1-4
1907965|NCT02987517|Other|Increased running cadence gait retraining|Runners use an increased cadence, or step rate, 7.5% greater than baseline preferred cadence
1907966|NCT02987517|Other|Forefoot Strike gait retraining|Runners use a forefoot strike running gait instead of a rear foot strike running gait.
1907967|NCT02987517|Other|Strengthening exercises|foot and ankle strengthening exercises performed by all subjects to prepare musculoskeletal tissues for requirements of new running gait.
1965316|NCT00574080|Drug|Induction/Consolidation Etoposide|40 mg/m2 by continuous infusion Days 1-4
1965317|NCT00574080|Drug|Induction Pegfilgrastim|6 mg Days 6 and 13
1907971|NCT02987010|Drug|IDH305|Isocitrate Dehydrogenase 1 inhibitor
1965318|NCT00574080|Drug|Transplant 1 Dexamethasone|20 mg Days -4, -3, -2, -1 and +4, +5, +6, and +7
1907973|NCT02984683|Drug|SAR566658 (ACT14884)|Pharmaceutical form:Solution Route of administration: Intravenous
1907974|NCT02984995|Drug|Quizartinib|A novel second-generation FLT3 inhibitor
1965319|NCT00574080|Drug|Transplant 1 Cisplatin|20 mg/m2 by continuous infusion Days -3 and -2
1965320|NCT00574080|Drug|Transplant 1 Adriamycin|20 mg/m2 by continuous infusion Days -3 and -2
1965321|NCT00574080|Drug|Transplant 1 Cyclophosphamide|800 mg/m2 by continuous infusion Days -3 and -2
1965322|NCT00574080|Drug|Transplant 1 Etoposide|80 mg/m2 by continuous infusion Days -3 and -2
1907981|NCT02980874|Drug|suprachoroidal CLS-TA + IVT aflibercept|suprachoroidal injection of CLS-TA following a 2 mg intravitreal injection of aflibercept
1907982|NCT02980874|Drug|suprachoroidal sham + IVT aflibercept|suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
1965323|NCT00574080|Drug|Transplant 1 Melphalan|50 mg/m2 Days -2 and -1
1965324|NCT00574080|Drug|Transplant 1 and 2 Pegfilgrastim|6 mg Day +6
1965325|NCT00574080|Procedure|Autologous Peripheral Blood Stem Cell Transplant (ASCT)|Day 0
1965326|NCT00574080|Drug|Transplant 2 Carmustine|300 mg/m2 Day -5
1907987|NCT02978625|Other|Laboratory Biomarker Analysis|Correlative studies
1907988|NCT02978625|Biological|Nivolumab|Given IV
1907989|NCT02978625|Biological|Talimogene Laherparepvec|Given IT
1907990|NCT02977052|Drug|Ipilimumab|
1907991|NCT02977052|Drug|Nivolumab|
1907992|NCT02977052|Procedure|Surgery|Surgery will be done at 6 weeks
1907993|NCT02977052|Procedure|Blood for PBMCs|Blood will be taken for translational research on PBMCs
1907994|NCT02977052|Procedure|Biopsies|Biopsies will be taken during screening and at relapse.
1965327|NCT00574080|Drug|Transplant 2 Etoposide|200 mg/m2 Days -5, -4, -3, -2
1965328|NCT00574080|Drug|Transplant 2 Cytarabine|400 mg/m2 Days -5, -4, -3, -2
1965329|NCT00574080|Drug|Transplant 2 Melphalan|140 mg/m2 Day -1
1907998|NCT02976545|Device|fMRI|fMRI examination
1907999|NCT02976545|Behavioral|psychiatric evaluation|psychiatric evaluation
1908000|NCT02975804|Device|Tymo|All children will be calibrated using the Tymo in a static sitting position in each treatment session. The amplitude of the force and weight distribution generated by the child between the two sides of the body will be recorded. This information will be used to set up the Tymo as a training module (the intervention) by the software, in which the child will move the trunk forward, backward and sideways to participate in a computer game in sitting. The child will choose which game they want in each treatment session and they have to stay on the same game for at least 10 minutes before changing to another game.
1965330|NCT00574080|Drug|Transplant 2 Dexamethasone|20 mg Days -5, -4, -3, -2, +4, +5, +6, +7
1965331|NCT00574080|Drug|Transplant 1 and 2 Bortezomib|1 mg/m2 Days -4, -1, +3, +7
1965332|NCT00574080|Drug|Transplant 1 and 2 Thalidomide|200 mg Days -4 to +5
1965333|NCT00568178|Drug|Losartan Potassium|"Losartan Use During the Double-Blind Treatment Phase:
Losartan potassium was administered orally as tablets; 25 or 50 milligrams (mg); or as a liquid suspension 2.5 mg/mL prepared for participants who weighed less than 25 kilograms (kg) or for those participants unable to swallow tablets. During the double-blind period, participants were initially randomized to either a once-daily weight-dependent dose of approximately 0.7 mg/kg (25 mg tablet; up to 50 mg per day) and at 2-weeks the dose was increased to a once-daily maximum weight-dependent dose of 1.4 mg/kg. The maximum dose of losartan, as specified in the protocol, was 50 mg/day (if the patient weighed <50 kg)
or 100 mg/day (if the patient weighed ≥50 kg).
Losartan Use During the Treatment Extension Phase:
Dose modifications of the drug were left up to the discretion of the Investigators based on each participant's level of tolerance."
1965334|NCT00568178|Other|Comparator: Placebo (Losartan)|Placebo (losartan suspension), administered orally, once daily for 12 weeks
1965335|NCT00568178|Drug|Comparator: amlodipine besylate|Amlodipine besylate (1 mg/mL) liquid suspension, oral administration, titrated to 0.2 mg/kg/day (5 mg maximum dose) per day for 12 Weeks
1965336|NCT00568178|Other|Comparator: Placebo (amlodipine besylate)|Liquid suspension, 1mg/mL, titrated to 0.2 mg/kg/day (5 mg maximum dose) once daily, for 12 weeks
1965337|NCT00568178|Other|Placebo (Losartan)|Normotensive patients randomized to losartan placebo for 12 weeks.
1965338|NCT00568178|Drug|Enalapril Maleate|Enalapril 2.5-, 5-, 10-, and 20-mg tablets or enalapril suspension (1 mg/mL), oral administration, once daily for 36 months.
1965339|NCT00566475|Other|telemedicine|School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
1908024|NCT02969408|Drug|ABS eMDPI|ABS eMDPI
1908025|NCT02969382|Drug|SEP-363856|One SEP-363856 capsule (50 mg or 75 mg) daily for four weeks
1908026|NCT02969382|Drug|Placebo - Cap|One Placebo capsule daily for 4 weeks
1908028|NCT02968368|Drug|Ferric maltol|
1908029|NCT02968368|Other|Placebo|
1908033|NCT02966782|Drug|venetoclax|Tablet
1908034|NCT02966782|Drug|azacitidine|Powder for injection, subcutaneously or intravenous
1908036|NCT02966223|Radiation|MRI and HIDA scan|Pre y90 therapy each subject will undergo a HIDA and MRI scan. 3 months post Y90 - Each subject will undergo a second HIDA scan and MRI scan
1965350|NCT00560755|Biological|ProQuad®|ProQuad® manufactured with recombinant human albumin (rHA) is an investigational combined attenuated live virus vaccine for vaccination against measles, mumps, rubella and varicella viruses.
1908044|NCT02962869|Drug|BAY987517|50 μl/ cm*2 of the test article is applied directly to two sites on the skin and covered with the appropriate patch. Twenty-four (24) hours later, the patches are removed. The test sites are lightly wiped with a dry cloth/tissue and 3μl/ cm*2 of test article is reapplied directly to the skin of the test site designated for irradiation, and lightly spread over the test site. Forty-eight (48) hours later the procedure is repeated to the same test sites. This process is repeated twice weekly for a total of six exposures. (Formulation number: Z43-078)
1908045|NCT02962869|Other|Untreated skin|One site is patched without treatment as control
1908048|NCT02960815|Biological|Intanza|
1908049|NCT02960815|Biological|Mutagrip|
1908050|NCT02960815|Drug|Aldara|
1908054|NCT02961218|Drug|Ilaris, Canakinumab|Monthly doses of 300 mg canakinumab subcutaneously (s.c)
1908055|NCT02961218|Drug|Placebo|Monthly doses of placebo to match the administered dose of canakinumab s.c.
1965354|NCT00535626|Device|Trident® Tritanium™ Acetabular Shell|Trident® Tritanium™ Acetabular Shell
1908058|NCT02957006|Device|Loop Recorder|Observation of Loop Recorder implanted for clinical reasons
1965364|NCT00499746|Drug|tramadol|oral dose, once per day
1908068|NCT02952196|Drug|drug administration|administering drug to patient with amphetamine addiction
1965365|NCT00499746|Drug|placebo|oral dose, once per day
1965366|NCT00499746|Drug|Hydromorphone|oral dose, once per day
1965367|NCT00499746|Drug|Methylphenidate|oral dose, once per day
1908082|NCT02951741|Other|RTHRA group|hematologic variables measurement in patients undergoing revision total hip replacement
1908085|NCT02951364|Drug|LDV/SOF|90/400 mg tablet administered orally once daily
1965383|NCT00429858|Drug|S-1|S-1 is given as follows: 25 mg/m2 bid on days 1-7 and 15-21 of the cycle (28 days)
1965384|NCT00429858|Drug|gemcitabine hydrochloride|Patients will receive gemcitabine at a dose of 1,000 mg/m2 i.v. at a fixed-dose rate (FDR) infusion of 10 mg/m2/minute (100 minutes), once a week for 3 consecutive weeks, followed by one week rest. Each 4 week period is referred to as a treatment cycle
1908097|NCT02944617|Other|Laboratory Biomarker Analysis|Correlative studies
1908098|NCT02944617|Dietary Supplement|Micronutrient-Fortified Probiotic Yogurt|Receive Activia yogurt
1908099|NCT02944617|Drug|Sunitinib|Must be received as standard of care chemotherapy
1908100|NCT02944682|Other|Liquefied petroleum gas (LPG) cookstove|The intervention consists of a high-quality locally-available liquefied petroleum gas (LPG) stove having at least two burners, a continuous supply of LPG fuel for 30 months, and the promotion of stove use on an exclusive basis for cooking. The intervention will be provided free of charge to all intervention households upon enrollment. On a weekly basis, study staff will examine stove condition, perform any repairs necessary, and measure and record weight of LPG tanks in order to anticipate need for refills.
1908109|NCT02940756|Drug|artesunate-amodiaquine|Tablets containing 25 mg of artesunate and 67.5 mg of amodiaquine: one tablet daily for three days children weighing 4.5 to 8 kg, and tablets containing 50 mg of artesunate and 135 mg of amodiaquine: one tablet daily for three days for children weighing 9 to 17 kg.
1908110|NCT02940756|Drug|artemether-lumefantrine|"Tablets containing 20 mg of Artemether and 120 mg of Lumefantrine. Each dose to be taken with high-fat food or drinks (for example milk).
One tablet twice daily for children weighing 5 to <15 kg, two tablets twice daily for those weighing 15 to <25 kg and three tablets twice daily for those weighing 25 to < 35 kg, for three days."
1908111|NCT02940756|Drug|Dihydroartemisinine-piperaquine|Tablets containing 20 mg of dihydroartemisinine and 160 mg of piperaquine. Half a tablet once daily for children weighing 5 to <7 kg, one tablet once daily for those weighing 7 to <13 kg, and two tablets once daily for those weighing 13 to <24 kg, for three days.
1908112|NCT02941783|Drug|Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)|Treatment parameters following the physician's decision based on the summary of product characteristics.
1908113|NCT02941614|Behavioral|Distress screening|A brief depression and anxiety screening instrument, the Patient Health Questionnaire (PHQ), will be administered to newly diagnosed breast cancer patients in the Distress Screening arm. The PHQ starts with a 2-item screen, and branches to the full screening instrument as needed.
1908114|NCT02938650|Drug|Nitrosomonas eutropha|Subjects will get nitrosomonas eutropha to apply for one week. There is only one arm to this study. Subjects will apply the medication twice a day for one week.
1908115|NCT02937740|Drug|NATESTO Testosterone Nasal Gel|"Participants will be instructed to administer 5.5 mg of testosterone (1 actuation) per nostril of NATESTO Testosterone Nasal Gel once in the morning and once in the evening (at least 6 hours apart), preferably at the same time each day for a total daily dose of 22 mg/day of testosterone. Patients should be instructed to completely depress the pump 1 time in each nostril to receive the total dose.
For three times daily (after Visit 4 [Day 90] if symptoms not adequately managed by a BID dose), NATESTO will be administered intranasally once in the morning, once in the afternoon and once in the evening (approximately 6-8 hours apart), preferably at the same time each day for a total daily dose of 33 mg/day of testosterone."
1908116|NCT02938520|Drug|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat.
1908117|NCT02938520|Drug|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose."
1908118|NCT02938520|Drug|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection.
1908119|NCT02938520|Drug|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
1908120|NCT02938520|Drug|ABC/DTG/3TC STR - Tablet|"It is a purple, biconvex, oval, tablet debossed with 572 Tri on one side, film-coated tablet contains abacavir sulphate equivalent to 600 mg of abacavir, dolutegravir sodium equivalent to 50 mg dolutegravir, and 300 mg of lamivudine. The inactive ABC/DTG/3TC tablet ingredients include D-mannitol, magnesium stearate, microcrystalline cellulose, povidone, and sodium starch glycolate."
1908121|NCT02938520|Drug|DTG Tablet|"It is a yellow, round, biconvex, 50 mg film-coated tablet debossed with SV 572 on one side and 50 on the other side. Each tablet of DTG also contains the following inactive ingredients: D-mannitol, microcrystalline cellulose, povidone K29/32, sodium starch glycolate, and sodium stearyl fumarate."
1908123|NCT02937779|Drug|Tenofovir disoproxil fumarate|tenofovir disoproxil fumarate 300 mg one tablet once daily from 24 weeks of amennorrhea to 6 weeks post-partum for HBe Ag positive women only.
1908124|NCT02937779|Device|Rapid tests HBe Ag|For all HBs Ag positive women
1908129|NCT02937207|Drug|Ke Chuan Liu Wei Mixture|Experience formula of famous traditional Chinese professor Yingen Wu
1908130|NCT02937207|Drug|Chuan Xiong Ping Chuan Mixture|Experience formula of famous traditional Chinese professor Changrong Shao
1908131|NCT02937207|Drug|Xie Wu Capsule|Experience formula of famous traditional Chinese professor Jianhua Hu
1908132|NCT02937207|Drug|Dan Ma Jia Tablet|Experience formula of famous traditional Chinese professor Xiaopu Xu
1908133|NCT02937207|Drug|Zhi Chuan Capsule|Experience formula of famous traditional Chinese professor Yingen Wu
1908134|NCT02937207|Drug|Bu Shen Na Qi Granule|Experience formula of famous traditional Chinese professor Changrong Shao
1908135|NCT02937207|Drug|Ke Chuan Liu Wei Mixture placebo|Low dose combination for treating prescription of Ke Chuan Liu Wei Mixture
1908136|NCT02937207|Drug|Chuan Xiong Ping Chuan Mixture placebo|Low dose combination for treating prescription of Chuan Xiong Ping Chuan Mixture
1908137|NCT02937207|Drug|Xie Wu Capsule placebo|Low dose combination for treating prescription of Xie Wu Capsule
1908138|NCT02937207|Drug|Dan Ma Jia Tablet placebo|Low dose combination for treating prescription of Dan Ma Jia Tablet
1908139|NCT02937207|Drug|Zhi Chuan Capsule placebo|Low dose combination for treating prescription of Zhi Chuan Capsule
1908140|NCT02937207|Drug|Bu Shen Na Qi Granule placebo|Low dose combination for treating prescription of Bu Shen Na Qi Granule
1908144|NCT02935686|Biological|Ad26.Mos4.HIV|Ad26.Mos4.HIV at a dose of 5*10^10 viral particles (vp), administered intramuscularly.
1908145|NCT02935686|Biological|Clade C gp140 plus adjuvant|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection administered intramuscularly.
1908146|NCT02935686|Biological|Clade C gp140/Mosaic gp140 plus adjuvant|Clade C gp140 and Mosaic gp140 (each 125 mcg of total protein) mixed with aluminum phosphate adjuvant, per 0.5 milliliter (mL) injection, administered intramuscularly.
1908147|NCT02935686|Other|Placebo|Placebo Containing 0.9 percent normal saline, administered intramuscularly.
1908148|NCT02935673|Drug|lumicitabine|Oral administration of lumicitabine as tablet.
1908149|NCT02935673|Drug|Placebo|Oral administration of matching placebo.
1908150|NCT02935608|Drug|BIIB074|Administered as specified in the treatment arm
1908151|NCT02935608|Drug|Placebo|Matched placebo
1908152|NCT02934776|Device|MRI machine|The Philips Ingenia 3.0T is an MRI machine intended to be used by specialist radiologists in the hospital. It is able to acquire high quality images of wide variety of organs. For imaging the prostate, T2-weighted turbo spin-echo images are normally obtained in three orthogonal planes (axial, sagittal and coronal). This device is been clinically used in the MRI department in Belinson hospital.
1908153|NCT02933489|Procedure|Contrast-enhanced Magnetic Resonance Imaging|Undergo AB-MR
1908154|NCT02933489|Procedure|Digital Tomosynthesis Mammography|Undergo DBT
1908155|NCT02933489|Other|Quality-of-Life Assessment|Ancillary studies
1908156|NCT02933489|Other|Questionnaire Administration|Ancillary studies
1908157|NCT02933086|Other|Specific exercises for lumbar stabilization|The Group 1 (G1) will perform therapy with specific exercises for lumbar stabilization whith the Swiss ball as a therapeutic resource, including warming; stretching of hamstrings, paraspinals, trapezes; phasic perineal exercise; tonic perineal exercise; pelvic lumbar synergism; trunk mobility; mobility of the shoulder girdle; balance; and slow pelvic balance.
1908158|NCT02933086|Other|Conventional therapy|The Group 2 (G2) will perform conventional therapy including stretching of lower limbs and trunk, with passive stretching of hamstrings; gluteus maximus; piriform; paraspinals; lumbar square; latissimus dorsi; scalene; trapezius.
1965413|NCT00392015|Biological|NMRC-M3V-Ad-PfCA|Malaria Vaccine
1965414|NCT00392015|Biological|NMRC-MV-Ad-PfC, NMRC-MV-Ad-PfA|Malaria Vaccines
1908170|NCT02928172|Device|qCON-qNOX|Each subject will have the qCON-qNOX monitor on his/her forehead + the BIS monitor
1908171|NCT02928172|Device|BIS|Each subject will have the BIS monitor on his/her forehead + the qCON-qNOX monitor
1908172|NCT02927639|Other|MyDiaText|The intervention will consist of daily text messages sent to the subject's personal mobile device.
1908179|NCT02926937|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet
Route of administration: oral"
1908180|NCT02926937|Drug|Placebo|"Pharmaceutical form: tablet
Route of administration: oral"
1908200|NCT02923193|Device|Shockwave Lithoplasty® Peripheral Lithoplasty System|The Shockwave Lithoplasty® System is a proprietary lithotripsy-enhanced balloon catheter that is designed to be delivered through the peripheral arterial system of the lower extremities to the site of calcified stenosis. Activating the lithotripsy within the device will generate pulsatile mechanical energy within the target treatment site, disrupt calcium within the lesion and allow subsequent dilation of a peripheral artery stenosis using low balloon pressure. The system consists of a balloon catheter with multiple integrated lithotripsy electrodes, and a generator.
1908201|NCT02923193|Drug|Medtronic IN.PACT (DCB)|The IN.PACT Admiral DCB is an over-the-wire (OTW) balloon catheter with a drug-coated balloon at the distal tip. The drug component, referred to as the FreePac™ drug coating, consists of the drug paclitaxel and the excipient urea. The device component physically dilates the vessel lumen by PTA, and the drug is intended to reduce the proliferative response that is associated with restenosis.
1908209|NCT02921971|Drug|SAR156597 (ACT14604)|Pharmaceutical form:Solution Route of administration: Subcutaneous
1908210|NCT02921971|Drug|Placebo|Pharmaceutical form:Solution Route of administration: Subcutaneous
1908216|NCT02918591|Drug|Empagliflozine|All 6type 2 diabetic participant will receive treatment with Empagliflozine during 2 month
1908217|NCT02917499|Device|TMS|Transcranial magnetic stimulation
1908218|NCT02917148|Other|Peripheral Venipuncture or Blood draw from Central Line|
1908219|NCT02915302|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.25 mL, Intramuscular (Pediatric Dose, 2016 2017 formulation)
1908220|NCT02915302|Biological|Fluzone® Quadrivalent Influenza Vaccine, No Preservative|0.5 mL, Intramuscular (2016 2017 formulation)
1908221|NCT02914184|Biological|HRV PCV-free liquid vaccine|Subjects will receive two doses of PCV-free HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
1908222|NCT02914184|Biological|Rotarix|Subjects will receive two doses of currently licensed lyophilised HRV vaccine at 6 and 12 weeks of age. The vaccine will be administered orally
1908231|NCT02912468|Drug|Dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution
Route of administration: Subcutaneous"
1908232|NCT02912468|Drug|Placebo|"Pharmaceutical form: Solution
Route of administration: Subcutaneous"
1908233|NCT02912468|Drug|Mometasone furoate nasal spray|"Pharmaceutical form: Suspension
Route of administration: Intranasal"
1908234|NCT02911909|Device|Delfi|Patients will receive standard of care post-operative ACL reconstruction rehabilitation plus the Delfi moderated blood flow restriction therapy.
1908235|NCT02911909|Other|Standard rehabilitation|Patients will receive standard of care post-operative ACL reconstruction rehabilitation
1908489|NCT02828670|Biological|blood sample|
1965443|NCT00322218|Drug|Zevalin Therapeutic Regimen|Zevalin Therapeutic Regimen: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
1965444|NCT00322218|Other|Observation|Observation
1908249|NCT02908048|Other|Blood samples|Blood samples collected at varying intervals over a two to three year period.
1908250|NCT02907749|Drug|Spironolactone|
1908251|NCT02907749|Drug|Carvedilol|
1908254|NCT02907216|Biological|Squarekids®|Three doses administered subcutaneously
1908255|NCT02907216|Biological|Rotarix™|Two doses administered orally
1908256|NCT02907177|Drug|Ponesimod|One tablet of ponesimod 20 mg administered orally once daily in the morning from Day 15 to EOT. To reduce the first-dose effect of ponesimod, an uptitration scheme will be implemented from Day 1 to Day 14 (with dose strength increasing from 2 mg to 20 mg).
1908257|NCT02907177|Other|Placebo|One tablet of matching placebo administered orally once daily in the morning
1908263|NCT02906787|Behavioral|BAS+|The goal of the BAS+ is to maintain a level of overall reward after cessation by structuring and enhancing opportunities for reinforcement to: (1) ensure that not smoking is as reinforcing as smoking; and (2) prevent an over-reliance on food as a substitute reinforcer for smoking so that PCWG does not precipitate smoking relapse.
1908264|NCT02906787|Behavioral|SC|Overeating and weight gain are common concerns reported during smoking cessation treatment. Per convention, SC will address these concerns through standard recommendations to consume low-calorie snack foods, drink water, eat nutritious meals, and exercise, but will not include skills to shape the use of these suggestions.
1908267|NCT02906020|Drug|GZ/SAR402671|Pharmaceutical form:capsule Route of administration: oral
1908268|NCT02906020|Drug|Placebo|Pharmaceutical form:capsule Route of administration: oral
1908269|NCT02905318|Drug|Palbociclib|125 mg orally on days 1-21 each 28 day cycle
1908272|NCT02903160|Drug|Abiraterone acetate|Abiraterone acetate 1000 mg PO daily
1908273|NCT02903160|Drug|Prednisone|5 mg PO twice a day
1908274|NCT02903160|Drug|Radium-223 dichloride|50 kBq/kg IV monthly
1908275|NCT02903160|Drug|cabazitaxel|25 mg/m2 IV every 3 weeks
1908276|NCT02903160|Drug|Carboplatin|Carboplatin AUC 4 IV every 3 weeks
1908277|NCT02903160|Drug|Enzalutamide|160 mg PO daily
1908285|NCT02900794|Device|Gold Laser|Under endoscopic visualization, the Gold Laser will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates. Suction/irrigation will be utilized as necessary.
1908286|NCT02900794|Procedure|Microdebridement|Under endoscopic visualization, the microdebrider will be utilized to perform 1) excision of the concha bullosa, 2) maxillary antrostomy, and 3) submucosal cauterization of the turbinates.
1908287|NCT02900781|Device|Steprite™|Steprite™ Device shoe insert monitoring device
1908288|NCT02900781|Other|Standard of care|No Device. Standard of care physical therapy
1998002|NCT01757821|Device|real 6-Hz primed low-frequency rTMS|10 minutes of 6-Hz stimulation (real priming) followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
1998003|NCT01757821|Device|Sham 6-Hz Primed low-frequency rTMS|10 minutes of sham priming stimulation followed by 10 minutes of 1-Hz low-frequency stimulation delivered to the nonstroke primary motor region
1998004|NCT01757821|Device|real 1-Hz rTMS only|20 minutes of low-frequency rTMS delivered to the nonstroke primary motor region
1998005|NCT01755091|Drug|Dronabinol|
1998006|NCT01755091|Drug|Placebo (for Dronabinol)|
1998008|NCT01750073|Drug|Cyclophosphamide|Given IV
1998009|NCT01750073|Drug|Doxorubicin Hydrochloride|Given IV
1998010|NCT01750073|Other|Laboratory Biomarker Analysis|Correlative studies
1998011|NCT01750073|Drug|Paclitaxel|Given IV
1998012|NCT01750073|Radiation|Radiation Therapy|Undergo RT
1998013|NCT01750073|Procedure|Therapeutic Conventional Surgery|Undergo mastectomy or breast conserving surgery
1998014|NCT01750073|Biological|Trastuzumab|Given IV
1998015|NCT01748448|Drug|Vitamin D|"prospective interventional randomized double blind placebo controlled trail
clinical setting (tertiary university hospital)
investigator driven, no pharmaceutical sponsor
cutaneous malignant melanoma patients
add- on study (placebo or vitamin D) on top of optimal standard care
1:1 inclusion ratio (placebo:Vitamin D)
randomisation after informed consent and screening"
1998016|NCT01748448|Drug|arachides oleum raffinatum|
1908298|NCT02898181|Device|Tragus nerve stimulation|Active LLTS will be performed by use of a transcutaneous electrical nerve stimulation (TENS) device with electrodes attached to the tragus of the ear.TENS will be applied continuously for 8 hours daily (4 hours twice daily)
1908302|NCT02894944|Biological|Theragene®,Ad5-yCD/mutTKSR39rep-ADP|Theragene®,Ad5-yCD/mutTKSR39rep-ADP is Adenovirus-mediated Double Suicide Gene Therapy
1908303|NCT02891824|Drug|atezolizumab + avastin + platinum-based chemotherapy|"atezolizumab will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression
avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression
platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
1908304|NCT02891824|Drug|placebo + avastin + platinum-based chemotherapy|"placebo will be administrated by intraveinous route at dose of 1200 mg or 800 mg during the induction period and will be continued in maintenance period at a dose of 1200mg until progression
avastin will be administrated by intraveinous route at dose of 15mg/kg or 10 mg/kg during the induction period and will be continued in maintenance period of at a dose of 15mg/kg until progression
platinum-based chemotherapy (Carboplatin combined with gemcitabine or paclitaxel or pegylated liposomal doxorubicin) will be administrated by intraveinous route at different doses during the induction period x 6 cycles"
1908305|NCT02892786|Other|Circulating Tumor Cells|"Patients with stage III and IV head and neck squamous cell carcinoma undergoing surgery were enrolled in this study
5 and 7.5 ml of peripheral venous blood will be taken before the surgery, just at the end of surgery and one week after surgery
Analysis was performed by RT-PCR and the CellSearch™ method using immunomagnetic and fluorescence approaches.
Patients will be followed every 3 months for two years."
1965473|NCT00248703|Drug|Docetaxel|Docetaxel 100 mg/m2 3 qw x 6
1965477|NCT00237822|Behavioral|Adherence Feedback (AF)|
1965478|NCT00237822|Behavioral|AF + Contingency Management (AF + CM)|
1965479|NCT00237822|Behavioral|AF + Motivational Enhancement Therapy (AF + MET)|
1908320|NCT02887885|Drug|Gynoflor|1 vaginal tablet daily for 12 days, followed by 3 vaginal tablets per week as maintenance therapy (Monday-Wednesday-Friday) for 6 weeks
1908321|NCT02887404|Other|Spine surgery analgesic pathway|Enhanced pain management care
1908322|NCT02887404|Other|Usual Care|Standard of pain management care
1908326|NCT02881567|Drug|Daclizumab|High yield formulation
1908335|NCT02879695|Biological|Blinatumomab|Given IV
1908336|NCT02879695|Biological|Ipilimumab|Given IV
1908337|NCT02879695|Other|Laboratory Biomarker Analysis|Correlative studies
1908338|NCT02879695|Biological|Nivolumab|Given IV
1908490|NCT02828618|Procedure|PDS (Primary Debulkdung Surgery)|PDS with maximum effort to achieve the goal of complete gross resection
1908340|NCT02879318|Drug|Gemcitabine|
1908341|NCT02879318|Drug|Nab-paclitaxel|
1908342|NCT02879318|Drug|Durvalumab|
1908343|NCT02879318|Drug|Tremelimumab|
1908344|NCT02877823|Behavioral|Treatment|Healthy Lifestyle Education, bottled water, pedometer, family navigator service
1908345|NCT02877823|Behavioral|Control|Healthy Lifestyle Education
1908356|NCT02871297|Drug|Vortioxetine|Target dose is 10 mg/day, however, the dose can be down- or uptitrated to 5, 15, or 20 mg/day.
1908357|NCT02870699|Device|Evonail|film-forming solution containing water Evaux naturally rich in lithium, strontium and manganese with UV filter
1908358|NCT02870699|Device|Placebo excipient|film forming excipient solution
1908360|NCT02870582|Drug|Donafenib|treatment drug
1908361|NCT02870582|Drug|Placebo|Best support treatment
1908362|NCT02870569|Drug|Donafenib 200mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the lower dose one.
1908363|NCT02870569|Drug|Donafenib 300mg|Donafenib is an oral multikinase inhibitor with antiproliferative and antiangiogenic effects.The arm is the higher dose one.
1908364|NCT02870257|Other|Strengthening protocol with progressive load|Strengthening protocol for scapular and shoulder muscles
1908365|NCT02870257|Other|Strengthening protocol without progressive load|Strengthening protocol for scapular and shoulder muscles
1908367|NCT02867241|Behavioral|Behavioral Early|Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
1908368|NCT02867241|Behavioral|Behavioral Late|After the close of the study, Participants will receive an intervention which includes motivational interviewing, biochemical feedback, air quality feedback, phone calls, and social media
1908369|NCT02866591|Other|mammography according to an auto-compression procedure|
1908370|NCT02866591|Other|mammography according to a standard procedure|
1908371|NCT02866591|Other|questionary|
1908373|NCT02865642|Drug|Serotonin Uptake Inhibitors|
1908374|NCT02865642|Drug|Placebo|
1908377|NCT02863419|Drug|semaglutide|Oral semaglutide once-daily.
1908378|NCT02863419|Drug|liraglutide|Subcutaneous (s.c.) injection once-daily.
1908379|NCT02863419|Drug|placebo|Placebo once-daily.
1908385|NCT02861586|Biological|MV-CHIK low dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection, 5xE4 (± 0.5 log) TCID50/dose
1908386|NCT02861586|Biological|MV-CHIK high dose|recombinant measles virus vaccine expressing Chikungunya virus antigens, powder for suspension for injection; 5xE5 (± 0.5 log) TCID50/dose
1908387|NCT02861586|Biological|Priorix®|lyophilized mixed preparation containing the attenuated Schwarz measles virus strain, the RIT 4385 strain of mumps virus (derived from the Jeryl Lynn strain) and the Wistar RA 27/3 rubella virus strain. Powder and solvent for suspension for injection
1908388|NCT02861586|Biological|physiological saline solution|sterile physiological saline solution 0.9% used as placebo
1908394|NCT02858973|Drug|Q203|
1908395|NCT02858973|Drug|Placebo|
1908400|NCT02856802|Drug|DFN-02|
1908401|NCT02856802|Other|DFN-02 Placebo|
1908407|NCT02856074|Biological|prise de sang|
1908408|NCT02856074|Other|quality of life questionnaire|
1908409|NCT02856009|Other|completion of a quality of life questionnaire|
1908410|NCT02855840|Other|completion of the quality of life questionnaire|
1908420|NCT02851433|Drug|total anaesthesia and postoperative inhaled sedation with Sevoflurane|
1908421|NCT02851433|Drug|total intravenous anaesthesia with Propofol.|
1908422|NCT02851420|Other|spectroscopy|
1908423|NCT02851394|Drug|Levobupivacaine|
1908424|NCT02851394|Drug|levobupivacaine|
1908425|NCT02851394|Drug|tramadol|
1965543|NCT00081939|Drug|Velcade|Two cycles of induction on days 1,4,8,11 at 1.0mg/m^2. Two cycles of consolidation on days 1,4,8,11 at 1.0mg/m^2. Maintenance year one 1.0mg/m^2 1,4,8,11 q 28 days.
1965544|NCT00081939|Drug|Thalidomide|Two cycles of VDTPACE 200mg thal days 4-7(cycle 1)and days 1-4 cycle 2 interim Thal 50mg qd between VTDPACE cycles and between cycle 2 and transplant. Thal 100mg between transplants d/c 7 days prior to each transplant. Consolidation therapy cycles 3 and 4 VDTPACE 200mg days 1-4 both cycles. Interim maintenance to maintenance 100mg qd. Maintenance year 1 thal 100mg qd. Maintenance years 2 and 3 Thal 100mg qd.
1908433|NCT02846623|Drug|Obinutuzumab|100 mg by vein on Day 1 of cycle 1. 900 mg by vein on Day 2 of cycle 1. 1000 mg by vein on Day 8 and 15 of cycle 1, and Day 1 of cycles 2 - 9.
1908434|NCT02846623|Drug|Atezolizumab|840 mg by vein on Days 1 and 15 of Cycles 2 - 9.
1908438|NCT02845765|Device|Dynamic Vessel Analyzer (DVA)|
1908439|NCT02845765|Drug|Phosphodiesterase type 5 Inhibitor (PDE5I)|
1908491|NCT02828618|Procedure|6 cycles of standard chemotherapy|6 cycles of standard chemotherapy after Primary Debuling Surgery
1908492|NCT02828618|Procedure|Timing of surgery after 3 cycles of standard NACT, IDS|Timing of surgery after 3 cycles of standard NACT
1908493|NCT02828618|Procedure|IDS|IDS with maximum effort to achieve the goal of complete gross resection after NACT
1908494|NCT02828618|Drug|3 cycles of standard chemotherapy|3 more cycles (for a total of 6) of standard chemotherapy after IDS
1965545|NCT00078572|Drug|capecitabine|Capecitabine daily dose divided and given twice daily orally, for 14 days, every 21 days. The capecitabine starting dose for the monotherapy arm was 2500 mg/m2 and for the combination arm was 2000 mg/m2.
1965546|NCT00078572|Drug|lapatinib (GW572016)|Lapatinib 1250 mg orally once daily
1908442|NCT02844582|Drug|Cabazitaxel|Given IV
1908443|NCT02844582|Drug|Prednisone|Given PO
1908449|NCT02837744|Device|Axiostat®|"Axiostat® is a sterile, non-absorbable haemostatic dressing intended to control profuse bleeding within minutes of application by providing an active mechanical barrier to the wound site.
Axiostat® stops moderate to severe bleeding due to cuts, abrasions, lacerations, venous/arterial punctures and more. Mechanism of action is such that Axiostat® is an extremely positive dressing that becomes very sticky in the presence of negatively charged blood and thus seals the wound area."
1908450|NCT02837744|Device|Standard Institutional Care Product|Band Size: 24 x 4 cm Cotton Gauze size : 5 x 5 cm
1908457|NCT02837328|Drug|Oral Magnesium Supplement|400 mg Magnesium Citrate 1x daily for 12 weeks
1908458|NCT02837328|Drug|Placebo|Placebo pill resembling 400 mg Magnesium Citrate 1x daily for 12 weeks
1908461|NCT02835859|Other|Dietary: saccharin|Assess the glycemic and hormonal responses to an oral glucose load preceded by an oral solution of NCASs (saccharin).
1908462|NCT02835859|Other|Estimate glucose absorptions|Indirectly estimate the rate of glucose absorption and gastric emptying by using 3-O-methyglucose (3-OMG) and acetaminophen, respectively.
1908467|NCT02835014|Behavioral|Mental Health Symptoms|Adolescents with T1DM will be asked to complete PHQ9 (depression screening), SCARED (anxiety screening) and UCLA PTSD (trauma screening)
1908468|NCT02835014|Behavioral|Self-efficacy regarding self-care and diabetes management|Adolescents with T1DM will be asked to complete the SEDM to asses self-efficacy for diabetes management
1908469|NCT02835014|Behavioral|Parenting Styles|Parents of adolescents with T1DM will be asked to complete the PSDQ to asses parenting style
1965564|NCT00068406|Radiation|3-Dimensional Conformal Radiation Therapy|
1965565|NCT00068406|Drug|Cisplatin|Given IV
1965566|NCT00068406|Procedure|Conventional Surgery|
1908477|NCT02831842|Drug|Anti-EGFR-Containing Regimen|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
1908478|NCT02831842|Drug|Bevacizumab-containing regimen|Study protocol does not specify any particular bevacizumab containing regimen. The data will be collected retrospectively.
1908479|NCT02831842|Drug|Chemotherapy|Study protocol does not specify any particular chemotherapy regimen. The data will be collected retrospectively.
1908512|NCT02826603|Drug|Secukinumab|300mg, s.c. at randomization, Weeks 1, 2 and 3 and thereafter 4-weekly till Week 48
1908513|NCT02826603|Drug|Ustekinumab|Per approved label, 45 mg or 90 mg s.c. based on subject weight (at randomization visit) to be administered at randomization, Week 4, 16, 28 and 40. At other timepoints subjects will receive placebo injections.
1908516|NCT02825836|Drug|M7583|"Capsules of 20 or 100 milligram (mg)
Dose escalation (Part I):
80 mg / day (3 initial days), continuing with 160 mg / day
300 mg / day
600 mg / day
900 mg / day"
1908517|NCT02825836|Drug|M7583|"Dose expansion (Part II)
- Optimal biological dose (OBD)/day"
1908519|NCT02825160|Drug|Ventavis (Iloprost, BAYQ6256)|The treatment of Ventavis should comply with the local product information
1965589|NCT00016718|Drug|Didanosine (ddI)|Antiretroviral Didanosine (ddI) : 240 mg/m^2 up to a maximum of 400 mg once daily
1965590|NCT00016718|Drug|Efavirenz (EFV)|Antiretroviral For Age Group 1 Efavirenz (EFV): dose adjusted for body size and for Age Groups 2 and 3 Efavirenz (EFV): up to a maximum of 600 mg once daily as a capsule ot 720 mg as an oral solution
1965591|NCT00016718|Drug|Emtricitabine (FTC)|Antiretroviral Emtricitabine (FTC): 6 mg/Kg up to a maximum of 200 mg once daily
1908529|NCT02824107|Biological|blood sample|
1908530|NCT02824107|Behavioral|questionnaires for psychosocial factors|
1908533|NCT02822989|Device|Vagus nerve stimulation|Patients will receive transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. The device is a handheld electrical pulse generator and a pair of electrodes to be placed at the ear for stimulation. The specific target at the ear will be the auricular branch of the vagus nerve which innervates the skin of the ear canal. Electrodes will be placed near/at the entrance to the canal of the ear to provide stimulation to the auricular branch.
1908534|NCT02822989|Device|Sham vagus nerve stimulation|Patients will receive sham transcutaneous stimulation of the auricular branch of the left vagus nerve for 5 minutes daily for 4 consecutive days. Sham stimulation will be performed in the identical manner as true transcutaneous stimulation except that the patient will not receive electrical stimulation of the vagus nerve.
1908579|NCT02811120|Other|venepuncture only|single venepuncture
1908580|NCT02811068|Other|venepuncture|single venepuncture
1988579|NCT02781961|Other|cellvizio|pCLE during gastroscopy
1908541|NCT02821572|Biological|blood sample|
1908542|NCT02821572|Procedure|spleen sample|
1908546|NCT02819479|Drug|25% Mannitol|"Route of administration:
In this study, the first step of the treatment will be performing osmotic blood-brain-barrier disruption with administration of intra-arterial 25% Mannitol into the appropriate cervical artery."
1908547|NCT02819479|Drug|Low-dose Intra-arterial Bevacizumab|"Route of administration:
In this study, the second step of the treatment will be administering intra-arterial bevacizumab into the appropriate cervical artery."
1908560|NCT02817633|Drug|TSR-022|TSR-022 is a humanized monoclonal IgG4 antibody
1908561|NCT02817633|Drug|anti-PD-1 antibody|
1908571|NCT02814071|Other|Early enteral feeding|Early enteral feeding as per description
1908573|NCT02812706|Drug|Isatuximab SAR650984|Pharmaceutical form:solution Route of administration: intravenous
1908574|NCT02813252|Genetic|JCAR015|No study drug is administered in this study. Patients who received JCAR015 in a previous trial will be evaluated in this trial for long-term safety and efficacy.
1908582|NCT02810028|Behavioral|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT) is a form of cognitive behavioural therapy focused explicitly on promoting psychological flexibility. An ACT programme suits the aims of the study because it targets avoidance of distress, promotes acceptance of illness through motivating meaningful activity outside of illness, improves the processes that underlie beliefs rather than by directly challenging beliefs, thus reducing possible trivialisation of the understandable distress caused by living with MD.
1908586|NCT02807558|Drug|SY-1425 (tamibarotene)|Continuous 28 day cycles of SY-1425 6 mg/m2/day orally divided into twice a day dosing.
1908587|NCT02807558|Drug|azacitidine|75 mg/m2/day IV or SC days 1-7 of a 28 day cycle in combination with SY-1425.
1908599|NCT02802293|Device|repetitive transcranial magnetic stimulation|The MagPro R30 is an advanced, high performance magnetic stimulator designed primarily for non-invasive clinical use. The non-invasive brain stimulation system will be used to deliver repetitive electromagnetic pulses in this research study's treatment of major depressive disorder.
1908600|NCT02802293|Device|robotic arm|This robotic system is based on a commercially available neurosurgical robot. The robot is mounted on a mobile (i.e. retractable wheels) cart which holds the robot controller and the TMS power supply and pulse-generation computer. The robotic system will be used for TMS coil positioning/targeting.
1908602|NCT02801942|Procedure|Inguinal lymph node fine needle aspirate biopsy|Inguinal lymph node will be localized by ultrasonography and sampled by 21-gauge needle and a 5 mL syringe using to and fro needle movement while applying 1 mL suction with the syringe. Up to 2 fine needle aspirate passages will be obtained, to derive immune cells.
1908603|NCT02801942|Procedure|Inguinal lymph node core biopsy|Inguinal lymph node will be localized by ultrasonography and following fine needle aspirate, an incision will be made. Up to five core biopsies will be obtained, to derive immune cells.
1908604|NCT02801942|Procedure|Peripheral blood collection|Blood sample (30 mL) will be collected, to derive immune cells.
1908605|NCT02801942|Other|Pre- and post-biopsy questionnaire|All subjects will be asked to complete a questionnaire about their expectations/experiences of undergoing the biopsy procedures.
1908610|NCT02801461|Device|extracorporeal shock wave therapy|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
1908612|NCT02800187|Device|ESWT|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs).
1908614|NCT02799368|Drug|CJ Plasma Solution A Injection|Intravenous plasma solution (Chloride 90 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
1908615|NCT02799368|Drug|CJ 0.9% Normal Saline Injection|Intravenous plasma solution (Chloride 154 mmoL/L) at 3 mL/kg over 1 hour pre-contrast, followed by the same solution intravenously at 1.5 mL/kg/hr for 4 hours. Intra-vascular low-osmolal or iso-osmolal contrast will be used.
1988600|NCT02774746|Other|35-week delivery|Induction at 35 weeks gestational age
1988601|NCT02774746|Other|38-week delivery|Observation to spontaneous delivery or induction at 38 weeks gestational age
1992953|NCT03268070|Device|Repetitive TMS over ipsilateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over ipsilateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
1908620|NCT02797964|Drug|SRA737|SRA737 will be administered orally once daily for each 28-day cycle. Subjects will receive a single dose of SRA737 between 4 to 7 days prior to starting the first cycle for PK profiling. Subjects can continue taking SRA737 if they are receiving clinical benefit and able to safely take the drug and follow the requirements of the study.
1908631|NCT02792387|Other|CVP measurement|CVP measurements had been performed with an electronic pressure transducer in spontaneously breathing non-ventilated patients. Central vein access was established trough the subclavian or internal jugular veins. Mean CVP was recorded for each patient, measured in mmHg.
1908632|NCT02792231|Drug|Ofatumumab subcutaneous injection|Patients randomized to the ofatumumab arm will receive subcutaneous injections of ofatumumab every 4 weeks
1908633|NCT02792231|Drug|Placebo orally matching to teriflunomide|Placebo orally, matching in appearance to teriflunomide, administered once daily
1908634|NCT02792231|Drug|Teriflunomide orally|Patients randomized to the teriflunomide arm will take teriflunomide orally once daily
1908635|NCT02792231|Drug|Placebo subcutaneous injection matching to ofatumumab|Placebo-containing syringes, matching in appearance to syringes containing ofatumumab, administered every 4 weeks
1908636|NCT02792218|Drug|Ofatumumab subcutaneous injection|Patients randomized to the ofatumumab arm will receive subcutaneous injections of ofatumumab every 4 weeks
1908637|NCT02792218|Drug|Placebo orally matching to teriflunomide|Placebo orally, matching in appearance to teriflunomide, administered once daily
1908638|NCT02792218|Drug|Teriflunomide orally|Patients randomized to the teriflunomide arm will take teriflunomide orally once daily
1908639|NCT02792218|Drug|Placebo subcutanous injection matching to ofatumumab|Placebo-containing syringes, matching in appearance to syringes containing ofatumumab, administered every 4 weeks
1994121|NCT03063528|Behavioral|Healthy Eating and Physical Activity|"Participants will be assigned to a group of 8-10 other pregnant women to work towards the same healthy eating or physical activity behavior challenge each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as drink 8 full glasses of water 3 times this week. Participants will track their healthy eating and physical activity behaviors in a mobile app. The HEPA condition will have access to podcasts and informational tips for having a healthy pregnancy through the study website. The HEPA condition will be able to log their weight on a daily basis and track their overall weight gain on a chart through the study website."
1908643|NCT02790463|Behavioral|Pharmacist-Led Intervention|Pharmacists will conduct outreach primarily via an automated telephone interactive voice recognition system and direct (telephone) contact
1994122|NCT03063528|Behavioral|Stress Reduction and Management|"Participants will be put into a group of 8-10 other pregnant women to work towards the same stress reduction and management goal each week for a total of 12 weeks. The challenges will not require travel or financial support, but will focus on modifying or encouraging daily lifestyle activities, such as take a 15 minute technology break each day this week. Participants will track their stress reduction and management behaviors in a mobile app. In addition, the SRAM condition will have access to meditation podcasts and informational tips for having a healthy pregnancy through the study website. Lastly, the SRAM condition will be able to rate their stress level on a daily basis and track their stress on a graph."
1994125|NCT03063307|Procedure|Atraumatic Restorative Treatment|
1994126|NCT03063307|Other|Silver Diamine Fluoride|
1908659|NCT02786927|Drug|Placebo ELLIPTA device|Placebo ELLIPTA is a DPI device containing powder for inhalation, to be inhaled orally once daily for 5-9 days. It contains two strips with 30 blisters per strip - one strip contains lactose monohydrate whereas the other strip contains lactose monohydrate blended with magnesium stearate.
1908660|NCT02786927|Drug|Placebo capsules for use in HANDIHALER device|Placebo capsules contain lactose monohydrate in the form of powder for inhalation, to be used with the HANDIHALER inhaler as an oral inhalation once daily for 5-9 days.
1908661|NCT02786927|Other|Inhaler Preference Questionnaire Version 1|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
1908662|NCT02786927|Other|Inhaler Preference Questionnaire Version 2|Consists of 5 questions to assess subjects' preference of device attributes and dosing regimens. The two versions of the questionnaire ask the same questions, but differ in the ordering of inhalers in their responses.
1908667|NCT02785666|Drug|grazoprevir/elbasvir, ribavirin|To investigate the virological efficacy and safety of grazoprevir/elbasvir ±ribavirin for HIV/HCV-coinfected MSM with a GT 1 and/or 4 infection
1908668|NCT02785666|Behavioral|Behavioural Intervention|To counsel the targeted population with a behavioral intervention regarding the reduction of sexual risk behaviour and recreational drug use.
1908669|NCT02785978|Drug|Levodopa acute challenge|"Inclusion visit (simultaneous video + ActiMyo recording):
Levodopa acute challenge and 2 hours of recording and medical monitoring"
1908670|NCT02785978|Other|Controlled environment tests (series of tasks of everyday life)|"Inclusion visit (simultaneous video + ActiMyo recording):
Controlled environment tests (series of tasks of everyday life)"
1908671|NCT02785978|Other|Standardized scales: MDS-UPDRS (Part II to IV) and RDRS|"Inclusion visit (simultaneous video + ActiMyo recording):
Standardized scales: MDS-UPDRS (Part II to IV) and RDRS"
1908672|NCT02785978|Device|ActiMyo recording|Continuous activity recording with ActiMyo during the 2 weeks of study participation
1908673|NCT02785978|Other|Diary completion|Daily patient logbook completion during the 2 weeks of study participation
1908678|NCT02784717|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|Decision regarding dose and duration of treatment made at the discretion of the attending investigator.
1908687|NCT02783898|Device|AliveCor Heart Monitor|Smart phone based ECG event recorder
1908701|NCT02777788|Drug|JinFuKang|treated with chemotherapy
1908702|NCT02777788|Drug|XingZaoRuanJian|treated with chemotherapy
1908703|NCT02777788|Drug|pemetrexed,docetaxel,gemcitabine,paclitaxel or vinorelbine combined with carboplatin、cis-platinum or nedaplatin|
1908721|NCT02773303|Device|Mente Autism™|A portable headband records EEG activity, and specialized algorithms convert the EEG activity into sonified binaural signals feeding them back to the user
1908722|NCT02773303|Device|Sham|a device externally identical to Mente Autism™, providing binaural beats but not tailor-made neurofeedback binaural beats
1908724|NCT02772744|Drug|Daclatasvir 60 MG Oral Tablet [Daklinza]|Daclatasvir (60 MG) is a potent, pan-genotypic inhibitor of the HCV NS5A protein
1908725|NCT02772744|Drug|Sofosbuvir 400 MG Oral Tablet [Sovaldi]|Sofosbuvir (400 MG) is a nucleotide analogue HCV NS5B polymerase inhibitor
1908726|NCT02772744|Drug|Ribavirin Oral Product|Ribavirin (twice-daily) dosed according to body weight (<75 kg, 1000 mg daily; ≥75 kg, 1200 mg daily)
1908748|NCT02764801|Drug|Ultrasound contrast agent (Contrast-enhanced ultrasound)|Intravenous injection of ultrasound contrast agent followed by saline flush though an angiocatheter in the arm or hand.
1908749|NCT02764801|Device|Logiq E9 Scanner (Contrast-enhanced ultrasound)|Ultrasound scanning using a commercial scanner with a C1-5-D broad-spectrum convex transducer followed by a RAB2-5-D broad-spectrum real-time 4D transducer.
1908761|NCT02761213|Drug|Oral sulfate solution (OSS)|Oral sulfate solution (OSS)
1908762|NCT02761213|Drug|2-L PEG/Asc|Low-dose polyethylene glycol plus ascorbic acid (2-L PEG/Asc) COOLPREP is a proprietary name of 2-L PEG/Asc.
1908768|NCT02760797|Drug|Emactuzumab|Emactuzumab will be administered IV every 3 weeks (every cycle) during Part I and every 3 or 6 weeks (every cycle or every other cycle) during Part II.
1908769|NCT02760797|Drug|RO7009789|RO7009789 will be administered IV every 3 weeks (every cycle).
1908778|NCT02756897|Drug|Ibrutinib|420 mg by mouth once daily in a 28 day cycle.
1908779|NCT02756897|Drug|Venetoclax|"At the start of cycle 4 Venetoclax taken by mouth as weekly dose escalation:
20 mg daily for 1 week, 50 mg daily for 1 week, 100 mg daily for 1 week, 200 mg daily for 1 week, then 400 mg daily for duration of treatment."
1908788|NCT02752412|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1908789|NCT02752412|Drug|Insulin glargine U100 (HOE901)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1908790|NCT02752412|Drug|Metformin|"Pharmaceutical form: tablet
Route of administration: oral"
1908826|NCT02748863|Drug|Placebo|2 mL + 2 x 1 mL Placebo s.c. at randomization, weeks 1, 3, and 4, thereafter 4-weekly until week 48
1908827|NCT02748863|Drug|Secukinumab 2 mL form|Secukinumab 300 mg/2mL + 2 x 1 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
1908828|NCT02748863|Drug|Secukinumab 1 mL form|Secukinumab 150 mg/1mL x 2 + 2 mL placebo s.c. at randomization, week 1 , 3, 4, thereafter 4-weekly until Week 48
1908829|NCT02746159|Device|Lutonix 035 Drug Coated Balloon PTA Catheter, Model 9004|
1908837|NCT02744768|Drug|Dasatinib|Adult Ph+ ALL (≥18 years old, with no upper age limit) patients will begin treatment with Dasatinib, 140 mg/day, from day 1 to day +84.
1908838|NCT02744768|Drug|Blinatumomab|"Upon induction:
patients in CHR will receive Blinatumomab at a dose of 15 µg/m²/day as continuous intravenous infusion (CIVI) at a constant flow rate for four weeks, followed by a two-week infusion-free interval, defined as one treatment cycle. At least 2 cycles should be administered, up to a maximum of 5 cycles, if deemed necessary."
1908860|NCT02736292|Behavioral|Mindfulness Practices for Healthcare Professionals|
1908861|NCT02736175|Drug|Dexamethasone|
1908862|NCT02736175|Other|Placebo Vehicle|
1908867|NCT02734004|Drug|Olaparib|Olaparib
1908868|NCT02734004|Drug|MEDI4736|MEDI4736 starting 4 weeks after Olaparib
1908877|NCT02732951|Drug|BI 1026706|
1908878|NCT02732951|Drug|Placebo|
1908930|NCT02719379|Biological|Pneumonococcal Polysaccharide Vaccine 23-valent (PPSV-23)|
1908931|NCT02720081|Drug|MK-1029 150 mg|150 mg tablet administered orally, once a day (QD), at bedtime
1908899|NCT02725593|Drug|Dapagliflozin|Dapagliflozin 10 mg tablets administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily, for the 28-week site and subject blinded long term extension.
1908900|NCT02725593|Drug|Dapagliflozin placebo|matching placebo tablets, administered orally once daily, for the 24-week blinded treatment period. Dapagliflozin 10mg tablets administered orally once daily,for the 28-week site and subject blinded long term extension.
1908903|NCT02725489|Biological|Vigil|Vigil is made up of irradiated autologous tumor cells which have been electroporated ex vivo with the Vigil plasmid designed to suppress expression of both the TGFβ1 and TGFβ2 proteins while simultaneously expressing rhGMCSF protein.
1908904|NCT02725489|Drug|Durvalumab|A human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody directed against programmed cell death ligand 1 (PD-L1)
1908917|NCT02723773|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
1908918|NCT02723747|Other|myocardial perfusion with magnetic resonance imaging|
1908932|NCT02720081|Drug|MK-1029 Matching-image Placebo|Matching-image placebo tablet administered orally, QD, at bedtime
1908933|NCT02720081|Drug|Montelukast 10 mg|10 mg tablet administered orally, QD, at bedtime
1908934|NCT02720081|Drug|Albuterol/Salbutamol 90 mcg - 100 mcg per inhalation|1 or 2 inhalations 4 times a day (QID) as needed (PRN) as a Rescue Medication
1908939|NCT02718677|Drug|Refacto|Observational - Non-Interventional Study
1908940|NCT02718417|Drug|carboplatin|Given Q3W during chemotherapy phase
1908941|NCT02718417|Drug|paclitaxel|Investigator choice of weekly or Q3W during chemotherapy phase
1908942|NCT02718417|Drug|Avelumab|Given Q3W in combination with carboplatin/paclitaxel during chemotherapy portion
1908943|NCT02718417|Drug|Avelumab|Given as single agent in maintenance portion Q2W
1908946|NCT02715726|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous
1908947|NCT02715726|Drug|placebo for alirocumab|Pharmaceutical form:solution Route of administration: subcutaneous
1908948|NCT02715726|Drug|ezetimibe|Pharmaceutical form:capsule Route of administration: oral
1908949|NCT02715726|Drug|placebo for ezetimibe|Pharmaceutical form:capsule Route of administration: oral
1908950|NCT02715726|Drug|atorvastatin|Pharmaceutical form:tablet Route of administration: oral
1908951|NCT02715726|Drug|rosuvastatin|Pharmaceutical form:tablet Route of administration: oral
1908952|NCT02715726|Drug|simvastatin|Pharmaceutical form:tablet Route of administration: oral
1908958|NCT02714660|Other|none, observational study|
1908962|NCT02713126|Drug|Placebo Solution|Placebo solution (normal saline), administered by inhalation over 10-15 minutes using a nebulizer, taken every 4 hours or 3 times per day during waking hours for 12 weeks
1908963|NCT02713126|Drug|Sodium Nitrite Inhalation Solution|Sodium Nitrite Inhalation Solution, 80 mg administered by inhalation over 10-15 minutes using a nebulizer, taken every 4 hours or 3 times per day during waking hours for 12 weeks
1908964|NCT02713126|Device|Accelerometer|External triaxial accelerometer is worn externally at the hip during exercise training sessions, and day/night to continuously measure activity levels, removed for bathing only.
1908965|NCT02713126|Other|Cardiac Exercise Training|Cardiac rehabilitation exercise training consisting of supervised endurance and strength exercise training of approximately one hour, 3 times per week for 12 weeks.
1908966|NCT02713022|Device|DEXA Scan|
1908967|NCT02713022|Behavioral|Godin Leisure Time Exercise Questionnaire (GLTEQ)|
1908968|NCT02712944|Drug|Testosterone|Testosterone
1908969|NCT02712944|Drug|Saline|Placebo
1909005|NCT02709655|Other|Placebo|Encapsulated tablet, orally
1909006|NCT02709317|Behavioral|Prevention Intervention|
1909007|NCT02709317|Behavioral|Brief Intervention|
1908982|NCT02711878|Behavioral|Let's Move Program|Participants will be asked to walk five times per week for twelve weeks for a minimum of 30 minutes while wearing a heart rate monitor and a pedometer. Participants will also receive weekly telephone calls from a member of the research team to monitor walking progress and to change walking duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
1908983|NCT02711878|Behavioral|Let's Flex Program|Participants will be asked to stretch five times per week for twelve weeks for a minimum of 30 minutes. Participants will also receive weekly telephone calls from a member of the research team to monitor progress and to change duration or intensity level based on their progress.After the twelve week period, participants will enter a maintenance exercise phase for weeks 13-17 in which they will be asked to maintain their exercise regimen.
1908984|NCT02711878|Behavioral|Group Motivational Interviewing|Participants will attend four separate group intervention sessions for 2.5 hours for four consecutive weeks at the beginning of the program. Groups will consist of 6-8 members and will focus on the rationale for aerobic exercise, barriers to exercise, finding time for exercise, how to set short and long term exercise goals, and use of self-monitoring to improve exercise engagement.
1908998|NCT02709746|Drug|Vortioxetine 10 mg/day|10 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
1908999|NCT02709746|Drug|Vortioxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed
1909000|NCT02709746|Drug|Fluoxetine 20 mg/day|20 mg/day, encapsulated tablet (with addition of lower initial dose levels). Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed
1909001|NCT02709746|Other|Placebo|Encapsulated tablet
1909002|NCT02709655|Drug|Vortioxetine 10 mg/day|"10 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).
Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
1909003|NCT02709655|Drug|Vortioxetine 20 mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).
Based on tolerability the dose may be reduced by 5 mg/day. No dose increase will be allowed"
1909004|NCT02709655|Drug|Fluoxetine 20mg/day|"20 mg/day, encapsulated tablet, orally (with addition of lower initial dose levels).
Based on tolerability the dose may be reduced by 10 mg/day. No dose increase will be allowed"
1909008|NCT02709915|Other|Breakfast Diet (Bdiet)|The Breakfast Ddiet consist of high-energy breakfast, medium-sized lunch and reduced in energy dinner, with distribution of calories: breakfast 50%, lunch 33% and dinner 17%. In this diet, the investigators will evaluate at baseline and at the end of 12 weeks of diet intervention, the diet efficacy on reducing HbA1c, the total daily insulin dose requirements (TDID), the efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion assessed with continuous monitoring system. The investigators will assess also the Clock Genes mRNA expression in white blood cells. at baseline and after 12 weeks of diet intervention
1909009|NCT02709915|Other|6Meal Diet (6Mdiet|The 6meal diet (6Mdiet) will consist in the traditional antidiabetic diet, consuming 6 small meals: breakfast, lunch and dinner and 3 snacks, with caloric distribution: breakfast 20%, lunch 25%, dinner 25% and 10% each of the 3 snacks. In this diet, the investigators will evaluate at the beginning and at the end of the study (12 weeks), the diet effects on reducing HbA1c, total daily insulin dose requirements (TDID), and the diet efficacy on reducing body weight, fasting plasma glucose (FPG) and overall glycemic excursion, using continuous monitoring system, The investigators will assess also at baseline and at the end of the diet intervention the Clock Genes mRNA expression in white blood cells.
1909069|NCT02696967|Drug|CLR325|CLR325 Concentrate for solution for infusion
1909070|NCT02696967|Other|Placebo|Normal saline
1909084|NCT02692976|Biological|mDC vaccination|Intranodal mDC vaccination
1909085|NCT02692976|Biological|pDC vaccination|Intranodal pDC vaccination
1909086|NCT02692976|Biological|mDC and pDC vaccination|Intranodal mDC/pDC vaccination
1909102|NCT02690974|Drug|LCZ696 (sacubitril/valsartan)|All patients will be treated with the LCZ696 (sacubitril and valsartan) tablets
1909109|NCT02688400|Drug|Diacerein|
1909110|NCT02688400|Drug|Celecoxib|
1909111|NCT02688400|Drug|Placebo|
1909113|NCT02686437|Other|TheraBand Kinesiology Tape|Kinesiology taping technique is designed to target muscles and lymphatic system. Limited research is available for specific conditions, including low back pain, but it is theorized to correct muscle function by inhibiting or facilitating the muscle, improve blood flow, reduce pain, and improve joint alignment.
1988617|NCT02768987|Behavioral|Bright 1 Bodies|A 12-week intensive lifestyle program utilizing group exercise classes adapted for this population, supplemented with coping skills training and diabetes self-management education.
1909123|NCT02683174|Device|Novel ambulatory patch (ZIO® XT Patch)|All enrolled patients will be fitted with a novel ambulatory patch (ZIO® XT Patch)
1909124|NCT02683174|Biological|BNP and hs-troponin I at 0 and 3 hours post ED attendance|All patients will have quantification of hs-troponin I (ARCHITECTSTAT high-sensitivity troponin I assay) and BNP (ALERE TRIAGE point-of-care BNP test; ALERE, San Diego, USA; www.alere.co.uk) at 0 and 3 hours post ED attendance.
1909125|NCT02681510|Drug|Varenicline|Standard FDA approved 12 weeks of treatment with Varenicline
1909126|NCT02681510|Drug|Nicotine Transdermal Patch|Standard FDA approved 12 weeks of treatment with Nicotine Transdermal Patch
1909127|NCT02681510|Drug|Nicotine Mini|Standard FDA approved 12 weeks of treatment with Nicotine Mini-Lozenge
1909128|NCT02681406|Behavioral|ACHESS|Smartphone based additions focused application, encouraging social support
1909129|NCT02681406|Behavioral|TMC|Brief telephone monitoring and counseling
1909133|NCT02680496|Device|Lokomat|A single walking trial in which the patient walks in the Lokomat with 60% guidance force for 30 minutes at comfortable walking speed (body-weight supported if necessary)
1909134|NCT02680496|Other|Treadmill|A single walking trial in which the patient walks on a treadmill for 30 minutes at comfortable walking speed (body-weight supported if necessary)
1909135|NCT02680496|Other|Overground|A single walking trial in which the patient walks overground for 30 minutes at comfortable walking speed (body-weight supported if necessary)
1909138|NCT02679079|Drug|NBI-98854|
1909139|NCT02679079|Drug|Placebo|
1909149|NCT02676349|Drug|mFolfirinox|oxaliplatin folinic acid irinotecan 5FU oxaliplatin
1909150|NCT02676349|Radiation|Chemoradiotherapy|conformational external irradiation (50.4 Gy) + capecitabine
1909151|NCT02676349|Procedure|surgery|1 to 4 weeks after neoadjuvant treatment according to tumour response
1909152|NCT02676349|Drug|Adjuvant chemotherapy|Gemcitabine or modified LV5FU (folinic acid+-bolus fluorouracil+ infusional fluorouracil)
1909153|NCT02676908|Other|Compression socks for 2 weeks|Patients in the intervention group will be asked to wear compression stockings for two weeks post-operatively
1909163|NCT02675478|Drug|AC220|
1988675|NCT02748577|Other|Questionnaires|Before the experimental session, participants will use REDCap to complete several questionnaires used to assess outcomes.
1988676|NCT02748577|Other|Quantitative Sensory Testing (QST) Pain Measurements|Investigators will administer noxious thermal stimulation to assess pain threshold temperatures and assess responses to pain on measures of pain intensity and pain unpleasantness
1909172|NCT02672865|Drug|Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|Hyperthermic intraperitoneal chemotherapy (HIPEC) is a procedure in which the internal parts of the abdomen are bathed in a warm solution of anti-cancer medications for 90 minutes.
1909188|NCT02669576|Behavioral|Mind body medicine day care clinic|Patients recieve an 11-week mind body day care clinic including elements of mindfullness based stress reduction (MBSR), yoga, acupuncture, education
1909189|NCT02669576|Other|Usual care|Patients continue usual care by their practitioner
1909190|NCT02668458|Procedure|High Flow nasal canula oxygen therapy|Pre-oxygenation with high-flow nasal canula oxygen therapy
1909191|NCT02668458|Procedure|Noninvasive ventilation|Pre-oxygenation with non-invasive ventilation
1909198|NCT02668770|Drug|MGN1703|"Dose Escalation Group Starting Dose: 15 mg on Days 1, 8, and 15 of each 21 day cycle.
Dose Expansion Group Starting Dose: Maximum tolerated dose from Dose Escalation Group."
1909199|NCT02668770|Drug|Ipilimumab|Dose Escalation and Dose Expansion Group Dose: 3 mg/kg by vein on Day 8 of a 21 day cycle.
1909203|NCT02667821|Other|Head positions and spinal manipulation|Each participant will undergo three separate test maneuvers. Neutral (0° rotation) neck position (condition 1) will be followed by block randomization between maximum voluntary rotation (condition 2) and a high-velocity-low-amplitude cervical manipulation targeted at C1-C2 (condition 3). Conditions 1 and 2 will be held for 1 minute before returning to neutral alignment. For the manipulation, the head will be repositioned at neutrality immediate. An experienced practitioner will perform the manipulation on the adjustable and pivotal MRI bed. After each condition, MRI of the upper neck and cerebrum for perfusion and blood flow will ensue.
1909209|NCT02664415|Biological|VRC01|40 mg/kg; administered IV
1909210|NCT02664415|Biological|Placebo for VRC01|Sodium Chloride for Injection 0.9%, USP; administered IV
1965970|NCT03312608|Diagnostic Test|Navigated transcranial magnetic stimulation|
1909214|NCT02663908|Drug|Degarelix|
1909215|NCT02663908|Drug|Leuprolide|
1965971|NCT03313947|Procedure|Ultrasound|Ultrasound to measure hyo-mental distance, neutral (Frankfort) position, maximal extended neck position to calculate ratio, width of the tongue between the lingual arteries, and tonsillar size (bilateral).
1965972|NCT03313947|Other|Questionnaire|"The following 6 questions will be asked during the preoperative visit:
While sleeping, does your child snore more than half the time?
While sleeping, does your child always snore?
Have you ever seen your child stop breathing during the night?
Does your child occasionally wet the bed?
Did your child stop growing at a normal rate at any time since birth?
Is your child overweight"
1909218|NCT02663362|Other|To evaluate the reproducibility of acquiring multi-nuclear data on a new 3T Philips Magnet|Outside standard MR instrumentation there will be no interventions.
1909219|NCT02662712|Drug|JNJ-56136379|JNJ-56136379 oral tablets will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
1909220|NCT02662712|Drug|Placebo|Matching placebo to JNJ-56136379 will be given in Part 1 (single dose escalation and multiple dose session) and Part 2 (multiple dose escalation).
1965973|NCT03313934|Combination Product|Hyaluronic Acid Filler and Platelet Rich Fibrin (PRF)|The use of Restylane-L to volumize the tear trough has been well documented. Combining Restylane-L with Platelet Rich Fibrin (PRF) will be studied to evaluate if PRF enhances the volumization and skin quality of the treated areas.
1965974|NCT03313934|Combination Product|Hyaluronic Acid Filler and Saline|This intervention will use saline as a control to compare with PRF when mixed with hyaluronic acid fillers. Saline will dilute the HA filler in the same way PRF will, however saline as no growth factors or properties that will enhance treatment.
1909223|NCT02661464|Biological|Ad26.ZEBOV|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to Ad26.ZEBOV vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
1909224|NCT02661464|Biological|MVA-BN-Filo|No vaccine will be administered in the current study. Safety data will be collected from participants who were previously exposed to MVA-BN-Filo vaccine in Phase 1, 2, or 3 clinical studies up to 60 months and also safety data will be collected from live born children to female participants up to 60 months after birth.
1965975|NCT03313921|Diagnostic Test|Online Manifest Refraction|"The online manifest refraction is performed with a web-based application and consists of an assessment of visual acuity, an assessment of spherical refractive error, and an assessment of cylinder refractive error. The software is a class 1 CE-approved medical device.
The automated refraction is measured with a regular office-based autorefractor device; TOPCON RM-8000."
1965977|NCT03313895|Behavioral|ACT|ACT stands for combined aerobic exercise and cognitive training.
1965978|NCT03313895|Behavioral|Cycling Only|Cycling on a recumbent stationary cycle
1965979|NCT03313895|Behavioral|Cognitive Training Only|Engage in cognitive training on a computer
1965980|NCT03313895|Behavioral|Stretching and Mental Stimulating Activities|Stretching exercises and mental stimulating activities on a computer
1965981|NCT03313882|Other|no intervention is involved|
1965982|NCT03313869|Dietary Supplement|XXS-2A + Omega-3 + Vitamin E + Selenium|Micronutrient cocktail supplementation with 560,7 mg/ day of polyphenols (3 pills/day), 2,1 g/day of omega-3 fatty-acids (3 pills/day), 168 mg/day of vitamin E and 80µg/day of selenium (1 pill/day)
1965983|NCT03313869|Dietary Supplement|control diet|habitual diet to be followed
1965984|NCT03313856|Drug|Guazuma Ulmifolia plus Tecoma Stans|Guazuma ulmifolia (313.6 mg) -Tecoma stans (86.4 mg) = 400 mg per capsule
1965985|NCT03313856|Drug|Calcinaned magnesia|Calcined magnesia 400 mg per capsule
1965987|NCT03313817|Device|Additional MRI sequences|"Patients will be hospitalized for suspicion of CRAO. An optimized MRI will be performed with specific sequences: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; 3D PD T1 after injection. A consultation of ophthalmology and a control MRI will be carried out one month after the CRAO. Again, specific sequences will be added: 3D T1 MSDE (Motion Sensitized Driven Equilibrium) dark blood; 3D Optimized diffusion centered on the optic nerves; DTI (Diffusion Tensor Imaging); 3D PD T1 after injection."
1909248|NCT02653521|Radiation|Dose adaptation|Replanning the treatment to adapt the change of PTV and movement of OARs to achieve an optimal dose distribution using online CBCT images.
1909263|NCT02650804|Drug|BPM31510 Nanosuspension Injection|
1909264|NCT02650804|Drug|Gemcitabine|
1966002|NCT03313778|Biological|mRNA-4157|Personalized cancer vaccine
1909266|NCT02648802|Procedure|Cavity shaving|Resect the residual cavity circumferentially (superior, inferior, medial, lateral) and the thickness of the cavity shaving depends on the surgeon's discretion (Recommended 0.5-1.0cm). The principles of the cavity shaving includes: 1) do not compromise the cosmetic outcomes; 2) covers the entire cavity;
1909267|NCT02648802|Procedure|Standardized BCS+CM assessment.|For standardized BCS(Chen K, et al. Ann Surg Oncol. 2012), we resect a rim of 1 cm macroscopically normal tissue around the tumor. The anterior and posterior margins of the tumor-containing specimen extended up to the subdermal plane of the skin and down to the pectoralis major fascia, respectively. The anterior and posterior CMs assessment will not be needed. A surgical blade was used for resecting the CMs (superior, inferior, medial and lateral) to render the thickness of the CMs as thin as possible. No procedures were required for distinguishing the inner and outer surface. They were then frozen and cut parallel, but not perpendicular to the largest surface area. CMs were defined as positive when in situ or invasive carcinoma was found intraoperatively by frozen-section analysis.
1909268|NCT02648724|Drug|Sym015|Sym015 is a mixture of two monoclonal antibodies Hu9006 and Hu9338. Both antibodies are humanized immunoglobulin G1 (IgG1), which specifically binds to non-overlapping epitopes in the extracellular domain of MET.
1966003|NCT03313778|Biological|Pembrolizumab|intravenous infusion
1966004|NCT03313765|Behavioral|Motivational interviewing (MI)|Brief MI intervention
1966005|NCT03313765|Other|Standard-of-care|Standard-of-care education and counseling
1966006|NCT03313752|Drug|Dapagliflozin 10Mg Tab|Dapagliflozin, will be administered according to the approved posology and to the approved dose as stated by Local Health Indication and by the Drug Brochure
1966007|NCT03313752|Other|Placebo|placebo
1966008|NCT03313739|Other|An Educational Program|An educational program was designed for self-care during menopause using teach back method.
1966009|NCT03313726|Drug|GnRH antagonist|Administration of GnRh antagonist after baseline PSMA-PET at day 0 and then repeated PSMA-PET scans at day 7, day 14 and day 28 to define the timeframe of the SUV-max.
1909276|NCT02646839|Device|CliniMacs TCR alpha-beta-Biotin system|Graft ex vivo depleted of T cell receptor (TCR) αβ+CD3+/CD19+ cells
1966010|NCT03313726|Drug|GnRH antagonist|Administration of GnRh-antagonist after baseline PSMA-PET at day 0 and then repeated scan at day in which SUV-max was observed in the Arm A (day 7, day 14 or day 28). Then robot assisted radical prostatectomy and lymphadenectomy are performed to verify the finding.
1966013|NCT03313700|Procedure|Robotic Assisted Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,robotic assisted distal gastrectomy will be performed in the experimental group.
1966014|NCT03313700|Procedure|Laparoscopic Assisted Distal Gastrectomy|After exclusion of T4b, bulky lymph nodes, or distant metastasis case,laparoscopic assisted distal gastrectomy will be performed in the comparator group.
1966016|NCT03313661|Drug|Cabergoline|cabergoline 0.5 mg twice weekly within 2 hrs of awakening plus gliclazide
1966017|NCT03313661|Drug|Gliclazide|gliclazide (60-120 mg)
1966018|NCT03313648|Procedure|Laparoscopic Hepatectomy|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
1966019|NCT03313648|Procedure|Radiofrequency Ablation|180 patients with recurrent HCC with recurrent nodular diameters of less than 5 cm and up to three nodules were randomly divided into LH (n=90) and RFA groups (n=90). Outcomes were monitored and evaluated during the 5-year follow-up period.
1966020|NCT03313635|Diagnostic Test|Men presenting with low-T|Evaluation of prealbumin levels.
1966021|NCT03312595|Device|Restrata TM Wound Matrix|The RestrataTM Wound Matrix is a sterile, single use device intended for use in local management of wounds
1966022|NCT03313609|Behavioral|Investigating Burnout in Intensive Care in Middle Incoming Turkey|single-group studies
1966023|NCT03313596|Drug|ADV-Tk|The first ADV-TK dose was administered during the operation; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into peritoneum tissues around the liver. The second and third ADV-TK dose was administered 60 days and 90 days after LT; 1.0×10(12) viral particles of ADV-TK in 100 mL of 0.9% saline were injected into the celiac artery (60 mL) and the superior mesenteric artery (40 mL) via femoral-artery puncture.
1966024|NCT03313596|Procedure|LT|Orthotopic LT and subsequent immunosuppression therapy
1966025|NCT03313583|Procedure|Transfusion of blood products|
1966026|NCT03313570|Drug|BGF MDI 320/14.4/9.6 μg|Budesonide, Glycopyrronium, and Formoterol Fumarate
1966027|NCT03313570|Drug|GFF MDI 14.4/9.6 μg|Glycopyrronium and Formoterol Fumarate
1966028|NCT03313570|Drug|BFF MDI 320/9.6 μg|Budesonide and Formoterol Fumarate
1966029|NCT03313557|Drug|Wee-1 kinase inhibitor AZD1775|Patients will receive AZD1775 300 mg orally once daily. Days 1 to 5 and 8 to 12 of a 21 day cycle (ie, 5 days on and 2 days off for Weeks 1 and 2 of a 21-day cycle). All patients must receive a serotonin receptor 3 (5-HT3) antagonist, ondansetron (Zofran) 8 mg orally/IV or granisetron (Kytril) 1 mg orally/IV prior to each dose of AZD1775. Dexamethasone 4 mg orally/IV will be given with each AZD1775 dose at a minimum on the first day of dosing of AZD1775 of every 5 day dosing period, unless contraindicated or not well-tolerated.
1966030|NCT03313544|Drug|Nivolumab|NIVOLUMAB
1966031|NCT03313544|Device|MRI|Cardiac MRI 6 MONTHS
1966032|NCT03313544|Biological|BLOOD SAMPLES|biological (BNP and troponin)
1966033|NCT03313544|Device|trans-thoracic echocardiography|1, 3 and 6 months
1966036|NCT03313518|Device|tDCS|15 patients received real anodal tDCS for 20 minutes daily for 10 consecutive days.
1966037|NCT03313518|Device|Sham tDCS|15 patients received sham anodal tDCS for 20 minutes daily for 10 consecutive days.
1966038|NCT03313505|Biological|S100B protein dosage|S100B protein dosage will be carried out, by a blood sample, on the earliest after admission and before 3th hour following brain injury S100B protein dosage will be left to the assessment of the emergency physician in charge of the patient
1966039|NCT03313505|Other|Brain CT scan|No injected brain CT-scan, regardless of the time between the brain injury and the arrival in the emergency unit. Realization of CT-scan will be left to the assessment of the emergency physician in charge of the patient
1966040|NCT03313492|Behavioral|UV4.me2|"UV4.me2 is an enhanced version of the original UV4.me web intervention and features the many of the same educational material and interactive components. New features/strategies for reach, effectiveness, and implementation include:
A mobile version of the site
Incentives in the form of clickable coupons and links to free samples for sun protection products (e.g., sunscreen)
Behavioral tracking and feedback, where users can set goals, track their progress, and receive tailored feedback"
1966041|NCT03313492|Behavioral|UV4.me|Original version of the UV4.me website, which offers education and tailored responses to interactive quizzes about current sun protective behaviors and barriers to engaging in sun protective behaviors.
1966042|NCT03313492|Behavioral|E-Pamphlet|"A free non-interactive e-pamphlet (Skin Cancer Prevention and Early Detection from the American Cancer Society). Includes information on skin cancer risk and prevention."
1966043|NCT03313479|Drug|Dexmedetomidine|Dexmedetomidine will be given with GS
1966044|NCT03313466|Behavioral|Internet cognitive behavioral therapy for insomnia (iCBTI)|An internet-based program for providing individually tailored CBTI based on participant responses to questions and performance on weekly guided sleep strategies.
1966045|NCT03313466|Behavioral|Class in sleeping well and improving insomnia|A group education session providing advice on healthy sleep habits and ways to improve common forms of insomnia.
1966048|NCT03313440|Other|High wheat fiber|Daily increased fiber intake by 18-22 grams/day. Products are provided in boxes that must be consumed each day during the intervention.
1966049|NCT03313440|Other|Low fiber|Control low fiber intervention. Products are provided in boxes that must be consumed each day during the intervention.
1966050|NCT03313427|Other|Physical Therapy Early Intervention|"At the UCIN:
Parental education to empower them on motor development and parent-infant relationship. Consisted on 6 sessions during the first weeks at the NICU.
Tactile and kinaesthetic stimulation managed by parents. 2 times a day, 15 minutes each, during 10 days.
At home:
Psychomotor Development Program for the baby; comprised of different exercises, in different phases, depending on child maturation stage. Started after hospital discharge until 2 months corrected age."
1909307|NCT02643173|Other|Volatile anesthetics|
1909308|NCT02643173|Other|Intravenous anesthetics|
1909309|NCT02642094|Drug|Rapamycin|Low dose of rapamycin at 2 mg/day for -5-7 days of treatment
1966051|NCT03313427|Other|Usual Care|NICU usual care
1909318|NCT02640404|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular. 2 doses 3 months apart
1909319|NCT02640404|Biological|Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, Intramuscular.
1909328|NCT02640612|Drug|BI 695501|
1966056|NCT03313375|Other|Continuous Exercise|Subjects will be asked to perform a 45 min exercise bout. 10 minutes will be a warmup (at a work rate associated with 50% heart rate max), 30 minutes at a wattage that elicits 75-80% heart rate max, and a 5 minute cool down period, returning them to approximately 50% heart rate max.
1966057|NCT03313375|Other|Aerobic Interval Exercise|Subjects will be asked to complete a 43 minute exercise session. To warm up, subjects will cycle at a work rate associated with 50% HRmax for 10 minutes. Wattage will then increase and subjects will do four 4-minute intervals at a work rate associated with 90%-95% HRmax, separated by 3 minutes of active recovery at a work rate associated with 50% HRmax. Subjects will be given a 5-minute cool-down period at a work rate associated with 50% HRmax.
1966064|NCT03313323|Biological|89Zirconium-labeled ipilimumab|Metastatic melanoma patients, who are treated with ipilimumab (3 mg/kg), will be infused with 89Zr-labeled ipilimumab within 2 hours after injection of the first and second standard ipilimumab doses. Peripheral blood mononuclear cells (PBMCs) will be collected for immunomonitoring.
1966066|NCT03313297|Drug|AZD4017|AZD4017 is a novel orally bioavailable small molecule inhibitor of 11β-HSD1 enzyme activity. It is potent and highly selective in vitro and in vivo. The half maximal inhibitory concentration (IC50) for inhibition of 11β-HSD1 activity (cortisone to cortisol conversion) is 2nM. AZD4017 is selective (> 2000x) for 11β-HSD1 over human recombinant 11β-HSD2 and the closely-homologous enzymes 17β-hydroxysteroid dehydrogenase 1 and 17β-hydroxysteroid dehydrogenase 3 in vitro.
1909359|NCT02636257|Procedure|Recessive Spherical Headed Silicone Intubation|Local anesthesia,regular disinfection, spread sterile towels, exposure operative side.2%lidocaine infiltration anesthesia to inferior orbital nerves, lacrimal punctum and lacrimal sac. Nasal cavity was packed with gauze soaked in 2%ephedrine with 1%tetracaine 15 minutes before procedure.A routine silicone tube of spherical intubation was performed. Dilatated lacrimal point to the end, then inserted the probe with line from lacrimal punctum to inferior meatus through nasolacrimal duct.Cut the line and flush the lacrimal duct physiological saline in 5 mL, flowing the line into the inferior meatus, then suctioned out the line with nasal endoscopy and extracted the probe and dilatated the lacrimal duct again. Insert the spherical silicone tube from lacrimal point to the lacrimal sac, reversing to vertical direction to ensure the tube is inserted into the nasolacrimal duct, then catch the above line but cut short the follow one and fix.Unobstructed lacrimal irrigation.
1909360|NCT02636257|Procedure|Dacryocystorhinostomy|Surgery was performed under local anesthesia.Incision was taken over anterior lacrimal crest.Medial palpebral ligament was identified.Orbicularis was separated.Reflection of periosteum and dissection of lacrimal sac from lacrimal fossa was done.Sac was excised to make'H'shaped anterior and posterior flaps. Bony osteum of sufficient size was made with bone punch.Nasal mucosa was cut to make anterior and posterior flaps.Subsequently anterior to anterior and posterior to posterior flaps were sutured.
1966067|NCT03313297|Drug|Placebo|Matching placebo
1966068|NCT03313284|Procedure|RMT|RMT consists of six bouts of 5-min of volitional hyperpnoea . After each RMT bout, participants will breathe room air for 5 minutes.
1966069|NCT03313284|Procedure|RMT + IH|RMT and IH consist of six bouts of 5-min of volitional hyperpnoea. After each RMT bout, participants will breathe a hypoxic gas mixture (10.5% O2 ) for 5 minutes.
1966070|NCT03313284|Procedure|Control|No intervention
1909365|NCT02635854|Other|Septic choc group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood at the admission in intensive care unit and 48 hours later for leukocyte-platelet aggregates measurements.
1909366|NCT02635854|Other|Orthopedic surgery group|Specific platelet activation markers, circulating leukocyte-platelet aggregates will be assessed in peripheral venous blood during the orthopedic surgical anesthesia consultation.
1966071|NCT03313258|Device|Standard of Care Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is blinded to the care team but not to the research personnel.
1966072|NCT03313258|Device|Active Warming Group|ZHF temperature monitor cable will be placed appropriately on the forehead by the care team under the direction of the research personnel. The research personnel will then connect this cable to a screen that is un-blinded to everyone so healthcare practitioners will be able to visually detect continuous temperature readings from the ZHF monitor.
1966073|NCT03313245|Other|No Intervention/Observational Study|No Intervention/Observational Study
1966074|NCT03313232|Other|ROAT with oxidized R-limonene at 1%, 0.3% and 0.1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at 1%, 0.3% and 0.1% concentrations
1966075|NCT03313232|Other|ROAT with oxidized R-limonene at 1%|A twice daily repeated open application test (ROAT) study for up to three weeks of exposure to oxidized R-limonene at a 1% concentration
1966076|NCT03313219|Drug|Gentuximab Injection|Gentuximab Injection (Recombinant anti-VEGFR2 human-mouse chimeric monoclonal antibody injection)
1966077|NCT03313206|Drug|Pembrolizumab|"Neo-adjuvant therapy :
Anti-PD1 antibody will be used (pembrolizumab, Merck®) intravenously at a dose of 200 mg every 3 weeks. The patient will receive 4 injections maximum over 12 weeks. According to the investigator's opinion, the 4th injection might be cancelled in order to perform surgery from week 10 and not after week 13.
Tumor response will be assessed 2 weeks after the last injection both clinically and radiologically (by CT-scan and MRI).
Maintenance therapy by anti-PD1 antibody (pembrolizumab, Merck®) will be then used intravenously at a dose of 200 mg every 3 weeks for a maximum period of one year, starting one month after the end of radiotherapy."
1966078|NCT03313206|Procedure|Surgery|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
1966079|NCT03313206|Radiation|IMRT|Surgery will be performed (endoscopically if possible) 3 weeks after the last injection, at the earliest week 10 and at the latest at week 13 and will be completed by radiotherapy using IMRT technology according to the International and European Rhinologic Societies guidelines.
1966080|NCT03313193|Other|Acupressure for Children in Treatment for a Childhood Cancer|This study will describe the benefits and risks of an acupressure intervention to decrease nausea/vomiting and other treatment-related symptoms compared to a control group receiving usual care. Children in Arm A will receive usual symptom management care + acupressure 5 days/week for ~20 treatments. Parents will be taught how to provide acupressure as well. Children in Arm B will receive usual care alone.
1966082|NCT03313167|Other|Non-interventional|Non-interventional
1966083|NCT03313154|Other|Neuropsychiatric screening|"Psychiatric diagnosis through:
clinical interview
the Advanced Neuropsychiatric Tools and Assessment Schedule (ANTAS), based on the SCID-I-NP (Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders-Non Patient Version);
HAM-D (Hamilton Scale for Depression);
PHQ-9 (Patient's Health Questionnaire-9 items);
MDQ (Mood Disorders Questionnaire);
YMRS (Young Mania Rating Scale);
ASRM (Altman Self Rating Mania scale);
BRIAN (Biological Rhythms Interview of Assessment in Neuropsychiatry).
Assessment of Quality of Life:
SF-12 (Short Form Health Survey-12 items).
Neuropsychological screening:
l) Addenbrooke's Cognitive Examination (ACE-R)."
1966084|NCT03313141|Diagnostic Test|Ultrasound|Volitional and non volitional respiratory tasks
1909381|NCT02631733|Drug|Ferumoxytol|Given IV
1909382|NCT02631733|Other|Laboratory Biomarker Analysis|Correlative studies
1909383|NCT02631733|Drug|Liposomal Irinotecan|Given IV
1909384|NCT02631733|Procedure|Magnetic Resonance Imaging|Undergo MRI
1909385|NCT02631733|Drug|Veliparib|Given PO
1966087|NCT03313102|Biological|blood samples|sample of 16 blood tubes
1966088|NCT03313089|Behavioral|"Papas más nutritivas (PSAN)"|"Activities of the project Papas más nutritivas"
1966089|NCT03313076|Drug|n-3 PUFA|n-3 PUFA QD for 6 weeks
1966090|NCT03313076|Drug|Vitamin D3|2000 IU QD for 6 weeks
1966091|NCT03313076|Drug|Vitamin D3 Matching Placebo|1 tablet QD for 6 weeks
1966092|NCT03313076|Drug|PUFA Matching Placebo|4 soft gels QD for 6 weeks
1966093|NCT03313050|Biological|Multivalent|Pneumococcal conjugate vaccine
1966094|NCT03313050|Biological|Tdap|Tetanus, diphtheria, acellular pertussis vaccine
1966095|NCT03313050|Biological|polysaccharide|23-valent pneumococcal polysaccharide vaccine
1966096|NCT03313037|Biological|Multivalent|Pneumococcal conjugate vaccine
1966097|NCT03313037|Biological|Prevnar 13|Pneumococcal conjugate vaccine
1966098|NCT03313037|Biological|PPSV23|Pneumococcal polysaccharide vaccine
1966099|NCT03313037|Other|Saline|Placebo
1909402|NCT02630615|Other|Blood draw|Whole blood will be collected using standard phlebotomy procedures
1992496|NCT03320733|Diagnostic Test|Dual energy CT scan with subtraction imaging|"The single source V2R kmAS dual energy CT system has several theoretical advantages compared, such as perfectly matched X-ray paths and the possibility of performing dual-energy processing using projection data.
Subtraction imaging is an accurate deformable registration algorithm that allows creation of iodine maps from matched pre- and post-contrast acquisitions. This algorithm can be applied to both single and dual energy CT."
1909409|NCT02629302|Other|animal assisted therapy|physiotherapy, speech therapy and occupational therapy in the presence of an animal
1909410|NCT02629302|Other|standard therapy|standard physiotherapy, speech therapy and occupational therapy
1909411|NCT02628067|Biological|pembrolizumab|intravenous infusion
1909414|NCT02628210|Other|map3® Cellular Allogeneic Bone Graft|Patients will receive map3® Cellular Allogeneic Bone Graft
1909415|NCT02626299|Drug|Docosahexaenoic acid - 800mg/day|All participants will take 1000 mg/DHA per day (1 capsule will be labeled with 200 mg; 2 capsules will be masked with 400 mg each)
1909416|NCT02626299|Drug|Docosahexaenoic acid - 200mg/day|The control group will receive 1-capsule containing 200 mg DHA/d.
1909417|NCT02626299|Other|Placebo|Participants will receive 2 capsules (masked) containing half soybean oil and half corn oil equaling 800 mg.The soybean and corn oil combination does not contain DHA.
1909418|NCT02627352|Procedure|Micropulse Transscleral Cyclophotocoagulation|In mTSCPC, a diode laser is used to damage tissue of the ciliary body, the tissue inside the eye that produces aqueous, the clear fluid in the eye that maintains intraocular pressure. This causes it to produce less aqueous.
1909419|NCT02627196|Device|BAROSTIM NEO® System|
1966102|NCT03312985|Procedure|ACAF surgery|The main surgical procedures include discectomy of the involved levels, thinning of the anterior part of the involved vertebrae, intervertebral cages, anterior plate and screws installation, bilateral osteotomies of the vertebrae, and antedisplacement of the vertebrae-OPLL complex
1966103|NCT03312985|Procedure|ACCF surgery|Removal of the vertebral body，exposed ossification of the posterior longitudinal ligament，and then removed
1966105|NCT03312959|Drug|hyperbaric bupvacaine in Peribulbar block|hyperbaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
1966106|NCT03312959|Drug|isobaric bupvacaine in Peribulbar block|isobaric bupivacaine in Peribulbar block will be injected in the posterior segment surgery
1966107|NCT03312946|Device|Modellata|treatment such as the Modellata electromedical device (Ibramed), in the abdomen, flanks, thigh posterior, inner thigh and buttocks.
1966110|NCT03312907|Drug|Belimumab|Belimumab will be administered as SC injection once weekly via autoinjector in thigh or abdomen
1909431|NCT02625974|Drug|Nifurtimox (BAYA2502)|"For pediatric subjects with body weight ≤ 40 kg: maximum dosage15 mg/kg/day in three divided doses For pediatric subjects with body weight > 40 kg: 8 - 10 mg/kg/day in three divided doses.
60 days of nifurtimox treatment"
1909432|NCT02625974|Drug|Nifurtimox (BAYA2502) followed by Placebo|"For pediatric subjects with body weight ≤ 40 kg: maximum dosage15 mg/kg/day in three divided doses For pediatric subjects with body weight > 40 kg: 8 - 10 mg/kg/day in three divided doses.
30 days of nifurtimox treatment followed by 30 days of placebo"
1966111|NCT03312907|Drug|Rituximab|Rituximab will be administered as IV infusion of 1000mg at Week 4 and Week 6
1966112|NCT03312907|Drug|Rituximab-placebo|Saline will be administered as IV infusions at Week 4 and Week 6
1966113|NCT03312907|Drug|Standard therapy (Including Immunosuppressants)|Standard therapy will contain stable SLE medications including immunosuppressant to be administered from baseline through Week 104.
1966114|NCT03312907|Drug|Standard therapy (Excluding Immunosuppressants)|Standard therapy excluding Immunosuppressant will contain anti-malarials, NSAIDs, and/or corticosteroids with presdnisone dose equivalent to <= 5 mg/day will administered by subjects in Arm A and B through Week 104.
1966115|NCT03312907|Drug|Steriod Taper|Steriod taper will include prednisone doses equivalent to =< 5 mg/day in all Arms through Week 104.
1966116|NCT03312894|Drug|TAK-653|TAK-653 tablets
1909439|NCT02623751|Drug|KHK2375|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.
Exemestane will be orally adminitered once daily."
1909440|NCT02623751|Drug|Exemestane|"KHK2375 will be orally administered once weekly. KHK2375 in combination with exemestane will be repeatedly administered in a 28-day cycle.
Exemestane will be orally adminitered once daily."
1966117|NCT03312894|Drug|Placebo|Placebo-matching tablets
1966118|NCT03312881|Diagnostic Test|quantitative sensory testing|multiple modality testing of generalized and localized changes in somatosensory perception
1966119|NCT03312881|Diagnostic Test|neuroimaging|magnetic resonance imaging (MRI)
1966120|NCT03312881|Other|Patient Reported Outcome Measures|neuropathic pain screening tool; validated questionnaires
1966122|NCT03312855|Drug|Revacept 80 mg|single dose, intravenous application of 80 mg Revacept
1966123|NCT03312855|Drug|Revacept 160 mg|single dose, intravenous application of 180 mg Revacept
1966124|NCT03312855|Drug|Placebo|single dose, intravenous application of Placebo solution
1966125|NCT03312842|Drug|CS1001|"In the dose escalation part, the dose levels will be escalated following a modified 3+3 dose escalation scheme.
In the dose expansion part, patients will be assigned to different groups based on their tumor type."
1966126|NCT03312816|Other|cookies enriched with POP|Cookies
1966127|NCT03312803|Procedure|Mini autogenous skin graft|mini-autogenous skin grafts and skin homograft versus autogenous skin grafts for covering post burn wounds in children.
1966128|NCT03312790|Device|Tasks|Augmented reality device Real condition
1966129|NCT03312777|Drug|Omnitram|Omnitram tablets overencapsulated
1966130|NCT03312777|Drug|Tramadol|Tramadol tablet overencapsulated
1966131|NCT03312777|Drug|Placebo|Microcrystalline powder overencapsulated
1966132|NCT03312764|Behavioral|Online diabetes prevention program|Digital delivery of Intensive behavioral counseling for diabetes prevention and healthy lifestyle management. Recipients have access to online curriculum, a live health coach, group-based communication forums, and connected technology to track weight and physical activity.
1966133|NCT03312764|Behavioral|Standard Care|One-on-one or small group sessions with a dietitian or a trained health professional to advise on physical activity, healthful nutrition and risk reduction for diabetes.
1966134|NCT03312751|Drug|Emapalumab|Emapalumab will be administered by intravenous infusion, twice weekly.
1966135|NCT03312738|Drug|Everolimus|Everolimus was formulated as tablets of 5-mg strength and was packaged into blister packs . Everolimus (two 5 mg tablets daily) are administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
1966136|NCT03312738|Drug|Exemestane|Exemestane 25 mg orally daily.
1966137|NCT03312738|Drug|Everolimus Placebo|Placebo was formulated to be indistinguishable from the everolimus tablets. Matching placebo (two tablets daily) are administered in a blinded manner on their respective treatment arms by continuous oral daily dosing.
1966138|NCT03312725|Device|WEB aneurysm embolization system|The WEB aneurysm embolization system is a class III device and consists of an implantable embolization device attached to a delivery device. The WEB is a mesh composed of single layers of braided nitinol tubes with platinum cores. The braids are held together by proximal and distal platinum/iridium radiopaque markers.
1966139|NCT03312712|Radiation|PET/CT scan|"PET/CT will be performed at Cambridge University Hospital's PET-CT unit, Cambridge.
Participants in Part A of the study (sarcoidosis and HVs) will receive one PET/CT scan. A Cine-CT scan will be performed immediately prior to the 18F-FDG PET/CT scan. Settings for the CT scans will be determined by clinical protocols, radiation dose will be kept as low as reasonably practicable (ALARP) consistent with UK legislation.
After 6 hours of fasting and if blood glucose concentration is ≤11mmol/L participants will proceed to undergo an 18FDG PET/CT scan.
18F-FDG will be administered intravenously at a dose of approximately 200 MBq.
Positron emission scanning will involve a 60-minute dynamic acquisition from the lungs."
1966140|NCT03312712|Other|LPS Challenge|In Part B, eight healthy volunteers will undergo an LPS challenge whereby each participant is injected with the challenge agent, Lipopolysaccharide (LPS), to invoke temporary mild lung inflammation. Each participant will have a PET/CT scan before and after the administration of LPS and the images will be assessed to determine whether these methods are able to detect true lung inflammation.
1966141|NCT03312712|Other|Saline Challenge|In Part B, four healthy volunteers will undergo a saline challenge as outlined above for the LPS challenge. Pre- and post-challenge scans will provide control data for the study.
1966142|NCT03312712|Diagnostic Test|Blood and urine sampling|For women whose post-menopausal status and/or pregnancy status is uncertain at screening, a blood sample will be collected to test for pregnancy and menopausal status (hormone profiling) before enrolling them on to the study. If pregnancy status is still uncertain at study visits, participants will have a urine pregnancy test before undergoing any PET/CT scans to ensure it is safe for them to continue in the study.
1966143|NCT03312699|Biological|Fluzone® quadrivalent|IIV4 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by intramuscular (IM) injection into the deltoid muscle.
1966144|NCT03312699|Biological|Fluzone High Dose|High Dose IIV3 vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
1966145|NCT03312699|Biological|Fluad|Fluad vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
1966146|NCT03312699|Biological|Vaqta|Vaqta vaccine will be administered as a 1 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
1966147|NCT03312699|Biological|Typhim Vi|Typhim Vi vaccine will be administered as a 0.5 mL dose, with a sterile, disposable syringe and needle by IM injection into the deltoid muscle.
1966148|NCT03312699|Biological|Vivotif|One capsule is to be swallowed approximately 1 hour before a meal with a cold or luke-warm [temperature not to exceed body temperature, e.g., 37 °C (98.6 °F)] drink on alternate days, e.g., days 1, 3, 5 and 7.
1966149|NCT03312686|Drug|PPI|Resolution of esophageal eosinophilia by a 2-month course of high dose PPI in patients will lead to improvement in esophageal distensibility, and thus should produce improvement in dysphagia symptoms.
1966150|NCT03312673|Other|Interview and tests of drawing.|The intervention will take place with patients followed for asthma at the Croix Rousse hospital. Patients agreeing to participate in the study will come to the hospital for one hour and a half. They will answer questionnaires and tests of drawing. Results Restitution Session (optional) is proposed to patients within the next 4 weeks during a routine consultation.
1966154|NCT03312621|Behavioral|Health Care Transition Care Coordination|These services included 1) a face-to-face systematic review of the readiness assessment with the participant/caregiver 2) a status assessment of ongoing healthcare transition planning and preparation; 3) monthly phone calls with the participant/caregiver to update and fill gaps in the healthcare transition action plan.
1966155|NCT03313622|Behavioral|Beads Task|Participants will be asked to make a series of decisions that involve combining information about the value and probability of potential rewards. Subjects will sit in front of a computer monitor and place their hand over a box with orange and blue button that they will be asked to press based on their idea of which one will be the majority in a jar full of orange and blue beads. This task should take 15-20 minutes to complete, not including EEG setup.
1909466|NCT02618512|Drug|SBC-103|
1909467|NCT02616666|Drug|Dapagliflozin|The product in study is dapagliflozin (FORXIGA™), 10 mg film-coated tablets, and FORXIGA™ should be prescribed according to the instructions in the SmPC and current practice, including up-titration (if considered appropriate by the investigator). Dapagliflozin will be given in combination with metformin.
1909468|NCT02616666|Drug|Standard of Care|The comparator arm consists of SOC. The SOC arm can be sulphonylurea (SU) or non-SU treatments. SU treatments will include any SU and the related insulin secretagogues repaglinide or nateglinide, each of them in combination with metformin. The non-SU treatments can be metformin and dipeptidyl peptidase 4 inhibitors (DPP-4i), or metformin and glitazones (pioglitazone) combination therapy. Other SGLT-2 inhibitors are excluded. All these treatments are approved in the UK for use in this patient population.
1966156|NCT03313622|Behavioral|PROVOC Tasks|Three tasks will be developed collaboratively with the participant and independent evaluator that involve the participant being exposed to triggers that are considered by him/her impossible to confront without ritualizing. There will also be a similar process involving objects that should not cause any distress to be used as a control. Sessions will be videotaped with AFAR system concurrent to recording of LFPs from VS and scalp EEG.
1966157|NCT03311594|Drug|Low Alcohol|Low Alcohol Consumption
1966158|NCT03311594|Drug|Moderate Alcohol|Moderate Alcohol Consumption
1966159|NCT03311594|Drug|Placebo Alcohol|Placebo Alcohol Consumption
1966160|NCT03311594|Other|Pain Induction|10% capsaicin solution placed on forearm and heat induction
1966161|NCT03311594|Other|No Pain Induction|Water placed on forearm
1966163|NCT03312439|Behavioral|Given advice|Based on results of testing the participants will be give advice with the general aim to decrease the future risk of non-communicable disease by increasing physical activity,
1909487|NCT02612857|Drug|IMO-8400 Dose Group 1|IMO-8400 Dose 1 subcutaneous injections once a week for 24 weeks.
1909488|NCT02612857|Drug|IMO-8400 Dose Group 2|IMO-8400 Dose 2 subcutaneous injections once a week for 24 weeks.
1909489|NCT02612857|Drug|Placebo|normal saline subcutaneous injections once a week for 24 weeks.
1966165|NCT03312361|Drug|15% oxygen|Participants will inhale 15% oxygen for 2 hours to see how it affects them.
1966167|NCT03312309|Procedure|personal embryo transfer|"According to the histological dating of endometrium of natural/hormone replacement cycle in control group, to explore the effectiveness of intervention by advanced or delayed personal embryo transfer .
The establishment of standard control group: Frozen embryo transfer patients according to the inclusion and exclusion criteria were evaluated for histological dating by endometrial biopsy on 7 days after ovulation/P+7. After routine time transfer in the frozen embryo transfer cycle, the standard of histological dating were determined according to the pregnancy outcome of the FET cycle .
pET in RIF patients was delayed one(ovulation +4/P+4, OV/P+4) / two days(OV/P+3) or advanced one day(OV/P+9). Day 5 blastocysts were transferred with this strategy in natural cycles."
1909498|NCT02610153|Drug|Vitamin K Antagonist|The vitamin K antagonists exert their anticoagulant effect through inhibition of the enzyme complex of vitamin K epoxide reductase subunit 1 with subsequent reduction of the gamma-carboxylation of certain glutamic acid molecules endpoints located on factors coagulation II (prothrombin), VII, IX and X and protein C or its cofactor protein S. This gamma-carboxylation has a significant bearing on the interaction of coagulation factors referenced with calcium ions. Without this reaction, blood clotting cannot be initiated. The dose must be adjusted to each patient at baseline and after regular basis, since the sensitivity to anticoagulants varies between individuals and can also vary throughout the treatment. For this, the Prothrombin Time (PT) is used and standardized ratio called International Normalised Ratio (INR).
1966174|NCT03312088|Device|Freedom Knee PCK Components|Total Knee Revision
1966175|NCT03312036|Device|Coupled plasma filtration and adsorption (CPFA)|"Patients affected by acute or acute on chronic liver failure are enrolled to undergo CPFA extracorporeal treatments and the standard medical therapy to recover their basal liver function or as a bridge to liver transplantation"
1966178|NCT03311633|Procedure|Percutaneous pinning time|Percutaneous pinning time will be compared in two groups: 3 versus 6 weeks.
1966180|NCT03311425|Drug|Methylprednisolone|Application of 40mg Depomedrol (methylprednisolone acetate) suspension into the retropharyngeal space prior to incision closure
1966181|NCT03311425|Drug|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
1966182|NCT03311282|Device|infants bottles|"angled/inclined teat that remains full of milk throughout the feeding to prevent the risk of air ingestion, gassy colic, hiccups and regurgitation and to keep the infant's neck in the right position;
extra-large, soft and rounded base to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion
flexors at the base to enhance elasticity and flexibility of the teat"
1966183|NCT03311282|Device|Infants Bottles|"large, rounded and soft teat to ensure maximum simulation of the maternal breast and a wide latch on for a correct suckling motion
non-inclined shape of the teat ideal from 4 months onwards, when the colic episodes have subsided and infant has more control of the neck.
flexors at the base to enhance elasticity and flexibility of the teat"
1966184|NCT03311282|Device|Infants Bottles|"teat with less rounded base to guarantee tighter lip support, which helps the sucking motion.
flexors at the base to enhance elasticity and flexibility of the teat"
1966185|NCT03311243|Procedure|Non surgical periodontal therapy|
1966186|NCT03311243|Drug|Chemical plaque control|
1966188|NCT03311204|Device|BlephEx|BlephEx is an instrument that contains a hand piece used to spin a medical grade micro-sponge along the edge of eyelids and lashes that helps in removing scurf and debris from eyelids and helps in exfoliating the lids. A new micro-sponge will be used for every subject to avoid cross-contamination. This procedure lasts for 6-8 mins.
1966189|NCT03311204|Other|Lid Hygenix|Foam-based hypoallergenic cleanser used to clean eyelid margins is used as a control intervention for the study.
1909522|NCT02607228|Drug|GS-5829|GS-5829 tablet administered orally once daily
1909523|NCT02607228|Drug|Enzalutamide|Enzalutamide capsules administered orally once daily
1909528|NCT02605304|Drug|Ledipasvir/sofosbuvir|Participants will receive one fixed dose tablet of LDV 90 mg/SOF 400 mg orally per day.
1909529|NCT02605304|Drug|Ribavirin|Based on weight at entry- For weight <75 kg, participants will receive one 1000 mg tablet orally per day. For weight >75 kg: participants will receive one 1200mg tablet orally per day.
1909530|NCT02605733|Device|EEG|amplitude integrated electroencephalography
1909531|NCT02605733|Device|NIRS|regional tissue oximetry
1966197|NCT03310151|Procedure|Imagined movements|Imagined wrist movements, 10-15 minutes, 4 times a day.
1909536|NCT02603887|Drug|Pembrolizumab|200 mg by vein every 3 weeks (one cycle=21 days) for up to 24 cycles.
1909543|NCT02603445|Drug|BCL201|
1909544|NCT02603445|Drug|Idelalisib|
1909545|NCT02603432|Biological|Avelumab|1 hour intravenous infusion every 2 weeks (Q2W) in 4 week cycles
1909546|NCT02603432|Other|Best Supportive Care|BSC will be administered as deemed appropriate by the treating physician, and could include treatment with antibiotics, nutritional support, correction of metabolic disorders, optimal symptom control and pain management (including palliative radiotherapy), etc. BSC does not include any active anti-tumor therapy, however local radiotherapy of isolated lesions with palliative intent is acceptable.
1909569|NCT02600819|Drug|E/C/F/TAF|E/C/F/TAF (150/150/200/10 mg) FDC tablets administered orally once daily
1966221|NCT03307785|Drug|Niraparib|Niraparib is a potent, orally active PARP1 and PARP2 inhibitor being developed as a treatment for patients with tumors that harbor defects in the homologous recombination DNA repair pathway or that are driven by PARP-mediated transcription factors.
1909575|NCT02598037|Dietary Supplement|Test meal|The test meal will contain the following features: 50% carbohydrate, 20% protein and 30% of total fat, and will be admnistrada after drawing blood fasting for 12 hours.
1909576|NCT02596997|Drug|Brincidofovir|Up to 100mg Brincidofovir twice weekly, not to exceed a total dose of 200mg each week
1909577|NCT02595918|Other|Laboratory Biomarker Analysis|Correlative studies
1909578|NCT02595918|Procedure|Nephrectomy|Undergo nephrectomy
1909579|NCT02595918|Biological|Nivolumab|Given IV
1966222|NCT03307785|Drug|TSR-042|TSR-042 is a humanized monoclonal antibody that binds with high affinity to PD-1 resulting in inhibition of binding to programmed death receptor ligands 1 and 2 (PD-L1 and PD-L2).
1966223|NCT03307785|Drug|Carboplatin-Paclitaxel|Carboplatin in combination with paclitaxel is a chemotherapy treatment that has been shown to be efficacious against a variety of different tumor types, including non-small cell lung cancer [NSCLC], ovarian cancer, endometrial cancer, and head and neck cancer.
1909599|NCT02594488|Device|Medtronic Reveal LINQ implantable cardiac monitor|The implantable cardiac monitor is implanted under the skin in the region of the thorax. It continuously monitors the heart's electrical activity for up to three years. Predefined arrhythmias are daily transmitted to a central core lab. In case of arrhythmias, specific guideline-based treatment is initiated within 48h.
1966227|NCT03307564|Device|TraceIT tissue marker injection|The TraceIT injection will be performed during the endoscopic fiducial placement which is the standard of care. CTs to serially confirm TraceIT positioning will be performed on the same day during patient visits for their middle (2nd or 3rd fraction) and last (5th fraction) radiation therapy treatments.
1909607|NCT02593032|Device|Pre-filled trays|Randomized Control Trial Patients in the research treatment group receive pre-filled, 3x7 disposable trays that separate their medication by dose and time (e.g. morning, afternoon, evening). These pre-filled trays are inserted into a connected, weekly pillbox that detects when pills are removed from its wells.
1909612|NCT02591628|Behavioral|HCTZ prescription conversion to chlorthalidone|The intervention is simply a prescription conversion and the main outcome is whether or not patients accept the conversion and treatment with chlorthalidone.
1909614|NCT02591186|Procedure|Acupuncture|Participants will receive 3 acupuncture sessions during IVF process
1909615|NCT02588521|Drug|AL-794|
1909616|NCT02588521|Other|Placebo/Vehicle|Suspension vehicle without active drug
1988699|NCT02729350|Behavioral|Guided Relaxation video clip|This intervention is a 12-minute guided relaxation intervention for reducing pain and stress in adult inpatients with sickle cell disease.
1988700|NCT02729350|Behavioral|Sickle Cell Disease Experience Discussion|This intervention is a 12-minute sickle cell disease experience discussion.
1909623|NCT02587403|Device|Fortiva™ Porcine Dermis|Fortiva Porcine Dermis implantation during repair of complex ventral hernia
1909624|NCT02587403|Device|Strattice™ Reconstructive Tissue Matrix|Strattice tissue matrix implanted during repair of complex ventral hernia
1988707|NCT02727985|Procedure|Pharmacist weaning schedule|individualized weaning schedule for each patient taking into account the amount of opioid, duration of opioid use, other adjunctive medications, and specific variables related to the patient.
1909633|NCT02586506|Drug|Placebo ELLIPTA inhaler|The ELLIPTA Dry Powder Inhaler (DPI) is a molded plastic two-sided inhaler that can hold two individual blister strips. Each strip will contain either lactose or a blend of lactose and magnesium stearate. Subjects will receive 1 inhalation once-daily until visit 2.
1909634|NCT02586506|Other|Questionnaire|ELLIPTA Inhaler Ease of Use Questionnaire is a four-point Likert scale. This questionnaire will be filled by investigator (designee) based on responses received from subject. Responses for the questionnaire are Very difficult, Difficult, Easy, Very easy. Subjects will be give either version A or B at Visit 2.
1909635|NCT02586116|Device|nanOss|nanOss Cervical Interbody Fusion Device with nanOss BA bone void filler.
1909636|NCT02586116|Device|C-Plus|C-Plus PEEK IBF Device with autograft
1988711|NCT02725892|Other|NIS observational stud|NIS observational study : Epidemiologic registry
1909640|NCT02585206|Behavioral|Personalization|"Phase I Factor
Personalized text messages using the participant's username and gender (Check out the EX Community for tips/support from other men who have quit. They've been there and can help you do this, QuitForever!). Both data points will be pulled from BecomeAnEX registration data."
1909641|NCT02585206|Behavioral|Integration|"Phase I Factor
Interactive messages to facilitate engagement via text with the 6 interactive intervention components of the BecomeAnEX web intervention:
Set your quit date Cigarette tracker Beat your smoking triggers Build your support system Choose a quit smoking aid Community
Integration will allow interaction with the web-based program via text message; for example, when a user sets a quit date via the website, it will trigger text messages tailored to the quit date; likewise, if a user sets a quit date via the text system, it will be populated in the website and drive the user experience online."
1909642|NCT02585206|Behavioral|Dynamic Tailoring|Individually tailored message to remind/reinforce users about BecomeAnEX information/tools they have already used, or to prompt users to take actions they have not yet taken.
1909643|NCT02585206|Behavioral|Message Intensity|"Phase I Factor
Varying levels of text message intensity over a 12-week period."
1909644|NCT02585206|Behavioral|Optimal-Adherence Text|Optimal-adherence text message intervention developed in Phase I
1966244|NCT03305458|Behavioral|TFCBT|treatment as usual
1966245|NCT03305458|Behavioral|eTFCBT|tablet-facilitated Trauma Focused Cognitive Behavioral Therapy (eTFCBT)
1909682|NCT02576548|Biological|MEDI4276|MEDI4276 is an investigational product
1909683|NCT02576808|Drug|Ginger extract|Ginger extract capsule at dose of 250 mg two times a day after meal daily for 42 days
1909684|NCT02576808|Drug|Loratadine|Loratadine tablet at dose of 10 mg one times a day after morning meal daily for 42 days
1909685|NCT02576626|Drug|indacaterol/glycopyrronium 110/50 Breezhaler®|
1909686|NCT02576626|Device|Placebo by Breezhaler®|
1909687|NCT02576626|Drug|ipratropium/salbutamol 0,5 mg, 2,5 mg by nebulisation|
1909688|NCT02576626|Device|Placebo by nebulisation|
1909692|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Attention and Stability of Mind|Completed at Week 1. Initial meditation exercises will be described and practiced to train attention skills (on breath) and create mental stability.
1909693|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Cultivating Insight into the Nature of Mental Experience|Completed at Week 2. Exercises to develop mindfulness will continue in order to promote mental stability and clarity.
1909694|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Self-compassion|Completed at Week 3: Techniques to analyze mental processes are introduced.
1909695|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Cultivating Equanimity|Completed at Week 4. Further analysis of mental processes.
1909696|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Appreciation and Gratitude for Others|Completed at Week 5. A reflection of all the things that bring us well-being are provided by or dependent upon other beings is encouraged.
1909697|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Developing Affection and Empathy|Completed at Week 6. The following concepts are presented and carefully considered: (1) cooperation and solidarity is essential for our survival and flourishing, as we are all extremely vulnerable and need each other; (2) hate and selfishness only cause suffering to others and ourselves and can only be prevented by cultivating sincere affection for others.
1909698|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Realizing Wishing and Aspiring Compassion|Completed at Week 7. Participants are invited to deepen their reflection on the reasons for gratitude, empathy, and affection for others, and see how they lead to feelings of compassion, or the wish for others to be free from suffering.
1909699|NCT02574559|Behavioral|Cognitive Based Compassion Training Session: Realizing Active Compassion|Completed at Week 8. The strategies used until this point will be reviewed in order to move from the wish for others to be free of suffering, toward the sense that we want to and must take steps to relieve their suffering.
1909700|NCT02574559|Behavioral|Meditation Session|20 minute session completed weekly after the Cognitive Training Session
1966275|NCT03300050|Biological|cH8/1N1 LAIV|One 0.5 mL dose contains cH8/1N1 LAIV titer of 10^7.5 +/- 0.5, egg infective dose 50%
1966276|NCT03300050|Biological|cH5/1N1 IIV + adjuvant|One 0.5 mL dose contains 15μg split hemagglutinin (HA) with AS03 adjuvant
1966277|NCT03300050|Biological|cH5/1N1 IIV|One 0.5 mL dose contains 15μg split hemagglutinin (HA)
1966278|NCT03300050|Biological|cH8/1N1 IIV + adjuvant|One 0.5 mL dose contains 15μg split hemagglutinin (HA) with AS03 adjuvant
1966279|NCT03300050|Biological|Normal saline|Administered as 0.25 mL nasal drops
1966280|NCT03300050|Biological|Phosphate buffered saline|Administered as 0.5 mL injection
1966284|NCT03299556|Other|WHT|Incorporating WHT into treatment for chronic pain. WHT includes patient and provider tracking of patient-reported pain, pain management, medication usage, functionality, depression, activity and sleep (measured by 3 axis actigraph); as well as prompts to subjects to engage in self-care, including non-pharmaceutical pain management therapies consistent with MPP training.
1966285|NCT03298906|Drug|Esketamine|Participants will self-administer one intranasal spray of 14 mg esketamine at Time 0 and again 5 minutes later on Day 1, a total dose of 56 mg in Treatment Period 1 and 2.
1966286|NCT03298906|Drug|Ticlopidine|Participants will receive 250 mg ticlopidine tablets orally twice daily on Day -9 through Day 1 in Treatment Period 2.
1909733|NCT02571361|Drug|Paracetamol (1g x 4)|Dose of 1 g given in 6 hour intervals the first 24 hours postoperatively
1909734|NCT02571361|Drug|Ibuprofen (400 mg x 4)|Dose of 400 mg given in 6 hour intervals the first 24 hours postoperatively
1909735|NCT02571361|Drug|Paracetamol (0,5 g x 4)|Dose of 0,5 g given in 6 hour intervals the first 24 hours postoperatively
1909736|NCT02571361|Drug|Ibuprofen (200 mg x 4)|Dose of 200 mg given in 6 hour intervals the first 24 hours postoperatively
1909737|NCT02571361|Drug|Placebo (x4)|Given in 6 hour intervals the first 24 hours postoperatively
1966293|NCT03299088|Other|Laboratory Biomarker Analysis|Correlative studies
1966294|NCT03299088|Biological|Pembrolizumab|Given IV
1966295|NCT03299088|Drug|Trametinib|Given PO
1966298|NCT03297515|Dietary Supplement|Madeos|Arm 1: Omega 3
1909744|NCT02570126|Biological|Varilrix HSA-free|2 doses will be administered, one at Day 0 and the other at Day 42
1909745|NCT02570126|Biological|Varilrix™|2 doses will be administered, one at Day 0 and the other at Day 42
1909746|NCT02569710|Drug|AL-335|
1909747|NCT02569710|Drug|ACH-3102|
1909748|NCT02569710|Drug|Simeprevir|
1966299|NCT03297515|Dietary Supplement|Placebo|Arm 2 : Placebo
1966308|NCT03295734|Behavioral|Aerobic exercise|Twice weekly centered based aerobic exercise + 3/week home-based walking
1966309|NCT03295734|Drug|Perindopril|4 mg qd titrated to 8 mg qd perindopril
1966310|NCT03295734|Drug|Losartan|50 mg qd titrated to 100 qd losartan
1966311|NCT03295734|Drug|HCTZ|12.5 mg qd titrated to 25 qd HCTZ
1909750|NCT02569281|Other|US-guided percutaneous electrolysis|US-guided percutaneous electrolysis consists of the application of a galvanic electrical current with an acupuncture needle in the soft tissue, in this case the supraspinatus tendon.
1909751|NCT02569281|Other|Eccentric exercise|An eccentric loading exercise program for the shoulder musculature, particularly the supraspinatus and infraspinatus muscles will be learned by the patients allocated to this group
1966331|NCT03292029|Diagnostic Test|T50 Calcification Inhibition Test (CIT)|Measurement of predialysis T50 CIT and fetuin-A values in serum of hemodialysis patients
1909767|NCT02565446|Device|Magnetic Resolution Elastography|Correlation between histology and MRE with respect to liver fibrosis and inflammation.
1909768|NCT02565446|Procedure|Bariatric surgery|Recruitment will be of patients who are scheduled to undergo bariatric surgery. During the time of surgery a liver biopsy will be taken clinically to identify liver disease. In addition, liver and fat tissue will be obtained for research purposes.
1966340|NCT03290287|Drug|Aclidinium bromide|Administered as monotherapy, concomitant with formoterol not in fixed-dose combination, or fixed-dose aclidinium/formoterol
1966341|NCT03290287|Drug|Other COPD medication|"Users of the following COPD medications:
Tiotropium
Other long-acting anticholinergic (LAMAs): glycopyrronium bromide, umeclidinium
LABA: formoterol, salmeterol, indacaterol
LABA/ICS (LABA in fixed-dose combinations with ICS): formoterol/budesonide, formoterol/beclometasone, formoterol/mometasone, formoterol/fluticasone, salmeterol/fluticasone, and vilanterol/fluticasone.
LAMA/LABA (approved or under regulatory review or in development): glycopyrrolate/formoterol, glycopyrronium/indacaterol, tiotropium/olodaterol, umeclidinium/vilanterol"
1988739|NCT02721875|Drug|Volasertib|
1988740|NCT02721875|Drug|Volasertib|
1988741|NCT02721875|Drug|Azacitidine|
1988743|NCT02720003|Device|LTX DCB|Treatment with a drug-coated balloon
1992497|NCT03320720|Other|Home Treatment|Patients with acute mental illness in need of inpatient care are treated at their houses by a mobile and multiprofessional care team if their health condition permits.
1909792|NCT02560155|Drug|Mupirocin 2% nasal ointement|Mupirocin nasal ointement 2x/d for 5 days preoperatively
1909793|NCT02560155|Drug|Chlorhexidine sol 4%|Shower with Chlorhexidine sol 4% once a day for 5 days preoperatively
1966354|NCT03287310|Drug|GSK3511294|GSK3511294 will be available as a clear or opalescent, colorless or yellow to brown solution for injection at unit dose strength of 150 milligrams per milliliter (mg/mL). GSK3511294 will be diluted in 0.9% weight by volume (w/v) sodium chloride to achieve the desired concentration for administration. GSK3511294 will be administered by SC injection.
1966355|NCT03287310|Drug|Placebo|Matching Placebo will consist of 0.9% w/v sodium chloride which will be administered by the SC route.
1966356|NCT03287310|Drug|Salbutamol/albuterol|Salbutamol/albuterol will be supplied to all subjects for use as rescue medication during the study.
1909798|NCT02559505|Biological|Seasonal IIV|Fluzone (Sanofi Pasteur) 0.25 mL administered intramuscularly to children between 6 and 35 months of age
1909799|NCT02559505|Other|Natural influenza infection|Children enrolled on presentation to their primary care provider with a natural influenza infection
1966357|NCT03288064|Dietary Supplement|Corinthian currant|Supplementation of 1.5 g CHO/kg BW in the form of Corinthian currant prior to exercise
1966358|NCT03288064|Dietary Supplement|Glucose drink|Supplementation of 1.5 g CHO/kg BW in the form of glucose drink prior to exercise
1966359|NCT03288064|Dietary Supplement|Water ingestion|Supplementation of 7ml/kg BW prior to exercise
1909806|NCT02559193|Other|Observational study, data collection only trial.|Data collection only trial design.
1909807|NCT02558712|Other|Technology-based Eye Care Services (TECS) Protocol|Extensive History will be taken. Distance auto-refraction measurements will be made on both eyes. Eye pressure using the iCare tonometer and central corneal thickness (CCT) using the corneal pachymeter will be taken for each eye. Participants will have fundus photos taken following the standard VA diabetic teleretinal protocol. Then participants will have OCT Macula and Nerve performed. After protocol complete, then patients will see an ophthalmologist for standard eye exam.
1909808|NCT02558465|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Treatment parameters following the summary of product characteristics and the physician's decision
1966371|NCT03284034|Device|CoolCurve|The right and left sides of the upper back fat will be randomly assigned to receive Cryolypolysis (CoolCurve + Advantage applicator) 35 minutes session, 3 sessions 30 days apart.
1966372|NCT03284034|Drug|ATX-101|The right and left sides of the upper back fat will be randomly assigned to receive The right and left sides of the upper back fat will be randomly assigned to receive ATX-101 (deoxycholic acid) injections, 3 sessions, 30 days apart.
1966375|NCT03284047|Drug|Botulinum toxin type A|Participants will be randomized to one of three botulinum toxin type A doses.
1966378|NCT03283917|Drug|Daratumumab|"Cycles 1-2 (28-day cycle): Daratumumab 16 mg/kg by vein on Days 1, 8, 15, and 22.
Cycles 3-6 (28-day cycle): Daratumumab 16 mg/kg by vein on Days 1 and 15.
Cycles 7-12 (28-day cycle): Daratumumab 16 mg/kg by vein on Days 1."
1966379|NCT03283917|Drug|Ixazomib|"Cycles 1-2 (28-day cycle): Ixazomib 4 mg by mouth on Days 1, 8, and 15 (3 mg if CrCl < 30 mL/min).
Cycles 3-6 (28-day cycle): Ixazomib 4 mg by mouth on Days 1, 8, and 15 (3 mg if CrCl < 30 mL/min).
Cycles 7-12 (28-day cycle): Ixazomib 4 mg by mouth on Days 1, 8, and 15 (3 mg if CrCl < 30 mL/min)."
1909838|NCT02555319|Device|Transcatheter Pulmonary Valve (TPV)|Transcatheter Pulmonary Valve Replacement
1966380|NCT03283917|Drug|Dexamethasone|Dexamethasone 20 mg by vein or by mouth on Days 1, 8, 15, and 22 of Cycle 1. Starting with Cycle 2 and beyond if 20 mg tolerated, dose-escalated to 40 mg.
1966387|NCT03282591|Drug|5 mg Serlopitant Tablets|Serlopitant Tablets
1966388|NCT03282591|Drug|Matching Placebo Tablets|Placebo Tablets
1909865|NCT02551523|Drug|Dolutegravir|92 patients will be simplified to once daily dolutegravir monotherapy
1909866|NCT02551523|Drug|Standard of care combinational antiretroviral therapy|
1909867|NCT02549638|Genetic|DNA Extraction|We will then extract DNA from tissue sections and blood and use a custom targeted sequencing panel of 23 cancer driver genes with significant mutations in squamous cell carcinoma that we have developed to find the prognostic biomarkers. The DNA will be used in a PCR reaction to generate amplicons for library preparation using Illumina Nextera XT library preparation protocol and targeted sequencing on the Illumina Hiseq sequencer. The reads will be aligned to the HG19 using BWA aligner and variant detection performed with Agilent SureCall and GATK analytic tools.
1966396|NCT03279250|Drug|LHRH Agonist|The type of LHRH agonist given depends on what the study doctor thinks is in participant's best interest and may be either Leuprolide, Goserelin, or Triptorelin.
1966397|NCT03279250|Drug|Apalutamide|240 mg tablets by mouth 1 time each day in a 28 day cycle.
1909874|NCT02548078|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administered intramuscular
1909875|NCT02548078|Biological|Nimenrix powder and solvent for solution for injection in pre-filled syringe; Meningococcal group A, C, W-135 and Y conjugate vaccine|A single dose administered intramuscular
1966398|NCT03279250|Drug|Abiraterone Acetate|1000 mg by mouth 1 time each day in a 28 day cycle.
1966399|NCT03279250|Drug|Prednisone|5 mg tablet by mouth 2 times each day in a 28 day cycle.
1966400|NCT03280030|Drug|Midostaurin|Midostaurin 50 mg [two 25 mg capsules] will be administered twice per day by mouth on day 8-21 during induction and consolidation phase; then continuously during continuation phase
1909879|NCT02547051|Other|Food Allergy Testing and Elimination Diet|Food allergy testing and elimination diet
1966401|NCT03280030|Drug|Placebo|Placebo two capsules will be administered twice per day by mouth on day 8-21 during induction and consolidation phase ; then continuously during continuation phase.
1909880|NCT02544503|Device|Single-pulse Transcranial Magnetic Stimulation (TMS)|Single-pulse Transcranial Magnetic Stimulation (TMS) is a brief magnetic pulse that is applied through an air-cooled coil to the section of the head that overlays the motor cortex of the brain. Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Single-pulse transcranial magnetic stimulation (TMS) will be administered at 1 month visit and 6 month visit.
1909881|NCT02544503|Device|Paired-pulse Transcranial Magnetic Stimulation (ppTMS)|Paired-pulse Transcranial Magnetic Stimulation (ppTMS) is two brief sequential magnetic pulses that are applied through an air-cooled coil to the section of the head that overlays the motor cortex of the brain.Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Paired-pulse transcranial magnetic stimulation (ppTMS) will be administered at 1 month and 6 month visit.
1909882|NCT02544503|Device|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS)|Low-frequency Repetitive Transcranial Magnetic Stimulation (rTMS) is a sequence of brief magnetic pulses that are applied through an air-cooled coil to the section of the head that overlays the motor cortex of the brain.Subjects will be comfortably seated in a dental chair surrounded by a frame that carries a coil holder to assist with the application of TMS to the brain. Low-frequency repetitive transcranial magnetic stimulation (rTMS) will be administered at 1 month and 6 month visit.
1909883|NCT02544503|Device|Sham Motor Cortex Stimulation|Sham motor cortex stimulation will be applied at 1 month and 6 month visit.
1909887|NCT02542891|Other|Blended CBT|
1909888|NCT02542891|Other|Treatment as Usual (TAU)|
1966406|NCT03277885|Other|chronic pain|work related chronic pain
1966409|NCT03276572|Drug|225Ac−J591|225Ac−J591 (13.3 KBq/Kg - 93.3 KBq/Kg or 0.36 uCi/Kg - 2.52 uCi/Kg) on day 1
1909894|NCT02540954|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|A dose of 2 mg aflibercept injected intravitreally
1966414|NCT03273153|Drug|Cobimetinib|Cobimetinib 60 mg tablets orally once daily on a 21 days on, 7 days off schedule.
1966415|NCT03273153|Drug|Atezolizumab|Atezolizumab 840 mg as IV infusion once in every 2 weeks.
1966416|NCT03273153|Drug|Pembrolizumab|Pembrolizumab 200 mg as IV infusion once in every 3 weeks.
1909904|NCT02539199|Drug|Misoprostol, modified-release pessary|Misoprostol pessary (7 ug/h) placed in vaginal fornix until labour is induced or maximum 24 hours
1909905|NCT02539199|Drug|Misoprostol, per-oral tablets|First day: 50 ug PO in every 4 hours maximum 3 times per day. Second day: 100 ug PO in every 4 hours maximum 3 times per day. Third day: 50 ug vaginally in every 4 hours maximum 3 times per day or until labour is induced.
1909906|NCT02539186|Biological|platelet rich plasma|Sono-guided injection with 3cc platelet rich plasma between carpal tunnel and median nerve
1909907|NCT02539186|Device|splint|
1909908|NCT02534701|Device|ERIC® and SOFIA™|a self-expanding clot retrieval system
1966428|NCT03272139|Drug|Bupivacaine|Anesthetic that will help treat pain and sensation after shoulder arthroscopy
1966429|NCT03272139|Device|Ultrasound|Ultrasound will help guide the anesthesiologist in performing the different nerve blocks
1988764|NCT02709265|Drug|amikacin/fosfomycin|single aerosolized dose
1988783|NCT02703779|Drug|Bortezomib|Bortezomib will be given to Group B participants by injection under the skin 11 days and 8 days before stem cell collection.
1988784|NCT02703779|Drug|Granulocyte colony-stimulating factor (G-CSF)|Granulocyte colony-stimulating factor (G-CSF) will be given to all participants by injection under the skin 4 days and 1 day before stem cell collection, and then continued until the stem cell collection is completed.
1988785|NCT02703779|Drug|Mozobil|Mozobil will be given to all participants by injection under the skin only if needed per Investigator.
1966430|NCT03271307|Behavioral|Quality improvement for PITC and partner referrals|In Aim 2, providers will receive training on the importance of HIV testing and their role in testing as part of outpatient and STI care, facilities will receive job aids on the importance of referring patients for HIV testing, and the study team will conduct regular monitoring and evaluation on provider-initiated testing and counseling (PITC) implementation. In Aim 2, providers will receive training on partner testing and referral mechanisms, facilities will receive job aids on the importance of partner testing, and the study team will conduct regular mentoring visits to the facility to advise providers.
1966431|NCT03271307|Diagnostic Test|Self-testing for OPD and STI clients and partners|In Aim 1, HIV self-testing will be carried out in a group setting among patients in the waiting area of OPD and STI clinics. Eligible clients will receive education about HIV testing and a demonstration of how to use and interpret results of a self-test kit will occur in the group setting, and participants will be allowed to view their results in the group setting or in a private setting. Participants will disclose their results to their provider if they choose. In Aim 2, HIV self-test kits will be provided to newly identified HIV-positive clients to distribute to their partners. Eligible clients will be counseled on the importance of HIV testing and will receive instruction and a demonstration on how to use the self-test kit.
1966435|NCT03271099|Other|Navigator|Patient Navigation services will be provided to try to eliminate barriers in pursuing survivorship surveillance
1966436|NCT03271151|Drug|Cymbalta|"Duloxetine (Cymbalta) is a serotonin and norepinephrine dual reuptake inhibitor (SNRI) that is an effective treatment for painful diabetic neuropathy. It is approved for major depressive disorder, generalized anxiety disorder, diabetic peripheral neuropathy, fibromyalgia, and chronic musculoskeletal pain"
1966437|NCT03271151|Other|Placebo|Placebo to compare outcomes against Duloxetine
1966440|NCT03270176|Drug|Debio 1143|Debio 1143 100 to 250 mg, capsule orally for 10 days every 2 weeks.
1966441|NCT03270176|Drug|Avelumab|Avelumab 10 mg/kg intravenous infusion every 2 weeks.
1966447|NCT03266471|Diagnostic Test|Baseline blood sample|Blood sample for cytokine measurements and genetics.
1966448|NCT03266471|Diagnostic Test|Baseline intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
1966449|NCT03266471|Other|Crohn's disease activity index (CDAI)|To determine response, a Crohn's Disease Activity Index (CDAI) score will be obtained at time point 1 and time point 2 in all enrolled CD patients. The CDAI is a well validated symptom index for CD which assesses 8 factors including stool frequency, abdominal pain, general well being, CD complications, HCT, and deviation from ideal body weight.
1966450|NCT03266471|Diagnostic Test|Post treatment blood sample|Blood sample for cytokine measurements after patients have been on therapy for at least 12 weeks but no more than 52 weeks.
1966451|NCT03266471|Diagnostic Test|Post treatment intestinal biopsies|Up to 20 additional biopsies will be obtained at the time of standard of care colonoscopy at least 12 weeks but no more than 52 weeks after initiation of therapy. It is not felt that additional biopsies substantially increases the risk of a colonoscopy. Cytokine measurements will be performed on the tissue collected.
1909947|NCT02525432|Biological|Placebo Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the placebo control group will undergo a sham bone marrow harvest and receive a placebo infusion of saline.
1909948|NCT02525432|Biological|Autologous BMMNC Infusion|In addition to the standard of care provided to all patients with traumatic brain injury, subjects assigned to the BMMNC treatment group will undergo a bone marrow harvest and then receive an autologous stem cell infusion.
1909955|NCT02522923|Other|Physical Therapist|The participant will receive an evaluation and intervention from a physical therapist. The patient will be referred onward to other providers as needed.
1909956|NCT02522923|Other|Primary Care Provider|The participant will receive an evaluation and intervention from a primary care provider. The patient will be referred onward to other providers as needed.
1909982|NCT02517476|Dietary Supplement|Nutritional therapy|Any nutritional product and route (i.e. food fortification, oral, enteral, parenteral) is possible to reach goals
1909983|NCT02516605|Drug|LJN452|LJN452 capsules administered once daily for 28 days
1909984|NCT02516605|Drug|Placebo|Matching placebo capsules administered once daily for 28 days
1909986|NCT02516813|Drug|MSC2490484A|Phase Ia: Subjects will receive a starting dose of 100 milligram (mg) or 50 mg of MSC2490484A orally once daily 1.5 hours prior each RT.
1909987|NCT02516813|Radiation|Fractionated RT|Phase Ia: Subjects will receive fractionated palliative RT (3 Gray [Gy] * 10 or 2 Gy * 33 to 35, 5 fractions per week [F/W]).
1909988|NCT02516813|Drug|Cisplatin|Cisplatin will be given twice at a dose of 100 milligram per square meter (mg/m^2) or weekly at a dose of 40 (mg/m^2).
1909989|NCT02516813|Drug|MSC2490484A|Phase Ib: Subjects will receive the assigned dose of MSC2490484A once daily orally.
1909990|NCT02516813|Drug|MSC2490484A|cPoP Study: Subjects will receive a single oral dose of MSC2490484A on Day 2, 1.5 hours before the start of RT.
1909991|NCT02516813|Radiation|Fractionated RT|Phase Ib: Subjects will receive fractionated RT (2 Gy x 33, 5 F/W).
1909992|NCT02516813|Radiation|Fractionated RT|cPoP study: Subjects will receive a single high dose of RT (10-25 Gy) on Day 1 given on Lesion 1 and a single high dose of RT (10-25 Gy) on Day 2 given on Lesion 2.
1966498|NCT03250663|Behavioral|Online Treatment response|Electronic treatment response survey to track use of study medication, EUCRISA (crisaborole) ointment 2%.
1966499|NCT03251924|Drug|BMS-986226|specified dose on specified days
1966500|NCT03251924|Biological|Nivolumab|specified dose on specified days
1966501|NCT03251924|Biological|Ipilimumab|specified dose on specified days
1966502|NCT03250988|Diagnostic Test|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
1966503|NCT03248908|Diagnostic Test|Pupillary dilation reflex|Perioperative pupillary dilation reflex assessment is executed every 10 minutes from start sedation until extubation in patients allocated to study arm Intervention 1 and Intervention 3
1910021|NCT02512458|Drug|Cabazitaxel|
1966504|NCT03248908|Other|Standard of care|Perioperative opioid administration based on the attending anesthesiologist decision (mainly including assessment of heart rate, blood pressure, and limb movement)
1910024|NCT02511678|Procedure|Cryoablation|Cryoablation is an FDA-cleared technology for selective ablation and treatment of different kinds of benign and malignant conditions. For cryoablation in the palliation of painful bone metastases, subject preparation, anesthesia, intra-operative monitoring, and postoperative management are identical to those of standard cryoablation routinely performed at all clinical centers participating in this study.
1910026|NCT02509494|Biological|Ad26.ZEBOV|Ebola Zaire vaccine, live, replication incompetent vaccine, sterile suspension of 0.5 milliliter (mL) intramuscular (IM) injection of 5*10^10 viral particles.
1910027|NCT02509494|Biological|MVA-BN-Filo|MVA‐BN‐Filo‐ is a live replication incompetent vaccine, 0.5 mL IM injection of 1*10^8 Infectious Unit (Inf. U.).
1910028|NCT02509494|Biological|Menveo|Menveo WHO-prequalified Meningococcal Group A, C, W135 and Y conjugate vaccine.
1910029|NCT02509494|Biological|Placebo|0.9% saline for injection
1992498|NCT03320720|Other|Treatment-as-usual|Patients with acute mental illness in need of inpatient care are treated in a psychiatric clinic.
1992499|NCT03320707|Drug|Daratumumab|Single SC dose of daratumumab will be administered, within one of 6 dose cohorts.
1992500|NCT03320707|Drug|Placebo|Placebo liquid will be administered as SC dose, within one of 6 dose cohorts.
1910039|NCT02507583|Drug|IGF-1R/AS ODN; Surgery with tissue harvest and implantation 20 diffusion chambers in the rectus sheath with IGF-1R/AS ODN within 24 hours of craniotomy, implanted for 48 hours.|
1992503|NCT03320681|Device|Electrical Stimulation|Percutaneous electrical nerve stimulation
1992504|NCT03320681|Other|Dry Needling Stimulation|Percutaneous nerve stimulation
1992505|NCT03320668|Other|Otago Program|"A nurse/physiotherapist supported by other professional who received instructor training will perform group education to 10 persons in the 1st, 2nd, 4th and 8th week and a reinforcement session six months after. For perform the follow-up, will be carry out a telephone call to the participant the months without training session (Following a protocol of predefined telephonic interview) reducing the number of falls and fall-related injuries, improving balance and strength, improving confidence in performing everyday activities without falling, and was also shown to be cost effective for the oldest old (aged 80 and over). It was designed to be delivered by physiotherapists and nurses trained by, and supervised by physiotherapists. Whilst it has been shown to be effective in four controlled trials of older primary care patients in New Zealand, it has not been tested in a primary care setting in the UK for feasibility, impact, acceptability and cost-effectiveness."
1992508|NCT03320642|Drug|Itacitinib|Itacitinib administered orally once daily at the protocol-defined dose.
1992509|NCT03320642|Drug|Calcineurin inhibitor|The CNI-based prophylaxis regimen will be identified by the investigator before the subject's enrollment and will consist of the combination of tacrolimus/methotrexate or cyclosporine A/mycophenolate mofetil. Antithymocyte globulin may be included at the treating investigator's discretion.
1992510|NCT03320629|Combination Product|apatinib S-1 radiotherapy|apatinib 500mg qd po S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
1992511|NCT03320629|Combination Product|S-1 radiotherapy|S-1 40-60mg/time bid po d1-14 q3w radiotherapy 50-60Gy/25-30times until disease progression or intolerable toxicity or patients withdrawal of consent
1992512|NCT03320616|Drug|EYP001a|Oral EYP001a capsules - 100 mg strength
1966514|NCT03248531|Drug|Bimekizumab|Bimekizumab in different dosages (dose 1 and 2).
1966515|NCT03248531|Drug|Adalimumab|Adalimumab in different dosages (dose 1, 2 and 3).
1966516|NCT03248531|Other|Placebo|Placebo will be provided matching Bimekizumab.
1966519|NCT03246074|Drug|Fostamatinib and Paclitaxel|"Drug: Fostamatinib (oral; 100 mg, 150 mg, or 200 mg)
Drug: Paclitaxel (60-80 mg/m2)"
1966536|NCT03245450|Drug|Eribulin mesilate|IV infusion
1966537|NCT03245450|Drug|Irinotecan hydrochloride|IV infusion
1966544|NCT03243708|Behavioral|Risk calculator|Venous thromboembolism (VTE) risk calculator embedded in the admission order set with personalized recommendation for prophylaxis
1966548|NCT03242590|Drug|LPCN 1021|Oral testosterone undecanoate
1966549|NCT03242408|Drug|LPCN 1021|Oral testosterone undecanoate
1910095|NCT02497612|Drug|Ferroquine SSR97193|Pharmaceutical form:Capsules Route of administration: oral
1966554|NCT03241771|Behavioral|Naloxone Navigator 1.0|Patients on chronic opioid therapy will be outreached via email, mail and phone. Within 1 month of enrollment into the trial, intervention participants will receive a link to the web-based resource to view. This is designed to provide overdose education, increase opioid risk awareness, and encourage patients to obtain naloxone.
1910096|NCT02497612|Drug|Artefenomel|Pharmaceutical form:Granules for suspension Route of administration: oral
1910097|NCT02497612|Other|Placebo|Capsules Placebo capsules are used to keep the same number of capsules in each weight band while keeping the ferroquine dose blinded. No patient will receive placebo only.
1966558|NCT03240042|Procedure|nasotracheal intubation|The participants either receive intubation via nasal route.
1910100|NCT02497716|Drug|Rivaroxaban (Xarelto, BAY59-7939|Single dose of reconstituted rivaroxaban granules
1966559|NCT03240042|Procedure|orotracheal intubation|The participants either receive intubation via oral route.
1910111|NCT02494570|Drug|ABI-009|
1966570|NCT03237481|Drug|HTX-011|HTX 011, 300 mg
1966571|NCT03237481|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 75 mg
1966572|NCT03237481|Drug|Saline placebo|Saline placebo
1966573|NCT03237481|Device|Luer-lock applicator|Applicator for instillation
1966574|NCT03237481|Device|Vial access device|Device for withdrawal of drug product
1910120|NCT02493751|Drug|Avelumab (MSB0010718C)|Avelumab with two dose levels: 10 mg/kg IV and 5 mg/kg IV every two weeks to find the maximum tolerated dose in combination with axitinib and continue treatment in a dose expansion.
1910121|NCT02493751|Drug|Axitinib (AG-013736)|Axitinib with two dose levels: 5 mg and 3 mg oral BID to find the maximum tolerated dose in combination with avelumab and continue treatment in a dose expansion.
1910122|NCT02493725|Drug|Eculizumab|
1910123|NCT02493725|Drug|Placebo|
1910126|NCT02491671|Device|Hemopatch|
1910127|NCT02491671|Procedure|standard preventive measures|
1966587|NCT03234114|Drug|Triple Antibiotic|aspirin 100 mg per day (Bayer), clopidogrel 75 mg per day (Sanofi), warfarin with targeted INR 2 (Shanghai Xinyi pharma co., LTD)
1910137|NCT02489214|Drug|donafenib tosilate tablets|200mg bid
1910142|NCT02489201|Drug|donafenib tosilate tablets|200mg,bid
1966595|NCT03232762|Dietary Supplement|Refined Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
1966596|NCT03232762|Dietary Supplement|Whole Grains|In week one each patient will have a text message or phone call to report on her diet and the information will be recorded as an attempt to assure compliance.
1966599|NCT03231800|Drug|dasotraline|dasotraline 2mg capsule once daily
1966600|NCT03231800|Drug|Placebo|Placebo capsule once daily
1910148|NCT02487472|Other|Data collection|Data sheet, ZBPI questionnaire and EQ-5D 5L Health state questionnaire
1966610|NCT03229278|Drug|Enzyme Inhibitor Therapy|Given trigriluzole PO
1966611|NCT03229278|Other|Laboratory Biomarker Analysis|Correlative studies
1966612|NCT03229278|Biological|Nivolumab|Given IV
1966613|NCT03229278|Biological|Pembrolizumab|Given IV
1966619|NCT03228251|Other|Stroke team simulation training|"The participating centers identify 3-4 senior staff of different professional backgrounds (e.g. senior neurologist, neurointerventionalist, head nurse) who will design a stroke team algorithm tailored to the local circumstances of the stroke center. The centers will be invited to a joint train-the-trainer seminar at the sponsor's institution where they present their algorithm to the participants of all seven stroke centers for discussion to invite suggestions for streamlining and improvement. The teams will be introduced to the concept of simulation-based stroke team training. After the seminar, the principal investigator and the stroke team trainer will visit all centers for one on-site stroke team training and provide teaching materials. Afterwards, each center will be invited to schedule two additional stroke team trainings with the stroke team trainer that will be led by e.g. the senior neurologist from the stroke unit with use of a simulation manikin."
1966621|NCT03227991|Behavioral|Safety Planning Intervention|The Safety Planning Intervention is a protocol driven, brief suicide prevention strategy that is a good fit for acute care settings. It involves a clinician working collaboratively with the patient to build a personalized safety plan that is documented using a templated paper form and includes warning sign identification, means restriction and personalized strategies to deescalate a suicide crisis.
1966622|NCT03227991|Behavioral|Risk factors and Warning signs|Printed information sheet listing suicide risk factors and crisis hotlines
1966623|NCT03227263|Drug|Bevacizumab|Bevacizumab (Avastin®) concentrate at 25mg/mL is diluted at 5 mg/kg for infusion every 14 days for 6 consecutive administrations
1966624|NCT03227263|Drug|sodium chloride 0.9%|0.9% of sodium chloride is infused every 14 days for 6 consecutive administrations
1910169|NCT02485704|Drug|spinosad topical suspension, 0.9%|Topically apply 0.9% suspension up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
1910170|NCT02485704|Other|Placebo|Placebo is the same as the drug minus the active ingredient spinosad (vehicle). Topically apply up to 120 mL (enough to cover the body from the neck down to the soles of the feet). One application for six hours.
1910176|NCT02484638|Drug|CSL689|Recombinant fusion protein, linking activated coagulation factor VII with albumin. Two dose levels (low dose, high dose) will be studied in Parts 1, 2, and 3.
1910177|NCT02484638|Drug|Eptacog alfa (activated)|Recombinant activated coagulation factor VII. Two dose levels (low dose, high dose) will be studied in Part 1.
1992515|NCT03320590|Diagnostic Test|Time Lapse (material to observe embryonic development)|The embryonic kinetics are recorded by Time lapse Primovision™ (Vitrolife). These kinetic parameters are analysed and annotated by only one person with expertise in this technology.
1992516|NCT03320577|Behavioral|Class instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
1992517|NCT03320577|Behavioral|DVD instruction of breathing exercises|Pranayama Breathing exercises practiced at least 5 times a week and log practice times
1992518|NCT03320577|Behavioral|Control|Log dinner times
1992519|NCT03320564|Diagnostic Test|F-18 FDG PET|Repeat scan performed by specially trained staff to reduce risk of repeat infiltration.
1992520|NCT03320551|Behavioral|Immersion program|Evaluate the impact of an already established one week long lifestyle immersion program sponsored by Whole Foods, Inc for their employees on anthropomorphic, clinical labs such as lipid levels, blood sugar and other markers of nutrition, quality of life and activity levels at baseline, at the end of the program and at 3 and 6 months
1992521|NCT03320538|Dietary Supplement|Jiangzhong Hou Gu® Mi Xi™|Jiangzhong Hou Gu® Mi Xi™ is an oatmeal-liked, solid food (dry or dissolved eating).
1992522|NCT03320538|Other|Placebo|The placebo was as sams as Jiangzhong Hou Gu® Mi Xi™ in respect of color, taste, and smell.
1992523|NCT03320538|Drug|Rabeprazole|Rabeprazole is produced by Shanghai Xinyi Pharmaceutical Corp. Ltd.
1992524|NCT03320525|Dietary Supplement|T-ChOS|T-ChOS 600 mg (two capsules, each 300 mg) daily in the morning 30 minutes before food.
1992525|NCT03320512|Behavioral|P3|P3 is an interactive smartphone app that utilizes social networking and game-based mechanics to improve PrEP adherence and persistence in PrEP care. The participant will install P3 on their phone, receive a guided tour of the app and a reminder card with the research coordinator's phone number and email address and instructed to contact the research coordinator immediately to report difficulties with any app components or to report any problems with their phone or phone service. A help link is embedded within the app that directly links to study staff if assistance is needed. P3 arm participants will have 24-hour access to all features of P3. After intervention completion (month 3), P3 participants who complete one activity in the app < 2 times per week on average over the intervention period will be eligible for re-randomization to their initial study condition arm or to receive LSPY, a more intensive adherence counseling approach, in order to evaluate the combined approach.
1966660|NCT03220802|Dietary Supplement|OMNI-BiOTiC PPI|The study product consists of a sachet containing 4g of yellowish powder made of corn starch, maltodextrin, fructo-oligosaccharide P6, inulin P2, vegetable protein and 11 bacterial strains (Bacillus coagulans W183, Bacillus subtilus W201, Bifidobacterium bifidum W23, Bifidobacterium lactis W52, Bifidobacterium lactis W51, Lactobacillus acidophilus W37, Lactobacillus acidophilus W22, Lactobacillus casei W56, Lactobacillus salivarius W24, Lactococcus lactis W19, Propionibacterium freudenreichii W200, in a concentration of 2 x 109 cfu/g).
1966661|NCT03221556|Behavioral|Engagement-Focused Care Coordination|Engagement interviewing is embedded within a traditional PCMH structure using motivational interviewing and shared decision making; it explores treatment options in the context of a patient's life circumstances, and helps her work through ambivalence to receiving care. In one to two sessions, providers disclose the probable diagnosis of depression, provide psycho-education, present treatment options, and engage clients in shared decision making to determine the most appropriate referral.
1966662|NCT03221556|Behavioral|Problem Solving Education (PSE)|Problem solving sessions are one-on-one, workbook-based interactions. Sessions comprise seven sequential steps: 1-defining a problem, 2-establishing goals for problem resolution, 3-generating multiple solution alternatives, 4-Implementing decision making guidelines, 5-evaluating and choosing solutions, 6-Implementing the preferred solutions, and 7-evaluating the outcome.
1966665|NCT03217604|Drug|Placebo|Treatment with placebo
1966666|NCT03217604|Drug|PF-06852231|Treatment with PF-06852231
1966667|NCT03217565|Drug|IV Tedizolid Phosphate|A single dose of tedizolid phosphate administered IV as a 0.8 up to 1.6 mg/mL solution
1966668|NCT03217565|Drug|Oral Suspension Tedizolid Phosphate|A single dose of tedizolid phosphate administered as an oral suspension
1910226|NCT02477150|Biological|Zostavax|Vaccination of a zoster vaccine (Zostavax)
1910227|NCT02477150|Biological|placebo|placebo administration
1966693|NCT03213158|Drug|Ixazomib Oral Capsule|Highly sensitized kidney transplant candidates on the waitlist for more than 24 months will receive ixazomib 3 mg (and dexamethasone 20 mg) on days 1, 8, and 15 of a 28 cycle for 12 months.
1966694|NCT03212742|Drug|Olaparib|We propose 7 dose levels to reach the target dose of 400 mg per day (200 mg twice daily) of olaparib continuously DL1 (starting dose level) : Olaparib 50 mg Q12H Monday to wednesday DL2 : Olaparib 100mg Q12H Monday to wednesday DL3: Olaparib 100mg Q12H Monday to friday DL4 : Olaparib 200mg Q12H Monday to wednesday DL5: Olaparib 200mg Q12H Monday to friday DL6: Olaparib 200mg Q12H, continously
1966695|NCT03212742|Drug|Temozolomide (TMZ)|TMZ will be given at the dose of 75mg/m²/day during radiotherapy period. TMZ will be re-introduced 4 weeks after the end of radiotherapy at the dose of 150mg/m²/day on days 1 to 5 every 28 days, for a total of 6 cycles.
1910248|NCT02472509|Drug|Ursodeoxycholic Acid|"Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.
Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose."
1966696|NCT03212742|Radiation|IMRT (Intensity Modulated Radiation Therapy)|Radiotherapy consists of fractionated focal irradiation at a dose of 2 Gy per fraction given once daily five days per week over 6 weeks, for a total dose of 60 Gy by 3D- Intensity-Modulated RT (IMRT)
1966698|NCT03211390|Diagnostic Test|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
1966699|NCT03211390|Diagnostic Test|Teleneurological Examination|A Vanderbilt neurologist will examine all consented residents using a telemedicine platform, with the assistance of a nurse at the subject's bedside. The neurologist will guide the nurse to perform elements of a physical examination to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
1966700|NCT03209960|Diagnostic Test|Bedside Referral Tool|Two Vanderbilt primary care providers (a nurse practitioner and a primary care physician) will examine all consented residents. Each primary care provider will perform elements of a physical exam guided by the bedside referral tool to determine if a referral to a movement disorders neurologist is required for a spasticity consultation.
1966701|NCT03209960|Other|Neurological Examination|The subject will undergo elements of the neurological examination during which the movement disorders neurologist will look specifically for the presence of spasticity. If spasticity is found to be present during the examination, the neurologist will rate the severity of the spasticity in all affected limbs and record whether they would recommend treatment for spasticity, and if so, which treatment(s) they believe would be beneficial for the subject.
1966704|NCT03209648|Drug|Debio 1450|Debio 1450, 40 mg capsule.
1966705|NCT03209648|Drug|Itraconazole|Itraconazole, 20 mL of 10 mg/mL solution.
1966706|NCT03208660|Drug|Fycompa|Oral suspension
1910260|NCT02471339|Other|Acceptance and Commitment Therapy (ACT)|Acceptance and Commitment Therapy (ACT), a newer generation of cognitive-behavioral therapy, focuses on encouraging individuals to engage in more adaptive ways of coping with pain.
1910261|NCT02470585|Other|Placebo|Capsule
1910262|NCT02470585|Drug|Veliparib|Capsule
1910263|NCT02470585|Drug|Veliparib|Capsule
1910264|NCT02470585|Drug|Carboplatin|Intravenous infusion
1910265|NCT02470585|Drug|Paclitaxel|Intravenous infusion
1910267|NCT02469857|Drug|AB103 0.5 mg/kg|
1910268|NCT02469857|Other|NaCl 0.9%|
1966714|NCT03205163|Biological|Recombinant FVIII (rFVIII) (Low Dose)|Participants will receive a single IV low dose of rFVIII.
1966715|NCT03205163|Biological|rFVIII (High Dose)|Participants will receive a single IV high dose of rFVIII.
1966716|NCT03205163|Biological|BIVV001 (Low Dose)|Participants will receive single IV low dose of BIVV001.
1910273|NCT02468193|Drug|Osilodrostat|Osilodrostat will be prescribed by the investigator. Osirodrostat 1 mg, 5 mg, 10 mg in the form of film-coated tablets will be used for oral administration
1910274|NCT02468102|Drug|Rivaroxaban (Xarelto, BAY59-7939)|"Treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).
Prevention of stroke and systemic embolism with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors, prior stroke or transient ischaemic attack (20 mg rivaroxaban [od], tablets).
Prevention of venous thromboembolism (VTE) in patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).
Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
1910275|NCT02468102|Drug|Standard of care drugs|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
1966717|NCT03205163|Biological|BIVV001 (High Dose)|Participants will receive single IV high dose of BIVV001.
1966722|NCT03206060|Drug|Lu-177-DOTATATE|Lu-177-DOTATATE IV at weeks 1, 8, 16 and 24
1966723|NCT03206060|Drug|Ga-68-DOTATATE|Ga-68-DOTATATE PET/CT at weeks 15 and 31
1966724|NCT03206060|Other|F-18-FDG|F-18-FDG PET/CT at weeks 15 and 31
1966725|NCT03206060|Drug|Amino Acid|L-Lysine Hydrochloride, L-Arginine Hydrochloride will be administered 30 minutes prior to each Lu-177- DOTATATE at weeks 1, 8, 16 and 24.
1966728|NCT03205553|Other|Standard of Care Treatment Group|Non-treatment group will be placed in silo at time of birth and subsequently serially reduced in silo with umbilical tape until the bowel contents are at the level of fascial and deemed suitable for closure. A drain will be placed at the top of the silo as described below to aspirate peritoneal fluid for sampling. These subjects will have no change in current clinical management by the neonatologists or pediatric surgeons and will not receive peritoneal dialysis fluid.
1966729|NCT03205553|Drug|Investigational Treatment Group|The Investigational treatment group will be treated with direct peritoneal resuscitation (DPR). These subjects will undergo DPR during the entirety of silo placement which is usually four to five days. The silo and drain placement will be placed as described below. No additional incisions will be made. These subjects will also be serially reduced with umbilical tape and closed as staged procedure which is the same as the non-treatment group.
1966731|NCT03203876|Biological|Lirilumab|Specified dose on specified days
1966732|NCT03203876|Biological|Nivolumab|Specified dose on specified days
1966733|NCT03203876|Biological|Ipilimumab|Specified dose on specified days
1966736|NCT03201965|Drug|Cyclophosphamide|Participants will receive 300 mg/m^2 of cyclophosphamide as an oral or IV dose.
1966737|NCT03201965|Drug|Bortezomib|Participants will receive 1.3 mg/m^2 of bortezomib as an subcutaneous (SC) injection.
1966738|NCT03201965|Drug|Dexamethasone, 40 mg|Participants of CyBorD alone arm will receive 40 mg dexamethasone orally or IV dose. Participants of CyBorD plus daratumumab arm will receive dexamethasone 20 mg orally or IV dose as premedication and 20 mg on the day after daratumumab dosing to make a total of 40 mg.
1966739|NCT03201965|Drug|Daratumumab|Participants will receive 1800 mg of daratumumab subcutaneously.
1910321|NCT02464787|Dietary Supplement|LifePak Nano|Two twin-sachet packets of seven (7) supplements twice per day, for the entire eight-week experimental period.
1910326|NCT02463396|Behavioral|MBCT for ADHD|
1966749|NCT03196765|Drug|Sobetirome|Once a day oral dose of the study drug
1966753|NCT03194139|Drug|GC4711 30 mg IV|GC4711 will be infused IV as a single dose of 30 mg (3 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totaling 250 mL, over a 60-minute period using a programmable pump
1966754|NCT03194139|Drug|GC4711 50 mg IV|GC4711 will be infused IV as a single dose of 50 mg (5 mL GC4711 at 10 mg/mL) in 245 mL normal saline, totalling 250 mL, over a 60-minute period using a programmable pump.
1966755|NCT03194139|Drug|GC4419 45 mg IV|GC4419 will be infused IV as a single dose of 45 mg (5 mL GC4419 at 9 mg/mL) in 245 mL normal (0.9%) saline, totalling 250 mL, over a 60-minute period using a programmable pump.
1966762|NCT03193151|Procedure|liver biopsy|5 mm fragment of liver transplant biopsy taken for clinical indication
1966763|NCT03192943|Drug|BMS-986205|Specified dose on specified days
1966764|NCT03192943|Biological|Nivolumab|Specified dose on specified day
1966765|NCT03192540|Other|Exercise|Participants will undergo an exercise protocol once a week, for eight weeks. Exercise will be continuous for one hour.
1966785|NCT03191630|Behavioral|Fitbit (Control)|Study procedures include group sessions at the OSU Transplant Clinic with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Session 1 for the control group will be identical to the Intervention with the only exception being that participants in the control group will not be asked to increase their step goal. Throughout their participation, subjects will be asked questions only about their use of the Fitbit activity tracker. The research team will not be in contact with them for 6 months, after which time there will be a final group session.
1992556|NCT03320317|Other|Learning session 2|Feedback report, Share (inter)national best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis
1992557|NCT03320317|Other|Learning session 3|Feedback report, Share best practices, Discussion, set priorities, teaching and improvement, Retrospective patient record analysis, Team measures
1992558|NCT03320317|Other|Learning session 4|Feedback report, Best practice symposium
1992559|NCT03320304|Device|Vagal Nerve Simulation (VNS) Therapy|A VNS Therapy System used for vagus nerve stimulation and consisting of an implantable VNS Therapy generator, lead, and external programming system.
1992561|NCT03320265|Drug|PC-mAb|Monthly treatment for 3 months (4 administrations)
1992562|NCT03320265|Drug|Placebo|Monthly treatment for 3 months (4 administrations)
1992563|NCT03320252|Device|Endurant Chimney Graft Technique|Medtronic Endurant II and Endurant IIs Stent Graft Systems and balloon-expandable covered stent graft systems approved for use in the renal arteries. These devices will be utilized in a chimney graft configuration.
1992564|NCT03320239|Behavioral|HIV risk assessment and tailored suggestions|The intervention contains: HIV risk investigation, tailored suggestions and free HIV testing link
1992565|NCT03320239|Behavioral|HIV risk behavior assessment|It only contains HIV risk behavior assessment and routine education
1992566|NCT03320239|Behavioral|placebo control|It only contains HIV/AIDS knowledge assessment and routine education
1992567|NCT03320226|Dietary Supplement|Probiotic 10 (Nature's Bounty)|The Probiotic 10 (Nature's Bounty) that contains 20 billion live cultures of Lactobacillus plantarum 299v (Lp299v®), Lactobacillus bulgaricus Lb-87, Lactobacillus paracasei DSM 13434, Lactobacillus plantarum DSM 15312, Lactobacillus salivarius Ls-33, Lactobacillus brevis Lbr-35, Lactobacillus acidophilus La-14, Bifidobacterium lactis Bl-04, Lactobacillus paracasei Lpc-37, Lactobacillus casei Lc-11, which are under Lactobacillus and Bifidobacterium.
1992570|NCT03320187|Drug|Nitroderm TTS|Transdermal nitroglycerin 5mg skin patch
1992571|NCT03320187|Drug|Dinoprostone|Dinoprostone 3gm vaginal tablet will be used as the study method of labor induction
1992572|NCT03320174|Drug|Tafenoquine|Tafenoquine 200mg
1992573|NCT03320174|Other|Placebo|Placebo
1992574|NCT03320148|Behavioral|Physiotherapist-led primary care model for back pain|"Assessment and screening: taking a history; screening for red flags, comorbidities, and risk factors of ongoing pain and disability; physical examination
Brief individualized intervention at the first visit: effective communication, cognitive reassurance, a few exercises, and advice/strategies to stay active.
Health services navigation: PT assistance with navigating healthcare services based on the assessment findings. First, red-flags requiring emergency or urgent referrals. Next, comorbid conditions that would benefit from care from other healthcare providers. Finally, referral to PT (if appropriate).
Providing additional physiotherapy care to people with an unmet need: Additional physiotherapy care will be provided to patients who have an identified need for physiotherapy but no physiotherapy coverage through private or government health insurance plans."
1992575|NCT03320148|Other|Usual care|The physician led primary care intervention will be unstandardized to best reflect standard clinical practice in Canada.
1992576|NCT03320135|Procedure|Enamel matrix derivative proteins|Open flap debridement to enamel matrix derivative to treat proximal furcation involvements.
1992577|NCT03320135|Procedure|Open Flap debridement|Open flap debridement will be performed to decontaminate the proximal furcation involvements.
1966786|NCT03191630|Behavioral|SystemCHANGE and Fitbit (Intervention)|Study procedures include group sessions with 10-12 participants for 6 months and a 6-month maintenance phase without contact from study personnel until month 12. Study personnel will demonstrate proper Fitbit activity tracker use, and teach participants to sync to their smartphone and retrieve data from their Fitbit. Subjects will be called to encourage them to increase their step goal 5% each month. Fitbit activity tracker reports will be reviewed and participants will be asked to identify what people or things influence their physical activity. Subjects will be asked what they are learning about physical activity, their contentment level with current physical activity, and if they want to make changes. Participants will continue for months, after which time there will be a final group session.
1910358|NCT02457208|Drug|Isoniazid (H)|
1910359|NCT02457208|Drug|Rifampicin (R)|
1910360|NCT02457208|Drug|Pyrazinamide (Z)|
1910361|NCT02457208|Drug|Ethambutol (E)|
1966788|NCT03188120|Drug|Spiriva Respimat|Drug
1966789|NCT03188796|Drug|Cholecalciferol|oral/enteral loading dose of 37.5 ml MCT including 540,000 IU vitamin D3 followed by 10 drops daily (4000 IU) for 90 days
1966790|NCT03188796|Drug|Placebo|oral/enteral loading dose of 37.5 ml MCT followed by 10 drops daily for 90 days
1966814|NCT03185819|Drug|Intranasal Placebo|Participants will receive placebo as intranasal dose to match intranasal esketamine.
1966815|NCT03185819|Drug|Midazolam Placebo Solution|Participants will receive placebo as oral dose to match midazolam drug.
1966816|NCT03185819|Drug|Midazolam|Participants will receive midazolam solution 0.125 mg/kg as oral dose to match placebo.
1910402|NCT02450812|Drug|Radium-223-dichloride (Xofigo, BAY88-8223)|according to Summary of Product Characteristics
1966817|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 28 mg as intranasal solution.
1966818|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 56 mg as intranasal solution.
1966819|NCT03185819|Drug|Esketamine|Participants will receive esketamine at a dose of 84 mg as intranasal solution.
1910406|NCT02448654|Drug|Tolcapone|Tolcapone will be compared to sugar pill
1910407|NCT02448654|Drug|Sugar Pill|The sugar pill (placebo) will be compared to tolcapone
1966830|NCT03180632|Drug|Lorazepam|Patient receives one or two tablet of 0,5mg Lorazepam according to body weight
1966831|NCT03180632|Other|Placebo|Patient receive one of two tablet of Placebo according to body weight
1966833|NCT03179956|Drug|Ribociclib|Treatment with ribociclib [600mg] will be from Days 1-14, with surgical resection on Day 14. Labs (CBC, CMP, coagulation parameters) and an ECG will be checked once in a window defined by days 9-12.
1966834|NCT03179761|Biological|Quadrivalent Inactivated Influenza Vaccine|Given intramuscularly
1966835|NCT03179761|Other|Laboratory Biomarker Analysis|Correlative studies
1966836|NCT03179761|Biological|Trivalent Influenza Vaccine|Given intramuscularly
1910426|NCT02445248|Biological|CTL019|Single arm
1966838|NCT03176264|Drug|PDR001|400 mg every 4 weeks
1966839|NCT03176264|Drug|bevacizumab|5 mg/kg every 2 weeks
1966840|NCT03176264|Drug|mFOLFOX6|Combination of chemotherapy administered every 2 weeks: oxaliplatin (85mg/m2), 5-Fluorouracil (2400mg/m2) and folinic acid (=leucovorin, 400mg/m2)
1966851|NCT03174613|Drug|LC51-0255|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
1966852|NCT03174613|Drug|Placebo|0.25mg, 0.5mg, 1mg, 2mg, 4mg, 8mg
1910462|NCT02441907|Drug|aflibercept|
1966872|NCT03170752|Behavioral|Cardiovascular Assessment Screening Program (CASP)|Step 1. Identification of patients; Step 2. Screening utilizing appropriate tools; and Step 3. Actions to follow up on the screening results.
1966875|NCT03170817|Diagnostic Test|Cardiac Perfusion Rest/Stress Digital PET/CT|"Patients with coronary artery disease undergo a N-13 ammonia rest/stress PET/CT scan.
These patients are given:
One 5-10 mCI N13-ammonia (13N-NH3) intravenously and undergo a rest digital PET/CT scan of ~20 minute duration.
A dose of 0.4 mg regadenoson (Lexiscan) intravenously over 10 seconds to increase blood flow to the heart
One 5-10 mCi N13-ammonia (13N-NH3) intravenously and undergo a stress digital PET/CT scan of ~20 minute duration
Total patient time will take approximately up to 120 minutes."
1910475|NCT02434705|Other|Antigen (wheat base soy sauce) spray|Patients having a clinically indicated endoscopy for Eosinphilic Esophagitis will have two biopsies from the esophageal body, 10 cm above the gastroesophageal junction. After biopsies are taken, approximately 10 cc of wheat based soy sauce will be sprayed though an endoscopic catheter onto the esophageal mucosa. The endoscopic examination will be completed and Two additional endoscopic biopsies will be taken 10 cm above the gastroesophageal junction.
1966876|NCT03170817|Drug|N-13 ammonia|5-10 mCi intravenous injection of N-13 ammonia radiopharmaceutical at rest and at stress
1966877|NCT03170817|Drug|Regadenoson|0.4 mg/5mL intravenous injection to induce pharmacologic stress (Astellas Pharma US, Inc.)
1910486|NCT02431247|Drug|Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide FDC|A tablet containing DRV 800 mg, COBI 150 mg, FTC 200 mg and TAF) 10 mg will be administered once daily.
1910487|NCT02431247|Drug|DRV/COBI FDC|A tablet containing DRV 800 mg and COBI 150 mg will be administered once daily.
1910488|NCT02431247|Drug|FTC/TDF FDC|A tablet containing FTC 200 mg and TDF 300 mg will be administered once daily.
1910489|NCT02431247|Drug|D/C/F/TAF FDC - Matching Placebo|Matching placebo of D/C/F/TAF FDC will be administered once daily.
1910490|NCT02431247|Drug|FTC/TDF FDC Matching Placebo|Matching placebo of FTC/TDF FDC will be administered once daily.
1910491|NCT02431247|Drug|DRV/COBI FDC Matching Placebo|Matching placebo of DRV/COBI FDC will be administered once daily.
1910495|NCT02428764|Drug|Nimotuzumab|Nimotuzumab was given 200 mg i.v. injection over 30 min on days 1 and 8
1910496|NCT02428764|Drug|Gemcitabine|Gemcitabine was given 1000 mg/m2 i.v. injection on days1 and 8.
1910497|NCT02428764|Drug|Carboplatin|carboplatin was given dosed to an area under the serum concentration-time curve (AUC) of 5 i.v. on day 1.
1910498|NCT02428764|Procedure|Surgery|Patients' resectability was assessed by a medical team, including thoracic surgeons, medical oncologists, and radiologists.
1966889|NCT03165994|Drug|APX005M|APX005M intravenous (IV) infusion
1966890|NCT03165994|Radiation|Radiation Therapy|Radiation therapy, total dose 5040cGy in 180cGy fractions
1910505|NCT02428010|Device|TMVR Implant|Implantation of the Twelve TMVR System
1966891|NCT03165994|Drug|Paclitaxel|Paclitaxel IV infusion
1966892|NCT03165994|Drug|Carboplatin|Carboplatin IV infusion
1966893|NCT03165994|Procedure|Surgical resection of tumor|Surgical removal of the tumor will occur between weeks 11-17
1966927|NCT03161665|Other|BMT Roadmap|The BMT Roadmap is a health IT System that has been developed for use on the Apple iPad® to give the patient and caregivers easy access to test results, current treatment and contact information to hopefully increase active participation and engagement in transplant care.
1910550|NCT02422498|Radiation|external beam radiation therapy|Radiation therapy to the target tumor will be delivered with external beam radiation therapy. In metastatic cases where the intent is palliative, the dose of radiation will be 3750 cGy delivered in 15 daily fractions, 4-5 days a week. In locoregionally recurrent cases where the intent is to enhance locoregional control, the dose of radiation will be 5000 cGy delivered in 25 fractions, 4-5 days a week plus an optional 10-14 Gy boost to areas of gross tumor.
1910551|NCT02422498|Drug|cisplatin|Cisplatin treatment should be initiated following study registration. The dose of cisplatin is established as 25 or 40 mg/m^2 ivpb once a week (+ 3 days) for 1-2 weeks prior to radiation. The length of one cycle of Cisplatin is 21 days.
1910552|NCT02422498|Procedure|Biopsy of Target Tumor|Biopsy of the tumor to be irradiated will be performed. Fresh tissue specimens will be sent to the laboratory for performance of the MSK-HRR Assay.
1910563|NCT02420106|Procedure|Osteopathic Manipulative Medicine|Osteopathic manipulative medicine involves manual technique to joints and soft tissue to improve movement.
1966963|NCT03153059|Other|Stool frequency|This study is just observational study.
1966967|NCT03153969|Device|SHOFU Beautifil II LS|Placed under manufacturer's instructions
1966968|NCT03153969|Device|3M/ESPE Filtek Supreme|Placed under manufacturer's instructions
1966969|NCT03152019|Drug|Protopic® (Tacrolimus) 0.1% ointment|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
1966970|NCT03152019|Drug|Placebo|About 0,1g of ointment is administered by the patient on nasal mucosa of each nostril twice a day for 6 weeks.
1966973|NCT03151408|Drug|Pracinostat|60 mg capsule
1966974|NCT03151408|Drug|Placebos|capsule
1966975|NCT03151408|Drug|Azacitidine|SC or IV injection
1966979|NCT03150628|Drug|Perioperative chemotherapy|Perioperative chemotherapy
1966980|NCT03150628|Procedure|Cytoreduction|Cytoreductive surgery
1910573|NCT02419612|Drug|Saxagliptin|
1910574|NCT02419612|Drug|Dapagliflozin|
1910575|NCT02419612|Drug|Glimepiride|
1910576|NCT02419612|Other|Placebo|
1966981|NCT03150628|Drug|HIPEC|Hyperthermic intraperitoneal chemotherapy (HIPEC) with 100mg/m2 cisplatin
1966986|NCT03148327|Drug|Durvalumab (MEDI 4736)|Early studies has shown to possibly reduce the growth of certain types of lung cancer
1966987|NCT03148327|Radiation|Radiotherapy|Stereotactic Body Radiation Therapy (SABR)
1966992|NCT03149003|Drug|DSP-7888 Dosing Emulsion|DSP-7888 Dosing Emulsion will be administered i.d. every 7 ± 1 day for Doses 1 to 5, every 14 ± 3 days for Doses 6 to 15, and every 28 ± 7 days for Doses 16 and above.
1966993|NCT03149003|Drug|Bevacizumab|Bevacizumab will be administered intravenously every 14 ± 3 days at 10 mg/kg.
1966997|NCT03147612|Drug|Ponatinib|During Cycle 1, Ponatinib 45 mg by mouth 1 time each day on Days 1-14. During Cycles 2 and beyond 30 mg by mouth taken 1 time every day while on study.
1966998|NCT03147612|Drug|Cyclophosphamide|Odd Cycles: Cyclophosphamide 150 mg/m2 by vein every 12 hrs for 6 doses on Days 1, 2, 3 of Odd Courses 1, 3, 5, 7.
1910595|NCT02415595|Drug|BMS-955176|HIV Maturation Inhibitor
1910596|NCT02415595|Drug|EFV|EFV
1910597|NCT02415595|Drug|TDF/FTC|TDF/FTC
1966999|NCT03147612|Drug|Mesna|Odd Cycles: Mesna 300 mg/m2 by vein on Days 1-3 of Odd Courses 1, 3, 5, 7. Continuous infusion daily for 24 hrs, starting approximately 1 hour prior to Cyclophosphamide and completing by approximately 12 hrs after the last dose of Cyclophosphamide.
1967000|NCT03147612|Drug|Rituximab|375 mg/m2 by vein on Days 1 and 11 of Odd Cycles 1 and 3, and on Days 1 and 8 of Even Cycles for patients with CD20 expression.
1967001|NCT03147612|Drug|Vincristine|"Odd Cycles: Vincristine 2 mg by vein on Day 1 and 11 of Odd Courses 1, 3, 5, 7.
Maintenance Therapy: Vincristine 2 mg by vein on Day 1 approximately every 28 days for 2 years."
1967002|NCT03147612|Drug|Dexamethasone|Odd Cycles: Dexamethasone 20 mg 1 time a day by vein or by mouth on Days 1-4 and 11-14 of Odd Cycles 1, 3, 5, 7.
1967003|NCT03147612|Drug|G-CSF|6 mg as an injection under the skin daily until blood counts recover on Day 4 of Odd Cycles 1, 3, 5, 7, and Even Cycles 2, 4, 6, and 8.
1967004|NCT03147612|Drug|Methotrexate (intrathecally)|"12 mg intrathecally (6 mg via Ommaya reservoir) on Day 2 of Odd Cycles 1, 3, and 5, and on Day 8 of Even Cycles 2, 4, and 6.
50 mg/m2 by vein followed by 200 mg/m2 over 22 hrs on Day 1 of Even Courses 2, 4, 6, and 8."
1967005|NCT03147612|Drug|Cytarabine (intrathecally)|"100 mg intrathecally on Day 7 of Odd Cycles 1, 3, and 5, and on Day 5 of Even Cycles 2, 4, 6, and 8.
0.5 g/m2 by vein 2 times each day on Days 2 and 3 of Even Courses 2, 4, 6, and 8."
1910611|NCT02413372|Drug|BMS-986036|
1910612|NCT02413372|Drug|BMS-986036|
1910613|NCT02413372|Drug|Placebo|
1910614|NCT02413372|Drug|BMS-986036|
1910615|NCT02413372|Drug|Placebo|
1910623|NCT02412410|Behavioral|Fatigue avoidance education|Grand Rounds presentation of consequences of fatigue and fatigue avoidance techniques
1967006|NCT03147612|Drug|Methotrexate|50 mg/m2 by vein followed by 200 mg/m2 over 22 hrs on Day 1 of Even Cycles 2, 4, 6, and 8.
1967007|NCT03147612|Drug|Cytarabine|0.5 g/m2 by vein 2 times each day on Days 2 and 3 of Even Cycles 2, 4, 6, and 8.
1967010|NCT03143491|Drug|SOR007 (Uncoated Nanoparticulate Paclitaxel) Ointment|1 mL of SOR007 applied topically to the ectocervix once-weekly for four weeks.
1967024|NCT03140891|Device|NHFOV|NHFOV is used as the noninvasive mode after extubation
1967025|NCT03140891|Device|NCPAP|NCPAP is used as the noninvasive mode after extubation
1967026|NCT03140059|Procedure|Open flap debridement|Open flap debridement will be performed to decontaminate root surface
1967027|NCT03140059|Procedure|Repeated application of aPDT|Repeated application of photodynamic therapy (aPDT) at 0, 1, 2, 7 and 14 days post-operatively.
1967028|NCT03138915|Procedure|HVPG measurement|HVPG obtained by means of catheterization of a hepatic vein with a balloon catheter.
1967029|NCT03138915|Procedure|CTA|Radiomic features were extracted from CTA images.
1967039|NCT03133273|Other|Oncogramme®|Patient is followed within the usual care for stage 4 colorectal cancer, but an Oncogramme test will be made and chemotherapy will be adapted to the results.
1967046|NCT03129100|Drug|Ixekizumab|Administered SC
1967047|NCT03129100|Drug|Placebo|Administered SC
1967048|NCT03130348|Drug|Bortezomib|Given SC
1967049|NCT03130348|Drug|Dexamethasone|Given PO
1967050|NCT03130348|Drug|Ibrutinib|Given PO
1967051|NCT03130348|Other|Laboratory Biomarker Analysis|Correlative studies
1967062|NCT03120923|Drug|Lidocaine 3 cc|
1967063|NCT03120923|Drug|Lidocaine 9 cc|9mL of 1% lidocaine plus 1mL of 40mg triamcinolone acetonide
1967064|NCT03120923|Drug|Triamcinolone Acetonide|
1910678|NCT02404467|Device|TF TAVI|Follow-up Observation of patients having received a TF-TAVI
1967070|NCT03118531|Device|Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System(34/38 mm)|The stenting procedure should be performed according to the Instructions for Use that is provided with each 34/38 mm Resolute Integrity stent.
1910687|NCT02401035|Drug|IV pantoprazole|Patients will receive 10 mg, 20 mg, or 40 mg IV pantoprazole determined by weight
1910690|NCT02401256|Drug|Efavirenz|"The study has 4 phases:
Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).
Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.
Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).
Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
1910691|NCT02401256|Drug|Bupropion|"The study has 4 phases:
Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).
Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.
Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).
Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
1910692|NCT02401256|Drug|Rosuvastatin|"The study has 4 phases:
Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).
Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.
Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).
Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
1910693|NCT02401256|Drug|Montelukast|"The study has 4 phases:
Phase 1 (control)-Subjects will receive simultaneously a single dose of bupropion 100 mg, montelukast 10 mg and rosuvastatin 5 mg (cocktail) by mouth (control).
Phase 2 (inhibition)- a single 600 mg oral dose of efavirenz (blood draw at 30 min and 1 hour) will be administered with the cocktail drugs.
Phase 3 (home treatment with efavirenz): Subjects will take efavirenz at home (600 mg/day for 17 days).
Phase 4 (Induction) - is the same as phase 2. Blood samples (0 to 120 hrs) and urine voided over 48 hrs (Phases 1, 2 and 4) are collected. Blood draws will be made in phase 3 for trough concentration measurements."
1967083|NCT03113994|Drug|Rosuvastatin Calcium|10mg Rosuvastatin, daily for 12 months
1967084|NCT03113994|Drug|Placebo Oral Tablet|Placebo, daily for 12 months
1967085|NCT03113994|Dietary Supplement|Coenzyme Q10|100mg CoQ10, daily for 12 months
1967086|NCT03113994|Dietary Supplement|Calcium Carbonate|1250mg Calcium Carbonate, daily for 12 months
1967087|NCT03113994|Dietary Supplement|Vitamin D|2000IU Vitamin D, daily for 12 months
1967088|NCT03114865|Drug|Blinatumomab|Cycle 1 - Days 1-7: 9 ug/day IV daily
1967089|NCT03114865|Drug|Blinatumomab|Cycle 1 - Days 8-28: 28 ug/day IV daily
1967090|NCT03114865|Drug|Blinatumomab|Cycle 2 - Days 1-28: 28 ug/day IV daily
1967091|NCT03114865|Drug|Dexamethasone|Day 1 of Cycle 1 and 2, prior to a step dose (such as cycle 1 day 8), or when restarting an infusion after an interruption of 4 hours or more: 20 mg IV
1967093|NCT03112980|Device|Transcatheter aortic valve implantation|(TAVI)
1967094|NCT03112980|Procedure|Surgical aortic valve replacement|(SAVR)
1967095|NCT03112434|Drug|Botulinum toxin type A|Botox injection in upper extremity for spasticity in pediatric CP patients
1967100|NCT03110653|Drug|Remifentanil|Remifentanil will be continued postoperatively, while being decreased (gradually by 30% every 15 mins)
1967101|NCT03110653|Drug|NaCl 0.9%|NaCl 0.9% will be administered postoperatively, while being decreased by 30% every 15 mins.
1910708|NCT02393924|Other|No intervention|
1967102|NCT03110107|Biological|Ipilimumab|Specified dose on specified days
1967103|NCT03110107|Biological|BMS-986218|Specified dose on specified days
1967104|NCT03110107|Biological|Nivolumab|Specified dose on specified days
1967105|NCT03108131|Drug|Cobimetinib|60 mg by mouth on Days 1−21 in a 28-day cycle.
1910715|NCT02391935|Drug|RCS-01|Cultured, autologous hair follicle cells suspended in cryomedium
1910716|NCT02391935|Drug|Placebo|Cryomedium
1910717|NCT02391935|Device|Sham injection|skin penetration of the needle without injection of liquid
1910718|NCT02391831|Other|Strength, function and activity measurements|
1910719|NCT02391831|Other|Muscle MRI|
1910720|NCT02391831|Other|Electrophysiology measurements|
1910721|NCT02391831|Other|Blood sampling for biomarker analysis|
1967106|NCT03108131|Drug|Atezolizumab|840 mg by vein on Day 1 and Day 15 in a 28-day cycle.
1967109|NCT03107325|Other|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
1967110|NCT03107325|Drug|F-18 Fluorodeoxyglucose|Participants will be asked to be imaged at an additional time point during an FDG PET study
1967111|NCT03107286|Drug|Tc-99M-MAG3|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MAG3
1967112|NCT03107286|Other|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
1910729|NCT02388165|Biological|Staphylococcus aureus 4-Antigen (SA4Ag) Vaccine|SA4Ag vaccine reconstituted in 0.5mL water for injection. Administered via IM injection, once 10 to 60 days prior to surgery
1910730|NCT02388165|Other|Placebo|Vaccine excipients reconstituted in 0.5mL water for injections. Administered via IM injection given 10 to 60 days prior to surgery
1910731|NCT02387996|Drug|Nivolumab|
1910732|NCT02387749|Genetic|mesenchymal stem cells|collection of stem cells by bone marrow biopsy from iliac crest, then culture for 1 month , then IV transfusion on 2 sessions to the same patient
1967113|NCT03107247|Drug|Tc-99M MDP|Participants will be asked to be imaged at an additional time point during a nuclear medicine study using Tc-99m MDP
1967114|NCT03107247|Other|Modification in acquisition protocol|Participants will be asked to be imaged at an additional time point.
1967115|NCT03107195|Drug|Imaging Time|Participants will be asked to be imaged at an additional time point.
1967121|NCT03105778|Diagnostic Test|standard blood draw as part of routine and fingerprick for capillary sample|All blood sample collection methods are standard routine procedures. These patients usually have an indwelling cannula from which blood samples are drawn. So no additional venipuncture is performed according to this study. The finger prick sample - taken only for study purposes - might be accompanied by small pain at the fingertip. But this pain is usually of short duration and tolerated very well. No unanticipated adverse events are expected to occur in this study.
1967123|NCT03104426|Drug|Darbepoetin Alfa|Darbepoetin alfa dosage 10microg/kg once a week for 8 weeks
1967124|NCT03102944|Diagnostic Test|Minicare BNP|no real intervention since only leftover materials are used from volunteers and samples are not tested on Minicare BNP IVD device near any volunteer.
1910745|NCT02384382|Drug|Enzalutamide|
1967133|NCT03096782|Drug|Busulfan|Busulfan test dose administered either as an outpatient prior to admission or as an inpatient on Day -10. Busulfan pharmacokinetics performed with the test dose and the first dose on Day -7 per standard of care. The doses of Days -6, -5, and -4 subsequently adjusted to target an AUC of 4,000 microMol.min-1. In the event that PK adjusting not possible a dose of Busulfan of 130 mg/m2 administered.
1967134|NCT03096782|Drug|Rituximab|Rituximab 375 mg/m given by vein for B cell malignancy on Day -11.
1967135|NCT03096782|Drug|ATG|"Plan 1: Rabbit ATG 1.25 mg/Kg by vein on Day -9, and 1.75 mg/Kg on Day -8.
Plan 2 and Plan 3: Rabbit ATG 1.25 mg/Kg by vein on Day -8, and 1.75 mg/Kg on Day -7."
1967136|NCT03096782|Drug|Fludarabine|"Plan 1: 10 mg/m2 by vein on Days -7 to -4.
Plan 2: 40 mg/m2 by vein on Days -5 to -2.
Plan 3: 40 mg/m2 by vein on Days -6 to -3."
1967137|NCT03096782|Drug|Clofarabine|30 mg/m2 by vein on Days -7 to -4.
1967138|NCT03096782|Radiation|Total Body Irradiation|"Plan 1: Low-Dose TBI 2 Gy given on Day -3.
Plan 3: 200 cGy given on Day -1."
1967139|NCT03096782|Procedure|Cord Blood Transplant|Cord Blood Transplant on Day 0.
1967140|NCT03096782|Drug|Mycofenolate mofetil|15mg/kg (actual body weight with a maximum dose of 1 gram twice daily) by vein or mouth from Days -3 to Day +100 in the absence of graft versus host disease.
1967141|NCT03096782|Drug|Tacrolimus|Starting dose 0.03 mg/kg or 0.015 mg/kg (ideal body weight) by vein starting on Day -2 and tapered around Day +180 if no graft versus host disease present.
1967142|NCT03096782|Drug|G-CSF|350 mg subcutaneously daily starting on Day 0 until engraftment.
1967143|NCT03096782|Drug|Melphalan|Plan 2: 140 mg/m by vein on Day -2.
1967144|NCT03096782|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6.
1967145|NCT03096782|Drug|Mesna|50 mg/kg by vein on Day -6.
1967148|NCT03094195|Drug|EMA401|EMA401
1967149|NCT03094195|Drug|Placebo|Placebo
1910769|NCT02377349|Biological|Boostrix™|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
1910770|NCT02377349|Drug|Saline placebo|One dose administered intramuscularly in the deltoid muscle of the non-dominant arm.
1910772|NCT02376361|Device|Transonic|"Access recirculation, access flow would be determined using the ultrasound dilution technique (Transonic system).
Within 90 min of the beginning of HD session HD03 sensors are clamped HD tubing lines
Recirculation, access flow will be performed according to HD03 Manual.
Post intervention evaluation is as per each arm follow up unless other follow up deemed necessary by the interventionalist."
1967160|NCT03093025|Drug|TS-121 10 mg|Orally taken once daily
1967161|NCT03093025|Drug|TS-121 50 mg|Orally taken once daily
1967162|NCT03093025|Drug|Placebo|Orally taken once daily
1967165|NCT03091673|Drug|Glucagon|0.5 or 1.0 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
1967172|NCT03086278|Drug|AST-008|AST-008 is a toll-like receptor 9 agonist.
1967173|NCT03087708|Drug|Naloxegol|Given PO
1967174|NCT03087708|Other|Placebo|Given PO
1967175|NCT03087708|Other|Laboratory Biomarker Analysis|Correlative studies
1967176|NCT03087708|Other|Quality-of-Life Assessment|Ancillary studies
1967182|NCT03078764|Other|Mobile health system|Patients will receive weekly automated IVR telephone calls for 12 weeks to assess their glycemic symptoms, medication adherence, dietary consumption, physical activity, sleep, and foot care. These 5-10 minute calls will follow a standardized Thai language IVR script developed specifically for this study.
1967183|NCT03078764|Other|E-mail reports and technical support for mHealth system|Nurses will also receive a technical troubleshooting guide, and have similar access to live telephone technical support. Once their patients' calls begin, nurses will begin receiving weekly e-mail reports summarizing each patients' assessment results, any active self-management problems the patients reported, and suggested strategies for supporting the patient's self-management.
1967185|NCT03077828|Drug|Carboplatin|Given IV
1967186|NCT03077828|Drug|Etoposide|Given IV
1967187|NCT03077828|Drug|Ifosfamide|Given IV
1967188|NCT03077828|Other|Laboratory Biomarker Analysis|Correlative studies
1967189|NCT03077828|Biological|Pembrolizumab|Given IV
1910790|NCT02370706|Drug|PIM447|pan-pim inhibitor
1910791|NCT02370706|Drug|Ruxolitinib|JAK1/JAK2 inhibitor
1910792|NCT02370706|Drug|LEE011|CDK4/6 inhibitor
1967192|NCT03076151|Drug|Tacrolimus monohydrate (ADOPORT®)|Pharmacokinetic of Tracrolimus (ADOPORT®) on 9 blood sampling by kinetics on 4 kinetics
1967202|NCT03068650|Biological|rindopepimut|Rindopepimut is an experimental cancer vaccine that may act to promote anti-cancer effects in patients who have glioblastoma multiforme (GBM) that expresses an EGFR mutation, called EGFRvIII. Data from, a randomized, controlled phase 2 study in patients with EGFRvIII positive progressive glioblastoma (the ReACT trial) suggested that vaccination with rindopepimut could improve survival. A randomized, controlled phase III study in patients with newly diagnosed EGFRvIII expressing GBM did not show a survival advantage from rindopepimut vaccination.
1910808|NCT02368743|Drug|mesalazine|
1910809|NCT02368717|Drug|Mesalazine Enema|
1910810|NCT02368717|Drug|Placebo Enema|
1967207|NCT03063632|Biological|Interferon Gamma-1b|Given SC
1967208|NCT03063632|Other|Laboratory Biomarker Analysis|Ancillary studies
1967209|NCT03063632|Biological|Pembrolizumab|Given IV
1967210|NCT03063749|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 2.0 mm - 4.0 mm
1967211|NCT03063749|Device|Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System|Medtronic Resolute Onyx™ Zotarolimus-Eluting Coronary Stent System, sizes 4.5 mm - 5.0 mm
1967212|NCT03063541|Drug|Acetylsalicylic acid|100 mg daily as one tablet
1967213|NCT03063541|Other|intensive blood pressure control|Patients are encouraged to seek any therapy to have a systolic blood pressure of 120 or below. They will be provided with a blood pressure measurement device and are advised to control blood pressure daily.
1967215|NCT03062761|Other|Infant Formula with prebiotics|Intervention group: Partially hydrolysed whey protein based infant formula containing prebiotics.
1967216|NCT03062761|Other|Standard Infant Formula|Control group: Intact cow's milk protein based infant formula containing prebiotics
1910818|NCT02367040|Drug|Copanlisib (BAY 80-6946)|Copanlisib is supplied as lyophilized preparation in a 6 mL injection vial. The total amount of copanlisib per vial is 60 mg. The solution for IV infusions is obtained after reconstitution with normal saline solution. Dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Copanlisib will be administered before rituximab.
1910819|NCT02367040|Drug|Placebo|Placebo is supplied as lyophilized preparation in a 6 mL injection vial. The developed placebo lyophilisate is equivalent to the 60 mg copanlisib formulation, with regard to the composition of excipients and the instructions for reconstitution and dose preparation. Placebo dosing will be administered on Days 1, 8 and 15 of each 28-day cycle. Placebo will be administered before rituximab.
1910820|NCT02367040|Drug|Rituximab|Rituximab dose 375 mg/m2 body surface weekly during Cycle 1 on Days 1, 8, 15 and 22, and then on Day 1 of Cycles 3, 5, 7 and 9.The solution for IV infusions is obtained after reconstitution of a calculated concentration of 1 to 4 mg/ml rituximab into an infusion bag containing sterile, pyrogen-free sodium chloride 9 mg/ml (0.9%) solution for injection or 5% D-Glucose in water.
1967227|NCT03057691|Other|antidepressive and anti-anxiety therapy|These therapies include antidepressants, antianxiety drugs and psychotherapy. Subjects choose the therapy follow their own will. All of the above-mentioned therapies are identified by experienced psychiatrists in the same center. The treatment information will be recorded in each visit. The study is considered non-interventional, and no antidepressive or anti-anxiety therapies are mandated.
1910832|NCT02366143|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle until loss of clinical benefit.
1910833|NCT02366143|Drug|Bevacizumab|Bevacizumab will be administered as IV infusion at a dose of 15 milligrams per kilogram (mg/kg) on Day 1 of each 21-day cycle until progressive disease, unacceptable toxicity, or death.
1910834|NCT02366143|Drug|Carboplatin|Carboplatin will be administered at area under the concentration-time curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
1910835|NCT02366143|Drug|Paclitaxel|Paclitaxel will be administered as IV infusion at a dose of 200 milligrams per square meter (mg/m^2) on Day 1 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurs first.
1910838|NCT02366949|Drug|BAY 1217389|"BAY 1217389 will be given orally, with a starting dose of 0.25 mg twice daily, on D1, D2, D8, D9, D15 and D16 of a 28 day cycle. BAY 1217389 will be dosed in combination with paclitaxel in Arm 1 (Experimental Treatment) and from Cycle 2 onwards in Arm 2 (Standard Treatment).
After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY 1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
In a higher dose level Cohort 4 > (or equal to) a relative bioavailability assessment of BAY 1217389 liquid capsule formulation compared to BAY 1217389 oral solution will be performed."
1910839|NCT02366949|Drug|Paclitaxel|Paclitaxel will be given once per week IV at 90 mg/m2 on D1, D8, and D15 of a 28 day cycle. Paclitaxel will be dosed as a single-agent in Cycle 1 of Arm 2 (Standard Treatment Arm), and in combination with BAY 1217389 in Arm 1 (Experimental Treatment Arm) and from Cycle 2 onwards in Arm 2 (Standard Treatment Arm). After Maximum tolerated dose (MTD) has been defined, expansion cohorts will be conducted at the MTD dose of BAY 1217389 and paclitaxel following an intermittent dosing schedule as defined in the dose escalation phase. Up to 12 to 15 breast cancer (triple negative) subjects are planned to be enrolled in the expansion cohort.
1967231|NCT03054844|Drug|Lidocaine|Lidocaine will be administered before administration of midazolam.
1967232|NCT03054844|Drug|Lidocaine and midazolam (PREMIX)|Lidocaine will be administered as a mixture with midazolam.
1967233|NCT03054844|Drug|Midazolam|Midazolam will be administered either after lidocaine, or as a mixture with lidocaine.
1967240|NCT03053687|Dietary Supplement|Nutritional supplementation standardized formula|Powder added to water, containing about 25% of recommended Daily Recommended Intake (DRI) for calories, high protein (25% of calories) and multivitamin and mineral (25%-100% of DRI for recommended daily allowance (RDA) or adequate intake
1967241|NCT03053687|Dietary Supplement|Placebo|Low caloric formula (Powder added to water) without added vitamins and mineral
1967251|NCT03049319|Device|Psoriashield in the presence of a non-UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a non-UV absorbing block.
1967252|NCT03049319|Device|Psoriashield in the presence of a UV absorbing block.|The psoriashield will be applied to patient's back in the presence of a UV absorbing block.
1967253|NCT03049319|Device|Psoriashield|The psoriashield will be applied to patient's back.
1910866|NCT02359006|Drug|Minocycline|Minocycline will be compared with placebo
1910867|NCT02359006|Drug|Placebo|Placebo will be compared with minocycline
1967254|NCT03049319|Device|Xtrac laser in the presence of a non-UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a UV absorbing block.
1967255|NCT03049319|Device|Xtrac in the presence of a UV absorbing block.|The Xtrac laser will be applied to patient's back in the presence of a non-UV absorbing block.
1967256|NCT03049319|Device|Xtrac laser|The Xtrac laser will be applied to patient's back.
1967259|NCT03048422|Drug|Dolutegravir|One 50 mg DTG tablet will be administered orally once daily
1967260|NCT03048422|Drug|Emtricitabine/tenofovir alafenamide|One fixed-dose combination tablet (FTC 200 mg/TAF 25 mg) will be administered orally once daily
1967261|NCT03048422|Drug|Emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (FTC 200 mg/TDF 300 mg) will be administered orally once daily
1967262|NCT03048422|Drug|Efavirenz/emtricitabine/tenofovir disoproxil fumarate|One fixed-dose combination tablet (EFV 600 mg/FTC 200 mg/TDF 300 mg) will be administered orally once daily
1967264|NCT03046108|Device|blind injection of Morton neuroma|Introduction of a needle based in anatomical landmark
1967265|NCT03046108|Drug|blind injection of Mepivacaine|blind injection of 1 cc of Mepivacaine Normon 2% ®
1967266|NCT03046108|Drug|blind injection of Triamcinolone|blind injection of 40 mg of triamcinolone (trigon depot ®)
1967267|NCT03046108|Device|ultrasound guided injection|Introduction of a needle based guided by ultrasound
1967268|NCT03046108|Drug|guided injection of mepivacaine|ultrasound guided injection of 1 cc of Mepivacaine Normon 2% ®
1967269|NCT03046108|Drug|guided injection of Triamcinolone|ultrasound guided injection of 40 mg of triamcinolone (trigon depot ®)
1910886|NCT02355301|Procedure|orthopedic|Compare the type of treatment chosen by the orthopedist with a functional assessment (ICF-WHO model)
1967272|NCT03045406|Drug|Apixaban|Tablets
1910890|NCT02354664|Other|Thoracic MRI|Imaging of the diaphragm will be completed during resting breathing, and then during a maximal voluntary ventilation maneuver.
1910891|NCT02354664|Other|Spirometry|Upright forced vital capacity (FVC)
1910892|NCT02354664|Other|Inspiratory Load Compensation|A spring-loaded pressure device will resist inspiration. The patient must generate the threshold inspiratory pressure to receive airflow. The changes in breathing timing, flow and volume will be recorded.
1967273|NCT03045406|Drug|Dalteparin|Injections
1910893|NCT02354664|Other|Maximal Inspiratory Pressure|Measure the maximal airflow on inhalation
1910894|NCT02354664|Other|Resting Breathing Pattern|The breathing pattern will be assessed when the subject is seated and in a relaxed state.
1910895|NCT02354664|Other|Respiratory Muscle Endurance Test|Evaluates the time limit that a participant can maintain ventilation while breathing with a submaximal inspiratory threshold load.
1967279|NCT03043391|Biological|Polio/Rhinovirus Recombinant (PVSRIPO)|PVSRIPO will be delivered intratumorally by convection-enhanced delivery (CED) using an intracerebral catheter placed within the enhancing portion of the tumor. A stereotactic biopsy will be performed prior to virus administration. Immediately following the stereotactically-guided tumor biopsy, a catheter will be implanted in the operating room at a site the same or different from that used for the biopsy using sterile techniques under general anesthesia. The entire volume of PVSRIPO to be delivered will be pre-loaded into a syringe by the investigational pharmacist and connected to the catheter under sterile conditions in the Pediatric Intensive Care Unit (PICU) just prior to beginning of infusion.
1967280|NCT03042104|Device|Edwards SAPIEN 3 THV|Patients in experimental arm will receive SAPIEN 3 THV.
1910902|NCT02353078|Drug|Sucralfate|Sucralfate slurry 1 gram four times daily for four weeks
1910903|NCT02353078|Procedure|Intraluminal Impedance|During the initial endoscopy, esophageal mucosal impedance will also be measured. This procedure involves passing a mucosal impedance probe through the endoscope and gently placing the tip of the probe on the esophageal mucosa. Measurements will be made at 2,5,10 and 15 cm above the gastroesophageal junction. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
1910904|NCT02353078|Device|Intraluminal Impedance|The mucosal impedance probe is a 2.13 mm catheter (tiny tube), called an Intraluminal Impedance, will be passed through the channel of the standard endoscope. There is no increased risk to the procedure and it adds approximately 2 minutes to the procedure.
1910905|NCT02352870|Behavioral|Computerised Cognitive Behavioural Therapy|Online treatment sessions are scheduled to last approximately one hour, completed independently by the participant on a weekly basis
1910906|NCT02352870|Behavioral|Telephone support|Telephone support calls are scheduled to last 30 minutes and and are received fortnightly at weeks: 2, 4 and 6.
1910909|NCT02351492|Procedure|Cholecystectomy and intraoperative cholangiography|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
1910910|NCT02351492|Procedure|Magnet resonance cholangio-pancreaticography|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
1910911|NCT02351492|Device|magnet resonance imaging|Patients get Magnet resonance cholangio-pancreaticography MRCP first. In case of detected gallstones, removal of the stones by endoscopic retrograde cholangiopancreaticography will be performed before gallbladder removal.
1910912|NCT02351492|Device|catheter|Patients with suspected bile duct obstruction intraoperative cholangiography IOC to investigate bile ducts.
1910924|NCT02347839|Procedure|Gefitinib-surgery-gefitinib|neoadjuvant gefitinib followed by surgery, followed by adjuvant gefitinib
1967291|NCT03041311|Drug|Trilaciclib|Trilaciclib IV
1967292|NCT03041311|Drug|Placebo|Placebo IV
1967293|NCT03041311|Drug|Carboplatin|Carboplatin IV
1967294|NCT03041311|Drug|Etoposide|Etoposide IV
1967295|NCT03041311|Drug|Atezolizumab|Atezolizumab IV
1967296|NCT03041025|Drug|GSK2330811|GSK2330811 will be provided in vials and packed in 1 vial per carton. Each vial will contain 1.2 mL fill with 1 mL extractable volume at 100 mg/mL.
1967297|NCT03041025|Drug|Placebo|Normal saline (0.9 percent weight per volume sodium chloride).
1967327|NCT03034304|Biological|MASCT-I|The final products of MASCT-I technology are dendritic cells (DC) and effector T cells
1967328|NCT03034304|Drug|Ifosfamide|2g/m2/d, intravenous drip for 30min. Administration is conducted for continuous 5 days. After 4 weeks, the above cycle is repeated for 6 continuous cycles
1967339|NCT03029871|Biological|Ad5-yCD/mutTKSR39rep-ADP Adenovirus|oncolytic adenovirus
1967351|NCT03023046|Drug|Cyclophosphamide|Given IV
1967352|NCT03023046|Drug|Dasatinib|Given PO
1967353|NCT03023046|Drug|Doxorubicin|Given IV
1967354|NCT03023046|Drug|Etoposide|Given IV
1967355|NCT03023046|Drug|Imatinib Mesylate|Given PO
1967356|NCT03023046|Other|Laboratory Biomarker Analysis|Correlative studies
1967357|NCT03023046|Drug|Prednisone|Given PO
1967358|NCT03023046|Biological|Rituximab|Given IV
1967359|NCT03023046|Drug|Vincristine Sulfate|Given IV
1967365|NCT03021850|Procedure|Flexibility training with or without different thermal modalities|Flexibility training of the hamstring muscles by passive static stretching of the hamstring muscles in 10 30-second repetitions, with a 10-second pause between each repetition associated with or without short-wave heating or cryotherapy
1967370|NCT03018808|Other|Minimal questionnaire|The minimal questionnaire is a reduced version of the medical interview and it will include questions about sociodemographic information, previous diagnosis of COPD, co-morbidities and smoking habits.
1967371|NCT03018808|Other|Medical interview|Medical interview includes medical history, sociodemographic and clinical information, including disease history, treatment history, smoking habits and use of biomass
1967372|NCT03018808|Other|CAT|The CAT is a questionnaire for COPD patients and is designed to measure the impact of COPD on a person's life over time.
1911037|NCT02324049|Drug|SBC-103|
1967393|NCT03018054|Drug|E6007|once daily administration
1911047|NCT02319460|Biological|Kcentra®|Kcentra®, Prothrombin Complex Concentrate (Human), is a blood coagulation factor replacement product that contains coagulation Factors II, VII, IX and X, and antithrombotic Proteins C and S as a lyophilized concentrate.
1911048|NCT02319460|Biological|Plasma|
1967394|NCT03018054|Drug|Placebo|once daily administration
1911065|NCT02316457|Biological|IVAC_W_bre1_uID|vaccination
1911066|NCT02316457|Biological|IVAC_W_bre1_uID/IVAC_M_uID|vaccination
1911068|NCT02316340|Drug|Vorinostat|400mg by mouth daily
1911069|NCT02316340|Drug|Hydroxychloroquine|600mg by mouth daily
1911070|NCT02316340|Drug|Regorafenib|160 mg by mouth daily
1911140|NCT02301130|Biological|mogamulizumab|Mogamulizumab will be administered intravenously (IV).
1967406|NCT03015532|Drug|HTX-011|
1967407|NCT03015532|Drug|Saline Placebo|
1967408|NCT03015532|Drug|Bupivicaine HCl|Bupivacaine HCl without epinephrine
1911090|NCT02308982|Drug|Immunoglobulins, Intravenous (Privigen)|
1911091|NCT02308982|Drug|Placebo|
1911092|NCT02307097|Procedure|Cognitive-Behavioural Bibliotherapy|
1911093|NCT02307097|Procedure|Cognitive-Behavioural Therapy|
1911094|NCT02307097|Other|WAIT|
1967409|NCT03015532|Drug|Ropivacaine|
1911111|NCT02304458|Biological|Ipilimumab|Given IV
1911112|NCT02304458|Other|Laboratory Biomarker Analysis|Correlative studies
1911113|NCT02304458|Biological|Nivolumab|Given IV
1911114|NCT02304458|Other|Pharmacological Study|Correlative studies
1911120|NCT02303054|Procedure|Bipolar Radiofrequency Focal Ablation|Men identified as having suspicious regions on a pre-biopsy mpMRI will be considered for enrollment. Following an MRI-US targeted biopsy of the prostate, men testing positive will be eligible for enrollment. All men enrolled in the study will undergo focal radiofrequency ablation and evaluated in follow-up.
1967419|NCT03013491|Drug|CX-072|
1967420|NCT03013491|Drug|ipilimumab|
1967421|NCT03013491|Drug|vemurafenib|
1967424|NCT03009981|Drug|Apalutamide|Patients randomized to Arm B will be instructed to take apalutamide 240 mg (four 60 mg tablets) orally once daily starting on cycle 1 day 1 and continuing throughout 52-week treatment period.
1967425|NCT03009981|Drug|Degarelix|Patients randomized to arm A will receive Degarelix every 28 days (+/- 4 days). Patients will receive loading dose of 240 mg (two 120 mg injections) on cycle 1 day 1, followed by maintenance dose of 80 mg subcutaneous injection on day 1 of subsequent cycles. Patients randomized to Arms B or C will receive degarelix at the same schedule in addition to other agents.
1967426|NCT03009981|Drug|Abiraterone Acetate|Patients randomized to Arm C will be instructed to take abiraterone acetate 1000 mg (four 250 mg tablets) and prednisone 5mg orally once daily starting on cycle 1 day 1 and continuing throughout 52-week treatment period.
1967427|NCT03009981|Drug|Prednisone|Patients randomized to Arm C will also be instructed to take prednisone 5 mg tablet once daily starting on cycle 1 day 1 and continuing throughout the 52-week treatment period.
1967430|NCT03009396|Drug|RHB-104|RHB-104; a fixed-dose combination of 95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
1967433|NCT03008447|Drug|LEM5|Single dose of lemborexant 5 mg administered within 5 minutes before bedtime.
1911136|NCT02301611|Drug|TLPLDC|Autologous tumor lysate, particle-loaded dendritic cell vaccine
1911137|NCT02301611|Drug|Placebo|
1967434|NCT03008447|Drug|LEM10|Single dose of lemborexant 10 mg administered within 5 minutes before bedtime.
1967435|NCT03008447|Drug|ZOL|Single dose of zolpidem 6.25 mg administered within 5 minutes before bedtime.
1967436|NCT03008447|Drug|PBO|Single dose of placebo administered within 5 minutes before bedtime.
1911141|NCT02301130|Biological|MEDI4736 (Durvalumab)|MEDI4736 will be administered intravenously (IV).
1911142|NCT02301130|Biological|tremelimumab|Tremelimumab will be administered intravenously (IV).
1911144|NCT02301325|Behavioral|Smoking research cigarettes with or without NRT|
1967451|NCT03003962|Biological|Durvalumab (MEDI4736)|PD-L1 monoclonal Antibody
1967452|NCT03003962|Drug|Paclitaxel + carboplatin|Chemotherapy Agents
1967453|NCT03003962|Drug|Gemcitabine + cisplatin|Chemotherapy Agents
1967454|NCT03003962|Drug|Gemcitabine + carboplatin|Chemotherapy Agents
1967455|NCT03003962|Drug|Pemetrexed + cisplatin|Chemotherapy Agent
1967456|NCT03003962|Drug|Pemetrexed + carboplatin|Chemotherapy Agent
1967457|NCT03003806|Device|DreaMed Advisor Pro|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted using the DreaMed Advisor Pro
1967458|NCT03003806|Other|Medical guided recommendation|Insulin pump settings (i.e, basal plan, correction factor, carbohydrate ratio and insulin activity time) will be adjusted by the medical team
1967460|NCT03003143|Drug|Vigabatrin 500 MG|
1967474|NCT02997228|Drug|Atezolizumab|Given IV
1967475|NCT02997228|Biological|Bevacizumab|Given IV
1967476|NCT02997228|Drug|Fluorouracil|Given IV
1967477|NCT02997228|Other|Laboratory Biomarker Analysis|Correlative studies
1967478|NCT02997228|Drug|Leucovorin Calcium|Given IV
1967479|NCT02997228|Drug|Oxaliplatin|Given IV
1967480|NCT02997228|Other|Quality-of-Life Assessment|Ancillary studies
1967490|NCT02997891|Diagnostic Test|everyday activity|To objectively quantify the everyday activity, there are a variety of instruments, without a currently gold standard. Therefore, in addition the investigators use objectified measurement parameters with the aid of a pedometer (GARMIN vivofit) on every three measuring time points (before surgery, 3 months after surgery, 6 months after surgery).
1967491|NCT02997891|Diagnostic Test|cognitive performance|Standardized neuropsychological assessment methods are used to assess the cognitive performance. To assess the degree of mobility, health status and the physical activity standardized questionnaires are used.
1967499|NCT02996201|Other|Completion of PRO-CTCAE items before consultation|Patients report PRO-CTCAE symptoms on a tablet computer before each cycle of chemotherapy
1967500|NCT02994953|Drug|Avelumab|Subjects will receive avelumab intravenous (IV) infusion every 2 weeks on Day 1 and Day 15 of each cycle.
1967501|NCT02994953|Drug|NHS-IL12|Subjects will receive Subcutaneous (SC) injection of NHS-IL12 in escalating doses on Day 1 of each cycle.
1967503|NCT02993315|Biological|nDC vaccination|
1967504|NCT02993315|Biological|placebo injection|
1967508|NCT02990936|Other|Tumor delineation|Measurement of tumor volume and neck nodes volume on a diagnostic CT and a pre-treatment CT by computerized delineation in order to calculate tumor growth velocity and tumor doubling time and describe tumoral kinetics patterns
1967512|NCT02991521|Procedure|Fast exam|Positional change before Fast exam
1967513|NCT02988973|Drug|roxadustat|Oral administration
1911197|NCT02292654|Drug|Olipudase alfa|Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous infusion
1967514|NCT02988973|Drug|DA|Subcutaneous administration
1967519|NCT02987972|Biological|V114 Lot 1|Lot 1: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
1967520|NCT02987972|Biological|V114 Lot 2|Lot 2: Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19F, 19A, 22F, 23F, 33F (2 mcg each), and serotype 6B (4 mcg) in each 0.5 mL dose
1967521|NCT02987972|Biological|Prevnar 13™|Pneumococcal capsular polysaccharide serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F (2.2 mcg) and 6B (4.4 mcg) in each 0.5 ml dose
1967524|NCT02987387|Device|SAPIEN XT THV|SAPIEN XT THV will be implanted in the pulmonic position.
1911212|NCT02288936|Drug|Enzalutamide|Enzalutamide 160 mg/day
1967535|NCT02978716|Drug|Trilaciclib|
1967536|NCT02978716|Drug|Gemcitabine|
1967537|NCT02978716|Drug|Carboplatin|
1967539|NCT02977611|Drug|Iron sucrose|Iron sucrose will be infused at dose of 500 mg over a one hour period
1967542|NCT02976337|Drug|Naloxone|active drug infusion
1967543|NCT02976337|Drug|Normal Saline|placebo comparator
1967544|NCT02975882|Drug|Irinotecan Hydrochloride|Given PO
1967545|NCT02975882|Other|Laboratory Biomarker Analysis|Correlative studies
1967546|NCT02975882|Drug|Nanoparticle Albumin-Bound Rapamycin|Given IV
1967547|NCT02975882|Other|Pharmacological Study|Correlative studies
1967548|NCT02975882|Drug|Temozolomide|Given PO
1967555|NCT02974790|Procedure|Echocardiography|Two-dimensional imaging echocardiography
1967559|NCT02972359|Drug|Neridronic acid|Neridronic acid administered as intravenous infusion.
1967565|NCT02969681|Drug|ascorbic acid|20g/day, D1-3, every 2 weeks
1967566|NCT02969681|Drug|Chemotherapy|"mFOLFOX6
Oxaliplatin 85 mg/m² d1 concurrent with
Leucovorin 400 mg/m², followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks
or FOLFIRI
CPT-11 180 mg/m² d1 concurrent with
Leucovorin 400 mg/m², followed by
Bolus 5FU 400 mg/m² , followed by
Infusional 5FU 2400 mg/m² over 46 hours, every 2 weeks with or without bevacizumab 5mg/kg, every 2 weeks"
1967567|NCT02969018|Drug|PF-06700841|
1911254|NCT02282930|Drug|ACTH (Acthar) Gel|Injected dose of 80 units subcutaneously twice weekly for 6 months.
1967568|NCT02969018|Other|Placebo|
1967579|NCT02963766|Drug|Dulaglutide|Administered SC
1967580|NCT02963766|Drug|Placebo|Administered SC
1967585|NCT02960230|Biological|K27M peptide|K27M peptide vaccine, combined with Tetanus Toxoid peptide, emulsified in montanide. Poly-ICLC will be given concurrently
1911266|NCT02281799|Drug|Azathioprine|"Patients will be commenced on an alternative thiopurine to that used initially, according to the standard dosing schedule used by their IBD clinician.
For example, if the initial thiopurine-related pancreatitis occurred while taking Azathioprine, the patient will be restarted on 6-MP, and vice versa."
1967608|NCT02952092|Drug|roxadustat|Oral
1967609|NCT02952092|Drug|Darbepoetine alfa|Intravenous
1967615|NCT02950103|Drug|Phosphoethanolamine|Phosphoethanolamine PO daily
1911298|NCT02279095|Drug|Palovarotene dose level 1|Palovarotene was taken orally once daily at approximately the same time each day.
1911299|NCT02279095|Drug|Palovarotene dose level 2|Palovarotene will be taken orally once daily at approximately the same time each day.
1911300|NCT02279095|Drug|Palovarotene dose level 3|Palovarotene will be taken orally once daily at approximately the same time each day.
1911301|NCT02279095|Drug|Palovarotene dose level 4|Palovarotene will be taken orally once daily at approximately the same time each day.
1967619|NCT02947204|Other|Intermittent oxygen monitoring|Oxygen saturation and vital signs will be measured intermittently at a frequency of every 4 hours by the bedside nurse through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
1967620|NCT02947204|Other|Continuous oxygen monitoring|Oxygen saturation will be measured continuously through the child's hospital stay until discharge. Vital signs will be completed every 4 hours.
1911318|NCT02275052|Drug|UMEC/VI DPI|The DPI will contain a total of 30 doses. Each DPI will be comprised of two double-foil, laminate blister strips. Each blister of one strip will consist of 62.5mcg of UMEC blended with lactose and magnesium stearate while each blister of other strip will consist of 25 mcg of VI blended with lactose and magnesium stearate. Each actuation of the DPI will deliver the contents of one blister from each strip simultaneously
1911319|NCT02275052|Drug|Placebo DPI|The placebo DPI, identical in appearance to the inhaler containing active study medication, will have two blister strips, each containing 30 blisters of lactose and magnesium stearate.
1911320|NCT02275052|Drug|Albuterol/salbutamol MDI|Albuterol/salbutamol MDI (metered-dose inhaler) or nebules will be permitted throughout the study as rescue medication, for use as-needed. Albuterol/salbutamol will be sourced from local commercial stock or provided centrally from GlaxoSmithKline. Nebules will not be supplied.
1911328|NCT02273661|Drug|Liposomal amphotericin B (Ambisome®)|
1911329|NCT02273661|Drug|placebo|
1911330|NCT02273375|Drug|MEDI4736|
1911331|NCT02273375|Drug|Placebo|
1911344|NCT02272257|Behavioral|Early Direct Access Physical Therapy|Physical Therapy management including Manual therapy, Exercise, and education including cognitive behavioral therapy.
1911345|NCT02272257|Behavioral|Physician management|Physician management including advice, medication, and referral to physical therapy or other provider.
1967637|NCT02942160|Biological|Collagenase Clostridium Histolyticum|
1967641|NCT02935842|Other|Specific SL-therapy|Provided by a professional speech-language therapist (SLT) on a one-to-one basis. In approx. 45 Minutes sessions, 3 times per week for 4 weeks in total.
1967642|NCT02935842|Other|Rhythmic Balance-Movement Training (rBMT)|Provided on a one-to-one basis. In approx. 30-45 Minutes sessions, 3 times per week for 4 weeks in total.
1911363|NCT02269917|Drug|D/C/F/TAF|Once-daily single-tablet regimen containing darunavir (DRV) 800 milligram (mg)/ cobicistat (COBI) 150 mg/ emtricitabine (FTC) 200 mg/ tenofovir alafenamide (TAF) 10 mg.
1911364|NCT02269917|Drug|Boosted Protease Inhibitor (bPI)|Boosted protease inhibitor (limited to darunavir [DRV] or atazanavir with low-dose ritonavir [rtv] or cobicistat [COBI], or lopinavir with rtv) as per current treatment regimen.
1911365|NCT02269917|Drug|FTC/TDF|Emtricitabine/tenofovir disoproxil fumarate (FTC/TDF).
1967654|NCT02931851|Other|ICU Families Website|Professionally developed website for relatives of ICU patients
1967655|NCT02931851|Other|Placebo|Standard Information provided online
1967661|NCT02928562|Other|exercise|cyclic exercise, aerobic exercise and resistant training exercise
1967662|NCT02928458|Drug|Omnipaque|
1967663|NCT02928458|Drug|MD-Gastroview|
1967673|NCT02927457|Drug|GSK2646264 1%|A cream for topical application with a concentration of 1% GSK2646264.
1967674|NCT02927457|Drug|Placebo|Subjects will receive matching Placebo topically.
1967675|NCT02927327|Device|Zero Echo Time (ZTE) scan for head attenuation|"The GE SIGNA PET/MR MP26 software platform includes the zero echo time (ZTE) scan for head attenuation and Q.Static. The ZTE MR software feature has the potential to enable better visualization of bones, including those in the head, by employing optimal head attenuation correction in PET/MR.
PET/MR ZTE MRAC"
1967676|NCT02927327|Device|Q.Static (Q. MRAC) for respiratory motion correction|"An improved Q.Static feature with Q. MRAC, where phase matching the MRAC with the quiescent phase is employed to get more accurate attenuation correction for our Q.Static PET images.
PET/MR Q Static (Q. MRAC)"
1911385|NCT02264210|Drug|Icotinib|Icotinib 125 mg three times daily (375 mg per day) by mouth for 12 months.
1967683|NCT02925676|Device|hyposafe H02|hypoglycaemia alarm device
1911400|NCT02261636|Drug|mesalazine|
1967698|NCT02923466|Biological|VSV-IFNβ-NIS|This is an open label single ascending dose phase I study designed to determine the safety profile and MTD after IT administration of a single dose of VSV-IFNβ-NIS in patients with refractory advanced/metastatic solid tumors.
1967699|NCT02923375|Biological|Mesenchymoangioblast-derived mesenchymal stem cells|The active agent in CYP-001 is allogeneic mesenchymoangioblast-derived mesenchymal stem cells (MCA-derived MSCs), which are produced using the proprietary Cymerus™ platform technology. Cymerus™ refers to the process of generating cell-based products from intermediate cells, MCAs, which in turn are derived from induced pluripotent stem cells or iPSCs. The iPSCs used in the Cymerus™ process were derived from blood donated by a fully-consented healthy adult donor, and were reprogrammed using a transgene-free, viral-free and feeder-free technique.
1967700|NCT02921425|Behavioral|patient health record|The study intervention involved the provision to study participants of targeted instruction and practice on use of two features of the Track Health (TH) function of the VA's patient health record (PHR) known as My HealthyVet (MHV) -- Journals and Vitals + Readings -- as a basis for promoting positive physical activity (PA) and dietary lifestyles. Seven interactive multimedia instructional modules were developed by the study team. These modules demonstrated on a computer screen how to enter PA and diet information into the Journals feature; how to add weight data into the Vitals + Readings feature; how to view these and other measures in tabular and graphical formats over different time frames; and the concept of possible cause-effect links between behavioral lifestyle and physiological outcome data. Participants were directed to enter food intake, PA, and weight information a specified number of times per week over the 3-month study period.
1911408|NCT02256306|Other|Plasma|1 unit of Plasma From Young Donors (Male, aged 30 or younger)
1967708|NCT02920983|Device|somofilcon A|contact lens
1967709|NCT02920983|Device|nelfilcon A II 2|contact lens
1967710|NCT02920983|Device|omafilcon A ll 2|contact lens
1967711|NCT02920320|Other|Internet-based self-help program|
1911423|NCT02250183|Device|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY|MEDIHONEY® GEL WITH ACTIVE LEPTOSPERMUM HONEY dressing is manufactured by the company Derma Sciences, Inc. and is a moist dressing made of Active Leptospermum Honey (+15) in combination with natural gelling agents. The gelling agents act to maintain the physical integrity and viscosity of the dressing, even in the presence of body heat and fluids. As a percentage of the overall dressing, MEDIHONEY® GEL dressings contains 80% honey. The dressing has a low pH and can help to lower the overall pH of wounds. The dressing also possesses a high osmotic potential, which assists in debridement.
1911424|NCT02250183|Device|Santyl|SANTYL® Ointment is an FDA-approved sterile enzymatic debriding ointment which contains 250 collagenase units per gram of white petrolatum USP. The enzyme SANTYL® is derived from the fermentation by Clostridium histolyticum. It possesses the unique ability to digest collagen in necrotic tissue. SANTYL® Ointment is indicated for debriding chronic dermal ulcers and severely burned areas.
1967722|NCT02914314|Drug|perampanel|oral suspension
1967724|NCT02912975|Other|Mirror treatment|The mirror treatment: The patient sits on a chair, both knees in 90 degrees flexion, both lower limbs undressed, and places a mirror of 100 cm x 25 cm along the trans-tibial amputation stump so that the uninjured limb is reflected in the mirror while the amputation stump can not be seen by the patient. The patient then performs slow repeated movements of the foot from neutral position into maximum flexion while closely observing the reflected image of the uninjured limb - the illusion of a limb regained - in the mirror. The procedure goes on uninterrupted for five minutes in the morning and in the evening in the home of the study patient.
1967725|NCT02912975|Other|Tactile treatment|In Tactile Treatment five different sensory stimuli is applied repeatedly to the skin of the affected part of the limb, in the actual case to the amputated limb from ten cm above the knee joint and distally to include the entire amputation stump: gentle touch with a feather, a brush, a piece of paper, a stone and a wooden stick. The stimuli are applied two times daily for five 5 minutes each time, one minute per material.
1967726|NCT02913313|Drug|BMS-986207|
1967727|NCT02913313|Biological|Nivolumab|
1911439|NCT02247414|Drug|Warfarin|From postoperative day 3, patients will receive oral Warfarin 2.5mg qd with titration of dose to maintain a target INR of 2-3 for 1 year.
1911440|NCT02247414|Drug|Dipyridamole|From postoperative day 3, patients will receive oral dipyridamole 25mg tid for three months.
1911441|NCT02247414|Drug|Aspirin|From postoperative day 3, patients will receive oral Aspirin Enterie Ccoated Tablets 100mg qd for 1 year.
1911442|NCT02247414|Drug|Low Molecular Weight Heparin|From postoperative day 3, patients will receive subcutaneous injection of Low Molecular Weight Heparin (4100 IU) once daily for first five days.
1911447|NCT02246634|Other|Diffusion Weighted MRI scan|Non-contrast diffusion weighted MRI scan of the liver
1911460|NCT02244983|Other|Patients History|History taking and drawing of a blood sample
1911466|NCT02243813|Drug|Psilocybin|Participants will receive 20 mg/70 kg of psilocybin in the first session and will receive either 20 or 30 mg/70 kg in the second session.
1911473|NCT02241356|Device|bifocals|bifocal glasses with an addition of 2.5 Dioptres
1911474|NCT02241356|Device|single vision glasses|single vision glasses
1911477|NCT02240186|Device|Microprocessor Knee (MPK)|MPKs are prosthetic knees that use a microprocessor to control the prosthetic knee mechanism and adjust knee stiffness.
1911478|NCT02240186|Device|Non-Microprocessor Knee (NMPK)|A NMPK is a mechanical knee with either hydraulic or pneumatic controls.
1911490|NCT02236611|Drug|Umeclidinium|Umeclidinium 62.5 mcg will be available as dry inhalation powder to be taken using a nDPI
1911491|NCT02236611|Drug|Glycopyrronium|Glycopyrronium bromide will be available as inhalation capsules, 44 mcg per capsule, taken using BREEZHALER inhalers
1911500|NCT02234778|Device|TGI SVF material via intramuscular injection|Each SVF-treated subject will receive up to 30 cc of the TGI SVF material via intramuscular injection (injections at multiple locations on the lower leg - up to 20 total injections) through a 23 gauge needle over a 2- to 4- minute period.
1911523|NCT02230839|Behavioral|Exercise|Participants will complete a progressive 6-month exercise training program, 4-5 days per week, 45 min per session (180 min per week), consisting mostly of walking (both outside and on an indoor treadmill) but with the option to include stationary cycling, elliptical and rowing machines, similar to what we have utilized previously to elicit significant improvements in insulin sensitivity in both middle-age and older adults (52-55). Beginning at week 8, these subjects will also perform 2 non-consecutive resistance exercise sessions per week, 30 min per session, focused on major muscle groups using resistance machines (total days of exercise will still be 4 to 5).
1911524|NCT02230839|Behavioral|Energy Restriction-Induced Weight Loss|The goal of the weight loss intervention will be to produce a weight loss of 10% body weight. A reduction of 500-1000 kcal/day - based on baseline weight -and low fat (<30% of calories from fat) diet will be used as part of the weight loss intervention.
1911540|NCT02229487|Other|Oral glucose tolerance|
1911541|NCT02229253|Drug|degarelix|
1911543|NCT02228148|Device|NFS|Cochlear Nucleus Fitting Software
1911544|NCT02228148|Device|CSS|Cochlear Nucleus Custom SoundTM Suite
1911549|NCT02227238|Drug|DTG|DTG is supplied as 50 mg tablets
1911550|NCT02227238|Drug|LPV/RTV|LPV/RTV is supplied as the LPV/RTV oral tablet, which contains 200 mg of LPV and 50 mg of RTV
1911551|NCT02227238|Drug|Two NRTIs|Investigators will choose a dual NRTI background regimen for each subject . In consultation with the medical monitor, 3TC may be added as a third NRTI to a dual-NRTI background regimen in subjects with chronic HBV infection and evidence of HIV resistance to 3TC
1967817|NCT02885441|Drug|Ketorolac|Tab Ketorolac, 10 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
1911553|NCT02226432|Procedure|- Postoperative Antagonistic Peripheral Magnetic Stimulation|"Selected patients will be treated with Selective peripheral Neurotomy followed by an standartized cycle of Selective Peripheral Magnetic Stimulation and classic post operative Kinesic Therapy.
Sham patients (n 10) will be treated with classic post operative Kinesic Therapy.
Comparision of both groups will be statistified"
1911554|NCT02226432|Device|Selective Peripheral Magnetic Stimulation|"Peripheral 1.5 tesla intensity, 10 Hz of Frequency, with eight saped bovine, of 30 minutes, aplied on antagonistic muscles, twice a week. Intensity will be infrathreshold, 80 per cent of the individual threshold (minimal amount of intensity producing always a muscle motor response in each particular patient)"
1911555|NCT02226432|Other|Kinesics|Session of classic Kinetic Rehabilitation and motor exercises, twice a week on Physicians´s office and dayly on patient´s home.
1967818|NCT02885441|Drug|Placebo|Tab Placebo, 10 mg, 3 times daily by mouth from time of enrollment until 72 hours from enrollment. For up to a maximum of 9 doses.
1967845|NCT02876172|Drug|MDMA|Two sessions of MDMA-assisted psychotherapy, one with an initial dose of 75 mg and the second with 100 mg MDMA given to a person with PTSD and a significant other without PTSD.
1967846|NCT02876172|Behavioral|CBCT|"A three-phase, 15-session, manualized treatment engaging an individual with PTSD and a concerned significant other"
1967858|NCT02873195|Drug|Atezolizumab|Given IV
1967859|NCT02873195|Biological|Bevacizumab|Given IV
1967860|NCT02873195|Drug|Capecitabine|Given PO
1967861|NCT02873195|Other|Laboratory Biomarker Analysis|Correlative studies
1967862|NCT02873195|Other|Placebo|Given IV
1911596|NCT02221453|Drug|Triamcinolone Acetonide|
1911601|NCT02218229|Device|Shock wave|Shock waves are defined a sequence of acoustic pulse characterized by a high peak pressure (100 MPa), fast pressure rise (< 10 ns) and short duration (10 μs). Different studies and clinical experiments have demonstrated the efficacy of shock waves in the treatment of musculoskeletal system such as chronic tendinopathies or hypertrophic pseudoarthrosis
1967876|NCT02868359|Other|No Intervention|The study is observational.
1967884|NCT02867020|Drug|Apalutamide|APALUTAMIDE 240-mg orally once daily (4 x 60-mg tablets) will be administered on a continual basis. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days.
1967885|NCT02867020|Drug|Abiraterone|Abiraterone acetate 1,000 mg (four 250 mg tablets) should be taken orally once daily, in combination with oral dose prednisone 5mg twice daily continuously. For the purpose of scheduling the study assessments and treatment compliance a treatment cycle is defined as 28 days
1967886|NCT02867020|Drug|ADT|Dosing of goserelin (dose and frequency of administration) will be consistent with the prescribing information and should only be adjusted if clinically indicated to achieve and maintain subcastrate concentrations of testosterone (50 ng/dL or 1.7 nM).
1967887|NCT02867020|Drug|Prednisone|Subjects will receive prednisone 10mg/day.
1967888|NCT02866812|Other|questionnaires assessing the state of fatigue, depression and anxiety|
1967890|NCT02865109|Drug|nusinersen|Administered by intrathecal injection
1967913|NCT02860650|Biological|Ad26.Filo|Ad26.Filo intramuscular (IM) injection at a dose of 9*10^10 viral particles (vp).
1967914|NCT02860650|Biological|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 5*10^8 infectious units (Inf U).
1967915|NCT02860650|Biological|Ad26.ZEBOV|Ad26.ZEBOV intramuscular (IM) injection at a dose of 5*10^10 vp.
1967916|NCT02860650|Biological|Placebo|IM injection of 0.9 percent saline.
1911638|NCT02212912|Behavioral|improvement intervention|"Evidence-based clinical pathway: It contained general guideline-based recommendations about acute stroke management. Standard operating procedures (SOP) of performance indicators. A quality coordinator:The role of the quality coordinator includes interacting with physicians once gaps in the incorporation of evidence-based interventions are identified, ensuring that all components of the quality improvement intervention are being used for every acute ischemic stroke (AIS) patient.Monitoring and feedback system of performance measures.
The system could view the level of implementation of prespecified performance measures at any time (per week recommended) , compare with the previous record of own study site and level of other clusters."
1911639|NCT02212912|Behavioral|no intervention|No intervention indicated that the physicians among control hospital provide routine
1967917|NCT02860650|Biological|MVA-BN-Filo|MVA-BN-Filo intramuscular (IM) injection at a dose of 1*10^8 Inf U.
1911661|NCT02207504|Drug|Crizotinib|Crizotinib is an ATP‐competitive small‐molecule inhibitor of the ALK, c‐Met/HGFR, RON, and ROS receptor tyrosine kinases.
1911662|NCT02207504|Drug|Enzalutamide|Enzalutamide is an androgen receptor signaling inhibitor.
1967942|NCT02857387|Biological|blood sample withdrawn|
1967958|NCT02846519|Drug|Esketamine|100-mcL spray of 14% esketamine solution (14 mg) for a total dose of 56 mg.
1967959|NCT02846519|Drug|Rifampin|2 capsules (300 mg each) of rifampin.
1911683|NCT02202551|Drug|ADS-5102|
1911684|NCT02202356|Drug|ALS-008176|
1911685|NCT02202356|Drug|Placebo|
1911686|NCT02203019|Drug|Propofol|Propofol will be administered for sedation in mechanically ventilated patients with sepsis.
1911687|NCT02203019|Drug|Dexmedetomidine|Dexmedetomidine will be administered for sedation in mechanically ventilated patients with sepsis.
1911688|NCT02203019|Drug|Fentanyl|"Fentanyl will be administered for analgesia in mechanically ventilated patients with sepsis. The use of Fentanyl is not an intervention of interest."
1911697|NCT02201004|Drug|TOFOGLIFLOZIN CSG452|Pharmaceutical form:tablet Route of administration: oral
1911698|NCT02201004|Drug|insulin|Pharmaceutical form:solution Route of administration: subcutaneous
1911699|NCT02201004|Drug|placebo|Pharmaceutical form:tablet Route of administration: oral
1967981|NCT02834754|Drug|Vedolizumab|Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin α₄β₇. Blocking the α₄β₇ integrin results in gut-selective anti-inflammatory activity. Vedolizumab was been approved by the Food and Drug Administration (FDA) in 2014 for achieving clinical response, achieving clinical remission, and achieving corticosteroid-free remission in adult patients with moderately to severely active Crohn's disease. We believe that use of vedolizumab constitutes a non-significant risk to the research subject. The dose of vedolizumab administered is 300mg IV
1967982|NCT02834754|Drug|placebo|Currently there are no clinical guidelines and no standard of care for the maintenance of surgically induced remission. There are no medications that have consistently been proven to be efficacious at preventing recurrent Crohn's disease and as such, no active equivalent arm is being used. Due to the lack of effective prophylactic therapy, many physicians and patients opt not to initiate medical therapy after surgery, rather wait until Crohn's disease recurs, or wait to perform a post-operative colonoscopy within 6-12 months of surgery, and decide on initiating Crohn's disease therapy based on endoscopic Rutgeerts; score. Therefore, acknowledging that many patients are not administered post-operative maintenance medications, we feel the placebo arm is justified.
1967986|NCT02833922|Behavioral|Women using Dot to avoid pregnancy|Women who have chosen to use Dot to prevent pregnancy will be followed for 13 cycles to assess perfect and typical use of the Dynamic Optimal Timing method.
1911723|NCT02197988|Drug|Exparel 1.33% (20ml Volume)|Transversus Abdominis Plane Block
1911724|NCT02197988|Drug|0.125% bupivicaine with 2 mcg/ml Fentanyl.|Thoracic Epidural Anesthesia
1968001|NCT02830269|Device|Transcranial Doppler ultrasonography measurements|Third ventricle diameter measurements with standard method (CT) and Transcranial Doppler ultrasonography
1911740|NCT02196350|Behavioral|Intervention A: Diet|subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice
1911741|NCT02196350|Behavioral|Intervention B: Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
1911742|NCT02196350|Behavioral|Intervention C: Diet and Exercise|subjects visit the physiotherapist three times weekly; subjects visit the dietitian at week 0, 1, 2, 6, 10 and 13 for dietary advice.
1911743|NCT02196909|Other|motor function and strength assessment|
1911744|NCT02196909|Other|NMR assessment|
1911745|NCT02196909|Other|24h urine and serum collection|
1911755|NCT02193971|Device|BS-DES (Biostable polymer drug-eluting stent)|
1911756|NCT02193971|Device|BD-DES (Biodegradable polymer drug-eluting stent)|
1911757|NCT02193971|Drug|Prasugrel 5mg|Use prasugrel 5mg daily for maintaning dose
1968019|NCT02827552|Other|skin biopsy|skin biopsy performed prior radiation to characterize in blind the individual radiosensitivity of the patient
1968045|NCT02821364|Other|Advanced Life Support|IV FLUIDS, INTUBATION
1968046|NCT02819635|Drug|ABT-494|Tablet
1968047|NCT02819635|Drug|Placebo|Tablet
1968048|NCT02818439|Other|evaluation of frailty|
1968052|NCT02815592|Drug|BMS-986012|
1968053|NCT02815592|Drug|Cisplatin|
1968054|NCT02815592|Drug|Etoposide|
1968055|NCT02815592|Drug|Platinum|
1968056|NCT02815592|Drug|Carboplatin|
1968057|NCT02815397|Drug|Metformin|given in addition to standard of care treatment
1968073|NCT02801656|Biological|Fecal Microbiota Transplantation|Oral, encapsulated FMT
1968074|NCT02801656|Drug|Vancomycin|Vancomycin po 125 mg qid x 10 days
1968075|NCT02801656|Biological|Fecal Microbiota Transplantation Placebo|Matching placebo to FMT
1968076|NCT02801656|Drug|Vancomycin Placebo|Matching placebo to Vancomycin
1968080|NCT02802020|Device|WallFlex Fully Covered Self Expanding Metal Stent|The WallFlex™ Pancreatic RX Fully Covered Soft Stent System consists of a flexible delivery system preloaded with a self-expanding pancreatic metal stent.
1911817|NCT02180672|Drug|Nasal Fluticasone|One spray per nostril, per day.
1911818|NCT02180672|Drug|Placebo|One spray per nostril, per day.
1911820|NCT02181231|Drug|venlafaxine XR|slow titration up to maximum dose of 300mg per day, will remain on venlafaxine XR for up to 32 weeks
1911821|NCT02181231|Drug|buprenorphine|randomized to either buprenorphine or placebo, dose range from 0.2 mg/ qd to 2mg/ qd
1911822|NCT02181231|Drug|Placebo|patients will remain on venlafaxine XR and be randomized to receive either placebo or buprenorphine for 8 weeks. at the end of the 8 weeks those who did not receive buprenorphine will be offered the opportunity to try it.
1968098|NCT02797431|Drug|Interleukin-7|IM administration of CYT107 recombinant glycosylated human IL-7 (SC administration for patients with INR>2.5 or platelet count < 35,000
1968099|NCT02797431|Drug|Placebo|IM administration of Placebo (SC administration for patients with INR>2.5 or platelet count < 35,000
1911843|NCT02177292|Radiation|Radiation Therapy|A high dose of radiation to the pelvic lymph nodes of 56 Gy (Gy/Gray = measure of amount of radiation) and at the same time give a boost (additional) radiation to the prostate itself (to 70 Gy).
1968107|NCT02794168|Drug|VAS203|Treatment
1968108|NCT02794168|Drug|Saline|Placebo
1968109|NCT02792283|Biological|whole blood collection|
1968112|NCT02791750|Other|questionnary of quality of life|
1911860|NCT02172950|Biological|rVIII‑SingleChain|Recombinant single-chain coagulation factor VIII
1988805|NCT02696603|Behavioral|Participant self-assessment surveys|At enrollment, participants are asked to complete a baseline health history and a participant-reported symptom inventory. Thereafter, participants are asked to respond to commonly used questions that assess Parkinson Disease symptoms and quality of life at regular intervals.
1988806|NCT02696603|Behavioral|Phonation|"Participants are asked to record themselves saying Aaah for 10 seconds using the iPhone microphone. This activity is designed to assess vocal features, including vocal tremor. The investigators extract features from the digital audio signals of these sustained phonations. The investigators apply feature selection and classifier algorithms and analyze these phonations using methods similar to those employed in the Parkinson Voice Initiative."
1988807|NCT02696603|Behavioral|Gait and balance|Participants are asked to walk back and forth for 30 seconds and then stand still for 30 seconds. Gait and balance are measured by gyroscope and accelerometer sensors. The investigators examine step-dependent and sequence-dependent features from these sensors. The investigators apply feature selection and classifier algorithms to analyze these data.
1988808|NCT02696603|Behavioral|Memory|Participants are asked to complete a visuospatial short-term memory game related to the Corsi block tapping test [Corsi, P.M. (1972)] as adapted by Kate Possin, PhD of the University of California San Francisco Memory and Aging Center (personal communication, 2015). In this activity, participants are presented with a grid of objects that change color in a set pattern. Participants are then asked to tap the objects in that same pattern. The investigators assess the sequence length completed.
1988809|NCT02696603|Behavioral|Dexterity|Participants are asked to tap on the phone screen with alternating fingers. This test can be done with either or both hands. The investigators record the rhythm, speed, and location of these taps using the touch sensors of the iPhone screen. The investigators assess participant dexterity through a combination of steadiness, speed, and tap precision.
1988810|NCT02696603|Behavioral|Participant open-response writing|Qualitative participant feedback is used to assess participant engagement with, understanding of, and acceptance of app-based research.
1988811|NCT02696603|Other|Parkinson mPower mobile application|Participants complete all described behavioral interventions via a dedicated iPhone app, Parkinson mPower.
1988812|NCT02694679|Behavioral|CBNH|The household-level intervention package targets health behaviors surrounding neonatal and maternal health, and diarrhea and respiratory illness prevention and management.
1988813|NCT02694224|Drug|vismodegib|Smo inhibitor
1988814|NCT02694224|Drug|Paclitaxel|Paclitaxel (80 mg/m2) weekly x 12 doses followed by sequential dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide (600 mg/m2) each 2 weeks x 4 doses with granulocyte macrophage colony stimulating factors (GM-CSF) support
1988815|NCT02694224|Drug|Epirubicin|dose dense Epirubicin (90 mg/m2) plus Cyclophosphamide each 2 weeks x 4 doses with GMCSF after Paclitaxel
1988816|NCT02694224|Drug|Cyclophosphamide|dose dense Cyclophosphamide (600 mg/m2) together with Epirubicin each 2 weeks x 4 doses with GMCSF after Paclitaxel
1968124|NCT02788045|Biological|Ad26.Mos.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 3 Ad26 vectors, one containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5 milliliter (mL) injection administered intramuscularly.
1968125|NCT02788045|Biological|Ad26.Mos4.HIV|Recombinant replication-deficient Ad26 vectored vaccine and consists of 4 Ad26 vectors, 2 containing a mosaic insert of envelope (Env) sequence, and 2 vectors containing mosaic inserts of Gag and Pol sequences (Ad26.Mos.1.Env + Ad26.Mos.2S.Env + Ad26.Mos1.Gag-Pol + Ad26.Mos2.Gag-Pol). Total dose is 5*10^10 viral particle per 0.5mL injection administered intramuscularly.
1968126|NCT02788045|Biological|Clade C gp140|Clade C gp140 vaccine containing 250 mcg of total protein, mixed with aluminum phosphate adjuvant, per 0.5 mL injection administered intramuscularly.
1968127|NCT02788045|Drug|Placebo|Normal saline 0.9 percent (%), 0.5 mL injection administered intramuscularly.
1911895|NCT02164539|Drug|FF|Fluticasone furoate is available as fluticasone furoate inhalation powder (100 mcg per blister), combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
1911896|NCT02164539|Drug|UMEC|Umeclidinium bromide is available as combination of fluticasone furoate/umeclidinium bromide inhalation powder (fluticasone furoate: 100 mcg per blister, umeclidinium bromide: 15.6, 62.5, 125, or 250 mcg per blister)
1911897|NCT02164539|Drug|VI|Vilanterol is available as vilanterol inhalation powder (25 mcg per blister) and combination of fluticasone furoate/vilanterol inhalation powder (fluticasone furoate: 100 mcg per blister, vilanterol: 25 mcg per blister)
1911909|NCT02162979|Drug|sildenafil|sildenafil 50mg BID for 2 weeks
1911910|NCT02162979|Drug|Placebo|
1968139|NCT02781311|Drug|setipiprant|Two 500 mg setipiprant tablets BID.
1968140|NCT02781311|Drug|placebo|Two placebo tablets BID.
1968143|NCT02780206|Other|Stable isotope amino acid infusion|such as glycerol, D2O, tyrosine, phenylalanine, glucose, arginine, and citrulline
1968146|NCT02775747|Biological|platelet rich plasma gel|Platelet rich plasma is prepared from fresh whole blood which is collected from a peripheral vein stored in acid citrare dextrose solution A (ACD-A)anticoagulant and processed to increase platelets by separating various components of blood
1968147|NCT02775747|Biological|saline|64 controlled women with recurrent cesarean section and fullfit to all inclusion and exclusion craiteria will reseve saline injection at time of wound closure
1911940|NCT02155855|Other|Telemedicine|Study group will test blood glucose at least 4 times a day Each time the meter timestamps the reading. All meter readings will upload to the cloud via Myglucohealth website, where they can be accessed by caregivers, including providers and parents. Parents will be notified by device about the blood glucose testing results. Provider will set device to alert patient or patient's family or send alerts if uploaded numbers are outside an identified range (<70 mg/dL > 300 mg/dL). As per the standard of care, parents are trained to administer sugar containing liquids, or inject extra insulin for hyperglycemia correction. Parents will be encouraged to contact study personnel if they are concerned about the diabetes control. Study personnel will access home blood glucose monitor data, and provide insulin dosing advice. Parents will be asked to upload blood glucose readings prior to each visit.
1911941|NCT02155855|Other|Control|Routine care
1911943|NCT02154477|Drug|intranasal insulin|
1911944|NCT02154477|Drug|placebo (intranasal saline)|
1968169|NCT02768701|Drug|Pembrolizumab|Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.
1968170|NCT02768701|Drug|Cyclophosphamide|A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
1968182|NCT02762955|Biological|BCD-057|BCD-057 is biosimilar of adalimumab (produced by BIOCAD).
1968183|NCT02762955|Biological|Humira®|Humira is the original adalimumab (produced by F. Hoffman-La Roche)
1968184|NCT02763566|Drug|Abemaciclib|Administered orally
1968185|NCT02763566|Drug|Anastrozole|Administered orally
1968186|NCT02763566|Drug|Letrozole|Administered orally
1968187|NCT02763566|Drug|Placebo|Administered orally
1968188|NCT02763566|Drug|Fulvestrant|Administered intramuscularly
1968189|NCT02762604|Behavioral|Imagined Gait Intervention|Phone-based imagined gait intervention: participants will be called by the experimenter three times a week and be asked to imagine walking, imagine talking and imagine walking-while-talking. They will also be asked to rate their visual and kinesthetic qualities of their images on a 1-5 scale following each trial.
1968190|NCT02762604|Behavioral|Visual Imagery Intervention|Phone-based visual imagery intervention: participants will be called three times a week by the experimenter and be asked to imagine concrete objects (e.g. octopus, teapot, and shovel). They will also be asked to rate their visual qualities of their images on a 1-5 scale following each trial.
1968193|NCT02761876|Behavioral|Mentor farmer training (Malawi)|Mentor farmers, 1 man, 1 woman, from each village will participate in a field visit to and training by existing mentor farmers in Malawi. Only the intervention arm of this study will receive mentor farmer training in Malawi, delayed intervention arm will receive mentor farmer training from farmers participating in the initial intervention in Tanzania.
1968194|NCT02761876|Behavioral|Mentor farmer training (Singida, Tanzania)|Mentor farmers will receive training in Singida, Tanzania on agroecology practices, climate change, nutrition, and gender equality. Intervention villages will receive training in 2016. Delayed intervention villages will receive training in 2019.
1968195|NCT02761876|Behavioral|Mentor farmer visits and facilitation|Mentor farmers will conduct monthly visits to participating households and support the households in conducting experimentation with agroecological practices and/or new behavior regarding nutrition and gender equality. Quarterly meetings among farmers within each village will be held to discuss progress and challenges of household experimentations. Intervention households will receive support and facilitation for approximately 2 years. Delayed intervention households will receive support and facilitation for approximately 6 months after end line survey.
1968204|NCT02759354|Other|Blood Sample|Blood sample at approx. 4 years of age
1968208|NCT02757352|Drug|Ixekizumab|Administered SC
1968209|NCT02757352|Drug|Placebo|Administered SC
1912002|NCT02139930|Behavioral|Normal Nicotine Control Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
1912003|NCT02139930|Behavioral|Immediate Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
1912004|NCT02139930|Behavioral|Gradual Nicotine Reduction Group|Participants will smoke experimental cigarettes for a period of 20-weeks.
1968224|NCT02754141|Biological|BMS-986179|Specified dose on specified days, intravenous (IV)
1968225|NCT02754141|Biological|Nivolumab|Specified dose on specified days, IV
1968227|NCT02752932|Other|Drug testing on PDX per Investigator's choice (upto 4)|Drug of Investigator's choice (upto 4 Ontario funded Chemotherapeutics) will be tested on PDX (Patient Derived Xenografts)
1968234|NCT02748798|Drug|HP 3He|3He will be hyperpolarized using a custom-built polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of helium gas.
1968235|NCT02748798|Drug|HP 129Xe|129Xe will be hyperpolarized using a Xemed polarizer to enhance its MRI signal. Hyperpolarization does not change the chemical or physical properties of xenon gas.
1968236|NCT02748798|Drug|PFP|Perfluoropropane (PFP) will be premixed and delivered to the participants with no further processing.
1968237|NCT02748798|Drug|SF6|Sulfur hexafluoride (SF6) will be premixed and delivered to the participant with no further processing.
1968238|NCT02748798|Device|129Xe Small and Large Human Lung Coil|The investigational 129Xe small and large quadrature lung coils are sensitive to 129Xe resonant frequencies and therefore will be paired with the investigational drug 129Xe. The size of the coil used will depend on the participants' body size.
1968239|NCT02748798|Device|3He Human Lung Coil|The investigational 3He quadrature lung coil is sensitive to 3He resonant frequencies and therefore will be paired with the investigational drug 3He.
1968240|NCT02748798|Device|PFP and SF6 Human Lung Coil|The investigational PFP and SF6 quadrature lung coil is sensitive to inert fluorinated gas resonant frequencies and therefore will be paired with both PFP and SF6.
1912042|NCT02134197|Drug|BAY1129980|Starting dose is 0.15mg/kg intravenous (I.V.) administration every 21 days.
1968253|NCT02742532|Drug|Oxytocin|Intranasal oxytocin 40 IU
1968254|NCT02742532|Drug|Placebo|Intranasal saline solution
1968269|NCT02740985|Drug|AZD4635|AZD4635 will be administered orally as a nanosuspension on a continuous schedule. The drug product will be constituted extemporaneously as an oral suspension by the patient immediately prior to dosing.
1968270|NCT02740985|Drug|Durvalumab|Durvalumab will be administered by intravenous infusion once every 4 weeks. Durvalumab should be reconstituted using aseptic techniques with sterile water for injection. The reconstituted solution will be diluted with 0.9% (w/v) saline prior to IV infusion.
1968273|NCT02737475|Drug|BMS-986178|Specified dose on specified days
1968274|NCT02737475|Drug|Nivolumab|Specified dose on specified days
1968275|NCT02737475|Drug|Ipilimumab|Specified dose on specified days
1968279|NCT02739022|Behavioral|Early Psychological Support for the Critically Ill (EPSCI)|early psychological support based on positive therapeutic suggestion
1912058|NCT02130869|Biological|CD133+ selected autologous stem cell infusion|Hematopoietic stem cells will be collected from children with high-risk solid tumors. After collection, they will be immuno-magnetically selected using CD133 as a marker in efforts to reduce tumor cell contamination in the stem cell graft. After high dose chemotherapy, those selected stem cells will be infused, followed shortly thereafter by an infusion of haploidentical natural killer cells.
1912059|NCT02130869|Biological|IL-2|Following infusion of haploidentical natural killer cells, interleukin-2 (IL-2) subcutaneously (SQ) will be given to support the in vivo survival of donor NK cells.
1912060|NCT02130869|Biological|hu14.18K322A|Participants with neuroblastoma (Group A) will receive hu14.18K322A intravenously (IV).
1912061|NCT02130869|Drug|Busulfan|Given IV - Group A only.
1912062|NCT02130869|Drug|Melphalan|Given IV - All groups.
1912063|NCT02130869|Biological|GM-CSF|Given SQ - All groups.
1912064|NCT02130869|Drug|Bendamustine|Given IV - Group B only.
1912065|NCT02130869|Drug|Etoposide|Given IV - Group B and Group C. In case of etoposide reactions, etoposide phosphate will be given.
1912066|NCT02130869|Drug|Cytarabine|Given IV - Group B only.
1912067|NCT02130869|Drug|Carboplatin|Given IV - Group C only.
1912068|NCT02130869|Device|Haploidentical natural killer cell infusion|NK cell product will be collected from donors using leukapheresis procedures. The autologous hematopoietic stem cell graft product will be positively selected using the investigational CliniMACS device and CD133 Microbead reagent. Following standard laboratory procedures, the NK cell product will be enumerated and assessed for viable cell content. NK cells will be infused by slow IV push over 3 to 15 minutes immediately after processing, evaluation and release testing.
1912069|NCT02130869|Biological|G-CSF|Given SQ - All Groups.
1912070|NCT02130869|Drug|Etoposide phosphate|In case of etoposide reactions, etoposide phosphate will be given IV. - Group B and Group C only.
1912071|NCT02130869|Device|CliniMACS|The mechanism of action of the CliniMACS Cell Selection System is based on magnetic-activated cell sorting (MACS). The CliniMACS device is a powerful tool for the isolation of many cell types from heterogeneous cell mixtures, (e.g. apheresis products). These can then be separated in a magnetic field using an immunomagnetic label specific for the cell type of interest, such as CD3+ human T cells.
1912079|NCT02128230|Drug|MEL-CFZ-TD-PACE|Melphalan and Carfilzomib will be given into a central venous catheter. Dexamethasone is a pill that is taken by mouth daily for 4 days. Thalidomide is a capsule taken by mouth for 4 days. Cisplatin, Adriamycin, Cyclophosphamide and Etoposide are all given into the vein (IV) by a continuous infusion through a central catheter for 4 days. After completion of the four days of continuous chemotherapy, a drug G-CSF will be given. This is a shot just under the skin to help the bone marrow and blood counts recover more quickly after chemotherapy.
1968288|NCT02731573|Drug|D-PLEX|D-PLEX will be administered as a single application during the open heart surgery (index procedure) immediately prior to sternal closure, as an adjunct to the standard care.
1968289|NCT02731573|Procedure|Open heart surgery|Subject will undergo open heart surgery according to standard of care
1968291|NCT02729194|Drug|Pazopanib|
1968292|NCT02729194|Other|Low Fat Diet|Registered subjects will take pazopanib by mouth with a low-fat meal (containing less than 400 calories and less than 10% fat or 10 grams per meal.
1968293|NCT02728518|Drug|Nebulized Amikacin|400mg twice daily nebulized amikacin
1968294|NCT02728518|Drug|Intravenous Amikacin|20mg/kg once daily intravenous amikacin
1968296|NCT02726438|Drug|Debio 1450|Debio 1450, 40 mg, powder for oral solution, for reconstitution in 5% dextrose in water.
1968299|NCT02723097|Behavioral|3 RP|
1968306|NCT02720523|Drug|ABT-494|Oral formulation
1968307|NCT02720523|Drug|Placebo|Oral formulation
1912098|NCT02122081|Radiation|radiation therapy|Undergo organ-sparing marrow irradiation BID on days -6 to -4
1912099|NCT02122081|Drug|cyclophosphamide|Given IV over 1-2 hours every 24 hours on days -3 to -2.
1912100|NCT02122081|Biological|anti-thymocyte globulin|
1912101|NCT02122081|Drug|tacrolimus|Given IV or PO
1912102|NCT02122081|Drug|methotrexate|Given IV
1912103|NCT02122081|Procedure|allogeneic bone marrow transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant on day 0
1912104|NCT02122081|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
1912105|NCT02122081|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic peripheral blood progenitor cell or bone marrow transplant
1912106|NCT02122081|Other|laboratory biomarker analysis|Correlative studies
1912113|NCT02121769|Drug|Omegaven|10% Omegaven 1g/kg/day, Intravenous by continuous infusion in conjunction with parenteral nutrition, until the patient no longer requires parenteral nutrition or until participation in the study is terminated.
1968320|NCT02714140|Behavioral|PB-HCT +|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and select those 2 PB-HCT options that jointly maximize the share of participants predicted to prefer at least one of the two options over all existing testing options. In addition, the investigators will offer a default option which combines the most common feature levels currently found in the study area.
1968321|NCT02714140|Behavioral|PB-HCT -|Participants will be offered 3 HIV testing options. The investigators will rank the predicted utility of all feasible HIV testing options for each participant and 2 PB-HCT options that are less preferred than the default option and whose utility differential to the default option is comparable to that of the more-preferred (PB-HCT +) options. In addition, the investigators will offer the same default option as in the PB-HCT + intervention, which combines the most common feature levels currently found in the study area.
1968322|NCT02714140|Behavioral|Economic incentive|Six months after the offer of testing options, all participants will be re-contacted. The date and location of participants' most recent HIV test will be ascertained; participants who did not test using either the more-preferred, less-preferred, or default options, will be asked if they had tested elsewhere. If they had not, they will be reminded of the options, and offered an incentive of 5,000 Tanzanian Shilling (~$3) to present for testing using any of the options; the incentive will be paid at the testing location.
1968327|NCT02709798|Drug|Shenfu Injection|
1968328|NCT02709798|Drug|5% Glucose Injection|
1968346|NCT02706626|Drug|brigatinib|Single arm phase 2 trial to investigate the clinical activity in patients with advanced non-small cell lung cancer
1968347|NCT02705105|Biological|Mogamulizumab + Nivolumab|i.v. administration
1968356|NCT02703571|Drug|ribociclib|
1968357|NCT02703571|Drug|Trametinib|
1912150|NCT02115048|Drug|Letrozole|
1912151|NCT02115048|Drug|Afatinib|
1968365|NCT02700568|Drug|axitinib|Initial dose of axitinib: 5 mg orally twice a day. Maintenance dose of axitinib: Increase or decrease dose based on individual safety and tolerability. Dose range of axitinib: 2 to 10 mg twice a day.
1968372|NCT02696785|Drug|Ixekizumab|Administered SC
1968373|NCT02696785|Drug|Placebo|Administered SC
1968374|NCT02696785|Drug|Adalimumab|Administered SC
1968383|NCT02689973|Behavioral|Self-Efficacy|"The introductory part included an abbreviated version of the education materials used in the control group. The self-efficacy materials and forms had four sections: (a) definitions of self-efficacy beliefs, (b) information on the importance of self-efficacy for goal pursuit, (c) recollecting a mastery experience, (d) persuasive statements evoking self-persuasive statements about self-efficacy beliefs. The materials ended with instructions for the following 7 days to recollect self-efficacy enhancing statements every morning. The procedures are based on a self-efficacy intervention by Luszczynska, Tryburcy et al. (2007).
Group and individual components were included. Setting: secondary and high schools."
1968384|NCT02689973|Behavioral|Planning|"The introductory part included an abbreviated version of the education materials used in the control group. The planning materials and forms had four sections: (a) information on the importance of planning, including examples of how planning works and what it affects, (b) instructions of what should be included in a good plan (the when, where, and how components), (c) formulating action and coping plans. The materials ended with instructions for the following 7 days to recollect/redo plans every morning.The procedures are based on a planning intervention by Luszczynska, Sobczyk, et al. (2007).
Group and individual components were included. Setting: secondary and high schools."
1988817|NCT02693834|Device|Posterior Leaf spring AFO|Posterior Leaf Spring AFO is an over the shelf polypropylene ankle foot orthosis to assist foot drop.
1988818|NCT02693834|Device|Double adjustable AFO|Double adjustable AFO is a custom AFO with double action metal upright joints
1988826|NCT02690584|Behavioral|Metacognitive therapy|
1988831|NCT02688088|Drug|Drug Cocktail|Administered orally
1988832|NCT02688088|Drug|Abemaciclib|Administered orally
1988835|NCT02687386|Drug|Mitoxantrone packaged EDV (EnGeneIC Delivery Vehicle)|EnGeneIC Delivery Vehicles (EDVs) are nanocells which can be loaded with anti-cancer drugs (mitoxantrone in this study) and targeted to tumor cells. These bacterially-derived nanocells are coated in bispecific antibodies (BsAb) that recognize oncogenic receptors on the tumor cell surface. Once bound to the tumour cell, the targeted and drug-loaded EDVs are endocytosed and release their toxic payload to destroy the tumor cell.
1997691|NCT01964430|Drug|nab-Paclitaxel 125 mg/m2|nab-Paclitaxel 125 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by intravenous (IV) administration, followed by gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 days cycle by IV administration for a total of 6 cycles
1997692|NCT01964430|Drug|gemcitabine 1000 mg/m2|nab-Paclitaxel 125 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by intravenous (IV) administration, followed by gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 days cycle by IV administration for a total of 6 cycles
1997693|NCT01964430|Drug|gemcitabine 1000 mg/m2|Gemcitabine 1000 mg/m2 on Days 1, 8, and 15 of a 28 day cycle by IV administration for a total of 6 cycles
1968385|NCT02689973|Behavioral|Education|"Participants received a set of educational materials about types of physical activity (PA), PA intensity, exercise calorie expenditure, myths about PA, strength and endurance training, stretching, and general healthy nutrition guidelines. The materials excluded planning and self-efficacy statements.
The materials ended with instructions for the following 7 days to recollect forms of MVPA every morning.
Group and individual components were included. Setting: secondary and high schools."
1968388|NCT02685202|Device|Mandibular advancement splint|A mandibular advancement splint (MAS), functions by comfortably positioning the patient's mandibular in a forward position, clearing the obstructed airway during sleep.
1968389|NCT02680795|Drug|Belinostat IV|"Cohort A:
Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
1912190|NCT02109744|Drug|Decitabine|
1968390|NCT02680795|Drug|Belinostat IV|"Cohort B:
Belinostat 1000mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
1968391|NCT02680795|Drug|Belinostat|"Cohort C:
Belinostat 750mg will be administered once daily on days 1 through 5 of one 21-day cycle via 30-minute IV infusion."
1968392|NCT02680301|Drug|0.1% triamcinolone CREAM|Patients will be asked to apply a topical steroid in a cream formulation to one extremity using the wet wrap technique.
1968393|NCT02680301|Drug|0.1% triamcinolone OINTMENT|Patients will be asked to apply a topical steroid in a ointment formulation to one extremity using the wet wrap technique.
1968394|NCT02679131|Drug|Belinostat|Belinostat will be administered once daily on days 1 to 5 of a 21-day cycle (up to 6 cycles) via 30-min. IV infusion.
1912205|NCT02106546|Drug|veliparib|Oral Capsule
1912206|NCT02106546|Drug|carboplatin|Intravenous infusion
1912207|NCT02106546|Drug|paclitaxel|Intravenous infusion
1912208|NCT02106546|Drug|placebo|Oral Capsule
1912211|NCT02106416|Procedure|PET/MRI|Simultaneous PET/MRI (3T system)
1968415|NCT02675114|Procedure|Surgical aortic valve replacement (SAVR)|SAVR with a commercially available bioprosthetic valve.
1968416|NCT02675114|Device|Transcatheter Aortic Valve Replacement (TAVR)|TAVR with the Edwards SAPIEN 3 Transcatheter Heart Valve and Edwards Commander Delivery System
1968421|NCT02672475|Drug|Galunisertib|Given PO
1968422|NCT02672475|Other|Laboratory Biomarker Analysis|Correlative studies
1968423|NCT02672475|Drug|Paclitaxel|Given IV
1968424|NCT02670343|Drug|Oral Testosterone Undecanoate|Subjects will receive a single dose containing 158 mg of testosterone undecanoate, equivalent to 200 mg testosterone.
1912232|NCT02102750|Drug|Preservative free tafluprost opthalmic solution|0.0015% eye drops q.d, in both eyes for 7 to 9 days
1968427|NCT02668341|Other|non-interventional|non-interventional survey study
1968433|NCT02665845|Drug|5-ASA|5ASA treatment (oral 5ASA will be given to all patients in this arm, in addition to topical 5ASA in patients who tolerate it).
1968434|NCT02665845|Drug|Corticosteroids|Corticosteroids will be given to all patients.
1912266|NCT02100722|Procedure|FFR guided PCI|
1912267|NCT02100722|Procedure|CABG|
1912275|NCT02099825|Drug|d-cycloserine and mifepristone|All participants will receive a one-time only dose of both, d-cycloserine and mifepristone at Session 2
1994128|NCT03058614|Drug|CEUS|In subjects randomized into the CEUS arm, 2 mL of Lumason will be injected as a single dose via a nephrostomy tube at the time of postoperative renal ultrasound, following by 5 mL of normal saline flush. Subjects will be given up to one additional dose injected in the same fashion as indicated during the imaging study to confirm opacification of the ureter.
1994129|NCT03058614|Diagnostic Test|Non-contrast CT scan|The CT scan performed in this study arm is regularly performed to evaluate the kidney and look for residual stones after surgery both at UCSF and around the world. It does not require contrast injection, so risks from contrast allergy or any injection are absent. A low dose protocol will be used, and therefore, subjects will be exposed to a very small amount of ionizing radiation as low as 1-2 mSv if randomized into this arm.
1994130|NCT03058614|Diagnostic Test|Capping trial|Subjects who are randomized into this study arm will undergo both nephrostomy tube capping and a low dose non-contrast CT scan on the first day after surgery. Successfully passing a capping trial is defined as the absence of fever, worsened flank pain, and leakage around the nephrostomy tube within 4 hours after capping the tube.
1912285|NCT02098343|Drug|APR-246|Intravenous infusion.
1912286|NCT02098343|Drug|Carboplatin and Pegylated Liposomal Doxorubicin Hydrochloride (PLD)|Intravenous infusion.
1912338|NCT02088099|Other|Treatment as usual|Participants in this arm will receive, experience, or provide the care that is usual and customary in their communities.
1912312|NCT02094222|Drug|RAVICTI|open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks
1968463|NCT02657213|Device|Minimed 640G with smartguard activated|Patients will be equipped with a Minimed 640G insulin pump coupled with Enlite sensor with SmartGuard activation
1968464|NCT02657213|Device|Minimed 640G with smartguard off|Patients will be equipped with Minimed 640G insulin pump coupled with Enlite glucose sensor without SmartGuard activation
1912318|NCT02092818|Drug|Riociguat(BAY63-2521)|The decision on clinical management of the patient including the actual treatment duration will be determined solely by the physician not by the clinical study protocol (CSP)
1968466|NCT02656667|Device|neuromuscular electrical stimulation|quadriceps strenghthening with neuromuscular electrical stimulation (medical device)
1968467|NCT02656667|Device|cycle ergometer training|quadriceps strenghthening with cycle ergometer training
1912321|NCT02091869|Other|Paper Asthma Action Plan|Participants will utilize a paper based asthma action plan to record asthma symptoms and medication usage.
1912322|NCT02091869|Device|Mobile Phone|Participant will be able to log peak flow data, medications, and symptoms in their mobile phones utilizing the mobile app.
1968468|NCT02656667|Other|Conventional pulmonary rehabilitation|excercise training on treadmill
1968469|NCT02656069|Drug|G-Pen™ (glucagon injection)|1 mg of pre-mixed liquid Xeris glucagon delivered via auto-injector
1968470|NCT02656069|Drug|Lilly Glucagon (glucagon injection [rDNA origin])|1 mg of Lilly glucagon reconstituted from lyophilized powder
1968476|NCT02653118|Biological|V503|
1968477|NCT02653118|Biological|GARDASIL|
1912337|NCT02088099|Other|Complex clinical intervention|The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
1968482|NCT02652052|Drug|Quercetin|Quercetin - take four 250mg capsules daily (total 1000 mg daily) for 3 consecutive days.
1968483|NCT02652052|Other|Standard of Care - Observation Only|Control Arm - Observation only
1968484|NCT02652052|Drug|Dasatinib|Dasatinib - take one 100 mg tablet by mouth once daily for 3 consecutive days
1994308|NCT03031938|Drug|Investigational medical product (IMP) administered in parent study|IMP as administered in parent study. IMP would have been either placebo, tanezumab, celecoxib, naproxen, diclofenac, administered in parent study
1994310|NCT03032965|Drug|Adenosine|"Subject will receive 6-24 mg of intravenous adenosine given rapidly for each PV in order to assess dormant PV conduction.
Subjects in this group will also receive isoproterenol to assess inducibility of AF with re-isolation of PVs and targeting non PV sources of AF if necessary.Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate."
1994311|NCT03032965|Drug|Isoproterenol|Isoproterenol will be infused through a femoral vein at rates of 5, 10, 15, and 20 μg/min for 2 minutes at each infusion rate. The isoproterenol infusion will be discontinued upon induction of AF, a decrease in systolic blood pressure to<85 mmHg, complaints of severe chest tightness, electrocardiographic changes suggestive of ischemia, or upon completion of the infusion protocol.
1994314|NCT03032757|Dietary Supplement|Essential amino acids|240 mg essential amino acids per kg body weight dissolved in 500 ml of water provided after exercise.
1994316|NCT03030950|Drug|Dexmedetomidine|to investigate the effect of dexmedetomidine on motor and sensory properties of adductor canal block
1994317|NCT03030950|Drug|Normal saline|to give normal saline to the other group as a placebo
1912346|NCT02085499|Device|non-synchronized NIMV|"During the study each infant will undergo a 2-hour period of NIMV at a frequency of 30 cycles per minute.
NIMV will be provided by a time cycled, pressure limited neonatal ventilator (Puritan Bennett 840, Covidien, Boulder, CO)."
1912347|NCT02085499|Device|Synchronized NIMV|"During the study each infant will undergo a 2-hour period of S-NIMV at a frequency of 30 cycles per minute.
S-NIMV will be provided by a time cycled, pressure limited neonatal ventilator, with leak compensation capacity and nasal flow triggered ventilation (Puritan Bennett 840, Covidien, Boulder, CO). Synchronization will be achieved by the leak compensation software and the internal sensor of the ventilator."
1912354|NCT02082015|Device|Low frequency rTMS|Intensity: 100% of resting motor threshold; Location: Motor hotspot in primary motor cortex for the dominant hand; Frequency: 1Hz; Number of total stimuli: 1800; Coil orientation: tangential to scalp
1912356|NCT02081378|Drug|ABL001|ABL001 will be administered orally in a dose escalation schedule.
1912357|NCT02081378|Drug|ABL001 + Nilotinib|ABL001 and Nilotinib will be administered orally in CML patients
1912358|NCT02081378|Drug|ABL001|ABL001 will be administered orally in Ph+ ALL patients
1912359|NCT02081378|Drug|ABL001+imatinib|ABL001 and imatinib will be administered orally in CML patients
1912360|NCT02081378|Drug|ABL001+dasatinib|ABL001+dasatinib will be administered orally in CML patients
1968505|NCT02638519|Other|Traditional Proton fMRI|Conventional proton fMRI will be performed. During the functional imaging acquisitions, the participant will be asked by the research team to perform simple tasks. These tasks will be completed while the participant breathes air (normal breathing).
1968506|NCT02638519|Other|Hyperpolarized Xenon-129 fMRI|HP 129Xe fMRI data will be acquired from all participants. Hyperpolarized xenon (NeuroXene) is expected to produce images that provide more clinically relevant information than traditional proton scans. Simple tasks will be performed by participants while breathing NeuroXene according to several inhalation procedures.
1968507|NCT02638519|Drug|Hyperpolarized Xenon-129|Participants will be asked to inhale specified amounts of NeuroXene according to several inhalation procedures. NeuroXene is the trade name for hyperpolarization of xenon-129 balanced with oxygen and nitrogen using a Xemed LLC polarizer. Hyperpolarization does not change the chemical or physical properties of xenon gas.
1968508|NCT02638519|Device|1H-129Xe Dual-Tuned Quadrature Head Coil|A 1H-129Xe dual-tuned quadrature head coil (Clinical MR Solutions, LLC) will be used in this study. The RF coil will be used to acquire MRI images of the human brain after inhalation of hyperpolarized xenon-129 gas, and permits the acquisition of both conventional proton and HP xenon gas images.
1912368|NCT02080286|Behavioral|Prism Adaptation|All participants will undergo prism adaptation, a form of behavioural therapy involving reaching and pointing movements while wearing glasses that induce an optical shift.
1912369|NCT02080286|Device|Anodal tDCS|"Participants will receive 1mA anodal tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.
The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
1912370|NCT02080286|Device|Sham tDCS|"Participants will receive 1mA sham tDCS over the left primary motor cortex. The active (positive) electrode will be centered on the scalp overlying the primary motor cortex and the reference (negative) electrode will be placed over the contralateral supraorbital ridge.
The stimulation will last 20 minutes and run concurrent with the duration of the prism adaptation therapy."
1968512|NCT02638909|Drug|ceritinib|Treatment with ceritinib will continue until patient experiences unacceptable toxicity that precludes further treatment, discontinues treatment at the discretion of the investigator or patient, starts a new anticancer therapy and/or dies.
1994323|NCT03029637|Device|RBBs with no or minimal preparation of their abutment teeth|Placement of resin bonded bridges on teeth with no or minimal cutting of their supporting teeth
1994324|NCT03029637|Device|RBBs with routine tooth preparation of their abutment teeth|Placement of resin bonded bridges on teeth after routine cutting of their supporting teeth
1994327|NCT03029364|Behavioral|Study Protocol|"Participants will complete two study protocols 7 - 14 days apart which includes:
2 x main trial days (max. 150 mins) involving body composition analysis, indirect calorimetry, a blood sample, optional muscle and / or adipose tissue biopsies and a maximal cardiorespiratory fitness test.
2 x lifestyle monitoring periods (physical activity and diet) for the prior 7 days before each main trial day.
Maintenance of habitual habits, dietary and physical activity behaviour patterns
We are observing biological / health parameters in a group of individuals who will be assessed under resting and exercising conditions. Additionally, there is an optional approx six-month follow up body composition assessment. The current study does not involve an intervention."
1994328|NCT03027479|Other|Samples|Blood samples, muscle biopsy, adipose tissue samples and ovarian cancer tumor sample
1994329|NCT03028532|Drug|Clomid|Participants will self-administer Clomid (50mg oral tablet) once daily for 30 consecutive days
1994332|NCT03027492|Other|Gluten free diet|The investigators will evaluate the modification of gynaecological disorder after a gluten (wheat)-free diet.
1994333|NCT03028467|Drug|GSK3196165 Dose 1|GSK3196165 is supplied as liquid and will be administered as SC injection.
1994334|NCT03028467|Drug|GSK3196165 Dose 2|GSK3196165 is supplied as liquid and will be administered as SC injection.
1912384|NCT02079064|Drug|Desflurane|Inhalational anesthetic
1912385|NCT02079064|Drug|Propofol|Intravenous anesthetic that can be given by continuous infusion
1968531|NCT02631876|Drug|IMGN853|
1968532|NCT02631876|Drug|Paclitaxel|
1968533|NCT02631876|Drug|Doxorubicin|
1968534|NCT02631876|Drug|Topotecan|
1968537|NCT02629822|Drug|MK-1439A|A single FDC tablet of MK-1439 100 mg/lamivudine 300 mg/tenofovir disoproxil fumarate 300 mg will be administered orally, once daily for up to 96 weeks. For some participants who continue into the study extension, study treatment will continue for an additional 96 weeks, approximately, through a total of approximately 192 weeks of treatment.
1912400|NCT02075489|Other|Acupressure treatment.|Acupressure will be provided 40 min/day, 2 days/week for 6 weeks (total of 12 sessions). Symptomatic veterans will receive standardized acupressure treatment for ~5 s on each acupoint until the subject gets the sense of soreness and numbness, and the procedure will be repeated three times. Kneading massage will be applied around eyes and forehead, and face will be swabbed by palm for ~ 5 min. Manipulation of these acupoints is aimed at helping to calm and ease the subject, lighten headache and migraine, relieve fatigue, and alleviate insomnia.
1912401|NCT02075489|Other|Reiki|Veterans in the control group will receive reiki treatment with the same dosage (40 min/session, 12 sessions in 6 wks). The practitioner will place his/her hands on the recipient in various positions covering head, the back of the torso, and the 4 limbs with fixed set of 12 hand positions. These covered areas will then be tapped and stroked, and practitioner will focus his/her gaze on these areas for 2-3 min, through which the healing energy is transferred to the subjects. In a format similar to acupressure treatment, it will be used as an inert control treatment to balance additional care the experimental group will receive.
1912408|NCT02073474|Drug|Sativex®|Contains delta-9-tetrahydrocannabinol (THC), 27 mg/mL; cannabidiol (CBD), 25 mg/mL; in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each actuation delivers THC 2.7 mg and CBD 2.5 mg.
1968558|NCT02624557|Drug|Alpelisib|Subjects will receive a single dose of 300 mg alpelisib.
1912427|NCT02068157|Other|Laboratory Biomarker Analysis|Correlative studies
1912428|NCT02068157|Drug|Photodynamic Therapy|Undergo image-guided I-PDT
1912429|NCT02068157|Drug|Porfimer Sodium|Given IV
1912436|NCT02065622|Drug|Adalimumab|
1912437|NCT02065622|Other|Placebo|
1912438|NCT02065570|Drug|Adalimumab|
1968566|NCT02617563|Device|Minimally invasive lumbar fusion|Patients will receive a single or double level instrumented fusion using a minimally invasive/MAST™ PLIF, TLIF, DLIF, OLIF, ALIF or MIDLF surgical procedure with a posterior fixation. For the use of a posterior fixation system, the CD Horizon® Spinal System, is mandatory in this study and will be either mini-open and/or percutaneous.
1912445|NCT02064387|Drug|GSK2857916|A clear or opalescent solution for IV infusion with unit dose strength of 20 mg/mililiter (mL) for multiple dose levels.
1912453|NCT02062775|Procedure|Use of self-fixating mesh for inguinal hernia repair|Parietex ProGrip will be used to repair inguinal hernia
1912454|NCT02062775|Procedure|Use of non-fixating mesh for inguinal hernia repair|Parietex Anatomic mesh will be used to repair inguinal hernias.
1912455|NCT02062775|Procedure|Absorbable tacks may be used in hernias >2cm|Patients randomized to the Parietex ProGrip study group will be further randomized to either receive absorbable tacks or no tacks if the hernia measures >2cm
1912461|NCT02061774|Drug|Acetaminophen|1 gram of intravenous Acetaminophen
1912462|NCT02061774|Drug|Placebo comparator|placebo comparator .9% NaCl (sodium chloride) 100 mL over will be administered intravenously over a period of 15 minutes, 15 minutes (+/- 10 minutes) prior to the anticipated time of incision and every 6 hours (+/- 30 minutes) after the initial dose for 24 hours
1968579|NCT02616120|Drug|SQJZ herbal mixtures|The SQJZ herbal mixtures is Chinese herb extracts. It contains Rehmannia glutinosa Libosch，Astragalus membranaceus (Fisch.) Bunge etc.( 29.375g, 2 times per day)
1968580|NCT02616120|Drug|Placebo|placebo contains 5%SQJZ herbal mixtures and 95% dextrin,identified to SQJZ herbal formula (29.375g, 2 times per day)
1968583|NCT02615704|Device|Active group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool and with MEMS
1968584|NCT02615704|Device|Active group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid with APP as support tool but without MEMS
1968585|NCT02615704|Device|Control group with MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool but with MEMS
1968586|NCT02615704|Device|Control group without MEMS|Patients treated with twice daily Brilique (ticagrelor) co administered with low dose of acetylsalicylic acid without APP as support tool and without MEMS
1968598|NCT02611427|Behavioral|Education/Self-efficacy|The education/self-efficacy group will 1) receive information about benefits of physical activity and national activity guidelines, 2) receive instruction on how to increase lifestyle walking, 3) use movement monitoring devices, 4) make a walking contract and 5) receive interval contract-directed encouragement from study personnel.
1968599|NCT02611427|Behavioral|Education|The education group will receive information about safe physical activity.
1968602|NCT02609659|Drug|ombitasvir/paritaprevir/ritonavir and dasabuvir|Tablet; ombitasvir coformulated with paritaprevir and ritonavir, dasabuvir tablet
1968603|NCT02609659|Drug|ribavirin|Tablet
1997699|NCT01962103|Drug|nab-paclitaxel|nab-paclitaxel 100-240 mg/m2 IV on Days 1, 8 and 15 of a 28-day cycle
1997701|NCT01960036|Behavioral|Mindful Awareness in Body-oriented Therapy|
1997702|NCT01960036|Behavioral|Womens Health Education|
1997711|NCT01954966|Drug|Progesterone|Participants will consume four pills of Progesterone over a period of four days. Participants will be asked to remain abstinent from smoking while taking Progesterone.
1997712|NCT01954966|Drug|Placebo|Participants will consume four pills of Placebo over a period of four days. Participants will be asked to remain abstinent from smoking while taking Placebo.
1997713|NCT01952470|Drug|Dornase Alpha|Once daily, 2.5ml inhaled dornase alpha (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
1997714|NCT01952470|Drug|Isotonic Saline.|Once daily, 5ml inhaled 0.9% normal saline (evening if able) with inhalational breathing routine (IBR). IBR consists of 4 slow deep breaths followed by 6 relaxed breaths, repeated until nebuliser is complete, coughing when the patient feels the need to expectorate. The patient will be instructed to sit in an upright position with upper limb support as able.
1997716|NCT01951469|Drug|Gefitinib and Pemetrexed/cisplatin|Gefitinib 250mg is Taken Orally on day 4-28,combined Pemetrexed/cisplatin chemotherapy on day 1-3, every 28 days
1997717|NCT01951469|Drug|Gefitinib mono-therapy|Gefitinib 250mg is Taken Orally everyday
1997718|NCT01951482|Drug|Pemetrexed/cisplatin|receive Pemetrexed/cisplatin every 21 days
1997719|NCT01951482|Drug|Bevacizumab and Pemetrexed/cisplatin|receive Bevacizumab 7.5mg/kg and Pemetrexed/cisplatin every 21 days
1997720|NCT01950390|Biological|Bevacizumab|Given IV
1997721|NCT01950390|Biological|Ipilimumab|Given IV
1997722|NCT01950390|Other|Laboratory Biomarker Analysis|Correlative studies
1997723|NCT01950156|Biological|HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant|Open Label, Non-Randomized, Safety/Efficacy study: patients will be vaccinated subcutaneously once a week with HLA-A*2402restricted URLC10, CDCA1, and KIF20A peptides with adjuvant.
1997724|NCT01948947|Device|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the dorsal lateral prefrontal cortex.
1997725|NCT01948947|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will be shielded from the magnetic field of the coil.
1997726|NCT01947894|Other|Non Interventional Study|Non Interventional Study
1997727|NCT01946854|Behavioral|Questionnaire|"Completion of 3 questionnaires at baseline and at final visit about quality of life, and 1 questionnaire about symptoms, diagnosis, treatment, prognosis, and patient's relationship with caregivers. These will take about 35-50 minutes to complete.
Completion of 3 quality of life questionnaires every 3 months for 1 year."
1968612|NCT02605395|Drug|IDIAZOLE 20mg DR tabs|IDIAZOLE 20mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg of rabeprazole sodium.
1968613|NCT02605395|Drug|PARIET 20 mg DR tabs|PARIET 20 mg DR tabs is a delayed-release, enteric-coated tablets containing 20 mg rabeprazole sodium.
1968614|NCT02603757|Dietary Supplement|cholecalciferol|2,000 IU of Vitamin D3 daily and 50,000 IU Vitamin D3 daily
1968630|NCT02597712|Drug|YF476|gastrin receptor antagonist
1968631|NCT02597712|Drug|YF476 placebo|placebo
1912523|NCT02053792|Biological|rIX-FP|Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP)
1968647|NCT02594501|Device|COBRA PzF|
1968648|NCT02594501|Device|Drug Eluting Stent|
1968649|NCT02594267|Drug|Pralatrexate Injection|"Drug: Folotyn (Pralatrexate Injection)
CHOP : Cyclophosphamide, Doxorubicin, Vincristine, & Prednisone"
1968668|NCT02588573|Device|1-Day Acuvue® Moist contact lens|
1968669|NCT02588573|Device|Clariti 1-day contact lens|
1968672|NCT02586480|Device|dual chamber pacemaker with SafeR algorithm|SafeR is an AVB management algorithm: it provides AAI pacing while continuously monitoring AV conduction, it switches to DDD when detecting AVB I, II or III, according to the following criteria: (1) AVB I: 6 long PR intervals, (2) AVB II: 3 blocked atrial events/12 cycles, (3) AVB III: 2 consecutive blocked atrial events. It switches back to AAI mode when needed.
1968710|NCT02574546|Procedure|Mastectomy|Unilateral breast cancers planning bilateral mastectomy procedures.
1968738|NCT02564744|Drug|Debio 1562|Debio 1562 will be given on the same day as rituximab, once every three weeks (Q3W) intravenously (IV) at the dose of 0.7 mg/kg on Day 1 of a 21-day cycle.
1968739|NCT02564744|Drug|Rituximab|Rituximab will be given on the same day as Debio 1562, Q3W IV at a dose of 375 mg/m^2 on Day 1 of a 21-day cycle.
1968740|NCT02565979|Dietary Supplement|resveratrol|Resveratrol will be given for 6 months, twice daily. One pill, which contains 75 mg of resveratrol, will be provided with lunch, and the other pill, also containing 75 mg will be given with dinner. So in total a dose of 150 mg/day will be given.
1968741|NCT02565979|Dietary Supplement|placebo|A placebo will given for 6 months, twice daily. One pill will be provided with lunch, and the other pill will be provided with dinner.
1968742|NCT02565511|Biological|CAD106 Immunotherapy|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
1968743|NCT02565511|Other|Placebo to CAD106|Participants will be given i.m. injections at Weeks 1, 7, 13 and quarterly i.m. injections (every 13 weeks) thereafter, until the last injection 3 month prior to completion of the Treatment Epoch.
1968744|NCT02565511|Drug|CNP520|CNP520 50 mg capsule p.o. for the duration of the Treatment Epoch.
1968745|NCT02565511|Other|Placebo to CNP520|Placebo to CNP520 p.o. for the duration of the Treatment Epoch
1968750|NCT02563821|Procedure|Patient Controlled Epidural Analgesia for third trimester termination of preganancy analgesia|
1968751|NCT02563821|Drug|Levobupivacaine|
1968752|NCT02563821|Drug|sufentanil|
1968753|NCT02563821|Drug|clonidine|
1968754|NCT02563821|Device|epidural catheter|
1968763|NCT02562235|Drug|Riociguat (Adempas, BAY63-2521)|The individual optimal (maintenance) dose is to be determined based on patients' monitoring of systolic blood pressure, well-being and clinical status.
1912614|NCT02037737|Drug|Abatacept|
1912625|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d|Docetaxel 75 mg/m2 + prednisone 10 mg/d + abiraterone 1000 mg/d in 21 day cycles.
1912626|NCT02036060|Drug|docetaxel 75 mg/m2 + prednisone 10 mg/d|Docetaxel 75 mg/m2 plus prednisone 10 mg/d in 21 day cycles.
1912651|NCT02032654|Drug|Flucloxacillin|
1912652|NCT02032654|Drug|Placebo (for flucloxacillin)|Sugar capsule manufactured to mimic flucloxacillin 500mg capsules
1912653|NCT02032823|Drug|Olaparib|Patients will be administred olaparib orally twice daily (b.i.d.) at 300 mg. Two (2) x 150 mg olaparib tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
1912654|NCT02032823|Drug|Placebo|Patients will be administred matching placebo. Two (2) tablets should be taken at the same times each morning and evening of each day, approximately 12 hours apart with approximately 240 ml of water.
1968802|NCT02547922|Biological|Anifrolumab|Administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
1968803|NCT02547922|Drug|Placebo|Administration administration every 4 week from Week 0 to Week 100 in addition to SOC which will continue until Week 112
1968805|NCT02544100|Other|Database Entry/Biospecimen Collection|blood, urine, CFS samples and medical data collected
1968825|NCT02540226|Drug|Intravenous tranexamic acid|
1968826|NCT02540226|Drug|Topical tranexamic acid|
1968827|NCT02540226|Drug|Intravenous saline|
1968828|NCT02540226|Drug|Topical saline|
1968829|NCT02539394|Drug|Methylprednisolone Acetate|Methylprednisolone Acetate is a corticosteroid known to reduce swelling and inflammation.
1968830|NCT02539394|Other|Hemostatic Matrix Kit|Hemostatic Matrix Kits help prevent uncontrollable bleeding in a operative site during a procedure.
1912684|NCT02025205|Device|Endobronchial Valve|Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve
1912685|NCT02024672|Other|Immediate postpartum placement of IUD|pelvic exam, transvaginal ultrasound (3 during the course of the study), bleeding and symptom diary
1968841|NCT02536118|Device|Micra Transcatheter Pacing System|The Micra system is a miniaturized single chamber pacemaker system that is delivered via catheter through the femoral vein and is implanted directly inside the right ventricle of the heart. The Micra implantable device is a self-contained, hermetically enclosed, miniaturized single chamber pacemaker. The device is fixated via four electrically inactive nitinol tines, located on the distal end of the device.
1968843|NCT02535208|Other|Restrictive transfusions based on SCOR assessment|RBC transfusions will be given to subjects either when participants' Hgb levels fall below defined values based on respiratory status or, despite not having reached their Hgb trigger threshold, if they manifest symptoms judged by the clinical care team to be consistent with anemia (i.e. apnea, bradycardia, or desaturation episodes) and subsequently have a NIRS evaluation that demonstrates an SCOR < 0.73.
1968844|NCT02535208|Other|Liberal transfusions|In the liberal group, RBC transfusions will be given to participants when their Hgb level falls below defined values that are based on respiratory support status, as is standard practice.
1968845|NCT02534506|Drug|Urelumab|
1968846|NCT02534506|Drug|Nivolumab|
1968848|NCT02532855|Drug|Sitagliptin|Sitagliptin 100 mg oral tablet
1968849|NCT02532855|Drug|Dapagliflozin|Dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Dapagliflozin 10 mg daily may be down-titrated to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
1968850|NCT02532855|Drug|Metformin|Supply of background metformin oral tablet(s) (at least 1500 mg daily) will be the responsibility of the participant throughout the duration of the study.
1968851|NCT02532855|Drug|Matching placebo to sitagliptin|Matching placebo to sitagliptin 100 mg oral tablet
1968852|NCT02532855|Drug|Matching placebo to dapagliflozin|Matching placebo to dapagliflozin 5 mg or 10 mg oral capsule. Up-titration to matching placebo to dapagliflozin 10 mg daily may be delayed if participant is unable to tolerate up-titration in the opinion of the investigator. Matching placebo to dapagliflozin 10 mg daily may be down-titrated to matching placebo to dapagliflozin 5 mg daily if participant is unable to tolerate the higher dose in the opinion of the investigator.
1968853|NCT02532855|Drug|Sulfonylurea|The dose of the sulfonylurea agent will be required to be at least 50% of maximum labeled dose, consistent with near maximum efficacy of the sulfonylurea agent.
1968861|NCT02531035|Drug|Sotagliflozin|Sotagliflozin, once daily, before the first meal of the day
1968862|NCT02531035|Drug|Placebo|Placebo, once daily, before the first meal of the day
1968867|NCT02520752|Drug|INC280|
1968868|NCT02520752|Drug|Midazolam|
1968869|NCT02520752|Drug|Caffeine|
1968873|NCT02521831|Drug|Spinal Anesthesia (bupivacaine)|Bupivacaine is an amide-type, long-acting local anesthetic. Brand names include Exparel, Marcaine, and Sensorcaine.
1968874|NCT02521831|Drug|General Anesthesia (isoflurane)|Isoflurane is a fluorinated ether with general anesthetic and muscle relaxant effects. Brand names include Forane and Terrell.
1968877|NCT02522806|Procedure|endometrial biopsy|Endometrial biopsy (EB) between J17 and J22 of previous ovarian hyperstimulation cycle
1968878|NCT02520089|Procedure|bone autograft of iliac crest|The investigators will take bone autograft of iliac crest of the patient and then apply into the site of pseudoarthrosis, this graft have osteogenic, osteoinductive and osteoconductive properties
1968879|NCT02520089|Procedure|Platelet Rich Plasma|Sample of 40 mL of peripheric blood and processed to obtain 5 mL of platelet rich plasma, and collocated into pseudoarthrosis
1912743|NCT02017457|Biological|Donor lymphocyte infusion|"On day 1 of cycle 2, 4 and 6 of Azacytidine, patients will be infused with donor lymphocytes (ideally on day 1 but in case of organizational problems, DLI can be administered until day 5) .
Patients with a sibling donor will receive:
5x10exp7 CD3+/kg on day 1 of cycle 2
5x10exp7 CD3+/kg on day 1 of cycle 4
10x10exp7 CD3+/kg on day 1 of cycle 6
Patients with an unrelated donor will receive:
1x10exp7 CD3+/kg on day 1 of cycle 2
5x10exp7 CD3+/kg on day 1 of cycle 4
10x10exp7 CD3+/kg on day 1 of cycle 6"
1912744|NCT02017457|Drug|Azacytidine|"Cycle 1: Subcutaneous administration of 100mg/m2/day for 5 days.
Cycle 2: Subcutaneous administration of 35mg/m2/day for 5 days. Cycles will be administered every 28 days.
All patients will receive at least 6 cycles of Azacytidine except if progression requests additional disease-related treatment such as hydroxyurea or other chemotherapeutic agents. In such cases, the patient will be excluded from the study and only disease status and survival status will be reported during the 3-year follow-up period. In case of complete remission after cycle 5, 2 additional cycles will be administered after achievement of complete remission.
In case of stable disease or partial response, Azacytidine will be continued until progression.
In case of disease progression after cycle 6, Azacytidine will be stopped."
1968882|NCT02515851|Drug|Exparel|
1912748|NCT02015117|Other|Laboratory Biomarker Analysis|Correlative studies
1912749|NCT02015117|Other|Pharmacological Study|Correlative studies
1912750|NCT02015117|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection of the tumor
1912751|NCT02015117|Drug|Trametinib|Given PO
1912752|NCT02015117|Radiation|Whole-Brain Radiotherapy|Undergo whole-brain radiation therapy
1968898|NCT02510482|Other|No intervention|
1912769|NCT02011919|Device|Echopulse|HIFU Under ultrasound guidance
1968904|NCT02507765|Other|Laboratory Biomarker Analysis|Correlative studies
1968905|NCT02507765|Radiation|Stereotactic Body Radiation Therapy|Undergo SBRT
1968906|NCT02507765|Procedure|Transarterial Chemoembolization|Undergo TACE
1968907|NCT02506673|Device|Zeiss, Cinema ProMED (audiovisual equipment)|
1913003|NCT01973998|Drug|Placebo|Inactive substance.
1968908|NCT02506673|Drug|Midazolam|
1968909|NCT02506673|Device|Skin Conductance Monitor|
1994335|NCT03028467|Drug|GSK3196165 Dose 3|GSK3196165 is supplied as liquid and will be administered as SC injection.
1994336|NCT03028467|Drug|Methotrexate|Methotrexate capsule/tablet 8-16 mg per week is given orally.
1994337|NCT03028467|Drug|Placebo|Placebo is supplied as liquid as sterile 0.9% sodium chloride solution and will be administered as SC injection.
1994338|NCT03028467|Drug|Folic acid|Folic acid tablet 5 mg per week is given orally.
1994339|NCT03027063|Behavioral|10,000 steps|Participants will be asked to achieve 10,000 steps daily and to participate in 30 minutes of continuous exercise of their choosing. They will also receive text messages during the week and weekly motivational call
1994340|NCT03027063|Behavioral|Usual Care|Participants will receive the ACC/AHA exercise guidelines
1994341|NCT03026777|Drug|intravenous crystalloid fluid, 500 mL|
1994343|NCT03025698|Drug|Eltrombopag|Tablet for oral use, once daily
1994344|NCT03025698|Drug|hATG|Horse ATG (ATGAM) (hATG) is not considered an investigational medicinal product (IMP)
1994345|NCT03025698|Drug|CsA|Cyclosporine (CsA) will be by supplied as either oral capsules or oral solution, administered twice a day
1994346|NCT03025308|Drug|Filgotinib|Tablet(s) administered orally once daily
1994347|NCT03025308|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
1994348|NCT03025256|Drug|Nivolumab|"Dose Escalation Intrathecal Nivolumab Starting Dose: 10 mg as an injection directly into CSF through Ommaya reservoir on Day 1 of each 14 day cycle for 2 cycles.
No intrasubject dose escalation, and subjects receive the same IT dose level during all subsequent cycles for up to 2 years, given tolerability.
Intravenous dose is 3 mg/kg for all participants.
Dose Expansion Intrathecal Nivolumab: Recommended dose from Intrathecal Nivolumab Dose Escalation Phase"
1994349|NCT03024775|Dietary Supplement|Wheat flour|Wheat flour will be administered three times per day for 15 days.
1994350|NCT03024775|Dietary Supplement|Placebo|Placebo (xylose) will be administered three times per day for 15 days.
1994351|NCT03024372|Device|AV Fistula creation with sutures|End-to-side anastomosis (of AV fistula) is to be constructed using sutures. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
1994352|NCT03024372|Device|AV Fistula creation with clips|End-to-side anastomosis (of AV fistula) is to be constructed using clips. The incision is to be irrigated and closed using Vicryl, Biosyn and skin glue.
1994356|NCT03023020|Drug|Aspirin|Dosing per current guidelines and local practice
1994357|NCT03023020|Drug|P2Y12 inhibitor|Dosing per current guidelines and local practice
1997728|NCT01947608|Drug|LDK378|750 mg. orally
1912779|NCT02008877|Drug|ganetespib|200 mg/m² IV on days 1, 8, and 15 intravenously over 1 hour
1912780|NCT02008877|Drug|Sirolimus|2mg taken orally once daily on a continuous dosing schedule; Loading dose 12 mg on cycle 1 day 1 only.
1912781|NCT02008773|Drug|Valacyclovir HCI 500 mg tablets|Valacyclovir HCI 500 mg capsules 6/day oral for 16 weeks
1912782|NCT02008773|Drug|placebo|placebo capsules 6/day oral for 16 weeks
1912802|NCT02004691|Drug|placebo (saline)|"Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for patients randomized to placebo.
Route of administration: intravenous infusion"
1912803|NCT02004691|Drug|GZ402665|"Pharmaceutical form: Powder for concentrate for solution for infusion administered once every two weeks during the 52 weeks of the primary analysis period for patients randomized to olipudase alfa, and during the extension treatment period for all patients.
Route of administration: intravenous infusion"
1968940|NCT02497469|Drug|Vedolizumab|Vedolizumab infusion
1968941|NCT02497469|Drug|Adalimumab placebo|Adalimumab placebo-matching injection
1968942|NCT02497469|Drug|Adalimumab|Adalimumab injection
1968943|NCT02497469|Drug|Vedolizumab placebo|Vedolizumab placebo-matching infusion
1968966|NCT02485301|Biological|GlaxoSmithKline (GSK) Biologicals' investigational recombinant chimpanzee adenovirus Type 3-vectored Ebola Zaire vaccine (ChAd3-EBO-Z) (GSK3390107A)|A single dose administrated intramuscular
1968967|NCT02485301|Drug|Placebo|A single dose administrated intramuscular
1912862|NCT01996098|Drug|6-month Icotinib|125 mg three times daily (375 mg per day) by mouth for 6 months
1912863|NCT01996098|Drug|12-month icotinib|125 mg three times daily (375 mg per day) by mouth for 12 months
1968984|NCT02480348|Device|Polymer-free DES (Drug Eluting Stent)|
1968994|NCT02474888|Other|blood specimen|blood specimen for serum rituximab level and serum anti-rituximab level at M1 and M3 after stop of induction rituximab treatment
1968995|NCT02475395|Device|TRAK device|Use of TRAK to attain sperm concentration measurement
1968996|NCT02473744|Other|subcutaneous drainage|After topic analgesia, three subcutaneous channels are created and an absorbent pad collects the lymphatic fluid.
1997773|NCT01919970|Other|Treatment as usual|This condition allows participants to seek out various services. Considering the number of possible treatment options, there is no way to identify or list them.
1997776|NCT01919164|Drug|AS902330 100 microgram (mcg)|AS902330 will be administered at a dose of 100 mcg in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
1997777|NCT01919164|Drug|AS902330 100 microgram (mcg)|AS902330 will be administered at a dose of 100 mcg in 2 cycles (at Baseline and Month 12), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
1997778|NCT01919164|Drug|AS902330 30 microgram (mcg)|AS902330 will be administered at a dose of 30 mcg in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
1968997|NCT02472691|Drug|Lenalidomide|Lenalidomide (investigational drug) will be added to standard of care (Aza and DLI) starting from day 1 for 21 days every 28 days for a maximum of 8 cycles. Starting dose of Lenalidomide 2.5 mg per day for the first 10 patients. If no dose limiting toxicity is identified in a first interim analysis, the next 10 patients will be treated with 5 mg per day. In case of no DLT after a second interim analysis, the remaining 30 patients are envisaged to be treated with 5 mg per day.
1968998|NCT02472691|Drug|Azacitidine|Starting on day 1 all patients will receive Azacitidine (standard of care) 75 mg/m2/d for 7 days every 28 days for up to 8 cycles.
1968999|NCT02472691|Biological|Donor Lymphocyte Infusions|DLIs will be given after cycle 4, 6 and 8 at a dose of 0.5-1x10^6 CD3/kg (1st DLI), 1-5x10^6 CD3/kg (2nd DLI) and 5-15x10^6 CD3/kg (3rd DLI).
1912886|NCT01994148|Procedure|Laparoscopy|In this study, laparoscopic intervention will be performed under carbon dioxide pneumoperitoneum (pressure, 10-12 mm Hg; flow volume, 8-10 L/min). A 12-mm trocar will be placed in the umbilicus with use of an open technique and to establish pneumoperitoneum.A 10-mm and a 5-mm trocar will be inserted in the right and left flanks,respectively.
1912890|NCT01991379|Drug|MEK162|Patients should take the study drug with a glass of water. MEK162 can be taken with or without food.
1912891|NCT01991379|Drug|Imatinib Mesylate (Gleevec®; STI571; NSC #716051)|
1912892|NCT01991379|Other|Blood draws|
1912893|NCT01991379|Procedure|biopsy|Following informed consent, the first 20 mandatory patients, except for patients who have already been treated with imatinib prior to consent, and subsequent voluntary patients enrolled on the phase II portion of the trial will undergo research biopsies. Patients should hold both imatinib and MEK162 doses on the day they undergo a biopsy.
1969003|NCT02469571|Dietary Supplement|Winclove 607|multispecies probiotic
1969004|NCT02469571|Dietary Supplement|Placebo|Placebo
1969005|NCT02469558|Dietary Supplement|Winclove 851 and 110|prebiotic and probiotic mixture
1969006|NCT02469558|Dietary Supplement|Placebo|white powder without pro/probiotic
1969018|NCT02467036|Behavioral|Family Based Behavioral Treatment|The intervention for both groups will be a 4-month Family-Based Behavioral Treatment (FBT), which includes dietary changes, physical activity changes, and behavioral therapy. Treatment is provided in separate parent and child groups. Families will learn to reduce caloric consumption and increase caloric expenditure (physical activity). Behavior therapy includes stimulus control, self-monitoring, goal setting and contracting, parenting skills, skills for managing high-risk situations, and maintenance and relapse prevention. Families will self-monitor caloric intake, breakfast consumption, physical activity, and hunger and satiety throughout the day.
1969058|NCT02454075|Drug|YF476|Gastrin receptor antagonist
1969059|NCT02453594|Biological|pembrolizumab|IV infusion
1969064|NCT02452034|Drug|Posaconazole IV solution|Posaconazole 300 mg IV solution (sterile)
1969065|NCT02452034|Drug|Posaconazole powder for oral suspension|Posaconazole 300 mg powder for oral suspension
1969066|NCT02450383|Drug|Acellular Dermal Matrix|Placement of acellular dermal matrix (Alloderm®) on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
1969067|NCT02450383|Procedure|Autologous subepithelial connective tissue graft|Placement of autologous subepithelial connective tissue graft on the buccal/coronal aspect of the alveolar ridge at the time of implant placement, following a two-stage approach
1969075|NCT02448641|Biological|SB623 Implant (2.5M)|2.5 million SB623 cells
1969076|NCT02448641|Biological|SB623 Implant (5.0M)|5 million SB623 cells
1969077|NCT02448641|Procedure|Sham surgery|
1969078|NCT02446743|Biological|Meningococcal Group B (rDNA Component adsorbed) (rMenB+OMV NZ)|In Group A, intramuscular Booster dose of In Group A, intramuscular Booster dose of Meningococcal Group B at 4 to 7.5 years after last dose. 4 blood samples were collected at: -Baseline (prior to boost dose), at 3, 7 and 30 days after boost dose. In Group B, 2 intramuscular doses of Meningococcal Group B at 0, 1-month schedule. 4 blood samples were collected at: Baseline (prior to first dose), at 30 days post first dose and at either 3 (Group B1) or 7 (Group B2) and 30 days post second dose
1912953|NCT01980888|Drug|Idelalisib|150 mg tablet administered orally twice daily
1912954|NCT01980888|Drug|Bendamustine|Administered intravenously at a starting dose of 90 mg/m^2 for up to 6 cycles. Dosing will be based on mg/m^2 of body surface area.
1912955|NCT01980888|Drug|Rituximab|Single-use vials administered intravenously weekly starting at 375 mg/m^2 on Day 1 (Week 0) and 500 mg/m^2 thereafter for a total of 6 infusions
1912956|NCT01980888|Drug|Placebo|Placebo to match idelalisib administered orally twice daily
1912959|NCT01980355|Drug|Tranexamic Acid|
1912960|NCT01980355|Other|Placebo|
1969091|NCT02440685|Drug|ASN002 Dose Escalation|Multiple ascending doses of ASN002 assigned by cohort
1969092|NCT02440685|Drug|ASN002 RD|Recommended dose of ASN002 from Part A
1969093|NCT02438878|Behavioral|Baby Behavior|
1912962|NCT01979666|Drug|nitrate patch|patients in the study group will get a nitrate patch
1912963|NCT01979666|Drug|placebo patch|control group patients will get a placebo patch
1912964|NCT01979666|Device|MRI scan|MRI scan after 6 weeks of treatment
1969101|NCT02436655|Procedure|surgical aortic valve replacement|open heart aortic valve replacement
1969108|NCT02427724|Drug|lidocaine 2.5%/prilocaine 2.5% topical anesthetic|
1969109|NCT02427724|Drug|lidocaine 7%/tetracaine 7% topical anesthetic|
1969110|NCT02427724|Drug|placebo vehicle|
1969111|NCT02427724|Device|Q-switched 532nm Laser|
1912979|NCT01977859|Drug|Nesiritide|
1912980|NCT01977859|Drug|Saline|
1969120|NCT02423109|Device|fanfilcon A|contact lens
1969121|NCT02423109|Device|enfilcon A|contact lens
1913002|NCT01973998|Drug|Roflumilast|PDE4 inhibitor
1969134|NCT02421185|Drug|JNJ-42756493 (erdafitinib)|"Part 1: Participants will receive 8 mg tablet once daily from Day 1 to 7, and then Day 15 to 21 of 28 days cycle or 8 mg orally once daily of 28 days cycle up to the maximum tolerated dose in order to determine the recommended Phase 2 dose.
Part 2: Recommended Phase 2 JNJ-42756493 (erdafitinib) dose determined in Part 1."
1969136|NCT02419521|Device|Resolute Onyx Stent - 2.25 mm - 4.0 mm|
1969137|NCT02416492|Biological|SB623 cells|SB623 cells will be implanted in the peri-infarct area using stereotactic surgery.
1969138|NCT02416492|Procedure|Sham Control|Sham Surgery (Partial burr hole only)
1969141|NCT02417311|Other|Skin biopsy, genotyping and disease phenotyping|Major steps of the project are (i) in depths clinical phenotyping and follow-up of the clinical course of probands (ii) genotyping of candidate genes involved in heart disease development and (iii) in vitro functional tests of engineered heart tissue (EHT), miniature beating heart muscles. These EHTs are generated from hiPSC (human induced pluripotent stem cells) lines derived from skin biopsies of each participant.
1969152|NCT02413398|Drug|Dapagliflozin 10 mg|Tablets administered orally once daily for 24 weeks. Randomization will be stratified by pre-enrolment anti-hyperglycemic therapy
1969153|NCT02413398|Drug|Matching Placebo for Dapagliflozin|Matching Placebo for Dapagliflozin tablets administered orally once daily for 24 weeks
1969155|NCT02412501|Device|Resolute Onyx Stent - 2.0 mm|Clinical Evaluation of the Medtronic Resolute Onyx Zotarolimus-Eluting 2.0 mm Stent
1969157|NCT02411643|Drug|topical calcipotriene 0.005% ointment|Affected area will be treated twice daily for 3 months
1969165|NCT02407873|Other|Non|
1969175|NCT02401737|Drug|NVR 3-778|
1969176|NCT02401737|Drug|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
1969177|NCT02401737|Drug|Pegasys|
1969194|NCT02393755|Drug|Capecitabine|Given PO
1969195|NCT02393755|Other|Laboratory Biomarker Analysis|Correlative studies
1969196|NCT02393755|Drug|Nintedanib|Given PO
1969197|NCT02393755|Other|Pharmacological Study|Correlative studies
1913068|NCT01958996|Drug|idarubicin|
1969205|NCT02388321|Drug|Ketamine|intranasal sub-dissociative dose ketamine for the treatment of moderate to severe pain in pediatric patients in the emergency department.
1969206|NCT02388321|Drug|Fentanyl|intranasal fentanyl for the treatment of moderate to severe pain in pediatric patients in the emergency department.
1913072|NCT01957735|Drug|BP31510 monotherapy|
1913073|NCT01957735|Drug|BP31510 in combination with chemotherapy|
1969214|NCT02383706|Device|ApneaLink Air|Overnight, home polysomnography device
1969215|NCT02383706|Behavioral|Berlin Quesionnaire|OSA screening questionnaire
1969216|NCT02383706|Behavioral|Epworth Sleepiness Scale|OSA screening questionnaire
1969217|NCT02383706|Behavioral|STOP-BANG questionnaire|OSA screening questionnaire
1969218|NCT02383706|Other|Physical exam|Physical exam of neck, mouth and upper airway
1913089|NCT01953575|Device|Mucosal Impedance|"Mucosal impedance- a (tiny tube) will be placed through the endoscope in your esophagus (swallowing tube) 5 cm above where your stomach and esophagus meet for 5 seconds.
At 10 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds
And at 20 cm above where your stomach and esophagus meet the catheter will be placed for 5 seconds.
This will determine if people with eosinophilic esophagitis (EoE) have an increased esophageal mucosa impedance (food getting into the esophageal tissue)."
1913098|NCT01952847|Other|Placebo|"mTOR Inhibitor Patient Group: Participants receive placebo beginning on Day 1 of an mTOR inhibitor based therapy. Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
Radiation Therapy to Esophagus Patient Group - Placebo taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times."
1913099|NCT01952847|Drug|Glutamine|"mTOR Inhibitor Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day anti-cancer therapy received. Participant to swish the drink for 10 seconds and swallow. Four weeks of treatment constitute 1 cycle for participants on mTOR inhibitor therapy.
Radiation Therapy to Esophagus Patient Group - Glutamine taken as a sugary drink by mouth. Participant will take the drink twice daily starting first day radiation therapy to the esophagus received. Participant to swallow the drink in small amounts several times."
1913100|NCT01952847|Behavioral|Questionnaires|"Questionnaire completion for mTOR Inhibitor Patient Group: At baseline, Day 1 of cycle 2 and beyond, after 6 months of chemotherapy, and at end of study visit.
Questionnaire completion for Radiation Therapy to Esophagus Patient Group: At baseline, Week 3, 4, 5, and 7 of radiation, and at end of study visit."
1913105|NCT01951105|Drug|Naproxen|Take one 250mg naproxen tablet three times a day for 12 weeks.
1913106|NCT01951105|Drug|Carbidopa/Levodopa|"12.5mg/50mg Carbidopa/Levodopa, administered orally as capsules, will be titrated up to TID over one week and then continued at that level for 4 weeks. If at the end of this initial 4 week period the participant has responded, the subject will be maintained on that dose for the duration of the treatment period (12 weeks total). If there has not been a response, the dose will be increased to 25mg/100mg Carbidopa/Levodopa TID for the following 4 weeks at which time the pain status will be re-evaluated. If a response has occurred, that dose will be maintained in a blinded manner for the following 4 weeks of treatment; if not, further dose-titration will occur to 50mg/200mg Carbidopa/Levodopa TID for the final 4 weeks. If a subject experiences an AE at higher doses, then the subject will be given the next lower dose that s/he was able to tolerate and then be maintained on that dose for the remainder of the 12 week dosing period."
1913107|NCT01951105|Drug|Placebo|Take two placebo capsules three times a day for 12 weeks.
1913126|NCT01947998|Drug|Rivaroxaban (Xarelto, Bay59-7939)|Patients who have been prescribed Rivaroxaban for the first time, divided in two subgroups: Naïve and Non Naïve. The Non Naïve are also divided in two subgroups: Recent switchers and Distant switchers.
1913127|NCT01947998|Drug|Warfarin|Patients who have been prescribed Warfarin for the first time, divided in two subgroups: Naïve and Non Naïve. The Non Naïve are also divided in two subgroups: Recent switchers and Distant switchers.
1913128|NCT01947985|Drug|Rivaroxoban (Xarelto, Bay59-7939)|"The treatment of deep vein thrombosis (DVT) or pulmonary embolism (PE), and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).
The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors (20 mg rivaroxaban [od], tablets).
The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).
Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
1913129|NCT01947985|Drug|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
1913130|NCT01947959|Drug|Rivaroxaban (Xarelto, Bay59-7939)|"The treatment of DVT or PE, and prevention of recurrent DVT and PE in adult patients (15 mg rivaroxaban twice daily [bid] for 3 weeks, then 15 mg or 20 mg once daily [od], tablets).
The prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (stroke prevention in atrial fibrillation [SPAF]) with one or more risk factors (20 mg rivaroxaban [od], tablets).
The prevention of venous thromboembolism (VTE) in adult patients undergoing elective hip or knee replacement surgery (recommended dose: 10 mg rivaroxaban [od] tablets for 35 days following hip replacement surgery and 14 days following knee replacement surgery).
Co-administered with acetylsalicylic acid (ASA) alone or with ASA plus clopidogrel or ticlopidine, for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (ACS) with elevated cardiac biomarkers (recommended dose 2.5 mg rivaroxaban tablets [bid])."
1913131|NCT01947959|Drug|Standard of care|For DVT/PE treatment and SPAF, standard of care is treatment with the most widely used vitamin K antagonist, phenprocoumon, and for the secondary prevention of ACS, standard of care is antiplatelet drug(s) such as low-dose acetylsalicylic acid, clopidogrel, dipyridamole, prasugrel, ticlopidine and ticagrelor.
1913141|NCT01944449|Dietary Supplement|Whey Protein (WPC) at breakfast|The type 2 diabetic subjects in Whey Protein (WPC) group will consume at breakfast WPC (35 g) in 250ml of milk, Total 42 g protein breakfast for 12 weeks.
1913142|NCT01944449|Dietary Supplement|Other Protein Sources at breakfast|The type 2 diabetic subjects in PBdiet will consume also 42 g of protein but from different sources : i.e soy,tuna, eggs, at breakfast in bottle mixed with 250 ml water twice a day (30 min before breakfast and before dinner) for 12 weeks.
1913143|NCT01944449|Dietary Supplement|Low Protein at breakfast|The type 2 diabetic subjects in CBdiet group will consume only 17 g protein, namely from at breakfast for 12 weeks.
1969343|NCT02371447|Drug|VPM1002BC|"Phase 1:
Induction: 6 intravesical instillations of VPM1002BC in 6-12 weeks (dose de-escalation in cohorts of 3-6 patients)
Phase 2:
Induction: VPM1002BC at RP2D established in phase I, 6 intravesical instillations in 6-12 weeks (n=39 including patients treated at RPD2 in phase I)"
1969352|NCT02364999|Drug|Bevacizumab-Pfizer|Bevacizumab-Pfizer: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles, followed by the assigned blinded bevacizumab monotherapy.
1969353|NCT02364999|Drug|Bevacizumab-EU|bevacizumab-EU: 15 mg/kg IV on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles followed by the assigned blinded bevacizumab monotherapy.
1969354|NCT02364999|Drug|Paclitaxel|Paclitaxel 200 mg/m2 via IV infusions on Day 1 of a 21-day cycle for each of at least 4 and no more than six (6) 21-day cycles.
1969355|NCT02364999|Drug|Carboplatin|carboplatin AUC =6.0 via IV infusions on Day 1 of a 21-day cyclefor each of at least 4 and no more than six (6) 21-day cycles.
1969357|NCT02363712|Device|APOS shoe|"It consists of two shoes each with two large convex rubber balls called Pertupods screwed into the plantar surface of the sole so that a person walks on these balls."
1969358|NCT02363712|Device|Sham-APOS shoe|It has the same appearance as the APOS shoe, but without the rubber ball attachment on the plantar surface.
1969373|NCT02359513|Drug|Antidepressants|bulimic patients are treated during 3 months
1969374|NCT02359513|Drug|Positron Emission Tomography (PET)|PET scan using [18F]MPPF is performed before and after (3 months)antidepressant treatment
1969379|NCT02356198|Drug|EXPAREL|transversus abdominis plane injection
1969380|NCT02356198|Drug|Intrathecal hydromorphone|Intrathecal opioid administration
1913200|NCT01934907|Other|Washing of packed RBC by normal saline|
1913206|NCT01933802|Biological|intrathecal administration of autologous MSC-NP|Autologous MSC-NPs administered intrathecally at a dose between 2 and 10 million cells, depending on ex vivo expansion characteristics. Three doses will be administered at 3 month intervals.
1913220|NCT01931215|Other|spinal anesthesia with intrathecal morphine|in addition to the standard spinal anesthesia drugs (bupivacaine and fentanyl), morphine is added
1913221|NCT01931215|Other|TAP-block with ropivacaine and clonidine|
1913228|NCT01927497|Procedure|Biological mesh assisted perineal closure|The eAPR procedure will be performed in an identical way as described for the control arm of the study, and this is preferably followed by an omental plasty. The intervention in the experimental arm consists of suturing an acellular biological mesh derived from porcine dermis in the pelvic floor defect (Strattice™, 6x10 cm). The mesh will be sutured at each side of the coccyx or distal sacrum with Prolene or PDS to the discretion of the surgeon. Laterally, the mesh is attached to the remainings of the levator complex and, anteriorly, to the transverse perineal muscle or posterior vaginal wall. A suction drain will be inserted and positioned on top of the mesh. The perineal subcutaneous fat and skin will be subsequently closed in layers similar to primary simple closure as performed in the standard arm.
1913229|NCT01927497|Procedure|Primary perineal closure|The perineal phase of the APR will be performed according to the principles of an extralevator APR, which means that the levator muscles will be laterally transected in order to leave a muscular cuff around the tumour. The coccyx will not be routinely resected, but only if indicated based on surgical exposure or oncological principles. The extent of excision of perineal skin and ischioanal fat will be as limited as oncologically justified. Preferably, an omental plasty is positioned in the pelvic cavity following resection. Closure of the perineum in the control arm consists of stitching the perineal subcutaneous fat together using interrupted Vicryl sutures in one or two layers. Subsequently, the skin will be closed using interrupted sutures according to the preference of the surgeon. Placement of a transabdominal or transperineal drain will be at the discretion of the surgeon.
1913233|NCT01926587|Drug|oral rigosertib|Oral rigosertib will be administered twice a day in fasting conditions for weeks 1, 2, and 3 of a 4-week cycle.
1913234|NCT01926587|Drug|Azacitidine|Starting on Day 1 of second week (Day 8) of the cycle, azacitidine will be administered by subcutaneous injection or intravenous infusion at the labeled daily dose of 75 mg/m2, for 7 days.
1969394|NCT02353598|Drug|Crenezumab dose level 1|Participants will receive crenezumb dose level 1 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
1969395|NCT02353598|Drug|Crenezumab dose level 2|Participants will receive crenezumb dose level 2 IV infusion once every 4 weeks up to Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
1969396|NCT02353598|Drug|Crenezumb dose level 3|Participants will receive crenezumb dose level 3 IV infusion once every 4 weeks upto Week 13 in double-blind treatment window or up to Week 61 in optional OLE window.
1969397|NCT02353598|Drug|Placebo|Participants will receive placebo matched to crenezumab IV infusion once every 4 weeks upto Week 13 in double-blind treatment window.
1969398|NCT02352714|Drug|Paracervical Nerve Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
1969399|NCT02352714|Drug|Sham Paracervical Block|Block randomization to receive lidocaine paracervical nerve block vs sham cervical block
1969400|NCT02351128|Drug|Lanreotide|
1913256|NCT01921985|Drug|Terlipressin|Terlipressin given as intravenous injections of 1mg iv in 100ml of NaCl every 6 hours (total duration of drug administration 120 hours, cumulative dose is 20mg).
1913257|NCT01921985|Drug|Placebo|Placebo (Saline 100 ml) administered every 6 hours (total duration of drug administration 120 hours).
1969424|NCT02345005|Device|The Gore® EXCLUDER® ILIAC BRANCH Endoprosthesis.|The Gore IBE device is a newly designed iliac branched device, that is used in combination with the widely accepted C3 Excluder endograft, for the exclusion of common iliac aneurysms and aorto-iliac aneurysms.
1969434|NCT02342626|Behavioral|Dashboard|With the health care provider, subjects will use the decision dashboard to augment the discussion of treatment options.
1969437|NCT02341625|Drug|BMS-986148|
1969438|NCT02341625|Biological|Nivolumab|
1913303|NCT01911091|Behavioral|Exercise|A 5-minute warm-up and a 5-minute cool-down prior to and following each exercise session, respectively. There will be alternating days of interval training and aerobic training. The interval training will be performed on an upright stationary bike, while the aerobic training will be performed on a treadmill. The interval training will consist of five-minute bouts of higher intensity alternated with 4 minutes of lower intensity for a total duration of 45 minutes. Intensity will increase each week. The aerobic training component will be fixed at a moderate intensity, but will increase in duration each week from 45 minutes to 75 minutes to 90 minutes during the third and final week.
1969451|NCT02330094|Drug|Gabapentin|"Gabapentin capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.
Both groups will receive other standard of care pain medications."
1969452|NCT02330094|Drug|Placebo|"Placebo capsules will be administered orally and titrated from 100 mg - 900 mg TID based on the patient's numeric pain score and creatinine clearance.
Both groups will receive other standard of care pain medications."
1969453|NCT02329262|Behavioral|Mentoring to be Active with Accelerometers|Trained high school mentors will deliver a 10 session curriculum targeting physical activity to younger teens.
1969454|NCT02329262|Behavioral|Planning to be Active with Accelerometers|Health education teachers will deliver the 10 session curriculum targeting physical activity to high school students enrolled in health courses.
1969455|NCT02327650|Procedure|The examinations for bones in joints of OA and RA patients|
1969463|NCT02322021|Drug|elenbecestat (E2609)|In the double-blind portion of the study, each participant will receive two tablets, which when combined will make up the required dose of elenbecestat (E2609) or placebo, to be administered orally once per day (QD) with food. During the OLE Phase, participants will receive a single tablet of elenbecestat (E2609).
1969464|NCT02322021|Drug|Placebo|In the double-blind portion of the study, each participant will receive two tablets, which when combined will make up the required dose of elenbecestat (E2609) or placebo, to be administered orally QD with food.
1969469|NCT02318147|Procedure|Fecal Microbiota Transplantation|FMT by retention enema with fresh bacteria from healthy donor
1969470|NCT02318147|Drug|The traditional treatment|the traditional treatments according to associated guidelines
1969523|NCT02303366|Radiation|Stereotactic Ablative Body Radiosurgery (SABR)|Stereotactic Ablative Body Radiosurgery (SABR) - a single 20Gy in 1 fraction.
1969524|NCT02303366|Drug|MK-3475|MK-3475 (200mg IV) on day 1 every 3 weeks for a total of 8 cycles.
1969532|NCT02294630|Drug|Surfactant|Two doses of surfactant to be administered as aerosol will be tested - 100 mg phospholipid/kg and 200 mg phospholipid/kg. Each dose will be tested at two dilutions and with two nebulizers. Each enrolled infant may receive a maximum of two aerosol treatments of a single dilution with a single nebulizer.
1969535|NCT02292537|Drug|nusinersen|Administered by intrathecal (IT) injection
1969536|NCT02292537|Procedure|Sham procedure|Small needle prick on the lower back at the location where the IT injection is normally made
1969541|NCT02289313|Behavioral|Healthy Youth Living Program|Physical activity and healthy eating program at the Alternative Learning Center co-developed by students, school staff and academic partners.
1913375|NCT01893658|Drug|Omalizumab|administration of a single dose together with the standard treatment
1913376|NCT01893658|Drug|Prednisone|standard treatment
1969552|NCT02284373|Other|Flexitouch for 1 month in addition to routine wound care|simultaneous wound care and pneumonic compression
1969553|NCT02284373|Other|Routine wound care for venous ulcers and lymphedema|wound care /dressings
1969554|NCT02284373|Device|Flexitouch pneumonic compression|pneumonic compression only
1913384|NCT01891643|Drug|Lenalidomide|
1913385|NCT01891643|Drug|Dexamethasone|
1913386|NCT01891643|Biological|Elotuzumab|
1969557|NCT02284893|Drug|Saxagliptin|administered orally once daily
1969558|NCT02284893|Drug|Dapagliflozin|administered orally once daily
1969559|NCT02284893|Drug|Sitagliptin|administered orally once daily
1969560|NCT02284893|Drug|Placebo matching with Saxagliptin|administered orally once daily
1969561|NCT02284893|Drug|Placebo matching with Dapagliflozin|administered orally once daily
1969562|NCT02284893|Drug|Placebo matching with Sitagliptin|administered orally once daily
1913395|NCT01889186|Drug|ABT-199|Tablet
1969579|NCT02282020|Drug|OLAPARIB|300 mg olaparib tablets taken orally twice daily. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria.
1969580|NCT02282020|Drug|Single agent chemotherapy|Treatment of relapsed disease with single agent chemotherapy based on physician's choice of weekly paclitaxel, topotecan, pegylated liposomal doxorubicin, or gemcitabine. All patients should continue to receive study treatment until objective radiological disease progression as per RECIST 1.1 as assessed by the investigator or the patient experiences unacceptable toxicity or they meet any other discontinuation criteria
1913417|NCT01884090|Behavioral|Youth Empowerment Solutions (YES)|Participants receiving the The 16-week, 30-session YES curriculum YES as a part of the 21st Century after-school program at middle schools that have high economic and academic needs. 21st Century is a U.S. Department of Education program which provides academic enrichment opportunities during non-school hours and during the summer for children who attend low-performing schools in areas with high poverty (U.S. Department of Education, 2009).
1969585|NCT02280291|Procedure|GA/sedation with a Single Shot, peripheral nerve block|A single shot peripheral nerve block will be used as the primary mode of pain control intraoperatively with adjunct pain medications prescribed for the patient to take as needed
1969586|NCT02280291|Procedure|GA/sedation with continuous, peripheral nerve block|A continuous peripheral nerve block delivered by the OnQ infusion system will be given in the post-operative period and removed within 48 hours of surgery. Adjunct pain medications will be prescribed for the patient to take as needed
1969587|NCT02280291|Drug|lidocaine|
1969588|NCT02280291|Drug|Propofol|
1969589|NCT02280291|Drug|Fentanyl|
1969590|NCT02280291|Drug|epinephrine,|
1969591|NCT02280291|Drug|bupivacaine|
1969592|NCT02280291|Device|OnQ infusion system|
1969619|NCT02271542|Drug|propofol|Propofol, 1-2 mg / kg after the installation is 100 to 200 mg / kg / min infusion for 30-60 minutes after application will be made and EDTA tubes with 2 ml blood sample will be taken. Determined from blood samples obtained by studying the polymorphism genotypes of patients will be exposed.
1913456|NCT01874756|Drug|LY500307 150mg|LY500307 150mg daily dose (6 capsules of 25mg) for 8 weeks
1913457|NCT01874756|Drug|LY500307 75mg|LY500307 75mg daily dose (3 capsules of 25mg and 3 capsules of placebo) for 8 weeks
1913458|NCT01874756|Drug|Placebo|6 placebo capsules daily for 8 weeks
1969644|NCT02255227|Biological|Prevenar 13|one dose for arm 1 and 2 doses for arm 2
1969645|NCT02255227|Biological|Pneumo 23|one dose
1913470|NCT01872884|Drug|Sevorane Remifentanil|Sevorane Remifentanil
1913471|NCT01872884|Drug|Remifentanil|Remifentanil
1969649|NCT02253992|Biological|Urelumab|
1969650|NCT02253992|Biological|Nivolumab|
1969651|NCT02252146|Drug|IMO-8400 given subcutaneously either weekly or twice weekly|
1969652|NCT02252172|Drug|Daratumumab|Daratumumab will be administered at a dose of 16 milligram per kilogram (mg/kg) by intravenous infusion, once a week for 8 weeks, then once every other week for 16 weeks, thereafter once every 4 weeks until documented progression of disease, unacceptable toxicity, or end of study (maximum up to 7 years).
1969653|NCT02252172|Drug|Lenalidomide|Lenalidomide 25 mg capsule orally on Day 1 through Day 21 of each 28-day cycle.
1969654|NCT02252172|Drug|Dexamethasone|Dexamethasone 40 mg orally or intravenously once in a week.
1969662|NCT02248285|Device|FilmArray™ Gastrointestinal (GI) Panel|BioFire Diagnostics, LLC (BioFire) has developed a polymerase chain reaction (PCR), high-resolution melting analysis instrument called the FilmArray™ and an associated reagent pouch that together are capable of simultaneously detecting multiple microorganisms in a single sample. The FilmArray™ Gastrointestinal (GI) Panel pouch contains freeze-dried reagents to perform nucleic acid purification and nested, multiplex PCR for the identification of common bacterial, viral, and parasite microorganisms responsible for infectious gastroenteritis. The test was made available for sale in the US and EU following FDA clearance and CE marking in May, 2014
1969663|NCT02247843|Genetic|βAS3-FB vector transduced BM CD34+ cells|BM CD34+ from SCD patients are transduced ex-vivo with the Lenti/βAS3-FB lentiviral vector. The transduced cells are then infused into the patient.
1969666|NCT02246218|Drug|RAVICTI|
1969668|NCT02243748|Other|Palliative Therapy|Receive individualized palliative care
1969669|NCT02243748|Other|quality-of-life assessment|Ancillary studies
1969670|NCT02243748|Other|questionnaire administration|Ancillary studies
1988849|NCT02681081|Other|Glucose Administration|For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
1988850|NCT02681081|Other|Intermittent Fasting|For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
1988851|NCT02681081|Other|Control|Normal food intake
1969675|NCT02240134|Behavioral|Education Intervention (Tx1)|The intervention will be a combination of a strong education campaign coupled with the distribution of inexpensive tools to the homes that will enable the residents to burn wood more efficiently.
1969676|NCT02240134|Device|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (Ultra Clean Air Purifiers, 3M, St. Paul, MN) will be placed in the same room as the wood stove. These units are rated by their ability to provide an equivalent amount of contaminant free air into the space, and have a smoke Clean Air Delivery Rate of 112. The electrostatically charged filters in these units are approximately 85% efficient at removing 0.2 micron particles (cigarette smoke size particles) and over 95% efficient at removing 3 micron particles. The unit will be operated on the high setting throughout the duration of the six-month assessment winter periods. Filters will be changed out by the Community Coordinator approximately once per month in an effort to maximize collection efficiency."
1969677|NCT02240134|Device|Placebo Intervention (Tx3)|"Similar to Tx1, a 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
1969678|NCT02240069|Behavioral|Education (Tx1)|Education on best burn practices
1913493|NCT01870778|Drug|RLX030|intravenous infusion
1913494|NCT01870778|Drug|Placebo|placebo
1969679|NCT02240069|Device|Air Filtration Unit Treatment (Tx2)|"A 20 x 18 Filtrete air filtration unit (3M, St. Paul, MN) will be placed in the same room as the wood stove"
1969680|NCT02240069|Device|Placebo Intervention (Tx3)|"A 20 x 18 Filtrete air filtration unit will be installed within the wood stove home. Instead of a high efficiency filter, the units will utilize a placebo filter."
1969689|NCT02238847|Device|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|Reintervention can occur in Arm 1 or Arm 2 with either a WallFlex™ Biliary RX Fully Covered or Uncovered Stent System
1913524|NCT01864564|Other|Early Screen|Women will be randomized to be screened for gestational diabetes at 14-18 weeks gestation (early=intervention) versus routine screening at 24-28 weeks.
1969730|NCT02221674|Drug|Tapentadol|Participants aged 6 months to less than 23 months.
1969731|NCT02221674|Drug|Tapentadol|Participants aged 1 month to less than 6 months.
1969732|NCT02221674|Drug|Tapentadol|Participants aged from birth (must be ≥37 weeks gestational age) to less than 1 month.
1913555|NCT01857349|Other|Chlora Prep|Surgical Scrub skin preparation
1913556|NCT01857349|Other|Dura Prep|Surgical Scrub skin preparation
1969749|NCT02208505|Drug|Dexmedetomidine + Remifentanil-low dose|single dose administration (0.5mcg/kg) 10 min before end of the surgery with maintain the infusion of remifentanil (TCI 1 ng/ml) until end of surgery
1969750|NCT02208505|Drug|Remifentanil-high dose|maintain the infusion of remifentanil until end of the surgery (TCI 2 ng/ml)
1969756|NCT02207803|Behavioral|Transition Assistance Program|
1969774|NCT02197767|Drug|rituximab|After successful enrollment, patients will be treated with an infusion dose of rituximab at Day 1 and at Day 15. CD 20+ cell count will be drawn pre and post infusion at Day 1, Day 28, Day 181, and Day 365. Patients will be retreated with a second dose of rituximab at 6 months independently of CD 20+ cell count.
1969786|NCT02194426|Drug|MP0250|Intravenous application by infusion of MP0250 at up to six dose levels, every other week for up to 24 infusions.
1969791|NCT02192905|Behavioral|Diabetes Prevention Program Lifestyle Intervention|
1913618|NCT01850654|Genetic|LS tumor screening|All participants with CRC or EC will have LS tumor screening (MSI, IHC, methylation if applicable).
1913619|NCT01850654|Genetic|Genetic testing|"Next-generation sequencing panel of several genes that increase the risk for hereditary cancers including the LS genes (MLH1, MSH2, MSH6, PMS2, EPCAM), polyposis genes (MUTYH, APC), and others.
The following study participants will have free genetic testing:
CRC and EC study participants with unmethylated MSI-high (MSI-H) tumors
CRC and EC study participants with microsatellite stable (MSS) or MSI-low (MSI-L) tumors who have abnormal IHC results and they do not have methylation of the MLH1 promoter
CRC study participants diagnosed with CRC <50 years, regardless of tumor studies or family history
CRC study participants diagnosed with CRC ≥ 50 years with a FDR with CRC or EC OR synchronous or metachronous CRC or EC throughout their life, regardless of tumor studies.
At-risk relatives of the individuals found to have LS are eligible for free single site genetic testing."
1913620|NCT01850654|Behavioral|Genetic Counseling|"The participants found to have LS or another type of hereditary cancer will have free genetic counseling.
At-risk relatives of the individuals found to have LS are eligible for free genetic counseling."
1913621|NCT01850654|Other|Biorepository|The biorepository is an optional part of the OCCPI. CRC and EC participants will contribute leftover tumor and blood samples, as well as a saliva sample. FDR of the CRC participants will contribute a saliva sample. The at-risk relatives of those found to have LS will contribute blood and saliva samples.
1913622|NCT01850654|Behavioral|Questionnaire|
1969807|NCT02186743|Other|Personalized Dietary Advice|Personalized dietary advice based on a commercially available blood test. Participants will be instructed to avoid eating selected foods for the duration of the intervention period (4 weeks). Some foods will be acceptable to consume every four days in rotation diet fashion.
1913635|NCT01845805|Drug|oral azacitidine|
1913636|NCT01845805|Other|Observation|
1913637|NCT01845805|Drug|First-line chemotherapy after recurrence|After disease recurrence, subjects on both Arm A and Arm B will start on a first-line chemotherapy (such as abraxane or gemcitabine).
1969819|NCT02180217|Drug|LCI699|
1969821|NCT02174627|Drug|Roxadustat|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
1969822|NCT02174627|Drug|Placebo|The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.
1969826|NCT02170090|Drug|Gemcitabine|Gemcitabine 1000mg/m2
1969827|NCT02170090|Drug|Cisplatin|Cisplatin 25mg/m2
1969828|NCT02170090|Drug|Capecitabine|Capecitabine 1250mg/m2
1913654|NCT01843400|Drug|BAY73-4506_Regorafenib|Patients treated with Regorafenib under practical manner for colorectal cancer.
1969844|NCT02163213|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-Derived Bovine Immunoglobulin /Protein Isolate (SBI) 5.0 g bid on Nutritional Status and intestinal functions in Subjects with IBS-D
1969845|NCT02163187|Device|Implantation of the InterStimTM|
1969846|NCT02163187|Behavioral|MSK BFI questionnaires|
1969847|NCT02163187|Behavioral|The Low Anterior Resection Score (LARS) questionnaires|
1913668|NCT01840345|Drug|N-acetyl-l-cysteine|1200 mg BID x 4 weeks
1913669|NCT01840020|Procedure|Gastric bypass|Surgical procedure in which the stomach is transected high on the body. The resulting small proximal gastric pouch is joined to any parts of the small intestine by an end-to-side surgical anastomosis.
1913670|NCT01840020|Procedure|gastric sleeve|Sleeve gastrectomy, a surgical procedure in which the stomach is reduced to about 25% of its original size, by surgical removal of a large portion of the stomach, following the major curve. The open edges are then attached together (often with surgical staples) to form a sleeve or tube with a banana shape.
1969848|NCT02163187|Behavioral|The EuroQOL5D questionnaires|
1969849|NCT02163187|Behavioral|The Fecal incontinence Quality of Life Scale (FIQOL) questionnaires|
1969852|NCT02160288|Drug|Botulinum Toxin-A|100 Units diluted in a 5 cc syringe at a concentration of 20U/mL
1969853|NCT02160288|Drug|Normal Saline|Dispensed in a 5 cc syringe
1913697|NCT01833442|Behavioral|Kundalini Yoga Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
1913698|NCT01833442|Behavioral|Relaxation Response Meditation|The trial will compare two very different meditation protocols. After the 4.5 month the patients will be reevaluated, and all patients will be merged together into a single group. Patients will then receive 9 - 12 more months of the meditation protocol.
1969885|NCT02150473|Drug|Adalimumab|adalimumab 40 mg every other week in combination with MTX for 24 weeks
1969886|NCT02150473|Drug|Placebo|Placebo the same amount as adalimumab
1969887|NCT02147925|Drug|Liraglutide combined with metformin|Liraglutide, 0.6mg per day for the first week, and will be increased to 1.2mg per day for the second week, and finally 1.8mg per day since the third week
1969888|NCT02147925|Drug|Insulin glargine combined with metformin|The initial dose will be 0.2 unit/kg/d
1969889|NCT02147925|Drug|Sitagliptin combined with metformin|The dose throughout the study will be 100mg per day.
1969896|NCT02134028|Drug|dupilumab SAR231893 (REGN668)|"Pharmaceutical form: Solution
Route of administration: Subcutaneous"
1969902|NCT02129634|Device|CB-PTA|
1969903|NCT02129634|Device|DEB-PTA|
1969908|NCT02121444|Drug|Interferon beta-1b (Betaferon, BAY 86-5046)|
1969909|NCT02121444|Device|BETACONNECT auto-injector.|
1969916|NCT02116036|Drug|Rivaroxaban|
1969918|NCT02113904|Drug|Adalimumab|6 injections (one every 15 days during 3 months)
1969919|NCT02113813|Drug|naquotinib|oral
1969920|NCT02113813|Drug|midazolam|oral
1969921|NCT02113787|Procedure|Pharmacokinetic study|Patients who are examen pharmacokinetic study after taking Topamax or Topiramate during 7 days
1969922|NCT02112695|Other|[11C]diprenorphine|3 micrograms [11C]diprenorphine - intravenous use - 1 time
1969940|NCT02112799|Drug|NVR 3-778|
1969941|NCT02112799|Drug|Placebo for NVR 3-778|Sugar pill manufactured to mimic the NVR 3-778 capsule
1969942|NCT02112799|Drug|Pegasys|
1969947|NCT02111577|Biological|Dendritic Cells DCVAC|DCVAC is the experimental therapy
1969948|NCT02111577|Biological|Placebo|DCVAC placebo is experimental vaccine placebo
1969949|NCT02111577|Drug|Docetaxel|Docetaxel and prednisone is Standard of Care First Line Chemotherapy
1969950|NCT02111577|Drug|Taxotere|
1913745|NCT01824199|Drug|Omeprazole|Patients with LA Grade B-D erosive esophagitis identified at the time of endoscopy will be prospectively recruited. Patients will undergo whole blood testing for CYP2C19 genotype and will be started on omeprazole 40 mg once daily in the morning 30 minutes before breakfast. The Mayo Dysphasia Questionnaire -30 day (MDQ-30day) will be used during the study. At the end of 8 weeks, patients will undergo dual probe pH/impedance testing on therapy and a clinically indicated endoscopy to rule out Barrett's esophagus and assess healing. CYP2C19 genotyping will be performed in the Mayo laboratory.
1913746|NCT01823315|Drug|MTX 1|MTX 0.4mg/(kg·d) intramuscularly (IM) on days 1-5
1913747|NCT01823315|Drug|MTX 2|MTX 100mg/m(2), IV, on day1 (after Act-d); MTX 200mg/m(2), IVgtt, on day1 (after MTX, 500ml NS, >4h)
1913748|NCT01823315|Biological|Act-d|Act-d 0.6mg/m(2), IV, on day1,2
1913749|NCT01823237|Device|Transcranial Magnetic Stimulation|
1913763|NCT01820884|Procedure|TH|Total hysterectomy
1913764|NCT01820884|Procedure|TH/BSO|Total hysterectomy and bilateral salpingo-oophorectomy
1913765|NCT01820884|Procedure|BPLND|bilateral pelvic and para-aortic lymph node dissection
1913766|NCT01820858|Drug|Paclitaxel|175 mg/m(2), intravenously (IV)
1913767|NCT01820858|Drug|Paraplatin (Carboplatin Injection)|AUC=5, IV
1913768|NCT01820858|Radiation|Pelvic Radiation|45-50 Gy
1913769|NCT01820858|Radiation|Vaginal Brachytherapy 1|5 Gy, 3 times
1913770|NCT01820858|Radiation|Vaginal brachytherapy 2|5 Gy, 2-4 times
1969966|NCT02102464|Device|LipiFlow treatment|The LipiFlow® Thermal Pulsation System is a prescription device intended for the application of localized heat and pressure therapy in adult patients with chronic cystic conditions of the eyelids, including meibomian gland dysfunction, also known as evaporative dry eye or lipid deficiency dry eye.
1996945|NCT02309944|Device|Prevena™ Incision Management System|At the close of surgery, the Prevena™ Incision Management System will be placed over the closed incision. It will be removed on post-operative day 2 or 3 as clinically indicated and prior to the patient's discharge from the hospital.
1913812|NCT01815476|Radiation|Radiation Therapy Positioning Intervention|All participants will receive an adjuvant XRT dose to the breast of 50Gy in 25 fractions using an IMRT technique. In both arms, boost to the surgical bed using a mini-tangent technique will be delivered at the treating oncologist's discretion. Acceptable boost doses are 1600cGy/8 fractions, 1000cGy/5 fractions or 1325cGy/25 fractions as a simulatenous integrated boost. Participants randomized to the supine arm will be positioned supine on an angled breast board, with the ipsilateral arm abducted over her head. Participants randomized to the prone arm will be positioned prone on a prone breast board with both arms immobilized above the participant's head. The us of a cushion-like VaclocTM device is permitted at the treating physician's discretion. Radiation beams will be shaped to encompass the breast volume requiring treatment in both arms.
1913824|NCT01811251|Drug|Pregabaline (150mg), Dexamethasone (20mg/5ml; 0.2mg/kg)|
1970012|NCT02090296|Drug|Hydroxyurea|
1970013|NCT02090296|Other|Placebo|
1970019|NCT02084121|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
1970029|NCT02065895|Device|Gain (reference)|The latest revision of the PID algorithm to verify that the scaling factor used to set KP as a function of TDD is robust to the changes in gain and target resulting from over- or under-calibration of the glucose sensor.
1970030|NCT02065895|Device|Gain decreased by a factor 0.8|
1970031|NCT02065895|Device|Gain increased by a factor 1.33|
1970032|NCT02065804|Drug|Bupivacaine|injection, once, 5 min
1913841|NCT01808573|Drug|neratinib|240 mg orally, once daily with food, continuously in 21 day cycles
1913842|NCT01808573|Drug|capecitabine|1500 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal. Taken on days 1 to 14 of each 21 day cycle.
1913843|NCT01808573|Drug|lapatinib|1250 mg orally, once daily, continuously in 21 day cycles
1913844|NCT01808573|Drug|capecitabine|2000 mg/m^2 daily in 2 evenly divided doses, orally with water within 30 minutes after a meal. Taken on days 1 to 14 of each 21 day cycle.
1970041|NCT02057666|Drug|Tasquinimod|A patient will initially receive 0.25 mg/day dose which will then be titrated through 0.5 mg/day (from Day 15) to a maximum of 1mg/day (from Day 29). If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
1970042|NCT02057666|Drug|Placebo|Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food (preferably the main evening meal).
1970053|NCT02046811|Behavioral|Patient activation and education (PAE)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface)
1970054|NCT02046811|Behavioral|PAE plus physician activation (PAE + MD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients
1970055|NCT02046811|Behavioral|PAE physician activation, plus teledermoscopy (PAE +MD +TD)|Text messaging and web-based tutorials for a 12-month duration (a website and smartphone interface), physician activation/educational materials about: (1) survivors' increased skin cancer risk; (2) the benefits of and the skills needed to conduct full-body skin exams; and (3) the importance of recommending routine SSE to patients, and participant receipt of a dermoscopic lens
1913866|NCT01804959|Dietary Supplement|Vivomixx probiotics|
1970066|NCT02042820|Other|In vivo confocal microscopy (IVCM)|IVCM is a sensitive tool for detecting dry eye-associated subclinical inflammation.
1970069|NCT02041598|Other|CHW Intervention|5 group educational sessions, 2 1v1 Visits with a CHW, Phone Calls as needed during 6-month study period
1970075|NCT02032134|Biological|Transfusion of Pooled Platelets Cryopreserved In DMSO|"Patients with severe thrombocytopenia will be admitted as in patients at the Hematology Unit of the Policlinic P. Giaccone- Palermo, if they require platelet transfusion (for bleeding, in preparation for surgery, after chemotherapy); they will receive buffy coat derived cryopreserved platelets,after thawing"
1996946|NCT02308956|Behavioral|Integrated mental health in primary care|A task-shared model of collaborative mental health care integrated into the primary care setting.
1996947|NCT02308956|Behavioral|Psychiatric nurse-led specialist care|A centralised, psychiatric nurse-led, hospital out-patient service with outreach from project outreach workers
1996952|NCT02307734|Behavioral|Quit Smoking for a Healthy Family|The experimental/intervention study arm focuses on providing smoking cessation education and support through 2 LHW outreach small group educational sessions (4-5 weeks apart) and 2 individual follow-up telephone calls to smoker and family participants separately at 2-3 weeks after each group session for a total of 4 intervention contacts over 2 months. The LHW and dyads will choose the site of sessions, such as the LHW's or a participant's home, or LHW Agency's office. Each small group session will last 90 minutes, be interactive, and involve sharing personal stories, learning using a flip chart, and setting individual goals. Each telephone call will be 15- 20 minutes to reinforce progress and provide support.
1996953|NCT02307734|Behavioral|Healthy Living|"In this comparison arm, participants will receive the same number of contacts on the same schedule and in the same format (2 small group sessions and 2 telephone calls). The comparison LHWs will receive training about Healthy Living focusing on nutrition and physical activity education. Participants will also receive the Smoking Cessation Resource Handout."
1913905|NCT01797965|Drug|BIIB019 (Daclizumab)|Participants will receive open-label treatment with BIIB019 150 mg subcutaneous injection every 4 weeks for up to 5 years.
1913908|NCT01797861|Procedure|Half-dose photodynamic therapy (PDT)|"At exactly 15 minutes after the start of the half-dose verteporfin infusion, the PDT treatment will take place. The area that has to be treated with the PDT laser is determined based on those hyperfluorescent area(s) on mid-phase (approximately 10 minutes) ICG-angiography that correspond to subretinal fluid accumulation in the macula on the OCT scan and hyperfluorescent hot spots on the mid-phase (approximately 3 minutes) fluorescein angiogram. The spot size will be defined based on diameter of the hyperfluorescent area on ICG angiography plus 1mm. The treatment is performed with standard fluency (50 J/cm2), a PDT laser wavelength of 689 nm, and a standard treatment duration of 83 seconds."
1913909|NCT01797861|Procedure|Micropulse laser (ML) treatment|"The following ML treatment settings will be used: a power of 1800 mW*, a duty cycle of 5%, frequency of 500 Hz, exposure time of 0.2 s per spot, spot size: 125 µm, minimal distance of spot from fovea: 500 µm.
* Subthreshold treatment is desired, meaning that no visible reaction due to laser treatment has to be seen in the retina. In virtually all patients, a power of 1800 mW wil not produce a visible discoloration of the retina after application of a laser spot with the aforementioned settings. If retinal discoloration is seen at a power of 1800 mW the power will be reduced with steps of 300 mW until there is no visible reaction. The first laser test spot will always be applied just outside the macular area."
1996972|NCT02306967|Procedure|resection of oral cancer|Oral cancer will be resected.
1996973|NCT02306967|Procedure|resection of oral cancer|Oral cancer will be resected
1996974|NCT02304354|Drug|Rituximab|For rheumatoid arthritis, MabThera is given as two intravenous infusions of 1000 mg with a two-week interval between them. Patients usually respond to treatment within 16 to 24 weeks of initial treatment. After 24 weeks, treatment can be repeated depending on the patient's response.
1996976|NCT02303444|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients can get sorafenib at any time during study.
1996977|NCT02303444|Drug|Other Multikinase inhibitors|Patients can get MKIs at any time during study.
1996980|NCT02298829|Drug|Subjects Previously Treated with AA4500|no treatment to be administered - observational only
1996981|NCT02299232|Drug|Dexmedetomidine|Drug: dexmedetomidine 100 mcg/mL was applied in 3 mcg/kg and 4 mcg/kg doses in 1 mL preperates, 0.5 mL for each nostril
1970083|NCT02026362|Biological|MASCT:Multiple Antigens Specific Cellular Therapy|autologous immune cytotoxic of T-lymphocytes (CTL) induced by dendritic cells, (DC) loaded with multiple antigens DC loaded with survivin p53 her2 ect total 17 antigens .
1970084|NCT02026362|Other|The foundation treatment including against hepatitis b virus treatment using nucleoside analogue drug and protect liver treatment|
1970087|NCT02022098|Drug|Cisplatin|A total of three cycles of cisplatin will be administered in a 1-hour IV infusion on days 2, 23 and 44. Cisplatin will be administered 0.5 hours after Debio 1143.
1970088|NCT02022098|Radiation|Radiotherapy|Standard fraction radiotherapy to the primary tumour will be delivered daily for 5 days per week over 7 weeks.
1970089|NCT02022098|Drug|Debio 1143|Debio 1143 solution
1913921|NCT01797458|Procedure|Hall Technique|"Technique:
Removal of dental plaque and rest of aliments from the cavity
Selection of the SSC
If the contact points are very tight, orthodontic separator elastics could be placed through the mesial and distal contacts and the SSC has to be fitted at a subsequent appointment
Dry the crown and fill with glass-ionomer luting cement
Place the crown over the tooth
Removal of cement excesses from the crown margins
The child should be asked to keep biting on the crown until the cement has set"
1913922|NCT01797458|Procedure|Non-Restorative Caries Treatment|"Technique:
Use high-speed bur to remove the undermined enamel and make the cavity accessible for plaque removal. Do not remove the contact area
Clean, dry the cavity and apply Duraphat® varnish fluoride (50/mg/ml)
Show the cavity to patient/parents and give them tooth-brushing instructions
Tell to parents that good plaque control is the key for this treatment
The recall interval for these patients is every 3 months."
1913923|NCT01797458|Procedure|Conventional Restoration|"Technique:
Local anesthesia should be used when needed
Complete caries removal and cavity preparation
Use a matrix band and a wedge to tightly hold the band against the tooth
Place the material (Compomer)
Check contacts and occlusion, and polish the restoration"
1913924|NCT01796392|Device|EBV|This study arm will undergo EBV treatment and also receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
1913925|NCT01796392|Other|Optimal Medical Management|This study arm will receive optimal medical management, including smoking cessation program support, pulmonary rehabilitation, usual medications and oxygen supplementation as necessary.
1970090|NCT02022098|Drug|Placebo|Matching placebo solution
1913936|NCT01794143|Drug|Sulfonylurea (glimepiride)|Used in accordance with labeling and/or usual practice.
1913937|NCT01794143|Drug|DPP-4 inhibitor (sitagliptin)|Used in accordance with labeling and/or usual practice
1913938|NCT01794143|Drug|GLP-1 receptor agonist (liraglutide)|Used in accordance with labeling and/or usual practice.
1913939|NCT01794143|Drug|Insulin (glargine)|Used in accordance with labeling and/or usual practice.
1913952|NCT01792583|Drug|Modafinil/armodafinil|
1970115|NCT02006758|Device|EnligHTN™ Renal Denervation System|The EnligHTN™ Renal Denervation System is designed to deliver radiofrequency (RF) energy to the renal nerves to achieve targeted denervation. The system consists of the EnligHTN™ RF Ablation Generator (generator), the EnligHTN™ Renal Artery Ablation Catheter (ablation catheter), and the EnligHTN™ Guiding Catheter (optional).
1995376|NCT02785003|Drug|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
1995377|NCT02785003|Drug|Alvimopan|All patients enrolled into the trial will be screened for eligibility for alvimopan utilization. Only in circumstances where patients are not on outpatient opioid medications and where they have not received any at time of arrival will alvimopan be administered. It will be given at least 30 minutes prior to surgery.
1995378|NCT02784756|Other|Quantiferon-CMV assay|
1995379|NCT02783443|Other|General anesthesia|General anesthesia
1995380|NCT02783443|Other|Regional anesthesia|Regional anesthesia
1995384|NCT02783781|Procedure|Cardiac surgery (extracorporeal circulation; beating heart)|"Patient's usual care as part of cardiac surgery, analysis of biological data collected at the time of arrival of the patient in the operating room.
Blood sample collection Urine sample collection"
1995386|NCT02782130|Behavioral|Epic Allies App Intervention|"The Epic Allies app addresses barriers to ART adherence through:
Users track health progress through an interactive dashboard, logging daily adherence for those on ART and, optionally, exercise, smoking, alcohol and drug use, and mood. Those not on ART will rate how close they are to getting on it.
Users pick medication reminder timing. The app sends weekly messages to users based on adherence progress and other tracked behaviors.
A key part of the app is contact between users to foster a setting that supports norms for medication-taking, reducing stigma related to HIV status and ART use. Users send and receive encouragement to spur behavior change, recognize positive behaviors, and inspire others to reach an adherence goal.
Users progress through Epic Allies' virtual world, creating allies with other users.
The Daily Dose newspaper has content to improve HIV/ART knowledge, promote disease management and increase drive and self-efficacy."
1995387|NCT02782130|Behavioral|Epic Allies - Control Branch|Subjects will receive weekly phone-based notifications to encourage the subjects to view educational information presented in the app.
1995390|NCT02781662|Behavioral|Pharmacist Home-Visit|
1995391|NCT02780960|Device|HPV self-testing|Patients will perform HPV testing themselves at home.
1995392|NCT02781740|Device|Continous Positive Air Pressure Device|
1995393|NCT02780141|Drug|roxadustat|Oral
1970129|NCT02002130|Drug|Maltodextrin|Maltodextrin as a placebo formulation for GABA
1970130|NCT02002130|Drug|Placebo GAD-alum|Placebo for GAD-alum injection
1970131|NCT02002130|Drug|Glutamic Acid Decarboxylase in alum formulation|GAD-alum SQ injection
1970132|NCT02002130|Drug|Gamma-Aminobutyric Acid|GABA powder taken by mouth
1970138|NCT01995513|Drug|Enzalutamide|160 mg by mouth once daily
1970139|NCT01995513|Drug|Abiraterone|1000 mg by mouth once daily
1970140|NCT01995513|Drug|Placebo for Enzalutamide|Sugar pill manufactured to mimic Enzalutamide 40 mg capsule
1970141|NCT01995513|Drug|Prednisone|5 mg by mouth twice daily
1970142|NCT01991184|Drug|GDC-0853|Multiple escalating doses
1970149|NCT01989598|Drug|Akt Inhibitor GSK2141795|Given PO
1970150|NCT01989598|Other|Laboratory Biomarker Analysis|Correlative studies
1970151|NCT01989598|Other|Pharmacological Study|Correlative studies
1970152|NCT01989598|Drug|Trametinib|Given PO
1995396|NCT02779764|Drug|roxadustat|Oral
1995397|NCT02778555|Behavioral|Questionnaires|
1995398|NCT02779400|Device|Self testing INR device|the procedure involves a series of repeated measurements of INR with the studied device
1995399|NCT02777580|Drug|Tenecteplase|Half dose Tenecteplase
1995400|NCT02777580|Drug|Clopidogrel|300 mg p.o. initial loading dose. Maintenance dose of 75 mg p.o. once daily. The maintenance dose of Clopidogrel (75 mg p.o. per day) should be continued for 1 year.
1995401|NCT02777580|Procedure|Coronary angiography|Coronary angiography followed by PCI or CABG if required, rescue PCI if required
1995402|NCT02777580|Procedure|Primary PCI|Primary PCI accoring to local standards
1995403|NCT02777138|Other|Maintaining a normal daily living lifestyle|participants will undertake a normal lifestyle with no alterations to daily living in order to access the differences in tissue (muscle and adipose) and systemic inflammation between the two age cohorts
1995404|NCT02776735|Drug|Sarilumab SAR153191 (REGN88)|Pharmaceutical form:Solution Route of administration: Subcutaneous
1995405|NCT02776839|Device|Mobile sensing|
1995407|NCT02774304|Device|arterial line|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
1995408|NCT02774304|Device|Cheetah®|In mechanically ventilated patients systolic pressure variation will be captured and passive leg raising with positive result fluid filling will be initiated.
1995409|NCT02774577|Other|whole body vibration training in vibrating platform in young|
1995410|NCT02774577|Other|whole body vibration training in vibrating platform in elderly|
1995411|NCT02774538|Other|Agreement between oral and cervical HPV infection|"A total of 165 women will have a Pap test and an oral brushing performed on the day of inclusion. Risk factors for oral HPV infection will be defined using a self-administered survey summarizing the demographics and sexual behaviors.
A second oral brushing up to 6 months will be performed during a standard follow-up visit."
1995420|NCT02772978|Drug|Tolcapone|Tolcapone is in the medication class of catechol-O-methyltransferase (COMT) inhibitors
1995421|NCT02772978|Drug|Placebo|A placebo is a tablet or capsule that looks like the study medication (in this case, tolcapone) but does not contain any active ingredients
1995422|NCT02770729|Drug|Moxifloxacin|Intracameral injection of moxifloxacin at conclusion of cataract surgery
1995423|NCT02770729|Drug|No injection of moxifloxacin|No intracameral injection of moxifloxacin at conclusion of cataract surgery
1995424|NCT02770144|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
1995425|NCT02770144|Behavioral|Access to Referral to Social Services|
1995428|NCT02770066|Device|Percutaneous transluminal renal angioplasty|"Angioplasty plus stenting (angioplasty in patients with fibromuscular dysplasia)
Adjuvant therapy in atherosclerotic renal artery stenosis - at the discretion of the treating physician
Antiplatelet therapy (usually standard)
Cholesterol-lowering drugs (usually standard)
Antihypertensive treatment with angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker (normally not contraindicated)
Smoking cessation, diet and physical activity (usually standard)"
1970160|NCT01986686|Procedure|Colon resection|Elective robotic/laparoscopic/open colon resection for diverticular disease.
1970165|NCT01976286|Other|Salicylic Acid Peels|
1970166|NCT01976286|Other|Glycolic Acid Peels|
1970167|NCT01973751|Drug|Budesonide|Inhaled powder of inhaled corticosteroid, 2 puffs (200mcg) twice a day for 8 weeks
1913998|NCT01779700|Drug|Fingolimod|0.5mg each day of 8 week cycle
1913999|NCT01779700|Drug|placebo|1 tablet each day of 8 week cycle
1970183|NCT01966445|Biological|GSK2849330|Solution containing 100 mg/millilter (mL) GSK2849330 for intravenous infusion
1970190|NCT01963481|Drug|Exemestane|
1970191|NCT01963481|Drug|Cyclophosphamide|
1970193|NCT01957969|Device|Sacral Nerve Stimulation|
1995431|NCT02769013|Other|Pre-treatment follow up|No active intervention; medical support provided if needed
1995432|NCT02769013|Other|S. haematobium treatment|Praziquantel-treatment for S. haematobium positive volunteers
1995433|NCT02769013|Other|Post treatment follow up|No active intervention; medical support provided if needed.
1995434|NCT02769013|Other|Olfactometer experiment|No active intervention; medical support provided if needed.
1995435|NCT02768285|Procedure|APICAL PATENCY|After determining the working length, a small and flexible size 10 K-file was inserted 1 mm beyond the WL.
1995436|NCT02768155|Other|Amniotic Fluid 4.0ml dose|Injection of Amniotic Fluid
1995437|NCT02768155|Other|Amniotic Fluid 2.0ml dose|Injection of Amniotic Fluid
1995438|NCT02768155|Other|Placebo Control|Normal Saline
1995439|NCT02768012|Behavioral|mindfulness-based cognitive therapy|Six two-hour small group sessions (6-9 participants) will be administered over 8 weeks focusing on MBCT. The intervention follows a written protocol to ensure fidelity of delivery. Participants will receive detailed manuals summarizing session content and home assignments (HAs), including mindfulness practices, audio versions of which will be available on an internet link.
1995440|NCT02766972|Procedure|Rapid Ventricular Pacing|Use of Rapid Ventricular Pacing to improve surgical clipping of intracranial aneurysms
1995441|NCT02766478|Drug|Genistein|Genistein is a natural supplement that comes from soy. Genistein will be taken orally (30 mg twice daily) for 12 weeks.
1995442|NCT02766478|Drug|Placebo|A placebo pill will be taken orally for 12 weeks.
1995445|NCT02765893|Other|No Foley|Patients will have Foley catheter removed 6 hours post-op.
1995446|NCT02764320|Other|Treatment Strategy|Both arms will initiate or optimize preventive medications. Subjects in the Discontinuation arm will stop overused medications and use an alternative rescue medication(s) with a limited frequency. Subjects in the Preventive Therapy Only arm will initiate or optimize preventive medications without immediately discontinuing the overused medication.
1995447|NCT02763033|Dietary Supplement|Bob's Red Mill®|
1995448|NCT02763033|Other|Starch Placebo|Standard bone marrow transplant (BMT) diet.
1995449|NCT02761980|Drug|Ibuprofen 250 mg / Acetaminophen 500 mg|Ibuprofen 250 mg / Acetaminophen 500 mg
1995450|NCT02761980|Drug|Ibuprofen 250 mg|Ibuprofen 250 mg
1995451|NCT02761980|Drug|Acetaminophen 500 mg|1 APAP 500 mg caplet
1995452|NCT02761980|Drug|Placebo|Placebo tablet
1995453|NCT02762370|Drug|FX006 32 mg|
1995454|NCT02762370|Drug|TCA IR 40 mg|
1995455|NCT02761837|Behavioral|IVR call/text|For patients under filling their inhaled corticosteroid or overusing B-agonist, the patient is contacted via IVR call or text
1995456|NCT02761837|Behavioral|Email|Patients under filling their inhaled corticosteroid or overusing B-agonist, the the patient is contacted via email
1995457|NCT02761187|Other|No Intervention|
1995463|NCT02760095|Drug|3 mg zinc sulfate supplement|
1995464|NCT02760095|Drug|0.5 mg of 13C10-retinyl-acetate|
1995465|NCT02758080|Other|Matching on the basis of molecular analysis|
1995466|NCT02758080|Other|Matching on the basis of physician's choice|
1995469|NCT02756832|Drug|Alogliptin Benzoate|Alogliptin benzoate tablets
1970194|NCT01956435|Device|Excimer Light Treatment|Excimer light treatment will be performed on one leg of every subject as the intervention while the subjects other leg will serve as a control
1970198|NCT01951326|Drug|RHB-104|95 mg clarithromycin, 45 mg rifabutin, and 10 mg clofazimine
1970199|NCT01951326|Drug|Placebo|5 placebo capsules administered orally BID
1970203|NCT01948297|Drug|Debio1347 (CH5183284)|Debio1347 (CH5183284) capsules or tablets for oral administration
1970204|NCT01948219|Device|ENTegral Artificial Larynx implant|
1970225|NCT01937052|Other|Sample collection|Participants will be offered the option to consent for blood (preferred) or saliva for DNA pharmacogenetic testing, and for additional samples for banking for future studies.
1970226|NCT01937052|Behavioral|Patient-reported outcomes|Patient reported outcomes (PROs) will be collected via electronic questionnaires that will be administered to patients at regular intervals per the study calendar; in most cases, this should coincide with medical oncology follow-up.
1970227|NCT01937039|Procedure|Sample collection|Blood, tissue, urine, and other samples may be collected
1970231|NCT01935934|Drug|Cabozantinib S-malate|Given PO
1970232|NCT01935934|Other|Laboratory Biomarker Analysis|Correlative studies
1970233|NCT01935934|Other|Pharmacological Study|Correlative studies
1970248|NCT01921140|Drug|Olaparib tablets|Olaparib dosing (2X 150mg tablets) following allocated meal
1970249|NCT01921140|Procedure|Pharmacokinetic sampling|Blood samples taken pre and post dosing with 2x 150 mg olaparib tablet
1970250|NCT01921140|Other|Dietary Fasted|2x 150 mg olaparib tablet formulation taken in fasted state. 5-14 days washout period
1970251|NCT01921140|Other|Dietary High Fat|2x 150 mg olaparib tablet formulation taken 30 minutes after allocated meal. 5-14 days washout period.
1914071|NCT01767766|Drug|TGR-1202|TGR-1202 Daily Oral Dose
1970257|NCT01916967|Drug|Desloratadine|Desloratadine 5 mg tablets, given orally, once daily in the evening for 2 weeks
1970258|NCT01916967|Drug|Placebo|Placebo tablets, given orally, once daily in the evening for 2 weeks
1970259|NCT01916980|Drug|Desloratadine 5 mg|Desloratadine 5 mg/day: one 5-mg tablet taken orally once daily in the evening for up to 12 weeks (Desloratadine 10 mg/day: two 5-mg tablets taken orally once daily in the evening for up to 8 weeks)
1970262|NCT01912937|Device|Angioplasty treatment with the CVI Drug-coated Balloon (DCB)|Angioplasty treatment with the CVI Paclitaxel-Coated, Percutaneous Transluminal Angioplasty (PTA) Balloon Catheter (CVI Paclitaxel-coated PTA Catheter)
1970264|NCT01907828|Device|Renal Artery Ablation|Renal artery denervation using the EnligHTN™ Renal Denervation System
1970265|NCT01907828|Device|Cardiac Ablation|Safire BLU™ Duo or Therapy Cool Path Duo Irrigated Ablation Catheter or Therapy Cool Flex Irrigated Ablation Catheter EnSite Velocity System Agilis NxT Guiding Introducer
1970276|NCT01907074|Drug|Cholates|Cholates is given intravenously (IV push) and by mouth, once per study visit
1970288|NCT01892982|Behavioral|Problem Solving Education tailored to NICU|
1970290|NCT01892293|Drug|Treatment with NY-ESO-1c259-modified T cells|"An intended total dose of ≥0.1-1e10 total cells will be administered as a single infusion. A low dose infusion of 1e8 to < 1e9 will be allowed for patients if cells do not expand sufficiently to reach the target dose range.
For patients whose disease progresses and whose tumor still expresses tumor antigen and HLA-A201, a second infusion of up to 5e10 cells may be given."
1970299|NCT01880814|Behavioral|Cognitive Behavioral Therapy (CBT)|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of CBT. If randomized to no treatment, termination session will be completed. If randomized to continuation of CBT, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of CBT or Caregiver-Child Treatment. Stage 2 will include six sessions and a termination session.
1995519|NCT02740335|Drug|Octaplex|OCTAPLEX will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
1995520|NCT02740335|Drug|Beriplex P/N (Kcentra)|Beriplex® P/N (Kcentra) will be administered by intravenous infusion at a rate of 0.12 mL/kg/min (~3 units/kg/min), up to a maximum rate of 8.4 mL/min (~210 units/min).
1995521|NCT02739646|Device|Functional MRI scan|7.0 Tesla functional MRI scan
1995522|NCT02739269|Other|Serum AMH measurement|Serum AMH is measured one month before the IVF treatment
1995523|NCT02739269|Other|AFC measurement|Early follicular phase AFC is measured one month before the IVF treatment
1995524|NCT02737280|Device|Airvo (TM, Fisher & Paykel Healthcare) - High flow oxygen therapy|High flow nasal cannula therapy with Airvo (TM, Fisher & Paykel Healthcare) device
1995525|NCT02737280|Device|MedKit Finland - Usual oxygen therapy|Oxygen therapy with normal nasal cannula (for example MedKit Finland) 0-2 l/min
1995529|NCT02734719|Device|Bonestim|
1995531|NCT02733406|Other|Target Controlled Infusion|
1995532|NCT02733406|Other|Velocity Controlled Infusion|
1995533|NCT02732184|Drug|Co-ArgI-PEG modified human arginase I|
1995534|NCT02730078|Behavioral|VEMOFIT|The VEMOFIT intervention involves four biweekly two hours sessions over a period of about six weeks, and a booster at three months follow-up. It consists of a mixture of 1) exploring illness perceptions and personal meanings of diabetes, 2) cognition-focused education on diabetes and practical skills in self-management and 3) emotion-focused training on recognising emotions in the self and others. Each group will consist of 10 to 12 participants of equal representation by the patients and their significant others.
1995535|NCT02730078|Behavioral|Attention-meetings (AG)|Patients in the health clinics randomised to the AG, will receive the usual T2D care by the clinic doctors and education by the clinic paramedics based on the recommendations in the Malaysian clinical guidelines. At T1, T2 and T4, patients (not including their significant others) in AG will be gathered in groups of 10-12 people for the primary and secondary outcomes evaluation. This session will include general discussion on feeling about and coping with T2D, social support at home and satisfaction with treatment and care received at the respective clinics.
1995536|NCT02729428|Device|MRI|Participants will undergo an MRI scan
1995539|NCT02728843|Drug|Deferiprone|600 mg tablets
1995540|NCT02728843|Drug|Placebo|Tablets that match the deferiprone tablets in appearance
1995541|NCT02728752|Drug|Octagam 10%|Patients to be treated with Octagam 10%
1995542|NCT02728752|Other|Placebo|Patients to be treated with a Placebo
1970300|NCT01880814|Behavioral|Caregiver-Child Treatment|Children will first be randomized into Stage 1 of CBT or Caregiver-Child Treatment. Stage 1 will include six sessions. After Stage 1, child's response to treatment will be evaluated. Responders will be re-randomized into Stage 2 of no treatment or continuation of Caregiver-Child Treatment. If randomized to no treatment, termination session will be completed. If randomized to continuation of Caregiver-Child Treatment, the treatment will include six sessions and a termination session. Insufficient responders will be re-randomized into Stage 2 of continuation of Caregiver-Child Treatment or CBT. Stage 2 will include six sessions and a termination session.
1914110|NCT01755897|Procedure|radical hysterectomy + pelvic lymph node dissection|
1914111|NCT01755897|Drug|Paclitaxel|135-175 mg/m(2) intravenously (IV) on day 1
1914112|NCT01755897|Drug|Cisplatin|75 mg/m(2) IV on day 2 and 3
1914113|NCT01755897|Drug|Cisplatin|35 mg/m(2) IV once a week
1914114|NCT01755897|Radiation|Pelvic RT|IMRT
1970310|NCT01873040|Behavioral|Social Media plus information pages|Participants will receive access to the study vaccine website information pages and social media feature including blogs, discussion forums, expert chats, and ask an expert.
1970311|NCT01873040|Behavioral|Vaccine Information Pages|Participants will receive access to the study vaccine website information pages.
1970349|NCT01861054|Drug|Reparixin|1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery
1970384|NCT01854710|Drug|ADASUVE 10 mg 2 doses 2 hours apart|Inhaled loxapine 10 mg 2 doses 2 hours apart
1970385|NCT01854710|Drug|Inhaled Placebo|Staccato placebo via inhalation x 2 at 2 hours apart
1970386|NCT01854710|Drug|Oral moxifloxacin 400 mg|Oral moxifloxacin 400 mg single dose
1970387|NCT01854710|Drug|Oral placebo|Oral capsule identical in appearance to moxifloxacin
1970395|NCT01853280|Drug|L-methylfolate|15mg/day L-methylfolate.
1970396|NCT01853280|Drug|OROS-Methylphenidate|All subjects will be treated with open-label OROS-MPH
1914213|NCT01740687|Device|ESS305 (Essure, BAY1454032)|Essure Permanent Birth Control
1914214|NCT01740687|Procedure|NovaSure|Nova Sure Endometrial Ablation
1914222|NCT01739413|Procedure|Anesthesia|Patients will be randomized to receive either epidural or general anesthesia for pain management throughout their surgery.
1970434|NCT01822132|Drug|Extended release naltrexone|
1970435|NCT01822132|Drug|Placebo|
1970439|NCT01819311|Behavioral|Attention Bias Modification|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe always replaces the neutral stimulus and never replaces the threatening stimulus. The intervention is based on the idea that attention can be shaped via repetitive computer based training methods, and training attention toward neutral stimuli will lead to a reduction in anxiety and its disorders.
1970440|NCT01819311|Behavioral|Placebo Attention Task|At each of eight sessions, participants complete 160 computer administered trials wherein a pair of threatening stimuli and neutral stimuli is presented simultaneously and then followed immediately by a probe. The probe replaces the neutral stimulus and the threatening stimulus with equal probability.
1970444|NCT01816763|Behavioral|NRS pain now|Eligible patients will be randomly assigned to complete a patient-reported 'NRS now' on a kiosk prior to making contact with a nursing staff vital signs screener.
1970445|NCT01816763|Behavioral|PEG|Eligible patients will be assigned to complete a patient-reported enhanced pain screening with the PEG on a tablet prior to making contact with a nursing staff vital signs screener.
1970469|NCT01789242|Drug|Carfilzomib|IV over 30 minutes on Days 1, 2, 8, 9, 15, and 16 every 28 days.
1970470|NCT01789242|Drug|Dexamethasone|Dexamethasone IV or PO on Days 1, 2, 8, 9, 15, and 16 every 28 days in patients with <VGPR after 4 cycles.
1970471|NCT01788631|Drug|Regadenoson|Regadenoson is an A2AR agonist that is a coronary vasodilator. It is chemically described as adenosine, 2-[4-[(methylamino)carbonyl]-1H-pyrazol-1-yl]-, monohydrate. Its molecular formula is C15H18N8O5. Regadenoson has an FDA indication for use in radionuclide myocardial perfusion imaging in patients unable to undergo adequate exercise stress. It has lower affinity for non-A2A adenosine receptor subtypes thought to be associated with some of the adverse effects associated with non-selective adenosine receptor agonists, which increase extracellular adenosine by blocking its uptake into cells. The maximal plasma concentration of regadenoson is achieved within 1 to 4 minutes after injection and parallels the onset of the pharmacodynamic response. Its half-life is approximately 2 to 4 minutes.
1970472|NCT01788631|Drug|Placebo|This study uses 0.9% Normal Saline (NS) as placebo. This is a sterile sodium chloride solution usually used to replenish fluids and electrolytes. It contains no additives, and is a standard solution used as placebo in clinical trials where the study drug is administration intravenously. NS will be prepared by investigational pharmacy.
1970478|NCT01782131|Drug|Posaconazole|
1970479|NCT01782131|Drug|Voriconazole|
1970480|NCT01780662|Drug|Brentuximab Vedotin|Given IV
1970481|NCT01780662|Drug|Gemcitabine Hydrochloride|Given IV
1970482|NCT01780662|Other|Laboratory Biomarker Analysis|Optional correlative studies (Part B only)
1995544|NCT02726646|Drug|Doxycycline|Application of 1 mg of doxyxycline microspheres at 4 sites (two means and two deep periodontal pockets) after mechanical debridement.
1995545|NCT02726646|Procedure|Mechanical debridement|Mechanical debridement (full mouth) of 45 minutes associated with the application of 1 mg of microspheres placebo in selected periodontal pockets.
1995546|NCT02726646|Drug|Placebo|The application of 1 mg of microspheres placebo
1995547|NCT02725684|Other|Observational study, no intervention|Observational study, no intervention
1995548|NCT02724163|Drug|Gemtuzumab ozogamicin|Antibody-conjugated chemotherapy agent.
1995549|NCT02724163|Drug|Liposomal daunorubicin|Anthracycline
1995550|NCT02724163|Drug|Mitoxantrone|DNA-reactive agent
1995551|NCT02724163|Drug|Fludarabine|A water-soluble fluorinated nucleotide analogue of the antiviral agent vidarabine.
1995552|NCT02724163|Drug|Cytarabine|Pyrimidine nucleoside analogue, an antineoplastic agent.
1995553|NCT02724163|Drug|Busulfan|Alkylsulfonate
1995554|NCT02724163|Drug|Cyclophosphamide|A nitrogen mustard alkylating agent from the oxazaphosphorine group
1995555|NCT02723318|Behavioral|Financial Coaching|One-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
1995556|NCT02723318|Behavioral|Access to Referrals to Social Services|
1995557|NCT02723357|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
1995558|NCT02723357|Behavioral|Access to Social Service Referrals|Access to referrals for common social needs.
1995559|NCT02723331|Drug|Nab-paclitaxel and gemcitabine for R-PDAC Patients|Nab-paclitaxel and gemcitabine, for R-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
1995560|NCT02723331|Drug|Nab-paclitaxel and gemcitabine for BR-PDAC Patients|Nab-paclitaxel and gemcitabine, for BR-PDAC patients, will be given in combination as neoadjuvant and adjuvant chemotherapy. Nab-paclitaxel will be administered by IV infusion at a dose of 125 mg/m2 over 30 minutes on Days 1, 8, and 15 of every 28-day cycle. Gemcitabine will be administered by IV infusion, immediately after the administration of nab-paclitaxel, at a dose of 1000 mg/m2 over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
1995561|NCT02723227|Behavioral|Financial Coaching|Enrollment in one-to-one financial coaching intervention to support savings, income, and credit while reducing debt using available tools in the community development field.
1995562|NCT02723227|Behavioral|Referral to Social Services|
1995563|NCT02722304|Biological|ARALAST NP 60 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
1995564|NCT02722304|Biological|ARALAST NP 120 mg/kg|ARALAST NP is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
1995565|NCT02722304|Biological|GLASSIA 60 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
1995566|NCT02722304|Biological|GLASSIA 120 mg/kg|GLASSIA is an Alpha1-Proteinase Inhibitor (A1PI) augmentation therapy
1995567|NCT02722304|Biological|Human Albumin 2%|Human albumin 2% (by appropriate dilution with normal saline solution)
1995568|NCT02723617|Other|MED 0.5|Participants will be fed a Mediterranean diet providing 0.5 oz. per day of lean beef.
1995569|NCT02723617|Other|MED 2.5|Participants will be fed a Mediterranean diet providing 2.5 oz. per day of lean beef.
1995570|NCT02723617|Other|MED 5.5|Participants will be fed a Mediterranean diet providing 5.5 oz. per day of lean beef.
1995571|NCT02723617|Other|AAD 2.5|Participants will be fed an average American diet providing 2.5 oz. per day of lean beef.
1995572|NCT02722005|Behavioral|Financial Coaching|One-to-one financial coaching focused on credit, debt, savings, and income supports.
1995573|NCT02722005|Behavioral|Access to referral to social services|Access to referral to a host of social services.
1995574|NCT02719977|Drug|CX5461|
1970486|NCT01777061|Drug|[11C]Acetate|intravenous injection of an average of 40 mCi of [11C]Acetate
1914313|NCT01724489|Drug|Growth hormone|
1914314|NCT01724489|Drug|Placebo|
1970498|NCT01774019|Device|WallFlex™ Biliary RX Fully Covered/Uncovered Stent System|
1970505|NCT01765751|Procedure|Manual Cervical Distraction|Manual Cervical Distraction (MCD) is a form of Low Velocity Variable Amplitude Spinal Manipulation (LVVA-SM). MCD procedure is performed with participant lying prone on a load instrumented table with moveable headpiece allowing guided head movement while recumbent. Clinician gently grasps posterior aspect of participant's neck with a broad contact (contact hand) between thumb and index finger at specific vertebral level. With opposite hand, clinician grasps control handle. Using contact hand, clinician exhibits superior traction to maintain a contact at a single vertebral level and ensuring a gentle movement via contact with control handle. Goal is to create a slow rhythmic (1-3 sec) localized distractive movement. In this trial, only axial distraction (Cox protocol 1) will be used.
1970506|NCT01765673|Device|Passy Muir Swallowing Self-Trainer|Comparison of the effects of different vibratory characteristics on the frequency of swallowing, time of initiation of swallowing with stimulation and urge to swallow. Will compare frequency of vibration, mode of vibration, pressure of device against neck, and duration of vibration. Each session will last no more than 1 hour with short breaks. Each participant can volunteer for up to three nonconsecutive sessions.
1970507|NCT01765530|Device|ETT cleaning maneuver|"EndOclear device will be used for ETT cleaning maneuver. This is a commercially available device. It consists of an ETT cleaning apparatus with a flexible central tube and a cleaning device at its distal end. The cleaning device has a mechanically expandable mesh structure which can be adapted to selectively move between a radially-collapsed position and a radially-expanded one. In operation, the collapsed cleaning apparatus is inserted into the ETT through a Y-shaped connector. The device is then expanded by a safety toggle protected trigger mechanism that, when fired, presses the device's smooth silicone disc against the inside surface of the ETT. The cleaning apparatus is then pulled out of the ETT removing mucus deposits and secretions.
We will add endOclear to the standard ICU practice, scheduling the systematic use of the device every 8 hours for the whole intubation period."
1970535|NCT01732445|Drug|ruxolitinib phosphate|Given PO
1970536|NCT01732445|Drug|danazol|Given PO
1970537|NCT01732445|Other|quality-of-life assessment|Ancillary studies
1970538|NCT01732445|Other|questionnaire administration|Ancillary studies
1970540|NCT01729039|Behavioral|standard balance rehabilitation|All subjects will perform balance and gait exercises in addition to the eye movement exercises and will be provided a written home exercise program (HEP) consisting of balance and gait exercises designed to improve postural stability and mobility with progressively more challenging tasks. Balance exercises will include maintaining stability in standing with vision and somatosensory cues altered, dynamic weight shifting and performing ankle, hip and step strategies. Gait activities will include negotiating uneven terrains and obstacles, gait with slow head turns focusing on objects, varied speed (speeding up and slowing down), and unpredictable starts and stops. Walking for endurance will be included in the HEP. Each participant will receive a customized balance and gait HEP based on identified impairments and will be progressed according to ability and level of assistance at home as is standard in PT.
1970541|NCT01729039|Behavioral|gaze stability|Vestibular adaptation and substitution exercises were designed originally based on the error signals (retinal slip) that induce changes in gain in the vestibular system and will be performed by the experimental group (GS). Adaptation exercises involve head movement while maintaining focus on a target, which may be stationary or moving. Typical progression of adaptation exercises involve increased velocity of head movement, movement of both target and head, target placed in a distracting visual pattern and maintenance of a challenging posture. Substitution exercises specifically attempt to facilitate use of alternative strategies, rather than teaching the specific strategies. During active eye-head exercise, a large eye movement to a target is made prior to the head moving to face the target, potentially facilitating use of preprogrammed eye movements.
1970542|NCT01729039|Behavioral|Control|The placebo exercises will consist of saccadic eye movements while the head is stationary and will be performed by the control group. These eye movements will be performed against a plain background in order to eliminate retinal slip and, therefore, eliminate the error signal for vestibular adaptation.
1970545|NCT01722916|Drug|Hyaluronidase|
1970553|NCT01714739|Drug|Lirilumab|Specified dose on specified days.
1970554|NCT01714739|Drug|Nivolumab|Specified dose on specified days.
1970555|NCT01714739|Drug|Ipilimumab|Specified dose on specified days.
1970561|NCT01708785|Behavioral|Single food Cue Exposure Treatment|Subjects will be exposed to the same set of 4 foods in each cue exposure treatment session.
1970562|NCT01708785|Behavioral|Multiple food Cue Exposure Treatment|Subjects will be exposed to a different set of 4 foods in each cue exposure treatment session.
1970563|NCT01708785|Behavioral|Partial Reinforcement - Enhanced Cue Exposure Treatment|Subjects will take random additional tastes of the food during cue exposure treatment.
1970564|NCT01708785|Behavioral|Partial Reinforcement -Consistent Cue Exposure Treatment|Subjects will consistently take the same tastes of the food during cue exposure treatment.
1970566|NCT01705080|Device|EnligHTN|Renal artery ablation with EnligHTN system used for all groups
1970568|NCT01702467|Drug|GSK2647544|Capsules containing 0.5mg to 50mg of GSK2647544.
1970569|NCT01702467|Drug|Placebo|Matching placebo capsules.
1970576|NCT01695564|Device|LARIAT LAA|The LARIAT snare device is an over-the-wire device guided over the LAA to enable ligation of the LAA. The LARIAT can be opened and closed as desired for ideal positioning without risk of suture deployment.
1970577|NCT01695564|Device|WATCHMAN|The WATCHMAN is an expandable device deployed in the LAA via a trans-septal catheter. The implanted device has a self-expanding nitinol frame to secure it in the LAA. The fabric of the WATCHMAN device is permeable to blood.
1970581|NCT01689740|Drug|Active placebo dose MDMA|Initial dose of 25 mg MDMA administered orally at the start of each of two separate psychotherapy sessions scheduled three to five weeks apart possibly followed by a supplemental dose of 12.5 mg MDMA 1.5 to 2.5 hours later.
1970582|NCT01689740|Drug|Full dose MDMA|Initial dose of 125 mg MDMA administered orally at the start of each of two psychotherapy sessions scheduled three to five weeks apart. In each case, it may be followed 1.5 to 2.5 hours later with 62.5 mg MDMA.
1970583|NCT01689740|Drug|125 mg MDMA (open label)|Initial dose of MDMA administered orally at the start of each of two psychotherapy sessions, supplement administered 1.5 go 2.5 hours later.
1970586|NCT01687712|Drug|AFOLIA|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
1970587|NCT01687712|Drug|Gonal-f® RFF|225IU subcutaneously, starting at the day of successful down-regulation for the first 5 days, followed by a treatment period with an increased dose until the point of ovulation induction has been reached
1970588|NCT01686178|Behavioral|Anti-smoking social marketing campaign|We will utilize industry market research tools to define the target audience (segment of community with high smoking prevalence and high social influence) and directly counter tobacco industry lifestyle marketing strategies through local promotion of a smokefree brand and branded bar and club events.
1914450|NCT01696942|Drug|Cimzia|400 mg subcutaneously at weeks 4, 6, and 8 after surgery, and then every 4 weeks
1914451|NCT01696942|Drug|Mesalamine|mesalamine 800 mg orally three times daily
1970603|NCT01682148|Procedure|Current clinical practice technique and high-concentration dilution|The same number and sites of injections/deposits per muscle will be given as pre study. With a Dysport dilution of 300U/mL the volume to be injected will vary in the interval of 0.1 mL to 0.7 mL per muscle.
1970604|NCT01682148|Procedure|NMJ targeted technique and low-concentration dilution|A single injection per muscle will be given in the midline of the band of NMJ zones. With a Dysport dilution of 100U/mL the volume to be injected will vary in the interval of 0.4 mL to 2.0 mL per muscle.
1970609|NCT01660750|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
1970610|NCT01660750|Drug|Cyclophosphamide|PO on days 1, 8, and 15 every 28 days
1970611|NCT01660750|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
1970633|NCT01641367|Drug|Darunavir|Participants will be administered darunavir orally as one 600 mg tablet twice a day (1200 mg per day) with food (must be taken with Ritonavir 100 mg twice a day [200 mg per day])
1970634|NCT01641367|Drug|Etravirine|Patients will be administered Etravirine orally as two 100 mg tablets or one 200 mg tablet twice a day (400 mg per day) following a meal.
1970635|NCT01641367|Drug|Emtricitabine/tenofovir disoproxil fumarate|Patients will be administered FTC/TDF orally as one fixed dose combination tablet (FTC 200 mg/TDF 300 mg) once daily, with or without food.
1970636|NCT01641367|Drug|Raltegravir|Participants will be administered Raltegravir orally as one 400 mg tablet twice daily (800 mg per day), with or without food
1970637|NCT01641367|Drug|Second line ART regimens are usually based on a boosted protease inhibitor (bPI) plus two nucleoside analogues (NRTIs)|LPV/r and ATV/r are the preferred bPIs for second-line ART. TDF + (3TC or FTC) or AZT + 3TC are the most frequent NRTI backbones. Cohort A will not include any of the new drugs; therefore, it is distinct from Cohorts B, C, and D.
1970638|NCT01641367|Drug|Study provided drugs according to patient resistance profile (DRV, ETR, RTV, FTC/TDF) + any in country available drug as applicable & available|For Cohort D, in many situations a patient will indeed receive the same regimen that patients are getting in Cohorts B and C if that is the best combination that can be obtained according to his/her resistance profile and drug availability (as for many countries there will be no further drug options beyond the available study drugs).
1970639|NCT01641367|Other|SOC adherence versus SOC+CPI adherence|"not participating in the adherence randomization; OR
randomized to SOC adherence; OR
randomized to SOC+CPI adherence."
1970640|NCT01641042|Biological|Meningococcal vaccine GSK134612|2 doses of the vaccine administered intramuscularly in the anterolateral thigh muscle of the non-dominant leg for subjects aged 12 months to 2 years and in the deltoid of the non-dominant arm for older subjects.
1970651|NCT01626352|Drug|Bendamustine|Patients will receive as an IV infusion bendamustine 90 mg/m^2 Days 1 and 2 of Cycles 1 through 6.
1970652|NCT01626352|Drug|Ofatumumab|Patients will receive as an IV infusion ofatumumab 1000-mg IV Days 1 and 8 during Cycle 1 only, and on Day 1 of Cycles 2 through 6
1970653|NCT01624662|Drug|Rescue Med|
1914510|NCT01685242|Drug|AC-170 0.24%|1 drop in each eye at 2 separate times during a 14 day period
1914511|NCT01685242|Drug|AC-170 0%|1 drop in each eye at 2 separate times during a 14 day period
1970662|NCT01622569|Drug|rescue med|rescue med
1970666|NCT01623310|Combination Product|Fluticasone Proprionate using OptiNose Device|
1970670|NCT01614392|Behavioral|Lower Extremity high velocity low force Power Training|Lower Extremity high velocity, low force Power Training
1970671|NCT01611792|Other|Stabilization exercise protocol|The stabilization exercise protocol consists of exercises focused on improving the ability of trunk muscles to stabilize the spine, beginning with training to isolate the deeper abdominal muscles as well as deep dorsal trunk muscles. Then patients were progressed to exercises that added leverage of the limbs while maintaining the co-contraction of the deeper abdominal muscles and deep dorsal trunk muscles while breathing normally. Various positions (e.g., supine and quadruped positions) were used to challenge the patients based on their tolerance. Finally, patients were progressed to exercises in more functional positions that included tasks/activities that were reported as challenging and/or painful; patients performed the tasks at the speed demanded by the particular task. Maintenance of the co-contraction of deep trunk muscles was emphasized during these functional activities.
1970672|NCT01611792|Other|Strength and conditioning exercise protocol|This protocol contained trunk strengthening and endurance exercises. It consisted of 3 phases: 1) initial strengthening of trunk flexors/extensors in single plane movements, 2) trunk and lower-extremity stretching as well as progression of trunk-strengthening exercises to include multi-planar trunk movements. Aerobic exercises were progressed as tolerated and patient education about body biomechanics were reinforced, and 3) trunk-strengthening exercises under dynamic conditions (e.g., unstable support surface and in multi-planar trunk movements). During the 10 week protocol, exercises became more challenging, and each subject had to complete at least the first phase before moving onto the next phase in order to be included in post-testing analyses. There was no specific focus on the deep abdominal or deep dorsal trunk muscles during any of these exercises.
1970673|NCT01610284|Drug|BKM120 Matching placebo|BKM120 matching placebo, daily oral
1970674|NCT01610284|Drug|Fulvestrant|Fulvestrant 500mg given intramuscularly at cycle 1 day 1, cycle 1 day 15 and at day 1 at each cycle thereafter
1970675|NCT01610284|Drug|BKM120|BKM120 100mg, daily oral capsules
1970676|NCT01605253|Drug|Eszopiclone|Eszopiclone has been approved by the US Food and Drug Administration (FDA) for the treatment of insomnia (inability to sleep). Eszopiclone has not been specifically approved by the FDA for people who have PTSD-related sleep disturbance.
1970677|NCT01605253|Drug|Placebo|The placebo used in this study looks exactly like eszopiclone but contains no active ingredients.
1970678|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; every 2 weeks from Week 0 through Week 50.
1970679|NCT01604343|Drug|Placebo|Form=solution for injection, route=subcutaneous use; Weeks 2, 6, and every 4 weeks through Week 104.
1970680|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50 or 100, form=solution for injection, route=subcutaneous use; every 2 weeks for 100 mg and every 4 weeks for 50 mg, Week 52 through Week 104.
1970681|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=100, form=solution for injection, route=subcutaneous use; Weeks 0, 2, and every 2 weeks through Week 104.
1970682|NCT01604343|Drug|Sirukumab|Type=exact, unit=mg, number=50, form=solution for injection, route=subcutaneous use; Weeks 0, 4, and every 4 weeks through Week 104.
1914546|NCT01677572|Drug|Aducanumab (recombinant, fully human anti-Aβ IgG1 mAb)|Participants will receive an infusion of Aducanumab on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic and assigned does levels. The infusion will be administered for approximately 1 hour. The study is conducted with a staggered, parallel group design, with the first 3 treatment arms conducted in parallel, 2 further treatment arms subsequently beginning in parallel and the 2 last treatment arms subsequently beginning in parallel. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 84 doses.
1914547|NCT01677572|Drug|Placebo|Placebo to mimic the low dose, mid-dose and high-dose treatment arms of the experimental intervention; administered by intravenous (IV) infusion on Days 1, 29, 57, 85, 113, 141, 169, 197, 225, 253, 281, 309, 337, and 365 (±2 days) at the study clinic. Qualifying participants can enter the long-term extension period at doses described in the treatment arms for up to an additional 84 doses.
1970701|NCT01596283|Procedure|Standard fluid management|The patient will receive standard fluid management
1970702|NCT01596283|Device|Goal directed fluid therapy with the Edwards EV1000 system|This arm will have fluid therapy guided by the Edwards EV1000 system.
1970703|NCT01594229|Drug|ABT-199|ABT-199 is taken orally once daily for 3 days out of each 28 day cycle. This is a dose escalation study, therefore the dose of ABT-199 will change throughout the study.
1970704|NCT01594229|Drug|Bendamustine|Bendamustine will be given by intravenous infusion for 2 days out of each 28 day cycle.
1970705|NCT01594229|Drug|Rituximab|Rituximab will be given by intravenous infusion for 1 day out of each 28 day cycle.
1970706|NCT01594385|Biological|Seprafilm|"Two sheets of the Seprafilm material will be applied at each reoperation. Each sheet will be cut into 1x1 inch squares and applied to the following anatomic areas:
Two Seprafilm pieces between the liver and the anterior abdominal wall
Four pieces over the exposed bowel surfaces anteriorly
Two slightly staggered pieces of Seprafilm in each colic gutter
Two pieces in the pelvic area.
If any of the above areas involve an anastomosis or bowel repair, then the Seprafilm should be placed at least 1 inch away from the anastomosis and/or bowel repair."
1970724|NCT01579214|Other|Cellular Phone Text Message Formats|Cellular phone text message formats to be sent to participants after abnormal laboratory results to communicate information and request early return to clinic.
1970746|NCT01567891|Biological|NYESO-1c259 T cells|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells. Patients will receive at least 1x10⁹ transduced cells, however the target dose for this protocol is for patients to receive 5x10⁹ transduced cells with a maximum possible dose of 6x10⁹ administered as a single intravenous (IV) infusion.
1970747|NCT01561586|Drug|Weekly cisplatin with RT|"Cisplatin 40mg/m2 IV Weekly For 6 Cycles.(The 6th cycle of cisplatin may be omitted if external beam radiation therapy has been completed) Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 40 mg/ m2 of cisplatin may be diluted in 250 ml 0.9% sodium chloride and administered over one or two hours.
Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day
External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
1970748|NCT01561586|Drug|Tri-weekly cisplatin with RT|"Tri-weekly cisplatin 75mg/m2 three cycles concurrent to radiation therapy
Cisplatin may be diluted and administered per established institutional guidelines. For general suggestion, 75 mg/m2 of cisplatin may be diluted in 500 ml 0.9% sodium chloride and administered over one or two hours (rate of 1 mg of cisplatin per minute).
Cisplatin will be given on the first day of external RT (Day 1), preferably, and must be given prior to radiation treatment on that day.
External beam RT will be followed by intracavitary brachytherapy. The total elapsed time for completion of external beam to the whole pelvis, intracavitary BT, and parametrial / nodal RT shall not exceed eight weeks (56 days)"
1914605|NCT01660958|Dietary Supplement|MNP|The formulation of the multiple micronutrient powder (MNP) was based on low micronutrient intake, low bioavailability of iron and zinc in the Indian diet, and current World Health Organization (WHO)and Indian recommendations regarding fortification and age-specific nutrient requirements. The MNP formulations were produced by a certified company in India and include: Iron, Vitamin A, Vitamin C, Folic Acid, Zinc, Vitamin B12 Vitamin B2, plus filler (maltodextrin). Placebo included riboflavin and maltodextrin.
1914606|NCT01660958|Behavioral|Early Learning|• Infant will benefit from interventions that are based on responsive parenting, whereby caregivers respond to children's cues, provide opportunities for exploration, and engage in nurturant and reciprocal communication.
1914624|NCT01658930|Procedure|Radical Hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. The uterus, cervix, medial 1/3 of parametria, 2cm of the uterosacral ligaments and upper 1-2cm of the vagina are to be removed en bloc. The uterine artery is ligated laterally to the ureters and the ureters are unroofed to the ureterovesical junction.
1914625|NCT01658930|Procedure|Simple hysterectomy + pelvic lymph node dissection|This procedure may be performed abdominally, laparoscopically, robotically or vaginally. Extrafascial hysterectomy involves removal of the uterus with cervix without adjacent parametria. The uterine arteries are transected medial to the ureters at the level of the isthmus and the uterosacral ligaments are transected at the level of the cervix. Surgeons should pay special attention to make sure that the whole cervix is removed. As such, a maximum of 0.5 cm of vaginal cuff can be removed to ensure the complete removal of the cervix.
1970765|NCT01553136|Drug|Varenicline|0.5 mg once per day for Days 1 to 3, 0.5 mg twice per day for Days 4 to 7, then two 0.5 mg tablets (1 mg) twice per day
1970769|NCT01550731|Behavioral|PREPARE website|Advance care planning website and materials plus an advance directive.
1970770|NCT01550731|Behavioral|Advance directive|The control group will only receive an advance directive.
1970774|NCT01540006|Other|Physical activity|50min of endurance training combined with 45min of calisthenics; 1-3x/week; 6-24 weeks
1970780|NCT01534299|Device|Medtronic Renal Denervation System|The Symplicity renal denervation system is comprised of a single-use, disposable catheter and a reusable radiofrequency (RF) generator. The Symplicity renal denervation system has CE Marking for the intended use of delivering low-level radiofrequency energy through the wall of the renal artery to denervate the human kidney.
1970784|NCT01524978|Drug|cetuximab|Escalating doses administered once weekly by intravenous infusion
1970785|NCT01524978|Drug|vemurafenib [Zelboraf]|Escalating doses given twice a day starting on Day 2
1970786|NCT01524978|Drug|vemurafenib [Zelboraf]|960 mg twice a day until disease progression, unacceptable toxicity, or withdrawal of consent
1970795|NCT01515787|Drug|FOLFOX (chemotherapy)|Oxaliplatin 85 mg/m^2 IV over 2 hours on day 1, leucovorin 400 mg/m^2 bolus IV over 2 hours on day 1 and 5-fluorouracil 400 mg/m^2 bolus over 5-15 minutes then 2400 mg/m^2 continual over 46-48 hours total dose IV on days 1-2. The treatment schedule repeats based on the group. Dose modifications are allowed based on adverse events.
1970796|NCT01515787|Other|5 FUCMT (chemoradiation)|5-fluorouracil 225 mg/m^2 per day continuous IV infusion administered concurrently with radiation therapy for 5 or 7 days per week OR capecitabine 825 mg/m^2 twice daily administered orally and concurrently with radiation therapy for 5 days per week. Dose modifications are allowed based on adverse events.
1970797|NCT01515787|Procedure|surgery|low anterior resection with total mesorectal excision
1970798|NCT01515787|Procedure|magnetic resonance imaging or endorectal ultrasound|
1970801|NCT01513408|Other|immunohistochemical detection of lymphocytes T CD8+/Foxp3 ratio|For each patients included the study, a tumour block from the initial biopsy, as well as a representative block of residual tumour (area of complete tumoral regression, area of partial tumoral regression or area of unmodified residual tumour) will be chosen by the initial pathologist in each investigating centre. Once the pathologist has verified the concordance between the images observed on the blocks sent from the investigating centres, and the associated pathology reports, immunohistochemical analysis will be performed on the slides prepared from each block.
1970802|NCT01512199|Drug|U3-1287|U3-1287: 18 mg/kg administered intravenously once every three weeks
1970803|NCT01512199|Drug|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
1970804|NCT01512199|Drug|Paclitaxel|Paclitaxel: 175 mg/m^2 administered intravenously once every three weeks
1970805|NCT01512199|Drug|U3-1287|The maximum tolerated dose as determined in Phase 1b portion (between 9 mg/kg and 18 mg/kg) administered intravenously once every three weeks
1970806|NCT01512199|Drug|Trastuzumab|Trastuzumab: 6 mg/kg up to 8 mg/kg administered intravenously once every three weeks
1970807|NCT01512199|Drug|Paclitaxel|Paclitaxel: 175 mg/m^2 administered intravenously once every three weeks
1914675|NCT01649856|Drug|CHOP|CHOP chemotherapy: cyclophosphamide, doxorubicin, vincristine, prednisone/prednisolone; 6 or 8 cycles
1914676|NCT01649856|Drug|rituximab [MabThera/Rituxan]|The first rituximab dose will be administered intravenously on Day of Cycle 1 at a dose of 375 mg/m2. Subsequent doses of 1400 mg are administered subcutaneously on Day 1 of each cycle, for a further 7 cycles
1914677|NCT01649856|Drug|rituximab [MabThera/Rituxan]|375 mg/m2 intravenously on Day 1 of each cycle, 8 cycles
1970808|NCT01512199|Drug|Placebo|Placebo: Dose corresponding to U3-1287 administered intravenously once every three weeks
1970810|NCT01510184|Drug|Zevalin (ibritumomab tiuxetan)|Day 1: Rituximab 250 mg/m2 intravenous infusion Days 7-9:Rituximab 250 mg/m2 intravenous infusion followed by Y-90-Zevalin 14.8 MBq/kg. In centers where biodistribution imaging is performed Day 1: Rituximab 250 mg/m2 intravenous infusion followed by In-111-Zevalin 185 MBq (5mCi), Days 3-4: Biodistribution imaging Days 7-9: Rituximab 250 mg/m2 intravenous infusion followed by Y-90-Zevalin 14.8 MBq/kg
1970816|NCT01505673|Drug|Liraglutide|Liraglutdie 1.8mg injected subcutaneously from pen device once daily for 6-months
1970817|NCT01505673|Drug|Saline|Placebo injection of 1.8mg saline once daily for 6-months
1914717|NCT01643499|Drug|oxaliplatin|Given IV
1914718|NCT01643499|Drug|irinotecan hydrochloride|Given IV
1914719|NCT01643499|Drug|leucovorin calcium|Given IV
1914720|NCT01643499|Drug|fluorouracil|Given IV
1914721|NCT01643499|Other|laboratory biomarker analysis|Correlative studies
1970838|NCT01477320|Drug|Pantoprazole 40 mg IV daily and tube feed.|"Patients randomized to the control group active Comparator will receive tube feed plus an Pantoprazole 40 mg IV daily."
1970839|NCT01477320|Other|Placebo and tube feed|"Patients randomized to Placebo group placebo Comparator will receive tube feed plus an Placebo."
1970841|NCT01469221|Drug|Apaziquone|Apaziquone 4 mg in 40 mL diluent
1970842|NCT01469221|Drug|Placebo|Matching placebo in 40mL diluent
1970846|NCT01464034|Drug|Carfilzomib|IV over 30 minutes on Days 1,2,8,9,15, and 16 every 28 days
1970847|NCT01464034|Drug|Pomalidomide|PO daily on Days 1-21, every 28 Days
1970848|NCT01464034|Drug|Dexamethasone|40 mg weekly PO or IV on Days 1, 8, 15, and 22, every 28 days.
1914735|NCT01639001|Drug|Crizotinib|250 mg two times daily [BID], oral, on a continuous daily dosing schedule. Cycles are defined in 21 day periods.
1914736|NCT01639001|Drug|Pemetrexed/Cisplatin|Option 1: Pemetrexed/Cisplatin; Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Cisplatin, 75 mg/m^2 will be administered by infusion after adequate hydration according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and cisplatin will be repeated every 3 weeks for a maximum of 6 cycles.
1914737|NCT01639001|Drug|Pemetrexed/Carboplatin|Option 2: Pemetrexed/Carboplatin. Pemetrexed, 500 mg/m^2, will be administered by intravenous infusion over 10 minutes or according to institutional administration timing on Day 1 of a 21-day cycle. Carboplatin, at a dose calculated to produce an AUC of 5 or 6 mg.min/mL will be administered by infusion according to institutional practices beginning approximately 30 minutes after the end of the pemetrexed infusion. Pemetrexed and carboplatin will be repeated every 3 weeks for a maximum of 6 cycles.
1914748|NCT01635166|Device|Delta Motion|A cementless acetabular cup with a pre-assembled ceramic liner for use in total hip replacement.
1914751|NCT01634919|Device|chronic hepatitis C|acoustic radiation force impulse ultrasonography
1970865|NCT01452399|Procedure|Shave margins|Partial mastectomy with shave margins.
1970866|NCT01452399|Procedure|No Shave Margins|Partial mastectomy without shave margins.
1970869|NCT01446809|Drug|Doxorubicin Hydrochloride|Given IV
1970870|NCT01446809|Radiation|External Beam Radiation Therapy|Undergo external beam radiation therapy
1970871|NCT01446809|Drug|Ifosfamide|Given IV
1970872|NCT01446809|Other|Laboratory Biomarker Analysis|Correlative studies
1914768|NCT01632241|Biological|Placebo plus standard therapy|Placebo plus standard therapy
1914769|NCT01632241|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10mg/kg plus standard therapy
1914770|NCT01632241|Drug|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; biologics and intravenous cyclophosphamide are not permitted.
1970873|NCT01446809|Drug|Pazopanib Hydrochloride|Given PO
1970874|NCT01446809|Other|Pharmacological Study|Correlative studies
1970875|NCT01446809|Other|Placebo|Given PO
1970876|NCT01446809|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1995607|NCT02711995|Drug|RenuGel|Injection augmentation is the injection of a filler material (Brand: RenuGel; generic: Carboxymethylcellulose) into the vocal cords through the skin of the neck, guided by the view from a flexible laryngoscope inserted through the nostril. The flexible laryngoscopy is identical to the procedure that the doctor has used to examine your vocal cords in the past. It is the routine diagnostic evaluation technique of voice disorders.
1995608|NCT02711995|Drug|Botulinum Toxin|Botulinum toxin treatment is the injection of botulinum toxin into the muscles of the vocal cords through the skin of the neck. This is identical to the injections you may have received in the past for your disorder.
1995609|NCT02711631|Behavioral|MedBIKE|MedBIKE is an exercise cardiac rehabilitation system that allows participants to perform clinical cardiac rehabilitation at home or at a local center, instead of having to travel to the hospital. It provides a high level of physiological monitoring to allow patient safety to be continually monitored while exercising.
1995611|NCT02710123|Other|Sub-Threshold exercise prescription|Participants will be given a prescription to exercise at 80% of their threshold HR for symptom exacerbation. HR Threshold will be monitored weekly and exercise level increased accordingly.
1995612|NCT02710123|Other|Structured stretching prescription|Participants will be given a prescription for daily stretching lasting approximately 20 minutes.
1995613|NCT02708797|Other|Magnetic resonance imaging|Patients and controls will first be studied with MRI. The total duration of MRI is about 60mn. These technic is not invasive.
1995614|NCT02708797|Other|Transcranial Doppler|Patients and controls will first be studied with TCD. The total duration of TCD is about 60mn. These technic is not invasive.
1995615|NCT02709018|Drug|losartan|Angiotensin receptor blocker (ARB)
1995616|NCT02709018|Drug|Placebo|Placebo
1995617|NCT02708966|Drug|Gymnema Sylvestre|Gymnema Sylvestre, 300mg capsules 2 times daily with the first bite of breakfast and dinner
1995618|NCT02708966|Drug|Placebo|Placebo, 300mg capsules 2 times daily with the first bite of breakfast and dinner
1995620|NCT02707523|Drug|Azithromycin 10 mg|
1995621|NCT02707523|Drug|Azithromycin 20mg|
1995622|NCT02707523|Drug|Placebo|
1995623|NCT02706184|Drug|E. coli Nissle suspension|Patients receive E. coli Nissle suspension
1995624|NCT02706184|Drug|Placebo|Placebo
1995627|NCT02706340|Other|No intervention - observational study only|
1995628|NCT02706041|Procedure|Definitive Closure Laparotomy|Subjects randomized to the definitive closure laparotomy arm will have the incision closed at the end of the exploratory laparotomy.
1995629|NCT02706041|Procedure|Damage Control Laparotomy|Subjects randomized to the damage control laparotomy arm will have the incision left open at the end of the exploratory laparotomy. The trauma team will evaluate the patient's clinical course to determine when the incision can be closed.
1995634|NCT02703012|Other|Adjustment of ventilator settings by EIT|Diagnostic maneuvers (change in tidal volume, recruitment maneuvers) will be performed to detect overdistention, tidal recruitment and recruitability. Tidal volume will be reduced if overdistention is detected by EIT. Positive end-expiratory pressure will be increased if tidal recruitment or recruitability are detected.
1995635|NCT02701374|Drug|TRK-700|
1995636|NCT02701374|Drug|Placebo|
1970908|NCT01428193|Drug|Flutamide|Subjects weighing > 50 kg will receive 250 mg orally twice a day, and subjects weighing < 50 kg will receive 125 mg orally twice a day.
1970909|NCT01428193|Drug|Progesterone|oral progesterone suspension (20 mg/ml, 25-100 mg) three times a day at 0700, 1500, and 2300 hr for seven days
1970910|NCT01428193|Drug|estrace|0.5-1 mg once a day for seven days
1970913|NCT01420679|Drug|Pralatrexate Injection|"Intravenous (IV) push administration over 30 seconds to 5 minutes via a patent IV line containing normal saline (0.9% sodium chloride).
Initial dose: 30 mg/m2
Administered weekly for 3 weeks of a 4-week cycle until criteria for discontinuation per the protocol are met."
1970922|NCT01414049|Procedure|On-pump CABG|Use of cardiopulmonary bypass (CPB) with cardioplegic arrest: on-pump CABG.
1970923|NCT01414049|Procedure|Off-pump CABG|CABG performed without the use of cardiopulmonary bypass (CPB) with cardioplegic arrest, surgery performed with the beating heart.
1970927|NCT01410097|Behavioral|Lifestyle intervention|Intensive Lifestyle Intervention that includes diet, physical activity, and behavior modification. The goal of the ILI intervention was for individuals to achieve and maintain a loss of at least 7% of initial body weight.
1970928|NCT01410097|Behavioral|Diabetes Support Education|It offers an educational program to participants including developing support groups. Providing such benefits helps retain these participants in the trial.
1970932|NCT01404754|Drug|Lactose (inactive placebo)|Placebo in an equivalent weight to MDMA will be administered in identical appearing capsules during one of two experimental sessions. An equivalent to the initial and supplemental dose will exist.
1970933|NCT01404754|Drug|3,4-methylenedioxymethamphetamine|125 mg MDMA will be administered in opaque capsules at the outside of one of two experimental sessions, and upon mutual agreement between the investigator and participant, 62.5 mg may be administered 1.5 to 2.5 hours later.
1970946|NCT01372618|Drug|SOM 230 / Pasireotide|SOM230/Pasireotide is a multi-receptor targeted somatostatin analogue. In this trial, 600 mcg of SOM230/Pasireotide are taken twice daily subcutaneously.
1970958|NCT01370798|Drug|promestriene|Promestriene cream 1%, 1g per day during 2 months, cutaneous application
1970959|NCT01370798|Drug|Placebo|Placebo of promestriene cream, 1g per day during 2 months, cutaneous application
1970960|NCT01370798|Procedure|Urethroplasty|Onlay-tube-onlay urethroplasty performed by a physician expert of this technique (at least 5 years of practical ability)
1970961|NCT01370798|Radiation|Wrist X ray|Wrist X ray to follow the degree of bone maturation
1970962|NCT01370798|Procedure|Blood test|Hormonal dosage: Oestradiol, testosterone, FSH-LH and AMH
1970963|NCT01369641|Procedure|Insertion of Pressure Equalization (PE) Tubes|If the subject consents to participate in the study, a separate consent for insertion of pressure equalization (PE) tubes will be obtained. The PE tubes will then be inserted into the posterior inferior quadrant of the tympanic membrane in the office under topical anesthesia.
1970964|NCT01369641|Drug|Sodium Thiosulfate (STS)|Drops of STS will be added to the experimental ear only prior to initial cisplatin infusion.
1970965|NCT01369641|Other|Saline (Placebo)|Drops of balanced saline solution will be added to the placebo comparator ear prior to initial cisplatin infusion.
1914858|NCT01612767|Device|PRO-Kinetic Energy Stent|Coronary artery stent implant
1970966|NCT01369641|Drug|Cisplatin|Cisplatin chemotherapy infusion in the dose range of 80-120mg/m2
1970970|NCT01364090|Drug|Pegylated interferon alfa 2b|Pegylated interferon alfa 2b 1.5 mcg/kg/week to a maximum of 150 mcg/week administered subcutaneously once weekly directly observed.
1970971|NCT01364090|Drug|Ribavirin|Ribavirin - 800-1400 mg daily according to weight taken orally with food, self administered in split doses.
1970980|NCT01352286|Genetic|Autologous Genetically modified T cells|"Patients will undergo myeloma restaging at days +42, +100, 6 months, 9 months and 1 year post infusion. At this point, in accordance with FDA Guidelines, all patients will enter long term follow up (LTFU) and be followed biannually for monitoring for gene transfer delayed adverse events until year 5 post infusion. From year 5, all patients will require annual LTFU visits for monitoring for delayed adverse events until year 15 after receiving the genetically modified T cells.
Patients whose disease progresses prior to year 1 will enter LTFU at time of progression; however these patients will be seen quarterly from progression until year 1 post infusion and then follow the LTFU schedule mentioned above."
1970983|NCT01339169|Drug|YF476|50 mg once daily for 12 weeks, with the option to increase to 75 mg or 100 mg once daily after 6 weeks, or decrease to 25 mg once daily, depending on response. After that, patients that have benefited from treatment may take 50 mg YF476 once daily for an additional up to 52 weeks.
1970991|NCT01338415|Drug|Bosentan|bosentan 2mg/kg b.i.d.
1970992|NCT01338415|Drug|Bosentan|bosentan 2mg/kg t.i.d.
1971002|NCT01334268|Device|Taxus Liberte Paclitaxel-Eluting Coronary Stent System|Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation
1971003|NCT01334268|Device|Resolute Zotarolimus-Eluting Coronary Stent System|Resolute Zotarolimus-Eluting Coronary Stent System Implantation
1971006|NCT01324700|Drug|Escitalopram|Escitalopram is an Antidepressant
1971007|NCT01324700|Drug|Placebo|Inactive ingredient matching the active medication in appearance
1971008|NCT01323387|Device|Interbody Fusion|allograft spacer + anterior plate
1971036|NCT01295112|Drug|Active bevacizumab and Sham dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Sham dexamethasone intravitreal implant: blunt needling of the sclera with no penetration of the globe
1971037|NCT01295112|Drug|Active bevacizumab and Active dexamethasone|Bevacizumab: 25 mg/mL, PRN dosing Dexamethasone intravitreal implant: 0.7 mg, single dose
1971043|NCT01292655|Drug|BMS-906024|
1914910|NCT01603368|Dietary Supplement|Lactobacillus reuteri|Oil drops with Lactobacillus reuteri DSM 17938, 125 million bacteria=0.2 ml per day
1914911|NCT01603368|Dietary Supplement|Placebo|Oil drops without Lactobacillus reuteri
1971049|NCT01287130|Drug|Cetuximab|Day 1 administer cetuximab 400 mg/m2 IV loading dose over 120 minutes. On days 8, 15 and 22 administer cetuximab 250 mg/m2 IV loading dose over 60 minutes
1914917|NCT01601353|Device|Tissue Genesis Cell Isolation System|Liposuction followed by injection of autologous adipose derived cells
1971050|NCT01287130|Drug|AZD6244|Given orally once or twice a day depending on dose level.On days 1, 8, 15 and 22. Repeat every 28 days
1971063|NCT01276379|Drug|FOLFIRI (m)|"FOLFIRI (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:
Irinotecan 180 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2), in infusion i.v., 120 minutes, on day 1.
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
1995637|NCT02701283|Device|Medtronic Transcatheter Aortic Valve Replacement Systems|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with Medtronic TAVR Systems
1995638|NCT02701283|Device|Surgical Aortic Valve Replacement (SAVR)|Treatment of severe aortic stenosis in subjects who have a low predicted risk of operative mortality for SAVR with a commercially approved surgical bioprothesis
1995639|NCT02700490|Behavioral|Psychotherapy|"Behaviour Therapy or Cognitive Behaviour Therapy which forms service as usual in primary care centres in Indonesia."
1995640|NCT02700724|Other|Immediate Surgery|
1995641|NCT02700724|Other|Observation|
1995642|NCT02700724|Procedure|Surveillance Cystoscopy and Urinary Cytology|Cytology and cystoscopy are done at the same time
1995645|NCT02700256|Behavioral|survey|All patients will submit a baseline survey following enrollment onto study. After successful completion of the AXR or 24-hour discharge pathway, the consented patient will be contacted by email or telephone for 5 days following discharge from surgery.
1995648|NCT02697396|Behavioral|Assessments|All participants, after consent, will be asked to complete the study contact form and then complete a baseline assessment with the RSA. This baseline assessment will take approximately 5 minutes.
1995649|NCT02697396|Other|Text Message Reminder|Participants randomly assigned to the text messaging group will receive a text message reminding them of their child's vaccination eligibility once a week, starting one week after exposure to the social marketing campaign and time of consent.
1995650|NCT02697396|Other|No Text Messaging|Participants in this arm will receive no additional vaccination reminders.
1995651|NCT02696083|Device|Provant Therapy System|
1995652|NCT02696434|Drug|Naltrexone|daily dosing
1995653|NCT02696434|Drug|Placebo|daily dosing
1995654|NCT02696434|Drug|Buprenorphine|daily dosing
1995655|NCT02695992|Drug|Metoprolol|Dosage 100 mg o.d.
1995656|NCT02695992|Drug|Diltiazem|Dosage 360 mg o.d.
1995659|NCT02692599|Biological|investigational live attenuated mumps vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
1995660|NCT02692599|Biological|control live attenuated mumps vaccine|The control vaccine was manufactured by Zhejiang VACN bio-pharmaceutical Co. Ltd.
1995663|NCT02690415|Procedure|Antibiotics Given|Patients who's treating physician prescribed antibiotics
1995664|NCT02690415|Procedure|Antibiotics not given|Patients who's treating physician did not prescribed antibiotics
1995667|NCT02689713|Drug|Voriconazole (topical)|The voriconazole (Vfend®-IV 200mg) will be applied topically to one of two skin graft sites at a concentration of 150 micromolar. Dialysates will be collected over 12 hours post-skin graft/voriconazole application for analysis in the lab of OLAM concentrations.
1995668|NCT02689713|Drug|Topical Placebo Group|Sterile water will be applied topically to the other of the two skin graft sites. Dialysates will be collected over 12 hours post-skin graft/sterile water application for analysis in the lab of OLAM concentrations.
1995669|NCT02689219|Drug|Brentuximab Vedotin|Both cohorts will be treated similarly and in parallel but analyzed separately.
1995670|NCT02688985|Drug|Ocrelizumab|Ocrelizumab will be administered as IV infusion.
1914922|NCT01602185|Drug|Dextromethorphan (drug used like antitussive)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
1914923|NCT01602185|Drug|Memantine (drug used in Alzheimer's disease)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
1914924|NCT01602185|Drug|Placebo (lactose)|The aim of this study is to evaluate if memantine or dextromethorphan gave in relay to ketamine maintains or induces a decrease of pain intensity
1971064|NCT01276379|Drug|FOLFOX-6 (m)|"FOLFOX6 (m) chemotherapy will be administered on day 1 of each 14-days-cycle. The administered doses will be:
Oxaliplatin 85 mg/m2 in infusion i.v., 120 minutes, on day 1 of each cycle.
l-Leucovorin 200 mg/m2 (or d,l-leucovorin 400 mg/m2) in infusion i.v., 120 minutes, on day 1.
One bolus i.v. (2-4 minutes) of 400 mg/m2 of 5-FU on day 1.
5-FU in continuous infusion (2400 mg/m2) administered through an ambulatory pump during 46-48 hours."
1971065|NCT01276379|Drug|Cetuximab|- 500 mg/m2 i.v. Every 2 weeks.
1914939|NCT01599663|Other|Pain management algorithm|The algorithm guide the clinicians to score ICU patients pain systematically with different pain assessment tools. The tools are the Numeric Rating Scale, Behavioral Pain Scale and Behavioral Pain Scale Non Intubated. The algorithm guide the clinicians to choose between the different pain assessment tools depending on the ICU patient's condition and ability to rate his own pain. Thereafter the algorithm guide the clinicians to treat pain depending on the pain intensity score.
1914946|NCT01597791|Device|Foley catheter|Foley catheter placement after CSE.
1914947|NCT01597791|Other|No foley catheter|Spontaneous Micturation/ Post Void Residual. the spontaneous micturition algorithm will be assessed for spontaneous micturition and post void residual (PVR) volumes via ultrasonography at regular time intervals.
1971084|NCT01256671|Drug|DHEA|Vaginal suppository containing 0.5% (6.5 mg) DHEA; daily dosing with one suppository for 52 weeks.
1971085|NCT01256112|Behavioral|Parent Supported Behavioral Intervention|Parents of participants receive training in behavioral support at home in order to facilitate lifestyle change associated with dietary choices and physical activity designed to produce gradual weight loss.
1971086|NCT01256112|Behavioral|Nutrition/Activity Education (NAE)|
1971088|NCT01250327|Device|Melody|insertion of a pulmonic valved stent
1971089|NCT01250327|Device|bare stent|insertion of a bare metal stent
1971090|NCT01250327|Procedure|Surgery|conventional surgery methode
1971092|NCT01239394|Drug|ofatumumab|Weekly infusion for 8 weeks
1992581|NCT03320109|Other|Vitamin D|
1992582|NCT03320096|Device|Microfocused ultrasound with visualization|Subjects will receive 2 treatments (day 1 and day 30), each at a 3.0mm depth and 0.30 Joule of energy. Treatment will be delivered in a 3 x 4 grid, 12 treatment squares, delivering 60 lines of treatment per square, i.e., 720 lines per axilla in each treatment (1440 lines total per treatment.)
1992584|NCT03321227|Other|Snack skipping|No snack provided
1992585|NCT03321227|Other|Whole eggs|2 whole eggs scrambled, provided as a snack
1992586|NCT03321227|Other|Egg whites|2 egg whites scrambled, provided as a snack
1992587|NCT03321227|Other|Egg yolks|2 egg yolks scrambled, provided as a snack
1992588|NCT03321227|Other|Yogurt|A serving of full fat yogurt that is isocaloric to the 2 whole egg test snack
1992589|NCT03319602|Device|Double trunk mask add above a nasal canulae|oxygenation only with nostril prongs
1992590|NCT03320018|Drug|Hydrogen|Hydrogen will be infused into bags of normal saline solution and administered intravenously, or infused into water for the patient to drink, as the patient's condition permits. This will be administered q 8 hours for 3 days.
1992591|NCT03320018|Drug|Minocycline|"Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.
Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period."
1992592|NCT03320018|Other|Placebo Hydrogen|Normal saline solution or water will be administered i.v. or p.o. respectively, in place of hydrogen solution.
1992593|NCT03320018|Other|Placebo Minocycline|Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.
1992595|NCT03319862|Procedure|Inferior pédicule gynaecomastia|Inferior pédicule gynaecomastia
1992596|NCT03319823|Drug|Thiazide Treatment Group|"Thiazide Treatment Group: Non-diabetics with sleep systolic blood pressure of 125-139 mm Hg and awake systolic blood pressure <160 mm Hg Participants will be treated with Indapamide 0.625mg once a day After 4 weeks of treatment, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring the investigators will repeat ambulatory blood pressure monitoring at 4, 8, and 12 weeks after treatment initiation.
If sleep systolic blood pressure is < 120 mm Hg, the investigators will continue treatment"
1971100|NCT01231620|Drug|Zanamivir|Zanamivir aqueous solution, 10 mg/mL, will be provided as a single use, sterile clear, colorless preparation in 20 mL clear glass vials.
1971101|NCT01231620|Drug|Placebo to match zanamivir|Placebo to match IV zanamivir will be provided as a normal saline solution of a matched volume.
1971102|NCT01231620|Drug|Oseltamivir|Oseltamivir will be provided as over-encapsulated 75 mg capsules.
1971103|NCT01231620|Drug|Placebo to match oseltamivir|Placebo to match oral oseltamivir will be provided as capsules with a common excipient of appropriate quality.
1971104|NCT01222780|Drug|Marqibo|"Marqibo® will be administered intravenously over 60 minutes (±10 minutes) every 7 days (±3 days) (Days 1, 8, 15, 22) for four doses (1 cycle). Cycles may be repeated every 28 days for a maximum of 6 cycles; additional cycles may be offered with evidence of acceptable toxicity and clinical benefit.
The trial follows a rolling phase I design with 2 to 6 subjects per dose level and standard definitions of MTD and DLT. At the MTD, a total of 6 additional subjects with relapsed or refractory ALL will be evaluated.
Detailed pharmacokinetic studies will be performed during the first treatment cycle"
1971113|NCT01212770|Drug|Apremilast 20mg|Apremilast 20 mg twice daily, orally
1971114|NCT01212770|Drug|Apremilast 30mg|Apremilast 30 mg twice daily, orally
1971115|NCT01212770|Drug|Placebo|
1971118|NCT01210352|Drug|oxymorphone HCl|Comparison of different dosages of drug, 0.05mg/kg, 0.10mg/kg, 0.15mg/kg or 0.20mg/kg oral liquid oxymorphone
1971121|NCT01205529|Drug|Procainamide|One time intravenous infusion of Procainamide administered over 30 minutes. Dosage is calculated as 10mg/kg based on subject's ideal body weight.
1971129|NCT01196416|Drug|Cisplatin|Given IV
1971130|NCT01196416|Drug|Gamma-Secretase Inhibitor RO4929097|Given PO
1971131|NCT01196416|Other|Laboratory Biomarker Analysis|Correlative studies
1971132|NCT01196416|Other|Pharmacological Study|Correlative studies
1971133|NCT01196416|Drug|Temozolomide|Given PO
1971134|NCT01196416|Drug|Vinblastine Sulfate|Given IV
1971143|NCT01192295|Drug|Oxycodone HCl controlled-release tablets|Oxycodone HCl controlled-release tablets at strengths of 10, 15, 20, 30, or 40 mg (20 mg - 240 mg daily) every 12 hours.
1915004|NCT01585103|Device|Cytosponge - Brushing|"Patients with eosinophilic esophagitis will be enrolled. Undergoing clinically indicated endoscopy and biopsy either for initial diagnosis or for monitoring the activity of their disease.
Two hours prior to endoscopy in the patients will be asked to swallow the Cytosponge. Briefly, the capsule and bunched up string are swallowed with water.
The string is held without any tension to allow the capsule to move into the stomach. The patient holds onto the string for five minutes after ingestion to allow the capsule to dissolve in the proximal stomach, where a spherical mesh of 3 cm diameter is released.
The back of the throat is then sprayed with 1% lidocaine and the expanded mesh withdrawn by pulling on the string with the patient's head in an extended position.
Following this, the clinically indicated endoscopy will be performed. Prior to biopsies we will do a brushing of the esophagus."
1971166|NCT01169350|Radiation|fludeoxyglucose F 18|Undergo 18F FDG and 18F FMISO PET/CT scans
1971167|NCT01169350|Other|18F-fluoromisonidazole|Undergo 18F FDG and 18F FMISO PET/CT scans
1971168|NCT01169350|Procedure|positron emission tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
1971169|NCT01169350|Procedure|computed tomography|Undergo 18F FDG and 18F FMISO PET/CT scans
1971170|NCT01169350|Other|laboratory biomarker analysis|Correlative studies
1915024|NCT01579162|Device|Cholate-24-13C (IND 65121) & Cholate-2,2,4,4-d4 (IND 65123)|"The FDA has indicated that liver function diagnostic testing with stable isotope labeled cholates would be considered a drug/device combination product. The drugs administered at each test visit will be:
20 mg Cholate-24-13C, IV (in the vein), dissolved in NaHCO3 and mixed with albumin.
40 mg Cholate-2,2,4,4-d4, oral, dissolved in NaHCO3 and mixed with juice.
The 3 test visits will be on separate days within a span of 30 days"
1971177|NCT01160393|Device|Miniaturized bypass system|Compare the conventional bypass system and miniaturized bypass system of the incidence of atrial fibrillation after cardiac surgery
1915030|NCT01576705|Drug|thyroid hormone and folinic acid|thyroid hormone 25microg or placebo in tablets folinic acid 5 mg or placebo in capsules
1971178|NCT01160211|Drug|lapatinib|1000 mg by mouth once a day
1971179|NCT01160211|Drug|trastuzumab|Loading dose of 8 mg/kg IV followed by the maintenance dose of 6 mg/kg IV every 3 weeks
1971180|NCT01160211|Drug|Aromatase inhibitor|Aromatase inhibitor (either letrozole, anastrozole, or exemestane) of investigator's choice given by mouth once daily
1971181|NCT01160211|Drug|lapatinib|1500 mg by mouth once daily
1971184|NCT01158950|Drug|Tolcapone|Drug: Tolcapone 200mg (single dose) administered at study visit
1971185|NCT01158950|Other|Placebo|Placebo (200mg) administered at study visit
1971186|NCT01158950|Drug|Entacapone|Entacapone 200mg (single dose) administered at study visit
1915052|NCT01573533|Biological|Rituximab|Rituximab will be infused intravenously on Day 1 and Day 15 at a dose of 375 mg/m2 up to a maximum of 1000mg per dose in children and at a dose of 1000 mg on Day 1 and Day 15 in adults.
1971198|NCT01132612|Drug|AIN457|secukinumab
1971199|NCT01132612|Drug|Placebo|placebo
1971204|NCT01125501|Dietary Supplement|Protandim|The product Protandim used in this study have ingredients derived from five botanical sources [Bacopa monniera, Silybum marianum (milk thistle), Withania somnifera (Ashwagandha), Camellia sinensis (green tea), and Curcuma longa (turmeric)].
1915060|NCT01573169|Drug|Enoxaparin|enoxaparin 0.4 ml sc per day for 10 days started 72 hours after the stroke
1915061|NCT01573169|Other|Graduated compression stockings and/or intermittent pneumatic compression and/or early mobilization|placebo standard therapy
1915068|NCT01571310|Other|Omitted Breakfast|Experimental:The patients in Omitted Breakfast day will omit the breakfast and will continue the overnight fast until lunch. They will eat only lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
1915069|NCT01571310|Other|Breakfast|"In the Active Comparator: The patients in the Breakfast day will consume breakfast (700 kcal) at 8:00 , lunch (700 kcal) at 13:30 and dinner (700 kcal) at 19:00
(YesB): The patients in YesB will eat all three mealswill consume three meals:"
1971222|NCT01108757|Drug|Bactrim|Bactrim DS BID for 3 days
1971223|NCT01108757|Other|Placebo|Corn starch capsules
1971224|NCT01107964|Drug|Oral Omega-3-acid ethyl esters|1 gram capsule by mouth four times daily for 45 days
1971225|NCT01107964|Drug|Placebo corn oil capsule|1 gram by mouth 4 times daily for 45 days
1971235|NCT01091363|Drug|nicotine patch|8-week nicotine patch therapy
1915099|NCT01565928|Drug|MDV3100|4 x 40 mg capsules, orally, once per day
1992954|NCT03268070|Device|Repetitive TMS over contralateral primary motor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral primary motor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain.Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
1992955|NCT03268070|Device|Sham Repetitive TMS over contralateral premotor cortex.|Sham rTMS will be applied over contralateral premotor cortex. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
1992956|NCT03268070|Device|Single TMS over extensor carpi ulnaris spot of motor cortex|Single-pulse TMS will be applied over the extensor carpi ulnaris (ECU) hotspot of primary motor cortex (M1) during motor training.TMS uses magnetism to excite neurons near the surface of the brain. TMS pulses will be applied at different strengths (30%-80% maximum stimulator output) and record subsequent activity of the ECU muscle using electromyography (EMG).
1992957|NCT03268005|Drug|Faster-acting insulin aspart|Faster aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
1992958|NCT03268005|Drug|Insulin aspart|Insulin aspart given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
1992959|NCT03268005|Drug|Insulin degludec|Insulin degludec given subcutaneously (s.c., under the skin) once a day for 16 weeks. Dose individually adjusted.
1992960|NCT03268005|Drug|Metformin|Only participants who took metformin before the study should take metformin tablets, same dose as before the study
1992961|NCT03267732|Biological|AM0010|AM0010 Alone
1992962|NCT03267056|Device|drug eluting balloon catheter (trade name: Orchid)|use drug eluting balloon catheter to inflate the stenosis or occlusion in superficial femoral artery(SFA) and/or popliteal artery
1992966|NCT03264508|Behavioral|Heat therapy|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 40°C water, sufficient to raise body core temperature to 38.5°C.
1992967|NCT03264508|Behavioral|Thermoneutral water immersion|30 sessions (3-4x per week for 8-10 weeks) of hot water immersion in 36°C water to prevent changes in body core temperature >0.2°C.
1992970|NCT03263871|Dietary Supplement|PTM202|PTM202 given twice daily for 30 days.
1992971|NCT03263871|Dietary Supplement|micro-nutrient sprinkles|Micro-nutrient sprinkles will be given twice daily for 30 days.
1992972|NCT03263702|Device|Computational Mapping Algorithm|This software enables high resolution temporospatial mapping of atria for the identification of drivers of AF. CMA receives data from standard of care, commercially available 3D Mapping Systems (St. Jude Ensite System) and catheters and processes the data in a unique way. Electrogram and anatomy data are fed from the commercially available 3D Mapping System to an adjacent laptop computer, via an Ethernet connection, that is running CMA. CMA then processes the electrogram data and generates a map of where the potential AF driver domains are located and superimposes those potential AF driver domain targets onto the 3D geometry of the anatomy (provided by the 3D mapping system).
1992973|NCT03263442|Drug|Thiamine|200 mg IV three times daily for seven days
1992974|NCT03263442|Drug|Normal saline|Normal saline IV three times daily for seven days
1992975|NCT03263416|Other|Dedicated and coordinated follow-up|"Coordinated follow-up performed by a dedicated nurse with consultations (before treatment initiation and during treatment) and a telephone follow-up during treatment period
Pharmaceutical conciliation before treatment initiation made by the Center Pharmacist
Completion of QLQ-C30 and GIRERD questionnaires"
1992976|NCT03263416|Other|Standard follow-up|- Completion of QLQ-C30 and GIRERD questionnaires
1992978|NCT03261401|Drug|M5717|Subjects will receive single ascending oral dose of M5717 after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
1992979|NCT03261401|Drug|M5717|Subjects will receive multiple ascending oral doses of M5717 after an overnight fast of at least 8 hours once daily for 3 days, followed by a 4-hour post-dose fast
1992980|NCT03261401|Drug|Placebo|Subjects will receive placebo matched to M5717
1992981|NCT03261401|Drug|M5717|Subjects will receive single ascending oral dose of M5717 from Part A or as applicable multiple ascending oral doses of M5717 from Part B after at least 8 hours of fasting together with water on Day 1, followed by a 4-hour post-dose fast
1992982|NCT03262740|Drug|BMS-986195|Oral administration of specified dose on specified days
1992983|NCT03262740|Drug|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
1915135|NCT01555905|Device|Threshold PEP or IMT device Phillips-Respironics|The subject will be instructed to take 8-15 deep, forceful breaths through the Threshold device, followed by at least 3 minutes of rest. The process will be repeated 3 more times for a total of 4 sets of 8-15 breaths. IMST will be completed three to five days per week, based upon the subject's daily baseline level of fatigue.
1971281|NCT01033617|Procedure|Injection of stem cells at time of coronary artery bypass grafting|Following completion of the distal coronary artery bypasses, autologous CD133+ stem cells,or placebo solution containing plasma and indistinguishable will be injected in the myocardium. A total of 2.0 ml with 10-15 injections will be injected.
1915155|NCT01550757|Behavioral|Embedded Peer Mentor|This intervention/condition consists of a formerly homeless individual embedded in the PACT or H-PACT clinic team. This person is responsible for community-based follow-up for homeless patients randomly assigned to him or her. In addition to structured, scheduled meetings with assigned study subjects, the peer mentor will also participate in PACT/H-PACT team meetings and serve as a liaison between the study subject and his or her primary care team. Peer mentors will be hired as VA term employees in Research.
1971296|NCT01009515|Drug|Paclitaxel, carboplatin, temozolomide|Combination chemotherapy was administered for up to 6 cycles
1971307|NCT00999102|Drug|Metoprolol|Comparison of Metoprolol and Nebivolol. Metoprolol succinate will be given at a dose of 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks. For nebivolol, dosage will be 5 mg and 10mg daily. Identical-appearing pills will be given, and the drugs will be given in randomized order without a placebo run-in.
1971308|NCT00999102|Drug|Nebivolol|Comparison of Metoprolol and Nebivolol. Metoprolol succinate will be given at a dose of 50 mg daily for 4 weeks, then 100 mg daily for 4 weeks. For nebivolol, dosage will be 5 mg and 10mg daily. Identical-appearing pills will be given, and the drugs will be given in randomized order without a placebo run-in.
1971313|NCT00996840|Drug|SB-681323 Intravenous 3mg|3 mg SB-681323 Intravenous administration infused over 4 hours
1971314|NCT00996840|Drug|SB-681323 Intravenous 7.5 mg|7.5 mg SB-681323 Intravenous administration infused over 24 hours
1971315|NCT00996840|Drug|SB-681323 Intravenous 7.5mg|7.5 mg SB-681323 Intravenous administration infused over 4 hours
1971316|NCT00996840|Drug|SB-681323 Intravenous 10mg|10 mg SB-681323 Intravenous administration infused over 24 hours
1971317|NCT00996840|Other|Placebo|Placebo to match intervention
1971318|NCT00985088|Biological|GSK2340274A|one or two intramuscular injections
1971319|NCT00985088|Biological|GSK2340273A|one or two intramuscular injections
1971320|NCT00985088|Biological|Saline placebo|One injection
1971339|NCT00976352|Drug|rAAV1-CMV-GAA (study agent) Administration|rAAV1-CMV-GAA via intramuscular injection into the diaphragm. Dose selection for cohort 1: 1.0 x 10e12 vector genomes Cohort 1 will have a total of 3 participants enrolled. Dose selection for cohort 2 and 3: 5.0 x 10e12 vector genomes rAAV1-CMV-GAA. Cohort 2 = 6 subjects.
1971340|NCT00976352|Other|RMST|After enrollment and screening visit, the subject will be given a RMST prescription and will complete RMST for a minimum of 4 weeks prior to study agent administration. RMST prescription will be adjusted as needed at Day 14, 90, 180, and 270.
1971346|NCT00947180|Behavioral|Biofeedback|Electromyographic (EMG) activity was recorded from sensors placed in the anal canal, averaged, and displayed to patients to help them learn to relax the pelvic floor muscles during straining.
1971347|NCT00947180|Other|Electrogalvanic stimulation|Electrical stimulation was applied to pelvic floor muscles through an anal plug. Frequency was 80 pulses per sec, and voltage was slowly increased from 0 to 150-350 volts as tolerated.
1971348|NCT00947180|Behavioral|Digital massage|Using a gloved finger, the therapist pressed on the levator ani as firmly as tolerated and moved the finger from side to side 3-4 times.
1992984|NCT03262727|Drug|BMS-986165|Oral administration of specified dose on specified days
1992985|NCT03262727|Drug|Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)|Oral Contraceptive
1992986|NCT03262701|Drug|Hydrogen Peroxide Gel, 13 weeks|13 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
1992987|NCT03262701|Drug|Hydrogen Peroxide Gel, 26 weeks|26 weeks of twice-daily use of custom tray application of 1.7% peroxide gel as an adjunct to scaling and root planing in the treatment of chronic periodontitis.
1992988|NCT03262376|Dietary Supplement|Minerals + Vitamins|A mineral and vitamin tablet
1992989|NCT03262376|Dietary Supplement|Botanical A|Botanical extract administered in capsule form
1992990|NCT03262376|Dietary Supplement|Botanical B|Botanical extract administered in capsule form
1992991|NCT03262376|Other|Placebo|Cellulose crystalline tablet
1992993|NCT03262337|Other|none, this is an observational study|none, this is an observational study
1992994|NCT03261960|Drug|BLI4700|Oral bowel preparation
1992995|NCT03261960|Drug|FDA Approved Bowel Preparation|Oral bowel preparation
1992996|NCT03259893|Device|AliveCor mobile ECG cardiac monitor|AliveCor mobile ECG cardiac monitor is capable of providing real-time heart telemetry using a smart phone. Participants will be instructed to transmit rhythm data twice weekly and during symptomatic AF.
1992997|NCT03259893|Behavioral|AF Program|The AF program includes a bundle of sub-interventions that target specific AF risk factors including hypertension, obesity, physical inactivity, sleep hygiene, and smoking. Participants randomized to the intervention group 2 will undergo counseling by the nurse and guided through the structured, goal-directed AF program. Each participant will receive an AliveCor cardiac monitor which is capable of providing real-time heart telemetry using a smart phone.
1992998|NCT03259893|Other|Standard of care|Guideline-directed medical therapy according to clinical standard practice at Boston Medical Center.
1992999|NCT03260855|Other|Questionnaires/Scales|Scale of Fear of Cancer Recurrence Inventory, Hospital Anxiety and Depression Scale, Evaluation of stress and life quality.
1993000|NCT03260855|Other|Human blood sample|The intervention is based on blood test.
1993001|NCT03260595|Drug|Crisaborole ointment 2%|Crisaborole ointment 2%
1993002|NCT03260595|Drug|Vehicle|Vehicle
1993003|NCT03260361|Other|Hypnosis, kinesitherapy, MEOPA|classical intervention
1993004|NCT03260361|Other|Usual practice|Usual practice with treatments and physio
1915196|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells 1 day following IV cyclophosphamide 200 mg
1915197|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 0.5 g/m2
1915198|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.0 g/m2
1915199|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 2.0 g/m2
1915200|NCT01543152|Genetic|SB-728-T|Infusion will be 5 to 30 billion ZFN modified CD4+ T cells up to 3 days following IV cyclophosphamide 1.5 g/m2
1915201|NCT01543087|Procedure|blood sampling|Blood sample collection at different time points
1915202|NCT01543087|Drug|bivalent rLP2086|A booster dose of bivalent rLP2086 at approximately 48 months following the final dose of the 2- or 3-dose primary bivalent rLP2086 vaccination series will be given at Visit 7.
1915206|NCT01542541|Drug|Rifaximin|550mg BID for 2 days
1971376|NCT00923364|Drug|Cyclophosphamide (CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
1971377|NCT00923364|Drug|Fludarabine(Fludara,Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
1971378|NCT00923364|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1 or 300 cGy on Day -1 (for 9/10 URD and Haplo patients)
1971379|NCT00923364|Procedure|Allogeneic HSC|stem cell transplant
1971380|NCT00923364|Drug|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
1915227|NCT01536834|Device|Medical Device|
1971394|NCT00902278|Biological|Fluvirin|one 0.5-mL dose via intramuscular injection
1971395|NCT00902278|Biological|Flulaval|one 0.5-mL dose via intramuscular injection
1971396|NCT00902278|Biological|Fluzone|one 0.5-mL dose via intramuscular injection
1971397|NCT00902278|Biological|Fluarix|one 0.5-mL dose via intramuscular injection
1971398|NCT00902278|Biological|Afluria|one 0.5-mL dose via intramuscular injection
1971417|NCT00874133|Procedure|Acupuncture|Acupuncture treatment for 12 weeks.
1971418|NCT00874133|Drug|Motilium|20 mg motilium thrice daily
1971419|NCT00866359|Drug|Apremilast (CC-10004)|"Treatment Phase Days 1-7: Titration from 10 mg BID apremilast tablets arm A (or matching placebo arm B) to 30 mg BID apremilast arm A(or matching placebo arm B) Day 8-84: Maintenance of 30 mg BID apremilast arm A (or matching placebo arm B) Dose reductions to 20 mg BID apremilast arm A (or matching placebo arm B) are permitted.
Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.
Day 92-169: Maintenance of 30 mg BID apremilast arm A or dose reductions to 20 mg BID apremilast arm A (if not previously down titrated)"
1971420|NCT00866359|Drug|Placebo|"Treatment Phase Days 1-7: Titration from 10mg BID matching placebo (arm B) to 30mg BID placebo (arm B) Day 8-84: Maintenance of 30mg BID placebo (arm B). Dose reductions to 20 mg BID matching placebo (arm B) are permitted.
Extension Phase All subjects will be given active drug Days 85-91: All placebo subjects from Treatment phase will be dose titrated from 10 mg BID apremilast tablets arm A to 30 mg BID Apremilast.
Day 92-169: Maintenance of 30 mg BID apremilast or dose reductions to 20 mg BID apremilast (if not previously down titrated)"
1971421|NCT00856609|Drug|Byetta (exenatide)|Exenatide is an injectable medication
1915257|NCT01531101|Behavioral|Individual psychodynamic psychotherapy|Individual psychodynamic psychotherapy with or without transference work. I.e. with or without relational therapist interventions focusing on the patient-therapist relationship.
1971422|NCT00856609|Behavioral|Weight loss|Because response to weight loss
1971423|NCT00856609|Other|Metabolic Chamber|The subject stays in the small room
1971424|NCT00856609|Drug|Placebo|
1971425|NCT00851201|Behavioral|Intensive lifestyle|"The intensive lifestyle intervention will include the standard intervention plus 1)12 core group modules for parents (to address roles and skills) and for children (to enhance motivation and skills and to provide physical activity), 3) Tailored support using a toolbox approach from community health workers as extensions of the Family Weight Management professional education staff, and 4) monthly after-core follow-up groups."
1971426|NCT00851201|Behavioral|Standard intervention|The Standard Intervention will receive: 1) an initial consult, which includes an overview of lifestyle goals, 2) quarterly follow-up, 3) and a monthly newsletter.
1971430|NCT00841568|Drug|OPC-41061|orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
1971431|NCT00832637|Drug|Cisplatin|Cisplatin is administered intravenously at 40 mg/m2 on day 1 and day 15, every 28 days. Cisplatin is administered following Gemcitabine. Cisplatin administration should occur with hydration with normal saline at 250 mL/ hour for at least 4 hours before and during Cisplatin administration. Additionally, Cisplatin administration should be preceded by osmotic diuresis with Mannitol 25%, 12.5 grams.
1995671|NCT02688985|Procedure|Lumber Puncture|Participants will receive LP as specified in individual arms.
1995672|NCT02688699|Procedure|EndoClot|"All patients enrolled and submitted to EMR or ESD in several units of Italian endoscopy will be divided into two different groups: in a first group will be included patients at the endoscopic end of which will be applied EndoClotTM based on the lesion removed in addition to the treatment Standard (drug injection, electrocoagulation, metal clips). The second group, on the other hand, includes patients in whom EndoClotTM will not be used.
Before the end of the procedure neither the endoscopist nor the patient will know the group because the group to which the patient is assigned will be written in a sealed envelope that will be opened only at the end of the procedure before the endoscope extraction: The use of EndoClotTM will depend on the group to which the patient belongs."
1995673|NCT02687191|Biological|PF-05230907|PF-05230907 IV bolus injection
1995674|NCT02686814|Device|17mm MDT-2215 aortic valve bioprosthesis|
1995675|NCT02685982|Device|Rhythmic Sensory Stimulation|"The stimulation consists of 30 minutes of daily stimulation with specially composed relaxing music tracks embedded with gamma frequency sounds of 30-70 Hz range.
In this study, the stimuli will be delivered with a portable sound device called Sound Oasis Vibroacoustic Therapy System (VTS-1000) unit, which is a low-voltage consumer product that has two built in mid to high frequency speakers and one built in low frequency (subwoofer-type) speaker. The low frequency sounds played by the subwoofer speaker is experienced as vibrotactile vibration. Although the Intervention of Interest in this study is the Rhythmic Sensory Stimulation with low-frequency sounds, the efficacy of the Sound Oasis VTS-1000 device to deliver the intervention will also be subject to observation."
1995676|NCT02686489|Other|Heated humidification|Water vapor (molecular water) will be added to the inspired gas of the spontaneously breathing tracheostomy patient by using the Fisher & Paykel Healthcare, (Auckland, New Zealand) AIRVO 2 Humidification System. The AIRVO 2 will provide respiratory gas flow at 2-60 L/min) that is conditioned to 37° C, 34° C, or 31° C (based on patient comfort) and 100% relative humidity via a heated breathing circuit.
1995677|NCT02686489|Other|Cool bland aerosol|Aerosol (particles of water suspended in gas) generated by a flow of gas through a pneumatically powered large volume jet nebulizer filled with sterile water (for inhalation) attached to a gas source via a flowmeter set between 10-15 L/min will add moisture to the inspired gas of the spontaneously breathing tracheostomy patient. The cold bland aerosol set-up will consist of corrugated aerosol tubing with one end connected to the nebulizer output port and the other end connected to a tracheostomy mask.
1995678|NCT02686021|Drug|Metamizole and Ibuprofen|Metamizole (1000mg) plus Ibuprofen (400mg) 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
1995679|NCT02686021|Drug|Metamizole and Placebo|Metamizole (1000mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
1995680|NCT02686021|Drug|Ibuprofen and Placebo|Ibuprofen (400mg) plus placebo 15 minutes prior to surgery, at 6 postoperative hours, and at 12 postoperative hours
1997779|NCT01919164|Drug|AS902330 30 microgram (mcg)|AS902330 will be administered at a dose of 30 mcg in 2 cycles (at Baseline and Month 12), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
1971432|NCT00832637|Drug|Erlotinib|100 mg orally daily. For grade 3 or 4 skin rash, erlotinib should be held until resolution of the rash to no more than grade 1 before resumption of erlotinib.
1971433|NCT00832637|Drug|Gemcitabine|Gemcitabine is administered intravenously at 1000 mg/m2 on day 1 and 15, every 28 days. The clinical formulation is supplied in a sterile form for intravenous use only. Vials of gemcitabine contain either 200 mg or 1 g of gemcitabine hydrochloride (HCl )(expressed as free base) formulated with mannitol (200 mg or 1 g, respectively) and sodium acetate (12.5 mg or 62.5 mg, respectively) as a sterile lyophilized powder. Hydrochloric acid and/or sodium hydroxide may have been added for pH adjustment.
1971434|NCT00832520|Drug|Remeron (mirtazapine)|"Mirtazapine 15 mg orally at bed time. Patients with a creatinine clearance < 50% or a bilirubin or transaminases > twice the upper limit of normal will take a 7.5 mg dose.
Drug Administration: Drug will be administered orally, every day for a period of 8 weeks
Dose modifications: None"
1971435|NCT00818779|Drug|Aliskiren|150 - 300 mg once daily for 6 weeks
1971436|NCT00818779|Drug|Amlodipine|5-10 mg once daily for 6 weeks
1971441|NCT00805948|Device|Talent Thoracic Stent Graft System|endovascular repair of descending thoracic aneurysms using the Talent Thoracic Stent Graft System.
1971445|NCT00803452|Drug|doxycycline|Oral doxycycline 100mg bid
1971446|NCT00803452|Drug|essential fatty acid|Oral essential fatty acid 1000mg per day
1971447|NCT00803452|Drug|azithromycin|topical 1% azithromycin daily to eye
1971450|NCT00796068|Drug|Cyclosporine|Given IV or PO
1971451|NCT00796068|Drug|Fludarabine Phosphate|Given IV
1971452|NCT00796068|Other|Laboratory Biomarker Analysis|Correlative studies
1971453|NCT00796068|Drug|Mycophenolate Mofetil|Given IV
1971454|NCT00796068|Radiation|Total-Body Irradiation|TBI administered day -1: 200 cGy (or escalated to 300 cGy, 400 cGy, or 450 cGy per protocol statistical section)
1971455|NCT00796068|Drug|Treosulfan|Given IV
1971456|NCT00796068|Procedure|Umbilical Cord Blood Transplantation|Undergo single or double unit UCBT
1971460|NCT00788684|Drug|ABT-263|ABT-263: oral solution or tablets, once daily dosing until disease progression
1971461|NCT00788684|Drug|rituximab|IV infusion once weekly for four doses
1971474|NCT00773643|Other|biopsy|A biopsy of the patient's temporalis muscle, subcutaneous adipose, and bone tissue is the experimental procedure. The procedure will not involve any extra incisions or dissection, as these tissues will be exposed during the reconstructive procedure. A very small fragment of each tissue type, 2mm X 2mm X 3mm biopsy, will be removed.
1971475|NCT00773994|Other|Normal Velopharyngeal Mechansim|The amount of radiation exposure that you will receive from this procedure is about 0.3 rem to the head and neck, with minimal exposure of the other body areas.
1971482|NCT00765973|Drug|Topotecan Liposomes Injection (TLI)|TLI dose on Days 1 and 8 of a 21-day treatment cycle (Starting dose: 1 mg/m2)
1971483|NCT00765973|Drug|Topotecan Liposomes Injection (TLI)|TLI dose on Day 1 of a 21-day treatment cycle (Starting dose: 2 mg/m2)
1915316|NCT01517867|Behavioral|Chicago Parent Program|The Chicago Parent Program is a 12-session group-based parenting skills intervention for parents of young children with behavior problems
1915317|NCT01517867|Behavioral|Parent-Child Interaction Therapy|Parent-Child Interaction Therapy is an individually-tailored coaching intervention for parents and young children with behavior problems
1971495|NCT00732563|Drug|chemotherapy|Given IV and Orally
1971496|NCT00732563|Procedure|lymphadenectomy|Removal of lymph nodes
1971497|NCT00732563|Procedure|neoadjuvant therapy|Tumor reduction
1971498|NCT00732563|Procedure|quality-of-life assessment|Correlative Study
1971499|NCT00732563|Procedure|therapeutic conventional surgery|Treatment for cancer
1971500|NCT00732563|Procedure|thoracic surgical procedure|removal of tissue
1971501|NCT00732563|Radiation|fludeoxyglucose F 18|given IV
1971502|NCT00732563|Radiation|radiation therapy|undergoing radiotherapy
1915332|NCT01514760|Other|Mobile-based Asthma Action Plan|"The participant will be distributed a mobile phone (iPhone or Android) at the time of consent. The mobile-based Asthma Action Plan application will be provided on the mobile device. The mobile phone based application features will include ambulatory peak flow and asthma symptoms diary, individualized treatment plan for routine care and during episodes of acute asthma symptoms, and education components to reinforce asthma self-management concepts. Participants will receive 3 daily messages from the Asthma Action Plan mobile application. A fourth rotating message will be sent twice weekly."
1971507|NCT00722865|Drug|Avastin|Given intravenously along with standard chemotherapy (Adriamycin, Bleomycin, Vinblastine and Dacarbazine) on days 1 and 15 of a 28-day cycle for a total of 6 planned cycles.
1971508|NCT00722683|Procedure|Ultrasound Imaging with Contrast|"An ultrasound contrast agent, Definity, will be administered started through the IV line already in use. The imaging will be performed to map vascular flow.
The breast will be scanned by a double ultrasound transducer system in a holder over the area of the breast to be biopsied. The machine will be set with different settings and the scan repeated, possibly multiple times."
1971515|NCT00704496|Drug|Pseudoephedrine|Pseudoephedrine is a 240 mg PO per day
1990190|NCT02164019|Procedure|long-stem cemented hemiarthroplasty (LSCH)|
1971524|NCT00680823|Drug|Ropivacaine|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
1971525|NCT00680823|Drug|Normal saline|1.5 mL IM to each side in to the lower cervical paraspinous muscles x 1.
1971531|NCT00656786|Drug|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day; beginning when the rash appears during EGFRi therapy.
1971532|NCT00656786|Drug|Menadione Topical Lotion|Menadione Lotion will be applied topically twice a day, starting 1 day before EGFRi therapy.
1971545|NCT00635999|Behavioral|Applied relaxation and self-control desensitization|Applied relaxation and self-control desensitization sessions will teach participants relaxation techniques and the use of imagery for coping with anxiety. Treatment will include 14 weekly sessions.
1971546|NCT00635999|Behavioral|Cognitive behavioral therapy (CBT)|CBT sessions will teach participants to identify ways in which they perceive themselves and the world and how to modify these thoughts to reduce anxiety. CBT will include 14 weekly sessions.
1971547|NCT00635739|Dietary Supplement|Whey protein|powdered, 46g supplement dissolved in fluids, twice daily
1971548|NCT00635739|Dietary Supplement|Maltodextrin placebo|powdered, 46g supplement dissolved in fluids, twice daily
1971551|NCT00619112|Drug|temozolomide|single arm study
1971558|NCT00602953|Other|No intervention planned.|This is a cross-sectional observational study, no intervention is planned.
1990191|NCT02164019|Procedure|intramedullary nailing (IMN)|
1990192|NCT02164019|Behavioral|questionnaires|
1971564|NCT00597766|Drug|Lidocaine|One-time Screening/Eligibility Neer's Test: 5 cc of 2% lidocaine
1971565|NCT00597766|Drug|Triamcinolone + Lidocaine|Low Dose -- One-time injection of 20 mg triamcinolone: 1.5 cc of normal saline, 0.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
1971566|NCT00597766|Drug|Triamcinolone + Lidocaine|Standard Dose -- One-time injection of 40 mg triamcinolone: 1 cc of normal saline, 1 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
1971567|NCT00597766|Drug|Triamcinolone + Lidocaine|High Dose -- One-time injection of 60 mg triamcinolone: 0.5 cc of normal saline, 1.5 cc of 40mg/cc of triamcinolone and 2 cc of 2% lidocaine
1971591|NCT00545714|Drug|Cyclophosphamide|Cyclophosphamide 250 mg/m^2 as IV infusion will be administered on Days 1 to 3 of first six 28-day cycles.
1971592|NCT00545714|Drug|Fludarabine|Fludarabine 25 mg/m^2 as IV infusion will be administered on Days 1 to 3 of first six 28-day cycles.
1971593|NCT00545714|Drug|Rituximab|Rituximab 375 mg/m^2 as IV infusion will be administered on Day 1 of Cycle 1; 500 mg/m^2 as IV infusion will be administered on Day 1 of Cycle 2 to 6; and 375 mg/m^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
1971597|NCT00508105|Procedure|tenotomy|This treatment group will undergo a technique that involves division of the tendon to gain access to the shoulder.
1971598|NCT00508105|Procedure|osteotomy|This group will use a technique that involves elevation of the tendon with a wafer of bone in order to gain access to the shoulder.
1971600|NCT00498160|Biological|Enriched Hematopoetic Stem Cell Infusion|Enriched Hematopoetic Stem Cell Infusion
1971601|NCT00497926|Biological|Enriched Hematopoietic Stem Cell Infusion|Enriched Hematopoietic Stem Cell Infusion
1971607|NCT00481091|Drug|ABT-263|"Phase 1 dosing under two different schedules: 14 days on drug, 7 days or (14/21) or continuous dosing.
Phase 2a dosing at the recommended phase 2a dose and schedule"
1971621|NCT00433966|Drug|Bivalirudin|Bivalirudin bolus of 0.75 mg/kg IV, followed by an infusion of 1.75 mg/kg/h as soon as logistically feasible (ideally in the emergency room).
1971622|NCT00433966|Drug|Unfractionated heparin|60 U/kg of IV heparin, started as soon as possible (ideally in the emergency room).
1971623|NCT00433966|Device|Bare metal stent|Uncoated bare metal stent
1971624|NCT00433966|Device|Paclitaxel-eluting stent|slow rate-release paclitaxel-eluting stent
1971637|NCT00408005|Drug|Asparaginase|Given IM or IV
1971638|NCT00408005|Drug|Cyclophosphamide|Given IV
1971639|NCT00408005|Drug|Cytarabine|Given IT, IV, or SC
1971640|NCT00408005|Drug|Daunorubicin Hydrochloride|Given IV
1971641|NCT00408005|Drug|Dexamethasone|Given IV or PO
1971642|NCT00408005|Drug|Doxorubicin Hydrochloride|Given IV
1971643|NCT00408005|Other|Laboratory Biomarker Analysis|Correlative studies
1971644|NCT00408005|Drug|Leucovorin Calcium|Given PO
1971645|NCT00408005|Drug|Mercaptopurine|Given PO
1971646|NCT00408005|Drug|Methotrexate|Given IT or PO
1971647|NCT00408005|Drug|Nelarabine|Given IV
1971648|NCT00408005|Drug|Pegaspargase|Given IM or IV
1971649|NCT00408005|Drug|Prednisone|Given IV or PO
1971650|NCT00408005|Radiation|Radiation Therapy|Some patients undergo testicular and/or prophylactic cranial RT
1971651|NCT00408005|Drug|Thioguanine|Given PO
1971652|NCT00408005|Drug|Vincristine Sulfate|Given IV
1971659|NCT00384111|Drug|R-CVP + Zevalin Therapeutic Regimen|Standard R-CVP followed by Zevalin Theraeputic Regimen: Day 1: 250 mg/m2 Rituxan followed by 5 mCi 111In Zevalin. Day 7: 250 mg/m2 Rituxan followed by 0.4 mCi/kg Zevalin
1971660|NCT00384111|Drug|R-CVP|Standard R-CVP
1993005|NCT03260335|Behavioral|Anxiety management strategy|Anxiety management strategy as per standard care plan
1993007|NCT03259542|Drug|Mifepristone 300 MG|mifepristone 300 MG (4 tablets) orally for a total of 1200 mg a day for 14 days; then mifepristone 300 mg (3 tablets) orally for a total of 900 mg a day for 28 days
1993008|NCT03259542|Drug|Itraconazole 100 MG|itraconazole 100 MG (2 capsules) orally for a total of 200 MG for the last 14 days of mifepristone dosing
1993012|NCT03258515|Drug|AZD6094 200 mg|A potent and selective small molecule mesenchymal epithelial transition (MET) kinase inhibitor with significant antitumor activity.
1993013|NCT03258515|Other|Placebo|AZD6094 matching placebo without any pharmacological activity.
1993014|NCT03258515|Drug|Moxifloxacin|A fluoroquinolone broad-spectrum antibiotic, produces a mild, but reproducible increase in QT interval corrected (QTc) in healthy normal participants at time to reach maximum concentration (tmax - approximately 2 hours (0.5 to 4 hours)). This effect is close to the ECG interval measured from the onset of the QRS complex (onset of the QRS complex to the J point) to the offset of the T wave (QT)/QTc effect that represents the threshold of regulatory concern, around 5 ms mean QTc interval prolongation.
1993015|NCT03257696|Diagnostic Test|Close-ended questionnaire|"Yes/no questionnaire used in order to identify reliable respondent and unreliable respondent"
1993016|NCT03257852|Drug|ASP5094|intravenously administration
1993017|NCT03257852|Drug|Placebo|intravenously administration
1993018|NCT03257852|Other|Methotrexate therapy|MTX must have been continuously orally administered for at least 90 days prior to screening, with stable dosage for at least 28 days prior to screening, and will be continuously administered with the same dosage throughout the study period.
1993019|NCT03256942|Device|Etermis 4®|Etermis 4® is a sterile non-pyrogenic physiological gel made of reticulated hyaluronic acid (HA) of non-animal origin.
1993020|NCT03256734|Other|Policy intervention|Incentive payment for physicians
1993021|NCT03256175|Procedure|Percutaneous Coronary Intervention|PCI technique (e.g. pre-dilatation vs. direct stenting and stent choice) was left to operator discretion. Stent post dilatation was permitted as per individual operator practice
1971705|NCT00283803|Drug|Flutamide|250 mg tid
1971706|NCT00283803|Drug|Leuprolide Acetate|7.5 mg q month
1971707|NCT00283803|Drug|Exisulind|Exisulind 125 mg
1971708|NCT00273013|Drug|GW274150|GW274150 will be available as 30 mg white oval tablets.
1971709|NCT00273013|Drug|Singulair|Singulair will be available as over encapsulated 10 mg orange tablets.
1971710|NCT00273013|Drug|Placebo|Matching placebo for Singulair and GW274150 will be available.
1971712|NCT00271193|Behavioral|Weight loss counseling|A comparison of weight loss advice provided by primary care physicians to advice plus brief weight loss counseling provided by medical assistants. Participants in both groups receive weight loss materials.
1915484|NCT01478698|Drug|Tissue Plasminogen Activator (tPA)|tPA 10mg per dose intraperitoneal
1915485|NCT01478698|Drug|recombinant deoxyribonuclease (DNase)|DNase 5mg per dose given intraperitoneally.
1915490|NCT01476007|Drug|oral Cobalamin (vitamin B12)|Intervention group: oral Optovite® B12 1000 gammas.
1915491|NCT01476007|Drug|intramuscular Cobalamin (vitamin B12)|Control group: intramuscular Optovite® B12 1000 gammas.
1971730|NCT00208026|Drug|Pimecrolimus 1% Cream|Open label single arm
1971738|NCT00194129|Drug|Lithium|Lithium monotherapy was initiated at 300 mg twice daily and titrated over 3-6 weeks to minimum blood levels of 0.8 meq/L.
1971739|NCT00194129|Drug|Divalproex|Divalproex was then initiated at 250 mg twice daily and increased over 3-6 weeks to minimum blood levels of 50 ug/ml.
1971740|NCT00194129|Drug|Placebo|Placebo pills that looked exact to divaloproex were provided to subjects and take twice daily.
1971756|NCT00142792|Device|NMES device with EMG-triggered and Cyclic capabilities|All groups will use the NeuroMove NM900 stimulator. Subjects will use the stimulator as described for their group (treatment arm) for two 40-minute sessions per day, 5 days per week for 8 weeks. Surface electrodes for all three groups will be placed over the affected EDC and ECR (finger and wrist extensor) muscles.
1990221|NCT02146924|Biological|Chimeric Antigen Receptor T-Cell Therapy|Receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes
1990222|NCT02146924|Other|laboratory biomarker analysis|Correlative studies
1990223|NCT02146924|Biological|Chimeric Antigen Receptor T-Cell Therapy|Receive CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/mem-enriched T-lymphocytes
1915557|NCT01462253|Drug|Clofarabine, Cyclophosphamide|"The proposed treatment schedule consists of a combination of Clofarabine plus Cyclophosphamide administered over 5 consecutive days (Treatment scheme).
Clofarabine concentrate for solution for infusion should be filtered using a 0.2 micron filter and diluted to a final concentration between 0.15 mg/mL and 0.4 mg/mL with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS), or 5% dextrose injection (D5W) USP or EP prior to infusion.
Cyclophosphamide should be prepared for parenteral use by adding 0.9% sterile sodium chloride solution. Solutions of cyclophosphamide may be injected intravenously without further dilution or may be infused following further dilution: Dextrose Injection, USP (5% dextrose), Dextrose and Sodium Chloride Injection, USP (5% dextrose and 0.9% sterile sodium chloride), 5% Dextrose and Ringer's Injection."
1971817|NCT00069238|Biological|Alemtuzumab (Campath)|Alemtuzumab (Campath) followed by etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) every 3 weeks for up to 6 cycles.
1971818|NCT00069238|Drug|EPOCH|Etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin (EPOCH) + Alemtuzumab (Campath) every 3 weeks for up to 6 cycles.
1971821|NCT00064753|Drug|High Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 50 mg Folic acid: 5.0 mg Vitamin B12: 1.0 mg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
1971822|NCT00064753|Device|Low Dose Multivitamin|Vitamin B6 (Pyridoxine HCl): 1.4 mg Folic acid: 0.0 mg Vitamin B12: 2.0 mcg Vitamin B1 (Thiamine HNO3): 1.5 mg Vitamin B2 (Riboflavin): 1.5 mg Vitamin C (Ascorbic Acid): 60 mg d-Biotin: 300 mcg Niacinamide: 20 mg Pantothenic Acid Calcium Pantothenate): 10 mg
1915579|NCT01458366|Drug|Bendamustine|"Phase 1: Given via IV at the following dose levels:
Level 1: 70 mg/m2
Level -1: 50 mg/m2
Level 2: 90 mg/m2
Level 3: 120 mg/m2
Phase II: Given via IV on Days 1 and 2 of each cycle at the maximum-tolerated dose level found in the Phase I portion of the study."
1971829|NCT00059267|Drug|HBIG, Epivir, Hepsera|
1971833|NCT00009945|Drug|clodronate|1600 mg PO daily
1971834|NCT00009945|Drug|placebo|2 pills PO daily
1971835|NCT00045708|Drug|ixabepilone|Given IV
1971836|NCT00045708|Other|pharmacological study|Correlative studies
1971837|NCT00045708|Drug|Anticonvulsant|Drugs that induce hepatic Metabolic enzymes
1915580|NCT01458366|Drug|Ofatumumab|"Phase II
Cycle 1: 300 mg via IV on Day 1 and 1000 mg via IV on Day 3
Cycles 2 and 3: 1000 mg via IV on Day 1"
1915581|NCT01458366|Drug|Carboplatin|Phase II: AUC 5 via IV on Day 2 of each cycle
1915582|NCT01458366|Drug|Etoposide|Phase II: 100 mg/m2 via IV on Days 1, 2, and 3 of each cycle
1915583|NCT01458366|Procedure|CT Scan|CT Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
1915584|NCT01458366|Procedure|PET Scan|PET Scan to assess disease after Cycle 2 (approximately 25 days) and 3-8 weeks post-treatment
1915585|NCT01458366|Genetic|Stem Cell Transplant (STC)|"For potential transplant candidates:
Autologous STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee
Allogeneic STC: after 2 cycles of BOCE upon discretion of Thomas Jefferson University hematopoietic stem cell transplant group and in agreement with the study PI or her designee"
1915619|NCT01452646|Other|Risk-adapted, MRD-directed therapy|The general objective of this study is that of setting up a multicentre, risk-adapted study that relies on pre-treatment cytogenetic/genetic features and post-consolidation assessment of MRD to establish the final risk assignment and treatment of younger (≤ 60 years) patients with AML. Aim of this clinical trial is to verify whether the delivery of a post remission therapy whose intensity is risk-driven will improve the outcome in terms of both increased anti-leukemic efficacy and reduced therapy-related toxicity.
1988882|NCT02670941|Drug|Ginger|The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar. The ginger oil contains 64.23% sesquiterpenes, 18.5% monoterpenes, and 3.28% aldehydes. The aroma of ginger is described as spicy, sweet, and warm.
1915711|NCT01434589|Behavioral|STICA Intervention|Manualized Short-term Treatment for Internet and Computer game Addiction (STICA) based on cognitive behavior-therapy (combining individual and group therapy)
1915717|NCT01431599|Radiation|short-course radiation|33Gy/10 fractions
1915718|NCT01431534|Drug|ridaforolimus|Ridaforolimus supplied as 10 mg enteric-coated tablets, orally, at escalating doses starting at 22 mg/m^2 based on body surface area (BSA), for 5 consecutive days each week in consecutive 28-day cycles
1988883|NCT02670941|Drug|Lavender|The lavender oil (LAV-110) was steam distilled from lavender grown in Kashmir Valley in India. The lavender oil contains 53.22% esters, 31.86% monoterpenols, and 4.88% oxides. The aroma of lavender is described as floral, fresh, herbaceous, and sweet.
1988884|NCT02670941|Drug|Orange|The orange oil (ORG-114) was cold-pressed and steam distilled from oranges in South Africa. The orange oil contains 97.21% monoterpenes, 0.73% aldehydes, and 0.7% monoterpenols. The aroma of orange is described as citrus, fresh, fruity, and sweet.
1988885|NCT02670941|Drug|Jojoba|"The jojoba oil is certified organic and pesticide-free pure oil. Jojoba has a mild scent and can be used as a fixative for other essential oils."
1988892|NCT02670408|Procedure|Endomyocardial biopsy|One of several endomyocardial biopsy bites taken as the standard of care
1988913|NCT02657005|Drug|TK216|Inhibitor of protein-protein interactions of EWS-FLI1 fusion protein
1915806|NCT01411410|Drug|Paclitaxel|"Paclitaxel (80 mg/m2 in Cohort 1, 2 and 3, 90 mg/m2 in Cohort 4) as 60-minute iv infusion once weekly on Days 1, 8, 15 and 22 (Day 22 in Cohort 1, 2 and 3 only) in 28-day cycles
The following intravenous premedications are required 30 to 60 minutes before paclitaxel infusion: Dexamethasone (10 mg), diphenhydramine (50 mg) and either cimetidine (300 mg) or ranitidine (50 mg)
Alternatively, for premedications other than dexamethasone, the standard institutional regimen is permitted."
1915807|NCT01411410|Drug|Copanlisib (BAY80-6946)|BAY80-6946 (0.6 mg/kg in Cohort 1, 0.8 mg/kg in Cohort 2, 3 and 4) as 60-minute iv infusion once weekly on Days 2, 9, 16 and 23 (Day 23 in Cohort 1, 2 and 3 only) in 28-day cycles
1915851|NCT01402336|Drug|GnRH antagonist (Cetrorelix)|In the first arm, cetrotide will be administrated from the first day during stimulation. In the second arm, cetrotide will be administrated from the sixth day during stimulation
1915852|NCT01402336|Drug|Conventional GnRH agonist (Triptorelin)|Patients in the agonist group were administered GnRH agonist started 5 days before discontinuation of the oral contraceptive.
1972088|NCT03315156|Diagnostic Test|Electrogustometery|Taste assessment using EGM
1972089|NCT03315143|Drug|Sotagliflozin (SAR439954)|"Pharmaceutical form: tablet
Route of administration: oral"
1972090|NCT03315143|Drug|Placebo|"Pharmaceutical form: tablet
Route of administration: oral"
1972094|NCT03315104|Biological|FLU-IGIV|Single dose, sterile liquid formulation for IV administration
1972095|NCT03315104|Other|Placebo for FLU-IGIV|Single dose, normal saline solution for IV administration
1972096|NCT03315091|Drug|Treatment A - AZD1775 administered under fasted conditions|Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules. Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fasted conditions. The drug class of AZD1775 is Wee-1 kinase inhibitor.
1972097|NCT03315091|Drug|Treatment B - AZD1775 administered under fed conditions.|"Premedication with Kytril (granisetron) 1 mg intravenously or Zofran (ondansetron) 8 mg intravenously within 30 to 40 minutes prior to administration of the AZD1775 capsules.
Single dose 300 mg AZD1775, (3 x 100 mg, printed capsules) administered orally under fed conditions.
The drug class of AZD1775 is Wee-1 kinase inhibitor."
1972098|NCT03315078|Biological|CD34+ HSCs transduced with the lentivirus vector, VSV-G pseudotyped CL20-4i-EF1α-hγc-OPT|Administered by intravenous (IV) infusion
1972099|NCT03315078|Drug|Palifermin|Administered by IV infusion at a dose of 60 mg/kg/day
1972100|NCT03315078|Drug|Busulfan|Administered by IV infusion at a dose of approximately 3 mg/kg per day
1972101|NCT03315065|Drug|Perfluorinated Gas/Oxygen Mixture|19-Fluorine (19F) MRI of the lungs with 21%/79% Oxygen/Perfluorinated Gas, ≤ 25 liters, gas and Mixture of 30% perfluoropropane and 70% oxygen to measure perfusion single visit, < 1 hour
1972102|NCT03315052|Drug|Budesonide|Oral steroid with high first-pass metabolism in liver
1972103|NCT03315052|Drug|Tacrolimus（FK506）|Calcineurin immunosuppressant
1972104|NCT03315052|Drug|Mycophenolate Mofetil|Immunosupressant
1972105|NCT03315052|Drug|Prednisone|Immunosuppresant
1972106|NCT03315039|Drug|Liposomal Annamycin|2-hour intravenous infusion liposomal annamycin daily for 3 consecutive days followed by 18 days off study drug (i.e., one treatment cycle = 21 days).
1972107|NCT03315026|Drug|Siltuximab|Siltuximab at 11mg/kg will be administered as a 1-hour infusion on day -7 and day +21 after stem cell infusion.
1972108|NCT03315026|Behavioral|The M.D. Anderson Symptom Inventory (MDASI)|assessments will be conducted at baseline (day -10 +/-3), day -2 (+/-1), , day +7 (+/-1 ), and day 30 (+/-3).
1972110|NCT03315000|Drug|Vilanterol and Fluticasone Furoate|Same as vilanterol arm description
1972111|NCT03315000|Drug|Fluticasone Furoate|Same as fluticasone arm description
1972112|NCT03315000|Drug|Placebos|Same as placebo arm description
1972115|NCT03314974|Biological|HSCT with TBI Regimen|Day -5 to -2: Total Body Irradiation Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus until taper day +100 Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
1972116|NCT03314974|Biological|HSCT with Non-TBI Regimen|Day -5 to Day -2: Busulfan and Fludaribine Day 0: Hematopoietic Stem Cell Transplantation Day +3 to +4: Cyclophosphamide Day +5: Tacrolimus until taper day +100 Day +5: Mycophenolate mofetil through day +35 or 7 days after engraftment, whichever day is later, if no acute GVHD
1972117|NCT03314935|Drug|INCB001158|Phase 1: INCB001158 administered orally twice daily at the protocol-defined dose. Phase 2: INCB001158 administered orally twice daily at the recommended dose from Phase 1.
1972118|NCT03314935|Drug|Oxaliplatin|Oxaliplatin administered intravenously at the protocol-defined dose and schedule.
1972119|NCT03314935|Drug|Leucovorin|Leucovorin at the protocol-defined dose and regimen.
1972120|NCT03314935|Drug|5-Fluorouracil|5-Fluorouracil at the protocol-defined dose and regimen.
1972121|NCT03314935|Drug|Gemcitabine|Gemcitabine at the protocol-defined dose and regimen.
1972122|NCT03314935|Drug|Cisplatin|Cisplatin at the protocol-defined dose and regimen.
1972123|NCT03314935|Drug|Paclitaxel|Paclitaxel at the protocol-defined dose and regimen.
1972124|NCT03314922|Drug|INCB050465|INCB050465 administered orally once daily for 8 weeks at the protocol-defined dose, followed by a once-weekly regimen at the same dose.
1972125|NCT03314909|Procedure|Hemodialysis|Participants in this group will be catheterize in the internal jugular vein and connect to a hemodialysis machine.
1972126|NCT03314909|Procedure|Hemoperfusion|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine.
1972127|NCT03314909|Procedure|HP-HD|Participants in this group will be catheterize in the internal jugular vein and connect to a hemoperfusion machine and then a hemodialysis machine for one course.
1972128|NCT03314896|Procedure|Laparoscopic surgery|
1972130|NCT03314870|Genetic|Genetic signature|To identify molecular signatures of EMT / immune status by using the random forest algorithm. The best signature will be measured by RT-qPCR and/or CATS-RNASeq technics.
1972131|NCT03314857|Device|SAPIEN XT THV|Edwards SAPIEN XT™ Transcatheter Heart Valve along with NovaFlex+ delivery system
1972132|NCT03314818|Device|Ultrasound 3D Imaging|"Carotid artery ultrasound will be used to:
Determine plaque presence and plaque burden Presence of stenosis
Additionally, Carotid Intima-Media Thickness (IMT) will be measured and aortic diameter will be measured by abdominal aortic ultrasound scanning.
Ultrasound of the Abdominal Aorta will be used to determine the presence and severity of stenosis or aneurism."
1972136|NCT03314792|Drug|Tapentadol|"Palexia depot 50 mg® (tapentadol depot 50 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. Palexia depot is repeated once after 12 hours.
Palexia 50 mg® (tapentadol 50 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 tablets/24-hour study period. Minimum 1 hour 15 minutes between tablets. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
1972137|NCT03314792|Drug|Oxycodone|"OxyContin 10 mg® (oxycodone extended-release 10 mg): Administered by the patient as oral premedication 1 hour before scheduled start of surgery. OxyContin is repeated once after 12 hours.
OxyNorm 10 mg® (oxycodone immediate-release 10 mg): Administered as oral rescue medicine. First possible administration in postoperative ward when the patient is awake and available for oral medication. Maximum 4 capsules/24-hour study period. Minimum 1 hour 15 minutes between capsules. The patient is instructed to take 1 tablet if pain is increasing and the minimum period since last tablet is exceeded."
1972138|NCT03314766|Device|IC-8 IOL|Patients previously implanted with an IC-8 IOL contralaterally or bilaterally will be evaluated for their long-term visual functions and overall satisfaction at least 12 months post-implantation
1972139|NCT03314753|Other|No interventions - retrospective data collection|No new patients will be enrolled within this project; only retrospective data will be collected on performed re-ablations within the FIRE AND ICE Trial
1972140|NCT03313973|Procedure|with self stretching same muscle|with self stretching
1972141|NCT03313973|Procedure|with self stretching of forearm muscles|without self stretching
1972142|NCT03314727|Other|High salt (NaCl) intake|Participants are asked to consume two high sodium-containing soups while monitoring their serum osmolarity levels
1972143|NCT03314714|Procedure|Acute bout of endurance exercise|Individuals will undergo an acute bout of endurance exercise for 90 min at 75% of maximal oxygen uptake.
1972144|NCT03314701|Device|Biphasic Intermittent Positive Airway Pressure (BIPAP)|"Following endotracheal intubation BIPAP mode will be started with:
Inspiratory positive airway pressure [IPAP] at 20 cmH2O
Expiratory positive airway pressure [EPAP] at 5 cmH2O
PRESSURE SUPPORT is difference between these two pressures [IPAP]- [EPAP]
Mandatory pressure will be delivered at rate of 10-12/min. To produce an end tidal carbon dioxide partial pressure in the range of 35-40 mmHg hypercapnia will not be allowed"
1972145|NCT03314701|Device|Airway Pressure Release Ventilation (APRV)|"high airway pressure (Phigh) will be set at 20 cmH2O
low airway pressure ( Plow) will be set at 5 cmH2O
the release phase setting will be adjusted to terminate the peak expiratory flow rate to ≥ 50%; release frequency of 10-12 cycles/min
T high at 4.5-6 seconds
T low at 0.5 to 0.8 second"
1972146|NCT03314688|Behavioral|Dietary/Physical Activity intervention|Motivational counseling to follow established dietary and exercise guidelines.
1972147|NCT03314688|Behavioral|Usual Care|Standard follow-up care and educational materials. Lifestyle counseling offered at the conclusion of the trial.
1972148|NCT03314675|Device|BIOTRONIK CRT-D|Pre-specified follow-up and measurements
1915933|NCT01376323|Drug|GSK256073 1mg|GSK256073 1mg capsule
1915934|NCT01376323|Drug|GSK256073 5mg|GSK256073 5mg capsule
1915935|NCT01376323|Drug|GSK256073 10mg|GSK256073 10mg capsule
1915936|NCT01376323|Drug|GSK256073 25mg|GSK256073 25mg capsule
1915937|NCT01376323|Drug|Placebo|placebo capsule
1915938|NCT01376323|Drug|Sitagliptin 100mg|Sitagliptin 100mg capsule
1972152|NCT03314649|Other|Observational study|Lavage of the Peritoneal Cavity
1972157|NCT03314623|Behavioral|Weight bearing as tolerated|If fracture is deemed stable the subjects will be allowed to weight bear immediately after surgery.
1972158|NCT03314610|Other|Gait speed|No intervention, only propose water and wait for need to void
1972159|NCT03314597|Other|Balance exercise|Patients in the balance exercise group received a personalized exercise program developed by an expert physiotherapist. There was no predefined duration for each item of the set of exercises, but all patients underwent an overall 45 min period training per day according to the same schedule. This schedule was based on the Otago Exercise Program and Practice Guidelines for the treatment of Parkinson's disease. Patients did not wear shoes for balance training. All exercises were performed without upper-limb support and with the supervision of a physiotherapist.
1972160|NCT03314597|Other|Mobile platform exercise|Patients entered the mobile platform and put on a security harness (no weight unloading), which they wore during the entire session on the platform training. The arms were free to move, but they were asked not to reach out for support. Each patient underwent 45 minutes of training (resting periods included), in which from 6 to 8 perturbation patterns were administered, each one lasting about 4 minutes. During training, the platform moved in the antero-posterior, latero-lateral and diagonal (45 deg) direction with respect to the body. The periodic platform displacement was 10 cm, regardless of the frequency, which could range from 0.3 to 0.6 Hz. Patients stood with eyes open and closed and feet together or 20 cm apart depending on the perturbation subtype.
1972161|NCT03314584|Device|Transcranial Magnetic Stimulation|Active-repetitive transcranial magnetic stimulation (rTMS) at the left motor cortex.
1972162|NCT03314584|Device|Sham Transcranial Magnetic Stimulation|Sham rTMS will consist of the same parameters as active, however, the subject will not receive the actual magnetic stimulation to the left motor cortex due to the use of a double sided Active/Sham coil used specifically for research studies.
1972163|NCT03314571|Other|analgesia for labor|A prospective database to study the determinants of labor pain and the resulting maternal non satisfaction.
1972164|NCT03314558|Other|pulmonary rehabilitation|a pulmonary rehabilitation program of 30 sessions, (3X1h/ week), will be followed by the COPD patients
1972165|NCT03314545|Procedure|laminate veneer with coronal post|laminate veneer with coronal post
1972166|NCT03314545|Procedure|post,core and crown|post,core and crown
1972167|NCT03314532|Procedure|TILA-TACE|After femoral artery catheterization, 5-Fr angiography catheters will be used for complete radiography of the celiac artery, the hepatic artery proper, left and right hepatic arteries and their branches, and 2.8-Fr micro-catheters will be used for complete radiography of the tumor's nutrient arteries. Lipiodol-epirubicin emulsions and 5% sodium bicarbonate injection solutions will be used for perfusion of chemotherapy drugs. Different sizes of embolic microspheres will be used alternatively for chemoembolization.
1972168|NCT03314519|Other|ultrasonography|Use ultrasound image to detect and grading of lung collapse
1972169|NCT03314519|Other|Fiberoptic|Use fiberoptic bronchoscope to assisst lung collapse
1972170|NCT03314506|Other|Exercise|Subjects will exercise on a treadmill for 1 hour at a moderate intensity (approximately 70% of their predicted VO2peak).
1972171|NCT03314493|Drug|Spironolactone 25Mg Tablet|Patients with coronary calcium score > 30 were treated with spironolactone for 12 months
1972172|NCT03314480|Diagnostic Test|Standardized physical examination|Standarized physical examination dedicated to assess a potential fracture in the maxillofacial or mandibular region.
1972173|NCT03314467|Diagnostic Test|polysomnography|"classical polysomnography
non invasive measurement of blood pressure
blood test: determination of HbA1c, glucose, C-peptide, hemoglobine, white bloodcell count, trombocytes"
1972174|NCT03314454|Drug|Beer|Common brands beer with similar calorie (125-150) and alcohol level (approximately 4.5% ABV)
1972175|NCT03314454|Device|Videotaped drinking session|Video-assisted alcohol topography to explore its utility as an indicator of alcohol use disorder
1972176|NCT03314441|Behavioral|Yoga|4 yoga lessons with and instructors on a 3 months period. Patients are asked to exercise yoga daily for 5 to 30 minutes.
1972177|NCT03314428|Behavioral|Gait retraining|Over a 4-week period, runners will be asked to increase their step rate to reduce knee loading during running. Specifically, they will have to increase their preferred step rate by 10% during weekly laboratory running sessions as well as during habitual running training. In the laboratory, runners will be provided with live visual/auditory biofeedback on step rate and asked to target a specific value representing 110% or preferred step rate. During their individual running sessions, runners will be wearing a GPS-enabled watch that will provide feedback on live step rate, and they will be asked to maintain the same value as in the laboratory.
1972178|NCT03314415|Device|Aldebaraan Nao H25|The Aldebaraan Nao H25 is a humanoid robot with the capability to interact with people through small movements, gestures, and speech. It does not physically touch the participant at any time.
1972179|NCT03314402|Drug|Jaktinib Dihydrochloride Monohydrate|Active Substance
1972180|NCT03314402|Drug|placebo|Placebo
1972181|NCT03314389|Device|Cochet bonnet esthesiometer|Cochet bonnet esthesiometer- To examine sensation
1972182|NCT03314376|Device|Prehabilitation program|"The intervention will be an 6-week program of individualized physiotherapy strength and muscular endurance with aerobic training, led by physiotherapists in groups of 8-10 participants. Each program will be individualized based on the evaluations of muscular strength and endurance as well as determination of aerobic-anaerobic zone transition described in previous studies In sessions of one hour 3 times a week. Each session will consist of 30 minutes of exercises performed on land followed by 20 minutes of continuous running in treadmill.
In week 1 and 2 participants carry out 3 sets of 15 repetitions (reps) to become familiar with the exercises. From week 3 onwards participants will perform 4 sets of 10 reps. If the participant can do more than 12 reps, weight will be increased. All exercises are conducted supervised to ensure proper technique and adequate progression."
1972183|NCT03314363|Diagnostic Test|blood gas analysis under citrate predilution|blood gas analysis of blood on different sample points and dialysis fluid
1972184|NCT03314363|Device|filter replacement|Using local protocol: stop and disconnect CRRT, replace filter and reconnect and restart CRRT.
1972185|NCT03314363|Device|IC|monitor patients during the whole study period with indirect calorimetry
1972186|NCT03314363|Drug|NaCl predilution|Replace citrate predilution with NaCl
1972187|NCT03314363|Diagnostic Test|blood gas analysis under NaCl predilution|repeat blood gas analysis of blood on different sample points and dialysis fluid
1972188|NCT03314363|Drug|double ultrafiltration|double the ultrafiltration fluid by augmenting post dilution fluid and keeping ultrafiltration at the same rate.
1972189|NCT03314363|Diagnostic Test|blood gas analysis under NaCl predilution and double ultrafiltration rate|repeat blood gas analysis of blood on different sample points and dialysis fluid
1972190|NCT03314337|Device|Pancreatic stent: PSOF COOK®|After removing the distal pancreas, PSOF COOK will be place in the main pancreatic duct
1972191|NCT03314324|Drug|ODM-201|ODM-201: 600 mg (2 x 300 mg tablets) twice daily with food equivalent to a total daily dose of 1200 mg. ODM-201 should be taken at similar times day, approximately 12 hours between doses.
1972192|NCT03314324|Drug|Enzalutamide|Enzalutamide: 160 mg/day (4 x 40 mg tablets) taken once a day preferably with food, preferably in the evening (Enzalutamide can generally be given with or without food, but in the present trial, it is preferable that it is given with food, to be consistent with ODM-201 intake).
1972194|NCT03314298|Drug|testosterone anastrozole|subcutaneous testosterone and anastrozole
1972195|NCT03314285|Other|Sleep Quality|Sleep quality to be measured by the Pittsburgh Sleep Quality Scale.
1972197|NCT03314259|Drug|Tamsulosin|Tamsulosin is a alpha blocker and has a good safety profile that has been used extensively in Urological patients. Potential safety issues would include a minimal risk of orthostatic hypotension and hypersensitivity reaction to tamsulosin in our study population
1915989|NCT01363284|Drug|Duloxetine|First week of placebo. then, initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 4 weeks
1972198|NCT03314259|Drug|Placebo Oral Tablet|placebo is a tablet made to mimic tamsulosin tablet with same size and colour with no active ingredient
1972199|NCT03314246|Other|FAST|Fasting Algorithm for Singaporeans with Type 2 Diabetes
1972200|NCT03314246|Other|Standard of care|Standard of care
1972201|NCT03314233|Procedure|DING|"Immediately after birth, the infant will be placed on a Lifestart trolley with an intact umbilical cord, intubated, and ventilated with the Children's Hospital of Philadelphia (CHOP) gentle ventilation protocol."
1972202|NCT03314220|Behavioral|preoperative preparation|Participants in the experimental group received standard care plus our newly developed, multicomponent family-centered preoperative preparation program. This program included the following: (1) a tour of the preoperative area and recovery room; (2) a 4-min cartoon video entitled 'I am not afraid of surgery,' which was tailored to the child; this video included 29 scenes that depicted a boy's surgical journey with a particular emphasis on strategies for addressing postoperative pain; and (3) familiarization with medical equipment such as name badges, disposable hair caps, anesthetic masks, EKG leads, and pulse oximeters, which were placed on a doll, to help children understand the surgical instruments and promote better cooperation at the time of anesthesia induction.
1972203|NCT03314194|Other|Plant Based Diet|Plant Based Diet for 4 Days Compared to Habitual Diet
1972204|NCT03314181|Drug|Venetoclax|Oral
1972205|NCT03314181|Drug|Placebo|Oral
1972206|NCT03314181|Drug|Daratumumab|Intravenous
1972207|NCT03314181|Drug|Bortezomib|Subcutaneous (preferred) or intravenous
1972208|NCT03314181|Drug|Dexamethasone|Oral or intravenous
1972209|NCT03314168|Other|Combined training|Resistance exercises performed with different volumes (i.e. one-single set and multiple-sets) and 20-25 minutes of aerobic exercise will be performed twice a week, during 12 weeks.
1972210|NCT03314168|Other|Control group|The physiotherapy sessions will be composed by stretching and joint mobilization exercises for all body muscles and will happen only 2 times per month.
1972211|NCT03314155|Diagnostic Test|Cerebral neuroinflammation evaluation|Pet scan following an injection of the radiotracer ([18F]DPA-714), to evaluate the neuroinflammation. MRI to evaluate functional and structural integrities. Blood test to analyze various inflammation marker (IL-6, Tumor Necrosis Factor (TNF) alpha, CRPus, and TSPO). And psychological scales to assess the depressive symptoms.
1972217|NCT03313960|Drug|"Afrezza plus One Drop | Premium"|"Participants in this group will receive insulin inhalation, prescribed by their physician, and will also receive One Drop | Premium (i.e., One Drop | Experts in-app coaching from a Certified Diabetes Educator (CDE) along with One Drop | Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop | Mobile app and 150 test strips per month for three months)."
1972218|NCT03313960|Other|"One Drop | Premium"|"Participants in this group will receive One Drop | Premium (i.e., One Drop | Experts in-app CDE coaching with the One Drop | Chrome Bluetooth-connected blood glucose meter that uploads results into the One Drop | Mobile app and 150 test strips per month for three months)."
1972224|NCT03314025|Drug|Tamsulosin Hydrochloride 0.4 MG|Peri-operative therapy of Tamsulosin Hydrochloride 0.4 milligrams daily for a total of 7 days.
1972225|NCT03314025|Drug|Placebo oral capsule|Peri-operative therapy of a Placebo oral capsule daily for a total of 7 days.
1972226|NCT03314012|Device|Catheter-Based Carotid Body Ablation|The Cibiem Transvenous Ultrasound System (CTUS) is a catheter based device delivering ultrasound energy to ablate the carotid body. The procedure is done via a percutaneous insertion of the CTUS and advancement through the femoral vein to the jugular vein in subjects with difficult to control hypertension. The procedure duration is expected to range between 60 to 90 minutes and is performed under fluoroscopic and ultrasound image guidance.
1916020|NCT01359267|Drug|99mTc-EC-DG|99mTc-EC-DG will be used before the SPECT/CT scans throughout the study to determine the its effectiveness. 20 mCi of 99mtc-EC-DG will be administered through a vein through a catheter. This will be done before the SPECT/CT scan at 4 weeks and 10 weeks.
1972227|NCT03313999|Device|Lymphedema Indentometer|The subject will sit down. The machine will be placed over their extremity/affected region. They will then be told the machine will be activated. They may or may not feel the machine touch them. A small pressure will be applied to the skin surface for 4 seconds. The computer will record the skin elasticity as change in resistance to compression over time during these 4 seconds. The entire procedure will take about a minute or less, after which the standard of care visit with the physical therapist will continue.
1916022|NCT01359514|Drug|Pregabalin|Initial dose of 75x2mg/d for one week, and then fixed dose of 150x2mg/d for the following 5 weeks
1916023|NCT01359514|Drug|Duloxetine|Initial dose of 30 mg/d will be given for one week, in order to minimize possible side effects and drop outs, and then a fixed dose of 60 mg/d will be given for additional 5 weeks
1972228|NCT03314129|Behavioral|UltimEyes|A computer program developed to improve contrast sensitivity and visual acuity.
1972229|NCT03314129|Behavioral|Contour Integration Training|A computerized program to improve contour integration (a form of perceptual organization).
1972230|NCT03314129|Behavioral|UltimEyes + Contour Integration Training|The combination of UltimEyes and Contour Integration Training
1972231|NCT03314129|Behavioral|MyBrainSolutions|A computer program consisting of exercises to improve cognition (attention, memory, planning) and to facilitate goal setting.
1972232|NCT03312868|Radiation|SBRT|Stereotactic Body Radiotherapy
1972233|NCT03313713|Dietary Supplement|Beta-glucans|Placebo consumption at breakfast (3 g per day)
1972234|NCT03313713|Dietary Supplement|Placebo|Placebo consumption at breakfast (3 g per day)
1972236|NCT03313414|Drug|Sofosbuvir/Velpatasvir Treatment for 14 days|14 day therapy with Sofosbuvir/Velpatasvir
1972237|NCT03312660|Dietary Supplement|Prebiotic group|Fermented dairy product with galacto-oligosaccharides (GOS), kefiran and other metabolites resulting from the fermentation with kefir granules.
1972238|NCT03312660|Dietary Supplement|Placebo group|Beverage with color, flavor and nutritional composition similar to the fermented dairy product but not containing the prebiotic components.
1972239|NCT03313388|Dietary Supplement|Drink|Beverage to be consumed
1972240|NCT03313362|Device|SPEAC System|Seizure Monitoring and Alerting System
1972241|NCT03313362|Device|video EEG|The Video EEG Monitoring Test (VEEG) is a high specialized form of an EEG test in where the patient is continuosly monitored by using a video recorder. This allows doctors to observe brainwaves activity during the time a seizure or spell is occurring.
1972242|NCT03313011|Diagnostic Test|Testing protocol for the study|All patients will see a Neurologist for a neuro exam and consult, see a Speech Pathologist for assessment of speech and language skills, see the Study Coordinator for neuropsych testing (brief tests of thinking, memory, visual spatial skills, etc), undergo an MRI of the brain and a DaTscan of the brain.
1972243|NCT03312998|Radiation|Xrays|Plain x-rays anteroposterior and lateral views to determine system failure
1972245|NCT03313401|Drug|Aflibercept|Intravitreal aflibercept injection
1972246|NCT03313401|Device|Specular microscopy|Specular microscopy measurement after intravitreal aflibercept injection
1972248|NCT03312478|Drug|Blood draw for insulin auto-anti body tests*|"Pharmaceutical form: N/A
Route of administration: N/A"
1972250|NCT03312335|Drug|Low-dose Aldesleukin (Proleukin®)|Subcutaneous injection of 1.5 million international units (MIU) of Aldesleukin (Proleukin®, Interleukin-2) once daily in 5-day courses every three weeks for a total of 4 cycles.
1972253|NCT03312179|Device|PCI and DES stenting|Percutaneous coronary intervention (PCI) and direct stenting (DES) of culprit lesion vessel.
1972254|NCT03312179|Drug|Incretins|Patients treated before study enrollment by incretin drugs (6 months drugs exposure)
1972255|NCT03312166|Device|Compression device|"interventions on patient are :
surgical excision of ear lobe keloid
application of compression device on sutured skin"
1972260|NCT03309735|Drug|Micronized progesterone|Utrogestan, 200 mg orally thrice a day until acute symptoms of the threat of termination of pregnancy (scarlet discharge from the genital tract, pain in the abdomen) and then Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
1972261|NCT03309735|Drug|Micronized progesterone|Utrogestan vaginally 200 mg twice a day and 200 mg orally once a day before bed
1972262|NCT03309735|Drug|Dydrogesterone|Duphaston, orally 40 mg once, then 10 mg every 8 hours until the symptoms disappear
1972263|NCT03311035|Procedure|Seton|The identification of the primary tract of the fistula and the placement of the thread can be performed in one single step. a non-absorbable, braided thread is inserted . After excision of the external opening and the extrasphincteric parts of the fistula, the thread is grasped and is pulled out of the anus .The thread is cut in two parts. The mucosa is incised over the muscular bridge . One thread is tied snugly around the muscle; the other is tied loosely .The snugly tied seton has to be replaced after 14 days to provide appropriate tension to cut slowly trough the muscle. This can easily be achieved with the second loosely tied seton . A new thread is folded in the middle and connected to the opened sling of the loose seton using a special knot shown in.The old thread is removed and in the same maneuver two new setons are placed. Again, one thread is tied snugly around the remaining portion of the sphincter muscle; the other is tied loosely .
1988924|NCT02654015|Device|Apollo MIES|Subjects will receive best medical management plus MIES (minimally invasive endoscopic surgery with use of the Apollo System.
1988925|NCT02654015|Other|Medical Management|Subjects will receive best medical management for intracranial hemorrhage
1988932|NCT02650713|Drug|Atezolizumab|Atezolizumab will be administered at a fixed dose of 1200 milligrams (mg) by intravenous (IV) infusion.
1988933|NCT02650713|Drug|RO6958688|Dose-Escalation: RO6958688 will be administered on Day 1 of each 21-day cycle (for QW schedule) or on Days 1, 8, and 15 of each 21-day cycle (for Q3W schedule) by IV infusion. Dose-Expansion: RO6958688 will be administered at dose and schedule identified in dose-escalation part.
1916076|NCT01345253|Drug|Belimumab|10mg/kg administered intravenously. Dosing at Weeks 0, 2, and 4, then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
1916077|NCT01345253|Drug|Placebo|Administered intravenously. Dosing at Weeks 0, 2, and 4, and then every 4 weeks through Week 48, with a final evaluation at Week 52. All study subjects will receive standard SLE therapies during the study.
1972264|NCT03311035|Procedure|LIFT technique|The internal opening was identified . The intersphincteric plane was entered via a curvilinear incision corresponding to the site of the internal opening at the intersphincteric groove. The intersphincteric plane was developed by meticulous scissor and diathermy dissection up to the tract. Once identified, a small, right-angled clamp was hooked underneath or a tape passed round it. the tract was then transfixed close to the internal sphincter with 2/0 polyglactin suture . Saline was gently injected through the external opening to confirm that the tract was no longer patent and it was then divided distal to the point of ligation . After light traction, a segment of the distal tract was excised and, if needed, any defect in the external sphincter was closed. The intersphincteric incision wound was re-approximated loosely with interrupted 2/0 Vicryl. Partial core-out of the fistula tract was performed from the external opening to the external sphincter.
1972268|NCT03309774|Diagnostic Test|questionnaires|"Children with Complex Regional Pain Syndrome (CRPS) will be filled questionnaires before and after relaxation sessions. These questionnaire evaluate the quality of life and pain of child
There will be:
Questionnaire KIDSCREEN 52
Visual Analogue Scale (EVA)
Neuropathic Pain 4 (DN4)
Pain of the child Gustave Roussy (DEGR)"
1972269|NCT03309774|Diagnostic Test|holter electrocardiogram|Children with Complex Regional Pain Syndrome (CRPS) will be have holter electrocardiogram before and after relaxation sessions.
1972270|NCT03309774|Diagnostic Test|blood pressure|Blood pressure of Children with Complex Regional Pain Syndrome (CRPS) will be measured by Nexfin monitor before and after relaxation sessions.
1972271|NCT03309774|Other|relaxation sessions|"Children with Complex Regional Pain Syndrome (CRPS) will be performed 20 relaxation sessions and 2 per week.
During relaxation sessions children will be recorded by voice recorder. Children should describe his feelings at the preceding session.
After every relaxation sessions children evaluate pain according to Eland Color Scale."
1916086|NCT01342211|Biological|Placebo|Intravenous placebo monthly during treatment phase.
1916087|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
1916088|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
1916089|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
1916090|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
1916091|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
1916092|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
1916093|NCT01342211|Drug|Satin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
1916094|NCT01342211|Biological|PF-04950615 (RN316)|Intravenous 10mg/mL based on weight monthly during treatment phase.
1916095|NCT01342211|Drug|Statin|Single daily dose of atorvastatin (40 or 80 mg), rosuvastatin (20 or 40 mg) or simvastatin (40 or 80 mg) from Day 1 to Day 141/ET.
1972278|NCT03307655|Other|Control (fertile semen donors)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.
Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
1972279|NCT03307655|Other|Patients (subfertile men)|"The sperm will be capacitated in the presence and absence of follicular fluid (FF). In a first set of experiments, the FF will be supplemented with L-Arginine and the NOS inhibitor L-NAME. In another set of experiments the same supplementations to the capacitation medium will be examined, but without using FF.
Changes in NOS expression, protein nitrosylation, PKA activity, tyrosine phosphorylation and tyrosine nitration in sperm will be determined."
1988946|NCT02643576|Behavioral|F&V Bonus|To examine the independent effect of offering an incentive (i.e. bonus dollars for fruit and vegetable purchases) to SNAP-like benefits to encourage the purchase of more healthful foods
1988947|NCT02643576|Behavioral|Restriction|To examine the independent effect of prohibiting the use of SNAP-like benefits to purchase foods high in discretionary calories (i.e.sugar-sweetened beverages, candy, or sweet baked goods) on food purchases and diet quality
1988948|NCT02643576|Behavioral|Bonus & Restriction|To examine the joint effects of prohibiting the use of SNAP benefits to purchase foods high in discretionary calories and offering an incentive to encourage the purchase of more healthful foods
1988951|NCT02642562|Drug|Iron (III) isomaltoside 1000|
1916121|NCT01339858|Drug|N-Acetyl Cysteine|NAC and matched placebo will be supplied in unmarked capsules. Each NAC capsule will contain 480 mg of NAC. Dosing will begin at 480 mg/d and titrated up by 480 mg/d each week until a maximum dose of 2880 mg/d (BID) is reached. This approximate dose was effective and well tolerated in a recent study of treatment refractory obsessive-compulsive disorder by Krystal and colleagues at Yale (16). In addition, a double-blind placebo controlled trial recently completed at IUSM Riley Hospital in children (age 4 to 12 years) with autism spectrum disorders used doses ranging from 900 mg/day to 4200 mg/day and reported no serious adverse events and found the agent well tolerated (15). Dose adjustments downward to 1920 mg/d will be permitted if tolerability issues are encountered at the maximum dose
1916122|NCT01339858|Other|sugar pill|matched placebo will be supplied in unmarked capsules. Dosing regimen will be the same as in the N-Acetyl Cysteine arm.
1972280|NCT03308500|Behavioral|High-intensity intermittent games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In HIIG children took part in 5 games per session; 2 velocity games and 3 small-sided games (such 3 vs 3 and 4 vs 4). This session included 4 minutes games and 2 minutes recovery. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
1972281|NCT03308500|Behavioral|Moderate intensity games|The intervention will last for 12-weeks, each group included participation in twice-week 40 minutes exercise sessions. In MIG children took part in 5 games per session. This session included 4 minutes games and 3 minutes recovery.
1972282|NCT03307915|Biological|Ad26.Mos4.HIV|Participants will receive Ad26.Mos4.HIV 5*10^10 vp as 0.5 mL IM injection at Weeks 0, 12 in Group 1 and at Weeks 0, 12, 24, 36 in Group 2.
1972283|NCT03307915|Biological|MVA-Mosaic|Participants will receive MVA-Mosaic 10^8 pfu as IM injection at Weeks 24 and 36.
1972284|NCT03307915|Biological|Clade C gp140 + Mosaic gp140|Participants will receive both Clade C gp140 125 mcg plus Mosaic gp140 125 mcg (250 mcg co-formulated with Aluminum phosphate adjuvant) IM at Weeks 24 and 36.
1972285|NCT03307915|Drug|Placebo|Participants will receive matching placebo as IM injection at Weeks 24, 36 in Group 1 and at Weeks 0, 12, 24, 36 in Group 3.
1972287|NCT03307434|Other|Athletics Injury Prevention Program|The Athletics Injury Prevention Program (AIPP) will be performed by experimental group twice a week. The AIPP is composed of 8 exercises including core stability, balance, pelvic stabilization, stretching and strengthening of the Achilles tendon and hamstrings.
1972288|NCT03307434|Other|regular training|The regular training will be performed by control group according to the standard practice.
1988967|NCT02639910|Biological|MOR00208|MOR208 dose: 12 mg/kg intravenous infusion
1988968|NCT02639910|Drug|Idelalisib|Idelalisib dose: 150 mg twice daily orally
1988969|NCT02639910|Drug|Venetoclax|Venetoclax dose: 400 mg once daily orally
1972294|NCT03306628|Other|CO2 Laser Administration|The CO2 fractional laser system will be applied at a pulse energy setting of 50 millijoules and a density of 100 spots/cm2 on one of the breast incisions (either one week after surgery or six weeks after surgery, depending on the randomization group).
1972295|NCT03306576|Device|ELS Extra composite|One of the teeth will be restored using ELS composite. Procedures will be done under local anesthesia if necessary. The preparation and restoration of the tooth will be done according to to the guidelines for ordinary restorative techniques.
1972296|NCT03306576|Device|ELS composite|the other teeth will be restored with a ELS resin composite with ordinary restorative techniques.
1972305|NCT03304847|Other|ablation|radio-frequency applications on arrhythmogenic substrate
1972306|NCT03304275|Behavioral|Tdap|Randomized controlled trial of 2 strategies to provide adults with the Tdap vaccine
1972307|NCT03304249|Behavioral|iAmHealthy Healthy Lifestyles Program|iAmHealthy is behavioral intervention focused on nutrition, behavior and physical activity that engages parents and children in treatment using mobile health (mHealth) technology. Meetings are approximately one hour. Participants will log in for 8 weekly group sessions, followed by 6 monthly sessions.
1972308|NCT03304249|Other|Newsletter|Weight loss materials delivered via a newsletter. Each newsletter will cover nutritional, exercise, and behavioral suggestions to improve the child's health. The newsletter will be sent in the mail once a month for 8 months.
1916162|NCT01328444|Drug|GSK 573719 +GW642444 125/25|125mcg/ 25mcg
1916163|NCT01328444|Drug|GSK573719 + GW642444 62.5/25|62.5mcg/25mcg
1916164|NCT01328444|Drug|GSK 573719 125|125mcg
1916165|NCT01328444|Drug|GSK 573719 62.5|62.5mcg
1916166|NCT01328444|Drug|GW642444 25|25mcg
1916167|NCT01328444|Drug|Plb|Comparator
1972311|NCT03302884|Other|biological sampling|Tumor and blood samples
1972318|NCT03300609|Biological|Panitumumab|Given IV
1972319|NCT03300609|Drug|Oxaliplatin|Given IV
1972320|NCT03300609|Drug|Leucovorin Calcium|Given IV
1972321|NCT03300609|Drug|Fluorouracil|Given IV
1972322|NCT03300609|Drug|Capecitabine|Given PO
1916181|NCT01324479|Drug|INC280|
1972323|NCT03300609|Other|Quality-of-Life Assessment|Ancillary studies
1972324|NCT03300609|Other|Laboratory Biomarker Analysis|Correlative studies
1972325|NCT03300401|Drug|Perflutren Lipid Microspheres|Receive intravenous injection just prior to ultrasound
1972326|NCT03300401|Drug|Sulfur Hexafluoride Lipid Microspheres|Receive intravenous injection just prior to ultrasound
1972327|NCT03300401|Device|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo Contrast-Enhanced Ultrasound Imaging
1972328|NCT03300401|Device|Positron Emission Tomography|Undergo PET/CT
1972329|NCT03300401|Device|Computed Tomography|Undergo CT scan
1972330|NCT03300401|Biological|Yttrium-90 (90Y)|Given IV
1972332|NCT03299621|Device|PLE (Phase Lag Entropy)|Monitoring of PLE value using the monitoring of PLEM™ device during propofol anesthesia.
1972333|NCT03299621|Drug|Muscle Relaxant|Monitoring of PLE value using the monitoring of PLEM™ device before and after the injection of muscle relaxant that used for tracheal intubation.
1972334|NCT03299595|Other|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
1972335|NCT03298386|Other|Systematic medication review with the STOPP/START tool|The STOPP / START tool includes a list of 42 substances / drug classes whose prescription could be discontinued based on specific criteria (81 STOPP criteria: Screening Tool of Older Person's Prescriptions) and a list of 34 clinical situations involving consideration of the usefulness of a new prescription (START criteria: Screening Tool to Action the Right Treatment).
1972336|NCT03299166|Drug|BHV-4157|BHV-4157, 140mg capsule QD
1972337|NCT03299166|Drug|Placebo|matching capsule QD
1972338|NCT03298984|Drug|Alvocidib|IV bolus followed by IV infusion
1972339|NCT03298984|Drug|Cytarabine|continuous infusion
1972340|NCT03298984|Drug|Daunorubicin|IV bolus
1972346|NCT03295721|Drug|HTX-011|HTX 011, 60 mg
1972347|NCT03295721|Drug|Saline Placebo|Saline placebo
1972348|NCT03295721|Drug|Bupivacaine HCl|Bupivacaine HCl without epinephrine, 50 mg
1972349|NCT03295721|Device|Luer-lock applicator|Applicator for instillation
1972350|NCT03295721|Device|Vial access device|Device for withdrawal of drug product
1916225|NCT01313637|Drug|GSK573719/GW642444 125/25mcg|125/25mcg
1916226|NCT01313637|Drug|GSK573719 125mcg|125mcg
1916227|NCT01313637|Drug|GW642444 25mcg|25mcg
1916228|NCT01313637|Drug|Placebo only|Placebo
1972366|NCT03294278|Other|ablation plus ICD|Defibrillator, radio-frequency catheter ablation
1972367|NCT03293719|Device|BPK-S Integration UC|Primary Knee Endoprosthesis
1972374|NCT03292367|Procedure|ldTRA|After puncture of left distal radial artery, coronary angiography and percutaneous coronary intervention, if needed, will be performed.
1972375|NCT03291210|Other|normal inspired oxygen fraction|receives inspired oxygen fraction of 0.3
1972376|NCT03291210|Other|high inspired oxygen fraction|receives inspired oxygen fraction of 0.8
1972388|NCT03287570|Device|Cettum|The treatment is applied twice a week for 15 minutes for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Electric moxibustion, Cettum (20X28X18mm) manufactured by K-medical Co.(Korea) is used.
1972389|NCT03287570|Procedure|Traditional indirect moxibustion|The treatment is applied twice a week for 6 weeks (12 sessions). 6 points (ST36, ST35, EX-LE4, SP9, SP10, ST34) are used for all the patients assigned to this group and investigator can be added up to 2 points depending on the patient condition. Traditional indirect moxibustion, Taekeukttum manufactured by Haenglim Seowon Medical Co.(China) is used. A total of three moxibustion cones are applied indirectly to each point per treatment session.
1972390|NCT03287570|Other|Usual care|The patients in this group maintain the usual treatment and self-care.
1916260|NCT01305863|Device|ASC coated ePTFE vascular graft|An ePTFE vascular graft in which the lumen of the graft has been coated with an autologous coating of adipose-derived stromal cells (ASC) prepared using an automated point-of-care processing instrument to facilitate isolation and concentration of autologous adipose-derived stromal cells and subsequent sodding of small-diameter vascular grafts.
1916261|NCT01305863|Device|Propaten graft|6 mm Gore PROPATEN® graft (heparin-coated ePTFE vascular graft, thin-walled removable-ring stretch)
1972399|NCT03283254|Behavioral|Practical Resources for Effective Postpartum Parenting|A preventive psychotherapy intervention for Postpartum Depression
1972400|NCT03283254|Behavioral|Enhanced Treatment As Usual|Psychoeducation about Postpartum Depression, referral to treatment in the community, clinical monitoring
1972418|NCT03275974|Biological|Carbon C 11 Glutamine|Given by IV
1972419|NCT03275974|Biological|Fluorine F 18 L-glutamate Derivative BAY94-9392|Given by IV
1916290|NCT01300962|Drug|BMK120|BKM120 PO 50, 80 or 100mg every day for each day of each 21 day cycle. Number of cycles: until progression of disease; unacceptable toxicity, withdrawal or death.
1916291|NCT01300962|Drug|Capecitabine|875-1250mg/m2 PO BID for two weeks followed by one week rest every three week cycle. Number of cycles: until progression of disease, unacceptable toxicity, withdrawal or death.
1916292|NCT01300962|Drug|BYL719|BYL719 200mg PO BID for 21 days (3 weeks) in combination with capecitabine 1000 mg/m2 PO BID for 2 weeks
1916293|NCT01300962|Drug|Trastuzumab|trastuzumab infusion on day 1 of each cycle.
1916294|NCT01300962|Drug|Lapatinib|lapatinib daily for 21 days in each cycle.
1972420|NCT03275974|Procedure|Positron Emission Tomography|Undergo PET scan
1916298|NCT01300611|Drug|TXA127 300 mcg/kg/day|Injection, 300 mcg/kg/day for 28 days
1916299|NCT01300611|Drug|TXA127 1000 mcg/kg/day|Injection, 1000 mcg/kg/day for 28 days
1972423|NCT03273647|Radiation|radiation|"A total dose of 40Gy will be delivered in 20 fractions at 2.0Gy/fraction, 5 fractions per week in 4 weeks.
The CTV encompassed the bilateral supraclavicular region, all mediastinal lymph nodes, the anastomosis site, and the left gastric and Celiac nodes."
1916306|NCT01299883|Other|Integrated vs Non-integrated Risk Education|Integrated group receives education about risk factors for both cancer and CVD whereas the non-integrated group receives information about CVD only to assess differences in health behavior outcomes.
1972436|NCT03272555|Other|WILD 5 Wellness Interventions|Students enrolled in the study will be asked to complete activities in five wellness elements including exercise, mindfulness, sleep, social connectedness and nutrition for 30 days.
1972437|NCT03270436|Behavioral|Traditional Diabetes Prevention Education|Faith based diabetes curriculum that teaches participants to connect faith and health.
1972438|NCT03270436|Behavioral|Pacific Diabetes Prevention Education|Family and community based diabetes prevention curriculum that teaches participants to engage their social support to have a healthy weight.
1972441|NCT03269032|Other|American Diet|"According to National Health and Nutritional Examination Survey (NHANES) data, the nutritional composition of the baseline typical American diet is 50%Carbohydrates, 15% Protein, 35% Fat, >11% Saturated Fatty Acids, <12% Monounsaturated Fatty Acids, and >8% Polyunsaturated Fatty Acids.
Participants will receive 3 meals and 1 snack for each day during the study period."
1972442|NCT03269032|Other|Mediterranean-style Diet|"The nutritional composition of the baseline typical Mediterranean-style diet is 46% Carbohydrates/Alcohol (red wine will be included in the Mediterranean diet only), 17% Protein, 32% Fat, <7% Saturated Fatty Acids, >18% Monounsaturated Fatty Acids and <5% Polyunsaturated Fatty Acids.
Participants will receive 3 meals and 1 snack for each day during the study period."
1972446|NCT03266536|Behavioral|Western diet|Western diet for 7 days: the meals in this Western diet will be provided by the Clinical Research and Trials Unit (CRTU) after participants meet with the nutrition staff (to discuss food preferences, how to obtain the meals). The meals will reflect a typical Western diet: a low fiber, high sugar diet with weight maintenance calories with < 10 grams fiber per day, and a typical US macronutrient calorie distribution of 50% carbs, 35% fat and 15% protein, with no alcohol. At least 50% of carbohydrates will be provided as simple sugars.
1972447|NCT03265145|Drug|Stiolto Respimat|Duration - 12 months
1972448|NCT03265145|Drug|ICS (Inhaled Corticosteroid) (Triple therapy)|Duration - 12 months
1972449|NCT03265145|Drug|LABA (Long-Acting Beta Agonist) (Triple therapy)|Duration - 12 months
1972450|NCT03265145|Drug|LAMA (Long-Acting Muscarinic Antagonist) (Triple therapy)|Duration - 12 months
1972453|NCT03265639|Dietary Supplement|P-inulin|
1972461|NCT03258749|Drug|Tiotropium|inhaled Tiotropium(18μg, qd)
1972462|NCT03258749|Drug|Formoterol|inhaled formoterol(4.5μg, bid)
1972466|NCT03256487|Drug|Buprenorphine|buprenorphine 0.3mg IV
1972467|NCT03256487|Drug|Morphine Sulfate|morphine 0.1 mg/kg IV (max 8mg per dose)
1972470|NCT03256799|Drug|Ivacaftor|Ivacaftor
1972473|NCT03255577|Procedure|Sentinel Lymph Node Biopsy (SLNB)|Sentinel Lymph Node Biopsy Patients with locally advanced breast cancer will undergo SLNB with dual tracer mapping followed by completion axillary lymph node dissection.
1972474|NCT03255317|Behavioral|Reinforcers|Memes/Gifs: Immediately after completing their daily ecological momentary assessment using the app, each participant is randomized to receive an inspirational or funny meme or gif that is displayed within the app. Life Insights: Immediately after completing both daily active tasks using the app, each participant is randomized to unlock a life insight. Life insights track data provided by the participant, are stored in a virtual library within the app, and are regularly updated with recent data points.
1972475|NCT03255317|Behavioral|Notifications|Reminder Push Notifications: All participants receive a push notification reminder from the app at 6pm (the time at which data collection opens) to complete their daily data collection activities. Each day, each participant will be randomized to receive either a generic reminder or a reminder that contains more detailed information (e.g., about upcoming incentives). Inspirational Push Notifications: Each day, each participant will be randomized to receive a push notification at 4pm that contains inspirational song lyrics or celebrity quotes.
1988990|NCT02633098|Drug|Artesunate 200mg|
1988991|NCT02633098|Drug|Placebo|
1988998|NCT02630069|Drug|CDP-choline|CDP-choline 500mg once a day for 12 weeks
1988999|NCT02630069|Drug|Placebo|Placebo 500mg once a day for 12 weeks
1989000|NCT02630069|Behavioral|Supportive psychotherapy|Supportive psychotherapy 1 session/2 weeks for 12 weeks
1989001|NCT02627794|Device|Restora™ Steroid eluting spacer|The Restora™ Steroid eluting spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
1989002|NCT02627794|Device|Silastic Silicone Spacer|The Silastic Silicone Spacer will be inserted into the middle meatal space after surgery. The spacer will be left in the middle meatus for a period of 6-8 days following surgery.
1972481|NCT03254134|Drug|Warfarin|patients treated with warfarin
1972482|NCT03254134|Drug|Dabigatran|patients treated with Dabigatran
1972487|NCT03252587|Drug|BMS-986165|administered orally
1972488|NCT03252587|Other|Placebo|administered orally
1972489|NCT03250598|Drug|AG-348|50 mg single-dose
1972490|NCT03250598|Drug|AG-348|5 mg single-dose
1972491|NCT03250598|Drug|AG-348|200 mg single-dose
1972492|NCT03250117|Drug|Ropinirole oral product|oral immediate-release ropinirole
1972493|NCT03250117|Drug|Ropinirole Implant|ropinirole hydrochloride/ethylene vinyl acetate
1972513|NCT03245515|Drug|BMS-986195|specified dose on specified days
1972514|NCT03244800|Drug|MEDI0382|MEDI0382 administered subcutaneously
1972515|NCT03244800|Drug|Placebo|Placebo administered subcutaneously
1972522|NCT03242915|Drug|Pembrolizumab|200mg IV every 3 weeks
1972523|NCT03242915|Drug|Carboplatin|AUC 5 IV every 3 weeks
1972524|NCT03242915|Drug|Pemetrexed|500 mg/m^2 IV every 3 weeks
1972526|NCT03240575|Drug|Tiotropium|Fixed Dose Combination
1972527|NCT03240575|Drug|Olodaterol|Fixed Dose Combination
1972528|NCT03240575|Drug|Fluticasone propionate|Fixed Dose Combination
1972529|NCT03240575|Drug|Salmeterol|Fixed Dose Combination
1972530|NCT03241719|Drug|IL-2|Subjects will receive vascularized composite allotransplantation (e.g. facial, hand and/or abdominal wall transplants) under conventional immune suppression. No sooner than 3 months after VCA, subjects will receive a protocol of daily recombinant IL-2 at low doses for 8 weeks.
1972535|NCT03238664|Procedure|Biopsy|Undergo biopsy of bladder tumor
1972536|NCT03238664|Device|High-Intensity Focused Ultrasound Ablation|Undergo laparoscopic HIFU
1972537|NCT03238664|Other|Laboratory Biomarker Analysis|Correlative studies
1972538|NCT03238664|Procedure|Radical Cystectomy|Undergo RARC
1972539|NCT03238664|Device|Ultrasonography|Undergo CEUS
1972540|NCT03238300|Drug|N-Acetylcysteine|N-Acetylcysteine pill.
1972541|NCT03238300|Drug|Placebo Oral Capsule|Sugar pill to mimic.
1972542|NCT03236415|Device|Xience Drug Eluting Stent|Patients will undergo insertion of a drug eluting stent with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
1972543|NCT03236415|Device|ABSORB Bioresorbable Vascular Scaffold|Patients will undergo insertion of a bioresorbable vascular scaffold with assessment of strut coverage using optical coherence tomography at 4 to 6 weeks after implantation.
1972544|NCT03235804|Dietary Supplement|Soy protein, honey and yogurt.|Participants will be asked to maintain their usual dietary intake and consume a nutritional supplement composed of soy protein, honey and yogurt twice daily (in two snacks) over 12 weeks. The addition of the nutritional supplement to a North American Dietary Pattern (described on the CON group diet) will result in a diet composed of, approximately, 22% of protein, 48% of carbohydrate and 30% of fat of total energy intake. The amount of protein is considered higher than the North American dietary pattern (i.e. 15%); however, still within the Acceptable Macronutrient Distribution Range (AMDR) recommended by the Dietary Guidelines for Americans (10-35%).
1972545|NCT03235115|Device|Methafilcon A IV|Contact Lens
1972546|NCT03235115|Device|Ocufilcon B|Contact Lens
1972547|NCT03235115|Device|Omafilcon A|Contact Lens
1972561|NCT03231306|Drug|Binimetinib|Adult subjects (18 years and older) will receive binimetinib by mouth twice daily of 45mg/dose. Pediatric subjects (1-17 years of age) will be treated on pediatric MTD or RP2D that is currently being established in an ongoing phase I study (NCT02285439).
1972562|NCT03231280|Device|SB-061|delivered via intra-articular injection
1972563|NCT03231280|Other|Placebo|Placebo delivered via intra-articular injection
1972569|NCT03229980|Drug|custodiol|30 ml/kg of Custodiol will be given to arrest the heart over 300 seconds repeated if the ischemic time continues more than 90 minutes
1972570|NCT03229980|Drug|Cold blood cardioplegia (large volume)|Hearts will be arrested with cold blood cardioplegia, first dose (arrest dose) will be 30 ml/kg and the frequent doses every 20 min will be 15 ml/kg
1972571|NCT03229980|Drug|Cold blood cardioplegia (small volume)|Hearts will be arrested with cold blood cardioplegia first dose (arrest dose) will be 10 ml/kg and the frequent doses every 20 min will be 5 ml/kg
1972572|NCT03229577|Behavioral|YESplus|Yoga-based breathing program.
1972573|NCT03229577|Behavioral|KORU|Mindfulness program.
1972574|NCT03229577|Behavioral|Emotional Intelligence|Emotional Intelligence program.
1972575|NCT03226665|Diagnostic Test|ultrasound|"definition of prevalence of US detected obstruction in patients referred to an emergency facilities with symptoms potentially suggestive for such diagnosis.
Moreover, which clue, if any, could reinforce the need of US intestinal study, such as anaemia, CRP, NLR, hypotension.
This information is not yet available elsewhere. Moreover, in this context, sensitivity and specificity of ultrasound vs. confirm by CT and other procedures will make more sense and will be consequently assessed."
1972578|NCT03226574|Drug|Resiniferatoxin|single dose (0.4, 1, 2, 4, 8, or 15 mcg), epidural injection
1989013|NCT02621437|Other|Osteopathy sessions|- Three osteopathy sessions every 14 days (D13, D27 and D41 post-surgery),
1989014|NCT02621437|Other|phone questionnaires|"Six phone questionnaires (D9, D20, D26, D34, D40 and D48):
pain questionnaire with digital scale,
quality of life survey: SF-12
HAD (Hospital and Anxiety Depression) questionnaire"
1972580|NCT03226353|Device|Somofilcon A|contact lens
1972581|NCT03226353|Device|Omafilcon A|contact lens
1972590|NCT03226067|Drug|GKT137831|GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
1972591|NCT03226067|Drug|Placebo oral capsule|Matching capsules.
1972593|NCT03224819|Drug|AMG 673|Open label.
1972602|NCT03221764|Drug|Amiodarone with CoSeal|CoSeal Surgical Sealant (Baxter Healthcare) consist of 2 formulations of synthetic polyethylene glycols, a dilute hydrogen chloride solution along with a sodium phosphate/sodium carbonate solution. These separate solutions are mixed at the time of application to form a hydrogel. Amiodarone hydrochloride powder (1mg/kg) will be mixed with CoSeal at the time of application to form an amiodarone containing hydrogel. The dosing of amiodarone is based on previous study using amiodarone hydrogel in post-operative coronary artery bypass patients [8]. This hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
1972603|NCT03221764|Device|CO2 driver|The amiodarone hydrogel will be delivered utilizing a CO2 driver along the pulmonary vein and arterial anastomoses, and to the surface right and left atria.
1972620|NCT03216109|Behavioral|Weekly telephone symptom assessment|Each patient who is enrolled in the intervention will receive a weekly phone call from the Research Assistant for a total of 9 months to assess symptoms using the Edmonton Symptom Assessment Scale. Results of the symptom assessments will be provided to the clinic staff (RN and MD) for review each week. Care plans will be generated using an electronic management platform
1972638|NCT03212313|Drug|Tozadenant|Two 60 mg tablets for a total single study dose of 120 mg
1972639|NCT03211663|Device|MOTO Medial® UKA|Knee replacement surgery with the MOTO Medial® UKA
1972642|NCT03207958|Drug|Belimumab|-Given over 1 hour
1972653|NCT03203642|Drug|Tesevatinib|A once daily dose of tesevatinib 50 mg in a round tablet form of white to off-white color.
1972654|NCT03203642|Drug|Placebo|A once daily dose of matching placebo.
1972655|NCT03202667|Drug|Empagliflozin 25mg|Treatment with empagliflozin 25mg once daily for 28 days
1972656|NCT03202667|Drug|Placebo|Treatment with Placebo oral tablet once daily for 28 days
1972657|NCT03199846|Other|Non-Interventional|Non-Interventional
1972663|NCT03195478|Drug|Nivolumab|Specified dose of Nivolumab on specified days.
1972664|NCT03195478|Drug|Ipilimumab|Specified Dose of Ipilimumab on specified days
1972665|NCT03195920|Device|Enhanced Lithotripsy System|The Enhanced Lithotripsy System is a type of lithotripsy system comprising a console, treatment head, and Acoustic Energy Focusing material. Operation of the Enhanced Lithotripsy System entails combined action of extracorporeal insonation and Acoustic Energy Focusing material to fragment urinary stones.
1972667|NCT03193398|Drug|BTRX-246040 oral capsule(s)|BTRX-246040 administered once daily to patients with MDD for 8 weeks
1972668|NCT03193398|Drug|Placebo oral capsule(s)|administered once daily to patients with MDD for 8 weeks
1972671|NCT03193437|Drug|Open Label Selinexor|Selinexor 60 mg oral tablets will be administered twice weekly, either on Monday/Wednesday or on Tuesday/Thursday or on Wednesday/Friday in a 3-weeks-on and 1-week-off schedule.
1972672|NCT03192332|Device|Stent-retriever thrombectomy with revascularization device of the Solitaire™ type|Mechanical thrombectomy with a stent-retriever revascularization device
1972673|NCT03192332|Drug|Intravenous thrombolysis with recombinant tissue-type plasminogen activator (IV t-PA)|Bridging thrombolysis (IV t-PA plus mechanical thrombectomy) according to current European and North American stroke guidelines.
1972684|NCT03190668|Drug|Bolus dose of Cefazolin|Mode of Cefazolin administration will be a intermittent bolus
1972685|NCT03190668|Drug|Continuous Cefazolin drip|Mode of Cefazolin administration will be a continuous drip
1972686|NCT03190668|Device|Paraspinal muscle microdialysis catheters|Two dialysis probes will be inserted into a paraspinal muscle
1972687|NCT03190668|Device|Subcutaneous microdialysis catheters|Two dialysis probes will be inserted into a paraspinal subcutaneous region
1972692|NCT03188081|Drug|Abatacept|Subcutaneous
1972696|NCT03187288|Drug|CFI-400945 Fumarate|CFI-400945 is an investigational drug that is being look at for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). CFI-400945 is an oral (taken by mouth) drug that blocks Polo-like kinase 4 (PLK4) activity. PLK4 is a protein that is important in regulating cell growth and division and cell death. Many tumors are shown to make too much PLK4. When there is too much PLK4 produced, it is believed to contribute to uncontrolled cancer cell growth and division. Therefore, by blocking this protein from working, it is believed to stop tumors from growing or shrink them.
1972703|NCT03184870|Drug|BMS-813160|specified dose on specified days
1972704|NCT03184870|Biological|Nivolumab|specified dose on specified days
1972705|NCT03184870|Drug|Nab-paclitaxel|chemotherapy regimen
1972706|NCT03184870|Drug|Gemcitabine|chemotherapy regimen
1972707|NCT03184870|Drug|5-fluorouracil (5-FU)|chemotherapy regimen
1972708|NCT03184870|Drug|Leucovorin|chemotherapy regimen
1972709|NCT03184870|Drug|Irinotecan|chemotherapy regimen
1972715|NCT03182439|Device|Fit Bit Blaze|Fit Bit Blaze Heart Rate Monitoring Device
1972716|NCT03182439|Device|Garmin Forerunner 235|Garmin Forerunner 235 Heart Rate Monitoring Device
1972717|NCT03182439|Device|Tom Tom Spark Cardio|Tom Tom Spark Cardio Heart Rate Monitoring Device
1972718|NCT03182439|Device|Apple Watch|Apple Watch Heart Rate Monitoring Device
1972719|NCT03181399|Drug|Triheptanoin|. Triheptanoin will be taken 4 times per day (approximately every 6 hours: prior to breakfast, lunch and dinner and a mid-afternoon snack) by mouth. It is dosed 4 times per day, divided evenly.
1972731|NCT03175198|Drug|Prazaxa Capsules|capsules
1972732|NCT03173560|Drug|lenvatinib|lenvatinib capsules
1972733|NCT03173560|Drug|everolimus|everolimus tablets
1972739|NCT03173092|Drug|Ixazomib|Ixazomib capsules
1972740|NCT03173092|Drug|Lenalidomide|Lenalidomide capsules
1972741|NCT03173092|Drug|Dexamethasone|Dexamethasone
1972742|NCT03172819|Biological|OBP-301|Intratumoral injection directly into the dose target region of a tumor at Day 1, Day 15, and Day 29.
1972743|NCT03172819|Drug|Pembrolizumab|200 mg Pembrolizumab is infused intravenously at Day 8. Thereafter infusion will continue every 3 weeks until discontinuation.
1972744|NCT03172520|Device|APS electrode|The APS electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the Medtronic Nerve Monitoring Systems.
1972745|NCT03172520|Device|Facial Nerve Monitor|The facial nerve monitoring system records the number of stimulations of the facial nerve during the operation and this data is stored on the device until it is shut down after the surgery is complete.
1972751|NCT03172143|Procedure|Mesenteric Sparing Ileocolic Resection|In this resection, the mesentery will be spared, or left in situ during resection.
1972752|NCT03172143|Procedure|High Ligation Ileocolic Resection|"In this resection, a high ligation is performed, where the feeding vessel is taken at its origin in order to take sufficient mesentery and lymph nodes with the colon specimen."
1972753|NCT03171311|Procedure|Angiographic guided PCI|Angiographic guided PCI is percutaneous coronary intervention performed by standard angiographic guided techniques
1972754|NCT03171311|Procedure|OCT guided PCI|OCT guided PCI is percutaneous coronary intervention (PCI) guided by intra vascular optical coherence tomography (OCT) scans
1989025|NCT02616484|Drug|Dichloroacetate (DCA)|Participants will receive the dosage of DCA (in liquid form) based on the genotyped GSTZ1 haplotype status. ECT carriers will receive 12.5 mg/kg/12hr DCA, which is the standard dose. EGT non-carriers will receive half that dose.
1989026|NCT02616484|Other|Placebo|Participants will receive the exact dose of placebo in liquid form given during DCA treatment arm. Liquid will be an exact replication of DCA formulation with no DCA added.
1989027|NCT02616484|Genetic|Genotype|Participants will be genotyped to determine GSTZ1 haplotype status for EGT carriers and EGT non-carriers will receive half that dose.
1989032|NCT02612662|Drug|AZD4076|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
1989033|NCT02612662|Drug|Placebo|Subcutaneous (SC) administration of single ascending doses; there will be no more than 2 mL per syringe/injection
1989034|NCT02613403|Drug|Grazoprevir+Uprifosbuvir+Ruzasvir|Two MK- 3682B 1,136 mg FDC tablets each containing 50 mg MK-5172 (GZR), 225 mg MK-3682 (UPR, formerly IDX21437), and 30 mg MK-8408 (RZR) taken once daily by mouth.
1989035|NCT02613403|Drug|Ribavirin|Two to three Ribavirin 200 mg (800 or 1000 or 1200 or 1400 mg total daily dose) capsules taken twice daily by mouth as part of a weight-based dosing regimen.
1972755|NCT03168750|Device|Femoral Component:Medacta Masterloc Stem and Medacta MPACT cup.|Total hip arthroplasty (THA) is one of the most commonly performed and successful orthopaedic operations in improving a patient's quality of life. Orthopaedic surgeons are continually striving to improve all aspects of care relating to this procedure whether this is improvements in implant technology, instrument improvement, or the technique involved in performing the procedure.The results of this study will establish the performance of the femoral component and acetabular component, and provide a general estimate of survivorship, clinical effectiveness and complications.
1972763|NCT03166631|Drug|BI 891065|Part A, B & C
1972764|NCT03166631|Drug|BI 754091|Part B & C
1972768|NCT03165747|Drug|VSL#3|8 strains of live bacteria: Bifidobacterium breve, B. longum, B. infantis, L. acidophilus, L. plantarum, L. paracasei, L. bulgaricus and Streptococcus thermophilus. 900 billion CFU taken orally daily in a single administration.
1972769|NCT03165747|Other|Placebo|Two placebo sachets taken orally daily in a single administration.
1972770|NCT03165136|Drug|Hydroxychloroquine|Hydroxychloroquine : 200 mg twice a day
1972771|NCT03165136|Drug|Placebo|placebo of hydroxychloroquine
1972791|NCT03162783|Drug|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.
1972792|NCT03162783|Drug|ADX-102 Ophthalmic Solution (0.1%)|ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.
1972793|NCT03162783|Drug|ADX-102 Ophthalmic Lipid Solution (0.5%)|ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.
1972795|NCT03161613|Other|Non-Interventional|Non-Interventional
1972805|NCT03157089|Drug|Afatinib|Film-coated tablet
1972806|NCT03157089|Drug|pembrolizumab|Solution for infusion
1972807|NCT03156504|Drug|Ketamine Hydrochloride|Subjects will receive three IV ketamine infusions at 0.5 mg/kg, infused over 100 minutes.
1972808|NCT03156920|Drug|Placebo|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
1972809|NCT03156920|Drug|Sumatriptan|Cilostazol is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan
1972810|NCT03156114|Drug|BI 754111|Day 1 of 3 week cycle
1972811|NCT03156114|Drug|BI 754091|Day 1 of 3 week cycle
1972812|NCT03154983|Drug|docetaxel|Diagnosed with metastatic gastric cancer patients (including the esophagogastric junction adenocarcinoma), DS(docetaxel and Tegafur)and Mesylate apatinib 6 cycles, the specific amount of usage: DS Docetaxel 75mg/m2 D1 IV.drop 1H（one hour）, Tegafur(BSA<1.25 40mg Po bid(twice a day), BSA >=1.25-<1.5 50mg Po bid, BSA >=1.5 60mg Po bid, Q21d(21 days a cycle)); Mesylate Apatinib 500mg Po QD（once a day)） continuous use, until disease deterioration.
1972813|NCT03155997|Drug|Abemaciclib|Administered orally.
1972814|NCT03155997|Drug|Standard Adjuvant Endocrine Therapy|Administered according to label instructions.
1972830|NCT03155451|Diagnostic Test|methylation markers screening|ctDNA extraction from plasma samples;bisulfite-treated DNA;DNA methylation levels by deep sequencing-Sequencing; data analysis
1972834|NCT03151551|Drug|Ixekizumab|Administered SC
1972835|NCT03151551|Drug|Adalimumab|Administered SC
1972836|NCT03150836|Drug|Durvalumab|All participants will receive durvalumab 1500 mg via IV infusion every 4 weeks for up to 13 doses.
1972837|NCT03150836|Drug|Tremelimumab|Participants receiving Regimen B (safety lead-in or expansion cohort) will be administered tremelimumab 75 mg via IV infusion every 4 weeks for 1 cycle or 2 cycles.
1972838|NCT03150836|Radiation|Radiation Therapy|In all arms of the study, participants will receive 5 fractions of radiation. The radiation dose will either be 6.6 Gy for a total dose of 33 Gy, or 6.0 Gy for a total dose of 30 Gy.
1972843|NCT03149822|Drug|Cabozantinib|Pharmaceutical form: tablets Route of administration: oral
1972844|NCT03149822|Drug|Pembrolizumab|Pharmaceutical form: solution Route of administration: injection
1989063|NCT02604173|Drug|Budesonide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
1989064|NCT02604173|Drug|Acetazolamide|Inhaled Budesonide vs. PO Acetazolamide vs. Placebo for prevention of Acute Mountain Sickness
1989065|NCT02604173|Drug|Placebo|Placebo pill and sham inhaler
1989066|NCT02603185|Drug|Hemay007|
1989067|NCT02603185|Drug|placebo|
1989071|NCT02599714|Drug|AZD2014|The triplet combination will be comprised of AZD2014 + palbociclib + fulvestrant.
1989072|NCT02599714|Drug|Placebo to match AZD2014|The doublet combination will be comprised of Matching AZD2014 placebo + palbociclib + fulvestrant.
1989073|NCT02599714|Drug|Palbociclib|cyclin dependent kinase inhibitor
1989074|NCT02599714|Drug|Fulvestrant|Fulvestrant hormonal therapy as background
1972849|NCT03148041|Other|health education program|"Intensive health education program for intervention group: 1.The introductory 30 minute Arabic lecture for increase level of the awareness of the participants regarding stroke. Lecture from the USA National Stroke Association, 2011, will be used. The lecture includes the following issues about stroke (1) definition; (2) signs and symptoms; (3) risk factors; (4) treatment; and (5) prevention.
2. Self-help materials will involve health education brochures regarding stroke and will be distributed for all participants at the time they are attending the lecture. The brochures which will be used for this study will be collected from the World Stroke Day 2016 Brochures, the Arabic version.
The routine care for control group: different lecture and brochures will be used"
1972850|NCT03145636|Device|vBloc Maestro Rechargeable System|Intra-abdominal vagal blocking neuromodulation device for the treatment of obesity
1972853|NCT03143153|Biological|Nivolumab|Specified dose on specified days
1972854|NCT03143153|Biological|Ipilimumab|Specified dose on specified days
1972855|NCT03143153|Drug|Cisplatin|Specified dose on specified days
1972856|NCT03143153|Drug|Fluorouracil|Specified dose on specified days
1972857|NCT03142165|Drug|BMS-986263|3 weekly doses of 90 mg infused intravenous administration
1972858|NCT03142165|Other|Placebo|Placebo
1972859|NCT03142165|Drug|Diphenhydramine|50 mg intravenous administration
1972860|NCT03142165|Drug|Famotidine|20 mg intravenous administration
1972861|NCT03141177|Biological|Nivolumab|Specified dose on specified day
1972862|NCT03141177|Biological|Ipilimumab|Specified dose on specified days
1972863|NCT03141177|Drug|Cabozantinib|Specified dose on specified days
1972864|NCT03141177|Drug|Sunitinib|Specified dose on specified days.
1972867|NCT03134599|Device|etafilcon A|contact lens
1972868|NCT03134599|Device|methafilcon A - Interozzo|contact lens
1972869|NCT03134599|Device|methafilcon A - CVI (CooperVision)|contact lens
1972870|NCT03134248|Device|Dailies Aquacomfort Plus toric daily disposable contact lenses|daily disposable contact lens
1972871|NCT03134248|Device|1-Day Acuvue Moist toric daily disposable contact lenses|daily disposable contact lens
1972872|NCT03134248|Device|MyDay A Toric daily disposable contact lens|daily disposable contact lens
1972873|NCT03133650|Drug|WST 11-mediated VTP therapy|Administration of WST11 in conjunction with endoscopic illumination at 753 nm emitted by a diode laser and administered to the participant by optical fibre catheters (cylindrical light diffusers) and a standard upper GI endoscope.
1972879|NCT03129542|Drug|Midodrine Hydrochloride 10 milligrams|Three doses taken by mouth every 8 hours.
1972880|NCT03129542|Drug|Placebo oral capsule|Three doses taken by mouth every 8 hours.
1972881|NCT03128268|Device|Imaging software for 4 dimensional images for Cardiac MRI|All enrollees will receive Cardiac MRI scans using Imaging software for 4 dimensional images for Cardiac MRI
1972882|NCT03126149|Drug|PF-06667272|Single ascending dose of PF-06667272
1972883|NCT03126149|Other|Placebo|Single dose of placebo
1972886|NCT03122366|Diagnostic Test|Detection of single nucleotide polymorphisms (SNP)|Asp299Gly SNP in the third exon of the TLR4 gene will be detected in blood
1972889|NCT03118739|Drug|RDEA3170 9 mg+Febuxostat 80 mg|Capsule administered orally, once daily for 24 weeks
1972890|NCT03118739|Drug|Placebo|Capsule administered orally, once daily for 24 weeks
1916781|NCT01216449|Drug|Intravenous Citalopram|Single dose of 20mg parenteral citalopram diluted in 250mL of 0.9% sodium chloride solution, infused over 30 minutes
1916782|NCT01216449|Drug|Normal Saline|Single dose of 250mL of 0.9% sodium chloride solution, infused over 30 minutes
1972897|NCT03116906|Drug|BI 685509|to be given for a total of up to 15 days
1972898|NCT03116906|Drug|Placebo|to be given for a total of up to 15 days
1972899|NCT03116373|Other|mandible fixation|Intubation device will be fixed on mandible
1972900|NCT03116373|Other|Maxilla fixation|Intubation device will be fixed on maxilla
1972902|NCT03112148|Drug|10 mg dose MR formulations,10 mg dose of tofacitinib IR solution|"For the the relative bioavailability (BA) assessment , the investigational product(s) are:
Test: 10 mg dose of age-appropriate MR formulations (MR-fast, MR-moderate, MR-slow). Each formulation contains 0.025 mg of tofacitinib/mg of microsphere. Reference: 10 mg dose of tofacitinib IR solution (1 mg of tofacitinib/mL).
For the the food effect assessment, the investigational product(s) are:
Test: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) c-oadministered with high-fat FDA breakfast. Reference: 10 mg dose of age-appropriate MR formulations (MR-fast or MR-slow) administered under fasted state."
1972904|NCT03110900|Drug|Haloperidol + lorazepam|Haloperidol + lorazepam + placebo
1972905|NCT03110900|Drug|Loxapine|loxapine + placebo
1972908|NCT03106428|Drug|MEDI7247|The study will enroll patients with R/R AML/MM/DLBCL who will receive MEDI7247 IV Q3W
1972916|NCT03098550|Biological|Nivolumab|Specified dose on specified days
1972917|NCT03098550|Biological|Daratumumab|Specified dose on specified days
1972918|NCT03097380|Drug|AZD2115|AZD2115
1972919|NCT03097380|Drug|SPIRIVA|Tiotropium
1916813|NCT01212588|Drug|mifepristone|Mifepristone 600mg (3x200mg tablets) once daily for seven days
1916814|NCT01212588|Drug|Placebo|3 tablets once daily for seven days
1972920|NCT03097380|Radiation|[11C]AZ13754366|Radioligand
1972934|NCT03092570|Device|With stimulation|ramp stimulation from 0 to 2 mA followed by 20 minutes of stimulation at 2mA while practicing during 3 of the 4 sessions
1972935|NCT03092570|Device|No stimulation|ramp stimulation from 0 to 2 mA followed by 30 sec of stimulation at 2mA.
1972936|NCT03092375|Drug|Glecaprevir/Pibrentasvir (G/P) 300mg/120mg|daily
1972937|NCT03092375|Drug|Ribavirin 200Mg Tablet|Weight-based 1000-1200 mg
1972941|NCT03089541|Behavioral|Contingency Management|Contingency Management for Biochemically verified cigarette abstinence
1972944|NCT03084640|Drug|CMP-001|Experimental CMP-001 in combination with Pembrolizumab.
1972945|NCT03084640|Drug|Pembrolizumab|Experimental CMP-001 in combination with Pembrolizumab.
1972946|NCT03081403|Device|Quantitative Sensory Testing|Study of detection thresholds of vibration, cold and pain related to the heat in the dominant hand of the subjects through the QST.
1972948|NCT03078790|Device|iPad|a 10 minute electronic guided deep breathing module offered via an iPad
1972950|NCT03075748|Device|TAAA Debranching Stent Graft System|The TAAA Debranching Stent Graft System is made up of two main body components and makes use of several off-the-shelf FDA-approved stent graft components. The two custom main body grafts are the thoracic bifurcation and the visceral manifold. The thoracic bifurcation is deployed in the thoracic aorta and provides the proximal seal for the device. The two limbs of the thoracic bifurcation allows for continued aortic flow while deploying the visceral segment. The visceral manifold is deployed within the larger 20 mm limb of the thoracic bifurcation to set the stage for the visceral debranching. The branches of the visceral manifold extend to the visceral vessel with the use of covered bridging stents and provide distal seal of the manifold.
1916833|NCT01208051|Drug|Cediranib Maleate|Given PO
1916834|NCT01208051|Other|Laboratory Biomarker Analysis|Correlative studies
1916835|NCT01208051|Drug|Lenalidomide|Given PO
1972951|NCT03073967|Drug|Pritelivir|100 mg tablets
1972952|NCT03073967|Drug|Foscarnet|Solution for iv infusion
1972956|NCT03071107|Behavioral|Multi-disciplinary intervention|Participants in the intervention group will receive a multifactorial, interdisciplinary, treatment program intended to target pre-frailty for a 4-month period following randomization (physical meetings at 2-monthly time points with telephone consultations between meetings). The interventions will be individually tailored to each participant based on their frailty characteristics at baseline and amended if other problems are identified during the intervention program. This intervention team will consist of a renal dietitian and physiotherapist, both of whom will be trained and accredited in behavioural therapy intervention skills, and will focus on improving nutritional status and physical strength through resistance exercise training. They will be supported by a Clinical Research Fellow who will provide additional medical assessment to determine any reversible medical causes of frailty.
1972957|NCT03068455|Biological|nivolumab|Specified Dose on Specified Days
1972958|NCT03068455|Biological|ipilimumab|Specified Dose on Specified Days
1972960|NCT03058861|Behavioral|Play Nicely Program|Play Nicely multimedia program and handbook that provides education about healthy discipline strategies.
1972961|NCT03062046|Device|RF ablation|RF ablation
1972962|NCT03060941|Behavioral|Physical activity education|Participants will be given educational materials on how to increase physical activity levels.
1972963|NCT03060941|Behavioral|Facility access|Participants will receive at 6 month membership to a local fitness facility.
1972964|NCT03060941|Behavioral|Supervised exercise sessions|Participants will attend weekly supervised exercise sessions with an exercise interventionist.
1972965|NCT03060941|Behavioral|Self-monitoring (Fitbit)|Participants will be given a Fitbit to monitor their physical activity levels.
1972966|NCT03060941|Behavioral|Active living counseling|Participants will attend 12 biweekly educational sessions about how to increase their physical activity levels.
1972971|NCT03056157|Behavioral|Adaptive Disclosure for Moral Injury and Loss|Ad-MIL is a 12-session treatment designed to address shame and guilt and to develop compassion for the self and the other. At the outset of AD-MIL, the investigators ask Veterans to enlist a family member or friend to provide support and to reinforce their plan for adaptive, purposeful functioning moving forward. The sessions that follow homework assignments involve a discussion to reinforce positive steps taken and identifying obstacles to completion (e.g., self-defeating beliefs). There is a special emphasis on discussing self-handicapping, namely feeling unworthy of getting better or living a good life. The goal is not only for Veterans to develop a sense of mastery in accomplishing tasks and to experience the benefits of the activities, but also to work on overcoming feelings of unworthiness.
1972972|NCT03056157|Behavioral|Present Centered Therapy|Participants randomized to the PCT arm will receive 12 sessions of therapy focused on problems occurring in the present (with no focus on trauma or re-visiting past experiences).
1916861|NCT01202331|Drug|mass treatment with oral azithromycin|For baseline and follow-up surveys prior to azithromycin distribution, a stratified random sample from two age groups will be chosen: 1) 60 study participants younger than 10 years old and 2) 60 study participants aged 10 years and above. Clinical examination will be performed and conjunctival swabs will be taken from all the study participants. Nasopharyngeal swabs will be collected in each community from 15 randomly selected children among the 60 participants under age 10 who were recruited for conjunctival swabbing. Then a single dose of azithromycin will be distributed according to study design: in tablet form for adults; a weight-adjusted tablet dose for children ages 8-10; and pediatric suspension for children ages 1 - 7.
1972980|NCT03053388|Drug|Nitric Oxide|Nitric Oxide given via inhalation in cycles
1972981|NCT03053388|Other|Supportive treatment|Supportive treatment (including oxygen)
1972987|NCT03049540|Drug|Tadalafil 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
1972988|NCT03049540|Drug|Placebo 20 MG|Multi-center, double-blind, 1:1 randomized, placebo-controlled clinical trial with Tadalafil
1916873|NCT01198860|Drug|CTH Chronic Hepatitis B|"Drug:
Tenofovir/ 300mg daily
Phyllanthus Urinaria/300mg daily
Adenosma Glutinosum/150mg daily
Eclipta Prostrata/150mg daily
Ascorbic Acid / 500mg daily"
1916891|NCT01196130|Behavioral|Cancer Symptom Questionnaire|5 minute questionnaire(s) completed at each study visit.
1916892|NCT01196130|Other|Biomarker Testing|Blood draw at each study visit for biomarker and cytokine testing.
1973007|NCT03037749|Drug|Alcohol beverage|Alcohol beverage
1973008|NCT03037749|Drug|Placebo beverage|Placebo beverage
1973012|NCT03036150|Drug|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
1973013|NCT03036150|Drug|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg
1973014|NCT03036124|Drug|Dapagliflozin|10 mg or 5 mg tablets given once daily, per oral use.
1973015|NCT03036124|Drug|Placebo|Placebo matching dapagliflozin 10 mg or 5 mg.
1973016|NCT03036098|Biological|nivolumab|Specified Dose on Specified Days
1973017|NCT03036098|Biological|ipilimumab|Specified Dose on Specified Days
1973018|NCT03036098|Drug|gemcitabine|Specified Dose on Specified Days
1973019|NCT03036098|Drug|cisplatin|Specified Dose on Specified Days
1973020|NCT03036098|Drug|carboplatin|Specified Dose on Specified Days
1973021|NCT03036007|Other|Prescribed Physical Activity|General physical activity prescribed by a physiotherapist
1973022|NCT03036007|Other|Exercises with Internet support|Neck-specific exercise with Internet support
1973027|NCT03034135|Drug|Disulfiram/Copper|Disulfiram/copper gluconate is taken three times a day.
1973028|NCT03033641|Device|Ablation procedure|All enrolled subjects who have ablation targets identified will undergo CARTOFINDER guided ablation (CFGA) followed by PVI. Subjects will be followed per the protocol schedule. Subjects who have no ablation target identified on the baseline CARTOFINDER map will undergo ablation per the institution's standard of care and be followed for 7 days for safety monitoring, then exit from the study.
1973033|NCT03029819|Behavioral|Mindfulness-based Addiction Treatment|Mindfulness-based Addiction Treatment (MBAT) consists of 8 weekly 2-hour sessions that teach mindfulness and cognitive-behavioral strategies for smoking cessation (Wetter et al., 2009).
1973034|NCT03029819|Behavioral|iQuit Mindfully|iQuit Mindfully involves text messages on each day between treatment sessions. The text messages provide mindfulness and cognitive-behavioral strategies and support for smoking cessation.
1973035|NCT03029819|Behavioral|Self-Help guide|Self-help materials for smoking cessation are based on the Treating Tobacco Use and Dependence Clinical Practice Guideline (Fiore et al., 2008).
1973036|NCT03029819|Drug|Nicotine Patch|Patch therapy (beginning the week before quit day) for participants who smoke >10 cigarettes/day will consist of 4 weeks of 21 mg patches, 1 week of 14 mg patches, and 1 week of 7 mg patches. Patch therapy for participants who smoke 5-10 cigarettes/day will consist of 4 weeks of 14 mg patches and 2 weeks of 7 mg patches.
1973037|NCT03029780|Biological|Opdivo|Specified dose on specified days
1973038|NCT03029780|Biological|Yervoy|Specified dose on specified days
1973044|NCT03023670|Procedure|cardiopulmonary bypass|Low flow of mixed oxygen / air (1:1L) will be used during the period of cardiopulmonary bypass
1973045|NCT03023670|Procedure|cardiopulmonary bypass|Low rate (4\min) with low tidal volume ( 2ml/kg ) will be used during the period of cardiopulmonary bypass.
1973046|NCT03022812|Other|Neck-specific exercise|Neck-specific exercise
1973048|NCT03018288|Drug|Pembrolizumab|Pembrolizumab at 200mg will be administered on day 1 as a 30 minute IV infusion (prior to RT) every 3 weeks during RT on days 1, 22 and 43. At one year, if patients are doing well they may continue pembolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
1973049|NCT03018288|Biological|HSPPC-96|One week post RT, patients will receive weekly x 4 a dose of HSPPC-96 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of TMZ. HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Patients who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if patients are doing well they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
1973050|NCT03018288|Drug|Temozolomide|TMZ will be administered on day 1 of radiation therapy (before RT treatment) and continue throughout RT at the dose of 75 mg/m2. Post RT: The starting TMZ dose will be 150 mg/m2/day for cycle 1, days 1-5, with a single dose escalation to 200 mg/m2/day (days 29-33) and for all subsequent treatment if no treatment-related adverse events greater than Grade 2 are noted. TMZ will be given for 6 cycles.
1973051|NCT03018288|Other|Placebo|One week post RT, patients will receive weekly x 4 a dose of HSPPC-96 0.4mL intradermal vaccine or placebo. HSPPC-96 vaccine or placebo will then be given 21 days after the day 5 dose of TMZ. HSPPC-96 vaccine or placebo vaccine will be given for 6 cycles or until supply runs out. Patients who receive placebo will be matched for number of vaccine injections that were generated by their tumor tissue. At one year, if patients are doing well they may continue pembrolizumab for 12 more months alone or in conjunction with HSPPC-96 or placebo vaccine if any is available.
1973052|NCT03018288|Radiation|radiation treatment|All patients will be treated with standard RT to approximately 60 Gy (180 Gy x 33 fractions or 200 Gy x 30 fractions).
1973053|NCT03019640|Biological|NK Cells|On D-5, the New Killer (NK) cell infusion administered by vein.
1973054|NCT03019640|Drug|Rituximab|On D-13 and D-7, administered at dose of 375 mg/m2 by vein.
1973055|NCT03019640|Drug|Carmustine|On D-12, administered at a dose of 300 mg/m2 by vein over 2 hours.
1973056|NCT03019640|Drug|Etoposide|On D-11 to D-8, administered at a dose of 200 mg/m2 by vein twice a day over 3 hours.
1973057|NCT03019640|Drug|Cytarabine|On D-11 to D-8, administered at a dose of 200 mg/m2 by vein twice a day over 1 hour.
1973058|NCT03019640|Drug|Melphalan|On D-7, administered at a dose of 140 mg/m2 by vein over 30 minutes.
1973059|NCT03019640|Drug|Lenalidomide|On D-7 to D-2, administered at a dose of 10 mg orally (PO).
1973060|NCT03019640|Drug|G-CSF|Dose of 5 mcg/kg/day (round up to the nearest vial) subcutaneously beginning on D+5, and continuing until evidence of an absolute neutrophil count (ANC) of 0.5 x 10^9/L per 3 consecutive days
1973061|NCT03019640|Biological|Auto SCT|On D0, autologous stem cell (Auto SCT) infusion minimum cell dose of 2e6 cells/kg.
1973062|NCT03019640|Other|Apheresis|Apheresis of up to 1 x 10^8 CD34+ cells/kg will be completed prior to beginning NK cell production. Process will start no less than 14 days (D-19) prior to infusion on D-5.
1973063|NCT03018275|Biological|Roseomonas mucosa|R mucosa grown in Hank's balanced salt solution. Bacteria is washed, quantitated spectrophotometrically, suspended in 10%-15% sucrose, and lyophilized.
1973067|NCT03018106|Drug|Ospemifene|Ospemifene is a selective estrogen receptor modulator (SERM), and it is the only SERM approved in the United States to treat moderate to severe dyspareunia associated with VVA. It is an oral medication that is taken as a 60mg tablet once daily. Food intake increases its absorption by 2 to 3-fold, and this is not impacted by the fat or calorie content of the food. It is metabolized primarily in the liver, and is excreted in feces.
1973068|NCT03018106|Drug|Vaginal conjugated estrogens|Conjugated estrogens are a mixture of several different estrogen salts derived from natural sources and blended to approximate the composition of estrogens in the urine of pregnant horses. The main components are sodium estrone sulphate and sodium equilin sulfate. Vaginal estrogen is considered the medication of choice for treating vulvovaginal atrophy (VVA).
1973073|NCT03016325|Drug|HNO Donor|Infusion
1973074|NCT03016325|Drug|Placebo|Infusion
1973075|NCT03015662|Other|Dry Needling Therapy|Dry needling procedures will be performed in the following pairs of muscles in the same intervention: occipital, splenius capitis, sternocleidomastoid (Clavicular branch TrPs 1, 2 and 3; sternal branch TrPs 1, 2, 3 and 4), scalene (anterior TrPs 1, and 2; medial TrP (Trigger Point) 1; posterior TrP 1), trapezius (upper TrPs 1, and 2; middle TrPs 5, 6 and 7; lower TrPs 3, and 4), supraspinatus (central point; myotendinous union; tendon insertion), infraspinatus (medial/superior; lateral/superior; lateral scapular side; medial scapular side), and multifidus (level C6).
1989075|NCT02599714|Drug|Placebo to match palbociclib|In the case of a chosen palbociclib dose less than 125 mg the triplet combination will include both palbociclib and matching palbociclib placebo to disguise the dose
1989076|NCT02598557|Drug|Exemestane|Given PO
1989077|NCT02598557|Other|Laboratory Biomarker Analysis|Correlative studies
1989078|NCT02598557|Other|Pharmacological Study|Correlative studies
1989079|NCT02598557|Other|Placebo|Given PO
1989080|NCT02598557|Other|Quality-of-Life Assessment|Ancillary studies
1989081|NCT02598557|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1973076|NCT03015662|Other|Myofascial Release Therapy|Patients will develope a myofascial therapy protocol, administered in the following order in the same intervention: deep fascia release in temporal region, suboccipital release, compression-decompression of temporomandibular joint, global release of cervicodorsal fascia, release of pectoral region, diaphragm release (transverse slide), and transverse diaphragmatic plane.
1973079|NCT03015181|Biological|VRC-HIVMAB075-00-AB|VRC07-523LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
1973080|NCT03014089|Biological|mRNA-1325|Escalating dose levels
1973081|NCT03014089|Other|Placebo|
1973090|NCT03006926|Drug|lenvatinib|4 mg capsules
1973091|NCT03006926|Drug|pembrolizumab (200 mg)|30-minute intravenous infusion
1973102|NCT03002623|Drug|CUDC-907|60 mg (2 (SqrRoot) 30 mg capsules) will be given orally once a day 5 days on and 2 days off.
1973103|NCT03001882|Biological|Nivolumab|Specified dose on specified days
1973104|NCT03001882|Biological|Ipilimumab|Specified dose on specified days
1973105|NCT03002389|Drug|Anoro Ellipta|inhaler approved by FDA (strength umeclidinium 65 microgram + vilanterol 25 microgram) One puff once a day for 30 days
1973106|NCT03002389|Drug|Arnuity Ellipta|inhaler approved by FDA (strength 250 microgram) One puff twice a day for 30 days
1973115|NCT02998528|Biological|Nivolumab|
1973116|NCT02998528|Biological|ipilimumab|
1973117|NCT02998528|Drug|cisplatin|
1973118|NCT02998528|Drug|vinorelbine|
1973119|NCT02998528|Drug|gemcitabine|
1973120|NCT02998528|Drug|docetaxel|
1973121|NCT02998528|Drug|pemetrexed|
1973122|NCT02998528|Drug|carboplatin|
1973124|NCT02996461|Biological|VRC-ZKADNA090-00-VP|VRC-ZKADNA090-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
1973125|NCT02996578|Dietary Supplement|polyphenol rich chocolate bar|High polyphenol content chocolate bar. Each participant will consume 581.4mg of polyphenols
1973126|NCT02996578|Dietary Supplement|polyphenol rich cocoa powder|High polyphenol content cocoa powder. Each participant will consume 6g containing 554mg of polyphenols
1973127|NCT02996578|Dietary Supplement|low polyphenol content chocolate bar|Low polyphenol content matched chocolate bar. Each participant will consume 198.5mg of polyphenols
1973128|NCT02996578|Dietary Supplement|low polyphenol content cocoa powder|Low polyphenol content cocoa powder. Each participant will consume 6g containing 191.2mg of polyphenols
1973131|NCT02994199|Other|Active video gaming|Participants will engage in active video game play using two off-the-shelf (OTS) and two adapted controllers using the Wii gaming console. Controllers are: OTS balance board, OTS gaming mat, Adapted balance board, Adapted gaming mat.
1973132|NCT02992522|Drug|Lenalidomide|Given PO
1973133|NCT02992522|Biological|Obinutuzumab|Given IV
1973134|NCT02992522|Drug|Venetoclax|Given PO
1973138|NCT02987556|Device|Continuous Glucose Monitoring|Collection of glucose data
1973139|NCT02987556|Device|External Insulin Pump|insulin delivery
1973140|NCT02987556|Other|telemdecine|Remote follow up by care health providers team
1973141|NCT02987556|Device|The Diabeloop Software (Model predictive control)|Diabeloop is a Closed-loop (CL) system with a Model Predictive Control (MPC) algorithm reinforced by a decisional matrix, uploaded on a dedicated android smartphone linked to Dexcom CGM and a Cellnovo insulin patch-pump. The Diabeloop software calculates the insulin dose according to the patient's needs.
1973142|NCT02987829|Drug|TRC253|TRC253 is a high-affinity, small molecule antagonist of the androgen receptor (AR) with inhibitory activity against wild type AR and specific mutated variants of AR. TRC253 blocks AR nuclear translocation as well as AR binding to DNA and is an antagonist of transcription for wild type AR and mutated AR. TRC253 is orally active and does not have agonist activity towards either the wild type or mutated ARs. TRC253 treatment in the Hershberger assay results in complete inhibition of androgen sensitive organ development. TRC253 is efficacious in an LNCaP xenograft model driven by F876L (also known as F877L) mutant AR.
1917073|NCT01161017|Drug|Amitriptyline|Initial dose of 12.5mg will be given for 2 days. Then, daily 25mg will be taken for additional 8 weeks
1917074|NCT01161017|Drug|Topiramate|For the first 5 days of treatment 25mg is prescribed and should be ingested in one evening dose. For another 5 days, 25g dose should be taken twice a day (morning and evening). For the next 5 days, morning dose will be 25mg; evening dose will be 50mg. For the remaining 6 weeks of treatment, a dose of 50mg twice a day will be advised
1973145|NCT02982954|Drug|Nivolumab|Specified dose on specified day
1973146|NCT02982954|Drug|Ipilimumab|Specified Dose on Specified Day
1973149|NCT02981472|Drug|Apixaban|Oral solution or tablet
1973150|NCT02981472|Drug|Vitamin K Antagonist (VKA)|1, 2.5, and 5 mg
1973151|NCT02981472|Drug|Low Molecular Weight Heparin (LMWH)|100mg/mL
1973152|NCT02979873|Drug|Sirolimus|Sirolimus will be started on day 1 for subjects in the Sirolimus arm. A baseline CBC will be obtained within one week of randomization, or on Day 0. Thereafter, CBC will be monitored on a weekly basis for subjects in both arms. In the event of relapse (see definition of outcomes Section 6.7), the patient shall return to the NIH CRC for evaluation to include bone marrow biopsy and aspirate to exclude clonal evolution to MDS. Assessment will include flow cytometry phenotyping of peripheral blood mononuclear cells for regulatory T-cells (Tregs, e.g. CD4+ CD25high FOXP3+) and regulatory dendritic cells (DCregs) and proteomics assay (research labs).
1973153|NCT02978690|Drug|BI655130|
1973156|NCT02974803|Drug|Dabrafenib|
1973157|NCT02974803|Drug|Trametinib|
1973164|NCT02968940|Biological|Avelumab|Avelumab 10 mg/kg intravenously (IV) every 2 weeks
1973165|NCT02968940|Radiation|Hypofractionated radiation therapy (HFRT)|Hypofractionated radiation therapy to a total dose of 30 Gy, delivered in 6 Gy per fraction for 5 consecutive daily fractions
1973171|NCT02960854|Biological|Nivolumab|Specified dose on specified days
1973172|NCT02960659|Drug|Metformin and Liraglutide|Metformin and Liraglutide
1973173|NCT02961348|Other|Early start of NOAC|Initiation of NOAC up until day 4 after acute ischemic stroke in patients with atrial fibrillation
1973174|NCT02961348|Other|Late start of NOAC|Initiation of NOAC between day 5 and day 10 after acute ischemic stroke in patients with atrial fibrillation
1973187|NCT02954536|Drug|pembrolizumab|
1973188|NCT02954536|Drug|trastuzumab|
1973189|NCT02954536|Drug|capecitabine|
1973190|NCT02954536|Drug|cisplatin|
1973191|NCT02954536|Drug|Oxaliplatin|Oxaliplatin may be administered instead, at a dose of 130 mg/m2/day as an I.V.over approximately 2 hours on Day 1 every 21-day cycles, up to a maximum of 8 cycles in the absence of disease progression or until other withdrawl criteria are met. Patients may begin with reduced dose of oxaliplatin 104 mg/m2 as starting dose if deemed necessary per the treating physician discretion. Oxaliplatin will be administered after the completion of the pembrolizumab infusion.
1973192|NCT02954536|Drug|5-Fluorouracil|Only for patients unable to take oral medications (because of certain circumstances such as malabsorption, difficulty swallowing, or other conditions that could affect intake of oral capecitabine medication), 5-FU may be administered instead, at a dose of 800 mg/m2/day as a continuous infusion over 5 days (Day 1 to Day 5 of each cycle), every 21 days. This decision should be made prior to registration by the treating physician; switching from capecitabine to 5-FU, or vice versa, will not be allowed during the study. 5-FU will be administered after completion of the cisplatin infusion.
1973193|NCT02952248|Drug|BI 754091|
1973196|NCT02951689|Dietary Supplement|Probiotic|
1973197|NCT02951689|Dietary Supplement|Placebo|
1973199|NCT02948426|Biological|Autologous Monocytes + ACTIMMUNE + SYLATRON|The autologous monocytes cell product in 250ml total volume of investigational combination (monocytes + ACTIMMUNE + SYLATRON) is infused via the intraperitoneal catheter over 30-60 min +/- 10 min every 28 days +/- 7 days until disease progression, limiting toxicity, intercurrent medical issues, or patient withdrawal. Dosing is based on a dose escalation design including an expansion cohort at the MTD.
1973201|NCT02945514|Other|DayTwo machine learning algorithm|Personally tailored nutrition insights based on DayTwo machine learning algorithm when combining facets of your postprandial glycemic response to food consumed during collection week and your individual gut microbiome composition
1973202|NCT02942264|Drug|TG02|"Phase I: Two treatment arms and several dose levels are planned; In the MTD finding part, TMZ with two alternate schedules (dd and mn) in combination with TG02 will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + TG02 versus dd/mn TMZ alone using a Bayesian clinical trial design. The dosage for the combination arm will be derived from the MTD determined in the Phase I component of the study."
1973203|NCT02942264|Drug|TMZ|"Phase I: In the MTD finding part, TMZ with two alternate schedules (dd and mn) in combination with TG02 will be administered; A cohort extension of both arms will be performed at each MTD and the treatment arm with a better progression free survival at 4 months (PFS4) will be selected for the combination treatment arm for Phase II; Patients will be randomized between two competing treatment arms: (winner of dd vs mn) TMZ + TG02 versus dd/mn TMZ alone using a Bayesian clinical trial design."
1973205|NCT02942277|Biological|Pfs25M-EPA/AS01|Pfs25, a surface antigen of zygotes and ookinetes in the mosquito stages of P.falciparum, is a lead candidate for developing a malaria transmission blocking vaccine. Recombinant Pfs25M was expressed in Pichia pastoris (P.pastoris). Recombinant ExoProtein A (EPA), a mutant, non-toxic protein corresponding to sequence of EPA of Pseudomonas aeruginosa (P.aeruginosa), was expressed in E.coli. Pfs25M and EPA were chemically crosslinked to form Pfs25M-EPA conjugate. AS01B will be mixed directly with the vialed conjugated Pfs25M for a final formulation of either 16mcg conjugated Pfs25M, 15mcg conjugated EPA in AS01 (25mcg MPL+ 25mcg QS21 liposomal formulation) for Arms 1a, 3a or 47mcg conjugated Pfs25M, 45mcg conjugated EPA in AS01 for Arms 1b, 3b, 3c, 3d. The fractional dose (Dose3) in Arm 3d will be 1/5th of the 47mcg conjugated Pfs25M dose in AS01 (final formulation of 9.4mcg conjugated Pfs25M, 3mcg conjugated EPA in AS01 [5mcg MPL+5mcg QS21 liposomal formulation]).
1989090|NCT02596503|Drug|Eribulin|Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.
1989091|NCT02596503|Drug|Irinotecan|Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.
1989092|NCT02596503|Other|Cefixime|Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.
1989093|NCT02596490|Behavioral|Questionnaires|"Phase 1: At end of second meditation and discussion session, couples complete complete a written review about the program in general and a questionnaire about their general health and well-being.
Phase 2: Couples complete 12 questionnaires before first meditation and discussion session. Questionnaires ask about participant's health, mood, level of fatigue, sleeping habits, their relationship, and quality of life. Same questionnaires completed 1 week after mediation sessions.
Phase 3: Participant complete 13 questionnaires before first mediation session, after last session, and again 3 months later. Questionnaires ask about participant's health, any symptoms they may be having, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. Partners complete 12 questionnaires about their health, mood, level of fatigue, sleeping habits, their relationship, and their quality of life. AC group completes same questionnaires with no intervention."
1989094|NCT02596490|Behavioral|Meditation and Discussion Sessions|"Phase 1: Participant and partner attend 2 meditation sessions with a mediation trained instructor. Each session will last about 60-90 minutes.
Phase 2 and 3: Participant and partner attend meditation class with a trained meditation instructor each week for 4 weeks. Each session will last about 60 minutes total. Meditation and discussion sessions videotaped."
1989095|NCT02596490|Behavioral|Cancer-Related Discussion Program|Phase 3: Participant and partner attend 1 discussion session each week for 4 weeks with a trained interventionist. During the discussion sessions, participants discuss issues for couples coping with cancer. Each session will last about 60 minutes.
1973206|NCT02942277|Biological|Pfs230D1M-EPA/AS01|Pfs230 is a malaria parasite antigen expressed in gametocytes and on the surface of emerging gametes in the mosquito host and is also a TBV target. Recombinant Pfs230D1M was expressed in P. pastoris. Recombinant EPA was expressed in E. coli. Pfs230D1M and EPA were chemically crosslinked to form Pfs230D1M-EPA conjugate. AS01B will be mixed directly with the vialed conjugated Pfs230D1M for a final formulation of either 13mcg conjugated Pfs230D1M, 10mcg conjugated EPA in AS01 (25mcg MPL+ 25mcg QS21 liposomal formulation) for Arms 2a, 3a or 40mcg conjugated Pfs230D1M, 31mcg conjugated EPA in AS01 for Arms 2b, 3b, 3c, 3d. The fractional dose (Dose #3) in Arm 3d will be 1/5th of the Pfs230D1M dose in AS01 (final formulation of 8mcg conjugated Pfs25M, 2mcg conjugated EPA in AS01 [5mcg MPL+ 5mcg QS21 liposomal formulation]).
1973207|NCT02942277|Other|AS01|AS01 is a liposome-based Adjuvant System containing the immunoenhancers MPL (3- Odesacyl- 4'-monophosphoryl lipid A) and QS- 21 (a saponin molecule purified from the bark extract of Quillaja saponaria Molina tree). There are two formulations in the AS01 family: AS01B Adjuvant System and AS01E Adjuvant System. While AS01B contains 50 microgram of MPL and 50 microgram of QS-21 per one human dose, AS01E contains half the quantity of each immunoenhancer, i.e. 25 microgram of MPL and 25 microgram of QS- 21. For this study, the AS01B adjuvant will be used at a diluted concentration similar to the concentration of AS01E.
1973208|NCT02942277|Biological|Bexsero (Comparator Vaccine)|Bexsero(R) is a FDA approved vaccine manufactured by GSK and is used to prevent invasive disease caused by Neisseria meningitidis serogroup B. It is approved for use in individuals aged 10 through 25 years and also has been provided to individuals at risk of meningococcal Group B infection. The vaccine is given at the standard dose of 0.5mL each given in 2 vaccinations.
1973209|NCT02942277|Biological|Fluarix|Fluarix(TM) is a FDA approved influenza vaccine indicated for the prevention of disease caused by influenza A. It is approved for use in persons 3 years of age and older. Fluarix(TM) is given at the standard dosing of 0.5mL in 1 vaccination.
1973210|NCT02942277|Other|Normal Saline|Sterile isotonic (0.9%) normal saline will be commercially procured in the US and shipped to Mali at ambient temperature. Normal saline will be administered in a 0.5 mL dose as an intramuscular injection. Normal saline will also be used for diluting Pfs25M-EPA and Pfs230D1M-EPA prior to formulation with AS01B for the lower dose groups in Bamako, Mali.
1973211|NCT02942277|Drug|Coartem|Artemether/lumefantrine (Coartem(R)) is a licensed antimalarial in the US and Mali for treatment of uncomplicated malaria. It has an excellent safety profile and is widely used to treat malaria. Subjects who may have any contraindications to the use of these drugs will be excluded at screening. All antimalarial medications used for the study, including Coartem which is used for pre-emptive treatment of all subjects in Arms and will be maintained at the study site. Coartem(R) will be provided as tablets for oral administration; and will be purchased from commercial sources and provided by the MRTC study team to subjects.
1973217|NCT02936154|Drug|PF-06650833|
1973218|NCT02936154|Drug|placebo|
1973219|NCT02935634|Biological|Nivolumab|
1973220|NCT02935634|Biological|Ipilimumab|
1973221|NCT02935634|Biological|Relatlimab|
1973222|NCT02933255|Biological|PROSTVAC-V/F|PROSTVAC-V (vaccinia) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 2x10^8 infectious units; PROSTVAC-F (fowlpox) will be administered subcutaneously in an extremity (e.g., thigh) at a dose of 1x10^9 infectious units.
1973223|NCT02933255|Drug|Nivolumab|Nivolumab is to be administered as a flat dose of 240 mg over approximately 60-minutes via IV infusion.
1973228|NCT02931838|Drug|BMS-986165|
1973229|NCT02931838|Drug|Placebo for BMS-986165|
1973233|NCT02927769|Biological|Nivolumab|Specified Dose on Specified Days
1973234|NCT02927769|Biological|brentuximab vedotin|Specified Dose on Specified Days
1973235|NCT02927769|Biological|bendamustine|Specified Dose on Specified Days
1973236|NCT02927236|Device|TMS|TBS is a type of TMS protocol.To administer the iTBS treatment, a MagVenture MagPro 100 with MagOption (MagVenture Inc, Alpharetta, GA) machine equipped with a figure-8 coil will be used.
1973237|NCT02926118|Dietary Supplement|Low glycemic load|Low glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
1973238|NCT02926118|Dietary Supplement|High glycemic load|High glycemic load diets will be consumed at breakfast, lunch and dinner for three consecutive days
1973255|NCT02918019|Drug|MSTT1041A|MSTT1041A will be administered as subcutaneous injections.
1973256|NCT02918019|Drug|Placebo|Placebo matched with MSTT1041A.
1973257|NCT02915159|Biological|Abatacept|
1917180|NCT01133678|Drug|Everolimus escalating dose|Phase I Portion (2 21-day cycles) Cisplatin (100mg/m2 day 1) Paclitaxel(175mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus escalating dose
1917181|NCT01133678|Drug|Everolimus or Placebo|Phase II Portion (2 28-day cycles) Cisplatin (100mg/m2 day 1) Paclitaxel(175mg/m2, day 1) Cetuximab(400 mg/m2 loading dose day 1 then 250mg/m2 weekly ) Everolimus dose determined in phase I
1973258|NCT02915159|Other|Placebo|
1973266|NCT02911142|Drug|Lenalidomide|Lenalidomide taken orally daily at assigned dose level on days 1 to 10, up to 25mg.
1973267|NCT02911142|Drug|Rituximab|During cycle 1, Rituximab will be administered on day 4 prior to the start of EPOCH. During cycles 2 to 6, Rituximab will be administered on day 6 of each cycle.
1973268|NCT02911142|Drug|Prednisone|Prednisone 60mg/m2/day PO days 6 to 10
1973269|NCT02911142|Drug|Etopside|Etopside 50mg/m2/day continuous intravenous infusion days 6 to 9.
1973270|NCT02911142|Drug|Doxorubicin|Doxorubicin 10 mg/m2/day continuous intravenous infusion days 6 to 9.
1973271|NCT02911142|Drug|Vincristine|Vincristine 0.4mg/m2/day continuous intravenous infusion days 6 to 9.
1973272|NCT02911142|Drug|Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.|Cyclophosphamide on day 10 (for 6 cycles), each patient will get a 750 mg/m2 dose.
1973274|NCT02911103|Procedure|DBS surgery|Unilateral thalamic DBS therapy
1973276|NCT02908750|Drug|Fexofenadine tablet dosing|Fexofenadine (P-gp substrate) 120mg taken once daily on Days 1 in Treatment Period 1 and Day 1 and Day 39 in Treatment Period 2
1973277|NCT02908750|Drug|Osimertininb tablet dosing|Osimertininb 80 mg taken once daily on Day 1 and Days 4 to 41 in Treatment Period 2
1973278|NCT02908672|Drug|Atezolizumab|Will be administered as per the schedule described in individual arm.
1973279|NCT02908672|Drug|Atezolizumab Placebo|Will be administered as per the schedule described in individual arm.
1973280|NCT02908672|Drug|Cobimetinib|Will be administered as per the schedule described in individual arm.
1973281|NCT02908672|Drug|Vemurafenib|Will be administered as per the schedule described in individual arm.
1973282|NCT02908672|Drug|Vemurafenib Placebo|Will be administered as per the schedule described in individual arm.
1973283|NCT02907593|Drug|Budesonide in Calfactant|Budesonide in Calfactant
1973284|NCT02906800|Drug|Digoxin|The digoxin dose will be adjusted to achieve a plasma concentration of 0.6-1.2 ng/ml according to current recommendations in heart failure patients (doses adapted to renal function, comorbidities, concomitant medications, age, and plasma concentration). The risk related to digoxin treatment will be minimized in our study since the duration of exposure to digoxin will be limited to 9 days every 3 weeks for 3 cycles (total duration of treatment 27 days).
1973291|NCT02899299|Biological|Nivolumab|
1973292|NCT02899299|Biological|Ipilimumab|
1973293|NCT02899299|Drug|Pemetrexed|
1973294|NCT02899299|Drug|Cisplatin|
1973295|NCT02899299|Drug|Carboplatin|
1973296|NCT02900092|Drug|CCD-1042|CCD-1042 at an oral dose of 225mg BID with uptitration to 450mg BID as tolerated for the duration of the 8 week trial.
1973303|NCT02898753|Drug|VAL-1221 3 mg/kg|VAL-1221 3 mg/kg IV every other week for 12 weeks, inclusive (7 infusions)
1973304|NCT02898753|Drug|VAL-1221 10 mg/kg|VAL-1221 10 mg/kg IV every other week for 12 weeks, inclusive (7 infusions)
1973305|NCT02898753|Drug|VAL-1221 30 mg/kg|VAL-1221 30 mg/kg IV every other week for 12 weeks, inclusive (7 infusions)
1973306|NCT02898753|Drug|RhGAA|Patients randomized to rhGAA will be maintained on their current dose and regimen of Myozyme or Lumizyme
1973310|NCT02894398|Drug|Palbociclib|"Capsules (commercially available, obtained from local pharmacies), 125mg daily, 21 days, 7 days off, cycles of 28 days.
Dose reductions: 100mg, 75mg (no change in administration schedule) Number of cycles: until disease progression, intolerable toxicity, death or any other reasons"
1973311|NCT02894398|Drug|Letrozole|Letrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 2.5mg/daily, oral intake
1973312|NCT02894398|Drug|Anastrozole|Anastrozole will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 1mg/daily, oral intake
1973313|NCT02894398|Drug|Exemestane|Exemestane will be administered as basic therapy (commercially available tablets, obtained from local pharmacies) as followed: 25mg/daily, oral intake
1973314|NCT02894398|Drug|Fulvestrant|Fulvestrant will be administered as basic therapy (commercially available injection, obtained from local pharmacies) as followed: 500mg/once monthly, intramuscular injection
1973317|NCT02892630|Other|No intervention|
1973318|NCT02891850|Drug|Adempas (Riociguat, BAY63-2521)|Film-coated tablets will be used in this study at a dosage of 0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg. Tablets will be administered orally.The starting dose is 1 mg TID; the intervals between drug intakes should be 6 to 8 hours. The dosage should be increased by 0.5 mg increments in 2 week intervals to 1.5 mg, 2.0 mg, and 2.5 mg TID (maximal total daily dose).
1973319|NCT02891850|Drug|Sildenafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
1973320|NCT02891850|Drug|Tadalafil|Patients randomized to the control arm will continue to receive stable doses of tadalafil (daily dose 20 to 40 mg) or sildenafil (daily dose at least 60 mg) as well as other supportive treatments at the discretion of the investigator.
1973342|NCT02884882|Other|Emotional induction|Score (from 1 to 10) rated the felt for each target emotions for the following 6 dimensions: joy, sadness, fear, disgust, anger, no emotion, after the presentation of short sequences of standardized films.
1973361|NCT02878473|Procedure|Deceased donor Liver Transplantation|Deceased donor orthotopic liver transplantation
1973367|NCT02875119|Drug|Griffithsin Gel|"Griffithsin Gel is a large biologic molecule that is intended for vaginal rather than systemic administration. In addition, Griffithsin Gel is being developed for the prevention of HIV infection and not as a therapeutic agent. The concentration of Griffithsin Gel associated with prevention of HIV in vitro and in vivo has been established in non-clinical studies (see Section 5). Studies have demonstrated that Griffithsin Gel is highly potent for HIV prevention and is effective at very low concentrations.
One 4 mL dose of PC-6500, designed to provide an adequate vaginal concentration of GRFT for the prevention of HIV, based on preclinical data, will be evaluated. Rising dose tolerance is not the goal of this study because GRFT is likely to be minimally absorbed systemically, if at all."
1973368|NCT02875119|Drug|Placebo Gel|Placebo Gel
1973370|NCT02872116|Drug|Nivolumab|Specified dose on specified days
1973371|NCT02872116|Drug|Ipilimumab|Specified dose on specified days
1973372|NCT02872116|Drug|Oxaliplatin|Specified dose on specified days
1973373|NCT02872116|Drug|Capecitabine|Specified dose on specified days
1973374|NCT02872116|Drug|Leucovorin|Specified dose on specified days
1973375|NCT02872116|Drug|Fluorouracil|Specified dose on specified days
1973378|NCT02871635|Drug|BI 695501|
1973379|NCT02871635|Drug|HUMIRA|
1973380|NCT02871401|Drug|Valganciclovir|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
1973381|NCT02871401|Drug|Placebo|Subjects with IPF currently tolerating pirfenidone treatment who have evidence of prior EBV or CMV infection will be randomized to valganciclovir or placebo for 12 weeks.
1973382|NCT02871284|Behavioral|Exercise|
1973384|NCT02869412|Other|Computer-Assisted Intervention|Use BCG website
1973385|NCT02869412|Other|Computer-Assisted Intervention|Use passive website
1973386|NCT02869412|Other|Quality-of-Life Assessment|Ancillary studies
1973387|NCT02869412|Other|Questionnaire Administration|Ancillary studies
1973388|NCT02867592|Drug|Cabozantinib S-malate|Given PO
1973389|NCT02867592|Other|Laboratory Biomarker Analysis|Correlative studies
1973390|NCT02867592|Other|Pharmacological Study|Correlative studies
1973391|NCT02868242|Drug|LDV/SOF|Tablet(s) administered orally once daily
1973392|NCT02868242|Drug|Placebo|Tablet(s) administered orally
1973396|NCT02864485|Procedure|live donor liver transplantation|live donor liver transplantation
1973401|NCT02864251|Biological|Nivolumab|
1973402|NCT02864251|Biological|Ipilimumab|
1973403|NCT02864251|Drug|Pemetrexed|
1973404|NCT02864251|Drug|Cisplatin|
1973405|NCT02864251|Drug|Carboplatin|
1973406|NCT02863094|Device|transcranial magnetic stimulation|
1989107|NCT02593825|Behavioral|START-Play intervention|"The START-Play group is a perceptual-motor approach, which uses self-initiated goal-directed movements to bolster orienting and attending to objects, while understanding basic relationships of cause and effect through manipulation and focused attention. Generally, activities focus on helping the child attend to significant environmental information, which can be correlated to forces useful for controlling posture and movement. Unlike passive movement therapy, the investigator's approach encourages activity and learning to solve problems linked by movement and manipulation of objects, which then scaffold cognitive skill; the focus is not on a normal movement pattern. Parents and children learn to problem-solve motor challenges, and link small motor changes to cognitive skills."
1989108|NCT02593825|Behavioral|Business as usual|May include active or passive movement, parent training, positioning, equipment modification, training other team members, functional skill training
1989109|NCT02592577|Biological|Autologous Genetically modified T cells, MAGEA10ᶜ⁷⁹⁶T|
1973420|NCT02859415|Drug|Mithramycin|Phase 1: 24 hour intravenous infusion of mithramycin given once every 14 days at escalating doses; Phase 2: 24 hour intravenous infusion of mithramycin given once every 14 days at MTD established in phase 1
1973421|NCT02859792|Drug|Riluzole|Riluzole capsules (25 or 50 mg) will be administered in the four dose level groups (i.e. 25 mg bid; 50 mg bid; 75 mg bid; 100 mg bid).
1973422|NCT02859792|Drug|Placebo|placebo capsules 25 or 50 mg
1973423|NCT02859792|Biological|Blood Samples|v1;v2;v3;v4
1973424|NCT02859467|Other|Kinesio Taping and Inhibitory Treatment Techniques|"Kinesio Taping on trapezius, infraspinatus, and paravertebral muscles
Inhibitory Treatment Techniques:
Release Technique of the trapezius muscle.
Release Technique for scalene muscles.
Technique suboccipital inhibition.
Technique hands crossed for induction dorsal superficial fascia."
1917303|NCT01109069|Drug|PCI-32765|Dose based on parent protocol
1973425|NCT02859467|Other|Exercise and Electrical Stimulation Therapy|Session for general physical activities (joint mobility, muscle strength and elasticity), and electrical stimulation therapy on para vertebral muscles.
1973432|NCT02858453|Drug|AQX-1125 100 mg|Synthetic SHIP1 activator
1973433|NCT02858453|Drug|AQX-1125 200 mg|Synthetic SHIP1 activator
1973434|NCT02858453|Drug|Placebo|Appearance and weight matched placebo tablets
1973435|NCT02858310|Biological|E7 TCR Transduced PBL cells|T cells genetically engineered with a TCR targeting HPV-16 E7 (E7 TCR) that display specific reactivity against HLA-A2+, HPV-16+ target cells
1973436|NCT02858310|Drug|pembrolizumab|Pembrolizumab is a monoclonal antibody that blocks PD-1, an inhibitory receptor on T cells, thereby preventing T cell inhibition. PD-1-blocking drugs have shown clinical activity in a variety of cancers. Preclinical studies demonstrate that blockade of PD-1 can improve the efficacy of genetically engineered T cells for cancer treatment
1973437|NCT02858310|Drug|aldesleukin|Following cell infusion the patient receives high-dose bolus aldesleukin, which is dosed to individual patient tolerance. Aldesleukin improves the survival of E7 TCR cells after infusion.
1973438|NCT02858310|Drug|fludarabine|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
1973439|NCT02858310|Drug|cyclophosphamide|Part of the non-myeloablative lymphocyte-depleting preparative regimen.
1973440|NCT02857426|Drug|Nivolumab|
1973441|NCT02856542|Drug|calcipotriol/betamethasone dipropionate gel in Applicator|Topical treatment of scalp using applicator device. The study as such is non-interventional as the intervention has been decided prior to and independently from the inclusion of the patient in the cohort to be observed.
1973443|NCT02856438|Drug|Elotuzumab|Specified dose on specified days
1973444|NCT02856438|Drug|Lenalidomide|Specified dose on specified days
1973445|NCT02856438|Drug|Dexamethasone|Specified dose on specified days
1973460|NCT02840721|Drug|PF-06480605|PF-06480605 500 mg IV Q2W x 7 Doses
1973461|NCT02840487|Biological|VRC-ZKADNA085-00-VP|VRC-ZKADNA085-00-VP is an investigational ZIKV DNA vaccine that is intended to prevent Zika virus infection.
1973462|NCT02840474|Biological|VRC-HIVMAB080-00-AB (VRC01LS)|"VRC01LS is an investigational human monoclonal antibody targeted to the CD4 binding site of HIV-1. VRC01LS is a modification of the VRC01 monoclonal antibody with the addition of the LS."
1973463|NCT02839681|Drug|Anetumab Ravtansine|Administered IV every 3 weeks
1973464|NCT02839330|Biological|aH5N1c|Intramuscular (IM) administration, containing 7.5 mcg H5N1 hemagglutinin antigen (HA) + 0.25 mL MF59 (approximately 0.5 mL total volume).
1973465|NCT02839330|Biological|Placebo|Placebo
1973468|NCT02836457|Drug|ELIQUIS (APIXABAN)|
1973479|NCT02832323|Biological|Reticera|A blood sample (before dialysis) under the usual conditions will be performed at D0 (= the day of Mircera® injection) 9 days (+/- 1 day) after each injection Mircera® for hemoglobin and reticulocytes dosage for a period of 6 months.
1973480|NCT02832167|Biological|BMS936558|Flat Dose
1973481|NCT02831049|Behavioral|Retrieval-extinction|Alcohol retrieval/alcohol extinction
1973482|NCT02831049|Behavioral|Extinction|Soft-drink retrieval/alcohol extinction
1973483|NCT02831049|Behavioral|Retrieval|Alcohol retrieval/soft-drink extinction
1973490|NCT02826343|Drug|Xenon129 MRI imaging|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
1973491|NCT02826343|Drug|Gadolinium MRI|subjects will receive at baseline and 3 month post Advair intervention (See next intervention)
1973492|NCT02826343|Drug|Advair (250mcg/50mcg) one puff twice a day|subjects will receive for 3 month duration between baseline and 3 month post Xenon129 MRI imaging and Gadolinium MRI.
1973493|NCT02826629|Device|Manual dexterity|Control of manual dexterity will be assessed by a force sensor (Power Grip Manipulandum, PGM)
1973494|NCT02826629|Device|Oculomotor movements|Oculomotor movements during behavioral task will be recorded using a video-oculography device
1973495|NCT02826629|Device|TMS coupled to EMG recording|The involvement of cortical inhibition in this volitional inhibition task will be studied by neuronavigation guided TMS coupled to EMG recording
1973496|NCT02826629|Other|Psychopathological evaluations|
1973497|NCT02826629|Other|Neuropsychological evaluations|
1973513|NCT02823652|Other|Counseling|Undergo usual care
1973514|NCT02823652|Other|Genetic Counseling|Complete remote counseling
1973515|NCT02823652|Other|Genetic Testing|Undergo germline testing
1973516|NCT02823652|Other|Internet-Based Intervention|Complete on-line genetic education
1973517|NCT02823652|Other|Survey Administration|Ancillary studies
1973523|NCT02821754|Drug|Durvalumab|Every 4 weeks for up to 13 doses.
1973524|NCT02821754|Drug|Tremelimumab|Every 4 weeks for up to 4 doses.
1973525|NCT02821754|Procedure|TACE|TACE will be performed on Day 36 (+/-96hrs).
1973526|NCT02821754|Procedure|RFA|RFA will be performed on Day 36 (+/-96hrs).
1973527|NCT02821754|Procedure|Cryoablation|Cryoablation will be performed on Day 36 (+/-96hrs).
1973528|NCT02818582|Drug|GS-5734|Daily GS-5734 delivered intraveneously (IV) for 5 days.
1973529|NCT02818582|Other|Placebo Comparator|Placebo delivered intraveneously (IV) for 5 days.
1973530|NCT02817776|Device|THERMOCOOL SMARTTOUCH® SF catheter|Radiofrequency Ablation
1973532|NCT02812238|Dietary Supplement|Nicotinamide riboside (NR)|NR at dose of 1000mg/day will be given for a period of 7 days in a double blinded fashion either from the start of tx or after 2-3 weeks of placebo pills.
1973533|NCT02812238|Other|Placebo|
1973535|NCT02810418|Drug|LMB-100|Arm A: Administered IV on days 1, 3 and 5 of a 21 day cycle for a maximum of 2 cycles; Arm B: Administered IV for 48, 72 or 96 hours continuously on the first 2 - 4 days (depending on dose level) of each 21 day cycle for a maximum of 2 cycles
1973536|NCT02810418|Drug|Nab-Paclitaxel|Administered IV on days 1, and 8 of each 21 day cycle for a maximum of 4 cycles
1973537|NCT02806856|Device|tDCS neuroConn|Cathodal on M1
1973538|NCT02806856|Device|Sham stimulation|Sham
1973543|NCT02805439|Drug|S47445 15mg|One tablet of S47445 15 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
1973544|NCT02805439|Drug|S47445 50mg|One tablet of S47445 50 mg taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
1973545|NCT02805439|Drug|Placebo|One tablet of placebo taken orally once a day during breakfast concomitantly to the current selective serotonin reuptake inhibitor treatment, starting the day after inclusion visit and ending the day of the W8 visit.
1973549|NCT02801006|Device|stenfilcon A|contact lens
1973550|NCT02801006|Device|etafilcon A|contact lens
1973555|NCT02799576|Device|Curved needle|In this arm, the curved block needle will be used for regional blockade
1973560|NCT02798536|Drug|LMB-100|Administered IV on days 1,3, and 5 of a 21 day cycle for up to 4 cycles (Arm A) or 2 cycles (Arm B)
1973561|NCT02798536|Drug|nab-paclitaxel|Cohort B only. Administered IV on days 1 and 8 of each 21 day cycle for up to 6 cycles.
1973562|NCT02798523|Drug|Solu-Medrol (methylprednisolone sodium succinate)|"Methylprednisolone sodium succinate for injection, USP (SOLU-MEDROL sterile powder, Pfizer, Inc.) is an anti-inflammatory glucocorticoid which occurs as a white, or nearly white, odorless hygroscopic, amorphous solid. It is very soluble in water and in alcohol; it is insoluble in chloroform and is very slightly soluble in acetone.
125-milligram Act-O-Vial (AOV) System: Each 2 mL AOV (when mixed) contains methylprednisolone sodium succinate equivalent to 125 milligrams methylprednisolone; also 1.6 mg monobasic sodium phosphate anhydrous; and 17.4 mg dibasic sodium phosphate dried."
1973563|NCT02798523|Drug|Topical methylprenisolone 0.1%|1 g Advantan emulsion 0.1% (Bayer) contains methylprednisolone aceponate (21-acetoxy-11beta-hydroxy-6alpha-methyl-17-propionyloxy-1,4-pregnadiene-3,20-dione) 1 mg, as the active ingredient. It is an oil-in-water emulsion containing medium chain triglycerides, caprylic-capric-stearic triglyceride, polyoxyethylene alcohol 2-stearylether, polyoxyethylene alcohol-21-stearylether, benzyl alcohol, disodium edetate, glycerol, and purified water.
1917403|NCT01086540|Biological|Rituximab|2 infusions, 1000 mg. each, 14 days apart
1917404|NCT01086540|Other|Placebo|2 infusions 14 days apart
1917405|NCT01086384|Drug|Fluticasone Furoate/GW642444|Combination inhaled corticosteroid and long-acting beta2-agonist
1917406|NCT01086384|Drug|Fluticasone furoate|Inhaled corticosteroid
1973564|NCT02798471|Drug|Edoxaban|15 or 30 mg tablets for participants 12 years of age to <18, and 60 mg edoxaban suspension for oral administration to participants under 12 years of age
1973565|NCT02798471|Drug|Standard of Care|Standard of care could include low molecular weight heparin (LMWH), vitamin K antagonist (VKA), or synthetic pentasaccharide (SP) Xa inhibitors.
1973566|NCT02796391|Drug|Very Low Nicotine Content (VLNC) Cigarettes|"Eligible participants will receive a 1-week supply (based on typical # cigarettes/day x 1.5) of normal nicotine content (NNC) (.8 mg nicotine yield) study cigarettes to smoke exclusively during one baseline week.
Study 1: Participants (n=20) will then be randomly selected to receive either the lowest nicotine dose of VLNC cigarettes, or gradual decreasing nicotine VLNC cigarettes, ten participants per each group, over the next four weeks.
Study 2: Participants (n=208) will be randomly assigned to 1 of 4 Study 2 Reduction Arms, 52 participants per arm."
1973567|NCT02796391|Behavioral|One on One Counseling|All participants will receive One on One Counseling.
1973571|NCT02793492|Device|Misago® RX Self-expanding Peripheral Stent|the Misago® RX Self-expanding Stent is a bare metal, nitinol stent
1973572|NCT02793128|Drug|MitoGel™ instillations|Treatment with MitoGel™ once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate CR will be treated with MitoGel™ once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first.
1973580|NCT02789345|Drug|Ramucirumab|Administered IV
1973581|NCT02789345|Drug|Necitumumab|Administered IV
1973582|NCT02789345|Drug|Osimertinib|Administered orally
1973585|NCT02788188|Biological|SAB-301|SAB-301 is a purified human immune globulin G (hIgG) polyclonal antibody designed to specifically bind to the MERS-CoV spike (S) protein, a component of the virion membrane that is responsible for binding of the virus to the host cell. The hIgG is purified from the plasma of immunized transchromosomic (Tc) bovines that were immunized with a recombinant spike protein produced in insect cells. SAB-301 is purified hIgG in a sterile liquid formulated in 10 mM glutamic acid monosodium salt, 262 mM D-sorbitol, 0.05 mg/mL Tween 80, pH 5.5. The drug product will be administered intravenously and will be diluted in saline per the clinical protocol.
1973586|NCT02788188|Other|Normal (9%) Saline|Normal (0.9%) saline in approximately the same volume as each cohort in the experimental drug arm.
1973587|NCT02788175|Biological|Entyvio (Vedolizumab)|A humanized monoclonal antibody that specifically binds to the alpha4beta7 integrin with MAdCAM-1, which in turn inhibits the migration of T-lymphocytes across the endothelium into GALT
1973588|NCT02784210|Drug|Methylprednisolone|1000mg/day for 5 days
1973589|NCT02784210|Drug|Methylprednisolone|1000mg/day for 3 days
1973599|NCT02778399|Drug|Placebo|Placebo tablets for oral administration once daily
1973600|NCT02778399|Drug|OBE2109|OBE2109 tablets for oral administration once daily
1973612|NCT02771249|Drug|rifapentene (RPT)|RPT is a long-acting rifamycin used in combination with INH in the treatment of LTBI.
1973613|NCT02771249|Drug|darunavir/cobicistat (DRV/c)|DRV is a protease inhibitor (PI) indicated in the treatment of HIV infection.33 DRV requires coadministration with RTV (100 mg once or twice daily) or COBI (150 mg daily), the latter of which has been coformulated into a fixed-dose tablet with DRV (DRV/c 800/150 mg).
1973614|NCT02771249|Drug|Isoniazid (INH)|INH is an antimycobacterial agent that can be used alone or in combination with RPT for the treatment of LTBI. Given with Pyridoxine (vitamin B6)
1990233|NCT02141204|Biological|Liquid Human Rotavirus Vaccine 444563|Oral administration
1990234|NCT02141204|Biological|Lyophilized Human Rotavirus Vaccine 444563|Oral administration
1990242|NCT02132754|Biological|MK-4166|
1990243|NCT02132754|Biological|Pembrolizumab|
1990246|NCT02131662|Drug|BAY1002670|0.5 mg of BAY1002670 once daily for 12 weeks
1990247|NCT02131662|Drug|BAY1002670|1 mg of BAY1002670 once daily for 12 weeks
1990248|NCT02131662|Drug|BAY1002670|2 mg of BAY1002670 once daily for 12 weeks
1990249|NCT02131662|Drug|BAY1002670|4 mg of BAY1002670 once daily for 12 weeks
1990250|NCT02131662|Drug|Placebo|Once daily for 12 weeks
1990251|NCT02130479|Behavioral|Contingency Management-Family Engagement|
1990252|NCT02130479|Behavioral|Treatment as Usual|
1990253|NCT02129257|Drug|AFLIBERCEPT|
1990254|NCT02129257|Drug|Irinotecan|
1990255|NCT02129257|Drug|5-Fluorouracil|
1990256|NCT02129257|Drug|Folinic Acid|
1973619|NCT02769962|Drug|CRLX101|"CRLX101 IV Q 2weeks Day 1 and Day 15, administered in 28 day cycles, until disease progression or development of intolerable side effects
Plus olaparib (PO days 3-13* and days 17-26*) administered in 28 day cycle, until disease progression or development of intolerable side effects.
P1: Dose Escalation P2: RP2
(* On days 13 and 26, only onedose of olaparib will be administered in the morning)"
1973620|NCT02769962|Drug|olaparib|"olaparib (PO days 3-13* and days 17-26* administered in 28 day cycles, until disease progression or development of intolerable side effects
Plus CRLX101 (IV Q 2weeks, Day 1 and Day 15) administered in 28 day cycles, until disease progression or development of intolerable side effects
P1: Dose Escalation P2: RP2D
(* On days 13 and 26, only onedose of olaparib will be administered in the morning)"
1973621|NCT02769429|Device|Ultrasound-guided CISB|This group will receive ultrasound-guided CISB with the catheter placed on the upper trunk of the brachial plexus
1973622|NCT02769429|Device|nerve stimulator-guided CCPVB|This group will receive landmark with nerve stimulator based needle placement and then nerve stimulator-guided CCPVB with the catheter placed on the 6th cervical spinal root
1973623|NCT02768103|Behavioral|task-based training|The 10-week training program is designed to incorporate requirements of motor learning and includes activities that require learning to coordinate the transferred Br with other synergists by producing pinch force in different upper limb postures and in a range of pinch openings. Biofeedback using a pinch dynamometer in self-selected postures provides feedback and knowledge of progress to the participant. A task board is used for practicing task-specific activities such as opening and closing zippers, using a remote, an ATM card, a key, and an electrical plug and focuses on pinch in dynamic conditions that require modulating force and maintaining specific positions. The pinch-pin device requires closing pinch-pins (clothes pin) of variable resistance ranging from approximately 1 to 8 lbs and placing them on rods arranged at different positions in the work space.
1917472|NCT01061671|Drug|simvastatin|40 mgms of simvastatin daily
1917473|NCT01061671|Drug|Placebo|Matched placebo pill daily
1973632|NCT02761447|Other|Treatment Traditional and Imaginary Motor Program|Amputees patients also conservative protocol will undergo physiotherapy techniques work Imaginary Motor. The first video will include two sequences of a harmonic gear that will allow the patient to examine, with the physiotherapist, the characteristics of the different body segments involved in locomotion and place the member in space. The second video include an analysis in five phases: a) relaxation of Benson, b) phase external imagination where cycles of normal running on a video provided by the physiotherapist, c) phase internal imagination where the patient will identify the problem discussed compared with the normal course presented in the video, d) recreation of images in the first person made an e normalized locomotion) closing his eyes, prompted the patient to mentally recreate sequences normal gait and analyzed and subsequently verbalize differences of these with respect to their own way of getting around.
1973633|NCT02761447|Other|Treatment Traditional and Mirror Therapy|Amputees patients also conservative protocol will undergo physiotherapy techniques mirror therapy work. The protocol will consist of mirror therapy sessions three days a week (25-30 minutes) for a month, where participants will move the intact limb looking in the mirror and imagining the movement of the limb with phantom sensation.
1973639|NCT02760953|Procedure|Cryoablation|Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection
1973640|NCT02760953|Drug|Epirubicin|Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
1973641|NCT02759835|Drug|osimertinib|single daily dose of osimertinib 80mg until progression
1973642|NCT02759835|Other|LAT|local ablative therapy. Subjects may undergo 1 of 3 local ablative procedures after initial progression on osimertinib: surgery, radiotherapy, radiofrequency ablation
1973643|NCT02759744|Device|ultrasound image-guided ablation device|ultrasound image-guided focal ablation - may be either laser ablation or cryotherapy
1973644|NCT02759731|Drug|Baricitinib|Cycle=28 days: Baricitinib: 1mg-4mg PO QD
1973645|NCT02758769|Biological|ORENCIA Subcutaneous Injection|
1973646|NCT02758275|Behavioral|Teaching: Individual (5606)|"Usual care and Teaching: Individual (5606): It consists of 6 educational sessions:
Behavior Modification (4360) Promotion of a behavior change.
Teaching Disease Process (5602) Assisting the patient to understand information related to a specific disease process.
Teaching: Prescribed Medication (5616) Preparing a patient to safely take prescribed medications and monitor for their effects.
Teaching: Prescribed Diet (5614) Preparing a patient to correctly follow a prescribed diet.
Teaching: Prescribed Exercise (5612) Preparing a patient to achieve and/or maintain a prescribed level of activity.
Coping Enhancement (5230) Assisting a patient to adapt to perceived stressors, changes, or threats that interfere with meeting life demands and roles."
1973647|NCT02758158|Device|Tri-modal imaging|This trimodal imaging system was developed in collaboration with Sogang University and is composed of three subsystems: ultrasound, photoacoustic and fluorescence. For this study, the fluorescence subsystem will not be used. The photoacoustic and ultrasound subsystems and data acquisition are controlled by a single workstation. The complete system is Canadian Standards Association (CSA) certified.
1973648|NCT02756078|Device|TEST Contact Lens|
1973649|NCT02756078|Device|CONTROL Contact Lens|
1973655|NCT02754154|Drug|Warfarin|
1973656|NCT02754154|Drug|Apixaban|
1973657|NCT02754154|Drug|Dabigatran|
1973658|NCT02754154|Drug|Rivaroxaban|
1973659|NCT02753361|Procedure|Ultrasound guidance|In the second arm, ultrasound will be used to guide the regional block
1973666|NCT02747004|Drug|Abemaciclib|Administered orally
1973667|NCT02747004|Drug|Tamoxifen|Administered orally
1973668|NCT02747004|Drug|Prophylactic Loperamide|Administered orally
1973669|NCT02744677|Device|SAPIEN 3 THV|SAPIEN 3 THV in the pulmonic position
1973670|NCT02743494|Drug|Nivolumab|Specified dose on specified days
1973671|NCT02743494|Other|Placebo|Specified dose on specified days
1973672|NCT02743598|Drug|Liraglutide|
1973673|NCT02743377|Other|PET|
1973674|NCT02743377|Other|MRI|
1973675|NCT02742662|Device|Wearable technology, smartscale|
1973676|NCT02742662|Behavioral|Smartphone applications|
1973677|NCT02742662|Behavioral|Standard Weight Management Visits|
1973678|NCT02741570|Biological|Nivolumab|
1973679|NCT02741570|Biological|Ipilimumab|
1973680|NCT02741570|Drug|Cetuximab/Erbitux|
1973681|NCT02741570|Drug|Cisplatin/Platinol|
1973682|NCT02741570|Drug|Carboplatin/Paraplatin|
1973683|NCT02741570|Drug|Fluorouracil/Adrucil|
1973684|NCT02740699|Drug|Rosuvastatin|Participants will receive 20-40 mg once daily
1973685|NCT02740699|Drug|Atorvastatin|Participants will receive 40-80 mg once daily
1973686|NCT02738775|Biological|Ublituximab|
1973687|NCT02738775|Drug|Placebo|
1973688|NCT02738905|Drug|Rifaximin|One 550 mg tablet taken orally two times a day.
1973689|NCT02737046|Drug|Belinostat|Belinostat will be administered as 1,000 mg/m2 IV infusion over 30 minutes on Days 1- 5 every 21 days (Exception as per FDA-approved Package Insert: In patients known to be homozygous for the UGT1A1*28 allele, the starting belinostat dose must be 750mg/m2) for up to 8 cycles.
1973690|NCT02737046|Drug|Zidovudine|Zidovudine shall be administered in the outpatient setting as 300 mg tablets orally (PO), three times daily (TID) for 21 days on cycles 1 to 8, followed by maintenance therapy (+/- IFN-alfa) up to the end of Month 12.
1973691|NCT02737046|Drug|Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
1973692|NCT02737046|Drug|Pegylated Interferon-Alfa-2b|OPTIONAL: For subjects receiving interferon therapy at baseline, continue Interferon alfa-2b 5 million IU daily or pegylated interferon alfa-2b 1.5 μg/kg once weekly, subcutaneously (SQ) for up to 12 months.
1973693|NCT02734186|Drug|Praziquantel|Anthelminthic
1973698|NCT02728206|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
1973699|NCT02724371|Device|Mentor Larger Size MemoryGel Ultra High Profile Breast Implant|The Mentor smooth and Siltex® larger size MemoryGel® Ultra High Profile (UHP-L) breast implants are large round silicone gel-filled breast implants. The devices are made with cross linked layers of silicone to provide the prosthesis with elasticity and integrity.
1973701|NCT02722148|Device|Novel Allergen-Specific Immune Signature Directed Approach to Dietary Elimination Therapy|A novel assay developed by the investigator to diagnose food allergens. Results from the assay are used to guide food elimination therapy for the treatment of Eosinophilic Esophagitis (EoE).
1973702|NCT02720744|Drug|Sodium Oxybate|
1973703|NCT02720744|Drug|Placebo|
1973705|NCT02719613|Drug|Elotuzumab|Patients will continue to receive treatment with the investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
1973706|NCT02719613|Drug|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by oral tablet administration at the last dose and schedule received in the previous study.
1973707|NCT02719613|Drug|Dexamethasone|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) solution administration at the last dose and schedule received in the previous study.
1973708|NCT02719613|Drug|Lenalidomide|Patients will continue to receive treatment with non-investigational study drug by oral capsule administration at the last dose and schedule received in the previous study.
1973709|NCT02719613|Drug|Bortezomib|Patients will continue to receive treatment with non-investigational study drug by intravenous (IV) or subcutaneous injection solution administration at the last dose and schedule received in the previous study.
1973711|NCT02717364|Drug|Yervoy|
1973716|NCT02709486|Drug|Tanezumab|2.5 mg
1973717|NCT02709486|Drug|Tanezumab|5 mg
1973718|NCT02709486|Drug|Placebo|Placebo
1973719|NCT02709226|Radiation|Radiation|Radiation therapy will be administered daily Monday-Friday at NCI, ROB unless the treatment schedule requires amendment in the event of inclement weather or federal holidays. Radiation therapy dose will be administered as per on consecutive treatment days, 5 fractions per week via a linear accelerator using 6 MV photons or greater. Dose escalation is as follows: dose level 1 (DL1) 3.5 Gy x 10; dose level 2 (DL2) 3.5 Gy x 12; dose level 3 (DL3) 3.5 Gy x 14. If 2 DLTs are observed in the second dose level a step down dose of 3.0 Gy x 14 fractions will be tested. If 2 DLTs are observed in the third dose level a step down dose of 3.0 Gy x 17 fractions will be tested. The study will have 3 planned re-irradiation dose levels, with 1 to 6 patients per dose level using the 3+3 design to define the MTD. The number of patients may be increased to 9 total patients at the MTD (provided no DLT) with a maximum of 21 evaluable patients enrolled.
1973727|NCT02707055|Drug|PF-05190457|Ghrelin Receptor Inverse Agonist
1973728|NCT02707055|Behavioral|MI-VF|Motivational Interviewing with Video
1973729|NCT02707055|Other|Placebo|Placebo
1973730|NCT02707055|Other|Counseling|Counselling Support
1973731|NCT02707042|Drug|Amoxicillin|Amoxicillin (Amoxil (Registered Trademark)): Each capsule of Amoxil, with royal blue opaque cap and pink opaque body, contains 500 mg amoxicillin as the trihydrate. The cap and body of the 500-mg capsule are imprinted with the product name AMOXIL and 500.
1973732|NCT02707042|Drug|Azithromycin|Azithromycin (Zithromax (Registered Trademark)): Tablets for oral administration are provided as red film-coated, oval-shaped tablets that contain 250 mg of azithromycin as the monohydrate. The tablets are engraved with Pfizer and 306 .
1973735|NCT02703415|Drug|Bupivacaine|caudal block with bupivacaine (0.25%) 1mg/kg
1973736|NCT02703415|Drug|Tramadol|caudal block with tramadol 1 mg/kg
1973740|NCT02701582|Device|FloTrac Sensor|Care based on algorithm and device.
1973741|NCT02701582|Other|FloTrac Algorithm Not Visible|Standard of Care
1973743|NCT02697773|Other|Placebo|Patient receives one dose of placebo to match tanezumab subcutaneously on Day 1 and one dose of placebo to match tanezumab subcutaneously at Week 8.
1973744|NCT02697773|Biological|Tanezumab 2.5 mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 2.5 mg subcutaneously at Week 8.
1973745|NCT02697773|Biological|Tanezumab 2.5mg/5mg|Patient receives one dose of tanezumab 2.5 mg subcutaneously on Day 1 and one dose of tanezumab 5 mg subcutaneously at Week 8.
1973755|NCT02686723|Other|Clinical and biomechanical evaluations|Clinical evaluation : demographics, clinic and functional testing. Biomechanical evaluation : isokinetic, motion analysis of 2 specific motion (drop vertical jump and cutting task) and anterior tibial translation with GnRB
1973756|NCT02677116|Drug|Olaratumab|Olaratumab administered IV.
1973757|NCT02677116|Drug|Doxorubicin|Doxorubicin administered IV.
1973758|NCT02677116|Drug|Vincristine|Vincristine administered IV.
1973759|NCT02677116|Drug|Irinotecan|Irinotecan administered IV.
1973760|NCT02677116|Drug|Ifosfamide|Ifosfamide administered IV.
1973761|NCT02677675|Behavioral|Intervention (reminder module)|Reminder module (delivered via SMS and telephone call reminders)
1973762|NCT02677220|Device|CI532 cochlear implant|
1973763|NCT02677155|Radiation|Radiotherapy|Radiotherapy 8 Gy single dose
1973764|NCT02677155|Biological|Rituximab|Intranodal injection 5 mg
1973765|NCT02677155|Biological|Autologous dendritic cells|Intranodal injection of 1 x 10 e8 cells
1973766|NCT02677155|Biological|GM-CSF|Subcutaneous injection of 50 ug
1973767|NCT02677155|Biological|Pembrolizumab|Intravenous infusion of 200 mg
1973768|NCT02678143|Drug|Alemtuzumab|
1973769|NCT02678143|Drug|Cyclophosphamide|
1973770|NCT02678143|Drug|Mycophenolate mofetil|
1973771|NCT02678143|Drug|Sirolimus|
1973772|NCT02678143|Drug|Fludarabine|
1973773|NCT02678143|Radiation|Total body irradiation|
1973774|NCT02678143|Procedure|Hematopoietic stem cell transplant|
1973777|NCT02669251|Drug|AZD9668|"Phase 1b Cycle= 14 days: Each dose level will increase by 60mg PO BID, up to a maximum of 240mg PO BID
Phase 2 Cycle=28 days: MTD PO BID"
1973778|NCT02669225|Radiation|[18F]florbetaben|PET radiotracer to image Amyloid beta
1973779|NCT02667587|Drug|Nivolumab|
1973780|NCT02667587|Drug|Temozolomide|
1973781|NCT02667587|Radiation|Radiotherapy|
1973782|NCT02667587|Other|Nivolumab Placebo|
1973783|NCT02667288|Drug|A-101 Solution|
1973786|NCT02661217|Drug|LCZ696|The target dose of LCZ696 is 200 mg twice daily. Starting dose of LCZ696 is either 50 or 100 mg, twice daily. The dose of LCZ696 should be doubled every 2-4 weeks to achieve the target dose of 200 mg twice daily, as tolerated by the patient.
1973787|NCT02659943|Biological|Anti-CD19-CAR T cells|Dose-escalation trial starting dose: 0.66x106 CAR+ T cells/kg(weight based dosing)(up to a maximum dose of 18x10^6 CAR+ T cells/kg) infuse on day 0
1973788|NCT02659943|Drug|Cyclophosphamide|300 mg/m2 IV infusion over 30 minutes on days -5, -4 and -3
1973789|NCT02659943|Drug|Fludarabine|30 mg/m2 IV infusion over 30 minutes administered immediately following the cyclophosphamide on days -5, -4,and -3
1973792|NCT02659020|Drug|Olaratumab|Administered IV
1973793|NCT02659020|Drug|Gemcitabine|Administered IV
1973794|NCT02659020|Drug|Docetaxel|Administered IV
1973795|NCT02659020|Drug|Placebo|Administered IV
1973805|NCT02657603|Drug|Lidocaine|Lidocaine injected through the new Catheter (LAX)
1973806|NCT02657603|Drug|Lidocaine|Lidocaine injected through the new Catheter (SAX)
1973807|NCT02657603|Procedure|LAX insertion of catheter|ultra sound guided cather insertion in the long axis (LAX) of the adductor canal
1973808|NCT02657603|Procedure|SAX insertion of catheter|ultra sound guided cather insertion in the short axis (SAX) of the adductor canal
1973810|NCT02654132|Drug|Elotuzumab|
1973811|NCT02654132|Drug|Pomalidomide|
1973812|NCT02654132|Drug|Dexamethasone|
1973815|NCT02652546|Drug|Assess Safety|Assess the safety of a 12-week course if CC-1150 in HIV-infected adults who have been on ART for greater than or equal to 1 year and have suppressed plasma viremia
1973816|NCT02652546|Drug|Effect of drug on viral load|Evaluate the effect of CC-11050 on plasma HIV-1 RNA levels by both conventional and single copy assay at week 12 and over all evaluable time points
1973817|NCT02652546|Drug|Effect of drug on T-cell count|Evaluate the effect of CC-11050 on CD4+ T cell counts and percentages at week 12 and over all evaluable time points
1973818|NCT02652546|Drug|Effect of drug on inflammatory biomarkers|Evaluate the effect of CC-11050 on markers of markers of systemic inflammation (TNF, IL-^, CRP, IFNg, sCD14, D-dimer) at week 12 and over all evaluable time points.
1973819|NCT02649868|Radiation|TAE|Transarterial embolization
1973820|NCT02649868|Radiation|RFA|Thermal ablation
1973821|NCT02649868|Device|LC Bead LUMI|LC Bead LUMI has been designed as a radiopaque version of the LC Bead
1973822|NCT02649855|Biological|PROSTVAC-V|It is a recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules (B7.1, ICAM-1, and LFA-3). It will be given subcutaneously, 2x10(8) infectious units.
1973823|NCT02649855|Biological|PROSTVAC-F|It is a recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules (B7.1, ICAM-1, and LFA-3). It will be given subcutaneously, 1x10(9) infectious units.
1973824|NCT02649855|Drug|Docetaxel|It is commercially available. It will be administered at 75 mg/m(2) intravenously.
1973825|NCT02649439|Biological|PROSTVAC -V|Recombinant Vaccinia Virus Vector Vaccine of the Genus Orthopopoxvirus
1973826|NCT02649439|Biological|PROSTVAC-F|Recombinant Fowlpox Virus Vector Vaccine of the Genus Avipoxvirus
1973827|NCT02644525|Drug|Imatinib Mesylate|Imatinib is a small molecule inhibitor which was US Food and Drug Administration (FDA) -approved for chronic myelogenous leukemia (CML) in 2001 which acts on the protein product of the Philadelphia chromosome, Bcr-Abl.
1973828|NCT02644525|Drug|Placebo|Placebo pills
1973834|NCT02639286|Drug|ISIS 304801|300 mg or placebo administered as SC
1973835|NCT02639286|Drug|Placebo|Placebo administered via SC
1973836|NCT02639273|Drug|Nalmefene|
1973837|NCT02639273|Other|Placebo|
1973838|NCT02639260|Drug|N-acetyl-mannosamine (ManNAc)|dose escalation
1973839|NCT02638948|Drug|BMS-986142|BMS986142 specific dose on specific days
1973840|NCT02638948|Drug|Placebo|Placebo of BMS-986142 specific dose on specific days
1973841|NCT02638948|Drug|Methotrexate|Methotrexate specific dose on specific days
1973849|NCT02633085|Device|Fixed Bearing or Mobile Bearing UKA|Fixed Bearing or Mobile Bearing UKA Patients who have undergone a primary Fixed Bearing or a Mobile Bearing UKA in either knee and are at a minimum 2 years post-op.
1973853|NCT02632409|Biological|Nivolumab|
1973854|NCT02632409|Other|Placebo|
1973866|NCT02627456|Biological|PfSPZ Vaccine|"PfSPZ Vaccine contains aseptic, purified, cryopreserved, radiation attenuated NF54 P. falciparum sporozoites (PfSPZ) produced and manufactured by Sanaria Inc, located in Rockville, Maryland, USA. It is manufactured in compliance with GMP regulations (21 CFR 211), and USP<71> sterility testing.
The diluent for PfSPZ Vaccine and Challenge is composed of phosphate-buffered saline (PBS) and human serum albumin (HSA). PBS was manufactured in compliance with GMP by Sanaria, Inc. HSA is a licensed product approved for parenteral, IV administration to humans."
1973867|NCT02627456|Biological|PfSPZ Challenge Material|PfSPZ Challenge are live and infectious aseptic, purified, cryopreserved NF54 P.falciparum sporozoites. PfSPZ Challenge is manufactured identical to PfSPZ Vaccine without irradiation.
1973868|NCT02627456|Drug|PBS and HSA Diluent|Sterile 0.9% normal saline is commercially procured in the US and shipped to Mali. Normal saline is a clear liquid, making it indistinguishable from the study product.
1973879|NCT02621021|Drug|Cyclophosphamide|Days -7 and -6, Cyclophosphamide 60 mg/kg/day IV in 250 ml D5W with mesna 15 mg/kg/day over 1 hr X 2 days.
1973880|NCT02621021|Drug|Fludarabine|Days -7 to -3, Fludarabine 25 mg/m2/day IVPB daily over 15-30 minutes for 5 days.
1973881|NCT02621021|Drug|Aldeslaukin|Day 0 (within 24 hours of cell infusion), Aldesleukin 720,000 IU/kg (based on total body weight) IV over a 15 minute infusion and continuing for up to 4 days (maximum 12 doses).
1973882|NCT02621021|Drug|Pembrolizumab|Day -2, day 21, day 42, and day 63, Pembrolizumab 2mg/kg IV over approximately 30 minutes.
1973883|NCT02621021|Biological|young TIL|Day 0 (two to four days after last dose of fludarabine), cells will be administered intravenously over 20 to 30 minutes.
1973884|NCT02617589|Drug|Nivolumab|
1973885|NCT02617589|Drug|Temozolomide|
1973886|NCT02617589|Radiation|Radiotherapy|
1973889|NCT02616250|Drug|Brimonidine 0.33% gel (Br)|
1973890|NCT02616250|Other|CD07805/47 (Br) placebo gel|
1973891|NCT02616250|Drug|Ivermectin 1% cream (IVM)|
1973892|NCT02616250|Other|CD5024 (IVM) placebo cream|
1917668|NCT01015118|Drug|Placebo|comparator to BIBF 1120
1917669|NCT01015118|Drug|Paclitaxel|Paclitaxel (standard chemo-therapy)
1917670|NCT01015118|Drug|BIBF 1120|comparison of BIBF 1120 in combination with chemotherapy and placebo in combination with chemotherapy (paclitaxel/carboplatin)
1917671|NCT01015118|Drug|Carboplatin|Carboplatin (standard chemo-therapy)
1917672|NCT01015118|Drug|Paclitaxel|Paclitaxel (standard chemo-therapy)
1917673|NCT01015118|Drug|Carboplatin|Carboplatin (standard chemo-therapy)
1973893|NCT02616094|Device|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 1|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
1973894|NCT02616094|Device|Multi-method Neuroendocrine and Neuroimaging Procedure Scan 2|The MRI scan will be conducted on a 3-T Siemens Trio MRI system equipped with a standard quadrature head coil, using T1 MPRAGE sequence for structural scanning and T2*-sensitive gradient-recalled single shot echo planar pulse sequence for functional scans. Two multimethod MRI scans will be conducted in the AD sample, while the controls will participate in a single scan.
1973895|NCT02615340|Drug|Melatonin|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
1973896|NCT02615340|Drug|Placebo|Study drug will be given at 21:00 - 23:59 daily, starting on the day of enrolment until ICU discharge, death, or up to 14 days, as most critically ill patients are at greatest risk of delirium in the first two weeks of admission. The study medication will be given by mouth (PO or per os) or if needed, via the feeding tube followed by a flush with 20mL water. Doses can be given up to midnight if administration needs to be delayed for procedures or investigations.
1973900|NCT02612545|Drug|Dihydroartemisinin-piperaquine (DHA-PPQ)|Co-formulated anti-malarial drug used as standard of care treatment for uncomplicated malaria in Cambodia
1973901|NCT02612545|Drug|Mefloquine (MQ)|ACT partner drug
1973902|NCT02612311|Biological|Obinutuzumab|Obinutuzumab: IV infusion
1973903|NCT02612311|Biological|Ublituximab|Ublituximab: IV infusion
1973904|NCT02612311|Drug|TGR-1202|TGR-1202: Oral daily dose
1973905|NCT02612311|Drug|Chlorambucil|Chlorambucil: Oral dose
1973908|NCT02610478|Biological|High-Titer Plasma|2 units of human plasma (FFP or FP24, 250-350 mL per unit, or pediatric equivalent) with influenza A/H1N1 and A/H3N2 HAI titers of at least 1:80.
1973909|NCT02610478|Biological|Low-Titer Plasma|2 units of human plasma (FFP or FP24, 250-350 mL per unit, or pediatric equivalent) with influenza A/H1N1 and A/H3N2 HAI titers of 1:10 or less.
1973910|NCT02607722|Drug|Nintedanib|
1973914|NCT02606708|Radiation|Accelerated intensity modulated radiation therapy (AIMRT)|
1973920|NCT02600715|Drug|Onabotulinumtoxin A (BoNT)|
1973921|NCT02600715|Drug|belladonna|Part of dosage of the compounded active B&O suppository of belladonna 16.2mg and morphine 7.5mg.
1973922|NCT02600715|Drug|Morphine|Part of dosage of the compounded active B&O suppository of belladonna 16.2mg and morphine 7.5mg.
1973923|NCT02600715|Drug|Placebo|matching placebo to B&O suppository
1973924|NCT02600715|Drug|Active B&O suppository of belladonna|belladonna 16.2mg and morphine 7.5mg
1973925|NCT02599896|Biological|VRC-HIVMAB080-00-AB (VRC01LS)|VRC01LS is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
1973926|NCT02599896|Biological|VRC-HIVMAB060-00-AB (VRC01)|VRC01 is an Investigational Monoclonal Antibody targeted to the CD4 binding site of HIV-1.
1973927|NCT02599402|Drug|Nivolumab|
1973928|NCT02599402|Drug|Ipilimumab|
1973929|NCT02597985|Other|Prehabilitation|Supervised exercise training intervention will include three sessions per week for four weeks at a Mayo Clinic system cardiac rehabilitation facility. The Rochester, Minnesota Cardiac Rehabilitation Program will provide guidance and oversight. Modes of aerobic exercise will include treadmill walking (the primary mode of training) supplemented with non-weight-bearing activities such as stationary cycling and combination arm/leg recumbent exercise (NuStep device), as needed. Intensity will be set using Borg Perceived Exertion Scale (RPE) ratings of 12-14 (somewhat hard), keeping patients below the threshold for more than mild angina.
1973930|NCT02597985|Other|Usual Care|
1973933|NCT02596035|Drug|Nivolumab|
1973945|NCT02594189|Other|Live recombinantly derived A/Bethesda/MM1/H3N2 virus|The human challenge virus will be administered intranasally to each participant using a nasal sprayer. A total volume of up to 2mL of virus will be administered.
1973946|NCT02593786|Drug|Nivolumab|
1973947|NCT02592798|Drug|Abatacept|
1973948|NCT02592798|Other|Normal Saline|
1973949|NCT02592798|Other|D5W|
1973952|NCT02589665|Drug|Mirikizumab|
1973953|NCT02589665|Drug|Placebo|
1973961|NCT02586896|Behavioral|Strengths-based Case Management (SBCM)|The six case management sessions for the proposed trial are based on those described in manuals developed by Dr. Rapp for two clinical trials, one supported by National Institute on Drug Abuse (NIDA) and another by the Centers for Disease Control (CDC). Each session is guided by specific objectives that promote linkage with and retention in substance abuse treatment, particularly pharmacotherapy for opioid dependence in a specialty or primary care setting. Objectives from the earlier trials will be adapted to fit the specific context of this trial, linking with and staying in treatment following an emergency department visit. Initiation of the relationship between client and case manager begins immediately following random assignment and termination takes place when either (1) six sessions have occurred; (2) ninety days have elapsed; or (3) clients discontinue involvement.
1973962|NCT02586896|Behavioral|Screening, Assessment, and Referral (SAR)|"The research assistant will provide these participants with an information sheet listing treatment (including both specialty treatment centers and primary care clinics that provide buprenorphine) and self-help resources in their community. The referral sheet includes names, addresses, and phone numbers of local addiction treatment agencies. Because the emergency department does not currently screen or refer systematically, the SAR condition represents a level of care significantly higher than treatment as usual. Participants will also receive an informational pamphlet about drug use and its consequences, addiction, and treatment."
1973964|NCT02583477|Drug|MEDI4736 in combination with nab-paclitaxel and gemcitabine|MEDI4736 in combination with nab-paclitaxel + gemcitabine chemotherapy regimen via IV infusion
1973965|NCT02583477|Drug|MEDI4736 in combination with AZD5069|MEDI4736 via IV infusion and oral AZD5069
1973966|NCT02583295|Behavioral|Music sound|The recorded preferred songs or music (commercially available) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
1973967|NCT02583295|Behavioral|Maternal sound|The recorded maternal voice (while they are singing the most popular songs their children like or telling a story to help their children to sleep) listened by CD player connected to the patient ears before induction of anesthesia and continued during intra operative period
1973968|NCT02583256|Biological|Adjuvanted QIV (aQIV)|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)
1973969|NCT02583256|Biological|Non-adjuvanted QIV|Non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
1973970|NCT02581969|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered 20-30 IU/kg 3 times a week
1973971|NCT02581969|Drug|Recombinant Factor VIII (Kogenate FS, BAY14-2222)|Administered only for bleeding episodes
1973974|NCT02581631|Biological|Nivolumab|
1973975|NCT02581631|Drug|Brentuximab Vedotin|
1973976|NCT02580773|Drug|Prophylactic anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a prophylactic dose (4500 UI/day)
1973977|NCT02580773|Drug|Curative anticoagulation ( INNOHEP®)|subcutaneous anticoagulation with low molecular weight heparin (tinzaparin) at a curative dose (175 UI/kg/day for 7 days)
1917777|NCT01004224|Drug|BGJ398|
1973980|NCT02579967|Drug|Immunosuppression Only Conditioning|Pentostatin 4 mg/m(2)/day IV on days -9 and -5, low-dose cyclophosphamide orally daily on days -9 through -2
1973981|NCT02579967|Drug|Reduced Intensity Conditioning|pentostatin 4 mg/m(2)/day IV on days -11 and -7, low-dose cyclophosphamide orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days - 3 and -2.
1973982|NCT02579967|Drug|Myeloablative Conditioning|Pentostatin 4 mg/m(2)/day IV on days -13 and -9, low-dose cyclophosphamide orally daily on days -13 through -6; busulfan IV, pharmokinetically dosed, on days -5, -4, -3, and -2.
1973983|NCT02579967|Drug|GVHD Prophylaxis|High-dose, post-transplantation cyclophosphamide (PTCy) 50 mg/kg on days +3 and +4, sirolimus 6 mg on days +5 through +180, and mycophenolate mofetil (MMF) on days +5 through +35 (exception of patients with DNA repair defects or telomere maintenance defects will get(PTCy) 25 mg/kg on days +3 and +4)
1973984|NCT02579967|Procedure|Allo BMT|Allogeneic blood or marrow transplantation
1973985|NCT02579967|Drug|Reduced Intensity MycophenolateMofetil Conditioning (RIC-MMF)|pentostatin 4 mg/m2/day IV on days -11 and -7, cyclophosphamide 5 mg/kg orally daily on days -11 through -4; busulfan IV, pharmokinetically dosed, on days -3 and -2.
1973986|NCT02579967|Drug|MMF GVHD Prophylaxis|Duration Level -2 to 1: Mycophenolate Mofetil(MMF) 15 mg/kg orally or IV three times a daily on days +5 through +35 or +25 or +18; Duration Level 2: NO Mycophenolate Mofetil(MMF)
1974001|NCT02574078|Drug|Nivolumab|
1974002|NCT02574078|Drug|Bevacizumab|
1974003|NCT02574078|Drug|Pemetrexed|
1974004|NCT02574078|Other|Best Supportive Care|Palliative radiation, palliative surgery and/or other best supportive care treatments
1974005|NCT02574078|Drug|nab-Paclitaxel|
1974006|NCT02574078|Drug|Paclitaxel|
1974007|NCT02574078|Drug|Docetaxel|
1974008|NCT02574078|Drug|Gemcitabine|
1974009|NCT02574078|Drug|Erlotinib|
1974010|NCT02574078|Drug|Crizotinib|
1974011|NCT02574078|Drug|Carboplatin|
1974012|NCT02572687|Drug|Ramucirumab|Administered IV
1974013|NCT02572687|Drug|MEDI4736|Administered IV
1974016|NCT02571569|Drug|BAY1093884|Single escalating dose with a starting dose of 0.3 mg/kg for the first cohort. Drug will be administered via IV infusion over 1 hour and SC injection. Based on safety, PK and PD results the doses for the other cohorts will be determined.
1974017|NCT02570308|Drug|IMCgp100|Bispecific soluble HLA-A2 restricted gp100-specific TCR fused to anti-CD3
1974022|NCT02566382|Procedure|arthroscopy arthrodesis of the shoulder|The shoulder surgery will be realized under arthroscopy only
1974023|NCT02564978|Drug|Minocycline|Capsule for oral administration
1974024|NCT02564055|Drug|GSK2894512 1% Cream|1.0% (10 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
1974025|NCT02564055|Drug|GSK2894512 0.5% Cream|0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
1974026|NCT02564055|Drug|Vehicle cream|White to off-white vehicle cream base to be applied topically
1974027|NCT02564549|Procedure|TRUS-guided biopsy|Patients on the TRUS biopsy-based arm will undergo annual systematic biopsies without any MRI staging or guidance.
1974028|NCT02564549|Procedure|mpMRI with targeted biopsy|Patients on the mpMRI- based arm will undergo annual mpMRI surveillance imaging, with image-guided targeted biopsies only as indicated by radiographic findings.
1974029|NCT02562755|Biological|Pexastimogene Devacirepvec (Pexa Vec)|Pexa-Vec is a vaccinia virus based oncolytic immunotherapy designed to stimulate the immune system following infection and replication within tumor cells.
1974030|NCT02562755|Drug|Sorafenib|"Sorafenib belongs to the pharmacotherapeutic group of antineoplastic agents, protein kinase inhibitors, ATC code: L01XE05.
Sorafenib is a multi-kinase inhibitor which has demonstrated both anti-proliferative and anti-angiogenic properties in vitro and in vivo.
Sorafenib is approved for the treatment of advanced HCC and is the Standard Of Care for this disease."
1974033|NCT02560519|Drug|Albumin solution|"Albumin solution will used for priming of the CPB(cardio-pulmonary bypass) tubing. : A mixture of 20% (200 mg/mL) albumin (Albuman® 200 g/L, Sanquin, the Netherlands) with Ringer's acetate solution in the final albumin concentration of 4%.
During surgery and the first 24 hours of ICU treatment, albumin 4% solution will be used up to 4000 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 4000 mL are needed for volume replacement therapy.The volume replacement therapy is not protocolled but will be based on the clinical decision."
1974034|NCT02560519|Drug|Ringers acetate solution|"The Ringers acetate solution will be used for priming of the CPB tubing. The CPB priming volume comprises only of Ringer´s solution.
During surgery and the first 24 hours of ICU treatment,Ringer´s acetate solution will be used up to 4000 mL for volume replacement therapy. Ringer's acetate solution is used thereafter, i.e. if more than 4000 mL are needed for volume replacement therapy during the second study phase. The volume replacement therapy is not protocolled but will be based on the clinical decision."
1974035|NCT02559687|Biological|pembrolizumab|IV Q3W
1974040|NCT02557100|Drug|Abatacept|
1974041|NCT02557100|Drug|Adalimumab|
1974042|NCT02557100|Drug|Methotrexate|
1917831|NCT00993161|Device|Motriplate|Number of contact couples
1917832|NCT00993161|Device|Motriplate|Number of contact couples
1974045|NCT02552602|Dietary Supplement|Multivitamin A|Multivitamin containing 7 micronutrients at recommended daily allowance (RDA)
1974046|NCT02552602|Dietary Supplement|Multivitamin B|Multivitamin containing 22 micronutrients at RDA
1974047|NCT02552602|Dietary Supplement|Multivitamin C|Multivitamin containing 22 micronutrients at three times the RDA
1974048|NCT02553460|Drug|ITMHA|Given intrathecally (IT).
1974049|NCT02553460|Drug|Dexamethasone|Given orally (PO) or naso-gastrically (NG) or intravenously (IV).
1974050|NCT02553460|Drug|Mitoxantrone|Given IV.
1974051|NCT02553460|Drug|Pegaspargase|Given IV. If participant is allergic to pegaspargase, Asparaginase Erwinia Chrysanthemi will be used.
1974052|NCT02553460|Drug|Asparaginase Erwinia Chrysanthemi|Asparaginase Erwinia Chrysanthemi will be used in case of allergy or intolerance of participant to PEG-asparaginase. Given IV (preferred) or intramuscularly (IM).
1974053|NCT02553460|Drug|Bortezomib|Given IV.
1974054|NCT02553460|Drug|Vorinostat|Taken PO or NG.
1974055|NCT02553460|Drug|Cyclophosphamide|Given IV.
1974056|NCT02553460|Drug|Mercaptopurine|Given PO or NG.
1974057|NCT02553460|Drug|Methotrexate|Given IV.
1974058|NCT02553460|Drug|Leucovorin Calcium|Leucovorin rescue PO or IV.
1974059|NCT02553460|Drug|Cytarabine|Given IV.
1974060|NCT02553460|Drug|Etoposide|Given IV. In case of participant allergy, etoposide phosphate (Etopophos®) will be given.
1974061|NCT02553460|Drug|Vincristine|Given IV.
1974065|NCT02547584|Procedure|Catheter ablation|Pulmonary vein antrum isolation (PVAI) plus entire posterior wall plus coronary sinus plus left part of the septum. This intervention will be received by all as standard of care
1974066|NCT02544035|Other|Type of Toy|Children will be presented with one of three (counterbalanced) toys targeted for their age group. When presented, each target toy will be paired with two additional toys from the same toy category; one targeted to the age group just below and one from the age group just above the target toy.
1974067|NCT02544035|Other|Play Partner (Either parent or friend)|For children ages 6 months-5 years, each child will first play alone then play with parent. For children ages 6-12 years, each child will first play alone then play with a friend.
1974068|NCT02543983|Drug|Ketamine|non-competitive N-methyl-D-aspartate receptor antagonist
1974069|NCT02542813|Drug|IM oxytocin 10 IU|IM oxytocin 10 IU is a colourless and clear sterile solution in a 1 mL ampoule containing 10 IU of oxytocin, which is administered intramuscularly
1974070|NCT02542813|Drug|IH oxytocin 50 mcg|IH oxytocin 50 mcg is a powder blend for inhalation in a hard capsule containing 50 mcg of oxytocin, which is administered by oral inhalation.
1974071|NCT02542813|Drug|IH oxytocin 200 mcg|IH oxytocin 200 mcg is a powder blend for inhalation in a hard capsule containing 200 mcg of oxytocin, which is administered by oral inhalation.
1974072|NCT02542813|Drug|IH oxytocin 400 mcg|IH oxytocin 400 mcg is a powder blend for inhalation in a hard capsule containing 400 mcg of oxytocin, which is administered by oral inhalation.
1974073|NCT02542813|Drug|IH oxytocin 600 mcg|IH oxytocin 600 mcg is a powder blend for inhalation in a hard capsule containing 600 mcg of oxytocin, which is administered by oral inhalation.
1974074|NCT02542813|Drug|Placebo|Placebo is a powder blend for inhalation in a hard capsule containing five inactive components, which is administered by oral inhalation.
1974075|NCT02543047|Device|Angioshield|Angioshield is applied to vein graft to provide Mechanical Support for Vein Grafts Used in CABG Surgery
1974076|NCT02543944|Drug|Gabapentin|N-type calcium channel blocker being examined for its potential efficacy to alleviate opioid withdrawal during buprenorphine-assisted detox and transition to depot naltrexone.
1974077|NCT02543944|Drug|Buprenorphine|All participants are stabilized on buprenorphine and then undergo a 10 day taper off buprenorphine.
1974078|NCT02543944|Drug|Clonidine|All participants who successfully taper off buprenorphine receive Clonidine (0.1 mg) prior to induction onto oral naltrexone.
1974079|NCT02543944|Drug|Naltrexone (oral)|All participants receive increasing doses of oral naltrexone over a 3 day period (day 1: 6.25 and 6.25 mg; day 2: 25 mg; day 3: 50 mg)
1974080|NCT02543944|Drug|Naltrexone (depot)|All participants who tolerate oral naltrexone at 50 mg will receive the naltrexone injection on either the same day as the 50 mg dose or the day after.
1974081|NCT02543944|Drug|Placebo|Microcrystalline cellulose
1974082|NCT02540629|Procedure|Bundled EMS CPR approach including dispatcher-assisted CPR, 3-person team CPR, and feedback CPR monitoring device|Gold standard EMS CPR refers to our bundled approach to providing high quality EMS CPR through one or more intervention(s) as applicable including 1) dispatcher-assisted CPR, 2) multi-tiered team CPR, and 3) feedback CPR.
1974088|NCT02538419|Behavioral|Peer Support|
1974089|NCT02538419|Behavioral|Individual Education|
1974090|NCT02537548|Other|Laboratory Biomarker Analysis|Correlative studies
1974091|NCT02537548|Procedure|Retroperitoneal Lymph Node Dissection|Undergo RPLND
1974094|NCT02535494|Other|Extensive training|We have developed a more in-depth education package to help participants better recognize and respond to an opioid overdose.
1974095|NCT02533843|Procedure|radiofrequency catheter ablation|Radiofrequency catheter ablation of atrial fibrillation with or without being guided by FIRMap (using RhythmView™ Workstation from TOPERA)
1974096|NCT02533323|Drug|gemcitabine|gemcitabine :1250mg/m2 (ivdrip) on days 1
1974097|NCT02533323|Drug|oxaliplatin|oxaliplatin :85 mg/m2 (ivdrip) on day 1
1974098|NCT02533323|Drug|pegaspargase|pegaspargase : 2500 IU/m2 (intramuscular injection)
1974099|NCT02532712|Drug|EC-18|EC-18 Soft-capsule (500mg/1 capsule)
1974100|NCT02532712|Drug|Placebo|Placebo with same shape and size
1974101|NCT02532426|Procedure|Muscle biopsy|The biopsy is performed on the vastus lateralis muscle at rest and 2 hours after an acute exercise, with a local anesthesia.
1974102|NCT02531880|Drug|Mangafodipir|A contrast agent previously approved for liver imaging with MRI, which contains manganese.
1974103|NCT02529891|Other|Measurement of VOC in exhaled air|Measurement of VOC in exhaled air during 10 min (tidal breathing) with a portable mass spectrometer
1990263|NCT02129140|Device|Hernia graft/mesh|observational group
1974105|NCT02527460|Drug|Anakinra|Participants will self-administer daily subcutaneous injections of anakinra for 8 weeks. The dose will be increased over the first four weeks to minimize injection site reactions. The target dose after four weeks is 300mg daily.
1974106|NCT02522611|Drug|Resiniferatoxin|Resiniferatoxin (RTX) is an ultrapotent agonist analog of capsaicin that targets a receptor expressed on specific dorsal root sensory ganglia (DRG) neurons and is expected to reduce pain within the targeted zone.
1974107|NCT02521558|Behavioral|Intervention Group|The investigators are interested in how practicing memory tasks can improve memory in patients with MCI and with AD. Specifically, patients will perform a set of cognitive rehabilitation tasks designed to train memory in order to determine if these tasks are effective in improving memory or slowing the progression of Alzheimer's disease. Patients will practice memory tasks for about an hour daily, for a total duration of 6 months. A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the Intervention Group exhibit weekly improvements and to determine if patients are regularly adhering to the tasks.
1974108|NCT02521558|Behavioral|Control Group|"The Control Group will not receive any cognitive rehabilitation tasks for a six month period. Instead, they will simply be given booklets of puzzles (e.g., word search, number puzzles, etc.) to work on for the duration of 6 months.
A research assistant or clinician will conduct weekly check-ins with each participant assess whether or not participants in the control group feel like they are benefiting from the puzzles.
Participants in the Control Group will be given a standard battery of neuropsychological tests prior to the the puzzles and after the puzzles to assess any changes in memory, language, attention, and executive functioning."
1974109|NCT02522364|Device|BioMonitor device|Implantation of a BioMonitor device and continuously monitoring heart rhythm for study duration
1974110|NCT02522364|Other|Standard|Clinical and intermittent electrocardiographic follow-up of patients
1974114|NCT02514551|Drug|Ramucirumab|Administered IV
1974115|NCT02514551|Drug|Paclitaxel|Administered IV
1974118|NCT02514070|Dietary Supplement|EPA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
1974119|NCT02514070|Dietary Supplement|DHA-rich fish oil|4 gel capsules, 3 times/day for 6 weeks
1974120|NCT02513030|Procedure|Defibrillation testing during ICD replacement|
1974121|NCT02511431|Drug|Lonafarnib|prenylation inhibitor to be administered daily at doses of 50 mg, 75 mg or 100 mg.
1974122|NCT02511431|Drug|Ritonavir|FDA approved drug for use of boosting other drugs. Will be used to boost ritonavir as they both use the same CYP system. Will be administered at 100 mg daily.
1974123|NCT02511431|Other|Placebo|Placebo
1974124|NCT02511028|Drug|Ferumoxytol|510mg (17mL) IV
1974128|NCT02509104|Drug|FDC capsule of dutasteride and tamsulosin|Each FDC capsule contains a mixture of dutasteride formulation (equivalent to 0.5 mg dutasteride) and tamsulosin (equivalent to 0.2 mg tamsulosin) and its physical appearance is hard shell capsule.
1974129|NCT02509104|Drug|Dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet|Coadministration of dutasteride soft gelatine capsule and tamsulosin HCl oral disintegrating tablet. Each soft gelatine capsule consist of 0.5 mg of dutasteride and physical appearance is Oblong, size 6, dull yellow capsule. Each oral disintegrating tablet consist of 0.2 mg of tamsulosin and its physical appearance is white, round standard convex.
1974136|NCT02504892|Drug|Everolimus|Everolimus is a commercial agent and is supplied by Novartis.
1974137|NCT02504866|Other|Excercise|Exercise training of different intensity
1974138|NCT02502786|Biological|humanized anti-GD2 antibody|
1974139|NCT02502786|Drug|GM-CSF|
1974140|NCT02501733|Device|Medacta GMK Sphere® Medial Knee Prosthesis|"There is no consensus within the Arthroplasty community as to whether a traditional post and cam-style Posterior Stabilized total knee device is superior to a medial-pivot, more congruent device. However, the majority of surgeons seem to prefer the former, though there is a minority that uses the latter device with great success.
To date, there have been few prospective trials directly comparing these devices, and none with the latest generation of Total Knee Arthroplasty implants. Almost all such studies have been retrospective and/or utilizing older generation devices."
1917936|NCT00975845|Other|BioCleanse Tibialis tendon|Outcomes of anterior cruciate replacement will be evaluated
1974160|NCT02495103|Drug|Vandetanib|Vandetanib is commercially available under the trade name CAPRELSA, but will be supplied by the manufacturer (AstraZeneca Pharmaceuticals, Wilmington, DE) for the purposes of the study.
1974161|NCT02495103|Drug|Metformin|Metformin is commercially available and manufactured by Bristol-Myers Squibb Company (Princeton, NJ) under the trade name GLUCOPHAGE.
1974167|NCT02488629|Drug|SCB01A|This study is a single arm, open-label, Phase II trial
1974168|NCT02488759|Drug|Nivolumab|
1974169|NCT02488759|Drug|Ipilimumab|
1974170|NCT02488759|Drug|BMS-986016|
1974171|NCT02488759|Drug|Daratumumab|
1974179|NCT02486965|Device|thermode (TSA-II model)|thermal stimulation with test thermode
1974180|NCT02486965|Other|Adapted Physical Activity|
1974181|NCT02486965|Other|Physical activity|
1974186|NCT02484417|Biological|RSV A2 Study Agent|Each adult volunteer will receive a single intranasal inoculation with RSV A2 with subsequent sampling of nasal secretions and blood draws.
1974187|NCT02484404|Drug|Olaparib|"Olaparib tablets will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days.
MEDI4736 (3mg/kg or 10mg/kg IV) and Olaparib tablets (200 mg or 300 mg BID)
Ph II - MEDI4736 + Olaparib at RP2D"
1974188|NCT02484404|Drug|Cediranib|"Cediranib will be given orally on a continuous dosing schedule. The DLT period will be one cycle, 28 days.
MEDI4736 (10mg/kg IV) and Cediranib (15 mg or 20 mg or 30 mg daily)
Ph II - MEDI4736 + Cediranib at RP2D"
1974189|NCT02484404|Drug|MEDI4736|Ph I - MEDI4736 will be administered once every 2 weeks for 12 months.
1974190|NCT02484456|Drug|AV 101 (4-Chlorokynurenine)|Glycine Receptor Antagonist
1974191|NCT02484456|Other|Placebo|Placebo pill
1990271|NCT02123368|Drug|Hyaluronic acid|Single intraarticular injection of Hyaluronic acid (Hyal One)
1990272|NCT02123368|Biological|10 million Bone marrow mesenchimal stem cells|10 million of Bone marrow mesenchimal stem cells
1990273|NCT02123368|Biological|100 million Bone marrow mesenchimal stem cells|100 million of Bone marrow mesenchimal stem cells
1990277|NCT02115542|Drug|Regorafenib|Four 40 mg regorafenib tables should be taken in the morning with approximately 8 fluid ounces (240 mL) of water after a low-fat (<30% fat) breakfast.
1974192|NCT02482298|Drug|Ticagrelor|Two arms: 1) 10 mg ticagrelor + 45 mg ticagrelor placebo or 2) 45 mg ticagrelor + 10 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening, at least 12 hours apart) from randomization until the end of treatment.
1974193|NCT02482298|Drug|Placebo|10 mg ticagrelor placebo + 45 mg ticagrelor placebo. Drugs taken orally, twice a day (morning and evening at least 12 hours apart) from randomization until the end of treatment
1974198|NCT02478775|Drug|Degarelix (GnRH antagonist)|Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
1974199|NCT02478775|Drug|recombinant FSH|Day-2: Blood samples will again be obtained every 10 minutes for 10 hours. Repeated boluses of exogenous recombinant FSH (rFSH) will be given by IV during this 10 hour visit.
1974209|NCT02471313|Drug|[18F] FMISO|Each patient will receive up to 10 mCi of [18F] FMISO
1974210|NCT02469246|Drug|F/TAF|Emtricitabine/tenofovir alafenamide (F/TAF) fixed dose combination (FDC) tablets administered orally once daily
1974211|NCT02469246|Drug|ABC/3TC|Abacavir/lamivudine (ABC/3TC) FDC tablets administered orally once daily
1974212|NCT02469246|Drug|ABC/3TC Placebo|Placebo to match ABC/3TC tablets administered orally once daily
1974213|NCT02469246|Drug|F/TAF Placebo|Placebo to match F/TAF tablets administered orally once daily
1974214|NCT02469246|Drug|Third antiretroviral agent|An allowed third antiretroviral agent of the participant's pre-existing regimen may include one of the following: ritonavir boosted lopinavir (LPV/r), atazanavir (ATV) + ritonavir (RTV), ATV + cobicistat (COBI) or ATV/COBI FDC, darunavir (DRV) + RTV, DRV+COBI or DRV/COBI FDC, efavirenz (EFV), rilpivirine (RPV), raltegravir (RAL), dolutegravir (DTG), maraviroc (MVC), or nevirapine (NVP).
1974215|NCT02468648|Drug|Sofosbuvir|An NS5B polymerase inhibitor that is already approved for use in combination with interferon and ribavirin for the treatment of HCV genotype 1 infection
1974216|NCT02468648|Drug|GS-5816|An NS5A replication complex inhibitor with potent activity against most strains of hepatitis C virus.
1974256|NCT02460783|Dietary Supplement|Boost A|Supplement providing 530 Kcal/Bottle
1974257|NCT02460783|Behavioral|Healthy Living Diet|Counseling and educational material on diet portion, consistency
1974258|NCT02457897|Drug|Liothyronine|Oral supplement given every 8 hours
1974263|NCT02447848|Drug|sufentanil sublingual 30 mcg tablet|
1974264|NCT02446626|Procedure|Skin biopsy|Optional 2-3mm skin punch biopsies will be performed.
1974265|NCT02446626|Procedure|Blood draw|Peripheral blood draws will be performed.
1974266|NCT02446626|Other|Xenodiagnosis|Larval ticks will be obtained from Dr. Sam Telford from a laboratory maintained tick colony at Tufts Veterinary School. These ticks are hatchedfrom eggs laid by ticks that have fed only on specific pathogen free laboratory animals that were purchased from established vendors. Between 25-30 larval ticks that have been aged and are known to be ready to attach will be placed on the study participant.
1974269|NCT02446457|Drug|Rituximab|375 mg/m2 by vein weekly for 4 weeks on Days 1, 8, and 15 of Cycle 1, and Day 1 of Cycle 2.
1974270|NCT02446457|Drug|Pembrolizumab|200 mg by vein every 3 weeks for a maximum of 16 infusions on Day 2 of Cycles 1 and 2, and on Day 1 of Cycles 3 - 16.
1974271|NCT02446457|Drug|Lenalidomide|"Dose Escalation Phase Starting dose of Lenalidomide 5 mg on Days 1-14 of each cycle for up to 12 cycles.
Dose Expansion Phase Starting Dose of Lenalidomide is maximum tolerated dose from Phase 1."
1974274|NCT02443298|Drug|ABBV-066|Monoclonal IgG Antibody
1974275|NCT02443298|Drug|Placebo|Matching placebo for ABBV-066
1974276|NCT02439281|Drug|Clonidine|Only the Ropivacaine /clonidine group will receive clonidine (2mcg/kg) injected with ropivacaine.
1974277|NCT02439281|Drug|Ropivacaine|One hundred pediatric patients (10-17 years old) scheduled for laparoscopic appendectomy will be randomized to the two treatment groups: the Ropivacaine Group will receive ropivacaine 0.5% (10 ml) injected bilateral in Both groups will receive ropivacaine 0.5% (10 ml) injected bilaterally for the rectus sheath block
1974279|NCT02438826|Drug|LY2951742|Administered SQ
1974280|NCT02438826|Drug|Placebo|Administered SQ
1974283|NCT02435433|Drug|Ramucirumab|Administered IV
1974284|NCT02435433|Drug|Placebo|Administered IV
1974285|NCT02430480|Drug|Goserelin|10.8mg administered subcutaneously every 12 weeks (2 doses)
1974286|NCT02430480|Procedure|mpMRI|Multiparametric MRI - One at baseline and after 6 months of treatment
1974287|NCT02429830|Device|LINX device|The LINX device is a permanent implant placed at the area of the lower esophageal sphincter (LES) and is designed to augment a weak LES and minimize or eliminate GERD-related symptoms.
1974288|NCT02428296|Drug|Sirolimus|Low dose sirolimus will be given in daily dosing to achieve trough levels of 2-6 ng/ ml.
1974289|NCT02427269|Other|Specimen Collection|"1 10mL red tube and 1 8.5mL yellow tube for serum, plasma, and buffy collection
Up to 10 research-specific biopsies obtained from the esophagus during the routine care EGD.
Four biopsies will be taken from the midpoint of the current BE (or midpoint of previous BE if the patient has already received ablation for previous BE),
Two biopsies from normal squamous epithelium, and
One biopsy from each area of esophageal nodularity seen during the procedure
Pathology slides from routine care biopsies taken during the enrollment procedure, as well as retrospective pathology slides from routine care biopsies taken prior to enrollment on the study.
Up to 4 cytology brushes during the procedure."
1974290|NCT02426918|Drug|Debio 1450 IV|Intravenous (IV) form of Debio 1450 will be supplied in vials containing 50 mg of active pharmaceutical ingredient (API). Intravenous infusions of Debio 1450 (160 mg and 80 mg) will be administered over a 2-hour period BID every 12 hours within a 2-hour window (12 ± 2 hours).
1974291|NCT02426918|Drug|Debio 1450 Oral|Oral forms of Debio 1450 will be provided as white, opaque, hard gelatin capsules containing 50 mg drug substance (equivalent to 40 mg of Debio 1450).
1974292|NCT02426918|Drug|Linezolid|Linezolid for oral administration will be provided as 600-mg film-coated compressed tablets.
1974293|NCT02426918|Drug|Debio 1450 Oral Placebo|Debio 1450 placebo will be supplied as white, opaque, hard gelatin capsules.
1974294|NCT02426918|Drug|Linezolid Placebo|Linezolid placebo will be supplied as film-coated compressed tablets.
1974295|NCT02426918|Drug|Vancomycin IV|Vancomycin will be administered BID every 12 ± 2 hours at doses of 1 g or 15 mg/kg as specified in local protocols, with the infusion rate adjusted to 2 hours.
1974297|NCT02423057|Drug|TdCyd|Methylation-mediated silencing of genes is an epigenetic mechanism implicated in carcinogenesis; agents that inhibit this mechanism are of clinical interest because of their potential to re-activate silenced tumor suppressor genes. The nucleoside analog 4'-thio-2'-deoxycytidine (TdCyd) is incorporated into DNA where it engages the active site of DNA methyltransferase I (DNMT1), a maintenance methyltransferase that contributes to the hypermethylation and silencing of tumor suppressor genes. TdCyd offers an improvement over current DNMT inhibitors by virtue of a higher incorporation rate into DNA at lower levels of cytotoxicity; treatment with TdCyd is anticipated to result in the inhibition of tumor growth due to DNMT1 depletion at oral doses that are well tolerated in extended dosing schedules.
1974299|NCT02421822|Other|Fitwits office tool and games|Physician-led narration of Fitwits office tool during well child and subsequent visits over one year with distribution of Fitwits games during first visit.
1974304|NCT02421419|Drug|Dexamethasone Sodium Phosphate|adreno-cortical steroid anti-inflammatory drug
1918085|NCT00948285|Procedure|MRI|magnetic resonance imaging (MRI)
1974305|NCT02421419|Drug|Xylocaine|a local anesthetic agent
1974306|NCT02421419|Drug|Sodium Chloride|Sodium chloride is a sterile, nonpryogenic solution for fluid and electrolyte replenishment
1974310|NCT02416674|Procedure|abdominal wall transplantation|transfer of abdominal wall tissues from an organ donor to a pacient with a large abdominal wall defect.
1974311|NCT02416674|Drug|Immunosuppressive Agents|Recipients of abdominal wall transplants will need to receive global immunosuppression with tacrolimus, mycophenolate mofetil and prednisone.
1974312|NCT02417454|Dietary Supplement|ProbioStick|"One sachet daily, without or without meals (3 x 10^9 CFU per sachet)
(Lactobacillus helveticus R0052 and Bifidobacterium longum subsp. longum R0175)"
1974313|NCT02417454|Other|Placebo|One sachet daily, without or without meals (0 CFU per sachet)
1974314|NCT02415556|Drug|Regular Human Insulin|Regular human insulin 40 IU daily over 24 weeks
1974315|NCT02415556|Drug|Placebo|Intranasal sterile saline 40 IU daily over 24 weeks
1974316|NCT02415400|Drug|Apixaban|
1974317|NCT02415400|Drug|vitamin K antagonist|
1974318|NCT02415400|Drug|Acetylsalicylic acid|
1974319|NCT02415400|Other|Acetylsalicylic acid placebo|
1974320|NCT02413307|Other|Compassion Focused Therapy (self-practice)|Daily practice of the CFT exercises for a minimum of five minutes per day. This is completed for a period of three weeks.
1974321|NCT02411760|Procedure|3 Tesla Magnetic Resonance Imaging|Assessment of the performance of DWI/ADC measurements alone, and as an adjunct to dynamic contrast enhanced (DCE) MRI in diagnosing/characterizing breast cancer.
1974322|NCT02411227|Behavioral|VR Driving|Baseline: Tactical scenario, composite score Post-Assessment: Tactical scenario composite score
1974326|NCT02409368|Drug|Nivolumab|
1974327|NCT02408887|Procedure|Total Thyroidectomy (TT)|Total removal of thyroid
1974328|NCT02408887|Procedure|Prophylactic central neck lymph node dissection(pCND)|Lymph node dissection
1974329|NCT02407054|Drug|LY3023414|Administered orally
1974330|NCT02407054|Drug|Enzalutamide|Administered orally
1974331|NCT02407054|Drug|Placebo|Administered orally
1974332|NCT02405754|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score
1974338|NCT02397473|Drug|LY2951742|Administered SC
1974339|NCT02397473|Drug|Placebo|Administered SC
1974345|NCT02392455|Drug|treatment|Docetaxel plus nintedanib until progression or intolerability
1974346|NCT02392442|Other|Saline|180 of normal saline instilled in six 30 mL aliquots into the left (lingual) and right (middle lobe) lung segments (360 mL total)
1974347|NCT02392442|Biological|Endotoxin|4 ng/kg in final volume of 2 ml
1974358|NCT02388906|Drug|Ipilimumab|
1974359|NCT02388906|Drug|Nivolumab|
1974360|NCT02388906|Other|Placebo matching Ipilimumab|
1974361|NCT02388906|Other|Placebo matching Nivolumab|
1974362|NCT02389192|Drug|ZMAPP|ZMappTM, a combination of three mouse/human chimeric monoclonal antibodies (mAbs; c4G6, c2G4, and c13C6-FR1) directed against Ebola virus glycoprotein epitopes
1974363|NCT02389309|Drug|Dasatinib|Dasatinib given twice daily by mouth for 21 days of a 28 day cycle.
1974364|NCT02389309|Drug|Cyclophosphamide|Cyclophosphamide by mouth once daily for 21 days of a 28 day course.
1974365|NCT02389309|Drug|Temsirolimus|Temsirolimus by vein once weekly for 3 consecutive weeks of a 28 day course.
1974366|NCT02386072|Drug|mirabegron|oral
1974367|NCT02386072|Drug|antimuscarinic medication|oral
1974368|NCT02383498|Other|GI-6301 Placebo|GI-6301 Placebo will consist of USP-grade or equivalent 0.9% Sodium Chloride for Injection. Doses of GI-6301 placebo will be drawn into labeled syringes by an independent, unblinded pharmacist or designee.
1974369|NCT02383498|Biological|GI-6301 Vaccine (Yeast- Brachyury)|GI-6301 Vaccine is a heat-killed, recombinant yeast-based vaccine engineered to express the transcription factor, Brachyury. The Brachyury gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wildtype yeast) to produce the final recombinant vaccine product.
1974370|NCT02383498|Radiation|Radiotherapy|Standard of care
1974371|NCT02383498|Device|wGT3X-BT Actigraph|wGT3X-BT is small, non-invasive, portable watch accelerometer worn on the subject's wrist for Cycle 1 through Cycle 9
1974372|NCT02379442|Biological|MSC|MSC are an adherent, fibroblast-like cell population found in the bone marrow. Allogeneic MSC for treatment can be grown from bone marrow aspirates or biopsies of normal donors.
1974374|NCT02378753|Biological|rVSVΔG-ZEBOV|The rVSVΔG-ZEBOV vaccine is comprised of a single recombinant VSV isolate (11481 nontypeable) modified to replace the gene encoding the G envelope GP with the gene encoding the envelope GP from ZEBOV (Kikwit, 1995 strain).
1974377|NCT02379273|Device|Nucleus Hybrid L24 Implant|Subjects have already been implanted with the Nucleus Hybrid L24 implant.
1974380|NCT02374567|Drug|Phenobarbital|
1974381|NCT02374567|Drug|Phenytoin|
1974382|NCT02374567|Drug|Carbamazepine|
1974383|NCT02374567|Drug|Oxcarbazepine|
1974384|NCT02374567|Drug|Valproic Acid|
1974385|NCT02374567|Drug|Lamotrigine|
1974386|NCT02374567|Drug|Topiramate|
1974387|NCT02374567|Drug|Gabapentin|
1974388|NCT02374567|Drug|Levetiracetam|
1974389|NCT02374567|Drug|Pregabalin|
1974390|NCT02374567|Drug|Lacosamide|
1918147|NCT00936910|Drug|amphotericin B liposomal (Ambisome)|After enrollment, antifungal therapy will be instituted consisting of both systemic and antifungal lock therapy. Systemic therapy will be amphotericin B liposomal (Ambisome) administered IV in a dose of 3-5 mg/kg/day (or other antifungal based upon standard of care) combined with antifungal lock therapy. The antifungal lock therapy consists of placing sufficient amphotericin B liposomal (Ambisome [2 mg/ml]) lock solution into the infected central venous catheter (CVC) and allowing it to dwell uninterruptedly for 8 to 12 hours per day for 10-14 days (largest CVC = 2.3 mL).
1974391|NCT02374567|Drug|Clonazepam|
1974392|NCT02374567|Drug|Biperiden|
1974393|NCT02374567|Drug|Levomepromazine|
1974394|NCT02374567|Drug|Fluphenazine|
1974395|NCT02374567|Drug|Perphenazine|
1974396|NCT02374567|Drug|Perazine|
1974397|NCT02374567|Drug|Thioridazine|
1974398|NCT02374567|Drug|Haloperidol|
1974399|NCT02374567|Drug|Melperone|
1974400|NCT02374567|Drug|Pipamperone|
1974401|NCT02374567|Drug|Bromperidol|
1974402|NCT02374567|Drug|Benperidol|
1974403|NCT02374567|Drug|Sertindole|
1974404|NCT02374567|Drug|Ziprasidone|
1974405|NCT02374567|Drug|Flupentixol|
1974406|NCT02374567|Drug|Chlorprothixene|
1974407|NCT02374567|Drug|Zuclopenthixol|
1974408|NCT02374567|Drug|Fluspirilene|
1974409|NCT02374567|Drug|Pimozide|
1974410|NCT02374567|Drug|Clozapine|
1974411|NCT02374567|Drug|Olanzapine|
1974412|NCT02374567|Drug|Quetiapine|
1974413|NCT02374567|Drug|Sulpiride|
1974414|NCT02374567|Drug|Tiapride|
1974415|NCT02374567|Drug|Amisulpride|
1974416|NCT02374567|Drug|Prothipendyl|
1974417|NCT02374567|Drug|Risperidone|
1974418|NCT02374567|Drug|Aripiprazole|
1974419|NCT02374567|Drug|Paliperidone|
1974420|NCT02374567|Drug|Diazepam|
1974421|NCT02374567|Drug|Oxazepam|
1974422|NCT02374567|Drug|Lorazepam|
1974423|NCT02374567|Drug|Bromazepam|
1974424|NCT02374567|Drug|Clobazam|
1974425|NCT02374567|Drug|Alprazolam|
1974426|NCT02374567|Drug|Hydroxyzine|
1974427|NCT02374567|Drug|Buspirone|
1974428|NCT02374567|Drug|Chloral Hydrate|
1974429|NCT02374567|Drug|Flurazepam|
1974430|NCT02374567|Drug|Nitrazepam|
1974431|NCT02374567|Drug|Triazolam|
1974432|NCT02374567|Drug|Lormetazepam|
1974433|NCT02374567|Drug|Temazepam|
1974434|NCT02374567|Drug|Midazolam|
1974435|NCT02374567|Drug|Brotizolam|
1974436|NCT02374567|Drug|Zopiclone|
1974437|NCT02374567|Drug|Zolpidem|
1974438|NCT02374567|Drug|Zaleplon|
1974439|NCT02374567|Drug|Melatonin|
1974440|NCT02374567|Drug|Clomethiazole|
1974441|NCT02374567|Drug|Diphenhydramine|
1974442|NCT02374567|Drug|Promethazine|
1974443|NCT02374567|Drug|Imipramine|
1974444|NCT02374567|Drug|Clomipramine|
1974445|NCT02374567|Drug|Opipramol|
1974446|NCT02374567|Drug|Trimipramine|
1974447|NCT02374567|Drug|Amitriptyline|
1974448|NCT02374567|Drug|Nortriptyline|
1974449|NCT02374567|Drug|Doxepin|
1974450|NCT02374567|Drug|Maprotiline|
1974451|NCT02374567|Drug|Amitriptyline oxide|
1974452|NCT02374567|Drug|Fluoxetine|
1974453|NCT02374567|Drug|Citalopram|
1974454|NCT02374567|Drug|Paroxetine|
1974455|NCT02374567|Drug|Sertraline|
1974456|NCT02374567|Drug|Fluvoxamine|
1974457|NCT02374567|Drug|Escitalopram|
1974458|NCT02374567|Drug|Tranylcypromine|
1974459|NCT02374567|Drug|Moclobemide|
1974460|NCT02374567|Drug|Mianserin|
1974461|NCT02374567|Drug|Trazodone|
1974462|NCT02374567|Drug|Mirtazapine|
1974463|NCT02374567|Drug|Bupropion|
1974464|NCT02374567|Drug|Venlafaxine|
1974465|NCT02374567|Drug|Reboxetine|
1974466|NCT02374567|Drug|Duloxetine|
1974467|NCT02374567|Drug|Agomelatine|
1974468|NCT02374567|Drug|Pyritinol|
1974469|NCT02374567|Drug|Piracetam|
1974470|NCT02374567|Drug|Donepezil|
1974471|NCT02374567|Drug|Rivastigmine|
1974472|NCT02374567|Drug|Galantamine|
1974473|NCT02374567|Drug|Memantine|
1974474|NCT02374567|Drug|Nicergoline|
1974475|NCT02374567|Drug|Acamprosate|
1974476|NCT02374567|Drug|Lithium|
1974483|NCT02372006|Drug|afatinib|
1974484|NCT02371681|Drug|Moxifloxacin|TB drug
1974485|NCT02371681|Drug|Pyrazindamide|TB drug
1974486|NCT02371681|Drug|Rifampicin|TB drug
1974487|NCT02371681|Drug|Isonizaid|TB drug
1974490|NCT02369653|Drug|Apixaban|
1974491|NCT02369653|Other|No systemic anticoagulant prophylaxis|
1974497|NCT02364973|Other|PET-MRI|The study patients undergo positron emission tomography (PET) after informed consent is obtained
1974498|NCT02364336|Drug|Peginterferon alfa-2a|
1974499|NCT02363335|Drug|Placebo|
1974500|NCT02363335|Drug|Roflumilast/Sitagliptin|Both Roflumilast and Sitagliptin
1974501|NCT02363335|Drug|Sitagliptin|
1974502|NCT02363335|Drug|Roflumilast|
1974503|NCT02363322|Drug|ZMApp|Triple monoclonal cocktail of antibodies against Zaire species of Ebola virus
1974504|NCT02363322|Other|Treatment A|Optimized standard of care for Ebola virus infection
1974508|NCT02362425|Drug|N-acetylcysteine|
1974519|NCT02356159|Biological|Rituximab|Rituximab: 375 mg/m2 IV, day 1 for patients with CD20-positive disease
1974520|NCT02356159|Drug|Conditioning Chemotherapy|Fludarabine:30 mg/m2 per day IV infusion over 30 minutes, daily On days -6, -5, -4, and -3 Cyclophosphamide:1200 mg/m2 per day IV infusion over 2 hours on Days 6, -5, -4, -3 Mesna: 1200 mg/m2 per day IV infusion, Daily on days 6, -5,-4, and -3 Furosemide: 20 mg IV flat dose on days -6, -5, -4, -3
1974521|NCT02356159|Drug|TMS|Tacrolimus: 0.02 mg/kg , start day 3. Continue IV or PO. Taper will begin at day +60 if no acute GVHD then at day +100 and discontinue at day +180 as tolerated. Methotrexate: 5 mg/m2 IV over 15 minutes on days 1, 3, 6, and 11. Sirolimus: 12 mg PO on days -3 to 60, followed by a taper if GVHD does not develop.
1974522|NCT02356159|Drug|FLAG|Fludarabine:25 mg/m2 per day IV over 30 minutes, Daily on days 1-5 Cytarabine: 2,000 mg/m2 IV over 4 hours,on Days 1, 2, 3, 4, 5 Filgrastim: 5 mcg/kg per day SC beginning 24 hours PRIOR to initiation of chemotherapy
1974523|NCT02356159|Drug|EPOCH-F|Fludarabine:25 mg/m2 per day IV infusion over 30 minutes, daily on days 1-4. Etoposide :50 mg/m2 per day continuous IV infusion over 24 hours on days 1-4. Doxorubicin:10 mg/m2/day CIV, days 1-4. Vincristine: 0.4 mg/m2 per day continuous IV infusion over 24 hours daily on days 1-4 Cyclophosphamide: 750 mg/m2 IV infusion over 30 minutes on day 5 Prednisone:60 mg/m2 per day PO daily on days 1-5. Filgrastim: 5 mcg/kg per day SC or IV.
1974524|NCT02356159|Procedure|Hematopoietic Stem Cell Transplant|Hematopoietic stem cell transplant
1974525|NCT02356159|Drug|Palifermin|Escalating doses of palifermin given during transplant phase
1974535|NCT02347865|Drug|AMG 162 - Prolia|500 patients
1974536|NCT02347865|Drug|AMG 162 - Prolia|250 patients, one year later
1974537|NCT02346461|Drug|ManNac.|At doses of 3,000 mg and 6,000 mg twice daily for a total dose of 6,000 and 12,000 mg per day
1974538|NCT02346461|Drug|ManNac|At doses of 6,000 mg twice daily (12,000 mg per day).
1974539|NCT02344810|Drug|c-Met inhibitor AMG 337|Given PO
1974540|NCT02344810|Other|placebo|Given PO
1974541|NCT02344810|Drug|oxaliplatin|Given IV
1974542|NCT02344810|Drug|leucovorin calcium|Given IV
1974543|NCT02344810|Drug|fluorouracil|Given IV
1974544|NCT02344810|Other|pharmacological study|Correlative studies
1974545|NCT02344810|Other|laboratory biomarker analysis|Correlative studies
1974546|NCT02345226|Drug|FTC/RPV/TAF|200/25/25 mg FDC tablets administered orally once daily
1974547|NCT02345226|Drug|EFV/FTC/TDF Placebo|Tablets administered orally once daily
1974548|NCT02345226|Drug|EFV/FTC/TDF|600/200/300 mg FDC tablets administered orally once daily
1974549|NCT02345226|Drug|FTC/RPV/TAF Placebo|Tablets administered orally once daily
1974550|NCT02345252|Drug|FTC/RPV/TAF|FTC/RPV/TAF (200/25/25 mg) FDC tablets administered orally once daily
1974551|NCT02345252|Drug|FTC/RPV/TDF Placebo|FTC/RPV/TDF placebo tablets administered orally once daily
1974552|NCT02345252|Drug|FTC/RPV/TDF|FTC/RPV/TDF (200/25/300 mg) FDC tablets administered orally once daily
1974553|NCT02345252|Drug|FTC/RPV/TAF Placebo|FTC/RPV/TAF placebo tablets administered orally once daily
1974558|NCT02344290|Drug|Pitavastatin|One tablet (4 mg) taken once daily, orally with or without food
1974559|NCT02344290|Drug|Placebo|One tablet taken once daily, orally with or without food
1974562|NCT02338999|Radiation|PET/CT|The combined PET/CT scans provide
1974563|NCT02338999|Drug|Pioglitazone|Increases insulin sensitivity in muscle.
1974564|NCT02338999|Procedure|Vascular function studies|Non-invasive
1974565|NCT02338973|Drug|Interferon gamma-1b|
1974566|NCT02335918|Drug|Combination of varlilumab and nivolumab|"Phase I: Varlilumab dosing will be dependent on the cohort assigned in combination with 3 mg/kg of nivolumab every two weeks.
Phase II: Patients with CRC, RCC or GBM enrolled in Phase ll will receive 3.0 mg/kg of varlilumab in combination with 240 mg of nivolumab every 2 weeks. Patients with SCCHN or ovarian cancer will receive varlilumab at a dose of either 3 mg/kg every 2 weeks, 3 mg/kg every 12 weeks, or 0.3 mg/kg every 4 weeks, in combination with 240 mg of nivolumab every 2 weeks.
Patients may be discontinued from receiving study treatment based on the results of disease assessments or if experiencing intolerable side effects."
1974567|NCT02335307|Genetic|CYP2D6 genotyping|CYP2D6 genotype results and an interpretive report will be placed in the electronic medical record to assist the physician with prescribing medication for pain management.
1974568|NCT02335307|Other|Pain assessment questionnaire|A pain assessment questionnaire will be administered at baseline and 3 months.
1974569|NCT02335307|Other|Physician assessment|20-item survey administered to physicians treating patients enrolled in the study
1974570|NCT02334462|Biological|Pfs230D1M-EPA/Alhydrogel|
1974571|NCT02334462|Biological|Pfs25M-EPA/Alhydrogel|
1974572|NCT02334462|Drug|TWINRIX|
1974573|NCT02334462|Drug|Menactra|
1974574|NCT02326818|Procedure|BoNT injection|
1974575|NCT02326818|Procedure|US guidance|
1974576|NCT02326818|Procedure|E-stim Guidance|
1974577|NCT02322203|Dietary Supplement|Niacin Extended Release|Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days. Subjects will then be escalated to 2000 mg/day for 14 weeks.
1974582|NCT02320058|Drug|Ipilimumab|
1974583|NCT02320058|Drug|Nivolumab|
1974587|NCT02317341|Drug|Ketamine|Single intravenous dose
1974588|NCT02317341|Drug|Placebo (saline)|Given intravenously over 40 minutes
1974589|NCT02317341|Drug|Ketamine|Single intravenous dose given over 40 minutes
1974590|NCT02317341|Drug|Midazolam|Given intravenously over 40 minutes
1974591|NCT02317341|Drug|Midazolam(placebo)|Given intravenously over 40 minutes
1974592|NCT02317549|Drug|LB1148|
1974593|NCT02317549|Drug|Placebo|
1974599|NCT02315612|Biological|CD22-CAR|CD22-CAR cells will be infused on Day 0 after induction chemotherapy regimen.
1974600|NCT02315625|Drug|Sunitinib|37.5 mg once daily will continue until progression
1974601|NCT02315625|Drug|Everolimus|"10 mg daily
x 10 mg tablets or
x 5 mg tablets or
4 x 2.5 mg tablets"
1974602|NCT02315625|Procedure|Surgery|Cytoreductive surgery only on patients for whom it is indicated. Performed within 3 months of first dose of study drug.
1974603|NCT02316353|Biological|C1-esterase inhibitor|
1974606|NCT02312310|Dietary Supplement|cocoa flavanols|12 weeks administration of cocoa flavanol
1974611|NCT02311361|Drug|Durvalumab|10 mg/kg, mg IV, every two weeks for up to 13 month; 10 mg/kg, IV, every four weeks for up to 8 month
1974612|NCT02311361|Drug|Tremelimumab|75 mg IV, every 4 weeks for 16 weeks
1974613|NCT02311361|Radiation|Sterostatic body radiation therapy (SBRT)|8Gy x 1; 5Gy x 5
1974614|NCT02311374|Other|Brain connectivity and physiology|fMRI to measure ADC during wake and sleep states
1974615|NCT02311582|Biological|MK-3475|
1974616|NCT02311582|Device|MRI-guided laser ablation|
1974617|NCT02311582|Procedure|Surgical resection/debulking|"Optional
Standard of care"
1974618|NCT02311582|Procedure|Biopsy|"If no surgical resection/debulking
Phase II patients only"
1974619|NCT02311582|Procedure|Blood draw for research purposes|"Phase II patients only
Drawn prior to MLA or biopsy/surgical resection procedure, and immediately prior to each the first dose of MK-3475. Subsequently, research blood will be drawn at doses 2, 4, 6, 9, 18, and 36."
1974620|NCT02311582|Procedure|Cervical lymph node fine needle aspiration|"Optional
Time of surgical procedure and 6 weeks +/- 1 week after surgical procedure"
1974621|NCT02307656|Drug|Atazanavir|
1974622|NCT02307656|Drug|Cobicistat|
1974623|NCT02307656|Drug|Active Pharmaceutical Ingredient|
1974635|NCT02305563|Drug|BMS-936564|
1974636|NCT02305563|Drug|Cytarabine|
1974637|NCT02301364|Drug|Buparlisib (BKM120)|Buparlisib 100 mg once daily.
1974638|NCT02298946|Drug|AMP-224|10mg/kg on day 1 then every 14 days for a total of 6 doses.
1974639|NCT02298946|Radiation|Stereotactic Body Radiation Therapy(SBRT)|Dose Level 1: 8Gy x 1 day Dose Level 2: 8Gy x 3 days
1974640|NCT02298946|Drug|Cyclophosphamide|200mg/m2 IV on day 0
1974641|NCT02298933|Drug|Eculizumab|300 mg single-use vials
1974643|NCT02297139|Drug|Dasatinib|
1974650|NCT02287649|Other|blood sample|
1974651|NCT02287883|Other|Observational: Patient Activation and Engagement (PAE)|Observational: Patients receive care from clinics with either low or high levels of patient activation and engagement activities.
1974652|NCT02287025|Drug|Regorafenib (Stivarga, BAY73-4506)|Dose(s) 160 mg tablet (4 tablets per day at 40 mg) daily for 3 weeks on / 1 week off
1974653|NCT02287025|Other|iPAD application|Investigators were supported with enhanced drug-specific information via an iPad application (SMART).
1974654|NCT02287025|Other|Bayer specialist|The treating investigator will have access to the prescribing information and have ability to consult a Bayer specialist, should questions arise.
1974660|NCT02285114|Drug|F/TAF|F/TAF tablets administered orally once daily
1974661|NCT02285114|Drug|3rd ARV agent|A 3rd antiretroviral (ARV) agent of the participant's pre-existing regimen may include one of the following: boosted atazanavir (ATV), boosted lopinavir (LPV), boosted darunavir (DRV), efavirenz (EFV), nevirapine (NVP), raltegravir (RAL), or dolutegravir (DTG). Cohort 2, Group 1 will receive only boosted PIs (ATV, LPV or DRV).
1974662|NCT02282878|Dietary Supplement|High/Low Sodium Diet|All patients will receive 2 weeks of the high sodium diet followed by a 1 week washout and then 2 weeks of the low sodium diet
1974667|NCT02282904|Drug|Pre-Transplant Conditioning Medications|Busulfan, Fludarabine, Cyclophosphamide
1974668|NCT02282904|Other|Haploidentical Cellular Infusion|The infusion of the collected and donated haploidentical family member's cells to serve as a graft for the patient recipient
1974669|NCT02282904|Drug|Post-Trasnplant Medications|Sirolimus, Cyclophosphamide
1974670|NCT02282904|Radiation|Total Body Irradiation|Total body irradiation as part of the conditioning regimen, this is within clinical scope of practice for pre-transplant treatment
1974671|NCT02281773|Drug|BI 409306 100 mg QD|
1974672|NCT02281773|Drug|BI 498306 50 mg QD|
1974673|NCT02281773|Drug|Placebo|
1974674|NCT02281773|Drug|BI 498306 25 mg QD|
1974675|NCT02281773|Drug|BI 409306 10 mg QD|
1990278|NCT02114138|Procedure|pathogenesis of perioperative acute kidney injury|understand pathogenesis of perioperative acute kidney injury in elective and emergent surgery
1990279|NCT02114138|Diagnostic Test|urine collection|urine collection will be performed on both the control group and hospitalized participants
1994506|NCT02988947|Other|PNE+HyP|This is a combined PNE and Hypnosis psychological intervention. PNE is a cognitive based approach that highlights the biopsychosocial model of pain and focuses on neurophysiological and neurobiological processes and pain representation. Hypnosis aims at promoting pain control, increasing positive coping strategies, and targeting positive psychological variables.
1994509|NCT02987530|Drug|Dolutegravir|Oral use, 50mg/day
1974676|NCT02281760|Drug|Dabrafenib Mesylate|Description: Dabrafenib mesylate (GSK2118436B) is a potent and selective BRAF kinase inhibitor. This inhibition suppresses downstream activity of pERK, a biomarker, and has antiproliferative activity against BRAF mutant tumors.The mode of action is consistent with ATP competitive inhibition.
1974677|NCT02281760|Drug|Trametinib Dimethyl Sulfoxide|Trametinib dimethyl sulfoxide is a reversible, highly selective, allosteric inhibitor of mitogen-activated extracellular signal regulated kinase 1 (MEK1) and MEK2. Tumor cells commonly have hyperactivated extracellular signal-related kinase (ERK) pathways in which MEK is a critical component. Trametinib dimethyl sulfoxide inhibits activation of MEK by RAF kinases and MEK kinases.
1974678|NCT02280824|Procedure|CA-TAVR|Transcaval acesss for transcatheter
1974681|NCT02279888|Device|CardioMEMS HF System|Pulmonary artery pressure sensor
1974682|NCT02279732|Biological|Paclitaxel|
1974683|NCT02279732|Biological|Carboplatin|
1974684|NCT02279732|Biological|Ipilimumab|
1974685|NCT02279732|Other|Placebo|0.9% sodium chloride injection, USP, or 5% dextrose injection
1974686|NCT02280252|Drug|Paclitaxel|Paclitaxel (including Abraxane), 30 mg/m2 twice per week. Paclitaxel will be given IV over 1 hour, Abraxane® will be administered over 30 min, and administered on a Monday/Thursday or Tuesday/Friday schedule.
1974687|NCT02280252|Radiation|Radiation therapy|Patients will receive a total dose of 45 Gy to the breast, axilla and supraclavicular area at 1.8 Gy/fraction, +14 Gy to the original palpable tumor at 2 Gy/fraction (total 32 fractions)
1974691|NCT02274766|Drug|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
1918309|NCT00900497|Biological|White Blood Cells/Granulocytes|Granulocytes collected by apheresis, cross-matched for ABO-Rh and common antibodies, HLA-mismatched to avoid engraftment
1974692|NCT02274766|Other|Placebo|Oral capsules to be administered once nightly at bedtime, for 13 weeks.
1974693|NCT02274415|Biological|Vaccination with the combined vaccine (Prevenar13 ®)|
1974694|NCT02274415|Biological|Vaccination with the polysaccharide vaccine (Pneumo 23 ®)|
1974695|NCT02273960|Drug|BMS-986004|
1974696|NCT02272647|Drug|IM Saline Placebo (0.25 ml)|
1974697|NCT02272647|Drug|IM Estradiol valerate (2.5 mg)|
1974698|NCT02272647|Drug|IM Saline Placebo (0.5 ml)|
1974699|NCT02272647|Drug|IM Estradiol valerate (5.0 mg)|
1974700|NCT02272647|Drug|Oral Micronized Progesterone|
1974701|NCT02272647|Drug|Oral Placebo|
1974702|NCT02272647|Drug|Ghrelin (0.3 ug/kg)|
1974703|NCT02272647|Drug|Medroxyprogesterone - Acetate|
1974704|NCT02272647|Drug|Oral Placebo|(in lieu of Medroxyprogesterone)
1974708|NCT02268903|Drug|Diuretics : Furosemide|Furosemide 80mg in one single direct intra venous injection
1974709|NCT02268903|Drug|Placebo|Placebo in one single direct intra venous injection
1974710|NCT02269072|Drug|Testosterone|Testosterone cream applied daily for two weeks
1974711|NCT02269072|Drug|Nesiritide|Administered IV once during the study
1974712|NCT02269072|Drug|Leuprolide|Administered twice during the study by injection
1974713|NCT02269072|Drug|Anastrozole|Daily pill for 8 weeks
1974714|NCT02269072|Drug|Placebo|Inert cream otherwise identical to testosterone cream applied daily for two weeks
1974716|NCT02265796|Drug|Ranolazine|"Ranolazine 500mg tablet
500mg tablet two times per day for 7 days then,
500mg tablet (1000mg) two times per day for 15 weeks"
1974717|NCT02265796|Drug|Sugar pill|"500mg tablet two times per day for 7 days then,
500mg tablet (1000mg) two times per day for 15 weeks"
1974718|NCT02262832|Drug|Metreleptin|
1974720|NCT02262819|Other|Killed Bacteria|S. aureus, commensal coagulase-negative staphylococcal species, and Gram-negative commensals, such as Roseomonas and Pseudomonas species
1974724|NCT02258451|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|Up to 6 cycles of radium-223 dichloride 50kBq/kg body (55 kBq/kg after implementation of National Institute of Standards and Technology [NIST] update)
1974725|NCT02258451|Drug|Placebo (saline)|Up to 6 cycles of saline injection
1974726|NCT02258451|Drug|Exemestane|25 mg once daily with or without food Dosage and administration of exemestane must be in compliance with the local labels in each of the participating countries and in line with standard practice guidelines.
1974727|NCT02258451|Drug|Everolimus|10 mg tablet once daily after a meal Dosage and administration of everolimus must be in compliance with the local labels in each of the participating countries and in line with standard practice guidelines.
1974730|NCT02256189|Drug|Sitagliptin|Treatment with sitagliptin 100mg QD for four weeks followed by hyperinsulinemic hypoglycemic clamp
1974731|NCT02256189|Drug|Placebo|Treatment with placebo QD for four weeks followed by hyperinsulinemic hypoglycemic clamp
1974735|NCT02249065|Drug|Brimonidine|
1974764|NCT02233829|Drug|Methylphenidate|Brain Dopamine Reactivity
1974765|NCT02233829|Drug|C-11 Raclopride|Brain Dopamine Receptor
1974773|NCT02233088|Behavioral|ELM Group|"ELM participants are trained to portion their meals according to the Perfect Plate method, a modified version of the USDA's ChooseMyPlate.gov. The stress management focuses on mindful living, cognitive restructuring; the enhancement of positive emotions. The physical activity component focuses on reduction of sedentary activity (by increasing daily step counts) and moderate-to-vigorous physical activity."
1974774|NCT02233088|Other|ELM Classes|ELM classes will be administered through Rush Generations program and focus on health education.
1974775|NCT02233088|Other|ELM Individual|ELM Individual arm participants will receive education materials on metabolic syndrome and diet, exercise, stress reduction recommendations. The participants will be recommended to follow these guidelines and discuss/seek support from their health care provider (visits at baseline, 3 and 6 months will be recommended.
1974776|NCT02231892|Device|TMS|HAC coil (real rTMS or sham rTMS)
1974777|NCT02231879|Drug|Plerixafor|Plerixafor (Mozobil ) is a specific antagonist of the chemokine receptor CXCR4. It is FDA approved since 2008 for use in combination with G-CSF to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin s lymphoma (NHL) and multiple myeloma (MM). CXCR4 is the gene mutated in WHIM syndrome and is hyperfunctional in this disorder. Our previous studies have demonstrated that low dose treatment of WHIM patients with this agent is safe and suggested efficacy at reducing infection frequency and improving wart burden.
1974778|NCT02231879|Drug|G-CSF|G-CSF (NeupogenTM) is FDA-licensed and the standard of care for severe chronic neutropenia, and will be used as the control or comparator drug in this study. G-CSF is a recombinant human protein produced in E. coli that is identical in amino acid sequence with the exception of an additional N-terminal methionine to a naturally occurring cytokine made by human monocytes, fibroblasts, and endothelial cells. G-CSF acts on specific receptors to regulate the proliferation and differentiation of neutrophil progenitors, and augments the bone marrow release and function of mature neutrophils. It has minimal effects on other hematopoietic cell types. Its effect on bone marrow release of neutrophils is mediated in part by interfering with CXCL12 availability at CXCR4.
1974779|NCT02231853|Biological|MVST|MVST Infusion
1974780|NCT02231853|Biological|MVSTr|"PBMCs will be collected by apheresis prior to mobilization for Hematopoietic stem cells collection, donor apheresis will be used partially to prepare DLIs per PI specification and remaining will be further processed by elutriation.
Monocytes and Lymphocytes are cryopreserved for further manufacture of MVSTr."
1974784|NCT02226861|Device|CliniMACS CD34 selection system|Stem cells will be selected with the CliniMACS system before transplant.
1974785|NCT02225132|Drug|Hydroxyurea|
1974792|NCT02223286|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score
1974795|NCT02219841|Procedure|radiofrequency catheter ablation|
1918402|NCT00878592|Behavioral|Dietary and life style modification|This group will receive a weight management and life style modification program. It consists of up to 6 weekly sessions of nutritional and physical exercise education. These initial sessions will concentrate on lifestyle modifications program including healthy food selections, emphasizing reduced fat consumption (<=30% of daily calories) and restriction of proteins to create a daily negative energy balance of ~500 kcal/day. Participants will be encouraged to start with 10 minutes of outdoor or at home physical activity such as walking or cycling then gradually increase the activity duration up to 30 minutes daily.
1974798|NCT02217345|Drug|Growth hormone|
1974799|NCT02217345|Drug|Placebo|
1974800|NCT02215967|Drug|Cyclophosphamide|300 mg/m2 IV over 30 minutes on days -5, -4, and -3
1974801|NCT02215967|Drug|Fludarabine|30 mg/m2 IV over 30 minutes immediately following the cyclophosphamide on day -5, -4, and -3
1974802|NCT02215967|Biological|Anti-BCMA CAR T cells|0.3x106- 15.0x106 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
1974804|NCT02211768|Procedure|MRI, FDG-PET/CT scans|Per standard of care
1974805|NCT02211768|Procedure|[18F]-FLT-PET/CT scans|Per research study
1974810|NCT02208102|Procedure|Radio-frequency catheter ablation|
1974811|NCT02207231|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4 and q8w thereafter through Week 252 (Group 1). 100 mg by subcutaneous injection at Weeks 16, 20 and q8w thereafter through Week 252 (Group II). 100 mg by subcutaneous injection at Week 52 and q8w thereafter through Week 252 (Group III).
1974812|NCT02207231|Drug|Placebo for guselkumab|Subcutaneous injections to maintain the blind.
1974813|NCT02207231|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 47.
1974814|NCT02207231|Drug|Placebo for adalimumab|Subcutaneous injections to maintain the blind.
1974817|NCT02203513|Drug|LY2606368|105 mg/m2 IV once every 14 days of a 28 day cycle
1974818|NCT02203526|Drug|TEDDI|Temozolomide, etoposide, doxil, dexamthasone, ibrutinib (TEDDI) given every 3 weeks for up to six cycles for second cohort and 5 cycles (cycles 2-6) for first cohort.
1974819|NCT02203526|Biological|Rituximab|Rituximab given with TEDD and TEDDI every 3 weeks for up to 6 cycles
1974820|NCT02203526|Drug|Cytarabine|Cytarabine given via Ommaya reservoir (IT therapy) on Day 1 and day 5 of Cycles 2-6 for both cohorts.
1974821|NCT02203526|Drug|TEDD|Temozolomide, etoposide, doxil, dexamthasone, (TEDD) given on first cycle for first cohort.
1974822|NCT02203526|Drug|Ibrutinib|Ibrutinib given on Day -14 to Day -1 on Cycle 1 for both groups.
1974828|NCT02202434|Device|Lotus Valve System|Transcatheter aortic valve replacement (TAVR) with the Lotus Valve System
1974829|NCT02202434|Device|CoreValve Transcatheter Aortic Valve Replacement System|Transcatheter aortic valve replacement (TAVR) with CoreValve Transcatheter Aortic Valve Replacement System
1974830|NCT02202434|Device|LOTUS Edge Valve System|Transcatheter aortic valve replacement (TAVR) with the LOTUS Edge Valve System
1974831|NCT02199496|Biological|Ustekinumab|Ustekinumab is an IL-12 and IL-23 antagonist biologic drug that is FDA approved to treat psoriasis and Crohn's disease. Ustekinumab may offer a specific and welltolerated new treatment for CVID-related enteropathy.
1974833|NCT02196922|Device|Telehealth Self Management (TSM)|Experimental: Telehealth Self Management (TSM) TSM is defined as a weekly clinical telehealth visit and self-monitoring of daily vital signs utilizing a subject monitor which connects from the subject's residence, via a standard telephone line to the provider station.
1974834|NCT02196922|Other|Standard of Care|Patients receiving standard of care experience typical chronic care management received by Medicare patients.
1974843|NCT02194166|Drug|Trastuzumab|Trastuzumab IV or SC will be administered as described.
1974844|NCT02194166|Drug|Paclitaxel|Paclitaxel will be administered in accordance with local hospital practice.
1974845|NCT02194166|Drug|Docetaxel|Docetaxel will be administered in accordance with local hospital practice.
1918444|NCT00867815|Drug|Diagnostic procedures|The patients will not receive any study drug in this study. The patients will have ophthalmological (eye) examinations, blood work and will complete an interview
1974855|NCT02190279|Drug|18F DCFBC|Each subject will receive a single i.v. dose of 18F DCFBC by bolus injection at a rate of approximately 1 ml/3-5 sec.
1974860|NCT02184585|Drug|Treatment sequence A|FDC 1 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CJ) and tamsulosin pellets (0.2 mg) version 1.
1974861|NCT02184585|Drug|Treatment sequence B|FDC 2 - Fixed dose combination capsule of dutasteride and tamsulosin hydrochloride (0.5 mg/0.2 mg). Each capsule will contain dutasteride (0.5 mg) (CL) and tamsulosin pellets (0.2 mg) version 2.
1974862|NCT02184585|Drug|Treatment sequence C|Co-administration of dutasteride 0.5 mg capsule (Oblong, size 6, dull yellow capsules: Commercially available) and tamsulosin hydrochloride 0.2 mg tablet (White, round standard convex tablet: Commercially available).
1974865|NCT02181595|Other|Group reading and discussion|
1974870|NCT02179515|Biological|MVA-brachyury- TRICOM|It is an active cancer immunotherapy administered via subcutaneous injection.
1974872|NCT02174731|Drug|Roxadustat|Roxadustat will be administered orally three times a week (TIW) to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
1974873|NCT02174731|Drug|Epoetin alfa|Epoetin alfa will be administered TIW consistent with approved prescribing information for epoetin alfa to achieve an Hb level of 11 g/dL and maintain a Hb level of 11±1 g/dL.
1974885|NCT02163681|Drug|Hyperpolarized Helium-3 MRI of the chest|hyperpolarized helium-3 is an inhaled gaseous contrast agent for MRI and permits the acquisition of high quality imagined of lung ventilation.
1974886|NCT02163226|Radiation|Hypofractionated Radiation Treatment|Participants receive standard hypofractionated regimen of 3 Gy x 10 fractions, 1 radiation treatment a day for 5 days in a row.
1974887|NCT02163226|Radiation|One Radiation Treatment|12 Gy x 1 fraction or 16 Gy x 1 fractions adaptively depending on the size of the metastases or gross tumor volume (GTV).
1974888|NCT02163226|Behavioral|Questionnaire|Questionnaire completion at months 1, 2, 3, 4, and 6 and then every 3 months after that for at least 3 years. Questionnaires ask about pain, pain relief, and quality of life.
1974894|NCT02156804|Drug|Nivolumab (BMS-936558)|
1974895|NCT02156089|Other|Highly unsaturated omega-3 fatty acids|Nitrient - Matched Placebo of 3 g/d of macademia nut oil (in comparison to 3 g/d of omega-3 highly unsaturated fatty acids).
1974897|NCT02155465|Drug|Ruxolitinib|"Ruxolitinib 10mg PO BID
Ruxolitinib 15mg PO BID
Ruxolitinib 20mg PO BID"
1918480|NCT00859885|Drug|Antithrombotic treatment|antiplatelets, anticoagulants
1918481|NCT00859885|Device|percutaneous device closure of PFO|umbrella device for PFO closure
1974898|NCT02155465|Drug|Erlotinib|Erlotinib 150mg PO QD
1974899|NCT02154568|Drug|hyperpolarized helium MRI of the chest|Using hyperpolarized helium as an inhaled gaseous contrast agent for MRI, we will measure the velocity of inhaled breath in the trachea.
1918484|NCT00858702|Drug|olmesartan medoxomil and a CCB|olmesartan medoxomil tablets and a CCB tablet once daily for 8 weeks
1918485|NCT00858702|Drug|olmesartan medoxomil and a diuretic|olmesartan medoxomil tablets and a diuretic tablet, once daily for 8 weeks
1974900|NCT02153983|Drug|Colchicine 0.6 mg given|Colchicine 0.6 mg given twice daily
1974901|NCT02153983|Drug|Placebo capsules given|Placebo capsules given twice daily
1974902|NCT02153957|Behavioral|Physical Activity|12 weeks of enhanced physical activity with Zamzee monitor.
1974905|NCT02153918|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
1974906|NCT02153918|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
1974907|NCT02153905|Drug|Aldesleukin|Administered at a dose of 720,000 IU/kg (based on total body weight) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
1974908|NCT02153905|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1974909|NCT02153905|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
1974910|NCT02153905|Biological|Anti-MAGE-A3 HLAA* 01-restricted TCR|Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes via non-filtered tubing, gently agitating the bag during infusion to prevent cell clumping.
1974916|NCT02152631|Drug|Abemaciclib|Administered orally
1974917|NCT02152631|Drug|Erlotinib|Administered orally
1974922|NCT02142387|Other|BLS CPR program with dispatcher assisted CPR simulation|
1974923|NCT02141490|Drug|Ferumoxytol|All patients will receive a dose of 7.5mg/kg Fe Ferumoxytol
1974924|NCT02136914|Drug|ADS-5102|Oral capsules to be administered once nightly at bedtime, for 25 weeks
1974925|NCT02136914|Other|Placebo|Oral capsules to be administered once nightly at bedtime, for 25 weeks
1974928|NCT02132468|Drug|fosbretabulin tromethamine|60 mg/m2, IV on Day 1, 8 and 15 of a 3-week cycle; 3 cycles or until progression or unacceptable toxicity
1974929|NCT02130882|Drug|benralizumab|An afucosylated humanized antibody to IL-5 receptor alpha
1974930|NCT02130882|Other|Placebo|A sterile solution containing 20 mM histidine/histidine-HCl, 0.25 M trehalose dihydrate, and 0.006% (w/v) polysorbate 20, pH 6.0, in saline
1974933|NCT02124083|Drug|Vorinostat|Histone deactylase inhibitor
1974961|NCT02111850|Biological|Anti-MAGE-A3-DP4 TCR|On day 0 (one to four days after the last dose of fludarabine) cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes
1974962|NCT02111850|Drug|Cyclophosphamide|On days -7 and -6, Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
1974963|NCT02111850|Drug|Fludarabine|On days -5 to -1, Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1974964|NCT02111850|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
1974968|NCT02108002|Drug|Vorinostat|
1974969|NCT02107326|Device|Webdia Software|
1974970|NCT02106910|Device|Cytosponge|The Cytosponge is a simple, non-endoscopic device developed for endoscopic screening of subjects at risk for Barrett's esophagus (BE) by investigators at the University of Cambridge in the U.K. The Cytosponge is an ingestible gelatin capsule enclosing a compressed spherical polyurethane mesh sponge of 3 cm diameter, the center of which is attached to a string (Astralen, braided synthetic non-absorbable suture) (Figure 1). The capsule and string are swallowed with water. The string is held at the mouth without tension by means of a 7 cm cardboard tab attached to the string, and esophageal peristalsis and gravity move the capsule into the stomach. After 5 to 7 minutes (during which the gelatin capsule dissolves and the sponge is liberated), the sponge is withdrawn by gentle traction on the string and as it does so, collects cells from the lining of the esophagus. The sponge is placed in fixative for 48 hours, then the cells are pelleted, and processed into paraffin blocks
1974971|NCT02105766|Drug|Alemtuzumab|Immunosuppressant
1974972|NCT02105766|Drug|Sirolimus|Immunosuppressant
1974973|NCT02105766|Drug|Cyclophosphamide|Immunosuppressant
1974974|NCT02105766|Drug|Pentostatin|Immunosuppressant
1974975|NCT02105766|Drug|Radiotherapy|Immunosuppressant and myelosuppressant
1975006|NCT02101138|Drug|Dexpramipexole|Dexpramipexole (KNS 760704) is a synthetic amino-benzothiazole developed for use in amyotrophic lateral sclerosis (ALS)
1975007|NCT02102204|Drug|AMG 416|Subjects will be administered IV AMG 416 at the end of thrice weekly hemodialysis sessions. Dose titration is at the discretion of the Investigator and based upon the values of the site's local PTH and Ca (cCa, total Ca, or ionized Ca). The frequency of these laboratory draws is at the discretion of each individual Investigator. At a minimum however, Ca and albumin must be measured monthly. Subjects entering from the open-label parent studies 20120231 or 20120334 will receive an initial dose of AMG 416 identical to the last dose received in the parent study. Subjects entering from the randomized, double-blind parent Study 20120360, will receive an initial dose of 2.5 mg AMG 416. All subjects will receive AMG 416 until approximately 2.5 years after the first subject enrols.
1975015|NCT02096081|Drug|IncobotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
1975016|NCT02096081|Drug|OnabotulinumtoxinA|20U injection: equal aliquots of 0.1 mL (4U) to 5 injection points; mode of application: intramuscular injection
1975017|NCT02096471|Drug|PD-0325901|
1975018|NCT02093533|Drug|Eculizumab|
1975022|NCT02090556|Drug|Abatacept|
1975023|NCT02089217|Procedure|Carotid endarterectomy (CEA)|Carotid endarterectomy
1975024|NCT02089217|Device|Carotid Stenting (CAS)|Carotid stenting
1975025|NCT02089217|Other|Intensive Medical Management - no CEA|Intensive Medical Management alone - no CEA
1975026|NCT02089217|Other|Intensive Medical Management - no CAS|Intensive Medical Management alone - no CAS
1975027|NCT02081638|Drug|Aspirin 81 mg daily|81 mg tablet, daily
1975028|NCT02081638|Drug|Atorvastatin 40 mg daily|40 mg tablet, daily. In subjects on certain antiretroviral medications, ATV dosing will be adjusted in accordance with DHHS guidelines .
1975031|NCT02069080|Drug|64-Cu-plerixafor|"Five subjects with CXCR4-positive tumor sample(s) will be administered an initial intravenous (IV) infusion of 64Cu-plerixafor of up to 8+0.8 mCi (0.48+0.048 rem) not to exceed 5 g of 64Cu-plerixafor at Day 0. These subjects will undergo an initial lowdose CT scan followed by 3 consecutive torso PET scans as soon as practical after the infusion, and 2 additional PET/CT scans at 4 hours +/- 1 hour and 24 hours +/- 2 hours post-infusion. Human dosimetry will be calculated based on these results, and a maximum dose will be used, not to exceed the calculated limit of a total effective dose of 5 rem, or the radiation exposure limit for each organ.
The remaining subjects with CXCR4-positive (n=15) and CXCR4-negative (n=5) tumor sample(s) will be administered 64Cu-plerixafor at the same or a newly calculated dose and will undergo 1 PET/CT scan between 1 and 4 hours post-infusion."
1975035|NCT02065011|Drug|UshStat|Long-term follow up of patients who received UshStat in a previous study
1975038|NCT02064517|Device|MTA|Creation of a barrier apicale in the MTA
1975039|NCT02064517|Device|Hydroxide of calcium|Revascularisation pulpaire with some hydroxide of calcium
1975043|NCT02054104|Biological|H1299 Lysate Vaccine|1x10^8 H1299 cells mixed with 1 mL ISCOMATRIX adjuvant diluted to 1 ISCO units administered in 2 IM injections q cycle. (1 cycle = 28 days) for 6 cycles if no toxicity and then up to an additional 6 cycles if immune response is evident after the first 6 cycles.
1975044|NCT02054104|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle for 6 cycles if no toxicity and then up to an additional 6 cycles if immune response is evident after the first 6 cycles. Treatment is suspended while evaluating immune response.
1975045|NCT02054104|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle for 6 cycles if no toxicity and then up to an additional 6 cycles if immune response is evident after the first 6 cycles. Treatment is suspended while evaluating immune response.
1994510|NCT02987530|Drug|Darunavir-cobicistat|Oral use, 800-150mg/day
1994511|NCT02987530|Drug|Emtricitabine-Tenofovir|Oral use, Emtricititabine : 200mg/day Ténofovir : 245mg
1994512|NCT02987998|Drug|Cisplatin|Cisplatin (50mg/m2 IV D1, 8, 29, 36)
1994513|NCT02987998|Drug|Etoposide|Etoposide (50mg/m2 IV D1-5, 29-33)
1994514|NCT02987998|Drug|Pembrolizumab|Pembrolizumab (200mg IV D1, 21, 42)
1994515|NCT02987998|Drug|Radiation|Radiation (1.8Gy/D to 45Gy in 25 fractions)
1994516|NCT02988609|Device|fMRI|fMRI at 3 different times after concussion: just after concussion (V1), once players have clinically recovered (V2) and 3 months after V2 (V3).
1994518|NCT02987543|Drug|olaparib|300 mg (2x 150 mg tablets) twice daily
1994519|NCT02987543|Drug|enzalutamide|160 mg (4 x 40 mg capsules) once daily
1994520|NCT02987543|Drug|abiraterone acetate|1,000 mg (4 x 250 mg tablets) once daily
1994521|NCT02987881|Behavioral|Home-based aerobic exercise and nutritional counseling|Moderate walking and running with nutritional counseling at study visits.
1994522|NCT02987205|Device|Revanesse Ultra|NLF correction
1994523|NCT02987205|Device|Restylane|NLF Correction
1994526|NCT02986360|Behavioral|Vidscrip educational video|Vidscrip educational video provide to women
1994527|NCT02985658|Drug|Veliparib|"Patients will start veliparib at 300 mg po BID days 1 through 21 of the first 21 day cycle, then increase to 400 mg po BID days 1 through 21 of each subsequent cycle, as tolerated by the patient.
At the treating investigator's discretion, and with principal investigator approval, veliparib may be used in combination with cisplatin and/or vinorelbine. Veliparib (300mg) will be dosed po BID on Days 1 through 14 of each 21-day cycle.
The patient will receive therapy as long as there is therapeutic benefit"
1994528|NCT02985658|Drug|Cisplatin|Cisplatin will be administered intravenously (75 mg/m2) on Day 1 of each cycle
1994529|NCT02985658|Drug|Vinorelbine|Vinorelbine will be administered intravenously on Day 1 and Day 8 of each 21-day cycle
1994530|NCT02985541|Drug|Levonorgestrel IUS (Mirena, BAY86-5028)|Levonorgestrel intrauterine delivery system (IUS) with an initial in vitro release rate of 20 μg Levonorgestrel per day
1994536|NCT02982460|Other|Isoinertial + eccentric exercise|A session of isionertial + eccentric exercise covers the activity, strength and endurance of scapular muscles.
1994537|NCT02982460|Other|Eccentric exercise|A session of eccentric exercise covers the strength of scapular muscles.
1994538|NCT02981862|Other|CaptHPV method|"10 ml of blood sample will be made before the beginning of all treatment. This blood sample will be sent to the CERBA Laboratory for analysis.
In parallel, a standard anatomopathological and virological analysis will be carried out from a biopsy or from a tumor sample by the Tumor Biology Unit at Lorraine Institute of Oncology
The results of both analyzes will be compared blindly."
1975063|NCT02042157|Behavioral|Bidet use|Participants used a bidet, a device installed on the toilet that provides fresh water to help clean the bottom and genitalia after having a bowel movement or urinating.
1975064|NCT02042157|Other|Regular toileting|Patients in the control arm will toilet as usual.
1975065|NCT02037295|Dietary Supplement|Nutritional (over and underfeeding)|
1975066|NCT02037295|Dietary Supplement|Oral Vancomycin|
1975067|NCT02034409|Device|Pulsed Low Intensity Ultrasound|20 minutes daily for 48 weeks
1975068|NCT02034409|Device|Sham Comparator|20 minutes daily for 48 weeks
1975076|NCT02027701|Biological|IgPro20|
1975077|NCT02023983|Other|Early discharge|Early discharge (within 72 hours) of selected patients with low risk of complications after myocardial infarction with ST segment elevation, treated with successful percutaneous coronary intervention
1975078|NCT02023983|Other|Standard discharge|Discharge after myocardial infarction with ST segment elevation in a standard way accordingly with present practice and physician´s decision (usually 4th-7th day)
1975080|NCT02019641|Other|Aerobic Exercise Training|
1975081|NCT02019641|Other|Education|
1975082|NCT02019758|Drug|Oral Viscous Budesonide|Oral Viscous Budesonide - 1mg/4mL, 4mL of slurry twice daily
1975083|NCT02019758|Drug|Fluticasone MDI|Fluticasone multi-dose inhaler - 4 puffs twice daily (880 mcg, twice daily)
1975084|NCT02019758|Drug|Placebo slurry|Slurry of sucralose - 4mL twice daily
1975085|NCT02019758|Drug|Placebo inhaler|Placebo inhaler - 4 puffs twice daily
1975086|NCT02019693|Drug|INC280|Supplied by Novartis as film-coated tablet for oral use.
1975087|NCT02019667|Drug|SGS-742|
1975088|NCT02019667|Drug|Placebo|
1975089|NCT02015104|Biological|TICE Bacillus Calmette-Guerin (BCG)|TICE BCG for intravesical use, is an attenuated, live culture preparation of the Bacillus of Calmette and Guerin (BCG) strain of Mycobacterium bovis
1975090|NCT02015104|Biological|PANVAC|A recombinant virus vector vaccine containing genes for human CEA, MUC-1 and three co-stimulatory molecules (designated TRICOM): B7.1, ICAM-1 (intercellular adhesion molecule-1), and LFA-3 (leukocyte function-associated antigen-3).
1975091|NCT02015065|Drug|Vandetanib|Administered orally once per day continuously using a 28 day cycle until disease progression or unacceptable toxicity
1975092|NCT02014818|Device|CoCr-EES|
1975093|NCT02014337|Drug|Mifepristone and Eribulin in combination|Single Arm, Two Parts Part 1: Dose Escalation Phase to determine MTD and RP2D in up to 20 patients Part 2: Dose Expansion Phase at RP2D in 20 patients
1975095|NCT02011945|Drug|Dasatinib|
1975096|NCT02011945|Drug|Nivolumab|
1975097|NCT02010151|Other|NAD-CPR|When Dispatcher detects OHCA, short message service (SMS)about the OHCA event and information about the location of nearest AED is sent to trained laypersons within geographically accessible area.
1975098|NCT02009384|Drug|Ipilimumab|administration of IV ipilimumab for up to 4 cycles
1975114|NCT02001714|Behavioral|Group Behavioral Treatment|Group Behavioral Treatment class is a two hour class taught by certified interventionist covering urinary system anatomy, bladder health and self management strategies, pelvic floor training, pelvic floor muscle contracting techniques, and bladder training. Slides and handouts supplement the content of the class.
1994539|NCT02981836|Biological|Investigational live attenuated varicella vaccine|The investigational vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
1994540|NCT02981836|Biological|diluent of lyophilized vaccine|The diluent of lyophilized vaccine was manufactured by Sinovac (Dalian) Vaccine Technology Co., Ltd.
1994541|NCT02981563|Other|Time Together|For a fixed time during the day, staff dedicates their time to exclusively engage with the patients. Different activities will be offered to both patients and staff, such as playing board games, taking a walk, or having individual conversations. Other duties of more administrative nature, visits and meetings will be performed at other times during the day. Through this, opportunities for interaction are both created and protected.
1994542|NCT02980744|Behavioral|Sedentary behaviour intervention|The intervention is based on socio-cognitive theory and focuses on building and increasing confidence (self-efficacy) to make a behaviour change. Output from the activity monitor (i.e. activPAL) will provide visual feedback of usual activity. Action plans targeting areas of high sedentary behaviour will be developed. A wrist-worn Misfit activity monitor is used as a self-monitoring tool throughout the intervention. This commercially available device provides activity information in real time, and sets daily targets for physical activity. A checklist will be used to address: 1) use of walking aids; 2) incidence of falls; 3) review and progression of home exercise program; and 4) quality of walking. The intervention visits will be conducted by a physical therapist.
1994543|NCT02979613|Drug|TAF|25 mg tablet administered orally once daily
1994544|NCT02979613|Drug|TDF|300 mg tablet administered orally once daily
1994545|NCT02979613|Drug|TAF Placebo|Tablet administered orally once daily
1994546|NCT02979613|Drug|TDF Placebo|Tablet administered orally once daily
1994547|NCT02979587|Device|Harmony TPV System|The Harmony™ TPV is comprised of a 22mm porcine pericardium valve, sewn to a polyester-covered nitinol frame. The Harmony Delivery System is a 25 Fr coil loading catheter delivery system.
1994548|NCT02979015|Drug|alirocumab SAR236553 (REGN727)|"Pharmaceutical form: Solution for injection
Route of administration: Subcutaneous"
1994549|NCT02979015|Drug|placebo|"Pharmaceutical form: Solution for injection
Route of administration: Subcutaneous"
1975117|NCT02001051|Procedure|Adrenalectomy|Surgery to remove tumor when enrolled in the protocol.
1975118|NCT02001051|Other|Observation|Observation for 6 months prior to surgery
1975124|NCT01990560|Drug|Mifepristone|All patients in the study will receive daily Mifepristone for 6 months and primary and secondary outcomes will be assessed before and after the 6 month treatment period
1975125|NCT01989546|Drug|BMN 673|PARP inhibitor; has been shown to cause single-agent synthetic lethality in BRCA1/2- and PTEN-deficient cell lines, and has potent antitumor activity in animal models of tumors harboring mutations in DNA repair pathways.
1975126|NCT01989533|Biological|Ad4-mgag|
1975127|NCT01989533|Biological|Ad4-EnvC150|
1975130|NCT01988285|Other|Specimen Collection|Blood collection, possible saliva collection, possible urine collection, and biopsy collection
1975131|NCT01988285|Other|Questionnaires|Subjects will complete a questionnaire utilizing validated symptom-specific instruments (Mayo Dysphagia Scale; GERD-HRQL Scale). The questionnaire will also record patient demographics, medical history, and current and past medication use
1975132|NCT01981551|Drug|PF-03084014|Treatment with the selective small-molecule >=-secretase inhibitor PF- 3084014 caused significant tumor shrinkage in patients with unresectable desmoid tumors in an early-phase clinical trial.
1975133|NCT01981525|Drug|Metformin|Treatment will be administered primarily on an outpatient basis. Patients will be instructed to take 500 mg metformin by mouth 1, 2 or 3 times a day or 1000 mg twice per day depending on dose level. Patients will receive metformin at level 1 dose for 2 weeks. If dose is tolerated, patient will receive level 2 dose for 2 weeks and if tolerated will escalate to level 3 dose, and if tolerated will escalate to level 4 dose. Metformin will be taken for 14 weeks.
1975134|NCT01978535|Drug|Iron infusion|5 mg/kg of intravenous iron sucrose supplied as Venofer (TM) with a maximum dose of 200mg. Iron sucrose will be diluted to 1 mg of elemental iron in 1 mL of NaCl 0.9% with a maximum volume of 210 mL.
1975135|NCT01978535|Drug|Normal saline infusion|Normal saline (NaCl 0.9%) 5 mL/kg up to a maximum volume 210 mL
1975140|NCT01967537|Drug|68Gallium DOTATATE|Fasting is not required prior to the imaging study. An IV line with a large bore (21 gauge or more) will be placed preferably in the antecubital vein, and, with the patient supine, around 5mCi of the 68Ga-DOTATATE will be administered intravenously, followed by incubation for approximately 60 minutes. Then the patient will be positioned in a PET/CT scanner and images from the upper thighs to the base of the skull will be obtained. In patients with tumor induced osteomalacia, images from the top of the head to the toes will be obtained.
1975141|NCT01967537|Procedure|Radio-guided surgery|Using 68Gallium DOTATATE
1993059|NCT03251287|Diagnostic Test|Exercise Stress Transthoracic Echocardiogram|On the second visit day of this arm, participants will be asked to lie, semi-erect, on an exercise bed for up to 90 minutes. The echocardiogram will be performed at rest and during peak exercise. The exercise will be in the form of a pedal bike. The exercise levels will be worked out from an upright bicycle exercise test completed by the participants prior to randomization.
1993062|NCT03249844|Drug|Methylprednisolone + prednisolone|"The experimental intervention consists of 5 consecutive days Methylprednisolone at a daily single intravenous dose of 20 mg/kg body-weight (max 1 g/day) followed by a 6-week course of tapering Prednisolone given at a daily single oral dose in the morning:
week 1, oral Prednisolone 2 mg/kg/day (max 60 mg/day),
week 2, oral Prednisolone 1.5 mg/kg/day (max 50 mg/day),
week 3, oral Prednisolone 1 mg/kg/day (max 40 mg/day),
week 4, oral Prednisolone 0.75 mg/kg/day (max 30 mg/day),
followed by a further taper over 2 weeks."
1993063|NCT03249961|Device|Sham TDCS|Placebo stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
1975143|NCT01967576|Drug|Axitinib (AG-013736)|Axitinib will be given as self-administered oral doses at the initial level of 5 mg every 12 hours continuously in a 28-day cycle. All patients will be evaluated for dose escalation beginning at week 4. In addition to the starting dose level of 5 mg every 12 hours, two additional levels (7 and 10 mg on every-12-hour schedules) will be considered. An interval of at least 4 weeks must elapse between any dose escalations.
1975144|NCT01967823|Biological|Anti-NY ESO-1 mTCR PBL|Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-NY ESO-1 mTCR PBL and high dose aldesleukin. On day 0,cells (1x10e9 to 2x10e11) will be infused intravenously on the Patient Care Unit over 20-30 minutes.
1975145|NCT01967823|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
1975146|NCT01967823|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1975147|NCT01967823|Drug|Aldesleukin|Aldeskeukin 720,000 IU/kg IV (based on total body weight) over 15 minutes every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses)
1975148|NCT01966003|Drug|Carboplatin|Administered at an area under the concentration-time curve (AUC) 6 by IV infusion Q3W
1975149|NCT01966003|Drug|Paclitaxel|Administered 200 mg/m² IV Q3W
1975150|NCT01966003|Drug|ABP 215|Administered 15 mg/kg Q3W by IV infusion
1975151|NCT01966003|Drug|Bevacizumab|Administered 15 mg/kg Q3W by IV infusion
1975156|NCT01953913|Drug|Afatinib|Patient will receive afatinib once daily
1975158|NCT01950507|Drug|Budesonide|
1975159|NCT01950507|Drug|Fluconazole|
1975160|NCT01950507|Drug|Voriconazole|
1975161|NCT01946529|Drug|vincristine|Dosage and route of administration: Infants < 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m^2 IV day 1 (max. dose 2 mg).
1975162|NCT01946529|Drug|doxorubicin|Dosage and route of administration: Infants < 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants > 1 year of age 75 mg/m^2 CI over 48 hours, days 1-2.
1975163|NCT01946529|Drug|cyclophosphamide|Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
1975164|NCT01946529|Drug|ifosfamide|Dosage and route of administration: Infants < 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants > 12 months of age 1800 mg/m^2 IV over 60 minutes x 5 days, days 1-5.
1975165|NCT01946529|Drug|etoposide|Dosage and route of administration: Infants < 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children > 1 year 100 mg/m^2 daily IV over 60 minutes days 1-5.
1975166|NCT01946529|Drug|temozolomide|Dosage and route of administration: Temozolomide 100 mg/m^2 PO once daily, days 1-5.
1975167|NCT01946529|Drug|temsirolimus|Dosage and route of administration: Temsirolimus 35 mg/m^2 IV once day 1 and day 8.
1975168|NCT01946529|Drug|bevacizumab|Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
1975169|NCT01946529|Drug|sorafenib|Dosage and route of administration: 90 mg/m^2/dose PO BID
1975170|NCT01946529|Procedure|surgery|If participant meets the criteria, they will have surgical resection of their tumor.
1975171|NCT01946529|Radiation|radiation|If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
1975172|NCT01945333|Behavioral|Cognitive remediation|Cognitive remediation sessions include working on computer based cognitive exercises and participating in a verbal discussion.
1975183|NCT01931202|Drug|Escitalopram|Escitalopram is an antidepressant of the selective serotonin reuptake inhibitor (SSRI) class. It is FDA approved for the treatment of major depressive disorder (MDD) and generalized anxiety disorder (GAD) in adults and children over 12 years of age.
1975184|NCT01928394|Biological|Nivolumab|
1975185|NCT01928394|Biological|Ipilimumab|
1975186|NCT01928394|Drug|Cobimetinib|
1975190|NCT01924858|Drug|GSK2647544 oral|GSK2647544 100 mg will be supplied as a size 0 swedish orange hard gelatin capsules filled with white/slightly colored granule. Subjects will receive a single oral dose of GSK2647544 100 mg (2 X 50mg capsules) with 150 mL of tepid water approximately 2 hours prior to the IV infusion of [18F]-GSK2647544 and a PET scan.
1975191|NCT01924858|Drug|[18F]GSK2647544 IV bolus|[18F]GSK2647544 will be supplied as a clear, colourless solution free from visible particle. A maximum dose up to 2 mg with a maximum dose volume of 25 mL will be administered as IV bolus over 60 seconds.
1975197|NCT01920711|Drug|LCZ696|LCZ696 50mg, 100mg and 200 mg dosage strengths will be available for dose adjustments.
1975198|NCT01920711|Drug|Valsartan|Valsartan 40mg, 80mg and 160mg dosage strengths will be available for dose adjustments.
1975203|NCT01915212|Biological|HSV529|This is a replication-defective HSV-2 vaccine. 20 subjects in each of 3 study groups will be injected with vaccine or placebo in a 3:1 ratio as Day 0, Day 30, and Day 180.
1975205|NCT01908426|Drug|Cabozantinib tablets|
1975206|NCT01908426|Drug|Placebo tablets|
1975207|NCT01907100|Drug|Nintedanib|triple kinase inhibitor; 200mg starting dose
1975208|NCT01907100|Drug|Pemetrexed|backbone chemo
1975209|NCT01907100|Drug|Cisplatin|backbone chemo
1975210|NCT01907100|Drug|Cisplatin|backbone chemo
1975211|NCT01907100|Drug|Pemetrexed|backbone chemo
1975212|NCT01907100|Drug|Placebo|Nitedanib matching placebo
1975213|NCT01906944|Drug|Bupivacaine 0.25%|Bupivacaine is a local anaesthetic drug belonging to the amino amide group.
1975214|NCT01906944|Drug|Triamcinolone|Triamcinolone is a long-acting synthetic corticosteroid.
1975215|NCT01906021|Procedure|CT/CBCT thermometry method|The study consists of acquiring one or maximum two additional CT or CBCT of the liver during hepatic RFA or MWA and analyzing the images to obtain a temperature map
1975216|NCT01906021|Procedure|Ablation Probe|Temperature measured with thermocouples (current clinically approved method consisting of invasive needle placement for point measurement in area of concern)
1975217|NCT01898793|Drug|Fludarabine|
1975218|NCT01898793|Drug|Cyclophosphamide|
1975219|NCT01898793|Procedure|Leukapheresis|
1975220|NCT01898793|Biological|Cytokine-induced killer cells|
1975221|NCT01898793|Biological|Aldesleukin|
1975222|NCT01898793|Drug|ALT-803|
1975223|NCT01895777|Drug|dabigatran etexilate|Age and weight appropriate capsule dose (combination of 50 mg, 75 mg and 110 mg capsules) or pellets or oral liquid formulation
1975224|NCT01895777|Drug|standard of care|Low molecular weight heparin or vitamin K antagonist prescribed in an open label fashion for 3 months (these medications will not supplied in this study as IMP)
1975225|NCT01893775|Biological|Hu-Mik- Beta-1|Hu-Mik-Beta-1 every 3 weeks for a total of 3 doses (given on day 1, week 3 and week 6)
1975226|NCT01892774|Procedure|Radiofrequency catheter ablation|Extended PVAI plus ablation of non-pulmonary vein (non-PV) triggers and complex fractionated electrograms (CAFÉ)
1975227|NCT01891994|Drug|Eltrombopag|administration of eltrombopag for 6 months
1975228|NCT01888939|Other|Walking on a Treadmill|
1975229|NCT01888939|Other|Sedendary Activities Only|
1975235|NCT01878006|Genetic|OPRM1 AA118|
1975236|NCT01878006|Drug|Morphine|
1975237|NCT01878006|Drug|Placebo|
1975238|NCT01878006|Genetic|OPRM1 GX118|
1975239|NCT01875601|Biological|Recombinant human interleukin-15 (rhIL-15)|Continuous infusion rhIL15 IV
1975240|NCT01875601|Biological|NK Cell Infusion|Infuse expanded NK cells at Day 0 after 2 days of Cyclophosphamide lymphodepletion
1975241|NCT01875250|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
1975242|NCT01875250|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
1975243|NCT01875250|Drug|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
1975248|NCT01868906|Drug|18F-FMISO|18F-FMISO-PET scanning, for tumor hypoxia assessment before radio-chemotherapy.
1975249|NCT01868906|Procedure|PET without SCS|PET-scanning using 18F-fluoromisonidazole without SCS
1975250|NCT01868906|Device|SCS|Electrical stimulation of spinal cord, minimally invasive neurosurgical technique used to treat refractory pain and ischemic syndromes.
1975251|NCT01868906|Procedure|PET without/with SCS|Second PET-scanning using 18F-fluoromisonidazole: without/with SCS
1975252|NCT01868906|Radiation|Radiotherapy|Standard radiation therapy
1975253|NCT01868906|Drug|Temozolomide|Standard treatment with concurrent and adjuvant Temozolomide.
1975254|NCT01867411|Drug|Nicotine Patch|
1975255|NCT01867411|Drug|E-Cigarettes (V2cigs)|
1975256|NCT01867333|Biological|PROSTVAC-F/TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
1975257|NCT01867333|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
1975258|NCT01867333|Biological|Enzalutamide (Xtandi)|An androgen receptor inhibitor.
1975259|NCT01867320|Drug|Raltegravir|
1975260|NCT01866839|Device|Graft Manipulation (CD34+ Selection)|
1975264|NCT01863550|Drug|bortezomib|Given SC or IV
1975265|NCT01863550|Drug|lenalidomide|Given PO
1975266|NCT01863550|Drug|dexamethasone|Given PO
1975267|NCT01863550|Drug|carfilzomib|Given IV
1975268|NCT01863550|Procedure|quality-of-life assessment|Ancillary studies
1975269|NCT01863550|Other|laboratory biomarker analysis|Optional correlative studies
1975272|NCT01862796|Behavioral|Weight Loss|Participants receive either a weight-maintaining diet or a 35% calorie reduced diet
1975273|NCT01862796|Behavioral|Weight Loss|6-week heart-healthy dietary intervention; 35% calorie reduced diet
1975274|NCT01862796|Behavioral|Food Intake|6-week heart-healthy dietary intervention; 35% calorie reduced diet
1975275|NCT01862718|Procedure|Thermal Ablation|On Thursday in the first week, subject will receive the radiofrequency ablation.
1975276|NCT01862718|Procedure|Standard External Beam Radiation Therapy|During those 2 weeks, subject will receive radiation on Monday, Wednesday and Friday.
1975278|NCT01862029|Drug|Roflumilast|Selective phosphodiesterase 4 (PDE4) inhibitor
1975279|NCT01861808|Other|Lumbar puncture|The only intervention is the lumbar puncture on the patients to obtain a Cerebrospinal Fluid sample
1975283|NCT01861106|Genetic|Allogeneic HSC|Stem cell transplant
1975284|NCT01861106|Drug|Busulfan Test dose|0.8 mg/kg IV infusion over 2 hours one time dose administered 5 to 14 days prior to start of preparative regimen (Days -11 to -20)
1975285|NCT01861106|Drug|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
1975286|NCT01861106|Drug|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 2 hours once daily on Days -6, -5, -4 and -3 (weight based dosing)
1975287|NCT01861106|Drug|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 minutes once daily on days -6 and -5 (weight based dosing) or 50 mg/kg IV infusion over 2 hours on day -6 (weight based dosing) or 50/kg IV once daily x 2 doses on days +3 and +4
1975288|NCT01861106|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1
1975289|NCT01861106|Drug|Equine Anti-Thymocyte Globulin|30mg/kg IV (in the vein) once daily x 3 days on Days -6, -5, -4 (3 doses total)
1975290|NCT01861093|Procedure|Cord Blood Units|Transplant
1975295|NCT01857895|Drug|Exenatide|Prefilled pen containing 2.4 mL of drug will be transferred into MiniMed Paradigm Real-Time Revel device for subcutaneous infusion.
1975297|NCT01856907|Drug|Sitagliptin-Metformin|Experimental -DPP-4 inhibitor- oral medication
1975298|NCT01856907|Drug|Metformin|Biguanide- insulin sensitizer
1975299|NCT01856907|Drug|Placebo pill|Will evaluate effect of lifestyle and diet only
1975300|NCT01856920|Biological|GI-6207 [Recombinant Saccharomyces cerevisiae-CEA (610D)]|GI-6207 is a heat-killed, recombinant yeast-based vaccine engineered to express the full length human carcinoembryonic antigen (CEA), with a modified gene coding sequence to code for a single amino acid substitution (asparagine to aspartic acid) at the native protein amino acid position 610, which is designed to enhance immunogenicity. A plasmid vector containing the modified human CEA gene is used to transfect the parental yeast strain (S. cerevisiae W303 - a haploid strain with known mutations from wild-type yeast) to produce the final recombinant vaccine product.
1975303|NCT01856335|Other|Patient Education|
1975304|NCT01856335|Other|exercise: increase physical activity/goal setting|
1918806|NCT00799864|Drug|Rilpivirine|Patients will receive rilpivirine tablet 25 milligram or adjusted dose orally once daily for 240 weeks.
1918807|NCT00799864|Drug|Zidovudine|Type=exact, form= appropriate pediatric formulation, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
1918808|NCT00799864|Drug|Abacavir|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
1918809|NCT00799864|Drug|Tenofovir disoproxil fumarate|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
1918810|NCT00799864|Drug|Lamivudine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
1918811|NCT00799864|Drug|Emtricitabine|Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients will receive this selected NRTI once daily for 240 weeks.
1975312|NCT01853618|Drug|Tremelimumab|Weekly x6 doses and then 12 weeks apart
1975313|NCT01853618|Procedure|TACE|"For Cohort A (BCLC Stage C patients): TACE or radiofrequency ablation (RFA) will be performed once only.
For Cohort B (BCLC Stage B patients): TACE may be repeated (as per standard of care) on months 3, 7, and 13, and q6 months thereafter (if indicated).
Cohort B will only be recruited following completion of the dose-escalation portion of Cohort A."
1975314|NCT01853618|Procedure|Radiofrequency Ablation (RFA)|"For Cohort A (BCLC Stage C patients): TACE or radiofrequency ablation (RFA) will be performed once only.
For Cohort B (BCLC Stage B patients): TACE may be repeated (as per standard of care) on months 3, 7, and 13, and q6 months thereafter (if indicated).
Cohort B will only be recruited following completion of the dose-escalation portion of Cohort A."
1975315|NCT01853618|Radiation|SBRT|Cohorts C (Advanced HCC, BCLC Stage C): SBRT will be performed once only, also on Day 36 (+/- 96hrs).
1975316|NCT01853618|Procedure|Cryoablation|Cohorts D (Advanced HCC, BCLC Stage C): cryoablation will be performed once only, also on Day 36 (+/- 96hrs).
1975317|NCT01853930|Behavioral|PAECT (Platform for Administering Eye movement Control Training).|The PAECT meta program will incorporate all of the exercises that the investigators have developed and validated over the course of our previous Merit Review grants (Seiple, Szlyk et al., 2005, 2011). The PAECT platform will be designed to allow patients to easily run the training exercises in their homes and to practice at their convenience. The PAECT will employ an executive component that will keep track of the exercises that are practiced and record performance. Each time a subject opens the platform, it will choose the exercise for that subject based upon previous training and performance.
1975322|NCT01853111|Biological|Interleukin-2|
1975323|NCT01851460|Device|Cool-tip RF Ablation System|RFA therapy will be administered according to the instructions of the RFA device manufacturer.
1975324|NCT01851369|Drug|TRC 102|TRC102 has been shown to potentiate the activity of temozolomide by preventing BER and allowing cleavage of TRC102 bound DNA, which will cause DNA strand breaks in cancer cells. We hypothesize that oral TRC102 can be safely co administered with TMZ and would potentiate DNA damage caused by TMZ resulting in antitumor responses.
1975331|NCT01842386|Drug|Rituximab/Rituxan|Rituximab is a genetically engineered chimeric murine/human monoclonal antibody targeting the CD20 antigen expressed on the surface of normal and malignant B cells. It is an FDA-approved drug for the treatment of rheumatoid arthritis and non-Hodgkin's Lymphoma. We have received permission from the FDA to use rituximab for this study.
1975336|NCT01839500|Drug|Trastuzumab|Trastuzumab administered in accordance with routine care practice.
1975338|NCT01835691|Dietary Supplement|Vitamin D2 (ergocalciferol)|50,000 units once a week for 12 weeks
1975339|NCT01835691|Dietary Supplement|Vitamin D3 (cholecalciferol)|50,000 units once a week for 12 weeks
1975340|NCT01833832|Drug|Cisplatin|Patients who are successfully debulked will then undergo HIPEC with cisplatin.
1975341|NCT01833832|Procedure|Cytoreductive surgery|Patients will undergo cytoreductive surgery to achieve a CC of 0 or 1.
1975342|NCT01833832|Drug|sodium thiosulfate|sodium thiosulfate will be given to limit the toxicity of cisplatin
1975343|NCT01832090|Device|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier.
1975346|NCT01824394|Device|nMARQ Navigation Catheters|
1975347|NCT01824394|Device|NaviStar ThermoCool Catheters|
1975348|NCT01822912|Other|Heart Failure Disease Management Program|Subjects will be assessed 3 times a week while in SNF.
1975349|NCT01822912|Other|Heart Failure Usual Care|Subjects will receive standard of care.
1975359|NCT01820572|Drug|Belatacept|
1975360|NCT01820572|Drug|Tacrolimus|
1975361|NCT01820572|Drug|Cyclosporine|
1975362|NCT01818440|Other|3D Roadmap software|Two scanning methods will be used by doctors to position catheters in the blood vessels to deliver the chemotherapy and close the blood supply to the tumor.
1975363|NCT01818440|Other|Fluoroscopy|Patients will have the procedure performed with regular fluoroscopy (X-ray). Regular fluoroscopy is the standard method.
1975365|NCT01812694|Behavioral|Controlling Gestational Weight Gain|Behavioral weight control
1975366|NCT01806909|Biological|Ad4-H5-Vtn|
1975368|NCT01804296|Device|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
1975369|NCT01804270|Device|Repetitive transcranial magnetic stimulation (rTMS)|Active treatments with repetitive transcranial magnetic stimulation (rTMS) consists of treatment settings of 120% magnetic field intensity relative to the patient's resting motor threshold, at 10 pulses per second (10 Hz) for 4 seconds, with an intertrain interval of 26 seconds for a total of 75 trains per treatment session.
1975376|NCT01802073|Drug|Oral Vancomycin|
1975377|NCT01799538|Drug|albuterol inhaler|
1975378|NCT01799538|Procedure|PFT|
1975379|NCT01799538|Drug|albuterol nebulizer|
1975383|NCT01794117|Drug|Anakinra|An initial dose of anakinra 100 mg/day will be administered daily via self-administered subcutaneous injection. If pustule formation persists at this dose, anakinra dose may be escalated up to 200 mg/day injected subcutaneously daily at week 4
1975384|NCT01792115|Drug|Vitamin E 200 IU/d|Supplement-low dose; Subjects randomized to vitamin E 200 IU/day for 24 weeks; invited to optional extension of open-label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
1975385|NCT01792115|Drug|Vitamin E 400 IU/d|Supplement-intermediate dose; Subjects randomized to vitamin E 400 IU/day for 24 weeks; invited to optional extension of open-label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
1975386|NCT01792115|Drug|Vitamin E 800 IU/d|Supplement High Dose; Subjects randomized to vitamin E 800 IU/day for 24 weeks; invited to optional extension of open-label vitamin E 800 IU/day for up to 120 weeks following the initial 24 week period.
1975387|NCT01792115|Behavioral|Diet and Exercise|Diet and Exercise
1975388|NCT01786902|Drug|DA-3002|
1975389|NCT01786135|Drug|SGN-CD19A|SGN-CD19A (IV) once every 21 days (3 weeks) or 42 days (6 weeks)
1975390|NCT01784861|Drug|X-82|
1975391|NCT01784861|Drug|Everolimus|
1975392|NCT01784861|Procedure|Blood draws for pharmacokinetic testing|
1975393|NCT01780545|Drug|OGX-427|"Three doses of 600 mg OGX-427 will be administered IV during the loading dose period (days -9 to -1). Following completion of the loading dose period, 600 mg OGX-427 will be given IV weekly on days 1, 8, and 15 of each 21-day cycle. OGX-427 must be administered prior to docetaxel on day 1 of each cycle.
Following completion of 10 cycles of docetaxel, 600 mg OGX-427 will continue to be administered by IV weekly as maintenance therapy in Arm A participants who do not have disease progression (i.e., stable disease or better). Participants without documented disease progression who have discontinued from study treatment not due to toxicity related to OGX-427 can also continue to receive OGX-427 maintenance as long as they have completed disease assessments following at least 2 cycles of chemotherapy. Maintenance with OGX-427 will continue until disease progression or unacceptable toxicity."
1975394|NCT01780545|Drug|Docetaxel|"For Arm A Only: Docetaxel should be administered immediately following the completion of the OGX-427 infusion.
For Both Arms: Docetaxel (75 mg/M2) will be administered IV on Day 1 of each 21 day cycle for a maximum of 10 cycles."
1975395|NCT01778556|Biological|Metreleptin|Recombinant analog of the human hormone, leptin
1975407|NCT01767675|Procedure|Secondary Cytoreductive Surgery|
1975408|NCT01767675|Drug|Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC)|
1975409|NCT01767675|Drug|platinum-based systemic chemotherapy postoperatively|5 cycles
1975410|NCT01767675|Drug|platinum-based systemic chemotherapy postoperatively|6 cycles
1975411|NCT01763541|Drug|leuprolide acetate|Given to both arms to induce hypogonadism
1975412|NCT01763541|Drug|Anastrozole|Given to men to prevent conversion of administered testosterone to estradiol.
1975417|NCT01755195|Drug|Cabozantinib|Cabozantinib inhibits multiple RTKs implicated in tumor growth, metastasis, and angiogenesis, and targets primarily MET and VEGFR2.
1975420|NCT01748825|Drug|AZD1775|AZD1775 is an inhibitor of Wee1-kinase.In preclinical models, AZD1775 selectively enhanced chemotherapy-induced death of cells deficient in p53 signaling.
1975423|NCT01747148|Drug|AVI-7100 versus placebo|dose-escalating AVI-7100 versus placebo
1975424|NCT01747213|Drug|BNC|
1975434|NCT01732458|Drug|Aprepitant|Administered as a single oral dose on Day 1 between 1 and 3 hours prior to expected induction of anesthesia. Aprepitant was supplied in a sachet containing a powder for suspension (PFS) that was reconstituted up to total volume of 5 mL using potable water.
1975435|NCT01732458|Drug|Placebo to Aprepitant|
1975436|NCT01732458|Drug|Ondansetron|Administered IV at a dose of 4 mg for participants >40 kg in weight and 0.1 mg/kg for participants ≤40 kg in weight. In participants <1 month of age, the dose of ondansetron was administered per the product label or based on local standard of care. Ondansetron was supplied by the Sponsor as vials or ampules, depending on the country.
1975437|NCT01732458|Drug|Placebo to match ondansetron|Participants in the aprepitant regimen received normal saline IV (provided by the site) as the placebo for ondansetron on Day 1, immediately prior to induction of anesthesia.
1975439|NCT01723696|Dietary Supplement|Vitamin C +prenatal vitamin|Pregnant smoking women will be randomized to daily vitamin C (500 mg) versus daily placebo
1975440|NCT01723696|Dietary Supplement|Placebo tablet+prenatal vitamin|
1975441|NCT01721876|Drug|placebo|comparator
1975442|NCT01721876|Drug|volasertib|'Investigational Medicinal Product
1975443|NCT01721876|Drug|low dose cytarabine|background medication
1975444|NCT01721876|Drug|low dose cytarabine|background medication
1975445|NCT01718730|Device|Transcranial Magnetic Stimulation (TMS)|Single and paired-pulse TMS applied to the motor cortex will collect measures of cortical excitability and inhibition.
1975446|NCT01718730|Device|Magnetic Resonance Spectroscopy and Imaging|MRS/MRI Scans will examine glutamate concentrations in the motor cortex and anterior cingulate cortex.
1975447|NCT01716312|Drug|Omalizumab|First dose will be 600 mg SQ (under the skin) infusion and subsequent doses will be 300 mg SQ infusion every 4 weeks.
1975448|NCT01712659|Drug|Ruxolitinib|Ruxolitinib 20 mg orally twice daily for 28 days. Patient may continue to receive treatment until PD.
1975449|NCT01712620|Drug|Spironolactone|Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.
1975450|NCT01712620|Drug|Placebo|Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
1975451|NCT01712308|Drug|Sotatercept|"Higher Dose Group: 0.5 mg/kg dose subcutaneously on Day 1 every 3 weeks.
Lower Dose Group: 0.3 mg/kg dose subcutaneously on Day 1 every 3 weeks.
Myelofibrosis on Treatment with Ruxolitinib Group: 0.75 mg/kg dose subcutaneously on Day 1 every 3 weeks."
1975453|NCT01707394|Drug|Apixaban|
1975454|NCT01703169|Drug|Eltrombopag|Oral eltrombopag 150mg/day by mouth starting on Day 1 with dose modification over 12 weeks to a maximum of 300mg/day determined by platelet count
1975455|NCT01697579|Drug|Fosaprepitant 150 mg|Administered IV as a single dose
1975456|NCT01697579|Drug|Fosaprepitant 60 mg|Administered IV as a single dose
1975457|NCT01697579|Drug|Fosaprepitant 20 mg|Administered IV as a single dose
1975458|NCT01697579|Drug|Placebo Fosaprepitant|Administered IV as a single dose
1975459|NCT01697579|Drug|Ondansetron|Administered IV
1975460|NCT01697579|Drug|Fosaprepitant 5 mg/kg|Administered IV as a single dose
1975464|NCT01688999|Drug|Cabozantinib|60 mg PO daily each 28 day cycle. Treatment continues until toxicity or disease progression.
1975465|NCT01688466|Drug|Pomalidomide|0.5 mg/day without Dose Escalation and 0.5 mg/day- 2.0 mg/day PO QD(every day) of each 28 day cycle
1975466|NCT01685840|Other|Usual Care|Usual Care
1975467|NCT01685840|Device|Biomarker-guided care NT-proBNP|Device: NT-proBNP
1975470|NCT01683994|Drug|Cabozantinib|assigned dose daily or twice a day (depending on dose level)during each 21 day cycle. Treatment may continue until disease progression or intolerable toxicity.
1975471|NCT01683994|Drug|Docetaxel|75mg/m2 IV over approximately 60 minutes on cycle 1 day 1 and repeated every 21 days until disease progression or intolerable toxicity.
1975472|NCT01683994|Drug|Prednisone|5 mg PO twice a day during each 21 day cycle until disease progression or intolerable toxicity.
1975473|NCT01683084|Drug|Telmisartan|
1975474|NCT01683084|Drug|Placebo|
1975480|NCT01677156|Diagnostic Test|CORUS CAD|Age/Sex/Gene Expression Score
1975481|NCT01672346|Procedure|PVAI followed by adenosine provocation|All patients will undergo PVAI and ablation of the posterior wall of the LA using an open-irrigated ablation catheter and under general anesthesia. After PV isolation is achieved, all will undergo PVAI followed by adenosine provocation test with 24 mg of adenosine to check for PV reconnection. Upon identification, additional RF energy would be used to ablate those sites (that were revealed by adenosine-provocation).
1995758|NCT02661529|Other|Saline/Air Mixture|The Saline/Air mixture consists of 10 milliliters of sterile saline and 0.5 milliliters of air agitated together in a syringe prior to injection.
1995759|NCT02661529|Other|Saline/Blood Mixture|The Saline/Blood mixture consists of 9 milliliters of sterile saline and 0.5 - 1.0 milliliters of blood agitated together in a syringe prior to injection.
1995764|NCT02659761|Drug|dolutegravir/abacavir/lamivudine|600 mg abacavir, 50 mg dolutegravir and 300 mg lamivudine single tablet taken orally, once daily, during 96 weeks
1997780|NCT01919164|Drug|Placebo|Matching placebo will be administered in 2 cycles (at Months 6 and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
1975484|NCT01660100|Procedure|Pulmonary vein antrum isolation (PVAI)|In this group, only standard PVAI will be performed during the primary procedure. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum remains isolated will enter follow-up; however, patients who have pulmonary vein-left atrium reconnection will undergo an re-isolation. Patients who have pulmonary vein antrum re-isolation are subject to a 3rd procedure 3 months later to check the status of pulmonary vein-left atrium connection. Patients will enter follow-up for long-term outcome only after permanent PVAI is confirmed by a repeat procedure.
1975485|NCT01660100|Procedure|PVAI plus left atrial posterior wall (LAPW) isolation|In this group, PVAI will be extended to the entire LAPW to achieve LAPW isolation during the primary ablation. Three months later, a 2nd procedure will be performed in all subjects regardless of the recurrence of atrial arrhythmias. Subjects in whom pulmonary vein antrum and LAPW remain isolated will enter follow-up; however, patients who have pulmonary vein antrum and/or LAPW reconnection will undergo a re-isolation. Patients who have pulmonary vein antrum and/or LAPW re-isolation are subject to a 3rd procedure three month later to check the presence of pulmonary vein antrum and/or LAPW re-connection. Patients will enter follow-up for long-term outcome only after PVAI and LAPW isolation are proven by a repeat procedure.
1975486|NCT01658878|Biological|Nivolumab|
1975487|NCT01658878|Drug|Sorafenib|
1918986|NCT00761267|Drug|Anidulafungin|"Day 1: loading dose of 3 mg/kg (not to exceed 200 mg) Day 2 onwards: maintain a dose of 1.5 mg/kg (not to exceed 100 mg). Minimum total treatment duration is 14 days. Minimum IV anidulafungin treatment duration is 10 days for subjects with microbiologically confirmed ICC and 5 days for subjects at risk of candidiasis; followed by oral fluconazole 6-12 mg/kg/day (not to exceed 800mg/day).
Maximum treatment duration with anidulafungin is 35 days."
1918987|NCT00761267|Drug|Fluconazole|Subjects may be switched to oral fluconazole [6-12 mg/kg/day (not to exceed 800mg/day] provided they meet specified criteria. Maximum total treatment duration is 49 days.
1975488|NCT01658878|Drug|Ipilimumab|
1975489|NCT01658878|Drug|Cabozantinib|
1975492|NCT01648348|Biological|Anti-Endoglin Chimeric Monoclonal Antibody TRC105|Given IV
1975493|NCT01648348|Biological|Bevacizumab|Given IV
1975494|NCT01648348|Other|Laboratory Biomarker Analysis|Correlative studies
1975495|NCT01648348|Other|Pharmacological Study|Correlative studies
1975496|NCT01648348|Other|Quality-of-Life Assessment|Ancillary studies
1975504|NCT01642056|Drug|EPI-743|
1975505|NCT01634750|Drug|ManNAc|Single dose
1975506|NCT01633229|Procedure|Bone Marrow Stromal Cell Infusion|
1975507|NCT01631617|Drug|Trimethoprim/sulfamethoxazole (TMP/SMZ)|800/160 orally every 12 hours for 14 days
1975508|NCT01631617|Drug|Cephalexin|500 mg orally every 8 hours for 14 days
1975509|NCT01631617|Drug|Doxycycline|20 mg orally every 12 hours for 56 days or 100 mg orally every 12 hours for 56 days
1975510|NCT01631617|Other|Sodium hypochlorite|6 % dilute bleach
1975511|NCT01629082|Drug|Clofarabine|
1975512|NCT01629082|Drug|Lenalidomide|
1919019|NCT00752206|Drug|Saracatinib|Oral Agent
1919020|NCT00752206|Drug|Placebo|Oral Agent
1975519|NCT01623167|Drug|Eltrombopag|
1975520|NCT01623167|Drug|Horse Anti-Thymocyte Globulin (ATG)|
1975521|NCT01623167|Drug|Cyclosporine A (CSA)|
1975526|NCT01621581|Genetic|Convection enhanced delivery/AAV2-GDNF|
1975527|NCT01617421|Behavioral|Yoga|
1975529|NCT01603706|Procedure|Echo guided implantation group|Lead placement according echo strain imaging result
1975530|NCT01601626|Drug|Lopinavir/Ritonavir|Two LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry to Week 72.
1975531|NCT01601626|Drug|Lopinavir/Ritonavir|Four LPV 200 mg/RTV 50 mg fixed-dose combination tablets orally twice daily from entry through Week 72.
1975532|NCT01601626|Drug|Raltegravir|400 mg orally twice daily from entry to Week 72.
1975533|NCT01601626|Drug|Isoniazid|300 mg orally once daily from entry through Week 24.
1975534|NCT01601626|Drug|Pyridoxine|25 mg orally once daily from entry to Week 24.
1975535|NCT01601626|Drug|Pyrazinamide|20 to 30 mg/kg orally once daily (not to exceed 2 g per day) from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
1975536|NCT01601626|Drug|Ethambutol|15 to 20 mg/kg orally once daily from entry through Week 8 study visit (or until completion of intensive TB treatment as determined after dose adjustment in accrual period 1 participants).
1975537|NCT01601626|Drug|Rifabutin|300 mg of rifabutin orally once until LPV/RTV is started; then the dose will be reduced to 150 mg daily from the start of LPV/RTV through Week 24.
1975538|NCT01601626|Drug|Rifampin|Weight-based dose; for weight < 45 kg: 450 mg orally once daily; for weight > 45 kg: 600 mg orally once daily, from entry to week 24.
1975540|NCT01593696|Biological|Anti-CD19- CAR|Cells extracted, followed by induction chemotherapy before CD19-CAR infusion (dose escalation.)
1975541|NCT01593254|Drug|Imatinib|
1975542|NCT01593254|Drug|Dasatinib|
1975543|NCT01591746|Drug|Botulinum Toxin Type A|100 Units of Botulinum toxin A diluted in 5 mL 0.9% Sodium Chloride in the pectoralis major muscle in each operated breast.
1975544|NCT01591746|Drug|Sodium Chloride Solution|5 mL 0.9% NaCl injection to the pectoralis major muscle in each operated breast.
1975546|NCT01585402|Drug|Etidronate|20mg/kg oral 14days on / 10 weeks off cyclical drug schedule
1975547|NCT01585402|Procedure|MRI|Visit on day 0 and visit at 36 month
1975548|NCT01585402|Procedure|CT Scan|Baseline visit, and visit on day 0, visit at 12, 24 , 36 months
1975549|NCT01585402|Procedure|ABI|At baseline and visit 1-7 every 6 months
1975550|NCT01585402|Procedure|Treadmill|visit 1-7 every 6 months
1975551|NCT01585402|Procedure|Dexa Scan|Visit1, 3, 5, 7 every 12 months
1975552|NCT01585402|Procedure|Hand X-ray|Visit1, 3, 5, 7 every 12 months
1975553|NCT01583686|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1975554|NCT01583686|Biological|Anti-mesothelin CAR|Patients will receive a nonmyeloablative but lymphocyte depleting preparative regimen consisting of cyclophosphamide and fludarabine followed by IV infusion of anti-mesothelin CAR engineered PBL. On day 0, cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes (between one and four days after the last dose of fludarabine).
1975555|NCT01583686|Drug|Cycolphosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
1975556|NCT01583686|Drug|Aldesleukin|Aldesleukin (based on total body weight) 72,000 IU/kg IV over a period of 15 minutes approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
1975557|NCT01578317|Biological|H5N1 vaccine plus MF59 adjuvant|
1975558|NCT01578317|Biological|H5N1 vaccine without adjuvant|
1975564|NCT01573429|Other|deuterated-Bisphenol A (d-BPA)|
1975567|NCT01572506|Procedure|Biotin RBC survival|
1975570|NCT01572480|Drug|Carfilzomib|Cycle 1 ONLY: Carfilzomib 20 mg/m2 per dose, days 1 and 2; Carfilzomib 36 mg/m2 per dose, days 8, 9, 15, and 16 Cycles 2-8: Carfilzomib 36 mg/m2 per dose, days 1, 2, 8, 9, 15, and 16
1975571|NCT01572480|Drug|Revlimid|"Cycles 1-8: 25 mg/day, days 1-21 every 28 days (exception: lenalidomide is NOT given on cycle 1, day 1).
Cycles 9 and beyond: 25 mg/day, days 1-21 every 28 days"
1975572|NCT01572480|Drug|Dexamethasone|20 mg/dose, days 1, 2, 8, 9, 15, 16, 22, and 23 (exception: dexamethasone is NOT given on cycle 1, day 1)
1975573|NCT01572038|Drug|Docetaxel|Participants may receive 'docetaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
1975574|NCT01572038|Drug|Nab-paclitaxel|Participants may receive 'nab-paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
1975575|NCT01572038|Drug|Paclitaxel|Participants may receive 'paclitaxel' taxane chemotherapy as per investigator's choice, administered in line with the respective product information and/or recognized clinical practice guidelines.
1975576|NCT01572038|Drug|Pertuzumab|Participants will receive pertuzumab 840 milligrams (mg) IV on Day 1 or Day 2 of Cycle 1, followed by 420 mg IV on Day 1 or Day 2 of each subsequent 3-week cycle.
1975577|NCT01572038|Drug|Trastuzumab|Participants will receive trastuzumab (Herceptin) 8 milligrams per kilogram (mg/kg) IV on Day 1 or Day 2 of Cycle 1, followed by 6 mg/kg IV on Day 1 or Day 2 of each subsequent 3-week cycle, administered in line with the respective product Information and/or recognized clinical practice guidelines.
1975578|NCT01557855|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score
1975581|NCT01557517|Drug|Clobetasol Oral Rinse|Cycle= up to 4 weeks Patients will rinse oral cavity with 10cc of clobetasol 0.05% oral rinse for 2 minutes 3 times a day.
1975582|NCT01557517|Drug|Placebo oral rinse|Patients will rinse oral cavity with 10cc of placebo oral rinse for 2 minutes 3 times a day.
1975583|NCT01553461|Procedure|Cord Blood Transplant|
1919064|NCT00745615|Drug|laquinimod 0.3 mg|Tablet formulation taken by participants in the double-blind period. Participants in the 0.3 mg treatment arm took one tablet of laquinimod 0.3mg once a day (plus a placebo tablet). Participants in the 0.6 mg treatment arm took two tables of laquinimod 0.3 mg once each day.
1919065|NCT00745615|Drug|Laquinimod 0.6 mg|Capsule formulation taken by participants in the open-label period. Participants took one capsule each day.
1919066|NCT00745615|Drug|Placebo|One tablet taken each day for participants in the laquinimod 0.3 mg treatment arm during the double-blind period.
1975584|NCT01553214|Drug|Filgrastim (G-CSF)|Recombinant G-CSF is available from the Clinical Center pharmacy in colorless glass, single-use vials containing 480 mcg G-CSF in 1.6 mL vials (300 mcg/mL). It is formulated as a sterile, clear, colorless liquid in 10 mm sodium acetate buffer at pH 4.0. The quantitative composition (per mL) is: Recombinant human G-CSF 300 mcg Acetate 0.59 mg Mannitol 50 mg Tween 80TM 0.004% Sodium 0.035 mg Water for injection (qs ad) to 1.0 mL Storage: The intact vials of G-CSF should be stored under refrigeration (2-8 degrees Celsius). Administration: G-CSF is administered subcutaneously, with the entire contents of one 1.6 mL vial given in one injection 12 to 24 hours prior to apheresis.Stability: G-CSF in the intact vial is stable for 36 months when stored in a refrigerator at 2-8 degrees Celsius. A single brief exposure (up to 7 days) to elevated temperatures (<37 degrees Celsius) does not affect the stability. G-CSF should not be frozen, and vials that have been frozen should not be used.
1975585|NCT01553214|Drug|Dexamethasone|Oral dexamethasone is available from the Clinical Center pharmacy as green 4 mg tablets. The tablets contain the following inactive ingredients: lactose monohydrate, magnesium stearate, starch, sucrose, FD&amp;C Green No. 3, FD&amp;C Yellow No. 10, and FD&amp;C Yellow No. 6. They are packaged in unit-dose blister pack strips. Storage: Dexamethasone tablets should be stored at room temperature (20-25 degrees Celsius). Administration: Dexamethasone is administered as two 4-mg tablets 12 hours prior to apheresis (approximately one hour after dinner the evening prior to apheresis). Stability: Dexamethasone is stable for 36 months when stored at room temperature in an unopened blister pack.
1975586|NCT01553201|Drug|Botuninum toxin A|
1975587|NCT01553188|Drug|AMG 386|AMG 386 dose will be calculated using the subject s actual body weight (Kg). Supplied in 240 mg v will be administered as an IV infusion using an intravenous infusion pump given over a 60-minute period.
1975588|NCT01553188|Drug|Abiraterone|A 1,000 mg dose of abiraterone should be taken orally once daily
1975589|NCT01553188|Drug|Prednisone|Prednisone should be taken orally either, at 5mg twice a day for each dose or 10 mg once a day a patient s preference.
1975590|NCT01551771|Drug|GW824575|Investigational treatment - Swedish Orange Coloured, opaque hard gelatin capsule
1975591|NCT01551771|Drug|GW824575 matched-placebo|Placebo
1975595|NCT01540630|Drug|CNV1014802|CNV1014802 150mg tid for 28 days. Dose may be increased to 350mg bid following interim evaluation of efficacy.
1975596|NCT01540630|Drug|Placebo|Double-blind placebo comparator for 28 days.
1975602|NCT01534598|Drug|FdCyd + THU|Intravenous FdCyd with THU has been evaluated in a Phase I clinical trial with some preliminary evidence of activity. This trial will investigate oral administration of the drugs, which was shown be feasible in an expansion cohort of the previous trial.
1975605|NCT01524536|Drug|Corticosteroids|
1975606|NCT01520207|Drug|Mannitol (20%)|0.25g/kg/hour (maximum rate 25g/hour; maximum 75g per session; maximum volume 375mLs per session)
1975607|NCT01520207|Drug|0.9% saline|1.25mL/kg/hour; maximum 125mLs/hour; maximum total volume 375mLs per treatment
1975609|NCT01517100|Drug|Nabllone|CB Agonist
1975610|NCT01517100|Drug|CP-945,598|Cannabinoid Receptor 1 antagonist
1975611|NCT01517100|Procedure|Hypoglycemic Clamp|Assesses beta cell response
1975612|NCT01517100|Drug|Euglycemic-Hyperinsulinemic Clamp|Measures insulin sensitivity
1975615|NCT01512810|Procedure|Lymphadenectomy|Lymphadenectomy recommended, including: obturator, iliac (internal, external, common) and aortic lymph nodes
1975620|NCT01505062|Genetic|UshStat|Single dose, 3 ascending dose cohorts, followed by two maximum tolerated dose cohorts
1975623|NCT01503164|Device|Positive Pressure Therapy (PAP)|Positive pressure therapy is the standard of care for managing obstructive sleep apnea. It entails wearing a mask that is connected to the PAP device which deliver pressure to the upper airway during sleep.
1975624|NCT01503164|Behavioral|LifeStyle Counseling|Subjects randomized to the lifestyle (and nutritional) counseling arm will be given advice on a balanced dietary and exercise plan.
1975626|NCT01500733|Drug|PCI 32765|420 mg daily
1975627|NCT01495598|Drug|Pomalidomide|5 mg p.o. for 21 of 28 days
1919116|NCT00734877|Drug|M-VTD-PACE|2 cycles of induction therapy with M-VTD-PACE and PBSC collection after the 1st cycle. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying single dose MEL 200 mg/m2 with adjustments for age and renal function. Consolidation will consist of 2 cycles of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
1919117|NCT00734877|Drug|TT3-LITE Regimen (L-TT3)|The TT3-LITE Regimen (L-TT3) will employ only 1 cycle of induction therapy with MVTD-PACE and, as in S-TT3, PBSC collection following recovery from this one and only induction treatment. MEL-based tandem transplant will be administered 6 weeks to 3 months apart, applying fractionated MEL200mg/m2 in 4 successive daily fractions of 50mg/m2 (MEL50 x 4) with addition of VTD with adjustments for age and renal function. Consolidation will consist of only 1 cycle of dose-reduced VTD-PACE. Maintenance treatment will employ VRD for 3 years.
1975628|NCT01492504|Drug|Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)|Observational study - No Intervention [(subjects were previously treated with Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052)]
1975631|NCT01492309|Device|Active Transcranial Magnetic Simulation|Subjects will be given active TMS 5 days per week for 4 weeks for a total of 20 sessions. Each session will last approximately 10 minutes.
1975632|NCT01492309|Device|Sham Transcranial Magnetic Stimulation|Subjects will be given sham TMS 5 days per week for 4 weeks for a total of 20 sessions. The sham coil contains a shielding mechanism which diverts the magnetic field away from the patient. The sham treatment will last approximately 10 minutes.
1975634|NCT01486030|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score
1975637|NCT01479348|Drug|[F-18]-5-FLUORO-2'-DEOXYCYTIDINE|This study involves two F-18 FdCyd PET/CT imaging sessions, one performed before receiving a treatment dose of FdCyd + THU, and a second performed while receiving a treatment dose of FdCyd + THU as prescribed by the Phase 1 protocol. You will be required to have an IV catheter put into a vein in your arm for each PET/CT imaging study.
1975638|NCT01468922|Drug|Pazopanib|VEGFR inhibitor
1975639|NCT01468922|Drug|ARQ 197|MET inhibitor
1975640|NCT01468844|Drug|Minocycline|
1975641|NCT01468831|Drug|Minocycline|
1975642|NCT01460160|Drug|Dasatinib|Tablets, Oral, 60 mg/m2, Once daily, 2 years or until unacceptable toxicity
1975643|NCT01459237|Drug|Acthrel|Ovine Corticorelin
1975644|NCT01454596|Biological|Anti-EGFRvIII CAR transduced PBL|On day 0 (one to four days after the last dose of fludarabine),cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes.
1975645|NCT01454596|Drug|Aldesleukin|IV Aldesleukin(based on total body weight) over 15 minute approximately every eight hours (+/- one hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses).
1975646|NCT01454596|Drug|Fludarabine|Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1975647|NCT01454596|Drug|Cyclophosphamide|Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
1975648|NCT01454102|Biological|Nivolumab|
1975649|NCT01454102|Drug|Gemcitabine|
1975650|NCT01454102|Drug|Cisplatin|
1975651|NCT01454102|Drug|Pemetrexed|
1975652|NCT01454102|Drug|Paclitaxel|
1975653|NCT01454102|Drug|Carboplatin|
1975654|NCT01454102|Drug|Bevacizumab|
1975655|NCT01454102|Drug|Erlotinib|
1975656|NCT01454102|Biological|Ipilimumab|
1919151|NCT00725946|Drug|Iodine-124|
1919152|NCT00725946|Radiation|PET/CT with Iodine-124|
1975659|NCT01445561|Drug|Interleukin-2 (100,000 international units)|100,000 international units/m2 daily for 5 days
1975660|NCT01445561|Drug|Interleukin-2 (200,000 international units)|200,000 international units/m2 daily for 5 days
1975661|NCT01445535|Biological|Rituximab|Rituximab will be given with siplizumab and EPOCH (combo chemo) every 21 days
1975662|NCT01445535|Drug|EPOCH|EPOCH (combo chemo)will be given with siplizumab and rituximab every 21 days
1975663|NCT01445535|Biological|Siplizumab|Siplizumab will be given with EPOCH (combo chemo) and rituximab every 21 days
1975666|NCT01445418|Drug|AZ2281 + Carboplatin|Cohort 1: Dose escalation: AZD2281 po bid qd + IV carboplatin D8 of each 21-day cycle.; Cohort 2: Expanded cohort treated at the MTD of the combination identified in Cohort 1.
1975671|NCT01445054|Drug|111Indium CHX-A DTPA trastuzumab|The 111Indium-trastuzumab will be administered in the Clinical Center, Nuclear Medicine Department intravenously over a 10-15 minute period using an intravenous catheter
1975673|NCT01443936|Biological|Ad4-H5-VTN vaccination-tonsillar route|
1975674|NCT01443936|Biological|Ad4-H5-vaccination-oral route|
1975675|NCT01441063|Drug|Zidovudine|Zidovudine (AZT) 600 mg orally q6 hours (every 6 hours)
1975676|NCT01441063|Drug|Tocilizumab|Tocilizumab 8mg/kg every 2 weeks
1975677|NCT01441063|Drug|Valganciclovir (VGC)|Valganciclovir (VGC) 900 mg orally q12 hours (every 12 hours) on days 1-5 of a 14-day cycle.
1975678|NCT01441037|Drug|Danazol|
1975679|NCT01439386|Procedure|Catheter ablation|PVAI with or without CTI ablation
1975680|NCT01439386|Procedure|Catheter ablation|CTI ablation only
1975681|NCT01435018|Drug|Coformulated EFV/FTC/TDF|"The following ART regimens may be used:
EFV/FTC/TDF (Atripla®) 200 mg/300 mg/600 mg orally once daily at bedtime or
FTC/TDF 200 mg/300 mg (Truvada®) orally once daily at bedtime plus EFV (Stocrin®) 600 mg orally once daily at bedtime or
FTC/TDF 200 mg/300 mg (Truvada®) orally once daily plus nevirapine (NVP) 200 mg orally twice daily or
FTC/TDF 200 mg/300 mg (Truvada®) orally once daily plus PI/r at standard dosing"
1975682|NCT01435018|Drug|Etoposide|"Beginning on day one of the chemotherapy cycle, ET will be given orally in a dose of 50 mg twice daily for 7 consecutive days for the first cycle. If there is no Grade ≥ 2 toxicity attributable to ET after the first cycle, the dose will be escalated to 150 mg daily for 7 days in divided doses of 100 mg/50 mg for the second cycle. After the second cycle, if there is no Grade ≥ 2 toxicity attributable to ET, the dose will be escalated to 100 mg twice daily for 7 days for the third and subsequent cycles.
Treatment with ET will continue for six cycles at the maximum dose achieved or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the A5263/AMC 066 CMC, has determined that alternative therapy is required, whichever occurs first."
1975683|NCT01435018|Drug|Bleomycin and Vincristine (BV)|"BV will be administered on day one of each chemotherapy cycle.
Vincristine sulfate will be administered at a dose of 2 mg (fixed dose) in a volume of 2 mL over 1 minute into the sidearm of a rapidly flowing intravenous infusion every 3 weeks. The vincristine infusion will be followed by bleomycin as detailed below.
Bleomycin sulfate will be administered at a dose of 15 units/m2 over 10 minutes every 3 weeks.
Treatment with BV will continue for six cycles, or until toxicity requiring discontinuation of study chemotherapy, or the site investigator, after consulting with the A5263/AMC 066 CMC, has determined that alternative therapy is required, whichever occurs first."
1975684|NCT01435018|Drug|Paclitaxel (PTX)|Paclitaxel will be administered by IV infusion in 200 mL, 250 mL, or 500 mL of 5% dextrose or 0.9%Sodium Chloride for injection at a dose of 100 mg/m2 Body Surface Area (BSA) every 3 weeks.
1975685|NCT01434602|Drug|everolimus|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; dose escalation from 5mg to 10 mg daily
1975686|NCT01434602|Drug|sorafenib|Patients will be treated with daily everolimus (days 1-28) in combination with sorafenib; There is not a defined set maximum number of cycles that a patient may have; dose escalation from 400 mg bid, 7 days on and 7 days off to 800 mg bid
1975690|NCT01423630|Dietary Supplement|Probiotics and fruit fibre|probiotics and fruit fibre
1975698|NCT01419535|Drug|Mifepristone|
1975699|NCT01417546|Drug|NHS-IL-12|NHS-IL12 is an investigational agent supplied to investigators by the manufacturer EMD Serono, Inc.
1975705|NCT01391962|Drug|Cediranib|Cediranib, a small molecule inhibitor of VEGF receptor tyrosine kinases, is showing preliminary evidence of activity in patients with ASPS.
1975706|NCT01391962|Drug|Sunitinib|Sunitinib, a small molecule inhibitor of VEGF receptor tyrosine kinases, is showing preliminary evidence of activity in patients with ASPS.
1975707|NCT01386359|Drug|No Intervention|No Intervention. Subjects are previously treated with Nulojix (belatacept)
1975708|NCT01383512|Device|ARMEO Spring|Use of the device 1 hour per day, 5 days per week during 4 weeks
1975709|NCT01383512|Other|Self rehabilitation|Subject have to realised alone rehabilitation exercises 1 hour per day, 5 days per week during 4 weeks.
1975714|NCT01377753|Device|Visualase Thermal Therapy System|Used for performing Laser Induced Thermal Therapy to destroy malignant or unwanted tissue by delivering laser energy sufficient to cause coagulation and necrosis of the tissue.
1975715|NCT01369901|Behavioral|A functional exercise program|
1975716|NCT01369901|Behavioral|A stretching exercise program|
1975718|NCT01362803|Drug|AZD6244|AZD6244 orally every 12 hours on continuous daily schedule for cycles of 28 days until unacceptable PD
1975721|NCT01353391|Drug|Metformin|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
1975722|NCT01353391|Drug|Placebo Comparator|500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
1975723|NCT01352962|Drug|Gemcitabine|1,000mg/m2 IVPB over 30 min x 1
1975724|NCT01352962|Drug|Carboplatin|AUC 5** IVPB over 30 min x 1
1975725|NCT01352962|Drug|Lenalidomide|Escalating Doses starting at 2.5 po daily up to 25 mg po daily until MTD is reached.
1975726|NCT01342029|Drug|Ranolazine|"This drug is approved by the U.S. Food and Drug Administration (FDA) for treatment of chronic angina.
500-1,000 mg po bid for 2 weeks"
1975727|NCT01342029|Drug|Placebo|500-1,000 mg po bid for 2 weeks
1975728|NCT01338987|Procedure|Allogeneic HSC Transplantation|Allogeneic HSC Transplantation
1975729|NCT01338987|Drug|Lupron|Lupron: 30 mg intramuscular injection(for adult) or 11.25 mg (for patients <18 years) between day -13 and day -20 pre-HSCT but definitely prior to initiation of preparative regimen as a 4 month intramuscular injection for patients > 18 years and as a 3 month injection (adult preparation) for patients < 18 years
1975730|NCT01338987|Drug|18F FLT|18F FLT: 0.07 mCi/kg with a maximum of 3 mCi On day + 28 (+/- 5 days)
1975731|NCT01338987|Drug|Cyclophosphamide|Cyclophosphamide: 60 mg/kg IV on days -4 and -3 (for Adults > 22 years) or Cyclophosphamide: cyclophosphamide 50 mg/kg IV, Days -5, -4, -3, -2. (For Pediatric </= 22 years)
1975732|NCT01338987|Drug|Methotrexate|Methotrexate:10 mg/m2 IV on day +1, and 5 mg/m2 IV Days + 3, 6, 11
1975733|NCT01338987|Drug|Tacrolimus|Tacrolimus:0.02 mg/kg/day CIV on day -1.
1975734|NCT01338987|Radiation|Total Body Irradiation|Total Body Irradiation (TBI) 1200 cGy fractionate twice daily (lung block) Days -8, -7, -6, -5 (adult), -9, -8, -7, -6 (ped)
1975737|NCT01335399|Drug|Lenalidomide|Capsules, Oral, 25 mg, once daily, on Days 1-21, Repeat every 28 days until subject meets criteria for discontinuation of study drug
1975738|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, weekly, on Days 1, 8, 15, 22, Repeat every 28 days until subject meets criteria for discontinuation of study drug
1975739|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 28 mg, once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
1975740|NCT01335399|Drug|Dexamethasone|Tablets, Oral, 40 mg, once daily, on Days 8 & 22 (cycles 3-18); Days 8, 15, 22 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
1975741|NCT01335399|Drug|Dexamethasone|Solution, Intravenous (IV), 8 mg, Once daily, on Days 1, 8, 15, 22 (cycles 1&2) ; Days 1 &15 (cycles 3-18); Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
1975742|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 10 mg/kg, weekly, on Days 1, 8, 15, 22 (cycles 1&2); Days 1 and 15 (cycles 3-18), Repeat every 28 days until subject meets criteria for discontinuation of study drug
1975743|NCT01335399|Biological|Elotuzumab (BMS-901608; HuLuc63)|Solution, Intravenous (IV), 20 mg/kg, Day 1 (cycle 19 and beyond), Repeat every 28 days until subject meets criteria for discontinuation of study drug
1975745|NCT01326715|Drug|Mangafodipir (Teslascan)|Contrast Agent
1975746|NCT01319565|Drug|Aldesleukin|For both arms: Administered at a dose of 720,000 IU/kg IV (based on total body weight) as an intravenous bolus over a 15 minute period approximately every eight hours (+/- 1 hour) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum 15 doses).
1975747|NCT01319565|Drug|Cyclophosphamide|For both Arms: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W with Mesna 15 mg/kg/day X 2 days over 1 hr.
1975748|NCT01319565|Drug|Fludarabine|For both Arms: 25 mg/m/2/day IVPB daily over 30 minutes for 5 days.
1975749|NCT01319565|Biological|Young Tumor Infiltrating Lymphocytes|For both Arms: Cells will be infused intravenously (i.v.) on the Patient Care Unit over 20 to 30 minutes via non-filtered tubing,gently agitating the bag during infusion to prevent cell clumping (minimum 1 X 10e9 and up to a maximum of 2 X 10e11 lymphocytes).
1975750|NCT01319565|Procedure|12Gy total body radiation|single dose of IV ondansetron 0.15 mg/kg IV prior to total body radiation (TBI). Patients will receive 2Gy of TBI twice a day for 3 days (total dose 12Gy) using a linear accelerator in Radiation Oncology.
1975751|NCT01317095|Device|Sternalock Rigid Fixation|Patients will have their sternum closed by rigid fixation using Sternalock plates.
1975753|NCT01316770|Drug|Dexamethasone|
1975754|NCT01313429|Drug|Cyclophosphamide|50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
1975755|NCT01313429|Biological|Allogenic tumor Cell Vaccine (K562)|4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.
1975756|NCT01313429|Drug|Celecoxib|400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
1975758|NCT01309399|Drug|Teriparatide|six weeks of teriparatide
1975759|NCT01309399|Other|placebo|placebo
1975760|NCT01306019|Other|Gene-modified CD34+ Hematopoietic stem cells|Infusion of transduced autologous CD34+ Hematopoietic stem cells
1975761|NCT01306019|Drug|Busulfan|Pre gene therapy conditioning regimen
1975762|NCT01306045|Drug|AZD6244|75 mg bid po
1975763|NCT01306045|Drug|MK-2206|200 mg qd po
1975764|NCT01306045|Drug|Lapatinib|1500 mg qd po
1975765|NCT01306045|Drug|Erlotinib|150 mg qd po
1975766|NCT01306045|Drug|Sunitinib|50 mg qd po
1975767|NCT01306045|Procedure|Molecular Profiling|Molecular profiling of tumor tissue
1975768|NCT01296074|Drug|Corticosteroid|500mg Methylprednisolone will be in the priming of cardiopulmonary bypass.
1975769|NCT01295944|Drug|Carboplatin|Carboplatin will be given on day 1 of each cycle; the carboplatin dose should be calculated using the Calvert formula: Carboplatin dose (mg) = target AUC x (CrCl + 25; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizumab may be continued at the discretion of the treating physician
1975770|NCT01295944|Drug|Bevacizumab|Bevacizumab will be administered on days 1 and 15 of each cycle. Bevacizumab will be administered at a dose of 10 mg/kg; The total duration of treatment will be 6 cycles. After cycle 6, carboplatin should be discontinued, but bevacizumab may be continued at the discretion of the treating physician.
1975772|NCT01295515|Drug|Pegylated Interferon Alpha 2b (PEGINTRON)|pegylated preparation of interferon alpha 2b
1975776|NCT01294332|Other|Rehabilitation|Aerobic Exercise Training
1975777|NCT01293214|Procedure|Limb transplantation|
1975778|NCT01287104|Biological|NK Cell Infusion|Post-transplant Day 21 (plus-minus 3 days): (1 x 105, 1 x 106 or 1 x 107) NK cells/kg by IV infusion. Followed by a second NK cell infusion of the same cell dose, on Day 49 plus-minus 7 days.
1975779|NCT01287104|Biological|Stem Cell Infusion|Transplant Day 0: >4 x 106/kg CD34+ stem cells by IV infusion Filgrastim, 5 microgram/kg per day SQ from day 0 until ANC >5000/microliters x2
1975780|NCT01287078|Drug|Cyclosporine Inhalation Solution|
1975781|NCT01287026|Device|Balloon catheter for right heart catheterization|
1975782|NCT01287026|Drug|Gadopentate Dimeglumine (Gadolinium); Contrast Agent|
1975783|NCT01287026|Procedure|Right Heart Catheterization|
1975784|NCT01287026|Procedure|Cardiac Real-time MRI|
1975785|NCT01287026|Procedure|Vascular Hemostasis|
1975788|NCT01285310|Drug|Apremilast 30 mg|30 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 30mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
1975789|NCT01285310|Drug|Apremilast 20 mg|20 mg oral Apremilast tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in the active treatment / active treatment extension phase.
1975790|NCT01285310|Drug|Placebo|Oral Placebo tablets administered twice daily (BID) for 24 weeks during the placebo-controlled phase followed by 20mg Apremilast tablets administered BID for up to 1.5 years in active treatment / active treatment extension phase. Participants who are nonresponders will advance early to 20 mg Apremilast BID at Week 16.
1975797|NCT01273168|Drug|Z-Endoxifen|Genetic polymorphisms in CYP2D6 and concomitant medications alter tamoxifen metabolism, limiting exposure to the active metabolite endoxifen. These factors are associated with a higher rate of recurrence and shorter disease-free survival in breast cancer patients receiving tamoxifen. Administration of endoxifen directly to patients is anticipated to bypass the effects of CYP2D6 polymorphisms and concomitant medications and provide adequate active drug levels in all treated patients, resulting in clinical benefit
1975798|NCT01273207|Drug|Inhaled Cyclosporine Solution|
1975807|NCT01258972|Device|Tryton Side Branch Stent with main branch DES|Tryton Side Branch Stent
1975808|NCT01258972|Device|POBA|Balloon angioplasty
1975809|NCT01258608|Drug|Mapatumumab|Mapatumumab will be supplied as a lyophilized formulation in 10 mL vials containing 100 mg mapatumumab for intravenous infusion at the dose of 30 mg/kg.
1975810|NCT01258608|Drug|Placebo|Normal saline solution for intravenous infusion will be administered as placebo for mapatumumab
1975811|NCT01258608|Drug|Sorafenib|Sorafenib will be supplied as tablets, each containing 274 mg sorafenib tosylate, equivalent to 200 mg of sorafenib, to be administered 400 mg (2 x 200 mg tablets) orally twice daily.
1975812|NCT01251302|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score
1975814|NCT01239368|Procedure|Adoptive Immunotherapy|Th1.rapa cell infusion will be evaluated after administration of a 7-day or 14-day course of immunedepleting chemotherapy (pentostatin plus cyclophosphamide regimen).
1975815|NCT01239368|Biological|Rapamycin-Generated Autologous Th1/Tc1 Cells|Six Th1.rapa cell doses will be tested in cohorts of 1-6 subjects each: ranging from 10e5 to 15 x 10e6 cells/kg of body weight.
1975816|NCT01239368|Biological|Th1/TC1 Rapa Cell Therapy|Th1/TC1rapa: 5 x 10e6 cells/kg
1975817|NCT01237067|Drug|Carboplatin|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
1975818|NCT01237067|Drug|Olaparib|A phase I 3 + 3 safety run-in will optimize tablet olaparib dose (d1-7) in combination with carboplatin on day 1. The carboplatin dose through the randomized portion of the trial will be AUC4. Subsequent accrual will randomize patients to one of 2 schedules on cycle 1 with the other schedule on cycle 2. A: olaparib d1-7 > carbo d8; B: carbo d1 > olaparib d2-8. Cycle 3-8 will be schedule B. After 8 cycles of carboplatin, olaparib will be administered alone on a daily basis.
1975821|NCT01222754|Drug|Lenalidomide|"With radiation therapy five days per week, concurrent doses of lenalidomide daily in a standard Phase I dose escalation design.
Maintenance dosing of lenalidomide, post-radiation, for 21 days of a 28 day course."
1975822|NCT01222754|Radiation|XRT, 54-59.4 Gy|Radiation therapy five days per week to a prescription dose of 54-59.4 Gy, with concurrent administration of lenalidomide
1975823|NCT01218854|Device|Needle angle measurement|The tool for measuring the needle angles will be an FDA-approved EM tracking system. At no time will the needle enter tissue that it wouldn t have otherwise entered as neither system will be used to perform the biopsies at this time.
1975830|NCT01200940|Other|Sucralose|
1975831|NCT01200940|Other|Aspartame|
1975832|NCT01200940|Other|Acesulfame-Potassium|
1975844|NCT01192568|Drug|Oxybutynin|10% Oxybutynin Chloride Topical Gel, 0.5 g, 0.75 g, and 1 g/day, administered transdermally.
1975846|NCT01181154|Drug|rituximab (Mabthera®)|1000 mg at day 1 and day 15
1975847|NCT01181154|Drug|Placebo|equivalent volume total
1975849|NCT01176006|Procedure|Reduced-intensity hematopoietic stem cell|Stem cell transplant
1975850|NCT01176006|Drug|Fludarabine(Fludara, Berlex Laboratories)|40 mg/m2 IV (in the vein) over 30 minutes (in the vein) once daily on Days -6, -5, -4, and -3 or 30 mg/m2 IV over 30 minutes (in the vein) once daily on Days -6, -5, -4, -3, and -2
1975851|NCT01176006|Drug|Cyclophosphamide(CTX, Cytoxan)|14.5 mg/kg IV (in the vein) infusion over 30 min on days -6, and -5
1975852|NCT01176006|Procedure|Total Body Irradiation (TBI)|200 cGy on Day -1
1975853|NCT01176006|Drug|Busulfan (Busulfex)|3.2 mg/kg IV (in the vein) over 2 hours once daily on Days -6, -5, -4 and -3 (weight based dosing) or on days -4, -3 and -2
1975854|NCT01175993|Other|Exercise|Elliptical training focused on speed
1975855|NCT01175993|Other|Mood Therapy|Bright light therapy
1975860|NCT01174121|Biological|Young TIL|On day 0, cells will be infused intravenously over 20 to 30 minutes (one to four days after the last dose of fludarabine).
1975861|NCT01174121|Drug|Aldesleukin|Aldesleukin 720,000 IU/kg IV (based on total body weight) over 15 minutes approximately every eight hours (+/- 1hr) beginning within 24 hours of cell infusion and continuing for up to 5 days (maximum of 15 doses.)
1975862|NCT01174121|Drug|Cyclophosphamide|On day -7 and day -6: Cyclophosphamide 60 mg/kg/day X 2 days IV in 250 ml D5W over 1 hr.
1975863|NCT01174121|Drug|Fludarabine|On day -5 to day -1: Fludarabine 25 mg/m2/day IVPB daily over 30 minutes for 5 days.
1919363|NCT00681109|Drug|2.5% IL-1Ra|2.5% custom made topical IL-1Ra three times a day in both eyes for three months
1919364|NCT00681109|Drug|Placebo|custom eye drop to be applied three times a day in both eyes for three months
1919365|NCT00681109|Drug|5% IL-1Ra|5% custom made topical IL-1Ra to both eyes 3 times a day for 3 months
1975864|NCT01174121|Drug|Pembrolizumab|Day -2, day 21, day 42, and day 63, Pembrolizumab 2mg/kg IV over approximately 30 minutes.
1975869|NCT01168037|Device|Endovascular aortic repair with branched/fenestrated stent-graft|Insertion via bilateral femoral access, stent-graft deployment under fluoroscopic guidance, complementary stenting of visceral arteries, control angiogram
1975870|NCT01168037|Procedure|Open Surgical Repair|aortic replacement with revascularization of visceral arteries
1975871|NCT01159522|Drug|SCB01A|This is an open-label, single-arm, dose-escalation, safety and tolerability study. Eligible subjects will be assigned to a SCB01A dose level at the time of study entry and scheduled to receive two treatment cycles with SCB01A for the observation of DLT. A treatment cycle is defined as a three-hour infusion of SCB01A given every 21 days. Unless any off-study criteria are met, the study period of each subject can be up to two cycles.
1975872|NCT01151930|Drug|SCB01A|This is a companion study to the protocol SCB01A-01 intended to provide long-term continued administration to subjects that completed Protocol SCB01A-01 on a compassionate basis. It is an open-label, single-arm study of SCB01A in subjects who have completed 2 cycles of treatment under the SCB01A-01 protocol.
1975873|NCT01145209|Drug|Fludarabine Phosphate|Given IV
1975874|NCT01145209|Biological|Ofatumumab|Given IV
1975875|NCT01145209|Drug|Cyclophosphamide|Given IV
1975876|NCT01143558|Procedure|Skin Biopsy|
1975877|NCT01143558|Device|Xenodiagnosis|
1975878|NCT01143558|Procedure|Blood Drawing|
1975879|NCT01143545|Biological|Allogeneic Tumor Cell Vaccine (K562)|Subcutaneous injection monthly for 6 months
1975880|NCT01143545|Drug|Celecoxib|400 g po bid
1975881|NCT01143545|Drug|cyclophosphamide|50 mg po bid
1975887|NCT01119846|Drug|GSK1292263|GSK1292263 is an immediate-release round, white, film-coated tablet provided in 3 strengths, 25mg, 75mg and 200mg being developed for the treatment of type 2 diabetes.
1975888|NCT01119846|Drug|GSK1292263 matching placebo|Matching placebo to active drug GSK1292263
1975889|NCT01119846|Drug|Sitagliptin|"Sitagliptin (Januvia) 100mg tablets are beige, round, film-coated tablets with 277 on one side."
1975890|NCT01118715|Device|Compression glove|A compression glove worn during recovery from distal radius fracture
1975898|NCT01117506|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score
1975902|NCT01101880|Biological|filgrastim|Given SC
1975903|NCT01101880|Drug|clofarabine|Given IV
1975904|NCT01101880|Drug|cytarabine|Given IV
1975910|NCT01092195|Biological|Gardasil|3 separete 0.5 ml intramuscular
1975911|NCT01092182|Drug|EPOCH-R|EPOCH-R every 21 days for 6 cycles
1975912|NCT01092182|Drug|EPOCH-RR|EPOCH-R every 21 days for 3 cycles
1975913|NCT01091545|Radiation|DBT and FFDM|Women in the study will once undergo both standard FFDM screening (2-views) and DBT (1 view, MLO). This will result in a doubled radiation dose compared to only 2-view FFDM, which is the standard procedure for women in the screening program.
1975914|NCT01087294|Procedure|Allogeneic stem cell transplant|Allogeneic stem cell transplant
1975915|NCT01087294|Biological|Anti-CD19-chimeric-antigen-receptor- transduced T cell|Patients receive T cells genetically engineered to express an anti-CD19 CAR. Whole PBMC will be cultured in the presence of 50 ng/mL anti-CD3 (OKT3) and 300 IU/mL aldesleukin.
1975916|NCT01087294|Drug|Cyclophosphamide|180 mg/m2 IV infusion over 30 minutes on days -4, -3 and -2
1975917|NCT01087294|Drug|Pentostatin|4 mg/m2 IV infusion over 30 minutes following the cyclophosphamide on day -4
1975918|NCT01083108|Procedure|Roux-en-Y Gastric Bypass|
1975919|NCT01083108|Behavioral|Caloric Restriction|
1975920|NCT01080716|Biological|WRSS1 vaccine|Single, oral dose of WRSS1
1975921|NCT01080716|Biological|Placebo vaccine|Placebo vaccine
1975922|NCT01079806|Drug|Entecavir|Tablets/oral solution, 0.015 mg/kg up to 0.5 mg, administered orally, once daily, for 96 to144 weeks, depending on response
1975923|NCT01079806|Drug|Placebo|Tablets/oral solution, 0 mg, administered orally, once daily, for 48 to 96 weeks, depending on response
1975928|NCT01062425|Radiation|Radiation Therapy|2 Gy daily 5 days per week for a total of 60 Gy over 6 weeks. Either intensity-modulated radiation therapy (IMRT) or 3D conformal radiation therapy (3D-CRT) may be used, but the same treatment must be used for the entire course of treatment.
1975929|NCT01062425|Drug|Cediranib|Cediranib (20mg/day in all phases) will be administered in combination with daily temozolomide during the 6 weeks of the chemoradiation phase of this study, will continue as monotherapy for 4 weeks after conclusion of chemoradiation, and will then be administered in combination with temozolomide for 24 weeks (6 cycles) and up to 48 weeks (12 cycles).
1975930|NCT01062425|Other|Placebo|Placebo (20mg/day in all phases) will be administered in combination with daily temozolomide during the 6 weeks of the chemoradiation phase of this study, will continue as monotherapy for 4 weeks after conclusion of chemoradiation, and will then be administered in combination with temozolomide for 24 weeks (6 cycles) and up to 48 weeks (12 cycles).
1975931|NCT01062425|Drug|Temozolomide|Temozolomide will be administered continuously to patients at a daily oral dose of 75mg/m2 from day 1 of radiotherapy to the last day of radiation for 42 days or a maximum of 49 days if radiation is delayed. In the first post-radiation cycle of combination cediranib or placebo + temozolomide, the temozolomide will be administered at 150mg/m2/day on days 1-5 of the 28-day cycle. If this combination is well-tolerated the temozolomide dose will be increased to 200mg/m2/day on days 1-5 of the 28-day cycle for cycles 2-6.
1975932|NCT01059786|Drug|Pentostatin|28 patients to pentostatin 4 mg/m2 days 1 and 15 of each cycle.
1975933|NCT01059786|Drug|Rituximab|Rituximab 375 mg/m2 on day 1, 15 for 6 x 28-day cycles (all 68 patients)
1975934|NCT01059786|Drug|Bendamustine|28 patients to bendamustine 90 mg/m2/day, days 1 and 2 each cycle
1919467|NCT00660751|Drug|Duloxetine|SNRIs
1975954|NCT01032239|Drug|intrathecal baclofen|ITB test, implant, 6 months follow-up
1975955|NCT01030900|Biological|campath|campath plus EPOCH and rituximab every 3 weeks for up to 6 cycles
1919480|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 1 (rMenB Lot 1)|One dose of rMenB Lot concomitantly with the routinely administered infant vaccines
1919481|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 2 (rMenB Lot 2)|One dose of rMenB concomitantly with the routinely administered infant vaccines
1919482|NCT00657709|Biological|Serogroup B meningococcal Vaccine lot 3 (rMenB Lot 3)|One dose of rMenB concomitantly with the routinely administered infant vaccines
1919483|NCT00657709|Biological|Infanrix Hexa|Routine vaccination
1919484|NCT00657709|Biological|Menjugate|One dose of the routinely administered infant vaccines + MenC vaccine
1919485|NCT00657709|Biological|Prevenar|Routine vaccination
1975956|NCT01030900|Biological|Rituximab|rituximab plus EPOCH and campath every 3 weeks for up to 6 cycles
1975957|NCT01030900|Drug|EPOCH|EPOCH plus rituximab and campath every 3 weeks for up to 6 cycles
1975968|NCT01006707|Drug|Ondansetron|In this cross-over study, the blinded patient will receive saline placebo in one session and ondansetron in the other. The order is decided with a randomization table. If ondansetron is randomly chosen, an 8mg IV Bolus will be given at the start of the study for 30 minutes by the unblinded investigator.
1975978|NCT00999375|Behavioral|Education|
1975979|NCT00999375|Behavioral|Problem Solving|
1975980|NCT00999375|Behavioral|Social Learning|
1975981|NCT00999375|Behavioral|Behavior Modification|
1975984|NCT00977691|Procedure|PBMC Transplant|
1975985|NCT00977691|Drug|Alemtuzumab (Campath )|
1975986|NCT00977691|Drug|Sirolimus (Rapamune )|
1975987|NCT00977691|Drug|Cyclophosphamide (Cytoxan )|
1975988|NCT00977691|Procedure|Low Dose Irradiation|
1975989|NCT00977977|Drug|Rituximab Infusion|2 infusions (each 1000 mg) separated by 2 weeks; repeated after 6 months
1975990|NCT00977977|Drug|Oral Cyclosporine|Daily therapy for 6 months (3-5 mg/kg), then tapered and discontinued
1975993|NCT00967785|Drug|Mozobil (TM)|
1975994|NCT00961064|Drug|Eltrombopag|
1975995|NCT00950248|Drug|Idebenone|
1975996|NCT00942877|Drug|AZD2171|Cediranib (AZD2171), a VEGF/KIT tyrosine kinase inhibitor, has demonstrated antitumor activity in early phase clinical trials in adult and pediatric patients with ASPS.
1976006|NCT00932152|Drug|fulvestrant (Faslodex)|Fulvestrant (Faslodex) IM 250 mg monthly after a loading dose of 500 mg on day 1 and 250 mg on day 15 of cycle 1.
1976007|NCT00932152|Drug|anastrozole (Arimidex)|Anastrozole (Arimidex) 1 mg orally QD
1976008|NCT00932152|Drug|Bevacizumab (Avastin)|Bevacizumab (Avastin) 15 mg/kg IV, every 21 days
1976009|NCT00932152|Drug|Best supportive care|Subjects will not receive any chemotherapy for NSCLC nor will they received anti-cancer surgery, immunotherapy, radiotherapy or hormonal therapy. Among the therapies they may take are therapies considered acceptable include, but are not limited to, antibiotics, analgesics, antiemetics, thoracentesis, pleurodesis, blood transfusions, and/or nutritional support (enteral or parenteral
1976011|NCT00927784|Biological|Mesenchymal Precursor cells (RevascorTM)|Participants will receive intramyocardial injections of low dose (25 million) or higher dose (75 million) MPCs (in sequential cohorts).
1976012|NCT00927784|Drug|Cryoprotective media alone|Participants will receive intramyocardial injections of cryoprotective media (placebo).
1976013|NCT00926640|Drug|Belinostat|6 cycles of belinostat 400 mg/m2/24h X2 administered by CIV
1976014|NCT00926640|Drug|Cisplatin|6 cycles at 60mg/m2 IV on day 2
1976015|NCT00926640|Drug|Etoposide|6 cycles 80 mg/m2 IV daily X3 beginning day 2.
1976019|NCT00923013|Drug|Cladribine|Cladribine 0.15 mg/Kg/day by 2-hour i.v. infusion days 1-5. The infusion time may be changed to 1 hour at the discretion of the PI.
1976020|NCT00923013|Drug|Rituximab|Rituximab 375 mg/m2 i.v. infusion every week x8, begin day 1 in half of randomized patients and in all HCLv patients, and then again in all patients at least 6 months later when HCL is detected by blood FACS.
1976021|NCT00923520|Drug|dimethane sulfonate (DMS612, NSC 281612)|DMS 612 on day 1 and 2 with doses starting at 3.5mg/m2 to 18.5mg/m2 until MTD is reached
1976022|NCT00923351|Drug|Tumor Purged/CD25 Depleted Lymphocytes|
1976023|NCT00923351|Biological|Tumor Purged/CD25 Depleted Lymphocytes with Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH pulsed dendritic cells (minimum of 1 X 10e6 cells/kg) on Day2.
1976024|NCT00923351|Drug|rhIL-7|rhIL-7 (20 mcg/kg/dose SQ) approx. 48 hours prior to vaccine) Day 0, Day 14, Day 28 and Day 42
1976025|NCT00923351|Biological|Tumor Lysate/KLH Pulsed Dendritic Cell Vaccine|Tumor lysate/KLH Pulsed dendritic cell vaccine (1-5 X 10e7 cells/injection site, given in 3 sites intradermal) on Day 2, Day 16, Day 30, Day 44, Day 56, Day 70.
1976027|NCT00922883|Drug|Eltrombopag (Promacta)|
1976028|NCT00922883|Drug|Eltrombopag|
1976029|NCT00920439|Biological|PoliorixTM|Single dose, intramuscular administration.
1976030|NCT00912509|Drug|riboflavin|riboflavin 0.1% is applied every 2 minutes for 30 minutes
1976031|NCT00912509|Device|UVX Light|UVX 365 nm wavelength light source is applied with continued application of riboflavin 0.1%
1976032|NCT00908752|Drug|Brivanib|Tablets, Oral, 200 mg, once daily, until disease progression or toxicity
1976033|NCT00908752|Other|Brivanib Placebo|Tablets, Oral, 0 mg, once daily, until disease progression or toxicity
1976034|NCT00908752|Procedure|TACE Therapy|Trans-Arterial Chemo-Embolization Therapy
1976049|NCT00890162|Drug|Epinephrine|
1976050|NCT00890162|Procedure|Bone Marrow Apsiration|
1976051|NCT00890162|Drug|Omalizumab (Xolair)|
1976058|NCT00813228|Drug|Sitagliptin (Januvia)|
1976077|NCT00771901|Drug|tauroursodeoxycholic acid|1750 mg/day for four weeks. Seven pills daily, 2 with breakfast, 2 with lunch, and 3 with dinner.
1976078|NCT00771901|Other|placebo|7 pills daily for 4 weeks
1976079|NCT00771901|Drug|sodium phenylbutyrate|20g/day for four weeks.
1976085|NCT00739362|Behavioral|Behavioral Weight Loss Treatment|
1976086|NCT00739362|Procedure|Transcranial Direct Current Stimulation (TDCS)|
1976087|NCT00739362|Device|Transcranial Direct Current Stimulation (TDCS)|
1976088|NCT00739362|Behavioral|Appetite Control|
1976089|NCT00739362|Procedure|Appetite Control|
1976090|NCT00739362|Device|Weight Control|
1976091|NCT00739362|Behavioral|Weight Loss|
1976093|NCT00729911|Procedure|Atrial Fibrillation ablation|Radio-frequency catheter ablation of atrial fibrillation
1976094|NCT00729911|Drug|Amiodarone|Taken orally on a daily basis.
1976097|NCT00720785|Drug|NK cells +CliniMACs CD3 and CD56 systems|
1976100|NCT00706381|Drug|Sincalide|
1976101|NCT00706381|Drug|Ursodiol Acid|
1976102|NCT00706381|Procedure|High Fat/Low Fat Diet|
1976103|NCT00689936|Drug|Lenalidomide and low-dose dexamethasone|"Lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg 20mg, or 25 mg capsules, given either days 1-21 of each 28 day cycles or given every other day for 21 days until documentation of PD.
Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle up to disease progression"
1976104|NCT00689936|Drug|Lenalidomide plus low-dose dexamethasone given for 18 four-week cycles|"lenalidomide - oral, 2.5mg, 5mg, 10mg, 15mg, 20 mg or 25 mg capsules given on days 1-21 of each 28 day cycle or every other day for 21 days for 18 cycles.
Dexamethasone - oral 4mg tablets for a total dose of 20mg or 40 mg given days 1,8,15 and 22 of each 28 day cycle for 18 cycles"
1976105|NCT00689936|Drug|Melphalan, Prednisone and Thalidomide|Melphalan - oral, 2mg tablets dosed at either 0.25mg/kg, 0.125 mg/kg, 0.20mg/kg or 0.10mg/kg on days 1-4 of each 42 day cycle up to 12 cycles Prednisone - oral, 5mg, 10mg, 20 mg and 50 mg tablets dosed at 2mg/kg daily days 1-4 of each 42 day cycle for up to 12 cycles Thalidomide - oral, 50mg, 100mg and 200 mg capsules dosed at either 100mg or 200 mg daily on days 1-41 of each 42 day cycle for up to 12 cycles
1976106|NCT00687115|Behavioral|Weight Loss|liquid diet at 50% of weight maintaining intake
1976107|NCT00687115|Behavioral|Overfeeding|Overfeeding at 150% of weight maintaining intake
1976108|NCT00687115|Behavioral|Overfeeding Low Pro|Overfeeding 150% of normal intake at <5% protein
1976109|NCT00684788|Behavioral|Contingency management|
1976110|NCT00684775|Behavioral|employment-based reinforcement|"Vivitrol, an extended-release depot formulation of naltrexone, will be used. Participants will be offered an inpatient opioid detoxification and oral naltrexone induction. Participants who complete the oral naltrexone induction (N=40) will be randomly assigned to one of two groups. Both groups will be invited to work in the Therapeutic Workplace and will be prescribed depot naltrexone for 6 months. Participants in the Work Plus Naltrexone Contingency condition will earn access to working and earning salary by taking depot naltrexone injections once per month. Work Plus Naltrexone Prescription participants will be encouraged to take depot naltrexone monthly, but access to working and earning salary will not be contingent on doing so."
1976111|NCT00678821|Procedure|Excerise Training|
1976112|NCT00678821|Procedure|Patient Education (Placebo)|
1976113|NCT00674583|Biological|GSK Biologicals' meningococcal vaccine GSK134612|Intramuscular administration, 1 dose
1976114|NCT00674583|Biological|Menjugate|Intramuscular administration, 1 dose
1976116|NCT00651794|Behavioral|Teamwork training|Crew Resource Management (CRM) is an aviation training program mandated for all crew members that teaches human factors concepts, communication skills, and teamwork behaviors that can prevent and manage error. Over the last six years the study team has translated these behaviors to neonatal resuscitation and demonstrated that they can be reliably measured. Adding teamwork instruction to the existing NRP, based upon CRM, may be a method to improve communication, teamwork, and the overall quality of neonatal resuscitation.
1976117|NCT00651794|Behavioral|Standard NRP curriculum|The existing NRP course, taught to most caregivers in the United States who care for newborns, focuses on teaching the technical aspects of neonatal resuscitation with little attention paid to communication and teamwork.
1976118|NCT00651794|Behavioral|Skills practice with low-fidelity mannequin|
1976119|NCT00651794|Behavioral|Skills practice with high-fidelity mannequin|SimBaby mannequins (Laerdal Medical Corp, Stavanger, Norway) were used in the high-fidelity skills stations. These mannequins have simulated heart tones, breath sounds, pulses, and cries.
1976120|NCT00649766|Behavioral|tailored newsletter|Tailored newsletter that addresses each person's stage of change, barriers to getting eye exams, and knowledge of eye exams and eye disease
1976121|NCT00649766|Behavioral|targeted newsletter|Targeted newsletter that contains messages about barriers to getting eye exams and presents facts about glaucoma and African-Americans.
1976143|NCT00578032|Behavioral|Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment|All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
1976156|NCT00562289|Drug|aspirin|during the follow up
1976157|NCT00562289|Drug|Antivitamins K or rivaroxaban or dabigatran or apixaban|during the follow up
1976158|NCT00562289|Device|Devices for PFO closure|endovascular treatment no longer than 21 days after the random.
1976159|NCT00531128|Behavioral|High/Low Sitosterol|
1976160|NCT00528437|Drug|temozolomide, thiotepa, carboplatin, 13-cis-retinoic acid|13-cis-retinoic acid, when absorbed, may be subject to first-pass metabolism and subsequent plasma (and tumor) concentrations will depend on the rate of metabolism to the inactive 4-oxo metabolite.
1976161|NCT00514046|Drug|Vandetanib|once daily continuously (28 day cycles)
1976162|NCT00500617|Diagnostic Test|Corus CAD|Age/Sex/Gene Expression Score
1976163|NCT00491751|Drug|atorvastatin|atorvastatin 40 or 80 mg/day
1976164|NCT00491751|Drug|ascorbic acid|ascorbic acid 500 mg/day
1976165|NCT00491751|Drug|Placebo|matching placebo
1976173|NCT00450463|Drug|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant DNA technology in yeast Saccharomyces cerevisiae). Sargramostim is a 127 amino acid glycoprotein, altered from the native, natural human GM-CSF molecule; the position 23 arginine has been replaced with a leucine to facilitate the expression of the protein in yeast.
1976174|NCT00450463|Drug|Flutamide (Eulexin)|Orally administered, nonsteroidal, competitive antagonist of testosterone and other androgens at androgenic receptors and may alter the nuclear translocation of the androgen/receptor complex.
1976175|NCT00450463|Biological|PROSTVAC-F/ TRICOM|A recombinant fowlpox virus vector vaccine containing the genes for human PSA and three costimulatory molecules.
1976176|NCT00450463|Biological|PROSTVAC-V/TRICOM|A recombinant vaccinia virus vector vaccine containing the genes for human PSA and three co-stimulatory molecules.
1976182|NCT00424047|Drug|CC-5013 plus dexamethasone|25 mg daily for 21 days every 28 days.
1976183|NCT00424047|Drug|Dexamethasone plus Placebo|Oral pulse dexamethasone is administered at a dose of 40mg daily on Days 1-4, 9-12, and 17-20 of each 28 day cycle for Cycles 1 through 4. Beginning with Cycle 5, the oral dexamethasone dosing schedule will be reduced to 40mg daily for Days 1-4 every 28 days. In addition, oral placebo capsules will be administered for 28 days of every cycle.
1976184|NCT00421707|Drug|GW876008|
1976185|NCT00421707|Other|Placebo|
1976195|NCT00395538|Drug|PTH 1-34|Given twice daily by subcutaneous
1976196|NCT00391170|Drug|Topical Dexamethasone|
1976197|NCT00391170|Drug|Placebo|
1976200|NCT00374140|Drug|RAD001 (everolimus)|10 mg by mouth daily without interruption for 3-week cycles until disease progression or intolerable toxicities
1976201|NCT00372320|Genetic|Gene Transfer|
1976202|NCT00372320|Drug|AdhAQP1|
1976203|NCT00370890|Drug|Adjuvant chemotherapy (gemcitabine and cisplatin)|Gemcitabine 1000 mg/m2 in 250 ml NS over 30 mins IV on Day 1 and 8 Cisplatin 40 mg/m2 in 1L NS over 2 h IV on Day 1 and 8 Cycle repeated every 3 weeks for total of 6 cycles
1976207|NCT00355641|Drug|Ropinirole Extended Release (XR)|Dose range of Ropinirole XR of 0.5mg to 6.0mg daily
1976208|NCT00353158|Drug|Doxycycline|100mg twice daily for 3 days. Two hours after the last dose of doxycycline is taken in the clinic, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
1976209|NCT00353158|Drug|Voriconazole|After taking voriconazole for (Bullet)7 days to achieve a steady state of voriconazole for subjects, on-medication phototesting with ssUVR, UVA, and visible light will be performed.
1976214|NCT00345943|Other|MRI|Magnetic Resonance Imaging scans
1976215|NCT00345943|Behavioral|Neuropsychological Testing|Neuropsychological tests
1976216|NCT00345345|Drug|Alemtuzumab (Campath)|
1976217|NCT00340938|Procedure|Blood testing|
1976218|NCT00339768|Drug|Amoxicillin/omeprazole|To treat Helicobacter pylori infections. 2 week course of amoxicillin 1gm bid, omeprazole 20mg bid. This factorial trial also investigated a supplement of vitamin C, vitamin E and selenium and a garlic supplement.
1976219|NCT00339469|Dietary Supplement|LIFE|We are evaluating the effects of a legume enriched, low glycemic index, high fermentable fiber diet, on CRP, and C-peptide participants with four possible combinations of the risk factors insulin resistance and history of adenomatous polyps. In a randomized crossover design controlled feeding study each participant consumed the above experimental diet and a control diet for four weeks with a two week washout period between diets. 65 male participants were recruited and randomized into four groups. A secondary objective is to assess whether these endpoints change by IR status or a history of adenomas. In addition, potential fecal markers of CRC risk are being measured to assess changes in gastrointestinal inflammation, including mRNA from exfoliated fecal colonocytes. To our knowledge this is the first controlled feeding study: 1. to examine the effects of legumes or a low GI diet on markers of inflammation
1976220|NCT00322127|Drug|AMD3100|
1976221|NCT00321555|Drug|Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin|LMB-2 Infusion: 40 micro-g/Kg will be infused in 50 ml of 0.9% NaCl and 0.2% albumin via over 30 minutes every other day for 3 doses. Patients may receive up to six treatment cycles every 4 weeks.
1976222|NCT00315744|Drug|Salmeterol/fluticasone|Salmeterol/ fluticasone are a type of long acting beta-agonist (LABA). Salmeterol 50 microgram/ fluticasone 100 microgram combination will be administered to eligible subjects via inhalation route.
1976223|NCT00315744|Drug|Fluticasone propionate|Fluticasone propionate is a type of LABA. Fluticasone 100 microgram dose will be administered to eligible subjects via inhalation route.
1976224|NCT00315744|Drug|Salbutamol|Salbutamol metered dose inhaler will be provided to all subjects as a rescue medication.
1976225|NCT00314795|Drug|peginesatide|
1976233|NCT00304187|Drug|Erythromycin|Erythromycin, 250 mg or 500 mg, three times a day for 6 weeks
1976234|NCT00304187|Drug|Placebo|Placebo, 250 mg or 500 mg, three times a day for 6 weeks
1976239|NCT00267865|Drug|Methotrexate|6000 mg/m2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patient s urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.
1976240|NCT00267865|Drug|Rituximab|375 mg/m2 IV day 1 of each cycle prior to administration of high-dose methotrexate
1976241|NCT00267865|Drug|Leucovorin|Leucovorin calcium doses will be administered orally or by short IV infusion over 15 minutes
1976242|NCT00255801|Drug|Targretin® (bexarotene)|
1976243|NCT00255801|Drug|pegylated liposomal doxorubicin hydrochloride|
1976247|NCT00229632|Drug|Idebenone|Idebenone is a short-chain benzoquinone derivative of similar structure to ubiquinone (coenzyme Q10). This compound was synthesized and developed initially by Takeda Chemical Industries, Ltd. (Osaka, Japan) and designated as CV-2619. The chemical name for idebenone is 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benxoquinone. Santhera Pharmaceuticals (Liestal, Switzerland) LLC, will supply drug for this study as specified by a clinical trial agreement.
1976256|NCT00214422|Radiation|External Beam Radiation|Radiation will be given in dose escalations from 5040 cGy to a maximum of 5900cGy to lymph nodes.
1976263|NCT00195637|Drug|Immune Globulin|
1976270|NCT00109174|Procedure|Magnetic Resonance Spectroscopy|To measure relative concentrations of 13C-labeled metabolites with Mass Spectroscopy technique
1976272|NCT00101140|Drug|anti-thymocyte globulin|
1976273|NCT00101140|Drug|fludarabine phosphate|
1976274|NCT00101140|Drug|thiotepa|
1976275|NCT00101140|Procedure|biological therapy|
1976276|NCT00101140|Procedure|bone marrow ablation with stem cell support|
1919757|NCT00605839|Device|GlucoPak|We will be giving participants Glucopak devices and monitoring them closely over the 6 month period.
1919758|NCT00605839|Device|Cell Phone|We will provide cell phones and access to the clinic to facilitate communications
1919759|NCT00605839|Other|Usual Care|This intervention was usual care, without either device.
1976277|NCT00101140|Procedure|chemotherapy|
1976278|NCT00101140|Procedure|non-specific immune-modulator therapy|
1976279|NCT00101140|Procedure|peripheral blood stem cell transplantation|
1976280|NCT00101140|Procedure|radiation therapy|
1976281|NCT00098072|Procedure|Heart Catheterization|
1976282|NCT00098072|Drug|Nitric Oxide|
1976283|NCT00098072|Drug|Nitric Oxide/INO Pulse Delivery|
1976284|NCT00098072|Drug|Sodium Nitrite|
1976285|NCT00092222|Drug|Etoposide|Etoposide 50 mg/m2 /day continuous intravenous infusion (CIVI) over 24 hours x 4 days (days 1-4) of 21 day cycle. A maximum of 6 cycles of R-EPOCH-R will be administered except in exceptional circumstances.
1976286|NCT00092222|Drug|Interferon-alpha|Ages 18 and over: Initial dose of 7.5 million units subcutaneous, three times weekly x 14 days; subsequent dosesincrease dose as tolerated each 14 days to a maximum of 45 million units subcutaneous three times weekly; Ages 12-17: Initial dose of 5 million units/m2 subcutaneous, three times weekly x 14 days Subsequent doses: Increase dose as tolerated each 14 days to a maximum of 30 million units/m2 subcutaneous, three times weekly
1976287|NCT00092222|Drug|Rituximab|Rituximab 375 mg/m2 IV day 1, shall be administered prior to Doxil injection. When combined with EPOCH chemotherapy, Rituximab will be given on days 1 and 5.
1976288|NCT00092222|Drug|Zidovudine|Cycle 1: Zidovudine 600 mg PO QID x 7-21 days in outpatient setting;600 mg PO q6hours x 7-21 (Intravenous zidovudine 300 mg q 6 hours may be substituted) days for inpatients; Cycle 2 and beyond: 600 mg PO QID x 7 days in outpatient setting; 600 mg PO q 6 hours x 7 days (300 mg q 6 hours may be substituted)
1976289|NCT00092222|Drug|Liposomal Doxorubicin|21 day cycle; 20 mg/m2 Liposomal Doxorubicin given on day 1 and shall be administered after completion of Rituximab infusion from 2 to 6 cycles.
1976290|NCT00092222|Drug|Bortezomib|1.3 mg/m2 IV days 1, 4, 8, and 11. Cycle length is 21 days.
1976291|NCT00092222|Drug|Valganciclovir|Cycle 1: Valganciclovir 900 mg PO BID x 7-21 days in outpatient setting; 900 mg PO q 12 hours x 7-21 days for inpatients; Cycle 2 and beyond: 900 mg PO BID x 7 days for outpatients; 900 mg PO q 12 hours x 7 days (Intravenous ganciclovir 5 mg/kg may be substituted) for inpatients
1976292|NCT00092222|Drug|Doxorubicin|10 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
1976293|NCT00092222|Drug|Vincristine|0.4 mg/m2 /day CIVI over 24 hours x 4 days (days 1-4) of 21 day cycle.
1976294|NCT00092222|Drug|Cyclophosphamide|Cyclophosphamide: if CD4 < 100 cells/mm3, 187 mg/m2 IV (Day 5) if CD4 (Bullet) 100 cells/mm3, 375 mg/m2 IV (Day 5) of 21 day cycle.
1976295|NCT00092222|Drug|Filgrastim (G-CSF)|Filgrastim 300 micrograms subcutaneous daily beginning day 6 until absolute neutrophil count recovery 5000 cells/mm3 (Pegfilgrastim may be substituted with PI approval, at the recommended dose of one 6mg syringe)
1976296|NCT00092222|Drug|Prednisone|Prednisone 60 mg/m2/day PO x 5 days (days 1-5)of 21 day cycle.
1976297|NCT00092222|Drug|Sirolimus|Maximum daily dose of 40 mg given as a single agent on 21 day cycle.
1976298|NCT00088413|Biological|PANVAC-V|A recombinant vaccinia virus vector vaccine containing genes for human CEA, MUC-1 and three co-stimulatory molecules: B7.1, ICAM-1, and LFA-3.
1976299|NCT00088413|Biological|PANVAC-F|A recombinant fowlpox virus vector vaccine containing genes for human CEA, MUC-1, and three co-stimulatory molecules:B7.1, ICAM-1, and LFA-3.
1976300|NCT00088413|Drug|Sargramostim (GM-CSF, Leukine)|A recombinant human granulocyte-macrophage colony stimulating factor (GM-CSF) produced by recombinant DNA technology in yeast (Saccharomyces cerevisiae). It is a commercially available drug administered subcutaneously.
1976301|NCT00085982|Drug|Metreleptin|
1976302|NCT00082147|Procedure|Biopsy|Patients will then undergo endorectal coil MR imaging of the prostate gland, including conventional anatomic imaging and dynamic-contrast-enhanced MRI During MR imaging, 4 to 10 needle biopsy cores of the prostate will be obtained using a trans-rectal needle guide system (APT-MRI).
1976304|NCT00076180|Biological|Hu-MiK-Beta-1|Hu-MiK-Beta-1 administered as an intravenous infusion over 90- minutes.
1976305|NCT00074490|Drug|Rituximab|Rituximab:375 mg/m2/day IV, day 1 (for CD20+ patients)
1976306|NCT00074490|Drug|Fludarabine|Fludarabine:25 mg/m2/day IV, days 1-4
1976307|NCT00074490|Drug|Etoposide|Etoposide: 50 mg/m2/day CIV, days 1-4
1976308|NCT00074490|Drug|Doxorubicin|Doxorubicin:10 mg/m2/day CIV, days 1-4
1976309|NCT00074490|Drug|Vincristine|Vincristine:0.4 mg/m2/day CIV, days 1-4
1976310|NCT00074490|Drug|Cyclophosphamide|Cyclophosphamide, 750 mg/m2/day IV, day 5
1976311|NCT00074490|Procedure|PBSC transplantation|PBSC transplantation, peripheral blood progenitor cell transplantation, transplantation, peripheral blood stem cell
1976312|NCT00074490|Genetic|T cell DLI with sirolimus generated donor TH-2 cells|The cell of the Th2 cells will attempt to be held constant for each study receipient (target dose 2.5 x 107 Th2/kg; minimum dose will be 1 x 107 Th2/kg).
1976313|NCT00074490|Drug|Prednisone|Prednisone:60 mg/m2/day PO, days 1-5
1976314|NCT00074490|Procedure|Allogeneic HSCT|Allogeneic Hematopoietic Stem Cell Transplant
1976315|NCT00074490|Drug|Filgrastim|Filgrastim:5 mcg/kg/day SC, day 6 (require ANC > 1000, two values; or ANC > 5000 cells/ul on one occasion)
1976316|NCT00074490|Genetic|T-Rapa cell DLI|The dose of Th2 cells or unmaniipulated donor T cells will attempt to be held constant for each study recipient (target dose 2.5 x 107 Th2/kj; minimum dose will be 1 x 107 Th2/kj)
1976322|NCT00069069|Drug|Intransal instillation of E-selectin|Intranasal recombinant human E-selectin
1976323|NCT00065676|Procedure|Oral glucose tolerance test|
1976325|NCT00061568|Procedure|Radiotherapy|
1976326|NCT00061568|Drug|Alemtuzumab (Campath )|
1976327|NCT00061568|Drug|Sirolimus (Rapamune )|
1976328|NCT00061347|Procedure|Fiducial marker placement|Placement of fidicual markers under MRI guidance for localization of radiaiton treatment
1976329|NCT00061360|Drug|Sirolimus (Rapamune)|
1976330|NCT00056160|Drug|CC-5013|Subjects in the CC-5013/Dex treatment group took 25 mg of lenalidomide orally once daily on Days 1 to 21 and a matching placebo capsule once daily on Days 22 to 28 of each 28-day cycle.
1976331|NCT00056160|Drug|Dexamethasone|Subjects in the CC-5013/Dex and Placebo/Dex treatment groups took 40 mg of dexamethasone orally once daily on Days 1 to 4, 9 to 12, and 17 to 20 of each 28-day cycle for the first 4 cycles of therapy. Beginning with Cycle 5, the dose of dexamethasone was reduced to 40 mg orally once daily on Days 1 to 4 for the remaining cycles.
1976332|NCT00054756|Drug|TRH (Thyrotropin Releasing Hormone)|
1976333|NCT00003838|Procedure|Stem cell transplantation|
1976334|NCT00044304|Drug|Imatinib Mesylate|Imatinib is a tyrosine kinase inhibitor that selectively inhibits bcr-abl, c-kit and the plateletderived growth factor receptor tyrosine kinases. Imatinib mesylate was approved by the FDA for use in patients with advanced phase CML and in patients in chronic phase failing first line interferon therapy and in as well as for the treatment of gastrointestinal stromal tumors. Drugs used to treat CML have historically been of benefit in the treatment of HES.
1976335|NCT00039624|Radiation|Brachytherapy|Patients will receive two HDR brachytherapy implants (950-1050 cGy/implant) before and at the end of a course of external beam radiotherapy (4600 cGy, 2Gy/day).
1976336|NCT00033891|Drug|Infliximab|
1976337|NCT00006505|Procedure|Islets|
1976338|NCT00006436|Biological|Rituximab|2 doses of rituximab every cycle: first dose on Day 1 and 2nd dose on Day 5
1976339|NCT00006436|Biological|filgrastim|Figrastim day 6 until ANC reaches 5000 after the nadir, every cycle
1976340|NCT00006436|Drug|EPOCH|combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
1976353|NCT00001964|Drug|Cyclosporine|
1976354|NCT00001849|Drug|Pentetreotide|
1976355|NCT00001849|Drug|18-F-fluorodeoxyglucose|
1976356|NCT00001849|Drug|(18F)-L-3,4-dihydroxyophenylalanine (18F-DOPA)|
1976357|NCT00001806|Other|Genetic Education and Counseling|Group Education and Counseling
1976358|NCT00001806|Other|Genetic Education and Counseling|Individual Education and Counlseing
1976359|NCT00001626|Drug|Antithymocyte globulin &amp; Cyclosporin A|40 mg/kg daily for 4 days
1976360|NCT00001626|Drug|Cyclophosphamide &amp; Cyclosporin A|1 hour IV infusion of 50 mg/kg daily for 4 days
1976361|NCT00001563|Biological|Filgrastim|Filgrastim after EPOCH-R from Day 6 for 10 days every cycle.
1976362|NCT00001563|Biological|Rituximab|EPOCH-R every 3 weeks for up to 6 cycle
1976363|NCT00001563|Drug|EPOCH|EPOCH-R every 3 weeks for up to 6 cycle
1976364|NCT00001529|Drug|G-CSF|
1976366|NCT00001337|Drug|EPOCH|Combination chemotherapy given with Rituximab (EPOCH-R) IV every 3 weeks for 6 cycles.
1976367|NCT00001337|Biological|Rituximab|Rituximab given on Day 1 of combination chemotherapy (EPOCH-R) every 3 weeks for 6 cycles.
1976368|NCT00001303|Drug|Reference Endotoxin|
1976369|NCT00001303|Drug|Inhaled Nitric Oxide|
1997781|NCT01919164|Drug|Placebo|Matching placebo will be administered in 4 cycles (at Baseline and Months 6, 12, and 18), wherein each cycle will include 3 once-weekly intra-articular injections over a period of 3 consecutive weeks, with follow-up to 2 years.
1997782|NCT01918774|Behavioral|Cognitive behavior therapy for work success (CBTw)|The CBTw program includes 12 sessions that are delivered in a weekly one-hour group format. Sessions focused on identifying and modifying maladaptive thoughts related to work, enhancing self efficacy and beliefs in one's ability to succeed at work, identifying and addressing personal barriers to work, and increasing beneficial coping strategies that can be applied across employment settings, including during the job search phase and working on the job. The intervention is tailored toward both employed and unemployed persons seeking community work. Session content includes the following modules: Introduction-Work goals and work story; CBT model and work; Thinking about work; Barriers to work; Coping with stress and anxiety; Coping with anger and difficult emotions; Communication at work; Dealing effectively with people at work; Managing work success; Personal work success plan.
1997783|NCT01915810|Behavioral|Questionnaires|Questionnaire completion on Weeks 3, 2, and 1 before quitting smoking, on quit day, and weeks 1, 2, 3, 4, and 8 after quitting smoking.
1997784|NCT01915810|Behavioral|Phone Counseling|Patients receive counseling about quitting smoking over the phone about 1 - 2 weeks before scheduled quit day.
1997785|NCT01915810|Other|Breath Test|Breath test administered to check for tobacco consumption weeks 3, 2, and 1 before quitting smoking, on quit day, and weeks 1, 2, 3, 4, and 8 after quitting smoking.
1976370|NCT03315182|Biological|rAAV9.CMV.hNAGLU|Adeno-associated virus serotype 9 carrying the human NAGLU gene under the control of a CMV enhancer/promoter (rAAV9.CMV.hNAGLU) will be delivered one-time through a venous catheter inserted into a peripheral limb vein. The vector will be delivered undiluted over 10 to 20 minutes, under light to moderate sedation as needed. Dosing volume will be approximately 2-5 mL/kg, depending on final vector product concentration and subject cohort. A tapering course of prophylactic enteral prednisolone will be administered.
1976371|NCT03316898|Drug|AGN-242071|AGN-242071 capsules administered once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
1976372|NCT03316898|Drug|Placebo|Placebo capsules once daily to patients receiving donepezil 10 mg with or without memantine as prescribed per standard of care.
1976373|NCT03316898|Drug|Donepezil|Donepezil 10 mg as prescribed by the physician as per standard of care.
1976374|NCT03316898|Drug|Memantine|Memantine as prescribed by the physician as per standard of care.
1976375|NCT03316885|Device|Clareon® IOL|Foldable, single-piece posterior chamber IOL intended for long-term use over the lifetime of the cataract patient. This device is CE-marked (European Conformity) in the countries with participating Investigators.
1976376|NCT03316872|Drug|Pembrolizumab|Pembrolizumab is a humanized monoclonal antibody (mAb) of the IgG4/kappa isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2.
1976377|NCT03316872|Radiation|Stereotactic Body Radiotherapy (SBRT)|SBRT involves delivery of high doses of radiation therapy in smaller fractions
1976378|NCT03316859|Drug|Naloxegol 25 MG|Naloxegol 25 mg administered 1 hour pre-operatively
1976379|NCT03316859|Other|Placebo pill|Placebo pill administered 1 hour pre-operatively
1976380|NCT03316846|Behavioral|Internet-Delivered Cognitive Behavioral Therapy|
1976381|NCT03316833|Device|Resolute Onyx|Percutaneous coronary revascularization of patients with unprotected left main coronary artery disease up to intermediate anatomical complexity (defined by a SYNTAX score <33), must be performed with the exclusive use of drug-eluting stents of the Resolute Onyx TM family
1976384|NCT03316807|Biological|60 µg dose hepatitis B vaccine|three-dose, 60 µg per dose
1976385|NCT03316807|Biological|20 µg dose hepatitis B vaccine|three-dose, 20 µg per dose
1976387|NCT03316781|Drug|HLX03|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
1976388|NCT03316781|Drug|adalimumab|80 mg SC at Week 0, 40 mg SC at Week 1, and 40 mg every other week thereafter.
1976389|NCT03316755|Behavioral|Exposure|Exposure to pamphlet
1976390|NCT03316742|Combination Product|Intervention 1|Intervention 1 includes providing participants with a high fiber food product, protein source, high intensity sweetener and adult multivitamin.
1976391|NCT03316742|Combination Product|Intervention 2|Intervention 2 includes providing participants with an alternative dietary fiber source, milk protein, high intensitysweetener and adult multivitamin.
1976392|NCT03316729|Drug|DS-9231|DS-9231 in saline solution for intravenous infusion
1976393|NCT03316729|Drug|Placebo|Placebo is matching saline solution for intravenous infusion
1976395|NCT03316703|Procedure|Conventional open surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.
The vertebral fixation system will be applied through the conventional open approach (group A)."
1976396|NCT03316703|Procedure|Minimally invasive percutaneous surgery|"Surgical treatment will be performed by stabilizing the fractured vertebral segment (proximal vertebra and vertebra distal to fractured vertebra and fractured vertebra) by means of a 6.5 mm or 6.5 mm diameter polyaxial pedicle screw system. In the fractured proximal and distal vertebrae to the vertebrae, screws will be used up to the vertebral body and fractured vertebra will use shorter screws that do not penetrate the vertebral body. In the fractured vertebra, single or bilateral pedicle screw will be used according to the degree of involvement of the pedicle of the fractured vertebra.
The vertebral fixation system will be applied through the minimally invasive percutaneous approach (group B) according to allocation after randomization."
1976400|NCT03316677|Procedure|Intraoperative testing of colorectal anastomoses|"Insert a Foley catheter through the anus into the rectum.
Insufflate the Foley balloon with 5 cc of air.
Air tight leak test with saline and insufflating air: fill the pelvic space with 500 CC of warm saline
Insufflate air into the rectum up to a pressure of 35 mmH2o as measured by external manometer
Remove the saline from the pelvic space.
Inject diluted dye (methylene blue) in to the rectum up to a pressure of 35 mmH2o measured by external manometer
Remove the methylene blue from rectum.
NB the above procedures are standard practice for assessing the quality of colorectal anastomoses during colorectal surgery.
The purpose of the study is to compare these standard methods of evaluation to determinant which method is superior"
1976401|NCT03316677|Procedure|Stapled colorectal anastomoses|After the resection we do the stapled colorectal anastomosis with a standard circular stapler as part of the regular procedure
1976402|NCT03316664|Behavioral|Integrated Neurocognitive Therapy (INT)|Information already included in arm/group description.
1976403|NCT03316664|Behavioral|Integrated Psychological Therapy (IPT)|Information already included in arm/group description.
1976404|NCT03316664|Other|COGPACK|Information already included in arm/group description.
1976405|NCT03316651|Drug|GM-CSF|"After the patients were randomly divided into two groups, they will receive whole lung lavage (WLL), and then one of the two groups with continue the next step as follows:
Induction period: The time of beginning is 1 week after whole lung lavage, aerosolized GM-CSF was given for 7 days (150ug bid), and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle, a total of 6 cycles (3 months) were known as the induction period.
Maintenance period: maintenance period came up after the induction period. The dose of aerosolized GM-CSF was reduced to 150ug/d for three times a week, and then the durg was stopped for 7 days, the 2 weeks was designed as a cycle and maintenance period lasted for 9 months."
1976406|NCT03316638|Drug|W0101 - Cohort A1|Administered once every 2 weeks (Q2W)
1976407|NCT03316638|Drug|W0101 - Cohort A2|Administered every 3 or 4 weeks (Q3W or Q4W)
1976408|NCT03316638|Drug|W0101 - Expansion Phase|Administered according to recommended dose for expansion
1976409|NCT03316625|Diagnostic Test|Bone densitometry measurement|Bone Densitometry and measurement of body composition
1976410|NCT03316612|Dietary Supplement|Vaccinium Myrtillus L. extract|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
1976411|NCT03316612|Dietary Supplement|Placebo|Twice a day, 2 tablets each time. Do not take any other medicine, traditional Chinese medicine, or dietary supplements.
1976412|NCT03316599|Drug|Gemcitabine|Gemcitabine is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells.
1976413|NCT03316599|Drug|Nab-paclitaxel|Nab-paclitaxel is a chemotherapy agent. Chemotherapy agents are medicines that kill cancer cells
1976414|NCT03316599|Drug|Ficlatuzumab|It is selective recombinant humanized hepatocyte growth factor (HGF) inhibitory immunoglobulin G subclass 1 monoclonal antibody which blocks the MET tyrosine kinase receptor.
1976415|NCT03316586|Drug|Nivolumab|Nivolumab is an experimental antibody drug that may make the immune response more active against cancer.
1976416|NCT03316586|Drug|Cabozantinib|Cabozantinib may help to shrink or stabilize breast cancer
1976418|NCT03316560|Biological|rAAV2tYF-GRK1-RPGR|Adeno-associated virus vector expressing a human RPGR-ORF15 gene
1976420|NCT03316534|Drug|Aspirin|Aspirin (100 mg once a day)
1976422|NCT03316495|Behavioral|PAMPHLET|EXPOSURE TO PAMPHLETS
1976423|NCT03316482|Drug|Leuplin DPS 11.25mg|Leuplin DPS 11.25mg s.c. every 12 weeks
1976424|NCT03316469|Drug|Clomiphene Citrate|100 mg daily will be provided to the subjects to be taken for 5 days starting from day 2 of their spontaneous periods
1976425|NCT03316469|Diagnostic Test|Follicular growth|Follicular growth assessment by TVU will be performed at day 12 of the menstrual period.
1976426|NCT03316456|Diagnostic Test|Observational: Stool Sample Collection|"Observational: Stool Sample Collection
- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
1976427|NCT03316456|Diagnostic Test|Observational: Blood Sample Collection|"Observational: Blood Sample Collection
- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
1976428|NCT03316456|Diagnostic Test|Observational: Urine Sample Collection|"Observational: Urine Sample Collection
- Samples will be collected on the day of the first dose of chemotherapy, then subsequently every Monday, Wednesday, Friday until Day 28 of chemotherapy, death, or discharge from the hospital, whichever occurs sooner."
1976431|NCT03316430|Other|Podocyturia quantification|Podocyturia quantification at first planned prenatal care visit before 16 weeks of gestation
1976432|NCT03316417|Other|Renal Tolerance to Immunotherapy|The main objective is to describe the renal tolerance of these innovative therapies within a population homogeneous of patients.
1976433|NCT03316391|Other|Dosage of urinary podocyturia|Dosage of urinary podocyturia at admission, delivery and post-partum visit
1976434|NCT03316378|Drug|Ropivacaine injection|single dose, subcutaneous injection
1998020|NCT01742949|Device|Heated humidification (ThermoSmart)|
1998021|NCT01744483|Device|PVC ETT|Placement of a PVC-cuffed ETT in the setting of emergent intubation.
1998022|NCT01744483|Device|PUC ETT|Placement of a PUC-cuffed ETT in the setting of emergent intubation.
1998023|NCT01744483|Device|PUC-CASS ETT|Placement of a PUC-cuffed in the setting of emergent intubation, followed by continuous aspiration of subglottic secretions for the duration of mechanical ventilation.
1998025|NCT01741259|Drug|Meperidine|
1998026|NCT01732718|Drug|Atorvastatin|Subjects will receive either: 1)atorvastatin for 6 weeks, followed by a 4-week washout period, then receive the other intervention (placebo)for 6 weeks; or 2) the other intervention (placebo) for 6 weeks, washout for 4 weeks, then atorvastatin for 6 weeks.
1998027|NCT01732718|Drug|Placebo for atorvastatin|Inactive substance in tablet form made to mimic atorvastatin 40mg tablet
1998028|NCT01732419|Behavioral|Home-based training|Home-based exercise training for cardiac patients.
1998029|NCT01732419|Behavioral|Centre-based training|Usual exercise training in an outpatient setting.
1998031|NCT01729923|Drug|Capecitabine|Given PO
1998032|NCT01729923|Drug|Celecoxib|Given PO
1998033|NCT01729923|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1998034|NCT01729923|Other|Laboratory Biomarker Analysis|Correlative studies
1976440|NCT03316339|Drug|Dexmedetomidine|Opioid-free anesthesia
1976441|NCT03316339|Drug|Remifentanil|Opioid anesthesia
1976442|NCT03316326|Drug|Tegafur-gimeracil-oteracil potassium|40 mg bid, D1-14
1976443|NCT03316326|Drug|Oxaliplatin|85 mg/m2, D1
1976444|NCT03316326|Drug|Irinotecan|150 mg/m2, D8
1976445|NCT03316313|Diagnostic Test|Hepatitis C Antibody|Patients who received a blood test to screen for the Hepatitis C virus.
1976446|NCT03316300|Combination Product|Renexus®|Surgery to receive one Renexus® device implant.
1976447|NCT03316300|Procedure|Sham|Non-penetrating sham procedure to mimic implant procedure.
1976450|NCT03316274|Drug|Intra-lesional injection of nivolumab|All participants will receive 10mg in 1 mL injection into a single KS lesion in the skin, every 2 weeks for 4 doses.
1976451|NCT03316248|Other|visual feedback|in the study group, subjects were applied for example prosthetic weight bearing exercises in front of the mirror. They watched their reflected image while doing exercises.
1976452|NCT03316248|Other|usual prosthetic rehabilitation|prosthetic weight bearing and balance exercises were applied to the control group for 9 sessions.
1976453|NCT03316222|Drug|GNS561|Escalating doses to be administered 3 times a week.
1976454|NCT03316196|Behavioral|COGENT COGNITIVE TRAINING|Computer-administered cognitive training program. COGENT is a modified working memory capacity task designed to train cognitive functioning. COGENT was designed to contain high interference across trials. By requiring repeated practice with utilization of interference control across trials, COGENT is thought to enhance plasticity of cognitive systems and improve performance. That is, training is based on the premise that learning-based neural changes will occur via repeated exposure to a task demanding cognitive control resources
1976455|NCT03316196|Behavioral|Non training computer condition|The non-training condition requires participants to complete a similar computer task for the same length of time. The non-training is a modified working memory capacity task designed to be inert. The non-training condition was designed to contain relatively less interference demands across trials. Participants are required to remember the same total number of items as in COGENT (i.e., storage requirements were equivalent), but the task contains relatively less interference inherent in the task.
1976456|NCT03316183|Other|Perioperative and postoperative management|Cerebral oximetry informed perioperative management
1976457|NCT03316170|Behavioral|Social Support|A brief phone consultation (10-15 minutes via phone) about free or low-cost resources that may help them address unmet social support needs, and a written directory of a range of social support resources delivered via mail.
1976458|NCT03316170|Drug|NRT Sampling|"A brief phone consult (10-15 minutes via phone) germane to smoking cessation akin to brief advice, a written summary of the benefits of smoking cessation, evidence-based approaches to quit, and the basics of nicotine replacement therapy (NRT) delivered via mail, and a free, 2-week supply of nicotine patches and lozenges delivered via mail."
1976459|NCT03316157|Dietary Supplement|ProSure|Patients will take 2x 220mL nutritional supplements per day for 8 weeks and be given dietary advice to optimise their nutrition
1976460|NCT03316157|Behavioral|Physical Exercise|Patients will receive an individualised exercise regimen consisting of 60 minutes aerobic and 3x resistance elements per week
1976461|NCT03316144|Biological|JS001|Dose escalation study evaluating three dose levels (1, 3 and 10 mg/kg) of JS001. Subjects will be assigned to a dose schedule in the order of study entry.
1976462|NCT03316131|Drug|RDEA3170|Randomized patients will receive orally once daily fixed dose of RDEA3170 in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: RDEA3170 + febuxostat + dapagliflozin; Treatment B: RDEA3170 + febuxostat + placebo
1976463|NCT03316131|Drug|Febuxostat|Randomized patients will receive orally once daily fixed dose of febuxostat in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: RDEA3170 + febuxostat + dapagliflozin; Treatment B: RDEA3170 + febuxostat + placebo
1976464|NCT03316131|Drug|Dapagliflozin|Randomized patients will receive orally once daily fixed dose of dapagliflozin in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: RDEA3170 + febuxostat + dapagliflozin; Treatment B: RDEA3170 + febuxostat + placebo
1976465|NCT03316131|Other|Dapagliflozin matched placebo|Randomized patients will receive orally once daily fixed dose of dapagliflozin matched placebo in 2 treatment sequences AB or BA for 7 consecutive days. Treatment A: RDEA3170 + febuxostat + dapagliflozin; Treatment B: RDEA3170 + febuxostat + placebo
1976466|NCT03316118|Drug|bupivacaine|Group 1 will receive genicular nerve block using bupivacaine
1976467|NCT03316118|Drug|saline|Group 2 will receive genicular nerve block using normal saline
1976468|NCT03316105|Device|Elira Investigational TENS device|TENS unit placed on skin will deliver electric stimulation to abdominal area.
1976470|NCT03316079|Other|Chest physiotherapy techniques|Respiratory manual CPT
1976471|NCT03316079|Device|Mechanical insufflation-exsufflation|CPT + MI-E (4 series of 5 inspiratory-expiratory cycles at +/- 40 cmH2O, 3 seconds of inspiratory time, 2 seconds of expiratory time and 1 second pause between cycles).
1976472|NCT03316066|Procedure|stellate ganglion block with ropivacaine 0.2% 5 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
1976473|NCT03316066|Procedure|stellate ganglion block wit ropivacaine 0.2% 2 mL|Each patient will undergo two stellate ganglion blocks and receive both volumes of local anesthetics in random order. The stellate ganglion blocks will be separated by 3 weeks in order to assure that no residual effects from the previous block will influence the results.
1976474|NCT03316053|Other|Tissue sample for genetic testing|Tissue sample to be obtained during routine endoscopy
1976475|NCT03316040|Behavioral|Join-In-Circuit on AIDS, Love & Sexuality|"The Join In Circuit on HIV, love and sexuality is a mobile learning system on the core topics of reproductive health and HIV and AIDS, targeting young people. JIC works with person-to-person communication in order to give an opportunity for discussion and for providing information in an open, engaging atmosphere. The JIC uses interactive exercises, pictorial aids and edutainment strategies to promote behavior change among young people aged 15 years and older."
1976476|NCT03316014|Other|Adverse drug reaction|description of the adverse drug reactions (ADR) and the drugs involved in pediatrics
1976477|NCT03316001|Other|Review of multidetector row computed tomography scans|multidetector row computed tomography scans
1976478|NCT03315988|Other|Adoption of a vegan diet|Adoption of a vegan diet The participants of this study wil be asked to adopt a vegan diet under the supervision of a Registered Dietitian.
1976479|NCT03315975|Biological|Inactivated influenza vaccine|One dose of quadrivalent inactivated influenza vaccine
1976480|NCT03315962|Behavioral|SPIRIT Intervention|The intervention will include implementing a teaching collaborative among group of DHOs and TB Supervisors, enabling text messaging between DHOs and front line providers, and establishing a report collaborative where DHOs will receive feedback on the performance of their district in administering IPT compared to other districts.
1976481|NCT03315962|Combination Product|Single Pill Combination|Among the districts randomized to the DHO Intervention Arm, a sub-sample of individuals in the district who are eligible for IPT will receive a single pill combination (SPC) of INH/B6/TMP-SMX for IPT. The control group will receive non-coformulated INH, B6 and TMP-SMX for IPT.
1976482|NCT03315962|Other|Reduced Refill Frequency Intervention|Among the districts randomized to the DHO Intervention Arm, a sub-sample of individuals in the district who are eligible for IPT will be randomized to attend refill visits less frequently than monthly. Refill visits will occur at 1 month and 3 months post-IPT start. The control group will be randomized to monthly refill visits in accordance with Ugandan Ministry of Health (MoH) guidelines.
1976483|NCT03315949|Drug|Polyethylene Glycol|Different method for bowel cleansing using same bowel cleanser
1976488|NCT03315910|Behavioral|Motivational Interviewing (MI)|two, 20-minute counseling sessions
1976489|NCT03315910|Drug|Nicotine Replacement Therapy (NRT)|receive 6 weeks of NRT patch with dosing dependent upon reported baseline cigarettes per day
1976490|NCT03315910|Drug|Nicotine Lozenge|6 weeks of NRT 2mg lozenge
1976491|NCT03315910|Behavioral|Message Framing|health communication literature and quitting messages
1976492|NCT03315910|Other|saliva sample|saliva samples from those reporting abstinence and analyze samples
1976495|NCT03315884|Procedure|Iliac segment recanalization and stenting Iliac segment Common Femoral Artery (CFA)|"Retrograde femoral access. Brachial access. Standard endovascular access is performed under local anesthesia and affected arterial segment is visualized. Stenosis or artery occlusion is passed with hydrophilic guide. In case of occlusion transluminal or subintimal (often mixed) artery recanalization is performed. To maximize the preservation of the affected artery initial patency, occlusion recanalization is performed by ante-and retrograde accesses. Then stenosis or occlusion predilation is performed with balloon catheter (balloon catheter diameter is smaller than the affected artery diameter for 1-2 mm). After control angiography stent is installed in the aorta-iliac area throughout the lesion (lesion diameter corresponds to the stenotic arteries diameter). In aorta-iliac zone balloon-expandable and self-expandable stents are used."
1998035|NCT01729923|Other|Quality-of-Life Assessment|Ancillary studies
1998036|NCT01729923|Radiation|Radiation Therapy|Undergo radiation therapy
1998037|NCT01729923|Radiation|Stereotactic Radiosurgery|Undergo stereotactic radiosurgery
1998038|NCT01729923|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
1998039|NCT01729845|Drug|Cytarabine|Given IV
1998040|NCT01729845|Drug|Decitabine|Given IV
1998041|NCT01729845|Drug|Etoposide|Given IV
1998042|NCT01729845|Other|Laboratory Biomarker Analysis|Correlative studies
1998043|NCT01729845|Drug|Mitoxantrone Hydrochloride|Given IV
1998044|NCT01729468|Drug|Aspirin|Aspirin, 160 mg per day until 34 weeks of gestation
1998045|NCT01729468|Drug|Placebo|Placebo, 160 mg per day until 34 weeks of gestation
1998046|NCT01723163|Behavioral|Abstinence Reinforcement Therapy (ART)|Veterans randomized to the intervention will receive cognitive-behavioral telephone counseling (TC), a tele-medicine clinic for access to nicotine replacement (NRT), and mobile contingency management (mCM)
1998047|NCT01723163|Behavioral|Telephone Counseling and NRT|Veterans randomized to the control group will receive cognitive-behavioral telephone counseling (TC) and a tele-medicine clinic for access to nicotine replacement (NRT)
1976496|NCT03315884|Procedure|Iliac segment recanalization, stenting and plastic Common Femoral Artery (CFA) patch|Standard access to the CFA is performed. Outflow ways and CFA capability for reconstruction are determined. The puncture of the general CFA (retrograde) is performed and the introducer 7Fr. is set. Recanalization of iliac artery occlusion. It is necessary to cross the iliac occlusion in a retrograde fashion first and secure aortic inflow before making the arteriotomy. An ipsilateral, a contralateral and a brachial approaches are used depending on the clinical situation. If the retrograde access to the aorta failed, you use the antegrade crossing of the iliac occlusion with no intention to reenter the lumen in the CFA. After the recanalization and balloon angioplasty of iliac artery we completed the procedure with endarterectomy of CFA, patch closure and iliac stenting. The preference is to perform endarterectomy and patch before iliac stenting because it can be difficult to access the true lumen in a difficult CFA lesion. Controlling angiography were performed. Closing approach.
1976503|NCT03315832|Drug|Valsartan|The active treatment is valsartan, an orally active, potent, and specific angiotensin II receptor antagonist. The treatment will be initiated (80 mg, daily) at 5±4 days following aortic valve intervention. The dose will be increased at 160 mg daily 13±2 days after aortic valve intervention and, if well tolerated, for the remaining period of the study.
1976504|NCT03315832|Drug|Placebo Oral Tablet|The comparative treatment will be a placebo; tablets of valsartan and placebo have a similar appearance and administration mode. Patient in the control group will receive a placebo using the same protocol as the valsartan group.
1976505|NCT03315819|Procedure|Bankart repair|Arthroscopic repair of anterior capsulo-labral lesions using the Bankart technique.
1976506|NCT03315819|Procedure|Immobilization interne rotation|Immobilisation in rotation Internal (Dujarrier) 3 weeks then rehabilitation
1976507|NCT03315806|Other|Beetroot juice|140 mL of beetroot juice cointaning approximately 9 mmol of nitrate
1976508|NCT03315806|Other|Placebo|140 mL of beetroot juice isent of nitrate
1976511|NCT03315780|Drug|Dulaglutide|Administered SQ
1976512|NCT03315780|Drug|Placebo|Administered SQ
1976513|NCT03315767|Diagnostic Test|ARFI-elastography and portal vein flow measurement|Liver and spleen-elastography assessed by ARFI-technique and the portal vein flow value-assessment by ultrasound investigation.
1976514|NCT03315767|Diagnostic Test|HVPG-measurement|Evaluation of Portal Hypertension by HVPG-measurement
1976515|NCT03315754|Drug|TOOKAD Soluble 4 mg/kg|Vascular targeted photodynamic therapy using TOOKAD Soluble
1976516|NCT03315741|Drug|Pirfenidone 267 MG [Esbriet]|Tolerability of drug
1976517|NCT03315728|Other|Quality Improvement Strategy|Quality improvement strategy The 18 month Quality Improvement Strategy includes 3 months preparation, 12 months intervention, 3 months local knowledge translation. The intervention includes Readiness Consultations to assist in understanding available resources to address and adopt diabetes and chronic disease prevention and care strategies. Community teams receive a series of 3 workshops (in-person/virtual) followed by action periods where the team carry out and evaluate PDSAs they develop to improve diabetes care. Coaching is provided by Western during the 3-4 month action periods. FNDSS is a webbased secure community portal system for communities to develop a diabetes registry/surveillance system and generate reports and plan QI initiatives.
1976521|NCT03315676|Drug|Oral Bonoprazan|To examine the efficacy of oral Bonoprazan in patients with NSAIDs-induced Erosions and/or Ulcers
1976522|NCT03315676|Drug|Oral Esomeprazol|To examine the efficacy of oral Esomeprazol in patients with NSAIDs-induced Erosions and/or Ulcers
1976523|NCT03315663|Other|Sweetch App & DBWS|Usual care for prediabetes management, Sweetch app, weight monitoring via digital body weight scale (DBWS).
1976524|NCT03315663|Other|Sweetch App Alone|Usual care for prediabetes management, Sweetch app alone.
1976525|NCT03315637|Procedure|Fetoscopic repair of spina bifida|Fetoscopic intrauterine repair of open spina bifida
1976526|NCT03315624|Device|Dialyzer|Three hemodiafiltration sessions assigned to one type of dialyzer FX Coral 600, FX 600 and FX CorDiax 600
1976527|NCT03315611|Drug|'Eucerin AtopiControl Lotion' (for the body)|Treatment with Eucerin AtopiControl Lotion
1976528|NCT03315611|Other|Allergen challenge chamber|Exposure to Dactylis glomerata pollen in an environmental challenge chamber
1976529|NCT03315598|Procedure|Electroacupuncture|lectroacupuncture is a form of acupuncture where a small electric current is passed between pairs of acupuncture needles. According to some acupuncturists, this practice augments the use of regular acupuncture, can restore health and well-being, and is particularly good for treating pain.
1976530|NCT03315585|Device|steep pulse device|Applying the steep pulse to treat the patients with Prostate cancer
1976531|NCT03315572|Other|Interviewer administered version of ease of use items|The adult ease of use items will be modified to incorporate language appropriate for pediatric subjects. The interview will be administered by trained clinic-staff for subjects aged 5 to 7 years and those aged 8 to 11 years having difficulty in reading.
1976532|NCT03315572|Other|Self-administered version of ease of use items|The interview will be self-administered by subjects aged 8 to 11 years.
1976533|NCT03315572|Other|Caregiver version of ease of use items|Caregivers will be asked questions regarding their observations and experiences while their child was using ELLIPTA inhaler.
1976534|NCT03315559|Drug|[14C]-GSK2269557 IV infusion|The [14C]-GSK2269557 solution will be available in dosing strength of 10 µg, administered as single dose IV infusion over 15 minutes. It will be prepared by dissolving a hemisuccinate salt (GSK2269557T) in normal saline.
1976535|NCT03315559|Drug|GSK2269557 via DPI|GSK2269557 DPI will be available with dosing strength of 1000 µg, administered as oral inhalation intended to inhale twice. It will be prepared by blending GSK2269557 hemisuccinate salt (GSK2269557H) with lactose and magnesium stearate.
1976536|NCT03315559|Drug|[14C]-GSK2269557 oral solution|The [14C]-GSK2269557 solution will be available with dosing strength of 800 µg, administered as single dose orally. It will be prepared by dissolving [14C]-GSK2269557 hemisuccinate salt (GSK2269557T) in water.
1976537|NCT03315546|Radiation|radiotherapy delivery in deep-inspiration|Radiotherapy delivery i deep-inspiration versus free-breathing
1976538|NCT03315533|Drug|Duloxetine 30 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
1976539|NCT03315533|Drug|Duloxetine 60 milligrams (MG)|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
1976540|NCT03315533|Drug|Placebo Oral Tablet|Once a patient's history and screening results have been cleared by a physician investigator, the participant will be randomized by the study site investigational drug services (IDS) to receive duloxetine (30mg or 60mg) vs. placebo
1976543|NCT03315494|Drug|SKI-O-703 capsule|SKI-O-703 200 mg capsule with no inactive excipients.
1976544|NCT03315494|Drug|Placebo capsule|Placebo 180 mg capsule filled with microcrystalline cellulose.
1976545|NCT03315481|Procedure|SAX catheter insertion|Suture-method catheter inserted in the short axis of the adductor canal
1976546|NCT03315481|Procedure|LAX catheter insertion|Suture-method catheter inserted in the long axis of the adductor canal
1976548|NCT03315442|Other|Caffeine versus Energy Drink|Caffeine group consumed 200mg of caffeine one time, while the energy drink group consumed 1 16 ounces of energy drink.
1976549|NCT03315429|Diagnostic Test|stress echocardiography|stress testing of patients with functional mitral regurgitation
1976550|NCT03315416|Other|Speech Sound Assessment|Formal standardised speech sound assessment typically used as part of standard NHS care by Speech and language Therapists
1976551|NCT03315403|Diagnostic Test|LytA targeted quantitative polymerase chain reaction (qPCR)|LytA qPCR and cultures will be performed on samples of the upper respiratory tract (nasopahrynx, oropharynx, saliva, sputum if available)
1976553|NCT03315377|Procedure|Lunate-Capitate Fusion (LCF)|Operation with lunate-capitate-fusion (LCF)
1976554|NCT03315377|Procedure|Four Corner Fusion (4CF)|Operation with four-corner-fusion (4CF)
1976555|NCT03315364|Drug|Oral paclitaxel|Oral administration on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
1976556|NCT03315364|Drug|Paclitaxel injection|Premedication, intravenous infusion on D1, D8 and D15 of 4-week cycle until progression, unacceptable toxicity or withdrawal of informed concent
1976557|NCT03315351|Procedure|Brachytherapy|"Before it starts, a consultation will be done to collect patient's informations and disease history, a clinical exam will be done and an evaluation of radio-chemotherapy toxicity will be realized.
The brachytherapy include a pulsating flow treatment driven by RMI and CT-scan"
1976558|NCT03315351|Other|PET-scan|"The patient will undergo 2 PET-scan during the clinical trial:
the first one is additional to the brachytherapy
the second one is realized 4 months after the brachytherapy"
1976565|NCT03315312|Drug|Fluoride Varnishes|Fluoride varnish is randomly applied on randomly selected first permanent molar. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
1976566|NCT03315312|Drug|Fissure Sealants|Resin-based fissure sealant is applied on contra-lateral first permanent molar and each child serves as its own control. This study uses a natural clinical setting, where clinicians use methods and procedures that are routinely applied in public dental clinics.
1976567|NCT03315299|Drug|ASP2215|Subject will take ASP2215 by mouth daily for 28 day cycles
1976568|NCT03315286|Device|SHADE Ultraviolet Sensor|Patients will wear device for 1 year in addition to their own method of photo-protection.
1976569|NCT03315286|Behavioral|Standard of care counseling|Patients will use their own method of photo-protection
1976570|NCT03315273|Other|Test battery to measure the motor imagery ability|Participants will perform 3 different tests to measure the motor imagery ability
1976574|NCT03315221|Other|Test product|HMF with added lipids - Intervention group
1976575|NCT03315221|Other|Control product|Commercially available HMF (without lipids) - control group
1976578|NCT03315195|Dietary Supplement|Oral nutritional supplement (ONS)|ONS supplement by 500 kcal/day for 14 days
1976580|NCT03314636|Drug|Carfilzomib|See in arm description
1976581|NCT03314636|Drug|Lenalidomide|See in arm description
1976582|NCT03314636|Device|PET-CT|See in arm description
1976583|NCT03314636|Drug|Dexamethasone|See in arm description
1976584|NCT03315130|Drug|RA101495|Daily subcutaneous (SC) injection
1976585|NCT03315130|Drug|Placebo|Daily subcutaneous (SC) injection
1976586|NCT03314987|Dietary Supplement|L-carnosine|a naturally occurring di-peptide
1976587|NCT03314987|Other|placebo|an identically appearing supplement
1976588|NCT03314883|Diagnostic Test|D-US AECOPD|Diaphragm ultrasound evaluation in AECOPD patients undergoing non invasive ventilation, with regard to thickening (%) and excursion (millimeters)
1976589|NCT03314103|Biological|One shot of the varicella-zoster virus vaccine|One shot of the live attenuated varicella-zoster virus vaccine (with live virus >=4.3 LgPFU per dose)
1976590|NCT03314103|Biological|one shot of placebo|one shot of placebo with no live virus
1976591|NCT03314311|Behavioral|Rehabilitation programme|The RESTORE trial is a 12 week multi-disciplinary intervention involving exercise, nutrition advice and education sessions
1976592|NCT03314272|Device|Space Glucose Control|Development of a closed loop control system via Space Glucose Control that automatically infuses insulin on the basis of an automated algorithm, which integrates a continuous glucose signal, could help overcome these obstacles and permit strict glycemic control without increasing the workload.
1976593|NCT03314142|Other|Glucose as reference food|Ten subjects (male: 7, female: 3) consumed 50g glucose diluted in 250ml water, tested three times, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
1976594|NCT03314142|Other|White bread as reference food|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from white bread along with 250ml water, tested twice, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120min.
1976595|NCT03314142|Other|Bread enriched with coarse wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with coarse wheat bran along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
1976596|NCT03314142|Other|Bread enriched with fine wheat bran|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
1976597|NCT03314142|Other|Bread enriched with fine wheat bran and carob seed flour|Ten subjects (male: 7, female: 3) consumed 50g available carbohydrates from bread enriched with fine wheat bran (obtained by milling of the coarse bran) in which 10% of the flour was substituted with carob seed flour (CSFB) along with 250ml water, tested once, in different weeks, within 5-10min. Fingertip capillary blood glucose samples were taken at baseline, 15, 30, 45, 60, 90 and 120 min.
1976599|NCT03313674|Device|Bright Light Therapy|Light box that emits light at 10,000 lux or higher and has been demonstrated to regulate circadian rhythm that is aberrant in the SAD population
1920181|NCT00499135|Other|Computed Tomography|Correlative studies
1920182|NCT00499135|Other|Fluorothymidine F-18|Correlative studies
1920183|NCT00499135|Other|Laboratory Biomarker Analysis|Correlative studies
1920184|NCT00499135|Other|Pharmacological Study|Correlative studies
1920185|NCT00499135|Other|Positron Emission Tomography|Correlative studies
1920186|NCT00499135|Drug|Sunitinib Malate|Given PO
1920205|NCT00493298|Drug|natalizumab|According to the local prescribing information
1976600|NCT03312101|Other|exercise program|functional exercises consisting of a therapeutic exercise program based on concentric strengthening the gluteal muscles (maximus, medius and minimus) , the tensor fasciae latae muscle and the pyramidal muscle; ischiotibial muscle stretching ; and empowerment in eccentric and stretching of the gastrocnemius muscle, soleus muscle, tibialis posterior muscle and flexor of the big toe muscle,
1976606|NCT03309826|Device|Positive Airway Pressure|Auto-PAP titration followed by fixed PAP treatment
1976607|NCT03309826|Device|Nasal Dilator Strip|Nightly use of nasal dilator strip
1976608|NCT03308955|Drug|Tramadol|400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
1976609|NCT03308955|Procedure|Ultrasound guided Quadratus Lumborum block|Ultrasound guided Quadratus Lumborum block type II with 0.3 ml/kg % 0.25 bupivakain+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
1976610|NCT03308955|Procedure|Ultrasound guided placebo Quadratus Lumborum block|Ultrasound guided placebo Quadratus Lumborum block type II with 0.3 ml/kg saline % 0,9+400 mg tramadol, IV 4 mg/ mL tramadol solution into 100 mL normal saline; PCA settings: 0.3 mg/kg bolus, 10 mg Demand dose and 20 min lock out interval, six-hour limit infusion to attain 100 mg. Maximum daily dose was set at 400 mg.
1976611|NCT03309059|Device|water and soap|Use of soap and water in the area and subsequent diaper placement disposable.
1976612|NCT03309059|Device|zinc oxide|Use of soap and water sanitation and application of zinc oxide.
1976613|NCT03309059|Device|Non-Irritant Barrier Film|Use of soap and water hygiene and application of Non Irritant Barrier Film.
1976616|NCT03307057|Behavioral|Social Communication Growth Charts (SCGC)|The Social Communication Growth Charts (SCGC) is a web-based tool that parents can access to teach them the social communication milestones that are developing from 6 to 24 months of age. The SCGC has an explore function with hundreds of video clips illustrating 80 social communication milestones and a support video that has narration explaining how the parent in the video is supporting the child's development. The SCGC also has a charting function that parents can use by answering questions about their child's social communication milestones and then view charts in 5 developmental domains. Parents in the SCGC condition are also invited to a bi-weekly online Guided Tour to join other parents in a group meeting, like a book club, as they go through the SCGC.
1976617|NCT03307057|Behavioral|Parent-Implemented (P-I) Condition|"The Parent-Implemented (P-I) condition is based on the Early Social Interaction (ESI) model, which is an evidence-based parent-implemented intervention involving active and productive engagement for 5 hours per day, 5 days per week for toddlers with ASD. ESI teaches parents how to support their child's social communication, language, play and behaviors in everyday routines, activities, and places.
Weekly home sessions with a family navigator include:
developing the visit agenda
intervention implementation including: guided/caregiver practice, feedback and problem solving
planning for parent implementation between sessions
Families can also access the Autism Navigator How-To Guide for Families (a self-guided, web-based course), the Online Guided Tour for the How-To Guide (an online group to engage families), and have the opportunity to interact with other families who suspect their child has autism through audio or video conferencing or typed chat."
1976618|NCT03307057|Behavioral|Clinician-Implemented (C-I) Condition|The Clinician-Implemented (C-I) condition is based on the core principles of empirically-supported naturalistic developmental behavioral interventions (NDBI) for infants and toddlers with or at-risk for ASD, including Early Start Denver Model (ESDM), Project ImPACT (Improving Parents As Communication Teachers), Pivotal Response Treatment (PRT), and Early Social Interaction (ESI). The goal of C-I NDBI is to use naturalistic, developmental, and behavioral strategies with infants at-risk for ASD to improve social-communication, which includes eye contact, gesture use, intentional vocalizations, and language. Parents are not actively involved in C-I NDBI intervention sessions, though they may observe and the clinician will be given information about current social-communication targets.
1976619|NCT03306459|Diagnostic Test|SF-36 (Short Form Health Survey)|"Symptom Checklist-90-Revision (SCL-90-R): self-report questionnaire of 90 items on a 5-point Likert scale clustered in 9 primary scales (somatization, obsessive-compulsive, interpersonal sensitivity, depression, anxiety, hostility, phobic anxiety, paranoid ideation and psychoticism).
State-Trait-Anger-Expression-Inventory, version 2 (STAXI-2): self-report questionnaire of 57-items on a 4-point scale distributed in different dimensions: State-Anger, Trait-Anger Expression Anger (in-out) and Anger Control (in-out) Short Form Health Survey (SF-36), an instrument composed by 8 subscales: Physical Functioning, Physical Role Function, Bodily Pain, General Health, Vitality, Social Functioning, Emotional Role Function and Mental Health.
Female Sexual Function Index (FSFI) a 19-item self-report measure of female sexual function providing scores on 6 domains (desire, arousal, lubrication, orgasm, satisfaction, pain) as well as a total score."
1994550|NCT02977962|Behavioral|Cognitive-Behavior Therapy|This therapy has been designed for adolescents with high functioning ASD and involves 16 weekly session where the participant learns coping skills related to addressing anxiety (e.g., exposure therapy, cognitive therapy, social skills training).
1994551|NCT02977962|Other|Treatment as Usual|Those who choose to participate will be enrolled in the 16 week study. They will required to attend 3 assessments - pre-treatment (week 0), mid-treatment (week 8), and post-treatment (week 16). Those in this group will not receive the Cognitive-Behavior Therapy, and instead will undergo therapy for their anxiety as they usually would, whether by using medication or working with a therapist.
1976623|NCT03305809|Drug|LY3154207|Administered orally.
1976624|NCT03305809|Drug|Placebo|Administered orally.
1976625|NCT03304353|Other|Self-managed protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.
The participants in the self-managed group are instructed in performing the exercise with a load as heavy as possible but no higher than 8RM and for as many sets as possible every other day."
1976626|NCT03304353|Other|Predetermined protocol|"Participants will be asked to complete a heel raise standing with the forefoot on a step. The toes are maximally dorsi flexed by placing a towel underneath them. The participant is instructed to perform a heel raise to maximal plantar flexion in the ankle joint and afterwards to lower the heel to maximal dorsiflexion. Supporting oneself for balance by placing the hands on a wall or a rail is allowed.
The participants in the predetermined group are instructed in performing the exercise at a 12RM for three sets during week 1 and 2, at a 10RM for four sets during week 3 and 4, and at an 8RM for five sets from week 5 and onwards."
1976629|NCT03302754|Drug|Alemtuzumab|Alemtuzumab (Campath®) is a recombinant DNA-derived humanized monoclonal antibody directed against CD52. Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Neomycin is not detectable in the final product. Alemtuzumab is a sterile, clear, colorless, isotonic pH 6.8-7.4 solution for injection. Alemtuzumab is supplied in single-use clear glass ampules containing 30 mg of Alemtuzumab in 3 mL of solution. Single use vial of alemtuzumab contains 30 mg alemtuzumab, 8 mg sodium chloride, 1.44 mg dibasic sodium phosphate, 0.2 mg potassium chloride, 0.2 mg monobasic potassium phosphate, 0.1 mg polysorbate 80, and 0.0187 mg disodium edetate dihydrate.
1976631|NCT03302078|Drug|BI 1015550|Fed state
1976632|NCT03302078|Drug|BI 1015550|Fasted state
1976634|NCT03299634|Other|printed questionnaire|For each eligible participant, a full history will be obtained according to a questionnaire followed by thorough clinical examination.
1976635|NCT03295539|Device|'Indigo' Mechanical thrombectomy system|"Removal of acute clot from the artery causing ischaemia, using the mechanical aspiration system by Penumbra Inc called INDIGO"
1976636|NCT03296787|Drug|TAK-954|TAK-954 intravenous infusion.
1976637|NCT03295942|Drug|OMP-336B11|OMP-336B11 is an engineered human protein that was designed to bind to the GITR receptor on T cells and activate the immune system to recognize and eliminate cancer cells.
1976638|NCT03294356|Other|FT210771|An electronic cigarette
1976639|NCT03294356|Other|FT210751|An electronic cigarette
1976640|NCT03294356|Other|6T30134157764|An electronic cigarette
1976641|NCT03294356|Other|G41A7C071|An electronic cigarette
1976642|NCT03294356|Other|M011161212|An electronic cigarette
1976643|NCT03294356|Other|FT21002|A combustible cigarette
1976644|NCT03294798|Biological|Human Serum Albumin/interferon alpha2b fusion protein|In experiemental groups, each subject will recieve 600,750,900mg once per two weeks during multiple dose period.
1976645|NCT03294798|Biological|Pegasys|In comparator group, each subject will recieve 180mcg once per week.
1976646|NCT03294694|Drug|Ribociclib|Each treatment cycle lasts 28 days. Ribociclib, 1 time per day by mouth for 21 days, followed by 1-week of rest (28-day cycle)
1976647|NCT03294694|Drug|PDR001|Each treatment cycle lasts 28 days. (PDR001) will be administered once every 28 days (by intravenous infusion) over about 30 minutes (or up to 2 hours, if necessary) for the first infusion and over about 30 minutes for all following infusions.
1976648|NCT03294694|Drug|Fulvestrant|Each treatment cycle lasts 28 days. Fulvestrant will be administered during Cycle 1 on days 1 and 15, and then on day 1 of each 28-day cycle thereafter.
1976649|NCT03294655|Behavioral|Pilot Resilience Building Intervention|The intervention will include a brief one-on-one visit in which psychoeducational information on building resilience will be given via a PowerPoint presentation, which will include exercises for the participants to engage in over the following four weeks in their daily lives. After the presentation participants will also develop a personalized intervention plan where they will choose at least five areas of the American Psychological Association 10 Strategies for Building Resilience on which to specifically focus. Participants will also receive a pamphlet of abbreviated information from the PowerPoint presentation.
1920298|NCT00475280|Procedure|Geriatric assessment adapted therapy|Geriatric assessment is performed before the induction phase starts.
1920299|NCT00475280|Procedure|Stem cells autotransplantation|Stem cells autotransplantation is performed after consolidation treatment
1976653|NCT03293784|Combination Product|Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab (3 mg/kg) injected at Week 0, 3, 6, and 9 with Certolizumab injected at the dose of 400mg at weeks 0, 3, and 6, and at the dose of 200mg at week 9.
Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Certolizumab (200 mg) injected from week 12 and then every 2 weeks."
1976654|NCT03293784|Combination Product|Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab|"Induction phase: Nivolumab (1mg/kg) and Ipilimumab 3 mg/kg injected at Week 0, 3, 6, and 9 with Infliximab (5mg/kg) injected at weeks 0, 3 and 6.
Maintenance phase: Nivolumab (3 mg/kg) alone injected from week 12 and then every 2 weeks with Infliximab (5mg/kg) injected from week 14 and then every 8 weeks."
1976655|NCT03292601|Device|Cinch Smart Strap|"The study device is a small (with dimensions of 1.5 x 2 x 3/8 and weighing approximately 0.9-oz) Bluetooth-enabled and battery-powered monitor with Velcro strap that attaches to orthopaedic braces for scoliosis in place of the traditional strap and buckle. When the Velcro strap is tightened, the device measures tension in Newtons with the vector of force parallel to and away from the device, reflecting the pulling force required to keep the brace fitted on the patient."
1976656|NCT03292601|Other|Cinch Mobile App|The Cinch App allows patients and parents to track and edit treatment information, sync data from the Cinch Smart Strap, and view compliance data. The app connects via Bluetooth to the Cinch Smart Strap and allows patients and parents save and sync data from the device.
1976657|NCT03292172|Drug|Atezolizumab|Atezolizumab will be given intravenously (IV) at a fixed dose of 1200 mg on Day 1 of each cycle, every 3 weeks.
1976658|NCT03292172|Drug|RO6870810|RO6870810 will be injected SC,at initial planned doses of 0.30, 0.45, or 0.65 mg/kg, QD for the first 14 days of a 21-day cycle.
1976664|NCT03289117|Device|Novel gel installation device procedure|Catheter change with novel device Each subject will undergo catheter change with novel gel instillation device
1976665|NCT03289117|Device|Standard procedure|Catheter change with standard procedure Each subject will undergo catheter change with standard procedure
1976666|NCT03289273|Drug|Regorafenib (Stivarga, BAY73-4506)|As per the treating physicians discretion
1976667|NCT03288545|Drug|enfortumab vedotin|Intravenous (IV) infusion on days 1 and 8 every 21 days
1976668|NCT03288545|Drug|pembrolizumab|IV infusion on day 1 every 21 days
1976669|NCT03288545|Drug|atezolizumab|IV infusion on day 1 every 21 days
1976670|NCT03286907|Behavioral|Online videos|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise and receive reminders at month 1, 2, 4, 6 & 8.
1976671|NCT03286907|Behavioral|Online videos and MI|Watch two online short health promotion videos (five minutes each), complete a self-administered online exercise, receive 15 minutes motivational interviewing through telephone and reminders at month 1, 2, 4, 6, & 8.
1920347|NCT00465855|Combination Product|Hyperbaric Oxygen (HBO2) - 3 sessions|"Before patients are offered an opportunity to participate in this study, they will receive a single hyperbaric oxygen session. During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.
For the second and third hyperbaric oxygen sessions, the subject will breathe 100% oxygen delivered at 2 atm abs for 90 minutes with two 5-minute air breathing periods."
1920348|NCT00465855|Combination Product|Hyperbaric Oxygen (HBO2) - 1 session|"During the first session, hyperbaric oxygen will be administered at 3.0 atmospheres absolute (atm abs) for 25 minutes breathing oxygen, 5 minutes air breathing, 25 minutes oxygen breathing, 5 minutes air breathing, pressure reduced to 2.0 atm abs for 30 minutes breathing oxygen, 5 minutes air breathing, and 30 minutes oxygen breathing.
The second and third chamber sessions are sham sessions: room air delivered at 1.0 atmospheres absolute for 90 minutes with two sham 5-minute air breathing periods."
1976672|NCT03286907|Behavioral|Control group|Receive online health communication messages about prevalence of some common mental health problems among MSM and introduction of stress reduction exercises
1976673|NCT03285958|Behavioral|STEPS Intervention|Participants in the STEPS (Seniors Tracking Exercise for Pain Self-management) intervention will receive a commercially-available, wearable physical activity monitor. They will be asked to wear this monitor during waking hours for 6 weeks, reporting their daily step count every evening. The way in which participants report steps will change every 2 weeks. For the first 4 weeks of the study, participants will report via Interactive Voice Response (IVR) calls for 2 weeks and SMS text messages for 2 weeks. For the final two week period, research staff will help participants to set up the monitor to automatically send daily step counts to STEPS project staff. This can be done through a smartphone, tablet, or computer.
1976674|NCT03286556|Drug|Autoantibody Reductive Therapy|TPE x 9, rituximab x 2, IVIG x 4. See arm/group descriptions for additional details.
1976675|NCT03286556|Drug|Treatment as Usual (TAU)|Antibiotics and steroids
1976678|NCT03282916|Drug|Valacyclovir|Valacyclovir hydrochloride 1g caplet
1976679|NCT03282916|Drug|Placebo|Placebo sugar pill 1g caplet
1976681|NCT03281681|Drug|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion with a starting dose of 60 mg/m2 once weekly. If this regimen is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 67 mg/m2 i.v. If the 67 mg/m2 dose is well tolerated for at least three sequential weekly treatments the patient's dose may be escalated to 75 mg/m2 i.v. once weekly for the remainder of the study. Dosing will be conducted once per week for a total of 16 weeks.
1976687|NCT03279978|Drug|BI 730357|up to 28 days
1976688|NCT03279978|Drug|Placebo|up to 28 days
1976689|NCT03279978|Drug|Midazolam|Dose groups 4 & 5 only
1976690|NCT03277274|Drug|TAK-954|TAK-954 intravenous infusion
1976691|NCT03275753|Other|Visual Function Tests|All subjects will undergo a battery of visual function tests
1976692|NCT03274674|Other|I-PRF|Venous blood will be taken from the patient every session and I-PRF will be created in the centrifuge.I-PRF injected on one side of bilateral thin gingival thickness.Microneedle application plus I-PRF injected on the other side in patients with bilateral region with thin gingival phenotype.Apply once a week and one month after the end of the injections, the patient will be called to the control.
1976693|NCT03272347|Drug|MK-8591|MK-8591 at 0.25 mg, 0.75 mg or 2.25 mg is orally administered QD in capsule form for up to 52 weeks. After Week 60 a selected dose may be administered.
1976694|NCT03272347|Drug|Placebo to MK-8591|Placebo to MK-8591 is orally administered QD in capsule form for up to 52 weeks
1976695|NCT03272347|Drug|Doravirine|Doravirine 100 mg is orally administered QD in tablet form for up to 120 weeks
1976696|NCT03272347|Drug|Placebo to Doravirine|Placebo to Doravirine is orally administered QD in tablet form for up to 52 weeks
1976697|NCT03272347|Drug|Lamivudine|Lamivudine 300 mg is orally administered QD in tablet form for up to 52 weeks
1976698|NCT03272347|Drug|Placebo to Lamivudine|Placebo to Lamivudine is orally administered QD in tablet form for up to 52 weeks
1976699|NCT03272347|Drug|MK-1439A|MK-1439A consisting of 100 mg Doravirine + 300 mg Lamivudine + 300 mg tenofovir disoproxil fumarate is orally administered QD in tablet form for up to 120 weeks.
1976700|NCT03272347|Drug|Placebo to MK-1439A|Placebo to MK-1439A is orally administered QD in tablet form for up to 52 weeks
1976701|NCT03272113|Behavioral|SKIP-IT|A theory-based intervention using narrative, images and embedded behaviour change techniques, delivered via text-messaging.
1976702|NCT03271424|Diagnostic Test|Oraquick HIV Self Test - Choice|This is an oral swab in home HIV test.
1976703|NCT03271424|Diagnostic Test|Atomo HIV Self Test - Choice|This is a blood finger prick in home HIV test.
1976704|NCT03271424|Diagnostic Test|Oraquick HIV Self Test and Atomo HIV Self Test - Both|This is an oral swab in home HIV test and this is a blood finger prick in home HIV test.
1976705|NCT03268473|Other|Non-surgical periodontal therapy|Experimental: Non-surgical periodontal therapy (scaling and root planing) and supportive periodontal therapy
1976706|NCT03268473|Other|Delayed non-surgical periodontal therapy|Delayed non-surgical periodontal therapy (scaling and root planing) after the 3 month visit
1976707|NCT03267043|Behavioral|Family Nurture Intervention (FNI)|Subjects will be guided by the nursing staff through an enhanced program of mother/infant interactions, which include skin-to-skin holding.
1976708|NCT03267043|Behavioral|Standard Care|Established routine care provided on the NICU floor by specially trained health care professionals.
1976709|NCT03264456|Diagnostic Test|[18F] fluciclovine PET/MRI|[18F] fluciclovine PET/MRI
1976710|NCT03265808|Drug|allogeneic human mesenchymal stem cells (allo-hMSCs)|Forty (40) subjects will be treated with a single administration of allogeneic hMSCs: 100 x 106 (100 million) allo-hMSCs of cells delivered via a single peripheral intravenous infusion.
1976711|NCT03265808|Drug|Placebo|Forty (40) subjects will be treated with a placebo administration consisting of 1% human albumin serum in Plasma-Lyte A delivered via a single peripheral intravenous infusion.
1976714|NCT03263208|Drug|Cyclophosphamide|patients will receive a standard pre-conditioning regime with cyclophosphamide 0.6-0.8g/m2/day IV for 2 days(Day-5 to day-4).
1976715|NCT03263208|Drug|Fludarabine|Fludarabine 25-30mg/m2/day IV for 3 days(Day-5 to day-3).
1976716|NCT03263208|Biological|CD19 CAR-T|CD19 CAR-T cells will be administered after completion of the chemotherapy.
1976718|NCT03259087|Drug|MK-3866|Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) at Hour 0 on Day 1 of treatment period.
1976721|NCT03256708|Dietary Supplement|Prolardii|Prolardii: 2 capsules per day for 12 to 15 days
1976722|NCT03256708|Dietary Supplement|Placebo|Inactive ingredients
1994554|NCT02976961|Other|Supportive care|Information, guidance, supportive care, and psychological intervention
1994555|NCT02975674|Device|MT-12 dental implant|Placement of the MT-12 dental implant with Morse taper implant-abutment connection
1994556|NCT02975674|Device|CON.INT dental implant|Placement of the CON.INT dental implant with internal hexagon implant-abutment connection
1994557|NCT02974855|Biological|PF-06741086|PF-06741086 subcutaneous (SC) injection
1994558|NCT02974855|Biological|PF-06741086|PF-06741086 SC injection
1994559|NCT02974855|Biological|PF-06741086|PF-06741086 SC injection
1994560|NCT02974855|Biological|PF-06741086|PF-06741086 intravenous (IV) infusion
1976723|NCT03257917|Other|Understanding value in Metastatic Breast Cancer|The overall objective of this project is to gain knowledge about out-of-pocket (OOP) expenses and lost opportunity costs among metastatic breast cancer (MBC) patients. To achieve this objective, MBC patients will be asked to participate in a short, 37-question survey asking questions about the financial burden, OOP expenses, and opportunity costs related to their cancer care.
1976724|NCT03255733|Device|Intense Therapeutic Ultrasound Treatment|
1976725|NCT03255174|Biological|EVARREST® Fibrin Sealant Patch|EVARREST Fibrin Sealant Patch is a sterile, bio-absorbable combination product consisting of two constituent parts— a flexible matrix and a coating of biological components (human plasma‐derived fibrinogen and thrombin) embedded in a flexible composite patch component.
1920429|NCT00445692|Drug|Clarithromycin|Given PO
1920430|NCT00445692|Drug|Dexamethasone|Given PO
1920431|NCT00445692|Drug|Lenalidomide|Given PO
1976729|NCT03254602|Device|Intense Therapeutic Ultrasound Treatment|
1976730|NCT03253497|Drug|Chlorobenzene Liquid|before induction will be used for oropharynx
1976734|NCT03247790|Drug|Lasmiditan|Administered orally
1976737|NCT03247985|Device|PROLENE Polypropylene Tacking Mesh|Prolene mesh is a polypropylene plastic mesh (10 x 15 cm) implant fixed with titanium tacks
1976738|NCT03247985|Device|ProGrip Self-fixating Mesh|"ProGrip™ self-fixating mesh is a tack-free fixation mesh for use in open & laparoscopic hernia repairs. It is composed of absorbable Monofilament Polylactic Acid microgrips on one surface integrated with a lightweight Monofilament Polyethylene Terephthalate. The micro grips act as a kind of Velcro to the soft tissue surfaces resulting in self-fixation"
1976739|NCT03247582|Drug|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
1976740|NCT03247569|Drug|Edoxaban|Edoxaban according to Package Information (Summary of Product Characteristics (SmPC)).
1976745|NCT03246230|Biological|Hepatitis B vaccine (HBV)|Licensed pediatric HBV vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
1976746|NCT03246230|Biological|Bacillus Calmette-Guérin (BCG)|Licensed BCG vaccine will be administered at birth (Day of Life 0) or delayed to Day of Life 7.
1976753|NCT03241550|Drug|isavuconazonium sulfate|IV infusion
1976755|NCT03238781|Drug|Placebo|Placebo Comparator
1976756|NCT03238781|Drug|AMG 301|Investigational Product
1976757|NCT03238781|Drug|AMG 301|Investigational Product
1976761|NCT03234010|Other|FT21092|An electronic cigarette
1976762|NCT03234010|Other|FT21093|An electronic cigarette
1976763|NCT03234010|Other|FT21096|An electronic cigarette
1976764|NCT03234010|Other|FT21097|An electronic cigarette
1976765|NCT03233997|Other|FT21018|An electronic cigarette
1976766|NCT03233997|Other|FT21033|An electronic cigarette
1976767|NCT03233997|Other|FT21034|An electronic cigarette
1976768|NCT03233997|Other|FT21035|An electronic cigarette
1976769|NCT03230838|Drug|Ceftolozane|Ceftolozane 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days
1976770|NCT03230838|Drug|Tazobactam|Tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 7 to 14 days
1976771|NCT03230838|Drug|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 7 to 14 days.
1976772|NCT03230097|Drug|BI 409306|twice daily
1976773|NCT03230097|Drug|Placebo|twice daily
1976774|NCT03226249|Procedure|Computed Tomography|Undergo FDG-PET/CT
1976775|NCT03226249|Drug|Dacarbazine|Given IV
1976776|NCT03226249|Drug|Doxorubicin Hydrochloride|Given IV
1976777|NCT03226249|Radiation|Fludeoxyglucose F-18|Undergo FDG-PET/CT
1976778|NCT03226249|Other|Laboratory Biomarker Analysis|Correlative studies
1976779|NCT03226249|Biological|Pembrolizumab|Given IV
1976780|NCT03226249|Procedure|Positron Emission Tomography|Undergo FDG-PET/CT
1976781|NCT03226249|Drug|Vinblastine Sulfate|Given IV
1976782|NCT03225287|Drug|RA101495|Subjects will continue to receive the final maintenance dose they were receiving in the qualifying study.
1920500|NCT00433511|Biological|Bevacizumab|Given IV
1920501|NCT00433511|Drug|Cyclophosphamide|Given IV
1920502|NCT00433511|Drug|Doxorubicin Hydrochloride|Given IV
1920503|NCT00433511|Other|Laboratory Biomarker Analysis|Correlative studies
1920504|NCT00433511|Drug|Paclitaxel|Given IV
1920505|NCT00433511|Other|Placebo|Given IV
1920506|NCT00433511|Other|Quality-of-Life Assessment|Ancillary studies (closed as of 5/28/10)
1976791|NCT03222349|Drug|Diazepam Buccal Soluble Film|Subjects will receive a single dose of DBSF . DBSF is provided in a range of doses from 5 to 12.5 mg . The appropriate dose of DBSF will be assigned on the basis of age and weight using an interactive web response system (IWRS) during check-in for the subject's first treatment period.
1976792|NCT03219866|Device|Nebulizers|Patients treated and discharged on nebulized bronchodilators
1976793|NCT03219866|Device|Dry Powder Inhaler|Patients treated and discharged on Dry Powder Inhalers
1976794|NCT03219866|Drug|Brovana|Subjects will receive a long-acting B2-agonist(LABA; Brovana, twice daily)
1976795|NCT03219866|Drug|Pulmicort|Subjects will receive a corticosteroid (ICS; Pulmicort, twice daily)
1976796|NCT03219866|Drug|Atrovent|Subjects will receive a short-acting anti-cholinergic (SAMA; Atrovent, three times a day)
1976797|NCT03219866|Drug|Advair Diskus|Subjects will receive a LABA/ICS (Advair Diskus, twice daily)
1976798|NCT03219866|Drug|Spiriva HandiHaler|Subjects will receive a long-acting anticholinergic (LAMA-Spiriva Handihaler, once daily)
1976801|NCT03217682|Other|Music Therapy|Music therapy sessions
1976802|NCT03217682|Other|Massage Therapy|Massage therapy sessions
1976803|NCT03217136|Drug|Ceftolozane|Ceftolozane 20 mg/kg (maximum 1 g) administered IV every 8 hours for between 5 to 14 day
1976804|NCT03217136|Drug|Tazobactam|Tazobactam 10 mg/kg (maximum 0.5 g/dose) administered IV every 8 hours for between 5 to 14 days
1976805|NCT03217136|Drug|Metronidazole|Metronidazole 10 mg/kg (maximum 1.5 g/day) administered IV every 8 hours for between 5 to 14 days. Participants =< 28 days old, start with a loading dose of 15 mg/kg; then if =< 2 kg are dosed 7.5 mg/kg/ every 12 hours; or if > 2 kg are dosed 10 mg/kg every 8 hours.
1976806|NCT03217136|Drug|Meropenem|Meropenem 20 mg/kg (maximum 1 g/dose) administered IV every 8 hours for between 5 to 14 days
1976807|NCT03217136|Drug|Placebo for Metronidazole|Placebo for Metronidazole administered IV every 8 hours for between 5 to 14 days.
1976825|NCT03209869|Biological|Ex vivo Expanded and Activated Haploidentical Donor NK Cells|Haploidentical donor NK cells that are expanded and activated under current GMP conditions using K562-mbIL15-41BBL.
1976826|NCT03209869|Biological|Hu14.18-IL2|The immunocytokine, hu14.18-IL2, is a fusion protein comprised of one molecule of the anti-GD2 humanized monoclonal antibody, hu14.18, fused to two molecules of the cytokine, interleukin-2.
1976827|NCT03208322|Other|Non-Interventional|Non-Interventional
1976831|NCT03206632|Drug|BI 690517|single dose
1976832|NCT03206632|Drug|Placebo|single dose
1976834|NCT03205709|Other|Computerized Cognitive Training|Computerized online cognitive training will be used to target specific cognitive abilities and neural networks to potentially improve cognitive functioning through neuroplasticity.
1976835|NCT03205709|Other|Crossword Puzzles|These are intended to mimic crossword puzzles in newspapers.
1976836|NCT03203005|Drug|IMA970A plus CV8102 and Cyclophosphamide|"Study treatment starts with a single intravenous infusion of 300mg/m2 Cyclophosphamide.
Three days later patients start vaccination therapy with IMA970A plus CV8102 Each vaccination consists of a dose of 6.80 milligrams (mg) IMA970A (containing approx. 400 micrograms [µg] of each individual peptide) followed by a dose of 50 µg CV8102. First IMA970A is injected intradermally (i.d.) and about 10 minutes later CV8102 is injected i.d. at the same vaccination site in close proximity. Patients will receive 4 vaccinations at weekly intervals followed by 5 vaccinations at 3-weekly intervals for a total duration of about 4.5 months."
1976837|NCT03198494|Other|Acoustic 1Hz Stimulation|1Hz acoustic pulses delivered during sleep via headphones
1976838|NCT03198494|Other|Sham Background Noise|Background Noise used as a control
1976839|NCT03198039|Behavioral|Meditation|Isha Kriya (IK) meditation approximately 12 minutes, twice a day
1976842|NCT03194737|Device|UroLift System Procedure|Minimally invasive procedure in patients with acute urinary retention secondary to BPH.
1976843|NCT03193450|Behavioral|telephone-based re-education|Patients will receive a repeated instruction by telephone in terms of both calling and message at the forth, seventh, tenth day after the start of treatment.
1976844|NCT03193450|Behavioral|First education at the clinic|Patients will receive an instruction card about the drug administration at the clinic by doctors.
1920577|NCT00415233|Biological|recombinant thyroid-stimulating hormone|Recombinant thyroid stimulating hormone (rhTSH) should be given at a dose of 0.9mg by intramuscular injection on two consecutive days before ablation.
1920578|NCT00415233|Radiation|Radiodine ablation without rhTSH|Patients in this group do not receive rhTSH pre ablation.
1976848|NCT03192150|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
1976849|NCT03192150|Other|Vehicle|Placebo twice daily for 16 days
1976850|NCT03192137|Drug|ISV-305|Dexamethasone in DuraSite® 2 twice daily for 16 days
1976851|NCT03192137|Other|Vehicle|Placebo twice daily for 16 days
1976859|NCT03188523|Drug|MK-8504 =< 240 mg|After at least an 8-hour fast, a single oral dose =< 240 mg MK-8504 will be administered in capsule form.
1976860|NCT03188523|Drug|MK-8504 100 mg|After at least an 8-hour fast, a single oral dose of 100 mg MK-8504 will be administered in capsule form.
1976861|NCT03186287|Other|Eccentric training|Eccentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
1976862|NCT03186287|Other|Concentric training|Concentric phase of resistive shoulder exercises will be performed three sets of 15 repetitions once a day for 12 weeks using therabands. Participants will be supervised by the physiotherapist 3 days a week for the first 6 weeks, 2 days a week for the next 3 weeks and 1 day a week for the last 3 weeks.
1976863|NCT03186287|Other|Standard physiotherapy|The participants will receive standard physiotherapy. The standard physiotherapy exercises will be supervised by the physiotherapist, same as intervention exercises.
1976864|NCT03185897|Other|Non-treatment, seroprevalence|Non-treatment study examining the prevalence of preexisting immunity to adeno-associated virus (AAV)
1976868|NCT03187002|Device|Transcutaneous electrical nerve stimulation (TENS)|Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacy—documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.
1976869|NCT03187002|Drug|Moderate IV Sedation|IV sedation with fentanyl and versed
1920600|NCT00407186|Drug|cisplatin+capecitabine|cisplatin 20 mg/m2 (i.v., q 1 w, 5 weeks), capecitabine 575 mg/m2 (b.i.d., oral, on radiotherapy days.
1920601|NCT00407186|Radiation|radiotherapy|45 Gy in 25 fracions (5 days/week)
1920602|NCT00407186|Drug|epirubicin+cisplatin+capecitabine|3 courses q 3 w: epirubicin 50 mg/m2 (i.v., day 1), cisplatin 60 mg/m2 (i.v., day 1), capecitabine 1000 mg/m2 (b.i.d., oral, day 1-14)
1976870|NCT03187002|Other|SHAM: Transcutaneous electrical nerve stimulation (TENS)|Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding
1976871|NCT03187002|Other|SHAM: Moderate IV Sedation|Sham IV to ensure blinding
1976874|NCT03179891|Drug|Pharmacokinetics and Safety of Diazepam Buccal Soluble Film|Comparative Pharmacokinetics and Safety of DBSF in subjects with epilepsy under conditions when they are not experiencing seizures (Interictal Period A) or when they are experiencing seizures (Ictal/peri-ictal Period B).
1976879|NCT03175211|Drug|BI 456906|single dose
1976880|NCT03175211|Drug|Placebo|single dose
1976881|NCT03175900|Drug|Naoan dripping pills|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.
Procedure: MRI scanning (fMRI and DTI）"
1976882|NCT03175900|Drug|Placebo|"Patients will take 20 pills(1000mg) after meal twice a day for 12 weeks, Fenbid can be taken if headache is unbearable, but make sure the records(including attack time, drug dosage, pain intensity and duration) are written down as detailed as possible.
Procedure: MRI scanning (fMRI and DTI)"
1976883|NCT03173976|Drug|Zoledronic Acid|Zoledronic acid, a member of bisphosphonate class, inhibits bone resorption.
1976888|NCT03172403|Diagnostic Test|Height and weight|Height and weight will be measured to estimate cachexia degree at the time of anaesthetic consultation. (V1)
1976889|NCT03172403|Diagnostic Test|Blood samples|Blood samples will be collected for measuring myostatin on blood at the time of anaesthetic consultation, the day before resection surgery, follow-ups at 1, 3 and 6 months. (V1, V2, V3, V4, V6)
1976890|NCT03172403|Diagnostic Test|Skeletal muscle force|Skeletal muscle force will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
1976891|NCT03172403|Diagnostic Test|Skeletal muscle index|Skeletal muscle index will be determined from Computerized Tomography (CT)-scan at the time of anaesthetic, follow-ups at 1, 3 and 6 months. (V1, V3, V4, V6)
1976892|NCT03172403|Diagnostic Test|Muscle biopsy|Muscle biopsy will be performed during resection surgery under general anaesthesia. (V2)
1976894|NCT03168737|Drug|[18F]FAZA|"On Day 1, participants injected with [18F]FAZA at 5.2 MBq/kg one hour before PET-CT scanning.
Cohort A undergoes the follow-up administration of [18F]FAZA and PET-CT scanning under the identical scheme on Day 2. Cohort B undergoes the follow-up administration of [18F]FAZA and PET-CT scanning under an identical scheme on Day 3, 4 or 5, depending on the outcome of the interim analysis."
1976895|NCT03168737|Procedure|PET-CT Scan|"Group A has 5 [18F]FAZA PET-CT scans on Day 1 of the study and 5 imaging sessions on Day 2.
Based on what is learned from Group A, Group B will have 5 or less [18F]FAZA PET-CT scans on Day 1 and will have 5 or less [18F]FAZA PET-CT scans on either Day 2, 3, 4, or 5."
1976898|NCT03167242|Drug|KAF156 and LUM-SDF|Exploration of different dose combinations of KAF156 and LUM-SDF. In Part B, up to three arms will be repeated in children 2 to 12 Years to confirm safety and efficacy from Part A.
1976899|NCT03167242|Drug|Coartem|Control arm
1976902|NCT03165045|Drug|Spiolto® Respimat®|6 weeks
1976905|NCT03163043|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
1976906|NCT03158688|Drug|Dexamethasone|Dexamethasone 40 mg will be taken orally or by IV infusion weekly. The IV administration of dexamethasone must be given on carfilzomib and/or daratumumab IV infusion days. Dexamethasone IV will be given on successive days at a split dose of 20 mg each treatment day on weeks with carfilzomib and/or daratumumab infusions. All subjects regardless of age will be required to receive 20 mg of dexamethasone on days 1 and 2 of cycle 1 (as a preinfusion medication for daratumumab infusion) followed by 20 mg of methylprednisolone or equivalent on the third day.
1976907|NCT03158688|Drug|Daratumumab|Daratumumab will be administered as an IV infusion. On days 1 and 2 of cycle 1, daratumumab will be administered at a split-dose of 8 mg/kg in 500 mL normal saline. The dose of 16 mg/kg in 500 mL normal saline will be given once weekly as a single infusion for the remaining doses of the first 2 cycles (ie, days 8, 15, and 22 of cycle 1; and days 1, 8, 15, and 22 of cycle 2), then every 2 weeks for 4 cycles (cycles 3 to 6), and then every 4 weeks for the remaining cycles or until disease progression. The administration may be within ± 2 days for each scheduled dose.
1976908|NCT03158688|Drug|Carfilzomib|"Carfilzomib will be administered as an intravenous (IV) infusion. On days when more than 1 investigational product is administered, the required order of administration is as follows: dexamethasone, pre-infusion medications for daratumumab, carfilzomib, daratumumab, and post infusion medications for daratumumab.
Carfilzomib will be dosed twice weekly over 30 ± 5 minutes, on days 1, 2, 8, 9, 15, and 16 of each 28-day cycle. The administration may be within ± 2 days for each scheduled dose. The dose will be 20 mg/m2 on cycle 1 days 1 and 2 and 56 mg/m2 beginning on cycle 1 day 8 and thereafter.
Each subject's first dose of carfilzomib will be calculated based upon baseline body surface area (BSA). Dose should be capped based on a BSA of 2.2 m2."
1976911|NCT03158103|Drug|MEK162|MEK162 at 30mg twice daily
1976912|NCT03158103|Drug|Pexidartinib|pexidartinib 600mg daily (400mg in the morning, 200mg at night) for 4 weeks (1 cycle)
1976913|NCT03155750|Other|Zero Time Exercise|Zero Time Exercise encourage people to increase physical exercise by simple movements that can be done any time at any places. We offer a 2-session training course to train the subjects to do zero-time exercise.
1976914|NCT03155750|Other|Sleep hygiene education|We offer a 2-session education course to teach the subjects about sleep hygiene practice.
1976928|NCT03149809|Drug|solifenacin|Antimuscarinic bladder relaxant, antagonizes bladder muscarinic receptors
1976929|NCT03149809|Behavioral|Pelvic floor muscle exercise-based behavioral therapy|Multicomponent intervention including fluid management, constipation management and behavioral techniques incorporating pelvic floor muscle-exercise based urge suppression and self-monitoring to reduce overactive bladder symptoms
1976930|NCT03149575|Drug|VAL-083, Dianhydrogalactitol|VAL-083 given by intravenous infusion at a dose 40 mg/m2 IV on days 1, 2, and 3 of a 21-day treatment-cycle, for up to 12, 21-day treatment cycles
1998131|NCT01655719|Drug|Pioglitazone|
1998132|NCT01655030|Dietary Supplement|creatine monohydrate|
1998133|NCT01655030|Dietary Supplement|placebo|
1998134|NCT01652872|Biological|Darbepoetin alfa|Darbepoetin alfa will be presented as single use prefilled syringes. Investigational product will be administered subcutaneously every 4 weeks for the duration of the treatment period.
1998135|NCT01651806|Drug|Tranexamic Acid standard dose|Uniform 1 gram dosing
1998136|NCT01651806|Drug|Tranexamic Acid weighted dose|Weighted dose--20mg/kg of the drug will be given
1998137|NCT01651806|Drug|Females receiving a uniform dose of TA|Patients will receive a uniform 1 gm dose of tranexamic acid prior to tourniquet release during a primary TKA.
1998139|NCT01650649|Drug|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID [e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 (3 tablets)QID, etc] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
1976931|NCT03149575|Drug|Physician's Choice of Salvage Therapy - temozolomide|"The product label for temozolomide (Temodar®) provides the following dosing information.
Newly Diagnosed GBM: 75 mg/m2 for 42 days concomitant with focal radiotherapy followed by initial maintenance dose of 150 mg/m2 once daily for Days 1-5 of a 28-day cycle of Temodar® for 6 cycles.
Refractory Anaplastic Astrocytoma: Initial dose 150 mg/m2 once daily for 5 consecutive days per 28-day treatment cycle."
1976932|NCT03149575|Drug|Physician's Choice of Salvage Therapy - lomustine|"The product label for lomustine (CeeNu; lomustine; CCNU) provides the following dosing information.
The recommended dose of lomustine in adult and pediatric patients as a single agent in previously untreated patients is 130 mg/m2 as a single oral dose every 6 weeks In individuals with compromised bone marrow function, the dose should be reduced to 100 mg/m2 every 6 weeks."
1976933|NCT03149575|Drug|Physician's Choice of Salvage Therapy - carboplatin|"The product label for (Paraplatin) carboplatin Injection provides the following dosing information.
As a single agent at a dosage of 360mg/m2 IV on day 1 every 28 days Alternatively, the carboplatin dose may be calculated by the Calvert formula below Calvert formula for carboplatin dosing: Total Dose (mg) = (target AUC) x (GFR + 25), where AUC = area under the curve and GFR = glomerular filtration rate."
1976936|NCT03146247|Drug|Apremilast;Apremilast;Apremilast 10 MG; 20 MG; 30 MG Oral Tablet|All patients are scheduled to receive Apremilast with a titration phase of one week, followed by 23 weeks of regular treatment.
1976937|NCT03143751|Drug|NaCl20% (Continuous hyperosmolar therapy)|"Early intravenous administration (<24 hours after traumatic brain injury) of NaCl20% for a minimal duration of 48 hours (continued for as long as is necessary to prevent intracranial hypertension)
1-hour bolus (15 g if Na+ < 145 mmol/L; 7.5 g if 145 < Na+ < 150 mmol/L; or no bolus) followed by 1 g/hour as long as Na+< 150 mmol/L, reduced to 0.5 g/L if 150 < Na+ < 155 mmol/L, Discontinuation when 155 mmol/L<Na+"
1976940|NCT03131687|Drug|LY3298176|Administered SC
1976941|NCT03131687|Drug|Dulaglutide|Administered SC
1976942|NCT03131687|Drug|Placebo|Administered SC
1976943|NCT03117686|Diagnostic Test|lung ultrasound|"lung ultrasound with positive B-line pattern in patients after lung transplantations and healthy volunteers at sea level and high altitude (4600 m) at Mountb Kilimanjaro"
1976944|NCT03118908|Dietary Supplement|Amberen|Amberen is a succinate-based dietary supplement previously shown to help provide relief for common menopausal symptoms.
1976945|NCT03118908|Dietary Supplement|Smart B|Smart B contains vitamins B1, B2, B6, B9, B12 and sodium fumarate.
1976946|NCT03118908|Dietary Supplement|Placebo|Placebo capsules are identical to Amberen and Smart B capsules.
1976947|NCT03117712|Diagnostic Test|Delirium Scores|"Confusion Assessment method for the ICU (CAM-ICU) and
The Intensive Care Delirium Screening Checklist (ICDSC)
Delirium Scores will be measured at the following timepoints:
Postoperative day (POD) 1
POD 2
POD 5"
1976948|NCT03117712|Diagnostic Test|Carotis duplex sonography|"Carotis duplex sonography for perfusion flow will be evaluated at the following timepoints:
Before induction of anaesthesia
Before going on cardiopulmonary bypass (CBP)
During CPB, 5 min after aortic cross clamping
After CPB
24 hours after CPB"
1976949|NCT03117712|Diagnostic Test|TCD for detection of HITS|"Transcranial Doppler ultrasound (TCD) for detection and differentiation of high-intensity transient signals (HITS) in both middle cerebral arteries (MCAs) into artefacts, solid, and gaseous cerebral microemboli (CME) will be performed at the following timepoints:
During cannulation of the ascending aorta
After aortic cross-clamp
After opening of the aortic cross-clamp
During decannulation"
1976950|NCT03117673|Other|transesophageal echocardiography measurements|transesophageal echocardiography will be done routinely during the procedure. We will do additional measurements of the maximal TR velocity
1976953|NCT03107858|Drug|Norepinephrine|Norepinephrine infusion will be used at a starting dose of 0.05μg/kg/min. Dose range: 0.05 -0.15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
1976954|NCT03107858|Drug|Dopamine|Dopamine infusion will be used at a starting dose of 5μg/kg/min. Dose range: 5 -15 μg/kg/min. Infusion will be started with arterial decamping and continues till 24 hours postoperative
1976955|NCT03105804|Other|FT21039|An electronic cigarette
1976956|NCT03105804|Other|FT21041|An electronic cigarette
1976957|NCT03105804|Other|FT21044|An electronic cigarette
1976958|NCT03105804|Other|FT21042|An electronic cigarette
1976959|NCT03104595|Drug|EC-18|oral administration
1976960|NCT03102437|Device|Optimizer Smart System|The Optimizer Smart System delivers non-excitatory cardiac contractility modulating (CCM) electrical signals to the heart muscle. Treatment group subjects receive five non-contiguous one-hour periods of CCM signals per day.
1976962|NCT03095391|Device|VFI|The IV administered visible fluorescent injectate (VFI)™ agent is comprised of a mixture of 2 different molecular weight carboxymethyl dextran molecules (5 kD and 150 kD) with different fluorescent dye molecules attached.
1976963|NCT03095391|Device|Iohexol|Iohexol is a contrast enhancement agent which, following intravascular injection, is distributed in the extracellular fluid compartment and is excreted unchanged by glomerular filtration.
1976964|NCT03095651|Biological|MK-5160 low dose|MK-5160 low dose, subcutaneous daily for 12 days
1976965|NCT03095651|Biological|MK-5160 medium dose|MK-5160 medium dose, subcutaneous daily for 12 days
1976966|NCT03095651|Biological|MK-5160 high dose|MK-5160 high dose, subcutaneous daily for 12 days
1976967|NCT03095651|Biological|Glargine 0.4 U/kg|Glargine 0.4 U/kg, subcutaneous daily for 12 days
1976968|NCT03095651|Biological|Placebo to Glargine|Placebo to glargine, subcutaneous daily for 12 days
1976969|NCT03095651|Biological|Placebo to MK-5160|Placebo to MK-5160, subcutaneous daily for 12 days
1976970|NCT03095651|Drug|Dextrose|20% solution of dextrose; adjusted to maintain the various glycemic levels at 100 mg/dL given as a continuous intravenous infusion for 6-30 hours.
1976971|NCT03095651|Biological|Glargine 0.6 U/kg|Glargine 0.6 U/kg, subcutaneous daily for 12 days
1976972|NCT03091738|Drug|Ramelteon Pill|Patients with compensated cirrhosis and insomnia will be provided ramelteon
1976973|NCT03089645|Biological|MEDI5083 monotherapy|Dose-escalation MEDI5083 monotherapy
1976974|NCT03089645|Biological|MEID5083 with durvalumab|MEDI5083 dose-escalation with durvalumab therapy
1976979|NCT03072238|Drug|Ipatasertib|Oral tablets, 400 mg, given once daily (QD) beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity
1976980|NCT03072238|Drug|Abiraterone|Oral tablets of abiraterone, 1000 mg QD, taken on an empty stomach and swallowed whole with water, plus prednisone/prednisolone, 5 mg twice daily (BID)
1976981|NCT03072238|Drug|Placebo|Oral tablets (matched to ipatasertib appearance), given QD beginning on Day 1 of Cycle 1 until disease progression or intolerable toxicity
1976982|NCT03064841|Drug|No Treatment|No treatment
1976983|NCT03057951|Drug|Empagliflozin|once daily
1976984|NCT03057951|Drug|Placebo|once daily
1976985|NCT03057977|Drug|Empagliflozin|once daily
1976986|NCT03057977|Drug|Placebo|once daily
1976987|NCT03056053|Drug|Zolpidem|Commercially available tablets of zolpidem (5 or 10 mg) for oral use
1976994|NCT03052764|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injection into the bladder.
1976995|NCT03052764|Drug|Placebo (saline)|Placebo (saline) injection into the bladder.
1976996|NCT03050736|Drug|VAL-083 (Dianhydrogalactitol)|VAL-083 given by intravenous infusion with a starting dose of 20 mg/m2 IV. Escalating doses to be administered in sequential dose cohorts.
1976997|NCT03049111|Biological|Der f|Inhalation of Der f in mild asthmatics who are sensitive to Der f.
1976998|NCT03046043|Procedure|pulmonary vein isolation|pulmonary vein isolation is conducted on the junction between the left atrium and pulmonary vein
1976999|NCT03046043|Procedure|Low-Voltage & CFAE guided ablation|In CFAE guided ablation,. Within low voltage zone, CFAE areas defined by shortest SCI and high ICL are identified.-Areas with the shortest SCI and high ICL within low voltage areas should be targeted first, followed by longer SCI regions (up to 120ms). Radiofrequency energy is delivered at target sites for 30-60 sec until the local electrogram is completely eliminated.
1977000|NCT03044080|Drug|IncobotulinumtoxinA|Three consecutive injections of 200-300 units of IncobotulinumtoxinA (Xeomin ®) under ultrasound guidance. The IncobotulinumtoxinA will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
1977001|NCT03044080|Drug|OnabotulinumtoxinA|ree consecutive injections of 200-300 units of OnabotulinumtoxinA (Botox ®) under ultrasound guidance. The BoNT/A will be distributed according to the individual clinical pattern of spasticity: plantar flexor muscles (triceps sural: gastrocnemius and soleus), tibialis posterior, flexor digitorum longus.
1977002|NCT03043703|Device|AirSense 10 AutoSet for Her|Positive airway pressure
1977003|NCT03043690|Dietary Supplement|Ammonium succinate|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
1977004|NCT03043690|Other|Placebo|2 capsules of ammonium succinate-based dietary supplement (one white, 200 mg, and one orange, 200 mg), once a day, in the morning with a meal, for 90 days.
1977005|NCT03042325|Drug|Alogliptin|Alogliptin tablets
1989125|NCT02590003|Drug|Carboplatin|
1989126|NCT02590003|Drug|Nab-paclitaxel|
1989128|NCT02587143|Drug|Ethyl chloride|Nurses will administrate ethyl chloride vapocoolant spray on patient's skin a few seconds before arterial puncture (of cubital arteria).
1989129|NCT02587143|Drug|Alcohol|Nurses will use an alcohol-based spray as placebo on patient's skin a few seconds before arterial puncture (of cubital arteria).
1977006|NCT03041493|Behavioral|Electronic cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
1977007|NCT03041493|Behavioral|traditional cigarette|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will serve as both baseline measures for subsequent acute exposure to nicotine and as measures of chronic nicotine exposure. The second encounter will be scheduled 4 hours after the first encounter. At that time a blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
1977008|NCT03041493|Behavioral|(sham cigarette) - no actual exposure to cigarettes|During the first encounter, blood pressure and endothelium-dependent relaxation (EDR) will be measured by flow mediated dilatation (FMD), and a small peripheral IV catheter will be placed in the participant's median antecubital or cephalic vein. A blood sample (10 mL) for EPCs and F2-isoprostanes will be collected. One urine sample will also be collected for measurement of urinary F2-isoprostanes, cotinine and creatinine. These will be compared to the second set of laboratory measurements done at the second encounter that will be scheduled 4 hours after the first encounter. At that time an additional blood sample (5 mL) for EPCs will be collected followed by harvesting of vascular endothelial cells for eNOS and NF-κB expression.
1977014|NCT03041324|Biological|SB-913|Single dose of each of the 3 components of SB-913: ZFN1, ZFN2 and hIDS Donor
1977015|NCT03037905|Other|SignatureSuite™ OR Integration System by STERIS Corporation|SignatureSuite™ OR Integration System by STERIS Corporation is a product that includes software to control the audio and visual components of the operating room in order to provide a more relaxed and calming environment for patients prior to their surgery. It automatically dims lights, plays pleasant music or sounds of nature over the in-room speakers, and provides scenes of nature on video screens stationed in viewing range of the patient. As anesthesia is administered to the patient, the system automatically adjusts the light and sound systems to come up to surgeon-preferred preset stations. The process happens in reverse as the patient emerges from general anesthesia so that they awaken in the same environment as when they arrived in the OR.
1977016|NCT03035448|Behavioral|Questionnaires|"Participants complete 3 assessment questionnaires during an already-scheduled office visit. These questionnaires should take about 9 minutes to complete.
Participant completes 3 questionnaires after watching the second video about whether they think 1 of the videos was better than the other, and about their attitude toward psychology services. These questionnaires should take about 4 minutes to complete."
1977017|NCT03035448|Other|Video Presentation|Participant watches 2 videos showing actors playing a doctor, counselor, and patient, discussing psychology service options.
1977018|NCT03034785|Device|FlexiMitt|The proposed research designs and fabricates a new technological innovation in wearable soft-sensors, called flexi-mitts, for measuring force modulation and joint angles of the hand (wrist and fingers) of toddlers.
1977021|NCT03031691|Drug|brontictuzumab|starting dose of 1.5mg/kg administered intravenously (IV)
1977022|NCT03031691|Drug|trifluridine/tipiracil|
1977023|NCT03028584|Behavioral|Survey|Subjects (cancer patients and clinicians) will complete up to 2 surveys.
1977024|NCT03027388|Drug|LB-100|LB-100 will be infused over 2 hours via syringe pump in the OR. The dose established from a Phase I study will be 2.33 mg/m(2).
1977025|NCT03027245|Drug|Eribulin|
1977028|NCT03021265|Drug|T80/A5/H12.5 FDC|Drug
1977029|NCT03017872|Drug|N(t)RTIs|Choice of N(t)RTI determined by clinician, guided by either genotypic resistance testing or use of a protocol-specified algorithm for N(t)RTI selection.
1977030|NCT03017872|Drug|Dolutegravir|50mg tablet by mouth once daily for 96 weeks.
1977031|NCT03017872|Drug|Darunavir|800mg tablet by mouth once daily for 96 weeks.
1977032|NCT03017872|Drug|Ritonavir|100mg tablet by mouth once daily for 96 weeks.
1977033|NCT03017209|Dietary Supplement|Locally-prepared bar|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
1977034|NCT03017209|Dietary Supplement|USAID Corn Soy Blend Plus|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
1977035|NCT03017209|Other|Placebo|School children in first grade will receive their supplement 5 days a week in the morning before school starts. Younger children will receive the supplement 5 days a week in the morning at the community health center, distributed by community health workers. The teachers and community health workers will record amount of supplement consumption daily during the study, and will report the information weekly to the local research team throughout the intervention period.
1977036|NCT03012477|Drug|Cisplatin|Cisplatin will be given on the first day of every cycle. Each cycle is 21 days long.
1977037|NCT03012477|Drug|AZD1775|The first dose of AZD1775 will be administered in clinic on the first day of the second cycle. Subsequent doses will be taken approximately 12 hours apart for a total of five doses. Each cycle is 21 days long.
1977038|NCT03010150|Behavioral|Questionnaire|"Participants complete an assessment questionnaire at baseline.
Six months after radiation therapy, participant completes another assessment questionnaire that will also ask about adherence to swallowing exercises."
1977039|NCT03010150|Procedure|Blood Draw|Blood (about 1-2 teaspoons each time) drawn to measure the level of cytokines in participant's blood at baseline, and 6 months after radiation therapy.
1977040|NCT03007693|Drug|JNJ-61393215|Participants will receive JNJ-61393215 for 7 days.
1977041|NCT03007693|Drug|Placebo|Participants will receive JNJ- 61393215 matching placebo for 7 days.
1977042|NCT03005171|Drug|Bupivacaine|Thoracic epidural bupivacaine infusion
1977043|NCT03005171|Drug|Lidocaine|Intravenous lidocaine infusion
1977044|NCT03004586|Device|25-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
1977045|NCT03004586|Device|22-Gauge Needle|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed by using a 25-gauge needle.
1977046|NCT03004586|Procedure|Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration (EBUS-TBNA)|Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) performed.
1977047|NCT03005717|Drug|LIPO-202|
1977048|NCT03005717|Drug|Placebo for LIPO-202|Lyophile manufactured to mimic LIPO-202 lyophile.
1977049|NCT03003494|Drug|Spiolto® Respimat®|observations taken in a period of approximatley 6 weeks
1977050|NCT03000764|Other|skin biopsies|"Biopsies (12 G) will be performed :
in non-irradiated breast skin
in irradiated breast skin"
1977051|NCT03000764|Other|blood samples|"blood samples are collected:
10 ml in EDTA tube
2,5 ml in PAXgene Blood RNA tube
4 ml in EDTA tube"
1977052|NCT02999477|Drug|Pembrolizumab|Pembrolizumab will be administered in clinic every three weeks.
1977053|NCT02999477|Drug|Nab-Paclitaxel|Nab-Paclitaxel will be administered in clinic every week.
1977054|NCT02999477|Procedure|Biopsy|Biopsies for research purposes will be performed at three separate timepoints during treatment.
1977055|NCT02999672|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered as Regimen A (2.4 mg/kg/week IV infusion) or Regimen B (3.6 mg/kg Q3W IV infusion) until unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurs first.
1977056|NCT02998047|Drug|Lintuzumab AC 225|Lintuzumab-Ac225 is an immunoconjugate [antibody: anti-CD 33 antibody and radioactive isotope: Actinium (225Ac)] for the treatment of multiple myeloma.
1977057|NCT02985957|Biological|Nivolumab|Specified dose on specified days
1977058|NCT02985957|Biological|Ipilimumab|Specified dose on specified days
1977059|NCT02972658|Drug|Lanabecestat|Administered orally
1977060|NCT02969941|Other|transcranial magnetic stimulation|
1977061|NCT02968342|Device|Vaginal progesterone 8%|vaginal self application
1977062|NCT02957968|Drug|Doxorubicin|60 mg/m2 once every 2 weeks for 4 cycles.
1977063|NCT02957968|Drug|Cyclophosphamide|cyclophosphamide 600 mg/m2 (AC) once every 2 weeks for 4 cycles.
1977064|NCT02957968|Drug|Paclitaxel|Paclitaxel 80 mg/m2 IV once weekly for 12 weeks.
1977065|NCT02957968|Drug|Carboplatin|carboplatin AUC 1.5 once weekly for 12 weeks.
1977066|NCT02957968|Drug|Decitabine|Given IV
1977067|NCT02957968|Drug|Pembrolizumab|Given IV
1977074|NCT02952053|Device|MTrP Group|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.
1 session in soleus muscle. 10 fast in and fast out needle insertions."
1977075|NCT02952053|Device|TB Group|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.
1 session in soleus muscle. 10 fast in and fast out needle insertions."
1977076|NCT02948036|Other|Plasticity-based adaptive cognitive treatment|This study employs a mobile-device delivered treatment program. Participants will be asked to use the assigned treatment program for approximately 30 minutes per session, up to seven sessions per week, over 6 weeks (30 total sessions)
1977077|NCT02946931|Drug|Prizbind|Idarucizumab
1977078|NCT02942615|Other|limit heart dose|limit heart dose: Dmean≤6Gy,V30≤20%,V10≤50%
1977079|NCT02941900|Genetic|MC1R genotyping|
1977080|NCT02941900|Behavioral|MC1R Testing Website|The website includes three educational modules about genetic testing with corresponding knowledge questions.
1977081|NCT02941900|Behavioral|Baseline Survey|
1977082|NCT02940626|Drug|ASN100|monoclonal antibody combination of ASN-1 and ASN-2
1977083|NCT02940626|Drug|Placebo|Placebo
1977084|NCT02932332|Other|High-flow Oxygen|Optiflow Respiratory Humidifier used to deliver HFOx. Oxygen flow will be maximized (set between 20 and 60 L/min), if tolerated, to minimize dyspnea. FiO2 will be set at 100%.
1977085|NCT02932332|Other|Low-flow Oxygen|Low-flow Oxygen will be delivered by Optiflow in an identical manner to high flow, except provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
1998421|NCT01379898|Drug|Doxazosin|Starting dosage of doxazosine in hypertensive subjects:8 mg q.d. (=4 mg b.i.d.)and in normotensive subjects starting dose 4 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 48 mg q.d. .(=24 mg b.i.d.)
1998517|NCT01285037|Drug|Cetuximab|Cetuximab given via IV infusion once weekly, 400mg/m2 for first dose and 250mg /m2 for subsequent doses. If LY2801653 treatment is stopped due to toxicity after a minimum of 4 cycles, cetuximab may be continued until disease progression. In the event cetuximab treatment is stopped, participants may continue on study drug until disease progression, unacceptable toxicity, or other withdrawal criterion is met.
1977086|NCT02932332|Other|High-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
1977087|NCT02932332|Other|Low-flow Air|Two level air flow (high and low) will be delivered by Optiflow in an identical manner to oxygen air flows, except that researchers will use pressurized air instead of oxygen. LFOx and LFAir will be provided at 2 L/min using a nasal cannula identical to that used for high-flow devices.
1977088|NCT02929329|Drug|Omecamtiv Mecarbil|Oral omecamtiv mecarbil twice daily for up to 208 weeks with dose level determined by periodic blood testing
1977089|NCT02929329|Drug|Placebo|Oral placebo twice daily for up to 208 weeks
1977090|NCT02926066|Drug|AAV2-hAADC|Dosage form: Aqueous solutionDose(s): 2.371x1011 vg/case Dosing schedule: Intracerebral infusion, single doseMechanism of action (if known): supplement a gene defect
1977098|NCT02919787|Drug|Gemcitabine|Adjuvant treatment
1977099|NCT02919787|Drug|5-FU|Neoadjuvant treatment
1977100|NCT02919787|Drug|Capecitabine|Adjuvant treatment
1977101|NCT02919787|Drug|Oxaliplatine|Neoadjuvant treatment
1977102|NCT02919787|Drug|Irinotecan|Neoadjuvant treatment
1977103|NCT02919787|Procedure|Pancreatic surgery|
1977104|NCT02914236|Device|Vivaer Stylus|Delivery of low-power, temperature-controlled, radiofrequency energy to the tissues of the internal nasal valve area
1920960|NCT00320424|Drug|Fondaparinux|
1977111|NCT02910284|Biological|Observational|
1977112|NCT02905331|Drug|Guselkumab|Participants will receive 100 mg of Guselkumab as 100 mg/mL solution via SelfDose device.
1977113|NCT02905331|Drug|Placebo|Participants will receive matching placebo supplied in a PFS assembled in a SelfDose device.
1977114|NCT02903680|Drug|Dexamethasone group|The intervention of interest was the administration of dexamethasone 0.6 mg/kg IV (max 15 mg) before departure from the ED. The control group received a similar looking placebo (NaCl 0,9% IV) with the same volume.
1977115|NCT02903680|Drug|Placebo group|Normal Saline 0,9% same volume
1977122|NCT02894658|Device|LipiFlow system|LipiFlow System is an in-office FDA approved treatment that relieves meibomian gland obstruction through the use of heat and pulsatile pressure.
1977123|NCT02894658|Procedure|Warm compresses|"Warm compresses will be applied to fellow eye and that eye will undergo daily treatment with eyelid scrubs using a warm wash cloth and no tears baby shampoo every morning and warm compresses on the eyelids for 5-10 minutes twice a day. Patients will be instructed on how to perform proper lid hygiene at the initial visit."
1977124|NCT02893293|Drug|Ferumoxytol-enhanced magnetic resonance imaging|Eligible patients receive a single ferumoxytol-dose and follow-up magnetic resonance imaging to evaluate success of stem cell transplant
1977125|NCT02893293|Device|Magentic Resonance Imaging|Both arms will receive MRI
1977127|NCT02891070|Drug|FS VH S/D 500 s-apr|
1977128|NCT02891070|Device|DuraSeal Dural Sealant|
1977129|NCT02890992|Drug|alirocumab SAR236553 (REGN727)|Pharmaceutical form:solution Route of administration: subcutaneous injection
1977130|NCT02890992|Drug|statins|Pharmaceutical form:tablet Route of administration: oral
1977131|NCT02890992|Drug|ezetimibe|Pharmaceutical form:tablet Route of administration: oral
1977132|NCT02890992|Drug|cholestyramine|Pharmaceutical form:tablet Route of administration: oral
1977133|NCT02890992|Drug|fenofibrate|Pharmaceutical form:tablet Route of administration: oral
1977134|NCT02890992|Drug|omega-3 fatty acids|Pharmaceutical form:tablet Route of administration: oral
1977135|NCT02890992|Drug|nicotinic acid|Pharmaceutical form:tablet Route of administration: oral
1977142|NCT02891226|Drug|Mirikizumab|
1977143|NCT02891226|Drug|Placebo|
1977144|NCT02885493|Behavioral|tests|
1977145|NCT02881879|Biological|Allergovac depot DPT/DF (50:50)|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly dose increasing injections at the initiation phase plus 3 maintenance monthly injections
1977146|NCT02875106|Device|12-point-ECG|routine recording will be 300 seconds
1977147|NCT02875106|Device|Polar V800|routine recording will be 300 seconds
1977148|NCT02875106|Device|360° eMotion FAROS SET + Belt|routine recording will be 300 seconds
1977149|NCT02875106|Device|Adidas Micoach smart run|routine recording will be 300 seconds
1977150|NCT02875106|Device|TomTom Runner Cardio HRM|routine recording will be 300 seconds
1977151|NCT02873169|Other|Implantable cardioverter-defibrillator|Collection of clinical, biological, hemodynamic and rhythmic data
1977154|NCT02870777|Other|MRD-directed therapy|The purpose of this study is to establish risk stratification based on cytogenetics at diagnosis and MRD analysis after induction chemotherapy and before consolidation chemotherapy to determine whether a MRD directed therapy for low and intermediate AML patients has positive results in terms of overall survival.
1977155|NCT02866071|Drug|Ketamine Hydrochloride|50mg IN Ketamine Hydrochloride
1977156|NCT02866071|Drug|Placebo-Comparator|50mg IN Placebo
1977157|NCT02864407|Drug|Vahelva Respimat(Tiotropium + Olodaterol)|2.5 microgram and 2.5 microgram 2 puffs comprise one medicinal dose
1977158|NCT02864342|Device|Arm 1: BreatheMate device with application|The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. Subjects will receive audio-visual daily reminders (beeps and flashes) on the BreatheMate Bluetooth device. The bluetooth device transmits this data to a cellular phone that is provided to all subjects in the study. Subjects in the intervention group will also receive audio-visual alerts (beeps, flashes) from the bluetooth device to take their medication.
1977159|NCT02864342|Device|Arm 2: BreatheMate device without application|"The service known as 'BreatheMate' is a patient support tool that monitors daily Symbicort inhaler use. The BreatheMate service includes a bluetooth monitoring device that is attached to subjects' Symbicort pMDI inhaler which automatically detects and logs their maintenance medication use. The functionality of audio-visual daily reminders (beeps and flashes) is deactivated for this control group.
The BreatheMate service also includes a cellular phone that will display whether the Bluetooth monitoring device is paired and communicating with the cellular phone. The Bluetooth device will transmit data regarding medication usage to the cellular phone."
1977160|NCT02864264|Drug|BMS-986184|
1977161|NCT02864264|Drug|Placebo matching BMS-986184|
1977162|NCT02861417|Drug|Busulfan|"First Busulfan dose based on actual body weight and given by vein over three hours by controlled-rate infusion pump.
Group 1 and 2: Busulfan administered at dose calculated to achieve a total (including first two doses delivered on day -13 and -12) systemic exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies.
Group 3 and Group 4: Busulfan administered at dose calculated to achieve a total (including first two doses delivered on day -20 and day -13) system exposure of 20,000 ± 12% µMol-min based on the pharmacokinetic studies."
1977163|NCT02861417|Drug|Thiotepa|Haplo Patients Only: 5 mg/kg by vein on Day -7 only in haploidentical transplant recipients. Patients weighing 20% above their ideal body weight dosed according to adjusted body weight.
1977164|NCT02861417|Drug|Fludarabine monophosphate|"Fludarabine dosed per actual body weight/actual body surface area.
Fludarabine 40 mg/m2 by vein on Days -6 to -3."
1977165|NCT02861417|Procedure|Stem Cell Infusion|Fresh or cryopreserved bone marrow or peripheral blood progenitor cells infused on Day 0.
1977166|NCT02861417|Drug|Mesna|Mesna 10 mg/kg by vein prior to the first dose of post transplant cyclophosphamide. Mesna repeated every 4 hours for a total of ten (10) doses. Participants dosed on actual body weight unless they weigh more than 20% above their ideal body weight, in which case dosed according to the adjusted body weight.
1977167|NCT02861417|Drug|Cyclophosphamide|50 mg/kg by vein on Days + 3 and + 4. Participants dosed on actual body weight unless they weigh more than 20% above their ideal body weight.
1977168|NCT02861417|Drug|Tacrolimus|Tacrolimus administered at starting dose of 0.015 mg/kg/day (ideal body weight) as a 24 hour continuous infusion daily adjusted to achieve a therapeutic level of 5-15 ng/ml starting Day +5. Tacrolimus changed to oral dosing when tolerated and can be tapered off after Day +90 if no GVHD is present.
1977169|NCT02861417|Drug|Mycophenolate Mofetil|15 mg/kg/dose (max 1000 mg per dose based on actual body weight) by mouth every 8 hours. Given from Day +5 until Day +100 followed by a weekly taper thereafter by 500 -1000 mg.
1977170|NCT02861417|Drug|G-CSF|5 mcg/kg/day subcutaneously beginning on Day +7, and continuing until the absolute neutrophil count (ANC) is > 500 x 10/L for 3 consecutive days.
1977173|NCT02860130|Drug|Prismocitrate 18|Modality of CVVHDF
1977174|NCT02860130|Other|No Anticoagulation|Modality of CVVHDF
1977175|NCT02859181|Dietary Supplement|Amino Acid Intake|Amino acid intakes will be varied at 0.2-2.67 g/kg/d
1977179|NCT02854865|Other|echocardiography|assess whether GLPSS measured during cardiac surgery using AFI is superior to E/Ea ratio in estimation of LVFP measured as PCWP
1977180|NCT02854631|Drug|Selonsertib|18 mg tablet administered orally once daily
1977181|NCT02854631|Drug|Prednisolone|40 mg (4 x 10 mg tablets) administered orally once daily
1977182|NCT02854631|Drug|Placebo|Selonsertib placebo tablet administered orally once daily
1977183|NCT02850419|Drug|ThermoDox (Thermally Sensitive Liposomal Doxorubicin)|A dose of 40 mg/m2 will be administered at each cycle for a total of 6 cycles. ThermoDox will be administered in conjunction with hyperthermia.
1977184|NCT02850419|Radiation|Radiation Therapy|A total of 40 Gy in 20 fractions of 2 Gy per fraction will be administered. Up to 66 Gy of radiation therapy can be administered however institutional guidelines should be followed.
1977185|NCT02850419|Device|Superficial Hyperthermia|Thermal dose is an one-hour treatment at a temperature between 40 and 43 degrees Celsius at the target site.
1977186|NCT02848833|Drug|JARDIANCE 10mg|T2DM with JARDIANCE 10mg
1977187|NCT02848833|Drug|JARDIANCE 25mg|MT2DM with JARDIANCE 25mgax
1977188|NCT02844842|Biological|Allergovac Poliplus|
1977189|NCT02842632|Other|theoretical test|The theoretical test is a multiple choice test which consists of 50 questions with 1 point per question (max. 50 points). It will be done before the teaching, after the 2 teaching sessions and 3 Months after the study
1977190|NCT02842632|Other|practical test|The practical test is an evaluation of 11 basic perioperative TEE examination on the simulator (CAE Vimedix Simulator). Each view is evaluated on a scale of 0 to 10 according to predetermined criteria including image angle, overall clarity and visualization of 3 major anatomic structures pertinent to each view. Each view can receive a maximum score of 10 and each study a maximum of 109 (ME asc. aortic LAX has only 2 main structures). It will be done after the first and second teaching session, and 3 Months after the study.
1977191|NCT02838420|Drug|Alectinib|Alectinib capsules will be administered orally at a dose of 600 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
1977192|NCT02838420|Drug|Crizotinib|Crizotinib capsules will be administered orally at a dose of 250 mg BID until disease progression, unacceptable toxicity withdrawal of consent, or death.
1977193|NCT02835495|Behavioral|HELP Vets Intervention|This intervention involves a dietary weight loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight loss of approximately 0.3 kg per week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 min/week.
1977194|NCT02835495|Behavioral|Individual Education Program|Participants will receive two individual sessions with a nutritionist during the first 3 months. In these sessions, the nutritionist will cover basic aspects of healthy eating and activity to support weight loss, discuss existing community resources and increased physical activity and weight loss. These participants will also receive a monthly newsletter on topics related to healthy lifestyle.
1977195|NCT02835638|Device|Adaptative Servo Ventilation|the ASV treatment will be observed during this study on the patients included
1977196|NCT02834338|Device|activity tracking for autofeedback|The intervention group receives an unblinded wristband. The handling of the activity trackers is explained to the patients and a predefined mobilization end-point (step-count) for the first five PODs is targeted. The target step-count was set at the 85% quartile obtained from a previous pilot study. The patients are assessed and monitored two times daily between 9 and 11 o'clock AM and between 3 and 5 o'clock PM by a surgical fellow or a study nurse throughout their hospital stay for read-out of the step count, assurance of the proper use and functioning, and for communication of the autofeedback.
1977218|NCT02813915|Device|NICOM|Use of NICOM and PLR to obtain patient fluid status
1977219|NCT02811692|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection
1977220|NCT02807181|Drug|Cisplatin-gemcitabine|Systemic chemotherapy
1977221|NCT02807181|Device|Radiation: SIRT + chemotherapy (cisplatin-gemcitabine)|SIR-Spheres microspheres followed by systemic chemotherapy
1977222|NCT02806869|Drug|Single dose of ibuprofen (800 mg tablet)|
1977223|NCT02806869|Dietary Supplement|Pulmocare, two 8.0 oz (236.6 mL) cans|
1977224|NCT02801344|Dietary Supplement|Normal|test drink which contains low amount of amino acids (0.14 g/kg/day)
1977225|NCT02801344|Dietary Supplement|Moderate|test drink which contains moderate amount of amino acids (0.40 g/kg/day)
1977226|NCT02801344|Dietary Supplement|High|test drink which contains high amount of amino acids (1.03 g/kg/day)
1977227|NCT02801344|Other|Controlled-diet|the diet containing 0.8 g protein /kg/day
1977228|NCT02799602|Drug|BAY1841788 / darolutamide (ODM-201)|600mg (2 tablets of 300 mg) of darolutamide (ODM-201)/placebo twice daily with food, equivalent to a total a daily dose of 1200 mg in addition to standard ADT (luteinizing hormone releasing hormone (LHRH) agonist/antagonist or orchiectomy) and 6 cycles of docetaxel
1977229|NCT02799602|Drug|Standard ADT (androgen deprivation therapy)|As prescribed by the treating physician.
1977230|NCT02799602|Drug|Docetaxel|As prescribed by the treating physician.
1977231|NCT02799602|Drug|Placebo|Placebo matching darolutamide (ODM-201) tablets in appearance, bid orally with food, in addition to standard ADT (luteinizing hormone releasing hormone [LHRH] agonist/antagonist or orchiectomy) and 6 cycles of docetaxel.
1977232|NCT02794480|Device|ELLIPTA DPI|It is the inhaler with two blister strips containing white coloured powder, one placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate. It is given as oral inhalation (Inhalation powder)
1977233|NCT02794480|Device|GSK MDI|It is the placebo inhaler with clear liquid containing propellant (1,1,1, 2- Tetrafluoroethane). It is given as oral inhalation (Inhalation Aerosol).
1977234|NCT02794480|Device|AZ MDI|It is the placebo inhaler with clear liquid. It is given as oral inhalation (Inhalation Aerosol).
1977235|NCT02792699|Drug|ABP 798|
1977236|NCT02792699|Drug|Rituximab|
1977237|NCT02791191|Drug|LY3202626|Administered orally
1977238|NCT02791191|Drug|Placebo|Administered orally
1977239|NCT02790723|Genetic|sc-rAAV2.5IL-1Ra|Self-complementing, recombinant AAV carrying IL-1Ra cDNA produced by the University of North Carolina Vector Core
1977240|NCT02790554|Device|Moyo strap-on|Continous monitoring
1977241|NCT02790554|Device|Hand-held Doppler|Intermittent monitoring
1977242|NCT02783573|Drug|Lanabecestat|Administered orally
1977243|NCT02783573|Drug|Placebo|Administered orally
1977244|NCT02782715|Radiation|Stereotactic Body Radiation Therapy (SBRT)|Patients will be treated on study with a course of SBRT treatment by a radiation oncologist. Three SBRT dose levels targeting the primary tumor will be evaluated; level I: 6 Gy x 5 fractions (a common palliative dose), level II: 8 Gy x 5 fractions, and level III: 10 Gy x 5 fractions (a common definitive dose).
1977245|NCT02782715|Procedure|Microwave Ablation (MWA)|Performed under sedation using ultrasound and computed tomography (CT) guidance for percutaneous antenna placement and confirmation. Depending on size and location of tumor, one to three antennas (Certus 140; NeuWave Medical) will be used. The system is an FDA-approved, high-powered third-generation MW device that uses CO2 gas cooling to prevent shaft heating. The gas cooling allows the probes to be stuck into tissue by creating a small ice ball at the tip using the Joule-Thomson method, similar to the tissue cooling mechanism of cryoablation systems. Probes are 17-gauge, and various ablation zone configurations are available depending on the probe selected. An ablation protocol using the 65W power setting for 5 minutes will be used for most patients. Ultrasound will be used for real-time monitoring of the extent of ablation to achieve a 5mm margin beyond tumor, and immediate post-procedure imaging performed using contrast-enhanced CT (CECT) for patients with adequate renal functions.
1977246|NCT02782780|Behavioral|Cognitive Behavioral Therapy for Insomnia (CBTi)|CBTi is a multicomponent treatment that seeks to teach patients about sleep and the factors that affect sleep (e.g., homeostatic regulation, circadian rhythm, age, social and work schedule) and to work with the patients toward minimizing unwanted arousal at bedtime and altering sleep habits to increase sleep propensity and regularity. The intervention is 8-weeks long.
1977247|NCT02781558|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily
1977248|NCT02781558|Drug|RBV|RBV tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1977253|NCT02776007|Device|Libre Flash CGMS|
1977254|NCT02776007|Device|Self-Measurement Blood Glucose|Patients will use their personal glucose meter to perform Self-Measurement Blood Glucose
1977255|NCT02772588|Drug|ARN-509|
1977256|NCT02772588|Drug|Abiraterone|
1977257|NCT02772588|Drug|Leuprolide|
1977258|NCT02772588|Radiation|stereotactic, ultra-fractionated radiotherapy|
1977259|NCT02771548|Procedure|Anterior Cruciate Ligament Reconstruction|
1977260|NCT02770170|Drug|BI 655064 dose 1|
1977261|NCT02770170|Drug|BI 655064 dose 2|
1977262|NCT02770170|Drug|BI 655064 dose 3|
1977263|NCT02770170|Drug|Placebo|
1977264|NCT02768038|Other|Observational|Blood, stool ja biopsy specimens
1977265|NCT02765646|Device|Coronary stent procedure (CSP)|
1977266|NCT02765256|Drug|Fluconazole|400mg orally once daily (Day 1-14)
1977267|NCT02765256|Drug|Vancomycin|500mg oral suspension 4 times daily (Day 1-14)
1977268|NCT02765256|Drug|Neomycin|neomycin 1000 mg orally three times daily (Days 1-3)
1977269|NCT02765256|Drug|Ciprofloxacin|ciprofloxacin 750 mg orally twice daily (Day 4-14)
1977270|NCT02765256|Drug|Polyethylene Glycol 3350|238 g dissolved in 64 ounces of Gatorade or Crystal Lite on day 2
1977271|NCT02765256|Drug|Promethazine|PRN (as needed) Promethazine 12.5mg up to every four hours (Days 1-3).
1977277|NCT02756247|Drug|Buparlisib|
1977278|NCT02756247|Drug|Ibrutinib|
1977279|NCT02755181|Behavioral|Experimental|with functional imaging and behavioural measurements at baseline and 4 weeks
1977280|NCT02754167|Biological|PRS-080#022-DP|Hepcidin antagonism to mobilize iron and to treat anemia
1977281|NCT02754167|Biological|PRS-080-Placebo#001|Placebo comparator
1977282|NCT02750319|Drug|Amiodarone|
1977283|NCT02750319|Drug|N-Acetylcysteine|
1977284|NCT02750319|Drug|Placebo|
1977285|NCT02749422|Device|MagStim RapidStim2|Repetitive transcranial magnetic stimulation (TMS)
1977286|NCT02750358|Drug|Enzalutamide|
1977287|NCT02750358|Behavioral|assessment|
1977288|NCT02733081|Procedure|Simplified IUD Insertion|IUD Insertion with no bimanual pelvic exam or uterine sounding.
1977289|NCT02732899|Drug|Sirolimus|
1977290|NCT02732899|Drug|EYLEA|
1977291|NCT02730819|Drug|Illuminate Cream|Topical compound applied daily
1977292|NCT02720354|Other|[11C]‑DMDPA|
1977293|NCT02717962|Drug|VAL-083, Dianhydrogalactitol|The dosing regimen for patients will be VAL-083 (40 mg/m2) administered IV for 3 consecutive days at the beginning of every 21-day cycle. Patients will continue to receive VAL 083, for up to 12, 21-day treatment cycles or until they fulfill one of the criteria for study discontinuation.
1977294|NCT02713204|Drug|REGN910-3|
1977295|NCT02713204|Drug|Intravitreal Aflibercept Injection (IAI)|
1977296|NCT02712008|Drug|REGN910-3|
1977297|NCT02712008|Drug|Intravitreal Aflibercept Injection (IAI)|
1977298|NCT02707393|Drug|Fludarabine|infusion
1977299|NCT02707393|Drug|Thiotepa|infusion
1977300|NCT02707393|Drug|Melphalan|infusion
1977301|NCT02707393|Drug|ATG|infusion
1977302|NCT02707393|Drug|Cyclosporine A|infusion, orally if possible
1977303|NCT02707393|Drug|Mycophenolate mofetil|infusion
1977304|NCT02707393|Biological|bone marrow or peripheral blood stem cells|infusion
1977305|NCT02705053|Device|CGM and Insulin Pump|Dexcom G4 Platinum CGM with Share AP Receiver Roche Accu-Chek insulin pump.
1977306|NCT02705053|Device|Closed-Loop Control System|"The devices that will be used in the Closed-Loop Control System include the following components:
DiAs - a smart-phone medical platform; Dexcom G4 Platinum connected to DiAs via Bluetooth CGM receiver; Roche Accu-Chek insulin pump connected to DiAs via wireless Bluetooth; Remote Monitoring Server connected to DiAs via 3G or local Wi-Fi network, and Zone-MPC and HMS algorithms running on DiAs (MPC and HMS)"
1977307|NCT02702427|Biological|virus-specific T-Cells|infusion
1977308|NCT02702518|Drug|rhDNase I|rhDNase I, 0.1% eye drops 4 times a day for 8 weeks
1977309|NCT02702518|Drug|Vehicle|Drug vehicle 4 times a day for 8 weeks
1977310|NCT02694744|Drug|patiromer|8.4 g/day starting dose, administered orally
1977311|NCT02690428|Device|Immunostimulating Interstitial Laser Thermotherapy|Immunostimulating Interstitial Laser Thermotherapy (imILT) is a specific form of thermotherapy, which, in addition to destroying tumor tissue, has been optimized to cause a tumor specific immunologic response.
1977312|NCT02690935|Drug|2LALERG|Homeopathic drug
1977313|NCT02690935|Drug|Placebo|Placebo
1977314|NCT02673203|Device|Continuous Glucose Monitoring System (CGMS)|The CGMS consists of 3 parts: sensor, transmitter and monitor. The small sensor measures the glucose levels from the interstitial tissue. The transmitter is attached on top of the sensor and connects wirelessly to the monitor. The sensor is sterile and comes in an unopened package. It has a plastic wire-like tip that is placed under the skin and continuously measures the glucose levels. One of the study physicians will insert the CGMS wire-like tip under the volunteer's skin with the use of the DEXCOM sensor insertion kit. The transmitter is snapped to the sensor pod and the sensor/transmitter unit will be attached to the skin with an adhesive patch. The monitor is the size of a small hand-held device with a digital screen that displays a graph showing the glucose levels from the previous 4-24 hours.
1977315|NCT02673203|Behavioral|Food log|The Food Record will ask about amount and type of food consumed throughout the day. The participants will also register how hungry they are before the meal and how full they feel after they ate, and type and duration of physical activity
1977316|NCT02664285|Other|closure of subcutaneous tissue|the subcutaneous fat will be closed with three to five interrupted sutures. The sutures were tied until the tissue was adequately re-approximated, but not as hard as possible to avoid necrosis after cesarean section in diabetic patients.
1977317|NCT02664285|Other|No closure of subcutaneous tissue|the subcutaneous fat will not sutured after cesarean section in diabetic patients.
1977318|NCT02659826|Device|anodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a direct current (DC) stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (anode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 milliampere (mA), fade in and fade out of 10 seconds, during 20 minutes.
1977319|NCT02659826|Device|cathodal tsDCS|Transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The active electrode (cathode) will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during 20 minutes.
1977320|NCT02659826|Device|sham tsDCS|sham transcutaneous spinal cord stimulation will be delivered through a DC stimulator (NeuroConn Plus, Germany) using a pair of saline-soaked sponge electrodes (35cm²). The electrode anode will be placed between the eleventh and the twelfth thoracic vertebra) and the reference electrode, over the right arm (deltoid muscle). Will be delivered a current intensity of 2.5 mA, fade in and fade out of 10 seconds, during only 30 seconds but the volunteers will continue with electrodes montage for 20 minutes.Thus, early sensations (eg. mild to moderate tingling or itch) on stimulation site will be experienced without inducing any modulatory effects.
1977321|NCT02659826|Device|Gait training|It consists of moderate gait training exercise for 20 minutes. To ensure that the exercise will be performed at moderate intensity will be used the 64% - 76% of maximum heart rate (HRmax = 220-age). Heart rate will be monitored every three minutes through a heart polar. In addition will be monitored perceived effort, gait speed and inclination of the treadmill. The Borg scale will be used to evaluate perceived effort. This is an analogue scale graded from 6 (light exercise) to 20 points (exhaustive exercise). Information about the exercise on the treadmill will be noted in the evolution record.
1977322|NCT02659826|Device|High frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. rTMS protocols was based on previous studies. High frequency protocol: 20 hertz (Hz), 90% RMT, 45 trains, 40 stimuli per train, inter interval of 28 seconds, 1800 stimuli. After each rTMS session, presence of adverse effects will be computed.
1977323|NCT02659826|Device|Low frequency rTMS|Initially, the higher cortical representation area (hotspot) of first right dorsal interosseous (FDI) muscle will be determined through a figure-eight coil connected to the magnetic stimulator (Rapid2, Magstim, UK) held manually and positioned over the scalp (C3 - 10/20 System) at an angle of 45 degrees from the midline pointed to the target muscle (FDI). Thereafter, RMT will be measure. Low frequency protocol: 1Hz, 90% RMT, 1500 stimuli (1 train). After each rTMS session, presence of adverse effects will be computed.
1998504|NCT01311687|Drug|pomalidomide|4 mg pomalidomide will be administered by mouth on Days 1-21 of each 28-day treatment cycle until disease progression
1998569|NCT01233609|Drug|Placebo|Dosage per subject weight- same schedule as the active comparator
1921193|NCT00250484|Device|Transcranial Magnetic Stimulation|1Hz transcranial Magnetic Stimulation for 10 days for 26 minutes each day
1921194|NCT00250484|Device|Sham Transcranial Magnetic Stimulation|Sham procedure of transcranial Magnetic Stimulation for 10 days for 26 minutes each day
1977324|NCT02659826|Device|sham rTMS|The hotspot of first right dorsal interosseous (FDI) muscle will be determinate through a figure-eight coil connected to the magnetic stimulator positioned over the motor primary cortex (C3). Then, the motor threshold (RMT) of FDI will be measure. Sham rTMS will be performed with low frequency (1Hz, 90% RMT, 1500 stimuli) protocol using two coils. The first one - connected to the stimulator - will be positioned on a coil support close to the volunteer but not visible. Therefore, characteristic stimulation noises will be audible. The second - disconnected to the stimulator - will be placed over left primary motor area. After each rTMS session, presence of adverse effects will be computed.
1977325|NCT02658643|Procedure|Continuous suture technique|The BDA is performed as continuous suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
1977326|NCT02658643|Procedure|Interrupted suture technique|The BDA is performed as interrupted suture with two separate all-layer suture for the behind - and front-wall of the anastomosis
1977327|NCT02656797|Drug|Topical Amphotericin-B 0.4% liposomal gel|Topical Amphotericin-B 0.4% liposomal gel
1977328|NCT02653391|Drug|Elamipretide 1.0% Ophthalmic Solution|Each subject will receive one drop of Elamipretide 1.0% ophthalmic solution in the randomly selected study eye BID and one drop of vehicle ophthalmic solution BID in the fellow control eye.
1977329|NCT02653391|Drug|Elamipretide 3.0% Ophthalmic Solution|A group of subjects will receive one drop of Elamipretide 3.0% ophthalmic solution in both eyes BID
1977333|NCT02640235|Device|CELSTAT|
1977334|NCT02640235|Device|Surgicel Original|
1977335|NCT02637895|Drug|Placebo|
1977336|NCT02637895|Drug|Vortioxetine|
1977337|NCT02633800|Drug|Patritumab|Patritumab initial loading dose is 18 mg/kg IV over 60 minutes followed by a maintenance dose of 9 mg/kg IV over 60 minutes (± 10 minutes) every three weeks
1977338|NCT02633800|Drug|Cetuximab|Cetuximab 400 mg/mg/m^2 IV loading dose, followed by 250 mg/m^2 weekly
1977339|NCT02633800|Drug|Cisplatin|Cisplatin at 100 mg/m^2 IV infused over 1 hour, every three weeks up to a maximum of 6 cycles
1977340|NCT02633800|Drug|Carboplatin|Carboplatin IV over 30 to 60 minutes, every 3 weeks for a maximum of 6 cycles
1977341|NCT02633800|Drug|Placebo|Placebo to match patritumab
1977342|NCT02632747|Drug|Empagliflozin|Empagliflozin will be taken once daily
1977343|NCT02632747|Drug|Placebo (matching empagliflozin)|Placebo will be taken once daily
1977344|NCT02632747|Drug|ramipril|Ramipril will be taken once or twice daily
1977347|NCT02628249|Dietary Supplement|Base protein|0.8 g/kg/d of protein provided as crystalline amino acid modeled after egg protein
1977348|NCT02628249|Dietary Supplement|Sufficient protein|1.75 g/kg/d protein provided as crystalline amino acid modeled after egg protein.
1977349|NCT02628249|Dietary Supplement|Branched chain amino acids|Branched chain amino acids modeled after egg protein.
1977350|NCT02628249|Dietary Supplement|Essential amino acids|Essential amino acids modeled after egg protein.
1977351|NCT02628249|Dietary Supplement|Non essential amino acids|Non essential amino acids modeled after egg protein.
1977355|NCT02627235|Behavioral|DIAL|The physical activity intervention is based on Social Cognitive Theory and includes feedback on physical activity progress via IVR system and monthly graphic-based feedback letters delivered in the mail. Messages will encourage incremental increases until national PA guidelines are reached and provide specific information on cancer risk reduction.
1977356|NCT02627235|Behavioral|Wait List Control|Access to DIAL intervention 12 weeks following baseline assessment.
1977357|NCT02625428|Drug|Optison|
1977358|NCT02624869|Biological|evolocumab (AMG 145)|Administered by subcutaneous injection
1977360|NCT02622321|Drug|Emicizumab|Emicizumab will be administered subcutaneously at a dose of 3 milligrams per kilogram per week (mg/kg/week) for 4 weeks followed by 1.5 mg/kg/week up to the end of the study.
1977361|NCT02622321|Drug|rFVIIa|In case of a breakthrough bleed, participants will receive a bypassing agent, preferably rFVIIa, at the lowest expected dose to achieve hemostasis (no more than 90 micrograms per kilogram as an initial dose).
1977362|NCT02618577|Drug|Edoxaban|"Edoxaban will be applied at the therapeutic dose approved for stroke prevention in non-valvular AF, i.e. 60 mg OD with a reduction of dose to 30 mg OD in patients with one of the following characteristics:
Impaired renal function (CrCl 15-50 ml/min), or low body weight (≤60 kg), or patients receiving the glycoprotein p inhibitors cyclosporin, dronedarone, erythromycin, or ketoconazole."
1977363|NCT02618577|Drug|ASA|ASA 100 mg tablets or Placebo
1998570|NCT01233843|Drug|carboplatin|70 mg per m2 and per day for four days. day 1; day 22; day 43
1998571|NCT01233843|Drug|5 fluorouracil|600mg per m2 per day for four days. 3 cycles day 1; day 22; day 43
1998572|NCT01233843|Radiation|radiation therapy|total dose: 70 grays. The patient receives 2 grays per day; five days a week during 7 weeks
1998573|NCT01232946|Drug|liraglutide|1.8mg subcutaneous qd for 3 months
1998574|NCT01232946|Drug|insulin detemir|5units subcutaneous bid titrated to fasting glucose of <130mg/dL for 3 months
1998575|NCT01232946|Drug|liraglutide plus insulin detemir|liraglutide 1.8mg subq qd plus insulin detemir 5units bid titrated to fasting blood glucose <130mg/dL for 3 months.
1977364|NCT02615171|Behavioral|RELAX-AS; Device: smartphone; Other: physical activity|Participants will participate in a 6-month weight loss intervention which will include: fifteen 15-minute weight loss counseling visits lead by a weight loss clinician; handouts related to nutrition and exercise to read outside of the study visit; and use of the RELAX app developed by the study team. Participants will be instructed to use RELAX app daily for: diet and physical activity logging; monitoring stress level; receiving information to cope with stress; charts to see how they are doing over time; and receive feedback reports given to them and their PCP, which includes information about how they are doing toward their goals. We will also encourage participants to meet with their physician to discuss feedback reports. Weight loss clinicians and PCP will review participant's progress using the RELAX-web program.
1977365|NCT02615171|Behavioral|DIET-AS; Device: smartphone; Other: physical activity|Participants will participate in a 6-month weight loss intervention which will include: fifteen 15-minute weight loss counseling visits lead by a weight loss clinician; handouts related to nutrition and exercise to read outside of the study visit; and use of a diet app. The app will be designed to help people stay on track with their weight loss goals. Participants will be instructed on to use it daily to track diet and physical activity.
1977366|NCT02615171|Behavioral|DIET; Other: physical activity|Participants will participate in a 6-month weight loss intervention which will include a fifteen 15-minute weight loss counseling visits lead by a weight loss clinician and handouts related to nutrition and exercise to read outside of the study visit.
1977367|NCT02612220|Procedure|BioFoam® Surgical Matrix|Complete hemostasis is achieved by direct application of BioFoam® (Cryolife Inc., Kennesaw, GA) to the transection surface area of the liver. In addition, the surgeon may use conventional methods such as argon beam coagulation and warm sponges. If more than one syringe of BioFoam® is required to cover the entire transection surface area, a second syringe maybe used. BioFoam® Surgical Matrix will be used according to the supplier's instructions.
1977368|NCT02612220|Other|Conservative hemostasis|Complete hemostasis will be achieved without the use of topical agents
1977369|NCT02607683|Drug|XAF5 (concentration A: 0.1%)|
1977370|NCT02607683|Drug|XAF5 (concentration B: 0.035%)|
1977371|NCT02607683|Drug|Matching placebo|
1977372|NCT02606136|Drug|pamrevlumab (FG-3019)|pamrevlumab (FG-3019), 10 mg/mL, single dose vials
1977373|NCT02602951|Other|Pilot MRI program|Pilot MRI program
1977374|NCT02602951|Other|MRI with 4D Flow sequence|MRI with 4D Flow sequence
1977383|NCT02592434|Drug|CP-690,550 (tofacitinib)|"During the open label run in phase, all subjects will receive active tofacitinib oral tablets or oral solution twice daily (BID) orally, at a dosage based on the subject's body weight as specified below.
During the double blind, placebo controlled phase, subjects will receive either active tofacitinib oral tablets/oral solution or matching placebo oral tablets/oral solution, twice daily (BID), at a dosage specified below.
Body Weight (Dosage in tablet [BID] or solution [BID]):
5<7kg (2mg or 2mL); 7<10kg(2.5mg or 2. mL); 10 <15kg (3mg or 3mL); 15<25kg (3.5mg or 3.5mL); 25<40kg (4mg or 4mL); 40kg (5 mg or 5 ml).
Oral solution (1 mg/mL) is used for subjects <40 kg. Oral tablets (5 mg) are used for subjects >=40 kg."
1977384|NCT02592434|Other|placebo|matching placebo tablet or solution for tofacitinib
1977385|NCT02590120|Dietary Supplement|Enteral nutrition|
1977386|NCT02584790|Device|Laryngoscope with NBI system|All post-radiotherapy 8 weeks NPC patient will routinely undergo laryngoscope examination (WL system) and NP biopsy will be taken at the same time to determine if there is any residual NPC. In this study, laryngoscope with NBI system will be used. NBI system will be turn on during the post radiotherapy 8 week laryngoscope examination in additional to routine WL system
1977387|NCT02581865|Drug|NBI-98854|
1977388|NCT02581865|Drug|Placebo|
1977389|NCT02579876|Drug|Viaskin Milk 500 mcg|Biological: Viaskin Milk 500 mcg Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing 500 mcg cow's milk proteins.
1977390|NCT02579876|Drug|Viaskin Placebo|Biological: Viaskin Placebo Subjects epicutaneously administered daily (up to 24 hours application per day) with a patch containing a matching placebo formulation.
1977391|NCT02579057|Drug|Furosemide Injection Solution (SCP-101)|
1977392|NCT02579057|Drug|Furosemide Injection Solution, USP|
1977393|NCT02576821|Other|Neurological examinations|
1977394|NCT02576821|Other|Neuropsychological examinations|
1977395|NCT02576821|Other|Clinical examinations|
1977396|NCT02576821|Radiation|MRI 3T|
1977397|NCT02576821|Radiation|MRI 7T|
1977398|NCT02575586|Device|Intervention-Dry Needling|"Deep Dry Needling into the site of the latent medial Myofascial Trigger Point of the soleus muscle.
1 session in soleus muscle moving the needle up and down ten times."
1977399|NCT02575586|Device|Control-Dry Needling|"Deep Dry Needling distal to Myofascial Trigger Point but into the same taut band.
1 session in soleus muscle moving the needle up and down ten times."
1977405|NCT02572167|Drug|brentuximab vedotin|1.8 mg/kg by intravenous (IV) infusion for up to 4 cycles
1977406|NCT02572167|Drug|nivolumab|3 mg/kg by intravenous (IV) infusion for up to 4 cycles
1977407|NCT02561247|Device|Prismaflex HF20 CRRT Filter|
1977408|NCT02561247|Device|Prismaflex® System 7.10|
1998707|NCT01071057|Drug|Naloxone|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
1977409|NCT02558972|Drug|Northera (Droxidopa)|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
1977410|NCT02558972|Drug|Placebo|Study #1 -Supine monitoring is performed for 30 minutes before administration of a single 600mg oral dose of Northera or placebo assigned randomly, After 2 hours supine a 70 degree upright tilt will performed for 10 minutes. On another day, subjects previously given Northera will receive placebo and vice versa and studies repeated.
1977411|NCT02558972|Drug|Northera (Droxidopa)|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
1921306|NCT00210665|Drug|Trabectedin|Type= exact number, unit= mg/m2, number= 1.5, form= intravenous infusion, route= intravenous use. 1.5mg/m2 as 24hr infusion on day 1 of each 21 day cycle
1977412|NCT02558972|Drug|Placebo|Study #2 -Patients will randomized to receive Northera or placebo for two weeks after which they will return for instrumented tilt studies as in Study 1. Doses of Northera will be titrated upwards by 100mg/dose every 48 hours from a starting dose of 100mg three times a day to a maximum of 600mg three times a day. Doses will be reduced to the preceding dose if systolic BP>140mmHg or diastolic BP>80mmHg measured in the seated position at home using an automated ambulatory blood pressure cuff 2 hours after receiving an oral dose. Doses will also be reduced if supine BP measured with the head of the bed elevated upon awakening in the morning exceeds 150/90 mmHg. Following a 1 week wash out period, subjects will receive the alternative treatment for 2 additional weeks and instrumented laboratory studies repeated.
1977413|NCT02553772|Drug|Carboxymethylcellulose Based Eye Drop|Carboxymethylcellulose based eye drop administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
1977414|NCT02553772|Drug|Carboxymethylcellulose Sodium 0.5%|Carboxymethylcellulose sodium 0.5% (REFRESH OPTIVE® ADVANCED) administered as 1-2 drops in each eye, as needed, at least 2 times daily for 90 days.
1977415|NCT02553642|Drug|Nivolumab|
1977416|NCT02553642|Drug|Nivolumab plus Ipilimumab|
1977418|NCT02527759|Behavioral|Survey|
1977419|NCT02520128|Radiation|Intensity modulated radiotherapy (IMRT)|Intensity modulated radiotherapy (IMRT) is an advanced radiotherapy technique that is able to deliver a highly conformal dose to a target with improved sparing of the surrounding normal tissues from moderate to high radiation doses. IMRT is likely to be of particular benefit for tumours that have complex shapes, or those in close proximity to sensitive normal tissues and critical organs. Reducing the dose to normal tissues may in turn reduce the acute and late side effects of treatment. IMRT can be delivered from multiple fixed beam angles or through rotational arc applications such as volumetric modulated arc therapy (VMAT) and tomotherapy. The radiotherapy is delivered using multiple small beams (beamlets) of non-uniform intensity.
1977420|NCT02518308|Behavioral|Mindfulness-Based Stress Reduction|The Mindfulness-Based Stress Reduction program involves instruction in mindfulness meditation and yoga.
1977421|NCT02508896|Biological|AFFITOPE® AT04A+adjuvant|subcutaneous injection
1977422|NCT02508896|Biological|AFFITOPE® AT06A+adjuvant|subcutaneous injection
1977423|NCT02508896|Biological|Adjuvant without active component|subcutaneous injection
1977434|NCT02499874|Drug|Efavirenz|oral Efavirenz 400mg
1977435|NCT02499874|Drug|tenofovir /emtricitabine|tenofovir 245 mg/emtricitabine 200mg
1977436|NCT02499874|Drug|tenofovir/lamivudine|tenofovir 245mg/lamivudine 300mg
1977437|NCT02499874|Drug|lamivudine/zidovudine|lamivudine 300mg/zidovudine 600mg
1977441|NCT02498613|Other|18F-Fluoromisonidazole|Correlative studies
1977442|NCT02498613|Drug|Cediranib Maleate|Given PO
1977443|NCT02498613|Other|Laboratory Biomarker Analysis|Correlative studies
1977444|NCT02498613|Drug|Olaparib|Given PO
1977445|NCT02498613|Procedure|Positron Emission Tomography|Correlative studies
1977446|NCT02494869|Behavioral|Nonlinear Aerobic Training|
1977447|NCT02494869|Other|Height, Weight, BMI measure|
1977448|NCT02494869|Other|Blood draw|
1977449|NCT02494869|Other|Cardiopulmonary exercise test|
1977450|NCT02487069|Procedure|HSCT from MSD|HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
1977451|NCT02487069|Procedure|HSCT from MUD|HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
1977452|NCT02487069|Procedure|HSCT from HRD|HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
1977453|NCT02487069|Drug|Cyclosporin A|CsA is used in all the patients for GVHD prophylaxis.
1977454|NCT02487069|Drug|Methotrexate|MTX is used in all the patients for GVHD prophylaxis.
1977455|NCT02487069|Drug|Antithymocyte globulin|ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
1977456|NCT02487069|Drug|Mycophenolate mofetil|MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
1977461|NCT02482441|Drug|OMP-131R10|There are 5 planned dose cohorts of OMP-131R10. Dose escalation will follow a traditional 3+3 framework. Treatment will be continued until progressive disease or unacceptable toxicity.
1977462|NCT02482441|Drug|FOLFIRI|Treatment will consist of OMP-131R10 and the FOLFIRI chemotherapy regimen.
1977463|NCT02480374|Biological|GEN-1|
1977464|NCT02480621|Drug|Liposomal Bupivacaine with Bupivacaine|Pain medications injected locally during surgery around affected ankle.
1977465|NCT02478632|Drug|Subjects do not receive study medication in this study 202094|Participants do not receive study medication in this study 202094.
1977466|NCT02478151|Device|OrganOx Metra|Normothermic machine perfusion (NMP) Metra device
1977469|NCT02476435|Device|Active rTMS|Strong electromagnetic fields (~2Tesla) generated briefly but repetitively (1Hz) applied for 30mins, in five sessions per week for 3 weeks
1977470|NCT02476435|Device|Placebo rTMS|Placebo electromagnetic fields generated briefly but repetitively applied for 30mins, in five sessions per week for 3 weeks
1977471|NCT02476188|Procedure|Sample of Blood|
1977472|NCT02472483|Behavioral|Cognitive and Behavior Therapy (CBT)|20-weeks CBT
1977473|NCT02472483|Behavioral|Mindfulness Based Cognitive Therapy (MBCT)|8-weeks MBCT
1977504|NCT02464657|Drug|Nivolumab|"Phase I Starting Dose of Nivolumab: 1 mg/kg by vein on Day 24 of a 28 day cycle.
Phase II Starting Dose of Nivolumab: Maximum tolerated dose from Phase I."
1977505|NCT02464657|Drug|Idarubicin|Phase I and Phase II dose of Idarubicin 12 mg/m2 by vein daily for 3 on Days 1 - 3 of a 28 day cycle.
1977506|NCT02464657|Drug|Cytarabine|Phase I and Phase II dose of Cytarabine (Ara-C) 1.5 g/m2 by vein daily on Days 1 - 4 of a 28 day cycle.
1977507|NCT02464657|Drug|Solu-medrol|Phase I and Phase II dose of Solu-medrol 50 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
1977508|NCT02464657|Drug|Dexamethasone|Phase I and Phase II dose of Dexamethasone 10 mg by vein daily for 3 - 4 days with Ara-C on Days 1 - 4 of a 28 day cycle.
1977511|NCT02453334|Drug|Injectafer|
1977512|NCT02453334|Other|Normal Saline|
1977513|NCT02446249|Biological|AAV2hAQP1|Infusion of gene therapy
1977514|NCT02446704|Drug|Olaparib|
1977515|NCT02446704|Drug|Temozolomide|
1977516|NCT02444910|Drug|KDT501|600mg twice daily, Oral, for 10days; then 800mg twice daily, Oral, for 10 days; then 1,000mg twice daily, Oral, for 8 days.
1977517|NCT02438670|Device|PID control algorithm|
1977518|NCT02438670|Device|MPC control algorithm|
1989130|NCT02588339|Drug|Panobinostat|Panobinostat (PANO) will begin 5 days (Day -5) before transplant day (Day 0). All participants will take PANO by mouth once a day, three times a week (48 hours apart), every week for 26 weeks (approximately 6 months). PANO will be provided by Novartis as 5-mg pink gelatin capsules.
1989131|NCT02588339|Drug|Sirolimus|Sirolimus will be given the day before transplant and continued daily for at least one year. SIR will be administered starting on day -1 and thereafter. Dosing will be adjusted to maintain therapeutic targets per Moffitt institutional standards.
1989132|NCT02588339|Drug|Tacrolimus|Tacrolimus as an infusion or as a pill will begin 3 days before transplant (day -3) and following Moffitt institutional guidelines for dosing. Tacrolimus will be given for at least 50 days and participants will remain on Tacrolimus for as long as it is necessary per standard of care.
1989133|NCT02586675|Drug|Tamoxifen|Tamoxifen will be taken orally once daily on a continuous daily schedule (e.g., days 1-28 of each 28 day cycle).
1989134|NCT02586675|Drug|Ribociclib|"Ribociclib (LEE011) will be taken orally once daily on days 1-21 of each 28 day cycle. Days 22-28 will be a rest period from dosing with Ribociclib. In the continuous cohort, 400 mg ribociclib will be given daily (QD)."
1989135|NCT02586675|Drug|Goserelin|Goserelin will be given as an injectable subcutaneous implant on day 1 of every 28 day cycle. This will be given in pre-menopausal and peri-menopausal women.
1977519|NCT02437942|Other|Biomechanics led physical therapy rehabilitation|Rehabilitation intervention will consist of movement control (3 days per week), whole body strength and power (2 days per week), linear running mechanics (3 days per week), multi-directional mechanics (3 days per week), conditioning sessions (2 days per week). Rehabilitation will continue until physical therapist deems the athlete ready to return to sport.
1977520|NCT02425501|Drug|Aflibercept (Eylea, BAY86-5321)|Administration by intravitreal injection
1977521|NCT02421380|Drug|Hyperpolarized Pyruvate|
1977525|NCT02419924|Device|"the Bottom's Up"|A modified toilet seat that supports the perineum, preventing excessive pelvic floor descent and laxity which can cause constipation.
1977526|NCT02416401|Other|Computerized Plasticity-Based Adaptive Cognitive Training|
1977527|NCT02416401|Other|Commercially available computerized training|
1977529|NCT02410512|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 [PD-L1] antibody|Atezolizumab will be administered intravenously.
1977530|NCT02410512|Drug|MOXR0916, a humanized agonist anti-OX40 monoclonal antibody|MOXR0916 will be administered intravenously.
1977531|NCT02403674|Drug|MK-1439A|One MK-1439A tablet taken by mouth
1977532|NCT02403674|Drug|ATRIPLA™|One ATRIPLA™ tablet taken by mouth
1977533|NCT02403154|Device|Internal Fixator|Internal fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are inserted under the skin, internally.
1977534|NCT02403154|Device|External fixator|External fixator refers to pins usually inserted into the iliac bones and then connected together by clamps and bars that are outside of the body.
1977535|NCT02404103|Drug|Flunisolide HFA|
1977536|NCT02393859|Drug|Blinatumomab|If the patient is enrolled in the initial phase of the study, he/she will receive one cycle of blinatumomab. If the patient is enrolled in the adaptive phase of the study, the patient will receive three cycles of blinatumomab.
1977537|NCT02393859|Drug|Conventional Consolidation Chemotherapy|If the patient is enrolled in the initial phase of the study, he/she will receive one block of standard consolidation chemotherapy. If the patient is enrolled in the adaptive phase of the study, the patient will receive three blocks of consolidation chemotherapy.
1977538|NCT02392611|Drug|GS-5829|Tablet administered orally
1977539|NCT02392611|Drug|Exemestane|Tablets administered orally once daily
1977540|NCT02392611|Drug|Fulvestrant|Administered intramuscularly every 28 days
1977541|NCT02391662|Drug|Nab-paclitaxel 125 mg/m2 weeks 1,2,3/4|Nab-paclitaxel 125 mg/m2 days 1,8 & 15 in a 28 days cycle
1977542|NCT02391662|Drug|Gemcitabine 1000 weeks 1,2,3/4|Gemcitabine 1000 days 1,8 & 15 in a 28 days cycle
1977543|NCT02378350|Device|Hemodialysis treatment (no specific device is defined)|
1977544|NCT02378350|Drug|Peritoneal Dialysis treatment (no specific drug is defined)|
1977545|NCT02378818|Behavioral|Force task, preference task, discount task, learning task.|Force task, preference task, discount task, learning task.
1977546|NCT02375685|Biological|Gevokizumab|
1977547|NCT02376166|Drug|Metformin|850 mg PO twice daily for the remainder of the study period (the dose of metformin will be increased to the 850 mg PO twice daily dose in the absence of grade > 1 toxicities)
1977552|NCT02372396|Behavioral|Compassion Meditation (CM)|Compassion meditation is a meditative practice focused on the wish that others and the self may be free of suffering. Because this particular form of meditation has been shown to elicit positive emotion and feelings of connection with other people, it is uniquely well suited to addressing PTSD, which is characterized by strong negative affect, deficits in positive emotion and social connectedness.
1977553|NCT02372396|Behavioral|Relaxation|Relaxation Training is selected as the control condition because it is a good match for nonspecific aspects of the meditative practice (e.g., attention, support, contact with a mental health provider) and it is structurally similar to meditation (e.g., restful, in session and at home exercises).
1977556|NCT02368366|Behavioral|Therapist Guided Face to Face Family Problem Solving|Families assigned to this arm will meet with the therapist in person at the medical center TBI clinic. Sessions will last approximately 60 minutes and cover didactic content using printed handouts provided as part of a family workbook.
1977557|NCT02368366|Behavioral|Therapist Guided Online Family Problem Solving|Families assigned to this arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. Each session of online F-PST consists of a self-guided online portion providing didactic content regarding the desired skill (i.e., problem-solving), video clips showing individuals and families modeling the skill, and exercises and assignments giving the family an opportunity to practice the skill. During synchronous, videoconference sessions with the therapist, the family will review the online materials and practice the problem-solving process.
1977558|NCT02368366|Behavioral|Self-Guided Online Family Problem Solving|Families in the self-guided, online F-PST arm will receive a password enabling them to access the online intervention materials throughout the course of the intervention. They will receive access to the same web-modules as the therapist-guided group, but will review them on their own without therapist support. Participants in this group will be encouraged to complete web modules at the same schedule as participants in the other groups. If the family fails to log on or complete web modules, they will receive reminders via phone, text, or e-mail.
1977559|NCT02368353|Other|Cognitive behavioral therapy|
1977560|NCT02368353|Other|Supportive therapy|
1977561|NCT02362451|Biological|Autologus elutriated monocyte placebo vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
1977562|NCT02362451|Biological|ME TARP vaccine|20x10^6 viable cells/dose at weeks 3, 6, 9, 12, 15 and 24
1977563|NCT02362464|Biological|ME TARP vaccine|Dose of 20 x 10^6 viable cells multiepitope TARP dendritic cell vaccine given intradermally every 3 weeks at weeks 3, 6, 9, 12, 15 and 24.
1977564|NCT02361944|Drug|Oxygen|
1977565|NCT02358850|Drug|Norco (Hydrocodone and Acetaminophen)|Norco (Hydrocodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN (as needed) pain following Tonsillectomy for 14 days
1977566|NCT02358850|Drug|Percocet (Oxycodone and Acetaminophen)|Percocet (Oxycodone and Acetaminophen) 5/325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
1977567|NCT02358850|Drug|Dilaudid (hydromorphone)|Dilaudid (hydromorphone) 2 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
1977568|NCT02358850|Drug|Tylenol (Acetaminophen)|Tylenol (Acetaminophen) 325 mg tab Take 1-2 tabs by mouth every 4-6 hours PRN pain following Tonsillectomy for 14 days
1977569|NCT02356562|Drug|Ombitasvir/ABT-450/r|Tablet
1977570|NCT02356562|Drug|Dasabuvir|Tablet
1977571|NCT02356562|Drug|Sofosbuvir|Tablet
1977572|NCT02356562|Drug|Ribavirin|Tablet
1977573|NCT02355535|Drug|PAC-1|PAC-1 is taken orally on days 1-21 of a 28-day cycle.
1977574|NCT02354820|Other|Evidence Based Constipation Reminders|
1977575|NCT02349867|Drug|Gemcitabine|Given IV
1977576|NCT02349867|Drug|Sorafenib|Given PO
1977577|NCT02349867|Drug|Vorinostat|Given PO
1977578|NCT02349867|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D CRT
1977579|NCT02349867|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1977580|NCT02349867|Other|RosetteSep|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by negative-selection techniques (RosetteSep). Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
1977581|NCT02349867|Other|DEPfff|Circulating tumor cells (CTCs) will be captured and analyzed, when detected. Pancreatic cancer has been a difficult tumor in which to detect CTCs (41). Utilization of techniques that do not require cell surface marker expression will be explored. Samples will either be analyzed by with the ApoStream dielectrophoretic field-flow fractionation (DEPfff) enrichment device. Peripheral blood samples will be collected at several time-points for CTC enumeration and to evaluate CD95 density.
1977582|NCT02344420|Procedure|Echocardiography|"The devices used within the study are the legally marked CRT devices from BIOTRONIK. CRT-P and CRT-D. As this is a post market study, all devices have a CE label and are used within their intended use. There are no study specific limitations nor mandatory device settings for the study.
Subjects will undergo a standard echo assessment at baseline, 6 and 12 month follow up visit in order to assess the baseline characteristics and the changes as response to resynchronization."
1977583|NCT02344420|Behavioral|Minnesota Living Heart Failure Questionnaire (MLHF)|MLHF will be obtained at baseline, 6 and 12 month FU. The goal of this questionnaire is to measure the subjects perception of how their heart failure and treatment affect their life. Questions are focused on physical, socio-economic, and psychological impairments that persons with congestive heart failure frequently attribute to their condition.
1977584|NCT02344420|Procedure|Six minute walk test|The test will be performed at baseline, 6 and 12 month FU. The purpose of the test is to determine how far a patient can walk in six minute and relate it with the heart failure.
1977585|NCT02344420|Behavioral|Self assessment score|patient will complete a self assessment questionnaire at 2, 6 and 12 month FU for the calculation of the Packer Score at 12 month.
1977586|NCT02342795|Other|e-cigarette|
1977587|NCT02342795|Other|cigarette substitute|
1977588|NCT02322229|Drug|Ocriplasmin 0.125 mg in a 0.1 mL volume|
1977589|NCT02321514|Device|Tendyne Mitral Valve System|Transcatheter mitral valve replacement
1977591|NCT02317016|Procedure|Pharmacokinetic sampling - AZD9291|Blood sampling to measure AZD9291
1977592|NCT02317016|Drug|AZD9291 tablet dosing|Part A: AZD9291 80mg tablet taken from Days 4 to 35. Part B: AZD9291 80mg tablet taken daily for 12 months.
1977593|NCT02317016|Drug|Rosuvastatin|Rosuvastatin (BCRP substrate) 20mg taken once daily on Days 1 and 32 (Part A) .
1977594|NCT02317016|Procedure|Pharmacokinetic sampling - rosuvastatin|Blood sampling to measure rosuvastatin levels
1977595|NCT02317016|Procedure|Pharmacokinetic sampling - AZ5140 and AZ7550|Blood samples to measure levels of AZ5140 and AZ7550
1977613|NCT02298387|Drug|OMP-305B83|intravenous (in the vein) infusions
1977614|NCT02293616|Dietary Supplement|Nitrate Rich Beetroot Juice|Nitrate rich beetroot juice diet supplement will be consumed by subjects.
1977615|NCT02293616|Dietary Supplement|Placebo|
1977616|NCT02289898|Drug|Demcizumab|administered intravenously
1977617|NCT02289898|Drug|Abraxane®|administered intravenously
1977618|NCT02289898|Drug|gemcitabine|administered intravenously
1977619|NCT02289898|Drug|Placebo|
1977620|NCT02286726|Drug|CPX-351|"CPX-351 - Lower Dose Group Induction: CPX-351 50 units/m2 by vein on Days 1, 3, and 5 for up to 2 courses.
Consolidation: Participants achieving complete remission may receive consolidation treatment with CPX-351. A course of consolidation treatment consists of 2 doses of CPX-351 (Days 1 and 3). Up to 4 cycles of consolidation may be administered.
CPX-351 - Higher Dose Group Induction: CPX-351 75 units/m2 by vein on Days 1, 3, and 5 for up to 2 courses.
Consolidation: Participants achieving complete remission are eligible to receive consolidation treatment with CPX-351. A course of consolidation treatment consists of 2 doses of CPX-351 (Days 1 and 3). Up to 4 cycles of consolidation may be administered.
CPX-351 - Maximum Tolerated Dose Level Group If safety demonstrated for both of the sub-MTD dose levels, and escalation deemed feasible above 75 units/m2, then CPX-351 100 units/m2 administered."
1977621|NCT02286726|Behavioral|Phone Call|After completion of treatment, participant receives phone call from study staff every month for as long as the study doctor thinks it is needed. Each call should last about 5-10 minutes.
1977622|NCT02285361|Drug|GIOTRIF 20mg|NSCLC with GIOTRIF 20mg
1977623|NCT02285361|Drug|GIOTRIF 40mg|NSCLC with GIOTRIF 40mg
1977624|NCT02285361|Drug|GIOTRIF 30mg|NSCLC with GIOTRIF 30mg
1977625|NCT02283372|Drug|nab-Paclitaxel|
1977626|NCT02283372|Drug|Gemcitabine|
1977627|NCT02283372|Radiation|Intensity modulated radiation|
1977628|NCT02280772|Dietary Supplement|Glucomannan|
1977629|NCT02280772|Dietary Supplement|Maltodextrin|
1977630|NCT02275533|Other|Clinical Observation|Undergo standard of care clinical observation
1977631|NCT02275533|Other|Laboratory Biomarker Analysis|Correlative studies
1977632|NCT02275533|Biological|Nivolumab|Given IV
1977636|NCT02265536|Drug|LY3022855|Administered IV
1977637|NCT02260791|Drug|FKB327|Solution of FKB327 for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
1977638|NCT02260791|Drug|Humira®|Solution of Humira® for subcutaneous injection administered in a dose of 40 mg every 2 weeks for 22 weeks.
1977641|NCT02253316|Biological|Ixazomib|
1977642|NCT02253316|Drug|Lenalidomide|
1977643|NCT02253316|Drug|Dexamethasone|
1977644|NCT02249585|Device|Standard abdominal pressure|Abdominal pressure maintained 12mmHg throughout laparoscopic colon surgery
1977645|NCT02249585|Device|Low abdominal pressure|Abdominal pressure maintained 8mmHg throughout laparoscopic colon surgery
1977646|NCT02249585|Drug|Conventional neuromuscular blockade|Anesthesia induction with rocuronium 0.4mg/kg and maintenance with rocuronium 0.15mg/kg to maintain TOF 1-2 twitch
1977647|NCT02249585|Drug|Deep neuromuscular blockade|Anesthesia induction with rocuronium 0.8mg/kg → maintenance with rocuronium 0.3mg/kg to maintain PTC 1-2 twitch
1977648|NCT02245737|Drug|Lanabecestat|Administered orally
1977649|NCT02245737|Drug|Placebo|Administered orally
1977651|NCT02243449|Procedure|Once daily screening|In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, continuous positive airway pressure (CPAP) less than or equal to 5 cm H2O or PS less than or equal to 8 cm H2O with PEEP less than or equal to 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for patients enrolled at their centre.
1977652|NCT02243449|Procedure|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. To pass the 'readiness to wean screen' and undergo an SBT, specific criteria must be met. The initial SBT will be conducted in the same manner as in the once daily screening arm. The subsequent SBTs will be 30 -120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and with the use of different humidification strategies. Each centre will be asked to choose one technique for all patients enrolled at their centre.
1977653|NCT02238626|Drug|Placebo (for MN-166)|
1977654|NCT02238626|Drug|MN-166|
1977655|NCT02237196|Biological|AMG 157|AMG 157 will be administered once every 4 weeks at dose of 700 mg intravenously. Each AMG 157 dose will be administered at least 1 day before immunotherapy through week 24, then on the same day as immunotherapy thereafter.
1977656|NCT02237196|Biological|Cat Immunotherapy|A standardized allergen extract licensed in the United States for allergen immunotherapy, and is formulated as a long-acting suspension for subcutaneous injection
1977657|NCT02237196|Biological|Cat Immunotherapy Placebo|Placebo for allergen-specific immunotherapy administered subcutaneously
1977658|NCT02237196|Biological|AMG 157 Placebo|Placebo for AMG 157 administered intravenously
1977659|NCT02237183|Drug|Iloprost|Given via inhalation
1977660|NCT02237183|Other|Laboratory Biomarker Analysis|Correlative studies
1977661|NCT02237183|Other|Placebo|Given via inhalation
1977662|NCT02237183|Other|Quality-of-Life Assessment|Ancillary studies
1977663|NCT02237183|Other|Questionnaire Administration|Ancillary studies
1977664|NCT02235012|Drug|Ketamine|"KETAMINE PANPHARMA 250 mg/5mL, solution for infusion :
Initial rapid infusion of 0,23 mg/kg
Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min
Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
1977665|NCT02235012|Drug|Placebo|"CHLORURE DE SODIUM 0,9 % MACOPHARMA :
Initial rapid infusion of 0,23 mg/kg
Infusion from minute 2 to minute 30 : 0,00967 mg/kg/min
Infusion from minute 31 to minute 120 : 0,00483 mg/kg/min"
1977666|NCT02234089|Drug|Degarelix|According to medical practice
1977667|NCT02234089|Drug|LHRH agonist (Leuprorelinacetat, Goserelinacetat, Buserelinacetat, Triptorelinacetat)|According to medical practice
1977668|NCT02228525|Drug|selinexor (KPT-330)|
1977669|NCT02227550|Drug|Vitamin K antagonist|any locally used VKA, INR 2-3, min. 30 days according to aplicable medical guidelines and local clinical routin
1977670|NCT02227550|Drug|Apixaban|factor Xa inhibitor Apixaban min. 30 days 5 mg twice daily (fix dose) dose reduction Apixaban 2,5 mg twice daily in patients who fulfill tow of the following criteria at the time of randomisation: chronic kidney disease (serum creatine >= 1.5 mg/dl (133mM), <= 60 kg body weight or age >= 80 years.
1977679|NCT02218918|Behavioral|Ground walk training|3 times a week and 6 weeks
1977680|NCT02218918|Behavioral|Supervised Treadmill Walk training|3 times a week and 6 weeks
1977681|NCT02213731|Other|Holter monitoring|Subjects will wear holter monitors at baseline, 6 months and 12 months.
1921603|NCT00083174|Drug|exemestane|one 25 mg tablet daily in am
1977682|NCT02204072|Drug|BI 836845|
1921605|NCT00005799|Drug|fludarabine phosphate|Given IV
1921606|NCT00005799|Radiation|total-body irradiation|Undergo low-dose TBI
1921607|NCT00005799|Procedure|nonmyeloablative allogeneic hematopoietic stem cell transplantation|Undergo nonmyeloablative HSCT
1921608|NCT00005799|Procedure|allogeneic bone marrow transplantation|Undergo nonmyeloablative allogeneic bone marrow transplantation
1921609|NCT00005799|Procedure|peripheral blood stem cell transplantation|Undergo nonmyeloablative allogeneic PBSC transplantation
1921610|NCT00005799|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
1921611|NCT00005799|Drug|cyclosporine|Given PO
1921612|NCT00005799|Drug|mycophenolate mofetil|Given PO
1921613|NCT00005799|Other|pharmacological study|Correlative studies
1921614|NCT00005799|Other|laboratory biomarker analysis|Correlative studies
1977683|NCT02204072|Drug|Enzalutamide|
1977684|NCT02204072|Drug|Enzalutamide|
1977685|NCT02202408|Drug|SKI2670|Oral, Single Dose
1977686|NCT02202408|Drug|Placebo|Same shape as the experimental drug
1977690|NCT02195479|Drug|Velcade|Participants will receive velcade 1.3 mg/m^2, as subcutaneous injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9.
1977691|NCT02195479|Drug|Melphalan|Participants will receive melphalan 9 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9.
1977692|NCT02195479|Drug|Prednisone|Participants will receive prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9.
1977693|NCT02195479|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as intravenous infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or study end.
1977694|NCT02195479|Drug|Dexamethasone|Participants administered with dexamethasone 20 mg IV or PO is given 1 hour or less prior to daratumumab infusion as pre medication and prednisone substitute.
1977699|NCT02193048|Other|This study will evaluate a new clinical scoring system in patients receiving routine treatment|Treatment for Crohn's disease will be performed routinely based on the treating physicians clinical determination and patients' needs.
1977706|NCT02182115|Drug|antiseptic bundle|"Chlorhexidine gluconate liquid soap for bathing daily.
Chlorhexidine gluconate mouthrinse to use twice daily.
Nasal mupirocin to apply twice daily."
1977707|NCT02182115|Drug|standard of care|Surgeon's instructions may include advising patients to use an antiseptic soap prior to surgery.
1977708|NCT02181738|Drug|Nivolumab|
1977709|NCT02181738|Drug|Doxorubicin|
1977710|NCT02181738|Drug|Vinblastine|
1977711|NCT02181738|Drug|Dacarbazine|
1977712|NCT02175004|Drug|IONIS-TTR Rx|300 mg IONIS-TTR Rx administered once weekly
1921668|NCT00066573|Drug|anastrozole|Given orally
1921669|NCT00066573|Drug|exemestane|Given orally
1977724|NCT02162576|Device|Propeller Health intervention|The Propeller Health system works through the provision of information to patients and their providers. With the Propeller Health sensor device in place, each actuation of a patient's rescue inhaler is recorded with an automatic time stamp; in many circumstances, the location at which the device is actuated is also captured and recorded. Actuation data are then securely transmitted to Propeller Health where events and an assessment of asthma control can be viewed in secure online interfaces. The information is also compiled into individual reports that are returned to the patient and his or her provider. Patients also receive customized suggestions for asthma management based on their actuation history.
1977725|NCT02160847|Behavioral|DRIVE Program|The DRIVE program (Developing Relationships that Include Values of Eating and Exercise) is a home-based parent training program, which involves 15 sessions focusing on parent-child interactions, health and nutrition, and physical activity
1977726|NCT02159404|Biological|Immunotherapy|
1977727|NCT02157363|Procedure|Repositioning|
1977728|NCT02157363|Procedure|Single positioning|
1977729|NCT02155647|Drug|Avelumab|Avelumab will be administered at a dose of 10 milligram per kilogram (mg/kg) as 1-hour intravenous infusion once every 2 weeks until therapeutic failure, significant clinical deterioration, unacceptable toxicity, or any criterion for withdrawal from the trial or investigational medicinal product occurs.
1977735|NCT02151461|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
1977736|NCT02151461|Drug|Metformin|500 mg metformin BID until day 14 with dose escalation at day 14 to 850 mg metformin BID
1977737|NCT02151461|Drug|Mid Metformin|1100 mg of Leucine in combination with 250 mg Metformin BID
1977738|NCT02151461|Drug|High Metformin|1100 mg of Leucine in combination with 500 mg Metformin BID
1977739|NCT02135848|Drug|GSK1278863|GSK1278863
1977740|NCT02135848|Drug|Placebo|Placebo
1977741|NCT02131896|Other|Interventional arm-Mediterranean diet|
1977742|NCT02131896|Other|Control Arm- regular nutritional instructions in accordance with the accepted nutritional guidelines|
1977743|NCT02124070|Drug|rh Growth Hormone|
1977744|NCT02118012|Drug|Chlorcyclizine HCL plus Ribavirin|RBV+ chlorcyclizine HCl (75 mg twice daily)
1977745|NCT02118012|Drug|Chlorcyclizine HCL Only|chlorcyclizine HCl (75 mg twice daily)
1977746|NCT02116725|Other|Shower gel with zinc|Standard shower gel (Sanex) supplemented with zinc sulfate.
1977747|NCT02116725|Other|Plain shower gel|Standard shower gel (Sanex).
1977748|NCT02116725|Other|Distilled water|Sterile distilled Water.
1977749|NCT02114606|Device|Cytosponge™ Cell Collection Device (Cytosponge)|The Cytosponge™ Cell Collection Device (Cytosponge) is intended to collect surface cells from the esophagus. The device consists of a swallowable capsule, which dissolves in the body cavity, releasing a self-expandable sponge. The sponge is then retrieved from the esophagus using an attached cord. During the retrieval process, the sponge collects cells from the most superficial layer of the esophageal mucosa. Once removed from the body cavity, the sponge and cells are retained for investigation and/or testing. The Cytosponge™ Cell Collection Device (Cytosponge) received 510(k) clearance from the FDA on November 26, 2014 (K142695). The Cytosponge ™ Cell Collection device is a Class II product under 21 CFR 874.4710 esophagoscope (flexible or rigid) and accessories.
1977767|NCT02108977|Other|Videoconferencing Genetic Consultation|Patients will travel to CBOC and receive genetic counseling session via videoconferencing
1977768|NCT02108977|Other|Teleconferencing Genetic Consultation|Patients will receive genetic counseling session via telephone (usual treatment)
1977769|NCT02108964|Drug|EGF816|EGF816 will be dosed once daily. On the first day of each treatment Cycle, the patient receives an adequate drug supply for self-administration at home. The investigator must emphasize compliance with the study treatment and will instruct the patient to take EGF816 exactly as prescribed.
1977770|NCT02105324|Device|Bionic Pancreas|Automated blood glucose control via a closed-loop bionic pancreas device.
1977771|NCT02105324|Other|Usual Care|As a comparator control, usual diabetes camp care with the participant's own insulin pump.
1977772|NCT02104557|Other|Non intervention|Non intervention
1977773|NCT02104557|Other|Non intervention|Non intervention
1977800|NCT02099214|Device|3Tesla cardiac MRI|
1977801|NCT02099214|Device|Electrocardiogram (EKG)|
1977802|NCT02099214|Biological|Iron and cardiac markers|Serum iron, serum transferrin, transferrin saturation, serum ferritin, NT-proBNP
1977803|NCT02099214|Biological|Pregnancy test|Beta-hCG
1977804|NCT02099214|Device|Echocardiography at rest|Transthoracic echocardiograph
1977805|NCT02099214|Biological|Urinary pregnancy test|
1977806|NCT02099214|Device|3Tesla abdominal MRI|
1977807|NCT02092220|Device|Bionic Pancreas|
1977808|NCT02092220|Device|Insulin pump with or without CGM|
1977809|NCT02090569|Device|Functional micro-Doppler Sonography (fmDS)|"Craniotomy according to MRI images
Dura opening
Sulcal Localization using neuronavigation
Functional micro-Doppler Sonography including morphologic (Bmode) and functional measurement of the cerebral blood volume dynamics at high spatio-temporal resolution (100µm-20ms) using high-frequency (15MHz) ultrasound. At least 5 2-minute periods of spontaneous data will be recorded with a sampling rate for data acquisition of 15KHz and highpass filter of 10 to 70 Hz.
Exeresis of the dysplasic tissue
Control using fmDS before wound closure"
1977810|NCT02070757|Drug|ceftolozane/tazobactam|Ceftolozane/tazobactam is an antibacterial consisting of a co-formulation of ceftolozane, a novel antipseudomonal cephalosporin and tazobactam, a well-established beta(β)-lactamase inhibitor (BLI) being developed for the treatment of serious bacterial infections.
1977811|NCT02070757|Drug|Meropenem|Meropenem is a broad spectrum injectable antibiotic widely used to treat serious infections such as ventilator-associated bacterial pneumonia and hospital-acquired bacterial pneumonia.
1977812|NCT02068794|Other|Laboratory Biomarker Analysis|Correlative studies
1977813|NCT02068794|Procedure|Mesenchymal Stem Cell Transplantation|Given IP
1977814|NCT02068794|Biological|Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter|Given IP
1977815|NCT02064764|Drug|Renal nerve denervation|
1977816|NCT02064764|Device|Cryoablation|
1977817|NCT02063425|Drug|Fluoxetine|1 pill of 20mg / day, during 3 months
1977818|NCT02063425|Drug|Placebo of fluoxetine|1 pill of 20mg/day, during 3 months
1977827|NCT02046070|Drug|Cyclophosphamide|Cyclophosphamide tablets
1977828|NCT02046070|Drug|Ixazomib (MLN9708)|Ixazomib (MLN9708) capsules
1977829|NCT02046070|Drug|Dexamethasone|Dexamethasone tablets
1998658|NCT01144455|Drug|Gemzar (Gemcitabine)|1,000 mg/m2 administered IV over 30 minutes on Days 1, 8 and 15 of a 28-day cycle.
1977830|NCT02043015|Behavioral|Condom choices|Men will receive the condom package that includes an assortment of styles, sizes, features and colors at their baseline visit, and will be able to get more condoms for free at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
1977831|NCT02043015|Behavioral|Condom-compatible lubricant choices|Men will receive condom-compatible lubricant that will include different types of lubricant (e.g., silicone-based) and different packaging (individual sachets or flat, discreet packages) at their baseline study visit, and participants will be able to access enhanced condom-compatible lubricant at any time after that visit by coming to a study clinic during clinic hours, or during a scheduled study visit.
1977832|NCT02043015|Behavioral|Couples HIV counseling and testing (CVCT)|Participants will be invited to schedule couples voluntary HIV counseling and testing (CVCT) appointments with a clinic counselor at any point after they complete their baseline study visit.
1977833|NCT02043015|Drug|Pre-exposure prophylaxis with FTC/TDF|For men who meet eligibility criteria, PrEP with Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) will be made available beginning one month into the study. Men who express interest and meet eligibility criteria at their baseline visit can initiate PrEP at 1 month if they test negative for HIV. For men with extenuating circumstances, whose risk profile changes, of those who become more comfortable with the PrEP intervention through enrollment in the study, PrEP will be available to initiate at the 4 month visit. Men who accept PrEP will be required to have clinic visits, in addition to the regularly scheduled study visits, one month after starting PrEP and at least every 3 months afterward to monitor blood creatinine, AST/ALT and phosphorus levels.
1977834|NCT02043015|Other|Staff and provider MSM and LGBT sensitization training|The training for clinicians will focus on specific sexual health issues for MSM, including taking sexual histories in a non-judgmental way, physical examination techniques including anal examinations, and collection of rectal swabs for STI testing. Trainings will include topics about stigma, sexual identity and coming out, anal sex, STIs, and mental health. Training on LGBT sensitization will be provided for medical providers and staff in target clinics.
1977835|NCT02043015|Behavioral|HIV Testing and Risk-reduction counseling|Risk-reduction counseling will be provided to all men at baseline and additionally at 3, 6, and 12 month visits, with an additional counseling session for men on PrEP at their initiation visit (either month 1 or 4), their 1-month follow-up visit (either month 2 or 5) and at their 9 month visit. Risk reduction counseling will be client-centered counseling, according to CDC's Fundamentals of HIV Prevention Counseling protocol.
1977836|NCT02043015|Behavioral|Linkage to care|Men will be linked to needed services including HIV care and treatment for positives identified at baseline or during the study, including antiretroviral medications, and mental health services. At the end of their baseline visit, participants will receive service referral handouts for HIV care and treatment, mental health services, and other resources, as appropriate. Men who test positive for STIs will be treated at the clinic site.
1977837|NCT02033369|Drug|Pramipexole|Dose will be started at 0.125 mg bid, and increased by 0.25 mg/day every 3-4 days to a target range of 1.0 - 2.5 mg/day
1977842|NCT02021955|Behavioral|guideline treatment recommendations|Primary care clinicians receive guideline concordant treatment recommendations for their patients discharged from hospital for a COPD exacerbation.
1977843|NCT02013674|Biological|Allogeneic hMSCs|Allogeneic Adult Human Mesenchymal Stem Cells (MSCs) delivered via injection
1977844|NCT02008513|Biological|AFFITOPE® AD02|
1977845|NCT02008513|Biological|Placebo|
1977846|NCT02007044|Drug|Ibrutinib|"Ibrutinib Subgroup 1 started on Day 1 of cycle 1 at dose of 420 mg (3 x 140-mg capsules) orally once daily in each 28 day cycle.
Ibrutinib Subgroup 2 started on Day 2 of cycle 1 at dose of 420 mg (3 x 140-mg capsules) orally once daily in each 28 day cycle.
Patients in the iR group alternatingly assigned to subgroups 1 and 2, the purpose is to compare rituximab infusion reactions."
1977847|NCT02007044|Drug|Rituximab|Rituximab 375 mg/m2 given intravenously on Day 1, Day 8, Day 15, and Day 22 , and then continued once every 4 weeks only on Days 1 during cycles 2 - 6.
1977848|NCT02001220|Procedure|Once daily screening|"In the 'once daily screening arm', RTs will screen invasively ventilated patients between approximately 06:00 - 08:00 hours daily.
The initial SBT will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will choose one technique to be used for all patients enrolled at their centre."
1977849|NCT02001220|Procedure|At least twice daily screening|In the 'at least twice daily' screening arm patients will be screened at a minimum between approximately 6:00-8:00 hours and 13:00-15:00 hours daily. Initial SBT will be conducted in the same manner as once daily screening arm. Subsequent SBTs will be 30-120 minutes in duration and may be conducted with any one of the following techniques: T-piece, CPAP < to 5 cm H2 O or PS < 8 cm H2 O with PEEP < 5 - 10 cm H2O. Higher levels of PEEP (8-10 cm H2O). Higher levels of PEEP (8-10 cm H2O) will be permitted (and recorded) to allow for clinician discretion in conducting SBTs in specific patients (e.g., obese, chronic obstructive pulmonary disease) and use of different humidification strategies. Each centre will be asked to choose one technique to be used for all patients enrolled at their centre.
1977850|NCT01969409|Drug|Rituximab|i.v. rituximab given on two occasions 14 days apart.
1977851|NCT01969409|Drug|Placebo|Subjects randomized to placebo will receive two i.v. doses of 5% dextrose in water (D5W) in the same schedule as the rituximab subjects. The D5W and rituximab preparations will be indistinguishable.
1977852|NCT01967641|Drug|buprenorphine/naloxone combination|Buprenorphine/naloxone (Bup/Nx; Suboxone sublingual tablets, Reckitt Benckiser) will be administered sublingually at daily doses of 2/0.5, 8/2 mg, and 16/4 mg, which are within the recommended dose range for treating both pain and opioid abuse. The total daily dose will be divided and administered on a QID dosing regimen (0.5/0.125, 2/0.5, and 4/1 mg QID at 0830, 1230, 1730, 2130). Each participant will be tested with all three doses in random order for two weeks at each dose (one week of stabilization followed by one week of testing). Following completion of the 7-week inpatient phase, participants will be maintained on 16/4 mg Bup/Nx.
1977853|NCT01965145|Drug|Gevokizumab|Sterile solution administered subcutaneously
1977854|NCT01965145|Drug|Placebo|Sterile solution administered subcutaneously
1977855|NCT01961323|Drug|Nebivolol|Doses will be titrated based on weekly visits during the first 2 weeks to achieve a target SBP<140 and DBP <90 mm Hg. If BP remains uncontrolled after 2 weeks of treatment, indapamide will be added at a dosage of 2.5 mg/day. If the therapeutic goal is still not achieved by 4 weeks, patients will be withdrawn from the study.Upward titration will be halted, and the previous dosage level resumed, if at any point systolic blood pressure falls to ≤ 100 mmHg, even if the individual remains asymptomatic.
1977857|NCT01939223|Drug|Regorafenib (Stivarga, BAY73-4506)|Four tablets of 40mg taken orally daily in the morning, dose of 160 mg for 21 days of treatment followed by 7 days without treatment
1977858|NCT01939223|Drug|Placebo|Four tablets taken in the morning orally daily for 21 days of treatment followed by 7 days without treatment
1977859|NCT01938573|Drug|Cisplatin|Given IV
1977860|NCT01938573|Drug|Gemcitabine Hydrochloride|Given IV
1977861|NCT01938573|Drug|Sirolimus|Given PO
1977862|NCT01938573|Procedure|Cystectomy|Undergo cystectomy when appropriate
1977863|NCT01938638|Drug|BAY1143572|
1977867|NCT01926886|Drug|trastuzumab [Herceptin]|6 mg/kg intravenously (IV) every 3 weeks, 3 cycles
1977868|NCT01926886|Drug|trastuzumab [Herceptin]|600 mg subcutaneously every 3 weeks, administered via a hand-held syringe by a trained HCP at the hospital, 3 cycles
1977869|NCT01926886|Drug|trastuzumab [Herceptin]|600 mg/kg subcutaneously every 3 weeks, administered via a hand-held syringe by a HCP at the patient's home, 6 cycles
1977870|NCT01922076|Other|Laboratory Biomarker Analysis|Correlative studies
1977871|NCT01922076|Other|Pharmacological Study|Correlative studies
1977872|NCT01922076|Radiation|Radiation Therapy|Undergo radiation therapy
1977873|NCT01922076|Drug|WEE1 Inhibitor AZD1775|Given PO
1977874|NCT01919216|Drug|Citalopram|
1977875|NCT01916824|Drug|Any FDA Approved Antidepressant|Any FDA-approved antidepressant prescribed within standard dose range to treat Major Depressive Disorder will be taken for 6 weeks. Psychiatric follow-up will be performed during the study participation. At the end of the study, these participants will receive assistance in transitioning their care to another provider, depending on their individual circumstances.
1977876|NCT01911546|Drug|everolimus + low-dose tacrolimus|
1977882|NCT01866592|Drug|Adalimumab|Study participants will receive the FDA-approved dosing schedule for Adalimumab (Humira): an initial dose of 80mg followed by a 40mg maintenance dose every other week up to 52 weeks.
1977883|NCT01864200|Biological|crotilidae polyvalent immune fab (ovine)|crotilidae antivenom
1977884|NCT01864200|Biological|Placebo|
1977885|NCT01862250|Drug|Clonidine (Duraclon®)|"Clonidine at dosing intervals of 4, 6, 8, 12, 18 or 24 hours. If the following is observed the event will be recorded, and no additional clonidine will be given and blood will be drawn to measure plasma level of clondine.
10 mm Hg reduction in MAP or MAP ≤ 40 mm Hg sustained for ≥30 min after administration
20% drop in HR from the infant's baseline, sustained for ≥30 min after administration
HR ≤70/min, sustained for ≥30 min after administration"
1977886|NCT01862016|Procedure|APRV|Pressure ventilation mode allowing early spontaneous breathing
1977887|NCT01862016|Biological|arterial blood gas measurement each morning|
1977888|NCT01861236|Drug|Firmagon® (degarelix)|Monthly subcutaneous injections
1977889|NCT01859741|Drug|OMP-59R5|OMP-59R5 administered intravenously
1977890|NCT01859741|Drug|Etoposide|administered intravenously
1977891|NCT01859741|Drug|Placebo|administered IV
1977892|NCT01859741|Drug|Cisplatin or Carboplatin|administered intravenously
1977893|NCT01857518|Other|-Diagnostic, clinical and psycho-behavioral assessments -Neuroimaging: T1-MRI, DTI-MRI, fMRI|"Visit V1: Diagnostic and clinical assessments
Visit V2: psycho-behavioral assessment and neuroimaging
Visit V3: Diagnostic and clinical assessments
Visit V4: psycho-behavioral assessment and neuroimaging"
1977894|NCT01853748|Drug|Trastuzumab|
1977895|NCT01853748|Drug|Paclitaxel|
1977896|NCT01853748|Drug|Trastuzumab emtansine|
1977897|NCT01845974|Device|ThermoCool® SF NAV Catheter|The experimental group will receive the low flow catheter (ThermoCool® SF NAV Catheter) All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
1977898|NCT01845974|Device|ThermoCool® catheter|The control group will receive the higher flow catheter (ThermoCool® catheter). All data will be collected pre and post procedure therefore patients will act as their own control within each therapeutic group.
1977899|NCT01844596|Behavioral|behavioral communication strategy|Community Health Workers with an additional tailored behavioral communication strategy.
1977900|NCT01844596|Behavioral|Behavioral communication strategy, plus smartphone-based tool|Community Health Workers with a tailored behavioral communication strategy, also equipped with smartphone-based tool linked to the AMPATH Medical Record System (AMRS).
1989158|NCT02578706|Drug|Clopidogrel|Clopidogrel 75mg
1989159|NCT02578706|Drug|Aspirin|81 mg
1989160|NCT02578706|Drug|Placebo|
1977901|NCT01837329|Drug|Tetrathiomolybdate|"Dose Escalation - Dose level -1: 20 mg TM orally 3 x daily x 21 days in combination with carboplatin IV area under the curve (AUC) = 6 and pemetrexed IV 500/mgm2 day 1 x 1 cycle.
Dose level 1: 40 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.
Dose level 2: 60 mg TM orally 3 x daily x 21 days in combination with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 1 cycle.
Patients in the dose-expansion cohort will continue on carboplatin and pemetrexed (without TM) at the discretion of the treating physician.
Dose Expansion - Maximum tolerated dose of TM determined from the dose-escalation cohorts combined with carboplatin IV AUC = 6 and pemetrexed IV 500 mg/m2 day 1 x 4 cycles."
1977913|NCT01817374|Drug|Definity (Perflutren Lipid Microspheres)|This is a pilot study to evaluate quantitative VCEUS imaging for determining early breast cancer response to neoadjuvant chemotherapy, comparing results with volume change on grayscale US and planar CEUS, and correlating imaging findings with pathological response on surgical specimens.
1977920|NCT01775475|Drug|cyclophosphamide|Given IV
1977921|NCT01775475|Drug|doxorubicin hydrochloride|Given IV
1977922|NCT01775475|Drug|vincristine sulfate|Given IV
1977923|NCT01775475|Drug|prednisone|Given PO
1977924|NCT01775475|Drug|lomustine|Given PO
1977925|NCT01775475|Drug|etoposide|Given PO
1977926|NCT01775475|Drug|cyclophosphamide|Given PO
1977927|NCT01775475|Drug|procarbazine hydrochloride|Given PO
1977928|NCT01775475|Other|laboratory biomarker analysis|Correlative studies
1977929|NCT01775072|Genetic|molecular profiling of tumors|"Part A is the molecular profiling of tumors. No new tumor biopsies will be performed in the context of Part A. If a pt does have a surgery or tumor biopsy , leftover tissue (or an additional core) from this procedure may be used for molecular profiling. Clinical Assay(s): This testing will be performed in the CLIA-certified Molecular Diagnostics Service laboratory. Research Assay(s): This protocol will also be used as a platform to pilot the use of investigational next-generation profiling technologies .including whole exome sequencing, whole genome sequencing RNA sequencing cell-free tumor DNA/RNA sequencing, proteomics, & others. To confirm the findings obtained on these assays using an orthogonal assay, additional sequencing such as Sanger,Sequenom, MiSeq or IMPACT testing may be utilized in either the CLIA or non-CLIA setting Part B: DTC Cohort Pts successfully registered to Part B of this study will be eligible for minimal risk collection & research biopsies."
1977930|NCT01775072|Genetic|Clinical Germline Analysis|"Part C: Clinical Germline Analysis Participants who have donated a matched normal peripheral blood sample for comparison to somatic sequence will be offered the opportunity to have that germline DNA sample analyzed for the presence of deleterious or likely deleterious mutations in genes on the MSK-IMPACT panel that are known to be linked to inherited susceptibility or that are included on consensus lists of genes that should undergo secondary analysis (e.g. the ACMG list)."
1977933|NCT01756326|Drug|PREOB® Implantation|
1977934|NCT01756326|Procedure|Bone Autograft|
1977935|NCT01751646|Dietary Supplement|Vitamin D3 50,000 IU|Group A: Vitamin D3 50,000 IU orally every four weeks by DOT
1977936|NCT01751646|Dietary Supplement|Vitamin D3 placebo|Group B: Vitamin D3 placebo orally every four weeks by DOT
1977937|NCT01748890|Device|Sonoelastography|Sonoelastography is an imaging technology predicated on reproducible differences in the backscattered ultrasound signal produced by compression of tissues of varying stiffness.
1977938|NCT01748292|Drug|0.5 mg ranibizumab|Subject will receive drug (ranibizumab) via intravitreal injections (IVT) at every visit.
1977939|NCT01744171|Biological|Recombinant Human Hsp110-gp100 Chaperone Complex Vaccine|Given ID
1977940|NCT01744171|Other|Laboratory Biomarker Analysis|Correlative studies
1977941|NCT01739829|Device|DIABECELL (R)|10,000 IEQ per kg body weight (Total Dose) Administered in two doses: 5,000 IEQ/kg three months apart.
1977942|NCT01739829|Device|DIABECELL (R)|20,000 IEQ per kg body weight (Total Dose) Administered in two doses: 10,000 IEQ/kg three months apart
1977943|NCT01737398|Drug|IONIS-TTR Rx|300 mg IONIS-TTR Rx administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.
1977944|NCT01737398|Drug|Placebo|Placebo administered subcutaneously 3 times on alternate days in the first week and then once-weekly for 64 weeks.
1977945|NCT01736397|Drug|Ferric Citrate|Dose depends on serum phosphorus levels collected at each study visit.
1977946|NCT01736397|Drug|Placebo|
1977947|NCT01730118|Biological|Autologous Ad HER2 dendritic cell vaccine|Autologous AdHER2 tranduced dendtitic cell vaccine manufactured under GMP conditions from cryopreserved patient monocytes here at hte NIH CC DTM. Vaccine is administered intradermally at assigned dose level at weeks 0, 4, 8 and 24 of the study.
1977948|NCT01710306|Behavioral|Phase 2|Nurse care manager interventions with shared decision making compared to outreach as usual OEF/OIF/OND outreach.
1977949|NCT01693523|Drug|Minocycline|100 mg by mouth two times a day (200 mg/day).
1977950|NCT01693523|Other|Placebo|Matching placebo capsules by mouth twice a day.
1977951|NCT01693523|Behavioral|Questionnaires|Questionnaires completed at baseline, 1 time each week during drug/placebo administration, and at end of study visit.
1977952|NCT01670110|Drug|Pasireotide LAR|Injectible, 60mg per month
1977953|NCT01670110|Drug|Placebo|To be injected once per month
1977954|NCT01656902|Drug|NOVOCART® 3D plus|Two-Step intervention: 1) cartilage cells are collected from the patient during arthroscopy 2) collected cartilage cells are cultivated in a sterile environment, seeded in an organic matrix scaffold and implanted into the defect location (knee, femur)
1977955|NCT01656902|Procedure|Microfracture|single-step treatment: defect location (knee, femur) is debrided, then bone plate is drilled mechanically to allow cells from the bone marrow to move to the defect location and to develop a scar tissue
1977956|NCT01628718|Behavioral|Adaptive Disclosure (AD)|Adaptive Disclosure (AD) is an eight-session fully manualized and piloted intervention designed specifically for Marines with PTSD stemming from a variety of traumatic deployment experiences. The approach combines imaginal exposure to activate trauma-related emotions and beliefs and cognitive and experiential techniques to modify maladaptive interpretations of the implication of various combat and operational experiences that contribute to symptoms and dysfunction.
1977957|NCT01628718|Behavioral|Cognitive Processing Therapy, cognitive version only (CPT-C)|"Cognitive Processing Therapy (CPT) is a 12-session manualized therapy for posttraumatic stress disorder. The theory behind CPT conceptualizes PTSD as a disorder of non-recovery in which erroneous beliefs about the causes and consequences of traumatic events produce strong negative emotions and prevent accurate processing of the trauma memory and natural emotions emanating from the event. A significant contributor to the interruption of natural recovery process is the ongoing use of avoidance as a coping strategy. CPT incorporates trauma-specific cognitive techniques to help individuals with PTSD more accurately appraise these stuck points and progress toward recovery."
1977958|NCT01623739|Procedure|Placement of a dental implant|Type 1 implant placement Type 2 implant placement
1977959|NCT01624194|Drug|Oxytocin nasal spray|24IU BID (3 x 0.1 mL [4IU] sprays per nostril twice daily for 4-weeks.
1977960|NCT01624194|Drug|Placebo|3 x 0.1 mL sprays per nostril twice daily for 4-weeks.
1977965|NCT01617460|Drug|Aripiprazole|Flexibly dose administered orally once daily
1977966|NCT01600079|Biological|ZOSTAVAX™|ZOSTAVAX™ (Zoster Vaccine Live) administered in routine clinical conditions of use
1977972|NCT01572298|Device|allograft alone|use of MinerOss allograft plus Alloderm GBR membrane and tenting screws
1977973|NCT01572298|Device|allograft with alloderm|use of a combined autogenous graft and MinerOss allograft plus Alloderm GBR membrane and tenting screws
1977974|NCT01557998|Behavioral|Point of Care CD4 count and peer case management|HIV-positives will receive prevention with positives (PwP) counseling and point of care CD4 counts. Those with CD4 <500/μL will be assigned a peer case manager to link the person to ART at study-participating HIV clinics, support ART and PwP adherence and care retention.
1977975|NCT01553058|Drug|Adalimumab (Humira)|Humira will be given at an initial dose of 80mg followed by 40 mg the second week, subsequent doses will be given at 40mg and follow FDA dosing schedule.
1977976|NCT01553058|Drug|Placebo Injection|Placebo injection will be given according to the same dose and schedule as the active comparator.
1977977|NCT01553058|Other|NB-UVB phototherapy|Phototherapy will be given 3 times per week according to the Fitzpatrick scale for skin types.
1977980|NCT01536197|Procedure|Gastric bypass|Roux-en-Y gastric bypass
1977981|NCT01536197|Procedure|Gastric banding|Laparoscopic adjustable gastric banding
1977982|NCT01536197|Procedure|Sleeve gastrectomy|Sleeve gastrectomy surgery
1977983|NCT01529008|Drug|Core decompression/PREOB® implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of PREOB® into the necrotic lesion (single administration).
1977984|NCT01529008|Drug|Core decompression/placebo implantation|All patients will undergo a core decompression under general anesthesia combined with the implantation of placebo into the necrotic lesion (single administration).
1977985|NCT01516905|Drug|NM404|injection of either 2.0mCi or 5.0mCi I-124 NM404
1977986|NCT01514357|Drug|Nesiritide (BNP)|NATRECOR® (nesiritide) is a sterile, purified preparation of human B-type natriuretic peptide (hBNP), and is manufactured from E. coli using recombinant DNA technology. Each 1.5 mg vial contains a white- to off-white lyophilized powder for intravenous (IV) administration after reconstitution.
1977987|NCT01514357|Drug|Placebo|Placebo will be administered subcutaneously instead of active drug (nesiritide) in a blind fashion in the second arm of the study.
1989169|NCT02577887|Device|Patients implanted with a St. Jude Medical pacemakers|
1989173|NCT02575521|Drug|Propofol-Dexmedetomidine group|Porofol (1.5-2 mg/kg/h) infusion, Dexmedetomidine (0.2-1µg/kg/h) infusion and Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value). Maintenance infusions will start immediately after induction.
1989174|NCT02575521|Drug|Sevoflurane group|Sevoflurane at a concentration of 2-2.5%., Fentanyl in repeated doses (50µ) when needed (heart rate or mean arterial blood pressure increase more than 20% of the basal value).
1977988|NCT01503528|Procedure|Motor Sparing Nerve Block|Continuous Motor sparing knee block (60mL of 0.5% ropivacaine with 10 mg Morphine, 30 mg Ketorolac and 150 mcg of epinephrine as the initial bolus) initiated in the preoperative period in the block room as per the standard practice and continued until discharge. Patients will be connected to an Ambit infusion pump in the postoperative period set to deliver ropivacaine 0.2% at a basal infusion rate of 7 mL/Hr with patient controlled boluses of 5mL every hour for breakthrough pain.
1977989|NCT01503528|Procedure|Peri-articular Catheters|3 peri-articular catheters inserted at the end of surgery followed by periarticular infiltration with ropivacaine 0.2% and wound infusions will be continued until discharge using elastomeric devices.
1977990|NCT01502319|Behavioral|Cognitive therapy|Interventional studies conducted by the consortium focus on a range of cognitive and cognitive-behavioral techniques including cognitive therapy.
1977991|NCT01493024|Drug|Zirconium silicate (ZS)|Randomized escalating doses (0.3g, 3g and 10g) of ZS (fractionated, protonated microporous Zirconium Silicate, an oral sorbent) administered 3 times (tid) daily with meals.
1977992|NCT01493024|Drug|Placebo|Randomized to mimic escalating doses of experimental drug administered 3 times (tid) daily with meals.
1977993|NCT01448642|Drug|Atorvastatin|Atorvastatin loading dose of 80mg before PCI, reloading dose of 80mg 24 hours after PCI, and atorvastatin 40mg for 30 days
1977994|NCT01448642|Drug|Placebo|Matching placebo before PCI and 24 hours after PCI. Atorvastatin 40mg for 30 days
1977995|NCT01444027|Behavioral|Problem Solving Therapy|Problem-solving therapy (PST) focuses on behavioral change principles derived from this theoretical framework. PST addresses four skills: 1) problem definition and formulation, which involves gathering data and information, articulating the issue in clear terms, identifying the challenge, and setting realistic goals; 2) generation of alternative strategies; 3) decision making; and 4) solution implementation. The intervention is delivered in a series of interactions with the interventionist.
1977996|NCT01430689|Biological|Inactivated Influenza Vaccine Trivalent Types A and B|"Pregnant Woman: Randomization to receive IM injection of Vaxigrip Influenza Vaccine once
Household and Woman/Infant surveillance
Home visits weekly until the infant is born and reaches 6 months of age
If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
1977997|NCT01430689|Biological|Meningococcal Polysaccharide-Diphtheria Toxoid Conjugate Vaccine|"Pregnant Women - Randomized to receive IM injection of Menactra once
Household and Woman/Infant surveillance
Home visits weekly until the infant is born and reaches 6 months of age
If the woman, her infant or other household contact has signs and symptoms consistent with Influenza Like Illness (ILI)a nasal and oropharyngeal swab will be obtained"
1977999|NCT01422161|Drug|Botulinum Toxin commonly known as BOTOX®|"A total dose between 200-300 units of Botulinum toxin will be administered across 12 muscles of the affected hand.
The control group will receive a placebo injection. There will be 1 treatment cycle during the 9 week study."
1978000|NCT01420926|Drug|Bortezomib|Given SC
1978001|NCT01420926|Drug|Decitabine|Given IV
1978002|NCT01420926|Other|Laboratory Biomarker Analysis|Correlative studies
1978003|NCT01420926|Other|Pharmacological Study|Correlative studies
1978004|NCT01420926|Other|Quality-of-Life Assessment|Ancillary studies
1978005|NCT01420926|Other|Questionnaire Administration|Ancillary studies
1978006|NCT01409200|Other|ADT Therapy|ADT for 8 weeks (specific drugs/dose/frequency not mandated by protocol) then up to 6 more months of hormone therapy following assignment to study group.
1978007|NCT01409200|Drug|Axitinib|5 mg by mouth twice a day for 30 day cycle.
1978008|NCT01409200|Procedure|Prostatectomy|Radical prostatectomy and pelvic lymph node dissection approximately 8 months after androgen deprivation therapy (ADT) with or without open label Axitinib.
1978009|NCT01395641|Drug|gene therapy|AAV2-hAADC viral vector will be injected into bilateral putamen by stereotactic surgery.
1978011|NCT01361243|Behavioral|NOURISH+|6 week face-to-face parent intervention.
1978012|NCT01361243|Behavioral|Wellness Group|1 week face-to-face family group followed by 6 informational mailings on childhood overweight and obesity.
1978013|NCT01336413|Drug|Pregnenolone|Pregnenolone 50 mg BID x 14 DAYS, followed by Pregnenolone 150 mg BID x 14 DAYS, followed by Pregnenolone 250 mg BID x thereafter for the remainder of the 8-week trial
1978014|NCT01336413|Drug|Placebo|Same as active comparator, except placebo dispensed.
1978016|NCT01295671|Behavioral|Provision of beverages|Home delivery of specified beverage type
1978017|NCT01294319|Drug|Mifepristone|
1978018|NCT01294319|Drug|Placebo|
1978019|NCT01294319|Drug|Spironolactone|
1978020|NCT01287013|Device|Xperguide CT|Imaging
1978021|NCT01287013|Device|Computed Tomography|Imaging
1978022|NCT01277783|Device|Medtronic Model 6227ATS deflectable delivery catheter|Endocardial Left Ventricular pacing lead delivery
1978023|NCT01277783|Device|Medtronic Model 6248HS, 6248JL, or 6248JS delivery catheter|Endocardial Left Ventricular pacing lead delivery
1978024|NCT01277783|Device|Medtronic Model 3830|Endocardial Left Ventricular pacing
1978035|NCT01206062|Other|Intensive control of SBP|"Participants in the Intensive arm have a goal of SBP <120 mm Hg. Use of once-daily antihypertensive agents will be encouraged unless alternative frequency is indicated/necessary. One or more medications from the following classes of agents will be provided by the study for use in managing participants in both randomization groups to achieve study goals:
Angiotension converting enzyme (ACE)-inhibitors Angiotension receptor blockers (ARBs) Direct vasodilators Thiazide-type diuretics Loop diuretics Potassium-sparing diuretics Beta-blockers Sustained-release calcium channel blockers (CCBs) Alpha1-receptor blockers Sympatholytics
Combination products will be available, depending on cost, utility, or donations from pharmaceutical companies."
1978036|NCT01206062|Other|Standard BP arm|Participants in the Standard BP arm have a goal of SBP <140 mm Hg. The same medications used in the Intensive BP arm will be used for the Standard BP arm.
1978041|NCT01187381|Drug|Trastuzumab|Trastuzumab according to local standard of care and in line with the current summary of product characteristics/ local guidelines
1978047|NCT01126801|Drug|Estradiol|Oral estradiol 1.0 mg/day for four weeks.
1978048|NCT01126801|Other|Placebo control|Placebo control matched to estradiol tablets. Daily dosing for one month.
1978049|NCT01123382|Device|Intramuscular Electrical Stimulator|A sterile percutaneous IM electrode is implanted in the shoulder using a 20-gauge hypodermic needle and connected to an external cable. The exit site and electrode are covered by a bandage, but the cable extends out. After a one week stabilization period, the cable is connected to a stimulator. A self-adhesive surface electrode serves as the indifferent electrode. Stimulation intensity is set by the investigator. The prescription for daily stimulation treatment will be 6 hrs. The duty cycle and daily dose will remain constant throughout the treatment, but stimulus parameters may be adjusted by the research staff as deemed appropriate. The treatment period will be 3 weeks, after which the electrode will be removed. Total time of electrode implantation is no more than 29 days.
1978050|NCT01123382|Other|Outpatient Therapy|Subjects will receive 8 hrs of outpatient therapy over a four week period from a treating therapist, coupled with prescribed daily home exercises. The therapist will implement an individualized treatment plan consistent with the needs of the participant.
1978051|NCT01118208|Other|Blister packaging medications|Dispensing prescription medications on pre-filled blister package cards.
1978052|NCT01118208|Other|Dispense as usual|Dispensing prescription medications in standard pill bottles.
1978053|NCT01118026|Drug|ABVD|doxorubicin 25 mg/m^2 IV bleomycin 10 units/m^2 IV vinblastine 6 mg/m^2 IV dacarbazine 375 mg/m^2 IV
1978054|NCT01118026|Drug|BEACOPP|bleomycin 10 units/m^2 IV on Day 8 etoposide 200 mg/m^2 IV on Days 1, 2 and 3 doxorubicin 35 mg/m^2 IV on Day 1 cyclophosphamide 1250 mg/m^2 IV on Day 1 vincristine 1.4 mg/m^2 IV on Day 8 procarbazine 100 mg/m^2 orally on Days 1-7 prednisone 40 mg/m^2 orally on Days 1-14
1978055|NCT01118026|Radiation|radiation therapy|
1978056|NCT01117818|Biological|active: AFFITOPE AD02|vaccination
1978057|NCT01117818|Biological|control: Placebo|vaccination
1978058|NCT01114724|Device|Valiant Thoracic Stent Graft with the Captivia Delivery System|All subjects will be implanted with this device
1978059|NCT01108393|Drug|Agomelatine A|"Agomelatine 25 mg film-coated tablet
Agomelatine 2x25mg film-coated tablet"
1978060|NCT01108393|Drug|Placebo|Placebo
1978061|NCT01094743|Device|galyfilcon A prototype lens|Silicone hydrogel contact lens
1978062|NCT01094743|Device|lotrafilcon B lens|Silicon Hydrogel contact lens
1978063|NCT01093547|Procedure|Blood samples|Samples taken monthly
1978064|NCT01093547|Procedure|Measure of peritoneal ultrafiltrates|Measured by the investigators intermittently and by the patients themselves on a monthly basis
1978065|NCT01070199|Behavioral|liquid to liquid|"• One test session will involve presentation of a glass of clear cherry-flavored unthickened beverage (Kool-Aid, Kraft Foods Inc., White Plains, NY). This session will be referred to as the Liquid to Liquid session as the participants will be consuming a liquid and be told that the consistency in their stomach will be a liquid."
1978066|NCT01070199|Behavioral|liquid to solid|This session involves a solution of calcium chloride and a solution of sodium alginate. The participant will be instructed to pour the cherry-flavored beverage/alginate solution into the calcium chloride. The result is a solid mass. They are allowed to examine the solution to confirm the solid texture and consistency.Participants will be told that this same reaction will occur in their stomach when the session's beverage is consumed due to the effect of gastric acid on the solution. But, the participant will be consuming the same cherry-flavored beverage as in the 1st session. Thus, they will believe that their GI tract will be challenged with a solid mass, but in reality, the challenge is the same (i.e., liquid).Therefore, the only difference between the test sessions is expectation.
1978067|NCT01070199|Behavioral|solid to liquid|"• This session will involve the same dense gelatin cubes previously described, but participants will be told that the solid cubes will turn to liquid when they come into contact with the acid in their stomach. This trial will be known as Solid to Liquid. A demonstration of the Solid to Solid and Solid to Liquid phases will be shown to the participant before they consume the load. Both phases exhibited by placing two cubes into separate containers filled with similar looking clear liquids. The Solid to Solid phase container will contain cold water so the cube stays in solid form. The Solid to Liquid phase container will contain hot water that will quickly dissolve the cube into a liquid form."
1978068|NCT01070199|Behavioral|solid to solid|"Participants will be presented with dense gelatin cubes. These 1 x 1 x 1 cubes will have a solid appearance and require mastication, but is isocaloric to the beverage. However, after mastication and gastric processing, the solid rapidly breaks down into a clear fluid.However, participants will be informed that the cubes will remain the same solid consistency in their stomach. The masticatory process and stimulus form will be standardized through the use of a metronome. Participants will be required to chew the solid cube at a fixed rate prior to swallowing. Thus, adding to the cognitive impression that they are eating a solid when essentially the GI challenge will be similar to the beverage."
1978069|NCT01042379|Drug|Standard Therapy|Paclitaxel: 80 mg/m2 IV during the 12 weekly treatment cycles post randomization; Doxorubicin: 60 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16; Cyclophosphamide: 600 mg/m2 IV after completion of the 12 weekly treatment cycles and prior to surgery for weeks 13-16
1978070|NCT01042379|Drug|AMG 386 with or without Trastuzumab|Arm is closed.
1978071|NCT01042379|Drug|AMG 479 (Ganitumab) plus Metformin|Arm is closed.
1978072|NCT01042379|Drug|MK-2206 with or without Trastuzumab|Arm is closed.
1978073|NCT01042379|Drug|AMG 386 and Trastuzumab|Arm is closed.
1978074|NCT01042379|Drug|T-DM1 and Pertuzumab|Arm is closed.
1978075|NCT01042379|Drug|Pertuzumab and Trastuzumab|Pertuzumab: 840 mg IV (loading dose) week 1 and 420 mg every 3 weeks (weeks 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) week 1 and 2 mg/kg weekly (weeks 2-12) post-randomization
1978076|NCT01042379|Drug|Ganetespib|Arm is closed.
1978077|NCT01042379|Drug|ABT-888|Arm is closed.
1978078|NCT01042379|Drug|Neratinib|Arm is closed.
1978079|NCT01042379|Drug|PLX3397|Arm is closed.
1978080|NCT01042379|Drug|Pembrolizumab - 4 cycle|Arm is closed.
1978081|NCT01042379|Drug|Talazoparib plus Irinotecan|Arm is closed.
1978082|NCT01042379|Drug|Patritumab and Trastuzumab|Patritumab: 18 mg/kg loading of patritumab (cycle 1) followed by 9 mg/kg thereafter (cycles 4, 7, 10) post-randomization; Trastuzumab: 4 mg/kg (loading dose) cycle 1 and 2 mg/kg cycles (weeks 2-12) post-randomization Doxorubicin + Cyclophosphamide: Cycles 13-16
1978083|NCT01042379|Drug|Pembrolizumab - 8 cycle|Pembrolizumab: 200mg IV cycles 1,4,7,10,13,14,15,16 Paclitaxel: 80 mg/m2 IV cycles 1-12 Doxorubicin + Cyclophosphamide: Cycles 13-16
1978084|NCT01042379|Drug|SGN-LIV1A|SGN-LIV1A: 2.5 mg/kg IV cycles 1,4,7,10 Doxorubicin + Cyclophosphamide: Cycles 13-16
1978085|NCT01035606|Behavioral|training in goal-directed attention regulation|training in goal-directed attention regulation
1978086|NCT01035606|Behavioral|brain health education|brain health education workshops
1978087|NCT01035606|Behavioral|computer-assisted training in goal-directed attention regulation|computer-assisted training in goal-directed attention regulation, with trainer guidance and cognitive games to practice skills
1978097|NCT01010984|Device|LC beads loaded with Doxorubicin|During each TACE, 2 vials (1 vial, 75mg Doxorubicin) of 100-300 micrometer size LC beads loaded with doxorubicn will be delivered to the liver tumor(s). Total Doxorubicin dose for each TACE is 150mg
1978098|NCT01005576|Drug|Transplant conditioning regimen of alemtuzumab, fludarabine, and melphalan|Days -50 to -21: Hydroxyurea 30mg/kg po Day -22: Alemtuzumab 3mg IV Day -21: Alemtuzumab 10mg IV Day -20: Alemtuzumab 15mg IV Day -19: Alemtuzumab 20mg IV Day -8: Fludarabine 30mg/m2 IV Day -7: Fludarabine 30mg/m2 IV Day -6: Fludarabine 30mg/m2 IV Day -5: Fludarabine 30mg/m2 IV Day -4: Fludarabine 30mg/m2 IV Day -4: Thiotepa 8mg/kg IV Day -3: Melphalan 140mg/m2 IV Day 0: Stem cell infusion
1978107|NCT00979407|Biological|Influenza vaccine GSK2340272A|Two intramuscular injections at Day 0 and Day 21
1978108|NCT00979407|Biological|Influenza vaccine GSK2340274A|Two intramuscular injections at Day 0 and Day 21
1978109|NCT00972309|Biological|TARP peptide vaccine|TARP peptides administered every 3 weeks for 5 vaccinations with a booster dose at weeks 48 and 96
1978110|NCT00972309|Biological|TARP dendritic cell vaccine|TARP pulsed dendritic cells administered every 3 weeks for 5 vaccinations with a booster dose at weeks 48 and 96
1978116|NCT00940173|Device|DIABECELL(R)|10,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
1978117|NCT00940173|Device|DIABECELL(R)|15,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
1978118|NCT00940173|Device|DIABECELL(R)|20,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
1978119|NCT00940173|Device|DIABECELL(R)|5,000 IEQ/kg injected into the peritoneal cavity via laparoscopy
1978121|NCT00907218|Drug|Varenicline (Chantix)|Upon completion of screening procedures and meeting eligibility criteria, subjects will begin taking varenicline daily until Week 6 of the study. At Week 6 they will discontinue varenicline and return one week later for their final study visit to assess return of ADHD symptomatology. Subjects will start on 0.5 mg of varenicline per day for the first week of treatment. The dose will be increased to 0.5 mg twice a day at the end of week 1 visit, and then increased to 1 mg twice a day at the end of week 2 visit, to remain at this dose until the week 6 visit. At week 6, all subjects will be openly discontinued from varenicline, to return to the office the following week for re-assessment one week off the medication. If significant adverse effects (AE) occur, the daily dose may be reduced by 0.5 to 1 mg. At subsequent visits, a higher dose may be resumed if tolerated. Maximum dose will be 2 mg daily.
1978122|NCT00899847|Procedure|Autologous peripheral blood stem cells (auto-PBSC) transplantation|"Auto-PBSC ≥ 2 to 3 x 10e6 CD34+ cells/kg are intravenously (IV) infused as part of the combination stem cell therapy.
and allogeneic stem cells are administered intravenous (IV) infusion to reestablish hematopoietic function in patients whose bone marrow or immune system is damaged or defective"
1978123|NCT00899847|Procedure|Allogeneic peripheral blood stem cells (allo-PBSC) transplantation|Allo-PBSC (target collection ≥ 5 x 10e6 CD34+ cells/kg) are intravenously (IV) infused as part of the combination stem cell therapy.
1978124|NCT00899847|Drug|Filgrastim|"Filgrastim is administered subcutaneously (SC) at 10 µg/kg/day for auto-PBSC mobilization starting day 2 of mobilization until the last day of apheresis.
Filgrastim is administered SC at 5 µg/kg/day from Day 6 after auto-PBSC infusion to hematologic recovery.
Filgrastim is administered SC at 16 µg/kg/day for donor allo-PBSC mobilization at from Day - 4 to Day 0, prior to allo-PBSC collection."
1978125|NCT00899847|Drug|Cyclophosphamide|Cyclophosphamide is administered intravenously (IV) at 4 g/m2 on Day 1 of the auto-PBSC mobilization regimen.
1978126|NCT00899847|Drug|Melphalan|Melphalan is administered after CSP at 200 mg/m2 intravenously (IV) on Day -2 before auto-PBSC infusion.
1978127|NCT00899847|Drug|Cyclosporine|Cyclosporine is administered by mouth (PO) for allo-PBSC graft vs host disease (GvHD) prophylaxis at 5 mg/kg from Day -3 through Bay +56. Tacrolimus may substituted.
1978128|NCT00899847|Radiation|Total lymphoid irradiation|Total lymphoid irradiation is administered at 80 centigrey (cGy) on Day -11 to -7; and Day -4 to -2 before alllo-PBSC infusion. TLI is also administered at 80 centigrey (cGy) x 2 on Day -1 before alllo-PBSC infusion.
1978129|NCT00899847|Biological|Rabbit anti-thymocyte globulin|ATG 1.5 mg/kg is administered intravenously (IV) on Day -11 to -7 before allo-PBSC infusion.
1978130|NCT00899847|Drug|Mycophenolate Mofetil 250mg|MMF is administered at 15 mg/kg 3x/day by mouth (PO) after allo-PBSC through Day 40, followed by 10% dose reduction weekly (dose taper) through day 96, and adjusted if there is evidence of MMF-related GI toxicity or excessive myelosuppression
1978131|NCT00899847|Drug|Solumedrol|Solumedrol 1 mg/kg is administered intravenously (IV) on Day -11 to -7 as a premedication for ATG and allo-PBSC infusion
1978132|NCT00899847|Drug|Diphenhydramine|Diphenhydramine 25 to 50 mg is administered as a premedication for the ATG; allo-PBSC; and DLI infusions.
1978133|NCT00899847|Drug|Acetaminophen|Acetaminophen 650 mg is administered as a premedication for the ATG and allo-PBSC infusions.
1978134|NCT00899847|Drug|Hydrocortisone|Hydrocortisone 100 mg is administered intravenously (IV) is a premedication for the allo-PBSC and DLI infusions.
1978135|NCT00888628|Biological|Purified Pancreatic Islets|Islet after kidney transplant in patients with type I diabetes.
1978136|NCT00888628|Drug|Etanercept|Given as induction for islet cell transplant
1978140|NCT00813007|Behavioral|Questionnaires|5 Questionnaires at differing times before and after surgery.
1978141|NCT00805194|Drug|placebo plus docetaxel|placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
1978142|NCT00805194|Drug|BIBF 1120 plus docetaxel|BIBF 1120 2 times daily along with standard therapy of docetaxel
1978145|NCT00790569|Drug|nicotine|Given transdermally and orally
1978146|NCT00790569|Drug|varenicline|Given orally
1978147|NCT00790569|Other|placebo|Given orally
1978148|NCT00782795|Drug|Pioglitazone|Participants will be randomized to either pioglitazone or placebo. The dosing is 30 mg taken once daily for 48 weeks.
1978149|NCT00774124|Other|telemonitoring|Women will transmit their blood glucose levels, fetal movement counts, and insulin doses via the Internet and/or IVR system at least three times per week
1978150|NCT00774124|Other|Standard of care|Health data (blood glucose levels and insulin doses) will be recorded in a paper log book which will be reviewed at prenatal visits.
1978154|NCT00760006|Drug|Unasyn|Subjects will receive the antibiotic or the saline placebo 30 minutes prior to the initial incision in their palatoplasty procedure. The FDA approved antibiotic used for this study is Unasyn. Unasyn is a first-line measure, used by ENT surgeons at Children's Hospital of Pittsburgh for antibiotic treatment of virtually all ear, nose and throat infections. The use of Unasyn for this study is off-label as with the majority of antibiotics used with children. Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm
1978155|NCT00760006|Other|saline solution|Subjects will receive a one time dose of 50mg/kg prior to surgery, not to exceed a total of 2gm.
1978156|NCT00733343|Device|Europe: AutoSet CS (USA: VPAP Adapt SV)|At least 3 hours average daily usage time
1978159|NCT00669188|Behavioral|Administration of information|
1978161|NCT00625404|Drug|Truvada|Daily single oral tablet of Truvada - a fixed-dose combination of emtricitabine (FTC; 200 mg) and tenofovir disoproxil fumarate (TDF; 300 mg).
1978162|NCT00625404|Other|Placebo|Daily single oral tablet of Placebo. Tablets are identical to Truvada tablets in taste and appearance; however, they contain no active ingredients.
1978163|NCT00616941|Biological|NY-ESO-1 OLP4|1 mg of NY-ESO-1 OLP4 will be diluted in 0.5 mL of D5W and administered subcutaneously as a single injection.
1978164|NCT00616941|Biological|NY-ESO-1 OLP4 + Montanide|1 mg of NY-ESO-1 OLP4 will be diluted in 0.5 mL of D5W, mixed with 0.5mL of Montanide and administered subcutaneously as a single injection.
1978165|NCT00616941|Biological|NY-ESO-1 OLP4 + Montanide + Poly-ICLC|1 mg NY-ESO-1 OLP4 + 1.4 mg Poly-ICLC emulsified in 1 mL Montanide and administered subcutaneously as two injections.
1978166|NCT00601900|Biological|Bevacizumab|Given IV
1978167|NCT00601900|Other|Laboratory Biomarker Analysis|Correlative studies
1978168|NCT00601900|Drug|Letrozole|Given PO
1978169|NCT00601900|Other|Questionnaire Administration|Ancillary studies
1978170|NCT00601900|Drug|Tamoxifen Citrate|Given PO
1978171|NCT00591838|Radiation|Stereotactic Body Radiation Therapy (SBRT)|
1978178|NCT00573833|Other|questionnaire administration|
1978179|NCT00573833|Procedure|quality-of-life assessment|
1978180|NCT00573833|Radiation|brachytherapy|
1978181|NCT00573872|Radiation|Radiosurgery|"Phase I: 20-25 Gy in 5 fractions
Phase II: 9-24 GY in 1 fraction"
1978182|NCT00571909|Procedure|video thorascopic splanchnicectomy (VSPL)|VSPL is a minimally invasive technique using 1-2cm incisions through which a camera and surgical tools are placed inside the thoracic cavity and the idea of the procedure is to cut the pain pathway linking the splanchnic ganglion with pain centers in the hypothalamus
1978183|NCT00490503|Procedure|Magnetic Resonance Imaging (MRI)|3 Scans performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
1978184|NCT00490503|Procedure|Magnetic Resonance Spectroscopy (MRS)|3 MRI Scans with MRS performed before chemotherapy, 21 days (plus or minus 3 days) after start chemotherapy (Day 1 = your first day of chemotherapy), and at end of chemotherapy/before surgery.
1978185|NCT00468117|Procedure|Islet transplantation|
1978186|NCT00468117|Biological|Antithymocyte Globulin|Participants will begin receiving ATG 2 days prior to the initial islet transplant and will continue to receive ATG until Day 2 post-transplant.
1978187|NCT00468117|Biological|Daclizumab or Basiliximab|Daclizumab or Basiliximab will be used for subsequent transplants.
1978188|NCT00468117|Biological|Etanercept|Etanercept will be given on the day of transplant and on Days 3, 7, and 10 post-transplant.
1978189|NCT00468117|Biological|Allogenic human purified pancreatic islets|200 ml suspension of allogenic human purified islets
1978190|NCT00439205|Device|FastEEM4 System|The FastEEM4 probe is moved toward the edge of the lesion(s) until it measures what appears to be normal mouth tissue.
1978191|NCT00439205|Device|Multispectral Digital Microscope|The MDM instrument will take pictures of abnormal-appearing and normal-appearing areas in the mouth.
1978192|NCT00434837|Procedure|Initial graft tension during ACL reconstruction surgery|The amount of tension that is applied to the graft at the time of fixation is being performed with the knee in two different positions. When the knee is at 30 degrees of flexion, the resulting laxity is approximately 2 mm less than the contralateral leg. When the tension is performed with the knee in extension (0 degrees of flexion), the the laxity is equal to that of the contralateral leg. Both methods are commonly used in clinical practice. The effect it may have on articular cartilage remains unknown.
1978193|NCT00432159|Device|Cervical TDR|Cervical total disc replacement using a DISCOVER Artificial Cervical Disc.
1978194|NCT00432159|Device|ACDF with plate|Anterior cervical discectomy followed by insertion of allograft spacer and placement of an anterior plate.
1978195|NCT00414726|Drug|NBO (Normobaric Oxygen)|High-flow oxygen delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
1978196|NCT00414726|Drug|Room Air|Room Air delivered via a facemask. A total of 240 individuals with acute ischemic stroke will be randomized 1:1 to receive either room air or oxygen administered at 30-45 L/min via a simple facemask for 8 hours.
1978197|NCT00413699|Drug|CP-690,550|5 mg PO BID open label; may increase to 10 mg PO BID to provide greater control of RA if no related AEs are present. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
1978198|NCT00413699|Drug|CP-690,550|10 mg PO BID open label; may decrease to 5 mg PO BID for mild to moderate AEs. May be off study drug temporarily for up to 28 days for mild to moderate AEs.
1978199|NCT00409565|Drug|Cetuximab|"Cetuximab 400 mg/m2 IV over 120 minutes on day 1 of cycle 1 ONLY
Cetuximab dose will be 250 mg/m2 IV over 60 minutes weekly on ALL subsequent administrations"
1978200|NCT00409565|Drug|Bevacizumab|Once every 3 weeks, 15 mg/kg of bevacizumab will be given by IV infusion after cetuximab has been given
1978201|NCT00401817|Drug|Bevacizumab|15 mg/kg on day 1 of each of 6 cycles
1978202|NCT00401817|Drug|Rituximab|"Rituximab will be administered prior to CHOP on day 3 of every cycle for a total of 6 cycles.
The dose to be administered is:
Rituximab: 375 mg/m2"
1978203|NCT00401817|Drug|CHOP|Standard CHOP chemotherapy will be administered at full dose every 21 days for a total of 6 cycles. The doses to be used are: Cyclophosphamide: 750 mg/m2 IV on day 3 Doxorubicin: 50 mg/m2 IV on day 3 Vincristine: 1.4 mg/m2 IV (not to exceed 2.0 mg total) on day 3 Prednisone: 100 mg PO days 3 - 7
1978204|NCT00383760|Drug|eribulin mesylate|Given IV
1978205|NCT00374452|Behavioral|ATHENA-Hypertension clinical decision support system|ATHENA display provides guideline-based recommendations to clinicians at the time of patient care.
1978206|NCT00357929|Procedure|Permissive hypercarbia|
1978214|NCT00300053|Device|stem cell injection|
1978215|NCT00287495|Drug|BAY 43-9006|BAY 43-9006 200 mg once daily with dose escalation up to 400 mg twice daily
1978216|NCT00287105|Drug|Standard chemotherapy + Imatinib|Patients receive Imatinib together with the standard chemotherapy regimen of phase IB and after each of three consecutive blocks of the standard chemotherapy in the consolidation phase
1978217|NCT00272844|Drug|crystalline cholesterol oil-based suspension|200 mg/mL suspension of crystalline cholesterol in oil. Dosage (generally 75-300 mg/kg/day in divided doses) is based on initial cholesterol levels and regulated to increase, yet maintain, cholesterol levels no higher than normal ranges.
1978218|NCT00247624|Drug|Eszopiclone|Eszopiclone 3 mg every night for 8 weeks
1978219|NCT00247624|Drug|Fluoxetine|Fluoxetine 20 mg every morning for 9 weeks
1978220|NCT00247624|Drug|Placebo|Placebo every night for 8 weeks
1978221|NCT00221117|Device|Neuroprosthesis|The Compex Motion neuroprostesis, developed by Drs. R. Popovic and Thierry Keller,and company Compex SA, ia a flexible device designed to improve grasping function in both SCI and stroke patients.This multi-channel surface stimulation system for grasping provides both palmar and lateral grasp , and holds a number of advantages over the other existing neuroprostheses.
1978227|NCT00214097|Procedure|Radiotherapy|Daily radiation to prescribed dose
1978228|NCT00202553|Drug|Perindopril|
1978229|NCT00202592|Drug|Perindopril|
1978230|NCT00202579|Drug|Ivabradine|
1978231|NCT00202540|Drug|S18986|
1978232|NCT00202566|Drug|Ivabradine|
1978233|NCT00142506|Drug|sildenafil citrate and questionaires|"Hormone therapy patients will be instructed to begin the study drug simultaneously or within 1 month of start of hormone therapy. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand open label, flexible dose fashion. Hormone patients will be offered on demand Sildenafil for approximately 15-21 months.
Hormone therapy patients will complete assessments at baseline (within 4 weeks of start of study treatment) each month (only IIEF and QOL) before start of radiotherapy, at start of radiotherapy and at months 3, 6, 9, 12 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
1978234|NCT00142506|Drug|placebo tablets and questionaires|"Non-hormone therapy patients will be instructed to begin the study drug 3 days prior to start of radiotherapy. Patients beginning study drug anytime between 3 days before start of radiotherapy and 2 weeks after the first day of radiotherapy will also be acceptable. These patients will then continue to take the study drug for approximately 6 months following start of radiotherapy.
In addition, during prophylactic phase (drug and placebo prophylactic arms) patients will have the opportunity to utilize oral 50 mg. tablets of Sildenafil Citrate in an on demand, open label, flexible dose fashion. Non-hormone patients will be offered on demand Sildenafil for approximately 12 months.
Assessments (IIEF, IPSS, QOL) will be completed by non-hormone therapy patients at baseline (within 4 weeks of start of study treatment) and at approximately months 3, 6, 9, 12, 18 and 24 from start of radiotherapy. Testosterone assessments will take place at baseline, and months 12 and 24."
1978235|NCT00127231|Behavioral|Brief alcohol intervention based on Project Treat|The brief intervention will include two sessions that review drinking patterns and behavior change strategies as well as two telephone calls to reinforce session content.
1978236|NCT00127231|Behavioral|Standard care|Hazardous/binge female drinkers will be identified in the Johns Hopkins Hospital HIV clinic and will be randomized to brief intervention or standard care. Outcome measures will include: alcohol/drug use, engagement in an on-site alcohol support group and other substance abuse treatment services, HIV-risk behaviors, HIV disease markers and treatment compliance, and psychiatric symptoms.
1978237|NCT00110149|Biological|rituximab|
1978238|NCT00110149|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1978239|NCT00101829|Drug|Rituximab|1000 mg intravenous infusion
1978240|NCT00073957|Biological|rituximab|
1978241|NCT00073957|Drug|cytarabine|
1978242|NCT00073957|Drug|liposomal cytarabine|
1978243|NCT00073957|Drug|methotrexate|
1978244|NCT00073957|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1978245|NCT00006184|Drug|Myeloma Immunoglobulin Idiotype Vaccine|3 subcutaneous (SC) injections of myeloma protein within 10 weeks before stem cell collection the first (week 0), second (week 2), and third injection (week 6) with Id-KLH (0.5 mg SC day 1)
1978246|NCT00006184|Drug|Bortezomib|Induction chemotherapy: 1.3 mg/m^2 bolus intravenous injection twice weekly for 2 weeks (days 1, 4, 8, 11) followed by 10 day rest period (day 12-21)
1978247|NCT00006184|Drug|Cyclophosphamide|Induction chemotherapy: 600 mg/m^2 day 4 Transplant: 1200 mg/m^2 intravenous x 4 days (days -6, -5, -4, -3)
1978248|NCT00006184|Drug|Cyclosporine|Transplant: 2 mg/kg intravenous every 12 hours continuous intravenous or by mouth (PO) until day + 180
1978249|NCT00006184|Drug|Doxorubicin hydrochloride|Induction chemotherapy: 10 mg/m^2 day continuous intravenous (CIV) days 1-3
1978250|NCT00006184|Drug|Etoposide|Induction chemotherapy: 50 mg/m^2 day continuous intravenous days 1-3
1978251|NCT00006184|Drug|Fludarabine phosphate|Induction chemotherapy: 25 mg/m^2 day intravenous days 1-3 Transplant: 30 mg/m^2 day x 4 days (days -6, -5, -4, -3 )
1978252|NCT00006184|Drug|Prednisone|60 mg/m^2 day 1-4
1978253|NCT00006184|Drug|Vincristine Sulfate|Induction chemotherapy: 0.5 mg/m^2 day continuous intravenous days 1-3
1978254|NCT00006184|Drug|Methotrexate|Transplant: 5 mg/m^2 intravenous on days +1, +3, +6, +11
1978255|NCT00006184|Biological|GMCSF (granulocyte macrophage colony stimulating factor)|250 mcg/m^2 subcutaneously every day, days 1-4
1978256|NCT00006184|Biological|GCSF (granulocyte colony stimulating factor)|10 mcg/kg per day subcutaneously daily from day 5 until absolute neutrophil count (ANC) > 1000/ul x 2 days
1989186|NCT02569671|Device|Straumann Bone Level Tapered Implant - Immediate Placement|Immediate placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
1989187|NCT02569671|Device|Straumann Bone Level Tapered Implant - Delayed Placement|Delayed placement of a Straumann Bone Level Tapered Dental Implant for replacement of a singe tooth.
1989188|NCT02569398|Drug|JNJ-54861911, 5 mg|Two JNJ-54861911, 5 milligram (mg) tablets orally once daily up to 54 months.
1989189|NCT02569398|Drug|JNJ-54861911, 25 mg|One JNJ-54861911, 25 mg tablet and one matching placebo tablet orally once daily up to 54 months.
1989190|NCT02569398|Drug|Placebo|Two matching placebo tablets orally once daily up to 54 months
1989223|NCT02564926|Drug|Dapagliflozin|Subject who will be randomized to the 'Dapagliflozin arm' will be treated with dapagliflozin 10mg + Metformin 1000 mg as Diabetes Treatment
1989224|NCT02564926|Drug|Glimepiride|Subject who will be randomized to the 'Glimepiride arm' will be treated with glimepiride 1-2mg + Metformin 1000 mg as Diabetes Treatment
1989225|NCT02563522|Genetic|VM202|gene therapy
1989226|NCT02563522|Other|Placebo|Standard of care plus placebo
1989241|NCT02555553|Behavioral|CBT-GSH with Noom Monitor|This intervention is cognitive behavioral treatment with a smartphone application
1989248|NCT02552225|Drug|Amitriptyline|Subjects in this arm will receive pills composed of amitriptyline and Avicel (cellulose filler)
1989249|NCT02552225|Other|Placebo|Subjects in this arm will receive pills composed only of Avicel (cellulose filler)
1989263|NCT02546583|Drug|Increased Intravenous Bolus Loop Diuretic Dose (Bumetanide or Furosemide)|An increase to 2.5x the Visit 1 dose of loop diuretic (bumetanide or furosemide).
1989264|NCT02546583|Drug|IV Chlorothiazide|
1989265|NCT02547909|Procedure|probe-based Confocal Laser Endomicroscopy|"Eligible women will be offered to undergo pCLE examination. Conscious sedation will be offered to all patients, who will choose to receive it or not. pCLE will be done using a standard gastroscope, reaching a distance of 25 cm from the anus, to the level of the rectosigmoid angle.
At this point, 2.5 ml fluorescein 10% will be injected. The pCLE probe (GastroFlex-UHD probe, Mauna Kea tech, Paris, France) will be inserted through the endoscope working channel and images will be recorded from areas suspected of harboring an endometriotic tissue."
1989266|NCT02547909|Device|Cellvizio|
1989267|NCT02547909|Drug|fluorescein 10%|
1989270|NCT02544763|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1989271|NCT02544763|Drug|Placebo|Yellow oily solution containing the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1989272|NCT02544750|Drug|GWP42003-P|Yellow oily solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1989276|NCT02543892|Biological|PATH-wSP|Streptococcus pneumoniae Whole Cell Vaccine, Inactivated and Adsorbed to Aluminum Hydroxide
1989277|NCT02543892|Biological|Placebo|Normal Saline
1989285|NCT02542072|Device|comfilcon A|contact lens
1989286|NCT02542072|Device|samfilcon A|contact lens
1989291|NCT02539368|Drug|Inflectra (infliximab)|
1989322|NCT02527265|Drug|Afrezza|"Pharmaceutical form: powder
Route of administration: inhalation"
1989334|NCT02517593|Genetic|Polygenic Risk Score|A Polygenic Risk Score (PRS) is a blood based genetic test which assesses 77 common breast cancer susceptibility loci (Single Nucleotide Polymorphisms). The PRS has been retrospectively validated and categorizes women into three categories of lifetime risk of developing breast cancer: Low Risk (<15% lifetime risk), Above Average Risk (15 to 40%), and high risk (>40%).
1989346|NCT02515513|Procedure|Muscle Tissue Biopsy Sample|During surgical resection, to enter the abdominal cavity, anterior muscle groups such as the rectus abdominous muscle. This group of muscle is divided. During division, muscle fibers are released from fascial group and discarded off the operative field. This will be the target for specimen collection.
1989356|NCT02513563|Drug|Carboplatin|Participants will be treated with carboplatin (area under the curve 5 (AUC5) will be used to determine the dosage) twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
1989357|NCT02513563|Drug|Paclitaxel|Participants will be treated with paclitaxel 175 mg/m^2 twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
1989358|NCT02513563|Drug|AZD1775|Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
1989361|NCT02511106|Drug|AZD9291 80 mg/40 mg|The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily.
1989362|NCT02511106|Drug|Placebo AZD9291 80 mg/40 mg|The initial dose of Placebo AZD9291 80 mg once daily can be reduced to 40 mg once daily.
1989363|NCT02509026|Biological|Etanercept|50 mg subcutaneous, once weekly, 24 weeks
1989413|NCT02498665|Drug|DSP-7888 Dosing Emulsion|"Dose escalation cohort: Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally or subcutaneously in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase.
MDS cohort 1: Patients will be intradermally administered of DSP-7888 at 10.5 mg every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks.
MDS cohort 2: Patients will be intradermally administered of DSP-7888 at 10.5 mg every 2 weeks until Week 24, and then every 4 weeks."
1989420|NCT02497287|Drug|Esketamine (Intranasal Spray)|Open-Label Induction Phase: Participants will self-administer esketamine intranasally twice per week for 4 weeks as a flexible dose regimen (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years). Participants >= 65 years old will start at a dose of 28 mg on Day 1. Optimization/Maintenance Phase: Participants will self-administer esketamine intranasally (56 mg or 84 mg for those < 65 years; 28 mg, 56 mg or 84 mg for those >= 65 years) once weekly then individualized to either once weekly or once every other week based on the severity of depressive symptoms. Transferred-entry responder participants from ESKETINTRD3005 >= 65 years old will start at a dose of 28 mg in Week 5.
1989421|NCT02497287|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
1989422|NCT02497287|Drug|Escitalopram (Oral Antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. The minimum therapeutic dose is 10 mg/day. Participants >= 65 years of age will be titrated up to 20 mg/day, but can lower the dose to 10 mg/day for tolerability.
1989423|NCT02497287|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
1989424|NCT02497287|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated for participants < 65 years of age up to a dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day. For participants >= 65, it can be titrated up to a dose of 150 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 75 mg/day.
1989428|NCT02496520|Biological|dendritic cells|vaccines with dendritic cells pulsed with tumor lysate
1989429|NCT02496520|Procedure|Surgery as needed by the patient´s tumor and stage|
1989430|NCT02496520|Drug|Chemotherapy as needed by the patient´s tumor and stage|
1989431|NCT02496520|Radiation|Radiation therapy as needed by the patient´s tumor and stage|
1998659|NCT01144455|Drug|TH-302|240 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
1998660|NCT01144455|Drug|TH-302|340 mg/m2 of TH-302 will be administered IV over 30 minutes on Days 1, 8 and 15 of every 28-day cycle.
1998666|NCT01139970|Other|Laboratory Biomarker Analysis|Correlative studies
1998667|NCT01139970|Other|Pharmacological Study|Correlative studies
1998668|NCT01139970|Drug|Temozolomide|Given PO
1998669|NCT01139970|Drug|Veliparib|Given PO
1998670|NCT01129245|Drug|celebrex|400 mg PO daily intermittently based on hormone and ultrasound findings
1998671|NCT01129245|Drug|Placebo|
1998672|NCT01124058|Drug|warfarin|"Patients will be randomized to re-start warfarin at their maintenance dose or at a loading dose (1.5 times the maintenance dose for 3 days, then resumption of warfarin dosing as per the maintenance dose)."
1998673|NCT01124058|Drug|Warfarin|"Maintenance dose is the amount of warfarin that a patient required to maintain a therapeutic INR."
1998684|NCT01112813|Drug|Lithium Carbonate|0.4-0.8 mmol/L for 2 months
1998688|NCT01107015|Device|Tailored Patient Intervention|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. Patients may provide their PCPs with printed copies of their logbooks and other information but physicians do not have access to the patient portal system. Patient action plans summarizing the patient-entered data and identifying possible self-management actions for improving their diabetes control are electronically sent to the patients every 2.5 months.
1998689|NCT01107015|Device|Patient-physician intervention|"Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a web portal where they may choose to review their patients' electronic logbooks. This is raw patient data that have not been analyzed."
1998690|NCT01107015|Device|Patient and PCP intervention with analyzed data|Patients select one of two mobile phone models, receive a one-year unlimited mobile phone data and phone service plan, receive the study treatment phone software and have access to the web-based individual patient portal. Given system-driven guidance on when to test blood glucose (bg) based on disease status, medication regimen, and time of poorest control. Patients enter bg data, carbohydrates consumed, diabetes medications taken and miscellaneous comments regarding diabetes self-care. Messages are sent to the patient's mobile phone giving feedback on entered data. Entered data are captured in real-time in the web-based logbook. PCPs are provided access to a secure web portal where they can see their patients' electronic logbooks. PCPs are provided with data analysis reports. The PCP is reminded that all data analysis is based on patient-entered, unvalidated data. The PCP has the option to use this information and remains responsible for all treatment decisions.
1998691|NCT01097746|Drug|Carboplatin|AUC 5 by vein Day 1 of Cycles 1-6.
1998692|NCT01097746|Drug|Paclitaxel|80 mg/m2 by vein (IV) over about 3 hours on Day 1 followed by Carboplatin, then on Days 8 and 15 of Cycle 1 Paclitaxel alone. On Day 1 of Cycles 2-6 Paclitaxel is followed by Carboplatin and Bevacizumab, then on Days 8 and 15 only Paclitaxel.
1998693|NCT01097746|Drug|Bevacizumab|15 mg/kg IV over about 1 ½ hours on Day 1 of Cycles 2-6.
1998708|NCT01071057|Drug|Saline/Morphine|Basal infusion of 20µg/kg/hour, bolus dose of 20µg /kg, lockout of 5 minutes with hourly maximum not to exceed 150µg /kg/hr, maximum 6 bolus doses. Subject pain relief will be assessed and documented by nursing staff and supervised by the Acute Pain Service (APS). Morphine will be titrated to subject need according to APS PCA protocol.
1998813|NCT00931632|Drug|Inhaled Nitric Oxide|Inhaled Nitric Oxide will be administered continuously starting at 20ppm into the inspiratory limb of the ventilator circuit in mechanically ventilated subject using an INOvent delivery system of by nasal cannula as needed for 24 days of therapy.
1998814|NCT00931632|Drug|Placebo|Nitrogen gas will be administered in the same manner as the experimental drug.
1998815|NCT00925119|Drug|Atenolol|12.5 mg twice daily of atenolol for 1 week; increased to 25 mg twice daily for a total of 8 weeks, if the medication is well tolerated
1998828|NCT00902577|Drug|18F-Fluoromisonidazole|Undergo FMISO PET scans
1998829|NCT00902577|Procedure|Magnetic Resonance Imaging|Undergo MRI
1998830|NCT00902577|Procedure|Positron Emission Tomography|Undergo FMISO PET scan
1998831|NCT00894816|Dietary Supplement|Lactobacillus F19|Infant cereals with the addition of Lactobacillus paracasei subsp. paracasei strain F19 (LF19)10E8 CFU per serving
1998832|NCT00894816|Dietary Supplement|Placebo|Infant cereals without any addition
1998833|NCT00893776|Other|Task Training|Task training is the movement of balls in an individually prescribed fashion using the SaeboFlex orthosis on the affected extremity.
1998839|NCT00878527|Device|CircuLite Synergy Pocket Circulatory Assist Device|Goal of successful implantation and follow-up for at least three months
1998840|NCT00878163|Other|Diagnostic Laboratory Biomarker Analysis|Correlative studies
1998841|NCT00878163|Drug|Erlotinib Hydrochloride|Given PO
1998842|NCT00878163|Drug|Gemcitabine Hydrochloride|Given IV
1998843|NCT00878163|Drug|Vismodegib|Given PO
1998844|NCT00876031|Drug|trofosfamide, idarubicin, etoposide|oral maintenance therapy for 6 months
1998848|NCT00857220|Drug|eszopiclone|One 2 mg tablet per day for 12 months
1998849|NCT00857220|Drug|eszopiclone|one 3mg tablet per day for 12 months
1998852|NCT00844792|Dietary Supplement|Lycopene, Vitamin D3, Selenium, Green Tea Extract, Vitamin E|Twice a day with meals. Lycopene - 20 mg, Vitamin D3 - 200 IU, Selenium - 100 mcg, Green Tea Extract - 75 mg, Vitamin E - 50 IU
1998853|NCT00844792|Drug|Placebo|Twice a day with meals.
1998860|NCT00834093|Biological|Epstein-Barr Virus Specific Immunotherapy|Two infusions given fourteen days apart, with a possible third infusion given 8 weeks later.
1998874|NCT00810446|Drug|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.
2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily.
3.Inhibition of disseminated Mycobacterium avium complex (MAC) disease associated with HIV infections : The usual adult dosage for oral use is 300 mg of rifabutin once daily.."
1998875|NCT00811317|Device|Closed-loop|Computer algorithm developed by Firas El-Khatib and Edward Damiano at Boston University that controls sub-cutaneous infusion of insulin and glucagon to regulate blood glucose to target
1998876|NCT00811148|Procedure|Tissue Bank|Collection of clinical data and tumor tissue.
1998878|NCT00802919|Drug|Varenicline|Varenicline 1-2 mg/day
1998879|NCT00802919|Drug|Placebo for varenicline|Placebo
1998882|NCT00794066|Procedure|measuring the ankle brachial index|"Assessment of the ankle brachial index using the boso-ABI-system 100 (www.boso.de)."
1998883|NCT00780715|Drug|Gliclazide MR|30mg daily increased to 60mg if HbA1c > 7% at 3 months
1998884|NCT00780715|Drug|Sitagliptin|Sitagliptin 100mg daily for 6 months
1998885|NCT00780715|Drug|Pioglitazone|Pioglitazone 30mg daily , increased to 45mg daily if HbA1c >7% at 3 months. 6 months duration
1998886|NCT00780715|Drug|Metformin|Metformin 500 mg od for 1 week, bd for 1 week, 1g mane 500 mg nocte 1 week, 1g bd there after. Total of 6 months treatment
1998887|NCT00777920|Drug|Ambrisentan|Ambrisentan tablet administered orally once daily
1998888|NCT00770328|Drug|Pentoxifylline|400mg PO TID x 8 weeks
1998889|NCT00770328|Drug|Placebo|PO TID x 8 weeks
1998893|NCT00756509|Drug|Nilotinib|800 mg/d orally
1998896|NCT00742963|Drug|TH-302|"TH-302 will be administered by IV infusion over 30-60 minutes on Days 1 and 8 of a 21-day cycle.
Dose escalation dose levels:
Dose level -1 (if needed): 180 mg/m2 Starting dose: 240 mg/m2"
1998897|NCT00742859|Drug|betrixaban|orally, once daily for at least 3 months
1998898|NCT00742859|Drug|Warfarin|Warfarin will be prescribed by the investigator according to the standard of care.
1992182|NCT03322436|Diagnostic Test|HeartLinc kit|Samples are collected and analyzed afterwards
1992183|NCT03323281|Other|Neuropsychological assessments|Maintenance of approximately 1h30 with a neuropsychologist or a physician trained in neuropsychological assessments in Diabetic Type 1 or Type 2 with foot wound hospitalization and Diabetic Type 1 or Type 2 without a foot wound or antecedent Of foot wound (podological risk grade 0 to 2, including foot of Charcot)
1992184|NCT03323268|Device|PetCO2 monitoring|CO2 analyzer on ventilator expiratory lane. On-line, continuous, and noninvasive monitor. Routine use in anesthesia and intensive care units.
1992185|NCT03323255|Device|repeated transcranial magnetic stimulation continuous theta-burst stimulation|cTBS
1992186|NCT03323255|Device|SHAM repeated transcranial magnetic stimulation|SHAM stimulation
1992187|NCT03323242|Device|LigaSure|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with LigaSure
1992188|NCT03323242|Device|Harmonic Ultrasonic dissector|The dissection of the small blood vessels and the connective tissue in the hepatoduodenal ligament is carried out with Harmonic Ultrasonic dissector
1992189|NCT03323229|Diagnostic Test|Enhanced communications & ultrasound|Paramedics will perform standardised point-of-care ultrasound scan protocols (specific to the patient's symptom set) and record a short (<1 minute) video summarising the patient's condition and current management. These will be transmitted via satellite to consultants at the receiving hospital before the ambulance leaves the incident scene. The emergency department consultants will provide support and advice on continuing patient management via standard ambulance communications systems while it is en route to the hospital.
1992190|NCT03323216|Diagnostic Test|6-minute walk test|"The 6-minute walk test is a functional test established in the clinic to assess the performance of a patient. The patient walks continuously for 6 minutes without interruption as far as possible. Breaks, speed changes and running are allowed.
Test is performed prior the CRT implantation and 6 months after the CRT implantation."
1992191|NCT03323216|Diagnostic Test|Study specific questionnaire|"Study specific questionnaire
The questionnaire is performed prior the CRT implantation and 6 months after the CRT implantation."
1992192|NCT03323216|Procedure|Blood collection|"Blood collection during surgery:
coronary sinus
arterial
peripheral venous
Blood collection 6 months after surgery:
- peripheral venous"
1992193|NCT03323203|Device|FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA|Tissue oxygenation was monitored using a tissue oximeter based on near-infrared spectroscopy (FORE-SIGHT Elite, CASMED, Inc., Branford, Connecticut, USA). The oximeter had four cables with each cable connected to an adhesive probe.
1992194|NCT03323190|Behavioral|Inpatient COPD education|
1992195|NCT03323177|Dietary Supplement|Gender specific nutritional standardized formula|Patients will continue to consume the study formula until final height: gender specific powder added to water containing about 25% of recommended DRI for calories, high protein (25% of calories) and multi vitamin and mineral (255-100%) of DRI for recommended daily allowance (RDA) or adequate intake
1992196|NCT03323177|Other|Follow-up only|Patients who are reluctant to continue to consume the study formula will come to follow-up visits only without any intervention until final height is reached
1992197|NCT03323164|Drug|Timolol Maleate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
1992198|NCT03323164|Drug|Brimonidine Tartrate|Instillation of one drop in each eye, one-time. Obtaining of OCT angiography scans after 2 hours of instillation.
1992199|NCT03323151|Drug|Ixazomib|Ixazomib 3 mg by mouth on days 1, 8 and 15 by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ixazomib 3 mg) or escalated (Ixazomib 4 mg) dependent on dose-limiting toxicities.
1992200|NCT03323151|Drug|Ixazomib|Ixazomib by mouth on days 1, 8 and 15 of a 28 day cycle until progression or unacceptable toxicity. Dosage as determined in Phase I portion of study.
1992201|NCT03323151|Drug|Ibrutinib|Ibrutinib 560 mg by mouth days 1-28 of a 28 day cycle. Dose may be de-escalated (Ibrutinib 420 mg) or escalated (Ibrutinib 560 mg) dependent on dose-limiting toxicities.
1992202|NCT03323151|Drug|Ibrutinib|Ibrutinib by mouth days 1-28 of a 28 day cycle until progression or unacceptable toxicity. Dosage as determined in Phase I portion of study.
1992203|NCT03323138|Procedure|Ex-PRESS and phacoemulsification|
1992204|NCT03323125|Other|Self-Assessment Questionnaire|Self-assessment questionnaire with sun exposition, sun protection, vitiligo severity and vitiligo outbreaks, will be suggested to patient during medical consultation.
1992205|NCT03323112|Biological|influenza vaccine|Vaccine for prevention of influenza. Vaccines change by influenza season.
1992206|NCT03323099|Behavioral|N-of-1|Participants in the N-of-1 arm will use the Eureka mobile application and AliveCor device to tracking their AF episode frequency and severity and execute at least one N-of-1 trial with the goal of identifying and better controlling their AF triggers.
1992207|NCT03323099|Behavioral|Data Tracking|Participants in the data tracking arm will use the Eureka app and AliveCor device to record daily AF frequency and severity and daily AliveCor readings for a period of 10 weeks.
1992208|NCT03323086|Behavioral|Brief Intervention (BI) with Technology Extender|One, 45-60 minute BI, followed by three months of access to technology extenders
1992209|NCT03323086|Other|Brochure|Brochures provided one time
1992211|NCT03323060|Device|Transanal endoscopic surgical procedure|Resection of tumors or lesions
1992216|NCT03323034|Drug|Irinotecan Hydrochloride|Given IV
1992217|NCT03323034|Drug|Pevonedistat|Given IV
1992218|NCT03323034|Other|Pharmacological Study|Ancillary studies
1992219|NCT03323034|Drug|Temozolomide|Given PO
1992220|NCT03323021|Biological|Dehydrated human amnion/chorion membrane|dehydrated human amnion/chorion membrane
1992221|NCT03323021|Other|Standard of Care|Standard of Care
1992223|NCT03322995|Other|Initial molecular profile-directed therapy|The identification of the molecular targets prior to treatment may facilitate the selection of the most effective chemotherapeutic agent, individualized for each patient's tumor.
1992224|NCT03322995|Drug|Chemotherapy|After the first restaging evaluation, further treatment may be based on treatment response. Patients who demonstrate a response may be maintained on the same chemotherapy for an additional two months. Patients who have stable disease may change to a different chemotherapy for an additional two months. If a patient was receiving gemcitabine-based chemotherapy, the alternative chemotherapy would be FOLFIRINOX. If a patient was receiving a 5-FU based chemotherapy, the alternative chemotherapy would be gemcitabine/nab-paclitaxel.
1992225|NCT03322995|Radiation|Chemoradiation|A second restaging assessment will be performed after a total of four months of chemotherapy, using imaging (CT scan) and biomarker evaluation (serum CA19-9). In the absence of local disease progression that is deemed inoperable or metastatic disease progression, patients will be treated with chemoradiation (50.4Gy in 28 fractions). If the profiling identifies that no chemotherapy will be beneficial, then, the patient will receive chemoradiation without induction chemotherapy.
1992226|NCT03322995|Procedure|Surgery|In the absence of local disease progression that is deemed inoperable or metastatic disease progression, patients will be offered surgical resection.
1992228|NCT03322969|Drug|Paclitaxel/DDP|receiving the modified chemotherapy
1992229|NCT03322969|Drug|XELOX/SOX|receiving the original chemotherapy
1992230|NCT03322956|Other|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).
The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
1992232|NCT03322917|Biological|PRP autologous|Autologous platelet rich plasma: 1 drop / 6 times a day during 6 weeks
1993064|NCT03249961|Device|Anodal TDCS|Excitatory stimulation is applied to the left motor cortex while participants perform a motor task in the right hand. During the motor task, participants use their right hand to pinch a force transducer that controls an on-screen cursor to navigate between a start position and a sequence of 5 other positions to the right.
1993065|NCT03249961|Device|Transcranial Magnetic Stimulation (TMS)|Participants will receive Transcranial Magnetic Stimulation (TMS) to allow research investigators to determine the location of the left motor cortex.
1993068|NCT03247725|Other|pain app|Pain Monitor app has been developed by a multidisciplinary pain expert panel, including physicians, psychologists, and nurses. Content has been validated in a previous study and usability has been shown to be excellent.
1993069|NCT03247725|Other|Treatment as usual (medical)|Patients will be offered the usual treatment for their pain, which is not changed by study participation
1993070|NCT03248882|Drug|Placebo|Placebo
1993071|NCT03248882|Drug|PF-05221304|PF-05221304, Experimental Drug
1993072|NCT03248804|Behavioral|Soy group|
1993073|NCT03248804|Behavioral|Non-soy group|
1993077|NCT03248570|Drug|Pembrolizumab|All subjects will receive pembrolizumab 200mg IV every 3 weeks until disease progression or unacceptable toxicity.
1993078|NCT03248570|Drug|Chemotherapy|At time of progression, all subjects will also have the option of receiving taxane-based chemotherapy followed by repeat pembrolizumab for those who have a clinical response to chemotherapy. Chemotherapy regimen will be at the discretion of the treating physician, and may consist of docetaxel or cabazitaxel with or without a platinum agent (e.g. carboplatin). A minimum of 4 cycles and a maximum of 8 cycles of chemotherapy will be given.
1993080|NCT03248141|Drug|Hemophilia B standard half-life|Benefix
1993081|NCT03248141|Drug|Hemophilia B extended half-life|Alprolix
1993082|NCT03248141|Drug|Hemophilia A standard half-life|Xyntha and other standard half-life agents
1993083|NCT03248141|Drug|Hemophilia A extended half-life|Eloctate and Adynovate
1993084|NCT03248128|Drug|FF/VI via ELLIPTA DPI|ELLIPTA DPI inhaler will contain two individual blister strips; the first strip will contain FF(50 or 100 mcg) and second strip will contain VI (25 mcg).
1993085|NCT03248128|Drug|FF via ELLIPTA DPI|ELLIPTA DPI inhaler will contain a single blister strip of FF (50 or 100 mcg).
1993086|NCT03247738|Drug|Cangrelor|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
1993087|NCT03247738|Other|Placebo|Patients will be randomly assigned 1:1 to receive either cangrelor or matching placebo. The bolus will be administered at the same time of a 180 mg crushed ticagrelor loading dose and infusion will be continued for 2 h.
1993088|NCT03246464|Device|Orthokeratology lenses|Rigid gas permeable contact lenses
1993089|NCT03246464|Device|Single-vision spectacles|Regular single vision spectacles
1993091|NCT03247244|Drug|Cannabis|THC 10%, CBD <0.5%
1993092|NCT03247244|Drug|Cannabis|THC 8.6%, CBD 8.6%
1993093|NCT03247244|Drug|Cannabis|THC 0.6%, CBD 14%
1993094|NCT03247205|Behavioral|HipERS|This is a graduated, functionally-based exercise intervention conducted in the participant's home. The intervention incorporates verbal encouragement and positive reinforcement, role modeling, assessment of and elimination of unpleasant sensations associated with an activity, and confidence building through activity repetition. The exercise component includes 1) strengthening exercises, 2) range of motion exercises, 3) balance training, 4) functional training, such as chair rising, ambulation training, and stair climbing, 5) transfer practice, 6) adjusting walking aides, and 7) adapting and modifying environment; with a focus on lower extremity tasks in all these areas.
1993095|NCT03246113|Drug|Cannabis|Cannabis cigarettes provided by NIDA that contain high levels of CBD (4.8%) and low levels of THC (3.23%). Patients will smoke one-half (1/2) to two (2) cannabis cigarettes prior to receiving chemoradiation.
1993096|NCT03246113|Drug|Temozolomide|Oral alkylating agent with demonstrated antitumor activity.
1993097|NCT03246113|Radiation|Radiation Therapy|standard fractionation radiotherapy of 60 Gy in 30 treatments with temozolomide.
1993098|NCT03246620|Drug|Olanzapine oro-dispersible 5Mg Tab|Patient allocated to this arm will be given 5 mg olanzapine oro-dispersible tablet and an encapsulated placebo tablet
1993099|NCT03246620|Drug|Haloperidol 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated haloperidol tablet and an oro-dispersible placebo tablet
1993100|NCT03246620|Drug|Diazepam 2Mg encapsulated Tab|Patient allocated to this arm will be given 2 mg encapsulated diazepam tablet and an oro-dispersible placebo tablet
1993101|NCT03246906|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo HCT
1993102|NCT03246906|Drug|Cyclophosphamide|Given IV
1993103|NCT03246906|Drug|Cyclosporine|Given PO
1993104|NCT03246906|Drug|Mycophenolate Mofetil|Given PO
1993105|NCT03246906|Drug|Sirolimus|Given PO
1993106|NCT03245593|Other|Shared-decision making process|Completion of the Ottawa Personal Decision Guide to help guide care with the support of online and printed material describing the therapeutic options available
1993107|NCT03245593|Other|standard care|Care of patients according to standard practice of managing patients with bipolar disorder
1993108|NCT03245827|Drug|Clomiphene|clomiphene capsule 25mg twice a week
1993109|NCT03245827|Drug|Placebo|placebo capsule 25mg twice a week
1980474|NCT03317288|Device|Dabir Air overlay|The Dabir Air overlay is a low profile alternating pressure overlay that is designed to place on top of mattress and operation room table.
1980475|NCT03318445|Drug|Rucaparib|All participants will take rucaparib by mouth
1980476|NCT03318445|Drug|Irinotecan|Patients in the dose escalation phase, and patients in the dose expansion phase who have received prior PARP inhibitor therapy, will be given irinotecan by in combination with rucaparib.
1980477|NCT03318419|Drug|Cladribine|5mg/㎡ d1-5
1980478|NCT03318419|Drug|G-CSF|300ug d0-14
1980479|NCT03318419|Drug|Cytarabine|10mg/㎡ q12h SC d1-14
1980480|NCT03318419|Drug|Pegaspargase|2500U/m2 im d1
1980481|NCT03318406|Device|Bronchoscopic thermal vapor ablation|Bronchoscopic vapor delivery to airway segment(s) targeted for treatment
1980482|NCT03318393|Drug|Bivalirudin|Continuous infusion
1980483|NCT03318393|Drug|Unfractionated heparin|Continuous infusion
1980484|NCT03318380|Procedure|Dynamic Contrast-Enhanced Ultrasound Imaging|Undergo CEUS
1980486|NCT03318354|Drug|Torrent's Olmesartan Medoxomil Tablets 40 mg|
1980487|NCT03318354|Drug|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
1980488|NCT03318341|Device|TheraBracelet & Stimulation|The device will apply wrist vibration at a subthreshold (imperceptible) level.
1980489|NCT03318341|Device|TheraBracelet & Sham|The device will apply no vibration.
1980491|NCT03318315|Drug|AS03|AS03 oil-in-water emulsion adjuvant.
1980492|NCT03318315|Biological|Inactivated influenza H7N9 vaccine|Monovalent 2017 H7N9 inactivated influenza vaccine
1980493|NCT03318315|Biological|Influenza Virus Quadrivalent Inactivated Vaccine|A seasonal quadrivalent inactivated influenza vaccine (IIV4), prepared from influenza viruses propagated in embryonated chicken eggs, protecting against 2 influenza A subtypes (H1N1 and H3N2) and 2 influenza B subtypes (B Yamata lineage and B Victoria lineage).
1980494|NCT03318302|Other|Survey|Survey of the adult population in Israel
1980495|NCT03318289|Behavioral|Ving Tsun|The VT training regimen is designed to improve reactive balance control, lower extremity muscle strength and balance confidence in the elderly. It comprises 9 VT sticking-hand drills that must be practised with a partner. Participants will be trained to respond rapidly to upper body perturbations and to maintain body balance. Those joined the VT training group will attend a one-hour supervised VT training session at an elderly community centre 2 times per week for 12 weeks.
1980498|NCT03318263|Diagnostic Test|next-generation sequencing (NGS)|ESR1, PI3KCA and AKT extensive exon sequencing will be performed using NGS (Miseq Illumina) at the Biopathology department, Institut de Cancérologie de Lorraine (ISO15189 certified lab). Samples taken at baseline (t0), at progression (tp) and 3 months before progression (tp-3) will be systematically analyzed. The intermediate samples will be stored and kept for additional studies. Follow up assessment will be performed according to prescriber's directions.
1980499|NCT03318250|Device|Dorsal Root Ganglion Stimulation|During the Dorsal Root Ganglion implant , SCS leads will be implanted using a TransGrade Dorsal Root Ganglion Technique. Antibiotic prophylaxis is performed prior to surgery for both trial and permanent implant phase. Using the technique lead placement will be performed through a small skin incision under local anaesthesia supplemented by conscious sedation. The leads will be placed along the DRG to obtain stimulation coverage over as much of the pain area as possible. After the leads have been implanted, x-ray or fluoroscopy images will be taken to record the final lead locations. Once intervention is completed participants will assigned either DRG-LF and Burst3D device programme.
1980500|NCT03318224|Other|none (observational study)|only assessments via questionnaires, no interventions
1980501|NCT03318211|Drug|Magnesium Sulfate|Intravenous ampules of MgSo4 was given to only to control group after delivery
1980502|NCT03318198|Other|Enhanged Attending Supervision|Attendings were randomized at the start of the study to begin in the enhanced supervision arm where they attended resident work rounds. They then crossed over to the control arm where they did not attend work rounds. The outcomes were assessed between the two periods during which the attending participated in the study; attending work rounds vs. not attending work rounds.
1980503|NCT03318198|Other|Standard of Care|Attendings participated directly in new patient rounds but did not see patients previously known to the team with the residents.
1980504|NCT03318185|Procedure|gasless single-port laparoscopic surgery|The single-port laparoscopic surgery is performed when the maneuvering room is provided by external suspension system.
1980505|NCT03318185|Procedure|conventional laparoscopic surgery|The multi-port laparoscopic surgery is performed when the belly is inflated with carbon dioxide to provide maneuvering room.
1980506|NCT03318172|Device|Spinal Cord Stimulator|Implantation of spinal cord stimulator in patients included in the study and divided in conventional and high density stimulation groups
1980507|NCT03318159|Drug|Posaconazole|"Dosing of posaconazole Posaconazole tablet 300 mg twice daily on day 1; Maintenance dose: 300 mg once daily on day 2 and thereafter. Treatment period: 4 weeks
*if posaconazole tablet intolerance: posaconazole suspension 200mg tid"
1980508|NCT03318146|Device|drug delivery system|The EXP-LP sustained released formula inserted into a small punctual plug. The plug is designed to release the drug over a period of up to 6 months in a slow release profile.
1980509|NCT03318146|Drug|XALATAN®|one drop in the affected eye(s) once daily in the evening
1980511|NCT03318120|Behavioral|Progressive Resistance Training|Participants will perform required resistance training exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
1980512|NCT03318120|Behavioral|Standardized Exercise Training|Participants will perform required stretching, balancing, and strengthening exercises at regular intervals for a period of up to 3 years. They will be tested at a baseline visit, then every 6 months for a total of at least 5 visits. During these visits, they will be asked to complete the following: questionnaires about quality of life and depression, tests to measure strength and motor function, tests to measure cognition, an orientation session to learn a precision griping task, structural and functional MRI scans of the brain, measurement of brain waves using a non-invasive technique called electroencephalography (EEG) and muscle activity using electromyography (EMG), measurement of brain function with TMS, pregnancy test (if applicable).
1980516|NCT03318081|Behavioral|cognitive function rehabilitation and bias modification|cognitive rehabilitation focus on the deficits executive funcitin and elevated cognitive bias
1980517|NCT03318068|Other|Yoga Intervention|The yoga intervention will consist of a combination of yoga postures, gentle stretches, breathing techniques and relaxation. The sessions will be delivered one-on-one and will be adapted to accommodate the patients each day.
1980520|NCT03318029|Dietary Supplement|Vitamin D supplementation|Vitamin D supplementation of 600 IU daily for 12 weeks
1980521|NCT03318029|Dietary Supplement|Placebo|rice flour with no vitamin D
1993116|NCT03244722|Dietary Supplement|Very-low calorie Diet (VLCD)|Structured, intensive dietary intervention using liquid meal replacements aimed at providing 800 kcal/day with a weight loss goal of 15% from baseline
1993117|NCT03244722|Other|Standard of care (SOC)|Standard referral to nutrition services and consultation with registered dietitian to determine appropriate caloric needs for healthy weight management
1993118|NCT03244553|Drug|Prucalopride|5 day treatment
1993119|NCT03244501|Other|Active tSMS|A cylindrical neodymium magnet is placed above the scalp.
1993120|NCT03244501|Other|Sham tSMS|A cylindrical piece of nonferrous metal (brass). This is not attracted to magnets, and is identical in weight and appearance to active magnets.
1993121|NCT03243461|Drug|Temozolomide + Valproic Acid|Valproic acid additionally to simultaneous radiochemotherapy with temozolomide
1993122|NCT03243461|Drug|Temozolomide + Chloroquine|Chloroquine additionally to simultaneous radiochemotherapy with temozolomide
1993123|NCT03242057|Other|NAVA|Infant will be extubated to NAVA, settings based per protocol
1980522|NCT03318016|Drug|Cyclophosphamide|"ATO at a fixed dose of 0.15 mg/kg/d IV followed by Cyclophosphamide on day 4 as a single IV dose along with Mesna (in subjects receiving >1000mg/m2 Cy) and hydration for a maximum of 6 doses in the following dose escalation schema:
Cohort -1 (3-6 subjects, if needed): Cyclophosphamide 500 mg/m2
Cohort 1 (3-6 subjects): Cyclophosphamide 1000 mg/m2
Cohort 2 (3-6 subjects): Cyclophosphamide 2000 mg/m2
Cohort 3 (3-6 subjects): Cyclophosphamide 3000 mg/m2
Cohort 4 (3 subjects): Cyclophosphamide 4000 mg/m2"
1980523|NCT03318003|Device|Auto-PAP|Women will be using the Auto-PAP device nightly from randomization to end of pregnancy
1980524|NCT03317990|Procedure|NeuroSAFE procedure|When the prostate is removed from within the patient as it is disconnected from its attachments. The specimen will then be painted (right=blue, left =black) by the operating surgeon and delivered expediently to the pathologist who will perform frozen section analysis of the painted areas. The pathologist will remove the pre-painted surface of the gland (which had been in contact with the neurovascular bundles) using a sharp blade. The tissue sample will be snap frozen and embedded in OCT. If a positive margin is reported by the pathologist, the entire neurovascular bundle on the affected side will be removed and sent for formal pathological examination.
1980527|NCT03317964|Other|Saliva sample|Extract sample of saliva only once
1980528|NCT03317951|Other|Novel integrated care concept (NICC)|Integrated care concept including, e.g., call center, guideline therapy, tablet and medical devices
1980529|NCT03317951|Other|Standard care|Guideline therapy according to the guidelines of the European Society of Cardiology (ESC).
1980530|NCT03317938|Device|Fecobionics|Fecobionics is a new device for studying defecation
1980532|NCT03317912|Drug|Lidocaïne 2%|Continuous infusion during per and postoperative periods
1980533|NCT03317912|Drug|Placebo (for Lidocaïne)|Continuous infusion during per and postoperative periods
1980534|NCT03317899|Procedure|Hematopoietic Cell Transplantation|Undergo auto HSCT
1980535|NCT03317899|Drug|Tbo-filgrastim|Given subcutaneously
1980537|NCT03317873|Dietary Supplement|Testmeal A|The tesmeal A is is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
1980538|NCT03317873|Dietary Supplement|Testmeal B|The tesmeal B is plain rice, with a seaweed sauce, fortified with labelled iron as stable iron isotope as ferrous sulfate
1980543|NCT03317834|Device|Navio ™ Robotic-assisted Surgical System|Total Knee Replacement
1980544|NCT03317808|Diagnostic Test|Different exercise|Testing the difference between Heavy slow resistance and convential exercise, based on SPADI
1980545|NCT03317795|Drug|Levonorgestrel IUS|LNG-IUS was FDA-approved for the treatment of heavy menstrual bleeding in 2009 and previously for contraception in 2000. The LNG-IUS is a T-shaped device with a polyethylene body containing a hormone reservoir, holding a total of 52 mg of levonorgestrel. LNG-IUS initially releases 20 micrograms of the progestin per day, which decreases to less than half that amount after 5 years of use. The levonorgestrel causes stromal pseudodecidualization, decreases endometrial thickness, and lowers uterine vascular density.
1980546|NCT03317795|Drug|Tranexamic Acid|Tranexamic Acid was FDA-approved for the treatment of heavy menstrual bleeding in 2009. Tranexamic Acid is a plasminogen-activator inhibitor that blocks fibrinolysis and reduces plasmin activity. A special formulation was designed for the treatment of heavy menstrual bleeding that reduces gastrointestinal side effects, brand name Lysteda which will be prescribed as 1300 mg to be taken three times per day for up to 5 days of the menstrual period.
1980547|NCT03317782|Device|NoL index|The NoL/PMD-200 (Medasense Biometrics Ltd, Ramat Yishai, Israel) is a multi-parameter index (0-100) that incorporates heart rate, heart rate variability (0.15-0.4 Hz band power), plethysmograph wave amplitude, skin conductance level, number of skin conductance fluctuations (NSCF), and their time derivatives9 using a non-linear regression technique. A higher index indicates higher nociception, and an index <20 indicates adequate analgesia.
1980552|NCT03317756|Other|Patient Educational Intervention|Patients will view 5-6 videos that will help them with pre-identified patient barriers to achieving RA low disease activity
1980553|NCT03317756|Other|Patient Control|Patients will receive an attention control
1980554|NCT03317743|Drug|NOV140101 (IDX1197HCl)|The dose levels will be escalated following a 3+3 dose escalation scheme.
1980556|NCT03317717|Drug|Meditoxin|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
1980557|NCT03317717|Drug|Botox|injection of MEDITOXIN into EDB muscle of one foot and BOTOX into the same muscle of contralateral foot in equal doses
1980558|NCT03317704|Behavioral|Speed endurance training|Speed endurance training
1980559|NCT03317691|Diagnostic Test|electrocardiogram diagnosed by artificial intelligence|According to coronary angiogram results, the accuracy of STEMI patients' electrocardiogram diagnosis by artificial intelligence was evaluated.
1980560|NCT03317678|Dietary Supplement|BioKefir|BKP BioKefir (Lifeway Foods) is a lactose-free fermented milk product containing 12 different bacteria provided in a drink.
1980561|NCT03317678|Dietary Supplement|Non-fermented milk|A non-fermented milk drink.
1980562|NCT03317665|Device|Mesh for hernia repair|Permacol, Parietex, Progrip, Strattice Perforated, and Surgimend.
1980566|NCT03317639|Behavioral|Behaviour Change Wheel model guided intervention|Interventions are developed on a psychological model, the Behaviour Change Wheel (BCW) .The fundamental of BCW consists of three essential elements: capability, motivation, and opportunity. Improving individual's capability, providing motivation, and increasing opportunities are goals of behaviour change intervention. To achieve the goals, 9 intervention components have been proposed in the BCW framework, and 6 components will be used in current study.
1980567|NCT03317626|Diagnostic Test|Cold Stimulus (ice) Test|Standard of care epidural will be inserted. The study procedure will be to use a cold stimulus (ice) to assess the subjects for hypesthesia the dermatomes of the lower abdomen at 15 minutes and if necessary at 30 minutes after the epidural is inserted. Hypesthesia to cold will be taken a sign of successful lumbar epidural block.
1980568|NCT03317613|Drug|Qutenza|Patients suffering from neuropathic pain will receive patch of capsaicin (qutenza) on the painful zones. Three months after the first application, patients will be allowed to receive another patch if necessary. They will be able to receive one every three months. They will be followed in the study during one year after the first patch application.
1980569|NCT03317600|Device|Lidocaine|Intervention is a nerve block with Lidocaine 2% with Adrenaline.
1980570|NCT03317600|Drug|Placebo|"Intervention is a placebo nerve block with isotonic saline"
1980571|NCT03317587|Behavioral|INSPIRE|Eight week program of weekly group sessions with homework assignments addressing beauty ideals, establishing a healthy relationship with food and exercise, and tolerating and managing uncomfortable emotions. Participants will complete questionnaires are separate time points (one week before the program, one week after the program, and 1 month after the program) to evaluate the impact of the program on various behavioral and psychological outcomes.
1980572|NCT03317574|Drug|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
1980573|NCT03317574|Drug|botulinum toxin type A|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas
1980574|NCT03317548|Diagnostic Test|progesterone|according progesterone level to decide fresh or frozen embryo transfer
1980575|NCT03317548|Diagnostic Test|day 3 embryo|according day 3 embryo to decide fresh or frozen embryo transfer
1980580|NCT03317509|Procedure|repetitive transcranial magnetic (rTMS)|Real rTMS high frequency stimulation (25 HZ), with intensity of 80% of resting motor threshold detected from the hand motor area, with total 2000 pulses for each hemisphere for 10 consecutive sessions totally over period of 10 days. Sham rTMS is the same pulse as the first group but with the coil placed perpendicular to the scalp.
1980587|NCT03317457|Biological|Durvalumab and Tremelimumab|immun checkpoint inhibitor
1980588|NCT03317457|Drug|Doxorubicin|Anthracycline
1980589|NCT03317444|Drug|TRC101|Oral suspension
1980590|NCT03317444|Drug|Placebo|Oral suspension
1980592|NCT03317418|Other|ATR-FTIR Spectrophotometry|Spectrometry imaging
1980593|NCT03317405|Other|Laboratory Biomarker Analysis|Correlative studies
1980594|NCT03317405|Other|Pharmacological Study|Correlative studies
1980595|NCT03317405|Other|Placebo|Apply to the skin
1980596|NCT03317405|Other|Questionnaire Administration|Ancillary studies
1980597|NCT03317405|Drug|Z-Endoxifen Hydrochloride|Apply to the skin
1980598|NCT03317392|Other|Laboratory Biomarker Analysis|Correlative studies
1980599|NCT03317392|Drug|Olaparib|Given PO
1980600|NCT03317392|Radiation|Radium Ra 223 Dichloride|Given IV
1980601|NCT03317379|Behavioral|Peer mentorship|Weekly meetings with a recovered peer mentor once per week. Dyads discuss eating disorder symptoms and how to overcome them.
1980602|NCT03317379|Behavioral|Social support mentorship|Weekly meetings with a social support mentor who has not personally struggled with an eating disorder, once per week. Dyads engage in activities unrelated to the eating disorder (e.g., a movie, a community event, volunteer work).
1980603|NCT03317379|Behavioral|Recovery Record use with mentor|Recovery Record is a smart phone or web-based application designed to provide recovery support to eating disorder patients. Includes a number of features aimed to promote recovery, such as a meal tracking, prompts for completing meals/snacks, tracking for additional symptoms such as stress and mood, motivational messages, information about coping strategies, and capacity to share logged data with clinicians and mentors.
1980604|NCT03317366|Drug|ARQ 092|Open-label expanded access for ARQ 092 capsules
1980608|NCT03317340|Other|Background Sounds|Background music or sound of running water
1980609|NCT03317327|Drug|Nivolumab|Nivolumab is a humanized antibody used in cancer immunotherapy.
1980610|NCT03317327|Radiation|Radiotherapy (RT)|Radiotherapy (RT) will be given to a total dose of 60 Gy (1,5 Gy fractions twice daily) for a total period of 4 weeks
1980611|NCT03317314|Diagnostic Test|Lung Biopsy during LVAD Implantation|Lung Biopsy during LVAD Implantation
1980612|NCT03317301|Drug|HL151|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (1Tab)+Talion Tab (Placebo)(1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (Placebo)(1Tab)
1980613|NCT03317301|Drug|Talion Tab|2 times a day(Day, Night), 2 weeks of treatment / Day: HL151 (Placebo)(1Tab)+Talion Tab (1Tab), Night: HL151 (Placebo)(1Tab)+Talion Tab (1Tab)
1980614|NCT03317067|Drug|Dexmedetomidine|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
1980615|NCT03317067|Other|Placebo|The 4D trial is an investigator-initiated, prospective, multicenter, randomized, double-blinded, two-arm trial, randomizing 300 non-intubated ICU patients with diagnosis of agitated delirium to receive dexmedetomidine or placebo as a cure
1980616|NCT03317275|Device|18F-Fluoride-PET/MRI|facet joint injection guided by the anatomical localization of causative structures by PET/MRI compared to standard assessment techniques.
1980617|NCT03317275|Procedure|facet injection|facet joint local anesthetic and corticosteroid injection according to the 18F-Fluoride-PET/MRI result or based on current standard clinical practise (MRI and clinical correlation) respectively
1980618|NCT03317275|Other|pain assessment by VAS|VAS questionnaire immediately before the facet joint injection, at 15 minutes, 1 day, 1 week and 1 month after the injection, as performed routinely in our institution.
1980619|NCT03317249|Diagnostic Test|ECG|12-lead electrocardiogram
1980620|NCT03317249|Diagnostic Test|heart rate monitor|24-hour heart rate monitor used to calculate mean heart rate and heart rate variability
1980621|NCT03317249|Diagnostic Test|Autonomic Nervous System (ANS) Activity|"Heart Rate Variability (HRV) and Baroreflex sensitivity (BRS):
Resting and exercise HRV and BRS calculated from ECG, Dundee Step test and blood pressure measurements."
1980622|NCT03317249|Diagnostic Test|Haemodynamic variables|Cardiac output (CO), stroke volume (SV) and systematic vascular resistance (SVR) will be assessed and calculated using a non-invasive, inert gas re-breathing technique whereby expired gases will be sampled and analysed alongside and blood pressure measurements.
1980623|NCT03317249|Other|Echocardiogram|optional (for non-IST participants only)
1980624|NCT03317236|Drug|Quetiapine|A fixed 50 mg exteded release formulation.
1980625|NCT03317223|Drug|CJ-12420/Clarithromycin/Amoxicillin|CJ-12420 or Lansoprazole +Clarithromycin/Amoxicillin will be administrated twice a day, for 7 days
1993124|NCT03242057|Other|NIPPV|Infant will be extubated to NIPPV, settings detailed in protocol
1993125|NCT03243227|Other|Neurodynamic techniques|4 sessions of Neurodynamics treatment will be provided by and experienced physiotherapist. It will include manual therapy, median nerve gliding exercise, median nerve tension exercise. patients will continue the exercises as home exercise program during and after the treatment period.
1993126|NCT03243227|Other|Exercise therapy|AROM exercise stretching exercise strengthening exercise 4 sessions
1993127|NCT03242954|Other|Parental Permission Required|Consent requirement where the participant is required to obtain their parent's permission to participate in the trial.
1993128|NCT03242954|Other|Adult permission required|Consent requirement where the participant is required to obtain an adult's permission to participate in the trial.
1993129|NCT03242954|Other|Autonomous consent|Consent requirement where the participant is not required to get anyone's permission to participate in the trial.
1980626|NCT03317210|Drug|iron sucrose (200 mg VENOFER®)|According to hemoglobin level at the start of the therapy, the women were either treated with intravenous iron and rhEPO or with intravenous iron only twice weekly.
1980627|NCT03317210|Drug|recombinant human erythropoietin (10,000 U EPREX®)|According to hemoglobin level at the start of the therapy, the women were treated with rhEPO twice weekly.
1980628|NCT03317197|Drug|Control Group|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) only
1980629|NCT03317197|Drug|Experimental Group 1|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle)
1980630|NCT03317197|Drug|Experimental Group 2|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
1980631|NCT03317197|Drug|Experimental Group 3|Using Epinephrine(1 mg/cardiopulmonary resuscitation(CPR) cycle), Vasopressin(20 international unit(IU)/cardiopulmonary resuscitation(CPR) cycle) and Steroid(Methylprednisolone, 40 mg at first cycle)
1980632|NCT03317184|Procedure|Periumbilical incision|A periumbilical incision is made at the abdominal midline for hand-assisted laparoscopic donor nephrectomy.
1980633|NCT03317184|Procedure|Pfannenstiel incision|Pfannenstiel incision is made as a slightly curved horizontal line just above the pubic symphysis for hand-assisted laparoscopic donor nephrectomy.
1980639|NCT03317145|Device|Neuromuscular electrostimulation (NMES) device|A mobile peroneal nerve stimulator
1980640|NCT03317145|Device|Intermittent pneumatic compression (IPC) device|A foot pump or foot compression device
1980641|NCT03317132|Behavioral|IPS|One year of IPS Support
1980645|NCT03317093|Drug|Ceftobiprole Medocaril|1 single intravenous dose of 500 mg of Mabelio (Ceftobiprole Medocaril) perfused for 2 hours at D0
1980646|NCT03317093|Other|Blood samples and cerebrospinal fluid|Before and immediately before the end of the perfusion and then at 0.5h, 1h, 3h, 6h, 12h and 24h.
1980648|NCT03317041|Other|Capacitive-resistive electric transfer (Tecar) therapy|The Tecar treatment group will receive 45 minutes of Tecar therapy treatment. Subjects will lay down with the face down and two metallic plaques situated under each quadriceps muscle all over all the treatment. The treatment will start with the automatic capacitive energy transfer for 10-min where the capacitive plaque is situated on the sole of each foot with an elastic band. After that, the capacitive plaque will be pulled out. Then, the resistive electrode will be moved longitudinally through different muscles with massage lotion during 15-min per each lower extremity. The treatment will conclude with the automatic capacitive energy transfer for 10-min and the capacitive plaque situated on the sole of each foot with an elastic band.
1980650|NCT03317015|Drug|triamcinolone XRG5029|"Pharmaceutical form: spray solution
Route of administration: nasal"
1980651|NCT03317015|Drug|fluticasone|"Pharmaceutical form: spray solution
Route of administration: nasal"
1980655|NCT03316976|Drug|Dexlansoprazole|Dexlansoprazole delayed-release capsule.
1980656|NCT03316963|Drug|Neostigmine Methylsulfate|After the patient demonstrates snoring and obstruction collapse, the patient will receive the study medication (neostigmine methylsulfate 1mg/mL) into the soft palate with co-administration of intravenous glycopyrrolate 0.2mg. At each of 5 injection sites on the soft palate , 0.5 mL (0.5mg) of neostigmine methylsulfate will be administered, yielding a total of 2.5mg (2.5mL) of neostigmine methylsulfate. The medication will be administered using a 5mL syringe on a 27 gauge needle. Following administration of neostigmine, the patient will be observed for an additional 4 minutes to examine both vibration and sound emanating from the soft palate. The anticipated time under sedation will be 14 minutes.
1980660|NCT03316924|Procedure|Foreskin resection|During the pediatric surgery consultation, the doctor will decide between Foreskin resection, orchidopexie or inguinal hernia repair.
1980661|NCT03315234|Genetic|SNPs associated with CAD|Genotyping will be carried out by Real-Time PCR
1980664|NCT03316794|Drug|SC-005|intravenous
1980665|NCT03316547|Other|Sensory-Based Intervention|
1980673|NCT03315169|Other|External dressing|Application of external dressing whilst perianal abscess cavity heals.
1980674|NCT03315169|Other|Packing of perianal abscess cavity|Internal packing of perianal abscess cavity - standard treatment.
1980675|NCT03315923|Drug|Rituximab|Patients will receive 1 g of rituximab (two vials of RediTux 500 mg/50 ml) in 500 cc normal saline serum through intravenous infusion and this will be repeated two weeks later. This cycle will be repeated every 6 months. Along with rituximab, patients will receive 100 mg of methylprednisolone, 10 mg of chlorpheniramine, and 500 mg of acetaminophen. Before each cycle, patients will be evaluated regarding complete blood count (CBC)-diff, blood urea nitrogen (BUN), Cr, and liver function tests.
1980676|NCT03315923|Drug|Glatiramer Acetate|Patients will receive 20 mg of glatiramer acetate on a daily basis through subcutaneous injection. It can be increased to 40 mg daily based on the neurologist decision. Patients will undergo electrocardiography before starting the treatment to find any abnormal finding. Also, lab tests will be checked for them prior to the treatment, including CBC-diff, BUN, Cr, and liver function tests.
1980677|NCT03315897|Drug|Erythropoietin|40.000 IU/ml Erythropoietin (Epoetin alpha; Eprex) diluted with 100 ml saline (0.9% NaCl) is administered 12 times as intravenous infusions over 15 minutes.
1980678|NCT03315897|Drug|Saline|1 ml NaCl is administered 4 times as intravenous infusions over 15 minutes
1980685|NCT03315520|Drug|Bendamustine|"BeEAC conditioning regimen:
bendamustine 200 mg/м2 D-6 - D-5; cytarabine 400 mg/м2 D-4 - D-1; etoposide 400 mg/м2 D-4 - D-1; cyclophosphamide 140 mg/м2 totally, divided in 4 days (D-4 - D-1)"
1980692|NCT03315325|Biological|Human kisspeptin-10 (metastin 45-54)|Kisspeptin-10 (metastin 45-54, Calbiochem, Darmstadt, Germany) is a potent HPG-axis stimulator and control reproduction.
1980694|NCT03315247|Behavioral|Telephone-Based CBT|The Tele-CBT sessions focus on introducing the cognitive behavioural model of overeating and obesity, scheduling healthy meals and snacks at regular time intervals and recording consumption using food records, scheduling pleasurable alternative activities to overeating, identifying and planning for difficult eating scenarios, and reducing vulnerability to overeating by solving problems and challenging negative thoughts. Participants are expected to complete CBT homework between sessions, such as completing food records, engaging in pleasurable and self-care activities, and completing a variety of worksheets.
1980695|NCT03316092|Diagnostic Test|optical coherence tomography|screening and monitoring all patients who are to use or have been using oral Hydroxychloroquine
1980696|NCT03315013|Procedure|SLATE II|The SLATE II algorithm is a series of questions and procedures that allow a study clinician to determine if antiretroviral therapy for HIV can be started immediately (same-day) or if additional care or services are needed before ART initiation.
1980697|NCT03314740|Drug|Paclitaxel|Comparator active compound
1980698|NCT03314740|Drug|Cediranib|Experimental compound
1980699|NCT03314740|Drug|Olaparib|Experimental compound
1980707|NCT03313830|Dietary Supplement|Whey Protein Hydrolysate (WPH) or Intact Whey Protein (WHEY) Ingestion|Subjects will ingest WPH or WHEY mixture on two separate study days. The anabolic response to the nutrients will be examined.
1980720|NCT03313453|Device|PuriCare (HEPA Air Cleaner)|The active comparator group is a group that uses machines that have the same functions as those on the market. In intervention group, two air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The air cleaner will be operated continuously for 6 weeks. Inside the air cleaner, a device for measuring the quality of the indoor air is built in. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
1980721|NCT03313453|Device|Mock device of PuriCare|The Control group operates the air-cleaner with the same appearance as the experiment group. However, all the filters including HEPA filter will not be inserted in this group (mockup devices). Two mockup air-cleaners will be activated, one in the living room (covers 91 m2) and the other in the bedroom (covers 58 m2). The mockup devices will be operated continuously for 6 weeks. Same as active comparator group, a device for measuring the quality of the indoor air is built in the mockup air cleaner. It will be used to compare indoor air quality before and after air cleaner operation. In order to maintain the double-blind setting, a label for 'prohibition of opening' will be attached to the joint of the outer case, and a sticker to cover the air quality measurement display part built in the air cleaner itself will be attached.
1980726|NCT03312972|Radiation|HDR Brachytherapy|HDR Brachytherapy implant, deliver 1 fraction, Up to 30 Gray (Gy) to target lesion
1980729|NCT03311256|Diagnostic Test|Tissue Transit Time|Determination of Tissue Transit Time as a prognostic and diagnostic factor
1980730|NCT03312452|Device|Hospira plum pump|The Hospira plum pump enables the clinician to program a specific volume of intravenous fluid and define a period of time over which to administer this fluid.
1980731|NCT03312452|Device|Gravity drip device|Study subjects assigned to this group will receive intravenous fluid via a gravity drip device during their surgery.
1980736|NCT03312283|Drug|lucentis|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
1980737|NCT03312283|Drug|QL1205|intravitreal injection of 0.5 mg (0.05 ml), Q4W, continuous administration for 3 times (D1, D29, D57)
1980739|NCT03311646|Other|Normal nicotine content cigarettes|Participants will smoke research cigarettes that have a normal nicotine content
1980740|NCT03311646|Other|Lower nicotine content cigarettes|Participants will smoke research cigarettes that have a lower nicotine content
1980758|NCT03309228|Other|individual interviews|Semi-structured individual interviews with patients, relatives and general practitioners.
1996078|NCT02572323|Drug|Tesamorelin|Tesamorelin is an injectable medication already approved by the U.S. FDA to treat abdominal fat accumulation in HIV
1996080|NCT02571075|Other|Auricular acupuncture|The ear will be cleaned with alcohol prior to insertion of the needles. Five sterile, single-use, gold needles will be placed in each ear according to the figure below. The needles penetrate about a millimeter (or 4/100ths of an inch) into the skin.
1996081|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
1996082|NCT02569957|Drug|Topotecan Hydrochloride|Given IV
1996083|NCT02569957|Drug|Acetylcysteine|Given IV and PO
1996084|NCT02568943|Drug|Panobinostat|Panobinostat (PAN [LBH589]) is an orally administered pan-deacetylase inhibitor (DACi) belonging to a structurally novel class of compounds deregulating cell proliferation and survival mechanisms of cancer cells.
1980759|NCT03308435|Diagnostic Test|Geriatric assessment|the assessment includes functional tests (hand grip strength, SPPB (Short Physical Performance Battery)) and questionaires Euro-QoL 5D, LUTS, GDS, ADL, iADL, dietary recall).
1980760|NCT03308435|Diagnostic Test|Psychiatric assessment|Psychiatric assessments includes HAMD-17 as well as Beck depression inventory, hospital anxiety and depression scale, SF36, PTSS-10
1980761|NCT03308435|Diagnostic Test|Inflammatory assessment|analysis will include arginase, ADMA, SDMA, homoarginine, aminoacids + metabolites, tryptophan, kynurenine, kynurenine acid, cortisol, ACTH, Metanephrine, myeloperoxidase,
1980762|NCT03308435|Diagnostic Test|Cardiological assessment|ECG, echocardiography
1980784|NCT03306160|Other|48-hour blood pressure ambulatory monitoring|at first-time dialysis after enrollment, each patient will receive brachial and central blood pressure monitoring for 48 hours using a validate and commercially available device Mobil-O-Graph (IEM, Germany).
1980799|NCT03301220|Drug|Daratumumab SC|Participants will receive daratumumab 1800 mg by SC injection once weekly for Cycles 1 and 2 (Days 1, 8, 15, and 22 of each week), every 2 weeks for Cycle 3 to Cycle 6 (Days 1 and 15), and thereafter every 4 weeks (Day 1) up to 36 months or until confirmed disease progression, unacceptable toxicity or withdrawal from the study treatment, study or study completion. Each cycle is 28 days in duration.
1980802|NCT03301298|Drug|SXC-2023 or Placebo|Oral capsule
1980803|NCT03300960|Drug|Provera 10 mg.|One 10 mg tablet of MPA (Medroxyprogesterone acetate) is administered every 24 hours from the onset of Controlled Ovarian Stimulation (COS), until the day of triggering.
1980804|NCT03300960|Drug|Ganirelix (GnRH antagonist)|One ampoule of Ganirelix (GnRH antagonist) a day once diameter of follicles are 14 mm diameter on average until triggering.
1980828|NCT03296696|Drug|AMG 596|Drug
1980844|NCT03292432|Behavioral|TERA Intervention|"A sequence of adherence support strategies implemented at care visits and as needed on the basis of EDM data. Components include: (1) remote education/preparation with an adherence coach conducted with vsee software (video conferencing) at site at baseline, week 4 and week 12; (2) one-way text alert at dose time when bottle has not yet been opened for that dosing window (users can disable this on request); (3) missed dose two-way outreach text asking What's the plan? which gets sent to both the participant's phone and a study phone; and (4) implementation of the coach-outreach (phone, text, remote counseling) triggered by missed doses or as a check-in to inquire about the well-being of the youth (once per week when no other contact with coach occurred the week prior)."
1980845|NCT03292432|Behavioral|Standard of Care|Cell-phone reminders, patient-education, adherence planning (medication management), and checking-in on adherence at clinical care visits, as well as Viral load (VL) monitoring with patient feedback on VL, are used at sites. Less common, but available as a general service at some sites, on several websites, and at many pharmacies, youth may also receive text messages at dose times, for appointment reminders, and for refill reminders.
1980882|NCT03283826|Drug|ATA188|Allogeneic EBV-directed T-cell therapy
1980906|NCT03282227|Drug|M207 Microneedle System|M207 Microneedle System 3.8 mg
1980907|NCT03282357|Device|Radiesse injectable implant (dermal filler)|Subdermal injection.
1980908|NCT03282357|Device|Restylane injectable implant (dermal filler)|Subdermal injection
1980911|NCT03280615|Dietary Supplement|Omega 3 fatty acids|Omega 3 fatty acids will be provided in a dose of 3.7 g/day, that should be enough to rise red blood cell levels of eicosapentanoic and docosahexanoic acids
1980912|NCT03280615|Dietary Supplement|Corn oil|Corn oil will be the placebo comparator for omega 3 fatty acids supplement
1980930|NCT03277105|Drug|Dara SC|Participants will receive a fixed dose of Dara SC as 1800 mg daratumumab with rHuPH20 2000 U/mL, once weekly in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
1980931|NCT03277105|Drug|Dara IV|Participants will receive Dara IV 16 mg/kg once weekly at in Cycle 1 and 2, every 2 weeks in Cycle 3 to 6, every 4 weeks in Cycle 7 and thereafter until disease progression, unacceptable toxicity or the end of study.
1980935|NCT03277040|Other|CSA membership|Bi-weekly fresh food delivery
1980940|NCT03276286|Device|Nativis Voyager|Nativis Voyager treatment combined with standard of care radiotherapy and temozolomide
1980946|NCT03274453|Drug|Ketamine|0.12 mg/kg/hr of ketamine post surgery
1980947|NCT03274453|Drug|Saline|0.12 mg/kg/hr of saline post surgery
1980950|NCT03274258|Drug|Nivolumab|"During Part A, Nivolumab 3 mg/kg given by vein over about 30 minutes each on Day 1 of Cycles 1-4.
During Part B, Nivolumab 480 mg by vein every 4 weeks for up to 2 years, or until disease progression or unacceptable treatment-related toxicity."
1980951|NCT03274258|Drug|Ipilimumab|During Part A, Ipilimumab 1 mg/kg given by vein over about 30 minutes each on Day 1 of Cycles 1-4.
1980956|NCT03272009|Drug|EYP001a|Capsules administered orally. Number of morning and evening capsules depending on treatment arm
1980957|NCT03272009|Drug|Placebo|Placebo capsules for oral administration, identical in appearance to the EYP001a capsules
1980958|NCT03272009|Drug|Entecavir|Tablets administered orally
1980959|NCT03272009|Drug|peg-interferon alfa-2a|Ready-to-Use pre-filled syringes for subcutaneous injection
1980987|NCT03262844|Behavioral|Conservative treatment|The conservative treatment group will be given diet and nursing guidance, then the drug treatment or physiotherapy will be given according to the conditions of patients. Patients with bladder dysfunction will be guided to perform routine intermittent catheterization with help of their parents.
1980988|NCT03262844|Procedure|Capsule surgery|"In the multiple segments of the spine, articular facet joint and intervertebral disc will be resected to achieve the effect of decompression.
Specific surgical segments, osteotomy range, decompression degree of each patient needs to be designed individually."
1981017|NCT03256474|Other|Multimodal Therapy|Drugs, external applications like chest wraps, inhalations
1993142|NCT03241563|Drug|Sodium Deoxycholate|
1993143|NCT03241563|Drug|Triamcinolone|Triamcinolone 40mg/ml
1993144|NCT03241485|Drug|Intrathecal morphine|6micrograms/kilogram of intrathecal morphine administered in the spinal space.
1993145|NCT03241485|Drug|Placebo|Saline intrathecal given in the same manner as the intervention groups.
1993146|NCT03241134|Other|Dry needling|Dry needling (DN) is a myofascial treatment technique, in which a thin, solid filiform needle is inserted directly into the MTrP. During dry needling, local twitch responses (LTR) can be elicited. These are involuntary contractions of muscle fibers, leading to muscle relaxation, an increase in blood flow,recovery of the muscle metabolism and thus a reduction of pain and stiffness.
1993147|NCT03241134|Other|Sham needling|During sham needling, a solid, filiform needle is inserted in the skin surface at the trigger point location, without penetrating the fascia and muscle tissue.
1993148|NCT03241121|Behavioral|Time restricted feeding|To eat only during a self-selected window of 12 hours, with no advice on nutrition quality, quantity or caloric intake
1993149|NCT03241121|Behavioral|Regular dietary advices|Regular dietary advices by a trained dietitian or research nurse according to current nutrition guidelines
1993150|NCT03241121|Device|Eating patterns|Data collection on eating patterns via the smartphone app
1993152|NCT03241056|Behavioral|CBT for Maladaptive Beliefs about Memory|The novel intervention is a manualized 2-session cognitive behavioural therapy. Agenda elements, including psycho-education, discussion prompts, and homework exercises are standardized across participants. In session 1, participants are taught about the cognitive theory of checking, the research support behind this theory, and how it may apply to their own checking behavior. A homework exercise is introduced and practiced to test out this theory. In session 2, the homework results are reviewed. Further education is shared on the nature of memory and the relationship to checking, and a discussion regarding how this applies to the participant's checking then takes place. A second homework exercise is introduced to test this theory.
1993153|NCT03241056|Other|Treatment as Usual|Treatment as Usual (TAU) during patients' time on our waitlist in our clinic will depend on at what point they have been recruited. It may consist of a 2-session group psychoeducational intervention on anxiety, any medications prescribed by their referring physicians, and/or independent therapy/counseling they may be seeking on the side. TAU for community participants will include any treatments they are currently seeking. Information about participation in such interventions will be collected during the course of the study (at each assessment visit) in order to accurately characterize participants' TAU in the current study.
1993154|NCT03241030|Drug|Sucralfate|Will receive 20mg/kg/dose up to 1 gram.
1993155|NCT03241030|Other|Placebo|Will received placebo solution of similar quantity to that of the weight based dose of sucralfate.
1993156|NCT03241030|Drug|Acetaminophen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
1993157|NCT03241030|Drug|Ibuprofen|All patients will receive analgesia, either acetaminophen 15mg/kg or ibuprofen 10mg/kg depending on medication administration prior to arrival in the Emergency Department and at the discretion of the treating physician, in addition to either the experimental drug or placebo.
1993158|NCT03240965|Diagnostic Test|FEES (flexible endoscopic evaluation of swallowing)|Endoscopical swallowing study in stroke patients only
1993159|NCT03240965|Other|Sensitivity threshold|Determining sensitivity threshold using a pudendal electrode
1993160|NCT03240965|Diagnostic Test|Taste-/smell-test|Taste-/smell-test
1993161|NCT03240965|Diagnostic Test|Neuropsychological testing|Neuropsychological testing for neglect, agnosia
1993632|NCT03163095|Device|Open Abdomen Management with AbThera dressing|"The abdominal fascia will not be closed, but a temporally abdominal closure (TAC) dressing, such as AbThera dressing, will be placed to protect the viscera with active Negative Pressure Peritoneal Therapy.
The time that the TAC dressing will be changed will be left to the discretion of the attending surgeon, but practice guidelines mandate either formal abdominal closure or dressing change at 24-72 hours from placement.
Blood samples and peritoneal fluid will be drawn up to 72 hours after enrollment."
1981023|NCT03255655|Device|Intense Therapeutic Ultrasound Treatment - ITU|
1981024|NCT03255616|Other|mechanical stimulation|The main intervention consists of mechanical non-painful low- and high pressure stimuli to the back of healthy subjects and CLBP patients
1981025|NCT03255616|Drug|Topical Anesthetic|In order to disentangle the contribution of cutaneous afferents to brain activity, a topical anesthetic will be applied to block skin areas that are co-stimulated by the mechanical stimulation. For this purpose, half of the participants in each group receive a cutaneous topical anesthetic (EMLA®, Astra Zeneca: 2.5 % lidocaine/2.5 % prilocaine) in form of a cream applied on the target spinal segments
1981026|NCT03255616|Other|Hydrating cream|As a control to the topical anesthetic, half of the subjects receive a hydrating cream
1981027|NCT03255603|Other|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
1981028|NCT03255603|Other|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
1981029|NCT03255603|Other|Resistant Starch Type 4 Supplementation|Ten participants will supplement their normal dietary intake with RS4 daily for four consecutive weeks, with each week the amount of RS4 provided being increased (10 g, 20 g, 35 g and 50 g/day).
1981030|NCT03255603|Other|Digestible Starch Supplementation|Ten participants will supplement their normal dietary intake with digestible starch daily for four consecutive weeks, with each week the amount of starch provided being increased.
1981031|NCT03255200|Device|ReActiv8 Implantable Stimulation System|Implantable electrical stimulation system.
1981032|NCT03255096|Drug|RO6870810|RO6870810 subcutaneously (SC) at dose of 0.30, 0.45, or 0.65 milligram per kilogram (mg/kg) on Days 1-14 of 21-day cycles.
1981033|NCT03255096|Drug|Venetoclax|Venetoclax tablets orally at dose of 400 mg once daily (QD) continuously for 21 days.
1981034|NCT03255096|Drug|Rituximab|Rituximab intravenously (IV) at dose of 375 mg/m^2 weekly during the first 21-day cycle (C1) and on day 1 of each cycle thereafter.
1996097|NCT02567422|Drug|ATR Kinase Inhibitor VX-970|Given IV
1996098|NCT02567422|Drug|Cisplatin|Given IV
1996099|NCT02567422|Other|Laboratory Biomarker Analysis|Correlative studies
1996100|NCT02567422|Other|Pharmacological Study|Correlative studies
1996101|NCT02567422|Radiation|Radiation Therapy|Undergo radiation therapy
1996102|NCT02567409|Drug|ATR Kinase Inhibitor VX-970|Given IV
1996103|NCT02567409|Drug|Cisplatin|Given IV
1996104|NCT02567409|Drug|Gemcitabine Hydrochloride|Given IV
1996105|NCT02567409|Other|Laboratory Biomarker Analysis|Correlative studies
1996106|NCT02567409|Other|Pharmacological Study|Correlative studies
1996107|NCT02566304|Drug|Fludarabine|Given IV
1996108|NCT02566304|Radiation|Total-Body Irradiation|Undergo TBI
1996109|NCT02566304|Biological|T Cell-Depleted Donor Lymphocyte Infusion|Undergo DLI
1996110|NCT02566304|Drug|Cyclophosphamide|Given IV
1996111|NCT02566304|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
1996112|NCT02566304|Procedure|Allogeneic Hematopoietic Stem Cell Transplantation|Undergo PBSC transplant
1996113|NCT02566304|Drug|Tacrolimus|Given PO
1996114|NCT02566304|Drug|Mycophenolate mofetil|Given IV
1996115|NCT02567253|Procedure|Cytoreductive surgery|Complete or nearly complete (CC-0 or CC-1) macroscopic cytoreduction at the time of surgery of peritoneal carcinomatosis from ovarian cancer
1996116|NCT02567253|Drug|IPEC with Cisplatin (75mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (75mg/m²) , during 90min
1996117|NCT02567253|Drug|IPEC with Cisplatin (100mg/m²)|Intraperitoneal normotherm (37°C) administration of Cisplatin (100mg/m²), during 90min
1996118|NCT02567253|Drug|Hypertherm IntraPEritoneal Chemotherapy with Cisplatin (75mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (75mg/m²), during 90min
1996119|NCT02567253|Drug|HIPEC with Cisplatin (100mg/m²)|Intraperitoneal hypertherm (41°C) administration of Cisplatin (100mg/m²), during 90min
1996122|NCT02566499|Device|Breast Microwave Imaging|A Breast Microwave Imaging Procedure will be carried out on volunteers who have abnormal x-ray mammograms, prior to the volunteer undergoing a biopsy to confirm diagnosis (as part of their normal care).
1996123|NCT02566993|Drug|Lurbinectedin (PM01183)|
1996124|NCT02566993|Drug|Doxorubicin (DOX)|
1996125|NCT02566993|Drug|Cyclophosphamide (CTX)|
1996126|NCT02566993|Drug|Vincristine (VCR)|
1996127|NCT02566993|Drug|Topotecan|
1996128|NCT02565836|Drug|fixed-dose activated prothrombin complex concentrate|"FEIBA VH 500 units IV one time for INR less than 5. FEIBA VH 1000 units IV one time for INR greater than 5.
Check INR after infusion and may repeat dose if INR still elevated"
1996129|NCT02565836|Drug|variable-dose inactivated prothrombin complex concentrate|"Kcentra 25 units/kg IV one time for INR less than 4. Kcentra 35 units/kg IV one-time for INR 4 to 6. Kcentra 50 units/kg IV one-time for INR greater than 6.
Check INR after infusion and may repeat dose if INR still elevated."
1996132|NCT02562846|Other|Psychological testing and biological sample collection|For this study, there will be psychological tests, blood and hair sample collections, and part of the patients will undergo an MRI.
1996133|NCT02562443|Drug|rigosertib|Patients will receive intravenous rigosertib 1800 mg/24 hr for 3 days every 2 weeks for first 8 cycles, then every 4 weeks thereafter + best supportive care (BSC).
1981052|NCT03252002|Drug|BAY1101042|Single oral dose of 10 mg, 20 mg, 30 mg, 40 mg, 50 mg or optionally 5 mg BAY 1101042 (given as 5 mg MR tablets) or corresponding placebo followed by once daily dosing for 7 days
1981053|NCT03252002|Drug|Placebo|Single dose on Day 1 (00d) and once daily for 7 days from Day 3 (02d) until Day 9 (08d)
1981072|NCT03248492|Drug|DS-8201a|DS-8201a is sterile lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered as low, medium and high intravenous (IV) doses for Part 1 of the trial. The dose for Part 2 will be determined based on results from Part 1.
1981120|NCT03241186|Drug|Ipilimumab|1mg/kg
1981121|NCT03241186|Drug|Nivolumab|3mg/kg
1981122|NCT03241186|Drug|Nivolumab|480mg
1981133|NCT03237156|Drug|TAK-906|TAK-906 capsules
1981134|NCT03237156|Drug|TAK-906 Placebo|Placebo capsules
1981136|NCT03234972|Drug|Daratumumab|Daratumumab will be administered as an IV infusion at a dose of 16 mg/kg weekly for the first 3 cycles, q3w on Day 1 of Cycles 4-9, and then q4w thereafter.
1981137|NCT03234972|Drug|Velcade|Velcade will be administered at a dose of 1.3 mg/m^2 SC on Days 1, 4, 8 and 11 of each 21-day cycle.
1981138|NCT03234972|Drug|Dexamethasone|Dex will be administered orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11 and 12 of the first 8 Velcade treatment cycles.
1981139|NCT03235388|Other|Audit filters|Institutional implementation of audit filters
1981165|NCT03228667|Drug|ALT-803 + Pembrolizumab|"Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks (Week 1 and Week 4 of each treatment cycle).
Patients will receive 20 µg/kg ALT-803 administered by subcutaneous injection once a week for the first five weeks of each six-week cycle."
1981166|NCT03228667|Drug|ALT-803 + Nivolumab|"Patients will receive 240 mg nivolumab as an intravenous infusion over 60 minutes every two weeks (Week 1, Week 3, and Week 5 of each treatment cycle).
Patients will receive 20 µg/kg ALT-803 administered by subcutaneous injection once a week for the first five weeks of each six-week cycle."
1981167|NCT03228472|Device|non invasive brain stimulation|"TDCS stimulation will be administered for 5 consecutive days at 2 mA for 20 minutes.
TMS stimulation parameters will be: 10 Hz frequency; 100% RMT intensity; Train duration 10 sec (100 stimuli); Inter-train interval 1 minute; n. Total of the terrors 12; Duration of a session about 13 minutes."
1981168|NCT03228472|Device|sham stimulation|Placebo treatment
1981173|NCT03226769|Device|TrueTear|Intranasal application of TrueTear device for approximately 8 minutes at Day 0, for approximately 3 minutes at Day 7 and then daily use of TrueTear per Patient Guide with assessments at Day 7, Day 14 and Day 30.
1981174|NCT03226769|Device|Thermalon Dry Eye Compress|Application of Thermalon Dry Eye Compress at Day 0, Day 7 and daily use as per label instructions with assessments at Day 7, Day 14 and Day 30.
1981185|NCT03227224|Drug|Placebo|Participants will receive 2 placebo capsules matching JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
1981186|NCT03227224|Drug|JNJ-42847922|Participants will receive 2 capsules of JNJ-42847922 once daily orally from Day 1 to Day 41 (Week 6).
1981187|NCT03227653|Drug|Efavirenz-containing cART|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
1981188|NCT03227653|Drug|Non-efavirenz containing cART|Weight-based dosing according to the National Guidelines for the Management of HIV and AIDS
1981196|NCT03225352|Drug|500 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 500mg
1981197|NCT03225352|Drug|1000 mg acetylsalicylic acid (Aspirin, BAYE4465)|Single intake of 1 tablet, 1000mg
1981198|NCT03225352|Drug|400 mg ibuprofen(Nurofen)|Single intake of 1 tablet, 400mg
1981199|NCT03225352|Drug|400 mg ibuprofen (Dolormin Extra)|Single intake of 1 tablet, 400mg
1993207|NCT03232827|Behavioral|Unflavored-sweetened waterpipe tobacco|Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
1993208|NCT03232827|Behavioral|Unflavored-very low sweetened waterpipe tobacco|Pre-weighed unflavored-sweetened waterpipe tobacco will be prepared.
1993209|NCT03233243|Drug|Rosuvastatin Oral Tablet|Patients with 18F-NaF-positive plaques will be treated with 20 mg of rosuvastatin daily for six months, except in patients who need a 55% LDL reduction to achieve recommended targets (rosuvastatin 40 mg). A second visit (visit 2) will take place eight weeks after therapy initiation to monitor for compliance and adverse events report: therapy will be discontinued if there is an elevation of creatine kinase over five times the ULN with myalgia or alanine amino-transferase three times the ULN.
1993213|NCT03232970|Other|Full Plate Diet|12 weekly sessions on how to incorporate more fiber in the diet.
1993214|NCT03232892|Drug|Trametinib|Trametinib 2mg, once daily, PO, 28-day cycles
1993215|NCT03230942|Other|Pre-operative education|Verbal and booklet about symptoms and physical conditions pos knee replacement
1993216|NCT03230942|Other|Pos-operative rehabilitation|Physical therapy treatment
1993217|NCT03231787|Diagnostic Test|Platelet function assay|"Plateletworks is an in vitro diagnostic screening assay for the determination of % platelet aggregation or % platelet inhibition.
It will be used to measure platelet function after withdrawal of the antiplatelet agent.
If there are more than 80,000 functional platelets, the patient will be operated on within the next 24 hours."
1993218|NCT03231657|Diagnostic Test|Placental biomarkers|sFlt1 and P1GF levels and sFlt1/PlGF ratio
1993219|NCT03230916|Drug|IMI/REL FDC|IMI/REL is supplied as a single fixed dose combination (FDC) vial; which is administered at a maximum dose of 15 mg/kg IMI and 15 mg/kg CIL (up to 500 mg IMI and 500 mg CIL) and 7.5 mg/kg REL (up to 250 mg REL).
1993220|NCT03229915|Behavioral|cognitive processing therapy|Group therapy for PTSD patients
1993221|NCT03228732|Drug|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
1993222|NCT03228732|Drug|Placebo Oral Tablet|There will be two 2-day inpatient visits with 8-weeks of treatment with placebo between those visits.
1993223|NCT03228732|Drug|Fluoxetine|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine between those visits.
1993224|NCT03228732|Drug|DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with DHEA between those visits.
1993225|NCT03228732|Drug|Fluoxetine and DHEA|There will be two 2-day inpatient visits with 8-weeks of treatment with fluoxetine and DHEA between those visits.
1993232|NCT03227471|Drug|IVA|150-mg IVA film-coated tablet for oral administration
1993233|NCT03227471|Drug|TEZ/IVA|100-mg TEZ / 150-mg IVA fixed dose combination (FDC) tablet for oral administration.
1993234|NCT03227471|Drug|VX-445|VX-445 tablet for oral administration.
1993235|NCT03227471|Drug|Matched Placebo|Matched placebo.
1993236|NCT03227471|Drug|TEZ|50-mg tablet for oral administration.
1993237|NCT03227471|Drug|VX-561|50-mg tablet for oral administration.
1993239|NCT03227718|Behavioral|VOR and coordination measurements|measurement of VOR and VOR suppression in addition to hand-eye coordination tasks
1981219|NCT03222973|Drug|BIIB033 (opicinumab)|Administered as specified in the treatment arm
1981220|NCT03222973|Drug|Placebo|Administered as specified in the treatment arm
1981231|NCT03219528|Drug|Rifaximin 550 MG|Rifaximin 550 mg three times daily for 14 days
1981232|NCT03219528|Other|Low FODMAP Diet|Low FODMAP dietary intervention for 4 weeks
1981238|NCT03218553|Drug|Dexamethasone|Dexamethasone : first dose : 0,2mg.kg-1 at the end of the surgical procedure, second dose (0,2 mg.kg-1) 24 hours after the surgery
1981239|NCT03218553|Drug|Placebos|placebo : first infusion at the end of the surgical procedure, second 24 hours after the surgery
1981240|NCT03217812|Drug|Velcade|Participants will receive velcade 1.3 mg/m^2, SC injection, twice weekly at Weeks 1, 2, 4 and 5 in Cycle 1 followed by once weekly at Weeks 1, 2, 4 and 5 in Cycles 2 to 9 of Treatment Arm A and B.
1981241|NCT03217812|Drug|Melphalan|Participants will receive melphalan 9 mg/m^2, orally, once daily on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
1981242|NCT03217812|Drug|Prednisone|Participants will receive prednisone 60 mg/m^2, orally, once daily, on Days 1 to 4 of each cycle up to Cycle 9 Treatment Arm A and B.
1981243|NCT03217812|Drug|Daratumumab|Participants will receive daratumumab 16 mg/kg as IV infusion, once weekly, for 6 weeks in Cycle 1 and then once every 3 weeks, in Cycle 2 to 9 and thereafter, once every 4 weeks until documented progression, unacceptable toxicity, or the end of study in Treatment Arm B.
1981246|NCT03215381|Drug|[11C]AZD1390|[11C]AZD1390
1981251|NCT03214380|Drug|LY900014|Administered SC
1981252|NCT03214380|Drug|Insulin Lispro|Administered SC
1981253|NCT03214380|Drug|Insulin Glargine|Administered SC
1981254|NCT03214380|Drug|Insulin Degludec|Administered SC
1981255|NCT03214367|Drug|LY900014|Administered SC
1981256|NCT03214367|Drug|Insulin Lispro|Administered SC
1981257|NCT03214367|Drug|Insulin Glargine|Administered SC
1981258|NCT03214367|Drug|Insulin Degludec|Administered SC
1981302|NCT03205150|Drug|LIK066|LIK066 tablets will be taken orally once daily
1981303|NCT03205150|Drug|Placebo|Placebo tablets will be taken orally once a day
1981319|NCT03199690|Drug|Dolutegravir|Antiviral (integrase inhibitor)
1981320|NCT03199690|Drug|Rifampicin|Antibiotic
1981321|NCT03200860|Drug|Empagliflozin 10 MG|10 mg daily, oral, 30 days
1981322|NCT03200860|Drug|Placebo Oral Tablet|Matching Placebo, 10 mg daily, oral, 30 days
1981334|NCT03197493|Drug|carbidopa-levodopa 25-100 mg|High Dose: daily oral administration 2 tablets TID Intermediate Dose: daily oral administration 1 tablet TID
1981352|NCT03192358|Diagnostic Test|Videofluoroscopic Swallowing Examination|During the videofluoroscopy, subjects will take up to 21 sips of liquid, ranging in thickness from thin (like water), to extremely-thick (like pudding or custard). The liquids will be mixed with E-Z-Paque barium sulfate, to allow it to be visible on the x-ray.
1981353|NCT03192358|Other|Tongue Strength Measurement|"We will measure tongue strength using a tongue pressure measurement system called the Iowa Oral Performance Instrument (IOPI). A small disposable bulb filled with air will be placed in the mouth, just behind the front teeth. Participants will be asked to press their tongue upwards against the bulb as hard as they can, three (3) times at the front of the tongue and three (3) times at the back of the tongue (i.e., total of six (6) maximum isometric tongue presses). Participants will also be asked to swallow their saliva with the bulb placed in their mouth, three (3) times.
Tongue pressure measurement will be completed twice in the data collection session - once at the beginning, and once at the end (following the videofluoroscopy)."
1981360|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 1|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
1981361|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 2|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
1981362|NCT03191383|Biological|RSV vaccine (GSK3003891A) formulation 3|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
1981363|NCT03191383|Drug|Placebo (Formulation buffer S9b)|Single dose administered intramuscularly at Day 0 in the deltoid region of the non-dominant arm
1981374|NCT03188991|Drug|NanoPac®|NanoPac® (Sterile Nanoparticulate Paclitaxel) for intracystic injection via endoscopic ultrasound-guided injection (EUS-FNI)
1981375|NCT03188965|Drug|BAY1895344|The starting dose of BAY1895344 will be 5 mg 2 times daily (BID, every 12hours, except on C1D1 when BAY1895344 is administered once daily) for 3 days on / 4 days off in a weekly schedule (in a 21-day cycle) with no break between cycles.
1981383|NCT03187301|Drug|APL-130277|APL-130277 single dose
1981384|NCT03187301|Drug|Placebo|Placebo single dose
1981385|NCT03187301|Drug|Moxifloxacin|moxifloxacin 400mg single dose
1981416|NCT03175432|Behavioral|Neurocognitive Exam|Neurocognitive exam given to English speaking participants at baseline and on Day 1 of Cycles 5, 9, and every 4 cycles after that.
1981417|NCT03175432|Behavioral|Questionnaires|Symptom and Quality of Life Questionnaires completed at baseline and on Day 1 of Cycles 5, 9, and every 4 cycles after that.
1981418|NCT03175432|Drug|Bevacizumab|15 mg/kg by vein every 3 weeks.
1981419|NCT03175432|Drug|Atezolizumab|1200 mg b vein every 3 weeks.
1981423|NCT03174457|Drug|Micafungin|Intravenous
1981426|NCT03173573|Drug|FDL176|CFTR modulator
1981427|NCT03173573|Drug|Placebo|Placebo for FDL176
1981436|NCT03170427|Device|Impedance cardiography|hemodynamic variation measured by impedance cardiography in healthy pregnant undergoing to cesarean section treated with 8mg or 6mg of levobupivacaine
1981437|NCT03170427|Diagnostic Test|Sensory levels|Sensory levels are checked using ice test cold
1981438|NCT03170427|Diagnostic Test|Motor block|motor block is measured by modified Bromage scale
1981439|NCT03170427|Diagnostic Test|Sensory level|Sensory levels are checked using touch with alcohol puffs
1981445|NCT03169972|Biological|ADYNOVATE|Antihemophilic Factor (Recombinant), PEGylated
1981470|NCT03163446|Biological|CF-301|CF-301, 0.25 mg/kg, given as a single 2 hour iv infusion
1981471|NCT03163446|Drug|Placebo|Placebo, given as a single 2 hour iv infusion
1981479|NCT03160534|Other|preoperative exercise|Each intervention session contains a stretching part and aerobic training
1981480|NCT03161379|Drug|Cyclophosphamide|Cyclophosphamide 200 mg/m2 will be administered one day prior to vaccination (day 0). First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
1981481|NCT03161379|Drug|Nivolumab|Nivolumab (240 mg) will be administered one day prior to vaccination. First dose will be given within 4 to 6 weeks after chemotherapy. 3 weeks after the first dose of immunotherapy the second dose will be given.
1981482|NCT03161379|Drug|GVAX Pancreas Vaccine|Vaccine will be administered one day after cyclophosphamide and nivolumab. 3 weeks after the first dose of immunotherapy the second dose will be given.
1981483|NCT03161379|Radiation|Stereotactic Body Radiation (SBRT)|SBRT (6.6 Gy over 5 days) will be started during the second dose of immunotherapy (3 weeks after the first dose of immunotherapy).
1981507|NCT03153761|Other|CSD170201AA|A moist snuff product
1981508|NCT03153761|Other|CSD170201AB|A moist snuff product
1981523|NCT03149328|Other|Educational Support|In the intervention group, clinicians will be provided with PRO feedback for use in their clinical practice. They will also receive educational support on how to use PRO data at point of care.
1998899|NCT00740870|Device|Transcatheter Pulmonary Valve replacement|Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
1998900|NCT00740805|Drug|Cyclophosphamide|Given IV
1998901|NCT00740805|Drug|Doxorubicin Hydrochloride|Given IV
1998902|NCT00740805|Other|Laboratory Biomarker Analysis|Correlative studies
1998903|NCT00740805|Other|Pharmacological Study|Correlative studies
1998904|NCT00740805|Drug|Veliparib|Given PO
1998905|NCT00731731|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo radiotherapy
1998906|NCT00731731|Procedure|Cognitive Assessment|Ancillary studies
1998907|NCT00731731|Other|Laboratory Biomarker Analysis|Correlative studies
1998908|NCT00731731|Drug|Temozolomide|Given PO
1998909|NCT00731731|Drug|Vorinostat|Given PO
1998910|NCT00729378|Other|skeletal loading|impact activities, 3 times per week, increasing (up to 40) of jumps and height (from 6 inches to 18 inches per repetition) over the initial 2 months. New activities will be introduced approximately every 2-3 months and continually stress the skeleton over 2 years.
1998911|NCT00725322|Drug|Botulinum Toxin A|Subcutaneous injection of Botulinum Toxin Type A into the patient's scar tissue
1998912|NCT00725322|Drug|Placebo - Saline|Subcutaneous Saline injection given at site of scar neuroma
1998913|NCT00722280|Procedure|Hand Transplantation|"This program is the primary site for a novel immune modulation protocol for hand and/or forearm transplantation using donor bone marrow stem cells. This protocol, otherwise called the Pittsburgh Protocol has been published and implemented in 8 hand/forearm transplantations. The Pittsburgh hand transplant program is the only center that has experience with the Pittsburgh Protocol to reduce the number and dosing of immunosuppressive drugs used to prevent rejection of hand/forearm transplants."
1998914|NCT00720590|Drug|Atazanavir|400 mg of atazanavir (two 200-mg capsules) per day for 4 weeks
1998915|NCT00720590|Drug|Lopinavir/ritonavir|400 mg/100 mg of lopinavir/ritonavir (three soft-gel capsules, each containing 133.3 mg lopinavir and 33.3 mg ritonavir) twice per day with food for 4 weeks
1998916|NCT00720590|Drug|Placebo|Daily dose of placebo for 4 weeks
1998917|NCT00718263|Drug|Nilotinib|
1998918|NCT00718263|Drug|Imatinib|
1998919|NCT00714129|Other|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is the similar composition of their current diet.
1998920|NCT00714129|Other|Dietary intervention (calorie restricted diet)|Participants in Aim 2 will receive a calorie restricted diet. This group will receive all their food for approximately 8 weeks which is lower in simple sugars, specifically fructose.
1998923|NCT00709696|Drug|Placebo|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
1998924|NCT00709696|Drug|Varenicline|Days 1 - 3 (0.5 mg tablet, q.d.), Days 4 - 7 (0.5 mg tablet, b.i.d.), and Day 8 - 21 (1 mg tablet, b.i.d.).
1998925|NCT00699816|Biological|Immuncell-LC|Activated T lymphocyte
1998929|NCT00691626|Behavioral|CBT for Insomnia plus Imagery Rehearsal|patients receive standard CBT for insomnia and psychoeducation combined with techniques of imagery rehearsal aimed at reducing posttraumatic nightmare frequency and distress
1998930|NCT00691626|Behavioral|CBT for Insomnia plus psychoeducation|patients receive standard CBT for insomnia combined with psychoeducation
1998935|NCT00676715|Drug|Placebo|Placebo matching to ocrelizumab administered as IV infision in Cycle 1 Day 1.
1998936|NCT00676715|Drug|Ocrelizumab|Two infusion of ocrelizumab 300 mg separated by 14 days in cycle 2. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.
1981528|NCT03147911|Genetic|Blood sampling for genetic test|"Patients with Atrial Fibrillation(AF) and CHA2DS2-VASc score of 0~1 in men, 1~2 in women.
Genomic DNA extractions from the blood samples will be performed following the manufacturer instructions."
1981543|NCT03143101|Biological|FluMist Quadrivalent 2017-2018 formulation|Two 0.2-mL doses of vaccine with the second dose administered approximately 4 weeks after the first dose. Each 0.2-mL dose will contain 10^7±0.5 fluorescent focus units (FFU) of each vaccine strain.
1981544|NCT03143101|Biological|FluMist Quadrivalent 2015-2016 formulation|Two 0.2-mL doses of vaccine with the second dose administered approximately 4 weeks after the first dose. Each 0.2-mL dose will contain 10^7±0.5 fluorescent focus units (FFU) of each vaccine strain.
1981545|NCT03143101|Biological|FluMist Trivalent 2015-2016 formulation|Two 0.2-mL doses of vaccine with the second dose administered approximately 4 weeks after the first dose. Each 0.2-mL dose will contain 10^7±0.5 fluorescent focus units (FFU) of each vaccine strain.
1981546|NCT03141359|Radiation|SBRT|Primary tumor SBRT
1981547|NCT03141359|Drug|Carboplatin|concurrent chemotherapy
1981548|NCT03141359|Drug|Paclitaxel|concurrent chemotherapy
1981549|NCT03141359|Drug|cis Platinum|concurrent chemotherapy
1981550|NCT03141359|Drug|Etoposide|concurrent chemotherapy
1981551|NCT03141359|Radiation|IMRT|mediastinal radiation
1981566|NCT03138356|Drug|2.5 mg saxagliptin / 5 mg dapagliflozin / 850 mg metformin XR FDC tablet|Used in Treatment B and Treatment E.
1981567|NCT03138356|Drug|2.5 mg saxagliptin / 5 mg dapagliflozin / 1000 mg metformin XR FDC tablet|Used in Treatment A and Treatment D.
1981568|NCT03138356|Drug|5 mg dapagliflozin / 850 mg metformin XR FDC|Used in Treatment H.
1981569|NCT03138356|Drug|5 mg dapagliflozin / 1000 mg metformin XR FDC|Used in Treatment G.
1981570|NCT03138356|Drug|2.5 mg ONGLYZA® (saxagliptin) tablet|Used in treatments C and F.
1981571|NCT03138356|Drug|5 mg Forxiga® (dapagliflozin) tablet|Used in treatments C, F and I.
1981572|NCT03138356|Drug|500 mg Glucophage XR®|Used in treatments C, F and I.
1981573|NCT03136991|Drug|AZD4831|Participants will receive AZD4831 once daily, orally, for a period of 10 days. Note: Additional doses (for cohorts 2,3&4) are provisional and could be adjusted based on the emerging data after the review of all available safety or other pertinent data from the previous dose by the Safety Review Committee (SRC).
1981574|NCT03136991|Drug|Placebo|Participants will receive placebo matching the AZD4831 dose, once daily, orally, for a period of 10 days.
1981577|NCT03136263|Drug|Oxytocin nasal spray|Single-dose intranasal oxytocin (24 IU; Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
1981578|NCT03136263|Drug|Placebo nasal spray|Single-dose intranasal placebo (inactive ingredients of Syntocinon® nasal spray, Victoria Pharmacy, Zürich, Switzerland)
1981579|NCT03136120|Drug|Ipratropium Bromide|Single dose of 500 mcg Ipratropium nebulizer solution will be administered to all subjects via inhalation route using nebulizer for 10 minutes. Ipratropium bromide is a clear, colorless nebulizer solution available in white plastic ampoules.
1981580|NCT03136120|Procedure|Flexible Bronchoscopy/Biopsy|After biopsy samples required for diagnosis have been collected, additional one to two TBCB samples will be taken for this study. 3-5 endobronchial biopsy samples will be taken from up to 5 subjects to compare drug distribution in proximal and distal lung.
1981583|NCT03134222|Drug|Filgotinib|200 mg tablets administered orally once daily with or without food
1981584|NCT03134222|Drug|GS-9876|30 mg tablets administered orally once daily with or without food
1981585|NCT03134222|Drug|Filgotinib placebo|Tablets administered orally once daily with or without food
1981586|NCT03134222|Drug|GS-9876 placebo|Tablets administered orally once daily with or without food
1981588|NCT03132467|Drug|Tremelimumab|75 mg by vein on Day 1 of each cycle for 2 doses/cycles.
1981589|NCT03132467|Drug|Durvalumab|1500 mg by vein on Day 1 for 2 doses/cycles.
1981590|NCT03132467|Procedure|Core Breast Tumor Biopsy|Participant have a core breast tumor biopsy before participant begins treatment, at the end of Cycle 2, and during participant's surgery.
1981598|NCT03131908|Drug|GSK2636771|"Phase I Starting Dose of GSK2636771: 300 mg by mouth given for 21 days.
Phase II Dose of GSK2636771: Maximum tolerated dose from Phase I."
1981599|NCT03131908|Drug|Pembrolizumab|Phase I and II Dose of Pembrolizumab: 200 mg given by vein every 3 weeks.
1998937|NCT00676715|Drug|Ocrelizumab|Ocrelizumab 1000 mg IV infusions was administered on cycle 1 Day 1.
1998938|NCT00676715|Drug|Ocrelizumab|Ocrelizumab 300 mg was administered in cycle 1 followed by an infusion of ocrelizumab 600 mg on Day 1. A single infusion of ocrelizumab 600 mg was administered on Day 1 of cycles 3 and 4.
1998939|NCT00676715|Drug|Avonex|Avonex was administered weekly intramuscular injections of 30 mcg in cycle 1 Day 1.
1998940|NCT00675961|Behavioral|Brief Counseling Intervention (BCI)|Two-tiered BCI characterized by both primary and secondary interventions. Primary BCI treatment format consists of 6 discussions delivered monthly in the first 6 months of standard TB treatment. 10-15 minutes long. Secondary BCI is delivered on a monthly basis while receiving TB treatment. 5-10 minutes long.
1998941|NCT00675961|Drug|Naltrexone|Opioid antagonist, which decreases the pleasurable response to and craving for alcohol consumption. Oral; single daily dose of 50 mg per day for 6 months.
1998942|NCT00675961|Other|BCI + Naltrexone|Combination of the two previous interventions
1998943|NCT00675961|Behavioral|Treatment as Usual|Services provided by psychologists and narcologists (additions specialists) employed by the Tomsk Oblast TB Services.
1998944|NCT00672204|Biological|Allogeneic islets of Langerhans transplant|Up to 3 intraportal infusions of cadaveric pancreatic islets of Langerhans. Each infusion to contain at least 5,000 islet equivalents/kg body weight.
1998945|NCT00672204|Drug|Raptiva|Treatment Day -1 pretransplant to Treatment Day 90 after tx.: 1.0 mg/kg/wk SQ; Treatment Day 91 to Treatment Day 365: 0.5 mg/kg/wk SQ;
1998946|NCT00672204|Drug|Sirolimus|Initial dose 0.1 mg/kg PO on day -2, followed by 0.05 mg/kg daily, whole blood 24-hour trough adjusted to target 3-15 ng/ml as tolerated
1998947|NCT00672204|Drug|anti-thymocyte globulin|2.0 mg/kg on days -2, and -1 IV
1998948|NCT00665457|Biological|filgrastim|
1998949|NCT00665457|Drug|capecitabine|
1998950|NCT00665457|Drug|celecoxib|
1998951|NCT00665457|Drug|cyclophosphamide|
1998952|NCT00665457|Drug|docetaxel|
1998953|NCT00665457|Drug|doxorubicin hydrochloride|
1998954|NCT00665457|Genetic|gene expression analysis|
1998955|NCT00665457|Genetic|polymorphism analysis|
1998956|NCT00665457|Genetic|protein expression analysis|
1998957|NCT00665457|Genetic|reverse transcriptase-polymerase chain reaction|
1998958|NCT00665457|Other|imaging biomarker analysis|
1998959|NCT00665457|Other|immunohistochemistry staining method|
1998960|NCT00665457|Other|laboratory biomarker analysis|
1998961|NCT00665457|Other|pharmacogenomic studies|
1998962|NCT00665457|Procedure|dynamic contrast-enhanced magnetic resonance imaging|
1998963|NCT00665457|Procedure|needle biopsy|
1998964|NCT00665457|Procedure|neoadjuvant therapy|
1998965|NCT00665457|Procedure|radiomammography|
1998966|NCT00665457|Procedure|ultrasound imaging|
1998968|NCT00658814|Drug|Azacitidine|Given IV or SC during induction; given SC during consolidation and maintenance
1998969|NCT00658814|Drug|Gemtuzumab Ozogamicin|Given IV
1998970|NCT00657618|Drug|Sodium Stibogluconate (SSG)|100 mg/ml/vial. Treatment for laboratory-confirmed leishmaniasis with SSG 20mg/kg/d intravenously (IV) for 10 days or 20 days; visceral leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days as a second line of therapy for those failing or intolerant of Ambisome; and mucosal leishmaniasis will be treated with SSG 20mg/kg/d IV for 28 days.
1998972|NCT00641797|Drug|Meclizine|medication administration 25mg PO one time
1998973|NCT00641797|Other|Epley Maneuver|Patient has vestibular rehabilitation utilizing the Epley Maneuver.
1998974|NCT00641797|Drug|Lorazepam|Lorazepam 1 - 5mg PO/IV prn
1981604|NCT03129139|Drug|Minnelide™Capsules|Minnelide™ is a water soluble disodium salt variant of triptolide an heat shock protein (HSP) inhibitor.
1981613|NCT03128606|Drug|GLPG3067 single dose|GLPG3067 oral suspension, single ascending doses, daily
1981614|NCT03128606|Drug|Placebo single dose|Placebo, oral suspension, daily
1981615|NCT03128606|Drug|GLPG3067 multiple dose|GLPG3067 oral suspension, multiple ascending doses, daily for 14 days
1981616|NCT03128606|Drug|Placebo multiple dose|Placebo, oral suspension, daily for 14 days
1981617|NCT03128606|Drug|GLPG3067 oral suspension|GLPG3067 oral suspension, single dose, daily
1981618|NCT03128606|Drug|GLPG3067 oral tablet|GLPG3067 oral tablet, single dose, daily
1981619|NCT03128606|Drug|GLPG3067/GLPG2222 multiple dose|GLPG3067 oral suspension and GLPG2222 oral suspension, multiple doses, daily for 14 days
1981620|NCT03128606|Drug|GLPG3067/Placebo multiple dose|GLPG3067 oral suspension and placebo oral suspension, multiple doses, daily for 14 days
1981621|NCT03128112|Other|Exam room with poster|This intervention will assess whether a novel educational exam room poster can effectively prompt patients to ask pediatricians about their children's weight status and improve patents' perceptions of their children's weight status.
1981622|NCT03127644|Drug|Sodium Zirconium Cyclosilicate (ZS) 5g|Suspension administered 5g orally three times daily for 48 hours.
1981623|NCT03127644|Drug|Sodium Zirconium Cyclosilicate (ZS) 10g|Suspension administered 10g orally three times daily for 48 hours.
1981624|NCT03127644|Drug|Placebo|Placebo suspension administered orally placebo three times daily for 48 hours.
1981630|NCT03124537|Behavioral|App condition 1|This group will be given the App with the accelerometer to count steps, the daily schedule, and walking maps. It involves setting step goals and the use of an accelerometer to calibrate number of steps to distance and time using an individual's gait, and to provide step counts. (2) There will be an interface with map programs to create walking routes for work, home, and in new locations when traveling, based on how much time is available to walk. (3) They will use a daily planner to determine when they can walk and for how long. They will use the App for 3 months.
1981631|NCT03124537|Behavioral|App condition 2|This group will be given the same App as condition 1 with the accelerometer and step counter, daily schedule, and walking maps. In addition, the social contacts component will be added. This feature will link friends, co-workers, or neighbors in one's walk contact list to find out if someone is available to walk at a given time. They will use the App for 3 months.
1981632|NCT03124537|Behavioral|App Condition Control|This group will just receive the accelerometer program to set daily step goals and to count steps. They will monitor their steps over a 3-month period.
1981633|NCT03122899|Device|SIJ fusion with iFuse-3D|Minimally invasive SIJ fusion with iFuse-3D titanium implant (usually 3 implants per SIJ).
1981640|NCT03117361|Drug|plitidepsin|
1981641|NCT03117361|Drug|Bortezomib|
1981642|NCT03117361|Drug|Dexamethasone|
1981643|NCT03116347|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (IGI, 10% with rHuPH20)
1981644|NCT03116347|Biological|KIOVIG|100 mg/ml solution for infusion
1981645|NCT03116347|Biological|Cuvitru|200 mg/ml solution for subcutaneous injection
1981682|NCT03101358|Drug|SOR007 (Uncoated Nanoparticle Paclitaxel) Ointment|One (1) Finger Tip Unit (FTU), or approximately 0.5 g, of SOR007 ointment will be applied topically to a 50 cm2 treatment area.
1981684|NCT03100838|Drug|NIFEdipine 60 MG|Reference Drug
1981685|NCT03100838|Drug|NIFEdipine 60 MG|Test Drug
1981686|NCT03100838|Drug|omeprazole/sodium bicarbonate|Proton Pump Inhibitor/Antacid for drug-drug interaction
1981687|NCT03100838|Device|SmartPill (TM)|Gastric pH measurement using SmartPill (TM) Technology
1998975|NCT00641797|Drug|Diphenhydramine|25 - 50mg PO/IV once prn
1998976|NCT00641797|Drug|Ondansetron|Ondansetron 4 - 8 mg PO/IV prn
1998977|NCT00639015|Drug|Phenylephrine|Titrated phenylephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
1998978|NCT00639015|Drug|Norepinephrine|Titrated norepinephrine to maintain mean arterial pressure between 65-75 mmHg over a period of 12 hours from the onset of septic shock.
1998979|NCT00626626|Drug|Dose Level I|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 500 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion.
1998980|NCT00626626|Drug|Dose Level 2|Hydrocortisone 100 mg IV 30 minutes prior to each dose of Clofarabine. Ondansetron 16 mg PO or IV or another comparable antiemetic should be given prior to each dose of Clofarabine. An additional similar dose should be given prior to Cyclophosphamide dose. Clofarabine 30 mg/M2 -8 through - 4 (5 doses) infusion. Alemtuzumab on day -8 only and after Clofarabine. Cyclophosphamide 1000 mg/m2 Days -8 and -7 (2 doses) given over 1 hour beginning 4 hours after the beginning of Clofarabine infusion (patients 4-9)
1998981|NCT00616759|Procedure|electroconvulsive therapy|electroconvulsive therapy as usual
1998982|NCT00616759|Procedure|electroconvulsive therapy plus propofol|electroconvulsive therapy identical to the comparator group except that propofol 0.5 mg/kg is given intravenously 15 seconds after the electrical stimulation at each treatment in order to terminate the ECT-induced seizure
1998983|NCT00616759|Drug|propofol|Propofol 0.5 mg/kg intravenously given 15 seconds following electrical stimulation
1998984|NCT00609284|Drug|cetuximab|D-7, D1, D8, D15, D22, D29, D43, D50
1998985|NCT00609284|Drug|Carboplatin, 5FU concomitant|Carboplatin 70mg/m²/D ; 5FU 600 mg/m²/D, D1-4, D22-25, D43-46
1998986|NCT00609284|Radiation|Radiotherapy|70 Gy in 7 weeks
1998995|NCT00594789|Other|Information letters|Information letters under Manitoba Health letterhead will be sent out to physician(s) and/or patient connected with a fracture that meets specific criteria. To address concerns over discontinuous care of patient seen at the time of fracture and for subsequent follow-up, the physician notification will specifically target the individual involved in the initial report to Manitoba Health as well as the primary care physician (using an algorithm developed by the Manitoba Centre for Health Policy). The notification will provide a general recommendation for osteoporosis assessment in addition to a copy of the BMD testing requisition since BMD testing is usually justified in this setting. The notification will not dictate what testing or treatment needs to be performed.
1998997|NCT00588991|Drug|Carboplatin|Given IV
1998998|NCT00588991|Other|Laboratory Biomarker Analysis|Correlative study
1998999|NCT00588991|Drug|Topotecan Hydrochloride|Given IV
1999000|NCT00588991|Drug|Veliparib|Given orally
1999007|NCT00586339|Biological|Cervarix TM|Intramuscular injection, 3 doses
1999008|NCT00586339|Biological|Placebo Control|Intramuscular injection, 3 doses
1999010|NCT00576654|Drug|Irinotecan Hydrochloride|Given IV
1999011|NCT00576654|Other|Laboratory Biomarker Analysis|Correlative studies
1999012|NCT00576654|Other|Pharmacological Study|Correlative studies
1999013|NCT00576654|Drug|Veliparib|Given PO
1999063|NCT00499083|Drug|tamoxifen citrate|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
1999064|NCT00499083|Genetic|gene expression analysis|IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
1999065|NCT00499083|Genetic|protein expression analysis|Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration.
1981693|NCT03099109|Drug|LY3321367|Administered IV
1981694|NCT03099109|Drug|LY3300054|Administered IV
1981695|NCT03099239|Biological|hCT-MSC infusion|hCT-MSCs are a product of allogeneic cells manufactured from digested umbilical cord tissue that is expanded in culture, cryopreserved and banked.
1981702|NCT03096795|Drug|MEDI3506|"Single doses of MEDI3506 for SAD
Multiple doses of MEDI3506 for MAD"
1981703|NCT03096795|Drug|placebo|"Single doses of placebo for SAD
Multiple doses of placebo for MAD"
1981714|NCT03093155|Drug|Ixabepilone|"Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.
Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response"
1981715|NCT03093155|Drug|Bevacizumab|"Bevacizumab will be administered at 10 mg/kg intravenously days 1, 15 of a 28-day cycle over one hour. Bevacizumab will be infused after ixabepilone. The first dose of bevacizumab will be administered intravenously over 90 minutes; the second dose may be administered over 60 minutes if no prior reaction to previous infusion; subsequent doses may be administered over 30 minutes if no prior reaction to previous infusion.
Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response."
1999096|NCT00468923|Drug|Rosuvastatin|Rosuvastatin 10 mg once daily
1999111|NCT00404755|Drug|escitalopram|Escitalopram: wk 1: 10 mg/d; wks 2-3: 20 mg/d; wk4: 30 mg/d; wks 5-6: 40 mg/d
1999112|NCT00404755|Drug|bupropion|bupropion XL 150 mg/d increasing as tolerated and not remitted by 150 mg/d to maximal dose of 450 mg/d
1999113|NCT00404755|Drug|imipramine|imipramine 50 mg/d increasing twice weekly by 50 mg/increase to 200 mg/d, then 50 mg increase/week to 300 mg/d; all dose increases if tolerated and not remitted
1999114|NCT00397813|Drug|Cyclosporine|Given PO
1999115|NCT00397813|Drug|Fludarabine Phosphate|Given IV
1999116|NCT00397813|Other|Laboratory Biomarker Analysis|Correlative studies
1999117|NCT00397813|Drug|Mycophenolate Mofetil|Given PO
1999118|NCT00397813|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo transplantation
1999119|NCT00397813|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
1999120|NCT00397813|Radiation|Total-Body Irradiation|Undergo TBI
1999121|NCT00392236|Device|2-way pager|Participants will receive messages daily to take their medication via a 2-way pager for 6 months. Once the message is received the participant will respond whether or not he/she took the medication and reason for not taking.
1999122|NCT00392236|Behavioral|Treatment as usual|Participants will receive treatment as usual.
1999123|NCT00390429|Drug|docetaxel|Given IV
1999124|NCT00390429|Drug|erlotinib hydrochloride|Given orally
1999125|NCT00388674|Drug|entecavir|Tablets / Oral Solution, Oral, ETV = 0.5 mg - 1 mg, once daily, Investigator/Patient decision
1999126|NCT00388674|Drug|Other anti-HBV medication|Tablets / Oral Solution, Oral, depends on chosen active comparator, depends on chosen active comparator, Investigator/Patient decision
1999127|NCT00365157|Drug|Eribulin Mesylate|Given IV
1999128|NCT00365157|Other|Laboratory Biomarker Analysis|Correlative studies
1999129|NCT00365157|Other|Pharmacological Study|Correlative studies
1999130|NCT00343642|Dietary Supplement|Time and attention + fructo-oligosaccharide placebo|2 teaspoons of placebo powder daily
1999131|NCT00343642|Dietary Supplement|dietary therapy + fructo-oligosaccharide placebo|Medical nutrition therapy and 2 teaspoons of placebo powder
1999132|NCT00343642|Drug|Time and attention + active fructooligosaccharide supplementation|2 teaspoons of fructooligosaccharides daily
1999133|NCT00336063|Drug|Azacitidine|Given SC
1999134|NCT00336063|Other|Laboratory Biomarker Analysis|Correlative studies
1999135|NCT00336063|Other|Pharmacological Study|Correlative studies
1999136|NCT00336063|Drug|Vorinostat|Given PO
1999137|NCT00334789|Drug|Belinostat|Given IV
1999138|NCT00334789|Drug|Isotretinoin|Given orally
1999139|NCT00334789|Other|Pharmacological Study|Correlative studies
1999140|NCT00331409|Drug|Everolimus|2.5 mg by mouth daily
1999141|NCT00331409|Drug|imatinib mesylate|600 mg by mouth daily
1999146|NCT00321685|Biological|Bevacizumab|Given IV
1999147|NCT00321685|Drug|Capecitabine|Given PO
1999148|NCT00321685|Drug|Fluorouracil|Given IV
1981731|NCT03089281|Device|CRT-D|Commercially approved quadripolar Boston Scientific Cardiac Resynchronization Therapy Defibrillator (CRT-D) devices and future generations of BSC X4 CRT-D devices approved by the appropriate regulatory bodies will be included in the trial. All devices utilized in the study will include SmartDelay™ and must be capable of providing SmartDelay recommendations for both biventricular pacing (BiV) and Left Ventricular (LV) only pacing.
1981732|NCT03088267|Drug|amphetamine extended-release oral suspension, 2.5 mg/mL|5 mL1 (5 mg), 7 mL (17.5 mg) or 8 mL (20 mg) PO
1981733|NCT03088267|Drug|Placebo extended-release oral suspension|6, 7 or 8 mL PO
1981737|NCT03086148|Drug|Ketamine|Ketamine will be administrated intravenously at dural opening, with the total dose of 0.5 mg/kg and continual infusion for 40 minutes.
1981738|NCT03086148|Drug|Normal saline|Normal saline will be administrated intravenously at dural opening, with the total dose of 0.5 ml/kg and continual infusion for 40 minutes.
1981739|NCT03086369|Drug|Olaratumab|Administered IV
1981740|NCT03086369|Drug|Nab-paclitaxel|Administered IV
1981741|NCT03086369|Drug|Gemcitabine|Administered IV
1981742|NCT03086369|Drug|Placebo|Administered IV
1981743|NCT03085095|Drug|Relugolix|Relugolix 120 mg tablet administered orally once daily
1981744|NCT03085095|Drug|Leuprolide Acetate|leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in some Asian countries), every 3-months (3-M) by subcutaneous or intramuscular injection
1981753|NCT03081039|Drug|Carboplatin|Arm A: Carboplatin or Cisplatin every 21 days for 6 cycles. Dose based on weight.
1981754|NCT03081039|Drug|Cisplatin|Arm A: Cisplatin or Carboplatin every 21 days for 6 cycles. Dose based on weight.
1981755|NCT03081039|Drug|Gemcitabine|"Arm A: Given with either Cisplatin or Carboplatin every 21 days for 6 weeks. Dose based on individuals weight.
Arm B: Gemcitabine alone every 21 days for 6 cycles. Dose based on weight."
1981756|NCT03080974|Drug|Nivolumab|Given post-operatively every two weeks for a total of 4 doses. Dose based on weight.
1981757|NCT03080974|Procedure|Irreversible Electroporation|Non-thermal ablation of tumor
1999149|NCT00321685|Drug|Leucovorin Calcium|Given IV
1999150|NCT00321685|Drug|Oxaliplatin|Given IV
1999151|NCT00321685|Radiation|Radiation Therapy|Undergo radiotherapy
1999152|NCT00321685|Procedure|Therapeutic Conventional Surgery|Undergo surgical resection
1999162|NCT00310401|Drug|Albuterol|5 mg nebulized q4h
1999163|NCT00310401|Drug|Saline|1.0 cc diluted with saline in identical fashion to study drug and administered by nebulizer every 4 hours
1999164|NCT00303719|Biological|anti-thymocyte globulin|"ATG dose is 15 mg/kg intravenous (IV) every 12 hours for 6 doses on days -6, -5, and -4.
Those that should/will receive ATG in the preparative regimen:
Related donor recipients who have not had exposure to combination chemotherapy in the 6 months preceding transplant should
Unrelated donor recipients who have not had exposure to combination chemotherapy in the 3 months preceding transplant will
Unrelated donor recipients who have had only a single induction cycle for the treatment of ALL/AML or MDS or CML blast crisis should
Recipients with a prior autologous transplant in the year prior to second transplant do not require ATG."
1999165|NCT00303719|Drug|cyclophosphamide|Cyclophosphamide will be given in a two hour infusion, total dose 50 mg/kg on day -6.
1999166|NCT00303719|Drug|cyclosporine|Patients will receive cyclosporine A (CSA) therapy beginning on day -3 maintaining a level of >200. For adults the initial dose will be 2.5 mg/kg IV over 2 hours every 12 hours. For children < 40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours. Patients will receive CSA until day +100.
1999167|NCT00303719|Drug|fludarabine|Fludarabine 30 mg/m^2/day intravenous (IV) on day -6 through day -2., total dose 150 mg/m^2 for 5 days.
1999168|NCT00303719|Drug|mycophenolate mofetil|Mycophenolate mofetil (MMF) 1.5 gram twice a day (BID) or if < 50 kg will be given 15 mg/kg orally(po) BID,beginning on day -3, and discontinue at day +30 or 7 days after engraftment (3 consecutive days of absolute neutrophil count (ANC) > 0.5 x 109 /L).
1999169|NCT00303719|Procedure|stem cell transplantation|On day 0, if related donor, stem cells are infused via central line. If unrelated donor, marrow/PBSC is infused after arrival and processing on day 0.
1999170|NCT00303719|Radiation|total body irradiation|The dose of TBI will be 200 cGy given in a single fraction on day -1.
1999171|NCT00303719|Drug|filgrastim|Patients with white blood cell (WBC) counts < 2500 any time after stem cell infusion will be started on G-CSF support at Day +5 at a dose of 5 mcg/kg intravenously or subcutaneously (IV/SQ) daily rounded to vial size until absolute neutrophil count (ANC) > 2500 for 2 consecutive days.
1999178|NCT00282412|Biological|Hematopoietic Stem Cell Transplantation|Allogeneic Hematopoietic Stem Cell Transplantation
1999179|NCT00268385|Other|Laboratory Biomarker Analysis|Correlative studies
1999180|NCT00268385|Other|Pharmacological Study|Correlative studies
1999181|NCT00268385|Drug|Temozolomide|Given orally
1981773|NCT03077685|Drug|NanoPac®|Subjects with locally advanced pancreatic adenocarcinoma located in the tail or body of the pancreas will receive intratumoral (ITU) NanoPac® (Sterile Nanoparticulate Paclitaxel) via endoscopic ultrasound-guided direct injection. Prior to study entry, subjects will have received standard of care (SOC) treatment (including IV chemotherapy) and hematologic recovery will be confirmed before NanoPac® is administered.
1981774|NCT03077659|Drug|NanoPac®|Subjects with prostate cancer scheduled for prostatectomy will have NanoPac® injected intratumorally under image guidance directly into the lobe of the prostate with the dominant lesion 4 weeks prior to prostatectomy.
1981775|NCT03074942|Drug|Reslizumab|Reslizumab 3 mg/kg once / every 4 weeks during 24 weeks
1981780|NCT03074045|Drug|Levonorgestrel (Kyleena, BAY86-5028)|Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
1981781|NCT03074045|Drug|Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)|COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
1981782|NCT03073200|Drug|Ixekizumab|Administered SC
1981783|NCT03073200|Drug|Placebo|Administered SC
1999182|NCT00268385|Drug|Vorinostat|Given orally
1999185|NCT00257712|Drug|TH9507 human growth hormone releasing hormone (GHRH)|1mg subcutaneous injection given daily for 20 weeks
1999186|NCT00249444|Drug|Mirtazapine|Mirtazapine
1999187|NCT00249444|Drug|Placebo|placebo
1999190|NCT00233324|Drug|Surfactant|Intubation and administration of surfactant by 1 hour of age.
1999191|NCT00233324|Device|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure/Positive End Expiratory Pressure (CPAP/PEEP) begun in the delivery room and continuing in the NICU
1999192|NCT00233324|Drug|Supplemental oxygen with target saturation of 85 to 89%|Supplemental oxygen in the range of 85% to 89% until the infant is no longer requiring ventilatory support or oxygen
1999193|NCT00233324|Drug|Supplemental oxygen with target saturation of 91 to 95%|Supplemental oxygen in the range of 91% to 95% until the infant is no longer requiring ventilatory support or oxygen.
1999201|NCT00186121|Drug|Anastrozole (Arimidex)|
1999202|NCT00186121|Drug|Goserelin (Zoladex)|
1999208|NCT00158678|Procedure|IMRT 75 Gy|50 Gy in PTV1 and 25 Gy in 10 fractions in PTV2
1999209|NCT00158678|Procedure|Conventional radiotherapy 70 Gy|50 Gy in PTV1 and 20 Gy in PTV2
1999210|NCT00158678|Drug|concomitant cisplatin|100 mg/m2 D1, D22, D43
1999214|NCT00135278|Procedure|CSF Drainage|See Detailed Description
1999215|NCT00135278|Procedure|No CSF Drainage|See Detailed Description
1999216|NCT00126581|Drug|Carboplatin|Given IV
1999217|NCT00126581|Drug|Erlotinib Hydrochloride|Given PO
1999218|NCT00126581|Other|Laboratory Biomarker Analysis|Correlative studies
1999219|NCT00126581|Drug|Paclitaxel|Given IV
1999221|NCT00114101|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous PBSCT
1999222|NCT00114101|Other|Laboratory Biomarker Analysis|Correlative studies
1999223|NCT00114101|Drug|Lenalidomide|Given PO
1999224|NCT00114101|Drug|Melphalan|Given IV
1999225|NCT00114101|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo autologous PBSCT
1999226|NCT00114101|Other|Placebo|Given PO
1999227|NCT00112931|Biological|rituximab|
1999228|NCT00112931|Other|No treatment|
1999229|NCT00101179|Drug|Azacitidine|Given SC
1999230|NCT00101179|Drug|Entinostat|Given orally
1999231|NCT00098475|Drug|Dexamethasone|Given PO
1999232|NCT00098475|Other|Laboratory Biomarker Analysis|Optional correlative studies
1999233|NCT00098475|Drug|Lenalidomide|Given PO
1981794|NCT03069989|Drug|GSK3008348|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal yellow colored solution in a 5mL vial with 20 millimeter (mm) stopper and aluminium seal.
1981795|NCT03069989|Drug|Placebo|Solution for nebulisation. Available as clear colorless to pale yellow colored solution in a 5mL vial with 20mm stopper and aluminium seal.
1981796|NCT03069989|Drug|[18F]-FBA-A20FMDV2|Radio-labeled peptide ligand for PET scan. Available as intravenous (IV) infusion, 20 mL.
1981819|NCT03060980|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini-pump delivering exenatide 20/60 mcg/day
1981820|NCT03060980|Drug|Empagliflozin (oral)|10 mg/day and 25 mg/day
1981821|NCT03060980|Drug|Glimepiride (oral)|1-6 mg/day
1981828|NCT03061201|Biological|SB-525|Single dose of investigational product SB-525
1981831|NCT03060837|Diagnostic Test|Preoperative Parameters|Preoperative Hmg and serum creatinine levels
1981832|NCT03060837|Other|Peroperative Parameters|Scope duration, perforation, hemorrhage, etc. complications
1981833|NCT03060837|Other|Postoperative Parameters|Stone-free rates, complications like postoperative hemorrhage and fever, hospital stay, etc
1981834|NCT03060837|Other|Movement of kidney|Changes in renal stone position during simultaneous normal ventilation and single lung ventilation.
1981835|NCT03060837|Procedure|single lung ventilation|Patients in this group will intubated with an endotracheal tube and then a bronchial blocker will be placed with the help of a fiberoptic bronchoscope or will be intubated with a double lumen endobronchial tube. One lung ventilation will be applied
1981836|NCT03060837|Procedure|standard ventilation|Patients in this group will be intubated with standart single lumen endotracheal tubes and standart two lung ventilation will be applied.
1981854|NCT03054753|Behavioral|Abduction brace wearing time analysis|To evaluate the patient´s abduction brace wearing time a sensor = Orthotimer® (Rollerwerk, 72336 Balingen, Germany, www.orthotimer.com) is implanted in the abduction brace. The sensor measures the body temperature of the patient. Through that the wearing time can be evaluated.
1981855|NCT03054389|Other|Qualitative Interview - Participants/ Patients|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Participants/ Patients
1981856|NCT03054389|Other|Qualitative Interview - Investigators and Study Coordinators|Qualitative interviews to understand the patient experience with the AskBio009-101 Study - Investigators and Study Coordinators
1981890|NCT03041688|Drug|Decitabine|Given IV
1981891|NCT03041688|Other|Laboratory Biomarker Analysis|Correlative studies
1981892|NCT03041688|Drug|MDM2 Inhibitor AMG-232|Given PO
1981893|NCT03041688|Other|Pharmacological Study|Correlative studies
1981896|NCT03039192|Drug|Esketamine|Intranasal esketamine solution 84 milligram (mg)
1981897|NCT03039192|Other|Placebo|Intranasal Placebo solution
1999234|NCT00098475|Drug|Thalidomide|Given PO
1999235|NCT00095784|Drug|Decitabine|Given SC
1999236|NCT00095784|Other|Laboratory Biomarker Analysis|Correlative studies
1999239|NCT00003196|Drug|chemotherapy|Undergo cytoreductive chemotherapy
1999240|NCT00003196|Radiation|total-body irradiation|Undergo TBI
1999241|NCT00003196|Procedure|peripheral blood stem cell transplantation|Undergo allogeneic PBSC transplant
1999242|NCT00003196|Drug|cyclosporine|Given IV or PO
1999243|NCT00003196|Drug|mycophenolate mofetil|Given PO
1999244|NCT00003196|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic PBSC transplant
1999245|NCT00003196|Biological|therapeutic allogeneic lymphocytes|Undergo DLI
1999246|NCT00082641|Biological|autologous dendritic cell-adenovirus p53 vaccine|Given subcutaneously on one of two schedules
1999247|NCT00003270|Biological|anti-thymocyte globulin|IV
1999248|NCT00003270|Biological|filgrastim|IV
1999249|NCT00003270|Drug|busulfan|IV
1999250|NCT00003270|Drug|cyclophosphamide|IV
1999251|NCT00003270|Drug|cyclosporine|IV
1999252|NCT00003270|Drug|methylprednisolone|IV
1999253|NCT00003270|Procedure|bone marrow ablation with stem cell support|IV
1999254|NCT00003270|Procedure|umbilical cord blood transplantation|IV
1999255|NCT00003270|Radiation|radiation therapy|High energy X-rays
1999257|NCT00070499|Drug|Dasatinib|Given PO
1999258|NCT00070499|Drug|Imatinib Mesylate|Given PO
1999259|NCT00070499|Other|Laboratory Biomarker Analysis|Correlative studies
1999260|NCT00064129|Biological|Ipilimumab|Given IV
1999261|NCT00064129|Other|Laboratory Biomarker Analysis|Correlative studies
1999262|NCT00064129|Other|Pharmacological Study|Correlative studies
1999263|NCT00064129|Biological|Sargramostim|Given SC
1999264|NCT00060528|Drug|Recombinant Fowlpox-GM-CSF|
1999265|NCT00060528|Drug|Recombinant Fowlpox-PSA (L155)-TRICOM (PROSTVAC-F/TRICOM)|
1999266|NCT00060528|Drug|Recombinant Vaccinia-PSA (L155)-TRICOM (PROSTVAC-V/TRICOM)|
1999267|NCT00060528|Drug|Recombinant Human GM-CSF|
1999268|NCT00045201|Drug|Erlotinib Hydrochloride|Given orally
1999269|NCT00045201|Drug|Irinotecan Hydrochloride|Given IV
1999271|NCT00001208|Other|Botulinum Toxin|
1981910|NCT03034109|Device|Transcranial Direct Current Stimulation|TDCS involves sending a weak electrical current to the brain to modulate brain functions.
1981927|NCT03029585|Drug|NanoPac® 100 mg/m2|Single intraperitoneal injection of 100 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
1981928|NCT03029585|Drug|NanoPac® 200 mg/m2|Single intraperitoneal injection of 200 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
1981929|NCT03029585|Drug|NanoPac® 300 mg/m2|Single intraperitoneal injection of 300 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
1981930|NCT03029585|Drug|NanoPac® 400 mg/m2|Single intraperitoneal injection of 400 mg/m2 NanoPac® during cytoreductive surgery, followed by standard-of-care IV carboplatin and IV paclitaxel treatment
1981931|NCT03029585|Drug|Standard of Care Intravenous Chemotherapy|Cytoreductive surgery followed by standard-of-care IV carboplatin and IV paclitaxel treatment
1981941|NCT03028415|Device|AMPLEX®|A bone graft substitute
1981942|NCT03028415|Procedure|Autogenous Bone Graft (ABG)|Control material administered by surgical implant
1993240|NCT03227445|Device|ELLIPTA placebo DPI|ELLIPTA is a dry powder inhaler used via oral route. It will be a placebo DPI with two strips with 30 blisters per strip. First strip will contain lactose monohydrate and the second strip will contain lactose monohydrate blended with magnesium stearate.
1993241|NCT03227445|Device|DISKUS placebo DPI|DISKUS is a dry powder inhaler used via oral route. It will be a placebo DPI with one blister strip that will contain lactose monohydrate.
1993242|NCT03227445|Device|HandiHaler DPI|HandiHaler is a dry powder inhaler used via oral route. It will be a DPI with placebo capsules that will contain lactose monohydrate.
1993243|NCT03227445|Other|Inhaler preference questionnaires|Preference questionnaires will be given to subjects to understand the inhaler preference. There will be 2 types of questionnaire, preference questionnaires 1 and 2, which will be randomized at visit 3 (Day 56).
1993248|NCT03225846|Drug|WVE-120102|WVE-120102 is a stereopure antisense oligonucleotide (ASO)
1993249|NCT03225846|Drug|Placebo|0.9% Sodium Chloride
1993250|NCT03225833|Drug|WVE-120101|WVE-120101 is a stereopure antisense oligonucleotide (ASO)
1993251|NCT03225833|Drug|Placebo|0.9% Sodium Chloride
1993252|NCT03225716|Drug|Ulocuplumab|Ulocuplumab is a type of protein called an antibody that attacks CXCR4
1993253|NCT03225716|Drug|Ibrutinib|Ibrutinib small-molecule inhibitor of Bruton's tyrosine kinase (BTK) with potential antineoplastic activity
1993255|NCT03225105|Drug|M3541|Subjects will receive M3541 orally in combination with fractionated palliative RT for two consecutive calendar weeks (that is, Monday through Sunday, with Saturday and Sunday as M3541 / RT holidays).
1993256|NCT03225105|Radiation|Palliative Radiotherapy (RT)|Subjects will receive RT dose of 30 Gray (Gy) given in 10 fractions (3 Gy given per fraction day) administered over two consecutive calendar weeks (that is, Monday through Sunday, with Saturday and Sunday as M3541 / RT holidays).
1993257|NCT03224351|Drug|TEZ/IVA|100-mg TEZ/150-mg IVA fixed-dose combination (FDC) tablet for oral administration
1993258|NCT03224351|Drug|VX-659|80-mg VX-659 tablet for oral administration
1993259|NCT03224351|Drug|IVA|150-mg IVA tablet for oral administration
1993260|NCT03224351|Drug|Matched Placebos|Placebo will be used as a comparator.
1993261|NCT03224351|Drug|TEZ|50-mg tablet for oral administration.
1993262|NCT03224351|Drug|VX-561|50-mg VX-561 tablet for oral administration.
1981943|NCT03027466|Behavioral|Self-affirmation induction|Participants will be randomly assigned to one of 4 conditions as part of a 2 (Integrated affirmation: Affirmation texts present versus absent) X 2 (Baseline affirmation: questionnaire present versus absent) design (these affirmations are described below). Those in the control condition will receive no changes to the app (standard of care control condition).Booster affirmation: Participants will receive an integrated affirmation every time they spontaneously report experiencing a craving. These will show up in a screen that shows Tips. We will be able to assess how many times participants reported experiencing a craving and thus saw a booster message.
1981955|NCT03023059|Drug|Carbidopa-Levodopa, 25 Mg-100 Mg Oral Tablet|See Arm description
1981960|NCT03022318|Drug|carbidopa-levodopa 25-100 mg tablets|See arm/group descriptions
1981961|NCT03021499|Drug|Voclosporin|calcineurin inhibitor
1981962|NCT03021499|Drug|Placebo Oral Capsule|matching placebo capsule
1993307|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
1993308|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
1993309|NCT03215134|Other|Self-criticism intervention|Compassion Focused Therapy (Gilbert, 2010) adapted to focus specifically on reducing self-criticism. This intervention was originally developed for a student population (Rose, McIntyre & Rimes, submitted) and is now being evaluated in a primary mental-health service.
1993310|NCT03216031|Behavioral|Gardening programme|3 groups with up to 10 patients and 2-4 students/staff members each should meet once per week for about 1 hour to engage in gardening activities at the falls prevention growing site. Each participant will attend the programme 8 times.
1993311|NCT03215940|Drug|Delta-9-Tetrahydrocannabinol|An oral dose of Delta-9-Tetrahydrocannabinol (THC) will be given once a day for five day with pain ratings taken before and after each dose every day.
1993312|NCT03215940|Drug|Cannabidiol|An oral dose of Cannabidiol (CBD) will be given once a day for five day with pain ratings taken before and after each dose every day.
1993313|NCT03215940|Drug|Placebos|An oral placebo will be given once a day for five day with pain ratings taken before and after each dose every day.
1993318|NCT03214666|Drug|161533 with Bolus Test Dose|"Bolus Test Dose: 20% of Daily Continuous Infusion Dose.
If at the end of the 4 hour PK/PD period there are no ongoing treatment related toxicities > CTCAE Grade 2 , the patient will receive 161533 TriKE at the assigned CI dose for 3 sets (infusion block #1, #2, and #3) of 4 consecutive 24 hours infusions separated by a 72 hour rest.
Dose level 1 - Bolus test dose .5 μg/m2 - Daily continuous infusion dose 2.5 μg/m2/day.
Dose level 2 - Bolus test dose 1 μg/m2 - Daily continuous infusion dose 5 μg/m2/day.
Dose level 3 - Bolus test dose 2 μg/m2 - Daily continuous infusion dose 10 μg/m2/day.
Dose level 4 - Bolus test dose 3 μg/m2 - Daily continuous infusion dose 15 μg/m2/day.
Dose level 5 - Bolus test dose 4 μg/m2 - Daily continuous infusion dose 20 μg/m2/day.
Dose level 6 - Bolus test dose 5 μg/m2 - Daily continuous infusion dose 25 μg/m2/day."
1993319|NCT03214666|Drug|161533 Only|"Patients will receive three consecutive blocks of four 24 hour continuous infusions of 161533 TriKE at the phase I MTD separated by a 72 hour rest (no bolus test dose is given).
Dose level 1 - Daily continuous infusion dose 2.5 μg/m2/day.
Dose level 2 - Daily continuous infusion dose 5 μg/m2/day.
Dose level 3 - Daily continuous infusion dose 10 μg/m2/day.
Dose level 4 - Daily continuous infusion dose 15 μg/m2/day.
Dose level 5 - Daily continuous infusion dose 20 μg/m2/day.
Dose level 6 - Daily continuous infusion dose 25 μg/m2/day."
1993320|NCT03214250|Drug|APX005M|Administer intravenously once every 28-day Cycle
1993321|NCT03214250|Drug|Nivolumab|Administer intravenously twice every 28-day cycle
1993322|NCT03214250|Drug|Nab-Paclitaxel|Administer intravenously on 3 times every 28-day cycle
1993323|NCT03214250|Drug|Gemcitabine|Administer intravenously 3 times every 28-day cycle
1993337|NCT03213626|Drug|Cabozantinib 40 MG|To be taken orally once daily
1993338|NCT03213626|Drug|Erlotinib 100Mg Tab|To be taken orally once daily
1982012|NCT03001050|Device|PINPOINT System|To use the camera probe and identify the tendon and footprint vascularity at the time of surgery
1982021|NCT02997553|Drug|Indocyanine green|Each patient receive injection of indocyanine green just before surgery Specify total dose : 2.5 mg/ml (Intravenous use)
1982022|NCT02997553|Drug|Technetium99|"Each patient receives injection of Technetium 99 ( injected in subcutaneously) before surgery.
Lymphoscintigraphy is performed to identify the sentinel node"
1982023|NCT02997553|Device|Optonuclear probe|The detection of sentinel lymph node will be conducted by an optonuclear probe able to detect the radioactive and the fluorescence signal during surgery.
1982043|NCT02993159|Drug|Afimoxifene|Applied to the breast
1982044|NCT02993159|Other|Laboratory Biomarker Analysis|Correlative studies
1982045|NCT02993159|Other|Placebo|Given PO
1982046|NCT02993159|Other|Placebo|Applied to the breast
1982047|NCT02993159|Drug|Tamoxifen Citrate|Given PO
1982073|NCT02986542|Procedure|Femoral artery catheterization|The intervention will be performed by a single experienced individual.
1982079|NCT02983383|Procedure|TAP block group (Group T)|At the end of the operation, patients in Group T in the supine position will have a USI probe placed at the middle point between the costal edge and iliac crest (within the Petit triangle) after necessary antiseptic conditions are ensured. Then after the abdominal muscle layers are observed, the needle (Stimuplex Ultra 22G, 100mm, B.Braun, Germany) tip will be advanced through the muscle layers and pass the fascia, feeling the fascial click, monitored by USI in controlled fashion. After feeling the second click (passing the internal oblique muscle fascia), a test dose of 0.5-1 ml saline will be administered to determine the localization of the needle tip. Then noting the location, with frequent aspiration local anesthetic agent will be administered to the neurofascial plane for TAP block.
1982080|NCT02983383|Procedure|spinal anesthesia|Patients in Group P will have adjuvant added to spinal anesthesia (25 G, Quincke spinal anesthesia needle, Egemen,Turkey).
1982081|NCT02981342|Drug|Abemaciclib|Administered orally
1982082|NCT02981342|Drug|LY3023414|Administered orally
1982083|NCT02981342|Drug|Gemcitabine|Administered IV
1982084|NCT02981342|Drug|Capecitabine|Administered orally
1982093|NCT02978157|Drug|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.
1982094|NCT02978157|Drug|esomeprazole+bismuth+tetra+levo|esomeprazole 40 mg b.d., bismuth 120 mg q.d.s., tetracycline 500 mg q.d.s., and levofloxacin 500 mg o.d.
1982099|NCT02976324|Device|external diaphragmatic pacemaker group|9 counts per minute, with stimulate frequency 40 Hz
1982111|NCT02973087|Biological|von Willebrand factor (Recombinant)|
1982112|NCT02973087|Biological|Antihemophilic Factor (Recombinant)|
1982119|NCT02971501|Biological|Bevacizumab|Given IV
1982120|NCT02971501|Other|Laboratory Biomarker Analysis|Correlative studies
1982121|NCT02971501|Drug|Osimertinib|Given PO
1982122|NCT02971163|Behavioral|SynDA|SynDA is a paper-based, personalized decision aid which gives information to patients about their medical condition (i.e. syncope), future risk, and options for care. It is written in lay language and aims to create an informed conversation between a patient and their ED provider.
1982128|NCT02965040|Drug|Roxadustat|Oral
1982131|NCT02964039|Behavioral|Error reduction|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs toward mechanically-appropriate mediolateral locations, having the effect of reducing the errors in foot placement that are often present among individuals who have experienced a stroke.
1993344|NCT03211767|Dietary Supplement|Aged garlic extract|Each capsule contains 600mg of aged garlic extract powder
1993345|NCT03211767|Dietary Supplement|Placebo|Each capsule contains cellulose as a filler.
1993346|NCT03210662|Radiation|External Beam Radiotherapy (EBRT)|"Participants receive EBRT to a dose of 20-50 Gy in fractions sizes of 3 Gy or less. Standard of care fractionated radiation doses utilized according to disease histology. Patients with MCL, FL, MZL, mycosis fungoides and other low grade lymphomas treated to a dose of 20-24 Gy at 3 Gy fractions or less. Participants with more aggressive histologies, including DLBCL, Primary mediastinal B cell lymphoma (PMBCL) T cell lymphomas and other aggressive or transformed NHLs treated to a dose of 40-50 Gy in 3 Gy fractions or less.
Treatment administered 5 days per week, excluding holidays and weekends."
1993347|NCT03210662|Drug|Pembrolizumab|200 mg by vein every 3 weeks beginning on Day 2.
1993348|NCT03209362|Combination Product|SI-613|SI-613 will be repeated intra-articularly administered.
1993349|NCT03209362|Combination Product|Placebo|Placebo will be repeated intra-articularly administered.
1993353|NCT03207932|Procedure|Central vein catheterisation|ultrasound guided versus landmark central vein catheterisation
1993354|NCT03207360|Behavioral|Pain Coping Skills|Participants will be trained in pain coping skills and meaning-centered psychotherapy. The intervention will consist of 4 weekly in-person sessions that will last between 45 and 60 minutes.
1993355|NCT03206996|Behavioral|Exposure therapy|"The therapist, child and family collaborate to set short and long term goals, develop the exposure hierarchy and Subjective Units of Distress (SUD) scale and design their challenge activities (i.e., exposures). The exposure hierarchy lists activities in ascending order from minimal exposure/minimally difficult (e.g, toilet is not flushed and bathroom door is closed while child walks by) to maximum exposure/maximally difficult (e.g., toilet is flushed repeatedly while child is inside the stall with the door closed). Treatment begins with exposure to activities on the lower end of the hierarchy, with adjustments as indicated, to present stimuli that provide a just-right level of difficulty as indicated by the participant's SUD level and therapists clinical judgment. Participants communicate the level of difficulty using their individualized SUD scale. Additionally, the child and family complete home exercises with exposures."
1993356|NCT03206996|Behavioral|Psycho-education|Child and caregiver receive education and training will be provided to improve the participant's self-awareness of his/her behavioral and emotional response to auditory stimuli, his/her ability to self-report anxiety/emotional response levels, as well as his/her ability to identify useful arousal level modulation/coping strategies. During this phase, the child, caregiver and therapist will collaborate to identify the participant's Subjective Units of Distress Scale (SUD) from 0-10 with each level defined, particularly for what levels are tolerable or intolerable.
1993357|NCT03206996|Behavioral|Caregiver education/home program development|Parents will be provided with education on home programs to facilitate treatment gains. Home programs will be designed specifically for each participant. Parent education and home programs are provided either concurrently or after the exposure phase for the family to apply these methods to other settings. Home programs can continue as a maintenance program after treatment has ended. At the end of the treatment phase, the study team will conduct the following assessments for a third time: (1) the Sensory Profile, a clinical tool commonly used in OT to assess parent reports of sensory processing difficulties in children, (2) Parent Stress Index - 4 to evaluate stress related to parent-child interactions, and (3) the Modified Khalfa Hyper-acusis Questionnaire to assess the level of hyper-sensitivity to sound.
1993358|NCT03206957|Diagnostic Test|Funduscopic examination and retinal photography|A standardized funduscopic examination and retinal photography will be performed by an ophthalmologist focusing on optic nerve.
1993359|NCT03206957|Diagnostic Test|Serum levels of endostatin and angiogenesis factors|Serum levels of endostatin, angiopoietin and vaso endothelial growth factor will be analyzed
1982132|NCT02964039|Behavioral|Error augmentation|During training sessions, a custom-built force-field will exert forces on the legs while participants walk. These forces will push the legs away from mechanically-appropriate mediolateral locations, having the effect of amplifying the errors in foot placement that are often present among individuals who have experienced a stroke.
1982133|NCT02964039|Behavioral|Activity matched control|During training sessions, participants will interface with a custom-built force-field while they walk. The force-field will essentially get out of the way, producing minimal forces on the legs, and having no direct effect on the errors in foot placement that are often present among individuals who have experienced a stroke.
1982134|NCT02963285|Other|Nasopharyngeal temperature probe|Nasopharyngeal temperatures will initially be recorded 30 minutes after induction of anesthesia. Nasopharyngeal probes will then be withdrawn at the designated increment for each age group and will be equilibrated for 5 minutes before the temperature is recorded. Thereafter, the nasopharyngeal withdrawal sequence will be repeated.
1982139|NCT02961062|Drug|SAF312|
1982140|NCT02961062|Drug|Placebo|
1982153|NCT02956122|Biological|GLASSIA|GLASSIA [Alpha1-Proteinase Inhibitor (Human)]
1982154|NCT02956122|Drug|methylprednisolone or equivalent steroid|The conventional steroid treatment (methylprednisolone or equivalent steroid) will be supplied by the investigators per their institutional practice.
1982155|NCT02956122|Biological|Albumin|The control vials contain human albumin 20% in 50 mL normal saline solution in glass vials (for non-United States (US) Countries), or Flexbumin 25% in 50 mL in normal saline solution in plastic IV bags (for US).
1982156|NCT02955355|Biological|HYQVIA|
1982169|NCT02951052|Drug|Cabotegravir (CAB) tablet|It is a white oval shaped film coated 30 mg tablets for oral administration. CAB Tablet is composed of cabotegravir sodium, lactose monohydrate, microcrystalline cellulose, hypromellose, sodium starch glycolate, magnesium stearate, and white film-coat
1982170|NCT02951052|Drug|Rilpivirine (RPV) tablet|"It is a 25 mg tablet with off-white, round, biconvex, film-coated and debossed on one side with TMC and the other side with 25. Each tablet contains RPV hydrochloride, and the inactive ingredients croscarmellose sodium, lactose monohydrate, magnesium stearate, polysorbate 20, povidone K30 and silicified microcrystalline cellulose"
1982171|NCT02951052|Drug|Cabotegravir - Injectable Suspension (CAB LA)|It is a sterile white to slightly pink suspension containing 200 mg/mL of CAB as free acid for administration by intramuscular (IM) injection. Each vial is for single-dose use containing a withdrawable volume of 2.0 mL, and does not require dilution prior to administration. CAB LA is composed of cabotegravir free acid, polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection
1982172|NCT02951052|Drug|Rilpivirine - Injectable Suspension (RPV LA)|It is a sterile white suspension containing 300 mg/mL of RPV as the free base. The route of administration is by intramuscular (IM) injection. Each vial contains a nominal fill of 2.0 mL, and does not require dilution prior to administration. RPV LA requires refrigeration and must be protected from light. RPV LA is composed of RPV free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection.
1982173|NCT02951052|Drug|2 NRTIs plus an INI, NNRTI, or PI|"Acceptable stable (initial or second) ARV regimens include 2 NRTIs plus:
INI with the exception of ABC/DTG/3TC (either the initial or second cART regimen)
NNRTI (either the initial or second cART regimen)
Boosted PI (or atazanavir [ATV] unboosted) (either the initial or second PI-based cART regimen)"
1982177|NCT02949921|Device|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
1982197|NCT02942576|Drug|Edoxaban|Edoxaban 60 mg once-daily or 30 mg once-daily in selected subjects.
1982198|NCT02942576|Drug|VKA-Based Regimen|Dosed at International Normalised Ratio (INR) levels, which is a test of how long it takes for blood to clot. Standard of Care treatment in Canada, Italy, Poland, Hungary, Czech Republic, UK, Taiwan and Korea.
1982199|NCT02942576|Drug|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Germany, Belgium, and the Netherlands.
1982200|NCT02942576|Drug|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in France.
1982201|NCT02942576|Drug|VKA-Based Regimen|Dosed at INR levels. Standard of Care treatment in Spain.
1982208|NCT02939625|Device|muscle training|
1982209|NCT02939625|Device|Continue Positive Airway Pressure|
1982210|NCT02939625|Device|bilevel positive airway pressure|
1982213|NCT02937831|Biological|RIXUBIS|
1982228|NCT02932618|Biological|von Willebrand factor (Recombinant)|
1982229|NCT02932618|Biological|Antihemophilic Factor (Recombinant)|
1982230|NCT02932943|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
1982231|NCT02932943|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
1982232|NCT02931448|Device|Dosage of the blood HbCO thanks to the carboxymeter MASIMO RAD 57|
1982233|NCT02930837|Drug|alteplase|
1982235|NCT02930551|Drug|Lidocaine|
1982236|NCT02930551|Drug|Isotonic Saline|
1982269|NCT02922231|Biological|RIXUBIS|Recombinant Factor IX (rFIX) for intravenous use
1982291|NCT02916550|Behavioral|Breathing exercise|Participants will perform a paced breathing intervention (slow breathing) prompted by pseudorandomized remote reminders (scheduled reminders plus non scheduled reminders), through cellular phone application.
1982321|NCT02904278|Other|Teen Pocket PATH® Mobile Application|Participants in the intervention group will receive the mobile application for improving adherence to their post-transplant medications. The intervention will prompt, remind, and warn participants when medications are due, inform parents when medication management is completed, and engage parents when no action is undertaken.
1982322|NCT02904278|Other|Control Group: Standard of Care|Adolescents and parents/guardians assigned to the Standard Care Condition will receive standard clinical care per standard site procedures.
1982323|NCT02904096|Device|Radiesse injectable implant and 2% lidocaine HCL|Radiesse injectable implant injected in small boluses (0.2-0.5cc/bolus). No more than 0.5cc per bolus. No more than 3 cc (2 syringes) will be injected per hand.
1982328|NCT02901197|Behavioral|Education and Reminder Posters|See arm description
1982329|NCT02901197|Other|Policy Change|See arm description
1982334|NCT02899377|Radiation|18F-FDG PET/CT Imaging|pSS subjects (in fasting conditions) will receive one-time bolus IV injection of 200 MBq of 18F-FDG. After 60 minutes of administration, a PET scan will be performed with static scanning acquired for up to 30 to 40 minutes.Other name: 18F-FDG
1982335|NCT02899377|Radiation|11C-MET PET/CT Imaging|"Subjects (post meal) will receive one-time bolus IV injection of 500 MBq of 11C-MET. This will be followed by PET scan and dynamic scanning of the salivary gland region for approximately 40 minutes. A static scan will then be performed (within 5 minutes) with the whole body CT followed by the PET covering the head to hip with a duration of same range for approximately 20 to 30 minutes.
Other Name:11C-MET"
1982336|NCT02899377|Procedure|MRI Imaging with intravenous contrast with gadoterate meglumine|Eligible subjects will receive a one-time IV injection of 0.1mmol/kg of gadoterate meglumine followed by a multi-parametric MRI scanning.
1982337|NCT02899377|Procedure|Minor Salivary gland (labial) biopsy|A minor salivary gland biopsy will be performed at Visit 2 for pSS subjects only.
1982352|NCT02895945|Biological|Antihemophilic Factor (Recombinant), Porcine Sequence (BAX802)|In case of major surgery, FVIII target level is ≥80% for major surgeries/ procedures and ≥50% for minor surgeries/ procedures.
1982358|NCT02891837|Drug|L-citrulline|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass, but after removal of any crystalloid base;
Addition of study medication at a concentration of 200 μmol/L given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations to compensate for fluids containing L-citrulline that may be removed from the patient during the course of the operation and thus to maintain the concentration of 200 μmol/L;
Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;
9 mg/kg/hr continuous infusion for up to 48 hours."
1982359|NCT02891837|Other|Placebo|"Bolus of 150 mg/kg at the initiation of cardiopulmonary bypass;
Addition of placebo matched for volume given as a bolus during bypass. This may be administered as a one-time bolus or multiple administrations during bypass;
Bolus of 20 mg/kg 30 minutes after decannulation from cardiopulmonary bypass;
9 mg/kg/hr continuous infusion for up to 48 hours."
1982392|NCT02875132|Drug|pembrolizumab|pembrolizumab at 200mg IV infusion every 3 weeks
1982404|NCT02871375|Device|Delefilcon A multifocal contact lenses|Multifocal contact lenses worn in a daily wear, daily disposable modality (new pair of lenses each morning)
1982405|NCT02871375|Device|Habitual multifocal contact lenses|Multifocal contact lenses worn per subject's habitual prescription and habitual daily wear modality
1982408|NCT02864758|Drug|Rivaroxaban (Xarelto, BAY59-7939)|Tablets, 20mg once daily
1982409|NCT02864758|Drug|Vitamin K antagonists|Tablets, dose is based on International Normalized Ratio
1982410|NCT02864758|Drug|dabigatran (Pradaxa)|Tablets, 150 mg twice daily
1982411|NCT02864147|Drug|9-valent HPV vaccine|All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
1982412|NCT02864147|Drug|Imiquimod|At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
1982414|NCT02860559|Biological|TBX-1400|Hematopoietic stem cells transplantation
1982420|NCT02858583|Procedure|CC+SI|chest compression will be delivered during sustained inflation (CC+SI). The duration of each sustain inflation is 20sec. After 20sec a pause of 1sec id done before the next sustained inflation is delivered for another 20sec. Chest compressions are given continuously. This approach is continued until return of spontaneous circulation.
1982421|NCT02858583|Procedure|3:1 C:V|During 3:1 C:V. 3 chest compressions are given, then stopped and then 1 inflation is given. This approach is continued until return of spontaneous circulation.
1982425|NCT02855697|Drug|Olaparib|300 mg taken twice daily, equivalent to a total daily dose of 600 mg
1982426|NCT02855697|Drug|Cediranib|20mg dose of cediranib was selected for this study
1982427|NCT02855697|Drug|Platinum-based Chemotherapy|1 or 2 two courses of platinum-based chemotherapy administered depending on trial entry point.
1982450|NCT02849210|Biological|Allergovac depot with Olea europaea pollen extract|Subcutaneous immunotherapy in depot presentation in a rapid dose escalation scheme: 6 weekly increasing dose injections at the initiation phase plus 3 maintenance monthly injections.
1982459|NCT02844036|Procedure|Percutaneous angioplasty|
1982460|NCT02844036|Procedure|Balloon angioplasty|
1982461|NCT02844036|Procedure|Right heart catheterization|
1982462|NCT02844036|Procedure|Echocardiography|
1982463|NCT02844036|Other|A six-minute walking test|
1982464|NCT02844036|Procedure|Functional respiratory investigations|
1982465|NCT02844036|Procedure|Pulmonary tomography or pulmonary angiography|
1982466|NCT02844036|Other|Biological parameters|
1982469|NCT02840903|Drug|Iopromide (Ultravist, BAY86-4877)|8 settings for CT Angiography as described in group description.
1982483|NCT02834689|Behavioral|Walking|Walking on a treadmill at 3.5 METS for 50 minutes
1982484|NCT02834689|Behavioral|Seated Control|Sitting for 50 minutes
1982485|NCT02834312|Drug|Estetrol|All treatments (E4 [2.5 mg, 5 mg, 10 mg, 15 mg] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
1982486|NCT02834312|Drug|Placebo|1 capsule will be administered QD per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
1982531|NCT02824042|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine given IV On Day 1 of each 21-day treatment cycle Part 1: Cycle 1 Day 1: 6.5 mg/kg of body weight (BW) Cycle 2 Day 1: 0.6 mg/kg BW Part 2: Cycle 1 Day 1: 6.5 mg/kg BW Cycle 2 Day 1: 6.5 mg/kg BW (planned dose) Continuous treatment: Cycles ≥3 Day 1: 6.5 mg/kg BW once every 3 weeks (Q3W)
1982532|NCT02824042|Drug|Itraconazole|Itraconazole 100 mg oral capsules given by mouth Cycle 1 (Day 18): 200 mg twice daily (BID) (Days 19 - 21): 200 mg once daily (QD) Cycle 2 (Days 1-8): 200 mg QD 12 days in total (Part 1 or Part 2)
1982535|NCT02821325|Other|MRI|"Patients undergoing a total knee arthroplasty, will undergo additional MRI's. One MRI pre-operatively.
2nd MRI post-operatively on day 1. 3rd MRI post-operatively on day 2."
1982541|NCT02818114|Behavioral|Peer Enhanced Prolonged Exposure|Peer support interventions as adjunct to prolonged exposure
1982542|NCT02815995|Drug|Durvalumab|Age group ≥ 18: Durvalumab 1500 mg by vein every 4 weeks for 4 cycles. After Week 16, participant may continue to receive durvalumab alone by vein for an additional 32 weeks (8 doses).
1982543|NCT02815995|Drug|Tremelimumab|Age group ≥ 18: Tremelimumab 75 mg every 4 weeks for 4 cycles.
1982550|NCT02809105|Drug|linaclotide|Oral administration once daily
1982551|NCT02809105|Drug|Placebo|Oral administration once daily
1982552|NCT02801084|Behavioral|Reduced environmental stimulation|"Participants will complete one arm involving four sequential float sessions. Float 1: chair float. Participants will first float in a comfortable chair in the supine position, for up to 90 minutes. The chair is in a room with sound and light attenuation. Orthostatic blood pressure (BP) will be measured before and after each float. Anxiety and body image will be measured afterwards.
Float 2: open pool float. Participants will float for up to 90 minutes in an open pool (8 foot diameter, no enclosure). Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.
Floats 3 & 4: domed pool float. Participants will float for up to 90 minutes in a domed pool the same size as the open pool, with an enclosure wall and 8 foot tall ceiling. Orthostatic BP will be measured before and after each float. Anxiety and body image will be measured afterwards.
Each float will occur approximately 1 to 7 days apart."
1982556|NCT02799745|Drug|Enzalutamide|Oral
1982557|NCT02799745|Other|Active Surveillance|
1982589|NCT02780388|Biological|MEDI4920|MEDI4920 CD40L
1982590|NCT02780388|Other|Placebo|0.9% saline for injection
1982597|NCT02777372|Drug|Sertraline|Sertraline will be provided at a dose of 50 mg daily for up to 3 weeks, depending on the length of a woman's luteal phase. Medication will be taken only during the luteal phase. Women will initiate sertraline treatment upon determining that they have ovulated (using a urine LH Kit) and remain on sertraline until onset of their next menstrual period at which time they will stop taking the medication.
1982600|NCT02776514|Drug|Triamcort|Fluoroscopic guided injection in the knee joint
1982601|NCT02776514|Drug|Platelet-rich-plasma|
1982602|NCT02776514|Drug|Suplasyn1|
1982603|NCT02776514|Drug|Placebo|
1982615|NCT02768363|Biological|aglatimagene besadenovec|Aglatimagene besadenovec will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second aglatimagene besadenovec injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
1982616|NCT02768363|Biological|placebo|Placebo will be delivered to the prostate via trans-rectal ultrasound guided injection followed by 14 days of oral prodrug, valacyclovir. The second placebo injection will be 2-3 weeks after the first followed by 14 days of valacyclovir.
1982617|NCT02768363|Drug|valacyclovir|Oral prodrug to be given for 14 days starting the day after each aglatimagene besadenovec or placebo injection.
1982619|NCT02769481|Drug|Bexagliflozin|20 mg, tablet
1982620|NCT02769481|Drug|Placebo for Bexagliflozin|20 mg inactive tablet to match active comparator
1982621|NCT02769481|Drug|Glimepiride|2, 4 or 6 mg, capsule
1982622|NCT02769481|Drug|Placebo for Glimepiride|2, 4 or 6 mg inactive capsule to match the active comparator
1982626|NCT02764489|Biological|Factor VIII Inhibitor Bypassing Activity (nanofiltered, vapor heat-treated)|
1982643|NCT02751918|Drug|Anetumab ravtansine (BAY94-9343)|Anetumab ravtansine will be administered by 1-hour IV infusion on Day 1 of every 21-day treatment cycle. The starting dose of anetumab ravtansine in the first dose cohort in Part 1 will be 5.5 mg/kg of body weight.
1982644|NCT02751918|Drug|Pegylated Liposomal Doxorubicin|Pegylated liposomal doxoribicin will be administered by 1-hour IV infusion on Day 1 of every 21-day treatment cycle at a dosage of 30 mg/m2 of body surface area. Application will be after anetumab ravtansine infusion.
1982657|NCT02746081|Drug|BAY1436032|The selected starting dose of BAY1436032 is 300 mg/day (150 mg BID) to be administered orally continuously in tablet form in 21-day cycles. Adjustments to this schedule may be made if warranted by information collected during the course of the study. The maximum feasible dose of BAY1436032 is expected to be 3000 mg/day.
1982658|NCT02745743|Drug|BAY1251152|Weekly infusion of BAY1251152 in 21-day cycles.
1982661|NCT02742792|Other|Resistance training|Twenty-four strength training sessions consisted in exercises of extension and flexion knees, lat pull-down, elbow extension and flexion, sitting bench press and hip abduction.
1982662|NCT02742792|Other|Advice on Lifestyle|Patients receive advice on lifestyle. Patients will be asked to participate in the elderly group meetings the basic health unit linked to the hospital.
1982663|NCT02743078|Drug|Bevacizumab|Vascular endothelial growth factor A (VEGF-A) angiogenesis inhibitor
1982664|NCT02743078|Device|TTFields|Tumor treating low intensity, intermediate frequency electric fields
1982665|NCT02743351|Biological|ProTmune|Ex-vivo, programmed mobilized peripheral blood (mPB) cells
1982666|NCT02743351|Biological|Control Arm|Untreated mobilized peripheral blood (mPB) cells
1982667|NCT02741323|Drug|Maraviroc|Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR < 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).
1982668|NCT02741323|Drug|Placebo|Initial dose of 300 mg twice daily (150mg twice daily if co-prescribed with a potent CYP3A inhibitor or 600mg twice daily if co-prescribed with a potent CYP3A inducer). Will be modified if GFR < 30, if co-prescribed with a potent CYP3A inhibitor or inducer, or if the calcineurin inhibitor used for maintenance immunosuppression is changed to cyclosporine (which is only allowed for tacrolimus toxicity).
1982669|NCT02738203|Drug|Vaginal 2% Lidocaine|Patient-administered vaginal Lidocaine jelly verse surgical lubricant jelly
1982670|NCT02738203|Drug|Surgical Lubricant Jelly|Patient-administered vaginal surgical lubricant jelly verse Lidocaine jelly
1982680|NCT02727764|Genetic|ART-I02|Single Intra-articular injection in the metacarpophalangeal (MCP), proximal interphalangeal (PIP), or distal interphalangeal (DIP) joint
1982688|NCT02722200|Drug|hydrocortisone|Hydrocortisone will be used as the steroid of choice because it is bio-identical to cortisol and is subject to the same metabolism as cortisol.
1982689|NCT02722200|Other|saline|Saline will be used as the placebo comparator. It will be administered in the same manner as the active drug.
1982697|NCT02720445|Drug|Nicotine Transdermal Patch|21mg Nicotine transdermal patches worn during waking hours. Active dose will titrate up from 3.5mg to 21mg in the first 6 weeks of treatment, remain at 21mg for 22.5 months, and then taper down in the final month of treatment.
1982698|NCT02720445|Drug|Placebo Patch|Matching placebo patches worn during waking hours.
1982699|NCT02717923|Other|maintenance treatment with capecitabine plus cetuximab|Using a maintenance treatment strategy of capecitabine plus cetuximab as a treatment option in mCRC after first-line 5-FU-based chemotherapy plus cetuximab
1982700|NCT02718495|Drug|PTI-428|
1982701|NCT02718495|Drug|Placebo|
1982702|NCT02717507|Drug|Carvedilol|Given PO
1982703|NCT02717507|Other|Laboratory Biomarker Analysis|Correlative studies
1982704|NCT02717507|Other|Pharmacological Study|Correlative studies
1982705|NCT02717507|Other|Placebo|Given PO
1982706|NCT02717507|Other|Quality-of-Life Assessment|Ancillary studies
1982707|NCT02717507|Other|Questionnaire Administration|Ancillary studies
1982710|NCT02716194|Biological|BAX 826|
1982711|NCT02716194|Biological|Octocog alfa|
1982725|NCT02707705|Device|Apply an auricular acupuncture protocol by stimulating specific points of the ear with needles inserted on adhesive tape (Pyonex®).|"Intervention Description :
The auricular acupuncture protocol is based on an anxiolytic triad of three points selected according to the World Health Organization classification. These points are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear. The detected points are treated by application of adhesive tape with needles of diameter 0.2 mm and length 0.9 mm.
Data collected :
T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency
T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects
T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects
T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
1982726|NCT02707705|Device|Apply a device having no real effect|"The three points of the protocol are detected and located precisely by a differential detector starting with the right ear, and in the absence of response, the points are searched on the left ear.The detected points are treated by application of adhesive tape without needle.
Data collected :
T0 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure and cardiac frequency
T1 : anxiety VAS, pain VAS, APAIS, ANI, arterial pressure, cardiac frequency and side effects
T2 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects
T3 : anxiety VAS, pain VAS, arterial pressure, cardiac frequency and side effects"
1982727|NCT02707705|Procedure|Disinfection|The ear is disinfected by applying Chlorhexidine®.
1982734|NCT02705482|Biological|MEDI0562|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
1982735|NCT02705482|Biological|Tremelimumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
1982736|NCT02705482|Biological|Durvalumab|Subjects will remain on treatment until unacceptable toxicity, documentation of progressive disease (PD), or development of other reason for treatment discontinuation.
1982740|NCT02703623|Drug|Abiraterone acetate|1000 mg by mouth daily in a 21 day cycle.
1982741|NCT02703623|Drug|Prednisone|5 mg by mouth twice daily in a 21 day cycle.
1982742|NCT02703623|Drug|ARN509|4 tablets (60 mg each) by mouth daily in a 21 day cycle.
1982743|NCT02703623|Drug|Ipilimumab|3 mg/kg by vein every 3 weeks for 4 weeks starting Day 1 of Cycles 4, 5, 6, and 7. Study cycle is 21 days.
1982744|NCT02703623|Drug|Cabazitaxel|25 mg/m2 by vein once every 3 weeks for 4 weeks starting on Day 1 of Cycles 4, 5, 6, and 7. Study cycle is 21 days.
1982745|NCT02703623|Drug|Carboplatin|AUC 4 by vein once every 3 weeks for 4 weeks starting on Day 1 of Cycles 4, 5, 6, and 7. Study cycle is 21 days.
1982746|NCT02703272|Drug|Ibrutinib|Participants will receive Ibrutinib (dose 240 mg/m^2 /329 mg/m^2 per day) during part 1 and part 2.
1982747|NCT02703272|Drug|Rituximab|Participants will receive a cumulative dose of rituximab 750 mg/m^2 as a part of RICE/RVICI regimen in part 1 and part 2 per cycle.
1982748|NCT02703272|Drug|Ifosfamide|Participants will receive a cumulative dose of Ifosfamide 9 g/m^2 and 10 g/m^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
1982749|NCT02703272|Drug|Carboplatin|Participants will receive a cumulative dose of carboplatin 635 mg/m^2 and 800 mg/m^2 as a part of RICE and RVICI regimen respectively in part 1 and part 2 per cycle.
1982750|NCT02703272|Drug|Etoposide|Participants will receive a cumulative dose of etoposide 300 mg/m^2 in part 1 and part 2 as a part of RICE regimen per cycle.
1982751|NCT02703272|Drug|Vincristine|Participants will receive a cumulative dose of vincristine 1.6 mg/m^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
1982752|NCT02703272|Drug|Idarubicin|Participants will receive a cumulative dose of idarubicin 20 mg/m^2 in part 1 and part 2 as a part of RVICI regimen per cycle.
1982753|NCT02703272|Drug|Dexamethasone|Participants will receive a cumulative dose of dexamethasone 100 mg/m^2 in part 1 and part 2 as a part of RICE/RVICI regimen per cycle.
1982759|NCT02700386|Combination Product|Adjuvant Hypofractionated Radiation|Hypofractionation is the delivery of radiotherapy in single daily doses greater than the 180-200 cGy. Hypofractionation, through use of larger doses per fraction and fewer total treatments, is a method of shortening overall treatment time in breast cancer therapy.
1982760|NCT02697058|Biological|BAX2398 + 5-FU/calcium levofolinate|BAX2398 (a liposomal formulation of irinotecan) in combination with 5-FU/calcium levofolinate
1982761|NCT02697058|Drug|5-FU/calcium levofolinate|5-FU/calcium levofolinate alone
1982762|NCT02696902|Drug|MEDI3902|Active
1982763|NCT02696902|Other|Placebo|Placebo
1982769|NCT02696317|Device|Senofilcon A contact lenses with HydraLuxe™|Contact lenses worn during Period 1 or 2, as randomized
1982770|NCT02696317|Device|Senofilcon A contact lenses|Contact lenses worn during Period 1 or 2, as randomized
1982785|NCT02692677|Drug|JNJ-42756493|Participants will receive a single oral solution at a dose of 12 milligram (mg) of unlabeled JNJ--42756493 admixed with 14C- labeled JNJ--42756493.
1982790|NCT02690337|Drug|DS-1123|starting intravenous (IV) dose of 0.1 mg/kg.
1982801|NCT02683785|Drug|GSK3196165|GSK3196165 will be supplied as a liquid and will be administered as a subcutaneous injection. The drug will be administered weekly for 5 injections, then every other week for 3 further injections.
1982802|NCT02683785|Drug|Placebo|Matching placebo will be administered as above.
1982805|NCT02682147|Drug|Sildenafil|One dose of 20 mg Sildenafil will be given one hour before CT imaging
1982817|NCT02675270|Behavioral|Phonological|This treatment involves picture viewing and word repetition.
1982818|NCT02675270|Behavioral|Orthographic|This treatment involves picture viewing, reading, and writing.
1982819|NCT02675270|Behavioral|Semantic|This treatment involves learning about the semantic features (meaning) of each trained word.
1982820|NCT02675270|Behavioral|Lexical|This treatment involves learning about the lexical features (letters and sounds) of each trained word.
1982821|NCT02675270|Behavioral|Untrained|These words are not trained during the treatment phase.
1982822|NCT02674997|Biological|Factor VIII|Licensed Factor VIII products. Study is brand agnostic
1982836|NCT02671136|Device|Hyperbaric Oxygen therapy|
1982837|NCT02671136|Other|Conventional Wound Therapies|
1982850|NCT02654977|Drug|Metreleptin|MyaLept (Recombinant-methionyl Human Leptin (r-metHuLeptin) METRELEPTIN) subcutaneous injections
1982853|NCT02652260|Drug|MK-1439A - Blinded|A single tablet FDC containing doravirine 100 mg, lamivudine (3TC) 300 mg and tenofovir disoproxil fumarate (TDF) 300 mg administered orally, once daily for 12 weeks during the Blinded Period
1982854|NCT02652260|Drug|MK-1439A - Open-Label|A single-tablet FDC containing doravirine 100 mg, 3TC 300 mg and TDF 300 mg administered orally, once daily for either 12 or 24 weeks during the Open-Label Period; and also an additional 96 weeks during the Open-Label Extension period.
1982855|NCT02652260|Drug|ATRIPLA^TM|A single tablet FDC containing efavirenz (EFV) 600 mg, emtricitabine (FTC) 200 mg, and TDF 300 mg administered orally, once daily for 12 weeks during the Blinded Period
1982856|NCT02652260|Drug|Placebo to ATRIPLA^TM|A single placebo to ATRIPLA^TM tablet administered orally, once daily for 12 weeks during the Blinded Period
1982857|NCT02652260|Drug|Placebo to MK-1439A|A single placebo to MK-1439A tablet administered orally, once daily for 12 weeks during the Blinded Period
1982879|NCT02640482|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
1982880|NCT02640482|Drug|Placebo for ABT-493/ABT-530|tablet
1982888|NCT02639091|Drug|BAY 94-9343|"In Part 1 of the study, anetumab ravtansine (BAY 94-9343) will be administered by 1-hour IV infusion with a starting dose of 5.5mg/kg(BW) on Day 1 of every treatment cycle (Q3W).
In Part 2 of the study, anetumab ravtansine (BAY 94-9343) will be administered on Day 2 of Cycle 1 and then on Day 1 of Cycle 2 and all subsequent cycles (Q3W)"
1982889|NCT02639091|Drug|Pemetrexed|Administered at the dose of 500 mg/m2 body surface area (BSA) by 10-minute IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
1982890|NCT02639091|Drug|Cisplatin|Administered at the dose of 75 mg/m2 (BSA) by 2-hour IV infusion on Day 1 of every treatment cycle (Q3W) in both parts of the study
1982891|NCT02638805|Drug|ITCA 650 20/60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 20/60 mcg/day
1982892|NCT02638805|Drug|ITCA 650 60 mcg/day|ITCA 650 osmotic mini pump delivering exenatide 60 mcg/day
1982894|NCT02637804|Device|stenfilcon A|contact lens
1982895|NCT02637804|Device|narafilcon A|contact lens
1982896|NCT02637804|Device|delefilcon A|contact lens
1982899|NCT02634723|Biological|Octocog alfa (recombinant human coagulation factor VIII)|
1982909|NCT02626910|Other|No intervention|No intervention
1982910|NCT02624037|Other|Individualized Dosage Precision IFX Dashboard|Pharmacokinetic Dashboard Recommended Dosage and Dosing Frequency of Infliximab
1982924|NCT02615691|Biological|PEGylated Recombinant Factor VIII|Polyethylene glycol (PEG)-ylated full-length recombinant FVIII (rFVIII)
1982936|NCT02607423|Drug|Cisplatin|Given IV
1982937|NCT02607423|Procedure|Computed Tomography|Undergo 18F-FDG PET/CT
1982938|NCT02607423|Drug|Docetaxel|Given IV
1982939|NCT02607423|Radiation|Fludeoxyglucose F-18|Undergo 18F-FDG PET/CT
1982940|NCT02607423|Drug|Gemcitabine Hydrochloride|Given IV
1982941|NCT02607423|Drug|Pemetrexed Disodium|Given IV
1982942|NCT02607423|Procedure|Positron Emission Tomography|Undergo 18F-FDG PET/CT
1982943|NCT02606084|Drug|Esketamine|Participants will self-administer esketamine solution intranasally 28 milligram (mg) on Day 1.
1982944|NCT02605525|Biological|SM101|Human soluble recombinant Fcγ Receptor IIB
1982945|NCT02605525|Other|Placebo|L-histidine-buffered saline with mannitol, sucrose, and polysorbate 20
1982950|NCT02604160|Drug|LY3113593|Administered by slow intravenous (IV) infusion.
1982951|NCT02604160|Drug|Placebo|Administered by slow intravenous (IV) infusion.
1982962|NCT02598882|Device|videogame|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute guided activity through an active video game
1982963|NCT02598882|Device|treadmill|Patients will be an assessment of quadriceps muscle strength by surface electromyography, before and after a 30-minute activity in treadmill.
1982964|NCT02598791|Other|GIP|Glucose-dependent insulinotropic polypeptide (4 pmol/kg/min)
1982965|NCT02598791|Other|GLP-1|glucagon-like peptide-1 (1 pmol/kg/min)
1982966|NCT02598791|Other|NaCl (placebo)|i.v. NaCl
1982967|NCT02598661|Drug|Imetelstat|Imetelstat will be administered at a starting dose of 7.5 milligram per kilogram (mg/kg) given intravenously every 4 weeks, until disease progression, unacceptable toxicity, or withdrawal of consent, or lack of response.
1982968|NCT02598661|Drug|Placebo|Matching Placebo to Imetelstat will be administered.
1982994|NCT02593188|Biological|HYQVIA|Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase
1983022|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) evaluation
1983023|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Standard treatment
1983024|NCT02585960|Biological|PEGylated Recombinant Factor VIII|Intensified treatment
1983025|NCT02586233|Drug|DS-1040b|IV infusion of DS-1040b
1983026|NCT02586233|Drug|placebo|placebo IV infusion
1983027|NCT02584777|Biological|Pacritinib|QD (Once a day)
1983028|NCT02583711|Device|Activity sensor (3 axis accelerometer)|Patient cohort will wear the activity sensor from pre-admission clinic until discharge after surgical procedure
1983029|NCT02583165|Biological|MEDI1873|Subjects will receive MEDI1873 by intravenous administration
1983076|NCT02566889|Drug|Infliximab|Participants in the dose escalation group will escalate dose from infliximab 5 mg/kg q8w to 10 mg/kg q8w at the time of loss response. Participants in the reference group will be maintained on infliximab 5 mg/kg q8w.
1983077|NCT02564718|Drug|Rivaroxaban(Xarelto,BAY59-7939)|Body weight adjusted dosing of rivaroxaban to achieve a similar exposure in the range as that observed in adults treated for venour thromboembolism (VTE) with 20 mg once daily.
1983085|NCT02562651|Drug|Doxycycline|Doxycycline bid for the first 7 days after primary anterior STEMI
1983086|NCT02562651|Other|Standard care for STEMI|Invasive and medical treatment for STEMI according to guidelines
1983087|NCT02560818|Other|collection of a blood sample and breast tissue|a blood sample and a breast tissue sample will be collected in healthy women during their breast reduction surgery
1983088|NCT02560818|Other|use of a previous blood collection for patients|
1983089|NCT02560168|Device|MyoVista device|MyoVista device is a standard EKG device with additional capabilities in detecting cellular level myocardial electrophysiological signals. The device involves placing leads on the chest, similar to a traditional EKG device
1983090|NCT02560168|Device|Computed tomographic coronary angiography|Traditional method of detecting coronary artery disease. CTA will be performed using 64-detector row or higher scanners with electrocardiographic gating in accordance with the Society of Cardiovascular Computed Tomography (SCCT) guidelines. Approximately 80 to 100 ml of intravenous contrast, followed by 50 to 80 ml of saline, will be administered at a rate of 5 ml/s via a power injector through an antecubital vein (on forearm near the elbow).
1983091|NCT02560168|Device|Transthoracic Echocardiography|
1983092|NCT02556463|Drug|MEDI9197|Subjects will receive MEDI9197 every 4 weeks
1983093|NCT02556463|Biological|durvalumab|Subjects will receive durvalumab every 4 weeks
1983094|NCT02556463|Radiation|radiation|palliative radiation every 4 weeks
1983095|NCT02556203|Drug|Rivaroxaban (Xarelto, BAY59-7939)|10 mg OD (once-daily)
1983096|NCT02556203|Drug|Acetylsalicylic acid|75 - 100 mg OD (for first 90 days only in arm 1)
1983097|NCT02556203|Drug|Clopidogrel|75 mg OD for first 90 days
1983098|NCT02555878|Drug|Rivaroxaban|Rivaroxaban 10 milligram (mg) tablet will be administered orally once daily for 180 days.
1983099|NCT02555878|Drug|Placebo|Placebo tablet will be administered orally once daily for 180 days.
1983103|NCT02554396|Drug|PRX-100|ophthalmic solution
1983104|NCT02554396|Drug|Placebo|saline ophthalmic solution
1983117|NCT02547012|Drug|esomeprazole+amox+levo+tetra|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d., and tetracycline 500 mg q.d.s.
1983118|NCT02547012|Drug|esomeprazole+amox+levo|esomeprazole 40 mg b.d., amoxicillin 500 mg q.d.s., levofloxacin 500 mg o.d.,
1983119|NCT02546908|Other|No Intervention|This is an observational study. No study medication is provided will be provided as part of participation. Participants disease status, overall survival (OS), PFS, MFS, SRE-free survival, and time to castration (TTC) will be analyzed according to treatments prescribed while enrolled in the registry. All treatment decisions will be made at the discretion of the investigator or treating physician.
1983123|NCT02545049|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
1983124|NCT02545049|Drug|Placebo|Matching placebo to be taken orally, once daily.
1983137|NCT02540993|Drug|Finerenone (BAY94-8862)|10 mg or 20 mg Finerenone tablet to be given orally, once daily.
1983138|NCT02540993|Drug|Placebo|Matching placebo to be taken orally, once daily.
1983140|NCT02540356|Biological|BAX69 Single-Route Arm|Intraperitoneal (IP) only
1983141|NCT02540356|Biological|BAX69 Double-Route Arm|Intravenous (IV) infusion + intraperitoneal (IP) infusion
1983144|NCT02536846|Drug|Olanzapine|All subjects will take a single 2.5 mg dose of olanzapine (Zyprexa Zydis) followed by a 5 mg dose for 14 days. (2.5 mg/d for 1 day, 5 mg/d for 14 days).
1983150|NCT02535312|Drug|Cisplatin|Given IV
1983151|NCT02535312|Other|Laboratory Biomarker Analysis|Correlative studies
1983152|NCT02535312|Drug|Methoxyamine|Given PO
1983153|NCT02535312|Drug|Pemetrexed Disodium|Given IV
1983154|NCT02535312|Other|Pharmacological Study|Correlative studies
1983155|NCT02534974|Device|NOSTEN|
1983160|NCT02531516|Drug|Apalutamide|
1983161|NCT02531516|Drug|Bicalutamide|
1983162|NCT02531516|Drug|Bicalutamide Placebo|
1983163|NCT02531516|Drug|Apalutamide Placebo|
1983164|NCT02531516|Drug|GnRH (agonist)|
1983165|NCT02531516|Radiation|74-80 Grays (units of radiation)|
1983167|NCT02525861|Biological|GLASSIA|60 mg/kg BW administered at a rate of 0.2 mL/kg/min
1993360|NCT03206957|Diagnostic Test|Renal and low urinary tract Doppler ultrasound|"Measurements of each kidney will include maximum renal bipolar length in a sagittal plane, renal width and thickness in an axial plane perpendicular to each other at the level of renal hilum and cortical thickness. Intensity of corticomedullary differentiation will estimated.
Doppler ultrasound examination will assess renal arterial resistivity indexes"
1993361|NCT03206957|Diagnostic Test|Urinalysis|Urinalysis assessments will include assessments of microalbuminuria and microalbuminuria to creatinuria ratio. A spot urine sample will be collected from first morning void.
1993362|NCT03206957|Diagnostic Test|Anthropometric measures and vitals signs|weight, height and blood pressure will be assessed
1993369|NCT03205696|Drug|Antiretrovirals|The antiretroviral (ARV) regimen provided by the clinician must follow DHHS guidelines for antiretroviral naïve adolescents and adults
1993370|NCT03205605|Drug|oxybutynin|patch
1993371|NCT03205605|Drug|oxybutynin|gel
1993375|NCT03205176|Drug|AZD5153|"The intervention is AZD5153.
AZD5153 is to be taken as oral capsules once per day for 21 days in Cohorts 1-6a. Dosing will continue until disease progression or other study discontinuation criteria are met."
1993376|NCT03205176|Drug|AZD5153|"The intervention is AZD5153.
In Cohort 6b AZD5153 capsules will be taken two times per day for 3 consecutive days followed by 4 days of no drug for a total of 21 days."
1993377|NCT03204318|Drug|Relugolix|Relugolix 40 mg oral tablet
1993378|NCT03204318|Drug|Relugolix Placebo|Sugar pill manufactured to match relugolix in size, shape, color and odor
1993379|NCT03204318|Drug|Low-dose Hormonal Add-back|Over-encapsulated estradiol 1.0 mg and norethindrone acetate 0.5 mg co-formulated tablet
1993380|NCT03204318|Drug|Low-dose Hormonal Add-back Placebo|Over-encapsulated sugar pill manufactured to match estradiol and norethindrone acetate co-formulated tablet
1983171|NCT02521376|Drug|Entospletinib|Entospletinib 100 mg tablet administered orally twice daily
1983181|NCT02514473|Drug|VX-809|
1983182|NCT02514473|Drug|Placebo|
1983183|NCT02514473|Drug|VX-770|
1983184|NCT02513797|Device|LARIAT + PVI|Left Atrial Appendage ligation with the LARIAT System initially performed followed by adjunctive pulmonary vein isolation catheter ablation in staged procedures
1983185|NCT02513797|Device|Pulmonary Vein Isolation|Perform pulmonary vein isolation (PVI) catheter ablation procedure using a contact force sensing, irrigated radiofrequency catheter approved by FDA for the treatment of atrial fibrillation.
1983196|NCT02511795|Drug|AZD1775|"AZD1775 will be given twice daily (PO BID) over 3 days (6 doses) on Days 1-3 and 8-10 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.
Olaparib will be given orally BID on Days 1-14."
1983197|NCT02511795|Drug|Olaparib|"AZD1775 will be given twice daily (PO BID) over 5 days (10 doses) on Days 1-5 and 8-12 of each 21 day cycle combined with olaparib PO BID on Days 1-14 of each 21 day cycle.
Olaparib will be given orally BID on Days 1-14."
1983200|NCT02509286|Drug|5-Fluorouracil|2600 mg/m² (24 hours), d1 every two weeks;
1983201|NCT02509286|Drug|Leucovorin|200 mg/m² in 250 ml NaCl 0.9%, d1 every two weeks;
1983202|NCT02509286|Drug|Oxaliplatin|85 mg/m² in 500 ml G5% over 2h, d1 every two weeks;
1983203|NCT02509286|Drug|Docetaxel|50mg/m2 in 250 ml NaCl 0.9% over 1h, d1 every two weeks;
1983204|NCT02509286|Drug|Carboplatin|Dose-dependant: 2mg/ml/min AUC in 500ml Glucose 5%, day 1, 8, 15, 22 and day 29.
1983205|NCT02509286|Drug|Paclitaxel|50mg/m2 in 500ml NaCl 0.9% over 1 h, day 1, 8, 15, 22 and day 29;
1983206|NCT02509286|Radiation|Neoadjuvant radiation|41.4Gy given in 23 fractions of 1.8Gy on days 1-5, days 8-12, days 15-19, days 22-26 and days 29-31.
1983208|NCT02507349|Behavioral|Person-Centered Care|Decision support center staffed by peers. Patient uses the CommonGround program prior to medication visit to prepare a personal report, with support from peer(s). The CommonGround report expresses goals for medication, how other strategies help with functioning, current problems, and medication side effects. Patient brings report into the medication visit. Prescriber and patient discuss medication options, and prescriber enters the shared decision into CommonGround during the visit.
1983209|NCT02507349|Behavioral|Measurement-Based Care|Clinic staff asks each patient to use a tablet computer to complete a brief assessment of symptoms and problems prior to medication visit. Prescriber views assessment results on office computer and discusses next steps in medication management with the patient.
1993381|NCT03204981|Device|Intramural Needle Ablation|The needle-tipped ablation catheter that will be used for the IN ablation uses radiofrequency like a standard RF ablation catheter, but delivers energy through an extendable/retractable needle.
1993382|NCT03204981|Procedure|Ablation|standard ablation
1993388|NCT03204331|Drug|Relugolix|Relugolix 40 mg oral tablet
1993389|NCT03204331|Drug|Relugolix Placebo|Sugar pill manufactured to match relugolix in size, shape, color and odor
1993390|NCT03204331|Drug|Low-dose Hormonal Add-back|Over-encapsulated estradiol 1.0 mg and norethindrone acetate 0.5 mg co-formulated tablet
1993391|NCT03204331|Drug|Low-dose Hormonal Add-back Placebo|Over-encapsulated sugar pill manufactured to match estradiol and norethindrone acetate co-formulated tablet
1993392|NCT03202784|Drug|BCX7353|BCX7353
1993393|NCT03203460|Behavioral|High-intensity aerobic interval training (HIIT)|A 12-week, supervised, HIIT aerobic exercise program consisting of alternating vigorous- and low-intensity intervals
1993394|NCT03203447|Drug|suprachoroidal CLS-TA + IVT aflibercept|suprachoroidal injection of CLS-TA following a 2 mg intravitreal injection of aflibercept
1993395|NCT03203447|Drug|suprachoroidal sham + IVT aflibercept|suprachoroidal sham procedure following a 2 mg intravitreal injection of aflibercept
1993396|NCT03203161|Procedure|bariatric surgery|Roux-and-Y Gastric Bypass or Sleeve gastrectomy
1993397|NCT03202888|Behavioral|Intervention|QuesGen-created mobile responsive website tool, Family Input for Quality and Safety.
1993398|NCT03201172|Device|Primary Unicompartmental Knee Arthroplasty|Primary implantation of an unicompartmental knee implant
1993399|NCT03201419|Drug|FE 201836|Oral solution for daily intake
1993400|NCT03201419|Drug|Desmopressin|Desmopressin Orally Disintegrating Tablet (ODT)
1993401|NCT03201419|Drug|Placebo oral solution|Manufactured to mimic experimental drug
1993402|NCT03201419|Drug|Placebo ODT|Manufactured to mimic active comparator drug
1993403|NCT03199911|Drug|Topical Anti-Infective Product|Topical antibiotic ointment will be erythromycin. If the patient has an erythromycin allergy, bacitracin will be prescribed. If the patient cannot obtain either (i.e. lack of availability at the pharmacy), polysporin-bacitracin will be prescribed. Allergy to all 3 study drugs means that a patient will be excluded from the study.
1993404|NCT03199911|Drug|Topical Ointment|Artificial tear ointment
1993405|NCT03200977|Other|Non-Interventional|Non-Interventional
1993406|NCT03200509|Other|Physical Activity Intervention|Participants will receive a group exercise program, health coaching sessions and an activity monitor.
1993407|NCT03200509|Other|Control group|Participants will receive a group exercise program, sham health coaching sessions and a sham activity monitor.
1993408|NCT03200080|Drug|Tozadenant|2, 4, 6 or 8 Tozadenant 60 mg tablets
1993409|NCT03200080|Drug|Placebo oral tablet|2, 4, 6 or 8 Tozadenant matching placebo tablets
1993410|NCT03200080|Drug|d-amphetamine|2 or 4 capsules, each containing 2 over-encapsulated d-amphetamine 5 mg tablets
1993411|NCT03200080|Drug|Placebo oral capsule|2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet
1993412|NCT03199794|Biological|OBIZUR|Treating physician will determine treatment regimen and frequency of laboratory and clinical assessments according to routine clinical practice.
1993413|NCT03199521|Other|Thrombin generation assays, Thromboelastography (TEG), and Global Thrombosis Test (GTT)|Global Thrombosis Test (GTT): assesses formation of the blood clot and how easily can this be broken down once formed) Thromboelastography (TEG) :assesses the properties of a blood clot and how easily can be broken down Thrombin generation assays: assesses the formation of a blood clot and the potential of thrombolysis via the introduction of different buffer solutions
1993415|NCT03198650|Drug|Acalabrutinib|Acalabrutinib
1993416|NCT03198221|Drug|Golytely|bowel preparation
1993417|NCT03198221|Drug|Prepopik|bowel preparation
1993418|NCT03199313|Drug|Sutezolid|Sutezolid supplied as tablets and matching placebo for oral administration.
1993419|NCT03199313|Drug|Placebo Oral Tablet|Matching Sutezolid placebo
1993420|NCT03199040|Drug|Durvalumab|-Human monoclonal antibody
1993421|NCT03199040|Biological|Neoantigen DNA vaccine|-The vaccine will be given by the TDS-IM system
1993422|NCT03199040|Device|TDS-IM system (Inchor Medical Systems)|-At each vaccination time point, patients will receive two injections at separate sites.
1993423|NCT03199040|Procedure|Peripheral blood draw|-Baseline, following completion of standard of care therapy, Day 1, Day 57, Day 113, Day 159, and 1 year after initiation of neoantigen DNA vaccine therapy
1993424|NCT03198871|Drug|Acetaminophen Injectable Product|The interventional group will receive 1 gram intravenous acetaminophen at the start of wound closure to be repeated every 6 hours for 48 hours postoperatively
1983258|NCT02493868|Drug|Esketamine|Open-label induction phase: Direct entry participants start at a dose of 56 mg on Day 1. On Day 4, the dose may be increased to 84 mg or remain at 56 mg. From Day 8 to 22, dose may be increased to 84 mg, remain the same or be reduced to 56 mg from 84 mg per protocol, at investigator's discretion based on efficacy and/or tolerability. On Day 25, a dose reduction from 84 mg to 56 mg is permitted but no dose increase is permitted. Optimization Phase: Direct-entry and transferred-entry participants will self-administer intranasal esketamine (same dose) for first 4 weeks, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: All participants assigned to esketamine will self-administer intranasal esketamine once weekly or once every other week based on depressive symptoms.
1983259|NCT02493868|Drug|Placebo|Optimization Phase: Transferred-entry participant will self-administer intranasal placebo at weekly treatment sessions for the first 4 weeks of this phase, then individualized to either once weekly or once every other week based on depressive symptoms. Maintenance Phase: Direct-entry and transferred-entry participants assigned to placebo will self-administer matching intranasal placebo once weekly or once based on depressive symptoms.
1983260|NCT02493868|Drug|Duloxetine (Oral Antidepressant)|Duloxetine could be selected as the oral antidepressant medication by the investigator based on review of Massachusetts General Hospital - Antidepressant Treatment Response Questionnaire (MGH-ATRQ) and relevant prior antidepressant medication information. The minimum therapeutic dose is 60 milligram per day (mg/day).
1983261|NCT02493868|Drug|Escitalopram (Oral antidepressant)|Escitalopram could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Escitalopram will be titrated upto a maximum dose of 20 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 10 mg/day.
1983262|NCT02493868|Drug|Sertraline (Oral Antidepressant)|Sertraline could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Sertraline will be titrated upto a maximum dose of 200 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 50 mg/day.
1983263|NCT02493868|Drug|Venlafaxine Extended Release (XR) (Oral Antidepressant)|Venlafaxine Extended Release could be selected as the oral antidepressant medication by the investigator based on review of MGH-ATRQ and relevant prior antidepressant medication information. Venlafaxine Extended Release will be titrated upto a maximum dose of 225 mg/day, but if not tolerated the dose can be reduced to the minimum therapeutic dose of 150 mg/day.
1983275|NCT02491099|Drug|Afatinib|Afatinib, 40 mg orally once daily on a 21 day cycle for the first 12 weeks, then every 28 days for subsequent cycles until progression
1983277|NCT02489318|Drug|Apalutamide|Participants will receive apalutamide 240 mg (4 x 60 mg) tablets orally once daily in each 28 day treatment cycles.
1983278|NCT02489318|Drug|Placebo|Participants will receive Placebo orally once daily in each 28 day treatment cycles.
1983279|NCT02489318|Drug|Androgen Deprivation Therapy (ADT)|All participants will receive and remain on a stable regimen of ADT (gonadotropin releasing hormone analog [GnRHa] or surgical castration). The choice of the GnRHa (agonist or antagonist) will be at discretion of the Investigator. Dosing (dose and frequency of administration) will be consistent with the prescribing information.
1983293|NCT02477904|Other|Ketogenic Diet|Dietary
1983298|NCT02476032|Device|Prof applied oxalate|Crest Sensi-Stop strips (Procter & Gamble™) with the active ingredient will be placed on the qualifying teeth by a dental professional.
1983299|NCT02476032|Device|Self applied oxalate|Subjects will apply the strips (Procter & Gamble™), that contain the active ingredient, by themselves following the manufacturer's instructions.
1983300|NCT02476032|Device|Prof applied placebo|Crest Sensi-Stop strips (Procter & Gamble™) without the active ingredient will be placed on the qualifying teeth by a dental professional.
1983301|NCT02474589|Drug|tecovirimat|Study is based on Animal Regulatory Rule
1983302|NCT02474589|Other|Placebo|Does not apply
1983306|NCT02471521|Other|Mask ventilation|Mask ventilation is performed after administration of rocuronium or not. Initial inspiratory pressure is set as 10 cmH2O and increased gradually by 2 cmH2O until gastric insufflation is detected by either of two methods. Tracheal intubation is done after detection of gas.
1983307|NCT02471521|Drug|Rucoronium|Rocuronium 0.6 mg/kg is injected before mask ventilation in muscle relaxant group or after finish of study in non-relaxant group.
1983311|NCT02468024|Procedure|Lung Surgery|Sublobar Lung Resection
1983312|NCT02468024|Radiation|Radiation therapy|Stereotactic Ablative Radiotherapy, 54 Gy in 3 fractions
1983313|NCT02465957|Biological|aNK (NK-92)|A natural killer cell line recovered from a patient with large granular lymphoma
1983321|NCT02466659|Device|CIAO therapy Amblyz glasses|3-hour CIAO Therapy Amblyz glasses
1983326|NCT02465437|Drug|JBT-101|JBT-101 5 mg q am, 20 mg q am, or 20 mg bid on Days 1-28. JBT-101 20 mg bid on Days 29-84.
1983327|NCT02465437|Drug|Placebo|Placebo q pm (with JBT-101 5 or 20 mg q AM) or placebo bid on Days 1-28. Placebo bid on Days 29-84.
1983328|NCT02465437|Drug|Part B Open-Label Extension|JBT-101 20mg bid on Days 1-364
1983357|NCT02460978|Drug|Dapagliflozin|Tablets
1983358|NCT02460978|Other|Placebo for dapagliflozin|Tablets
1983362|NCT02458690|Behavioral|Beating the Blues (BtB)|BTB is a widely used, empirically supported, stand-alone CBT program for depression designed for primary care patients and appropriate for adults with little computer experience and a 5th-6th grade reading level. BtB utilizes an interactive, multimedia format to deliver eight 50-minute, weekly therapy sessions. Although sessions are tailored to each patient's problems, general topics include challenging dysfunctional thoughts, activity scheduling, problem solving, graded exposure, task breakdown, sleep management, and relapse prevention. Patients are also assigned tailored homeworks that are customized to their needs and reviewed at the start of each session.
1983363|NCT02458690|Behavioral|Problem Solving Treatment in Primary Care (PST-PC)|PST-PC is a manualized, empirically supported CBT developed for use by healthcare professionals in primary care. The focus of the 6-10 30-minute sessions is teaching patients approaches for solving current problems contributing to depression. We are delivering PST-PC via telephone.
1983364|NCT02458690|Drug|Antidepressant Medications|The IMPACT treatment manual provides guidelines for using antidepressants, such as selecting a medication, titrating, switching to another medication, managing side effects, and avoiding drug interactions. The depression clinical specialist (DCS) will work with the patient's primary care provider to develop a plan that follows the IMPACT algorithm. Primary care providers will manage prescriptions. To optimize eIMPACT for CVD risk reduction, we will restrict the list of antidepressants to SSRIs (except paroxetine) and serotonin-norepinephrine reuptake inhibitors (SNRIs).
1983365|NCT02458690|Other|Usual Care|Patients randomized to usual primary care for depression are informed of their depression diagnosis, encouraged to follow-up with their primary care provider, and provided a list of local mental health services. The patient's primary care provider will receive a letter indicating that their patient has a depressive disorder and was randomized to usual care. This letter also provides a list of local mental health services. Like those in the intervention group, usual care patients continue to have access to services that are part of usual care in the targeted systems. There are no restrictions on the care received.
1983382|NCT02448810|Biological|BAX69 + infusional 5-FU/LV|"Study Part 1: Safety Run-in
Administered weekly as part of a 4 week treatment cycle
Intravenous injection"
1983383|NCT02448810|Biological|BAX69 + panitumumab|"Study Part 1: Safety Run-in
Administered weekly as part of a 4 week treatment cycle
Intravenous injection"
1983384|NCT02448810|Biological|BAX69 + 5-FU/LV|
1983385|NCT02448810|Biological|BAX69 + panitumumab|
1983386|NCT02448810|Drug|Standard of Care|"Investigator's choice
Dose according to drug label"
1983387|NCT02448810|Biological|Standard of Care|"Investigator's choice
Dose according to drug label
Choice includes panitumumab in KRAS &NRAS wt group only"
1983388|NCT02449889|Drug|highly purified human chorionic gonadotropin|
1983389|NCT02449889|Drug|recombinant human chorionic gonadotropin|
1983390|NCT02448381|Drug|SGX301 (synthetic hypericin)|0.25% SGX301 in USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
1983391|NCT02448381|Drug|Placebo|USP Hydrophilic Ointment applied twice per week, covered by opaque bandage for 12-24 hours, then treated with an initial dose of 5 J/cm^2 fluorescent light.
1983400|NCT02445313|Device|Nidek MP-3|Nidek MP-3 device to be used to take images which will allow measurement of GA in patients with AMD
1983423|NCT02433938|Procedure|Tibial nerve stimulation|patients underwent a three days postoperative transcutaneous tibial nerve stimulation
1983424|NCT02433938|Procedure|Sham tibial nerve stimulation|patients did not undergo a postoperative transcutaneous tibial nerve stimulation
1983439|NCT02427464|Genetic|VM202|gene therapy
1983440|NCT02427464|Genetic|placebo|
1983445|NCT02423525|Drug|Afatinib|
1983449|NCT02422550|Device|MRI|Participants enrolled on this protocol may undergo multiple MRI examinations periodically over the course of their treatment and follow-up if they are participating in a development project related to tumor response assessment. Volunteers enrolled on this protocol may undergo multiple MRI examinations periodically for studies of reproducibility.
1983450|NCT02422264|Biological|Infanrix hexa|• All subjects will receive Infanrix hexa at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. Infanrix hexa is administered intramuscularly to the right thigh.
1983451|NCT02422264|Drug|Prevnar13|• All subjects will receive Infanrix hexa co-administered with Prevenar13* at 2 and 4, at 3 and 5, at 2, 4 and 6 months or at 2, 3 and 4 months, depending on the immunisation schedule of the country. *In some countries/regions with an Infanrix hexa 3-dose vaccination schedule, Prevenar 13 could be administered as 2-doses or 3-doses primary vaccination schedule (according to the routine national immunisation schedule). Prevnar13 is administered intramuscularly to the left thigh.
1983452|NCT02419937|Drug|Tocilizumab|162 mg subcutaneously once (vs. 0.9% normal saline placebo injection once in placebo arm)
1983453|NCT02419937|Drug|Placebo|Saline injection
1983454|NCT02418312|Drug|histamine-2 receptor antagonist (famotidine)|famotidine (40 mg qd) plus thienopyridine
1983455|NCT02418312|Drug|Placebo|placebo plus thienopyridine
1983464|NCT02415673|Device|Fixed orthodontics appliance and arch wire|Two nickel-titanium alignment and leveling sequences were employed
1983465|NCT02414841|Drug|vonapanitase|
1983466|NCT02414841|Drug|Placebo|
1983469|NCT02412111|Drug|ivacaftor|
1983470|NCT02412111|Drug|VX-661|
1983471|NCT02412111|Drug|Placebo|
1983472|NCT02411578|Drug|G-Pen Mini™ (glucagon injection)|"1st BG check, 1st treatment
BG is 50-69 mg/dl, treatment is 150 µg of glucagon
BG is 40-49 mg/dl, treatment is 300 µg of glucagon
15 min later, 2nd BG check, 2nd treatment
BG is 60-69 mg/dl, no treatment
BG is 50-59 mg/dl, treatment is 150 µg of glucagon
BG is <50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon
30 minutes later, 3rd BG check, 3rd treatment
BG is >=70, no treatment
BG is <70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon
(150 µg of glucagon per syringe)"
1983473|NCT02411578|Other|Glucose Tablets|"1st BG check, 1st treatment
BG is 50-69 mg/dl, treatment is 15 grams of carbohydrates
BG is 40-49 mg/dl, treatment is 30 grams of carbohydrates
15 min later, 2nd BG check, 2nd treatment
BG is 60-69 mg/dl, no treatment
BG is 50-59 mg/dl, treatment is 15 grams of carbohydrates
BG is <50 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon
30 minutes later, 3rd BG check, 3rd treatment
BG is >=70, no treatment
BG is <70 mg/dl, treatment is participant's preferred oral carbohydrate and not mini-dose glucagon
(5 grams of fast-acting carbohydrates (D-Glucose) per tablet)"
1983474|NCT02410200|Drug|dimethyl fumarate|
1993425|NCT03198871|Drug|Sodium Chloride 0.9%, Intravenous|The placebo group will be given an intravenous placebo of saline solution at wound closure and repeated every 6 hours for 48 hours postoperatively.
1993426|NCT03199365|Behavioral|Immersive Assessment|Participants undergo immersive assessment involving examination of the home food and physical activity (PA) environments, objective and self-reported PA, nutritional intake, and demographics and relevant psychosocial measures.
1993427|NCT03199365|Behavioral|Household Food Inventory (HFI)|Participants complete a self-administered household food inventory (HFI).
1993428|NCT03199365|Device|Accelerometer|Participants to wear an accelerometer device for 7 consecutive days to measure physical activity.
1993429|NCT03199365|Behavioral|Questionnaires|"Group 1: Participants complete a food frequency questionnaire at the home visit, and a 24-hour recall questionnaire within 3 weeks after the home visit.
Group 2: Participants complete a 24-hour recall questionnaire at the home visit, and a food frequency questionnaire within 3 weeks after the home visit."
1993430|NCT03199365|Behavioral|Interviews|Open-ended, in-depth interviews conducted with up to 24 Latino family dyads to explore attitudes, behaviors, barriers and facilitators, and social support related to healthy eating and PA, with a particular emphasis on the family dyad context.
1993431|NCT03197805|Diagnostic Test|PAM 50 test|Patients with an equivocal-HER2 breast cancer (IHC Score 2 and equivocal ISH defined as HER2/Chr17 ratio <2 and 4 ≤HER2 gene number copy < 6) will be eligible for RNA genomic test (PAM 50 test). The use of genomic test could help the oncologist to define the better therapeutic decision in a HER2 equivocal population.
1993432|NCT03196895|Behavioral|Weight reduction training|6 one-hour sessions of conventional weight reduction training
1993433|NCT03196895|Behavioral|PPG training|Four 90-minute sessions of glycemic load and exercise training
1993434|NCT03196895|Behavioral|discrete BG feedback|Blood glucose feedback from structured self-monitoring of blood glucose
1993435|NCT03196895|Behavioral|continuous BG feedback|blood glucose feedback from continuous glucose monitoring
1993436|NCT03197519|Behavioral|TCApp|During these 12 weeks, in addition to TAU, the patient from the experimental group should use TCApp at least once a day, completing at least one self-record daily and/or contacting his/her therapist via chat when needed. The therapist responsible for the online monitoring should, at least once a week, connect to the online platform and perform the following actions: follow the patient's daily self-records, generate personalized reports or graphs and communicate with him/her via chat. After a 12-week period, patients from the experimental group and their therapists will stop using the TCApp application (they will be discharged).
1993437|NCT03197519|Behavioral|TAU|The TAU control group will receive treatment as usual, that is to say, the standard face-to-face CBT, offered by the different ED units in Spain.
1993438|NCT03197389|Drug|Pembrolizumab|Biological: humanized anti-PD-1 monoclonal antibody humanized anti-PD-1 monoclonal antibody is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with the combination of PD-1 with its ligands, PD-L1 and PD-L2.
1993439|NCT03197077|Procedure|blood sampling|comparison between corifollitropin alfa and follitropin beta in IVM cycles
1993440|NCT03197077|Procedure|transvaginal ultrasound scanning|comparison between corifollitropin alfa and follitropin beta in IVM cycles
1993441|NCT03197077|Procedure|oocyte retrieval for IVM|comparison between corifollitropin alfa and follitropin beta in IVM cycles
1993442|NCT03197077|Drug|Corifollitropin Alfa|Single injection of 100 micrograms of corifollitropin alfa
1983485|NCT02406677|Other|Study voucher card|Study voucher card to offset any patient copayments or medication costs for the filling of any prescriptions of clopidogrel or ticagrelor
1983491|NCT02400723|Behavioral|Progressive Muscle Relaxation|Progressive Muscle Relaxation is a treatment in which individuals tense and release their muscle groups in a sequential order. This helps reduce anxiety and tension. It also teaches individuals to differentiate between muscle tension and relaxation.
1983492|NCT02400723|Behavioral|Diaphragmatic Breathing|Diaphragmatic breathing is a way in which people breathe using their diaphragm. This type of breathing has been found to promote relaxation and reduce stress.
1983493|NCT02400723|Other|Psychoeducation (Placebo)|DVD-delivered psychoeducation. Participants will view videos that contain information about what anxiety is and information about one's well-being. This condition is an attention placebo control.
1983511|NCT02392026|Drug|Metronidazole Gel|Metronidazole Vaginal Gel 1.3% administered via applicator
1983519|NCT02377960|Behavioral|IMB model-based initiation of antihypertensive medication|1.An IMB model-based initiation of medication i.e. a nine-point check list to be fulfilled by physician and patient together when ordering the antihypertensive medication for the first time
1983520|NCT02377960|Behavioral|Tailored SMS-text message support|2.Tailored SMS-text message support for the first 12 months of medication. At the beginning (2 weeks), text messages are send on daily basis and focused on medications-reminders and coping with potential side-effects of medication. After that, text messages will be sent less often and the focus will change to keeping up with medication and reminding of importance of performing adequate home BP self-monitoring, achieving the BP target and attending clinical appointments.
1983521|NCT02377960|Behavioral|Usual care|Usual care
1983522|NCT02379052|Drug|Dupilumab|
1983523|NCT02379052|Drug|Placebo|
1983544|NCT02365519|Biological|LME636 ophthalmic solution|
1983545|NCT02365519|Biological|LME636 Vehicle|Inactive ingredients used as a placebo comparator
1983546|NCT02366130|Drug|Ra-223 dichloride|55 kBq/kg by vein on Day 1 of each 28 day cycle, and then every four weeks thereafter for 6 cycles.
1983547|NCT02366130|Drug|Denosumab|120 mg by subcutaneous (SC) injections on Day 1 of Cycles 2-5.
1983548|NCT02366130|Drug|Hormone Therapy|A single hormonal agent administered daily while on study. Physician to decide what type of hormone therapy participant will receive.
1983549|NCT02365480|Drug|Berberine Chloride|Given PO
1983550|NCT02365480|Other|Laboratory Biomarker Analysis|Correlative studies
1983551|NCT02365480|Other|Placebo|Given PO
1983554|NCT02363387|Behavioral|Incentives for Viral Suppression|Incentive group participants will receive incentives for maintaining suppressed and undetectable viral loads. The incentive program will employ high magnitude incentives, provide incentives for decreases in viral load early in treatment before a patient's viral load has reached undetectable levels, arrange frequent incentives early in treatment and reduce the frequency of incentives as participants achieve progressively longer periods of viral load suppression, arrange a schedule of escalating incentives for sustained suppression of viral load, and the intervention will be maintained for two years.
1983555|NCT02363387|Behavioral|Standard HIV Medical Care|The best HIV medical care available in each participant's medical clinic.
1983558|NCT02360943|Other|4 blood samples|PK and / or PD measurements during hospitalization
1983571|NCT02352883|Procedure|Magnetic Resonance Imaging|Undergo MRI
1983572|NCT02352883|Procedure|Therapeutic Conventional Surgery|Undergo mastectomy
1983573|NCT02352883|Procedure|Therapeutic Surgical Procedure|Undergo wide local excision
1983574|NCT02352883|Radiation|Radiation Therapy|Undergo radiation therapy
1983575|NCT02352883|Drug|Endocrine Therapy|Undergo endocrine therapy
1983576|NCT02352883|Other|Quality-of-Life Assessment|Ancillary studies
1983577|NCT02352883|Other|Laboratory Biomarker Analysis|Correlative studies
1983578|NCT02352883|Other|Cytology Specimen Collection Procedure|Correlative studies
1983583|NCT02348593|Drug|JZP-110|
1983584|NCT02348619|Drug|JZP-110|
1983590|NCT02348606|Drug|JZP-110|
1983621|NCT02335424|Biological|pembrolizumab|IV infusion
1983626|NCT02334683|Device|Electrical stimulation|The purpose of this study is to investigate the use of two ways of locating the muscle for botulinum toxin (BoNT) injection for the treatment of focal hand dystonia and upper limb spasticity located by either electrical stimulation using a needle or ultrasound using sound waves.
1983627|NCT02334683|Device|Ultrasound|The purpose of this study is to compare how the muscle is located by either electrical stimulation using a needle or ultrasound using sound waves.
1983636|NCT02317692|Behavioral|Parent training|
1983639|NCT02313909|Drug|Rivaroxaban (Xarelto, BAY59-7939)|15 mg, once daily, orally, tablet
1983640|NCT02313909|Drug|Aspirin (Acetylsalicylic acid, BAY1019036)|100 mg, once daily, orally, tablet
1983641|NCT02313909|Other|Rivaroxaban-Placebo|Matching placebo, once daily, orally, tablet
1983642|NCT02313909|Other|Aspirin-Placebo|Matching placebo, once daily, orally, tablet
1983655|NCT02310802|Drug|OBE001 dose 1|OBE001 dispersible tablets for single oral administration
1983656|NCT02310802|Drug|OBE001 dose 2|OBE001 dispersible tablets for single oral administration
1983657|NCT02310802|Drug|OBE001 dose 3|OBE001 dispersible tablets for single oral administration
1983658|NCT02310802|Drug|Placebo|Placebo dispersible tablets for single oral administration
1983659|NCT02311413|Drug|Cat-PAD|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
1983660|NCT02311413|Drug|Placebo|The assigned study intervention will be administered by intradermal injection into the flexor surface of the forearm.
1983685|NCT02299700|Other|No Intervention|The usability of the Janssen Autism Knowledge Engine (JAKE) as a system to monitor clinical outcomes in Autism Spectrum Disorder (ASD) will be observed.
1983693|NCT02292784|Drug|Retosiban|This is a safety follow-up study of infants and children exposed to retosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
1983694|NCT02292784|Drug|Atosiban|This is a safety follow-up study of infants and children exposed to atosiban comparator during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product.
1983695|NCT02292784|Drug|Placebo|This is a safety follow-up study of infants and children exposed to matching placebo for retosiban/ atosiban during their mother's participation in a Phase III treatment study for SPTL. Infants enrolled in this study will not be administered any investigational product
1983703|NCT02285816|Biological|MG1MA3|MG1MA3: Boosting component of Oncolytic Vaccine
1983704|NCT02285816|Biological|AdMA3|AdMA3: Priming component of Oncolytic Vaccine
1983706|NCT02283268|Biological|Recombinant von Willebrand Factor (rVWF)|rVWF will be administered by intravenous bolus infusion. Participants planned for major surgery will undergo a baseline pharmacokinetic assessment prior to surgery. The peri- and postoperative substitution regimen will be individualized according to the PK results, intensity and duration of the hemostatic challenge, and the institution´s standard of care.
1983715|NCT02276612|Drug|E/C/F/TAF|150/150/200/10 mg FDC tablet administered orally once daily with food
1983716|NCT02270736|Drug|IncobotulinumtoxinA|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
1983717|NCT02270736|Drug|Placebo|Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl).
1983718|NCT02270203|Radiation|Pelvic CT at 5 years post-op|Pelvic CT at 5 years post-op
1983726|NCT02265406|Drug|Anti-Infective Agents|
1983727|NCT02265406|Drug|Placebo|
1983728|NCT02264678|Drug|Administration of AZD6738 in combination with carboplatin|An oral formulation of AZD6738 will be used. In Module 1 Part A, patients will receive a single dose of AZD6738 on Day 1, followed by multiple dosing in combination with carboplatin. A maximum of 6 cycles (21 days per cycle) of treatment will be given. In Module 1 Part B, patients will receive AZD6738 and carboplatin at the dose, frequency and schedule recommended from Module 1 Part A.
1983729|NCT02264678|Drug|Administration of AZD6738|An oral formulation of AZD6738 will be used. In Module 2 Part A1, patients will receive a single dose of AZD6738 on Day 1, followed by 4 to 6 days washout, before multiple dosing.
1983730|NCT02264678|Drug|Administration of AZD6738 in combination with olaparib|An oral formulations of AZD6738 and olaparib will be used. In Module 2 Part A2, patients will receive a single dose of AZD6738 followed by 4 to 6 days washout, before multiple dosing with AZD6738 and olaparib. In Module 2 Part B, patients will receive AZD6738 and olaparib at the dose, frequency and schedule recommended from Module 2 Part A2.
1983731|NCT02264678|Drug|Administation of AZD6738 in combination with MEDI4736|An oral formulation of AZD6738 will be used. MEDI4736 is given via IV infusion. In Module 3 Part A patients will receive and initial single dose of AZD6738 on Day 1, followed by multiple dosing in combination with MEDI4736. In Module 3 Part B expansion cohorts will receive AZD6738 at the dose, frequency and schedule recommended from Module 3 Part A, in combination with MEDI4736.
1983733|NCT02262741|Biological|MEDI4736|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
1983734|NCT02262741|Biological|tremelimumab|Tremelimumab will be administered by IV infusion in combination with MEDI4736.
1993443|NCT03197077|Drug|Follitropin beta|Daily injection (three days) of follitropin beta
1993444|NCT03197077|Drug|oral contraceptive pill pretreatment (Marvelon)|Daily administration of the oral contraceptive pill (Marvelon) for 21 days. Administration of the combined oral contraceptive pill will start after a blood test that demonstrates basal E2 levels and a negative serum hCG level.
1993445|NCT03197038|Behavioral|Partially supervised home-based walking exercise|Participants will be asked to exercise at home by walking at a moderate intensity. Each participant will receive an exercise prescription. Participants will receive a heart rate monitor. The heart rate monitors will be used to achieve a desired exercise intensity and to monitor adherence levels. The participants will receive biweekly to weekly phone calls, and monthly in person meetings will be used to address any barriers, provide encouragement, and progress the exercise.
1993446|NCT03197038|Behavioral|Control|Participants will be asked to exercise at home by walking at a moderate intensity. The participants will receive biweekly phone calls, but will not receive a heart rate monitor, individual exercise prescription, or meet with the investigators monthly.
1993449|NCT03196375|Drug|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
1993450|NCT03196375|Drug|Placebo ODT|Placebo ODT taken three times daily for 28 days
1993451|NCT03196505|Drug|Exparel 266 MG Per 20 ML Injection|Liposomal bupivacaine 20mL of injectable saline diluted with 60 ml of 0.25% Marcaine and 20 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive a 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
1993452|NCT03196505|Drug|Bupivacaine|60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
1993453|NCT03196284|Drug|Concizumab|A loading dose of 0.5 mg/kg will be given as the first dose, followed by 0.15 mg/kg (with potential stepwise dose escalation to 0.25 mg/kg) administered daily s.c. (subcutaneously, under the skin). Treatment duration is 24 weeks in the main trial, and up to 52 weeks in the extension phase
1993454|NCT03196284|Drug|Eptacog alfa|A single dose of 90 μg/kg eptacog alfa one week after dosing with concizumab. On-demand treatment during bleeding episodes in both treatment arms
1993457|NCT03193567|Biological|HEKT cell|3 cycles of HEKT cell treatment
1993458|NCT03194893|Drug|Alectinib|Alectinib capsules 600 mg twice a day (BID) orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
1993459|NCT03194893|Drug|Crizotinib|Crizotinib capsules 250 mg BID orally until no further clinical benefit is to be expected, unacceptable toxicity, availability of commercial supply, withdrawal of consent, or death, whichever occurs first.
1993460|NCT03194763|Diagnostic Test|coronary angiography|computed tomography acquisitions performed on a revolution CT
1993466|NCT03191903|Drug|Cingal|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose with a nominal 18 mg of triamcinolone hexacetonide (TH)
1993467|NCT03191903|Device|Monovisc|A chemically cross-linked sodium hyaluronate supplied as a 4-mL unit dose
1993468|NCT03191903|Drug|Triamcinolone Hexacetonide|20 mg/ml supplied as 1 mL unit dose of Triamcinolone Hexacetonide
1993469|NCT03191851|Device|standard device|paracentesis using standard
1993470|NCT03191851|Device|Melody Device|paracentesis using Melody Device
1983760|NCT02240810|Device|Percutaneous coronary intervention (Promus PREMIER)|Interventional coronary artery stenting with Promus PREMIER study stent.
1983772|NCT02233738|Behavioral|Group Motivational Interviewing (GMI)|Participants randomized to Group Motivational Interviewing (GMI) will receive four structured, back-to-back, 90-minute sessions consistent with the central principles and spirit of Motivational Interviewing (MI). GMI, which is based on a manualized protocol, is specifically designed for dually diagnosed Veterans. A focus of the intervention creates awareness of the relationship between the substance use and co-existing psychiatric disorder and the importance of treating both.
1983773|NCT02233738|Behavioral|Control Treatment Condition (CT)|"Control Treatment Condition (CT): Participants in CT will attend four sessions equal in time and length to GMI (i.e., 90 minutes) and will involve the following topics: A popular 'box activity': participants will anonymously write evocative questions on slips of paper involving their personal concerns that are placed in a box and, when randomly selected, opened for group discussion (e.g., How do I talk to my family about my alcohol problem?), money management with feedback (2 sessions), and cooking-home maintenance."
1983790|NCT02216084|Drug|Recombinant ADAMTS13|"rADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) is a lyophilized formulation for intravenous injection. The lyophilized rADAMTS13 is reconstituted with sterile water for injection.
Subjects will receive an intravenous injection with rADAMTS13 at a dose of either 5 U/kg bodyweight (Cohort 1), or 20 U/kg bodyweight (Cohort 2), or 40 U/kg bodyweight (Cohort 3)."
1983795|NCT02210091|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|Pharmacokinetic (PK) analysis of ADVATE
1983796|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Pharmacokinetic (PK) analysis of BAX 855
1983797|NCT02210091|Biological|PEGylated Recombinant Factor VIII|Prophylaxis treatment
1983798|NCT02205970|Device|TENS|In the active group there was only one application with interactive TENS (n = 42) with the final parameters of frequency between 90 and 150pps and pulse duration between 300 and 400μs and intensity level of tolerance, lasting 35 minutes.
1983799|NCT02205970|Device|TENS (sham)|In the placebo group, there was a simulated single application, following the same procedures as the active TENS group, also for 35 minutes.
1983800|NCT02204917|Drug|OPTISON|Contrast-enhanced Voiding Urosonography (ceVUS) with intravesical administration of OPTISON for vesicoureteral reflux detection and urethral imaging in children. VCUG examination as part of the standard care.
1983810|NCT02196415|Device|Biplanar Radiography|standard biplanar radiography of the foot
1983814|NCT02196051|Other|Exercise Training|Six weeks of exercise
1983815|NCT02193295|Behavioral|Dietary consultations|Dietary consultations and caloric restriction to reduce liver and intra myocellular fat content and improve tissue specific insulin sensitivity
1983824|NCT02190149|Biological|ADVATE (Antihemophilic Factor [Recombinant])|
1983825|NCT02190149|Biological|RIXUBIS (Coagulation Factor IX [Recombinant])|
1983826|NCT02190747|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day. Powder filled hard gelatin capsules will be opened and the contents added onto specific food.
1983827|NCT02190747|Drug|Placebo|
1983828|NCT02188719|Biological|Anti-Thymocyte Globulin - Rabbit|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects will be given a dose range of 3.0-4.5 mg/kg total, in divided doses of 1.5 mg/kg/day. Subjects who meet eligibility criteria for Thymoglobulin® administration will be given 1.5 mg/kg intravenously (IV) on post-operative day 3, within 72 hours of transplantation. Additional doses of 1.5 mg/kg IV will be administered until CD3 count is <50/mm^3 or when the maximal dose of 4.5/mg/kg has been given.
1983829|NCT02188719|Biological|darTreg Infusion|A single dose darTreg infusion (Cohorts 2 - 4) will be received as per protocol.
1983830|NCT02188719|Drug|Everolimus|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Subjects meeting eligibility criteria for Treg-supportive IS regimen will begin EVR no sooner than 30 days after liver transplantation and no later than 44 days after transplantation; with target trough levels of 6-8 μg/L.EVR target trough levels will be further reduced to 4-6 μg/L 24 - 26 weeks after transplantation.
1983831|NCT02188719|Drug|Tacrolimus|"Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Between 30 and 44 days following transplant: Subjects who are not eliminated by Exclusion Criteria C1 (Protocol Section 14.3.1) will proceed in the study and receive either TAC-based or EVR- based IS, based on eligibility Criteria C2 (Section 4.3.4 )
TAC-based IS: reduce TAC trough level to 3-8 μg/dL; continue MMF
EVR-based IS: reduce TAC trough level to 3-8 μg/dL; EVR target trough level of 6-8 μg/dL; decrease then discontinue MMF"
1993471|NCT03191851|Device|Melody Device with Pump|paracentesis using Melody Device with Pump
1993478|NCT03191201|Drug|Ferric Carboxymaltose|Ferric Carboxymaltose 1000 mg iron element will be diluted in 250 mL of a commercially available sterile 0.9% sodium chloride solution.
1993479|NCT03191201|Drug|0.9% sodium chloride solution|250 mL of a commercially available sterile 0.9% sodium chloride solution.
1993480|NCT03191838|Other|Audiovisual Distraction|The interventional group will be given audiovisual equipment. An Apple iPad will be attached to a Mayo stand and placed approximately 12-15 inches from the patient's face. Noise canceling headphones will be connected to the iPad. A movie of the subject's choosing will be shown on the iPad with a comfortable level of sound.
1993483|NCT03190213|Drug|Pembrolizumab Injection|Pembrolizumab at a dose of 200 mg will be administered as an IV infusion over 30 minutes every 3 weeks until disease recurrence or discontinuation due to unacceptable toxicity for a maximum of 2 years. We anticipate on average patients will remain on treatment for approximately 24 weeks.
1993484|NCT03190083|Device|2-dimensional mammogram|This is standard of care for breast cancer diagnosis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
1993485|NCT03190083|Device|digital breast tomosynthesis (DBT)|The radiation dose from this/these procedure(s) will be no more than 0.4mSv for a bi-lateral breast tomosynthesis. The new breast cancer patients will be scheduled for the mammogram after diagnosis at the time of surgical appointment. The radiologist reviewing the tomosynthesis images will be separate and blinded from the radiologist who reviewed the initial 2-D mammogram.
1993486|NCT03189485|Drug|the radiotracer 18F-AV-1451|Subjects will receive a single IV bolus injection target dose of approximately 370 MBq (10 mCi ± 20%) of 18F-AV-1451 At approximately 75 minutes post dose, scanning will begin. An approximately 30-minute acquisition (six 5 minute intervals) will be performed
1983832|NCT02188719|Drug|Mycophenolate mofetil|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. 1000 mg total daily dose. MMF will be initiated within 24 hours of transplantation. MMF must be discontinued as soon as target EVR trough levels have been achieved.
1983833|NCT02188719|Drug|Prednisone|Liver transplantation/Treg-supportive immunosuppression (IS) treatment. Solumedrol 500 mg will be given IV on the day of transplantation. Additional Solumedrol will be prescribed according to site-specific standard of care. Oral prednisone should be initiated once oral medication is tolerated.
1983834|NCT02188719|Drug|Acetaminophen|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 650mg of acetaminophen will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
1983835|NCT02188719|Drug|Diphenhydramine|Pre-medication for single dose darTreg infusion (Cohorts 2 - 4). 25-50mg of diphenhydramine will be administered intravenously or by mouth 30-60 minutes prior to the darTreg infusion.
1983836|NCT02188719|Drug|Anti-Infective Prophylaxis|Intravenous ganciclovir and/or oral Valcyte will be administered for the prophylaxis of cytomegalovirus (CMV) and Epstein-Barr Virus (EBV) for at least six months after liver transplantation.
1983837|NCT02188719|Procedure|Leukapheresis|"Leukapheresis is necessary to ensure collection of adequate numbers of autologous Tregs to support ex vivo expansion of darTregs for infusion after liver transplantation.
Participants enrolled in Cohorts 3 and 4 will undergo leukapheresis. Participants enrolled in Cohort 2 will have either whole blood collection or leukapheresis for the purpose of isolating autologous Tregs for later manufacture. If a cohort 2 subject has a hemoglobin level >/=10.5 gm/dL, he or she will undergo phlebotomy. If the patient has a hemoglobin level </=10.5 gm/dL and remains eligible for the study, the patient will undergo leukapheresis."
1983838|NCT02188719|Procedure|Blood draws|Blood draws are necessary to carefully and frequently evaluate allograft function after liver transplantation and treatment with Treg-supportive IS as well as after darTreg infusion. Peripheral blood samples will be collected and analyzed per protocol throughout subject participation in this study.
1983839|NCT02188719|Procedure|Liver biopsies|Subjects will have a liver biopsy for this study 12-14 weeks after transplantation. For subjects receiving darTregs, a second biopsy will be performed 7-10 days after darTregs infusion.
1983840|NCT02188719|Procedure|Liver transplantation|Inclusion in this trial is in the setting of subjects defined as having end-stage liver disease and listed for primary solitary liver transplant.
1983842|NCT02187159|Drug|DS-5565|DS-5565 15 mg tablet for oral administration
1983843|NCT02187159|Drug|Pregabalin|Pregabalin 150 mg capsule for oral administration
1983844|NCT02187159|Drug|Placebo tablet|Placebo tablet (matching DS5565) for oral administration
1983845|NCT02187159|Drug|Placebo capsule|Placebo capsule (matching pregabalin) for oral administration
1983854|NCT02170402|Biological|Octocog alfa (recombinant human coagulation factor VIII)|"Part 1: Pharmacokinetic (PK) analysis - Subset of 24 participants
Part 2: On-demand treatment regimen
Part 3: Prophylaxis treatment regimen"
1983857|NCT02167711|Drug|SIRT Yttrium-90|
1983862|NCT02163577|Drug|KRN23|
1983867|NCT02161458|Drug|Escitalopram 20mg for 2 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 2 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
1983868|NCT02161458|Drug|Escitalopram 20mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 20 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
1993487|NCT03189303|Device|Primary Uncemented Total Hip Arthroplasty|The study devices are the Pinnacle Hip System acetabular cup with a Summit or Corail femoral stem
1993488|NCT03187769|Drug|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
1993489|NCT03187769|Drug|Olanzapine|Daily oral dosing
1993490|NCT03188705|Drug|Clopidogrel|Participants will receive 300 mg of clopidogrel on the first day, then 75 mg per day for the next 6 days. Measures of pharmacodynamics will be assessed pre- and post-drug administration.
1993491|NCT03188705|Drug|Aspirin|Participants will receive a single dose of 324 mg aspirin on the last day of clopidogrel administration.
1993492|NCT03188458|Other|Blood sample|Blood samples will be collected from infants prior to their first routine primary pertussis vaccination (At Visit 2 [approximately 4-8 weeks of age]).
1993493|NCT03188055|Other|Best Case/Worst Case communication tool|"The communication tool promotes dialogue and patient deliberation, and supports shared decision making in the context of life-limiting illness. Building on a conceptual model of shared decision-making proposed and the practice of scenario planning our intervention is designed to lead to a discussion of patient preferences and consideration of outcomes.
The surgeon verbally describes the best case, worst case, and most likely outcomes for each treatment option—incorporating rich narrative from clinical experience and translation of probabilistic information—while drawing a diagram of those options. The surgeon also writes details about each option on the diagram. The narrative and graphic help family and patients formulate and express preferences."
1993494|NCT03187925|Other|open, transcervical versus rigid endoscopic treatment|The goal of the project is to perform the first prospective, multi-institutional long-term (5 year) study comparing the outcomes of open, transcervical versus rigid endoscopic treatment of cervical esophageal diverticulum and cricopharyngeal dysfunction in resolving associated symptoms, complications, and recurrence rates of dysphagia surgery. This study will also include cricopharyngeal bar as it pertains to an early Zenker's diverticulum.
1983869|NCT02161458|Drug|Escitalopram 30mg for 8 weeks|30 cognitively normal adults aged 60-85 will receive escitalopram 30 mg for 8 weeks; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., active drug) administration.
1983870|NCT02161458|Drug|Placebo|Additionally, 30 cognitively normal adults aged 60-85 will receive a placebo; amyloid beta levels in the CSF will be measured at baseline (before drug administration) and following the full study drug (i.e., placebo) administration.
1983886|NCT02144285|Drug|LY3113593|Administered IV
1983887|NCT02144285|Drug|LY3113593|Administered SC
1983888|NCT02144285|Drug|Placebo|Administered IV
1983889|NCT02144285|Drug|Placebo|Administered SC
1983890|NCT02141438|Drug|Radium-223 dichloride (Xofigo, BAY88-8223)|An alpha particle-emitting radioactive therapeutic agent indicated for the treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease
1983909|NCT02128282|Drug|CX-4945|Capsules administered twice daily on Days 0, 1 and 2, and Days 7, 8 and 9 of each 21 day cycle.
1983910|NCT02128282|Drug|Cisplatin|25 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21 day cycle.
1983911|NCT02128282|Drug|Gemcitabine|1,000 mg/m.sq. administered by IV infusion on Days 1 and 8 of a 21 day cycle.
1983912|NCT02128217|Drug|Ribavirin|Participants will receive weight-based RBV orally, 2 times a day, every morning and every evening, with food. Weight under 75 kg, 600 mg (3 tablets) morning and 400 mg (2 tablets) evening. Weight over 75 kg, 600 mg (3 tablets) morning and 600 mg (3 tablets) evening. The dose of RBV will be based on subject's weight at entry. Changes in weight after entry do not require a change in dose. Doses will only be changed for toxicity management.
1983913|NCT02128217|Drug|Sofosbuvir|Participants will receive one 400 mg tablet of sofosbuvir orally every morning with food.
1983914|NCT02128217|Drug|Ledipasvir/Sofosbuvir|Participants will receive one daily fixed-dose combination tablet orally every morning of 90 mg of LDV and 400 mg of SOF.
1983920|NCT02120352|Drug|GSK744|White to almost white oval shaped film coated 30 mg tablets for oral administration.
1983921|NCT02120352|Drug|GSK744 LA|Sterile white to slightly colored suspension containing 200 mg/mL of GSK744 as free acid (GSK1265744 free acid), polysorbate 20, polyethylene glycol 3350, mannitol, and water for injection, packaged in a 3 mL USP Type I glass vial, for administration by IM injection
1983922|NCT02120352|Drug|TMC278 LA|Sterile white suspension containing 300 mg/mL of TMC278 as free base, poloxamer 338, sodium dihydrogen phosphate monohydrate, citric acid monohydrate, glucose monohydrate, sodium hydroxide, water for injection, packaged in a 2 mL USP Type I glass vial, for administration by IM injection.
1983923|NCT02120352|Drug|ABC/3TC|ABC/3TC fixed dose combination (FDC) oral tablet, containing 600 mg of ABC (as abacavir sulfate) and 300 mg of 3TC
1983924|NCT02120352|Drug|RPV|Off-white, round, biconvex, film-coated 25 mg Rilpivirine (RPV) tablets for oral administration. Eligible subjects switching from the oral regimen to the IM regimen in the Extension Period will receive 2 weeks of RPV 25 mg once daily, from Week 102 through Week 104
1983925|NCT02117791|Drug|Riociguat (ADEMPAS, BAY63-2521)|The treatment of Riociguat should comply with the local product information (start dose: 3 mg/day, maximum dose: 7.5 mg/day)
1983926|NCT02116803|Drug|dovitinib|
1983927|NCT02116803|Drug|fulvestrant|
1983931|NCT02114515|Behavioral|Hospital usual care|Written discharge instructions provided to patients prior to hospital discharge.
1983932|NCT02114515|Behavioral|Patient Navigator|A Patient Navigator will provide social support, literacy appropriate education, and act as a conduit between the patient and the patient's medical team
1983933|NCT02114515|Behavioral|Peer-led telephone support line|The peer-led telephone support line will provide social support, peer-to-peer coaching, and facilitate communication with the patient's medical care team.
1983952|NCT02111564|Drug|Rivaroxaban, 10 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening >= 50 mL/min will receive 10 mg rivaroxaban tablet with or without food.
1983953|NCT02111564|Drug|Rivaroxaban, 7.5 mg|Patients, randomly allocated to the rivaroxaban arm, with a creatinine clearance at screening from 30 to 49 mL/min will receive 7.5 mg rivaroxaban tablet with or without food.
1983954|NCT02111564|Drug|Placebo|All patients, randomly allocated to the placebo arm, will receive one placebo tablet with or without food.
1983979|NCT02093741|Biological|Octocog alfa (recombinant human coagulation factor VIII) [ADVATE]|The investigators shall determine all treatment regimens according to product labeling information and standard practice.
1983987|NCT02081300|Drug|Oral testosterone undecanoate, LPCN 1021|
1983988|NCT02081300|Drug|Topical testosterone gel 1.62 %|
1983990|NCT02078427|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|
1984001|NCT02071420|Behavioral|Active Workstation Intervention|Participants in the experimental group will receive a seated active workstation at their work setting for 16 weeks.
1984002|NCT02071420|Behavioral|Ergonomic Intervention|Participants of both arms will receive a face to face ergonomic workstation optimization intervention. This consultation will take 30 minutes to complete and will be performed at the participant's actual work station.
1984003|NCT02071420|Behavioral|Email Intervention|Participants of both arms will receive three emails per week for 16 weeks. Messages will be consistent with what they hear in the ergonomic intervention (e.g., encourage taking breaks from sitting at work and adjusting posture to be in line with ergonomic principles).
1984004|NCT02071420|Device|Bluetooth enabled device (Wahoo Fitness Blue SC sensor) and accompanying iPod application.|
1984009|NCT02064959|Other|Hypothermia|rapid induction of hypothermia to 35°C followed by maintenance at 33°C
1984011|NCT02060058|Drug|Stop trial intervention for boceprevir, PEG-IFN and RBV|"Stop trial intervention for patients with 32 week therapy (arm A): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.
Stop trial intervention for patients with 48 weeks therapy (arm B): for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped.
Stop trial intervention for for null responder or cirrhotic patients: (arm C) for all patients, if HCV RNA is more than 100 IU/ml at week 12 or HCV RNA is detectable at week 24, therapy will be stopped."
1984014|NCT02054806|Biological|Pembrolizumab|IV infusion
1984032|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 20 µg/mL)|20 µg/mL iloprost nebulizer solution, inhaled with FOX nebulizer
1984033|NCT02032836|Drug|lloprost(Ventavis,BAYQ6252, 10 µg/mL)|10 µg/mL iloprost nebulizer solution, inhaled with I-Neb nebulizer
1984041|NCT02031822|Procedure|US-guided Greater Occipital Nerve Injection|Medication injected around the greater occipital nerve: 2ml 0.5% bupivacaine with epinephrine 1:200,000 and Depo-Medrol 40mg.
1984050|NCT02027961|Biological|MEDI4736|MEDI4736
1984051|NCT02027961|Drug|Dabrafenib|Dabrafenib
1984052|NCT02027961|Drug|Trametinib|Trametinib
1984065|NCT02018887|Drug|LY2969822|Capsules administered orally
1984066|NCT02018887|Drug|Placebo|Capsules administered orally
1984083|NCT02002754|Drug|Bambuterol Hydrochloride tablets|Bambuterol Hydrochloride tablets(10mg) 3 tablets qd for three days(swallowed by warm water at 0.5-1h after each meal)
1984112|NCT02002884|Drug|IncobotulinumtoxinA (8 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
1984113|NCT02002884|Drug|IncobotulinumtoxinA (6 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% odium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
1984114|NCT02002884|Drug|IncobotulinumtoxinA (2 Units per kg body weight)|Active ingredient: Clostridium Botulinum neurotoxin Type A free from complexing proteins. Solution for injection prepared by reconstitution of powder with 0.9% Sodium Chloride (NaCl); Mode of administration: intramuscular injection into spastic muscles.
1984115|NCT01999868|Biological|Ustekinumab|"Ustekinumab interferes with the actions of proteins, interleukin 12 (IL12) and interleukin 23 (IL23), which reduces inflammation (swelling) in the skin. Stelara™ is the trade name for ustekinumab and is approved by the U.S. Food and Drug Administration (FDA) to treat psoriasis.
Dose:
Participants who weigh <= 100 kg at study entry will receive 45 mg of ustekinumab.
Participants who weigh > 100 kg at study entry will receive 90 mg of ustekinumab."
1984116|NCT01999868|Biological|Abatacept|"Abatacept (one form of the protein called CTLA4-Ig) interacts with the immune system, reducing the activity of T-cells and may prevent relapse. Orencia™ is the trade name for abatacept, and it is approved by the FDA to treat rheumatoid arthritis in adults.
Dose:
125 mg sub-cutaneous injection"
1984117|NCT01999868|Procedure|Placebo for Ustekinumab|The abatacept treatment group will also receive subcutaneous placebo for ustekinumab (sterile normal saline) at week 16 and week 28, corresponding to the ustekinumab dosing regimen.
1984118|NCT01999868|Drug|Placebo for Abatacept|The ustekinumab treatment group will also receive weekly subcutaneous injections of placebo for abatacept from week 12 to week 39, corresponding to the abatacept dosing regimen.
1984126|NCT01991483|Drug|LY2928057|Administered intravenously
1984127|NCT01991483|Drug|Placebo|Administered intravenously
1984128|NCT01989793|Drug|Losartan|Losartan will be given in increasing doses to those in the losartan arm.
1984129|NCT01989793|Drug|Placebo|Placebo will be given to those in placebo arm
1984130|NCT01989156|Other|THS 2.2 Menthol (mTHS 2.2)|THS 2.2 Menthol ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
1984131|NCT01989156|Other|Menthol Conventional Cigarette (mCC)|Subject's own preferred brand of mCC ad libitum for 5 days in confinement prolonged by 86 days in an ambulatory setting
1984132|NCT01989156|Other|Smoking Abstinence (SA)|SA for 5 days in confinement prolonged by 86 days in an ambulatory setting
1984133|NCT01987908|Drug|Aes-103|The active ingredient in Aes-103 is 5-hydroxymethyl furfural (5-HMF). Aes-103 and matching placebo are administered in a liquid oral formulation.
1984134|NCT01987908|Other|Placebo|
1984151|NCT01968655|Biological|OBI-1|
1984163|NCT01961375|Drug|Levonorgestrel- Intra Uterine System (BAY 86-5028_Mirena)|Levonorgestrel 52 mg intrauterine system with release rate of upto 20 mcg/day, Intrauterine insertion
1984164|NCT01957150|Drug|Fluticasone Furoate/Vilanterol|Dry white powder containing 100 mcg of Fluticasone Furoate blended with lactose per blister was administered by NDPI. Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
1984165|NCT01957150|Drug|Vilanterol|Dry white powder containing 25 mcg of Vilanterol micronised drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister was administered by NDPI.
1984176|NCT01946191|Behavioral|Health coach electronic communication and support|Health coach reviews responses to weight-related surveys and provides feedback and advice
1984177|NCT01946191|Behavioral|Online self-monitoring|Tracking weight, calories, fat grams, and physical activity in electronic personal health record
1984178|NCT01946191|Behavioral|Real-time updates to Primary Care physicians|Primary care physicians will receive updates through electronic health record system before each scheduled appointment
1984182|NCT01945593|Biological|PEGylated Recombinant Factor VIII|
1984183|NCT01942590|Drug|Clenbuterol|
1984184|NCT01942590|Drug|Placebo|
1984185|NCT01941654|Radiation|preemptive local ablative therapy|
1984186|NCT01941654|Drug|Oral TKI|
1984189|NCT01939847|Other|Treatment suggestion|Based on any actionable findings of the molecular profiling results, the investigators will come up with a suggestion for approved treatment or for clinical trial by referencing institutional clinical trials or potentially nationwide possibilities (www.clinicaltrials.gov).
1984190|NCT01937390|Drug|Tiotropium Bromide 2.5 µg|Respimat® inhaler and cartridge Solution for inhalation
1984191|NCT01937390|Drug|Indacterol 300 µg|inhalation powder
1984192|NCT01937390|Drug|Tiotropium Bromide 18 µg|HandiHaler® device Inhalation powder, hard capsule
1984193|NCT01937390|Drug|Indacterol 150 µg|inhalation powder
1984202|NCT01933958|Drug|Regorafenib (Stivarga, BAY73-4506)|The usual dosage is 160 mg of Regorafenib/ STIVARGA taken orally after meal once daily for 3 weeks on therapy followed by 1 week off therapy to comprise a cycle of 4 weeks.
1984205|NCT01931462|Device|Microwave pre-coagulation|The Certus 140™ system is used for microwave pre-coagulation of the tissue around the part of the kidney to be removed. This is done in place of the standard clamping to stop blood loss.
1984212|NCT01921270|Drug|Low Dose - AbobotulinumtoxinA|"Participants will receive low dose AbobotulinumtoxinA injections. Location of injections will be determined by the clinician to treat the individual's dystonic symptom.
Muscles that may be included for in injection for OMD with Jaw Closing:
Medial Pterygoid 50 units, Masseter 25 units
Muscles that may be included in injection for OMD with Jaw Opening:
Lateral Pterygoid 50 units, Anterior digastrics 10 units
Muscle that will be included in injection for OMD with Tongue Protrusion:
Genioglossus 7.5 units"
1984214|NCT01918072|Other|Clinical innovation|Technology-based intervention that combines interactive communication with women's health specialists and ongoing education
1984221|NCT01913405|Biological|PEGylated Recombinant factor VIII (rFVIII)|
1984224|NCT01907802|Drug|Dabrafenib|Given PO
1984225|NCT01907802|Other|Laboratory Biomarker Analysis|Correlative studies
1984226|NCT01907802|Other|Pharmacogenomic Study|Correlative studies
1984227|NCT01907802|Other|Pharmacological Study|Correlative studies
1984230|NCT01899729|Drug|IMO-8400|IMO-8400 0.075 mg/kg q wk x 12 wk by subcutaneous injection
1984231|NCT01899729|Drug|IMO-8400|IMO-8400 0.15 mg/kg q wk x 12 wk by subcutaneous injection
1984232|NCT01899729|Drug|IMO-8400|IMO-8400 0.3 mg/kg q wk x 12 wk by subcutaneous injection
1984233|NCT01899729|Drug|Saline Placebo|Saline q wk x 12 wk by subcutaneous injection
1984234|NCT01898585|Drug|Zelboraf|Vemurafenib 960 mg twice a day until progressive disease, unacceptable toxicity, consent withdrawal, death, reasons deemed by the treating physician or study termination.
1993709|NCT03150979|Other|Provision of a cane|The participants will receive a single-point cane and will be instructed to use it all the time during locomotion. Weekly, they will receive a phone call, to ensure that they are using the cane and to clarify any doubts. A home visit may be conducted, if necessary.
1993710|NCT03150979|Other|Control|The control group will be instructed to to perform stretching of the lower limb muscles daily and keep their daily activities, without the use of a cane. They will also receive weekly phone calls, to ensure similar level of attention to that of the the participants in the experimental group.
1993714|NCT03150719|Drug|TEZ/IVA|TEZ 100 mg/IVA 150 mg fixed-dose combination tablet.
1993715|NCT03150719|Drug|IVA|IVA 150 mg tablet.
1993716|NCT03150719|Drug|Placebo|Placebo matched to TEZ/IVA fixed-dose combination tablet.
1993717|NCT03150719|Drug|Placebo|Placebo matched to IVA tablet.
1993719|NCT03149211|Drug|UB-421|Subjects will receive 13 doses of the UB-421 by intravenous infusion at 25 mg/kg bi-weekly (Cohort 2, 26 weeks).
1993720|NCT03149211|Drug|current standard HAART treatment|Subjects will receive current standard HAART treatment as the active control group.
1993721|NCT03149146|Other|Clinical Decision Making (CDM) Workshop|Participants will be provided the Clinical Decision Making workbook which will be used as a guideline to practice decision making. A workshop was chosen rather than other methods of presenting the guideline so that participants could receive feedback and guidance from the instructors and from the other participants. Active learning educational environment will be encouraged and the workshop require group and individual participation and also assist the participants in reflection on their decisions.
1993722|NCT03149146|Other|Clinical Decision Making (CDM) Workbook|Participants are encouraged to read and do exercises which was written in the workbook for a week and they also are asked to recall their recent patient case or use their patient as the example case and answer the questions from the Clinical Decision Making workbook.
1993723|NCT03148470|Device|Sham iTBS|Placebo stimulation
1993724|NCT03148470|Device|Sham cTBS|Placebo stimulation
1993725|NCT03148470|Device|intermittent theta burst stimulation (iTBS)|Excitatory rTMS
1993726|NCT03148470|Device|continuous theta burst stimulation (cTBS)|inhibitory rTMS
1993727|NCT03148457|Drug|Early treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Early treatment will be started within 48 hours after symptom onset (minor and moderate ischaemic stroke) or at day 6 + 1 day after symptom onset (major ischaemic stroke)
1993728|NCT03148457|Drug|Late treatment with Rivaroxaban (Xarelto®), Dabigatran (Pradaxa®), Apixaban (Eliquis®) or Edoxaban (Lixiana®)|Patients in the control arm will receive late treatment as per current recommendations (i.e. minor ischaemic stroke after day 3 + 1 day, moderate ischaemic stroke after day 6 + 1 day and major ischaemic stroke after day 12 + 2 day).
1993729|NCT03148379|Device|Customized patient instruments|Single use efficiency instruments and cutting blocks specifically made for each patient using pre-op MRI or CT scans to make bone cuts and select implant size.
1984277|NCT01859312|Drug|Hydrocortisone (Solucortef)|
1984278|NCT01859312|Device|Insulin pump (Medtronic)|
1993730|NCT03148379|Device|Traditional Metal Instruments|Traditional metal instrument will be used to make bone cuts and size the components in this control group.
1993731|NCT03146481|Drug|Aceclofenac|Aceclofenac 100 mg tablet given one hour before starting the root canal treatment
1993732|NCT03146481|Other|Placebo|Placebo tablet given one hour before starting the root canal treatment
1993733|NCT03147677|Drug|Alfacalcidol|
1993734|NCT03147677|Drug|Irbesartan|
1993736|NCT03146689|Drug|Topical NSAID|Applied four times daily
1993737|NCT03146689|Drug|Topical Capsaicin|Applied four times daily
1993738|NCT03145259|Drug|Diclofenac Epolamine Patch|patch
1993739|NCT03145259|Drug|diclofenac sodium solution|solution
1993740|NCT03145818|Other|VD-HCBS|Like the participant-directed programs developed for Medicaid programs,VD-HCBS maximizes Veteran-centered care and independence. VD-HCBS provides Veterans with a monthly financial allotment based on an assessment of the extent of their need for assistance with personal care due to injury or the impact of disease
1993741|NCT03145207|Drug|Lidocaine patch|lidocaine patch
1993742|NCT03143660|Behavioral|Coaching|The eight weekly 30-minute Fitline calls provide personalized behavioral counseling and coaching to guide parents in improving their child's weight-related behaviors through targeted lifestyle changes recommended by the AAP for Stage 1, Prevention Plus. Calls are scheduled at a time convenient for the parent, including nights and weekends, with one nutritionist assigned to a family for consistency.
1993743|NCT03143660|Behavioral|Materials|The workbook contains tips and practical strategies for implementing the AAP-recommended behavior changes discussed in the counseling sessions to support families in making lifestyle changes.
1993744|NCT03144128|Dietary Supplement|Vitamin D|5,000IU vitamin D given daily for 12 weeks
1993745|NCT03144128|Dietary Supplement|Placebo|Placebo capsules given daily for 12 weeks
1993746|NCT03143920|Combination Product|Hyperbaric Oxygen Therapy-|Hyperbaric oxygen therapy provides 100% medical grade oxygen at 2.4 atmospheres of absolute pressure with a Class A multiple person chamber or Class B single person chamber. Hyperbaric chambers are classified as a Class II medical device and have been FDA cleared.
1993747|NCT03143868|Behavioral|Exercise Modality|The overall aim of this study is to compare how acute exercise modality (e.g. resistance exercise vs. aerobic exercise) differentially influence hormonal and behavioral indices of appetite regulation and ad libitum energy intake. Both conditions will also be compared to a non-exercise control condition.
1993748|NCT03141632|Drug|Dulaglutide|Evaluation visit with assessment of fluid intake
1993749|NCT03141632|Other|Placebo|Evaluation visit with assessment of fluid intake
1993750|NCT03141593|Drug|Vitamin D: liquid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
1993751|NCT03141593|Drug|Vitamin D: liquid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
1993752|NCT03141593|Drug|Vitamin D: solid form, start weekly|Patient will start treatment with weekly schedule, and switch after 3 months to monthly schedule for another 3 months.
1993753|NCT03141593|Drug|Vitamin D: solid form, start monthly|Patient will start treatment with monthly schedule, and switch after 3 months to weekly schedule for another 3 months.
1993754|NCT03141905|Other|Sick-Day Protocol|Sick-Day Protocol (instructions for holding and resumption of certain medicines in the event of dehydrating illness) and IVSDRS weekly remote monitoring
1993755|NCT03141905|Other|Usual Care|Standard clinical care
1993756|NCT03141710|Dietary Supplement|20 ml of prebiotic per day|12 volunteers will take 20ml of prebiotic per day for 12 weeks
1993757|NCT03139721|Device|Mosiac model 305, model 310, and ultra model 305|Aortic or mitral valve replacement
1993758|NCT03140995|Behavioral|Walking Programme|The programme will be devised using incremental targets for daily walks based on the 6-20 Borg of rating of perceived exertion scale (Borg RPE). They will be instructed that they should be moderately short of breath on exertion i.e. unable to comfortably hold a conversation while walking
1993759|NCT03140826|Drug|meropenem|Antibiotics to treat infections.
1993760|NCT03140618|Other|The light and environment project in psychiatric inpatient care|"Complete rebuilding of a hospital ward.
The ward layout is remodeled and different devices and services are installed such as light, sound, and color settings, increased opportunities for physical activity, social harmony, privacy, peace, and quiet. A comfort room and a activity room will be built."
1993761|NCT03140358|Drug|Atropine sulfate 0.01%|Atropine 0.01%
1993762|NCT03140358|Drug|Placebo|placebo
1993763|NCT03140293|Drug|Lidocaine injection|Injectable anesthesia is 1-2mL of 2% lidocaine via a 22 gage needle, given at the anticipated site of CVS needle puncture immediately before procedure.
1993764|NCT03140293|Drug|Gebauer Ethyl Chloride Spray|Gebauer Ethyl Chloride Spray is a topical anesthetic spray which is sprayed continuously for 3-7 seconds from a distance of 3-9 inches at the site where the chorionic villus sampling is expected to take place.
1993765|NCT03139838|Behavioral|EHR-Based Intervention A|Intervention A will be a prompt for clinicians to document an estimated prognosis for patients at 6 months, and an assessment of predicted functional outcome if expected to survive.
1984294|NCT01853319|Drug|Regorafenib (BAY73- 4506)|160 mg regorafenib per oral every day for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off)
1984302|NCT01850082|Procedure|Vein Harvesting Procedures|"Open Vein Harvesting is the traditional method of saphenectomy for CABG. It is performed under direct vision using a single long incision or, more commonly, multiple smaller incisions (referred to as bridging technique) along the course of the vein. This approach minimizes manipulation and direct trauma to the conduit but is associated with potential for discomfort and leg wound healing complications. Endoscopic Vein Harvesting is a minimally invasive procedure that was developed to eliminate the need for long incisions associated with OVH. EVH reduces the risk of wound infections and other leg wound complications but may be more traumatic to the conduit than OVH."
1984304|NCT01846611|Drug|Trabectedin|1.1 mg/m2 administered intravenously over approximately 3 hours on Day 1 of each 21-day treatment cycle
1984305|NCT01846611|Drug|DOXIL|30 mg/m2 administered intravenously over approximately 90 minutes on Day 1 of each 21-day treatment cycle
1984306|NCT01846611|Drug|Dexamethasone|20 mg administered intravenously on Day 1 of each 21-day treatment cycle approximately 30 minutes prior to study drug infusion
1984307|NCT01846611|Drug|DOXIL|50 mg/m2 administered intravenously over approximately 90 minutes on Day 1 of each 28-day treatment cycle
1984308|NCT01846702|Drug|Placebo|Given as a SC injection.
1984309|NCT01846702|Drug|LY3084077|Given as a SC injection.
1984314|NCT01828983|Behavioral|Telephone support groups|
1984315|NCT01828983|Other|Education webinars|
1984343|NCT01800162|Drug|Methotrexate|Two Dose Protocol: The patient will receive the first dose of MTX 50mg/m2 on treatment day 0. She will receive a second dose of MTX 50mg/m2 on treatment day 4 and a serum hCG level will be drawn. Subsequent doses of MTX will be administered based on hCG levels.
1984344|NCT01800162|Procedure|Uterine Evacuation|Uterine evacuation or dilation and curettage. At the clinician's discretion, this can be performed using local anesthesia, sedation or general anesthesia and can use a manual or electrical evacuation.
1984345|NCT01800162|Other|Expectant Management|Pregnancy will be expectantly managed using serum hcg monitoring.
1984348|NCT01794780|Drug|LABA based treatment: indacaterol|LABA based treatment: indacaterol
1984349|NCT01794780|Drug|LAMA based treatment: tiotropium|LAMA based treatment: tiotropium
1984350|NCT01794780|Drug|LABA/ICS based treatment: salmeterol/fluticasone|LABA/ICS based treatment: salmeterol/fluticasone
1984351|NCT01794780|Drug|LABA/ICS based treatment: budesonide/formoterol|LABA/ICS based treatment: budesonide/formoterol
1984352|NCT01794780|Drug|theophylline based treatment|theophylline based treatment
1984353|NCT01793935|Drug|Sensoril®|Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
1984354|NCT01793935|Drug|Placebo|Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
1984355|NCT01791478|Drug|PI3K inhibitor BYL719|Given PO
1984356|NCT01791478|Drug|letrozole|Given PO
1984357|NCT01791478|Other|laboratory biomarker analysis|Correlative studies
1984358|NCT01791478|Other|pharmacological studies|Correlative studies
1984363|NCT01790659|Drug|WR 279,396|WR 279,396 is a topical cream of paromomycin 15% and gentamicin 0.5%
1984364|NCT01790659|Drug|Paromomycin|Paromomycin alone
1984369|NCT01788111|Other|Low back exercises 1|Excentric / concentric extension type exercises
1984370|NCT01788111|Other|Low back exercise 2|Traditional low back training
1984373|NCT01785771|Drug|ITCA 650 (exenatide in DUROS)|
1984381|NCT01778010|Drug|Modafinil|modafinil (0, 200, and 400 mg/day)
1984382|NCT01778010|Drug|Cocaine|smoked cocaine (0, 12, 25, and 50 mg)
1984391|NCT01764880|Drug|SST0001 (Roneparstat)|SST0001 once daily for 5 or 10 days in a cycle of 28 days.
1984392|NCT01765790|Biological|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"Dosing every 2 weeks
Intravenous injection"
1984393|NCT01765790|Biological|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|"Dosing weekly
Intravenous injection"
1984400|NCT01757405|Biological|Recombinant Factor VIIa BI (rFVIIa BI)|Administered approximately every 3 hours as an intravenous bolus injection on-demand
1984401|NCT01757405|Biological|Recombinant Factor VIIa BI (rFVIIa BI)|Administered as a single intravenous bolus injection on-demand
1984402|NCT01756638|Drug|Abiraterone|Abiraterone will be administered orally as 1000 milligram (mg) per day for 28-daily dosing cycles which will be continued until disease progression or unacceptable toxicity.
1984403|NCT01756638|Drug|Prednisolone|Prednisolone will be administered orally as 5 mg tablets twice daily for 28-daily dosing cycle which will be continued until disease progression or unacceptable toxicity.
1984406|NCT01749501|Drug|Rocuronium|0.6 mg/Kg once
1984407|NCT01749501|Other|Placebo|Normal saline same amt as 0.6mg/kg of study drug
1984411|NCT01744561|Behavioral|Exercise Intervention|Add three hours of intense physical activities per week to baseline activities. Weekly exercise should include at least 30 minutes of strength building activities and at least two hours of aerobic activities. Exercise bouts lasting 20 min or longer will be counted with respect to total weekly training time.
1984413|NCT01738672|Drug|Inhaled nitrous oxide|Administration of nitrous oxide for labor analgesia
1984414|NCT01736579|Drug|Immune Globulin Intravenous (Human), 10% (IGIV, 10%)|
1984432|NCT01725126|Drug|GSK2890457|Provided as powder and capsule.
1984433|NCT01725126|Drug|Metformin|"Tablet
Part A: Single doses on Day 1 and Day 42 orally
Part B: Subject continues usual metformin dose through Run-in, and resumes after Treatment Period completed
Part C: Subject continues usual metformin dose throughout study"
1984434|NCT01725126|Drug|Placebo|Provided as powder and Capsule.
1984435|NCT01725126|Drug|Liraglutide|"Provided as Injection. 6mg/mL, 3mL injector pen that permits doses of 0.6mg, 1.2mg, and 1.8mg
Subcutaneous injection 18 weeks dosing (Stabilization and Treatment Periods, Part B only"
1984441|NCT01721044|Drug|Placebo|Administered orally
1984442|NCT01721044|Drug|Baricitinib|Administered orally
1984449|NCT01705977|Biological|Placebo plus standard therapy|Placebo plus standard therapy
1984450|NCT01705977|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
1984451|NCT01705977|Other|Standard therapy|Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressives; other biologics are not permitted.
1984453|NCT01700439|Device|EDWARDS INTUITY valve|Surgical replacement of the aortic valve with the EDWARDS INTUITY valve.
1984509|NCT01641809|Drug|GSK1265744 10 mg|GSK1265744 10 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
1984510|NCT01641809|Drug|GSK1265744 30 mg|GSK1265744 30 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
1984511|NCT01641809|Drug|GSK1265744 60 mg|GSK1265744 60 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase of the study and in combination with Rilpivirine 25 mg in the Maintenance Phase of the study.
1984512|NCT01641809|Drug|Efavirenz 600 mg|Efavirenz 600 mg will be administered orally once daily in combination with investigator-selected background NRTIs in the Induction Phase and Maintenance Phase of the study.
1984513|NCT01641809|Drug|Rilpivirine 25 mg|Rilpivirine 25 mg will be administered orally once daily in combination with GSK1265744 10 mg, 30 mg and 60 mg in the Maintenance Phase of the study.
1984514|NCT01641809|Drug|Placebo|Placebo matching to GSK1265744 will be administered along with GSK1265744 10 mg and 30 mg in the Induction phase and Maintenance phase of the study.
1984515|NCT01641809|Drug|Abacavir/Lamivudine (ABC/3TC) or Tenofovir/Emtricitabine (TDF/FTC)|The background dual NRTI therapy for all arms in the Induction Phase and Efavirenz 600 mg arm in the Maintenance Phase will be either abacavir 600 mg + lamivudine 300 mg (ABC/3TC) or tenofovir 300 mg + emtricitabine 200 mg (TDF/FTC) as selected by the Investigator.
1984524|NCT01631656|Drug|Azelaic acid|15% gel, twice daily, 6 weeks
1984525|NCT01631656|Device|Nd:Yag laser|Treatment with Nd:Yag laser of half the face, once at Week 2.
1984537|NCT01614093|Drug|Oxytocin|Single dose intranasal oxytocin (24 IU)
1984538|NCT01614093|Drug|Placebo|Placebo- Sugar pill
1984539|NCT01614210|Drug|Tamoxifen|All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.
1984540|NCT01614210|Procedure|Breast cancer surgery|Breast cancer surgery
1984541|NCT01611090|Drug|Ibrutinib|Type=exact number, unit=mg, number=420 , form=capsule, route=oral use. Capsule is taken once daily continuously.
1984542|NCT01611090|Drug|Bendamustine hydrochloride|Type=exact number, unit=mg, number=70 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Days 2-3 and Cycles 2-6, Days 1-2.
1984543|NCT01611090|Drug|Rituximab|Type=exact number, unit=mg, number=375 mg/m2 and 500 mg/m2, route=intravenous use. Administered intravenously on Cycle 1, Day 1, and Cycles 2-6, Day 1, respectively.
1984544|NCT01611090|Drug|Placebo|Form=capsule, route=oral use. Capsule is taken once daily continuously.
1984552|NCT01599819|Biological|Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method|1 PK infusion of ADVATE (low dose in Cohort 1, high dose in Cohort 2)
1984553|NCT01599819|Biological|PEGylated Recombinant Factor VIII|1 PK infusion of BAX 855 (low dose in Cohort 1, high dose in Cohort 2)
1984556|NCT01597401|Drug|Aes-103|300 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
1984557|NCT01597401|Drug|Aes-103|1000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
1984558|NCT01597401|Drug|Aes-103|2000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
1984559|NCT01597401|Drug|Aes-103|4000 mg Aes-103 powder reconstituted in orange juice to a volume of 100 mL per single dose for oral administration.
1984560|NCT01597401|Drug|Placebo|Orange juice vehicle, a solution that is highly similar in appearance to the Aes-103 orange juice solution.
1984590|NCT01560780|Drug|Prasugrel|one 10 mg tablet by mouth daily
1984591|NCT01560780|Drug|Placebo|placebo similar in appearance to prasugrel
1984594|NCT01558661|Drug|AG-013736 (AXITINIB)|All eligible patients will receive a starting axitinib dose of 5 mg twice daily (BID) taken orally in 4-week (28-day) cycles. Patients who tolerate axitinib with no adverse events related to study drug above CTCAE v. 4.0 Grade 2 for a consecutive 2-week period may have their dose increased by one dose level according to the discretion of the treating physician (NOT allowed for patients with blood pressure (BP) > 150/90 mm Hg or who are receiving antihypertensive medication). This dose escalation is not mandatory. RECIST v1.1 tumor assessments will be made at baseline (CT or MRI) and then approximately every 2 cycles (or every 8 weeks (+/- 1 week)). After 10 months, imaging will be done every 3 cycles (or every 12 weeks (+/- 1 week)). Patients may remain on study until progression of disease or unacceptable toxicity.
1984595|NCT01556425|Drug|Vivitrol|Participants receiving this intervention will receive the FDA-approved dose, route, and schedule of administration of VIVITROL. The dose of VIVITROL of 380 mg will be delivered intramuscularly every 4 weeks.
1984596|NCT01556425|Behavioral|Employment-based opiate abstinence reinforcement|This intervention will require participants to provide opiate-negative urine samples on Monday, Wednesday and Friday to maintain their maximum pay. If a participant provides an opiate-positive urine sample, or fails to provide a scheduled sample, their base pay will be reset from $8 per hour to $1 per hour. On each day after the reset that the participant provides a urine sample that meets the opiate abstinence criteria and attends the workplace for at least 5 minutes, their base pay will increase by $1 per hour until it reaches the maximum of $8 per hour.
1984597|NCT01556425|Other|Usual Care Control|Participants receiving this intervention will be invited to attend the workplace and outpatient drug abuse counseling.
1984598|NCT01555125|Drug|secukinumab 150 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 150 mg treatment as open label for the remainder of the extension treatment period
1984599|NCT01555125|Drug|secukinumab 300 mg|After the data base lock of week 52 data has been performed, subjects will receive secukinumab 300 mg treatment as open label for the remainder of the extension treatment period
1984600|NCT01555125|Drug|placebo|Subjects who were on placebo at Week 52 cannot continue in the extension treatment period
1984603|NCT01541670|Drug|Anti-Macrophage Migration Inhibitory Factor (Anti-MIF) Antibody|Intravenous injection
1984628|NCT01508910|Biological|Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of Auto-CD34+ cells
1984629|NCT01508910|Biological|Placebo: Diluent used to suspend Auto-CD34+ cells|10 intramyocardial injections of 0.2 mL per injection site of placebo
1984630|NCT01508910|Other|Standard of care|Standard of care for refractory angina
1984631|NCT01507896|Biological|Recombinant factor IX|Following a loading dose with BAX326, participants will receive BAX326 as a bolus infusion. The treatment regimen will be determined by the intensity and duration of the hemostatic challenge and the institution´s standard of care. The dose will be tailored to raise FIX concentration to at least 80%-100% of normal for major surgeries and to at least 30%-60% of normal for minor surgeries.
1984634|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Primary vaccination (6 study arms of 50 subjects each): 3 intramuscular injections containing either dose A, B or C in an adjuvanted or non-adjuvanted formulation (6 different formulations) given in monthly intervals (recruited in 3 sequential cohorts)
1984635|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|Booster vaccination 9-12 months after first vaccination in Section 1 subjects
1984636|NCT01504347|Biological|Multivalent recombinant OspA Lyme Borreliosis Vaccine|3 intramuscular injections at monthly intervals (using 2 formulations selected from Section 1) in seronegative and seropositive subjects (N=350) and a booster vaccination at 6 months or at 9-12 months (Cohorts 4: seronegatives; Cohort 5: seropositives)
1984640|NCT01488994|Biological|BAX326|All participants underwent a pharmacokinetic evaluation with BAX326 (recombinant Factor IX) followed by twice weekly prophylactic treatment for 6 months or for at least 50 exposure days, whichever occurred last.
1984641|NCT01487265|Drug|BKM120 and Erlotinib|BKM120 and Erlotinib will be given once daily. Erlotinib 100 mg PO will be administered. During Cycle 1-Week 1 all patients will receive 80 mg PO daily BKM120. After the first week of Cycle 1, the dose of BKM120 will escalate to 100 mg PO daily and treatment will continue as long as there are no unexpected or prohibitive toxicities, or disease progression.
1984645|NCT01485796|Biological|Immune Globulin Infusion (Human), 10%|Subcutaneous administration will be used in Study Epochs 1 and 2.
1984646|NCT01485796|Biological|Recombinant human hyaluronidase|rHuPH20 will be administered subcutaneously (SC) immediately before each SC IGI, 10% infusion, through the same needle, at a rate of 1 to 2 mL/min.
1984654|NCT01473095|Drug|ARQ 092|Subjects in this study will receive ARQ 092 orally at dose levels specified for their respective dose cohorts. Dosing will begin at 10 mg every other day (QOD) and will escalate until the MTD or RP2D is determined. Cycles will be repeated in four-week (28 day) intervals until progression of disease, unacceptable toxicity, or another discontinuation criterion is met. In the case of toxicity, dose adjustment will be permitted.
1984656|NCT01460498|Drug|Azacitidine (AZA)|Starting Dose 50 mg/m2 by subcutaneous or by vein for 3 days of a 28 day cycle.
1984657|NCT01460498|Drug|Tyrosine kinase inhibitor (TKI)|Continuation of dose already receiving during previous 6 months.
1984658|NCT01460498|Drug|Azacitidine|75 mg/m2 daily for 3 days, unless MTD defined at lower dose level in Phase I then that would become dose used for Phase II.
1984659|NCT01460147|Other|DXA scan + MRI|This is a non-drug study. Subjects will receive a dual-energy X-ray absorptiometry (DXA) scan (in the main osteoporosis study) and will undergo magnetic resonance imaging (in the MRI substudy).
1984668|NCT01436968|Biological|ProstAtak®(AdV-tk) + valacyclovir|"Patients will receive three courses of ProstAtak® each consisting of AdV-tk injection + oral valacyclovir. AdV-tk injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:
The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.
The second injection will be 0-3 days before initiation of radiation therapy.
The third injection will be 15-22 days after the 2nd injection.
The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each AdV-tk injection.
Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
1984669|NCT01436968|Biological|Placebo + valacyclovir|"Patients will receive three courses each consisting of placebo injection + oral valacyclovir. Placebo injection will be delivered to the prostate via trans-rectal ultrasound guided injection as follows:
The first injection will be given at least 15 days and not more than 8 weeks before starting radiation.
The second injection will be 0-3 days before initiation of radiation therapy.
The third injection will be 15-22 days after the 2nd injection.
The prodrug, valacyclovir, will be administered at a fixed dose for 14 days after each placebo injection.
Standard external beam radiation therapy will be delivered to the prostate. Short-term androgen deprivation therapy (maximum of 6 months) is optional but must be decided before enrollment to allow for stratification."
1984671|NCT01412385|Biological|Immune Globulin Subcutaneous (Human), 20%|Subcutaneous infusion (regulated via a pump), Epoch 2 only (all subjects)
1984672|NCT01412385|Biological|Immune Globulin Intravenous (Human), 10%|Intravenous infusion (regulated via a pump)
1984673|NCT01412385|Biological|Human Normal Immunoglobulin (Subcutaneous - Intramuscular Immunoglobulin)|Subcutaneous infusion (regulated via a pump)
1984677|NCT01391546|Biological|1 dose at Day 0|1 dose 0.65 mL
1984678|NCT01390389|Drug|Coenzyme Q10|"Single pill consists of 400 mg and is delivered PO.
CoQ10 dosing guidelines:
Visit 1 (baseline) start at 400mg once a day for two weeks
Visit 2 (within 7 days of baseline visit) increase to 800 mg once a day for two weeks
The dosage of CoQ10 can be titrated in a more gradual manner depending on clinical response and tolerability of the medication, but cannot be titrated any more rapidly than the schedule above."
1984690|NCT01369108|Device|Flowable composite|Restoration of small Class V and I cavities in molar and premolar teeth
1984691|NCT01369108|Device|Conventional composite restorative|Restoration of small Class V and I cavities in molar and premolar teeth
1984697|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 0.3 mg/kg, Every 3 weeks, Indefinitely depending on response
1984698|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 2 mg/kg, Every 3 weeks, Indefinitely depending on response
1984699|NCT01358721|Drug|BMS-936558 (Anti-PD-1)|Solution, Intravenous infusion, 10 mg/kg, Every 3 weeks, Indefinitely depending on response
1984701|NCT01356693|Drug|Bromelin|Ananas comosus extract (3,3g) on vehicle: methylparaben, propylparaben, honey from Apis mellifera, sodium benzoate, ethilic alcohol, water) 5ml. Given in single dose.
1984702|NCT01356693|Drug|Placebo|Placebo with mimicking characteristics of experimental drug
1984715|NCT01345669|Drug|Placebo|Once daily
1984716|NCT01345669|Drug|Afatinib|Once daily
1984719|NCT01332851|Behavioral|Promoting First Relationships (PFR)|PFR is a parenting intervention based on attachment theory and is strengths based. It is a 10 week intervention that is delivered in the home of the family.
1984720|NCT01332851|Behavioral|Resource and Referral|Needs assessment, followed with a resource packet sent by mail
1984721|NCT01330953|Drug|Placebo|Administered intravenously
1984722|NCT01330953|Drug|LY2928057|Administered intravenously
1984732|NCT01312909|Drug|Varenicline 1mg BID|Oral Varenicline 1mg BID, or 1/2 that dose (0.5mg BID) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
1984733|NCT01312909|Drug|Varenicline 0.5mg BID|Oral Varenicline 0.5mg BID, or 1/2 that dose (0.5 QD) for those subjects that weigh less than or equal to 55kg at baseline, for twelve weeks, follow-up through Week 52
1984734|NCT01312909|Drug|Placebo|Oral placebo for twelve weeks,follow-up through Week 52
1984735|NCT01311466|Procedure|Liver transplantation|
1984736|NCT01308567|Drug|Cabazitaxel (XRP6258)|Pharmaceutical form: Solution for injection; Route of administration: Intravenous
1984737|NCT01308567|Drug|Docetaxel (XRP6976)|Pharmaceutical form: Solution for injection'; Route of administration: Intravenous
1984738|NCT01308567|Drug|Prednisone|Pharmaceutical form: Tablet; Route of administration: Oral
1984739|NCT01305213|Biological|Bevacizumab|Given IV
1984740|NCT01305213|Drug|Fosbretabulin Tromethamine|Given IV
1984741|NCT01305213|Other|Laboratory Biomarker Analysis|Correlative studies
1984747|NCT01287598|Drug|Regorafenib (Stivarga, BAY73-4506)|BAY73-4506 administered once a daily (od) in a 21-day on / 7-day off schedule
1984748|NCT01287598|Drug|Warfarin|CYP 2C9 (warfarin) at Cycle 1
1984749|NCT01287598|Drug|Omeprazole|CYP 2C19 (omeprazole) at Cycle 1
1984750|NCT01287598|Drug|Midazolam|CYP 3A4 (midazolam) at Cycle 1
1984751|NCT01287598|Drug|Rosiglitazone|CYP2C8 (rosiglitazone) at Cycle 1
1984752|NCT01286779|Biological|BAX 326 (Recombinant factor IX)|The treatment with BAX 326 will be at the discretion of the investigator and will consist of either twice weekly prophylactic treatment with 50 IU/kg, modified prophylaxis, or on-demand treatment.
1993766|NCT03139838|Behavioral|EHR-Based Intervention B|Intervention B will entail a prompt for clinicians to provide a reason for not offering patients and their families the alternative of care focused entirely on comfort despite recommendations from critical care professional societies to do so for patients at high risk for death or severely impaired functional recovery.
1993767|NCT03138993|Behavioral|Patient decision aid|Web-based patient decision aid plus a paper workbook.
1993768|NCT03138993|Behavioral|General sleep education|Web-based information about sleep plus a paper workbook
1993769|NCT03138083|Drug|OMO-1|OMO-1 is a small molecule inhibitor of the enzymatic activity of the MET receptor tyrosine kinase
1993770|NCT03136978|Diagnostic Test|Evaluation of M1 and M2 macrophages by flow cytometry.|To assess surface expression of macrophage markers, tissue samples will be stained for flow cytometry with fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CCR7 and CD80 to identify M1, whereas fluorochrome-conjugated monoclonal antibodies against CD14, CD68, CD163 and CD206 to identify M2.
1993771|NCT03137043|Other|Questionnaire|Subjects will be given an Electronic Case Report Form (eCRF) with a series of questionnaire such as Asthma Control Test, Morisky-Green Questionnaire and St George's Respiratory Questionnaire.
1993772|NCT03137043|Other|Software of Big Data|Software of big data is a powerful data treatment algorithm works closely with Spanish Data Protection Agency as an example on how to reuse clinical information without conflicting with necessary data privacy. The system will process a vast amount of information (big data), so that the impact of random errors will be minimized.
1993773|NCT03136744|Behavioral|Sit Less with MS|The Sit Less with MS intervention has a total duration of 16 weeks and consists of two stages: sit less and move more stages. During the first stage (sit less), we will conduct coaching sessions with participants every week and the focus will be on interrupting their sitting time every 30 minutes. Facebook and Twitter will be also used to provide information and supplement coaching sessions. During the second stage, the focus will be on encouraging the participants to move more by replacing sitting with light intensity activities frequently throughout waking hours.
1993774|NCT03136484|Drug|Semaglutide|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
1993775|NCT03136484|Drug|Canagliflozin|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
1993776|NCT03136484|Drug|Placebo (canagliflozin)|Following a dose escalation phase of 8 weeks, semaglutide 1.0 mg once-weekly(administered subcutaneously, s.c., under the skin) and canagliflozin placebo once-daily (administered orally, as a tablet). Subjects will continue on their pre-trial daily dose of metformin.
1993777|NCT03136484|Drug|Placebo (semaglutide)|Following a dose escalation phase of 8 weeks, canagliflozin 300 mg once-daily (administered orally, as a tablet) and semaglutide placebo (administered subcutaneously, s.c., under the skin). Subjects will continue on their pre-trial daily dose of metformin.
1993778|NCT03136237|Drug|BCX7353|Day 11-18 for Cohort 1, Day 7-14 for Cohort 2, Day 1 for Cohort 3
1993779|NCT03136237|Drug|Digoxin|Day 1 of Cohort 1
1993780|NCT03136237|Drug|BCX7353 + digoxin|Day 19 of Cohort 1
1993781|NCT03136237|Drug|Rosuvastatin|Day 1 of Cohort 2
1993782|NCT03136237|Drug|rosuvastatin + BCX7353|Day 15 of Cohort 1
1993783|NCT03136237|Drug|Cyclosporine + BCX7353|Day 14 of Cohort 3
1993784|NCT03135873|Dietary Supplement|Mastiha|Mastiha is a natural product of Greece and has a license of manufactures Foods for Particular Nutritional Uses and of National Organization of Medicines (EOF).
1993785|NCT03135873|Dietary Supplement|Placebo|Placebo is designed to have identical characteristics with verum.
1993788|NCT03132753|Behavioral|SUPPORT|SUPPORT clients will be offered 12 months of support service with a recovery coach. The recovery coach will guide the client through their recovery, offering guidance and support, while coordinating their treatment services, including support services. The program will provide clients with $1,000 worth of vouchers to cover the cost of additional flexible support services over the 12 months of program enrollment, which will be personalized to fit the needs of the client. These cost vouchers will cover support services, such as housing, employment services, substance use treatment, transportation, childcare, educational or vocational services, or aftercare planning. The costs of each service is determined by the service provider. Further, the recovery coach will assist the client in choosing appropriate services and coordinating/monitoring service completion.
1993992|NCT03093363|Other|Pharmacist's intervention|"Pharmacist's intervention with asthmatic patients:
Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
Explanation of asthma and inflammation
Explanation of triggers and how to avoid it
Explanation of asthma treatments
Explanation of the inhalation technique with a physical demonstration
Emphasis on treatment adherence
Assessment of comorbidities and their treatment
Emphasis on influenza vaccination"
1984776|NCT01253421|Drug|Amisulpride|single low-dose pharmacological challenge, 50 mg amisulpride
1984777|NCT01253421|Drug|Placebo|single-dose placebo capsule
1984802|NCT01227044|Drug|Naltrexone|NTX arm will receive monthly extended release NTX doses at 380mg (4 mL), administered as an intramuscular gluteal injection at 4-week intervals.
1984803|NCT01227044|Other|Placebo + Medication Management/Medication Coaching|Placebo + Medication Management/Medication Coaching
1984806|NCT01218438|Biological|Immune Globulin Intravenous (Human), 10% Solution|Intravenous infusion with IGIV, 10%
1984807|NCT01218438|Drug|Immune Globulin Subcutaneous (Human), 20% Solution|Subcutaneous infusion with IGSC, 20%
1984839|NCT01191372|Drug|placebo control|sterile saline for injection
1984840|NCT01191372|Drug|ARC19499|Anti-tissue factor pathway inhibitor (TFPI) aptamer
1984841|NCT01187446|Procedure|TSEBT|12Gy
1984842|NCT01187446|Drug|Vorinostat|Calculated per patient
1984849|NCT01186484|Drug|JNJ-212082|250 mg, 500 mg or 1000 mg once daily up to discontinuation for any reasons such as progression of the disease or up to the transition to extension study.
1984850|NCT01178294|Biological|OBI-1|Intravenous infusion
1984853|NCT01175213|Biological|IGSC - rHuPH20 then IGSC or IGIV|"Treatment Period:
As this was an extension of Study 160603 (NCT00814320), participants continued on the same doses and treatment intervals of Immune Globulin Subcutaneous Solution (IGSC), 10% and recombinant human hyaluronidase (rHuPH20) used for the last infusions in epoch 2 of Study 160603.
After 3 infusions, participants changed to 2-week infusions, if agreed with investigator and participant.
Followed by
Safety Follow-up Period:
Participants were treated either subcutaneously (SC) with IGSC, 10% weekly (dose-weekly equivalent of most recent intravenous [IV] dose adjusted per body weight x 1.37) or IV with Immune Globulin Intravenous (Human) (IGIV), 10%, every 3-4 weeks (weekly dose equivalent was 100% of the most recent IV dose) as agreed with the investigator and participant."
1984854|NCT01175213|Biological|IGIV, 10% only|"Participants were treated with IGIV, 10% only throughout the study.
Note: IGIV, 10% is the same product as IGSC, 10%"
1984866|NCT01162499|Drug|Exendin-(9-39)|IV infusion of exendin-(9-39) for 5 hours
1984867|NCT01162499|Other|Vehicle|Normal saline (vehicle) infusion for 5 hours at 0.06 mL/kg/hr
1984868|NCT01159210|Biological|Prothrombin complex concentrate (coagulation factors IX, II, VII and X in combination)|Intravenous infusion; regimen is guided by the pre-treatment international normalised ratio (INR); dosage and duration of replacement therapy depend on the severity of the disorder, on the location and extent of bleeding and on the patient´s clinical condition.
1984869|NCT01154816|Drug|Alisertib|Given orally
1984870|NCT01154816|Other|Laboratory Biomarker Analysis|Correlative studies
1984871|NCT01154816|Other|Pharmacological Study|Correlative studies
1984892|NCT01128881|Biological|Factor IX Concentrate (purified, virus-inactivated)|Intravenous injection/infusion; dose for prophylaxis: 20-40 IU/kg bodyweight, twice weekly (which may be adjusted to the subject´s bleeding pattern and lifestyle); dose for bleeding episodes and surgery: according to the Summary of Product Characteristics and the Product Information Leaflet of the respective country.
1984895|NCT01127529|Biological|Protein C Concentrate (Human)|Commercially available Ceprotin will be prescribed, obtained and administered by the investigator according to local standard of care.
1984898|NCT01121250|Behavioral|Telephone Discussion Groups|Each telephone discussion group will meet 12 times during six months. The one-hour calls will be semi-structured conference calls with education, training in coping skills and cognitive restructuring, and support. A Participant Workbook will include comprehensive materials for all sessions and topics, other resources, and red flag resources - areas that may exacerbate problems, add a level of difficulty or distress, and/or indicate a need for referrals (e.g., unsafe behaviors, substance abuse, spouse abuse, PTSD, depression, traumatic brain injury).
1984899|NCT01121250|Behavioral|Education sessions|Participants will have 12 sessions (delivered using slides and telephone) that cover the same education content, without skills building or support, over six months. They will also receive the Participant Workbook.
1984904|NCT01104402|Device|Home lung function and symptom monitoring|subjects in the intervention arm will measure spirometry and CF symptoms with the use of a handheld device.
1984905|NCT01101867|Drug|Aspart fixed dose|fixed dose
1984906|NCT01101867|Drug|Aspart flexible dose|dose based upon carbohydrate intake and total daily requirements
1984907|NCT01093885|Drug|Ambrisentan|"Drug is dispensed in tablet form. Ambrisentan with anti-fibrotic to assess benefit on skin
Dosing of ambrisentan will begin at 5mg daily for the first month. Half the patients will remain at 5mg daily, while the remaining patients will be increased to a maintenance dose of 10mg daily on the fourth week."
1984908|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
1984909|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
1984910|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
1984911|NCT01090492|Drug|PF-00489791|Subjects with Secondary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
1984912|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 4 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
1984913|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 4 mg once a day for the second 4 week cross over period
1984914|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive PF-00489791 20 mg once a day for the first 4 week cross over period and then placebo once a day for the second 4 week cross over period
1984915|NCT01090492|Drug|PF-00489791|Subjects with Primary Raynaud's Phenomenon will receive placebo once a day for the first 4 week cross over period and then PF-00489791 20 mg once a day for the second 4 week cross over period
1984923|NCT01063101|Dietary Supplement|Fucoidan (extract of Laminaria japonica)|Capsule (300 mg/capsule) - oral administration - 5 different dose levels - BID
1984924|NCT01063101|Other|Placebo|Cellulose filled capsule - oral administration - 5 different dose levels - BID
1984926|NCT01033422|Drug|CF101|CF101 1 or 2 mg tablets orally every 12 hours for 16 weeks
1984927|NCT01033422|Drug|Placebo for|Matching placebo tablets orally every 12 hours for 16 weeks
1984932|NCT01022424|Drug|OPC-41061|Repeated oral administration at doses of 15 mg twice daily (morning and evening)
1984935|NCT01015807|Drug|Bupivacaine Placebo|2 x 20mL 0.9% NaCl
1984936|NCT01015807|Drug|Clonidine Placebo|2 x 1mL 0.9% NaCl
1984937|NCT01015807|Drug|Bupivacaine|2 x 20mL 0.375% Bupivacaine = 150 mg Bupivacaine
1984938|NCT01015807|Drug|Clonidine|2 x 1ml Clonidine = 150 µg Clonidine
1984966|NCT00981253|Behavioral|SMT-enhanced Cardiac Rehabilitation|Standard exercise-based cardiac rehabilitation, three times per week, enhanced with weekly stress management training for 12 weeks.
1984967|NCT00981253|Behavioral|Standard Cardiac Rehabilitation|Supervised exercise, three times per week, for 12 weeks.
1984977|NCT00977574|Biological|Bevacizumab|Given IV
1984978|NCT00977574|Drug|Carboplatin|Given IV
1984979|NCT00977574|Drug|Ixabepilone|Given IV
1984980|NCT00977574|Other|Laboratory Biomarker Analysis|Correlative studies
1984981|NCT00977574|Drug|Paclitaxel|Given IV
1984982|NCT00977574|Drug|Temsirolimus|Given IV
1984998|NCT00942188|Drug|LY2189102|2 subcutaneous injections weekly for 12 weeks.
1984999|NCT00942188|Drug|Placebo|2 subcutaneous injections weekly for 12 weeks.
1985005|NCT00939393|Device|FESS instruments with or without balloon treatment|Intervention with metal instruments with or without balloon treatment
1985006|NCT00939393|Device|Balloon Sinuplasty|Balloon dilatation of sinuses
1985012|NCT00929669|Drug|pasireotide LAR|pasireotide LAR 80 mg IM once a month
1985019|NCT00899275|Other|biologic sample preservation procedure|
1985020|NCT00897325|Other|Cytology Specimen Collection Procedure|Correlative studies
1985021|NCT00897325|Other|Laboratory Biomarker Analysis|Correlative studies
1985029|NCT00871910|Drug|SCH 727965|SCH 727965 2 hour IV infusion on Day 1 of each 3 week cycle, administered in dose-escalating cohorts (Part 1 of the trial)
1985030|NCT00871910|Drug|SCH 727965|SCH 727965 8 hour IV infusion on Day 1 of each 3 week cycle,in dose-escalating cohorts
1985031|NCT00871910|Drug|SCH 727965|SCH 727965 24 hour IV infusion on Day 1 of each 3 week cycle, in dose-escalating cohorts
1985032|NCT00871910|Drug|SCH 727965|SCH 727965 29.6 mg/m2 2 hour IV infusion on Day 1 of each 3 week cycle
1985033|NCT00871910|Drug|Aprepitant|Oral aprepitant in Cycle 1 or Cycle 2, depending on the study arm: 125 mg 1 hour prior to the SCH 727965 infusion on Day 1, and 80 mg on Days 2 and 3.
1985034|NCT00871910|Drug|Ondansetron|Ondansetron 32 mg IV 30 minutes prior to the SCH 727965 infusion on Day 1 of Cycles 1 and 2.
1985035|NCT00871910|Drug|Dexamethasone|Oral dexamethasone in Cycles 1 and 2: 12 mg 30 minutes prior to the SCH 727965 infusion on Day 1, and 8 mg in the morning on Days 2, 3, and 4.
1985049|NCT00835731|Drug|misoprostol|400mcg misoprostol, buccal administration, 1 time dosing 3-4 hours before abortion by D&E
1985050|NCT00835731|Device|Dilapan-S, vitamin B-12|One Dilapan-S rod placed in the cervix 3-4 hours before abortion by D&E. Control: 1000mcg vitamin B-12, buccal administration 3-4 hours before abortion by D&E
1985052|NCT00829413|Drug|SonoVue®|SonoVue (2.4 mL)
1985059|NCT00816660|Biological|Recombinant von Willebrand factor : recombinant FVIII (rVWF:rFVIII)|Single dose, dose escalation, various cohorts
1985060|NCT00816660|Biological|Marketed plasma-derived VWF/FVIII concentrate|Cross-over: recombinant FVIII (rVWF:rFVIII) and marketed plasma-derived VWF/FVIII concentrate
1985065|NCT00805441|Drug|LY686017|50 mg daily by oral route for 12 weeks
1985066|NCT00805441|Drug|Placebo|Daily by oral route for 12 weeks
1985067|NCT00804999|Drug|Clear Care|neutralized Clear Care
1985068|NCT00804999|Drug|ReNu MultiPlus MPS|overnight soak in solution
1985069|NCT00804999|Drug|OPTI-FREE RepleniSH MPDS|overnight soak in solution
1985084|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered
1985085|NCT00782106|Biological|Recombinant human hyaluronidase + immune globulin intravenous|"IV infusion of IGIV, 10% to determine pharmacokinetics
Intervention as in Arm 1: Dose (calculated) of rHuPH20 followed by subcutaneous infusion of IGIV, 10% to determine tolerability: doses of rHuPH20 and IGIV, 10% to be increased, as tolerated and as per protocol, until a full 4-week IgG dose can be administered"
1985086|NCT00781898|Drug|Depot naltrexone|Vivitrol® extended release naltrexone 380 mg per month delivered in monthly intramuscular injections.
1985087|NCT00781898|Other|Treatment as Usual (TAU)|Treatment as Usual (TAU) community treatment provided to the participant
1985092|NCT00772200|Procedure|psychosocial assessment and care|Complete COG Standard Neuropsychological and Behavioral Battery testing
1985093|NCT00772200|Procedure|cognitive assessment|Complete COG Standard Neuropsychological and Behavioral Battery testing
1985094|NCT00772200|Other|quality-of-life assessment|Ancillary studies
1985095|NCT00772200|Other|questionnaire administration|Ancillary studies
1985110|NCT00736749|Procedure|Assessment of Therapy Complications|Complete patient response form and Health Status Update Form
1985111|NCT00736749|Other|Questionnaire Administration|Complete patient response form and Health Status Update Form
1985114|NCT00735891|Drug|First-Line Treatment|Docetaxel 75 mg/m2, Carboplatin AUC=6,Bevacizumab 15 mg/kg administered in 21-day cycles on day 1 of each cycle.
1985115|NCT00735891|Drug|Maintenance|Bevacizumab 15 mg/kg maintenance in 21 day cycles for up to 18 cycles.
1985116|NCT00735891|Drug|Second-Line Treatment|Arm A: Pemetrexed 500 mg/m2 plus Bevacizumab 15 mg/kg administered in 21 day cycles on Day 1 of each cycle. Arm B: Pemetrexed 500 mg/m2 administered in 21 day cycles on Day 1 of each cycle.
1985128|NCT00718718|Drug|CNTO 136 100 mg|CNTO 136 100 mg will be administered subcutaneously (under the skin) every 2 or 4 weeks as per the appropriate randomized arm.
1985129|NCT00718718|Drug|CNTO 136 50 mg|CNTO 136 50 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
1985130|NCT00718718|Drug|CNTO 136 25 mg|CNTO 136 25 mg will be administered subcutaneously every 4 weeks from Week 0 to Week 24.
1985131|NCT00718718|Drug|Placebo|Placebo will be adminstered subcutaneously as per the appropriate randomized arm.
1985132|NCT00718718|Drug|Methotrexate|Stable dose of methotrexate will be maintained through Week 24.
1985146|NCT00699218|Device|Magnetic Stimulator Rapid2 made by Magstim Company Ltd. U.K.|High frequency repetitive TMS given daily on weekdays for 3 weeks
1985160|NCT00661427|Biological|cetuximab|Cetuximab 500 mg/m^2 IV over 2 hours every other week
1985161|NCT00661427|Biological|cetuximab|Cetuximab 750 mg/m^2 IV over 3 hours every other week
1985170|NCT00620945|Drug|Phenoxybenzamine|"Use of Phenoxybenzamine:
Loading dose given at the time of going on CPB:
For patients with obstructing lesions on systemic side:
0.25 mg/kg dose in the bypass circuit
None intravenous
For patients without obstructing left sided lesions:
0.5 mg/kg in the bypass circuit
0.5 mg/kg I.V. at cannulation
Maintenance dose given in the post-operative period:
0.3 mg/kg I.V. every 8 hours till oral intake is started or for first 48 hours
0.3 mg/kg P.O. every 8 hours for next 24 hours
0.15 mg/kg P.O. every 8 hours for next 24 hours and then stop
Hold PBZ if the patient is on norepinephrine infusion or the mean arterial pressure is lower than that allowed for the age group"
1985174|NCT00614822|Drug|Carboplatin, Pemetrexed and Bevacizumab|Carboplatin AUC 5 IV day 1 over 30-60 minutes Pemetrexed 500 mg/M2 IV day 1 over 10 minutes Bevacizumab 15 mg /kg IV day over 90 minutes dose 1, 60 minutes dose 2, 30 minutes subsequent doses. Repeat every 3 weeks for total of 6 cycles
1985175|NCT00607022|Device|dental implant|This longitudinal human clinical trial is designed to measure implant stability with the resonance frequency analyzer (Osstell, Integration Diagnostics AB, Sweden) at time of implant placement and up to 16 weeks post placement. delivered. No further follow-up will be done with the resonance frequency approach.
1985176|NCT00597805|Behavioral|questionnaires/interviews|All patients who agree to participate will be interviewed for a baseline quality of life assessment prior to surgery. A brief in hospital interview will follow in the peri-operative period. In the ensuing months, patients will be interviewed at approximately 3, 6 and 12 months post-operatively (eg: 3 month interview will be done between 8-16 weeks and 6 month interview between 20-28 months post-operatively). Annual interviews in years two through five will be employed to determine areas for future study and solicit narrative on transition toward cancer survivorship.
1985180|NCT00591942|Device|Full ceramic crowns or 3-unit fixed partial dentures.|Subjects who met the inlcusion/excluson criteria received two ceramic crowns or one three-unit dental bridge on posterior teeth. The crowns and dental bridge were cemented using two different dental adhesives. Follow-up to assess sensitivity of the crowns/bridges occur at 24 hrs. and 1 week post seating by telephone. Clinical visits to assess sensitivity and the integrity of the crowns/bridges occur at 6, 12, 18 and 24 months post seating of the restorations.
1985197|NCT00571324|Drug|Exendin-(9-39)|A short term intravenous infusion of the study drug, exendin-(9-39), will be given over 6 hours.
1985198|NCT00571324|Other|Vehicle|A short term intravenous infusion of normal saline, or the vehicle, will be given over 6 hours.
1985199|NCT00570089|Drug|Ranolazine|500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
1985200|NCT00570089|Drug|Placebo|Placebo, 500mg, orally twice daily for 2 weeks, assuming tolerance, followed by 1000mg orally twice daily for an additional 2 weeks. If the participant is unable to increase dose secondary to side effects, she will remain on 500mg twice daily for the second 2-week interval.
1985217|NCT00541866|Drug|voreloxin injection and cytarabine|"Stage 1 - Escalating doses of voreloxin on days 1 and 4 in combination with a 5-day continuous IV (in the vein) infusion dose of 400 mg/m2 cytarabine
Stage 2 - Same as stage 1 except voreloxin administered at the maximum tolerated dose established in stage 1"
1985233|NCT00496964|Drug|Botulinum toxin A + exercise|Injection of 100 units Botox (Botulinum toxin type A) into the Vastus Lateralis of the study leg + 12 weeks of exercise for patellofemoral pain
1985234|NCT00496964|Drug|Placebo|Injection of 2 cc placebo containing 0.1cc sodium bicarbonate 8.4% (1meq/cc), 0.9cc normal saline and 1 cc of lidocaine into the vastus lateralis of the study leg followed by 12 weeks of exercise for patellofemoral pain syndrome
1985257|NCT00464815|Biological|Meningococcal vaccine GSK134612|One intramuscular dose
1985258|NCT00464815|Biological|Mencevax™ ACWY|One subcutaneous dose
1985259|NCT00464568|Drug|GSK256066|
1985288|NCT00381797|Biological|Bevacizumab|Given IV
1985289|NCT00381797|Radiation|Fludeoxyglucose F-18|Undergo fludeoxyglucose F18 PET
1985290|NCT00381797|Drug|Irinotecan Hydrochloride|Given IV
1985291|NCT00380744|Drug|LY2189102|
1985292|NCT00380744|Drug|placebo|
1985293|NCT00376688|Other|Laboratory Biomarker Analysis|Correlative studies
1985294|NCT00376688|Drug|Temsirolimus|Given IV
1985298|NCT00357656|Drug|Recombinant Protein-Free Factor VIII (rAHF-PFM)|"An initial loading dose will be administered intravenously over a period <= 5 minutes (maximum of infusion rate of 10 mL/minute) within 60 minutes prior to surgery dose in order to maintain a minimum target FVIII level of at least 80% of normal.
CI will start prior to surgery as soon as the loading dose has been administered, at a rate calculated according to a formula provided by the sponsor.
All study product must be administered with a syringe pump running at an infusion rate according to the dosing regimen, but always >= 0.4 mL/h."
1985299|NCT00357656|Drug|Recombinant Protein-Free Factor VIII (rAHF-PFM)|The treatment schedule for intermittent BI of rAHF-PFM will begin with the administration of the loading dose according to the dose recommendations provided by the sponsor. If required by the hemostatic challenge, additional boluses may be administered after a blood sample for FVIII determination has been drawn. All infusions of rAHF PFM will be given over a period <= 5 minutes (maximum infusion rate, 10 mL/min).
1985300|NCT00350545|Drug|Rituximab|375 mg/m2;IV infusion once weekly for four doses (days 1,8,15,22); option for second 4-week course at week 9
1985301|NCT00350545|Drug|Prednisone|1 mg/kg; po per day with taper
1985302|NCT00350545|Drug|cyclosporine A|trough 200-300 or lower; po
1985303|NCT00350545|Drug|tacrolimus|trough 5-10 or lower; po
1985318|NCT00333528|Drug|Human butyrylcholinesterase (HuBChE) derived from human plasma|Intramuscular administration
1985319|NCT00333528|Drug|Placebo: Normal saline|Intramuscular administration
1985320|NCT00333515|Drug|Human Butyrylcholinesterase (HuBChE) derived from human plasma|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
1985321|NCT00333515|Drug|Placebo: Normal saline|Administration via IV infusion at a rate of 50 mg/min (2 mL/min)
1993828|NCT03126266|Radiation|re-irradiation|if DIPG has progressed or recurred at 180 days or later from completion of primary radiation therapy, a second course of radiation therapy will be given
1993831|NCT03123731|Behavioral|Control Arm|Wearing Physical Activity Monitor
1993832|NCT03123731|Behavioral|iSTEP|Physical Activity Intervention
1993833|NCT03123731|Behavioral|iSTEP|Physical Activity and Diet Intervention
1993836|NCT03122470|Device|MRI guided biopsy|The MRI guided biopsy will preferentially be performed using a 3 tesla (3T) Siemens Verio, or 3T Siemens Skyra machine. The multiparametric MRI exam will consist of T1-, T2- and diffusion weighted imaging with or without post-contrast perfusion studies. magnetic resonance fingerprinting (MRF) will be performed before contrast injection. The MRI will be interpreted by two specified radiologists from the research team.
1993837|NCT03122470|Procedure|TRUS biopsy|The TRUS biopsy will be performed per current standard of care. Biopsy cores will be sent to pathology in separately labeled specimen cups. The final pathological results will be compared with pre-biopsy MRI findings.
1993838|NCT03121287|Other|Imaging Biomarkers|Whole lung volumetric CT scans
1993839|NCT03121287|Other|Pulmonary|Pulmonary Function Tests & 6 minute hall walk
1993840|NCT03121287|Other|Imaging|Cardiac MRI
1993841|NCT03121287|Other|Specimen Collection|Blood draw
1993842|NCT03121261|Drug|levobupivacaine|Comparing: 0.5% levobupivacaine 15 milligrams (mg) , 0.015% clonidine 50 micrograms (mcg) and 40% glucose 0.5 milliliters (ml) with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
1993843|NCT03121261|Drug|clonidine|Comparing: 0.5% levobupivacaine 15 mg , 0.015% clonidine 50 mcg and 40% glucose 0.5 ml with 0.5 levobupivacaine 15 mg , 0.9% saline 0.33 ml and 40% glucose 0.5 ml
1993846|NCT03120793|Device|Esophageal balloon catheter|Measurements obtained from mechanically ventilated patients with ARDS in the supine, upright and prone positions
1993849|NCT03118713|Drug|metformin|oral
1993850|NCT03118713|Drug|ipragliflozin|oral
1993851|NCT03118713|Drug|glimepride|oral
1993852|NCT03119337|Other|Text-based follow-up|2wT clients will receive automated daily texts from days 1-14. If a 2wT VMMC client responds that he suspects an AE, a VMMC nurse will exchange modifiable, scripted texts with clients to determine symptoms, frequency, and severity. Then, if deemed necessary, the client will be asked to return to clinic the following day or earlier. If 2wT patients do not respond to texts on Day 2 or Day 7, the same MoHCC tracing process will be activated, after which they will be considered LTFU. All study participants will be asked to come to the clinic for study-specific, Day 14 follow-up to review healing and verify adverse event reporting. At Day 42, we will implement a brief text-based survey with 2wT clients to ascertain complete healing, providing stronger inferences at study completion.
1993993|NCT03093363|Other|Questionnaires for control group|- Detailed questionnaire on asthma and treatments (atopy, comorbidities, smoking status, asthma control, adverse effects of treatments, etc.)
1993994|NCT03092791|Biological|Sabin-Based Inactivated Poliomyelitis Vaccine (sIPV)|sIPV intramuscular injection
1993995|NCT03092791|Biological|Reference IPV|Reference IPV intramuscular injection
1985358|NCT00298896|Drug|SNS-595 Injection|
1985376|NCT00214734|Drug|rAHF-PFM|
1985382|NCT00189982|Drug|Antihemophilic Factor Manufactured and Formulated without Added Human or Animal Proteins (rAHF-PFM)|"Treatment regimens were determined by the investigator, and may have been any combination of standard prophylaxis (25 to 50 IU/kg body weight, 3 to 4 times per week), investigator-determined prophylaxis, and/or on-demand treatment (dose selected by investigator). Once the treatment regimen was established, the regimen was to be maintained for the duration of the study, unless clinical reasons necessitated a change.
The treatment of bleeding episodes and perioperative management was at the discretion of the investigator and consistent with the institution's standard of care."
1985383|NCT00194779|Drug|doxorubicin hydrochloride|Given IV
1985384|NCT00194779|Drug|cyclophosphamide|Given PO
1985385|NCT00194779|Drug|paclitaxel|Given IV
1985386|NCT00194779|Biological|filgrastim|Given SC
1985387|NCT00194779|Drug|capecitabine|Given PO
1985388|NCT00194779|Drug|methotrexate|Given IV
1985389|NCT00194779|Drug|vinorelbine tartrate|Given IV
1985390|NCT00194779|Procedure|needle biopsy|Correlative studies
1985391|NCT00194779|Procedure|therapeutic conventional surgery|Undergo definitive breast surgery
1985392|NCT00194779|Other|immunohistochemistry staining method|Correlative studies
1985393|NCT00194779|Biological|trastuzumab|Given IV
1985394|NCT00194779|Drug|tamoxifen citrate|Given PO
1985395|NCT00194779|Drug|letrozole|Given PO
1985396|NCT00194779|Other|laboratory biomarker analysis|Correlative studies
1985401|NCT00186628|Procedure|nonmyeloablative allogeneic hematopoietic cell transplant|TLI is administered ten times in 80cGy fractions on day -11 through day -7 and day -4 through day -1. TLI is administered from a 6 MeV linear accelerator (photon beam).
1985402|NCT00186628|Drug|Cixutumumab|10 mg/kg, IV
1985403|NCT00186628|Drug|Paclitaxel|80 mg/m2, IV
1985404|NCT00161707|Drug|Aerosolized, Recombinant Alpha 1-Antitrypsin|
1985405|NCT00162019|Drug|Human Plasma-Derived Coagulation Factor VIII Concentrate (Virus Inactivated by Polysorbate 80 Treatment and Vapor Heat Treatment)|
1985406|NCT00162006|Drug|Immune Globulin Intravenous (Human), 10% Triple Virally Reduced Solution|
1985407|NCT00161993|Drug|Immune Globulin Intravenous (Human), 10% TVR (Triple Virally Reduced) Solution|
1985408|NCT00161993|Drug|Gammagard S/D (Solvent/Detergent)|
1985409|NCT00161720|Drug|Protein C Concentrate (Human) Vapor Heated|
1985410|NCT00157105|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
1985411|NCT00157118|Drug|Protein C Concentrate (Human) Vapor Heated|
1985413|NCT00157092|Drug|Aerosolized, Recombinant Alpha 1-Antitrypsin|
1985414|NCT00157079|Biological|Immune Globulin Intravenous (Human), 10%|
1985415|NCT00157053|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
1985416|NCT00157040|Drug|Antihemophilic factor, recombinant, manufactured protein-free|
1985436|NCT00098137|Drug|Olmesartan|
1985446|NCT00003056|Drug|cyclosporine|
1985447|NCT00003056|Drug|cyclosporine and methotrexate|
1985457|NCT00003800|Other|immunohistochemistry staining method|
1985458|NCT00003800|Other|laboratory biomarker analysis|
1985459|NCT00003800|Procedure|radionuclide imaging|
1993996|NCT03092791|Biological|sIPV Placebo|sIPV placebo-matching intramuscular injection
1993997|NCT03092323|Drug|Pembrolizumab|Pembrolizumab will be administered at 200 mg intravenously every 3 weeks for patients on the treatment arm.
1985882|NCT03318783|Drug|GSK2256294|GSK2256294 will be administered in a single dose once daily enteral for a duration of 10 days.
1985883|NCT03318783|Drug|Placebo|Placebo will be administered in a single dose once daily enteral for a duration of 10 days.
1985884|NCT03320031|Drug|Linagliptin|Take linagliptin 5mg a day.
1985885|NCT03320031|Drug|Humalog Mix 75/25|Administer subcutaneous premixed insulin twice a day.
1985890|NCT03320005|Other|Resistance training group|Resistive exercises for legs and arms
1985891|NCT03319992|Device|Upper Arm Rehabilitation Light Exoskeleton (RH-LEXOS)|RH-LEXOS is a robotic exoskeleton device to support the rehabilitation of stroke patients. This system is conceived for the force assistance, integrated in a Virtual Reality system that allows implementing rehabilitative exercises highly interactive and engaging for the patients. Passive, assisted and active mobilization of upper arm is provided through the use of the exoskeleton robotic device within high intensive, repetitive, task-oriented exercises and an objective and reliable mean for monitoring patients' progress.
1985892|NCT03319966|Other|Neurovision Rehabiliation|Neurovision rehabilitation used to treat oculomotor dysfunction following traumatic brain injury.
1985893|NCT03319953|Drug|TAK-041|TAK-041 suspension
1985894|NCT03319953|Drug|Placebo|TAK-041 placebo-matching suspension
1985895|NCT03319953|Drug|Second generation antipsychotics|Second generation antipsychotics medication for standard of care therapy
1985897|NCT03319927|Behavioral|IPM educational workshop and consultation|The interventions include a baseline assessment conducted by a research assistant and objective measures of pesticide exposure (center dust samples, children's silicone wristbands), review of assessment by the nurse child care health consultant, goal setting with the director, educational workshop, 7 monthly consultation visits, and post-intervention review of goals and post-assessment findings (conducted by research assistant and objective measures of pesticide exposure).
1985898|NCT03319901|Drug|Venetoclax|"Venetoclax is an inhibitor of Bcl-2. Bcl-2 is critical for keeping cancer cells alive.
By inhibiting Bcl-2, venetoclax promotes cancer cell death."
1985899|NCT03319901|Drug|Standard Chemotherapy|Standard treatment of chemotherapy is administered
1985900|NCT03319888|Device|CPAP|continuous positive pressure in the airway
1985901|NCT03319888|Other|conservative treatment|conservative treatment group with lifestyle modifications
1985902|NCT03319875|Device|Epiduroscopic Laser Discectomy|Caudal epidural space after passing through sacral hiatus
1985904|NCT03319849|Combination Product|Renexus®|Surgery to receive one Renexus® device implant.
1985905|NCT03319849|Procedure|Sham|Non-penetrating sham procedure to mimic implant procedure.
1985909|NCT03319810|Biological|Octagam 10%|FDA approved human normal immunoglobulin solution ready for intravenous administration
1985910|NCT03319797|Drug|NOVOCART® Inject plus|Treatment with NOVOCART® Inject plus (Autologous chondrocyte implantation)
1985911|NCT03319784|Drug|Ketorolac|Patients assigned to Toradol group will receive a single dose of 60mg of Ketorolac (Toradol) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
1985912|NCT03319784|Drug|Triamcinolone Acetonide|Patients assigned to Steroid group will receive 80mg of Triamcinolone Acetonide (Kenalog) mixed with 8mL of 1% lidocaine with epinephrine 1:100,000.
1985913|NCT03319771|Behavioral|Treadmill Walking Exercise Training|12-weeks of supervised, progressive treadmill walking exercise training
1985914|NCT03319771|Behavioral|Stretching-and-toning Exercise Training|12-weeks of supervised, stretching-and-toning exercise training
1985917|NCT03319745|Drug|Pembrolizumab|Participants receive 200 mg of Pembrolizumab by vein every 3 weeks for a total of two cycles at weeks 1 and 4.
1985918|NCT03319732|Drug|Arbaclofen|Arbaclofen is the active R enantiomer of baclofen.
1985919|NCT03319706|Drug|Torrent's Olmesartan Medoxomil Tablets 40 mg|
1985920|NCT03319706|Drug|Daiichi Sankyo Inc's Benicar Tablets 40 mg|
1985921|NCT03319693|Genetic|Somatic Genetic|NGS analysis
1985922|NCT03319680|Other|Citrate dialysate|Compare the effect of citrate dialysate with acetate dialysate
1985923|NCT03319667|Drug|Isatuximab SAR650984|"Pharmaceutical form: Solution for infusion
Route of administration: Intravenous (IV)"
1985924|NCT03319667|Drug|Bortezomib|"Pharmaceutical form: Lyophilized powder for injection
Route of administration: Intravenous/Subcutaneous"
1985925|NCT03319667|Drug|Lenalidomide|"Pharmaceutical form: Capsules
Route of administration: Oral"
1985926|NCT03319667|Drug|Dexamethasone|"Pharmaceutical form: Tablets, ampoules or vials for injection
Route of administration: Oral/Intravenous"
1985927|NCT03319667|Drug|Acetaminophen (paracetamol) or equivalent|"Pharmaceutical form: Tablets
Route of administration: Oral"
1985928|NCT03319667|Drug|Ranitidine or equivalent|"Pharmaceutical form: Solution for injection
Route of administration: Intravenous"
1985929|NCT03319667|Drug|Diphenhydramine or equivalent|"Pharmaceutical form: Solution for injection
Route of administration: Intravenous"
1985930|NCT03319654|Diagnostic Test|DNA fragmentation by TUNEL assay|Direct DNA fragmentation testing with terminal deoxyuridine nick end labeling (TUNEL) assay.
1985931|NCT03319641|Diagnostic Test|PSMA-PET/CT scan|perform a PSMA-PET/CT scan in patients with locally advanced, recurrent and/or metastastic ACC or SDC
1985932|NCT03319628|Drug|XMT-1536|XMT-1535 will be administered once every 21 days until disease progression, unacceptable toxicity, or either the patient or study physician determines it is in the best interest of the patient to discontinue participation in the study.
1985933|NCT03319615|Behavioral|Dietary energy restriction|
1985935|NCT03319589|Dietary Supplement|Supplement|locally prepared biscuit with low sugar content (less than 10% weight) designed to facilitate growth and cognitive development
1985939|NCT03319550|Dietary Supplement|Casein|see experimental description
1985940|NCT03319550|Dietary Supplement|Whey|see experimental description
1985941|NCT03319550|Dietary Supplement|Leucine-enriched whey|see experimental description
1985942|NCT03319537|Drug|pevonedistat|Pevonedistat will be administered as an IV infusion at a dose of 50 mg/m2 days 1, 3, and 5 of a 21-day cycle.Treatment will be administered as an outpatient.
1985943|NCT03319537|Drug|Pemetrexed and cisplatin|Pemetrexed, 500 mg/m2 and cisplatin, 75 mg/m2, will be given at fixed doses on day 1 of each cycle.
1985944|NCT03319511|Other|spinal group|plain bupivacaine 0.5%,1.5 ml plus dexmedetomidine 5 μg. once injection.
1985945|NCT03319511|Other|paravertebral group|plain bupivacaine 0.5%, 0.3 ml (1.5 mg)/kg plus dexmedetomidine 0.5 μg /kg divided between the T2 and T4 levels.
1985946|NCT03319498|Other|Peppermint Oil Vapor|"2ml of the oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
1985947|NCT03319498|Other|Mineral Oil Vapor|"2ml of the mineral oil will be placed in the urine collection hat that fits into the bowl of the toilet. Participants will then sit on the toilet in normal fashion, exposing their perineum to the vapor of the oil. The perineum will NOT come into contact with the oil directly - only the vapor from the oil will contact the perineum."
1985948|NCT03319485|Device|ExAblate Pallidotomy|ExAblate Pallidotomy for Parkinson's Disease
1985949|NCT03319485|Device|Sham ExAblate Pallidotomy|ExAblate MRgFUS Sham Procedure
1985950|NCT03319459|Drug|FATE-NK100|FATE-NK100 is a donor-derived NK cell product comprised of ex vivo activated effector cells with enhanced anti-tumor activity
1985951|NCT03319459|Drug|Cetuximab|Epidermal growth factor receptor inhibitor antineoplastic agent
1985952|NCT03319459|Drug|Trastuzumab|HER2/neu receptor inhibitor
1985953|NCT03319433|Device|Perfusion Index|Use of non-invasive pulse oximeter to determine perfusion index
1985956|NCT03319407|Device|EPAD monitoring system|EPAD system will be used as part of routine care
1985957|NCT03319394|Behavioral|The First Twenty|The First Twenty workouts were part of an online training program that provided resistance and endurance exercises, nutritional information, and mental performance guidance. The intervention, created by firefighters for firefighters, was a 10-week periodized program with workouts increasing in frequency and intensity each week.
1985958|NCT03319394|Behavioral|Comparison|Documentation of having previously taken or concurrent enrollment in a 1 credit hour fitness class offered through the community college. HPER 240, Lifetime Fitness, introduced the student to basic fitness principles, physical activity and the relationship to a healthy lifestyle. The course was graded based on an initial assessment/orientation and participation; the student was required to log hours at the community college gym. This course was waived at the discretion of the Fire Academy Director if the student proved they had an active gym membership at a local gym facility.
1985959|NCT03319381|Behavioral|Following new SOPs|The new SOPs comprised early whole-body CT, damage control surgery, and the use of goal-directed coagulation management and are based on the ATLS® concept, which was the strictly followed protocol before implementation of the new SOPs
1985960|NCT03319368|Other|Targeted gown and glove use|Gown and glove use for high risk care activities in high risk residents
1985961|NCT03319355|Behavioral|cognitive behavioral therapy|exercise therapy
1985962|NCT03319342|Behavioral|Behavioral Dietary Intervention|Consume additional fruits and vegetables
1985963|NCT03319342|Behavioral|Behavioral Intervention|Perform acts of kindness to others
1985964|NCT03319342|Behavioral|Behavioral Intervention|Perform acts of kindness to self
1985965|NCT03319342|Behavioral|Behavioral Intervention|Perform self-kindness meditation
1985966|NCT03319342|Other|Questionnaire Administration|Ancillary studies
1985967|NCT03319329|Device|Indirect Calorimetry|REE measurements were using IC (Cosmed, Quark RMR 2.0, Indirect Calorimetry Lab, Italy). A standard protocol for conducting the measurement was followed (Schlein & Coulter, 2014);(P. Singer & Singer, 2016); (Taku Oshima et al., 2016). Before each measurement, the metabolic monitor was allowed to warm up for 30 min, and then gas and flowmeter calibrations were performed by an experienced dietitian or healthcare professional. The REE was recorded after a 30 min non-fasting steady state according to RMR protocol and manufacturer instructions.
1985968|NCT03319316|Drug|Durvalumab|Combination of durvalumab + tremelimumab treatment
1985969|NCT03319316|Drug|Tremelimumab|Combination of durvalumab + tremelimumab treatment
1985970|NCT03319290|Genetic|BRCA1 and BRCA2|Genetic breast and ovarian cancer testing
1985971|NCT03319277|Other|Decreased opiate prescription|The experimental group will receive 5 tablets of oxycodone 5mg at time of discharge with a paper backup prescription for an additional 10 tablets.
1985972|NCT03319277|Other|Routine opiate prescription|The comparator group will receive 28 tablets of oxycodone 5mg at time of discharge.
1985978|NCT03319238|Other|ketamine|The aim of this study is to evaluate the safety of use, benefits and risks of repeated use of ketamine for each patient with chronic pain in different structures of pain management.
1985979|NCT03319212|Device|senofilcon A contact lenses|Senofilcon A Daily Disposable Contact Lenses
1985980|NCT03319199|Dietary Supplement|"SLIM WATER"|2 grams of L- CARNITINE and 150 mg MAGNESIUM for a duration of 16 weeks
1985981|NCT03319199|Other|Placebo - water|for a duration of 16 weeks
1985982|NCT03319186|Procedure|EDIT Management|"EDIT management
Volumetric Pleural MRI for pre-aspiration pleural cavity volume
Large volume pleural aspiration with recording of intra-pleural pressure during aspiration
Volumetric Pleural MRI for post-aspiration pleural cavity volume
Computation of PEL250, defined as the rolling average of pleural elastance over the preceding 250ml aspirated.
MaxPEL250 ≥ 14.5 cm H2O/L: allocated to 1st-line IPC MaxPEL250 < 14.5 cm H2O/L: allocated to 1st-line TP
EDIT-directed 1st-line treatment to be delivered within 24 hours; if insufficient residual pleural fluid to allow standard Seldinger insertion technique then Boutin-type needle used for pneumothorax induction and guide wire insertion."
1985983|NCT03319186|Procedure|Chest drain and talc pleurodesis|Intercostal chest drain insertion and talc slurry instillation according to British Thoracic Society guidelines
1985984|NCT03319173|Behavioral|Dietary intervention|"Subjects in the experimental group will receive clinically regulated meal plans designed to facilitate prolonged benign dietary ketosis (BDK) in order to regulate glucose with restored insulin sensitivity focused at reversing the impaired capacity to switch between fat and carbohydrate oxidation.
Subjects in the control group will follow the their current dietary protocol (Standard American Diet-SAD)."
1985985|NCT03319160|Device|Defibrillation|Wearable Cardioverter Defibrillator
1985986|NCT03319147|Dietary Supplement|Active|4g of essential amino acids
1985987|NCT03319147|Dietary Supplement|Placebo|4g of maltdextrin
1985989|NCT03319121|Drug|Empirical therapy group|Receive extended release lansoprazole (Dexlansoprazole, Takeda Pharmaceuticals, Japan) 60 mg daily for 2 weeks.
1985990|NCT03319121|Drug|Guided therapy group|Receive Dexlansoprazole 30 mg daily for GERD, 60 mg daily for GERD with erosive esophagitis for 8 weeks and Theophylline SR 250 mg daily for functional chest pain for 4 weeks.
1985991|NCT03319108|Other|Exercise|Pulmonary Rehabilitation Program for 8 weeks
1985992|NCT03319095|Device|Intravaginal Electrical Nerve Stimulation|The Intervention group will receive Intravaginal Electrical Nerve Stimulation using Quark® Dualpex equipment. The selected current will be biphasic, and the stimulation parameters will be: 50 Hz frequency, pulse width of 200 microseconds, contraction time (Ton) of 5 seconds, relaxation time (Toff) of 10 seconds, intensity of current defined according to the sensitivity (tolerance) of the patient, and total stimulation time of 20 minutes once a week delivered by an experienced Physiotherapist. In the last 10 minutes of each electrical nerve stimulation session women will be requested to perform voluntary PFM contractions along with the contractions induced by the electrical stimulation. Women will not be instructed to perform any aditional exercise or therapy at home.
1985993|NCT03319082|Combination Product|Corneal Collagen Cross-linking|Photrexa Viscous (riboflavin 5'-phosphate in 20% dextran ophthalmic solution), Photrexa (riboflavin 5'-phosphate ophthalmic solution), and the KXL System (UV Irradiation).
1985994|NCT03319069|Radiation|Hypofractionated radiotherapy|Hypofractionated radiotherapy 43,5 GY/15 fractions (f)/3ws. to chest wall and supraclavicular nodal region.
1985995|NCT03319069|Radiation|Conventional fractionated radiotherapy|50 Gray(GY)/ 25f/5 weeks(5w) to chest wall and supraclavicular nodal region
1985996|NCT03319056|Other|Air purifier|active- or sham-mode air purifier used in 6 classrooms in a school with a crossover design
1985997|NCT03319043|Drug|Chanqin granules|All patients enrolled in the research are treated with Budesonide + Formoterol Fumarate dry powder (160/4.5ug bid) for inhalation. Patients in treatment group are given additional Chanqin granules 10g three times a day; and analogous for the controlled group.
1985998|NCT03319017|Procedure|Multiple-trauma patients|"The blood samples of the patients who agreed on this research are obtained in order to check their inflammatory response factor, and then their medical records are checked to find their initial ABGA result, lactate, C-reactive protein(CRP) known as initial inflammatory response, and procalcitonin.
A patient's whole blood is collected in the tube with ethylene diaminetetracetic acid (EDTA) treatment. A modified method of Boyum's technique is applied so as to separate polymorphonuclear neutrophils. The separated polymorphonuclear neutrophils is collected so as to check apoptosis. And then, in the separated plasma, interleukin(IL)-6 and tumor necrosis factor(TNF)-α are measured, and its correlation with oxygen saturation will be analyzed."
1985999|NCT03319004|Device|apply phase lag entropy sensor|apply phase lag entropy sensor as well as bispectral index sensor on forehead during the sedation using propofol
1986000|NCT03318991|Procedure|Laser prostatectomy|Patients with symptomatic benign prostate obstruction (BPO) will be assigned under randomisation to treat with GreenLight laser or thulium laser.
1986001|NCT03318978|Drug|[14C]-benzo[a]pyrene|Oral micro-dose range (25, 50, 100 and 250 ng)
1986002|NCT03318952|Drug|lidocaine|A buccal infiltration injection followed by 2-3 interpapillary injections and possibly more if needed of 2% lidocaine with 1:100,000 epinephrine will be administered.
1986003|NCT03318952|Drug|articaine|A single buccal infiltration injection of 4% articaine with 1:100,000 epinephrine will be administered
1986005|NCT03318913|Other|Placebo|5g of the sucralose administered as white plastic capsules
1986006|NCT03318913|Other|Fish protein hydrolysates|5g of the FPH dissolving in 100 mL of water
1986012|NCT03318887|Drug|Sofosbuvir/daclatasvir with or without ribavirin|Direct-acting antiviral treatment for hepatitis C virus infection
1986013|NCT03318874|Device|Blephasteam|Steam delivery goggles, once daily
1986014|NCT03318874|Device|THERA°PEARL Eye Mask|Heat delivery device, delivering heat to the eyelids, once daily
1986015|NCT03318874|Drug|Hylo-comod|Tear substitute containing hyaluronic acid, four times daily
1986016|NCT03318861|Genetic|Autologous genetically modified anti-BCMA CAR transduced T cells (KITE-585)|A conditioning chemotherapy regimen of fludarabine and cyclophosphamide will be administered followed by a single infusion of CAR transduced autologous T cells (KITE-585)
1986017|NCT03318848|Other|Video during simulation|The intervention group simulated the bed bath while watching the video, under the supervision of the tutor
1986018|NCT03318835|Drug|Thalidomide combined with R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6 Thalidomide 200mg PO QN D1-21
1986019|NCT03318835|Drug|R-CHOP|rituximab 375 mg/m2,ivgtt D1 cyclophosphamide 750 mg/m2 iv D2 vincristine 1.4 mg/m2 [capped at 2.0 mg], iv D2 doxorubicin 50 mg/m2 iv D2 prednisone 100 mg/m2 per day PO D2-6
1986020|NCT03318822|Device|Q-Collar|An externally-worn medical device that applies mild jugular compression
1986021|NCT03318809|Drug|AMG 986|AMG 986
1986022|NCT03318796|Device|Coronary Artery Stenting|Interventional coronary artery stent placement in De novo bifurcation lesions of the MB & SB
1986023|NCT03318471|Drug|MgSo4|50 mg/kg MgSo4 in 100 ml 0.9 sodium Chloride 15 minutes prior to anesthesia induction over 15 minutes
1986024|NCT03318471|Drug|0.9% NaCl|100 ml 0.9% NaCl 15 minutes prior to anesthesia induction over 15 minutes
1986026|NCT03318757|Drug|Bupivacaine Extended Release Liposome Injection|Bupivacaine Extended Release Liposome Injection (Exparel) 133 mg diluted in 10ml of normal saline (13.3 mg/ml) will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
1986027|NCT03318757|Drug|Bupivacaine HCl|10ml of Bupivacaine HCl 0.5% will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
1986028|NCT03318757|Other|Placebo|10ml of normal saline will be injected with a 25 gauge needle directly into the gingiva surrounding the surgical site at the conclusion of surgery.
1986031|NCT03318731|Other|Sugar Pill|Taken orally in capsule form
1986032|NCT03318731|Dietary Supplement|Fenugreek Extract, Low Dose|Taken orally in capsule form
1986033|NCT03318731|Dietary Supplement|Fenugreek Extract, High Dose|Taken orally in capsule form
1986034|NCT03318718|Drug|Anesthesia with non-depolarizing NMBA Rocuronium|Non- depolarizing NMBA Rocuronium will be used until full paraspinal muscle Relaxation. Muscle relaxation during surgery will be performed using intraoperative boli intermediate duration non-depolarizing NMBA, rocuronium (0.3 mg/kg) until good surgical conditions are achieved.
1986035|NCT03318718|Diagnostic Test|TOF measurement|TOF (Train-of-four) measurements will be performed at baseline 5 minutes after induction after the effect of succinylcholine will have run off. Moreover, TOF measurements will be performed 5 minutes after each rocuronium bolus
1986036|NCT03318718|Diagnostic Test|MEP measurement|MEPs (motor evoked potentials) are routinely obtained after intubation and before surgery, then every 10min during the critical preparation and closing phases of surgery and every 5min during the correction phase. In addition MEPs will be measured after the administration of the NMBA rocuronium. Baseline values for amplitudes and latencies are obtained directly prior to the start of the correction phase of the surgery.
1986038|NCT03318692|Procedure|spondylodesis|Dorsal instrumentation with transpedicular screws (spondylodesis)
1986039|NCT03318692|Procedure|CT|CT of operated area is performed within 7 days of surgery
1986041|NCT03318666|Behavioral|Supporting Our Valued Adolescents (SOVA)|"The SOVA intervention includes:
a welcome email to the websites (adolescents also get a SOVA intro video and mobile app)
adolescents will have access to the website specifically for adolescents: sova.pitt.edu
parents will have access to the website specifically for parents: wisesova.pitt.edu
These anonymous websites aim to: (1) challenge negative health beliefs and increase depression/anxiety knowledge through daily blog posts enhanced with peer commentary; (2) promote social support through online peer interactions; and (3) encourage parent-adolescent mental health communication through same day blog posts with questions for discussion. Parents and adolescents cannot log on to each other's sites. The sites are moderated by our research team."
1986042|NCT03318666|Other|Enhanced Usual Care|A social worker at the Center for Adolescent and Young Adult Health (CAYAH) clinic helps to facilitate referrals from the adolescent healthcare provider (AHCP) and contacts patients who do not schedule for within-CAYAH appointments.The study will send an extra email to the parent and adolescent that contains the content of the depart summary as well as a list of psychoeducational materials, how to contact the AHCP, CAYAH social worker, and crisis resources and the AHCP's treatment recommendation which are obtained from the electronic health record.
1986043|NCT03318640|Behavioral|Mindfulness|Patient will have 8 sessions (1h30) of mindfulness based on Kabat-Zinn program during one month
1986044|NCT03318627|Device|Sterile Spring Scale|Measuring intraoperative tension of tendon of rotator cuff tear
1986045|NCT03318614|Dietary Supplement|Probiotics M-63|B. infantis M63 (2.5 x 109 cfu/g per sachet) was given to Probiotics M-63 group for three months.
1986046|NCT03318614|Other|Control group|No probiotic intervention was given to the control group for three months.
1986048|NCT03318588|Procedure|Vitrectomy|Pars plana vitrectomy
1986049|NCT03318575|Device|autoRIC|Automated Remote Ischemic Conditioning
1986050|NCT03318575|Device|autoRIC Sham|Automated Remote Ischemic Conditioning Sham
1986052|NCT03318549|Diagnostic Test|Visual Performance tests|The overall goal of this proposal is to improve our understanding of functional disability in glaucoma by using virtual reality tests to investigate objective performance during simulated daily life activities.
1986055|NCT03318523|Drug|Placebo|Administered as specified in the treatment arm
1986056|NCT03318523|Drug|BIIB054|Administered as specified in the treatment arm.
1986057|NCT03318510|Device|Laser Speckle Flowgraphy|A commercially available LSFG system (LSFG-NAVI; Softcare Co., Ltd., Fukuoka, Japan) will be used in the present study. The LSFG device consists of a fundus camera equipped with a diode laser with a wavelength if 830 nm and charge-coupled device.
1986058|NCT03318497|Drug|3'-deoxy-3'-[F-18] fluorothymidine: [F-18]FLT|Given IV The experimental 18F-FLT-PET/CT is required to be completed before initiation of chemotherapy. Labs and correlative radiology, as directed per clinical care, are required within 30 days prior to 18F-FLT-PET/CT; and 18F-FDG-PET/CT is required within 30 days before the 18F-FLT-PET/CT. Follow-up will comprise 24 months of standard practice treatment and follow up.
1986059|NCT03318497|Procedure|Computed Tomography|Undergo PET/CT
1986060|NCT03318497|Procedure|Positron Emission Tomography|Undergo PET/CT
1986061|NCT03318497|Other|Laboratory Biomarker Analysis|Correlative studies
1986062|NCT03318484|Drug|Optimal Medical Care|Aspirin 100mg once a day, Atorvastatin 20mg once a day and Antihypertensive Agents if necessary.
1986063|NCT03318484|Combination Product|Sonodynamic therapy|SDT treatment is the combination of sonosensitizer administration and target atherosclerotic lesions ultrasound exposure. Sinoporphyrin sodium (DVDMS) as sonosensitizer, is dissolved in 0.9% sodium solution for following skin test and intravenous injection. 0.01mg/ml DVDMS solution (0.1ml) is prepared for skin test followed by 0.04 mg/ml DVDMS solution intravenous injection (0.2mg/kg). The target atherosclerotic lesions are marked on the corresponding skin with ultrasound guidance and underwent ultrasound exposure after 4 hours incubation. The therapeutic ultrasonic transducer is fixed to the marked skin site for 15min of each lesion. Ultrasound parameters included intensity of 1.8W/cm2 for femoral lesions, resonance frequency: 1.0 MHz and duty factor: 30%.
1986065|NCT03317028|Drug|CS02 tablet and placebo tablet|Subjects receive CS02 tablet or placebo tablet BID daily with a stable dose of metformin monotherapy of ≥ 1500 mg/day for 12 weeks treatment.
1986066|NCT03318133|Procedure|anesthesia|in this study, we plan to make a prospective, multicenter, randomized controlled clinical trial to compare the effects of general anesthesia with endotracheal intubation and ultrasound-guided combined lumbar plexus and sciatic nerve block with sedative anesthesia on the prognosis of elderly patients with hip fracture to clarify the clinical value of combined lumbar plexus and sciatic nerve block with sedative anesthesia in elderly patients with hip fracture.
1986068|NCT03318042|Other|Walnuts|The group consumed a daily serving of walnuts (30 g) or 200 mL pomegranate juice for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
1986069|NCT03318042|Other|Pomegranate juice|Those volunteers who were allergic to nuts consumed 200 mL pomegranate juice daily for 3 days and provided a sample of urine as well as a swab specimen from the inner cheek
1986073|NCT03317886|Procedure|pancreaticoduodenectomy|pancreaticoduodenectomy for pancreatic ductal adenocarcinoma
1986081|NCT03317535|Procedure|General anesthesia|Patients will be injected with propofol, remifentanil and muscular relaxant with controlled ventilation.
1986082|NCT03317535|Procedure|Local anesthesia|Patients will be injected with Dexmeditomidine and remifentanil.
1986083|NCT03317535|Procedure|Spontaneous breath|Patients will be kept spontaneous breath.
1986084|NCT03317535|Procedure|Controlled ventilation|Patient will be kept with controlled ventilation.
1986089|NCT03317431|Other|mechanical ventilation|mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5.
1986090|NCT03317353|Device|Vestibular rehabil.: CDP|Vestibular rehabilitation, ten sessions
1986091|NCT03317353|Device|Vestibular rehabil.: optokinetic stimuli|Vestibular rehabilitation, ten sessions
1986092|NCT03317353|Other|Vestibular rehabil.: home exercises|Exercises performed twice a day for two weeks. Approximate duration of each session: 15 minutes
1986111|NCT03316820|Drug|K0706|Study treatment with water after an overnight fast
1986112|NCT03316820|Drug|K0706|Study treatment with water after food
1986116|NCT03316365|Other|Rhythmic Auditory Stimulation (RAS)|The experimental group (continuous treatment) trained daily with Rhythmic Auditory Stimulation (RAS) for 24 weeks. The control group (intermittent treatment) trained with RAS for 8 weeks, discontinued training for 8 weeks, and resumed training with RAS for 8 weeks. During treatment subjects walked for 30 minutes in a home-based environment with metronome-click embedded music downloaded to an MP3 player and listened to either free-field or via headphones. For the first 8 weeks subjects had 3 metronome rates available to choose from: 100, 105, and 110% of internal usual cadence. During the second 8 weeks available rates were 105, 110 and 115%; and during the last 8 weeks 110, 115, 120%. The control group started their last training segment at 105, 110, and 115%, but could request a change to the faster rates if comfortable.
1986118|NCT03316287|Device|Hearing aid|Smart hearing aid to allow collection of real time hearing aid usage data
1986119|NCT03316287|Device|Mobile phone|Mobile phone linked with the hearing aids to allow users to change the device settings and perform additional listening tests
1986120|NCT03316287|Device|Sensor|Wearable biosensor for the collection of physiological data
1986125|NCT03315845|Other|Palpation of bony landmarks for neuraxial anaesthesia.|"Manual palpation of anterior and posterior iliac crests; lumbar spinous processes; scapulae; and sacral cornua.
Ultrasound of neuraxial anatomy to assess depth to epidural space."
1986132|NCT03314090|Drug|Silicone Gels|silicone gel (Dermatix Ultra, Menarini, Singapore) was applied twice per day. The amount used being similar in size to a grain of rice.
1986136|NCT03312634|Drug|Palovarotene|Palovarotene will be taken orally once daily at approximately the same time each day following a meal.
1986150|NCT03313349|Behavioral|Psychotherapy: 1. cognitive therapy 2.family intervention|Psychotherapy delivered by trained psychologist for the student and the student´s parents
1986151|NCT03313310|Behavioral|Employment Intervention|Participants will meet 4 times for 4 workshops. Workshops will be in groups of 6-8. Every participant will complete each workshop sequentially with the group they are assigned to. These workshops will be based on the pre-existing iFOUR program with modifications based on Community Advisory Board (CAB), focus group, and interviewer feedback.
1986152|NCT03313128|Other|Sanitation|Improved sanitation facility
1986153|NCT03313115|Behavioral|Sleep/Wake Protocol|"During the day, a nurse will observe if the following elements were completed for each participant:
no caffeine after 3 pm
encourage activities to prevent napping (document % of day spent napping)
Lights on, blinds/door open
Reasonable effort for some noise in room
Eye glasses, hearing aids applied
Chair position/mobility at least 2x30 minutes
At night, a nurse will observe if the following elements were completed for each participant:
Appropriate pain control
Optimize room temperature
Warm bath before 2200
TV off by 2200
Prevent unnecessary alarms after 2200
Close curtains to room by 2200
Dim room lights by 2200
Family out of room by 2200
Door partially or fully closed after 2200
Number of RN interruptions after 2200
Offer eye mask/ear plugs
Medications administered for sleep (dilaudid, fentanyl oxycodone, haldol, quetiapine, propofol, melatonin, or other)
Dim hallway lights by 2200
Nurses station quiet"
1986160|NCT03311516|Other|New functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to a new FIT
1986161|NCT03311516|Other|functional insulin therapy|the patient receives the dietary devices and the instructions for the adaptation of the insulin bolus dose according to FIT
1986162|NCT03311490|Device|Spraino|"Participants allocated to the intervention group will use Spraino® as a measure to prevent future lateral ankle sprains during all on-court practice sessions and matches. Spraino® is an adhesive polytetrafluoroethylene (PTFE or Teflon) patch. It is developed with the intent of minimizing lateral shoe- surface friction whenever initial contact is carried out in an inverted position of the ankle joint. Each Spraino® PTFE patch has a minimum durability of 20 hours use and will be provided by the trial sponsor, Spraino® ApS. The participants allocated to the intervention group will receive four pairs of the Spraino® patches via postal service or by hand delivery on a monthly basis, or upon request if material is worn out prematurely during the 52-week trial period."
1986171|NCT03310411|Drug|Lasmiditan|Administered orally
1986172|NCT03310411|Drug|Sumatriptan|Administered orally
1986173|NCT03310411|Drug|Placebo for Lasmiditan|Administered orally
1986174|NCT03310411|Drug|Placebo for Sumatriptan|Administered orally
1986177|NCT03310281|Device|HOLD: Videogame|Videogame-like digital therapy
1986191|NCT03308201|Drug|Hemay022|"Part one: Hemay022 tablets will be taken orally once daily in doses of 200mg, 300mg,400mg or 500mg for 28 days in combination with exemestane.
Part two: Hemay022 tablets will be taken in OTR dose group in combination with exemestane."
1986192|NCT03308201|Drug|exemestane|Part one and Part two: Exemestane will be taken in 25mg once daily.
1986193|NCT03308669|Drug|Lasmiditan|Administered orally
1986194|NCT03308669|Drug|Placebo|Administered orally
1986195|NCT03308669|Drug|Topiramate|Administered orally
1986197|NCT03307590|Drug|Dexmedetomidine|Caudal block by dexmedetomidine and bupivavaine
1986198|NCT03307590|Drug|Bupivacaine|Caudal block by bupivavaine alone
1986199|NCT03306914|Other|Albumin resuscitation|Albumin 5% is used as the intra-operative colloid
1986200|NCT03306914|Other|Hydroxyethylstarch resuscitation|Hydroxyethyl starch 6% is used as the intra-operative colloid
1986201|NCT03306914|Drug|Albumin 5%|Infusion of Albumin 5% intra-operatively
1986202|NCT03306914|Drug|Hydroxyethylstarch 6%|Infusion of Hydroxyethylstarch 6% intra-operatively
1986206|NCT03305536|Dietary Supplement|Vitamin K2 (Menaquinone 7) + Vitamin D3|Vitamin K2 + Vitamin D3 arm will be compared with Vitamin D3 arm to slow of reverse the progression of the disease
1986207|NCT03306121|Drug|TPF+CCRT|Patients receive paclitaxel liposome (135mg/m2 on day 1) ,5-fluorouracil (3750mg/m2 civ 120h) and cisplatin (75mg/m2 on day 1-3) every three weeks for two cycles of induction chemotherapy before radiotherapy, then received radical radiotherapy and cisplatin (100mg/m2) concurrent every three weeks during radiotherapy (D1,D22,D43 of RT) versus patients receive cisplatin (80mg/m2 separate injection on day 1) and 5-fluorouracil (4000mg/m2 civ 96h) every four weeks for three cycles after the concurrent cisplatin (100mg/m2 separate injection on day 1) every three weeks for three cycles during radiotherapy.
1986208|NCT03306121|Drug|CCRT+ PF|patients receive cisplatin (80mg/m2 separate injection on day 1) and 5-fluorouracil (4000mg/m2 civ 96h) every four weeks for three cycles .
1986209|NCT03306121|Radiation|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
1986210|NCT03305822|Drug|LY900014|Administered SC
1986211|NCT03305822|Drug|Insulin Lispro|Administered SC
1986231|NCT03300388|Dietary Supplement|Omega-3 (DHA-rich dietary supplement)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
1986232|NCT03300388|Dietary Supplement|Placebo (olive oil)|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
1986233|NCT03300388|Other|Resistance training|Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks.
1986248|NCT03297489|Procedure|Diagnostic Microscopy|Undergo observation via intravital microscopy
1986249|NCT03297489|Drug|Fluorescein Sodium Injection|Given IV
1986250|NCT03297489|Other|Laboratory Biomarker Analysis|Correlative studies
1986252|NCT03295695|Diagnostic Test|Fluoro-D-glucose-positron Emission Tomography|2-deoxy-2-[18F]Fluoro-D-glucose-positron Emission Tomography (FDG-PET): within 2 weeks of obtaining first echocardiogram; within two weeks of obtaining follow-up echocardiogram.
1986253|NCT03295695|Biological|2-deoxy-2-[18F]fluoro-D-glucose (FDG)|"2-deoxy-2-[18F]fluoro-D-glucose (FDG) labeled autologous human erythrocytes (RBCs): Approximately 10 mls of packed human erythrocytes are collected from the patient and labeled with ≈5-10 milliCuries of commercially available United States Pharmacopeia (USP)-grade FDG (≈5-10 picograms FDG) (Vendor: Cardinal Health) under sterile conditions in a Good Manufacturing Practice (GMP)-certified laboratory.
Synthesized RBCs: The cell suspension is manually infused via syringe through an indwelling peripheral venous catheter over the course of 1 minute, using an infusion method approved by the Moffitt Cancer Center (MCC) radiation safety officer."
1986254|NCT03295695|Diagnostic Test|Echocardiogram|Echocardiogram: prior to start of chemotherapy; post-treatment regimen.
1986257|NCT03296748|Procedure|trans-obturator tape inside-out usingsoft tapes.|trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
1986258|NCT03296748|Procedure|anterior colporraphy|
1986273|NCT03294135|Biological|Encepur Adults|One dose of the vaccine can be administered at any one unscheduled visit depending on the detection of NT below 10. It will be administered intramuscularly into the non-dominant deltoid.
1986280|NCT03292692|Behavioral|OurRelationship|Online intervention with coach support
1986282|NCT03292393|Behavioral|Financial reward|In contingency management, financial rewards are contingent upon an individual changing behavior. In our study, financial incentives are contingent upon group behavioral changes.. In the intervention phase participants will be randomly assigned to one of the three treatment arms and they will receive the financial incentive that corresponds to their treatment arm. Data will be collected for four months and all participants will continue receiving a compensation for participation
1986283|NCT03292393|Behavioral|Social norms|To build social norms the study adds a group component to a contingency management model. In contingency management, financial rewards are contingent upon an individual changing behavior. Social norms are expected to emerge as a result of the designed group contingency management, monthly-facilitated meetings at a local clinic, and daily basis interaction through social media. The intervention will build social norms that improve medication adherence of each member of a group. A three-arm randomize trial is designed to test this hypothesis. Hypertensive patients will be randomly assigned to a group contingency management (GCM) arm, an individual contingency management (ICG) arm, or a control arm.
1986284|NCT03292393|Device|Home Blood Pressure Monitoring|Participants will be reminded that they will receive and learn how to use a Home Blood Pressure Monitor (HBPM) device that participant will keep for the duration of the study
1986285|NCT03292393|Device|Medication adherence assessment|Participants will be informed that they will receive and learn how to use eCap, a medication event monitoring system that participants will return after completing the study. The project nursing student will count the number of pills the participant currently has and make a record of it on the Data Collection form.The participant will provide the project nursing student with his/her antihypertension prescription records so that the dosage amount and number of pills can be recorded on the Data Collection form.
1986291|NCT03291600|Behavioral|Virtual Psychiatric Care|Virtual psychiatric care for perinatal depression will be offered to participants, in addition to care as usual, for a 12-week period by their treating perinatal psychiatrist. Virtual care will be delivered by video-based visits through the Ontario Telemedicine Network (OTN). The treating psychiatrist may request that an intervention group participant present for in-person care at any visit, and this may include need for behavioural activation, or another health-related indication at the discretion of the treating psychiatrist.
1986292|NCT03291496|Other|Blood Collection|Blood will be collected on day 4 of life and then approximately every 3 days until 21 days of life. For preterm neonates that have suspected sepsis an additional 300 µl of blood will be samples one time per week until discharge.
1986293|NCT03291496|Other|Blood Collection|A single 300 µl blood sample will be collected once the term neonate is >24 hours old.
1986298|NCT03290664|Biological|CD3-/CD19-|CD3-/CD19- will be infused along with IL-2 on Day 0 following a preparative regimen of Fludarabine and Cyclophosphamide.
1986299|NCT03290664|Biological|CD3-/CD56+|CD3-/CD56+ will be infused along with IL-2 on Day 0 following a preparative regimen of Fludarabine and Cyclophosphamide.
1986306|NCT03290079|Drug|Pembrolizumab|Pembrolizumab Day 1 of each 3 week cycle.
1986307|NCT03289962|Drug|RO7198457|RO7198457 will be administered by intravenous (IV) infusion, in 21-day cycles.
1986308|NCT03289962|Drug|Atezolizumab|Atezolizumab will be administered by IV infusion, in 21-day cycles.
1986313|NCT03288792|Device|RI8 device imaging|RI8 Device imaging for adjunctive detection of breast cancer
1986331|NCT03286751|Drug|LY900014|Administered SC
1986332|NCT03286751|Drug|Insulin Lispro|Administered SC
1986333|NCT03286218|Drug|Lasmiditan|Administered orally
1986334|NCT03286218|Drug|Alprazolam|Administered orally
1986335|NCT03286218|Drug|Placebo|Administered orally
1986347|NCT03283696|Drug|Olaratumab|Administered IV
1986348|NCT03283696|Drug|Doxorubicin|Administered IV
1986349|NCT03283696|Drug|Ifosfamide|Administered IV
1986350|NCT03283696|Drug|Mesna|Administered per standard of care
1986351|NCT03282851|Drug|MSB11456|Subjects will receive a single injection of MSB11456 on Day 1.
1986352|NCT03282851|Drug|US-licensed Actemra|Subjects will receive a single injection of US-licensed actemra on Day 1.
1986353|NCT03282851|Drug|EU-approved RoActemra|Subjects will receive a single injection of EU-approved RoActemra on Day 1.
1986354|NCT03281239|Diagnostic Test|Laser doppler, blood tests, and holter ECG|"Diagnostic tests :
laser doppler
blood tests
Holter ECG. No drug and no placebo were used in this arm."
1986360|NCT03281369|Drug|5-Fluorouracil (5-FU)|5-FU 2400 milligrams per square meter (mg/m^2) by continuous intravenous (IV) infusion over 46 hours on Days 1 and 2 and Days 15 and 16 of every 28-day cycle.
1986361|NCT03281369|Drug|Leucovorin|Leucovorin: 100 mg/m^2 IV over 2 hours on Days 1 and 15 of every 28-day cycle.
1986362|NCT03281369|Drug|Oxaliplatin|Oxaliplatin: 100 mg/m^2 administered by IV infusion over 2 hours on Days 1 and 15 of every 28-day cycle.
1986363|NCT03281369|Biological|Atezolizumab|Atezolizumab: 840 mg by IV infusion on Days 1 and 15 of every 28-day cycle.
1986364|NCT03281369|Drug|Cobimetinib|Cobimetinib: 60 mg by mouth once a day on Days 1−21 of every 28-day cycle
1986365|NCT03281369|Biological|Ramucirumab|Ramucirumab: 8 mg/kg administered by IV infusion over 60 minutes on Days 1 and 15 of every 28-day cycle.
1986366|NCT03281369|Drug|Paclitaxel|Paclitaxel: 80 mg/m^2 administered by IV infusion on Days 1, 8, and 15 of every 28-day cycle.
1986367|NCT03281369|Biological|PEGylated recombinant human hyaluronidase (PEGPH20)|PEGPH20: 3 micrograms per kilogram (mcg/kg) administered by IV infusion on Days 1, 8, and 15 of every 21-day cycle.
1986368|NCT03281369|Drug|BL-8040|BL-8040: 1.25 mg/kg administered by subcutaneous (SC) injection on Days 1−5 during the 5-day priming period prior to Cycle 1; 1.25 mg/kg administered by SC injection three times a week (Days 1, 3, 5, 8, 10, 12, 15, 17, and 19 of every 21-day cycle).
1986369|NCT03281369|Drug|Linagliptin|Linagliptin: 5 mg orally once a day of every 21-day cycle.
1986370|NCT03281369|Biological|Atezolizumab|Atezolizumab: 1200 mg administered by IV infusion on Day 1 of every 21-day cycle
1986371|NCT03281369|Drug|Cobimetinib|Cobimetinib: 40 or 60 mg (depending on the recommended dose determined during the safety run-in phase) by mouth once a day on Days 1−21 of every 28-day cycle.
1986372|NCT03282318|Drug|ASP6294|Subcutaneous (SC) injection
1986373|NCT03282318|Drug|Placebo|SC injection
1986387|NCT03277378|Device|lead placement followed by BurstDR stimulation|lead placement followed by BurstDR stimulation
1986409|NCT03274999|Device|TrueTear Intranasal Application|Intranasal application of TrueTear device for approximately 3 minutes at Day 0 and Day 14 (±11 days)
1986410|NCT03274999|Device|TrueTear Extranasal Application|Extranasal application (control) of TrueTear device for approximately 3 minutes at Day 0 and Day 14 (±11 days)
1986418|NCT03273842|Biological|PF-06881894|pre-filled syringe 6 mg
1986419|NCT03273842|Biological|US-approved Neulasta|pre-filled syringe 6 mg
1986432|NCT03270332|Drug|albuterol first then placebo|inhalation of 270μg albuterol (3 puffs) through a spacer at visit 2 and inhalation of placebo (3 puffs) through a spacer at visit 3
1986433|NCT03270332|Drug|placebo first then albuterol|inhalation of placebo(3 puffs) through a spacer at visit 2 and inhalation of 270ug albuterol (3 puffs) through a spacer at visit 3
1986438|NCT03268863|Device|Virtual Reality|Google Cardboard virtual reality headset
1986439|NCT03268863|Other|Cold Pressor|A cold ice water bath for use in pain/discomfort simulation
1986485|NCT03261141|Combination Product|(PV-RQOL),(APA) ,Acoustic analysis|"severity and character of dysphonia (measured by Auditory Perceptual Assessment using a modified GRBAS scale which gives scores as regard the degree and severity of dysphonia and its character.
Acoustic Analysis of voice : which is Computerized Speech Laboratory analysis of voice that gives the following measures jitter (%), shimmer (dB), and harmonic to noise ratio (H/N).
the degree of social ,emotional ,functional and physical disturbance ,if present in those children with voice disorders by application of The Arabic Pediatric Voice Related Quality of Life (PV-RQOL)."
1986490|NCT03260517|Device|Medtronic Coronary Drug-Coated Balloon Catheter|Medtronic Paclitaxel Coronary Drug-Coated Balloon Percutaneous transluminal coronary angioplasty
1986503|NCT03258177|Other|Virtual Visit|Participants will be given information about how to enroll in virtual care. Participants will use their own camera-enabled device with internet connection to see and speak to the medical professional in real-time and complete the virtual follow-up visit.
1986505|NCT03257891|Drug|Cabazitaxel|Cabazitaxel will be administered every 21 days
1986511|NCT03256695|Drug|ABS eMDPI|The ABS eMDPI dose will be 90 mcg, 1 to 2 inhalations every 4 hours as needed.
1986514|NCT03256058|Procedure|Reinflation after early deflation|the tourniquet would be inflated immediately before incision and deflated after the use of the cement , and 10 minutes later (after the hardening of the cement) , reinflate the tourniquet and deflate at the end of the operation. The total time of tourniquet inflation is controlled within 90 minutes.
1986515|NCT03256058|Procedure|Control|The tourniquet would be inflated immediately before incision and deflated at the end of the operation. The inflation of tourniquet should not last more than 90 minutes.
1986516|NCT03255057|Device|Hemolung Respiratory Assist System|Treatment with a medical device called the Hemolung RAS. The Hemolung RAS includes three components: the Hemolung Controller, the Hemolung Cartridge, and the Hemolung Catheter. The intervention is use of the Hemolung RAS to provide partial lung support for acute hypercapnic lung failure by filtering carbon dioxide from venous blood using a central venous catheter through which venous blood is pumped at flows of 350-550 milliliters per minute to and from an external circuit containing a hollow fiber membrane blood gas exchanger (with heparin-coated fibers) integrated with a centrifugal pump.
1986517|NCT03255057|Device|Invasive mechanical ventilation|Lung support for acute lung failure applied with a mechanical ventilation device that uses positive pressure to mechanically inflate the lungs and facilitate exhalation via an endotracheal tube or tracheotomy.
1986546|NCT03251482|Drug|JNJ-64179375 0.3 mg/kg|JNJ-64179375 0.3 milligram per kilogram (mg/kg) intravenous (IV) infusion as a single dose on Day 1.
1986547|NCT03251482|Drug|JNJ-64179375 0.6 mg/kg|JNJ-64179375 0.6 mg/kg IV infusion as a single dose on Day 1.
1986548|NCT03251482|Drug|JNJ-64179375 1.2 mg/kg|JNJ-64179375 1.2 mg/kg IV infusion as a single dose on Day 1.
1986549|NCT03251482|Drug|JNJ-64179375 (Dose to be Determined)|JNJ-64179375 IV infusion (Dose to be determined) as a single dose on Day 1.
1986550|NCT03251482|Drug|JNJ-64179375 A mg/kg|JNJ-64179375 Dose A mg/kg IV as a single dose on Day 1.
1986551|NCT03251482|Drug|JNJ-64179375 B mg/kg|JNJ-64179375 Dose B mg/kg IV as a single dose on Day 1.
1986552|NCT03251482|Drug|JNJ-64179375 C mg/kg|JNJ-64179375 Dose C mg/kg IV as a single dose on Day 1.
1986553|NCT03251482|Drug|JNJ-64179375 D mg/kg|JNJ-64179375 Dose D mg/kg IV as a single dose on Day 1.
1986554|NCT03251482|Drug|Placebo JNJ-64179375|Matching JNJ-64179375 placebo (normal saline) administered as IV infusion as a single dose on Day 1.
1986555|NCT03251482|Drug|Apixaban placebo|Matching apixaban placebo administered orally twice a day for 10 to 14 days.
1986556|NCT03251482|Drug|Apixaban 2.5 mg|Apixaban 2.5 mg administered orally twice a day for 10 to 14 days.
1986561|NCT03249142|Drug|ARM A Durvalumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)
ADJUVANT :
If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.
If residual tumor at interval debulking surgery : the tremelimumab 75 mg IV will be added to the durvalumab-chemotherapy combination at day 1 of cycle 2 before a salvage surgery. Durvalumab 1125 mg IV (with one cycle of tremelimumab 75 mg IV post S3) will be pursued in maintenance treatment, up to 1 year or until disease progression, unacceptable toxicity or patient withdrawn."
1986562|NCT03249142|Drug|ARM B Durvalumab/Tremelimumab/chemotherapy association|"NEO-ADJUVANT Cycle 1 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV alone (day1), every 3 weeks Cycle 2 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV + tremelimumab 75 mg IV (day1) Cycle 3 : carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV + durvalumab 1125 mg IV (day1)
ADJUVANT :
If complete surgical resection at interval debulking surgery : 3 cycles of durvalumab 1125 mg IV + carboplatin AUC 5 IV + paclitaxel 175 mg/m² IV at day1, every 3 weeks.
If residual tumor at interval debulking surgery : patients will be treated according to investigator choice."
1986563|NCT03248947|Drug|buprenorphine/naloxone|To relieve opioid withdrawal symptoms and craving, buprenorphine/naloxone will be prescribed by the study-physician and dispensed by the study-pharmacist on a monthly basis. The median expected dose is 16 mg daily, though adjustment by the study physician may be needed due to increased withdrawal and craving from previous study visits. Medication will be provided in the form of a sublingual film.
1986564|NCT03248947|Other|Pharmacist-administered buprenorphine/naloxone maintenance care|Following buprenorphine/naloxone induction/stabilization with the physician, participants with opioid use disorder will be transferred to the care of pharmacists for the maintenance phase of treatment. Maintenance visits will occur monthly with the pharmacist at the pharmacy location for six months. Buprenorphine/naloxone will be dispensed by the pharmacist at the monthly study visits following participant assessment, communication with the physician, and prescription form the physician.
1986581|NCT03246152|Drug|Bevacizumab|Repeated intravitreal injections of Bevacizumab monthly
1986588|NCT03247023|Device|Implantation of Integra Cadence Total Ankle Sysyem|Primary Ankle Arthroplasty
1986604|NCT03245489|Drug|Pembrolizumab|200mg intravenous (IV) over 30 minutes
1986605|NCT03245489|Drug|Clopidogrel|75mg/day oral
1986606|NCT03245489|Drug|acetylsalicylic acid|81mg/day oral
1986607|NCT03244995|Behavioral|Questionnaires|"Couple-Based Mind-Body (CBMB) Group and Waitlist Control Group complete baseline measures (T1) prior to group assignment. Study staff will tell Waitlist Control Group when to complete these questionnaires as the timing will match up to the sessions of the Couple-Based Mind-Body (CBMB) Group participants.
All participants complete about 10 questionnaires before the first session, after the last session (usually 6 weeks later) and three months after study completion. The questionnaires ask about health, mood, sleeping habits, relationship, and quality of life. It should take about 45 minutes to complete these questionnaires."
1986608|NCT03244995|Behavioral|Mind-Body Intervention|CBMB group receives 4 sessions over the course of 6 weeks (+/- 1 week; 60 min. each) with one session per week.
1986609|NCT03244995|Other|Compact Discs (CD's) + Printed Materials|At couples first session, CDs and instructions given for practicing meditation at home.
1986610|NCT03244995|Behavioral|Phone Calls|"Couples in CBMB group receive up to two weekly booster phone calls to ascertain participants complete the homework and answer questions regarding the exercises."
1986624|NCT03241888|Drug|Megestrol Acetate|At a dosage of 160 mg/day
1986625|NCT03241888|Device|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|Active ingredient: levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
1986636|NCT03241914|Drug|Megestrol Acetate|At a dosage of 160 mg/day
1986637|NCT03241914|Device|Levonorgestrel-releasing Intrauterine System(LNG-IUS)|levonorgestrel 52mg. It is a hormone-releasing T-shaped intrauterine system.
1986669|NCT03238963|Drug|BI 1467335|Once daily
1986670|NCT03238963|Drug|Placebo|Once daily
1986699|NCT03232983|Drug|LY900014 (SC)|Administered SC
1986700|NCT03232983|Drug|LY900014 (IV)|Administered IV
1986703|NCT03231917|Procedure|Water Infusion first|In this group patients will receive a colonoscopy with water infusion for mucosal inspection and then receive a colonoscopy with CO2 insufflation.
1986704|NCT03231917|Procedure|CO2 Insufflation First|In this group patients will receive a colonoscopy with CO2 insufflation for mucosal inspection and then receive a colonoscopy with water infusion .
1986705|NCT03232138|Drug|Sulforaphane|Sulforaphane (SF) is a naturally occurring substance (phytochemical) found in cruciferous vegetables.
1986706|NCT03232138|Drug|Placebo|Inactive ingredients
1986718|NCT03229538|Drug|Methylprednisolone|IV Steroid pre-operative and intra-operative
1986719|NCT03229538|Drug|Isotonic saline|Isotonic saline pre-operative and intra-operative
1986720|NCT03228940|Drug|RVX000222|oral, BID
1986721|NCT03228706|Behavioral|Know Your Medicine - Take It For Health (KYM-TIFH)|The KYM-TIFH employed psychosocial, educational and behavioral approach. It was designed based on the application of multiple behavior change theories and persuasion theory as recommended by Slater (1999). The cross-theoretical framework for the message design of intervention as recommended by Slater (1999) involved theories such as Transtheoretical Model (TTM) (Prochaska & Velicer 1997), Theory of Reasoned Action (TRA) (Ajzen & Fishbein 1980), Protection Motivation Theory (PMT) (Rogers 1975), Elaboration-Likelihood Model (ELM) (Petty and Cacioppo 1986) and Social Cognitive Theory (SCT) (Bandura 1992) as in Table 2. Nonetheless, the intervention embraces the philosophy of patients' empowerment, which had found to be effective in engaging patients to produce behavioral change among diabetes patients (Anderson 1995; Anderson et al 1995). Hence, the facilitators are trained to employ a non-didactic approach in facilitating the and eliciting the learning among the group members.
1986742|NCT03223233|Other|procalcitonin level|serum procalcitonin level will be measured in both groups.
1986746|NCT03224702|Drug|M6495|Subjects will receive M6495 on Day 1
1986747|NCT03224702|Drug|Placebo|Subjects will receive placebo matched to M6495 on Day 1
1986758|NCT03222583|Drug|ABT-493/ABT-530|Tablet; ABT-493 coformulated with ABT-530
1986759|NCT03222583|Drug|Placebo|Tablet; matching placebo
1986778|NCT03218748|Behavioral|Honest, Open, Proud (HOP)|"Three lessons, one for each two-hour session plus one booster session
Considering the pros and cons of disclosure:
Discussion of one's idea of identity and mental illness, weighing the costs and benefits of (non-) disclosure
Different ways to disclose:
Discussion of different levels of (non-) disclosure, considering costs and benefits of each level, selecting persons to disclose to and how to test them out, anticipating responses of others to one's disclosure
Telling one's story:
Practice how to tell one's story, identifying peers who might be helpful with the coming out process
Booster session Reviewing previous intentions to disclose one's mental illness, discussion whether one disclosed and evaluating this experience"
1986799|NCT03215979|Procedure|Platelet enriched plasma administration|It is a blinded administration of platelet enriched plasma in the temporal fascia used to cover the auricular reconstruction frame, during the second stage of the procedure. The use of platelet enriched plasma is focused to improve the integration rate of the full-thickness split skin graft
1986800|NCT03215979|Procedure|Placebo Arm|5 ml of saline 0.9%will be applied in the temporal fascia as a placebo used to compare to the experimental group.
1986825|NCT03213964|Biological|FATE-NK100|"FATE-NK100 Infusion (Day 0)
The FATE-NK100 product will be placed in approximately 100 cc of 5% human serum albumin.
Dose Level 1: 1 x 10^7 cells/kg IP
Dose Level 2: >1x10^7 cells/kg to ≤3x10^7 cells/kg
Dose Level 3: Complete FATE-NK100 bag (≥3 x 10^7 to ≤ 10 x 10^7 cells/kg)"
1986826|NCT03213964|Drug|Interleukin-2|"Interleukin-2 (begin Day 0): 6 million units three times a week for a total of 6 doses. For patients weighing less than 45 kilograms, the IL-2 will be given at 3 million units/m2 three times a week for 6 doses.
The 1st dose will be given immediately (within 30 minutes) after the FATE-NK100 cell infusion on Day 0 as an inpatient. The remaining doses will be given in an outpatient setting."
1986831|NCT03209401|Drug|Niraparib|an oral PARP inhibitor
1986832|NCT03209401|Drug|Carboplatin|a platinum-based injection
1986840|NCT03207503|Procedure|fMRI|Patients will undergo fMRI imaging to assess areas of the brain that are active during emotion regulation. No clinical benefit of MRI imaging is anticipated.
1986841|NCT03207399|Drug|Epclusa|Patients will be treated with this drug for 12 weeks post lung transplant.
1986875|NCT03202420|Other|TOPS|Take Off Pounds Sensibly (TOPS) is a national, nonprofit, peer-led, group-based, weight loss program that offers a comprehensive program on diet and physical activity with group support for weight management.
1986876|NCT03201757|Drug|ALKS 3831|Olanzapine + samidorphan, daily oral dosing
1986891|NCT03199820|Device|Cook cervical balloon|trans-cervical balloon catheter for out-patient labour induction
1986892|NCT03199820|Drug|Prostin E2 Vaginal Suppository|Propess Vaginal suppository for out-patient Labour induction
1986939|NCT03193307|Drug|Microgynon|Run in period & Treatment Period
1986940|NCT03193307|Drug|BI 409306|Day 18 & 29 (Treatment Period)
1986944|NCT03192163|Other|Survey|31 question survey with questions regarding non-identifying demographic information such as age and gender. This survey also contains questions about acne treatment preferences, racial/ethnic background, and cultural identity in addition to a few Willingness to Pay questions.
1986978|NCT03186482|Drug|Descovy® (TAF/FTC)|25/200 mg once daily for 28 days (DAYS 1-28).
1986979|NCT03186482|Drug|Viread® (TDF)|245 mg once daily for 28 days (DAYS 57-84).
1986980|NCT03186482|Drug|Rifadin® (Rifampicin)|600 mg once daily for 28 days (DAYS 29-56).
1986981|NCT03186209|Biological|Benralizumab|Benralizumab subcutaneously on study week 0 until study week 40 inclusive.
1986982|NCT03186209|Biological|Placebo|Placebo subcutaneously on study week 0 until study week 40 inclusive.
1986992|NCT03181659|Procedure|Manual Therapy, Therapeutic Education, Therapeutic Exercice|They will receive 8 sessions (2 sessions per week) of joint and neural manual therapy, and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation. The therapeutic exercise program is based on stabilization of the lumbopelvic region.
1986993|NCT03181659|Procedure|Therapeutic Education, Therapeutic Exercice|They will receive a total of 8 sessions (2 sessions per week) of therapeutic exercise based on the stabilization of the lumbopelvic region and will receive 4 sessions (1 session per week) of neuroscience education in which mirror therapy and image observation.
1987014|NCT03179436|Biological|MK-1308|MK-1308 is administered intravenously (IV) during Dose Escalation Phase at either dose level 1 or dose level 2, and is administered IV during Dose Confirmation Phase at either dose level 1 or dose level 2.
1987015|NCT03179436|Biological|Pembrolizumab|Pembrolizumab is administered IV at 200 mg on Day 1 of each cycle starting Cycle 2 for the Dose Escalation Phase or starting Cycle 1 of the Dose Confirmation Phase.
1987020|NCT03177239|Drug|Nivolumab|"Dosage Form: Nivolumab BMS-936558-01 Solution for Injection Potency: 100 mg (10 mg/mL) Primary Packaging: 10 mL vial Appearance: Clear to opalescent colourless to pale yellow liquid. May contain particles.
Storage Condition: 2 to 8°C. Protect from light and freezing."
1987021|NCT03177239|Drug|Ipilimumab|Dosage Form: Ipilimumab Solution for Injection Potency: 200 mg (5 mg/mL) Primary Packaging: 40 mL vial Appearance: Clear, colourless to pale yellow liquid. May contain particles. Storage Condition: 2 to 8°C. Protect from light and freezing.
1987047|NCT03170518|Drug|Canagliflozin 100 mg|Canagliflozin 100 mg tablet will be administered orally (by mouth) once-daily.
1987048|NCT03170518|Drug|Canagliflozin 300 mg|Canagliflozin 300 mg tablet will be administered orally once-daily.
1987049|NCT03170518|Drug|Placebo|Matching placebo tablet will be administered orally once-daily.
1987055|NCT03170232|Drug|Danirixin 35 mg tablets|Danirixin 35 mg (as hydrobromide hemihydrate salt) is a white film coated oval shaped tablet. It will be provided in a labeled high-density polyethylene (HDPE) bottle with desiccant.
1987056|NCT03170232|Drug|Placebo|Placebo is a white film coated oval shaped tablet. It will be provided in a labeled HDPE bottle with desiccant.
1987057|NCT03170232|Device|Metered dose inhaler (MDI) sensor device|MDI sensor devices will be fitted onto rescue medication MDI devices to electronically record rescue medication usage.
1987058|NCT03170232|Drug|Rescue medication|Subjects may continue to use rescue medication(s) via their usual route. Allowed medications are: short acting beta agonists (SABA) (e.g., albuterol/salbutamol); short acting muscarinic antagonists (SAMA) (e.g., ipratropium); short acting combination (SABA/SAMA) bronchodilators, (e.g. Duoneb, Combivent)
1987070|NCT03166124|Drug|LY900014|Administered SC
1987071|NCT03166124|Drug|Insulin Lispro|Administered SC
1987093|NCT03162094|Drug|AVX012 Ophthalmic Solution Low dose|Ocular topical administration of AVX Ophthalmic Solution Low dose
1987094|NCT03162094|Drug|AVX012 Ophthalmic Solution High dose|Ocular topical administration of AVX Ophthalmic Solution High dose
1987095|NCT03162094|Drug|Placebo (vehicle)|Ocular topical administration of placebo (vehicle Ophthalmic Solution)
1987104|NCT03163004|Behavioral|Implementation of standing desks|Three standing desks will be introduced to the classroom
1987157|NCT03150498|Drug|BTD-001|BTD-001 in fed vs fasted state
1987164|NCT03148756|Drug|Dalbavancin|Dalbavancin 1500 mg, intravenous (IV) administration over 30 minutes on Day 1, and on Day 8
1987165|NCT03148756|Drug|Standard of Care|Antibiotic consistent with Standard of Care (SOC), based on baseline pathogen, for 4 to 6 weeks
1987177|NCT03146780|Procedure|Conventional impression|"A dental impression is a negative imprint of hard (teeth) and soft tissues in the mouth from which a positive reproduction (or cast) can be form using alginate material. They are made by using a container which is designed to roughly fit over the dental arches (trays)."
1987178|NCT03146780|Procedure|Digital Scan 1|Direct intra-oral digital scans using Sirona Omnicam software.
1987179|NCT03146780|Procedure|Digital Scan 2|Direct intra-oral digital scans using Planmeca Planscan software.
1987180|NCT03146780|Procedure|Digital Scan 3|Direct intra-oral digital scans using 3M True Definition software.
1987187|NCT03144934|Drug|GX-I7|Interleukin-7 (IL-7) is T cell growth factor that can be used for treating lymphopenia patients. GX-I7 is a protein drug recombining human IL-7 and hybrid Fc (hyFc). HyFc made by Genexine is composed of hinge-CH2 region of Immunoglobulin D (IgD) and CH2-CH3 region of Immunoglobulin G4 (IgG4). The recombined region is not exposed and each region's characteristics can reduce immunogenicity and improve the efficacy of drug. Consequently, it will be able to treat the patients with lymphopenia in effective ways.
1987188|NCT03144934|Drug|Placebo|This is the placebo of GX-I7 described above.
1987227|NCT03136367|Other|Option Grid|The Option Grid(TM) encounter decision aid for early stage breast cancer surgery is a one-page, evidence-based summary of available options presented in a tabular format.
1987228|NCT03136367|Other|Picture Option Grid|The Picture Option Grid was derived from the Option Grid for early stage breast cancer. It uses the same evidence and integrates images and simpler text, thus exploiting pictorial superiority. The Picture Option Grid has been specifically designed for women of lower SES and low health literacy.
1987253|NCT03130036|Other|Low-Carbohydrate Diet|Participants assigned to the Modified Ketogenic-Mediterranean Diet will keep their carbohydrate consumption below 20 grams per day throughout the 6-week intervention.
1987254|NCT03130036|Other|Low-Fat Diet|Participants assigned to the Low-Fat Diet will be encouraged to limit their amount of fat intake to <40 grams/day, while eating plentiful fruits, vegetables, and carbohydrates containing adequate fiber.
1987263|NCT03126591|Drug|Olaratumab|Administered IV
1987264|NCT03126591|Drug|Pembrolizumab|Administered IV
1987272|NCT03123744|Drug|Palbociclib 125mg|Palbociclib 125 mg is administered orally at a starting dose of 125 mg/day for three weeks followed by one week off. Study evaluations include physical exams, performance status, vital signs, laboratory blood tests, and radiographic or MRI imaging.
1987283|NCT03119454|Drug|Diprospan|Intramuscular
1987291|NCT03114592|Other|mHealth tool|"The curriculum in the mHealth tool was derived in consultation with patient safety, informatics and adult educational curricula experts, and is comprised of clinical vignettes describing the post-hospital discharge stories of two hypothetical AKI survivors. opics of emphasis included NSAID risk awareness and avoidance of volume depletion when ill (Sick Day Protocol)."
1987292|NCT03114475|Radiation|CO2 laser irradiation|CO2 laser irradiation will be applied onto the enamel surrounding the orthodontic bracket
1987293|NCT03114475|Other|Placebo|No irradiation is going to be applied in the intervention. Just a red light will be used as placebo.
1987301|NCT03112590|Biological|Interferon-gamma (IFN-γ)|Phase 1: IFN-γ 50 or 75 mcg/m^2 SQ x 3 days/week for 12 weeks. Phase 2: IFN-γ at Recommended Phase II Dose (RP2D) subcutaneously (SQ) x 3 days/week, for 12 weeks.
1987302|NCT03112590|Drug|Paclitaxel|Phase 1 and Phase 2: Paclitaxel 80 mg/m^2/week, for 12 weeks.
1987303|NCT03112590|Drug|Trastuzumab|Phase 1 and Phase 2: Trastuzumab 8 mg/kg intravenous (IV) loading dose on cycle 1/day 1 (C1D1), followed by 6 mg/kg on subsequent cycles every 3 weeks, for 12 weeks.
1987304|NCT03112590|Other|Pertuzumab|Phase 1 and Phase 2: Pertuzumab 840 mg IV loading dose on C1D1, followed by 420 mg on subsequent cycles every 3 weeks, for 12 weeks.
1987305|NCT03112590|Procedure|Post Therapy Surgery|Phase 2: Participants will be assessed for surgery following the fourth cycle of study therapy (or earlier if study treatment is cancelled due to unmanageable side effects).
1987306|NCT03112486|Procedure|blood draw|Blood draws will be collected via venipuncture or IV at hours 0, 6, 12, 18, 24, 48, 72, 96, 120, 144 (10 draws total). Each draw would be approximately 20 mL of blood (but no less than 10 mL).
1987309|NCT03112200|Procedure|Subchondroplasty with Arthroscopy|The Subchondroplasty® (SCP®) Procedure targets and fills bone defects with AccuFill® Bone Substitute Material utilizing an arthroscopic / percutaneous approach. Using intraoperative fluoroscopy, the bone defect is localized relative to MRI findings The appropriate AccuPort® Delivery Cannula is drilled to the bone defect. AccuFill® Bone Substitute Material is then injected into the subchondral bone defect. The calcium phosphate (CaP) fills the edematous void and hardens within the Bone Marrow Lesion. The CaP is resorbed over time and replaced with new bone during the healing process.
1987310|NCT03112200|Procedure|Arthroscopy Alone|An endoscopic examination, therapy and surgery of the knee joint.
1987324|NCT03107013|Drug|[14C]-BTD-001|Carbon-14 labeled BTD-001
1987355|NCT03103893|Drug|Rapamycin|topical formulation
1987380|NCT03097133|Drug|Esketamine|Participants will receive intranasal esketamine 84 milligram (mg) two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
1987381|NCT03097133|Drug|Placebo|Participants will receive intranasal placebo two times per week for 4 weeks (Days 1, 4, 8, 11, 15, 18, 22, and 25).
1987382|NCT03097133|Other|Standard of Care|The standard of care antidepressant treatment (antidepressant monotherapy or antidepressant plus augmentation therapy) will be determined by the treating physician(s) based on clinical judgement and practice guidelines prior to randomization, and the treatment will be initiated on Day 1.
1987390|NCT03096886|Behavioral|Computer-Augmented Cognitive Behavioral Therapy|"The model of CCBT, Good Days Ahead (GDA) will be utilized, it has been found that it is not inferior to CBT in MDD treatment efficacy. CCBT participants will complete 9 modules of the GDA program, including 240 minutes of computer training; participants will also meet with a therapist on 6 occasions for a total of 180 minutes of clinician administered cognitive behavioral therapy."
1987402|NCT03093090|Dietary Supplement|Water|6 oz
1987403|NCT03093090|Dietary Supplement|Parmalat™ Whole Milk|6 oz
1987404|NCT03093090|Dietary Supplement|Similac Pro-Advance™|6 oz
1987405|NCT03093090|Dietary Supplement|Ensure Plus™|6 oz
1987406|NCT03093090|Drug|Furosemide 20 MG|Furosemide is a loop diuretic (water pill) that prevents your body from absorbing too much salt.
1987414|NCT03092765|Drug|E6011|Intravenous administration
1987415|NCT03092765|Drug|Placebo|Intravenous administration
1987423|NCT03089918|Drug|11C-JNJ-63779586|Participants will receive IV injection with 11C-JNJ-63779586 in Part A and Part B.
1987428|NCT03087357|Other|SmartNIPT|A novel, non-next generation sequencing (NGS) test that is designed to perform as well as conventional NGS screening while being simpler and less expensive.
1987445|NCT03082261|Device|Prodigy, Prodigy MRI or Proclaim Elite IPG|Subjects will be permanently implanted with either a Prodigy, Prodigy MRI or Proclaim Elite IPG
1987457|NCT03079856|Behavioral|Brief Intervention|"Intervention for emerging adults (EAs) seeking care in the ED. The intervention will be rooted in motivational interviewing (MI) and will be guided by social cognitive, self-determination, and the trans-theoretical theories. The ED visit presents a teachable moment for intervening to promote health behavior, therefore eligible EAs will receive a ~30 minute MI-based session in the ED. In order to capitalize on and potentially extend this moment, participants will receive daily booster notifications delivered through a secure mobile app that they will download to their phone at enrollment."
1987458|NCT03079102|Drug|Nitric Oxide|An endogenous gaseous signaling molecule which stimulates soluble guanylate cyclase and may act via S-nitrosation, nitrite/nitrate or nitrated fatty acid formation.
1987459|NCT03079102|Drug|Nitrogen|Nitrogen is the carrier gas (vehicle) for iNO. Subjects receiving placebo will receive equivalent doses of nitrogen.
1987470|NCT03078751|Drug|Ribociclib|"Ribociclib 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).
Ribociclib will be supplied in the form of 200 mg tablets."
1987471|NCT03078751|Drug|Placebo|"Placebo 600 mg daily on days 1 to 21 of a 28-day cycle for 26 cycles (approximately 24 months).
Placebo will be supplied in the form of 200 mg tablets."
1987472|NCT03078751|Drug|Adjuvant endocrine therapy|Tamoxifen 20 mg daily, or letrozole 2.5 mg daily, or anastrozole 1 mg daily, or exemestane 25 mg daily (male patients will be treated with tamoxifen 20 mg daily) for a total duration of at least 60 months. In premenopausal women, adjuvant endocrine therapy will include GnRH agonist administered every 28 days.
1987475|NCT03078036|Genetic|Germline BRCA Test (blood)|If unavailable from the patient medical records, gBRCA gene mutation status will be tested as aligned to local clinical practice using a blood sample obtained preferably during routine clinical practice. (Note: Blood samples may be shipped to a central laboratory for testing and storage, based on local regulations for shipment of blood samples.)
1987476|NCT03078036|Genetic|FoundationOne Dx Genomic Profile (archival Tumour Specimen)|"Archival tumour specimen will be requested from all patients in the informed consent, but is not required for study enrolment (optional consent). Where sufficient archival tumour specimen is available and patients have consented to tumour specimen testing, FoundationOne Dx genomic profiling may take place as follows:
Tumour Specimen: Acceptable samples include formalin-fixed, paraffin embedded (FFPE) tissue (preferred) or FFPE specimens, including core needle biopsies, fine-needle aspirates and effusion cytologies.
Tumour Testing (optional): archival tumour specimens, where available, will be tested for mutations in HRR genes including BRCA1 and BRCA2 and other genomic alterations using the FoundationOne Dx genomic profile."
1987477|NCT03078036|Other|Follow-up|"Patients who test positive for a gBRCA gene mutation, and/or sBRCA or other HRR gene mutations (optional testing), will be followed prospectively for assessment of treatment patterns and associated clinical outcomes up to 30-months.
- Patients who test negative for gBRCA gene mutations, sBRCA and other HRR gene mutations, no further data will be collected post baseline. Patients presenting other genomic alterations that are identified by the FoundationOne Dx genomic profile will not continue beyond baseline as part of this study."
1987491|NCT03072043|Drug|APR-246|Phase 1b: Dose escalation of APR-246 via intravenous (IV) infusion, with starting dose of 100 mg/kg lean body weight (LBW). Phase 2: APR-246 at maximum tolerated dose (MTD).
1987492|NCT03072043|Drug|Azacitidine|Azacitidine is administered subcutaneously (SC) or via IV at 75 mg/m^2.
1987497|NCT03071536|Drug|Furosemide Injection|Furosemide 1.5 mg/kg intravenously at 3 hours post-reperfusion of kidney allograft
1987498|NCT03072446|Device|Gel-Beads embolic material|Patients will receive embolization of their uterine fibroids using Gel-Beads.
1987502|NCT03070249|Behavioral|Professional Quality of Life (ProQoL) scale|COMPASSION SATISFACTION AND COMPASSION FATIGUE (PROQOL) measures how compassion for those who are cared for can affect providers in positive and negative ways. Questions about experiences, both positive and negative, as a provider reflecting the frequency experiences within the last 30 days. 1=Never 2=Rarely 3=Sometimes 4=Often 5=Very Often
1987525|NCT03063242|Drug|Sargramostim|Study participants (n=5 per project) will receive subcutaneous injection of sargramostim (6 ug/kg) daily until maximal mDC levels are achieved, as determined by a dose response curve.
1987526|NCT03063242|Biological|Blood samples|Blood samples will be drawn at baseline and during each subsequent visit
1987527|NCT03064165|Drug|Bupivacaine-epinephrine|Nerve block with 15 mL bupivacain 5 mg/mL with epinephrine 5 µg/mL.
1987528|NCT03064165|Procedure|Sham block|Injection as for obturator nerve block, but with placebo
1987529|NCT03064165|Procedure|Obturator nerve block|Postoperative obturator nerve block
1987530|NCT03064165|Drug|Sodium Chloride 9mg/mL|Placebo
1987548|NCT03060538|Drug|BFKB8488A|Administered subcutaneously starting on Day 1 and according to dosing schedule.
1987549|NCT03060538|Other|Placebo|Administered subcutaneously starting on Day 1 and according to dosing schedule.
1987554|NCT03061214|Drug|Semaglutide 0.5 mg|Up to 0.5 mg semaglutide injected subcutaneously (s.c., under the skin) once-weekly (OW) for 30 weeks
1987555|NCT03061214|Drug|Semaglutide 1.0 mg|Up to 1.0 mg semaglutide injected subcutaneously once-weekly for 30 weeks
1987556|NCT03061214|Drug|Sitagliptin placebo|Sitagliptin placebo tablets taken once-daily for 30 weeks
1987557|NCT03061214|Drug|Sitagliptin|100 mg sitagliptin tablets taken once-daily for 30 weeks
1987558|NCT03061214|Drug|Semaglutide placebo 0.5 mg|Semaglutide placebo (0.5 mg) injected subcutaneously once-weekly for 30 weeks
1987559|NCT03061214|Drug|Semaglutide placebo 1.0 mg|Semaglutide placebo (1.0 mg) injected subcutaneously once-weekly for 30 weeks
1987578|NCT03054909|Biological|ALT-803 Subcutaneous|Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)
1987579|NCT03054909|Biological|ALT-803 Intraperitoneal|Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).
1987605|NCT03051997|Behavioral|Caregiver Contingency Management + Usual Drug Court Treatment|In addition to receiving JDC treatment as usual described below, caregiver participants will receive prize draws for engaging in activities consistent with their adolescents' successful completion of the JDC program during the time the youth is actively involved in JDC and substance abuse treatment. Specific activities that may be reinforced include: attendance at drug court hearings; accompanying the youth to probation meetings; participating in home visits; attendance at the youth's drug treatment sessions; attendance at mental health provider meetings; attending groups for parents of youth with substance abuse issues; and completing other verifiable treatment-related activities. All activities will meet the goals of (directly or indirectly) enhancing caregiver participation in the JDC and/or treatment process. Caregivers will receive escalating chances for tangible reinforcers each week for completing up to 3 of the activities agreed upon by the caregiver and the therapist.
1987606|NCT03051997|Behavioral|Usual Drug Court Treatment|Standard outpatient substance abuse treatment services that a young person would receive while participating in JDC.
1987620|NCT03047707|Diagnostic Test|S-Shearwave and TE|S-Shearwave elastography and Transient elastography (TE) are performed to evaluate hepatic stiffness.
1987625|NCT03046927|Drug|Ergocalciferol|Each subject on the experimental arm will receive one capsule of ergocalciferol per week for 2 months; and then once every 2 weeks for 10 months
1987626|NCT03046927|Other|Placebo|Each subject on the placebo arm will receive one capsule of placebo per week for 2 months; and then once every 2 weeks for 10 months
1989481|NCT02483351|Other|Liberal Red Blood Cell Transfusion Strategy|RBC Transfusion strategy with hemoglobin trigger of 100g/L
1989482|NCT02483351|Other|Restrictive Red Blood Cell Transfusion Strategy|Optional RBC Transfusion with hemoglobin trigger of <=80g/L
1987670|NCT03035916|Other|Transversus abdominis plane block|Participants in this group receive ultrasound-guided TAP block under bilateral costal margin with multiple injections of 40ml 0.375% ropivacaine after the induction of general anesthesia, 30 minutes later the surgery will be started.
1987671|NCT03035916|Other|Epidural anesthesia|Participants in the Epidural group receive a epidural block (T8-9) with 2 mL of 1.6% lidocaine as a test dose before induction. After a successful placement of epidural catheter, the block then is established with 5 mL of 0.375% ropivacaine and continous infusion of 0.375% ropivacaine(5 mL/h) during the surgery.
1987672|NCT03035916|Other|control|The Control group receives standard IV-inhaled general anesthesia.
1987673|NCT03036852|Drug|SOF/VEL|400/100 mg fixed-dose combination (FDC) tablet(s) administered orally once daily
1987674|NCT03036839|Drug|LDV/SOF|90/400 mg fixed- dose combination (FDC) tablet administered orally once daily
1987722|NCT03023930|Other|Standard Dissemination Practice|Emergency department provider education using a grand rounds format. The content of the lecture will cover the scope of the opioid problem, ED specific facts related to the epidemic, potential models of intervention including the results of publications outlining the efficacy of ED-initiated BUP.
1987723|NCT03023930|Other|Implementation Facilitation (IF)|"IF involves a formative evaluation to identify the specific and dynamic needs of stakeholders and the context for implementation of evidence-based practices. This evaluation informs the initial tailoring and refinement of the IF, which includes a bundle of services tailored to meet site-specific needs, such as identifying and engaging local stakeholders, providing extensive ongoing education, tailoring program to the site and monitoring performance and offering feedback."
1987739|NCT03019289|Drug|pridopidine (90 mg)|single dose will be administered in Cohort 1. Other optional cohorts 2 and 3 may include single dose 0.5 mg, 1 mg, 2.5 mg, 5 mg, 10 mg, 22.5 mg, 45 mg, or 67.5 mg. The dose will be selected based on the results obtained from Cohorts 1 and 2.
1987745|NCT03017924|Device|Q collar|q-collar concussion prevention device
1987747|NCT03016715|Drug|Sirolimus 2%|
1987748|NCT03016715|Drug|Vehicle|
1987772|NCT03010423|Drug|Nicorandil|Subjects will be administered nicorandil 5 milligram (mg) tablet, three times a day for 12 weeks
1987773|NCT03010423|Drug|Standard treatment|Subjects will continue to take the standard treatment, which is stabilized at least one month before screening period without any other newly added drugs. The standard treatment will include but is not limited to aspirin/clopidogrel, calcium channel blockers (CCB), angiotensin-converting-enzyme inhibitor (ACEI)/Angiotensin receptor blockers (ARBs), beta-blockers, statins if condition permits.
1987797|NCT03002077|Drug|Rapastinel|Rapastinel pre-filled syringes for IV injections.
1987807|NCT03000569|Drug|SAGE-217|
1987808|NCT03000569|Drug|Antiparkinson Agents|
1987809|NCT03000530|Drug|SAGE-217|
1987810|NCT03000530|Drug|Placebo|
1987831|NCT02994927|Drug|CCX168|Orally administered
1987832|NCT02994927|Drug|Prednisone|Orally administered
1987833|NCT02994927|Drug|Cyclophosphamide|Orally or intravenously administered
1987834|NCT02994927|Biological|Rituximab|Intravenously administered
1987835|NCT02994927|Drug|Azathioprine|Orally administered
1987837|NCT02995590|Drug|Hyperpolarized Helium|Hyperpolarized Helium can be used as a Contrast Agent for Lung Images using MRI.
1987851|NCT02991495|Biological|Stamaril, Sanofi Pasteur|"Full dose
Fractional dose: one fifth (1/5)"
1987852|NCT02991495|Biological|Yellow fever vaccine, Bio-Manguinhos|"Full dose
Fractional dose: one fifth (1/5)"
1987853|NCT02991495|Biological|Yellow fever vaccine, Institut Pasteur|"Full dose
Fractional dose: one fifth (1/5)"
1987854|NCT02991495|Biological|Yellow fever vaccine, Chumakov Institute|"Full dose
Fractional dose: one fifth (1/5)"
1987877|NCT02987686|Drug|Topical Infliximab|Aside from the standard treatment, patients will receive topical infliximab ( 10mg/ml) four (4) time per day for four (4) weeks.
1987887|NCT02983799|Drug|OLAPARIB|300 mg olaparib tablets taken orally twice daily
1987888|NCT02984111|Drug|normal saline|
1987889|NCT02984111|Drug|erythropoietin|
1987896|NCT02981680|Procedure|Remote Ischemic Preconditioning (RIPC)|Remote ischemic preconditioning (RIPC) is a phenomenon in which brief ischemia of one organ or tissue, provokes a protective effect that can reduce the mass of infarction caused by vessel occlusion and reperfusion.
1987897|NCT02981680|Procedure|sham-RIPC|
1987909|NCT02977780|Drug|Temozolomide|Temzolomide capsules
1987910|NCT02977780|Drug|Neratinib|Neratinib tablets
1987911|NCT02977780|Drug|CC-115|CC-115 capsule
1987912|NCT02977780|Drug|Abemaciclib|Abemaciclib capsules
1987919|NCT02975245|Procedure|Semen collection and analysis|Semen sample will be collected prior to the initiation of chemotherapy and one week after the first round of chemotherapy.
1987943|NCT02968290|Procedure|Cataract Surgery|Implant of intraocular lens hydrophobic or Implant of intraocular lens hydrophilic (Device)
1987944|NCT02968290|Device|Alcon AcrySof SA60AT|Implant of intraocular lens hydrophobic
1987945|NCT02968290|Device|Bausch Lomb AkreosA|Implant of intraocular lens hydrophilic
1987967|NCT02961556|Drug|AJG555|Participants will receive 1 to 6 sachets daily per participants' age and conditions.
1987974|NCT02959125|Other|NutFish Based Food Supplementation|Cookies contain 500 Calories and 15 gram protein make from nut and ocean fish
1987975|NCT02959125|Dietary Supplement|Multiple micronutrients|Vitamin A 5000 iu, vitamin D 400 iu, vitamin C 100 mg, vitamin B1 7.5 mg, vitamin B2 3 mg, vitamin B6 10 mg, vitamin B12 10 mcg, fluoride 1 mg, Fe fumarate 91 mg, niacinamide 20 mg, Ca pantothenate 7.5 mg, folic acid 400 mcg, Zn 5 mg, Ca lactate 250 mg, copper 0.1 mg, iodine 0.1 mg
1987976|NCT02959125|Behavioral|Health Education in Pregnancy Class|Health education on pregnancy, complication, and breastfeeding by research team members
1987977|NCT02959125|Other|Government Food Supplementation|Cookies contain 500 Calories and 5 gram protein make from flour and egg
1987978|NCT02959125|Dietary Supplement|Fe Supplementation|Ferrous Fumarate 60mg and folic acid 0.400 mg
1987981|NCT02957617|Drug|BIIB074|Participants will receive an initial dose orally twice daily (BID) for up to 12 months.
1987983|NCT02957422|Dietary Supplement|1% Milk|1.5 gallons of 1% milk will be delivered to the participant's home weekly. Participants will be asked to drink 3 cups per day for 3 months.
1987984|NCT02957422|Dietary Supplement|Control|Participants will continue on their regular low dairy diet of ≤1.5 dairy serving/day.
1987985|NCT02954887|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1987992|NCT02954211|Device|repetitive transcranial magnetic stimulation (rTMS)|"rTMS can be given to either the stroke or nonstroke hemisphere. For the nonstroke hemisphere, priming rTMS will be given to the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by 25-s OFF period. The ON-OFF cycling continues for 10 min. Principal rTMS follows priming and is applied at the same intensity at 1 Hz continuously for 10 minutes. The rationale for 6-Hz priming is to make the 1-Hz principal rTMS more effective. The after-effects of the principal rTMS are inhibition of the underlying neurons in the nonstroke hemisphere, which has a facilitating effect on the stroke hemisphere.
For the stroke hemisphere, rTMS will involve 6-Hz stimulation at the optimal spot at an intensity of 90% of threshold at a frequency of 6 Hz for a 5-s ON period followed by a 25-s OFF period. The ON-Off cycling continues for 10 minutes. With either form of rTMS, the desired effects of the rTMS are facilitation of the neurons in the stroke hemisphere."
1987993|NCT02954211|Behavioral|Physical therapy|Following the total rTMS treatment and a 3-minute break, physical therapy treatment will commence. The physical therapy treatment will consist of 15 minutes of finger movement tracking training followed by 15 minutes of virtual hand exercises. The tracking involves placing an small device on the weak hand that records finger motion and moving the index finger into finger extension and flexion to track a computer screen cursor as accurately as possible along a target track. The virtual hand exercises involve placing the weak hand in front of a computer with a program that will show a virtual hand and some blocks on a computer screen. The patient will attempt to stack the blocks by doing active hand movements that control the virtual hand. Another virtual hand exercise involves using the thumb and index finger to pluck petals from a virtual flower shown on the screen. There are further exercises like this.
1987994|NCT02953548|Drug|GWP42003-P|Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
1987998|NCT02951988|Drug|Rapastinel|Rapastinel pre-filled syringes for IV injections.
1987999|NCT02951988|Drug|Placebo-matching Rapastinel|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
1988004|NCT02950168|Procedure|Edoxaban|Edoxaban according to Summary of Product Characteristic (SMPC)
1988019|NCT02945631|Radiation|PTV56|total dose of 56 Gy in 2.0 Gy/fraction x 28 fractions.
1988020|NCT02945631|Radiation|PTV50.4|total dose of 50.4 Gy in 1.8 Gy /fraction x 28 fractions.
1988021|NCT02944019|Drug|Edoxaban|Prescribed according to approved label
1988022|NCT02943577|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
1988023|NCT02943577|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
1988024|NCT02943564|Drug|Rapastinel|Rapastinel pre-filled syringes for weekly IV injections.
1988025|NCT02943564|Drug|Placebo|Placebo-matching rapastinel pre-filled syringes for weekly IV injections.
1988042|NCT02940106|Device|Cryotop device|a different device for oocyte vitrification (with a very high cooling rate)
1988043|NCT02940106|Device|CBSvit device|a different device for oocyte vitrification (with a lower cooling rate)
1988050|NCT02937818|Drug|Durvalumab and Tremelimumab|Durvalumab + tremelimumab via intravenous (IV) infusion every 4 weeks (q4w), starting on Week 0, for up to a total of 4 months (4 cycles) followed by durvalumab monotherapy via IV infusion q4w, starting on Week 16 until PD, or for other discontinuation criteria.
1988051|NCT02937818|Drug|AZD1775 and carboplatin (CBPT)|AZD1775 twice daily (oral) for 2.5 days from Day 1 + CBDP area under the curve 5 (Day1) (IV); every 3 weeks.
1988052|NCT02937532|Behavioral|GHE + TOBT training|All subjects will receive 45 minutes of GHE, followed by 45 minutes of TOBT program twice a week for 8 weeks.
1988053|NCT02937532|Behavioral|CBT + TOBT training|All subjects will receive 45 minutes of CBT, followed by 45 minutes of TOBT program twice a week for 8 weeks.
1988060|NCT02937285|Drug|Interferon beta 1a|Subcutaneous injection of 44µg 3 times a week
1988061|NCT02937285|Drug|Mitoxantrone|10 mg / m² monthly infusion for 6 months
1988067|NCT02935309|Drug|Lenvatinib|Pre-surgery Lenvatinib, days 1 - 5. Dose Escalation Levels: 1.) 10 mg by mouth (PO) daily (QD); 2.) 14 mg PO QD; 3.) 20 mg PO QD; 4.) 24 PO QD.
1988068|NCT02935309|Drug|Capecitabine|Pre-surgery Capecitabine, 850 mg/m^2, twice a day (BID) on days 1-5 for 5½ -6 weeks.
1988069|NCT02935309|Radiation|External Radiation Therapy (XRT)|Pre-surgery RT: Participants will receive 6 weeks of radiation therapy. The radiation sessions will be daily, Monday through Friday, except for holidays.
1988071|NCT02933437|Drug|Ajmaline|Ajmaline 1milligram/kilogram max dose as bolus intravenous over 10 minutes with continuous ECG monitoring
1988074|NCT02933606|Drug|BNC210|
1988075|NCT02933606|Drug|Placebo|
1988085|NCT02930824|Genetic|CYP2C19 genotyping|All proton pump inhibitors are metabolized in part by the CYP2C19 enzyme, which is encoded by the highly polymorphic CYP2C19 gene. Based on variations within this gene the effectiveness of the drug may be reduced.
1988100|NCT02927080|Drug|ACE-083|Recombinant fusion protein.
1988101|NCT02927080|Drug|ACE-083 or placebo|Recombinant fusion protein or buffer solution.
1988104|NCT02926664|Other|measurement of qSOFA|qSOFA will be measured at H0, H1 and H3
1988108|NCT02923583|Biological|M834|
1988109|NCT02923583|Biological|US-Sourced Orencia®|
1988110|NCT02923583|Biological|EU-Sourced Orencia®|
1988111|NCT02923115|Drug|DS-1040b|injection
1988112|NCT02923115|Drug|placebo|0.9% Sodium Chloride Injection
1988117|NCT02921516|Behavioral|N'ap Grandi|Eight 90-minute adolescent cognitive behavioral modules and four 90-minute caregiver cognitive behavioral modules, delivered in weekend workshops over a 1 month period, with the last two modules for joint participation of adolescents and caregivers.
1988118|NCT02921516|Behavioral|N'ap Grandi - A|Eight 90-minute adolescent cognitive behavioral modules delivered in weekend workshops over a 1 month period.
1988119|NCT02921516|Behavioral|Health Promotion - A|Eight 90-minute adolescent health promotion modules delivered in weekend workshops over a 1 month period.
1988132|NCT02921035|Drug|Rebif (Interferon beta-1a)|Rebif will be administered at a dose of 44 mcg, sc, tiw.
1988146|NCT02914522|Drug|Filgotinib|Tablet(s) administered orally once daily
1988147|NCT02914522|Drug|Placebo to match filgotinib|Tablet(s) administered orally once daily
1988162|NCT02911740|Other|Urine LAM Ag test|TB diagnostic assay
1988164|NCT02908555|Other|No intervention|This is a descriptive study with no intervention
1988165|NCT02908685|Drug|Placebo|Placebo will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
1988166|NCT02908685|Drug|RO7034067|RO7034067 will be administered orally (via mouth) or through a feeding tube (naso-gastric or gastrostomy tube).
1988170|NCT02908178|Procedure|Sentinel lymph node biopsy (SLNB)|Intervention is defined as that the DCIS patient has undergone SLNB. Patients in each cohort (group) include those who underwent SLNB (intervention) and those who did not (control).
1988179|NCT02907398|Device|Inspire therapy|
1988180|NCT02907398|Other|No intervention|
1988186|NCT02901548|Drug|Durvalumab|Durvalumab will be given every 4 weeks at 1500 mg/kg IV for total of 12 months/13 doses.
1988187|NCT02901548|Procedure|Cystoscopy with Biopsy|Cystoscopy with biopsy and transurethral resection of the bladder tumor (TURBT) (if indicated) will be performed at baseline, month 3, 6, 9, 12, 18, and 24. The month 6 and 24 cystoscopy will be done in the operating room with mapping biopsy. Rest of the cystoscopic exam with biopsy will be performed in the out-patient office setting and if clinically indicated will be repeated in the operating room. Participants will be off study if any of the biopsies document muscle invasive (T2 or above) urothelial carcinoma. Participants will also be off study if their month 6, 9, 12, 18 biopsies show persistent (month 6) or recurrent CIS or invasive (T1 or above) urothelial carcinoma. Otherwise, participants will remain on study until after the month 24 mapping biopsy.
1988196|NCT02900820|Other|Discontinuing antibiotic therapy|Patients assigned to this group will be asked to discontinue antibiotic therapy.
1988197|NCT02900820|Other|Continuing antibiotic therapy|Patients assigned to this group will be asked to complete antibiotic therapy.
1988206|NCT02898207|Other|Laboratory Biomarker Analysis|Correlative studies
1988207|NCT02898207|Drug|Olaparib|Given PO
1988208|NCT02898207|Drug|Onalespib|Given IV
1988209|NCT02898207|Other|Pharmacological Study|Correlative studies
1988248|NCT02887703|Behavioral|Sensory Augmentation|Sensory augmentation is a technique of augmenting or replacing compromised sensory information. In the context of sensory-based balance impairments, a sensory augmentation device provides cues of body motion that supplement an individual's remaining intact sensory systems.
1988254|NCT02884635|Drug|ASP1707|Oral
1988255|NCT02884635|Drug|Placebo|Oral
1988271|NCT02875015|Drug|Liposomal Bupivacaine|20 mL of Liposomal Bupivacaine (EXPAREL) will be diluted in 80 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars
1988272|NCT02875015|Drug|Bupivacaine Hydrochloride and Lidocaine|Bupivacaine Hydrochloride (HCL) and Lidocaine. Fifty mL of 0.05% Marcaine and 30 mL of Lidocaine will be diluted in 100 mL of injectable saline used for hydro-dissection of the vesicovaginal space and along the track of the sling trocars during the placement of a suburethral sling.
1988273|NCT02875015|Procedure|Suburethral Sling|A retropubic, transobturator or mini-sling will be placed in the usual fashion followed by diagnostic cystoscopy.
1988276|NCT02874014|Radiation|Hypofractionation Proton beam therapy with Concurrent Treatment of the Prostate and Pelvic Nodes|
1988281|NCT02873273|Drug|Dexamethasone|Sustained delivery system containing 5.0 mg of dexamethasone programmed to release an estimated 10 μg per day
1988317|NCT02858206|Radiation|IMRT simultaneous integrated boost|To achieve a prophylactic dosage and radical dosage of 1.8Gy and 2.14Gy once respectively
1988318|NCT02858206|Drug|Nimotuzumab|nimotuzumab 400mg per week which start from 1 week before radiotherapy and in the following 4 weeks
1988319|NCT02858206|Drug|Paclitaxel|Paclitaxel from 45 to 60 mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
1988320|NCT02858206|Drug|Nedaplatin|Nedaplatin 25mg/m2 per week which start from 1 week before radiotherapy and in the following 4 weeks
1988321|NCT02858206|Procedure|Esophagectomy|Radical esophagectomy 4-6 weeks after neoadjuvant therapy
1988324|NCT02855268|Drug|RG-012|RG-012 in 0.3% sodium chloride
1988325|NCT02855268|Drug|Placebo|matching placebo for injection
1988356|NCT02851056|Biological|Survivin Vaccine|"Pre-transplant vaccination : The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, Human Leukocyte Antigen - antigen D Related (HLA-DR)+ by flow-cytometry) is 15 x 10^6 cells. A minimum of 1 x 10^6 cells and a maximum of 20 x 10^6 cells will be administered.
Post-transplant vaccination: The target dose of Survivin+ Dendritic cells (survivin+, CD11c+, HLA-DR+ by flow-cytometry) is 15 x 10^6 cells. A minimum of 1 x 10^6 cells and a maximum of 20 x 10^6 cells will be administered."
1988357|NCT02851056|Procedure|Autologous Hematopoietic Cell Transplantation|The participant's own cells are collected from their blood, frozen, and then given back to them after they receive chemotherapy.
1988358|NCT02851056|Biological|Prevnar 13|13-Valent Pneumococcal Conjugate Vaccine (PCV13, Prevnar13). Co-Immunization: All participants will be co-immunized with Prevnar at each time they receive the survivin vaccine. This vaccine will be administered intramuscular (IM) 0.5cc.
1988359|NCT02851056|Drug|Granulocyte-colony Stimulating Factor|After the first survivin vaccination, participants will be mobilized with G-CSF.
1988362|NCT02851511|Behavioral|Cognitive Training|Cognitive Training employs an eight component, PositScience BrainHQ suite via its researcher portal.
1988363|NCT02851511|Device|tDCS (active stimulation)|A Soterix Clinical Trials Direct Current Stimulator will apply 20 minutes of 2.0mA direct current through two biocarbon rubber electrodes encased in saline soaked 5cm x 7cm sponges (8cc of 0.9% saline solution per sponge) placed over the frontal cortices at F3 and F4 (10-20 system).
1988364|NCT02851511|Device|tDCS (sham stimulation)|Sham stimulation is performed with the same device and all procedures will be identical except for the duration of stimulation. Participants will receive 30 seconds of 2 mA of direct current stimulation at the beginning of the session. Participants habituate to the sensation of tDCS within 30-60 seconds of stimulation. This procedure provides the same sensation of tDCS without the full duration of stimulation, making it a highly effective sham procedure.
1988365|NCT02851511|Behavioral|Educational Training|Educational training involves watching educational videos produced by the National Geographic Channel, which cover a range of topics such as history, nature, and wildlife. Participants will be asked to complete questions on the content of the videos to ensure sustained attention.
1988369|NCT02846532|Drug|Rivaroxaban|Participants will receive oral suspension containing rivaroxaban 1 milligram per milliliter (mg/ml) twice daily in Part A and Part B. Following total daily doses of Rivaroxaban will be administered based on the weight of the participants: 7 to <8 kilogram (kg) will receive 2.2 milligram (mg); 8 to <10 kg will receive 3.2 mg; 10 to<12 kg will receive 3.4 mg; 12 to <20 will receive 4.0 mg and 20 to <30 will receive 5.0 mg.
1988370|NCT02846532|Drug|Acetylsalicylic Acid|Participants will receive 5 milligram per kilogram (mg/kg) of acetylsalicylic acid once daily up to 12 months in Part B.
1988385|NCT02842073|Drug|Naltrexone|Standard clinical doses of naltrexone 50 mg/d dispensed by the UNC Investigational Drug Services. Naltrexone will be initiated at 25 mg/d from Days 7-9 and then go to 50 mg/d for Days 10-84.
1988386|NCT02842073|Drug|Bupropion|Standard clinical doses of bupropion-XL 300 mg/d (lower seizure risk) dispensed by the UNC Investigational Drug Services. Bupropion XL will be initiated at 150 mg/d on Days 1-4 and increased to 300 mg/d for Days 5-84.
1988395|NCT02839707|Drug|Atezolizumab|Given IV
1934293|NCT02938351|Behavioral|Collaborative care|
1988396|NCT02839707|Biological|Bevacizumab|Given IV
1988397|NCT02839707|Other|Laboratory Biomarker Analysis|Correlative studies
1988398|NCT02839707|Drug|Pegylated Liposomal Doxorubicin Hydrochloride|Given IV
1988399|NCT02839707|Other|Quality-of-Life Assessment|Ancillary studies
1933165|NCT03308721|Drug|NNC9204-1177 A 1.0 mg/mL|"Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
Dose gradually increased to 6000 μg."
1933166|NCT03308721|Drug|PLACEBO|Participants will get 1 or more injections into the skin of the stomach area once each week for 12 weeks.
1933167|NCT03308708|Drug|Norepinephrine infusion|Norepinephrine infusion (5miclml) is immediately started after spinal anesthesia. Rate starts at 30 ml/h and modified according to hemodynamic state
1933171|NCT03308682|Drug|177Lu-DOTA-EB-TATE|The patients were intravenously injected with single dose 0.50GBq-0.70GBq (13.5-18.9 mCi) of 177Lu-DOTA-EB-TATE and monitored at 2, 24, 72, 120 and 168 hours post-injection.
1933176|NCT03308643|Drug|Oxytocin|Patients will receive intravenous oxytocin infusion just before the surgery after the induction of general anesthesia.
1933177|NCT03308643|Other|saline|Patients will receive intravenous normal saline infusion just before the surgery after the induction of general anesthesia.
1933214|NCT03308331|Other|Tobacco smoking and nicotine patch|Tobacco smoking at each participant's regular cigarette. Over-the-counter nicotine patch use
1933178|NCT03308630|Behavioral|Yoga based Energy Alignment and Mantra|"Yoga intervention was based on the concept that there is not just a physical body, but a subtle energy body can be bound with residue of stress, unprocessed emotions, and excess mental energy. Using Yoga based practices combined with Mantra chants, Music and energy alignments poses, stress induced pain can be alleviated."
1933179|NCT03308604|Drug|Polysiloxane Gd-Chelates based nanoparticles (AGuIX)|"Three intravenous injections of AGuIX will be delivered.
The first injection of AGuIX will be delivered intravenously the 1st day and the 11th day of EBRT. The first injection will be preceded with an MRI (unenhanced T1 and T2 sequences) then followed with another MRI performed 4 hours later, to monitor tumor uptake.
Irradiation will be performed after the second MRI.
The second injection will be followed by an MRI 4 hours later
The third injection will be delivered intravenously the day of the brachytherapy procedure. Intravenous hydration will be performed during all brachytherapy courses to ensure AGuIX clearance.
Up to three dose levels may be explored: 20mg/kg (level -1), 30 mg/kg (level 1) and 50 mg/ kg (level 2). The starting dose level will be 30mg/kg."
1933180|NCT03308604|Radiation|External beam radiotherapy (EBRT)|to the pelvis, with intensity modulated technique: 45 Gy in 5 weeks, with integrated boost to 55 - 57.5 Gy in case of macroscopic lymph node metastases
1933181|NCT03308604|Radiation|Uterovaginal brachytherapy|15 Gy (maximal interval between EBRT and brachytherapy: 14 days).
1933182|NCT03308604|Drug|Chemotherapy (cisplatin)|Concomitant weekly intravenous cisplatin 40 mg/m2 will be delivered (total 5 cycles).
1933183|NCT03308591|Drug|NACT|Platin based chemotherapy
1933184|NCT03308591|Procedure|RT+PLND|radical hysterectomy+pelvic lymphadenectomy
1933185|NCT03308591|Drug|Adjuvant chemotherapy|Platin based chemotherapy
1933186|NCT03308578|Drug|Atorvastatin|Subjects randomized to this arm will receive 40 mg capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
1933187|NCT03308578|Drug|Placebo oral capsule|Subjects randomized to this arm will receive placebo capsules, once daily dose for the first 4 weeks followed by 2X40mg capsules, once daily dose for remaining 5 months of the study
1933188|NCT03308565|Biological|Autologous, Adipose derived Mesenchymal Stem Cells|The mesenchymal stem cells will be collected and expanded from the subjects adipose tissue.
1933197|NCT03308487|Dietary Supplement|vitamin D3 (1000 IU)|
1933198|NCT03308487|Dietary Supplement|Vitamin D3 (2000 IU)|
1933199|NCT03308474|Other|Routine care as per site standard.|Physician's choice according to patient's needs.
1933200|NCT03308461|Drug|Fecal Microbiota suspension|The prepared microbiota suspension was infused into mid-gut.
1933206|NCT03308422|Behavioral|parental representations|parental representations of the impact of the use of screens on their preschool children health and development
1933207|NCT03308409|Other|Low-intensity extracorporeal shock wave therapy (Li-ESWT)|Low-intensity shock waves are acoustic wavelengths which are transmitted continuously at a frequency between 16 and 20 megahertz for under 10 microseconds. They generate a pressure pulse and transport energy as they propagate through a medium. Three different methods can be used to generate this type of wave: electro-hydraulics, electro-magnetics and piezoelectricity. Regardless of the method, when the shock waves are applied to an organ they interact with the deep tissue. This causes stress and small mechanical traumas, activating the release of angiogenic factors which induce new vascularization of the affected tissue, thereby improving blood flow.
1933211|NCT03308370|Biological|Platelet rich plasma|10 ml of blood will be drawn from the patients on an anticoagulant then it will be centrifuged to get platelet rich plasma that will be injected in the melasma lesions of the patients after its activation with calcium chloride.
1933213|NCT03308344|Behavioral|Mindfulness training|The present MT program includes topics related to mindfulness, emotion regulation, and compassion. The content will be delivered in 15 hours via in-person and online sessions over 6 weeks.
1933218|NCT03308266|Diagnostic Test|electromyography|
1933219|NCT03308253|Device|Stimulan Rapid Cure|Calcium sulfate dissolvable beads
1933220|NCT03308253|Drug|Vancomycin|0.5 g Vancomycin per patient
1933221|NCT03308253|Drug|Tobramycin|120 mg tobramycin per patient
1933222|NCT03308253|Other|Standard of Care|Standard of care provided at Hamilton General Hospital consisting of dressings for the wound.
1933223|NCT03308240|Behavioral|Magic Therapy|As described in the arm description
1933226|NCT03308188|Behavioral|E-health program|The Goalistics Chronic Pain Management Program, referred to as the E-health program in EMPOWER, was developed from cognitive, behavioral, interpersonal, and self-management interventions with demonstrated efficacy in traditional face-to-face or group settings. It is patient-centered, having been developed based on substantial input from people with chronic pain and chronic pain professionals.
1933229|NCT03308162|Behavioral|Cognitive behavioral experiential group therapy|The Kickstart Health Program is a Cognitive-Behavioral Experiential Therapy (CBET) that is administered via a person-centered group therapy format. Participants receive multiple therapeutic components that include psychoeducation, cognitive behavioral therapy, motivational interviewing, mindfulness, and acceptance and commitment therapy. Participants will also meditate and exercise in the group.
1933230|NCT03308149|Drug|infiltration with triamcinolone and bupivacaine|facet joint infiltration
1933231|NCT03308136|Procedure|1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.|1) In group A, 1ml of local anesthetics (1% Lidocaine) were injected into the subcutaneous layer.
1933232|NCT03308136|Procedure|1ml of a local anesthetics (1% idocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.|2) In group B, 1ml of a local anesthetics (1% Lidocaine) are first injected into the subcutaneous layer, followed by 3~4ml of local anesthetics to the muscle layer along the expected needle pathway.
1933233|NCT03308136|Drug|1% Lidocaine|1% Lidocaine
1933234|NCT03308123|Other|Observational study, not interventional|Not an intervention study
1933235|NCT03308110|Drug|PF-06650833|Two formulations of PF-006650833
1933236|NCT03308097|Behavioral|PrEP Mobile Messaging Intervention|See group description
1933237|NCT03308097|Behavioral|Enhanced Standard of Care|See group description
1933238|NCT03308084|Drug|Methylprednisolone|Application of 80mg Depomedrol (methylprednisolone acetate) suspension into the transforaminal space prior to incision closure
1933239|NCT03308084|Drug|Dexamethasone|Administration of 10mg Dexamethasone IV intraoperatively
1933240|NCT03308071|Behavioral|Hypnosis|Hypnotic induction, relaxation, and guided imagery specific to perioperative symptoms will be administered.
1933241|NCT03308058|Behavioral|Breastfeeding computer education|Breastfeeding computer education
1933242|NCT03308045|Biological|pEYS606|pEYS606 is a DNA plasmid solution administered by electrotransfection into the ciliary muscle
1933243|NCT03308032|Behavioral|Intervention|SDL intervention employs a comprehensive engagement design that includes seven innovative strategies: 1) customization of content of the training curriculum to fit individual learner's needs; 2) tailoring the length of trainings by using short video clips to allow caregivers flexibility in completing the curriculum; 3) using an instructional format (SCHOLAR) designed to maximize active learning during each training lesson; 4) progress tracking to help the learner stay focused and motivated; 5) a recommendation algorithm that facilitates the learner's transition from one training topic to the next; 6) behavioral economics-based messages, to re-engage the learner if he/she stops participating
1933244|NCT03308032|Behavioral|Control|Participants in the control group will be invited to a comparable online training course consisting of all of our training video clips, without the interactive engagement design features. These represent standard video training based on evidence-based content.
1933245|NCT03308019|Device|Photodynamic therapy|In groups 1 and 2, aPDT was performed after SRP. The protocol for aPDT is described elsewhere. Briefly, using a blunt needle, 0.005% of Methylene blue was applied into the periodontal pocket and left in place for 10 seconds. The dye was then irradiated with a diode laser (670 nanometers) at 150 milliwatts. In each dye filled periodontal pocket, laser irradiation was performed for one minute using a flexible tip. In the present study, aPDT was performed once, at baseline, by a trained dentist.
1933246|NCT03308019|Procedure|Scaling and root planing (SRP)|In both groups, SRP was performed in one session under local anesthesia using handheld Gracey curettes No. 5/6. One trained dental hygienist blinded to the study groups and subgroups made 9 to 10 strokes in a vertical (apico-coronal) direction and the inclination between scaler tips and roots was maintained as zero. When the curved explorer indicated a smooth and hard dental surface, SRP was judged as completed. In all individuals, SRP was done in one session without any assigned time limit for completion.
1933308|NCT03307577|Drug|UHE-101 Cream|Topical cream containing investigational drug at a concentration of 1%
1933309|NCT03307577|Other|Vehicle Cream|Topical cream containing no drug (i.e., placebo)
1933247|NCT03308006|Biological|Stem cells|Participants will be exposed to e abdominal liposuction procedure under local anesthesia for stem cells harvesting. Stem cells will be separated from fat cells in the adipose tissue then activated in Tissue Culture Lab at Research Center- Jeddah. The activated stem cells will be injected into the knee joint via 22G spinal needle. The intra-articular stem cells injections will be performed under Ultrasound guidance at the theater under spinal anesthesia. Each patient will receive 1.0× 108 stem cells in 3 mL of normal saline.
1933248|NCT03307993|Drug|Idalopirdine|Idalopirdine 60-120 mg daily dose
1933249|NCT03307980|Genetic|SPK-9001|Observational long-term safety follow-up study of subjects previously treated in the SPK-9001-101 protocol
1933251|NCT03307954|Device|Ekso Therapy (Exoskeleton Suit)|
1933252|NCT03307954|Other|Usual Physiotherapy|
1933253|NCT03307941|Drug|Monalizumab|Monalizumab (IPH2201) is given at the recommended dose of 10 mg/kg, intravenously (infusion during 60 minutes) every two weeks
1933254|NCT03307941|Drug|Oxaliplatin|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
1933255|NCT03307941|Drug|5-Fluorouracil|A total of 4 cycles of FOLFOX is administrated every 2 weeks with one cycle 15 days prior to the radiotherapy and 3 cycles during the radiotherapy whatever the level
1933256|NCT03307941|Radiation|Metabolic|Radiation therapy must start the first day of FOLFOX chemotherapy. Radiation is given once daily for 5 consecutive days; on the days that the patient receives chemotherapy (and monalizumab when applicable), chemotherapy (and monalizumab) should be given prior to radiotherapy.
1933257|NCT03307941|Other|Metabolic|18-FDG-PET scan will be performed just before the beginning of radio-chemotherapy (D10-D14) and will be blinded for investigators and patients. Another 18-FDG-PET will be performed before surgery (surgery Day-5 to surgery Day -1) to exclude metastatic evolution
1933258|NCT03307941|Procedure|Surgery|Surgery is performed preferably 8 weeks after the completion of the radio-chemotherapy, and it should not be performed less than one week after the last dose of monalizumab
1933259|NCT03307928|Diagnostic Test|Cardiopulmonary Exercise Test Protocol|The CPET was performed in a cycle ergometer with electromagnetic braking using an Inbrasport (Inbrasport, Porto Alegre, Rio Grande do Sul, Brazil). Following a 5-min warm-up against no resistance (0 W), the work rate was increased using a ramp protocol (5-10 W.min-1) until maximum exercise tolerance. Verbal encouragements were given during the CPET to ensure maximal effort.
1933260|NCT03307928|Diagnostic Test|Polysomnography Assessment|The polysomnography assessment was carried out during an entire night of sleep in the participant's residence with no use of sedatives. The variables were monitored by an Embletta portable respiratory monitor (Embla, Embletta® Gold, EUA), previously validated, and in agreement with manufacturer's instructions. The Embletta monitor was capable to monitor continuously the pulse oximetry, to detect respiratory efforts, to measure the airflow, and to record snoring episodes. Additionally, HR was continually measured by the analysis of pulse waves by oximetry. Finally, brain and muscle activities were monitored by electrodes and oxygen desaturation (O2D) was defined as the amount of reduction in O2S in 4%/h.
1933265|NCT03307902|Biological|Imiquimod + ID HBVv|Imiquimod ointment + intradermal 10μg Sci-B-Vac vaccine
1933266|NCT03307902|Biological|Aqueous + ID HBVv|Aqueous ointment + intradermal 10μg Sci-B-Vac vaccine
1933267|NCT03307902|Biological|Imiquimod + IM HBVv|Imiquimod ointment + intramuscular 10μg Sci-B-Vac vaccine
1933268|NCT03307876|Other|autologous PPP injection|autologous platelet poor plasma (PPP) injection taken from the participants own blood is injected in to all patients.
1933269|NCT03307863|Drug|Carbamazepine-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
1933270|NCT03307863|Drug|Topiramate-Implant|Women with epilepsy using carbamazepine for at least 3 months will have an etonogestrel-releasing implant inserted
1933271|NCT03307863|Drug|Implant|Women without epilepsy and not using an anti-epileptic drug will have an etonogestrel-releasing implant inserted
1933272|NCT03307850|Other|Observation During Exercise and Stress|"Patients with type 1 diabetes (T1D) on an insulin pump will be studied for 5 weeks in the outpatient setting performing their normal activities, to include their normal diet and exercise, while assessing the amount of type of exercise performed, and emotional stress levels, using stress sensor, questionnaires and salivary cortisol levels.
Subjects at the William Sansum Diabetes Center will perform graded exercise on a treadmill for up to 45 minutes with all activity and stress monitors running, achieving 30 and 60% calculated heart rate reserve, once during the study. Subjects at Mayo Clinic will perform a graded exercise test on a treadmill to determine V02max and ensure stable cardiac status, once during the study."
1933273|NCT03307837|Drug|CA-008|The active moiety of CA-008, capsaicin that has certain properties for treatment of post-operative pain.
1933274|NCT03307837|Drug|CA-008 Placebo|Placebo product
1933275|NCT03307824|Device|Synthetic glue IfabondTM|Use of the synthetic glue IfabondTM
1933276|NCT03307824|Procedure|Glue-Free Suture Technique|Suture Technique
1933310|NCT03307551|Drug|Propofol|Propofol delivery will be controlled using automated closed loop anaesthesia delivery system which will control propofol delivery rate to consistent anaesthetic depth (BIS-50) feedback from the patient (CLADS group)
1933277|NCT03307811|Other|22 gauge needle liver biopsy|EUS will be performed. Specimens obtained from each pass will be placed in a separate biopsy jar. If the third pass does not result in sufficient diagnostic material, a 19 G will be used. A maximum of 3 passes will be made using the alternate needle. The total number of passes with the 22 G needle and the 19 G needle is 6. Data will be collected about the procedure and the performance of the needles for each procedure.
1933281|NCT03307772|Dietary Supplement|Probiotics|
1933282|NCT03307772|Dietary Supplement|Prebiotics|
1933283|NCT03307772|Dietary Supplement|Prebiotics and Probiotics|
1933284|NCT03307772|Dietary Supplement|Placebo|
1933285|NCT03307616|Drug|Nivolumab|"Arm A: Nivolumab 3 mg/kg by vein every 2 weeks (+/-3 days) on weeks 1, 3, and 5.
Arm B: Nivolumab 1 mg/kg by vein on week 1 followed by Nivolumab 3 mg/kg by vein every 2 weeks (+/- 3 days) on weeks 3 and 5.
Arm C: Nivolumab 3 mg/kg by vein every 2 weeks (+/-3 days) on weeks 1, 3, 5 and 7.
Arm D: Nivolumab 1 mg/kg by vein on week 1 followed by Nivolumab 3 mg/kg by vein every 2 weeks (+/-3 days) on weeks 3, 5 and 7."
1933286|NCT03307616|Drug|Ipilimumab|Arm B and D: Ipilimumab 3 mg/kg by vein on week 1.
1933287|NCT03307616|Radiation|Radiation Therapy|Arm C and D: Participants have radiation therapy 1 time each day, 5 days a week (Monday through Friday) from Day 15 to Day 47.
1933288|NCT03307746|Drug|Varlilumab|"Rituximab is a so-called direct-targeting mAb, which binds to the CD20 molecule on the surface of normal and malignant B cells. The mAb then engages immune effectors cells, such as macrophages, through Fc:Fc gamma receptor interaction, leading to tumour cell killing by antibody directed cellular cytotoxicity and/or phagocytosis (ADCC/ADCP).
Varlilumab (1F5, CDX-1127) is a recombinant and fully human IgG1kappa mAb that binds to human CD27 with high affinity (62). As far as we are aware, it is the only anti-CD27 mAb in clinical development. Once bound, varlilumab blocks CD70 binding to CD27."
1933289|NCT03307733|Behavioral|walking and behavour change techniques|a Fitbit pedometer with individualised step targets and partaking in a closed Facebook group
1933290|NCT03307720|Drug|Gonadotropin Releasing Hormone Agonists (GNRH-A)|Administration of a gonadotropin releasing hormone agonist (GnRH-a) (0,2 ml) subcutaneously, 36 hours before ovum pick-up in IVF treatments.
1933291|NCT03307720|Drug|Human chorionic gonadotropin|Administration of Human chorionic gonadotropin (HCG) 250 IU subcutaneously , 36 hours before ovum pick-up in IVF treatments.
1933292|NCT03307694|Diagnostic Test|Ultrasound|All ultrasound images will be acquired by an in-house ultrasound technologist using a Verasonics Vantage (Verasonics Inc., Kirkland, Washington, USA) ultrasound system. During imaging, the technologist will position the Verasonics transducer, under b-mode guidance, in planes overlying the thyroid nodules approximating those obtained during previous clinical ultrasound scans.
1933293|NCT03307694|Diagnostic Test|Shear wave elasticity imaging|"Shear wave elasticity imaging (SWEI) is obtained during the standard ultrasound session. The generation of shear wave images consists of two important steps called pushing and tracking. First, in the pushing mode, a long focused ultrasound beam is transmitted to perturb tissue, generating ultrasonic shear waves in tissue that propagate perpendicular to the direction of pushing. In the tracking mode, shear wave propagation is observed and recorded. Because the speed of shear waves is a function of Young's modulus, these data reveal information about the stiffness of underlying biological tissue."
1933294|NCT03307694|Diagnostic Test|Multi-angle compound shear wave elasticity imaging|The multi-angle compound SWEI (MAC-SWEI) algorithm, which generates shear images based on multiple angled push beams, has the potential to generate more accurate shear wave images in the context of thyroid imaging. To assess the MAC-SWEI technique, shear wave images will be used to generate estimates of the relative stiffness of lesions via their normalized Young's modulus.
1933300|NCT03307668|Device|CaReSR-1S|CaReSR-1S is a sterile, ready for use round implant based on a dense matrix of native Collagen type I.
1933301|NCT03307668|Device|Microfracture|Microfracture is an articular cartilage repair surgical technique that works by creating tiny fractures in the underlying bone. This causes new cartilage to develop from a so-called super-clot.
1933305|NCT03307759|Drug|Pembrolizumab|Pembrolizumab
1933306|NCT03307759|Radiation|Radiotherapy (SABR)|Radiotherapy
1933307|NCT03306563|Diagnostic Test|Sample collection|Samples of blood, urine and saliva will be collected at up to five successive time points.
1933311|NCT03307551|Drug|Propofol|Propofol delivery will be controlled using infusion pumps which will be manually controlled to deliver propofol to maintain consistent anaesthetic depth (BIS-50). (Manual group)
1933312|NCT03307356|Other|Uterine Transplant|Transplant of a uterus from a deceased donor
1933313|NCT03307343|Behavioral|Intervention|The intervention will be delivered by trained research staff who are exercise physiologists or behavioral lifestyle counselors. This target reflects a recent expert statement concluding that desk-based workers should reduce workday sedentary behavior by 2-4 hr (by increasing standing and movement). The approach will combine: behavioral strategies (self-monitoring, goal setting, problem solving, social support, stimulus control), environment modification (sit-stand attachment), and proximal (activity prompter) and distal (text messages) external prompts. The initial in-person session will occur at the participant's office location. During months 2 and 3, one-on-one in-person meetings will occur at the research lab. Telephone intervention contacts will occur in the 3rd week of months 1-3.
1933315|NCT03307239|Other|cold application|"We manufactured two ice packs (17 × 12 cm) with a combined weight of 600 g. The ice packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the ice packs was approximately 25 cm in diameter around the chest tube.
For patients of the experimental group, they were received 15-minutes cold application."
1933316|NCT03307239|Other|tap water packs application|"We manufactured two tap water packs (17 × 12 cm) with a combined weight of 600 g. The tap water packs were inserted into adjustable wraps made in our hospital so that they can be fixed next to the skin on each side of the chest tube in patients awaiting CTR. The combined contact area of the tap water packs was approximately 25 cm in diameter around the chest tube.
For patients of the sham group, they were received 15-minutes tap water application."
1933317|NCT03307187|Behavioral|GLB Adapted for Individuals with Impaired Mobility|The 12-month Group Lifestyle Balance program, Adapted for individuals with Impaired Mobility (GLB-AIM) promotes 5% - 7% weight loss by reducing calories and increasing energy expenditure to 150 minutes of weekly activity. The 23 GLB-AIM sessions were delivered through monthly in-person and teleconference calls. Participants were encouraged to self-monitor daily caloric/fat intake and physical activity using materials to accurately measure daily calories and exercise, which included a food scale, measuring cups and spoons and a loaned Garmin vívofit® activity tracker and heart rate monitor. Participants shared their logs with lifestyle coaches over the 13 core sessions and lifestyle coaches provided positive reinforcement, feedback, and problem solving techniques as needed.
1933319|NCT03306940|Drug|Botulinum Toxin Type A|patients were injected to the normal side with dose of 1.25 units/per site
1933324|NCT03305783|Procedure|cholecystectomy|elective cholecystectomy performed due to gallstones, cholecystitis or other non-malignant conditions and therefore done regardless of the protocol of this study.
1933329|NCT03303690|Procedure|Ankle Spacer (AS)|All included patients will be treated by means of surgical implantation of the Ankle Spacer prosthesis in an open manner replacing the talar side of the tibiotalar joint.
1933333|NCT03302715|Genetic|Mucosal tissue sampling|Mucosal tissue sampling for DNA analysis
1933370|NCT03285984|Other|0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride|Toothpaste containing 0% Sodium Bicarbonate without herbs plus 923ppm Sodium Fluoride
1933336|NCT03301038|Drug|Rifampin|Rifampin 5 mg/kg (max 300 mg) daily for 8 weeks, followed by rifampin 10 mg/kg (max 600 mg) daily for 8 weeks.
1933340|NCT03298152|Procedure|CERASMART Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using CERASMART blocks
1933341|NCT03298152|Procedure|Emax Endocrown|Endocrown fixed restoration used to restore endodontically treated anterior teeth using Emax material
1933342|NCT03296163|Drug|MB02 (Bevacizumab Biosimilar Drug)|15 mg/kg IV every 3 weeks on Day 1
1933343|NCT03296163|Drug|EU-approved Avastin®|15 mg/kg IV every 3 weeks on Day 1
1933344|NCT03296163|Drug|Carboplatin|Carboplatin AUC 6 IV every 3 weeks on Day 1 6 cycles
1933345|NCT03296163|Drug|Paclitaxel|Paclitaxel 200 mg/m2 IV every 3 weeks on Day 1 for 6 cycles
1933346|NCT03295500|Radiation|Dose fraction forms|The investigators divide the participants randomly into 3 groups by SPSS 19.0.Three groups participants receive the different dose fraction(49Gy/7f,54Gy/6f and 55Gy/5f),which also means different Biologic Equivalent Dose.Through the research,the investigators want to find out the optimum dose fraction method,which makes the treatment safe, effective and personalized.
1933352|NCT03293654|Drug|MB02|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
1933353|NCT03293654|Drug|US licenced Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
1933354|NCT03293654|Drug|EU approved Avastin®|Solution for intravenous infusion, single dose of 3mg/kg, administered as 90-minute infusion.
1933355|NCT03292588|Biological|Mepolizumab|Mepolizumab at a dose of 100 mg administered every 4 weeks by subcutaneous injection.
1933356|NCT03292588|Drug|Placebo|Placebo at a dose of 100 mg administered every 4 weeks by subcutaneous injection.
1933357|NCT03290885|Combination Product|Combined contact aspiration/Stent Retriever Technique|Combined contact aspiration/SR is performed using a balloon-guide catheter (BGC). A 0.021 to 0.027 inch inner lumen microcatheter with a 0.014 to 0.016 inch micro-wire inside is introduced into a large-bore aspiration catheter and this construct is introduced into BGC. The BGC is placed into the origin of the cervical internal carotid artery (ICA). The catheter is advanced past the thrombus over the micro-wire to allow the SR deployment. The SR is deployed across the occlusion. Then the large bore distal access catheter is advanced to contact the proximal edge of the SR. The aspiration pump is connected to the large bore distal access catheter. After at least 90 sec, the SR and the large bore distal access catheter are pulled out as an unit from the BGC and the patient. Manual aspiration is also be applied to the BGC during the pull-out manoeuver which is performed after the temporary inflation of the balloon at the tip of the BGC to ensure flow arrest into the carotid
1933358|NCT03290885|Device|Stent retriever technique|"The technique used should be in accordance with the device instruction for use. A large bore balloon guide catheter has to be placed into the cervical ICA.
A suitable delivery microcatheter is navigated over a micro-wire into the occluded major coronary artery MCA and across the occlusion. A control superselective angiogram may be used to document the extent of occlusion and thrombus. The stent retriever device is then deployed across the occlusion.
After at least 90 seconds, removal should occur with proximal occlusion by inflation of the balloon guide catheter."
1933367|NCT03285984|Other|67% Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride|Toothpaste containing 67 percent (%) Sodium Bicarbonate with 6 herbs plus 923parts per million (ppm) Sodium Fluoride
1933368|NCT03285984|Other|67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride|Toothpaste containing 67% Sodium Bicarbonate without herbs plus 923 ppm Sodium Fluoride
1933369|NCT03285984|Other|62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium|Whitening Toothpaste containing 62% Sodium Bicarbonate with 6 herbs and 5% w/w silica plus 923 ppm Sodium
1933376|NCT03284775|Device|Intraoperative ultrasound|Patients will undergo transsphenoidal surgery in the usual manner except that an intraoperative ultrasound device will be available for use to better visualise the tumour and surrounding neurovascular structures.
1933382|NCT03282656|Biological|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a|single infusion of autologous bone marrow derived CD34+ HSC cells transduced with the lentiviral vector containing a short-hairpin RNA targeting BCL11a
1933383|NCT03283319|Biological|3.75 ug Panblok H7|0.5 mL recombinant Panblok H7 influenza vaccine antigen 15 ug/mL.
1933384|NCT03283319|Biological|7.5 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 30 ug/mL.
1933385|NCT03283319|Biological|15 ug Panblok H7|Mix 0.5 mL recombinant Panblok H7 influenza vaccine antigen 60 ug/mL.
1933386|NCT03283319|Biological|MF59|0.5 mL MF59 (39 mg squalene/mL ) adjuvant.
1933387|NCT03283319|Biological|AS03|0.5 mL AS03 (42.4 mg squalene/mL ) adjuvant.
1933390|NCT03281629|Device|Active TMS stimulation|Multiple trains of active transcranial magnetic stimulation in a day, for multiple days.
1933391|NCT03281629|Device|Sham TMS stimulation|Multiple trains of sham transcranial magnetic stimulation in a day, for multiple days.
1933394|NCT03279289|Drug|Aflibercept|4 mg/kg administered intravenous infusion on day 1
1933395|NCT03279289|Drug|Irinotecan|180 mg/m2 intravenous infusion
1933396|NCT03279289|Drug|folinic acid (dl racemic)|400 mg/m2 intravenous infusion
1933397|NCT03279289|Drug|5Fluorouracil|400 mg/m2 intravenous bolus
1933398|NCT03279289|Drug|5-FU|2400 mg/m2 continuous intravenous infusion over 46 hours
1933400|NCT03278600|Genetic|tissue-of-origin (ORIGIN-PanCA○R) profiling|90-gene assay to predict the primary tumor site
1933405|NCT03276143|Drug|BAY1213790|single dose intravenous infusion
1933406|NCT03276143|Drug|Enoxaparin|daily subcutaneous injection
1933407|NCT03276143|Drug|Apixaban|twice daily oral administration
1933408|NCT03276442|Other|Low-fat dietary intervention|Low-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
1933409|NCT03276442|Other|High-fat dietary intervention|High-fat diet (5-7 days) preceding extended wakefulness under standardized conditions
1933414|NCT03275376|Drug|Atorvastatin 10mg|Atorvastatin or placebo will be administered according to randomized allocations.
1933415|NCT03275376|Drug|Placebo Oral Tablet|Atorvastatin or placebo will be administered according to randomized allocations.
1933419|NCT03271489|Drug|Elagolix|Tablets
1933420|NCT03271489|Drug|E2/NETA|Capsules
1933421|NCT03271489|Other|Elagolix Placebo|Tablets
1933422|NCT03271489|Other|E2/NETA Placebo|Capsules
1933437|NCT03267186|Drug|Ibrutinib|Given PO
1933438|NCT03267186|Other|Laboratory Biomarker Analysis|Correlative studies
1933440|NCT03266133|Behavioral|Sleep Education for Pregnancy|Sleep education specific to pregnancy
1933441|NCT03265223|Drug|0.2% ropivacaine|Intraperitoneal instillation versus intraincisional infiltration
1933444|NCT03262012|Drug|BGF MDI (PT010)|Budesonide, Glycopyrronium, and Formoterol Fumarate Inhalation Aerosol, BGF MDI, PT010
1933445|NCT03262012|Drug|GFF MDI (PT003)|Glycopyrronium and Formoterol Fumarate Inhalation Aerosol, GFF MDI, PT003
1933446|NCT03262012|Drug|BFF MDI (PT009)|Budesonide and Formoterol Fumarate Inhalation Aerosol, BFF MDI, PT009
1933447|NCT03262012|Drug|Symbicort® Turbohaler® Inhalation Powder|Budesonide and Formoterol Fumarate Inhalation Powder, Symbicort® Turbohaler® Inhalation Powder, Symbicort Turbohaler
1933454|NCT03262025|Procedure|Operated|Patients were either managed conservatively or underwent emergency laparotomy
1933509|NCT03243734|Device|trūFreeze® System spray cryotherapy|Subjects where trūFreeze® System spray cryotherapy is performed
1933923|NCT03090191|Biological|Placebo|Normal saline solution (0.9% sodium chloride)
1933465|NCT03254953|Behavioral|self-monitoring of body weight|- weigh daily for 3 months and track their weight using the MyFitnessPal mobile app
1933466|NCT03254953|Behavioral|self-monitoring of diet|"track their diet (food and drinks) daily using the MyFitnessPal mobile app
when they are asked to track diet will vary based on the arm"
1933467|NCT03254953|Behavioral|weekly personalized feedback + lessons + action plans|- these are additional evidence-based intervention components
1933468|NCT03254940|Behavioral|Charge|Text messaging-based study to determine effect of different components on weight loss.
1933469|NCT03254745|Other|Pharmacist led pharmaceutical care|The intervention in the study will be a pharmacist's intervention that will be provided to rheumatoid arthritis patients in order to improve their treatment outcomes. It will be in the form of a single (1) session by pharmacist (face-to-face) followed by written material for use at home. The pharmacist will look at the patient's baseline data and provide counseling. The venue for counseling will be the hospitals.
1933470|NCT03254199|Drug|FLX-787-ODT (orally disintegrating tablet)|FLX-787-ODT taken three times daily for 28 days
1933471|NCT03254199|Drug|Placebo ODT|Placebo ODT taken three times daily for 28 days
1933476|NCT03250832|Drug|TSR-033|TSR-033 is a humanized monoclonal antibody (IgG4)
1933477|NCT03250832|Drug|Anti-PD-1|PD-1 is an IgG4 antibody
1933484|NCT03249792|Drug|MK-2118|IT injection
1933485|NCT03249792|Biological|Pembrolizumab|IV infusion
1933487|NCT03248427|Drug|Ribociclib|Ribociclib flat-fixed dose of 600 mg daily (three 200-mg capsules), days 1 to 21 of a 28-days cycle.
1933488|NCT03248427|Drug|Letrozole 2.5mg|Daily continuous
1933489|NCT03248427|Drug|Doxorubicin|60 mg/m2 as a continuous IV perfusion
1933490|NCT03248427|Drug|Cyclophosphamide|600 MG/M2 in a 30 minutes IV infusion
1933491|NCT03248427|Drug|Paclitaxel|80 mg/m2, in one hour IV infusion
1933492|NCT03246776|Drug|Halometasone Triclosan|Halometasone Triclosan . The study product will be applied topically twice a day (morning and evening) for 14 days of treatment
1933493|NCT03247322|Other|Pharmacist-led medication therapy using mHealth application|This cohort of participants will receive clinical pharmacist-led supplemental medication therapy monitoring and management, utilizing a smartphone-enabled mHealth application, integrated with televisits and home-based monitoring of blood pressures and glucoses (when applicable).
1933494|NCT03246490|Other|All Participants|all participants will participate in the same protocol involving drinking alcohol to a .08 g% blood alcohol level
1933495|NCT03245346|Drug|GEA|Thoracic epidural catheterization will be performed and epidural anesthesia will be maintained with 0.25% ropivacaine during surgery. General anesthesia will be maintained with inhalation (sevoflurane) and muscle relaxants will be administered when considered necessary.
1933496|NCT03245346|Drug|PCEA|Patient-controlled epidural analgesia (0.15% ropivacaine infusion) will be provided after surgery.
1933497|NCT03245346|Drug|GA|General anesthesia will be maintained with inhalation (sevoflurane) and sufentanil infusion, and muscle relaxants will be administered when considered necessary.
1933498|NCT03245346|Drug|PCIA|Patient-controlled intravenous analgesia (1ug/ml sufentanil) will be provided after surgery.
1933499|NCT03245164|Other|Physiotherapy group exercises|Physiotherapy exercises had aerobic, balance, strength exercises with music.
1933500|NCT03245164|Other|Basketball program|Basketball education presented the techniques about playing basketball and basketball games were played.
1933516|NCT03242356|Other|Questionnaire to assess of the application of the current French guidelines as to fasting during labor.|"Questionnaire focuses on :
oral intake of clear fluid during the labor
oral intake of solid meal during the labor
fasting duration for solid and liquids
instruction received as to fasting during labor, nature of these instructions, and who given the instruction (midwife, nurse anesthetist, …)
discomfort related to thirst during labor
discomfort related to hunger during labor
We will also record several medical data as to the course of pregnancy and delivery, analgesia technique, history and characteristics of the parturient."
1933518|NCT03239626|Radiation|POHIM-RT|postoperative adjuvant IMRT with hypofractionation (2.5 Gy/fraction, 16 fractions, once a day)
1933519|NCT03240133|Drug|BCX7353|oral liquid formulation
1933520|NCT03240133|Drug|Placebo|oral liquid formulation to match BCX7353
1933523|NCT03240016|Drug|Pembrolizumab|200mg IV D1
1933524|NCT03240016|Drug|abraxane|125mg/m^2 D1 and D8
1933529|NCT03239613|Other|POHIM-CCRT|postoperative adjuvant concurrent chemotherapy with hypofractionated IMRT (2.5 Gy/fraction, 16 fractions, once a day)
1933530|NCT03239769|Procedure|thyroidectomy|Thyroidectomies have different approaches. The aim of this study was to evaluate and compare the aesthetic effects of different access procedures in patients with differentiated thyroid carcinoma (DTC).
1933531|NCT03238079|Biological|10% IGIV|300-900 mg/kg
1933534|NCT03236974|Drug|Standard Arm - Fulvestrant|500 mg Fulvestrant administered as two consecutive 5 ml intramuscular injections on Day 1, one in each buttock
1933535|NCT03236974|Drug|AZD9496|Administered at 250 mg bd orally for 5-14 days commencing on Day 1, and continuing up to the day of biopsy
1933538|NCT03234569|Procedure|sonoHSG|This procedure uses agitated saline to produce air bubbles at the time of the Sonohysterogram which optimizes fallopian tube visualization. The sonoHSG is free of radiation and use of contrast. In this study, in order to produce the air bubbles at the time of the sonohysterogram, the investigators will be using a continuous saline-air device that may produce a technically superior image.
1933547|NCT03232112|Drug|Exenatide 2 MG Injection|Subcutaneous injection once-weekly
1933548|NCT03232112|Drug|BD PosiFlush (saline)|Subcutaneous injection once-weekly
1933549|NCT03231033|Drug|Pioglitazone|Participants will receive three doses of Pioglitazone, 15 mg/day for 12 weeks, 30 mg/day for 12 weeks, and 45 mg/day for 12 weeks
1933553|NCT03229616|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
1933554|NCT03229616|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
1933555|NCT03229616|Drug|Etoposide (VP-16)|Etoposide was administered at 15 mg/kg/day on days −3 to −2.
1933563|NCT03226171|Drug|Dose-adjusted SK-1403|SK-1403 is to be administered to patients for the whole treatment periods (52 weeks), with individual dose adjustment
1933564|NCT03225599|Other|Cranial Osteopathic Manipulative Medicine|"The hands will be placed on the head using the vault hold (bilateral thumbs are off the head, index fingers on the temporal bones, middle fingers on the sphenoid bones, ring fingers on the mastoid and the 5th fingers on the occipital bone). Diagnosis and treatment of restrictions palpated on the scalp will be made using this hand position"
1933568|NCT03224390|Other|digital family planning screening and referral service|Clients text the service and receive a free call back to complete an automated family planning counseling session that results in a set of recommended methods that fit the client's preferences. The client is matched to family planning providers that offer these methods, and the service sends a referral code that the client can redeem at a facility. When someone receives a referral code, the service tracks them through their encounter with a provider to learn about their experience with the service, the provider, and their choice in contraception. The service also follows-up with clients who do not act on referrals to better understand their reasons and tries different behavioral nudges to promote uptake of contraception. The service does not pay costs the client may incur at a facility.
1933576|NCT03220243|Drug|MSC-AFP|Eligible patients will be treated with a fistula plug that has been coated with autologous mesenchymal stromal cells.
1933577|NCT03219034|Device|oral appliance - A|Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth and uses a Midline Traction Mechanism to advance the mandible. The coupling mechanism is located at a single point midline, allows adjustment by incremental protraction (advancement) of the mandible.
1933578|NCT03219034|Device|oral appliance - B|Anti-snoring intra-oral appliance that consists of two custom fitted trays which fit over the upper and lower teeth uses a Bilateral Thrust Mechanism to advance the mandible. The trays are engaged by means of adjustable lugs.
1933579|NCT03217838|Drug|AZD2811|AZD2811 is a potent and selective inhibitor of Aurora B kinase. It has been incorporated into a nanoparticle suitable for intravenous administration.
1933580|NCT03216057|Dietary Supplement|Omega-3 fatty acid 3 grams per day|Each capsule contains 400 mg of eicosapentaenoic acid and 200 mg of docosahexaenoic acid. We allocated five capsules per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 2000 mg of eicosapentaenoic acid and 1000 mg of docosahexaenoic acid per day (3 gr of Omega 3 per day) by mouth for 12 weeks. The trademark is Omega RX Dr.Sears Zone labs Inc.
1933581|NCT03216057|Dietary Supplement|Placebo|Placebo Comparator: Placebo Each capsule contains 600 mg of soybean oil. We allocated five capusles per day, three in the morning and two at night, every 12 hours (8.00 am and 8:00 pm), therefore the subject ingest 3000 mg of soybean oil per day (3 gr soya oil per day) by mouth for 12 weeks.
1933582|NCT03214822|Dietary Supplement|H2MF|As described in the Experimental Arm description.
1933592|NCT03214406|Drug|Arm & Hammer Advance White Brilliant Sparkle (Test product)|20% sodium bicarbonate
1933593|NCT03214406|Drug|Crest Cavity Protection Regular Toothpaste (Negative Control)|Negative control
1933606|NCT03213275|Other|Microbiome Sequencing, Neurophysiologic Assessment, Immunological test|Stool sampling, aEEG, VEP, NIRS, ydTCR, Treg, biomarker
1933607|NCT03209947|Diagnostic Test|Ulnar nerve Ultrasound|No drug and no placebo were used in this arm. Patients were followed by Ultrasound approach by measure of ulnar nerve surface
1933608|NCT03208244|Drug|Clinically prescribed direct acting antiviral|HCV treatment for 12 weeks
1933613|NCT03207113|Behavioral|Ned|Prostate cancer survivorship application.
1933618|NCT03205085|Radiation|magnetic resonance imaging|assessment of right heart dimensions and function by cardiac magnetic resonance Imaging.
1933619|NCT03205085|Procedure|2D and 3D trans-thoracic echocardiography|assessment of right heart dimensions and function by 2D and 3D trans-thoracic echocardiography
1933620|NCT03205085|Other|Blood samples|Blood samples for assays of immune inflammatory biomarkers (InterLeukin-18, CXCL9 or interferon
1933625|NCT03206151|Drug|CMAB009|for injection only
1933626|NCT03206151|Drug|Irinotecan|for injection only
1933627|NCT03206151|Drug|Folinic acid|for injection only
1933628|NCT03206151|Drug|5-fluorouracil|for injection only
1933629|NCT03201913|Drug|TTC-352|Phase 1 study to determine the maximum tolerated dose (MTD) of TTC-352.
1933630|NCT03200470|Other|No intervention: sample collection study|Sample collection and collection of laboratory values
1933638|NCT03197883|Other|Test Product|Restoring lipid balm
1933639|NCT03197883|Other|Cleanser|Moisturizing facial cleanser
1933640|NCT03197883|Other|Sunscreen|SPF (Sun Protection Factor) 50 sunscreen
1933643|NCT03197597|Other|Strain isolation from the nasopharynx|B. pertussis strains has been collected from the nasopharynx of the patients during the clinical visit
1933646|NCT03194334|Behavioral|Vegetarian diet|
1933647|NCT03194334|Dietary Supplement|creatine and beta-alanine|
1933648|NCT03194334|Dietary Supplement|Placebo|pills
1933658|NCT03191552|Device|SPIO (stabilizing input pressure orthosis)|"SPIO 2 hours will receive conventional exercise therapy with the garment on during 2 hours.
SPIO 6 hours group will wear the SPIO 4 hours more in addition to 2 hours during therapy.
(conventional exercises :range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills"
1933659|NCT03191552|Other|conventional exercises|range of motion, strengthening, trunk control and strengthening exercises and exercises to improve fine and gross motor skills
1933666|NCT03190798|Drug|Canagliflozin 300mg|"Canagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor. It works by decreasing the amount of sugar the body absorbs, and increasing the amount of sugar that leaves the body in the urine.
Administered in 300mg tablets."
1933667|NCT03190798|Drug|Placebo|Placebo for Canagliflozin
1933668|NCT03189875|Other|Standard of Care|Participants will be followed as per local routine clinical practice
1933669|NCT03189719|Biological|Pembrolizumab|200 mg administered IV Q3W on Day 1 of each cycle.
1933670|NCT03189719|Drug|Placebo|Placebo to pembrolizumab (saline) administered IV Q3W on Day 1 of each cycle.
1933671|NCT03189719|Drug|Cisplatin|80 mg/m^2 administered IV Q3W on Day 1 of each cycle. Duration of cisplatin treatment will be capped at 6 cycles.
1933672|NCT03189719|Drug|5-FU|800 mg/m^2/day (4000 mg/m^2 total per cycle) administered as continuous IV infusion on Days 1 to 5 (120 hours) of each cycle, or per local standard for 5-FU administration.
1933673|NCT03188432|Drug|Carboplatin|Given IV and IP
1933674|NCT03188432|Drug|Paclitaxel|Given IV
1933675|NCT03188432|Other|Quality-of-Life Assessment|Ancillary studies
1933676|NCT03188432|Other|Questionnaire Administration|Ancillary studies
1933677|NCT03188432|Procedure|Surgical Procedure|Undergo CRS
1933678|NCT03186508|Behavioral|Optimize Sleep (OS)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
1933711|NCT03174730|Behavioral|Growth Mindset|The intervention is aimed at creating more flexible thinking about addiction to tobacco. Participants will be sent tips by email to help foster the belief that people can overcome addiction to smoking.
1933679|NCT03186508|Behavioral|Optimize Sleep-Plus (OS-Plus)|"All children will receive 8 sessions during active treatment: two in-person weekly, three in-person biweekly, and 3 monthly sessions conducted by phone. All families will be asked to complete 3 sleep challenges (at weeks 8, 16, and 20). During maintenance, families will continue with monthly phone contact."
1933688|NCT03183791|Behavioral|RELAXaHEAD app|The Research Volunteers (RV) will explain the rationale for PMR and load the RELAXaHEAD app onto the patients' smartphones. The RV will review the app with the subject, focusing on user knowledge, usability, and engagement. The patient will perform the 5 minute PMR session and discuss the optimal time and place to practice PMR at home. Subjects will also enter their headache log daily on the app.
1933689|NCT03183791|Behavioral|Monitored Usual Care (MUC)|To match the time spent with the RV, patients will be given a general education session consisting of basic migraine information, such as evidence-based ways to treat headaches: treat early, limit acute medications < 2-3 days/week, and call the primary care physician (PCP) if abortive medications are used more frequently. The RV will load the app onto the patients' smartphones but the PMR component will be blocked on the version of the app that the MUC patients receive. All patients will be asked to track headache frequency, intensity, and acute medication use on app.
1933703|NCT03181308|Drug|Carotuximab (TRC105)|Anti Endoglin Antibody
1933704|NCT03181308|Drug|OPDIVO|Programmed Death Receptor-1
1933707|NCT03175380|Biological|bacillus Calmette-Guérin|BCG injection for prevention of tuberculosis
1933708|NCT03174834|Other|Bladder Stimulation technique|The bladder stimulation technique is performed following genital cleaning with a 2% castile soap towelette, which is part of the sterile clean catch urine collection cup kit. For the technique, infants will be held under their armpits by a parent over the bed, with legs dangling in males and hips flexed in females. The nurse or technician will then alternate between bladder stimulation maneuvers: gentle tapping in the suprapubic area at a frequency of 100 taps per minute for 30 seconds followed by lumbar paravertebral massage maneuvers for 30 seconds. These two stimulation maneuvers will be repeated until micturition begins, or for a maximum of 300 seconds.
1933712|NCT03174730|Behavioral|SmartQuit|This is an Acceptance and Commitment Therapy based intervention designed a smoking cessation smartphone application.
1933713|NCT03174314|Behavioral|standard object battery and training sequence|Used to examine human localization and identification performance. Object battery will include: trip hazards ('pucks' with various height/width combinations to represent children's toys, street debris, rocks, pets, etc.), furniture (chairs, desks, couches, benches), people, walls, and corridors. Objects will be recorded by placing them to the right or left on the path-of-travel. Raw sensor outputs for single obstacles and walls in isolation (trip-hazard pucks with 8 heights, chair, desk, person, wall) and the same set of single obstacles against a wall. This set of 23 raw sensor traces can be used in various combinations (e.g., encountering a curb and then a person, or a chair) to create a training sequence that will help experimentally naïve subjects to understand the correspondence between tactile stimulation and the real-world scenario it is intended to depict.
1933715|NCT03174067|Drug|Buprenorphine|The participant receives buprenorphine
1933716|NCT03174067|Drug|Clonidine|The participant receives clonidine
1933718|NCT03170544|Drug|MK-1092, low dose 1|MK-1092, low dose 1 SC, as a single dose under the euglycemic clamp, in healthy participants
1933719|NCT03170544|Drug|MK-1092, low dose 2|MK-1092, low dose 2 SC, as a single dose under the euglycemic clamp, in healthy participants
1933720|NCT03170544|Drug|MK-1092, middle dose|MK-1092, middle dose SC, as a single dose under the euglycemic clamp, in healthy participants
1933721|NCT03170544|Drug|MK-1092, high dose 1|MK-1092, high dose 1 SC, as a single dose under the euglycemic clamp, in healthy participants
1933722|NCT03170544|Drug|MK-1092, high dose 2|MK-1092, high dose 2 SC, as a single dose under the euglycemic clamp, in healthy participants
1933723|NCT03170544|Drug|Glargine 3.0 nmol/kg|Glargine 3.0 nmol/kg, SC, as a single dose
1933724|NCT03170544|Drug|Lispro 1.2 nmol/kg|lispro (Humalog®), 1.2 nmol/kg, IV infusion SC over 3 hours as a single dose starting ~12 hours after MK-1092 administration.
1933725|NCT03170544|Drug|MK-1092|MK-1092, SC, as a single dose, dose selection based on Part 1. Up to 4 doses may be tested in Part 3 which may be different from MK-1092 doses tested in Part 1.
1933726|NCT03170544|Drug|Placebo|Placebo to glargine, SC, as a single dose
1933727|NCT03170544|Drug|Placebo|Placebo to MK-1092, SC, as a single dose
1933728|NCT03170544|Other|Dextrose|20% solution for continuous infusion for the duration of the glucose clamp as needed to maintain blood sugar at pre-clamp target levels.
1933729|NCT03169829|Dietary Supplement|Standard Diet|"Adapted from National Kidney Foundation guidelines for HD1
Animal only Protein
Refined only Grains
Limit Dairy
Low-k only"
1933730|NCT03169829|Dietary Supplement|Low-k|"•¼ Animal, ¾ Plant Proteins
•½ Refined, ½ Whole Grain
Limit Dairy, provide Soymilk Dairy
Low-k only Fruit and Vegetables"
1933731|NCT03169829|Dietary Supplement|Standard|"•¼ Animal, ¾ Plant Proteins
Refined, ½ Whole Grain
•Limit Dairy, provide Soymilk Dairy
Low-k, Fruit and Vegetables
High-k Fruit and Vegetables"
1933732|NCT03169751|Device|Brain Sentinel Monitoring and Alerting System|The Brain Sentinel Monitoring and Alerting System is indicated for use as an adjunct to seizure monitoring in adults in the home or healthcare facilities during periods of rest. The device is to be used on the belly of the biceps muscle to analyze surface electromyographs (sEMG) signals that may be associated with generalized tonic-clonic (GTC) seizures and to provide an alarm to alert caregivers of unilateral, appendicular, tonic extension that could be associated with a GTC seizure. The System records and stores sEMG data for subsequent review by a trained healthcare professional.
1933735|NCT03168425|Other|Tailored prescription|Participants will be prescribed an opioid tablet number based on a formula derived from inpatient opioid use
1933736|NCT03168425|Other|Control|Participants will be prescribed 30 tablets of oxycodone 5mg
1933737|NCT03168165|Other|Pain neuroscience education training|PNE training will consist of 6 weeks online training followed by one day training session.
1933739|NCT03167541|Drug|Test|RB naproxen sodium tablets (2x220mg)
1933740|NCT03167541|Drug|Reference|Aleve naproxen sodium tablets (2x220mg)
1933741|NCT03167203|Biological|Human Embryonic Stem Cell-Derived Retinal Pigment Epithelial|Participants who have received sub-retinal transplant of hESC-RPE cells in an AIRM sponsored clinical trial
1933742|NCT03166787|Other|Charcoal hookah|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with either charcoal for 30 min each.
1933743|NCT03166787|Other|E-coal hookah|"The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young hookah smokers are randomized to smoke the same popular Starbuzz tobacco product heated with electrically (Global First e-coal, ) for 30 min each."
1933744|NCT03166787|Other|Cigarette|The Myocardial Blood Flow (MBF) will be measured at rest and during the last minute of a 3-minute bout of handgrip at 30% Maximal voluntary contraction. This sequence will be performed before and after 12 young cigarette smokers smoke 2 cigarettes down to the stub over 30 min (to simulate real-world use).
1933745|NCT03166787|Drug|Carbon Monoxide inhalation|A subset (n=8) of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling 0.3 CO gas from a Douglas bag.
1933746|NCT03166787|Other|Room Air inhalation|A subset 8 of the young hookah smokers will return on a later day and will be randomized to have coronary endothelial function assessed before and after inhaling room air from a Douglas bag.
1933747|NCT03166787|Drug|vitamin C|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with either i.v. vitamin C .
1933748|NCT03166787|Drug|tadalafil|in a subset of 6 subjects the study team will repeat the Myocardial Contrast Echocardiography and speckle tracking studies after pretreatment with one dose of oral tadalafil.
1934824|NCT02758613|Drug|LY3009104|Administered orally.
1933749|NCT03165734|Drug|Pacritinib|Oral administration. Supplied in capsules containing 100 mg (as the free base) in red cap/gray body size 0 opaque hard gelatin capsules. The inactive ingredients are microcrystalline cellulose, magnesium stearate, and polyethylene glycol 8000. Each capsules contains 146 mg of pacritinib citrate, which is equivalent to 100 mg pacritinib free base
1933757|NCT03162536|Drug|ARQ 531|ARQ 531 will be orally administered once per day under fasted conditions (1 hour prior to or 2 hours after a meal) and is available in tablets in strengths of 5 mg or 20 mg.
1933758|NCT03161340|Drug|Rapamycin|Patients will take Rapamycin 4 days before IVF until 12 days after IVF
1933759|NCT03160547|Other|Lower Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
1933760|NCT03160547|Other|Higher Protein/Amino Acid Group|Protein targets will be set using pre-ICU dry actual weight. For patients with BMI >30, ideal body weight based on a BMI of 25 will be used. We will endorse the guidelines for energy targets set forth by ASPEN/SCCM, especially as it pertains to the obese patient.
1933767|NCT03159416|Drug|Inclisiran|Inclisiran is a synthetic, chemically modified small interfering ribonucleic acid (siRNA) targeting proprotein convertase subtilisin kexin type 9 (PCSK9) messenger ribonucleic acid (mRNA) with a covalently attached triantennary N-acetylgalactosamine (GalNAc) ligand.
1933771|NCT03158220|Biological|V503|V503 vaccination, 0.5 mL in a 3-dose regimen administered on Day 1, Month 2, and Month 6
1933774|NCT03155893|Drug|ODV Placebo (Matching 25 mg ODV)|Participants will receive ODV placebo (matching 25 [mg] ODV [1*25 mg tablet]) once daily in Treatment A and B from Day 1 to 16 and Treatment C on Day 1.
1933775|NCT03155893|Drug|ODV Placebo (Matching 200 mg ODV)|Participants will receive ODV placebo (matching 200 mg ODV [4*50 mg tablets]) on Days 1 and 2 in Treatment E.
1933776|NCT03155893|Drug|ODV Placebo (Matching 125 mg ODV)|Participants will receive ODV placebo (matching 125 mg ODV [2*50 mg tablets + 1*25 mg tablets]) orally once daily on Days 3 to 7 in Treatment E.
1934825|NCT02758613|Drug|Placebo|Administered orally.
1933777|NCT03155893|Drug|ODV Placebo (Matching 100 mg ODV)|Participants will receive ODV placebo (matching 100 mg ODV [2*50 mg tablets] orally once daily on Days 8 to 14 in Treatment E.
1933778|NCT03155893|Drug|SMV Placebo (Matching 150 mg SMV)|Participants will receive SMV Placebo (matching 150 mg SMV [2*75 mg capsules]) orally once daily administered from Day 1 to 16 in Treatment A, B and on Day 1 in Treatment C.
1933779|NCT03155893|Drug|AL-335 Placebo (matching 1200 mg AL-335)|Participants will receive a single dose of AL-335 placebo (matching 1200 mg AL-335 [3*400 mg tablets]) administered orally on Day 15 in Treatment A and B.
1933780|NCT03155893|Drug|Moxifloxacin Placebo (matching 400 mg moxifloxacin)|Participants will receive a single dose of moxifloxacin placebo (matching 400 mg moxifloxacin [1*400 mg capsule]) administered orally on Day 1, 15 and 16 in Treatment A, on Day 1, 2 and 15 in Treatment B and on Day 1, 2, 15 and 16 in Treatment C.
1933781|NCT03155893|Drug|ODV 25 mg|Participants will receive ODV 25 mg orally once daily administered on Days 2 to 16 in Treatment C.
1933782|NCT03155893|Drug|ODV 200 mg|Participants will receive ODV 200 mg (4*50 mg tablets) orally once daily will be administered on Days 1 and 2 in Treatment F.
1933783|NCT03155893|Drug|ODV 125 mg|Participants will receive ODV 125 mg (2*50 mg tablets + 1*25 mg tablets) once daily administered on Days 3 to 7 in Treatment F.
1933784|NCT03155893|Drug|ODV 100 mg|Participants will receive ODV 100 mg (2*50 mg tablets) orally once daily administered on Days 8 to 14 in Treatment F.
1933785|NCT03155893|Drug|SMV 150 mg|Participants will receive SMV 150 mg (2*75 mg capsules) orally once daily administered on Days 2 to 16 in Treatment C.
1933786|NCT03155893|Drug|AL-335 1200 mg|Participants will receive a single oral dose of AL-335 1200 mg (3*400 mg tablets) administered on Day 15 in Treatment C.
1933790|NCT03150589|Drug|SB11 (Proposed ranibizumab biosimilar)|SB11 (proposed ranibizumab biosimilar) 0.5mg via intravitreal injection every 4 weeks
1933791|NCT03150589|Drug|Lucentis (ranibizumab)|Lucentis (ranibizumab) 0.5mg via intravitreal injection every 4 weeks
1933796|NCT03142841|Other|RESCUE Problem Solving Intervention|This is an education and support intervention for caregivers of Veterans with stroke. The investigators will teach study participants about the COPE model of problem solving and guide them through the application of this model in their caregiver role. They will receive tailored stroke education.
1933797|NCT03141658|Drug|TS-134|Multiple dose titrations from 10 mg to 20 mg once daily for 6 days
1933798|NCT03141658|Drug|TS-134|Multiple dose titrations from 10 mg to 60 mg once daily for 6 days
1933799|NCT03141658|Drug|Placebo|Multiple doses of placebo once daily for 6 days
1933800|NCT03141658|Other|Ketamine|0.23 mg/kg bolus over one minute on Screening (baseline) and Day 6
1933813|NCT03139552|Other|Apple Crisp|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of apple crisp in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
1933840|NCT03128528|Drug|Placebo Oral Tablet|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.
and provided by the sponsor."
1933814|NCT03139552|Other|Tea|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe) of tea in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
1933815|NCT03139552|Other|Oatmeal|Subjects tasted the three recipes (full sugar recipe, reduced sugar recipe, and reduced sugar plus spice recipe of oatmeal in a randomized sequence schedule. Tastings for each test item (apple crisp, tea and oatmeal) were done during separate weeks. Subjects tasted each recipe of an item at one sitting (ie: subject completed apple crisp tastings during one seating during first week, oatmeal tastings during one seating the next week and tea tastings during one seating the next and final week).
1933816|NCT03137628|Other|colectomy, GA and MV|"general anesthesia protocol: anesthesia induction (midazolam 0.1mg/kg, sufentanil 0.5ug/kg, etomidate 0.3mg/kg, cisatracurium 0.2mg/kg); anesthesia maintenance [sevoflurane 1.5-3%, cisatracurium 0.1mg/kg/h, sufentanil is supplemented during the entire surgical procedure according to patients' anesthetic situation, dexmedetomidine（used conditionally）0.4ug/kg/h].
mechanical ventilation protocol: tidal volume 6-8 ml/kg, positive end-expiratory pressure 5 cmH2O, oxygen concentration 40%; respiratory rate 10-15/min, inspiratory/expiratory ratio 1:1.5."
1933825|NCT03135379|Device|Heated ultrasound gel|"Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) set to medium setting (102 degree fahrenheit)."
1933826|NCT03135379|Device|Room temperature gel|Gel stored in Thermasonic Gel Warmer (Model 82-03 LED, 120V) turned off.
1933828|NCT03134079|Other|apple crisp|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
1933829|NCT03134079|Other|tea|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
1933830|NCT03134079|Other|oatmeal|Subjects tasted three items (apple crisp, tea and oatmeal) in a randomized sequence schedule to allow for tasting the three recipes (full sugar recipe, reduced sugar recipe and reduced sugar plus spice recipe) over three weeks. Oatmeal and tea were served together as a breakfast meal and tastings of oatmeal and tea were done over 3 weeks and tastings for apple crisp (served alone) were done over 3 different weeks. Subjects tasted one of the three recipes at each weekly seating.
1933833|NCT03133390|Drug|Atezolizumab 1200 mg|1200 mg (flat dose) in 250 mL normal saline (NS) Intravenously (IV); 3 weeks (21 days)
1933834|NCT03133390|Drug|Bevacizumab 15 mg/kg IV|Bevacizumab 15 mg/kg1 in normal saline (NS) Intravenously (IV); 3 weeks (21 days)
1933837|NCT03127735|Drug|BAY1436032|"BAY1436032 administered continuously as a single agent dosed twice a day orally on Days 1 to 28 of a 28-day cycle.
Patients may continue treatment with BAY1436032 until disease progression, development of other unacceptable toxicity or Investigator discretion."
1933838|NCT03128593|Drug|JR-141|IV infusion (lyophilized powder), 0.01-2.0 mg/kg/week
1933839|NCT03128528|Drug|Empagliflozin 10mg|"Each patient, after the run-in/wash-out phase, will be randomly assigned in a doubleblind fashion to one of the two treatment sequences according to a randomisation list.
and provided by the sponsor."
1933842|NCT03128008|Drug|Carboplatin|Single arm non randomized open label study. Subjects will recieve standard of care Carboplatin IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
1933843|NCT03128008|Drug|Paclitaxel|Single arm non randomized open label study. Subjects will receive standard of care Paclitaxel IV once a week. Chemotherapy is given concurrently with daily hyperfractioned radiation therapy.
1933844|NCT03128008|Radiation|Daily hyperfractionated radiation therapy|All subjects will recieve 6 fractions(2Gy per fraction) of radiation therapy weekly. All subjects will complete an interim PET-CT after 48Gy-54Gy of RT . Subjects with a complete response on PET will complete RT at 60 Gy; subjects who have residual disease on interim PET and meet strict planning constraints eligibility will proceed to boost RT for a total RT dose of 72Gy. Interim PET-CT response will be measured using PERCIST criteria.
1933845|NCT03124563|Behavioral|Control Group|Participants will wear a Fitbit Zip for 5 weeks to record their daily step data. The first week of the study will provide a baseline measurement of steps. After this week, participants in this condition will begin receiving daily emails asking them to report their step count in a questionnaire. The participants in this condition will not receive any components of the intervention including: scheduling, maps, or activity goals.
1933846|NCT03124563|Behavioral|Implementation Intention Condition|Participants will wear a Fitbit Zip for 5 weeks to record their daily step data. The first week of the study will provide a baseline measurement of steps. After this week, participants will receive maps of different routes near their home and/or work of varying distances and step counts. They will also begin receiving daily emails asking them to report their step count. Additionally, they will be asked to review their schedule for the next day and identify times when they could add steps into their schedules, and to record their daily step data in the daily questionnaire. The participants in this arm will receive all components of the intervention including: scheduling, maps, and activity goals.
1933847|NCT03126773|Drug|BAY86-4891|Drospirenone 0.25 mg + estradiol hemihydrate 0.5 mg (Angeliq Micro, G03FA17).Dosage form is one tablet a day.
1933848|NCT03126747|Drug|BAY86-5300_YAZ-Flex|Patients with endometriosis-associated pelvic pain and/or dysmenorrhea are enrolled solely after the physician's decision of YazFlex treatment in routine clinical practice.
1933849|NCT03126136|Device|Nicom (TM)|Heart rate, arterial pressure and cardiac output measurements (monitor NICOM) performed in the dorsal decubitus position and in the left lateral decubitus
1933850|NCT03124641|Device|Hypothermic oxygenated perfusion (HOPE)|HOPE for 1 hour via the portal vein in a recirculating and pressure controlled system (2-3 mm Hg), 0.1 ml/g liver/min, perfusion volume 3-4 L, Belzer (UW) machine perfusion solution, perfusate temperature 10 °C, perfusate oxygenation pO2 of 60-80 kPa
1933851|NCT03124641|Procedure|Conventional cold storage (CCS)|Conventional static cold storage (CCS) on temperature 4-6 °C from organ procurement
1933855|NCT03124199|Drug|Rifaximin|Rifaximin 400 mg/8 h added to the standard triple therapy
1933857|NCT03121820|Drug|Memantinol tablets, 20 mg|"Bioequivalence Memantine Hydrochloride (JSC GEROPHARM, Russia) 20 mg film-coated tablets fasting condition"
1933858|NCT03121820|Drug|Akatinol Memantine® tablets, 20 mg|Bioequivalence Memantine Hydrochloride (Merz Pharma GmbH & Co. KGaA, Germany) 20 mg film-coated tablets fasting condition
1933861|NCT03120351|Drug|Lidoderm 5 % Topical Patch|Patients will receive Lidoderm topical 5% lidocaine patches. Those will be placed to affected area up to three patches as needed for pain 12 hours on and 12 hours off
1933862|NCT03120351|Drug|Placebo patch|2) Group II: Patients will receive placebo patches. Those will be placed to affected area at dose up to three patches as needed for pain 12 hours on and 12 hours off
1933871|NCT03110523|Drug|X0002|Before the first screening visit, there is a pre-Screening Telephone Call or email interview, the Screening Period of at least 14 days up to 3 weeks will consist of two visits for the assessment of eligibility including radiographic evaluation of the target knee joint space, all screening visits and double-blind treatment visit (week 2, 5, 10, 15, and 20 visits) are show in Study Flow Chart of Double-blind Period, and the open label period will be started from the Week 20 visit. All subjects treated with active drug or placebo complete the 20-week double-blind study will enter the Open-label study and will be treated with active drug, X0002 for 32 weeks.
1933872|NCT03110523|Drug|Placebo|Before the first screening visit, there is a pre-Screening Telephone Call or email interview, the Screening Period of at least 14 days up to 3 weeks will consist of two visits for the assessment of eligibility including radiographic evaluation of the target knee joint space, all screening visits and double-blind treatment visit (week 2, 5, 10, 15, and 20 visits) are show in Study Flow Chart of Double-blind Period.
1933922|NCT03090191|Biological|Clostridium difficile vaccine|Toxoid-based Clostridium difficile vaccine
1933876|NCT03107052|Drug|Fremanezumab|Fremanezumab
1933877|NCT03105817|Device|Asymmetric cellulose triacetate (ATA™)|Each patient underwent 12 sessions of haemodialysis with the usual schedule, changing the usual dialyzer
1933878|NCT03105518|Drug|Fentanyl|0.5, 1 mcg/kg
1933879|NCT03105518|Drug|Acetaminophen|Single + Oxycodone
1933880|NCT03105518|Drug|Oxycodone|With Acetaminophen
1933883|NCT03104985|Device|LASMIK|the physiotherapeutic device LASMIK (Registration Certificate in Russia № RZN 2015/2687 dated 25.05.2015).
1933884|NCT03104985|Other|Conventional therapy|"An elastic compression of lower extremities,
Pharmacotherapy,
Topical treatment"
1933885|NCT03105297|Device|Prototype nasal dilator strip|External Prototype Nasal Dilator strip. GSK prototype nasal dilator AB 2R11. All the participants used nasal dilator strip throughout the active phase of the study (Day 1 to Day 28). Followed by that all the participants used the nasal strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
1933886|NCT03105297|Other|No Strip|All participants used the no strip on Day 29 or 30 in Nasal resistance phase of the study as per their randomization sequence.
1933890|NCT03101904|Dietary Supplement|Beetroot Juice|
1933891|NCT03101904|Dietary Supplement|Placebo|
1933893|NCT03101462|Biological|Licensed Trivalent FluMist|
1933894|NCT03101462|Biological|Inactivated Trivalent Influenza Vaccine (TIV)|
1933895|NCT03101150|Drug|400 IU Vitamin D3|Antenatal multivitamin
1933896|NCT03101150|Drug|4000 IU Vitamin D3|4000 IU Vitamin D3 (cholecalciferol) daily = 40 drops daily
1933897|NCT03101033|Device|Mechanical epidural neuroplasty|Guided by X-ray transillumination,an epidural needle will be inserted through sacral hiatus. A catheter （BS epidural catheter, BioSpine Co., Ltd, Korea） will be inserted through the epidural needle to the epidural space where disc herniation locates, mechanical adhesiolysis will be implemented.
1933898|NCT03101033|Drug|Transforaminal epidural compound betamethasone injection|Guided by X-ray transillumination, A puncture needle will be inserted to the intervertebral foramen in the vicinity of affected nerve root, and steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan®, Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected.
1933899|NCT03101033|Drug|Caudal epidural compound betamethasone injection|steroid injectant consists of 1 ml of Compound Betamethasone Injection (Diprospan® Schering-Plough Labo N.V., Belgium) and 4ml of 0.2% lidocaine will be injected through the epidural catheter after mechanical epidural neuroplasty.
1933900|NCT03101033|Drug|Epidural hyaluronidase injection|Hyaluronidase of 1500 IU （Sine®, SPH NO.1 Biochemical and Pharmaceutical Co., LTD）will be injected through the epidural catheter after mechanical epidural neuroplasty and caudal epidural compound betamethasone injection.
1933901|NCT03100734|Biological|Benepali|As specified in the treatment arm
1933902|NCT03100734|Biological|Enbrel|As specified in the treatment arm
1933903|NCT03100734|Device|Benepali Pen|As specified in the treatment arm.
1933904|NCT03100604|Drug|desflurane,|Patients were divided into two groups according to inhalation agent administered for the surgery; Sevofluran, Group S (n=25) and Desfluran, Group D (N=25).
1933905|NCT03100604|Drug|Sevoflurane|For a drug, use generic name if established. Use the same name as in the associated Arm/Group Description(s).
1933909|NCT03096496|Other|QoL questionnaires|Quality of life questionnaires
1933912|NCT03094832|Drug|ARQ 092|Subjects will receive ARQ 092 orally at the dose level and administration schedule specified for their respective dose cohort on a 28 day schedule.
1933913|NCT03092518|Procedure|Surgery|Heated Intraperitonial Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitocycin C and sodium thiosulfate
1933914|NCT03092518|Drug|Cisplatin|Cisplatin (90mg/m2) will be administered via circuit to the peritoneal cavity.
1933915|NCT03092518|Drug|Mitomycin C|Mytomycin C 10mg/m2 will be administered via circuit to the peritoneal cavity
1933916|NCT03092518|Drug|Sodium Thiosulfate|Sodium Thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
1934826|NCT02758171|Drug|Empagliflozin|
1933924|NCT03089073|Drug|Minirin Melt®|60μg or 120μg once daily at bedtime
1933931|NCT03082846|Radiation|hypofractionated radiation|The simultaneous integrated boost-intensity modulated technology is adopted to increase both the dose in the surgical cavity and residual tumor (PTV1).The dose at each fraction is gradually increased from 2.8 Gy/f (total of 20 times) with an escalating dose interval of 0.4 Gy in PTV1, until dose-limiting toxicity is present,the highest target single dose is 4 Gy/f. The planning target volume (PTV2) including the 2 cm region around surgical cavity and residual tumor remain unchanged, with 2.5 Gy each time and a total of 50 Gy/20f.
1933932|NCT03082846|Drug|Temozolomide chemotherapy|Temozolomide(TMZ) is administered orally every day at 75 mg/m2 during radiotherapy and at 150-200 mg/m2 for 12 cycles following completion of chemoradiotherapy.
1933933|NCT03082027|Diagnostic Test|ultrasonography|ultrasonography of median nerve
1933936|NCT03081858|Drug|TSD-001|Administered via intravesical instillation.
1933937|NCT03081806|Drug|X0002|Before the first screening visit, there is a pre-Screening Telephone Call or email interview, the Screening Period of at least 14 days up to 3 weeks will consist of two visits for the assessment of eligibility including radiographic evaluation of the target knee joint space, all screening visits and double-blind treatment visit (week 2, 4, 8, 12 visits) are show in Study Flow Chart of Double-blind Period, and the open label period will be started from the Week 12 visit (see Table 2). All subjects treated with active drug or placebo complete the 12-week double-blind study will enter this Open-label study and will be treated with active drug, X0002.
1933944|NCT03077620|Drug|Suvorexant|Participants will be given a sleep aid (10mg suvorexant) at bedtime for two consecutive nights that they are spending in a research unit.
1933945|NCT03077620|Drug|Placebo|Participants will be given a placebo at bedtime for two consecutive nights that they are spending in a research unit.
1933948|NCT03076554|Drug|Avelumab|Avelumab will be administered at a dose of 10 mg/kg intravenously once every two weeks until disease progression or development of intolerable adverse events.
1933949|NCT03076645|Behavioral|Facilitator support and education|Group engaged with facilitator support and education
1933952|NCT03073798|Drug|Roflumilast|500 mcg of Roflumilast which is a prescription medicine used in adults with severe COPD to decrease the number of flare-ups or the worsening of COPD symptoms
1933953|NCT03073798|Drug|Placebo|500 mcg of placebo is used
1933954|NCT03073603|Drug|Discontinuation of disease modifying therapy|Participants who will discontinue their current MS drug. No other changes to their treatment occur.
1933955|NCT03073603|Drug|Standard of Care|Participants who remain on their current Disease Modifying Therapies (DMTs) without any changes. DMTs include ~14 formulations/doses of drugs approved in the US by the FDA that alter the natural history of the disease.
1933956|NCT03072810|Behavioral|Positive mindfulness program|4 week program consisting of 8 modules. Each module comprises an introduction video (approx. 10 minutes), a daily meditation (approx. 10 minutes) and a daily activity.
1933957|NCT03070392|Biological|IMCgp100|IMCgp100 is to be administered at 20 mcg cycle 1 day1, then 30 mcg cycle 1 day 8, then 68 mcg cycle 1 day 15 and weekly thereafter by IV infusion over 15 minutes until confirmed disease progression or unacceptable toxicity
1933958|NCT03070392|Drug|Dacarbazine|Dacarbazine is to be administered at 1,000 mg/m2 of body surface area IV infusion every 3 weeks until disease progression or unacceptable toxicity
1933959|NCT03070392|Biological|Ipilimumab|Ipilimumab is to be administered at 3 mg/kg IV infusion over 90 minutes every 3 weeks for a total of 4 treatments
1933960|NCT03070392|Biological|Pembrolizumab|Pembrolizumab is to be administered at 2 mg/kg IV infusion over 30 minutes every 3 weeks until confirmed disease progression or unacceptable toxicity
1933961|NCT03069313|Dietary Supplement|Vitamin B12|Vitamin B12 2500 micrograms sublingually per day over the course of 90 days (+/- 10 days)
1933964|NCT03067740|Drug|Bupivacaine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) after excision of the appendix.
1933965|NCT03067740|Drug|Dexmedetomidine|intraperitoneal instillation of bupivacaine 0.25% ( 2mg/kg) plus dexmedetomidine 1mcg/kg after excision of the appendix.
1934088|NCT03019575|Drug|Corifollitropin alfa|Corifollitropin alfa 100 μg (body weight ≤60 kg) or 150 μg (body weight >60 kg) by SC injection, once every 2 weeks for 64 weeks (Day 1/Week 0 through Week 64).
1933966|NCT03067701|Drug|Carbon Monoxide|In healthy young adults 18-39 years of age, The investigator will determine if intermittent inhalation of 0.1% CO, from a 1-Liter bag once every minute for 30-40 min at a level that approaches the CO boost with hookah smoking, augments endothelial function.
1933967|NCT03066921|Dietary Supplement|Probiotic packet|Probiotic formulation will be given at a dose of one packet thrice daily for 24 weeks, amounting to a total of 300 billion colony forming units(CFU)/day. Each packet contains 100 billion viable lyophilized bacteria of three strains of Lactobacillus viz Lactococcus lactis subsp. Lactis LL358 (BCRC910699)、Lactobacillus salivarius LS159 (BCRC910700) and Lactobacillus pentosus and excipients.
1933968|NCT03066921|Dietary Supplement|Placebo|Placebo packet will be given at a dose of one sachet thrice daily for 24 weeks; Placebo packet contain all excipients as present in packets (without the 3 strains of bacteria as mentioned above).
1933969|NCT03066440|Drug|Normal saline|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in normal saline for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
1933970|NCT03066440|Drug|Lactated Ringers|All intravenous fluids used in the treatment of pediatric diabetic ketoacidosis will be based in lactated ringer's solution for participants in the interventional arm instead of normal saline (as given to participants in the control arm).
1933976|NCT03064113|Drug|Placebo|
1933977|NCT03064113|Drug|TD-4208 700 μg|
1933978|NCT03064113|Drug|TD-4208 350 μg|
1933979|NCT03064113|Drug|Ipratropium 500 μg|
1933989|NCT03055936|Drug|Levodopa|Levodopa 50 mg or 100 mg or 150 mg
1933990|NCT03055936|Drug|Carbidopa|Carbidopa 12,5 mg or 25 mg or 65 mg
1933991|NCT03055936|Drug|ODM-104|ODM-104 50 mg or 100 mg
1933992|NCT03054805|Drug|Magnesium Oxide|Magnesium oxide 250 mg per day for children with weight < 15 kg, 500 mg per day for weight <15-30 kg, and 1000 mg per day for weight > 30 kg
1933993|NCT03054805|Drug|MIYAIRI-BM|MIYAIRI-BM 1 g (1package) per day for children with weight < 15 kg, 2g per day for weight 15-30 kg, and 3g per day for weight > 30 kg
1933994|NCT03053518|Device|iPro2 CGM with Enlite sensors|A professional, blinded, continuous glucose monitoring device will be inserted on the abdominal region to measure interstitial glucose every 5 min for 4 times / day.
1933995|NCT03053518|Behavioral|LifeStyle|Isocaloric diets (breakfast, lunch, dinner, and 2 snacks), which will be prepared and delivered daily, including 2 days each of low, moderate, and high glycemic load (GL) foods.
1933997|NCT03052036|Procedure|Coronary Angiography|Coronary angiograhy to determine location of blocked or narrowed arteries.
1933998|NCT03052036|Procedure|Coronary revascularisation|PCI or CABG will be performed following coronary angiography at the discretion of the treating cardiologist.
1933999|NCT03052036|Other|Optimal Medical Therapy|Patients to receive conservative treatment in the form of guideline recommended secondary prevention therapy including antiplatelet therapy, statins, ACE Inhibitors and beta blockers.
1934000|NCT03051646|Drug|Acetylsalicylic acid|650 mg dose of acetylsalicylic acid is administered in a capsule one hour prior to exercise
1934001|NCT03051646|Drug|Placebo Oral capsule|Placebo capsule is administered one hour prior to exercise
1934005|NCT03050541|Drug|Oral MDMA|This is a between subjects, double-blind, placebo controlled design. We are administering oral MDMA to healthy volunteers to measure its effects on the encoding, consolidation, and retrieval stages of memory.
1934006|NCT03050541|Drug|Placebo|
1934008|NCT03051035|Drug|KO-947|Intravenous administration
1934156|NCT02987868|Drug|Amino acid supplement|An orally administered supplement of the proprietary amino acid derivative
1934827|NCT02758171|Drug|Linagliptin|
1934011|NCT03049605|Device|Magnetic therapy|low intensity pulsed magnetic therapy with a frequency of 200 Hertz and intensity of 50 Gauss . Magnetic device will be applied on each patient from a comfortable supine lying position. After the connection of appliance to electrical supply, the actions of PEMF will be directed and adjusted over lumbar spine, hip regions and calf muscles of both lower limbs.
1934012|NCT03049605|Device|laser therapy|laser therapy of Helium neon infrared laser (850 nano-meter) was used in continuous wave mode from a comfortable prone lying position on the whole plantar surface of the foot and the lumbo-sacral area by four points, and two points laterally to the spine.
1934013|NCT03049605|Drug|Only medical treatment|Fifteen patients with diabetic peripheral neuropathy were treated with antidiabtic drugs and lyrica 150 milligram daily
1934017|NCT03048188|Other|wound dressing|Manuka honey wound dressing
1934018|NCT03046212|Device|Transcutaneous electrical nerve stimulation|TENS: it was applied in the conventional mode, through four self-adhesive electrodes of size 5x9cm positioned about five centimeters from the edges of the surgical scar, with frequency of 100 Hz and pulse duration of 100μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was it increased during the application time with their permission.
1934019|NCT03046212|Other|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, flexion and extension of the knees and adduction and abduction of the hips, in both lower limbs. All exercises were performed with the patient in the supine position in the bed, in 10 repetitions.
1934020|NCT03046225|Device|Transcutaneous electrical nerve stimulation|TENS was applied in the conventional mode, through two self-adhesive electrodes of size 5x9cm positioned parallel to the lumbar spine, on the nerve roots of L3, L4 and L5, with frequency of 100 Hz and pulse duration of 100 μs, for 30 minutes. The intensity was adjusted according to the maximum tolerance of the patient and was gradually increased, with his permission, during the application time.
1934021|NCT03046225|Device|Continuous passive movement device|CPM device was used for 30 minutes and realized continuous passive flexion and extension of the operated knee.
1934022|NCT03046225|Other|Exercises|Active exercises of plantar flexion and dorsal flexion of the ankles, adduction and abduction of the hips and flexion and extension of the operated knees. All exercises were performed in 10 repetitions, with the patient positioned in the supine position in the bed.
1934026|NCT03044561|Drug|Sildenafil Citrate|25 mg orally, 4 times per day for 21 days
1934027|NCT03044561|Drug|matching placebo|orally, 4 times per day for 21 days
1934035|NCT03036865|Drug|BOS161721|Single dose administered IV or SC
1934036|NCT03036865|Drug|Placebo|Single dose administered IV or SC
1934157|NCT02987868|Drug|Placebo|A non-active orally administered supplement of the proprietary amino acid derivative
1934053|NCT03032588|Biological|sIPV|Participants will receive single dose (0.5 milliliter [mL]) of sIPV as a suspension for intramuscular injection on Day 1.
1934054|NCT03032588|Biological|cIPV|Participants will receive single dose (0.5 mL) of cIPV as a suspension for intramuscular injection on Day 1.
1934055|NCT03033160|Drug|Estradiol Ring|
1934058|NCT03031899|Procedure|Biopsy|rose bengal stain and toluidine is applied over a premalignant lesion and positively stained lesions are subjected to biopsy.
1934059|NCT03031899|Device|Rose Bengal|
1934060|NCT03031899|Device|toluidine blue|
1934061|NCT03031873|Device|MRI perfusion imaging|Evaluate the evolution of progressive obliteration of the AVM nidus
1934064|NCT03030872|Device|Predicate and Investigational|
1934065|NCT03030417|Drug|LMP744|Indenoisoquinolines, such as LMP744, are potent inhibitors of the enzyme topoisomerase I (Top1). Top1 is necessary for transcription, replication, recombination, and the repair of double-strand DNA breaks. It relaxes the supercoiled DNA by introducing a single-strand break, generating a free strand that rotates around the Top1-bound DNA complex. In the absence of external triggers, Top1-DNA cleavage complexes are generally short lived. Top1 inhibitors are potent anticancer agents because they stabilize the formation of the Top1- DNA cleavage complex in tumor cells, which induces DNA damage, delays DNA repair, and results in cell cycle arrest and apoptosis. LMP744 exhibited antitumor activity with lower toxicity than other agents in preclinical studies. Treatment of patients with LMP744 is expected to reduce tumor burden at doses that are well-tolerated.
1934069|NCT03027648|Procedure|Placement of levonorgestrel-releasing intrauterine system|All the patients accepted treatment of levonorgestrel-releasing intrauterine system
1934070|NCT03028870|Drug|V120083|Capsules
1934071|NCT03028870|Drug|Naproxen|Capsules
1934072|NCT03028870|Drug|Placebo|Capsules to match V120083 and/or naproxen
1934074|NCT03024112|Device|Heated humified high-flow nasal cannula Oxygen|
1934075|NCT03024112|Other|Standard oxygen therapy|
1934080|NCT03019887|Drug|risperidone, haloperidol, olanzapine, quetiapine, aripiprazole, paliperidone, levomepromazine, perphenazine|
1934082|NCT03020576|Device|Amadeo Hand Robot Device|This is a robotic device designed to offer rehabilitation to remediate weakness and limitations of range of motion of the hand and fingers.
1934083|NCT03020576|Other|Conventional Therapy|This arm involves treatment using conventional methods designed to promote range of motion, strength, coordination and function at the level of the shoulder, elbow, wrist and hand.
1934089|NCT03019575|Drug|hCG|hCG 500-5000 IU by SC injection; first dose will be administered on the last day of Week 12 (Day 85), and treatment will continue, twice a week, from Week 13 through Week 64.
1934093|NCT03018964|Procedure|Solo surgery|Solo surgery using a camera scope holder in single incision laparoscopic cholecystectomy
1934094|NCT03018964|Procedure|operation with a camera operator in SILC|conventional single incision laparoscopic cholecystectomy with a scopist
1934096|NCT03017612|Device|Raindrop Near Vision Inlay|A single-arm study to evaluate the effectiveness of a 2 mm corneal inlay (Raindrop Near Vision Inlay) for the treatment of presbyopia (age-related near vision loss). The anterior curvature of the cornea is re-shaped after implanting the Raindrop Near Vision Inlay in the non-dominant eye under a femtosecond laser flap to improve near and intermediate vision.
1934097|NCT03017196|Other|My Life, My Healthcare Discussion Aid|The My Life, My Healthcare instrument is a conversational tool designed to help patients and clinicians discuss capacity in clinical conversations of primary care.
1934098|NCT03016676|Other|Spinal Manipulation|High velocity low amplitude thrust (HVLA) to the lumbar region of the spine between L1 and L5 vertebrae. The exact level thrust will be at the discretion of the treating practitioner determined by the level with the greatest perceivable motion restriction. The HVLA thrust will be performed with the patient side lying in a neutral.They take part in 12 treatment visits, 10 to 20 minutes sessions of SM over 2 weeks. Light soft tissue techniques (i.e., active and passive muscle stretching, and ischemic compression of tender points) may be used as needed to facilitate the manual therapy.
1934099|NCT03016676|Other|Exercise therapy|Self education, supervised exercise visits, and home exercise. The overall objectives are to help patient's mange their LBP and prevent future LBP recurrences. Total number of visits 12.Each visit starts with 10 minutes of self-care education to help patients establish and monitor goals aligned with the exercise program and enhance their understanding of LBP. Participants will be taught the importance of movement and activity, pain management techniques, and methods for developing spinal posture awareness during activities of daily living (e.g., lifting, pushing, pulling, sitting, getting out of bed, and using a backpack).
1934105|NCT03012841|Device|Arctic Front Advance Cardiac CryoAblation Catheter|Cryoablation
1934106|NCT03012529|Drug|Rifampin|Subjects who are randomly assigned to adjunctive rifampin will receive a 600 mg oral daily dose targeted for a six-week period. If a subject experiences gastrointestinal intolerance on once daily dosing, the study drug may be administered as rifampin 300 mg twice a day.
1934107|NCT03012529|Drug|Riboflavin Placebo|A placebo capsule will be administered daily to match frequency and duration of rifampin interventional drug. For the purpose of mimicking urine discoloration when taking rifampin, riboflavin will be added to the placebo to produce a urine discoloration effect.
1934108|NCT03011099|Device|Robotic exoskeleton training|During the training, subjects will wear a lower extremity exoskeleton robotic walking device. Subjects will participate in individualized treatment sessions which may include: sit to stand, static and dynamic standing balance, weight shifting, walking, turning, and stand to sit. Each training session will last up to 90 minutes (60 minutes of training with 30 minutes for setup, don/doff of device) and training will be held 5 days per week for 3 weeks with a total of 15 sessions. During the training period, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise.
1934109|NCT03011099|Other|Conventional physical therapy|During the training, subjects will receive conventional physical therapy that is designed to facilitate/promote gait. This will include individualized treatment sessions for each subject and may involve stretching, strengthening, balance training, standing, and gait training. Subjects will not be able to participate in any form of robotic assisted or body weight supported treadmill training. Each training session will last up to 60 minutes and training will be held 5 days per week for 3 weeks with a total of 15 sessions. Consistent with the RET group, subjects will be required to maintain the same amount and level of regular daily physical activity and exercise during study period.
1934110|NCT03010800|Device|Yoni.Fit Group A|Abbreviated Pad Test with Yoni.Fit in place followed by repeat test without Yoni.Fit in place.
1934111|NCT03010800|Device|Yoni.Fit Group B|Abbreviated Pad Test without Yoni.Fit in place followed by repeat test with Yoni.Fit in place.
1934112|NCT03007810|Drug|Hemay005|Subjects will be randomized into 6 cohorts(10mg, 20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
1934113|NCT03007810|Drug|Placebos|Subjects will be randomized into 5 cohorts(20mg, 40mg, 80mg, 120mg, 180mg) orally single dose
1934114|NCT03006146|Drug|Sargramostim|Participants will receive a single administration of inhaled sargramostim (either 125 mcg or 250 mcg dose)
1934158|NCT02988622|Device|Fraxel Laser|One half of the scar is treated with Fraxel Laser
1934159|NCT02988622|Device|CO2 Laser|One half of the scar is treated with CO2 Laser.
1934115|NCT03006666|Behavioral|CHW Training|"CHWs will be trained in DM concepts, motivational interviewing, brief action planning, and stages of behavior change. CHWs will participate in a 105- hour core competency training. CHWs will conduct mock telephone counseling calls with trained standardized patients to enhance skills, gain feedback and develop confidence in these techniques.
In addition to these training experiences, CHWs will have letter templates, motivational interviewing scripts, and protocols available for patient outreach to standardize and guide patient outreach .
The completion of the CHW training will be followed by a final examination of knowledge and evaluation of trial encounters with mock participants (consisting of research staff and advisory board members).
Individuals who do not pass will receive intensive remediation and be required to repeat the examination.
Community Health Worker Coaching Intervention."
1934116|NCT03006666|Behavioral|Data Only|The teams randomly allocated to the Control Group will receive monthly lists of their pre-DM patients and information on the availability of DM prevention resources. They will not have access to Community Health Workers.
1934117|NCT03005041|Other|Biotene mouthwash|Participants will rinse their mouth with 15 mL of Biotene mouthwash swishing for 30 seconds.
1934118|NCT03005041|Other|Bottled mineral water|Participants will rinse their mouth with 15 mL of the water swishing for 30 seconds.
1934119|NCT03004508|Dietary Supplement|Gingko Biloba Extract|120mg/day, twice a day, 6 month
1934120|NCT03004508|Dietary Supplement|Placebo|120mg/day, twice a day, 6 month
1934121|NCT03004196|Drug|Probiotic Toothpaste|G.D Probiotic Toothpaste bacteriocin Lactic Acid Bacteria
1934122|NCT03004196|Drug|Dr. Reddy's Clohex|0.20% Chlorhexidine Mouthwash
1934123|NCT03004196|Other|Control Group|No Probiotic toothpaste & Chlorhexidine Mouthwash
1934125|NCT03002168|Dietary Supplement|Alpha-cyclodextrin|Alpha-cyclodextrin is approved by the Food and Drug Administration as a dietary ingredient.
1934126|NCT03002168|Dietary Supplement|Placebo|Placebo tablets identical in appearance to the active comparator
1934127|NCT03002168|Radiation|Triolein radiolabeled with 100 microcuries of 3^Hydrogen|A MicroCurie (µCi) is a measure of radioactivity.
1934128|NCT03002168|Radiation|Tripalmitin radiolabeled with 20 microcuries of 14^Carbon|A MicroCurie (µCi) is a measure of radioactivity.
1934129|NCT03002337|Behavioral|Aromatherapy massage|All of the participants in the aromatherapy group underwent aromatherapy massage for 70 minutes every two weeks between 16 to 36 weeks GA (ten sessions total). The aromatic massage oils were composed of 2 c.c. lavender (Lavandula angustifolia) blended with 98 c.c. almond oil. This concentration of the mixed essential oil was kept at room temperature for massage use.
1934130|NCT03002337|Behavioral|Yoga exercise|Prenatal yoga was offered in six 70-minute yoga sessions per week for 20 weeks, with 10-12 women in each session. Each participant should attend two sessions of yoga every two days, held in a quiet room near the prenatal clinic. Yoga specifically designed for women during the second and third trimesters, was guided by a midwife who was certified as a yoga instructor. Yoga included physical postures/ stretch, deep breathing, guided imagery, and deep relaxation. Before each posture/stretch, the instructor guided participants to relax each body part and calm their mind.
1934131|NCT03000439|Drug|In open-label phase: treatment with tofacitinib|Treatment with investigational drug
1934132|NCT03000439|Drug|In double-blind phase: treatment with tofacitinib or placebo in 1:1 ratio|Treatment with investigational drug or placebo
1934133|NCT02996500|Drug|PF-06650833|Investigational
1934134|NCT02996500|Drug|Placebo|Placebo
1934135|NCT02996500|Drug|Tofacitinib|Investigational
1934136|NCT02996825|Drug|Gemcitabine Hydrochloride|Given IV
1934137|NCT02996825|Other|Laboratory Biomarker Analysis|Correlative studies
1934138|NCT02996825|Biological|Mirvetuximab Soravtansine|Given IV
1934139|NCT02996825|Other|Pharmacological Study|Correlative studies
1934141|NCT02993393|Other|Teacher|The teachers' questionnaire based on table of specification of the learning contents, consisted of 4 parts: airway evaluation, patient preparation, strategic planning and follow up care.
1934142|NCT02993393|Other|Student|The students' questionnaire comprised 3 parts: learning content, process and evaluation.
1934145|NCT02991131|Drug|Tedizolid (Sivextro, BAY 11-70438)|Anti-infective agent
1934146|NCT02991131|Drug|Linezolid|Linezolid
1934147|NCT02990507|Other|AVEED: Arm rotation, video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
1934148|NCT02990507|Other|AVEED: Arm rotation, without video display|Participants rotate arm cranks for 5 minutes then rest for 5 minutes.
1934149|NCT02990507|Other|AVEED: Leg rotation, arm-energy input, video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
1934150|NCT02990507|Other|AVEED: Leg rotation, arm-energy input, without video display|Participants rotate leg cranks for 5 minutes then rest for 5 minutes.
1934160|NCT02988596|Other|Multidimensional Active Rehabilitation|Participants will be asked to complete activities aimed at: stabilization of symptoms, impairment reduction, activity integration, recovery acceleration and sport specific application during a 20 minute session at least 4 times a week. Activities will be selected by the supervising clinician with respect to the specific impairment presentation of each participant. Session logs will be completed by each clinician and will include the following information: initial symptom checklist, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
1934161|NCT02988596|Other|Enhanced Graded Exertion|Participants will be asked to use their symptoms to guide their activity from the time of their injury until they are asymptomatic. Once they are asymptomatic they will begin the graded exertion (Zurich Protocol). During this time clinicians will complete session logs that include the following information: initial symptom checklist, phase of graded return to play progression, activity parameters, percentage of rest during the session, participants rating of perceived exertion, and final symptom checklist, session satisfaction rating, and session feedback.
1934164|NCT02988349|Other|Colgate® Sensitive Pro-Relief® toothpaste|Subjects will be instructed to brush their teeth twice daily for 3 min using Colgate® Sensitive Pro-Relief® toothpaste for 2 weeks.
1934168|NCT02986620|Genetic|IDH mutation test performed at diagnosis or relapse until January 31st, 2019.|Observation of the test result.
1934173|NCT02984761|Radiation|Stereotactic Radiotherapy|Stereotactic radiotherapy uses high doses of ionizing energy to treat cancer cells with image guidance. The treatment is delivered in an outpatient setting, and for purposes of this trial is delivered in 3-5 fractions.
1934174|NCT02984761|Procedure|Anatomic Pulmonary Resection|An anatomic pulmonary resection is an oncologic procedure that dissects out an anatomically defined segment of the lung to remove all of the lung tissue around a lung tumor. It requires an operation with general anesthesia, with a short hospital stay. The procedure entails removal of lymph nodes inside the chest that might not be easily accessible without an operation.
1934180|NCT02981511|Device|optiflow|Optiflow device used for preoxygenation
1934189|NCT02975024|Device|laser speckle contrast imaging of the oral mucosa|Non-invasive method to measure tissue blood perfusion applied for oral mucosa
1934190|NCT02975024|Device|wound fluid measurement|Wound fluid at the wound margin is collected using filter strip and volumetrically measured by Periotron 8010 instrument.
1934191|NCT02975024|Device|quantitative determination of VEGF|For the quantitative determination of VEGF in the fourth day wound fluid sample the Human VEGF Quantikine ELISA Kit will be used.
1934200|NCT02975154|Device|Microcurrent therapy|The microcurrent therapy will be applied with electrodes that are fixed around the knee. The two electrodes of channel A will be placed at the inner and outer side of the knee that is most affected by pain. The two electrodes of channel B will be placed above and below the patella. An apparatus with CE certificate will be used.
1934201|NCT02975089|Dietary Supplement|"multi-nutrient supplement"|"1.3g/d multivitamins & minerals powder
Leaflet content (same as control)"
1934202|NCT02975089|Dietary Supplement|"multi-nutrient & soy protein supplement"|"1.3g/d multivitamins & minerals powder
16g/d isolated soy protein powder
Leaflet content (same as control)"
1934203|NCT02975089|Dietary Supplement|Nutrition education on balanced diet & food supplement|"Nutrition education with a designed plate
10g/d mixed nuts (cashews, pumpkin seeds, walnuts, macadamia, pine nuts, and almonds)
25g/d milk powder (skimmed and calcium added)
Leaflet content (same as control)"
1934206|NCT02974647|Drug|Ruxolitinib|
1934212|NCT02973178|Device|Scanadu Urine Device|Device to allow lay user to perform urinalysis test at home.
1934213|NCT02971930|Biological|BAY94-9027|Intravenous infusion of BAY94-9027
1934217|NCT02965989|Procedure|Online training of a nursing technique|The professionals with participant in the experimental arm receive an online training of a technique of extraction of blood culture and other arm the professionals no receive any training. They work as usual.
1934218|NCT02966509|Behavioral|EPAC|Each patient will receive a lay health worker who will engage and educate patients on goals of care documentation and will continue to address goals of care for at least 6 months with patients after enrollment in the study.
1934219|NCT02966015|Device|Coloplast test catheter|This is a newly developed catheter
1934220|NCT02965287|Other|Serum metabolomics profiling|The serum samples will be used to get a metabolomic profile
1934221|NCT02965534|Device|Spectacle/Glasses|
1934222|NCT02964949|Drug|Edoxaban|Edoxaban will be provided in blister packs with active and placebo tablets maintaining the blind, i.e., one 60 mg active tablet and a 15 mg placebo or one 60 mg active tablet and a 15 mg active tablet. Transition doses of 30 mg + 15 mg edoxaban are provided in 14-tablet blister packs.
1934227|NCT02958761|Biological|intraarticular injections of platelet lysate|
1934228|NCT02958761|Drug|hyaluronic acid|intraarticular hyaluronic acid (20 mg/2 mL; Hyalgan, Fidia, Abano Terme, Italy) injections at the same intervals
1934263|NCT02951273|Other|Study of cerebral blood flow|"Measurements are conducted from before induction of anaesthesia and until 2 hours after the start of surgery and include internal carotid artery blood flow, mean arterial pressure, heart rate, stroke volume, cardiac output, total peripheral resistance, forehead skin blood flow and haemoglobin concentrations, depth of anaesthesia, and frontal lobe, skin, and muscle oxygenation. Further measurements are conducted during hyperventilation before induction of anaesthesia and during hypo-, normo- and hypercapnia during anaesthesia.
Blood samples are obtained from the arterial line for evaluation of the arterial CO2 tension and markers of mesenteric traction syndrome. Total volume of blood sampled is less than 75 ml."
1934269|NCT02951598|Drug|Florbetapir F 18 PET Scan|Florbetapir F 18 positron emission tomography (PET) scan performed at baseline to confirm amyloid status. Participants who previously tested amyloid positive were exempt. No therapeutic investigational drug(s) intended to treat AD will be administered.
1934270|NCT02950883|Drug|Active Treatment Group 7% Hypertonic Saline|"Drug: 7% Hypertonic Saline (HS) 4 mL of HS will be administered via inhalation twice daily for 48 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI compressor (PARI Vios® Pro in USA, PARI BOY SX in Australia and Europe).
Other Names:
Hyper-Sal™, inhaled saline"
1934271|NCT02950883|Drug|Control Group 0.9% Isotonic Saline|"Drug: 0.9% Isotonic Saline (IS) 4 mL of IS will be administered via inhalation twice daily for 48 weeks The delivery system is the same as that for the test product.
Other Names: Normal saline"
1934273|NCT02949674|Drug|Ropivacaine|It will be used as a analgesic dose in surgical site before surgery.
1934274|NCT02949674|Drug|Bupivacaine|It will be used as a analgesic dose in surgical site before surgery.
1934275|NCT02949557|Procedure|Decortication + bone grafts|
1934281|NCT02946229|Device|Ultrasound scan|The GE Vivid S70 Ultrasound System will be used to detect signals associated with extravascular lung fluid, cardiac velocity time integral (VTI), and inferior vena cava (IVC) collapsibility.
1934294|NCT02937636|Other|Stannous fluoride|Experimental dentifrice containing 0.454% w/w stannous fluoride & 0.0721% w/w sodium fluoride containing1450 parts per million (ppm) fluoride
1934295|NCT02937636|Other|Sodium monofluorophosphate|Dentifrice containing 0.14% w/w sodium monofluorophosphate containing1400 ppm fluoride
1934296|NCT02936648|Other|QI|HCV Testing QI
1934297|NCT02936544|Drug|BAY987521|Each 50 cm*2 test site area of a subject requires 100 mg of a test material to obtain a standard 2 mg/cm*2 test application. (Formulation Code:Z09-054)
1934302|NCT02930590|Other|Alternating low pressure mattress with air loss function|IsoAir, Stryker, USA
1934303|NCT02930590|Other|Gel mattress|IsoGel, Stryker, USA
1934304|NCT02930590|Other|Basic foam|Standard hospital mattress
1934307|NCT02929407|Drug|FE 204205|
1934308|NCT02929407|Drug|Placebo|
1934309|NCT02928380|Device|Experimental Denture Adhesive|Participants received a single application of test denture adhesive with a Flat Ribbon Nozzle as 3 Continuous strips those were applied to upper denture and one continuous strip that was applied to the lower denture which were placed in the mouth.
1934310|NCT02928380|Device|Reference (Marketed) Denture Adhesive|Participants received a single application of marketed denture adhesive with a flat ribbon nozzle as a 3 dabs those were applied to upper denture and 2 dabs those were applied to lower denture, which were placed in the mouth.
1934319|NCT02928393|Drug|Basmisanil|Basmisanil immediate-release granules at a dose of 240 mg will be given orally twice daily for 90 days.
1934320|NCT02928393|Drug|Placebo|Placebo matched to basmisanil immediate-release granules will be given orally twice daily for 90 days.
1934321|NCT02928276|Other|RheumaKit: Prediction of the response to anti-TNFs DMARDs|
1934323|NCT02927951|Drug|Pregabalin|150mg bid
1934324|NCT02927951|Drug|Placebo|150mg bid
1934325|NCT02927691|Device|EMST|
1934326|NCT02927691|Behavioral|smTAP|
1934327|NCT02925741|Other|Silk-Like Linens|Synthetic moisture-wicking fabric
1934328|NCT02925741|Other|Standard Bed Linen|Standard cotton bed linen will be maintained and changed as needed.
1934332|NCT02924662|Other|There is no intervention.|
1934333|NCT02924051|Behavioral|Motivational Interviewing|"Baseline and monthly assessment of barriers/facilitators of dietary change, ambivalence to change and coaching to resolve barriers and ambivalence."
1934336|NCT02923895|Other|Stannous fluoride|0.454% weight by weight (w/w) stannous fluoride containing 1100 parts per million (ppm) fluoride
1934337|NCT02923895|Other|Sodium monofluorophosphate|0.76% w/w sodium monofluorophosphate containing 1000 ppm fluoride
1934347|NCT02920970|Device|narafilcon A|contact lens
1934348|NCT02920970|Device|stenfilcon A|contact lens
1934349|NCT02920957|Device|comfilcon A|contact lens
1934350|NCT02920957|Device|senofilcon C|contact lens
1934353|NCT02918435|Behavioral|WE CARE|The WE CARE survey consists of 12 questions used to identify six unmet material needs (education, employment, food security, housing, childcare, household heat). It will be administered at health supervision visits during the WE CARE phase at each study site. The Family Resource Book will contain resource information sheets for each of these needs listing available community resources. A physician champion will conduct regular booster sessions every 4 months and train new providers should there be staff turnover.
1934367|NCT02911857|Biological|canakinumab|Patients will continue the study drug based on the final dose and regimen administered at the end of the CACZ885N2301 study. All patients will receive 1 or 2 ACZ885 subcutaneous injections every 4 or 8 weeks.
1934373|NCT02909361|Drug|Fulvestrant|500 mg on days 0, 14, and 28, and every 28 days thereafter
1934374|NCT02908594|Device|Medical Exercise Peddler 3000, Medi-Bike, Taiwan|"A horizontal electromagnetic cycle ergometer (Medical Exercise Peddler 3000, Medi-Bike, Taiwan) was used for the exercise program. The cycling equipment includes the resistance of 6 Levels, from Level 1 the lightest to Level 6 the heaviest. Other indicators examined are RPM (rotary per minute), DICT (The distance for this exercise), TIME (The time of exercise). This is the simplest way to use this Motion Exercise Machine. Press the ST / SP (Start/ Stop) button to start an exercise program for 30 minutes."
1934375|NCT02908854|Other|Adding spices and herbs to school lunch vegetables|Direct measurement of school lunch vegetable intake among students both before and after spices and herbs are added.
1934376|NCT02908217|Drug|Tocilizumab|6 Intravenous infusions of tocilizumab in a dosage of 8 mg/kg (or 4 mg/kg depending on biological results as mentioned by the SPC of Tocilizumab for the rheumatoid arthritis) every 4 weeks.
1934377|NCT02908217|Drug|Placebo|6 Intravenous infusions of placebo every 4 weeks.
1934382|NCT02906358|Behavioral|Clinic-based pain self-care|
1934383|NCT02906358|Behavioral|Community-based pain self-care|
1934386|NCT02905240|Device|nSTRIDE APS|single intra-articular injection
1934387|NCT02905240|Device|Saline|single intra-articular injection
1934394|NCT02902185|Drug|ART plus Chidamide|Chidamide will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
1934395|NCT02902185|Drug|ART plus Placebo|Placebo will be administrated 10mg each time, twice a week, interval not less than 3 days for 12 weeks.Antiretroviral therapy will be kept during entire study.
1934396|NCT02899104|Drug|Xofigo (Radium-223 dichloride, BAY88-8223|Xofigo is indicated for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases and no known visceral metastatic disease.
1934397|NCT02899988|Drug|Mirikizumab|Administered SC
1934398|NCT02899988|Drug|Placebo|Administered SC
1934399|NCT02899520|Other|Reference method|Electrostimulation associated to perineal training
1934400|NCT02899520|Other|CMP ® method|Method based on Knowledge and Control of Perineum
1934401|NCT02899455|Drug|HGP0904|
1934402|NCT02899455|Drug|HGP0608|
1934403|NCT02899455|Drug|HGP0816|
1934404|NCT02899455|Drug|HGP0904 Placebo|
1934405|NCT02899455|Drug|HGP0816 Placebo|
1934406|NCT02898922|Biological|hepatitis B vaccine made by Recombinant DNA Techniques in Saccharomyces Cerevisiae|20 μg HBsAg/1.0ml per dose, Shenzhen Kangtai Biological Products Co., Ltd., Shenzhen, Guangdong Province, China
1934408|NCT02896231|Drug|PLB1001|PLB1001 is a capsule in the form of 25 mg and 100mg, twice daily.
1934446|NCT02890446|Behavioral|upper arm training on the InMotion 2 shoulder robot|"Both groups practiced shoulder and elbow exercises on a robotic arm device under an external focus or internal focus practice condition.
Practiced arm reaching in a clock-like design to facilitate horizontal shoulder flexion, extension, abduction, adduction.
12 sessions--3 times a week for 4 weeks"
1934447|NCT02890108|Dietary Supplement|Sugar sweetened beverages|350 cc (1 can) of sugar sweetened beverage
1934448|NCT02890108|Dietary Supplement|Artificially sweetened beverages|350 cc (1 can) of artificially sweetened beverage
1934459|NCT02886572|Radiation|Stereotactic radiosurgery|Linear-accelerator-based, single-isocenter, image-guided stereotactic radiosurgery
1934460|NCT02886767|Other|skin to skin contact|The researchers facilitated initial SSC between intervention-group participants and their infants within 24 hours of birthing under conditions that did not adversely affect spontaneous mother-infant SSC nor interfere with the early initiation of breastfeeding. Because it is standard practice to discharge vaginal-birth mothers on the third postpartum day, this study implemented the intervention during the first three postpartum days for both vaginal and cesarean birth cases.
1934461|NCT02886598|Drug|degarelix|
1934464|NCT02880293|Drug|melphalan|melphalan (140 mg/m2 IV on day -7)
1934465|NCT02880293|Drug|fludarabine|fludarabine (40 mg/m2/d on days -5 through -2)
1934466|NCT02880293|Drug|thiotepa|thiotepa (5 mg/kg IV on day -67)
1934467|NCT02880293|Drug|Cyclophosphamide|cyclophosphamide (50 mg/kg IV on day +3 and +4)
1934468|NCT02880293|Drug|Mesna|
1934469|NCT02880293|Drug|Mycophenolate Mofetil|(15 mg/kg PO/IV TID)
1934470|NCT02880293|Drug|Filgrastim|
1934471|NCT02880293|Drug|Tacrolimus|
1934474|NCT02878044|Other|Thyroid Decision Aid|The Thyroid Decision Aid is a tool designed to help clinicians and patients discuss treatment options for thyroid nodules.
1934475|NCT02876718|Drug|Rivaroxaban (Xarelto, BAY 59-7939)|No specified dosing or dosage in the study. The treatment decision falls within current practice and the prescription of the medicines is clearly separated from the decision to include the patient in the study.
1934476|NCT02877940|Device|ProSeal Laryngeal mask airway|ProSeal was inserted in mechanically ventilated patients undergoing elective surgeries.
1934477|NCT02877940|Device|Laryngeal Tube Suction- Disposable|LTS-D was inserted in mechanically ventilated patients undergoing elective surgeries.
1934478|NCT02877940|Device|i-gel|i-gel was inserted in mechanically ventilated patients undergoing elective surgeries.
1934479|NCT02876757|Drug|5ARI|Exposure to finasteride/dutasteride
1934480|NCT02876276|Procedure|Hyaluronic acid filler|Papillary augmentation with HA dermal fillers was considered as the test group
1934486|NCT02873104|Device|truSculpt rf device|radiofrequency device
1934488|NCT02873481|Behavioral|Centering Pregnancy Care plus Yoga (CPC+Y)|Gentle prenatal yoga for 30 minutes at the end of the Centering Pregnancy Care session
1934499|NCT02867943|Other|Effects of respiratory rate on gapCO2|respiratory rate was started at 10 breaths/min and added by 2 breaths/min every 60 min up to 16 breaths/min
1934503|NCT02864732|Other|Rehabilitation exercises|
1934504|NCT02864732|Device|Electrical Stimulation|
1934509|NCT02863679|Drug|Tetracaine hydrochloride gel|Tetracaine hydrochloride gel contains 1% tetracaine hydrochloride, and a fair dose of fungicide, lubricants, remove foam agent, as the long-term local anesthetics.
1934510|NCT02863575|Drug|Ibuprofen/Caffeine|Ibuprofen/Caffeine fixed-dose combination
1934511|NCT02863575|Drug|Ibuprofen|Ibuprofen capsule
1934512|NCT02863575|Drug|Placebo|Placebo treatment
1934518|NCT02860169|Behavioral|Participants self-administered questionnaire and assessment|Participants self-administered questionnaire and assessment includes Picture Rating, Picture Surfing Task, Questionnaire and VAS scales, Cognitive Function Assessment, RTI, AST, ERT , RVP.
1934526|NCT02858388|Device|Sinuclean Nebules 45|Nebulization of solution
1934527|NCT02858388|Other|Saline solution|Nebulization of solution
1934528|NCT02856672|Device|Supreme Laryngeal Mask Airway|Supreme Laryngeal Mask Airway
1934529|NCT02856672|Device|Laryngeal Tube Suction Disposable|Laryngeal Tube Suction Disposable
1934531|NCT02857504|Device|double lumen tube with a hook|The tube with the hook (after passing the bronchial cuff trough the vocal cords) was rotated for 180 degrees to the left and removed the stylet and when the hook passed the vocal cords, the tube was rotated for 90 degrees back to the right and push it into the bronchus. Following formula was used for the right depth (height (cm)/10 + 12 (cm)) of the tube without the hook. The tube with hook was inserted into the bronchus so that hook was placed on the carina and stopped.
1934532|NCT02857504|Device|double lumen tube without a hook|Tube without the hook was inserted with the following technique: after the bronchial cuff was passed the vocal cords, the stylet was removed and the tube was rotated 90 st towards left.
1934533|NCT02854111|Other|ice cream|The ice cream was made by nutritionists in Ramathibodi Hospital. It consisted of cornstarch, milk, sucrose, milk powder, egg yolk, and banana which contained carbohydrate 73.9 g, fat 27.7 g, protein 18.9 g for a total of 620.9 kcal with a cost of 35 bahts. The time for complete ingesting 75-g glucose and ice cream was 5 and 15 minutes, respectively.
1934534|NCT02854111|Other|75 g-glucose|The 75-g glucose is used for standard oral glucose tolerance test.
1934535|NCT02851823|Device|Periodontal curettes|
1934536|NCT02851823|Device|Er-YAG+Nd-YAG lasers|
1934541|NCT02852551|Drug|PAT-1251|
1934542|NCT02852551|Drug|Placebo|
1934545|NCT02851758|Other|autologous mitochondria transplantation|Autologous mitochondria obtained from the subject's own skeletal muscle will be injected into the ischemic myocardium
1934546|NCT02851225|Other|telemedicine transmission of biological results|telemedicine transmission of biological informations
1934547|NCT02850822|Drug|Demethylation drug|Demethylation drug,such as Decitabine
1934548|NCT02850822|Drug|Chemotherapy regimen|Chemotherapy regimen,such as CAG, G-CSF 5-10ug/kg/day on days 4 and 17；Aclacinomycin 7mg/m2/day on days 4 and 11；Cytarabine 20mg/m2/day on days 4 and 17.
1934549|NCT02850263|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept for the treatment of DMO by the patient.according to the prescribing physician.
1934550|NCT02850263|Drug|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent [Ophthalmologicals / Antineovascularisation agents (S01LA05)] for the treatment of DMO by the patient.according to the prescribing physician.
1934551|NCT02850263|Drug|Anti-VEGF therapies including: Eylea Aflibercept, VEGF Trap-Eye, BAY86-5321) and Ophthalmologicals / Antineovascularisation agents (S01LA05)|Anti-VEGF exposure is defined as treatment with intravitreal aflibercept or another agent [Ophthalmologicals / Antineovascularisation agents (S01LA05)] for the treatment of DMO by the patient.according to the prescribing physician.
1934552|NCT02849002|Device|BrainPulse|Jan Medical's BrainPulse measures the brain motion caused by pulsatile blood flow from the cardiac cycle, referred to as the BrainPulse signal. The BrainPulse measures skull acceleration in response to the brain motion using an array of sensors placed on the head.
1934555|NCT02846870|Other|Visually enhanced prostate cancer educational presentation|Receive visually enhanced prostate cancer educational presentation
1934556|NCT02846870|Other|Standard prostate cancer education presentation|Receive standard prostate cancer education presentation
1934557|NCT02846025|Dietary Supplement|Folate and capsule of oil hazel|rich diet aministracao folate and capsule of oil hazel
1934558|NCT02846025|Dietary Supplement|Folate and placebo|rich diet aministracao folate and placebo
1934559|NCT02846025|Dietary Supplement|antioxidant and placebo|antioxidant diet (90μg folate) and placebo capsule
1934560|NCT02845700|Behavioral|Perceptual Retraining Treatment|"Perceptual retraining involves the systematic presentation of diluted malodors (i.e., odors perceived as threatening). For each individual, vials on either side of a pre-determined and ideographic detection threshold will be presented. During the retraining, participants will be given feedback to shift their bias away from the malodorous target stimuli. For example, in the context of diluted solutions participants will be given the feedback that they are correct when a neutral response is given to solutions that are above the starting threshold (stronger malodor) and incorrect when a target is endorsed that is below the starting threshold (weaker malodor)."
1934561|NCT02845700|Behavioral|Sham Neutral training|Control condition using systematic presentation of diluted neutral-neutral odor pairs.
1934564|NCT02842801|Other|Hip manipulation|High-amplitude and low-velocity thrust mobilization
1934565|NCT02841787|Behavioral|iCBT for late life depression|
1934572|NCT02838901|Drug|Beet it Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%); 70ml bottle
1934573|NCT02838901|Drug|Beet It Placebo Beetroot juice|Concentrated organic beetroot (98%) and lemon juice (2%) with nitrate extracted; 70ml bottle. Beet It Placebo Beetroot juice.
1934576|NCT02836860|Other|Tactile stimuli|Both groups will receive tactile stimuli: hand touch on the right and left lumbar multifidus muscles at L4-5
1934577|NCT02837016|Device|Wearable biofeedback|
1934578|NCT02837016|Behavioral|Relaxation Treatment|group-based relaxation treatment based on mindfulness meditation principles
1934579|NCT02835443|Device|Deep Brain Stimulation|Electrical stimulation of the dentate nucleus area of the cerebellum.
1934580|NCT02835469|Drug|Menotrophin|
1934581|NCT02835456|Device|Sharklet Catheter insertion|
1934582|NCT02835456|Device|Silicone Foley Catheter insertion|
1934583|NCT02835053|Other|Frailty|Participants will be defined as frail based on the Johns Hopkins ACG Frailty Defining Diagnoses Indicator, which will be applied to available health administrative data in the 3 years preceding index hospital admission. If no frailty defining diagnoses are present participants will be defined as not frail
1934590|NCT02833337|Radiation|Cone-beam computed topography|This study used a retrospective database of preexisting data that included patients treated as part of routine periodontal and oral surgery therapy for each patient's needs. All the patients signed an inform consent approving using their radiographic data for research purposes.
1934591|NCT02831569|Drug|Loxoprofen sodium|
1934592|NCT02831569|Drug|Methocarbamol|
1934593|NCT02831660|Drug|idarucizumab|
1934609|NCT02825966|Device|LifeVest|Wearable Cardioverter Defibrillator
1934614|NCT02825706|Other|Educational physiotherapy group|20 patients with hemophilia were randomly allocated to an educational intervention or to a control group. The educational intervention was performed every two weeks during 15-week and home exercises were performed once a day, 6 days a week, in the same time
1934615|NCT02825550|Device|Taiwan ACE Beads|The procedure is similar with conventional TACE. Radiologist inject lipiodol with doxorubicin first, then use Taiwan ACE Beads instead of Gelfoam or polyvinyl alcohol.
1934616|NCT02824770|Behavioral|Dimming of lights and decreasing noise level|The study intervention will include dimming of lights and decreasing noise level. The lights will be dimmed to 40 lux and the doors of the side-room will be closed to decrease the noise level below 40 dB between 11:00 p.m.-5:00 a.m
1934617|NCT02824770|Drug|Bupivacaine (Bustesin®) via Pain Buster ® system|Patients will receive continous infusion of Bupivacaine (Bustesin®) via Pain Buster ® system into the wound at a rate of 5cc/hour
1934618|NCT02824770|Drug|Tramadol HCl (Tramosel®) via PCA system (Gemstar®)|Patients will receive infusion of Tramadol HCl (Tramosel®) via patient-controlled analgesia system (Gemstar®)
1934619|NCT02824770|Procedure|Major abdominal surgery|Any major abdominal surgery (e.g. colectomy, gastrectomy)
1934623|NCT02823665|Drug|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 on glucose metabolism and insulin secretin after glucose and protein ingestion.
1934624|NCT02823665|Drug|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism.
1934628|NCT02822612|Device|Binocular OCT prototype|Testing will begin using a prototype binocular OCT system. Subjects will undergo the full suite of diagnostic assessments offered by the system at that time (i.e., visual acuity, ophthalmic history, pupillometry, ocular motility, perimetry, anterior segment and posterior segment OCT imaging).
1934630|NCT02821416|Biological|Benralizumab|Benralizumab subcutaneously on study day 0 until study week 16 day 1 inclusive
1934631|NCT02821416|Other|Placebo|Placebo subcutaneously on study week 0 until study week 16 day 1 inclusive
1934632|NCT02821143|Other|usual palliative care|Residents in the control group will receive usual palliative care usually delivered in their nursing homes , according to the habits of the healthcare team and their physician.
1934723|NCT02786355|Other|Frova bougie|Squeezing Ambu bag and ventilating through a Frova bougie and measuring mean volumes of air delivered
1934633|NCT02821143|Other|Telemedicine consultation|"Establishment of an initial multiprofessional Telemedicine consultation involving a palliative care physician and / or geriatrician, and other physician coordinator of nursing homes, health care team and if possible the patient's treating physician (patient and / or family may participate if they want to).
The aim is to define and formalize:
Aid to collection and application of advanced directives according to Leonetti Act if the resident is able to do so, or collection of confidence personal choices.
Definition of the objectives of care and patient's life and therapeutic adaptation with a focus on pain and uncomfortable symptoms.
Access to a mobile team of palliative care or geriatric hospitalization at home, a hospice network, if the patient's situation requires.
In case of medical worsening :
Possibility of access to consultations and use of emergency by tele-expertise or decision support within a maximum period of 72 hours, with the same objectives that above."
1934634|NCT02818998|Biological|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|
1934635|NCT02820051|Device|Transcutaneous CO2 monitor|Measurement and surveillance of transcutaneous CO2 pressure (PtcCO2) to determine PtcCO2 behavior for each sedation group.
1934636|NCT02820051|Drug|Midazolam|The initial dose was 0.05 mg/kg. Additional doses of 2 mg of midazolam were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
1934637|NCT02820051|Drug|Propofol|The initial dose was 0.1 mg /kg. Additional doses of 10 mg of propofol were allowed to reach a score level of three to four in the Observer´s assessment of alertness/ sedation scale.
1934638|NCT02820051|Drug|Nalbuphine|The starting dose was 2 mg with additional doses of 1 mg if it was necessary.
1934639|NCT02820051|Drug|Lidocaine|Lidocaine spray was applied to the nasal mucosa and pharynx for bronchoscope nostril insertion, and only in the pharynx for bronchoscope oral insertion. Topical lidocaine was applied using the spray-as-you-go technique, at a maximum dose of 7 mg/kg.
1934640|NCT02819518|Biological|Pembrolizumab|IV infusion
1934641|NCT02819518|Drug|Nab-paclitaxel|IV infusion
1934642|NCT02819518|Drug|Paclitaxel|IV infusion
1934643|NCT02819518|Drug|Gemcitabine|IV infusion
1934644|NCT02819518|Drug|Carboplatin|IV infusion
1934645|NCT02819518|Drug|Normale Saline Solution|IV infusion
1934647|NCT02816918|Device|Extraluminal use of Univent bronchial Blocker|"Patients assigned to the Extraluminal use of Univent Blocker group were first inserted Univent bronchial Blocker into the glottis via direct laryngoscopy then advanced the Blocker to the target bronchus until slight resistance was encountered.A conventional tracheal tube with appropriate size was intubated via direct laryngoscopy into the appropriate depth, inflating the tracheal tube cuff, and fixing the tube firmly at the patient's mouth with cloth tape .
So the Univent Blocker Extraluminal of the endotracheal tube,then the fibreoptic bronchoscopy was inserted into the tracheal tube and guided bronchial blocker cuff to the target main bronchus under direct vision"
1934648|NCT02816918|Device|Innerluminal use Univent bronchial Blocker|Patients in Innerluminal use of Univent Blocker group: When the endotracheal tube had been intubated via direct laryngoscopy, the bronchial blocker was advanced Innerluminal of the endotracheal tube and directed into the right or left mainstem bronchus, then the fibreoptic bronchoscopy was inserted into the tracheal tube. After further pushing and twisting, the bronchial blocker tube will move into the mainstem bronchus under direct vision by FOB.the tracheal tube cuff is inflated with the tube being fixed firmly at the patient's mouth with cloth tape
1934649|NCT02817152|Procedure|Periodontal ultrasonic debridement|Periodontal pockets received periodontal ultrasonic debridement intervention.
1934650|NCT02817152|Device|Debridement plus low-level laser therapy|Ultrasonic debridement plus low-level laser therapy.
1934652|NCT02815644|Drug|empagliflozin/linagliptin FDC|empagliflozin/linagliptin fixed-dose combination (FDC) film-coated tablet
1934653|NCT02814890|Procedure|Video-assisted Pneumonectomy|Video-assisted Pneumonectomy under general anesthesia.
1934654|NCT02814890|Procedure|Thoracic paravertebral block|The procedure is guided by ultrasound combined with nerve stimulator at T3-4, T4-5, T5-6, T6-7 of surgical side.
1934657|NCT02814318|Biological|Vaginal and rectovaginal swab cultures|The only intervention that will occur in this study is obtaining vaginal and recto-vaginal swab cultures upon admission to the labor and delivery room and every two hours to follow until 8 hours after administration of IV vancomycin or IV penicillin.
1934658|NCT02813798|Drug|Rivipansel|A single 840mg dose of Rivipansel over 20 minutes
1934663|NCT02809989|Drug|Ovaleap®|"About 6-8 weeks of observation per patient from start of the stimulation therapy with Ovaleap® depending on the duration of the required stimulating therapy. Up to 10-11 months per patient for follow-up but only if in case of songraphically intact intrauterine pregnancy to determinate the Baby-Take-Home-Rate (live-births)."
1934664|NCT02809703|Other|Survey Questions|Subjects will receive surveys via direct mail. They will be given the opportunity to opt in to receive a phone call regarding quality of life.
1934668|NCT02807272|Drug|Tipifarnib|Oral tablet
1934671|NCT02806245|Other|Biventricular pacing|"Randomization into one of 3 study arms for acute phase and for extended phase.
Measurement of baseline variables on arrival to CCU. Acute pacing protocol (order of pacing randomized):
Atrial sensing- right ventricular pacing 10 min.
5 min no pacing (washout).
Atrial sensing - biventricular pacing 10 min.
5 min no pacing (washout).
Intrinsic rhythm
5 min no pacing (washout). Start extended phase pacing according to randomization. Measure hemodynamic variables 10 min after start of pacing.
Measure hemodynamic variables 30 min after start of pacing. Pacing hiatus for 60 minutes at 24 hours with measurement of hemodynamics without pacing and after reinitiating pacing.
Stop pacing at 72 hours or after extubation, whichever comes first. For those patients who are extubated before 72 hours: measurements will be taken before extubation and one hour after extubation. Pacing will then be stopped."
1934672|NCT02803437|Drug|Radium-223 dichloride (Xofigo, BAY 88-8223)|Xofigo treatment will be performed according to the product label in Japan under the routine clinical practice.
1934675|NCT02804399|Drug|PF-06463922|100 mg oral dose on day 1 in period 1 and on day 8 in period 2
1934676|NCT02804399|Drug|rifampin|600 mg QD from day 1 to day 12 in period 2.
1934681|NCT02803801|Behavioral|Build Your Parenting Toolkit Program|Ten session program, with a mix of parents-only lectures and parent and child Cooking Clubs.
1934682|NCT02803788|Drug|ramosetron, ondansetron, dexamethasone|prevention of post-operative nausea vomiting
1934687|NCT02802007|Device|Elipse Intragastric Balloon|
1934688|NCT02800642|Drug|Eylea (Aflibercept, VEGF Trap-Eye, BAY86-5321)|The recommended dose for intravitreal aflibercept is 2 mg equivalent to 50 μL Study treatment will be administered at baseline and at monthly intervals until stabilization of disease. When stability is achieved, the treatment interval can be extended based on visual and anatomic outcomes as judged by the treating investigator.
1934689|NCT02799641|Drug|Diazepam|5 mg Diazepam
1934690|NCT02799641|Drug|Lidocaine|2 ml of 2% lidocaine
1934691|NCT02799641|Other|Placebo pill|Placebo pill
1934692|NCT02799641|Other|Placebo injection|Placebo injection
1934697|NCT02799290|Biological|ADIPOSE TISSUE EXTRACT|Adipose tissue extract is obtained on site with lipoaspirate adipose tissue prepared though incubation and filtration
1934698|NCT02799290|Biological|PLATELET-RICH PLASMA GEL|Autologous platelet rich plasma is obtained onsite and activated following commercial kit instructions
1934704|NCT02794220|Device|CN electronic cigarette 10 mg|Inhalation
1934705|NCT02794220|Device|CN electronic cigarette 15 mg|Inhalation
1934706|NCT02794220|Device|Nicorette Inhalator 15 mg|Inhalation
1934707|NCT02794220|Other|Cigarette|Inhalation
1934710|NCT02794038|Device|Soberlink Cellular Device|BAC breath analyzer
1934711|NCT02794038|Device|BACtrack S80 Pro|BAC breath analyzer
1934712|NCT02793141|Other|No intervention|No intervention will be administered
1934715|NCT02792062|Drug|TAK-385 40 mg|TAK-385 40 mg
1934718|NCT02788487|Device|Tongue retaining device|Tongue retaining device is used for 3 weeks
1934719|NCT02788487|Device|CPAP|CPAP is used for 3 weeks
1934720|NCT02787707|Drug|Persumac|2.7 grams Persumac powder (Iranian traditional medicine remedy composed from sumac and Bunium Persicum) every 8 hour
1934721|NCT02787707|Drug|lactose|2.7 grams Lactose every 8 hour
1934833|NCT02754440|Device|Trima Accel System with Version 7.0 Software|Platelet Apheresis Procedure
1934724|NCT02786147|Other|Breast Cancer Genetics Referral Screening Tool 3.0|"The B-RST is a simple yet effective validated screening tool to quickly identify individuals who may be at risk for hereditary breast and ovarian cancer and should be referred for cancer genetic counseling to formally evaluate their family history and discuss the benefits and limitations of genetic testing for hereditary breast and ovarian cancer.
Clinic staff will give each patient arriving for a screening mammogram appointment a packet and briefly inform them about the opportunity to participate in a research study and that these materials can help them decide whether or not to participate.
Patients who indicate that they are interested in completing the B-RST screening while in the clinic will be provided with an electronic tablet that has a secure internet browser tab open to the web-based study version of the screening tool (the B-RST 3.0)."
1934725|NCT02786147|Other|Standard Handout|A document explaining the patient's positive test result indicating that they are at increased risk for HBOC (Hereditary Breast or Ovarian Cancer) which includes information on how to obtain cancer genetics services through Winship.
1934726|NCT02786147|Other|Physician Notification|Primary care physician or ordering physician will be notified vie EeMR that the patient screened positive on the B-RST. The note provides specific instructions on how to refer the patient for cancer genetic counseling services.
1934727|NCT02786147|Other|Automatic Follow-Up by Genetic Counseling Staff|Within 1-2 weeks after the mammogram appointment, patients will receive a phone call from a genetics counseling staff person to explain their screening result and to offer to set up a genetics counseling appointment.
1934728|NCT02785770|Drug|PF-04447943|Single oral dose of PF-04447943 administered as an extemporaneously prepared solution
1934729|NCT02785770|Device|Placebo|Single oral dose of matching placebo for PF-04447943 administered as an extemporaneously prepared solution
1934730|NCT02785770|Drug|Moxifloxacin|Single oral dose of moxifloxacin administered as tablet
1934731|NCT02785055|Procedure|Thoracic Epidural Placement|Thoracic Epidural Placement
1934732|NCT02785055|Drug|Bupivacaine 0.05%|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
1934733|NCT02785055|Drug|Hydromorphone 0.01mg/mL|Delivery of epidural solution containing both bupivacaine 0.05%/hydromorphone0.01mg/mL solution
1934734|NCT02784002|Drug|Ridinilazole|
1934735|NCT02784002|Drug|Fidaxomicin|
1934736|NCT02783807|Device|Eyenez Retinal Camera v200|
1934737|NCT02783807|Device|Volk Pictor Ret 1|
1934745|NCT02779777|Drug|Tipifarnib|900 mg b.i.d. Days 1 -7, 15-21 in 28-day cycle
1934747|NCT02779166|Drug|Celecoxib|Received 400mg celecoxib prior to surgery
1934748|NCT02779166|Drug|placebo|
1934762|NCT02775240|Drug|Digoxin|0.5 mg (2 x 0.25 mg) Digoxin oral dose
1934763|NCT02775240|Drug|Maribavir|200mg twice a day for 8 days
1934764|NCT02775240|Drug|Dextromethorphan|30 mg oral dose
1934767|NCT02773836|Other|Questionnaire|Questionnaire: To evaluate the impact of the implementation of the EU Tobacco Products Directive (TPD) and Framework Convention on Tobacco Control (FCTC)
1934768|NCT02773602|Drug|Dexamethasone|200 μgm/kg of dexamethasone in 1 ml saline
1934769|NCT02773602|Drug|Clonidine|2 μg/kg of clonidine in 1 ml saline
1934770|NCT02773602|Drug|Normal Saline|1 ml of saline added to the ropivacaine, 0.2%, 1 ml/kg
1934771|NCT02773381|Drug|semaglutide|Oral administration once-daily.
1934772|NCT02773381|Drug|placebo|Oral administration once-daily.
1934773|NCT02772016|Drug|Colla corii asini|15 g of Colla corii asini in powder form daily for 4 weeks
1934820|NCT02759419|Drug|Adempas (Riociguat, BAY63-2521)|0.5 to 2.5 mg in 0.5 mg increments (according to individual adapted optimal dose determined in originating study) administered three times daily (tid)
1934776|NCT02772562|Biological|PROSTVAC-V/F|"0.5 ml containing at least 2 x 108 Infectious Units (Inf.U) PROSTVAC-V given on day 1.
0.5 ml containing at least 1 x 109 Inf.U PROSTVAC-F given on days 15, 28, 57, 85, 113, 141."
1934778|NCT02772419|Drug|benralizumab|SC administration
1934779|NCT02772419|Drug|benralizumab|SC administration
1934780|NCT02772419|Drug|Placebo|SC administration
1934781|NCT02770534|Procedure|blood test|10mls extra mls of blood taken during usual phlebotomy procedures
1934783|NCT02771171|Radiation|CT Scan|CT imaging
1934785|NCT02768194|Device|Stannous fluoride|Dentifrice containing 0.454% stannous fluoride
1934786|NCT02768194|Other|Sodium monofluorophosphate|Dentifrice containing 0.76% sodium monofluorophosphate
1934787|NCT02768194|Other|Mineral water|Commercially available mineral water
1934788|NCT02768168|Drug|dezocine|receive dezocine 0.1 mg/kg
1934789|NCT02768168|Other|normal saline|receive matching placebo (equal volume of normal saline)
1934790|NCT02767128|Drug|Triferic|
1934791|NCT02767128|Drug|Fer-In-Sol|
1934792|NCT02767128|Drug|Shohl's solution|
1934793|NCT02766855|Drug|Cysteamine|Patients were asked to use topical cysteamine 0.55% eye drops every 2 hours while awake to both eyes.
1934794|NCT02766062|Other|metabolic syndrome|metabolic syndrome
1934795|NCT02766283|Drug|iodinated contrast agents|Intravascular application
1934796|NCT02766179|Device|CPAP|CPAP is used for 6 weeks
1934797|NCT02766179|Device|Somnoguard|Somnoguard is used for 6 weeks
1934801|NCT02764970|Drug|Ivabradine 7.5mg orally|additive use to the standard medication with bisoprolol
1934802|NCT02764450|Device|Astralis 10 HPM|The cavity to be filled is in quadrant I or III
1934803|NCT02764450|Device|Astralis 10 RM|The cavity to be filled is in quadrant II or IV
1934804|NCT02763501|Procedure|closure of mesenteric defects|Closure of mesenteric defects by use of non-absorbable running sutures in RCT; and according to the choice of the surgeon in the non-RCT
1934805|NCT02763501|Procedure|non-closure of mesenteric defects|Mesenteric defects are left open
1934806|NCT02763943|Behavioral|Pharmacist-led, technology enabled education intervention|Prospective, non-randomized, pilot study assessing the feasibility and potential efficacy of a 6-month, pharmacist-led, technology enabled education intervention on improving medication safety and cardiovascular risk factor control in adult solitary kidney transplant recipients with a secondary aim of assessing if the impact of the intervention varies by race.
1934807|NCT02761642|Drug|r-HuEPO|All participants will receive r-HuEPO 30000 International Units (IU) SC injection once in every week for a total of 12 weeks.
1934812|NCT02761694|Drug|ARQ 751|Subjects will receive ARQ 751 orally at the dose level and administration schedule specified for their respective dose cohort on a 28 day schedule.
1934817|NCT02760056|Drug|Liothyronine sodium|Subjects will be divided into 4 groups of progressively escalating doses. Each group will have 6 subjects 4 will recieve the active treatment and 2 will receive the placebo. The first group will receive 25 mcg twice daily for one week. The second group will receive 37.5 mcg twice daily for one week. The third group will receive 50 mcg twice daily for one week. The forth group will receive 75 mcg twice daily for one week.
1934818|NCT02760056|Drug|Placebo|Patient will receive a matching placebo to take twice daily for one week.
1934819|NCT02759432|Other|High-intensity interval exercise training|
1934834|NCT02752594|Biological|probiotic|Probiotic was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
1934835|NCT02752594|Other|placebo|placebo was administered for a period of 14 consecutive days. Saliva was collected on Day 1, before intervention and on Day 15, after intervention
1934836|NCT02753127|Drug|Napabucasin|Napabucasin 240 mg will be administered orally, twice daily, with doses separated by approximately 12 hours (480 mg total daily dose).
1934837|NCT02753127|Drug|Fluorouracil|
1934838|NCT02753127|Drug|Leucovorin|
1934839|NCT02753127|Drug|Irinotecan|
1934840|NCT02753127|Drug|Bevacizumab|
1934843|NCT02752490|Drug|Liberal use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask with any category 2 tracing as defined by ACOG10 at the discretion of the primary nurse or physician
1934844|NCT02752490|Drug|Indicated use of maternal oxygen|Administration of maternal oxygen, 100% FiO2 at 10L/min via nonrebreather face mask only in the setting of a category 2 tracing with recurrent late fetal heart rate decelerations, prolonged fetal deceleration, fetal tachycardia, or minimal to absent fetal heart rate variability lasting 30 minutes or greater. Maternal oxygen is discontinued once these conditions have resolved and may be readministered if they recur.
1934851|NCT02752217|Other|Inspiratory Muscle Training|Inspiratory muscle training at 25%MIP with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
1934852|NCT02752217|Other|Control|Inspiratory muscle training at 2 cmH2O with Slow breathing at 6 breath per min with BreatheMAX device for 8 weeks at home
1934853|NCT02750917|Drug|Lornoxicam|At the end of surgery patients in group LORNOXICAM received one pill of 8 mg lornoxicam every 12 hours in the surgery day and first postoperative day.
1934854|NCT02750917|Drug|Etoricoxib|At the end of surgery patients in the ETORICOXIB group received one pill of 120 mg etoricoxib at the end of surgery and a second one after 24 hours. This group also received placebo pills at 12 h, between the active pills.
1934855|NCT02749396|Drug|Betaseron (Interferon beta-1b, BAY86-5046), Bayer HealthCare AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
1934856|NCT02749396|Drug|Extavia (interferon beta-1b), Novartis Pharma AG|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
1934857|NCT02749396|Drug|Rebif (interferon beta-1a), Merck Serono Europe Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
1934858|NCT02749396|Drug|Plegridy (peginterferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
1934859|NCT02749396|Drug|Avonex (interferon beta-1a), Biogen Idec Ltd|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
1934860|NCT02749396|Drug|MSDMDs other than Betaseron (Interferon beta-1b, BAY86-5046)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
1934861|NCT02749396|Other|No MSDMDs therapy (control)|Information will be obtained from the databses DPP (FIN) and MBR (SWE, NOR)
1934867|NCT02750306|Drug|Suvorexant 10 mg|
1934868|NCT02750306|Drug|Suvorexant 20 mg|
1934869|NCT02750306|Drug|Placebo|Placebo to suvorexant
1934870|NCT02748785|Drug|Methotrexate|Methotrexate will be continued
1934871|NCT02748785|Biological|Seasonal Influenza vaccine|all subjects will be vaccinated with a seasonal influenza vaccine
1934873|NCT02747524|Other|Vita Mamba peanut butter paste|
1934874|NCT02744742|Drug|Decitabine|Decitabine was administered at 20mg/m2/day on days -14 and -10.
1934875|NCT02744742|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
1934876|NCT02744742|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
1934877|NCT02744742|Drug|Granulocyte Colony-Stimulating Factor(G-CSF)|G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.
1934878|NCT02744820|Drug|GMC-252-L-Lysine Salt|1 dose by oral route, once a day, 28 days
1934879|NCT02744820|Other|Placebo|Matching doses by oral route, once a day, 28 days
1934880|NCT02744703|Drug|total-etch adhesive|comparator use of total-etch adhesive
1934881|NCT02744703|Drug|CAPE-T|experimental group
1934882|NCT02744703|Drug|self-etch adhesive|comparator use of total-etch adhesive
1934883|NCT02744703|Drug|CAPE-S|experimental group
1934884|NCT02743962|Device|Therapeutic Wand|The therapeutic wand will be used to apply a gentle caudad pressure on the pelvic floor, encouraging a release and gentle stretch of the muscles. The participants will follow a protocol of sweeping gently along one side then the other to find tender or tight areas, and then to apply the wand to relax and stretch the muscles for up to 5 minutes in total, twice weekly for the duration of the study.
1934885|NCT02743962|Other|Routine physiotherapy control|Provision of routine physiotherapy care as control
1934891|NCT02739321|Device|Sound to Sleep System turned on|The sound to sleep system will be turned on during this arm of the study
1934892|NCT02739607|Behavioral|Transdiagnostic program|This transdiagnostic program is based on the general Cognitive Behavioral Therapy (CBT) principles and targets core higher order factors such as negative affectivity and emotion dysregulation, using common intervention techniques applicable across disorders. The program was designed to directly address the aversive emotional experiences often reported by clients, hoping to reverse participants' maladaptive thinking style and dysfunctional behaviors.
1934893|NCT02739100|Drug|Triferic|
1934894|NCT02739113|Biological|Cultivated oral mucosal epithelial cell|Cell therapy for treating severe limbal stem cell deficiency using cultivated autologous oral mucosal epithelial cells.
1934895|NCT02737891|Drug|Tesofensine/Metoprolol|Tesofensine 0.5 mg + Metoprolol 100 mg
1934896|NCT02737891|Drug|Placebo|
1934900|NCT02737917|Other|Oxygen|15 L of oxygen will be delivered to the patient by nasal cannula during the apnea period of rapid sequence intubation.
1934901|NCT02737917|Other|Standard of care|Rapid sequence intubation
1934903|NCT02737397|Drug|JMI-001 (SJP-304 and SJP-223)|
1934904|NCT02737397|Drug|SJP-304|
1934905|NCT02737397|Drug|SJP-223|
1934906|NCT02737397|Drug|placebo|
1934909|NCT02735629|Drug|CX1739 - 300 mg|Ampakine CX1739 - 300 mg
1934910|NCT02735629|Drug|CX1739 - 600 mg|CX1739 - 600 mg
1934911|NCT02735629|Drug|CX1739 - 900 mg|CX1739 - 900 mg
1934912|NCT02735629|Drug|Placebo|Placebo to 300 mg CX1739
1934913|NCT02735018|Drug|Epinephrine 1:100,000|Inferior alveolar nerve block with Epinephrine 1:100.000
1934914|NCT02735018|Drug|Epinephrine 1:200,000|Inferior alveolar nerve block with Epinephrine 1:200.000
1934915|NCT02735499|Drug|onabotulinum toxin A|Onabotulinum toxin A is installed into the bladder and EMDA (Electromotive Drug Application) is applied for 30 minutes
1934916|NCT02735187|Device|Blue light treatment|Phototherapy of localized psoriasis vulgaris plaque with a wearable device emitting blue light at 453nm.
1934917|NCT02735187|Drug|Vitamin D|Treatment of contralateral localized psoriasis vulgaris plaque with Vitamin D creme (Daivonex)
1934920|NCT02732756|Behavioral|Healthy Sleep Duration|This study examines healthy sleep duration as related to improved functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are able to obtain 9 hours of nightly sleep (9.5 hours in bed, leaving up to ½ hour to fall asleep). Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
1934921|NCT02732756|Behavioral|Shortened Sleep Duration|This study examines shortened sleep duration as related to poorer functioning in adolescents with ADHD. Adolescent participants will be instructed to go to bed at a time such that they are in bed for 6.5 hours per night. Researchers will work with the adolescent and their family to problem-solve how to accomplish this sleep duration goal.
1934922|NCT02731560|Drug|Rituximab|"Rituximab was administered as an intravenous infusion as per approved protocol on Day 1 and day 14. The protocol stipulated the administration of intravenous hydrocortisone 100 mg and oral pheniramine maleate 43.5 mg as pre-medication. The Rituximab itself was given as a 1 gm infusion slowly over a period of 4-6 hours.
This was done either by a specialist nurse or a trained doctor."
1934928|NCT02727816|Device|filcon IV I (BC 8.6)|control lens
1934929|NCT02727816|Device|filcon IV I (BC 8.7)|control lens
1934930|NCT02727816|Device|ocufilcon D|test lens
1934931|NCT02727816|Device|methafilcon A (BC 8.6)|control lens
1934932|NCT02727816|Device|methafilcon A (BC 8.7)|control lens
1934933|NCT02727816|Device|somofilcon A|test lens
1934943|NCT02727036|Dietary Supplement|Pumpkin seed oil|1 gram capsule of Pumpkin seed oil.
1934944|NCT02727036|Dietary Supplement|Pumpkin seeds|4.1 grams (1½ teaspoons/~0.15ounces) of pumpkin seeds
1934945|NCT02727049|Other|Osteopathic manipulative medicine (OMM)|Osteopathic manipulative medicine includes all types of manual therapies to gently restore and/or optimize one's natural joint, muscle, and other soft tissue balance.
1934946|NCT02725957|Drug|Trehalose for IV Infusion|
1934947|NCT02725957|Drug|Saline 0.9% IV|
1934951|NCT02725281|Other|Stress ball|The patients in this group were given stress ball into their both palms 5 min before the lithotripsy and told to squeeze the ball whenever they would like until end of the process. This ball was medium hard and has been made of high quality silicon.
1934952|NCT02725281|Other|Music|The patients in this group were also listened to the music chosen by them with a headset from 5 min before until the end of lithotripsy. Types of music played for the patients were Turkish folk music, Turkish art music, Turkish arabesque music, Turkish pop music, foreign pop music, rock music, and classical music.
1934953|NCT02724644|Biological|COLLAGENASE CLOSTRIDIUM HISTOLYTICUM|Injectable intervention
1934954|NCT02724644|Biological|Placebo Comparator|
1934955|NCT02724618|Drug|Curcumin|120mg/d oral nanocurcumin (3 capsules of SinaCurcumin®40 per day) 3 days before and during radiotherapy
1934956|NCT02724618|Radiation|RT|EBRT is delivered as Intensity-Modulated Radiation Therapy (IMRT) or 3D-conformal RT
1934957|NCT02724618|Drug|Placebo|Placebo (3 placebo capsules of SinaCurcumin®40 per day), 3 days before and during radiotherapy
1934958|NCT02724592|Device|self assembling peptide P11-4 (Curodont™ Repair)|Applying of self assembling peptide P11-4 (Curodont™ Repair) on teeth with initial caries lesions
1934959|NCT02724592|Device|fluoride varnish (Duraphat®)|Applying fluoride varnish (Duraphat®) on teeth with initial caries lesions
1934960|NCT02722759|Other|hemoglobin measurement|
1934961|NCT02723201|Drug|TAK-020 Captisol Oral Solution|TAK-020 solution.
1934962|NCT02723201|Drug|TAK-020-CCT|TAK-020 co-crystal tablet
1934963|NCT02723201|Drug|TAK-020-SDT|TAK-020 Solid dispersion tablet.
1934964|NCT02723201|Drug|TAK-020-IRT|TAK-020- immediate release tablet.
1934965|NCT02723201|Drug|TAK-020 Solid Formulation|TAK-020 solid formulation.
1934966|NCT02722239|Drug|Xigduo XR|a single oral dose of modified release fixed dose combination film-coated tablet consisting of 10 mg dapagliflozin IR and 1000 mg metformin hydrochloride extended release
1934967|NCT02722239|Drug|Metformin ER (Glucophage® long)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
1934968|NCT02722239|Drug|Dapagliflozin (Forxiga)|co-administration of a single oral dose of 10 mg dapagliflozin film-coated tablet (Forxiga™) and two tablets 500 mg metformin hydrochloride extended release tablets (Glucophage® long).
1934969|NCT02720718|Device|Stratafix|
1934970|NCT02720718|Device|Vicryl|
1934971|NCT02720614|Radiation|Hypofractionated radiation/chemotherapy|Procedure: Radiation Therapy Drug: Vinorelbine Drug: Carboplatin Drug: Paclitaxel Drug: Cisplatin
1934974|NCT02718794|Procedure|Simulation training|spend 3 hours for each of 10 nurse anesthetist students with 4 scenarios
1934975|NCT02718794|Procedure|Problem-based learning|spend 3 hours for PBL steps with each of 10 nurse anesthetist students
1934976|NCT02718248|Device|CHESS Mobile Health smart phone application|A smart phone application designed to reduce intentional self-harm through problem solving e-therapy.
1934977|NCT02718248|Behavioral|Problem solving therapy|Face to face problem solving therapy every week for six weeks.
1934978|NCT02716714|Drug|ingenol mebutate gel 0.015%|-Face or Scalp arm (Referred to Face/Scalp arm): Apply ingenol mebutate gel 0.015% once daily for 3 consecutive days
1934979|NCT02716714|Drug|ingenol mebutate gel 0.05%|-Trunk or Extremities arm (Referred to Trunk/Extremities arm): Apply ingenol mebutate gel 0.05% once daily for 2 consecutive days
1934980|NCT02714868|Behavioral|Project TEAM|Project TEAM is a manualized, group-based intervention designed to be co-facilitated by an experienced leader with a disability (disability advocate) and a licensed service provider (such as an occupational therapist, social worker, or educator). Project TEAM includes eight group sessions and two experiential learning field trips for each participant. Weekly phone calls with peer mentors with disabilities support achievement of each participant's personal activity goal.
1934981|NCT02714868|Behavioral|Matched Comparison|Participants set goal to try a new activity in the community
1934982|NCT02713724|Behavioral|physical exercise|DAPS-group will follow a personal adjusted training program including instructions from a personal trainer Standard-group will receive a membership at a gym but limited instructions
1934983|NCT02713724|Behavioral|limited physical exercise|The standard group will receive a membership at a gym but limited instructions and no access to a personal trainer
1934984|NCT02713711|Radiation|phototherapy|Twelve sessions of phototherapy (UV-B) according to individual initial evaluation of Minimal Erythema Dose (MED).
1934985|NCT02713711|Procedure|balneotherapy|Twelve sessions of 15 minutes of balneotherapy (warm water, 32 °C and natural sea salt, 250 g/L).
1934986|NCT02713711|Procedure|balneophototherapy|Twelve sessions of both balneotherapy and phototherapy treatments.
1934987|NCT02713672|Other|Dose adjustment according to genotype|Patients in the intervention group received a dose adjustment according to their CYP2D6 or CYP2C19 genotype based on guidelines of the KNMP
1934988|NCT02712476|Drug|mannitol|This drug is in our routine use of neuroanesthesia, are given in peroperatifyl brain relaxation
1934989|NCT02712476|Drug|Furosemide|This drug is can be used alone or with mannitol for brain relaxation
1934990|NCT02712476|Drug|placebo|mannitol alone is compared with placebo
1934995|NCT02712554|Drug|Treatment A low dose CL-108|Treatment A low dose CL-108
1934996|NCT02712554|Drug|Treatment B high dose CL-108|Treatment B high dose CL-108
1934997|NCT02712554|Drug|Treatment C low dose M366|M366 Low Dose
1934998|NCT02712554|Drug|Treatment D high dose M366|M366 High Dose
1934999|NCT02712554|Drug|Placebo|Placebo
1935000|NCT02710643|Drug|OFATUMUMAB|8 weekly infusion of 1000 mg total dose
1935001|NCT02712021|Other|Lycra suit and physiotherapy treatment|Garments will be fitted by an occupational therapy with the treating therapist and child neurologist present. The garments will be constructed of Lycra with the possibility of adding reinforcing panels or derotation bands. All the children will be involved in regular physiotherapy treatment (2-3/week).
1935002|NCT02712021|Other|physiotherapy treatment|All the children will be involved in regular physiotherapy treatment (2-3/week).
1935003|NCT02711891|Drug|Loperamide|Following lance one, 0.2 grams of loperamide 5% gel was applied from a sterile syringe to the participants previous lance site within an 8 mm diameter circular plastic mold. The loperamide gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The loperamide gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
1935004|NCT02711891|Drug|Drug, placebo gel|Following lance one, 0.2 grams of gel alone was applied to the participants previous lance site within an 8mm diameter circular plastic mold. The gel was rubbed lightly on the skin surface for one minute using a gloved finger swirled into the mold site. The mold was removed and the site was covered with a transparent occlusive dressing left in place for 30 minutes. At 30 minutes the gel was removed with gauze, the skin cleaned with an alcohol wipe and the second lance was done within the same location as the first. The placebo gel was also swabbed to the forearm within the 8 mm mold and left in place for 30 minutes.
1935005|NCT02711644|Behavioral|Supportive Lifestyle Counselling|Each participant will meet with the intervention Registered Dietitian twice in pregnancy and have two follow-up phone calls. Participants in this group will have on-going, supportive discussions with the intervention Registered Dietitian about healthy lifestyles in pregnancy. Discussion topics with the intervention Registered Dietitian at each visit will be participant-centered, allowing the participant to guide the conversation. These conversations will be reinforced at every future contact made throughout pregnancy.
1935006|NCT02711644|Behavioral|Standard Lifestyle Counselling|Each participant will meet in person with their respective Registered Dietitian twice in pregnancy and have two follow-up phone calls. At these visits, each participant will complete questionnaires and have anthropometric assessments (height/weight). From home, each participant will also complete online questionnaires at week 26, and week 34. Postpartum,each participant will complete an online questionnaire. Optional postpartum participation includes a focus group in the postpartum period and the option to meet with a Registered Dietitian postpartum.
1935007|NCT02711267|Drug|5% Zovirax® cream|(manufactured by GlaxoSmithKline Pharma in Canada, distributed in the USA by Valeant Pharmaceuticals North America LCC, Bridgewater,NJ 08807)
1935008|NCT02711267|Drug|5% Aciclostad cream|(STADA Arzneimittel GmbH, Vienna, Austria)
1935009|NCT02711267|Drug|5% Aciclovir cream 1A Pharma|(1A Pharma GmbH, Vienna, Austria)
1935010|NCT02711267|Drug|5% Zovirax Cold Sore Cream|(GlaxoSmithKline Consumer Health Care, Brendfort, UK; Marketing authorization holder: Beeham Group PLC, Brendfort, UK)
1935011|NCT02711267|Drug|5% Zovirax® cream (Austria)|(GlaxoSmithKline Pharma GmbH, Vienna, Austria)
1935012|NCT02711267|Procedure|OFM|Sampling method for interstitial fluid
1935013|NCT02711267|Device|OFM Probe|Sampling probe used during OFM
1935014|NCT02711267|Device|OFM Pump|Pump used to operate OFM probes
1935018|NCT02708485|Other|Physical exercise|A 3-month walking program (3 times a week for 12 weeks) on treadmill supervised by a physiotherapist. Duration of the exercise is progressively increased from 15 min to 45 min over a 6-week period and the intensity of the exercise is moderate (a 12-13 score on Borg scale).
1935021|NCT02708017|Procedure|Ultrasound guided bilateral subcostal TAP block|ultrasound guided bilateral subcostal TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray,with the help of portable ultrasound machine using probe frequency of 11 Mega Hertz,ultrasound probe was positioned parallel to the costal margin near the midline,the rectus abdominis muscle was identified ,probe was gradually moved laterally and obliquely along the subcostal margin and the transversus abdominis muscle identified lying posterior to the rectus muscle.the 20Gauge,100millimeter long needle was introduced at the lateral edge of the rectus muscle ,from medial to lateral,in plane of the ultrasound beam.After confirmation of the plane with saline, 20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
1935022|NCT02708017|Procedure|Ultrasound guided bilateral posterior TAP block|ultrasound guided bilateral posterior TAP block was performed after induction of general anaesthesia.after all aseptic measures,abdomen was prepared with antiseptic spray.with the help of portable ultrasound machine using probe frequency of 11Mega Hertz,ultrasound probe was positioned transversely to the abdominal wall in the midaxillary line between the iliac crest and coastal margin,and carefully moved posteriolaterally for optimal identification of plane.the 20G,100mm long needle was introduced anteriorly and in line with the probe,from medial to lateral,and advanced until it reached the fascial plane between the internal oblique and transversus abdominis muscle.upon reaching the plane ,20ml of 0.375% solution of bupivacaine was injected on each side of the abdomen.
1935025|NCT02706067|Drug|Orlistat|Participants will receive orlistat on an intermittent basis as 120 milligrams (mg) three times a day: once with breakfast, once with lunch, and once with dinner. In case of weight relapse (increase 2.5 percent [%] or more from Baseline) orlistat will be administered for up to 2 months or until weight regain reaches 0% from Baseline. For special occasions (feasts, birthdays, anniversaries) orlistat will be given for up to 3 days.
1935026|NCT02706951|Drug|ABT-494|Oral tablet
1935027|NCT02706951|Drug|Methotrexate|Oral capsule
1935028|NCT02706951|Drug|ABT-494 matching placebo|Oral tablet
1935029|NCT02706951|Drug|Methotrexate matching placebo|Oral capsule
1935041|NCT02704702|Drug|Fimasartan|
1935042|NCT02704702|Drug|Rosuvastatin|
1935043|NCT02704702|Drug|Fimasartan + Rosuvastatin|
1935044|NCT02704715|Procedure|general anesthesia,orbital operation|to evaluate the pain under general anesthesia
1935046|NCT02703077|Procedure|Spyglass|Endoscopic direct view of the bile ducts
1935047|NCT02703077|Procedure|Balloon dilation of the papilla|Using a hidrostatic balloon the major papilla will be dilated to facilitate the stone removal
1935048|NCT02703077|Procedure|EHL (electrohydraulic lithotripsy)|With a probe a direct view lithotripsy will be performed
1935049|NCT02703077|Procedure|ERCP (Endoscopic retrograde cholangiopancreatography)|Endoscopic procedure to identify and treat biliary diseases
1935050|NCT02704104|Device|Application of AC5 Hemostatic agent|Application of the hemostatic agent will be applied to the skin lesion directly as prescribed
1935051|NCT02704104|Device|Standard application of water resistant dressing|Application of a water resistant dressing to the skin lesion as prescribed
1935058|NCT02702011|Drug|empagliflozin medium dose|
1935059|NCT02702011|Drug|empagliflozin low dose|
1935060|NCT02702011|Drug|empagliflozin high dose|
1935061|NCT02702011|Drug|placebo|
1935062|NCT02701049|Other|Methods to collect SO/GI information in the ED|In Mode 1, all patients presenting to the ED will have SO/GI information collected verbally by the nurse, which is standard of care. In Mode 2, all patients presenting to the ED will have SO/GI information collected in a non-verbal manner, in which the registrar will ask them to complete an electronic form.
1935071|NCT02699099|Dietary Supplement|Vitamin A|Oral administration of Vitamin A (1 dose)
1935072|NCT02699099|Biological|Candidate Plasmodium falciparum malaria vaccine|Intramuscular administration of SB257049 vaccine (4 doses)
1935073|NCT02699099|Biological|MR-Vac|Subcutaneous injection of a combined measles and rubella vaccine (1 dose)
1935074|NCT02699099|Biological|Stamaril|Intramuscular injection of a yellow fever vaccine (1 dose)
1935078|NCT02699411|Device|Dry needling|dry needling Travell and Simons
1935079|NCT02699411|Other|Stability and propioception|Start excursion balance test, WOMAC; ROM, EVA.
1935080|NCT02698436|Device|Acne Mask|The light therapy device contains a combination of red and blue light-emitting diodes. The device is applied once daily, in the evening for a duration of 10 minutes
1935081|NCT02698436|Drug|2.5% Benzoyl Peroxide Treatment|The BPO treatment is applied twice daily, once in the morning and once in the evening
1935082|NCT02698033|Drug|Peanut flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
1935083|NCT02698033|Other|Toasted oat flour|A Double-blind, placebo-controlled food challenge will consist of two challenges performed on separate days. One challenge will consist of 7 doses of peanut given every 20 minutes in increasing amounts up to a total of 7 grams of whole peanut (4 grams of peanut protein) masked by inclusion in vehicle food. The other challenge will consist of placebo material given similarly.
1935084|NCT02697994|Other|Sterile Water|0.1 ml intracutaneous sterile water injections into the skin surrounding the Michaelis rhomboid over the sacral area.
1935085|NCT02697994|Other|Dry Injections|dry injections into the skin surrounding the Michaelis rhomboid over the sacral area.
1935086|NCT02697214|Device|Fitbit Charge HR|Fitbit Charge HR heart rate monitoring device.
1935087|NCT02697214|Device|Apple Watch|Apple Watch heart rate monitoring device.
1935088|NCT02697214|Device|Mio Fuse|Mio Fuse heart rate monitoring device.
1935089|NCT02697214|Device|Basis Peak|Basis Peak heart rate monitoring device.
1935090|NCT02696642|Drug|Anetumab ravtansine (BAY94-9343)|All subjects will receive anetumab ravtansine 6.5 mg/kg BW (body weight) once every three weeks
1935091|NCT02696226|Drug|SAVR Warfarin|Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
1935092|NCT02696226|Drug|SAVR Aspirin|Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
1935093|NCT02696226|Drug|TAVR Warfarin and clopidogrel|Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
1935094|NCT02696226|Drug|TAVR Aspirin and clopidogrel|Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
1935096|NCT02694601|Dietary Supplement|Caffeine|For each 4-hour visit, a dose of 0 mg/kg, 2.5 mg/kg or 5 mg/kg of Caffeine is given during a standardize breakfast follow by repeated blood sampling.
1935098|NCT02694562|Device|40um Embozene TANDEM Microspheres|40um Embozene TANDEM Microspheres loaded with Irinotecan (up to 150 mg).
1935099|NCT02694653|Drug|Placebo|100 mL of normal saline IV given 30 minutes prior to elective c/section incision vs acetaminophen 1000 mg IV
1935100|NCT02694653|Drug|Acetaminophen|1000 mg acetaminophen in 100 mL normal saline IV given 30 minutes prior to elective c/section incision vs placebo
1935101|NCT02692482|Device|hydrocellular polyurethane foam multilayer dressing|Application of hydrocellular polyurethane foam in the sacral region within 24 hours of admission and replaced when detaches or gets wet or dirty in addition to standard care
1935102|NCT02692482|Procedure|standard care|Standard care: PU risk assessment using the Braden scale within 24 hours of admission. Place patient on pressure mattress (static or alternating pressure) if Braden score <18, daily inspection of the skin in the various pressure points and moving the patient every 4 hours after surgery. Management of possible incontinence, humidity control and prevention of skin damage and rubbing/friction during postural changes as per hospital procedure.
1935103|NCT02692235|Dietary Supplement|carnitine|1500 mg/d l-carnitine-l-tartrate
1935104|NCT02692235|Dietary Supplement|leucine|1500 mg/d l-leucine
1935105|NCT02692235|Dietary Supplement|carnitine & leucine|2000 mg/d l-carnitine-l-tartrate and 4000 mg/d l-leucine
1935106|NCT02693561|Behavioral|Deep Breathing Exercises|Technical Deep Breathing: Deep breathing is to deep breath and slowly through the nostrils until total lung capacity. At the end of inspiration is kept a few seconds of apnea and started after the expiration slowly. End-expiratory apnea will remain a few seconds to start new inspiration cycle. With this process the individual breathe about 6 times per minute. Breath learning occurs through visual feedback. In the intervention group will be held deep breathing for 10 minutes. Subjects will be instructed to deep breath for 10 minutes 2 times a day for 15 days beyond the period in which they cleft, which is one of the symptoms of withdrawal syndrome. Control and frequency of deep breathing will be obtained weekly through specific daily fill, which will be provided weekly.
1935107|NCT02693561|Behavioral|Self-Help Book|Reading the self-help book.
1935108|NCT02693132|Behavioral|Supervised (SUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of supervised moderate-to-vigorous intensity physical activity.
1935109|NCT02693132|Behavioral|Unsupervised (UNSUP-PA)|Weight loss intervention that involves an energy restricted diet plus the inclusion of 150 minutes per week of unsupervised moderate-to-vigorous intensity physical activity.
1935110|NCT02693132|Behavioral|Step-based (STEP)|"Weight loss intervention that involves an energy restricted diet plus the inclusion of physical activity in the form of 10,000 steps/day with 2,500 brisk steps/day."
1935111|NCT02693106|Dietary Supplement|Dietary supplement|Each participant has to go through a total of 8 visits, each visit corresponding to a standardize breakfast taken alone (control visit) or with one of the dietary supplements evaluated (5 g of leucine, 3.6 g of butyrate, 7.2 g of butyrate, 5 g of octanoate, 10 g of octanoate, 1.95 g of carnitine or 65 g of butter fraction rich in MCT) follow by a period of 4-hour with multiple blood sampling.
1935114|NCT02693574|Drug|Clarithromycin|
1935115|NCT02693574|Drug|Levofloxacin|
1935124|NCT02687919|Other|Modified Paleo diet|Nine cups of vegetables and some fruits, meat protein including organ meat, and complete abstinence from products containing gluten (wheat, barley, rye, etc.), dairy, potatoes, and legumes (beans, lentils, peanuts, soy, etc.)
1935125|NCT02686034|Device|gammaCore-S|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment, or take their usual rescue medication.
1935126|NCT02686034|Device|gammaCore-S Sham|At onset of migraine pain, the subject self-administers a bilateral treatment with the gammaCore nVNS Sham device (2 minutes on the right side, and 2 minutes on the left side). If their headache pain has not improved after 15 minutes, they administer another bilateral treatment with the Sham device. If they are not pain-free at 2 hours, they have the option to administer a third bilateral treatment with the Sham device, or take their usual rescue medication.
1935130|NCT02685436|Drug|Omeprazole and domperidone|wheezy infants with abnormal MII-pH or reflux esophagitis will be given omeprazol(10mg/once/day) and domperidone (0.2mg/kg/day t.d.s)
1935135|NCT02684058|Drug|dabrafenib|dabrafenib oral, twice daily.
1935136|NCT02684058|Drug|trametinib|trametinib oral, once daily.
1935137|NCT02683577|Drug|telotristat etiprate|
1935138|NCT02681172|Drug|Neuraceq (florbetaben 18F)|Florbetaben 18F is given as an i.v. injection followed by a flush of sodium chloride solution to ensure full delivery of the dose.
1935139|NCT02681172|Procedure|PET|A brain PET scan is usually taken 90 minutes after the i.v. injection of florbetaben 18F.
1935140|NCT02681367|Other|Freeze all policy|Cryopreservation of human blastocysts for freeze all group has been employed using vitrification. The blastocysts were transferred after thawing in a frozen-thawed cycle.
1935142|NCT02679729|Drug|AZD5634 for inhalation|Solution, citrate buffer, saline nebulizer solution; strength 0.1 - 5 mg/g; administered by jet nebulizer
1935143|NCT02679729|Drug|AZD5634 for infusion|Solution, citrate buffer, saline solution for infusion; strength 0.013 mg/mL
1935144|NCT02679729|Other|Placebo|inactive substance
1935147|NCT02678416|Drug|IV Acetaminophen|IV formulation
1935148|NCT02678416|Drug|IV Morphine|IV formulation
1935149|NCT02678416|Other|Placebo tablet|tablet
1935150|NCT02678416|Drug|Acetaminophen tablets|oral formulation
1935151|NCT02678416|Other|IV Placebo|IV formulation
1935153|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-long-term|Stem cell infusion are administrated once three months for 3 times with the cell count of 3*10^8/kg/once.
1935154|NCT02676856|Procedure|hematopoietic stem cell microtransplantation-short-term|Stem cell infusion are administrated once every 45 days for 3 times with the cell count of 3*10^8/kg/once.
1935155|NCT02676856|Drug|Conditioning for CR group|For the patients in CR group, the conditioning regimen is high-dose Ara-C (3g/m2 q12h d1-3).
1935156|NCT02676856|Drug|Conditioning for Non-CR group|For the patients in Non-CR group, the conditioning regimens include: IAC（IDA 12mg/m2 d1-3，Ara-C 200 mg/m2 d1-7， Cladribine 5mg/m2 d1-5) or HD Ara-C(high-dose Ara-c 3g/m2 q12h d1-3).
1935157|NCT02676518|Other|serum|Serum for serum anti-Mullerian hormone, 2-hour 75 gram oral glucose tolerance test and lipid profiles
1935158|NCT02675231|Drug|Abemaciclib|Administered Orally
1935159|NCT02675231|Drug|Trastuzumab|Administered IV
1935160|NCT02675231|Drug|Fulvestrant|Administered IM
1935161|NCT02675231|Drug|Standard of Care Single Agent Chemotherapy|Standard-of-care single-agent chemotherapy of physician's choice administered according to product label
1935165|NCT02675322|Drug|Danlou Tablets|Danlou tablets were approved by China Food and Drug Administration for the treatment of ischemic heart disease in 2005 (Z20050244).
1935166|NCT02675322|Other|Placebo|Placebo with no chemical effects.
1935167|NCT02673008|Biological|donor lymphocyte infusion|DLI was administered at a median dose of 1.0 (range 0.7-1.4) ×10*8 mononuclear cells/kg.
1935168|NCT02673268|Procedure|Mastectomy|
1935169|NCT02673268|Device|Da Vinci Robot Xi|
1935170|NCT02672631|Other|physical examination|Investigators will apply for evaluate clinical median nerve function to all of groups. (Adductor pollicis power (x/5), sense exam(normal/hipoestesia/anestesia) of hand, tinnel test(+/-), DASH score, DN4 neuropathic pain score)
1935171|NCT02672631|Other|DTI|Investigators will apply for evaluate median nerve healing countable results to all of groups (apparent diffusion coefficient for avarage diffusion (ADC) and fractional anisotropy diffusion orientation(FA) - FA :0 means diffusion is homogenic FA:1 means tissue has heterogenic diffusion
1935172|NCT02672631|Other|ENMG|Investigators will apply for evaluate median nerve healing countable results to all of groups. And they will evaluate motor nerve transmission speed, sensitive nerve transmission speed and united muscle action potential
1935173|NCT02672384|Procedure|Dental examination and a point of care P. gingivalis test (Denka Seiken Co (Japan) )|Dental examination Study exams (oral and blood sample collection)
1935174|NCT02670629|Procedure|Partial reduction with overriding position|The patient was subjected to an alignment instead of an anatomic reduction; this means that the fracture was left in an overriding position, after this, the patient was placed in a short arm cast for 6 weeks.
1935175|NCT02670629|Procedure|Closed anatomic reduction|The patient was subjected to an anatomic reduction; this means that the fracture was completely reduced, after this, the patient was placed in a short arm cast for 6 weeks.
1935176|NCT02671760|Drug|SM-1|3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
1935177|NCT02671760|Drug|Comparator|2-drug combination comprised of 5 mg zolpidem and 0.5 mg lorazepam
1935178|NCT02671760|Drug|Placebo|Placebo
1935179|NCT02671708|Drug|Idarubicin（IDA）|Idarubicin was administered at 15mg/m2/day on days -12 and -10.
1935180|NCT02671708|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
1935181|NCT02671708|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
1935184|NCT02670304|Drug|letrozole|letrozole from the day of oocyte retrieval for 5 days
1935185|NCT02670304|Drug|Aspirin|aspirin from the day of oocyte retrieval for 5 days
1935186|NCT02670252|Drug|Busulfan (BU)|Busulfan was administered at 3.2 mg/kg/day on days −7 to −4.
1935187|NCT02670252|Drug|Cyclophosphamide (CY)|Cyclophosphamide was administered at 60 mg/kg/day on days −3 to −2.
1935188|NCT02670252|Radiation|Total Body Irradiation (TBI)|Total Body Irradiation was given 4.5 Gy TBI/day on days -5 and -4.
1935191|NCT02668822|Drug|Etonogestrel (ENG) 125 μg + 17β-estradiol (E2) 300 μg vaginal ring|Up to 4 cycles of ENG-E2 125 μg/300 μg administered intravaginally. Each cycle will consist of 21 days of vaginal ring use followed by 7 ring-free days.
1935192|NCT02668822|Drug|Placebo vaginal ring|Up to 4 cycles of placebo administered intravaginally. Each cycle will consist of 21 days of placebo vaginal ring use followed by 7 ring-free days.
1935193|NCT02668822|Drug|Ibuprofen|Ibuprofen tablets, to be taken orally, will be provided to the participants for use as rescue medication for dysmenorrhea treatment throughout the study. Participants may take 400 mg every 4 hours as needed for pelvic pain/cramping.
1935197|NCT02668692|Drug|LEO 80185 gel|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
1935198|NCT02668692|Drug|Dovobet ® ointment|calcipotriol hydrate 52.2 µg/g [equivalent to 50.0 µg/g calcipotriol] plus betamethasone dipropionate 0.643 mg/g, applied once daily to psoriasis lesions
1935199|NCT02667951|Other|A home-based caregiver-training program|This training program consisted of two weekly sessions, each lasting 2 to 3 hours. Following the training sessions, further assurance and consultation were provided in monthly telephone follow-ups, and progress in behavior management was evaluated.
1935200|NCT02666300|Other|TaperGuard ETT|tracheal intubation with TaperGuard ETT
1935201|NCT02666573|Device|Fotosan 630, CMS Dental, Copenhagen, Denmark|The PDT system consists of a hand-held rechargeable light-emitting diode (LED) light source (Fotosan® 630 device, CMS Dental, Copenhagen, Denmark) and 0.1 mg/mL toluidine blue photosensitiser. The LED light source has a wavelength between 620 to 640 nm and peak of 630 nm and a power density between 2000 to 4000 mW/cm2.
1935202|NCT02666573|Other|Scaling and root planing|Scaling and root debridement of the residual pockets were performed using ultrasonic device and hand curettes until root surfaces felt hard and smooth. The sites were then polished using rubber cup and prophylaxis paste.
1935203|NCT02666508|Other|Plaque identifying toothpaste|Plaque identifying toothpaste with targetol
1935204|NCT02666508|Other|Non-plaque identifying toothpaste|Non-plaque identifying toothpaste without targetol
1935205|NCT02665455|Device|FreeStyle Libre Flash Glucose Monitoring System|"Subjects will wear the FreeStyle Libre Flash Glucose Monitoring System masked for 14 days.
During these 14 days subjects will be asked to perform 4 blood glucose tests (meals time and before bedtime) per day. At the same time as the blood glucose test a sensor scan is performed."
1935206|NCT02665221|Other|No Treatment Arm|Participants randomized to the control group will have no topical treatment at the injection site of the first full dose of Plegridy.
1935207|NCT02665221|Drug|Topical Preparation H arm|Preparation H (phenylephrine) treatment first full dose incidence injection site reaction.
1935215|NCT02663752|Procedure|Bone marrow aspirate|Patients experiencing a hematological response and patients not experiencing a hematological response while on deferasirox treatment received a new bone marrow aspirate in order to investigate the presence of differential gene expression between those two groups
1935216|NCT02663752|Drug|Deferasirox|Patients are already on commercial deferasirox before entering the study.
1935217|NCT02661828|Other|Two-Week Antidepressant Taper Regimen|Days 1-7: 50% of baseline antidepressant dose taken; Days 8-14: 25% of baseline antidepressant dose taken; Day 15: Stop antidepressant.
1935218|NCT02661828|Other|One-Week Antidepressant Taper Regimen|Days 1-3: 50% of baseline antidepressant dose taken; Days 4-7: 25% of baseline antidepressant dose taken; Day 8: Stop antidepressant.
1935219|NCT02661594|Drug|Amisulpride 5 mg|Therapeutic dose of amisulpride
1935220|NCT02661594|Drug|Amisulpride 40 mg|Supra-therapeutic dose of amisulpride
1935221|NCT02661594|Drug|Moxifloxacin|Positive control for assay sensitivity
1935222|NCT02661594|Drug|Placebo|Placebo comparator to establish baseline for calculating change in QTcF
1935225|NCT02660229|Drug|Oxycodone Hydrochloride|Oxycodone injection
1935226|NCT02660229|Drug|Morphine Sulphate|Morphine sulphate injection
1935230|NCT02657252|Drug|Glucose|Sclerotherapy of telangiectasis in one lower limb.
1935231|NCT02657252|Drug|Polidocanol with Glucose|Sclerotherapy of telangiectasis in one lower limb.
1935232|NCT02657174|Device|low level laser in auricular acupuncture points|40 third molars surgeries will be performed in a conventional manner. At the end of surgery, low level laser will be applied at auricular points for prevention of inflammation and pain in the immediate post-operative period (baseline).The operator will mark the points that will be irradiated on the outer atrium of the patient with red gel pen to avoid interference with red laser (λ = 660 nm). The low level laser points will be irradiated in the same operated side.
1935233|NCT02657174|Device|low level laser device off in auricular acupuncture points|40 surgeries will be performed in the conventional manner, identically to the G1. The patient will receive low level laser with a protection of lead in the laser nozzle, in order to block the passage of light, in the same auricular points used in G1.
1935234|NCT02656251|Drug|0.12% Clorhexidine with alcohol|Use of 0.12% Clorhexidine with alcohol every 12 hours for 04 days
1935235|NCT02656251|Drug|placebo|Use of placebo every 12 hours for 04 days
1935236|NCT02656251|Drug|0.12% Clorhexidine without alcohol|Use of 0.12% Clorhexidine without alcohol, every 12 hours for 04 days
1935237|NCT02654652|Dietary Supplement|LactoFos|Patients will receive the product twice a day during seven days after surgical treatment
1935238|NCT02654652|Dietary Supplement|Maltodextrin|Patients will receive maltodextrin twice a day during seven days after surgical treatment
1935244|NCT02653183|Device|Active Comparator: Aquacel Surgical|Post-operative all-in-one self-adherent soft silicone coated foam dressing
1935245|NCT02653183|Device|Experimental: Mepilex Border Post-Op|Aquacel Surgical is a sterile, one piece post-operative dressing
1935246|NCT02653872|Drug|AZD7986|Oral solution, single dose, dilution from concentrate
1935247|NCT02653872|Drug|Verapamil|Extended release tablet for oral use
1935248|NCT02653872|Drug|Itraconazole|Oral solution
1935249|NCT02653872|Drug|Diltiazem|Extended release capsule
1935252|NCT02650128|Device|Shockwave Coronary Rx Lithoplasty® System|The Shockwave Coronary Rx Lithoplasty® System is a proprietary balloon catheter system designed to deliver localized, lithotripsy-enhanced, balloon dilatation of calcified, stenotic, de novo coronary arteries. Energizing the lithotripsy electrodes will generate pulsatile mechanical energy within the target treatment site and will disrupt calcium within the lesion and allow subsequent dilatation of a coronary artery stenosis using low balloon pressure. The system consists of a rapid exchange balloon catheter with integrated, internal lithotripsy electrodes and a Shockwave generator.
1935253|NCT02651116|Drug|Dextromethorphan Hydrobromide|15 mg/ 10 mL: 10 mL of Dextromethorphan Hydrobromide
1935254|NCT02651116|Drug|Placebo|10 mL Placebo
1935255|NCT02651116|Device|Cough recording device|FDA approved device validated for use in adults and children
1935257|NCT02650947|Dietary Supplement|Sucralose|Consumption of capsules containing either 200 mg sucralose (equivalent to diet soda 3 cans) per day for four weeks
1935258|NCT02650947|Dietary Supplement|Placebo|Consumption of empty capsule everyday for 4 weeks
1935259|NCT02650557|Procedure|angiography|angiography or arteriography is a medical imaging technique used to visualize the inside, or lumen, of blood vessels and organs of the body, with particular interest in the arteries, veins, and the heart chambers. This is traditionally done by injecting a radio-opaque contrast agent into the blood vessel and imaging using X-ray based techniques such as fluoroscopy.
1935260|NCT02650180|Device|Soberlink Cellular Device|Alcohol Breath Analyzer
1935315|NCT02641561|Drug|Normal Saline|standard IVF would include 0.9% normal saline (NS) solution used during all endoscopic procedures. 0.9% NS includes equal parts sodium and chloride.
1935262|NCT02648646|Other|Otago Exercise Programme and Walk with Ease|The Otago Exercise Programme is a falls prevention program that is successful at reducing falls in adults 65+ years of age. Briefly, this program includes flexibility, progressive lower extremity strengthening with ankle weights, and balance exercises. The investigators are replacing the Otago walking program with the evidence-based Arthritis Foundation's Walk With Ease program.
1935263|NCT02647281|Drug|GSK3389404|GSK3389404 is supplied as solution for injection vial. Each vial contains 100 mg/mL of GSK3389404. It's physical appearance is clear colourless to slightly yellow solution.
1935264|NCT02647281|Drug|Matching Placebo|Placebo is supplied as solution for injection vial. It's physical appearance is clear colourless solution.
1935265|NCT02648217|Drug|insulin degludec/insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
1935266|NCT02648217|Drug|biphasic insulin aspart|Injected subcutaneously (s.c., under the skin)twice daily. The pre-trial insulin will be discontinued.
1935269|NCT02647515|Drug|ranibizumab|
1935270|NCT02646488|Behavioral|Million Hearts ABCS 6 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
1935271|NCT02646488|Behavioral|Million Hearts ABCS 9 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
1935272|NCT02646488|Behavioral|Million Hearts ABCS 12 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
1935273|NCT02646488|Behavioral|Million Hearts ABCS 15 Months|The ABCS refer to the following: Aspirin in high-risk individuals (A), Blood pressure control and management (B), Cholesterol management (C), and Smoking cessation (S).
1935274|NCT02646488|Behavioral|Standard Care Regimen 9 Months|
1935275|NCT02646488|Behavioral|Standard Care Regimen 12 Months|
1935276|NCT02646488|Behavioral|Standard Care Regimen 15 Months|
1935277|NCT02646488|Behavioral|Standard Care Regimen 18 Months|
1935278|NCT02646488|Behavioral|Standard Care Regimen 21 Months|
1935279|NCT02646488|Behavioral|Standard Care Regimen 24 Months|
1935280|NCT02646488|Behavioral|Standard Care Regimen 27 Months|
1935281|NCT02646488|Behavioral|Follow Up Post Intervention 21 Months|
1935282|NCT02646488|Behavioral|Follow Up Post Intervention 24 Months|
1935283|NCT02646488|Behavioral|Follow Up Post Intervention 27 Months|
1935284|NCT02646488|Behavioral|Follow Up Post Intervention 30 Months|
1935285|NCT02646488|Behavioral|Follow Up Post Intervention 33 Months|
1935286|NCT02645461|Drug|endocannabinoid palmitoylethanolamide (PEA)|Endocannabinoid palmitoylethanolamide (PEA) (ultramicronized) 600 mg twice daily
1935287|NCT02645461|Drug|Riluzole|Riluzole 50 mg twice daily
1935288|NCT02645253|Drug|AZD7594 inhalation powder (200 μg)|200 μg AZD7594 inhalation powder via multi-dose dry powder inhaler (DPI)
1935289|NCT02645253|Drug|AZD7594 inhalation powder (400 μg)|Cohort 2: 400 μg AZD7594 inhalation powder via multi-dose DPI Cohort 3: 1600 μg (4 x 400 μg inhalations) AZD7594 inhalation powder via multi-dose DPI
1935290|NCT02645253|Drug|AZD7594 pressurized inhalation suspension (200 μg)|400 μg (2 x 200 μg inhalations) AZD7594 pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
1935291|NCT02645253|Drug|AZD7594 placebo inhalation powder|AZD7594 placebo inhalation powder via multi-dose DPI
1935292|NCT02645253|Drug|AZD7594 placebo pressurized inhalation suspension|AZD7594 placebo pressurized inhalation suspension via pressurized metered dose inhaler (pMDI)
1935293|NCT02645019|Device|Cuffed ETT or LMA|
1935296|NCT02643160|Other|Functional Trunk Training|The intervention includes neurodevelopment treatment, muscle strengthening and functional activities of trunk region
1935297|NCT02644135|Drug|Halo Oral Spray|Three sprays per use, total = 9 sprays per day
1935298|NCT02644135|Drug|Halo Placebo|Three sprays per use, total = 9 sprays per day
1935300|NCT02642679|Device|Opticell Ag|Opticell Ag+ applied to STSG donor site
1935301|NCT02642913|Drug|Enzalutamide|
1935302|NCT02642913|Drug|Enzalutamide with Sorafenib|
1935303|NCT02642835|Procedure|vaginal wall mesh|retrospective review of case series
1935309|NCT02642198|Device|Surveyor S12 and S19 patient monitor|Non-invasive blood pressure measurement
1935313|NCT02641561|Drug|Indomethacin|Indomethacin is a non-steroidal anti-inflammatory drug (NSAID) which is commonly used to reduce inflammation caused by gout, osteoarthritis and rheumatoid arthritis. It acts by blocking the cyclo-oxygenase 1 and 2 (COX) receptors. It has also been implicated to prevent post-ERCP pancreatitis
1935314|NCT02641561|Drug|Lactated Ringer's Solution|Lactated ringer's solution (LR), is an intravenous fluid (IVF) used commonly during endoscopic procedures and operative procedures. It's composition is similar to that of humans including sodium, chloride, potassium, calcium and lactate. Studies have implicated the use of this fluid in pancreatitis treatment and prevention of post-ERCP pancreatitis
1935316|NCT02641561|Drug|Placebo|Placebo would be a suppository 50 mg x 2
1935317|NCT02640755|Drug|[14C]AZD2014|Radiolabelled dual TORC1/TORC2 inhibitor
1935318|NCT02640755|Drug|Multiple dose AZD2014|Dual TORC1/TORC2 inhibitor
1935319|NCT02640755|Drug|Fulvestrant|Hormonal Agent
1935320|NCT02640755|Drug|Paclitaxel|Taxane
1935325|NCT02639598|Drug|Flunarizine|"as in arm descriptions"
1935326|NCT02639598|Drug|Topiramate|"as in arm descriptions"
1935328|NCT02639338|Drug|SOF/VEL/VOX|SOF/VEL/VOX (400/100/100 mg) FDC tablet administered orally once daily with food
1935329|NCT02639338|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily without regard to food
1935332|NCT02639247|Drug|SOF/VEL/VOX|400/100/100 mg FDC tablet administered orally once daily with food
1935333|NCT02639247|Drug|SOF/VEL|400/100 mg FDC tablet administered orally once daily without regard to food
1935334|NCT02639169|Other|Music Therapy|apply live music through the techniques of music therapy
1935335|NCT02638454|Procedure|Acute Resistance Exercise|1 bout of high-intensity resistance exercise at 80% of the individuals 1 repetition maximum
1935336|NCT02636712|Device|ImageReady™ MR Conditional Pacing System|
1935337|NCT02636569|Drug|topical DFMO+diclofenac twice daily|"Topical DFMO Diclofenac Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from two locations at the baseline visit. The biopsy will be taken from one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.
After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun."
1935338|NCT02636569|Drug|placebo|"placebo Each subject will be seen for a screening visit as well as a baseline visit and a visit at month 1. As part of the study small biopsies will be taken from two locations at the baseline visit. The biopsy will be taken from one area that is typically exposed to the sun as well as a site that is typically protected from sun light. A biopsy is a small surgical procedure where a small piece of your skin is removed.
After applying the medications for 30 days you will return to the clinic for your 30 day visit. At this visit you will again have two biopsies taken. One of these biopsies will be from the skin on your arm that was treated with medication for the prior 30 days, and the other biopsy will be from a site that typically is not exposed to the sun."
1935339|NCT02637622|Other|Best-Worst Scaling (Case 2)|Respondents receive questions asking them to choose the best and worst features of a hypothetical medication.
1935340|NCT02637622|Other|Discrete Choice Experiment|Respondents receive questions asking them to choose the medication they prefer between a pair of hypothetical medications.
1935341|NCT02637609|Other|Likert Scale|Respondents receive questions asking them to rate each barrier or facilitator for diabetes self-management.
1935342|NCT02637609|Other|Best-Worst Scaling (Case 1)|Respondents receive questions asking them to choose the best and worst factors that affect their diabetes self-management among a list of barriers and facilitators.
1935343|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon)|single fixed-combination dose tablets
1935344|NCT02637037|Drug|dapagliflozin/metformin XR 5/500 mg reference drug (Humacao)|single fixed-dose combination tablets
1935345|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon)|single fixed-dose combination tablets
1935346|NCT02637037|Drug|dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)|single fixed-dose combination tablets
1935347|NCT02637024|Radiation|APBI: 30 Gy|30 Gy in 5 fractions of 6 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
1935348|NCT02637024|Radiation|APBI: 27.5 Gy|27.5 Gy in 5 fractions of 5.5 Gy, delivered daily, Monday to Friday, over a period of 5-8 days. A multiple small field 3D-conformal or intensity modulated radiation therapy (IMRT) technique will be used.
1935349|NCT02636816|Drug|carbetocin|drug used to increase the tone of uterine muscle to prevent post partum hemorrhage after cesarean delivery.
1935353|NCT02636309|Behavioral|physical therapy at work|gymnastcis, exercise orientation, ergonomics, acupuncture at work setting
1935354|NCT02636166|Other|Clearblue Investigational Pregnancy test|Clearblue Investigational Pregnancy test
1935355|NCT02636166|Other|Professional pregnancy test|Alere Professional use pregnancy test
1935356|NCT02636166|Other|Clearblue Marketed Pregnancy test|Clearblue Marketed Pregnancy test
1935357|NCT02636049|Drug|Triferic|Triferic is supplied as sterile 5 mL ampules containing 5.44 mg/mL of iron in water for injection. Each 5 mL ampule contains 27.2 mg of Triferic iron.
1935358|NCT02635672|Drug|BAY 1251152|The starting dose of Cohort 1 will be 5 mg IV (30 minute infusion) fixed dose once weekly (5 mg/week) for 21 day cycles.
1935361|NCT02635529|Procedure|OFD+ DFDBA|After Phase I therapy, patient's were assigned for OFD+DFDBA group. Mucoperiosteal flap were reflected.After Open Flap Debridement (OFD), DFDBA graft was placed for the treatment of intrabony defects.
1935362|NCT02635529|Procedure|OFD+ DFDBA+ AM|After Phase I therapy, patient's were assigned for OFD+DFDBA + AM group. Mucoperiosteal flap were reflected. After Open Flap Debridement (OFD). DFDBA and AM was placed for the treatment of intrabony defects.
1935363|NCT02635438|Drug|Unique Pharmaceutical Laboratories, India|Clotrimazole troche/ lozenges, 10 mg 5 times a day for 14 consecutive days
1935364|NCT02635438|Drug|Roxane Laboratories Inc., USA|Clotrimazole Troche/ Lozenges USP, 10 mg 5 times a day for 14 consecutive days
1935365|NCT02634255|Drug|Rocuronium elective surgery|Rocuronium onset time in patients undergoing inguinal herniorrhaphy
1935366|NCT02634255|Drug|Rocuronium emergency surgery|Rocuronium onset time in patients undergoing appendectomy
1935367|NCT02634255|Drug|Propofol|
1935368|NCT02634255|Drug|Fentanyl|
1935369|NCT02634255|Other|Ringer Lactate|
1935370|NCT02634255|Device|Acceleromyography device|
1935372|NCT02633566|Device|Plantar orthoses|
1935373|NCT02631135|Drug|Remifentanil|In case of tachycardia or hypertension the opioid dose was reduced, in case of bradycardia or hypertension the opioid dose was increased
1935374|NCT02631135|Drug|Propofol|BIS values were arranged 40-60 until the end of operation
1935375|NCT02631135|Drug|Dexmedetomidine|0.5 microgram/kg infusion, no changes
1935376|NCT02631135|Drug|Rocuronium|0.5 mg/kg iv for intubation, no change
1935377|NCT02632526|Drug|AZD5718 oral suspension crystalline form (1 to 100 mg/mL) (Part A)|Oral suspension single dose
1935378|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part A)|Single and multiple doses
1935379|NCT02632526|Drug|AZD5718 placebo oral suspension|Single and multiple doses
1935380|NCT02632526|Drug|AZD5718 oral suspension amorphous (1 to 100 mg/mL) (Part B)|Single and multiple doses
1935386|NCT02632032|Drug|Insulin|"Monitoring insulin therapy of campers based on their usual regimen (one of the following):
premixed insulin in the morning and evening,
premixed insulin in the morning, regular insulin in the afternoon and premixed insulin in the evening,
regular insulin in the morning and afternoon, and premixed insulin in the evening.
Education of campers on different aspects of diabetes care:
monitoring of blood glucose
injection of insulin
adaptation of insulin doses according to blood glucose and during exercise
correction of hypoglycemia
dietary advice"
1935387|NCT02630381|Device|Unfocused extracoporeal shock wave therapy|"Shock waves are acoustical pulses that are characterized by high amplitude (~500 bar) and short rise time (~20 ns), which are followed by a longer low-magnitude negative wave (~-100 bar). Extracorporeal shock waves are widely used to disintegrate kidney stones, which is called lithotripsy. In orthopedics, shock wave therapy, called orthotripsy, is used safely in a variety of musculoskeletal disorders like non unions, osteonecrosis of the hip, Achilles and patellar tendinopathy, lateral epicondylitis of the elbow and fasciitis plantaris.
Until recently extracorporeal shock wave therapy for musculoskeletal disorders was applied with a focused character, in which the waves converge in a focal point similar to lithotripsy. For the prevention of fractures in osteoporosis a focused character is not preferable because large skeletal regions have to be treated, so unfocused shock waves have been developed."
1935388|NCT02631057|Drug|Dabigatran|Dabigatran 110 mg coupsle twice a day or 75 mg x 2 capsles twice a day
1935389|NCT02631057|Drug|Wafrarin|Warfarin tablet (adjustment by each patients)
1935390|NCT02630459|Drug|AMG 334 Dose Level 1|Investigational Product
1935391|NCT02630459|Drug|Placebo|Placebo Comparator
1935392|NCT02630459|Drug|AMG 334 Dose Level 2|Investigational Product
1935393|NCT02630459|Drug|AMG 334 Dose Level 3|Investigational Product
1935394|NCT02629588|Behavioral|Multimodal or Unimodal Sensory stimulation|multimodal sensory stimulation, unimodal sensory stimulation, auditory stimulation, complex stimulation, median nerve stimulation.
1935634|NCT02581917|Other|Cytology Specimen Collection Procedure|Undergo collection of PBMC samples
1935406|NCT02626377|Behavioral|Support provided by social worker|Caregivers randomized in intervention arm will receive an information booklet (which informs about existing structures and actions) and will receive support provided by a social worker schedule every 6 months during two years. The support duration will be one hour and will be defined as two parts: administration of the LASA questionnaire, and a standardized semi directive interview to assess needs.
1935407|NCT02626377|Other|Information booklet receipt|Caregivers will only receive an information booklet (which informs about existing structures and actions)
1935411|NCT02626897|Device|GENEActiv Original Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
1935412|NCT02626897|Device|ActiGraph GT3X Accelerometer|Wrist-worn device measuring accelerations as a measure of daily activity.
1935413|NCT02626117|Device|LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. Diode (GaAlAs) laser with a wavelength of 820 nm and a power of 1.5 watt in a continuous mode was applied to remove the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
1935414|NCT02626117|Device|Sham LASER deepithelialization|the selected participants were assigned in test and control. Under LA full thickness flap was reflected until the mucogingival junction and recipient area was prepared. The connective tissue graft harvested from palate was placed on the root surface and secured with 5-0 absorbable sutures. sham LASER deepithelialisation was applied to the sulcular epithelium. The connective tissue graft was placed on the root surface at the level of the CEJ and then secured with 5-0 absorbable sutures in both test and control sites using sling suture..
1935415|NCT02626611|Drug|Omalizumab|Omalizumab is an anti-Immunoglobulin E antibody injection and will be administered per product insert from weeks 0 through 16 of the study.
1935416|NCT02626611|Drug|Food Flour Buildup|Food flours identified as allergic (based on food challenge), will be introduced at week 8. The food dose will be escalated every 2 weeks up to 2000 milligrams of each of the food flours. Subjects are required to reach 300 milligrams at week 16 to continue to week 30. Subjects must tolerate 2000 milligrams per food by week 28 in order to be randomized.
1935417|NCT02625402|Behavioral|Brief interactive decision aid|The Healthwise Shared Decision Points in booklet version for hip and knee osteoarthritis
1935418|NCT02625402|Behavioral|Long video decision aid|Health Dialog DVD and booklet decision aids for hip and knee osteoarthritis
1935419|NCT02625259|Drug|MLN1117|MLN1117 capsules
1935420|NCT02625259|Drug|Lansoprazole|Lansoprazole capsules
1935421|NCT02625259|Drug|MLN1117|MLN1117 capsules
1935425|NCT02624713|Behavioral|obesity treatment|"Parents' education groups for nutrition and healthy behavior with a dietician and a social worker every 2 weeks for5 months, for a total of 10 meetings. This part of the intervention aimed at providing parents with effective tools for modification of lifestyle and the family environment.
Children's individual therapy consisted of 6 individual meetings with a family physician, a physical therapist specializing in children's physical activity, and a dietician. This part of the intervention aimed at modifying nutrition and lifestyle; the physical therapist can help children incorporate physical activity into their routine.
Physical activity groups for the children, with individual physical fitness monitoring. twice a week for 6 months. ."
1935426|NCT02622997|Other|Refrigerated|Self-sample taken and refrigerated immediately then stored in laboratory at -20oC until testing
1935427|NCT02622997|Other|Incubated at 25oC for 1 week|Self-sample taken and refrigerated immediately then incubated at 25oC for 1 week in laboratory then at -20oC until testing
1935428|NCT02622997|Other|Incubated at 25oC for 2 weeks|Self-sample taken and refrigerated immediately then incubated at 25oC for 2 weeks in laboratory then at -20oC until testing
1935429|NCT02623218|Device|Acupuncture|An acupuncture needle is a device intended to pierce the skin in the practice of acupuncture. The device consists of a solid, stainless steel needle. The device may have a handle attached to the needle to facilitate the delivery of acupuncture treatment.
1935430|NCT02623218|Device|Sham Acupuncture|Sham acupuncture will be performed at the same locations as verum acupuncture. Streitberger sham acupuncture needles look like real acupuncture needles, and appear as though the skin is being penetrated during the insertion technique, however they do not pierce the skin.
1935431|NCT02622958|Drug|PH94B|"PH94B is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg PH94B).
Dosing is sex-specific:
Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg
Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
1935432|NCT02622958|Other|Placebo|"Placebo is self-administered intranasally as needed or as necessary, no more than four doses per day for male and female subjects. Each spray delivers 50 µL (0.8 µg Placebo).
Dosing is sex-specific:
Males: two (2) sprays (100 µL) are to be administered to each nostril, for a total dose of 3.2 µg
Females: one (1) spray (50 µL) is to be administered to each nostril, for a total dose of 1.6 µg"
1935439|NCT02622529|Other|Screening through questionnaires|Distribution of Questionnaires to every participant within the single existent Arm at three times.
1935442|NCT02620878|Device|artificial pancreas|Patients will be randomly assigned to receive either 3 days of automated closed-loop insulin delivery (intervention) followed by 3 days of sensor -augmented pump therapy (control), or the inverted sequence.
1935443|NCT02620878|Other|sensor augmented pump|During this control period (comparator arm) the patients will use sensor augmented pump. This period will be compared to the same period of artificial pancreas
1935445|NCT02620631|Drug|Morphine|Subjects receive intrathecal morphine pre-operatively to determine its level of efficacy in acute pain control post-operatively when used in conjunction with post-operative PCA morphine
1935446|NCT02620631|Drug|Placebo|Subjects receive intrathecal, preservative-free normal saline pre-operatively in conjunction with post-operative PCA morphine
1935447|NCT02620566|Procedure|Bupivacain- Caudal|Bupivacain for caudal blocks, Group C received 1 ml kg of 0.25% (maximum volume 20 ml).
1935448|NCT02620566|Procedure|Bupivacaine- Local|Bupivacain for Local Wound Infiltration Group L received 0,2 ml kg 0,25% (maximum volume 4 ml).
1935449|NCT02620176|Device|Transcutaneous vagal nerve stimulation|Trans-auricular vagal nerve stimulation
1935457|NCT02614274|Dietary Supplement|Nutraceutical joint health formulation|A Proprietary Blend
1935458|NCT02614794|Drug|Tucatinib|Treatment will be administered in cycles of 21 days each. Tucatinib 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days.
1935459|NCT02614794|Drug|Capecitabine|Treatment will be administered in cycles of 21 days each. Tucatinib 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days.
1935460|NCT02614794|Drug|Trastuzumab|Treatment will be administered in cycles of 21 days each. Tucatinib 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days.
1935461|NCT02614794|Drug|Placebo|Treatment will be administered in cycles of 21 days each. Tucatinib 300 mg or placebo will be given orally twice daily (PO BID). Capecitabine will be given at 1000 mg/m2 PO BID on Days 1-14 of each 21-day cycle. Trastuzumab will be given as a loading dose of 8 mg/kg intravenously (IV) followed by 6 mg/kg once every 21 days.
1935462|NCT02614729|Other|Standard Protein-Plant, Even Distribution (SP-PLANT-EVEN)|Diet contains all plant proteins. Meals are evenly distributed throughout the day.
1935463|NCT02614729|Other|Standard Protein-Beef, Even Distribution (SP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
1935464|NCT02614729|Other|High Protein-Beef, Even Distribution (HP-BEEF-EVEN)|Diet contains combination of beef and plant proteins. Meals are evenly distributed throughout the day.
1935465|NCT02614729|Other|High Protein-Beef, Uneven Distribution (HP-BEEF-UNEVEN)|Diet contains combination of beef and plant proteins. Meals are unevenly distributed throughout the day.
1935502|NCT02607982|Radiation|Radiotherapy|Radiotherapy was given concurrently on the first day of the first cycle of chemotherapy. The GTV received 60Gy (30 fractions at 2Gy per fraction) and CTV was 40 Gy (20 fractions at 2Gy per fraction). Radiotherapy was delivered in three-dimensional conformal technique (3D-CRT) and no intensity-modulated radiotherapy was used.
1935633|NCT02582216|Device|3D augmented reality|
1935466|NCT02614690|Procedure|No Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to No Split Cast will have a cast that is not split, this is known as closed cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
1935467|NCT02614690|Procedure|Univalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Univalve Cast will have a cast that is split on only one side of the cast, this is known as univalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
1935468|NCT02614690|Procedure|Bivalve Split Cast of forearm fractures|"Enroll 20 patients per arm: patients who present for long arm casts after closed reduction of forearm fractures will be randomized to one of 3 arms. Patients randomized to Bivalve Cast will have a cast that is split on both sides of the cast, this is known as bivalve cast. The cast will be applied according to our Standard of Care casting. Patients will be then undergo follow-up for clinical and radiographic examinations based on the routine fracture management protocol for approximately 3 months."
1935469|NCT02611791|Device|Radiofrequency|The application of RF was through Tecatherap-VIP unit (VIP-Eletromedicina, Argentina) with bipolar method, using a gauntlet of 2cm, and the coupling electrode, which was located in the sacral region (fig x). For the application, participants were placed in a supine position with legs in lithotomy position, it was used water soluble gel for coupling and slide of the gauntlet. The application in external labia majora was made in the caudal-cranial direction, with constant movement and electrode lightly pressed. (fig) During the session, the heat level was monitored verbally and by infrared digital thermometer. The intensity was gradually increased, and at the time when the temperature reached values between 39-41ºC, the intensity was reduced two points and the procedure was maintained for two minutes.
1935470|NCT02611791|Device|Radiofrequency - OFF|The treatment protocol for the control group was identical, differing only in relation to the RF equipment, which was turned off, but a water-soluble gel was used, heated by a resistor, preventing the patient from knowing to which group she belonged. Just the physiotherapist who performed the procedure knew which group the patient belonged to.
1935471|NCT02612259|Dietary Supplement|TRYPTOPHAN|at the dose of 3,5 m/kg/ day divided in two capsules
1935472|NCT02612259|Other|PLACEBO|at the dose of 3,5 m/kg/ day divided in two capsules
1935473|NCT02609308|Other|Short leg cast|Immobilization with short leg cast with a dorsiflexed foot for two weeks
1935474|NCT02609308|Procedure|Platelet-rich plasma|Will be applied 5 mL of autologous platelet-rich plasma under the lateral malleolus, over the anterior talofibular ligament
1935478|NCT02610842|Other|Handbook|"The handbook named Hands on - a hand care guide in Systemic Sclerosis contains instructions about the Systemic Sclerosis and hand exercises."
1935485|NCT02608710|Drug|RDEA3170 4.5 mg|
1935486|NCT02608710|Drug|RDEA3170 6 mg|
1935487|NCT02608710|Drug|RDEA3170 12 mg|
1935488|NCT02608879|Procedure|Oral Mucosa Deterging and Periodontal Debridement (OMDP)|OMDP consists of a regimen of frequent professional oral prophylaxis including tooth cleaning, tooth polishing and flossing, and the cleaning of the periodontum and oral mucosa. This is an intervention that is implemented prior to and maintained throughout the entire cycle of the radiation or chemoradiation.
1935489|NCT02608879|Procedure|Standard of Care Oral Hygiene Instructions|Subjects assigned to this intervention will receive standard of care oral hygiene instructions, including in-person instruction and materials to reference at home. Subjects will also have their teeth brushed and flossed bi-weekly by a dental professional.
1935490|NCT02608879|Device|Dental scaling, ultrasonic|An ultrasonic dental scaler will be used to clean the teeth
1935491|NCT02608879|Drug|Chlorhexidine|Non-alcoholic chlorhexidine will be used as part of the OMDP protocol
1935492|NCT02608762|Radiation|standard adjuvant local radiation therapy or cranial radiation therapy|
1935493|NCT02607800|Drug|SOF/VEL/VOX|SOF/VEL/VOX tablet administered orally once daily
1935494|NCT02607800|Drug|SOF/VEL|SOF/VEL tablet administered orally once daily
1935498|NCT02607735|Drug|SOF/VEL/VOX|SOF/VEL/VOX tablet administered orally once daily
1935499|NCT02607735|Drug|Placebo|SOF/VEL/VOX placebo tablet administered orally once daily
1935500|NCT02607982|Drug|Paclitaxel|PTX 135 mg/m2 was administered intravenously over 3 hours on Day 1 and Day 29 with standard premedications.
1935501|NCT02607982|Drug|Oxaliplatin|oxaliplatin (125mg/ m²) was given as a 2 hours infusion. Chemotherapy was started concurrently with radiation on day 1.
1935503|NCT02606500|Drug|Elonva|"20 obese women will be the study group and 20 normal weighing women will be the control group. Both groups will receive 150 mcg of Elonva for controlled ovarian hyperstimulation (COH). GnRH antagonist will be used to prevent premature LH surge. Additional daily doses of 200 IU of rFSH will be used if necessary. hCG will be used for oocyte maturation. 2 mature follicles will be aspirated separately in each patient. CC samples will be collected and stored on -80 oC for subsequent analysis. Clinical and molecular parameters of IVF success will be assessed and compared between the groups.
The exclusion criteria will be: polycystic ovary syndrome, severely abnormal sperm parameters, and age > 38 years."
1935504|NCT02606903|Drug|BI 695501 prefilled syringe|
1935505|NCT02606903|Drug|BI 695501 autoinjector|
1935507|NCT02606643|Procedure|Slight traction|Slight traction will be applied to the balloon catheter
1935508|NCT02606643|Procedure|Foley Catheter to no traction|No traction will be applied to the catheter
1935509|NCT02606643|Device|Foley Catheter|
1935513|NCT02605486|Drug|Palbociclib|
1935514|NCT02605486|Drug|Bicalutamide|
1935515|NCT02604758|Behavioral|The Psychiatric Nursing Approach Based On The Tidal Model|To provide individualized care for patients in the experimental group, the One-to-One Sessions were initiated and interventions were performed in line with the goals of the persons and the aims of the research. The interventions were selected from interventions regarding with coping and self-esteem from the Nursing Interventions Classification(NIC) system.The One-to-One sessions help the person recognize change and focus the person on achievement and goals.Taking into account the basic process of the Tidal Model, care stages, the following interview plan was drawn up, containing the details of the interviews to be carried out with people with alcohol dependency, and the One-to-One Sessions were held in line with this plan two times per week.
1935516|NCT02604537|Drug|Celestone|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 6 mg/ml celestone OR
1935517|NCT02604537|Drug|Ketorolac|1 cc of 1% lidocaine (without epinephrine) plus 1 cc of 30 mg/ml of ketorolac
1935521|NCT02602652|Biological|a live attenuated chimeric JE vaccine|"The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.
At the second visit (D28), blood samples were collected for evaluate the immunogenicity."
1935528|NCT02603211|Device|tactile imaging sensor or system made in our laboratory|This is a camera with elastomer tip and LED lights. It is a harmless device.
1935529|NCT02602288|Behavioral|Ask, Advise, Refer|WIC clinic staff ask about children's secondhand smoke exposure (SHSe), advise about harms of SHSe, and refer to smoking cessation resources
1935530|NCT02602288|Behavioral|Telebased tobacco counseling|Telephone counseling to promote parent's smoking cessation and behaviors to protect children from secondhand tobacco smoke
1935531|NCT02602288|Behavioral|Telebased nutrition counseling|Telephone counseling to promote nutritious eating practices in the family.
1935532|NCT02602288|Device|Mobile phone smoking cessation application|Smartphone based application to support smoking cessation efforts
1935533|NCT02602288|Device|Mobile phone nutrition application|Smartphone based application to support healthy eating habits
1935534|NCT02602288|Drug|Nicotine polacrilex|Over the counter nicotine replacement therapy in gum or lozenge form.
1935535|NCT02601430|Other|BOLD-MRI|A fixed air cuff will be placed on the index limb at the level of the calf and will be inflated to a level which induces the loss of the pedal Doppler signal. Inflation will be maintained for 180 seconds, then will be rapidly deflated and BOLD MR imaging will be initiated.
1935548|NCT02601170|Biological|Platelet-Rich Plasma Intra-Articular Injection|
1935549|NCT02601170|Drug|Hyaluronic Acid Viscosupplementation|
1935550|NCT02601105|Drug|Centella Asiatica|1% Centella Asiatica in lipoderm
1935551|NCT02601105|Drug|Placebo Vehicle Cream|Lipoderm cream
1935552|NCT02600845|Device|ACCU-CHEK AVIVA CONNECT|ACCU-CHEK Connect Diabetes Management System contains ACCU-CHEK aviva connect blood glucose monitoring system, ACCU-CHEK connect diabetes management app, ACCU-CHEK connect online diabetes management system.
1935553|NCT02600585|Biological|Recombinant Influenza Vaccine|Intramuscular injection of study vaccine
1935554|NCT02600585|Biological|Inactivated Influenza Vaccine|Intramuscular injection of study vaccine
1935555|NCT02600403|Device|Optical Coherence Tomography (OCT)|Optical Coherence Tomography (OCT) is a machine that scans the eyes and has the capability of measuring the thickness of the various layers of the retina and NFL.
1935556|NCT02600403|Device|Diopsys Visual Evoked Potential (VEP)|Diopsys Visual Evoked Potential (VEP) is an imaging system that measures the electrical signal from the eye to the brain by using electrodes placed on the forehead and back of the head.
1935557|NCT02600403|Device|Visual Field|Visual field testing is done to evaluate the extent of side vision loss a patient has with various diseases of the eye, including glaucoma.
1935561|NCT02596867|Drug|propanolol|Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed
1935562|NCT02596854|Device|Neurological MRI|Neurological MRI image collection
1935567|NCT02596321|Drug|Mitizax|Allergen extract
1935568|NCT02596321|Drug|Placebo|Placebo tablet
1935571|NCT02596009|Device|Breezhaler®|No active drug or placebo will be administered to patients during this study. Each patient will be required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient is required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
1935572|NCT02596009|Device|Ellipta®|No active drug or placebo will be administered to patients during this study. Each patient will be required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient is required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
1935573|NCT02596009|Device|Handihaler®|No active drug or placebo will be administered to patients during this study. Each patient will be required to inhale via all three (03) study devices (Breezhaler®, Ellipta® and Handihaler®). Each patient is required to produce at least three (03) inhalational profiles via each inhalational device, following the training and demonstration for correct inhalational procedure, for each device.
1935574|NCT02596750|Device|Microneedle Roller|200 micrometer length microneedles (MR2 roller, Clinical Resolution Laboratories, Inc.) mounted on a disposable roller
1935575|NCT02596750|Device|Sham microneedle Roller|Flat roller without microneedles
1935576|NCT02596750|Drug|Topical 4% lidocaine|
1935577|NCT02594475|Procedure|Endoscopic retrograde cholangiopancreatography|"Endoscopic retrograde cholangiopancreatography is started using conventional duodenoscope (TJF 240 or 260V, Olympus Optical Co., Ltd, Tokyo, Japan) in randomly assigned left lateral position or prone position.
Selective bile duct cannulation is performed using wire-guided cannulation.
In case of difficult cannulation, precut is performed using a needle-knife.
After selective cannulation, cholangiogram is obtained using ERCP catheter, and endoscopic sphincterotomy and/or endoscopic papillary balloon dilation is performed."
1935579|NCT02593305|Dietary Supplement|Super Beets|Nitrate rich beetroot powder (10g/day) for 4 weeks
1935580|NCT02593305|Dietary Supplement|Super Beets Placebo|Nitrate deficient beetroot powder (10g/day) for 4 weeks
1935581|NCT02593630|Device|Unicirc circumcision|Unicirc circumcision under topical (EMLA) anaesthesia, wound sealing with cyanoacrylate tissue adhesive
1935582|NCT02593552|Device|DriveCam|Video event monitoring device
1935585|NCT02592486|Biological|Simultaneous administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine and influenza vaccine simultaneously.
1935586|NCT02592486|Biological|Sequential administration of Pneumovax NP® and Fluvic HA syringe®|Injections of pneumococcal vaccine 2 weeks after the injection of the influenza vaccine.
1935587|NCT02592460|Other|poor-polyamines diet|Patients in this will receive a poor-polyamines diet during a week before and a week after foot surgery
1935588|NCT02592460|Other|high polyamines diet|Patients in this will receive a high-polyamines diet during a week before and a week after foot surgery
1935589|NCT02590406|Procedure|Beach chair (BC) and ZEEP|Table Position: Beach chair, Inclination of the upper part of the table at 25 degrees, breaking at the patient's hips ZEEP: 3 minutes pre-oxygenation with tidal volumes, FiO2 100%, mouth piece used as a ventilatory interface
1935590|NCT02590406|Procedure|Reverse Trendelenburg and NIPPV|"Table Position: Reverse Trendelenburg, Inclination of the whole table at 25 degrees from an horizontal plane, head up.
NIPPV: 3 minutes of pre-oxygenation with 8 cm H2O positive pressure and 10 cm H2O PEEP. Trigger set at 1,5 L/min, mouth piece is used as a ventilatory interface"
1935591|NCT02591290|Biological|Meningococcal (Groups A, C, Y and W 135) Polysaccharide Diphtheria Toxoid Conjugate|0.5 mL, Intramuscular (2 doses at 8 weeks interval)
1935592|NCT02589405|Drug|Benzoyl Peroxide|
1935593|NCT02589405|Other|Dermotivin® Soft Liquid cleanser|
1935594|NCT02589405|Other|Cetaphil® Dermacontrol Moisturizer SPF30|
1935596|NCT02589093|Device|Stimulation|
1935602|NCT02586025|Drug|FEC Chemotherapy|Fluorouracil 500-600 milligrams per square meter (mg/m2), epirubicin 90-120 mg/m2, and cyclophosphamide 500-600 mg/m2 by intravenous (IV) infusion every 3 weeks for three cycles (Cycles 5-7). FEC chemotherapeutic agents will be administered following surgery on Day 1 of each specified cycle.
1935603|NCT02586025|Procedure|Surgery|All participants who are eligible for surgery will undergo surgery and have their pathologic response evaluated.
1935604|NCT02586025|Drug|Docetaxel|Docetaxel IV infusion in 3-week cycles. Neoadjuvant treatment: 75 mg/m2 for Cycles 1-4.
1935605|NCT02586025|Drug|Pertuzumab|Pertuzumab IV infusion in 3-week cycles. Prior to surgery (neoadjuvant treatment): 840 milligrams (mg) loading dose for Cycle 1, followed by 420 mg for Cycles 2-4. After surgery and 3 cycles of FEC chemotherapy (adjuvant treatment): 840 mg loading dose for Cycle 8, followed by 420 mg for Cycles 9-20)
1935606|NCT02586025|Drug|Placebo|Placebo by IV infusion in 3-week cycles as neoadjuvant treatment (Cycles 1-4)and as adjuvant treatment (Cycles 8-20)
1935607|NCT02586025|Drug|Trastuzumab|Trastuzumab IV infusion in 3-week cycles. Neoadjuvant treatment: 8 milligrams per kilogram (mg/kg) loading dose for Cycle 1, followed by 6 mg/kg for Cycles 2-4. Adjuvant treatment: 8 mg/kg loading dose for Cycle 8, followed by 6 mg/kg for Cycles 9-20.
1935612|NCT02585700|Biological|Influenza vaccine, split inactivated|Seasonal trivalent inactivated influenza vaccine (TIV), inactivated split virion, purified by sucrose gradient ultracentrifugation. The vaccine is produced in hen`s eggs, and inactivated with beta-propiolactone.
1935613|NCT02585700|Biological|Phosphate buffered saline|0.5 mL of phosphate buffered saline
1935614|NCT02583230|Behavioral|MedLink System|"Patient adherence to anti depressant medication will be accomplished by 1) monitoring adherence and providing feedback to patient (e.g. prompting patient to take medication); 2) monitoring side effects and treatment response and providing in-the-moment feedback and support; 3) activating the patient to take appropriate action (e.g. call the prescribing physician) based upon monitoring data; 4) providing standardized education and positive reinforcement to the patient.
The care team will be supported and activated by being provided 1) suggested guideline-congruent actions and 2) timely information regarding the patient's status."
1935616|NCT02584361|Procedure|Round window approach|In this group the insertion of the electrode into cochlea will be performed through an incision in the membrane (paracentesis) of the round window (round window approach = RWA).
1935617|NCT02584361|Procedure|Cochleostomy|In this group the insertion of the electrode into cochlea will be performed by drilling a hole in cochlea (cochleostomy).
1935618|NCT02583633|Drug|Transdermal nitroglycerin|
1935619|NCT02583633|Drug|nifedipine|
1935620|NCT02583178|Device|Aegis Sierra Ligation System|The SLS is a series of devices designed for epicardial ligation of the left atrial appendage through a minimally invasive transcatheter approach.
1935621|NCT02581553|Drug|lesinurad/allopurinol 200/300 FDC tablets|
1935622|NCT02581553|Drug|lesinurad 200 mg|
1935623|NCT02581553|Drug|allopurinol 300 mg|
1935624|NCT02581553|Drug|lesinurad/allopurinol 200/200 FDC tablets|
1935625|NCT02581553|Drug|allopurinol 200 mg|
1935626|NCT02582840|Drug|Dapagliflozin 5mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
1935627|NCT02582840|Drug|Dapagliflozin 10mg|Dapagliflozin, a blood glucose lowering drug. Oral dose
1935628|NCT02582840|Drug|Placebo tablet|Placebo tablet. Oral dose
1935629|NCT02582450|Other|Patients with haemophilia|Piloting of reliability and validity of the Spanish version of the Veritas-Pro questionnaire.
1935630|NCT02582372|Drug|Dexmedetomidine and bupivacaine|10 micrograms of dexmedetomidine plus 12,5 mgrs of bupivacaine subarachnoideal
1935631|NCT02582372|Drug|Fentanyl and bupivacaine|25 micrograms of fentanyl plus 12,5 mgrs of bupivacaine subaracnoideal
1935632|NCT02581735|Other|Patients with haemophilia|"Using the platform Upatient, patients with hemophilia will register for one year, the prophylactic treatment who receive at home. Likewise, they indicate a replacement therapy as a result of joint bleeds.
At baseline, a month, 6 months and at the end of the study, patients shall complete two questionnaires. The same way in the initial evaluation and end of the study, the clinical joint status will be evaluated with HJHS scale ."
1935635|NCT02581917|Other|Laboratory Biomarker Analysis|Undergo metabolic analysis
1935636|NCT02582294|Other|Questionnaire|
1935639|NCT02578537|Drug|Ticagrelor|Ticagrelor group:all patients receive ticagrelor (180 mg loading dose, then 90 mg twice daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
1935640|NCT02578537|Drug|Clopidogrel|Clopidogrel group:all patients receive clopidogrel (600 mg loading dose, then 75 mg once daily followed for 30 days). All patients were given aspirin 100 mg per day unless they were intolerant. For those not previously given aspirin, a loading dose of 300 mg was preferred.
1935641|NCT02577107|Drug|ranibizumab|"This prospective, randomized, open label study will enroll patients with neovascular AMD who are naïve to anti-VEGF therapy or have not received intravitreal anti-VEGF therapy for the previous 3 months.
Monthly injections of 0.5mg Ranibizumab during 3 month Blood sample (plasma/serum) will be collected at baseline (pre-dose), 3h post-injections and days 1, 3, 7 and 28, following doses 1 and 3 for PK and systemic VEGF analysis. The lab staff will be blinded for treatment allocation.
Plasma VEGF concentration will be measured by a blinded laboratory using Quantikine® ELISA kits. Serum ranibizumab concentration will be determined using validated ELISA assay."
1935642|NCT02577107|Drug|Conbercept|"This prospective, randomized, open label study will enroll patients with neovascular AMD who are naïve to anti-VEGF therapy or have not received intravitreal anti-VEGF therapy for the previous 3 months.
Monthly injections of 0.5mg Conbercept during 3 month Blood sample (plasma/serum) will be collected at baseline (pre-dose), 3h post-injections and days 1, 3, 7 and 28, following doses 1 and 3 for PK and systemic VEGF analysis. The lab staff will be blinded for treatment allocation.
Plasma VEGF concentration will be measured by a blinded laboratory using Quantikine® ELISA kits. Serum Conbercept concentration will be determined using validated ELISA assay."
1935644|NCT02577718|Drug|Nitroglycerin - citrate - ethanol (NiCE)|Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
1935645|NCT02575781|Drug|SAR428926|Pharmaceutical form:concentrate for solution for infusion Route of administration: intravenous
1935653|NCT02574858|Drug|QRH-882260|The investigational agent to be used in this study is a fluorescently-labeled peptide composed of a 7-amino acid sequence attached to Cy5.
1935654|NCT02574832|Drug|Lidocaine Administration|The lidocaine dose will be determined using a 9:1 biased-coin sequential allocation method. For the first participant, the starting dose will be 32 mg of 2% isobaric lidocaine (1.6 mL). Two outcomes will be possible: satisfactory or unsatisfactory anesthesia.
1935655|NCT02573610|Drug|DE-108|Subjects will be assigned to receive DE-108 ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
1935656|NCT02573610|Drug|Levofloxacin 0.5%|Subjects will be assigned to receive Levofloxacin 0.5% ophthalmic solution to be administrated one drop a time 3 times daily for 3 days prior and for 14 days following cataract surgery.
1935657|NCT02574377|Drug|A: myDC vaccination|
1935658|NCT02574377|Drug|B: pDC vaccination|
1935659|NCT02574377|Drug|C: combined myDC/pDC vaccination|
1935660|NCT02573948|Other|no intervention is assessed|
1935729|NCT02559440|Drug|mometasone furoate|50μg, 1 puff in each nostril every evening
1935730|NCT02559440|Drug|Placebo|1 puff in each nostril every evening
1936797|NCT02337725|Drug|TVP-1012|TVP-1012 Tablets
1935661|NCT02573701|Drug|Guideline treatment (Risperidone, administered orally)|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
1935662|NCT02573701|Behavioral|"Psychosocial treatment"|"Participants will receive the Guideline Treatment (risperidone, administered orally) plus Behavioral Intervention: psychosocial treatment included psychoeducation social skills healthy life style habits exercise in group"
1935663|NCT02573701|Drug|Treatment as Usual (any other antipsychotic)|Participants will receive the Treatment as Usual (atypical antipsychotic) plus Behavioral Intervention: psychosocial treatment assigned by clinician.
1935664|NCT02573155|Drug|Dose 1, AZD8871 50 μg (Part 1)|50 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
1935665|NCT02573155|Drug|Dose 2, AZD8871 100 μg (Part 1)|100 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
1935666|NCT02573155|Drug|Dose 3, AZD8871 300 μg (Part 1)|300 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
1935667|NCT02573155|Drug|Dose 4, AZD8871 600 µg (Part 1)|600 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
1935668|NCT02573155|Drug|Dose 5, AZD8871 1200 µg (Part 1)|1200 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
1935669|NCT02573155|Drug|Dose 6, AZD8871 1800 μg (Part 1)|1800 µg of AZD8871 on Day 1; each dose of AZD8871 inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
1935670|NCT02573155|Drug|Placebo, AZD8871 placebo (Part 1)|AZD8871 placebo on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
1935671|NCT02573155|Drug|Treatment A, AZD8871 dose A (Part 2)|AZD8871 dose A once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler (Genuair®)
1935672|NCT02573155|Drug|Treatment B, AZD8871 dose B (Part 2)|AZD8871 dose B once on Day 1; each dose of AZD8871 placebo inhalation powder will be administered via single-dose dry powder inhaler(Genuair®)
1935673|NCT02573155|Drug|Treatment C, Indacaterol 150 μg (Part 2)|150 μg of Indacaterol once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (Onbrez Breezhaler®) as 1 hard capsule
1935674|NCT02573155|Drug|Treatment D, Tiotropium 18 μg (Part 2)|18 μg of Tiotropium once on Day 1; each dose of Indacaterol dry inhalation powder will be administered via a dry powder inhaler (HandiHaler®) as 1 hard capsule
1935675|NCT02571192|Drug|SHP626|single oral dose 50mg SHP626 with approximately 5.95 μCi RAD
1935676|NCT02571192|Radiation|5.95 μCi RAD|
1935677|NCT02571686|Device|Surveyor S4|
1935678|NCT02571491|Drug|Ketamine Hydrochloride|50 mg/ml, IV (in the vein) during surgery operation, followed by IV ketamine hydrocloride perfusion 2mcg/Kg/min before and until 72 hours after operation Number of Cycles: until progression or unacceptable toxicity develops.
1935679|NCT02571491|Other|Placebo|50 mg/ml, IV (in the vein) during surgery operation, followed by IV placebo perfusion 2mcg/Kg/min before and until 72 hours after operation
1935680|NCT02571491|Drug|Remifentanil|at doses of 0.3 mcg / kg / min during and until the end of the surgical operation
1935681|NCT02571491|Drug|Morphine hydrochloride|at the dose of 150 mcg / kg, 60 minutes before the extubation procedure and until 72 hours after operation by intravenous infusion
1935682|NCT02571335|Behavioral|Intensive Training|"Week 1: Ratio of continuous and interval training of 2:1. Entry point at day one with 20 min of continuous, physiologically defined heart rate controlled cycling at 50-60 rounds per minutes at 75% of HRpeak.
Resistance training is performed with 70% of the subjective-felt 1-round maximum with three sets and 10-12 repetitions and three exercises for the upper and lower extremities.
Week 2 Progression of endurance training: 4x5 minutes with 2 Minutes between each interval performed at 80% of HRmax Progression resistance training: 75% of the subjective-felt 1-round maximum with three sets and 8-10 repetitions and three exercises for the upper and lower extremities.
Week 3 Same as week 2."
1935683|NCT02571335|Behavioral|Normal Training|The control intervention is the normal rehabilitation program of the Valens clinic.
1935686|NCT02569632|Biological|Trumenba Vaccine (Wyeth/Pfizer Pharmaceuticals)|All subjects will receive three doses of a Trumenba, a U.S.-licensed meningococcal vaccine. Each 0.5 mL dose contains 60 micrograms of each FHbp variant (total of 120 micrograms of protein), 0.018 mg of PS80 and 0.25 mg of Al³+ as AlPO4 in 10 mM histidine buffered saline at pH 6.0. Trumenba is administered as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.
1935688|NCT02569190|Device|Walkbot|Robot assisted gait training
1935689|NCT02569086|Other|Blood draw|
1935690|NCT02568735|Drug|Dexketoprofen|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
1935691|NCT02568735|Drug|Etoricoxib|After total hip replacement surgery patient were given either etoricoxib or dexketoprofen
1935731|NCT02559440|Drug|Oxymetazoline + Placebo|1 puff of Oxymetazoline +1 puff of Placebo in each nostril every evening
1935692|NCT02568475|Behavioral|"Provision of Go to the Hospital or Stay Here?"|Residents and families randomly assigned to the intervention group (one half of the residents and one half of the families enrolled) are given the new Decision Aid to review with an RA trained for this purpose by the investigators. The Decision Aid provides information on risks and benefits of acute care transfer and information on advance care planning, resident and families' right to be involved in the decision. Resident or family member is also asked to re-read it and think about it over the subsequent 14 days.
1935693|NCT02567708|Drug|GSK2269557 DPI|GSK2269557 will be supplied as a lactose blend in a DISKUS DPI with a unit dose strength of 500 mcg. 2 inhalations will be taken every morning before breakfast.
1935694|NCT02567708|Drug|Placebo DPI|Placebo will be lactose in a DISKUS DPI. 2 inhalations will be taken every morning before breakfast.
1935695|NCT02568267|Drug|Entrectinib|TrkA/B/C, ROS1, and ALK inhibitor
1935696|NCT02567552|Drug|Subcutaneous progesterone|subcutaneous progesterone 25 mg/day
1935697|NCT02567552|Drug|Intramuscular progesterone|intramuscular progesterone 50 mg/day
1935698|NCT02566135|Device|Tracheal Intubation|Following general anaesthesia I-gel was inserted. After proper placement . ventilating bougie was inserted. Once it's placement is confirmed I-gel was removed keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie then it (v.bouggie) was removed . Proper placement of endotracheal tube was confirmed by bilateral equal chest excursion and air entry on auscultation, absence of gastric insuffflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for I-gel, ventilating bougie and endotracheal tube.
1935699|NCT02566135|Device|Tracheal Intubation|Following general anaesthesia C-LMA was inserted. Aftre proper placement ventilating bougie was inserted. It's placement was confirmed and C-LMA was removed after deflation of cuff keeping the ventilating bougie in situ. Then appropriate sized endotracheal tube was railroaded over ventilating bougie. It's placement was confirmed by bilateral equal air entry and chest excursion, absence of gastric insufflation sound over epigastrium and 'sine' wave on capnography. Maximum 3 attempts were allowed for C-LMA , ventilating bougie and endotracheal tube.
1935700|NCT02566785|Other|Balance Intervention|The multi-component balance intervention will be 1x per week in supervised group sessions and 2x a week sessions at home. Sessions will begin with a 5 minute warm up of major muscle groups using flexibility exercises and end with a cool down. Sessions will focus on improving static balance in the initial stages, then progress to dynamic balance.
1935701|NCT02566759|Drug|TAK-831|TAK-831 oral suspension.
1935702|NCT02566759|Drug|TAK-831 Placebo|TAK-831 placebo-matching oral suspension.
1935708|NCT02563899|Drug|Umeclidinium|Umeclidinium (GSK573719) 1.85% will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be available at a concentration of 18.5 milligrams (mg) umeclidinium parent per gram. 2 mg of this formulation will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of formulation applied daily to both axillae is expected to range between approximately 204 and 680 mg. Total daily dosage of the active pharmaceutical ingredient (umeclidinium parent) to both axillae will range between approximately 3.8 and 12.6 mg. If certain pre-specified criteria for safety and tolerability are met, consideration will be given to decreasing the dose by decreasing the concentration of the topical formulation to 1.15% for the remaining subjects. This lower strength formulation will contain 11.5 mg parent per gram.
1935709|NCT02563899|Drug|Vehicle|The vehicle will be supplied as a clear, colorless solution, free from visible particulates, for topical application. This formulation will be similar to the umeclidinium formulation except that it will be devoid of the umeclidinium parent. 2 mg of the vehicle will be applied per square centimeter of the axilla, once a day at night before going to bed for 14 days. The total amount of vehicle applied daily to both axillae is expected to range between approximately 204 and 680 mg.
1935710|NCT02564263|Biological|pembrolizumab|IV Q3W
1935711|NCT02564263|Drug|paclitaxel|IV on Days 1, 8, and 15 of every 28-day (4-week) cycle
1935712|NCT02564263|Drug|docetaxel|IV on Day 1 of every 21-day (3-week) cycle
1935713|NCT02564263|Drug|irinotecan|IV on Day 1 of every 14-day (2-week) cycle
1935722|NCT02561910|Device|Laparoscopic hernia repair|Preperitoneal mesh implantation because of inguinal hernia disease using the laparoscopic technique
1935723|NCT02561806|Drug|Ixekizumab|Administered SC
1935724|NCT02561806|Drug|Ustekinumab|Administered SC
1935725|NCT02560779|Drug|TRC105|Bi-weekly TRC105 will be given with standard-dose sorafenib.
1935726|NCT02560779|Drug|Sorafenib|Bi-weekly TRC105 will be given with standard-dose sorafenib.
1935727|NCT02559388|Drug|Montelukast|
1935728|NCT02559388|Drug|placebo|Placebo (For Montelukast) Placebo pills manufactured for mimic 10 milligram montelukast pills
1936798|NCT02337725|Drug|Placebo|Placebo tablets.
1935732|NCT02559440|Drug|Placebo + placebo|1 puff of placebo +1 puff of Placebo in each nostril every evening
1935733|NCT02559440|Drug|mometasone furoate + Placebo|1 puff of mometasone furoate +1 puff of Placebo in each nostril every evening
1935734|NCT02559440|Drug|mometasone furoate + Oxymetazoline|1 puff of mometasone furoate +1 puff of Oxymetazoline in each nostril every evening
1935735|NCT02557399|Drug|Duac® fixed dose combination gel|Duac® fixed dose combination gel containing clindamycin phosphate 1.2% and benzoyl peroxide 3%.
1935736|NCT02557399|Drug|ADA 0.1% gel|ADA 0.1% gel containing 0.1% of adapalene.
1935737|NCT02557399|Drug|CLDM 1% gel|CLDM 1% gel containing clindamycin phosphate 1.2% (1% as clindamycin).
1935739|NCT02557282|Other|Retrospective CTP cases processed with Carestream software.|Retrospective CTP cases were processed using Carestream software and compared to the predicate device software.
1935740|NCT02555852|Drug|esomeprazole|Exposure to esomeprazole (ATC A02BC05, B01AC56, M01AE52, A02BD06) will be defined as a prescription for esomeprazole on the same day as a ≥ 30 day NSAID prescription.
1935741|NCT02555852|Drug|omeprazole|Exposure to omeprazole (ATC A02BC01, A02BD01) will be defined as a prescription for omeprazole on the same day as a ≥ 30 day NSAID prescription.
1935742|NCT02555852|Drug|pantoprazole|Exposure to pantoprazole (ATC A02BC02, A02BD04) will be defined as a prescription for pantoprazole on the same day as a ≥ 30 day NSAID prescription.
1935743|NCT02555852|Drug|lansoprazole|Exposure to lansoprazole (ATC A02BC03, A02BD07, A02BD03, A02BD02) will be defined as a prescription for lansoprazole on the same day as a ≥ 30 day NSAID prescription.
1935744|NCT02555852|Drug|rabeprazole|Exposure to rabeprazole (ATC A02BC04) will be defined as a prescription for rabeprazole on the same day as a ≥ 30 day NSAID prescription.
1935745|NCT02555852|Drug|cimetidine|Exposure to cimetidine (ATC A02BA01) will be defined as a prescription for cimetidine on the same day as a ≥ 30 day NSAID prescription.
1935746|NCT02555852|Drug|ranitidine|Exposure to ranitidine (A02BA02) will be defined as a prescription for ranitidine on the same day as a ≥ 30 day NSAID prescription.
1935747|NCT02555852|Drug|famotidine|Exposure to famotidine (A02BA03) will be defined as a prescription for famotidine on the same day as a ≥30 day NSAID prescription.
1935748|NCT02555852|Drug|nizatidine|Exposure to nizatidine (A02BA04) will be defined as a prescription for nizatidine on the same day as a ≥ 30 day NSAID prescription.
1935749|NCT02555852|Drug|niperotidine|Exposure to niperotidine (A02BA05) will be defined as a prescription for niperotidine on the same day as a ≥ 30 day NSAID prescription.
1935750|NCT02555852|Drug|roxatidine|Exposure to roxatidine (A02BA06) will be defined as a prescription for roxatidine on the same day as a ≥ 30 day NSAID prescription.
1935751|NCT02555852|Drug|ranitidine bismuth citrate|Exposure to ranitidine bismuth citrate (A02BA07) will be defined as a prescription for ranitidine bismuth citrate on the same day as a ≥ 30 day NSAID prescription.
1935752|NCT02555852|Drug|lafutidine|Exposure to lafutidine (A02BA08) will be defined as a prescription for lafutidine on the same day as a ≥ 30 day NSAID prescription.
1935753|NCT02555852|Drug|cimetidine combinations|Exposure to cimetidine combinations (A02BA51) will be defined as a prescription for cimetidine combinations on the same day as a ≥ 30 day NSAID prescription.
1935754|NCT02555852|Drug|famotidine combinations|Exposure to famotidine combinations (A02BA53) will be defined as a prescription for famotidine combinations on the same day as a ≥ 30 day NSAID prescription.
1935755|NCT02557035|Drug|Palonosetron|
1935756|NCT02557035|Drug|Dexamethasone|
1935757|NCT02556632|Drug|Curcumin-based Gel|Applied topically
1935758|NCT02556632|Procedure|Dermatologic Complications Management|Apply HPR Plus topically
1935759|NCT02556632|Other|Laboratory Biomarker Analysis|Correlative studies
1935760|NCT02556632|Other|Placebo|Apply placebo gel topically
1935761|NCT02556632|Other|Questionnaire Administration|Ancillary studies
1935763|NCT02553928|Drug|Memantine (once daily)|
1935764|NCT02553928|Drug|Memantine (twice daily)|
1935771|NCT02554045|Drug|Tadalafil|Patients will take tadalafil 2.5 mg tablet every morning for 8 weeks and then withdraw tadalafil for 8 weeks
1935772|NCT02554045|Drug|Placebo|Patients will take placebo tablet every morning for 8 weeks and then withdraw placebo for 8 weeks
1935773|NCT02552615|Other|body awareness therapy|
1935774|NCT02552615|Other|core stabilization exercises|
1935775|NCT02552615|Other|traditional exercises|
1935776|NCT02553538|Behavioral|Patient Navigation|Navigators utilized TopCare to track these patients, reach out to them in their own language, and provide intense outreach to help them complete cancer screening.
1935825|NCT02533726|Other|Patient Sensor|A small sensor with adhesive backing is applied to the upper chest (midline) of the patient. Sensor tracks and records body movement and position, and displays this on a User Dashboard located on a computer at the bedside.
1935898|NCT02515175|Biological|Matrix-M2|Matrix-M2 is derived from fractionated Quillaja saponins, phosphatidylcholine, and cholesterol.
1935779|NCT02550938|Device|Invisalign|The Invisalign® System consists of a series of clear plastic aligners that are intended to replace conventional wire and bracket technology for many orthodontic cases. Each custom manufactured aligner exerts gentle, continuous forces to move teeth incrementally from their original state to a final, treated state. Each aligner is worn for a defined period of time , then replaced by the next in the series until the final position is achieved. For years, orthodontists and dentists have used removable appliances for orthodontic treatment. Today, with the application of computer technology and custom manufacturing, Invisalign treats a broader range of cases with greater precision.
1935781|NCT02549573|Drug|APOKYN|Subjects in the APOKYN+ group will administer his/her usual dose of APOKYN at the PT clinic, as instructed by the Physical Therapist. These subjects will not take carbidopa/levodopa for at least 3 hours before or during the PT Intervention Visit.
1935782|NCT02549573|Behavioral|Physical Therapy|All subjects will participate in a standardized PT intervention
1935783|NCT02550106|Drug|OMALIZUMAB|sub cutaneous injections of 300 mg every 4 weeks until Week 8.
1935784|NCT02550093|Drug|Normal Saline|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing.
1935785|NCT02550093|Drug|Oxytocin|Each subject will receive nasal spray(s) into each nostril of 4 Units up to 32 units of study drug prior to Thermal Evaluation System Testing.
1935786|NCT02549222|Other|Standard of Care|
1935792|NCT02546622|Biological|Factor VIII Replacement Products for Hemophilia which were FDA approved after January 1, 2013|
1935793|NCT02546622|Biological|Factor IX Replacement Products for Hemophilia which were FDA approved after January 1, 2013|
1935798|NCT02544074|Behavioral|neuropsychological testing|standard neuropsychological testing including brief standardized assessments
1935799|NCT02543424|Behavioral|Motor, cognitive and neuropsychological assessment|Cognitive and motor testing and/or experimental cognitive or motor changes and/or cognitive or motor rehabilitation depending on part of the study investigated.
1935801|NCT02541019|Drug|Ondansetron|4 mg IV, one minute before the anesthesia induction and 4 mg IV three times a day during two days after the surgery.
1935802|NCT02541019|Drug|Palonosetron|75 mcg IV, one minute before the anesthesia induction.
1935803|NCT02540486|Other|Long-acting insulin glargine titration web tool (LTHome)|The LTHome study arm will receive insulin glargine titration instructions from the LTHome web-based tool
1935804|NCT02540486|Other|Diabetes Education|Individual diabetes education, detailed instructions on the use of the blood glucose monitor and unlimited availability of blood glucose monitoring supplies.
1935805|NCT02541422|Dietary Supplement|N Acetyl Cysteine|
1935806|NCT02541422|Other|placebo|
1935807|NCT02541942|Other|No treatment given|For patient convenience, genetic material will be collected in the form of saliva samples.
1935808|NCT02540369|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Administration by intravitreal injection.Muti-target Anti-VEGF agent. Dosing would be at physicians discretion.
1935809|NCT02539654|Drug|EXE844 Sterile Otic Suspension, 0.3%|
1935810|NCT02539654|Procedure|Tympanostomy Tube Insertion|
1935811|NCT02539212|Device|microwave ablation|ultrasound-guided microwave ablation is performed to treat hepatocellular carcinoma patients
1935812|NCT02539212|Device|radiofrequency ablation|ultrasound-guided radiofrequency ablation is performed to treat hepatocellular carcinoma patients
1935822|NCT02535416|Drug|ARC-520|
1935823|NCT02533726|Other|Optimal Turning|Patients within this arm will receive optimal turning practices. Nurses caring for these patients will receive real-time quantitative measures of patient turning procedures from the User Dashboard and provide a visual advisory to the nurse for the time to next turn.
1935824|NCT02533726|Other|Standard Care Practices|Patients within this arm will receive standard preventative care practices - that is, nurses will provide standard care as necessary, without the aid of visual advisories from a patient sensor.
1935895|NCT02515656|Drug|POLYGYNAX®|
1935896|NCT02515656|Drug|GYNODAKTARIN®|
1935897|NCT02515656|Drug|Placebo|
1935827|NCT02534480|Drug|NGP 555|Gamma-secretase modulator for the treatment of Alzheimer's disease
1935828|NCT02533895|Biological|AV0113 DC-CIT|Mature loaded DCs will be injected intra-nodally into tumour free lymph nodes or subcutaneously close to tumour free lymph nodes at weekly intervals for at least 6 weeks.
1935829|NCT02533895|Other|Data evaluation|"For obtaining a clearer picture of AV0113's utility in the treatment of bone and soft tissue sarcoma, a LT follow-up investigation of the 14 Sarcoma patients, which will be treated using the AV0113 DC-CIT technology, is planned, in order to gather first evidence for a potential LT effect of DC-CIT with AV0113.
Furthermore, a comparison of the 14 sarcoma patients treated with AV0113 DC-CIT with a cohort of matched historic control patients that were treated using standard of care will be conducted. It is planned to analyse 42 control sarcoma patients that will be matched for disease, recurrences, relapses etc"
1935830|NCT02533102|Drug|E7050|100 mg tablet administered orally
1935833|NCT02533453|Biological|Bydureon|exenatide once weekly
1935834|NCT02533284|Drug|Magnesium Sulfate|preemptive US guided TAP block will be done using Bupivacaine 0.25% plus 0.5 gm MgSo4 in M group).
1935835|NCT02533284|Drug|bupevecaine|US guided TAP using Bupevecaine 0.25 %
1935836|NCT02533284|Drug|saline|US guided TAP using placebo (saline)
1935837|NCT02533167|Other|skin to skin|initiating skin to skin is not currently the standard of care at our facility so there is 1 interventional arm for this study. control group of no skin to skin until recovery room already established as is the standard of care.
1935838|NCT02532959|Device|Diagnostic Breath Analysis|Conduct exhaled breath samples
1935843|NCT02530528|Drug|CHG|Varied application times
1935844|NCT02530554|Drug|CHG|Varied application times
1935845|NCT02530541|Drug|CHG|Varied application times
1935846|NCT02529592|Biological|Endotoxin|
1935847|NCT02529592|Biological|Placebo|
1935848|NCT02528786|Other|No Intervention|No study drug will be administered in this study.
1935849|NCT02528305|Other|High-intensity Interval Training|2 minute warm-up at 50rpm, then increase to 100rpm. Weight added to bike (7% body weight for men 6% body weight for women). Continue effort for 6 seconds, then passive rest for at least 1 minute. Total 5 sprints in sessions 1-3, 6 sprints in session4, 7 sprints in sessions 5&6, 8 sprints in sessions 7&8, 9 sprints in sessions 9&10 and 10 sprints in sessions 11&12.
1935851|NCT02526667|Drug|Chlorhexidine Gluconate|comparison with other CHG products
1935852|NCT02526667|Other|Vehicle|Cloth with Excipients no CHG
1935853|NCT02526667|Drug|2% Chlorhexidine Gluconate Solution|CHG solution
1935854|NCT02524977|Behavioral|Decision Support|Provision of recommended antithrombotic therapy based on atrial fibrillation decision support tool that uses both stroke and bleeding risk
1935855|NCT02524977|Behavioral|Educational Intervention Only|Educational conference series
1935856|NCT02525341|Other|Hatha yoga|A sequence of 8 - 10 core yoga poses, breathing and relaxation techniques were practiced in each yoga class, and 2 - 3 new poses were introduced progressively in each of the yoga session. Props such as blocks, blankets, belts, mats, and chairs were used during the session.
1935857|NCT02525341|Other|Aerobic and strengthening exercises|A 15 minute of gentle aerobic exercise and a 30 minute of strengthening program that includes both isometric (without moving the joints) and isotonic (moving the joints) exercises of the lower extremities were taught to the participants.
1935858|NCT02525341|Other|General education|One-time Arthritis Foundation educational brochures focusing on the disease process, diet and exercise and OA management education were given.
1935859|NCT02524691|Device|Use of Rapid Immunoassay Tests for the Detection of PROM|Patient will undergo both rapid immunoassay tests for the detection of PROM and the standard of care for the diagnosis of PROM using a sterile speculum (SSE). Women who cannot be confirmed clinically by the SSE will undergo an ultrasound evaluation to determine the amniotic fluid index. The patient will be treated according to the results of the SSE and ultrasound, not the results of rapid immunoassay tests. The provider conducting the SSE will be blinded to the results of the rapid immunoassay tests.
1935862|NCT02521259|Device|BIS|BIS monitoring provides the patient's depth of consciousness, enables us to monitor safe, optimal anesthesia for each patient.
1935865|NCT02522403|Procedure|Rehabilitation|The investigators will be apply fake laser therapy in the patients with distal radius fracture, with the device in an off position; plus the patients will be teaching to do rehabilitation exercise in flexion, extension, pronation and supination of the wrist and forearm, and to do cubital and radial deviation exercise. The investigators delivered to all patients a graphic demonstration of the exercise
1935866|NCT02522403|Device|Low Lever Laser acupuncture|The investigators will be used a low lever laser device, to apply in ten selected acupuncture points, each point will be irradiated for 30 seconds at 8000 Hz, this therapy is useful for tissue regeneration and stimulate the acupuncture points, plus an antinociceptive effect.
1935867|NCT02522286|Behavioral|Ask 3 Questions|"Participants were asked to bring an Ask 3 questions flyer into their appointment to use if they needed to make a choice about their health care during their appointment. These 3 questions have been shown to help patients make more informed decisions about their healthcare."
1935868|NCT02522286|Behavioral|Open Communication|"Open Communication includes a combination of interventions. 1) Participants used a Visit Companion Booklet to write out issues they would like to discuss with their physician during their appointment before showing up. They were also asked to write out any next steps decided on during their appointment and to repeat back to their doctor what they wrote before leaving.
2) Patients watched a short, informational cartoon video to better understand the Visit Companion Booklet.
3) Participating physicians received a training through the use of a Standardized Patient Instructor as a means of providing convenient, individualized training on communication techniques. Dyads (physicians and their medical assistants) were trained on how to incorporate the Visit Companion Booklet into workflow."
1935869|NCT02521948|Device|MANTA Vascular Closure Device|The MANTA device developed by Essential Medical, Inc., is a vascular closure device (VCD) intended for use in catheterization laboratories following percutaneous cardiac or peripheral procedures that use the retrograde common femoral artery access route for large bore (10‐18F) interventional devices.
1935874|NCT02518919|Other|Child life intervention|The participants will receive IV ketamine for sedation. In addition in this arm, 'Child Life Intervention', comfort measures provided by a trained child life therapist during painful procedures.
1935875|NCT02518919|Other|Music listening|The participants will receive IV ketamine for sedation. In addition in this arm, 'Music Listening' to music chosen by the patient using headphones
1935880|NCT02517931|Procedure|Sphenopalatine Ganglion Block|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in 2% viscous lidocaine into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1mL of 0.5% bupivacaine will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
1935881|NCT02517931|Procedure|Placebo|Subjects will be asked to blow out each nostril. They will then be laid supine with a small shoulder roll and intranasal phenylephrine 0.25% (RhinallⓇ) will be sprayed once into each nostril to preemptively minimize bleeding. SPGB will be performed by inserting long cotton tipped applicators saturated in carboxymethylcellulose based lubricant (i.e. K-Y Jelly®) into nostril until properly seated in the posterior nasopharynx. These will be left in place for 10 minutes and then 1 mililiter of normal saline will be administered down the plastic hollow shaft of each applicator via an 18g angiocatheter. The applicators will remain in place for 10 more minutes and then be removed.
1935882|NCT02517866|Drug|Azilsartan Medoxomil|Azilsartan medoxomil tablets
1935883|NCT02517658|Other|Video|Watching a YouTube video containing post tonsillectomy discharge instructions.
1935884|NCT02517658|Other|Standard discharge teaching|Receiving standard post tonsillectomy discharge instructions from the nurse prior to discharge.
1935885|NCT02517580|Dietary Supplement|Vitamin K2 (MK7)|
1935887|NCT02517567|Device|Delefilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
1935888|NCT02517567|Device|Narafilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
1935889|NCT02517567|Device|Somofilcon A contact lenses|Daily disposable, silicone hydrogel contact lenses used according to manufacturer's instructions
1935890|NCT02517567|Other|No intervention|
1935891|NCT02517047|Device|CareTRx|CareTRx is a novel device that can be applied to most MDI (meter dose inhaler) device and leverages mobile and cloud computing to objectively assess and provide real-visualize feedback to patients and providers around medication adherence and disease control in pediatric asthma.
1935892|NCT02515903|Procedure|Intra-endoscopic surgery|Intra-endoscopic surgery for evacuation of ICH
1935893|NCT02515903|Procedure|Placebo:stereotactic aspiration surgery|Placebo:stereotactic aspiration surgery for evacuation of ICH
1935899|NCT02515175|Biological|GEN-003|HSV-2 protein subunit vaccine consisting of 2 recombinant T cell antigens: internal fragment of the immediate early (IE) protein ICP and glycoprotein D
1935900|NCT02515175|Drug|Placebo|0.9% Normal Saline
1935905|NCT02514772|Biological|GP2013 - A Proposed biosimilar rituximab|
1935906|NCT02514772|Biological|Originator rituximab - Rituxan ® or MabThera ®|
1935912|NCT02513719|Device|XIENCE PRIME SV Everolimus Eluting Coronary Stent|Patients receiving XIENCE PRIME SV Everolimus Eluting Stent
1935915|NCT02513459|Drug|ABBV-066|dose regimen 1
1935916|NCT02513459|Drug|ABBV-066|dose regimen 2
1935917|NCT02512822|Procedure|Noninvasive Radiofrequency TruSculpt|Heating subcutaneous fat up to 45℃ continuously at least 3 minutes without surface damage and induces adipocytes apoptosis.
1935918|NCT02512575|Drug|AZD9567 Monohydrat|AZD9567 oral suspension 0.5 to 10 mg/ml
1935919|NCT02512575|Drug|Placebo oral suspension/ Placebo capsule|Matching placebo
1935920|NCT02512575|Drug|Prednisolone|Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
1935924|NCT02512081|Other|No intervention applied|No intervention applied
1935925|NCT02512055|Drug|Ketamine|Repeated ketamine 2 mg/kg administration intravenously for sedation during each radiotherapy sessions
1935926|NCT02510196|Behavioral|reminder|
1935929|NCT02509117|Drug|PF-06751979 single ascending dose|PF-06751979 administered as a single dose (solution/suspension) in cross-over fashion. Each subject may receive up to 4 study treatments (placebo and up to 3 doses of PF-06751979). The dose levels are 3 mg, 12 mg, 40 mg, 160 mg.
1935930|NCT02509117|Drug|Placebo single dose|Matched Placebo solution/suspension administered as single dose.
1935931|NCT02509117|Drug|PF-06751979 multiple ascending dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days to parallel cohorts. The dose levels are 5 mg, 15 mg, 50 mg.
1935932|NCT02509117|Drug|Placebo multiple dose|Matched Placebo (solution/suspension)administered daily for 14 consecutive days.
1935933|NCT02509117|Drug|PF-06751979 multiple dose|PF-06751979 (solution/suspension) administered daily for 14 consecutive days. The dose level is 50 mg.
1935934|NCT02509117|Drug|PF-06751979 multiple dose|Matched Placebo (suspension/solution) administered daily for 14 consecutive days to parallel cohorts.
1935937|NCT02508701|Behavioral|Message X Onsite/Offsite Vaccination|Personal, Altruistic Message vs Generic Message Inside-Dormitory Vaccination vs. Student Health Center Vaccination
1935938|NCT02508428|Device|Total Hip Replacement (Marathon)|Comparison of Marathon and Enduron polyethylene
1935939|NCT02508428|Device|Total Hip Replacement (Enduron)|
1935943|NCT02508181|Device|I-gel|supraglottic airway device without cuff
1935944|NCT02508181|Device|LMA Supreme|supraglottic airway device with cuff
1935945|NCT02508259|Drug|Suramin|20 mg/kg IV in 50 ml saline over 30 minutes
1935946|NCT02508259|Drug|Saline|50 ml IV over 30 minutes
1935947|NCT02507219|Drug|Ibuprofen|On the day of sessions 2-4, subjects will receive either placebo, 200 mg of ibuprofen or 600 mg of ibuprofen after signing the consent form for this study in a randomized, double-blind, counter balanced order. Each study session will occur 1-2 weeks following the previous session. Ibuprofen will be capsuled, and identical placebo capsules will be produced.
1935948|NCT02506920|Dietary Supplement|Six different types of fat in a meal in random order|Oral fat tolerance test
1935949|NCT02506686|Drug|Meropenem|Meropenem i.v.
1935950|NCT02506101|Device|narrow-band ultraviolet B phototherapy|There are two types of UVB: broad band and narrow band, with the major difference being that narrow band emits a smaller range of ultraviolet light, typically 311-312 nm. NB-UVB is a clinically indicated treatment for vitiligo lesions and treatments are usually administered in an outpatient setting 3 times a week.
1935957|NCT02503826|Drug|Sufentanil|low dose
1935958|NCT02503826|Drug|Sufentanil|moderate dose
1935959|NCT02503826|Drug|Sufentanil|high dose
1935960|NCT02503826|Drug|Midazolam|Midazolam 2 mg, sufentanil 0.5 mcg/kg, propofol 2 mg/kg, cisatracurium 2 mg/kg for induction, continuous infusion of propofol, remifentanil and cisatracurium to maintain bispectral index (BIS) value between 40 and 60 for maintenance.
1935961|NCT02503826|Drug|propofol|
1935962|NCT02503826|Drug|cisatracurium|
1935963|NCT02503761|Drug|Meropenem.|Infants in both groups will receive a loading dose of 20 mg/kg/dose every 8 hours for sepsis and 40 mg/kg/dose every 8 hours in meningitis and pseudomonas infection
1935964|NCT02503085|Drug|Ibuprofen Suspension|
1935965|NCT02502019|Device|HEMOBLAST Bellows|HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by conventional procedures is ineffective or impractical.
1935966|NCT02501447|Behavioral|Guided audio-visual relaxation|
1935967|NCT02500979|Drug|Pramlintide acetate|Pramlintide acetate administered by a separate pump
1935968|NCT02500979|Drug|Placebo|Placebo administered by separate pump
1935969|NCT02500979|Drug|Lispro insulin U-100|Subjects will be stabilized on a separate insulin pump and administered lispro insulin throughout the study, except during both inpatient treatment periods (Visit 4 and Visit 5)
1935970|NCT02500979|Drug|Regular insulin U-100|Use during two in-patient treatment periods (visits 4 and 5) and administered by separate pump
1935975|NCT02500160|Device|Patient specific instrumentation (MRI)|
1935976|NCT02500160|Device|Patient specific instrumentation (CT)|
1935977|NCT02499991|Behavioral|memory|keep track of social events in diary for memory recall. Used by treatment group
1935978|NCT02500628|Drug|Metformin|500 mg po after baseline testing of heart rate
1935979|NCT02497846|Device|TEOSYAL® PureSense Redensity [I]/MicronJet®|According the instruction of use, 3 injections of TEOSYAL® PureSense Redensity [I]will be performed all the 3 weeks. The used needle will be the MicronJet® microneedles for product injection. And the last visit (of control) will be performed 3 weeks after the last injection.
1935989|NCT02498457|Other|low calcium dialysis|patients in this group will receive low calcium dialysis for 1 year.
1935994|NCT02497040|Drug|Levobupivacaine|local injection
1935995|NCT02497040|Drug|Bupivacaine|local injection
1935996|NCT02497040|Drug|placebo|local injection
1935997|NCT02496702|Device|Training on Interactive Modulare Tiles|Training with the Interactive Modulare Tiles
1935998|NCT02496650|Drug|Dexmedetomidine|DEX infusion in doses 0,2-1,4 μg/kg/hr
1935999|NCT02495792|Device|Biofeedback Sensor|Tibia accelerometer strapped to distal tibia to detect tibial shock
1936003|NCT02493881|Device|intraoperative neuromonitoring|NIM-Response 3.0 Intraoperative Neuromonitoring System (Medtronic Xomed, Jacksonville, FL, USA) was used to record the EMG amplitude signal for the anterior and/or posterior branches of recurrent laryngeal nerves (RLNs).
1936006|NCT02492867|Radiation|Response-driven Adaptive Radiation Therapy|
1936007|NCT02492867|Drug|Carboplatin|
1936008|NCT02492867|Drug|Paclitaxel|40 mg/m^2 IV
1936009|NCT02492867|Device|FDG-PET|
1936010|NCT02492867|Device|V/Q SPECT|
1936011|NCT02492958|Biological|Staphylococcus aureus 4-antigen vaccine|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
1936012|NCT02492958|Biological|Placebo|a single 0.5 mL dose of investigational product into the deltoid muscle in the upper arm
1936013|NCT02491463|Biological|GSK vaccine GSK3389245A low dose|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
1936014|NCT02491463|Biological|GSK vaccine GSK3389245A high dose|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
1936015|NCT02491463|Biological|Bexsero|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
1936016|NCT02491463|Drug|Placebo|2 doses administered intramuscularly at Day 0 and Day 30 in the deltoid region of the non-dominant arm
1936017|NCT02491398|Drug|Bendamustine + Rituximab|
1936018|NCT02491073|Other|blood draw|Investigate the possibility of assay artifacts impacting the measurement of thyroid hormones, in particular FT4 and FT3, in ESL treated subjects compared to non-ESL-treated subjects.
1936019|NCT02489578|Other|other|retrospective cohort study
1936020|NCT02489708|Behavioral|Cessation Counseling|Nurses will be trained to use Electronic Medical Record system to counsel families about second hand smoke exposure. Saliva samples will be obtained from 15 children at baseline and at follow-up to explore the effects of the nurse intervention.
1936021|NCT02488135|Device|Floseal Hemostatic Matrix|Floseal Hemostatic Matrix is a gel like fibrin glue used topically in the nasal cavity and applied with a syringe.
1936022|NCT02488135|Procedure|Traditional Nasal Packing|Using either vaseline gauze or nasal merocels. These will be placed in the anterior nasal cavity using nasal speculum and forceps.
1936023|NCT02487862|Behavioral|Stress Reduction Protocol|Stress Reduction Protocol
1936024|NCT02487810|Behavioral|Cognitive load|Patients in the intuition arm of the study will be asked to complete a memorization task while they are answering survey questions.
1936025|NCT02487810|Behavioral|Deliberative instructions|Patients in the deliberative arm will be given instructions to take their time and deliberate on their decisions
1936026|NCT02486328|Drug|Midazolam|Dosage adjustment
1936027|NCT02486328|Drug|Meperidine|Dosage adjustment
1936028|NCT02486328|Drug|Remifentanil|Dosage adjustment
1936029|NCT02486328|Drug|Propofol|Dosage adjustment
1936030|NCT02487498|Drug|QVA149|QVA149 capsules for inhalation, delivered via QVA149 SDDPI
1936031|NCT02487498|Drug|Umeclidinium/vilanterol|Umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
1936032|NCT02487498|Drug|Placebo (umeclidinium/vilanterol )|Matching Placebo to umeclidinium/vilanterol for inhalation, delivered via ELLIPTA® inhaler
1936033|NCT02487498|Drug|Placebo (QVA149)|Matching Placebo to QVA149 capsules for inhalation, delivered via QVA149 SDDPI
1936040|NCT02486861|Other|optical coherence tomography|
1936041|NCT02486692|Other|AboutFace Website|AboutFace is an informational website that utilizes digital storytelling to describe PTSD symptoms and treatment for PTSD.
1936042|NCT02486510|Drug|Maraviroc|"Patients randomized to experimental control will start Maraviroc treatment before, during and after chemotherapy until lymphocytes level recovery.
Maraviroc Dose: 300 mg/12 hours For patients receiving an HIV-protease inhibitor (except tipranavir or Fosamprenavir), the dose will be reduced to 150 mg/12hours For patients receiving Efavirenz dose the dose will be 600 mg/12hours"
1936043|NCT02486406|Drug|ombitasvir|
1936044|NCT02486406|Drug|paritaprevir|
1936045|NCT02486406|Drug|ritonavir|
1936046|NCT02486406|Drug|dasabuvir|
1936047|NCT02486406|Drug|ribavirin|
1936048|NCT02484859|Drug|Remifentanil|Remifentanil infusion will be started with a bolus dose of 0.5 µg/kg before the induction, and will be continued throughout the surgery at a dose of 0.25-0.5 µg/kg/min. At the end of the surgery, the infusion will be lowered to 0.05 µg/kg/min, and continued until the patient is extubated.
1936049|NCT02484859|Drug|Tramadol|1 mg/kg tramadol will be added to 100 ml of isotonic fluid, and will be administered intravenously in exactly 30 minutes via pump. The infusion will be started just before the induction.
1936050|NCT02484859|Drug|Metoprolol|5 mg of metoprolol will be administered intravenously in 2 minutes after the administration of neuromuscular blocking agent (rocuronium).
1936053|NCT02484807|Other|no intervention, only observation of different groups|
1936063|NCT02483637|Device|RejuvenAir|Device: RejuvenAir
1936064|NCT02482870|Device|Macintosh laryngoscope|Cormack-Lehane grade was determined using Macintosh laryngoscope.
1936065|NCT02482870|Device|King Vision video laryngoscope|Cormack-Lehane grade was determined using King Vision video laryngoscope.
1936067|NCT02483156|Drug|Two tablets of EHCV in Single Dose each tablet containing SOF 200 mg, RBV 500 mg and Natural anti-hemolytic (AH) at 200 mg|The fixed dose EHCV combinations in Single Dose (2 tablets) once daily each tablet containing SOF 200 mg, RBV 500 mg, and Natural anti-hemolytic (AH) at 200 mg. Subjects will take 2 tablet with food for 12-24 weeks.
1936068|NCT02483156|Drug|Sofosbuvir tablet (SOF) 400 mg - once daily|SOF is manufactured as a 400 mg tablet for oral administration. Subjects will take 1 tablet for a total dose of 400 mg orally once daily in the morning with RBV and with food for 12-24 weeks.
1936069|NCT02483156|Drug|Ribavirin (RBV) 1000 mg - splitted on 2 doses daily - 600 mg on morning and 400 mg on evening|RBV (1000 mg.) splitted on 2 doses daily - 600 mg on morning and 400 mg on evening with SOF and with food for 12-24 weeks.
1936073|NCT02480816|Dietary Supplement|Mineral water|Intake of 1 L per day of the mineral water (BW or CW) with main meals, crossover design
1936076|NCT02481141|Drug|5-ALA-SFC|Study product will be in the form of white-opaque capsules for oral administration, containing either 50, 75, or 100 mg of active 5-ALA - SFC
1936077|NCT02481141|Drug|Placebo|
1936078|NCT02479581|Procedure|ERAS group|Intravenous infusion of flucloxacillin sodium 1g an hour before operation
1936079|NCT02479581|Procedure|ERAS group|"No routine bowel preparation;
Normal eating 1 days before the operation;
No drinking 2h and solid food 6h before the operation;
Drink 10% glucose 250ml 3h before operation ;
Gastric mucosal protective agent was given 3 days before operation(Esomeprazole Magnesium Enteric-coated tablets 40mg/d);"
1936080|NCT02479581|Procedure|ERAS group|Emphasize the preoperative psychological preparation for patients.
1936081|NCT02479581|Procedure|ERAS group|Received subcutaneous recombinant human erythropoietin (rhEPO)150（international unit/kg） once very two days from 2 days after hospital admission to 5 days postoperatively；
1936082|NCT02479581|Procedure|ERAS group|No scopolamine and morphine before surgery; No midazolam; No anti - choline drugs;
1936083|NCT02479581|Procedure|ERAS group|Solu-Medrol®:5mg/kg intravenous infusion during the surgery;
1936084|NCT02479581|Procedure|ERAS group|"Apply Transesophageal Echocardiography（TEE）after anesthesia induction;
Goal-directed fluid management."
1936085|NCT02479581|Procedure|ERAS group|"Infusion of Human Albumin Grifol®20% 50ml;
Ultrafiltration(TERUMO CARDIOVASCULAR SYSTEMS (TERUMO®));
Shorten the Cardio-pulmonary Bypass line；
Continuous near infrared spectrum monitoring of cerebral oxygen saturation(MNIR-P100（chongqingmingxi®）)"
1936086|NCT02479581|Procedure|ERAS group|Monitor urine volume closely, over 0.5ml/kg·h.
1936087|NCT02479581|Procedure|ERAS group|Protective ventilation strategy：Low tidal volume about 6~8ml/kg and positive end expiratory pressure（PEEP） combined with lung recruitment maneuver
1936088|NCT02479581|Procedure|ERAS group|"Bilateral thoracic paravertebral block before induction of anesthesia;
Fast channel anesthesia:
Induction use Sufentanil 0.5~1ug/kg, Vecuronium for Injection 0.15mg/kg and Etomidate 0.2~0.6mg/kg; ②. Maintain use Remifentanil Hydrochloride for Injection 0.1~0.4ug/kg·min, Propofol Injection 2~6mg/kg·h, Sevoflurane 0.5~1.5（minimum alveolar concentration） and Infusing Dexmedetomidine which load dose 0.5μg/kg in 10min then changed into 0.5-1.0μg/kg·h,Vecuronium 0.06~0.12mg/kg·h; ③. Intravenous hydromorphone Hydrochloride Injection 0.15mg/kg before surgery over."
1936089|NCT02479581|Procedure|ERAS group|"Drink water after 6h, 200ml once, 2~3 times / day，
early ambulation，mobilization within 48 h,
Intravenous the conventional antiemetic drugs Tropisetron hydrochloride Injection 12mg qd；
Intravenous the lansoprazole 30mg q12h."
1936090|NCT02479581|Procedure|Conventional control group|Routine preoperative psychological preparation for patients.
1936091|NCT02479581|Procedure|ERAS group|After operation use Ropivacaine 100mg infiltrating intercostal wound and self-controlled intravenous analgesia pump is applicable(Sufentanil 0.05ug/kg·h combine with Ketamine 40ug/kg·h).
1936092|NCT02479581|Procedure|Conventional control group|"Routine bowel preparation;
Liquid food eating 2 days before the operation;"
1936093|NCT02479581|Procedure|Conventional control group|Intramuscular injection of scopolamine 0.3mg combined with morphine 10mg before surgery;
1936094|NCT02479581|Procedure|Conventional control group|"Induction use Sufentanil 0.5~1ug/kg, Vecuronium 0.15mg/kg and Etomidate 0.2~0.6mg/kg,Midazolam0.05~0.1mg/kg ;
Maintain use Sufentanil 1~2ug/kg·h, Propofol 4~12mg/kg·h, Sevoflurane 1~3(minimal alveolar concentration)， Vecuronium 0.06~0.12mg/kg·h;"
1936095|NCT02479581|Procedure|Conventional control group|Use self-controlled intravenous analgesia pump containing Sufentanil 0.07ug/kg·h
1936096|NCT02479581|Procedure|Conventional control group|Intravenous infusion of dexamethasone 20mg during the surgery
1936097|NCT02479581|Procedure|Conventional control group|Intravenous infusion of flucloxacillin sodium 1g before the operation
1936099|NCT02480543|Drug|Misoprostol (cytotec)|
1936100|NCT02478086|Dietary Supplement|use amine acids parenteral 3.5g|"Group A we administered standard doses of amino acids was administered (3.5gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.
The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
1936101|NCT02478086|Dietary Supplement|use amine acids parenteral 4g|"Group B we administered high doses of amino acids was administered (4 gr) the study of renal function baseline urea, creatinine and BUN were measured within 24 h after birth in order to avoid any alteration cost by mother alter kidney function, afterwards the same markers were measured at the day 7, 14, 21 and 28. These markers were measure using orto-clinical diagnostic series 50-0278 USA.
The anthropometric measurements were assessed weekly by the same person to avoid bias (cephalic perimeter and height); weight was measured weekly using the same scale (SECA model 3741321009, Germany). All anthropometric and lab results were kept in a collection sheet."
1936110|NCT02477046|Biological|tOPV|administered per protocol
1936111|NCT02477046|Biological|bOPV|administered per protocol
1936112|NCT02477046|Biological|IPV|administered per protocol
1936113|NCT02477358|Procedure|Platelet Rich Fibrin endodontic revascularization therapy|An in vivo model utilizing mature teeth previously treatment planned for extraction, treating in accordance to the procedure documented by Johns et al. (2013), reimplanting teeth and following for three to four months before extracting and performing histological analysis.
1936114|NCT02477358|Biological|Platelet Rich Fibrin|Biological from patients own blood. No additives.
1936115|NCT02476955|Drug|ARQ 092 + carboplatin + paclitaxel|Subjects will receive ARQ 092 orally at dose levels specified for their respective dose cohorts plus carboplatin (AUC6, intravenously, Day 1) plus paclitaxel (175 mg/m2, intravenously, Day 1) on a 21-day schedule.
1936116|NCT02476955|Drug|ARQ 092 + paclitaxel|ARQ 092 will be administered orally at 200 mg BID weekly (Cohort 1P) of a 28-day cycle in combination with an IV infusion of paclitaxel (80 mg/m2). ARQ 092 will be administered once a week on Day 1, Day 8, Day 15, and Day 22 of each 28-day cycle; paclitaxel will be administered once a week on Day 1, Day 8, and Day 15 for three consecutive weeks followed by one week off of each 28-day cycle.
1936117|NCT02476955|Drug|ARQ 092 + anastrozole|ARQ 092 will be administered orally at 200 mg QD, 5 days on/9 days off (Cohort 1A) of a 28 day cycle in combination with anastrozole which will be administered orally at 1 mg QD continuously.
1936122|NCT02475317|Drug|Placebo|Subjects will receive matching placebo
1936151|NCT02471768|Procedure|CORONARY ANGIOGRAM AND CENTRAL AORTIC WAVEFORM ANALYSIS|coronary angiogram
1936153|NCT02470390|Drug|Fentanyl|Lazanda (nasal spray), Subsys (sub-lingual) and intravenous fentanyl
1936154|NCT02469714|Behavioral|Peer Navigator Intervention|Peer navigators will be Hispanics/Latinos with a mental illness in recovery who will complete and meet certification for the peer navigator training program that will be evolved out of the mixed methods process. Investigators propose the peer navigators will enhance patient engagement in integrated care which will, in turn, improve physical and mental health and wellness of patients in this group
1936155|NCT02469064|Other|Respiratory muscle training|Respiratory muscle training is done twice every day, with 3 series of 10 repetitions each, with a resting pause of two minutes between series (during resting time, patient is connected to mechanical ventilation again). We adjust initial load for respiratory muscle training as 50% of MIP. At the end of every training session, we assess dyspnea (perceived effort) using Modified Borg Scale (23). Four physical therapists are in charge of Respiratory muscle training, these therapists work at ICU and have experience with critically ill patients.
1936156|NCT02469064|Other|Cardiopulmonary Physical Therapy|Control group receives Cardiopulmonary Physical Therapy every 6 hours, physical therapy and mechanical ventilation management
1936157|NCT02467257|Dietary Supplement|Gum Arabic|oral ingestion of 30 gram every day for 12 weeks
1936158|NCT02466477|Genetic|GeneSight Psychotropic (GEN)|Patient DNA will be collected for all subjects and measured for variations in drug target genes and in drug metabolizing genes.Recommendations for optimal choices and dose adjustments for the 33 most commonly prescribed antidepressant and antipsychotic medications will be provided to subjects randomized to the GEN arm. This pharmacogenomic-based interpretive report will be provided to treating clinicians of patients in the GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
1936159|NCT02466477|Genetic|Enhanced-GeneSight Psychotropic (E-GEN)|The E-GEN test incorporates into the existing GEN product new markers that are predictive of side effect of antipsychotic-induced weight gain (AIWG). The pharmacogenomic-based interpretive report from E-GEN will be provided to treating clinicians of patients in the E-GEN arm of the study, allowing clinicians to use the report to support their treatment decisions.
1936160|NCT02466477|Other|Treatment as Usual (TAU)|Subjects randomized to the TAU arm will also require collection of patient DNA. A pharmacogenomic-based interpretive report will be generated from GEN, however, this report is not provided to the treating clinician until completion of the study.
1936161|NCT02466750|Biological|Western Equine Encephalitis (WEE) Vaccine|Western Equine Encephalitis (WEE) Vaccine, Inactivated, Dried, TSI-GSD 210, Lot 3-1-92
1936164|NCT02466087|Drug|Magnesium chloride|Four supplements a day for 6 weeks.
1936167|NCT02465567|Drug|BGF MDI 320/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
1936168|NCT02465567|Drug|GFF MDI 14.4/9.6 μg|Glycopyrronium, and Formoterol Fumarate
1936169|NCT02465567|Drug|BGF MDI 160/14.4/9.6 μg|Budensonide, Glycopyrronium, and Formoterol Fumarate
1936170|NCT02465567|Drug|BFF MDI 320/9.6 μg|Budensonide, and Formoterol Fumarate
1936171|NCT02465203|Drug|Previous treatment in DEB025 study|Follow-up after DEB025 active study
1936172|NCT02465099|Device|Ultrasonic Dissection (UD)|Ultrasonic energy will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) posterior spinal fusion (PSF)
1936173|NCT02465099|Device|Electrocautery Dissection (ED)|Electrocautery dissestion will be used as the primary means for soft tissue dissection in patients diagnosed with adolescent scoliosis undergoing multilevel (>=6) posterior spinal fusion (PSF)
1936197|NCT02464228|Drug|Tipifarnib|oral
1936204|NCT02461433|Device|Prevena|Prevena Incision Management system
1936205|NCT02461433|Device|Standard Dressing|This involves standard of care dressing including but not limited to gauze.
1936206|NCT02460991|Device|DEB-TACE|
1936207|NCT02460991|Drug|Sorafenib|
1936209|NCT02461719|Drug|CYPORIN N EYE DROPS 0.05%(TJCS eye drop)|1 drop twice/day for 12 weeks to both eyes.
1936210|NCT02461719|Drug|Restasis|1 drop twice/day for 12 weeks to both eyes. Invert the unit dose vial a few times to obtain a uniform, white, opaque emulsion before using.
1936211|NCT02462057|Other|Email message regarding the HealthyFood benefit|
1936212|NCT02459418|Drug|Afolia|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:
Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
1936213|NCT02459418|Drug|US Gonal-f®|"During the Cross-Over Pharmacokinetic Phase, subjects will be randomly assigned to receive one of the following treatment sequences:
Sequence A: Single subcutaneous injection of 225IU Afolia on study day 1, followed by a single subcutaneous injection of 225IU US Gonal-f® on study day 27.
Sequence B: Single subcutaneous injection of 225IU US Gonal-f® on study day 1, followed by a single subcutaneous injection of 225IU Afolia on study day 27"
1936214|NCT02460562|Device|S-PRG filler|"Surface pre-reacted glass-ionomer (S-PRG) filler is a new type of biological material. This new material is being used in the formulation of dental product as filling materials. It has an anti-plaque effect which will release ions to alter the pH of the surrounding environment when it comes into contact with water or acidic solutions. These ions will exert their effect on caries prevention.
The amount of S-PRG filler that is put in the standard resin denture base is 20% by weight. They are incorporated into the resin denture base and maintain the mechanical properties as required by ISO 1567."
1936215|NCT02460562|Device|PMMA resin|Polymethyl methacrylate (PMMA) resins have been used for the fabrication of resin denture base for 50 years. The advantages of PMMA resin that most notably is the ease of fabrication with very simple equipment but a limitation is the fragility because of its physical properties that include low flexural strength and surface hardness.
1936216|NCT02460432|Device|Paclitaxel-eluting metal Stent|Insertion of Niti-S Mira-Cover III Biliary Stent using ERCP
1936217|NCT02460432|Device|Covered Metal Stent|Insertion of ComVi Biliary Covered Stent using ERCP
1936218|NCT02460380|Drug|Vitamin D3|Women allocated to vitamin D arm received one capsule 50.000 IU of vitamin D3 once weekly for eight weeks.
1936219|NCT02460380|Other|Placebo|Women in the placebo arm received once capsule of placebo once weekly for eight weeks
1936220|NCT02459951|Other|clenched fist|Observation of performance on a standardized behavioral task pre- and post- administration of Botox A in the context of routine care. Clinical assessment and judgment will be used to determine dosing and which muscles contribute to the hand deformities of a given participant.
1936221|NCT02459223|Dietary Supplement|Nutritional biscuits and khichadi|Nutritional biscuits and Khichadi.
1936222|NCT02459223|Dietary Supplement|Khichadi|Khichadi.
1936223|NCT02459171|Other|Questionnaire|Once at enrollment, subjects will complete an enrollment question to capture poultry exposure and other demographic information. Information will be updated if needed at annual follow-up and at final visits.
1936224|NCT02459171|Other|Blood sample|"Participants will have a 3-mo blood sample drawn for serological testing at enrollment, and at annual follow-up and final visits.
For subjects who test positive for influenza A by rapid test or PCR (index case) on nasal swab at the biweekly or weekly visits, two 3-ml blood samples will be obtained from the index case on day 1 for serological testing for antibodies against avian influenza viruses and for isolating and studying PBMCs. Blood samples will also be obtained on day 1 from all household contacts of the index case. Additional 3-ml blood samples will be obtained on day 14 for serology and PBMCs."
1936225|NCT02459171|Other|Nasal wash|Nasal washes will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Nasal washes will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
1936226|NCT02459171|Other|Throat swab|Throat swabs will be obtained from subjects who test positive for influenza A by rapid test or PCR on nasal swab (index case). Throat swabs will also be obtained from all household contacts of the index case. The index case and household contacts will be re-sampled on days 3, 6, 9 and 14 post initial diagnosis date.
1936227|NCT02458287|Biological|Bococizumab 150mg|Bococizumab autoinjector (pre-filled pen) combination Product. 150mg every 2 weeks for 10 weeks, subcutaneous injection.
1936228|NCT02458287|Biological|Bococizumab 75mg|Bococizumab autoinjector (pre-filled pen) combination Product. 75mg every 2 weeks for 10 weeks, subcutaneous injection.
1936229|NCT02458287|Biological|Bococizumab 150mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination Product. 150mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
1936230|NCT02458287|Biological|Bococizumab 75mg placebo|Bococizumab placebo autoinjector (pre-filled pen) combination product. 75mg placebo every 2 weeks for 10 weeks, subcutaneous injection.
1936231|NCT02456961|Procedure|iontophoresis of riboflavin|
1936232|NCT02456961|Procedure|epithelium-off|
1936233|NCT02456961|Procedure|Corneal collagen crosslinking|Standard surface UVA irradiation (370 nm, 3 mW/cm2; UFalink, Russian Federation) was then applied at a 5-cm distance for 30 minutes. During UVA exposure, hypotonic riboflavin drops were continued every 2 minutes.
1936234|NCT02456961|Device|galvanizator, Potok-1|Device for providing iontophoresis procedure
1936235|NCT02456961|Drug|Dextralink|Riboflavin 0,1% + Dextran T-500
1936236|NCT02456961|Drug|Riboflavin 0,1%|
1936237|NCT02456961|Device|UFalink|device for UVA irradiation - providing UVA light - 370 nm, 3 mW/cm2
1936238|NCT02457325|Drug|Surgery with 2% articaine|During and after lower third molars surgeries, clinical efficacy of the local anesthetic articaine 2% in association with 1:200,000 adrenaline was study.
1936239|NCT02457325|Drug|Surgery with 4% articaine|During and after lower third molars surgeries, clinical efficacy of the local anesthetic articaine 4% in association with 1:200,000 adrenaline was study.
1936240|NCT02457182|Other|Mindfulness-based Stress Reduction (MBSR)|
1936241|NCT02457182|Other|Usual medical therapy|
1936242|NCT02456896|Drug|Oxcarbazepine|After baseline assessments, patients in test group will be prescribed Tab. Oxcarbazepine (600mg/daily in two divided dose for 1 week followed by 900mg/daily in two divided dose for next 3 weeks).
1936243|NCT02453555|Drug|Linagliptin|
1936244|NCT02453555|Drug|Empagliflozin placebo + linagliptin placebo|Matching placebo empagliflozin + linagliptin
1936245|NCT02453555|Drug|Empagliflozin + linagliptin low dose|tablet
1936246|NCT02453555|Drug|Linagliptin lacebo|Matching placebo linagliptin
1936247|NCT02453555|Drug|Empagliflozin + linagliptin high dose|tablet
1936248|NCT02453750|Drug|Hypersaline|Subject will inhale 5 mls of 3% hypertonic saline for 7 minutes by nebulizer. Sputum production (with cough) will be attempted post inhalation. A maximum of 3 hypertonic saline inhalations will be attempted if inhalation does not generate a productive cough. If sputum induction is not successful and the FEV1 falls <10%, the concentration of inhaled hypertonic saline will increase from 3 to 4%. If 5 mls of 4% hypertonic saline inhaled for 7 minutes does not produce a productive cough we will proceed to 5%. If 5 mls of 5% hypertonic saline inhaled for 7 minutes does not produce a productive cough the test is complete and the sample is labelled 'no sputum collected'. If FEV1 falls >10%, the previous step will be repeated.
1936249|NCT02453750|Drug|Bronchodilator Response|A bronchodilator (Salbutamol 200 mcg or 2 puffs inhaled via spacer device) will be administered to all subjects in the pulmonary function laboratory. 15 minutes after administration of the bronchodilator spirometry will be repeated. This is performed routinely in CDH clinic and is not an additional test for this study.
1936250|NCT02453685|Drug|biphasic insulin aspart 30|Injected s.c./subcutaneously once daily with the largest meal Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
1936251|NCT02453685|Drug|insulin glargine|Injected s.c./subcutaneously once daily at the same time every day, with the possibility of treatment intensification with insulin aspart (Basal-bolus arm) Subjects should continue their pre-trial metformin and sulfonylurea dosages all throughout the trial while other oral antidiabetic drugs will be discontinued.
1936252|NCT02453685|Drug|insulin aspart|Injected s.c./subcutaneously once daily.
1936253|NCT02453646|Device|NexSite HD Patients|Measurement of CRBSI rate and other device related adverse events in patients with NexSite HD Catheter.
1936257|NCT02453321|Procedure|Continuous Femoral Nerve Block|A 27g plastic catheter placed below the inguinal crease to perform a conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
1936258|NCT02453321|Procedure|Nerve Block, Continuous Adductor Canal|A 27g plastic catheter placed on the anterior medial thigh midway between the groin and knee to provide a local anesthetic conduction blockade of the sensory components of the femoral nerve in order to decrease pain in the knee after total knee arthroplasty
1936259|NCT02453321|Procedure|Continuous Sciatic Nerve Block|A transgluteal approach to the sciatic nerve is use to place a 27g catheter. It will only be dose postoperatively after verifying sciatic nerve function still intact. The infusion will be 0.003% bupivacaine at 2ml/hr. This is not the intervention of interest, but our institution's predominant practice is to include the sciatic nerve block as part of the analgesic regimen for total knee arthroplasty.
1936260|NCT02453321|Drug|Bupivacaine|The concentration of the continuous infusion of bupivacaine though the peripheral nerve catheters will be 0.0625% for the femoral and adductor canal blocks and the concentration for the sciatic continuous catheter will be 0.03%.
1936261|NCT02452905|Drug|Nitazoxanide|
1936262|NCT02452905|Drug|Placebo (for Nitazoxanide)|
1936264|NCT02451917|Drug|Glargine|Comparison of Glargine Insulin versus NPH on glucose levels.
1936265|NCT02451917|Drug|NPH insulin|Comparison of Glargine Insulin versus NPH on glucose levels.
1936266|NCT02452593|Other|"Tibial stimulation and pelvic floor exercises"|A group will make tibial nerve stimulation and the other will make pelvic floor training. After 8 weeks the patients exchanges their therapeutic approaches for over 8 weeks
1936274|NCT02449915|Drug|Bupivacaine|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the liposomal bupivacaine arm will have 30mL dilutional volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
1936275|NCT02449915|Drug|Placebo|At the completion of the procedure, and at least 20 minutes after the injection of lidocaine with epinephrine (routine for the surgical procedure), those subjects in the placebo arm will have 30mL total volume injected. Ten mL will be injected into the perineum in the posterior vaginal area and 20 mL will be injected the port site wounds in the abdomen (5 sites, 4 ml per incision).
1936281|NCT02448134|Behavioral|Youth Access|Community youth will participate in various school-and-community-wide pro-social, anti-alcohol activities.
1936283|NCT02447471|Device|Nexfin|Nexfin cuff placed on finger to measure blood pressure
1936284|NCT02447328|Drug|Fulvestrant|fulvestrant (Faslodex®) 500mg/month for about 6 months with an additional 500mg dose given 14 days after the initial dose injection.
1936294|NCT02446340|Drug|dalazatide|Different doses of drug, subcutaneous injection twice per week for a total of 9 doses.
1936295|NCT02446340|Drug|placebo|Placebo delivered via subcutaneous administration twice per week for a total of 9 doses
1936296|NCT02444936|Drug|ZOSTAVAX|Shingles vaccine
1936298|NCT02445911|Drug|KQ-791|Capsules administered orally
1936299|NCT02445911|Drug|Placebo|Capsules administered orally
1936301|NCT02444546|Other|Laboratory Biomarker Analysis|Correlative studies
1936302|NCT02444546|Biological|Sargramostim|Given SC
1936303|NCT02444546|Biological|Wild-type Reovirus|Given IV
1936304|NCT02443987|Other|Intravenous fluid|500ml infusion of 0.9% Sodium Chloride intravenously.
1936305|NCT02443740|Drug|PF-05251749|Single ascending doses of PF-05251749 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 3 mg, 30 mg, 200 mg, 800 mg and placebo
1936306|NCT02443740|Drug|PF-05251749|Single ascending doses of PF-05251749 as extemporaneously prepared solution/suspension, once every 2 week in a cross over study: 10 mg, 100 mg, 400 mg, and placebo
1936307|NCT02443740|Drug|PF-05251749|Single dose (Maximum Tolerated Dose) of PF-05251749 as extemporaneously prepared solution/suspension
1936308|NCT02442713|Drug|fluvoxamine|fluvoxamine: 50-300mg/day
1936309|NCT02443311|Drug|Pimecrolimus 1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.
1936310|NCT02443311|Drug|Betamethasone 17-valerate 0.1% cream|Patients were instructed to apply a thin layer of mixed equal amounts (½ ml) of the study medication and the adhesive gel base per application guided by the graduation on the plastic syringe on the oral lesions, 4 times daily, for a total of 1month. The patients were asked not to eat, drink, for 30 minutes after each application.Topical antifungal Miconazole 2% gel (Miconaz, oral Medical Union Pharmaceutical, Cairo, Egypt) was applied only in the fourth week of treatment period to avoid secondary candidiosis
1936311|NCT02443103|Drug|Guanabenz acetate|
1936312|NCT02440204|Procedure|Intubation|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be injected according to their group and intubation will be performed 90 seconds after.
1936313|NCT02440204|Drug|Remifentanil|After setting the end-tidal sevoflurane concentration in a predetermined concentration, remifentanil will be administered according to their group in 1 minute to prevent remifentanil induced rigidity or complications.
1936314|NCT02440204|Drug|Sevoflurane|The end-tidal sevoflurane concentration will be set as predetermined, which starts from 2.5 vol% and adjusted by the up-and-down study model which have been described by Dixon JW et al.
1936315|NCT02441647|Device|KL029 Intimate Lubricant Gel|
1936316|NCT02441608|Device|KL029 Intimate Lubricant Gel|All the volunteers will receive the application of four dressings (3 placebos and 1 containing the tested product). After a certain period of time, photoirritation and photosensitization will be measured through the evaluation of tested region.
1936317|NCT02441309|Drug|Mifamurtide|
1936318|NCT02441309|Drug|Ifosfamide|
1936319|NCT02440594|Behavioral|Enhanced BHL Program|Subjects or the caregivers will work with a BHP to provided additional support and education beyond the services received in the Standard Clinical Monitoring Module.
1936320|NCT02440243|Drug|Purethal|prerseasonal course of SCIT - three years
1936321|NCT02440243|Drug|Purethal -placebo|preseasonal course of SCIT - three years
1936323|NCT02437149|Behavioral|Video|Real stories video presentation about distracted driving. Produced by the National Highway Traffic Safety Administration.
1936324|NCT02437149|Behavioral|Power Point|Brief power point presentation with information about distracted driving. Produced by the National Highway Traffic Safety Administration.
1936325|NCT02437149|Behavioral|Brochure|Brochure with the National Highway Traffic Safety Administration information about distracting driving.
1936326|NCT02436915|Other|Real tDCS|Transcranial direct current stimulation (tDCS) enables noninvasive, selective and sustained modulation of cortical activation. tDCS works by sending low-level currents between two or more scalp electrodes, which alters brain polarity and thus, perfusion and cortical excitability.
1936327|NCT02436915|Other|Sham tDCS|For sham tDCS, current will only be applied for the first 60 seconds of each 20 minute session. This is a reliable sham control as sensations arising from tDCS diminish considerably after the first minute of stimulation.
1936328|NCT02435147|Drug|denosumab|Patients will receive denosumab 60 mg subcutaneously every six months as part of their standard osteoporosis treatment.
1936329|NCT02435875|Other|no intervention|Antihypertensive drug as intervention is used to see if it can improve baroreflex sensitivity to stable perioperative hemodynamic
1936334|NCT02434887|Device|KL029 Intimate Lubricant Gel|
1936338|NCT02434497|Drug|Rosuvastatin 20mg|Active drug 1 or 2 tablets will be taken taken orally, QD, either in the morning or in the evening
1936339|NCT02433808|Drug|Neostigmine Group|Neostigmine will be used to reverse neuromuscular block at the conclusion of the surgical procedure. The effect on muscle strength will be determined using the TOF-Watch-SX and clinical examination
1936340|NCT02433808|Other|No Neostigmine group|Saline will be administered to patients at the end of the surgical procedure when neuromuscular function has recovered
1936341|NCT02433782|Other|Myofascial therapy|Maneuver of pressure and sliding over the anterolateral compartment of the leg Maneuver of pressure and sliding on the back of the leg Liberation technique of the popliteal fascia Maneuver of pressure and sliding on the anterior thigh Maneuver of pressure and sliding on the iliotibial tract Maneuver of pressure and sliding on the hamstring muscle region. Induction maneuver of ankle anterior compartment Induction maneuver of knee anterior chamber
1936342|NCT02433288|Other|Smart phone based patient support tool|The smart phone application used on the patients' smart phones will contain both the patient support tool and the questions for the clinical evaluation in the form of the Rosuvastatin Adherence questionnaire (RAQ), Beliefs about Medicine Questionnaire - General (BMQ-G), (Horne, 1999) and a Lifestyle questionnaire (LSQ) on disease understanding, lifestyle and treatment awareness. Patients in the Active group will also receive feedback on their daily rosuvastatin treatment as entered in the patient support tool.
1936343|NCT02433288|Other|Control application: only for data collection|the patients will have no access to the smart phone-based patient support tool. However, a smart phone application will be used to prompt patients with the questions for the clinical evaluation (RAQ, BMQ-G and LSQ).
1936344|NCT02432300|Behavioral|Emotion Builder|Total of 8 therapy sessions with the Emotion Builder over approximately four (4) weeks (2 sessions a week)
1936352|NCT02430311|Drug|Olaparib|Tablet-150mg, Oral
1936353|NCT02430311|Drug|Paclitaxel|Injection
1936354|NCT02430311|Drug|Olaparib|Tablet-100mg, Oral
1936359|NCT02428699|Other|Emulsified cod liver oil product|Participants are required to consume the dose (30 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
1936360|NCT02428699|Other|Non-emulsified cod liver oil product|Participants are required to consume the dose (5.8 mL) within 1 min, followed by up to 300 mL of apple juice which needs to be consumed within 2 min
1936361|NCT02427607|Drug|Perampanel|Perampanel 2 mg tablets. Doses of perampanel can be adjusted based on clinical judgment. A minimum perampanel dose of 2 mg per day is required to continue in the study. The maximum daily dose of perampanel permitted will be 12 mg per day.
1936362|NCT02427100|Behavioral|Diet/Physical Activity|Diet/Physical Activity Intervention
1936363|NCT02426801|Device|Inhaler sensor|Inhaler sensor strap that tracks inhaler use via a pressure sensitive switch.
1936364|NCT02426801|Behavioral|Mobile application for asthma adherence|Mobile phone application that sends reminders, allows patients to see their medication use, and provides points and other incentives for medication use.
1936365|NCT02426541|Drug|Dapagliflozin|Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
1936366|NCT02426541|Drug|Placebo|Matching placebo to Dapagliflozin 10 mg Tablets, Oral, Once Daily, 8 weeks
1936367|NCT02426125|Drug|Ramucirumab|Administered IV
1936368|NCT02426125|Drug|Docetaxel|Administered IV
1936369|NCT02426125|Drug|Placebo|Administered IV
1936370|NCT02424318|Drug|Topiramate|topiramate 25mg twice 1 week -> topiramate 50mg twice 7 weeks
1936617|NCT02371616|Other|Sodium monofluorophosphate|1426 ppm fluoride as sodium monofluorophosphate
1936373|NCT02424968|Biological|Anti-Thymocyte Globulin|Given per standard institutional practice
1936374|NCT02424968|Drug|Cyclosporine|Given PO
1936375|NCT02424968|Other|Laboratory Biomarker Analysis|Correlative studies
1936376|NCT02424968|Drug|Mycophenolate Mofetil|Given PO
1936377|NCT02424968|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo nonmyeloablative allogeneic HSCT
1936378|NCT02424968|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo PBSC transplant
1936379|NCT02424968|Biological|Therapeutic Allogeneic Lymphocytes|Receive CD8+ memory T-cells via IV
1936380|NCT02424968|Radiation|Total Nodal Irradiation|Undergo TLI
1936384|NCT02424708|Drug|Reduced Glutathione 100mg|100mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
1936385|NCT02424708|Drug|Reduced Glutathione 200mg|200mg GSH delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
1936386|NCT02424708|Drug|Placebo|Saline delivered intranasally, three times a day for 12 weeks, in 1 cc sterile saline using a syringe with a Mucosal Atomization Device (MAD) tip.
1936387|NCT02424630|Device|Ultrasound-guided ISB|ISB was performed by one anesthesiologist under ultrasound-guidance. The superior, middle, and inferior trunks of the brachial plexus were identified approximately 2 cm above the clavicle. A 50 mm 22-gauge needle was introduced percutaneously using an out-of-plane technique. The needle was placed beside each trunk in succession, and 2.5 mL ropivacaine was injected into each site. The total volume of ropivacaine used for ISB was 7.5 mL.
1936388|NCT02424630|Device|Arthroscopy-guided SSNB|At the end of the surgery, SSNB was performed under arthroscopic guidance by one shoulder arthroscopist. The suprascapular ligament was found using the lateral portal for visualization. The supraclavicular ligament was visualized at the end of the conoid ligament when the arthroscope was advanced following the coracoclavicular ligament. A 23-gauge spinal needle was introduced in a posteroanterior direction at a 20° angle percutaneously and 7 cm medial to the lateral margin of the acromion. Then, the needle was placed at the upper margin of the suprascapular ligament and advanced slightly under arthroscopy-guidance. After suctioning the saline from the portal, the injection material was administered according to the random assignment.
1936389|NCT02424630|Drug|Placebo|
1936390|NCT02424630|Drug|Ropivacaine|All the regional blocks in this study were performed using ropivacaine, except for arthroscopy-guided SSNB using placebo (10 mL normal saline)
1936392|NCT02424344|Drug|Aclidinium/Formoterol|Aclidinium bromide/Formoterol fumarate FDC 400/12μg dry powder for oral inhalation twice daily via Genuair inhaler
1936393|NCT02424344|Drug|Placebo|Dose-matched placebo dry powder for oral inhalation twice daily via Genuair inhaler
1936394|NCT02423135|Biological|Autologous blood transfusion|Volunteers make a blood donation and after 36 days of storage this blood is re-infused in the same volunteers.
1936395|NCT02423824|Biological|Liraglutide|Study participants will received the following study intervention in addition to 'standard of care' treatment: Adjunctive liraglutide will be initiated at 0.6 mg for the first 1 week, then increased to 1.2 mg with the option of increasing to 1.8 mg thereafter based on efficacy/tolerability (n=15 in each group). Liraglutide will be adjunctively administered to a conventional antidepressant, antipsychotic and mood stabilizing agent at guideline-concordant therapeutic plasma levels. Subjects will be randomized to receive liraglutide for a 4 week period. No major change in the pharmacological regimen will be permitted during the 4 week trial unless required for medical reasons.
1936396|NCT02423720|Behavioral|Audio-Based Mindfulness|Audio-based mindfulness tracks (MP3 format).
1936397|NCT02423694|Device|electro-acupuncture|"8 acupoint: Guanyuan, Zigong (bilateral), Tianshu(bilateral), Sanyinjiao(bilateral), Hegu(bilateral), Taichong(bilateral), Baihui, Yintang.
Every patient is supposed to have 36 times acupuncture treatment. 30 minutes per time. Baihui, Yintang, Zigong (bilateral), Tianshu (bilateral) are applied with electro-acupuncture device with dilatational wave, current frequency: 10/50Hz, intensity: 0.5~1.0 mA"
1936398|NCT02423694|Drug|escitalopram oxalate tablets|escitalopram oxalate tablet, once a day, 0.5 hour after breakfast, oral taken, 10mg, for 12 weeks
1936399|NCT02422823|Drug|Articaine|Injection of 1.8mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
1936400|NCT02422823|Drug|Articaine|Injection of 3.6mL of 4% articaine with 1: 100,000 epinephrine in block the inferior alveolar nerve in patients with irreversible pulpitis of mandibular molar in 40 patients
1936401|NCT02422823|Drug|Epinephrine|
1936499|NCT02409927|Dietary Supplement|MCT homogenate|10% MCT homogenate mixed with skim milk in a standardized breakfast
1936500|NCT02409927|Dietary Supplement|Placebo|skim milk with a standardized breakfast
1936407|NCT02421289|Drug|Efavirenz|There will be adjusted dose of efavirenz in CYP2B6 guide group
1936408|NCT02421289|Drug|Efavirenz|If the patients was diagnosed as hypersensitivity to EFV, they will receive boosted-PI instead.
1936409|NCT02421289|Other|CYP450 2B6|All patients will be monitored drug level which should be in therapeutic level.
1936410|NCT02421198|Behavioral|YMCA Family Diabetes Prevention Program (YFDPP)|12 week, group education to promote behavioral change delivered either face-to-face or via a combination of face-to-face and mobile technologies
1936420|NCT02419742|Drug|Carboplatin|TCH regimen: Carboplatin dose = Target Area Under Curve (AUC) (6 milligrams*milliliter/minute [mg*mL/min]) multiplied by (Glomerular Filtration Rate [GFR] + 25). Carboplatin will be administered as IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
1936421|NCT02419742|Drug|Cyclophosphamide|AC-TH regimen: Cyclophosphamide 600 mg/m^2 IV bolus every 3 weeks for 4 cycles (Cycles 1 to 4).
1936422|NCT02419742|Drug|Docetaxel|AC-TH regimen: Docetaxel 100 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8). TCH regimen: Docetaxel 75 mg/m^2 IV bolus every 3 weeks for 6 cycles (Cycles 1 to 6).
1936423|NCT02419742|Drug|Doxorubicin|Participants will receive Doxorubicin 60 mg/m^2 administered as I.V. bolus injection over 5 to 15 minute every 3 weeks for 4 cycles for AC-TH regimen.
1936424|NCT02419742|Drug|Paclitaxel|AC-TH regimen: Paclitaxel 175 mg/m^2 IV infusion every 3 weeks for 4 cycles (Cycles 5 to 8).
1936425|NCT02419742|Drug|Trastuzumab|AC-TH regimen: For weekly administration, 4 milligrams per kilograms (mg/kg) loading dose on Day 1 of Cycle 5, followed by 2 mg/kg on Day 8 of Cycle 5 and 2 mg/kg every week for 4 cycles (up to Cycle 8). For 3 weekly administration, 8 mg/kg loading dose on Day 1 of Cycle 5, followed by 6 mg/kg every 3 for 4 cycles (up to Cycle 8). From Day 1 of Cycle 9, 6 mg/kg will be administered every 3 weeks up to Cycle 22. TCH regimen: For weekly administration, 4 mg/kg loading dose followed by 2 mg/kg weekly from Cycles 1 to Cycle 6. For 3 weekly administration, 8 mg/kg loading dose followed 6 mg/kg every 3 weeks from Cycles 1 to 6. From Cycle 7, 6 mg/kg every 3 weeks up to Cycle 18. All administrations will be intravenous (IV) infusion.
1936426|NCT02419300|Device|ultrasoungraphy|pelvic ultrasonography and Doppler
1936427|NCT02417701|Other|Laboratory Biomarker Analysis|Correlative studies
1936428|NCT02417701|Other|Pharmacological Study|Correlative studies
1936429|NCT02417701|Drug|Sapanisertib|Given PO
1936430|NCT02418819|Drug|PF-06412562 3mg BID|PF-06412562
1936431|NCT02418819|Drug|PF-06412562 9mg BID|PF-06412562
1936432|NCT02418819|Drug|PF-06412562 45mg BID|PF-06412562
1936433|NCT02418819|Other|Placebo|Placebo
1936434|NCT02418182|Drug|Acetaminophen|Acetaminophen total dose of 1000mg
1936435|NCT02418182|Drug|placebo|subjects randomized to this group will be given placebo tablets
1936436|NCT02416310|Device|TEAS|According to ancient Chinese medical books, acupoints SP6 and ST36 are chosen and identified.The patients in TEAS group received electrical stimulation with the 'disperse-dense' waves. Non-acupoint is located 2cm interior to the ST36 and SP6.For group TEAS and Sham, TEAS will be administered 30 minutes prior to surgery and continued until the end of the surgery.Control patients will receive the same treatment without electrical stimulation.
1936442|NCT02417233|Behavioral|SMS text message|bi-weekly behavioral messages and bi-weekly check-in messages
1936443|NCT02417233|Behavioral|SMS text message + Peer Navigation|bi-weekly behavioral messages plus personalized peer navigation
1936444|NCT02416726|Device|Nextseq500 sequencer|The sequencer will be used to detect the gene mutations of the primary tumor, metastatic LN and peripheral blood samples obtained from patients.
1936501|NCT02409914|Other|PET and MRI exams|FDG PET scan and T1-weight MRI were obtained within an average time frame of 3 weeks.
1936454|NCT02415179|Drug|Inhaled Mometasone/formoterol|Inhaled Mometasone/formoterol (100/5 microgram) 2 puffs twice daily via metered dose inhaler for 6 weeks
1936455|NCT02415179|Drug|Inhaled Fluticasone/Salmeterol|Inhaled Fluticasone/Salmeterol (125/25 microgram) 2 puffs twice daily delivered by using metered dose inhaler for 6 weeks
1936456|NCT02415166|Biological|INFLUENZA VACCINE|THE PURPOSE OF THE STUDY IS TO EVALUATE THE EFFICACY OF THE SEASONAL INFLUENZA VACCINE IN PEOPLE WITH MAJOR DEPRESSIVE DISORDER
1936457|NCT02415166|Other|NaCl-saline placebo|placebo
1936458|NCT02413684|Behavioral|Patient engagement toolkit|"Pack Health LLC and Duke will develop a patient engagement toolkit known as Packs to help empower and engage patients. These disease-specific, evidence-based kits are scientifically designed to improve patient involvement in their own care"
1936459|NCT02413918|Drug|iloperidone|Qualifying subjects will take iloperidone starting at 2mg and up to a minimum of 12mg, maximum of 24mg, for 20 weeks in conjunction to the subjects current lithium, and or divalproex, and or lamotrigine.
1936460|NCT02413554|Drug|Rivastigmine patch|acetylcholine esterase inhibitor
1936461|NCT02412852|Drug|Sodium nitrite|Sustained release formulation of sodium nitrite
1936462|NCT02412852|Drug|Placebo|Placebo tablets
1936463|NCT02413151|Behavioral|Exercise training program|The exercise sessions will be hospital-based, 3 times a week for 60 minutes each, on non-consecutive days for 6 months. Selected the aerobic interval training (AIT) method for the development of cardiopulmonary system and the inclusion of resistance and sensorimotores exercises. The AIT comprises 4 interval training periods (high intensity) and 3 active pauses (moderate intensity) between interval training periods. The patient will warmup for 10 minutes at 50% to 60% of HRpeak from CPET, before walking to four 4 minutes intervals at 90 to 95% of peak HR. Each interval, including the last one, is separate by 3 minutes active pauses, walking at 60% to 70% of HRpeak. Total aerobic exercise time at this moment will be 28 minutes and will be maintain to the end of ExT intervention period.
1936464|NCT02413151|Device|Cardiac resynchronization therapy (CRT)|Implantation will be performed according to standard techniques of biventricular pacing. The CRT includes a generator and three leads, used to correct ventricular dyssynchrony.
1936465|NCT02412644|Drug|apremilast|
1936466|NCT02412618|Drug|Mifepristone|Progesterone antagonist
1936467|NCT02412618|Drug|Misoprostol|Prostaglandin E1
1936468|NCT02412618|Dietary Supplement|Placebo|Tasteless, odorless, sugar based pill
1936469|NCT02412488|Other|Insertion of the Reveal LINQ device in the out of cathlab setting|"Insertion of the Reveal LINQ device in the out-of-cathlab setting (out of the operating room, cardiac catheterization or electrophysiology laboratory)."
1936470|NCT02412189|Procedure|Maintained blood pressure|Norepinephrine therapy to maintain preanesthesia blood pressure
1936471|NCT02412189|Drug|Norepinephrine|Norepinephrine therapy to maintain preanesthesia blood pressure
1936477|NCT02409784|Dietary Supplement|Ketogenic diet|4 days 4:1 (lipids:protein/carbohydrates) ketogenic diet
1936478|NCT02410460|Drug|clonidine|
1936479|NCT02410460|Drug|glycopyrrolate|
1936480|NCT02410460|Drug|propofol|
1936481|NCT02410460|Drug|ketamine|
1936482|NCT02410460|Drug|marcaine|
1936483|NCT02410460|Drug|scopolamine|
1936484|NCT02410460|Drug|midazolam|
1936485|NCT02410460|Device|ondansetron|
1936486|NCT02410460|Drug|metoclopramide|
1936487|NCT02410460|Drug|glycopyrrolate|
1936488|NCT02410460|Drug|lidocaine|
1936489|NCT02410460|Drug|famotidine|
1936490|NCT02410460|Drug|desflurane|
1936491|NCT02410460|Drug|sevoflurane|
1936492|NCT02410304|Device|Xrays|Clinical evaluation
1936493|NCT02410304|Device|Ultrasound (B mode )|
1936494|NCT02410304|Device|Ultrasound (D mode)|
1936496|NCT02410161|Dietary Supplement|alpha-linolenic acid-rich supplement|each participant consumed one 1000 mg capsule of flaxseed oil four times per day for 4 weeks, providing a total of 2 g/d of ALA. The capsules used were a commercially available flaxseed oil supplement containing ALA at 56% of total fatty acids (Jamieson, Toronto, ON, Canada). The other main fatty acids present in flaxseed oil include linoleic acid (18%), oleic acid (16%), palmitic and stearic acid (10% combined).
1936497|NCT02410018|Device|OCL 503 (uterine artery embolization)|Transcatheter embolization of the uterine artery(ies) using an embolic agent.
1936498|NCT02409927|Dietary Supplement|MCT oil|100% pure MCT oil mixed with skim milk in a standardized breakfast
1936502|NCT02409277|Other|Experimental: Standard vs Intensive e-AT Intervention|Patients will be self-monitoring their symptoms weekly using the e-AT, either the Standard or Intensive versions of the e-AT, completing the Asthma Control Test. As patients complete their assessments each week, the clinics will be able to see how each patient is doing, and follow-up when a patient is showing high symptoms for that week, potentially avoiding Emergency Room visit, and/or hospitalization.
1936505|NCT02408367|Behavioral|Exercise|30 minutes endurance training at 75% of the Maximum heart rate
1936506|NCT02408367|Behavioral|Relaxation|30
1936507|NCT02408263|Procedure|Total Hip Replacement|Total Hip Replacement is a surgical procedure whereby the diseased cartilage and bone of the hip joint is surgically replaced with artificial materials.
1936508|NCT02408263|Procedure|Total Knee Replacement|Total Knee Replacement is a procedure which involves replacement of all three compartments of the knee (the medial compartment (inside aspect of the knee), the lateral compartment (outside of the knee) and the patellofemoral compartment (in front of the knee)).
1936509|NCT02408068|Drug|Dexamethasone|Dexamethasone used to suppress endogenous cortisol secretion
1936510|NCT02408068|Drug|Chronocort: fasted|single dose of 20mg modified release hydrocortisone in the absence of food
1936511|NCT02408068|Drug|Immediate release hydrocortisone: fasted|single dose of 20mg immediate release hydrocortisone in the absence of food
1936512|NCT02408068|Drug|Chronocort: fed|single dose of 20mg modified release hydrocortisone in the presence of food
1936515|NCT02406612|Device|X-Seal 6F Vascular Closure Device|
1936516|NCT02406443|Drug|Sitaglitpin|Oral DPP-4 inhibitor, 100 mg tablet administered once daily for 28 days
1936517|NCT02406443|Other|Placebo|Oral tablet (no medicinal ingredients) administered once daily for 28 days
1936521|NCT02405325|Behavioral|Physical Activity|intervention activities will remain at the daily level, including using pedometers, having daily goals, attendance at Peer lead group walks and recognition of efforts through monthly celebrations and bi-weekly goal tracking with peer Health Coaches.
1936522|NCT02403479|Drug|Topical silver colloid|Patients will be provided with a standardized silver colloid spray and asked to place two sprays into each nostril daily for a total of three consecutive months. The commercially available silver colloid product, Sovereign Silver Mineral Supplement, will be used.
1936523|NCT02403479|Other|Topical Saline|
1936524|NCT02404389|Drug|Investigational Treatment|Topical application for two treatment cycles with twice daily applications, separated by a 4 week treatment pause and followed by 8 week treatment free follow-up.
1936525|NCT02404389|Drug|Active comparator|Topical treatment with Aldara 3 times per week. The group will be open-label, but however blinded to the efficacy assessor, and followed by 8 week treatment free follow-up.
1936530|NCT02403999|Other|Test shampoo|Oilatum Soothe &amp; Protect Shampoo
1936531|NCT02403999|Other|Test bath foam|Oilatum Soothe & Protect Bath Foam
1936532|NCT02403999|Other|Test head to toe wash|Oilatum Soothe & Protect Head to Toe Wash
1936533|NCT02403843|Device|RNS System|The RNS System provides closed loop responsive brain stimulation. In response to detection of previously identified electrocorticographic activity, the neurostimulator delivers stimulation to the seizure foci by way of the leads to interrupt the activity before the patient experiences clinical seizures. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
1936536|NCT02402166|Drug|SPD489|All subjects will begin with 5mg of SPD489 daily and will be titrated until optimal dose is reached (5, 10, 15, 20, and 30mg)
1936539|NCT02398825|Drug|Ponatinib|Ponatinib is given orally 30 mg daily, with dose adjustment to 15 mg daily once a BCR-ABL1 level minor or equal to 0.1% (MMR) has been achieved and confirmed in the next test, 4 weeks apart. A return to prior, 30 mg, dose is due in case of return of BCR-ABL1 transcripts level to > 1%. Dose adjustments for toxicity are detailed in the protocol.
1936541|NCT02398448|Drug|Allopurinol 300 mg; undergranulated, high hardness condition|There will be a period for interim analysis after administration of Regimen B to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
1936542|NCT02398448|Drug|Allopurinol 300 mg; alternative condition 2|There will be a period for interim analysis after administration of Regimen C to determine the formulation within the process design space that provides the desired in vitro dissolution variant for dosing in the subsequent study period
1936543|NCT02398448|Drug|Allopurinol 300 mg; alternative condition 3|
1936544|NCT02397122|Biological|platelet-rich fibrin|autologous platelet-rich fibrin was isolated from venous blood of each patient by defined centrifugation methods
1936545|NCT02397122|Procedure|connective tissue graft|connective tissue graft was harvested from the palatal region of each patient by single incision method
1936546|NCT02397122|Procedure|coronally advanced flap|buccal gingival flap was raised by sharp-blunt-sharp dissection and positioned coronally to cover connective tissue graft (and platelet-rich fibrin gel)
1936547|NCT02396576|Behavioral|Telehealth Intervention|The telehealth model will integrate developmental, behavioral, (DB) and mental health services (MH) into pediatric primary care using videoconferencing that will be tested with children in low-income, urban communities.
1936548|NCT02394600|Drug|Grastek®|one tablet daily for four months
1936549|NCT02394600|Drug|Placebo|one tablet daily for four months
1936550|NCT02395185|Other|Bottle Administration|Patients are given a bottle during the casting process. Contents of bottle depend on the arm to which they are randomized.
1936551|NCT02394821|Drug|Polihexanide 2%|
1936552|NCT02394821|Drug|Metronidazole 0.8%|
1936553|NCT02393040|Other|PRP/Saline|"PRP/Saline: Two groups were defined: group A and group B. Group A received treatment with PRP on the right half-head and placebo on the left half-head while group B received administration of PRP on left half-head and placebo on the right half-head.
Same patient will be injected with PRP and a saline solution. Each patient will be injected on half-head."
1936556|NCT02392403|Device|Nucleus CI532 cochlear implant|
1936557|NCT02390960|Drug|Sildenafil Cream|Patients will be instructed to apply pre-weighed SST-6006 to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
1936558|NCT02390960|Drug|Placebo Cream|Patients will be instructed to apply the pre-weighed placebo cream to the non-erect penile skin area at the time of dosing. Patients will then massage the cream into the penile shaft and glans for a maximum of 3 minutes.
1936559|NCT02390960|Device|Penile Plethysmography (RigiScan)|During each dosing period, penile plethysmography will be utilized to evaluate efficacy of SST-6006 verses placebo cream. Each plethysmography session will be approximately 75 minutes.This includes a 15 minute 'baseline' period where patients are told to remain in the flaccid state and 60 minutes during which time patients will watch a series of erotic videos.
1936562|NCT02390557|Other|YES Health|Intervention Arm
1936563|NCT02388269|Device|gammaCore®-G|The gammaCore®-G device is a reusable, hand-held, portable device consisting of two 3.0 VDC batteries (not replaceable or user serviceable), signal generating and amplifying electronics, and two buttons for operator control of the signal amplitude. The device provides visible (light display) and audible feedback on device and stimulation status
1936564|NCT02387593|Device|ENDOCUFF|One endocuff device is placed at the tip of colonoscope prior to colonoscopy baseline
1936565|NCT02387476|Device|FRESCA Nasal Mask|FRESCA nasal mask
1936566|NCT02387476|Device|CPAP Nasal Mask|CPAP nasal pillow and nasal mask
1936567|NCT02387190|Other|Telenursing monitoring|"The telenursing program protocol is based on:
Contact the patient by telephone, weekly;
Distribution and explanation of the educational booklet;
Filling a diary of symptoms and signs; 4) Record, management and markdown visits in case of non-elective visits, hospitalization or fatal episodes. Also, the following aspects shall be observed: help requests associated with illness, adaptations for living with the disease, effects of drugs in daily life, availability of financial resources for disease management, self-image; emotional and social support."
1936568|NCT02385227|Other|Exclusive blu™ e-cigarette A1|Classic Tobacco rechargeable e cigarette
1936569|NCT02385227|Other|Exclusive blu™ e-cigarette A2|Magnificent Menthol rechargeable e cigarette
1936570|NCT02385227|Other|Exclusive blu™ e-cigarette A3|Cherry Crush rechargeable e cigarette
1936571|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B1|Classic Tobacco rechargeable e cigarette and a usual brand combustible cigarette
1936572|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B2|Magnificent Menthol rechargeable e cigarette and a usual brand combustible cigarette
1936573|NCT02385227|Other|Dual blu™ e-cigarette and usual brand B3|Cherry Crush rechargeable e cigarette and a usual brand combustible cigarette
1936574|NCT02385227|Other|Nicotine product cessation C|Nicotine cessation
1936575|NCT02385526|Device|Vagus Nerve Stimulation Therapy|Stimulation of the left tenth cranial nerve via VNS Therapy
1936576|NCT02383927|Drug|Tipifarnib|FTase inhibitor
1936577|NCT02383017|Dietary Supplement|Shroom Tech Sport|STS will be given every day in accordance to company guidelines for 12 weeks.
1936578|NCT02383017|Dietary Supplement|Placebo|Placebo will be given in the same fashion as the STS pills guidelines for 12 weeks.
1936579|NCT02382744|Device|Ultrasound Guidance|Ultrasound guidance will be used to place a saphenous nerve block
1936580|NCT02382744|Device|Ultrasound guidance and nerve stimulation|Ultrasound guidance and nerve stimulation will be used to place a saphenous nerve block
1936618|NCT02371395|Other|Realtime amplification (RealAmp)|Molecular assay for the diagnosis of malaria.
1936585|NCT02381015|Genetic|Genetic Risk Score: Number Format|Genetic Risk Score: Number + Pictograph Genetic risk score based on validated panel of 46 single nucleotide polymorphisms previously identified to be associated with Prostate Cancer risk by Genome Wide Association Studies, presented to subjects as a number.
1936586|NCT02381015|Genetic|Genetic Risk Score: Number + Pictograph|Genetic Risk Score: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
1936587|NCT02381015|Behavioral|Family History: Number Format|Family History: Number Format Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
1936588|NCT02381015|Behavioral|Family History: Number + Pictograph|Family History: Number + Pictograph Risk information conveyed as either a number or a number + pictograph, depending on randomization group.
1936589|NCT02379585|Drug|Doxorubicin|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
1936590|NCT02379585|Drug|cyclophosphamide|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
1936591|NCT02379585|Drug|paclitaxel|For patients with HER2 negative breast cancer: doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 2 weeks for four cycles followed by paclitaxel (T) 75 mg/m2 every 2 weeks for four cycles (dose-dense AC + T).20
1936592|NCT02379585|Drug|docetaxel|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
1936593|NCT02379585|Drug|Trastuzumab|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
1936594|NCT02379585|Drug|Pertuzumab|For patients with HER2 positive breast cancer: docetaxel (T) 75 mg/m2 every 3 weeks for four cycles. Trastuzumab (H, 8mg/kg for 1st cycle, then 6 mg/kg in subsequent 3 cycles), Pertuzumab (P, 840 mg for 1st cycle, then 420 mg in subsequent 3 cycles) will be given concurrently with docetaxel for a total of 4 cycles before surgery. For patients who do not achieve pCR, adjuvant chemotherapy with doxorubicin (A) 60 mg/m2 plus cyclophosphamide (C) 600 mg/m2 every 3 weeks for four cycles will be given, followed by trastuzumab 6 mg/kg every 3 weeks to complete 1 year of treatment. For patients with pCR, only trastuzumab 6 mg/kg every 3 weeks will be given adjuvantly to complete 1 year of treatment (TPH + AC).21
1936595|NCT02379221|Drug|lidocaine-epinephrine|2% lidocaine 1:100k epinephrine nerve block injection
1936596|NCT02379221|Drug|Topicaine gel|4% Topicaine gel
1936597|NCT02378935|Drug|GS-9857|GS-9857 100 mg tablet administered orally once daily with food
1936598|NCT02378935|Drug|SOF/VEL|SOF/VEL (400/100 mg) FDC tablet administered orally once daily with food
1936599|NCT02378935|Drug|RBV|RBV tablets administered orally in a divided daily dose according to weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1936601|NCT02378662|Biological|MDGN201 TARGTEPO|MDGN201 TARGTEPO secreting EPO
1936602|NCT02378220|Genetic|Pharmacogenetic testing|Pharmacogenetic testing via YouScript® Personalized Prescribing System
1936604|NCT02377063|Dietary Supplement|Pressed Juice|Subjects will be taking vegetable/fruit juice supplementation for 3 days. Blood, urine and stool samples will be collected at baseline, day 4 and day 17.
1936605|NCT02375932|Behavioral|Pre-Visit Tool|Patients receive a secure electronic message from their primary providers asking them to prepare for their visit by reviewing important areas of care and identifying their top priorities for discussion at a scheduled visit
1936606|NCT02375932|Behavioral|Usual Care Control|Patients continue to receive usual care from their primary care provider
1936607|NCT02373865|Drug|Sitagliptin|Sitagliptin will be given in a daily dosage of 100 mg
1936608|NCT02373865|Drug|Glimepiride|Glimepiride will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
1936609|NCT02373865|Drug|Sitagliptin-Placebo|Sitagliptin-Placebo will be given additional to Glimepiride (blinded). It will be given in a daily dosage of 100 mg
1936610|NCT02373865|Drug|Glimepiride-Placebo|Glimepiride-Placebo will be given additional to Sitagliptin (blinded). It will be given in a starting daily dosage of 1 mg which will be adapted up to 6 mg
1936611|NCT02373228|Other|Audio signal processing (applied offline before playback)|
1936612|NCT02372175|Biological|Dengue-1 Virus-Live Virus Human Challenge (DENV-1-LVHC)|Dengue subtype 1 Challenge Virus (DENV-1) strain 45AZ5 administered as a single injection.
1936613|NCT02370420|Biological|Platelet-Rich Plasma|Autologous Platelet-Rich Plasma will be applied by a intra-articular injections
1936614|NCT02370420|Behavioral|rehabilitation exercises|Patients would been shown rehabilitation exercises, to perform them at home
1936615|NCT02371616|Device|Calcium sodium phosphosilicate|5% w/w calcium sodium phosphosilicate
1936616|NCT02371616|Other|Sodium fluoride|1426 ppm fluoride as sodium fluoride
1936619|NCT02371343|Dietary Supplement|Fish oil, Ocean plus|Ocean Plus, 1200 mg, EPA 384 mg DHA 252 mg, total omega-3 782 mg, 50 soft gel, Ocean®, Germany
1936620|NCT02371343|Dietary Supplement|Sunflower Oil|
1936621|NCT02371200|Device|Brain Sentinel Seizure Detection and Warning System|The detection device is worn on the bicep brachii muscles and is intended to alert a remote caregiver of a GTC seizure and provide a record of GTC seizure activity.
1936622|NCT02371187|Drug|Dapagliflozin|Dapagliflozin tablets, 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
1936623|NCT02371187|Drug|Placebo|Matching placebo for Dapagliflozin 5 mg, one per day for the first 14 days, increase to two per day for 70 days.
1936624|NCT02370043|Drug|KQ-791|Capsules administered orally while fasting, in up to 3 periods
1936625|NCT02370043|Drug|KQ-791 (after meal)|Single dose of KQ-791 in capsules, after a meal, in 1 period
1936626|NCT02370043|Drug|Placebo|Capsules, administered orally, in 1 period
1936627|NCT02370368|Device|XBOX Kinect Just Dance 2014|The XBOX Kinect Just dance 2014 is videogame based interactive dance programme designed to encourage activity while gaming.
1936628|NCT02370004|Procedure|Resistive Flexibility and Strength Training|"RFST is a physical therapy technique where a certified practitioner extends or flexes a joint with the subject actively resists the motion applied by the practitioner.
During the RFST treatment a subject will lie on a massage table while the practitioner holds the subject's arm or leg and flexes or extends the limb, instructing the patient to resist the flexion or extension produced by the practitioner. The process is repeated a number of times for each muscle while varying joint positions."
1936629|NCT02369926|Procedure|Multiple Sclerosis Functional Composite|The MSFC is a diagnostic test that measures multiple sclerosis symptoms. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. The MSFC is administered in-person at the study site.
1936630|NCT02369926|Procedure|Mobile Multiple Sclerosis Functional Composite|The mMSFC is a diagnostic test that measures multiple sclerosis symptoms from. It includes a timed walk test, 9-hole peg test, and paced auditory serial addition test. All aspects of this exam are completed from a participant's home using remote sensing technology and video conferencing.
1936631|NCT02369848|Device|Shockwave Lithoplasty System|
1936638|NCT02368535|Other|Survey|25-item questionnaire on pereception of interdisciplinary rounds
1936639|NCT02367781|Drug|Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody|"Atezolizumab will be administered as IV infusion at a dose of 1200 milligrams (mg) on Day 1 of each 21-day cycle. Atezolizumab will be administered to participants who are randomized to Arm A (Atezolizumab + Nab-Paclitaxel + Carboplatin) and to participants in Arm B (Nab-Paclitaxel + Carboplatin) who cross over at progression."
1936640|NCT02367781|Drug|Carboplatin|Carboplatin will be administered at area under the concentration curve (AUC) 6 milligrams per milliliter per minute (mg/mL/min) on Day 1 of each 21-day cycle.
1936641|NCT02367781|Drug|Nab-Paclitaxel|Nab-paclitaxel will be administered as IV infusion at a dose of 100 milligrams per square meter (mg/m^2) on Days 1, 8, and 15 of each 21-day cycle.
1936642|NCT02367781|Drug|Pemetrexed|Switch maintenance to pemetrexed can be administered within 6 weeks of Day 1 of the last induction cycle.
1936643|NCT02367742|Behavioral|Endurance Activity (EA)|Subjects have followed a program of endurance activity consisting in a 30 minute walk, 5 times/week. Exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
1936644|NCT02367742|Behavioral|EA + Resistance Training (RT)|"Subjects have followed a program combining endurance activity (EA) and resistance training (RT) consisting in a 60 minute work session, 3 times/week consisting in:
Walk (30 minutes): exercise intensity started from the 60% of the maximum heart rate and raised up to the 75%.
Musculation (30 minutes): training of the bigger muscle groups (chest, shoulders, arms, abdomen, back, glutei and legs). Exercise intensity started from the 65% of the maximum rated load and raised up to the 75%."
1936645|NCT02367131|Drug|Jardiance|Empagliflozin
1936656|NCT02366468|Drug|0.5 mg ranibizumab|
1936657|NCT02366468|Drug|0.5 mg ranibizumab|
1936660|NCT02364388|Device|Imagio Scan|The Imagio breast imaging system is indicated for use by a qualified and trained healthcare provider for opto-acoustic (OA) evaluation of breasts in women who are referred for a diagnostic breast ultrasound work-up due to a suspicious mass (including both palpable and non-palpable) or an imaging finding such as mammographic mass, architectural distortion, asymmetry or suspicious calcifications.
1936661|NCT02364271|Biological|point-of-care test for H-FABP|Patients were tested with an H-FABP point-of-care test according to the instructions of the manufacturer. It is a rapid chromatographic immunoassay designed for quantitative determination of H-FABP in blood samples using a reader QuickSens®Ω100 (8sens.biognostic GmbH, Germany). This test has a limit of detection of 2 µg/L, a 99th percentile cut-off value of 7 µg/L, and a coefficient of variation of less than 10% at 5 µg/L. The test requires a 120 µL blood sample and the result was interpreted at 15 minutes after sample application. The test was invalid if no control line is visible. In such a case, the measurement was repeated immediately. The research assistant performed the H-FABP point-of-care tests, was blinded to the CACS results and TIMI scores.
1936662|NCT02364271|Radiation|Coronary CT Angiography|Patients underwent CACS on a 64-slice multidetector CT scanner. Images were acquired during a single breath hold, using prospective ECG gating with imaging triggered at 70% of the R-R interval (collimation 16x2.5 mm, voltage 120 KeV, current 150 mAs). The computer software automatically defined the presence of calcified lesions as those greater than 130 Hounsfield units. A radiologist blinded to the H-FABP results and TIMI scores then calculated the CACS by selecting only calcified lesions specifically located within the coronary arteries, along with a description of whether the scan result is normal (CACS = 0), or shows minimal (1 to 10), mild (11 to 100), moderate (101 to 400), or severe (>400) calcification.
1936663|NCT02364271|Other|Thrombolysis in myocardial infarction score|An English- and Cantonese-speaking research nurse obtained the TIMI scores which consists of seven variables from each eligible patient.
1936664|NCT02364271|Biological|routine blood test for hs-cTnT|Patient had routine venipuncture blood taking for hs-cTnT measurement in the central laboratory of the hospital. Normal level of hs-cTnT is below 14ng/L.
1936665|NCT02364271|Other|HEART score|The modified HEART score of each patient was determined retrospectively by a research assistant.
1936667|NCT02362789|Biological|Secukinumab 300 mg|
1936668|NCT02362282|Behavioral|Gait training|Treatment will include coordination exercises and over ground gait training for impaired muscle groups and related gait deficits. The therapy will be provided by a clinical physical therapist specializing in rehabilitation for stroke patients, according to established, conventional guidelines. The protocol was used in the investigators' prior studies, and is designed to restore voluntary control of ankle dorsiflexion during swing phase; hip flexion during swing phase, knee flexion at toe-off, knee flexion during swing phase; knee extension before heel strike; knee control during stance phase; pelvic control during stance phase; and whole body balance control during weight shifting. Newly-learned coordinated movements will be integrated into practice of coordinated gait components. Cognitive rehabilitation will begin with the least difficult aspects of attention control, and progress to the more difficult. Home practice and generalization exercises will be assigned.
1936669|NCT02362282|Behavioral|cognitive training|Cognitive training is designed to enhance attention, intention, executive function, decision making and reaction time. Commercially available computer software will be used, as well as custom cognitive training.
1936670|NCT02362282|Behavioral|Arm training|Treatment will include coordination exercises for reaching and grasping. Activities will include movement of shoulder, elbow, wrist and fingers.
1936671|NCT02361593|Procedure|assistance of a transparent cap|Patients will receive endoscopic injection of lauromacrogol with assistance of a transparent cap.
1936672|NCT02361593|Procedure|without a transparent cap|Patients will receive routine endoscopic injection of lauromacrogol without use of transparent cap.
1936673|NCT02359344|Drug|CNV1014802|
1936674|NCT02359344|Drug|Placebo|
1936675|NCT02360631|Drug|Chantix|A drug used to treat nicotine addiction.Chantix is approved by the FDA to be given to help people quit smoking.
1936676|NCT02360631|Drug|Placebo|Health education counseling will be provided to all participants.
1936677|NCT02359305|Drug|Acetaminophen|Acetaminophen given either IV or rectally
1936679|NCT02359838|Other|Baseline Geriatric Screening/Assessment|All patients receive baseline geriatric screening/assessment by a research assistant to determine frailty status.
1936680|NCT02359838|Other|Geriatrician Co-Management|A board-certified geriatrician embedded in the oncology clinic will co-manage patients randomized to this arm.
1936681|NCT02359721|Drug|tablet clarithromycin 500 mg (Clarino-500) orally|orally
1936682|NCT02359916|Other|Time delays on delivery of less healthy snacks|
1936683|NCT02359916|Other|25%/$0.25 discount on healthy snacks|
1936684|NCT02359916|Other|25%/$0.25 tax on less healthy snacks|
1936685|NCT02359058|Drug|Ramucirumab|Administered IV
1936686|NCT02359058|Drug|Capecitabine|Administered orally
1936687|NCT02359058|Drug|Cisplatin|Administered IV
1936688|NCT02359058|Drug|S-1|Administered orally
1936689|NCT02359058|Drug|Oxaliplatin|Administered IV
1936690|NCT02357537|Behavioral|Combined Anti-inflammatory Diet (CAID)|The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
1936691|NCT02357706|Device|APAP A (ResMed AirSense AutoSet)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
1936692|NCT02357706|Device|APAP B (Apex iCH Auto)|Commercially available device used to treat obstructive sleep apnea. The device automatically senses breathing and adjusts delivered pressure based on obstructive events
1936693|NCT02357472|Drug|dehydroepiandrosterone|high dose group treatment represent for 50mg t.i.d and standard dose group represents for normal treatment with 25mg t.i.d. Each patients in these two group will take one capsule each time and three times a day for three months before entering into IVF cycles.
1936696|NCT02357043|Device|Dario Blood Glucose Monitoring System|Finger-stick obtained with BGMS
1936697|NCT02357043|Device|YSI|Finger-stick sample obtained by nurse/technician to be tested with YSI
1936698|NCT02356211|Other|Multifactorial Falls Assessment|The Geriatric Multifactorial Falls Assessment Clinic is a component of GERIACTRIC-PACT, a frail-elderly primary care patient-centered medical home with care provided by an inter-professional teamlet consisting of a geriatrician, geriatric nurse practitioner, clinical pharmacist, licensed practical nurse, nurse care manager, social worker, and dietitian. GERIATRIC-PACT operates with increased ancillary support compared to Primary Care PACT. Falls assessment patients were referred by primary care providers and were evaluated and treated by the GERIATRIC-PACT teamlet, including ordering of tests and medication adjustment, with an average of two visits and active follow-up for one year.
1936699|NCT02356211|Other|Falls e-consult|Electronic medical record review for falls assessment (Falls e-consult) was also available to primary care physicians during the time of the study. Recommendations were made based on information available in the EMR, but without the benefit of a history and physical targeted at falls assessment.
1936701|NCT02355028|Drug|LHA510 ophthalmic suspension|
1936702|NCT02355028|Drug|LHA510 vehicle|Inactive ingredients used as a placebo comparator
1936703|NCT02355028|Drug|Ranibizumab ophthalmic solution|For intravitreal (IVT) injection
1936704|NCT02354976|Drug|Placebo|Placebo matching to Omega-3 carboxylic acids (olive oil)
1936705|NCT02354976|Drug|Omega-3 carboxylic acid|4 g administered as 4 x 1 g capsules
1936706|NCT02354976|Drug|Fenofibrate 200mg|200mg capsule administered once daily
1936707|NCT02354976|Drug|Placebo|Placebo matching to fenofibrate 200mg
1936709|NCT02353299|Drug|Silenor 6 mg|Silenor 6 mg single nighttime dose.
1936710|NCT02353299|Drug|zolpidem 10 mg|Zolpidem 10 mg single nighttime dose
1936714|NCT02350660|Dietary Supplement|cow's milk|daily consumption of cow's milk
1936715|NCT02350660|Dietary Supplement|peanut powder|peanut oral immunotherapy
1936716|NCT02351700|Drug|IV Caldolor (IV Ibuprofen)|Compare addition of IV Caldolor (IV ibuprofen) intraoperatively and postoperatively against IV ibuprofen placebo added intraoperatively and postoperatively.
1936717|NCT02351700|Drug|IV Ibuprofen placebo|Compare addition of IV ibuprofen placebo intraoperatively and postoperatively against IV Caldolor (IV ibuprofen) added intraoperatively and postoperatively.
1936719|NCT02351245|Other|observation|
1936720|NCT02351271|Device|Femto LDV Z8|Femtosecond laser-assisted cataract pre-treatment: Capsulotomy and lens fragmentation, followed by ultrasound phacoemulsification
1936721|NCT02351271|Device|Manual capsulorhexis&lens fragmentation|Control treatment where the capsulorhexis is performed manually and the lens fragmentation is performed by the stop and chop technique with the phaco emulsification device
1936722|NCT02349646|Device|Implantation with the commercially available Axium neurostimulator|
1936726|NCT02349295|Drug|Ixekizumab|Administered SC
1936727|NCT02349295|Drug|Placebo|Administered SC
1936728|NCT02346643|Device|Implantation with the commercially available Axium Neurostimulator|
1936729|NCT02347605|Drug|Nicotine lozenge 4 mg|
1936730|NCT02347605|Drug|Placebo lozenge|
1936732|NCT02345512|Device|Lycra Splinting Garment|Wearing of lycra splinting garment for 6 weeks
1936742|NCT02345291|Drug|NRD135S.E1|A small chemical entity for treatment of neuropathic pain NRD135S.E1
1936743|NCT02345291|Drug|Placebo to match NRD135S.E1|Placebo capsule to match NRD135S.E1 capsules
1936752|NCT02345161|Drug|Triple FF/UMEC/VI|The combination will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip). It will have 100 mcg of FF (blended with lactose) per blister, 62.5 mcg of UMEC (blended with lactose and magnesium stearate) per blister and 25 mcg of VI (blended with lactose) per blister.
1936753|NCT02345161|Drug|Placebo to match FF/UMEC/VI|The placebo (Lactose) will be provided as inhalation via an ELLIPTA DPI having 30 doses (2 strips with 30 blisters per strip).
1936754|NCT02345161|Drug|Budesonide/Formoterol|The combination (400 mcg Budesonide/12 mcg Formoterol) will be provided as inhalation via TURBOHALER with 60 doses.
1936755|NCT02345161|Drug|Placebo to match Budesonide/Formoterol combination|The placebo (Lactose) will be provided as inhalation via TURBOHALER with 60 doses.
1936756|NCT02345161|Drug|Albuterol/salbutamol|Albuterol/salbutamol will be available as an inhalation via metered-dose inhaler (MDI) with a spacer and will be issued for reversibility testing at Visit 1 Albuterol/salbutamol MDI or NEBULES™ for as needed (prn) use throughout the study will be provided starting at Visit 1.
1936757|NCT02345018|Procedure|Mechano-chemical ablation|Treatment with mechano-chemical ablation
1936759|NCT02343432|Drug|Triamcinolone|Triamcinolone
1936760|NCT02343432|Drug|Epidural Volume|Epidural Volume
1936761|NCT02343432|Drug|Bupivacaine|Bupivacaine
1936762|NCT02344316|Drug|Melatonin|Taken at 9 PM or 1 hour before bedtime, whichever is earlier
1936763|NCT02344316|Other|Placebo|Matching placebo taken at 9 PM or 1 hour before bedtime, whichever is earlier
1936764|NCT02342600|Drug|Pazopanib|A kinase inhibitor indicated for the treatment of patients with advanced renal cell carcinoma and advanced soft tissue sarcoma who have receive prior chemotherapy.
1936765|NCT02342600|Drug|Trametinib|A kinase inhibitor indicated for the treatment of patients with unresectable or metastatic melanoma with BRAF V600E or V600K mutations as detected by an FDA-approved test.
1936768|NCT02341352|Drug|fluoride varnish|Sodium fluoride 50mg/ml
1936769|NCT02341352|Biological|Immunoglobulin Yolk|anti—Streptococcus mutans IgY
1936770|NCT02341352|Dietary Supplement|Probiotics|2g/day，Lactobacillus rhamnosus HN001, Bifidobacterium lactis Bi-07, Bifidobacterium lactis HN019, maltodextrin, fructose, skimmed milk powder
1936771|NCT02340845|Biological|Bromelain and Comosain|Treatment of solid tumors in advanced stage of lung, breast, colon, ovary, cervix, uterus, prostatic, and liver
1936772|NCT02339909|Behavioral|Fixed financial incentive|"Participants receiving the fixed financial incentive intervention will be sent a screening appointment letter offering them a fixed amount of £10 if they attend their screening appointment."
1936773|NCT02339909|Behavioral|Probabilistic financial incentive|"Participants receiving the probabilistic financial incentive intervention will be sent a screening appointment letter offering them an entry into a lottery with at least a 1 in 100 chance of winning £1000 if they attend their screening appointment."
1936774|NCT02339909|Behavioral|Control|"Participants receiving the active comparator, (i.e. control) intervention, will be sent the standard diabetic retinopathy screening appointment letter."
1936775|NCT02340351|Device|Auricular acupuncture|Auricular acupuncture according to the the NADA protocol includes the needling of five specific acupuncture points on both ears: point 51 (= Sympathetic point), point 55 (= Shen Men), point 95 (= Kidney point), point 97 (= Liver point) and point 101 (= Lung point). All points were acupunctured with fine sterile single use steel needles with the size of 0.25 x 20 millimetres. The needles were inserted about 2-3 millimetres, so that the needle point pierces the skin and is just positioned in the cartilage of the ear. They remained in position for 30 minutes.
1936776|NCT02340351|Procedure|Progressive muscle relaxation|Progressive muscle relaxation was carried out by the method of Bernstein and Borkovec. All participants were asked to close eyes while sitting comfortably. Each group session included 16 main exercises of consciously tensing and relaxing specific groups of muscles.
1936777|NCT02340091|Device|HA IDF plus|
1936778|NCT02340091|Device|HA IDF|
1936779|NCT02340078|Device|HA IDF II plus|
1936780|NCT02340078|Device|HA IDF II|
1936790|NCT02339389|Other|Maternal ventilation|Measuring maternal ventilation after placement of epidural analgesia compared to baseline
1936791|NCT02339103|Other|Warmed IV fluids|1 Liter of warmed IV fluids at 42 degrees celsius
1936792|NCT02339103|Other|Warmed perfusion pads|Neoprene perfusion pads placed on the palms and soles to rewarm through focusing on the arteriovenous anastomoses
1936795|NCT02338362|Drug|Fluticasone propionate inhaler|fluticasone propionate 250 µg metered-dose inhaler
1936796|NCT02338362|Drug|Saline placebo inhaler|saline metered dose inhaler
1936799|NCT02337764|Drug|TVP-1012 1mg with levodopa|TVP-1012 1mg Tablets with levodopa, A levodopa combination drug will be concomitantly administered in principle without change in the dose regimen throughout the study period from the start of the screening period.
1936800|NCT02337738|Drug|TVP-1012 1mg|TVP-1012 1mg Tablets
1936801|NCT02337738|Drug|TVP-1012 0.5mg|TVP-1012 0.5mg Tablets
1936802|NCT02337738|Drug|Placebo|Placebo Tablets
1936803|NCT02337257|Drug|Cholecalciferol|subjects will receive one pill per day which contains 4000 IU/d for 16 weeks
1936804|NCT02337257|Drug|Placebo|subjects will receive placebo one pill per day for 16 weeks
1936805|NCT02337387|Biological|Blosozumab|Administered SC
1936806|NCT02337387|Other|Placebo|Administered SC
1936810|NCT02335632|Drug|Probiotics (Lacidofil®)|7 days of cultured Lactobacillus rhamnosus R0011/acidophilus R0052 (120 mg/day)
1936811|NCT02335632|Drug|Placebo|For probiotics
1936812|NCT02335216|Device|Implantation with the commercially available Axium neurostimulator|
1936813|NCT02335203|Drug|Depot medroxyprogesterone acetate|One injection intragluteally of 400mg depot medroxyprogesterone acetate at the time of the patient's first visit with the Program in Womens' Oncology
1936814|NCT02335203|Other|Placebo|One injection intragluteally of 1mL Normal Saline (0.9% Sodium Chloride) at the time of the patient's first visit with the Program in Womens' Oncology
1936815|NCT02335229|Device|Implantation with the commercially available Axium Neurostimulator|
1936817|NCT02334800|Drug|Palbociclib 75 mg Capsule|Single oral 75 mg dose of palbociclib followed by serial PK sampling up to 192 hours post-dose (up to 120 hours post-dose for the healthy volunteer cohort).
1936818|NCT02332824|Drug|TAK-272 tablets|
1936819|NCT02332824|Drug|Placebo tablets|
1936820|NCT02332824|Drug|Candesartan cilexetil tablets|
1936821|NCT02332720|Drug|Grazoprevir|One grazoprevir 100 mg tablet (Part A), or two MK-3682B tablets each containing grazoprevir 50 mg (Part B), taken q.d. by mouth.
1936822|NCT02332720|Drug|Uprifosbuvir|Two or three MK-3682 150 mg (300 or 450 mg total daily dose) tablets (Part A), or two MK-3682B tablets each containing MK-8742 225 mg (Part B), taken q.d. by mouth.
1936823|NCT02332720|Drug|Elbasvir|One MK-8742 50 mg tablet (Part A), taken q.d. by mouth.
1936824|NCT02332720|Drug|Ruzasvir|Six ruzasvir 10 mg (60 mg total daily dose) capsules (Part A), or two MK-3682B tablets each containing ruzasvir 30 mg (Part B), taken q.d. by mouth.
1936825|NCT02332720|Drug|MK-3682B|Two FDC tablets, each containing grazoprevir 50 mg + elbasvir 225 mg + ruzasvir 30 mg (Part B), taken q.d. by mouth.
1936826|NCT02332720|Drug|RBV|RBV 200 mg capsules taken b.i.d. by mouth at a total daily dose of 800 mg - 1400 mg based on participant body weight.
1936829|NCT02332135|Procedure|microwave ablation|First, the investigators detect the iPTH levels of all the patients in the investigators' blood purification center. The patients whose iPTH are between 300pg/ml and 800pg/ml and who have parathyroid nodular or diffuse hyperplasia demonstrated on ultrasound imaging or radioisotope scan are chosen to involve in this study. Patients are divided into 2 groups at random, the control group and the microwave ablation group. In the microwave ablation group, patients will accept microwave ablation. Oral medicines, if needed, will be taken according to the the suggestions in K/DOQI guideline.
1936830|NCT02332135|Drug|active vitamin D|The control group will be treated by active vitamin D and other general treatment,such as dietary phosphate restriction and phosphate binders,according to the suggestions in K/DOQI guideline.
1936831|NCT02331992|Behavioral|Adherence program|Participants will receive supportive messages while enrolled in the program.
1936833|NCT02330614|Other|Bleaching by peroxide carbamide 10%|bleaching were treated with 10% carbamide peroxide (CP) gel (Whiteness Perfect, FGM) to each subject With verbal instructions for 3 weeks with daily applications of 1 hour according to manufacturers indications
1936834|NCT02330614|Other|Nothing - control group|Only NEO-FFI test , data used as control
1936844|NCT02330081|Device|Mirasol treatment of whole blood|"Subject will be infused with two products at the same time:
radio-labeled platelets derived from subject's stored whole blood which has been treated with Mirasol.
radio-labeled platelets derived from subject's untreated fresh whole blood."
1936845|NCT02329795|Radiation|Radiotherapy|60 Gy in 30 fractions, 5 days a week, modulated arc therapy.
1936846|NCT02329795|Drug|Temozolomide|Concomitant: 75 mg/m2 5 days a week from start of radiotherapy. Adjuvant: 150/200 mg/m2 in 5 days per 28 days in 6 months.
1936848|NCT02327156|Drug|dexmedetomidine|adding dexmedetomidine to the local anesthetic
1936849|NCT02327052|Other|No intervention was performed.|No intervention was performed.
1936856|NCT02326545|Behavioral|MindLight|MindLight is a video game that uses neurofeedback as part of game mechanics. Participants play for 5 hours total over 3 weeks. Measures taken pre, post, and 3-month follow-up.
1936857|NCT02326545|Behavioral|Online CBT|Five sessions of power point slides that cover primary concepts and homework of cognitive behavioral therapy. Adapted for children. Measures taken pre, post, and 3-month follow-up.
1936860|NCT02326025|Drug|Olaratumab|Administered IV
1936861|NCT02326025|Drug|Doxorubicin|Administered IV
1936865|NCT02325245|Drug|Metformin|Metformin tablet 500 mg three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, metformin will continue until 24 weeks.
1936866|NCT02325245|Drug|Placebo|Placebo three times a day for 16 weeks. If there is no significant outcome obtained between two arms in 16 weeks, placebo will continue until 24 weeks.
1936867|NCT02324972|Drug|AQX-1125|Synthetic SHIP1 activator
1936868|NCT02324972|Drug|Placebo|
1936869|NCT02324803|Drug|pazopanib|continuous treatment of 800 mg pazopanib once daily until disease progression
1936870|NCT02324361|Device|Physical Activity Monitor|The Fitbit Zip is a wireless physical activity monitor that will be worn by the index child during waking hours, and will be used to assess daily active time for the duration of the study.
1936871|NCT02324361|Behavioral|Evidence-based information on healthy family routines|Educational dimensions include nutrition, frequency of family meals, child's screen time, bedtime routines, physical activity, and sleep hours.
1936874|NCT02322710|Device|Urgotul: Low-adherent dressing|
1936875|NCT02322710|Device|TulleGras M.S.: Vaseline gauze|
1936876|NCT02323048|Drug|methamphetamine|: Twenty milligrams of MA (Desoxyn; Lundbeck Inc) tablets will be crushed and placed in 10 ml of Ora-Sweet syrup. Placebo drinks will consist of 10 ml of Ora-Sweet alone.
1936877|NCT02323048|Drug|placebo|Placebo (sugar pill)
1936879|NCT02320903|Device|VillageWhere App|
1936880|NCT02319096|Other|Whole body vibration therapy|Whole body vibration therapy using the Galileo machine as therapy for pelvic floor muscle training
1936881|NCT02319174|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
1936882|NCT02318797|Behavioral|Patient Self-Directed Care|Patient self-management toolkits, web portal with information on health conditions, personal health care use data, health tracking tools and wellness programs
1936883|NCT02318797|Behavioral|Provider-Supported Integrated Care|Registered nurse on staff at community mental health centers with access to patient-level physical health information to: 1) work with patients on coordinating their care, 2) enhance communication between providers and payer, and 3) provide patient wellness support and education
1936884|NCT02318095|Drug|Gemcitabine/nab-Paclitaxel|Prospective, single arm study ; eligible subjects will recieve 2 cycles of neoadjuvant Gemcitabine/nab-Paclitaxel. Restaging will be completed post chemotherapy.
1936885|NCT02318095|Radiation|Radiation therapy|5 fractions of hypofractionated IGRT or IMRT at 5Gy per fraction will be delivered before surgery. Restaging will be completed post radiation therapy.
1936886|NCT02318095|Other|Sugical resection|Surgical resection of the pancreas post radiation therapy
1936887|NCT02318095|Drug|Adjuvant chemotheapy|Adjuvant chemotherapy may be given after surgery at the clinical discretion of the medical oncologist
1936890|NCT02317861|Drug|RDEA3170|Oral Treatment
1936891|NCT02317861|Drug|Febuxostat|Oral Treatment
1936892|NCT02317861|Drug|Benzbromarone|Oral Treatment
1936897|NCT02317042|Device|Juno|'Juno' is the ventilator unit. It will have a flow generator which will deliver air pressure to the participant during sleep. It will have a water tub for humidification, and a single tube circuit which will be connected to a vented face mask. It will have the ventilator programs: Spontaneous Timed (ST) mode, Intelligent Volume Assured Pressure Support (iVAPS) and Automatic Expiratory Positive Airway Pressure (AutoEPAP) iVAPS programed into the software. It is also compatible with <4 L/min oxygen therapy. It is for people who weight at least 13 kg (when in ST mode), or at least 30 kg (when in iVAPS or AutoEPAP iVAPS modes).
1936899|NCT02314975|Device|AcceleDent vibrational device|Supplementary vibrational force with fixed appliances
1936900|NCT02314975|Device|Sham AcceleDent device|Supplementary sham-vibrational device with fixed appliances
1936901|NCT02314975|Other|Fixed appliance only|Fixed appliance treatment only
1936904|NCT02315261|Procedure|Epidural Anesthesia|This is an observational audit, reviewing the implementation of a standard care practice and requiring de-identified data collection only. All collected data will be that which is routinely part of normal clinical practice. The Research staff will systematically collect data on each patient. Some information can be obtained from the medical record, intraoperative anesthetic record, acute pain service record, etc whereas other information has to be obtained from direct observation at the bedside.
1936905|NCT02314936|Dietary Supplement|Litesse powder containing 12 g polydextrose|12 g polydextrose
1936906|NCT02314936|Dietary Supplement|Litesse powder containing 8 g polydextrose|8 g polydextrose, 4 g maltodextrin
1936907|NCT02314936|Dietary Supplement|Litesse powder containing 4 g polydextrose|4 g polydextrose, 8 g maltodextrin
1936908|NCT02314936|Dietary Supplement|Placebo|12 g Maltodextrin
1936909|NCT02312882|Drug|Tofacitinib administration|5 mg of tofacitinib will be taken by mouth twice a day for three months.
1936916|NCT02310230|Device|ExSpiron Respiratory Variation Monitor|Non-invasive monitoring of minute ventilation, tidal volume, and respiratory rate.
1936927|NCT02305030|Drug|BIA 9-1067|
1936928|NCT02305030|Drug|Warfarin|
1936929|NCT02303873|Drug|Alendronate|Alendronate was administrated as 70 mg/week orally (Fosamax, Merck Sharp & Dohme．LTD.).
1936930|NCT02303626|Drug|BCX4161|
1936931|NCT02303626|Drug|Placebo|
1936932|NCT02303574|Drug|AZD7986, oral solution, 1 to 50 mg/mL|Starting dose in single ascending dose part: 5 mg
1936933|NCT02303574|Drug|Placebo, oral solution|Matching placebo
1936934|NCT02302859|Drug|Nicotine Patch|Participants receive an 8 week supply of Nicotine patches.
1936935|NCT02302859|Behavioral|Questionnaires|Questionnaire completion at baseline on laptop, then weekly for 8 weeks on smartphone, then 3 months after smartphone intervention.
1936936|NCT02302859|Other|Pamphlet|Pamphlet given to participant describing health and financial reasons to quit smoking.
1937014|NCT02290249|Device|Glidescope|Manikin was intubated by different novice personal with glidescope videolaryngoscope
1937015|NCT02290249|Device|Airtraq|Pediatric manikin was intubated by novice personal with airtraq
1936937|NCT02302859|Behavioral|Phone Counseling Sessions|"Standard Treatment (ST) Group: Participants receive 8 phone counseling sessions (one session per week) for support in quitting smoking. The calls should last about 15 minutes.
Automated Treatment (AT) Group: Participants receive brief video clips with advice on how to quit smoking over smartphone, as well as interactive text and picture messages once a week for 8 weeks. The video clips will be about 5 minutes long.
Participants also have access to additional counseling content on the smart phone, which can be used at any time."
1936938|NCT02302859|Other|Saliva Test|Participants complete saliva cotinine test 3 months after intervention.
1936939|NCT02302859|Device|Smart phone|"Standard Treatment (ST) Group: Participants receive proactive phone counseling (8 sessions) over the 8-week period for support in quitting smoking. The call will last about 15 minutes.
Automated Treatment (AT) Group: Participants receive brief advice to quit smoking (tailored video clips) and an 8-week automated intervention (interactive text messages and graphical messages) for support in quitting smoking via smartphone."
1936943|NCT02302417|Procedure|Spirometry|Classification of respiratory diseases by Spirometry will be performed to differentiate subjects between Asthma only, ACOS, and COPD only. Spirometry obtained from measurements in the past 6 months is acceptable for purposes of this study. For subjects without spirometry in the past 6 months, spirometry will be performed to obtain pre- and post-bronchodilator Forced Expiratory Volume in one second (FEV1), Forced Vital Capacity (FVC) and reversibility
1936944|NCT02302417|Other|ACOS clinical questionnaire|The 41-question questionnaire includes questions concerning the following: a) response to bronchodilator, b) disease progression, c) variations in symptom, d) atopic history, e) symptom triggers, f) vagal bias, g) burden of disease, h) symptom presentation, i) emotional aspects, and j) age of onset. In addition, two questions will capture patient perception of his/her respiratory disease and the physician's diagnosis
1936945|NCT02301793|Behavioral|Nurse education in contemporary format|Education about VTE was delivered through a web-based contemporary interactive format
1936946|NCT02301793|Behavioral|Nurse education in traditional format|Education about VTE was delivered through a web-based traditional linear Powerpoint format with voice over.
1936949|NCT02300298|Drug|Nintedanib|Nintedanib
1936950|NCT02300298|Drug|Docetaxel|Docetaxel
1936952|NCT02300207|Device|electronic acupuncture treatment instrument|Electroacupuncture was performed using small-sized (1.5 cm) cutaneous electrode pads placed bilaterally at the PC-6 points of the forearms (Supplementary Figure 1). The intensity of the electrical stimulation was adjusted to produce the most intense tolerable electrical sensation without muscle contractions or uncomfortable feelings at a frequency of 50 Hz using the Hwato electronic acupuncture treatment instrument (Model No. SDZ-II; Suzhou Medical Appliances Co, Ltd, Suzhou, China).
1936953|NCT02300168|Procedure|Sleeve gastrectomy|Laparoscopic sleeve gastrectomy (LSG) is a restrictive procedure which consists in creating a narrow tube-like stomach, designed to decrease appetite by reducing the ability of the stomach to distend.
1936956|NCT02300038|Drug|Lidocaine (Xylocaine)|perineuromally administration of 1 ml lidocaine
1936957|NCT02300038|Dietary Supplement|NaCl|perineuromally administration of NaCL
1936958|NCT02299375|Drug|Losmapimod tablets|Losmapimod tablets will be provided as 15 mg strength in a formulation containing lactose. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period.
1936959|NCT02299375|Drug|Placebo tablets|Placebo tablets will be provided in a formulation containing lactose and visually matching the losmapimod tablets. Administered orally, twice daily approximately 12 hours apart and with food and water for the duration of the treatment period. Participants will be instructed to take their medication with a full glass of water twice-daily within 30 minutes after meals for the duration of their treatment period
1936960|NCT02298803|Device|Holter and Glucose monitoring|"(i) Continuous Glucose Monitoring A sterile disposable glucose-sensing sensor will be inserted into the subcutaneous tissues in either the abdomen or the upper outer quadrant of the patient's buttock. This sensor automatically measures the change in glucose in interstitial fluid every 5 minutes. The monitor will be worn for two days.
(ii)Holter Monitoring The Holter monitor to capture cardiac conduction, specifically QT interval, will be worn for the same period as the continuous glucoe monitor with study participants encouraged to perform regular daily activities."
1936961|NCT02299089|Drug|octreotide FluidCrystal® injection depot|
1936962|NCT02297152|Device|FLIP HOLE|The subjects had to use the masturbator aid at least five times per week for six weeks, during a minimum of five minutes without never overcoming half daily hour and during intercourse. The device Flip Hole is a masturbation aid made from Thermoplastic Elastomer (a silicone like substance) that the user inserts their penis in to for stimulation.
1936963|NCT02297815|Drug|Broad-spectrum antibiotics AOM:|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, or ceftriaxone
1936964|NCT02297815|Drug|Broad spectrum antibiotics acute sinusitis|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil or ceftriaxone
1936965|NCT02297815|Drug|Broad spectrum antibiotics GAS pharyngitis|Amoxicillin-clavulanate, azithromycin, cefdinir, cefprozil, cefuroxime axetil, cephalexin, ceftriaxone, or sodium cefadroxil
1936966|NCT02297815|Drug|Narrow spectrum antibiotics AOM|Amoxicillin
1936967|NCT02297815|Drug|Narrow spectrum antibiotics GAS pharyngitis|Amoxicillin or penicillin
1936968|NCT02297815|Drug|Narrow spectrum antibiotics acute sinusitis|Amoxicillin
1937016|NCT02289690|Drug|Veliparib|Varying doses administered on Days -2 to 5 in a 21-day cycle
1936969|NCT02297230|Radiation|radiation therapy|Concurrent RT (to start within one week from first dose of Paclitaxel/Trastuzumab) to breast, supraclavicular, axillary fields, 45 Gy @ 1.8 Gy/fraction, + 14 Gy @ 2 Gy/fraction to the primary tumor. At the end of chemo-radiation, Trastuzumab will be continued weekly until surgery and as per standard of care after surgery for up to 1 year total.
1936970|NCT02297230|Drug|Capecitabine|Capecitabine (Xeloda®) 750 mg/m2 twice/daily given orally. Treatment should begin on day 1 of radiation therapy. The two doses should be taken about 30 minutes after eating (eg. after breakfast and after dinner). Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks after radiation).
1936971|NCT02297230|Drug|Trastuzumab|Trastuzumab (Herceptin®) treatment will be administered weekly, together with one of the two weekly doses of Paclitaxel. The first dose will be 4mg/kg given IV over 90 minutes. Subsequent weekly doses will be given at a dose of 2 mg/kg/week IV over 30 minutes. The treatment with Trastuzumab will continue weekly after the completion of the radiation treatment until surgery and thereafter as per standard of care up to 1 year post surgery.
1936972|NCT02297230|Drug|Paclitaxel|Paclitaxel 30 mg/m2 twice per week given IV over 1 hour. Treatment will be administered on a Monday/Thursday or Tuesday/Friday schedule.The radiation treatment will start within 1 week from the first dose of paclitaxel and trastuzumab. Pre-meds for paclitaxel should be based on the institutional standards; it is suggested that dexamethasone (Decadron®), 20 mg IV, be given with the first paclitaxel dose. If the patient tolerates the treatment, the dexamethasone may be tapered and/or discontinued for subsequent doses. Treatment will be given for 10 weeks (for 6 weeks during radiation and for 4 weeks following radiation).
1936973|NCT02297191|Procedure|Thoracolumbar Interfascial Plane Block|"All participants will have two injections at the same vertebral level on each side of the back. Each injection will consist of four 5cc incremental injections with aspiration prior to each 5cc of injectate of 0.5% Ropivicaine. . Each side of the back will be injected with 20cc of .05% Ropivicaine. Ultrasound will be used in real time to guide the needle.
Ultrasound images will be saved using the nomenclature TLIP Anatomy
Photos will only include surface anatomy of the low-to-mid back.
Participants will be assessed for evidence of adverse reaction to local anesthesia (tinnitus, disorientation, or perioral numbness) with each 5cc dose of local anesthetic. If any adverse reactions are noted the dosing will be stopped."
1936974|NCT02297191|Drug|Ropivicaine|
1936978|NCT02296658|Radiation|intensity-modulated radiotherapy|A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks) to all patients.
1936979|NCT02296658|Drug|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy.
1936980|NCT02295189|Drug|Ketorolac Tromethamine|anti-inflammatory injection
1936981|NCT02295189|Drug|Triamcinolone Acetonide|corticosteroid injection
1936982|NCT02296502|Other|DSM|Comparing use of DSM-IV versus DSM-5 criteria for autism spectrum disorder
1936983|NCT02296580|Device|Nativis Voyager RFE Therapy|Nativis Voyager Radiofrequency Energy Therapy
1936984|NCT02294305|Drug|Vortioxetine|
1936985|NCT02294305|Drug|Placebo|
1936987|NCT02294461|Drug|Enzalutamide|Oral
1936988|NCT02294461|Drug|Placebo|Oral
1936989|NCT02292927|Behavioral|Prehabilitation|Introduction of a physical exercise training programme, psychological counselling and smoking cessation advice
1936990|NCT02293512|Behavioral|Coping Effectiveness Training for tinnitus|A CET psycho-educational intervention to increase understanding of stress and coping with tinnitus, and to better learn how to match appropriate coping strategies, based on whether the stressful situation is changeable or not.
1936991|NCT02293512|Behavioral|Cognitive-behavioral therapy (CBT)|CBT treatments for tinnitus target the reduction of psychopathology by altering cognitive distortions, automatic thoughts, and core beliefs, as well as behavioral techniques to reduce physiological arousal.
1936992|NCT02293512|Behavioral|Acceptance and Commitment Therapy for tinnitus|An ACT psycho-educational intervention to reduce distress and resistance about having tinnitus and to increase committed actions based on one's values.
1936993|NCT02293395|Drug|Acetylsalicylic acid|ASA 100 mg enteric-coated tablet once daily orally.
1936994|NCT02293395|Drug|Rivaroxaban|Rivaroxaban 2.5 mg tablet twice daily orally.
1936995|NCT02293395|Drug|Clopidogrel|Clopidogrel 75 mg once daily orally.
1936996|NCT02293395|Drug|Ticagrelor|Ticagrelor 90 mg twice daily orally.
1936997|NCT02293304|Other|Self-etch approach|The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
1936998|NCT02293304|Other|Etch-and-rinse approach|After acid etching for 15 seconds, the sound and caries-affected dentin will be kept moist.The adhesive will be vigorously agitated on the entire enamel and dentin surfaces for 20 seconds, according to the manufacturer's recommendations.The brush will be scrubbed on the dentin surface under manual pressure followed by gentle air thinning for five seconds and finally light curing for 10 seconds.
1936999|NCT02293265|Drug|Short Acting Beta Agonist (SABA)|Participants requiring a spirometry measurement will be administered a SABA in a metered dose inhaler (MDI) during the reversibility assessments
1937000|NCT02292953|Other|Serum Prolactin levels|blood samples will be drawn from patients undergoing ICSI to analyse serum prolactin levels
1937006|NCT02292550|Drug|LEE011|CDK 4/6 inhibitor
1937007|NCT02292550|Drug|Ceritinib|ALK inhibitor
1937008|NCT02291601|Drug|Chlorhexidine Gluconate|comparison with other CHG products
1937009|NCT02291601|Other|Vehicle|Cloth with Excipients no CHG
1937010|NCT02291601|Drug|2% Chlorhexidine Gluconate Solution|CHG solution
1937017|NCT02289690|Drug|Carboplatin|Administered on Day 1 via intravenous infusion in a 21-day cycle
1937018|NCT02289690|Drug|Etoposide|Administered on Days 1 to 3 via intravenous infusion in a 21-day cycle
1937020|NCT02289820|Biological|MEDI7510|RSV sF antigen plus adjuvant
1937021|NCT02289820|Biological|IIV|Marketed Inactivated Influenza Vaccine
1937022|NCT02289820|Biological|Placebo|Sterile saline
1937023|NCT02288390|Procedure|Oral care in mechanically ventilated patients|Oral care comparing Chlorhexidine and toothbrush versus Miswak ( the twig of Arak, Salvadora perscia, tree)
1937028|NCT02288169|Behavioral|COPE|We propose to test a brief, effective intervention with outpatients in a cancer center, with the goal of teaching patients symptom management skills for self-identified symptoms of highest priority to patients. The proposed randomized clinical trial will test the efficacy of the COPE intervention with patients with symptoms of moderate to high intensity, distress, frequency or interference with their lives as a result of their cancer.
1937029|NCT02288169|Behavioral|Support/Attention Control|The attention control group will receive supportive visits from the research team at the cancer center and subsequent meetings during clinic visits plus 2 subsequent supportive telephone calls
1937031|NCT02287870|Drug|Chloroprocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 3% chloroprocaine.
1937032|NCT02287870|Drug|Lidocaine|60 patients undergoing lower limb or lower abdominal surgery from three hospitals in China received 2% lidocaine.
1937034|NCT02286960|Drug|Steroid|A short 4 day course is administered to the first group of patients with voice disorders before the initiation of voice therapy.
1937035|NCT02286960|Dietary Supplement|Lactose Pills|4 day course 2 x 20mg per da
1937036|NCT02286830|Drug|Zoledronic acid|Zoledronic acid will be given to all participants for two years. Then patients will be randomized to A receive 2 more years of treatment or B stop treatment.
1937040|NCT02286570|Device|Glidescope|videolaryngoscope used for endotracheal intubation
1937041|NCT02286570|Device|Airtraq|videolaryngoscope used for endotracheal intubation
1937042|NCT02286570|Device|Fastrach|intubating laryngeal mask airway used for blind endotracheal intubation
1937047|NCT02285907|Other|Macronutrient and Fiber Matched BEEF|The participants will consume the macronutrient and fiber matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef (Cargill, KS). Soy fiber (Nutritional Designs, NY) was added to the BEEF meal to match total final content between meals.The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
1937048|NCT02285907|Other|Macronutrient and Fiber Matched SOY|The participants will consume the macronutrient and fiber matched SOY lunch on a single testing day. SOY contained 33% protein, 43% CHO, and 24% fat; the SOY meal contained 24 g of textured soy protein concentrate (Boca Foods, WI).
1937049|NCT02285907|Other|Serving Size Matched BEEF.|The participants will consume the serving size matched BEEF lunch on a single testing day. BEEF contained 33% protein, 43% CHO, and 24% fat; the BEEF meal contained 24 g of beef protein from 96% lean ground beef patty (Cargill, KS).
1937050|NCT02285907|Other|Serving Size Matched SOY|The participants will consume the serving size matched SOY lunch on a single testing day. SOY contained 24% protein, 49% CHO, and 24% fat; the SOY meal contained 14 g of textured soy protein concentrate (Boca Foods, WI).
1937054|NCT02285023|Other|CU-Q2oL|"The patients will be explained how to complete the Urticaria Activity Score (UAS7) form for evaluating their severity of chronic urticaria symptoms at home.
At the 2nd visit, collect the 1st UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 1st DLQI and CU-Q2oL questionnaire and get the 2nd UAS7 form and two-week appointment to follow up.
At the 3th visit, collect the 2nd UAS7 assessment. Assessment the severity of chronic urticaria symptoms. The patients fill the 2nd DLQI and CU-Q2oL questionnaire."
1937061|NCT02284659|Device|Functional Electrical Stimulation (FES)|FES (50Hz / 500us)
1937062|NCT02284659|Device|FES- Sham|
1937063|NCT02284542|Procedure|Awake|Upon approximate lead positioning, the patient is brought to a conscious sedated state while maintaining local anesthetic. Stimulation of the spinal cord through the paddle lead is accomplished with an external pulse generator, while communicating with the patient regarding paresthesia coverage of painful regions.
1937064|NCT02284542|Procedure|Non-Awake|"The patient is maintained under general anesthesia for the full duration of the implant. Upon approximate lead positioning, bilateral EMG of myotomes overlapping dermatomal regions of pain are monitored. Stimulation is delivered through the lead by an external pulse generator in order to elicit compound muscle action potentials (CMAPs) in the target regions. Lead placement is targeted to have symmetric CMAPs (i.e. physiologic midline) and adequate coverage of the painful regions as described by Falowski et al.
(Falowski et al., 2011)."
1937065|NCT02283801|Drug|Eslicarbazepine acetate|
1937066|NCT02283801|Drug|Lamotrigine|
1937067|NCT02284035|Drug|Raltegravir/3TC|MK0518B (Raltegravir/3TC) (300mg/150mg) twice daily, administered orally in the 300/150 mg film-coated tablets according to instructions in the prescribing information.
1937068|NCT02284035|Drug|EFV/TDF/FTC|standard combination therapy
1937069|NCT02284035|Drug|ATV/r + TDF/FTC or DRV/r + TDF/FTC|
1937070|NCT02284035|Drug|DTG+ABC/3TC DTG+TDF/FTC EVG/cobi/TDF/FTC RAL+TDF/FTC|
1937071|NCT02284035|Drug|EFV plus ABC/3TC or RPV/TDF/FTC|
1937072|NCT02284035|Drug|ATV/r plus ABC/3TC|
1937073|NCT02284035|Drug|DRV/r + ABC/3TC or LPV/r + ABC/3TC or LPV/r + TDF/FTC|
1937074|NCT02284035|Drug|RAL plus ABC/3TC|
1937075|NCT02284035|Drug|Other ART regimens|
1937078|NCT02282670|Drug|DA-5204|
1937079|NCT02282670|Drug|Stillen tab.|
1937087|NCT02280798|Procedure|Endometrial Biopsy|4 endometrial biopsy
1937088|NCT02281474|Drug|Nilotinib|
1937089|NCT02279641|Drug|RDEA3170 10 mg|
1937090|NCT02279641|Drug|allopurinol 300 mg|
1937091|NCT02280668|Other|Icing Therapy|Participants will be randomly assigned into 3 experimental groups. Icing Protocol 1 has participants apply cold packs under the supervision of the principal investigators to their elbow flexor region for 10 minutes on, 10 minutes off, followed by an additional 10 minutes on, starting at time 0. Icing Protocol 2 follows the same procedure but it begins 6 hours after the participant has completed their eccentric muscle damaging exercise and is to be done at home without the supervision of the principal investigators. Both protocols require the participants to repeat their icing procedures every 24 hours until their involvement with the study is finished, which is 7 days in duration. The third experimental group is the control group and will not participate in an icing therapy during the duration of the study.
1937092|NCT02280668|Other|the eccentric muscle damage exercise|
1937093|NCT02279238|Procedure|cardiac rehabilitation|"It is a cross over study in which the participants are assigned for two test simultaneously with washout time of 6 hrs . 5th POD patients are randomly assigned to either 6 minute walk test or 3 minute ramp walk test as first test with 6 hours of rest [Washout time] in between the two test.
6 MWT : The patient is instructed to walk for a period of 6 minute on a 30 meters Hallway with its extent being demarcated by the placement of 2 cones at the extremes of the Hall.
3 MRWT : The patient is instructed to walk for a period of 3 minute on a Ramp with an elevation of 30 degree and length of 20 meters with its extent being demarcated by the placement of 2 cones at the extremes of the ramp.
The data of [HR, SPO2, PSG RPE scale, Distance walked, BP] the participants are collected before, during and after the completion of each lap [according to American Thoracic Society [ATS] protocol]."
1937094|NCT02280096|Drug|4-aminopyridine|Each patient will take two capsules every 6 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study. After 22 weeks of treatment and 2 weeks of wash-out period, this group of patients will start placebo branch.
1937095|NCT02280096|Drug|Placebo|The placebo arm will include Microcrystalline Cellulose placebo
1937096|NCT02280044|Biological|Challenge with C. jejuni|Challenge with C jejuni
1937097|NCT02280239|Drug|Acetaminophen|one-time dose of acetaminophen 650mg given via the enteral route (via the gut)
1937098|NCT02280239|Drug|Placebo|one-time dose of placebo (identical capsule) given via the enteral route (via the gut)
1937099|NCT02279108|Drug|indocyanine green|One injection, 2.5 milligrams per patient, intradermal use
1937100|NCT02279108|Drug|isotope|One injection, 20 MBq techntium99, intradermal use
1937102|NCT02277639|Device|CD3+/CD19+ delpletion using CliniMACs device follwing reduced intensity conditioning|Reduced intensity conditioning with chemotherapy followed by stem cell transplant using the CliniMACs device to deplete CD3+ CD19+ peripheral stem cells.
1937103|NCT02278289|Device|ultrasound|Patients in the ultrasound therapy group were treated with US therapy for 5 minutes each session, twice per week for 8 weeks.
1937104|NCT02278289|Procedure|paraffin therapy|Patients in the paraffin therapy group were treated with the dip-and-wrap method of paraffin bath therapy in the hospital twice per week for 8 weeks. The temperature of the paraffin bath was maintained at approximately 55°C
1937105|NCT02278263|Drug|Tranexamic Acid|Given intravenously or topically
1937106|NCT02278263|Drug|Normal saline (0.9% NaCl)|Administered in all 3 groups
1937109|NCT02277756|Device|thermode|thermal stimulation with test thermode
1937110|NCT02277743|Drug|dupilumab|
1937111|NCT02277743|Drug|placebo|
1937114|NCT02276638|Device|Specular Microscope|Nidek CEM-530
1937115|NCT02276638|Device|Specular Microscope|Konan CELLCHECK XL
1937116|NCT02276040|Drug|periarticular bupivicaine and liposomal bupivicaine|Participants will receive Exparel (liposomal bupivacaine). Exparel is a FDA approved product. Exparel is an extended-release formulation of bupivacaine consisting of microscopic lipid-based particles that diffuse over an extended period. The result is pain relief that can last up to 96 hours after surgery. Extended-release liposomal bupivacaine-based analgesics were shown to provide extended pain relief and decrease opioid (pain medication) use. At the conclusion of the total joint arthroplasty procedure, Exparel is administered via injection into the joint (periarticular bupivicaine and liposomal bupivicaine).
1937117|NCT02275923|Device|Reveal LINQ™ Insertable Cardiac Monitor|Insertable cardiac monitor
1937118|NCT02274311|Drug|Clomiphene Citrate|Clomiphene citrate, 50 mg, orally for three months
1937121|NCT02274649|Behavioral|one-to-one peer mentoring|Each patient received one-to-one peer mentoring each week during rehabilitation and for 90 days post discharge
1937122|NCT02274649|Behavioral|general peer support|General (traditional) peer support includes introduction and provision of support services upon request
1937125|NCT02274272|Other|ADR-1|two ADR-1 capsules, once daily, QD
1937126|NCT02274272|Other|GMNL-263|two GMNL-263 capsules, once daily, QD
1937127|NCT02274272|Other|placebo|two placebo capsules, once daily, QD
1937128|NCT02272413|Drug|Chemotherapy|
1937129|NCT02272413|Drug|BI 695502|
1937130|NCT02272413|Drug|bevacizumab|
1937131|NCT02272413|Drug|Chemotherapy|
1937132|NCT02273050|Drug|Saxagliptin 5 mg|Tablet, Oral, 5 mg, Once daily in the morning
1937133|NCT02273050|Drug|Placebo 5 mg for Saxagliptin|Tablet, Oral, 5 mg, Once daily in the morning
1937134|NCT02273050|Drug|Placebo 500 mg for metformin (with titration)|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
1937135|NCT02273050|Drug|Metformin 500 mg with titration|Tablet, 500 mg, Once daily in the evening the first two weeks and thereafter according to titration.
1937136|NCT02273037|Device|Fetal heart rate Doppler|A wind-up, handheld fetal heart rate monitor Doppler developed by Power-free Education Technology Doppler (www.pet.org.za)
1937137|NCT02273037|Procedure|Partograph|Graphical documentation of labour progress, and maternal and fetal well-being.
1937142|NCT02271984|Drug|L-PZQ (MSC2499550A)|L-PZQ tablet 20 milligram per kilogram (mg/kg) single dose orally dispersed in water after meal.
1937143|NCT02271984|Drug|Cysticide|Cysticide tablet 40 mg/kg given with water orally after a meal.
1937144|NCT02271984|Drug|L-PZQ (MSC2499550A)|L-PZQ tablet 10 mg/kg single dose orally dispersed in water after meal.
1937145|NCT02271984|Drug|L-PZQ (MSC2499550A)|L-PZQ tablet 30 mg/kg single dose orally dispersed in water after meal.
1937146|NCT02271984|Drug|L-PZQ (MSC2499550A)|L-PZQ tablet 20 mg/kg single dose orally dispersed in water without meal.
1937147|NCT02271984|Drug|L-PZQ (MSC2499550A)|L-PZQ tablet 20 mg/kg single dose directly disintegrated orally without water after meal.
1937148|NCT02271880|Other|Medication as usual|Physicians will prescribe medication as usual to the adolescent.
1937149|NCT02271880|Other|Medication as usual + STAR|Physicians will prescribe medication and adolescents and their parents will receive 6 sessions of psychosocial treatment to improve adolescents' motivation to use medication and to develop parent/teen contracting with the goal of setting medication adherence goals.
1937150|NCT02271594|Behavioral|Intensive Training on Best Insulin Injection Technique|The intervention consists of instructing patients in whom LH is detected and who are currently injecting into it to move injections to non-LH areas; reducing insulin doses initially by 10-20% to avoid hypoglycaemia and then titrating to target control; instructing these patients to correctly rotate sites (leaving 1 cm between injection punctures and allowing used sites to heal for 2-4 weeks before injecting in them again); instructing these patients to forego needle reuse; and instructing these patients to switch to 4 mmx32G needles. A battery of tools (described below) will be used to deliver and reinforce this training, including frequent contact by phone or other electronic means after the initial training.
1937151|NCT02271451|Device|Q collar|collar worn around neck
1937253|NCT02243865|Device|Chordate System S200 + CT100 (placebo treatment)|
1937309|NCT02230579|Drug|MMV390048 5mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
1937152|NCT02271061|Device|Kinesio tape|Elastic therapeutic tape is one type of elastic tape that is widely used for various treatment including rehabilitation and sports injuries . The elastic therapeutic tape has different characteristics from other kind of tape. It has ability to stretch around 130 - 140% from original length and recoil back to starting length after applying the tape. Tape produces pulling force on skin which lifts and folds layers of epidermis . Pulling force provides an appropriate alignment which can facilitate and inhibit muscle contraction.It has been claimed for several benefits such as supportingly injured muscles, increased proprioception, stimulated and inhibited muscle activity, relieved pain, increased range of motion, and improved blood and lymph flow.
1937153|NCT02271061|Device|Control tape|Apply tape in same technique without tension.
1937154|NCT02270671|Behavioral|ABMT|Attention Bias Modification Training
1937155|NCT02270671|Other|Placebo|Placebo Training
1937159|NCT02269371|Other|Auricular Acupuncture|Standard of care weight loss intervention plus auricular acupuncture at Shen Men, Point Zero, and Appetite Control Point/Hunger Point in each ear.
1937160|NCT02269371|Other|Sham Acupuncture|Standard of care weight loss intervention plus sham acupuncture at three nonacupoints in each ear.
1937163|NCT02267577|Device|Sphygmo: Automatic Blood Pressure Monitor|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals.
1937164|NCT02267538|Drug|dexmedetomidine hydrochloride for injection|"Before anesthesia, dexmedetomidine hydrochloride for injection (200 ug/2 ml) will be diluted with normal saline to 50 ml (final dexmedetomidine concentration 4 ug/ml).
Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes (i.e., dexmedetomidine 0.6 μg/kg in 10 minutes), followed by continuous infusion at a rate of [0.1*kg] ml/h (i.e., dexmedetomidine at a rate of 0.4 μg /kg/h) until the end of surgery.
At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h (i.e., dexmedetomidine at a rate of 0.1 ug/kg/h) and continued until the end of mechanical ventilation after surgery."
1937165|NCT02267538|Drug|0.9% sodium chloride for injection|"Before anesthesia, 0.9% sodium chloride for injection 50 ml will be prepared.
Before the induction of anesthesia, a loading dose will be administered by intravenous infusion at a rate of [0.9*kg] ml/h for 10 minutes, followed by continuous infusion at a rate of [0.1*kg] ml/h until the end of surgery.
At the end of surgery, the infusion rate will be decreased to [0.025*kg] ml/h and continued until the end of mechanical ventilation after surgery."
1937167|NCT02267135|Biological|Secukinumab 300 mg|Secukinumab 300 mg will be provided in 1 mL prefilled syringes of 150 mg. Each dose of 300 mg secukinumab will consist of two secukinumab 150 mg injections once weekly for 5 weeks (Baseline, Weeks 1, 2, 3 and 4), followed by dosing every four weeks starting at Week 8 through Week 20 inclusive. In order to maintain the blinding, patients will receive additional placebo injections at Weeks 13, 14 and 15. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur of days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
1937168|NCT02267135|Biological|Placebo|Placebo will be provided in 1 mL prefilled syringe. Each placebo dose will consist of two placebo injections once weekly for five weeks (Baseline, Weeks 1, 2, 3 and 4), then after four weeks at Week 8. At Week 12, PSSI responders will continue on placebo and receive their injections once weekly for five weeks (Weeks 12, 13, 14, 15 and 16), then followed by dosing after four weeks at Week 20. PSSI non-responders will be switched to receive 300 mg secukinumab at Weeks 12, 13, 14, 15 and 16, then after four weeks at Week 20. The patients (or caregivers) will self-inject each dose at the study site under the supervision of site personnel when injections occur on days of study visits. The injections not occurring during a study visit will be done by the patients (or caregivers) at home.
1937173|NCT02265822|Drug|melatonin in children premedication|
1937174|NCT02265822|Drug|midazolam in children premedication|
1937175|NCT02263963|Drug|Exparel|In this arm as described above the intervention will be TAP block injection under ultrasound guidance using Exparel.
1937176|NCT02263963|Procedure|TAP Block|no intervention will be done to this arm.
1937177|NCT02264353|Drug|Donepezil|Donepezil 10mg before sleep
1937178|NCT02264353|Drug|placebo|One piece of placebo before sleep
1937179|NCT02263014|Behavioral|Questionnaires|Screening questionnaire completed at baseline. Surgery decision questionnaires completed at surgical consult visit, and at 1, 6, 12, and 18 months after the surgery is completed.
1937183|NCT02263482|Other|control|No intervention during the 8-weeks period of the study because of awaiting evaluation for cardiac rehabilitation or transplantation
1937184|NCT02263482|Other|moderate-intensity group|Patients will be submitted to a 8-weeks training program with inspiratory muscle trained at 30% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (50% 1 RM, increased every 2-weeks).
1937185|NCT02263482|Other|low-intensity group|Patients will be submited to a 8 weeks training program, with inspiratory muscle trained at 15% of the maximal inspiratory pressure (30 minutes/session/7 days/week) + peripheral muscle trained with exercises of upper limbs and lower limbs (0,5 kg each)
1937186|NCT02263365|Drug|Loperamide|Loperamide 12mg per day (4mg t.i.d) for 2 weeks post discharge
1937187|NCT02262507|Device|Q Collar|Q30 collar - collar designed to be worn around the neck to apply slight pressure to jugular veins
1937188|NCT02263092|Behavioral|Physical exercise|The intensity of physical exercise will be determine by the maximum heart rate (max HR) using the formula (220 - age). For the high intensity, the intensity will between 79-95% xx% of maxHR; moderate intensity, 64-76% of maxHR; mild intensity, 57-63% of maxHR. Furthermore, during the physical exercise the heart rate will be continuous evaluate by the POLAR and the rate perceived scale will be register in each 3 minutes by the modified Borg scale
1937189|NCT02263092|Device|tDCS|Current will be applied by a DC stimulator (NeuroConn, Germany) using a pair of saline-soaked sponge electrodes (surface 35 and 36cm²). tDCS will be applied to Cz and Oz according to International 10-20 EEG system. In the anodal tDCS, the anode will be placed in Cz and cathode in Oz. In the cathodal tDCS the inverse position will be done. Parameters of current intensity and duration (dose) used were 2 mA stimulation intensity for 20 minutes with current ramping up and down of 10 seconds each.For sham, the same position of anodal tDCS will be assumed, however, current duration is only 30 seconds, with current ramping up and down of 10 seconds each. Moreover, the electrostimulation device is automatically turned off without patient's perception. Thus, patients experience early sensations (mild to moderate tingling) in stimulation site without inducing effect. Moreover, after each tDCS session, patients will answer adverse effects questionnaire.
1937190|NCT02263092|Behavioral|Rest|15 or 30 minutes seat without move the legs
1937193|NCT02262130|Drug|Omalizumab|
1937198|NCT02259699|Other|Decision Aid|PCOA will be designed to accomplish 2 objectives: 1) it will educate patients and allow them to assimilate information about the differences in outcomes and survival between IP and IV therapies; and 2) it will help patients make the difficult trade-offs between these two treatment options.
1937199|NCT02258256|Device|Sphygmo|A team of engineers from Rice University has recently developed Sphygmo, an ambulatory, low-cost blood pressure monitor for use in the diagnosis and management of pre-eclampsia in low-resource hospitals
1937200|NCT02256995|Device|uChek|The uChek TM urine analyzer is a semi-automated urinalysis system, installed as an application on a smartphone. It makes use of a smartphone's camera to automatically read urine dipsticks.
1937207|NCT02255500|Drug|Bupivacaine FNB|A single administration of bupivacaine HCl 0.5% with epinephrine 1:200,000 in 20 mL volume will be administered within 2 hours prior to the surgical procedure as an ultrasound-guided FNB.
1937208|NCT02255500|Drug|EXPAREL Infiltration|A single dose of EXPAREL 266 mg expanded to 60 mL with preservative-free sterile normal saline will be infiltrated into the surgical site just prior to wound closure.
1937209|NCT02255110|Drug|TH-302|TH-302 will be administered at a dose of 300 milligram per square meter (mg/m^2) by intravenous infusion over 30 minutes on Days 1 and 8 of every 21-day cycle until the evidence of significant treatment-related toxicity or progressive disease.
1937210|NCT02255110|Drug|Doxorubicin|Doxorubicin will be administered at a dose of 75 mg/m^2 by intravenous injection (over at least 5 minutes) or by intravenous infusion over 6-96 hours on Day 1 of every 21-day cycle starting 2 to 4 hours after completion of TH-302 administration until the evidence of significant treatment-related toxicity or progressive disease.
1937211|NCT02254304|Drug|Rebif®|Rebif® (interferon beta-1a) will be administered at a dose of 44 microgram (mcg) subcutaneously using RebiSmart™ auto-injector three times a week for a total duration up to 12 months.
1937212|NCT02252939|Radiation|X-Ray|X-ray as part of standard care
1937214|NCT02251106|Device|Lumbar corset (Quickdraw, Aspen Medical Products)|The corset (a.k.a. brace) is made of webbing and elastic. It is wrapped around the trunk and tightened with Velcro and a series of cords (like tying shoes).
1937217|NCT02250417|Other|Wave sleep surface|The Wave sleep surface is designed to be used as a bed surface and with any combinations of sleep pillows, bed linens, and bed clothes and intended to avoid the supine position during sleep.
1937218|NCT02250443|Drug|BYM338 (Bimagrumab)|
1937224|NCT02249182|Drug|LDV/SOF|LDV/SOF FDC tablet(s) administered orally once daily
1937225|NCT02249182|Drug|Placebo to match LDV/SOF|Placebo to match LDV/SOF FDC tablet administered orally once
1937226|NCT02249182|Drug|RBV|Ribavirin (RBV) oral solution or capsules will be administered orally in a divided daily dose based on weight
1937227|NCT02249182|Drug|LDV/SOF|LDV/SOF FDC granules administered orally once daily
1937228|NCT02248974|Other|LVAD Decision Aid|"Decision aids are interventions or tools designed to facilitate shared decision making and patient participation in health care decisions.
This Decision Aid was designed to discuss treatment options for patients in end-stage heart failure (i.e LVAD PLACEMENT, PALLIATIVE and SUPPORTIVE CARE)."
1937229|NCT02248922|Drug|TIS or TIP|300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
1937230|NCT02247739|Biological|Recombinant human C1 inhibitor|
1937231|NCT02247739|Other|Placebo|
1937232|NCT02247427|Device|Cardiac Resynchronization Therapy Device|Cardiac Resynchronization Therapy Device pacing activity, on or off
1937233|NCT02246777|Device|Ex-PRESS™ Glaucoma Filtration Device, Model P50PL|
1937234|NCT02246647|Other|saccharides|saccharides will be compared in IBS-C vs healthy participants
1937235|NCT02246647|Procedure|esophagogastroduodenoscopy|duodenal biopsies will be collected from IBS-C volunteers and healthy volunteers
1937236|NCT02246647|Procedure|flexible sigmoidoscopy|colonic biopsies will be collected from IBS-C volunteers and healthy volunteers
1937237|NCT02246998|Drug|STB|Stribild (STB; EVG 150 mg/COBI 150 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily with food
1937238|NCT02246998|Drug|TVD|Truvada (TVD; FTC 200 mg/TDF 300 mg) tablet administered orally once daily with food
1937239|NCT02246998|Drug|ATR|Atripla (ATR; EFV 600 mg/FTC 200 mg/TDF 300 mg) tablet administered orally once daily on an empty stomach at bedtime
1937240|NCT02246998|Drug|RTV|Ritonavir (RTV) 100 mg tablet administered orally once daily with food
1937241|NCT02246998|Drug|ATV|Atazanavir (ATV) 300 mg capsule administered orally once daily with food
1937242|NCT02246998|Drug|ABC/3TC|Abacavir/Lamivudine (ABC 600 mg/3TC 300 mg) tablet administered orally once daily with food
1937243|NCT02246998|Drug|Iohexol|Iohexol 1500 mg solution administered intravenously at baseline, and at Weeks 4, 8, 16, and 24
1937244|NCT02246309|Device|Embryoscope Time Lapse System|The EmbryoScope® time-lapse system is a unique platform facilitating improved IVF treatment, flexible work routines and effective communication, through comprehensive documentation of embryo development and evolving improvements in selection.
1937245|NCT02246309|Device|Standard Embryo Culture|Standard embryo culture in a Standard water jacketed carbon dioxide/low oxygen incubator system.
1937246|NCT02245815|Dietary Supplement|use probiotics Boucardii|group A will be administered the lactobacillus boucardii probiotic (1x109 colonies forming units (UFC) per day for 3 weeks). The diagnosis of NEC will be made using the Bell criteria by the attending physician. Gastric tolerance will be measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) will be measured at the beginning and at the end of treatment.
1937247|NCT02245815|Dietary Supplement|use probiotics Multi-species|Group B will be administered multi-species probiotic (1x109 colonies forming units (UFC) per day for 3 weeks). The diagnosis of NEC will be made using the Bell criteria by the attending physician. Gastric tolerance will be measured, the number and the characteristics of the feces before and after the administration of the probiotic, and also the levels of (IgA s) will be measured at the beginning and at the end of treatment.
1937250|NCT02244047|Drug|Bifidobacterium breve|
1937251|NCT02244047|Drug|Placebo (for Bifidobacterium breve)|
1937252|NCT02243865|Device|Chordate System S200 + CT100 (active treatment)|
1937254|NCT02243215|Other|Access to a portable trainer for laparoscopic skills|Participants will have a portable trainer available to allow training at their convenience, and will be able practice on-site at Center of Clinical Education and at their local hospital.
1937257|NCT02240823|Other|adipose derived stem cells|
1937259|NCT02240667|Drug|Dabigatran etexilate|150 mg or 110 mg capsules twice daily
1937260|NCT02240667|Drug|Phenprocoumon|International Normalized Ratio (INR) 2-3
1937263|NCT02239939|Device|Vest|light weight, adjustable, vest to be worn underneath clothes that weight can be added to
1937264|NCT02239939|Behavioral|Diet|Participants will undergo a 22 week dietary weight loss intervention which will incorporate dietary practices for achieving weight loss while minimizing muscle and bone loss. Participants will be instructed by the Registered Dietitian to follow a low calorie diet. Individual calorie goals will be adjusted during the study if necessary to achieve a targeted weight loss goal of at least 8%, but no more than 12%, within the intervention time frame.
1937266|NCT02239224|Biological|Placebo|Patients will enter the double-blind treatment period and will receive 30-minute IV infusions of Placebo according to their random treatment assignment.
1937267|NCT02239224|Biological|ATYR1940|Patients will enter the double-blind treatment period and will receive 30-minute IV infusions of ATYR1940 according to their random treatment assignment.
1937276|NCT02236065|Procedure|Umbilical cord blood therapy|
1937277|NCT02236065|Biological|Filgrastim|
1937278|NCT02235987|Drug|saline|Eligible patients are to receive saline as placebo comparator, followed by 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
1937279|NCT02235987|Drug|octreotide|Eligible patients are to receive saline as placebo comparator, followed by 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
1937280|NCT02235987|Drug|DG3173|Eligible patients are to receive saline as placebo comparator, followed by 300 µg octreotide as active comparator, followed by four ascending doses of 100 µg, 300 µg, 900 µg and 1800 µg DG3173. All treatments will be administered consecutively to all patients as single subcutaneous bolus injections.
1937281|NCT02235870|Device|Obalon Intragastric Balloons|Intragastric Balloon System to aid in portion control.
1937282|NCT02235870|Device|Sham Device|Sham Intragastric Balloon
1937283|NCT02235870|Behavioral|Nutrition and Lifestyle Program|Nutrition and lifestyle program reviewed with subjects every 3 weeks for 6 months.
1937284|NCT02234752|Drug|Galantamine ER|
1937285|NCT02234752|Drug|Memantine XR|
1937286|NCT02234687|Drug|Pomaglumetad Methionil 160mg|Pomaglumetad Methionil 160mg, one dose, one time
1937287|NCT02234687|Drug|Pomaglumetad Methionil 40mg|Pomaglumetad Methionil 40mg, one dose, one time
1937288|NCT02234687|Drug|Placebo|Placebo, one dose, one time
1937289|NCT02233543|Drug|QVA149|Delivered once daily via single-dose dry powder inhaler
1937290|NCT02233543|Drug|QVA149 Placebo|Placebo delivered once daily via single-dose dry powder inhaler
1937293|NCT02232113|Drug|CERA|changing frequency of administration from once to twice monthly under a fixed total monthly dose of CERA
1937296|NCT02232269|Other|Black Coffee|
1937297|NCT02232269|Other|Grapefruit Juice|
1937298|NCT02232269|Other|Water|
1937299|NCT02232269|Drug|Felodipine|
1937300|NCT02232178|Drug|2 100mg Xaracoll implants|
1937301|NCT02232178|Drug|3 100mg Xaracoll implants|
1937302|NCT02232178|Drug|150mg Bupivacaine HCl injection|
1937303|NCT02232087|Drug|salmeterol (as salmeterol xinafoate)|2, 6, and 12 inhalations
1937304|NCT02232087|Drug|fluticasone propionate|2, 6, and 12 inhalations
1937305|NCT02231580|Drug|BN82451B|BN82451B capsule
1937306|NCT02231580|Drug|Placebo|Placebo capsule
1937307|NCT02230306|Drug|Cobimetinib|60mg once a day; will be taken on days 1-21 of each 28 day treatment cycle; will be taken in combination with Vemurafenib;
1937308|NCT02230306|Drug|Vemurafenib|960mg twice a day; 28 day treatment cycle; will be taken in combination with Cobimetinib;
1937310|NCT02230579|Drug|MMV390048 20mg|"Supplied as powder in bottle formulation for reconstitution pre-dose."
1937311|NCT02230579|Drug|MMV390048 60mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
1937312|NCT02230579|Drug|MMV390048 120mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
1937313|NCT02230579|Drug|MMV390048 220mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
1937314|NCT02230579|Drug|MMV390048 340mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
1937315|NCT02230579|Drug|MMV390048 475mg|"Supplied as powder in bottle formulation for reconstitution pre-dose"
1937316|NCT02230579|Drug|Placebo to match MMV390048|"Supplied as powder in bottle formulation for reconstitution pre-dose"
1937317|NCT02230579|Drug|MMV390048 x mg|dose to be determined based on emerging data
1937318|NCT02230397|Other|plantaricin a (active product)|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
1937319|NCT02230397|Other|placebo product|Product application: 8 weeks (one on the right and one on the left face side randomly) twice a day, in the morning and in the evening, with a mild massage
1937320|NCT02230332|Drug|Alendronate|
1937321|NCT02230332|Drug|Placebo|
1937322|NCT02229474|Behavioral|CST Intervention|The CST intervention comprises 14 sessions lasting 1-2 hours across 7 weeks. The CST manual has been adapted for use in this setting by members of our study team. Each session has a theme. Activities include tasks aimed at engaging participants in cognitive and physical tasks designed to improve quality of life. Sessions will be led and facilitated by a study nurse or occupational therapist. The sessions will be held at a local health centre of village hall.
1937323|NCT02227329|Drug|Ethanol|Prophylactic ELT will be administered at the time when the HPN is not being infused.
1937324|NCT02227329|Drug|Heparin Lock|
1937325|NCT02227329|Drug|Normal Saline|
1937326|NCT02227303|Behavioral|lifestyle modification instructional and motivational sessions|
1937327|NCT02226263|Dietary Supplement|probiotics Lactobacillus acidophilus boucardii|Using sterile technique, the probiotic with 1x109 [CFU] Lactobacillus acidophilus boucardii strain was added at a dose of 125 mg/ kg/dose twice daily for 4 weeks to fresh supplement breast milk or formula for preterm infants.
1937328|NCT02225587|Biological|Prevnar 13™|Pneumococcal vaccine containing serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F. Injections are to be administered into the deltoid muscle of the upper arm.
1937329|NCT02225587|Biological|Pneumovax™ 23|Pneumococcal vaccine containing serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19A, 19F, 20, 22F, 23F, and 33F. Injections are to be administered into the deltoid muscle of the upper arm.
1937330|NCT02225587|Biological|Placebo|Injections are to be administered into the deltoid muscle of the upper arm.
1937331|NCT02225691|Device|Paired testing of blood glucose Accu-Chek®|Patients in the paired testing arms will undergo training on paired testing with Accu-Chek® Active blood glucose meters. The paired testing training would include (1) how and when (testing regimen) to perform paired testing, and (2) how to respond to paired testing readings via lifestyle modifications, self-adjustment of insulin dose and additional testing, if applicable. Please refer to Annex A for further details of the training.
1937332|NCT02224638|Device|TheraHoney HD|Honey
1937333|NCT02224638|Device|SkinTegrity|Hydrogel
1937341|NCT02224274|Drug|Clopidogrel|
1937342|NCT02224274|Drug|Ticagrelor|
1937343|NCT02224612|Device|Medline Pediatric Face Masks|Medline Face Masks
1937344|NCT02224612|Device|KC Childs Mask|
1937345|NCT02224300|Behavioral|Internet-based education of venous leg ulcer nursing care|Intervention is delivering the ELC (Electronic Learning of venous leg ulcer nursing care) to home health-care nurses (registered nurses, public health nurses and licensed practical nurses) . The ELC development was based on the integrative literature review about nurses' knowledge gaps on venous leg ulcer nursing care. The pedagogical basis of the ELC is constructivism and blended learning approach. The ELC comprises contact learning and distance learning. Content of ELC is evidence-based information already existing in Internet and the basis of the information is the Finnish Current Care Guidelines for Chronic leg ulcers (2014), which are evidence-based clinical practice guidelines. They are intended as basis for ulcer treatment decisions, and guidelines can be used by nurses and other healthcare professionals.
1937346|NCT02224235|Drug|Aspirin|75-325 mg q.d. aspirin until study completion (recommended indefinitely for stent patients)
1937347|NCT02224235|Device|Resolute Integrity DES|Resolute Integrity DES
1937348|NCT02224235|Device|COBRA PzF|
1937349|NCT02224235|Drug|DAPT|At the discretion of the investigator as to which DAPT is administered (per local practice)
1937352|NCT02223702|Drug|Amoxicillin|500 mg, 3 times per day for 7 days
1937353|NCT02223702|Drug|Metronidazole|500 mg, 3 times per day, for 7 days
1937354|NCT02223702|Drug|Moxifloxacin|400 mg, once in a day for 7 days.
1937355|NCT02223689|Procedure|Skin Affix|
1937357|NCT02222909|Other|Co-developed IT intervention|The IT-based intervention is being co-developed with the community based organizations in the intervention group, and comprises tools to improve referral and tracking of clients, use of volunteers, and direct communication with hospital staff members
1937358|NCT02222896|Drug|Chlorhexidine Gluconate|comparison with other CHG products
1937359|NCT02222896|Other|Vehicle|Cloth with Excipients no CHG
1937360|NCT02222896|Drug|2% Chlorhexidine Gluconate Solution|CHG solution
1937361|NCT02222337|Behavioral|Nueva Vida Intervention|The psycho-educational format of the Nueva Vida Intervention is led by trained interventionists who have the survivors and caregivers go into different rooms to discuss the same topic. This format will allows them each to express their thoughts and feelings without inhibitions or concerns over how their survivor or their caregiver might respond. The specific topics for each wave of the intervention participants will be determined from a larger list of possible topics, with each group including the following core topics: Impact of Cancer on the Family, Spirituality and Cancer, Stress Management, Balancing Physical and Emotional Needs and Improving Communication.
1937362|NCT02220465|Behavioral|PA+ Smoking Cessation (LMPA)|
1937363|NCT02220465|Behavioral|Standard Care Smoking Counseling (SCC)|
1937367|NCT02221583|Drug|Astagraf XL|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
1937368|NCT02221583|Drug|Prograf|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
1937369|NCT02221583|Drug|Mycophenolate mofetil|Two PK profiles will be obtained in each subject. Each subject will receive either Astagraf XL 8mg daily or Prograf® 4mg every 12 hours in combination with MMF 1000mg every 12 hours. A full 24 hour PK profile will be constructed. After at least a one week washout period, the patient will be crossed over to the alternative tacrolimus formulation (Astagraf XL or Prograf®) in combination with MMF 1000mg every 12 hours and the PK profile repeated.
1937370|NCT02220881|Device|Mold making silicone toe separator|Each subject in the controlled receives the custom-made mold making silicone toe separator made by certified orthotist and the recommendation of use the proper shoes without determination of current drug use
1937371|NCT02220881|Other|Observation|The participants in this groups will be educated on how to care the hallux valgus without any intervention. The follow up will be on the 3rd, 6th, 9th and 12th month.
1937372|NCT02218463|Drug|Estradiol cream 0.01%|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
1937373|NCT02218463|Drug|Cetaphil|Apply a pea-sized amount to the labial adhesion with lateral traction twice daily
1937374|NCT02219230|Device|Active knee (Ossur Power Knee II)|Prosthetic knee with active control system.
1937375|NCT02219230|Device|Adaptive knee (Ossur Rheo)|Prosthetic knee with adaptive control system.
1937376|NCT02219230|Device|Passive knee (Various manufacturers)|Prosthetic knee with mechanical control system.
1937377|NCT02219087|Drug|Liposomal bupivacaine|
1937378|NCT02219087|Drug|ropivacaine, morphine ,ketorolac, methylprednisolone|Standard of care analgesia
1937379|NCT02219048|Drug|Placebo|680 micrograms BID, Orally inhaled placebo for 12 weeks
1937380|NCT02219048|Drug|PF-03715455|680 micrograms BID, Orally inhaled PF-03715455 for 12 weeks
1937381|NCT02218697|Biological|Influsplit™ Tetra (Fluarix™ Tetra)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
1937382|NCT02218697|Biological|Pneumovax™ 23|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
1937383|NCT02218697|Biological|Placebo (Saline)|Intramuscular injection, 1 dose each in Control and Co-Ad groups.
1937384|NCT02218320|Drug|Raltegravir|
1937385|NCT02218320|Drug|Dolutegravir|
1937386|NCT02218320|Procedure|Colonoscopy with biopsy|This procedure is not standard of care for patients receiving combination antiretroviral therapy (cART), but is necessary to obtain tissue samples.
1937387|NCT02218203|Drug|Dextromethorphan|Administered in 4 periods (placebo, low dose, medium dose, and high dose) for each subject
1937388|NCT02218203|Drug|Lidocaine|0mg, 1mg, 2mg, and 4mg Lidocaine per kg of lean body mass (LBM), during each of the 4 dextromethorphan periods (placebo, low dose, medium dose, and high dose)
1937389|NCT02218203|Drug|Placebo (Dextromethorphan)|0mg Dextromethorphan
1937390|NCT02218203|Drug|Placebo (Lidocaine)|0mg/kg LBM Lidocaine
1937391|NCT02216526|Other|Cetaphil® Restoraderm|
1937392|NCT02216526|Other|Excipial|
1937393|NCT02217800|Drug|saline|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
1937394|NCT02217800|Drug|DG3173|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
1937395|NCT02217800|Drug|octreotide|Eligible patients are to receive a constant 23 hour subcutaneous infusion of saline as placebo comparator and will be randomized in an equal ratio to one of three treatment sequences of doses of 920, 2760 and 5520 µg DG3173 by constant 23 hour subcutaneous infusions in a random sequence followed by three subcutaneous injections of 300 µg octreotide at approximately 8 hour intervals as an active comparator.
1937396|NCT02215668|Procedure|Physical exercise|Exercise muscle stretching and body warming.
1937397|NCT02214017|Device|A videotelephone, TandBerg E20,|
1937398|NCT02214017|Behavioral|Behavioral motivation|Optimization of medical care in diabetes
1937399|NCT02214771|Drug|Fidaxomicin|oral
1937400|NCT02214771|Drug|Treatment for CDI other than fidaxomicin Type|Oral
1937401|NCT02214277|Device|Cerebral Protection System-The SENTINEL System with TAVR|Claret Medical Sentinel Cerebral Protection System is intended for use as an embolic protection system to contain and remove embolic material (thrombus/debris) that may enter the carotid arteries.
1937402|NCT02214277|Device|TAVR|
1937403|NCT02213042|Drug|Lapatinib|Lapatinib is available as 250-mg orange tablets. Subjects randomized to the Lapatinib plus Trastuzumab arm are to receive 1000 mg per day of Lapatinib, so will be instructed to take 4 x 250 mg tablets per day. Lapatinib should be taken either 1 hour (or more) before a meal or 1 hour (or more) after a meal
1937404|NCT02213042|Biological|Trastuzumab|Trastuzumab is a sterile, white to pale yellow, preservative-free lyophilized powder for IV administration. Trastuzumab will be administered on Day 1 of the start of Lapatinib or in conjunction with the first cycle of chemotherapy, as an 8 mg/kg loading dose. Subsequently, Trastuzumab will be administered q3weekly as a 6 mg/kg maintenance dose. At the discretion of the investigator, weekly Trastuzumab can be given in either of the three treatment arms (loading dose 4mg/kg followed by weekly administration of 2mg/kg)
1937405|NCT02213627|Drug|Corifollitropin alfa|
1937406|NCT02213627|Drug|Recombinant FSH|
1937407|NCT02213627|Drug|HP-hMG|
1937409|NCT02211638|Drug|Candesartan Cilexetil|Candesartan Cilexetil tablet
1937412|NCT02211287|Other|'Comfort Care at the End of Life for Persons with Dementia'|A guide for caregivers to provide information on the trajectory of the disease, clinical issues, decision-making processes, and symptom management. The guide is written in a Q&A form and can help answer frequent family questions.
1937413|NCT02211287|Other|Project Nurse - ACP Facilitator|A nurse will receive training in the 'Respecting Choices Facilitator Curriculum' - an online program consisting of a series of six critical thinking modules designed for healthcare professionals who want to enhance their ACP facilitation skills. Local training resources in Northern Ireland will supplement.
1937416|NCT02210247|Drug|EXPAREL|
1937417|NCT02210026|Device|Seattle-PAP|We propose to test the hypothesis that by introduction of variation in airway pressure Seattle bubble nasal continuous positive airway pressure (Seattle-PAP) reduces work of breathing in very low birth weight infants more effectively than standard bubble nasal continuous positive airway pressure.
1937418|NCT02209259|Other|PROMIS Upper Extremity Function|
1937419|NCT02209259|Other|Pain intensity|
1937420|NCT02209259|Other|PROMIS depression|
1937421|NCT02209259|Other|Positive affect negative affect scale (PANAS)|
1937422|NCT02209259|Other|standard PCS|
1937423|NCT02209259|Other|positively-adjusted version of the PCS|
1937424|NCT02209090|Procedure|maternal modified sims position|Maternal Modified Sims position during at least 40 minutes for each 60 minutes
1937425|NCT02209090|Procedure|maternal free positions|At least 40 minutes each hour during labour
1937426|NCT02208752|Other|Exercises|exercise program on strengthening the rotator cuff muscles and motor control of the scapula
1937427|NCT02207244|Drug|Guselkumab 100 mg|100 mg by subcutaneous injection at Weeks 0, 4, 12, and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon randomized treatment group and PASI response (Group I). 100 mg by subcutaneous injection at Weeks 16 and 20. Starting at Week 28, participants will continue to receive guselkumab 100 mg through Week 72 depending upon PASI response (Group II). Starting at Week 28, participants will receive guselkumab 100 mg through Week 72 depending upon PASI response (Group III). All participants will receive guselkumab q8w starting at Week 76 through Week 252.
1937428|NCT02207244|Drug|Placebo for guselkumab|Placebo for guselkumab at Week 16, starting at Week 28, participants will continue to receive placebo for guselkumab through Week 72 depending on randomized treatment group and PASI response (Group I), at weeks 0, 4, 12 and starting at week 28 thereafter up to week 72 depending upon PASI response (Group II), at weeks 0, 4, 12, 16, and 20, starting at week 28 through week 72 depending upon PASI response (Group III).
1937429|NCT02207244|Drug|Adalimumab|80 mg by subcutaneous injection at Week 0, then 40 mg at Week 1 and every 2 weeks (q2w) thereafter through Week 23.
1937430|NCT02207244|Drug|Placebo for adalimumab|Placebo for adalimumab [two 0.8 milliliter (mL) injections] at week 0 followed by one 0.8 mL injection at weeks 1, 3, 5, and every 2 week (q2w) through Week 23 (Group I and II).
1937436|NCT02207569|Device|CoreValve Evolut R TAVR system|
1937437|NCT02207972|Device|Use of Ultrasound|The ultrasound imaging of the lumbar spine in different scanning planes facilitates the identification of the landmarks necessary for appropriate epidural space location in pregnant patients. There are two acoustic windows that are effective for lumbar spine sonographic assessment: one seen on the transverse approach, and the other seen on the longitudinal paramedian approach. The ultrasound single-screen method using the transverse approach of the lumbar spine provides reliable information regarding the landmarks required for labor epidurals. The correct interspace and midline position are identified for correct placement of the CSE analgesia.
1937438|NCT02207972|Procedure|No ultrasound used|Palpation of anatomical landmarks is used for placement of labor analgesia
1937441|NCT02206347|Behavioral|attention focus|
1937442|NCT02205203|Device|Mayo Clinic Anxiety Coach|Mayo Clinic Anxiety Coach is a smartphone application based on cognitive-behavioral treatment for anxiety disorders (i.e., exposure-based therapy) that can be used as 1) a stand-alone treatment requiring minimal provider contact, and 2) an augmentation of face-to-face treatment that increases clinician fidelity and patient adherence to evidence-based treatment. The design of Anxiety Coach is based on evidence and theory suggesting that information and communication technologies (ICTs) are well-suited for encouraging behavior change through 1) scheduled reminders to engage in therapeutic exercises, 2) point of performance support, 3) individually tailored information, 4) real-time symptom assessment, and 5) readily accessible asynchronous communication.
1937443|NCT02205203|Other|Treatment as Usual|In the TAU condition therapists provide treatment consistent with their orientation and clinical judgment. Previous research suggests that TAU will include supportive therapy, relaxation, and cognitive restructuring. The format of treatment will be 6 to 12, 50-minute, face-to-face therapy sessions in the therapist's office, with flexibility to leave the office (e.g., for exposure).
1937445|NCT02204267|Other|prolonged ECG monitoring|Start of long-term ECG immediately after admission to the stroke unit by using a portable ECG recorder for a max. duration of 7 days (or hospital discharge)
1937446|NCT02204267|Device|ECG|
1937451|NCT02202161|Drug|GSK2330672|GSK2330672 will be available in 10 mg, 20 mg, 30 mg, and 90 mg oral solution to be administered BID for 14 days. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
1937452|NCT02202161|Drug|Placebo|Matching placebo will be available as oral solution to be administered for 14 days, BID. Subjects are to drink contents of dosing bottle (45 ml) followed by 2 x 50 ml rinses of bottle and then an additional 95 ml water for a total volume of 240 ml consumed
1937453|NCT02202161|Drug|Sitagliptin|Sitagliptin will be available as film-coated tablets Tablet of 50 mg to be administered orally, BID, for 14 days
1937454|NCT02202161|Drug|Metformin|Metformin will be available as 850 mg white to off-white, film-coated tablets; to be administered BID orally during run-in through Day 14
1937459|NCT02199964|Drug|Cyclosporin 0.05% emulsion|Topical therapy for dry eye
1937460|NCT02199964|Drug|Endura, Refresh artificial tears|Over the counter therapy for dry eye, used 4 times a day
1937461|NCT02199795|Device|Contralaterally Controlled Neuromuscular Electrical Stimulation|
1937462|NCT02199795|Device|Cyclic Neuromuscular Electrical Stimulation|
1937463|NCT02198651|Drug|Adalimumab|Subcutaneously
1937464|NCT02198651|Other|Placebo|Subcutaneously in the double blind period
1937477|NCT02199028|Drug|Hyaluronidase|If assigned to hyaluronidase week, subjects will inject 1 milliliter (ml) Hylenex (150 units/ml) into the catheter hub prior to connecting the insulin infusion set. They will then give a catheter fixed prime of 0.7 cc to clear the infusion set of hyaluronidase. On the morning of day 3 during a Hyaluronidase week, a second dose of 1ml Hylenex (150 units/1ml) will be injected through the catheter hub prior to breakfast using the Duo Infusion Set Tubing. They will then reconnect their pump catheter and give a fixed prime of 0.7 cc to clear the infusion set of hyaluronidase.
1937478|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence Low->High)|
1937479|NCT02197910|Other|Comparisons of two kind of pasta with low or high content of wheat bioactive peptides (sequence High->Low)|
1937480|NCT02198508|Drug|DFX(Deferasirox)|
1937481|NCT02198508|Drug|DFP(Deferiprone)|
1937482|NCT02198014|Other|Manual Therapy|"5 minutes. Thermotherapy shallow to 50 cm away from the knee. 15 minutes. Joint traction, grade I-II. Fixation of distal femur with cinch and manual fixation of proximal tibia. Patient in prone position and the traction is carried out in the submaximal ranges of flexion and extension.
10 minutes. Passive muscle stretching of quadriceps (within the limits of mobility), through compression muscle, passive muscle stretching and relaxation of muscle.
10 minutes. Isometric and resisted exercises of quadriceps, in submaximal ranges, of flexion and extension.
10 minutes. Proprioception exercises with unipodal support, with and without visual support, and posterior destabilization.
10 minutes. Local cryotherapy with ice pack."
1937483|NCT02198014|Other|Educational Physiotherapy|"Theory. Introduction to hemophilia: clinic and treatment; Anatomy and biomechanics of knee; Anatomy of ankle musculature; Function of muscles and haematomas treatment; Haemarthrosis, synovitis and arthropathy: clinical manifestations; Proprioception: definition and importance in hemophilia; and Physical activity and sport: risks and benefits.
Practice: exercises in favor of gravity; active exercises for mobility and pain management; knee proprioception exercises; isometric and isotonic exercises of quadriceps; swimming and cycling technique."
1937484|NCT02196506|Drug|Placebo + ADT|Placebo + ADT Placebo + FDA Approved Antidepressant (ADT)
1937485|NCT02196506|Drug|Brexpiprazole +ADT|Brexpiprazole + ADT Tablet, Oral, 2mg brexpiprazole and FDA Approved Antidepressant (ADT)
1937486|NCT02197481|Procedure|Clamp-Crushing technique|Liver transection during hepatectomy by monopole electronicknife and blood vessel forceps, but without BiClamp forceps
1937487|NCT02197481|Device|BiClamp forceps|liver transection during hepatectomy by BiClamp forceps
1937488|NCT02197377|Device|Group LMA Unique™|The supraglottic airway devices were deflated fully before insertion.
1937489|NCT02197377|Device|Group LMA Supreme™|The supraglottic airway devices were deflated fully before insertion.
1937495|NCT02195284|Device|ELLIPTA|Dry powder inhaler (placebo) with two blister strips. One placebo strip containing lactose monohydrate and a second placebo strip containing lactose monohydrate blended with magnesium stearate
1937496|NCT02195284|Device|DISKUS/ACCUHALER|Placebo inhaler with one blister strip containing lactose monohydrate.
1937497|NCT02195284|Device|MDI|Placebo inhaler containing propellant (1,1,1, 2-Tetrafluoroethane)
1937498|NCT02195284|Device|TURBUHALER|Placebo inhaler containing lactose monohydrate.
1937502|NCT02194933|Drug|Brexpiprazole|Brexpiprazole 2 mg/day, once daily dose, tablet, orally, for 6 weeks - Brexpiprazole 4 mg/day, once daily dose, tablet, orally, for 6 weeks
1937505|NCT02194907|Device|Functional Magnetic Resonance Imaging|Participants in each group will be trained using functional magnetic resonance imaging to regulation brain activity in anterior insula cortex (experimental group) or primary auditory cortex (placebo comparator).
1937506|NCT02193984|Behavioral|Peer support|
1937508|NCT02193373|Other|Osteopathic Manual Medicine|Osteopathic Manual Medicine
1937509|NCT02193373|Other|Sham|Osteopathic Manual Medicine
1937567|NCT02179671|Drug|Gefitinib|Gefitinib once daily followed by MEDI4736
1937568|NCT02179671|Drug|AZD9291|AZD9291 once daily followed by MEDI4736
1937516|NCT02191111|Behavioral|Task-focused facilitation|An external, task-focused facilitation, informed by an evaluation of contextual factors using the Alberta Context Tool (ACT), will be applied to train community pharmacies to develop alternative team processes that enable a greater number of medication management services to be provided to patients with diabetes, hypertension, and/or dyslipidemia.
1937519|NCT02191397|Drug|Bupropion|Bupropion is an extended-release plain creamy white colored tablet which contains bupropion hydrochloride equivalent to 150 mg of bupropion.
1937520|NCT02191397|Drug|Bupropion Matching Placebo|Bupropion hydrochloride matching placebo tablets will be supplied to maintain blinding
1937521|NCT02191397|Drug|Escitalopram|Escitalopram is available as a Swedish orange capsule containing escitalopram oxalate equivalent to 10 mg of escitalopram.
1937522|NCT02191397|Drug|Escitalopram Matching Placebo|Escitalopram oxalate matching placebo tablets will be supplied to maintain blinding
1937523|NCT02191917|Procedure|Respiratory muscle strength measurements by different techniques.|
1937524|NCT02189837|Biological|Evolocumab|Administered by subcutaneous injection
1937525|NCT02189837|Drug|Atorvastatin|Administered by mouth
1937526|NCT02189837|Drug|Placebo to Evolocumab|Administered by subcutaneous injection
1937527|NCT02189837|Drug|Placebo to Atorvastatin|Administered by mouth
1937528|NCT02188875|Behavioral|SMS Text Messages & Fitbit One|The primary aim was to test text-messaging in its basic form to prompt physical activity. A secondary aim was to examine the effects of the Fitbit One.
1937529|NCT02188875|Behavioral|Fitbit One Only|Active controls received a Fitbit One to facilitate self-monitoring (and no text messages)
1937530|NCT02188017|Drug|Acthar gel|Given 80 units daily for 10 days, then randomized to receive either 40 or 80 units twice a week
1937531|NCT02188420|Device|Transcranial Magnetic Stimulation (Magstim)|
1937532|NCT02188407|Drug|Sevoflurane|MAC 3-5 V% during surgery
1937533|NCT02188407|Drug|Propofol|Propofol group (P group)- The group anaesthesied with propofol
1937537|NCT02187913|Dietary Supplement|Resistant starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a snack bar containing resistant starch. The test snack bar will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the snack bar will be consumed four hours later.
1937538|NCT02186938|Device|FloTrac|
1937539|NCT02187237|Device|YOLO TOUCH Low Level Laser|
1937540|NCT02186873|Drug|Placebo|Participants will receive matching placebo.
1937541|NCT02186873|Drug|Golimumab|Participants will receive 2mg/kg of intravenous infusions of golimumab .
1937542|NCT02186210|Device|prewarming|recovery slope StO2
1937544|NCT02185014|Drug|Adalimumab|Subjects will receive the standard every other week dosing regimen until Week 40. Subjects have the ability to dose-escalate to weekly dosing and de-escalate back to every other week.
1937545|NCT02184572|Biological|GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762)|1 dose administered subcutaneously (SC) in the tricep region of left arm.
1937546|NCT02184572|Biological|Merck & Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine|1 dose administered SC in the tricep region of left arm.
1937547|NCT02184572|Biological|Varivax® (Merck & Co., Inc.)|1 dose administered SC in the tricep region of right arm at Visit 1 (Day 0), with either Inv_MMR vaccine or one of the two Com_MMR vaccine lots.
1937548|NCT02184572|Biological|Havrix®|1 dose administered intramuscularly (IM) in the anterolateral region of the right thigh at Visit 1 (Day 0), with either Inv_MMR vaccine or one of the two Com_MMR vaccine lots.
1937549|NCT02184572|Biological|Prevnar 13® (Pfizer Inc.)|1 dose administered IM in the anterolateral region of the left thigh at Visit 1 (Day 0), with either Inv_MMR vaccine or one of the two Com_MMR vaccine lots in US children only.
1937550|NCT02182999|Device|InfiltraLong-Katheter 19G x 420mm, Pajunk|Wound catheter with multiple and laterally aligned holes is inserted through the intact skin via an 16G iv catheter 2 cm proximal-laterally from the proximal end of the dorsomedial skin incision and placed subcutaneously through the wound and medially around the first metatarsal so that the tip projects into the interdigital space 1/2.
1937551|NCT02182999|Drug|NaCl 0,9%|The catheter is connected to the perfusor line filled with saline 0.9% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
1937552|NCT02182999|Drug|Ropivacaine|The catheter is connected to the perfusor line filled with ropivacain 0.2% to allow continuous wound infiltration at a rate of 2 ml/h for 24 hours.
1937553|NCT02182492|Drug|Clarithromycin|Clarithromycin 250 mg tablet once daily for 3 months
1937554|NCT02182492|Drug|Glucocorticoid|Fluticasone propionate nasal spray 200 μg/d for 3 months
1937555|NCT02180659|Drug|sublingual buprenorphine tablets|
1937556|NCT02180659|Drug|Buprenorphine implant|
1937557|NCT02180659|Drug|placebo implants|
1937558|NCT02180659|Drug|sublingual placebo tablets|
1937569|NCT02179671|Drug|Selumetinib+Docetaxel|Selumetinib twice daily + docetaxel, followed by MEDI4736
1937570|NCT02179671|Drug|Tremelimumab|Tremelimumab every 4 weeks followed by MEDI4736
1937573|NCT02180035|Dietary Supplement|Symbiotic|6g sachet composition: Lactobacillus paracasei, Lactobacillus rhamnosus, Lactobacillus acidophillus, Bifidobacterium lactis and fructooligosaccharides. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. The dietary supplement should be taken every day for 6 months.
1937574|NCT02180035|Dietary Supplement|Maltodextrin (placebo for symbiotic)|6g sachet of maltodextrin, a complex carbohydrate. Each patient was instructed to consume two sachets per day, one in the morning and another before bedtime, diluted in 100 ml of filtered or boiled water at room temperature. Placebo should be taken daily for 6 months.
1937575|NCT02180035|Behavioral|Nutritional intervention|Nutritional intervention consists of dietary prescription (nutritional eating plan) for healthy eating based on the Dietary Guidelines for the Brazilian Population and Clinical Manual on Food and Nutrition in HIV-infected Adults Care, both Brazil Ministry of Health guidelines, in addition to nutritional counseling for preexistent clinical conditions.
1937576|NCT02179892|Drug|Bupivacaine Extended-Release Liposome Injection (Exparel)|266mg/30mL of Exparel will be injected via unilateral TAP block
1937577|NCT02179892|Drug|Bupivacaine and Dexamethasone Injection|As a combination injection, 28 ml of 0.375% bupivacaine and 8 mg/2ml of dexamethasone will be injected via unilateral TAP block.
1937578|NCT02179892|Drug|IV Acetaminophen|Intravenous (IV) acetaminophen 1000 mg every 8 hours for 8 doses.
1937579|NCT02179892|Drug|Oral Acetaminophen|Oral acetaminophen 650 mg every 6 hours.
1937580|NCT02178891|Device|extra short implant|
1937584|NCT02178449|Drug|Dexamethasone acetate|
1937585|NCT02178449|Drug|Placebo|
1937586|NCT02178449|Drug|Ropivacaine|
1937587|NCT02177942|Other|Test beverage powder (High Proteins and added micronutrients)|High protein and added Micronutrients at recommended dietary allowance levels
1937588|NCT02177942|Other|Control beverage powder (Low protein and no added micronutrients)|Low protein and no added micronutrients
1937589|NCT02176226|Behavioral|IntelliCare|Behavioral interventions for depression and anxiety via a mobile phone application, IntelliCare.
1937590|NCT02177539|Drug|Cyclopentolate|Traditional scheme. Cyclopentolate, repeat dosage 5 minutes and then wait 40 minutes to retinoscopy. Total wait 45 minutes.
1937591|NCT02177539|Drug|Cyclopentolate+tropicamide+phenylephrine|New scheme. All drugs together and wait 30 minutes for retinoscopy
1937592|NCT02176291|Drug|Buprenorphine|low-dose buprenorphine (range 0.2 mg/day -- 2.0 mg/day)
1937593|NCT02176291|Drug|Placebo|matched placebo
1937596|NCT02175927|Drug|Lansoprazole|antisecretory drug of each quadruple therapy
1937597|NCT02175927|Drug|Bismuth Potassium Citrate|one component of each quadruple therapy
1937598|NCT02175927|Drug|Metronidazole|antibiotic of each quadruple therapy
1937599|NCT02175927|Drug|Amoxicillin|antibiotic of high dose amoxicillin based quadruple therapy
1937600|NCT02175927|Drug|Tetracycline|antibiotic of classical quadruple therapy
1937604|NCT02174913|Device|bispectral index|Bispectral index (BIS) is one of several technologies used to monitor depth of anesthesia.
1937607|NCT02173899|Biological|varicella-1|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
1937608|NCT02173899|Biological|varicella-3|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
1937609|NCT02173899|Biological|varicella-5|Give the second varicella vaccine (a single 0.5 ml) and get blood samples at 0, 35-42 day
1937610|NCT02173704|Biological|Bexsero®|Four doses administered in the anterolateral area of the right or left thigh.
1937611|NCT02173704|Biological|Routine vaccines|Infanrix-IPV + Hib®, Prevenar-13®, Engerix-B®, Priorix® and Varilrix® administered in the anterolateral area of the right or left thigh.
1937612|NCT02170363|Device|Left Ventricular Assist System (LVAS)|Implantation of left ventricular assist device for hemodynamic support
1937613|NCT02168933|Device|308 nm excimer laser|Biweekly treatments with 308 nm excimer laser for a total of 8 weeks
1937614|NCT02168933|Device|Sham laser|Sham laser treatment to the control side.
1937789|NCT02135107|Drug|E3810|E3810 10mg will be administered orally twice daily during the treatment period, and 10mg will be administered twice daily during the maintenance period.
1937615|NCT02168777|Drug|Refametinib (BAY86-9766)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.
In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
1937616|NCT02168777|Drug|Regorafenib (Stivarga, BAY73-4506)|"Refametinib twice daily (b.i.d.) in combination with intermittent regorafenib once daily (q.d.) at the assigned dose level.
In Phase 1b dose escalation, regorafenib will be administered in a 3-weeks-on / 1-week-off schedule except in one cohort, that uses regorafenib 2 weeks on / 2 weeks off regimen (dose level -2). In Phase 2, the recommended Phase 2 dose (RP2D) for refametinib-regorafenib combination therapy will be used."
1937617|NCT02168543|Drug|Alendronate|
1937618|NCT02168543|Drug|Placebo|
1937619|NCT02168309|Drug|Labetalol|Titrate up for blood pressure control
1937620|NCT02168309|Drug|Nifedipine|Titrate up to achieve blood pressure control
1937625|NCT02166424|Dietary Supplement|Omega-3 polyunsaturated fatty acids|
1937626|NCT02166424|Dietary Supplement|Olive oil|
1937627|NCT02166619|Device|tDCS + physical therapy|"Bihemispheric tDCS involves application of very low-amplitude direct currents (2 mA or less) via surface scalp electrodes. It produces a sub-sensory level of electrical stimulation wich remains imperceptible by most people during application. In a small percentage of patients, it may cause minimal discomfort with a mild tingling sensation, which usually disappears after a few seconds. Depending on the polarity, tDCS can increase or decrease corticomotor excitability. Anodal tDCS is able to facilitate neurons depolarization - increasing cortical excitability - while, on the other hand, cathodal tDCS hyperpolarizes the resting membrane potential, reducing the neuronal firing and the cortical excitability.
Other: Physical Therapy"
1937631|NCT02165735|Other|Patient Empowerment and Autonomy Training|Participants will be given supports to address patient autonomy, competence and development of provider-patient relationships.
1937632|NCT02165735|Behavioral|Patient Empowerment and Autonomy Training|
1937634|NCT02164929|Procedure|TAP block|
1937635|NCT02164929|Procedure|Epidural|
1937636|NCT02164929|Procedure|Paravertebral block|
1937637|NCT02164929|Drug|Acetaminophen 1g IV|
1937638|NCT02164929|Drug|Dexamethasone 4mg|
1937639|NCT02164929|Drug|Midazolam up to 2mg|
1937640|NCT02164929|Drug|Propofol 1-2.5 mg/kg|
1937641|NCT02164929|Drug|Sevoflurane to keep a bispectral index of between 40-60|
1937642|NCT02164929|Drug|Local infiltration with 10 mL of plain ropivacaine 0.25%|
1937643|NCT02164929|Drug|Lidocaine|1.5% lidocaine
1937644|NCT02164929|Drug|Epinephrine|1:200,000 epinephrine
1937645|NCT02164929|Drug|Hydromorphone|400-800 mcg Hydromorphone will be given preoperatively
1937646|NCT02164318|Other|Handgrip training|
1937647|NCT02164318|Drug|Nitroglycerin ointment|
1937648|NCT02164032|Drug|Intranasal insulin administration|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
1937649|NCT02164032|Drug|Insulin Dilution Buffer (Novo Nordisk)|intranasal insulin (40 IE) Actrapid (100IE/mL); two 0.1 ml puffs per nostril) or placebo (insulin dilution buffer Novo Nordisk; two 0.1 ml puffs per nostril) four times a day (in total 160 IE Actrapid per day) before each main meal and before going to bed. 40 IE IN insulin enhances insulin concentration in the CSF without any changes in systemic insulin and glucose concentration, and no risk for hypoglycemia
1937650|NCT02164032|Other|1H magnetic resonance spectroscopy|1H MR spectroscopy and imaging will be performed on the on on the 3.0-T Tim Trio System (Siemens Erlangen Germany). MR Spectroscopy and imaging measurements will last no more than 90 minutes all together.
1937651|NCT02163837|Drug|rifaximine|
1937654|NCT02163538|Device|articulating Enseal|Vessel-sealing device used for laparoscopic hysterectomy.
1937655|NCT02163538|Device|Ligasure device|Vessel-sealing device used for laparoscopic hysterectomy.
1937656|NCT02163486|Device|Group U (UNIQUE)|Before LMA-Unique was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the LMA-Unique cuff.
1937657|NCT02163486|Device|I-GEL|"Before I-gel was inserted, to lubricate the surface in contact with the palate a water-based gel without local anesthetic was applied to completely cover the I-GEL cuff.
I-GEL: K-Y Jelly® is a registered trademark of Johnson and Johnson Inc"
1937730|NCT02145390|Procedure|Transurethral Resection of the Bladder Tumor & Cystoscopy|"TURBT and Cystoscopy will be performed by the participating urologist prior to start of neoadjuvant chemotherapy, per the study protocol:
Cystoscopic evaluation
Bimanual examination under anesthesia,
Transurethral resection of the bladder tumor,
Biopsy of the prostatic urethra including both mucosa and stroma using a resection loop."
1937663|NCT02161536|Device|Motus GI CleanC Device|
1937664|NCT02161250|Dietary Supplement|Resistant Starch|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing resistant starch. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
1937665|NCT02161250|Dietary Supplement|Control|Each subject will complete 2 testing days (randomized and crossover design). On each of 2 test days, subjects will arrive at the Purdue Clinical Research Center after a 12-h fast and will consume a beverage containing maltodextrin. The test beverage will be consumed along with a standard meal provided at the start of the test day. A second standard meal that does not contain the beverage will be consumed four hours later. Below is what will be included in the test bar.
1937666|NCT02161120|Other|Traditional Finnish rye bread|
1937667|NCT02161120|Other|Low FODMAP rye bread|
1937668|NCT02161055|Drug|Insulin|"Insulin dose was selected in accordance with the Yale Insulin Infusion Protocol.
• Amount of insulin (u) = [fasting blood glucose (mmol/L) × 18-100] × 10 × body weight (kilogram) × 0.6 ÷ 1000 ÷ 2"
1937670|NCT02159976|Drug|Pantoprazole|
1937671|NCT02159976|Drug|Amoxicillin|
1937672|NCT02159976|Drug|Clarithromycin|
1937673|NCT02159976|Drug|Metronidazole|
1937674|NCT02159976|Drug|Tetracycline|
1937675|NCT02159976|Drug|Bismuth|
1937679|NCT02159287|Drug|Enoxaparin|1 mg of enoxaparin per kilogram of body weight subcutaneous every 12 hour
1937680|NCT02159287|Drug|Heparin|1000 unit per hour continuous intravenous infusion of heparin sodium
1937681|NCT02158975|Drug|MLN9708|
1937687|NCT02158364|Drug|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)|Freeze-dried live attenuated measles and rubella combined vaccine (Schwarz FF-8 strain/TO-336 strain)
1937688|NCT02157519|Other|Mobile Application Intervention|Participants assigned to the intervention group will receive the mobile application intervention for approximately three months after enrollment. The mobile app intervention will consist of completing an initial chemotherapy treatment plan, responding to weekly assessments regarding symptoms, side effects, and medication adherence, as well as receiving personalized feedback about responses. The results from patient surveys within the app will also be transmitted in real-time to the participants' oncology clinicians via a HIPAA-compliant, secure email.
1937689|NCT02156908|Drug|D-serine|D-serine 60 mg/kg
1937690|NCT02156908|Drug|Placebo|
1937914|NCT02111187|Drug|LDE225|
1937691|NCT02157168|Behavioral|Community health worker|"Community health workers (CHWs) in Hispanic communities, often referred to as promotoras, are members of the community who use resource sharing, partnership development, education, outreach, health promotion, and disease prevention strategies to improve the health of their communities.
The intervention itself consists of a 45-minute one-on-one presentation and tailored planning session delivered by a CHW in a community setting of the new member's choosing. Presentations (in English or Spanish) will be delivered using a tablet computer or a hand held flipchart. Two booster telephone interactions will be performed at 2 and 4 months."
1937694|NCT02156037|Behavioral|Diabetes Dashboard Intervention|The Diabetes Dashboard Intervention Condition involved a program of five, in-person, one-on-one diabetes education and behavior change visits with a diabetes nurse or diabetes dietician, scheduled at baseline, two weeks, one month, three months, and six months post-enrollment.
1937695|NCT02156037|Behavioral|Usual Diabetes Care|The UDC condition was delivered by four bicultural, bilingual diabetes nurses and diabetes dietitians who comprised the clinical site's long-standing, in-house diabetes program.
1937699|NCT02154763|Drug|Ropivacaine|
1937700|NCT02154152|Drug|Homoeopathic Medicine causticum 200c|
1937701|NCT02153723|Drug|Glatiramer Acetate|
1937706|NCT02151851|Biological|Certolizumab Pegol|"Active substance: Certolizumab Pegol
Pharmaceutical Form: Prefilled syringes
Concentration: 200 mg/ml
Route of administration: Subcutaneous injection"
1937707|NCT02151851|Drug|Methotrexate|"Active substance: Methotrexate
Pharmaceutical form: Tablet
Concentration: Maximum dose 10 mg per week
Route of administration: Oral"
1937708|NCT02151851|Other|Placebo|"Active substance: Placebo
Pharmaceutical form: Prefilled syringes
Concentration: 0.9 % saline
Route of Administration: Subcutaneous injection"
1937717|NCT02150330|Drug|Dehydroepiandrosterone (DHEAS)|
1937718|NCT02147574|Procedure|Anti-peristaltic ileosigmoid anastomosis|1,Laparoscope Sub-total Colectomy： After the entire colon mobilization,the ileum is resected at 10cm from ileocecum and 10-15cm colon up to peritoneal reflection is reserved. The ileocolic artery should be reserved carefully.2, Intestinal tract reconstruction: The terminal ileum is turned over 180°in anti-clockwise direction along the superior mesenteric vein long axis. To avoid the small mesenteric torsion , we should turn the broken edge towards inside. The terminal ileum and 10-15cm colon anastomose in anti-peristaltic direction,the anastomotic length is 8-10 cm.3, Sewn the space between anastomotic Intestine and posterior peritoneum. A drain is placed in the abdominal cavity and another one is placed in anal canal.
1937719|NCT02148848|Drug|Risedronate|Take risedronate 35 mg orally every week
1937720|NCT02148835|Other|Sausage: Triomeg|Commercial sausages enriched with 330 - 510 mg EPA+DHA / 100 g Approximate average composition of active product per 80 g Sausage (Triomeg): 250 mg EPA+DHA as ethyl-ester Energy content 500 kJ (120 kcal), protein 12 g, Carbohydrates 0.8 g, total fat 9 g, of which 2.8 g saturated fatty acids, 4.5 g monounsaturates, 1.4 g polyunsaturates. sodium 0.66 g.
1937721|NCT02148835|Other|Sausage: Control|Control sausage: as active, but no EPA+DHA ethyl-ester.
1937722|NCT02147613|Other|High intensity interval training|3 days per week at 85-90% peak heart rate (4x4 bouts) for 1 month (12 sessions of exercise)
1937723|NCT02147613|Other|Moderate intensity exercise training|3 days/week, 30 mins at 70% Peak heart rate for 1 month (12 sessions of exercise)
1937724|NCT02147587|Drug|Tofacitinib|5 mg twice daily of tofacitinib with background methotrexate for 12 weeks
1937725|NCT02147587|Drug|Placebo|Placebo tablets twice daily with background methotrexate for 12 weeks
1937726|NCT02147353|Drug|Sinecatechins 15% Ointment|Following cryotherapy, half of the subjects will be randomized to treatment with sinecatechins ointment twice daily starting one week after cryotherapy (Week 1).
1937727|NCT02147353|Drug|Cryotherapy alone|Cryotherapy will be standardized in all subjects and for all treated lesions.
1937728|NCT02145507|Drug|SOLX|SOLX is regulated as a drug but is not intended to provide a direct therapeutic benefit.
1937729|NCT02144519|Behavioral|Healthy Eating and Physical Activity|Create partnerships with ASPs to help facilitate changes in programming to meet the National Afterschool Alliance's HEPA Standards.
1937788|NCT02135107|Drug|E3810|E3810 10mg will be administered orally twice daily during the treatment period (unblinded), and 10mg will be administered once daily during the maintenance period (double-blind).
1937731|NCT02145390|Radiation|Intensity Modulated Radiation Therapy|"For subjects with complete response to neoadjuvant chemotherapy. Subjects will receive 25 daily fractions (5 weeks) of radiation therapy for 5 days a week (Monday to Friday) except on weekends or holidays, when remaining fractions will be added to the end of treatment. The overall schema is for IMRT based radiation to the entire bladder, prostate (in men) and the pelvic lymph nodes:
Pelvic lymph nodes: 45 Gy in 25 fractions at 1.8 Gy per fraction.
Whole bladder and prostate: 50 Gy in 25 fractions at 2.0 Gy per fraction.
Tumor boost area: 60-65 Gy in 25 fractions at 2.4-2.6 Gy per day
Final boost dose will be determined at the discretion of the treating physician based on normal tissue exposure and volume."
1937732|NCT02145390|Behavioral|Expanded Prostate Cancer Index Composite Short Form 12|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
1937733|NCT02145390|Behavioral|International Prostate Symptom Score|Quality of life questionnaire to be administered to subjects at intervals defined by the study protocol.
1937734|NCT02144701|Dietary Supplement|Lactobacillus rhamnosus GG|Given PO
1937735|NCT02144701|Other|laboratory biomarker analysis|Correlative studies
1937736|NCT02144675|Drug|choline magnesium trisalicylate|Given PO
1937737|NCT02144675|Drug|idarubicin|Given IV
1937738|NCT02144675|Drug|cytarabine|Given IV
1937739|NCT02144675|Other|laboratory biomarker analysis|Correlative studies
1937740|NCT02144506|Other|T&E|
1937741|NCT02144506|Other|OTAGO|
1937742|NCT02143700|Other|Cognitive assessment|Patients are going to be assessed regarding the outcome measures
1937743|NCT02142829|Drug|EXPAREL|
1937744|NCT02142829|Drug|On-Q Pain Ball|bupivacaine HCl 0.25%
1937745|NCT02141386|Other|PACR (Plasticity-based, Adaptive, Computerized Cognitive Remediation)|
1937746|NCT02141113|Drug|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)"
1937747|NCT02141113|Drug|Guanfacine Hydrocholride|"mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)
mg Guanfacine Hydrochloride (orally)"
1937748|NCT02140476|Device|Bipolar vessel sealing and cutting device|This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
1937749|NCT02140476|Procedure|Conventional thyroidectomy|Tie and suture technique. This device will be used in half of the patients with thyroid goiter and half of the patients with papillary thyroid cancer.
1937750|NCT02140762|Biological|MenABCWY|Effectiveness
1937751|NCT02140762|Biological|MenACWY|Effectiveness
1937752|NCT02140112|Biological|Trichuris suis ova|
1937753|NCT02140112|Other|Placebo|
1937754|NCT02139969|Device|GreenLight XPS Laser System|
1937755|NCT02139124|Drug|Placebo|Oral placebo capsule
1937756|NCT02139124|Drug|PRC-063 25 mg|Oral 25 mg capsule - active
1937757|NCT02139124|Drug|PRC-063 45 mg|Oral 45 mg capsule - active
1937758|NCT02139124|Drug|PRC-063 70 mg|Oral 70 mg capsule - active
1937759|NCT02139124|Drug|PRC-063 100 mg|Oral 100 mg capsule - active
1937760|NCT02138864|Radiation|18F-FP-(+)-DTBZ|no available
1937761|NCT02137798|Device|Radio-frequency catheter ablation|Radio-frequency atrial fibrillation catheter ablation includes circumferential PV isolation and voltage-map guided substrate modification, which means low voltage zone (amplitude < o.5 mV) will also be ablated.
1937762|NCT02138578|Radiation|SBRT|
1937763|NCT02138578|Radiation|RFA|
1937764|NCT02138539|Other|Herbal depigmenting agent (Epionce)|A two product herbal pigmentation reducing regimen is applied twice a day to either the left or right side of the face for a duration of 4 months.
1937765|NCT02138539|Drug|Hydroquinone|Hydroquinone 4% is applied twice a day to either the left or right side of the face for a duration of 4 months.
1937766|NCT02138227|Behavioral|Assisted CEaD Condition|In the assisted condition, participants use the CEaD training materials supplemented with simulators to practice the communication skills. OPO requesters will be assisted by having the CEaD DVD supplemented through working the scenarios with live simulated patients who will be trained to act out the scenarios with the OPO requesters and provide feedback.
1937767|NCT02138227|Behavioral|Autonomous CEaD Condition|In the autonomous condition, participants view the CEaD training materials on a DVD along with a self-training guide.
1937772|NCT02136693|Drug|Psyllium fiber|3.5 g /day of pure Psyllium fiber for 180 days after STARR
1937773|NCT02136693|Drug|Placebo|3.5 g /day of inert compound for 180 days after STARR
1937774|NCT02136680|Other|CASA Education|Basic palliative competencies for outpatient use.
1937775|NCT02136446|Device|EchoGlo Nerve Block Catheter|Catheter used for a paravertebral anesthesia block
1937776|NCT02136446|Device|Pajunk® Nerve Block Catheter|Nerve Block Catheter
1937777|NCT02136420|Drug|Promethazine|Subject receives promethazine
1937778|NCT02136420|Behavioral|Hyper gravity training|Subject receives hypergravity training before testing
1937779|NCT02136420|Drug|Placebo|Placebo
1937780|NCT02136420|Behavioral|No hypergravity training|Subjects do not receive normal Earth gravity
1937781|NCT02135601|Other|Water colonoscopy|Colonoscopy will be performed without medications and aided by water infusion in-lieu of air insufflation during insertion of the colonoscope. The water infusion involves putting warm sterile water into the colon to open up the colon for advancement of the colonoscope until the end of the colon (cecum) is reached. The water is delivered through scope irrigation channel by an infusion pump equipped with a foot switch which will be controlled by the endoscopist. Infused water used to cleanse residual fecal matter will be suctioned as needed to clear the colonic lumen.
1937790|NCT02135107|Drug|E3810|E3810 20mg will be administered orally twice daily during the treatment period, and 10mg will be administered once daily during the maintenance period.
1937791|NCT02135107|Drug|E3810|E3810 20mg will be administered orally twice daily during the treatment period, and 10mg will be administered twice daily during the maintenance period.
1937792|NCT02134951|Drug|Ketamine|intravenous infusion of saline solution with ketamine
1937793|NCT02134951|Drug|Normal saline|Normal saline will be used for placebo in this group
1937798|NCT02132910|Other|RESTORE Intervention|
1937800|NCT02131324|Drug|DFD06 Cream|
1937801|NCT02131324|Drug|Comp01|
1937802|NCT02131805|Radiation|Electronic Skin Surface Brachytherapy|
1937803|NCT02131805|Behavioral|Quality of life assessment|
1937809|NCT02131155|Drug|Placebo|Once daily
1937810|NCT02131155|Drug|Afatinib|Once daily
1937811|NCT02130570|Other|Multi-Model Intensive Discharge Intervention|"Inpatient medication safety interventions
Inpatient discharge advocate
Structured visiting nurse (VNA) appointments
Post-discharge phone call by primary care personnel within 2 business days of discharge
Structured post-discharge clinic appointment with PCP and other PCMH personnel within 2 weeks of discharge
Improved communication between inpatient and primary care teams
High-risk patients will receive additional interventions as needed:
Home pharmacist visit
Enrollment in the Partners integrated Care Management Program (iCMP)
Enrollment in telemedicine programs for patients with CHF
Palliative care consultation regarding goals of care
Novel health information technology to facilitate communication and transfer of clinical information"
1937814|NCT02129738|Device|LoFric catheters|LoFric single use catheters to be used 4-6 times daily for 4 weeks.
1937817|NCT02129894|Device|abdominal Binder|placement of abdominal binder
1937819|NCT02128828|Drug|cenicriviroc|cenicriviroc given once daily for 24 weeks; number of pills dependent on recommended modifications based on patient's other antiretroviral medications and certain other medications anticipated to interact with cenicriviroc
1937820|NCT02127710|Drug|AZD6094|AZD6094 is a potent and selective small molecule cMet kinase inhibitor.
1937821|NCT02127632|Device|Endotracheal Tube|ETT:Ruschelit, Teleflex Medical Snd. Bhd. Malaysia. Ref:112482
1937822|NCT02127632|Device|Laryngeal Mask Airway-Supreme|"Before LM-S was inserted, to lubricate the surface in contact with the palate a water-based K-YTM gel (Johnson & Johnson Ltd. Maidenhead, UK) without local anesthetic was applied to completely cover the LM-S cuff. Depending on the patient's body weight For <50 kg, no. 3 Between 50-70 kg, no. 4 Between 70-100 kg, no. 5 LM-S (The Laryngeal Mask Company Limited, Singapore) was inserted.
Other Names:
LM-S (The Laryngeal Mask Company Limited, Singapore) serial number: 175030 lot: hmabw7"
1937824|NCT02125669|Procedure|Laser treatment|Pulsed dye laser 595nm
1937825|NCT02125669|Device|SHAM-Treatment|using the pulsed dye laser (PDL) laser without releasing a pulse
1937826|NCT02124850|Drug|Motolimod|
1937827|NCT02124850|Drug|Cetuximab|
1937828|NCT02124850|Drug|Nivolumab|
1937829|NCT02124889|Behavioral|Weekly Internet surveys|Subjects in this arm will receive weekly Internet surveys asking them how their treatment is working, how often they took the medication, and how easy it was to use the medication.
1937915|NCT02109484|Biological|P2VP8 Subunit Vaccine 10mcg|10 mcg
1937916|NCT02109484|Biological|P2VP8 Subunit Vaccine 30 mcg|30 mcg
1937917|NCT02109484|Biological|P2VP8 Subunit Vaccine 60mcg|60 mcg
1937918|NCT02109484|Biological|Placebo|
1937832|NCT02124265|Drug|CeraLyte 90|"This is a prospective pilot study of patients with moderate-major burn wounds (20-65% TBSA).
Patients who meet inclusion/exclusion criteria will be enrolled in the study upon admission to the Burn Unit.
Fluid requirements will be calculated according to the Parkland Formula (4 cc/kg/% Total Body Surface Area) administered over 24 hours since time of injury.
5. Patients will be monitored according to standard of care.
a. If gastric residuals are >300cc, ORT will be stopped and only IV fluid resuscitation will be used."
1937833|NCT02122796|Other|Acupuncture|Acupuncture involves inserting thin, sterile needles into the skin at certain points in the body.
1937834|NCT02123329|Behavioral|Pharmacist delivered smoking cessation program|"The first session will be time-intensive taking around 30 minutes. In this session, the study pharmacist will facilitate the participant's preparation to quit. The participant will select a quit date within the next 2-4 weeks. The pharmacist will discuss with the participant the benefits of smoking cessation and will provide him or her with tailored behavioral and lifestyle strategies.
To prevent nicotine withdrawal symptoms, the participant will be offered nicotine replacement therapy (NRT) The first follow-up session will be scheduled after 1 week of the participant's quit day and will take around 20 minutes. In this session, the pharmacist will determine the participant's smoking status and assess the NRT tolerability.
• If the participant fails to quit smoking, the pharmacist will carefully review the participant's experience during the attempt to quit and will work through the identified problems"
1937835|NCT02123329|Other|Control arm (i.e: regular care)|Participants in the control group will receive 5-10 minutes of unstructured brief smoking cessation advice by the pharmacist. In addition they will be provided with educational materials about smoking cessation and will be offered nicotine replacement therapy (NRT).
1937836|NCT02123251|Behavioral|Financial Incentives|This intervention will examine the effects of incentives on improving adult diabetic Medicaid beneficiaries' health outcomes and reducing associated costs through healthy behavior changes in their diabetes self-management. Incentives focus on improving self-management of diabetes, compliance with ADA recommended preventive, treatment and management measures, primary biometric measures of diabetes, and eliminating barriers to a healthy lifestyle
1937837|NCT02123251|Behavioral|Control|
1937838|NCT02121834|Drug|LY3050258|
1937839|NCT02121834|Drug|Placebo|
1937840|NCT02121808|Procedure|NIPPV|"Ventilation: non-invasive positive pressure ventilation (NIPPV)
Positive end-expiratory pressure: 10 cmH20 Pressure support: 5 - 20 cm H2O for tidal volume of 10 mL / kg (ideal body weight)"
1937841|NCT02121808|Procedure|Tidal volume|Tidal volume spontaneous ventilation, no assistance.
1937842|NCT02122146|Drug|PF-06664178|Part 1 - PF-06664178 will be administered intravenously every 21 days in cohorts of 2 or more patients starting at a dose of 0.15 mg/kg. Increases in dose will continue until MTD is determined.
1937843|NCT02122146|Drug|PF-06664178|Part 2 - patients with select tumor types (Non Small Cell Lung Cancer ovarian cancer, and breast cancer ) will be treated at the MTD selected in Part 1.
1937844|NCT02121912|Device|FPH Pilairo Q CPAP mask|CPAP nasal-pillow mask
1937845|NCT02121912|Device|Any other market released nasal or nasal-pillow CPAP mask|Any other market released nasal or nasal-pillow CPAP mask
1937846|NCT02122237|Device|Cefaly tDCS|Cefaly tDCS (transcranial direct current stimulation) is able to modify cortical excitability, in particular cathodal tDCS decreases it. The side effects of tDCS are minor, especially sensations of itching and scalp paresthesias.
1937847|NCT02120716|Behavioral|Health Check-Up for Expectant Moms|Participants randomly assigned to the treatment condition will receive a 60-minute brief intervention on the Tablet PC after the baseline assessment. The software will personalize the intervention content based on the current risk status of each participant and will include a plan addressing endorsed risks. Within one month of baseline, there will be a 15-20 minute, computer-delivered booster session reviewing the personalized plan and identifying barriers in the reduction or risks and/or meeting the goals in the plan.
1937848|NCT02121366|Procedure|EUS-guided ethanol ablation|Diagnostic evaluation for suspected insulinoma is performed by cytology or immunohistochemistry. EUS-FNA is performed to obtain samples. After puncturing with the needle, ethanol under the guidance of EUS was injected into the lesion. The amount of ethanol is administrated according to the size of lesion.
1937849|NCT02121301|Drug|SkQ1|
1937850|NCT02121301|Drug|Placebo SkQ1 (Vehicle)|
1937851|NCT02120950|Drug|Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)|Eylea is administered as an intravitreal injection
1937852|NCT02120950|Other|Visudyne|Photodynamic therapy is a combined therapy of drug (Visudyne) applied to reinforce the action of a device (laser)
1937855|NCT02119936|Device|Heart Rate Variability Biofeedback, emWave too|
1937856|NCT02119936|Behavioral|use of emWave Technology (Heartmath)|
1937857|NCT02119884|Drug|Terlipressin|Patients in the terlipressin group receive a single IV injection of 2 mg of terlipressin and a continuous IV infusion of normal saline.
1937858|NCT02119884|Drug|Octreotide|Patients in high dose octreotide receive a single injection of 100μg octreotide and continuous IV infusion of 50 μg/h of octreotide.
1937859|NCT02119871|Procedure|Bilateral Open Pleurae|Both pleurae are opened Right pulmonary vein drainage
1937860|NCT02119871|Procedure|Right Pleura Open|Right pleura open Left ventricular apical drainage
1937861|NCT02117427|Biological|MDGN201 TARGTEPO|Erythropoietin secreted by TARGTEPO transduced with MDGN201
1937862|NCT02119351|Device|ViaValve™ Safety IV Catheter|Safety peripheral IV catheter with a blood control feature
1937863|NCT02119351|Device|ProtectIV® Plus Safety IV Catheter|Safety peripheral IV catheter with no blood control feature
1937864|NCT02118428|Device|Mirasol-treated Whole Blood|Fresh Whole Blood treated with the Mirasol Pathogen Reduction Technology System for Whole Blood
1937865|NCT02118428|Other|Untreated Whole Blood|Fresh Whole Blood for transfusion
1937919|NCT02109484|Biological|Cohort B2 P2VP8 D1|second highest tolerated dose from Cohort B1
1937866|NCT02117999|Device|Transepithelial corneal cross-linking using iontophoresis|The procedure involves a constant current source and two electrodes. The active electrode is a bath tube, which includes a stainless steel grid, placed into the cup at a minimal distance from the cornea. The reservoir is filled with dextran-free, hypotonic riboflavin-5-phosphate solution. The generator applies a constant current of 1mA for a preset period of 5 min. After the riboflavin administration by iontophoresis, the cornea is irradiated using a UVA lamp of 10mW/cm2 for 9 minutes.
1937867|NCT02117999|Device|Standard corneal cross-linking|In the standard CL, the epithelium is mechanically removed. Then, a solution of riboflavin is instilled each minute for 30 minutes. Corneas are irradiated using a UVA lamp of 3mW/cm2 for 30 minutes.
1937868|NCT02117674|Procedure|standard forward-viewing colonoscopy|examination of the colon with a conventional colonoscope
1937869|NCT02117674|Procedure|full-spectrum colonoscopy|examination of the colon with full-spectrum colonoscope
1937870|NCT02117674|Procedure|right colon retroflexion|examination of the right colon with scope retroflexion (both with conventional and fuse scope)
1937871|NCT02117596|Drug|Sirolimus|"Tacrolimus (Prograf®) At 6 months post-transplantation, patients will have Prograf® tapered by 25% per week such that they will be off of this medication by 7 months post-transplantation.
Sirolimus (Rapamune®):
At 6 months post-transplantation, all patients will be administered Sirolimus at a dose of 1.65-2.79 mg/m2/day as a tablet or liquid (administered q 12 hours)."
1937872|NCT02117180|Other|FODMAP's diet|The safety and efficacy of a low FODMAP diet will be evaluated in a convenience sample of children with functional gastrointestinal disorders, over a 6 week intervention period.
1937878|NCT02115828|Drug|Vismodegib|
1937879|NCT02115113|Drug|Everolimus|"Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration.
At 5 months after transplant, doses will be adjusted to achieve C-0h blood trough level target ranges 6-10 ng/mL.
Tacrolimus withdrawal should be completed by 6 months after transplant."
1937880|NCT02115113|Drug|Everolimus|Commercial product labeled according to local requirements will be provided as 0.25 mg and 0.75 mg tablets for oral administration. At 5 months after transplant, doses will continue to be adjusted to achieve C-0h blood trough level target ranges 3-8 ng/mL.
1937881|NCT02115113|Drug|Tacrolimus|Commercial product labeled according to local requirements will be provided as 0.5 mg, 1.0 mg and 5.0 mg capsules for oral administration. At 5 months after transplant, doses will continue to be adjusted to achieve C-0h blood trough level target ranges 3-5 ng/mL.
1937882|NCT02114385|Biological|V503|
1937883|NCT02114385|Biological|GARDASIL|
1937884|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
1937885|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
1937886|NCT02114203|Drug|placebo for PDE9i|oral dose, every 12 hours for 28 days
1937887|NCT02114203|Drug|PDE9i|oral dose, every 12 hours for 28 days
1937905|NCT02111993|Device|Standard Defibrillation Testing|Once the ICD is implanted, Standard Defibrillation Threshold (DFT) testing will begin. A low energy shock will be delivered to the heart at the peak of the T wave to induce ventricular fibrillation (VF). Once VF is induced, a rescue shock of 25J will be delivered to restore sinus rhythm. This process will be repeated once more after 5 minutes.
1937906|NCT02111993|Device|Upper Limit of Vulnerability Testing|Once the ICD is implanted, Upper Limit of Vulnerability (ULV) testing will commence. An 18 J shock will be delivered will at different points from the t-wave. If VF is not induced with any of these shocks, then the ULV will be considered to be 18J. If VF is induced, then a 25 J rescue shock will be delivered.
1937907|NCT02111980|Device|RF Assure Scanning|CIED and temporary pacemaker patients will be scanned with RF surgical sponge detection wand and mat as well as with and without the RF sponge. The scanning will only be conducted on the device scheduled for removal. Patients will have device interrogated before and after scanning (for CIEDs) to determine if there have been any clinically significant changes in programming or settings due to scanning with RF technology. Vitals will be monitored and recorded before, during, and after scanning.
1937920|NCT02109484|Biological|Cohort B2 P2VP8 D2|Highest tolerated dose from Cohort B1
1937921|NCT02110758|Other|Patient-Centered Oncology Care|Patient-Centered Oncology Care addresses six domains: track & coordinate referrals, provide access and communication, identify and coordinate patient populations, plan and manage care, track & coordinate care, and measure and improve performance.
1937922|NCT02110693|Other|Tablet administration|Participant will self-administer substance use screening instrument on a tablet computer.
1937923|NCT02110693|Other|Interviewer administration|Interviewer will administer the substance use screening instrument
1937924|NCT02110485|Other|Patient Activation Tool|An interactive tablet based tool designed to (1) teach patient activation strategies; (2) provide evidence-based information about a health condition, (3) help patient/caregiver dyads recognize and clarify their own values, and (4) provide guidance in decision making and communication among those involved with the decision.
1937925|NCT02109861|Drug|Melphalan|A microdose of 2 mg/m2 iv Melphalan (1% of standard dose) is given two hours prior to planned standard dose Melphalan
1937926|NCT02109861|Drug|Bortezomib|A microdose of 0.013 mg/m2 iv Bortezomib (1% of standard dose) is given two hours prior to planned standard dose Bortezomib
1937927|NCT02109861|Drug|Dexamethasone|A microdose of 0.4 mg iv Dexamethasone (1% of standard dose) is given two hours prior to planned standard dose of Dexamethasone
1937928|NCT02109042|Drug|Blosozumab|Administered subcutaneous (SC)
1937932|NCT02106390|Biological|Meningococcal group B Vaccine, rMenB+OMV NZ|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
1937933|NCT02106390|Biological|Meningococcal ACWY Conjugate Vaccine, MenACWY|4 doses administered intramuscularly on Days 1, 61, 121 and 301 with blood draw visits at Days 1, 151, 301 and 331 and who will receive reminder calls at 2 and 4 days after each vaccination visit and safety calls on Days 201 and 251.
1937934|NCT02107092|Drug|Sodium Zirconium Cyclosilicate|Oral 10g once daily with breakfast for 11 months.
1937935|NCT02106598|Drug|fluorescent cRGDY-PEG-Cy5.5-C dots|
1937936|NCT02106481|Drug|Femoral Nerve Catheters|"Catheter will be bolused with 0.5 % ropivacaine around the femoral nerve and occlusive dressing applied over the catheter.
Patients with CFNB will receive ropivacaine 0.2% infusion (the infusion rate will be dependent on the clinical judgement of the anaesthesiologist)"
1937937|NCT02106481|Drug|Single Shot Femoral Nerve Blocks|The group with SSFNB will receive a femoral nerve block before the surgery in the pre-operative area guided by a nerve stimulator and ultrasound. A bolus of 0.5 % ropivacaine will be injected around the femoral nerve.
1937938|NCT02106325|Drug|Ketamine|IV of Ketamine (.25mg/kg)
1937939|NCT02106325|Drug|Diphenhydramine|Intravenous Diphenhydramine (25mg) at the time of presentation to Emergency Department
1937942|NCT02105116|Drug|fludarabine phosphate|Given IV
1937943|NCT02105116|Drug|cytarabine|Given IV
1937944|NCT02105116|Biological|donor lymphocytes|Undergo infusion of donor lymphocytes
1937945|NCT02105116|Other|laboratory biomarker analysis|Correlative studies
1937946|NCT02105116|Drug|G-CSF|Given IV
1937948|NCT02104505|Drug|Gamma Tocopherol 700 mg capsules,|2 capsules QD
1937949|NCT02104505|Drug|Placebo|Safflower oil capsules
1937950|NCT02104414|Drug|Exparel|266 mg/20mL Exparel (to be diluted with 10 mL sterile saline to make 30 mL)
1937951|NCT02104414|Drug|Bupivacaine HCl with Epinephrine|75mg/30mL 0.25% Bupivacaine HCl with epinephrine
1937952|NCT02104414|Drug|Normal Saline|30mL Normal Saline
1937953|NCT02104284|Procedure|methacholine and mannitol bronchial challenge tests|"Airway hyperresponsiveness is a common feature of asthma. Methacholine and mannitol are two representative agonists for bronchial challenge. They have theoretically different mechanisms of action, and may have different diagnostic properties. However, their difference has not been directly evaluated among Korean adults. In this study, we compare the diagnostic properties of methacholine and mannitol bronchial provocation tests.
Asthmatic patients and non-asthmatic controls were recruited prospectively from four referral hospitals in Korea. Participants were challenged with each of methacholine and mannitol inhalation on different days. Their diagnostic utility was evaluated by calculating their sensitivity, specificity, positive/negative predictive values for asthma diagnosis."
1937954|NCT02104180|Device|Urgotul|sterile, hydrocolloid dressing, that consist of a polyester fabric coated with hydrocolloid particles and vaseline
1937955|NCT02104180|Device|TulleGras M.S.|Sterile dressing that consists of viscose tissue coated with mineral vaseline
1937956|NCT02103608|Device|Glide|
1937957|NCT02103023|Drug|Imiquimod ointment|5% 250mg imiquimod ointment
1937958|NCT02103023|Drug|Aqueous cream|aqueous cream
1937959|NCT02103023|Biological|Intradermal influenza vaccine|intradermal trivalent influenza vaccine (Intanza15)
1937960|NCT02103023|Biological|Intramuscular influenza vaccine|intramuscular trivalent influenza vaccine (Vaxigrip)
1937970|NCT02101515|Other|Length of Second Stage|The experimental group will have one additional hour in the second stage of labor
1937971|NCT02101216|Drug|Prurisol|Experimental Drug
1937972|NCT02101216|Drug|Ziagen|Active comparator
1937973|NCT02100670|Drug|1% diclofenac sodium plus 3% menthol|To be applied four times daily for 10 days.
1937974|NCT02100670|Drug|1% diclofenac sodium plus 0.09% menthol|To be applied four times daily for 10 days.
1937975|NCT02100670|Drug|3% menthol|To be applied four times daily for 10 days.
1937976|NCT02100670|Drug|Placebo with 0.09% menthol gel|To be applied four times daily for 10 days.
1937977|NCT02100124|Behavioral|Reproductive Life Planning (RLP)|
1937978|NCT02100124|Behavioral|Contraceptive Action Planning|
1937979|NCT02100124|Behavioral|Contraception information|
1937980|NCT02098369|Behavioral|Written education material (basic)|Education material on COPD distributed to all participants.
1937981|NCT02098369|Behavioral|Additional education material|Additional education material sent to participants in the proactive and reactive arms.
1937982|NCT02098369|Behavioral|PELICAN-Proactive|In the proactive arm, calls will be initiated by the coach. The phone calls will involve educational and social support components. PELICAN is grounded on the social cognitive theory of behavior change and seeks to improve patient adherence by addressing patient self-efficacy and outcome expectancy.
1937983|NCT02098369|Behavioral|PELICAN-Reactive|Participants allocated to the reactive PELICAN group will be offered the opportunity to access the COPD Foundation Infoline toll-free.
1937993|NCT02097511|Drug|Sarpogrelate pretreatment|Sarpogrelate hydrochloride 100 mg pretreatment three times a day for three days
1937994|NCT02097511|Drug|Sarpogrelate|Sarpogrelate hydrochloride 100 mg three times a day
1937995|NCT02097511|Drug|Metoprolol|Metoprolol Tartrate 100 mg once a day
1937996|NCT02096263|Biological|Infanrix hexa|3 doses administered intramuscularly in the right thigh.
1937997|NCT02096263|Biological|Pediarix|3 doses administered intramuscularly in the right thigh
1937998|NCT02096263|Biological|ActHIB|4 doses administered intramuscularly in the upper left thigh
1937999|NCT02096263|Biological|Pentacel|4 doses administered intramuscularly in the right thigh
1938000|NCT02096263|Biological|Engerix-B|2 or 3 doses administered intramuscularly in the upper left thigh
1938001|NCT02096263|Biological|Infanrix|1 dose administered intramuscularly in the right thigh
1938002|NCT02096263|Biological|Hiberix|1 dose administered intramuscularly in the left thigh
1938003|NCT02096263|Biological|Prevnar13|3 doses administered intramuscularly in the lower left thigh
1938004|NCT02096263|Biological|Rotarix|2 doses administered orally
1938005|NCT02094664|Device|Heated and humidified oxygen|
1938008|NCT02094976|Device|Jackson surgical table|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Jackson table with two padded supports on each side. The supports were positioned under the lateral chest and at the iliac crest.
1938009|NCT02094976|Device|Wilson frame|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a Wilson frame. The supports were positioned vertically from shoulder to iliac crest.
1938010|NCT02094976|Device|Chest roll|After standard total intravenous anesthesia using propofol and remifentanil continous infusion, patients were turned to the prone position on a chest roll. The supports were positioned vertically from shoulder to iliac crest.
1938011|NCT02094755|Other|Blood draw only|Blood draw only
1938017|NCT02092987|Other|Social work support|All study participants will be provided access to social support services at Riverstone Senior Life services
1938018|NCT02092987|Other|Educational material|All participants receive educational material about dementia and caregiving in addition to information about resources for persons with dementia and their caregivers, including resources at the Alzheimer's Association such as support groups, and clinical and service resources available citywide.
1938019|NCT02092025|Drug|Azilsartan|Azilsartan tablets
1938020|NCT02091921|Drug|Ticagrelor|All patients will be switched from clopidogrel to ticagrelor 90 mg twice daily for two weeks and the VerifyNow and VASP platelet reactivity assays repeated, samples will be collected before and 6±1 hours after the last ticagrelor dose.
1938021|NCT02091674|Device|Hyaluronic acid|Injected gel
1938022|NCT02091401|Device|Springfusor infusion pump|
1938023|NCT02091401|Other|IV administration|
1938024|NCT02091401|Drug|Magnesium Sulfate|
1938033|NCT02090985|Procedure|Lipomodelling of symptomatic peri-stomal skin contour abnormalities|
1938034|NCT02090010|Procedure|Seldinger technique|"The aimed vessel(subclavian vein) is punctured with a sharp hollow needle, syringe is detached and guidewire is advanced through the lumen of the needle, and the needle is removed.
After that catheter is passed over the guidewire into the vessel."
1938035|NCT02090010|Procedure|Modified Seldinger technique|The aimed vessel is punctured with the needle that is covered with guiding sheath. After vessel is punctured, guiding sheath is instantly slid over the needle into the vessel. The needle is removed, guidewire is advanced through the sheath, central catheter is placed into the vessel.
1938037|NCT02089997|Drug|Sodium risedronate|Sodium risedronate tablets
1938038|NCT02089503|Other|intravitreal injections of Lucentis|intravitreal injections FOR ALL PATIENTS of Lucentis as required in the normal condition of use
1938039|NCT02088905|Behavioral|Parent Child Interaction Therapy|Parent-Child Interaction Therapy (PCIT) is a research-supported parent coaching intervention that has been found to be highly effective among typically developing preschoolers presenting with a range of mental health concerns, especially defiance and noncompliance.6 PCIT holds considerable promise as a potentially effective treatment for children with ASD because it directly addresses the behaviors parents of children with ASD report to be most problematic for them - defiance, stubbornness, and temper tantrums. PCIT is theoretically consistent with other approaches that have shown promise in treating ASD (i.e., behaviorally-based); however, PCIT is unique in that it incorporates a socially-based initial phase which may have some unique benefits for children with ASD.
1938043|NCT02088034|Behavioral|Prometra led intervention|Behavioral life-style program lead by a team of trained community health workers (called promotoras) with 2 principal goals - encouraging participants to lose 7% of their total weight and complete 150 minutes of moderate physical activity per week.
1938044|NCT02088034|Drug|Metformin Therapy|Participants in this group will receive metformin 850 mg bid for one year.
1938045|NCT02088034|Other|Usual Care|Participants in this arm will attend one physician visit to discuss healthy lifestyle behaviors and will receive standard educational materials.
1938049|NCT02087046|Device|Deep Brain Stimulation with the Libra System|Deep Brain Stimulation programmed to eliminate tremor
1938050|NCT02085473|Biological|Subcutaneous Injection|Subcutaneous Injection
1938051|NCT02083861|Device|Sam Ultrasonic Diathermy Device|Patients apply the Sam Ultrasonic Diathermy Device daily for 4 hours of continuous therapeutic ultrasound at 3 megahertz (MHz) frequency and 0.132 Watts/cm2.
1938052|NCT02083614|Procedure|to clamp or release the catheter for 2 days before removal|
1938053|NCT02082119|Radiation|Hypofractionated IMRT|Hypofractionated IMRT
1938055|NCT02081690|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
1938056|NCT02081573|Behavioral|Brief CBT|During the course of the twice/month diabetes management phone sessions the nurse care manager will work collaboratively with the patient to identify a dysfunctional belief that may be affecting adherence and could be improved by a brief CBT intervention (5-7 minutes). The care manager will utilize the CBT phone app to identify a CBT intervention that will be most appropriate for the situation. Each intervention is described step by step in the app. The nurse will go through the intervention and when completed will assure the patient's understanding.CBT interventions are geared towards helping the patient identify and restructure thinking that is impairing successful self-management of a chronic disease
1938057|NCT02081456|Other|Soft Tissue Mobilization|
1938058|NCT02081456|Device|Therapeutic Ultrasound|
1938059|NCT02079857|Other|Standard protocol|Subjects will receive a standard treatment
1938060|NCT02079857|Other|Individualized protocol|Subjects will receive an individualized treatment
1938061|NCT02079857|Other|Sham acupuncture/Placebo moxa|Subjects will receive sham acupuncture/placebo moxa
1938062|NCT02080871|Device|Stenting of the Common and/or External Iliac Arteries|Balloon expandable stenting of iliac occlusive disease.
1938063|NCT02080832|Drug|Citalopram|20 mg or 40 mg daily for 8 weeks
1938064|NCT02080832|Drug|Placebo|Placebo daily for 8 weeks
1938065|NCT02080468|Drug|lomitapide|20 mg
1938066|NCT02080468|Drug|EE/norgestimate|1x0.035-mg EE/0.25-mg norgestimate tablet
1938067|NCT02080455|Drug|lomitapide|20 mg dose
1938068|NCT02080455|Drug|Atorvastatin|80 mg
1938071|NCT02079831|Behavioral|Energy Restriction|"Participants will receive an intervention specifically designed for adolescents and their group assignment that relies on nutrition education, nutritional counseling, social cognitive therapy, behavioral strategies, self-monitoring, portion size reduction, and increased physical activity.
Participants will get an individualized dietary meal plan. Dietary counseling will be based on the MyPlate guidelines with extra attention and focus on appropriate protein food choice. Also in accordance to the MyPlate guidelines, all participants will be instructed to increase physical activity to 60 minutes a day as aerobic physical activity."
1938072|NCT02079831|Behavioral|Higher protein|The higher protein group will be instructed to consume 30% of energy as protein, with 25% and 45% of energy from fat and carbohydrate, respectively.
1938073|NCT02079831|Behavioral|Lower Protein|The lower protein group will be instructed to consume 15% of energy as protein, with 25% and 60% of energy from fat and carbohydrate, respectively.
1938074|NCT02079558|Drug|Carbetocin|Carbetocin with single 100 microg IV dosage was used in this investigation
1938075|NCT02079558|Drug|Oxytocin|Oxytocin with 30 international units (IU) IV infusion was used in this investigation
1938076|NCT02078661|Drug|PG101|A topical gel containing either 1% or 0.25% PG101 active.
1938077|NCT02079493|Device|ConforMIS iTotal (CR) knee implant system and any off-the-shelf standard knee implant system from various manufacturers.|
1938081|NCT02077790|Device|CASIA Cornea/Anterior Segment OCT SS-1000|"The SS-1000 is a three-dimensional, non-contact, non-invasive high resolution optical coherence tomography imaging device based on the principal of Swept Source OCT. The system achieves high resolution imaging of 10 μm (Axial) and 30 μm (Transverse) and high speed scanning of 30,000 A-scans per second."
1938083|NCT02076230|Drug|[14C] TH-302 (Label 1)|[14C]-labeled TH-302 (Label 1) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
1938084|NCT02076230|Drug|[14C] TH-302 (Label 2)|[14C]-labeled TH-302 (Label 2) will be administered as intravenous infusion over 30 minutes on Day 1 of Part A.
1938085|NCT02076230|Drug|Unlabeled TH-302|Unlabeled TH-302 will be administered along with labeled TH-302 at the dose of 340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Day 1 of Part A, followed by recommended Phase 2 dose (RP2D) of 480 mg/m^2 as monotherapy infusion over 30 minutes on Days 8 and 15 of Part A; and on Days 1, 8 and 15 of Part B, until progression of the disease, unacceptable toxicity, withdrawal of consent by the subject, loss to follow up, or death.
1938090|NCT02075658|Device|AirSeal® System-Interventional|The AirSeal® System consists of an insufflation, filtration, and recirculation system (AirSeal® IFS), a triple lumen filtered tube set, and a valve free trocar (AirSeal® Access Port). The device enables peritoneal access with a novel mechanism to maintain pneumoperitoneum without a mechanical seal.
1938091|NCT02075658|Device|Conventional Insufflator and Trocar|Conventional insufflator and trocars are used in standard procedures and will serve as the base for comparison of the study device (AirSeal® System).
1938095|NCT02073929|Drug|Liraglutide|GLP-1-analogue Liraglutide
1938096|NCT02073929|Drug|placebo|
1938099|NCT02072928|Biological|botulinum toxin Type A|botulinum toxin Type A (BOTOX®) prescribed as standard of care in clinical practice.
1938100|NCT02071706|Device|PET/MRI system|
1938101|NCT02072135|Drug|Exparel|
1938102|NCT02071953|Device|Experimental adhesive w/out phosphoric acid in post. rest.|Experimental adhesive without phosphoric acid in posterior restorations
1938103|NCT02071953|Device|Experimental adhesive with phosphoric acid in post. rest.|Experimental adhesive with phosphoric acid in posterior restorations
1938104|NCT02071043|Drug|Capecitabine|Capecitabine 1000 mg/m2 ，orally taken 30 minutes after meal, bid ， d 1~14 every 3
1938105|NCT02071043|Drug|Oxaliplatin|Oxaliplatin：130mg/m2， iv infusion over 2h，d1,every 3 weeks
1938110|NCT02069184|Drug|IV Acetaminophen|1gm IV. 1st dose at the cord clamping and 3 more doses given every 6th hourly
1938111|NCT02069184|Other|Saline as placebo|100ml saline IV. 1st dose of 100 ml at cord clamping and 3 more 100ml doses every 6th hourly.
1938112|NCT02069119|Drug|OPC-108459|
1938113|NCT02069119|Drug|Placebo|
1938114|NCT02069041|Biological|Ramucirumab|Administered IV.
1938115|NCT02069041|Drug|FOLFOX4|Administered IV.
1938116|NCT02068508|Drug|Pioglitazone|Pioglitazone Tablets
1938117|NCT02067000|Behavioral|Obstructive Sleep Apnea|Questionnaire about CPAP perceptions
1938118|NCT02067676|Biological|Capsule-Conjugate Campylobacter Vaccine (CJCV1)|The capsule of Campylobacter jejuni strain 81-176 (CPS81-176) conjugated to the mutated diphtheria toxin cross-reacting material 197 (CRM197) (lyophilized CPS-CRM197 conjugate) (CJCV1)
1938119|NCT02067676|Drug|Alhydrogel®, aluminum hydroxide adjuvant (alum)|
1938121|NCT02066844|Drug|Celestone|2cc
1938122|NCT02066844|Drug|Lidocaine|5cc
1938130|NCT02063802|Drug|metformin|total dose: 1 gr per day (250mg tablets). The patient takes 2 tablets with breakfast and 2 tablets with dinner and 2 placebo tablets with food by mouth for four months.
1938131|NCT02063802|Dietary Supplement|Conjugated Linoleic Acid|total dose: 3gr/día(500mg capsules). The patient takes 2 capsules with breakfast, 2 capsules with lunch and 2 capsules with dinner for four months.
1938132|NCT02063802|Drug|Placebo|Total dose 6 tablets per day. The patient takes 2 tablets with breakfast, two tablets with lunch and two tablets with dinner by mouth for four months
1938133|NCT02063802|Behavioral|Healthy habits program|
1938134|NCT02063685|Drug|R-CHOP or R-bendamustine|"As induction therapy all patients will receive 6 courses of:
Rituximab: 375 mg/m² day 1 iv Cyclophosphamide: 750 mg/m² day 1 iv Doxorubicin: 50 mg/m² day 1 iv Vincristine: 1.4 mg/m² day 1 iv (max dose 2mg) Prednisone: 100 mg day 1-5 os To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 21 days.
or 6 courses of:
Rituximab: 375 mg/m² day 1 iv Bendamustine: 90 mg/m² day 1 and 2 iv. To allow administration of all drugs on the same day, Rituximab rapid infusion is permitted starting from cycle 2. Cycles are to be repeated every 28 days."
1938135|NCT02063685|Drug|Observation|not maintenance therapy and followed-up with MRD monitoring.
1938136|NCT02063685|Drug|Maintenance weekly x4|Four weekly doses of Rituximab (375 mg/m²). Rituximab could be repeated for MRD positive for a maximum of three courses
1938137|NCT02063685|Drug|Ibritumomab Tiuxetan + Maintenance|single dose of (90)Y Ibritumomab Tiuxetan (0.4 mCi/kg). Following RIT patients will continue maintenance with Rituximab (375 mg/m² every 2 months) for a total of 11 infusions.
1938138|NCT02063685|Drug|Standard Maintenance|Rituximab 375 mg/m² every 2 months for 2 years. Maintenance will have to be started no more than 12 weeks after the last induction chemoimmunotherapy infusion.
1938139|NCT02063217|Drug|Sodium Oxybate|Sodium oxybate h.s.
1938140|NCT02063217|Behavioral|Sleep deprivation|36hr sleep deprivation
1938141|NCT02063087|Other|Head CT Decision Aid|The decision aid, Head CT Choice, educates parents regarding how the clinician determined the severity of their child's head trauma, their child's quantitative risk for a clinically-important TBI, the pros and cons of cranial CT compared to active observation, and what signs and symptoms parents should watch for in the next 24 hours that should prompt a return visit to the ED.
1938142|NCT02062034|Drug|Ubiquinone|400mg daily of oral ubiquinone for 24 weeks
1938252|NCT02046564|Drug|Placebo|
1938253|NCT02046616|Drug|tocilizumab [RoActemra/Actemra]|162 mg administered subcutaneously weekly
1938143|NCT02062034|Drug|Combined antioxidant therapy|(1 mg copper, 20 mg zinc, 180 mg vitamin C, 30 mg vitamin E, 1 mg zeaxanthin, 4 mg astaxanthin, 10 mg lutein) daily of oral, all of them in one Tablet for 24 weeks
1938144|NCT02062034|Drug|Placebo|100 mg of oral placebo with identical appearance, form, size than ubiquinone and antioxidant combined therapy for 24 weeks
1938145|NCT02060890|Other|specialized tumor board recommendation|feasibility of a specialized tumor board to come up with treatment recommendations no later than 35 days from surgery.
1938146|NCT02060461|Device|FS200 Laser|
1938147|NCT02059005|Behavioral|Specialized Community Disease Management|Specialized Community Disease Management is 90-day program that employs specialized teams including a trained clinical social worker and a peer-specialist community health worker who provide evidence-based telephone continuing care, home visits, and focus on patients' substance use following hospital discharge.
1938148|NCT02059005|Behavioral|Treatment As Usual|Treatment as Usual is a 90-day, post-discharge program that consists of medical monitoring by nurses and community health workers who have no special training in working with substance use disorder patients, and does not address substance use.
1938150|NCT02058966|Drug|Entacapone|Entacapone 200 mg oral dose
1938151|NCT02058966|Drug|Methamphetamine|Methamphetamine 20 mg oral dose
1938152|NCT02058966|Drug|Placebo|capsules compounded to be of similar appearance to the active drugs
1938157|NCT02059460|Drug|Terlipressin|Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively
1938158|NCT02059460|Drug|placebo|
1938159|NCT02059434|Drug|LAS190792 Dose 1|
1938160|NCT02059434|Drug|LAS190792 Dose 2|
1938161|NCT02059434|Drug|LAS190792 Dose 3|
1938162|NCT02059434|Drug|LAS190792 Dose 4|
1938163|NCT02059434|Drug|LAS190792 Dose 5|
1938164|NCT02059434|Drug|LAS190792 Dose 6|
1938165|NCT02059434|Drug|LAS190792 Dose 1 (Part 2)|
1938166|NCT02059434|Drug|LAS190792 Dose 2 (Part 2)|
1938167|NCT02059434|Drug|Tiotropium 18 μg|
1938168|NCT02059434|Drug|Indacaterol 150 μg|
1938169|NCT02059434|Drug|Placebo|
1938170|NCT02059395|Other|Mastery based learning|Participants are allowed to follow the course content at their own speed
1938171|NCT02059395|Other|Time based learning|Participants follow the traditional Canadian Heart and Stroke Foundation Heartsaver Course according to the official course layout
1938176|NCT02057289|Drug|Micafungin|Micafungin (trade name Mycamine) is an echinocandin antifungal drug developed by Astellas Pharma. It inhibits the production of beta-1,3-glucan, an essential component of fungal cell walls. Micafungin is administered intravenously. It received final approval from the U.S. Food and Drug Administration on March 16, 2005, and gained approval in the European Union on April 25, 2008.
1938177|NCT02057120|Procedure|Kinesio Taping|Application of Kinesio (Kinesio Tex Gold ®) of black color. The tape will be applied from proximal to distal, leaving the anterosuperior iliac spine Bottom, passing over the Rectus Femoris and ending in the region of the anterior tibia tuberosity with a voltage of 25 %.
1938178|NCT02057120|Device|Kinesio Taping placebo|The volunteer who is allocated at random in the placebo group will receive an application of Kinesio transverse way the rectus femoris muscle, in order to verify a possible placebo effect of application of tape.
1938179|NCT02057068|Behavioral|SLEEP-E Dyads Sleep Hygiene and Cognitively Based Compassion Training|Adaptive prescriptions for the individualized components of the sleep intervention will be written for each dyad based upon dyad-specific risk factors, sources of sleep disturbance, nature of sleep problems and baseline sleep hygiene practices. In addition to the adaptive prescriptions, each dyad will receive a core intervention component consisting of a sleep hygiene psycho-education curriculum and compassion meditation training delivered by the E-Tablets.
1938180|NCT02056782|Drug|PGX-ODSH-2013-AML-1|"Eligible patients will receive idarubicin at 12 mg/m2 days 1-3 of induction plus a seven-day continuous infusion of cytarabine at 100 mg/m2/day days 1-7 of induction. For consolidation, patients younger than 60 will receive cytarabine at 3 grams/m2 over 3 hours every 12 hours days 1, 3, and 5 of the cycle. Patients over 60 will come off study following induction.
In induction, ODSH will be administered as a 4 mg/kg bolus 30 minutes after the first idarubicin dose followed immediately by a continuous intravenous ODSH infusion of 0.25 mg/kg/hour for 24 hours daily for seven consecutive days (days 1-7) for a total of 168 hours of continuous ODSH infusion.
In consolidation, ODSH will be administered as a 4 mg/kg bolus 30 minutes after completion of the first 3-hour infusion of cytarabine, followed immediately by a continuous ODSH intravenous infusion of 0.25 mg/kg/hour for 24 hours daily for five consecutive days (days 1-5) for a total of 120 hours of continuous ODSH infusion."
1938254|NCT02045979|Drug|BI 695501|BI 695501 single s.c. injection
1938181|NCT02056431|Behavioral|IVR Intervention Group|595 participants will receive 3 interactive voice response (IVR) calls (2nd, 4th, and 6th month post-treatment start date) to collect information on medication use, side effects, rating of side effects, and pain symptoms to be fed back to their physicians.
1938184|NCT02056002|Other|Usual Care|- Standard CPAP educational training
1938185|NCT02056002|Other|Peer-Buddy System|"Two 30-minute in person sessions with Peer Buddy
Standard CPAP educational training
Eight phone conversations with Peer Buddy over 3 months
Subsequent 3 months use of phone system to contact Peer Buddy as needed
One Month Visit:
- Home visit to collect CPAP information
Three Month Visit:
Questionnaires
Psycho Motor Vigilance Test (PVT) Video Game
Collect CPAP information
Measure weight
Measure blood pressure
Six Month Visit:
Questionnaires
PVT (Video game)
Collect CPAP information
Measure Weight
Measure Blood Pressure
Evaluate the program and Peer Buddy"
1938186|NCT02056002|Other|Usual Care|- Educational Brochures
1938187|NCT02056002|Other|Usual Care|- Educational DVD videos mailed to participant
1938188|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 50 mg subcutaneous administration at every two weeks (Q14D SC) for 16 week
1938189|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 100 mg Q14D SC for 16 week
1938190|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|Atorvastatin plus PF-04950615 150 mg Q14D SC for 16 week
1938191|NCT02055976|Drug|Placebo|Atorvastatin plus PF-04950615 Placebo Q14D SC for 16 week
1938192|NCT02055976|Drug|Ezetimibe|Atorvastatin plus Ezetimibe 10 mg oral administration once daily for 16 week (open)
1938193|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|50 mg Q14D SC for 16 week
1938194|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|100 mg Q14D SC for 16 week
1938195|NCT02055976|Drug|Bococizumab (PF-04950615;RN316)|150 mg Q14D SC for 16 week
1938196|NCT02055976|Drug|Placebo|Placebo Q14D SC for 16 week
1938197|NCT02054845|Behavioral|Body awareness therapy|"Experimental condition: BEWARE training group The physical and psychosocial elements of the training sessions will be complementary: psychological techniques are used to induce and endure wearing-off and physical techniques are used to improve body awareness to cope with the off-periods.
Specifically the following techniques will be applied:
Body scan
Psychoeducation
Acceptance Commitment Therapy / Mindfulness skills (sustained attention, concentration, non-reactivity, nonjudging of experience)
Body Awareness Training
Exposure training (imaginary exposure to induce response fluctuations)
Training in cueing techniques to overcome problems with initiation and freezing
Visual Feedback training
Relaxation techniques"
1938198|NCT02054845|Other|Physical therapy|Control condition: Treatment as Usual The control group will receive treatment as usual based on the current guidelines for physical therapy in patients with Parkinson's Disease, with the same training schedule of 2x per week for 1,5 hours during 6 weeks. Group treatment will contain exercises for balance, walking, posture, transfers, arm/hand dexterity, strength, flexibility, relaxation and physical condition.
1938199|NCT02053753|Drug|Denosumab CP4|Denosumab produced by a process referred to as CP4, administered subcutaneously.
1938200|NCT02053753|Drug|Denosumab CP2|Denosumab produced by a process referred to as CP2, administered subcutaneously.
1938201|NCT02054247|Device|ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2, 5 days a week for a total of 15 sessions
1938202|NCT02054247|Device|pulsed ultrasound|a frequency of 1 megahertz and with an intensity of 1 W/cm2 and a pulsed mode duty cycle of 1:4, 5 days a week for a total of 15 sessions
1938203|NCT02054247|Device|placebo ultrasound|same ultrasound device as described above seemed to be working but without delivering any output, 5 days a week for a total of 15 sessions
1938204|NCT02054130|Drug|Placebo|Placebo
1938205|NCT02054130|Drug|MEDI9929 - Low Dose IP|Subcutaneous repeating dose
1938206|NCT02054130|Drug|MEDI9929 - Medium Dose IP|Subcutaneous repeating dose
1938207|NCT02054130|Drug|MEDI9929 - High Dose IP|Subcutaneous repeating dose
1938208|NCT02053233|Device|Walkbot group|"The physiotherapist typed patient's information then Walkbot would adjust itself to this data and the exoskeleton legs lengthen or shorten to the patient. The computer screen would provide information about speed, duration, cadence and distance. The monitor in front of the patient can offer image and feedback during the therapy process for patients.
The whole Walkbot training process was observed by one physiotherapist and should be always ready to adjust the unloading, duration, speed and guidance force of Walkbot according to patients' different situation such as muscle spasticity, gait quality, labor-consuming and observe the changes of patients' state."
1938209|NCT02053233|Device|Control group|The control group received conventional functional rehabilitation for 40 min/session, 2 sessions/day, 5 days/week for 4 weeks, 40 sessions in all. After 4-week intervention all subjects received conventional physical therapy only, 40 min/day, 5 days/week for 4 weeks. During the test period, general rehabilitation and drug treatment can be done at the same time.
1938212|NCT02053584|Device|Dario™ Blood Glucose Meter|Each subject will undergo a finger prick and also provide a venous blood sample
1938213|NCT02053584|Device|YSI2003|Blood samples will be tested using YSI (gold standard) for comparison to evaluate accuracy.
1938214|NCT02051933|Drug|Botox|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL Botulinum toxin type A. The dose of botulinum toxin will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Botox will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in Botox (rounded to the nearest 30U interval change from 200U, with a maximum of 300U).
45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
1938255|NCT02045979|Drug|adalimumab-EU source|adalimumab-EU source single s.c. injection
1938215|NCT02051933|Drug|Placebo|"At the time of definitive fixation, the hospital's investigational pharmacy will provide four syringes containing 0.5mL 0.9% sodium chloride solution . The dose of 0.9% sodium chloride will be calculated based on the patient's weight in kilograms, such that a total dose of 200U of Placebo will be used for a 70kg individual. The dosage will scale linearly in proportion to the patient's body weight, such that each kilogram change results in a 3U change in placebo(rounded to the nearest 30U interval change from 200U, with a maximum of 300U).
45-55 kg: 140U 55-65 kg: 170U 65-75 kg: 200U 75-85 kg: 230U 85-95 kg: 260U 95-105 kg: 290U 105-115 kg: 300U"
1938216|NCT02051556|Behavioral|Physical Therapy WSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the most affected side (WSI).
1938217|NCT02051556|Behavioral|Physical Therapy BSI|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down (these two parts were the same for all the groups) and an active part that includes exercises with a number of repetitions according to the aim of potentiating the least affected side (BSI).
1938218|NCT02051556|Behavioral|Physical Therapy ST|Each session has duration of one hour and includes a first part of warming up, a final part of cooling down and an active part that includes exercises with a number of repetitions according to the aim of potentiating both sides equally (ST). In this case the number of repetitions was the same for both sides.
1938219|NCT02051296|Drug|Minocycline|RCT blinded placebo trial
1938220|NCT02051296|Drug|placebo|
1938221|NCT02049359|Other|Texting|Bidirectional texting once weekly for 12 weeks
1938222|NCT02050373|Radiation|Low-Level laser|
1938226|NCT02048241|Behavioral|Parent Management Training|This is a psychological treatment that focuses on decreasing tantrums and outbursts by reducing the ability of the tantrum to coerce parents into giving in to the demand that precipitated the tantrum.
1938227|NCT02048241|Other|Placebo|Weekly dispensation of pills matching Intuniv but without the active medication
1938228|NCT02048241|Drug|Intuniv|Weekly administration of medication in doses as per protocol
1938229|NCT02049112|Device|Salivary equivalent|14-day treatment with salivary equivalent sticks
1938230|NCT02049112|Device|Aequasyal|14-day treatment with Aequasyal oral spray
1938231|NCT02049112|Device|Biotene|14-day treatment with Biotene oral spray
1938232|NCT02048826|Device|FINGER I|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting I
1938233|NCT02048826|Device|FINGER II|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting II
1938234|NCT02048826|Device|FINGER III|FINGER is a robot that measures finger movements and allows patients to play computer game using those movements. Patients will be exercising with FINGER using setting III
1938242|NCT02048423|Drug|Ketamine|IV Ketamine, 0.5 mg/kg X 15 mins. in PACU
1938243|NCT02047929|Other|Asthma Shared Decision Making (SDM) Toolkit|A potential solution to improving asthma outcomes is the use of patient-centered approaches like Shared Decision Making (SDM), identified by both the Institute of Medicine and the Patient-Centered Outcomes Research Institute as an important new means of improving patient outcomes. In the SDM process, patients and their health care providers are engaged jointly in making decisions about medical tests and treatments. The research team for this proposal was funded by the Agency for Health Care Research and Quality to build, disseminate and evaluate a novel Asthma SDM Toolkit - The Asthma Comparative Effectiveness Study. The Toolkit development was completed in 2010 and has been in evaluation for 2 years. Initial results show marked improvement in patient adherence to medications, decreases in utilization of the ED and hospital for asthma care. This study will continue to evaluate the Toolkit in a wide array of practices across NC while testing a new method of dissemination.
1938244|NCT02046603|Drug|DMARDs|non-biologic disease-modifying antirheumatic drugs, up to recommended dose allowed
1938245|NCT02046603|Drug|corticosteroids|</= 10 mg/day prednisone or equivalent allowed
1938246|NCT02046603|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC weekly, 52 weeks
1938247|NCT02047500|Drug|TH-302|TH-302 will be administered at a dose ranging from 170-340 milligram per square meter (mg/m^2) as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
1938248|NCT02047500|Drug|Nab-paclitaxel|Nab-paclitaxel will be administered at a dose ranging from 100-125 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
1938249|NCT02047500|Drug|Gemcitabine|Gemcitabine will be administered at a dose ranging from 800-1000 mg/m^2 as intravenous infusion over 30 minutes on Days 1, 8 and 15 of every 28-day cycle until evidence of progressive disease, intolerable toxicity or subject withdrawal.
1938250|NCT02046668|Drug|spironolactone|spironolactone 25mg daily for 12 weeks
1938251|NCT02046564|Drug|ASC-01|
1938256|NCT02045979|Drug|adalimumab-US source|adalimumab-US source single s.c. injection.
1938259|NCT02046148|Biological|GBS trivalent vaccine|Intramuscular injection - Liquid formulation of a vaccine containing polysaccharide capsules from serotypes Ia, Ib, and III of the Group B Streptococcus and conjugated to the Corynebacterium diphtheriae CRM197 carrier protein
1938260|NCT02046148|Biological|Placebo|Intramuscular injection - Normal saline
1938263|NCT02044874|Drug|APD356-lorcaserin hydrochloride|
1938264|NCT02044874|Drug|Placebo|
1938265|NCT02044419|Drug|lomitapide|
1938266|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the abdomen
1938267|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the upper arm
1938268|NCT02043301|Biological|Bococizumab (PF-04950615; RN316)|Single 150 mg PF-04950615 dose administered SC to the thigh
1938269|NCT02043704|Drug|IV Acetaminophen|Details covered in arm description.
1938270|NCT02043652|Drug|Chloroquine|Patients will receive 3-day treatment with chloroquine in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
1938271|NCT02043652|Drug|Primaquine|Patients will receive 7-day treatment with primaquine, in conjunction with chloroquine, in accordance to treatment guidelines in Brazil. All patients will receive the same treatment as there is no comparison arm.
1938272|NCT02043340|Drug|indocyanine green|ICG group - scaling and root planing with application of 810 nm diode laser and ICG at a concentration of 5 mg/mL. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
1938273|NCT02043340|Device|LASER|LASER group - scaling and root planing with application of 810 nm diode laser Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
1938274|NCT02043340|Procedure|Scaling and Root Planing|SRP group - scaling and root planning. Primary parameters included estimation of decrease in percentage of viable bacteria at baseline, immediate post treatment and end of 1 week and Lactate dehydrogenase (LDH) levels at baseline and end of 1 week. Secondary parameters included site-specific measures of plaque, gingivitis, pocket depth (PD) and clinical attachment loss (CAL) at specific time intervals.
1938275|NCT02041923|Behavioral|H-HOPE|Infant remediation using a developmentally appropriate multisensory intervention addresses the specific behavioral organization needs of premature infants. Maternal redefinition and re-education by a nurse-community advocate team uses participatory guidance to address the needs of mothers of premature infants.
1938279|NCT02040649|Other|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
1938280|NCT02040649|Other|Control, sedation (propofol, midazolam)|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
1938283|NCT02040779|Drug|Beclomethasone dipropionate breath-actuated inhaler|Participants are instructed to rinse their mouth and expectorate (not swallow) after study drug administration.
1938284|NCT02040779|Drug|Placebo breath-actuated inhaler|Placebo breath-actuated inhaler (BAI) 1 inhalation twice daily for a total daily dose of 0 mcg.
1938285|NCT02040779|Drug|albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period
1938328|NCT02034006|Drug|Ranibizumab|All patients will receive a single initial intravitreal injection of ranibizumab 0.5 mg/0.05 ml as per CHMP approval. Further injections might be required when monitoring reveals disease activity. Disease activity, defined as reduced visual acuity and/or signs of lesion activity, will be evaluated based on clinical examination (BCVA, fundus), and/or optical coherence tomography (OCT), and/or fluorescein angiography (FAG). Bilateral treatment is allowed provided at least 14 days of intercurrence.
1939526|NCT01790594|Biological|Anti-thymocyte Globulin (Rabbit)|
1938286|NCT02039856|Other|Evidence Based Quality Improvement (EBQI) Intervention Practices|Intervention at eight of 12 study sites consisting of VISN/facility-level stakeholder panel meetings designed to set evidence-based priorities for quality improvement (QI) in the context of local data and needs; local practice quality improvement team design meetings; QI training and education; iterative formative data feedback; across intervention-practice QI collaboration calls; and practice facilitation. Local leadership, QI champions and frontline staff will develop and implement innovation projects aimed at improving aspects of WH PACT implementation based on site-level and VISN priorities in the context of national PACT and WH guidelines.
1938287|NCT02039856|Other|Routine PACT Implementation (Naturalistic Control Practices)|PACT implementation is a nationally mandated initiative in VA primary care and women's health clinic settings, with audit-and-feedback of PACT-related performance measures, incentives for achievement of PACT attributes and continual guidance on PACT and WH policy and procedures from VA primary care and women's health leaders.
1938293|NCT02038322|Device|The Stork - Conception Aid|
1938294|NCT02037568|Behavioral|fPER|"Briefly in order, the sessions will include: 1) Overview and introduction to stress management, 2) Stress and the mind-body connection, 3) How our thoughts can lead to stress, 4) Coping with stress, 5) Strategies for maintaining energy and stamina, 6) Coping with uncertainty and fear of unknown, 7) Managing changing relationships/communicating needs, and 8) Getting the support they need, modeled after a successful intervention for patient groups. Manualization is crucial for successful wider implementation. Sessions 9 and 10 will provide booster sessions in which the interventionist will assess current challenges for the caregiver, provide review, and emphasize further coping skills training that might assist the caregiver in managing current stressors such as coping with the new normal."
1938295|NCT02037438|Other|CONV care for the diagnosis and treatment of sleep disorders|The Conventional (CONV) intervention will utilize standard-of-care diagnostic and treatment procedures for new patients with sleep disorders at the Stanford Sleep Medicine Center
1938296|NCT02037438|Other|PCCM for the diagnosis and treatment of sleep disorders|The Patient-Centered Outcomes and Coordinated Care Management (PCCM) intervention will follow a new methodology for the diagnosis and treatment of sleep disorders. It also incorporates the utilization of a web-based interactive portal that provides specific and relevant information and resources for patients, health care providers, and allied health professionals. The portal is designed to facilitate informed health care decisions among patients and health care providers through improved access to medical data and enhanced communications.
1938298|NCT02037061|Drug|Bupivacaine|Intraoperatively the patient will receive 10ml of bupivacaine injected into the sacrospinous ligament.
1938299|NCT02037061|Other|Normal Saline|
1938300|NCT02036645|Biological|MEDI1814 for IV injection|Monoclonal antibody for IV Injection
1938301|NCT02036645|Biological|MEDI1814 for Subcutaneous Injection|Monoclonal antibody for subcutaneous injection
1938302|NCT02036645|Biological|IV Placebo|Placebo for IV injection
1938303|NCT02036645|Biological|Placebo for Subcutaneous Injection|Subcutaneous Placebo Injection
1938304|NCT02036294|Other|BREATHE program|A patient and family- centered transitional care intervention that includes a comprehensive biopsychosocial assessment, a tailored treatment plan, a tailored disease management program, and care management support services .
1938305|NCT02036294|Other|Usual Care|Standard Healthcare Services
1938306|NCT02034916|Drug|talazoparib|
1938307|NCT02035917|Device|Locking plate|
1938308|NCT02035917|Device|Non-Locking plate|
1938309|NCT02034799|Biological|Bioseal Fibrin Sealant|
1938310|NCT02034799|Other|Standard of Care (SoC)|
1938313|NCT02035436|Other|Non-sedation|Patients are awake or have natural sleep during mechanical ventilation. Pain is treated with morphine iv.
1938314|NCT02035436|Other|Control: Sedation|Continuous iv-sedation (propofol first 48 hours, from then midazolam) to Ramsey 3-4 with a daily wake up attempt, where sedation is stopped until patient is awake.
1938315|NCT02034942|Other|Non-sedation|
1938316|NCT02034942|Other|Sedation, control|
1938319|NCT02034500|Biological|S. sonnei 1790GAHB|
1938320|NCT02034500|Biological|Placebo|
1938321|NCT02033616|Biological|AVOVA-1|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
1938322|NCT02033616|Biological|MC|Comparison of a cancer treatment containing autologous dendritic cells loaded with tumor associated antigens (TAA) from autologous self-renewing tumor cells vs. a cancer treatment containing autologous immune cells.
1938323|NCT02034149|Behavioral|general management|All participants received a general education with the knowledge on care for early chronic kidney disease recently establishes by the National Health Insurance system. We then used the cross-theoretical model to assess the intervention among the three groups.
1938324|NCT02034149|Behavioral|self-management|Participants in the self-management group are expected to emphasize on self-managed interventions, including self-monitoring and records keeping, self-education with DVD courses. We negotiated their behavior change set goals for them etc.
1938325|NCT02034149|Behavioral|peer-assisted management|The peer-assisted management group received similar program for 3 months, the peer oriented group activities followed, including group discussions to share experience and sports map etc.
1938326|NCT02034019|Drug|Dexamethasone|
1938327|NCT02034019|Drug|Punctum Plug|
1938329|NCT02033941|Drug|Meganatural-Az Grapeseed Extract|Meganatural-Az® doses: 30mg / day for 2 weeks; 4 weeks of 600 mg/day, 4 weeks 1000mg / day
1938330|NCT02033941|Drug|Placebo|Subjects receive capsules identical in appearance to the active agent with the same incremental schedule
1938331|NCT02033499|Behavioral|SMBG|Blood glucose levels are tested once daily.
1938338|NCT02032173|Drug|Main group|Patient will start in the main group with 6 monthly ranimizumab IVTs until month 5. Additional mandatory IVTs will be done at months 8 and 11. At months 14, 17, 20 and 23, IVTs will be done if BCVA loss is comprised between 9 and 5 letters (included). If patient did not loose more than 4 letters, no injection has to be performed at the visit. Criteria to stay in the main group are : 1°) at Month 3, 4 letters (included) improvement compared to baseline (Day 0) OR an improvement in CSF ≥ 0.1 log OCT compared to baseline (Day 0); 2°) at Month 6, a stable VA is obtained based on the months 4, 5 and 6 BCVA score; 3°) at Months 8, 11, 14, 17, 20 and 23, no BCVA decrease by more than 10 letters (excluded) compared with the highest BCVA score since the beginning of the study.
1938339|NCT02031237|Radiation|Single Fraction Stereotactic Radiosurgery (SRS)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
1938340|NCT02031237|Radiation|Fractionated Whole Brain Radiation Therapy (WBRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
1938341|NCT02031237|Radiation|Fractionated Stereotactic Radiation Therapy (FSRT)|Intervention will not be assigned by the investigator. Treatment determination will be made prior to study enrollment.
1938342|NCT02031237|Device|Magnetic Resonance Imaging (MRI) Assessments|MRI scans will include a routine clinical MRI series.
1938343|NCT02031640|Drug|Beclomethasone dipropionate|
1938344|NCT02031640|Drug|Placebo|
1938345|NCT02031640|Drug|Albuterol/salbutamol|Rescue medication (albuterol/salbutamol hydrofluoroalkane (HFA) MDI [90 mcg ex-actuator] or equivalent) for use on an as-needed basis for the immediate relief of asthma symptoms throughout the treatment period.
1938352|NCT02029651|Device|E-glove system|Novel rehabilitation system using game for upper extremity rehabilitation for patients with stroke
1938353|NCT02029651|Procedure|Conventional occupational therapy|conventional occupational therapy
1938354|NCT02029274|Drug|BAF312 0.5 mg|BAF312 0.5 mg once daily
1938355|NCT02029274|Drug|BAF312 2 mg|BAF312 2 mg once daily
1938356|NCT02029274|Drug|BAF312 10 mg|BAF312 10 mg once daily
1938357|NCT02029274|Drug|Placebo to BAF312|Placebo to BAF312 once daily
1938358|NCT02027376|Drug|LDE225|
1938359|NCT02027376|Drug|Docetaxel|
1938361|NCT02026986|Behavioral|sleep deprivation|sleep deprivation for one night
1938362|NCT02025972|Procedure|Allogeneic umbilical cord blood therapy|
1938365|NCT02025322|Behavioral|Peer Mentoring|"Participants in the Peer Mentoring arm will be paired with a Peer Mentor for the duration of the 4-month intervention. Peer Mentors are HIV-positive patients who demonstrate high levels of medication and treatment adherence and are knowledgeable about HIV/AIDS and barriers to care. During the 4-month intervention, Peer Mentors will contact participants weekly via in-person, phone, or email, with the option to provide more frequent contact, if needed. Peer Mentors will provide social support and remind participants to take their medications and attend upcoming medical appointments.
Study participants will also attend four monthly, one hour workshops on HIV/AIDS, medication adherence, health literacy, and health and wellness, which will be developed and co-facilitated by Peer Mentors."
1938369|NCT02024646|Drug|210 mg brodalumab|210 mg brodalumab administered via subcutaneous injection.
1938370|NCT02024646|Drug|140 mg brodalumab|140 mg brodalumab administered via subcutaneous injection.
1938371|NCT02024646|Drug|Placebo|Placebo administered via subcutaneous injection until week 24.
1938372|NCT02024308|Drug|Fludarabine|50 mg/m2, IV (in the vein) in combination with cytarabine 1.4mg/m2/d for 5 days with each cycle of 28 days. Number of cycles: 4
1938373|NCT02024308|Drug|Cytarabine|2000mg/m2/12h, IV (in the vein) for 3 days with each cycle of 28 days. Number of cycles: 4
1938374|NCT02022722|Drug|Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride|The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.
1938375|NCT02022722|Procedure|Pelvic Rehabilitation|Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy
1938377|NCT02023385|Device|BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with BTL-9000 LLLT for the release of fat and lipids from these cells
1938378|NCT02023385|Device|sham BTL-9000 LLLT|Irradiation of adipocyte cells within the fat layer with sham BTL-9000 LLLT for the release of fat and lipids from these cells
1938379|NCT02023281|Behavioral|Exercise|The experimental group will engage in mild-moderate level of exercise. This program will be structured and clinically supervised. Exercise will take place 2-3 days per week for a duration of 30-45 mins. for 12 weeks.
1938380|NCT02023151|Drug|Omalizumab|
1938381|NCT02023151|Drug|Placebo injection|
1938385|NCT02021942|Drug|SOM230 LAR|SOM230 LAR in a dosage of 60 mg is administered i.m. once every 4 weeks.
1938386|NCT02021643|Drug|Sofosbuvir|Sofosbuvir 400 mg tablet administered orally once daily
1938387|NCT02021643|Drug|RBV|Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (< 75kg = 1000 mg and ≥ 75 kg = 1200 mg)
1938388|NCT02021643|Drug|PegIFNα|Pegylated interferon alfa-2a (PegIFNα) 180 µg/0.5 mL pre-filled syringe administered subcutaneously once a week
1938389|NCT02021565|Behavioral|In-home Training and Provision of Assistive Technology (prn)|Assistive Technology Specialists (ATSs), experts on assistive technology devices and how to performing transfer tasks, train Veteran and caregiver dyads to safely, skillfully, and (when appropriate) independently perform four activities of daily living (ADLs): transferring in and out of bed, toileting, and bathing. During the baseline assessments, ATSs also recommend assistive technology equipment (grab bars, bed rails, raised toilet seats, etc.), environmental modifications, adaptive methods, and energy conservation techniques. On the first day of the intervention, ATSs provide and install recommended equipment and train the dyad to complete the three ADLs using the recommended the modified methods.
1938395|NCT02020837|Procedure|Lymphaticovenous Micro-Anastomosis|
1938398|NCT02020226|Drug|TH-302|480 mg/m2 30 min IV infusion on Days 1, 8, and 15 of a 28 day cycle
1938399|NCT02020005|Other|Non-flavored 2mg nicotine gum|
1938400|NCT02020005|Other|Non-flavored 4mg nicotine gum|
1938401|NCT02020005|Other|Mint-flavored 2mg nicotine gum|
1938402|NCT02020005|Other|Mint-flavored 4mg nicotine gum|
1938403|NCT02020005|Other|Non-flavored nicotine inhaler|
1938404|NCT02020005|Other|Mint-flavored nicotine ihaler|
1938405|NCT02019719|Drug|GSK1278863|GSK1278863 will be supplied as film coated tablets for oral administration containing 1 mg, 2 mg, or 5 mg of GSK1278863.
1938406|NCT02019719|Drug|Placebo|Film coated tablets of GSK1278863 matching placebo for oral administration.
1938407|NCT02019173|Behavioral|Boot Camp Balance Training|Intense physical rehabilitation directed at improving balance and mobility will be provided to individuals in a group setting (6 participants in a group) for 4 weeks, 3 days a week for 6 hours per day.
1938408|NCT02019589|Drug|Progesterone|
1938409|NCT02019589|Drug|Placebo|
1938410|NCT02019277|Drug|Docetaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
1938411|NCT02019277|Drug|Nab-paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
1938412|NCT02019277|Drug|Paclitaxel|Dosing regimen to be determined by the investigator, routine clinical practices.
1938413|NCT02019277|Drug|Pertuzumab|Pertuzumab will be administered on Day 1 of the first treatment cycle as a loading dose of 840 mg, followed by 420 mg as an intravenous infusion every 3 weeks.
1938414|NCT02019277|Drug|Trastuzumab|Trastuzumab will be administered at a fixed dose of 600 milligrams (mg) per 5 milliliter (mL) subcutaneously every 3 weeks.
1938417|NCT02017899|Biological|S. sonnei 1790GAHB|
1938418|NCT02017899|Biological|Placebo|
1938419|NCT02018653|Drug|Calcium Alumina-Silicate (CASAD)|1 gram by mouth every 6 hours for up to 6 days.
1938420|NCT02018653|Other|Placebo|1 by mouth every 6 hours for up to 6 days.
1938421|NCT02018653|Behavioral|Questionnaire|Questionnaire completion at baseline about diarrhea and other symptoms.
1938422|NCT02018770|Radiation|Phototherapy|Portable Cluster 9 PainAway ® diodes manufactured by Multi Radiance Medical ® (Solon, OH-USA), being 1 905 nm diode (1 mW average power 10 W of peak power, spot of 0.44 cm2), 875 nm diodes 4 (17.5 mW average power for each diode, spot of 1 cm2) and 670 nm diodes 4 (15 mW average power for each diode1 spot, cm2), frequency of 1000 Hz, irradiation time of 300 seconds, energy delivered from 39.3 Joules.
1938423|NCT02018770|Radiation|Placebo phototherapy|The volunteers will be subjected to the same Groups ' intervention and placebo pen Phototherapy.
1938424|NCT02016612|Device|Seri Surgical Scaffold|An FDA approved Bioabsorbable mesh Seri Surgical Scaffold will be utilized in the study as an internal hammock mesh support of the breast.
1938425|NCT02017405|Other|Serum-derived bovine immunoglobulin protein isolate (SBI)|Serum-derived bovine immunoglobulin protein isolate is a specially formulated light-colored protein powder composed of immunoglobulin (IgG) and other serum proteins similar to those found in colostrum and milk. Serum-derived bovine immunoglobulin protein isolate does not contain any milk products such as lactose, casein, or whey. Serum-derived bovine immunoglobulin protein isolate is gluten-free, dye-free, and soy-free. Serum-derived bovine immunoglobulin protein isolate is manufactured in accordance with current Good Manufacturing Practice (cGMP) and FDA guidelines for medical food ingredients.
1938426|NCT02017405|Other|Matching Placebo|
1938427|NCT02017223|Device|Knowme Device Wear|
1938428|NCT02017145|Drug|Chloraprep|
1938429|NCT02015000|Procedure|P.E.R.F.A.M.T|Surgical Result of Primary and Recurrent Pterygium by Using Pterygium Extended Removal followed by Fibrin Glue Assisted Amniotic Membrane Transplantation (P.E.R.F.A.M.T)
1938430|NCT02016183|Drug|Candesartan cilexetil / hydrochlorothiazide|Candesartan cilexetil / hydrochlorothiazide combination tablets
1938434|NCT02014519|Procedure|Blood sampling|A blood sample (2.5 mL) will be collected from all subjects
1938435|NCT02014519|Other|Data collection|Active questioning
1938440|NCT02013986|Drug|etomidate|0.3mg/kg IV only once during induction of general anesthesia
1938441|NCT02013986|Drug|midazolam|midazolam 0.1mg/kg IV only once before using of etomidate/propofol during induction of general anesthesia
1938442|NCT02013986|Drug|propofol|2mg/kg IV only once during induction of general anesthesia
1938443|NCT02013700|Biological|Allogeneic Adult Human Mesenchymal Stem Cells (hMSCs)|
1938444|NCT02013700|Biological|matched placebo|The placebo will be 25 ml of Plasma-Lyte A with 1% HSA in a Cryostore bag.
1938445|NCT02013570|Drug|Dexmedetomidine|2µg/kg dexmedetomidine in 2 ml normal saline (1 ml per tonsil),
1938447|NCT02013011|Procedure|recruitment maneuver(RM) and positive end expiratory pressure(PEEP) or PEEP only|application of recruitment maneuver(RM) and positive end expiratory pressure(PEEP) in RM and PEEP group and application of only PEEP in PEEP group
1938448|NCT02012790|Other|Diet|The dietary intervention provides dietary counseling, whole foods (enough for 2 meals and 2 snacks per day) including study oils
1938449|NCT02012478|Behavioral|MI- informed SMS program|
1938450|NCT02011724|Device|Apligraf|
1938451|NCT02011867|Device|Cork Electrode|
1938454|NCT02007733|Other|Serial Weights|We will collect serial weights on all children enrolled in this study.
1938455|NCT02007733|Other|IVC/Aorta Ultrasound|We will perform an ultrasound assessment of the IVC and Aorta size in each child enrolled.
1938456|NCT02007733|Other|Clinical Assessment|We will perform a clinical assessment of dehydration status in each child enrolled in the study, as well as collect data on mid-upper arm circumference, length, symptoms and demographic information.
1938457|NCT02009046|Behavioral|SEI Classroom Curriculum|Participants receive the 12-session Sexuality Education Initiative (SEI) classroom curriculum. The SEI classroom curriculum covers anatomy, abstinence, contraception and protection, STIs and HIV/AIDS, media messages, gender, relationships, rights and responsibilities, pregnancy, sexuality, peer pressure, negotiation and coercion, and decision making. These sessions are delivered over a two-month period. Each curriculum session is about 45 minutes in length.
1938458|NCT02009046|Behavioral|Control Classroom Curriculum|Participants receive the 3-session basic control curriculum. The control curriculum includes 3 sessions on sexually transmitted infections, anatomy and birth control delivered over a two- or three-week period. Each curriculum session is about 45 minutes in length.
1938459|NCT02009046|Behavioral|3 School Wide Components|"Participants receive all three school wide components. The peer education and advocacy component recruits, trains and supervises students through an after-school leadership program to serve as resources to peers, organize health events, and refer students to school-based clinic services. The parent education component provides sessions for parents of students, covering reproductive health, teen pregnancy, and parent-teen communication, together with a parent education booklet for widespread use. This clinical services linkages includes clinic without walls health services on campus, including pregnancy/STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It includes training for teachers and staff to distribute condoms as needed."
1938460|NCT02009046|Behavioral|1 School Wide Component|"Participants receive one of the three school wide components, the clinical services linkages. This component includes clinic without walls health services on campus for students, including pregnancy and STI testing, contraceptive consultation and prescriptions, condom distribution, counseling, and referrals. It also includes training for teachers and school staff to distribute condoms to students as needed."
1938461|NCT02009007|Drug|dopamine|continuous infusion during operation
1938462|NCT02009007|Drug|phenylephrine|continuous infusion of phenylephrine during operation
1938470|NCT02006888|Drug|IBI-10090|
1938471|NCT02006888|Drug|Placebo|Placebo
1938472|NCT02007096|Drug|Transabdominal Plane Block|0.25% bupivacaine injection in 6 different locations in abdomen. Weight <100kg: 50ml total; weight >100kg: 60ml total
1938473|NCT02007096|Drug|Non Transabdominal Plane Block|Saline injection in 6 different locations in abdomen. Weight <100kg: 50ml; weight >100kg: 60ml
1938474|NCT02006940|Device|miniprobe Alveoflex|Alveoflex uses 488nm laser, generating real time moving images with an optical area of 600μm at a video frame rate of 12 images per second and a focus depth of 50μm
1938475|NCT02006056|Drug|Ondissolve|Patients will take Ondissolve (8mg) on the day of the radiation treatment at least one hour prior to treatment and repeat approximately 6-8 hours later in the day (bid). For patients who are being treated with 20Gy in 5 fractions, or 30 Gy in 10 fractions, this group will take Ondissolve twice (bid) on each day of treatment, at least 1 hour prior to treatment and also on weekends or holidays in between treatment.
1938476|NCT02006056|Radiation|Palliative Radiation Therapy|Patient will receive palliative radiation therapy considered emetogenic for bone metastases.
1938477|NCT02006069|Device|MPP|"All patients enrolled in the study will be implanted (according to current Guidelines) with an MPP compatible CRT device.
The MPP feature will be evaluated in two study phases. Patients randomized to MPP in Phase I will have MPP programmed per the physician's discretion (no mandated MPP programming) and patients randomized to MPP in Phase II will have MPP programmed per protocol requirements (mandated MPP programming)."
1938478|NCT02004574|Drug|Calcipotriol/betamethasone dipropionate gel|"All enrolled subjects will receive Xamiol® gel once daily for 8 weeks during the induction period and then will be assessed according to IGA at the end of 8-week induction period. Those subjects determined to be Responder by IGA will be randomized to one of the following three treatment groups and they will continue their therapy with randomized maintenance regimens for the duration of additional 8 weeks."
1938479|NCT02005718|Drug|Cholecalciferol|
1938480|NCT02005575|Drug|Bupivacaine and Dexamethasone|The standard of care is to use a regional block solution containing both decadron and bupivicaine.
1938481|NCT02005575|Drug|Placebo|
1938482|NCT02005354|Device|Trans-cutaneous Electrical Nerve Stimulation (TENS)|Patients in whom a bone marrow biopsy is planned will be randomised to one of two groups - a Placebo Comparator group where the TENS machine will be set at the lowest sensory threshold and an Active Comparator group where the TENS machine will be set at a recognised analgesic level (>50Hz and below the pain threshold for the patient).
1938483|NCT02005354|Drug|Standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)|All patients will receive standard pain relief (ie. local anaesthetic with or without inhaled nitrous oxide)
1938499|NCT02003118|Drug|AKR 202|
1938500|NCT02003118|Drug|Placebo|
1938501|NCT02003053|Device|Inspiratory Muscle Trainer|
1938502|NCT02002897|Device|Fractional carbon dioxide laser|Fractional carbon dioxide laser (10,600 nm), a session once per month, total of 3 sessions with full clinical evaluation and investigations before and one month after the last session of treatment.
1938503|NCT02002897|Device|Ultraviolet A1 phototherapy (UVA1)|localized UVA1 phototherapy (340-400 nm), low dose irradiation, at a rate of 3 sessions per week , total of 24 sessions with full clinical evaluation and investigations before and after treatment and clinical follow up one month after treatment.
1938506|NCT02001987|Drug|tocilizumab [RoActemra/Actemra]|162 mg administered once weekly by subcutaneous injection.
1938507|NCT02001844|Device|Trial Foot Orthoses (FOs)|"Trial Group:
The children who were randomly introduced into this group received the pre-formed semi-rigid FOs. The FOs were used as an off the-shelf device and subsequently customised with chair side modifications. In order to reproduce the exact same aesthetical appearance as the control FOs, grey poron (1mm) and black EVA (0.75mm) was used as well to cover the trial FOs.
Furthermore, depending on the type of correction applied to the trial patient, the black EVA also allowed the correction applied on the surface of the device to be masked."
1938628|NCT01978093|Biological|Pediarix®|3 doses administered IM in the left upper anterolateral thigh at Day 0, Month 2 and Month 4. 2 doses administered IM in the left upper anterolateral thigh at Day 0 and Month 2 and 1 dose administered IM in the right upper anterolateral thigh at Month 4 in the PedHIB Group.
1938629|NCT01978093|Biological|Rotarix®|2 doses administered orally at Day 0 and Month 2 each in the HibCY Group and PedHIB Group.
1938508|NCT02001844|Device|placebo foot orthoses (FOs)|"The control FOs, or placebo FOs was supplied to patients who were randomly included in the control group. The control FOs was made of leather board (1mm), grey Poron (1mm), and black EVA (0.75mm) as covering. This thin inner sole did not have any sort of biomechanical support, nor had it any effect on the distribution of pressure, as it was completely flat. In addition, the placebo FOs did not present with any intrinsic or extrinsic correction underneath the sub-talar-joint (STJ).
The use of black EVA as the covering material and the leather-board as a base, allowed for gathering of a dynamic impression over the 6 months of the trial."
1938509|NCT02000180|Behavioral|Progressive Group|
1938510|NCT02001298|Drug|remifentanil|
1938511|NCT02001298|Drug|nitroprusside|
1938517|NCT01999569|Drug|Letrozole|Letrozole administered daily through the time of ovulation.
1938520|NCT01999114|Drug|Buprenorphine transdermal patch|Buprenorphine transdermal patch applied transdermally for 7-day wear
1938521|NCT01999114|Drug|Naltrexone tablet|Naltrexone tablet; 1 tablet taken orally every 12 hours
1938522|NCT01999114|Drug|Placebos (for TDS and for naltrexone and for moxifloxacin)|Matching placebos
1938523|NCT01999114|Drug|Moxifloxacin tablet|Moxifloxacin tablet; 1 tablet taken orally on Days 6, 13 and 17
1938524|NCT01998243|Device|preoperative intragastric balloon ( IGB-BIB®)|An intragastric balloon (BIOENTERICS INTRAGASTRIC BALLOON (BIB) SYSTEM)is placed endoscopically under conscious sedation was kept in the stomach during minimum 6 months. Patients were also treated with proton bomb inhibitors, and prokinetics to control gastroesophageal reflux . The balloon was endoscopically removed with the patient under general anesthesia to avoid bronco-aspiration related problems
1938525|NCT01996644|Drug|Sertaline|
1938526|NCT01995825|Drug|lamotrigine|lamotrigine tablet 100mg twice a day for two weeks
1938532|NCT01995201|Drug|DMARD|non-biological disease-modifying antirheumatic drugs at stable dose
1938533|NCT01995201|Drug|methotrexate|stable dose
1938534|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg subcutaneously (SC) qw, Weeks 1-24
1938535|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw or q2w, Weeks 24-48
1938536|NCT01995201|Drug|tocilizumab [RoActemra/Actemra]|162 mg SC qw, Weeks 24-48
1938539|NCT01994629|Biological|MenACWY-CRM|MenACWY-CRM
1938540|NCT01994629|Biological|MenACWY-TT|MenACWY-TT
1938546|NCT01991145|Procedure|Umbilical Cord Blood therapy|HLA (Human Leukocyte Antigen) typing
1938547|NCT01991145|Biological|Erythropoietin alfa|
1938548|NCT01991145|Other|Rehabilitation|Active rehabilitation
1938549|NCT01991145|Procedure|Placebo UCB|
1938550|NCT01991145|Biological|Placebo EPO|
1938551|NCT01994226|Drug|Low-dose colchicine|"Route of Administration: Tablet - Oral Use
Dose: 500 mcg (one tablet) every eight hours for four days"
1938552|NCT01994226|Drug|Naproxen 750 mg/250 mg|"Route of Administration: Tablet - Oral Use
Dose: Single initial dose of 750 mg (three tablets) followed by 250 mg (one tablet) every eight hours for up to seven days"
1938553|NCT01993927|Drug|Voglibose|Voglibose Tablets / Voglibose OD Tablets
1938554|NCT01991522|Behavioral|Curriculum Group|
1938555|NCT01991522|Behavioral|Self-directed learning group|
1938556|NCT01989676|Biological|PF-05280014|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the PF-05280014 regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
1938630|NCT01978093|Biological|Prevnar 13®|4 doses administered IM in the left lower anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 each in the HibCY Group and PedHIB Group.
1938631|NCT01978093|Biological|PedvaxHIB®|3 doses administered IM in the right upper anterolateral thigh at Day 0, Month 2 and Month 10-13 in the PedHIB Group.
1938557|NCT01989676|Drug|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m^2 and then 60 mg/m^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
1938558|NCT01989676|Biological|Herceptin®|Concentrate for solution for infusion, sterile vial 150 mg. Initial dose of 4 mg/kg over 90 minutes (depending on tolerability) IV infusion, then 2 mg/kg over 30 to 90 minutes (depending on tolerability) IV infusion weekly until disease progression. Following completion of the paclitaxel administration period and beginning no earlier than Week 33 of the study, the Herceptin® regimen may be changed at the discretion of the investigator to every 3 weeks at a dose of 6 mg/kg infused over 30 to 90 minutes depending on tolerability.
1938559|NCT01989676|Drug|Paclitaxel|A nonaqueous solution intended for dilution with a suitable parenteral fluid prior to intravenous infusion. Paclitaxel is available in 30 mg (5 mL), 100 mg (16.7 mL), and 300 mg (50 mL) multidose vials. Each mL of sterile nonpyrogenic solution contains 6 mg paclitaxel. The starting dose of paclitaxel will be 80 mg/m^2 by IV infusion over 60 minutes (duration of infusion may be modified according to local standard of care, if applicable). Provision is made for dose reduction to 70 mg/m^2 and then 60 mg/m^2 as needed. In the absence of disease progression in the judgment of the investigator or prohibitive toxicity, patients will receive treatment with paclitaxel for at least 6 cycles or until maximal benefit of response is obtained, in the judgment of the investigator.
1938560|NCT01990742|Behavioral|Palliative Care Team (PCTeam)|Palliative care teams will be established and will round with residents in the intervention nursing homes.
1938561|NCT01989312|Procedure|intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
1938562|NCT01989312|Procedure|Supraclavicular block and ultrasound-guided ulnar, median and radial nerve blocks.|Supraclavicular block with 20 mL of lidocaine 1.5% + epinephrine 5µg/mL and the addition of ultrasound-guided ulnar, median and radial nerve blocks. For that 12 mL of local anesthetic solution of a 50:50 mixture of lidocaine 2% and levobupivacaine 0.5% (4 mL/nerve) was used.
1938563|NCT01989312|Device|Intravenous cannulation.|A 18-or 20-gauge intravenous (iv) catheter was placed to the contralateral arm according to the surgical site
1938564|NCT01989312|Device|Routine ASA monitoring|Monitorization with ECG, noninvasive blood pressure and spO2.
1938565|NCT01989312|Drug|Premedication midazolam|Premedication with 0.03 mg/kg midazolam iv
1938566|NCT01989312|Drug|Lidocaine|
1938567|NCT01989312|Drug|Epinephrine|
1938568|NCT01989312|Drug|Levobupivacaine|
1938569|NCT01989741|Other|Sleep restriction|4 hours sleep by night during one week
1938570|NCT01990287|Device|SCS and PNfS|Spinal Cord Stimulation (SCS) in combination with Peripheral Nerve Field Stimulation (PNfS). The SCS leads will be placed in the Thoracolumbar region and the PNfS lead will be placed subcutaneously in the area of pain.
1938571|NCT01990287|Device|SCS Alone|Spinal Cord Stimulation (SCS) only. The SCS leads will be placed in the Thoracolumbar region only.
1938572|NCT01988103|Drug|Apremilast|20 mg tablet twice a day for 68 weeks
1938573|NCT01988103|Drug|Apremilast|30 mg tablet twice a day for 68 weeks
1938574|NCT01988103|Drug|Placebo|Placebo tablet twice a day for 16 weeks
1938575|NCT01989208|Other|SG1002|200 mg capsules will be administered BID for 7 days, then doubled to 2 capsules BID for 7 days and doubled again to 4 capsules BID for the final 7 days.
1938576|NCT01988376|Device|Surepath|A liquid-base method of Pap smear for screening the recurrence of cervical cancer
1938577|NCT01988376|Device|Conventional Pap smear|Conventional Pap smear
1938578|NCT01987037|Behavioral|neuropsychomotor assessment|Children with autism spectrum disorders pass a specific battery test (NP-MOT) for a neuropsychomotor assessment. This neuropsychomotor assessment is administered in a half-day maximum. This battery aims to investigate passive muscle tone (shoulders, limbs, and trunk), standing and synkinesia, static and dynamic balance, tonic laterality (extensibility and dangling of hands and feet to identify the tonic dominant side), laterality of use, fine-digit movements, digital tactile gnosis, and body spatial integration (knowing left from right: for oneself and that of others, and with regard to objects).
1938579|NCT01986920|Drug|A-101 25%|Low Dose Concentration of A-101
1938580|NCT01986920|Drug|A-101 32.5%|Mid Dose Concentration of A-101
1938581|NCT01986920|Drug|A-101 40%|High Dose Concentration A-101
1938582|NCT01986920|Drug|A-101 Vehicle|Placebo
1938584|NCT01986647|Behavioral|On the Move group exercise|
1938585|NCT01986647|Behavioral|Standard group exercise|
1938586|NCT01985867|Dietary Supplement|Lactobacillus casei rhamnosus Lcr35|Eligible children will receive Lactobacillus casei rhamnosus Lcr35 (8×10^8 CFU, twice daily, orally for 4 weeks)
1938587|NCT01985867|Dietary Supplement|Placebo|Eligible children will receive placebo (maltodextrin), twice daily, orally for 4 weeks
1938632|NCT01978093|Biological|Havrix®|2 doses administered IM in the left upper anterolateral thigh at Month 10-13 and Month 16-19 each in the HibCY Group and PedHIB Group.
1938633|NCT01978730|Drug|high dose group of SaiLuoTong capsule|high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
1938634|NCT01978730|Drug|low dose group of SaiLuoTong|low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.
1938588|NCT01984892|Drug|Poly-ICLC|"Cycle 1-Weeks 1 and 2: 1mg Poly-ICLC intratumoral (IT) injections (t=6) into same lesion over 2 weeks.
Weeks 3-9: 1mg Poly-ICLC 2x/week intramuscularly (IM) into thighs or upper arms.
Week 10: No treatment. CT scan of chest, abdomen, pelvis and extremities or neck; possible MRI brain scan.
Cycle 2-Weeks 11 and 12: 1mg Poly-ICLC IT injections (t=6) into same lesion over 2 weeks.
Weeks 13-19 - 1mg Poly-ICLC 2x/weekly IM in thighs or upper arms.
Weeks 20-26: no treatment. Week 26, evaluate response in absence of inflammation.
Maintenance - Weeks 27-36: For patients with stable disease or response; IM poly-ICLC injections; evaluation of clinical and immune response. Week 38 repeat tumor assessment, optional biopsy
Follow Up via phone every 3 months for 30months, after completion of treatments."
1938594|NCT01985334|Drug|Glycopyrronium|Glycopyrronium 50 µg capsule for inhalation via SDDPI once per day
1938595|NCT01985334|Drug|SABA|Short-acting β2-adrenergic agonist (SABA) as per approved by each country and as prescribed for each patient, used as background therapy
1938596|NCT01985334|Drug|LABA|Long Acting Beta Agonist (LABA) as per approved by each country and as prescribed for each patient, used as background therapy
1938597|NCT01985334|Drug|Indacaterol maleate and glycopyrronium bromide|Indacaterol maleate and glycopyrronium bromide fixed dose combination (110/50 µg) capsule for inhalation via SDDPI, once a day
1938598|NCT01985334|Drug|LAMA|Long Acting Muscarinic Antagonist (LAMA) as per approved by each country and as prescribed for each patient, used as background therapy
1938599|NCT01985334|Drug|SAMA|Short-acting muscarinic antagonist (SAMA) as per approved by each country and as prescribed for each patient, used as background therapy
1938600|NCT01985334|Drug|ICS|Inhaled corticosteroid (ICS) as per approved by each country and as prescribed for each patient, used as background therapy
1938601|NCT01985308|Device|MRT-Active|
1938602|NCT01985308|Device|MRT-SHAM|
1938603|NCT01984398|Drug|Androxal 12.5 mg Formulation A|
1938604|NCT01984398|Drug|Androxal 12.5 mg Formulation B|
1938605|NCT01984398|Drug|Androxal 25 mg Formulation A|
1938606|NCT01984398|Drug|Androxal 25 mg Formulation B|
1938609|NCT01984242|Drug|Atezolizumab|1200 mg IV q3w
1938610|NCT01984242|Drug|Bevacizumab|15 mg/kg IV q3w
1938611|NCT01984242|Drug|Sunitinib|50 mg orally once daily for 4 weeks, followed by 2 weeks of rest
1938612|NCT01983930|Behavioral|Kundalini yoga and meditation|Participants will participate in a 60 minute yoga and meditation session weekly for 12 weeks and will be assigned a daily Kirtan kriya meditation (12 minute duration) for 12 weeks.
1938613|NCT01983930|Behavioral|Memory Training|Participants will attend a weekly memory training class for 12 weeks as well as receive daily memory homework (12 minute duration) for the 12 weeks.
1938614|NCT01981772|Drug|4% lidocaine with 1:100,000 epinephrine|
1938615|NCT01981772|Drug|4% buffered lidocaine with 1:100,000 epinephrine|
1938616|NCT01982786|Radiation|Image guided external beam radiotherapy with or without brachytherapy boost|image guided external beam radiotherapy (IGRT) or IGRT with high dose rate (HDR) brachytherapy boost
1938617|NCT01982786|Radiation|Brachytherapy|Brachytherapy boost
1938618|NCT01982773|Behavioral|Virtual Hope Box Smartphone App|Smartphone app
1938619|NCT01982773|Behavioral|Enhanced Treatment as Usual|Printed materials
1938620|NCT01982643|Drug|naltrexone plus bupropion|Participants will receive a monthly injection of extended-release depot naltrexone (XR-NTX; as Vivitrol®) plus once-daily bupropion extended-release tablets (BRP; as Wellbutrin XL®) for 8 weeks.
1938621|NCT01981434|Other|Video game based obesity education|The intervention will be in the form of a videogame in which both parent and their children will participate. We will develop a game that incorporates lessons from research on avatars (e.g., the Proteus Effect), and game dynamics to explore ways to increase healthy eating and exercise.
1938622|NCT01979614|Drug|Serelaxin|Serelaxin solution diluted in 5% glucose volume/volume (v/v) solution
1938623|NCT01979614|Other|Placebo|5% v/v glucose solution
1938624|NCT01979978|Other|Healthy Buddies Curriculum|"Each week, intermediate students will receive a 45-minute healthy-living lesson plan from their classroom teacher. Later that week, intermediate students will serve as peer mentors (Buddies), teaching a 30-minute lesson to their younger students. The Physical activity (i.e.Go Move!) component of the lesson plans includes 30-minutes of structured aerobic fitness sessions, called fitness loops, with the student pairs twice weekly. The dietary (Go Fuel!) component includes lessons about distinguishing nutritious and from unhealthy (nutrient poor-energy rich) foods and beverages. The body image (Go Feel Good!) component, the students are taught to value classmates based on individual traits rather than peer influence."
1938625|NCT01979952|Drug|Matching Placebo|twice daily dosing
1938626|NCT01979952|Drug|Nintedanib|gelating capsule
1938627|NCT01978093|Biological|Hib-MenCY-TT (MenHibrix®)|4 doses administered intramuscularly (IM) in the right upper anterolateral thigh at Day 0, Month 2, Month 4 and Month 10-13 in the HibCY Group.
1938635|NCT01978730|Drug|the control group|The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
1938636|NCT01978080|Device|Kinesia HomeView|
1938637|NCT01978132|Procedure|forearm ischemia and reperfusion|both arms will be subjected to 20 minutes of forearm ischemia and 20 minutes of reperfusion.
1938640|NCT01977469|Behavioral|High and low strength training in COPD Patients|Comparison of different intensity strength training associates with aerobic training in patients with COPD
1938641|NCT01977352|Drug|Liposomal bupivacaine|liposomal bupivacaine (EXPAREL®; 88 mg in 20 cc)
1938642|NCT01977352|Drug|Bupivacaine 0.25%|20 cc of bupivacaine 0.25%
1938644|NCT01976741|Drug|BAY1163877|Oral administration twice daily. Starting dose is 100 mg per patient in the first cohort and will be escalated in other cohorts depending on any dose-limiting toxicities.
1938645|NCT01976728|Drug|Gonadorelin acetate 10µg/pulse|
1938646|NCT01976728|Drug|Gonadorelin acetate 15µg/pulse|
1938647|NCT01976728|Drug|Gonadorelin acetate 20µg/pulse|
1938648|NCT01976728|Drug|Placebo|
1938649|NCT01976637|Other|no compression|no compression stockings worn during the study
1938650|NCT01976637|Device|compression|compression stockings class II (23-32 mm Hg) worn during the day for up to 3 weeks
1938651|NCT01975922|Behavioral|Enhanced Milieu Teaching|Enhanced Milieu Teaching (EMT) is a conversation-based model of early language intervention that uses child interest and initiations as opportunities to model and prompt language use in everyday contexts.
1938652|NCT01975324|Drug|dalfampridine|dalfampridine 10 mgs or placebo twice a day for two weeks, wash out period of two weeks, dalfampridine 10mgs or placebo twice a day for two weeks
1938653|NCT01975324|Drug|Placebo|placebo (sugar pill) twice a day for two weeks
1938654|NCT01975545|Drug|Fluor varnish|Dental varnish will be applied to one anterior superior teeth in a random side.
1938655|NCT01975545|Drug|Fluor varnish with nanoparticles|Dental varnish with silver nanoparticles will be applied to one anterior superior teeth in a random side.
1938656|NCT01975428|Device|Withings Blood Pressure monitor|Home blood pressure monitor. Participants will measure their blood pressure 2 times per day up to 3 times per week.
1938657|NCT01975428|Device|iBG Star Blood Glucose Monitor|Participants will measure their blood glucose up to 4 times per day, every day.
1938658|NCT01975428|Device|Alive Cor Portable ECG mopnitor|Portable electrocardiogram. Subjects will monitor their cardiac rhythms only when they have symptoms.
1938659|NCT01975428|Behavioral|Diese Management Program|
1938660|NCT01975090|Device|SENTRY IVC Filter|The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.
1938661|NCT01974050|Behavioral|Text message surveillance|
1938663|NCT01973361|Device|Ultrasound debridement|Ultrasound-assisted wound debridement with saline irrigant applied for 5 - 15 minutes until visible and removable non-viable appearance tissue is removed to reveal a healthy appearance wound bed.
1938664|NCT01973361|Device|Best practice wound care|Participants will receive moist wound care with addition of silver alginate dressing for visual cues of infection.
1938665|NCT01972724|Drug|Pioglitazone|Pioglitazone tablets
1938671|NCT01972412|Behavioral|telephone support|Telephone support for four months about healthy diet, physical activity and medication use.
1938672|NCT01971203|Drug|seroquel xr|Quetiapine target dosage will be 150 mg/day, beginning at 50 mg/day
1938673|NCT01971203|Behavioral|CBT|16 weeks of treatment
1938674|NCT01970943|Other|Placebo|Placebo will be compared to No Intervention.
1938677|NCT01969214|Device|IQP-MM-101|"Dissolve the effervescent tablets in half a glass of water, to be taken orally
1 tablet, 3 times a day"
1938678|NCT01969591|Procedure|fast-track surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
1938679|NCT01969591|Other|conventional postoperative surgery|Patients with colorectal cancer will undergo laparoscopic colorectal resection, and will be divided into two groups. Protocols for fast-track group includes skipping preoperative mechanical bowel preparation, early restoration of diet and early postoperative ambulation.
1938880|NCT01924429|Drug|Lisdexamphetamine|Escalating stepped dose titration: 30, 50 or 70mg
1938680|NCT01969240|Other|Chest Pain Choice Decision Aid|The clinician will review the decision aid with the patient. The decision aid will be used as a tool to facilitate discussion and educate the patient regarding the rationale for their evaluation up to that point in the ED visit and their individual risk for a heart attack or pre-heart attack. The clinician will provide the patient with management options consistent with both the patient's values and preferences and the clinician's level of comfort.
1938681|NCT01968993|Device|nanOss Bioactive - posterolateral gutter|Participants will undergo instrumented PLF at one or two adjacent levels from L2-S1 with PEEK interbody cages (containing allograft or autograft) using nanOss Bioactive in combination with autograft and bone marrow aspirate in the posterolateral gutter on one side. Autograft alone will be used in the opposite posterolateral gutter.
1938682|NCT01968577|Drug|Rosuvastatin|Rosuvastatin 40 mg before percutaneous coronary intervention
1938683|NCT01968447|Other|hypocapnia|
1938684|NCT01968447|Other|normocapnia|
1938687|NCT01968070|Drug|LY3127760|Administered orally
1938688|NCT01968070|Drug|Celecoxib|Administered orally
1938689|NCT01968070|Drug|Placebo|Administered orally
1938690|NCT01967680|Procedure|Non-sedation for intubated, mechanically ventilated patients|
1938691|NCT01967680|Procedure|Controlgroup, sedation with daily wake-up trial|
1938693|NCT01966276|Drug|Methyl-P plus Nutrient Formula|"Week 1 (take the following together twice a day-at breakfast and lunch)
One tablet of Methyl-P (5mg)
Four tablets of CFS Nutrient Formula
Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):
Two tablets of Methyl-P (10mg)
Four tablets of CFS Nutrient Formula"
1938694|NCT01966276|Drug|Methyl-P plus Nutrient matched placebos|"Week 1 (take the following together twice a day-at breakfast and lunch)
One tablet of Methyl-P Placebo
Four tablets of CFS Nutrient Placebo
Week 2 to Week 12 (take the following together twice a day-at breakfast and lunch):
Two tablets of Methyl-P Placebo
Four tablets of CFS Nutrient Placebo"
1938699|NCT01965782|Drug|[^14C]-LY3023703|Administered orally
1938700|NCT01964521|Device|Mepilex Transfer Ag|
1938702|NCT01963728|Drug|Insulin, Isophane|daily dosing based on fasting morning glucose levels
1938703|NCT01963728|Drug|insulin glargine|daily dose based on fasting morning glucose levels
1938706|NCT01963169|Behavioral|TO-BoneHealth Program (Bone Power Program)|The 8-week TO-BoneHealth program include: (1) web learning modules, (2) moderated discussion boards, (3) an Ask-the-Experts section, and (4) a virtual library. In addition, a tool kit and video lecture library are also available to participants. The program will be closed after 8 weeks, and there will be no eNewsletter or bi-weekly follow-ups of bone health behavior goal attainment. After 8 weeks, participants will receive a monthly e-mail informing them of the upcoming surveys.
1938707|NCT01963169|Behavioral|TO-BoneHealth Plus Program (Bone Power Plus Program)|This intervention includes the 8-week TO-BoneHealth program followed by bi-weekly theory-based eNewsletters with follow-up of each individual's maintenance of bone health behaviors for 10 months.
1938708|NCT01962285|Drug|propofol targel controlled infusion|slow stepped propofol target controlled infusion using Schinider´s pharmacokinetic parameters seriated venous blood sampling
1938709|NCT01962207|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the non-dominant arm
1938710|NCT01962571|Drug|Erythropoietin alfa|
1938711|NCT01962571|Drug|Placebo|
1938714|NCT01962688|Device|Handheld ultrasound|Handheld ultrasound determination of IVC diameter
1938715|NCT01962688|Device|Sham ultrasound|sham ultrasound to facilitate blinding
1938716|NCT01961089|Device|Galilei Lens Professional|
1938717|NCT01961505|Drug|Topical compound tripterygium|Topical compound tripterygium was applied for the pain and swollen joints on non-woven fabric for 1 hour, twice per day.
1938718|NCT01961505|Drug|Placebo|The topical placebo recipe composes viscous agent which matches by the sucrose, and the usage and dosage were the same as the topical compound tripterygium group.
1938720|NCT01961167|Device|PI 13-05|
1938721|NCT01960569|Drug|active product ( Thrombexx) assigned to arm 1|Dispense 2-3 cm of cream or gel, 2-3 times per day and carry out a light massage until complete
1938722|NCT01960569|Other|Placebo assigned to arm 2|
1938723|NCT01959464|Drug|Crinone vaginal progesterone gel|Crinone vaginal progesterone gel is inserted in the female vaginal using the pre-filled applicator.
1938724|NCT01959464|Drug|Placebo vaginal gel|Placebo vaginal gel is inserted in the female vagina using the pre-filled applicator.
1938725|NCT01955954|Device|Canary Breathing System|The Canary Breathing System is a biofeedback device meant to assist patients in the re-training of normal breathing patterns.
1938726|NCT01957085|Other|Observation only, no intervention|HCV ab and RNA measured from leftover sera and plasma from the clinical laboratory
1938727|NCT01956656|Drug|lotus leaf mouthwash|Saline mouthwash to be used for 4 days twice daily by one group the other group the lotus leaf mouthwash
1938729|NCT01954602|Procedure|Guide-wire cannulation|Direct guide-wire hovering a few millimeters through the catheter or sphincterotome
1938730|NCT01954602|Procedure|Sphincterotome assisted guide-wire cannulation|Sphincterotome is inserted initially a few millimeters through the papillary orifice
1938731|NCT01955434|Drug|Cyclophosphamide|Given PO
1938732|NCT01955434|Other|Laboratory Biomarker Analysis|Correlative studies
1938733|NCT01955434|Other|Pharmacological Study|Correlative studies
1938734|NCT01955434|Other|Quality-of-Life Assessment|Ancillary studies
1938735|NCT01955434|Drug|Smac Mimetic LCL161|Given PO
1938739|NCT01955096|Procedure|fast-track surgery|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
1938740|NCT01955096|Procedure|conventional postoperative care|The included patients will be randomly divided to two groups :30 that will undergo LAG with FTS rehabilitation programme and 31 that also will undergo LAG but receive conventional postoperative care.Laparoscopy-assisted gastrectomy will be carried out in this approach.There will be no difference in the surgical procedures of both groups.The criteria for discharge are: tolerance of solid diet, return of bowel habits and ability to walk on their own.
1938744|NCT01953783|Drug|IXAZOMIB|
1938745|NCT01954264|Procedure|Capillary blood sample|Capillary blood sample (up to 200µL) for determination of PP (blood slides).
1938746|NCT01954264|Other|Data collection|Prospective data collection at the study visit by the internet based Electronic Case Report Form (eCRF)
1938747|NCT01954251|Biological|Herpes Zoster vaccine GSK 1437173A|2 doses administered intramuscularly (IM) in the deltoid region of the non-dominant arm.
1938748|NCT01954251|Biological|GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A|2 doses administered intramuscularly (IM) in the deltoid region of the dominant arm.
1938749|NCT01953874|Device|MV ASV|Minute ventilation-targeted servo-ventilation therapy.
1938750|NCT01953874|Drug|Optimized Medical Treatment|Beta Blockers, ACE inhibitor or ARB, loop diuretics and/or spironolactone as appropriate, statin if indicated, aspirin and/or warfarin if indicated
1938751|NCT01953796|Drug|clomiphene|For both protocols follow up of the follicular growth has been made by frequent tvUSS monitoring, which have the advantage of providing direct information about the size and number of follicle and measurement of endometrial thickness during clomiphene medication.
1938752|NCT01953211|Drug|combined oral contraceptives|
1938753|NCT01952964|Other|JUC spray dressing|"Intervention group Care of Tenckhoff catheter exit site using spray dressing. The detailed procedures will be introduced by the nurse according to the protocol of the unit. Please refer to Appendix III for details.
Skin test with JUC spray will be carried out prior to the usage of JUC spray dressing for caring the exit site. For the first three days after patient has been discharged, study team members will perform telephone follow up. Patients are reminded to report for signs and symptoms of infection or physical damage of catheter noted. A routine follow up at the Renal Unit will be arranged at eight weeks intervals."
1938757|NCT01952015|Biological|Secukinumab|Secukinumab 150 mg, provided in a 1 mL prefilled syringe (one syringe for 150 mg dose, two syringes for the 300 mg dose)
1938758|NCT01950780|Drug|Ruxolitinib|A fixed dose of ruxolitinib (20mg) will be self-administered orally twice daily for 12 to 24 weeks. Dosing may be decreased or held if needed due to adverse effects.
1938759|NCT01949090|Biological|Investigational H7N1 vaccine GSK2789869A|Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.
1938760|NCT01949090|Biological|Placebo|Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.
1938761|NCT01949649|Behavioral|Peer-Led Group Intervention|
1938762|NCT01949649|Behavioral|Internet-Based Intervention|
1938763|NCT01949649|Behavioral|Clinician-Led Group Intervention|
1938764|NCT01949649|Behavioral|Education Video|
1938765|NCT01949636|Other|Functional Magnetic Resonance Imaging|
1938766|NCT01949571|Drug|Mirtazapine (REMERON, Schering-Plough-Organon)|During the first and second phase of the study,the mirtazapine group received 30 mg of mirtazapine daily. During the third phase, the mirtazapine group received 15 mg of mirtazapine.
1938767|NCT01949480|Procedure|Thoracotomy|
1938768|NCT01949480|Procedure|Video-Assisted Thoracoscopic Surgery (VATS)|
1938815|NCT01939977|Drug|Calcifediol|5 drops/day during 6 months. On Month 1 it can be increased up to 7 drops/day. If this occurs then, on Month 3, it can decreased to 5 drops/day or continue 7 drops/day until end of treatment.
1938816|NCT01938001|Drug|Rituximab|Rituximab 375mg/m^2 IV every week in Cycle 1 (Days 1, 8, 15 and 22) on Day 1 of every 28 day cycle from Cycles 2 to 5
1938769|NCT01948557|Behavioral|Infant feeding counselling and support|"Counselling of appropriate feeding practices as recommended in WHO/UNICEF/UNAIDS guidelines on HIV and infant feeding. Subsequent intensive, home-based support of exclusive breastfeeding or safe replacement feeding according to mothers' selection of feeding practice. Counselling contacts with mothers varied over time. 1-2 antenatal contacts. After delivery, home visits by infant feeding counsellors 3-4 times in first 2 weeks then every 2 weeks until 6 months.
Outcome data collected by separate field based team who were blinded to mothers HIV status and infant feeding practice."
1938770|NCT01948310|Drug|Ranolazine|Comparison of Ranolazine 1000mg twice per day versus placebo twice per day
1938771|NCT01948310|Behavioral|Aerobic Exercise|Aerobic exercise 3 times per week, 45 minutes per session at an intensity of 10-20 beats per minute below the angina threshold (heart rate at which angina symptoms began on the stress test)
1938772|NCT01948310|Drug|Placebo|Comparison of placebo twice per day vs. Ranolazine 1000mg twice per day
1938773|NCT01947283|Behavioral|DECIDE-PA|The DECIDE-PA intervention teaches patients strategies for asking questions and communicating more effectively with their behavioral health care provider in order to improve shared decision making.
1938774|NCT01947283|Behavioral|DECIDE-PC|The DECIDE-PC intervention trains providers in patient-centered communication techniques and encourages providers to be receptive to patients who take a more active role during the clinical encounter in order to improve shared decision making.
1938775|NCT01946802|Device|Frontal 4 channel EEG|Simultaneous conventional EEG and SEDline monitoring for 30 minutes during and after therapeutic hypothermia
1938776|NCT01945996|Behavioral|TExT MED|educational , motivational, medication reminder and healthy living challenge text messages sent to patient's cell phone
1938777|NCT01945996|Behavioral|FANS|supporter curriculum of messages, consisting of educational/motivational messages, and support challenges
1938778|NCT01945489|Biological|onabotulinumtoxinA|OnabotulinumtoxinA (BOTOX®) injected into the detrusor.
1938779|NCT01945489|Drug|Normal saline|Normal saline (placebo) injected into the detrusor.
1938780|NCT01945216|Drug|Alogliptin|Alogliptin tablets
1938782|NCT01944462|Behavioral|Pharmacist Pneumococcal Vaccine Program (PPVP)|1.5 hour educational intervention delivered onsite at collaborating senior center consisting of 3 components: presentation about pneumococcal disease and the vaccine given by a infectious disease-certified pharmacist; 2) skits given by volunteer actors at the senior center to illustrate real world scenarios related to pneumococcal disease and the vaccine; 3) action planning to consist of small group breakouts led by licensed pharmacists and 4) vaccination day which is an optional component following the education program, for participants eligible to receive the vaccine. Vaccination to be provided free of charge to eligible participants who opt to receive it.
1938787|NCT01943227|Other|Enthalpy|
1938788|NCT01941095|Drug|Azathioprine|Participants may receive azathioprine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to Baseline.
1938789|NCT01941095|Drug|Chloroquine|Participants may receive chloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to Baseline.
1938790|NCT01941095|Drug|Hydroxychloroquine|Participants may receive hydroxychloroquine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to Baseline.
1938791|NCT01941095|Drug|Leflunomide|Participants may receive leflunomide as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to Baseline.
1938792|NCT01941095|Drug|Methotrexate|Participants may receive methotrexate as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to Baseline.
1938793|NCT01941095|Drug|Sulfasalazine|Participants may receive sulfasalazine as a concomitant therapy with tocilizumab as per physician's judgment at a stable dose that was initiated at least 4 weeks prior to Baseline.
1938794|NCT01941095|Drug|Tocilizumab|Participants will receive tocilizumab at a fixed dose of 162 mg SC QW either as monotherapy or in combination with non-biologic DMARDs.
1938795|NCT01941732|Drug|Sildenafil|
1938796|NCT01941745|Drug|Half normal saline|2 ml/kg
1938797|NCT01941745|Drug|Low Dose rhCC10|1.5 mg/kg study drug (rhCC10)
1938798|NCT01941745|Drug|High dose rhCC10|5 mg/kg in 2 ml/kg
1938799|NCT01940939|Device|Repetitive Transcranial Magnetic Stimulation|
1938800|NCT01940705|Other|Hearing-Aid Informational Guide|Printed take-home guide on hearing aids
1938801|NCT01940705|Other|Hearing-Aid DVD|Take-home DVD about hearing aids
1938802|NCT01940705|Behavioral|Teach-back Technique|Counseling/Educational session using the teach-back technique to review information about their hearing aids
1938803|NCT01940705|Other|Standard of Care|standard of care hearing-aid orientation as provided by clinical audiologist
1938809|NCT01939106|Device|One Piece Drainable Pouch|
1938810|NCT01939288|Device|Neuromuscular stimulator followed by IPC|
1938811|NCT01939288|Device|IPC followed by neuromuscular stimulator|
1938814|NCT01939977|Drug|Paricalcitol|1 capsule/day for 6 months. On Month 1 and Month 3 it can be increased up to 2 capsules/day or decreased down to 1 capsule/48 hours.
1938817|NCT01938001|Drug|Lenalidomide|Lenalidomide 20mg by mouth (PO) QD on Days 1 to 21 every 28 days up to 12 cycles
1938818|NCT01938001|Drug|Placebo|Placebo (identical matched capsule) PO QD Days 1 to 21 every 28 days
1938824|NCT01937624|Device|Diagnostic Ultrasound|
1938825|NCT01937624|Radiation|X-ray imaging|
1938826|NCT01937650|Drug|Radiotherapy plus metronidazole|Metronidazole was added to the standard radiotherapy that is routinely used.
1938827|NCT01937507|Drug|HAI with FOLFOX|HAI with FOLFOX q 3 weeks
1938836|NCT01935193|Drug|lysine acetylsalicylate|
1938837|NCT01935648|Drug|Ropivacaine|
1938838|NCT01934192|Drug|GSK962040 50 mg|GSK962040 50 mg will be administered once daily enteral dose through NG tube up to 7 days.
1938839|NCT01934192|Drug|Metoclopramide 10 mg|Metoclopramide will be administered IV every 6 h
1938840|NCT01934192|Drug|Placebo NG|Matching placebo once daily enteral dose will be administered through NG tube up to 7 days
1938841|NCT01934192|Drug|Placebo IV|Placebo will be administered IV every 6 hours
1938842|NCT01933113|Device|Deep Brain Stimulation of the Lateral Hypothalamic Area|
1938843|NCT01933919|Drug|fluvoxamine maleate|
1938844|NCT01933919|Drug|placebo|
1938847|NCT01933516|Drug|GP2013|GP2013
1938848|NCT01933243|Drug|Fish oil|Participants will take 4 capsules daily
1938849|NCT01933243|Drug|Placebo pill|Participants will take 4 capsules daily
1938850|NCT01931319|Drug|Intravenous baclofen|
1938851|NCT01931410|Drug|Misoprostol|
1938852|NCT01931358|Biological|ALVAC-HIV|1 mL intramuscular injection containing 10^6 CCID50/dose
1938853|NCT01931358|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
1938854|NCT01931358|Biological|ALVAC-HIV Placebo|1 mL per injection
1938855|NCT01931358|Biological|AIDSVAX B/E Placebo|1 mL per injection
1938856|NCT01931059|Drug|Risperidone|
1938858|NCT01930747|Drug|rocuronium|measure effect on laparoscopic workspace
1938859|NCT01930747|Drug|Sevoflurane|1 MAC sevoflurane inhalation is given
1938860|NCT01930747|Drug|remifentanyl|remifentanyl is given in infusion
1938861|NCT01929707|Drug|LY3050258|
1938862|NCT01929707|Drug|Placebo|
1938863|NCT01929382|Drug|interferon gamma 1b|Standard therapy vs dose titration
1938865|NCT01928537|Drug|rigosertib sodium|
1938870|NCT01925937|Drug|Atorvastatin|
1938871|NCT01925937|Drug|Coenzyme Q10|
1938872|NCT01925937|Drug|placebo for coenzyme Q10|
1938875|NCT01925027|Device|Nano+ DES|All patients will be treated with the NanoTM Polymer-free Sirolimus Coronary Stent System. All patients will undergo angiographic (QCA) investigation at baseline (pre- and post-procedure) and at 3 months follow-up. All patients will undergo OCT investigation at 3 months follow-up. All patients will be evaluated clinically at 3, 4, 5 months (for patients with 6 months OCT follow-up evaluation will be at 8 months) and at 1 and 2 years.
1938878|NCT01924364|Device|Tissue Genesis Cell Isolation System™ (CIS)|In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The concentrated fat to be injected into the subject from the fat grafting procedure will be processed by the Tissue Genesis Cell Isolation System™ (CIS) device. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient. Additionally, data from our current study assessing volume retention after fat grafting for facial deformities (IRB # PRO09060101) will be used for comparison.
1938879|NCT01923961|Drug|5 M NaCl solution|Infusion of 5 M NaCl adjusted at target NaCl concentration in plasma.
1938881|NCT01924533|Drug|Olaparib|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy olaparib dose will be 300mg twice daily.
1938882|NCT01924533|Drug|Paclitaxel|IV infusion over 1 hour at 80 mg/m2 weekly on days 1, 8 and 15 of a 28 days schedule.
1938883|NCT01924533|Drug|Placebo|Tablets-at a dose of 100mg orally twice daily, throughout each cycle (28 days); Once paclitaxel dosing is stopped, the planned monotherapy placebo dose will be 300mg twice daily.
1938884|NCT01922024|Device|LRT55 Testing|Testing on the Unyvero LRT55
1938885|NCT01923064|Drug|Lipiodol|endoscopic injection of lipiodol + cyanoacrylate + lipiodol for gastric varices
1938886|NCT01923064|Drug|Lauromacrogol|endoscopic injection of lauromacrogol + cyanoacrylate + lauromacrogol for gastric varices
1938887|NCT01922102|Drug|Ranibizumab 0.5mg|0.5 mg ranibizumab (intravitreal injections)
1938888|NCT01922102|Drug|Rranibizumab 0.5 mg|0.5 mg ranibizumab (intravitreal injections)
1938889|NCT01922102|Drug|Verteporfin PDT|Verteporfin for intravenous injection delivered by intravenous infusion followed by the light application
1938894|NCT01921751|Radiation|3-Dimensional Conformal Radiation Therapy|Undergo 3D-CRT
1938895|NCT01921751|Drug|Capecitabine|Given PO
1938896|NCT01921751|Drug|Gemcitabine Hydrochloride|Given IV
1938897|NCT01921751|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1938898|NCT01921751|Other|Laboratory Biomarker Analysis|Correlative studies
1938899|NCT01921751|Drug|Paclitaxel Albumin-Stabilized Nanoparticle Formulation|Given IV
1938901|NCT01921166|Drug|clomiphene plus gonadotropins|clomiphene plus gonadotropin ovulation induction
1938902|NCT01921166|Drug|Leuprolide flare|Leuprolide flare ovulation induction
1938905|NCT01919307|Device|Auricular acupuncture|The NADA Protocol for auricular acupuncture will be performed by the PI, a certified NADA protocol practitioner, using sterile, single-use, Seiren 0.22mm, one cm disposable detox needles. Both ears will be sterilized with alcohol swabs. There will be no electrical or other stimulation performed. Needles will be placed subcutaneously with one half twirl upon insertion to the following 5 points (in order per ear): Sympathetic, Shen Men, Kidney, Liver, Lung. Needles will remain in place for 40 minutes and will then be removed in the same order as they were inserted. Needles that become dislodged will be replaced per typical NADA protocol.
1938906|NCT01919190|Drug|EXPAREL|
1938907|NCT01919190|Drug|Placebo|
1938908|NCT01918813|Drug|vancomycin, mupirocin ointment|contact precautions, topical decolonization of MRSA by a bath with 4% chlorhexidine daily for 3-5 days
1938910|NCT01918488|Dietary Supplement|Standardized salt diet|200 mmol NaCl per day given as three meals daily for 4 consecutive days.
1938911|NCT01918488|Drug|Amiloride|Amiloride tablet 20 mg two times daily (morning and afternoon) for two consecutive days.
1938912|NCT01917318|Drug|Iloperidone|"Subjects will receive oral iloperidone for 8 weeks. The first 2 weeks of treatment is called titration period and during this time the dose of iloperidone will be increased periodically from 1mg to a maximum of 8mg depending on response and tolerability.
During the remaining 6 weeks of treatment, called stable dose period, the subjects will receive a stable dose of iloperidone(defined during titration period)"
1938913|NCT01917318|Drug|Placebo|During 8 weeks subjects will receive oral placebo
1938914|NCT01917188|Behavioral|Full simulation and education|
1938915|NCT01917188|Behavioral|See simulation room, usual education|
1938919|NCT01915771|Drug|lomitapide|20 mg dose
1938920|NCT01916460|Procedure|Endoscopic Ultrasound Fine Needle Aspiration (EUS-FNA)|After the subjects meet the criteria for enrollment in the study, gastroparetic patients will undergo linear EUS examination of the stomach wall one day prior to their surgery to obtain single or multiple core biopsies of the stomach body wall using the 19-gauge core biopsy needle under EUS guidance. The pathologist will be in the room to assess the adequacy of the sample after each pass. Once the pathologist deemed that the obtained sample is sufficient, the procedure will be terminated
1938921|NCT01916460|Device|19 guage fine needle aspiration needle|
1938922|NCT01915069|Drug|Cilostazol|
1938923|NCT01913834|Drug|Forsteo|Subcutaneous administration 20 micrograms
1938924|NCT01913834|Drug|CP046 PTH CriticalSorb|Comparison of different doses of drug and nasal delivery devices
1938926|NCT01913340|Drug|Erythropoietin|1000 U/kg/dose IV x 5 doses
1938927|NCT01913340|Drug|Normal saline|placebo: NS IV x 5 doses
1938928|NCT01913327|Drug|Aripiprazole|
1938929|NCT01913327|Drug|Risperidone|Week One, Risperidone 1 mg po qd; Week Two, 2 mg po qd; Week Three, 4 mg po qd; Week Four, 6 mg po qd; Week Five (and thereafter), 8 mg po qd.
1938930|NCT01913327|Drug|Modafinil|Single-dose 200 mg once orally, versus placebo single-dose, added-on to antipsychotic medication.
1938931|NCT01913301|Drug|Alagebrium|
1939008|NCT01891760|Device|Dermagraft|Dermagraft treatment regimen of one application applied topically to the ulcer, weekly, for a maximum of 8 weeks (8 application maximum).
1939009|NCT01891760|Device|Profore|Four-layer compression bandaging therapy.
1938932|NCT01912729|Behavioral|Networked Peer Support with Peer Guide|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a peer guide. The peer guide will be another high school student around the same age as participants.
1938933|NCT01912729|Behavioral|Networked Peer Support with Clinician Coach|Participants will have access to tools and lessons based on Cognitive Behavior Therapy through a web application that can be accessed on a smartphone or computer. Additionally, participants will have access to a private social network that connects them with other participants in the study. Participants will be supported by a clinical psychologist.
1938934|NCT01912794|Other|Sensory Intervention|"full sensory information, whose participants will practice balancing tasks without constraint sensory body;
sensory constraint, whose participants will practice the same balance tasks with constraint body of visual and tactile information from the soles of the feet;
control, whose participants will exercise activities involving cognitive and upper limbs."
1938941|NCT01910948|Drug|omega-3 polyunsaturated fatty acids|The included patients will be randomly divided into two groups A and B, two groups of patients 4 days before operation begin to give parenteral nutrition: A: the control group of normal intravenous nutrition. B: the trial group,add omega-3 polyunsaturated fatty acids 0.2 g/kg to parenteral nutrition, no use on the day of surgery, postoperative 2 days continue to add omega-3 polyunsaturated fatty acids 0.2 g/kg.
1938942|NCT01910519|Biological|Influenza A (H5N1) Virus Monovalent Vaccine with AS03 adjuvant|
1938943|NCT01910519|Biological|Influenza A (H5N1) Virus Monovalent Vaccine without AS03 adjuvant|
1938944|NCT01909648|Other|Blood withdrawal|
1938945|NCT01909648|Genetic|Blood withdrawal|
1938946|NCT01909154|Biological|Mesenchymal stromal cell therapy|
1938947|NCT01908946|Behavioral|SMS reminders|SMS reminders for vaccination visit at 6, 10 and 14 weeks of life.
1938948|NCT01908907|Dietary Supplement|DHA oil administered at 50 mg/d (0.18ml) Or MCT oil administered at 0.18 ml|
1938949|NCT01908907|Dietary Supplement|Placebo Group:MCT oil administered at 0.18 ml as an oil emulsion|
1938950|NCT01908816|Drug|ranibizumab|One injection of Ranibizumab 0.5 mg and retreatment according to disease activity and/or visual impairment on an as needed regimen (PRN)
1938951|NCT01908062|Drug|Extended Release Naltrexone|
1938952|NCT01908062|Other|Treatment As usual|
1938953|NCT01908517|Behavioral|HPV Vaccine Electronic Reminders|The intervention group will receive 4 education messages, 2 reminder/education messages, as well as 1 baseline and 1 final assessment survey. Control group participants will receive 2 contacts throughout the study, 1 at baseline and 1 at their final assessment survey. Up to two reminder contacts will be used if surveys are not completed for both intervention and control group participants. Preference for receipt of reminders will be obtained from the information study card parents complete at study enrollment. Enrollment card content, educational messages and patient- reminders will all be developed with community input.
1938954|NCT01907815|Drug|Akt Inhibitor GSK2141795|Given PO
1938955|NCT01907815|Other|Laboratory Biomarker Analysis|Correlative studies
1938956|NCT01907815|Drug|Trametinib|Given PO
1938957|NCT01907217|Device|ECT Mecta 5000M|ECT is administered twice weekly with hand-held electrodes using the Mecta 5000M device following a standard stimulus dosing protocol. Seizure duration is measured by EEG monitoring. Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia with suxamethonium (0.5-1.0 mg/kg) as muscle relaxant. Seizure threshold (ST) is established by a method of limits at the first session and subsequent treatments will be given at 1.5 x ST for BT ECT and 6.0 x ST for RUL ECT. To reflect routine clinical practice, number of ECT treatments is determined by referring physicians who will be blind to randomisation. The treatment period varies between patients to allow up to 12 administrations of ECT, i.e. up to 6 weeks.
1938958|NCT01907217|Drug|Methohexitone|Methohexitone (0.75-1.0 mg/kg) is used for anaesthesia along with suxamethonium (0.5-1.0 mg/kg)for muscle relaxation. Anesthesia is the same for both arms of the trial.
1938959|NCT01907217|Drug|Suxamethonium|Suxamethonium (0.5-1.0 mg/kg)is used for muscle relaxation along with Methohexitone (0.75-1.0 mg/kg) for anaesthesia. Anesthesia is the same for both arms of the trial.
1938961|NCT01905137|Drug|Intervention-Botulinum Toxin Type A|Patients will receive 200 units of Botulinum Toxin A diluted in 20 mL of preservative free saline to their pelvic floor followed by pelvic floor physical therapy.
1938962|NCT01905137|Drug|placebo|
1938965|NCT01905397|Device|Conventional wound therapy|Sterile bandages and wound coverings
1939010|NCT01891487|Drug|Track A|Bimatoprost 0.03% solution applied to eyebrow
1939011|NCT01891487|Drug|Track B|Refresh Tears applied to eyebrows
1939431|NCT01808768|Drug|Alcaftadine|Alcaftadine 0.25% one dorp each eye daily for 1-2 weeks.
1938966|NCT01905397|Device|Negative pressure wound therapy|The Prevena Incision Management System covers and protects the incision from external infectious sources, while negative pressure removes fluid and infectious material from the surgical incision. The ActiVAC pump may be used with the Prevena dressings as well in some situations to achieve negative pressure.
1938968|NCT01904682|Drug|Oral rigosertib|Dose of 560 mg consists of two (2) 280 mg soft gel capsules of rigosertib.
1938969|NCT01903252|Drug|TP05|3.2g/day once daily for 12 weeks (blinded), 1.6g/d - 4.8g/d up to week 38 (open label)
1938970|NCT01903252|Drug|Asacol|3.2g/d twice daily for 12 weeks (blinded), switch to 1.6g/ - 4.8g/d TP05 up to week 38 (open label)
1938971|NCT01903720|Drug|dexamethasone implant|OZURDEX® (700 µg dexamethasone implant) administered intravitreally on day 0, and approximately every 4 months as needed (based on physician judgment) for up to 12 months.
1938975|NCT01903031|Device|Etonogestrel/ethinyl estradiol vaginal ring (NuvaRing)|NuvaRing is made of ethylene vinylacetate copolymers (28% and 9% vinylacetate) and magnesium stearate, is latex free, and contains 11.7 mg etonogestrel and 2.7 mg ethinyl estradiol. NuvaRing has an outer diameter of 54 mm and a cross-sectional diameter of 4mm. Once NuvaRing is inserted into the vagina, the ring should remain in place (not be removed) continuously for 3 weeks (21 days). After being in place for the first 21 days of the study, the ring may be removed after the day 21 study visit evaluations have been completed.
1938976|NCT01903031|Drug|Efavirenz|Participants will receive EFV 600 mg daily with two or more NRTIs
1938977|NCT01903031|Drug|Atazanavir/Ritonavir|Participants will receive ATV/r 300 mg/ 100 mg daily with tenofovir (TDF) 300 mg and 1 or more additional NRTIs
1938978|NCT01902914|Procedure|Hearing Aids Evaluation|Functional Gain Sound field Speech Audiometry
1938979|NCT01902459|Biological|EVARREST™ Fibrin Sealant Patch|
1938980|NCT01902459|Other|Standard of Care|
1938981|NCT01902095|Device|Tooth powder|Each participant was handed over a sealed pack containing a teeth cleaning kit that included tooth powder (test) or toothpaste (control) and a new soft toothbrush along with written and verbal instructions of usage. They were advised to brush their teeth twice a day with the given dentifrices and tooth brush for two weeks.
1938982|NCT01902095|Device|Tooth paste (control)|Active Comparator
1938983|NCT01901276|Drug|Omeprazole 40 mg bid|As above.
1938984|NCT01900353|Other|brushing methods|
1938985|NCT01900769|Drug|Blood Volume Dilution|
1938986|NCT01899703|Drug|GSK2330672|GSK2330672 oral preserved solution 1.5mg/g will be supplied in amber glass bottles and as per randomization schedule subject will receive 45 mg BID from Day 1 to 3 and 90 mg BID from Day 4 to 14 of one of the two treatment periods.
1938987|NCT01899703|Drug|Placebo|Placebo oral preserved solution will be supplied in amber glass bottles and as per randomization schedule subject will receive placebo BID from Day 1 to 14 of one of the two treatment periods. .
1938988|NCT01899703|Drug|Ursodeoxycholic acid|UDCA 250 mg will be supplied in capsule form. The subjects, who are taking UDCA at the time of Run-in-period, will be continued on the same total daily dose of drug but converted to a standardized formulation and a standardized dosing regimen administering the entire daily dose once daily in the evening before bedtime. Once daily dosing of UDCA will continue for the duration of the study.
1938989|NCT01899300|Device|Metal Stent (WallFlex™ Esophageal RX)|
1938990|NCT01898273|Drug|I-124-CLR1404|single-dose, intravenous
1938991|NCT01898611|Drug|Ghrelin|2:1 ratio placebo to ghrelin
1938992|NCT01898611|Other|Resistance training|The exercise intervention will focus on twice weekly progressive strength training, taught by a certified fitness professional, to be performed in the home using dumbbells, an exercise step, and ankle weights.
1938993|NCT01897207|Biological|Dendritic cell application|S.C. injection of peptide pulsed autologous dendritic cells
1938994|NCT01896700|Drug|Methylphenidate|Escalating dose of methylphenidate, 20mg, 40mg, 60mg/day, for 2 weeks each
1938995|NCT01896700|Drug|Placebo|Escalating matched dose of placebo
1938996|NCT01895647|Device|EMS|Electric muscle stimulation with programmed warm-up, stimulation and cool-down in 32 minutes
1938997|NCT01894919|Biological|rMenB + OMV vaccine (1 dose at study month zero)|
1938998|NCT01894919|Biological|rMenB + OMV vaccine (2 doses 1 month apart)|
1938999|NCT01894620|Device|rTMS real-sham|In this intervention patients receive 4 weeks of rTMS treatment with real coil and then 4 weeks of treatment with sham coil; there will be 4 weeks of break between the two blocks of treatment.
1939000|NCT01894620|Device|rTMS sham-real|In this intervention patients receive 4 weeks of rTMS treatment with sham coil and then 4 weeks of treatment with real coil; there will be 4 weeks of break between the two blocks of treatment.
1939001|NCT01894152|Device|XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)|Subjects receiving XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
1939002|NCT01893645|Device|Pronto-7|A new point-of-care pulse co-oximeter that offers a non-invasive and quick spot-checking of Hb (SpHb).
1939003|NCT01894087|Behavioral|TBI - Cohort 1|
1939004|NCT01894087|Behavioral|TBI - Cohort 2|
1939005|NCT01892865|Other|Scheduling using historical means|Scheduling will be performed taking into account historical means only for anesthetic, operative, and turn around time
1939006|NCT01892865|Other|Scheduling using regression modeling system|A regression model that uses predictor of operative length will be used to predict operative, anesthetic, and turn around time length
1939007|NCT01892228|Behavioral|Immediate post-screening treatment education|immediate treatment education after screening to decrease time from initial HIV screening to treatment implementation
1939012|NCT01890707|Procedure|Endotracheal intubation|Administer: Fentanyl:1mcg/kg prior to induction, additional doses to maintain blood pressure and heart rate within 20% of preoperative values, Propofol:2mg/kg,succinylcholine, 0.5mg/kg,to be followed with Rocuronium if necessary,bolus: 0.4mg/kg, Sevoflurane and oxygen to be titrated to maintain BIS value of 40-60.
1939013|NCT01890707|Procedure|Deep Sedation|IV administration of Propofol,initial rate 100ug/kg/min, titrated to maintain BIS 65-75,Fentanyl,Ketamine,1mcg/kg,0.5mg/kg,additional 10mg increments for analgesia/movement.
1939014|NCT01890707|Drug|Fentanyl (Sublimaze TM)|
1939015|NCT01890707|Drug|fluoromethyl hexafluoroisopropyl ether (Sevoflurane TM)|
1939016|NCT01890707|Drug|Succinylcholine (Suxamethonium chloride)|
1939017|NCT01890707|Drug|Rocuronium (Zemuron TM)|
1939018|NCT01890707|Drug|Propofol (Diprivan TM)|
1939019|NCT01890707|Drug|Ketamine|
1939020|NCT01888172|Behavioral|Weight Watchers Online Program|Access to the Weight Watchers Online program available via the Internet on personal computers, tablet computers, and smartphones.
1939021|NCT01888172|Device|Philips ActiveLink|Provision of a key-chain sized physical activity monitor that interfaces with the Weight Watchers website to promote exercise and give feedback on progress towards exercise goals.
1939022|NCT01888172|Behavioral|Eating and Activity Newsletter|General information on healthy eating and physical activity habits and the medical consequences of overweight/obesity and weight loss.
1939023|NCT01887288|Drug|Capecitabine|650 mg/m^2 PO b.i.d.
1939024|NCT01887288|Drug|Digoxin|0.25 mg once daily
1939030|NCT01885663|Procedure|Umbilical cord blood therapy|Intravascular umbilical cord blood therapy
1939031|NCT01885923|Device|ITAREPS|Program ITAREPS (Information Technology Aided Relaps Prevention in Schizophrenia)
1939032|NCT01885221|Behavioral|Multimedia Support Intervention|
1939033|NCT01884350|Drug|Apixaban|
1939034|NCT01882894|Device|Custom PFO|PFO made out of thermoplastic material molded to the patient's foot
1939035|NCT01882894|Other|Faux orthosis|Foam cut out
1939036|NCT01884155|Procedure|Allogeneic umbilical cord blood therapy|
1939037|NCT01884077|Device|Reverse Shoulder Arthroplasty|REVERSE In a Reverse Total shoulder the ball is located on the shoulder blade (glenoid) and the socket is located on the arm bone (humerus), exactly the opposite of the situation in a conventional total shoulder. The ball (glenosphere) is screwed to the bone of the shoulder blade. The cup (humeral sock¬et) is fixed to a stem that is cemented down the inside of the arm bone (humerus).
1939038|NCT01884077|Device|Total Shoulder Arthroplasty|TOTAL In a conventional Total shoulder, the arthritic surface of the ball is replaced with a metal ball with a stem that is press fit in the inside of the arm bone (humerus) and the socket is resurfaced with a component.
1939039|NCT01884025|Behavioral|Get Moving and Get Well|Walking Class
1939040|NCT01884025|Behavioral|Health and Humor Class|Class about the role of humor in health
1939041|NCT01883141|Device|MultiSpot pacing|Subjects will receive pacing from one right ventriclar lead and one left ventricular catheter/lead with multiple LV pacing spots
1939042|NCT01883141|Device|MultiVein pacing|Subjects will receive pacing from one right ventriclar lead and two left ventricular catheter/lead(s)
1939043|NCT01883141|Device|Standard biventricular pacing|Subjects will receive standard biventricular pacing from one right ventriclar lead and one left ventricular catheter/lead
1939044|NCT01883063|Device|Surgical Treatment|Patients will be treated for distal radius fractures surgically with a WRx™ Intramedullary Nail
1939045|NCT01883063|Device|Non surgical Treatment (Cast or splint)|Patients will be treated for distal radius fractures non surgically with a cast or splint
1939046|NCT01881828|Drug|Metformin (glucophage)|The strength of each tablet will be 500 mg. Participants will build up to a daily dose over four weeks by taking one tablet per day for 7 days, one tablet twice daily for 7 days, one tablet in morning and 2 tablets at night for 7 days, and then 2 tablets in the morning and 2 tablets at night, daily throughout the remainder of the study treatment period.
1939047|NCT01881828|Other|oral placebo|
1939048|NCT01882829|Drug|dextromethorphan/quinidine|up to 45/10 mg every 12 hours in patients with TRD with a short 7 day tapering period in which subjects are tapered off 45/10 mg dose from twice a day to once daily for an additional 7 days at post 8-week treatment period to minimize the potential for discontinuation effects
1939049|NCT01882283|Dietary Supplement|Tea Treatment Group|This intervention was a crossover trial, during which each patient experienced both placebo and tea treatment arms
1939052|NCT01881750|Behavioral|Pivotal Response Training|12 week program on instruction of Pivotal Response Training, consisting of group meetings and individual sessions.
1939053|NCT01881750|Behavioral|Parent Education Group|12 week program consisting of offering/discussion information for parents. No pivotal response training provided.
1939056|NCT01881477|Procedure|kinetics modalities|"The duration of the intervention will be approximately 30 minutes to 1 hour and will take place 5 days a week. They constantly monitor the vital signs and signs of exercise intolerance.
The intervention consists of four levels of complexity. The progression in kinetic patterns based on muscle strength during exercise Kinetic methods begin with passive movements and patients are assisted in the movement slowly until they are active, culminating in movements against resistance, in all joints, with a minimum of 10 repetitions for each joint.
Additionally, it promotes the adoption and sitting positions long and short legged and walk."
1939059|NCT01881009|Device|ePID Algorithm on an Android Platform with Remote Monitoring|Medtronic Overnight Closed-Loop System: Revel insulin pump, Enlite sensor, Minimed transmitter, ePID algorithm on an Android platform with remote monitoring.
1939060|NCT01879826|Device|Aculaser applied to kidney points|The patient will receive aculaser, performed by licensed acupuncturist, to known kidney acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure.
1939061|NCT01879826|Device|Aculaser applied to sham points|"The patient will receive aculaser, performed by licensed acupuncturist, to sham acupuncture sites. In addition, the patient will still receive standard pain control protocols with anesthetic medications like lidocaine plus ketamine or fentanyl and versed during the biopsy, along with pain management after the procedure."
1939062|NCT01878929|Drug|Allergen(Tree, Grass, Weeds)|Greer is manufacture of all allergen extract used in this study.
1939063|NCT01878084|Other|bioactive glass (sol-gel)|Extraction sockets will be augmented using bioactive glass (sol-gel)
1939064|NCT01878084|Other|empty extraction socket|Extraction socket will be left empty
1939070|NCT01876251|Drug|PF-03084014|Tablet, 10 mg, twice a day
1939071|NCT01876251|Drug|PF-03084014|Tablet, 50 mg, twice a day
1939072|NCT01876251|Drug|PF-03084014|Tablet, 100 mg, twice a day
1939073|NCT01876251|Drug|Docetaxel|Solution for IV infusion 75 mg/m^2, every 3 weeks
1939074|NCT01876251|Drug|Docetaxel|Solution for IV infusion 100 mg/m^2, every 3 weeks
1939075|NCT01876628|Drug|Flucloxacillin and Clindamycin|Clindamycin dose 300mg four times each day for 2 days, within 48 hours of commencing flucloxacillin. Clindamycin is over-encapsulated and externally identical to placebo.
1939076|NCT01876628|Drug|Flucloxacillin and placebo|Placebo is externally identical to the over-encapsulated clindamycin and is taken four times each day for 2 days
1939078|NCT01876043|Drug|plitidepsin|
1939079|NCT01875861|Other|Evidence-Based Quality Improvement Plus Facilitation|The intervention involves researchers partnering with clinical stakeholders, offering tailoring in local implementation strategies to address barriers to metabolic side-effect monitoring and management. External facilitation to support, problem-solve and refine implementation will be provided for a six-month implementation phase.
1939080|NCT01874418|Other|Biomarker|Oligomeric beta-amyloid 42 in serum, as well as, monomeric beta-amyloid 42, total tau and phosphorylated tau in CSF
1939081|NCT01875341|Device|NCPAP; Nasal continuous positive airway pressure.|Patients will be randomized to receive either therapeutic or sub-therapeutic NCPAP; Nasal continuous positive airway pressure treatment. In patients randomized to therapeutic NCPAP, treatment pressures will be increased until apneas and hypopneas are prevented during all sleep stages. In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
1939082|NCT01875341|Device|NCPAP Nasal Continuous Positive Airway Pressure-sub-therapeutic treatment group|In the sub-therapeutic treatment group, pressure will be left unchanged at the lowest possible value for the NCPAP device. Pressure settings for NCPAP therapy will be determined by Dr. J. Leech, collaborator and specialist in sleep disorders. Treatment will be continued for a total of 6 weeks.
1939084|NCT01874600|Device|Brain Sentinel Seizure Detection Device and Warning System|The Brain Sentinel Seizure Detection Device and Warning System is designed to monitor Epilepsy patients and alerts caregivers that a GTC seizure is occurring
1939087|NCT01874444|Device|1|repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 1000 stimuli of 1Hz rTMS over the left DLPFC (110% motor threshold) followed by 2000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment. Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS
1939088|NCT01874444|Device|2|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left temporal cortex (110% motor threshold), each consisting of 4 days of rTMS treatment.
Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
1939089|NCT01874444|Device|3|"repetitive transcranial magnetic stimulation (Figured 8-Coil MCF-B65): 3000 stimuli of 1 Hz rTMS over the left frontal cortex (110% motor threshold) each consisting of 4 days of rTMS treatment.
Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
1939090|NCT01874444|Device|4|"Sham rTMS, applied with the same combination of parameters as active rTMS, except for the number of stimulations per session.
Participants will have an MRI scan and MEG recoding at the performed a week before rTMS. And MEG recording after 7day the application of rTMS."
1939307|NCT01832207|Device|Transcutaneous electrical nerve stimulation|
1939092|NCT01871857|Drug|Hypertonic saline and epinephrine|
1939093|NCT01871857|Drug|Normal saline and epinephrine|
1939097|NCT01872871|Drug|Paracetamol|paracetamol with local anesthetic eye drop versus placebo with local anesthetic eye drops
1939098|NCT01872871|Drug|Topical anaesthetic drop with placebo|
1939099|NCT01872260|Drug|LEE011|LEE011 - 28 day cycles (21 days followed by a 7 day break) for Arms 1, 3. LEE011 28 days cycles (continuous) Arm 4.
1939100|NCT01872260|Drug|Letrozole|Letrozole 2.5 mg/day
1939101|NCT01872260|Drug|BYL719|BYL719 - 28 days cycle (continuous) for Arm 1; 3 and 4
1939102|NCT01870297|Drug|LY3025876|Administered SQ
1939103|NCT01870297|Drug|Placebo|Administered SQ
1939104|NCT01870297|Drug|Liraglutide|Administered SQ
1939105|NCT01871441|Radiation|Total-body irradiation|Undergo TBI
1939106|NCT01871441|Biological|Donor lymphocytes infusion (DLI)|Undergo DLI
1939107|NCT01871441|Drug|Cyclophosphamide|Given IV
1939108|NCT01871441|Procedure|Allogeneic hematopoietic stem cell transplantation (HSCT)|Undergo haploidentical allogeneic HSCT
1939109|NCT01871441|Drug|Tacrolimus|Given IV
1939110|NCT01871441|Drug|Mycophenolate mofetil|Given IV
1939111|NCT01870518|Device|Bilateral GPi DBS|
1939112|NCT01870518|Device|Bilateral STN DBS|
1939119|NCT01868789|Radiation|Weightbearing CT|
1939124|NCT01867424|Drug|Eovist|0.1 ml/kg Eovist will be administered intravenous (IV) to each patient
1939128|NCT01867307|Drug|Empagliflozin|
1939129|NCT01867307|Drug|BI 10773|open label
1939130|NCT01867047|Drug|ACE-I Cessation group|"Subjects stop ACE-I 48 hours prior to surgery. Examples of possible ACE-I drugs include:
benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
1939131|NCT01867047|Drug|ACE-I Continuation group|"Subjects take ACE-I through day of surgery. Examples of possible ACE-I drugs include:
benazepril (Lotensin), captopril (Capoten), enalapril (Vasotec, Epaned), fosinopril (Monopril), lisinopril (Prinivil, Zestril), moexipril (Univasc), perindopril (Aceon), quinapril (Accupril), ramipril (Altace), trandolapril (Mavik)"
1939132|NCT01867216|Drug|Placebo|Administered orally as capsules
1939133|NCT01867216|Drug|LY2922470|Administered orally as capsules
1939136|NCT01865773|Procedure|HFR dialysis|HFR is a dialysis technique that combines the processes of diffusion, convection and adsorption. In this double chamber hemodiafiltration system, the ultrafiltrate is reinfused after its passage (and opportune modification) through a resin cartridge.
1939137|NCT01865708|Drug|Ethanol Lock|Ethanol lock, utilizing 74% ethanol, will begin within 24 hours of urinary catheter placement. The lock will be done every 24 hours for 1 hour. The volume that will be instilled depends upon the fill volume of the catheter, which is imprinted by the manufacturer on each catheter. Once the alcohol is in the catheter, the proximal end of the catheter will be clamped for 1 hour. After the 1 hour dwell time, the clamp will be removed and the alcohol in the lumen of the catheter will be flushed out by the patient's own urine output.
1939138|NCT01865539|Device|Custom Foot Orthotic|Custom foot orthotic with custom design pads
1939139|NCT01865539|Device|Sham Orthotic|Leather insert without the custom design pads
1939140|NCT01865448|Dietary Supplement|Omega-3 DHA|Patients take daily 2 tablets of placebo
1939308|NCT01832207|Device|Placebo transcutaneous electrical nerve stimulation|
1939309|NCT01831843|Device|Group C|non-heated, non-humidified conventional breathing circuit was used in group C patient
1939141|NCT01863420|Radiation|Bone Marrow-sparing Intensity-Modulated Radiotherapy|Use Bone Marrow-sparing Intensity-Modulated Radiotherapy to limit the dose of active bone marrow in radiation fields. The BM regions on the T1-weighted images that showed a signal intensity equal to or slightly higher than that of muscle were contoured as active BM
1939142|NCT01864473|Other|Kshar Sutra|The Kshar Sutra is a standard medicated thread smeared with Kshar of Apamarga (Achyranthus Aspera), Shnuhi (Euforbia Nerrifolia) which has quality of cutting and Haridra (Curcuma longa) which is used as a antiseptic. This combination of medicine on the thread helps in debridement and simultaneously healing of track. After conformation of vaginal fistula the track was cleaned with betadine and Hydrogen peroxide. The Kshar Sutra was tied covering the entire underlying track for simultaneous cutting and healing under all aseptic precaution. The patient was discharged on the next day of procedure. Patient was advice for Sitz bath with lukewarm water. The Kshar Sutra was changed weekly.
1939143|NCT01864213|Drug|Ametop cream|
1939146|NCT01863758|Biological|Human-cl rhFVIII|
1939147|NCT01863563|Device|QuickClot|1 application of treatment to each tonsil/adenoid removal area
1939148|NCT01863056|Other|Sit-Stand Desk|Subjects were asked to participate in the study for a total period of three months. Based on randomization, either the first or third month involved the active intervention to use an adjustable sit-stand desk. The other two months required the subjects to follow their usual work routine without the adjustable sit-stand desk. The control period month involved all the same measurements as the active intervention month, whereas the washout period, which was the 2nd (middle) month, did not involve any measurement and there was no contact with the subjects during the washout month.
1939149|NCT01863030|Device|Phasix mesh implant|
1939151|NCT01861587|Device|tDCS|20 minutes of either real or sham stimulation
1939152|NCT01861418|Other|Lumbopelvic Manipulation|Participant will lie in supine position. The treating investigator (TI) will stand on opposite side of low back pain. Participant will clasp his/her hand behind the neck. TI will side bend participant's spine towards non-painful side. TI will reach through participant's hands and perform spinal rotation away from painful side. TI's other hand will be placed over anterior superior iliac spine (ASIS) of painful side. TI will take up the slack and maintain pressure on the ASIS for 5-10 seconds and ask the participant whether he/she can tolerate the pressure. If participant can tolerate the pressure for at least 5 seconds, verbal permission will be obtained from participant and TI will proceed and apply a high-velocity low-amplitude posterior thrust force over the ASIS.
1939153|NCT01861418|Other|Sham manipulation|Each participant will be asked to lie in a supine position. The treating investigator will stand on the opposite side of the low back pain. Then, the participant will be asked to clasp his/her hand behind the neck. The treating investigator will side bend the participant's spine towards the non-painful side to mid-range. The treating investigator will reach through the participant's hands and perform a spinal rotation away from the painful side to the mid-range. The treating investigator's other hand will be placed over the anterior superior iliac spine (ASIS) of the painful side.
1939154|NCT01860651|Behavioral|Web-monitoring|During the E-health intervention, symptoms and FC are monitored closely through the web-program and treatment will be initiated by symptoms and elevated FC.
1939155|NCT01860014|Drug|Poractant alfa|Curosurf: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
1939156|NCT01860014|Drug|Beractant|Survanta: 100 mg/kg-intratracheal, just after pulmonary hemorrhage
1939157|NCT01860391|Device|Diammine Silver Fluoride|Diammine SIlver Fluoride will be applied to teeth. The levels of silver and fluoride in saliva will be measure up to 7 days
1939163|NCT01858207|Procedure|Transcatheter Arterial Chemoembolization|traditional TACE, conventional TACE
1939164|NCT01858207|Procedure|Radiofrequency ablation|simultaneous multiple electrodes and switching RF controller
1939165|NCT01858207|Drug|Doxorubicin|TACE will be done according to the current method in our center. We use intra-injection of lipiodol mized with doxorubicin when the catheter was placed in the superselective location very close to the tumor. Gelfoam sponge was then injected to temporarily occlude the arterial blood flow.
1939166|NCT01858428|Device|Cardiovascular Ingenuity (CVI) Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|The CVI Paclitaxel-coated PTA Catheter is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA) coated with paclitaxel using a proprietary carrier.
1939167|NCT01858428|Device|EverCross Percutaneous Transluminal Balloon Catheter|The control device is a commercially available PTA balloon catheter (EverCross™ 0.035 PTA Balloon Catheter, Covidien, Plymouth, MN 55441, USA).
1939168|NCT01858415|Device|TriPollar|
1939169|NCT01858402|Drug|Paracetamol|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
1939170|NCT01858402|Drug|Dipyrone|15 mg/kg IV (premixed with 0.9% sodium chloride to a total of 50 ml), preoperative single dose
1939171|NCT01858363|Device|CVI Paclitaxel-coated Percutaneous Transluminal Angioplasty Balloon Catheter|
1939172|NCT01858363|Device|Bare Percutaneous Transluminal Angioplasty Balloon Catheter|
1939173|NCT01859091|Device|The Zeltiq System|Non-invasive cooling is applied to the treatment area with a defined cooling rate and duration.
1939523|NCT01792817|Device|Sham GammaCore device|Treatment with sham stimulator
1939180|NCT01857661|Device|sound generator|hearing aid with an integrated sound generator
1939181|NCT01857661|Device|hearing aids with only amplification|
1939182|NCT01855867|Drug|Coformulated Elivitegravir (150mg), Combicistat (150mg), Emtricitabine (200mg), Tenofovir DF (300mg)|
1939183|NCT01856790|Device|ePID closed loop system|Insulin pump controlled by closed loop unit and algorithm
1939184|NCT01856790|Drug|liraglutide|Liraglutide is a long-acting analog of human GLP-1 that works as a GLP-1 receptor agonist
1939185|NCT01856595|Drug|PF-06291874|The dosing schedule is 5, 15, 50 and 150 mg QD for 14 days for the first 4 cohorts in Part A. The dosing schedule for the first cohort in Part B is 15 mg QD for 14 days. Doses for part A cohort 5 and Part B cohorts 2 and 3 are TBD QD for 28 days.
1939186|NCT01856595|Drug|Placebo|Placebo tablets will be administered QD in each of the cohorts for 14 days (Part A cohorts 1-4 and Part B cohort 1) or 28 days (Part A cohort 5 and Part B cohorts 2 and 3).
1939187|NCT01856491|Device|RELIANCE 4-FRONT™ Passive Fixation lead implantation|Implantation of transvenous defibrillation lead with passive fixation mechanism.
1939188|NCT01856270|Drug|Amitriptyline|Participants with headache will be enrolled within the first 12 weeks after injury and will be randomly assigned to 2 groups (see Table 1 for summary of protocol). Group 1 will be assessed within 3 months of injury (baseline, Day 0) (when they will receive their initial ramp-up dosage containers; see Table 2 for dosing), Day 30 and Day 60 (to monitor compliance and distribute study drug), and for final outcome on Day 90. Group 2 will be assessed within 3 months of injury (baseline, Day 0) but will not receive medication until their Day 30 visit. Those in group 2 who report headache at Day 30 will receive their initial dosage container and will then be reassessed at Day 60 (to monitor compliance and distribute study drug) and Day 90 (final outcome).
1939196|NCT01855789|Drug|Placebo|Participants will receive methotrexate matching placebo.
1939197|NCT01855789|Drug|Tocilizumab|Participants will receive tocilizumab 162 mg subcutaneously weekly (in participants weighing >/= 100 kg) or 162 mg subcutaneously every 2 weeks (in participants weighing <100 kg).
1939198|NCT01855789|Drug|methotrexate|Participants will receive stable oral dose of MTX (15 to 25 mg/week).
1939199|NCT01855360|Drug|Tauroursodeoxycholic Acid and Doxycycline|
1939200|NCT01855243|Drug|regular insulin|
1939201|NCT01855243|Drug|70/30 insulin|
1939202|NCT01855243|Drug|Glargine|
1939203|NCT01855243|Drug|glulisine|
1939204|NCT01854931|Behavioral|Tai Ji Quan|single aim intervention
1939205|NCT01854762|Drug|Raltegravir|a raltegravir-based antiretroviral regimen (AZT+3TC+Raltegravir) will be administered for intervention arm patients (AZT+3TC will be administered in a fixed combination of AZT 300mg +3TC 150 mg, BID. Raltegravir will be administered in a dosis of 1 400 mg pill BID).
1939206|NCT01854762|Drug|Lopinavir/Ritonavir|The second arm (comparator)patients will use a regimen composed by AZT+3TC (same dosis/schedule of active arm)+ LPV 200mg combined with rtv 50 mg, 2 pills BID
1939207|NCT01853501|Procedure|Autologous fat grafting|ADSC ovary injection
1939212|NCT01854476|Device|pad-gauze with tranexamic acid (Hemostopan™)|The use of pad-gauze containing tranexamic acid (Hemostopan™)
1939213|NCT01854125|Biological|autologous bone marrow mesenchymal stem cells transplantation|Autologous MSCs were infused to patients using interventional method via hepatic artery . The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes.
1939214|NCT01854125|Biological|autologous bone marrow msenchymal stem cells transplantation|
1939215|NCT01853462|Device|proprioceptive neuromuscular facilitation exercise program|ten individual sessions (approximately one hour per session) of a proprioceptive neuromuscular facilitation exercise program by a physiotherapist
1939216|NCT01853462|Device|balance exercise program|ten individual sessions (approximately one hour per session) of a balance exercise program by a physiotherapist
1939217|NCT01853540|Drug|Sildenafil|
1939218|NCT01853878|Biological|Recombinant PRAME protein combined with the AS15 Adjuvant System GSK2302032A|Intramuscular administration
1939219|NCT01853878|Biological|Placebo|Intramuscular administration
1939222|NCT01853137|Device|Fixed Lingual Mandibular Growth Modificator (FLMGM)|Novel Class II functional appliance, a fixed version of double-plate appliance
1939527|NCT01790594|Drug|Tacrolimus|There may be an opportunity to withdraw tacrolimus at week 40
1939223|NCT01852799|Drug|PAD Followed by ASCT|"Drug: Bortezomib, Bortezomib (1.3mg/m2, iv, on day 1, 4, 8, 11, of each 28 day cycle)
Drug: Adriamycin (Doxorubicin) /EPI, Adriamycin (Doxorubicin) (9 mg/m2, iv, on days 1-4 of each 28 day cycle) or EPI (15mg/m2, iv, on days 1-4 of each 28 day cycle)
Drug: Dexamethasone, Dexamethasone (20mg, iv, on days 1-4, 8-11of each 28 day cycle)
After received induction therapy, patients will proceed to receive ASCT based on the willing of the patients and the decision of the investigators."
1939224|NCT01852513|Drug|QNASL|
1939225|NCT01852513|Drug|Placebo nasal spray|
1939228|NCT01850030|Drug|Dydrogesterone 30 mg|Oral Dydrogesterone 10 mg tablets tid
1939229|NCT01850030|Drug|Micronized Progesterone 600 mg|Intravaginal micronized progesterone 200 mg capsules tid
1939230|NCT01850030|Drug|Placebo progesterone|Placebo intravaginal micronized progesterone 200 mg capsules tid
1939231|NCT01850030|Drug|Placebo dydrogesterone|placebo oral dydrogesterone 10 mg tablets tid
1939232|NCT01850745|Other|Multidisciplinary support program|Multidisciplinary support program that included counselling about relevance of adherence by hepatologist, nurse and pharmacist. Psychologist and psychiatrist support if needed.
1939236|NCT01848821|Device|OASIS Ultra|Porcine derived intestinal submucosa
1939237|NCT01848821|Device|Wound VAC Standard Therapy|Negative pressure wound device aka wound VAC will be placed on the standard therapy half of the wound
1939238|NCT01849263|Drug|Ibrutinib|Given PO
1939239|NCT01849263|Other|Laboratory Biomarker Analysis|Correlative studies
1939240|NCT01849055|Drug|Placebo|Administered orally
1939241|NCT01849055|Drug|LY3023703|Administered orally
1939242|NCT01849055|Drug|Celecoxib|Administered orally
1939243|NCT01848184|Device|PARIETEX™ Composite Ventral Patch for ventral hernia repair|
1939245|NCT01847690|Drug|Hydrocortisone|Cortef 5 mg tablets per os, 2x5 mg, one day, one time
1939246|NCT01847014|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily.
1939247|NCT01847209|Procedure|Video-Assisted Thoracic Surgery (VATS) wedge resection|
1939248|NCT01845298|Drug|Rifampicin 600 mg|The investigators will administer a single dose of rifampicin 600 mg to study subjects in order to conduct a pharmacokinetic study of rifampicin absorption.
1939251|NCT01845636|Drug|Donepezil|Donepezil 5mg will be given for 4 weeks and if tolerated, the dose will be increased to 10 mg per day. The dose range of 5 to 10 mg of donepezil per day will be continued for the study duration, and this is the recommended dose for donepezil in the treatment of mild to moderate Alzheimer's disease.
1939252|NCT01845636|Drug|Atropine|A single acute dose of 1 mg of atropine nasal spray is administered to the nostril. The dose chosen reflects clinical doses typically used by Ear, Nose, and Throat (ENT) physicians.
1939253|NCT01845363|Drug|Cefazolin used in antimicrobial prophylaxis|"Cefazolin administered a first dose of 2g in anesthetic induction, followed by continuous dosage of 1g diluted in 250mL of saline solution for two hours.
Two samples of subcutaneous tissue were collected for analysis: the first soon after the incision, and a second before skin synthesis.
The samples were processed by HPLC."
1939254|NCT01844284|Device|XIENCE PRIME®/XIENCE Xpedition™|Subjects receiving XIENCE PRIME®/XIENCE Xpedition™
1939255|NCT01844284|Device|Absorb™ BVS|Subjects receiving Absorb™ BVS
1939256|NCT01844141|Drug|70% alcohol|After phenolization of the ingrown toenail the wound is irrigated with 15 cc solution of 70% alcohol plus 0.5% clorhexidine
1939257|NCT01844141|Drug|70% alcohol - 0.5% clorhexidine|In the intervention group five rounds of 3 ml wash of 70% alcohol - 0.5% clorhexidine was used to irrigate the exposed area of the nail to neutralize any residual effect of phenol and found out how much residual phenol is still in the wound.
1939260|NCT01843803|Other|patient inventory|Patients in the intervention arm will complete an inventory of their preferences, resources, and life circumstances that may affect their care. The inventory will be completed on an iPad, and a copy of the results will be given to the patient's provider at the time of their visit.
1939261|NCT01843803|Other|attention control|Patients will view a brief healthy living video on an iPad
1939262|NCT01842958|Device|Straumann Bone Level Implants, 4.1 mm implant diameter|Straumann Bone Level Implants, 4.1 mm implant diameter
1939263|NCT01842958|Device|Straumann Bone Level Implants, 3.3 mm implant diameter|Straumann Bone Level Implants, 3.3 mm implant diameter
1939264|NCT01843621|Biological|DEN vaccine F17|The dengue booster vaccine was administered subcutaneously in the non-dominant arm (deltoid). The tetravalent, live attenuated DEN F17 vaccine was administered in this study. This pre-transfection formulation contained dengue virus types 1, 2, 3 and 4 (DEN-1, -2, -3 and -4).
1939310|NCT01831843|Device|Group E|breathing tube which apply humidity and heat (Evaqua™ Breathing Circuits manufactured by Fischer & Paykel)was used in group E patient
1939265|NCT01843608|Other|Physical Intervention|The exercise program will be designed and conducted by qualified in Physical Activity and Sport Sciences. The exercise program will consist in a combined two days per week of supervised training program and one day per week of briskly walking by themselves, following a document, designed by the specialist trainer, which will be given at the beginning of the program. The intervention will have a duration of 12 consecutive weeks. The intensity will be increasing progressively from 65% to 85% of heart rate. The intensity will be controlled by heart rate monitor trademark POLAR FT7 in aerobic exercise and with the number of repetitions (from 8 to 15) and sets (from 2 to 3) in strength exercises. Prescription intensity will be done using Karvonen equation, recommended method to work with risk population.
1939266|NCT01843231|Device|g-CathTM EZ Suture Anchor Delivery Catheter|Use of the g-Cath EZ Suture Anchor Delivery Catheter for the placement of g-cath EZ suture anchors as an early weight loss intervention + diet and exercise as compared to those in the diet and exercise control group
1939267|NCT01843231|Other|Diet and Exercise Control Group|Patients in a diet and exercise only control group that will be compared to those in the g-Cath EZ Suture Anchor Delivery Catheter treatment group
1939268|NCT01842620|Drug|Metformin|Oral antidiabetic agent
1939274|NCT01842048|Other|Hyperthermia|
1939275|NCT01842048|Radiation|External-beam radiotherapy|
1939276|NCT01841762|Drug|Macitentan|Macitentan tablet, dose of 10 mg, once daily
1939277|NCT01841606|Drug|Ondansetron|Time of administration of drug
1939278|NCT01838304|Device|Probability ramp control|Decision support software that calculates propofol doses appropriate for age and weight of the patient
1939279|NCT01838304|Device|Monitoring|Manual recording of drug doses determined by CRNA
1939281|NCT01838395|Drug|Ara-C|IV
1939282|NCT01838395|Drug|BL-8040|SC
1939283|NCT01837823|Drug|rosuvastatin|All subjects will receive rosuvastatin 40mg/day for 8-12 weeks
1939284|NCT01837654|Behavioral|Performing Plantarflexion during urodynamic test|
1939285|NCT01838031|Other|thyroid screening|The thyroid function and antibody will be measured immediately. The subclinical hypothyroidism will be treated individually.
1939290|NCT01836549|Drug|imetelstat sodium|Given IV
1939291|NCT01835990|Device|geko|The geko is a neuromuscular stimulation device that stimulates the common peroneal nerve resulting in contraction of the leg muscles and increased venous and arterial flow. It is Health Canada approved for prevention of deep venous thrombosis.
1939292|NCT01835990|Device|IPCs|devices that pneumatically compress the leg, resulting in increased venous blood flow.
1939293|NCT01835782|Drug|L-Serine|
1939294|NCT01835418|Drug|Amlodipine|crossover comparison of amlodipine vs lisinopril
1939295|NCT01834846|Procedure|no-touch|The saphenous vein is exposed by a longitudinal incision, and all visible side branches ligated. The vein is then isolated together with a pedicle of surrounding tissue and manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
1939296|NCT01834846|Procedure|conventional|The saphenous vein is exposed by a longitudinal leg incision, skeletonized from surrounding tissue, and side branches ligated. The vein is removed from the leg immediately after dissection, manually distended and stored in a combination of blood and saline using a syringe, according to standard procedure at St. Olav's Hospital.
1939297|NCT01834872|Device|Amigo|
1939298|NCT01834872|Device|Manual ablation|
1939299|NCT01833871|Other|Three dimensional Power Doppler to the myometrial mass|Trans-vaginal 3D power Doppler Ultrasonographic examination will be done for all participants prior to surgery. The ultrasonographic examination will provide data related to lesion size, lesion volume, vascular location (location), vascular index (VI), flow index (FI), and vascular-flow index (VFI). The region of interest will include the entire region of the uterine mass. The virtual organ computer aided analysis (VOCAL) software for the analysis of 3D power Doppler histograms will be used with computer algorithms to form indices of blood flow and vascularization. All data will be collected and compared with the post operative histopathology results.
1939300|NCT01833871|Other|Uterine artery Doppler|uterine artery Doppler indices(RI,PI) are measured for all cases with myometrial mass
1939301|NCT01833858|Drug|Low dose HCG|Low dose hCG (200 IU per day) will be given daily when at least six follicles of 12 mm will be observed and E2 (Estradiol) levels are higher than 600 ng/l, until the day of the HCG trigger administration.
1939302|NCT01833858|Drug|Placebo|Patients received rFSH injections with Placebo starting on cycle day 3 of the stimulation cycle until the day of hCG trigger administration.
1939311|NCT01831843|Device|Group M|Heated humid tube with a warming device (Mega Acer kit manufactured by Acemedical,Seoul Korea)was used in group M patient
1939312|NCT01831050|Biological|Bivalent Oral Polio Vaccine (bOPV)|Produced by Sanofi Pasteur, Lyon, France, bivalent OPV vaccine contains types 1 and 3 polioviruses and it is indicated for supplementary immunization activities in children from 0 to 5 years of age to prevent or contain outbreaks caused by these 2 serotypes.
1939313|NCT01831050|Biological|Trivalent Oral Polio Vaccine (tOPV)|Produced by Sanofi Pasteur, Lyon, France, trivalent OPV vaccine contains types 1, 2, and 3 polioviruses and it is indicated for routine and supplementary prevention of poliomyelitis in children from 0 to 5 years of age.
1939314|NCT01831050|Biological|Monovalent Oral Polio Vaccine Type 2 (mOPV2)|Licensed monovalent OPV type 2 vaccine (mOPV2) by Glaxo SmithKline, Rixensart, Belgium. Polio Sabin Mono Two (oral) is a monovalent, live attenuated poliomyelitis virus vaccine of the Sabin strain Type 2 (P 712, Ch, 2ab), propagated in MRC5 human diploid cells.
1939315|NCT01831050|Biological|Sanofi-Pasteur IPV (Sanofi IPV)|Inactivated poliovirus vaccine is produced by Sanofi-Pasteur as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
1939316|NCT01831050|Biological|Glaxo SmithKline IPV (GSK IPV)|Inactivated poliovirus vaccine is produced by Glaxo SmithKline, Rixensart, Belgium, as a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
1939317|NCT01831050|Biological|Serum Institute of India IPV (SII IPV)|Inactivated poliovirus vaccine produced by Nederland's Vaccin Instituut in Bilthoven, The Netherlands (acquired recently by Serum Institute of India [SII]) is licensed in the producing country and prequalified by the WHO. It consists of a sterile suspension of 3 types of poliovirus. Each dose of vaccine (0.5 mL) contains 40 D antigen units of Mahoney strain (Type 1); 8 D antigen units of MEF-1 strain (Type 2); and 32 D antigen units of Saukett strain (Type 3).
1939318|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Meal time dosing is defined as injecting 0-2 minutes before the meal.
1939319|NCT01831765|Drug|insulin detemir|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Administrated once or twice daily.
1939320|NCT01831765|Drug|insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted.
1939321|NCT01831765|Drug|Faster-acting insulin aspart|Injected subcutaneously (s.c., under the skin), dose individually adjusted. Post meal time dosing is defined as injecting 20 minutes after the start of the meal.
1939322|NCT01831635|Other|Methodological pens|Randomisation of branded pen, non-branded pen and no pen
1939323|NCT01831635|Other|Methodological compensation|Randomisation of a £10 monetary reimbursement for expenses on completion of the study
1939324|NCT01831635|Other|Methodological trolley tokens|Trolley tokens to be randomly assigned to half of cases and General Practice controls.
1939329|NCT01831089|Drug|PM01183 + paclitaxel +/- bevacizumab|"PM01183: 1 mg and 4 mg vials. Powder for concentrate for solution for infusion
paclitaxel: 6 mg/ml concentrate for solution for infusion
bevacizumab: 25 mg/ml concentrate for solution for infusion
Once a recommended dose is defined for the PM01183 and weekly paclitaxel combination, the feasibility of adding bevacizumab to this combination will be explored in a prospectively selected cohort of patients"
1939330|NCT01830400|Drug|Eslicarbazepine Acetate tablets|The Eslicarbazepine Acetate (ESL) Summary of Product Characteristics (SPC) recommended a starting dose of 400 mg once-daily (QD) which was increased to 800 mg QD after one or two weeks. Based on individual response, the dose was increased to 1200 mg QD. Treatment decisions were made by clinicians in agreement with the participant, and were independent of participation in the study.
1939331|NCT01830478|Drug|Lenalidomide|Lenalidomide 20 mg p.o. once daily, days 1-21 every 28 days, for 6 cycles
1939332|NCT01830478|Drug|Rituximab|Rituximab 375 mg/m2 intravenously, day 14 of every course for 6 cycles
1939333|NCT01829087|Drug|Botox|
1939334|NCT01829087|Drug|placebo|
1939337|NCT01827735|Drug|Aldesleukin (Proleukin)|A single, subcutaneous dose will be given administered with the maximum dose allowed 1.5 X 106 IU/M2.
1939338|NCT01828255|Device|SENSIMED Triggerfish®|
1939340|NCT01826149|Drug|Propofol 1.0mcg|Propofol dosage titration to achieve effect site concnetration at 1.0 mcg/ml using target controlled infusion.
1939341|NCT01826149|Drug|Propofol 2.0mcg|Propofol dosage titration to achieve effect site concnetration at 2.0 mcg/ml using target controlled infusion.
1939342|NCT01826149|Drug|Propofol 3.0mcg|Propofol dosage titration to achieve effect site concnetration at 3.0 mcg/ml using target controlled infusion
1939343|NCT01826565|Procedure|Rotational technique|90 degree rotation
1939386|NCT01816529|Drug|0.1% solution of sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
1939387|NCT01816529|Drug|Saline (0.9%)|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
1939344|NCT01825798|Drug|Metformin|Metformin will be dispensed in a liquid suspension of 100 mg/mL. For children 6-9 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, metformin will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if metformin is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if metformin is well-tolerated, the dose will be increased to 850 mg twice daily.
1939345|NCT01825798|Drug|Placebo|The placebo hydrochloride oral solution will be prepared to match the appearance, smell and taste of the metformin as closely as possible. For children from 6-9 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. For children from 10-17 years of age, placebo will be started at 250 mg at their evening meal for 1 week, followed by the addition of a 250 mg dose at breakfast for 1 week. At the Week 2 visit, if placebo is well-tolerated, the dose will be increased to 500 mg twice daily. At the Week 4 visit, if placebo is well-tolerated, the dose will be increased to 850 mg twice daily.
1939346|NCT01826227|Procedure|Positron Emission Tomography|
1939347|NCT01826227|Radiation|18F-Fluoro-2-deoxy-D-lucose|
1939348|NCT01826227|Procedure|Cytoreductive surgery|
1939349|NCT01826422|Dietary Supplement|EPA and DHA|Each capsule contains 245mg of DHA, 45mg of EPA, other omega 3 50mg, oleic acid 60mg and Vitamin E 7.5 I. U.
1939350|NCT01826422|Dietary Supplement|Placebo Comparator: Sunflower oil|The placebo capsules will also contain sunflower oil. Each gram contains: myristic (C14: 0 0) 1 mg, palmitic (C16: 0) 62mg, stearic (C18: 0) 43mg, palmitoleic (C16: 1) 1mg, oleic (C18: 1) 202mg, linolenic (C18: 3) 1mg and linoleic (C18: 2) 632mg.
1939351|NCT01824979|Device|CPAP mask ( Pilairo)|
1939352|NCT01824979|Procedure|Other CPAP mask|
1939353|NCT01822405|Drug|pentoxifylline with tocopherol|Pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day,oral during 6 months
1939354|NCT01822405|Other|pentoxifylline+tocopherol + Hyperbaric Oxygen Therapy|"pentoxifylline 800 mg/day (400 mg/12hours) + Vitamin E (alfa-tocopherol) 1000 mg/day, oral during 6 months.
Hyperbaric Oxygen Therapy at 100% in 25 sessions of 90 minutes 5 days per week (5 weeks) at 2,4 Ata in Hyperbaric chamber, starting in 3 or 9 weeks after randomization and beginning of drug treatment."
1939359|NCT01821274|Drug|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
1939360|NCT01821274|Drug|Vehicle Cream|0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
1939361|NCT01821274|Drug|0.1% solution o sodium lauryl sulfate (SLS)|0.2 mL applied topically to the infrascapular area of the back will serve as a positive control.
1939362|NCT01821274|Drug|Saline 0.9%|0.2 mL applied topically to the infrascapular area of the back will serve as a negative control.
1939363|NCT01820026|Drug|Imipenem|second line therapy
1939364|NCT01820026|Drug|Vancomycin|Second line therapy
1939365|NCT01820026|Drug|azithromycin|Second line therapy
1939366|NCT01820026|Drug|Cefotaxime|Standard antibiotic therapy
1939367|NCT01820026|Drug|Amoxicillin|Standard therapy
1939368|NCT01820455|Drug|Chlorhexidine, Mupirocin|Chlorhexidine baths and intranasal mupirocin ointment once daily for five days
1939369|NCT01820455|Drug|Soap baths, Lubricating Jelly|Soap and water baths with lubricating jelly to the nares, once daily for 5 days
1939370|NCT01820351|Other|static stretching exercise on 3 times a week during 8 weeks. Sets number: three of 30 seconds with intervals of equal duration|
1939371|NCT01819064|Drug|Atropine|intravenous atropine in low doses does not cause bradycardia
1939372|NCT01819064|Drug|Atropine|IV dose at 5 mcg/kg
1939373|NCT01819610|Drug|SPRIX|
1939374|NCT01819129|Drug|Faster-acting insulin aspart|Mealtime FIAsp administered subcutaneously (s.c., under the skin). Dose individually adjusted.
1939375|NCT01819129|Drug|Insulin aspart|Mealtime insulin aspart administered subcutaneously (s.c., under the skin). Dose individually adjusted.
1939376|NCT01819129|Drug|Insulin glargine|Administered s.c. once daily at subjects' pre-trial dose. Subjects will continue their metformin treatment without changing the frequency or dose throughout the trial.
1939377|NCT01818284|Drug|Filgrastim|5 µg/kg in the morning daily for 4 days.
1939378|NCT01818284|Drug|Plerixafor|240 µg/kg subcutaneously in the evening on the fourth day of Filgrastim mobilization.
1939379|NCT01818284|Procedure|Apheresis Procedure|"The apheresis procedure will start in the morning of day 5, approximately 10 to 11 hours after the administration of Plerixafor.
The apheresis procedure may continue beyond day 1 until the target dose of 4x106 CD34+ cells/kg (recipient's weight) is obtained."
1939380|NCT01817270|Biological|Live Attenuated Varicella Vaccine|
1939381|NCT01817491|Other|American Heart Association Diet|
1939382|NCT01817491|Other|Reduced Fat Vegan Diet|
1939384|NCT01816529|Drug|Diltiazem Hydrochloride 2% Cream|0.2 g applied topically to the infrascapular area of the back.
1939385|NCT01816529|Drug|Vehicle Cream|Vehicle Cream, 0.2 g (contains no active pharmaceutical ingredient) applied topically to the infrascapular area of the back.
1939430|NCT01808131|Drug|Lesinurad|Tablets, 400 mg QD
1939390|NCT01816620|Drug|Lenalidomide, Dexamethasone|"12 cycles of lenalidomide and dexamethasone, each cycle lasts 28 days. For patients with Ccr equal to or higher than 30ml/min, oral lenalidomide 10mg once daily for days 1-21 out of a 28 cycle.
For patients with Ccr lower than 30ml/min, oral lenalidomide 10mg once every other day for days 1-21 out of a 28 cycle.
All the patients take Dexamethasone orally 40mg once weekly for day 1,8,15,22 out of a 28 cycle."
1939391|NCT01816594|Drug|BKM120|Neo-adjuvant BKM120 (oral pan-class I PI3K inhibitor, continuous daily dosing). BKM120 will be administered orally 100 mg/day.
1939392|NCT01816594|Drug|Trastuzumab|Trastuzumab is a humanized monoclonal antibody directed against the extracellular juxtamembrane domain of the HER2 receptor. Administered 4mg/kg i.v. load followed by 2mg/kg i.v. weekly.
1939393|NCT01816594|Drug|Paclitaxel|Paclitaxel is a cytotoxic agent with proven antitumor activity in a variety of solid tumors. The antitumor activity of paclitaxel is based on tubulin-binding and stabilization of non-functional microtubule bundles, thereby blocking normal mitotic spindle development and subsequent cell division. Administered weekly 80mg/m2 i.v.
1939394|NCT01816594|Drug|Placebo|Neoadjuvant BKM120 placebo Administered orally 100 mg/day.
1939395|NCT01816191|Drug|Diltiazem Hydrochloride Cream and Oral Diltiazem|
1939396|NCT01816048|Drug|TAK-700|TAK-700 will be administered at 300mg twice per day on 28-day continuous cycles
1939397|NCT01816048|Radiation|Fluorine F 18 Sodium Fluoride|Undergo NaF F18 PET/CT scan
1939398|NCT01816048|Procedure|Positron Emission Tomography|Undergo 18F NaF PET/CT scan
1939399|NCT01816048|Procedure|Computed Tomography|Undergo 18F NaF PET/CT scan
1939400|NCT01815424|Drug|placebo|placebo BID for 16 weeks and then re-randomized into active groups
1939401|NCT01815424|Drug|CP-690,550|CP-690,550 5mg BID for 52 weeks
1939402|NCT01815424|Drug|CP-690,550|CP-690,550 10mg BID for 52 weeks
1939403|NCT01815073|Biological|Live Attenuated Varicella Vaccine + Live Attenuated JE Vaccine|
1939404|NCT01815073|Biological|Live Attenuated Varicella Vaccine|
1939405|NCT01815073|Biological|live attenuated JE vaccine|
1939406|NCT01813474|Drug|olaparib|tablet oral
1939407|NCT01812005|Drug|alisertib|Given PO
1939408|NCT01812005|Biological|rituximab|Given IV
1939409|NCT01812005|Other|laboratory biomarker analysis|Laboratory correlative studies will be performed
1939410|NCT01811771|Biological|Shanchol vaccine|Shanchol vaccine contains whole cell inactivated heat killed and formalin killed bacteria consisting of 600 ELISA Units (EU) of lipopolysaccharide (LPS). It consists of formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973). It also contains 300 EU LPS of heat-killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of formalin killed V. cholerae Ogawa classical biotype (Cairo 50); 300 EU LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48); and 600 EU LPS of formalin killed V. cholerae O139 (4260B) (9). The vaccine has no detectable cholera toxin. Vaccine is packaged as liquid formulations in 1.5-ml doses. No buffer is needed for administered.This vaccine is licensed in India and WHO prequalified.
1939411|NCT01810978|Dietary Supplement|Bifidobacterium lactis plus inulin|5 billion unit Bifidobacterium lactis plus 900 mg inulin per day will be given
1939412|NCT01810978|Dietary Supplement|Maltodextrin|same amount of maltodextrin per day will be given as placebo
1939413|NCT01810861|Other|There is no intervention in this study|This is a non-interventional study.
1939414|NCT01809899|Behavioral|consent procedure|Enhanced consent entails a more detailed consent process
1939415|NCT01809483|Device|Bandage contact lens|Bandage contact lens : contact lenses (material senofilcon A; base curve 8,8 mm; power - 0,50; diameter 14 mm)
1939416|NCT01809483|Device|Pressure patching|Pressure patching : using 2 pieces of sterile gauze. The first gauze placed vertically and the second placed horizontally, then fixed with adhesive tape so that eyelid can not move.
1939417|NCT01809470|Behavioral|FIFA2013|Playing FIFA2013 for 1 hour
1939418|NCT01809470|Behavioral|Call of Duty|Playing Call of Duty for 1 hour
1939419|NCT01809470|Behavioral|Watching TV|Watching TV for 1 hour
1939420|NCT01809210|Drug|selumetinib|2 x 25mg capsules bd continuously in cohort 1 (with gemcitabine and cisplatin). If tolerated - next cohort 3 x 25mg capsules bd continuously. if higher doses are explored, required number of capsules will be provided. Option to administer on D2-19 of each 21 day cycle if required to assess tolerability of combinations with chemotherapy
1939421|NCT01809210|Drug|gemcitabine|1250 mg/m2 iv on Day 1 and 8 of each 21 day cycle. If combination not tolerated, option to give 1000 mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
1939422|NCT01809210|Drug|cisplatin|75 mg/m2 iv on Day 1 of each 21 day cycle. If combination not tolerated, option to give 50 mg/m2 iv on Day 1 or 25mg/m2 iv on Day 1 and Day 8 of each 21 day cycle
1939423|NCT01809210|Drug|carboplatin|If it is not possible to identify a tolerable combination of selumetinib, gemcitabine and cisplatin, cisplatin may be replaced with carboplatin (AUC5) iv on Day 1 of each 21 day cycle
1939424|NCT01809210|Drug|pemetrexed|Gemcitabine may be replaced with pemetrexed 500 mg/m2 iv on Day 1 of each 21 day cycle.
1939425|NCT01808144|Drug|lesinurad|Tablets, 400 mg once daily (QD)
1939426|NCT01808144|Drug|lesinurad|Tablets, 200 mg QD
1939427|NCT01808781|Other|Exercises plus walking program|"Exercise group Consist of functional exercises such as mini-squats, sit to stand, and exercises with use of thera-bands. For each exercise, participants will be taught to perform the concentric phase forcefully and as fast as they can and return to the initial position slowly and with control. Participants will be asked to perform the exercises 3 times per week as a home exercise program daily throughout the 8-week intervention period. Additionally, they will be asked to wear a pedometer daily throughout the 8-week intervention to monitor steps. A step goal will be provided to gradually increase daily to become somewhat active or active by the end of the 8-week intervention."
1939428|NCT01808781|Other|Walking only program|Participants will be asked to wear a pedometer and instructions for use just as the exercise group. They will also will given a step goal just as the participants in the exercise group and will similarly be asked to record number of steps form their pedometer in a daily log along with the minutes of moderate and vigorous physical activity throughout the 8-week intervention period.
1939429|NCT01808131|Drug|Lesinurad|Tablets, 200 mg QD
1939432|NCT01807650|Drug|Oleogel-S10 ointment and non-adhesive wound dressing|One randomly assigned wound half is treated with Oleogel-S10 and non-adhesive wound dressing
1939433|NCT01807650|Device|Non-adhesive wound dressing alone|The other wound half is treated with non-adhesive wound dressing alone.
1939436|NCT01807858|Dietary Supplement|Bifidobacterium lactis|5 billion active Bifidobacterium lactis
1939437|NCT01807858|Dietary Supplement|Bifidobacterium lactis plus İnülin|5 billion Bifidobacterium lactis plus 900 mg İnülin per day will be given
1939438|NCT01807858|Other|Maltodextrin|Maltodextrin
1939439|NCT01807858|Dietary Supplement|İnulin|900 mg inulin per day will be given
1939440|NCT01806662|Drug|Ustekinumab|Injection of monoclonal antibody against the p40 subunit of IL-12/23
1939441|NCT01806662|Other|Placebo|Injection of placebo
1939442|NCT01806896|Drug|PF-02545920|"Dose will be titrated up every 2 days by 5mg increments: 5mg Days 1-2, 10mg days 3-4, 15mg days 5-6, and reach 20 mg from Days 7 to Day28.
Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
Treatment for 28 days."
1939443|NCT01806896|Drug|Placebo|"- Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
Dosing for 28 days."
1939444|NCT01806896|Drug|PF-02545920|"5mg dose
Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
Dosing for 28 days."
1939445|NCT01806896|Drug|Placebo|"Orally, approx. Q12H (range 10-14 hours), administered at least one hour prior to, or two hours after meals.
Dosing for 28 days."
1939446|NCT01805895|Drug|Minocycline|This arm will receive a total of 5 doses of minocycline. Dose 1 will be 400mg IV within 12-hours of onset of symptoms. Dose 2 will be 400mg oral, given daily on days 2-5 . Each dose is 24 hours apart.
1939447|NCT01804842|Drug|Met DR|metformin delayed-release tablets
1939448|NCT01804582|Other|Family Navigator consultation|"Telephone contact from the trained family navigator to the parent participant several times over the 90 day study time period. Components of the service include the following:
(1)family engagement; (2) inquiry about psychosocial resource needs related to schools, outpatient child treatment, support programs, or mental health resources for other household family members; (3) discuss potential benefits/challenges of options and parent preferences/priorities for care; (4) assessment on perceived barriers to seeking resources; (5) collaborative problem solving to address barriers; (6) discuss options for follow up plan."
1939449|NCT01804023|Other|HEC placebo gel applicators|"Participants will handle, but not insert, 4 applicators containing HEC placebo gel.
Participants will vaginally insert and removed 8 applicators containing HEC placebo gel. Gel will be expelled in to the vagina from only 2 applicators."
1939450|NCT01803204|Other|Booklet - Preoperative Educational|the patients receive a booklet during the preoperative phase. The educational session with a booklet will occur before the surgery.
1939451|NCT01803711|Drug|Desvenlafaxine|
1939452|NCT01803711|Dietary Supplement|Omega 3 Fatty acids|
1939453|NCT01803711|Drug|Placebo (for Omega 3 fatty acid supplement)|
1939454|NCT01803464|Other|Botox plus low-magnitude vibration|Half of the children who receive Botox treatment will be randomly assigned to receive a high-frequency, low magnitude vibration treatment. The other half of the children who receive Botox treatment and are randomly assigned to the Botox-only group will be offered the vibration treatment at the end of the study.
1939455|NCT01803464|Drug|Botox|Children will not receive vibration treatment. Children in the Botox-only group will be offered vibration treatment at the end of the study.
1939456|NCT01803451|Drug|exendin-(9-39)|hyperglycemic clamp-meal tolerance test is designed to assess insulin secretion before and after meal ingestion
1939457|NCT01803451|Drug|exendin -(9-39)|2-day meal tolerance tests with labeled oral and IV glucose using exendin-(9-39) infusion are designed to evaluate the role of GLP-1 signaling on glucose tolerance and glucose kinetics.
1939460|NCT01802710|Behavioral|Psychological support|
1939461|NCT01802710|Other|No intervention|
1939462|NCT01802450|Drug|Dasatinib|
1939469|NCT01802203|Device|truFreeze Spray Cryotherapy|spray cryotherapy
1939470|NCT01801956|Behavioral|physical activity|free membership of a sport club
1939471|NCT01801956|Other|Motivational interview|Four motivational interviews by instructors of the local sport club
1939472|NCT01801956|Other|Virtual arena|Uploading of training data from a GPS-watch to a virtual arena
1939474|NCT01801202|Device|LightSheer Duet HS handpiece|The approach to be studied here relies on a cleared modality, the LightSheer Duet High Speed (HS) that uses 805 nm diode laser with vacuum (K053628).
1939475|NCT01800838|Drug|silicon phthalocyanine 4|Given topically
1939476|NCT01800838|Drug|photodynamic therapy|Undergo DPT
1939477|NCT01800838|Other|pharmacological study|Correlative studies
1939478|NCT01800838|Other|laboratory biomarker analysis|Correlative studies
1939479|NCT01800461|Other|OPC-Stroke|Occupational therapy coaching intervention
1939480|NCT01800461|Other|Usual care|Usual community care
1939481|NCT01800019|Drug|Nicotine Replacement Therapy (NRT)|
1939482|NCT01800019|Drug|Varenicline|
1939524|NCT01790594|Biological|Belatacept|The first dose of belatacept will be administered approximately 24-48 hours after the last dose of Anti-Thymocyte Globulin (Rabbit).
1939483|NCT01800019|Behavioral|HIV Tailored Quit Smoking Counseling|"A cognitive behavioral therapy (CBT) oriented smoking cessation program tailored to HIV positive individuals.
People Living with HIV/AIDS (PHA) tailored Canadian HIV Quit Smoking Counseling Intervention. It consists of face-to-face counseling sessions with a trained smoking cessation counsellor at randomization, on the identified quit date, and then at weeks 4, 8, 12, and 24."
1939484|NCT01798550|Drug|Enoxaparin|Twice daily dosing
1939485|NCT01799460|Drug|The Comprehensive Treatment Regimen of Traditional Chinese Medicine|"①ShenQiMoShen Decoction: which plays vital therapeutic effect in the CTR,the dosage is 150ml per serving and two services per day.Dosage and administration:150ml per time,twice per day
②HuoXueTongMai Capsule : which plays a vital role of promoting blood circulation and removing blood stasis. Its main components are the leeches. Dosage and administration: 4 capsules 3 times daily.
③HeiLiaoDou Particle: which will be prescribed when hypoproteinemia (serum albumin concentration≤30g/L)occurred and should be stopped taking until the serum albumin is above 30g/L. Dosage and administration: 2 packages 3 times daily."
1939486|NCT01799460|Drug|The immunosuppressive agents|According to Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guideline for glomerulonephritis
1939487|NCT01798589|Drug|Ethylenediamine dihydrochloride|1 allergen panel containing 2 allergen and 2 control patches
1939488|NCT01797822|Drug|dexamethasone, artificial tears|
1939489|NCT01798225|Drug|Placebo|Participants received mechanical periodontal therapy, oral hygiene instructions and placebo pills.
1939490|NCT01798225|Drug|Doxycycline|Participants received mechanical periodontal therapy, oral hygiene instructions and Doxycycline 100mg x 14 pills (to be taken one a day for 14 days)
1939491|NCT01798056|Biological|GSK 1437173A|2 doses administered by intramuscular (IM) injection into the deltoid muscle of the non-dominant arm.
1939492|NCT01798056|Drug|Placebo|2 doses administered by IM injection into the deltoid muscle of the non-dominant arm.
1939493|NCT01797094|Biological|botulinum toxin Type A (44U)|44 units botulinum toxin Type A (total dose) per treatment. 24 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
1939494|NCT01797094|Biological|botulinum toxin Type A (32U)|32 units botulinum toxin Type A (total dose) per treatment. 12 U injected into bilateral Crow's Feet Line areas and 20 U injected into Frown Line area.
1939495|NCT01797484|Drug|Ranolazine|Improvement of myocardial microcirculation
1939496|NCT01797406|Other|Air insufflation|Air is inflated into the bowel to help searching the cavity while advancing the colonoscope until reaching the cecum
1939497|NCT01797406|Other|Water injection|Water was injected through the working channel instead of air to follow the intestinal cavity until reaching the caecum .
1939498|NCT01797081|Biological|botulinum toxin Type A (24 U)|24 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
1939499|NCT01797081|Biological|botulinum toxin Type A (12 U)|12 units botulinum toxin Type A (total dose) injected into bilateral Crow's Feet Line areas per treatment.
1939500|NCT01797081|Other|Normal Saline|Normal saline (placebo) injected into bilateral Crow's Feet Line areas per treatment.
1939502|NCT01795846|Other|Allergen specific immunotherapy and placebo injections|
1939503|NCT01795638|Drug|Sodium chloride|
1939504|NCT01795638|Drug|Placebo|sterile water, 0.4 ml/kg every 6 hours on days of life 7-35.
1939510|NCT01795417|Device|RF XP200|Four weekly non-invasive periorbital wrinkles treatment with RF XP200 device
1939511|NCT01795417|Device|XP200 RF device|4 RF treatments of periorbital region on one side of the face
1939514|NCT01791517|Other|Solution 1 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to all four lens care solution in a random order
1939515|NCT01791517|Other|Solution 2 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
1939516|NCT01791517|Other|Solution 3 (Test)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
1939517|NCT01791517|Other|Solution 4 (Control)|Each subject, for each lens type (Lens A, Lens B or Lens C) will be exposed to each lens care solution in a random order
1939518|NCT01793311|Other|decaffeinated coffee|contains caffeine 0.5-2 mg
1939519|NCT01793311|Other|regular dose coffee|contains 91.8 mg of caffeine
1939520|NCT01793311|Other|high dose coffee|contains 144 mg of caffeine
1939521|NCT01793220|Other|SMS reminder|A text message reminder service will be sent 7 and 1 days(s) prior to the patients appointment at their Psychosis Community Service.
1939522|NCT01792817|Device|GammaCore|Treatment with active gammacore vagus nerve stimulator
1939528|NCT01790594|Drug|Mycophenolate mofetil|Mycophenolate mofetil will be administered at a target dose of 1000 mg by mouth twice daily (e.g., BID) beginning on the day of surgery or post-operative day 1 depending upon when during the day the surgery is completed (maximum MMF dosing is 2G per day). MMF will be adjusted based on clinical complications (such as neutropenia). Myfortic® (mycophenolate sodium) may be used as a replacement for MMF. Mycophenolate sodium will be dosed at 720 mg PO BID. Mycophenolate sodium will be adjusted based on clinical complications.
1939529|NCT01790165|Drug|TDT067 and Lamisil|Topical administration of TDT067 and single oral administration of 250 mg Lamisil tablet
1939535|NCT01788943|Drug|Nictonie Patch, Verenacline|
1939536|NCT01788826|Procedure|Prophylactic mesh|Closure of midline laparotomy using a prophylactic mesh. The midline is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1. Then, a prefascial large-pore low-weight 5 cm wide polypropylene mesh (Optilene Mesh Elastic, B.Braun) is fixed covering the midline closure. The mesh is fixed in the prefascial plane with absorbable monofilament interrupted sutures, USP 2/0.
1939537|NCT01788826|Procedure|No prophylactic mesh closure|Closure of midline laparotomy without mesh. The laparotomy is closed with a running absorbable monofilament suture with a suture/wound length ratio 4:1. The material is a monofilament uncoated suture made of poly-4hiydroxybutirate (Monomax, B.Braun) USP 1.
1939542|NCT01788059|Other|injection the mesenchymal stem cell in non union site|
1939545|NCT01787604|Procedure|Aortic Root Reimplantation Procedure|Modified Florida Sleeve.
1939546|NCT01787604|Procedure|Aortic Valve Reimplantation Procedure|David I
1939547|NCT01787097|Drug|Symbicort®, Formoterol, Budesonide|Formeterol is Long acting beta 2-agonist (LABA) whereas Budesonide is inhaled corticosteroids (ICS).Patients will randomly receive one-off dose-administration of inhaled treatment (each medication will be taken as two puffs, all via a dry-powder inhaler device = Turbuhaler® to achieve the TOTAL doses).
1939548|NCT01785927|Other|ABCD|Rifampicin, isoniazid, pyrazinamide, and levofloxacin dry powders will be administered to each patient by randomization. Each formulation will be assigned the code, such as A, B, C, or D, and the treatment sequences will be generated as ABCD (sequence 1), BCDA (sequence 2), CDAB (sequence 3) and DABC (sequence 4). On the first day of drug dosing in period I, volunteers will be randomly assigned to a sequence of treatments as indicated in a pre-printed randomization scheme, which was generated using block randomization with block sizes of 4 and 6, and the allocation ratio of 1:1. Subjects will be stratified by sex. Subjects in sequence 1 will receive treatment A during the first study period and will then cross over to receive treatment B, C, and D at the second, third and fourth periods, respectively (each after a 7-day washout period).
1939549|NCT01784770|Drug|Azithromycin IV|"The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with community-acquired pneumonia due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for at least two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 500 mg, administered as two 250-mg tablets to complete a 7- to 10-day course of therapy.
The recommended dose of ZITHROMAC (azithromycin for injection) for the treatment of adult patients with pelvic inflammatory disease due to the indicated organisms is: 500 mg as a single daily dose by the intravenous route for one or two days. Intravenous therapy should be followed by azithromycin by the oral route at a single, daily dose of 250 mg to complete a 7-day course of therapy."
1939550|NCT01784926|Procedure|Intraocular lens repositioning by scleral suturing|
1939551|NCT01784926|Procedure|Intraocular lens exchange with retropupillary iris-claw lens|
1939552|NCT01783522|Drug|glutamine|Dose of 15 grams twice times daily (to equal 30 grams a day) for a period of 4 months.
1939553|NCT01783522|Other|quality-of-life assessment|Ancillary studies
1939554|NCT01783522|Other|placebo|Given PO
1939555|NCT01784172|Device|electroacupuncture group|Procedure: electro-acupuncture;Points: Bilateral Zhongliao (BL33) Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Bilateral BL33 are given acupuncture of 50～60mm with 30～45°angle to inward and downward by 75mm filiform needle. Bilateral BL35 are given acupuncture of 50～60mm to outward and upward by 75mm filiform needle. Twirl, lift and thrust for 3 times, until local sour and heavy feeling coming.The electric stimulator is applied to bilateral BL33 and BL35, with continuous wave,50 Hz and electric current 1- 5mA.Every session lasts for 30 min per day.The participants are treated continuously for 6 weeks for 3 sessions a week, 18 sessions for each patient in all. The treatment is designed based on recent literature research in 10 years, former result and expert consensus.
1939556|NCT01784172|Device|sham electroacupuncture group|Procedure: sham electroacupuncture;Points: Bilateral sham Zhongliao (BL33) sham Huiyang(BL35).Specially-made pad is stick on pierced acupoints. Both sham BL33 and BL35 are given non-penetrating needling with blunt needle. Twirl, lift and thrust for 3 times. The sham electric stimulator is applied to bilateral sham BL33 and sham BL35. The mental wire has been cut off with a same outlook as the treatment group. The electric stimulator is looked normal but with no current output. Length of Treatment and the treatment sessions are the same as treatment group.
1939557|NCT01783847|Drug|Recombinant human erythropoietin (EPO)|4000 units per vial
1939558|NCT01783743|Other|TT Training Program and Recognition Card|The intervention is an additional training program on trichiasis recognition and a TT recognition card to assist community treatment assistants in recognizing TT cases and referring them to surgery.
1939559|NCT01782729|Drug|Tacrolimus|Tacrolimus ointment, 0.03 percent twice a day for pediatric population for 4 weeks or until 1 week after the affected areas defined for treatment at baseline are completely cleared, whichever is first.
1939560|NCT01782807|Procedure|Salpingectomy or Fimbriectomy|
1939561|NCT01782495|Drug|ABT-450/r/ABT-267|tablet
1939562|NCT01782495|Drug|ABT-333|tablet
1939563|NCT01782495|Drug|ribavirin (RBV)|tablet
1939564|NCT01781702|Drug|Pelubiprofen 30 mg|
1939565|NCT01781702|Drug|Celebrex 200 mg|
1939566|NCT01782287|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
1939567|NCT01782287|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
1939568|NCT01782274|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
1939569|NCT01782274|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
1939570|NCT01781988|Drug|carboplatin, gemcitabine , pametrexed|"A.individual therapy :enrolled patients with ERCC1 negative tumors who received carboplatin and a third-generation agent (gemcitabine or pametrexed) based on RRM1 or TS expression. If RRM1 protein was negatively expressed in the tumor tissues, gemcitabine was used, whereas pemetrexed was used if RRM1 was positively expressed and TS was negatively expressed.
B.non-individualized therapy :enrolled patients who received carboplatin and a third-generation agent but were not based on ERCC1, RRM1, or TS expression."
1939572|NCT01781286|Behavioral|High Protein|250 kcal; 40% Protein; 40% Carbohydrate; 20% Fat
1939573|NCT01781286|Behavioral|Low Protein|5% Protein; 50% Carbohydrates; 45% Fat
1939574|NCT01779089|Drug|Minocycline 100 mg po bid for 6 months|Minocycline 100 mg po bid or placebo for 6 months
1939575|NCT01779089|Drug|placebo|
1939580|NCT01777308|Biological|Meningococcal conjugate vaccine GSK134612|Single dose to be administrated intramuscularly in the deltoid of the non-dominant arm
1939581|NCT01777347|Drug|3% Saline|Two 4 mL nebulization of 3% saline with 20 minutes interval
1939582|NCT01777347|Drug|0.9% Normal Saline|Two 4 mL nebulization of 0.9% normal saline with 20 minutes interval
1939583|NCT01777295|Biological|Adjuvanted Hepatitis B surface antigen (HBsAg) candidate vaccine GSK2231392A.|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1939584|NCT01777295|Biological|EngerixTM-B|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1939585|NCT01777295|Biological|Placebo|Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
1939586|NCT01777256|Drug|GSK2586184 50 mg|GSK2586184 tablet will be administered orally as twice daily dose of 50 mg (1 x 50 mg tablet) up to 12 weeks.
1939587|NCT01777256|Drug|GSK2586184 100 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 50 mg tablet) up to 12 weeks.
1939588|NCT01777256|Drug|GSK2586184 200 mg|GSK2586184 tablet will be administered orally as twice daily dose of 200 mg (1 x 200 mg) up to 12 weeks.
1939589|NCT01777256|Drug|GSK2586184 400 mg|GSK2586184 tablet will be administered orally as twice daily dose of (2 X 200 mg) up to 12 weeks.
1939590|NCT01777256|Drug|Placebo|Matching placebo tablet will be administered orally twice daily up to 12 weeks.
1939591|NCT01777139|Drug|Retigabine IR|Retigabine IR tablets will be available in 5 strengths: 50 mg, 100 mg, 200 mg, 300 mg, and 400 mg.
1939593|NCT01776983|Device|Photosensitivity under the influence of immunocomp|Siascopy measurement of reflected light
1939594|NCT01775462|Drug|EDI200|3 or 10 mg/kg of EDI200
1939595|NCT01776008|Drug|Akt Inhibitor MK2206|Given PO
1939596|NCT01776008|Drug|Anastrozole|Given PO
1939597|NCT01776008|Drug|Goserelin Acetate|Given SC
1939598|NCT01776008|Other|Laboratory Biomarker Analysis|Correlative studies
1939599|NCT01776008|Procedure|Neoadjuvant Therapy|Given before standard-care surgery
1939600|NCT01776008|Other|Pharmacological Study|Correlative studies
1939601|NCT01776008|Procedure|Therapeutic Conventional Surgery|Undergo standard-care surgery
1939602|NCT01775722|Device|port wine stain|port wine stain
1939607|NCT01775878|Device|Telemonitoring Device|Telemonitoring device was installed in patients' homes
1939608|NCT01775124|Drug|Ranibizumab|Intravitreal injections of 0.5 mg Ranibizumab
1939609|NCT01774942|Other|All teeth out, full dentures, dental implants, blood draw|All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
1939610|NCT01774591|Drug|Azilsartan medoximil|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
1939611|NCT01774591|Drug|Placebo|All subjects were randomized to 80mg azilsartan medoxomil (azilsartan) daily or placebo and followed for six months.
1939612|NCT01773096|Drug|Methylnaltrexone|Patient will receive methylnaltrexone on postoperative day 3 on a weight based dose and again 24 hours later if required.
1939613|NCT01773096|Drug|Senna, docusate sodium, bisacodyl, magnesium hydroxide, Miralax|Standard institutional bowel protocol will begin on post-operative day 1. Miralax,Docusate sodium or senna will be given on a weight-based dosing. If no bowel movement in 72 hours, bisacodyl or magnesium hydroxide will be added.
1939614|NCT01773070|Drug|ABT-450/ritonavir|Drug is not administered -- this study is follow-up for subjects previously receiving the drug.
1939615|NCT01773070|Drug|ABT-333|Drug is not administered -- this study is follow-up for subjects previously receiving the drug.
1939616|NCT01773070|Drug|ABT-267|Drug is not administered -- this study is follow-up for subjects previously receiving the drug.
1939617|NCT01773928|Biological|Vero cell-derived trivalent influenza vaccine manufactured with the modified manufacturing process (VCIV modified)|
1939618|NCT01773928|Biological|VCIV manufactured with the current manufacturing process (VCIV current)|
1939619|NCT01773928|Biological|Fluzone®, licensed trivalent influenza vaccine (TIV)|
1939620|NCT01773954|Drug|Intravitreal Aflibercept Injection More|Increased time between visits
1939621|NCT01773954|Drug|Intravitreal Aflibercept Injection Less|Reduced time between visits
1939622|NCT01772199|Drug|GSK239512|White to almost white, round tablets. Once daily orally, started at 10 mcg and titrated to the maximum tolerated dose, Up to the highest dose of 80 mcg (10 mcg first week, 20 mcg second week, 40 mcg third week, 80 mcg fourth week) followed by 44 week maintenance treatment period
1939623|NCT01772199|Drug|Placebo|White to almost white, round tablets. Once daily orally.
1939624|NCT01773005|Drug|Ofirmev|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia and intravenous Acetaminophen (1000 mg Ofirmev) at the time of surgical wound closure, followed by 800 mg Caldolor plus 1000 mg Ofirmev every 6 hours until discharge for a total of up to 120 hours (5 days)
1939625|NCT01773005|Drug|Caldolor|Subject receives the interventional drug, intravenous ibuprofen (800 mg Caldolor) at the induction of anesthesia, followed by 800 mg Caldolor every 6 hours until discharge or for a total of up to 120 hours (5 days)
1939626|NCT01772446|Behavioral|SMS MESSAGING|SMS MESSAGING TO MOBILE PHONE TO REMEMBER THE NEXT CONTROL OF GLYCATED DIABETES
1939627|NCT01772108|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
1939628|NCT01770782|Procedure|Surgically Assisted Rapid Maxillary Expansion (SARME)|Surgical technique is performed with subtotal LeFort I osteotomy with separation of the pterygomaxillary fissure.The procedure was performed under general anesthesia using endotracheal intubation. Following the osteotomies, the expander screw was activated to 1.6 mm intraoperatively until a small diastema was observed between the upper central incisors. The incision was sutured along two planes.
1939629|NCT01770782|Other|Laser Scanner|Laser Scanner Vivid 9i was used to digitize the study models. The 3d virtual dental casts is a reliable copy of the original dental casts. On this virtual casts all measurements (linear, area and volume of the palate) was done to evaluate the stability after SARME.
1939630|NCT01771666|Device|(IC-GREEN™) SPY Elite® Imaging|
1939631|NCT01771419|Device|Loop-tip wire (Cook Medical) for the cannulation of the CBD|
1939632|NCT01771419|Device|Cannulotome CT-25mm Cook Medical|
1939633|NCT01771276|Device|g-Cath Suture Anchor Delivery Catheter|Evaluate changes in emptying, hormones, satiety and weight loss with use of the g-Cath Suture Anchor Delivery Catheter in maximizing g-Cath Suture Anchor placement to as high as 25 anchors.
1939634|NCT01771055|Procedure|Galactose|Galactose dripped into the abdomen after surgery
1939635|NCT01771055|Procedure|Standard surgical methods|
1939636|NCT01769716|Procedure|Umbilical Cord Blood administration|
1939638|NCT01769456|Behavioral|3MV|Many Men, Many Voices (3MV) is based on Social Cognitive Theory and the Transtheoretical Model of Behavior Change. 3MV is a group-level intervention that addresses behavioral and social determinants and other factors influencing the HIV/sexually transmitted infection (STI) risk and protective behaviors of Men having sex with men (MSM) of color. The other factors include cultural, social and religious norms, racial identity and degree of connectedness to communities, HIV/STI interactions, sexual relationship dynamics, and the social influences of racism and homophobia.
1939639|NCT01769456|Behavioral|PCC|Personalized Cognitive Counseling (PCC) is based on the Model of Relapse Prevention and Gold's Self-Appraisal of Risk Behavior. PCC is a 1-hour, single-session, individual level intervention administered by a trained counselor in a clinic setting. Counselors ask the client to recall and describe in as much detail, a recent encounter of unprotected anal sex with another man of unknown or sero-discordant HIV status. The client then identifies and expresses thoughts, feelings, or attitudes that might have led to the high-risk behavior. The client and counselor examine and identify thoughts that may have led the client to decide to engage in high transmission risk sex. The client and counselor agree on strategies that can be used to deal with similar situations in the future.
1939640|NCT01769456|Drug|Emtricitabine/tenofovir (FTC/TDF (Truvada®))|All subjects will be provided with daily FTC/TDF (Truvada®) as Pre-exposure prophylaxis (PrEP) for 48 weeks.
1939759|NCT01744912|Drug|Ublituximab|Ublituximab is a novel monoclonal antibody targeting CD20
1939760|NCT01744912|Drug|Lenalidomide|Lenalidomide has both immunomodulatory and anti-angiogenic properties which could confer antitumor and antimetastatic effects
1939761|NCT01743677|Drug|CP-690,550|Single dose 100 mg (5 x 20 mg tablets)
1939641|NCT01768806|Behavioral|PLAY Project Intervention for Autism|Children diagnosed with autism were recruited to the PLAY Project Intervention grant and assigned to a community standard arm (CS) or a CS plus PLAY Project arm of the study. Those in the PLAY Project arm of the study received a one time per month home visit to train caregivers in the PLAY Project methods including video feedback and caregivers also receive mid month feedback based on the video review of interaction.
1939642|NCT01768806|Behavioral|Special education pre-school|Special education preschool services included 10-12 hours per week of educational services including speech and language and occupational therapy
1939645|NCT01767844|Dietary Supplement|Creatine|Creatine, often found in meat and fish, make up an essential part of the systems that provide energy to the muscles for movement and exercise.
1939646|NCT01767844|Dietary Supplement|Placebo|
1939647|NCT01766284|Device|NIRIS 1300e|Optical coherence tomography (OCT) is similar to ultrasound pulse-echo imaging, with optical scatter rather than acoustic reflectivity being measured. OCT employs harmless near-infrared light technology which uses low coherence interferometry to produce an image (based on optical scattering) of tissue microstructure.
1939650|NCT01765296|Drug|CG100649|2 mg capsule
1939651|NCT01765296|Drug|Celecoxib|200 mg capsule
1939652|NCT01765296|Drug|Placebo|Mimic for CG100649 2 mg capsule and for celecoxib 200 mg capsule
1939653|NCT01764893|Other|PTNS plus solifenacin|12 weekly treatments with percutaneous tibial nerve stimulation with 5 mg of solifenacin; an additional 4 weeks of solifenacin for a total of 15 weeks of study drug.
1939654|NCT01764893|Other|Placebo|12 weekly treatments with percutaneous tibial nerve stimulation with placebo; an additional 4 weeks of placebo for a total of 15 weeks of placebo.
1939655|NCT01762839|Drug|Single-Dose IV Oritavancin Diphosphate|Intravenous oritavancin will be administered via two dedicated, peripheral venous lines one in each arm. The infusion will last approximately 3 hours.
1939656|NCT01762839|Drug|Placebo|IV placebo will be administered via two dedicated, peripheral venous lines one in each arm. The infusion will last approximately 3 hours.
1939657|NCT01762839|Drug|Moxifloxacin|Subjects randomized to the open label Moxifloxacin treatment arm will only receive a 400 mg moxifloxacin tablet and will not receive a placebo infusion.
1939661|NCT01762930|Drug|Shanchol|Each dose of the vaccine contains inactivated whole cell, heat killed and formalin killed bacteria measured as ELISA Units (EU) of lipopolysaccharide (LPS). It contains formalin-killed V. cholerae Inaba, El Tor biotype (strain Phil 6973; 600 EU); heat-killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); formalin killed V. cholerae Ogawa classical biotype (Cairo 50; 300 EU); LPS of heat-killed V. cholerae Inaba, classical biotype (Cairo 48; 300 EU); and formalin killed V. cholerae O139 (4260B; 600 EU).
1939662|NCT01761942|Dietary Supplement|fatty acids preparation- eye-q|3x2 tablets daily by 70 days
1939663|NCT01760187|Drug|lomitapide|
1939664|NCT01759810|Biological|Dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes|
1939665|NCT01759810|Biological|Dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes|
1939666|NCT01759459|Drug|Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
1939667|NCT01759459|Drug|Buffered Lidocaine|The medication will be administered immediately prior to receiving peripheral IV catheter placement
1939668|NCT01759459|Drug|Bacteriostatic Normal Saline|The medication will be administered immediately prior to receiving peripheral IV catheter placement
1939671|NCT01758393|Drug|Prednisone|
1939672|NCT01757678|Device|Measured FFR|Fractional Flow Reserve
1939676|NCT01756846|Other|usual care|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
1939677|NCT01756846|Other|use of HEART risk score|During 14 months, patients presenting with chest pain to the ED of participating hospitals will be included in the study. First, all hospitals will apply 'usual care' to all patients, i.e. risk assessment and subsequent management without application of the HEART score. Then, during a 14 month period, each 1,5 month 1 randomly allocated hospital will sequentially start to apply the HEART score in all chest pain patients (intervention period); during this intervention period patients with a HEART score 0-3 will not be admitted to the hospital, and patients with a HEART score above 3 will be treated according to current guidelines.
1939678|NCT01756560|Drug|dexamethsone|
1939679|NCT01756560|Drug|Bupivacaine|
1939680|NCT01756742|Other|Respiratory physiotherapy|"The respiratory physiotherapy intervention included:
Mobilisation techniques: limb exercises (passive, active assisted, or active resisted)
Chest physiotherapy: it included a Controlled breathing program, pursed lips breathing (PLB), active expiration and incentive spirometry."
1939681|NCT01756742|Other|Conservative treatment|Conservative medical treatment intervention for pleural effusion.
1939682|NCT01756664|Other|Sunscreen|
1939683|NCT01756664|Other|Vaseline|
1939684|NCT01756573|Drug|Dexamthsone|
1939685|NCT01756573|Drug|Bupivacaine|
1939686|NCT01756196|Drug|Spinal Steroid Injection|Steroid Injection
1939688|NCT01755689|Biological|Meningococcal vaccine GSK134612|One dose administered intramuscularly (IM) in the deltoid of the right arm.
1939689|NCT01755689|Biological|Cervarix®|Three doses administered intramuscularly (IM) in the deltoid of the left arm.
1939690|NCT01755689|Biological|Boostrix®|One dose administered intramuscularly (IM) in the deltoid of the left arm.
1939691|NCT01755572|Drug|Liraglutide|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
1939692|NCT01755572|Drug|Placebo|Single cross-over study, 1 arm starting with liraglutide for 3 weeks crossed-over to placebo for 3 weeks, and 1 arm starting with placebo with cross-over to liraglutide for 3 weeks.
1939693|NCT01755260|Other|Jejunostomy tube feeding|The patients at this arm receive the nutritional support through the feeding jejunostomy tube; they can only eat or sip water through mouth
1939694|NCT01755221|Other|Single-center prospective evaluation of the Restech pH probe|All subjects will have a pH probe placed at their initial clinic visit and will have the probe removed 24 hours later. They will start on PPI medication (as per the standard of care) after probe removal. Subjects will have a follow up clinic visit 8-12 weeks after the initial visit. At the follow up visit, all subjects will have the option of a second probe placement to assess the effects of PPI therapy on reflux events.
1939695|NCT01754831|Device|Fluoride varnish|Topical application of fluoride varnish on present teeth
1939696|NCT01754688|Other|Bilirubin Induced Neurologic Dysfunction II score|
1939697|NCT01753570|Drug|MP-424|MP-424: 750mg every 8 hours (q8h) for 12 weeks
1939698|NCT01753570|Drug|RBV|RBV: 600 - 1000 mg/day based on body weight for 48 weeks
1939699|NCT01753570|Drug|IFN beta|IFN: 600 MIU/day, 6 days/week for initial 4 weeks following to 3 days/week
1939703|NCT01751971|Drug|Inspired oxygen (40%)|Supplemental oxygen at approximately 40% e.g. via Pink venturi mask
1939704|NCT01751971|Other|Sham|Medical air with 21% oxygen e.g. via Pink venturi mask
1939705|NCT01751906|Device|Absorb BVS|"Scaffold diameters: 2.5, 3.0 and 3.5 mm
Scaffold lengths: 8, 12, 18, and 28 mm The 3.0 x 18 mm Absorb BVS will be used for the Lead-In. Both the 8 mm and 12 mm lengths will be available for the 2.5/3.0 mm diameter Absorb BVS. Only the 12 mm length will be available for the 3.5 mm diameter.
The commercially approved CE marked device will be used in geographies where it is commercially available. The commercially approved CE marked 23mm Absorb BVS device will not be used in this study.
Bioabsorbable drug eluting stent implantation for improving coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
1939706|NCT01751906|Device|XIENCE|"Commercially approved XIENCE Family Stent System, inclusive of XIENCE V, XIENCE PRIME, XIENCE Xpedition, XIENCE Alpine, XIENCE Pro (OUS only), and XIENCE ProX (OUS only).
Stent diameters: 2.5, 2.75, 3.0, 3.25, 3.5 and 4.0 mm
Stent lengths: 8, 12, 15, 18, 23, and 28 mm. The 3.25 mm is only available for XIENCE Xpedition
For geographies where these devices are commercially available, the investigational sties may use only their locally approved devices
To improve coronary luminal diameter in patients, including those with diabetes mellitus, with ischemic heart disease due to de novo native coronary artery lesions (length ≤ 24 mm) with a reference vessel diameter of ≥ 2.5 mm and ≤ 3.75 mm."
1939762|NCT01743677|Drug|Placebo|Single dose placebo tablets (5 tablets)
1939763|NCT01743677|Drug|Moxifloxacin|Single dose Avelox 400 mg tablet
1939871|NCT01729598|Drug|Valproic Acid|generic valproic acid tablets packaged in placebo-matched capsules.
1939872|NCT01729598|Drug|Placebo|Placebo capsule without active study medication in identical capsules as experimental medicine.
1939708|NCT01750541|Drug|Haloperidol|
1939709|NCT01750541|Drug|Valproate|
1939710|NCT01750229|Device|Medtronic RestoreSensor Frequency Setting 1|Frequency Setting 1
1939711|NCT01750229|Device|Medtronic RestoreSensor Frequency Setting 2|Frequency Setting 2
1939712|NCT01750229|Device|Medtronic RestoreSensor Frequency Setting 3|Frequency Setting 3
1939713|NCT01750229|Device|Medtronic RestoreSensor Frequency Setting 4|Frequency Setting 4
1939714|NCT01749826|Drug|Morphine Sulfate|15mg sustained release morphine sulfate, with a maximum dose of 120mg. Patients will be titrated up to a maximum dose of 8 pills a day for one month.
1939715|NCT01749384|Biological|Bevacizumab|Given IV
1939716|NCT01749384|Other|Laboratory Biomarker Analysis|Correlative studies
1939717|NCT01749384|Other|Pharmacological Study|Correlative studies
1939718|NCT01749384|Drug|Tivantinib|Given PO
1939719|NCT01749306|Biological|ABH001|ABH001 applications topically every 4 weeks (±1 week) with protocol-specified dressings until wound healed or up to 44 weeks
1939720|NCT01749306|Other|Control wound treatment|Control wound care with protocol-specified dressings every 4 weeks (±1 week) up to 20 weeks with optional cross-over to ABH001 for additional 20 weeks
1939721|NCT01749033|Other|Group 1 Classic|"Active Comparator: Group 1 classic
Group 1 Using the classic inserting technique and completely deflated LMA recommended in the LMA manual."
1939722|NCT01749033|Other|Group 2 pre-inflated|Group 2 (pre-inflated): Using the recommended inserting technique with the pre-inflated volume that exists in a LMA from the manufacturer.
1939723|NCT01749033|Other|Group 3 ELLIA|Group 3 (ELLIA): Using the ELLIA technique
1939725|NCT01748383|Procedure|Transplantation of BMMCs|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. BMMCs were obtained by the method of the gradient centrifugation. Autologous BMMCs in the number 93±43 million transplantation by balloon catheter performed into IRA at once after stent implantation.
1939726|NCT01748383|Procedure|Transplantation of CD 133+ cells|The wing of the ilium was punctured under the local anesthesia for receiving of autologous BMCs. 100 ml of bone marrow aspirate was taken. Autologous CD133 + cells were obtained by the method of the magnetic separation. Phenotyping of the transplanted cells was performed by the cytofluorimetry. Autologous CD 133+ BMCs in the number 5,7 (0,45;9,0) million transplantation by balloon catheter performed into IRA at once after stent implantation.
1939727|NCT01748383|Procedure|stenting of IRA|The only stent implantation
1939729|NCT01748240|Drug|Azacitidine and oral vorinostat|In patients still responding after six cycles, the drugs will continue to be supplied, and follow up until death or unacceptable tolerance will be continued in all patients.
1939733|NCT01746901|Drug|Placebo|Placebo solution + Placebo ALO-02 (intact)
1939734|NCT01746901|Drug|intact ALO-02 60 mg/7.2 mg|Placebo solution + ALO-02 60 mg/7.2 mg (intact)
1939735|NCT01746901|Drug|crushed ALO-02 60 mg/7.2 mg|crushed ALO-02 60 mg/7.2 mg in solution + placebo ALO-02 (intact)
1939736|NCT01746901|Drug|crushed oxycodone IR 60 mg|crushed oxycodone immediate-release (IR) 60 mg in solution + placebo ALO-02 (intact)
1939737|NCT01746901|Drug|crushed ALO-02 40 mg/4.8 mg|crushed ALO-02 40 mg/4.8 mg in solution + placebo ALO-02 (intact)
1939738|NCT01746901|Drug|crushed oxycodone IR 40 mg|crushed oxycodone immediate-release (IR) 40 mg in solution + placebo ALO-02 (intact)
1939739|NCT01746589|Device|bilateral myopic LASIK|200 kHz WaveLight® FS200 Femtosecond Laser and the WaveLight® Allegretto Wave® Eye-Q Laser
1939740|NCT01745367|Drug|Tivozanib Hydrochloride|
1939741|NCT01745367|Drug|paclitaxel|
1939742|NCT01746069|Behavioral|Quit smoking combined cessation programme|Support sms messages to patient's mobile phone and health advice
1939743|NCT01746069|Behavioral|health advice|routine clinical practice
1939744|NCT01746017|Drug|Placebo|Administered orally as capsules
1939745|NCT01746017|Drug|LY2922470|Administered orally as capsules
1939746|NCT01744743|Procedure|levothyroxine|Women with TSH≥97.5%th and/or FT4≤2.5%th will accept levothyroxine 150ug daily and follow-up every 4 weeks.
1939747|NCT01744704|Drug|rhNGF 0.5 µg/mL Sentinel|
1939748|NCT01744704|Drug|rhNGF 5 µg/mL Sentinel|
1939749|NCT01744704|Drug|rhNGF 20 µg/mL Sentinel|
1939750|NCT01744704|Drug|rhNGF 20 µg/mL Part A|
1939751|NCT01744704|Drug|rhNGF 60 µg/mL Part A|
1939752|NCT01744704|Drug|rhNGF 180 µg/mL Part A|
1939753|NCT01744704|Drug|rhNGF 20 µg/mL Part B|
1939754|NCT01744704|Drug|rhNGF 20 µg/mL Part B cohort 0M|
1939755|NCT01744704|Drug|rhNGF 60 µg/mL Part B|
1939756|NCT01744704|Drug|rhNGF 180 µg/mL Part B|
1939757|NCT01744704|Drug|Placebo Part A|
1939758|NCT01744704|Drug|Placebo Part B|
1939764|NCT01743560|Drug|RAD001|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer will be treated with oral RAD001 at a dose of 10mg daily and oral exemestane 25mg daily. The study treatment for an individual patient will begin on Study Day 1 and will continue until the last patient enrolled has completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
1939765|NCT01743560|Drug|Exemestane|All postmenopausal women with oestrogen receptor positive locally advanced or metastatic breast cancer will be treated with oral RAD001 at a dose of 10mg daily and oral exemestane 25mg daily. The study treatment for an individual patient will begin on Study Day 1 and will continue until the last patient enrolled has completed the study at day 336 or until disease progression; unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
1939766|NCT01743469|Drug|Tasquinimod|1 capsule:initially at 0.5 mg/day, increasing to 1 mg/day, maintaining 0.5mg/day or decreasing to 0.25mg after at least 2 weeks.
1939767|NCT01743157|Drug|Biochemo + bevacizumab then ipilimumab|Bevacizumab 7.5mg/kg week 1,repeat weeks 4,7,10 (cycles 2, 3, & 4)
1939768|NCT01743144|Drug|Magnesium Sulfate|Magnesium sulphate (MgSO4) 10% solution is going to be used, an initial MgSO4 bolus dose 30mg/kg (i.e. 0.3mL/kg) will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous infusion of 10 mg/kg/hr (i.e. 0.1 ml/kg/h). Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
1939769|NCT01743144|Drug|normal saline|normal saline (NaCl 9%) is going to be used, an initial normal saline bolus dose 0.3ml/kg will be infused over 10 minutes after endotracheal intubation. This will be followed by a continuous normal saline infusion of 0.1 ml/kg/h. Infusion will continue during the entire intraoperative course and will be terminated with the discontinuation of sevoflurane
1939771|NCT01741480|Other|Early warning system monitoring.|General hospital ward patients will be monitored 24/7 for clinical deterioration using the early warning system developed at Washington University.
1939772|NCT01741480|Other|routine care|
1939773|NCT01742780|Procedure|Proximal Humerus Intraosseous Vascular Access|EZ-IO Intraosseous Vascular Access System
1939774|NCT01742273|Drug|Vitamin K1|Vitamin K1 to slow vascular calcification
1939779|NCT01742078|Drug|LY2541546 - IV|Administered IV
1939780|NCT01742078|Drug|LY2541546 - SC|Administered SC
1939781|NCT01742078|Drug|Placebo|Administered IV or SC
1939782|NCT01742091|Drug|LY2541546 - SC|Administered SC
1939783|NCT01742091|Drug|LY2541546 - IV|Administered IV
1939784|NCT01742091|Drug|Placebo - SC|Administered SC
1939785|NCT01742091|Drug|Placebo - IV|Administered IV
1939786|NCT01739972|Drug|Levothyroxine|Levothyroxine in a capsule form, once daily, with appropriate dosage to keep TSH in the normal range.
1939787|NCT01739972|Drug|Desiccated thyroid extract|Armour thyroid in a capsule form, once daily, with appropriate dosage to keep TSH in normal range.
1939789|NCT01741207|Drug|N-acetylcystein|Active Comparator: N-acetylcystein receive N-acetylcystein in addition to standard treatment
1939790|NCT01741012|Drug|Gardasil|0.5 ml Gardasil vaccine in single dose prefilled syringes at Visit 2, Visit 4 and Visit 6
1939798|NCT01739764|Drug|Vemurafenib|Vemurafenib will be given based on the last dose of the antecedent study (minimum 480 mg orally BID).
1939799|NCT01739699|Drug|Acetaminophen|
1939800|NCT01739699|Drug|Placebo|
1939801|NCT01739335|Drug|Mifepristone (600 mg/day) or placebo (sugar pill)|600 mg/day mifepristone or placebo (sugar pill) for one week
1939802|NCT01739231|Biological|ACE527|~10^10 cfu ACE527 administered on Days 0, 28, and 56
1939803|NCT01739231|Biological|ACE527 + dmLT|~10^10 cfu ACE527 + 25 ug dmLT administered on Days 0, 28, and 56
1939804|NCT01738477|Biological|Boostrix|Single dose intramuscular administration.
1939805|NCT01738334|Behavioral|Active comparator (meditation) with healthy subjects|"The control group with healthy subjects that was participate in meditation (active control group)"
1939806|NCT01738334|Behavioral|Meditation|"In the eight weeks following the first session of cognitive tests, the participants made a practice of weekly meditation group lasting 2 hours. Practices with each group (patients and active controls) occurred on different days. With regard to meditation practices were performed in a sitting posture with emphasis on daily life. Each weekly session involved meditation practices with trained professional, practical proposals for home exercise and a discussion group. Meditation compact discs (CDs)were given to participants for practices at home, which proposed activities for 5 minutes to 1 week and 2 weeks for 10 minutes 3-5, and finally 15 minutes for 6-8 weeks. After 8 weeks of treatment the second session of tests was held that involved the same tasks in session 1."
1939863|NCT01729897|Drug|Etomidate|
1939809|NCT01736241|Drug|LY3053102|Administered SQ
1939810|NCT01736241|Drug|Placebo|Administered SQ
1939812|NCT01737229|Device|Application of Biodentine™ (RD94), dentin substitute|
1939813|NCT01736995|Behavioral|Functional Family Therapy|
1939814|NCT01736995|Behavioral|Motivational Enhancement Tx/Cognitive Behavioral Tx|
1939815|NCT01736995|Behavioral|Contingency Management|
1939819|NCT01736371|Drug|1% Sevoflurane|In this group of patients, the maintenance of anesthesia is done by 1% sevoflurane + propofol infusion. Propofol infusion is adjusted according to the Bispectral Index.
1939820|NCT01736371|Drug|Propofol|In this group the maintenance of anesthesia is maintained by only propofol infusion.
1939821|NCT01736371|Drug|Sevoflurane|In this group only sevoflurane was used for maintenance of anesthesia. the dose of sevoflurane is adjusted to maintain Bispectral Index within 45 and 55.
1939822|NCT01737697|Drug|Zirconium silicate (acute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered 3 times (tid) daily with meals for 48 hours.
1939823|NCT01737697|Drug|Zirconium silicate (subacute phase)|Randomized oral doses (1.25g, 2.5g, 5g, and 10g) of microporous, fractionated, protonated zirconium silicate administered once a day prior to the morning meal for 12 days.
1939824|NCT01737697|Drug|Placebo|Randomized to mimic doses of experimental drug administered 3 times (tid) daily with meals for 48 hours during the acute phase.
1939825|NCT01737697|Drug|Placebo ( subacute phase)|Randomized to mimic doses of experimental drug administered once a day prior to the morning meal for 12 days during the subacute phase.
1939826|NCT01735279|Drug|fish oil|
1939827|NCT01734746|Procedure|blue dye and radioactive tracer|
1939828|NCT01734525|Drug|Anidulafungin|Anidulafungin at a dose of 200 mg in the first day and 100 mg daily afterwards
1939829|NCT01733680|Drug|amiloride|Subjects will take either amiloride hydrochloride or placebo for 8 weeks.
1939830|NCT01733680|Behavioral|Behavioral|Each week of the study, subjects will complete the AISRS, BRIEF-A, and CGI to measure symptom improvement
1939831|NCT01733472|Drug|GA-arm, remifentanil|"Remifentanil and propofol will be delivered intravenously via TCI pumps according to the Marsh and Minto algorithm"
1939832|NCT01733472|Drug|placebo|
1939833|NCT01733212|Drug|Ginger|
1939836|NCT01732640|Drug|Afatinib|Afatinib will be supplied as film-coated tablets. Available dosage strengths will be 20, 30, or 40 mg. Tablets will be supplied in HDPE, child-resistant, tamper-evident bottles.
1939837|NCT01732640|Drug|Paclitaxel|Induction chemotherapy: 175 mg/m2 day 1 every 21 days for 2 cycles (IV infusion as per institutional standard).
1939838|NCT01732640|Drug|Carboplatin|Carboplatin is available as a sterile lyophilized powder in single-dose vials containing 50 mg, 150 mg, or 450 mg of carboplatin. Each vial contains equal parts by weight of carboplatin and mannitol. Commercial supplies of carboplatin will be used in this trial.
1939839|NCT01732640|Drug|Cisplatin|Concurrent chemotherapy: 40 mg/m2 once weekly for 7 cycles (IV infusion as per institutional standard).
1939840|NCT01732640|Radiation|Intensity Modulated Radiation Therapy|Standard Fractionation 70 Gy /35 fractions at 2 Gy/day for 5 days per week.
1939841|NCT01731912|Drug|Degarelix|Given SC
1939842|NCT01731912|Radiation|External Beam Radiation Therapy|Undergo standard EBRT
1939843|NCT01731912|Other|Laboratory Biomarker Analysis|Correlative studies
1939844|NCT01731860|Device|Additional PET Scan|Additional PET Scan with no additional radiopharmaceutical administration.
1939845|NCT01731834|Other|Vibrocompression and aspiration of secretions|The 20 children, study participants will be randomly assigned to different groups, where 10 children will be evaluated during vibrocompression maneuver, and another 10 will be assessed on the aspiration procedure. Randomization will be performed using an opaque envelope for specifying which group selection technique is evaluated.
1939846|NCT01731691|Biological|α1 Proteinase Inhibitor|Prolastin-C treatment in HIV disease will be compared with placebo treatment in HIV disease and no treatment in uninfected volunteers.
1939851|NCT01730573|Procedure|interscalene block|This arm patients will receive inter scalene block which will be ultrasound and nerve stimulator guided.
1939852|NCT01730573|Procedure|Suprascapular and Axillary nerve block|This arm patients will receive Suprascapular and axillary nerve blocks which will be ultrasound guided and nerve stimulator guided.
1939853|NCT01731093|Drug|AT-001|
1939854|NCT01731093|Drug|Placebo|
1939873|NCT01726803|Other|Early Physical Therapy|The early physical therapy arm includes 4 total sessions. The first 2 sessions include use of thrust spinal manipulation with exercises for range of motion and strengthening of the spine. The final 2 sessions include the exercise component only.
1939874|NCT01726803|Other|Usual Care|The usual care intervention includes advice and education to remain active and provision of the Back Book highlighting these recommendations. Pharmaceuticals may be prescribed at the discretion of the primary care provider. Follow-up visits to primary care provided are recommended for all patients dissatisfied with their progress.
1939875|NCT01726725|Drug|desflurane|
1939876|NCT01726036|Device|Gomco Circumcision Clamp|
1939877|NCT01726036|Device|Mogen Circumcision Clamp|
1939878|NCT01726400|Drug|Pegylated interferon alpha|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
1939879|NCT01726400|Drug|Ribavirin|Subcutaneous weekly pegylated interferon alpha and daily oral ribavirin treatment as per standard treatment. The dosages for interferon and ribavirin are as per therapeutic guidelines and are based on weight, genotype and previous treatments.
1939884|NCT01724658|Drug|Testosterone undecanoate|testosterone undecanoate 40 mg orally twice a week
1939885|NCT01724658|Drug|placebo|placebo orally twice a week with progynova 1 mg oral daily
1939886|NCT01724645|Dietary Supplement|Korean traditional diets|"The consumption of Korean traditional diets reflecting the characteristics of Korean traditional diets without the limitation of calories has an effect on control of cardiovascular risk factor, so this study instructed all subjects of the intervention group to consume about 2,100kcal of served meals freely.
The Korean Traditional diets, which encourages the intake of cooked rice, vegetables,soup,Kimchi and soy fermented foods."
1939887|NCT01724645|Dietary Supplement|Control group|"Told to  eat as usal diets."
1939888|NCT01724229|Drug|Kendall Body Wash & Shampoo; Moisture Barrier Cream; 2-in-1 Cleanser; Antifungal Cream|
1939889|NCT01723072|Biological|Omalizumab|Humanized monoclonal antibody against human IgE
1939890|NCT01723072|Drug|Placebo|Placebo to omalizumab
1939894|NCT01721681|Biological|FACTOR X|
1939895|NCT01721746|Biological|BMS-936558|
1939896|NCT01721746|Drug|Dacarbazine|
1939897|NCT01721746|Drug|Carboplatin|
1939898|NCT01721746|Drug|Paclitaxel|
1939899|NCT01721759|Drug|Nivolumab|
1939900|NCT01721460|Drug|Dexmedetomidine|Dexmedetomidine infusion will be started with a loading dose of 1 mcg/Kg over ten to 20 minutes followed by a maintenance infusion of 0.7 mcg/Kg/hr until stable sedation is achieved.
1939901|NCT01721408|Drug|Tigecycline|every 12 hours (an initial intravenous dose of 100 mg followed by 50 mg twice a day approximately every 12 hours) and placebo intravenous doses every 12 hours beginning 6 hours after the initial intravenous dose of tigecycline for at least for 5 days and up to 14 days.
1939902|NCT01721408|Drug|Imipenem/cilastatin|every 6 hours intravenously, and the imipenem/cilastatin will be dosed by 500mg/500mg for the subjects with creatinine clearance equal or above 71ml/min/1.73m2 or dose will be adjusted by Schedule of Study Drug Administration for Subjects with Renal Impairment.
1939903|NCT01721200|Other|Decision Support Tool|Educational decision support tool for patients with rheumatoid arthritis
1939904|NCT01721200|Other|Usual Care|Subjects randomized to the Usual Care Group will receive their biologic drug teaching from the rheumatologist as part of their routine care.
1939905|NCT01720277|Biological|HD Fluzone Vaccine|
1939906|NCT01720277|Biological|SD Fluzone Vaccine|
1939907|NCT01720485|Drug|Desloratadine + Prednisolone|1 tablet 3 times a day
1939908|NCT01720485|Drug|Dexchlorpheniramine + Betamethasone|1 tablet 3 times a day
1939909|NCT01720173|Biological|Dalantercept|Given SC
1939910|NCT01720173|Other|Laboratory Biomarker Analysis|Correlative studies
1939915|NCT01719874|Biological|TCN-032|
1939916|NCT01719874|Biological|Placebo (saline)|
1939917|NCT01719302|Drug|Gemcitabine|1500 mg/m^2 given days 1 and 15 of every 28 day cycle for a total of 4 cycles
1939918|NCT01719302|Drug|Docetaxel|50 mg/m^2 on days 1 and 15 of each 28 day cycle for a total of 4 cycles
1939919|NCT01719302|Drug|Pazopanib|Starting dose of 400 mg/day starting 72 hours after docetaxel/gemcitabine administration for 10 days (days 4-13 and 18-27) of each 28 day cycle for a total of 4 cycles. Dose will be increased by 200 mg/day for each cohort until the maximum tolerated dose is identified.
1939921|NCT01718301|Drug|boceprevir|
1939922|NCT01718301|Drug|Ribavirin|
1939923|NCT01718301|Drug|Peginterferon alfa-2a|
1939924|NCT01718301|Drug|Peginterferon alfa-2b|
1939925|NCT01718353|Drug|CABAZITAXEL (XRP6258)|Pharmaceutical form: solution Route of administration: intravenous
1939926|NCT01718353|Drug|DOCETAXEL (XRP6976)|Pharmaceutical form: solution Route of administration: intravenous
1939927|NCT01718353|Drug|prednisone|Pharmaceutical form: tablet Route of administration: oral
1939928|NCT01716962|Other|Infusion of 6% tetrastarch for a total of 500 ml|
1939932|NCT01715740|Drug|Chinese Herbal Medicine (CHM)|Each CHM capsule, weighing 500mg, consists of XFS 250 mg and QSFFT 250 mg.
1939933|NCT01715740|Drug|Placebo|Encapsulated powder with similar taste, color, odor to intervention Chinese herbal medicine
1939934|NCT01716104|Drug|Afalaza|Safety and Efficiency
1939935|NCT01716104|Drug|Placebo|Safety and Efficiency
1939936|NCT01715025|Drug|E2Nomac|Women will start the first cycle of the COC on the first day of their period in the treatment phase of the study
1939937|NCT01714323|Behavioral|Extended Care|A 3-month program after hospital discharge with these 2 components: (1) Free Medication - A 30-day supply of FDA-approved medication (nicotine replacement, bupropion, or varenicline) given at hospital discharge and refillable for a total of 90 days to encourage medication use and adherence; (2) Interactive Voice Response (IVR) Triage to Telephone Counseling from a national quitline provider (Alere Wellbeing, Inc., previously Free & Clear). IVR aims to encourage medication adherence and enhance counseling efficiency by identifying smokers who need post-discharge support. Immediate transfer of a patient from automated IVR call to live telephone counselor will facilitate a successful connection to counseling.
1939938|NCT01714323|Behavioral|Standard Care|Standard care consists of a handout with information about how to contact the state telephone quitline for additional smoking cessation support and to use smoking cessation medication as recommended by the hospital smoking counselor.
1939939|NCT01714024|Device|Zimmer Trabecular Metal Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
1939940|NCT01714024|Device|Zimmer Titanium Test Cylinder|For all subjects 2 titanium and 2 trabecular 2.9-3.0 mm x 5 mm test cylinders will be implanted in alveolar bone. One of each type will be removed at 2 weeks. The remaining two will be removed at 4 weeks.
1939941|NCT01713777|Drug|"Lamotrigine Generic A"|
1939942|NCT01713777|Drug|"Lamotrigine generic B"|
1939943|NCT01713010|Other|Predictive indexes of weaning from mechanical ventilation|
1939944|NCT01712997|Drug|Iloprost|
1939945|NCT01712997|Drug|Bosentan|
1939946|NCT01712607|Other|Preoperative Warm-Up training|Preoperative Warm-Up training
1939947|NCT01712529|Behavioral|Supervised physical exercise|Women with systemic lupus erythematosus with availability to perform physical exercise were allocated in exercise group (EG) to practice supervised physical exercise for one hour, three times a week for 16 weeks. Those who were not available for this activity were allocated in the control group (CG). Intervention consisted of walking at speed of the ventilatory threshold-1 heart rate obtained from cardiopulmonary exercise test and monitored by frequency meter.
1939948|NCT01712321|Drug|Vilazodone|Vilazodone 20mg or 40mg taken once daily by mouth
1939949|NCT01712321|Drug|Placebo|Placebo matching Vilazodone 20mg or 40mg, taken once daily by mouth
1939952|NCT01711047|Procedure|Radiofrequency catheter Ablation|In this arm, catheter ablation would be performed in the left atrium and would include pulmonary vein isolation and linear ablations (roof and mitral isthmus lines)
1939953|NCT01711047|Procedure|Radiofrequency catheter ablation|In this arm, catheter ablation would be performed in the left atrium, including pulmonary vein isolation, linear ablations (roof and mitral isthmus lines) and Complex Fractionated Atrial Electrograms (CFAE) ablation.
1939954|NCT01711879|Drug|Aflibercept|Details covered in arm description
1939955|NCT01711372|Device|Groundskeeper|A game created to be played on Sifteo Cubes to be used as a diagnostic aid for ADHD.
1939956|NCT01711619|Device|subcutaneous nerve stimulation|subcutaneous nerve stimulation plus optimized medical management
1939957|NCT01711619|Other|Optimized Medical Management|Optimized medical management
1939958|NCT01710995|Drug|Zegerid|
1939959|NCT01710995|Drug|Losec|
1939960|NCT01710891|Procedure|CMAC videolaryngoscope|patients are intubated using the CMAC video laryngoscope
1939961|NCT01710891|Procedure|Direct Laryngoscopy|Patients undergo their first intubation attempt using direct laryngoscopy with a C-MAC device with the video display covered with a hood.
1939962|NCT01710761|Dietary Supplement|Placebo|Same form factor and flavor as test lozenge but contains no active ingredients
1939963|NCT01710761|Dietary Supplement|Nitrate supplement with caffeine|Lozenge consisting of beetroot and 75 mg caffeine
1939964|NCT01710553|Other|Glucophage 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
1939965|NCT01710553|Other|Metformin GSK 1000mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 1000 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 1000 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
1939966|NCT01710540|Other|Metformin GSK 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
1939967|NCT01710540|Other|Gluocophage 850mg|EVALUATE BIOEQUIVALENCE BETWEEN METFORMIN 850 MG TABLETS MANUFACTURED BY SAVIPHARM J.S.C, VIETNAM AND GLUCOPHAGE® 850 MG TABLETS MANUFACTURED BY MERCK SANTE S.A.S.2, RUE DU PRESSOIR VERT-45400 SEMOY-FRANCE AND BE REGISTERED IN VIETNAM IN HEALTHY, ADULT, HUMAN MALE SUBJECTS UNDER FASTING CONDITION
1939969|NCT01710254|Drug|Regadenoson MRI|AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.
1939970|NCT01709188|Behavioral|Musical Dual Task Training|
1939971|NCT01709188|Behavioral|Walking and Talking|
1940068|NCT01687972|Device|Absorbable sutures|placement of absorbable sutures at cesarean section
1939972|NCT01709695|Drug|Guanfacine Hydrochloride XR|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
1939973|NCT01709695|Drug|Placebo|Weekly adjustments based on parent ratings of symptoms, side effects, and health status per vital signs up to 4mg maximum dose
1939976|NCT01710046|Drug|(CP-6890,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
1939977|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
1939978|NCT01710046|Drug|(CP-690,550) Tofacitinib|2 x 5 mg oral capsules taken twice daily (every 12 hours) for 12 weeks
1939979|NCT01710046|Drug|Placebo|2 matching oral capsules taken twice daily (every 12 hours) for 12 consecutive weeks
1939980|NCT01709110|Drug|Teriparatide|Administered SC
1939981|NCT01709110|Drug|Risedronate|Administered orally
1939982|NCT01709110|Drug|Placebo|"Teriparatide arm placebo administered orally.
Risedronate arm placebo administered SC."
1939983|NCT01709110|Drug|Calcium|Administered orally
1939984|NCT01709110|Drug|Vitamin D|Administered orally
1939985|NCT01709032|Drug|Deferasirox and deferiprone|
1939986|NCT01708629|Drug|210 mg brodalumab|210 mg brodalumab administered SC
1939987|NCT01708629|Drug|140 mg brodalumab|140 mg brodalumab administered SC
1939988|NCT01708629|Drug|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
1939989|NCT01708629|Drug|placebo|placebo administered SC
1939990|NCT01708603|Drug|210 mg brodalumab|210 mg brodalumab administered SC
1939991|NCT01708603|Drug|140 mg brodalumab|140 mg brodalumab administered SC
1939992|NCT01708603|Drug|ustekinumab|45 mg or 90 mg ustekinumab administered SC per the labeled dosing regimen.
1939993|NCT01708603|Drug|placebo|Placebo administered SC
1939994|NCT01708590|Drug|210 mg brodalumab|210 mg brodalumab administered subcutaneous (SC)
1939995|NCT01708590|Drug|140 mg brodalumab|140 mg brodalumab administered subcutaneous (SC)
1939996|NCT01708590|Drug|placebo|Placebo administered subcutaneous (SC)
1939997|NCT01707485|Drug|amoxicillin|dosed 75-100 mg/kg/day (standardized dosing)
1939998|NCT01706718|Dietary Supplement|Bread|
1939999|NCT01706263|Other|MAXCLARITY II (2.5% BPO) Foam Cleanser|Available over the counter.
1940000|NCT01706263|Other|MAXCLARITY II (2.5% BPO) Foam Treatment|Available over the counter.
1940001|NCT01706263|Other|MAXCLARITY II (0.5% Salicylic Acid) Toner Foam|Available over the counter.
1940002|NCT01705860|Biological|Santyl|
1940003|NCT01705587|Drug|teriparatide|20 microgram once-daily subcutaneous injection
1940004|NCT01704820|Procedure|Retroflexion in the right colon|
1940007|NCT01702285|Drug|CUDC-101|200-500 mg CUDC-101, orally administered, twice daily, in continuous 21 day cycles until disease progression or other discontinuation criteria are met.
1940008|NCT01702766|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
1940009|NCT01702753|Dietary Supplement|Bifidobacterium animalis subsp. lactis|
1940010|NCT01702571|Drug|Trastuzumab Emtansine|Participants will receive trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) intravenously on Day 1 of a 3-week cycle every 3 weeks until unacceptable toxicity, withdrawal of consent, or disease progression.
1940011|NCT01702428|Biological|GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762)|Single dose administered subcutaneously (SC) in the tricep region of the left arm at Visit 1 (Day 0).
1940012|NCT01702428|Biological|Merck &amp; Co., Inc.'s M-M-R®II (also called M-M-R Vax Pro®), combined measles-mumps-rubella virus vaccine|Single dose administered SC in the tricep region of the left arm at Visit 1 (Day 0).
1940013|NCT01702428|Biological|Varivax® (Merck & Co., Inc.)|Single dose administered SC in the tricep region of the right arm at Visit 1 (Day 0), with either one of the three Inv_MMR vaccine lots or one of the two active control Com_MMR vaccine lots.
1940014|NCT01702428|Biological|Havrix®|Single dose administered intramuscularly (IM) in the anterolateral region of the right thigh at Visit 1 (Day 0), with either one of the three Inv_MMR vaccine lots or one of the two active control Com_MMR vaccine lots.
1940015|NCT01702428|Biological|Prevnar 13® (Pfizer Inc.)|Single dose administered IM in the anterolateral region of the left thigh at Visit 1 (Day 0), with either one of the three Inv_MMR vaccine lots or one of the two active control Com_MMR vaccine lots in the US only.
1940017|NCT01700036|Drug|Alpha-1-Antitrypsin (AAT)|AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.
1940018|NCT01699477|Device|ExAblate 4000 focused ultrasound brain intervention|Non-invasive brain intervention using MR-guided focused ultrasound
1940019|NCT01698879|Drug|Mylotarg|"Cohort 1 (20 evaluable patients):
GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1. Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine (cytosine arabinoside): 100 mg/m^2 IV continuous infusion on days 1 to 7, to begin 4 hours after the administration of GO.
Cohort 2 (20 evaluable patients):
G-CSF: 150 mcg/m^2, SC, days 0 to 7, to begin 12 to 18 hours before treatment with Gemtuzumab. GO: 3 mg/m^2 (maximum 5 mg), IV infusion, 2 hours, day 1.
Idarubicin: 12 mg/m^2, IV, 30 minutes, on days 2, 3, 4. Cytarabine (cytosine arabinoside): 100 mg/m^2 IV continuous infusion on days 1 to 7, to begin 4 hours later after the administration of GO."
1940064|NCT01688037|Drug|NBI-98854|25 mg capsule
1940065|NCT01688037|Drug|NBI-98854|50 mg capsule
1940066|NCT01688037|Drug|Placebo|
1941956|NCT01275300|Drug|81 mg Aspirin|5 days taking 81 mg Aspirin
1940020|NCT01698463|Other|Identification of patients at risk, tailored exercise prescription, motivational interviewing, review of behavioural outcomes|"The intervention was delivered in two visits and two follow-up phone calls.
Physician identifies that the patient is at risk of falls or fractures
Visit one: individualized exercise prescription by a physiotherapist.
Visit two: motivational interviewing (behavioural counselling) by kinesiologist
Phone call 1 and 2: Kinesiologist reviews behavioural components (action planning, coping planning, coping self-efficacy, intentions."
1940021|NCT01697852|Other|Indoor residual spraying with bendiocarb|2 rounds of indoor residual spraying with bendiocarb insecticide, 4 months apart
1940022|NCT01697852|Other|LLIN by universal coverage campaign|Long lasting Insecticide treated mosquito net
1940023|NCT01696799|Drug|Econazole Nitrate|
1940024|NCT01696799|Drug|placebo|
1940025|NCT01695954|Drug|Pitavastatin|Pitavastatin 2 mg tablets taken at bedtime in Arm A and in the morning in Arm B.
1940026|NCT01695954|Drug|Darunavir|Darunavir 400 mg tablets x 2 taken daily in Arm B
1940027|NCT01695954|Drug|Ritonavir|Ritonavir 100 mg tablets taken daily in Arm B
1940028|NCT01695954|Drug|Efavirenz|Efavirenz 600 mg tablets taken at bedtime in Arm A
1940033|NCT01694966|Drug|Methylene Blue MMX®|
1940034|NCT01694966|Drug|Placebo|Sugar pill manufactured to mimic Methylene Blue MMX® tablet.
1940035|NCT01694719|Behavioral|Brief Behavioral Activation Treatment for Depression|
1940036|NCT01694719|Behavioral|Cognitive Control Training|
1940037|NCT01693939|Device|FS200 Femtosecond Laser|
1940038|NCT01693289|Drug|metformin plus letrozole|
1940039|NCT01693289|Procedure|ovarian drilling|
1940040|NCT01692886|Biological|7-valent Pneumococcal Conjugate Vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
1940041|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 4-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
1940042|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 2-Month Visit, 4-Month Visit, 6-Month Visit, and 12-Month Visit, respectively
1940043|NCT01692886|Biological|13-valent Pnumococcal Conjugate vaccine|suspension in prefilled syringe for intramuscular injection; 0.5 mL; one dose at 3-Month Visit, 5-Month Visit, and 12-Month Visit, respectively
1940044|NCT01692743|Behavioral|Home Monitoring|Participants log onto the TELE-IBD website weekly to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
1940045|NCT01692743|Behavioral|Home Monitoring|Participants log onto the TELE-IBD website every other week to answer questions about disease symptoms, adherence, side effects, to check body weight and to receive educational content. Participants receive self action plans after each self-testing session. Alerts are generated to the nurse coordinator if certain clinical criteria are met.
1940048|NCT01691430|Dietary Supplement|2 cranberry capsules|Two cranberry capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
1940049|NCT01691430|Dietary Supplement|Placebo|Two placebo capsules qd (each capsule containing 36mg proanthocyanidin, total 72mg PAC)
1940050|NCT01691027|Behavioral|Practice tracing objects and printing with a stylus on a tablet computer|Subjects will have three training modules on a tablet computer: scotoma awareness, line and curve tracing, and video games. The order of modules will be different for different groups of subjects. Training on a module will cease when the subject reaches a performance criterion. Retinal assessments will occur after each training module completion.
1940054|NCT01690221|Drug|VEN 307|VEN307 applied three times a day, in and around the anus, for 28 days.
1940055|NCT01690221|Drug|Placebo|Placebo cream applied three times a day, in and around the anus, for 28 days.
1940056|NCT01689974|Drug|Ipilimumab|Ipilimumab will be administered alone on day 4, 25, 46 and 67.
1940057|NCT01689974|Other|Radiation Therapy and Ipilimumab|Radiation is given over one week interval On the fourth day of radiation (day 4)Ipilimumab is administered and repeated on Days 25, 46 and 67.
1940058|NCT01689701|Dietary Supplement|Hizikia Fusiformis extract|Hizikia Fusiformis extract(1.3g/d)
1940059|NCT01689701|Dietary Supplement|Placebo|Placebo(1.3g/d)
1940061|NCT01688596|Drug|Bupivacaine|Bupivacaine (0.25%) will be injected through the closed trocar incisions after completion of the laparoscopic hysterectomy case.
1940067|NCT01687972|Device|Insorb absorbable staples|Placement of Insorb absorbable staples at cesarean section
1940071|NCT01687725|Device|Renal denervation using Symplicity Catheter system|percutaneous selective renal sympathetic nerve ablation with the use of the Symplicity Catheter system
1940072|NCT01687296|Drug|fluticasone propionate inhalation solution|2×0.5mg/2ml twice daily nebulized to treat an acute exacerbation of asthma for 7 days
1940073|NCT01687296|Drug|oral prednisone|once daily (2mg/kg.day, up to 40mg/day for 4 days, then 1mg/kg.day or half of the original dose, up to 20mg/day for 3 days) to treat an acute exacerbation of asthma for 7 days
1940074|NCT01687296|Drug|placebo inhalation solution|4ml 0.9% saline nebulized twice daily
1940075|NCT01687296|Drug|placebo tablet|placebo soluble tablet, oral ,once daily
1940076|NCT01687296|Drug|salbutamol|Salbutamol MDI 2 puffs twice daily or Nebules twice daily, and can be increased up to every 4 hours on an as-needed basis, through the treatment period.
1940077|NCT01687179|Drug|sirolimus and hydroxychloroquine|This will be a phase I dose escalation study of the combination of sirolimus (2 mg adjusted to keep trough levels between 5-15 ng/ml) and hydroxychloroquine (200 mg or 400 mg) taken orally daily.
1940078|NCT01686854|Behavioral|Cognitive Behavioral (B)|a 12 months training program in small groups (max 10 persons) about problem solving strategies. Each 90 minute lesson will be given by clinicians, psicologist, dieticians, according cognitive behavioural approach and strategies.
1940079|NCT01686854|Other|Prescriptive Diet (A)|prescribed diet, with a reduction of 500 Kcal for overweight-1° degree obese, and of 800-1000 Kcal for 2° degree obese patients respect caloric requirement, in compliance with Italian guidelines (INRAN 2003).
1940080|NCT01685229|Device|Balloon sinus dilation|Subjects electing continued medical therapy group will not have balloon sinus dilation intervention. Subjects electing balloon sinus dilation group will have balloon sinus dilation intervention.
1940081|NCT01685697|Procedure|Mask ventilation with a Laerdal face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the intervention group.
1940082|NCT01685697|Procedure|Mask ventilation with a F&P face mask|Mask leak will be measured using a respiratory function monitor. Mask ventilation will be analyzed over a period of 5 minutes. The mean mask leak will be compared to the control group.
1940087|NCT01684592|Behavioral|Phone-based postpartum continuing care|PPCC Counselors will make initial contact with participants in the experimental group at 36 weeks gestation (i.e., one week prior to full-term), will call again within one week after the baby's birth, and eight additional times over the course of the first six months postpartum. The PPCC protocol will be developed based on the 5 A's (standard of care during pregnancy) and the Recovery Management Checkup model where relapse is expected and efforts are made to take a more proactive approach to identify women who are having cravings or have relapsed and re-intervene with them as soon as possible to assist them in regaining smoking abstinence. Women in the experimental group will also have the option of calling the PPCC line 24 hours a day, 7 days a week.
1940088|NCT01684592|Behavioral|Standard care|All women will receive the standard of care approach (5 A's and referral to a 24/7 quit line postpartum) from MWC during pregnancy. The 5 A's brief intervention was modified by ACOG for use with pregnant women and is recommended to help pregnant women quit smoking. It includes the following steps: Ask about tobacco use, Advise to quit, Assess willingness to make a quit attempt, Assist in quit attempt, and Arrange follow-up.
1940089|NCT01683864|Drug|HIPEC with mytomycin and cisplatin|
1940090|NCT01683864|Procedure|Diagnostic laparoscopy one year after gastrectomy|for all 3 arms
1940091|NCT01683786|Drug|Pegintron + Riba|Pegylated IFN-α2b at 1.5 µg/kg of body weight/week and ribavirin 800~1400 mg/day
1940094|NCT01681836|Drug|"Non-radioactive heavy 15N-labeled sodium nitrite"|15N-labeled sodium nitrite 20 mg once
1940095|NCT01681836|Drug|15N-labeled sodium nitrate|15N-labeled sodium nitrate 1,000 mg once
1940096|NCT01681992|Biological|GSK Biologicals measles, mumps and rubella vaccine live (GSK 209762)|Single dose administered subcutaneously (SC) of either Inv_MMR_Min or Inv_MMR_Med depending on group assigned followed by a second SC injection of Inv_MMR_Release about 6 weeks later.
1940097|NCT01681992|Biological|Merck &amp; Co., Inc.'s M-M-R®II, combined measles-mumps-rubella virus vaccine live|Single dose administered by SC injection of either Com_MMR_L1 or Com_MMR_L2 depending on group assigned followed by a second dose SC injection of either Com_MMR_L1 or Com_MMR_L2 about 6 weeks later.
1940098|NCT01681992|Biological|Varivax® (Merck & Co., Inc.)|Single dose SC injection administered at Visit 1 (Day 0) with either one of two Inv_MMR vaccine lots (Inv_MMR_Min or Inv_MMR_Med) or one of two active control Com_MMR vaccine lots (Com_MMR_L1 and Com_MMR_L2).
1940099|NCT01681992|Biological|Havrix®|Single dose Intramuscular injection (IM) administered at Visit 1 (Day 0) with either one of two Inv_MMR vaccine lots (Inv_MMR_Min or Inv_MMR_Med) or one of two active control Com_MMR vaccine lots (Com_MMR_L1 and Com_MMR_L2).
1940100|NCT01681992|Biological|Prevnar 13® (Pfizer Inc.)|Single dose Intramuscular injection (IM) administered at Visit 1 (Day 0) in subjects enrolled in US with either one of two Inv_MMR vaccine lots (Inv_MMR_Min or Inv_MMR_Med) or one of two active control Com_MMR vaccine lots (Com_MMR_L1 and Com_MMR_L2).
1940195|NCT01659866|Drug|gentamicin|2 mg/kg intravenously 1 hour before the procedure
1940103|NCT01680939|Drug|Morphine|0.2-0.5 mg/kg PO q4h
1940104|NCT01680939|Drug|Ibuprofen|10mg/kg PO q6hrs
1940105|NCT01680783|Device|Non invasive ventilation using a helmet hyperbaric device|"Patients randomized to the intervention group will receive noninvasive ventilation delivered via a latex-free helmet connected to the ventilator by conventional tubing.
If endotracheal intubation is required, the helmet will be removed and the patient will be intubated without delay."
1940106|NCT01680783|Other|Noninvasive ventilation via facemask|Patients assigned to the conventional ventilation group will continue noninvasive ventilation via facemask
1940107|NCT01680653|Drug|Mini-glucagon|Mini dose glucagon given for glucose <70 mg/dl at a dose of 1unit/year of age
1940108|NCT01680653|Device|Remote monitoring|Provides real-time continuous glucose monitoring
1940109|NCT01680653|Dietary Supplement|Carbohydrates and remote monitoring|16 grams of carbohydrate with remote monitoring
1940110|NCT01680653|Dietary Supplement|Carbohydrates No remote monitoring|Carbohydrates for hypoglycemia and no remote monitoring
1940111|NCT01680224|Behavioral|Healthy Weight|
1940112|NCT01680224|Behavioral|Project Health|
1940113|NCT01680224|Behavioral|Placebo Control|Participants will view a video on overweight and obesity
1940114|NCT01679964|Drug|Raltegravir switch|Isentress (400mg) bid + 2 NRTI (at least 2 nucleoside or nucleotide reverse transcriptase inhibitors and no other protease inhibitors)
1940115|NCT01679405|Drug|BIBW 2992|single arm study
1940116|NCT01680120|Procedure|Continuous spinal anaesthesia|"Standard monitoring including continuous electrocardiogram, noninvasive automated arterial blood pressure and pulse oximetry will be applied.
Subarachnoid puncture will be performed with a 18-gauge Tuohy needle at the L4-5 or L3-4 interspace using a midline approach. Three cm of a 22-gauge catheter will be introduced cephalad through the needle. The initial dose is arbitrarily chosen as 1 ml of 0.5 % isobaric bupivacaine on the basis of clinical experience, the local anaesthetic will be injected through the catheter over 5-10 s. After completion of injection the patients remain in the lateral position for 5 min and then will be returned to the supine position.
Successive injections of 0.2 ml of 0.5 % isobaric bupivacaine will be performed every 15 min until a satisfactory sensory level is obtained (T12)."
1940117|NCT01678924|Drug|AGN-214868|AGN-214868 given as injections into the area of pain on Day 1.
1940118|NCT01678924|Drug|AGN-214868 Placebo (Vehicle)|AGN-214868 placebo (vehicle) given as injections into the area of pain on Day 1.
1940119|NCT01678443|Biological|indium In 111 anti-CD45 monoclonal antibody BC8|Given IV
1940120|NCT01678443|Radiation|yttrium Y 90 anti-CD45 monoclonal antibody BC8|Given IV
1940121|NCT01678443|Procedure|peripheral blood stem cell transplantation|Undergo autologous peripheral blood stem cell transplant
1940122|NCT01677312|Procedure|Pancreatic Biopsy|A FNA needle will be used to biopsy the pancreatic mass. The rates of diagnostic accuracy (%) will be assessed. Diagnostic accuracy is defined as the proportion of patients in whom a definitive diagnosis can be obtained within a predetermined number of FNA passes.
1940123|NCT01677312|Procedure|Histological Samples|The proportion of patients (%) in whom a histological tissue can be obtained when performing a biopsy of the pancreas using a specific needle will be assessed.
1940124|NCT01677221|Device|Acleara Acne Treatment System|
1940126|NCT01676987|Drug|Fixed combination of budesonide and formoterol|Delivered dry powder inhaler for 12 weeks.
1940127|NCT01676987|Drug|Budesonide|Delivered dry powder inhaler for 12 weeks.
1940128|NCT01676376|Device|eSVS Mesh treated saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be treated with eSVS Mesh and implanted in the right or left coronary system.
1940129|NCT01676376|Other|Control saphenous vein graft|During coronary artery bypass graft surgery, one SVG will be randomized to be the control (no eSVS Mesh) and implanted in the right or left coronary system.
1940130|NCT01673893|Device|ClearWay™ Rx catheter|
1940134|NCT01672008|Drug|NOX-100|
1940135|NCT01671475|Device|microEEG (Bio-Signal microEEG)|"At the core, the Bio-Signal microEEG, is an FDA approved miniature, battery-operated, multi-channel, and portable system that records wideband bioelectric signals. The microEEG combines the characteristics of low noise and small size, due to a number of fundamental design characteristics. It records, amplifies, and digitizes the signals at a point very close to the electrodes. This allows the length of the wires between electrodes and the recorder's amplifiers to be very short, keeping them out of the way. Short wires also reduce any inconvenience signal artifacts or other problems that may be associated with the length of the wires. The microEEG's dimensions are about 2x2x1."
1940136|NCT01671332|Drug|Docetaxel|IV over 60 minutes, 75 mg/m2
1940137|NCT01671332|Drug|Suramin|IV over 30 minutes
1940138|NCT01671332|Drug|Docetaxel|IV over 60 minutes. 56 mg/m2
1940139|NCT01671319|Drug|docetaxel + cyclophosphamide + pegfilgrastim|docetaxel 75 mg/m2 + cyclophosphamide 600 mg/m2 IV every 2 weeks x 4 cycles plus pegfilgrastim 6mg sq 24-48 hours post day 1 of each cycle
1940141|NCT01669434|Drug|Take ACE-I|These chronic medications will be given on the morning of surgery.
1940142|NCT01669434|Drug|Hold ACE-I|These medications, although taken chronically by patients in this intervention, will not be given on the morning of surgery.
1940196|NCT01659866|Drug|amikacin|5 mg/kg intravenously 1 hour before the procedure
1940197|NCT01659866|Drug|aztreonam|2000 mg intravenously 1 hour before the procedure
1940143|NCT01669421|Drug|Alpha-1 Antitrypsin (human)|Comparison of Zemaira (Alpha 1 Antitrypsin Human) 120 mg/kg/weekly for four weeks versus 2 phases with same drug administered at standard doses of 60 mg/kg/weekly for four weeks each
1940144|NCT01669096|Biological|GSK Biologicals' investigational TB vaccine GSK 692342|2 doses administered intramuscularly according to a 0, 1 month schedule (Day 0 and Day 30), in the deltoid region of the arm
1940145|NCT01668966|Drug|Tocilizumab|Participants will receive tocilizumab 8 mg/kg IV every 4 weeks for up to 104 weeks.
1940147|NCT01666145|Device|Advanced Image Guidance|Patients with hepatocellular carcinoma will be treated through laparoscopic microwave ablation surgery, in which the surgeon will utilize a new guidance system for needle placement.
1940148|NCT01666444|Drug|pegylated liposomal doxorubicin (PLD)|
1940149|NCT01666444|Drug|VTX-2337|TLR8 Agonist
1940150|NCT01666444|Drug|Placebo|
1940151|NCT01666652|Biological|4 µg TDENV-PIV with Alum adjuvant|
1940152|NCT01666652|Biological|1 µg TDENV-PIV with AS03B1 adjuvant|
1940153|NCT01666652|Other|Phosphate buffered saline|
1940154|NCT01666652|Biological|1 µg TDENV-PIV with Alum adjuvant|
1940155|NCT01666652|Biological|1 µg TDENV-PIV with AS01E1 adjuvant|
1940156|NCT01665430|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, up to 104 weeks
1940157|NCT01664871|Device|DIammine SIlver Fluoride|Concentrations of Silver and Fluoride in the DSF used for study were 24.9% and 5.5%, respectively Average total weight (calculated volume) of Diammine Silver Fluoride applied was 7.57 mg (6.04 µL), corresponding to a mean application of 0.33 mg Fluoride based on the lot analysis. The mean total amount of Silver applied to the 3 teeth was 1.50 mg.
1940158|NCT01664858|Other|3T CMR|3Tesla Cardiac Magnetic Resonance Imaging
1940159|NCT01664858|Other|SPECT|SPECT: Single Photon Emission Computed Tomography
1940160|NCT01664858|Other|CT calcium score|CT calcium score
1940161|NCT01664858|Other|CT coronary angiography|CT coronary angiography
1940162|NCT01664858|Other|X-Ray coronary angiography|X-Ray coronary angiography
1940163|NCT01664598|Drug|tocilizumab [RoActemra/Actemra]|8 mg/kg iv every 4 weeks, 104 weeks
1940164|NCT01663701|Other|Simplified severe sepsis protocol|This protocol consists of an early aggressive fluid strategy, and, when appropriate, blood transfusion and titratable dopamine. Monitoring is based on physical exam findings.
1940165|NCT01663701|Other|Usual care|Patients are managed according to admitting doctors' orders
1940168|NCT01663077|Drug|Clozapine|A fixed dose of Clozapine 300 mg/day (150 mg x 2)for 3 month
1940172|NCT01662778|Drug|Fluticasone Propionate 50 micrograms|Drug: Fluticasone Propionate Dose 50 micrograms (total dose), Monodisperse aerosol with two differemt particle size of drug (1.5, 6.0 microns) generated by Spinning Top Aerosol Generator (STAG)
1940173|NCT01662778|Drug|Inhaled, Metered dose inhaler, 250 micrograms dose (total dose)|Inhaled, Metered dose inhaler, 250 micrograms dose (total dose), delivered via spacer
1940174|NCT01662778|Drug|Placebo monodisperse aerosol dose|Solvent only delivered, no drug
1940175|NCT01662297|Drug|Quetiapine|Quetiapine will be administered at a dosage prescribed by veterans' current providers for the treatment of insomnia.
1940176|NCT01662297|Drug|Trazodone|Veterans willing to switch from quetiapine to trazodone for the treatment of insomnia will receive up to 400mg of trazodone daily.
1940177|NCT01662440|Biological|Rabies|Subjects received three doses of Rabies, whole virus vaccine (inactivated, Germany).
1940178|NCT01662440|Biological|Japanese Encephalitis|Subjects received two doses of Japanese Encephalitis vaccine.
1940179|NCT01662440|Other|Placebo|Subjects received either two, three, four or five doses of normal saline, 0.9% w/v sodium chloride depending on the vaccine group.
1940180|NCT01661712|Device|Transcutaneous electrical stimulation (SOSATS device, MORGAN Innovation&Technology ltd., Petersfield, UK)|"The SOSATS unit is a first generation sleep apnoea research device which is programmed and controlled by an external PC or laptop via a visual interface.
It stimulates the pharyngeal dilator muscles in order to reduce sleep apnoea."
1940181|NCT01661712|Device|Sham stimulation (SOSATS device, MORGAN Innovation&Technology ltd., Petersfield, UK)|The patient will undergo a sleep study with sham transcutaneous electrical stimulation. The setup will be identical to the intervention, but a blinded mode in the software application will stop triggering electrical current despite indicating on the monitor that stimulation is being applied.
1940182|NCT01660386|Drug|Sitagliptin|100mg po once
1940183|NCT01660386|Drug|Saxagliptin|5mg po once
1940184|NCT01660386|Drug|Glimepiride|2mg po once
1940185|NCT01660386|Drug|Blank control|the subjects take no medication at experimental day and start bi-phase hyperglycaemic clamp at 9am.
1940186|NCT01659866|Drug|Ciprofloxacin|500 mg orally 2 hours before prostate biopsy
1940187|NCT01659866|Drug|trimethoprim-sulfamethoxazole|1 double strength tablet orally 2 hours before the procedure and again 12 hours later
1940188|NCT01659866|Drug|cefuroxime|500 mg orally 2 hours before the procedure then again 12 hours later
1940189|NCT01659866|Drug|ceftriaxone|500 mg intramuscularly 2 hours before the procedure
1940190|NCT01659866|Drug|gentamicin|2 mg/kg intramuscularly 2 hours before the procedure
1940191|NCT01659866|Drug|amikacin|5 mg/kg intramuscularly 2 hours before the procedure
1940192|NCT01659866|Drug|aztreonam|500 mg intramuscularly 2 hours before the procedure
1940193|NCT01659866|Drug|imipenem|500 mg intramuscularly 2 hours before the procedure
1940194|NCT01659866|Drug|ceftriaxone|2000 mg intravenously 1 hour before the procedure
1940198|NCT01659866|Drug|imipenem|1000 mg intravenously 1 hour before the procedure
1940199|NCT01658618|Biological|HP802-247|
1940200|NCT01657253|Drug|PRO-148|Instill one drop in each eye four times a day (QID), for 60 days
1940201|NCT01657253|Drug|Systane|Instill one drop in each eye four times a day (QID), for 60 days
1940202|NCT01658254|Other|survey by email|"The intervention consists in an email to be sent to the sponsor and/or principal investigator of randomly assigned trials. This email will notify them that their trial's primary completion date is over a year old and will ask the reasons why they have not posted results on the registry. Several reasons will be proposed, and investigators or sponsors will be asked to reply by sending back an email or through a website where the same questions will appear. A follow-up email will systematically be sent 7 days after, with similar content (appendix2). The emails will be sent as direct emails, without attached files, with the edit subject Posting basic results. The controlled group will receive no intervention."
1940205|NCT01658059|Other|Homeopathic remedy|drops of the homeopathic remedy will be taken twice a day before the treatment and once on the morning of the treatment day.
1940206|NCT01658059|Other|Placebo|drops of the placebo will be taken twice a day before the treatment and once on the morning of the treatment day.
1940207|NCT01657266|Drug|PRO-155|instill one drop 2 times a day (BID) for 30 days
1940208|NCT01657266|Drug|Nevanac|instill one drop 2 times a day (BID) for 30 days
1940209|NCT01657305|Drug|Oleogel-S10 ointment and non-adhesive wound dressing|One randomly assigned wound half is treated with Oleogel-S10 and non-adhesive wound dressing
1940210|NCT01657305|Device|Non-adhesive wound dressing alone|The other wound half is treated with non-adhesive wound dressing alone.
1940211|NCT01655550|Other|Withhold oral contrast|The intervention is to withhold oral contrast
1940213|NCT01656200|Biological|Live attenuated Japanese encephalitis vaccine SA14-14-2|Live attenuated Japanese encephalitis vaccine SA14-14-2
1940214|NCT01655173|Behavioral|Cognitive behaviour therapy|"The CBT intervention consisted of five elements: (a) structure, (b) group setting, (c) psycho-education, (d) social training and (e) CBT.
The participants were presented with the session plan for the whole year and given a binder in which they kept all materials. In addition, each session followed a strict agenda: (1) introduction and presentation of the agenda of the day, (2) resume of homework assignments from the previous session, (3) psycho-educative lecture and discussions on the session topic, (4) coffee break with buns or sandwiches, and social interaction, (5) relaxation or mindfulness exercise, (6) discussions and exercises on the session topic, (7) distribution of homework and (8) evaluation and end of session."
1940215|NCT01655173|Behavioral|Recreational activity intervention|The therapists did not provide any deliberate interventions, such as psychoeducation, social training or CBT. Instead, the intervention relied on structure and group setting only. During the first session the participants were asked to write down group activities they would like to engage in. The therapists created a list of the suggested activities, such as visiting museums, board game playing, cooking, restaurant visits, boating, cinema and taking walks. The participants voted for the activity of the next session.
1940216|NCT01655069|Drug|Solifenacin succinate|Oral suspension
1940217|NCT01653340|Device|Senza™, High Frequency Spinal Cord Stimulator for Refractory Chronic Migraine|http://nevro.com/corporate/system-us
1940219|NCT01654393|Other|Triage nurses applying the OAR|Triage nurses applying the OAR during assessment and ordering foot/ankle x-rays as necessary.
1940220|NCT01654315|Device|Myomo Robotic Arm|Patients are administered rehabilitative therapy using only the Myomo robotic device targeting their affected arms on 3 days/week during a 8 week period.
1940221|NCT01653912|Drug|GSK2110183 in combination with carboplatin and paclitaxel|Phase I is a dose escalation evaluation of increasing doses of GSK2110183 administered on a continuous daily schedule in combination with carboplatin AUC 5 and paclitaxel 175mg/m2 given every three weeks for a maximum 6 cycles. The dosing regimen identified in Phase I will then be evaluated in Phase II, a single arm study focused on clinical efficacy. Treatment with the three drug regimen will continue for a maximum of 6 x 21 day cycles followed by continuous GSK2110183 at the single agent MTD. Subjects may continue on study drug until progression, death or unacceptable toxicity.
1940222|NCT01653704|Behavioral|observational role|observational role in crisis scenario
1940223|NCT01653704|Behavioral|active role|active role in managing crisis scenario
1940224|NCT01653626|Other|package of 3 interventions|Emergency Obstetric Care training, social marketing approach and link TBS with public sector services
1940273|NCT01646580|Drug|ciclopirox|Doses of 1.0% cream. Topical cream application. Twice daily for 28 days. Duration of treatment: 28 days with four weeks follow-up.
1940274|NCT01646515|Drug|Placebo|"Capsule, appears identical with udenafil, will be provided by Dong-A pharmaceutical company.
Patients will receive 50 mg of placebo drug two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks"
1940562|NCT01584557|Drug|Tolvaptan or Samsca|uncoated tablet, 30mg, once per day, for up to 7 days.
1940563|NCT01584557|Drug|placebo or sugar pill|sugar pill
1940226|NCT01653405|Behavioral|Outreach, Education, and Motivational Interviewing|Patients in the bottom 25% of TTR at baseline will receive an outreach message delivered at a routine care visit. The outreach message will inform them that their control is poor and this puts them at risk for bad outcomes. They will be offered an invitation to attend an education session to learn more about how to self-manage warfarin therapy. This session will be delivered by local clinical staff, using materials that we will provide. Finally, we will educate local clinical staff in the use of motivational interviewing (MI) and will provide a manual to help them deliver MI-based care. They will be asked to deliver MI-based care specifically to patients in the intervention group.
1940227|NCT01653795|Device|LMA Unique: control device|LMA Unique will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5. The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
1940228|NCT01653795|Device|LMA Supreme: comparison device|LMA Supreme will be placed in children based on a computer generated randomization. One of four different sizes of airways will be used: 1.5, 2.0, or 2.5, The size of the airway device will be determined according to the manufacturer's guidelines that are standardized by the patient's weight in kilograms.
1940229|NCT01653236|Drug|Boceprevir|
1940230|NCT01653236|Drug|Peginterferon alfa-2b|
1940231|NCT01653236|Drug|ribavirin|
1940235|NCT01651793|Other|Active comparator 1|High flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
1940236|NCT01651793|Other|Active comparator 2|High flavanol, high theobromine, low caffeine, single dose administration in hot water vehicle
1940237|NCT01651793|Other|Active comparator 3|Low flavanol, high theobromine, high caffeine, single dose administration in hot water vehicle
1940238|NCT01651793|Other|Active comparator 4|Low flavanol, low theobromine, high caffeine, single dose administration in hot water vehicle
1940239|NCT01651793|Other|Inactive comparator|No flavanol, no theobromine, no caffeine, single dose administration in hot water vehicle
1940240|NCT01650415|Drug|Erythropoietin|twice a week for 1 month
1940241|NCT01650415|Drug|Placebo erythropoietin|twice a week for 1 month
1940242|NCT01650935|Behavioral|diet|When the first set of urine samples confirmed hyperoxaluria (urine oxalate>32.8), the patients will enter the study. After a run-in period of 3 weeks patients are allocated into 2 groups that I already explained in the arms section.The patients are visited in the beginning, after 6 weeks and at the end of the study
1940243|NCT01650883|Dietary Supplement|Cholecalciferol|Cholecalciferol 50,000 IU PO every 10 days for 40 days
1940244|NCT01650883|Dietary Supplement|Cholecalciferol 5,000 IU|Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
1940245|NCT01649596|Device|3M Bair Paws Flex Gown and Bair Paws Model 875 Warmer|
1940246|NCT01649596|Other|Standard of care - warm blankets|
1940247|NCT01649947|Drug|Paclitaxel|"Paclitaxel will be given at a dose of 200 mg/m2(by IV over 3 hours on Day 1). Cycles every 3 weeks for 4-6 Cycles.
Prior to receiving paclitaxel, all patients will receive the following premedication:
Dexamethasone 20 mg po 12 and 6 hours prior to paclitaxel infusion (patients may be treated with dexamethasone 20 mg iv < 1 hour prior to infusion with paclitaxel if the patient did not take the oral dexamethasone)
Diphenydramine 50 mg iv (or equivalent) < 1 hour prior to paclitaxel infusion
Ranitidine 50 mg iv < 1 hour prior to paclitaxel infusion (alternatively other H2-blockers may be used)"
1940248|NCT01649947|Drug|Carboplatin|Carboplatin will be given at AUC = 6 by IV over 15-30 minutes on Day 1 immediately following paclitaxel. Cycles every 3 weeks for 4-6 Cycles.
1940249|NCT01649947|Drug|Hydroxychloroquine|Hydroxychloroquine will be given as a flat dose of 200 mg orally BID (total daily dose of 400 mg). Cycles every 3 weeks for 4-6 Cycles.
1940250|NCT01649947|Drug|Bevacizumab|"Cohort 1 only:
Bevacizumab will be given by IV on Day 1 of each 21-day cycle at a dose of 15 mg/kg. Cycles every 3 weeks for 4-6 Cycles."
1940251|NCT01649427|Drug|Simulect|Induction Therapy: 2x20mg; day 0 and day 4 post Tx
1940252|NCT01649427|Drug|Steroids|recommended on Day 14 after transplantation steroid dose is reduced to 5 mg prednisolon or eqivalent. A minimum dose of 5 mg prednisolon or equivalent should be continued until Month 6.
1940253|NCT01649427|Drug|Prograf|0.15 mg/KG Transplantation to Month 1: 8 - 12 ng/ml Month 1 to Month 3: 5 - 10 ng/ml Month 3 to Month 6: 5 - 8 ng/ml
1940254|NCT01649427|Drug|Tacrolimus Hexal|0.15 mg-Kg Transplantation to Month 1: 8 - 12 ng/ml Month 1 to Month 3: 5 - 10 ng/ml Month 3 to Month 6: 5 - 8 ng/ml
1940255|NCT01649271|Drug|Herceptin|3-weekly
1940256|NCT01649271|Drug|afatinib|at MTD level
1940257|NCT01649271|Drug|trastuzumab|3-weekly
1940258|NCT01649271|Drug|Herceptin|weekly
1940259|NCT01649271|Drug|afatinib|at MTD level
1940260|NCT01649271|Drug|afatinib|escalating dose
1940266|NCT01648322|Drug|F-627|subcutaneous injection given 1 per chemotherapy.
1940267|NCT01648322|Drug|Neulasta® (pegfilgrastim)|Single dose injection given once per chemotherapy cycle.
1940268|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 0.25mg/kg IV administration
1940269|NCT01648153|Other|Placebo (saline)|To compare the efficacy and biomarker changes between placebo and active groups
1940270|NCT01648153|Biological|GSK1070806|To investigate the efficacy and biomarker changes of GSK1070806 after 5mg/kg IV administration
1940271|NCT01647282|Drug|locally-applied minocycline HCl (1 mg)|
1940272|NCT01647282|Procedure|scaling and root planing (Sc/RP)|
1941203|NCT01442818|Drug|Dilaudid IV Scheduled|Nurse administered IV Dilaudid 0.5mg every 2 hours.
1940275|NCT01646515|Drug|Udenafil (Zydena)|Udenafil (Zydena), a newly developed PDE-5 inhibitor by Dong-A pharmaceutical company, will be administered to patients in this group, 50 mg two times a day for 4 weeks, and then the dosage will be escalated to 100 mg two times a day for next 8 weeks.
1940276|NCT01646203|Biological|IMC-TR1|Administered intravenously
1940277|NCT01645072|Other|Low glycemic index diet|Diet modification in addition to ongoing anti epileptic drug treatment. Medium and high-GI carbohydrates (GI >55) will be eliminated from the diet and only food items with low glycemic index (GI <55) will be allowed. Parent will be given a list of low glycemic index food items. They will also be given a list of food items (medium and high glycemic index) which should be avoided.
1940278|NCT01645072|Other|Control group|The ongoing anti epileptic drug treatment will be continued without change.
1940279|NCT01645787|Drug|4-aminopyridine|10 mg/twice daily
1940280|NCT01645787|Drug|Placebo|Crossover study involving one trial with sugar pill (placebo)
1940281|NCT01645046|Drug|Coenzyme A|Coenzyme A 200mg per day.
1940282|NCT01645046|Drug|Coenzyme A|Coenzyme A 400mg per day.
1940283|NCT01645046|Drug|Placebo|Capsule without coenzyme A.
1940284|NCT01644565|Biological|Recombinant fimbrial adhesin dsc14CfaE-sCTA2/LTB5|
1940285|NCT01644565|Biological|Recombinant fimbrial adhesin dscCfaE|
1940286|NCT01644565|Biological|Modified E. coli heat labile enterotoxin LTR192G|
1940287|NCT01644851|Behavioral|Executive function training|Computer-based training in executive functions, administered via www.lumosity.com website.
1940295|NCT01641796|Drug|Paromomycin|Paromomycin Topical Cream applied to all lesions once a day for 20 days
1940296|NCT01640899|Device|Shoe Insoles|Shoe insoles is an orthotic devices which are used to prevent, relieve, or reduce pain in lower extremities. The insoles give a mechanical support for the body by put it in a good alignment.
1940297|NCT01641198|Procedure|Dental implants|Each of 58 subjects received 3 types of screw parallel wall mandibular implants (Branemark, Swede-Vent and Screw-Vent) at 5 different sites for a total of 290 implants.
1940299|NCT01641380|Behavioral|Text Messaging Intervention|"Online enrollment in the Compliance for Life® (CFL) system through iReminder)
Welcome Message 24 hrs after enrollment
Appointment Reminder prior to 3 month injection cycles
Monthly health reminders i. Condom use ii. Weight control iii. Side Effect Management 5.6-month STD testing reminder
6.Call for missed appointment or no reply to appointment reminder (or other text message)"
1940300|NCT01640366|Device|PICO|Single-use negative pressure wound therapy system
1940305|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
1940306|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
1940307|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
1940308|NCT01637493|Drug|Pegfilgrastim|Single SC injection of the appropriate dose of drug ranging from 30 mcg/kg to 200 mcg/kg at postchemotherapy 48hr in cycle 2, followed by two doses SC injection of the appropriate dose of drug ranging from 15 mcg/kg to 100 mcg/kg at postchemotherapy 48hr in cycle 3.
1940309|NCT01638429|Drug|Neomycin and Rifaximin|Neomycin: 500mg po bid for 10 days Rifaximin: 550mg po tid for 10 days
1940310|NCT01637870|Device|Prevena negative pressure wound system|Placement of negative pressure wound system at the time of cesarean delivery for those at increased risk for wound complication
1940313|NCT01636830|Device|Toothbrush type|Evaluate the use of toothbrushes with bristles soft and medium
1940314|NCT01635140|Radiation|Hypofractionated radiotherapy|A total dose of 39 Gy in daily fractions of 3 Gy, 5 Fractions per week
1940315|NCT01635140|Radiation|Conventional arm|A total dose of 54 Gy in 30 fractions giving 1.8 Gy per fraction.
1940317|NCT01633801|Device|Use of high flows versus oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
1940318|NCT01633801|Device|oxygen therapy|Once extubation has taken place the child will be placed either on traditional oxygen therapy or high flow nasal cannulae according to randomization.
1941957|NCT01275300|Dietary Supplement|Niaspan|dosage
1940319|NCT01633099|Drug|Decitabine|"Number of Cycles: 4 cycles.
Dose and drug delivery(decitabine):
The 1st cycle: 20 mg/m2, (iv,>1 hour) d1-10 of each 28 day cycle. The 2nd-4th cycle:If bone marrow blast cells≥5%, the following cycle is the same as the 1st cycle.
If bone marrow blast cells<5%, the following cycle:decitabine 20 mg/m2, (iv,>1h) on d1-5 of each 28 day cycle.
If Grade 4 neutropenia（<0.5×10E9/L）come arise after 5 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 4 days(20 mg/m2, IV ,>1h, on d1-4 of each 28 day cycle).If Grade 4 neutropenia（<0.5×10E9/L）come arise after 4 days' cycle of decitabine and lasts more than 14 days in last cycle,the next cycle will decrease dose to 3 days(20 mg/m2, IV,>1h, on d1-3 of each 28day cycle)."
1940320|NCT01632891|Drug|Lopinavir/ritonavir|Participants will receive two 200 mg/50 mg tablets of lopinavir/ritonavir orally twice daily starting on study day 1 for 15 days.
1940321|NCT01632891|Drug|Emtricitabine/tenofovir disoproxil fumarate|Participants will receive one 200 mg/300 mg tablet of Emtricitabine/tenofovir disoproxil fumarate orally once daily starting on study day 1 for 15 days.
1940322|NCT01632891|Drug|Efavirenz|Participants will receive one 600 mg tablet of efavirenz orally once daily starting on study day 1 for 15 days.
1940323|NCT01632891|Drug|Nevirapine|If unable to take efavirenz, participants will receive on 200 mg tablet of nevirapine orally once daily starting on study day 1 for 15 days.
1940324|NCT01632891|Drug|Efavirenz|Participants will receive one 600 mg tablet of efavirenz orally once daily starting on study day 16 for 15 days.
1940325|NCT01632891|Drug|Nevirapine|For those participants unable to take efavirenz and who have not taken nevirapine in Step 1, participants will receive one 200 mg tablet of nevirapine orally once daily starting on study day 16 for 15 days for participants.
1940326|NCT01632891|Drug|Nevirapine|Participants unable to take Efavirenz who have taken nevirapine in Step 1 will received one 200 mg tablet or nevirapine orally twice daily starting on study day 16 for 15 days (unless not clinically warranted per discretion of the site investigator (see section 7.0 of study).
1940327|NCT01632891|Drug|emtricitabine/tenofovir disoproxil fumarate|Participants will receive one 200 mg/300 mg tablet of emtricitabine/tenofovir disoproxil fumarate orally once daily starting on study day 16 for 15 days.
1940328|NCT01632891|Drug|trimethoprim/sulfamethoxazole|Participants will receive one 160 mg/800 mg tablet of trimethoprim/sulfamethoxazole orally once daily starting on study day 16 for 15 days.
1940329|NCT01632579|Drug|LY3023703|Administered orally
1940330|NCT01632579|Drug|Placebo|Administered orally
1940331|NCT01632579|Drug|Celecoxib|Administered orally
1940334|NCT01631448|Biological|Fibrin Glue|The biological adhesive will be applied to the study group, with the spray technique in two atmospheres of pressure in a total amount of 10 ml.
1940339|NCT01629953|Other|Group vocational intervention|Group based manualized vocational rehabilitation
1940340|NCT01629953|Other|Supported Employment Condition|Veterans in this condition will receive a proven group based manualized vocational rehabilitation intervention
1940341|NCT01630811|Drug|Nuedexta|Nuedexta (Dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg) will be given once daily for 7 days. If well-tolerated, it will be given every 12 hours for the next 7 weeks.
1940342|NCT01628640|Other|Laboratory Biomarker Analysis|Correlative studies
1940343|NCT01628640|Other|Pharmacological Study|Correlative studies
1940344|NCT01628640|Biological|Recombinant Vesicular Stomatitis Virus-expressing Interferon-beta|Given intratumorally
1940345|NCT01629381|Drug|Rivaroxaban|10 mg os once daily for 1 week
1940346|NCT01629381|Drug|placebo|10 mg os once daily for 1 week
1940349|NCT01628198|Device|Celcius Thermacool Catheter or Chilli II Cooled Ablation Catheter|"Saline-Irrigated Radiofrequency Ablation Catheter will be placed in the renal arteries in a circumferential manner and energy will be delivered to create 4 burn lesions.
There are 2 devices that can be used---this is optional, based on physician preference:
Celcius Thermacool Catheter Biosense Webster, Inc Diamond Bar, California
or
Chilli II Cooled Ablation Catheter Boston Scientific Corporation San Jose, California"
1940350|NCT01628523|Other|For inclusion in the study, patients will have to require mechanical ventilation either via an endotracheal tube or tracheostomy tube.|Mechanical ventilation via an endotracheal tube or tracheostomy tube
1940351|NCT01628016|Behavioral|a word dot-probe task for training procedure|During a two-week period, 8 sessions of a modified dot probe task for attentional bias modification training (ABMT) condition, 8 sessions of a classic dot probe task for placebo training (PT) condition, only assessment for blank control condition.
1940352|NCT01627912|Other|Robola, Cabernet Sauvignon wines|4 treatments on separate days: the subjects randomly consumed 4ml of drink [white wine or red wine or 12.5% ethanol or water]/kg of individual, parallel with a standardized meal.
1940355|NCT01625871|Drug|tablets artemether/lumefantrine|six doses of oral tablets of artemether/lumefantrine
1940549|NCT01588236|Drug|placebo|3 capsules of placebo tid (morning, midday, and evening)
1940550|NCT01587898|Drug|GSK1278863|Tablet
1940551|NCT01587898|Other|Placebo|Tablet
1940356|NCT01625416|Behavioral|Case management, information technology/mHealth innovations, psychotherapy, and psychopharmacology.|All patients randomized to receive the stepped care management procedures will meet with the trauma support specialist (TSS) prior to discharge from the hospital, who will provide coaching on use of mobile technology for mental health concerns. The TSS will complete follow-up correspondence across the three month time period to assess mental health functioning and use of information technology that addresses medical concerns. Patients who report barriers to mHealth technologies and request additional therapeutic services for mental health concerns assistance will receive evidence-based motivational interviewing and cognitive behavioral intervention procedures that can span up to 3-months.
1940357|NCT01625039|Behavioral|Employee wellness programme|The experimental group was subjected to a wellness programme based on the principles of cognitive behaviour therapy (CBT) as well as weekly supervised exercise classes over six weeks.
1940358|NCT01625039|Behavioral|Comparator (Once off educational session and educational materials)|Once off educational session and educational materials
1940359|NCT01624298|Behavioral|Trauma Focused Cognitive Behavioral Therapy|TF-CBT (www.musc.edu/tfcbt) is a therapy that helps children/youth ages 5-18 years and their families who have been affected by traumatic events and/or traumatic grief. Components include psychoeducation, relaxation, affective modulation, cognitive processing, Trauma Narrative (gradual exposure), In-vivo exposure, Con-joint session, and Enhancing safety skills. Youth and caregivers are seen once a week for approximately 12 weeks.
1940363|NCT01623596|Drug|Fingolimod|
1940364|NCT01623596|Drug|Disease Modifying therapy|
1940365|NCT01623440|Drug|Placebo|Pill form, participant dosed one time an hour before fMRI.
1940366|NCT01623440|Drug|Naltrexone|50 mg pill given one time, one hour before fMRI
1940367|NCT01622179|Procedure|sewed indirectly|The epitenon was repaired and sewed indirectly.
1940368|NCT01622179|Procedure|sewed directly|The epitenon was unrepaired and sewed directly.
1940369|NCT01622556|Drug|Fludarabine|35 mg/m2 IV/day x 5 days
1940370|NCT01622556|Drug|Busulfan|.8 mg/kg IV Q6h x 8 doses
1940371|NCT01622556|Drug|Thymoglobulin|1.5 mg/kg/day x 3 days
1940372|NCT01622556|Radiation|Total Body Irradiation|150 cGy for 2 days
1940373|NCT01622556|Biological|Umbilical Cord Blood|Two partially HLA-matched UCB units. Each unit must match at a minimum of 4 of 6 at HLA-A, -B, -DRB1 loci with the recipient.
1940377|NCT01622010|Behavioral|Allied Health Education Class Option|An Allied Health Education Class is provided as part of standard care on an optional basis. It involves a one time attendance at a 90 minute class which provides basic education from a multidisciplinary team.
1940378|NCT01622010|Other|Physiotherapy treatment intervention on referral|The option exists for referral to physiotherapy, according to standard protocol, for assessment and individual exercise prescription.
1940379|NCT01622010|Device|Keeping the Beat with Physiotherapy: Heart Failure edition|Educational DVD covering the basics of physiotherapy education for the patient with heart failure.
1940380|NCT01621802|Biological|Priorix|One dose administered subcutaneously in the triceps region of the right arm.
1940381|NCT01621802|Biological|M-M-R II|One dose administered subcutaneously in the triceps region of the right arm.
1940382|NCT01621802|Biological|Kinrix|One dose administered by deep intramuscular injection in the upper left deltoid.
1940383|NCT01621802|Biological|ProQuad|One dose administered subcutaneously in the triceps region of the left arm.
1940384|NCT01621230|Drug|epidural 0.125% bupivacaine with fentanyl 2 mcg/cc infusion|"Randomization will occur when the woman reaches 8 cm cervical dilation. Group II will receive a 100mL cassette of fentanyl 10mcg/mL (to be infused at 10mL/hr). Group I will receive a 100mL epidural cassette of 0.125% bupivacaine with fentanyl 2mcg/mL to be infused at 10mL/hr. Both groups will have the same rate of epidural infusion such that the patient, nurse, obstetrician, and anesthesia providers will be blinded to the randomized treatment group.
The patient may request a 5mL bolus from the epidural infusion every 30 minutes if pain relief is inadequate. The study regimen will continue until spontaneous delivery of the infant or until which time operative vaginal delivery or cesarean delivery is planned."
1940385|NCT01621230|Drug|fentanyl 10 mcg/cc epidural infusion|"Randomization will occur when the woman reaches 8 cm cervical dilation. Group II will receive a 100mL cassette of fentanyl 10mcg/mL (to be infused at 10mL/hr). Group I will receive a 100mL epidural cassette of 0.125% bupivacaine with fentanyl 2mcg/mL to be infused at 10mL/hr.Both groups will have the same rate of epidural infusion such that the patient, nurse, obstetrician, and anesthesia providers will be blinded to the randomized treatment group.
The patient may request a 5mL bolus from the epidural infusion every 30 minutes if pain relief is inadequate. The study regimen will continue until spontaneous delivery of the infant or until which time operative vaginal delivery or cesarean delivery is planned."
1940386|NCT01620671|Procedure|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
1940387|NCT01620671|Procedure|Surgical repair of perforated peptic ulcer|Perforated peptic ulcer located in the stomach and the duodenum will be repaired by either primary repair or omentoplasty.
1940388|NCT01620658|Device|0.5mm XPF cap|"Interventionalist wear a XPF 0.5mm lead equivalent cap during fluoroscopy guided interventions.
XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
1940389|NCT01620658|Device|0.3mm XPF cap|"Interventionalist wear a XPF 0.3mm lead equivalent cap during fluoroscopy guided interventions.
XPF is a trademark of BloXR (Salt lake City, UT) for a new bi-layer (Barium/Bismuth) radiation attenuation material."
1940390|NCT01620658|Device|Standard cap|Interventionalist wear a standard fabric cap during fluoroscopy guided interventions.
1940391|NCT01619982|Drug|Cefazolin pre-operative prophylaxis|Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery.
1940392|NCT01619982|Drug|Vancomycin hydrochloride|Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is > 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is > 8 hours in duration.
1940393|NCT01619891|Dietary Supplement|Vitamin D|100mcg per day
1940394|NCT01619852|Drug|.9 normal saline placebo|Administration of .9 normal saline placebo as a bolus and as maintenance throughout the length of the surgical procedure.
1940395|NCT01619852|Drug|Group L (lidocaine)|Group L will receive a 1.5 mg/kg bolus of intravenous lidocaine followed by a 2mg/kg/hr infusion that will be started at the time of surgical induction and will be discontinued one hour after the end of the surgical procedure.
1940396|NCT01619371|Device|Simplisse Double Electric Breast Pump|Use of breast pump for 10 minutes.
1940397|NCT01619150|Drug|Etoricoxib, followed by placebo (matching tablet, without active ingredient)|Sequence 1: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use. Sequence 2: 1 tablet of matching placebo daily for 4 weeks, for oral use.
1940398|NCT01619150|Drug|Placebo (matching tablet, without active ingredient), followed by etoricoxib|Sequence 1: 1 tablet of matching placebo daily for 4 weeks, for oral use. Sequence 2: 1 tablet of 60 mg etoricoxib daily for 4 weeks, for oral use.
1940399|NCT01617213|Drug|Melphalan|200 mg/m2/IV
1940400|NCT01617213|Drug|Lenalidomide|10 mg daily continuously for the first 3 months, then increased to 15 mg daily as long as the patient tolerates the drug.
1940402|NCT01617083|Drug|Azithromycin|Antibiotic used to treat infections
1940403|NCT01617083|Drug|Placebo|Thickening compound with sugar and flavoring
1940404|NCT01616082|Behavioral|Low Calorie Diet (LCD)|A Diet History Questionnaire will be completed, and the subjects will have dietary counseling and be provided shakes. The low calorie diet will begin, to continue for a period of 8 weeks.
1940405|NCT01616082|Drug|Phentermine|"Individuals not on track to achieve their target weight by four weeks will receive the drug Phentermine to promote weight loss. Then, following eight weeks LCD (or four weeks LCD + four weeks LCD+Phentermine), in the event that they did not achieve the target weight loss, subjects will be given the option to continue with the LCD + Phentermine for up to an additional 12 weeks, under a doctor's supervision.
Protection Against Risk:
Prior to administering any phentermine, a history and physical including EKG will be conducted (at the screening visit) and will be used to determine whether the participant is clear to receive the medication.
Participants will see the study doctor or nurse practitioner at every study visit after the drug is initiated."
1940406|NCT01614912|Drug|SM-13496|40 or 80 mg once daily orally
1940407|NCT01614899|Drug|SM-13496 40mg|once daily orally
1940408|NCT01614899|Drug|SM-13496 80mg|once daily orally
1940409|NCT01614899|Drug|Placebo|once daily orally
1940410|NCT01615575|Procedure|Transanal haemorrhoidal dearterialisation|Closure of the arterial blood flow to the haemorrhoidal plexus, using a dedicated proctoscope with a Doppler probe, and a rectal mucopexy
1940411|NCT01615575|Procedure|Stapler haemorrhoidopexy|Haemorrhoidopexy with a single dedicated circular stapling device (PPH 03, Ethicon Endo-Surgery, Ohio, USA).
1940412|NCT01614847|Drug|Artificial tears|At random, subjects will receive hypo-osmolar artificial tear or a control (normal saline).
1940414|NCT01614353|Other|Electronic Diaries|Participants (N=30) will maintain electronic diaries to record spontaneous thoughts and perceptions regarding the use of a newly prescribed drug over 30 days.
1940415|NCT01614353|Other|Hermeneutic Interviews|Half of the enrolled participants (n=15) will participate in 2 hermeneutic interviews conducted in an interpretive phenomonological approach to generate an interpretation of the meaning of medication taking.
1940552|NCT01585766|Biological|MEDI-551 IV|Associated Dosage Level x 2 MEDI-551 IV
1940553|NCT01585766|Biological|MEDI-551 SC|Associated Dosage Level X 1 MEDI-551 SC
1940554|NCT01585766|Drug|Placebo IV|Placebo IV x 2
1940555|NCT01585766|Drug|Placebo SC|Placebo SC x 1
1940422|NCT01613807|Drug|Insulin LISPRO|Humalog® Mix50/50™ [50% insulin lispro protamine suspension and 50% insulin lispro injection, (rDNA origin)], three times daily at mealtime. Dose determined by blood glucose history.
1940423|NCT01613807|Drug|Insulin, Long-Acting and Insulin LISPRO|Long-acting insulin three times daily on rising, mid-afternoon, and before bed, and insulin lispro three times daily at mealtime. Doses determined by blood glucose history and carbohydrate content of the meal.
1940433|NCT01611454|Device|XPF thyroid collar|Interventionalist wear the experimental (XPF) thyroid collar during fluoroscopy guided interventions.
1940434|NCT01611454|Device|Standard 0.5mm lead equivalent thyroid collar|Interventionalist wear a standard 0.5mm lead equivalent thyroid collar during fluoroscopy guided interventions.
1940435|NCT01612013|Drug|Sodium bicarbonate plus saline|Sodium bicarbonate solution (Sodium bicarbonate 8.4%, Equiplex, Brazil) was given by adding fifteen ampoules of sodium bicarbonate (150 mEq of sodium) to 1 L of 5% dextrose. Infusion in bolus began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
1940436|NCT01612013|Drug|Intravenous NAC plus saline|Acetylcysteine (Flucistein 100 mg/ml, Neo Química, Brazil) was given via IV bolus at a rate of 150 mg/kg in 500 ml dextrose 5% over 60 min immediately before contrast exposure and followed by 50 mg/kg in 500 ml dextrose 5% during the contrast exposure and for 6 hours after the procedure. Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
1940437|NCT01612013|Drug|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during the contrast exposure and for 6 hours after the procedure. Sodium bicarbonate solution(150 mEq of sodium) was began 60 min prior to the start of contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during the contrast exposure and for the next 6 hours after the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
1940438|NCT01612013|Drug|Saline|Saline (0.9 percent) was given IV at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
1940439|NCT01612013|Drug|NAC plus saline|Acetylcysteine was given via intravenous bolus at a rate of 150 mg/kg over 60 min immediately before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Saline (0.9 percent) was given intravenous at a rate of 1 ml/Kg/h over 60 min prior and followed at the same rate during and for the next 6 hours the procedure.
1940440|NCT01612013|Drug|NAC plus sodium bicarbonate plus saline|Acetylcysteine was given intravenous at a rate of 150 mg/kg over 60 min before contrast exposure and followed by 50 mg/kg during and for 6 hours after the procedure. Sodium bicarbonate solution (150 mEq/L of sodium) was given in bolus began 60 min before contrast administration at 3.5 ml/Kg/h, decreased to 1.18 ml/Kg/h during and for the next 6 hours of the procedure. Saline was given intravenous at a rate of 1 ml/Kg/h over 60 min prior to the start of contrast administration and followed at the same rate during and for the next 6 hours after the procedure.
1940441|NCT01611259|Drug|Rituximab and Lenalidomide|Rituximab 375 mg/m² i.v. day 1 Lenalidomide 20 mg p.o. daily for 21 days Cycles should be repeated every 28 days. Restaging should be performed after three cycles. In case of at least stable disease, patients should receive another three courses of therapy. Patients with documented CR after 6 courses will stop therapy/study, while patients with PR or SD will be given another two cycles for a maximum of 8 cycles.
1940442|NCT01611194|Drug|Hyperbaric oxygen (HBO2) at 1.5 atms|The Hyperbaric oxygen (HBO2) at 1.5 atms (active) group (hyperbaric oxygen-chamber compressed to 1.5 atm abs and breathing 100% oxygen). Each participant should complete 40 sessions over the course of 12 weeks, one session per day, five per week.
1940443|NCT01611194|Drug|Sham control 1.2 atms|The chamber will be compressed with air to 1.2 atm abs to simulate the active group. Participants will don a hood and breathe 21% oxygen (room air). Each participant will complete 40 sessions, one session per day, five sessions per week, within 12 weeks following randomization. Breathing air at a pressure of 1.2 atm abs is equivalent to inhaling 25% oxygen at sea level pressure (1.0 atm abs).
1940445|NCT01610427|Procedure|Blood sample collection|Blood samples will be collected in all subjects at two time points, at the Screening Visit (Day 0) and at the Sample Collection Visit (Day 15)
1940446|NCT01610271|Device|Air Barrier System (Nimbic)|ABS is a device that blows a stream of purified air over the surgical site creating a barrier that prevents the intrusion of bacteria.
1940447|NCT01609296|Device|IN.PACT Admiral™ Drug Eluting Balloon|IN.PACT Admiral™ percutaneous transluminal angioplasty (PTA) paclitaxel drug eluting balloon.
1940448|NCT01608581|Other|multimedia burn awareness campaign|Television commercials x4 delivered 86 times over 10 days plus logo in print media daily in two papers in two cities
1940449|NCT01607775|Device|Implantation of a PEEK-cage|A commercially avaliable cuboid cervical cage will be implantet
1940450|NCT01607775|Device|PMMA-cage|The in-house produced cervical cage will be implanted
1940451|NCT01607372|Drug|GSK2245035|GSK2245035 nasal spray solution. A solution formulation in saline, preserved with Benzalkonium Chloride and Disodium Edetate
1940452|NCT01607372|Device|Type 1 amber glass bottle|fitted with a metered Valios VP7 pump
1940453|NCT01607372|Other|Placebo|As for GSK2245035 nasal spray solution except for omission of the active ingredient
1940454|NCT01607658|Drug|Placebo|placebo intranasal gel administered prn, 2-8 hours before a planned sexual event
1940455|NCT01607658|Drug|Low dose TBS-2|Low dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
1940456|NCT01607658|Drug|Medium dose TBS-2|Medium dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
1940457|NCT01607658|Drug|High dose TBS-2|High dose testosterone intranasal gel administered prn 2-8 hrs before a planned sexual event
1940458|NCT01607749|Behavioral|Educational Program|"Schools in the intervention group received the educational program Asthma, Sport and Health, as validated by our group. This program will be taught to students in three lessons with equipment designed and developed by the research group to be taught within the curriculum of physical education subject.
Teachers of physical education specialists responsible for the project at each center will receive the training curriculum for use in a training seminar for a school day by researchers from the health of our group. Once familiar with the educational package of three sessions taught his students and fellow faculty (on different days for teachers and students) within 15-30 days."
1940459|NCT01607749|Other|Usual Asthma Information for teachers|Common asthma information for teachers
1940460|NCT01606930|Behavioral|Patient Primer Tool|"The instrument is completed before the scheduled appointment and is designed to prompt patients to reflect on their specific goals for the medical encounter, prioritize those goals, and to Prime them to engage in a discussion centered on their concerns and expectations. In addition, participants will be encouraged to bring this form into their physician visit and use it to engage their clinician in a discussion about their health needs."
1940461|NCT01606709|Drug|GnRH agonist|GnRH agonist 1mg one dose
1940462|NCT01606709|Drug|hCG|5,000 IU one dose
1940463|NCT01607073|Drug|Verapamil|"Verapamil will be prepared as a solution. A 50mg/ml oral suspension may be made with immediate release tablets and either a 1:1 mixture of Ora-Sweet and Ora-Plus or a 1:1 mixture of Ora-Sweet SF and Ora-Plus will be used.
Children will start on a 4 weeks titration period:
Week 1: 1mg/kg/day divided BID Week 2: 2mg/kg/day divided BID or TID Week 3: 3mg/kg/day divided BID or TID Week 4: 4mg/kg/day divided TID
In event of adverse events, and in consultation with the family and treating physician, the dosage may be decreased to 2mg/kg/day and remain at that dose for the remainder of the study."
1940464|NCT01605890|Drug|emtricitabine / tenofovir disoproxil fumarate / raltegravir .|"emtricitabine : 200 mg/day and tenofovir disoproxil fumarate : 300 mg/day, included in one pill of Truvada® QD.
raltegravir : 400 mg x 2/day, 400 mg in one pill of Isentress® BID."
1940465|NCT01604824|Drug|alirocumab|Randomized, double-blind treatment period may be followed by open-label treatment with alirocumab for all patients if certain criteria are met.
1940466|NCT01604824|Drug|placebo|
1940467|NCT01605435|Drug|Ghrelin|The first three participants will receive 2 mcg/kg as a single subcutaneous dose at Visit 3, 5 mcg/kg as a single subcutaneous dose at Visit 4, and 10 mcg/Kg as a single subcutaneous dose at visit 5. There will be 3-10 days between visits. The next three participants will receive either the same dosing at the first three, a regimen that includes an intermediate dose (e.g., 7.5 mcg/kg), or higher (e.g., 12, 15, and 18 mcg/kg) doses.
1940472|NCT01605019|Device|CoSeal|3 - 8mls of Coseal
1940473|NCT01605019|Device|BioGlue® Surgical Adhesive|Total amount applied - 8 mls
1942146|NCT01238718|Drug|Lidocaine|lidocaine 1.5 mg/kg intravenously
1940476|NCT01603836|Biological|bone allogaft with bone marrow concentrate|In forty cases, the PLF was done with spongious allograft chips alone (Group I). In another forty cases, spongious allograft chips were mixed with BMC (Group II), where the mesenchymal stem cell (MSCs) concentration was 1.74 x104/L at average (range, 1.06-1.98 x104/L). Patients were scheduled for anteroposterior and lateral radiographs at 12 and 24 months after the surgery and for CT scanning at 24 months after the surgery. Fusion status and the degree of mineralization of the fusion mass were evaluated separately by two radiologists blinded to patient group affiliation.
1940477|NCT01602822|Drug|3 drug regimen: Tenofovir DF and Emtricitabine; Ritonavir-boosted Atazanavir|TDF 300mg and FTC 200mg fixed-dose combination tablet (TDF/FTC) once daily, and atazanavir, one 300mg tablet and one 100 mg ritonavir given once daily
1940478|NCT01602822|Drug|Ritonavir, Atazanavir, Truvada|
1940479|NCT01602393|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 48 weeks
1940480|NCT01602393|Drug|CHF 5074 2x|oral tablet, 2x, once a day in the morning for 48 weeks
1940481|NCT01602393|Drug|CHF 5074 3x|oral tablet, 3x, once a day in the morning for 48 weeks
1940482|NCT01601431|Device|Cap Assisted Colonoscopy|Plastic transparent cap added to the distal end of the colonoscope which can increase adenoma detection rate
1940483|NCT01601431|Device|Conventional colonoscopy|Regular colonoscopy as per standard clinical guidelines
1940488|NCT01602172|Behavioral|Brief Alcohol Intervention|3 part intervention: Part I is 15-minute multi-component motivational discussion in hospital which includes personalized risk feedback, advice to abstain or reduce consumption, and the negotiation of an individual change plan. Part II is 15-minute follow-up in hospital to reinforce Part I. Part III is 15-minute follow-up telephone call at 2 weeks to reinforce Part I.
1940489|NCT01602172|Other|Lifestyle brochures|Set of educational brochures/brochures which contain information and tips for healthy lifestyle behaviors such as alcohol and tobacco use, weight management, and physical activity to discuss with the Research Assistant. Approximately two weeks later, the Research Assistant will call patients in this condition at home for a 5-15 minute session to review the brochures and discuss any questions that s(he) may have.
1940490|NCT01601496|Device|FUSION™ Vascular Graft|All subjects receive FUSION™ Vascular Graft at baseline implant procedure
1940491|NCT01602068|Drug|40 mg/mL Dexamethasone phosphate ophthalmic solution|Transcleral iontophoresis delivery of EGP-437 (dexamethasone phosphate formulated for ocular iontophoresis)
1940492|NCT01602068|Drug|100 mM sodium citrate buffer solution|Transcleral iontophoresis delivery of 100 mM sodium citrate buffer solution
1940493|NCT01600716|Biological|OnabotulinumtoxinA|OnabotulinumtoxinA 100 U is administered into the detrusor at Day 1 in the onabotulinumtoxinA 100 U arm. After a minimum of 12 weeks, patients in both the onabotulinumtoxinA 100 U arm and the placebo arm could request/qualify for an onabotulinumtoxinA injection.
1940494|NCT01600716|Drug|Placebo (Normal Saline)|Placebo (normal saline) is administered into the detrusor at Day 1.
1940495|NCT01600586|Device|Pacifier-Activated-Lullaby system (PAL).|Pacifier-Activated-Lullaby system (PAL).
1940497|NCT01599884|Drug|N-acetylcysteine|1800 mg twice daily for 8 weeks
1940498|NCT01599884|Drug|Oral acetylcysteine|Identical placebo pills twice daily for 8 weeks
1940499|NCT01599689|Other|Mirrors Intervention|"Coaching in the use of two types of mirrors to support mental status and attention, physical mobility, and sense of body awareness and ownership, as well as patient dignity and privacy in self-care.
To be administered at set times and in a standardised way by ICU nursing and physical therapy teams."
1940501|NCT01598922|Behavioral|Internet Cognitive Behavioral Therapy|8 weeks of online treatment program
1940502|NCT01598701|Drug|Acetaminophen|Intravenous Acetaminophen, 1000 mg/100mL, Every 6 hours, Infused over 15 minutes.
1940503|NCT01598701|Drug|Placebo|100 mL 0.9% Sodium Chloride
1940504|NCT01597765|Drug|curcuminoids, N-acetylcysteine, deferiprone and vitamin E|receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day deferiprone 50 mg/kg/day and vitamin E 400 IU/day
1940505|NCT01597765|Drug|Curcuminoids and alpha-tocopherol|group 1: receiving curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day group 2: receiving vitamin E 400 IU/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day
1940506|NCT01597687|Procedure|Blood collection|1 blood sample will be collected from each subject.
1940507|NCT01597687|Other|Data collection|Quality of Life and HE questionnaires.
1940508|NCT01597388|Drug|AZD2014|Single dose followed by multiple dosing or twice daily dosing for 2 days folllowed by 5 days off each week, or twice daily dosing on the first and fourth day of the week
1940509|NCT01597388|Drug|Fulvestrant|IM monthly after loading dose
1940510|NCT01596985|Procedure|Ablation using the PlasmaJet system|Ablation of the inner surface of the cyst is then performed using the PlasmaJet system in coagulation mode set at 40, at a distance averaging 5 mm from the tip of the handpiece, and with an exposure time limited to 1 to 2 seconds on each site. Care is taken not to leave any untreated sites and to ablate the edges of the invagination site and the corresponding peritoneal implants on the adjacent broad ligament.
1940558|NCT01586104|Radiation|intensity-modulated radiation therapy|Undergo cardiac-sparing whole lung IMRT
1940559|NCT01586091|Drug|Levocetirizine|levocetirizine 5 mg once daily
1940560|NCT01586091|Drug|Fexofenadine|fexofenadine 60 mg twice daily, oral
1940561|NCT01585207|Drug|vigabatrin|3 tablets, bid for 8 weeks
1940511|NCT01596985|Procedure|Cystectomy|"Surgical excision of an ovarian endometrioma by cystectomy involves three distinct areas, each requiring a different excision procedure. Area A from where cyst invagination originates, measures 1 cm² on average and is revealed by lysing adhesions between the ovary and the adjacent broad ligament, leading to the characteristic chocolate fluid evacuation. The excision by scissors of area A allows the surgeon to identify a cleavage plane close to the cyst wall, which can be followed without significant bleeding (area B). Should adhesions appear in the cleavage plane, they are coagulated and cut, so as not to strip the ovarian cortex. Close to the ovarian hilus, for complete cyst removal, adhesions require coagulation using bipolar current and section by scissors (area C)."
1940516|NCT01595646|Drug|Saline|Saline, administered intranasally twice per day for a 16 week duration
1940517|NCT01595646|Drug|Insulin detemir|20IU of insulin detemir, administered intranasally twice per day for a 16 week duration (total of 40IU insulin detemir per day)
1940518|NCT01595646|Drug|Insulin|20IU insulin, administered intranasally twice per day for a 16 week duration (total of 40IU insulin per day)
1940519|NCT01595581|Drug|Testosterone|8 weeks supraphysiologic dose testosterone enanthate
1940520|NCT01595581|Drug|Saline|Placebo for 8 weeks
1940521|NCT01595347|Drug|Hyper-oxigenated fatty acid|Aplicación tópica de Mepentol (R) en zonas de riesgo de úlceras por presión (sacro, caderas y talones) 1 aplicación/24 horas
1940522|NCT01595347|Other|Olive oil's cream|Application Olive oil's cream to 60% in areas at risk of pressure ulcers (sacrum, hips and heels) 1 application / 24 hours
1940523|NCT01594528|Other|pain tests|pain induction with pressure application or ischemia on the arm
1940524|NCT01595204|Procedure|Diagnostic laparoscopy|"Laparoscopy will be performed in each case of clinical/radiological suspicious primary advanced ovarian/peritoneal cancer.
After the introduction of the trocar and the optic, pneumoperitoneum is induced and one or two ancillary trocars are inserted in the iliac fossae bilaterally or where it is possible. A careful complete abdominal and pelvic inspection is carried out in order to identify any possible cause of non optimal cytoreduction. All peritoneal surfaces and the gutters are closely examined and the liver is evaluated by rotating the laparoscope 360° through the umbilical port using grasping forceps as retractors. The small bowel loops and mesentery are evaluated by carefully folding back the various intestinal segments. The pelvis is explored after the bowel loops are retracted in the upper abdomen when possible. At the end of laparoscopy, a PI value is elaborated, based on table given to participant centers."
1940525|NCT01595009|Drug|RAD001|
1940526|NCT01595217|Device|3T MRI|diffusion weighted imaging(DWI) of biliary tract with GE Signa 3-tesla device
1940528|NCT01593761|Drug|CG400549|960mg QD at fed state approx 1 hour after meal
1940529|NCT01592747|Drug|Memantine Hydrochloride (HCl)|Patients randomized to the full dose arm will continue taking memantine at the same tolerability and weight based dose achieved in lead-in Study MEM-MD-91. Dosing will be once daily for 12 weeks.
1940530|NCT01592747|Drug|Memantine Hydrochloride (HCl)|Patients randomized to the reduced dose arm will take memantine at the tolerability and weight based dose that they received in lead in Study MEM-MD-91 reduced by at least 50%. Dosing will be once daily for 12 weeks.
1940531|NCT01592747|Drug|Placebo capsules|Patients randomized to the placebo will be dosed once daily for 12 weeks.
1940532|NCT01592799|Procedure|Throat swab and/or nasopharyngeal swab|Samples will be tested to quantify the inpatient and ER visits burden of laboratory-confirmed influenza.
1940533|NCT01592799|Other|Data collection|Log Sheet will be used to collected data on a monthly basis for the following age groups: < 6 months; 6-23 months; 24-59 months; > 5 years.
1940534|NCT01591785|Drug|Retapamulin 1% ointment|Retapamulin 1% ointment for 5 days AND clobetasol propionate foam for 14 days
1940535|NCT01591785|Drug|Placebo|Placebo ointment for 5 days AND clobetasol propionate foam for 14 days
1940537|NCT01591096|Drug|Tissue plasminogen activator (Activase®)|Investigation labeled tPA will be obtained for all sites by the Core Pharmacy as commercially available recombinant tPA (Genentech as Activase®) for IV administration. The Bayesian method of toxicity probability intervals will be used to select one of the following three dose tiers (0.75, 0.9, 1.0 mg/kg) of IV tPA. The dose escalation for the two age groups (2-10, 11-17 years) will be performed independently. The maximum dose for each tier will be reached at a weight of 90 kg.
1940538|NCT01590368|Device|Marketed electrode|12 electrodes will be placed on the subject for an ECG reading to be taken
1940539|NCT01590368|Device|"Modified test electrode"|12 electrodes with modified adhesive will be placed on the subject to allow an ECG reading to be taken
1940540|NCT01590082|Drug|Doxycycline|"Phase I Starting Dose: 200 mg by mouth twice a day on Day -6 of Cycle 1 (1 week before Day 1 of Cycle 1 starts)
Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
1940541|NCT01590082|Drug|Ipilimumab|Phase I and II: 3 mg by vein on Day 1 of each 21 day cycle for 4 cycles.
1940542|NCT01590082|Drug|Temozolomide|Phase I and II: 200 mg/m2 by mouth on Days 1 - 4 of each 21 day cycle for 4 cycles.
1940543|NCT01589263|Drug|onaBoNT-A + placebo|"200 U prostate injection once
Arms: ARM 1: onaBoNT-A + placebo"
1940544|NCT01589263|Drug|Tamsulosin + placebo|0.4 mg capsule daily for 3 months Arms: ARM 2: Saline + Tamsulosin
1940546|NCT01587599|Behavioral|counseling|The patients grouped to the intervention cohort receive pharmaceutical care by a pharmacist during the study period.
1940547|NCT01588236|Drug|KYG0395|3 KYG0395 capsules tid (morning, midday, and evening)
1940548|NCT01588236|Drug|KYG0395|3 KYG0395 capsules 2 times a day (bid) (morning and evening) plus 3 capsules of placebo (midday)
1940564|NCT01581593|Biological|Kedrion IVIG 10%|Dosage form - Intravenous (IV) infusion of Kedrion IVIG 10%; Dosage - 300 to 900 mg/kg body weight (bw); Frequency - every 21 to 28 days; Duration - 12 months
1940565|NCT01581411|Drug|Tissue Plasminogen Activator|Intra-ophthalmic artery injection of 2 mg t-PA over 10 minutes followed by 10 mg t-PA over 2 hours
1940566|NCT01581710|Drug|Montelukast to placebo|Subjects will receive montelukast (4 mg or 5 mg) Each treatment period consists of 2 weeks
1940567|NCT01581710|Drug|Placebo to montelukast|Subjects will receive matching placebo. Each treatment period consists of 2 weeks
1940568|NCT01582152|Drug|TPI287|"Phase I Starting Dose: 160 mg/m2 given by vein on Day 1 every three weeks of a 42 Day cycle.
Phase II Starting Dose: Maximum Tolerated Dose (MTD) from Phase I."
1940569|NCT01582152|Drug|Bevacizumab|Arm A + B: 10 mg/kg by vein every 2 weeks of a 42 day cycle.
1940570|NCT01580787|Device|Balance Training with Nintendo Wii Fit|The participants of the study trained 10 balance games during 14 sessions.
1940571|NCT01580787|Other|Physical Therapy|Patients of the control group was trained with balance exercises.
1940572|NCT01579630|Drug|Pemetrexed 500mg/m2 iv|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
1940573|NCT01579630|Drug|Pemetrexed 500mg/m2 iv and Gefitinib 250 mg|EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
1940574|NCT01580007|Drug|Active Sodium Phenylbutyrate and active cholecalciferol|Sodium Phenylbutyrate: 500 mg twice daily orally for 2 months Cholecalciferol: 5000 IU once daily orally for 2 months
1940575|NCT01580007|Drug|Placebo Sodium Phenylbutyrate plus active cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Cholecalciferol: 5000 IU once daily for 2 months
1940576|NCT01580007|Drug|Active Sodium Phenylbutyrate and placebo cholecalciferol|Sodium phenylbutyrate: 500 mg twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
1940577|NCT01580007|Drug|Placebo Sodium Phenylbutyrate plus placebo cholecalciferol|Placebo Sodium Phenylbutyrate: twice daily orally for 2 months Placebo cholecalciferol: once daily orally for 2 months
1940578|NCT01579357|Other|blood samples|"Draw blood samples in week 1 (day 1 and day 5), in week 4 (day 1 and day 5) and in week 7 (day 1 and day 5).
day 1: pre dose, 30,60,90,120,150,180,240,300 and 360min day 5: pre dose, 30,60,90,120min"
1940580|NCT01578967|Drug|Brentuximab vedotin|IV, 1.8mg/kg, every 3 weeks for 6 cycles.
1940581|NCT01578967|Drug|ABVD|"Doxorubicin - 25mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.
Bleomycin - 10u/m2 IV, Day 1 and 15, every 28 days, 2-6 cycles Vinblastine - 6mg/m2 IV over 3-5 minutes, Day 1 and 15, every 28 days, 2-6 cycles.
Dacarbazine - 375mg/m2 IV over 30 minutes, Day 1 and 15, every 28 days, 2-6 cycles."
1940583|NCT01578486|Drug|salsalate|open-label trial of salsalate 3g/day for 12 weeks.
1940584|NCT01577901|Other|Clearblue Advanced|Pregnancy test
1940587|NCT01576770|Device|lidocaine/tetracaine transdermal patch (NDC 43469-864-01)|70 mg lidocaine / 70 mg tetracaine
1940588|NCT01576770|Drug|Gebauer's Ethyl Chloride|Spray is to be applied topically to skin (dorsum of the hand for study purposes)until it turns white or for up to 10 seconds.
1940589|NCT01576406|Drug|crizotinib|crizotinib 250 mg twice a day
1940590|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
1940591|NCT01576406|Drug|crizotinib|crizotinib 250 mg twice a day
1940592|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
1940593|NCT01576406|Drug|crizotinib|crizotinib 250 mg once a day
1940595|NCT01575808|Device|GP1101|Endovascular Device Implantation
1940596|NCT01575717|Drug|Vitamin D3 4000 IU|Participants with serum 25-hydroxyvitamin D levels of less than or equal to 15ng/ml will take 4000 IU of vitamin D3 daily by mouth for 6 months
1940597|NCT01575717|Drug|Vitamin D3 2000 IU|Participants with serum 25-hydroxyvitamin D levels of greater than 15 ng/ml and less than or equal to 25ng/ml will take 2000 IU of vitamin D3 daily by mouth for 6 months
1940603|NCT01575275|Drug|aminolevulinic acid|Given PO
1940604|NCT01575275|Procedure|therapeutic conventional surgery|Undergo surgery
1940605|NCT01574807|Drug|3% mepivacaine/2% lidocaine with 1:100,000 epinephrine combo|1.8 mL of 3% mepivacaine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine compared to an injection of 1.8 mL of 2% lidocaine with 1:100,000 epinephrine followed by 1.8 mL of 2% lidocaine with 1:100,000 epinephrine.
1940606|NCT01574144|Device|AVIVO™ PiiX Patch Monitor System|External monitoring for 30 days post-discharge.
1940607|NCT01573598|Drug|Placebo|Matching placebo given orally, once per day
1940608|NCT01573598|Drug|Vilazodone|Vilazodone, 20 mg per day, oral administration
1940609|NCT01573598|Drug|Vilazodone|Vilazodone, 40 mg once per day, oral administration
1942147|NCT01238718|Drug|Placebo|normal saline
1940613|NCT01573052|Drug|Chlordiazepoxide|25mg qid x 3 days then tapered over 3 days
1940614|NCT01573052|Drug|Gabapentin|300mg qid x 3 days then tapered over 3 days
1940622|NCT01571479|Procedure|2- mini-instrument|"The patient was positioned in the supine position with the head and right side up.
Under general anesthesia, pneumoperitoneum (12 mmHg) was established after an 11-mm port was placed through 11-mm transumbilical incision by the open method.
A 10-mm 0-degree laparoscope was inserted through this umbilical port. A 5-mm trocar was then placed in the epigastric area, and the surgeon determined through 'laparoscopic surgical view' whether the 2-mm mini-instrument could be used as the right subcostal port . If the 2-mm mini-instrument could be used as the right subcostal port, a 2-mm trocar was inserted . If not, a 5-mm trocar was inserted for the right subcostal port. Therefore, this point is the unique difference between the two groups."
1940623|NCT01570868|Drug|Ponatinib|Starting dose: 30 mg by mouth once daily.
1940624|NCT01570621|Procedure|peroral endoscopic myotomy|A 3-cm incision is made into the mucosa after injection of saline and methylene blue. A submucosal tunnel is created from the mid-esophagus to the gastric cardia by a triangle-tip knife. The circular muscle fibers or full-thickness muscle are divided by the triangle-tip knife over a length of 6-20 cm on the esophagus, starting 3 cm below the initial mucosal incision, and extended 3-4cm onto the gastric cardia. The mucosal entry site is closed using standard endoscopic clips at last.
1940627|NCT01570192|Drug|IV meropenem|Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
1940628|NCT01570192|Drug|I.V. Meropenem|"Subjects assigned to this group will receive IV meropenem (2 g infused over 3 hrs q 8 hr).
Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage"
1940629|NCT01570192|Drug|Parenteral aminoglycoside; tobramycin for injection USP OR gentamicin sulfate injection solution concentrate 5mg.kg IV q24h; amikacin sulfate injection USP 20 mg/kg IV q24h|a parenteral aminoglycoside (tobramycin or gentamicin-5mg/kg IV Q24h or amikacin 20 mg/kg IV Q24h)
1940630|NCT01570192|Drug|Linezolid or Vancomycin (per institutional guidelines) will be available for MRSA coverage.|Linezolid or vancomycin (per institutional guidelines) will be available for MRSA coverage.
1940631|NCT01570192|Device|tobramycin nebulization|tobramycin nebulization 600mg/day
1940632|NCT01569191|Other|Non-Pharmaceutical Tear Supplement|artificial tear supplement (Hypromellose)
1940633|NCT01569191|Device|Eye Gel Mask Blue placed over the closed eyes|Bag fill with temperature retention gel
1940634|NCT01569191|Drug|ELESTAT® (epinastine HCl ophthalmic solution) 0.05%|1 drop on single occasion after exposure to grass pollen
1940635|NCT01569659|Drug|Lurasidone|80 mg/day for up to 30 weeks
1940636|NCT01569659|Drug|Lurasidone|Up to 240 mg/day for up to 30 weeks
1940637|NCT01569451|Drug|Rituximab|intravenous (IV) infusion of 1000 mg of rituximab on study days 1 (baseline visit) and 15
1940638|NCT01569451|Drug|Glatiramer Acetate|20 mg injected subcutaneously daily
1940639|NCT01569022|Device|CPAP|CPAP Treatment for 12 weeks
1940640|NCT01569022|Device|MAD|MAD Treatment for 12 weeks
1940643|NCT01567527|Drug|Intramuscular (IM) Depot Aripiprazole|Formulation: Intramuscular (IM) Depot Aripiprazole Formulation 400 mg or 300 mg, once a month injection
1940644|NCT01567527|Drug|Intramuscular (IM) Depot Placebo|Formulation: Intramuscular (IM) Depot Placebo 400 mg or 300 mg, once a month injection
1940645|NCT01567514|Procedure|Glass ionomer cement lining|Resin-modified glass ionomer lining
1940646|NCT01566773|Drug|PT001 MDI|Administered as two puffs BID for 14 days
1940647|NCT01566773|Drug|Tiotropium Bromide|Taken as 1 capsule containing 18 µg of tiotropium via the Handihaler DPI
1940648|NCT01566773|Drug|PT001 Placebo MDI|
1940649|NCT01566396|Device|A3F|A3F fractional RF treatments for facial wrinkles
1940650|NCT01564654|Device|iTotal KRS|Total Knee Replacement System
1940651|NCT01564979|Drug|preseptal injection of botulinum toxin type A|botulinum toxin type A (Botox)2.5 units, 5 points
1940652|NCT01564979|Drug|pretarsal injection of Botulinum toxin type A|Botulinum toxin type A 2,5 units, 5 points
1940657|NCT01564277|Drug|rasburicase|Given IV
1940658|NCT01564277|Drug|allopurinol|Given PO
1940659|NCT01563913|Drug|Docosahexaenoic Acid (DHA)|Docosahexaenoic Acid (DHA) 2 grams per day taken for 1.5 years
1940660|NCT01563913|Drug|Placebo|Sugar Pill, taken for 1.5 years
1940661|NCT01562444|Other|Blood Sampling|Annual blood draws
1940662|NCT01561989|Dietary Supplement|cholecalciferol|Given PO
1940663|NCT01561989|Other|questionnaire administration|Ancillary studies
1940664|NCT01561989|Biological|trivalent influenza vaccine|Given IM
1940671|NCT01560377|Device|PINPOINT Endoscopic Fluorescence Imaging System|The PINPOINT system will be used to provide real-time endoscopic visible and endoscopic NIR fluorescence imaging. PINPOINT enables surgeons to perform routine visible light endoscopic procedures as well as further visually assess vessels, blood flow and related tissue perfusion with near infra-red imaging during minimally invasive surgery
1940672|NCT01559142|Drug|Infliximab with azathioprine (IIFX + AZA)|Infliximab with azathioprine during whole one year study
1940673|NCT01559142|Drug|Infliximab (IFX alone)|Infliximab continuously; azathioprine stopped in 26 week
1940677|NCT01558830|Drug|ranolazine|ranolazine 500mg twice daily, may increase to 1000 mg twice daily for therapy optimization in treating chronic stable angina
1940678|NCT01558830|Drug|placebo|one pill twice daily, to increase to two pills twice daily to mirror standard ranolazine treatment strategy
1940679|NCT01558622|Drug|dexketoprofen trometamol|50mg intravenous infusion
1940680|NCT01558622|Drug|tramadol hydrochloride|100mg intravenous infusion
1940681|NCT01558622|Drug|pethidine hydrochloride|50mg intravenous infusion
1940682|NCT01558622|Drug|dexketoprofen trometamol + tramadol hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
1940683|NCT01558622|Drug|dexketoprofen trometamol + pethidine hydrochloride|intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
1940684|NCT01558622|Drug|vitamin c|500mg intravenous infusion
1940686|NCT01556100|Drug|18F-DTBZ AV-133|A total 40 PD subjects will be included in this study. PD subjects between 20 and 80 years of age may be eligible for this study. Candidates are screened with a medical history and physical examination, and blood test.
1940687|NCT01555099|Drug|AZD5423|oral inhaled
1940688|NCT01555099|Drug|Budesonide|oral inhaled
1940689|NCT01555099|Drug|Placebo|oral inhaled
1940690|NCT01555021|Genetic|Genotyping assays|"Patients will be asked for a saliva sample. If the patient is in the Assay-Guided Treatment group (as opposed to the Treatment as Usual group), their saliva will be genotyped. Their psychiatrists will be given the results of the tests and then they will decide which antidepressants to use. The genotyping test is a one-time occurrence that happens at the beginning of the study. Patients who are in the Treatment as Usual group will have their saliva samples stored.
Patients will receive questionnaires to measure their mood, side effects, and symptoms.
Patients will be asked for a blood sample. Those in the AGT group will have the sample processed to see the amount of antidepressant present in their blood. Those in the TAU group will have their blood samples stored for future use.
Patients will be asked to participate in 3 follow-up phone calls to measure their mood."
1940691|NCT01553916|Drug|Lithium Carbonate|
1940692|NCT01553916|Radiation|Prophylactic cranial irradiation|
1940827|NCT01525043|Drug|Naproxen|Naproxen 500mg BID for the first 2 weeks
1940698|NCT01550341|Drug|Buprenorphine/naloxone|2/0.5, 8/2 sublingual tabs; dosage based on medical assessment; medications taken once per day for 12 months duration.
1940699|NCT01550939|Device|Ophthalmic Biometer|One complete biometry examination
1940700|NCT01550471|Drug|Alvesco/Omnaris, QVAR/Beconase, Placebo/Placebo|Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
1940701|NCT01550471|Drug|Alvesco/Omnaris, Placebo/Placebo, QVAR/Beconase|Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID
1940702|NCT01550471|Drug|QVAR/Beconase, Alvesco/Omnaris, Placebo/Placebo|QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID
1940703|NCT01550471|Drug|QVAR/Beconase, Placebo/Placebo, Alvesco/Omnaris|QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID, Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD
1940704|NCT01550471|Drug|Placebo/Placebo, Alvesco/Omnaris, QVAR/Beconase|Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD, QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID
1940705|NCT01550471|Drug|Placebo/Placebo, QVAR/Beconase, Alvesco/Omnaris|Placebo Nasal Spray QD/Placebo Inhalation Aerosol BID, QVAR Inhalation Aerosol 40 mcg BID/Beconase AQ Nasal Spray 168 mcg BID, Alvesco Inhalation Aerosol 80 BID/Omnaris Nasal Spray 200 mcg QD
1940706|NCT01549171|Drug|Iloprost|supplement in culture medium during culture in the lab. The concentration is 1 uM.
1940707|NCT01549171|Other|normal saline|Supplement with vehicle only no Iloprost.
1940708|NCT01550146|Drug|Dexamethasone acetate|iv. dexamethasone 0.1 mg/kg
1940709|NCT01550146|Drug|Placebo|iv. Normal Saline 0.1 ml/kg
1940710|NCT01549938|Dietary Supplement|Cholecalciferol|20,000 IU cholecalciferol capsule, given once weekly for 16 weeks.
1940711|NCT01549938|Dietary Supplement|Placebo|Microcellulose capsule identical in appearance to treatment
1940714|NCT01549652|Drug|Ondansetron|"Prevention of Physical Dependence: After 1 month of oral morphine therapy, patients will go to the Stanford human opioid physiology lab for opioid withdrawal testing for Visit #1. Patients will be randomized in a double-blind fashion to treatment crossover assignments (placebo vs. 32 mg ondansetron) that will be conducted on 2 separate visits at least 1 week apart. Patients will continue to take oral morphine therapy until both study visits are complete.
Treatment of Opioid Withdrawal: Patients will be randomized into 2 groups: control arm (placebo) or prevention arm (8 mg ondansetron). Patients will go to the Stanford human opioid physiology lab for opioid withdrawal testing for Visit #1. After Visit #1, patients will undergo 1 month of oral morphine therapy. Patients will be instructed to take a treatment pill (placebo vs. ondansetron) with each dose of morphine. Then, patients will return to the Stanford human opioid physiology lab for Visit #2, which will be identical to Visit #1."
1940715|NCT01547520|Drug|Meperidine|intramuscular, 25 mg, 5 to 10 minutes before EGD
1940716|NCT01547520|Drug|normal saline|25 ml of normal saline, intramuscular, 5 to 10 minutes before EGD
1940717|NCT01549093|Drug|Gemcitabine,Carboplatin,Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 Continued Pumping into vein with saline,Each pump use 48hours and the dosage is 7.5mg/m2*2 ,on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle,Continued using 2-6cycles.
1940718|NCT01549093|Drug|Gemcitabine(G) Carboplatin(C) Endostar|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; Endostar:7.5 mg/m2 injecting into vein for 4 hours with saline on day 1 to day 14, discontinuancing for 7 days and 21 days is one cycle.Continued using 2-6cycles
1940719|NCT01549093|Drug|Gemcitabine(G) Carboplatin(C)|Gemcitabine(G):1000mg/m2 iv on d1,8 q3w; Carboplatin(C):AUC 5 iv on d1 q3w; 21 days is one cycle.Continued using 2-6cycles
1940722|NCT01548118|Biological|HPV 16/18 vaccine, 0,5ml|Subjects were planned to receive HPV vaccine 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
1940723|NCT01548118|Biological|Placebo control, 0.5ml|Subjects were planned to receive three doses of the placebo control 0.5ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
1940724|NCT01548118|Biological|HPV 16/18 vaccine, 1.0ml|Subjects were planned to receive HPV vaccine 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule
1940725|NCT01548118|Biological|Placebo control, 1.0ml|Subjects were planned to receive three doses of the placebo control 1.0ml administered intramuscularly according to a 0, 2, 6 month vaccination schedule.
1940726|NCT01548079|Drug|Ursodeoxycholic Acid (UDCA)|20mg/kg/day UDCA in three weeks
1940727|NCT01547585|Other|Standardized soy containing muffin|Standardized muffin containing two levels of soy
1940728|NCT01547299|Drug|Enzalutamide|
1940729|NCT01547299|Drug|Leuprolide|
1940730|NCT01547299|Drug|Dutasteride|
1940731|NCT01545583|Drug|LY3016859 IV|Administered IV
1940732|NCT01545583|Drug|Placebo IV|Administered IV
1940733|NCT01545583|Drug|LY3016859 SC|Administered SC
1940734|NCT01545583|Drug|Placebo SC|Administered SC
1940735|NCT01547091|Biological|Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs)|-The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.
1940736|NCT01547091|Drug|Rheumatoid Arthritis With Disease-Modifying Drugs (DMARDs)|-Patients will be treated by conventional drugs (DMARDS) for alleviating disease.
1940737|NCT01547091|Biological|UC-MSC+DMARDS|The UC-MSCs will be infused intravenously(single dose, 4x10^7 cells).The interval time is 3 months, and the study lasts for 12 months with 4 times infusion.Meanwhile,patients will be treated by conventionally drugs if the disease is still not alleviated.
1940738|NCT01547052|Behavioral|DBT for children|intervention consists of weekly individual 45 min. sessions, twice per week 60 min. group sessions, and every other week 90 min. sessions with parents
1940739|NCT01547052|Behavioral|Supportive-Educational therapy|weekly individual 45 min sessions, twice per week 60 min. group sessions and every other week parent sessions.
1940740|NCT01546857|Drug|Placebo|Placebo
1940741|NCT01546857|Drug|Gapabentin|400mg orally at 9pm day of surgery and the first evening post operatively.
1940742|NCT01546168|Device|esophageal deviation with IDE device|esophageal deviation during AF ablation
1940743|NCT01545466|Behavioral|Mindfulness Based Stress Reduction (MBSR)|MBSR involves 8 weekly 2 hour classes and one 4-6 hour retreat after the 6th class
1940744|NCT01544283|Drug|Synera® (lidocaine 70 mg and tetracaine 70 mg) topical patch|Synera consists of a thin, uniform layer of a local anesthetic formulation with an integrated, oxygen-activated heating component that is intended to enhance the delivery of the local anesthetics. The drug formulation is an emulsion in which the oil phase is a eutectic mixture of lidocaine 70 mg and tetracaine 70 mg. The surface area of the entire Synera patch is approximately 50 cm2, 10 cm2 of which is active. The 40 cm2 perimeter is a medical grade adhesive. The Synera patches used in this study are the commercially available form.
1940745|NCT01544283|Drug|Triamcinolone Acetonide|Triamcinolone Acetonide is a synthetic glucocorticoid corticosteroid with marked anti-inflammatory action, in a sterile aqueous suspension suitable for intralesional and intra-articular injection. Each mL of the sterile aqueous suspension provides 40 mg of triamcinolone acetonide, with sodium chloride for isotonicity, 0.9% (w/v) benzyl alcohol as a preservative, 0.75% carboxymethylcellulose sodium, and a 0.04% polysorbate 80; sodium hydroxide or hydrochloric acid may have been added to adjust pH between 5.0 and 7.5. At the time of manufacture, the air in the container is replaced by nitrogen.
1940746|NCT01542671|Behavioral|Intervention|"Lifestyle Counselor meetings at baseline, 6 months, and 12 months
Structured eating plan
Tailored nutritional and exercise tips. Weekly: months 1-12, biweekly: months 13-18, and monthly: months 19-24.
Monthly Motivational phone calls with Lifestyle Counselor for the first year
4 informational DVDs over the two year period
Feedback on submitted food and exercise journals"
1940747|NCT01542671|Behavioral|Control|"Lifestyle Counselor meetings at baseline, 6 months, and 12 months
Structured eating plan
5 informational NIDDK mailings over the two year period"
1940748|NCT01542398|Behavioral|Family-Focused, Community-Based, Resilience-Targetting Psychosocial Intervention|A 12-module manualised intervention focusing on reducing psychological distress, improving family and community functioning and boosting daily functioning of adolescents through the use of Mobile Cinema Screenings and task-based, participatory, group-sessions
1940749|NCT01541839|Device|Septal Stapler|This device is a stapler designed to place resorbable implants into the nasal septum. Each device contains 8 staples.
1940750|NCT01541891|Drug|PRO-148 Ophthalmic Solution|PRO-148 Ophthalmic Solution applied four times per day (c/6 hours) during 60 days.
1940751|NCT01541891|Drug|Active Comparator: SYSTANE ® Ophthalmic Solution|Sterile solution containing polyethylene glycol 400, propylene glycol, hydroxypropyl-guar, boric acid, calcium chloride, magnesium chloride, potassium chloride, sodium chloride, zinc chloride and polyquad (polidronium chloride) 0,001%. four times per day (c/6 hours) during 60 days.
1940752|NCT01541761|Behavioral|Family groups|The group sessions are designed to facilitate on-going interaction among consistent groups of 6 - 8 parents and other care givers with infants the same age and will be coordinated with scheduled well child care visits. They will be conducted in English and Spanish. The groups will focus on nutrition and, parenting.
1940753|NCT01540513|Drug|NM404|"injection of 5.0mCi I-124 NM404 Arms: I124-NM404 brain metastases or GBM imaging
Other Names:
PET imaging with I-124 NM404"
1940754|NCT01540513|Drug|NM404|injection of an experimental imaging agent, 5mCi I-124NM404
1940755|NCT01540019|Drug|Paullinia cupana|50mg of Paullinia cupana as capsule, twice daily
1940757|NCT01538745|Drug|Ketamine|0.3 mg/kg ketamine IVP over 5 minutes. Total of two possible doses.
1940758|NCT01538745|Drug|Morphine|0.1 mg/kg Morphine IVP over 5 minutes. Total of two possible doses.
1940759|NCT01538693|Drug|escitalopram oxalate|10 mg 4.5 hours prior to testing
1940760|NCT01538693|Drug|Cyproheptadine|8mg 4.5 hours prior to testing
1940761|NCT01538693|Drug|sugar pill|4.5 hour prior to testing
1940762|NCT01538693|Other|Graded intensity exercise|modified bruce protocol for peak oxygen consumption testing
1940828|NCT01525043|Drug|Synera patch twice daily|1 synera patch to cover the treatment area applied for 4 hours, twice daily for the first 2 weeks
1940763|NCT01538680|Drug|Regorafenib (BAY73-4506)|"Subjects will receive 160 mg regorafenib po every day (qd) for 3 weeks of every 4 week cycle (i.e., 3 weeks on, 1 week off). Subjects will continue on treatment until at least one of the following occurs (main criteria):
Progressive Disease (PD). The subject may continue treatment at the investigator's discretion.
Death Unacceptable toxicity Subject withdraws consent Treating physician determines discontinuation of treatment is in the subject's best interest Substantial non-compliance with the protocol"
1940767|NCT01538043|Other|local mud-pack therapy and balneotherapy|local mud-pack therapy and thermal-mineral bath at Chianciano Terme Spa Center (Siena, Italy) for a total of 12 applications carried out over a period of two weeks
1940768|NCT01537289|Device|Pigtail catheter insertion (Cook)|insertion of pigtail catheter to decompress pneumothorax
1940769|NCT01537289|Device|chest tube (28-French)|inserting chest tube to decompress pneumothorax
1940770|NCT01536678|Drug|Levothyroxine|Single dose of 600mcg of test formulation of levothyroxine administered in dosing period 1 or 2.
1940771|NCT01536678|Drug|Levothyroxine|Single dose of 600mcg of reference formulation of levothyroxine administered in dosing period 1 or 2.
1940772|NCT01536795|Drug|WR279 396 with Tegaderm Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days with polyurethane dressing
1940773|NCT01536795|Drug|WR 279, 396 with Gauze and Tape Dressing|Ointment containing paromomycin sulphate (15%) and gentamicin sulphate (0.5%) - in a base (AQIC)applied for 20 days
1940774|NCT01535742|Device|Ambu Aura-i size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
1940775|NCT01535742|Device|air-Q ILA size 1.5|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
1940776|NCT01535742|Device|Ambu Aura-i size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
1940777|NCT01535742|Device|air-Q ILA size 2|Device will be placed and fiberoptic tracheal intubation will be performed and timed. Laryngeal grade of view will also be assessed
1940778|NCT01535352|Behavioral|Mom-Net|"The Mom-Net intervention is an internet-facilitated cognitive-behavioral intervention for depression, adapted from the CWDC, and tailored to mothers of young children. Mom-Net has several core components: 1. A guided course for self-regulated learning of CBT skills. 2. A system of professional support in which coaches provide weekly 15-20 min phone check-ins (coach calls) in order to encourage and facilitate progress through the intervention and respond rapidly to participant queries and emergencies. In this regard, coaches benefited from: a) a 'behind the scenes administration page on the website that enabled them to track participants' progress through the intervention and use this information to tailor coaching sessions; and b) an automated system for alerting coaches/supervisors when participants were in crisis. 3. A coach-moderated bulletin board that approximated the social support provided by group administration."
1940779|NCT01535352|Behavioral|Coach-facilitated Treatment as Usual|Participants in the facilitated usual care (FUC) condition will receive assistance in accessing mental health interventions through community providers that serve low-income individuals. In order to control for the supportive attention provided to mothers in the MN condition by the weekly coach calls, mothers in the FUC condition will receive weekly check-in calls from research staff during the intervention period. Participants in both conditions will receive Booster calls during the follow-up period.
1940780|NCT01535443|Drug|PRO-155 Ophthalmic Solution 0.09 %|PRO-155 Ophthalmic Solution 0.09 % applied twice to day during 10 days..
1940781|NCT01535287|Drug|Dexmedetomidine|"Active study agent: Dexmedetomidine at 1 microgram/kilogram Intramuscular (IM) Placebo study agent: Same volume as the study drug of placebo (normal saline).
All blinding, labeling, preparation, storage of agents done by the pharmacist. The drug will be administered into the deltoid muscle by using a TB syringe attached to a 3/4 inch length and 25 Gauge width needle by anesthesia provider after the induction of general anesthesia by the anesthesia provider."
1940782|NCT01535092|Drug|Silibinin|20mg/Kg daily by intravenous infusion, for 14-21 days pre-OLT and for 7 days post-OLT
1940783|NCT01535092|Drug|Placebo|Saline, daily infused for 14-21 days pre-OLT and for 7 days post-OLT
1940784|NCT01534416|Drug|Bupivacaine|Subjects are injected paracervically with 10 ml of 0.5% bupivacaine with 1:200000 units epinephrine prior to surgical incision.
1940785|NCT01534416|Drug|Normal Saline|Subjects are injected paracervically with 10 ml of normal saline prior to surgical incision.
1940786|NCT01533714|Biological|Olokizumab|"Solution for injection with a concentration of Olokizumab of 100 mg/mL Subjects will receive CDP6038 at a dose of 120 mg every two weeks.
This study will continue until approval of the marketing application for the indication of RA in the subject's country or region or until further notice from UCB."
1940787|NCT01532375|Dietary Supplement|Kochujang|Kochujang (32g/day) for 12weeks.
1940788|NCT01532375|Dietary Supplement|placebo|placebo(32g/day) for 12weeks
1940789|NCT01532674|Device|Antimicrobial photodynamic therapy (Periowave) and scaling and root planing|"ROOT PLANNING PROCEDURE:
The procedure is the same as in the control group
APPLICATION PROCEDURES OF THE PHOTOSENSITIZING AGENT :
The photosensitive agent : Formulation Periowave Treatment Kit-2ml
Application of the photosensitive using a blunt needle at the bottom of the periodontal pocket with circular movements covering the entire perimeter of the tooth.
Application of diode laser with a peak of 8.5 cm. long with a curvature of 60 degrees and flexible. Making a move in and out from the apical region to the more coronal region of the periodontal pocket. Each tooth has a working time of 60 seconds.
All the periodontal pockets will be treated subgingivally
Elimination of the photosensitive by irrigation"
1940790|NCT01532674|Procedure|scaling and root planing|"ROOT PLANNING PROCEDURE:
An unique operator ( independent from the explorer) will do the root planing for both the test and control group.
Every procedure will be done under local anaesthesia: Ultracain with Epinephrine 40/0,01 mg/ml. NORMON. It will be done a first session of root planning in the first and forth quadrant and in a 48 hours the root planning of the second and the third quadrant will be done. Every session wil be done with this material: Ultrasonic: Satelec suprasson p5 with ultrasonic tip H3, manual scalers: HU-FRIEDY 1/2, 7/8, 11/12, 13/14, 13/14 columbia.
* The session will finish as soon as the operator have removed all the supragingival and subgingival calculus and plaque."
1940791|NCT01532518|Drug|Nepadutant|Nepadutant oral solution
1940792|NCT01532388|Behavioral|eScreen|Web based self-monitoring of problematic alcohol and drug use.
1940793|NCT01532115|Drug|BIA 9-1067|50 mg and 800 mg of BIA 9-1067 (single-dose)
1940794|NCT01532115|Drug|Placebo|single-dose
1940795|NCT01532115|Drug|moxifloxacin|400 mg moxifloxacin (single-dose)
1940799|NCT01531582|Drug|minocycline|The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
1940800|NCT01531504|Device|ViKY UP|laparoscopic-assisted hysterectomy procedure
1940801|NCT01531842|Procedure|Conj flora Antibiotic resistance|Patients will either receive a drop of topical antibiotic before and after the intravitral injection or no topical antibiotics (only typical prep with betadine).
1940802|NCT01530178|Drug|Sitagliptin|In each intervention arm the participant receives a different dose of sitagliptin.
1940803|NCT01529229|Drug|Dexchlorpheniramine + Betamethasone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
1940804|NCT01529229|Drug|Desloratadine + Prednisolone|Children (2 to 5 years): 2.5 ml 3 times a day Children (6 to 12 years): 5.0 ml 3 times a day
1940807|NCT01528839|Drug|L-Thyroxine|L-Thyroxine as addon to ongoing stable antidepressant and /or mood stabilizing therapy: week 1: 100 mcg; week 2: 200 mcg: week 3 to week 6: 300 mcg
1940808|NCT01528839|Drug|Placebo|
1940809|NCT01528124|Drug|LY3025876|Given as a SC injection
1940810|NCT01528124|Drug|Placebo|Given as a SC injection
1940814|NCT01526577|Drug|LC23-1306|LC23-1306 10, 30, 100, 200, 400, 600 mg Placebo 10, 30, 100, 200, 400, 600 mg
1940815|NCT01526577|Drug|placebo|LC23-1306 placebo
1940816|NCT01526577|Drug|Ticagrelor|Ticagrelor 90mg
1940817|NCT01527110|Drug|Intravenous (IV) zanamivir|Zanamivir aqueous solution 10mg/mL, 600mg of IV zanamivir infusion twice daily for 5 days
1940818|NCT01526161|Drug|inhaled fluticasone propionate|100 micrograms
1940819|NCT01526161|Drug|salmeterol|50 m
1940820|NCT01526161|Drug|Montelukast|Double blind double dummy
1940821|NCT01525888|Procedure|stop angiotensin converting enzyme inhibitor or angiotensin receptor blocker (ACE-I/ARB)|stoping for 6 days treatment with angiotensin converting enzyme inhibitor or angiotensin receptor blocker
1940822|NCT01525875|Drug|Magnesium Oxide|"Part 1: 1000 mg elemental magnesium (given as one 800 mg capsule of magnesium oxide two times daily).
Part 2: 1500 mg elemental magnesium (given as two 500 mg capsules of magnesium oxide in the morning and three 500 mg capsules of magnesium oxide in the evening)."
1940823|NCT01525875|Drug|Placebo|1000 mg (one 500 mg capsule two times daily) of placebo.
1940826|NCT01525329|Drug|5-Fluorouracil|All patients will receive one cream, 5-Fluorouracil, and will be instructed to apply the cream according to the randomization schema to AKs on either the right or left side of the face/scalp once a day for 6 days prior to PDT. A baseline measurement of the tumor's ability to produce PpIX will be done by applying methyl-aminolevulinic acid (Metvixia® topical cream) to the selected AKs and using the Aurora© dosimeter. Prior to Metvixia, and again 3 hours after application, surface measurements of the PpIX fluorescence will be taken. Then, the two largest precancer lesions (one on the left side, one on the right side) will be biopsied under local anesthesia, followed by red light PDT (lasting ~8 minutes). The biopsy sites will be shielded from the light with a circular spot bandage.
1940829|NCT01525043|Drug|Synera patch for 12hrs/day|1 synera patch to cover the treatment area applied for 12 hours, daily for the first 2 weeks
1940830|NCT01525043|Drug|Naproxen|500mg bid
1940831|NCT01525043|Drug|Synera|Topical appication of single patch to elbow for 12hrs/day
1940832|NCT01525043|Drug|Synera|Single patch applied to elbow for 4hrs/twice daily
1940836|NCT01522755|Device|Pacing system implant with the CapsureFix MRI pacing lead model 5086|Pacing system implant with the CapsureFix MRI pacing lead model 5086
1940837|NCT01523782|Drug|GRASPA|Each patient will receive GRASPA at day 3 of the induction 1 phase. If no toxicity related to investigational product is observed and if the patient's state of health allows it, a second injection, at the identical dose, will be administered at Day 6 of Induction 2 phase
1940838|NCT01523574|Drug|Vitamin E|Vitamin E 400mg PO orally
1940839|NCT01523574|Drug|Placebo|Placebo, given orally
1940840|NCT01523249|Device|Lumbar 3D ultrasound scanning and palpation (Ultrasonix )|Paramedian ultrasound scanning of L2-3 and L3-4 lumbar interspaces to visualize ligamentum flavum. Palpation of the same intervertebral spaces to identify spine midline and needle insertion point.
1940841|NCT01522443|Drug|cabozantinib|Tablets taken orally once daily.
1940842|NCT01522443|Drug|mitoxantrone|Given by IV once every 3 weeks.
1940843|NCT01522443|Drug|prednisone|Taken twice a day orally by mouth. Commercially-obtained prednisone tablets will be over-encapsulated in order to blind identity.
1940844|NCT01521806|Dietary Supplement|Dietary Fiber|Dietary fiber will be added to snack foods
1940845|NCT01520688|Drug|Fluticasone, Budesonide, Beclomethasone|Fluticasone 100 mcg bid Budesonide 180 mcg bid Beclomethasone 80 mcg bid
1940846|NCT01520688|Drug|Fluticasone, Beclomethasone, Budesonide|Fluticasone 100mcg BID Beclomethasone 80 mcg BID Budesonide 180 mcg BID
1940847|NCT01520688|Drug|Budesonide, Fluticasone, Beclomethasone|Budesonide180 mcg BID Fluticasone 100 mcg Beclomethasone 80 mcg BID
1940848|NCT01520688|Drug|Budesonide, Beclomethasone, Fluticasone|Budesonide 180 mcg BID Beclomethasone 80mcg BID Fluticasone 100mcg BID
1940849|NCT01520688|Drug|Beclomethasone, Fluticasone, Budesonide|Beclomethasone 80 mcg BID Fluticasone 100mcg BID Budesonide 180 mcg BID
1940850|NCT01520688|Drug|Beclomethasone, Budesonide, Fluticasone|Beclomethasone 80mcg BID Budesonide 180 mcg BID Fluticasone 100mcg BID
1940851|NCT01519635|Drug|Aliskiren|Drug therapy will be started with an initial 2 weeks on Aliskiren 150 mg followed by a titration to 300 mg Aliskiren if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
1940852|NCT01519635|Drug|Hydrochlorothiazide|Drug therapy will be started with an initial 2 weeks HCTZ 12.5 mg followed by a titration to 25 mg HCTZ if the treatment is well tolerated. A first baseline measurements will be performed before initiating therapy and a second after 8 weeks of treatment (24h after last drug intake) to assess the chronic effect.
1940855|NCT01519947|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|50-250 mcg sc according to local label
1940856|NCT01519414|Other|Laboratory Biomarker Analysis|Optional correlative studies
1940857|NCT01519414|Other|Placebo|Given PO
1940858|NCT01519414|Drug|Tivantinib|Given PO
1940859|NCT01518790|Drug|polyethylene glycol 3350|PEG 3350 (238 grams) mixed with 1.9 L (64 oz) of Gatorade, given in 8 oz increments every 15-30 minutes until complete starting at 18:00 on day prior to colonoscopy (max time to completion 6 hours).
1940860|NCT01516957|Drug|AMG 827|140 mg AMG 827 SC (subcutaneous)
1940861|NCT01516957|Drug|Placebo|Placebo SC (subcutaneous)
1940862|NCT01516957|Drug|AMG 827|280 mg AMG 827 SC (subcutaneous)
1940863|NCT01516957|Drug|AMG 827|210 mg AMG 827 SC (subcutaneous)
1940864|NCT01517776|Drug|Cilengitide|Cilengitide 1800 mg/m² i.v. twice weekly with a mandatory platelet-count dependent dose adaptation rule
1940865|NCT01517776|Drug|Temozolomide|Temozolomide 75 mg/m²/d p.o. for 6 weeks, followed by 1 week rest with a mandatory platelet-count dependent dose adaptation rule
1940866|NCT01517711|Drug|Tramadol|Tramadol hydrochloride Extended Release(ER) will be supplied as tablets of Ultram® ER 100mg. Tramadol ER (100-300mg) or matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
1940867|NCT01517711|Drug|Placebo|Matching placebo will be self-administered by oral route every morning (with or without food) for 6 weeks. Patients will be instructed to take it the same way (either with food or without food) each time they take their dose. Each patient will be provided with 1 week supply of Tramadol ER or matching placebo on visits 2 (week 0) and 3 (week 1) and 2 weeks supply on visits 4 (week 2) and 5 (week 4).
1940871|NCT01516424|Drug|Blonanserin|tablet,4mg,b.i.d
1940872|NCT01516424|Drug|Risperidone|tablet,2mg,b.i.d,
1941244|NCT01435135|Biological|ALVAC-HIV|1 mL per injection containing 10^6 CCID50/dose administered
1940877|NCT01515176|Drug|Dinaciclib|Given IV
1940878|NCT01515176|Other|Laboratory Biomarker Analysis|Correlative studies
1940879|NCT01515176|Biological|Ofatumumab|Given IV
1940880|NCT01515176|Other|Pharmacological Study|Correlative studies
1940881|NCT01514396|Device|Surgiseal|surgical glue
1940882|NCT01514383|Device|Cyanoacrylate (Octylseal )|surgical adhesive
1940883|NCT01513538|Device|TherapyGuide|Use of TherapyGuide function to help programming the device
1940884|NCT01513395|Behavioral|Interval bladder emptying|"Participants randomized to the Interval arm (cervical assessment 15 minutes or more after voiding) will be notified of their allocation and asked to immediately use the rest room and attempt to void completely. A synchronized clock will be located in this restroom, and each participant will be asked to note the time that she completes voiding. This will be confirmed by the research staff by noting the time the participant enters and exits the restroom. The participant will return to the waiting room or ultrasound room. Any indicated trans-abdominal ultrasound imaging will be performed, and preparations will be made for the vaginal ultrasound. The participant will be asked not to void prior to the vaginal ultrasound. Cervical assessment will take place at a minimum of 15 minutes from voiding time."
1940885|NCT01512667|Drug|MK-0822|1 single, oral dose (50 milligram [mg] tablet) of MK-0822 will be administered on Day 1.
1940887|NCT01511991|Drug|Sevoflurane dosage titration|comparisons of the effect of the 10 min-inhalation of each concentration of sevoflurane, 1.0 inspired vol%, 2.0 inspired vol% and 3.0 inspired vol% (T1, T2 and T3)
1940888|NCT01509872|Behavioral|Trauma Focused Cognitive Behavioral Therapy|9 sessions of manualised, culturally modified, group-based trauma-focused cognitive behavioral therapy
1940889|NCT01509872|Behavioral|Child Friendly Space|9 sessions of a manualised, culturally appropriate, non trauma-focused psychosocial intervention
1940890|NCT01509677|Drug|Roflumilast|500 μg tablet, once daily, oral administration in the morning after breakfast
1940891|NCT01509677|Drug|Placebo|tablet, once daily, oral administration in the morning after breakfast
1940892|NCT01509326|Other|chiropractic treatment|12 sessions over 4 weeks
1940893|NCT01509326|Device|Dr. Zaxx pillow|Daily use of an acupressure pillow
1940894|NCT01508091|Behavioral|energy restricted mediterranean-type diet|Prescription of diet 25 % lower than actual total energy expenditure in overweight or moderately obese premenopausal women
1940895|NCT01508091|Behavioral|25 % calorie restriction|25 % calorie restriction respect total energy expenditure
1940896|NCT01506843|Biological|Mite, Mite and Bacterial or Placebo|All treatments were given by sublingual route according to schedule of EAACI, with some modification. Patients received up-dosing sublingual drops once a day, reaching in approximately 3 months a monthly maintenance dose of 36 μg of Der p 1 given three times a week in alternate days for mite, mite and bacterial allergen extract, and no Der p 1 and no bacterial components in the placebo group. Doses were delivered by using vials equipped with a metered-dose dropper, and subjects were instructed to hold the solution under the tongue for 2 min and not to eat or drink for 60 min after the dose. Subjects self-administered the treatment at home. Adjustments in the schedule were made on an individual basis according to standard guidelines for specific immunotherapy
1940897|NCT01506895|Drug|darapladib|Experimental compound 160 mg dose
1940898|NCT01506895|Drug|placebo|Placebo to match
1940904|NCT01505361|Biological|Lactobacillus salivarius PS2|9 log10 (colony-forming units), freeze-dried powder, daily for 30 week of pregnancy until birth
1940905|NCT01505361|Biological|Excipient (milk powder)|100 mg/once a day from 30 week of pregnancy until birth
1940906|NCT01505335|Device|US depth measurements|Measurement of the distance between the apex of the drilled implant site and the IAC
1940907|NCT01505010|Procedure|Renal denervation|Renal denervation in the intervention group
1940908|NCT01503593|Device|Calcium Phosphate, Calcium Sulphate|1cc of Calcium Phosphate and 1cc of Calcium Sulphate
1940913|NCT01501955|Device|Metaphyseal Hip Prosthesis|Metaphyseal Hip Prosthesis (MHP) hip replacement
1940914|NCT01501955|Device|Stanmore|Stanmore hip prosthesis
1941360|NCT01409096|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
1940915|NCT01501695|Drug|5LGr|Dosage form:Granule Strength:5 gram/sack Dosage:1 sack for patients less than 12 yrs 1.5 sacks for patients 13-18 yrs. Frequency: three times per day. Duration: 8 weeks.
1940916|NCT01501695|Drug|tiapride|"dosage form: tablet Strength:100 mg Dosage: For patients 5-12 yrs: 50mg bid for first 2 weeks, then 100 mg, bid for next 6 weeks; for patients 13-18 yrs:100mg bid for first 2 weeks, then 200 mg bid for next 6 weeks.
Total duration:8 weeks."
1940917|NCT01501695|Drug|placebo|mimetic granule: same with 5LGr mimetic tablet: same with tiapride
1940918|NCT01501617|Biological|Hair Stimulating Complex (HSC)|Study preparation (experimental) of 0.8 mL will be injected intradermally at Baseline and Week 6.
1940919|NCT01501617|Device|Dulbecco's Modified Eagle Medium, DMEM|Study preparation (placebo comparator) of 0.8 mL will be injected intradermally at Baseline and Week 6.
1940920|NCT01500369|Other|sphygmomanometer cuff inflations|": Patients in the treatment group will receive three sequential sphygmomanometer cuff inflations on their right upper arm after induction of anesthesia in the operating room. The cuff will be inflated by the OR nurse up to 200 mmHg for five minutes each occasion, with five minutes deflation in between inflations. Following this pre-conditioning phase, routine anesthesia procedures will be implemented. The entire pre-conditioning phase will last 30 minutes."
1940921|NCT01500369|Other|standard of care|Placebo Comparator
1940922|NCT01500096|Drug|American ginseng|American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the intervention arms for this study. Participants will be randomized to American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
1940923|NCT01500096|Dietary Supplement|Placebo for American ginseng|"Placebo for American ginseng 1000 mg/day and 3000 mg/day will be evaluated in the control arms for this study. Participants will be randomized to placebo for American ginseng 1000 or 3000 mg/day capsules taken daily for four weeks.
Arms: Placebo for American ginseng 1000 mg/day, Placebo for American ginseng 3000 mg/day"
1940924|NCT01499459|Genetic|autologous mesenchymal stem cell transplantation|Every patient is given 1x106 MSCs per kg infused via peripheral vein.
1940925|NCT01499160|Drug|letrozole|Drug is are to be taken orally. 2.5 mg once daily
1940926|NCT01499160|Drug|lapatinib|Drug is to be taken orally. 1,500 mg once daily in the first part of the study and then 1,250 mg once daily in the second part of the study (after initial progression)
1940927|NCT01499160|Drug|everolimus|Drug is to be taken orally. 5 mg once daily.
1940928|NCT01498172|Biological|MAGE-A3 ASCI|5 doses every 3 weeks
1940929|NCT01498172|Biological|BCG|1 intravesical dose /week for 6 weeks
1940930|NCT01497613|Behavioral|PRISM C: Computer Condition|A specialized computer system designed to support social connectivity and access to resources; knowledge and prospective memory
1940931|NCT01497613|Behavioral|PRISM B: Notebook Condition|Telephone check-in calls and a notebook that contains information about community resources, games; topics of interests to seniors; a calendar and contact list.
1940932|NCT01496157|Drug|18F-DCFBC|A bolus of 10 mCi (370 MBq) [9-11 mCi (333-407 MBq)] of 18F-DCFBC will be injected into the IV line by slow IV push.
1940934|NCT01495221|Drug|Alfilbercept|All patients will receive 2.0 mg intravitreal aflibercept injection.
1940935|NCT01495052|Dietary Supplement|organic naked oat with whole germ (ONOG)|The experimental product was ONOG (Inner Mongolia Sanzhuliang Natural Oats Industry Corporation), which was produced in the northwest part of China, applying with the organic standards. Participants in the 50g and 100g-ONOG plus diet groups were asked to replace their customarily used staple food with oat porridge containing 50g or 100g ONOG.
1940936|NCT01495013|Drug|1mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
1940937|NCT01495013|Drug|2mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
1940938|NCT01495013|Drug|3mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
1940939|NCT01495013|Drug|4mg Glimepiride/10mg Atorvastatin FDC|1 tablet by mouth once a day
1940940|NCT01495013|Drug|1mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
1940941|NCT01495013|Drug|2mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
1940942|NCT01495013|Drug|3mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
1940943|NCT01495013|Drug|4mg Glimepiride/20mg Atorvastatin FDC|1 tablet by mouth once a day
1940944|NCT01495013|Drug|1mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
1940945|NCT01495013|Drug|2mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
1940946|NCT01495013|Drug|3mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
1940947|NCT01495013|Drug|4mg Glimepiride|1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
1940948|NCT01495013|Drug|10mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
1940949|NCT01495013|Drug|20mg Atorvastatin|1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
1940950|NCT01494883|Behavioral|Mindfulness Based Stress Reduction|A weekly training of eight sessions lasting two and a half hours.
1940951|NCT01493960|Drug|Kappaproct|30 mg rectal dose at week 0 and 4
1940952|NCT01493960|Drug|Placebo|Rectal dose at week 0 and 4
1940953|NCT01492686|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
1940954|NCT01492686|Drug|Placebo|Two ampoules of placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). The following treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
1940955|NCT01492686|Drug|MCI-186 in open label phase|All patients after the double blind phase may receive MCI-186 in 7th until 12th treatment - observation cycles at the patients' will.
1940956|NCT01493284|Device|Transcatheter Aortic Valve Implantation|Placement of the SJM Portico aortic valve with a transfemoral delivery system
1941010|NCT01482039|Procedure|Sequential ultrasound|Abdominal ultrasound first; obtain 3 adequate measurements. If 3 adequate views not obtained or if measurement less than 3 cm, perform transvaginal ultrasound for measurement.
1940957|NCT01493232|Other|buccalized occlusion|Making a set of complete denture with new Buccalized Occlusion that is different from current occlusion in my country. In this type just buccal casps of mandibular teeth will be connect to the central fossa of maxillary teeth and lingual casps have not contact.
1940958|NCT01493050|Drug|Sevelamer Carbonate|1600 mg (two 800 mg in the form of tablets or powder to be diluted in water) TID with meals for 26 weeks
1940959|NCT01493050|Drug|calcium carbonate|1200 mg of calcium carbonate TID with meals for 26 weeks
1940962|NCT01492699|Drug|PRX-03140|50 mg PRX-03140 capsules once daily for 2 weeks. After 2 weeks, the dose will increase to 100mg PRX-03140 once daily for 10 weeks.
1940963|NCT01491841|Drug|Bendamustine + Rituximab + Pixantrone|Maximum tolerated dose and optimal dose schedule of pixantrone in combination with static dose bendamustine (120mg/m2 on Day 1 of each 21 day) and rituximab (375mg/m2 on Day 1 of each 21 day cycle).
1940966|NCT01492140|Procedure|Subdermal Injection|Injection of dermal filler
1940967|NCT01492140|Device|Artiste Assisted Injection System|The Artiste™ Assisted Injection System is an air-powered device used to assist clinicians in injecting fluids into the body. The Artiste System was designed specifically to assist in the delivery of dermal fillers for the aesthetic correction of facial wrinkles, folds, and scars.
1940968|NCT01491958|Drug|atorvastatin|"donors-will receive atorvastatin 40 mg/day orally at least 14 days before anticipated first day of stem cell leukapheresis (LP) until successful completion of leukapheresis according to institutional guidelines.
Patients-will receive atorvastatin 40 mg starting at least 7 days before initiation of transplant conditioning regimen, to permit a 1 week observation period to rule out any atorvastatin-induced side effects before initiation of transplant conditioning. Patients will continue on atorvastatin with standard GVHD prophylaxis with tacrolimus and methotrexate until end of GVHD prophylaxis according to institutional standard guidelines, or until development of endpoint, which ever should occur first."
1940969|NCT01491958|Drug|Tacrolimus|beginning on Day -2 through approximately Day +180 (that is, approximately 6 months after Day 0)
1940970|NCT01491958|Drug|methotrexate|Day +1, +3, and +6 and +11
1940971|NCT01491178|Drug|Prazaxa|Dabigatran etexilate
1940972|NCT01491256|Drug|Pre-procedural High dose atorvastatin loading|Atorvastatin 80 mg loading within 24 hours plus 40mg busting within 2 hours before percutaneous coronary intervention
1940973|NCT01491256|Drug|No pre-procedural high-dose atorvastatin loading|atorvastatin 10mg administration within 24 hours before percutaneous coronary intervention
1940974|NCT01491217|Drug|Paclitaxel|HM30181AK 15 mg tablet + Paclitaxel 10mg, 30mg capsules
1940975|NCT01491204|Drug|Paclitaxel+HM30181|oral, 3times for 4weeks
1940976|NCT01490814|Procedure|Electrical isolation of the pulmonary veins|Device: ArcticFront® Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or ArcticFront® Advance Cardiac CryoAblation Catheter System with the FlexCath Steerable Sheath or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
1940977|NCT01490814|Procedure|Electrical isolation of pulmonary veins|Device:NaviStar® ThermoCool® Irrigated Tip Ablation Catheter in combination with 3D mapping system CARTO or any future development generations of this product line, provided they are CE marked and the centre has the experience of at least 10 procedures before including a patient into the study.
1940978|NCT01490788|Drug|TNX-102 2.4 mg, Fasting conditions|TNX-102 2.4 mg - 1 gelcap once under fasting conditions.
1940979|NCT01490788|Drug|TNX-102 2.4 mg, Fed conditions|TNX-102 2.4 mg, 1 gelcap once given under fed conditions.
1940980|NCT01490788|Drug|Cyclobenzaprine 5 mg, Fasting conditions|Cyclobenzaprine 5 mg, 1 tablet once under fasting conditions
1940981|NCT01490359|Behavioral|Men Making a Difference HIV/STD Risk Reduction Intervention|Developed based on social cognitive theory and extensive formative research, Men Together Making a Difference HIV/STD risk-reduction intervention consists of 6 75-minute modules designed to increase beliefs that support condom use; skill and self-efficacy to use condoms; and HIV/STD risk-reduction knowledge. Two modules are implemented in each of 3 weekly sessions. It is highly structured and implemented in small groups of 9 to 15 men led by a male, isiXhosa-speaking facilitators using standardized intervention manuals. It includes interactive exercises, games, brainstorming, role-playing, take-home assignments, group discussions, and videos, produced specifically for the interventions, shot in authentic township settings, including a shebeen (i.e., an informal alcohol outlet).
1940982|NCT01490359|Behavioral|Health Promotion Control|The health-promotion intervention was designed to control for non-specific features including group interaction and special attention. It was structurally similar to the HIV/STD risk-reduction intervention in that it contained activities similar to the HIV/STD risk-reduction intervention but focused on behaviors linked to the risk of heart disease, hypertension, stroke, diabetes, and certain cancers-leading causes of morbidity and mortality among South Africans. It also consisted of 6 75-minute modules implemented 2 modules per week during 3 weekly sessions led by isiXhosa speaking male facilitators. It was designed to increase fruit and vegetable consumption and physical activity and decrease excessive alcohol consumption.
1941011|NCT01482039|Procedure|Transvaginal ultrasound|Obtain 3 transvaginal ultrasound cervical length measurements
1941012|NCT01482195|Genetic|Recombinant Adeno-Associated Virus|Ocular Subretinal Injection of a Recombinant Adeno-Associated Virus
1941013|NCT01482351|Device|Continuous Positive Airway Pressure [CPAP]|Study participants with sleep apnea will choose to use or not use a continuous positive airway pressure (CPAP) machine to treat their apnea after a consultation with their doctor. Dosage of CPAP will be individually determined using standardized methods in an overnight CPAP titration polysomnography.
1940983|NCT01489579|Behavioral|Brief, Structured, Telephone Counseling for Tobacco Cessation as Part of a Cardiovascular Risk Reduction Service|"The patients in the BST counseling group will receive tobacco cessation counseling by a trained CPCRS pharmacist as part of their routine CPCRS care. The counseling will not be scripted, but must contain three key components (recommendation to quit, discussion/recommendation of tobacco cessation medications, and discussion/recommendation of tobacco cessation methods/strategies (Appendix C). These are the same items measured by the National Committee for Quality Assurance (NCQA) for Healthcare Effectiveness and Data Information Set (HEDIS) reporting. A standard KPCO document will be mailed to the patients following the BST counseling containing information about available resources (Ready to quit patient handout)"
1940984|NCT01489579|Behavioral|Usual Care|Pharmacists randomized to Usual Care will continue to provide interventions/procedures they normally would according to usual care practices. These interventions include any of the following: no action, mailed information on the resources available to help aid tobacco cessation, telephone counseling, and/or assistance in getting tobacco cessation medications. Pharmacists who are randomized to Usual Care will be asked to continue their current approach for tobacco cessation recommendations
1940985|NCT01488136|Drug|Diazoxide|Diazoxide 7mg/kg, given 2 hours before the start of the clamp study
1940986|NCT01488136|Drug|Placebo|Lactose Ph capsules (Placebo)
1940987|NCT01488279|Drug|Dexamethasone|2.5 mg daily x 7 days
1940988|NCT01487122|Radiation|Continuous microwave|Continuous microwave through a great circular electrode, 15 cm from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
1940989|NCT01487122|Radiation|Pulsed microwaves|Pulsed microwaves through a great circular electrode, 15 cm away from the neck, 20 minutes, 80 watts, 15 sessions in 3 weeks
1940990|NCT01487122|Procedure|Sham microwaves|Unplugged microwave generator, great circular electrode, 15 cm away from the neck, 20 minutes, 15 sessions in 3 weeks
1940992|NCT01486849|Drug|CK-2017357|Total daily oral dose of 250 mg (125 mg BID) of CK-2017357 for 7 days followed by total daily oral dose of 375 mg (125 mg AM and 250 mg PM) for 7 days followed by total daily oral dose of 500 mg (250 mg BID) of CK-2017357 for 7 days
1940993|NCT01486849|Drug|Placebo|Matching placebo tablets BID for 21 days
1940994|NCT01486511|Procedure|Liver resection|Hepatectomy including both minor and major.
1940995|NCT01486511|Radiation|Computed Tomography|Computed Tomography +/- pulmonary angiography
1940996|NCT01486316|Device|Reveal XT® Insertable Cardiac Monitor|If not previously implanted, a non-experimental insertable cardiac monitor will be implanted to collect information on the patients' heart condition as inputs into the heart failure risk status algorithm (during guided follow-up only, Guided arm: 6-18 months, Control arm: 12-18 months).
1940997|NCT01486316|Other|Heart Failure Risk Status Diagnostic|"The experimental IDENTIFY-HF Risk Status developed for this study will be used to change standard device data to a heart failure risk status. The risk status and standard device trend data are provided to study doctors for remote management of their patients' heart failure using study specific protocols. The risk status inputs are: night heart rate, heart rate variability, atrial fibrillation burden, ventricular rate during atrial fibrillation, patient activity.
Based on pre-defined thresholds for each of the above inputs, as well as data trends, a heart failure score is derived. The heart failure score is then classified as: Low, Medium, High, or Very High."
1940999|NCT01485718|Dietary Supplement|Glucomannan|Participants in the glucomannan arm will receive glucomannan 2 capsules 30 minutes before the three largest meals of the day for 12 weeks
1941000|NCT01485718|Dietary Supplement|Placebo|Participants in the placebo arm will receive placebo 2 capsules 30 minutes before the three largest meals of the day.
1941001|NCT01485614|Drug|Sitagliptin|Sitagliptin 100 mg tablet administered orally once daily
1941002|NCT01485614|Drug|Metformin|Metformin 500 mg tablets administered orally starting at 500 mg/day and uptitrated by 500 mg every week to a final dose of 1000 mg twice daily
1941003|NCT01485614|Drug|Placebo to sitagliptin|Matching placebo to sitagliptin 100 mg tablet administered orally once daily
1941004|NCT01485614|Drug|Placebo to metformin|Matching placebo to metformin 500 mg tablets, 2 tablets administered orally twice daily
1941005|NCT01485614|Drug|Glycemic Rescue 1|Participants in the sitagliptin arm who require glycemic rescue will receive metformin in both Phase A and Phase B. Participants in the placebo arm who require glycemic rescue will receive metformin in Phase A. Participants on background insulin will NOT have their insulin doses up-titrated, but will be rescued with metformin.
1941006|NCT01485614|Drug|Glycemic Rescue 2|Participants in the placebo arm who have switched to metformin in Phase B and require glycemic rescue will receive sitagliptin. Participants on background insulin will NOT have their insulin doses up-titrated, but will be rescued with sitagliptin.
1941007|NCT01485614|Biological|Glycemic Rescue 3|Participants who require glycemic rescue after Glycemic Rescue 1 or 2, will receive open-label insulin. Participants on background insulin therapy will have the dose of their background insulin up-titrated.
1941008|NCT01485120|Device|Blood pressure monitoring with GE Healthcare DASH4000 and Carescape V100|BP readings with marketed cuff with DASH4000 or V100 Patient Monitor and BP readings with Investigational BP cuff and DASH4000 Patient Monitor and V100 Patient Monitor
1941009|NCT01482169|Drug|FFR Measurement with IV Adenoscan® then with Regadenoson|Testing will be completed during a Left Heart Catheterization (LHC). The first 48 eligible patients enrolled will receive an initial infusion of IV Adenoscan® through a peripheral vein at 140 mcg/kg/min. FFR measurements will be obtained utilizing a coronary pressure guide wire once peak hyperemia has been achieved. It takes about 84 seconds to reach peak hyperemia with Adenoscan®. Subsequently, these subjects will receive a dose of regadenoson at 0.4 mg through the same peripheral access site. FFR measurements will be obtained once peak hyperemia is achieved, which takes less than 30 seconds with regadenoson. Patients who react to either medication will be supported conservatively under close scrutiny.
1941014|NCT01480843|Drug|Glargine|Use of glargine with/without other glucose lowering agent to simplify insulin regimen in older adults
1941015|NCT01481714|Drug|Sodium picosulphate, magnesium oxid and citric acid|"A sachet mixed with 250 mL of water at 18:00 pm
A sachet mixed with 250 mL of water at 21:00 pm
A minimum of 4 litres of fluid were recommended throughout the preparation"
1941016|NCT01481714|Drug|Sodium picosulphate/magnesium oxide and citric acid|"The day before the procedure:
- A sachet mixed with 250 mL of water at 18:00 pm, followed by 2 litres of clear liquids
The day of the procedure:
A sachet administered at 5:45 am, followed by 1,5 litres of fluid intake up to 7 am for colonoscopies scheduled from 9 to 11 am.
A sachet administered at 6:45 am, followed by 1,5 litres of fluid intake up to 8 for colonoscopies scheduled after 11 am."
1941017|NCT01481688|Other|Exercise|Exercise During Dialysis Patients will be asked to carry out cycling exercise for 60 minutes during the third quarter of their routine haemodialysis session. Exercise can be carried out in ten minute bouts with several minutes rest between bouts.
1941018|NCT01481688|Other|Extra time|An extra 30 minutes will be added to the currently prescribed treatment time of each patient.
1941019|NCT01480245|Drug|GSK2402968|6mg/kg/week
1941020|NCT01479985|Other|CDM Tool|Participants will be required to complete the CDM tool and receive a tailored print out of their contraceptive options based on survey answers
1941021|NCT01479426|Dietary Supplement|EFLA400|EFLA400(960mg/day)for 12 weeks
1941022|NCT01479426|Dietary Supplement|Placebo|Placebo(960mg/day) for 12 weeks
1941023|NCT01479049|Drug|MP (moderate potassium) group|Hearts were arrested with cold blood cardioplegia with moderate potassium concentration (K+, 10mmol/L)during cardiac operation
1941024|NCT01479049|Drug|HP (High potassium) group|Hearts are arrested with cold blood cardioplegia with high potassium concentration (K+, 20mmol/L)during cardiac operation.
1941025|NCT01478282|Drug|Rivaroxaban|20 mg/day, oral administration maintained for 5 days
1941026|NCT01478282|Drug|Dabigatran|150 mg/12 hours, administered orally, treatment maintained for 5 days
1941027|NCT01478776|Dietary Supplement|omega-3|4 cap 1 gr omega-3 per day for 10 weeks
1941028|NCT01478776|Dietary Supplement|placebo|patient with type 2 diabetes who receive 4 cap placebo/day for 10 weeks
1941029|NCT01476098|Drug|Placebo|SB-705498 placebo
1941030|NCT01476098|Drug|SB-705498|400 or 600mg oral SB-705498
1941033|NCT01474395|Drug|D-serine|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
1941034|NCT01474395|Drug|placebo|Subjects will then undergo three treatment visits. Each visit will begin with a pre treatment MMN/visual motion paradigm. Subjects will then receive DSR (60 mg/kg) or placebo and begin a one-hour SBR intervention. SBR will begin approximately 30 minutes after drug administration, to coincide with peak serum DSR level. Finally, to evaluate the effects of SBR and NMDA treatment on neurophysiology, subjects will complete a post treatment ERP paradigm. Treatment days will be separated by 1 week to reduce carryover effect. To increase power, each subject will undergo two DSR treatment days and 1 placebo day, with the placebo day selected randomly from among the three treatment days, in counter balanced order. Treatment assignment (drug and SBR) will be double blinded. Follow-up cognitive and safety measures will also be completed on the final treatment day.
1941035|NCT01474395|Behavioral|Sensory Based remediation paradigm|Every subject will receive sensory based remediation on each treatment visit: Three 80-tone pair blocks will be used per session (~1 hour with breaks). To minimize practice effects, we will use a different base tone for each treatment day (e.g. 500, 1000, and 2000 Hz), also in a randomized counter-balanced order. To assess the improvement over a treatment day, we will record the ratio of the frequencies in all tone pairs. To correct this non-normal distribution we take the natural log of each of these ratios to determine the tone matching threshold.
1941036|NCT01474382|Drug|OraVerse|1.8mL dental cartridge delivered in doses of either 1/4, 1/2 or 1 cartridge depending on subject weight
1941037|NCT01474382|Other|Sham injection|No drug administered, simulation of injection used in same manner as drug
1941040|NCT01471665|Drug|GSK2190915 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor. Dosing will occur once daily for up to 16 days.
1941041|NCT01471665|Drug|Placebo|Placebo will be administered once daily for up to 16 days.
1941042|NCT01472445|Drug|Vitamin D3|Vitamin D 10,000 IU/day
1941043|NCT01472445|Drug|Vitamin D3|Vitamin D 400 IU/day
1941051|NCT01470612|Drug|CP-690,550|5 mg tablets, BID, for at least 12 months
1941052|NCT01470612|Drug|CP-690,550|10 mg tablets, BID, for at least 12 months
1941053|NCT01470326|Drug|Bazedoxifene|For adults, take 1 tablet (20 mg of the active ingredient) at a time, once a day.
1941054|NCT01469013|Drug|LY3009104|Capsules administered orally
1941055|NCT01469013|Drug|Placebo|Capsules administered orally
1941056|NCT01469013|Drug|LY3009104|Tablets administered orally
1941057|NCT01469013|Drug|Placebo|Tablets administered orally
1941058|NCT01467739|Device|Ambu ® aScope®|
1941059|NCT01467739|Device|a conventional reusable fiberscope|
1941060|NCT01468402|Procedure|Magnetic Resonance Image|The leiomyomas were evaluated individually. MR was used to evaluate morphology: the radiological dimension(s) of the leiomyoma and uterus and the volume. The number of leiomyoma fibroids was determined, and their location in the myometrium. Perfusion and the characterization of the T2 signal were also evaluated.
1941061|NCT01468168|Drug|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
1941062|NCT01468168|Drug|DE-101 Ophthalmic Suspension|Ophthalmic suspension; QID
1941063|NCT01468168|Drug|DE-101 Ophthalmic Suspension Vehicle|Ophthalmic suspension vehicle; QID
1941064|NCT01468051|Biological|four doses of Euvax B vaccine|40 μg (2 ml) four doses of Euvax B vaccine
1941065|NCT01468051|Biological|20 μg (1 ml) three doses of Euvax B vaccine|20 μg (1 ml) three doses of Euvax B vaccine (recombinant hepatitis B surface antigen adsorbed on aluminium hydroxide adjuvant- LG Chem, Korea)
1941068|NCT01467427|Drug|nonacog beta pegol|A single dose of 40 U/kg will be administered intravenously, i.v. (into the vein) once weekly.
1941069|NCT01466751|Behavioral|Computerized Neurobehavioral Intervention|Targeted, computerized interventions completed from the participants' own home on a computer.
1941070|NCT01467297|Drug|ceftidoren|ceftidoren 200 mg bid for 5 days
1941071|NCT01467297|Drug|levofloxacin|levofloxacin 500 mg once daily for 7 days
1941072|NCT01467115|Radiation|Radiotherapy|3D conformal radiation therapy or Intensity-Modulated Radiation Therapy (IMRT) with or without Image Guided Radiation Therapy (IGRT) will be used for all patients. Radiotherapy will be delivered in 1.8 to 2.25 Gy fractions daily, five days per week excluding holidays, for a total of 66-72 Gy delivered to the Gross Tumor Volume (GTV, defined below) plus appropriate margin and 44-59.4 Gy to at-risk lymph nodes as determined by primary tumor characteristics. Alternative fractionation and dosing schema may be used as deemed appropriate for an individual case. For IMRT, the minimum Planning Target Volume (PTV) dose should be 90% of the prescription dose and a minimum of 95% of the PTV should receive the prescribed dose.
1941073|NCT01467115|Drug|Leucovorin|5FU is given after, or at the midpoint, of the leucovorin infusion. Leucovorin is usually administered by I.V. bolus injection or short (10-120 minutes) I.V. infusion but oral formulation may be substituted should supply warrant.
1941074|NCT01467115|Biological|Cetuximab|Cetuximab will be given for the duration of radiotherapy. A loading dose of intravenous cetuximab at 400mg per square meter body-surface area will be given over two hours up to seven days prior to initiation of radiation treatments or on the day of the first treatment (drug information detailed below). Thereafter, cetuximab will be given weekly over 60 minutes at a dose of 250 mg per meter squared. Intravenous diphenhydramine (50 mg) will be given as premedication.
1941075|NCT01467115|Drug|Filgrastim|Neupogen®: 300 mcg/mL (1 mL, 1.6 mL). May be administered undiluted by SubQ injection. May also be administered by I.V. bolus over 15-30 minutes in D5W, or by continuous SubQ or I.V. infusion. Do not administer earlier than 24 hours after or in the 24 hours prior to cytotoxic chemotherapy.
1941076|NCT01467115|Drug|Erythropoetin|Subcutaneous or intravenous
1941077|NCT01467115|Drug|Cisplatin|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
1941078|NCT01467115|Drug|Fluorouracil|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
1941079|NCT01467115|Drug|Docetaxel|One cycle of induction chemotherapy will be comprised of docetaxel on day 1 and cisplatin and 5-fluorouracil given days 1, 8, and 15. Intravenous docetaxel will be administered over one hour at a dose of 75 mg per square meter of body-surface area, followed by intravenous cisplatin at 35 mg per square meter, administered during a period of 0.5 to 3 hours weekly. After completion of the cisplatin infusion, intravenous fluorouracil will be given as a bolus at 1000 mg per square meter, followed by leucovorin at the dose of 350mg/m2. There will be total 4 cycles of chemotherapy of which 2 cycles will be prior to radiation therapy and 2 cycles will be post-radiation.
1941120|NCT01459263|Device|ClariVein|Using the ClariVein device, the GSV will be occluded.
1941201|NCT01443442|Drug|Loteprednol etabonate|Topical ocular aqueous formulation, one drop per instillation, four times per day for 14 days
1941202|NCT01442818|Drug|Dilaudid PCA|PCA setting of 0.3mg demand dose, 8 minute lock out interval, and 5mg 4-hour limit.
1941080|NCT01467050|Other|Application of STOPP/START criteria|"The researcher will apply the STOPP/START criteria to the cases randomised to this intervention. This will occur at the point of recruitment into the study and consists of applying STOPP/START criteria to the list of prescribed medications the patient is taking at that time point.
Where potentially inappropriate medications (PIM's) are identified using the intervention, these are highlighted to the medical team with primary responsibility for the patient both verbally and in writing. The relevant registrar will be contacted in person or via telephone by the researcher and informed of the PIM's in addition to a standard medication advice form inserted into the patients' notes also highlighting the PIM's."
1941081|NCT01467050|Other|Normal pharmaceutical care|The normal process of medication prescription and review by the attending medical team.
1941082|NCT01467024|Other|CDPHL Algorithm|Supplemental testing algorithm performed by the CDPHL.
1941083|NCT01466387|Biological|Typhoid Vi Polysaccharide Vaccine|One dose of typhoid Vi polysaccharide vaccine.
1941084|NCT01466387|Biological|Yellow Fever Vaccine|One dose of yellow fever vaccine.
1941085|NCT01466387|Biological|Japanese Encephalitis Vaccine|Two doses of Japanese Encephalitis Vaccine.
1941086|NCT01466387|Biological|Rabies Vaccine|Three doses of Rabies vaccine.
1941087|NCT01466387|Biological|MenACWY-CRM Vaccine|One dose of MenACWY-CRM vaccine.
1941088|NCT01465828|Drug|Clopidogrel|Patient will be randomized to this intervention will receive in the first time the high clopidogrel dose and after 14 days we will change their therapy with standard dose of prasugrel (crossover).
1941089|NCT01465828|Drug|prasugrel|Patient will be randomized to this intervention will receive in the first time the standard dose of prasugrel and after 14 days we will change their therapy with high dose of clopidogrel (crossover).
1941090|NCT01465516|Drug|Boceprevir|"Baseline assessments must be obtained on the day of or prior to enrollment and prior to administration of the first dose of any study drug (BOC, PEG-IFN alfa-2b, or ribavirin).
Using the RGT guidelines in patients who are previously untreated: all patients will receive a lead-in treatment of PR for 4 weeks, then BOC will be added to PR for 4 weeks; based on patient's week 8 HCV RNA results"
1941091|NCT01464918|Device|Endoscopic submucosal dissection (ESD) using device, MASTER|Performing endoscopic submucosal dissection (ESD)of the gastric/colon cancer using the device, MASTER
1941092|NCT01464775|Other|NBI|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
1941093|NCT01464775|Other|White light|Women will be randomized to white light/NBI versus white light/white light laparoscopic surgery
1941094|NCT01464593|Drug|Lyso-Thermosensitive Liposomal Doxorubicin|Thermally sensitive liposomal doxorubicin 50 mg/m2 single 30 minute intravenous infusion.
1941095|NCT01464593|Other|5% Dextrose Solution|Single 30 minute intravenous infusion
1941096|NCT01464593|Drug|ThermoDox|ThermoDox is a Lyso-thermosensitive Liposomal Doxorubicin designed to be used in conjunction with thermal ablation.
1941097|NCT01464346|Device|Enlite Sensor|
1941098|NCT01464060|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Dual therapy for 7 days: 40 mg omeprazole and 1g amoxicillin every 12h. After dual therapy continue with a quadruple therapy for 7 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h.
1941099|NCT01464060|Drug|PPI, amoxicillin, metronidazole and clarithromycin|Quadruple therapy for 14 days: 40 mg omeprazole, 1g amoxicillin, 500 mg metronidazole and 500 mg clarithromycin every 12h
1941100|NCT01463631|Drug|LY3007113|Administered orally
1941109|NCT01461824|Drug|Depot medroxyprogesterone acetate (DMPA)|75mg, 104mg and 150mg DMPA, IM, every 12 weeks for 12 months
1941110|NCT01461499|Drug|Aliskiren|The patient will start taking one a daily 150 mg/day of aliskiren. In case blood pressure doesn't reach the target (SBP/DBP < 130/80 mmHg), higher dose of aliskiren will be given.In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
1941111|NCT01461499|Drug|any angiotensin receptor blockers|The patient will start taking one a standard dose of an ARB in Japan. In case blood pressure doesn't reach the target (SBP/DBP < 130/80 mmHg), higher dose of the ARB will be given. In case the blood pressure doesn't achieve the target, another anti-hypertensive drug other than RAS inhibitors (DRI, another ARB or ACE-inhibitor) or potassium-retaining diuretics will be added from the minimum effective dose.
1941112|NCT01460771|Device|TDCS (Transcranial Direct-current Stimulation)|active TDCS
1941113|NCT01460771|Device|sham TDCS (Transcranial Direct-current Stimulation)|TDCS at 0mA
1941114|NCT01460667|Drug|IV acetaminophen|IV acetaminophen 1000 mg (100 mL) every 6 hours over 30 hours
1941115|NCT01460667|Drug|IV normal saline|0.9% normal saline IV, every 6 hours over 30 hours.
1941116|NCT01460017|Procedure|Deep Sclerectomy|Non penetrating glaucoma surgery is a new procedure in adults that has less post operative complications with good results, it is to be applied in children.
1941117|NCT01460017|Procedure|Combined Trab|Combined trabeculectomy and trabeculotomy is a standard surgery for congenital glaucoma, however, it has its known complications.
1941118|NCT01459718|Drug|Deferasirox|Deferasirox monotherapy treatment of intensive iron chelation treatment. Medication label will comply with the Greek legal requirements and be printed in Greek. A subject identifier will be entered on the medication label.
1941119|NCT01459718|Drug|Deferasirox + Deferoxamine|Deferasirox-DFO regimen for intensive iron chelation treatment. Medication labels will comply with the Greek legal requirements and will be printed in Greek. A subject identifier will be entered on the medication label.
1941121|NCT01458522|Drug|fPHT|"If after initial treatment with fPHT any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered:
The subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period.
The subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period.
The subject experiences an AE that precludes further use of the first study drug.
If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
1941122|NCT01458522|Drug|LCM|"If after initial treatment with LCM any of the following occurs, the subject will have reached the end of the first treatment arm and will cross over and begin receiving the other drug, ie, the one not originally administered:
The subject subsequently has another seizure within 24 hours following the 2-hour post-rebolus observation-only period.
The subject does not receive a rebolus but has a seizure within 24 hours following the 2 hour post-bolus observation-only period.
The subject experiences an AE that precludes further use of the first study drug.
If crossover occurs, the subject will start over with the second drug, going through the same observation-only period, rebolusing (if necessary), and study assessments with the second drug, beginning with the Baseline assessments."
1941124|NCT01457924|Drug|Ofatumumab 3mg|3mg of investigational product
1941125|NCT01457924|Drug|Ofatumumab 30mg|30mg of investigational product
1941126|NCT01457924|Drug|Ofatumumab 60mg|60mg of investigational product
1941127|NCT01457924|Drug|Placebo|Placebo
1941128|NCT01457573|Drug|Solifenacin (Vesicare) 5 mg orally at the same time.|"Drug: Tamsulosin 0.4 mg in combination with Solifenacin 5 mg
All men will receive morning dosing with Tamsulosin (Flomax) 0.4 mg and Solifenacin (Vesicare) 5 mg orally at the same time."
1941129|NCT01457040|Drug|TBI+CY+VP-16|CR Cohort will receive conditioning regimen of TBI+CY+VP-16: TBI: 4.5Gy/d, -5d, -4d; CY: 60mg/kg/d, -3d, -2d; VP-16: 15mg/kg/d, -3d, -2d
1941130|NCT01457040|Drug|FA+TBI+CY+VP-16|NR Cohort will receive conditioning regimen of FA+TBI+CY+VP-16: Flu: 35mg/m2/d: -10~-6d; AraC: 1g/m2/d, -10d~-6d; TBI: 4.5Gy/d, -5d,-4d; CY:60mg/kg/d, -3d, -2d; VP-16: 15mg/kg, -3d, -2d
1941131|NCT01455584|Drug|HM781-36B tablets|Q1X28D/4W for HM781-36B tablets
1941132|NCT01455779|Device|Lyrette|"The Verathon Transurethral RF System (Lyrette® System) is indicated for the treatment of female urinary stress incontinence (SUI) due to hypermobility in women who have failed conservative treatment and who are not candidates for surgical therapy.
The treatment is a 9 minute non-surgical procedure completed using local anesthesia during a single office visit. Women are discharged home with no incisions, dressings, or catheters immediately following treatment."
1941133|NCT01455571|Drug|HM781-36B|Q1DX14/2W for 3W HM781-36B
1941134|NCT01454635|Drug|Sertraline|dosage,frequency and duration
1941135|NCT01455337|Drug|pentoxifylline|400mg tid
1941136|NCT01455337|Drug|Prednisolone|40mg qd
1941137|NCT01455233|Drug|besivance|topical ocular antibiotic, 1 drop in study eye QID starting 3 days prior and for 7 days following cataract surgery
1941138|NCT01455233|Drug|vigamox|topical ocular antibiotic, 1 drop in study eye QID for 3 days prior and for 7 days following cataract surgery
1941139|NCT01455155|Other|Creative therapy (art and music therapy)|Creative therapy composed of groups of activities relating to music and art sciences 8 sessions (2 sessions per week for 4 weeks) These activities emphasized on stimulating of cognition, physical, emotion, communication, social relationship, and spiritual domains.
1941140|NCT01455155|Other|Physical therapy|Physical therapy composed of a series of physical therapy program including types of exercises and gait training if possible (5 times/week).
1941141|NCT01454908|Device|Oxford Partial Knee|The Oxford partial knee contains tibial and medial components and a mobile meniscal bearing.
1941142|NCT01454362|Drug|Nicotine|Inhalation of nicotine.
1941143|NCT01453530|Drug|Sugammadex|A single dose of sugammadex 2 mg/kg iv
1941144|NCT01453530|Drug|Neostigmine/Glycopyrrolate|A single dose of neostigmine 0.04 mg/kg iv plus glycopyrrolate 0.01 mg/kg iv
1941145|NCT01453530|Other|Placebo|Placebo
1941151|NCT01453959|Drug|Fludrocortisone|Fludrocortisone in a dose of 0.4 mg/day for 7 days
1941152|NCT01453959|Other|Diet cycles|Two cycle of diets: low salt diet(40mEq Sodium/day by 7 days) and high salt diet (240mEq Sodium/day by 7 days)
1941153|NCT01453010|Other|Self-directed Upper Limb SaeboFlex Training|"Participants undergo a 12 week self directed upper limb training programme with the SaeboFlex upper limb orthosis. Training consists of a maximum of 3 x 45 minute sessions a day.
Participants are closely monitored at least once a week by a saebo-trained therapist."
1941154|NCT01452516|Device|nanOss Bioactive Bone void filler|Instrumented posterolateral gutter fusions using nanOss Bioactive bone void filler
1941155|NCT01452516|Device|Interbody FCage|Lumbar fusion using interbody cages with autograft. This will be done in conjunction with the posterolatreal gutter fusion
1941156|NCT01453140|Drug|Cyclophospahmide and Sirolimus|"On the first day of treatment, cyclophosphamide will be administered at a dose of 4g/m2 IV x 1 dose. Patients who are >40% above ideal weight will be dosed based on adjusted weight and adjusted BSA.
One day after the administration of cyclophosphamide, patients will receive sirolimus 6 mg PO x 1 and on the following day will start sirolimus at a dose of 2 mg PO daily."
1941157|NCT01453140|Drug|Low dose IL-2, Cyclophosphamide and Sirolimus|"Patients in treatment arm B will be receiving low-dose IL-2 in conjunction with the cyclophosphamide and sirolimus.
IL-2 will be administered at a dose of 0.5E6 IU/m2 SQ daily x 8 weeks followed by 4 weeks off, starting 14 days after the cyclophosphamide."
1941158|NCT01453140|Drug|Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus|"Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza). The Vidaza will be initiated between day 27 and 32 following the cyclophosphamide.
The dose administered will be 10 mg SQ daily for 5 days followed by 3 weeks off."
1941159|NCT01453348|Biological|MenACWY-CRM|Novartis meningococcal ACWY conjugate vaccine will be administered intramuscularly (IM) on day 1.
1941160|NCT01453348|Biological|Combined inactivated hepatitis A & recombinant hepatitis B|Combined inactivated hepatitis A and recombinant hepatitis B vaccine will be administered by IM on days 1, 8 & 29 for subjects unprimed with hepatitis A and B; and a single booster injection on day 1 for primed subjects.
1941161|NCT01453348|Biological|Recombinant hepatitis B vaccine|Recombinant hepatitis B vaccine will be administered intramuscularly on days 8 and 29
1941162|NCT01453348|Biological|Inactivated hepatitis A vaccine|Inactivated hepatitis A will be administered intramuscularly on days 8 and 29.
1941163|NCT01450956|Drug|Sevoflurane|Sevoflurane will be given at a concentration of 2% through oxygenator during CPB
1941164|NCT01450956|Other|Control|Patients will receive only oxygen and air through oxygenator
1941165|NCT01450267|Drug|Inhaled Reduced Glutathione|10 mg/kg, twice daily, 12 months
1941166|NCT01450267|Drug|Physiological solution|0,13 ml/kg body weight, twice daily, 12 months
1941167|NCT01450137|Drug|Tocilizumab + Glucocorticoids (GCs)|Tocilizumab 8mg/kg every 4 weeks until week 52.
1941168|NCT01450137|Drug|Placebo + Glucocorticoids (GCs)|Placebo every 4 weeks until week 52.
1941169|NCT01449916|Other|Simplified Severe Sepsis Protocol|Early fluid protocol, early blood cultures and antibiotics; blood cultures and titrated dopamine in selected patients; monitoring based on vital signs and physical examination
1941170|NCT01449643|Device|Threshold|
1941171|NCT01449643|Device|Sham Threshold|
1941172|NCT01448564|Other|Laser therapy|The therapeutic effects of low intensity lasers are: (i) analgesic and anti-inflammatory, (ii) regeneration, (iii) tissue healing and (vi) recovery from muscle fatigue.
1941173|NCT01448564|Other|Placebo laser therapy|The application of laser therapy will be a low intensity laser.
1941174|NCT01447667|Procedure|Magnetic resonance elastography|Magnetic resonance elastography before RFA and Liver biopsy of 2 HCC tissue and 2 non tumor liver parenchyma tissue
1941175|NCT01447277|Procedure|Sciatic Block|Performing a sciatic block in addition to a femoral block preoperatively
1941176|NCT01447277|Procedure|Femoral Block only|Performing a preoperative sciatic nerve block only
1941177|NCT01446913|Device|Standard CPAP Intervention|
1941178|NCT01446913|Behavioral|Enhanced CPAP Intervention|
1941187|NCT01445886|Drug|Indigo Naturalis Oil Extract|The participants applied indigo naturalis oil extract topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
1941188|NCT01445886|Drug|Calcipotriol Solution|The participants applied calcipotriol solution topically to one of two bilaterally symmetrical psoriatic finger nails twice daily for 24 weeks.
1941189|NCT01445925|Procedure|Pulmonary vein isolation (PVI)|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside pulmonary vein (PV) ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA). A 20-pole PV mapping catheter will be used to confirm electrical isolation. If the patient is in atrial fibrillation at this stage, sinus rhythm would be restored with electrical cardioversion and PVI would be confirmed in sinus rhythm
1941190|NCT01445925|Procedure|Pulmonary vein isolation + linear lesions|Using a 4mm irrigated tip radiofrequency ablation catheter a series of lesions >2 mm outside PV ostia will be made to encircle and electrically isolate the pulmonary veins in two ipsilateral pairs (wide area circumferential ablation, WACA)34. A 20-pole PV mapping catheter will be used to confirm electrical isolation. Once PVI has been achieved, patients will go onto to receive additional linear ablation lesions. These will include a left atrial roof line, mitral isthmus line, (including ablation inside the coronary sinus if necessary), and ablation on the cavotricuspid isthmus. If the patient is in atrial fibrillation at this stage, the acute end-point would be signal obliteration at the ablated area. Once sinus rhythm is restored with electrical cardioversion, PVI would be confirmed in sinus rhythm and conduction block across the LA roof line, Mitral line and CTI will then be verified with appropriate pacing manoeuvres.
1941191|NCT01445925|Drug|Pharmacological Substrate modification|at least 6 weeks therapy with oral amiodarone prior to the ablation procedure and 6 weeks post.
1941192|NCT01445301|Drug|GSK2585823(CLDM 1%-BPO 3% gel)|Topical gel in 1 g containing clindamycin 10 mg and benzoyl peroxide 30 mg
1941193|NCT01445301|Drug|CLDM 3% gel twice daily|Topical gel containing clindamycin 10 mg/1 g gel
1941194|NCT01444846|Drug|SPI-1005 Low dose|Oral capsules, 200 mg ebselen, twice daily, 4 days
1941195|NCT01444846|Drug|SPI-1005 Middle dose|Oral capsules, 400 mg ebselen, twice daily, 4 days
1941196|NCT01444846|Drug|SPI-1005 High dose|Oral capsules, 600 mg ebselen, twice daily, 4 days
1941197|NCT01444846|Drug|Placebo|Oral capsules, 0 mg ebselen, twice daily, 4 days
1941198|NCT01444508|Drug|"Ringer-lactate SAD"|Lactated Ringer's is administrated intravenously in the dosis of max. 35 ml/kg during the operation after securing normovolaemia with Nexfin Monitor at induction of the anaesthesia: if bolus infusion of 200 ml increases stroke volume more than 10 % the patient is not assumed normovolaemic and bolus infusions are repeated until normovolaemic status is achieved.
1941199|NCT01444508|Drug|HES 130/04|"Voluven is administered intravenously in the doses of max. 35 ml/kg during the operation. Normovolaemia is achieved in the same way as described in intervention by Ringer-lactate SAD."
1941200|NCT01443442|Drug|bepotastine besilate, 1.5%|Topical ocular aqueous formulation, oen drop per instillation, twice per day for 14 days
1942600|NCT01153932|Drug|GSK2402968|Subcutaneous injection
1941204|NCT01441700|Procedure|Prone and Supine emergence from anaesthesia|Aims: The aim of this study was to compare haemodynamic changes and to evaluate the incidence of coughing, laryngospasm, loss of monitoring in patients undergoing lumbar disc surgery extubated in prone position and supine position. Settings and design: This open-level prospective randomized study was carried out in 50 patients who were admitted for elective lumbar surgery. Methods: The patients were randomly allocated to one of the two groups of 25 each at conclusion of surgery. First group was extubated in prone position and second in supine position at conclusion of surgery. Supine group patients were rolled back and prone group patients were left undisturbed. Extubation was done after complete reversal of neuromuscular block. Heart rates, Mean Arterial Pressure were noted at various points of time. Coughing, laryngospasm, vomiting, monitor disconnection if any were also noted. Statistical methods: Data was analyzed using
1941207|NCT01442623|Other|Vestibular Rehabilitation|"The patients in the Nintendo Wii Vestibular Rehabilitation group will undergo a standardised 6 week program of vestibular rehabilitation using the Nintendo Wii Fit Plus at home 5 times a week. They will perform a series of exercises and games on the Wii Fit Plus that are designed to challenge and retrain balance. They will be seen once a week by a physiotherapist for review and progression of exercises.
Patients in the Conventional Vestibular Rehabilitation group will undergo a standardised program of conventional vestibular rehabilitation using conventional balance exercises (Herdman 2007) 5 times a week. They will be seen once a week by a physiotherapist to progress exercises and will receive a standardised home exercise program."
1941208|NCT01441882|Drug|Dasatinib|Given PO
1941209|NCT01441882|Other|Laboratory Biomarker Analysis|Correlative studies
1941210|NCT01441882|Other|Pharmacological Study|Correlative studies
1941213|NCT01439581|Device|Mapping System|Pressure Sensing coverlet on ICU bed and provides real time feedback to assist in effective patient repositioning
1941218|NCT01439360|Biological|Quadrivalent seasonal influenza vaccine(Flu D-QIV) GSK2321138A|Intramuscular injection
1941219|NCT01439360|Biological|Havrix Junior|Intramuscular injection administered to subjects aged 12 months or older
1941220|NCT01439360|Biological|Prevenar 13|Intramuscular injection administered to subjects less than 12 months of age
1941221|NCT01439360|Biological|Varivax/ProVarivax|Intramuscular injection administered to subjects more than 12 months of age
1941222|NCT01439360|Biological|Varilrix|Subcutaneous injection administered to subjects more than 12 months of age
1941223|NCT01439308|Drug|Placebo|SB-705498 placebo
1941224|NCT01439308|Drug|SB-705498|12mg intranasal SB-705498
1941225|NCT01438866|Other|Fissure sealant|Preventing dental caries in primary molars by applying fissure sealants and fluoride varnish, and comparing caries preventive effect of sealants with fluoride varnish.
1941226|NCT01438866|Other|Fissure sealants and fluoride varnish|Comparing preventive effect of fissure sealants and fluoride varnish on occlusal surfaces of primary molars
1941227|NCT01439009|Drug|Tolvaptan|Once-daily oral administration of one tolvaptan 15 mg tablet in the morning
1941228|NCT01439009|Drug|Placebo of tolvaptan|Once-daily oral administration of one placebo tablet in the morning
1941229|NCT01438086|Drug|mecasermin|Intracoronary bolus
1941230|NCT01438086|Drug|mecasermin|Intracoronary bolus
1941231|NCT01438086|Drug|0.9% sodium chloride injection|Intracoronary bolus
1941232|NCT01437852|Biological|StrataGraft Skin Tissue|StrataGraft® skin tissue is provided as a suturable circular patch of stratified epithelial tissue composed of a living dermal matrix (containing dermal fibroblasts) overlaid with human epidermal keratinocytes (NIKS®).
1941233|NCT01437046|Drug|Doxazosin|Doxazosin 16mg/day
1941234|NCT01437046|Drug|Placebo|
1941237|NCT01435512|Behavioral|PTSD-Focused CBT for Partner Violence|PTSD-Focused CBT (PFCBT) will consist of 12 2-hour weekly sessions,led by two project therapists. In each session, group members will discuss materials and do assignments to practice skills.
1941238|NCT01435382|Biological|PF-04950615|Dose A - single-dose intravenous infusion
1941239|NCT01435382|Biological|PF-04950615|Dose B - single-dose subcutaneous injection
1941240|NCT01435382|Biological|PF-04950615|Dose C - single-dose subcutaneous injection
1941241|NCT01435382|Biological|PF-04950615|Dose D - single-dose subcutaneous injection
1941242|NCT01435369|Drug|CT-011|The monoclonal antibody, CT-011 is administered intravenously at 2 dosage levels, 1.5mg/kg and 6.0 mg/kg to patients with metastatic melanoma. The study drug will be given every other week for a total of up to 27 study drug infusions for about 12 months.
1941243|NCT01434524|Drug|LIVACT|LIVACT contains 13.0 g of free amino acids
1941245|NCT01435135|Biological|AIDSVAX B/E|1 mL per injection (300 ug dose/antigen for a total of 600ug/dose administered)
1941246|NCT01435135|Biological|ALVAC-HIV Placebo|1 ml per injection
1941247|NCT01435135|Biological|AIDSVAX B/E Placebo|1 ml per injection
1941248|NCT01434810|Procedure|Window tinting film for filtered sunlight phototherapy|Six hours per day of filtered sunlight phototherapy for 1 to 10 days.
1941249|NCT01434810|Device|Conventional phototherapy|Conventional phototherapy unit will be used for infants randomized to this arm for 1 to 10 days.
1941250|NCT01433614|Drug|Epirubicin|75 mg/m2 i.v. every 3 weeks, both study arms
1941251|NCT01433614|Drug|Paclitaxel|175 mg/m2 i.v., every 3 weeks study arm A 155 mg/m2 i.v., every 3 weeks study arm B
1941252|NCT01433614|Drug|Capecitabine|1650 mg/m2 p.o. days 1-14 every 3 weeks study arm B
1941255|NCT01429935|Drug|Ginger powder|capsules contain 500mg Ginger powder,every 6hours,for 5 days
1941256|NCT01429935|Drug|Ibuprofen|capsules of Ibuprofen 400 mg, every 6 hours for 5 days
1941257|NCT01429935|Other|placebo|capsules contain starch
1941258|NCT01429792|Drug|peginterferon alfa-2a [Pegasys]|standard treatment, subcutaneously weekly
1941259|NCT01429792|Drug|ribavirin [Copegus]|standard treatment, orally daily
1941260|NCT01429766|Other|Respiratory Training|"All patients shall be sent for respiratory training to the physiotherapy department. Patients shall be counseled about respiratory training by trained staff in their own vernacular. Whenever possible, patients shall be provided one Spiroball device and taught how to use the device. In addition/alternatively patients will be taught to do pranayam(breath exercises). Patients provided with spiroball shall be instructed to use the spiroball by the prescribed technique. The following visit schedule shall be observed
st visit Within one day of the date of simulation
nd visit Date of Radiotherapy start Subsequently 2 visits per week during radiotherapy course shall be conducted (Tuesdays, Thursdays)"
1941261|NCT01429272|Drug|Minocycline|100 mg po bid for 6 weeks
1941262|NCT01429272|Drug|Aspirin|81 mg po bid for 6 weeks
1941263|NCT01429272|Drug|placebo|placebo for minocycline and/or aspirin
1941264|NCT01428453|Drug|250mg rilapladib|Experimental Drug
1941265|NCT01428453|Drug|placebo|Placebo comparator
1941266|NCT01428440|Radiation|18FML10|apoptosis imaging radio ligand
1941267|NCT01427972|Drug|LY2623091|Administered orally
1941268|NCT01427972|Drug|Eplerenone|Administered orally
1941269|NCT01428024|Device|Restylane Lip Volume|Treatment of up to 1,5 ml product for upper and lower lip, respectively at week 0 and week 12.
1941270|NCT01428024|Device|Restylane Lip Refresh|Treatment of up to 0,5 ml product for upper and lower lip, respectively at week 0 and week 12.
1941274|NCT01427062|Other|experimental|Subjects in the experimental group were trained the speed and amplitude of anticipatory postural adjustment during fall-prone activities and postural response to perturbation during walking. Training was provided with preparatory cues, computerized machines and treadmill.
1941275|NCT01427062|Other|control|Subjects in control group were provided with strength training of leg muscles using machines and during functional activities.
1941276|NCT01425281|Device|Abbott Vascular XIENCE Everolimus Eluting Coronary Stent System|XIENCE implantation in the treatment of coronary artery disease.
1941277|NCT01425281|Device|Abbott Vascular ABSORB Everolimus Eluting Bioresorbable Vascular Scaffold System|ABSORB BVS implantation in the treatment of coronary artery disease.
1941278|NCT01425801|Drug|LAS100977|Dry powder inhalation,Once daily, single dose
1941279|NCT01425801|Drug|Reference|Pressurized inhalation suspension, Once daily , single dose
1941280|NCT01425801|Drug|Placebo|Dry powder inhalation or Pressurized inhalation
1941281|NCT01424670|Drug|Delamanid|100mg BID for 2 months and 200mg QD for 4 months
1941282|NCT01424670|Drug|Placebo|Matching Placebo
1941283|NCT01424670|Drug|Optimized Background Regimen (OBR)|• Selection and administration of the treatment medications (i.e. OBRs) will be based on WHO's Guidelines for the programmatic management of drug-resistant TB, in conjunction with national TB program guidelines in each country. ARVs will be administered as standard-of-care.
1941284|NCT01424670|Drug|Antiretrovirals (ARVs)|• HIV treatment (i.e. ARVs) will be based on WHO guidelines and recommendations, and in compliance with local/national guidelines for HIV in South Africa (each site). ARVs will be administered as standard-of-care.
1941285|NCT01424514|Drug|SB-705498|12mg intra nasal
1941286|NCT01424514|Drug|Placebo|Placebo intra nasal
1941287|NCT01424397|Drug|SB-705498|12mg intranasal
1941288|NCT01424397|Drug|FP|200ug intranasal
1941289|NCT01424397|Drug|placebo|placebo intranasal
1941290|NCT01423812|Drug|Twice-daily Darunavir/ritonavir|Subjects remain on regimens containing Darunavir 600mg plus Ritonavir 100mg twice-daily
1941291|NCT01423812|Drug|Once-daily Darunavir/ritonavir|Subjects switched from Darunavir 600mg plus Ritonavir 100mg twice-daily at baseline to Darunavir 800mg plus Ritonavir 100mg once-daily for 48 weeks
1941292|NCT01424241|Drug|Sandostatin LAR|This will be a open label dose escalation study of Sandostatin LAR 10 Mg, 20Mg, 30 Mg up to 40 mg if necessary.
1941293|NCT01423253|Drug|Lurasidone|Lurasidone 20, 40, or 60 mg/day, orally, once daily (QD) in the evening, with a meal or within 30 minutes after eating, flexibly dosed
1941294|NCT01422668|Other|Khalas dates|every subject recieved 50 grams reducing carbohydrates equivalent of khalas dates
1941295|NCT01422408|Drug|Fluocinonide Cream|Given topically
1941296|NCT01422408|Procedure|Management of Therapy Complications|Receive fluocinonide cream
1941297|NCT01422408|Other|Questionnaire Administration|Ancillary studies
1941400|NCT01398566|Behavioral|SuperBetter play|average 10 min of game play per day for 6 week period
1941301|NCT01422135|Drug|AG200-15|A transdermal contraceptive delivery system for LNG and EE. A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
1941302|NCT01421056|Drug|CHF 5074 1x|oral tablet, 1x, once a day in the morning for 24 weeks
1941303|NCT01421056|Drug|CHF 5074 2x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 20 weeks
1941304|NCT01421056|Drug|CHF 5074 3x|oral tablet, 1x, once a day in the morning for 4 weeks, followed by oral tablet, 2x, once a day in the morning for 4 weeks, followed by oral tablet, 3x, once a day in the morning for 16 weeks
1941306|NCT01421225|Procedure|Closed-loop therapy|Subjects' insulin dose will be adjusted based on a proportional-integral-derivative algorithm using the continuous glucose monitor readings from 10 PM - noon.
1941307|NCT01421225|Procedure|Standard Insulin Pump Therapy|Patients will receive standard insulin pump therapy as per their usual home insulin protocol.
1941308|NCT01420614|Procedure|Femoral approach|diagnostic and interventional procedures by femoral artery access
1941309|NCT01420614|Procedure|Radial approach|diagnostic and interventional procedures by radial artery access
1941310|NCT01420536|Procedure|Occlusal scheme|"Before enrollment, all participants will receive conventional complete dentures adjusted according to the bilateral balanced occlusion concept.
Following randomization, canine guidance will be achieved by adding composite resin (Restorative Z100, 3M Brazil, Sumaré, SP, Brazil) on the lingual surface of the maxillary canines. A sham comparator will also employ the addition of composite, but without changing eccentric contacts."
1941311|NCT01420302|Procedure|Nurse directed insulin titration|Nurse directed insulin titration to establish glycemic control in the target range of 80-110 mg/dL
1941312|NCT01420302|Procedure|LOGIC-Insulin|Blood glucose control (80-110 mg/dL) guided by the LOGIC-Insulin algorithm
1941313|NCT01420016|Behavioral|Prioritized Clinical Decision Support|Eighteen primary care clinics will be blocked on size and on patient characteristics, and each clinic randomly assigned to one of 2 study arms. All consenting PCPs will be allocated to the study arm that their clinic is assigned to and the estimated 400 eligible adults with 10-year CVR >= 10% under the care of each consenting physician will be allocated to the same treatment arm as their PCP.
1941314|NCT01419925|Biological|Two Multimeric-001 administrations followed by TIV|Two administrations of non adjuvanted M-001, 500 mcg followed by TIV at intervals of 19-23 days
1941315|NCT01419925|Biological|One administration of Multimeric-001 followed by TIV|One administration of non adjuvanted Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
1941316|NCT01419925|Biological|One administration of adjuvanted M-001 followed by TIV|One administration of adjuvanted (Aluminum phosphate) Multimeric-001, 500 mcg, followed by TIV at intervals of 19-23 days
1941317|NCT01419925|Biological|One administration of placebo followed by TIV|One administration of saline (Placebo)followed by TIV at intervals of 19-23 days (serving as an active comparator)
1941318|NCT01417832|Drug|Resin infiltration / adhesive|Treatment at baseline of one caries lesion with a resin infiltration conducted under rubber-dam isolation with the Icon-DMG pre-product; treatment at baseline of another caries lesion with an adhesive under rubber-dam isolation with the Prime Bont NT - Dentsply.
1941319|NCT01417832|Drug|Placebo|In this split-mouth design study, one of the three randomly selected approximal lesions will be treated with an infiltrant resin, one will be treated with an adhesive resin.
1941320|NCT01417663|Drug|Alt-711|Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
1941321|NCT01417663|Behavioral|Physical exercise training|Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
1941326|NCT01416818|Drug|Xiaoyao Pill|herb extracts,were received two times a day for 12 weeks without dose changing.
1941327|NCT01416818|Drug|Bupleurum+Ginkgo|herb extracts, were received two times a day for 12 weeks without dose changing.
1941328|NCT01416818|Drug|placebo|The placebo looked like herb extracts and were also received two times a day for 12 weeks without dose changing.
1941329|NCT01414257|Drug|Methotrexate (MTX)|Methotrexate should be administered at the weekly dose of 6 mg orally once a week or twice or three times a week by subdividing the weekly dose into the relevant number of portions. When administering the subdivided doses, MTX should be administered at the interval of 12 hours on Day 1 to Day 2. When the weekly dose is subdivided into two portions, suspend the administration for the remaining 6 days. When the weekly dose is subdivided into three portions, suspend the administration on the remaining 5 days. Repeat this weekly cycle. The dose should be adjusted as appropriate depending on the age, symptom, tolerability, and response to the MTX Preparation in individual patients. The weekly dose should not be higher than 16 mg.
1941333|NCT01414504|Biological|Prevenar + PPV|0.5mL dose of Prevenar at 0-1-2 months, 0.5mL Pneumovax at 9 months and 0.1mL Pneumovax at 3-5 yrs
1941334|NCT01414504|Biological|Infant PCV (Prevenar) + PPV at 9 months|0.5mL Prevenar at 1-2-3 months,0.5mL Pneumovax (PPV) at 9 months, 0.1mL Pneumovax at 3-5 yrs
1941335|NCT01414504|Biological|No Prevenar + PPV at 9 months|no Prevenar, 0.5mL Pneumovax at 9 months, 0.1mL Pneumovax at 3-5 yrs
1941336|NCT01414504|Biological|Control|control, 0.1mL Pneumovax at 3-5yrs
1941337|NCT01412632|Drug|Remifentanil, propofol and citanest|iv remifentanil iv propofol im citanest
1941338|NCT01412866|Behavioral|Electronic decision support system with CO monitor feedback|Web-based electronic decision support system (EDSS) with carbon monoxide monitor and health-checklist
1941339|NCT01412866|Behavioral|Electronic decision support system without CO monitor feedback|Web-based electronic decision support system (EDSS) with health-checklist feedback alone
1941340|NCT01412710|Drug|Cholecalciferol|4000 IU or 6000 IU given once daily, orally for 6 months.
1941341|NCT01411995|Drug|2% lidocaine gel|3-5cc of 2% lidocaine gel will be applied to the lip of the cervix and within the endocervical canal prior to IUD insertion
1941342|NCT01411995|Drug|Water based lubricant|3-5cc of water based lubricant will be applied to the lip of the cervix and within the endocervical canal prior to IUD insertion
1941343|NCT01411852|Drug|0.9% Sodium Chloride 250 mL bolus|Emergency Medicine Systems (EMS) agencies and in-hospital providers will be given the option to utilize either systolic blood pressure (SBP) or radial pulse as the endpoint for fluid resuscitation to patients randomized to the experimental group. Patients will receive a 250 ml bolus of normal saline (NS) only if the SBP is less than 70 mmHg or the radial pulse is not palpable. If the SBP is greater than or equal to 70 mmHg or the radial pulse is palpable, NS will be given to keep the vein open. The presence or absence of a radial pulse or the SBP will be documented before and after each bolus. The study will continue repeating the randomization procedure using only 250 ml bags of NS until 2 hours after arrival to the hospital or until hemorrhage control is achieved whichever occurs first.
1941344|NCT01411852|Drug|0.9% Sodium Chloride 2000 mL bolus|Emergency Medicine Systems (EMS) personnel and in-hospital providers will utilize the systolic blood pressure SBP as the endpoint for delivering fluid resuscitation to patients randomized to the control group. If the SBP is equal to or less than 90 mmHg, the EMS personnel will start infusing a 1000 ml bolus of normal saline (NS) and will continue using only 1000 ml bags of NS as needed. If the total fluid resuscitation exceeds 2 liters, fluid will be stopped when the SBP exceeds 110 mmHg and restarted as necessary to maintain a goal SBP of 110 mmHg. The fluid will be given as rapidly as possible. This fluid resuscitation protocol will continue until either 2 hours after hospital arrival or until control of hemorrhage is achieved whichever occurs first.
1941345|NCT01411371|Procedure|Catheter ablation of persistent atrial fibrillation|Catheter ablation of AF as described previously by our group (e.g. Hunter et al, Heart 2010).
1941346|NCT01411371|Drug|Medical treatment alone|Medical treatment of persistent AF as 'normal care'. Patients are randomised to medical treatment alone for atrial fibrillation. Treatment will be as per current guidelines for persistent atrial fibrillation, with rate control as first line (using beta-blockers, calcium channel blockers and digoxin as indicated) and rhythm control as second line (using sotalol, dronedarone, or amiodarone as indicated). (Both groups will receive standard heart failure medication including angiotensin converting enzyme inhibitors, beta blockers, aldosterone antagonists, and diuretics as indicated).
1941347|NCT01411085|Drug|Risperidone + Desipramine|
1941356|NCT01410058|Dietary Supplement|Moringa oleifera|leaf powder
1941357|NCT01408108|Procedure|Laparoscopic hiatal repair with sub-lay partially absorbable lightweight mesh|"A fashioned according to the dimensions of hernia defect partially absorbable lightweight mesh Ultrapro™ (Ethicon, Inc.) will be sutured to both crura with 3 to 5 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures (as tension-free repair). Subsequent 2 to 3 interrupted non-absorbable sutures will approximate crura to completely cover a mesh to preclude its contact with the esophagus (original sandwich sub-lay technique)."
1941358|NCT01408108|Procedure|Laparoscopic primary posterior crural repair|"Posterior cruroraphy will be performed with 3 to 4 interrupted non-absorbable (Ethibond™ 3-0 by Ethicon, Inc.) sutures.
In the both arms laparoscopic procedure will be done in a standard fashion: reduction of hernia with excision of hernia sac and mobilization of distal esophagus, exposure of borders of hiatal opening including crura posteriorly to esophagus, repair if hiatal hernia defect (30 Fr esophageal bougie is used), a short (2,5 - 3,5 cm) 360° fundoplication wrap (floppy-Nissen procedure) (30 Fr esophageal bougie is used)."
1941359|NCT01409096|Drug|Pregnenolone|Pregnenolone is a naturally occurring neurosteroid that is synthesized from cholesterol in the adrenal glands and central nervous system.
1941362|NCT01408498|Drug|Testosterone|Topical administration of testosterone gel. Participants receive a one-time, single dose of 10 g of 1% testosterone gel.
1941363|NCT01408459|Dietary Supplement|Tomato Product|Motivational Telephone Counseling weekly
1941364|NCT01408459|Dietary Supplement|Control|No Motivational telephone Counseling
1941365|NCT01407926|Other|Nurse-Led Mental Health Promotion Intervention|The nurse-led intervention is a multi-faceted 6-month program led by a Registered Nurse that involves regular home visits, monthly case conferences, and evidence-based assessment and management of depression using an interprofessional approach.
1941366|NCT01406652|Procedure|Two-stage bursectomy|Debridement, drainage, and secondary closure of septic bursitis during two surgical interventions
1941370|NCT01406223|Drug|Varenicline|
1941371|NCT01406223|Drug|Bupropion|
1941372|NCT01406223|Drug|Nicotine patches|
1941373|NCT01406223|Other|Placebo varenicline|
1941374|NCT01406223|Other|Placebo bupropion|
1941375|NCT01406223|Other|Placebo patch|
1941376|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
1941377|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
1941378|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16.
1941379|NCT01405196|Biological|PF-04236921|subcutaneous injection; administered at day 1, weeks 8, 16
1941380|NCT01405144|Drug|5-fluoruracil|5% 5-fluoruracil cream, twice a day, during 3 weeks
1941381|NCT01405144|Procedure|5-fluoruracil|The same 30 patients will be submitted to 4 weekly application of superficial peeling using 5% 5-fluoruracil in propyleneglycol as vehicle. The applications will be performed by physician (one of the co-investigators)
1941382|NCT01403116|Drug|oral testosterone undecanoate|Starting dose: 200 mg T (as TU) BID. Doses may be titrated up to a maximum dose of 300 mg T (as TU) BID or down to a minimum dose of 100 mg T (as TU) BID based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
1941383|NCT01403116|Drug|topical testosterone gel 1%|Starting dose: 5 g T applied once daily. Doses may be titrated up to a maximum dose of 10 g daily or down to a minimum dose of 2.5 g daily based on serum T values collected at 4-6 hours post AM dose on Days 30 and 60.
1941384|NCT01404013|Drug|ICS/LABA|Budesonide 160µg and Formoterol 4.5µg, 1puff ,twice a day, for 8 weeks
1941385|NCT01404013|Drug|Montelukast|Montelukast 10mg ,every night, for 8 weeks
1941386|NCT01404013|Drug|ICS/LABA and Montelukast|Budesonide 160µg and Formoterol 4.5µg, 1puff, twice a day, for 8 weeks; Montelukast 10mg ,take orally ,every night for 8 weeks
1941387|NCT01404000|Drug|Iodinated Active Charcoal (IodoCarb)|3 g will be given as an oral suspension once daily for 56 days
1941388|NCT01403246|Drug|Lenalidomide; Chlorambucil|MTD of lenalidomide given in combination with chlorambucil
1941389|NCT01402011|Procedure|shoulder injections|injections of 1 mL of solution in the following tendons: supraspinatus, infraspinatus, teres minor ( on greater tuberosity), subscapularis ( on lesser tuberosity), long tendon of biceps ( on supra-glenoid tubercle), short tendons of biceps on coracoid process, and the inferior glenohumeral ligament, anteriorly and posteriorly. If symptomatic the insertion of the teres minor and the triceps on the scapula.
1941390|NCT01402492|Drug|Buprenorphine + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
1941391|NCT01402492|Drug|Placebo + Naltrexone|Following a successful naloxone challenge, induction onto extended-release naltrexone by injection (Vivitrol®), and a final assessment of eligibility, participants will be randomly assigned to one of the three conditions: 4mg buprenorphine plus naltrexone, 16 mg buprenorphine plus naltrexone, or placebo plus naltrexone for 8 weeks of treatment. Random assignment will be on a 1:1:1 ratio to one of three conditions. Randomization will be stratified according to site and opioid use levels.
1941395|NCT01400477|Drug|DMXB-A-SR|Experimental Study Drug: 3-2, 4 dimethoxybenzylidene anabaseine sustained release (DMXB-A-SR)
1941396|NCT01400477|Other|Placebo|Placebo Comparator
1941397|NCT01400308|Drug|Mupirocin + Chlorhexidin|"Treatment after protocol described in the Consensus document and GEIH-SEIMC SEMPSPH Version 31/10/07. It is a protocol of 5 days (nasal mupirocin and chlorhexidine, potentially plus systemic antibiotics and 7 days)"
1941398|NCT01400308|Device|Prontoderm MRSA Kit|"Treatment after protocol established for Prontoderm® for five days and eventually plus systemic antibiotics.
Prontoderm® is a Class III medical device"
1941399|NCT01398644|Other|Phlebotomy and erythrocytapheresis|Phlebotomy- removal of 500 ml whole blood Erythrocytapheresis- removal of 300-800 ml erythrocytes
1942601|NCT01153932|Drug|matched placebo|Subcutaneous injection
1941401|NCT01398358|Behavioral|Parents of Preschoolers Series|"The POPS-Parent intervention consists of eight 60-90 minute lessons about preventing childhood obesity followed by four 10-minute reinforcing telephone contacts. Each lesson includes opportunities for parents to develop and practice skills, and a discussion of strategies to overcome challenges and problem-solving techniques, with an emphasis on building knowledge and self-efficacy.
The POPS-Child Intervention uses children's stories with embedded healthy nutrition themes. Five lessons (6 books) are delivered over 12 weeks. Activities include classroom cooking experiences, games/activities associated with the story's nutrition themes, and goal setting. Family Links and Parent Pages are sent home to reinforce content from school to home."
1941402|NCT01398358|Behavioral|Incredible Years Series|"The Parent component (BASIC) is a group-based program (12-14 weeks, 2 hours/week) focused on enhancing parenting skills such as using effective praise, incentives, and limit-setting, and handling misbehavior. Parents complete homework activities that will be reviewed in group sessions and receive follow-up reinforcement phone calls.
For the Child component (Dinosaur School), 60, 15-20 minute lessons are delivered during Circle Time in Head Start classrooms followed by small group activities. The curriculum focuses on teaching self-regulation skills, problem-solving strategies, and prosocial behaviors.
Teachers are trained in classroom management strategies."
1941403|NCT01396616|Device|Experimental - Toric Intraocular lenses|Toric Intraocular Lenses will be implenated with cataract patients having astigmatism
1941404|NCT01397422|Drug|ADS-5102 (extended release amantadine HCl)|Oral capsules to be administered once daily at bedtime, for 8 weeks
1941405|NCT01397656|Procedure|Bystander CPR using 30:2 ratio versus continuous compression|Participants will use 2 CPR techniques, one with 30 compressions to 2 ventilations and the other with continuous compressions without ventilation
1941406|NCT01396317|Drug|Tocilizumab|Tocilizumab is a humanized anti-interleukin-6 receptor antibody that has been FDA approved for the treatment of rheumatoid arthritis (RA). This molecule binds to the IL-6 binding site of human IL-6 receptor, and competitively inhibits IL-6 signaling.
1941408|NCT01394796|Dietary Supplement|Epigallocatechin-3-gallate (EGCG)|EGCG normally works as a dietary supplement. EGCG administration in Down syndrome patients will result in an improvement of their cognitive performance.A a daily oral dose containing 9 mg/kg (range 6.9-12.7) of EGCG is given during three months.
1941409|NCT01394796|Drug|Placebo|No active treatment is given.
1941411|NCT01394081|Other|Enhanced Enrollment or Engagement (EEE) Intervention Outreach A|A consists of motivational interviewing, education outreach, and patient navigation.
1941412|NCT01394081|Other|Outreach B - modified EEE|Consists of education and patient navigation
1941413|NCT01394081|Other|Outreach C (Control)|Outreach C is education only (about VA resources and medical care)
1941414|NCT01394003|Drug|LY2584702|administered orally
1941415|NCT01393977|Procedure|rehabilitation of limb function|only receive rehabilitation of limb function
1941416|NCT01393977|Procedure|Stem Cells Transplantation|mesenchymal stem cells derived from umbilical cord are transplanted directly into subarachnoid by Lumbar puncture
1941417|NCT01393158|Drug|Apremilast|30 mg by mouth twice daily for a total of 124 weeks.
1941418|NCT01393522|Drug|Milnacipran|titration schedule starting with 12.5mg per day increasing to 50mg twice a day, starting with day 1 to day 90 and then will taper down.
1941419|NCT01393522|Drug|Placebo|Tablet will be titrated 1 tablet once a day increased per protocol to 2 tablets twice a day, with a starting dose of 12.5mg per day to 50 mg twice a day
1941420|NCT01392963|Drug|Clostridium botulinum toxin type A neurotoxin complex|Botulinum Toxin Type A: Neurotoxin Complex
1941421|NCT01392963|Other|0.9% NaCl solution|0.9% NaCl Solution: Placebo Comparator
1941424|NCT01392339|Procedure|Continuous Positive Airway Pressure (CPAP)|Continuous Positive Airway Pressure (CPAP) is a method of respiratory ventilation used primarily in the treatment of obstructive sleep apnea
1941427|NCT01390298|Other|Observational|Observational study only
1941428|NCT01389232|Device|SeriScaffold® Surgical Scaffold|A CE Marked, 510(k) cleared, knitted, multi-filament, bioengineered, silk mesh indicated for use as a transitory scaffold for soft tissue support and repair
1941429|NCT01389362|Drug|Chinese herbal medicine (Radix Rehmanniae and Radix Astragali)|2 sachets to be taken daily
1941430|NCT01389362|Drug|Placebo comparator|2 sachets to be taken daily
1941431|NCT01388712|Dietary Supplement|Lactobacillus reuteri DSM 17938|Patients, who met inclusion criteria, will receive following medicaments during 8 weeks: Lactobacillus reuteri DSM 17938 in form of chewing (one tablets containing 10^8CFU).
1941432|NCT01388712|Dietary Supplement|Placebo|Patients, who met inclusion criteria, will receive an identical to probiotic looking and tasting placebo.
1941433|NCT01389128|Other|protocol with non pharmacological resources|application protocol using the combination of non-pharmacological resources: standing upright pelvic mobility in the ball, alternating stance associated with lumbosacral massage and shower;
1941465|NCT01378676|Drug|Placebo|Three matching placebo tablets once daily for 14 days (Part A) or three matching placebo tablets once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
1941566|NCT01355796|Drug|Xylo-pentane-1,2,3,4 5-pentol|5 ml of 15 % aerosolized 2 times per day
1943016|NCT01052155|Other|Urine Drug Testing|LC/MS/MS Laboratory Evaluation
1941434|NCT01387633|Other|Educational intervention for family members/caregivers of people with diabetes mellitus through telephone contact|For family members/caregivers: telephone contacts will be conducted in day and time which family member/caregiver prefers, and he/she may make collect calls to the researcher always he/she judges it necessary during the period of study. Phone contacts will be recorded to ensure the registration of orientation given, using a digital phone recorder PCTEL. And they will be arranged with the technique of motivational interviewing that includes the skills to ask, listen and inform. For this, protocols based on these skills, which the covered topics will be those worked in group sessions through Diabetes Conversation Maps. Voice quality related to the tone, volume and clarity as well as the skills and strategies to listen to the interviews will be worked under the guidance of an audiologist
1941435|NCT01387633|Other|Educational intervention group for people with diabetes through Diabetes Conversation Maps|For people with diabetes mellitus: educational interventions will be conducted in accordance with the assumptions of the Social Cognitive Theory, through Diabetes Conversation Maps , whose use is consistent with this theory (ADA, 2007). Diabetes Conversation Maps are a tool which involves people in the learning process about the disease, to make them able to process information more effectively and use them in making daily decisions in the management of diabetes mellitus (DM). It is recommended that this tool is used in small groups of three to ten people, in order to provide dynamic discussions among the participants (ADA, 2007). Currently, the maps that cover the following learning contexts: How the Body and Diabetes Work, Healthy Eating and Physical Activity, and Medication Treatment and Monitoring of Blood Glucose; Achieving the Goals with the Insulin and Weather Map of Diabetic Foot are available for the Brazilian Portuguese language.
1941436|NCT01387607|Drug|pregabalin|Pregabalin capsule, 300-450mg/day, twice daily
1941437|NCT01387607|Drug|placebo|Placebo, twice daily
1941438|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Phacoemulsification through small clear corneal incision
1941439|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Phacoemulsification through clear corneal incision
1941440|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Microcoaxial Phacoemulsification through 1.8mm incision
1941441|NCT01385878|Procedure|Microcoaxial Phacoemulsification|Microcoaxial phacoemulsification through 2.2mm incision
1941442|NCT01385176|Device|Vagal Nerve Stimulation|Patients randomized to therapy arm with receive right vagal nerve stimulation. Patients randomized to control arm will not receive right vagal nerve stimulation for the first 6-months post-implant, after which they will also receive therapy.
1941443|NCT01384799|Drug|CUDC-101|CUDC-101 will be administered as a 1 hour intravenous infusion three times per week for a one week run-in (week -1) and then as part of the combination treatment on weeks 1-7. If the 225 mg/m2 dose is tolerated in the first cohort, the dose will be increased to 275 mg/m2. If the 225 mg/m2 dose is not tolerated, the dose will be decreased to 175 mg/m2. If 175 mg/m2 is not tolerated the dose will be further decreased to 150 mg/m2.
1941444|NCT01384799|Drug|Cisplatin|Cisplatin will be administered intravenously at a dose of 100 mg/m2 on days 2, 23 and 44 of the seven week combination treatment course.
1941445|NCT01384799|Radiation|Radiation Therapy|The initial target volume encompassing the gross and subclinical disease sites will receive 2.0 Gy per fraction, five fractions per week. The gross disease sites will receive 70 Gy in 35 fractions over seven weeks and the subclinical disease sites will receive 56 Gy in 35 fractions, again over seven weeks.
1941446|NCT01385098|Dietary Supplement|Vitamin D3 and Calcium|1500 mg of calcium citrate plus 1000 IU of vitamin D3 and 1000 IU of vitamin D3 bariatric supplements per day
1941447|NCT01383135|Drug|FPPRGD2|radiopharmaceutical administered for imaging, up to 14 mCi i.v.
1941448|NCT01383018|Device|AMS Penile Prosthesis Devices|Non-interventional device registry. Outcomes for patients receiving marketed AMS penile prosthesis devices.
1941449|NCT01380275|Drug|Docetaxel (Taxotere)|This study : Docetaxel 100 mg/m2 mixed in D5W or N/S IV over 60 min: Day 1. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
1941450|NCT01380275|Drug|Irinotecan|This study : Irinotecan 80 mg/m2 mixed in D5W IV over 90 min: Days 1 and 8. Premedications : Dexamethasone 3 mg/m2 PO or IV 12 hours and 1 hour prior to docetaxel administration. A third dose of dexamethasone will be given 8 hours following docetaxel infusion. Patients should not be treated with docetaxel if they did not start the PO premedication the previous day. Parenteral pheniramine maleate may be given prior to docetaxel if patient has had a previous hypersensitivity to the agent. If used, pheniramine maleate (1 mg/kg IV) should be administered 30 minutes prior to infusion and every six hours thereafter, as needed.
1941451|NCT01382680|Device|Guidewire|Use of a guidewire at ERCP for cannulating a stenosis of the biliary tract and for applying a therapeutic device (stent, dilation catheter, others)
1941452|NCT01381822|Drug|TH-302|TH-302: administered by IV infusion over 30 or 60 minutes on Days 8, 15 and 22 of a 42 day cycle.
1941453|NCT01381796|Drug|NP101|comparison of NP101 with minor patch modifications
1941454|NCT01381796|Drug|sumatriptan succinate|tablet, 100 mg
1941455|NCT01380119|Biological|V7|experimental arm
1941456|NCT01380119|Other|placebo|placebo pill
1941461|NCT01379508|Drug|Telbivudine 600mg|
1941462|NCT01379508|Drug|Tenofovir disoproxil fumarate 300mg|
1941463|NCT01378923|Behavioral|REVAMP|The Re-entry values and mindfulness program (REVAMP) is an 8 session group intervention designed for jail inmates nearing release into the community
1941464|NCT01378923|Behavioral|TAU|have access to standard jail programs and services
1941466|NCT01378676|Drug|CK-2017357|One 125 mg CK-2017357 tablet and two matching placebo tablets once daily for 14 days (Part A) or one 125 mg CK-2017357 tablet and two matching placebo tablets once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
1941467|NCT01378676|Drug|CK-2017357|Two 125 mg CK-2017357 tablets and one matching placebo tablet once daily for 14 days (Part A) or two 125 mg CK-2017357 tablets and one matching placebo tablet once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
1941468|NCT01378676|Drug|CK-2017357|Three 125 mg CK-2017357 tablets once daily for 14 days (Part A) or three 125 mg CK-2017357 tablets once daily for 14 days taken concurrently with 50 mg riluzole (Part B)
1941472|NCT01375946|Drug|AG200-15|A transdermal contraceptive delivery system for LNG and EE. A total of 3 patches will be worn during the study. Each patch will be worn for 1 week followed by a patch free week.
1941473|NCT01375634|Drug|Midazolam|2 mg intravenous over 2 minutes For patients >60 years of age or with history of pulmonary disease, 1 mg intravenous over 2 minutes
1941474|NCT01375400|Drug|Aspirin|Administration of 300 mg of aspirin, per os.
1941475|NCT01375400|Biological|blood sample|2 blood samples will be performed
1941476|NCT01375374|Drug|Lacosamide|4-Week Titration Period: start dose Lacosamide (LCM) is 100 mg/day - up-titration of 100 mg/week LCM 8-Week Maintenance Period: dose can change first 4 weeks with 100 mg/week, must remain between 300 mg/day and 600 mg/day. Dose must remain stable last 4 weeks.
1941477|NCT01375374|Drug|Levetiracetam|Levetiracetam (LEV) is taken at a stable dose 30 days before study entry and is ≥ 1000 mg/day at the first visit. The LEV dose may not be changed at any time.
1941478|NCT01375010|Drug|Vitamin D3|2000 mg QD
1941479|NCT01375010|Other|Placebo|An inactive treatment that is intended to provide baseline measurements for the experimental protocol of a clinical trial, in this case, the vitamin D3.
1941480|NCT01375010|Drug|Vitamin Supplements|Specially formulated supplements (Tishcon, Inc.) that contain 500 mg of calcium (carbonate) and 500 IU of vitamin D3 to be taken twice daily with breakfast and dinner (1000 mg of elemental calcium and 1000 IU of vitamin D).
1941481|NCT01374516|Biological|Live, attenuated, dengue serotype 1, 2, 3, 4 virus|0.5 mL, Subcutaneous
1941482|NCT01374516|Biological|Placebo: NaCl 0.9% solution|0.5 mL, Subcutaneous
1941483|NCT01374932|Device|CPAP|Continuous positive airways pressure (CPAP)
1941485|NCT01373229|Drug|Lenalidomide + Plerixafor (+ Rituximab)|"Lenalidomide 5mg by mouth (PO) daily beginning cycle 1 day 1.
Stage 1: increase by 2.5mg every 7 days to a maximum dose of 10mg.
Stage 2: plerixafor will be added after 28 days of 10mg dose maintenance and white blood cell count (WBC) <100.0 x 109 / L.
Dose cohorts of escalating subcutaneous (SC) thrice weekly plerixafor with continuous 10mg lenalidomide:
Cohort 1: 0.24 mg/kg
Cohort 2: 0.32 mg/kg
Cohort 3: 0.42 mg/kg
Cohort 4: 0.54 mg/kg
Stage 3: Rituximab 375mg/m2 will be added on day 1 of cycles 5-12, day 1 of combination therapy for subjects with PR.
Subjects will then continue single agent lenalidomide until disease progression."
1941488|NCT01372683|Other|Dietary Intervention|Comparison of oat based breakfast cereals
1941489|NCT01372085|Drug|LY2584702 Reference Formulation|Administered orally
1941490|NCT01372085|Drug|LY2584702 Test Formulation|Administered orally
1941491|NCT01372085|Drug|Placebo|Administered orally
1941492|NCT01370811|Drug|OC oral solution treatment A|
1941493|NCT01370811|Drug|OC oral solution treatment B|
1941494|NCT01370811|Drug|OC oral solution treatment C|
1941495|NCT01370811|Drug|OC oral solution treatment D|Placebo
1941498|NCT01371279|Device|Intra-Cardiac Echocardiography guided atrial fibrillation ablation|8-F or 10-F phase array ICE-probe
1941499|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The Zemaira® dose used will depend on the patient's body weight. For example, a patient weighing 150 pounds would be infused with approximately ½ cup containing 8.4 grams of Zemaira®. Patients will be admitted to hospital for infusion. The I.V. infusion will be approximately 1 teaspoon/minute. Patients will receive weekly infusions of Zemaira® for 8 or 12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood will be collected (IRB approval #R04-003). The blood sample will be used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
1941500|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The Zemaira® dose used was dependent on the patient's body weight. For example, a patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of Zemaira®. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of Zemaira® for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
1941535|NCT01362322|Biological|Boostrix TM (new syringe presentation)|Single dose, intramuscular administration in a new syringe presentation
1941536|NCT01362322|Biological|Boostrix TM (previous syringe presentation)|Single dose, intramuscular administration in previous syringe presentation
1941564|NCT01355874|Drug|Iferanserin + Placebo|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 7 days followed by placebo ointment BID for 7 days during the double blind.
1941501|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The Zemaira® dose was dependent on the patient's body weight. For example, a patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of Zemaira®. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of Zemaira® for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
1941502|NCT01370018|Biological|alpha-1-Proteinase Inhibitor|The alpha-1-Proteinase Inhibitor dose used was dependent on the patient's body weight. For example, a patient weighing 150 pounds was infused with approximately ½ cup containing 8.4 grams of alpha-1-Proteinase Inhibitor. Patients were admitted to hospital for infusion. The I.V. infusion was approximately 1 teaspoon/minute. Patients received weekly infusions of alpha-1-Proteinase Inhibitor for 8-12 weeks. At the time of infusion, 40ml (3 Tablespoons) of blood was collected (IRB approval #R04-003). The blood sample was used to monitor viral load, CD4 cell numbers and function, cholesterol, triglycerides, LDL and HDL, and alpha-1-Proteinase Inhibitor.
1941503|NCT01369342|Drug|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
1941504|NCT01369342|Drug|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
1941505|NCT01369342|Drug|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).
1941506|NCT01369329|Drug|Group 2 ustekinumab 130 mg|Type=exact, unit=mg, number=130, form=solution for injection, route= intravenous use, in a single dose.
1941507|NCT01369329|Drug|Group 3: ustekinumab approximately 6 mg/kg|Type=range, unit=mg/kg, number=6, form=solution for injection, route= intravenous use, in a single dose.weight-range based ustekinumab doses approximating ustekinumab 6 mg/kg: 260 mg (weight <= 55 kg), 390 mg (weight > 55 kg and <= 85 kg), and 520 mg (weight > 85 kg).
1941508|NCT01369329|Drug|Group 1: Placebo|Form=solution for injection, route=intravenous use, in a single dose.
1941511|NCT01368549|Other|Metanx® (a medical food)|Metanx® is an orally-administered medical food, and each tablet contains 3mg of L-methylfolate, 35mg of Pyridoxal-5'-phosphate, and 2 mg of Methylcobalamin- which are the biologically active and immediately bioavailable forms of folate, vitamin B6, and vitamin B12, respectively. Dosage will be 1 tablet BID.
1941512|NCT01367275|Drug|Brivanib|800 mg (4 x 200 mg tablets) self-administered orally at approximate same time each day on a continuous daily schedule Days 1-14 of 14 day cycle.
1941513|NCT01367275|Drug|Irinotecan|180 mg/m^2 by vein on Day 1 of a 14 day cycle.
1941516|NCT01364584|Drug|Exenatide|Subcutaneous injection 2.5 micrograms (mcg) to 10 mcg twice per day (BID)
1941517|NCT01364584|Drug|Placebo|Subcutaneous injection 2.5 mcg-10 mcg BID
1941518|NCT01364233|Device|MotifMESH|Polytetrafluoroethylene (cPTFE) macroporous mesh
1941519|NCT01364233|Device|MotifMESH|Surgical mesh
1941523|NCT01363479|Drug|Oral palonosetron|
1941524|NCT01363479|Drug|I.V. palonosetron|
1941525|NCT01363479|Drug|Dexamethasone|
1941528|NCT01362309|Drug|d-cycloserine.|50 mg administered on two occasions.
1941529|NCT01362790|Drug|Pentostatin|Regimen A: Cycle 1: 4 mg/m2 on days 1, 5 and 9 of 30 day cycle Cycles 2-4: 4 mg/m2 on day 1 of 21 day cycle Regimen B: Cycle 1: 4 mg/m2 on days 1, 5, 9, 13 and 17 of 38 day cycle Cycles 2-6: 4 mg/m2 on days 1 and 5 of 25 day cycle
1941530|NCT01362790|Drug|Cyclophosphamide|Regimen A:Cycle 1: 200 mg/day on days 1-12 of 30 day cycle Cycles 2-4: 200 mg/day on days 1-4 of 21 day cycle Regimen B:Cycle 1: 200 mg/day on days 1-20 of 38 day cycle Cycles 2-4: 200 mg/day on days 1-8 of 25 day cycle
1941531|NCT01362790|Biological|SS1(dsFv)PE38 - lot 073I0809|Regimen A: Cycle 1: assigned dose level on days 10, 12 and 14 of 30 day cycle Cycles 2-4: assigned dose level on days 2, 4 and 6 of 21 day cycle Regimen B: Cycle 1: assigned dose level on days 18, 20 and 22 of 38 day cycle Cycles 2-4: assigned dose level on days 6, 8 and 10 of 25 day cycle
1941532|NCT01362790|Biological|SS1(dsFv)PE38 - lot FIL129J01|"Regimen A:
Cycle 1: assigned dose level on days 10, 12 and 14 of 30 day cycle Cycles 2-4: assigned dose level on days 2, 4 and 6 of 21 day cycle"
1941533|NCT01362140|Drug|Darbepoetin alfa|Administered by subcutaneous injection every 3 weeks
1941534|NCT01362140|Drug|Placebo|Administered by subcutaneous injection every 3 weeks
1941537|NCT01361919|Procedure|Feedback during CPR training|"Students in this group will receive training in BLS skills according to the 2005 AHA/ILCOR guidelines, using the ZOLL R Series™ defibrillator with an attached accelerometer pad that will be placed on the sternum of the manikin and visible to the user. Students will be told to perform compressions on top of the accelerometer pad. Participants will be taught to use and follow the audio and visual feedback provided by the accelerometer and defibrillator to optimize their CPR performance (depth, rate, and minimal hands-off time). After the simulated cardiac arrest scenario, a data card containing the raw data collected from the accelerometer and defibrillator will be downloaded onto a laptop and used as a demonstration and training tool. This data will be used to correct the students' performance by visually demonstrating the difference between ideal and suboptimal CPR performance."
1941538|NCT01361919|Procedure|No Feedback during CPR Testing or Training|"A standard no feedback defibrillator (ZOLL M series) will be used for teaching, immediate testing and 12 week (retention) testing. In order to collect CPR performance data, a simulation manikin with an attached accelerometer pad hidden from view within its chest will be used. Subjects will be told to perform compressions on top of the manikin's chest. During the test, subjects will be informed that data on their performance will be recorded but they will not be told how this will occur."
1941539|NCT01361919|Procedure|Feedback During CPR Testing|Students in this group will be tested using a five minute basic vfib arrest scenario and an R-series defibrillator and told to perform compressions on top of the accelerometer pad. The hexagonal icon will be visible but no prompting on its usage will be delivered during testing.
1941540|NCT01361919|Procedure|No Feedback During CPR Testing|"A standard no feedback defibrillator (ZOLL M series) will be used for immediate testing and 12 week (retention) testing."
1941541|NCT01361217|Drug|Fluoxetine|1x20mg oral fluoxetine capsules by mouth daily on Study Day 5, then 3x20mg fluoxetine capsules by mouth daily on Study Days 6 through 18.
1941542|NCT01360398|Procedure|Blood sample|Blood samples will be collected from all patients at enrolment, at follow-up visits, at exacerbation visits, and during the final visit.
1941543|NCT01360398|Procedure|Sputum sample|Sputum will be collected from all patients at enrolment, at monthly follow-up visits, at exacerbation visits, and during the final visit. Sputum will be obtained by spontaneous expectoration or induced by stimulation according to standard methods.
1941544|NCT01360398|Procedure|Nasopharyngeal swab|Nasopharyngeal swabs will be collected from all patients at enrolment and from a subcohort of 30 patients at monthly follow-up visits and at exacerbation visits during the first year.
1941545|NCT01360398|Procedure|Urine sample|Urine samples will be taken at enrolment and exacerbation visits from all subjects and from the same subcohort of 30 patients providing nasopharyngeal swabs, at monthly follow-up visits during the first year.
1941546|NCT01360398|Procedure|End tidal breath sample|Breath samples will be collected from all patients at enrolment, at follow-up visits (monthly), at exacerbation visits, and during the final visit.
1941547|NCT01360398|Other|Data collection|Patient interview, diary cards review and questionnaires completion
1941548|NCT01360398|Other|Tests|Urine pregnancy test, chest CT-scan, lung function testing and 6-min walk test
1941549|NCT01360242|Procedure|MIMI procedure (two-step strategy)|A second coronary angiogram is performed 24-48 hours later and the physician is free to decide on the best treatment, i.e. surgery, medical treatment, or stent implantation (drug-eluting stent if indicated for on-label patients). If stenting is required and the thrombus is still too large (greater than twice the artery width), the physician could postpone stent implantation for days or weeks.
1941550|NCT01360242|Procedure|Immediate Stenting (one-step strategy)|The physician is encouraged to implant a stent after the thrombus aspiration (drug-eluting stent if indicated for on-label patients).
1941553|NCT01359722|Drug|N-acetylcysteine|N-acetylcysteine is administered at a dose of 150mg/kg in 500mL of saline EV in 1 hour followed by a dose of 50mg/kg in 500 mL of saline IV within 6 hours, beginning the infusion together to surgery.
1941554|NCT01359722|Drug|Control|The control group will receive only the infusion of saline in the same doses and infusion rate.
1941556|NCT01357785|Procedure|Cell therapy|The use of periodontal ligament stem cells for periodontal regeneration
1941557|NCT01357564|Other|Tailored Activity Program|Intervention Protocol: In session #1, the interventionist, an occupational therapist (OT), meets with the caregiver and introduces the intervention goals. The OT provides and reviews a 3-ring binder which contains written educational materials about dementia, importance of taking care of self, communication strategies and other educational materials. Also provided and reviewed will be a copy of Mace and Rabins' book, The 36 Hour Day. The OT will interview the caregiver to obtain information about previous roles, habits, past and current daily routines, caregiver and Veteran preferences and interests. The OT will also observe interactions, noting communication and management style. The OT will also meet with the Veteran, observe social capacity using the Peavy Comportment scale and administer the Dementia Rating Scale (DRS-2).
1941560|NCT01355575|Drug|Rifaximin|Rifaximin tablet, oral administration, 400mg twice daily for 6 weeks.
1941561|NCT01355900|Procedure|Total knee arthroplasty performed under tourniquet|Comparison of the different tourniquet tactics.
1941562|NCT01355874|Drug|Iferanserin|0.5% iferanserin ointment (containing 10 mg of iferanserin) BID for 14 days during double blind.
1941563|NCT01355874|Drug|Placebo|Placebo ointment BID for 14 days during double blind.
1941565|NCT01355796|Drug|Xylitol|Aerosolized 15% xylitol, 5 ml twice a day for 2 weeks
1941567|NCT01355341|Drug|HERBMED PLUS|500 mg Twice day for 6 month with lunch and dinner.
1941568|NCT01355497|Drug|GTx-024|subjects will be randomized to receive GTx-024 for the duration of the trial.
1941569|NCT01355497|Drug|placebo|subject will receive placebo for the duration of the trial
1941570|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 0.3 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
1941571|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 2.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
1941572|NCT01354431|Biological|nivolumab|Solution, Intravenous (IV), 10.0 mg/kg, every 3 weeks (Q 3 weeks), Until Progressive disease (PD), toxicity or discontinue for other reasons
1941574|NCT01353495|Device|APM Graft (BIOTAPE XMTM)|Patients randomized to the APM group will, following surgical debridement for their diabetic foot wounds, receive a single application of an APM graft (BIOTAPE XMTM, Wright Medical Technology, USA) with dressing changes taking place weekly. All necrotic tissue will be removed from the wound prior to application. BIOTAPE XMTM will be sutured or stapled in place under a silver-based non-adherent dressing (Silverlon, Argenta Medical). Therapy will then be followed by a moisture-retentive dressing (hydrogel bolster) until complete epithelialization has occurred.
1941577|NCT01351545|Drug|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs)|A multicenter access and distribution protocol for unlicensed cryopreserved cord blood units (CBUs) for transplantation in pediatric and adult patients with hematologic malignancies and other indications
1941578|NCT01350934|Drug|alendronate 70-mg/vitamin D3 5600 IU combination tablet (Fosamax Plus)|one combination tablet once weekly
1941579|NCT01350934|Drug|Calcitriol|0.25 μg once daily orally
1941580|NCT01350934|Dietary Supplement|Calcium 500 mg|one 500 mg tablet once daily
1941581|NCT01350453|Behavioral|LifeCIT|Participants will be asked to aim to wear the C-MIT for 9 hours a day for 5 days/week, including 4-6 hours of structured activities per day: two 30-60 minute sessions of web-based activities and 3-4 hours practicing everyday activities.
1941582|NCT01350453|Behavioral|Standard Care|Participants will receive their usual care from their NHS provider.
1941583|NCT01350102|Drug|Bacitracin|Participants will be treated with Bacitracin to their wound until 100% wound healing, which may take up to 6 months to achieve.
1941584|NCT01350102|Drug|AmeriGel®|Participants will be treated with AmeriGel® to their wound until 100% wound healing, which may take up to 6 months to achieve.
1941585|NCT01350102|Procedure|Hemoglobin A1c|Hemoglobin A1c levels will be performed and reviewed every three months to assess its relationship to wound healing
1941586|NCT01350102|Dietary Supplement|Vitamin C|Participants will be treated with Vitamin C supplements 1000 mg daily until 100% wound healing, which may take up to 6 months to achieve
1941587|NCT01350141|Other|Placebo|An infusion lasting approximately 60 minutes
1941588|NCT01350141|Drug|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
1941589|NCT01350141|Drug|PF-04950615 (RN316)|An infusion lasting approximately 60 minutes
1941590|NCT01348906|Procedure|intermittent normoxia|3 cycles of 5/5 min normoxia/hyperoxic reperfusion during cardioplegia arrest in adult valve replacement
1941591|NCT01347866|Drug|PF-05212384|PF-05212384 intravenous infusion weekly starting at 110 mg.
1941592|NCT01347866|Drug|PD-0325901|PD-0325901 Oral twice daily (BID) dosing 2 mg BID 3 weeks on 1 week off
1941593|NCT01347866|Drug|PF-05212384|PF-05212384 intravenous infusion weekly starting at 95 mg.
1941594|NCT01347866|Drug|irinotecan|Irinotecan by intravenous infusion at 180 mg/m2 every two weeks (Q x 2 week)
1941595|NCT01347801|Drug|GLP-1|GLP-1 1,2pmol/kg/min i.v. infusion for 4 hours
1941596|NCT01347801|Drug|Placebo (Saline)|Normal saline (NaCl 0,9%)
1941597|NCT01347801|Drug|TNF-alfa|1000ng/m2 BSA/hour i.v. infusion for 4-6 hours
1941598|NCT01347801|Other|OGTT|Oral glucose tolerance test with 75 g glucose
1941599|NCT01347801|Other|IVGTT|Intravenous glucose tolerance test with infusion of 20% glucose matching the glucose profile of the corresponding OGTT
1941600|NCT01347593|Drug|ceftizoxime|ceftizoxime (cefizox) injection either after clamping the cord
1941601|NCT01346371|Drug|Bepreve (bepotastine ophthalmic solution) 1.5%|Must add drops twice a day every day while enrolled in trial.
1941603|NCT01346137|Drug|Meloxicam|15 mg versus 30 mg per day P.O. for 15 days during 3 menstrual cycles
1941606|NCT01345188|Drug|Ranexa|1000 mg Ranexa orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
1941607|NCT01345188|Drug|Placebo|1000 mg placebo orally once daily titrated as tolerated after 1 week up to taking 1000 mg twice daily.
1941608|NCT01344239|Procedure|Limb remote ischemic preconditioning(LRIP)|LRIP consisted of three cycles of left upper limb ischemia induced by inflating a blood pressure cuff on the left upper arm to 200mmHg, with an intervening 5 minutes of reperfusion, during which time the cuff was deflated.
1941609|NCT01344226|Drug|loteprednol 0.5% ophthalmic solution|Lotemax to be used QID starting day of cataract surgery and 21 days after for total of 22 days.
1941610|NCT01344083|Drug|T1210|2 drops T1210 once a day
1941611|NCT01344083|Drug|Olopatadine hydrochloride|2 drops once a day Olopatadine
1941612|NCT01343095|Device|Foam Earplugs|Standard Foam Earplugs applied from 10pm-6am nightly. (Sperian Technologies, manufacturer)
1941613|NCT01343095|Device|Noise Canceling Headphones|Noise Canceling headphones applied over the ears between 10pm-6am nightly. Model is Bose QuietComfort 15, manufactured by Bose Technologies.
1941614|NCT01342588|Procedure|Electric pulse train stimulation|Electric pulse train stimulation of regular probes and screw drivers used in track creation and screw placement Using a standard neurophysiological work station, a series of square wave pulses will be delivered through standard probes and screw drivers using an alligator clip during pedicle probing and screw insertion (4 Hz for 50-200 μsec at 10-30 μAmp)
1941617|NCT01341405|Drug|CG100649|capsule, 2 mg, once daily for 28 days
1941618|NCT01341405|Drug|Celecoxib|capsule, celecoxib 200 mg, once daily for 28 days
1941619|NCT01341405|Drug|CG100649|capsule, 4 mg, once daily for 28 days
1941627|NCT01340898|Biological|Meningococcal vaccine GSK 134612|Intramuscular injection
1941628|NCT01340898|Biological|SynflorixTM|Intramuscular injection
1941629|NCT01340898|Biological|Infanrix-IPV/HiberixTM|Intramuscular injection
1941632|NCT01340300|Behavioral|Exercise training|Two supervised exercise sessions per week
1941633|NCT01340300|Drug|Metformin|Oral metformin QD for two weeks, then BID
1941634|NCT01340300|Other|Educational information|educational information
1941635|NCT01340339|Device|Phototherapy|Fluorescent reverse phototherapy (7 white lights 5cm below the base of acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
1941636|NCT01340339|Device|Phototherapy|super LED reverse phototherapy (17 bulbs arranged in 42 x 31 cm in blue base acrylic cot), with spectral irradiance of 8-12microwatts/cm2/nm; daily; until bilirubin reaches level that indicates suspension of therapy
1941637|NCT01339845|Biological|ShanChol|Each dose of the vaccine contains whole cell Killed inactivated V.cholerae O1 and O139 strains.Vaccine is packaged as liquid formulations in 1.5-ml doses. The vaccine is given two doses separated by a two week interval and administered orally.
1941638|NCT01339845|Behavioral|Vaccine and behaviour|Together with vaccination the community health worker will offer a hand washing station and water treatment facilities that include both hardware and a software component. The idea of the handwashing station is to bring together with soap and water that people need for handwashing, especially for handwashing after defecation. The hardware for water treatment is a chlorine dispenser that is a reservoir which holds sodium hypochlorite and dispenses a measured dose of the dilute sodium hypochlorite into a 15 liter water tank. Community residents can collect water directly from the 15 L water tanks into their own personal water storage vessels. The community health worker will negotiate with compound residents for the development of a water treatment system.
1941642|NCT01337986|Drug|Dalfampridine/Placebo|Weeks 1-3: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 5-8: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks.
1941643|NCT01337986|Drug|Placebo/Dalfampridine|Weeks 1-3: Placebo (sugar pill) 1 tablet every 12 hours for 3 weeks. Weeks 4-5: 2 weeks of wash-out. Weeks 6-8: Dalfampridine 10mg (1 tablet) every 12 hours for 3 weeks.
1941644|NCT01337869|Procedure|Bascom Cleft Lift|Patients are positioned prone. The skin incision is drawn on the natal cleft, marking out the area of skin to be excised. The skin from this side of the natal cleft is then elevated. The skin on the opposite side of the cleft then is undermined to a distance required to allow primary closure of the defect away from the midline without tension. The elevated skin island is excised. The sinuses remaining in the deeper tissues are curetted thoroughly. Hemostasis is maintained. A 12F low-suction drain is sited and fat of the natal cleft then is approximated by using an absorbable suture. The wound is closed with a 3-0 polypropylene suture.The drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
1941645|NCT01337869|Procedure|Limberg Flap|Patients are positioned prone. The area to be excised is mapped-out, and the flap is designed. The area to be excised is mapped on the skin in a rhomboid form. The skin incision is deepened to the presacral fascia. Tissue is removed en bloc. After removing the rhombic excision, the Limberg fascia cutaneous flap is prepared through the right or left-side gluteus maximus fascia. The flap is fully mobilized and transposed medially to fulfill the rhombic defect without any tension. Hemosthasis is accomplished. A 12F low-suction drain is sited and wound is closed in two layers: the subcutaneous tissue with absorbable suture and the skin with 3/0 polypropylene. drain remains in situ to time that drainage amount decreases below 20 ml/day. The suture is removed in the clinic 10 day after surgery.
1941646|NCT01337700|Drug|Milnacipran|Patients will receive a titrated dose of milnacipran increasing to a maximum of 100mg a day over the 12 week study period. Dosing will be based on a fixed schedule that will be monitored using a side effect profile.
1941647|NCT01337700|Drug|Placebo|Subjects will be given placebo tablets at dosing corresponding to the fixed schedule between 12.5mg and 100mg.
1941648|NCT01337687|Drug|Intranasal Oxytocin|Oxytocin administered intranasally twice a day via 1 12 unit puff to each nostril, totaling 48 IU a day.
1941649|NCT01337687|Drug|Placebo|Saline will be administered intranasally twice a day via 1 puff per nostril, totaling 48 IU a day.
1941650|NCT01336634|Drug|Dabrafenib|Dabrafenib study treatment will be provided by GSK as 50 mg and 75 mg hydroxypropyl methylcellulose (HPMC) capsules. Each capsule contains 50 mg or 75 mg of free base (present as the mesylate salt).
1941651|NCT01336634|Device|Trametinib|Trametinib study treatment will be provided as 0.5 mg and 2 mg tablets. Each tablet will contain 0.5 mg or 2 mg of trametinib parent (present as the DMSO solvate)
1941654|NCT01335828|Device|Medical ultrasound device (ShearWave system)|"Echography (all modes) and elastography ShearWave system"
1941655|NCT01333943|Procedure|Study Group: Experimental|The study group will receive the saphenous nerve block, at the level of the adductor canal. The block will be under ultrasound guidance. The local anesthetic will be 15 ml of 0.5% bupivicaine. The study group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
1941656|NCT01333943|Procedure|Control Group|The control group will receive the femoral nerve block. The block will be under ultrasound guidance. The local anesthetic will be 30 ml of 0.25% bupivicaine. The control group will also receive a combined spinal epidural, with 2.5 ml of 0.5% bupivacaine as the spinal agent. Additional drugs include anti-emetics, specifically Ondansetron (4 mg).
1941657|NCT01333761|Device|Cardiox FDS|The Cardiox Shunt Detection system consists of a sensor placed in contact with the outer ear, similar to a finger probe used to detect oxygen levels in blood. Through an intravenous line, ICG (indocyanine green) at a dosage of 10 mg (2 mL of 5 mg/mL ICG solution) per test, is administered into the right or left antecubital fossa. The presence of ICG in the veins within the outer ear are detected, and the results are displayed on a monitor. All patients will also be evaluated with TCD and TEE for the presence of RTLS.
1941658|NCT01332838|Procedure|Compression stockings|standard 30to 40 mm Hg thigh high compression stockings
1941659|NCT01332838|Device|compression stockings (Sigvaris )|Specialized monoleg compression
1941660|NCT01333202|Other|Fresh lime|fresh lime were used every time the participants began to crave cigarettes and as often as they needed. To correctly use it, fresh lime needed to be washed and cut into several small pieces by 1st cutting each lime into quarters and then each quarter further into 4 pieces. When needed, subjects were told to suck each piece of lime and thereafter chew the lime skin. To maintain freshness, the remaining slices were to be covered with plastic wrap and stored in the refrigerator as soon as possible.
1941663|NCT01331382|Dietary Supplement|Trans- resveratrol|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
1941664|NCT01331382|Other|Placebo (silica)|All 23 participants who completed the study took part in 3 conditions; receiving either 250mg resveratrol, 250mg resveratrol with 20mg piperine or placebo on separate days (with a 48hr-14 day wash-out period between each treatment) with the order dictated by Latin square. Treatment was in the form of powder and administered in capsule form, in a double blind manner.
1941665|NCT01331330|Device|Deep Brain Stimulation|Normal DBS Programming
1941666|NCT01331330|Device|Deep Brain Stimulation|Low Programming
1941667|NCT01331499|Device|Bipolar Sealer (Aquamantys)|Standard of care blood sparing techniques along with the use of bipolar sealer
1941668|NCT01331499|Procedure|Standard of Care|Standard of care blood sparing techniques without the useof bipolar sealer
1941669|NCT01331408|Device|Macrolane VRF30|Injection of Macrolane VRF30 in buttocks. The sum of injected volume of Macrolane VRF30 at initial treatment and touch-up must not exceed 400 ml per Subject
1941670|NCT01331759|Device|Neuropattern™|Neuropattern™ is a diagnostic tool aiming at measuring states of activity and reactivity of interfaces involved in the communication between the brain and peripheral bodily organs in stressful situations. The concept of Neuropattern™ assumes the states of the various interfaces to be describable by characteristic patterns of simultaneous activation of biological, psychological and symptomatic variables. Neuropattern™ assesses endophenotypes through the medical history, various questionnaires for the patient or study subject, analyses of saliva cortisol and the heart rate variability and derives hypotheses on recommendations for an effective and efficient treatment.These recommendations are based on evaluated medical and psychological therapeutic methods but specified through additional biopsychological understanding. This form of individualized therapy should reduce nonresponsiveness to therapy.
1941671|NCT01331161|Biological|ZOSTAVAX|shingles vaccine, one dose
1941672|NCT01330706|Drug|Polihexanide|The investigators compared intraoperative antiseptic irrigation using 0.9% saline solution and 0.1% polihexanide.
1941673|NCT01330134|Drug|lidocaine|2ml 1% lidocaine placed onto surface of the skin immediately prior to 1% lidocaine subcutaneous injection
1941674|NCT01330134|Drug|lidocaine|1% lidocaine subcutaneous injection alone
1941675|NCT01330082|Other|Adjunctive Photodynamic Therapy|using Light-emitting diod(LED) (625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark) in the presence of toluidine blue O (TBO)
1941676|NCT01330082|Other|Light-emitting diod Irradiation|625-635nm,200mw/cm2 ,30 s for each site, fotoson CMS Dental ,Denmark
1941677|NCT01330082|Other|applying Photosensitizer|toluidine blue O is applied at the bottom of each periodontal pocket
1941678|NCT01329042|Drug|Potassium-sodium citrate|The treated group was given oral potassium-sodium citrate 81 mEq/day The control group received no treatment
1941679|NCT01328015|Drug|Oxybutynin 5 mg pills|"½ pill oral 12/12h for 3 days
01 ½ pills oral morning and evening for 3 days Continue 1 pill oral 2x/day for three weeks."
1941680|NCT01328002|Drug|Milnacipran|Maximum tolerated dose (50, 75, or 100 mg/day tablets) determined at start of study; for 8 weeks
1941681|NCT01328002|Drug|Placebo|matching placebo tablets daily
1941682|NCT01327573|Drug|eculizumab|"Eculizumab Induction 600mg IV every 7 days for 4 doses
Eculizumab 900mg IV 7 days later
Eculizumab Maintenance 900mg IV every 14 days for total of 26 weeks"
1941726|NCT01313767|Drug|Botulinum toxin type A|Botulinum toxin type A
1941727|NCT01313767|Drug|Botulinum Toxin type A|Botulinum Toxin type A
1941683|NCT01327157|Procedure|occlusal adjustment, Dental cleaning|Visual analogue scale, before and after treatment. Dental cleaning at first query. Gnathostats models in the maximal intercuspal position before and after treatment Occlusal adjustment in the teeth that are causing some interference of jaw closure, reaching a maximum contact dental . It prompted the patient to perform the act of swallowing for 3 times to reach a terminal axis of rotation of the jaw and from this start to do occlusal adjustment. Will be held palpation of the large muscles, masseter and temporal on both sides and compared with the marks of carbon found in the teeth. After this procedure starts the adjustment following the rules of Guichet
1941684|NCT01327157|Procedure|Visual analog scale, Dental cleaning|"Initial consultation, dental cleaning and performing the visual analog scale. Consultation three months after achieving visual analog scale final
VAS at the first inquiry
VAS at the last inquiry
dental cleaning in the first inquiry"
1941685|NCT01326780|Drug|1.2% JNJ 10229570-AAA|1.2% JNJ 10229570-AAA 1.2% cream applied once daily to the face for 12 weeks
1941686|NCT01326780|Drug|2.4% JNJ 10229570-AAA|2.4% JNJ 10229570-AAA 2.4% cream applied once daily to the face for 12 weeks
1941687|NCT01326780|Drug|3.6% JNJ 10229570-AAA|3.6% JNJ 10229570-AAA 3.6% cream applied once daily to the face for 12 weeks
1941688|NCT01326780|Other|Vehicle control|Color matched cream vehicle, applied once daily to the face for 12 weeks
1941689|NCT01326455|Device|Terumo TR wristband|
1941690|NCT01326455|Device|Terumo TR wristband|
1941691|NCT01326455|Device|Clo-Sur-P.A.D.|
1941692|NCT01323946|Biological|GSK Biologicals' investigational vaccine GSK1562902A|Three intramuscular injections
1941693|NCT01321606|Dietary Supplement|Lactobacillus rhamnosus HN001|Subjects will be given a pill formulation of a probiotic L. rhamnosus HN001 to be taken once a day, at a dose of 1 x 10^10 organisms
1941694|NCT01321606|Dietary Supplement|sugar pill (placebo)|Placebo identical to the active product will be given
1941695|NCT01321320|Other|Active muscle stimulation|Neuromuscular Electrical stimulation will be applied to one leg (randomly assigned).
1941696|NCT01321047|Drug|Propofol|propofol (0.5 mg/kg body weight; 10 mg if age > 70 or ASA class III-IV)
1941697|NCT01321047|Drug|BPS|midazolam (0.05 mg/kg body weight; 1 mg if age > 70 or ASA class III-IV) fentanyl (50 µg; 25 µg if age > 70 or ASA class III-IV) propofol (0.5 mg/kg body weight)
1941698|NCT01319994|Drug|Metformin|Metformin treatment
1941699|NCT01319994|Drug|Placebo|Placebo treament
1941700|NCT01320254|Drug|Cisplatin, Gemcitabine, Panitumumab|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8 Panitumumab 9mg/kg BW at day 1
1941701|NCT01320254|Drug|Cisplatin, Gemcitabine|Cisplatin 25mq/sq.m. at day 1+8 and Gemcitabine 1000mg/sq.m. at day 1 + 8
1941702|NCT01320176|Biological|Investigational HIV vaccine dose A|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
1941703|NCT01320176|Biological|Investigational HIV vaccine dose B|The vaccine will be administered by intramuscular route into the deltoid muscle preferentially of the non dominant arm at Month 0 and Month 3
1941704|NCT01319760|Device|Impella 2.5 support|Patients enrolled in the Impella arm will receive 24 hours of post-PCI hemodynamic support using the Impella 2.5
1941705|NCT01319760|Other|Control|Standard care for STEMI patients post-PCI from ACC/AHA Guidelines
1941706|NCT01319019|Drug|GSK961081|Comparison of different doses and dosing regimens of the drug
1941707|NCT01319019|Drug|Salmeterol|Positive control
1941708|NCT01319019|Drug|Placebo|Placebo arm
1941709|NCT01319123|Device|Drawtex dressing|The dressing is indicated for moderately to heavily exuding wounds such as venous leg ulcers
1941710|NCT01318928|Drug|Metronidazol|metronidazol. 400mg x 3 per day for 10 days
1941711|NCT01318226|Drug|ATx08-001|ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
1941712|NCT01318226|Drug|Placebo|Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
1941713|NCT01317940|Dietary Supplement|Vitamin D and Calcium Citrate|"Vitamin D (10,000 int.units/ml) 100,000 int. units (10ml) by mouth once every two months x 3 times (total treatment period approximately 6-7 months)
Calcium Carbonate (1,000 mg/tab = 400 mg elemental calcium/tab) 2,000 mg (2 chewable tabs) by mouth every day for approximately 6-7 months"
1941714|NCT01317472|Drug|dexlansoprazole|60 mg dexlansoprazole QAM (1 hour AC) for 2 months
1941715|NCT01317784|Device|Rapid tests for HIV, HCV, HBV, and syphilis|Choice of 16 different rapid tests. Only 12 manufacturer and names are shown because some are used with both blood and oral fluid. When they are used on both specimens, they are counted as two tests.
1941716|NCT01317784|Device|HIV/HCV|Choice of 10 different tests for HIV and hepatitis C.
1941717|NCT01317784|Device|HIV/syphilis|Choice of 7 different tests for HIV and syphilis
1941718|NCT01317784|Device|HIV only|Choice of 4 different tests for HIV only.
1941719|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed with Bausch + Lomb Sensitive Eyes Saline. The lenses will then be placed into Biotrue multi-purpose solution and soaked for at least 10 hours but no more than 24 hours prior to lens insertion into one eye.
1941720|NCT01317030|Device|Contact Lens Wear|Senofilcon A lenses will be rubbed and rinsed each side with Bausch + Lomb Sensitive Eyes Saline just prior to lens insertion into fellow eye.
1941721|NCT01317030|Other|Non-Contact Lens Wear|No intervention
1941722|NCT01316510|Dietary Supplement|Bifidobacteria infantis|1 billion organisms twice daily either through a feeding tube or by mouth for 6 weeks or until discharge
1941723|NCT01316510|Other|Placebo|Dilute Nutramigen formula
1941728|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable: SAPIEN XT™ vs. AVR; Inoperable: SAPIEN XT™ vs. SAPIEN®
1941729|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable: SAPIEN XT ™vs. AVR
1941730|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Inoperable: SAPIEN XT™ vs. SAPIEN®
1941731|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|Operable: SAPIEN XT™ vs. AVR
1941732|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|High risk: SAPIEN 3™ vs. historical control; Intermediate risk: SAPIEN 3™ vs. historical control
1941733|NCT01314313|Device|TAVR Implantation of the Transcatheter Aortic Valve Prosthesis|High risk: SAPIEN 3™ vs. historical control Intermediate risk: SAPIEN 3™ vs. historical control
1941734|NCT01313819|Drug|PK-Merz® 200mg/500ml inj(Amantadine) , Normal saline 500ml inj|IV amantadine at 200 mg in 500 cm3 of saline solution or normal saline 500 cm3 given over a 3-h period, twice a day for 2 days along with the pre-existing dopaminergic and non-dopaminergic medication
1941735|NCT01312922|Drug|PNB01 fixed dose combination of pipamperone and citalopram|oral once daily administration
1941736|NCT01312922|Drug|Citalopram|oral once daily administration
1941737|NCT01312922|Drug|Pipamperone|oral once daily administration
1941738|NCT01313559|Drug|Pasireotide|Given IM
1941739|NCT01313559|Drug|Everolimus|Given PO
1941740|NCT01313559|Other|Laboratory biomarker analysis|Correlative studies
1941741|NCT01312402|Drug|topical brinzolamide 1% in 5mL ophthalmic medication|1 drop three times a day in both eyes on days 2,3 and 4
1941742|NCT01312402|Drug|Placebo in 5 mL dispenser|Placebo ophthalmic solution in 5 mL dispenser; 1 drop three times a day on days 2,3 and 4
1941743|NCT01310790|Procedure|lactate group:lactate acide clearance directed group; ScvO2 group:ScvO2 directed group;control group|"Patients assigned to lactate group started with the resuscitation to achieve a CVP of 8 to 12 mmHg and MAP 65 to 90 mmHg. Then if ScvO2 was less than 70 percent, red cells were transfused to achieve a hematocrit of at least 30 percent. After the CVP, MAP, and hematocrit achieved the goals, dobutamine was given until the ScvO2 was 70 percent or higher. Arterial blood lactate concentration was obtained at 6 hours and try to achieve lactate clearance was >30%.
Patients in the ScvO2 group received the treatment as ScvO2 directed therapy protocol for at least 6 hours and maintained for 72 hours. The protocol was the same as that of lactated directed therapy with the exception of blood lactate concentration testing.
Patients in the control group received the treatment as the same protocol for maintaining CVP and MAP in that of lactated directed therapy. ScvO2 and arterial blood lactated concentration were not necessary to obtain."
1941744|NCT01310725|Procedure|Coronary artery bypass grafting|Bypass of stenoses in coronary arteries using different types os vessels as conduit.
1941745|NCT01310647|Drug|Testosterone|Transdermal testosterone (20µg/kg/day)from day 24 of the previous cycle to day 2 of the ICSI cycle
1941746|NCT01310647|Drug|Estradiol|Transdermal estradiol (200µg/day)from day 20 of the previous cycle to day 3 of the ICSI cycle
1941747|NCT01310647|Drug|CombEq|"(150µg Desogestrel + 30µg Ethinylestradiol)/day during the luteal phase of the two cycles prior to the ICSI.
Valerate estradiol 4mg/day during 10 days, starting the second day of the cycle prios to the ICSI cycle."
1941748|NCT01310036|Drug|erlotinib [Tarceva]|150 mg orally daily
1941749|NCT01309737|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
1941750|NCT01309737|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
1941751|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
1941752|NCT01309737|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous Treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
1941755|NCT01309165|Behavioral|CO-OP|CO-OP, a client-centred, performance-based, problem solving approach has 7 key features including: client-chosen goals, dynamic performance analysis, cognitive strategy use, guided discovery, and a specific 10-session intervention format. The client and the therapist work together, using the Canadian Occupational Performance Measure (COPM), to select 3 skills and establish baseline skill performance. In the second meeting, when CO-OP actually begins, the approach is introduced to the client and the global cognitive strategy (GOAL-PLAN-DO-CHECK) is learned. In all subsequent sessions this strategy is used as the main problem-solving framework to facilitate skill acquisition.
1941756|NCT01309165|Behavioral|Standard Occupational Therapy|Participants randomized to the SOT group will receive usual out-patient rehabilitation services, with slight modifications. Specifically, a research assistant will administer the COPM to assist participants to self-select 4 personally meaningful skills. The treating SOT occupational therapists will be asked to log the activities completed in each session, and the amount of time spent in therapy.
1941757|NCT01308983|Drug|Amiloride|Amiloride 10 mg orally once a day for 16 weeks
1941758|NCT01309113|Drug|VAC BNO 1095 film coated tablets|3 dosages: Placebo, 10 mg of VAC BNO 1095 once daily in the morning, 10 mg of VAC BNO 1095 twice daily in the morning and in the evening
1941759|NCT01307930|Drug|Anidulafungin|Anidulafungin 100 mg IV (each volunteer will only receive one dose of the study drug)
1941760|NCT01308008|Behavioral|home exercise/physical activity (PA) enhancement program with behavioral support|Initial on-site personal trainer-based functional aerobic program followed by home intervention consisting of functional exercise training and enhanced physical activity with nurse telephonic behavioral support
1941761|NCT01308008|Behavioral|flex and toning health education program|Initial flex and toning program continued on follow-up along with health education
1941762|NCT01307865|Drug|injectable poly-L-lactic acid|Each patient will receive up to 1 vial of Sculptra Aesthetic total to both midface complexes at each of 3 treatment sessions, spaced 6 weeks apart.
1941763|NCT01307397|Drug|RO5185426|960 mg twice daily orally
1941767|NCT01306058|Drug|TRC 105|15 mg/kg IV every 2 weeks
1941768|NCT01306058|Drug|Sorafenib|400 mg bid continuously in a 28 days cycle
1941858|NCT01288521|Drug|Tacrolimus + Ketoconazole|Pharmacokinetic profiling of tacrolimus (AUC0-24h) in subjects receiving tacrolimus + keotconazole 200 mg every 12 hours x 3 doses.
1941769|NCT01305733|Drug|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline|The injectant mixture consists of 150 mg levobupivacaine mixed with 30 mg ketorolac and 0.5 mg adrenaline
1941770|NCT01305733|Other|saline injection|saline
1941771|NCT01302977|Procedure|Fetal tracheal occlusion|Insertion of a detachable balloon inside fetal trachea by percutaneous fetoscopy
1941772|NCT01302808|Drug|erlotinib hydrochloride|
1941773|NCT01302808|Drug|romidepsin|
1941774|NCT01302808|Other|laboratory biomarker analysis|
1941775|NCT01302808|Other|pharmacological study|
1941776|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
1941777|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
1941778|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
1941779|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
1941780|NCT01301456|Biological|Placebo|Single subcutaneous injection of placebo
1941781|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
1941782|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
1941783|NCT01301456|Biological|PF-04856883|Single subcutaneous injection of PF-04856883
1941784|NCT01301456|Biological|Placebo|Multiple weekly subcutaneous injections of placebo for 3 weeks
1941785|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
1941786|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
1941787|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
1941788|NCT01301456|Biological|PF-04856883|Multiple weekly subcutaneous injections of PF-04856883 for 3 weeks
1941791|NCT01301625|Device|MitraClip Implant|Percutaneous mitral valve repair using MitraClip implant.
1941792|NCT01301300|Device|Disinfecting Cap|Replace standard practice with using the disinfecting cap
1941795|NCT01301001|Drug|Placebo oral capsule|Placebo 2 capsules am and 3 capsules pm
1941796|NCT01301001|Drug|Gabapentin|Gabapentin 1200 mg am and 1800 mg pm
1941797|NCT01300637|Drug|Metformin|metformin 500 mg/pill; target dose 1500 mg/day for 24 weeks
1941798|NCT01300637|Drug|placebo|identical-appearing pill of placebo
1941799|NCT01300364|Drug|Reboxetine|8mg/day.
1941800|NCT01300364|Drug|citalopram (SSRI)|30mg/day
1941801|NCT01298869|Biological|HPV-6/11/16/18 vaccine|HPV-6/11/16/18 vaccination 3 doses at day 1, month 2, and month 6
1941806|NCT01298934|Drug|LBH589|Dose escalation study starting at 20mg by mouth three times a week, given weekly for 24 weeks in the phase I portion of the study.
1941807|NCT01299870|Drug|AED treatment plus placebo|Your usual AED(s) treatment with placebo for 12 weeks followed by 4 weeks washout period, and then Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) treatment for 12 weeks.
1941808|NCT01299870|Drug|Keishibukuryogan|Keishibukuryogan, (2.5 g of granulate filled in capsules) three times a day for a total of 7.5 g a day with your usual AED(s) for 12 weeks followed by 4 weeks washout period, and then your usual AED(s) treatment with placebo for 12 weeks.
1941809|NCT01296711|Biological|CDP6038|100mg/ml solution for injection 120 mg subcutaneously (sc) every 2 weeks
1941810|NCT01296321|Behavioral|Tailored Internet-administrated CBT-Treatment|"This intervention contains 6-8 text-based self-help modules in which 4 modules are fixed (the first three and the last) and the rest are prescribed following the diagnostic telephone interview. These modules contain material on panic disorder, social phobia, stress management, assertiveness training, concentration, relaxation among other things."
1941811|NCT01296321|Behavioral|Waitlist|Passive waitlist during 8-10 weeks.
1941812|NCT01296191|Drug|Moxifloxacin|One drop 4 times daily for 3 days and one drop the day of sample collection
1941813|NCT01296191|Drug|besifloxacin|One drop 4 times daily for 3 days and one drop on day of sample collection
1941816|NCT01295619|Device|I-020805|A thin layer of I-020805 applied up to two times on the sutured dura mater
1941817|NCT01295606|Drug|Cefazolin|iv cefazolin (50mg/kg, 3 times a day) will be given as a routine prophylaxis treatment
1941818|NCT01295528|Device|Comparison test|Yuyue medical BP meter, accuracy: ±1mmHg and range: 0-300mmHg.
1941822|NCT01294267|Device|Impella 2.5 Circulatory Support system insertion|Femoral angiography will be performed, and if the anatomy is suitable, the femoral artery preclosure technique will be employed. The Impella 2.5 will be inserted through th femoral artery into the left ventricle. Anti-coagulation will be titrated to achieve a therapeutic ACT level. Organ perfusion and Hemodynamic data will be collected during simulated VTs and throughout the course of the case. The performance level of the device may be adjusted during the case to quantify hemodynamic effects
1941823|NCT01294241|Drug|Sericare®|"Sericare® on one half of the skin lesion (each time when the wound dressing is changed, normally every 24-48 hours)
Non-adhesive wound dressings alone on the other half of the skin lesion"
1941825|NCT01293201|Drug|STAHIST|STAHIST dosed one tablet, BID
1941826|NCT01293201|Drug|Placebo|Placebo identical in appearance to IMP, dosed one tablet BID
1941827|NCT01291901|Biological|NP2|NP2 is a replication defective HSV-1 based gene transfer vector engineered to express human preproenkephalin. The drug will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
1941828|NCT01291901|Biological|Placebo|The placebo (vehicle) will be injected intradermally corresponding to the distribution of the malignancy-related pain. The total amount to be injected will be a dose volume of 1.0 ml delivered in a single session on Study Day 0.
1941829|NCT01291407|Drug|S-1|S-1,30mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
1941830|NCT01291407|Drug|S-1|S-1,40mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
1941831|NCT01291407|Drug|S-1|S-1,50mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner
1941832|NCT01291407|Drug|S-1|S-1,60mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
1941833|NCT01291407|Drug|S-1|S-1,70mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
1941834|NCT01291407|Drug|S-1|S-1,80mg/m2/d,peroral BID,in treatment days concurrently with radiation therapy in a standard manner.
1941835|NCT01290445|Drug|varenicline|This is a non-interventional study. Exposure in utero to varenicline is observed, not assigned.
1941836|NCT01290445|Behavioral|cigarette smoke from maternal smoking|This is a non-interventional study. Exposure in utero to cigarette smoke from maternal smoking is observed, not assigned.
1941837|NCT01290445|Other|Non-Exposure|This is a non-interventional study. Non-exposure in utero to varenicline and cigarette smoke from maternal smoking is observed, not assigned.
1941840|NCT01290692|Biological|TVI-Brain-1|Following surgery, tumor tissue is used to generate a cancer vaccine. Patients are vaccinated with neutralized cells to initiate an immune response. Following vaccinations, the patient's white blood cells are collected, the white blood cells are stimulated and expanded, and are then reinfused into the patient's blood.
1941841|NCT01290601|Drug|Tafenoquine|Tafenoquine: 2 capsules (200mg base/capsule for a total of 400mg base) and 4 chloroquine placebo capsules for 2 days, followed by 2 tafenoquine capsules and 2 chloroquine placebo capsules for 1 day, followed by 1 primaquine placebo capsule/day for 14 days.
1941842|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 2 day, followed by chloroquine (500 mg chloroquine phosphate) and tafenoquine placebo x 1day, followed by primaquine, 15 mg/day for 14 days.
1941843|NCT01290601|Drug|tafenoquine|Tafenoquine (600 mg base) and chloroquine placebo x 1d, chloroquine placebo x 2 days, followed by primaquine placebo for 14 days.
1941844|NCT01290601|Drug|Chloroquine + Primaquine|Chloroquine (1000 mg chloroquine phosphate) and tafenoquine placebo x 1 day, followed by chloroquine (1000 mg chloroquine phosphate) x 1 day, followed by chloroquine (500 mg chloroquine phosphate) x 1day, followed by primaquine, 15 mg/day for 14 days.
1941845|NCT01290874|Drug|Tiotropium|Tiotropium bromide 18 mcg once daily for one year of treatment.
1941846|NCT01290874|Drug|Salmeterol|Salmeterol 50 mcg twice daily for one year of treatment.
1941847|NCT01290874|Drug|Formoterol|Formoterol 12 mcg twice daily for one year
1941848|NCT01290237|Drug|intravenous vancomycin hydrochloride|see description of study arms
1941849|NCT01289912|Drug|RAD001|"RAD001 is formulated as tablets of 5.0 mg strength, blister-packed under aluminum foil in units of 10 tablets and dosed on a regular basis. Matching placebo will be provided as a matching tablet and will also be blister packed under aluminum foil in units of 10. RAD001 or matching placebo tablets should be opened only at the time of administration as drug is both hygroscopic and light-sensitive.
Patients will be instructed to take 4.5 mg/m2 of RAD001 or matching placebo orally with a glass of water at regular intervals at the same time (delete: each day) in the morning after a light, nonfat breakfast."
1941850|NCT01289769|Drug|Dexmedetomidine|dexmedetomidine 0.7 microgram per kilogram in saline 20 ml given within 10 minutes before intubation
1941851|NCT01289769|Drug|Placebo|normal saline 20 ml( the same volume as dexmedetomidine) giving within 10 minutes.
1941852|NCT01289067|Drug|Satraplatin|Satraplatin 80mg/m2 day 1-5 every 35 days Prednisone 5 mg twice daily every 35 days
1941853|NCT01288976|Device|MitraClip|The MitraClip System includes a MitraClip device, a Steerable Guide Catheter, and a MitraClip Delivery System that enables placement of the MitraClip device on the mitral valve leaflets
1941854|NCT01288976|Drug|Medical Management|The Non-Surgical Medically Managed Heart Failure (HF) Group consists of patients with mitral regurgitation (MR) in whom the MR is managed non-surgically based on standard hospital clinical practice. Patients with MR who receive a pacemaker, Implantable Cardiac Defibrillator (ICD) and/or Cardiac Resynchronization Therapy (CRT) treatments may be included
1941855|NCT01288976|Procedure|Mitral Valve Surgery|The Mitral Valve Surgery Group consists of patients with MR in whom the MR is managed surgically (repair or replacement) based on standard hospital clinical practice. Patients with concurrent coronary artery bypass grafting (CABG) or aortic/tricuspid valve or and other cardiac procedure except atrial fibrillation surgery are excluded.
1941856|NCT01288937|Drug|Milnacipran|"Patients will be randomly assigned to receive milnacipran 100 mg/day (including a 1 week dose titration period):
Day 1: 12.5 mg once Day 2 3: 25 mg/day (12.5 mg twice daily) Day 4 7: 50 mg/day (25 mg twice daily) After Day 7: 100 mg/day (50 mg twice daily)"
1941857|NCT01288937|Drug|Placebo|"Patients will be randomly assigned to placebo for 9wks (including a 1 week dose titration period):
Day 1: 12.5 mg once Day 2 3: 25 mg/day (12.5 mg twice daily) Day 4 7: 50 mg/day"
1941859|NCT01288521|Drug|Tacrolimus alone|Pharmacokinetic profiling of subjects on a stable dose of tacrolimus (AUC 0-24h)
1941860|NCT01288833|Device|Close focus HD NBI Colonoscopy System|Technically improved colonoscope with close focus high definition narrow band imaging. Optical specifications include a 2mm near field focal depth.
1941864|NCT01285999|Device|PROMUS Element Coronary Stent System|Everolimus-eluting Coronary Stent
1941865|NCT01285999|Device|TAXUS Liberté Coronary Stent System|Paclitaxel-eluting Coronary Stent
1941866|NCT01286935|Drug|Safinamide|
1941867|NCT01286935|Drug|Safinamide|
1941868|NCT01286935|Drug|Placebo|
1941875|NCT01286051|Drug|Follistim administration|adminstation of FSH for ovulation induction
1941876|NCT01286051|Drug|Follistim plus Ganirelix|Follistim plus single injection of ganirelix
1941877|NCT01285830|Dietary Supplement|Lactobacillus reuteri|The mothers started taking Lactobacillus reuteri ATCC 55730 (BioGaia AB, Stockholm, Sweden) or placebo four weeks before term and continued to do so daily until delivery. After birth, the baby commenced with the same study product as the mother at 1-3 days of age and continued daily for one year. The daily intake, five oil droplets, corresponded to 1 x 100 000 000 colony forming units (CFU)
1941878|NCT01285830|Dietary Supplement|Placebo|The placebo consists of the same oil that the active study product but without any bacteria and is not possible to differentiate from the active product by smell, taste or visual appearance
1941879|NCT01285700|Drug|Lamazym|ERT, infusion weekly
1941880|NCT01285349|Behavioral|Couple HIV/STI prevention intervention|
1941881|NCT01285349|Behavioral|Couple-based HIV prevention|
1941882|NCT01285349|Behavioral|Individual HIV/STI prevention|
1941883|NCT01285349|Behavioral|Couple Wellness Promotion|
1941884|NCT01284348|Drug|ACE-011 - 15 mg|15 mg subcutaneous injection every 42 days, up to 4 doses/cycles
1941885|NCT01284348|Drug|ACE-011 - 30 mg|30 mg subcutaneous injection every 42 days, up to 4 doses/cycles
1941886|NCT01284348|Drug|ACE-011 - 45 mg|45 mg subcutaneous injection every 42 days, up to 4 doses/cycles
1941887|NCT01285206|Device|Carbon polymer warming blanket|Routine practice ( + no carbon polymer blanket) versus use of HotDog carbon polymer warming blanket throughout day surgery procedure
1941888|NCT01284842|Other|24-Hour-Call|one 24-Hour-Call within the regular surgical schedule
1941889|NCT01284478|Drug|Dexamethasone Implant|Ozurdex (Dexamethasone Implant), 0.7 mg will injected intravitreally
1941890|NCT01284413|Drug|S-1, Gemcitabine, Cisplatin|S-1 is given daily for 7 consecutive days and gemcitabine and cisplatin are infused on day1. The cycle is repeated every 2 weeks.
1941891|NCT01283711|Device|apollo device|RF treatments for wrinkles and rhytides reduction
1941892|NCT01283386|Drug|chlorambucil|10 mg/m2 orally on Days 1-7 of each 28-day cycle, 6 cycles
1941893|NCT01283386|Drug|cyclophosphamide|150 mg/m2 iv or orally on Days 1-3 of each 28-day cycle, 6 cycles
1941894|NCT01283386|Drug|fludarabine|20 mg/m2 iv or 32 mg/m2 orally Days 1-3 of each 28-day cycle, 6 cycles
1941895|NCT01283386|Drug|rituximab [MabThera]|375 mg/m2 iv on Day 1 of cycle 1, 500 mg/m2 iv on Day 1 of cycles 2-6 (28-day cycles)
1941896|NCT01282151|Drug|Taxotere|Docetaxel 60 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
1941897|NCT01282151|Drug|Pemetrexed|Pemetrexed 500 mg/m2 q3 weeks Cisplatin 70 mg/m2 q3 weeks
1941898|NCT01281969|Drug|Gamunex Intravenous Immunoglobulin|2.0 gm/kg total, IV (in the vein), over 2 days
1941899|NCT01281969|Drug|Placebo|Normal saline, IV (in the vein), over 2 days
1941903|NCT01280682|Drug|rituximab|anti-CD20 monoclonal antibody 125mg/m^2 day1 day8 day15 day22 repeat after six months (only day1 and day8)
1941904|NCT01280942|Behavioral|EWS Nursing Alerts|An automated algorithm (EWS) will identify patients at potential risk of clinical deterioration. When a patient satisfies the algorithm, a nurse on the patient's ward will be notified. S/he will assess the patient and institute any interventions that are clinically required.
1941905|NCT01280942|Device|Wireless Remote Sensor|A subset of patients will be consented to wear a wireless sensor device which will monitor heart rate and level of oxygen in the blood.
1941906|NCT01280903|Behavioral|STAR Intervention|The 24-week modified Staying Active with Arthritis (STAR) intervention, guided by self-efficacy theory and modified to address comorbid hypertension, consists of 6 weekly individual face-to-face exercise sessions by a licensed physical therapist, 9 biweekly telephone counseling sessions by a registered nurse to continue the use of self-efficacy strategies, and lower extremity exercise and fitness walking being carried out at home between sessions. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
1941948|NCT01275664|Drug|Carboplatin|Given IP
1941949|NCT01275664|Drug|Cisplatin|Given IP
1941950|NCT01275664|Drug|Dexamethasone|Given PO
1941951|NCT01275664|Drug|Granisetron Transdermal Patch|Apply one patch to upper arm
1941952|NCT01275664|Procedure|Management of Therapy Complications|Ancillary studies
1941953|NCT01275664|Other|Questionnaire Administration|Ancillary studies
1941954|NCT01275300|Dietary Supplement|5 days of placebo followed by 600mg niacin|600 mg niacin
1941955|NCT01275300|Dietary Supplement|aspirin first|5 days taking 81 mg Aspirin followed by a single dose of 600 mg Niacin
1941907|NCT01280903|Behavioral|Attention-Control|Attention-Control is a 24-week general health education program for older adults that consists of 6 weekly telephone sessions by a registered nurse followed by 9 biweekly telephone sessions by a registered nurse. There will be no contact with participants during weeks 7, 9, 11, 13, 15, 17, 19, 21, and 23. Topics include cancer screenings; immunizations; osteoporosis; low vision; hearing loss; talking with your primary care provider; eating healthy (two parts); sleep and aging; injury prevention (two parts: balance problems and falls); oral health; foot care; and mental health (depression). During the 6-month follow-up period, the participants will be contacted briefly by telephone by a registered nurse at weeks 30, 36, and 48 for a general check-up.
1941908|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance plus|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer and a mobile phone physical activity diary.
1941909|NCT01280812|Behavioral|Mobile phone based physical activity intervention with maintenance regular|This group will receive a mobile phone software program and a pedometer. Over a 3-month period, participants in this group will be asked to wear a pedometer, use a mobile phone physical activity diary, and respond daily physical activity messages or video clips. Over a 6-month maintenance period, participants will be asked to continue using a pedometer.
1941910|NCT01280812|Behavioral|Pedometer only|This group will receive a pedometer. Over a 9-month period, participants in this group will be asked to wear a pedometer.
1941911|NCT01280201|Drug|Pazopanib|Single arm of pazopanib 800 mg (2x400mg) given once daily as a single agent.
1941912|NCT01280409|Drug|Metformin|Subjects will receive metformin 850 mg PO daily for 7 days, then metformin 850mg PO twice a day for the next 5 weeks
1941913|NCT01280409|Drug|Placebo|Subjects will receive a placebo (similar in size, taste, color) once daily for 7 days, then twice daily for the next 5 weeks.
1941914|NCT01279967|Drug|ADI-PEG 20|36.8mg/m2 based on BSA, weekly treatment for 6 months
1941915|NCT01279980|Other|Epidural|Epidural analgesia inserted prior to surgery to stay in until at least the second postoperative day
1941916|NCT01279980|Other|Local anaesthetic wound catheter|The catheter will be used to infuse the wound with local anaesthetic for 48 hours post op.
1941917|NCT01278498|Drug|Escitalopram|first week:5mg 2nd week~12 week:10mg
1941918|NCT01278498|Drug|sugar pill|first week:5mg 2nd week~12 weeks:10mg
1941919|NCT01279707|Biological|humanised monoclonal antibody, veltuzumab|Veltuzumab with modified UKALL XII induction chemotherapy. Veltuzumab will be administered at 200 mg/m2 IV on Day 8 and subsequently, (if tolerated on Day 8), over 1 hour on Days 15, 22, 29.
1941920|NCT01279707|Biological|humanised monoclonal antibody epratuzumab|Epratuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29.
1941921|NCT01279707|Biological|humanised monoclonal antibodies veltuzumab and epratuzumab|Epratuzumab + Veltuzumab with modified UKALL XII induction chemotherapy. Epratuzumab will be administered at 360 mg/m2 IV over 1 hour on Days 8, 15, 22 and 29. Veltuzumab will be administered at 200 mg/m2 IV over 2 hours on Day 8 and over 1 hour on Days 15, 22 and 29. Veltuzumab will be infused 1 hour after the infusion of epratuzumab.
1941922|NCT01279681|Biological|bevacizumab|Given IV
1941923|NCT01279681|Drug|capecitabine|Given PO
1941924|NCT01279681|Drug|fluorouracil|Given IV
1941925|NCT01279681|Drug|leucovorin calcium|Given IV
1941926|NCT01279681|Drug|oxaliplatin|Given IV
1941929|NCT01279083|Drug|DE-112|Topical ocular solution
1941930|NCT01279083|Drug|DE-112|Topical ocular solution
1941931|NCT01279083|Drug|DE-112|Topical ocular solution
1941932|NCT01279083|Drug|DE-112|Topical ocular solution
1941933|NCT01279083|Drug|DE-112 Vehicle Solution|Topical ocular solution
1941934|NCT01279083|Drug|Timolol Maleate Solution|Topical ocular solution
1941935|NCT01277887|Behavioral|Cognitive-Behavioral Counseling|The cognitive-behavioral intervention integrates standard smoking counseling adapted from the American Lung Association Freedom from Smoking program along with cognitive-behavioral techniques for improving insomnia.
1941936|NCT01277887|Behavioral|Smoking Cessation Counseling|The smoking cessation counseling intervention will incorporate standard psychoeducational and behavioral smoking counseling techniques adapted from the American Lung Association Freedom from Smoking program.
1941937|NCT01276509|Drug|PF-00547659 SC injection|Placebo delivered SC, 3 doses separated by 4 weeks
1941938|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
1941939|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
1941940|NCT01276509|Drug|PF-00547659 SC injection|Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
1941941|NCT01276639|Drug|CP-690,550|10 mg oral BID, Continuous treatment for 52 Weeks
1941942|NCT01276639|Drug|CP-690,550|5 mg oral BID, Continuous treatment for 52 Weeks
1941943|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 10 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
1941944|NCT01276639|Drug|Placebo/CP-690,550|0 mg oral BID, Continuous treatment for 16 Weeks; 5 mg oral BID, Continuous Treatment for 36 Weeks (after completion of 16 Weeks of Placebo)
1941945|NCT01275638|Drug|Prednisolone|Soon after the presumptive diagnosis of severe sepsis, initial laboratory specimens were obtained within 2 hours, and the patients were randomized to treatment with prednisolone or placebo groups. The treatment groups were determined by a computer-generated randomization procedure (in a 1:1 ratio). The steroid group received prednisolone at a moderate-dose (20 mg/day). Prednisolone was given intravenously at 06.00 (10 mg) 14.00 (5 mg) and 22.00 (5 mg) for 10 days. The standard therapy group received a placebo infusion containing physiological saline solution in an identical manner. Patients and their primary physicians were blinded as to which therapy was administered.
1941946|NCT01275664|Procedure|Adjuvant Therapy|Ancillary studies
1941947|NCT01275664|Drug|Aprepitant|Given IV and PO
1941958|NCT01275300|Drug|Celebrex and niacin|Data will be handled exactly like phase 1.
1941959|NCT01275118|Device|Tecnis Multifocal IOL|Presbyopia correcting IOL
1941960|NCT01275118|Device|crystalens Accommodating IOL|Presbyopia correcting IOL
1941961|NCT01274988|Procedure|Deep brain stimulation|Deep brain stimulation of bilateral nucleus accumbens
1941962|NCT01274988|Other|methadone maintenance treatment|methadone maintenance treatment
1941966|NCT01274741|Behavioral|Creating Change (therapy model)|Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD. It has 17 topics, which in this study are conducted once per week in hour-long sessions. The treatment focuses on exploring how PTSD and SUD arose and interacted across the patient's life, including, constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
1941967|NCT01274741|Behavioral|Seeking Safety|Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy specifically designed for integrated treatment of patients with current PTSD and SUD. It consists of 25 topics evenly divided among cognitive, behavioral, and interpersonal topics. Each topic provides a new theme relevant to both disorders; for this study we will offer 17 of the 25 topics and conduct one topic per session.
1941968|NCT01274728|Procedure|Percutaneous coronary intervention|Percutaneous coronary intervention with at least use of drug-eluting balloon and if necessary cross-over to bail-out stenting with BMS.
1941969|NCT01274520|Device|The Medtronic Portable Bypass System (PBS®)|Will be used for machine perfusion of liver grafts.
1941970|NCT01274026|Drug|sapropterin dihydrochloride|"In 30 PKU patients found previously to exhibit no decrease in blood PHE levels behavioral and cognitive function, neurotransmitter levels, and gene expression of enzyme activity will be measured at baseline and after 4 weeks of Kuvan administration. Rating inventories of executive function performance and behavior will be administered to patients and parents.
Urine neurotransmitters, blood microarray expression, and plasma amino acids will be measured (plasma PHE and TYR levels will also be measured at weeks 1 and 2). Nutrient analysis of 3 day food diaries will be conducted."
1941971|NCT01273337|Biological|ALD-401|3 mL ALDHbr cells isolated from autologous bone marrow given as a one-time infusion via intracarotid infusion.
1941972|NCT01273337|Procedure|Sham Procedure|Sham bone marrow harvest and sham product infusion procedures.
1941974|NCT01273012|Drug|Probiotic - Infloran|Drug:Probiotic - Infloran (TM) 1 cap (1 billion CFU of L. acidophilus and 1 billion CFU of B. bifidum) PO bid or tid
1941985|NCT01271348|Drug|Etoricoxib|Etoricoxib film tablet, 90 mg, q.d.
1941986|NCT01271348|Drug|placebo|Placebo tablet, q.d.
1941987|NCT01271010|Drug|Cyclophosphamide|Participants will receive cyclophosphamide 250 mg/m^2 IV or 250 mg/m^2 orally on Days 1-3 of each cycle.
1941988|NCT01271010|Drug|Fludarabine|Participants will receive fludarabine 25 mg/m^2 IV or 40 mg/m^2 orally on Days 1-3 of each cycle.
1941989|NCT01271010|Drug|Rituximab|Participants will receive, 375 mg/m^2 IV on Day 1 of Cycle 1, then 500 mg/m^2 IV on Day 1 of each subsequent cycle.
1941990|NCT01269983|Other|Fascial Manipulation|8 treatment session in 4 weeks: every week both fascial manipulation and standard physiotherapy
1941991|NCT01270568|Other|Positive Psychology|Weekly exercises focused on optimism, gratitude, altruism, and other positive affective states
1941992|NCT01270568|Behavioral|Relaxation Response|Daily practice of relaxation response, reviewed on a weekly basis
1941993|NCT01270568|Behavioral|Recollection|Subjects record daily events on a weekly basis for 8 weeks
1941994|NCT01270152|Drug|Ascorbic Acid|comparing three different doses of ascorbic acid: 50 mg, 100 mg and 200 mg administered inside the catheter and maintained for up to 60 minutes
1941995|NCT01269047|Drug|Pramlintide|Start at 15 mcg capped at 60 mcg before breakfast and supper subcutaneously for 4 months
1941996|NCT01269047|Drug|Exenatide|Start at 1.25 mcg, capped at 5 mcg, subcutaneously, before breakfast and supper for 4 months
1941997|NCT01269047|Drug|Insulin|Rapid acting and long acting, subcutaneously, according to their regimen for the entire duration of the study.
1941998|NCT01269749|Radiation|RAI treatment|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with 131I. In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
1941999|NCT01269749|Drug|ATD Group|Characteristics of study population. We will recruit a total of 150 patients diagnosed with GD younger than 18 years of age. All subjects are to be treated with antithyroid drugs (ATDs). In this trial, children will not be randomized to treatment, but will be treated per physician prescribed care. To ensure an equal distribution of age and gender between the two groups of children, we stratify enrollment by gender (male vs. female) and age (5-10 yrs, 10-15 yrs, 15-18 yrs).
1942000|NCT01269463|Drug|Methylphenidate Hydrochloride Extended Release Capsules|Methylphenidate Hydrochloride Extended Release Capsules to be dosed once daily
1942001|NCT01269463|Drug|Placebo|Capsule without active drug
1942002|NCT01268748|Procedure|Conventional laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using two 12 mm ports and two 5 mm ports
1942003|NCT01268748|Procedure|Experimental laparoscopic procedure|Patients allocated to this group will undergo laparoscopic cholecystectomy using only a transumbilical SILS port
1942004|NCT01268280|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
1942005|NCT01268280|Drug|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
1942006|NCT01268280|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
1942007|NCT01268046|Drug|Estradiol|1 mg/day for 30 days administered through a capsule
1942008|NCT01268046|Drug|Placebo oral capsule|Administered daily for 30 days.
1942009|NCT01268059|Drug|Carboplatin/Paclitaxel/MEDI-575|Subjects will receive carboplatin/paclitaxel and MEDI-575 every 21 days for up to 6 cycles. MEDI-575 may continue alone after 6 cycles unless there is evidence of disease progression or intolerance of study treatment.
1942010|NCT01268059|Drug|Carboplatin/Paclitaxel|Subjects will receive carboplatin/paclitaxel (paclitaxel 200 mg/m2 and carboplatin AUC=6 mg/mL*min) for up to 6 cycles unless there is evidence of disease progression or intolerance of study treatment.
1942011|NCT01268059|Drug|Carboplatin/Paclitaxel/MEDI-575|Subjects will receive carboplatin/paclitaxel (paclitaxel 200 mg/m2 and carboplatin AUC=6mg/mL*min) plus MEDI-575 at dose determined in the Dose Determination Phase. Carboplatin/paclitaxel and MEDI-575 to be given once every 21 days as an IV infusion for up to 6 cycles. MEDI-575 may continue alone after 6 cycles unless there is evidence of disease progression or intolerance of study treatment.
1942012|NCT01267864|Drug|Metoclorpamide|10mg IVSS
1942013|NCT01267864|Drug|Ketorolac|30g IVSS
1942014|NCT01267864|Drug|Valproate|1gm IVSS
1942015|NCT01267188|Drug|NBI-98854|powder in bottle, prepared doses at 12.5, 25, and 50 mg q.d. administered for up to 12 days consisting of three treatment periods of 4 days each
1942016|NCT01266174|Drug|Eltoprazine|Comparison of eltoprazine, dosed orally, for 8 weeks
1942017|NCT01266174|Drug|Placebo|Placebo to match eltoprazine
1942018|NCT01266993|Biological|Nimenrix (GSK134612 vaccine)|Intramuscular, 1 dose
1942019|NCT01266161|Drug|Ibuprofen 600 mg ER|One 600 mg caplet dosed at 0, 12, 24 and 36 hours
1942020|NCT01266161|Drug|Placebo|One placebo caplet dosed at times 0, 12, 24 and 36 hours
1942021|NCT01265901|Drug|Sunitinib|As per label.
1942022|NCT01265901|Biological|GM-CSF|Intradermal injection of GM-CSF as adjuvant.
1942023|NCT01265901|Drug|Cyclophosphamide|One single low-dose i.v. infusion prior to the first vaccination
1942024|NCT01265901|Drug|IMA901|Intradermal vaccinations with IMA901 vaccine.
1942025|NCT01265719|Other|No intervention other than routine medical care|Subjects continuously treated with Latanoprost for at least one month Latanoprost treatment during the study period.
1942026|NCT01265719|Other|No intervention other than routine medical care|Subjects not treated with any topical prostaglandin analogues or continuously treated with topical prostaglandin analogues for less than one month before the baseline examination, and unlikely to be treated with topical prostaglandin analogues during the study period.
1942027|NCT01264679|Drug|Ferumoxytol|IV Ferumoxytol
1942028|NCT01264718|Behavioral|Effects of Parent Mentors on Insuring Minority Children|After random assignment to the Parent Mentor group,the minority low-income parent of a Medicaid/CHIP eligible child will meet with a Parent Mentor to receive instruction and help on completing, submitting, and maintaining Medicaid/CHIP insurance for their child.
1942030|NCT01264120|Behavioral|Health Psychology Intervention|The health psychology intervention will involve a bariatric rehabilitation service (BRS) which will involve those allocated to the intervention receiving usual care plus three 50 minute sessions with a health psychologist pre-operatively (1 week before surgery), perioperatively (before they are discharged from hospital) and at 3 month follow up.
1942031|NCT01262976|Biological|GSK's investigational vaccine 692342|Intramuscular, 2 doses
1942032|NCT01262976|Biological|Physiological saline|Intramuscular, 2 doses
1942037|NCT01261780|Device|MC-5A|45 minutes daily x 10 treatments (given over the course of 2 weeks)
1942038|NCT01261780|Drug|Sham device|Sham therapy daily x 45 minutes for 10 treatments (given over course of 2 weeks)
1942039|NCT01261611|Drug|Botulinum type A toxin (Dysport RU®)|I.M. (in the muscle) injection on day 1 of up to 5 treatment cycles.
1942040|NCT01261611|Drug|Botulinum type A toxin (Dysport®)|I.M. injection on day 1 of treatment cycle 1.
1942041|NCT01261611|Drug|Placebo|I.M. injection on day 1 of treatment cycle 1.
1942042|NCT01261338|Drug|olestra|non-absorbable dietary fat
1942045|NCT01258764|Drug|Lisinopril|Lisinopril 10 mg oral, once daily for four week cycle and a 2 week cycle
1942046|NCT01258764|Drug|Hydrochlorothiazide|Hydrochlorothiazide 25 mg oral, once daily for 4 week cycle and a 2 week cycle
1942047|NCT01259050|Drug|Zinc and Copper|Optizinc 90 mg/d Copper 1 mg
1942048|NCT01258322|Drug|Pioglitazone|The patients were randomized divided into 2 groups; one received no pioglitazone for lowing triglyceride, one with oral pioglitazone (Actos®, Takeda®) 15mg once daily for 12 weeks. After a four-week wash out, patients then continued with the alternate therapy.
1942050|NCT01257542|Drug|Dextromethorphan|A single 10 mL dose of Children's Triaminic Syrup (Dextromethorphan Hydrobromide 7.5 mg per 5 mL (total dose of 15 mg)
1942051|NCT01257542|Drug|Placebo|A single 10 mL dose of matching placebo syrup
1942052|NCT01256788|Device|Euflexxa|4 injections of 2ml of Euflexxa
1942053|NCT01256788|Other|Saline|4 injections of 3 ml of sterile saline
1942054|NCT01256879|Drug|cimetidine|cimetidine 200mg total dose (single dose) per arm
1942055|NCT01256632|Drug|Ranibizumab|All study eyes will receive 0.5mg, of intravitreous monthly injections of ranibizumab, for four initial doses,(Day 0, Month 1, Month 2, and Month 3),with scheduled follow-up visits monthly for 12 months. Re-treatment after.
1942057|NCT01255488|Behavioral|Access to EBN-Search (without full-text manuscripts)|Family nurse practitioner access to EBN-Search without availability of full-text manuscripts.
1942058|NCT01255358|Drug|Dexamethasone|dexamethasone encapsulated in human erythrocytes. One infusion per month of about 10-15 mg of dexamethasone. The treatment covers 1 month of therapy-
1942059|NCT01254019|Drug|GSK2402968 6mg/kg/week|subcutaneous
1942060|NCT01254253|Device|Percutaneous coronary intervention, PCI|PCI was performed using standard techniques for CTO.
1942067|NCT01253200|Device|Blazer® Open-Irrigated Ablation Catheter|Blazer® Open-Irrigated Ablation Catheter
1942068|NCT01253200|Device|Control Catheter|Open-irrigated radiofrequency ablation catheters that have received FDA market approval for the treatment of type 1 atrial flutter
1942069|NCT01252563|Drug|Amlodipine|Usual adult dosage is 2.5-5 mg of amlodipine given orally as a single daily dose. Dosage should be adjusted depending on the patient's symptoms. The dose can be raised up to 10 mg once daily for patients who show inadequate response.
1942070|NCT01251887|Dietary Supplement|Linoleic Acid|
1942071|NCT01251887|Dietary Supplement|Docosahexaenoic Acid|
1942072|NCT01251887|Dietary Supplement|Eicosapentaenoic Acid|
1942073|NCT01251965|Drug|Ruxolitinib|"Phase I - Starting dose of 50 mg by mouth twice a day for 28 day cycle.
Phase II - MTD reached in Phase I."
1942074|NCT01251822|Drug|PEG 3350 plus electrolytes|Each sachet of PEG 3350 is dissolved in 125 mL of water. Patients receive two sachets of PEG 3350 plus electrolytes followed by two placebo tablets for the first 14 days, after which dosage adjustment is permitted, according to effect. Each patient is treated for 28 days in total.
1942075|NCT01251822|Drug|Prucalopride|"Patients less than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by two prucalopride 1 mg tablets for 28 days.
Patients more than 65 years of age receive a solution containing two sachets of reconstituted placebo followed by one prucalopride 1 mg tablet and one placebo tablet for 28 days."
1942076|NCT01251744|Procedure|Blood sample|Blood sample at study entry, every two months during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
1942077|NCT01251744|Procedure|Cord blood sample|Cord blood sample taken at the time of delivery.
1942078|NCT01251744|Procedure|Saliva swab|Saliva swab taken at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
1942079|NCT01251744|Procedure|Urine sampling|Approximately 10 mL of urine will be sampled at study entry, every month during pregnancy, at pregnancy conclusion and one month after pregnancy conclusion.
1942080|NCT01251744|Procedure|Vaginal swab|Vaginal swab taken at study entry, every month during pregnancy and one month after pregnancy conclusion.
1942081|NCT01250548|Biological|apremilast|30 mg BID apremilast taken orally for the first 12 weeks followed by responders randomized to either 30 mg BID apremilast (oral) or 30 mg BID placebo (oral) for 8 weeks
1942082|NCT01250548|Other|Placebo|
1942085|NCT01250496|Drug|Aminophylline|75 mg of intravenous aminophylline
1942086|NCT01250496|Drug|Placebo|Matching 0.9 Normal Saline (sterile salt water)administered intravenously.
1942087|NCT01250444|Other|Inspiratory Muscle Training|Breathing exercises associated to the use of a training device with predetermined pressure load, daily, 30 minutes per day, during eight weeks.
1942088|NCT01250236|Drug|brimonidine 0.1%|brimonidine 0.1% eye drops twice daily
1942089|NCT01250236|Drug|placebo|sodium hyaluronate 1.8mg/ml eye drops twice daily
1942090|NCT01250210|Drug|levonorgestrel and ethinyl estradiol|pregnancy prevention
1942091|NCT01249027|Device|XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)|Patients who receive XIENCE V® Everolimus Eluting Coronary Stent System (EECSS)will be invited to participate in the study.
1942094|NCT01248585|Drug|Dexamethasone|2 x 4 mg dexamethasone (dex) tablets taken once daily for 5 days
1942095|NCT01248585|Drug|Placebo|2 placebo tablets taken once daily for 5 days
1942096|NCT01248975|Drug|FP/SAL 250/50mcg BID|FP/SAL 250/50mcg BID
1942097|NCT01248975|Drug|GSK2190915 200mg QD (AM)|GSK2190915 200mg QD (AM)
1942098|NCT01248975|Drug|GSK2190915 100mg QD (AM)|GSK2190915 100mg QD (AM)
1942099|NCT01248975|Drug|Montelukast 10mg QD (PM)|Montelukast 10mg QD (PM)
1942100|NCT01248975|Drug|Placebo tablets (2) (AM)|Placebo tablets (2) (AM)
1942101|NCT01248975|Drug|Placebo capsule (PM)|Placebo capsule (PM)
1942102|NCT01248104|Drug|Tranexamic Acid|Infusion during cardiac surgery
1942103|NCT01248104|Drug|Aminocaproic Acid|Infusion during cardiac surgery
1942104|NCT01247350|Drug|LY3009104|Administered orally
1942105|NCT01247350|Drug|Placebo|Administered orally
1942148|NCT01239069|Drug|DE-110 ophthalmic suspension high dose|ophthalmic suspension; high dose; QID
1942106|NCT01246050|Other|3 days of training in HF management|HF training includes didactic lectures, case discussions and interactive symposia, course materials including teaching material, textbooks, copies of HF clinical guidelines and patient education material for distribution, participation in HF Clinics and Inpatient Heart Failure Rounds.
1942107|NCT01246050|Other|Access to clinical pharmacist services|Including medication and disease teaching, adjustment and uptitration
1942108|NCT01246050|Other|Quarterly analysis of physician compliance|Individualized confidential, non-punitive feedback to providers from a set of prespecified core HF performance measures.
1942109|NCT01245517|Other|Education|Dietary Phosphorus Education Program
1942110|NCT01245426|Drug|GW870086 2mg|oral inhalation
1942111|NCT01245426|Drug|GW870086 4mg|oral inhalation
1942112|NCT01245426|Drug|GW870086 Placebo|oral inhalation
1942113|NCT01245426|Drug|GW870086 1mg|oral inhalation
1942114|NCT01245426|Drug|GW870086 3mg|oral inhalation
1942115|NCT01245335|Device|BMAC injection|Injection of 40 ml of autologous bone marrow aspirate concentrate (BMAC injection) prepared with the SmartPReP2 BMAC System
1942116|NCT01245335|Device|Placebo injection|Injection of placebo into ischemic tissue of the lower extremity
1942117|NCT01244334|Drug|Difluprednate ophthalmic emulsion 0.05%|Difluprednate ophthalmic emulsion 0.05%: 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
1942118|NCT01244334|Drug|Prednisolone acetate 1%|Prednisolone acetate 1% : 29 days total, total of 7 drops prior to surgery, and 3 more following surgery while at the surgery center, then Q2H on day of surgery, then QID for 1 week, then BID for 1 week, then stop.
1942119|NCT01244685|Device|Deltex CardioQ Probe|Deltex CardioQ probe will be placed nasally in the operating room by the anesthesia team and fluid management will be administered via anesthesia protocol.
1942120|NCT01244451|Drug|Ofatumumab|Ofatumumab will be administered at the dose of 300 mg IV D1 and 1000 mg IV D8 1st course; 1000 mg IV D1, 2nd -6th courses.
1942121|NCT01244451|Drug|Bendamustine|Bendamustine will be infused at the doses of 70 mg/m2 IV on days D1 and D2 of each course.
1942125|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
1942126|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
1942127|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
1942128|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
1942129|NCT01243151|Biological|PF-04950615 (RN316)|Infusion every week
1942130|NCT01243580|Drug|Ortho-Cyclen (r)|an oral contraceptive containing 35 µg of EE and 250 µg of norgestimate (NGM) in a 21 - 7 day regimen.
1942131|NCT01243580|Drug|AG200-15 containing LNG and EE|transdermal contraceptive delivery system delivering 100 - 120 mcg of LNG and 25 - 30 mcg EE
1942132|NCT01243268|Drug|Twynsta tablet|Telmisartan and Amlodipine T40/A5, T80/A5 and T40/A10
1942133|NCT01242501|Behavioral|60 Minute HIV/STI risk reduction counseling|Single session risk reduction counseling delivered in STI clinic settings in South Africa.
1942134|NCT01242501|Behavioral|20-Min education session|Patients receive a single 20 min education session for STI/HIV information.
1942135|NCT01241318|Drug|Chlorhexidine gluconate (4%)|Chlorhexidine is a topical antiseptic that has long been tested for safety and widely used in developed country hospitals, pre-surgical antiseptic technique, wound cleaning and disinfection. Mothers will be instructed to apply 10 ml of 4% chlorhexidine once a day following the infants bath every day from birth until three days after the cord completely separates from the infant's body.
1942136|NCT01241318|Procedure|Dry cord care|Mothers will be instructed to keep their infants' umbilical cord stumps clean and dry and to not apply any foreign substances to the cord stump.
1942137|NCT01242241|Drug|Propofol|Each Obese child/subject in this group will receive a predetermined dose of propofol ranging from 1.0mg/kg to 4.25mg/kg to induce loss of consciousness depending on the response (presence or absence of lash reflex) of the preceding patient to his/her assigned dose (biased coin design)
1942138|NCT01242241|Drug|Propofol|This arm of patients(non-obese)will act as the control group for the obese children. Each non-obese child/subject will receive a predetermined dose of propofol from a range of 1.0mg/kg to 4.25mg/kg depending on the response of the previous patient to their assigned dose( biased coin design)
1942139|NCT01241812|Behavioral|Lower limb muscle strengthening|Participants in the exercise group will receive a lower limb strengthening program consisting of 6 exercises targeting the quadriceps, hamstrings, and hip abductor groups. They will perform these exercises at home 4 times per week (3 sets of 10 repetitions per exercise). Over the course of the intervention, each participant will consult with the physiotherapist a total of 5 times (once per week in weeks: 1,2,3,5, and 8) to ensure proper performance of exercises and safe progression of resistance.
1942140|NCT01241786|Drug|Revlimid|Lenalidomide PO daily Day 1-21. For patients with baseline calculated creatinine clearance ≥ 30 ml/min and < 60 ml/min the starting dose is 5 mg every other day (odd numbered days during Days 1-21). For patients with baseline calculated creatinine clearance ≥ 60 ml/min the starting dose is 5 mg daily on Days 1-21).
1942141|NCT01241786|Drug|Azacitidine|Azacitidine 75 mg/m2 IV or SC D 1-5
1942142|NCT01241500|Drug|ON 01910.Na|The dose of ON 01910.Na will be 1800 mg/24 hr as a continuous intravenous infusion for 72 hours every other week for the first 16 weeks then every 4 weeks afterwards. Infusion bags must be changed every 24 hours and a new infusion bag must be used for each of the subsequent 24 hours until completion of the total 72-hour infusion time.
1942143|NCT01241461|Drug|LY2584702|"Dose escalation starting at 50 mg. On day 1, subjects will receive a single oral dose. After a two day observation period, subjects will receive oral doses twice daily for a 28 day cycle.
Patients may continue 28 day cycles of twice daily dosing until discontinuation criteria are met."
1942144|NCT01240889|Drug|Fluticasone|nasal spray
1942145|NCT01240889|Drug|Fluticason|2 sprays per day in each nostril
1942149|NCT01239069|Drug|DE-110 ophthalmic suspension low dose|ophthalmic suspension; low dose; QID
1942150|NCT01239069|Other|Placebo|DE-110 ophthalmic suspension vehicle;QID
1942151|NCT01239030|Drug|Methylphenidate Hydrochloride Extended Release Capsules|Biphentin Methylphenidate ER Once-A-Day Capsules
1942152|NCT01238926|Dietary Supplement|PD vitamin supplementation|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid
1942153|NCT01238926|Other|PD exercise intervention|Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
1942154|NCT01238926|Other|PD vitamin + exercise|25 mg/day of Vitamin B6 2,000 mcg/day of Vitamin B12 5 mg/day of Folic Acid Cardiovascular training (treadmill and StairMaster), 20 min; and strength training (2 sets of 15 repetitions of 60-70% of 1 repetition maximum [RM]) using machines that provide the following motions: knee extension, knee flexion, leg press, elbow flexion, elbow extension, seated dip.
1942155|NCT01238536|Procedure|Epidural steroid with local anesthetic injection|Epidural steroid injectate will be 2cc of 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
1942156|NCT01238536|Procedure|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
1942157|NCT01238536|Drug|Epidural steroid injection|Epidural steroid injectate will be 2cc of .25 - 1% lidocaine followed by 1-3 cc of 40 mg/cc Kenalog (i.e. 40-120 mg Kenalog) or an equivalent steroid medication (depo-medrol 60-120 mg, betamethasone 6-12 mg or dexamethasone 8-10 mg) in an opaque syringe.
1942158|NCT01238536|Drug|Epidural local anesthetic injection|Epidural injectate will be 2cc of .25-1% lidocaine followed by 1-3cc of 1% lidocaine in an opaque syringe.
1942159|NCT01237769|Drug|Vitamin D3|2200 IU/day
1942160|NCT01237769|Behavioral|Lifestyle advice|Diet and exercise
1942161|NCT01237899|Drug|LY2623091|Administered orally
1942162|NCT01237899|Drug|Placebo|Administered orally
1942163|NCT01237899|Drug|Eplerenone|Administered orally
1942164|NCT01237821|Drug|BenzaClin|Topical, 1% Clindamycin/5% Benzoyl Peroxide, BID, 12 weeks
1942165|NCT01237821|Drug|Effaclar|Topical, Bid, 12 weeks
1942166|NCT01236742|Device|ortho-k lenses|nightly wear of orthokeratology lenses to correct vision
1942167|NCT01236742|Device|single-vision glasses|daily wear of spectacle glasses to correct vision
1942168|NCT01237678|Drug|IMGN901|Phase 2 regimen is IMGN901, Carboplatin, and Etoposide. IMGN901 to be given on days 1 and 8 every 21 days.
1942169|NCT01237678|Drug|Carboplatin and Etoposide|
1942170|NCT01237470|Procedure|Desarda technique|no mesh technique with undetached strip of external oblique aponeurosis placed at the floor of inguinal canal
1942171|NCT01237470|Procedure|Lichtenstein technique|hernioplasty with the usage of plain polypropylene mesh
1942172|NCT01235949|Biological|GSK1024850A (SynflorixTM)|Intramuscular injection, 4 doses
1942173|NCT01235949|Biological|Infanrix hexa|Intramuscular injection, 3 doses
1942174|NCT01235949|Biological|Infanrix-IPV/Hib|Intramuscular injection, 1 dose
1942175|NCT01235949|Drug|Ibuprofen|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
1942176|NCT01235949|Drug|Paracetamol|Oral administration, 3 doses in the 24 hours following vaccination with an interval of 6-8 hours between doses and with dosage based on the subject's body weight
1942177|NCT01236560|Biological|Bevacizumab|Given IV
1942178|NCT01236560|Drug|Temozolomide|Given PO
1942179|NCT01236560|Drug|Vorinostat|Given PO
1942180|NCT01236521|Drug|Analgesic and co-analgesic therapy|"During the baseline assessment, the nurse care managers will determine current and past treatments for chronic lower back pain and establish whether or not patients have had an adequate trial (i.e., were analgesics sufficiently dosed). If not, the nurse care manager in conjunction with study doctors will recommend an adjustment of the patients' opioid or initiate treatment with a co-analgesic with appropriate dosing and scheduling.
The Patients in the PHARM arm will be asked to sign an opioid treatment agreement at enrollment."
1942181|NCT01236521|Behavioral|Pain self-management/coping skills treatment|There will be 8 sessions that will last a maximum of 45-minutes to optimize participants' attentiveness and performance required by the cognitive demands of pain coping skills training. Each session will adhere to a common structure organized into three parts: 1) check-in; 2) intervention, and 3) wrap-up. Prior to each session participants will be asked to rate the strength and perceived impact for up to four pain beliefs that participants and the psychologist identified together. The sessions will occur during the scheduled clinical contacts (by telephone or face-to-face depending on patient preferences) at: with one week of baseline, 2 and 4 weeks, and months 2, 3, and 4 and skills reinforced at months 6 and 9. The content of these sessions are designed to modify coping strategies found to be related to pain and disability. Briefly, patients will be trained in a variety of evidence-based skills found to help reduce pain and improve function.
1942182|NCT01235351|Drug|Clopidogrel|Clopidogrel 75 mg daily, 150 mg daily, 225 mg daily, and 300 mg daily based on genotype
1942183|NCT01234558|Drug|GLYX-13|single IV dose
1942186|NCT01233791|Drug|Vaginal Diazepam Suppository|10mg compounded vaginal suppository
1942187|NCT01233791|Drug|Placebo Suppository|Patients will be asked to use one vaginal suppository every night for 28 days
1942192|NCT01232868|Biological|trivalent Influenza vaccine (TIV)|0.5 ml IM as a single dose in a prefilled syringe.
1942193|NCT01232738|Drug|rasagiline|rasagiline 2 mg daily for 12 months
1942194|NCT01231243|Procedure|in-office bleaching with/without light|Two clinical sessions of tooth bleaching will be performed in each patient with a 1-week interval between them. In each session, three 15-min applications of the gel will be done using one of the two concentrations under investigation. In half of the sample of each concentration, the gel will be activated with a LED/laser device for a total of 3 min, as specified by the DMC manufacturer.
1942204|NCT01231490|Drug|Placebo|Placebo
1942205|NCT01231490|Drug|Naproxen|Capsule
1942206|NCT01230593|Drug|Tobrex Drops and Ointment|Tobrex drops will be given to the affected eye 3x/day, and Tobrex ointment will be given at night before bed.
1942207|NCT01230593|Drug|Tobradex Drops and Ointment|Tobradex drops will be given to the affected eye 3x/day, and Tobradex ointment will be given at night before bed.
1942208|NCT01230593|Other|Hot Compresses|Hot compresses 3x/day to eyelids
1942209|NCT01229449|Drug|Ibuprofen/acetaminophen|One tablet of ibuprofen 200 mg plus acetaminophen 500 mg and one placebo tablet
1942210|NCT01229449|Drug|Ibuprofen/acetaminophen (higher dose)|Two tablets of ibuprofen 200 mg plus acetaminophen 500 mg
1942211|NCT01229449|Drug|Nurofen Plus®|Two tablets ibuprofen 200mg plus codeine 12.8mg (Nurofen Plus®)
1942212|NCT01229449|Drug|Panadeine® Extra|Two tablets acetaminophen 500 mg plus codeine 15 mg (Panadeine® Extra)
1942213|NCT01229449|Drug|Placebo|Two placebo tablets
1942214|NCT01229280|Drug|Darifenacin|Single dose 7.5 mg tablets of darifenacin
1942215|NCT01229280|Drug|Darifenacin|Single dose 7.5 mg tablets of Darifenacin
1942216|NCT01228734|Drug|Cetuximab|Cetuximab will be administered every 7 days at an initial dose of 400 milligram per square meter (mg/m^2) at 5 milligram per minute (mg/min) and 250 mg/m^2 at 10 mg/min for subsequent infusions until progression of disease, withdrawal of consent, or unacceptable toxicity to cetuximab.
1942217|NCT01228734|Drug|Oxaliplatin|Oxaliplatin 85 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
1942218|NCT01228734|Drug|Folinic Acid|FA 200 mg/m^2 infusion over 120 minutes on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
1942219|NCT01228734|Drug|5Fluorouracil|5-FU as a bolus of 400 mg/m^2/day intravenously over 2-4 minutes followed by 600 mg/m^2/day infusion over 22 hours on Day 1, Day 2, and then every 2 weeks until progression of disease, withdrawal of consent, or unacceptable toxicity.
1942220|NCT01227811|Drug|Darifenacin|Single oral dose Darisec(R) 15.0 mg
1942221|NCT01227811|Drug|Darifenacin|Single oral dose Enablex(R) 15 mg
1942222|NCT01227187|Drug|Drotrecogin alfa activated|We plan to determine the optimal dose of Xigris needed to achieve PTT between 65 and 100 secs. The study will test different dose regimens of Xigris. The initial patients will receive Xigris dosed at an infusion rate of 12 mcg/kg/h via the pre-filter arterial drip chamber via a standard intravenous pump. The PTT will be assessed from blood samples drawn at baseline,15,30,60,120 and 180 mins. The dose of Xigris will be adjusted in the following patients if the afferent PTT rises above 100 secs (normal range 25-40 secs) or if PTT remains <65 secs. If PTT remains less than 65 secs, the dose will be increased to the second dose regiment of 18 mcg/kg/hr. The dose escalation will continue in increments of 6 mcg/kg/h to a maximum dose of 36 mcg/kg/h. Each patient will receive Xigris only once.
1942223|NCT01226485|Drug|RXDX-109|50 - 1000 mg administered orally for at least two 28 day cycles. Patients who demonstrate clinical benefit may receive treatment until discontinuation criteria are met.
1942224|NCT01226615|Drug|Chondroitin sulphate (Condrosan®)|800mg (two capsules of 400mg each) taken once a day for four months
1942225|NCT01226615|Drug|Placebo|Two placebo capsules taken once a day for four months.
1942226|NCT01225783|Other|Self measurement of limb volume +water displacement|Comparison will be made between self measurement is two types of tape measure compared with water displacement
1942227|NCT01225523|Drug|Paclitaxel; Cisplatin; 5-Fluorouracil|Two preoperative cycles with Paclitaxel 200 mg/m² d1, Cisplatin 60 mg/m² d1, 5-Fluorouracil 700 mg/m² d1-5 repeated every 3 weeks followed by resection
1942228|NCT01225523|Drug|Paclitaxel; Cisplatin; 5-Fluorouracil; Capecitabine|Two postoperative cycles with Paclitaxel 200 mg/m²/day d1, Cisplatin 60 mg/m²/day d1, 5-Fluorouracil 700 mg/m²/day d1-5 repeated every 3 weeks Among patients with no responses to preoperative chemotherapy, Capecitabine 625 mg/m² twice-daily dose as alternatives to infused 5-Fluorouracil in the postoperative chemotherapy regimen
1942229|NCT01224678|Dietary Supplement|vitamin D|Given orally
1942230|NCT01224678|Other|placebo|Given orally
1942233|NCT01224522|Procedure|Visionaire|Implantation of a Genesis II Total Knee by means of Visionaire patient matched cutting blocks.
1942234|NCT01224522|Procedure|Standard surgical technique|Implantation of Genesis II Total Knee system by means of standard surgical technique.
1942238|NCT01222091|Drug|Propranolol|
1942239|NCT01222091|Drug|Placebo|
1942240|NCT01223183|Drug|hypertonic saline (7%)|single treatment by inhalation
1942241|NCT01223183|Drug|isotonic saline|single treatment by inhalation
1942242|NCT01222871|Drug|Triamcinolone|Triamcinolone
1942243|NCT01222871|Drug|Triamcinolone|Nasopore Triamcinolone soaked sponge
1942244|NCT01221701|Behavioral|In-Home Cognitive Behavioral Psychology|Adapted form of CBT that is delivered in the home setting, uniquely designed for young, low income new mothers, and is explicitly integrated with home visitation. IH-CBT is delivered by a masters level therapist. It consists of 15 weekly sessions and 1 booster session provided 1 month after the 15th session.
1942245|NCT01221857|Drug|NiCord®|NiCord® is a cell-based product composed of umbilical cord-derived ex vivo expanded stem and progenitor cells.
1942246|NCT01221792|Drug|Carvedilol|"Oral, twice daily dosing using 3.125 mg tablets.
1 week titration (6.25 mg/day)prior to a 3 week flexible dosing option ranging from 6.25 mg/day to 15.625 mg/day followed by a 1 week taper (6.25 mg/day)."
1942247|NCT01221792|Drug|Placebo|Non active comparator
1942248|NCT01221181|Drug|Eculizumab|"900 mg IV once a week x 4 weeks, 1200 mg IV week 5, then 1200 mg IV every 2 weeks through week 53.
Patients will be observed for 60 minutes after the first 5 infusions, then 30 minutes after all subsequent infusions. Patients will not be allowed to take other immunomodulatory therapies during the study period but will continue on their other non-immunomodulatory therapies (e.g. ACE inhibitors, -statins, aspirin) without modifications unless clinically indicated. All patients, if unvaccinated, will be given N. meningitidis vaccine at least two weeks prior to first eculizumab exposure. All female patients of childbearing potential will be asked to use adequate contraception methods during treatment and up to 5 months following discontinuation of eculizumab treatment."
1942249|NCT01220973|Drug|atorvastatin calcium|
1942250|NCT01220973|Drug|celecoxib|
1942251|NCT01220973|Other|laboratory biomarker analysis|
1942252|NCT01220726|Drug|Botox/Placebo|Botox/Placebo injection
1942253|NCT01220726|Drug|Botox/Placebo|Botox/Placebo injection
1942254|NCT01219322|Drug|Sodium bicarbonate|single use of sodium bicarbonate and sterile water for injection 1:1 concentration 50 cc
1942255|NCT01219322|Drug|normal saline|intravenous normal saline volume equivalent to sodium bicarbonate
1942256|NCT01220414|Drug|Naltrexone,|50 mg of naltrexone
1942257|NCT01220414|Drug|Placebo|sugar pill
1942258|NCT01220167|Drug|Ondansetron|"Participants were served dinner to ensure a minimum of 10 hours of fasting. Participants were dosed with a 3 day washout period between each administration.
Blood samples were obtained."
1942259|NCT01220167|Drug|Ondansetron|"Participants were served dinner to ensure a minimum of 10 hours of fasting. Participants were dosed with a 3 day washout period between each administration.
Blood samples were obtained."
1942260|NCT01218126|Drug|losmapimod|comparison of different dosages of drug
1942261|NCT01218126|Drug|placebo|placebo comparison with active
1942262|NCT01218672|Device|GreenLight XPS vs. TURP|"GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.
Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study."
1942263|NCT01218113|Biological|GSK Biologicals HIV Vaccine 732462|2 or 3 doses according to protocol schedule
1942264|NCT01218113|Drug|Placebo|1 or 3 doses according to protocol schedule
1942265|NCT01218204|Drug|10mg atorvastatin|10mg
1942266|NCT01218204|Drug|80mg atorvastatin|80mg
1942267|NCT01218204|Drug|GSK1292263 Placebo|Placebo
1942268|NCT01218204|Drug|100mg GSK1292263|100mg
1942269|NCT01218204|Drug|300mg GSK1292263|300mg
1942270|NCT01218204|Drug|800mg GSK1292263|800mg
1942271|NCT01218204|Drug|10mg ezetimibe|10mg
1942272|NCT01218204|Other|Washout|No interventions - washout period
1942273|NCT01217190|Drug|Ondansetron Orally Dissolving Film|Two-wy cross-over study to compare ondansetron ODSF with Zofran ODT
1942274|NCT01217190|Drug|Ondansetron Orally Disintegrating Tablet|Two way cross-over study to compare ondansetron ODSF with Zonfran ODT
1942275|NCT01217190|Drug|Ondansetron OSF|Two way cross-over study to compare ondansetron ODSF with Zonfran ODT
1942276|NCT01217788|Drug|PH94B intranasal spray|Comparison of PH94B single dose intranasal spray and Placebo single dose intranasal spray
1942277|NCT01217489|Procedure|Breast scan - Electrical Impedance Mammography|Scanning of the breast on a non-invasive device, using harmless minute electrical currents
1942278|NCT01217385|Drug|systemic chemotherapy|
1942279|NCT01217385|Other|laser spectroscopy|
1942280|NCT01217385|Procedure|breast imaging study|
1942281|NCT01217385|Procedure|magnetic resonance imaging|
1942282|NCT01217385|Procedure|mammography|
1942283|NCT01217385|Procedure|neoadjuvant therapy|
1942284|NCT01217385|Procedure|therapeutic conventional surgery|
1942285|NCT01217385|Procedure|ultrasound imaging|
1942286|NCT01217307|Drug|Metformin|Metformin 500mg twice daily during 4 months
1942287|NCT01217307|Drug|Placebo|Placebo twice daily during 4 months
1942318|NCT01212848|Device|Transcranial Magnetic Stimulation|Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.
1942319|NCT01212848|Device|Transcranial Magnetic Stimulation - Sham Comparator|"The control group will receive an identical dosing schedule of sham repetitive TMS over three days."
1942288|NCT01217138|Device|Epinephrine autoinjector|We used 2 epinephrine autoinjector trainers and wrapped them by a gray sticky paper. Then,modified one of the trainers by changing gray safety cap to red with an atomizer paint and placing a yellow arrow pointing to the black injection tip.We provided three-step written and visual instruction sheet to use epinephrine autoinjector in Turkish same as given on the original trainer and changed that of the second trainer according to the modifications we made. Scoring system originally devised by Sicherer et al was used. Participants successively doing all steps were accepted to demonstrate autoinjector use correctly. Participants who tackled with black tip of autoinjector in order to eject needle after removing safety cap was regarded as unsuccessful since this may cause unintentional injection of epinephrine. All participants were scored and timed separately.
1942289|NCT01216566|Device|Occiflex Device|This device is a computerized robotic platform that allows continuous mobilization of the cervical spine in a three dimensional space. The patients undergoes biweekly 20 minute therapeutic session for 6 weeks
1942290|NCT01216332|Drug|High-dose trivalent inactivated influenza vaccine|0.5 mL of high-dose trivalent inactivated influenza vaccine, either one dose or 2 based on whether the patient has previously received standard dose trivalent inactivated influenza vaccine.
1942291|NCT01216332|Drug|Standard dose trivalent inactivated influenza vaccine|0.5 mL standard dose trivalent inactivated influenza vaccine
1942295|NCT01215318|Procedure|Feasability|
1942296|NCT01214629|Drug|LY2523355|Administered intravenously on days 1, 2,3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 alone arm is 0.125mg/m2.
1942297|NCT01214629|Drug|LY2523355|Administered intravenously on Days 1, 2,3 of each 21-day cycle for at least 2 cycles. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met. Starting dose for LY2523355 + pegfilgrastim is 4mg/m2.
1942298|NCT01214629|Drug|pegfilgrastim|6 mg administered subcutaneously on day 4 of each 21-day cycle for the 2 planned cycles and for any subsequent cycles of LY2523355 received.
1942299|NCT01214850|Biological|Meningococcal B Recombinant + Outer Membrane Vesicle vaccine (rMenB+OMV NZ)|
1942300|NCT01214850|Biological|MenACWY-CRM conjugate vaccine|
1942301|NCT01214850|Biological|Japanese Encephalitis vaccine|
1942302|NCT01214837|Biological|MenACWY-CRM|This group received a 3-dose primary series at 2, 4, and 6 months of age and a toddler dose at 12 months of age. Approximately half of the subjects had serum collected at Month 3, and the remainder had serum collected at Month 4.
1942303|NCT01214837|Biological|MenACWY-CRM|This group received a 2-dose primary series at 2 and 4 months of age and a toddler dose at 12 months of age.
1942304|NCT01214837|Biological|Routine Vaccines|Each 0.5 mL dose of the pneumococcal 13-valent conjugate vaccine (diphtheria CRM197 protein) is formulated to contain approximately 2.2 μg of each of Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 7F, 9V, 14, 18C, 19A, 19F, 23F saccharides.
1942305|NCT01214655|Drug|LY2523355|Administered intravenously for at least 2 cycles. Cycle length is 21 days. Participants may continue on study drug until disease progression, unacceptable toxicity or other withdrawal criterion is met.
1942306|NCT01214642|Drug|pegfilgrastim|Administered subcutaneously
1942307|NCT01214642|Drug|LY2523355|Administered intravenously
1942308|NCT01214265|Device|EMKinetics non-invasive Magnetic neurostimulator|Patients will be treated with 12 weekly sessions of magnetic stimulation of the posterior tibial nerve at 20 hz using the EMKinetics non-invasive Magnetic neurostimulator.
1942309|NCT01213407|Drug|Trivax, Temozolomide, Surgery, Radiotherapy|"Trivax: 5 x 10e6 dendritic cells, intranodal in 500 µl NaCl, weeks 7, 8, 9, 10, 12, 16, 20, 24, 28, 32
Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy
Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6.
Break: weeks 7, 8, 9, 10.
Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31."
1942310|NCT01213407|Drug|Temozolomide, Surgery, Radiotherapy|"Irradiation: 2 Gy per fraction once daily, five days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6, total dose 60 Gy
Temozolomide concomitant to radiotherapy: 75 mg/m²/day, 5 days per week (Mo-Fr), weeks 1, 2, 3, 4, 5, 6
Break: weeks 7, 8, 9, 10
Temozolomide adjuvant: 150 mg/m²/day, five days per week (Mo-Fr), week 11; 200 mg/m²/day, five days per week (Mo-Fr), weeks 15, 19, 23, 27, 31"
1942313|NCT01213524|Behavioral|sensorimotor replacement|denicotinized cigarettes
1942314|NCT01213524|Drug|42 mg transdermal nicotine replacement|2 21-mg nicotine patches
1942315|NCT01213524|Drug|Placebo transdermal nicotine|2 placebo patches matched to 21-mg nicotine patches
1942316|NCT01213524|Other|usual brand smoking|participant smokes usual brand of cigarette
1942320|NCT01212809|Device|Juvéderm Ultra|Split-face injection of Juvéderm Ultra into vertical lip rhytids and radial cheek lines on one side of face
1942321|NCT01212809|Device|Cosmoderm 1|Split-face injection of Cosmoderm 1 into vertical lip rhytids and radial cheek lines on one side of face
1942322|NCT01212367|Biological|SCH 721015|1.0 x 10e12 viral particles on Days 1 and 4
1942323|NCT01212367|Biological|SCH 721015|3.0 x 10e11 viral particles on Days 1 and 4
1942324|NCT01211587|Drug|safinamide|Safinamide will be provided in tablets equivalent to 50 mg in blisters. After randomization, patients receiving safinamide will take two 50 mg tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
1942325|NCT01211587|Drug|placebo|Identical placebo tablets will be provided in blisters. After randomization, patients receiving placebo will take two tablets once per day for 12 weeks (weeks 1-12). During the open label phase, patients will receive 100mg of safinamide once per day (two 50 mg tablets) for 12 weeks (weeks 13-24).
1942326|NCT01210612|Device|five-toed socks|five-toed socks usage
1942327|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
1942328|NCT01210560|Drug|Tolvaptan MR|20 mg Tolvaptan MR capsule(morning and afternoon); Placebo capsules/tablets (morning and afternoon) for 7 days
1942329|NCT01210560|Drug|Tolvaptan MR|60 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
1942330|NCT01210560|Drug|Tolvaptan IR|90 mg Tolvaptan IR tablet(morning); 30 mg Tolvaptan IR tablet (afternoon); Placebo capsules (morning and afternoon) for 7 days
1942331|NCT01210560|Drug|Tolvaptan MR|120 mg Tolvaptan MR capsule(morning); Placebo capsules/tablets (morning and afternoon) for 7 days
1942332|NCT01209598|Drug|Palbociclib|"Treatment will consist of either:
Schedule 2/1: Palbociclib 200mg given once daily by mouth for 14 consecutive days, followed by 7 days of rest. A cycle will be defined as 21 days.
Schedule 3/1: Palbociclib 125mg given once daily by mouth for 21 consecutive days, followed by 7 days of rest. A cycle will be defined as 28 days. Following the positive results of the study, a new Expansion Cohort has been added to permit enrollment of up to 20 additional patients.
Expansion Cohort: Dosed as per Schedule 3/1. Capsules should be taken with food."
1942333|NCT01209923|Device|BC1|Body composition measures taken twice at the same visit for BIA, DEXA, and hydrostatic weighing.
1942334|NCT01209611|Procedure|Autologous bone marrow mononuclear cells|Autologous bone marrow-derived mononuclear cells, after isolated by density gradient centrifugation from bone marrow aspiration and resuspended in saline, will be transplanted subcutaneously to expanded skin. The number of infused cells will be 1x10e6/cm2.
1942335|NCT01209611|Procedure|Placebo|Patients will have mimical bone marrow aspiration under local anesthesia following with saline injection to expanded skin.
1942340|NCT01208012|Drug|Victoza®|Patients taking Metformin at individual dose and Liraglutide 0.6 mg once daily for the 1st week, 1.2 mg daily for another 5 weeks, 1.8 mg daily for another 6 weeks. When arrived at the dosage of 1.8 mg daily and the dose is not tolerated by the patient, the dose of Liraglutide can be decreased.Liraglutide is injected in the subcutaneous tissue once daily
1942341|NCT01207752|Drug|Systane Balance|Artificial tear emulsion drop
1942342|NCT01207752|Drug|Optive Lubricant Eye Drops|Artificial tear eye drop
1942343|NCT01207726|Drug|Azacitidine|Given SC
1942344|NCT01207726|Drug|Entinostat|Given PO
1942345|NCT01207726|Other|Laboratory Biomarker Analysis|Correlative studies
1942348|NCT01205880|Drug|Calcitriol ointment|twice daily
1942349|NCT01205880|Drug|Clobetasol spray|twice daily
1942351|NCT01205568|Procedure|Transcatheter Cutting Balloon therapy|
1942352|NCT01205568|Procedure|High Pressure Balloon Angioplasty|
1942354|NCT01205165|Drug|Adefor dipivoxil|All enrolled subjects were enrolled to adefovir dipivoxil arm.
1942355|NCT01204424|Device|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)|minimal-invasive sinus floor augmentation with the DKK and SVP (JEDER Syst.)
1942356|NCT01204424|Device|minimal invasive crestal sinus lift with the JEDER Systh.|"The mucous membrane is opened from the toothless part of the maxillary crest up to the bone and the bone is scraped by a cylindrical cutter in the shape of a tunnel up to slightly underneath the maxillary sinus membrane and hydraulic pressure is being built up within the DKK. A centrally placed drill within the DKK slowly moves in the direction of the membrane. At the moment of the first minimal perforation of the remaining bone the pressurized fluid pushes the membrane back and ensures that the membrane is not perforated by the drill.
The SVP is used to generate hydraulic vibrations, which help to further raise the membrane from the bone (principle of the percussion drill). After the maxillary sinus membrane has successfully been elevated, the working fluid is extracted and bone replacement material is introduced via the bore."
1942359|NCT01204710|Biological|IMC-3G3|15mg/kg I.V. Days 1 and 8
1942360|NCT01204710|Drug|Mitoxantrone|"Mitoxantrone 12 mg/m2 I.V. Day 1
Mitoxantrone is to be administered for up to 12 cycles (total cumulative dose of mitoxantrone is restricted to ≤ 144 mg/m2)"
1942364|NCT01204528|Drug|Zemplar|Vitamin D receptor activator (VDRA)
1942365|NCT01203189|Drug|ketoconazole 2% foam|Subjects in the F group will apply ketoconazole 2% foam to the scalp twice daily for four weeks.
1942366|NCT01203189|Drug|ketoconazole 2% shampoo|Subjects in the S group will wash their hair twice weekly for four weeks with ketoconazole 2% shampoo.
1942368|NCT01201863|Drug|Androgel (Testosterone Gel)|2.5 gram stickpacks administered with starting dosage of 5g increasing to a max of 10g.
1942369|NCT01201863|Drug|Androgel Placebo|2.5 gram stickpacks with starting dose of 5g increasing to max of 10g.
1942370|NCT01200030|Behavioral|electrical stimulation with exercises|electrical stimulation with exercises
1942371|NCT01200030|Behavioral|placebo stimulation with exercises|placebo stimulation with exercises
1942372|NCT01200485|Drug|Rasburicase|"Cycle 1: All receive 3 mg/kg by vein on Day 1, plus as needed dosing (until day 5), during Cycle 1.
Cycle 2 Arm A: 0.15 mg/kg by vein on Day 1 of Cycle 2, plus as needed dosing (until day 5), during Cycle 2."
1942373|NCT01200485|Drug|Allopurinol|Arm B: 300 mg/day by vein over 30 minutes each day on days 1-5 of cycle 2 in 21 day cycle.
1942374|NCT01199731|Drug|GSK2248761 100 mg once daily|1 100mg capsule OAD plus matching placebo
1942375|NCT01199731|Drug|GSK2248761 200 mg once daily|2 100mg capsules OAD
1942376|NCT01199731|Drug|Etravirine|2 100mg tablets twice daily
1942377|NCT01198431|Behavioral|Sleep duration|Duration of sleep per night
1942378|NCT01198587|Drug|Zinc Sulfate|"For children ages 6month to 1 year, 12.5mg orally daily for 14 days mixed in 60 mL of fluid.
For children aged 1 year and above 25mg orally daily for 14 days mixed in 60 mL of fluid."
1942383|NCT01198132|Dietary Supplement|Cholecalciferol (Vitamin D3)|Subjects will be receiving 100 000 International units (IU - 1 IU is biological equivalent of 0.025µg cholecalciferol) twice monthly, i.e. one dose fortnightly (equivalent to a daily dose of approximately 7142 IU) during the 24-month period.
1942384|NCT01197105|Biological|Use of natural product (Schinus terebinthifolius)|Mouthwash (0,3125% of schinus terebinthifolius) 10mL per day during 14 days.
1942385|NCT01196195|Drug|Kaletra dosed once daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = once daily.
1942386|NCT01196195|Drug|kaletra dosed twice daily|Lopinavir/Ritonavir tablets. Dose = 200/50mg or 100/25mg. Frequency = twice daily.
1942387|NCT01196819|Procedure|DES implantation|Implant DES for CAD cases
1942388|NCT01196117|Device|14 days of CPAP therapy|14 days of continuous positive airway pressure (CPAP) therapy with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
1942389|NCT01196117|Device|14 days of placebo therapy|14 days of placebo therapy - use of guaifenesin with salivary cortisol measurement and Epworth Sleepiness Score (ESS) documentation
1942403|NCT01196533|Device|Non invasive peripheral blood monitoring|non invasive monitoring
1942404|NCT01195545|Device|Veritas® Collagen Matrix|biological mesh in hernia repair
1942405|NCT01195792|Drug|GSK1521498|GSK1521498 2mg or 5mg will be given for up to 35 days and subjects will be assessed weekly
1942406|NCT01195792|Drug|Placebo|Placebo will be given for up to 35 days and subjects will be assessed weekly
1942407|NCT01195129|Device|MicroVention Hydrogel coil|Micro Vention Hydrogel Coils
1942408|NCT01195129|Device|Non-hydrogel coils|Cerecyte or bare platinum coils
1942411|NCT01194518|Behavioral|Lifestyle Intervention Program|
1942412|NCT01194271|Drug|Leuprolide Acetate|22.5 mg administered as a single intramuscular 3 month depot.
1942413|NCT01194271|Drug|Ipilimumab|10 mg/kg by vein administered as 2 single doses, 3 weeks apart after hormone therapy.
1942414|NCT01194271|Procedure|Radical Prostatectomy|Surgery to remove prostate gland approximately 4 weeks after the second dose of Ipilimumab.
1942415|NCT01193530|Device|Bright Light Therapy Device|30 minutes every day for 14 days.
1942416|NCT01193530|Device|Dim Red Light Therapy Device|Initially 30 minutes every day for 14 days where red light device accounts for placebo.
1942417|NCT01193530|Behavioral|Questionnaires|Weekly
1942418|NCT01193530|Behavioral|Study Diaries|Daily logs
1942419|NCT01193257|Drug|Orteronel + prednisone|Orteronel and prednisone will be administered orally twice a day continuously throughout the study until disease progression is documented
1942420|NCT01193257|Drug|Placebo + prednisone|Placebo and prednisone will be administered orally twice a day continuously throughout the study until disease progression is documented
1942421|NCT01191541|Drug|Ara-c|"Drug: ATRA 25mg/m2 day until complete remission (CR)
Drug: As2O3 Induction:0.15-0.2mg/kg d1-28 iv Consolidation: 0.15-0.2mg/kg d1-28 iv in cycle 2 Drug: Idarubicin 10 mg/m2 days1-3 in Consolidation1 Drug: Ara-C some patients consolidation with Ara-C in cycles 3 and 4. Ara-c 1g/m2 d1-3 iv Drug: DNR 45 mg/m2 days1-3 in Consolidation 3 and 4"
1942422|NCT01192100|Behavioral|Breakfast Skipping|Participants will continue to skip breakfast each morning.
1942423|NCT01192100|Behavioral|Normal Protein Breakfast Meals|Participants will consume normal protein breakfast meals each morning.
1942424|NCT01192100|Behavioral|Protein-rich Breakfast Meals|Participants will consume protein-rich breakfast meals each morning.
1942425|NCT01192035|Drug|Efavirenz or Nevirapine|"2 NRTIs (lamivudine 150 mg bis in die - twice a day (BID) and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 NNRTI (efavirenz 600 mg omne in die - once daily (OD) or nevirapine 200 mg OD for the first 2 weeks and after that 200 mg BID). Efavirenz will be used in all male patients according to national HIV guidelines. Pregnant patients and female patients with a child bearing potential will be treated with nevirapine if CD4+ cell count is ≤ 350 cells/mm3 with close monitoring of liver enzymes during the first 12 weeks in patients with CD4+ cell count >250 cells/mm3. Females beyond childbearing age will be treated with efavirenz."
1942426|NCT01192035|Drug|Ritonavir-boosted lopinavir|2 NRTIs (lamivudine 150 mg BID and either zidovudine 300 mg BID if hemoglobin is ≥ 8 g/L or stavudine 30 mg BID if hemoglobin is < 8 g/L) and 1 PI (ritonavir-boosted lopinavir 400/100 mg BID).
1942427|NCT01190020|Drug|Lubiprostone|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
1942428|NCT01190020|Drug|Lubiprostone Control|Colonic transit study performed and stool/symptom diaries will be reviewed. Eligible subjects will be given a lactulose breath test and randomized to Lubiprostone or placebo. Treatment group receives 24 mcg Lubiprostone twice daily and placebo group receives pills (identical in appearance to the study drug) for one month. Subjects will be asked to maintain a daily stool/symptom diary for duration of the study. In the middle of the study a research coordinator will call the subjects to take questions/concerns and record adverse events. Lactulose breath test will be repeated, constipation questionnaire filled out, colon transit study performed.
1942429|NCT01190228|Biological|Japanese encephalitis chimeric virus|0.5 mL (single dose), Subcutaneous
1942430|NCT01190228|Biological|Japanese encephalitis chimeric virus|0.5 mL (single dose), Subcutaneous
1942431|NCT01190228|Biological|Varicella vaccine|0.5 mL (single dose), Subcutaneous
1942432|NCT01190202|Procedure|Blood sampling|Capillary blood samples collected by finger/heel prick
1942433|NCT01190202|Procedure|Assessment of body temperature|Assessment of axial body temperature with a digital thermometer
1942434|NCT01189656|Biological|HBV DNA Vaccine|HBV DNA Vaccine, 1mg/ml/syringe, formulation
1942435|NCT01189058|Procedure|Repetitive Transcranial Magnetic Stimulation (rTMS)|TMS can affect discrete functional ares of motor cortex offering non-invasive, painless mapping and modulation of motor systems. Inhibitory rTMS (1Hz)has been shown to safely lower motor cortex excitability in normal patients as well as adult and pediatric stroke patients. Dose is 20 minutes per day (1200 stimulations) x 10 days administered over the non-lesioned M1.
1942436|NCT01189058|Procedure|Constraint-induced movement therapy (CIMT)|CIMT uses gentle restraint of the fully functional upper extremity to promote functional gains in the affected upper extremity. CIMT is well established to be safe and is likely effective in children with hemiplegic cerebral palsy, many of whom have perinatal stroke as studied here. A custom-fitted, bivalved cast is applied and worn for >90% of waking hours for the 2 weeks of active treatment according to protocol with daily assessments for comfort.
1942437|NCT01188460|Behavioral|Sleep diary|Completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
1942438|NCT01188460|Behavioral|Self-help manual for insomnia|Implementation of chapters of self-help manual at home, and completion of sleep diary in terms of time in bed, hours of sleep, time to fall asleep, number of awakenings, and sleep quality
1942439|NCT01187966|Drug|Safinamide|
1942440|NCT01187966|Drug|Safinamide|
1942441|NCT01187966|Drug|Placebo|
1942444|NCT01186653|Drug|budesonide / formoterol|budesonide / formoterol, 400 micrograms/9 micrograms one IH bd
1942445|NCT01186653|Drug|fluticasone/salmeterol|fluticasone/salmeterol, 250 micrograms/25 micrograms two puffs bd, dose as per NICE guidelines
1942446|NCT01186809|Biological|in vitro expanded Cytokine Induced Killer (CIK) cells|Three infusions of donor Cytokine Induced Killer (CIK) cells will be administered according to a dose escalating program, starting 3 weeks after second Donor Lymphocyte Infusions (DLI). Cytokine Induced Killer administrations will be separated by 3 weeks intervals
1942447|NCT01186172|Drug|Ethanol-lock therapy|Daily ethanol-lock with 70% ethanol instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
1942448|NCT01186172|Drug|Antibiotic-lock|Daily antibiotic-lock according to 2009 IDSA Guidelines,instilled in device dead-space, leaved in place for the longest possible interval, and then discarded. For dialysis devices, it is acceptable to leave the lock in place between dialysis sessions. Lock therapy will be continued for 7 days.
1942449|NCT01185821|Drug|BAF312|
1942450|NCT01185236|Drug|simvastatin/ezetimibe|simvastatin/ezetimibe 10/20mg once daily for 12weeks
1942555|NCT01165229|Biological|Placebo|Intramuscular injection.
1942451|NCT01185236|Drug|atorvastatin 20mg|atorvastatin 20mg once daily for 12weeks
1942452|NCT01184196|Drug|Swab area with Betadine|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
1942453|NCT01184196|Drug|Swab area with ChloraPrep|A swab will be taken over the operative knee before surgical site preparation is started, after preparation has taken place, and 24 hours post-surgery.
1942454|NCT01183923|Other|Broccoli Sprouts|Broccoli Sprouts will be eaten daily in a sandwich form.
1942455|NCT01183143|Drug|Follitropin alpha (Gonal-F)|In a common setting, for OI the starting daily dose of Gonal-F will be 75-150 IU generally not exceeding beyond 225 IU. The starting dose of Gonal-F in IVF/ICSI will be 150-225 IU/day not exceeding beyond 450 IU/day.
1942456|NCT01183559|Drug|ZD6474 (Zactima)|
1942457|NCT01183260|Device|Zimmer Trabecular Metal Revision Cup|Revision of the acetabular cup
1942458|NCT01183260|Device|Zimmer Modular Cup|Revision of the acetabular cup
1942459|NCT01183156|Behavioral|Re-invitation letter|Re-invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
1942460|NCT01183156|Behavioral|Invitation to educational meeting|Invitation will be sent 6 weeks prior to educational meeting date and followed by a reminding letter 3 weeks later. Educational meetings will be held in a local culture developement centers and conducted by a medical team responsible for the Polish Colorectal Cancer Screening Program. The aim of the meeting is to overcome barriers to screening colonoscopy. The program of the meeting is tailored to individual needs, doubts, and concerns of the participating group as assessed using brief survey at the beginning of the meeting. The major points to be discussed are: risk and benefit of screening, colorectal cancer risk, pain and sedation, preparation to colonoscopy, consecutive stages of the procedure, comfort and embarrassment.
1942461|NCT01182441|Device|WATCHMAN Device|WATCHMAN Left Atrial Appendage Closure Technology
1942462|NCT01182441|Drug|Warfarin|Warfarin dosage prescribed by study physician to adequately maintain an INR of 2.0-3.0
1942463|NCT01181596|Device|ultrasound probing|Ultrasound probing and imaging data collection.
1942464|NCT01181479|Drug|AG200-15 transdermal patch|Transdermal patch containing ethinyl estradiol and levonorgestrel
1942465|NCT01181479|Drug|Oral Contraceptive|Low dose oral contraceptive containing 20 mcg ethinyl estradiol and 100 mcg Levonorgestrel in 21 day regimen
1942466|NCT01180478|Device|White Light|White Light Cystoscopy
1942467|NCT01180478|Device|Narrow Band Imaging|Narrow Band Imaging
1942468|NCT01179282|Biological|dust mite extract or placebo|intervention will be to stop study drug or placebo
1942469|NCT01179750|Device|Ultrasonic Coagulating Shears|comparison of operated groups between with Ultrasonic Coagulating Shears and without them.
1942470|NCT01179659|Drug|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
1942471|NCT01179191|Drug|morphine sulfate and naltrexone hydrochloride (EMBEDA)|Capsules in dose strengths ranging from 20 to 100 mg morphine sulfate with 0.8 to 4 mg of naltrexone hydrochloride taken either once or twice daily with a starting dose calculated using the total daily dose of the current opioid being converted from until a stable dose is achieved or six weeks which ever comes first.
1942472|NCT01179646|Drug|Pantoprazole 40 mg DR Tablet vs. Protonix 40 mg DR Tablet|Single dose crossover BE study
1942476|NCT01178411|Drug|ARQ 197 as monotherapy or in combination with other drug(s)|ARQ 197 as monotherapy or in combination with other drug(s) at the same dose(s), and same schedule(s) in which they were originally enrolled.
1942477|NCT01177696|Behavioral|Psychotherapeutic intervention|A psychotherapeutic intervention will be 8 sessions of 90 minutes in a pilot study groups. This intervention has been initially developed for family caregivers of patients with dementia.
1942478|NCT01177566|Drug|pimecrolimus|pimecrolimus 1% cream twice daily
1942479|NCT01177566|Device|topical medical device|Eletone cream three times daily
1942480|NCT01176435|Drug|Levodopa|Solution taken orally three times a day.
1942481|NCT01176435|Drug|Levodopa|Solution taken orally three times a day.
1942482|NCT01176435|Drug|Levodopa|Solution taken orally three times a day.
1942483|NCT01176617|Device|Reveal XT implantable loop recorder|All study participants will receive the Reveal XT implantable loop recorder immediately after completion of the ablation procedure.
1942487|NCT01175889|Device|E-Z Clean ACE Blade|The prospective assessment of the E-Z Clean ACE electrosurgical electrodes using the ACE Blade in the ACE Mode for targeted procedures such as abdominoplasty, bilateral breast reduction, bilateral breast lifts, bilateral brachioplasty, bilateral lateral thigh and buttocks lifts, or any combination thereof.
1942488|NCT01175876|Device|remote limb ischemic preconditioning|Remote limb ischemic preconditioning consisted of five 5-min cycles of right upper arm ischemia/reperfusion, which was induced by an automated cuff-inflator placed on the right upper arm which was inflated to 200 mmHg for 5mins followed by deflating the cuff for 5mins
1942489|NCT01175876|Procedure|Carotid Artery Stenting|Carotid Artery Stenting is an invasive therapy of carotid stenosis.
1942493|NCT01173302|Biological|Rabies vaccine, manufactured by ChengDa|1 dose before the antibody is tested
1942494|NCT01173016|Drug|Laronidase|Laronidase 0.58 mg/kg intravenously (IV) once a week for a maximum of 2 years
1942495|NCT01172652|Drug|Ziprasidone|The minimum dose during study participation will be 40 mg/day, and the maximum dose allowed will be 160 mg/day.
1942496|NCT01172652|Drug|Placebo|Inactive control
1942497|NCT01171885|Drug|0.9% saline|20 ml of 0.9% saline
1942498|NCT01171885|Drug|Ropivacaine|20 ml of Ropivacaine 0.25%.
1942499|NCT01171885|Drug|Ropivacaine|20 ml of Ropivacaine 0.5%.
1942500|NCT01171209|Drug|Interferon-beta and human leukocyte Interferon-α|One single injection of interferon(IFN)- β and one single injection of human leukocyte IFN-α (Multiferon® ) 6 MIU s.c. with 1-7 days follow-up.
1942501|NCT01171664|Drug|Placebo|Tablet, one BID
1942502|NCT01171664|Drug|STAHIST|STAHIST in tablet form dosed one BID
1942503|NCT01171560|Procedure|endotracheal intubation|The patients will be randomized to one of two groups: EZ Blocker or conventional double lume tube. After induction of anesthesia, intubation using respective device will be performed in dorsal position.
1942504|NCT01170065|Drug|BIBF 1120|Intermediate dose BIBF 1120 twice daily
1942505|NCT01170065|Drug|BIBF 1120|High dose BIBF 1120 twice daily
1942506|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 twice daily
1942507|NCT01170065|Drug|BIBF 1120|Low dose BIBF 1120 once daily
1942508|NCT01169532|Drug|ridaforolimus|Given PO
1942509|NCT01169532|Drug|vorinostat|Given PO
1942510|NCT01169532|Procedure|biopsy|Optional correlative studies
1942511|NCT01169532|Other|pharmacological study|Correlative studies
1942512|NCT01169532|Other|laboratory biomarker analysis|Correlative studies
1942522|NCT01168908|Drug|Sildenafil|20mg tablet three times daily
1942523|NCT01168700|Drug|aged garlic extract|Aged garlic extract, 1.2 g per day for 12 weeks
1942524|NCT01168700|Drug|Placebo|Placebo 1.2 g per day for 12 weeks.
1942525|NCT01168453|Behavioral|head position change|AL-US distance measure using the ultrasound in two different head position
1942526|NCT01168401|Biological|Bivalent Norovirus Vaccine|"2 Doses 28 days apart Cohort A: 18-49 Years
Cohort A1: IM Norovirus Bivalent VLP Vaccine (5/5 mcg)
Cohort A2: IM Norovirus Bivalent VLP Vaccine (15/15 mcg)
Cohort A3: IM Norovirus Bivalent VLP Vaccine (50/50 mcg)
Cohort A4: IM Norovirus Bivalent VLP Vaccine (150/150 mcg)
Cohort B: 50-64 years IM Norovirus Bivalent VLP Vaccine at the chosen dose from Cohort A
Cohort C: 65-85 years IM Norvirus Bivalent VLP Vaccine at the chosen dosage from Cohort A
Cohort D: 18-49 Years of Age IM Norovirus Bivalent VLP Vaccine at the Chosen Dosage from Cohort A"
1942527|NCT01168401|Biological|Saline|Two doses 28 days apart
1942528|NCT01167348|Procedure|auricular acupressure|Investigator will put a tape with a 0.5mmx0.5mm seed on the specific positions on the ear of participants of intervention group, and participants will be asked to press these specific positions 3 times a day.
1942529|NCT01167907|Drug|0.2% ropivacaine|0.2% ropivacaine by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
1942530|NCT01167907|Drug|saline|saline (control) by elastomeric infusion pump at 5ml/h started within 6h of catheter placement
1942531|NCT01167179|Behavioral|nurse-led consultation|Content of the intervention The intervention consists of structured and standardised nursing follow up consultations comprising a thorough needs assessment, supportive counseling, adequate referral to other care providers if necessary and improvement of the continuity of follow-up care. The goals of nursing follow-up care are summarised as helping patients (and often their partners too) to cope with the physical and psychosocial consequences of treatment and help them to gradually adjust to 'the life after', and into survivorship.
1942532|NCT01167569|Drug|Ascorbic Acid|Ascorbic Acid/Placebo 10mg/kg body weight X2 in Operating Room followed by Ascorbic Acid/Placebo 5mg/kg x 48 hours.
1942533|NCT01167569|Other|5 % Dextrose Water or Normal Saline|100 ml D5W or NS X 2 in operating room and then every 4 hours for 48 hours.
1942534|NCT01167452|Drug|Sulfamethoxazole/trimethoprim|2 DS tablets of trimethoprim/sulfamethoxazole x 1 dose
1942535|NCT01167712|Biological|Bevacizumab|Given IV
1942536|NCT01167712|Drug|Carboplatin|Given IV
1942537|NCT01167712|Procedure|Computed Tomography|Correlative studies
1942538|NCT01167712|Drug|Paclitaxel|Given IV
1942539|NCT01167712|Procedure|Therapeutic Conventional Surgery|Undergo surgery
1942540|NCT01166438|Drug|Botulinum toxin A (Botox A®)|A single intradetrusor injection of 100U botulinum toxin A in 10 mL plus 0.1 mL of indigo carmine administered during cytoscopy. Between 100 and 200ml of saline is instilled into the bladder prior to injection to allow adequate visualization of the entire bladder urothelium. The treating physician will inject a total of 10.1 mL of the masked substance into approximately 15 to 20 different detrusor muscle sites under direct visualization using disposable needles. Injections will be spread out to equally cover the posterior bladder wall and dome, but spare the bladder trigone and ureteral orifices.
1942541|NCT01166438|Drug|Solifenacin 5mg|Oral Solifenacin 5mg once a day for up to 6 months
1942542|NCT01166438|Drug|Solifenacin 10mg|Oral Solifenacin 10mg once a day for up to 4 months
1942543|NCT01166438|Drug|Trospium chloride|Oral Trospium XR 60mg once a day for up to 2 months
1942544|NCT01166984|Drug|AB103|AB103 intravenous one infusion
1942545|NCT01166412|Drug|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|6.5mg patch daily for 11 weeks
1942546|NCT01166412|Drug|levonorgestrel patch with BMI <32 kg/m2|6.5mg patch daily for 11 weeks
1942547|NCT01166412|Drug|levonorgestrel patch with BMI 32 kg/m2 to <40 kg/m2|12.5mg patch daily for 11 weeks
1942548|NCT01166412|Drug|levonorgestrel patch with BMI <32 kg/m2|12.5mg patch daily for 11 weeks
1942549|NCT01166568|Device|PresVIEW Scleral Implants|Subjects are implanted with the PresView Scleral Spacing Implants, and followed for 24 months.
1942550|NCT01166594|Drug|Bevacizumab|Intrableb injection
1942551|NCT01166594|Drug|Control|intrableb BSS injection
1942552|NCT01165840|Drug|Dapsone|100 mg PO x 1 dose
1942553|NCT01164956|Drug|methylphenidate|taken orally
1942554|NCT01165229|Biological|Herpes Zoster Vaccine GSK1437173A|Intramuscular injection
1942556|NCT01165073|Dietary Supplement|Osmolite and B.C.A.A.|Feeding inserted into enteral tubes
1942557|NCT01165073|Dietary Supplement|Normal oral intake & supplementation if necessary|Enteral nutrition
1942558|NCT01164098|Drug|Rituximab|Induction therapy
1942559|NCT01163682|Other|Electro-acupuncture|Subjects will be placed in prone position and acupuncture sites will be cleaned with alcohol preparation. Stainless steel disposable acupuncture needle (diameter 0.25mm) will be inserted into the skin to appropriate depth needed to elicit de qi(approximately 3-4mm). Selected acupuncture points will be attached to2 leads connected to an electro-stimulator that generates 2 Hz of mixed pulsatile intervals for a total of 30 minutes. The acupuncturist will return two times during the treatment at 10 and 20 minutes with needles in situ to check on the patients and needles. Needles not attached to the electro-stimulator will be manipulated manually to elicit de qi one time during the treatment.
1942560|NCT01163682|Other|Sham acupuncture|Will be utilizing a sham control that consists of collapsible acupuncture needle so that there is no penetration of skin. The sham needles will be place on 4 non specific body points. The elecrto-stimulator will be attached to the needles for 30 minutes but will not be turned on. The acupuncturist will return two times during the treatment at 10 and 20 minutes to check on the patient. The acupuncturist will touch the collapsible acupuncture needs to simulate the manipulation of the needles.
1942563|NCT01162486|Drug|Rifampin & midazolam|rifampin - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
1942564|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 5 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
1942565|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 10 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
1942566|NCT01162486|Drug|rifapentine & midazolam|rifapentine - tablet, 15 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
1942567|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 20 mg/kg, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
1942568|NCT01162486|Drug|rifapentine and midazolam|rifapentine - tablet, 2.5 mg/kg lower than previously tolerated dose cohort, daily 15 days midazolam - liquid syrup, 15 mg, days 1 and 15
1942569|NCT01162005|Drug|Tacrolimus|dosage : 0.1-0.2 mg/kg/day divided two target trough level : 5 - 10 ng/mL Total duration (tacrolimus) : 1 year
1942570|NCT01161693|Device|TROOP® elevation pillow|Maternal Comfort after CSE during elective Cesarean Section in relation to adequate height of Anesthetic Block
1942571|NCT01161693|Device|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
1942572|NCT01161693|Device|TROOP® elevation pillow|designed by an American bariatric anaesthesiologist Dr Craig Troop, plastic covered foam pillow with an elevation angle of 20 degrees which can simply be placed on the operating table
1942573|NCT01161524|Drug|Perampanel|2 mg titrated up to 8-12mg maximum; taken once daily
1942574|NCT01161524|Drug|Placebo|Matching Placebo taken once daily.
1942575|NCT01160198|Drug|ferrous ascorbate|100 mg elemental iron
1942576|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 1 OD|60 mg elemental iron
1942577|NCT01160198|Dietary Supplement|ferrous bisglycinate chelate 2 OD|120 mg elemental iron
1942578|NCT01160354|Drug|Plerixafor|Starting at 240 mcg/kg daily subcutaneous (SQ) injection on Days 1-5, 4-6 hours before a 1 hour (+/- 30 minutes) IV administration of Clofarabine
1942579|NCT01160354|Drug|Clofarabine|Fixed dose of 30 mg/m2/day during Induction cycle (20 mg/m2/day in consolidation cycles).
1942580|NCT01160224|Drug|GW766944|Drug: GW766944 (Active Drug Treatment)
1942581|NCT01160224|Other|Placebo|This is placebo to match.
1942582|NCT01158157|Biological|ACAM2000|Percutaneous administration of a droplet (2.5µg) of ACAM2000 using a bifurcated needle.
1942583|NCT01158976|Dietary Supplement|Docosahexanoic Acid|450 mg DHA daily beginning at 16-21 weeks gestation and continuing up to time of delivery
1942584|NCT01158976|Other|Placebo|soybean oils with strawberry flavoring
1942587|NCT01158521|Drug|pazopanib hydrochloride|Oral pazopanib hydrochloride once daily for up to 18 weeks in the absence of disease progression or unacceptable toxicity.
1942588|NCT01158521|Procedure|therapeutic conventional surgery|Patients undergo either partial or radical nephrectomy at least 7 days after completion of pazopanib hydrochloride.
1942589|NCT01156805|Other|Educational program|The intervention consisted of the promotion of healthy eating habits and physical activity by means of the educational methodology Investigation, Vision, Action and Change (IVAC). At the beginning and at the end of 1st phase of the study (2006 and 2008) the weight and height of each child was measured in situ, while the families were given a self-report physical activity questionnaire and the Krece Plus quick test
1942590|NCT01155778|Biological|Recombinant human heparan N-sulfatase|10 mg monthly via an IDDD
1942591|NCT01155778|Biological|Recombinant human heparan N-sulfatase|45 mg monthly via an IDDD
1942592|NCT01155778|Biological|Recombinant human heparan N-sulfatase|90 mg monthly via an IDDD
1942593|NCT01155596|Behavioral|negative pressure ventilator use|Body ventilators that assist ventilation by applying intermittent subatmospheric pressure around the thorax, abdomen, or airway and periodically expand the chest wall and inflate the lungs. They are relatively simple to operate and do not require tracheostomy. Chest cuirass is used in this study.
1942594|NCT01154764|Drug|CG100649|I period: CG 100649 single dose 6 mg II period: Ketoconalzole + CG100649 at the same time washout period: 42 days
1942595|NCT01154764|Drug|CG100649 and ketoconazole|I period: ketoconazole 400 mg + CG100649 6 mg II period: CG 100649 single dose 6 mg washout period: 42 days
1942596|NCT01155388|Drug|Ferumoxytol|IV Ferumoxytol
1942597|NCT01155388|Drug|Ferrous sulfate|Oral iron preparation
1942598|NCT01155375|Drug|Ferumoxytol|IV Ferumoxytol
1942599|NCT01155375|Drug|Ferrous fumarate|oral iron preparation
1942604|NCT01154088|Biological|Mencevax ACWY|One dose, Subcutaneous injection
1942605|NCT01154088|Biological|GSK Biologicals' meningococcal serogroup A, C, W-135, Y tetanus toxoid conjugate investigational vaccine [GSK 134612]|One dose, Intramuscular injection
1942606|NCT01153165|Drug|Citalopram|Participants will be commenced on Citalopram 20mgs daily. At week 4 participants will be assessed for response to treatment . If no response, dose of Citalopram will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
1942607|NCT01153165|Drug|Placebo|Participants in the control group will receive a matched placebo. At week 4 participants will be assessed for response to treatment. If no response, dose of placebo will be increased to 40mgs for the remaining 8 weeks of the study. Patients who respond will remain on 20mgs for remaining 8 weeks.
1942609|NCT01152996|Drug|Vortioxetine|Vortioxetine tablets
1942610|NCT01152515|Drug|Remifentanil|Control group : stopping of propofol and remifentanil infusion Remifentanil group : stopping of propofol and maintenance of remifentanil infusion
1942613|NCT01149915|Drug|TH-302|TH-302 will be administered as a 30-minute intravenous infusion daily for 5 days every 21 days. Patients who successfully complete a 3-week treatment cycle without evidence of significant treatment-related toxicity or clinically significant progressive disease will continue to receive treatment for up to six cycles.
1942614|NCT01149499|Drug|Valacyclovir|1000 mg Tablet
1942615|NCT01149499|Drug|Valacyclovir|1000 mg Tablet
1942616|NCT01149746|Drug|Tamsulosin|Test 0.4 mg Capsule
1942617|NCT01149746|Drug|Tamsulosin|Reference Listed 0.4 mg Capsule
1942618|NCT01149265|Behavioral|Online support group|Expressive writing involves people writing about their thoughts and feelings, often upsetting ones, for a short period of time.
1942619|NCT01149265|Behavioral|Expressive writing|Online support groups are internet forums where like-minded people give and receive both informational and emotional support.
1942620|NCT01148459|Biological|GSK Biological's Investigational Malaria Vaccine 257049|All infants enrolled to group A will receive 3 doses of the experimental vaccine. The vaccine will be administered intramuscularly.
1942621|NCT01148459|Biological|Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.
The vaccine will be administered intramuscularly"
1942622|NCT01148459|Biological|Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).|"To ensure consistent vaccine availability, three cell culture rabies vaccines from two manufacturers may be sourced for this trial (Aventis-Pasteur and Novartis). It will be ensured that an individual child will receive all 3 doses of cell culture rabies vaccine from the same product.
The vaccine will be administered intramuscularly."
1942623|NCT01148563|Device|Tele-health Monitoring|Daily tele-health monitoring data will be collected from randomized participants.
1942624|NCT01146795|Drug|Carboplatin, paclitaxel, and bevacizumab|"Carboplatin will be administered at an AUC of 5-6 (at the discretion of the physician) day 1 every 3 weeks, paclitaxel 175 mg/m2 over 3 hours day 1 every 3 weeks and bevacizumab 15 mg/kg day 1 every 3 weeks.
After 3 cycles of chemotherapy patients will be considered for surgical cytoreduction. Patients must fulfill ALL of the following criteria to be considered eligible for surgical exploration. 1) ≥50% reduction in pretreatment CA-125 and 2) No medical contraindications to surgery.
After surgical cytoreduction all patients will receive an additional 6 cycles of chemotherapy (cycles 4-9) regardless of disease status at the time of exploration. Chemotherapy should be re-instituted within 6 weeks of the surgical procedure. Bevacizumab will be omitted from cycle 4 of chemotherapy. Patients who do NOT undergo surgical resection should receive cycles 4-9 of therapy. In this instance bevacizumab may be included in cycle 4."
1942625|NCT01148316|Drug|fluoxetine|drops or capsules, 10 to 80mg/Day for 14 weeks (first treatment) and as add-on to group CBT non-responders for additional 14 weeks
1942626|NCT01148316|Behavioral|Group cognitive-behavioral therapy|weekly, 2 hour sessions with one therapist and one co-therapist for 14 weeks and as add-on to fluoxetine non-responders for additional 14 weeks
1942627|NCT01147965|Biological|AD5 CEA Vaccine|AD5[E1-, E2b-]-CEA Vector Vaccine
1942628|NCT01147510|Drug|Combination of low ICS and montelukast|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m and take orally a tablet of Singulair® 10mg one time per day.
1942629|NCT01147510|Drug|Monotherapy of medium dose ICS|Two puffs of Pulmicort ® turbuhaler 200µg/puff between 7 a.m. and 10 a.m. and between 7 p.m. and 10 p.m. two times per day
1942630|NCT01147211|Drug|MK2206|MK-2206 will be administered orally in a starting dose level of 135 mg on a schedule of Qwk in repeating 3-week treatment cycles in combination with gefitinib in continuous 21-day cycles for the duration of the study
1942631|NCT01145833|Other|Immediate Treatment Group|The immediate treatment group starts the 5-month treatment right after baseline assessment.
1942632|NCT01145833|Other|Delayed Treatment Group|The delayed treatment group does not start treatment immediately after the baseline assessment. This group serves as the control group, by not receiving any treatment for 5 months. After the 5 months, the delayed group participants are asked to come in for a second assessment that involves completion of surveys and measurement of height, weight, and physical activity level. After this assessment is completed, the delayed group participants can begin the 5-month treatment.
1942706|NCT01127880|Drug|Ancef or Clindamycin|1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
1942707|NCT01127880|Drug|Placebo|.9% Normal Saline as a placebo
1942635|NCT01146002|Drug|Guanfacine (sustained release)|Treated with study drug once screening and initial testing is completed (see protocol above)
1942636|NCT01145924|Procedure|EBUS TBNF|Transbronchial needle forceps will be use with the EBUS TBNA scope
1942637|NCT01144988|Drug|Bevacizumab / Irinotecan|Bevacizumab (10mg/kg KG) Irinotecan (125 mg/ m2 or 340 mg/m2 depending on usage of EIAED)
1942638|NCT01144663|Biological|Meningococcal vaccine GSK134612|4- or 3-dose intramuscular injection
1942639|NCT01144663|Biological|MenC-CRM197|3-dose intramuscular injection
1942640|NCT01144663|Biological|MenC-TT|3-dose intramuscular injection
1942641|NCT01144663|Biological|DTPa-HBV-IPV/Hib|4-dose intramuscular injection
1942642|NCT01144663|Biological|Pneumococcal conjugate vaccine|4-dose intramuscular injection
1942646|NCT01144416|Biological|SCH 900962 / Corifollitropin alfa / Org 36286|SCH 900962 will be provided as ready-for-use prefilled syringes containing 150 μg corifollitropin alfa per 0.5 mL. On day 2 or 3 of the menstrual cycle, a single dose of 150 μg corifollitropin alfa will be administered by subcutaneous injection in the abdominal wall in the morning.
1942647|NCT01144416|Biological|RecFSH / follitropin beta|RecFSH will be provided as a ready-for-use solution in 900 IU cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of recFSH will be done in the morning by daily injections in the abdominal wall. A starting dose of 300 IU will be administered and fixed for at least 7 days.
1942648|NCT01144416|Drug|Placebo for SCH 900962|"Supplied as a pre-filled syringe containing an identical solution when
compared to SCH 900962, however without the active ingredient corifollitropin alfa. On Day 2 or 3 of the menstrual cycle (=Stimulation Day 1), a single dose of placebo SCH 900962 is to be administered in the morning by subcutaneous injection in the abdominal wall."
1942649|NCT01144416|Drug|Placebo for recFSH|Supplied as identical ready-for-use solution, but without the active ingredient, in cartridges for subcutaneous injection with the Follistim Pen. Starting on day 2 or 3 of the menstrual cycle (=Stimulation Day 1), administration of placebo-recFSH will be done by daily injections in the abdominal wall in the morning for a period of 7 days.
1942652|NCT01144143|Drug|Infliximab|the study drug will be injected into the joint through a needle
1942653|NCT01144143|Drug|Placebo|the placebo will be injected into the joint through a needle
1942654|NCT01144143|Drug|Standard of Care: Methylprednisolone acetate|Methylprednisolone acetate will be injected into the joint through a needle
1942655|NCT01143870|Other|"Diabetes Report Card"|"Enrolled participants will receive an individualized diabetes report card which depicts their current level of diabetes control in one of three ways--hemoglobin A1C, face, or letter grade."
1942656|NCT01141907|Behavioral|Navigator Team Intervention|The intervention is aimed at controlling heart failure (HF) and preventing exacerbations and hospitalizations by improving self management behaviors with the support of the Home Automated Telemonitoring (HAT) system. The intervention will be delivered by a RN-community health navigator (CHN) team over three months to HF patients and their caregivers in their home and via telephone and HAT system. The intervention will be initiated during the index hospitalization or as soon as possible after randomization. The RN-CHN team will collaborate with the participants, their caregivers, and their usual source of HF care. Intervention strategies include tracking of weight and HF symptoms to provide automated feedback regarding self management and plan of care, enhancing medication and symptom self management, promoting HF care follow up, and using a patient centered record to promote communication with providers.
1942657|NCT01141907|Other|Usual heart failure care|Participants assigned to usual care are treated by their usual source of HF care in the usual manner and in accordance with the American College of Cardiology/American Heart Association Guidelines for the management of HF. Usual care for HF patients admitted to Johns Hopkins Hospital also includes the following: 1) Referral to HF clinic if the patient has no usual source of care and 2) HF patient education booklet.
1942658|NCT01142258|Drug|Trazodone|Trazodone tablets, 50 mg, 10pm (before bedtime) for 14 days.
1942659|NCT01142258|Drug|Placebo|Inactive or inert pill which will be used as a comparator
1942663|NCT01138852|Drug|Ampicillin-sulbactam|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
1942664|NCT01138852|Drug|Cefuroxime|Patients were randomly assigned to receive either 1.5g of cefuroxime, or 3g of ampicillin/ sulbactam intravenously after the time the umbilical cord was clamped
1942665|NCT01137955|Drug|Rifaximin|Rifaximin 400mg orally three times a day for 10 days total
1942666|NCT01137955|Drug|Placebo|Placebo orally three times a day for 10 days total
1942704|NCT01128608|Procedure|PCO2 Acid Perfusion and 0.1N HCI Perfusion|A small tube will be inserted through the nostril and into the esophagus. A mild CO2 solution or a mild saline solution will be administered for aprox. 10 minutes during which you will be asked questions regarding any symptoms you may experience.
1942705|NCT01128101|Drug|Spironolactone|The group who receive spironolactone, the dose employed will be 25 mg each other day and titrated to 25 mg daily according to potassium.
1942790|NCT01112059|Drug|Doxycycline|100 mg twice a day for 8 days
1942667|NCT01137305|Other|VR- training|"Prospective randomization if 50 subjects to either three months of structured VR- training or no training; basic VR- skills assessment and a serial assessment of defined soft skills: self- efficacy, stress- coping and motivation prior to randomization; basic VR- skills measured within seven modules of the VR- simulator LapSim®: camera and instrument navigation, coordination, grasping, lifting and grasping, clip applying and diathermy cutting in different levels of difficulty- medium and hard referring to time to complete task, economy of instrument motion and tissue damage; intervention group: sessions of 45 minutes each twice a week for three months; control group: no training"
1942668|NCT01137149|Behavioral|Behavioral Activation Therapy|Behavioral activation is a 12 week psychotherapeutic intervention utilizing a semi-structured format. Initial sessions focus on specific areas (Assessment and orientation, Activation, Problem Solving, Goal Setting, Overcoming Barriers, Avoidance) interspersed as needed by sessions that focus on individual issues and applications. In these sessions the therapists maintains the session structure, but can use techniques presented in earlier sessions based on their functional analysis of the particular case. Parents participate in at least two of the ATA sessions but more active parental participation can be included as needed.
1942669|NCT01137149|Behavioral|Treatment as Usual- Psychotherapy|The TAU condition will be implemented consistent with usual and customary clinical practices within the Child Psychiatry Clinic at Seattle Children's Hospital (SCH. Within the SCH system, TAU for a depressed adolescent will typically consist of an individual therapy approach with adjunct family sessions and pharmacotherapy as deemed necessary by the primary therapist. The therapeutic approach typically used is cognitive behavioral but is administered in an eclectic, non-manualized fashion. Therapists for the TAU arm of the study will be care providers currently working within the SCH system. For this phase of the study, we will draw on clinicians whose level of experience is comparable to that of the Behavioral Activation therapists.
1942670|NCT01135602|Drug|Topiramate|Topiramate 50-300 mg/day Orally Twice per day
1942671|NCT01136733|Drug|Lenvatinib|taken orally,once a day
1942672|NCT01136733|Drug|Everolimus|orally once a day
1942673|NCT01134562|Drug|Saline|Single IV injection
1942674|NCT01134562|Drug|KAI-4169|Single IV injection
1942675|NCT01135329|Drug|Fludarabine, Busulfan, Cyclophosphamide, Tacrolimus,|Fludarabine 30 mg/m2 IV once a day for 4 days Busulfan 0.8 mg/kg IV every 12 hours for 4 days Cyclophosphamide 50 mg/kg IV daily for 2 days
1942676|NCT01134965|Drug|Flibanserin plus Digoxin|Flibanserin 100 mg once daily for 7 days plus Digoxin 0.5 mg as single dose
1942677|NCT01134965|Drug|Digoxin|Digoxin 0.5 mg as single dose
1942678|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion. The patient will be contacted one and two years after the completion of their follow up questionnaire for a brief one-question survey regarding current employment status.
1942679|NCT01134172|Behavioral|survey web-based or telephone interview|Patients will be asked to complete a questionnaire at baseline, and then one at follow up, 3-4 months after treatment completion.
1942680|NCT01134055|Drug|pazopanib eye drops|A tyrosine kinase inhibitor of multiple receptors including vascular endothelial growth factor receptors and platelet-derived growth factor receptors.
1942681|NCT01134055|Drug|placebo|placebo eye drops
1942682|NCT01134055|Biological|ranibizumab intravitreal injection|Humanized recombinant monoclonal antibody fragment targeted against human vascular endothelial growth factor A
1942683|NCT01133158|Drug|Rituximab, Bendamustine, Mitoxantrone, Dexamethasone|Bendamustine: 90 mg/m2/day, days 1 and 2 of each cycle, iv Mitoxantrone: 6 mg/m2/day, day 1 of each cycle, iv DEXAMETHASONE 20 mg / day, days 1 through 5 of each cycle, od Rituximab: 375 mg / m 2 / day, day 1 of each cycle, iv
1942684|NCT01131572|Drug|N-acetylcysteine NAC|N-acetylcysteine in the treatment of Bulimia Nervosa
1942687|NCT01131182|Drug|Sitagliptin phosphate|Sitagliptin 100 mg tablet administered orally once daily over the Ramadan period.
1942688|NCT01131182|Drug|Comparator: Sulfonylurea|Sulfonylurea (glibenclamide, glimepiride, or gliclazide) administered orally daily over the Ramadan period as per physician's prescription
1942689|NCT01131182|Drug|Metformin|Participants could continue pre-study metformin as concomitant therapy during the study.
1942690|NCT01131104|Drug|PDE5 Inhibitors|Observational study of participants who have been prescribed phosphodiesterase type 5 (PDE5) inhibitors by their physician during routine clinical practice.
1942691|NCT01130662|Drug|combination therapy using decitabine and midostaurin|"Cohort 1:
Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 25mg bid days 8-21 of each cycle.
Cohort 2:
Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid days 8-21 of each cycle.
Cohort 3:
Decitabine 20mg/m2 IV daily on days 1-5 to be repeated every 28 days. Midostaurin 50mg bid x 28 days of each cycle."
1942692|NCT01130519|Drug|Bevacizumab|Commercially available. Administered by intravenous infusion.
1942693|NCT01130519|Drug|Erlotinib|Commercially available. Administered orally
1942694|NCT01130467|Drug|methylphenidate|IR-MPH were started on a dose of 5 mg tid po, and this was increased to 10 mg tid and then to 15 mg tid as necessary. OROS-MPH was started on a dose of 18 mg qd, and this was increased to 36 mg qd and then to 54 mg qd as necessary.
1942695|NCT01130467|Drug|Atomoxetine|Atomexetine was started (weight of 70 kg or less) 0.5 mg/kg/day orally and increased after a minimum of 3 days to a target dose of 1.2 mg/kg/day. The maximum dosage is 1.4 mg/kg/day or 100 mg/day (whichever is less).
1942696|NCT01130467|Behavioral|behavioral modification|Parenting and teaching skill education
1942697|NCT01130181|Drug|Cholecalciferol|loading dose of 540,000 IU of cholecalciferol via feeding tube or orally, then 5 monthly doses of 90,000 IU
1942698|NCT01130181|Drug|Placebo|Matching placebo
1942702|NCT01128842|Drug|Neratinib + Capecitabine|Neratinib: 240 mg, continuous daily OD Capecitabine: 1500 mg/m^2, BID
1942703|NCT01128608|Procedure|24-Hr Esohpageal pH Monitoring|There will be a 24-hr pH monitoring procedure and two 10-minute infusions each one week apart consisting of high PCO2 solution and 0.1 N HCI solution.
1942708|NCT01127841|Drug|Rituximab and Bendamustine|Rituximab: 375 mg/m2/day, day 1 of each cycle, iv. Bendamustine: 90 mg/m2/day, days1 and 2 fo each cycle, iv.
1942709|NCT01127282|Drug|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU)|Vitamin (vitamin A 15 mg,C 500 mg, E 400IU) 1T po for 5 days in addition to anti-viral agent and antipyretics
1942710|NCT01127282|Drug|Placebo (digestive tablet)|Placebo (digestive tablet) 1T po for 5 days in addition to anti-viral agent and antipyretics
1942711|NCT01126736|Drug|eribulin mesylate|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
1942712|NCT01126736|Drug|pemetrexed|Pemetrexed given at a dose of 500 mg/m2 as an IV infusion on Day 1 of a 21-day cycle. Patients will also receive dexamethasone and vitamin supplements as recommended in the prescribing information for pemetrexed.
1942713|NCT01126736|Drug|Eribulin mesylate (eribulin; E7389)|Eribulin mesylate (eribulin; E7389) administered as a 2-5 minute intravenous (IV) bolus in one of two dosing schedules for both the Phase Ib and Phase 2 portions: either Days 1 and 8 of a 21 day cycle in ascending doses of 0.7, 1.1, or 1.4 mg/m2 or on Day 1 of the 21-day cycle at doses at ascending doses of 0.9, 1.4, or 2.0 mg/m2.
1942714|NCT01126424|Drug|Solifenacin|tablet
1942715|NCT01126424|Drug|Oxybutynin|capsule
1942716|NCT01126424|Drug|Placebo|tablet
1942717|NCT01125033|Drug|Vitamin C & Vitamin E|The patients in this arm received one tablet of vitamin C (200 mg) and one capsule of vitamin E (400 mg) daily for 8 weeks
1942718|NCT01125033|Drug|Vitamin C|The patients in this arm received one tablet of vitamin C (200 mg) and one placebo capsule daily for 8 weeks.
1942719|NCT01125033|Drug|Vitamin E|The patients in this arm received one capsule of vitamin E (400 mg) and one placebo tablet daily for 8 weeks.
1942720|NCT01125033|Drug|Vitamin C Placebo & Vitamin E Placebo|The patients in this arm received one placebo capsule and one placebo tablet daily for 8 weeks.
1942721|NCT01125683|Drug|AZD1446|Capsule, oral single and multiple dose
1942722|NCT01125683|Drug|Donepezil|Capsule, oral and single dose
1942723|NCT01125683|Drug|Placebo|Capsule, oral and single dose
1942724|NCT01125215|Drug|0.75% capsaicin nanoparticle cream|0.75% capsaicin nanoparticle cream apply to area with neuropathic pain twice daily for 12 weeks
1942725|NCT01125215|Drug|Placebo|Identical cream base of nanoparticle apply to area with neuropathic pain twice daily for 12 weeks
1942726|NCT01125163|Dietary Supplement|Iron Supplement|multivitamin that provides 2mg/kg/day of iron given orally to infants when they are tolerating 120cc/dg/day of preterm formula or fortified breast milk until they reach 36 weeks adjusted post-menstrual age.
1942727|NCT01125163|Dietary Supplement|multivitamin|daily oral multivitamin without iron until 36 weeks adjusted post-menstrual age
1942730|NCT01123694|Other|Survey Study|Survey regarding quality of life
1942731|NCT01123135|Drug|Estrogen cream|1gm of estrogen vaginal cream [EVC] at bed time 3 times a week
1942732|NCT01123135|Drug|Placebo|Placebo
1942733|NCT01123538|Drug|Progesterone|200 mg/day oral micronized natural progesterone (e.g. Utrogestan® 100mg) + 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg) during a year
1942734|NCT01123538|Drug|Chlormadinone acetate|5 mg/day oral chlormadinone acetate (e.g. Luteran® 5mg)+ 0.05 mg/day transdermal (i.e. plaster) 17β-estradiol (e.g. Estraderm® 50µg)
1942736|NCT01122849|Device|Prototype Nasal Dilator|Prototype nasal dilator AB2R11
1942737|NCT01122849|Device|Marketed Nasal Strip|Breathe Right Nasal Strip- Clear small/medium
1942738|NCT01122849|Device|Placebo Nasal Strip|Placebo strip
1942742|NCT01121731|Drug|Interferon α-5|3 MIU or safe dose used three times a week (TIW) in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
1942791|NCT01112059|Other|placebo|placebo
1942743|NCT01121731|Drug|Interferon-α5 plus Interferon-α 2b|Interferon-α5 plus Interferon-α 2b. 1.5 MIU each, or safe dose used TIW in alternate days in combined therapy. 29 days of treatment. Subcutaneous injection.
1942744|NCT01121731|Drug|Interferon α-2b (INTRON® A)|3 million IU TIW in alternate days in monotherapy. 29 days of treatment. Subcutaneous injection.
1942745|NCT01121120|Drug|TXA127|300mcg/kg/day, administered subcutaneously for up to 28 days
1942746|NCT01121120|Drug|Placebo|300mcg/kg/day administered subcutaneously for up to 28 days
1942754|NCT01118910|Drug|Vusion|Vusion will be applied to areas of intertrigo
1942755|NCT01118754|Drug|DE-101 ophthalmic suspension|Ophthalmic suspention; QID
1942756|NCT01118754|Drug|DE-101 ophthalmic suspension|Ophthalmic suspension; QID
1942757|NCT01118754|Drug|DE-101 ophthalmic suspension vehicle|ophthalmic suspension vehicle; QID
1942758|NCT01119456|Biological|IMC-RON8|"5 mg/kg intravenously (i.v.)
Once a week for each 4-week treatment cycle, for a total of four doses per cycle.
Cohort 1"
1942759|NCT01119456|Biological|IMC-RON8|"10 mg/kg intravenously (i.v.)
Once a week for each 4-week treatment cycle, for a total of four doses per cycle.
Cohort 2"
1942760|NCT01119456|Biological|IMC-RON8|"15 mg/kg intravenously (i.v.)
Once a week for each 4-week treatment cycle, for a total of four doses per cycle.
Cohort 3"
1942761|NCT01119456|Biological|IMC-RON8|"15 mg/kg intravenously (i.v.)
Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.
Cohort 4"
1942762|NCT01119456|Biological|IMC-RON8|"20 mg/kg intravenously (i.v.)
Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.
Cohort 5"
1942763|NCT01119456|Biological|IMC-RON8|"25 or 30 mg/kg intravenously (i.v.)
Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.
Cohort 6"
1942764|NCT01119456|Biological|IMC-RON8|"30, 35, or 40 mg/kg intravenously (i.v.)
Once every 2 weeks for each 4-week treatment cycle, for a total of two doses per cycle.
Cohort 7"
1942765|NCT01119456|Biological|IMC-RON8|"20 or 25 mg/kg intravenously (i.v)
Once every week for each 4-week treatment cycle, for a total of four doses per cycle.
Cohort 8"
1942766|NCT01117610|Drug|Placebo (one of medication)|patients in Group C will receive none of medication preoperatively and intraoperatively
1942767|NCT01117610|Drug|Ropivacaine (epidural injection)|patient in group I will receive epidural injection of 0.1% ropivacaine 10ml before skin incision.
1942769|NCT01116427|Biological|abatacept|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52; Dosing: less than 60 kg, 500 mg; 60-100 kg, 750 mg; or greater than 100 kg, 1 gram
1942770|NCT01116427|Drug|Placebo|In core/extension phase: administered IV at weeks 0/28, 2/30, and 4/32, and then every 4 weeks until week 24/52
1942771|NCT01115894|Drug|Naltrexone|100 mg oral dosage daily for 12 weeks
1942772|NCT01115894|Behavioral|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
1942773|NCT01115894|Behavioral|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption.
1942774|NCT01115894|Drug|Placebo|Placebo
1942775|NCT01115842|Drug|Vitamin D|Vitamin D 4000IU per day for 5 days
1942776|NCT01115803|Drug|LY2584702|"Supplied as 25 mg and 100 mg capsules, administered orally for two 28-day cycles.
Starting dose is 50mg. Dose will be subsequently increased to 100mg, 200mg, and 300mg."
1942777|NCT01115803|Drug|Erlotinib|"Supplied as 25 mg, 100 mg, or 150 mg tablets, administered orally, daily for two 28-day cycles.
Starting dose is 150mg. Doses may be decreased in 50mg increments if necessary due to toxicity."
1942778|NCT01115803|Drug|Everolimus|"Supplied as 5 mg or 10 mg tablets, administered orally, daily for two 28-day cycles.
Starting dose is 10mg. Doses may be reduced to 5mg if necessary due to toxicity."
1942779|NCT01114646|Device|Cemented Hip Hemiarthroplasty|The cemented femoral prosthesis is a VerSys LD/Fx, Zimmer, Warsaw, IN.
1942780|NCT01114646|Device|VerSys Beaded FullCoat, Zimmer|The press-fit component is a VerSys Beaded FullCoat, Zimmer, Warsaw, IN,
1942781|NCT01114620|Biological|(GSK2340274A) Arepanrix™|Intramuscular administration, one dose
1942784|NCT01112982|Other|Magnetic Resonance Imaging|An MRI (with and without gadolinium contrast) of index joint will be performed (T1, T2, and STIR images).
1942785|NCT01112982|Other|Plain Radiographs|"Plain radiographs of index joint will be obtained and reviewed by two independent readers (radiologists)"
1942786|NCT01112982|Drug|Febuxostat|All subjects in the sub-study will be started on febuxostat 40mg daily at baseline. If their serum urate level is > 6.0 at months 1 or 3, then the febuxostat dose will be increased to 80mg daily.
1942787|NCT01112982|Drug|Colchicine|Colchicine will be dosed at 0.6mg by mouth BID for the first three months then 0.6mg daily from months 3 to 6, and then discontinued at month 6.
1942788|NCT01112735|Biological|FS VH S/D 4 s-apr (= two-component fibrin sealant, double virus inactivated, made from pooled human plasma)|Dosage form: spray (aerosolized sealant), Dosage frequency: once (1 layer). ARTISS will be applied onto the fascia or the wound bed.
1942789|NCT01112735|Procedure|Standard of care|Standard of care
1942792|NCT01111825|Drug|Temsirolimus|"A treatment cycle will consist of 28 days, according to the following schedule:
Weekly temsirolimus given MTD dose from phase I IV (8mg) intravenously on days 1, 8, 15, and 22 Phase I Design A standard, 3+3, dose escalation schedule will be used. Between 6 and 12 patients will likely be necessary to determine the MTD of temsirolimus in combination with neratinib. There will be no intrapatient dose escalation. The starting dose of temsirolimus is 8 mg administered intravenously weekly (dose level 1). Three patients will initially be enrolled in each cohort.
Phase 1
Dose escalation cohort:
• Weekly temsirolimus (8mg) intravenously on Days 1, 8, 15, and 22, and then 15mg intravenously weekly starting on Day 29."
1942793|NCT01111825|Drug|Neratinib|"A treatment cycle will consist of 28 days, according to the following schedule:
Neratinib PO once daily with food, preferably in the morning. Between 6 and 12 patients will likely be necessary to determine the MTD of temsirolimus in combination with neratinib. There will be no intrapatient dose escalation. Three patients will initially be enrolled in each cohort.
Phase 1
Dose escalation cohort:
• Weekly temsirolimus (8mg) intravenously on Days 1, 8, 15, and 22, and then 15mg intravenously weekly starting on Day 29."
1942794|NCT01110707|Drug|Recombinant human follicle stimulating hormone|After the pituitary desensibilization, all subjects were administered 300-450 IU of r-hFSH per day sc; afterwards, the dosage was adjusted according to the ovarian response. The administration of r-hFSH was terminated within the 36 hours prior to the administration of r-hCG.
1942795|NCT01110707|Drug|Recombinant human luteinizing hormone (Luveris)|On the sixth day of COS, subjects assigned to the group r-hFSH + r-hLH were administered 150 IU r-hLH per day sc while they continue r-hFSH treatment with a separate injection. Administration of r-hLH was also suspended 36 hours before administering r-hCG.
1942796|NCT01111474|Other|Cyanoacrylate|3 applications of cyanoacrylate (48 hours interval)at the cervical region of the sensitive tooth
1942797|NCT01111474|Radiation|Laser|This process was conducted three times with an interval of 48 hours between applications, according to laser's manufacturer advice Clean Line Easy Laser - LILT®, Clean Line Easy Laser Doctor Dental Products Industry LTDA, BRA). For dentin hypersensitivity, the application of 1J/cm2 is recommended for eight seconds at three points along the dental neck, using the infrared wavelength (660nm).
1942798|NCT01111253|Drug|Amoxicillin-clavulanate|"Amoxicillin-clavulanate: 4 times a day 1200 mg and switch to oral administration 3 times a day 625 mg after two days, for a total duration of 10 days.
In case of allergy to Amoxicillin-clavulanate: intravenous administration ciprofloxacin 2 times a day 400 mg and metronidazole 3 times a day 500 mg. In case of oral administration ciprofloxacin 2 times a day 500 mg and metronidazole 3 times a day 500 mg. For a total duration of 10 days."
1942799|NCT01110876|Drug|Vorinostat|"Phase I Starting Dose: 200 mg twice daily by mouth on Days 1-7, 15-21 of each 28 day cycle.
Phase II Dose: MTD from Phase I."
1942800|NCT01110876|Drug|Erlotinib|"Phase I Starting Dose: 200 mg by mouth daily on Days 1-21 of 28 day cycle. For patients on enzyme inducing anticonvulsants (EIACs), starting dose of 400 mg.
Phase II Dose: MTD from Phase I."
1942801|NCT01110876|Drug|Temozolomide|125 mg/m2 by mouth daily on days 1-7, 15-21 of each 28 day cycle.
1942802|NCT01110681|Device|Solesta (Dextranomer in gel of stabilized non-animal hyaluronate)|Submucosal injections. Re-treatment is allowed one month after initial treatment if the subject is still incontinent.
1942803|NCT01110655|Other|Intravenous hypertonic Saline|Intravenous 100mL bolus of 3% saline
1942804|NCT01110655|Other|Oral hypertonic saline|Oral 100mL bolus of 3% saline
1942805|NCT01110226|Drug|KML-001|"KML001 will begin given to patients first. It should be taken by mouth immediately prior to cisplatin infusion. Patients will be treated in cohorts of three beginning at 7.5 mg. The Dose will be increased until Maximum Tolerated Dose is established.
KML001 will be administered daily for 14 days of a 21 day cycle. Patients will have one week off."
1942806|NCT01110226|Drug|Cisplatin|Cisplatin will be given to all patients at a dose of 75 mg/m2 on day 1 of every 21 day cycle over 30 to 90 minutes through an intravenous infusion immediately after the first dose of KML-001
1942807|NCT01110057|Drug|Placebo|Placebo to match GW856553
1942808|NCT01110057|Drug|GS856553|GW586553 7.5mg bid
1942811|NCT01108380|Procedure|Plasma pheresis, Right portal vein embolization|"Plasma pheresis : With insertin of 2 intravenous line, plasmapheresis will be done with COBE BCT Inc. It will be performed under supervision of clinical laboratorians and doctors.
Right portal vein : Under ultrasonography guided, left portal vein be punctured. Right portal vein will be embolized by coil or gelfoam."
1942812|NCT01108172|Other|Virtual Ward|A multidisciplinary team to optimize medical and social care for patients residing in their own homes
1942813|NCT01108172|Other|Usual care|The usual care provided to patients after discharge from hospital
1942814|NCT01108094|Drug|Itraconazole|200 mg twice daily; oral
1942815|NCT01108068|Drug|Lithium|lithium will be given for 6 months to patients with OPPG, starting at a low dose of 2.5 mg/kg daily, gradually increasing until a lithium blood level of 0.3-0.6 ng/dl is achieved.
1942882|NCT01092364|Behavioral|Behavioral weight loss intervention|Behavioral lifestyle intervention for weight loss, compared to advice-only control.
1942883|NCT01090804|Device|BreatheMAX breathing device|secretion clearance, breathing exercise
1943477|NCT00972439|Drug|Oral Contraceptive: Ortho-Novum® 1/35|
1942819|NCT01106534|Drug|placebo + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive 18 months of placebo treatment in addition to aspirin.
1942820|NCT01106534|Drug|clopidogrel + aspirin OR prasugrel + aspirin|This population consists of subjects enrolled in the study who are free from death, MI, stroke, repeat coronary revascularization, major bleeding, and ST 12 months after stent implantation and who are compliant with 12 months of dual antiplatelet therapy following stent implantation and who are subsequently randomized to receive an additional 18 months of thienopyridine (clopidogrel or prasugrel) treatment in addition to aspirin.
1942821|NCT01106534|Device|XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)|XIENCE V Everolimus Eluting Coronary Stent System assigned to both the arms.
1942823|NCT01105832|Drug|Teriparatide|Teriparatide (Forsteo) 20 micrograms daily during four weeks
1942824|NCT01105572|Device|Intel Health Guide|An Internet-connected device with member-customized protocols and response algorithms. Participants interact with the Intel HealthGuide device, receiving immediate feedback, and also transmitting blood pressure, weights and responses to questions to a site monitored by their nurse case manager.
1942825|NCT01105572|Other|Case Management|Specialized Medicare Case Managers review and coordinate services for members with multiple and complex needs with identified gaps in their care Medicare Case Management staff strives to enhance the member's quality of life, support continuity of care, facilitate provision of services in the appropriate setting and manage cost and resource allocation to promote quality, cost-effective outcomes. Specially trained Medicare Case Managers collaborate with the member, family, caregiver, member authorized representative, treating practitioner, health care provider, community services and other Aetna programs to coordinate care, with a focus on member education and maximizing quality outcomes.
1942826|NCT01104675|Drug|ENMD-2076|275 mg (or 250 mg for BSA < 1.65) per day in oral capsules in 28 day continuous cycles
1942827|NCT01104415|Drug|Low Dose LX1606 - Day 1 (start)|150 mg LX1606 given three times daily for 14 days
1942828|NCT01104415|Drug|Mid-low dose LX1606 - Day 15 (start)|250 mg LX1606 given three times daily for 14 days
1942829|NCT01104415|Drug|Mid-high dose LX1606 - Day 29 (start)|350 mg LX1606 given three times daily for 14 days
1942830|NCT01104415|Drug|High dose LX1606 - Day 43 (start)|500 mg LX1606 given three times daily for 14 days
1942831|NCT01104415|Drug|4-Week LX1606 Open Label Dose Extension|Patients will enter 4-week extension period at optimal dose once achieved, based upon clinical response criteria and/or observation of dose-limiting toxicity.
1942832|NCT01104415|Drug|72-Week LX1606 Open Label Dose Extension|Upon completion of the 4-week stable-dose period, eligible subjects will have the option to continue treatment for an additional 72 weeks.
1942834|NCT01104181|Device|HC2 collection kit with a swab or brush|We will sample the anal canal for cells with either a swab and swab or swab and brush to determine which is superior
1942835|NCT01103843|Drug|Loading Dose Arm|Subjects who are thienopyridine naive will be randomized 1:1 to either clopidogrel 600 mg or prasugrel 60 mg loading dose at the time of PCI. A Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
1942836|NCT01103843|Drug|Maintenance Dose Arm|Verify Now P2Y12 platelet assay will measure platelet reactivity. Cross over to a loading dose and maintenance dose of alternate medication will occur based on level of platelet reactivity.
1942837|NCT01103167|Behavioral|control of ultrafiltration|During the interventional period, dry weight of patients will be adjusted according to the results of body composition.
1942838|NCT01103505|Device|ForeseeHome|
1942839|NCT01103453|Behavioral|Virtual Action Planning Supermarket (VAP-S) Software|"The VAP-S simulates a supermarket with multiple aisles displaying items. Several obstacles are designed to hinder the progression of the shopper along the aisles. In addition, virtual humans populate the supermarket. The VAP-S is designed so that the user enters the supermarket behind the cart and navigates within the supermarket via the keyboard keys. He is thus able to experience the environment personally without any intermediate. The task is to purchase 7 items from a list, proceed to the cashier and pay for them.
We propose 9 sessions of 45 minutes. The results will be analyzed to develop goals for intervention, together with the client to study his awareness of his performance of IADL and Executive functions and to enhance his motivation to participate in the intervention."
1942840|NCT01103245|Drug|Renin-Angiotensin-Aldosterone System (RAAS) Activation|Subjects will be receive a dose of Hydrochlorothiazide (HCTZ) for 12 weeks and be given a calculated diet during the last 5 days of this period. Serum potassium levels, urine samples, and blood levels of insulin secretion will be measured.
1942841|NCT01103245|Drug|Administration of Aliskiren, Spironolactone, or Placebo|Subjects will be receive a dose of Aliskiren, Spironolactone, or placebo for 4 weeks and be given a calculated diet during the last 5 days of this period. Serum potassium levels, urine samples, and blood levels of insulin secretion will be measured.
1942842|NCT01103245|Drug|Increased Dose, Combination, or Placebo|Subjects will be receive either an increased dose of the present medication (Aliskiren or Spironolactone) or a combination of the two or a placebo for 4 weeks and be given a calculated diet during the last 5 days of this period. Serum potassium levels, urine samples, and blood levels of insulin secretion will be measured.
1942843|NCT01103180|Drug|Escitalopram|10-20 mg of escitalopram daily for eight weeks (10mg for the first 2 weeks, 20mg thereafter)
1942844|NCT01102959|Device|Photographic Educational Material|Photographic Educational Material on Carbohydrate Counting
1942845|NCT01101672|Procedure|Single port laparoscopic colectomy|Patients will be operated by using the technique of single port laparoscopic colectomy by surgeon with experiences and training in this procedure. Laparoscopic instruments will be inserted to perform the procedure through a multi-channel single port which is placed via transumbilical incision. The same transumbilical incision will be extended to 3-4cm for extraction of specimen.
1942846|NCT01101672|Procedure|Conventional laparoscopic colectomy|Patient will be operated by techniques of conventional laparoscopic colectomy. A 10mm subumbilical incision is made for camera port, another 2-4 small incisions (5-10mm in size) will be made for placement of ports and insertion of laparoscopic instrument. A 3-4cm abdominal incision will be made for extraction of specimen.
1942850|NCT01101750|Biological|Quadrivalent HPV for types 6, 11, 16 and 18|Gardasil 0.5ml IM injection on day one, month 2, and month 6. Serum samples on day one, month 3 and month 7
1942851|NCT01101100|Drug|AMG 827|210 mg SC or 140 mg SC
1942852|NCT01099449|Drug|calcium gluconate|Given IV
1942853|NCT01099449|Drug|magnesium sulfate|Given IV
1942854|NCT01099449|Other|placebo|Given IV
1942855|NCT01099449|Drug|oxaliplatin|
1942856|NCT01099059|Drug|Amantadine|Amantadine 100-150 mg depending on weight (100 mg/day for <30 Kg and 150 mg/day for >30 Kg)
1942857|NCT01099059|Drug|ritalin|ritalin at a dose of 20-30 mg/day depending on weight (20 mg/day for <30 Kg and 30 mg/day for >30 Kg)
1942858|NCT01099046|Behavioral|Lifestyle|water intake, tympanic tubing, regular sleep
1942859|NCT01098474|Biological|GSK's investigational vaccine 692342|Intramuscular, 1 or 2 doses
1942860|NCT01098474|Biological|Tritanrix™ HB+Hib|Intramuscular, 3 doses
1942861|NCT01098474|Biological|Prevnar™|Intramuscular, 3 doses
1942862|NCT01098474|Biological|Polio Sabin™|Oral, 3 doses
1942863|NCT01098474|Biological|Menjugate™|Intramuscular, 3 doses
1942864|NCT01098006|Other|Blood withdrawal|Blood sampling
1942865|NCT01097330|Procedure|Ablation|Catheter based radiofrequency ablation for ischemic ventricular tachycardia scheduled to occur within 4 weeks after randomization
1942866|NCT01097330|Drug|Amiodarone|Amiodarone titrated to therapeutic levels as per standard of care and maintained on a dose of at least 200 mg (300 mg recommended) once a day for the duration of the study
1942867|NCT01095952|Device|AVNS ON|Delaying the AV-node by stimulating the parasympathetic nerves innervating the AV-node with high frequency burst pacing during the refractory period of the ventricle using a standard atrial lead at a septal position.
1942868|NCT01095731|Drug|Tiopronin|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
1942869|NCT01095731|Drug|Placebo|Dosage will be 1 gram, 3 times daily. Drug dosing will be initiated at time of aSAH confirmation, for a length of 14 days or at hospital discharge.
1942870|NCT01094717|Device|excimer vs sham excimer|half of lesions will be treated with excimer laser; half of lesions will be treated with sham excimer (opaque cover on the laser device)
1942873|NCT01093534|Drug|Placebo|Matching solifenacin placebo tablet
1942874|NCT01093534|Drug|solifenacin|Tablet for oral administration
1942875|NCT01094353|Procedure|Mini-sling|The minisling is a new intervention therapeutic option for surgical treatment in women with stress urinary incontinence. It is made of polypropylene monofilament mesh, held between two self-anchoring polypropylene columns in a fishbone design connected to two delivering needles.
1942876|NCT01094353|Procedure|Transobturator|Transobturator sling Unitape™ is an outside-in approach therapeutic option for surgical treatment in women with stress urinary incontinence
1942877|NCT01094184|Drug|bevacizumab [Avastin]|10 mg/kg every 2 weeks, or 15 mg/kg every 3 weeks intravenously infusion according to chosen chemotherapy schedule
1942878|NCT01093560|Dietary Supplement|fat feeding|Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat.
1942879|NCT01092676|Drug|Ibuprofen Regular Dosing|Regular dosing
1942880|NCT01092676|Drug|PRN dosing Ibuprofen|PRN dosing Ibupofen
1942892|NCT01090427|Drug|Ustekinumab - Half-Standard Dosage|Ustekinumab 0.375 mg/kg, 22.5 mg, or 45 mg based on body weight, administered subcutaneously (under the skin) at Weeks 0, 4, 16, 28, and 40.
1942893|NCT01090427|Drug|Ustekinumab - Standard Dosage|Ustekinumab 0.75 mg/kg, 45 mg, or 90 mg based on body weight administered subcutaneously at Weeks 0, 4, 16, 28, and 40.
1942894|NCT01090427|Other|Placebo|Placebo administered subcutaneously at Weeks 0 and 4 or at Week 12.
1942895|NCT01089010|Drug|Placebo|Matching placebo in capsules administered as a single oral dose.
1942896|NCT01089010|Drug|250 mg CK-2017357|250 mg CK-2017357 in capsules administered as a single oral dose.
1942897|NCT01089010|Drug|500 mg CK-2017357|500 mg CK-2017357 in capsules administered as a single oral dose.
1942898|NCT01088971|Dietary Supplement|Duolac7S|1 capsule two times everyday for 6 weeks
1942899|NCT01088971|Dietary Supplement|starch|1capsule two times everyday for 6 weeks
1942900|NCT01088555|Drug|Sodium thiosulfate|Oral administration of sodium thiosulfate pentahydrate 5% solution (American Regent) 10ml BID x 7 days
1942901|NCT01088568|Procedure|the implantation of toric implantable collamer lens|perform the implantation of toric implantable collamer lens for both eyes
1942902|NCT01088568|Procedure|customized laser-assisted in situ keratomileusis|perform Q-factor customized laser-assisted in situ keratomileusis for both eyes
1942903|NCT01088412|Drug|Somatropin (rDNA origin)|Dose, frequency and duration at discretion of attending physician.
1942906|NCT01088139|Dietary Supplement|Protein supplementation|Ready made protein supplement drinks with approximate protein content of 18-24g per 500ml per day. Caloric content is 490 to 530Kcal depending on the brand of drink.
1942907|NCT01087255|Device|Electronic Pillbox Monitoring System|Daily exposure for six months
1942908|NCT01087164|Behavioral|Compliance|Parent will either receive a high or no compliance condition where each is asked to endorse the importance of prevention cervical cancer or genital warts depending on their teen's gender.
1942909|NCT01087164|Behavioral|Message sidedness|Parent will receive either a one-sided or two-sided message about the HPV vaccine
1942910|NCT01086228|Device|XIENCE V / PROMUS stent|Patients receiving XIENCE V stent(s) or PROMUS stent(s) during their index procedure.
1942911|NCT01085812|Drug|F2695 SR|Drug: F2695 SR (40, 80 or 120 mg/day) Study drug is to be given orally, in capsule form, once daily.
1942912|NCT01085812|Drug|Placebo|Matching placebo to be given orally, in capsule form, once daily.
1942913|NCT01084655|Drug|TAK-700|TAK-700 with docetaxel and prednisone on a continuous schedule.
1942914|NCT01084655|Drug|Docetaxel|TAK-700 with docetaxel and prednisone on a continuous schedule.
1942915|NCT01084655|Drug|Prednisone|TAK-700 with docetaxel and prednisone on a continuous schedule.
1942916|NCT01084278|Drug|Colchicine|Colchicine tablets
1942917|NCT01084096|Behavioral|Increasing use of Antenatal Corticosteroids (ACS)|"Intervention clusters:
Increasing administration of ACS to pregnant women at high risk of preterm birth (HRPB) by providing health providers with kits containing dexamethasone, syringes, and instructions. Eligible women receive four injections of 6 mg dexamethasone from the kit or regimen of choice at the site.
Improving identification of women at HRPB by diffusing recommendations for ACS use to health care providers, training health care providers to identify signs of preterm labor and eligibility criteria for ACS use, providing reminders to healthcare providers on the use of the kits, and using a color-coded tape to measure uterine height to estimate gestational age in women at HRPB with unknown gestational age.
Control clusters: no specific intervention for comparison. Both intervention and control clusters: Birth attendants trained in essential newborn care of LBW infants and instructed to teach mothers how to provide care to premature infants."
1942918|NCT01083433|Behavioral|Diabetes related psychological counseling and education|The psychology intervention is based in part on an intervention to maintain parental support for diabetes care in adolescence which was developed by Anderson and colleagues (1999). The first session will include education to parents and children regarding the importance of sharing responsibility for treatment related tasks. The second session will include a discussion of the treatment sharing plan developed at the first visit and problems that may have occurred will be discussed. The third session will include a discussion of planning for possible future problems. Visits 1, 2, and 3 will include 30 minutes of diabetes education.
1942919|NCT01083433|Device|Continuous Glucose Monitor|Patients in the intensive diabetes clinic plus CGM group will wear the iPro after the baseline visit followed by every month for 4 months.
1942920|NCT01081223|Biological|Cancer vaccine plus immune adjuvant, plus activated white blood cells|Tumor tissue is used for cancer vaccine. Following vaccinations, white blood cells are collected, stimulated and expanded, and are then reinfused. The infusion is followed by a course of low-dose IL-2.
1942923|NCT01079741|Biological|NY-ESO-1 protein; Poly-ICLC; Montanide|"Phase I represents the dose-escalation component with Poly-ICLC given in combination with NY-ESO-1 and Montanide in an open-label fashion. The dose of Poly-ICLC will be increased stepwise from 0.35mg to 1.4mg while the dose of NY-ESO-1 antigen (100µg) and Montanide (1.1mL) will be held constant.
Phase II: The doses of NY-ESO-1 and Montanide will remain the same as in Phase I; the highest tolerated Phase I dose of Poly-ICLC will become the Phase II Poly-ICLC dose. In Phase II, patients will be randomized to a subcutaneous vaccination of NY-ESO-1 protein with Poly-ICLC alone dose TBD (Arm A) or with NY-ESO-1 protein, Poly-ICLC dose TBD and Montanide (Arm B)."
1942924|NCT01080196|Other|RENEW vs TRAD|"Subjects perform lower body resistance exercise via the RENEW protocol or via a standard of care protocol"
1942925|NCT01079702|Drug|Everolimus|Everolimus, administrated twice daily at a fixed total dose of 10 mg continuously.
1942926|NCT01079702|Drug|Capecitabine|Capecitabine administered bid for 14 days followed by 7 days rest. In this study, capecitabine will be dose escalated. The first dose level of capecitabine is 500 mg/m2 twice daily.
1942927|NCT01078168|Drug|Acitretin|30mg per day from Day 1 to Day 28
1942928|NCT01078168|Drug|Placebo|Placebo
1942930|NCT01076725|Device|Standard technique group|In the standard technique group (n = 63), the PLMA was inserted by index finger insertion technique.
1942931|NCT01076725|Device|Rotation technique group|The entire cuff of the PLMA was placed in the mouth without finger insertion in a midline approach and was rotated 90 degrees counterclockwise around the tongue. The PLMA was then advanced and rotated back until resistance was felt.
1942932|NCT01076686|Drug|Questionnaire and Physical Exam|A 10-question survey and a six-item physical exam were completed.
1942933|NCT01075945|Drug|Dihydroartemisinin- piperaquine|three tablets per day
1942934|NCT01075945|Drug|artemether- lumefantrine|twenty tablet in eight doses
1942939|NCT01074957|Device|Incentive Spirometry|Incentive Spirometry (IS) has been used extensively in postoperative period and consists of spontaneous deep breaths through a device which provides a visual feedback to maintain a maximum insuflation
1942940|NCT01074957|Device|Breath-Stacking Technique|An one-way valve device to promote the summation of successive inspiratory volumes while expiration was avoided
1942941|NCT01074957|Other|Exercise|Patients were taught huffing (forced expiration while the glottis is opened), supported cough (with patient's hands placed on the sternotomy incision) and mobilization, including active limb exercises, sit out of bed and deambulation (starting on the third postoperative day).
1942942|NCT01074814|Drug|(will be assigned based on molecular profile and RPMA)|treatment will be assigned based on IHC< FISH, DNA microarray and RPMA results
1942943|NCT01073228|Drug|EVP-6124|
1942944|NCT01073228|Drug|Placebo|
1942945|NCT01073059|Drug|Valproic acid and Ertapenem|
1942946|NCT01072734|Drug|Vaccine|Influenza vaccine
1942947|NCT01071525|Drug|Niacin\Laropiprant|Hypercholesterolemic patients with low HDL will receive Niacin\Laropiprant
1942948|NCT01071356|Behavioral|Intensive Motivational Interviewing|Weekly individual therapy sessions over 9 weeks (Intensive MI condition) consisting of supportive and directive interventions. The control condition consists on a single session of MI and nutritional education.
1942949|NCT01071356|Behavioral|Single session of Motivational Interviewing|
1942950|NCT01070368|Other|Commercial extract and in-house wheat extract|Patients with a history of wheat allergy underwent two skin test extracts, and open challenge with wheat. A blood test for specific IgE was performed in the same time.
1943010|NCT01053637|Drug|hydrocodone/acetaminophen|0.17 mg/kg hydrocodone component to max of 10 mg. If dose is vomited within 5 minutes, second dose may be administered.
1943011|NCT01053637|Drug|Sugar water|An equal volume of sugar water will be dispensed, as for the weight based 0.17 mg/kg hydrocodone solution given for the study drug
1942957|NCT01069315|Procedure|Type of fluid lavage solution|Comparison of castile soap solution vs. normal saline solution.
1942958|NCT01069315|Procedure|Type of fluid lavage pressure|Comparison of low pressure vs. high pressure.
1942959|NCT01069770|Drug|Sunitinib|50mg daily(4 weeks on & 2 weeks off), 2 cycles, until progression or unacceptable toxicity develops
1942960|NCT01070069|Device|PEVAR (ProGlide closure)|Percutaneous EVAR facilitated by the ProGlide closure device
1942961|NCT01070069|Device|SEVAR (IntuiTrak)|Standard vascular exposure for access prior to EVAR
1942962|NCT01070069|Device|PEVAR (Prostar XL closure)|Percutaneous EVAR facilitated by the Prostar XL closure device
1942963|NCT01068561|Biological|intravitreal injection of autologous bone marrow stem cells|One intravitreal injection of a 0.1-ml cell suspension containing around 10x106 bone marrow mononuclear stem cells(BMMSC). All treatments were performed by a single retinal specialist using topical proparacaine drops under sterile conditions (eyelid speculum and povidone-iodine). Autologous BMMSC were injected into the vitreous cavity using a 27 gauge needle inserted through the inferotemporal pars plana 3.0 - 3.5 mm posterior to the limbus. After the injection, central retinal artery perfusion was confirmed with indirect ophthalmoscopy. Patients were instructed to instill one drop of 0.3% ciprofloxacin into the injected eye four times daily for 1 week after the procedure.
1942964|NCT01067170|Device|Pneumatic Compression Stockings|Thigh-high pneumatic compression stockings
1942965|NCT01067508|Other|Fiji Water|Participants are asked to drink one liter of this silicon-rich water daily for three months.
1942966|NCT01066026|Device|Injection of hyaluronic acid in nasolabial folds|"The sides of injection were randomized and both the subject and the evaluator were blind to it. The injections were performed according through two different devices:
In one of the sides, the hyaluronic acid (Restylane®) was injected in its conventional pharmaceutical presentation, with a standard needle which is part of the product's kit;
In the other side, the hyaluronic acid (Restylane®) was injected through a metallic cannula, which replaced the needle of the product's kit.
Local analgesia was provided for both applications: topical analgesics 4% Lidocaine, for the application with the standard needle, and nerve block (Lidocaine 2%), where the application was performed with the metallic cannula."
1942967|NCT01066052|Other|0.15 IU/kg/day GH|Group Q = 0.15 IU/kg/day (was interventional at the time of protocol writing)
1942968|NCT01066052|Other|0.1 IU/kg/day GH|Group U = 0.1 IU/kg/day (was interventional at the time of protocol writing)
1942969|NCT01065480|Behavioral|Motivational Interviewing|Motivational interviewing is a directive, client-centered counseling style for eliciting behavior change by helping clients to explore and resolve ambivalence. Compared with nondirective counselling, it is more focused and goal-directed. The examination and resolution of ambivalence is its central purpose, and the counselor is intentionally directive in pursuing this goal.
1942970|NCT01064713|Drug|Tesetaxel|"Cohort A: 40 mg by mouth every 21 days.
Cohort B. 50 mg by mouth every 21 days."
1942971|NCT01063530|Device|DIammine SIlver fluoride|Application of Diammine SIlver Fluoride in cervical lesions
1942972|NCT01063530|Device|DIstilled water|Application of distilled water in cervical lesions
1942973|NCT01062009|Drug|Zinc sulfate|Zinc sulfate 200 mcg/ml in Normal Saline
1943012|NCT01053559|Drug|certolizumab pegol|400mg subcutaneous injections at week 0, week 2, week 4, then every 4 weeks thereafter
1942979|NCT01060943|Device|KOKEN|"atelocollagen filler
1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year."
1942980|NCT01060943|Device|Atelocollagen Filler|1ml pre-filled syringe. 3% atelocollagen is dissolved in PBS. Inject several times every 2 weeks or more weeks. Total amount should be limited up to 25ml per an year.
1942981|NCT01059500|Device|Pilot Phase|Non-intervention phase to test webtool technical reliability, accurate low PTP, and calibration.
1942982|NCT01059500|Device|Intervention group, receive the numeric PTP estimate|Receive the numeric PTP estimate for ACS and PE, and one of three testing recommendations. For ACS, PTP <2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5 to 5.5%: obtain a troponin I measurement at presentation and 120 minutes later, and if both are normal, no further testing; PTP >5.5%: proceed to provocative testing. For PE, PTP<2.5% with low clinical suspicion and available follow-up, no further testing; PTP 2.5-10%, obtain a quantitative D-dimer and if normal, no further testing. PTP 10-20%, proceed directly to pulmonary vascular imaging, and if PTP>20% consider empiric anticoagulation with heparin if no contraindications.
1942983|NCT01059500|Device|No Intervention|Standard (no webtool output)
1942984|NCT01059929|Drug|Dexmedetomidine|continuous IV infusion 0.2 - 1.5 ucg/kg/hour titrated to target RASS
1942985|NCT01059929|Drug|Propofol|continuous IV infusion (5 - 50 ucg/kg/min) titrated to target RASS
1942986|NCT01059929|Drug|Fentanyl|25 - 200 mcg IV every hour (as multiple IV pushes) as needed titrated to Non-Verbal Pain Scale
1942987|NCT01059929|Drug|Midazolam|0.01 - 0.1 mg/kg IV push every 10 minutes as needed for agitation (RASS>+2)
1942988|NCT01059929|Behavioral|Physical and Occupational Therapy|Daily therapy sessions targeting range of motion, strength, and mobility
1942989|NCT01059877|Device|1072nm infrared light stimulation|1072nm infrared light delivering 2.6J/sq cm over a 6 minute treatment period.
1942992|NCT01059318|Drug|Everolimus|
1942993|NCT01059318|Drug|Everolimus|
1942994|NCT01059318|Drug|Everolimus|
1942995|NCT01058512|Drug|NOV-205|"There will be 4 treatment Groups with 10 patients in each group:
Group A: 30 mg NOV-205 daily subcutaneous administration for 49 days
Group B: 30 mg NOV-205 daily subcutaneous administration for 98 days
Group C: 60 mg NOV-205 daily subcutaneous administration for 49 days
Group D: 60 mg NOV-205 daily subcutaneous administration for 98 days"
1942998|NCT01056302|Procedure|Surgical repair of maxillofacial trauma|Patients will undergo whatever needed surgical repair of maxillofacial trauma that is necessary. Records such as CT imaging and plaster models of the jaws will be utilized in the standard way to plan and carry out the surgery. The CT scan will also be used within the visuohaptic computational environment to develop and evaluate the user interface. The amount of time taken to work up and plan surgery using standard surgical practice and using the computational platform will be compared. Real surgical outcome will be compared to the simulated outcome using the proposed software tool.
1942999|NCT01056458|Other|auricular acupressure|use the tape of ear adhesive beads on shenmen and subcortical area of both ears after three meals and before bed for three minutes each area with alternating ears, twice a week to replace paste.
1943000|NCT01056458|Other|sham acupressure|use only tape without ear adhesive beads under the same ways
1943001|NCT01055496|Drug|inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone|"Day 1:
Rituximab at 375 mg/m2 Cyclophosphamide at 375 mg/m2 (cohort 1), 550mg/m2 (cohort 2), 750 mg/m2 (cohort 3, 4) Vincristine at 1.4 mg/m2 (max 2 mg)
Day 2 Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2, 3), 1.3 mg/m2 (cohort 4)
Days 1-5:
Prednisone at 40 mg/m2
Each cycle is 3 weeks, with a maximum of 6 cycles total."
1943002|NCT01055496|Drug|inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone|"Day 1:
Rituximab at 375 mg/m2 Gemcitabine at 500 mg/m2 (cohort 1, 2b, 3b), 1000mg/m2 (cohort 2a, 3a, 4, 5) Cisplatin at 37.5 mg/m2 (cohort 1, 2a), 50mg/m2 (cohort 2b, 3a), 75mg/m2 (cohort 3b, 4, 5)
Day 2:
Inotuzumab ozogamicin at 0.8 mg/m2 (cohort 1, 2a, 2b, 3a, 3b, 4), 1.3mg/m2 (cohort 5)
Days 1-4:
Dexamethasone at 40 mg
Each cycle is 3 weeks, with a maximum of 6 cycles total."
1943003|NCT01055028|Drug|Paclitaxel in combination with Bevacizumab|15 mg/kg, IV
1943004|NCT01055392|Drug|Lithium Carbonate|lithium carbonate tablets, 150 mg to 450 mg (target serum lithium level 0.25 mEq/L - 0.5 mEq/L), divided in two doses, two years.
1943005|NCT01055392|Drug|Placebo|Identical placebo tablets were administered twice-a-day for two years.
1943006|NCT01055249|Drug|Ibuprofen, Hydrocortisone|Ibuprofen 600 mg film coated tablets, b.i.d., Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
1943007|NCT01055249|Drug|Hydrocortisone|Hydrocortisone-21-acetate creme (25%) 15 microl/cm2 b.i.d.
1943008|NCT01054001|Drug|sildenafil 100mg|sildenafil 100mg per oral twice a week
1943009|NCT01054209|Device|Warming with warming mattress|"Reusable pressure relieving warming mattress. Principle use is to warm patients to prevent hypothermia peri-operatively.
Inditherm Alpha systems, OTM1: 1900mm x 585mm"
1943017|NCT01052597|Drug|curcumin|Curcumin capsule contains 250 mg curcuminoids, 2 capsule per time, 3 times a day for 12 months
1943018|NCT01052493|Drug|PP 1420|Single dose of PP 1420, administered subcutaneously. Dose levels: 2, 4, 8 mg.
1943019|NCT01052493|Drug|Placebo|0.9% (w/v) saline single-dose, administered subcutaneously
1943020|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340274A (alternative formulations)|Intramuscular injection, one or two doses
1943021|NCT01051661|Biological|GSK Biologicals' investigational vaccine GSK2340273A (alternative formulations)|Intramuscular injection, two doses
1943022|NCT01051661|Biological|Placebo|Intramuscular injection, one dose
1943023|NCT01051349|Biological|BIIB019 (Daclizumab)|Administered as specified in the treatment arm.
1943024|NCT01051349|Biological|trivalent seasonal influenza vaccine|All participants who participate in the 2013-2014 influenza vaccine substudy will receive the vaccine at the study site
1943025|NCT01051063|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A|Intramuscular injection
1943026|NCT01050231|Device|Type I Robotic Group (Functional activities and individual joints)|Subjects participate in 11 weeks of robotic training with the device: BONES (Biomimetic Orthosis Neurorehabilitation for Elbow and Shoulder) , 3 days per week, 1 hour per day with the robotic exercise program.
1943027|NCT01050231|Device|Type II Robotic therapy (Individual joints only)|Subjects participate in 11 weeks of training with the robotic device BONES, 3 days per week, 1 hour per day with a robot-assisted exercise program. The robotic exoskeleton assists in arm and hand movements as the patient plays interactive computer games.
1943028|NCT01049828|Other|No intervention|No treatment for tinnitus will occur in this study.
1943029|NCT01049399|Drug|tideglusib|800 mg of tideglusib as a powder for oral suspension once daily in fasting conditions for 52 weeks
1943030|NCT01049399|Drug|tideglusib|600 mg of tideglusib as a powder for oral suspension, administered once daily in fasting conditions for 52 weeks
1943031|NCT01049399|Drug|placebo|powder for oral suspension administered once daily in fasting conditions for 52 weeks
1943032|NCT01048554|Drug|Temozolomide|Temozolomide 75mg/m2 for six continuous weeks
1943033|NCT01048554|Drug|Bevacizumab|Bevacizumab 10mg/kg every 2 weeks without interruption
1943034|NCT01048307|Device|Prontosan wound irrigation solution|"Prontosan® Wound Irrigation Solution (experimental group):
• Active ingredients (Polihexanide 0.1%, Betaine 0.1%) cleansing the wound bed at dressing change with Prontosan® Wound
Saline (control group):
cleansing the wound bed at dressing change with saline; a sterile gauze dressing impregnated with the saline will be placed on the wound in the form of a moist compress and removed after approx.15 minutes;
placing the primary dressing (Profore® WCL): the dressing will be impregnated with saline;
fixing the dressing to the wound using multilayered elastic compression bandaging (Profore® bandaging system)."
1943035|NCT01047007|Drug|MK1775|MK1775 capsule, dosage of 65 mg or 120 mg, orally twice daily on days 1-5 of a 21 day cycle.
1943036|NCT01047007|Drug|Comparator: MK1775 in combination with 5-FU|MK1775 capsule, dosage ranging from 20 mg to 200 mg, orally twice or once daily on Days 1-5 in a 21 day cycle. 5-Fluorouracil, from 1000 mg/m2/day to 750 mg/m2/day, intravenous infusion for 4 consecutive days starting on Day 1.
1943037|NCT01047007|Drug|Comparator: MK1775 in combination with 5-FU/CDDP|MK1775 capsule, dosage ranging between 20 mg to 200 mg, orally twice or once daily on Days 1-5 in a 21day cycle; 5-Fluorouracil, from 1000 mg/m2/day to 750 mg/m2/day, intravenous infusion for 4 consecutive days starting on Day 1; Cisplatin, between 60 mg/m2 to 100 mg/m2, intravenous infusion on Day 1.
1943038|NCT01046461|Drug|Ramosetron, Aprepitant, Dexamethasone|"Day 1:
Aprepitant 125 mg PO, 1 hour before chemotherapy Ramosetron 0.6 mg IV, 30 min before chemotherapy Dexamethasone 12 mg PO, 30 min before chemotherapy
Day 2 - 3:
Aprepitant 80 mg PO. in the morning Dexamethasone 8 mg PO. in the morning
Day 4 Dexamethasone 8 mg PO. in the morning"
1943039|NCT01045954|Drug|Lispro Insulin and glargine insulin|Continuous glucose sensor will be inserted. Subject will be on an isocaloric diet and CGM downloaded daily. Insulin basal and bolus will be adjusted based upon treatment goals until goals reached
1943040|NCT01046188|Other|Knowledge Questionnaire|Administered before and after teaching intervention
1943041|NCT01046188|Other|Perceived Stress Scale|Administered before and after teaching intervention
1943042|NCT01046188|Other|Satisfaction questionnaire|Administered after the intervention and at study completion
1943043|NCT01046188|Other|Web-based IVF teaching|Web-based IVF teaching
1943044|NCT01046188|Other|Didactic lecture|Didactic lecture
1943045|NCT01045590|Drug|titration|Patients in the glibenclamide plus placebo treatment group Patients in the glibenclamide plus placebo treatment group who have FPG < 270mg/dL after the glibenclamide 5mg om run-in will continue to receive glibenclamide 5mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of < 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in the following sequence: from 5mg om, to 5mg om, 2.5mg on, to 5mg bd and 7.5mg om, 5mg on, to 7.5mg bd. The maximum total daily dose will not exceed 15 mg. A downward titration of glibenclamide using the above sequence in the reverse order can be used to maintain normoglycemia at any visit. Once the target HbA1c level of < 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
1943046|NCT01045590|Drug|titration|Patients in the glibenclamide + rosiglitazone treatment group who have FPG < 270mg/dL after the glibenclamide 5mg om run-in will receive glibenclamide 5mg om + rosiglitazone 4mg om. At every subsequent visit, the glibenclamide dose will be titrated to achieve the target HbA1c level of < 7%. If the HbA1c is > 7%, the dose of glibenclamide will be escalated in a similar fashion as above. The only exception is at visit 5 when the dose of rosiglitazone is increased (see next paragraph). Once the target HbA1c level of < 7% is achieved, the dose of glibenclamide is maintained. If at the glibenclamide dose of 7.5mg bd, the HbA1c is > 7% for 2 subsequent visits, the patient will be withdrawn from the study.
1943047|NCT01042951|Biological|ShanChol Cholera Vaccine|55 adults (18-45 year old) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Toddlers(2-5 years) will be given 2 doses of the bivalent whole-cell cholera vaccine 55 Younger children(12-23 months)will be given 2 doses of the bivalent whole-cell cholera vaccine
1943048|NCT01042951|Other|Placebo|55 adults (18-45 year old) will be given 2 doses placebo, 55 Toddlers(2-5 years) will be given 2 doses of placebo, and 55 Younger children(12-23 months)will be given 2 doses of placebo
1943049|NCT01041521|Drug|Lovaza|Lovaza at a dose of 4g per day with each 1g capsule containing approximately 465 mg of eicosapentaenoic acid (EPA) and 375 docosahexaenoic acid (DHA) for 24 months
1943050|NCT01041495|Drug|cyclobenzaprine ER (AMRIX)|active drug
1943051|NCT01041495|Drug|placebo|matching placebo for AMRIX
1943052|NCT01041313|Drug|Memantine|7 days prior to surgery, start taking 5mg memantine daily; 4 days prior to surgery, increase dose to 5mg twice daily; 2 days prior to surgery, increase dose to 10mg in the morning, and 5 mg in the evening; on the day of surgery, increase dose to 10mg twice daily, and continue on this dose until 14 days after surgery.
1943053|NCT01041313|Drug|Placebo|7 days prior to surgery, start taking one placebo tablet daily; 4 days prior to surgery, increase dose to one placebo tablet twice daily; 2 days prior to surgery, increase dose to 2 placebo tablets in the morning, and one placebo tablet in the evening; on the day of surgery, increase dose to 2 placebo tablets in the morning and 1 placebo tablet in the evening. On the first day after surgery through 14 days after surgery, take 1 placebo tablet twice daily.
1943054|NCT01041183|Drug|intravenous ramosetron|0.3 mg IV ramosetron (group I)
1943055|NCT01041183|Drug|oral ramosetron|0.1 mg oral ramosetron (group II)
1943056|NCT01041183|Drug|oral and IV ramosetron|0.1 mg oral ramosetron plus 0.3 mg IV ramosetron (group III).
1943057|NCT01041066|Drug|labetalol|0.4 mg/kg labetalol intravenously 4 min before intubation
1943058|NCT01041066|Drug|nicardipine|20 ㎍/kg nicardipine intravenously 4 min before intubation
1943059|NCT01040910|Drug|smoking of cannabis|smoking of cannabis, 2 cigarettes a day, equivalent to about 50 mg THC
1943060|NCT01040910|Drug|smoking cigarettes with placebo|smoking cigarettes with cannabis that was chemically treated so that most active ingredients were removed
1943061|NCT01039688|Drug|CP-690,550|Oral tablets administered at a dose of 5 mg BID for 24 months
1943062|NCT01039688|Drug|CP-690,550|Oral tablets administered at a dose of 10 mg BID for 24 months
1943063|NCT01039688|Drug|Disease-modifying antirheumatic drug|Oral capsules,administered as 10 mg per week for 4 weeks titrated to 15 mg per week for 4 weeks, then titrated to 20 mg week for 24 months
1943064|NCT01039805|Drug|GSK962040 (50 mg)|Cohort 1 = 50 mg
1943065|NCT01039805|Drug|Placebo|matching placebo
1943066|NCT01039805|Drug|GSK962040 (75 mg)|Cohort 2 = 75 mg
1943067|NCT01039467|Device|Medtronic Adapta Dual Chamber Pacemaker|Medtronic Adapta Dual Chamber Pacemaker
1943068|NCT01039701|Drug|AZD1446|capsules, oral, 3 times daily
1943069|NCT01039701|Drug|Placebo|capsules, oral, 3 times daily, 4 weeks
1943070|NCT01039233|Drug|Bicalutamide 50 mg Tablet vs Casodex® 50 mg Tablet|
1943072|NCT01038453|Dietary Supplement|Cholecalciferol 35 µg per day|"Cholecalciferol (Vitamin D3) oral 1 tablet 35 µg per day. Placebo oral 1 tablet per day. In total 35 µg per day.
In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
1943073|NCT01038453|Other|placebo tablet|placebo 2 tablet, once a day,
1943074|NCT01038453|Dietary Supplement|Cholecalciferol (Vitamin D3) 70 µg|"Cholecalciferol (Vitamin D3) oral 2 tablets each containing 35 µg. In total 70 µg per day.
In total 2 tablets per day per participant from Baseline to 16 weeks after delivery."
1943075|NCT01037738|Procedure|ACL reconstructive surgery and ACS/ Orthokin application|ACL reconstructive surgery and ACS/ Orthokin or Placebo intraarticular application on Day 0,1,6 and 10 postoperatively, regarding the Arm
1943077|NCT01036659|Drug|ecallantide - Kallikrein inhibitor that blocks the production of bradykinin|subcutaneous dose of 30mg of ecallantide or placebo (three 10 mg SC injections at three different sites ((arms, legs, abdomen). Injections are not to be administered at the attack location.
1943081|NCT01035021|Drug|use of rocuronium when the LMA is inserted|Anesthesia is induced with a propofol and remifentanil in both groups, however rocuronium 0.06 mg/kg is injected only in group R. Insertion of LMA is performed by the standard technique according to the manufacturer's instruction. In group N, rocuronium is administered for the operation.
1943082|NCT01034527|Other|Neuromuscular Training|Combination of exercises and phases to initiate lateral trunk perturbations that force the athlete to decelerate and control the trunk in order to successfully perform the techniques.
1943083|NCT01034527|Other|Speed Protocol|Sham training will consist of sagittal plane only running drills designs solely to enhance sprint speed. A sham sagittal plane sprint training protocol that will be instituted with the teams that are randomly selected for sham treatment. Five phases will be utilized to facilitate progressions designed to improve the athletes' forward sprinting speed. Training volume will be approximately equivalent for the TNMT and sham protocols. They each will take athletes approximately 30 minutes to complete
1943084|NCT01032954|Drug|Botulinum toxin|"The following list shows the indications for eligibility and total doses that will be applied in each part of the face, according to the consensus meeting recommendations, at the 1 visit:
Upper face:
Crow's feet wrinkles - 70 U
Glabella - 50 U
Forehead - 40 U
Mid face:
Lower eyelid - 5 U
Nasal wrinkles - 20 U
Malar wrinkles - 10 U
Lower face:
Peri-oral wrinkles - 15U
Asymmetric smile or gummy smile - 5U
Cellulitic chin - 20U
Marionette lines - 25 U According to the patients needs, the doses can vary ±10% in terms of the amount of units that will be injected.
Patients will be allocated in each group according to the total dose received at visit 1(described above). At visit 2, all the patients will receive a touch-up of a standard dose of 25 Units of Dysport®, distributed on the treated areas according patient's needs."
1943085|NCT01033708|Behavioral|narrative exposure therapy|Narrative Exposure Therapy (NET), an evidence-based trauma-focussed treatment, suitable for survivors of prolonged and repeated exposure to traumatic stress and childhood adversities
1943088|NCT01033136|Behavioral|Multiple Channel Exposure Therapy-Veterans|Individual therapy design completed twice a week over a 6-week period. The treatment will include psychoeducation about panic attacks and trauma and behavioral and cognitive exposure exercises.
1943089|NCT01033136|Behavioral|Cognitive-Processing Therapy|Participants will be randomly assigned to receive either MCET-V or cognitive processing therapy (CPT), a standard PTSD treatment. Patients in both the MCET-V and CPT conditions will receive 12, 90-minute sessions of individual therapy twice a week over a 6-week period.
1943093|NCT01032330|Device|occlusion treatment|Patients randomized to the occlusion treatment group will receive occlusion (patching) for 3 hours per day for at least 3 months. Choice of which eye to occlude, or whether to alternate daily, is at investigator's discretion.
1943094|NCT01032304|Drug|Erdosteine|One 300 mg capsule twice a day
1943095|NCT01032304|Drug|Placebo|One capsule twice a day
1943097|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 1.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.
Stage II: MEDI-545 1.0 mg/kg IV once every 2 weeks for a total of 79 doses."
1943098|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 3.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.
Stage II: MEDI-545 3.0 mg/kg IV once every 2 weeks for a total of 79 doses"
1943099|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 10.0 mg/kg IV, on Day 1 and once every 2 weeks from Day 29, for a total of 14 doses.
Stage II: MEDI-545 10.0 mg/kg IV once every 2 weeks for a total of 79 doses."
1943100|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 100 mg SC, on Day 1 and weekly or once every 2 weeks from Day 29, for a total of 14 doses.
Stage II: MEDI-545 100 mg SC once every 2 weeks for a total of 79 doses."
1943101|NCT01031836|Drug|MEDI-545|"Stage I: MEDI-545 1,200 mg IV once every 4 weeks from Day 1 for a total of 8 doses.
Stage II: MEDI-545 1,200 mg IV once every 4 weeks for a total of 40 doses"
1943102|NCT01031836|Drug|MEDI-545 600|"Stage I: MEDI-545 600 mg IV once every 4 weeks from Day 1 for a total of 8 doses.
Stage II: MEDI-545 600 mg IV once every 4 weeks for a total of 40 doses."
1943103|NCT01030848|Device|Total Knee Replacement (LCS rotating platform)|
1943104|NCT01031511|Behavioral|Cognitive Behavioural Therapy|16 weekly sessions of 1.5 hrs in small groups of 3-4 children conducted by 2 therapists
1943105|NCT01031511|Other|Social Recreational|16 weekly sessions of 1.5 hrs in small groups of 3-4 children, conducted by 2 therapists
1943106|NCT01031069|Biological|GSK Biologicals' HPV vaccine 580299|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
1943107|NCT01031069|Biological|Merck's Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Vaccine (Gardasil)|Subjects will receive three doses of the study vaccine administered intramuscularly according to a Day 0, Week 6, and Month 6 vaccination schedule.
1943108|NCT01030536|Drug|CAT-8015 Immunotoxin (Moxetumomab Pasudotox)|2-mL sized vials of CAT-8015 at a target concentration of 1.0 mg per vial
1943109|NCT01030614|Drug|Dexamethasone|intravenous dexamethasone 8 mgr before laparoscopic cholecystectomy or intravenous placebo before laparoscopic cholecystectomy
1943110|NCT01030614|Drug|placebo|One hundred five patients were randomized to receive intravenous placebo before laparoscopic cholecystectomy
1943111|NCT01030133|Device|Transcranial Magnetic Stimulation|Transcranial Magnetic Stimulation
1943112|NCT01030341|Device|CGMS and insulin pump|Use of continuous glucose monitoring system and insulin pump
1943113|NCT01030289|Device|transcranial direct current stimulation|transcranial direct current stimulation
1943114|NCT01030198|Device|RevLite (Laser Treatment)|
1943115|NCT01029496|Procedure|different time of umbilical cord clamping|"for normal birth(apgar score over 7),include:term ,preterm,normal birth or cesarean section : experimental group1: waiting until the ceased of the umbilical cord pulsing, then cut the cord.before cutting the cord, the baby is keeping warm and put over mother's abdomen.
control group 1-1: clamping and cut the cord within 10 second after birth. control group1-2: clamping and cut the cord 90 second after birth.
for in case of asphyxia(regardless term or preterm,normal birth or cesarean section born):
experimental group2: resuscitate on bed site with the cord unclamped until the umbilical cord ceased pulsing.
control group 2-1 clamping and cut the cord within 10 second. and resuscitate the baby after transfer to the Irradiation table."
1943116|NCT01029912|Device|Electrical stimulator|"6-week intervention
15 minutes of therapist-guided stimulated ankle exercise + 30 minutes of physical therapy in the laboratory twice a week.
Self-administered active repetitive ankle dorsiflexion exercise performed twice a day, 6 days a week at home using the device."
1943117|NCT01029782|Drug|IV cefazolin plus oral probenecid and placebo cephalexin|Intravenous cefazolin 2 g IV plus probenecid 1 g daily plus cephalexin placebo orally four times daily.
1943118|NCT01029782|Drug|Oral cephalexin and saline IV plus probenecid placebo|Cephalexin 500 mg orally four times daily plus saline IV and oral probenecid placebo daily
1943120|NCT01027702|Biological|Infusion of donor lymphocytes|A donor lymphocyte infusion will be given to provide T cells. There will be a dose escalation: 3 x 10^4, 4 x 10^4, 5 x 10^4, 6 X 10^4, 8 x 10^4, and 10 X10^4 cells/kg body weight. At least three patients will be assessed at each dose to determine safety before dose is increased.
1943121|NCT01028287|Drug|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 16 units ACTHargel sub-cutaneously every day.
1943122|NCT01028287|Drug|ACTH|Patients with nephrotic range proteinuria randomized to this group will receive 32 units ACTHargel sub-cutaneously every day.
1943123|NCT01027676|Drug|Study treatment|Gefitinib 250mg/QD plus vorinostat D1~7 & D15-21 / QD q 4weeks
1943124|NCT01027754|Drug|Varenicline|Days 1-3: 0.5 mg once a day Days 4-7: 0.5 mg twice a day Days 8-84: 1 mg twice a day
1943125|NCT01027754|Drug|Placebo|Days 1-3: 1 pill daily Days 4-7: 2 pills daily Days 8-84: 2 pills daily
1943126|NCT01027845|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 4 doses
1943127|NCT01027845|Biological|DTPa|Subcutaneous injection, 4 doses
1943128|NCT01027559|Drug|Sertraline|For those in the Sertraline treatment condition, visits to dispense medications, check for side effects and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84 in depressed subjects. Depressed patients will be treated with Sertraline starting with a dose of 50 mg daily on Day 1 of the study. For patients showing inadequate evidence of antidepressant response, the Sertraline dose will be increased up to a maximum dose of 200 mg daily. The daily Sertraline dose can be decreased in 50 mg increments, or as clinically indicated, in the presence of side effects until two weeks prior to the end of the study. No further changes in dose will be permitted in study subjects after the 10th week until the study is completed.
1943129|NCT01027559|Behavioral|Cognitive Behavioral Therapy|For those in the Cognitive Behavioral Therapy treatment condition, visits for the CBT sessions will occur on or about Day = 3,Day = 7,Day = 10,Day 14, Day 21, Day 28, Day 35, Day 42, Day 49, Day 56, Day 63, Day 70, Day 77, and Day 84. Visits to check for progress and administer the Hamilton Depression rating scale will occur at Day = 0 and on or about Day = 14, Day 28, Day 42, Day 56, Day 70 and Day 84 in depressed subjects. Depressed subjects will start their CBT treatment once their first MRI and computer testing sessions are completed, and will have two sessions per week for the first two weeks, followed by one session per week for the duration of the twelve week study.
1943130|NCT01027455|Device|Fisher and Paykel Insuflow (MR 860) Surgical Humidification Device|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
1943131|NCT01027455|Procedure|Laparoscopic Appendicectomy|Dry and Cold carbon dioxide gas insufflation
1943132|NCT01027455|Procedure|Laparoscopic Appendicectomy|Humidified warm carbon dioxide gas insufflation during laparosopic procedure
1943133|NCT01027416|Drug|Tamoxifen|Drug: Tamoxifen 20 mg orally 1x/day for 4 weeks
1943139|NCT01025505|Drug|Nilotinib|The dose of NIL is 800 mg daily (400 mg twice daily). It must be adapted according to specific guidelines in case of adverse events (AE). It cannot be increased.
1943140|NCT01025505|Drug|Imatinib|The dose of IM is 600 mg daily (300 mg b.i.d.). It must be adapted according to specific guidelines in case of AE. It cannot be increased.
1943141|NCT01025427|Drug|Raltegravir, tenofovir/emtricitabine|Ten elite controllers and 10 untreated non-controllers will be treated with open-label raltegravir/tenofovir/emtricitabine for 24 weeks.
1943142|NCT01025336|Other|Blood draw|Group 1.1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1 Group 1.2- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 1
1943143|NCT01025336|Other|Blood draw|Group 1- 0.5 mL dose of 13vPnC was administered in the deltoid muscle at year 0 and year 1 Group 2- 0.5 mL dose of 23vPS was administered in the deltoid muscle at year 0 and 0.5 mL dose of 13vPNC was administered in the deltoid muscle at year 1
1943145|NCT01023789|Device|ABSORB BVS|ABSORB Bioresorbable Vascular Scaffold (BVS) System implantation
1943146|NCT01024361|Device|CPAP|CPAP of 5 cm water pressure will be applied within 15 minutes after birth by Neopuff
1943147|NCT01023269|Device|InterStim Therapy|Neuromodulation therapy which delivers low level electrical stimulation to bladder wall for the treatment of overactive bladder with urinary incontinence.
1943148|NCT01024023|Device|EWA|Suitable participants randomised to the treatment arm to receive early walking aid and rehabilitation physiotherapy will be commenced immediately. Physiotherapy will continue after they receive their definitive prosthesis till they are comfortable and safe using it, at which stage they will be discharged and no further follow up will be performed.
1943149|NCT01024010|Drug|pentostatin|Given IV
1943150|NCT01024010|Drug|cyclophosphamide|Given IV
1943151|NCT01024010|Biological|ofatumumab|Given IV
1943152|NCT01024010|Procedure|laboratory biomarker analysis|Correlative study
1943153|NCT01024010|Other|flow cytometry|
1943154|NCT01024010|Genetic|protein expression analysis|Correlative study
1943155|NCT01024296|Device|Port Close|Device for applying loop suture to close surgical site
1943156|NCT01022580|Drug|Infasurf surfactant (ONY, Inc.)|Late doses of Infasurf 3ml/kg will be given to infants on study days 0, 2, 4, 6 and 8.
1943157|NCT01021956|Drug|STAKEL|Open-label,safety and exploratory efficacy study in subjects with active CNV followed for 12 weeks.During first stage(dose escalating stage) subjects assigned to group 1 to 4 will receive a single treatment of VTP at one of three light levels and one of two DLI.Second stage(dose confirmation)will be only initiated at a dose level which an effect has been seen at week 1 and there is no DLT at week 5.
1943158|NCT01021267|Drug|Saw palmetto berry extract|1x daily 1 capsule containing 320mg lipophilic extract
1943159|NCT01019733|Procedure|Intrathecal Autologous Stem Cells|Patients will be stimulated with Granulocyte Colony Stimulating Factor (G-CSF) 5 times, harvest bone marrow and infused 8 to 10 mL of stem cells (CD34+) by intrathecal via.
1943160|NCT01020435|Other|Spinal Manipulation|The procedure in its broadest definition describes the application of a load (force or displacement) to specific body tissues (usually vertebral joints) with therapeutic intent. The mechanical characteristics of SM can vary in terms of its duration and amplitude, (hence, the rate at which it is applied), as well as its anatomical location, choice of levers, direction of force application, and the vehicle used to apply the force (manually or mechanically assisted).
1943211|NCT01013532|Device|intima-medial thickness (IMT)|ultrasound measured IMT of both common carotid arteries
1943212|NCT01013532|Device|new asymptomatic brain hemorrhage|asymptomatic macrobleedings or microbleedings on GRE images
1943161|NCT01020435|Other|Sham Spinal Manipulation|The sham assessment procedures will be the same as those in the high velocity treatment group. The sham intervention is identical to this treatment protocol except for the placement of the treating clinicians pisiform contact. The force and vector applied will be the same.
1943162|NCT01019889|Drug|SCRT|4 capsules,three times daily, for 7days or within symptom disappearance
1943163|NCT01019889|Drug|YPS|4 capsules, three times daily, for 7days or within symptom disappearance
1943164|NCT01019889|Drug|Placebo|4 capsules, three times daily, for 7days or within symptom disappearance
1943165|NCT01019252|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants are provided with education about ADHD and instruction in organizational skills, reducing distractibility, and adaptive thinking.
1943166|NCT01019083|Drug|Placebo|Placebo will be given according to randomization list
1943167|NCT01019083|Drug|Placebo|Placebo will be given according to randomization list
1943168|NCT01019083|Other|Control|Control will be selected from the Arsenic non contaminated Area
1943169|NCT01019083|Drug|Zinc Sulphate|Zinc Sulphate will be given according to randomization list
1943170|NCT01019083|Drug|Albendazole and Secnidazole|Albendazole and Secnidazole will be given according to randomization list
1943171|NCT01019083|Other|Arsenic|Participant will be selected from the Arsenic Contaminated Area
1943172|NCT01018017|Drug|Placebo|For placebo product, the SRT2104 drug substance will be replaced by microcrystalline cellulose (Avicel® PH 105) to match the SRT2104 investigational product.
1943173|NCT01018017|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250mg SRT2104.
1943174|NCT01016262|Drug|MAX-002|MAX-002 1 g suppositories will be taken once daily at bedtime for 6 weeks during the double-blind phase. Completers at Study Week 6 will be offered to receive, on a voluntary basis, MAX-002 1 g suppositories once daily at bedtime for 8 weeks during the open-label phase.
1943175|NCT01016262|Drug|Placebo|Placebo suppositories will be taken once daily at bedtime for 6 weeks during the double-blind phase.
1943176|NCT01016262|Drug|Canasa®|Canasa® 1 g suppositories will be taken once daily at bedtime for 6 weeks during the double-blind phase.
1943177|NCT01015768|Device|ReNu Multiplus multipurpose disinfecting solution|New lenses (PureVision) soaked 6 hours to overnight in ReNu Multiplus
1943178|NCT01015768|Device|Control|A new lens (PureVision) is soaked for two hours in non-preserved saline
1943179|NCT01015612|Device|Medtronic CoreValve® System|The Medtronic CoreValve® System device is designed to replace the native aortic valve without the requirement for open heart surgery and without concomitant surgical removal of the failed native valve in patients with symptomatic severe aortic stenosis who have an elevated surgical risk
1943180|NCT01014767|Drug|Carboplatin|"Standard Arm, Cycle 2: 350 mg/m2 IV over 2 hours on day 2 and 3
All Arms, Cycles 4 & 6: 350 mg/m2 IV over 2 hours on day 2 and 3"
1943181|NCT01014767|Drug|Cisplatin|Cycles 1 & 2: 70 mg/m²/d IV over 6 hours on day 4
1943182|NCT01014767|Drug|Cyclophosphamide|"Standard Arm, Cycle 1: 1 g/m^2 IV over 1 hour on day 2 and 3
All Arms, Cycles 3 & 5: 1 g/m^2 IV over 1 hour on day 2 and 3"
1943183|NCT01014767|Drug|Dactinomycin|Cycles 1 & 2: 45 µg/kg/day (max. 2 mg), IV on day 1
1943184|NCT01014767|Drug|Doxorubicin|Cycles 1 & 2: 25 mg/m²/day IV over 12 hrs on days 1-3
1943185|NCT01014767|Drug|Etoposide|"Standard Arm (1), Cycles 1 & 2:
100 mg/m2 IV over 1 hour on days 1-5
All Arms, Cycles 4-6:
100 mg/m2 IV over 1 hour on days 1-5"
1943186|NCT01014767|Drug|Irinotecan|"Temozolomide Irinotecan arm (4), Cycles 1 & 2:
50 mg/m2/day x 5 days as 1 hour IV infusions"
1943187|NCT01014767|Drug|Leucovorin|Given with Methotrexate as leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
1943188|NCT01014767|Drug|Methotrexate|5g/m2 IV over 24 hours with leucovorin rescue at hour 42 given three times on days 1, 15 and 29.
1943189|NCT01014767|Drug|Temozolomide|150 mg/m2/day x 5 days orally and combined with irinotecan 50 mg/m2/day IV x 5 days as one hour infusions.
1943190|NCT01014767|Drug|Vincristine|"Standard Arm (1), Cycles 1 & 2 : 1.5 mg/m^2 IV over 15 minutes on day 5
Doxorubicin/cisplatin arm (2), Cycles 1 & 2: 1.5 mg/m^2/day (max. 2 mg), i.v. on days 8, 15
For all Groups, Cycles 3 - 6: 1.5 mg/m2 IV over 15 minutes on day 5"
1943202|NCT01013077|Drug|Optive|Use a minimum of 2 drops per day for 1 month.
1943203|NCT01013077|Drug|Soothe|Use a minimum of 2 drops per day for 1 month.
1943204|NCT01013077|Drug|New Emulsion|Use a minimum of 2 drops per day for 1 month.
1943205|NCT01013532|Drug|Cilostazol|Cilostazol 100mg bid
1943206|NCT01013532|Drug|Probucol|Probucol 250mg bid
1943207|NCT01013532|Drug|Aspirin|Aspirin 100mg qd
1943208|NCT01013532|Drug|placebo of cilostazol|same shape and size of active cilostazol
1943209|NCT01013532|Drug|placebo of aspirin|same size and shape of active aspirin 100mg
1943210|NCT01013532|Device|ankle-brachial index (ABI)|measurement of ABI every years during follow up
1943213|NCT01013532|Device|new ischemic lesions on follow-up FLAIR images|any new ischemic lesions
1943214|NCT01013285|Biological|bevacizumab|
1943215|NCT01013285|Drug|temozolomide|
1943216|NCT01013285|Radiation|external beam radiation therapy|
1943217|NCT01013129|Genetic|DNA analysis|saliva samples will be collected from men (probands) who join the study as well as from first degree relatives who join the study
1943218|NCT01013129|Genetic|polymorphism analysis|we will genotype DNA samples (buccal) from all probands and conduct a traditional case-control analysis
1943219|NCT01013129|Other|laboratory biomarker analysis|10ml blood specimen will be obtained and processed (on probands locally-consented and/or those who have an appointment at the VA in Portland, Oregon) to allow for analyses of erythrocyte fatty acids and future nutrient and DNA analyses
1943220|NCT01013129|Other|medical chart review|PSA results, prostate biopsy pathology reports and clinician notes related to the biopsy are reviewed for final data analysis
1943221|NCT01013129|Other|questionnaire administration|probands are asked to complete questionnaires on 1) family history of cancer, 2) diet history over the past year, 3) employment environment and risk factors and/or 4) changes to diet, medications since enrollment in originating case control study
1943222|NCT01013129|Procedure|evaluation of cancer risk factors|pathology reports will be reviewed for probands whose prostate biopsies reveal cancer; these factors will be evaluated for cancer risk factors
1943223|NCT01013129|Procedure|study of high risk factors|prostate biopsy pathology reports will be reviewed for high risk factors
1943224|NCT01012921|Device|barrier membrane|The in situ forming gel serves as a barrier membrane for Guided Bone Regeneration (GBR).
1943225|NCT01012921|Device|MembraGel|Device application at surgery
1943226|NCT01012921|Other|Bio-Gide® membrane|Device application at surgery
1943227|NCT01012843|Drug|Amoxicillin-Clavulanate|oral 875/125 mg tablets of Amoxicillin/Clavulanate 2 times a day for 10 days
1943228|NCT01012843|Drug|Placebo|oral Placebo tablets two times a day for 10 days
1943229|NCT01012375|Drug|AZD1446|10 mg capsule, oral dose
1943230|NCT01012375|Drug|AZD1446|80 mg capsule, oral dose
1943231|NCT01012375|Drug|AZD1446|80 mg capsule, oral dose
1943232|NCT01012375|Drug|Placebo|Matching capsule, oral dose
1943233|NCT01012089|Drug|Daptomycin|Daptomycin IV 5 mg/kg one time dose
1943234|NCT01011335|Biological|Monovalent rAT|10, 25, 50 or 100 μg
1943235|NCT01011335|Biological|Monovalent rLukS-PV|10, 25, 50 or 100 μg
1943236|NCT01011335|Biological|Bivalent rLukS-PV / rAT|10, 25 or 50 μg
1943237|NCT01011335|Biological|Placebo with adjuvant|Placebo with adjuvant
1943238|NCT01011335|Biological|Placebo|Placebo saline
1943239|NCT01010789|Drug|Armodafinil|flexible dose 150-250mg/day
1943240|NCT01010789|Drug|Armodafinil|150-250mg/day; flexible dose
1943241|NCT01010789|Drug|Matching placebo|Placebo comparator
1943243|NCT01010516|Drug|High-dose rosuvastatin|40 of rosuvastatin daily
1943244|NCT01010516|Drug|Statin plus fenofibrate|Existing statin plus micronised fenofibrate 200 mg daily
1943245|NCT01010516|Drug|Statin plus niacin ER/laropiprant|Existing statin plus extended-release niacin/laropiprant (1 g/day for the first month which will be uptitrated to 2 g/day for the next months)
1943246|NCT01009970|Drug|Rituximab|375 mg/m2 day 1
1943247|NCT01009970|Drug|Cyclophosphamide|750 mg/m2 day 2
1943248|NCT01009970|Drug|Vincristine|1,4 mg/m2 (max 2 mg) day 2
1943249|NCT01009970|Drug|Prednisone|40 mg/m2 day 2-6
1943250|NCT01009970|Drug|Doxorubicin|50 mg/m2 day 2
1943251|NCT01009671|Drug|ART 44|
1943252|NCT01009671|Drug|ART 50|
1943253|NCT01009255|Drug|GSK239512|Histamine H3 Antagonist
1943254|NCT01009255|Drug|Placebo|Placebo to match GSK239512
1943255|NCT01008319|Drug|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, another ultrasound and blood draw (to test progesterone level) will be done one week later to confirm no response to the medication dose. Medroxyprogesterone acetate (Provera) 10 mg per day for 10 days. Increased dose of clomiphene citrate for 5 days starting on cycle day 5. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
1943256|NCT01008319|Drug|clomiphene citrate|Clomiphene citrate 50 mg for 5 days starting on cycle day 5. Transvaginal ultrasound between cycle days 11 to 14 to determine if there is a dominant follicle. If NO dominant follicle present, a blood draw (to test progesterone level) will be done. Increased dose of clomiphene citrate for 5 days starting that day. A repeat transvaginal ultrasound in one week to determine if there is a dominant follicle. This process will be repeated at increased doses of clomiphene citrate (100 mg and 150 mg) until a dominant follicle(s) is present.
1943260|NCT01006369|Biological|bevacizumab|"Arm A: FOLFOX6 + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 5 mg/kg in 100 cc Normal Saline every 14 days on day one
Arm B: XELOX + Bevacizumab + Hydroxychloroquine: Bevacizumab will be administered intravenously 7.5 mg/kg in 100 cc Normal Saline every 21 days"
1943261|NCT01006369|Drug|XELOX regimen|Capecitabine will be started at a dose of 1,000 mg/m2/day bid po (total daily dose = 2,000 mg/m2) for 14 days (28 doses) of the 21 day cycle. This cycle will be repeated every 21 days. Oxaliplatin will be started at a dose of 130 mg/m2, in 250 ml of D5W over 2 hours given day 1 of each cycle. This cycle will be repeated every 21 days.
1943262|NCT01006369|Drug|hydroxychloroquine|hydroxychloroquine 200 mg po BID daily
1943263|NCT01006499|Drug|Pentoxifylline, pentaglobin|Pentaglobin 250mg/kg/d over 4 hour for three days Pentoxyfilline 6mg/kg/h over 4 hour for three days Pentaglobin 250mg/kg/d over 4 hour for three days+Pentoxyfilline 6mg/kg/h over 4 hour for three days Placebo (normal saline 5ml/kg over 4 hour for three days
1943264|NCT01005966|Drug|Sodium Fluoride Toothpaste|Test product
1943265|NCT01005966|Drug|Amine Fluoride Toothpaste|Test product
1943266|NCT01005966|Drug|Sodium monofluorophosphate/Sodium Fluoride Toothpaste|test product
1943267|NCT01005966|Drug|Placebo|placebo and washout treatment
1943268|NCT01005966|Drug|675 ppmf toothpaste|dose response
1943270|NCT01004744|Drug|Anastrozole|1mg PO daily for two weeks prior to scheduled surgery
1943279|NCT01004055|Device|Procellera™ Antimicrobial Wound Dressing|Dressing indicated for partial and full-thickness wounds. Dressing changes every 2-3 days, more frequently if needed
1943280|NCT01004055|Drug|ACTICOAT™ Antimicrobial Barrier Dressing|Dressing changes every 2-3 days, more frequently if needed
1943281|NCT01004055|Drug|Mepilex® Ag Silver Foam Dressing|Dressing changes every 2-3 days, more frequently if needed
1943282|NCT01004107|Device|Radiesse® Injectable Dermal Filler|Calcium hydroxylapatite particles suspended in an aqueous based gel carrier
1943283|NCT01003639|Drug|Acetazolamide|Subjects will begin with four 250 mg tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
1943284|NCT01003639|Drug|Placebo|Subjects will begin with four tablets daily. Tablets will be divided among two doses, taken with meals. Beginning on day 7, subjects will increase the dose by 1 pill every week until 16 tablets daily is reached (4 grams acetazolamide or placebo) or side effects prohibit increasing the dosage further. Thus, subjects who are able to tolerate the study medication will reach the maximum dose by day 84.
1943285|NCT01003639|Behavioral|Formal weight loss counselling program|Teleconference, web-based from central location, using site visits and subject self-assessment tools
1943286|NCT01003418|Biological|GSK2340272A GSK Biologicals' investigational influenza pandemic vaccine|Two doses; intramuscular administration
1943287|NCT01003418|Biological|InfanrixTM-IPV/Hib|Routine infant immunisation vaccine, three doses administered intramuscularly
1943288|NCT01003418|Biological|Prevenar|Routine infant immunisation vaccine, three doses administered intramuscularly
1943289|NCT01001975|Drug|Sunscreen Test Code: V53-028|Sunscreen formula containing 15% Zinc Oxide, 3% Avobenzone, and 1% Ensulizole
1943290|NCT01001975|Drug|Sunscreen Test Code: V53-030|Sunscreen formula containing 15% Zinc Oxide and 3% Avobenzone
1943291|NCT01001975|Drug|Standard SPF 4 Sunscreen|8% Homosalate Standard SPF 4 Sunscreen
1943292|NCT01001897|Drug|Misoprostol|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
1943293|NCT01001897|Drug|Placebo|400 micrograms of misoprostol or placebo inserted buccally or vaginally prior to IUD insertion
1943294|NCT01001260|Drug|No ASA|Alternative antiplatelet therapy instead of aspirin
1943295|NCT01001260|Drug|Low dose ASA|Low dose aspirin (81mg) prior to PTCA
1943296|NCT01001260|Drug|325 mg ASA|high dose of aspirin prior to PTCA
1943297|NCT01001338|Drug|RDEA594|Uricosuric agent for the treatment of gout.
1943298|NCT01001338|Drug|Placebo|Matching Placebo
1943299|NCT01001338|Drug|Allopurinol|Allopurinol
1943300|NCT01000935|Other|Platelet Rich Plasma|Patient's blood will be drawn prior to the start of the procedure. The processing disposable (PD) size of 60ml will be used to yield 7 ml of Platelet concentrate volume. Using the lateral portal, the applicator for the PRP will be positioned in between the bone and the repaired rotator cuff without a cannula. The inflow will then be closed and the arthroscopic fluid will be aspirated via the outflow cannula. All other cannulae will be removed, producing a dry subacromial space. The PRP and autologous thrombin will then be transferred to the sterile field and drawn up into a dedicated spray applicator kit (Smartjet) and applied to the site of repair. A dry arthroscopic check will be performed to evaluate the clot formation of the applied solution.
1943301|NCT01000935|Other|Platelet Rich plasma|The study group will have a surgical repair and will receive PRP treatment where the control group will undergo surgery without the PRP application.
1943302|NCT01000714|Drug|Psirelax|
1943303|NCT01000636|Procedure|Metvix PDT|"Methyl aminolevulinate cream will be applied for 3 hours on the whole target field.
The target field will then be exposed to red light using Aktilite 128 lamp."
1943304|NCT00999505|Drug|Amantadine|Amantadine 200mg twice a day over 12 weeks
1943305|NCT00999505|Drug|Placebo|Placebo capsules twice a day over 12 weeks
1943306|NCT00999492|Device|Tecnis® Multifocal (TMF)|Aspheric, diffractive multifocal intraocular lenses
1943352|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of initial process-manufactured GSK2340272A vaccine
1943309|NCT00998790|Device|American Medical Systems (AMS) AdVance™ Male Sling System|The AMS AdVance™ Male Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD). The AdVance™ Male Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
1943310|NCT00997347|Drug|Mifepristone and misoprostol|"200 mg oral mifepristone
800 mcg buccal misoprostol or 400 mcg sublingual misoprostol 24-48 hours after mifepristone"
1943311|NCT00997620|Drug|Fluticasone furoate Nasal Spray|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo
1943312|NCT00997620|Drug|Placebo|Fluticasone nasal spray 2 sprays each nostril will be compared to similar appearing placebo
1943318|NCT00996866|Drug|Vitamin D3|Vitamin D supplementation will follow an algorithm for initial vitamin D dosing and for dose changes. Subjects will receive 100 ug/day of vitamin D3 if their 25(OH)D level is less than 50nmol/L and 50 ug/day if their 25(OH)D level is between 50 and 80 ug/day.
1943319|NCT00996866|Drug|placebo|The placebo group will receive sugar pills appearing similar to the vitamin D capsules.
1943320|NCT00996307|Biological|MF59-eH1N1_f|3.75 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
1943321|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
1943322|NCT00996307|Biological|MF59-eH1N1_f|15 µg A/H1N1 antigen without MF59 adjuvant administered on study day 1 and day 22.
1943323|NCT00996307|Biological|MF59-eH1N1_f|7.5 µg A/H1N1 antigen with 50% MF59 adjuvant administered on study day 1 and day 22.
1943324|NCT00996281|Drug|Azilsartan medoxomil and chlorthalidone|Combination tablet.
1943325|NCT00996281|Drug|Olmesartan medoxomil and hydrochlorothiazide|Combination tablet.
1943326|NCT00995397|Drug|Dexchlorpheniramine 1% lotion|Small amount applied over the lesion twice a day for 7 days.
1943327|NCT00995397|Drug|Dexchlorpheniramine 1% cream|Small amount applied over the lesion twice a day for 7 days.
1943328|NCT00995722|Drug|Prednisone|Prednisone will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain 10mg of prednisone.
1943329|NCT00995722|Drug|Placebo|Placebo dosages will be adjusted based on combined measures of tolerability and efficacy. Capsules will contain matching placebo.
1943331|NCT00994734|Drug|Mifepristone|home administration of mifepristone
1943332|NCT00993967|Drug|idebenone|Idebenone 1350 mg/d, patients < or equal 45 kg Idebenone 2250 mg/d, patients > 45 kg
1943333|NCT00993759|Drug|3804-250A|3.2 ml applied topically after hand washing and at least every 3 hours while awake.
1943338|NCT00993070|Drug|Capsaicin|0.025% topical capsaicin applied 4 times per day for 8 weeks
1943339|NCT00993070|Drug|placebo|vehicle gel, applied 4 times per day for 8 weeks
1943344|NCT00992901|Drug|Exendin-(9-39)|A physiological study to evaluate the role of GLP-1 signaling in glucose tolerance and insulin secretion
1943345|NCT00992901|Drug|Atropine|A physiological study to evaluate the effect of neural activation on insulin secretion and glucose metabolism
1943346|NCT00992901|Drug|GLP-1 and GIP|A physiological study to evaluate the beta-cell sensitivity to different doses of exogenous gut hormones
1943347|NCT00992160|Drug|GW597599|GW597599 15mg tablet
1943348|NCT00992160|Drug|Placebo|Placebo to match GW597599 15mg tablet
1943349|NCT00992693|Drug|Ribavirin (Virazole) Injection|"The drug is to be administered in a volume of 50-100 ml of normal saline to be infused over 30-40 minutes.
1) Loading dose: 33 mg/kg (maximum dose 2.64 g)(1 dose) 2) Followed by a dose of 16 mg/kg (max dose 1.28 g) every 6 hours for the first 4 days (15 doses) 3) Followed by a dose of 8 mg/kg (maximum dose 0.64 g) every 8 hours for the subsequent 6 days (18 doses) Ten day course of treatment with follow up between day 28 to day 60."
1943350|NCT00992667|Drug|Apocynin nebulization|6 ml of apocynin of total dose 3 mg (0.5 mg/ml dissolved in sterile 0.9% NaCl as the study drug) has been nebulized for 15-20 min through the mouthpiece with using of a nose clip. A nebulizer Pulmo Aide AP-50 (DeVilbiss; Richmond, VA) was used (mass median aerosol diameter 3.1 mm, output 0.3 ml/min.)
1943351|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of initial process-manufactured GSK2340272A vaccine
1943353|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injection of new process-manufactured GSK2340272A vaccine
1943354|NCT00992511|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections of new process-manufactured GSK2340272A vaccine
1943355|NCT00992771|Drug|varenicline|up to 1mg BID for 8 weeks
1943356|NCT00992771|Drug|placebo|placebo matching varenicline, up to 1mg BID for 8 weeks
1943357|NCT00991731|Behavioral|Faith-based|The faith-based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered with biblical references to further guide the participants.
1943358|NCT00991731|Behavioral|Non-faith-based|The non-faith based intervention will include 24 group sessions. Sessions 1 - 16 will occur weekly, sessions 17 - 20 will occur bi-weekly, and sessions 21 - 24 will occur monthly. Sessions will be scheduled to last for 90 minutes each. This will include a 30-minute physical activity session (led by a trained exercise leader) and 60 minutes of group discussion (led by a Community Health Worker trained in group facilitation, familiarity with theology and health ministry education, and experience implementing group-based activities in faith settings). Group discussion content will be standardized to ensure consistent delivery. All items will be delivered without biblical references as in the faith-based intervention.
1943360|NCT00990288|Drug|Hemostatic Matrix|
1943361|NCT00990249|Drug|Busulfan|Test Dose 32 mg/m^2 by vein over 45 minutes on Day -8; following doses on Days -6 to -3 derived from pharmacokinetic (PK) testing done up to 11 times over 11 hours after test dose.
1943362|NCT00990249|Drug|Clofarabine|40 mg/m^2 by vein over 1 hour daily Day -6 through Day -3
1943363|NCT00990249|Drug|Thymoglobulin|0.5 mg/kg on Day -3, 1.5 mg/kg on Day -2 and 2.0 mg/kg on Day -1; only patients with HLA nonidentical or unrelated donors
1943364|NCT00990249|Procedure|Stem Cell Transplant|Stem cell infusion on Day 0.
1943371|NCT00989287|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
1943372|NCT00989716|Drug|Transdermal glyceryl trinitrate patch|5mg per day
1943373|NCT00989716|Drug|Pre-stroke antihypertensives|Continue or stop pre-stroke anti-hypertensives
1943374|NCT00989612|Biological|Influenza investigational vaccine GSK2340274A|Two intramuscular injections on Day 0 and Day 21, respectively
1943375|NCT00988936|Drug|[F-18]RGD-K5|Approximately forty (40) patients with non-squamous non-small cell lung cancer, metastatic breast cancer, metastatic colon or rectum cancer will receive chemotherapy plus Avastin® and will be imaged under PET/CT with [F-18]RGD-K5
1943377|NCT00988559|Biological|DNA vaccination|vaccination with pNGVL4a-CRT/E7(detox)
1943378|NCT00988559|Device|Gene gun vaccine|8 micrograms (group 1) or 16 micrograms (group 2)
1943379|NCT00988559|Biological|intramuscular vaccination|1mg (group 3) or 3mg (group 4) of pNGVLra-CRT/E7(detox) administered intramuscularly
1943380|NCT00988559|Biological|intra-lesional vaccine administration|1mg (group 5) or 3mg (group 6) of pNGVL4a-CRT/E7(detox)administered intra-lesionally
1943381|NCT00988559|Procedure|therapeutic resection of the lesion|at week 15, all residual lesions will be resected
1943382|NCT00988559|Drug|imiquimod|imiquimod applied to the cervix by the physician
1943383|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
1943384|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years supervised training two times a week for 12 months, and once a week during the next 12 months
1943385|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|20 µg (800 IU) of vitamin D per day for two years no supervised training (maintenance of their current level of physical activity)
1943386|NCT00986466|Dietary Supplement|exercise and vitamin D supplementation|placebo per day for two years no supervised training (maintenance of their current level of physical activity)
1943388|NCT00986167|Drug|Quetiapine XR|The daily dose of oral Quetiapine XR at the start of therapy is 300 mg on Day 1, 600 mg on Day 2 and up to 800 mg after Day 2. The dose will be adjusted within the usual effective dose range of 400 to 800 mg/day, depending on the clinical response and tolerability of the individual patient.
1943389|NCT00985634|Device|LeGoo|LeGoo internal vessel occluder. Usage (dose) as required and determined by surgeon.
1943390|NCT00985634|Device|Control|Vessel loops
1943391|NCT00985465|Biological|Pneumococcal vaccine GSK1024850A|Intramuscular injection, 1 or 2 doses
1943395|NCT00984659|Drug|Fluticasone propionate/salmeterol combination product|Fluticasone propionate/salmeterol combination product 250/50mcg DISKUS twice a day for 8 weeks
1943396|NCT00984659|Drug|Salmeterol|Salmeterol 50mcg DISKUS twice a day for 8 weeks
1943397|NCT00984659|Drug|Placebo|Placebo DISKUS twice a day for 8 weeks
1943398|NCT00983788|Drug|Bezafibrate|3 x 200 mg/ day
1943399|NCT00983788|Other|Placebo|Placebo
1943400|NCT00982319|Drug|Broccoli sprout extract (sulforaphane)|Women newly diagnosed with DCIS on core biopsy prior to definitive surgery will be randomized to either a prepartion of broccoli sprout extract and mango juice or a placebo preparation of mango juice alone. All women will be on a cruciferous free diet for the duration of the study (14 days) and complete a daily dietary check list. Twelve hour urine collections and blood samples will be collected at various time points during the study. Acceptability of the 14 day dose will be evaluated by monitoring indices of compliance, including urinary measurements of ITC excretion, the daily food check list and a questionnaire administered at the end of the study.
1943401|NCT00982319|Dietary Supplement|Mango juice without extract|Mango juice without broccoli sprout extract
1943402|NCT00983112|Drug|Human Fibrinogen and human thrombin (Evicel)|Product to be applied intraoperatively. No further administration will take place after this.
1943403|NCT00983112|Drug|Sodium Chlorure (Physiological saline)|Sterile concentration, local use.
1943404|NCT00982865|Drug|MSC1936369B|MSC1936369B will be administered to subjects at a dose of 1 to 120 milligram (mg) at escalating dose levels once daily up to 2 cycles (Each cycle of 21 days) and if the subject will be treated beyond 2 cycles the treatment continues until progressive disease or intolerable toxicity or investigator/subject decision.
1943405|NCT00982865|Drug|MSC1936369B|MSC1936369B will be administered to subjects at a dose of 1 to 255 mg at escalating dose levels once daily up to 2 cycles (Each cycle of 21 days) and if the subject will be treated beyond 2 cycles the treatment continues until progressive disease or intolerable toxicity or investigator/subject decision.
1943406|NCT00982865|Drug|MSC1936369B|Subjects in the regimen 2 food effect cohort will be sequentially assigned in a 1:1 ratio to either the fed/fasted sequence or fasted/fed sequence for Day 1 of Cycle 1 and Cycle 2. Subjects will be administered with MSC1936369B at a dose of 90-150 mg at escalating dose levels once daily up to 2 cycles (Each cycle of 21 days) and if the subject will be treated beyond 2 cycles the treatment continues until progressive disease or intolerable toxicity or investigator/subject decision.
1943407|NCT00982865|Drug|MSC1936369B|MSC1936369B will be administered to subjects at a dose of 60 to 90 mg at escalating dose levels once daily up to 2 cycles (Each cycle of 21 days) and if the subject will be treated beyond 2 cycles the treatment continues until progressive disease or intolerable toxicity or investigator/subject decision.
1943408|NCT00982865|Drug|MSC1936369B|MSC1936369B will be administered to subjects at a dose of 45 to 75 mg at escalating dose levels once daily up to 2 cycles (Each cycle of 21 days) and if the subject will be treated beyond 2 cycles the treatment continues until progressive disease or intolerable toxicity or investigator/subject decision.
1943409|NCT00982397|Device|Protecta Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D)|Secondary prevention subjects will have their device programmed to VF NID 18/24. VF NID (ventricular fibrillation number of intervals to detect) is a programmed parameter and indicates if 18 of the last 24 beat to beat intervals are shorter than the VF detection interval the device will detect ventricular fibrillation and initiate therapy to treat the rhythm.
1943410|NCT00982397|Device|Protecta Implantable Cardioverter Defibrillator (ICD) and Cardiac Resynchronization Therapy Defibrillator (CRT-D)|Secondary prevention subjects will have their device programmed to VF NID 30/40. VF NID (ventricular fibrillation number of intervals to detect) is a programmed parameter and indicates if 30 of the last 40 beat to beat intervals are shorter than the VF detection interval the device will detect ventricular fibrillation and initiate therapy to treat the rhythm.
1943413|NCT00981526|Drug|Telmisartan|"Telmisartan (plus existing clozapine or olanzapine treatment) 40mg/day for the first 2 weeks.
Telmisartan (plus existing clozapine or olanzapine treatment) 80mg/day for the next 10 weeks."
1943414|NCT00981526|Drug|Placebo|Placebo (plus existing clozapine or olanzapine treatment) for 12 weeks.
1943415|NCT00981526|Drug|Clozapine|Clozapine (plus telmisartan or placebo) for 12 weeks.
1943416|NCT00981526|Drug|Olanzapine|Olanzapine (plus telmisartan or placebo) for 12 weeks.
1943420|NCT00979563|Drug|HM30181AK tablet + Irinotecan tablets|HM30181AK 60 mg tablet + Irinotecan 20mg, 5 mg or 2mg tablets
1943421|NCT00979550|Drug|Imiquimod (Aldara)|.5 oz cream nightly to the affected area
1943422|NCT00979550|Drug|non-medicated petroleum cream|.5 oz cream nightly to the affected area
1943423|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose, and at dose of 80mg twice daily
1943424|NCT00979134|Drug|AZD4547|Patients start at a dose of 80 mg twice daily, with no washout
1943425|NCT00979134|Drug|AZD4547|Single dose is followed by washout 5-10 days before multiple dose
1943426|NCT00978796|Drug|Sitagliptin|Sitagliptin 100mg tablet taken orally once daily for 4 weeks and then switch over to sugar pill taken daily for 4 weeks
1943427|NCT00978796|Drug|Sugar Pill|Sugar pill taken daily for 4 weeks and then switched over to active comparator of sitagliptin 100mg tablet taken daily for 4 weeks
1943428|NCT00978068|Drug|LPV/r + 2 NRTIs|"Group 1
Lopinavir/ritonavir (LPV/r) +2 nucleoside reverse transcriptase inhibitor (NRTI)
The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL, in which case it will be Abacavir. Stavudine will be used in the event that a participant is unable to take Abacavir for safety or other reasons."
1943429|NCT00978068|Drug|NVP or EFV + 2 NRTIs|"Group 2
Nevirapine (NVP) or Efavirenz (EFV) + 2 NRTI
NVP will be used for children < 3 years of age and EFV for children ≥3 years of age. The same NRTI choice strategy will be used for both arms. Lamivudine will be used with all children. The second NRTI will be zidovudine unless the participant has a hemoglobin < 8 gm/dL, in which case it will be stavudine."
1943430|NCT00977028|Drug|Tumescent Local Anesthesia (lidocaine, epinephrine)|Tumescent solution of lidocaine (up to 1 gm per liter) and epinephrine (up to 1 mg per liter)with subcutaneous infiltration of up to 45 mg per kilogram
1943431|NCT00977028|Procedure|Liposuction|Subcutaneous infiltration of tumescent local anesthesia (large volumes of dilute lidocaine and epinephrine) on at least two different occasions, followed by sequential serum samples every two hours for HPLC determination of serum lidocaine concentration and peak serum lidocaine concentration, initially without subsequent liposuction and finally on the last occasion with liposuction
1943432|NCT00975884|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
1943433|NCT00976820|Biological|GSK2340274A|Two intramuscular injections
1943434|NCT00976820|Biological|GSK2340273A|Two intramuscular injections
1943435|NCT00976560|Drug|GW856553|Wet granulated tablets, film coated white, 9mm round, biconvex, plain faced, containing 2.5 mg of GW856553
1943436|NCT00976560|Drug|GW856553|Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
1943437|NCT00976560|Other|Placebo|Film coated white, 9mm round, biconvex, plain faced tablets obtained by direct compression.
1943440|NCT00976287|Procedure|Hepatic artery infusion|Patients with liver cirrhosis were randomly separated into two groups. Autologous MSCs were infused to patients using interventional method via hepatic artery for One group. The catheter was inserted to proper hepatic artery. After the catheter placed at proper hepatic artery was confirmed by angiography, autologous bone marrow MSCs were infused slowly for 20-30 minutes. The control group accepted conserved therapy.
1943441|NCT00976287|Procedure|Conserved Therapy|Conserved Therapy
1943442|NCT00976248|Drug|RAD001|Taken orally once a day
1943443|NCT00974922|Drug|aliskiren (Tekturna)|150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks
1943444|NCT00974922|Dietary Supplement|cholecalciferol (Vitamin D3)|3,000 I.U. once daily for 6 weeks.
1943445|NCT00974922|Dietary Supplement|Placebo|Placebo
1943446|NCT00974441|Drug|Divalproex Sodium|500 mg Extended Release Tablet
1943447|NCT00974441|Drug|Depakote®|500 mg Extended Release Tablet
1943448|NCT00974012|Drug|Divalproex Sodium|500 mg ER Tablet
1943449|NCT00974012|Drug|Depakote®|500 mg ER Tablet
1943450|NCT00972855|Drug|Bicalutamide|50 mg Tablet
1943451|NCT00972855|Drug|Casodex®|50 mg Tablet
1943452|NCT00973856|Other|PURELL VF481|One (1) pump of test product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
1943453|NCT00973856|Other|Placebo Comparator|One (1) pump of product (approximately 1.5ml) is applied to a wooden applicator and gently rubbed into the wart, then covered with a latex free adhesive bandage (it is not necessary to wait until dry) each night before bed
1943454|NCT00973674|Drug|Premarin IV|One time dose of Premarin IV
1943455|NCT00973674|Drug|Placebo|One time dose of Placebo
1943456|NCT00973479|Drug|Golimumab|Participants will receive 2 mg/kg of golimumab intravenously over 30 ± 10 minutes. Group 1: at Weeks 0, 4, and every 8 weeks thereafter (up to Week 100). Group II: Weeks 24, 28, and every 8 weeks thereafter (up to Week 100); Early escape: at Week 16, 20 and every 8 weeks thereafter (up to Week 100).
1943457|NCT00973479|Other|Placebo|Participants will receive placebo intravenous infusion over 30 ± 10 minutes as: Group I: at Week 16 and 24; Group II: at Weeks 0, 4, 12, 16, and 20; and for early escape: at Week 24.
1943458|NCT00973479|Drug|methotrexate (MTX)|Participants will be maintained on their stable dose of commercial MTX (between 15 to 25 mg/week) throughout the study.
1943459|NCT00973102|Drug|Premarin IV|One time dose of Premarin IV
1943460|NCT00973102|Drug|Placebo|One time dose of placebo.
1943461|NCT00973050|Drug|Bicalutamide|50 mg Tablet
1943462|NCT00973050|Drug|Casodex®|50 mg Tabelt
1943463|NCT00972985|Drug|modafinil|oral tablet, 100 mg, single acute dose
1943464|NCT00972985|Drug|methylphenidate|oral tablet, 20 mg, single acute dose
1943465|NCT00972985|Drug|lorazepam|oral tablet, 1 mg, single, acute dose
1943466|NCT00972985|Drug|placebo|oral tablet, single acute dose
1943467|NCT00972556|Drug|Gray Mineral Trioxide Aggregate (GMTA)|Once hemorrhage from the pulp chamber is under control using direct pressure of a sterile cotton pellet, pulp stumps are covered with a MTA paste, obtained by mixing 0.2g GMTA powder with sterile water in a powder to liquid ratio of 3:1 in weight. The GMTA will be then immediately covered with a zinc-oxide eugenol base (IRM) material.
1943468|NCT00972556|Drug|Diluted (20%) Formocresol (DFC)|After the pulp hemostasis is achieved with direct pressure of a sterile cotton pellet, a sterile cotton pellet dampened with 20% DFC will be placed in contact with the pulp for 5 minutes, followed by the immediate placement of a zinc-oxide eugenol base (IRM) material.
1943478|NCT00972439|Drug|Oral Contraceptive: Ovcon Fe®|
1943479|NCT00972270|Device|Impella LP 2.5|Insertion of the LP 2.5 IMPELLA circulatory support system that can be placed across the aortic valve using a single femoral site. The device pumps blood from the left ventricle into the ascending aorta at 2.5L/min.
1943480|NCT00972270|Device|Intra-Aortic Balloon Pump|The Intra-Aortic Balloon Pump consists of a cylindrical balloon that sits in the aorta and counterpulsates.
1943481|NCT00971321|Biological|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections
1943482|NCT00969475|Device|Lumenis fractional carbon dioxide laser|intra-operative laser resurfacing at time of wound closure
1943483|NCT00968513|Behavioral|Brief Intervention|(N=475) adds a stage-based manual, computer-delivered stage-tailored individualized feedback and brief cessation counseling sessions during hospitalization and repeated at months 3 and 6, and access to 12 weeks of nicotine replacement following hospitalization
1943484|NCT00968513|Behavioral|Extended Treatment|(N=475) builds upon our current brief treatment and provides 12 additional weeks of nicotine replacement (24 weeks total) with individualized, counselor-delivered motivational and manualized cognitive behavioral cessation treatment.
1943485|NCT00968513|Behavioral|Usual Care|brief cessation advice, a quit smoking guide, and nicotine replacement provided during hospitalization
1943486|NCT00969059|Drug|GW856553|GW856553 is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered 7.5mg bid, orally with food at breakfast and dinner.
1943487|NCT00969059|Drug|PLACEBO|Matching Placebo is a film coated white tablet, 9mm round, biconvex, plain faced. It will be administered orally with food at breakfast and dinner.
1943488|NCT00968994|Device|The exSALT™ SD7 Wound Dressing|The exSALT™ SD7 Wound Dressing is indicated for the management of partial and full thickness wounds, including decubitus ulcers, venous stasis ulcers, diabetic ulcers, first and second degree burns, grafts and donor sites, or other acute or chronic wounds. The dressing may be used over debrided and grafted wounds.
1943489|NCT00968994|Device|Xeroform® Petrolatum Dressing|Sterile, single use, non-adherent dressing consisting of absorbent gauze impregnated with Xeroform in a petrolatum blend.
1943490|NCT00968864|Device|CliniMACS® (T cell depletion)|Stem cells will be collected from donors after they receive Granulocyte colony-stimulating factor (G-CSF). The cells will be processed using the CliniMACS device to select for CD34+ stem cells and to deplete T cells. Recipients will receive conditioning therapy that is based on their disease type and then receive the CD34+ stem cells.
1943491|NCT00968851|Drug|EVP-6124|Arms: 1
1943492|NCT00968851|Drug|Placebo|Arm: 3
1943493|NCT00968851|Drug|EVP-6124|Arms: 2
1943494|NCT00968539|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
1943495|NCT00968539|Biological|GSK investigational vaccine GSK2340269A|Two intramuscular injections
1943496|NCT00968526|Biological|GSK investigational vaccine GSK2340272A|One intramuscular injections
1943497|NCT00968526|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
1943498|NCT00967941|Drug|Ancef (Antibiotic Prophylaxis)|Comparing the antibiotic treatment related to surgery
1943499|NCT00967941|Drug|Vancomycin and Cefazolin (Antibiotic Prophylaxis)|Comparing the antibiotic treatment related to surgery
1943500|NCT00967941|Drug|Daptomycin and Cefazolin (Antibiotic Prophylaxis)|Comparing the antibiotic treatment related to surgery
1943501|NCT00968253|Drug|Everolimus (RAD001)|Beginning dose of 5 mg tablets every other day by mouth followed by a big glass of water. First dose will occur 1 day before receiving chemotherapy.
1943502|NCT00968253|Drug|Cyclophosphamide|300 mg/m^2 intravenous (IV) over 3 hours every 12 hours x 6 doses on Days 1, 2, 3 (total dose 1800 mg/m2).
1943503|NCT00968253|Drug|Vincristine|2 mg IV on Day 4 and Day 11 ± 2 days.
1943504|NCT00968253|Drug|Doxorubicin|50 mg/m^2 IV over 24 hours via central venous catheter on day 4, after last dose of Cyclophosphamide given.
1943505|NCT00968253|Drug|Dexamethasone|40 mg IV or orally daily days 1-4 ± 2 days and days 11-14 ± 2 days.
1943506|NCT00968253|Drug|Mesna|600 mg/m^2 IV continuous infusion daily for 24 hours days 1-3.
1943507|NCT00968253|Drug|Methotrexate|200 mg/m^2 IV over 2 hours followed by 800 mg/m^2 IV over 22 hours day 1.
1943508|NCT00968253|Drug|Ara-C (Cytarabine)|3 gm/m^2 IV over 2 hours every 12 hours for 4 doses on days 2, 3.
1943509|NCT00968253|Drug|Methylprednisone|50 mg IV over 2 hours approximately every 12 hours for 6 doses days 1-3.
1943510|NCT00968253|Drug|G-CSF|10 mcg/kg/day (rounded) within 72 ± 48 hours after completion of chemotherapy until neutrophil recovery 1 x 109/L or higher. Pegfilgrastim (given at 6 mg subcutaneous for one dose approximately 24 hours after completion of the chemotherapy) may be substituted for G-CSF.
1943511|NCT00967304|Other|"Application of theMen continue and HER DOO2 rule"|"Consecutive patients will have theMen continue and HER DOO2 rule applied by the attending physician between 5 - 12 months after treatment for a first unprovoked objectively proven major VTE.
Men continue and HER DOO2 rule: all men continue oral anticoagulants and women with 2 or more of the following features after 5-7 months of OAT should continue oral anticoagulants:1) HER - any Hyperpigmentation, Edema and Redness of either lower extremity, 2) Vidas D-dimer ≥250ug/L, 3) Obesity - BMI ≥30 kg/m2 and 4) Older age - Age ≥65 years."
1943512|NCT00967148|Drug|Tinzaparin|The treatment arm will receive a subcutaneous injection of tinzaparin (4500U) daily beginning within two days of the decision to operate (within 6 weeks of surgical resection) weeks and continued for 4 weeks following resection.
1943513|NCT00966355|Drug|Terlipressin|loading with 2 mg IV, and then 1 mg IV every 4 hours for 5 days
1943514|NCT00966355|Drug|Somatostatin|loading with 250 microgram IV, and then 250 microgram/hour continuous IV for 5 days
1943515|NCT00966355|Drug|Octreotide|loading with 50 microgram IV, and then 25 microgram/hour continuous IV for 5 days
1943516|NCT00966381|Other|Exercise and weight loss intervention|randomized control trial, stratified by parity
1943518|NCT00965575|Drug|Melatonin|Sustained release formula (Brand: Jigsaw); dosage will be 9mg for all subjects.
1943519|NCT00965458|Biological|Alefacept|Weekly intramuscular injections of alefacept (15 mg) for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
1943565|NCT00955409|Drug|ACC-001|Vanutide Cridificar (ACC-001) 10µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
1943520|NCT00965458|Drug|Placebo|Weekly intramuscular injections of a placebo saline solution of equal volume to the alefacept group for 2 cycles of 12 weeks each, separated by a 12 week pause in treatment.
1943521|NCT00964600|Procedure|TAP blockade|15 cc Bupivacaine 0.25% ,injected bilaterally in the TAP blockade arm
1943522|NCT00964158|Biological|Pandemic influenza vaccine GSK2340272A|Two primary intramuscular (IM) injections and a booster IM injection
1943523|NCT00964054|Other|Public Health Dose of Exercise (PHD)|17.5 kcal per kilogram per week
1943524|NCT00964054|Other|Low Dose Exercise (LD)|7.0 kcal per kilogram per week
1943525|NCT00963846|Drug|placebo|matching pill placebo
1943526|NCT00963846|Drug|huperzine 0.2 mg BID|huperzine rising doses up to 0.2 mg BID
1943527|NCT00963846|Drug|huperzine 0.4 mg BID|huperzine rising doses up to 0.4 mg BID
1943528|NCT00963846|Drug|huperzine 0.8 mg BID|huperzine rising doses up to 0.8 mg BID
1943529|NCT00963794|Other|Electromagnetic measurement|RC screening was carried out using a Tissue Resonance InterferoMeter probe electromagnetic detector, which consists of a nonlinear oscillator placed in a cylindrical probe about 30 cm long, a radiofrequency spectrum analyzer, and dedicated computer software. Detection of RC is based on the decrease of the electromagnetic signal compared to the mean signal obtained in healthy subjects. The test was performed while the patient stood 120 cm from the receiver. The operator was on the opposite side of the examined pelvis. The detector was kept at close contact to the pelvis surface and was moved through six planes, to obtain a scan of the whole pelvis volume. Based on our previous study, we used the electromagnetic detection system at 465 MHz frequency, in a scale from 0 to 255 arbitrary U.
1943530|NCT00962702|Device|LAAx TigerPaw System|Exclusion of Left Atrial Appendage
1943533|NCT00962130|Device|Continuous glucose monitoring system|one or two monitors will be placed in the tissue to be transferred
1943534|NCT00962039|Drug|Citalopram|Participants will be randomly assigned to citalopram or placebo in a parallel groups design for 8 weeks of double-blind treatment beginning with 10 mg per day week 1, 20 mg per day week 2, and 40 mg per day week 4 or thereafter if response is suboptimal and there are no significant side effects.
1943535|NCT00961922|Other|Neurofeedback|30 sessions of neurofeedback will be given twice a week at the child's home. It will take about 15 weeks to complete the training.
1943536|NCT00961922|Other|Placebo feedback|Feedback based on a random signal generator and muscular tension instead of brain activity. 30 sessions at home, twice a week, total 15 weeks.
1943537|NCT00961714|Device|OsseoFix Spinal Fracture Reduction System|All enrolled into the study will be receiving the OsseoFix if meet inclusion / exclusion criteria.
1943538|NCT00961207|Drug|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
1943539|NCT00961207|Drug|Aliskiren|Aliskiren 150mg daily for 2 weeks and increased to 300 mg daily for 4 weeks.
1943540|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with adults.
1943541|NCT00960128|Drug|somatropin|The effectiveness and safety data collection with the use of Norditropin® in daily clinical practice with children.
1943542|NCT00960505|Other|Alternate day fasting|
1943543|NCT00960505|Other|Calorie restriction|
1943544|NCT00960505|Other|Control diet|
1943545|NCT00960024|Behavioral|Individual Placement and Support-vocational rehabilitation|Individual contact with an employment specialist, who works according to 7 core principles according to SE/IPS. 1) competitive employment as primary goal, 2) rapid job search, 3) eligibility based on client choice, 4) job search based on to client preferences, 5) integration with the mental health care team, 6) availability of time unlimited support at work 7) benefits counseling.
1943546|NCT00960024|Behavioral|Vocational rehabilitation available|The participants are offered vocational rehabilitation available at site
1943547|NCT00960011|Device|PROGRIP|Use of PROGRIP mesh for open inguinal hernia repair
1943548|NCT00960011|Device|POLYPROPYLENE|Use of Polypropylene mesh in open inguinal hernia repair
1943549|NCT00959062|Drug|clonidine|5 mcg/kg (maximum 200 mcg) enterally every 6 hours
1943550|NCT00959062|Drug|placebo|Preparation visually identical to clonidine.
1943551|NCT00958932|Behavioral|Speech recognition|The TEAM intervention is a program to increase communication with families, provide feedback to families about their refill adherence, assess asthma symptoms, deliver health communication messages, encourage parents to ask questions of asthma care managers, and facilitate refilling ICS prescription. Speech recognition calls will be tailored to specific situations including new or re-issued ICS prescriptions, failure to fill an initial prescription, failure to refill, or failure to refill following an ED visit, hospitalization, or oral steroid burst resulting from an asthma exacerbation.
1943552|NCT00958932|Behavioral|Speech recognition|Automated, speech recognition telephone calls
1943553|NCT00958724|Drug|treatment with neratinib (HKI-272) + vinorelbine|HKI-272 : 240 mg, continuous daily OD Vinorelbine : 25 mg/m2, Day 1 and 8 of 21 day cycle
1943554|NCT00958412|Drug|Proellex®|one (1) 25 mg capsule daily
1943555|NCT00957827|Drug|keflex|keflex 500 mg BID 5 days
1943556|NCT00957827|Drug|placebo|placebo BID for five days
1943557|NCT00956462|Drug|Ketorolac (NSAID) versus Dexamethasone (steroid)|Topical NSAID versus topical steroid after implantation of glaucoma drainage device
1943558|NCT00955552|Drug|Glucosamine sulphate and chondroitin sulphate association|glucosamine sulphate 500 mg and chondroitin sulphate 400 mg association T.I.D. before each meal
1943559|NCT00955552|Drug|Condroflex (Zodiac)|oral capsule of glucosamine sulphate 500 mg + chondroitin sulphate 400 mg thrice daily before meals. Period: 127 days
1943560|NCT00955981|Drug|RDEA594|Uricosuric agent for the treatment of gout
1943561|NCT00955981|Drug|Placebo|Matching placebo
1943562|NCT00955682|Biological|Meningococcal vaccine GSK134612|One intramuscular dose (Booster)
1943563|NCT00955682|Biological|Meningitec™|One intramuscular dose (Booster)
1943564|NCT00955409|Drug|ACC-001+ QS21|Vanutide Cridificar (ACC-001) 3µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
1943566|NCT00955409|Drug|ACC-001 + QS21|Vanutide Cridificar (ACC-001) 30 µg + QS-21 (50µg), IM on Day 1, Month 6, Month 12 and Month 18
1943567|NCT00955630|Drug|ranibizumab|3 monthly injections of ranibizumab followed by prn injections for the remainder of the study
1943568|NCT00955630|Drug|ranibizumab|prn injections of ranibizumab throughout the study
1943569|NCT00954304|Drug|HM30181AK 1mg|HM30181AK 1mg tablet
1943570|NCT00954304|Drug|HM30181AK 5mg|HM30181AK 5mg tablet
1943571|NCT00954304|Drug|HM30181AK 15mg|HM30181AK 15mg tablet
1943572|NCT00954304|Drug|HM30181AK 60mg|HM30181AK 60mg tablet
1943573|NCT00954304|Drug|Loperamide 2mg|Loperamide 2mg capsule
1943574|NCT00953173|Device|LAP-BAND AP® Adjustable Gastric Banding System|The LAP-BAND AP® is a device surgically implanted via a laparoscopic procedure. It is designed to induce weight loss in severely obese patients by limiting food consumption.
1943575|NCT00953784|Procedure|standard operating management|As previously described
1943576|NCT00953745|Drug|escitalopram and adjunctive aripiprazole and placebo|escitalopram 20 mg per day plus placebo for 10 weeks followed by escitalopram 20mg and aripiprazole 10 mg for 6 weeks
1943577|NCT00952770|Procedure|transradial coronary intervention|percutaneous coronary intervention with transradial approach
1943579|NCT00952341|Drug|aprepitant|Day 1: Oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Oral aprepitant 80 mg
1943580|NCT00952341|Drug|Comparator: Placebo to aprepitant|Day 1: Placebo to oral aprepitant 125 mg prior to administration of cisplatin; Days 2 and 3: Placebo to oral aprepitant 80 mg
1943581|NCT00952341|Drug|dexamethasone|Day 1: Oral dexamethasone 10.5 mg prior to administration of cisplatin; Days 2, 3, and 4: Oral dexamethasone 7.5 mg
1943582|NCT00952341|Drug|granisetron|Day 1: IV granisetron 3 mg prior to administration of cisplatin
1943583|NCT00952341|Drug|dexamethasone|Day 1: oral dexamethasone 6 mg prior to the administration of cisplatin; Days 2 and 3: oral dexamethasone 3.75 mg
1943584|NCT00951496|Biological|Bevacizumab|Given IV
1943585|NCT00951496|Drug|Carboplatin|Given IV
1943586|NCT00951496|Drug|Carboplatin|Given IP
1943587|NCT00951496|Drug|Cisplatin|Given IP
1943588|NCT00951496|Other|Laboratory Biomarker Analysis|Correlative studies
1943589|NCT00951496|Drug|Paclitaxel|Given IV
1943590|NCT00951496|Drug|Paclitaxel|Given IP
1943591|NCT00951496|Other|Quality-of-Life Assessment|Ancillary studies
1943592|NCT00951041|Biological|GSK investigational vaccine GSK2340272A|Two intramuscular injections
1943593|NCT00951041|Biological|GSK investigational vaccine GSK2340269A|Two intramuscular injections
1943594|NCT00950508|Procedure|High volume plasma exchange|3 high volume plasma exchanges over 3 days
1943595|NCT00950508|Procedure|Standard medical treatment|Standard medical treatment
1943598|NCT00949325|Drug|temsirolimus (Torisel) plus liposomal doxorubicin (Doxil)|Patients will be treated with temsirolimus weekly by iv and with liposomal doxorubicin (standard dose) by iv once every 28 days. Cohorts of patients receive sequentially increasing dose of temsirolimus until maximally tolerated dose (MTD) is reached. Once MTD (standard dose) is achieved, dosing will be with standard doses for each drug, but dosing will be modified based on toxicity.
1943599|NCT00948974|Behavioral|Cognitive Therapy|"Cognitive therapy (CT) highlights the identification and reappraisal of distorted or dysfunctional cognitions in the treatment of psychopathology. For example, socially anxious patients are taught to identify the thoughts and underlying beliefs that trigger strong emotional reactions (e.g., if I attempt to initiate a conversation I'll humiliate myself), and then replace these with more accurate, functional thoughts. There is a large body of research supporting the efficacy of CT for mood and anxiety disorders, and for social anxiety disorder in particular (Beck, 2005)."
1943600|NCT00948974|Behavioral|Acceptance and Commitment Therapy|ACT does not attempt to modify cognitions directly, but rather seeks to foster a mindful acceptance of whatever thoughts or feelings arise, while still pursuing specific behavioral goals. For example, the individual would be taught simply to notice the thoughts as if from a distance without attempting to modify them, and initiate a conversation. Like other newer mindfulness and acceptance-based models of CBT, ACT also expands the traditional focus on symptom reduction to include an emphasis on broader life goals. The scientific literature on ACT has expanded rapidly over the past ten years. Recent reviews conclude that it appears to be at least as effective as CT, and may work at least in part via distinct treatment mechanisms (Powers, Zum Vörde Sive Vörding, & Emmelkamp, 2009).
1943601|NCT00948805|Drug|GnRH agonist|3,6mg of goserelin acetate, 250mg of hCG, FSH variable dose according to the number of days required for appropriate ovarian stimulation
1943602|NCT00948805|Drug|Control|250mg of hCG, Zoladex, FSH variable dose according to the number of days required for appropriate ovarian stimulation
1943603|NCT00948025|Device|Hollow tube nerve conduit, synthetic or biosynthetic|Appropriately size matched hollow tube nerve conduit (Neurotube, NeuroLac, NeuraGen, NeuroMatrix, NeuroFlex)
1943604|NCT00948025|Other|Processed Human Nerve Tissue Scaffold|Implantation of appropriate length of processed human nerve tissue scaffold at time of surgery.
1943605|NCT00947375|Drug|Lamictal TM|First group patients received either haloperidol deaconate 50 mg in weekly intramuscular and Lamictal TM 150-200 mg in day per so for 12 weeks.
1945185|NCT00622895|Drug|fludarabine phosphate|Given IV
1943606|NCT00947375|Drug|Haloperidol Decanoate|Second group patients were given haloperidol deaconate 50 mg in weekly intramuscular and placebo per os for 12 weeks.
1943607|NCT00946556|Drug|Valacyclovir|1g po od for 2 months
1943608|NCT00946556|Drug|Placebo|Placebo po od for 2 months
1943609|NCT00946881|Drug|WST 11 -mediated -VTP|The WST11-mediated VTP procedure will consist of a single, 10 min, IV administration of WST11 at doses of either 2mg/kg, 4 mg/kg or 6 mg/kg, followed by light activation delivered through one or more transperineal interstitial optical fibers for 20 minutes using 753 nm laser light at escalating fixed energy doses of 200 J/cm and 300 J/cm, by escalating power at each energy to 167 mW/cm and 250 mW/cm, respectively. A brachytherapy-like template is used for the placement of the optical fiber(s) that are positioned in the prostate areas of interest under trans-rectal ultrasound image guidance.
1943610|NCT00945568|Drug|Aminoleban EN|benefits of this drug for patients who undergoing liver resection for HCC
1943611|NCT00945932|Drug|GW870086X|Investigational product
1943612|NCT00945932|Drug|Placebo|Placebo control
1943613|NCT00945594|Device|Cystoscopy|A 16 F flexible cysto urethroscope (Storz, Culver city, CA) is used for flexible cystoscopy. When rigid cystoscopy is performed, a 17F, 70° scope (Storz, Culver city, CA)
1943614|NCT00945282|Drug|GSK2248761|GSK2248761 30 mg capsule once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
1943615|NCT00945282|Drug|Lopinavir/ritonavir|Lopinavir 400 mg and ritonovir 100 mg every 12 hours for 28 days. Lopinavir/ritonavir is approved by the FDA as an HIV medication in the protease inhibitor class. Kaletra is a trademark of Abbott Laboratories.
1943616|NCT00945282|Drug|HAART|Highly Active Antiretroviral therapy of the doctor's choice.
1943617|NCT00945282|Drug|Placebo|Placebo is a capsule with no drug in it.
1943618|NCT00945282|Drug|GSK2248761|GSK2248761 10 mg -20 mg or 40 mg - 90 mg once a day for 7 days. GSK2248761 is an investigational (not approved by the FDA) HIV drug in the class of non-nucleoside reuptake inhibitor class.
1943619|NCT00944957|Drug|Raltegravir for the first 2 weeks|Patient receives raltegravir and efavirenz placebo during the first 2 weeks
1943620|NCT00944957|Drug|Efavirenz for the last 2 weeks|Patient receives efavirenz and raltegravir placebo during the last 2 weeks
1943621|NCT00944957|Drug|Efavirenz for the first 2 weeks|Efavirenz and raltegravir placebo for the first 2 weeks
1943622|NCT00944957|Drug|Raltegravir for the last 2 weeks|Raltegravir and efavirenz placebo for the last 2 weeks
1943623|NCT00944216|Drug|Salkera Emollient Foam|
1943624|NCT00943306|Drug|lomitapide|5-60 mg po every day
1943625|NCT00943904|Device|Interstim implant for SNS|stimulates third sacral nerve root
1943626|NCT00943475|Procedure|circumcision|circumcision by plastbell
1943627|NCT00942890|Device|NMES (EMPI 300PV stimulator) plus standard of care|In addition to the standard rehabilitation, the NMES treatment group will receive neuromuscular electrical stimulation to the quadriceps muscle of the residual and intact limb. The name of the NMES device is EMPI 300PV. NMES training will consist of performing 15 to 20 minute stimulation sessions with a 5-minute patient treatment log, 5 times per week for 12 weeks. During each training session, 15 NMES contractions per leg will be completed. Each contraction will be elicited by an electrical impulse (300PV) generated by a battery-operated device. This will be performed at home.
1943628|NCT00943046|Device|Pacemaker lead|Implantation of the SIELLO pacemaker leads
1943634|NCT00942201|Drug|Dexamethasone|Single loading dose in ED 0.6 mg/kg, rounded to nearest 2 mg,use 4 mg tabs max dose 16 mg.
1943635|NCT00942201|Drug|Dexamethasone|Firstdose in ED 0.6 mg/kg, rounded to nearest 2 mg, use 4 mg tabs max dose 16 mg; a prescription for second dose as above to be taken on day 3 after discharge
1943637|NCT00941941|Procedure|Non-mesh Hernia Repair|Non-mesh method for treatment of inguinal hernia without the use of a foreign material (mesh). It involves reinforcement of the weakened posterior wall of inguinal canal with a small, undetached strip of aponeurotic tissue of external
1943638|NCT00941941|Procedure|Mesh Hernia Repair|Mesh method for treatment of inguinal hernias by use of an implant (mesh) to reinforce the weakened posterior wall of the inguinal canal. The mesh is made of polypropylene material.
1943639|NCT00941382|Drug|Sibutramine-Metformin|sibutramine and metformin, 15 mg per day and 850 mg per day, respectively, in a single tablet, for 180 days
1943640|NCT00941382|Drug|Sibutramine|15 mg per day for 180 days
1943641|NCT00941382|Drug|Metformin|Metformin 850 mg per day for 180 days
1943642|NCT00941330|Drug|Exemestane|25 mg daily by mouth for 6 to 12 months.
1943643|NCT00941330|Drug|Docetaxel|Docetaxel (75 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
1943644|NCT00941330|Drug|Cytoxan|Cytoxan (600 mg/m²) into a vein once every 3 weeks for 6 cycles (6 times in about 24 weeks).
1943645|NCT00940407|Device|Photobiomodulation (Gentlewaves, Warp 10)|Two separate light emitting devices that are already approved for other indications are used. Treatment will consist of 18 treatments lasting approximately two minutes per treatment.
1943646|NCT00940368|Dietary Supplement|Provision of capsules containing ginger powder or placebo|"The patients(children and adolescents) will be provided with Capsules containing either ginger powder or placebo on the three days when they receive chemotherapy.
For weight category 1(20-40kg),6 capsules are given in three divided doses and the amount of ginger powder administered per day is 1 gram.
For weight category 2(40-60kg), 5 capsules are given in three divided doses and the amount of ginger powder administered per day is 2 gram."
1943647|NCT00940797|Drug|DMMET-01|60 days: 30 days; dose 1050.6 mg per day (before dinner)+ 30 days; dose 1050.6 mg twice a day 30 more days (before breakfast ando before dinner)
1943648|NCT00940797|Drug|Placebo|60 days: 30 days placebo once a day (before dinner) + 30 days twice a day (before breakfast and before dinner)
1943649|NCT00940498|Drug|PF-05212384 (also known as PKI-587)|Intravenous dosing once weekly infusion
1943652|NCT00940823|Device|Ahmed FP7 Valve|Implantation of Ahmed FP7 Valve to lower intraocular pressure in refractory glaucoma.
1943653|NCT00940823|Device|Baerveldt-350 Tube|Implantation of Baerveldt-350 Tube to lower intraocular pressure in refractory glaucoma.
1943654|NCT00939640|Behavioral|DASH/sodium-restricted diet (SRD)|Baseline diet will be assessed via Block Food Frequency Questionnaire, and 24-hour urinary sodium, potassium, and 8-isoprostanes will be measured. Subjects will then be assigned to 21 days of the DASH/SRD, with all food and beverages provided. Adherence will be assessed through a three-day food diary at the midpoint of the intervention, and at the end of the study urinary sodium, potassium, and 8-isoprostanes will again be measured.
1943655|NCT00937326|Drug|SRT2104|SRT2104 will be supplied as hard gelatin capsules, with each containing 250 mg.
1943656|NCT00937326|Drug|Placebo|Placebo will be supplied as hard gelatin capsules, with each containing an appropriate amount of placebo.
1943657|NCT00938340|Dietary Supplement|"Walnut meat"|Separated, ground walnut de-fatted nut meat incorporated into inert food carrier
1943658|NCT00938340|Dietary Supplement|Walnut Oil|Walnut oil extracted from nut meat and incorporated into inert food carrier
1943659|NCT00938340|Dietary Supplement|Walnut Skins|Separated, ground walnut skins incorporated into inert food carrier
1943661|NCT00937261|Drug|Risperidone|2mg - 8mg per day, for the duration of participation in the study
1943662|NCT00937261|Drug|Paliperidone|6mg - 12mg per day, for the duration of participation in the study
1943663|NCT00936299|Drug|Bupropion|Bupropion (target dose 300 mg/day) + cognitive behavioral therapy; matched placebo + cognitive behavioral therapy
1943664|NCT00934895|Drug|everolimus|Orally administered RAD001 will be initiated at 5 mg daily. Each cohort Phase I: administration will proceed based on escalation criteria. RAD001 will be given initially once every day. Doses will be adjusted per the dosing regimen for each cohort throughout the Phase I portion of the study
1943665|NCT00934895|Drug|abraxane|Doses of Abraxane will be calculated on Day 1 of each cycle using the patient's actual weight in the determination of body surface area. A variance of 5% of the calculated total dose will be allowed.
1943666|NCT00933634|Procedure|electrical cardioversion|External cardioversion was performed in anteroposterior position (right sternal body at the third intercostal space-angle of the left scapula); patients were submitted to a biphasic wave-form sequential shock of 100-150-200 J, if necessary.
1943667|NCT00933634|Drug|propafenone|Propafenone (2 mg/kg bolus) was administered to obtain pharmacolgic sinus rhythm conversion.
1943668|NCT00932438|Device|LC bead loaded with Irinotecan|Chemoembolization using LC beads loaded with 100mg Irinotecan in combination with Fluorouracil, Oxaliplatin, Leucovorin and Avastin alternating on a 2 weekly schedule
1943669|NCT00932438|Drug|FOLFOX6 and Avastin|Fluorouracil, Oxaliplatin, Leucovorin and Avastin given biweekly
1943670|NCT00932100|Drug|REG1|IV form, bolus dose. May be redosed. Control agent given as single re-dose at completion of intervention
1943671|NCT00932100|Drug|Heparin|IV dose per standard of care at the local institution
1943672|NCT00932360|Device|Transient Placebo TENS (Rehabilicare Maxima TENS)|Transient placebo TENS will be applied for one arm of the study
1943673|NCT00932360|Device|Active TENS (Rehabilicare Maxima TENS)|Active high frequency TENS will be use for Active TENS
1943674|NCT00932360|Device|No TENS (Rehabilicare Maxima TENS)|No TENS will have a TENS unit in place but not turned on to blind the investigator and subject
1943675|NCT00931255|Drug|Tacrolimus (FK506, Prograf)|3-10 mg, PO, BID based on 12 hour trough on serum blood levels, adjusted according to protocol
1943676|NCT00931255|Drug|Sirolimus (Rapamune, Rapamycin)|5 mg, PO, daily based on 24 hour serum blood levels, adjusted according to protocol
1943677|NCT00930943|Drug|Oxymorphone ER (Opana ER)|40 mg qd twice
1943678|NCT00930579|Drug|Metformin|1500 mg per day, divided 500 mg in the morning and 1000 mg in the evening, for at least two weeks prior to surgery
1943679|NCT00929994|Behavioral|Cardiac Rehabilitation|Individualized cardiac rehabilitation for 6 months, including health education sessions, as well as supervised exercise classes which include aerobic and resistance training.
1943681|NCT00928811|Drug|basiliximab|Simulect 20 mg intravenously day of transplant and day 4
1943682|NCT00928811|Drug|basiliximab|Simulect (basiliximab) 20mg intravenously day of transplant and day 4 post operatively. Then Monthly administration of Simulect (basiliximab) 40 mg intravenously for one year duration.
1943683|NCT00929097|Other|Implementation aids|"Patients and clinicians have access to a website with information on familial colorectal cancer risk; a risk assessment tool and decision aids
Clinicians receive the guidelines and a risk communication tool, as well as education"
1943684|NCT00929097|Other|Control|Dissemination of guidelines
1943685|NCT00928876|Drug|Anakinra (Kineret)|anakinra 150 mg s/c. daily for four weeks
1943686|NCT00928876|Drug|Placebo|placebo s/c daily for four weeks
1943687|NCT00928499|Device|Interstim (SNS)|Randomized Controlled Trial of Continuous vs. Cyclic Stimulation in Interstim Therapy
1943690|NCT00927238|Device|XL TDR|This will be a lateral approach discectomy and reconstruction with the insertion of the XL TDR device.
1943691|NCT00927238|Other|Lumbar fusion surgery|Lumbar fusion surgery
1943692|NCT00926900|Drug|D-cycloserine|50 mg at approximately 1.5 hours prior to cue-exposure training sessions
1943693|NCT00926900|Drug|Placebo|Placebo
1943724|NCT00920556|Drug|5.0g SRT501|5.0g SRT501 will be supplied in clinical kits as a powder which will be reconstituted with vehicle and water into a liquid suspension. SRT501 will be administered orally as a liquid suspension for 20 consecutive days in each 21 day cycle.
1943725|NCT00920556|Drug|Bortezomib|Bortezomib (1.3 mg/m2) will be given as an intravenous solution in a 3-5 second push on Day 1, 4, 8 and 11 in every 21 day cycle.
1943695|NCT00926003|Behavioral|Computerized cognitive rehabilitation therapy (CCRT)|8 weeks of 3 times weekly intervention for 45 min per session with Captain's Log program
1943696|NCT00926003|Behavioral|control group|no computer training
1943697|NCT00925795|Other|consumption 1. EVOO; 2. ROO|EVOO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by ROO in doses of 50 mL/daily for 20 days
1943698|NCT00925795|Other|consumption 1. ROO; 2. EVOO|ROO in doses of 50 mL/daily for 20 days; 14 days of wash-out period without olives and olive oil; followed by EVOO in doses of 50 mL/daily for 20 days
1943699|NCT00924677|Procedure|radiofrequency neurotomy for genicular nerve|RF cannula was advanced percutaneously towards areas connecting the shaft to epicondyle of femur or tibia. Lidocaine (1 mL of 2%) was injected before activation of the RF generator (NeuroThermTM, Morgan automation LTD, Liss, UK). RF electrode was inserted through RF cannula. The temperature of the electrode tip was raised to 70℃ for 90 seconds by radiofrequency generator.
1943700|NCT00924677|Procedure|radiofrequency neurotomy sham therapy|The placebo (sham) group received the same procedure without activation of the RF generator.
1943702|NCT00924820|Drug|Bevacizumab|10 mg/kg by vein over about 1 hour, every 2 weeks.
1943703|NCT00924755|Device|Biomerix Revive™ (surgical mesh for inguinal hernia repair)|Inguinal hernia repair using a tension-free onlay patch, Lichtenstein-style.
1943706|NCT00923663|Drug|Lenalidomide|25 mg Lenalidomide p.o. daily for 21 days
1943707|NCT00923078|Behavioral|Brain Fitness|The program entails six computer-based exercises that are designed to be very easy to use and require no computer experience. The exercises are calibrated to individual performance at the onset of training and adapt in difficulty to individual performance, giving constant feedback about progress. Our laboratory procedures include review of progress with the participant at the end of each session, intended to encourage motivation. Each of the six exercises focuses on a distinct process: (1) auditory processing speed, (2) discriminating sounds, (3) sound precision, (4) sound sequencing, (5) working memory, and (6) narrative memory.
1943708|NCT00923078|Behavioral|Cortex with Insight|The program entails five computer-based exercises designed with the same features of Brain Fitness, which train: (1) visual precision, (2) visual processing speed, (3) divided attention, (4) visual working memory, and (5) useful field of view.
1943709|NCT00923559|Other|Treatment as Usual at Child Health Centre|TAU involved scheduled health visitor calls at the local Child Health Centre (CHC), with paediatric checkups at 2 and 6 months of age. The health visitor is encouraged to promote attachment and to detect postnatal depressions. Mothers may be offered parental groups, infant massage or guidance promoting interaction, as well as appointments with a paediatrician or a child psychiatric psychologist. Within the TAU framework, additional treatment may be initiated by the health visitor or the mother. This will be registered at the end-point interview.
1943710|NCT00923559|Other|Mother-Infant Psychoanalytic treatment (MIP)|MIP (Norman, 2001; 2004) is a psychoanalytic method adapted to the requirements of the infant as analysand in the presence of his mother. The analyst strives to recruit the baby for an emotional interchange, though this does not imply any belief whatsoever that the infant understands verbal communication. Rather, the analyst addresses the baby to help him liberate emotions consolidated in symptoms such as screaming, avoiding maternal eye contact, and breast refusal. The analyst takes great care in enrolling the participant mother. This is to enhance her understanding of the baby's predicament and the nature of their relation, as well as giving her all space needed to vent her own frustration, depression and anxiety.
1943716|NCT00922558|Other|Evaluation of postural control|Children will be measured once using a Tetra-aximetric posturography method
1943717|NCT00921102|Drug|Bupivacaine|12.5 mg of a 5 mg/ml hyperbaric solution, intrathecally
1943718|NCT00921102|Drug|Morphine|200 µg of a 200 µg/ml solution, intrathecally
1943719|NCT00921102|Drug|Isotonic saline solution|"0.9% NaCl solution
0.1 ml, intrathecally in group Control and IV Atropine
0.1 ml, intravenously in group Control and Intrathecal Atropine"
1943720|NCT00921102|Drug|Atropine|"100 µg of a 1 mg/ml preservative-free solution
intrathecally in group Intrathecal Atropine
intravenously in group IV Atropine"
1943871|NCT00889642|Device|Iontophoretic Drug Delivery System with Epinephrine|Placebo- 0.179% Epinephrine
1943728|NCT00920218|Biological|Herpes Zoster Vaccine 1437173A|Different formulations of investigational vaccine (GSK 1437173A) administered in 2 or 3 doses intramuscularly.
1943729|NCT00920218|Biological|Placebo vaccine (saline)|1 or 3 doses of Placebo (saline) injected intramuscularly.
1943730|NCT00919230|Drug|Ferrous sulphate tablets|200mg twice daily for four weeks
1943731|NCT00918060|Drug|Camella sinensis gel|clinical effect of locally-delivered gel between Camella sinensis and placebo
1943733|NCT00918567|Drug|atomoxetine|open label treatment dosed up to 1.8mg/kg/day
1943734|NCT00918567|Behavioral|Behavior Modification Therapy|8 week behavioral modification course with school consultation, parenting groups using COPE and child social skills group
1943735|NCT00916487|Dietary Supplement|Fructosin|Three capsules of Fructosin before one of the hydrogen breath tests.
1943736|NCT00916331|Procedure|subcutaneous indwelling|vacuum drainage is indwelled in subcutaneous layer
1943737|NCT00916331|Procedure|intraarticular indwelling|vacuum drainage is indwelled in intraarticular space
1943738|NCT00916175|Dietary Supplement|P1&P2|"First period (4 weeks) intake food product P1&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet
Second period, cross over from AG&CC group, 4 weeks intake food product P1&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
1943739|NCT00916175|Dietary Supplement|P1&CC|"First period (4 weeks) intake food product P1&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.
Second period, cross over from AG&P2 group, 4 weeks intake food product P1&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
1943740|NCT00916175|Dietary Supplement|AG&P2|"First period (4 weeks) intake food product AG&P2 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.
Second period, cross over from P1&CC group, 4 weeks intake food product AG&P2 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
1943741|NCT00916175|Dietary Supplement|AG&CC|"First period (4 weeks) intake food product AG&CC (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet
Second period, cross over from P1&P2 group, 4 weeks intake food product AG&CC (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet"
1943742|NCT00916175|Dietary Supplement|TA (concentrated 5:1 aloe vera gel)|"First period (4 weeks) intake food product TA (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.
Second period, cross over from P3 group, 4 weeks intake food product TA (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
1943743|NCT00916175|Dietary Supplement|P3|"First period (4 weeks) intake food product P3 (in lemon gelatin 230 ml before breakfast) plus 1500 kilo calories diet.
Second period, cross over from TA group, 4 weeks intake food product P3 (in lemon gelatin 230 ml before breakfast and 230 ml after supper) plus 1500 kilo calories diet."
1943744|NCT00916149|Drug|levetiracetam|The dosage of levetiracetam will begin at 500mg twice per day (bid) for the first 4 days, and increase by 500mg every 5 days thereafter until a goal of 1500mg bid is reached. The subject will then remain on levetiracetam at 1500mg bid for 8 weeks, until the conclusion of the study. Medication will be supplied in 500mg tablets, to be taken orally.
1943745|NCT00916149|Drug|Lamotrigine|"The drug will be supplied in 25, 100 and 150mg tablets, to be taken orally per the titration schedule below:
The regimen will begin at 25mg once per day for the first two weeks, and increase to 50mg once per day during weeks 3 and 4. In week 5, the subject will take 50mg twice per day (bid). The dosage will increase to 50mg in the morning and 100mg at night during week 6. During week 7 the subject will take 100mg bid. During week 8, the subject will take 100mg in the morning and 150mg at night. At week 9, the subject will reach the target dose of 150mg bid. The subject will then remain on lamotrigine at 150mg bid for 7 weeks, until the conclusion of the study."
1943746|NCT00915538|Drug|pMD Symbicort 160/4.5|The subjects will receive Symbicort pMDI 160/4.5 pMDI used in conventional fashion, and have pulmonary function measured over 12 hours. Secondly on another day, they will receive pMDI using a valved holding chamber
1943747|NCT00915538|Drug|Symbicort|Symbicort 160/4.5 will be administered first first through a valved holding chamber, and on another day in the conventional fashion. Pulmonary functions will be measured ove r12 hours
1943748|NCT00915421|Procedure|Induction of therapeutic mild hypothermia|Rapid administration of 4°C cold normal saline to the peripheral vein, dose 5 - 30 ml/kg, to decrease body core temperature below 34°C
1943749|NCT00915018|Drug|Neratinib|Neratinib - 240 mg orally daily, administered once daily. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
1943750|NCT00915018|Drug|Trastuzumab|Trastuzumab - 4mg/kg IV initial loading dose followed by subsequent once weekly doses of 2mg/kg IV. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
1943751|NCT00915018|Drug|Paclitaxel|Paclitaxel - 80mg/m2 IV administered on days 1, 8, and 15 of a 28-day cycle. Treatment will be administered until documented disease progression, symptomatic deterioration, unacceptable toxicity, death or withdrawal of consent.
1943752|NCT00915031|Device|UroCool|Hypothermia Endorectal Device
1943753|NCT00913393|Drug|FG-3019|3 mg/kg FG-3019 IV every 2 weeks for 22 weeks
1943754|NCT00913393|Drug|FG-3019|10 mg/kg FG-3019 IV every 2 weeks for 22 weeks
1943755|NCT00913393|Drug|Placebo|Placebo IV every 2 weeks for 22 weeks
1943756|NCT00913627|Drug|ibuprofen|
1943757|NCT00913627|Drug|ibuprofen|
1943758|NCT00913627|Drug|naproxen|
1943759|NCT00913627|Drug|Placebo|
1943760|NCT00912990|Drug|Cisatracurium|
1943761|NCT00912990|Drug|Normal saline|
1943762|NCT00912574|Drug|GM-CSF-in-adjuvant|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:
1 ml saline
specified dose of GM-CSF in 1 ml saline
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
1943763|NCT00912574|Drug|Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:
1 ml saline
specified dose of GM-CSF in 1 ml saline
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
1943764|NCT00912574|Biological|GM-CSF and Montanide ISA-51|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:
1 ml saline
specified dose of GM-CSF in 1 ml saline
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
1943765|NCT00912574|Drug|Saline|"For each injection, patients will receive the following: In stage 1: Patients will be injected with a 1 ml emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant, in skin adjacent to a melanoma biopsy scar.
In stage 2: Patients will be randomized to receive an injection of one of the following in skin adjacent to the melanoma biopsy scar at one of two time points:
1 ml saline
specified dose of GM-CSF in 1 ml saline
an emulsion of 0.5ml Montanide ISA-51 adjuvant and 0.5 ml saline
an emulsion of specified dose of GM-CSF in 0.5 ml saline plus 0.5 ml Montanide ISA-51 adjuvant"
1943766|NCT00911820|Drug|Bevacizumab|Given intravenously on day one of every 3 week cycle
1943767|NCT00911820|Drug|Cisplatin|Given intravenously on days 1 and 8 of each three week cycle
1943768|NCT00911820|Drug|Irinotecan|Given intravenously on days 1 and 8 of every three week cycle
1943769|NCT00911820|Device|Docetaxel|Given intravenously on days 1 and 8 of every three week cycle.
1943773|NCT00910611|Device|Buzzy|"Buzzy, the vibrating cold pack, is pressed by parent or nurse immediately prior to immunizations. The vibration is activated and the device remains in place throughout the procedure, moving locations to complete the 4 shots."
1943774|NCT00909870|Device|Dermagraft(R)|Weekly application of Dermagraft(R) with Profore compression as a secondary layer, in combination with systematic surgical wound debridement.
1943775|NCT00909870|Device|Profore|Weekly application of Profore compression dressings, in combination with systematic surgical wound debridement.
1943776|NCT00908492|Behavioral|Education Control|Caregiver participants are provided with information about caregiver stress and discuss it individually with an interventionist who visits the home. The control intervention involves 5 visits over 6 months.
1943777|NCT00908492|Behavioral|Environmental Skill Building|The ESP intervention addresses home modifications and training in their use, instruction in strategies of problem-solving, energy conservation, safe task performance, fall recovery techniques, and balance and muscle strength training. Intervention is individualized for target areas identified in the initial client assessment and caregiver interview. The intervention involves using a problem solving approach and client-centred focus and the intervention assessment tools are individualized measures which determine the goals identified by the caregiver. It involves 5 visits over 6 months.
1943778|NCT00909220|Behavioral|Behavioral Activation|16 weekly study visits aimed at identifying avoidance patterns used in social or physical situations that contribute to depression and replacing them with reinforcing experiences using directive behavioral strategies
1943779|NCT00908830|Drug|mycophenolate mofetil|Patients will take thier own 500-mg tablets of mycophenolate mofetil
1943780|NCT00908817|Drug|triamcinolone acetonide|paste applied over tracheal tube for lubrication
1943781|NCT00908817|Drug|chlorhexidine gluconate|jelly applied over tracheal tube for lubrication
1943782|NCT00908791|Drug|Conjugated Linoleic Acid (CLA)|Conjugated linoleic acid (CLA, Clarinol™) oral soft gel capsules will be administered in an open-labeled, manner to all subjects enrolled in the study. Subjects will be treated with 7.5 grams of oral CLA daily, taken in divided dose, twice daily between 8 am and 12 noon and between 8 pm and 12 midnight. CLA will be taken for a minimum of ten days prior to surgical resection of their breast malignancy. In the event that the subject's surgical resection date is delayed, subjects may take CLA for up to 28 days. The last dose of CLA prior to the surgical resection will be taken at 12 midnight or as close as possible to that time and the patient will record the time of the last dosing.
1943784|NCT00908050|Drug|Botulinum toxin type A|"week 1: the patient will undergo the following: a. physical examination; b. sleep questionnaire c. bruxism questionnaire to establish a clinical diagnosis of bruxism; d. headache questionnaire; e. Clinical Global Improvement scale; f. masseter muscle measurement; g. anxiety questionnaire; h. demographic questionnaire;
week 2: The patient undergoes a polysomnogram (sleep study). The patient will spend one night (10:30pm-8:00am or until spontaneous awakening) in a sleep lab. During the sleep study, the following parameters will be recorded: electroencephalogram, electro-oculogram, upper airway resistance, heart rate, muscle activity; upper airway resistance,masseter muscles bilaterally. All recordings are performed using surface electrodes (self-adhesive to the skin), none of them invasive.
Study visit 3 (week 3): Patients are injected with botulinum toxin type A (BOTOX) 60 units in each masseter muscle and 35 in each temporalis muscle, bilaterally."
1943785|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive intravitreal injections of sirolimus (rapamycin) 352 µg in study eye on Days 0, 60, and 120.
1943786|NCT00908466|Drug|Sirolimus (rapamycin)|Will receive subconjunctival injections of sirolimus 1320 µg in the study eye on Days 0, 60, and 120.
1943787|NCT00907153|Dietary Supplement|Vitamin D|Vitamin D 300 mcg by mouth once daily for 12 weeks
1943788|NCT00907153|Drug|Placebo|Placebo by mouth once daily for 12 weeks
1943789|NCT00906737|Device|Ankle-bot|The Ankle-bot is a piece of robotic therapy equipment for the ankle. In this study, it will be used to guide and assist the subject into ankle flexion, extension, inversion and eversion.
1943872|NCT00888901|Drug|eltrombopag|eltrombopag tablets daily, in increasing dosage, for three months
1943790|NCT00906737|Other|Conventional focused ankle therapy|Conventional focused ankle therapy will be performed by a physical therapist.
1943791|NCT00906139|Drug|Propofol|Propofol dose: 0.5 mg/kg up to 400 mg
1943792|NCT00906139|Drug|Midazolam|Midazolam dose: 0.1 mg/kg
1943793|NCT00906139|Drug|Fentanyl|Fentanyl dose: 0.05 mg
1943794|NCT00905723|Drug|estradiol|1 mg daily for 6 months
1943795|NCT00905723|Drug|isoflavone|150 mg isoflavone daily for 6 months
1943796|NCT00905723|Drug|Placebo|sugar pill daily for six months
1943797|NCT00904969|Device|The AMS Male Transobturator Sling System|The AMS Male Transobturator Sling System was developed to treat urinary stress incontinence in men resulting from intrinsic sphincter deficiency (ISD) secondary to radical prostatectomy. The Male Transobturator Sling System procedure is minimally invasive and consists of using two single-use needle passers and passing them through two small incisions over the obturator foramen. The needles are pushed in an arc through the tissue and exited at a perineal incision. Once the passers are through the perineal incision, the Sling System mesh arms are attached to the needles which are then pulled back through the needle track to their points of origin over the obturator foramen. The Sling System is subsequently tensioned and all incisions are closed.
1943798|NCT00904969|Device|AdVance Male Sling|A transobturator sling for the treatment of post-prostatectomy incontinence
1943799|NCT00903786|Drug|perampanel|Patients will receive the same oral dosage (2 mg up to 12 mg once daily before bedtime) as used in the maintenance period of Study 231.
1943803|NCT00903760|Drug|Decitabine|Decitabine 20 mg/m^2 by vein daily over 1-2 hours for 5 days for both Group 1 and Group 2. Group 1 receives decitabine on Days 1-5 of Cycles 1-3, 7-9, 13-15, and 19-21; and Group 2 is on Days 1-5 of every cycle.
1943804|NCT00903760|Drug|Clofarabine|Clofarabine 10 mg/m^2 by vein daily over 1-2 hours for 5 days on Days 1-5 of Cycles 4-6, 10-12, 16-18, and 22-24.
1943810|NCT00902252|Device|Usual|All subjects will wear their usual pouching system for the first 21 days of the study.
1943811|NCT00902252|Device|Natura®|All subjects will wear the Natura® Flexible Skin Barrier with Flange (Stomahesive® or Durahesive®) in the US and Natura® Stomahesive® Flexible Skin Barrier with Flange in Europe for 14 days.
1943812|NCT00902252|Device|Vitala™|"After the successful completion of Stages 1 and 2, subjects will enter the ramp up schedule to allow the subject to adjust to the device. This consists of weekly increases in wear time of the Vitala™ device beginning with 4 hours of daily wear per week (Days 36 to 42), followed by 6 hours of daily wear time per week (Day 43 to 49), followed by 8 hours of daily wear time (Days 50 to 56) and progressing to 12 hours of daily wear per week (Day 57 to 215)."
1943813|NCT00902018|Drug|Promacta (eltrombopag)|Subjects will be treated with eltrombopag 75 mg once daily. Patients will be monitored 3 times a week for the first 2 weeks, and then monitored as clinically indicated as they continue eltrombopag dosing for 3-4 months.
1943814|NCT00901810|Device|Electronic Apex Locator|Electronic Apex Locator is used to find the apical foramen of the root canal. It uses a weak electrical current passed through the canal by endodontic file.
1943815|NCT00901810|Device|Dental Radiography|Radiography is used to measure the length of root canal by putting an endodontic file in the canal and taking the radiography to measure the length.
1943816|NCT00900601|Procedure|Arthrodesis to the sacroiliac joint and symphysis|"Standard surgical procedures will be used. When the patient has isolated pain in the symphysis isolated fixation will be performed. A 2x2 cm large bone block will be removed and replaced with spongy bone. For fixation the Matta-plate will be applied.
To the sacroiliac joint we use an anterior approach. A 2x1,5 cm large bone block will be removed and replaced with spongy bone from the iliac crest. For joint fixation we either use 2 plates or sacroiliac screws. The same procedure will be used on the other side in the cases with bilateral symptoms. Only one side will be operated at a time. After one year it will be decided if it's necessary to perform contralateral surgery."
1943828|NCT00898885|Procedure|oral biopsy|oral mucosa and salivary gland biopsy after bone marrow transplantation
1943829|NCT00897975|Dietary Supplement|red yeast rice|600 mg 3 capsules bid
1943830|NCT00897975|Drug|phytosterol|phytosterol 450 mg 2 tabs bid with food
1943831|NCT00897975|Behavioral|therapeutic lifestyle program|TLC - 12 weeks
1943832|NCT00897975|Drug|placebo|placebo
1943864|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver 4 mL of gel containing 0 mg of Nestorone® by pressing two times with the 2 mL dispenser head.
1943865|NCT00890825|Drug|AZD6244|oral capsules, 75mg twice daily
1943866|NCT00890825|Drug|docetaxel|75mg/m2 iv on day 1 of every 21 day cycle
1943867|NCT00890825|Drug|Placebo|placebo
1943868|NCT00890799|Device|Shanghai pmVSD occluder|Ventricular Septal Defects Occluders with sizes from 4mm to 20mm.
1943869|NCT00890799|Procedure|surgery|Patient in this group received open surgical repair of pmVSD.
1943870|NCT00889642|Device|Iontophoretic Drug Delivery System with Lidocaine/Epinephrine|Active- 10.5% Lidocaine/0.179% Epinephrine
1943834|NCT00896480|Biological|Immunotherapeutic GSK2132231A|Administration by intramuscular injection
1943835|NCT00896363|Drug|GSK163090 Tablets|Developed for the treatment of Major Depressive Disorder
1943836|NCT00896363|Drug|GSK163090 Placebo Tablets|Developed for the treatment of Major Depressive Disorder
1943837|NCT00895154|Behavioral|General Tutoring|Participants will be tutored for approximately 8-10 hours per month during the school year.
1943838|NCT00895154|Behavioral|Memory Training|Participants will receive memory training for approximately 8-10 hours per month during the school year.
1943839|NCT00895921|Drug|Olanzapine|Single intramuscular 10-mg dose
1943840|NCT00895921|Drug|Aripiprazole|Single intramuscular 9.75-mg dose
1943841|NCT00895700|Behavioral|web-based multifactorial intervention|12-week multi-factorial web-based behavioral intervention comprised of psycho-education, cognitive behavioral therapy (CBT) and relaxation therapy
1943842|NCT00895414|Drug|doxorubicin hydrochloride|Given IV 5-10 minutes on day 1. Treatment repeats every 14 days for 2 courses in the absence of disease progression or unacceptable toxicity.
1943843|NCT00895414|Drug|enalapril maleate|Given orally - Beginning 1 week before course 2, patients also receive oral enalapril maleate once daily until day 8 of course 2. OR Beginning 1 week before course 1, patients receive oral enalapril maleate once daily until day 8 of course 1.
1943844|NCT00895037|Drug|ReFacto AF (Moroctocog alfa)|Patients will be treated with intravenous infusion of ReFacto AF per dosing and frequency as prescribed by the subjects' treating physician. ReFacto AF® will be prescribed in the context of routine clinical practice in Germany and Austria, respectively
1943845|NCT00894608|Drug|letrozole + gonadotropins|patients in letrozole protocol for ovarian stimulation with letrozole combined with gonadotropins
1943846|NCT00894608|Drug|GnRHa + gonadotropins|patients in long GnRHa protocol for ovarian stimulation with GnRHa and gonadotropins
1943847|NCT00893724|Drug|Neutral pills with no medicinal effect|Neutral pills with no medicinal effect
1943848|NCT00893724|Dietary Supplement|Inosine; Tocopherols, Tocotrienol, CoQ10 combination capsule; Niacinamide SR; Viatmin C; N-acetyl Cysteine; Complete Multivitamin with all minerals|Inosine [SR] - 1[500mg] tablet bid Tocopherols [200IU], Tocotrienol [10mg], CoQ10 [50mg] - combination capsule bid Sustained Release Niacinamide - 1 [750mg] tablet bid Vitamin C - 1 [1000mg] sustained release tablet bid N-acetyl Cysteine - 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid
1943849|NCT00893724|Drug|Inosine; Tocopherol, Tocotrienol, CoQ10 combination capsule; Niacinamide; Vitamin C; N-acetyl Cysteine; Complete Multivitamin with all minerals; Minocycline|Inosine [SR] - 1 [500mg] tablet bid Tocopherol [200IU], Tocotrienol [10mg], CoQ10 [50mg] combination capsule bid Sustained Release Niacinamide 1 [750mg] tablet bid Vitamin C 1 [1000mg] sustained release tablet bid N-acetyl Cysteine 1 [600mg] sustained release tablet qd Complete Multivitamin with all minerals - 1 tablet (sustained release) bid Minocycline 1 [50mg] tablet qd
1943850|NCT00893438|Behavioral|FitNet treatment|web-based cognitive behavioural treatment for adolescents with CFS
1943851|NCT00893438|Other|Usual care|Usual care treatment for adolescents with CFS
1943852|NCT00892684|Dietary Supplement|Omega-3 long chain polyunsaturated fatty acids|2.7g ω-3 LCPUFA i.e., 1.6 g EPA and 1.1 g DHA and 23 mg alfa-tocopherol as an antioxidant
1943853|NCT00892684|Dietary Supplement|Soybean oil (placebo)|2.8 g soybean oil containing 2.5 g linoleic acid and 0.28 g α-linolenic and 36 mg alfa-tocopherol
1943854|NCT00891163|Drug|Synera™ Topical Patch (70 mg lidocaine/70 mg tetracaine)|30 minute applicable on antecubital fossa
1943855|NCT00891163|Drug|Placebo Patch|placebo
1943856|NCT00891878|Drug|capecitabine|Given orally
1943857|NCT00891878|Drug|sunitinib malate|Given orally
1943858|NCT00891839|Drug|Bendamustine|Bendamustine at 90 mg/m^2 intravenously (iv) on days 1 and 2 of each 28-day cycle. Dosage calculations for bendamustine are based on the patient's body surface area (BSA) at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
1943859|NCT00891839|Drug|Rituximab|Patients receive 375 mg/m^2 of rituximab, administered by iv infusion on day 1 of every 28-day cycle of treatment. Dosage calculations for rituximab are based on the patient's BSA at baseline, using actual weight for calculations. If there is a 10% change in a patient's weight during treatment, the most recent weight is used to recalculate the BSA. The new BSA is used in determining the doses to be administered in any subsequent cycles.
1943860|NCT00891319|Device|Electrical stimulator|"• 12-week intervention
Therapist-guided task practice performed twice a week in the research laboratory. (Device used for CCFES group but not for cNMES group during these sessions.)
Self-administered hand opening exercise performed twice a day, 5 days a week at home using the device."
1943861|NCT00891228|Drug|Testosterone|Two individual packets of T Gel, each with 5 g of gel applied to each arm delivering a total of 100 mg of T on the skin daily.
1943862|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 8 mg of Nestorone®. For 8 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (2 mg Nestorone® mL gel) by pressing two times with 2 mL dispenser head.
1943863|NCT00891228|Drug|Nestorone®|Nestorone® Gel will be delivered by a pump configured to deliver a metered volume of Nestorone® Gel containing 12 mg of Nestorone®. For 12 mg Nestorone® dose; Nestorone® Gel will be delivered in 4 mL volume (3 mg Nestorone®/mL gel) by pressing two times with 2 mL dispenser head.
1943955|NCT00873288|Other|questionnaire administration|
1943873|NCT00888901|Drug|corticosteroids (Aprednislon)|corticosteroids in decreasing dosage
1943874|NCT00889005|Other|Telephone Based Cognitive Behavioral Therapy|Five biweekly sessions of telephone based, trauma focused cognitive behavioral therapy with homework assignment
1943875|NCT00888511|Drug|Tarceva|Tarceva 150 mg/day
1943876|NCT00888511|Radiation|Radiotherapy|66 Gy/33 F/5 F per week for 5 weeks
1943877|NCT00888173|Drug|Brivanib Alaninate|Given PO
1943878|NCT00888173|Other|Laboratory Biomarker Analysis|Correlative studies
1943879|NCT00887783|Drug|Navelbine|Navelbine oral 150 mg of Vinorelbine administered in 3 weekly doses a week for 6-6½ weeks
1943880|NCT00887783|Radiation|irradiation-66 Gy|irradiation to 66 Gy (2 Gy x 30, 5 F á weeks)
1943881|NCT00887783|Radiation|irradiation-60 Gy|irradiation to 60 Gy (2 Gy x 30, 5 F á weeks)
1943882|NCT00887510|Drug|Hydrochlorothiazide|"25 mg tablet once daily for 6 weeks
Other Names:
HCTZ"
1943883|NCT00887510|Drug|Trandolapril|4 mg tablet once daily for 6 weeks
1943884|NCT00887432|Dietary Supplement|Cholecalciferol|Given PO
1943885|NCT00887432|Other|Laboratory Biomarker Analysis|Correlative studies
1943886|NCT00887432|Other|Patient Observation|
1943887|NCT00887432|Drug|Placebo Administration|Given PO
1943888|NCT00887432|Other|Quality-of-Life Assessment|Ancillary studies
1943889|NCT00887432|Other|Questionnaire Administration|Ancillary studies
1943890|NCT00885495|Drug|darunavir, ritonavir, rosuvastatin|darunavir 600 mg twice daily for 7 days ritonavir 100 mg twice daily for 7 days rosuvastatin 10 mg once daily for 7 days Combination of all three drugs for 7 days
1943891|NCT00885495|Drug|rosuvastatin, darunavir, ritonavir|rosuvastatin 10 mg daily for 7 days; darunavir 600 mg twice daily for 7 days with ritonavir 100 mg twice daily for 7 days; Combination of all three for 7 days
1943892|NCT00885651|Drug|Metoprolole (Selo-Zok ®)|Tablets, 200 mg, once a day, 10 days
1943893|NCT00885651|Drug|Placebo|
1943894|NCT00884650|Drug|oral analgesic|per clinical standard of care
1943895|NCT00884650|Drug|intravenous analgesic per pump|per clinical standard of care
1943896|NCT00884611|Device|Medtronic Real Time Continuous Glucose monitor|insulin pump delivery will be suspend when hypoglcyemia is predicted based on Medtronic real time continuous glucose monitor. Algorithym resides on a bedside computer
1943897|NCT00884052|Drug|levetiracetam|20 mg/kg loading dose; 5 mg/kg daily for 7 days.
1943898|NCT00884052|Drug|levetiracetam|40 mg/kg IV load; 10 mg/kg/day maintenance
1943899|NCT00883688|Drug|Bevacizumab|"10 mg/kg given by vein over 90 minutes for first injection (30-60 minutes for subsequent doses) every 2 weeks while on study (2 times during each 4-week study cycle)."
1943900|NCT00883688|Drug|Lapatinib|Pills of 700 mg/m^2/dose given orally 2 times each day.
1943901|NCT00883298|Drug|temozolomide and bevacizumab|oral temozolomide 100 mg/m2 days 1-5 & 15-19 every 28-day cycle plus intravenous bevacizumab 10 mg/kg days 1 & 5 every 28-day cycle
1943905|NCT00882557|Drug|daptomycin|intradialytic: 9 mg/kg during the last 30 minutes of dialysis
1943906|NCT00882557|Drug|daptomycin|6 mg/kg administered after a hemodialysis session
1943909|NCT00882115|Drug|BSE Extract|Broccoli sprout extract will be ingested by drinking a liquid formula in a volume equaling less than 1 cup at study Visits 6,7,8, and 9
1943910|NCT00882076|Drug|Etoposide, Mitoxantrone, Clofarabine|Cohort 1: Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6)20 mg/m2. Cohort 2:Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6)25 mg/m2 Cohort 3: Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (3 doses); Clofarabine (Days 2-6)30 mg/m2. Cohort 4: Etoposide (Days 1-5) 100 mg/m2; Mitoxantrone (Days 1-3) 8 mg/m2 (5 doses); Clofarabine (Days 2-6)30 mg/m2. In the event of excessive DLT in Cohort 1, a Cohort 0 will be explored: Cohort 0: Etoposide (Days 1-5) 100 mg/m2
1943911|NCT00882076|Drug|Clofarabine, Etoposide, Mitoxantrone|Retreatment doses should be as follows: Cohort 1: Etoposide (Days 1-4) 100 mg/m2; Mitoxantrone (Days 1-2) 8 mg/m2 (2 doses); Clofarabine (Days 1-4)20 mg/m2. Cohort 2:Etoposide (Days 1-4) 100 mg/m2; Mitoxantrone (Days 1-2) 8 mg/m2 (2 doses); Clofarabine (Days 1-4)25 mg/m2; Cohort 3: Etoposide (Days 1-4) 100 mg/m2; Mitoxantrone (Days 1-2) 8 mg/m2 (2 doses); Clofarabine (Days 1-4)30 mg/m2. Cohort 4: Etoposide (Days 1-4) 100 mg/m2; Mitoxantrone (Days 1-4) 8 mg/m2 (4 doses); Clofarabine (Days 1-4)30 mg/m2; Cohort 0: Etoposide (Days 1-4) 100 mg/m2; Mitoxantrone (Days 1-2) 8 mg/m2; Clofarabine (Days 1-4) 10 mg/m2.
1943912|NCT00880997|Drug|Doxazosin|The target dose of 8 mg will probably not be attained by some patients over a 8 week induction period (starting at week 1 of the overall 17 week study). We will try to increase the subjects' dose up to a minimum of 4 mg and optimum of 8 mg daily as once daily dosing. The starting dose will be 1 mg once daily at week 1, then 2 mg once daily at week 2, with 1mg/week induction rate for 8 weeks. They will be maintained on 4mg-8mg daily dosing until week 13. The subjects will be undergo the discontinuation from the study medication during weeks 14 -17.
1943913|NCT00880997|Drug|Placebo|Placebo daily dosing
1943914|NCT00880698|Biological|RotaTeq|2 mL solution of live reassortant rotaviruses, containing G1, G2, G3, G4 and P1A which contains a minimum of 2.0 - 2.8 x 10^6 infectious units (IU) per individual reassortant dose, depending on the serotype, and not greater than 116 x 10^6 IUs per aggregate dose
1943915|NCT00880698|Biological|Placebo|2 mL solution
1943916|NCT00880672|Drug|dutasteride|5mg, oral, daily, 2-4 weeks
1943956|NCT00872053|Device|Anklebot|"The Anklebot is a robotic device that is worn via a leather boot and knee brace (Fig.1). As the participant goes through a series of ankle-training games, the Anklebot can assist ankle movement throughout 3 planes."
1944917|NCT00676832|Drug|Placebo|Placebo solid capsule dosage form administered orally once daily.
1943917|NCT00880607|Drug|DepoDur™|DepoDur™ is a preparation of extended release lipid encapsulated morphine and is used specifically for epidural injection, outside the spinal fluid, for postoperative pain. This study is a prospective randomized double-blinded trial examining the effectiveness of single dose intrathecal morphine versus single dose extended release epidural morphine for postoperative pain control in pediatric posterior spinal fusion patients.
1943920|NCT00878787|Device|Transcranial magnetic stimulation|
1943921|NCT00879086|Drug|eribulin mesylate|"E7389 (eribulin mesylate) given at a dose of 1.4 mg/m^2 as a 2 - 5 minute intravenous (IV) bolus on Days 1 and 8 of a 21-day cycle.
The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
1943922|NCT00879086|Drug|ixabepilone|"Ixabepilone given at a starting dose of 32 or 40 mg/m^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle.
The Treatment Phase will include six cycles. Patients may enter the Extension Phase for additional cycles following the sixth cycle of treatment."
1943925|NCT00878852|Behavioral|Standard treatment|Participants will be randomly assigned to a standard treatment group. Patients allocated to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy
1943926|NCT00878852|Behavioral|Standard Treatment Plus Contingency Management Program|Participants assigned to this group will receive active treatment in form of 12-session intervention program. This program includes weekly intervention sessions developed according to the MET/CBT12 treatment protocol (Sampl, Kadden, 2001). Intervention includes Motivational interviewing (2 sessions) and Cognitive behavioral therapy (10 sessions). This treatment protocol will be supplemented with a contingency management intervention. Intervention will consist in a voucher program: negative urine-screens will be rewarded with vouchers. Voucher will have an increasing value. At the end of the program, vouchers can be changed by gifts. Potential gifts will be selected by the therapists and will be related to pro-social activities, aiming to change preexisting risk behaviours.
1943929|NCT00878371|Drug|morphine|All patients treated with Morphine during induction after the lumbar drain inserted. Morphine was prescribed as Standard of care post operatively
1943930|NCT00878215|Procedure|Phase 1-4,To localize anatomical points on the liver surface|The objectives of phase 1 are complete. Phases 2 and 3 will enroll concurrently. If the objectives of any phase are not met, then the study will be discontinued and postponed and the experimental protocol will be revised.
1943931|NCT00878202|Device|SCAD information system|Clinical follow-up and continuation of therapeutic education by telemedicine during 3 months
1943932|NCT00876993|Drug|Bevacizumab|Bevacizumab 10 mg/kg IV on day 1 and day 15 of a 28 day cycle
1943933|NCT00876993|Drug|Irinotecan|Irinotecan 125 mg/m2 on day 1 and day 15 of a 28 day course given IV for the first 3 dose levels. If the Maximum Tolerated Dose of temozolomide is not reached at dose level 3, then dose level 4 will be an escalation of irinotecan to 150mg/m2.
1943934|NCT00876993|Drug|Temozolomide|For the first cohort (dose level 0) of patients, dosing is 75 mg/m2/day day 1-5 of a 28 day course given PO for the first course. Doses will be escalated according to standard phase I dose escalation criteria. Dose levels are as follows (Dose level 1 = 125mg/m2, Dose level 2 = 175mg/m2, Dose levels 3 and 4 = 200 mg/m2)
1943935|NCT00874198|Procedure|Ventriculo-peritoneal Shunt|Surgical implantation of a ventriculo-peritoneal cerebrospinal fluid shunt with an adjustable valve system using the Codman-Hakim programmable valve system [pressure settings: 30 - 200 mmH20]
1943936|NCT00874237|Drug|1 (Staccato Loxapine)|Staccato Loxapine
1943937|NCT00874237|Drug|2 (Moxifloxacin)|Oral moxifloxacin
1943938|NCT00874237|Drug|3 (Placebo)|Placebo
1943939|NCT00873795|Drug|aripiprazole , sertraline|In this ten weeks,double-blind,placebo-control,randomized,fixed dose study, study,subjects were randomly assigned to treatment with aripiprazole 2.5mg/day plus sertraline 50mg/day or sertraline 50mg/day plus placebo.
1943942|NCT00874120|Drug|Phenylephrine Hydrochloride (HCl) Extended-Release tablets 30 mg|Phenylephrine HCl Extended-Release tablets 30 mg taken twice daily (12 hours apart) for 7 days.
1943943|NCT00874120|Drug|Placebo|Placebo taken twice daily (12 hours apart) for 7 days.
1943944|NCT00873353|Drug|capecitabine + erlotinib|"6 cycles (3 weeks each one) of :
capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks
erlotinib (Tarceva®) 150mg/day, oral. Days: every days"
1943945|NCT00873405|Procedure|Silastic® ring sleeve gastrectomy|SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
1943946|NCT00873405|Procedure|Silastic® ring gastric bypass|SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.
1943954|NCT00873288|Other|informational intervention|
1943957|NCT00872053|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs over a treadmill through position controlled trajectories that mimic normal human gait patterns.
1943958|NCT00870987|Biological|DNA vaccine prime|2 mg total dose (1 mg per construct in a volume of 1 mL)
1943959|NCT00870987|Biological|adenovirus type 5 vaccine boost|2 x 1010 particle units (pu) (1 x 1010 pu per each of 2 constructs including CSP and AMA1 respectively)
1943962|NCT00870727|Drug|Aripiprazole oral product|Minimum dose of 2mg per day to a maximum of 20 mg per day over 8-weeks of treatment.
1943963|NCT00870727|Drug|Placebo oral capsule|Placebo will identical in size and appearance to study drug.
1943973|NCT00869206|Drug|zoledronic acid|Given IV
1943974|NCT00868894|Drug|DE-104 medium concentration|Topical ocular application
1943975|NCT00868894|Drug|DE-104 high concentration|Topical ocular application
1943976|NCT00868894|Drug|Placebo|Topical ocular application
1943977|NCT00868894|Drug|0.005% latanoprost|Topical ocular application
1943979|NCT00868036|Procedure|Patch Testing|"Patch testing will be performed with a modified North American Contact Dermatitis Group (NACDG) standard series, cosmetics/preservative, fragrance, and textile series in all patients. Based on patient history, other appropriate allergen series will be added. After two days, patches will be removed and the areas will be inspected for type IV hypersensitivity reactions including papules, edema or vesicles.
Results will be graded and interpreted at a delayed read, 3-4 days after allergens are placed with patch testing."
1943980|NCT00868166|Drug|Olesoxime|2 capsules of TRO19622 (330mg) once a day with the noon meal as add-on therapy to riluzol 50mg bid
1943981|NCT00868166|Drug|Placebo Comparator|2 capsules of Placebo once a day with the noon meal as add-on therapy to riluzole 50mg bid
1943982|NCT00868140|Drug|pioglitazone|pioglitazone 45 mg
1943983|NCT00868140|Drug|Placebo|placebo daily
1943984|NCT00867334|Drug|Imatinib mesylate followed by a combination of imatinib mesylate & panitumumab|Patients will be entered into sequential cohorts with escalating doses of imatinib mesylate. After approximately 28 days of monotherapy treatment with imatinib mesylate, patients will be asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). All patients in this group will then receive imatinib mesylate in combination with standard-of-care doses of panitumumab. After approximately 1-2 months of combination treatment, patients will asked to have an additional liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study). Combination treatment will continue for the remainder of the subject's time in the trial.
1943985|NCT00867334|Drug|Standard-of-care treatment with panitumumab|Panitumumab as standard of care. After approximately 2-3 months of standard of care treatment, patients will asked to have a liver biopsy performed (this biopsy is voluntary and is not required for continued participation in the study).
1943986|NCT00867217|Drug|High Dose Vitamin D3|Drug: High Dose Vitamin D3 High Dose Vitamin D3 (3 capsules of 10,000 IU or placebo) weekly for 24 weeks Arms: Vitamin D
1943987|NCT00867217|Drug|Placebo|Drug: Placebo Placebo comparator Arms: Placebo
1943988|NCT00867100|Drug|AMG 827|This Phase 1 study will evaluate safety, tolerability, PK and PD of AMG 827 when administered as a single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
1943989|NCT00866840|Drug|riluzole|100 mg orally twice daily
1943990|NCT00866619|Biological|Malaria Vaccine 257049|Vaccine, 0.5mL per dose
1943991|NCT00866619|Biological|Meningococcal C Conjugate Vaccine|"Children enrolled to receive a comparator booster dose (i.e. those enrolled to R3C [children] or C3C [children]) will get 1 dose of Meningococcal C Conjugate Vaccine at the booster dose visit.
Infants enrolled to receive a comparator booster dose (i.e. those enrolled to R3C [infants] or C3C [infants]) will get 1 dose of Meningococcal C Conjugate Vaccine at the booster dose visit.
In addition, infants enrolled to receive a primary course comprising 3 doses of comparator vaccine (i.e. those enrolled to C3C [infants]) will get 3 doses of Meningococcal C Conjugate Vaccine.
Subjects will receive either Meningitec (Wyeth), NeisVac-C (Baxter) or Menjugate (Novartis). Note: where a subject is enrolled to receive 3 doses, each of the 3 doses will be from the same manufacturer"
1943992|NCT00866619|Biological|Cell-culture rabies vaccine|Children enrolled to receive a primary course comprising 3 doses of comparator vaccine (i.e. those enrolled to C3C [children]) will get 3 doses of cell-culture rabies vaccine. Subjects will receive either Human Diploid Cell Rabies Vaccine (Sanofi Pasteur) or Purified Chick Embryo Cell Culture Vaccine (i.e. Rabipur, or equivalent) (Novartis). Note: each of the 3 doses will be from the same manufacturer
1944153|NCT00834600|Drug|hydrochlorothiazide (HCTZ) or olmesartan|HCTZ 25 mg, increasing to 50 mg at 3-4 weeks or Olmesartan 20 mg, increasing to 40 mg at 3-4 weeks. If blood pressure >140/90 mmHg at 6 weeks, amlodipine 5 mg may be added
1943993|NCT00866619|Biological|TritanrixHepB/Hib|"Diptheria, Tetanus, whole-cell Pertussis, Hemophilus influenzae (type B) Hepatitis B vaccine (0.5 mL dose).
All infants enrolled to the trial will receive 3 doses of TritanrixHebB/Hib, a standard EPI-compatible vaccine, commonly administered to infants in sub-Saharan Africa."
1943994|NCT00866619|Biological|Polio Sabin Oral Polio Vaccine (GSK)|All infants enrolled to the trial will receive 3 doses of Polio Sabin Oral Polio Vaccine, a standard EPI-compatible vaccine, commonly administered to infants in sub-Saharan Africa
1943995|NCT00864721|Drug|Sutent|Sunitinib malate (Sutent) will be taken on an outpatient basis. Sunitinib malate (Sutent) should be taken at the dose of 37.5 mg/day by mouth; drug will only be taken Days 1-42 of each 42-day cycle.
1943996|NCT00864773|Procedure|intravitreal injection with anterior paracentesis|0.1cc Aqueous humor samples were taken each time an intravitreal injection of bevacizumab (2.5 mg in 0.1 ml)
1943997|NCT00863928|Drug|Belladonna and Opium Suppositories|Effects of Perioperative Belladonna and Opium Suppositories on Postoperative Pain
1943998|NCT00863122|Drug|lapatinib|1500 mg lapatinib by mouth per day for 10 days
1943999|NCT00861809|Drug|GSK962040 25 mg|25 mg
1944000|NCT00861809|Drug|Placebo|placebo comparator
1944001|NCT00861809|Drug|GSK962040 50 mg|50 mg
1944002|NCT00861809|Drug|GSK962040 1250 mg|125 mg
1944003|NCT00861380|Biological|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
1944004|NCT00861380|Biological|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|"3 or 4 Intramuscular injections, depending on the age at the time of first vaccination.
Control 3+1 and Control 2+1 groups, only for children < 12 months of age at the time of first study vaccination."
1944005|NCT00861380|Biological|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections. Control 3+1 and Control 2+1 groups, only for children >= 12 months of age at the time of first study vaccination.
1944006|NCT00860938|Drug|Budesonide|After 4 weeks of inhalative therapy with tiotropium (all patients), patient get randomized to receive either inhalative budesonide (1600ug per day or placebo
1944007|NCT00861107|Biological|AlloStim-7|intradermal injection once a week for 3 weeks
1944008|NCT00861107|Procedure|percutaneous tumor cryoablation|ablation of a tumor by percutaneous cryoablation under CT guidance
1944009|NCT00861107|Biological|AlloStim-7|intratumoral injection into cryoablated tumor lesion 1 hour after ablation
1944010|NCT00861107|Biological|AlloStim8 or AlloStim-9|intravenous infusion of AlloStim one week following ablation procedure. First cohort to receive 10^8 cell dose and if no toxicity dose escalates to 10^9 cell dose.
1944011|NCT00860171|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Autologous stem cells given via central catheter
1944012|NCT00860171|Radiation|Iodine I 131 Monoclonal Antibody BC8|Given IV
1944013|NCT00860171|Other|Laboratory Biomarker Analysis|Correlative studies
1944014|NCT00859976|Device|BoneMaster coated acetabular shell.|Bonemaster coated Exceed Acetabular Shell
1944015|NCT00859976|Device|Plasma Coated Acetabular Shell|Plasma HA coated Exceed Acetabular Shell
1944016|NCT00857727|Drug|Dexmedetomidine|Dexmedetomidine will be dissolved in saline. An initial loading dose of 1.0 mg/kg given over 10 minutes followed by a continuous infusion at 0.4-0.7 mg/kg/hour. Beginning approximately one hour prior to end of surgery and continuing for one hour of recovery in the PACU and the PICU. This, the maximum dose for any one patient will be 2.4 mg/kg
1944017|NCT00857727|Drug|Saline|Given by a continuous infusion
1944018|NCT00858286|Other|Spirometry, PEF measurements and diary cards to evaluate control of Asthma|No intervention is made with the existing therapy, but patient will perform spirometry and PEF evaluations together with a registration of control of asthma in diary cards and health economic parameters in questionnaires
1944020|NCT00857857|Drug|GW870086X|Investigational product
1944021|NCT00857857|Drug|FP|Positive control
1944022|NCT00857857|Drug|Placebo|Placebo control
1944027|NCT00857597|Procedure|Transoral Incisionless Fundoplication|The TIF procedure using the EsophyX system with SerosaFuse fasteners was designed to create full-thickness serosa-to-serosa plications and construct valves of 3-5 cm in length and 200-300° in circumference.
1944028|NCT00857597|Drug|Proton Pump Inhibitors; active control|Proton Pump Inhibitors; active control
1944029|NCT00856856|Device|Bioabsorbable Everolimus Eluting Coronary Stent|Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease
1944030|NCT00856284|Drug|Alogliptin|Alogliptin tablets
1944031|NCT00856284|Drug|Metformin|Metformin tablets
1944032|NCT00856284|Drug|Glipizide|Glipizide tablets
1944033|NCT00855478|Device|Cypher stent ™ or Cypher Select ™|Cypher drug-eluting stent
1944035|NCT00855205|Drug|Rituximab|Rituximab will be administered by IV infusion at a dose of 1000 mg (1 g) on day 1 and 15
1944084|NCT00848757|Behavioral|Intensive Lifestyle Intervention|"Women with pre-diabetes randomized to the ILI will attend an intensive 12-week group program of nutritional education, diet, behavior modification and structured exercise, which is based on the published curriculum from the DPP Lifestyle Balance program, but modified for a group format and to be more culturally and linguistically appropriate for this population."
1944038|NCT00854789|Biological|E75 + GM-CSF vaccine|The 1 ml by volume vaccine is administered intradermally in 0.5 ml inoculums at two different sites within 5 cm of each other on an extremity. Vaccinations will be given according to the schedule the patient has been assigned and will be administered in the same lymph node draining area (same arm or thigh). In addition, an optional booster inoculation as requested by previously vaccinated patients will be offered every 6 months for the duration of the protocol. The dose will be determined by the PI based on the patient's response to the initial vaccination series.
1944039|NCT00854750|Drug|ACTHAR|SQ weekly injections
1944040|NCT00854750|Drug|ACTHAR|SQ weekly injections
1944041|NCT00854750|Drug|ACTHAR|SQ weekly injections
1944042|NCT00854750|Drug|ACTHAR|SQ weekly injection
1944043|NCT00853125|Biological|therapeutic allogeneic lymphocytes|Patients with a partially HLA-matched family member who can serve as a hematopoietic stem cell transplant donor will receive partially HLA-matched irradiated donor lymphocytes approximately every 8 weeks depending upon response
1944044|NCT00853125|Drug|sunitinib malate|Sunitinib will be administered orally at a dose of 50 mg qd for 4 consecutive weeks followed by 2 weeks off for every cycle.
1944045|NCT00853671|Radiation|Cardiac CT|Adenosine- continuous infusion at 140mcg/ kg/ min for 2.5 min; IV contrast- total dose of 150cc; CT radiation - effective radiation dose of approximately 13mSv (tube voltage 120kV, tube current 340mAs for one retrospectively gated cardiac CT with tube current modulation and two prospectively gated cardiac CTs on a Dual Source scanner)
1944055|NCT00853047|Drug|Low Dose LX1606 Part 1|A low dose of LX1606; daily oral intake for 28 days
1944056|NCT00853047|Drug|Mid-Low Dose LX1606 Part 1|A mid-low dose of LX1606; daily oral intake for 28 days
1944057|NCT00853047|Drug|Mid-High Dose LX1606 Part 1|A mid-high dose of LX1606; daily oral intake for 28 days
1944058|NCT00853047|Drug|High Dose LX1606 Part 1|A high dose of LX1606; daily oral intake for 28 days
1944059|NCT00853047|Drug|Part 2 LX1606 Expanded Cohort|A dose of LX1606 to an expanded cohort based upon Part 1; daily oral intake for 28 days
1944060|NCT00853047|Drug|Placebo|Matching placebo dosing with daily oral intake for 28 days
1944061|NCT00853047|Drug|LX1606 Open Label Dose Extension|Patients can enter an eight-week extension period at current dose based upon qualification.
1944062|NCT00853047|Drug|LX1606 Open Label Extension 2|Patients can enter a 24-week extension period at current dose after the 8-week open-label extension period.
1944063|NCT00853047|Drug|LX1606 Open Label Extension 3|Patients can enter a 48-week extension period at current dose after the 8-week open-label extension period and the 24-week open-label extension period.
1944064|NCT00852644|Procedure|computed tomography|Standard CT scans
1944065|NCT00852644|Radiation|fludeoxyglucose F 18|standard doses with CT scans
1944066|NCT00852644|Radiation|hypofractionated radiation therapy|4 doses over 2 weeks
1944067|NCT00852644|Radiation|stereotactic radiosurgery|CyberKnife radiosurgery
1944068|NCT00851747|Drug|Subcutaneous Phosphatidylcholine and Deoxycholate Injections|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
1944069|NCT00851747|Drug|Saline|Group A will serve as a control and will receive only injections of saline as a placebo. Group B will receive saline injections on one side of the body and receive study drug injections on the contralateral side. Group C will receive only study drug injections
1944070|NCT00852280|Device|Treatment of 1/2 of skin graft with pulsed-dye laser|Pulsed-dye laser will be applied to 1/2 of the seam of the skin graft, using a 10mm spot size, and sufficient pulse-width and fluency to induce purpura.
1944071|NCT00852241|Drug|Restalyne and Perlane|One syringe of Perlane® (1.0cc) and one syringe of Restylane® (1.0cc) will be used total for both tear trough areas.
1944072|NCT00851344|Drug|GSK835726 (10mg)|GSK835726 (10mg) tablet
1944073|NCT00851344|Drug|GSK835726 (50mg)|GSK835726 (50mg) tablet
1944074|NCT00851344|Drug|GSK835726 (100mg)|GSK835726 (100mg) tablet
1944075|NCT00851344|Drug|Cetirizine (10mg)|Cetirizine (10mg) tablet as positive control
1944076|NCT00851344|Other|Placebo|Placebo to match active
1944077|NCT00851253|Radiation|stereotactic radiosurgery|Given in 2 fractionated doses or 5 fractionated doses
1944078|NCT00851149|Device|Sangvia blood sampling system|Blood collected from abdominal aortic repair patients are compared against blood collected from total hip replacement patients
1944079|NCT00850642|Drug|GSK2190195 100mg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor.
1944080|NCT00850642|Drug|Placebo|"Placebo :
2% (w/w) Ethanol, sucralose (5 mg/100 mL of oral solution) to 100 % (w/w) aqueous sodium carbonate buffer (0.010 M, pH 9-10)"
1944081|NCT00848393|Drug|Fentanyl|25 mcg/kg in two divided doses. half the dose will be given at induction and the second half will be given prior to incision.
1944082|NCT00848393|Drug|Fentanyl|patients will receive a total of 10mcg/kg of fentanyl. half the dose will be given at induction and the second half before incision.
1944083|NCT00848393|Drug|Dexmedetomidine and Fentanyl|Dexmedetomidine at 1mcg/kg loading dose over 10 minutes, followed by an infusion at a rate of 0.5mcg/kg/hr.in addition this group will receive a total of 10 mcg/kg fentanyl. Half the dose will be given at induction and the second half before incision.
1944085|NCT00847912|Drug|5-fluorouracil|"Apply thin layer of topical 5-FU 5% cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily 5-FU, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping 5-FU, if and only if the participant has not received at least the minimum 2 week (28 dose) course, 5-FU treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but 5-FU will be stopped."
1944086|NCT00847912|Drug|Placebo, vehicle control|"Apply thin layer of vehicle control cream twice daily to face and ears for 4 weeks. Treatment to be initiated immediately after randomization. If unable to tolerate the twice daily vehicle control cream, they will discontinue the treatment and initiate cool-down treatment with triamcinolone 0.1% cream twice daily until the symptoms resolve. At 3 weeks after stopping vehicle control cream, if and only if the participant has not received at least the minimum 2 week (28 dose) course, vehicle control cream treatment will be resumed on a once-daily basis to complete the 56 dose course. If this is not tolerated, the cool-down routine will be followed, but vehicle control cream will be stopped."
1944088|NCT00847340|Procedure|Biopsy Excisional|Biopsied from genital warts will be taken through an excisional procedure. Homeostasis will be obtained by using apply of Monsel solution. Biopsied sample will be splinted in order to obtain two pieces, one of them will be frozen (liquid Nitrogen) and designated to the HPV DNA PCR test (GP5, GP6) to be performed at the immunology lab at the National Cancer Institute in Bogotá. The other one will be kept in Formalin solution (10%) and sent to the pathology laboratory for haematoxiline - eosine paint and lecture.
1944089|NCT00847184|Device|Intubation|Intubation using the standard MacIntosh blade
1944090|NCT00847184|Device|Airtraq|Intubation with the use of the Airtraq technique
1944091|NCT00846690|Drug|benzocaine|20% benzocaine., topical placement onto site, minimal amount, for 1 minute
1944092|NCT00846690|Drug|TAC alternate gel|use 1 pump, place topically onto site, leave for 1-3 minutes
1944093|NCT00846599|Other|Omega-3 study meal|Participant will eat a study meal high in omega-3 fatty acids.
1944094|NCT00846599|Other|Saturated fat study meal|Participant will eat a study meal high in saturated fat.
1944095|NCT00846053|Procedure|[18F]FDG PET/CT|FDA-approved Investigational New Drug (IND) to use [18F]FDG in CF patients under the age of 18 years (PI: Robert Mach, MD, IND # 76079). Imaging data will be acquired with a Siemens Biograph 40PET/CT Tomograph. Research participants will be positioned supine in the scanner and a scout CT topograph obtained.
1944102|NCT00843388|Drug|Spironolacton (hexalacton(R))|Tablet Spironolacton 25 mg OD
1944103|NCT00843388|Drug|placebo tablet|placebo tablet 25 mg OD
1944106|NCT00841919|Drug|Glargine insulin|"The study group will receive Insulin Glargine as basal insulin. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
1944107|NCT00841919|Drug|NPH insulin and regular insulin|"The active control group will receive twice daily NPH insulin as basal insulin and bolus (prandial) insulin as regular insulin to be administered 30 minutes before meals. The administration of basal (prandial) regular insulin and food will be done as the current usual care on the hospital ward. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix B. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
1944108|NCT00841919|Drug|lispro insulin|"Bolus (prandial) insulin as lispro insulin (choice between pens or vials will be made). The administration of bolus (prandial) insulin pen or syringe will be delivered concurrently with the food tray (the concept of insulin pen/syringe on the food tray) by the nursing staff that together with hospital food services identifies the food tray for the patients in the study group. The protocol for initial insulin dose and subsequent dose adjustment has been developed by the Inpatient Diabetes Advisory Group and is detailed in appendix A. The patient will receive information regarding diabetes treatments, appropriate diet and diabetic self management which will be provided by the nursing and nutritional staff."
1944109|NCT00842959|Device|Invent ZO|monofocal aspheric IOL for implantation into capsular bag
1944110|NCT00842959|Device|XL Stabi ZO|monofocal aspheric IOL for implantation into capsular bag
1944111|NCT00842907|Drug|oral isotretinoin|one 20.0 mg capsule, once a day, every other day, during 24 weeks
1944112|NCT00842907|Drug|Tretinoin|0.05% tretinoin cream applied on face and forearms, once a day, in the night, during 24 weeks
1944113|NCT00842296|Device|RF ablation (ClosureFAST)|Segmental RF Ablation with the CLF catheter
1944114|NCT00841841|Drug|dipyrone and acetaminophen|The patients were randomly assigned to 2 groups of 15 patients, according to the drug prescribed as postoperative medication: Group I: dipyrone 500 mg every 6 hours (4 males, 11 females, mean age = 25.2 years) and Group II: paracetamol 750 mg every 6 hours (3 males, 12 females, mean age = 26.8 years)
1944115|NCT00841165|Device|Continuous Positive Airway Pressure|Full face CPAP at 5cm H2O and 100% oxygen
1944116|NCT00841165|Device|Non-rebreather oxygen mask|Oxygen administered through a non-rebreather mask
1944117|NCT00841828|Drug|Epirubicin, Cyclophosphamide, Taxotere, Herceptín, Lapatinib|"- EC (each 21 days for 4 cycles) -> T + lapatinib (each 21 days for 4 cycles) vs
EC (each 21 days for 4 cycles) -> T + herceptin (each 21 days for 4 cycles)"
1944118|NCT00841399|Biological|E75 + GM-CSF vaccine|Dose escalation scheme involving three patients each receiving injection of 100, 500, or 1,000 mcg E75 + GM-CSF monthly for 6 months. HLA-A2 and HLA-A3 status determined. HLA-A2+ and HLA-A3+ patients receive the vaccine; HLA-A2- and HLA-A3- enrolled to the control arm.
1944119|NCT00841308|Other|Decision to start and titrate drug treatment based only on home blood pressure monitoring|"Drug Treatment according to current Hypertension Guidelines. Decision to start and titrate drug treatment based on clinic and ambulatory blood pressure (Usual care arm) versus based on home blood pressure monitoring only (Home blood pressure monitoring arm)."
1944120|NCT00839813|Behavioral|Yoga|10 weeks of a trauma-sensitive yoga class
1944121|NCT00840749|Radiation|CyberKnife Stereotactic Radiotherapy|Central lesion dose/fractionation: 15 Gy x 4 fractions = 60 Gy; Peripheral lesion dose/fractionation: 20 Gy x 3 fractions = 60 Gy
1944122|NCT00840749|Procedure|Surgery|Both open thoracotomy and video assisted thoracotomy (VATS) are acceptable procedures. Surgery may consist of a lobectomy, sleeve resection, bilobectomy or pneumonectomy as determined by the attending surgeon based on the operative findings
1944123|NCT00839254|Biological|Pneumococcal conjugate vaccine GSK1024850A|2, 3 or 4 Intramuscular injections, depending on the age at the time of first vaccination
1944124|NCT00839254|Biological|GSK Biologicals' Engerix TM vaccine (Hepatitis B vaccine)|3 or 4 Intramuscular injections, depending on the age at the time of first vaccination only for children < 12 months of age at the time of first study vaccination.
1944125|NCT00839254|Biological|GSK Biologicals' Havrix TM vaccine (Hepatitis A vaccine)|2 Intramuscular injections only for children >= 12 months of age at the time of first study vaccination.
1944126|NCT00838175|Procedure|suture mediated closure|Suture mediated closure of femoral venous access
1944127|NCT00838565|Drug|Placebo|intravenous infusion on three consecutive months
1944128|NCT00838565|Drug|dose level 1|intravenous infusion on three consecutive months
1944129|NCT00838565|Drug|dose level 2|intravenous infusion on three consecutive months
1944130|NCT00838565|Drug|dose level 3|intravenous infusion on three consecutive months
1944131|NCT00838565|Drug|dose level 4|intravenous infusion on 3 consecutive months
1944132|NCT00838539|Drug|Neratinib|neratinib 40mg tablets will be taken orally in doses of either 120mg, 160mg, 200mg OR 240mg daily dose, for as long tolerated and the disease under study does not worsen.
1944133|NCT00838539|Drug|Temsirolimus|Temsirolimus will be administered intravenously once a week, at either 15mg, 25mg, 50, or 75mg, for as long as tolerated and the disease under study does not worsen.
1944134|NCT00838032|Drug|Quetiapine fumarate|Quetiapine fumarate should be initiated on Day 1 and titrated to at least 600 mg/day before Day 7 according to clinical experience and prescribe information. After Day 7, the dose of quetiapine fumarate should be adjusted between 600 mg/day to 750 mg/day at the discretion of the investigator.
1944135|NCT00838032|Drug|Haloperidol|Haloperidol should be initiated with the dose range from 5 mg/day to 15 mg/day from Day 1 to Day 5 (using injection) according to the clinical experience and prescribe information. After Day 7, the dose of haloperidol should be adjusted between 8 mg/day to 20 mg/day (change from injection to oral formulation between Day 6 to Day 7) at the discretion of the investigator.
1944136|NCT00838006|Device|heart rate variability biofeedback|Heart rate variability biofeedback, 3 session plus handheld device
1944137|NCT00838006|Device|Cognitive bias modification training|Cognitive bias modification training - 3 session plus handheld device
1944138|NCT00838006|Device|Sham Comparator|Subjects received iPod without a study app and no additional resilience training
1944139|NCT00837343|Drug|quetiapine fumarate tablet (Seroquel)|Investigational product: quetiapine fumarate tablet (Seroquel) , 25 mg, 200 mg, 300mg, manufactured by AstraZeneca.The total daily doses of quetiapine fumarate will be increased to 600mg/d on the 6th since enrolment day. At day 7 or later, the dose can be adjusted in the range of 400- 800mg/day.
1944140|NCT00837590|Drug|salsalate|Subjects will receive 2 months of treatment with 4 gram/day of oral salsalate divided into 3 doses.
1944141|NCT00837590|Drug|metformin|metformin po 1000mg bid
1944142|NCT00837590|Drug|lisinopril|lisinopril po 20mg qd
1944143|NCT00837434|Drug|Etanercept|50 mg dose of etanercept by subcutaneous injection
1944144|NCT00837434|Drug|Adalimumab|40 mg dose of adalimumab by subcutaneous injection
1944148|NCT00836927|Drug|ridaforolimus|Oral or IV deforolimus, as described in the parent protocol. If the parent protocol involves a combination of deforolimus with one or several other drugs, the additional drug(s) may be continued as described in the parent protocol.
1944149|NCT00836810|Drug|Timed Release Tablet Prednisone|Dose: 7mg, taken at 10pm every night for 2 weeks in the form of oral tablets.
1944150|NCT00836810|Drug|Prednisolone|Dose: 7mg, taken in the morning for 2 weeks in the form of oral tablets.
1944151|NCT00836758|Device|REMstar Auto with A-Flex|The CPAP device will be set-up at a sub-therapeutic pressure and will remain at this pressure for the entire night, if tolerated.
1944152|NCT00834600|Drug|olmesartan, hydrochlorothiazide, amlodipine|hydrochlorothiazide (HCTZ) 25mg OD, increased to 50 mg OD at 3 weeks. Olmesartan 20 mg OD, to be increased to 40 mg at 3 weeks. Amlodipine 5 mg, may be added at 6 weeks, if BP >140 mmHg
1944154|NCT00835458|Procedure|gastro-gastric fistula closure|The mucosa surrounding the orifice of the fistula will be ablated using standard endoscopic techniques. Remnants of mucosa will be treated with argon-plasma coagulation. The mucosa free orifice of the fistula will be closed using the Tissue Apposition System. Tissue anchors with attached threads will be deployed through the intestinal wall full thickness using delivery needles through the working channel of the endoscope. After two anchors are deployed on both sides of the fistulas' orifice a knotting element will be cinched down to approximate the two sides of the fistulas' orifice. The procedure will be repeated until the fistulas' orifice is securely closed.
1944155|NCT00835393|Drug|Pantoprazole Sodium 40 mg delayed-release tablets|1 x 40 mg
1944156|NCT00835393|Drug|PROTONIX® 40 mg delayed-release tablets.|1 x 40 mg
1944157|NCT00834860|Drug|peginterferon alpha-2a and ribavirin|They received peginterferon alpha-2a (180 μg/week) and weight-based ribavirin 1000-1200 mg/day, with a 24-week follow-up period.
1944158|NCT00834782|Procedure|IOP measurement|Measuring IOP
1944159|NCT00834106|Biological|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine|Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine injection at Day 1, Month 2, and Month 6.
1944160|NCT00834106|Biological|Comparator: placebo (unspecified)|Aluminum-containing Vaccine placebo injection at Day 1, Month 2, and Month 6.
1944161|NCT00834652|Drug|Sertraline|50 mg once a day, which may be increased to 200 mg once a day
1944162|NCT00834652|Drug|Metformin|Starting dose of 500 mg daily and increasing by 500 mg every 2 weeks to a total of 2,000 mg daily
1944165|NCT00832481|Drug|Repaglinide|Repaglinide (NovoNorm®): 0.5 mg/tablet, 1.0 mg/tablet
1944166|NCT00832481|Drug|Metformin|2 mg/tablet Metformin (Glucophage®): 0.5 g/tablet
1944167|NCT00833105|Device|AMES treatment|The AMES device rotates the fingers-thumb and the wrist over a range of 30 degrees while vibrators stimulate the tendons attached to muscles that move the hand. A treatment consists of 20 minutes of fingers-thumb movement, followed by 10 minutes of wrist movement. The subject's task is to assist the motion of the device.
1944168|NCT00832767|Procedure|SILS™ port laparoscopic cholecystectomy|This interventional arm will have a single incision laparoscopic cholecystectomy procedure.
1944169|NCT00832767|Procedure|Four Port Laparoscopic Cholecystectomy|This interventional arm will have a traditional four port laparoscopic cholecystectomy procedure.
1944170|NCT00831181|Drug|FOLFOX regimen|
1944171|NCT00831181|Drug|fluorouracil|
1944172|NCT00831181|Drug|leucovorin calcium|
1944173|NCT00831181|Drug|oxaliplatin|
1944174|NCT00831181|Procedure|adjuvant therapy|
1944175|NCT00831181|Procedure|neoadjuvant therapy|
1944176|NCT00831181|Procedure|quality-of-life assessment|
1944177|NCT00831181|Procedure|therapeutic surgical procedure|
1944178|NCT00830531|Drug|Bumetanide|Bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
1944179|NCT00830531|Drug|Normal Saline as Placebo|Normal Saline as placebo for bumetanide either 0.1 mg/kg, 0.2 mg/kg or 0.3 mg/kg IV administered together with standard phenobarbital therapy
1944180|NCT00830505|Drug|fluticasone/ salmeterol|2 puffs twice a day for 2 weeks
1944181|NCT00830505|Drug|fluticasone|2 puffs twice a day for 2 weeks
1944183|NCT00829751|Device|PureVision lenses soaked in ReNu Multiplus|Purevision silicone hydrogel lenses
1944184|NCT00829751|Device|PureVision lenses soaked in OptiFree RePlenish|Purevision silicone hydrogel lenses soaked in OptiFree RePlenish
1944185|NCT00829543|Procedure|guide-free sacroiliac corticosteroid injection|guide-free sacroiliac injection of triamcinolone acetonide 40 mg in each sacroiliac joint
1944186|NCT00828451|Biological|[5,5,5-2H3]leucine (stable isotope labeled leucine)|intravenous infusion of labeled leucine dissolved in 5% glucose water: priming dose of 18 micromoles (1.8 ml)/kg over 5 minutes, then 18 micromoles (1.8 ml)/hr for 6 hours; one infusion total
1944187|NCT00827658|Procedure|Local Block|total 3 cc injection (1.5 cc 1% plain lidocaine and 1.5 cc of 0.25% bupivicaine)
1944188|NCT00826748|Drug|Beclomethasone|The treatment with inhaled beclomethasone will be administered to Group A from Day 1 to Day 7 via a metered dose inhaler (QVAR 80 HFA) delivering 80 micrograms of beclomethasone per puff. QVAR will be purchased by the Department of Genetic Medicine. The dose will be 2 puffs twice a day for 7 days
1944189|NCT00826462|Drug|triamcinolone|Injection with triamcinolone 10 mg at start and at 3 weeks
1944190|NCT00826462|Drug|Placebo|Injection with sodium chloride at start and at 3 weeks
1944191|NCT00826462|Drug|Lidocaine|10 mg of lidocaine at start and at 3 weeks
1944192|NCT00826462|Other|Physiotherapy|12 treatments with deep friction massage, Mill's manipulation, soft tissue treatment and home exercises
1944193|NCT00826462|Drug|Naproxen|Naproxen 500 mg bid for 14 days
1944194|NCT00826150|Biological|BC-819|"Cohort #1: 60 mg IP weekly for 3 weeks, one week rest, then repeat for 2 more courses / 60 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.
Cohort #2: 120 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course.
Cohort #3: 240 mg IP weekly for 3 weeks, four week rest, then repeat for 1 more course."
1944195|NCT00825656|Drug|Sinol or Sinol-M nasal spray|"One spray in each nostril up to a maximum of 12 times / day on an as needed basis"
1944196|NCT00824863|Drug|ketoconazole 2% foam|topical antifungal foam to be applied to the folliculitis BID for 2-4 weeks.
1944197|NCT00824356|Drug|GSK1004723 (200mg)|Intranasal antihistamine.
1944198|NCT00824356|Other|Placebo|Equivalent to GSK1004723 in presentation etc.
1944199|NCT00824356|Drug|GSK1004723 (1000mg)|Intranasal antihistamine.
1944281|NCT00811226|Drug|olmesartan medoxomile alone or combined with hydrochlorothiazide,|olmesartan medoxomile 20mg/daily or 40mg/daily; olmesartan medoxomile 20mg plus 12.5 mg of hydrochlorothiazide daily; olmesartan medoxomile 40mg plus 12.5 mg of hydrochlorothiazide daily
1944282|NCT00811187|Drug|Lidocaine paracervical block|5cc 1% lidocaine injection in each paracervical region
1944283|NCT00811187|Drug|Normal Saline|5cc Normal Saline injection in each paracervical region
1945019|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 440 micrograms sirolimus each.
1944200|NCT00824096|Procedure|Bronchoscopy|The patients in our ICU intubated for > 24h and met weaning criteria, will be examined by bronchoscopy. Five ㏄ blood will be collected for checking CRP and cytokines before performing bronchoscopy. The proposed grading of post-extubation vocal cord finding were shown (Figure 1). The patients will be classified to two groups (Figure 2). The first group is these patients without swelling or swelling area ≦50% who will be extubated after bronchoscopic examination. These patients will be followed for 48 hours to monitor the incidence of PES. The second group is those patients who develop laryngeal edema with swelling area ≧50% or swelling in the whole vocal cord. Bosmin 2 ml local injection and Solu-medrol 40 mg I.V. Q6h for 1~4 days will be given. Bronchoscopy will be done if CLV ≧24% or after treatments for 3~4 days even with CLV ＜24%. The above treatments will be applied again if stridor develops. Extubation will be performed if no presence of laryngeal edema.
1944201|NCT00823888|Device|pneumatic brace|pneumatic knee brace with three trial conditions: air bladders inflated at 0psi, 7 psi, and 12 psi
1944202|NCT00823459|Drug|RAD001|RAD001 will be administered orally as once daily dose of 10 mg (two 5 mg tablets) continuously from study day 1 until progression of disease or unacceptable toxicity. Patients will be instructed to take RAD001 in the morning, at the same time each day. RAD001 may be taken with or without food.
1944203|NCT00823134|Device|ApneaLink Plus|Device used to evaluate for the presence of obstructive, central or mixed apneas
1944204|NCT00822120|Biological|bleomycin sulfate|
1944205|NCT00822120|Biological|filgrastim|
1944206|NCT00822120|Drug|ABVD regimen|
1944207|NCT00822120|Drug|BEACOPP regimen|
1944208|NCT00822120|Drug|cyclophosphamide|
1944209|NCT00822120|Drug|dacarbazine|
1944210|NCT00822120|Drug|doxorubicin hydrochloride|
1944211|NCT00822120|Drug|etoposide|
1944212|NCT00822120|Drug|prednisone|
1944213|NCT00822120|Drug|procarbazine hydrochloride|
1944214|NCT00822120|Drug|vinblastine sulfate|
1944215|NCT00822120|Drug|vincristine sulfate|
1944216|NCT00821223|Procedure|phacoemulsification and SICS|SICS with rigid IOL implantation Phaco with foldable IOL implantation
1944217|NCT00821223|Procedure|manual small incision surgery|
1944218|NCT00821223|Procedure|phacoemulsification|cataract surgery
1944219|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod|Part I: a cohort of 3 patients to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical resiquimod 1000 mg of the 0.2% gel on days 1, and 3. If no DLT observed, we will proceed to cohort 2 with Resiquimod dosing on days 1,3 and 5. If DLT is found in the second cohort, the trial will proceed to Part II; with the limited dosing for days 1 and 3 only, as used in the first cohort. If no DLT is found in second cohort, the trial will proceed to Part II with Resiquimod dosing for days1, 3 and 5.
1944220|NCT00821652|Drug|NY-ESO-1 protein; Montanide ISA®-51 VG; Resiquimod/placebo|Part II: Eligible patients will be randomized to receive a subcutaneous vaccination of 100µg NY-ESO-1 protein emulsified in 1.25mL Montanide ISA®-51 VG (day 1) followed by topical placebo gel (Arm A) or topical resiquimod gel (Arm B) on days 1, 3 and 5; or resiquimod dosing regimen established in Part I. The cycles will be repeated every 3 weeks for a total of 4 cycles (on Study week 1, 4, 7 and 10). All procedures may occur within + 3 days of the planned date.
1944223|NCT00820924|Drug|LAPATINIB|LAPATINIB 1500MG ORAL DOSE DAILY
1944224|NCT00820638|Device|myomo e100|use of the myomo e100 in home
1944225|NCT00820261|Other|oral rehydration therapy for diarrhea cases|Since rotavirus infection is a viral infection with no drug remedy, diarrhea cases will be managed according to the standard WHO protocol for the management of diarrhea. This will include oral rehydration treatment.
1944226|NCT00819988|Drug|Pregabalin|Pregabalin capsule 75 mg given preoperatively, then eith 50 mg or 25 mg given every 8 hours for 3 days postoperatively based on renal function
1944227|NCT00819988|Other|Sugar pill|Single dose given 30-60 minutes preoperatively, then given every 8 hours for 3 days postoperatively
1944228|NCT00819949|Device|Lokomat|The Lokomat is a motor driven exoskeleton device that employs a body weight support suspension system and treadmill. Attached to the lower limbs, the Lokomat moves the subject's legs through position controlled trajectories that mimic normal human gait patterns. This is accomplished by utilizing high quality computer-controlled motors that are precisely synchronized with the speed of the treadmill. The hip and knee joint angles are controlled in real time by software to achieve kinematically correct stepping behaviors. Each of the four motor-driven joints is individually controlled to correspond precisely to the desired joint angle trajectories. This system assures a precise match between the speed of the limb trajectory and the treadmill. In addition, sensors in the motors provide an indirect indicator of the amount of effort the patient is generating to achieve walking in an upright posture.
1944229|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
1944230|NCT00819923|Device|Percutaneous coronary intervention|Intra-coronary stenting
1944231|NCT00819416|Drug|5% albumin|5% albumin for the first 7 days of care in the ICU
1944232|NCT00819416|Drug|Normal Saline|Normal Saline for the first 7 days of care in the ICU
1944233|NCT00819390|Drug|Chloroquine|Taken orally, once daily, at a dose of 250 mg for 12 weeks.
1944234|NCT00819390|Drug|Placebo|Taken orally, once daily for 12 weeks.
1944235|NCT00818428|Behavioral|Speech Production Intervention|Individual speech therapy directed at teaching the child to articulation specific speech sounds or word shapes accurately using traditional procedures such as phonetic placement and imitated and spontaneous speech production practice with feedback from the clinician about accuracy of articulatory gestures and knowledge of results.
1944286|NCT00810745|Procedure|starr|stapled transanal rectal resection
1944479|NCT00770094|Device|Excimer Lasers|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment AMO/VISX CustomVue™ wavefront guided Excimer Laser System
1944236|NCT00818428|Behavioral|Speech Perception Intervention|Individualized intervention in which the Speech Assessment and Interactive Learning System is used to teach the child to identify recordings of words as either correct or incorrect pronunciations of the target word. In the event that the child is completely unable to pronounce the target speech sounds or word shapes focused stimulation activities are used to provide the child with further auditory exposure to the target forms. If the child stimulable for the target forms, the child is given opportunities the produce the target speech sounds or word shapes in the context of minimal pair games in which the child receives feedback about the communicative effectiveness of his or her attempts to produce the target words.
1944237|NCT00818428|Behavioral|Articulation Parent Group|Parents are taught to carry out home practice activities that focus on the child's ability to correctly articulate target speech sounds and word shapes.
1944238|NCT00818428|Behavioral|Dialogic Reading Parent Group|Parents are taught to read to their children using interactive techniques that help their children acquire new vocabulary, verbal reasoning abilities, and preliteracy skills.
1944239|NCT00817245|Drug|omeprazole, Amoxicillin, metronidazole|we will evaluate the effect of medication(anti h.pylori) on the remission of ICSCR
1944240|NCT00817791|Device|Hyperbaric oxygen pretreatment (GR2200)|2 hours/day,5 days before surgery
1944241|NCT00817648|Drug|Quetiapine|Quetiapine fumarate, 25mg/200 mg, the dose titration is carried in week 1. flexible doses(600-750 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
1944242|NCT00817648|Drug|risperidone|risperidone, 1mg/tablet, the dose titration is carried in week 1. flexible doses(3-6 mg/d) from week 2 to week 6. If a patient is intolerant, the doses can be adjusted as judged by investigator.
1944243|NCT00817063|Drug|alitretinoin|Patients receive alitretinoin 30mg one capsule daily for up to 24 weeks
1944244|NCT00817063|Drug|Placebo|Patients receive matching placebo for up to 24 weeks
1944245|NCT00817440|Other|Exercise|1 hour ergometer cycling on 65% of Vo2max, and then the same as arm 1.
1944246|NCT00817440|Other|Fasting|3 days of fasting and then the same as arm 1
1944247|NCT00817557|Drug|Loteprednol|Anti-inflammatory
1944248|NCT00817557|Other|Rewetter|
1944249|NCT00816868|Drug|erlotinib in combination with capecitabine|Erlotinib 150 mg Q.D. orally for 21 days plus Capecitabine 1000 mg/m2 twice daily for 2 weeks followed by 1 week break every 21 days Until PD, unacceptable toxicity or death.
1944250|NCT00816062|Device|Talent Abdominal Stent Graft|The Talent Abdominal Stent Graft is indicated for the endovascular treatment of abdominal aortic aneurysms with or without iliac involvement.
1944251|NCT00814853|Device|NAVA (Extubation readiness testing failures)|Patients who fail the ERT will be place in the mode of ventilation NAVA.
1944252|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 440 micrograms sirolimus in each eye.
1944253|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 220 micrograms sirolimus in each eye.
1944254|NCT00814944|Drug|Sirolimus|Subconjunctival injection of 880 micrograms sirolimus in each eye.
1944255|NCT00814944|Drug|Sirolimus|Subconjunctival injection of placebo in each eye.
1944266|NCT00813735|Drug|Eszopiclone|Eszopiclone 2mg daily at bedtime
1944267|NCT00813735|Drug|Placebo|Placebo daily at bedtime
1944268|NCT00813735|Drug|Escitalopram|Escitalopram 10mg or 20mg
1944269|NCT00814073|Drug|masitinib (AB1010)|masitinib (AB1010) 6 mg/kg/day per os
1944270|NCT00814073|Drug|placebo|matching placebo
1944271|NCT00813176|Device|Double Lumen Endotracheal Tube|
1944272|NCT00813176|Device|Arndt Bronchial Blocker|
1944273|NCT00812773|Drug|GSK2190915|Investigational Product
1944274|NCT00812214|Drug|eszopiclone|3 mg qhs
1944275|NCT00812214|Drug|placebo|
1944276|NCT00811928|Drug|Posaconazole|"40 mg/mL; 200 mg (5 mL) TID
Treatment was continued with each cycle of chemotherapy until:
The onset of a proven or probable diagnosis of invasive fungal infection (IFI)
3 chemotherapy cycles or
Total treatment duration up to 12 weeks (84 days)"
1944277|NCT00811928|Drug|Fluconazole|"50 mg/capsule (2 capsules), 150 mg/capsule (2 capsules);
400 mg QD
Treatment was continued with each cycle of chemotherapy until:
The onset of a proven or probable diagnosis of invasive fungal infection (IFI)
3 chemotherapy cycles or
Total treatment duration up to 12 weeks (84 days)"
1944278|NCT00810407|Drug|rifabutin|"Mycobutin® capsules150mg depending on the Investigator prescription. Frequency and duration are according to Package Insert as follows.  1.Tuberculosis : The usual adult dosage for oral use is 150 mg to 300 mg of rifabutin once daily.For the treatment of multiple-drug resistance tuberculosis, the usual dosage for oral use is 300 to 450 mg of rifabutin once daily.
2.Treatment of non-tuberculous mycobacterial diseases (including MAC disease) : The usual adult dosage for oral use is 300 mg of rifabutin once daily."
1945020|NCT00656643|Drug|Placebo|Two subconjunctival injections of placebo.
1945186|NCT00622895|Drug|Mycophenolic Acid|Given PO
1944287|NCT00810615|Other|Hyperbaric oxygen @ 2.4 ATA|Subject will breath 100% oxygen at 2.4 Atmospheres Absolute (ATA) in three 30 minute periods separated by 10 minutes of breathing air at 2.4 ATA. Hyperbaric exposures will be done up to 5 times per week with a total number of 30 exposures.
1944288|NCT00810563|Drug|Saline solution (laparoscopic tubal ligation)|5ml of saline solution in each portal of the trocar (2 portals)
1944289|NCT00810563|Drug|Bupivacaine|5ml of bupivacaine 0.5% in each trocar portal
1944290|NCT00808717|Drug|Atorvastatin|Atorvastatin 10 mg vs. 80 mg before intervention
1944291|NCT00808665|Drug|Intravenous infusion of Dexmedetomidine or 0.9% Saline|Patients will be given 0.7 mcg/kg/hr of dexmedetomidine over the first hour of surgery, followed by continuous infusion of 0.5 mcg/kg/hr of dexmedetomidine for the next 2 hours of surgery. Dexmedetomidine dose will be reduced to 0.2 mcg/kg/hr for the duration of the procedure and continued at that rate for four hours postoperatively. Patients in the placebo arm will receive an equal per-kg IV volume of 0.9% Sodium Chloride over the same periods. Drug administration will be controlled for both arms of the study using a continuous infusion pump.
1944292|NCT00808314|Drug|Rest/Dipyridamole Stress Rb-82 Myocardial Perfusion PET/CT|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 0.56 mg/kg of dipyridamole will be infused over 4 minutes. Three minutes after the completion of the infusion, approximately 60 mCi of Rb-82 will be infused. Peak stress images will be acquired with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan will be acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
1944293|NCT00808314|Drug|Rest/Lexiscan(TM) Stress Rb-82 Myocardial Perfusion PET|A CT scan will be acquired for attenuation correction of the rest image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding. This will be followed by infusion of approximately 60 mCi of Rb-82, 60 to 100 seconds after which resting images will be acquired with ECG-gating. Following rest imaging, 400 umg of Lexiscan(TM) will be injected, and then approximately 60 mCi of Rb-82 waill be infused. Peak stress images will be acquired in list mode with ECG-gating, starting 90 seconds after the the beginning of the infusion of Rb-82 and continuing for 5 minutes. A CT scan willbe acquired for attenuation correction of the stress image (9 mA, 120 kVp, 4.24 secs) during end-expiration breath-holding.
1944294|NCT00808405|Drug|acyclovir|400mg taken orally three times daily for 5 days
1944295|NCT00808405|Drug|matching placebo|matching placebo taken orally three times daily for 5 days.
1944298|NCT00807586|Drug|Solumedrol|100mg, given once within 2 hours of the end of the ablation procedure
1944299|NCT00807586|Drug|Placebo|Normal saline (1.6 cc)
1944300|NCT00806962|Drug|Adjuvant/Excipients|intranasal,14 mg chitosan, 3 mg mannitol, 3 mg sucrose and 50 mcg of MPL, 2 doses 21 days apart
1944301|NCT00806962|Device|placebo|intranasal, puff of air, 2 doses, 21 days apart
1944302|NCT00806962|Biological|Norwalk VLP Vaccine|intranasal, 50mcg, 2 doses--21 days apart
1944303|NCT00806962|Biological|Norwalk VLP Vaccine|Intranasal, 100 mcg, 2 doses, 21 days apart
1944304|NCT00806637|Procedure|Vessel sealing system uvulopalatoplasty (VSSU)|Vessel sealing system uvulopalatoplasty (VSSU) is a new technique for uvulopalatoplasty using a special biclamp forceps for better hemostasis control. Vessel sealing system (VSS) is a bipolar vascular sealing system, with integrated active feedback control. The tissue is grasped and compressed by the handpiece. After the instrument is removed, the seal is visible as a semitransparent window, which can safely be divided. Uvular tip is grasped with an Allis clamp and retracted back toward the soft palate. Excision of the uvula and the redundant part of soft palate is performed by the VSS handpiece. VSS is also used for hemostasis.
1944305|NCT00806637|Procedure|Uvulopalatal flap (UPF)|Uvulopalatal flap (UPF) is a standard uvulopalatoplasty technique. Uvulopalatal flap is usually performed as described originally by Powell et al. The soft palate was injected with 5 to 10 milliliters of 1% lidocaine with epinephrine solution. The mucosa, submucosa with glands, and fat on the lingual surface of the uvula and soft palate were removed with a scalpel. Bleeding was controlled with bipolar electrocoagulation. The uvular tip was amputated, and reflected back toward the soft palate, and fixated into its new position with multiple sutures of 3-0 chromic catgut.
1944306|NCT00806351|Drug|Active Anidulafungin|Subjects in this arm will receive active anidulafungin and placebo caspofungin
1944307|NCT00806351|Drug|Active Caspofungin|Subjects in this arm will receive active caspofungin and placebo anidulafungin
1944309|NCT00804843|Drug|Atorvastatin/niacin extended-release|80 mg tablet atorvastatin once daily, 10 mg tablet placebo to atorvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
1944310|NCT00804843|Drug|Atorvastatin|10 mg tablet atorvastatin once daily, 80 mg tablet placebo to atorvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
1944311|NCT00804843|Drug|Simvastatin|(Russia and Brazil) 80 mg tablet simvastatin once daily, 10 mg tablet placebo to simvastatin once daily, and niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
1944312|NCT00804843|Drug|Simvastatin|(Russia and Brazil) 10 mg tablet simvastatin once daily, 80 mg tablet placebo to simvastatin once daily, and placebo to niacin extended-release tablet starting at 500 mg daily and titrating to 2g daily. Treatment will be from 4 to 12 weeks.
1944344|NCT00800930|Biological|Sodium Butyrate|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of butyrate solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
1944313|NCT00804609|Drug|DepoDur following epidural lidocaine|"All participant underwent cesarean delivery. An epidural top-up anesthetic consisting of 2% lidocaine with epinephrine 1:200,000 and sodium bicarbonate (1 meq per 10 mL lidocaine) was given. The lidocaine solution was administered in 5 mL increments every 2.5 minutes until a T6 sensory level to touch was attained. Patients also received a 100 mcg dose of fentanyl epidurally after the lidocaine solution had been administered.
Provided delivery had occurred at least 60 minutes after the initial lidocaine administration, patients received EREM 8 mg (DepoDur™) administered through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug administration."
1944314|NCT00804609|Drug|DepoDur following spinal anesthetic|"Participants underwent an elective cesarean delivery with a combined spinal/epidural. All patients received 12 mg hyperbaric bupivacaine with 20 mcg fentanyl administered intrathecally. No local anesthetic was administered through the catheter. The combined spinal-epidural was performed at the L2/L3 or L3/L4 interspace and the intrathecal dose was injected over 5-10 s. A multiple orifice epidural catheter was threaded 5 cm into the epidural space.
Provided delivery had occurred 60 minutes after the intrathecal dose patients received EREM 8 mg (DepoDur™) through the epidural catheter. A 2 mL epidural saline flush was administered before and after drug."
1944315|NCT00805532|Behavioral|Behavioral Activation treatment|Behavioral Activation (BA)- modified to be delivered in 6-8, 60 minute sessions in a primary care setting. BA has also been modified to better address PTSD concerns
1944316|NCT00805532|Other|Usual VA Treatment for PTSD|Usual Care for PTSD (UC)-that is provided in the VA PTSD Specialty clinics. Actual clinical practice varies between sites and between providers within sites, as is typical of the VA health care system. Subjects assigned to Usual Care will be permitted to receive medical intervention (i.e., pharmacotherapy) and any additional psychotherapy deemed appropriate by the provider. They will also be offered a minimum of 6 sessions of individual therapy.
1944320|NCT00805558|Drug|moxifloxacin|400 mg moxifloxacin once daily for 7 days
1944321|NCT00805558|Drug|Ciprofloxacin plus metronidazole|Ciprofloxacin 1000 mg once daily for 7 days; Metronidazole 500 mg twice daily for 7 days
1944322|NCT00804115|Drug|Latanoprost with Pilocarpine vs Timolol or Cosopt|Timolol 0.5% bid or Cosopt bid Latanoprost 0.005% qhs Pilocarpine 2%
1944323|NCT00804102|Device|Transcorneal Electrical Stimulation|Neurostimulator drives Dawson-Trick-Litzkow electrode attached to patient eye. Different modi are used to stimulate patients.
1944324|NCT00804102|Device|DTL-electrode attached without energy|DTL-electrode attached to patient eye receives no energy from neurostimulator. Treatment times remain the same as used for each treatment arm.
1944325|NCT00802516|Dietary Supplement|stanol ester|enriched margarine
1944326|NCT00802516|Dietary Supplement|sterol ester|enriched margarine
1944327|NCT00802516|Dietary Supplement|No intervention|placebo margarine
1944333|NCT00802763|Device|NORMA-SENSE|Should be used by the clinician. the test usage will take up to 6 hours. The result reading will take few second.
1944336|NCT00802113|Drug|Fludarabine and Busulfan|Fludarabine 30 mg/m2 x 5 days Busulfan 3.2 mg/kg/day x 2 days GVHD Prophylaxis with MMF and FK506
1944337|NCT00802113|Drug|Fludarabine, Busulfan and ATG|Fludarabine 30 mg/m2 x 5 days Busulfan 3.2 mg/kg/day x 2 days Anti-Thymocyte Globulin 2.0 mg/kg/day x 4 days GVHD Prophylaxis with MMF and FK506
1944338|NCT00801931|Drug|TBI, Thiotepa, Cyclophosphamide, ATG|APatients will start their pre-conditioning regimen on Day -8. Fractionated TBI will be administered twice daily for 3 days on Days -8, -7, and -6. Patients will receive Thiotepa on Days -5 and-4, Cyclophosphamide on Days -3 and -2 and- rabbit antithymocyte globulin on Days -4, -3, -2 and -1The double cord blood infusion will be performed on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
1944339|NCT00801931|Drug|Busulfan, Melphalan, Rabbit ATG|Patients will start their pre-conditioning regimen on Day -9. Patients will receive busulfan twice daily on Days - 8, -7, -6, and -5 and Melphalan on Days -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2 and -1 with double cord blood infusion on Day 0. GM-CSF hematopoietic growth factor will start on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
1944340|NCT00801931|Drug|Busulfan, Fludarabine, Alemtuzumab|Patients will start their GVHD prophylaxis with Tacrolimus on Day -8. Patients will receive busulfan twice daily on Days -8, -7, -6, and -5; fludarabine on Days -7, -6, -5, -4, -3 and -2 and alemtuzumab on Days -5, -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
1944341|NCT00801931|Drug|Busulfan, Fludarabine, Rabbit ATG|Patients will start their GVHD prophylaxis with Tacrolimus on Day -6. Patients will receive busulfan twice daily on Days -6, and-5; fludarabine on Days -6, -5, -4, -3 and -2 and rabbit antithymocyte globulin on Days -4, -3, -2, and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
1944342|NCT00801931|Drug|Fludarabine, Cyclophosphamide, ATG|Patients with Fanconi's Anemia will start their pre-conditioning regimen on Day -6. Patients will receive TBI as a single fraction on Day -6. Patients will receive fludarabine and cyclophosphamide on Days - 5, -4, -3, and -2 and anti-thymocyte globulin (horse) on Days -5, -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
1944343|NCT00801931|Drug|Busulfan, Cyclosphosphamide, Rabbit ATG,|Patients with Selected Hemoglobinopathies and non-malignant diseaseswill begin fosphenytoin or phenytoin prophylaxis on Day -10. Patients will receive busulfan on days -9, -8, -7 and -6, cyclophosphamide on days -5, -4, -3, and -2 and rabbit antithymocyte globulin on days -4, -3, -2 and -1. The double cord blood infusion will be performed on Day 0. GVHD prophylaxis will consist of tacrolimus/MMF.
1945187|NCT00622895|Drug|tacrolimus|Given PO
1944345|NCT00800930|Biological|Saline|Patients will be instructed to lie on a bed (cholera cot) in left lateral position. A soft rectal catheter will be introduced by a nurse/physician, through which 80 ml of saline solution will be instilled slowly with a 50 ml plastic syringe. Patients will be asked to retain the enema for at least ½ hour by remaining supine for 30 minutes after the administration. However, if a patient cannot retain the enema for 30 minutes, he will be given a second round of enema immediately after defecation.
1944346|NCT00799617|Drug|AndroGel® (testosterone gel)|Testosterone levels will be measured at regular intervals in order to achieve a testosterone level in the desired range.
1944347|NCT00799617|Drug|Placebo|Testosterone levels will be measured at regular intervals.
1944348|NCT00798694|Drug|Xalatan|one drop of Xalatan Ophthalmic Solution instilled in right eye at bedtime
1944349|NCT00798694|Drug|Travatan Z|one drop of Travatan Z Ophthalmic Solution instilled in left eye at bedtime
1944351|NCT00797953|Drug|T89|A two-herb botanical drug product in 62.5mg capsule formulation. It is to be used as 125mg or 187.5mg twice daily.
1944352|NCT00797160|Drug|propofol|2mg/Kg IV in bolus before tracheal intubation
1944353|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'high target' study dose, which is estimated to be 800 picograms/ml
1944354|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day(every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'medium target' study dose, which is estimated to be 400-600 picograms/ml
1944355|NCT00796289|Drug|GnRH iontophoretic transdermal Lutrepatch|10 mg GnRH iontopheretic transdermal patch. A new patch is applied two times each day (every 12 hours). Delivery current and membrane thickness adjusted to deliver the 'low target' study dose, which is estimated to be 200 picograms/ml
1944356|NCT00796289|Drug|clomiphene citrate|Oral, 50 mg daily for 5 days
1944357|NCT00796289|Drug|placebo clomiphene citrate|oral, taken for 5 days
1944358|NCT00796289|Drug|placebo GnRH patch|Placebo transdermal patch with a high target delivery of placebo(every 90 minutes). New patch to be applied every 12 hours.
1944359|NCT00796861|Drug|Sunitinib|Patients will be given Sunitinib 50 mg orally daily for four weeks, followed by a two week holiday. For patients tolerating treatment, three cycles of treatment will be given (18 weeks total).
1944360|NCT00796445|Drug|GSK 2132231A|IM solution, a course of 13 injections will be administered over 27 months
1944361|NCT00796445|Drug|Placebo|IM solution, a course of 13 injections will be administered over 27 months
1944362|NCT00796354|Drug|MOVICOL|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
1944363|NCT00796354|Drug|Sugar Pill|sealed laminated sachet, 1 - 3 sachets daily for 4 weeks
1944364|NCT00796341|Procedure|PIPELLE ENDOMETRIAL SAMPLING|Pipelle endometrial sampling will be done twice between 7th to 10th day and 24th to 26th d in the cycle prior to IVF.
1944365|NCT00795977|Biological|dendritic cells, OK-432|Single Group Assignment
1944366|NCT00795275|Drug|Januvia (sitagliptin phosphate)|Januvia 100 mg po qd x 28 days for all subjects after baseline measures made
1944367|NCT00795236|Drug|Melatonin|One 0.5 mg tablet of melatonin will be taken by subjects who are free-running and willing to enter the intervention phase of the study. These subjects will take melatonin until entrainment status is confirmed or throughout the duration of the study.
1944368|NCT00794222|Device|Mobile Tracking Young People's Experiences (mobiletype)|A mobile phone self-monitoring program, based on momentary sampling techniques, that prompts young people to complete it four times a day. The program asks several questions about daily activities, mood, stress, eating and exercise.
1944369|NCT00794859|Drug|Sorafenib|400mg twice daily
1944370|NCT00793780|Drug|Naltrexone 25mg|Naltrexone 25mg caplets taken orally once a day for 8 weeks
1944371|NCT00793780|Other|Placebo|Placebo caplet (inactive substance) taken orally once a day for 8 weeks
1944374|NCT00792909|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose
1944375|NCT00792909|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 2 doses
1944376|NCT00790959|Behavioral|SASA!|"A community mobilization approach to try to change community and individual attitudes and behaviours that support both the perpetration of violence against women and HIV risk behaviours
The intervention team engages with four major groups of actors: community volunteers selected from the general public; community leaders (e.g. religious, cultural and local council leaders); resource persons (health care providers, police, etc); and institutional leaders. The community volunteers are a key component of the intensive intervention."
1944377|NCT00790959|Other|Control|"Control communities will receive the full SASA! intervention after completion of the SASA! Study.
For the duration of the study, they will receive a less intensive intervention comprising the Division-level elements of SASA! (involving community leaders, resource persons and institutional leaders) without the community volunteers."
1944378|NCT00790868|Drug|d-cycloserine|50mg
1944379|NCT00790868|Drug|placebo|50mg
1944380|NCT00790699|Device|I-PORT|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
1944381|NCT00790699|Other|standard injections|The study will compare injecting Symlin and insulin into a multiple injection port (I-PORT) vs. standard injections.
1944382|NCT00790582|Drug|lithium carbonate|The dosage of lithium carbonate will be adjusted for each individual. The maximum dose is 450mg/day.
1944383|NCT00790530|Behavioral|Automated Telephone Outreach with Speech Recognition|Automated Telephone Outreach with Speech Recognition
1944384|NCT00790530|Other|Usual Care|Usual Care
1944385|NCT00788502|Behavioral|Healing Touch|
1944386|NCT00788502|Behavioral|Desensitization Therapy|
1944387|NCT00788502|Behavioral|Standard Care|
1944388|NCT00789360|Drug|Placebo -- Active|Placebo followed by Active (Staccato Loxapine, 10 mg x 2)
1944389|NCT00789360|Drug|Active -- Placebo|Active (Staccato Loxapine, 10 mg x 2) followed by Placebo
1944390|NCT00788905|Device|Allient System|The Allient System uses a different type of blood pump and a lower volume of dialysate.
1944399|NCT00786409|Biological|Gardasil|0.5 ml Gardasil vaccine will be administered to each patient at months 0,2 and 6.
1944400|NCT00786123|Dietary Supplement|VSL#3|Dose: 4 capsules of VSL#3 daily for 6 weeks.
1944401|NCT00786123|Dietary Supplement|Placebo|Identical looking preparation of placebo taken at the same dose regimen as the active comparator
1944402|NCT00785174|Device|continuous positive airway pressure|respiratory assistance using face mask and positive expiratory pressure apllied by a Boussignac valve
1944403|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation can provide inspiratory pressure support and expiratory positive pressure
1944404|NCT00785174|Device|noninvasive pressure support ventilation|noninvasive pressure support ventilation provides an inspiratory aid and positive expiratory pressure using ventilator through face mask
1944405|NCT00784524|Biological|allogeneic large multivalent immunogen breast cancer vaccine|Allogeneic large multivalent immunogen breast cancer vaccine (1 x 10^7, 5-μm silica spheres) will be given as an intradermal injection every 28 days (+/- 3 days). Each vaccine dose will be 0.2 ml.
1944406|NCT00784524|Biological|aldesleukin|Subcutaneous aldesleukin (10 x 10^6 International Units) will be given on day 7 and day 8 after each LMI injection.
1944407|NCT00784758|Device|Fenzian Device|Three 20-minute treatments with the Fenzian Device per week for 5 weeks (for a total of 15 treatments)
1944408|NCT00784758|Device|Sham Device|Three 20-minute treatments with the sham device per week for 5 weeks (for a total of 15 treatments) (NOTE: This arm is similar to a placebo arm in a drug trial.)
1944409|NCT00784303|Drug|E7080|E7080 given orally continuously at 24 mg, once a day.
1944411|NCT00783263|Drug|Comparator: rosuvastatin 5 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 5 mg rosuvastatin for an additional 6 weeks.
1944412|NCT00783263|Drug|Comparator: rosuvastatin 10 mg|Participants who received open label rosuvastatin 5 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 10 mg once daily for 6 additional weeks.
1944413|NCT00783263|Drug|Comparator: rosuvastatin 10 mg + ezetimibe 10 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received 10 mg ezetimibe tablets once daily plus 10 mg rosuvastatin for an additional 6 weeks.
1944414|NCT00783263|Drug|Comparator: rosuvastatin 20 mg|Participants who received open label rosuvastatin 10 mg tablets once daily for 4 to 5 weeks then received rosuvastatin 20 mg once daily for 6 additional weeks.
1944415|NCT00782548|Drug|morphine sulfate sustained-release capsules|Capsules, 30 mg
1944420|NCT00781742|Drug|AZD6765|IV once per dosing day, multiple times during the treatment period
1944421|NCT00781742|Drug|Placebo|0.9% saline IV once per dosing day multiple times during the treatment period
1944422|NCT00781495|Device|Sensewear Bodymedia armband|To assess physical activity levels patients will wear Sensewear bodymedia armband
1944427|NCT00781287|Drug|3-drug anti-HIV therapy|3 FDA-approved drugs, including two nucleos(t)ide reverse transcriptase inhibitors and either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor (Low dose ritonavir can be used to enhance the protease inhibitor and is not considered one of the 3 anti-HIV drugs)
1944428|NCT00781287|Drug|Raltegravir|400 mg BID PO
1944429|NCT00780962|Drug|N-Acetycysteine (NAC)|"Experimental: 3 g NAC IV in 500 cc Normal Saline (NS) before CT, followed by 200 mg NAC/hour in NS at 67 cc/hour for up to 24 hours after CT.
Placebo: 500 cc NS before CT, followed by NS at 67 cc/hour after CT"
1944430|NCT00779402|Other|Placebo|Non autologous PAP loaded dendritic cells
1944431|NCT00779402|Biological|Provenge|Biologic: Immunotherapy with PAP loaded dendritic cells.
1944432|NCT00779324|Drug|Amantadine Hydrochloride|100 mg every morning and noon
1944433|NCT00779324|Drug|Placebo|one placebo tablet every morning and 12 Noon
1944434|NCT00777101|Drug|Neratinib|Tablets, 240mg once per day until disease progression or unacceptable toxicity
1944435|NCT00777101|Drug|Lapatinib|Tablets 1250mg once per day until disease progression or unacceptable toxicity.
1944436|NCT00777101|Drug|Capecitabine|Tablets 2000mg/m2 given in two evenly divided daily doses for first 14 days of each 21 day cycle. Given until disease progression or unacceptable toxicity.
1944480|NCT00770094|Device|Excimer Laser for the LASIK procedure|WaveLight ALLEGRETTO WAVE™ wavefront guided excimer laser treatment Bausch and Lomb Zyoptix™ wavefront guided Excimer Laser System
1945021|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 220 micrograms sirolimus each.
1944437|NCT00775931|Procedure|umbilical cord blood transplantation|Umbilical cord blood will be collected, processed and shipped according to existing protocols. 2 cord blood units will be utilized if available. The choice of units will be based on the HLA typing standards of the University of Minnesota Blood and Marrow Program. If 2 units are not available, a single unit may be used. If a single unit is used, the unit should provide at least 10 x 107 nucleated cells/kg recipient body weight.
1944438|NCT00775931|Drug|Campath-1H|Campath-1H will be administered 0.3 mg/kg subcutaneously per day for three days starting on Day -21 through Day -19.
1944439|NCT00775931|Radiation|Total Lymphoid Irradiation|Dose 500 cGy via anteroposterior (AP) and posteroanterior(PA) fields (250 cGy AP and 250 cGy PA).
1944440|NCT00775931|Drug|Cyclophosphamide|Cyclophosphamide (50 mg/kg/dose) will be given IV on day -4, -3, -2 and -1 over 2 hours. The total dose to be given over 4 days is 200 mg/kg for cord blood grafts-receiving patients only.
1944441|NCT00775931|Drug|Busulfan|patients<12 kg: 1.1 mg/kg/dose IV every 6 hours for 8 doses total; patients >12 kg: 0.8 mg/kg/dose IV every 6 hours for 8 doses. on Day -8 to -7 for donor grafts-receiving patients, and on Day -9 to -6 for cord blood grafts-receiving patients.
1944442|NCT00775931|Drug|Fludarabine monophosphate|Fludarabine (35 mg/m2 daily for 5 days, 175 mg/m2 total) will be administered IV over 30 minutes on days -6, -5, -4, -3, and -2 for donor grafts-receiving patients only.
1944443|NCT00775931|Procedure|marrow graft transplantation|Related donor marrow will be collected, processed and shipped according to existing protocols of the National Marrow Donor Program or other URD registry, with the goal of achieving a cell dose of ≥ 6.0 x 108 nucleated cells/kg. The proportion of cells that are CD34+ will be determined prior to the administration of the graft. This will allow a portion of the graft (2 x 106 CD34+ cells) to be frozen for a subsequent infusion on day +42.
1944447|NCT00774566|Procedure|PV-Isolation RF|Radiofrequency
1944448|NCT00774566|Procedure|PV-Isolation Cryo|Cryo-Balloon
1944449|NCT00774228|Device|I-ZIP Ocular Bandage|
1944450|NCT00774228|Device|Oasis 24 Hour Soft Shield Collagen Corneal Shield|
1944451|NCT00774202|Drug|Rituxan and Cyclophosphamide, Vincristine and Prednisone|'Rituxan and Cyclophosphamide, Vincristine and Prednisone' Interventions are as follows: Rituximab will be administered as an IV infusion at the standard dose of 375 mg/m2 for 4 doses. However, the schedule of the infusions will be different than the usual one: Rather than administrating the 4 doses once weekly, the first infusion will be given 5 days (± 3 days) prior to the first CVP, and the following 3 infusions will be given on the same day as the 3 cycles of CVP.
1944452|NCT00774202|Drug|Higher Dose of Rituximab|
1944453|NCT00774059|Device|Breast lift system|During a breast operation for ptosis a device is brought into the breast and attached to the ribs, to provide lifting of the breast
1944454|NCT00773058|Drug|hydrocortisone|hydrocortisone 100mg q8h
1944455|NCT00773058|Drug|placebo|normal saline 100ml q8h
1944456|NCT00772551|Drug|Raltegravir and ezetimibe|Group 1: raltegravir 400 mg orally twice daily for 10 days followed by 10 days of raltegravir 400 mg twice daily and ezetimibe 10 mg orally once daily for 10 days followed by a 10 days wash out period and ezetimibe 10 mg once daily for 10 days
1944457|NCT00772551|Drug|Ezetimibe and raltegravir|Group2: ezetimibe 10 mg orally once daily for 10 days followed by ezetimibe 10 mg and raltegravir 400 mg orally twice daily for 10 days followed by a 10 days wash out period and raltegravir 400 mg twice daily for 10 days
1944461|NCT00771667|Drug|Placebo (IP)|Induction phase (Week 0-8) (IP) - Placebo IV group
1944462|NCT00771667|Drug|Ustekinumab 1mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 1 mg/kg IV group
1944463|NCT00771667|Drug|Ustekinumab 3 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 3mg/kg IV group
1944464|NCT00771667|Drug|Ustekinumab 6 mg/kg (IP)|Induction phase (Week 0-8) (IP) - Ustekinumab 6mg/kg IV group
1944465|NCT00771667|Drug|Placebo IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
1944466|NCT00771667|Drug|Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Placebo IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 270 mg SC at Week 8 and 90 mg at Week 16
1944467|NCT00771667|Drug|Ustekinumab IV - Responder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Placebo SC at Week 8 and Week 16
1944468|NCT00771667|Drug|Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Responder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
1944469|NCT00771667|Drug|Ustekinumab IV - Nonresponder - Placebo SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Placebo SC at Week 8 and Week 16
1944470|NCT00771667|Drug|Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)|Maintenance phase (Week 8-36) (MP) - Receiving Ustekinumab IV at Week 0 - Nonresponder at week 6 - Receiving Ustekinumab 90 mg SC at Week 8 and Week 16
1944471|NCT00770341|Drug|Daptomycin 4 mg/kg|MK3009 (daptomycin) once daily by intravenous (IV) drip, 4 mg/kg for 7-14 days for skin and soft tissue infections (SSTI)
1944472|NCT00770341|Drug|Comparator: vancomycin|vancomycin 1g, twice daily (b.i.d.) by IV drip, for 7-14 days
1944473|NCT00770341|Drug|Daptomycin 6 mg/kg|MK-3009 (daptomycin) once daily by intravenous drip, 6 mg/kg for 14-42 days for septicemia or right-sided infective endocarditis
1944481|NCT00770094|Device|Excimer Laser for LASIK|WaveLight ALLEGRETTO WAVE™ wavefront optimized excimer laser treatment Bausch and Lomb Planoscan™ Excimer Laser System
1944482|NCT00769600|Drug|Itraconazole|Itraconazole 200 mg once daily
1944483|NCT00769600|Drug|Pemetrexed|
1944484|NCT00769392|Drug|Proparacaine|Drops of Proparacaine on the eye, administered as described in the package insert
1944485|NCT00769392|Drug|Tetracaine|Drops of Tetracaine on the eye, administered as described in the package insert
1944486|NCT00769392|Drug|Lidocaine|A cotton sponge(pledget)soaked with Lidocaine 4% placed over the conjunctiva
1944487|NCT00769392|Drug|Lidocaine|A subconjunctival injection of Lidocaine 2%
1944488|NCT00768469|Drug|HKI-272 + Paclitaxel|HKI-272: 240 mg, continuous daily OD Paclitaxel: 80 mg/m2 IV, day 1, 8, 15 of 28 day cycle
1944489|NCT00769002|Biological|FluShield, FluMist|Flu vaccine
1944490|NCT00768183|Other|KADIAN + Ethanol|Capsules 100 mg + 240 mL 40% ethanol in 4 shots of 60 mL
1944491|NCT00768183|Other|KADIAN + Water|Capsules 100mg + 240 mL in 4 shots of 60 mL
1944492|NCT00768183|Other|morphine sulfate IR oral solution + water|Solution 20mg/5mL, 235 mL of water in 1 shot of 55 mL (+ 5mL IR morphine) + 3 shots of 60 mL of water
1944493|NCT00767949|Biological|iSONEP|single intravitreal injection of 0.2, 0.6, 1.0, 1.4 or 1.8 mg/eye
1944494|NCT00765791|Procedure|Selective Neck Dissection Including Level IIB|Level IIB is dissected
1944495|NCT00765791|Procedure|Selective Neck Dissection Excluding Level IIB|Level IIB is not dissected
1944496|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 440 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
1944497|NCT00766337|Drug|Sirolimus in combination with ranibizumab|Combination therapy of 1320 micrograms sirolimus injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
1944498|NCT00766337|Drug|Placebo in combination with ranibizumab|Combination therapy of placebo injected subconjunctivally and 500 micrograms ranibizumab injected intravitreally over a 60 day treatment period.
1944499|NCT00765583|Drug|Restylane|Treatment of the nasolabial folds with Restylane at Day 0/Baseline, Month 4.5, Month 9 and Month 18.
1944501|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
1944502|NCT00765869|Other|Bowel cancer screening decision aid|A decision aid developed for adults with low levels of education and literacy making decisions about bowel cancer screening, using faecal occult blood test (FOBT)
1944503|NCT00765869|Other|Australian Government Bowel Cancer Screening booklet|A consumer booklet developed by the Australian Government for people taking part in the National Bowel Cancer Screening program
1944504|NCT00766168|Other|HDS HI 1.54; pahrifocon A|Contact Lens
1944505|NCT00766168|Device|FluoroPerm 30 RGP; paflufocon C|Contact lens daily wear
1944510|NCT00764699|Drug|rhIGF (Increlex)|rhIGF will be administered as a subcutaneous injection per the following schema: First 2 weeks: 40 mcg/kg BID; Weeks 3 and 4: 80 mcg/kg BID; Subsequent weeks: 120 mcg/kg BID.
1944511|NCT00763633|Drug|vitamin B6|high dose of vitamin B6
1944512|NCT00763633|Drug|vitamin B6|low vitamin B6
1944513|NCT00763880|Drug|Lidocaine|2% Lidocaine (no epinephrine) in the dose of 2.5 mg/kg to a maximum of 10mL will be instilled once into the fracture site in the form of a hematoma block.
1944514|NCT00763880|Drug|Saline|Volume of normal saline equivalent to providing 2.5mg/kg of 2% lidocaine, to a maximum of 10mL.
1944515|NCT00761891|Drug|Enteric-coated aspirin|enteric-coated aspirin 81mg daily for 2 weeks
1944516|NCT00761891|Drug|Chewable aspirin|chewable aspirin 81mg daily for 2 weeks
1944517|NCT00761280|Drug|trabedersen|
1944518|NCT00761280|Drug|temozolomide|
1944519|NCT00761280|Device|Drug delivery system for administration of AP 12009|Drug delivery system for Convection Enhanced Delivery consists of a portable pump (Pegasus vario or Pega vario) with drug reservoir (Pega Bag) and infusion line (Pega Line). Main implanted parts are the port access system (PORT-A-CATH) and the intratumoral catheter (Medtronic ventricular catheter).
1944520|NCT00761280|Procedure|Placement of Drug Delivery System|Surgery for placement of intratumoral catheter and subcutaneous port access system as per routine clinical practice. Stereotactical catheter placement controlled by CT.
1944521|NCT00761280|Drug|carmustine|
1944522|NCT00761280|Drug|lomustine|
1944523|NCT00759109|Biological|Peginterferon alfa-2b|Peginterferon alfa-2b, 50 μg, weekly, SC, for a period of 3 years.
1944524|NCT00759109|Other|Observation (no treatment)|No treatment was given to participants enrolled in the control arm (Arm B).
1944525|NCT00759408|Drug|BQ-123|6-120 µg/min
1944526|NCT00758264|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection.
1944527|NCT00758264|Biological|Pneumococcal vaccine GSK1024850A|Single dose intramuscular injection.
1944528|NCT00757523|Drug|Epiduo Gel|Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
1944529|NCT00757523|Drug|Duac Gel|Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
1944530|NCT00756938|Drug|losartan potassium|losartan potassium, dry powder, to be suspended in liquid and given orally, once daily; doses will start at 0.1 mg/kg, 0.3 mg/kg, and 0.7 mg/kg, respectively, in the three study arms and can be escalated up to 1.4 mg/kg (maximum dose 100 mg) until target blood pressure is reached.
1944781|NCT00706446|Drug|tiotropium bromide|tiotropium bromide one inhalation a day for one year, along with inhaled steroids at variable dosing based on patient's prior inhaled steroid dosing and treating physician's judgement.
1945022|NCT00656643|Drug|Sirolimus|Two subconjunctival injections of 880 micrograms sirolimus each.
1944531|NCT00756275|Drug|Nicotine Replacement Treatment (NRT)|Nicotine replacement treatment (NRT) will follow the clinical practice guidelines for nicotine patch for people smoking at least 10 cigarettes per day (USDHHS, 2000), modified to allow 12 weeks use (tapering recommended for people with AUDs by Hughes et al., 2003b): 21 mg/day for 4 weeks, 14 mg/day for 4 weeks, 7 mg/day for 4 weeks.
1944532|NCT00756275|Drug|varenicline|Varenicline (VAR, 2 mg/d in divided doses) will be administered as follows. VAR: participant takes 0.5 mg/d for the first 3 days, 1 mg/d (0.5 mg 2x/d) for the next 4 days, and 2mg/d (1.0mg 2x/d) for 12 weeks.
1944533|NCT00756275|Behavioral|Behavioral counseling for smoking cessation|The counseling consists of 10 sessions of Brief Advice (BA).BA is a simple smoking cessation counseling strategy: Assess smoking and initial interest in cessation, advise patient to quit smoking, assist patient in quitting, discussion of sobriety specific concerns, and cognitive-behavioral skills training. Medication management is conducted in every session, smoking cessation pamphlets are available. Session 1 (60 min, in-person) will be 1 week before Quit Day.Session 2 (30 min, in-person) takes place on Quit Day. Session 3 (10 min, in-person) will be 1 week later. Sessions 4-10 will be 5-10 min. telephone contacts at Weeks 2, 3, 4, 6, 8, 10, and 12 after Quit Day.
1944534|NCT00756275|Drug|Placebo patch|Commercially available matched placebo patches will be used for 12 weeks.
1944535|NCT00756275|Drug|Placebo|The placebos use identical opaque capsules to the varenicline condition, containing inert filler. Participant takes 1 placebo capsule per day for the first 3 days and 2 per day for 4 days and 12 weeks.
1944536|NCT00755716|Drug|Placebo (sugar pill)|patients receive
1944537|NCT00755716|Drug|Topiramate|25 mg per day for one week, 50 mg per day for one week, 100 mg per day for one week, 200 mg per day for 5 weeks, then one week taper
1944538|NCT00755716|Drug|Nicotine patch|On the quit date (after 2 weeks of Topiramate medication use), subjects also use 21 mg patch for 7 weeks and on week 8 subjects received 14 mg/day for 3 days then 7 mg for 4 days.
1944539|NCT00754845|Drug|letrozole|Given orally
1944540|NCT00754845|Other|placebo|Given orally
1944541|NCT00754819|Drug|Colchicine|1mg once daily
1944542|NCT00754819|Drug|Placebo|1 capsule daily
1944543|NCT00753935|Drug|aspirin|enteric-coated aspirin 81mg daily for 2 weeks
1944544|NCT00753935|Drug|aspirin|chewable aspirin 81mg daily for 2 weeks
1944545|NCT00754000|Other|Observation|AE monitoring and EPIC QOL survey
1944546|NCT00753402|Biological|Endotoxin, Lipopolysaccharide, LPS|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes)
1944547|NCT00753402|Biological|Endotoxin, Epinephrine|Clinical Center Reference Endotoxin, lot 2, sterile saline, 2 ng/kg, bolus IV administration (~5 minutes/Epinephrine 30mcg/kg/min
1944548|NCT00752869|Drug|dutasteride|0.5mg by mouth one time per day for 1 year
1944549|NCT00752869|Drug|placebo|one tablet per day for 1 year
1944550|NCT00752037|Drug|lopinavir/ritonavir and raltegravir|lopinavir/ritonavir 400/100 mg po b.id. in combination with raltegravir 400 mg po b.i.d.
1944551|NCT00752557|Drug|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 1.0 mg/mL.
1944552|NCT00752557|Drug|rhBMP-2/CPM injection and bisphosphonates, calcium, and vitamin D (oral bisphosphonate therapy)|Single, unilateral intraosseous injection of 6mL of rhBMP-2/CPM , 2.0 mg/mL.
1944553|NCT00752557|Drug|bisphosphonates, calcium, and vitamin D|Oral bisphosphonate therapy
1944556|NCT00752089|Drug|NaF/ KNO3/isopentane Dentifrice|Experimental toothpaste
1944557|NCT00752089|Drug|NaF/KNO3 Dentifrice|Experimental toothpaste
1944558|NCT00752089|Drug|NaF Dentifrice|Active comparator
1944559|NCT00752089|Other|Placebo Dentifrice|Placebo comparator
1944560|NCT00751855|Behavioral|Prolonged Exposure therapy|10 weekly sessions
1944561|NCT00751855|Drug|Hydrocortisone|30mg 45 minutes prior to each PE session including imaginal exposure (8 total)
1944562|NCT00751855|Drug|placebo|placebo
1944563|NCT00751907|Drug|atorvastatin|40mg daily for 4 months
1944564|NCT00751907|Drug|Placebo|Matching placebo daily for 4 months
1944565|NCT00751491|Drug|Adenosin|Intracoronary Adenosin 50 microg;
1944566|NCT00751491|Other|placebo|no intervention
1944567|NCT00751491|Drug|Clopidogrel|Clopidogrel 300/600 mg
1944571|NCT00750217|Drug|Buprenorphine patch and sublingual tablets|"Buprenorphine patch: 35 micro grams per hour 12 to 48 hours after last methadone intake.
Buprenorphine sublingual tablets: 2mg 48 and 60 hours after last methadone intake; 8mg 72 and 84 hours after last methadone intake; 8mg 96, 102 and 109 hours after last methadone intake."
1944572|NCT00750503|Behavioral|Behavioural and Pharmacotherapy for tobacco cessation|Professional help in the form of health awareness sessions, focus group discussion, one to one counseling and pharmacotherapy was provided to the employees by a team of doctors and counselors from Tata Memorial Hospital. Self reporting of tobacco history was validated with Rapid Urine cotinine test. Naked eye examination of oral cavity of all employees for detection of oral pre-cancers and cancers was conducted. Nursing staff and Doctors attached to the industry and from the local referral hospital were invited to participate as trainees during the active intervention sessions for local manpower development.
1944573|NCT00749203|Drug|Midazolam|single dose 0.045 mg/kg IV infused over 40 minutes
1944574|NCT00749203|Drug|Ketamine|Single dose 0.5 mg/kg IV (in the vein) infused over 40 minutes
1944869|NCT00688376|Drug|Placebo|"During the 12-week Double-Blind Phase, subjects will receive matching placebo tablets (3, 5, of 10 mg) once daily.
During the 12-week Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
1944575|NCT00749879|Drug|Proellex®|25 mg capsule administered once orally after subjects have been fed; 25 mg capsule administered once orally while subjects are fasting; 2, 25 mg capsules administered once orally after subjects have been fed; 2, 25 mg capsules administered once orally while subjects are fasting; and 2, 25 mg capsules administered once orally while subjects are fasting
1944576|NCT00749125|Drug|Escalitopram|10 mg by mouth once per day for first 2 weeks, with psychiatric re-evaluation every 2 weeks to determine if any change in dosage is required, with a maximum of 20 mg per day
1944579|NCT00749515|Drug|Deferoxamine|After a 3-day washout period from all chelation, all patients have a 12 hour infusion of 50mg/kg of deferoxamine with urine collection and pre and post blood sampling to assess iron and TIBC by atomic absorption.
1944580|NCT00749515|Drug|Deferasirox|After a 3-day washout period from all chelation, patients had a desferal challenge which was followed by a single dose of deferasirox, 35mg/kg orally with blood sampling taken pre-deferasirox and at intervals for 24 hours after the dose.
1944581|NCT00749515|Radiation|HIDA|All patients had a HIDA scan to assess physiologic liver clearance capacity.
1944582|NCT00749411|Drug|Placebo|matching placebo
1944583|NCT00749411|Drug|GSK233705/GW642444|The combination of the long-acting muscarinic antagonist GSK233705 and the long acting beta agonist GW642444 in a single inhaler.
1944584|NCT00749801|Drug|Nattokinase|2 capsules in the morning and before bed-time daily
1944585|NCT00748410|Drug|SB-656933|7 days repeat dose
1944586|NCT00748306|Drug|GSK2190915 - 100mcg|GSK2190915 is a high affinity 5-lipoxygenase-activating protein (FLAP) inhibitor
1944587|NCT00748306|Drug|Placebo|Matching Intervention Drug
1944588|NCT00748137|Device|ezy-BICC dose calculation card|small laminated table lists the dose of insulin to administer based on BGL and carbohydrate to be consumed - individualised for each study subject
1944589|NCT00748137|Other|Fixed dose|Approach where study subject is prescribed a set amount of carbohydrate to eat each meal and set dose of rapid acting insulin. Minor modifications may be made if the measured BGL is out of target
1944590|NCT00747773|Device|CryoSpray Ablation System|"CSA Medical, Inc. (formerly CryMed Technologies, Inc.) received FDA market clearance for the CSA System (CryoSpray AblationTM System, formally Cryo Ablator System) on April 21, 2006. It is a Class II device intended to be used as a cryosurgical tool for the destruction of unwanted tissue in the field of general surgery, specifically for endoscopic applications (K070893). As defined by the FDA, the CSA System is a cryosurgical unit with a liquid nitrogen cooled cryocatheter and accessories used to destroy tissue during surgical procedures by applying extreme cold"
1944591|NCT00746408|Other|Expert system guided tailored information|The prototype is realised by a web-based information system. The HTML web-interface guides the user through the search process by querying the information demand. This is done by an integrated expert system. The expert system uses a rule based inference to determine an internal diagnosis. Based on this internal diagnosis the system searches quality labeled websites and presents relevant information to the user.
1944592|NCT00746603|Drug|Simvastatin|All patients will start at 10mg of simvastatin, and then, based on results of interim evaluation escalated to 20mg and then 40. Patients will stay on maximally tolerated dose of drug until the end of the study at 26 weeks.
1944593|NCT00746252|Drug|risperidone|Children will have a flexible dose titration based on their unique response to the medication (assessed using clinical global improvement scores). Children will be treated for six months using daily, bid dosing.
1944594|NCT00746252|Drug|aripiprazole|children will have a flexible dosing titration based on their unique response (assessed using clinical global improvement scores). Children will be treated with daily medication for six months.
1944595|NCT00745823|Drug|Comparator: Raltegravir 400 mg b.i.d.|Raltegravir 400 mg tablet by mouth (PO) twice daily (b.i.d.) + two raltegravir placebo tablets + one tablet of TRUVADA™ once daily (q.d.)
1944596|NCT00745823|Drug|Experimental: Raltegravir 800 mg q.d.|Raltegravir 800 mg tablet PO q.d. + two raltegravir placebo tablets + one tablet TRUVADA™ q.d.
1944597|NCT00745823|Drug|TRUVADA™|One tablet TRUVADA™ q.d. (fixed combination 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate)
1944598|NCT00745420|Biological|Hematopoietic Stem Cell Transplantation|"The stem cell transplant preparative regimen is listed below. Day 0 is the day of the transplant. The - sign is the number of days before and the + sign is the number of days after the transplant.
Alemtuzumab: Children weighing 10 kg or more will receive 10 mg, 15 mg, and 20 mg intravenously (IV) on Days -21, -20, and -19, respectively
Fludarabine: 30 mg/m^2/day IV on Days -8 through -4
Melphalan: 140 mg/m^2 IV on Day -3
Rest on Days -2 and -1
Transplant occurs on Day 0
GVHD prophylaxis: Tacrolimus or cyclosporine beginning Day -3, methotrexate (7.5 mg/m2/day) Day 1, 3 and 6 and methylprednisolone/prednisone on Day +7 to +28 followed by a taper if there is no GVHD"
1944599|NCT00745199|Drug|cromolyn sodium|oral cromolyn sodium, capsule 135mg, 1 capsule 3 times daily for 8 weeks
1944600|NCT00745199|Drug|placebo|capsule contains 135 mg lactose, 1 capsule 3 times daily for 8 weeks
1944601|NCT00744861|Device|Low Intensity Pulsed Ultrasound|
1944602|NCT00744861|Device|Sham|
1944603|NCT00743977|Drug|Phenazopyridine HCl|100mg tablet in fasting state
1944688|NCT00724620|Biological|Peginterferon alfa-2b (SCH 054031)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
1944604|NCT00744315|Procedure|Mini-thoracotomy for intramyocardial injection of VEGF165|Patients with previous diagnosis of ischemic cardiopathy were included. The patient must accept and agree to be subject of clinical observation with current optimal treatment for at least 6 months. Following to that, subject undergoes intervention, in addition to consultation and assessments. Surgical technique -Ten injections VEGF165 will be made through a 25F butterfly needle in any ischemic territory where previously identified through scintigraphy. Dosis: 2.000 mg of VEGF165 in 5ml of saline solution. After the procedure, the patients will be kept in a recovery room for about 24hs and in the hospital until full clinical recovery.
1944605|NCT00742638|Drug|Quetiapine fumarate|Investigational product: quetiapine fumarate tablet 25 mg and 200 mg
1944606|NCT00742638|Drug|Sodium valproate|Sodium valproate tablet 200 mg
1944607|NCT00743379|Drug|TH-302|TH-302 will be administered by IV infusion over 30 minutes on Days 1, 8 and 15 of a 28- day cycle for Arm A and on Days 1 and 8 of a 21 day cycle for Arms B and C.
1944608|NCT00743145|Drug|Naltrexone|12 mg/70kg
1944609|NCT00743145|Drug|marijuana|0,2,4, or 6 puffs of 6.2% THC
1944612|NCT00742560|Biological|elotuzumab (HuLuc63)|Humanized Anti-CS1 Monoclonal IgG1 Antibody
1944613|NCT00742560|Drug|lenalidomide|25 mg PO days 1 though 21 of each 28 day cycle
1944614|NCT00742560|Drug|dexamethasone|40 mg PO days 8 and 22; 28 mg PO and 8 mg IV days 1 and 15 of each 28 day cycle.
1944615|NCT00741845|Drug|intravaginal metronidazole|high dose intravaginal metronidazole 750mg (with or without miconazole) to be compared to low dose intravaginal metronidazole 37.5mg
1944616|NCT00741260|Drug|Neratinib|Neratinib 240mg, continuous daily
1944617|NCT00741260|Drug|capecitabine|1500mg/m² of Capecitabine, on days 1-14 of each 21 day cycle.
1944618|NCT00741832|Device|Conical Positive Expiratory Pressure Device (C-PEP)|"Conical positive expiratory pressure device (C-PEP) in this study was designed on the principle of expiratory flow retardation. The principle occurs when exhaling through a small tube diameter, i.e. a small straw, pursed lip breathing, or positive expiratory pressure. Expiratory retardation, results from a decrease in tube diameter, creates flow resistance during exhalation. With flow resistance, the greater the flow the greater the back pressure, and the less the flow the lower the pressure. Expiratory retardation was applied in an attempt to facilitate exhalation and to relieve the air trapping.
The optimal design was found to be: cone shape, proximal diameter is 2.0 cm, distal diameter is 0.6 cm, and length is 2.5 cm.
Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing with the C-PEP device."
1944619|NCT00741832|Other|Control breathing|Subjects will rest for 10-15 minutes until HR, BP are stabilized. They will undertake 15 min of alternating quadriceps exercise (30% 1 RM) either breathing normally.
1944623|NCT00740246|Drug|VIT-45|
1944624|NCT00739960|Drug|Abatacept|10mg/kg IV (infusion directly into the vein of the arm) Day 1, week 2, week 4 and then every 4 week for 44 weeks.
1944625|NCT00738972|Drug|valsartan|80 mg valsartan. Duration: 12 months. Tablets
1944626|NCT00738972|Drug|pravastatin|40 mg pravastatin. Duration: 12 months. Tablets
1944627|NCT00738972|Drug|simvastatin|40 mg simvastatin. Duration: 12 months. Tablets
1944628|NCT00738972|Drug|ezetimibe (+) simvastatin|ezetimibe (+) simvastatin 10/40 mg. Duration: 12 months. Tablets
1944629|NCT00737841|Drug|Bifidobacterium breve|1.0 g of Bifidobacterium breve, taking orally, 3 times a day for 8 weeks.
1944630|NCT00737841|Drug|Placebo|1.0 g of placebo, taking orally, 3 times a day for 8 weeks.
1944631|NCT00737542|Drug|lidocaine|
1944632|NCT00737542|Drug|NACL 0.9%|
1944633|NCT00737672|Device|GORE VIABAHN Endoprosthesis with PROPATEN Bioactive Surface|Deployment of investigational stent graft at the venous anastomosis
1944634|NCT00737672|Procedure|Percutaneous Transluminal Angioplasty|Percutaneous Transluminal Angioplasty at the venous anastomosis
1944635|NCT00737412|Other|Probiotic: Bio-K+ CL1285|The probiotic Bio-K+ CL1285 RX®, a mixture of Lactobacillus acidophilus and Lactobacillus casei, contains over 50 billion living bacteria per administered dose.
1944636|NCT00737412|Other|Placebo|Matching capsules devoid of microorganisms
1944637|NCT00737620|Procedure|Prosthetic AV graft implantation|Surgical arteriovenous fistula creation with standard or propaten graft
1944640|NCT00735826|Drug|Vorinostat|Vorinostat will be administered orally once daily in an open-labeled, unblinded manner to all subjects enrolled in the study. Subjects will receive vorinostat 400 mg once daily on a continuous daily basis for 7 to 10 days prior to surgical resection. Vorinostat should be taken with food within 0 to 30 minutes of a meal if possible. Patients should take the medication at approximately the same time each day on an ongoing basis. Missed doses will not be made up.
1944644|NCT00735878|Drug|ABT-751 and Carboplatin|This primary objective of this Phase 1/2 study is to evaluate the DLT and MTD of escalating oral doses of ABT-751 given BID on Day 1 of each cycle for 7 days in combination with carboplatin given on a 21-day schedule. The carboplatin dose is fixed at AUC 6 and will be administered on Day 4 during the first cycle to facilitate the pharmacokinetic analysis. During the subsequent cycles both agents will be administered on Day 1. ABT-751 is administered at the following dose levels using the Simon rapid dose escalation model: 100, mg, 125 mg, 150 mg, 175 mg and 200 mg BID.
1944645|NCT00734539|Drug|fluconazole|6mg/kg IV/PO twice weekly for a total of up to 12-13 doses
1944646|NCT00734539|Drug|placebo|normal saline (IV) or 3 parts Ora Plus oral suspension vehicle and 1 part simethicone suspension (PO): will be given twice weekly PO/IV for a total of up to 12-13 doses
1944647|NCT00735254|Device|pulsed dye laser|patient will have scar treated with pulsed dye laser
1944648|NCT00735254|Device|Affirm Laser|patient will have scar treated with Affirm laser
1944649|NCT00735254|Device|combined PDL and Affirm Lasers|patient will have scar treated with Affirm and pulsed dye lasers
1944650|NCT00735254|Other|Placebo|patient will receive no treatment
1944651|NCT00735228|Device|Artificial pancreas|Artificial endocrine pancreas (NIKKISO Company)
1944652|NCT00734903|Behavioral|A Woman's Path to Recovery (WPR)|A Woman's Path to Recovery (WPR) is an evidence-based gender-specific treatment model for women with substance use disorder. It is a 12-session model that is conducted once per week in individual modality, with eight core sessions and four session topics that participants can select from a larger menu.
1944653|NCT00734903|Behavioral|Twelve-Step Facilitation (TSF)|Twelve-Step Facilitation (TSF) consists of a brief, structured, and manual-driven approach to facilitating early recovery from alcohol abuse/alcoholism and other drug abuse/addiction. It is intended to be implemented on an individual basis in 12 to 15 sessions and is based in behavioral, spiritual, and cognitive principles that form the core of 12-step fellowships such as Alcoholics Anonymous (AA) and Narcotics Anonymous (NA).
1944655|NCT00734032|Drug|SB480848 40mg EC Tablet|1 tablet once a day
1944656|NCT00734032|Drug|SB480848 80mg EC Tablet|1 tablet once a day
1944657|NCT00734032|Drug|SB480848 160mg EC Tablet|1 tablet once a day
1944658|NCT00734032|Drug|SB480848 Placebo Tablet|1 tablet once a day
1944661|NCT00733356|Drug|Vyvanse|Subject's will participate in an open-label dose optimization period and successful titration to an optimal dose of Vyvanse™, subjects will take their optimized dose of Vyvanse™ (30, 50 or 70 mg/day) during the week leading up to their final visit. During the study subject's will take their prescribed dose once a day in the morning with breakfast.
1944663|NCT00732524|Drug|Glipizide|Glipizide XL 10 mg once daily 30 mins before breakfast
1944664|NCT00732524|Drug|Glipizide and Glargine|Glipizide XL 10 mg daily 30 minutes before breakfast Insulin Glargine 10 units subcutaneously at bedtime daily
1944665|NCT00731770|Drug|fluticasone/salmeterol 250/50|250/50 1 puff bid
1944666|NCT00731770|Drug|placebo|placebo diskus 1 puff bid
1944667|NCT00731627|Drug|placebo|one tablet a day for up to 21 days
1944668|NCT00731627|Drug|simvastatin|simvastatin 40mg once a day for a maximum of 21 days
1944669|NCT00730301|Procedure|Bronchoscopic Lung Volume Reduction (BLVR)|Procedure under general anesthesia.
1944670|NCT00730262|Drug|TLN-4601|14 day continuous IV administration of TLN-4601 at 480 mg/m2/day followed by a 7-day recovery period
1944672|NCT00729053|Drug|IMO-2055|immunostimulatory oligonucleotide
1944673|NCT00728793|Drug|CUDC-101|Doses will be given by intravenous infusion over 1 hour on days 1-5 of each treatment cycle. Total treatment cycle duration will be 14 days. Additional treatment cycles will be administered until the subjects withdraws consent, experiences unacceptable toxicity, or if there is documented tumor progression.
1944674|NCT00727532|Drug|sorafenib tosylate|400mg by mouth twice daily for 28 consecutive days
1944675|NCT00727532|Procedure|diffusion-weighted magnetic resonance imaging|At baseline and just prior to surgery after sorafenib treatment
1944676|NCT00726596|Drug|hydroxychloroquine|Hydroxychloroquine will be taken at a dose of 200 mg twice per day in the first 27 patients (cohort A). Once cohort A completed, the dose of hydroxychloroquine will then be increased to 600mg per day (200mg three times per day)(cohort B).
1944677|NCT00725829|Drug|simvastatin|Simvastatin 40mg/d
1944678|NCT00725829|Drug|ezetimibe|ezetimibe 10mg/d
1944679|NCT00725829|Drug|placebo|placebo
1944681|NCT00725959|Behavioral|Online social networking HIV prevention|messages about HIV posted in online social networking sites
1944682|NCT00725283|Biological|GSK Biologicals' recombinant WT1 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK2130579A|Intramuscular administration
1944683|NCT00724971|Drug|Inotuzumab Ozogamicin (CMC-544)|1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
1944684|NCT00724971|Drug|Rituximab (Rituxan)|375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.
1944732|NCT00715611|Radiation|Intensity Modulated Radiation Therapy|IMRT will be administered over approximately 6 weeks at 50.4 Gy in 28 fractions with an optional SIB to gross residual disease (pending meeting normal tissue constraints).
1944870|NCT00688324|Drug|Acamprosate|Acamprosate 333mg, ii tablets PO tid x 2 weeks
1944689|NCT00724620|Drug|Ribavirin (SCH 018908)|All patients will receive peginterferon alfa-2b 1.5 ug/kg administered subcutaneously (SC) once weekly in combination with ribavirin (800-1200 mg/day) administered orally (PO) for a minimum period of 12 weeks. The total treatment duration will be as follows: 48 weeks for Early Responders, 72 weeks for Slow Responders, and 12 weeks for Nonresponders.
1944690|NCT00722098|Biological|DC Vaccine & Cyclophosphamide|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.
Patients will receive either CPA 300mg/m2 for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
1944691|NCT00722098|Biological|DC Vaccine & Placebo|"Patients will receive a fixed dose of about ≥15x106 viable dendritic cells per injection. Patients will receive a total of 8 doses of the vaccination with each individual dose being administered at weeks: 0, 2, 4, 6, 10, 14, 18 and 22. Responses will be evaluated and patients with SD, PR or CR may receive 4 more vaccine at 36, 48, 72 and 96 weeks, if there is vaccine available. The vaccine will be injected subcutaneously, in 3 separate injection sites (3.3.ml per site) in the upper and lower extremities.
Patients will receive saline for injections administered intravenously over a 2-hour infusion in the outpatient clinic 24 hours prior to DC vaccinations # 1, 3, 5, 6 and 7."
1944692|NCT00722176|Drug|BL-1020|10 mg
1944693|NCT00722176|Drug|BL-1020 10-30 mg|BL-1020 10-30 mg
1944694|NCT00722176|Drug|risperidone|risperidone
1944695|NCT00722111|Device|lingual press|lingual press (high-intensity, oral, non-swallowing)
1944696|NCT00722111|Behavioral|effortful swallowing|effortful swallowing (high-intensity swallowing)
1944697|NCT00722111|Behavioral|natural swallowing|natural swallowing (high frequency, low intensity swallowing)
1944698|NCT00722111|Behavioral|non-oral sham (control) exercise|non-oral sham (control) exercise
1944699|NCT00720902|Procedure|Blood draws|Subjects will have serum cardiovascular markers assessed
1944700|NCT00720902|Drug|Growth hormone releasing hormone (GHRH) and arginine|Subjects will receive GHRH and arginine intravenously and then have blood drawn at frequent intervals over a 90 minutes to assess growth hormone secretion.
1944701|NCT00720902|Procedure|Carotid ultrasound|Subjects will have an ultrasound of their neck to assess their carotid arteries to look for intima-medial thickness.
1944702|NCT00720902|Procedure|MRI|Subjects will have MRI and MR spectroscopy of the abdomen and lower extremities to assess for fat in internal organs and muscle.
1944703|NCT00720902|Procedure|Endothelial cell biopsy|Subjects will undergo endothelial cell biopsies to harvest endothelial cells to study. It will occur once and takes approximately 20 minutes. Patients will have an iv placed and then a sterile wire is passed back and forth in the iv a couple of times. Three wires are passed.
1944704|NCT00719888|Drug|Cyclophosphamide|Given IV
1944705|NCT00719888|Drug|Cyclosporine|Given IV and PO
1944706|NCT00719888|Procedure|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit UCBT
1944707|NCT00719888|Drug|Fludarabine Phosphate|Given IV
1944708|NCT00719888|Other|Laboratory Biomarker Analysis|Correlative studies
1944709|NCT00719888|Drug|Mycophenolate Mofetil|Given IV and PO
1944710|NCT00719888|Radiation|Total-Body Irradiation|Undergo TBI
1944711|NCT00719888|Procedure|Umbilical Cord Blood Transplantation|Undergo UCBT
1944712|NCT00719095|Drug|buprenorphine taper followed by naltrexone maintenance|direct comparison of 1-, 2- and 4-week durations of buprenorphine taper for treating prescription opioid abusers; those who successfully taper without resumption of illicit opioid use are subsequently transitioned to oral naltrexone therapy for the remainder of the 12-week trial; all participants receive a platform of intensive individual behavioral therapy and on-site urinalysis monitoring throughout the trial
1944713|NCT00719095|Behavioral|Behavioral therapy|
1944714|NCT00719576|Biological|Matrix-Induced Autologous Chondrocyte Implant (MACI)|Implantation
1944715|NCT00719576|Procedure|Microfracture|Microfracture
1944717|NCT00718094|Drug|Polyphenon E®|Oral capsules
1944723|NCT00716144|Drug|Talarozole|Oral Capsule Once Daily
1944724|NCT00716274|Drug|Atomoxetine|Atomoxetine will be administered at 1.0 to 1.4 mg/kg/day given orally once daily in the morning for 32 weeks
1944725|NCT00716274|Drug|Placebo|oral, daily, for 32 weeks
1944726|NCT00716976|Drug|sodium thiosulfate|Given IV
1944727|NCT00716976|Procedure|examination|Patients undergo audiological assessments periodically
1944728|NCT00715429|Drug|vitamin d|After a two-week wash-in, subjects will take a vitamin D capsule (50,000 units) once daily for 10 days, followed by a once weekly vitamin D (50,000 units) maintenance dose for 7 weeks.
1944729|NCT00715429|Drug|placebo|After a two-week wash-in, subjects will take a placebo capsule once daily for 10 days, followed by a once weekly maintenance dose for 7 weeks.
1944730|NCT00715611|Procedure|Pleurectomy/Decortication|Pleurectomy/decortication will be performed as per standard technique
1944731|NCT00715611|Drug|pemetrexed and cisplatin or carboplatin|The combination of pemetrexed and cisplatin or carboplatin will be given every 3 weeks for up to 4 cycles. Pemetrexed will be administered at 500mg/m2 as a 10-minute infusion. Cisplatin will be administered at 75mg/m2 as a 60-minute infusion. Carboplatin will be administered at an AUC of 5 over 30 minutes. Chemotherapy may be administered in the neoadjuvant or adjuvant setting.
1944779|NCT00706030|Drug|neratinib|Neratinib 240mg daily
1944780|NCT00706030|Drug|vinorelbine|vinorelbine 25 mg/m2 on day 1 and day 8 of a 21 days cycle.
1944736|NCT00715013|Drug|Patupilone|Patupilone
1944737|NCT00714415|Drug|BeneFIX|Patients will be treated in accordance with the requirements of the labeling of BeneFIX in Germany. The dosage and duration of therapy is to be determined by the physician to meet the patients' individual needs for treatment.
1944738|NCT00714246|Drug|Docetaxel, Carboplatin, Bortezomib|Phase II recommended dose is the highest dose level at which less than 2 patients (out of 6) experience dose limiting toxicity. A maximum of 4 cycles (1 cycle = 21 days) of chemotherapy will be administered to patients. Patients who demonstrate an ongoing response at the end of the 4th cycle of chemotherapy, may receive 2 more cycles of treatment.
1944739|NCT00714246|Drug|PS341|Patients will be enrolled to Phase 1 at the following dose levels: Level 1 - Carboplatin (day 1) 5 AUC mg/ml/min), Docetaxel (day 1) 60 mg/m2, Bortezomib (day 1,4,8,11) 0.7 mg/m2. Level 2A - Carboplatin (day 1) 6 AUC mg/ml/min), Docetaxel (day 1) 60 mg/m2, Bortezomib (day 1,4,8,11) 0.7 mg/m2. Level 2B - Carboplatin (day 1) 6 AUC mg/ml/min), Docetaxel (day 1) 60 mg/m2, Bortezomib (day 1,4,8,11) 1.0 mg/m2. Level 3 - Carboplatin (day 1) 6 AUC mg/ml/min), Docetaxel (day 1) 75 mg/m2, Bortezomib (day 1,4,8,11) 0.7 mg/m2. Level 4 - Carboplatin (day 1) 6 AUC mg/ml/min), Docetaxel (day 1) 75 mg/m2, Bortezomib (day 1,4,8,11) 1.0 mg/m2. Level 5 - Carboplatin (day 1) 6 AUC mg/ml/min), Docetaxel (day 1) 75 mg/m2, Bortezomib (day 1,4,8,11) 1.3 mg/m2
1944740|NCT00712699|Drug|Sequence 1: XR-MAS then placebo|XR-MAS given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
1944741|NCT00712699|Drug|Sequence 2 Placebo then XR-MAS|PBO given in non-identifying 5 mg capsules with instructions to start 1 capsule (5 mg/d) for one week, then increase to 2 capsules (10 mg/d) for week two, and 3 caps (15 mg/d) for week 3 following flexible, forced titration based on response and tolerance.
1944742|NCT00712491|Drug|Sirolimus|Three subconjunctival injections of 1320 micrograms sirolimus each.
1944743|NCT00712491|Drug|Sirolimus|Three intravitreal injections of 352 micrograms sirolimus each.
1944744|NCT00712296|Drug|ASHMI|6 capsules orally twice a day
1944745|NCT00712296|Drug|ASHMI|2 capsules orally twice a day
1944746|NCT00712296|Drug|Placebo|Placebo 6 capsules twice a day
1944747|NCT00712257|Device|Spectranetics Laser with adjunct PTA and Gore VIABAHN Endoprosthesis with Heparin Bioactive Surface|treatment for superficial femoral artery instent re-stenosis
1944748|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 10 mg per day for 29 days.
1944749|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 20 mg per day for 29 days
1944750|NCT00712114|Drug|HE3286|HE3286 will be administered orally. Dosing will be 40 mg per day for 29 days
1944751|NCT00711711|Other|Manual lymphatic drainage|Each patient will receive 5 treatments of 30 minutes by a trained physiotherapist, from day 2 to day 7 post surgery
1944752|NCT00711711|Other|relaxation|Each patient will receive 5 treatments of 30 minutes of tape recorded relaxation , from day 2 to day 7 post surgery
1944753|NCT00711269|Drug|SM-13496 (lurasidone HCl)|Lurasidone HCl: 40 mg/day
1944754|NCT00711269|Drug|SM-13496 (lurasidone HCl)|Lurasidone HCl: 80 mg/day
1944755|NCT00711269|Drug|Placebo|
1944756|NCT00711269|Drug|Risperidone|
1944763|NCT00708916|Drug|CC-10004|20 mg twice daily by mouth for 12 weeks, followed by a 4 week washout period and final assessment
1944766|NCT00709280|Drug|7% Hypertonic Saline (HS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
1944767|NCT00709280|Drug|0.9% Isotonic Saline (IS)|Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
1944768|NCT00708123|Drug|Sodium fluoride toothpaste|Various fluoride toothpastes containing 1350 ppm F, 1450 ppm F, 1400 ppm F and 250 ppm F
1944769|NCT00708123|Drug|Placebo toothpaste|Fluoride free toothpaste (0 ppm F)
1944770|NCT00708552|Drug|SB-742457|investigational drug
1944771|NCT00708552|Drug|Donepezil|comparator
1944772|NCT00708552|Drug|Placebo|comparator
1944773|NCT00708097|Drug|NaF|Fluoride
1944774|NCT00708097|Drug|Placebo|Placebo
1944775|NCT00708097|Drug|NaMFP|Fluoride
1944776|NCT00708305|Drug|Sodium Fluoride (NaF)|Different fluoride toothpastes containing between 1400ppmF - 1450ppmF of fluoride as NaF
1944777|NCT00708305|Drug|Placebo|Fluoride free toothpaste (0ppmF)
1944778|NCT00707434|Device|Guardian® blood-sugar monitoring device|The device has a small catheter that will be inserted subcutaneous tissue of the subject's abdomen or thigh set to continuously monitor glucose throughout the ICU stay for up to 15 days.
1944782|NCT00706446|Drug|Salmeterol|salmeterol diskus 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
1944783|NCT00706446|Drug|Formoterol|formoterol aerolizer 12 mcg 1 puff twice a day for 1 year, depending on which medication the patient was on before the start of the trial. The goal of this intervention is to continue the patient's current therapy of long-acting beta-agonists. In addition, the patients will be on inhaled steroids at variable doses, depending on what dose they were on at the start of the trial and based on the judgement of their treating physicians.
1944784|NCT00706446|Drug|Fluticasone propionate|Either fluticasone propionate diskus 100 mcg 1 puff twice a day or fluticasone propionate aersol in 44 mcg, 110 mcg, 2 puffs twice a day OR fluticasone propionate 220 mcg 2 puffs once a day for one year, depending on which dose the patient was on before the start of the trial.
1944785|NCT00706446|Drug|budesonide|Either budesonide 90 mcg 2 puffs twice a day or 180 mcg 2 puffs twice a day for one year, depending on which dose the patient was on before the start of the trial.
1944786|NCT00705900|Drug|LCD|2 applications / day for 12 weeks
1944787|NCT00705900|Drug|calcipotriol|2 applications / day for 12 weeks
1944788|NCT00706238|Biological|GSK Biologicals' Recombinant MAGE-A3 Antigen-Specific Cancer Immunotherapeutic (ASCI) GSK1203486A|IM administration
1944789|NCT00706407|Device|Fully integrated Uro-NIRS:UDS|As part of standard care subjects will be undergoing a standard bladder pressure diagnostic procedure. This standard procedure will involve the insertion of a catheter (a plastic tube) into the urethra and the measurement of pressure within the bladder. For subjects taking part in this study, the health of the bladder will measured by using light instead of pressure. A patch, the size of cell phone or deck of playing cards, will be taped to the skin in the middle of the abdomen, above the bladder. Using laser light that is 300 billion times weaker than the light from a regular household 100-Watt light bulb, the Laborie and Urodynamix device will take measurements through the skin without inserting anything into the body.
1944790|NCT00705484|Biological|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
1944791|NCT00705484|Drug|Standard Therapy|The standard therapy group will consist of subjects receiving a treatment regimen that does not include Remicade. The treatment of each standard therapy subject will be left to the discretion of the treating physician and may change during the course of a subject's participation in the registry.
1944792|NCT00705484|Biological|infliximab|The treating physician will determine the treatment regimen and dose of Remicade.
1944793|NCT00705783|Drug|Aripiprazole depot|Aripiprazole depot was supplied in 400 mg lyophilized vials. Patients received aripiprazole 300 mg if they were unable to tolerate aripiprazole 400 mg.
1944794|NCT00705783|Drug|Placebo depot|Placebo depot was supplied in 400 mg lyophilized vials.
1944797|NCT00703495|Device|transcranial oxygen saturation measurement (INVOS Somanetics 5100C)|rSO2 measurement
1944798|NCT00703313|Drug|1.5% levofloxacin ophthalmic solution|1 drop instilled at each visit
1944799|NCT00703313|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|1 drop instilled at each visit
1944800|NCT00703313|Drug|0.3% gatifloxacin ophthalmic solution|1 drop instilled at each visit
1944801|NCT00702962|Drug|Vorinostat, Carboplatin, Etoposide|Sequential cohorts of 3-6 patients will be entered to the following dose levels: Level 1 - Days 1-14: Vorinostat 200 mg po QD; Day 3: Carboplatin 6 AUC; Days 1,2,3: Etoposide 100 mg/m2. Level 2 - Days 1-14: Vorinostat 300 mg po QD; Day 3: Carboplatin 6 AUC; Days 1,2,3: Etoposide 100 mg/m2; Level 3: Days 1-14: Vorinostat 400 mg po QD; Day 3: Carboplatin 6 AUC; Days 1,2,3: Etoposide 100 mg/m2. Treatment cycles will be repeated every 3 weeks. A maximum of 4 cycles will be administered to each patient.
1944802|NCT00702962|Other|SAHA|Once the recommended phase II dose has been established and additional 15 patients will be enrolled. Days 1-4 Vorinostat recommended phase II dose po QD;Day 3 Carboplatin 6 AUC; Days 1,2,3 Etoposide 100 mg/m2. Treatment cycles will be repeated every 3 weeks. A maximum of 4 cycles will be administered to each patient. An additional 35 patients on the phase II portion of the trial will be required to achieve the outlined objectives.
1944803|NCT00700947|Drug|Beta-blocker therapy (TOPROL-XL® )|Patients who have been surgically treated for mitral regurgitation that start Beta-Blocker therapy.
1944804|NCT00701714|Drug|HX575 recombinant human erythropoietin alfa|Solution for injection (s.c.)
1944805|NCT00701714|Drug|ERYPO|Solution for injection (s.c.)
1944806|NCT00701480|Other|skin cleanser contained Hibiscus sabdariffa extract|face washing 2-3 times/day
1944807|NCT00701480|Other|marketed skin cleanser|face washing 2-3 times/day
1944808|NCT00701220|Drug|Atorvastatin Calcium|Atorvastatin Calcium starting at a 10 mg dose and may be increased up to 40 mg dose until cholesterol is lowered to an acceptable range. Blood will drawn every 2 weeks for the first 12 weeks to check the cholesterol level and adjust medication dosage. Cardiac MRI will be performed at the beginning and at the end of the 6 month study to measure the physical changes of the heart.
1944809|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
1944810|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 2 doses Intramuscular
1944811|NCT00700635|Biological|Menactra®: Meningococcal Polysaccharide Diphtheria Conjugate|0.5 mL, 1 dose Intramuscular
1944812|NCT00700453|Behavioral|Control group with no video game play|Subjects will abstain from all video game play during study participation.
1944813|NCT00700453|Behavioral|control 2|Subjects will play 1 week of violent video game play followed by 1 week of no video game play.
1944814|NCT00700453|Behavioral|VG1 group (2 weeks of violent video game play)|Subjects will play a violent video game for 2 weeks of study participation.
1944815|NCT00700453|Behavioral|Cognitive Training|Subjects will play a violent video game for 1 week followed by 1 week of Cognitive Training program.
1944871|NCT00688181|Device|The Prefyx PPS™ Pre-pubic Sling System|device designed to treat female stress urinary incontinence (SUI).
1945068|NCT00645944|Drug|Placebo|"Placebo or inactive substance (sugar pill)taken each night for all weeks of the study"
1944816|NCT00700336|Drug|pemetrexed, cisplatin and CBP501|"CBP501 for injection is provided in single dose vials (20 mg) containing a sterile lyophilized powder comprising CBP501 peptide acetate salt (peptide base units). For administration, vial contents are reconstituted in 5% Dextrose Injection, USP, and added to a 100 mL IV bag of 5% Dextrose Injection, USP.
Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.
Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
1944817|NCT00700336|Drug|pemetrexed and cisplatin|"Pemetrexed: A commercial formulation of pemetrexed will be used, with reconstitution in 20mL 0.9% sodium chloride solution for injection, then dilution to 100mL.
Cisplatin: A commercial formulation will be used and will be diluted in 250 mL of normal saline for administration."
1944818|NCT00699907|Drug|flutamide|Given orally
1944819|NCT00699504|Drug|cangrelor|IV bolus 60 mcg/kg; 8 mcg/kg x 3 hrs
1944820|NCT00699504|Drug|cangrelor|30 mcg/kg bolus; 4 mcg/kg/min x 3 hrs. Oral placebo capsule
1944821|NCT00699504|Drug|cangrelor|60 mcg/kg bolus; 8 mcg/kg/min x 3 hrs. Oral placebo capsule
1944822|NCT00699504|Drug|moxifloxacin|400 mg orally. Placebo IV bolus and infusion.
1944823|NCT00699504|Drug|placebo|placebo IV and oral
1944824|NCT00699322|Drug|Sitagliptin|100mg P.O. per day for 1month
1944825|NCT00699322|Drug|Glimepiride|2mg P.O. per day for 1 month
1944827|NCT00698945|Drug|Istalol and Optive|Istalol: one drop a day for 28 days Optive: one drop a day for 28 days
1944828|NCT00698945|Drug|Alphagan|Alphagan: two drops a day for 28 days
1944829|NCT00697606|Device|Seprafilm®|Seprafilm® placed at time of primary cesarean
1944830|NCT00697606|Other|Control|no Seprafilm® used at primary cesarean
1944834|NCT00697463|Drug|Teriparatide (PTH 1-34)|20 micrograms subcutaneous injection daily for 18 months
1944835|NCT00697164|Drug|Placebo|Saline Admission, day 1, day 2 3 days
1944836|NCT00697164|Drug|Erythropoietin|Erythropoietin, 1500 U/kg/day Admission, day 1, day 2 3 days
1944837|NCT00696683|Other|None, this is an observational study|
1944838|NCT00696514|Dietary Supplement|Vitamin B12, folic acid, Vitamin D3|500 µg vitamin B12; 0.4 mg folic acid; 600 IU vitamin D3 in one capsule, once per day
1944839|NCT00696514|Dietary Supplement|Placebo (Vitamin D3) - 600 IU per day|600 IU vitamin D3 in one capsule, once per day
1944840|NCT00695682|Drug|intravitreal injection of infliximab|All subjects will receive 0.5 mg/ 0.05 mL of infliximab by intravitreal injection at their first treatment visit or the 6 weeks visit if eligible for a repeat injection.
1944841|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
1944842|NCT00695617|Drug|trisodiumcitrate|trisodiumcitrate 1.035 M
1944843|NCT00695578|Drug|Biafine|ingredients: purified water, liquid paraffin, glycol monostearate, stearic acid, propylene glycol, paraffin wax, squalene, avocado oil, trolamine sodium alginate, cetyl palmitate, methylparaben, sorbic acid, propyl paraben and fragrance.
1944847|NCT00695253|Device|Endoluminal treatment of abdominal aortic aneurysms using the Medtronic/Talent Stent Graft|Stent-graft for AAA
1944848|NCT00691951|Drug|budesonide and budesonide/formoterol|
1944849|NCT00691301|Drug|cisplatin|
1944850|NCT00691301|Drug|pemetrexed disodium|
1944851|NCT00691600|Drug|oral trimethoprim/sulfamethoxazole|80 mg caps or 8 mg/ml suspension every 12 hours for 10 days
1944852|NCT00691600|Drug|Placebo|Placebo caps or suspension every 12 hours for 10 days
1944853|NCT00691600|Other|Observational Unit Short Stay|Patients with abscesses greater that 5cm to 10cm randomized to Observational Short Stay unit for up to 23 hrs.
1944854|NCT00691600|Other|Hospitalization|Patients with abscesses 5-10cm may be randomized to inpatient treatment
1944855|NCT00691587|Biological|KB001|Single low-dose, administered intravenously
1944856|NCT00691587|Biological|KB001|Single high-dose, administered intravenously
1944857|NCT00691587|Biological|Placebo|Placebo single-dose, administered intravenously
1944858|NCT00690885|Drug|interferon-alpha lozenges|150 IU natural human interferon-alpha lozenges for oral dissolution given 3 times per day for 4 weeks
1944859|NCT00690885|Drug|placebo lozenges|matching placebo lozenges
1944860|NCT00690378|Drug|NXL104/ceftazidime|125mg/500mg TID
1944861|NCT00690378|Drug|Imipenem/Cilastatin|4 x daily
1944862|NCT00689078|Drug|Prednisolone Acetate 1%|One drop OU
1944863|NCT00689078|Drug|Prednisolone Acetate 0.12%|One drop OU
1944864|NCT00689078|Drug|Loteprednol Etabonate 0.2%|One drop OU
1944865|NCT00689078|Drug|Artificial tears|One drop OU
1944866|NCT00688259|Other|supportive therapy|approximately 20 sessions of manualized psychotherapy to promote a strong alliance between the therapist and the participant in order to provide a safe place to discuss issues pertaining to recovery
1944867|NCT00688259|Other|cognitive-behavioral therapy for psychosis|approximately 20 sessions of individual manualized psychotherapy in which participants are taught to evaluate the data supporting beliefs that may interfere with recovery
1944868|NCT00688376|Drug|Donepezil hydrochloride|"During the 12-week Double-Blind Phase, subjects will receive oral donepezil hydrochloride tablets starting at a dose of 3 mg once daily. Doses will be increased incrementally at successive 3-week intervals on the basis of weight and tolerability. The final daily dose will be 3, 5, or 10 mg depending on body weight.
During the Blinded Extension Phase, all subjects will receive active treatment (donepezil)."
1944915|NCT00678080|Drug|Insulin (NPH and Regular)|Insulin will be administered based on maternal gestational age and maternal weight using NPH and Regular insulin. It will be administered subcutaneously 3 times a day
1944877|NCT00686725|Drug|Temozolomide|
1944878|NCT00686725|Radiation|Radiotherapy|
1944879|NCT00685932|Device|Mobius Retractor|The Mobius retractor is a dual ring elastic self retaining retractor that is inserted into the abdominal cavity after the peritoneal incision has been established. It is then left in place during the hysterotomy incision, delivery of the fetus, hysterotomy repair, inspection and irrigation.
1944881|NCT00685750|Procedure|Collection of tumor and blood samples|Samples will be collected before and after standard treatment
1944885|NCT00685230|Biological|Antivenin Centruroides (scorpion) equine immune F(ab)2|3 vials of Alacramyn reconstitued in 50 ml of normal saline as a IV infusion over 10 minutes.
1944886|NCT00685230|Other|Placebo|Placebo reconstituted in 50 ml of normal saline administered over 10 min
1944887|NCT00684957|Drug|Recombinant Human Growth Hormone|300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)
1944888|NCT00684957|Drug|Recombinant human IGF-1|30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
1944890|NCT00683462|Drug|Placebo|
1944891|NCT00683462|Drug|AZD3480|Capsules 5 mg/day (once a day) for 2 weeks
1944892|NCT00683462|Drug|AZD3480|Capsules 50 mg/day (once a day) for 2 weeks
1944893|NCT00683358|Biological|VEGFR1-A24-1084 (SYGVLLWEI)|HLA-A*2402-restricted VEGFR1-derived peptide (VEGFR1-A24-1084) 1mg emulsified with Montanide ISA51 will be subcutaneously injected 2 times weekly for total 16doses concurrently with conventional dose of gemcitabine 1,000mg/m2 BSA on 1st, 2nd, 3rd, 5th, 6th, 7th weeks for advanced/inoperable pancreatic cancer patients.
1944895|NCT00682448|Drug|Metformin|Drug: Metformin 500 mg po daily titrated up to but no greater than 2000 mg based upon fasting blood glucose during study visits over six months.
1944896|NCT00682448|Drug|Placebo|Drug: Placebo. Subjects will remain on placebo for 6 months.
1944897|NCT00682227|Biological|TTK, LY6K, and IMP-3 peptides|Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
1944898|NCT00680277|Dietary Supplement|spirulina ß-carotene|an acute dose of spirulina up to 5 g
1944899|NCT00680277|Dietary Supplement|spirulina ß-carotene|vitamin A value of spirulina ß-carotene
1944900|NCT00681005|Drug|rabeprazole|20 mg bid for 14 days
1944901|NCT00681005|Drug|pantoprazole|pantoprazole 40 mg bid
1944902|NCT00680498|Drug|Ranibizumab|Ranibizumab 0.5 mg
1944903|NCT00680498|Drug|Ranibizumab plus Photodynamic therapy|Ranibizumab 0.5mg, combined with photodynamic therapy with Verteporfin (dosage per label)
1944904|NCT00679926|Drug|Lopinavir/ritonavir and tenofovir|Four tablets of lopinavir/ritonavir and one tablet of tenofovir given once daily
1944905|NCT00679679|Drug|Metformin|Metformin 750 mg BID for 4 months
1944906|NCT00679679|Drug|Placebo|Diet counseling and exercise
1944907|NCT00679458|Drug|buprenorphine and low-dose naloxone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug, buprenorphine only, will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
1944908|NCT00679458|Drug|buprenorphine alone|each participant will be randomly assigned to order of study drug administration in a double-blind manner. Five doses of first study drug will be administered for 5 days, with each administration following the previous dose by not more than 2 days. Administration of the second study drug will follow at least 2 days after the completion of the first study drug with the same administration criteria. Medication will be administered IV, and assessments will continue for 6 hours after administration. Study drugs include 1) buprenorphine 0.3mg and naloxone 0.02mg and, 2) buprenorphine 0.3mg.
1944909|NCT00678652|Biological|Group B Meningococcal 8570 HOPS-G NOMV Vaccine|
1944914|NCT00678080|Drug|Metformin|Metformin 500 mg orally daily increased as needed to maintain glycemic control until a maximum of 2500 daily
1944916|NCT00677313|Drug|metreleptin|metreleptin injection
1944918|NCT00676832|Drug|COLAL-PRED|The study is a double-blinded and results have not been unblinded. Patients were randomized to one of four doses. A solid capsule dosage form was administered orally once daily at doses of 40 mg, 60 mg, 80 mg, or 120 mg.
1944919|NCT00676273|Device|TVT-Obturator (TVT-O)|sub urethral sling
1944920|NCT00676273|Device|TVT-Secur (TVT-S) (Hammock method)|suburethral sling
1944921|NCT00676013|Biological|AlloDerm|Application of AlloDerm over full thickness burn following excision
1944922|NCT00676013|Procedure|Skin Biopsy|Tissue Biopsy of study sites (AlloDerm, Integra, Homograft, Autograft only)
1944923|NCT00676013|Biological|Integra|Application of skin substitute over full thickness burn following excision.
1944924|NCT00676013|Biological|Autograft|Application of autograft over full thickness burn injury following excision of burn wound.
1944925|NCT00676013|Biological|Homograft|Application of homograft skin over full thickness burn injury following excision of burn wound.
1944926|NCT00676039|Drug|Venlafaxine|NOVO-Venlafaxine XR 75 mg (NOVOPHARM, Generic)
1944927|NCT00676039|Drug|Gen-Citalopram|Gen-Citalopram 40 mg (Genpharm, Generic)
1944928|NCT00676039|Drug|Effexor XR|Effexor XR 75 mg (Wyeth Pharmaceuticals, Brand Name)
1944929|NCT00676039|Drug|Celexa|Celexa 40 mg (Lundbeck, Brand Name)
1944930|NCT00675285|Drug|montelukast sodium|one tablet 5 mg once/day for 4 weeks
1944931|NCT00675285|Drug|placebo|one tablet 5 mg once/day for 4 weeks
1944932|NCT00674505|Device|Lumen Biomedical FiberNet Embolic Protection System|to demonstrate the safety and filter efficiency of the Lumen Biomedical FiberNet Embolic Protection System during the performance of primary renal stenting in the treatment of pts with a high grade ostial atherosclerotic renal lesion(s).
1944933|NCT00675025|Drug|Donepezil Hydrochloride (Aricept)|Liquid form Aricept - 5 mg/5 mL donepezil hydrochloride.
1944934|NCT00674635|Drug|GSK3152314A|Part A single IV dose; Part B 3 repeat IV dose at Day 1, Day 28 and Day 56; Part C single SC dose
1944935|NCT00674635|Drug|Placebo|matching placebo
1944938|NCT00673790|Drug|Nebivolol|Encapsulated Nebivolol 5 mg, 10 mg, 20, mg, 40 mg total daily dosage, oral administration
1944939|NCT00673790|Drug|HCTZ|Encapsulated Hydrochlorothiazide 12.5 mg or 25 mg total daily dosage, oral administration.
1944940|NCT00673790|Drug|Placebo|Placebo
1944941|NCT00674362|Biological|Certolizumab pegol|Two 200 mg subcutaneous injections at Week 0, Week 2, and Week 4 followed by 200 mg injections every 2 weeks until the last drug administration (Week 22)
1944942|NCT00674362|Biological|Placebo|Two 0.9% saline subcutaneous injections at Week 0, Week 2, and Week 4 followed by 0.9% saline injections every 2 weeks until the last drug administration (Week 22)
1944944|NCT00674219|Drug|Namenda (Memantine)|Namenda 10mg BID for 12 weeks
1944945|NCT00673894|Drug|Glutamine, sitagliptin|Glutamine 15g and 30g/sitagliptin 100mg
1944946|NCT00671203|Procedure|Reestablish colon blood flow|If ischemia is detected, and the detection in consistent with the physician's clinical view, blood flow to the colon is established using any of the known techniques that would be used had the diagnosis been made in the absence of T-Stat, which include changes in the deployment of stents and/or coils, reanastomosis, reimplantation, or stenting, of obstructed vessels, or other established techniques.
1944947|NCT00671034|Drug|calaspargase pegol|Given IV
1944948|NCT00671034|Drug|calaspargase pegol|Given IV
1944949|NCT00671034|Drug|DAUNOrubicin Hydrochloride|Given IV
1944950|NCT00671034|Drug|DOXOrubicin Hydrochloride|Given IV
1944951|NCT00671034|Drug|Cytarabine|Given IV, IT, or SC
1944952|NCT00671034|Drug|Prednisone|Given IV or PO
1944953|NCT00671034|Drug|methotrexate|Given IV, IT, or PO
1944954|NCT00671034|Drug|cyclophosphamide|Given IV
1944955|NCT00671034|Drug|mercaptopurine tablet|Given PO
1944956|NCT00671034|Drug|Dexamethasone|Given PO or IV
1944957|NCT00671034|Drug|thioguanine|Given PO
1944958|NCT00671034|Drug|pegaspargase|Given IV
1944959|NCT00671034|Drug|vincristine sulfate|Given IV
1944960|NCT00671034|Radiation|radiation therapy|Some patients undergo RT
1944961|NCT00671034|Other|laboratory biomarker analysis|Correlative studies
1944962|NCT00671034|Other|pharmacological study|Correlative studies
1944963|NCT00669877|Drug|Rituximab|375 mg/m2 IV days 1 +/- 2 days and 11 +/- 2 days for the odd courses of therapy, and days 1 +/- 2 days and 8 +/- 2 days for the even courses of therapy, first 4 courses.
1944964|NCT00669877|Drug|Cyclophosphamide|300 mg/m2 IV over 3 hours every 12 hours x 6 doses days 1, 2, 3 (total dose 1800 mg/m2) starting after rituximab completed (odd courses).
1944965|NCT00669877|Drug|Doxorubicin|50 mg/m2 IV over 2-24 hours via CVC on day 4 after last dose of cyclophosphamide given (odd courses).
1944966|NCT00669877|Drug|Vincristine|2 mg IV on day 4 +/- 2 days and day 11 +/- 2 days (odd courses)
1944967|NCT00669877|Drug|Dexamethasone|40mg IV or by mouth (P.O.) daily days 1-4 +/- 2 days and days 11-14 +/- 2 days (odd courses)
1944968|NCT00669877|Drug|G-CSF|10 mcg/kg
1944969|NCT00669877|Drug|Cytarabine|100 mg intrathecal day 7 +/- 2 days (odd courses); 3 gm/m2 IV over 2 hours every 12 hours for 4 doses on days 2, 3 (even courses).
1944970|NCT00669877|Drug|Methotrexate|200 mg/m2 IV over 2 hrs followed by 800 mg/m2 over 22 hrs on day 1 after the completion of Rituximab.
1944971|NCT00669656|Drug|Prostate Health Cocktail|3 capsules daily PO up 12 months
1944972|NCT00668421|Drug|CEP-701 (Lestaurtinib)|Lestaurtinib (CEP-701), oral formulation. Phase 1: 80 BID - 160 BID; phase 2: 140 mg
1944973|NCT00668850|Drug|Generex Oral-lyn™|Generex Oral-lyn™ spray in a split-dose fashion (half the dose immediately prior to the meal and half the dose immediately after the meal) + BID NPH insulin AM and PM as pre-randomization dose
1944974|NCT00668850|Drug|Regular human insulin|Regular human insulin 30 minutes before meals + BID NPH insulin AM and PM as pre-randomization dose.
1945069|NCT00645450|Drug|Propranolol|Weekly doses of short and long acting propranolol following recollection of traumatic memory
1945188|NCT00622895|Radiation|total-body irradiation|Undergo TBI
1944975|NCT00667615|Drug|rituximab, cyclophosphamide, etoposide, prednisone, vorinostat and QOL questionnaire, peg-filgrastim or filgrastim|Patients will be treated with 6 cycles of rituximab, cyclophosphamide, etoposide, prednisone and vorinostat every 4 weeks. Quality of life determinations will be obtained at the beginning of each cycle of chemotherapy and at each visit during the first year of followup.
1944978|NCT00665587|Procedure|Cox-MAZE III|Maze procedure according to standards of the department
1944979|NCT00665418|Drug|sevoflurane|sevoflurane 2.5% versus 4.7% (inhaled concentration) 10min each
1944980|NCT00665392|Drug|cisplatin|75 mg/m², day 1. 3 cycles
1944981|NCT00665392|Drug|docetaxel|75 mg/m² Day 1. 3 cycles
1944982|NCT00665392|Drug|fluorouracil|750 mg/m² day 1 to day 5. 3 cycles
1944983|NCT00665392|Drug|Cetuximab|400 mg/m² Day 1, 250 mg/m² Day 8 and Day 15. 3 cycles.
1944984|NCT00664599|Drug|Rituximab|Infusion of Rituximab, 1500 mg, two times with 15 days interval. Patients receive also Methotrexate (15 mg weekly) and Prednisolone (0.5 mg/daily).
1944985|NCT00664599|Drug|Cytotoxic Combination|Pulse cyclophosphamide 1000 mg in perfusion, once monthly monthly. Azathioprine 3 mg/kg/body weight daily + prednisolone 0.5 mg/kg/daily.
1944986|NCT00663689|Drug|erlotinib|erlotinib 150mg qd until disease progression or unacceptable toxicity.
1944987|NCT00663377|Drug|losartan|losartan 50-100mg for 16 weeks
1944988|NCT00664170|Drug|ANX-514|75 mg/m^2
1944989|NCT00664170|Drug|docetaxel|75 mg/m^2
1944990|NCT00664222|Drug|spironolactone + furosemide|spironolactone 25mg/day, 16 weeks and furosemide 20mg/day, 16weeks
1944991|NCT00663039|Drug|Oxytocin|24 IU oxytocin (or Placebo) in a total of 6 puffs (3 puffs per nostril)
1944992|NCT00663039|Drug|Placebo|Single dose (plus a booster dose) drug probe study using intranasal placebo
1944993|NCT00662246|Radiation|respiratory gated proton beam radiotherapy|- Prescription dose to PTV as according to the following dose escalation schema: Dose level 1: 60 GyE /20 fx, 3GyE fraction dose, 5 days/week. Dose level 2: 66 GyE /22 fx, 3GyE fraction dose, 5 days/week. Dose level 3: 72 GyE /24 fx, 3GyE fraction dose, 5 days/week.
1944994|NCT00661648|Device|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
1944995|NCT00661557|Biological|Meningococcal vaccine GSK134612|one dose, as intramuscular injection
1944996|NCT00661414|Biological|ASONEP (sonepcizumab/LT1009)|"ASONEP [sonepcizumab/LT1009] is supplied as a colorless,particulate-free, pH 6.5, sterile solution containing approximately 10 mg/mL or 20 mg/mL of drug.
The candidate drug is intended for single intravenous (iv) use administered over 90 minutes on a weekly basis."
1944997|NCT00661271|Behavioral|Mindfulness-based stress reduction (MBSR)|8 weekly sessions with instruction designed to enhance mindfulness--mindful meditation, mindful yoga, and discussion of mindfulness practice.
1944998|NCT00661271|Behavioral|Healthy topics|8 week health education program
1944999|NCT00660530|Drug|Lanthanum carbonate|Lanthanum carbonate 1 g to be chewed, three times daily with meals
1945000|NCT00660530|Drug|Lanthanum carbonate|Lanthanum carbonate 1 g crushed into a fine powder, three times daily with meal
1945001|NCT00660933|Drug|Iron sucrose|Iron sucrose 200 mg/day iv, (20 mg/ml) + 200 cc de NaCl 0,9%/day in 60 minutes per 2 days.
1945002|NCT00660933|Drug|NaCl|NaCl 0,9% 200 ml /day iv in 60 minutes per 2 days
1945005|NCT00659204|Drug|nano-silver gel exposed|SilvaSorb® gel applied topically to the hands with a limited exposure time of 10 minutes
1945006|NCT00659204|Drug|alcohol-based hand gel|Purell gel applied topically to the hands with a limited exposure time of 10 minutes
1945007|NCT00659698|Device|the closed-loop STG-22 system (Nikkiso Inc, Tokyo, Japan)|artificial pancreas
1945008|NCT00658879|Drug|Pegvisomant|"Pegvisomant 10, 15 or 20mg powder and solvent for solution for injection.
Dosage, Frequency : According to Japanese LPD.
Duration : According to the protocol of A6291023, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 5 years after the first administration."
1945009|NCT00658840|Drug|Capecitabine (Xeloda®)|Capecitabine is administered orally at a dose of 800 mg/m2 twice daily (total daily dose 1600mg/ m2) continuous regimen regimen during RT (5 days of treatment followed by a 2 day rest: Saturday and Sunday). Capecitabine is given approximately 12 hours apart and taken orally with water within 30 minutes after ingestion of food (breakfast or dinner).
1945010|NCT00658840|Radiation|Localization, simulation and immobilization|"Radiation dose and planning
Total dose 55.8Gy, 28 fractions, 6-7 weeks (1.8 Gy/day). A cone down after 45 Gy will be performed to emcompass GTV with a margin of 1-1.5cm.
Dose prescription : 90% isodose volume of prescribed dose encompassed PTV
The dose-volume histogram (DVH) of targets, such as GTV, CTV, and PTV, and the normal tissues, such as the liver, duodenum, stomach, the kidneys, spinal cord, etc., was calculated."
1945013|NCT00658359|Drug|Cyclosporine|Standard of care
1945014|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
1945015|NCT00658359|Drug|CP-690,550|CP-690,550 tablets dosed BID Months 12-72
1945017|NCT00657137|Drug|apricoxib + lapatinib + capecitabine|"apricoxib: 100 mg tablets, 400 mg/day
lapatinib: per package insert
capecitabine: per package insert"
1945018|NCT00657137|Drug|placebo + lapatinib + capecitabine|"placebo: 100 mg tablets, 400 mg/day
lapatinib: per package insert
capecitabine: per package insert"
1945024|NCT00655681|Drug|pamidronate|The pamidronate is mixed 1 to 10 (10 cc of saline for each 1 mg pamidronate), with a minimum volume of 50 cc saline. The medication is administered as an IV infusion to run at a rate beginning at 20 cc/hr, adjusting the rate so that the infusion will run over 4 hours. For children < 8 kg (80cc infusion), the rate would be 20 cc/hr and the duration would be determined by the volume.
1945025|NCT00655681|Other|saline|receives saline 10cc/kg over 4 hours post operatively in addition to routine post operative fluids
1945026|NCT00655499|Biological|panitumumab|
1945027|NCT00655499|Drug|irinotecan hydrochloride|
1945028|NCT00655499|Genetic|chromogenic in situ hybridization|
1945029|NCT00655499|Genetic|fluorescence in situ hybridization|
1945030|NCT00655499|Genetic|gene expression analysis|
1945031|NCT00655499|Other|laboratory biomarker analysis|
1945032|NCT00655161|Biological|GI-4000|subcutaneous injection, 40YU weekly for 3 weeks followed by monthly for 6 months them quarterly until recurrence
1945033|NCT00654459|Dietary Supplement|Mixture of Berberine, Policosanol, Red Yeast, Placebo|A tablet one a day for 6 weeks
1945036|NCT00654524|Drug|gonadotropin-releasing-hormone agonist (GnRHa) - Goserelin|The patient will be managed with GnRH-a injection (Goserelin 3.6mg) every 4 weeks for 6 months plus add-back therapy (Caltrate With Vitamin D 600mg p.o. q.d.& Livial 1.25-2.5mg p.o. q.d.) if needed.
1945037|NCT00653991|Behavioral|Socially Optimized Learning in a Virtual Environment (SOLVE)-IT|SOLVE-IT, a video game using computer-generated virtual agents, is the next generation of interactive media aimed at reducing risky sex among young MSM. Participants will interact in a virtual environment that focuses upon HIV prevention in a dating context.
1945039|NCT00652951|Biological|GSK Biologicals´ Pneumococcal Conjugate Vaccine (GSK1024850A)|Intramuscular injection, 3 doses in the primary vaccination and 1 dose in the booster vaccination
1945040|NCT00652951|Biological|Infanrix™ hexa.|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
1945041|NCT00652951|Biological|Pediacel™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
1945042|NCT00652951|Biological|Prevenar™|Intramuscular injection, , 3 doses in the primary vaccination and 1 dose in the booster vaccination
1945043|NCT00652743|Biological|Pandemic influenza vaccine GSK1562902A|IM administration
1945045|NCT00650871|Drug|GW679769|
1945046|NCT00650871|Drug|Placebo|
1945047|NCT00649701|Behavioral|Standard Text-Based Prevention Web Page|A link to the CDC.gov web page which describes HIV prevention among men who have sex with men.
1945048|NCT00649701|Behavioral|The Morning After|A dramatic video about 4 gay men addressing sexual risk reduction within the context of alcohol use.
1945049|NCT00649701|Behavioral|Talking About HIV|A documentary video addressing HIV disclosure, HIV testing, and condom use with the sub-context of drug use.
1945050|NCT00649701|Behavioral|Both Videos|Morning After and Talking About HIV videos
1945051|NCT00650338|Drug|DE-104 ophthalmic solution, low concentration|Topical ocular application
1945052|NCT00650338|Drug|DE-104 ophthalmic solution, medium concentration|Topical ocular application
1945053|NCT00650338|Drug|DE-104 ophthalmic solution, high concentration|Topical ocular application
1945054|NCT00650338|Drug|Placebo|placebo
1945055|NCT00650338|Drug|0.005% latanoprost|Topical ocular application
1945056|NCT00645918|Drug|clopidogrel|oral, 75 mg daily for 6 months starting on day of randomization
1945057|NCT00645918|Drug|placebo|oral, 6 pill loading dose on day of randomization; one pill daily for 6 months starting on day of randomization
1945058|NCT00645918|Drug|clopidogrel|oral, 450 mg loading dose on day of randomization; 75 mg daily for 6 months starting on day of randomization
1945059|NCT00646646|Drug|propofol|sedative
1945060|NCT00646646|Drug|dexmedetomidine|Sedative
1945061|NCT00646646|Drug|Midazolam|sedative
1945062|NCT00646646|Drug|saline placebo|saline placebo
1945063|NCT00646451|Drug|pregabalin|75 mg bid to 300 mg bid based on per subject tolerability
1945064|NCT00646451|Drug|placebo capsules|up to 4 capsules bid as tolerated
1945065|NCT00646204|Drug|Memantine|10 mg bid
1945066|NCT00646204|Drug|placebo|2 tabs bid
1945067|NCT00645944|Drug|Eszopiclone|Eszopiclone 2mg each night for the first week then Eszopiclone 3mg each night for the remaining weeks.
1945070|NCT00645450|Drug|Placebo|Weekly doses of placebo following recollection of traumatic memory
1945073|NCT00643565|Drug|Standard chemotherapy|As prescribed
1945074|NCT00643565|Drug|bevacizumab [Avastin]|7.5 mg/kg iv on day 1 of 9 x 3-week cycles, followed by 5 mg/kg iv on days 1 and 15 of each 4-week cycle
1945075|NCT00642434|Drug|carvedilol|variable
1945076|NCT00642434|Drug|metoprolol|variable
1945077|NCT00641134|Other|A: Home-Based exercise after Cardiac Rehabilitation|Home-Based exercise program,after CR, with reinforcement sessions
1945078|NCT00642148|Drug|GW856553|Active tablet
1945079|NCT00642148|Drug|Placebo|Placebo tablet and inhaler
1945080|NCT00642148|Drug|Seretide|Active comparator inhaler
1945087|NCT00640653|Behavioral|Abstinence-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence. The intervention is not an abstinence-until-marriage intervention; the target behavior is abstaining from sexual activity until later in life when the adolescent is more prepared to handle the consequences. The intervention does not contain inaccurate information, portray sex in a negative light, or employ a moralistic tone. It is not designed to affect condom use.
1945088|NCT00640653|Behavioral|Safer-sex-only HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for using condoms during sexual intercourse. The intervention is not designed to influence abstinence.
1945089|NCT00640653|Behavioral|Long comprehensive HIV/STD risk-reduction intervention|Participants will attend three sessions consisting of twelve 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active. The intervention consists of the safer-sex-specific content (4 hours), the abstinence-specific content (4 hours), and the general content that is common to both of the single-component interventions (4 hours).
1945090|NCT00640653|Behavioral|Short comprehensive HIV/STD risk-reduction intervention|Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for practicing abstinence and for using condoms if participants decide to be sexually active.
1945091|NCT00640653|Behavioral|Health promotion control intervention|"Participants will attend two sessions consisting of eight 1-hour modules that are designed to increase knowledge, motivation, and skill for avoiding cigarette smoking and for incorporating a healthful diet, aerobic exercise, and breast and testicular self-examinations. The control intervention will focus on reducing risk of heart disease, hypertension, diabetes, and certain cancers. The intervention provides a control for Hawthorne effects to reduce the likelihood that the HIV/STD interventions' effects can be attributed to group interaction and special attention."
1945092|NCT00640250|Biological|T.R.U.E. TEST® Skin Patch Test: Dose Response Allergens|"Disperse blue 106 in PVP, 0.15 mg/cm2 Disperse blue 106 in PVP, 0.050 mg/cm2 Disperse blue 106 in PVP, 0.017 mg/cm2 PVP Negative Control Bronopol in PVP, 0.75 mg/cm2 Bronopol in PVP, 0.50 mg/cm2 Bronopol in PVP, 0.25 mg/cm2 Bronopol in PVP, 0.125 mg/cm2
Test patches, with allergens, are placed at day one and removed 48 hours later. The duration of the study lasts 21 days. However, the subject is only exposed to the study allergens for 48 hours."
1945095|NCT00640159|Drug|Zelapar|Switch from oral selegiline to Zelapar 1.25 mg QD titrated to 2.5 mg QD
1945096|NCT00639431|Behavioral|direct observation|direct observation of another person's foot moving
1945097|NCT00639431|Behavioral|mental visualization|mentally imagining moving one's phantom foot/feet
1945098|NCT00639626|Drug|insulin detemir [rDNA origin] injection|Starting dose of 0.1-0.3 units/kg/day in a once daily subcutaneous injection.
1945099|NCT00638508|Drug|Ketorolac|Patients will receive Ketorolac at 5 mg/hr not to exceed 120 mg/day
1945100|NCT00638508|Drug|Ketorolac and Ropivacaine|Patients will receive Ketorolac at 5 mg/hr plus 0.5% Ropivacaine
1945103|NCT00636584|Drug|sodium nitroprusside|sodium nitroprusside infusion at 1 microgram/kg/min dose during rewarming period of cardiac operations
1945104|NCT00636584|Drug|placebo|placebo
1945105|NCT00636506|Device|AMS IPP 2005|
1945106|NCT00636350|Dietary Supplement|Pepper|pepper carotenoids as meals
1945107|NCT00635622|Drug|LACTIN-V|Vaginal application of single-use applicators pre-filled with LACTIN-V (Formulation 1) at 2 x 10^9 cfu/dose or placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
1945108|NCT00635622|Drug|Placebo control substance|Vaginal application of single-use applicators pre-filled with placebo control substance. The study product will be administered once daily for 5 consecutive days, followed by once weekly application over 2 consecutive additional weeks.
1945150|NCT00627640|Drug|Matching Placebo|Matching Placebo
1945111|NCT00635921|Drug|ziprasidone|Dose flexible from 40 to 200 mg/d during 12 weeks
1945112|NCT00635921|Drug|Placebo|flexible doses from 40 to 200 mg/d during 12 weeks
1945113|NCT00636116|Biological|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Anavip Maintenance Therapy
1945114|NCT00636116|Biological|Crotalinae (pit viper) equine immune F(ab)2|Anavip with Placebo Maintenance Therapy
1945115|NCT00636116|Biological|Crotalidae Polyvalent Immune Fab, ovine|CroFab with CroFab Maintenance Therapy
1945116|NCT00634283|Drug|venlafaxine|venlafaxine IR 150mg
1945117|NCT00635375|Device|LED fiberoptic blanket phototherapy (BiliSoft blue LED fiberoptic blanket phototherapy)|35-50 mW/cm2/nm
1945118|NCT00635375|Device|Metal halide phototherapy (Spot PT metal halide phototherapy)|29.3-57.6 mW/cm2/nm
1945119|NCT00635375|Device|LED bank phototherapy (Natus neoBlue LED bank phototherapy)|12-35 mW/cm2/nm
1945120|NCT00635375|Device|Metal halide plus LED fiberoptic blanket phototherapy (BiliSoft and Spot PT)|29.3-57.6 mW/cm2/nm and 35-50 mW/cm2/nm
1945121|NCT00633945|Drug|lenalidomide (Revlimid®)|The drug will be administered in oral form. The dosage of lenalidomide (REVLIMID®) will be lower or equivalent to the dosages indicated for the above uses. The dose will be as low as 5 mg every other day, or will be as high as 10 mg daily. Subjects will be treated with medication for 48 weeks.
1945122|NCT00633321|Biological|TA-NIC|TA-NIC vaccine will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
1945123|NCT00633321|Biological|Placebo|Placebo will be administered to each subject as 7 single doses administered at Weeks 0, 2, 4, 6, 8, 12, and 16.
1945124|NCT00633282|Behavioral|Life style intervention|"calorie limited diet: to subtract 500 kcal from daily mean calorie intake when entering the treatment
activity: medium intensity aerobic exercise for more than 150 min per week with heart rate around 50－70% of the maximal heart rate; or higher-intensity aerobic exercise for more than 90min per week with heart rate around 70% of the maximal heart rate"
1945125|NCT00633282|Drug|pioglitazone|pioglitazone tablet,15mg qd ,30 minutes before breakfast,for 16 weeks
1945126|NCT00633282|Drug|berberine|berberine tablet 0.5g tid,30 minutes before each meal,for 16 weeks
1945127|NCT00633022|Drug|GW856553 7.5 mg twice a day|GW856553 7.5 mg twice a day
1945128|NCT00633022|Drug|placebo|placebo
1945129|NCT00633022|Drug|GW856553 7.5 mg once a day|GW856553 7.5 mg once a day
1945130|NCT00632359|Drug|Lenalidomide|10 mg daily given for 12 months
1945131|NCT00632060|Procedure|Manual / Manipulative Therapy (M/MT)|Subjects will receive M/MT twice a week for 4 weeks
1945132|NCT00631137|Drug|testosterone gel|
1945133|NCT00631137|Procedure|questionnaire administration|
1945134|NCT00631553|Drug|perflutren lipid microspheres|1.3 ml in 30 ml of saline, infused into vein at 2ml / min and titrated for optimal image quality (not to exceed 10 ml/ min at any time).
1945135|NCT00631319|Drug|OROS HYDROMORPHONE|QD opioid pain reliever for OA pain-patients.
1945136|NCT00631254|Procedure|Allergen challenge|"Conventional allergen challenge: increasing allergen doses given by nebulisation through the mouth and stopped when a 20% fall in forced expiratory volume in one second is obtained.
Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.
Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
1945137|NCT00631254|Procedure|Allergen challenge|"Low dose allergen challenge: very low allergen doses given by nebulisation through the mouth. No more than a 5% fall in forced expiratory volume in one second.
Nasal allergen challenge: One drop of increasing allergen doses on nasal mucosa."
1945138|NCT00630981|Behavioral|Psychotherapy|Specific psychotherapy for dissociative disorders
1945139|NCT00630981|Drug|Pharmacological treatment (Quetiapine and/or Escitalopram)|Quetiapine for psychotic symptoms/Escitalopram if depressive disorders
1945140|NCT00630019|Drug|1.5% levofloxacin ophthalmic solution|Topical application
1945141|NCT00630019|Drug|0.5% moxifloxacin hydrochloride ophthalmic solution|Topical application
1945142|NCT00629122|Drug|Tacrolimus/Clotrimazole Troche|"Study day 1 (9 am): Initiate sublingual tacrolimus and clotrimazole troche x 5 doses.
Study day 3 (9 am): Collection of pharmacokinetic parameters around the 5th sublingual tacrolimus dose.
Study day 3 (9 pm): Start washout period, no drug administration (tacrolimus, clotrimazole).
Study day 5 (9pm): End washout period.
Study day 6 (9am): Initiate oral tacrolimus and clotrimazole troche x 5 doses.
Study day 8 (9 am): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose.
Study day 15: Participants will be contacted by telephone to assess for any adverse effects.
To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8)."
1945143|NCT00629122|Drug|Tacrolimus/Nystatin Suspension|"Study day 1 (9 am): Initiate sublingual tacrolimus and nystatin suspension x 5 doses.
Study day 3 (9 am): Collection of pharmacokinetic parameters around the 5th sublingual tacrolimus dose.
Study day 3 (9 pm): Start washout period, no drug administration (tacrolimus, nystatin).
Study day 5 (9pm): End washout period.
Study day 6 (9am): Initiate oral tacrolimus and nystatin suspension x 5 doses.
Study day 8 (9 am): Collection of pharmacokinetic parameters around the 5th oral tacrolimus dose.
Study day 15: Participants will be contacted by telephone to assess for any adverse effects.
To ensure that dietary intake does not affect the absorption profile of tacrolimus we will ensure that breakfast is given 15 minutes prior to drug administration on the days of pharmacokinetic assessment (study day 3 and 8)."
1945144|NCT00628914|Drug|escitalopram and eszopiclone|escitalopram 10mg tabs QD and eszopiclone 3 mg tabs QD for 8 weeks
1945145|NCT00628914|Drug|Escitalopram, eszopiclone, and placebo|Escitalopram 10mg tabs QD for 8 weeks; Eszopiclone 3mg tabs QD for initial 4 weeks then placebo tabs QD for final 4 weeks
1945146|NCT00628914|Drug|Escitalopram|Escitalopram 10mg tabs QD and placebo tabs QD for 8 weeks
1945147|NCT00628433|Drug|Placebo|Placebo
1945148|NCT00628433|Drug|HE3286|daily for 28 days
1945149|NCT00627640|Drug|Safinimide 50-100 mg/day|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
1945151|NCT00626678|Drug|Azathioprine|It is given in a consistent dosage of 2.5 mg/kg/day throughout the study
1945152|NCT00626678|Drug|Prednisone|Oral corticosteroid initiated at 2 mg/kg/day dosage. Dosage may be tapered primarily by 1/3 total dosage if no new blister, then 5 mg every three days to reach the daily dosage of 30 mg then tapered by 1.25 mg every week to reach daily dosage of 20 mg/day, then tapered by 1.25 mg every two weeks to reach daily dosage of 10 mg, then tapered by 1.25 mg monthly to reach daily dosage of 7.5 mg and continue this dosage for six months then tapered to 5 mg/day if no new lesions are observed as determined by clinical assessment of the investigator.
1945153|NCT00626678|Drug|Placebo|Placebo given in place of Azathioprine 2.5 mg/kg/day throughout the study
1945154|NCT00626912|Procedure|endovascular coil embolization|standard endovascular coil embolization with or without adjunct techniques
1945157|NCT00626665|Drug|Tadalafil|Tablets Tadalafil, 20 mg, alternate days, 6 weeks
1945158|NCT00626405|Biological|bevacizumab|Given IV over 30-90 minutes
1945159|NCT00626405|Drug|carboplatin|Given IV over 30 minutes
1945160|NCT00626405|Drug|paclitaxel albumin-stabilized nanoparticle formulation|Given IV over 30 minutes
1945161|NCT00626405|Drug|temozolomide|Oral temozolomide on days 1-5
1945162|NCT00624923|Drug|Salsalate|Salsalate, 500 mg, seven tablets daily by mouth, divided into two doses, for 30 months
1945163|NCT00624923|Drug|Placebo|Salsalate Placebo, seven tablets daily by mouth, divided into two doses, for 30 months
1945164|NCT00625573|Drug|Abraxane|100mg/m2 every week X's 3
1945165|NCT00625352|Drug|Gemcitabine, UFT|Gemcitabine 1,250mg/m2 IV on D1 and D8 of every 3 weeks combined with UFT 400mg daily PO for 14 days every 3 weeks. Gemcitabine will be administered to patients a maximum of 4 cycles, and then discontinued. UFT will be continued until progression.
1945166|NCT00624429|Drug|Budesonide respules|Budesonide respules 0.5 mg nebulized once a day for 4 months of the study.
1945167|NCT00624819|Biological|GSK1024805A|No vaccination in this trial
1945168|NCT00624819|Biological|Prevenar|No vaccination in this trial
1945169|NCT00624637|Other|aromatherapy massage|Ten minutes massage of hands, arms or feet with mandarin essential oil 1% (Citrus reticulata) or with carrier oil only
1945170|NCT00623766|Drug|Ipilimumab|10 mg/kg, administered as an intravenous infusion every 3 weeks during induction and every 12 weeks during maintenance
1945171|NCT00623766|Drug|Corticosteroid: Betamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with betamethasone
1945172|NCT00623766|Drug|Corticosteroid: Dexamethasone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with dexamethasone
1945173|NCT00623766|Drug|Corticosteroid: Fludrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with fludrocortisone
1945174|NCT00623766|Drug|Corticosteroid: Hydrocortisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with hydrocortisone
1945175|NCT00623766|Drug|Corticosteroid: Meprednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with meprednisone
1945176|NCT00623766|Drug|Corticosteroid: Methylprednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with methylprednisolone
1945177|NCT00623766|Drug|Corticosteroid: Prednisolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisolone
1945178|NCT00623766|Drug|Corticosteroid: Prednisone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with prednisone
1945179|NCT00623766|Drug|Corticosteroid: Triamcinolone|Participants in the corticosteroid-dependent arm for whom adequate control of metastatic brain lesion-related neurologic signs and symptoms required concurrent corticosteroid therapy with triamcinolone
1945180|NCT00624182|Biological|Peptide vaccine for URLC10|Increasing the doses of URLC10 peptides will be administered by subcutaneous injection on day 1, 8, 15, and 22 of each 28-day treatment cycles. Doses of 0.5, 1.0, 2.0mg/body are planned. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
1945181|NCT00624182|Drug|Gemcitabine|Gemcitabine will be administered intravenously at a fixed dose of 1000mg/m2 on day 1, 8, and 15. Repeated cycles of this therapy will be continued until patients develop progressive disease or unacceptable toxicity, or maximum 2 cycles, whichever occurs first.
1945182|NCT00624078|Drug|Antivenin Centruroides (scorpion) F(ab)2 Anascorp™|three vials diluted in 20 to 50 mL normal saline administered intravenously. Subsequent single vial doses of Anascorp, up to a total of five vials administered at thirty minutes intervals until resolution of symptoms.
1945184|NCT00623168|Drug|Ribavirin|7 Day multiple dosing regime based on weight and dosage day
1945189|NCT00622895|Procedure|bone marrow transplantation|Undergo transplantation
1945190|NCT00622895|Procedure|reduced intensity allogeneic hematopoietic stem cell transplantation|Undergo transplantation
1945191|NCT00622895|Procedure|quality-of-life assessment|Ancillary studies
1945192|NCT00622895|Other|laboratory biomarker analysis|Correlative studies
1945193|NCT00622895|Other|flow cytometry|Correlative studies
1945194|NCT00622895|Procedure|biopsy|Punch biopsy of skin involved with scleroderma
1945195|NCT00622895|Drug|cyclophosphamide|Given IV
1945196|NCT00620789|Drug|Escitalopram + CBT-I|"Escitalopram, 10 mg daily for the duration of the study (6 months)
CBT-I, four biweekly sessions during eight week Treatment phase."
1945197|NCT00620789|Behavioral|CBT-I plus placebo antidepressant medication|"CBT-I, 4 biweekly sessions, eight week Treatment phase.
Placebo,daily for duration of study(6 months)."
1945198|NCT00620789|Drug|Escitalopram|"Escitalopram, 10 mg daily for the duration of the study (6 months)
SH, four biweekly sessions during eight week Treatment phase"
1945199|NCT00622180|Device|Daavlin Spectra UVB Hand/Foot Box|Narrow-band ultraviolet B hand box
1945200|NCT00622180|Device|Excilite Focal 308-nm light|Excilite Focal 308-nm light
1945201|NCT00622076|Procedure|postoperative catheterization|postoperative catheterization after anterior colporrhaphy for five days versus two days.
1945202|NCT00621816|Drug|nitroprusside|nitroprusside continuous infusion, dose to be titrated to clinical effect
1945203|NCT00621816|Drug|placebo infusion|blinded placebo infusion, to be infused at same rate as open-label nitroprusside infusion
1945204|NCT00621309|Drug|Rifampicin|Rifampicin, an antibiotic used to treat TB, is administered at a dose of 300 mg day x 7 days to induce CYP3A5.
1945205|NCT00621309|Dietary Supplement|sulforaphane plus rifampicin|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes. Sulforaphane is administered daily for 7 days as a broccoli sprout extract, at a dose rate of 75 mg (~420 umoles)per day for 7 days. Rifampicin is also administered once per day at a dose rate of 300 mg/day for 7 days.
1945206|NCT00621309|Dietary Supplement|sulforaphane alone|Sulforaphane (SFN) is an isothiocyanate derived from the plant phytochemical, glucoraraphinin. It appears to inhibit ligand binding to the ligand activated nuclear transcription factor, Pregnane X-Receptor (PXR). This arm tests the hypothesis that SFN can block ligand binding to the PXR, thereby inhibiting transcriptional activation of PXR-regulated genes
1945207|NCT00620165|Drug|levetiracetam|Subjects will receive levetiracetam titrated up over 6 weeks to a maximum dose of 3000 milligrams (mg) per day, and then continue at 1500 mg twice daily for an additional 6 weeks.
1945208|NCT00620165|Drug|placebo|Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
1945209|NCT00620503|Drug|Proellex 25 mg|One Proellex 25 mg capsule for one day administered after being fed
1945210|NCT00620503|Drug|Proellex 25 mg|One 25 mg Proellex capsule for one day administered while fasting
1945211|NCT00620191|Drug|metformin|metformin 1000 mg twice a day titrated from 500 mg once a day
1945212|NCT00620191|Drug|placebo|placebo identical to metformin 2 tablets twice a day titrated from one table once a day
1945213|NCT00620061|Drug|Lubiprostone|24 mcg capsules twice daily (BID) for 9 months
1945214|NCT00619723|Drug|Citicoline|Citicoline is a psychostimulant/nootropic. It is an intermediate in the generation of phosphatidylcholine from choline.
1945215|NCT00619723|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
1945216|NCT00619723|Behavioral|Cognitive Behavioral Therapy (CBT)|Participants will receive manual-driven Cognitive Behavioral Therapy (CBT: two sessions each week for 4 weeks followed by weekly sessions, total 16 sessions) specifically designed for persons with bipolar 1 disorder and substance abuse, and provided by a therapist with experience in CBT.
1945217|NCT00619255|Behavioral|Adolescent Trauma Support Program|The study team will be organized into an adolescent trauma support service. The adolescent trauma support service will fundamentally restructure psychosocial care by integrating post-injury medical treatment with alcohol and PTSD detection and treatment. The adolescent trauma support specialists will deliver a stepped collaborative care intervention to adolescents and their families over the 6-12 months post-injury.
1945218|NCT00619034|Drug|Latanoprost, diclofenac and dorzolamide (eyedrops)|1 eyedrop twice daily in one week
1945219|NCT00619034|Drug|Diclofenac|dicolfenac eyedrops twice daily i one eye
1945220|NCT00619034|Drug|Dorzolamide|dorzolamide eyedrops twice daily, in one eye for one week
1945221|NCT00617500|Other|flower therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
1945222|NCT00617500|Other|therapeutic touch|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
1945223|NCT00617500|Other|auricular therapy|Each woman will perform 12 sessions of 20 to 30 minutes, depending on the treatment group, with weekly intervals performed in one of the consultation rooms.
1945224|NCT00617500|Drug|Hormones|Estradiol 1 mg and a drospirenone 2mg/day (3 months)
1945228|NCT00616564|Drug|GM-CSF|Concomitant Priming with GM-CSF
1945229|NCT00616980|Biological|CD34-positive cells|
1945230|NCT00616980|Biological|CD34-positive cells|
1945231|NCT00616980|Biological|Saline and 5% autologous plasma|
1945232|NCT00617266|Other|tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural Therapy only
1945452|NCT00562965|Drug|rituximab|IV administration, 375 mg/m² on day 1 of each cycle every 28 days, for up to 8 cycles.
1945233|NCT00617266|Other|Tobacco cessation intervention|Active Health Education and Tobacco Cessation Programme for tobacco users using Behavioural and Pharmaco-therapy
1945234|NCT00617266|Other|Tobacco cessation intervention|Distribution of pamphlets containing information on the hazards of tobacco
1945235|NCT00617266|Other|Tobacco cessation intervention|Active Health Education sessions (harmful effects of tobacco addiction) followed by focus group discussion for all BPO employees
1945236|NCT00613834|Drug|Lidocaine|5 ml intrauterine infusion of 4% lidocaine using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
1945237|NCT00613834|Drug|Sterile Saline|5 ml intrauterine infusion of sterile saline using a sterile 3 mm Novak curette will be infused slowly over 4 1/2 minutes
1945238|NCT00612820|Drug|GSK256066|200mcg bd,
1945239|NCT00612820|Drug|fluticasone propionate|200mcg od,100mcg bd
1945240|NCT00613184|Device|Nylon Flocked swab (Nasal secretion sampling)|Nasal Aspirate Nylon Flocked swab
1945241|NCT00613184|Device|Nylon Flocked swab (Nasal secretion sampling)|Nylon flocked swab Nasal Wash
1945242|NCT00613067|Drug|escitalopram|"Start with escitalopram 10mg
According to patient's symptoms, stay on 10mg or increase up to 20mg
Concomitant therapy : up to Xanax 0.5mg, or Ativan 1mg, not allowed above these dosages
Length of washout period will be at least 2 weeks for any psychotropic drugs"
1945243|NCT00612768|Biological|TRUE TEST Skin patch test Bioequivalence|"Thimerosal, 0.008 mg/cm2 in hydroxypropylcellulose
Thimerosal, 0.008 mg/cm2 in polyvinylpyrrolidone
Fragrance mix, 0.43 mg/cm2 in hydroxypropylcellulose with β-cyclodextrin
Fragrance mix, 0.43 mg/cm2 in polyvinylpyrrolidone with β-cyclodextrin
Patches are placed at day one and removed 48 hours. The duration of the study lasts 21 days. However, the subject is only exposed the the study allergen for 48 hours."
1945244|NCT00612118|Drug|GSK256066|200mcg bd
1945245|NCT00612118|Drug|azelastine hydrochloride|140mcg
1945246|NCT00612560|Drug|Anastrozole|1 mg per day
1945247|NCT00612560|Dietary Supplement|flaxseed|25 g per day ground
1945248|NCT00612560|Drug|Placebo|Placebo pill 1 per day
1945249|NCT00612443|Behavioral|Sham treatment|The sham/placebo treatment will consist of the RN graduate assistant standing near the table, slowly walking around from each side and to the foot of the table stopping periodically. The RN graduate assistant will be instructed to not focus on the patient in thought. While providing the placebo treatment the RN graduate assistant will mentally do multiplication equations. This serves as a distracter to keep the RN graduate assistant from setting intention or thoughts on the participant. At no time will the RN performing the placebo treatment move hands or arms over or around the participant or come in physical contact with the participant. The placebo treatment will be a minimum of 20 minutes but no greater than 30 minutes in length. A timer will be set in the treatment room to notify the practitioner of the time limit.
1945250|NCT00612443|Behavioral|Healing Touch|Behavioral: Healing Touch The Healing Touch intervention will consist of a brief meditative state in which the practitioners sets the intention of healing for the session. A hand scan to assess the biofield; consists of a technique of where the practitioner slowly moves her hands three to six inches above the body going from head to toe, to assess for any disturbances in the biofield; a non-contact Healing Touch treatment which will follow, to include a connection of the chakras. The chakras are connected by placing the hands above the body over each chakra, starting at the feet and progressing to the head. This will be followed by smoothing the biofield, achieved by the Practitioner slowly moving her hands above the body from the head and moving towards the feet (Hover-Kramer et al., 1996). At no time will the Practitioner make physical contact with the participant during the treatment. The treatment will be 20 minutes to 30 minutes in length.
1945251|NCT00610428|Drug|Staccato Prochlorperazine|Low dose
1945252|NCT00610428|Drug|Staccato Prochlorperazine|High dose
1945253|NCT00610428|Drug|Staccato Placebo|Placebo
1945254|NCT00611130|Drug|vigabatrin|Tablets twice a day for 9 weeks
1945255|NCT00611130|Drug|placebo|tablets twice daily for 9 weeks
1945256|NCT00610727|Drug|Prochlorperazine|10 mg IV over 2 min
1945257|NCT00610727|Drug|Prochlorperazine|0.5 mg IV over 5 sec
1945258|NCT00610727|Drug|Prochlorperazine|Staccato Prochlorperazine 0.625 mg
1945259|NCT00610727|Drug|Prochlorperazine|Staccato Prochlorperazine 1.25 mg
1945260|NCT00610727|Drug|Prochlorperazine|Staccato Prochlorperazine 2.5 mg
1945261|NCT00610727|Drug|Prochlorperazine|Staccato Prochlorperazine 5 mg
1945262|NCT00610727|Drug|Prochlorperazine|Staccato Prochlorperazine 10 mg
1945263|NCT00610727|Drug|Placebo|Staccato Placebo
1945264|NCT00610558|Device|positron emission tomography (PET)|FDG-glucose (10 mCi)
1945265|NCT00609271|Behavioral|low carbohydrate|<40 grams carbohydrate/day
1945266|NCT00609271|Behavioral|TLC diet|<35% fat, <7% saturated fat
1945267|NCT00609609|Procedure|Photopheresis|8-9 photopheresis treatments weekly for days 1-14, 6 treatments weekly from days 15-28, and after that 2 treatments weekly until day 60. After day 60, your doctor will decide whether ECP is worth continuing, and the frequency of treatments.
1945268|NCT00609609|Drug|Methylprednisolone|2 mg/kg daily with a taper to no less than 1 mg/kg/day by day 14, followed by a tapering schedule according to the suggested guidelines.
1945269|NCT00608972|Drug|Doxil|Doxil 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
1945270|NCT00608972|Drug|Carboplatin|Carboplatin 30 mg/m2 will be administered on Day 1 of each 28-day cycle.
1945271|NCT00608972|Drug|Bevacizumab|Bevacizumab 10 mg/kg will be administered on Day 1 immediately following chemotherapy and alone on Day 15 of each 28-day cycle.
1945272|NCT00609128|Drug|olopatadine|olopatadine one drop in one eye for two weeks
1945273|NCT00609063|Drug|Atorvastatin|80-mg atorvastatin capsules taken daily for 6 months
1945274|NCT00609063|Drug|Placebo|Placebo capsules taken daily for 6 months
1945275|NCT00608127|Device|LupusorbTM|Single treatment
1945276|NCT00607841|Drug|Ispinesib (SB-715992)|Phase I: Dose escalation of I.V. injection starting at 10mg/m2 on Days 1 and 15 of a 28 day cycle.
1945277|NCT00607841|Drug|Ispinesib (SB-715992)|Phase II: Fixed dose to be determined based on Phase I findings on Days 1 and 15 of a 28 day cycle
1945326|NCT00594932|Other|placebo|"oral placebo will be given in ascending doses during the first month and at full dose during the second and third month (or at lower dose if tolerance issues warrant)"
1945327|NCT00594932|Drug|Mycophenolate mofetil|Please see the Arm Description
1945279|NCT00607542|Drug|baclofen|2.5 mg oral baclofen tablets given three times a day; dose gradually escalated as specified in the protocol
1945280|NCT00607295|Drug|clino-san vaginal lubricant|Clino-san 2ml vaginal application 3 times per week for 12 weeks
1945281|NCT00607126|Device|Lokomat|locomotor training using body weight support on a treadmill
1945282|NCT00607126|Procedure|resistive training|resistive training using theraband and/or weights
1945283|NCT00606515|Drug|Liposomal paclitaxel|Patients will be given Liposomal paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
1945284|NCT00606515|Drug|Paclitaxel|Patients will be given paclitaxel intravenously in 3 hours with the dose of 175mg/m2 at the first day of chemotherapy. Cycle duration will be 21 days. Each patient will receive 3 cycles of therapy.
1945285|NCT00606697|Drug|GR205171|10 milligrams (mg)
1945286|NCT00606697|Drug|GW597599|15 mg
1945287|NCT00605319|Drug|Toviaz (Fesoterodine)|4mg to 8mg by mouth once daily
1945288|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide, (S)-(+)-2-[4-(3-fluorobenzyloxy) benzylamino] propanamide methanesulfonate, is an a-aminoamide derivative
1945289|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
1945290|NCT00605683|Drug|Safinamide (as add-on therapy)|Safinamide add-on therapy with subjects with IPD treated with single dopamine agonist
1945291|NCT00604175|Biological|Quadrivalent HPV vaccine|Quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine. All participants received the vaccine via intramuscular injection at baseline, Week 8 and Week 24.
1945292|NCT00603980|Drug|alprazolam|Staccato Alprazolam, single dose
1945293|NCT00603980|Drug|alprazolam|oral, immediate release
1945294|NCT00603980|Drug|placebo|Staccato placebo + oral placebo
1945295|NCT00603902|Drug|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
1945296|NCT00603902|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
1945297|NCT00603902|Drug|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
1945298|NCT00603291|Drug|Lorcaserin 10 mg QD|Lorcaserin 10 mg tablet each morning and placebo tablet each evening for a duration of 52 weeks.
1945299|NCT00603291|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 weeks.
1945300|NCT00603291|Drug|Matching Placebo|Matching placebo tablet each morning and evening for a duration of 52 weeks.
1945307|NCT00600990|Drug|GW597599|
1945308|NCT00601172|Drug|Casopitant|Experimental NK-1 receptor antagonist
1945309|NCT00601172|Drug|Dexamethasone and Ondansetron|Standard antiemetics
1945310|NCT00601172|Drug|Placebo|Placebo to match IV casopitant
1945311|NCT00599599|Behavioral|Prolonged Exposure Therapy|Participants will meet with a therapist twice a week for 5 weeks to complete the therapy. If the therapist and participant feel more sessions are needed, an additional 8 sessions will be provided.
1945312|NCT00598988|Procedure|traditional Chinese acupuncture|10 treatments over 6 weeks
1945313|NCT00598988|Other|standard medical care|standard care as provided by primary physician
1945314|NCT00598624|Drug|Treosulfan IV|Treosulfan i.v.: 14 g/m²/d from day -6 to day -4
1945316|NCT00598377|Drug|Tetracosactin|1 microgram tetracosactin, intravenous injection, once for the test
1945317|NCT00597870|Device|Endoluminal treament of thoracic lesions|Endoluminal treament of thoracic lesions with a thoracic stent-graft
1945322|NCT00597415|Drug|celecoxib|celecoxib 200mg
1945323|NCT00597415|Drug|placebo|placebo
1945324|NCT00597064|Drug|prednisone|oral prednisone 40 mg/day for 15 +/- 5 days
1945325|NCT00594932|Drug|mycophenolate mofetil|First treatment month: mycophenolate mofetil ascending doses orally Second treatment month to end of study: mycophenolate mofetil 3 gms/day (or less if tolerance issues arise)
1945362|NCT00585871|Drug|clonidine|0.1 mg tid
1945363|NCT00585871|Drug|metoprolol|25 mg tid
1945328|NCT00594997|Behavioral|Education|Students receive an educational intervention delivered by a member of our staff in conjunction with the teacher as well as a health education entertainer
1945329|NCT00594997|Behavioral|Control (pre and post surveys)|Students fill out a pre and post survey and then receive the same intervention given to the controls.
1945330|NCT00595621|Device|Enterra Multi-Channel Phased Gastric Pacemaker (MGP-1)|Multi-Channel Phased Gastric Pacemaker (MGP-1)
1945331|NCT00596258|Drug|A-007|applied topically for two 28-day cycles of 14 consecutive days of treatment each to the uterine cervix
1945332|NCT00593489|Other|Basal Insulin Initiation Strategy|This multifaceted intervention consists of (1) Diabetes Specialist Consultation Support which entails specialists and educators providing consultation for insulin initiation and titration for the 12 months following the Workshop. Support will consist of prearranged and scheduled communications to review and advise for the first 2 months and will continue on an ad hoc basis for the remaining 10 months, with communication initiated by the physician (2)Community Pharmacy Insulin Initiation consists of trained community pharmacists providing patient education insulin initiation. Education will consist of one individual teaching session, one hour in duration, to review the insulin prescription protocol, insulin injection method, management of hypoglycemia, and self-monitoring of blood glucose.
1945333|NCT00592449|Behavioral|Cognitive behavioral therapy (CBT) for insomnia|During CBT, participants will learn how to change their sleeping habits and reduce arousal and alertness while trying to sleep. Participants will attend 8 weekly CBT sessions with a psychologist.
1945334|NCT00592449|Behavioral|Behavioral desensitization treatment for insomnia|The behavioral desensitization treatment is designed to decondition states of arousal that interfere with sleep. Participants will attend 8 weekly behavioral desensitization treatment sessions with a psychologist.
1945335|NCT00592202|Device|Placement of an adjustable gastric band|Laparoscopic placement of an adjustable gastric band around the upper portion of the stomach and subsequent adjustments of the band via a subcutaneous port as needed to maintain appropriate restriction.
1945337|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
1945338|NCT00591669|Other|Definity|We will be placing one vial (1.3) of Definity® in 50 mL of preservative-free saline. Our infusions will be initiated at slightly lower than recommended starting rate (3mL/min) and will be adjusted as necessary to produce optimal enhancement. The rate will not exceed 10 ml/min and we will not give more than 1.3 mL of Definity® in 50mL saline in any 24-hour period.
1945339|NCT00591487|Drug|Lidocaine|Subcutaneous infiltration with Active/Placebo solutions with tumescent technique previous to suction assisted lipectomy. Patient abdomen and back will be divided in 4 zones anterior and posterior, one side (left or right) will be infiltrated with active solution and the other with placebo. The allocation of the side will be made with random numbers.
1945340|NCT00591162|Drug|Tetracycline|Two courses of IV Tetracycline(10mg./kg./day for two days)separated by a two week interval.
1945341|NCT00591162|Radiation|Duel Energy X-Ray Absorptiometry (DEXA)|DEXA before discharge from acute admission and again one year post burn.
1945342|NCT00591162|Procedure|Bone Biopsy|Bone biopsy to be taken in the operation room at the last skin grafting operation at the site of the iliac crest. A second bone biopsy will be taken one year later post discharge from the acute admission.
1945343|NCT00591123|Drug|FOLFOX and Erlotinib|Once every two weeks all patients will receive Oxaliplatin 85 mg/m2 IV, Leucovorin 400 mg/m2 IV and 5-FU 400 mg/m2 IV infusions, after which 5-FU 2400 mg/m2 IV will be given via pump for 46-48 hours at home. All patients will also be given Erlotinib, 100 mg orally daily for the first 4 weeks. Those patients who have not experienced toxicities will increase the dose level to 150 mg daily. Patients who have toxicities will remain at the 100 mg dose level or lower if necessary.
1945344|NCT00590473|Device|Interstim|Unilateral vs. Bilateral Placement of Interstim IPG
1945345|NCT00589797|Device|Activ-L Artificial Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
1945346|NCT00589797|Device|ProDisc Total Disc Replacement or Charite Atifical Disc|Implantation at one level of the lumbar spine, either L4/L5 or L5/S1.
1945349|NCT00589953|Drug|Erythropoietin|"5 of first 10 subjects (Group 1): 400 units/kg/dose once daily for 7 days 5 of next 10 subjects (Group 2): 800 units/kg/dose once daily for 7 days 20 of next 30 subjects (Group 3): 1000 units/kg/dose once daily for 7 days administered i.v. over 1 hour.
The volume of the study drug will be 1 mL in a 1 mL Tuberculin syringe to be administered over 1 hour."
1945350|NCT00589953|Drug|Saline placebo|Saline vehicle at a volume of 1 mL given over 1 hour intravenously once a day for the first seven days of life.
1945351|NCT00589901|Drug|capecitabine and cyclophosphamide|"capecitabine 1000 mg/m2 oral Bid d1-14
cyclophosphamide 65 mg/m2 oral Qd d1-14"
1945352|NCT00589706|Drug|MAb-425|MAb425 anti-epidermal growth receptor) and Iodine-125 will be given as an injection for a total of three treatments each separated by one week.
1945359|NCT00586924|Biological|CAT 8015 (Moxetumomab Pasudotox)|The dose level of the initial cohort will be 5 μg/kg so cohorts will be dosed at 5, 10, 20, 30, 40, 50, 60… μg/kg until toxicity supervenes.
1945360|NCT00585208|Drug|Ramelteon|Ramelteon 8mg daily
1945361|NCT00585208|Drug|Placebo|matching placebo for ramelteon 8mg daily
1945364|NCT00585546|Drug|clenbuterol|Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.
1945365|NCT00585247|Drug|Imiquimod|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
1945366|NCT00585247|Other|Placebo|Combining Topical Imiquimod 5% Cream With a Pulsed Dye Laser to Treat Port Wine Stain Birthmarks
1945367|NCT00584285|Other|Comparison of fluorescein patterns|Compare conventional contact lens fitting to fitting contact lenses based on corneal topography measurement
1945368|NCT00584012|Drug|Lovastatin and Docetaxel|Docetaxel (60 mg/m2) will be given on day 0 every three weeks in Phase I with incrementally increasing doses of lovastatin. Lovastatin will be administered p.o. following a four times a day schedule, for four consecutive days (days -1 to +2) and repeated every three weeks. For purposes of this phase I/II study, intermittent drug administration, six dose levels, ranging from 2 to 24 mg/kg/day (2, 4, 7, 10, 13, 18, and 24 mg) will be used. Once the maximum tolerated dose (MTD) of lovastatin has been determined, docetaxel will be escalated in a stepwise scheme from 60 to 80 to 100 mg/m2.
1945369|NCT00584922|Procedure|Endoscopy in group I (all patients)|Post procedure endoscopy, omeprazole 40 mg BID, sucralfate 1 gm BID for 2-4 weeks.
1945370|NCT00584662|Drug|Oxymetazoline Hydrochloride|Oxymetazoline Hydrochloride TWO SPRAYS BID
1945371|NCT00585052|Drug|Lovastatin and Paclitaxel|Paclitaxel will be given at 80 mg/m2 IV over 1 hour on day 1 and repeated weekly; lovastatin, 80 mg, po, daily will be self-administered by the subject.
1945372|NCT00583791|Device|Device closure with the AMPLATZER Muscular VSD Occluder|Device: AMPLATZER Muscular VSD Occluder
1945373|NCT00583804|Device|IST-12|Implanted stimulator and sensor device, with twelve implanted stimulating electrodes and two myoelectric signal recording electrodes.
1945374|NCT00583102|Drug|Lovastatin and Cytarabine|Cytarabine dosage: 3.0 g/m2 IV over 3 hours every 12 hours on days 3-7. Lovastatin dosage: The first dose level will be lovastatin at 0.5 mg/kg/day. After each patient reaches day 14 subsequent patients will be treated at incrementally increasing doses that are 1 mg/kg/day, 2 mg/kg/day, 4 mg/kg/day, 8 mg/kg/day, 12 mg/kg/day, 18 mg/kg/day, and 24 mg/kg/day. If MTD is not reached at this dose of 24 mg/kg/day further dose escalations will occur with a 33% increase in dose at each level rounded to the nearest mg/kg/day.
1945375|NCT00581893|Drug|Phenytoin|Phenytoin will be dosed to a target dose of 5 mg/kg qhs for one month
1945376|NCT00582998|Procedure|Standard Wound Dressing|Following repair of fracture of calcaneus, pilon or tibial plateau, a standard wound dressing is applied in the OR. Dressing is taken down post-op day 1 to evaluate draining, and if necessary, replaced. Dressing will be monitored for drainage every 48 hours until wound is clean, dry and intact.
1945377|NCT00582998|Device|VAC|Following repair of fracture of calcaneus, pilon or tibial plateau, a Vacuum Assisted Closure (VAC) device is applied in the OR. VAC cannister is evaluated for drainage, and if necessary, replaced. VAC sponge will be monitored for drainage every 48 hours, replaced if needed, until wound is clean, dry and intact.
1945378|NCT00582790|Drug|IL2|Interleukin-2 will be given at a starting dose of 7 MU/m2/day by subcutaneous injection days 1-5, on weeks 1 through 3, in four week (28 days) cycles.
1945379|NCT00582790|Drug|Zoledronic acid|Zoledronic acid will be given on day 1 intravenously over 15 or 30 minutes starting at 400mcg. If no significant increase in gamma delta-T cell augmentation is seen, the dose of zoledronic acid will be increased in the subsequent cycle up to a maximum dose of 3mg.
1945382|NCT00582010|Drug|inhaled nitric oxide|inhaled 80ppm for duration of surgery.
1945383|NCT00582010|Drug|nitrogen gas|inhaled
1945384|NCT00581685|Drug|Pregabalin, Celecoxib|Pregabalin (75mg BID) and Celecoxib(100mg BID) two weeks prior to hip arthroplasty and 3 weeks postoperatively.
1945385|NCT00581425|Biological|Imiquimod and Interferon alpha|Imiquimod first two weeks and last two weeks. Interferon middle five weeks.
1945386|NCT00580814|Drug|Methylphenidate|Methylphenidate
1945387|NCT00580606|Drug|Glycerinated peanut allergenic extract|Glycerinated peanut extract delivered sublingually.
1945388|NCT00580606|Drug|Placebo for peanut extract (glycerin)|Placebo (glycerin) delivered sublingually.
1945389|NCT00579280|Drug|quetiapine SR|flexible dosing, 50 mg up to a maximum of 300 mg per day for 8 weeks
1945390|NCT00579280|Drug|divalproex sodium ER|Flexible dosing, 500 mg up to a maximum of 3000 mg per day for 8 weeks
1945391|NCT00579280|Drug|placebo|placebo
1945392|NCT00580047|Drug|Zoledronic Acid|4mg IV Annually
1945393|NCT00580047|Drug|calcium and Vitamin D|1200 mg Calcium 800 International Units Vitamin D
1945394|NCT00580047|Drug|Alendronate|70mg weekly
1945395|NCT00579995|Drug|Oral N-Acetylcysteine|600 mg
1945396|NCT00579995|Drug|Intravenous Sodium Bicarbonate|3mL/kg/hr for one hour pre-procedure and infused at 1mL/kg/hr for 6 hours post-procedure
1945397|NCT00580489|Drug|either fentanyl or morphine|either morphine 4mg IV or fentanyl 50mcg IV
1945398|NCT00579085|Drug|Ketamine|IV Ketamine .35mg/kg times ten days.
1945399|NCT00579085|Other|IV NSS|Placebo inactive ingredients
1945400|NCT00579085|Other|Normal Saline|"INFUSION PLAN:
All patients will be infused intravenously with 100 ml of normal saline for four hours (25 ml/hr) daily for 10 days.Both patient arms will receive 2mg of Versed x two doses IV. They will also receive Clonidine (0.1 mg, po)"
1945401|NCT00578448|Drug|Belatacept|IV infusion
1945402|NCT00577577|Drug|rhIGF-I/rhIGFBP-3|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
1945403|NCT00577577|Drug|placebo|1.0 mg/kg rhIGF-I/rhIGFBP-3 or placebo daily, subcutaneous injections from baseline through the last day of the end of study visit.
1945450|NCT00563953|Drug|Liposomal pegylated doxorubicine|Four cycles of liposomal pegylated doxorubicine at 35 mg/m² IV combined with cyclophosphamide at 600 mg/m² on Day 1 every 4 weeks, and followed by paclitaxel 80 mg/m²/week for 12 weeks before surgery.
1945405|NCT00574808|Other|Outreach Facilitation implementing elements of the Chronic Care Model|"An outreach facilitator helps the practice identify areas for improvement, set goals and targets, and agree on the processes needed to reach them in order to improve the care delivery within the practices. Each facilitator will be assigned up to 12 practice sites. The first year of program implementation will involve frequent (once every 3-4 weeks) visits to the practices. Afterwards, the intervention will move into a sustainability mode, during which the frequency of visits will decrease to one every 6-8 weeks during the second year, and one every 12-15 weeks during the third year and thereafter. After the first year of program implementation, each facilitator will be able to take on 12 new practices during the second year, while still being able to sustain contact with the previous 12 practices. Similarly, in the third year, another set of 12 practices will begin the intense phase of program implementation."
1945406|NCT00573638|Device|Xal-Ease device to be used with Xalatan eye drops|This intervention is a drop instillation guide to be used in conjunction with the FDA approved Xalatan eye drop.
1945407|NCT00573950|Drug|cilostazol|50 mg two times a day for 2 weeks and then 100mg two times a day for 6 weeks
1945408|NCT00573950|Drug|Placebo|Placebo tablet comparable to 50mg cilostazol two times a day for 2 weeks and then placebo tablet comparable to 100mg cilostazol two times a day for 6 weeks
1945413|NCT00572819|Drug|Misoprostol|1000 micrograms of self-administered vaginal misoprostol compared to placebo 12 hours before operative hysteroscopy after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
1945414|NCT00572819|Drug|Placebo|Vaginal lactosum monohydricum administered 24 hours in postmenopausal women, compared to misoprostol after two weeks pretreatment with 25 micrograms daily vaginal oestradiol.
1945415|NCT00572195|Device|RNS® System|The previously implanted RNS® System is programmed to provide responsive stimulation. Upon detecting electrographic patterns, previously identified by the neurologist or neurosurgeon as abnormal, the Neurostimulator provides brief pulses of electrical stimulation through the Leads to interrupt those patterns. The typical patient is treated with a cumulative total of 5 minutes of stimulation a day.
1945416|NCT00570700|Drug|Dasatinib|150mg (3 pills) orally daily for as long as the drug benefits
1945419|NCT00570193|Drug|verteporfin (Visudyne)|Verteporfin (Visudyne) 6 mg/m2 at 300mW/cm2 given on week O and then at week 5, given as indicated per protocol; ranibizumab (Lucentis) 0.3 mg given at week 1
1945420|NCT00570193|Drug|ranibizumab (Lucentis)|ranibizumab (Lucentis) 0.3 mg on weeks 1,5,9,13,17,21,25,29,33&37 per study protocol
1945421|NCT00570128|Drug|Donepezil hydrochloride|Oral liquid.
1945422|NCT00570128|Drug|Placebo|Oral liquid.
1945426|NCT00569062|Drug|GW856553X|GW856553X 7.5mg BID for 6 weeks
1945427|NCT00569062|Other|Placebo|Placebo to match GW856553X
1945428|NCT00567671|Procedure|Corneal collagen|Corneal collagen cross-linking with riboflavin/UVA light
1945429|NCT00567671|Procedure|Sham comparator|Sham treatment
1945430|NCT00567905|Dietary Supplement|Green tea extract|main content is epigallocatechin gallate (EGCG, 58%)
1945431|NCT00567710|Drug|BL - 1020|10 mg/day
1945432|NCT00567710|Drug|BL - 1020|BL 1020 20-30 mg/day
1945433|NCT00567710|Drug|Placebo|Capsules
1945434|NCT00567710|Drug|Risperidone|Capsules
1945435|NCT00566813|Drug|Edmonton Protocol of steroid free immunosuppression|Islet of Langerhans 1-3 transplantations, daclizumab, sirolimus, tacrolimus
1945436|NCT00566813|Drug|Islets of Langerhans Transplantation|Islets of Langerhans 1-3 transplantations, Edmonton protocol of steroid free immunosuppression (daclizumab 5 doses, sirolimus daily,tacrolimus BID, with additional etanercept 3 doses, and exenatide BID-TID for 6 months after each transplant.
1945437|NCT00566371|Drug|atomoxetine|Patients will then be randomized (at Visit 2) to receive either atomoxetine or placebo for 4 weeks (Treatment Period); study drug will be titrated individually according to tolerability and efficacy (measured by ADHD-RS and CGI-I) completed at Visits 3, 4, 5, and 6) at 7-10 day intervals to a maximum dose of 1.8 mg/kg.
1945438|NCT00566371|Drug|placebo|placebo
1945439|NCT00566527|Biological|ProQuad® manufactured with recombinant Human Albumine|2-dose regimen of ProQuad® (0.5 mL per dose) given at a 3-month interval
1945448|NCT00564070|Behavioral|Enhanced treatment as usual plus adherence training|The single-session life-steps treatment targets informational, problem solving, and cognitive-behavioral steps that are geared toward improving medication adherence and diabetes self-management.
1945449|NCT00564070|Behavioral|Enhanced treatment as usual plus CBT-AD|The multiple-session CBT treatment is given after completion of the life-steps session. The CBT sessions focus on treatment of depressive symptoms as well as adherence to diabetes self-care.
1945451|NCT00562965|Drug|inotuzumab ozogamicin|IV administration, 1.8mg/m² on day 2 of each cycle every 28 days, for up to 8 cycles.
1945453|NCT00562965|Drug|rituximab|intravenous rituximab at a dose of 375 mg/m2 on day 1
1945454|NCT00562965|Drug|cyclophosphamide|intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
1945455|NCT00562965|Drug|vincristine|intravenous vincristine at a dose of 1.4 mg/m2 (not to exceed 2 mg) on day 1
1945456|NCT00562965|Drug|prednisone/prednisolone|oral prednisone/prednisolone at a dose of 40 mg/m2 on days 1 through 5
1945457|NCT00562965|Drug|mitoxantrone|mitoxantrone 10 mg/m2 intravenous on day 2
1945458|NCT00562965|Drug|fludarabine|fludarabine 25 mg/m2 intravenous on days 2 through 4
1945459|NCT00562965|Drug|dexamethasone|oral dexamethasone 20 mg/day on days 1-5
1945460|NCT00563186|Other|Admission to a novel hospital ward|Hospital admission to a ward with novel infection control design features (e.g., abundance of sinks, predominance of private rooms, absence of shared bathrooms/curtains, etc.)
1945461|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|AAISafeR/SafeR ON
1945462|NCT00562107|Device|Symphony DR 2550 and REPLY DR cardiac pacemakers|DDD(R) (SafeR OFF)
1945467|NCT00559845|Drug|FEC|As prescribed
1945468|NCT00559845|Drug|Paclitaxel|As prescribed
1945469|NCT00559845|Drug|bevacizumab [Avastin]|10mg/kg iv every 2 weeks
1945470|NCT00557531|Device|BL-1040|2 mL of BL-1040
1945471|NCT00557843|Drug|Bupivacaine|Wound perfusion with bupivacaine, plus patient controlled analgesia (PCA)
1945472|NCT00557843|Drug|Saline|Wound perfusion with placebo solution (isotonic saline) plus patient controlled analgesia (PCA)
1945473|NCT00556439|Drug|Abatacept|"Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:
Participants weighing less than 60kg will receive 500mg of abatacept.
Participants weighing 60 to 100kg will receive 750mg of abatacept.
Participants weighing more than 100kg will receive 1000mg of abatacept.
Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A participants will continue on abatacept."
1945474|NCT00556439|Drug|Placebo|Placebo abatacept infusions will be given monthly after random assignment at Month 3.
1945475|NCT00556374|Drug|Placebo|
1945476|NCT00556374|Drug|Denosumab|
1945477|NCT00556374|Drug|Non-steroidal aromatase inhibitor therapy|An approved non-steroidal aromatase inhibitor therapy (eg, anastrazole) in the adjuvant setting
1945478|NCT00555776|Drug|Gabapentin|Gabapentin, 600 mg bid for the first two weeks, increased to a maximum dose of 1800 mg per day during the next 6 weeks if necessary.
1945479|NCT00555776|Drug|placebo|placebo is given with the same definition as Gabapentin
1945480|NCT00555971|Drug|Omalizumab|aspirin desensitization will be carried out for all subjects with aspirin exacerbated respiratory disease who participate in the study, with subjects randomized 2:1 to receive either omalizumab or placebo, which will allow us to evaluate the study hypothesis
1945481|NCT00555971|Drug|placebo|aspirin desensitization will be carried out for all subjects with aspirin exacerbated respiratory disease who participate in the study, with subjects randomized 2:1 to receive either omalizumab or placebo, which will allow us to evaluate the study hypothesis
1945482|NCT00555893|Drug|Oseltamivir|"Adults and adolescents weighing greater than 88 pounds will receive one 75 mg oseltamivir capsule twice daily, with or without food for a total of 5 days (10 doses). Participants one year of age and older up to a maximum weight of 88 pounds will receive a liquid form of study medication containing oseltamivir at a concentration of 15mg/ml. The dose will be based on weight:
for weight <=33 lbs, dose=30 mg, volume per dose (15mg/mL)=2 mL two times per day x 5 days (10 doses); for weight 34-51 lbs, dose=45 mg, volume per dose (15mg/mL)=3 mL two times per day x 5 days (10 doses); for weight 52-88 lbs, dose=60 mg, volume per dose (15mg/mL)= 4 mL two times per day x 5 days (10 doses)"
1945483|NCT00555893|Drug|Placebo|Identical placebo capsule twice daily for 5 days (10 doses). Participants one year of age and older up to a maximum of 88 pounds will receive a placebo syrup. The dose will be based on weight as follows: <=33 pounds,2 mL doses, two times per day; 34 - 51 pounds, 3 mL doses, two times per day; 52-88 pounds, 4 mL doses, two times per day.
1945484|NCT00555841|Drug|ALC and Placebo|ALC and Placebo
1945485|NCT00555347|Drug|Armodafinil|Dosage 150-250 mg
1945486|NCT00555347|Drug|Placebo|Placebo
1945488|NCT00555321|Drug|Tacrolimus|Capsules, Oral, dosed to achieve 12 hour trough level of 6-12 ng/mL, twice daily, 52 weeks (Short Term [ST]), in accordance with local practice and the package insert, 4 years (Long-Term Extension [LTE])
1945489|NCT00555321|Drug|Basiliximab|Intravenous (IV), 20 mg, Day1 and Day 5
1945490|NCT00555321|Drug|Belatacept More Intensive (MI)|"Intravenous (IV),
10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 6, 8, 10, 12, 16, 20, and 24.
After 6 months (24 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-term extension [LTE])"
1945491|NCT00555321|Drug|Belatacept Less Intensive (LI)|"Intravenous (IV),
10 mg/kg on Days 1, 3 and 5, and at Weeks 2, 4, 8 and 12.
After 3 months (12 weeks) 5 mg/kg, every 4 weeks, 52 weeks (Short term [ST]), 5 mg/kg, every 4 weeks, 4 years (Long-Term Extension(LTE)"
1945492|NCT00555321|Drug|Mycophenolate Mofetil (MMF)|Intravenous (IV)/Capsules, IV/Oral, 1-2g/day, 52 weeks (Short term [ST]), ≤ 1 g/day, 4 years (Long-term extension [LTE])
1945493|NCT00554346|Drug|Arcoxia(etoricoxib 90 mg/tablet)|Arcoxia(etoricoxib 90 mg/tablet) or placebo, #1, 3 days
1945494|NCT00553540|Device|Back supports|The spinal / back supports are made of polymer shield covered by fabric and foam to be used externally to relieve back pain and offer spinal support. They are to be placed in the chair used in workstation related jobs.
1945495|NCT00553163|Behavioral|Gut focussed hypnotherapy|Gut focussed hypnotherapy
1945496|NCT00553163|Behavioral|Controlled educational sessions|Controlled educational sessions
1945497|NCT00552032|Drug|Mometasone Furoate nasal spray|Mometasone Furoate nasal spray 1 puff (50 mcg) per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
1945498|NCT00552032|Drug|Placebo|Placebo nasal spray 1 puff per nostril twice daily x 8 weeks. There was a blinded follow-up period of 16 weeks, resulting in study duration of 24 weeks (6 months).
1945499|NCT00550589|Drug|cidofovir|1.0% topical cream self-applied once daily for 5 consecutive days, with no treatment for the remaining 9 days (a treatment cycle). Subjects will receive up to 6 cycles of treatment.
1945500|NCT00550589|Genetic|DNA methylation analysis|formalin fixed biopsy collected at baseline and 6 weeks after treatment discontinuation
1945501|NCT00550589|Genetic|gene expression analysis|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
1945502|NCT00550589|Genetic|polymerase chain reaction|performed on punch biopsy specimens collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
1945503|NCT00550589|Procedure|biopsy|punch biopsy collected at baseline, after cycle 1, and 6 weeks after treatment discontinuation
1945504|NCT00550589|Procedure|histopathologic examination|Evaluated at baseline and 6 weeks after treatment discontinuation
1945505|NCT00550459|Drug|Tolvaptan|15-60 mg oral tablet given once a day for 21 days.
1945506|NCT00550459|Drug|Placebo|Placebo tablet given once daily for 21 days
1945507|NCT00550420|Drug|Rosiglitazone XR|experimental drug
1945508|NCT00549744|Drug|GSK256066|
1945509|NCT00549679|Drug|GSK256066|PDE4 inhibitor
1945510|NCT00549679|Drug|Placebo|Placebo
1945511|NCT00549107|Drug|Levosimendan|
1945512|NCT00549107|Drug|Milrinone|
1945513|NCT00549042|Drug|Drug: OROS® hydromorphone at 4, 8, 16, and 32 mg tablets will be used to provide doses of 12-64mg.|hydromorphone 4, 8, 16, and 32 mg tablets
1945514|NCT00549042|Drug|Oros Hydromorphone|Oros Hydromorphone
1945515|NCT00548496|Drug|SB-751689|SB-751689
1945516|NCT00548496|Other|Placebo|Placebo to match
1945517|NCT00548743|Behavioral|Screening and follow up|Two stage screening with EPDS and PHQ-9, treatment for depression at physician's discretion and follow up phone calls and visits
1945518|NCT00548743|Behavioral|Usual care|usual care for identification and management of postpartum depression
1945519|NCT00548730|Procedure|Bronchoscopy|The endoscopic examination of the bronchial tree will be performed using a commercially available flexible fluorescence bronchoscope and the flexible white light video-bronchoscope. Biopsies are taken of a normal region and all abnormal regions.
1945520|NCT00548171|Biological|Boostrix™|Intramuscular injection, 1 dose
1945521|NCT00547807|Other|Non-nutritive sucking|Non-nutritive sucking is applied by using a gloved finger
1945522|NCT00547807|Other|Swaddling|Swaddling is an age-old practice of wrapping infants snugly in swaddling cloths, blankets or similar cloth so that movement of the limbs is tightly restricted
1945523|NCT00547248|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 1 dose
1945524|NCT00547248|Biological|Tritanrix-HepB|Intramuscular injection, 1 dose
1945525|NCT00547248|Biological|Hiberix Hib vaccine|Reconstituted with Tritanrix-Hep B before injection
1945526|NCT00547248|Biological|Polio Sabin|Oral, 1 dose
1945527|NCT00547248|Biological|Poliorix|Intramuscular injection, 1 dose
1945528|NCT00547248|Biological|Prevenar (Wyeth)|Intramuscular injection, 1 dose
1945531|NCT00547300|Drug|Nebivolol, Metoprolol ER, Hydrochlorothiazide|Nebivolol QD, Oral Admin Metoprolol ER QD, Oral Admin Hydrochlorothiazide, QD, Oral Admin
1945532|NCT00546663|Drug|inhaled 7% hypertonic saline (HS)|"7% hypertonic saline administered twice daily for 14 days by nebulization.
A Pari Sprint Junior nebulizer equipped with a Pari Baby face mask and a Pari Proneb compressor will be used to administer the HS (PARI Respiratory Equipment, Inc., Midlothian, VA).
To minimize the risk of cough and bronchospasm with HS inhalation, infants will be pre-treated prior to each dose of HS with albuterol by metered dose inhaler"
1945533|NCT00546039|Drug|Genistein|Capsule, 30 mg, oral daily for 3 to 6 weeks
1945534|NCT00546039|Drug|Placebo|Capsule
1945535|NCT00545493|Drug|Tacrolimus|tacrolimus capsules, dosing according to blood trough levels: 12-15 ng/ml during months 1-6, 5-10 ng/ml during months 7-12 and 5-8 ng/ml thereafter
1945536|NCT00545493|Drug|i.v. immunoglobulins|infusions, dosing: initially on three consecutive days 0,4 g/kg KG, thereafter 0,4 g/kg KG every month, after 12 months of treatment every two months).
1945540|NCT00545584|Drug|sitagliptin phosphate|sitagliptin 100 mg once daily. Duration of treatment: 26 Weeks
1945541|NCT00545584|Behavioral|Comparator: Diet|Diet
1945542|NCT00545584|Behavioral|Comparator: Physical Activity|Physical Activity
1945543|NCT00543400|Drug|M118|75 IU/KG of M118, 100 IU/kg of M118 and 70 U/kg of unfractionated heparin given IV (in the vein) prior to Percutaneous Coronary Intervention. If procedure lasts longer than 30 minutes a 1/2 rebolus of the original therapy will be given.
1945544|NCT00543400|Drug|Unfractionated Heparin|Please see other invention description
1945545|NCT00543309|Drug|nesiritide|Nesiritide bolus 2 mcg/kg on CPB, then infusion of 0.015 mcg/kg/min. infusion dose may be adjusted
1945546|NCT00543309|Drug|milrinone|Milrinone 50 mcg/kg bolus on CPB, the infusion of 0.5 mcg/kg/min. Infusion rate may be adjusted
1945547|NCT00543309|Drug|placebo|Placebo bolus on CPB, then placebo infusion
1945548|NCT00543062|Drug|Inhaled prochlorperazine 10 mg + Oral placebo|Staccato prochlorperazine 10 mg + Oral placebo
1945549|NCT00543062|Drug|Inhaled prochlorperazine 5 mg + Oral placebo|Staccato prochlorperazine 5 mg + Oral placebo
1945550|NCT00543062|Drug|Inhaled prochlorperazine placebo + Oral placebo|Staccato prochlorperazine placebo + Oral placebo
1945551|NCT00543062|Drug|Inhaled prochlorperazine placebo + Oral moxifloxacin 400 mg|Staccato prochlorperazine placebo + Oral moxifloxacin 400 mg
1945552|NCT00542750|Drug|N-Acetylcysteine|N-Acetylcysteine 1200 mg twice daily for four weeks
1945553|NCT00541164|Drug|Coenzyme Q10|300 mg CoQ10 twice a day for 48 weeks
1945554|NCT00541164|Dietary Supplement|Coenzyme Q10|300mg CoQ10 twice a day for 24 weeks beginning at week 24 of the study
1945555|NCT00541931|Drug|Dietary Supplement: LifePak Nano|Daily use
1945556|NCT00541151|Device|MiniArc|sling system
1945557|NCT00541853|Drug|Candesartan|Candesartan upto 8mg
1945558|NCT00541853|Drug|Candesartan and Cilnidipine|Candesartan upto 8mg per day and Cilnidipine upto 20mg per day
1945559|NCT00541853|Drug|Candesartan plus non-CCB agents|Candesartan upto 8mg per day and other antihypertensive drugs except CCB and ACEI
1945560|NCT00541489|Drug|Naproxcinod|750 mg, bid
1945561|NCT00541489|Drug|Naproxen|500 mg, bid
1945562|NCT00541489|Drug|Placebo|bid
1945570|NCT00540007|Drug|Lenalidomide|
1945571|NCT00539500|Drug|Carboplatin|Carboplatin by vein over 24 hours x 4 days, dosing as determined at day 1.
1945572|NCT00539500|Drug|Etoposide|300 mg/m^2 by vein over 24 Hours x 4 Days
1945573|NCT00539500|Drug|Melphalan|70 mg/m^2 Intravenous Bolus x 3 Days
1945574|NCT00539500|Procedure|Stem Cell Infusion|Stem Cell Infusion (approximately 5x10^8 TNC cells/kg CD133+ selected) on Day 0.
1945575|NCT00539500|Device|ClinicMACS|Device used to process the blood and separate the CD 133+ cells needed for transplantation
1945576|NCT00537576|Drug|LACTIN-V|Arm 1: 5.0 x 10^8 cfu/dose 1x/day x 5 days total intravaginal. Arm 2: 1.0 x 10^9 cfu/dose 1x/day x 5 days total intravaginal. Arm 3: 2.0 x 10^9 cfu/dose 1x/day x 5 days total intravaginal. Arm 4: placebo 1x/day x 5 days total intravaginal.
1945577|NCT00537316|Biological|Infliximab (IFX)|IFX intravenous (IV) infusion dosed at 5mg/kg of body weight
1945578|NCT00537316|Drug|Azathioprine (AZA)|AZA 50 mg tablet dosed at 2.5 mg/kg of body weight orally every day
1945579|NCT00537316|Drug|Placebo to Azathioprine|Placebo to AZA tablet orally every day
1945580|NCT00537316|Drug|Placebo infusion|Placebo to IFX intravenous (IV) infusion
1945582|NCT00536692|Drug|mecamylamine|topical ocular drops
1945583|NCT00535470|Drug|0.04% Mechlorethamine gel|Mechlorethamine 0.04% PG applied to affected skin areas (lesions) once daily for up to seven (7) months. The frequency of application may be adjusted for toxicity. After seven (7) months, they will be terminated from the study.
1945585|NCT00534534|Behavioral|Repeated behavioural intervention without any drugs|"All these patients will be advised, i.e. undergo behavioural intervention, against alcohol use in the standard fashion as those in the standard group. No drugs will be used as part of the intervention. They also will undergo repeated interventions at outpatient visits at 6 mo intervals. They are re-examined at two years for alcohol consumption and for the number of recurrent pancreatitis during the two year period."
1945587|NCT00533065|Drug|Donepezil|week1 - week12: 1 tablet per day (5mg) week13 - week52: 1 tablet per day (10mg)
1945588|NCT00533793|Procedure|open fracture reduction|internal fracture fixation: osteosynthesis plates or intra-medullary nails
1945589|NCT00533780|Procedure|Healing Touch|
1945590|NCT00532597|Procedure|On-line hemodiafiltration|
1945591|NCT00532597|Procedure|Low flux hemodialysis|
1945592|NCT00532194|Drug|cediranib|Once-daily oral tablet starting dose 20mg
1945593|NCT00531167|Drug|combination of lamivudine+adefovir vs entecavir|Lamivudine 100 mg/day, Adefovir 10 mg/day, Entecavir 0.5 mg/day
1945594|NCT00531362|Drug|Plain aspirin|Plain aspirin 75 mg or 150 mg
1945595|NCT00531323|Drug|TMC125 once daily|Group 1 (n =12): subjects will receive TMC125 400 mg once daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 400 mg once daily
1945596|NCT00531323|Drug|TMC125 twice daily|Group 2 (n = 12): TMC125 200 mg twice daily for 14 days followed by 14 days of washout followed by efavirenz 600 mg once daily for 14 days followed by 14 days of TMC125 200 mg twice daily
1945600|NCT00530452|Drug|CG100649|Dual-acting COX-2 inhibitor & carbonic anhydrase inhibitor in gelatin capsules. Oral loading doses (2, 4, or 8 mg vs. placebo) followed by daily oral maintenance doses (0.3, 0.6, or 1.2 mg vs. placebo) for 20 days (total 21 days therapy).
1945601|NCT00530452|Drug|Silicified microcrystalline cellulose + talc|Gelatin capsules containing cellulose/talc matched for weight and color to experimental medication. Placebo administered orally 1x/day.
1945602|NCT00530127|Drug|placebo|Same dose and frequency as treatment
1945603|NCT00530127|Drug|deferiprone|100 mg/mL
1945604|NCT00530127|Drug|deferiprone|100 mg/mL
1945605|NCT00530127|Drug|placebo|Same dosage and frequency as study drug
1945606|NCT00530127|Drug|deferiprone|100 mg/mL
1945706|NCT00504829|Drug|atorvastatin|anti-dyslipidemia
1945607|NCT00529802|Drug|RAD001|take 2 tablets of RAD001 once a day by mouth (10 mg per day)
1945608|NCT00529048|Other|Oral Glucose Tolerance Test|The test is preformed 3 times with 3 different amounts of glucose (25g, 75g and 125g) deluded in 300ml of water.
1945609|NCT00529048|Other|Isoglycemic clamp|I.v. glucose infusion initiating the glucose responds curves from the OGTT
1945610|NCT00529048|Other|Gastric emptying rate|Paracetamol absorption test. Intake of 1,5g of paracetamol followed by measuring the absorption curve
1945611|NCT00528905|Drug|AZD3480|oral capsule
1945612|NCT00528892|Drug|Raltegravir|switching PI to raltegravir
1945613|NCT00528892|Drug|boosted PI|continue on boosted-PI
1945614|NCT00527540|Drug|Pegylated Interferon alpha 2a + Ribavirin|Pegaferon: Ampule, 180 microgram per week Ribaverin: Tablet, 10-15 mg/kg per day
1945615|NCT00527735|Drug|Ipilimumab|Ipilimumab, 10 mg/kg, administered as a single-dose, intravenously (IV), over 90 minutes depending on randomization every 3 weeks (up to 6 doses). Participants could receive additional maintenance ipilimumab at a dose of 10 mg/kg every 12 weeks starting 24 weeks after the first ipilimumab dose.
1945616|NCT00527735|Drug|Placebo|Matched placebo for ipilimumab administered as a single dose IV over 90 minutes every 3 weeks (up to 6 doses) as part of induction. Participants could also receive additional maintenance placebo administered IV over 90 minutes every 12 weeks starting 24 weeks after the first placebo dose.
1945617|NCT00527735|Drug|Paclitaxel|175 mg/m^2, administered as a single IV dose over 3 hours every 3 weeks (up to 6 doses). Dose modifications (reductions as well as delays) done as per product label.
1945618|NCT00527735|Drug|Carboplatin|Area under the concentration curve (AUC)=6, administered as a single IV dose over 30 minutes every 3 weeks (up to 6 doses) as per randomization. Dose modifications (reductions as well as delays) done as per product label.
1945619|NCT00527488|Drug|Degarelix|Two doses of 16 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
1945620|NCT00527488|Drug|Degarelix|One dose of 32 mg administered as a single administration will be evaluated for 42 days.
1945621|NCT00527488|Drug|Degarelix|Two doses of 32 mg each administered as two administrations (separated by 14 days) will be evaluated for 42 days.
1945622|NCT00527488|Drug|Degarelix|One dose of 64 mg administered as a single administration will be evaluated for 42 days.
1945623|NCT00526942|Behavioral|SAAGE-designed, visual memory-based cognitive training|Training sessions take 40 minutes per day, five days per week for a total goal of 15, 40-minute sessions.
1945624|NCT00526890|Dietary Supplement|selenomethionine|Oral Twice daily
1945625|NCT00526890|Drug|carboplatin|Weekly IV
1945626|NCT00526890|Drug|paclitaxel|Weekly IV
1945627|NCT00526890|Other|laboratory biomarker analysis|Correlative Study
1945628|NCT00526890|Radiation|radiation therapy|Undergoing radiation Therapy
1945629|NCT00526786|Device|CryoSpray Ablation System (510(k) NO: K070893)|no drug interventions specified
1945630|NCT00525993|Drug|etoricoxib 90mg 14 days|each patient in this group will receive 90mg once daily, for the 14 days treatment.
1945631|NCT00525993|Drug|etoricoxib 60mg daily for 14 days|Patients in this group will receive 60mg of the drug, daily
1945632|NCT00525967|Drug|Methadone plus Acetaminophen or Placebo|Methadone bid according to a established conversion morphine-to-methadone ratio plus Placebo or Acetaminophen qid
1945633|NCT00524472|Other|Hyperinsulinemic-normoglycemic clamp|Patients will be randomized to receive the hyperinsulinemic-normoglycemic clamp titrating the blood glucose to 80-110 mg/dL.
1945634|NCT00524472|Other|insulin at the standard of care levels|Subjects will be administered insulin at the standard of care levels established by the participating institution.
1945635|NCT00523913|Drug|rosiglitazone|
1945636|NCT00524589|Dietary Supplement|calcitriol|IV
1945637|NCT00524589|Drug|dexamethasone|Oral
1945638|NCT00524589|Genetic|protein expression analysis|Correlative Study
1945639|NCT00524589|Other|laboratory biomarker analysis|Correlative Study
1945640|NCT00524615|Drug|spironolactone|25 mg of spironolactone once daily or placebo for 2 months
1945641|NCT00523666|Drug|Galantamine (Reminyl®)|8mg - 24mg
1945642|NCT00523666|Drug|Placebo/Galantamine (Reminyl®)|"Patients are treated double-blind with placebo for 6 months, followed by treatment with Galantamine (Reminyl®) for another 6 months.
Dose scheme: 8mg-24mg"
1945643|NCT00522782|Drug|Nebulized Budesonide|Pulmicort Respules 0.5mg/2cc
1945644|NCT00522782|Device|Nitric Oxide Analyzer|Niox NO analyzer
1945645|NCT00522665|Drug|Irinotecan|Irinotecan 125 mg/m2 IV days 1 and 8
1945646|NCT00522665|Biological|Cetuximab|Cetuximab 250mg/m2 IV days 1, 8 and 15
1945647|NCT00522665|Biological|RAD001|Patients on Arm A will crossover and receive RAD001 at disease progression
1945648|NCT00522548|Drug|Myfortic (enteric coated mycophenolate sodium)|Patients in this group will receive Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, in combination with Myfortic (enteric-coated mycophenolate sodium, Prograf (tacrolimus) or its generic equivalent and corticosteroid immunosuppression.
1945649|NCT00522548|Drug|CellCept (Mycophenolate mofetil)|Patients in this group will receive Thymoglobulin (rabbit Anti-thymocyte globulin) induction immunosuppression, in combination with CellCept (mycophenolate mofetil) or its generic equivalent, Prograf (tacrolimus) or its generic equivalent and corticosteroid immunosuppression.
1945651|NCT00520949|Drug|Augmentin (Amoxicillin-clavulanic)|Amoxicillin-clavulanic acid 1 gram b.i.d
1945652|NCT00520949|Drug|Furoxone (furazolidone)|furazolidone 200 mg b.i.d
1945653|NCT00520949|Drug|Cebes (colloidal bismuth subcitrate)|colloidal bismuth subcitrate 240 mg b.i.d
1945654|NCT00520949|Drug|Esso (esomeprazole)|esomeprazole 40 mg b.i.d for 14 days
1945655|NCT00520884|Drug|ghrelin or saline|At time 0, an infusion (ghrelin or saline) will be started in one of the IV sites at a dose of 2.5 pmol/kg/min (an equivalent amount of saline will be infused in a stepwise fashion if it is the placebo dose). After 60 minutes, the infusion rate will be increased to 5 pmol/kg/min. After 120 minutes, the ghrelin infusion will be increased again to a dose of 10 pmol/kg/min, and will be continued until 180 minutes, when the infusion will be stopped. will be administered in an identical fashion.
1945707|NCT00504829|Drug|fenofibrate|anti-dyslipidemia
1945656|NCT00520039|Procedure|osteopathic manipulative medicine (OMM)|At each of the first three study visits, all subjects in the osteopathic manipulative medicine (OMM) group will receive OMM using the prescribed protocol.
1945657|NCT00520260|Drug|bromfenac|0.09%, BID, 6 weeks
1945658|NCT00520260|Drug|ketorolac|0.4%, BID, 6 weeks
1945659|NCT00519506|Other|ThromboView|Radiopharmaceutical, single dose, of the diagnosis of venous thromboembolism
1945660|NCT00518349|Device|Passive bending function|Colonoscope with a passive bending function
1945661|NCT00518349|Device|No passive bending function|Examination using standard colonoscope without passive bending function
1945662|NCT00518154|Drug|Pyridostigmine tablets|Patients will take 30mg tid PO for 12 weeks
1945666|NCT00515320|Drug|Fluoxetine|Once daily oral dispersible tablet 2mg 9mg or 18mg
1945667|NCT00515320|Drug|Placebo|Oral dispersible tablet placebo
1945671|NCT00514540|Drug|Docetaxel|75 mg/m^2 IV Over 60 Minutes On Day 1 Repeat Every 3 Weeks.
1945672|NCT00514540|Drug|Carboplatin|AUC = 5 IV Over 30 Minutes On Day 1 repeat every 3 weeks.
1945673|NCT00514449|Drug|Valacyclovir + Antipsychotic|1 g PO BID x 4 weeks after 4 weeks it goes up to 1.5 g PO BID x 12 weeks
1945674|NCT00514449|Drug|Placebo + Antipsychotic|2 pills twice a day x 4 weeks, after 4 weeks 3 pills twice a day x 12 weeks
1945675|NCT00513461|Drug|S-adenosyl-L-methionine disulfate p-toluene-sulfonate|Given PO
1945676|NCT00513461|Other|placebo|Given PO
1945677|NCT00513461|Other|laboratory biomarker analysis|Correlative studies
1945678|NCT00513461|Other|immunoenzyme technique|Correlative studies
1945679|NCT00513461|Other|high performance liquid chromatography|Correlative studies
1945680|NCT00511693|Behavioral|centralized osteoporosis coordinator|The regional osteoporosis coordinator will phone fracture patients and counsel them about their risk of osteoporosis, reiterating messages in the print material. The coordinator will also follow-up with family physicians by phone and send them a patient-specific reminder that informs them that their patient has experienced a fracture and they are at high risk for future fracture. As part of the reminder, a set of evidence-based recommendations about appropriate BMD testing and treatment based on the recent Canadian guidelines will be included. If the patient does not have a family physician, the regional osteoporosis coordinator will facilitate referral to the MOP.
1945681|NCT00511693|Behavioral|fall prevention|Fracture patients from hospitals receiving falls prevention advice will also be called by the osteoporosis regional coordinator. The patient will receive educational material and telephone counseling regarding fall prevention. During the call, patients will be encouraged to visit their family physician for fracture follow-up. They will not receive counseling or educational materials about osteoporosis at this time. Patients in the falls prevention group will receive the physician and patient osteoporosis program six months post-fracture.
1945682|NCT00511329|Drug|somatropin [rDNA origin] for injection|Genotropin will be started at 0.3 mg/kg/week administered by daily subcutaneous injection. Doses will be increased by weight at each visit. Additionally, we will monitor IGF-1 levels at month 3, and 6 and adjust the Genotropin dose to maintain IGF-1 levels in the 50th -75th percentile for ages.
1945683|NCT00511082|Drug|OPB-31121|Patients will receive OPB-31121 administered orally, once daily for 4 weeks.
1945684|NCT00510991|Device|nippv|
1945685|NCT00510198|Device|Cardiac Compass with OptiVol Fluid Status Monitoring|Review of Cardiac Compass with OptiVol Fluid Status Monitoring
1945686|NCT00509639|Drug|10% Metronidazole Ointment|Metronidazole 10% ointment applied perianally three times daily for four weeks. Placebo ointment applied perianally three times daily for four weeks
1945689|NCT00508261|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection
1945690|NCT00508261|Biological|Infanrix™ hexa|Single dose intramuscular injection
1945691|NCT00508261|Biological|Meningitec™|Single dose intramuscular injection
1945692|NCT00508196|Procedure|Dual chamber pacing with long AV delay|for 1 week
1945693|NCT00508196|Procedure|VVI pacing|30 min
1945694|NCT00508183|Procedure|single row|This method involves using a single row of anchor(s) to reattach the cuff to the bone.
1945695|NCT00508183|Procedure|double row fixation|"This technique, double row fixation, involves adding an extra anchor(s) over the number used for single row fixation. This extra anchor(s) is placed further inside the bone and may help to increase the fixation strength of the repair."
1945696|NCT00508066|Drug|Bupivacaine|Bupivacaine 0.25 - 0.5% @ 4ml/hr for 72 hours
1945697|NCT00508066|Drug|Normal Saline|Normal Saline, 4ml/hour for 72 hours.
1945698|NCT00506974|Drug|sodium oxybate|3.5 g of sodium oxybate or placebo on two of the five overnights.
1945699|NCT00506779|Drug|Imatinib Mesylate|"Phase I = 400 mg by mouth daily
Phase II (Arm 2) = 400 mg by mouth daily"
1945700|NCT00506779|Drug|Paclitaxel|175 mg/m^2 by vein Over 3 Hours Every 21 Days
1945701|NCT00506129|Drug|Fludarabine|25 mg/m^2 Given By Vein Daily for 5 Days Prior to Allogeneic Transplant.
1945702|NCT00506129|Drug|Melphalan|70 mg/m^2 Given By Vein Daily for 2 Days Prior to Allogeneic Transplant.
1945703|NCT00506129|Procedure|Allogeneic Transplant|Allogeneic transplant given by vein after completion of Fludarabine and Melphalan.
1945704|NCT00506129|Drug|Thymoglobulin|2 mg/kg/day by vein on days -3, -2 and -1 for patients receiving matched unrelated marrow/stem cells or mismatched related marrow.
1945705|NCT00504829|Drug|LCP-AtorFen|anti-dyslipidemia
1945708|NCT00504309|Drug|Omega-3 acid ethyl esters|4 g P-OM3
1945709|NCT00504309|Other|Corn oil placebo|4 g Placebo
1945710|NCT00503867|Device|SIR-Spheres microspheres|SIR-Spheres Yttrium-90 microspheres
1945711|NCT00500682|Drug|Placebo|9g /day (3 times a day)
1945712|NCT00500682|Drug|AST-120|9g /day (3 times a day)
1945713|NCT00501111|Drug|AZD3480|3 oral doses
1945714|NCT00501111|Drug|Donepezil|
1945715|NCT00501046|Drug|Placebo|9g /day (3 times a day)
1945716|NCT00501046|Drug|AST-120|9g /day (3 times a day)
1945721|NCT00500188|Drug|Imatinib Mesylate (Gleevec)|300 mg orally twice daily
1945722|NCT00499174|Procedure|conventional surgery|Radical prostatectomy
1945723|NCT00499174|Radiation|brachytherapy|high dose rate temporary seed implant; permanent seed implant.
1945724|NCT00499174|Radiation|external beam radiation therapy|3D conformal radiation therapy; intensity modulated radiation therapy.
1945725|NCT00499174|Procedure|Biopsies|Periodic repeat biopsies
1945730|NCT00498628|Drug|Quetiapine fumarate|Quetiapine fumarate- taken daily, for 12 weeks
1945731|NCT00498628|Other|Placebo|Placebo
1945732|NCT00497458|Drug|Testosterone|testosterone 40 or 80 mg once a day
1945733|NCT00496769|Drug|Apixaban|Tablets, oral, 5 mg (2.5 mg in patients meeting any 2 of the following criteria: 80 years of age and older, weight of 60 kilograms or less, and a serum creatinine level of 1.5 mg/dL or higher), twice daily, up to 156 weeks
1945734|NCT00496769|Drug|Acetylsalicylic acid|Tablets, oral, 81-324 mg, once daily, up to 156 weeks
1945735|NCT00496015|Biological|Pneumococcal conjugate vaccine GSK1024850A.|1 intramuscular injection.
1945736|NCT00496015|Biological|Infanrix hexa.|1 intramuscular injection.
1945737|NCT00496015|Biological|Meningococcal vaccine GSK134612.|1 intramuscular injection.
1945738|NCT00496015|Drug|Paracetamol.|Body weight of < 7 kg: none; Body weight of ≥ 7 kg to < 9 kg : 3 suppositories of 125 mg to be administered at 8h intervals after vaccination. Body weight of ≥ 9 kg: 4 suppositories of 125 mg to be administered at 6h intervals after vaccination.
1945741|NCT00495144|Drug|TH-302|
1945742|NCT00495053|Genetic|hMaxi-K|Three dose levels (5000µg /90 mL intravesical instillation, 10000µg/90 mL intravesical instillation, and 15000µg/90 mL intravesical instillation)
1945743|NCT00495053|Drug|hMaxi-K|Gene Transfer
1945744|NCT00495053|Other|Placebo|placebo (PBS-20% sucrose)
1945745|NCT00494208|Drug|Testosterone|Testosterone ester
1945746|NCT00494429|Drug|Morphine|Gestational Age< 29 weeks: A loading dose of 0.05 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.005 mg/kg/h.
1945747|NCT00494429|Drug|Morphine|Gestational Age>= 29 weeks: A loading dose of 0.1 mg/kg I.V. morphine over 30-minutes, followed by a continuous infusion of 0.01 mg/kg/h.
1945748|NCT00493610|Drug|N-acetylcysteine(Mucomyst)|
1945749|NCT00493467|Drug|Ibritumomab Tiuxetan (Zevalin)|"111In Zevalin (5 mCi of ^111In, 1.6 mg of Ibritumomab Tiuxetan) Intravenously Over 10 minutes on Day 1.
90Y Zevalin 0.3 or 0.4 mCi/kg Intravenously Over 10 minutes on Day 8."
1945750|NCT00493467|Drug|Rituximab|250 mg/m^2 Intravenously Over 4-6 Hours On Days 1 and 8.
1945751|NCT00492115|Device|Continuous positive airway pressure (CPAP)|therapeutic CPAP
1945752|NCT00492115|Device|Placebo CPAP|Ineffective CPAP
1945753|NCT00493025|Drug|cisplatin|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945754|NCT00493025|Drug|gefitinib|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945755|NCT00493025|Drug|paclitaxel|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945756|NCT00493025|Genetic|gene expression analysis|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945757|NCT00493025|Other|immunohistochemistry staining method|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945758|NCT00493025|Other|laboratory biomarker analysis|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945759|NCT00493025|Other|pharmacological study|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945760|NCT00493025|Procedure|adjuvant therapy|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945761|NCT00493025|Procedure|biopsy|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945762|NCT00493025|Procedure|conventional surgery|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945763|NCT00493025|Procedure|neoadjuvant therapy|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945764|NCT00493025|Radiation|radiation therapy|Combined Modality Paclitaxel, Cisplatin, ZD1839 and Radiotherapy Followed by Postoperative ZD1839
1945765|NCT00492648|Procedure|Blood sampling for assay of persistence of immunogenicity|Two blood samples: 30 and 42 months after first vaccination
1945766|NCT00492349|Drug|Varenicline|Varenicline 0.5mg po qd x 7 days then titrated to Varenicline 0.5mg po bid x 7 weeks
1945767|NCT00492349|Drug|Placebo|Placebo 0.5mg po qd x 7 days then titrated to Placebo 0.5mg po bid x 7 weeks
1945768|NCT00492310|Behavioral|yoga|vinyasa yoga
1945769|NCT00492310|Behavioral|cognitive therapy|cognitive behavioral therapy once weekly
1945770|NCT00492310|Behavioral|yoga|vinyasa yoga twice weekly with smoking cessation once weekly
1945771|NCT00492310|Behavioral|wellness|wellness program with smoking cessation
1945775|NCT00491322|Drug|Ergocalciferol|Ergocalciferol 50000 international units or matching placebo q week for 12 weeks
1945776|NCT00490789|Drug|sirolimus|daily oral sirolimus with dosage individualised by trough blood levels
1945777|NCT00490568|Drug|Rosiglitazone XR|Experimental drug
1945778|NCT00490282|Radiation|Intensity Modulated Radiation Therapy|IMRT Treatment Over 6-7 Weeks
1945779|NCT00490282|Radiation|Adaptive Radiotherapy|ART Treatment Over 6-7 Weeks
1945780|NCT00490204|Drug|Cetirizine|
1945781|NCT00489918|Drug|teriparatide|Macroflux® patch applied to the abdomen for 30 minutes daily
1945782|NCT00489918|Drug|teriparatide|FORTEO® injection administered subcutaneously (SC) either to the abdomen or thigh
1945783|NCT00488774|Other|Placebo|Matching placebo for golimumab, intravenous infusion administered at Week 0
1945784|NCT00488774|Drug|Golimumab 1 mg per kg|Golimumab 1 mg per kg intravenous (IV) infusion administered at Week 0
1945785|NCT00488774|Drug|Golimumab 2 mg per kg|Golimumab 2 mg per kg intravenous (IV) infusion administered at Week 0
1945786|NCT00488774|Drug|Golimumab 4 mg per kg|Golimumab 4 mg per kg intravenous (IV) infusion at Week 0
1945787|NCT00488683|Biological|MenACWY-CRM|One dose (0.5 mL) of MenACWY conjugate vaccine supplied as an extemporaneous mixing just before injection of the lyophilized component (MenA) reconstituted with the liquid component (MenCWY) was administered at 2-, 4-, and 12-months as IM injections in the anterolateral area of the right thigh.
1945788|NCT00488683|Biological|DTaP-Hib-IPV|IM injections of 3 doses of 0.5 mL each of DTaP-Hib-IPV supplied in prefilled vial were administered at 2-, 3-, and 4-months in the anterolateral area of the left thigh.
1945789|NCT00488683|Biological|PCV|IM injections of 3 doses of 0.5 mL each of PCV supplied in pre-filled syringe were administered at 2-, 4-, and 12-months (Groups 2 and 3) or 13-months (Group 1) in the anterolateral area of the left thigh.
1945790|NCT00488683|Biological|MMR|IM injection of one dose of 0.5 mL of MMR obtained by extemporaneous mixing just before injection of powder and the solvent for solution was administered at 13 months in the anterolateral area of the left thigh.
1945791|NCT00488683|Biological|Hib|IM injection of one dose 0.5 mL of Hib supplied in pre-filled syringe was administered at 13 months in the anterolateral area of the right thigh.
1945792|NCT00488020|Procedure|stem cells transplant|
1945793|NCT00487539|Biological|Placebo|Placebo subcutaneous injection (given under the skin by way of a needle) matching to golimumab administered at Week 0 and Week 2.
1945794|NCT00487539|Biological|Golimumab 100 mg|Golimumab 100 mg subcutaneous injection administered at Week 0 for Golimumab 100 mg -> 50 mg arm group and at Week 2 for Golimumab 200 mg -> 100 mg arm group.
1945795|NCT00487539|Biological|Golimumab 200 mg|Golimumab 200 mg subcutaneous injection administered at Week 0 for Golimumab 200 mg -> 100 mg arm group and at Week 2 for Golimumab 400 mg -> 200 mg arm group.
1945796|NCT00487539|Biological|Golimumab 400 mg|Golimumab 400 mg subcutaneous injection administered at Week 0 for Golimumab 400 mg -> 200 mg arm group.
1945797|NCT00487539|Biological|Golimumab 50 mg|Golimumab 50 mg subcutaneous injection administered at Week 2 for Golimumab 100 mg -> 50 mg arm group.
1945798|NCT00487253|Drug|Miltefosine|Oral Miltefosine, dosage 1,5mg -2,5mg/kg/day, during 28 days.
1945799|NCT00487253|Drug|Meglumine antimoniate|Parenteral meglumine antimoniate Amp of 5ml (83mg/ml). Dosage: 20mg/kg/day one doses IM, during 20 days.
1945800|NCT00486512|Drug|aspirin, 1,25-dihydroxycholecalciferol, calcium|Oral Calcitriol (1α 25-dihydroxy cholecalciferol) capsules, 0.5 µg (QD) Oral acetylsalicylic acid 37.5 mg and calcium carbonate 625 mg combination tablets (bid)
1945801|NCT00486512|Drug|placebo|placebo to oral Calcitriol (1α 25-dihydroxy cholecalciferol) capsules, 0.5 µg (QD) placebo to oral acetylsalicylic acid 37.5 mg and calcium carbonate 625 mg combination tablets (bid)
1945803|NCT00484640|Drug|Coumadin|
1945804|NCT00484874|Drug|I-131 Tositumomab therapeutic regimen|Tositumomab and I-131 tositumomab are given intravenously. A test dose is given followed by a larger treatment dose.
1945805|NCT00483301|Drug|Sorafenib (BAY 43-9006)|dosage
1945806|NCT00483301|Drug|ABI-007(Abraxane)|dosage
1945807|NCT00482677|Drug|temozolomide|Temozolomide (concurrent with radiation) 75 mg/m2 PO 3 weeks once a day, daily, from the first day to the last day of radiotherapy, but for no longer than 28 days, and then adjuvantly for up to 12 cycles (150 mg/m2 for the first 5 days of each cycle). Adjuvant TMZ may be escalated to 200mg/m2 in C2 onward if appropriate.
1945808|NCT00482677|Genetic|DNA methylation analysis|A stratified log-rank test, adjusting for the stratification factors (except centre) plus MGMT promoter methylation status, will be used as the primary method to compare the overall survival between the two arms
1945809|NCT00482677|Procedure|quality-of-life assessment|prior to randomization until end of study
1945810|NCT00482677|Radiation|Radiation|Short course radiotherapy
1945811|NCT00482001|Drug|donepezil|donepezil 5mg, once daily for 2 weeks
1945812|NCT00482001|Drug|Placebo (cornstarch)|1 capsule daily for 2 weeks
1945813|NCT00480441|Drug|Dronabinol|10mg capsules taken 4 times daily for 2 weeks and then tapered over 1 week
1945814|NCT00480441|Behavioral|BRENDA therapy|weekly therapy sessions for 6 weeks
1945815|NCT00480441|Drug|Placebo|4 capsules daily for 2 weeks followed by a 1 week taper
1945818|NCT00479427|Drug|GW842166|100 mg once daily
1945819|NCT00479427|Drug|Placebo|once daily
1945820|NCT00479687|Device|SUPARTZ|Supartz injection into the glenohumeral joint space.
1945821|NCT00479687|Device|Phosphate Buffered Saline|Saline injection into the glenohumeral joint space.
1945822|NCT00478738|Drug|GSK961081|
1945823|NCT00478933|Device|Defibrillator, Dual Chamber ; Implantable|Patient must wear a dual chamber ICD to remain in study. Can be enrolled 10 days prior to implant. Is excluded if device type changes.
1945824|NCT00478933|Procedure|Blood sampling|Blood sampling
1945825|NCT00477659|Drug|donepezil HCl (Aricept)|Oral donepezil 5mg/day for 4 weeks, followed by 10 mg/day for 8 weeks
1945826|NCT00478361|Drug|Gemcitabine hydrochloride|Gemcitabine 900 mg/m^2 IV over 90 minutes repeat every 14 days.
1945827|NCT00478361|Drug|Paclitaxel|135 mg/m^2 IV over 1 hour
1945828|NCT00478361|Drug|Doxorubicin hydrochloride|Doxorubicin 40 mg/m^2 IV over 20 minutes
1945829|NCT00478361|Drug|Pegfilgrastim|Subcutaneously injection on day 1.
1945830|NCT00478335|Drug|sildenafil|25 mg quaque die (QD) or 50 mg QD x 4 days based on subject weight
1945831|NCT00478335|Drug|calcitonin|one nasal spray daily for 4 days
1945832|NCT00478335|Drug|hydrochlorothiazide/amiloride|25 mg/2.5 mg BID or 50 mg/5 mg BID x 8 days depending on subject weight
1945833|NCT00478335|Drug|indomethacin|50 mg QD or 50 mg BID x 8 days depending on subject weight
1945834|NCT00478335|Drug|Placebo for sildenafil|one tablet daily for 4 days
1945835|NCT00478335|Drug|placebo for calcitonin|one nasal spray daily
1945836|NCT00477802|Biological|Botulinum Toxin Type A|Injected once during the course of the study.
1945837|NCT00477802|Biological|Placebo|Injected once during the course of the study.
1945840|NCT00476138|Drug|Epigallocatechin-gallate|
1945841|NCT00476047|Combination Product|Tositumomab and Iodine I 131 Tositumomab|Give IV
1945843|NCT00474916|Drug|KRN5500|Patients are seen weekly and dosed for pain with IV medication of active drug/KRN5500 or placebo . The dose can be escalated, from .6 mg/m2, to 1.2, 1.8, and 2.2 mg/m2.
1945844|NCT00474916|Drug|Placebo|Normal Saline given as dose escalation for placebo
1945845|NCT00474526|Biological|Meningococcal ACWY Conjugate Vaccine|
1945846|NCT00474526|Biological|DTaP-IPV-HBV|
1945847|NCT00474526|Biological|Hib|
1945848|NCT00474526|Biological|Rotavirus|
1945849|NCT00474526|Biological|Pneumococcal 7-valent Conjugate Vaccine|
1945850|NCT00474526|Biological|HAV|
1945851|NCT00474526|Biological|MMR-V|
1945852|NCT00474526|Biological|DTaP|
1945853|NCT00474266|Biological|Meningococcal vaccine GSK134612|Single dose intramuscular injection
1945854|NCT00474266|Biological|Priorix-Tetra™|2-dose subcutaneous injection
1945855|NCT00474266|Biological|Meningitec™|Single dose intramuscular injection
1945856|NCT00471887|Biological|CP-675,206|Patients will receive intravenous administration of CP-675,206 at a dose of 15mg/kg on Day 1 of an every 90 day cycles. For purposes of treatment visits and scheduling, each cycle is defined as a 90 day period. Patients may receive up to 8 dose (8 cycles) in a 24-month period until progression of disease or intolerable toxicity.
1945857|NCT00471614|Drug|NucleomaxX (contains uridine)|Escalated doses of NucleomaxX tid
1945858|NCT00471081|Biological|Meningococcal vaccine GSK134612|One or 2 intramuscular injections.
1945859|NCT00470171|Drug|Ursodesoxycholic acid|
1945864|NCT00469378|Drug|firategrast|900 (females) or 1200 (males) mg twice daily for 24 weeks
1945865|NCT00469001|Procedure|Treatment according NT Pro BNP level|
1945866|NCT00468130|Drug|Aripiprazole|Subjects under 40 kg will be started on 2.5mg per day of aripiprazole or placebo for the first week and increased to 5 mg at week 2. If clinically indicated (partial improvement with minimal or no side effects), the dosage will be increased each week by 2.5 mg until they reach a maximum of 10 mg at week 4. Medication will not be increased after week four but may be lowered in the case of adverse effects. Subjects over 40 kg will start at 5 mg and be increased to 10 mg at week 2. If clinically indicated, they will be increased each week by 5 mg until they reach a maximum of 20 mg at week 4. After week 4, the subject will remain on the same stable dose, unless the dose needs to be decreased due to adverse effects
1945867|NCT00467818|Dietary Supplement|Omega 3 fatty acids|The study will start with low doses and based on the weight of the individual the dosage will be increased biweekly.
1945868|NCT00467818|Other|Placebo|Smae dosage as that of omega 3 fatty acids
1945869|NCT00467324|Device|Aspire Medical Advance System|The treatment includes a device that is surgically implanted in the tongue and lower jaw. The purpose of the implant is to prevent obstruction of the upper airway thereby improving breathing during sleep.
1945870|NCT00467298|Behavioral|Exercise adherence|The exercise program includes endurance and strength training and warm-up and cool-down strategies. Emphasis is placed upon implementing and adhering to the exercise program at home following intervention completion.
1945871|NCT00467298|Behavioral|Self-management- prevention of illness|Instruction is provided regarding key elements of managing heart failure and COPD with emphasis upon individual adaptations to prevent exacerbations, unscheduled provider visits, and hospital admissions as well as promotion of daily activity.
1945872|NCT00467298|Behavioral|Self-management of illness|This component of the intervention stresses the use of an action plan that is implemented to c-manage bouts of mild illness and to identify symptoms of more serious illness, including appropriate actions.
1945873|NCT00466752|Drug|sorafenib tosylate|Given PO
1945874|NCT00466752|Genetic|microarray analysis|Correlative studies
1945875|NCT00466752|Other|immunohistochemistry staining method|Correlative studies
1945876|NCT00466752|Genetic|gene expression analysis|Correlative studies
1945877|NCT00466752|Procedure|needle biopsy|Correlative studies
1945878|NCT00466752|Procedure|therapeutic conventional surgery|Undergo prostatectomy
1945879|NCT00466752|Other|laboratory biomarker analysis|Correlative studies
1945880|NCT00466752|Genetic|western blotting|Correlative studies
1945881|NCT00466752|Genetic|RNA analysis|Correlative studies
1945882|NCT00466817|Other|Placebo|9 grams of powder which contains no Valganciclovir free base. The oral solution formulation comprises the following excipients: mannitol, lactose anhydrous, fumaric acid, sodium benzoate, saccharin sodium, flavor, and purified water.
1946043|NCT00431236|Drug|IV ondansetron hydrochloride|
1946044|NCT00431236|Drug|Oral dexamethasone|
1945883|NCT00466817|Drug|Valganciclovir|Mono-valyl ester pro-drug of ganciclovir, oral solution, provided as a 12 grams of powder containing 5 grams of Valganciclovir free base. The oral solution formulation comprises the following excipients: Providone K30, fumaric acid, sodium benzoate, sodium saccharin, mannitol, flavor, and purified water.
1945884|NCT00466102|Drug|RAD001|Tablet of 5 mg, 2 tablets (10 mg) are taken once daily during study therapy
1945885|NCT00466102|Drug|Placebo|2 tablets are taken once daily during study therapy
1945886|NCT00465543|Other|Mint tea high in rosmarinic acid|Mint tea high in rosmarininc acid contains 150mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
1945887|NCT00465543|Other|Mint tea low in rosmarinic acid|Mint tea low in rosmarininc acid contains 10mg of rosmarinic acid. To be consumed twice a day for 4 weeks. Brewed in 150ml of boiling water and allowed to steep for 10 minutes.
1945888|NCT00465699|Drug|Topical B12 0.07%|
1945889|NCT00465647|Drug|Hydromorphone|Oral hydromorphone solution dosed every 6 hours up to 9 doses. Dose is determined based on the expected weight range for each age group.
1945890|NCT00465595|Drug|psilocybin|The dose of psilocybin received in the two sessions will range anywhere from low to high.
1945891|NCT00464867|Biological|Whole cell killed cholera vaccine & probiotic|The oral cholera vaccine Dukoral will be administered to all study participants in two doses,two weeks between doses.Each dose of the formalin inactivated whole cell vaccine contains one mg of recombinant B subunit of cholera toxin(rCTB).The vaccine will be administered in bicarbonate-tartaric acid buffer to counteract the effect of low pH in the stomach.
1945894|NCT00464178|Drug|Bortezomilb|Bortezomilb will be administered at 1.3 mglm2 IVP on Days 1. 4, 8, and 11. Response will be assessed subsequent to each cycle. A total of 8 cycles would beplanned. Patients would be removed subsequent to Cycle 2. if progression of disease is documented.
1945896|NCT00463060|Drug|sunitinib malate (Sutent)|
1945897|NCT00463060|Procedure|radiotherapy|
1945898|NCT00462618|Drug|Quetiapine|
1945899|NCT00462618|Behavioral|Cogntive behavioral therapy|
1945900|NCT00462943|Drug|Omacetaxine mepesuccinate|"Induction: 1.25mg/m^2 subcutaneously twice daily for 14 consecutive days, every 28 days.
Maintenance: 1.25mg/m^2 subcutaneously twice daily for 7 consecutive days, every 28 days.
Response targets during induction vary by chronic myeloid leukemia (CML) subclass (chronic, accelerated, or blast phase). Participants will complete at least one cycle (14 days treatment of a 28 day cycle) of induction therapy before changing to maintenance therapy. Participants not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study."
1945901|NCT00462904|Drug|opebacan|
1945902|NCT00462735|Drug|cetuximab|
1945903|NCT00462735|Drug|hydroxyurea|
1945904|NCT00462735|Drug|fluorouracil|
1945905|NCT00462735|Procedure|chemotherapy|
1945906|NCT00462735|Procedure|radiotherapy|
1945907|NCT00462254|Drug|ROZEREM|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 4-11).
1945908|NCT00462254|Drug|Ramelteon|8 mg tablet orally 30 minutes before bedtime for 8 days (Days 15-22).
1945909|NCT00462124|Device|BioProtect biodegradable balloon implant|biodegradable balloon implant to extend the distance between prostate and anterior rectal wall
1945910|NCT00462124|Device|Ballon implantation|Implantation of the balloon between the prostate and the anterior rectal wall
1945911|NCT00460447|Drug|Gemtuzumab Ozogamicin|
1945912|NCT00460304|Drug|pramlintide|
1945913|NCT00460304|Procedure|continuous glucose monitoring|
1945914|NCT00460382|Drug|raltegravir potassium|400 mg twice a day
1945915|NCT00460382|Drug|darunavir/ritonavir|2 pills of 300 mg twice a day
1945916|NCT00460382|Drug|etravirine|2 pills of 100 mg twice a day
1945917|NCT00460382|Drug|Optimized background regimen|NRTIs and or enfuvirtide (investigator choice)
1945918|NCT00460187|Device|Percutaneous intervention of the carotid artery|
1945919|NCT00459615|Drug|Artesunate for Injection|
1945920|NCT00458393|Drug|Emtricitabine/tenofovir disoproxil fumarate|Fixed-dose coformulation of 200 mg emtricitabine and 300 mg tenofovir disoproxil fumarate
1945921|NCT00458393|Drug|Placebo|Placebo for emtricitabine/tenofovir disoproxil fumarate
1945922|NCT00457197|Drug|Placebo|Inactive ingredient matching the active medication in appearance.
1945923|NCT00457197|Drug|Quetiapine|Quetiapine is an atypical antipsychotic approved for the treatment of schizophrenia, bipolar disorder, and in the XR version along with an SSRI to treat major depressive disorder.
1945924|NCT00457366|Drug|Quetiapine|Quetiapine 300mg PO/Initial dose and repeat dose at 2 hours if deemed clinically necessary upto a maximum dose of Quetiapine 600mg PO QD
1945925|NCT00457366|Drug|Cocktail (Haloperidol, Lorazepam, Cogentin)|Haloperidol 5 mg im, Lorazepam 2 mg im, Cogentin 2 mg im; repeated at 2 hours as deemed clinically necessary
1945926|NCT00455897|Drug|GM-CSF|Given 11 days before day 1 of cycle 1 for 10 days
1945927|NCT00455897|Drug|CHOP|Administered as part of standard care
1945928|NCT00455897|Drug|Rituximab|Administered as part of standard treatment
1945929|NCT00456365|Drug|pravastatin|Pravastatin 20 mg daily (subject age 8-12 years) or 40 mg daily (subject age 13-21 years)
1945930|NCT00456365|Drug|Placebo|Placebo daily
1945931|NCT00455923|Drug|Seretide|
1945932|NCT00455923|Drug|Flixotide|
1945933|NCT00455845|Device|Levonorgestrel IUD|levonorgestrel IUD
1945934|NCT00455741|Drug|Estradiol infusion|Graded estradiol infusion of 0.1 mcg/kg/hr for 12 hr, 0.135 mcg/kg/hr for 12 hr, 0.165 mcg/kg/hr for 12 hr and 0.2 mcg/kg/hr for 60 hr.
1945935|NCT00455741|Drug|Progesterone infusion|Progesterone infusion of 4.77 nmol/kg/hr (1.5 mcg/kg/hr) for 24 hr and 6.36 nmol/kg/hr (2 mcg/kg/hr) for the final 24 hr of the 5-day study.
1945936|NCT00455013|Drug|Thymoglobulin|Induction therapy, IV infusion, All subjects will receive thymoglobulin 1.5-mg/kg i.v. infusion on Days 1 (day of transplant), 2, 3, and 4 (up to a maximum total dose of 6 mg/kg) i.v. infusion over at least 4 hours
1946097|NCT00416949|Procedure|radionuclide imaging|
1945937|NCT00455013|Drug|Belatacept|Belatacept arms will receive i.v. belatacept (10 mg/kg) on Days 1 and 5, and then every other week through Month 3 (Weeks 2, 4, 6, 8, 10, and 12), and then every 4 weeks through Month 6 (Weeks 16, 20, and 24). After 6 months, subjects will receive belatacept at the maintenance dose of 5 mg/kg every 4 weeks until completion of the trial
1945938|NCT00455013|Drug|Sirolimus|Sirolimus will be initiated at 5 mg/day on Day 1 (day of transplant) and continued through Day 2. The dosing will be adjusted subsequently to keep pre-dose (C0) levels at 7 - 12 ng/mL for the first 6 months, followed by 5 - 10 ng/mL thereafter
1945939|NCT00455013|Drug|Tacrolimus|The recommended total initial dose of tacrolimus is 0.1 mg/kg/day in two divided doses orally up to and including week 52. Post week 52 subjects assigned to the tacrolimus arm will receive tacrolimus orally in accordance with local practice and the package insert until completion of the trial
1945940|NCT00455013|Drug|Mycophenolate Mofetil (MMF)|Administered orally in a capsule or solution formulation in 2 divided doses on a consistent schedule in relation to time of day and meals. The dose should be 1 g bid; however 1.5 g bid may be administered at the investigator's discretion until completion of the trial
1945941|NCT00453895|Drug|Sunitinib|
1945942|NCT00453479|Drug|GSK233705B|
1945943|NCT00453180|Drug|N-acetylcysteine|Capsules available in 300 mg or 600mg strength. Target dose of n-acetylcysteine will be 60mg/kg/day TID. Dosage will be increased to this target dose from week 1 to week 3 barring side effects. Dose reduction will be allowed at any time for adverse side effects. Maximum dose of n-acetylcysteine will be 4200mg/day.
1945944|NCT00453180|Drug|Placebo|Subjects randomized to placebo arm will receive placebo pill for duration of study.
1945945|NCT00452335|Drug|Lubiprostone|12 mcg capsule once daily (QD)
1945946|NCT00452335|Drug|Lubiprostone|12 mcg capsule twice daily (BID)
1945947|NCT00452335|Drug|Lubiprostone|24 mcg capsule twice daily (BID)
1945948|NCT00451321|Drug|Otelixizumab|Infusion
1945949|NCT00450411|Radiation|brachytherapy|
1945950|NCT00450411|Radiation|125-Iodine|
1945951|NCT00450411|Radiation|103-palladium|
1945952|NCT00450190|Device|Electronic device; Electronic Auto-Injector of Saizen®|
1945953|NCT00449670|Biological|Influenza Vaccine GSK1562902A - 6 different formulations|3 doses for experimental groups & 4 doses for control groups, intramuscular injection
1945954|NCT00448669|Drug|Tenofovir Disoproxil Fumarate 300 mg + Emtricitabine 200 mg|Daily oral single dose pill containing 300 mg TDF and 200 mg FTC.
1945955|NCT00448669|Drug|TDF-FTC placebo|Placebo comparator for TDF-FTC
1945956|NCT00447759|Drug|Celecoxib|200-400mg daily in divided doses
1945957|NCT00447759|Drug|non-selective Non steroidal anti inflammatory Drug|taken orally
1945962|NCT00448058|Drug|GSK372475|daily administration during the 10-week treatment phase
1945963|NCT00448058|Drug|venlafaxine|daily administration during the 10-week treatment phase
1945964|NCT00448058|Drug|placebo|daily administration during the 10-week treatment phase
1945965|NCT00447083|Procedure|Ultraviolet Light|
1945966|NCT00446485|Drug|Ginkgo biloba standardized extract 24/6|tablets, 120 mg/day (60 mg two times daily) during 6 months
1945967|NCT00446485|Drug|Ginkgo Biloba standardized extract 24/6|tablets, 60 mg/day during 6 months
1945968|NCT00446485|Drug|placebo|placebo during 6 months
1945969|NCT00446966|Drug|Omega Three Polyunsaturated fatty acids|2 grams orally twice daily pre-operatively and 2 grams oraly daily after until primary endpoint or 14 days.
1945970|NCT00445887|Drug|levonorgestrel|Given orally
1945971|NCT00445887|Other|placebo|Given orally
1945972|NCT00445744|Drug|cyclophosphamide|Given IV
1945973|NCT00445744|Drug|busulfan|Given IV
1945974|NCT00445744|Drug|tacrolimus|Given IV or PO
1945975|NCT00445744|Drug|methotrexate|Given IV
1945976|NCT00445744|Genetic|cytogenetic analysis|Correlative studies
1945977|NCT00445744|Other|flow cytometry|Correlative studies
1945978|NCT00445744|Other|pharmacological study|Correlative studies
1945979|NCT00445744|Other|pharmacogenomic studies|Correlative studies
1945980|NCT00445744|Procedure|peripheral blood stem cell transplantation|Undergo PBPC transplantation
1945981|NCT00445744|Procedure|allogeneic hematopoietic stem cell transplantation|Undergo allogeneic transplantation
1945982|NCT00445458|Drug|HKI-272|neratinib 160 mg daily by mouth
1945983|NCT00445458|Drug|HKI-272|neratinib 240 mg daily by mouth
1945984|NCT00445458|Drug|Paclitaxel|paclitaxel 80 mg/m^2 weekly IV
1945985|NCT00445003|Drug|Ranibizumab|Intravitreal injection of 0.5 mg ranibizumab at baseline and 4 weeks
1945986|NCT00445003|Drug|Triamcinolone Acetonide|Intravitreal injection of 4 mg triamcinolone acetonide at baseline and sham injection at 4 weeks
1945987|NCT00445003|Behavioral|Sham injection|Sham injection at baseline and 4 weeks
1945988|NCT00445003|Procedure|Focal/grid laser|Focal/grid laser for diabetic macular edema was performed 3 days to 10 days after the injection for all treatment groups.
1945989|NCT00444418|Drug|Naltrexone|Naltrexone, 100 mg. oral dosage, daily for 12 weeks.
1945990|NCT00444418|Behavioral|Modified Behavioral Self-Control Psychotherapy|Moderation- and cognitive-behaviorally-based psychotherapy. Treatment goal of moderation of alcohol consumption. 12 weekly, 1-hour sessions.
1945991|NCT00444418|Behavioral|Brief Behavioral Compliance Enhancement Therapy|Brief supportive counseling to enhance compliance with medication and encourage goal-setting concerning alcohol consumption
1945992|NCT00444028|Drug|Loxapine thermal aerosol|
1945993|NCT00443781|Procedure|functional anesthetic discography|Functional Anesthetic Discography (F.A.D.) involves the placement and anchoring of a small catheter into a disc. After placement, functional testing is performed, in which the subject elicits his/her back pain via functional maneuvers or postures. Local anaesthetic is then delivered into the target disc through the catheter and the effect on functional back pain is noted.
1945994|NCT00443781|Procedure|provocative discography|"Provocative discography (PD) has been used as a preoperative diagnostic tool for patients with back pain attributed to degenerative disc disease considering lumbar disc surgery. During PD, a clinically suspected disc is accessed with a needle and injected under pressure with radiopaque contrast dye. The subject rates his/her experience of pain for intensity and whether the pain is exactly the same as (concordant) or different from (not concordant or discordant) typical back pain."
1945995|NCT00443846|Biological|RotaTeq®|
1945996|NCT00443846|Biological|NeisVac-C®|
1945997|NCT00442494|Drug|intravenous hydrocortisone|
1945998|NCT00442637|Drug|capecitabine + bevacizumab|Ca 1250 mg/m2 daily orally continuously, B 7.5 mg/kg i.v. q 3 w
1945999|NCT00442637|Other|observation|observation after induction treatment
1946000|NCT00442299|Device|Fractionated Plasma Separation and Adsorption (FPSA)|
1946001|NCT00442039|Drug|Lithium Carbonate|The starting dose of lithium was 300 mg for patients weighing < 20 kg
1946002|NCT00442039|Drug|Lithium Carbonate|The dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient‟s response and tolerability. The starting dose of lithium was 900 mg and the dose of lithium was increased weekly by 300 mg to maximum tolerated dose depending upon the patient‟s response and tolerability
1946003|NCT00442039|Drug|Lithium Carbonate|The starting dose of lithium was 900 mg and the lithium dose was increased by 300 mg every 3 days, (no more than twice weekly) to maximum tolerated dose based upon the patient‟s response and tolerability.
1946004|NCT00442039|Drug|Placebo|During the third phase, which is the Discontinuation Phase, patients will be randomized to either placebo or lithium treatment for up to 28 weeks.
1946005|NCT00441688|Drug|GI265235|
1946006|NCT00440596|Behavioral|Mindfulness based stress reduction|8 weeks group MBSR
1946007|NCT00440596|Behavioral|Progressive Muscle Relaxation|8 weeks PMR in group format
1946009|NCT00439972|Drug|Ortho-Cyclen (R)|The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study.
1946010|NCT00439972|Drug|Ortho Evra (R)|Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
1946011|NCT00439972|Drug|extended use of Ortho Evra (R)|The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
1946012|NCT00439699|Drug|Memantine|Mematine administration
1946013|NCT00439556|Drug|Carmustine|300 mg/m^2 IV on Day -6
1946014|NCT00439556|Drug|Cytarabine|100 mg/m^2 IV twice a day x 4 Days (Days -5 through -2)
1946015|NCT00439556|Drug|Etoposide|100 mg/m^2 IV twice a day x 4 Days (Days -5 through -2)
1946016|NCT00439556|Drug|Melphalan|100 mg/m^2 IV on Day -1
1946017|NCT00439556|Drug|Rituximab|375 mg/m^2 IV on Day -13; 1000 mg/m^2 on Days -6, 1, & 8.
1946018|NCT00439556|Drug|Bortezomib|1.3 mg/m^2 IV on Days -13, -6, -1 and +2.
1946019|NCT00439556|Other|Allogeneic Stem Cell Infusion|Allogeneic Stem Cell Infusion administered on Day 0.
1946020|NCT00437476|Drug|LPV/r|Lopinavir/Ritonavir 200/50 mg 2 cpr BID monotherapy - 26 weeks (A) or 24 weeks (B)
1946021|NCT00437476|Drug|Nucleoside Reverse Transcriptase Inhibitors|NRTIs for 26 weeks (A) or 24 weeks (B)
1946022|NCT00437476|Drug|PEG-IFNa 2a|PEG-IFNa 2a 180 mcg/week (48 weeks)
1946023|NCT00437476|Drug|Ribavirin|Ribavirin 1-1.2 g/day (48 weeks)
1946024|NCT00436969|Device|Orthovisc|Orthovisc injection
1946025|NCT00436969|Drug|Control|Celestone (betamethasone sodium phosphate and acetate) - 2 mL
1946026|NCT00436475|Drug|Vitamin D3 2,000 IU orally once daily|Vitamin D3 2,000 IU orally once daily
1946027|NCT00436475|Drug|Calcium Carbonate 400 mg orally twice daily|Calcium Carbonate 400 mg orally twice daily
1946028|NCT00436475|Drug|Vitamin D3-Placebo|Vitamin D3-Placebo
1946029|NCT00436475|Drug|Calcium-Placebo|Calcium-Placebo
1946030|NCT00435617|Device|Hand Mentor|Use of the Hand Mentor therapy device at home for 6 weeks. Therapy programs include spasticity reduction, motor control, and emg biofeedback for encouraging activity.
1946031|NCT00435461|Drug|Fluticasone furoate and fexofenadine|Fluticasone furoate and fexofenadine
1946038|NCT00432679|Drug|Rosiglitazone (BRL49653C)|study drug
1946039|NCT00432653|Drug|rituximab|
1946040|NCT00432042|Biological|ProQuad® and Infanrix® hexa|
1946041|NCT00431236|Drug|Oral Casopitant (GW679769)|
1946042|NCT00431236|Drug|IV Casopitant (GW679769)|
1946045|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 1|2 or 3 doses, intramuscular injection, at different time points.
1946046|NCT00430521|Biological|Pandemic influenza vaccine (GSK1119711A)-formulation 2|2 or 3 doses, intramuscular injection, at different time points.
1946047|NCT00430989|Drug|Nitrous Oxide|70% N2O V's No N2O
1946048|NCT00430989|Drug|Nitrous Oxide|N2O 70% v's No N2O
1946049|NCT00430482|Behavioral|Cognitive Behavioral Therapy|12 weekly sessions and 3 booster sessions of cognitive behavioral therapy
1946050|NCT00430482|Behavioral|Individual Counseling|12 weekly sessions and 3 booster sessions of individual counseling
1946051|NCT00430950|Drug|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ) tablets|olmesartan medoxomil (OM)+ hydrochlorothiazide (HCTZ)tablets 40mg/25mg + 20mg/25mg matching placebo tablets once daily for 8 weeks
1946052|NCT00430950|Drug|olmesartan medoxomil (OM)/ hydrochlorothiazide (HCTZ) 20mg/25mg|olmesartan medoxomil (OM)/hydrochlorothiazide (HCTZ)20mg/25mg tablet + 40mg/25mg matching placebo tablet once a day for 8 weeks
1946053|NCT00429312|Biological|JX-594|Thymidine kinase-deleted vaccinia virus plus GM-CSF
1946054|NCT00427986|Drug|Galactose, intravenous|
1946055|NCT00427908|Biological|meningococcal vaccine 134612|One intramuscular dose.
1946056|NCT00427908|Biological|Mencevax™ ACWY|One subcutaneous dose.
1946057|NCT00427908|Biological|Meningitec™|One intramuscular dose.
1946058|NCT00427193|Behavioral|Caloric Restriction (CR)|Participants follow a diet with 25% fewer calories than calculated at baseline over a period of 24 months
1946059|NCT00427193|Behavioral|Control|Participants continue their current diet for 24 months
1946060|NCT00426816|Drug|SB-649868|Active compound at doses of 10mg, 30mg and 60mg
1946061|NCT00426816|Drug|Placebo|Placebo to match SB-649868
1946062|NCT00426166|Device|Low Level Laser Therapy|Low Level Laser Therapy on Wound
1946073|NCT00424840|Drug|Bortezomib|The primary objective of phase I study is to define the maximum tolerated dose (MTD) of weekly bortezomib in combination with carboplatin and bevacizumab.
1946074|NCT00424554|Drug|temozolomide|"Temozolomide 75 mg/m^2 daily for 14 days prior to surgery.
As standard of care, it could also be given at the same dose for up to 28 days after surgery, per investigator discretion."
1946075|NCT00424489|Biological|Hematopoietic Stem Cell Transplantation|Autologous Hematopoietic Stem Cell Transplantation
1946076|NCT00424463|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days ) - observation (14 days) cycle is repeated eight times.
1946077|NCT00424463|Drug|Placebo of MCI-186|Two ampoules of placebo injection are intravenously administered once a day for 10 days during 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated eight times.
1946078|NCT00423956|Procedure|Repairing Induced tooth root resorption by ultrasound|Repairing Induced tooth root resorption by ultrasound
1946079|NCT00422812|Drug|Prochlorperazine thermal aerosol|
1946080|NCT00423020|Drug|Erythropoietin|
1946081|NCT00421759|Device|Vibrating Insoles|Participants wear vibrating sandals for 3 trials of 6 minutes, during a single lab visit. The sandal vibration is on during either first or second 3 minutes of the 6 minute trial, as they walk. Also, participants wear the sandals for 2 hours while sitting, with vibrations on for one visit and off for the other.
1946084|NCT00420771|Drug|Gabapentin|For the first week, one 400 mg Gabapentin capsule taken 3 times per day. For the second week, two 400 mg Gabapentin capsules taken 3 times per day. For the third week through the eighth week, three 400 mg Gabapentin capsules taken 3 times per day. For the ninth and last week, two 400 mg Gabapentin capsules taken 3 times per day for 3 days, then one 400 mg Gabapentin capsule taken 3 times per day for 4 days. Placebo study medication appears identical to active medication and is prescribed with an identical dosing schedule.
1946085|NCT00420940|Device|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
1946086|NCT00420940|Device|Juvent 1000 Dynamic Motion Therapy (DMT) Platform|Standing on a DMT whole-body vibration platform for 20 minutes per day at a frequency of 90 Hz and acceleration due to gravity of 0.3g
1946087|NCT00420641|Drug|GSK372475|GSK372475 1.0-1.5 mg/day
1946088|NCT00420641|Drug|Paroxetine|Paroxetine 20-30 mg/day
1946089|NCT00420641|Other|Placebo|Placebo to Match
1946090|NCT00419731|Drug|Bupropion|"Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.
Placebo, 25 mg, q.d., for 7 weeks."
1946091|NCT00419731|Drug|Bupropion + Naltrexone|"Bupropion, Sustained-release, 150 mg, q.d., for days 1-3, 150 mg, b.i.d., for balance of 7 weeks.
Naltrexone, 25 mg, q.d., for 7 weeks."
1946093|NCT00418925|Drug|Dronabinol|2.5 mg tablets; titrated over 14 days and 7 days steady dose
1946094|NCT00418028|Drug|drug: capecitabine|800 mg/m2 twice a day orally continuous administration until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
1946095|NCT00418028|Drug|capecitabine|1250 mg/m2 twice a day orally x 14 days every 3 weeks until disease progression or severe toxicity. Dose adjustments were made in patients with grade 3 or greater diarrhea or hand and food syndrome.
1946096|NCT00416949|Procedure|computed tomography|
1946098|NCT00416949|Procedure|single photon emission computed tomography|
1946099|NCT00416949|Radiation|iodine I 131|
1946100|NCT00416312|Biological|rituximab|
1946101|NCT00416312|Device|computed tomography|
1946102|NCT00416312|Procedure|positron emission tomography|
1946103|NCT00416312|Procedure|radionuclide imaging|
1946104|NCT00416312|Procedure|single photon emission computed tomography|
1946105|NCT00416312|Radiation|tositumomab and iodine I 131 tositumomab|
1946106|NCT00416312|Radiation|yttrium Y 90 ibritumomab tiuxetan|
1946107|NCT00415519|Drug|MCI-186|Two ampoules (60 mg) of MCI-186 injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
1946108|NCT00415519|Drug|Placebo of MCI-186|Two ampoules of Placebo injection are intravenously administered once a day, for successive 14 days, followed by 14 days observation period (first cycle). Then treatment (10 days' administration during 14 days) - observation (14 days) cycle is repeated five times (2nd-6th cycles).
1946109|NCT00414271|Drug|Capecitabine, doxcetaxol|
1946110|NCT00414622|Drug|DMXB-A|
1946111|NCT00413803|Procedure|4-hour thrice weekly in center hemodialysis|conventional hemodialysis
1946112|NCT00413803|Procedure|8-hour thrice weekly in center hemodialysis|long dialysis
1946113|NCT00412204|Drug|tiotropium bromide|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
1946114|NCT00412204|Other|Placebo|Subjects will be randomized to treatment with tiotropium or placebo. Double-blind medication will be dispensed in HandiHalers to be taken once daily in the morning for 22 days.
1946115|NCT00412035|Drug|Botulinum toxin A injection|10 units per kilo to maximum of 400 units
1946116|NCT00412035|Drug|saline injection|10 units per kilo to maximum of 400 units
1946117|NCT00410722|Dietary Supplement|Whole wheat and bran muffin|
1946118|NCT00410722|Dietary Supplement|Mixed tree nuts|
1946119|NCT00410423|Drug|Bortezomib with mitoxantrone, etoposide and cytarabine|All patients receive bortezomib in combination with mitoxantrone, etoposide and cytarabine. This is a 5 day chemotherapy regimen that is administered in the hospital.
1946120|NCT00409799|Drug|I-0401 (a new bone graft substitute)|1 time application
1946121|NCT00409539|Drug|Placebo|Placebo, 2 week duration.
1946122|NCT00409539|Drug|Placebo|Taken for the 8 week duration, in parallel with alternative arms (doses of 20, 40, 80 or 120mg SMP-986).
1946123|NCT00409539|Drug|SMP-986|Comparison of varying dosages (20, 40, 80 or 120mg) of SMP-986 against placebo. Dosing is to occur once daily, in the morning, for a duration of 8 weeks
1946124|NCT00408785|Drug|Botulinum Toxin Type A|botulinum toxin type A 100 units, human serum albumin 0.5 mg, sodium chloride 0.9 mg
1946125|NCT00408785|Drug|sodium chloride|sodium chloride 0.9 mg
1946126|NCT00408356|Drug|Zinc|
1946127|NCT00407758|Drug|enzastaurin hydrochloride|
1946128|NCT00406094|Drug|montelukast|10mg
1946129|NCT00406094|Drug|placebo|placebo
1946130|NCT00405353|Drug|Androgel 100mg gel|
1946134|NCT00404768|Drug|GSK221149A|6mg/h and 12 mg/h
1946135|NCT00404768|Drug|Placebo|Matched Placebo to Drug
1946136|NCT00404547|Drug|Ciclesonide|Asthma Care with Alvesco
1946137|NCT00404547|Drug|Usual Care Inhaled Glucocorticosteroids|Usual asthma care and dosage as chosen by the Primary Care Physician including inhaled steroid treatment
1946138|NCT00404261|Drug|Fluticasone/Salmeterol HFA|Fluticasone/Salmeterol HFA, 2 puffs twice daily
1946139|NCT00404235|Drug|carboplatin|
1946140|NCT00404235|Drug|paclitaxel albumin-stabilized nanoparticle formulation|
1946149|NCT00403117|Drug|Naltrexone|
1946150|NCT00403117|Drug|Marijuana|
1946151|NCT00403559|Drug|Elidel|
1946152|NCT00403390|Drug|Levothyroxine versus Levothyroxine|Randomized crossover study using 8 weeks of one form of levothyroxine, then 8 weeks of the other form of levothyroxine. The dose of medication does not change throughout the duration of the study.
1946153|NCT00403312|Behavioral|Smoking Cessation Behavioral Program|
1946154|NCT00403312|Drug|Nicotine Patch|
1946155|NCT00403312|Behavioral|Physical Activity|
1946156|NCT00403208|Procedure|Analgesia based sedation in ICU patients|
1946157|NCT00403169|Drug|lenalidomide|drug
1946158|NCT00402831|Biological|ProQuad® (prevention of measles, mumps, rubella and varicella)|route
1946159|NCT00402168|Drug|Belatacept|IV, IV Infusion, 5 mg/kg once every 28 days for one year
1946160|NCT00402168|Drug|Cyclosporine A|Tablets, Oral, Trough of 100-250 ng/mL, 2* daily for one year
1946161|NCT00402168|Drug|Tacrolimus|Tablets, Oral, Trough of 5-10 ng/mL, 2* daily for one year
1946162|NCT00401986|Device|Bronchial thermopladsty with the Alair System|Treatment of airways with the Alair System in PREDECESSOR STUDY
1946164|NCT00400517|Biological|sargramostim|administered subcutaneously, generally well tolerated doses range from 50-500 ug/m2/day
1946165|NCT00400517|Drug|thalidomide|doses up to 400 mg/day
1946166|NCT00400517|Procedure|conventional surgery|SOC care surgery
1946167|NCT00400517|Procedure|neoadjuvant therapy|post radical prostatectomy
1946168|NCT00400985|Device|Implantable device: monitoring of intrathoracic impedance using the OptiVol diagnostic tool.|SENSE-HF is not a randomized trial. Study divided in 3 phases among which the first is blinded to the diagnostic data.
1946169|NCT00400530|Drug|MK0217, alendronate sodium / Duration of Treatment: 1 Month|
1946170|NCT00400530|Drug|Comparator: Alendronate-Teva / Duration of Treatment: 1 Month|
1946171|NCT00399802|Drug|Odanacatib|odanacatib 50 mg tablet once weekly, 4 week treatment period.
1946172|NCT00399802|Drug|Comparator: zoledronic acid|one time zoledronic acid 4 mg IV infusion.
1946173|NCT00399802|Drug|Comparator: Placebo (unspecified)|odanacatib Pbo tablet once weekly, 4 week treatment period.
1946174|NCT00399802|Drug|Comparator: Placebo (unspecified)|zoledronic acid Pbo IV infusion, 4 week treatment period.
1946175|NCT00398593|Behavioral|Range of electronic pill dispensers with alarms|Patients will be offered 1. Counselling with education and/or 2. Electronic reminders
1946176|NCT00399243|Drug|Sumatriptan 4mg Statdose injection|4mg Sumatriptan Statdose injection for use as acute therapy in a cluster headache. Consistency of response in three attacks will be measured
1946177|NCT00398567|Drug|HKI-272|neratinib 160 mg daily by mouth
1946178|NCT00398567|Drug|Herceptin|Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter
1946179|NCT00398567|Drug|HKI-272|neratinib 160 mg daily by mouth
1946180|NCT00398567|Drug|Herceptin|Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter
1946181|NCT00398567|Drug|HKI-272|neratinib 240 mg daily by mouth
1946182|NCT00398567|Drug|Herceptin|Herceptin 4 mg/kg IV as a loading dose followed by Herceptin 2 mg/kg weekly thereafter
1946183|NCT00398580|Drug|Nanomilled testosterone|
1946184|NCT00398580|Drug|Nanomilled dutasteride|
1946185|NCT00398580|Drug|commercially available dutasteride|
1946186|NCT00398476|Drug|fluticasone propionate (FP)|200 micrograms (mcg); an aqueous suspension of microfine FP
1946187|NCT00398476|Drug|fluticasone furoate (FF)|110 mcg; an aqueous suspension containing 0.05% w/w of micronized FF
1946188|NCT00397943|Biological|GSK's candidate Mycobacterium tuberculosis vaccine 692342|Intramuscular injection, 2 doses at 0, 1 month
1946189|NCT00397943|Biological|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and adjuvant system|Intramuscular injection, 2 doses at 0, 1 month
1946190|NCT00397943|Biological|Comparator vaccine with recombinant Mycobacterium tuberculosis antigen and physiological saline|Intramuscular injection, 2 doses at 0, 1 month
1946191|NCT00397943|Biological|Control vaccine with the adjuvant system.|Intramuscular injection, 2 doses at 0, 1 month
1946192|NCT00397722|Drug|GW876008|
1946193|NCT00397722|Drug|paroxetine|
1946194|NCT00397020|Drug|divalproex ER|
1946195|NCT00397020|Drug|quetiapine|
1946196|NCT00397046|Drug|neratinib|HKI-272
1946197|NCT00396396|Drug|Acetylcysteine|
1946198|NCT00396006|Biological|Alpha1-Proteinase Inhibitor|60 mg/kg, weekly, intravenous infusion
1946199|NCT00396019|Drug|PEG-Intron|
1946200|NCT00395135|Drug|Lorcaserin 10 mg BID|Lorcaserin 10 mg tablet each morning and evening for a duration of 52 or 104 weeks.
1946201|NCT00395135|Drug|Matching Placebo BID|Matching placebo tablet each morning and evening for a duration of 52 or 104 weeks.
1946202|NCT00395317|Other|Placebo|placebo tablet
1946203|NCT00395317|Drug|Firategrast 150 mg|150 mg tablet
1946204|NCT00395317|Drug|Firategrast 300 mg|300 mg tablet
1946205|NCT00395031|Drug|Ziprasidone|Ziprasidone dose of between 40 mg po bid to 160 mg po bid for 8 weeks
1946206|NCT00394056|Drug|Vestipitant|NK1 receptor antagonist
1946207|NCT00394056|Drug|Vestipitant + Paroxetine|NK1 receptor antagonist and SSRI
1946208|NCT00394056|Other|Placebo|Placebo
1946209|NCT00392912|Drug|AndroGel (Solvay Pharmaceuticals)|Testosterone Replacement Therapy: AndroGel 1% 5g packets (Solvay Pharmaceuticals). Initial dosage: 5g daily (1 packet). Patients who do not achieve eugonadal levels of 400-600 mg/dL within 2 weeks will be raised to 10g daily.
1946210|NCT00393146|Drug|GW856553|Study drug
1946211|NCT00392951|Drug|sirolimus|Tablet or liquid; taken once or twice daily; dosage is based on establishing a serum trough of 5-15 ng/ml by high-performance liquid chromatography (initial loading dose of 3 mg/m2 then 2.5 mg/m2 with adjustment based on serum trough)
1946212|NCT00392041|Drug|Eszopiclone|3mg qpm for 12 weeks
1946213|NCT00392041|Drug|placebo|1 pill qpm for 12 weeks
1946214|NCT00391144|Procedure|intravitreal triamcinolone injection of avastin (1.25 mg)|
1946215|NCT00390910|Biological|Pneumococcal conjugate vaccine GSK1024850A|Intramuscular injection, 3 doses
1946216|NCT00390910|Biological|Infanrix hexa|Intramuscular injection, 3 doses
1946217|NCT00390871|Drug|Precedex|
1946218|NCT00390871|Drug|Propofol|
1946219|NCT00390845|Drug|SB681323|15 milligrams (mg)/day
1946220|NCT00390845|Drug|Placebo|
1946221|NCT00390208|Drug|ranibizumab, dexamethasone and verteporfin|One 500 microgram dose (0.05cc) intravitreal dexamethasone (10 mg/ml vial) in combination with Visudyne Photodynamic Therapy and 0.5 mg intravitreal Ranibizumab injection on the same day.
1946222|NCT00390208|Drug|Ranibizumab|One 0.5 mg intravitreal Ranibizumab injection
1946225|NCT00388414|Drug|duloxetine|30-60mg of duloxetine daily
1946226|NCT00388414|Drug|Placebo|Placebo pill once daily
1946227|NCT00386386|Other|hypodermoclysis via recombinant hyaluronidase-facilitated subcutaneous infusion|Above
1946228|NCT00385788|Drug|Gemcitabine|800 mg/m^2 IV over 30 minutes on Day -7 (1 day)
1946229|NCT00385788|Drug|Fludarabine|33 mg/m^2 IV over 30 minutes Day -5 to Day -2 (4 days)
1946230|NCT00385788|Drug|Melphalan|70 mg/m^2 IV over 30 minutes on Day -3 to Day -2 (2 days)
1946231|NCT00385788|Drug|Antithymocyte Globulin|"2 mg/kg IV on Day -4 and Day -3 (2 days) before stem cell transplantation.
If receiving transplant from matched unrelated donor (not a blood relative), a mismatched related donor (a blood relative, but not a full match), or receiving a cord blood transplant."
1946232|NCT00385788|Procedure|Allogeneic Stem Cell Infusion|Infusion of stem cells on Day 0.
1946233|NCT00385788|Drug|Tacrolimus|0.03 mg/kg beginning Day -2 by vein over 24 hours; when tolerable change to pill form given once daily for 3-4 months.
1946234|NCT00385788|Drug|Filgrastim (G-CSF)|Starting 1 week after transplant (Day +7) given as injection under the skin once daily until blood cell levels return to normal.
1946235|NCT00385788|Drug|Methotrexate|5 mg/m2 by vein on Days +1, +3, +6, and +11 to decrease risk of GVHD.
1946236|NCT00385255|Biological|Tetanus toxoid,reduced diphtheria toxoid&acellular pertussis|
1946237|NCT00384644|Device|NiRS measurment of tissue oxygenation|NiRS measurment of tissue oxygenation
1946238|NCT00385099|Drug|GW876008|
1946239|NCT00385008|Drug|Combination Product (sumatriptan succinate / naproxen sodium)|sumatriptan/naproxen sodium
1946240|NCT00385008|Drug|RELPAX(eletriptan) 40mg Tablet|eletriptan tablets
1946241|NCT00384839|Drug|azacitidine for injectable suspension|Vidaza: 75 mg/m2 for 5 consecutive days (Days 1-5) of each 28 day cycle. A cycle will equal to 28 days. Patient will receive a maximum of 12 cycles.
1946242|NCT00383708|Drug|lanreotide (Autogel formulation)|120 mg administered via deep subcutaneous injection every 28 days over 28 weeks.
1946243|NCT00383708|Drug|Pegvisomant|Administered at 40 to 120 mg per week via subcutaneous injection once or twice a week over 28 weeks.
1946244|NCT00383448|Drug|Clofarabine|days -7 through -3: 40 mg/m^2 intravenously over 2 hours
1946245|NCT00383448|Procedure|Total body Irradiation|Administration of TBI: The dose of TBI will be 200 cGy given in a single fraction on day -1. The dose rate will be between 10-19 cGy/minute prescribed to the midplane of the patient at the level of the umbilicus.
1946246|NCT00383448|Drug|Melphalan|day -2: 140 mg/m^2 intravenously over 30 minutes
1946247|NCT00383448|Biological|Hematopoietic Stem Cell Transplantation|receives infusion of stem cells on day 0
1946248|NCT00383448|Drug|Alemtuzumab|0.3 mg/kg intravenously (IV) days -12 through -8
1946249|NCT00383448|Drug|mycophenylate mofetil|Day -3 through Day 30: 1 gram three times daily (total daily dose 3 grams/day) if the recipient is >50 kg, or 15 mg/kg three times daily if the recipient is ≤50 kg. The same dosage is used orally or intravenously. Consider dose modification if renal impairment (GFR<25 mL/minute corrected)
1946250|NCT00383448|Device|Cyclosporine A|"Patients will receive CsA therapy beginning on day -3. Dosing of CsA will be 2.5 mg/kg/dose intravenously (IV); if the recipient body weight is <40 kg, dosing will be 3 times daily, and if > 40 kg twice daily. An attempt will be made to maintain a trough cyclosporine level of 250 mg/L to 350 mg/L. Once the patient can tolerate oral medications and has a normal gastrointestinal transit time, CsA will be converted to an oral form at a dose 2.5 x the current IV dose (maximum 12.5 mg/kg/day as initial oral dose).
CsA taper begins at day +100."
1946251|NCT00383448|Drug|Hydroxyurea|hydroxyurea (HU) beginning day -28 and continuing through alemtuzumab administration
1946252|NCT00382824|Drug|CoenzymeQ10|active drug
1946253|NCT00381667|Drug|GW642444M|M salt
1946254|NCT00381667|Drug|GW642444H|H salt
1946255|NCT00381667|Other|placebo|placebo
1946256|NCT00381394|Drug|sitamaquine|
1946257|NCT00381108|Drug|Placebo Tablet|Two tablets, twice daily.
1946258|NCT00381108|Drug|Pomegranate Tablet|Two tablets, twice daily.
1946259|NCT00380393|Biological|GSK malaria vaccine 257049 Vaccine|3 dose intramuscular injection
1946260|NCT00380393|Biological|Sanofi-Pasteur's Human Diploid Cell Rabies Vaccine|3 dose intramuscular injection
1946261|NCT00379990|Drug|GW274150|60 mg /day
1946262|NCT00379990|Drug|Prednisolone|7.5 mg/day
1946263|NCT00379990|Other|Placebo|Placebo
1946264|NCT00380354|Drug|GSK256066|
1946265|NCT00379821|Drug|Atovaquone-proguanil|Atovaquone-proguanil: once a day for 3 days, Pediatric tablet: 62.5 mg/25 mg, Full strength tablet: 250 mg/100 mg
1946266|NCT00379821|Drug|Artesunate|Artesunate: 4mg/kg once a day for 3 days, 50 mg tablet
1946267|NCT00379821|Drug|Azithromycin|Azithromycin 30 mg/kg once a day for 3 days, 200 mg/5cc suspension
1946268|NCT00379821|Drug|Chloroquine|Chloroquine: 10 mg/kg on days 0 and 1, 5 mg/kg/day on day 2, 100 mg tablet.
1946269|NCT00379756|Drug|LEVITRA (vardenafil)|active comparator
1946270|NCT00379756|Drug|placebo|placebo comparator
1946271|NCT00379600|Drug|rosiglitazone XR|
1946272|NCT00377728|Drug|GSK256066|
1946274|NCT00376337|Drug|Micafungin|IV
1946275|NCT00376337|Drug|Systemic antifungal therapy|IV
1946276|NCT00375609|Drug|PRT054021|
1946277|NCT00375752|Drug|Letrozole|2.5 mg.tablet.
1946278|NCT00375752|Drug|Zolendronic Acid|4 mg or an adjusted dose based on renal function in 100 ml physiologic (o.9%) normal saline, (as an intravenous infusion over no less than 15 minutes)
1946279|NCT00375167|Behavioral|Recovery Workbook Training (psychoeducational training)|
1946280|NCT00375219|Drug|Omacetaxine mepesuccinate|"Induction:
1.25 mg/m^2 subcutaneously, twice daily for 14 consecutive days every 28 days until response. Patients not demonstrating evidence of clinical response after 6 induction cycles will be considered for removal from the study.
Maintenance:
1.25 mg/m^2 subcutaneously, twice daily for 7 consecutive days in a 28-day cycle, for up to 3 years."
1946281|NCT00374907|Drug|Saxagliptin|Tablet, Oral, 5 mg, Once daily, (up to 12 weeks ST, up to 104 weeks LT)
1946282|NCT00374907|Drug|Placebo|Tablet, Oral, 0 mg, Once daily (up to 12 weeks ST)
1946283|NCT00374907|Drug|Metformin (blinded)|Tablet, Oral, 500 mg titrated to 1000 mg, Once daily (up to 104 weeks LT, starting at Week 12)
1946284|NCT00374907|Drug|Metformin (open-label)|Tablets, Oral, 500-1500 mg, as needed (starting in LT)
1946285|NCT00374556|Drug|eszopiclone, 2 mg, qhs|
1946286|NCT00374582|Device|Bodystat Quadscan 4000|device determining body composition and nutritional status
1946287|NCT00374582|Device|bodystat quadscan 400|device determining body composition and nutritional status
1946288|NCT00373672|Drug|armodafinil (Nuvigil)|armodafinil (Nuvigil)150 mg qd
1946289|NCT00373672|Drug|placebo|identical in appearance to active comparator
1946290|NCT00373542|Drug|ropinirole CR-RLS|
1946291|NCT00373399|Drug|Marijuana|Marijuana (0, 1.98, 3.56% THC), provided by the National Institute of Drug Abuse) was administered using a cued-smoking procedure, which produces reliable increases in heart-rate and plasma Δ9 THC. Each participant smoked each dose of mariuana on separate study days in this within-subject design.
1946292|NCT00373386|Drug|growth hormone|
1946293|NCT00372957|Drug|GW823093|
1946294|NCT00372229|Drug|Pre-emptive therapy|As prescribed
1946295|NCT00372229|Drug|valganciclovir [Valcyte]|900mg po for 100 days
1946296|NCT00372112|Drug|GW642444|GW642444H
1946297|NCT00372112|Other|Placebo|Placebo administered twice daily
1946299|NCT00370396|Biological|10 valent pneumococcal conjugate (vaccine)|
1946300|NCT00369577|Drug|Loxapine thermal aerosol|
1946301|NCT00368836|Device|BreathScreen PE|One minute of breath collection by tidal breathing into the BreathScreen PE and blood draw for D-dimer level
1946302|NCT00368173|Drug|rhIGF-I/rhIGFBP-3|
1946303|NCT00367458|Drug|Atorvastatin|80 mg atorvastatin oral daily
1946304|NCT00366834|Drug|Casopitant (GW679769) oral tablets|
1946305|NCT00366834|Drug|Casopitant (GW679769) intravenous|
1946306|NCT00366834|Drug|Dexamethasone intravenous|
1946307|NCT00366834|Drug|Ondansetron oral tablets|
1946308|NCT00366834|Drug|placebo|casopitant placebo
1946309|NCT00366535|Drug|Neurotropin|
1946310|NCT00366080|Drug|GSK189254|
1946311|NCT00365794|Drug|Topical testosterone (Androgel) 10 g/day|Testosterone therapy for 20 weeks
1946312|NCT00364910|Behavioral|Cognitive behavioral therapy (CBT)|Participants meet with a therapist for three to five sessions brief exposure-based CBT.
1946313|NCT00364910|Behavioral|Educational session and treatment as usual|Participants assigned to the educational session attend one meeting with a researcher to discuss the results from their evaluation. They could also be referred to a mental health clinic of their choice to help relieve their symptoms.
1946314|NCT00363480|Drug|Salmeterol/Fluticasone 50/250 µg|salmeterol/fluticasone combination 50/250 µg twice daily
1946315|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication + iron sulfate|A 10-day course of Hp infection sequential eradication therapy plus 6-weeks of iron supplementation
1946316|NCT00364104|Drug|Quadruple sequential Helicobacter pylori eradication therapy|A 10-day course of Hp infection sequential eradication therapy only plus 6-weeks of matching placebo of iron supplementation
1946317|NCT00364104|Drug|Ferrous sulfate|6-weeks of iron supplementation only plus 10-days matching placebo of Hp infection eradication therapy
1946318|NCT00364104|Drug|Placebo|Placebo only (10-days of matching placebo of Hp eradication therapy and 6-weeks of matching iron supplementation).
1946319|NCT00363727|Drug|ropinirole controlled-release (REQUIP CR) for RLS|
1946320|NCT00362908|Behavioral|Moderate Fat and Moderate Carbohydrate Diet|40% allowable fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
1946321|NCT00362908|Behavioral|Low Fat and High Carbohydrate Diet|20% fat diet (less than or equal to 7% saturated fat) consumed for 1 or 5 months
1946322|NCT00361712|Procedure|Epidural analgesia|
1946323|NCT00360230|Biological|Rabipur|3-dose intramuscular injection.
1946324|NCT00360230|Biological|GSK Biologicals' candidate Plasmodium falciparum malaria vaccine 257049|2 different formulations are tested. For each formulation, 3 different dosing schedules are tested
1946325|NCT00359294|Drug|Zalypsis (PM00104)|Intravenously over 1 hour daily for 5 days, every 3 weeks.
1946326|NCT00359073|Drug|montelukast|10 mg QD
1946327|NCT00359073|Drug|placebo|like placebo
1946328|NCT00358488|Drug|GSK159797 (10, 15, and 20mcg)|GSK159797 (10, 15, and 20mcg)
1946329|NCT00358488|Drug|salbutamol|salbutamol
1946330|NCT00358488|Drug|salmeterol 50mcg|salmeterol 50mcg
1946331|NCT00358488|Drug|placebo|placebo
1946332|NCT00356603|Drug|Sumatriptan Succinate|
1946333|NCT00356759|Drug|Prolongation of the interval between monitoring of warfarin|Warfarin is dosed according to INR to maintain INR 2.0-3.0 or for mechanical mitral valves or mechanical aortic valves with atrial fibrillation INR 2.5-3.5
1946334|NCT00356369|Biological|meningococcal ACWY (vaccine)|One intramuscular dose.
1946335|NCT00356369|Biological|Mencevax™ ACWY|One subcutaneous dose.
1946337|NCT00355342|Drug|fluticasone propionate/salmeterol powder|
1946338|NCT00355342|Drug|salmeterol powder|
1946339|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL IM of each vaccine. (DAPTACEL® + IPOL on Day 0 and Menactra on Day 30)
1946340|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine. (DAPTACEL® + Menactra® on Day 0 and IPOL on Day 30)
1946341|NCT00355121|Biological|Polysaccharide Diphtheria Toxoid Conjugate Vaccine|0.5 mL, IM of each vaccine (Menactra® + IPOL on Day 0 and DAPTACEL® on Day 30)
1946342|NCT00355056|Other|Sham Procedure|Sham Procedure
1946343|NCT00355056|Device|AMPLATZER PFO Occluder|Patients in this arm will receive the AMPLATZER PFO Occluder device
1946344|NCT00354172|Biological|aldesleukin|10 Million units subcutaneous every other day on days -13 (after Natural killer cell graft), -11, -9, -7, -5, -3) If < 45 kilograms (Kg) - interleukin (IL)-2 at 5 MU/m2
1946345|NCT00354172|Biological|filgrastim|All patients will receive filgrastim (same as granulocyte-colony stimulating factor or G-CSF) 5 mcg/kg/day intravenous (IV) (dose rounded to vial size) based on the actual body weight beginning on day +1 after umbilical cord blood (UCB) infusion. Granulocyte Colony Stimulating Factor (G-CSF) will be administered daily until the absolute neutrophil count (ANC) exceeds 2.5 x 10^9/L for three consecutive days and then discontinued. If the ANC decreases to <1.0 x 10^9/L, G-CSF will be reinstituted.
1946384|NCT00345358|Biological|Pneumococcal conjugate vaccine GSK1024850A.|1, 2, 3 or 4 Intramuscular injections, depending on age group
1946346|NCT00354172|Biological|natural killer cell (NK) therapy|All CD3 depleted cells will be given (less those required for product monitoring). The minimum size of a starting NK cell unit will be 700 million mononuclear cells before processing. NK cells (CD56+) and NK cell precursors (CD34+/CD7-, CD34+/CD7+, CD34-/CD7+) will be monitored and reported but will not serve as lot release.
1946347|NCT00354172|Drug|cyclophosphamide|Cyclophosphamide to be administered with high volume fluid flush and mesna on days-18 and -17 after fludarabine. Cyclophosphamide 60 mg/kg/day intravenously (IV) x 2 days, total dose 120 mg/m2 (days -18 and -17)
1946348|NCT00354172|Drug|cyclosporine|Patients will receive cyclosporine (CSA) therapy beginning on day -1 maintaining a level of >200 ng/mL. For adults the initial dose will be 2.5 mg/kg intravenously (IV) over 2 hours every 12 hours. For children <40 kg the initial dose will be 2.5 mg/kg IV over 2 hours every 8 hours.
1946349|NCT00354172|Drug|fludarabine phosphate|Fludarabine 25 mg/m2/day intravenously (IV) x 3 days, total dose 75 mg/m2 (days -18 to -16)
1946350|NCT00354172|Drug|methylprednisolone|"This modification will be enacted based on the engraftment stopping rule on all subsequent patients to stop natural killer (NK) cell reaction.
Methylprednisolone bolus 1000 mg intravenously (IV) will be administered day -1 and day 0 (before umbilical cord blood transplant) to suppress natural killer (NK) cell activity before transplant. Starting cyclosporin and mycophenolate mofetil (MMF) will also contribute to suppressing residual NK cell activity."
1946351|NCT00354172|Drug|mycophenolate mofetil|"All patients will begin mycophenolate mofetil (MMF) on day -1. Patients
≥ 45 kilograms will receive MMF at the dose of 3 grams/day divided into 2 or 3 doses. Pediatric patient (<45 kilograms) will receive MMF at the dose of 15 mg/kg. Use intravenous (IV) route between days -1 and +5, then, if tolerated, may change to by mouth (PO) between days +6 and +30.
Stop MMF at day +30 or 7 days after engraftment, whichever day is later, if no acute Graft Versus Host Disease. (Definition of engraftment is 1st day of 3 consecutive days of absolute neutrophil count [ANC] > 0.5 x 10^9 /L)."
1946352|NCT00354172|Procedure|Umbilical Cord Blood Transplantation (UCBT)|The product is infused via intravenous (IV) drip directly into the central line without a needle, pump or filter.
1946353|NCT00354172|Radiation|Total body irradiation (TBI)|"TBI 165 Gray (cGy) will be given twice daily for a total dose of 1320 cGy (days
-16 to -13)."
1946354|NCT00354809|Drug|GW679769|
1946355|NCT00352001|Drug|azacitidine|Azacitidine subcutaneously once daily on days 1-5 or days 1-5 and 8-12. Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
1946356|NCT00352001|Drug|lenalidomide|Oral lenalidomide once daily on days 1-14 or days 1-21.Treatment repeats every 28 days for up to 7 courses in the absence of relapse (after achieving complete or partial remission), disease progression, or unacceptable toxicity.
1946357|NCT00352469|Drug|Seroquel XR|Day 1 and 2 Seroquel XR 50 mg; Day 3-4 Seroquel XR 150mg;Day 5-42 Seroquel XR 300-400mg
1946358|NCT00351221|Drug|rhIGF-1/rhIGFBP-3|
1946359|NCT00351312|Device|special socks|
1946364|NCT00350337|Biological|Live attenuated tetravalent dengue vaccine|
1946365|NCT00349778|Drug|cyclophosphamide|
1946366|NCT00349778|Drug|etoposide|
1946367|NCT00349778|Drug|BCNU Melphalan|
1946368|NCT00347412|Drug|Paclitaxel and Carboplatin|"Paclitaxel and carboplatin: (All randomized patients)
All randomized patients will follow the established 21-day cycle of paclitaxel and carboplatin including the administration of pre-medications for these products per the package inserts. Paclitaxel and carboplatin cycles will be administered until documented disease progression or completion of 6 cycles of paclitaxel and carboplatin in the absence of response or unacceptable related toxicity, whichever comes first.
The initial dose of chemotherapy for every patient in the trial is 200 mg/m2 of paclitaxel,as a 3 hour infusion, followed by carboplatin at an area under the curve (AUC) of 6 mg/mL/min using the Calvert equation for carboplatin dosing."
1946369|NCT00347412|Drug|NOV-002 Injection in combination with Carboplatin vs. Paclitaxel and Carboplatin|"NOV-002: (Group A only)
Two 60mg intravenous boli given 3 hours apart administered the day prior to the first administration of paclitaxel and carboplatin cycle one
For each nominal 21-day paclitaxel and carboplatin cycle:
60mg given intravenously on Day 1, given one hour prior to paclitaxel and carboplatin
followed by 60mg subcutaneously daily for the next 20 days. If there is a delay in chemotherapy cycles, the patient will continue with daily, subcutaneous administration of NOV-002 until the next cycle of chemotherapy begins.
Patients randomized to NOV-002 Group A, will receive NOV-002 until disease progression, unacceptable NOV-002 related toxicity, or discontinuation of paclitaxel and carboplatin, whichever comes first."
1946374|NCT00347139|Drug|GW642444 (25, 100 & 400 mcg/day)|25, 100 and 400mcg/dose
1946375|NCT00347139|Drug|Salmeterol 50mcg|Salmeterol 50mcg
1946376|NCT00346775|Drug|Beclomethasone dipropionate|Beclomethasone dipropionate
1946377|NCT00346775|Drug|Flunisolide|Flunisolide
1946378|NCT00346073|Biological|Tetanus, reduced diph toxoids, acellular pertussis vaccine|
1946379|NCT00345969|Drug|Testosterone replacement therapy|Transdermal testosterone replacement therapy with Androgel(TM). Daily application of gel at 5 mg, 7.5 gm, or 10 gm for six months. Target serum total testosterone level between 500-900 ng/dl.
1946380|NCT00345969|Behavioral|Exercise training|Six months of supervised exercise training on site at academic medical center exercise facility. Exercise training consisted of 2 months of flexibility, balance, treadmill walking, and low resistance exercises, followed by 4 months of progressive resistance training.
1946381|NCT00345917|Device|Retinal transplantation instrument|
1946382|NCT00345917|Device|Fetal tissue.|
1946383|NCT00345449|Behavioral|Decision Aid|
1946385|NCT00345358|Biological|Infanrix IPV/Hib|4 intramuscular injections
1946386|NCT00345215|Behavioral|High Sodium Diet|250-350 mmol
1946387|NCT00345215|Behavioral|Low Sodium Diet|25-35 mmol
1946388|NCT00345124|Behavioral|high sodium diet|250-350 mmol
1946389|NCT00345124|Behavioral|Low Sodium Diet|25-35 mmol
1946390|NCT00344318|Biological|Pneumococcal conjugate vaccine GSK1024850A|3 Intramuscular injections.
1946391|NCT00344318|Biological|Prevenar|3 Intramuscular injections
1946392|NCT00344318|Biological|Tritanrix-HepB|3 Intramuscular injections
1946393|NCT00344318|Biological|Hiberix|Reconstituted with Tritanrix before injection
1946394|NCT00344318|Biological|Polio Sabin.|3 oral doses.
1946395|NCT00344318|Biological|Poliorix.|3 intramuscular injections
1946400|NCT00340080|Drug|Abacavir|
1946401|NCT00338949|Drug|Ziprasidone|Participants who are switched to ziprasidone will take a max daily dose of 200 mg, flexibly dosed based on symptoms and adverse effects.
1946402|NCT00338949|Drug|Standard atypical antipsychotic drug|Participants will remain taking the same medications of risperidone or olanzapine as they were before study entry.
1946403|NCT00336167|Drug|bezafibrate (drug)|
1946404|NCT00335738|Drug|liposomal vincristine sulfate|Given IV
1946405|NCT00335738|Drug|carboplatin|Given IV
1946406|NCT00335738|Drug|etoposide|Given IV
1946407|NCT00335764|Drug|sorafenib tosylate|given orally
1946408|NCT00335764|Drug|erlotinib hydrochloride|given orally
1946409|NCT00335764|Drug|tipifarnib|given orally
1946410|NCT00335764|Drug|temsirolimus|IV administration
1946411|NCT00335088|Drug|Moxifloxacin and Povidone Iodine vs Povidone Iodine|
1946412|NCT00334737|Drug|darbepoetin alfa|darbepoetin 10 mics/kg once a week SC for 10 weeks or until 35 completed weeks
1946413|NCT00334737|Drug|erythropoietin|Epo 400 units/kg 3 x weekly SC for 10 weeks or until 35 completed weeks gestation
1946414|NCT00334737|Drug|sham injection|sham injection
1946415|NCT00334152|Drug|casopitant|
1946416|NCT00333606|Procedure|Acupuncture|
1946417|NCT00333177|Behavioral|Cognitive remediation|Cognitive remediation training includes computerized cognitive training plus learning skills group.
1946418|NCT00333177|Behavioral|Health behavior training|Health behavior training includes group skills training in nutrition, exercise, and relaxation.
1946419|NCT00333177|Drug|Risperidone, administered orally|Oral risperidone at dosage judged optimal by treating psychiatrist
1946420|NCT00333177|Drug|Risperidone, administered via injection|Risperidone in injectable form every 2 weeks, starting with 25 mg and adjusted as needed
1946421|NCT00333177|Behavioral|Individual Placement and Support|Supported education/employment
1946422|NCT00332319|Drug|GW679769|
1946426|NCT00331149|Drug|Ropinirole prolonged release|
1946427|NCT00331149|Drug|ropinirole immediate release|
1946428|NCT00330863|Drug|Risperidone microspheres|Minimum dose is 12.5 mg every 2 weeks. Maximum dose is 75 mg every 2 weeks.
1946429|NCT00330863|Drug|Risperidone|Target dose is 4 mg/day.
1946430|NCT00330863|Drug|Olanzapine|Target dose is 15 mg/day.
1946431|NCT00330863|Drug|Quetiapine|Target dose is 600 mg/day.
1946432|NCT00330863|Drug|Ziprasidone|Target dose is 120 mg/day.
1946433|NCT00330863|Drug|Aripiprazole|Target dose is 20 mg/day.
1946434|NCT00330863|Drug|Paliperidone|Target dose is 6 mg/day.
1946435|NCT00330551|Behavioral|Group Skills Training and Psychoeducation|Group skills training sessions will be weekly throughout the study. The sessions will include group therapy meetings focused on everyday living skills, family education about schizophrenia, assessments of medication response, and individual meetings with a case manager for counseling and evaluations of schizophrenia symptoms.
1946436|NCT00330551|Behavioral|Individual Case Management|An individual therapist will provide therapy focused on everyday life skills and aid in interfacing with community agencies, work, and/or school settings.
1946437|NCT00330551|Drug|Oral Risperidone|Daily oral risperidone dosage will determined by treating psychiatrist.
1946438|NCT00330551|Drug|Risperidone in Long-Acting Injectable Form (Consta)|Participants will take a 25 mg dosage of injectable risperidone once every 2 weeks. Dosage will be adjusted if needed.
1946451|NCT00329680|Dietary Supplement|Eicosapentaenoic acid, Gamma-Linolenic Acid and Antioxidant Vitamins|An enteral diet will be given in accordance with the caloric goal calculated by the Harris-Benedict equation x 1.3. The enteral diet will be provided for a period of 7 days or until death OR start of oral diet OR start of parenteral diet OR discharge from the ICU OR decision from the attending physician/family/patient to no longer participate in this clinical study
1946452|NCT00329680|Dietary Supplement|Standard ICU enteral diet, isocaloric to the study diet|Patients will receive this diet in a blinded way using the same dose regimen specified previously and used in the study group
1946453|NCT00328900|Drug|Administration of 0,7 mg of atropine|
1946454|NCT00328900|Device|Measurement of skin conductance with Pain detector|
1946455|NCT00326924|Biological|Transfusion|PRBC blood transfusions.
1946458|NCT00325793|Drug|Nicardipine|
1946459|NCT00325507|Biological|TroVax®|
1946460|NCT00325286|Drug|Lithium Plus Extended- Release Carbamazepine|Preliminary phase subjects receive ERC-CBZ starting dose range from 100 to 200 mg b.i.d. and further titration up to a maximum dose of 1600 mg/day done at the discretion of the investigator. Titration phase will not extend beyond 2 weeks.Open label phase subjects stabilized on lithium and ERC-CBZ therapy will enter this phase for 6 months
1946461|NCT00324753|Behavioral|Communication|Communication sheet
1946462|NCT00324753|Behavioral|Standard of care|Standard of care brochures
1946463|NCT00324896|Drug|eszopiclone|eszopiclone
1946464|NCT00324896|Other|placebo|matching placebo administered at night
1946465|NCT00324506|Drug|Mycophenolate Mofetil (CellCept)|
1946466|NCT00324155|Drug|Ipilimumab|"Intravenous solution; intravenous; 10mg/kg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24, until disease progression, unacceptable toxicity or withdrawal of consent
In Maintenance phase: Only Ipilimumab: 10mg/kg, every 12 weeks will be continued until disease progression"
1946467|NCT00324155|Drug|Placebo|Intravenous solution; intravenous; 0 mg; one dose every 3 weeks for 10 weeks then one dose every 12 weeks starting at Week 24; until disease progression, unacceptable toxicity or withdrawal of consent
1946468|NCT00324155|Drug|Dacarbazine|Intravenous solution; intravenous; 850 mg/m^2; one dose every 3 weeks for 22 weeks, until disease progression, unacceptable toxicity or withdrawal of consent
1946469|NCT00323960|Drug|3 MPDN pulse + PDN|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years.
1946470|NCT00323960|Drug|3 MPDN pulse + PDN + CSA|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Cyclosporine 5 mg/Kg/day in 2 oral doses
1946471|NCT00323960|Drug|3 MPDN pulse + PDN + MTX|3 methylprednisolone pulses followed (30 mg/kg/pulse max 1 gram) followed by prednisone 2 mg/Kg/day to be tapered to 0.2 mg/kg/day in 6 months and then discontinued in 2 years; Methotrexate 15-20 mg/m2 once per week. Patients treated with MTX will receive concomitant folic or folinic acid according to the attending physician decision.
1946474|NCT00323414|Drug|PUFA (Opti-EPA)|EPA:DHA (360 mg EPA and 240 DHA in each capsule) 6 capsules-3 capsules by mouth 2 x per day x 48 weeks
1946475|NCT00323414|Drug|Placebo|Placebo gelcaps containing cornoil 6 capsules-3 capsules by mouth 2x per day x 48 weeks
1946476|NCT00322465|Drug|Tinidazole|2 gm single dose (4 tablets orally at 500 mg each).
1946477|NCT00322465|Other|Placebo|Placebo capsule will be filled with lactose only and be identical in appearance to the capsule of Azithromycin, Tinidazole, Doxycycline.
1946478|NCT00322465|Drug|Doxycycline|100 mg orally, twice daily for 7 days.
1946479|NCT00322465|Drug|Azithromycin|1 gram (gm) (2 tablets orally at 500 milligrams (mg) each).
1946480|NCT00322868|Drug|pioglitazone|
1946483|NCT00322023|Drug|D-serine|D-serine at following dose levels: 30 mg/kg, 60 mg/kg, and 120 mg/kg. PK/PD studies done at day 1. Medication will be administered as powder dissolved in liquid given in two divided doses daily for 4 weeks.
1946484|NCT00321971|Behavioral|Problem-solving therapy|The self-management intervention will train participants to effectively use problem-solving skills with the aim of strengthening their ability to cope and preventing the onset or worsening of depressive and anxiety disorders. All participants attend weekly individual training sessions, either in their home, another convenient location, or by telephone for a total of 9 weeks.
1946485|NCT00321971|Behavioral|Nutritional education program|The nutritional education program will be based on the new USDA dietary recommendations. All participants attend weekly individual training sessions, either in their home or another convenient location for a total of 6 weeks.
1946486|NCT00320398|Drug|Fondaparinux|
1946487|NCT00321477|Drug|GW679769 oral tablets|
1946488|NCT00320931|Device|PET/CT|
1946489|NCT00320450|Drug|SB-681323|
1946490|NCT00319839|Drug|Abraxane|260 mg/m2 IV over 30 minutes every 3 weeks
1946491|NCT00319839|Drug|Centuximab|Centuximab will be added to Abraxane if there is documented progression on single agent Abraxane. First dose: 400 mg/m2 IV over 120 minutes. Weekly:250 mg/m2 IV over 60 minutes Days 8 and 15 of cycle 1 and days 1, 8, 15 of all subsequent cycles
1946492|NCT00319956|Drug|Azithromycin|Give 10 mg/kg IV/PO daily for first 7 days, then give 5 mg/kg IV/PO daily for 35 days.
1946493|NCT00319956|Drug|D5W|Dose given daily, IV/PO, same volume that Azithromycin would be to equal 10 mg/kg for first 7 days, then 5 mg/kg for 5 weeks.
1946494|NCT00319423|Procedure|Patient education and supervised exercise|Patient education: 3 sessions Supervised exercise: 2-3 times/week for 12 weeks
1946496|NCT00318149|Biological|Fluarix, 4 adjuvanted candidate influenza vaccines|
1946497|NCT00316979|Device|Repetitive Transcranial Magnetic Stimulation (rTMS)|
1946498|NCT00314860|Drug|ropinirole Extended Release (XR)|
1946499|NCT00313560|Drug|erlotinib hydrochloride|Given orally
1946500|NCT00313560|Other|placebo|Given orally
1946501|NCT00312897|Drug|Omega-3 Fatty Acids|10 wk treatment period
1946502|NCT00312897|Drug|corn oil|placebo comparator
1946503|NCT00312663|Biological|Falciparum Malaria Protein 11 with AS01B adjuvant.|malaria experimental vaccine
1946504|NCT00312702|Biological|Falciparum Malaria Protein 11 with AS02A adjuvant|vaccine
1946505|NCT00312013|Drug|Nadroparin|Patients will received all standard anti-cancer treatments. Therapeutic doses of nadroparin will be administered, subcutaneous for 2 weeks followed by half therapeutic doses for 4 weeks. After 4 weeks of wash-out, subsequent 2 week periods of therapeutic doses will be given for a total of 6 cycles each separated by a 4 week wash out. The study treatment period ends at week 46 regardless of the number of cycles achieved.
1946506|NCT00311246|Drug|Adalimumab|Subjects will give themselves a dose of Adalimumab at 40 mg/every week by subcuetaneous injection for a total of 45 weeks.
1946507|NCT00310622|Device|HyperQ Signal recording|
1946515|NCT00310037|Drug|bortezomib|Given IV
1946516|NCT00309166|Biological|HPV vaccine|
1946517|NCT00306995|Biological|SB218352_15|Non-adjuvanted pandemic influenza A formulation 1 vaccine
1946518|NCT00306995|Biological|SB218352_8|Non-adjuvanted pandemic influenza A formulation 2 vaccine
1946519|NCT00306995|Biological|SB218352_4|Non-adjuvanted pandemic influenza A formulation 3 vaccine
1946520|NCT00306995|Biological|SB218352_2|Non-adjuvanted pandemic influenza A formulation 4 vaccine
1946521|NCT00306995|Biological|SB218352_8AL|Pandemic influenza A formulation 2 aluminium-adjuvanted vaccine
1946522|NCT00306995|Biological|SB218352_4AL|Pandemic influenza A formulation 3 aluminium-adjuvanted vaccine
1946523|NCT00306995|Biological|SB218352_2AL|Pandemic influenza A formulation 4 aluminium-adjuvanted vaccine
1946524|NCT00306163|Drug|Ciclesonide|inhaled Ciclesonide 160 µg, once daily in the morning
1946525|NCT00306163|Drug|Fluticasone|inhaled Fluticasone 100 µg, twice daily
1946526|NCT00306462|Drug|Magnesium sulfate|Intravenous magnesium sulfate 6g bolus, then increased by 1 g/hour till a maximum of 5g/hour; gradually wean down to 2 g/hour for a total of 48 hours once uterine contractions is < 6/hour.
1946527|NCT00306462|Drug|Oral Nifedipine or placebo|Oral nifedipine or placebo at 20 mg every 30 minutes for the first hour, then 20 mg every 3 to 6 hours not to exceed 180 mg in 24 hours, keep maintenance dose at 20 mg every 3 to 6 hours for a total of 48 hours if uterine contractions is < 6/hour.
1946528|NCT00306293|Drug|valacyclovir|valacyclovir
1946529|NCT00306176|Drug|Rosiglitazone|
1946530|NCT00305006|Procedure|Constraint-Induced Movement Therapy|90 hours
1946531|NCT00305006|Procedure|Hand-Arm Bimanual Intensive Therapy (HABIT)|90 hours
1946532|NCT00304356|Drug|Nitazoxanide|
1946533|NCT00303303|Biological|Crotaline Polyvalent Immune Fab (ovine) (active initial and maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; active maintenance therapy with 2 vials administered 6, 12, and 18 hours after initial control is achieved.
1946534|NCT00303303|Biological|Crotaline Immune Fab (ovine) (active initial therapy; placebo maintenance therapy)|Crotaline Polyvalent Immune Fab (Ovine), 4 vials initially; Second 4-vial dose two hours later if needed to achieve initial control of the envenomation syndrome; placebo maintenance therapy administered 6, 12, and 18 hours after initial control is achieved.
1946535|NCT00303303|Biological|Placebo|Placebo therapy in place of initial and maintenance antivenom therapy. Note that open-label rescue therapy is mandated if the envenomation syndrome becomes severe, or if progression of envenomation signs/symptoms has not spontaneously halted by 6 hours.
1946540|NCT00301951|Biological|anti-thymocyte globulin|
1946541|NCT00301951|Biological|sargramostim|
1946542|NCT00301951|Drug|busulfan|
1946543|NCT00301951|Drug|fludarabine phosphate|
1946544|NCT00301951|Drug|mycophenolate mofetil|
1946545|NCT00301951|Drug|tacrolimus|
1946546|NCT00301951|Procedure|umbilical cord blood transplantation|
1946550|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
1946551|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
1946552|NCT00299494|Drug|inotuzumab ozogamicin|IV, 1.8 mg/m2, q4w
1946553|NCT00299494|Drug|Rituximab|rituximab 375 mg/m^2 via IV infusion on Day 1
1946554|NCT00299182|Drug|AMG 531|Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm A: AMG531 - 1, 3, or 10 mcg/kg subcutaneous injection administered on on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
1946555|NCT00299182|Drug|Rituximab|375 mg/m^2 by vein over 4-6 hour infusion day 1, each cycle.
1946556|NCT00299182|Drug|Cyclophosphamide|300 mg/m^2 by vein over 3 hours every 12 hours for 6 doses (days 2-4), Cycles 1,3, & 5.
1946616|NCT00289198|Drug|Placebo|placebo nasal spray
1946557|NCT00299182|Drug|Vincristine|1.4 mg/m^2/dose (maximum 2 mg) by vein over 15 minutes Days 5 and 12, Cycles 1,3,& 5.
1946558|NCT00299182|Drug|Doxorubicin|50 mg/m^2/dose by vein over 15 minutes on Day 5 or by continuous infusion over 24-48 hours (days 5-6), Cycles 1,3,& 5.
1946559|NCT00299182|Drug|Dexamethasone|40 mg/day by mouth or by vein days 2-5 and 12-15, Cycles 1,3,& 5.
1946560|NCT00299182|Drug|Methotrexate|200 mg/m^2 by vein over 2 hours followed by 800 mg/m^2 over 22 hours Day 2, Cycles 2, 4 & 6.
1946561|NCT00299182|Drug|Cytarabine|3 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4; OR,1 g/m^2 by vein over 2 hours every 12 hours for 4 doses, days 3 & 4 for patients > 60 years and for patients with serum creatinine > 1.5 mg/dL; Cycles 2,4,& 6.
1946562|NCT00299182|Drug|Placebo|Arm A: Placebo - subcutaneous injection administered on days -5 and 5 (pre and post chemotherapy dose) beginning with Cycle 2; OR, Arm B: Placebo - subcutaneous injection administered on days 5 and 7 (post chemotherapy doses only) beginning with Cycle 2.
1946564|NCT00298883|Drug|Myfortic|Myfortic 360mg PO BID for six weeks
1946565|NCT00297882|Drug|Artemether-Lumefantrine , Amodiaquine-Artesunate|"Artemether-Lumefantrine(Co-Artem)=Artemether, 2mg/kg x 2(12h apart) and Lumefantrine, 12mg/kgx2 (12h apart).
Amodiaquine-ArtemetherD0(0H),D1(24H),D2(48H)- Artesunate 4mg/kg and Amodiaquine at 10mg/kg"
1946566|NCT00297219|Drug|Low dialysate calcium|1.25 mmol/L dialysate calcium
1946567|NCT00297219|Drug|high dialysate calcium|1.75 mmol/L dialysate calcium
1946568|NCT00297180|Drug|GW869682|
1946569|NCT00296725|Drug|Fluoxetine|wk 1: 10 mg/day; wks 2-3: 20 mg/day; wks 4-5: 40 mg/day; wk 6: 60 mg/day; wks 7-12: 80 mg/day *All increases only if tolerated.
1946570|NCT00296725|Drug|Imipramine|wk 1: 25 mg/day; wk 2: 50 mg/day; wk 3: 100 mg/day, 150 mg/day after 3 days; wk 4: 200 mg/day, 250 mg/day after 3 days; wks 5-6: 300 mg/day. *All increases only if tolerated.
1946571|NCT00296205|Drug|Cyclophosphamide|
1946572|NCT00295867|Drug|zoledronic acid|
1946573|NCT00294632|Drug|Lenalidomide|Starting Dose 10 mg By Mouth Daily on Days 1-21
1946574|NCT00294632|Drug|Rituximab|375 mg/m^2 By Vein Weekly for 4 Weeks
1946575|NCT00295022|Drug|Levocetirizine|
1946576|NCT00294866|Drug|Paricalcitol|Patients randomized to either receive Paricalcitol or have it held. After 4 weeks they are switched to the opposite intervention.
1946577|NCT00293228|Drug|Isoniazid|Isoniazid (5mg per kg up to 300 mg daily for 6 months)
1946578|NCT00293228|Drug|isoniazid|isoniazid (5mg per kg up to 300 mg daily for 6 months
1946579|NCT00293397|Device|doxorubicin hydrochloride|Doxorubicin eluting beads
1946580|NCT00293033|Drug|BEMA™ Fentanyl|
1946581|NCT00292942|Drug|Intravenous artesunate|
1946582|NCT00292929|Drug|Intravenous artesunate|
1946583|NCT00291928|Drug|Part A|Part A Cohort 1: HuMax-CD20 300 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 2: HuMax-CD20 700 mg at Days 0 and 14 or Placebo at Days 0 and 14 Cohort 3: HuMax-CD20 1000 mg at Days 0 and 14 or Placebo at Days 0 and 14
1946584|NCT00291928|Drug|Part B|Part B Group 1: HuMax-CD20 300 mg at Days 0 and 14 Group 2: HuMax-CD20 700 mg at Days 0 and 14 Group 3: HuMax-CD20 1000 mg at Days 0 and 14 Group 4: Placebo at Days 0 and 14
1946585|NCT00291356|Drug|GSK189075 oral tablets|
1946586|NCT00291356|Drug|GW869682 oral tablets|
1946587|NCT00291642|Drug|Levocetirizine|
1946588|NCT00290433|Drug|Cyclophosphamide|Cycle 1: 300 mg/m^2 by vein Over 3 Hours Twice Daily on Days 1, 2, and 3.
1946589|NCT00290433|Drug|Mesna|Cycle 1: 600 mg/m^2 by vein Continuous Infusion Over Days 1, 2, and 3.
1946590|NCT00290433|Drug|Vincristine|Cycle 1: 1.4 mg/m^2 by vein On Day 4 and 11.
1946591|NCT00290433|Drug|Methotrexate|Cycle 1 and 2: 200 mg/m^2 by vein Over 2 Hours on Day 1, followed by 800 mg/m^2 IV Over 22 Hours on Day 1.
1946592|NCT00290433|Drug|Ara-C|Cycle 1 and 2: 3 Gm/m^2 Over 2 Hours Twice Daily On Days 2 and 3.
1946593|NCT00290433|Drug|Dexamethasone|Cycle 1: 40 mg by vein or by mouth daily on Days 1-4 and 11-14.
1946594|NCT00290433|Drug|G-CSF|Cycle 1 and 2: 300 or 480 mcg subcutaneously 24 hours after end of Day 4 vincristine.
1946595|NCT00290433|Drug|Doxil|Cycle 1: 25 mg/m^2 by vein Over 1 Hour on Day 2.
1946596|NCT00290862|Device|Percutaneous Vertebral Augmentation of compression fractures|Study eligible patients with painful osteoporotic compression fractures will be randomized to percutaneous vertebroplasty with CORTOSS (treatment group) or PMMA (active control group).
1946599|NCT00290342|Biological|DTPa-IPV|3 intramuscular injections
1946600|NCT00290342|Biological|DTPa|3 intramuscular injections
1946601|NCT00290342|Biological|IMOVAX Polio®|3 intramuscular injections
1946602|NCT00289731|Biological|TWINRIX™|Intramuscular injection, 3 doses
1946603|NCT00289731|Biological|Engerix™-B|Intramuscular injection, 3 doses
1946604|NCT00289731|Biological|HAVRIX™|Intramuscular injection, 2 doses
1946605|NCT00289731|Biological|HB VAX PRO™|Intramuscular injection, 3 doses
1946606|NCT00289731|Biological|Vaqta™|Intramuscular injection, 2 doses
1946607|NCT00289653|Drug|Nicoderm|
1946608|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|15 IU/kg rAHF-PFM
1946609|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|30 IU/kg rAHF-PFM
1946610|NCT00289536|Biological|Antihemophilic factor, recombinant, manufactured protein-free|50 IU/kg rAHF-PFM
1946611|NCT00289315|Behavioral|Primary weight gain prevention|School-based program that modifies the school environment to promote healthy eating and physical activity
1946612|NCT00289315|Behavioral|Primary Prevention|School-based environmental program to promote healthy eating and physical activity.
1946613|NCT00289315|Behavioral|Primary and Secondary Prevention|School-based program that combines an environmental weight gain prevention program with a curriculum/internet-based program to promote weight loss in overweight students
1946614|NCT00289315|Behavioral|Control|Control program that does not include an active intervention for promoting healthy eating and physical activity.
1946615|NCT00289198|Drug|FF|fluticasone furoate 110 μg nasal spray
1946618|NCT00287989|Drug|erlotinib hydrochloride|
1946619|NCT00287989|Drug|paclitaxel|
1946620|NCT00288366|Drug|ziprasidone vs. aripiprazole|ziprasidone vs. aripiprazole dosed according to package insert
1946621|NCT00288366|Drug|aripiprazole vs. ziprasidone|aripiprazole vs. ziprasidone dosed according to package insert
1946624|NCT00287118|Drug|efalizumab=Raptiva|Each patient will receive an initial conditioning dose of 0.7 mg/kg/week followed by 1.0 mg/kg/week study drug during the treatment period, 23 weeks. If four or more consecutive doses have been missed, dosing should resume with the conditioning dose of 0.7 mg/kg and then continue receiving 1mg/kg/week thereafter. Study drug will be administered by SC injection.
1946626|NCT00283283|Biological|Fluzone® (Aventis Pasteur inactivated influenza vaccine)|A/H1N1, A/New Caledonia/20/99; A/H3N2, A/Fujian/411/2002; B, B/Shanghai/361/2002
1946627|NCT00282841|Procedure|ultrasound|single intravenous administration of max. 1.5ml ultrasound contrast agent (Definity), followed by max. 15min transcranial insonation using diagnostic ultrasound.
1946629|NCT00281762|Drug|NSAID|
1946630|NCT00281684|Drug|SB705498 400 mg|SB705498 400 mg
1946631|NCT00281684|Drug|SB705498 1000 mg|SB705498 1000 mg
1946632|NCT00281684|Drug|Placebo|Placebo
1946633|NCT00281684|Drug|Co-Codamol|Co-Codamol
1946634|NCT00280423|Drug|GW679769|
1946635|NCT00280436|Drug|GW679769|
1946636|NCT00279812|Behavioral|Selenomethionine (supplement) and selenium enriched onions|
1946640|NCT00278564|Biological|hematopoietic stem cell transplantation|Autologous hematopoietic stem cell transplantation
1946641|NCT00276380|Drug|EGb761 (Tanakan) and acetylsalicylic acid|EGb761 (Tanakan) 40mg tablets (2 tablets tid) 240mg/day AND acetylsalicylic acid (1 tablet once daily), 325 mg/day, for 6 months
1946642|NCT00276380|Drug|Placebo and acetylsalicylic acid|Placebo 40 mg tablets (2 tablets tid) AND acetylsalicylic acid, 325 mg/day (1 tablet once daily) for 6 months
1946643|NCT00274352|Drug|adalimumab|Adalimumab 40 mg administered subcutaneously once weekly or placebo injection administered once weekly for 12 weeks, followed by open-label adalimumab 40 mg administered subcutaneously weekly for an additional 12 weeks.
1946644|NCT00274339|Drug|Prevacid 30mg BID|
1946645|NCT00274339|Behavioral|Lifestyle changes of exercise and diet changes for weight loss and avoidance of reflux inducing foods.|
1946646|NCT00273039|Drug|paroxetine|
1946650|NCT00271999|Behavioral|Nocturnal home hemodialysis|Six times per week nocturnal home hemodialysis
1946651|NCT00271102|Procedure|anterior vaginal repair (colporrhaphy)|vaginal repair
1946652|NCT00271102|Procedure|abdominal paravaginal defect repair|abdominal repair
1946655|NCT00269087|Drug|fluticasone propionate/salmeterol combination DISKUS|
1946656|NCT00268996|Drug|SB-480848|SB-480848 is available as enteric-coated, free-base micronized tablet
1946657|NCT00268996|Drug|SB-480848 matching placebo|Placebo is available as enteric-coated, free-base micronized tablet
1946661|NCT00266851|Drug|Azithromycin|600 mg x 3 days, then 600 mg weekly x 11 weeks
1946662|NCT00266851|Drug|Placebo|Matching placebo
1946663|NCT00266877|Drug|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
1946664|NCT00266877|Drug|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
1946665|NCT00266877|Drug|HKI-272|320mg or 240mg daily by mouth. The starting dose was reduced from 320mg to 240mg per amendment #1 to the protocol for subject safety and tolerability.
1946668|NCT00265538|Behavioral|Patient education to engage provider in hypertension treatment discussion|Patients will receive a customized/tailored letter including most recent clinic blood pressure, current blood pressure medications and suggested htn medication(s)
1946669|NCT00265538|Behavioral|Financial incentive and health educator phone call|Patients may receive 20$ for discussing the intervention letter with their provider and 6 months copay reimbursement and/or the 20$ discussion incentive, 6 months copay reimbursement as well as a phone call reminder 1-2 days prior to their primary care appt.
1946670|NCT00265564|Behavioral|Modified Seeking Safety integrated into std outpatient SUD care|The Seeking Safety treatment involves two (one hour) sessions of manualized group therapy for 12 weeks.
1946671|NCT00265564|Behavioral|Standard outpatient SUD care|"Patients assigned to standard care meet twice weekly in Recovery 1 groups, which focuses on building abstinence."
1946672|NCT00265252|Drug|Alendronate|
1946673|NCT00265148|Drug|Rosiglitazone|Extended Release Tablets
1946674|NCT00265148|Other|Placebo|Placebo dummy to match
1946675|NCT00264615|Drug|lamotrigine extended-release|
1946676|NCT00263575|Drug|EN3267|EN3267 will be available in 100, 200, 300, 400, 600 (two 300 ug tablets), and 800 ug (two 400 ug tablets) doses
1946677|NCT00263562|Drug|Methylprednisolone plus prednisone taper|
1946678|NCT00263471|Drug|7-methylxanthine|
1946679|NCT00263341|Combination Product|NES/EE CVR|This is a Phase 3, multicenter, open-label study of a 21/7-day regimen of the 150/15 NES/EE CVR, in healthy women followed on an outpatient basis up to one year (13 cycles) of treatment over one year. Because of the stop treatment date of December 31, 2008 for all participants, women enrolling or re-enrolling in 2008 may not complete a full 13 cycles of treatment. Subjects may also participate in a 6 month follow-up period after the 300B study. The ring is designed to last for 12 months.
1946680|NCT00263250|Procedure|watchful waiting or tension-free hernia repair|
1946681|NCT00262678|Drug|EN3267|
1946682|NCT00261326|Drug|simvastatin|80 mg once daily
1946683|NCT00261326|Drug|placebo|calcium tablets once daily
1946684|NCT00261040|Procedure|minimally invasive total hip arthroplasty|minimally invasive total hip arthroplasty
1946685|NCT00261040|Procedure|Standard|standard approach hip surgery
1946686|NCT00259909|Other|GSK questionnaire|GSK questionnaire will demonstrate the validity, reliability and responsiveness as a tool for measuring subject-reported outcomes during an acute exacerbation of chronic obstructive pulmonary disease.
1946687|NCT00259909|Other|St. George's Respiratory Questionnaire|The SGRQ is a 50-item questionnaire with 76 weighted responses. It provides a Total score and three component scores: Symptoms (distress caused by respiratory symptoms), Activity (physical activities that cause or are limited by breathlessness), and Impacts (social and psychological effects of the disease). The Total score and each of the SGRQ sub-scores are scored from 0 to 100 where 0 indicates best and 100 indicates worst health.
1946688|NCT00259909|Other|Acute Short Form 12 version 2|The Acute SF-12v2 is a multipurpose short-form questionnaire with only 12 questions with two summary scores, the SF-12 Physical Component Summary (PCS-12) and the SF-12 Mental Component Summary (MCS-12). The scoring range for the PCS-12 and MCS-12 is 0 to 100, with a lower score indicating a poorer level of health
1946689|NCT00259909|Other|Global Efficacy questionnaire|Global Efficacy questionnaire will be administered in an electronic form to validate test-retest reliability, responsiveness and minimum important difference (MID)
1946690|NCT00259883|Drug|paroxetine|1 or 2 tablets once a day
1946691|NCT00260338|Biological|stem cell|mesenchymal stromal cell
1946692|NCT00260676|Procedure|change ventilation|reduction of tidal volume, increase of PEEP, recruiting maneuver, apnea test during CPAP
1946693|NCT00258128|Drug|salicylate|
1946694|NCT00258180|Biological|filgrastim|
1946695|NCT00258180|Drug|cyclophosphamide|
1946696|NCT00257816|Drug|Topotecan|2 mg/m2 IV on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
1946697|NCT00257816|Drug|Cisplatin|40 mg/m2 IV (Maximum total dose of 70 mg) on days 1, 8, 15, 22, 29 and once during parametrial boost (6 cycles)
1946698|NCT00257842|Procedure|Standard treatment, sham feedback and biofeedback therapy|
1946699|NCT00257725|Drug|Ritalin LA™|
1946700|NCT00256867|Drug|GSK523338|
1946701|NCT00256854|Drug|ropinirole controlled-release for RLS|
1946702|NCT00256750|Drug|Cyclosporine (CsA)|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months (ST), 100-250 ng/mL, daily, 24 months (LT)
1946703|NCT00256750|Drug|Belatacept LI (less intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
1946704|NCT00256750|Drug|Belatacept MI (more intensive)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months (ST), 5 mg/kg every 4 weeks, q 4 weeks, 24 months (LT)
1946705|NCT00256126|Drug|Saizen|blood sampling (10 ml) at baseline and one month (10 ml)
1946706|NCT00256594|Device|prescription form|Two prescription pads contained modified forms and two prescription pads were similar to the prescription pads the prescriber had been using. Providers completed 100 standard and 100 modified prescriptions
1946707|NCT00256451|Drug|Naltrexone|50 mg/day for two days prior to the alcohol challenge session
1946708|NCT00256451|Drug|placebo|placebo pills
1946709|NCT00256451|Other|alcohol|190 proof alcohol prepared to 11% volume mixed with fruit juice.
1946710|NCT00256451|Other|placebo alcohol|non-alcoholic placebo alcohol
1946711|NCT00256425|Behavioral|Cognitive rehabilitation|
1946712|NCT00256321|Drug|Oxaliplatin|
1946713|NCT00256321|Drug|Capecitabine|
1946714|NCT00256321|Drug|Celecoxib|
1946715|NCT00255944|Behavioral|Youthnet Internet-based program|Messages from the Youthnet program will be interactive and tailored specifically to HIV/STD risk reduction. Participants will be exposed to five flash computer vignettes of 30 seconds each, concerning condom attitudes, norms self-efficacy, and risk awareness.
1946716|NCT00255944|Behavioral|Control Internet based program|The control program will deliver standard STD/HIV prevention messages.
1946717|NCT00256282|Drug|Vinorelbine|30 mg/m2 IV over 6-10 min every 14 days
1946718|NCT00256282|Drug|Docetaxel|40mg/m2 IV over 1 hour every 14 days
1946719|NCT00256282|Drug|Sargramostim|250 mcg/m2 subcutaneous (SQ) daily (QD) x 10 days
1946720|NCT00256269|Drug|Oxaliplatin|40 mg/m2 IV over 60 minutes Every 21 days
1946721|NCT00256269|Drug|Irinotecan|60 mg/m2 IV over 60 minutes, immediately following oxaliplatin Every 21 days
1946722|NCT00256308|Drug|Oxaliplatin|70mg/m2 IV over 120 min once a week during radiation
1946723|NCT00256308|Procedure|Radiation|200 cGy/day - Megavoltage equipment with energy of Cobalt 60 or higher - Daily from Monday to Friday
1946724|NCT00254683|Device|PET/CT with FDG|PET/CT before start of neoadjuvant CRT, at 6 weeks, 12 weeks, following CRT completion and 12mo, 24mo following CRT for those considered complete responders
1946725|NCT00254176|Dietary Supplement|Parenteral cysteine-HCl supplementation|cysteine-HCl supplementation 121 mg per kg per day
1946726|NCT00254176|Dietary Supplement|Placebo - added premasol|Premasol 121 mg per kg per day
1946727|NCT00250822|Drug|Gemcitabine and Oxaliplatin|"Dose:
Gemcitabine 1000 mg/m2 - IV in about 60 minutes on days 1 & 15. Oxaliplatin 100 mg/m2 - IV over 2hr on days 2 & 16"
1946728|NCT00249834|Other|CONSORT calculator|The subject's Age, Body Mass Index (kg/m2), Number of follicles < 11 mm on a baseline ultrasound scan, Serum FSH level in the early follicular phase of a menstrual cycle were entered in an algorithm (CONSORT calculator), which then calculated the optimal fixed starting dose of r-hFSH for each subject according to her individual characteristics.
1946729|NCT00249808|Drug|Efalizumab - anti CD11a recombinant human monoclonal antibody|Each subject will receive 12 doses of 1 mg/kg/week during a period of 12 weeks. Depending on the response at 12 weeks patients might receive additional 8 to 12 weekly injections at 1.0 mg/kg/week.
1946734|NCT00248833|Biological|Meningococcal 44/76 MOS NOMV 5D|
1946735|NCT00248716|Drug|Ferrous gluconate and iron polysaccharide complex|Children with anemia will receive 5mg per kg per day of one of study medications. Treatment period for 3 months
1946736|NCT00248534|Biological|rituximab|
1946737|NCT00248534|Drug|methylprednisolone|
1946738|NCT00248534|Drug|temozolomide|
1946739|NCT00248040|Drug|Reparixin continuous infusion|Reparixin continuous infusion
1946740|NCT00248040|Drug|reparixin intermittent infusion|reparixin intermittent infusion
1946741|NCT00248040|Other|placebo infusion|placebo infusion
1946745|NCT00247728|Drug|PI-88|
1946746|NCT00246740|Drug|Periostat|In addition to standard care, patients will receive oral administration of 20 mg of doxycycline or placebo twice a day at least 2 days prior to surgery, on the day of surgery, and on postoperative days 1, 2, and 3.
1946747|NCT00246701|Drug|Simvastatin|Simvastatin
1946748|NCT00246701|Drug|Simvastatin + Lovaza|Simvastatin + Lovaza (omega-3-acid ethyl esters)
1946749|NCT00246636|Drug|Antara (fenofibrate) + Lovaza|Antara (fenofibrate) + Lovaza (omega-3-acid ethyl esters) [formerly known as Omacor]
1946750|NCT00246636|Drug|Antara (fenofibrate)|Antara (fenofibrate) + placebo
1946751|NCT00246129|Drug|Alemtuzumab|Monoclonal antibody induction therapy
1946752|NCT00246129|Drug|Daclizumab|Monoclonal antibody induction therapy
1946755|NCT00245037|Biological|therapeutic allogeneic lymphocytes|A population of lymphocytes therapeutically administered to a recipient individual who is genetically distinct from a donor of the same species.
1946756|NCT00245037|Drug|busulfan|"Busulfan is an alkylating chemotherapeutic agent which has been used in many high dose and reduced intensity regimens prior to allogeneic or autologous hematopoietic stem cell transplants. It is active in a wide variety of malignancies and in high-doses it is myeloablative.
IV busulfan is available and diluted and administered per package insert guidelines."
1946757|NCT00245037|Drug|cyclosporine|"Cyclosporine is a cyclic polypeptide immunosuppressive agent. It blocks the calcium-dependent calcineurin-mediated nuclear localization of nuclear factor of activated T cells (NFAT) following T-cell activation, thereby inhibiting transactivation of key T-cell response genes including Interleukin 2 (IL-2) and Interleukin 4 (IL-4).
- Starting on day -3, Cyclosporine (CSP) is given at a dose of 4.0 mg/kg p.o. b.i.d."
1946758|NCT00245037|Drug|fludarabine phosphate|"Fludarabine's active metabolite 2-fluoro-ara-A is an antimetabolite that inhibits DNA primase, DNA polymerase alpha and ribonucleotide nuclease.
Dosing: Days -4, -3 and -2: Fludarabine 30 mg/m2/day IV. Total dose equals 90 mg/m2.
Monitoring: Fludarabine level is not monitored.
Dose Adjustments: There are no provisions for fludarabine dose adjustments."
1946759|NCT00245037|Drug|mycophenolate mofetil|"Mycophenolate mofetil (MMF) is the morpholinyl ethyl ester of mycophenolic acid (MPA) and reversibly inhibits inosine monophosphate dehydrogenase, particularly the type II isoform that is more prominent in activated lymphocytes. As a result of the inhibition of de novo purine synthesis, proliferation of B- and T-lymphocytes is blocked and antibody production is inhibited.
Related Donors: MMF will be given daily at 15mg/kg q 12 hrs until day +28, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg).
Unrelated Donors: MMF will be given daily at 15mg/kg q 8 hrs until day +28, then given daily at 15mg/kg q 12 hours until day +56, then stop without tapering. Doses will be rounded to the nearest 250 mg (capsules are 250 mg)."
1946760|NCT00245037|Procedure|peripheral blood stem cell transplantation|"Bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT) are procedures that restore stem cells that have been destroyed by high doses of chemotherapy and/or radiation therapy. There are three types of transplants:
In autologous transplants, patients receive their own stem cells.
In syngeneic transplants, patients receive stem cells from their identical twin.
In allogeneic transplants, patients receive stem cells from their brother, sister, or parent. A person who is not related to the patient (an unrelated donor) also may be used."
1946804|NCT00226941|Drug|Cetuximab|Cetuximab may be administered via a gravity drip, infusion pump or syringe pump with in-line filtration. Cetuximab requires in-line filtration during administration. Calculate and draw the appropriate volume of cetuximab into a sterile syringe based on either the 400 mg/m2 initial dose or 250 mg/m2 weekly dose
1946805|NCT00225563|Device|Electronic Medical Record|
1946806|NCT00225836|Device|OVA (TENS apparatus)|
1946807|NCT00224887|Behavioral|In home nutrition counseling|
1946808|NCT00224562|Drug|TNF-alpha antagonists|
1946978|NCT00160680|Drug|Levocetirizine|
1946761|NCT00245037|Radiation|Total Body Irradiation (TBI)|"TBI is a form of radiotherapy used primarily as part of the preparative regimen for haematopoietic stem cell (or bone marrow) transplantation. As the name implies, TBI involves irradiation of the entire body, though in modern practice the lungs are often partially shielded to lower the risk of radiation-induced lung injury.
Toxicities: At the dosage used, side effects are not expected. Nevertheless, there may be fever, alopecia, parotitis, diarrhea, reversible skin pigmentation, mucositis and late effects including cataract formation, pulmonary damage, carcinogenesis, and sterilization.
Dosing: TBI will be given in one 200 cGy fraction from linear accelerator at a rate of 15-19 cGy/min."
1946762|NCT00245037|Drug|Granulocyte colony-stimulating factor (G-CSF)|"Granulocyte colony-stimulating factor (G-CSF or GCSF) is a colony-stimulating factor hormone. G-CSF is also known as colony-stimulating factor 3 (CSF 3).
It is a glycoprotein, growth factor and cytokine produced by a number of different tissues to stimulate the bone marrow to produce granulocytes and stem cells. G-CSF then stimulates the bone marrow to release them into the blood.
Toxicities: At the dosage used, the most common side effect will be medullary bone pain.
Dosing: 5 mcg/kg/day given per institutional standards (on approximately days 10-15 or not at all)."
1946763|NCT00245037|Drug|Phenytoin|This drug is used to prevent seizures while on chemotherapy.
1946764|NCT00245037|Drug|Methotrexate|Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments.
1946766|NCT00243516|Device|PREtest Consult|
1946767|NCT00242866|Drug|GW274150|The tablets used in this study will contain either 5mg or 30mg of GW274150
1946768|NCT00242866|Other|Placebo|Placebo to Match GW274150
1946769|NCT00243308|Drug|Serine proteinase-1 (Serp-1)|
1946771|NCT00241969|Behavioral|Behavioral plus Nutrition Treatment|This intervention will combine individualized nutrition counseling that targets increasing energy and fat intake and parent training of effective behavioral child management skills.
1946772|NCT00241969|Behavioral|Attention Control Treatment|This intervention will provide information about a number of aspects of their child's CF care and also provides anticipatory guidance for preschoolers.
1946773|NCT00241995|Drug|Anticonvulsants|
1946774|NCT00241839|Drug|Allopurinol|Allopurinol (300 mg capsule) was given for 8-10 weeks compared to placebo group after initial baseline testing. After two weeks on the Allopurinol, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the Allopurinol dosage was increased to 600mg (two 300 mg capsules)for the duration of the trial, 6-8 weeks.
1946775|NCT00241839|Drug|Placebo|Placebo capsule (matched in appearance for Allopurinol and labeled 300mg) was given for 8-10 weeks compared to the Allopurinol group after initial baseline testing. After two weeks on the placebo, a serum uric acid level was obtained. If the uric acid level was greater than 5.5, the placebo dosage was increased to 600mg (two 300 mg capsules)for the duration of the study, 6-8 weeks.
1946776|NCT00241839|Drug|Chlorthalidone|Chlorthalidone 25 mg was given daily for 5 weeks before baseline visit for testing and continued through out the study.
1946777|NCT00241839|Drug|Potassium chloride|Potassium Chloride 40-50meq was given daily for 5 weeks before baseline visit for testing and continued through out the study.
1946778|NCT00240630|Drug|sumatriptan succinate/naproxen sodium|Combination Tablet of Treximet
1946779|NCT00240630|Drug|placebo|placebo to match
1946780|NCT00240643|Drug|SB424323|
1946781|NCT00240617|Drug|sumatriptan succinate/naproxen sodium|comparator
1946782|NCT00240617|Drug|placebo|placebo to match
1946783|NCT00239694|Biological|Pneumococcal Vaccine|One time preventative vaccine
1946784|NCT00239694|Biological|Meningococcal Vaccine|One time preventative vaccine
1946785|NCT00239577|Biological|Live attenuated tetravalent dengue vaccine|
1946786|NCT00238433|Biological|filgrastim|5mcg/kg IVPB will be administered beginning on day +5 and continued until ANC> 1500 for 2 consecutive days.
1946787|NCT00238433|Drug|busulfan|3.2mg/kg/day for 3 days starting on day -8. Each dose of intravenous busulfan will be mixed in a concentration of 0.54 mg/ml of 0.9% saline and infused over 3 hours.
1946788|NCT00238433|Drug|melphalan|50mg/m2/day/iv, infused over 30 minutes on days -5 and -4. The reconstituted melphalan is diluted in 250cc normal saline to a concentration not greater than 0.4 mg/ml.
1946789|NCT00238433|Drug|thiotepa|250 mg/m2/day/iv on days -3 and -2
1946790|NCT00238433|Procedure|bone marrow ablation with stem cell support|The transplant therapy should begin within 2 weeks of registration, but no sooner then 30 days after the last dose of chemotherapy.
1946791|NCT00238433|Procedure|peripheral blood stem cell transplantation|Performed 36-48 hours following last chemotherapy dose.
1946792|NCT00234533|Drug|Somatropin (rDNA origin)|Daily subcutaneous injections, 0,025 - 0,05 mg/kg/day for 6 months.
1946793|NCT00231894|Drug|Pioglitazone|pioglitazone 15-45 mg/day
1946794|NCT00231894|Behavioral|Life style diet group|life style diet education group 1x/week
1946795|NCT00231894|Other|placebo|placebo comparator
1946796|NCT00229671|Device|Computerized Physician Order Entry|
1946797|NCT00229333|Drug|Escitalopram|
1946798|NCT00227877|Behavioral|Computer screen & brief physician advice|"Participants who are in the experimental arm will complete the CRAFFT screen on the computer and receive information on the computer regarding the health effects of substance use. Their provider will be given the results of their CRAFFT screen and a list of suggested talking point which they will use to guide a discussion with the patient about drug and alcohol use. Participants and their families will also receive educational brochures about substance use."
1946799|NCT00226499|Biological|Priorix-tetra™|2 IM doses
1946800|NCT00226499|Biological|Priorix™|2 IM doses in Group C, 1 IM dose in Group B
1946801|NCT00226499|Biological|Varilrix™|1 IM dose in Group B
1946802|NCT00226941|Drug|Oxaliplatin|Oxaliplatin is supplied as freeze-dried powder for IV infusion in vials containing 50 mg and 100 mg of the drug.
1946803|NCT00226941|Drug|Capecitabine|The calculated dose by cohort designation and body surface area (BSA) will be rounded down to allow equivalent morning and evening doses using a combination of 150 mg and 500 mg tablets.
1946814|NCT00223743|Drug|Zonisamide|study drug initially will taken as one 50-mg tablet a day, then the dose increased by one tablet each two weeks, to no more than 3 tablets (150 mg) taken twice a day.
1946839|NCT00223080|Biological|ALVAC-HIV vCP1521 + AIDSVAX|"1cc injected into left deltoid muscle at day 0,weeks 4, 12, 24
Prime/Boost Vaccination"
1946840|NCT00223080|Biological|ALVAC Placebo + AIDSVAX Placebo|"1cc ALVAC Placebo in left deltoid at day 0 and week 4
1 cc ALVAC Placebo + AIDSVAX Placebo in left deltoid on weeks 12 and 24"
1946841|NCT00222131|Drug|Esomeprazole|Esomeprazole 40 mg QD
1946842|NCT00222131|Other|Placebo|Placebo
1946844|NCT00221104|Drug|Pravastatin|
1946845|NCT00219661|Procedure|drainage of subglottic secretions (HiLo Evac tube)|
1946846|NCT00219349|Behavioral|Cognitive Behavioral Therapy|14 weekly sessions of individualized CBT
1946847|NCT00219349|Drug|escitalopram|10-20 mg per day for 12 weeks
1946848|NCT00215644|Drug|ECX|ECX given until progression of disease or unacceptable toxicity, for a maximum of 8 cycles- E= 50 mg per metre squared of Epirubicin given i.v. once every 3 weeks, C= 60 mg per metre squared of cisplatin given i.v. once every 3 weeks, X= 1250mg per metre squared divided into two oral doses of capecitabine given every day.
1946849|NCT00215644|Drug|Matuzumab + ECX|800mg matuzumab given i.v. (into the vein) once per week until progression or unacceptable toxicity, along with intervention in Arm 1 (ECX)
1946850|NCT00217217|Device|Echo-Planar Magnetic Resonance Imaging (EP-MRSI)|variable-setting low-frequency MRI
1946851|NCT00216788|Drug|Esomeprazole (Nexium) 40 mg/day|
1946852|NCT00216294|Drug|RG1068 (Synthetic Human Secretin)|
1946853|NCT00211341|Dietary Supplement|Vitamin A|Weekly single oral dose 7000 micrograms
1946854|NCT00214136|Radiation|radiotherapy|prostate radiation to 70Gy; nodal radiation to 56Gy
1946855|NCT00214045|Device|Flexible versus Rigid Cystoscopes|
1946856|NCT00213980|Drug|Zoledronate|4 mg IV over 15 minutes administered once every 12 weeks times 4
1946857|NCT00213148|Drug|Anastrozole 1mg|Anastrozole 1mg, once per day for 5 days.
1946858|NCT00213148|Drug|Anastrozole 5mg dose|Anastrozole 5mg, once per day for 5 days.
1946859|NCT00213148|Drug|Anastrozole 10mg dose|Anastrozole 10mg, once per day for 5 days.
1946860|NCT00213148|Drug|Clomiphene Citrate 50mg|Clomiphene Citrate 50mg, once per day for 5 days.
1946861|NCT00212888|Biological|Remune and ALVAC|"Group 1) Remune™ (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20);
Group 2) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC (1 ml i.m.) at weeks 8, 12, 16 and 20; or
Group 3) Remune™ placebo (1ml i.m.) at weeks 0, 12 and 20 and ALVAC placebo (1 ml i.m.) at weeks 8, 12, 16 and 20."
1946862|NCT00211237|Device|Balloon Kyphoplasty|Ballon Kyphoplasty is a minimally invasive technique aimed at reduction of VCFs using KyphX® Inflatable Bone Tamps followed by fracture fixation with KyphX® HV-R™ Bone Cement.
1946863|NCT00211237|Other|Non Surgical Management|Non-surgical treatment includes, but is not limited to, the following: back brace, pain medication, physical therapy, walking aids, bed rest, and radiation treatment.
1946864|NCT00211185|Drug|ONTAK (denileukin diftitox, DAB389 IL-2)|Ontak + CHOP every 3 weeks.
1946865|NCT00207636|Behavioral|Computer-based prostate cancer screening decision aid|
1946866|NCT00206336|Drug|Topiramate (drug)|
1946867|NCT00206323|Drug|Topiramate (drug)|
1946868|NCT00196989|Drug|Pioglitazone|
1946869|NCT00196989|Drug|GW677954|
1946870|NCT00205699|Drug|risperidone|randomized to begin 12 week trial of ziprasidone
1946871|NCT00205699|Drug|olanzapine|randomized to begin 12 week trial of olanzapine
1946872|NCT00205699|Drug|aripiprazole|randomized to 12 week trial of aripiprazole
1946873|NCT00205556|Procedure|on-line hemodiafiltration|addition of convective transport to regular dialysis treatment by using on-line hemodiafiltration
1946874|NCT00205556|Procedure|low flux hemodialysis|standard treatment
1946875|NCT00205504|Drug|Ortho Tri Cyclen|Ortho Tri Cyclen, one tablet daily, for 6 cycles
1946876|NCT00205179|Drug|Novasoy|100mg/day soy isoflavones
1946877|NCT00205179|Drug|Placebo|100mg/day matching placebo
1946879|NCT00203372|Drug|Bevacizumab 7.5 and TAC|Bevacizumab given intravenously at a dose of 7.5mg/kg every 3 weeks, followed by docetaxel, doxorubicin and cyclophosphamide (TAC).
1946880|NCT00203372|Drug|Placebo 7.5 and Docetaxel, Doxorubicin, and Cyclophosphamide (TAC)|placebo 7.5 will be adminitered intravenously every 3 weeks followed by TAC
1946881|NCT00203372|Drug|Bevacizumab 15 and TAC|one dose of Bevacizumab (15 mg/kg) will be administered intravenously every 3 weeks followed by TAC.
1946882|NCT00203372|Drug|Placebo 15 and TAC|one dose of placebo 15 will be administered intravenously every 3 weeks followed by TAC.
1946883|NCT00202748|Behavioral|Increase in activity to control weight|
1946884|NCT00202748|Behavioral|Increase in activity to control weight.|
1946885|NCT00202644|Drug|Anagrelide|Anagrelide hydrochloride 0.5mg capsules;initial dose administered will be 1.0mg/day administered as 0.5mg bid. The dose will be titrated such that the total daily dose is incremented by no more than 0.5mg per week as required depending on platelet reduction versus adverse event profile.
1946886|NCT00202644|Drug|Hydroxyurea|Hydroxyurea is 500mg hydroxycarbamide capsules; initial dose is 1000mg/day, administered in two divided doses (500mg/dose). Dose titrated to effect to achieve a response.
1946887|NCT00202618|Drug|Valsartan|
1946888|NCT00202618|Drug|Amlodipine|
1946889|NCT00202410|Biological|Bacille of Calmette-Guerin|A single intracutaneous dose of 0.1 mL freeze-dried BCG (1 mg/mL; Berna Institute, Basel).
1946890|NCT00202410|Other|placebo|subcutaneous administration of physiologic solution
1946891|NCT00195871|Drug|Prednisone, vincristine, daunorubicin , cyclophosphamide , L.-asparaginase, cytosine-arabinoside, methotrexate, etoposide|coventional dosages
1946892|NCT00195871|Procedure|hematopoietic stem cell allograft|conventional procedures
1946893|NCT00201760|Drug|Gemcitabine|1000 mg/m2 IV over 30 minutes on Days 1 and 8.
1946894|NCT00201760|Drug|Trastuzumab|2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.
1946895|NCT00201760|Drug|Cisplatin|30 mg/m2 IV on Day 1 and Day 8.
1946896|NCT00198107|Drug|Aripiprazole|Participants will receive 8 weeks of initial treatment with aripiprazole. If responsive to treatment, participants may be assigned to an additional 16 weeks of aripiprazole and then an additional 8 more weeks of aripiprazole with D-cycloserine. Dosing schedule for participants less than 50 mg maximum dose will be 10 mg per day. Dosing schedule for participants greater than 50 kg maximum dose will be 15 mg.
1946897|NCT00198107|Drug|Placebo|Participants assigned to placebo will take a placebo pill for the initial 8 weeks of treatment.
1946898|NCT00198107|Drug|D-cycloserine|D-cycloserine will be dosed in the range of 25 to 200 mg daily for the final 8 weeks of treatment.
1946899|NCT00197821|Biological|pneumococcal conjugate vaccine|Pneumococcal conjugate vaccine
1946900|NCT00197145|Drug|GW873140|400 mg twice daily
1946901|NCT00197054|Biological|RTS,S/AS02A and RTS,S/AS01B|
1946902|NCT00189904|Biological|IMVAMUNE (MVA-BN)|
1946917|NCT00193856|Drug|Leuprorelin Acetate|LH-RH analogue (LH-RHa) (Leuprorelin acetate 22.5 mg) will be delivered as a depot injection every 3 months. This will be administered as an intramuscular injection (IMI).
1946918|NCT00193856|Drug|Zoledronic Acid|Zoledronic acid 4 mg will be delivered as an intravenous infusion over 15 minutes once every 3 months for 18 months, in patients randomised to bisphosphonate therapy.
1946919|NCT00193856|Radiation|Conventional external beam therapy|The prescribed dose will be 66 Gy in 33 fractions of 2 Gy to the ICRU 50 point utilising a minimum of three fields with >= 6 MV photons.
1946920|NCT00192582|Behavioral|Motivational Interview with care plan and education|
1946922|NCT00189943|Biological|MVA-BN|
1946924|NCT00189228|Drug|Xolair|Patients are administered Xolair
1946925|NCT00187889|Drug|Eplerenone|Eplerenone 25 mg (1 pill) daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
1946926|NCT00187889|Drug|Placebo or sugar pill|Placebo blinded as 25 mg tablet(1 pill) once daily for 1 week then uptitrated to 50 mg (2 pills) daily for 15 weeks.
1946929|NCT00186706|Drug|Selenium|
1946933|NCT00186498|Drug|memantine|
1946936|NCT00181285|Device|High Frequency Chest Wall Oscillator|High velocity, low amplitude oscillatory airflow applied through a pneumatic vest worn over the thorax
1946937|NCT00183690|Procedure|Prolonged Exposure Therapy|Prolonged exposure therapy includes a trauma focused protocol and cognitive behavioral treatment for PTSD. Cognitive behavioral treatment includes psychoeducation, in vivo exposures, and imaginal exposures.
1946938|NCT00183690|Procedure|Active Psychotherapy|Active psychotherapy includes non-trauma focused therapy, based on time-limited psychodynamic treatment, which includes a formulation of a central issue and open-associative sessions exploring main conflicts and drives.
1946939|NCT00183443|Drug|Divalproex-extended release (DVP-ER)|Divalproex ER will be given in 250 mg or 500 mg tablets. Dosing is once a day, every day, for the duration of study participation, either 12 or 26 weeks.
1946940|NCT00183443|Drug|Lithium|Extended release lithium will be provided in 300 mg capsules. Participants will be dosed to a therapeutic blood level of lithium from 0.8 to 1.2 mcg/L.
1946941|NCT00183443|Drug|Quetiapine|Quetiapine will be dosed to efficacy, provided in 50 mg, 100 mg, 200 mg, or 300 mg pills.
1946942|NCT00183391|Drug|Atomoxetine|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
1946943|NCT00183391|Drug|Methylphenidate|Participants will be randomly assigned to receive either methylphenidate or atomoxetine for either 2 or 5 weeks, depending on how soon they respond to the treatment. After the 2- or 5-week period, participants will be crossed-over to receive whichever medication they did not receive in the first part of the study.
1946944|NCT00182143|Drug|LMWH (Fragmin, dalteparin)|Placebo AM dose (normal saline) and LMWH (Fragmin, dalteparin) 5000IU PM dose
1946945|NCT00182143|Drug|Unfractionated Heparin|5000 IU BID
1946946|NCT00181363|Device|Mamma board|
1946947|NCT00179998|Drug|Recombinant Human DNase (Pulmozyme)|Comparison of 2.5 mg in 3 ml diluent delivered by nebulization given daily for 6 months with 3 ml diluent placebo delivered by nebulization given daily for 6 months
1946948|NCT00181207|Device|pneumatic vest|
1946949|NCT00181168|Drug|Recombinant thyrotropin|
1946952|NCT00179010|Drug|Adenosine|Adenosine intrarterial (intrabrachial) infusion at 3 diferent doses for 15 minutes each
1946953|NCT00179010|Drug|Adenosine Mono Phosphate (AMP)|Intraterial infusion of AMP at 3 different doses for 15 minutes each (at equimolar doses as adenosine)
1946954|NCT00178646|Drug|Botox|Botox 75-150 units, single treatment only
1946955|NCT00178620|Drug|Retavase 10 U IV Bolus|Retavase IV Bolus, 10 U, one dose at time of myocardial infarction
1946956|NCT00178620|Procedure|Angioplasty/Heart Catheterization|"Candidates will receive all the approved standard therapy for heart attacks patients and will go directly for emergent heart catheterization.
Following local anesthesia, a small flexible tube (catheter) will be inserted in an artery of your leg and advanced to the arteries of your heart. By injecting x-ray contrast through the catheter, any blockage in the artery can be seen. If your heart attack artery is still blocked by blood clot or cholesterol deposits, it will be opened up by angioplasty (balloon surgery procedure to open the blocked artery) and stenting (placement of a slotted metal tube in the artery to prevent it from closing on itself)."
1946957|NCT00178620|Device|Drug eluting stent placed in heart attack related artery|Stents will be placed (if needed) during the end of the angioplasty/heart catheterization.
1946960|NCT00174980|Drug|perfluorocarbon emulsion (Oxycyte) infusion|one time dose of 3mL/kg over 15 minutes
1946961|NCT00170573|Drug|Caelyx|Caelyx 40 mg/ m2biweekly
1946965|NCT00176891|Procedure|Stem Cell Transplant|enzyme replacement 10-12 weeks prior to hematopoietic stem cell transplant (HSCT), and 8 weeks following
1946966|NCT00176891|Drug|Laronidase ERT|Laronidase ERT will be administered 10-12 weeks prior to HSCT, and 8 weeks following.
1946967|NCT00167934|Drug|Valproate|Depakote ER 500 mg to 3000 mg taken every night
1946968|NCT00167934|Drug|Placebo|Placebo given at same frequency as Valproate
1946969|NCT00167635|Behavioral|cognitive-behavioral|Cognitive-behavioral over 9 weeks
1946970|NCT00167414|Procedure|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy
1946971|NCT00167414|Radiation|Hypofractionated Stereotactic Body Radiation Therapy|Hypofractionated Stereotactic Body Radiation Therapy for treatment of limited metastases from breast cancer primary.
1946972|NCT00166660|Behavioral|NIDCAP (Newborn Individualized Developmental Care)|The NIDCAP model aims to create a relationship-based developmentally supportive care environment for the preterm infant and family. The theory proposes that care implementation that takes into account the infants' thresholds of disorganization is most supportive of long term outcome. Specifically, the intervention consisted of weekly neurobehavioral observations and reports of the experimental group infants' behavior with suggestions for parents and staff in ways to support each infant's development. The developmental specialists formally observed each infant's behavior weekly throughout the hospitalization, starting with the phase of the infant's initial stabilization, and then every seven days throughout hospital discharge and to 2wCA.
1946973|NCT00163293|Drug|Ciclesonide|Ciclesonide metered-dose inhaler
1946974|NCT00163293|Drug|Placebo|Ciclesonide placebo-matching metered-dose inhaler
1946975|NCT00162123|Drug|Ipilimumab|Intravenous solution, 0.3, 3, or 10 mg/kg; 1 dose every 3 weeks or every 3 months until patient discontinuation
1946976|NCT00153413|Behavioral|Women's health|
1946977|NCT00161005|Procedure|PCI|Immediate transport to invasive center after thrombolysis
1946979|NCT00158860|Drug|valaciclovir (VALTREX®)|
1946985|NCT00157651|Drug|warfarin|Daily oral warfarin with INR monitored weekly, adjusted to keep INR between 1.5 and 1.9
1946986|NCT00157651|Drug|placebo|matching placebo for warfarin, adjusted according to sham INR generated by unblinded warfarin monitor
1946987|NCT00157014|Drug|Tacrolimus|Oral
1946988|NCT00157014|Drug|Cyclosporine|Oral
1946989|NCT00157014|Drug|Mycophenolate mofetil|Intravenous and Oral
1946990|NCT00157014|Drug|Methylprednisolone|Intravenous
1946991|NCT00157014|Drug|Prednisone|Oral
1946992|NCT00153400|Behavioral|Women's health|
1946993|NCT00154076|Drug|Zonisamide|Initial dose is 100mg/day, increase after 2 weeks to 200mg/day. The maximum dose is 600mg/day.
1946994|NCT00154076|Drug|Topiramate|Initial dose is 25mg/day, increase every 1 week to 100mg/day. The maximum dose is 400mg/day.
1946995|NCT00153842|Drug|Bexarotene (targretin)|"Bexarotene oral capsules will be administered daily beginning on the initial day of chemotherapy (day 1).
Level 1: 300mg Level 2: 400mg"
1946996|NCT00153816|Drug|Calcium Carbonate|3 gm/daily; 1200 mg elemental calcium/daily; two tablets per day; 600 mg elemental calcium/tablet
1946997|NCT00153816|Drug|Vitamin D3|1000 IU/daily; two tablets per day; 500 IU per tablet
1946998|NCT00153816|Drug|placebo|placebo; two tablets per day
1946999|NCT00155441|Behavioral|cognitive-behavioral therapy|
1947000|NCT00152204|Drug|Sulfadoxine-pyrimethamine used for IPTi|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
1947001|NCT00152204|Drug|IPTi|Doses of IPTi with SP delivered alongside doses 2 & 3 of DTP/HB vaccination and alongside measles vaccination
1947002|NCT00152464|Drug|LEVOCETIRIZINE|
1947003|NCT00149396|Drug|NV1020|NV1020 dose levels: 3x10E6, 1x10E7, and 3x10E7 plaque forming units, administered via hepatic artery infusion, over 10 minutes and repeated every 1-2 weeks for 4-8 weeks
1947004|NCT00150527|Drug|Citalopram|40 mg, pill, single dose
1947005|NCT00150527|Drug|Escitalopram|20 mg, pill, single dose
1947006|NCT00150527|Drug|Dexamethasone|1 mg, pill, single dose
1947007|NCT00150527|Behavioral|Cold Pressor Test|single test
1947008|NCT00149838|Procedure|Prefrontal Repetitive Transcranial Magnetic Stimulation (rTMS)|Participants receive 120% motor threshold (MT) over left and right prefrontal cortex. Treatments will be administered daily for 3 weeks. Participants who show signs of improvement may continue Phase I for up to 3 additional weeks.
1947009|NCT00149838|Drug|Antidepressant Regimen|Particpants who acheive remission with rTMS may start antidepressant medication in phase III.
1947010|NCT00149838|Procedure|Sham Stimulation|The sham stimulation will mimic the sensation of rTMS but will not induce an intracerebral current. Treatments will be administered daily for 3 weeks.
1947011|NCT00149838|Procedure|Lower Dose rTMS|Participants who are unresponsive to Phase I treatment with rTMS will continue a lower dose of rTMS for an additional 3 to 7 weeks in Phase II.
1947012|NCT00149500|Behavioral|Coaching|
1947013|NCT00148941|Biological|Diphtheria, tetanus, pertussis, poliovirus type 1, 2 & 3|
1947014|NCT00146640|Drug|Prednisone|
1947015|NCT00145977|Drug|Alendronate|Subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal. This group will also receive alendronate 70 mg once weekly, according to standard recommendations.
1947016|NCT00145977|Drug|Control|All subjects will receive 600 mg of elemental calcium (as calcium citrate) and 500 mg of Vitamin D with their evening meal.
1947017|NCT00144846|Drug|albuterol sulfate inhalation aerosol|
1947018|NCT00146172|Drug|neratinib|HKI-272
1947021|NCT00143585|Procedure|intramyocardial delivery of either VEGF165 or placebo|
1947081|NCT00117598|Drug|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 25 mg IV once a week
1947023|NCT00140205|Drug|r-metHuLeptin|
1947024|NCT00141011|Drug|Ancrod (Viprinex)|0.167 IU/kg/hr (0.6 mL/kg/hr) IV for 2-3 hours
1947025|NCT00141011|Drug|Placebo|0.6 mL/kg/hr
1947026|NCT00137566|Drug|acetaminophen (paracetamol)|Paracetamol tablets, 50 mg/kg/day for 3 days.
1947027|NCT00137566|Other|Placebo|
1947028|NCT00138424|Drug|Cidofovir|Cidofovir is a marketed product for treatment of Cytomegalovirus disease (retinitis) in human immunodeficiency virus (HIV) infected patients. It is packaged as a sterile, hypertonic aqueous solution for intravenous infusion only. Dosages: 0.25 mg/kg, 0.5 mg/kg, and 1.0 mg/kg.
1947029|NCT00138424|Drug|Placebo|The control for this study is sterile, 0.9% normal saline for intravenous use.
1947030|NCT00136903|Drug|Prochymal - 2 million cells|2 million cells/kg actual body weight, intravenously on study Days 1 and 4
1947031|NCT00136903|Drug|Prochymal - 8 million cells|8 million cells/kg actual body weight intravenously on study Days 1 and 4
1947032|NCT00136604|Biological|Diphtheria-tetanus-pertussis-hep B/Hib-meningococcal A&C|
1947033|NCT00135512|Drug|bupropion hydrochloride|Study drug
1947034|NCT00135707|Dietary Supplement|Vitamins|"Vit C (500 mg) and Vit E (200 IU) per capsule, two capsules daily between 9 - 16 weeks gestation.
Placebo - two capsules daily between 9 - 16 weeks gestation."
1947035|NCT00135668|Drug|nitroprusside|nitroprusside IV infusion 0.3-3 mcg/kg/ min
1947036|NCT00134693|Drug|Prednisolone|
1947037|NCT00134693|Drug|SB-681323|
1947038|NCT00134550|Drug|Atorvastatin (10 mg or 80 mg)|
1947039|NCT00133926|Procedure|Treatment of periodontal disease|
1947040|NCT00129285|Drug|Modafinil Low Dose|modafinil 200 mg/day
1947041|NCT00129285|Drug|Modafinil High Dose|modafinil 400 mg/day
1947042|NCT00129285|Drug|Placebo|placebo 400 mg/day
1947043|NCT00128050|Drug|rFactor VIIa (Eptacog alfa, NovoNordisk)|rFVIIa will be admistered as single bolus at the dosage of 100 mcg/Kg b.w.
1947044|NCT00128050|Drug|rFVIIa|Patients with spontaneous supratentorial ICH will be treated with rFVII after hematoma evacuation
1947045|NCT00128050|Other|Sodiun chloride 0.9%|Bolus injection of sodium chloride 0.9% after surgical hematoma removal
1947046|NCT00127608|Biological|Chickenpox infection|
1947047|NCT00127673|Drug|Sertraline|The dose of sertraline will be up to 200 mg daily for 10 weeks. There will also be weekly meetings with study psychiatrist.
1947048|NCT00127673|Behavioral|Cognitive behavioral therapy (CBT)|CBT will include 10 weekly sessions of individual cognitive behavioral therapy.
1947049|NCT00127439|Procedure|Manually Assisted Locomotor Training|Individuals will receive 45 sessions of robotic or manually assisted locomotor training. The goal for each training session is to walk for no more than 30 minutes.
1947053|NCT00123903|Drug|metoprolol xl|
1947054|NCT00123903|Drug|carvedilol MR|
1947055|NCT00123903|Drug|lisinopril|
1947056|NCT00123110|Drug|metformin|Initiated on 500 mg daily and titrated up to 1000 mg twice a day during the first four weeks, remaining at that dose until 12 weeks
1947057|NCT00123110|Drug|leuprolide acetate|3.75 mg injection every 4 weeks (e.g. at baseline, 4, and 8 weeks)
1947058|NCT00123110|Drug|placebo pill|matching pill twice a day for 12 weeks
1947059|NCT00123110|Drug|placebo injection|matching injection every 4 weeks (e.g. baseline, 4, and 8 weeks)
1947060|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 2.5 mg, Once daily (24 weeks short term [ST], 42 months long term [LT])
1947061|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 5 mg, Once daily (24 weeks ST, 42 months LT)
1947062|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT)
1947063|NCT00121641|Drug|Placebo matching Saxagliptin|Tablets, Oral, 0mg, Once daily (24 weeks ST, 42 months LT)
1947064|NCT00121641|Drug|Metformin|Tablets, Oral, 500 mg, daily (42 months LT)
1947065|NCT00121641|Drug|Placebo matching Metformin|Tablets, Oral, 0 mg, daily (42 months LT)
1947066|NCT00121641|Drug|Saxagliptin|Tablets, Oral, 10 mg, Once daily (24 weeks ST, 42 months LT) Open Label
1947067|NCT00121641|Drug|Metformin|Tablets, Oral, 500-2000 mg (as needed for rescue)
1947068|NCT00121680|Drug|E7080|Oral.
1947069|NCT00121173|Biological|pNGVL4a-Sig/E7(detox)/HSP70 DNA vaccine|
1947070|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 2.5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
1947071|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 5 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
1947072|NCT00121667|Drug|Saxagliptin + Metformin|Tablets, Oral, 10 mg Saxagliptin (plus flexible metformin dose), Once daily (24 weeks ST, 42 months LT)
1947073|NCT00121667|Drug|Placebo + Metformin|Tablets, Oral, 0 mg, Once daily (24 weeks ST, 42 months LT)
1947074|NCT00121667|Drug|Pioglitazone|Tablets, Oral, 15 - 45 mg (as needed for rescue)
1947075|NCT00120900|Drug|GW406381|
1947076|NCT00119067|Biological|BioThrax or Anthrax Vaccine Adsorbed|
1947077|NCT00119106|Device|Tenofovir|
1947078|NCT00118716|Drug|Fluticasone propionate/salmeterol|
1947079|NCT00117663|Drug|Cessation of Hormone Replacement Therapy|
1947080|NCT00117598|Drug|Temsirolimus (CCI-779)|Temsirolimus 175 mg IV once a week for 3 weeks; followed by 75 mg IV once a week
1947200|NCT00074438|Drug|corticosteroids|Intravenous repeating dose
1947082|NCT00117598|Drug|Investigator's choice|"Any of the following single agent treatments:
Fludarabine 25 mg/m2 IV over 30 minutes daily for 5 consecutive days, every 28 days or oral administration, as appropriate.
Chlorambucil 0.1 (0.1-0.2) mg/kg PO daily for 3 to 6 weeks as required OR 0.4 (0.3 0.8) mg/kg PO every 21 to 28 days
Gemcitabine 1 gm/m2 IV over 30 minutes on days 1, 8 and 15 every 28 days or day 1 and day 8 every 21 days
Cyclophosphamide 300 (200-450) mg/m2 PO daily for 5 consecutive days every 21 to 28 days, OR 600 (400-1200) mg/m2 IV every 21 to 28 days
Cladribine 5 mg/m2 IV daily for 5 consecutive days, every 28 days for 2-6 cycles depending on response,
Etoposide 50 (50-150) mg/m2 IV daily for 3-5 days every 21 to 28 days OR 100 (50 300) mg/m2 PO daily for 3-5 days every 21 to 28 days
Prednisone 40 (20-60) mg/m2 PO daily or every other day
Dexamethasone 20(20-40) mg PO/IV daily for 5 consecutive days, every 14 - 28 day"
1947083|NCT00117325|Drug|GW685698X|Aqueous Nasal Spray 100mcg
1947084|NCT00116844|Drug|Valaciclovir|Valtrex 1g QD
1947085|NCT00116584|Drug|heliox|continuous heliox therapy
1947086|NCT00116558|Device|BiPAP|non-invasive positive pressure ventilation (NIPPV) - Early Intervention with NIPPV NIPPV involves mechanically assisted or generated breaths delivered through a tightly fitting nasal or facial mask
1947087|NCT00115778|Drug|Intravenous immunoglobulin|Intravenous immunoglogbulin 400mg/kg IV monthly
1947094|NCT00114777|Drug|Cyclosporin A|tablet, oral, 1st month target: 150-300 ng/mL, after 1st month target: 100-250 ng/mL, daily, 36 months, 100-250 ng/mL, daily, 84 months
1947095|NCT00114777|Drug|Belatacept Less Intensive Regimen (LI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 8 and 12, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
1947096|NCT00114777|Drug|Belatacept More Intensive Regimen (MI)|solution, IV, 10mg/kg: Days 1 and 5, Weeks 2, 4, 6, 8, 10,12, 16, 20, and 24, then 5 mg/kg every 4 weeks, q 4 weeks, 36 months, 5 mg/kg every 4 weeks, q 4 weeks, 84 months
1947097|NCT00114478|Drug|Epinephrine|
1947098|NCT00114478|Drug|albuterol (salbutamol)|
1947099|NCT00114140|Drug|temozolomide|
1947100|NCT00114140|Procedure|adjuvant therapy|
1947101|NCT00114140|Radiation|radiation therapy|
1947102|NCT00113555|Device|ACT (Adjustable Continence Therapy)|surgically implanted device
1947103|NCT00113308|Drug|GW406381|
1947104|NCT00113165|Drug|LAMICTAL extended-release|
1947105|NCT00111839|Drug|Pemetrexed|pemetrexed 500mg per metre squared given i.v. (into the vein) every 3 weeks until progression of disease or unacceptable toxicity
1947106|NCT00111839|Drug|Matuzumab + Pemetrexed|matuzumab 800mg given i.v. every week plus pemetrexed as in Group 1 until progression of disease or unacceptable toxicity
1947107|NCT00111839|Drug|Matuzumab + Pemetrexed|matuzumab 1600mg given i.v. every 3 weeks plus pemetrexed as in Group 1 until progression of disease or unacceptable toxicity
1947108|NCT00111800|Drug|GW0823093|
1947111|NCT00111241|Drug|aromatase inhibitors (letrozole, anastrozole)|
1947114|NCT00107744|Behavioral|Dietary protein|
1947115|NCT00107718|Drug|SB-485232|
1947116|NCT00106691|Drug|Toremifene 20 mg|20 mg once a day
1947117|NCT00106691|Drug|Placebo|placebo tablet identically appearing to the toremifene 20 mg tablet, administered daily for 360 days.
1947118|NCT00105950|Drug|lapatinib|Tyrosine kinase inhibitor administered daily at 1500 mg/kg
1947119|NCT00105508|Drug|Sarizotan HC1|
1947120|NCT00105521|Drug|Sarizotan HC1|
1947121|NCT00104403|Drug|GW679769|
1947122|NCT00104403|Drug|Dexamethasone|
1947123|NCT00104403|Drug|Ondansetron Hydrochloride|
1947124|NCT00103922|Drug|cilomilast|
1947125|NCT00103285|Drug|doxorubicin hydrochloride|Given IV or IT
1947126|NCT00103285|Radiation|3-dimensional conformal radiation therapy|Some patients undergo cranial radiotherapy
1947127|NCT00103285|Drug|cytarabine|Given IV or SC
1947128|NCT00103285|Drug|dexamethasone|Given IV or PO
1947129|NCT00103285|Drug|pegaspargase|Given IM
1947130|NCT00103285|Drug|methotrexate|Given IM or IT
1947131|NCT00103285|Drug|leucovorin calcium|Given PO
1947132|NCT00103285|Drug|mercaptopurine|Given PO
1947133|NCT00103285|Drug|cyclophosphamide|Given IV
1947134|NCT00103285|Drug|thioguanine|Given PO
1947135|NCT00103285|Drug|vincristine sulfate|Given IV
1947136|NCT00102960|Drug|Abacavir sulfate|Second Line Regimen: 8 mg/kg taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
1947137|NCT00102960|Drug|Didanosine|Second Line Regimen: Either 100 mg/m^2 or 120 mg/m^2 taken orally twice daily. Dosage depends on age. Guidelines for switching from first line to second line therapy are available in the protocol.
1947138|NCT00102960|Drug|Efavirenz|Second Line Regimen: taken orally once daily. Dosage depends on weight. Guidelines for switching from first line to second line therapy are available in the protocol.
1947139|NCT00102960|Drug|Lamivudine|First Line Regimen: 4 mg/kg taken orally twice daily
1947201|NCT00074438|Drug|placebo|Intravenous repeating dose
1947140|NCT00102960|Drug|Lopinavir/Ritonavir|First Line Regimen: taken orally twice daily. Dosage depends on age and weight.
1947141|NCT00102960|Drug|Nevirapine|Second Line Regimen: 150 - 200 mg/m^2 taken orally twice daily. Guidelines for switching from first line to second line therapy are available in the protocol.
1947142|NCT00102960|Drug|Zidovudine|First Line Regimen: 240 mg/m^2 taken orally twice daily
1947143|NCT00102908|Drug|Zoledronate|Zoledronate infusion
1947144|NCT00102908|Drug|Zoledronate placebo|Zoledronate placebo infusion
1947145|NCT00102869|Drug|levodopa|100mg levodopa per day over 10 days/ treatment phase
1947146|NCT00102492|Drug|GW679769|
1947147|NCT00101946|Drug|683699|
1947148|NCT00100828|Drug|irinotecan hydrochloride|
1947149|NCT00100230|Drug|docosahexaenoic acid OR corn/soy oil placebo|daily intake of DHA based on body weight or corn/soy oil placebo(oil not containing DHA; 4 year trial
1947150|NCT00100165|Drug|3-2,4 dimethoxybenzylidene 75 or 150 mg bid|3-2,4 dimethoxybenzylidene 75 or 150 mg bid
1947151|NCT00100165|Drug|Placebo|Placebo
1947158|NCT00098020|Procedure|Kidney needle biopsy|
1947159|NCT00098020|Procedure|DEXA Scan|
1947160|NCT00098020|Procedure|X-rays|
1947161|NCT00098020|Drug|Retinoids for Podocyte Disease|
1947162|NCT00097669|Other|folic acid|2 mg
1947163|NCT00097669|Dietary Supplement|Vitamin B6|25mg
1947164|NCT00097669|Dietary Supplement|Vitamin B12|500ug
1947165|NCT00097409|Drug|Ispinesib|
1947166|NCT00097331|Drug|SB683699|
1947167|NCT00093964|Drug|EMD 121974|"500 mg EMD 121974 IV (in the vein) twice weekly on Days 1 and 4 during a 4-week cycle for a total of 8 infusions per cycle.
Cycles will be repeated without pause until disease progression or unacceptable toxicity develops"
1947168|NCT00093964|Drug|EMD 121974|"2000 mg EMD 121974 IV (in the vein) twice weekly on Days 1 and 4 during a 4-week cycle for a total of 8 infusions per cycle.
Cycles will be repeated without pause until disease progression or unacceptable toxicity develops."
1947182|NCT00089973|Drug|Ispinesib|
1947183|NCT00087165|Biological|GTI-2040|
1947184|NCT00087165|Drug|docetaxel|
1947185|NCT00087165|Drug|prednisone|
1947187|NCT00084149|Drug|Abacavir sulfate, Lamivudine, and Zidovudine|antiretroviral therapy
1947188|NCT00084149|Drug|Lopinavir/Ritonavir|antiretroviral therapy
1947189|NCT00082628|Drug|Serostim®[somatropin (rDNA origin) for injection]|
1947192|NCT00002454|Biological|autologous tumor cell vaccine|
1947193|NCT00078338|Drug|Human interferon beta-1a and glatiramer acetate|
1947194|NCT00077064|Drug|captopril|
1947195|NCT00076622|Drug|Antidepressant medication|Participants assigned to continue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
1947196|NCT00076622|Drug|No antidepressant medication|Participants assigned to discontinue current medication will be monitored over a period of one year for recurrence of depression and related symptoms.
1947197|NCT00075335|Drug|AMD3100|
1947198|NCT00074438|Drug|methotrexate|Oral or parenteral repeating dose
1947199|NCT00074438|Drug|rituximab|Intravenous repeating dose
1947203|NCT00074308|Drug|imatinib mesylate|Given orally
1947204|NCT00074308|Biological|bevacizumab|Given IV
1947205|NCT00074308|Other|pharmacological study|Correlative studies
1947206|NCT00074308|Other|laboratory biomarker analysis|Correlative studies
1947212|NCT00073749|Drug|Inotuzumab ozogamicin [CMC-544]|CMC-544, IV, dose escalation trial
1947213|NCT00073073|Drug|Exemestane|exemestane 25 mg by mouth (PO) every day for two years
1947214|NCT00073073|Dietary Supplement|Calcium carbonate|calcium carbonate 1200 mg PO every day x 2 years
1947215|NCT00073073|Dietary Supplement|Vitamin D|Vitamin D 400 international units PO every day x 2 years
1947216|NCT00072982|Drug|fish oil|The object of this intervention is to determine whether treatment of rheumatoid arthritis with a combination of fish oil and borage seed oil is superior to treatment with either oil alone. Each arm of the study will take 13 capsules daily (divided doses) for 18 months.
1947217|NCT00072982|Drug|borage seed oil|Borage oil 13 capsules divided doses daily for 18 months
1947218|NCT00072982|Drug|combination fish oil and borage seed oil|Fish oil and borage seed oil capsules - 13 capsules to be be taken daily (divided doses) for a period of 18 months
1947219|NCT00072384|Drug|liposomal vincristine sulfate|Given IV
1947220|NCT00072384|Procedure|cryosurgery|Application of extreme cold to destroy abnormal or diseased tissue.
1947221|NCT00072384|Procedure|laser surgery|Surgery using a laser (instead of a scalpel) to cut tissue
1947222|NCT00072384|Drug|carboplatin|Given IV
1947223|NCT00072384|Drug|etoposide|Given IV
1947224|NCT00072384|Biological|filgrastim|Given subcutaneously
1947232|NCT00068367|Drug|erlotinib hydrochloride|150 mg per day, daily until disease progression
1947233|NCT00067522|Behavioral|User-independent contraception program|
1947234|NCT00067522|Behavioral|Future Planning Perspectives program|
1947235|NCT00067002|Procedure|Expanded allogeneic cord blood (CB)|Transplantation of Two Unmanipulated Cord Blood Units.
1947236|NCT00067002|Procedure|One Unmanipulated and One Expanded Cord Blood Unit|Transplantation of One Unmanipulated and One Expanded Cord Blood Unit.
1947237|NCT00067002|Drug|Rituxan|375 mg/m2 by vein on Day - 9 for patients with CD20 + malignancies.
1947238|NCT00067002|Drug|Melphalan|140 mg/m2 by vein on Day -8.
1947239|NCT00067002|Drug|Thiotepa|5 mg/Kg by vein on Day -7.
1947240|NCT00067002|Drug|Fludarabine|40 mg/m2 by vein on Days -6 to -3.
1947241|NCT00067002|Drug|Cyclophosphamide|50 mg/kg by vein on Day -6.
1947242|NCT00067002|Drug|Mesna|10 mg/kg by vein before the 1st dose of Cyclophosphamide, then 10 mg/kg every 4 hours for four more doses (total of 50 mg/Kg).
1947243|NCT00067002|Radiation|Total body irradiation (TBI)|Total body irradiation (TBI) given on Day -1 at 2 Gy.
1947244|NCT00066677|Biological|bevacizumab|
1947245|NCT00066677|Drug|docetaxel|
1947246|NCT00065182|Drug|Topotecan/Docetaxel combination|
1947247|NCT00065182|Drug|Docetaxel|
1947248|NCT00064337|Biological|filgrastim|
1947249|NCT00064337|Drug|cyclophosphamide|
1947250|NCT00064337|Drug|dexamethasone|
1947251|NCT00064337|Drug|melphalan|
1947252|NCT00064337|Drug|thalidomide|
1947253|NCT00064337|Procedure|peripheral blood stem cell transplantation|
1947254|NCT00060424|Drug|Cyclosporine|Given PO
1947255|NCT00060424|Drug|Fludarabine Phosphate|Given IV
1947256|NCT00060424|Procedure|Hematopoietic Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
1947257|NCT00060424|Other|Laboratory Biomarker Analysis|Correlative studies
1947258|NCT00060424|Drug|Mycophenolate Mofetil|Given PO
1947259|NCT00060424|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic peripheral blood stem cell transplant
1947260|NCT00060424|Radiation|Total-Body Irradiation|Undergo TBI
1947262|NCT00059254|Dietary Supplement|Oleic acid (OA)|OA-enriched (HI OA; fat, 40%; PA, 1.7%; OA, 31.4%)
1947263|NCT00059254|Dietary Supplement|Palmitic Acid (PA)|PA-enriched (HI PA; fat, 40% of energy; PA, 16.8%; OA, 16.4%)
1947266|NCT00058123|Drug|poly ICLC|
1947267|NCT00057213|Drug|Radafaxine|
1947268|NCT00055978|Drug|celecoxib|Given orally. 400mg twice daily for 6 months.
1947269|NCT00055978|Other|placebo|Given orally
1947270|NCT00054730|Drug|CX516 (Ampalex®)|
1947279|NCT00003830|Procedure|conventional surgery|Sentinel node resection immediately followed by axillary dissection.
1947280|NCT00003830|Procedure|Sentinel node resection followed by node examination|Sentinel node resection followed by node examination then axillary dissection if positive sentinel node. No axillary dissection for negative sentinel node.
1947281|NCT00053352|Procedure|conventional surgery|
1947282|NCT00053352|Drug|cisplatin|Given IV
1947283|NCT00053352|Drug|etoposide|Given IV
1947284|NCT00053352|Biological|bleomycin sulfate|Given IV
1947285|NCT00053352|Other|laboratory biomarker analysis|Correlative studies
1947286|NCT00003471|Drug|antineoplaston A10|
1947287|NCT00003471|Drug|antineoplaston AS2-1|
1947288|NCT00003456|Drug|antineoplaston A10|
1947289|NCT00003456|Drug|antineoplaston AS2-1|
1947290|NCT00052910|Drug|cisplatin|Given IV
1947291|NCT00052910|Drug|epirubicin hydrochloride|Given IV
1947292|NCT00052910|Drug|fluorouracil|Given IV
1947293|NCT00052910|Drug|leucovorin calcium|Given IV
1947294|NCT00052910|Radiation|radiation therapy|Given 5 days a week for 5 weeks
1947295|NCT00003472|Drug|antineoplaston A10|
1947296|NCT00003472|Drug|antineoplaston AS2-1|
1947297|NCT00003474|Drug|antineoplaston A10|
1947298|NCT00003474|Drug|antineoplaston AS2-1|
1947299|NCT00003535|Drug|antineoplaston A10|
1947300|NCT00003535|Drug|antineoplaston AS2-1|
1947307|NCT00004259|Drug|Nitrosourea (BCNU or CCNU)|
1947308|NCT00004259|Drug|temozolomide|
1947309|NCT00004259|Radiation|radiation therapy|
1947315|NCT00052442|Drug|pralatrexate|
1947316|NCT00012064|Biological|therapeutic autologous dendritic cells|Apheresis procedure collects peripheral blood mononuclear cells (PBMC) for the production of dendritic cell, which are admixed with irradiated tumor cells from autologous tumor cell line for vaccine product.
1947317|NCT00005803|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous transplantation
1947318|NCT00005803|Procedure|Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation|Undergo autologous-allogeneic tandem hematopoietic stem cell transplantation
1947319|NCT00005803|Drug|Carmustine|Given IV
1947320|NCT00005803|Drug|Cyclophosphamide|Given IV
1947321|NCT00005803|Drug|Cyclosporine|Given PO
1947322|NCT00005803|Drug|Cytarabine|Given IV
1947323|NCT00005803|Drug|Etoposide|Given IV
1947324|NCT00005803|Drug|Fludarabine Phosphate|Given IV
1947325|NCT00005803|Other|Laboratory Biomarker Analysis|Correlative studies
1947326|NCT00005803|Drug|Melphalan|Given IV
1947327|NCT00005803|Drug|Mycophenolate Mofetil|Given PO
1947328|NCT00005803|Procedure|Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation|Undergo allogeneic transplantation
1947329|NCT00005803|Procedure|Peripheral Blood Stem Cell Transplantation|Undergo allogeneic transplantation
1947330|NCT00005803|Biological|Therapeutic Autologous Lymphocytes|IV donor lymphocyte infusion
1947331|NCT00005803|Radiation|Total-Body Irradiation|Undergo radiotherapy
1947332|NCT00051363|Device|Active CPAP|Nightly nasal continuous positive airway pressure (CPAP)
1947333|NCT00051363|Device|Sham CPAP|Sham CPAP machine will be used for participants in the placebo group.
1947334|NCT00048815|Drug|Citalopram|
1947335|NCT00048815|Drug|St. John's Wort|
1947336|NCT00048048|Drug|methoxy polyethylene glycol-epoetin beta [Mircera]|Differing doses and frequencies of sc administration
1947337|NCT00047671|Drug|Citalopram|PDA Approved antidepressant
1947338|NCT00047411|Other|Cardiopulmonary Resuscitation|Immediate notification of EMS by telephone and prompt initiation of CPR, in accordance with published Basic Life Support guidelines
1947339|NCT00047411|Device|Automatic External Defibrillation|Use the AED first, in accordance with published guidelines for AED use, followed by a call to EMS and perform CPR as in the control group.
1947341|NCT00044278|Drug|lamotrigine|
1947342|NCT00044213|Drug|EDTA|Participants will receive 40 infusions of standard chelation solution.
1947343|NCT00044213|Drug|EDTA Placebo|Participants will receive 40 infusions of EDTA placebo.
1947344|NCT00044213|Dietary Supplement|High Dose Vitamin|
1947345|NCT00044213|Dietary Supplement|High Dose Vitamin Placebo|
1947346|NCT00043719|Drug|Nitroglycerin ointment|
1947347|NCT00043719|Drug|Calcium supplement with vitamin D|
1947348|NCT00040443|Drug|CX516 (Ampalex®)|
1947352|NCT00038649|Drug|Gleevec|400 mg orally twice daily
1947353|NCT00031486|Drug|Valacyclovir|Valacyclovir is a L-valyl ester of acyclovir. Valacyclovir is provided in 500 mg tablets, 4 tablets (500 mg tablets) 3 times a day (every 8 hours) for 90 days.
1947354|NCT00031486|Drug|Placebo|Placebo (identical to active drug in appearance) 500 mg tablets, 4 tablets 3 times daily for 90 days.
1947358|NCT00006411|Other|corneas assigned by donor age group|A web-based computer program was used to select a cornea from those available at the eye bank that met the study eligibility criteria. The program randomly selected a cornea based on a two-level minimization procedure which attempted first to balance for each surgeon the number of corneas from donors >=66 and <66 years old and then, when possible, to balance among age subgroups of 10-35, 36-50, 51-65, 66-70, and 71-75 years. The assignment was made without regard to recipient age or any other subject characteristics.
1947359|NCT00005780|Drug|EPOCH-R|EPOCH-R for 6 cycles
1947360|NCT00005780|Biological|GM-CSF|GM-CSF monthly with the vaccine for 5 doses
1947361|NCT00005780|Drug|Idiotype vaccine|1 injection of vaccine monthly for 5 doses
1947365|NCT00000387|Behavioral|Self-management therapy|Behavioral
1947366|NCT00000387|Behavioral|Self-management therapy|
1947367|NCT00000375|Drug|Nortriptyline-lithium (NOR-Li)|
1947368|NCT00000375|Procedure|Bilateral electroconvulsive therapy (ECT)|
1947369|NCT00000375|Drug|Continuation therapy|
1947370|NCT00000375|Behavioral|Continuation ECT|
1947371|NCT00004418|Drug|glyceryl trierucate|Glyceryl trierucate is an oil to reduce very long chain fatty acids
1947372|NCT00004418|Drug|glyceryl trioleate|Patients receive 2-4 tablespoons of a mixture of glyceryl trierucate and glyceryl trioleate oil once daily.
1988410|NCT02836600|Drug|LY3039478|Administered orally
1988419|NCT02833506|Other|Laboratory Biomarker Analysis|Correlative studies
1988420|NCT02833506|Biological|Recombinant NY-ESO-1 Protein|Given recombinant NY-ESO-1 protein SC
1988421|NCT02833506|Drug|Sirolimus|Given PO
1989621|NCT02440425|Drug|Pembrolizumab|Pembrolizumab: 200 mg, every (Q) 3 weeks, via intravenous (IV) infusion, until progression or toxicity (or up to 24 months). The first cycle will begin on day 8.
1989622|NCT02440425|Drug|Paclitaxel|Paclitaxel: 80 mg/m^2, Q week for 3 weeks, via IV infusion, until progression or toxicity (or complete response if at least 6 cycles, at the discretion of the investigator and participant). Cycle 1 will have an extra lead in week (4 weeks total) with Paclitaxel only on week 1.
1989624|NCT02438956|Dietary Supplement|Setria glutathione supplement|500 mg/day capsule taken in the morning for 120 days.
1989625|NCT02438956|Dietary Supplement|Crystalline Cellulose|500 mg/day capsule taken in the morning for 120 days.
1989629|NCT02436590|Device|Orthofix Physio-Stim Model 3315OA|Active device emits PEMF signal; placebo/control device does not emit PEMF signal
1989639|NCT02432703|Drug|JNJ-42165279|Participants will receive 25 milligram (mg) JNJ-42165279 orally once-daily from Day 1 up to 12 weeks.
1989640|NCT02432703|Drug|Placebo|Participants will receive a matching placebo orally once-daily from Day 1 up to 12 weeks.
1989790|NCT02373280|Procedure|7 day tailored therapy based on antimicrobial susceptibility testing|The participants will be received endoscopy guided biopsy procedure. Minimum inhibitory concentrations (MICs) were determined by the agar dilution method. The resistance to amoxicillin, clarithromycin, metronidazole, tetracycline and moxifloxacin will be evaluated. Based on antimicrobial susceptibility testing, the participants received PPI based triple therapy[Esomeprazole 40 mg bid 7 days (D1-D7)+amoxicillin 1000mg bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)], bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+amoxicillin 1 g bid 7 days (D1-D7)+clarithromycin 500mg bid 7 days (D1-D7)], bismuth quadruple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Tri potassium dicitrate bismuthate, 300 mg qid 7 days (D1-D7)+Metronidazole, 500 mg tid 7 days (D1-D7)+Tetracycline 500 mg qid 7 days (D1-D7)] or moxifloxacin triple therapy [Esomeprazole, 40 mg bid 7 days (D1-D7)+Moxifloxacin, 400 mg qd 7 days (D1-D7)+Amoxicillin 1 g bid 7 days (D1-D7)].
1989791|NCT02373280|Drug|PPI based triple therapy [Esomeprazole, amoxicillin, clarithromycin]|
1989792|NCT02373280|Drug|bismuth quadruple therapy [Esomeprazole, Tri potassium dicitrate bismuthate, Metronidazole, Tetracycline]|
1989793|NCT02373280|Drug|moxifloxacin triple therapy [Esomeprazole, Moxifloxacin, Amoxicillin]|
1989794|NCT02374021|Drug|Methotrexate|Subjects entering trial will continue on MTX dose of at least 15mg MTX/week. At the discretion of the treating rheumatologist, may be switched to SQ route.
1989795|NCT02374021|Drug|Sulfasalazine|1 gm bid
1989796|NCT02374021|Drug|Hydroxychloroquine|200 mg twice daily, not to exceed 6.5mg/kg
1989797|NCT02374021|Drug|Etanercept|50 mg SC weekly
1989798|NCT02374021|Drug|Adalimumab|40 mg SQ every other week
1989819|NCT02365142|Biological|100 million Bone marrow mesenchimal stem cells|100 million Bone marrow mesenchimal stem cells with PRGF
1989820|NCT02365142|Biological|Platelet Rich plasma (PRGF)|3 injections of PRGF
1989930|NCT02313415|Procedure|UC-MSCs therapy|Before considering whether patients meet the inclusion criteria, they are diagnosed as intrauterine adhesions with at least one unsuccessful hysteroscopic surgery. And after that there will be history taking, physical examination, ultrasound examination and hysteroscopy examination. If they agree to participate, they will receive separation of adhesions by hysteroscopy surgery and endometrial biopsies, then a collagen scaffold loaded with UC-MSCs will be transplanted into the uterine cavity. The procedure was performed after taking 6 mg/day × 10 days Progynova, continuous administration of the same dosage Progynova for 30 days and 60mg of progesterone were injected on the 30th day post-operation. Postoperative observation including ultrasound examination once a month for 3 times and hysteroscopy after 3 months. The doctor will select an appropriate time for pregnancy and follow-up including requiring patients to do some unscheduled visits.
1989944|NCT02309086|Biological|Autologous dendritic cells transduced with Ad encoding NS3|Patients will receive 3 different dosis of the vaccine via subcutaneous injection
1990379|NCT02049749|Behavioral|Immediate CARE|CARE is a group parent training informed by the principles of Parent Child Interaction Therapy and was developed by Trauma Treatment Training Center and CHOP Policy Lab. CARE has been used in many populations including residential treatment center/domestic violence shelter staff, daycare providers, graduate students, biological parents, and foster parents/caseworkers. Goals are to decrease stress for caregivers, improve child behavior, and enhance the caregiver-child relationship, family stability, and wellness. The training teaches parents to follow a child's lead thus building a connection and promoting positive behaviors. The focus is on giving attention to child's pro-social behavior and ignoring minor misbehavior. The second phase teaches techniques for giving effective commands.
1990384|NCT02048969|Drug|Flumazenil|A priming dose bolus of 0.4 mg of flumazenil will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
1990385|NCT02048969|Drug|Placebo|A priming dose bolus of 0.4 mg of placebo will be administered intravenously (Minute 0). At this time the 1H-MRS scan will begin. Over the next 6 minutes, a drip infusion of placebo mixed with saline will be administered to the patient at a rate of 0.1 mg per minute for a total of 7 doses during the scan. Total dose will be 1.0 mg.
1990399|NCT02039297|Other|Patient Centered Cloud-based Electronic System: Ambient Warning and Response Evaluation|Computer aided checklist and rounding tool implemented in the Intensive care unit environment
1990423|NCT02028000|Procedure|Insorb staples skin closure|Patients will be randomized to Insorb staples skin closure and compared to Monocryl and Vicryl group.
1990424|NCT02028000|Procedure|Monocryl skin closure|Patients will be randomized to Monocryl skin closure and compared to Insorb skin closure and Vicryl skin closure.
1990425|NCT02028000|Procedure|Vicryl skin closure|Patients will be randomized to Vicryl skin closure and compared to Insorb and Monocryl skin closure groups.
1990447|NCT02018978|Behavioral|Comprehensive Triaged HIV Prevention (CTHP)|"HIV Voluntary Counseling and Testing at Community Prevention Center-The center will be open to all community members.
Community Mobilization-HIV/AIDS and VCT information will be disseminated with pamphlets, community discussions, and meetings.
Risk Assessment and Triaged Counseling and Recruitment-Clients identified at high-risk for HIV infection and HIV-infected clients we be offered an additional counseling session. Participation will be incentivized. These clients will also be provided with up to 3 referral cards to give to sexual partners. If partners come for VCT, they will receive a small incentive.
Incentives & Support Activities - Modest and ethically appropriate incentives, including those providing nutritional support (food), health and hygiene benefits (bed nets), transport to access interventions, or income generation potential, will be provided for participation in some project interventions, and these will be graduated based on HIV risk potential."
1990457|NCT02015936|Behavioral|Six Week Physical Activity Intervention|Tailored Wii Fit prescription based on physical fitness assessments and a schedule of six home visits by an oncology RN.
1990458|NCT02015936|Other|Progress Reporting|Participants will keep a log to record the physical activities they have done with the Wii Fit during the 6-week period. Audio-recording may be included for quality control. Self-report data will be collected by Internet surveys through the University of South Florida (USF) Health Qualtrics application at baseline (T1) and at 6 weeks post-intervention (T2). The nurse will take small amount of the participant's hair (20 strands) for a hormone test during the first visit and last visit.
1990459|NCT02015819|Biological|E. coli CD-expressing genetically modified neural stem cells|Given intracranially
1990460|NCT02015819|Drug|flucytosine|Given orally
1990461|NCT02015819|Drug|leucovorin calcium|Given orally
1990462|NCT02015819|Other|pharmacological study|Correlative studies
1990463|NCT02015819|Other|laboratory biomarker analysis|Correlative studies
1990466|NCT02014116|Drug|LY3009120 capsule|Administered orally.
1990467|NCT02012387|Biological|Active|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
1990468|NCT02012387|Biological|Placebo|Two injections will be administered every four weeks for four months, we will administer 4 doses within 16 weeks
1990469|NCT02012387|Biological|Open labeled|Two injections will be administered every four weeks for 8 months, we will administer 4 doses within 32 weeks
1990539|NCT01971515|Drug|MSC2363318A|"Part 1: MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression. Additional dose escalations will continue until Maximum Tolerated Dose (MTD) is reached, the food effect will be investigated in a separate group.
Part 2 (Cohort 1): MSC2363318A will be administered orally once daily for repeated 21-day cycles until intolerable toxicity or disease progression in subjects with PAM pathway alterations.
Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle)."
1990540|NCT01971515|Drug|MSC2363318A plus Trastuzumab|"Part 2 Cohort 2: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Trastuzumab.
Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).
Trastuzumab is a recombinant IgGI kappa humanized monoclonal antibody administered weekly by intravenous infusion."
1990541|NCT01971515|Drug|MSC2363318A plus Tamoxifen|"Part 2 Cohort 3: MSC2363318A will be administered orally once daily for repeated 21-day cycles in combination with Tamoxifen.
Dose reductions or treatment interruptions will be made at the discretion of the Investigator. If treatment interruption is required due to an acute or less severe but intolerable MSC2363318A-related event, at least a 1-week break is recommended. If, at retreatment, the dose reduction is not required, then the continuous daily dosing regimen may be replaced with an intermittent dose regimen of 2 weeks on, 1 week off (i.e. daily dosing from Day 1 to Day 15 followed by no dosing on Day 16 to Day 21 of the cycle).
Tamoxifen is a nonsteroidal antiestrogen administered daily by oral administration."
1990543|NCT01970722|Procedure|therapeutic conventional surgery|Undergo surgery
1990544|NCT01970722|Drug|cisplatin|Given IP
1990545|NCT01970722|Drug|carboplatin|Given IP or IV
1990546|NCT01970722|Drug|paclitaxel|Given IP or IV
1990547|NCT01970722|Drug|pegylated liposomal doxorubicin hydrochloride|Given IP or IV
1990548|NCT01970722|Drug|gemcitabine hydrochloride|Given IP or IV
1990549|NCT01970722|Procedure|quality-of-life assessment|Ancillary studies
1990550|NCT01970722|Other|laboratory biomarker analysis|Correlative studies
1990551|NCT01969695|Drug|ABT-199|ABT-199 continuous once daily dosing
1990648|NCT01906671|Drug|Xaluprine|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
1990649|NCT01906671|Drug|Puri-Nethol|Comparison of plasma kinetics after administration of 6-mercaptopurine in the form of a tablet (Puri-Nethol) and in the form of an oral liquid formulation (Xaluprine). Each patient will be included in both arms of the study, because of the cross-over design.
1990662|NCT01888809|Behavioral|Comprehensive preventive services|Combined evidence-based services:Parents as Teachers Home visitation, Child-Parent Psychotherapy, and/or Interpersonal Psychotherapy with outreach support
1990663|NCT01888809|Behavioral|Screening and referral|
1990666|NCT01886859|Drug|Ibrutinib|Given PO
1990667|NCT01886859|Other|Laboratory Biomarker Analysis|Correlative studies
1990668|NCT01886859|Drug|Lenalidomide|Given PO
1990669|NCT01886859|Other|Pharmacological Study|Correlative studies
1990951|NCT01662505|Drug|Volasertib|Patient to receive volasertib
1990956|NCT01658813|Drug|5-Fluorouracil and Interferon|5-Fluorouracil Interferon-alfa-2b
1990986|NCT01639339|Biological|Placebo plus standard therapy|Placebo plus standard therapy
1990987|NCT01639339|Biological|Belimumab 10 mg/kg plus standard therapy|Belimumab 10 mg/kg plus standard therapy
1990988|NCT01639339|Drug|Standard therapy|"The standard therapies allowed in this study are:
- High-dose steroids (for example, methylprednisolone) plus cyclophosphamide for induction therapy followed by azathioprine for maintenance therapy
OR
- High-dose steroids plus mycophenolate for induction therapy followed by mycophenolate for maintenance therapy"
1990989|NCT01636687|Drug|Placebo|2 injections of placebo to secukinumab 150mg per dose
1990990|NCT01636687|Drug|Secukinumab 150mg|Secukinumab 150mg: 1 injection of 150 mg secukinumab and 1 injection of placebo to secukinumab 150mg per dose. After Week 52 database lock, study is open label so only 1 injection of secukinumab 150mg per dose will be administered
1990991|NCT01636687|Drug|Secukinumab 300mg|Secukinumab 300mg (2 injections of 150mg secukinumab per dose)
1990998|NCT01624805|Drug|hATG|"40 mg/kg by vein on Days 1 - 4.
35 mg/kg by vein on Days 1 - 4 (in patients with MDS age >/= 55)."
1990999|NCT01624805|Drug|Cyclosporine|5 mg/kg by mouth daily given in 2 divided doses starting on Day 1 and given for 6 months (180 days).
1991000|NCT01624805|Drug|Methylprednisone|1 mg/kg by vein daily for 4 days on Days 1 - 4, to be given prior to the hATG infusion.
1991001|NCT01624805|Drug|Pegfilgrastim|6 mg subcutaneously one time on Day 5 as needed to keep ANC >/= 1.5.
1991002|NCT01624805|Drug|Filgrastim|300-480 mcg subcutaneously on Day 5 as needed to keep ANC >/= 1.5.
1991020|NCT01602315|Drug|BYL719 as film-coated (FC) whole tablets|Oral alpha-specific PI3K inhibitor
1991021|NCT01602315|Drug|BYL719 as dispersible tablets (DT)|New formulation of the oral alpha-specific PI3K inhibitor
1991022|NCT01602315|Biological|cetuximab|Recombinant chimeric monoclonal antibody driven against EGFR
1991023|NCT01602315|Drug|BYL719 as film-coated (FC) drink suspension|Oral alpha-specific PI3K inhibitor
1991028|NCT01599520|Behavioral|Usual Care Only|"Patients will be given the Spanish-language version of Chemotherapy and You: Support for People with Cancer (La quimioterapia y usted: Apoyo para las personas con cancer) published by NCI. The intervention associate will review how it provides answers to common questions about chemotherapy, describes common side effects and their management, and identifies ways to obtain additional information. Patients will also be provided with a list of local support groups for cancer patients and informed that a social worker is available to meet with them without charge to discuss personal concerns or practical problems. At the first infusion, oncology nurses will provide all patients with standard education about the chemotherapy agents and anti-emetic agents to be administered, possible adverse reactions to these agents, and recommended precautions for avoiding illness and maintaining health."
1991032|NCT01595412|Procedure|Laparoscopic Resection Rectopexy|laparoscopic sigmoidectomy with suture rectopexy
1991033|NCT01595412|Procedure|Laparoscopic Ventral Rectopexy|laparoscopic ventral rectopexy with mesh
1991043|NCT01585519|Dietary Supplement|High/ Low Epicatechin Apples/ Apple Extract/ Granules|"(Group 1) Low Apple Diet (i.e. <1 portion per day) + 2 placebo capsules daily.
(Group 2) 2 x High Epicatechin Apples daily + 2 placebo capsules daily.
(Group 3) 2 x Low Epicatechin Apples daily + 2 placebo capsules daily.
(Group 4) Low apple diet + 2 x 4.4g of apple granules daily + 2 placebo capsules daily.
(Group 5) Low apple diet + 2 x Apple Extract Capsules daily."
1991044|NCT01586156|Drug|Carvedilol|Group 1 will receive 3.125mg carvedilol twice daily for six months.Group 2 will receive carvedilol in a dose escalation scheme.
1991045|NCT01586156|Drug|Carvedilol placebo|Placebo taken twice daily for 6 months
1991051|NCT01572922|Device|R2*-UTE|Ultra short echo time (UTE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
1991052|NCT01572922|Device|R2*-GRE|Gradient-echo (GRE) magnetic resonance imaging (MRI). Study participants will undergo an MRI examination of the liver on a 1.5T MRI and a 3T MRI scanner each. Because liver biopsy metal needle fragments could interfere with the MRI measurements, the MRI exams will always precede liver biopsy. Multi-echo GRE sequences will be used to acquire images with increasing TEs. Images of the liver will be obtained in transversal slice orientation through the center of the liver at the level of the origin of the main portal vein. At equivalent slice locations R2*-UTE scans will be performed.
1991053|NCT01572922|Procedure|Liver biopsy|Indications for liver biopsy include, but are not limited, to the need to quantify liver tissue iron and the need to obtain histopathological information of the liver tissue. Liver biopsies will only be performed if clinically indicated and will be done only once per patient. The technique to be used is coaxial percutaneous (transcapsular) technique; however, a coaxial transjugular technique may be performed in subjects with increased bleeding diathesis, since it is associated with less hemorrhagic risk. Healthy volunteers will not undergo liver biopsy.
1991093|NCT01534377|Behavioral|Interpersonal Psychotherapy for Adolescents|Adolescents will receive IPT-A a manualized intervention for depression and prevention of depression that emphasizes current interpersonal relationships, focusing on their immediate social context.
1991094|NCT01534377|Behavioral|Enhanced Care|Adolescents will receive enhanced care which is consistent with care typically provided in community settings to treat and prevent depression.
1991115|NCT01521975|Drug|Telbivudine, Adefovir dipivoxil|All patients will take Telbivudine 600 mg PO daily from baseline. Some patients will take Adefovir dipivoxil 10 mg PO daily if they meet the criteria of adding Adefovir dipivoxil.
1991116|NCT01515189|Biological|Ipilimumab|
1991142|NCT01471106|Drug|Dasatinib|"Group 1: 40 mg by mouth once a day.
Group 2: 80 mg by mouth once a day."
1991147|NCT01455519|Drug|Hydromorphone ER|Total target dose of 32 mg/day. All subjects will have a lead in for 2 weeks; then begin a 'forced' 2-week up-titration schedule as follows: 8mg/d (1 pill, 5 days), 16mg mg/d (2 pills, 5 days), and 24mg/d (3 pills, 5 days) then finally 32 mg/d (4 pills a day) for the 'stable dose' phase of the study, or identical placebo pills. If intolerable side effects occur, the dose may be reduced to last tolerable does, a minimum of 8 mg/day (or one pill a day), at the discretion of the PI. Subjects unable to tolerate 8 mg/day will be discontinued from the study. A 2-week down-titration will be used.
1991148|NCT01455519|Drug|Sugar pill|Sugar pill
1991149|NCT01452529|Drug|Hydrocodone bitartrate q24h film-coated tablets|Hydrocodone bitartrate q24h film-coated tablets 20 - 120 mg once daily
1991150|NCT01452529|Drug|Placebo to match hydrocodone bitartrate q24h tablets|Placebo to match hydrocodone bitartrate q24h film coated tablets 20 - 120 mg once daily
1991162|NCT01430455|Drug|Tranylcypromine|Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study
1996134|NCT02562443|Drug|Any approved or standard-of-care therapy|Patients will receive Physician's Choice of Treatment or alternative treatment which may include any approved or standard-of-care therapy, based on frequently used treatment for MDS (no experimental therapy) + best supportive care.
1991222|NCT01353703|Biological|Infanrix hexa™|Intramuscular, three doses
1991229|NCT01350401|Biological|NY-ESO-1|Cytoreductive chemotherapy followed by infusion with NYESO-1(C259) transduced autologous T cells
1991232|NCT01348256|Drug|Dendritic cells vaccine|Vaccination with autologous dendritic cells loaded with autologous tumor antigens
1991234|NCT01348347|Drug|Volasertib, low dose, d1q3w|Patient to receive low dose of Volasertib IV
1991235|NCT01348347|Drug|Volasertib, middle dose, d1q3w|Patient to receive middle dose of Volasertib IV
1991236|NCT01348347|Drug|Volasertib, high dose, d1q3w|Patient to receive high dose of Volasertib IV
1991244|NCT01339650|Drug|ABT-767|ABT-767 once or twice daily for a 28 day cycle
1991252|NCT01329354|Biological|Autologous effector lymphocytes expanded ex-vivo|Maintenance therapy with Rituximab every two months is the standard of care for patients with follicular lymphoma after induction therapy. The intervention consists on the administration of autologous effector lymphocytes expanded ex-vivo every two Rituximab administrations.
1991260|NCT01325506|Other|Questionnaire|Questionnaire, telephone interviews, and clinical follow-up
1991262|NCT01314911|Drug|Oseltamivir|One capsule twice daily of 75 mg oseltamivir; total dose: 150 mg/day for 5 days
1991300|NCT01264991|Procedure|Arthroscopic partial meniscectomy|The arthroscopic partial meniscectomy will be performed on an outpatient basis by experienced surgeons at a level of at least attending physicians or at the last year of residency. All arthroscopies will be performed in general anaesthesia combined with local anaesthesia. After general anaesthesia is induced, the knee will be examined for stability. Thereafter two standard portals on the lateral and medial side of the ligamentum patella will be created but no outflow cannula inserted. An arthroscope will be used with a pressure-controlled irrigation system. Tourniquet use will be according to surgeon preference. The strategy for the meniscectomy will be to preserve as much tissue as possible. A standard operation protocol will be used to document possible findings in cartilage, ligaments, synovium and the medial and lateral meniscus. Meniscus lesions and type of will be registered and changes in the articular cartilage will be classified according to the ICRS classification
1991301|NCT01264991|Procedure|Sham procedure|The placebo procedure will be performed under the same conditions as above. The patient will be fully sedated in general anaesthesia. As above, the stability of the knee will be examined. Local anaesthetic will be applied as above and 2 skin incisions will be made at the same location and the same size as above. Then the knee will be manipulated as if a real arthroscopy were being done, the spillage of water and all the other equipment needed for an arthroscopy will be used and manipulated. No instruments will enter the portals for arthroscopy to avoid the possibility of osteochondral lesions and unwanted interventions by the surgeon.
1991305|NCT01252329|Procedure|elective lymph node dissection|This entails selective lymph node dissection in patients with negative lymph node exams. The nodes dissected are those that drain from the high risk cutaneous squamous cell cancer. Subsequent radiation and/or chemotherapy may be administered in a small percentage of subjects, depending on the result of the neck dissection.
1991339|NCT01223352|Drug|bosentan|32 mg quadrisected dispersible tablet. The dosage of bosentan (2 mg/Kg) was adjusted according to the patient's body weight at initiation of the study treatment. Dosage readjustment was permitted after 12 weeks of treatment.
1991353|NCT01206816|Drug|BI 6727 + BIBW 2992|BI 6727 administered i.v. every 21 days + BIBW 2992 given orally once a day
1991355|NCT01205282|Drug|Pioglitazone|A modified dose finding method will be used to determine safety and dose response among three dose levels (0.25mg/kg QD, 0.5mg/kg QD, and 0.75mg/kg QD). The dose has been based on the per weight maximum adult dose. Specifically, the FDA has approved 45mg as the maximum adult dose. For a 60kg adult, this is 0.75mg/kg. There will be 14 weeks of active treatment.
1991356|NCT01205282|Drug|Placebo|There will be a 2 week period of placebo run-in.
1996135|NCT02562443|Drug|best supportive care (BSC)|Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.
1996136|NCT02562443|Drug|best supportive care (BSC)|Patients will receive best supportive care (BSC).
1991386|NCT01176591|Drug|Aprepitant|80 mg per session, oral administration.
1991387|NCT01176591|Drug|Placebo|Placebo, one per session, oral administration
1991388|NCT01175083|Biological|GSK1024850A (SynflorixTM)|2, 3 or 4 intramuscular injection
1991389|NCT01175083|Biological|Tritanrix-HepB/Hib|Intramuscular injection, 4 doses
1991390|NCT01175083|Biological|Polio Sabin|4 oral doses
1991403|NCT01152762|Procedure|Standardized Respiratory Physiotherapy|Standardized Respiratory Physiotherapy during 6 months
1991404|NCT01151813|Drug|Varenicline|Varenicline, oral target dose of 1.0 mg BID, one week titration.
1991405|NCT01151813|Drug|Placebo|Placebo
1991409|NCT01147653|Biological|Autologous UCB Reinfusion|Autologous umbilical cord blood (UCB) reinfusion
1991410|NCT01147653|Other|Placebo|Placebo
1991413|NCT01145885|Drug|BI 6727|PLK-1 inhibitor
1991728|NCT00596011|Drug|Polyphenon E|Polyphenon E, at a dose of 400 mgs EGCG (200 mgs BID) for 1 year in men diagnosed with HGPIN and ASAP.
1991729|NCT00596011|Drug|Placebo|Matching placebo BID
1991746|NCT00575042|Drug|Fenofibrate (Insoluble Drug Delivery-Micro Particle Fenofibrate (IDD-P)|160 mg per day
1991761|NCT00555581|Drug|Imatinib Mesylate|In initial phase, patients will be treated with Gleevec 400 mg daily for 12 months. In the extension phase, patients will be treated with Gleevec 400 mg daily for 27 months.
1991765|NCT00543439|Biological|Moroctocog alfa (AF-CC)|On-demand therapy for 6 months, followed by routine prophylaxis 25 IU/kg, administered every other day for 1 year.
1991766|NCT00543439|Biological|Moroctocog alfa (AF-CC)|"Routine prophylaxis crossover:
45 IU/kg, administered 2 times a week for 1 year followed by 25 IU/kg administered every other day for 1 year, or, 25 IU/kg, administered every other day for 1 year, followed by 45 IU/kg, administered 2 times a week for 1 year."
1991768|NCT00533845|Drug|On-Q Pain Pump|Bupivicaine .375% via on-Q pump will be infused at a rate of 2cc/hr intraperitoneally
1991808|NCT00481832|Drug|Cyclophosphamide|4gm/m2and100mg/kg
1991809|NCT00481832|Drug|Carmustine|15mg/kg, IV over 2 hours
1991810|NCT00481832|Drug|Etoposide|60mg/kg, IV over 4 hours
1991811|NCT00481832|Drug|Filgrastim|5-10mcg/kg, SQ
1991812|NCT00481832|Drug|Antithymocyte globulin|1.5mg/kg/dx5, IV
1991813|NCT00481832|Drug|Cyclosporine|5mg/kgbid,variable, po or IV
1991814|NCT00481832|Drug|Mycophenolate mofetil|15mg/kg,variable, po or iv
1991815|NCT00481832|Drug|rituximab|375mg/m2, IV
1991816|NCT00480025|Biological|GSK1572932A Antigen-Specific Cancer Immunotherapeutic|Intramuscular administration, 13 doses
1991817|NCT00480025|Biological|Placebo Control|Intramuscular administration, 13 doses
1991819|NCT00477087|Drug|Mitoxantrone|14mg/m2 IV
1991820|NCT00477087|Drug|GM-CSF|250mg 3/week
1991822|NCT00470366|Biological|pegfilgrastim|
1991823|NCT00470366|Drug|cisplatin|
1991824|NCT00470366|Drug|ifosfamide|
1991825|NCT00470366|Drug|paclitaxel|
1991829|NCT00440609|Drug|ranibizumab|0.5mg or 1.0mg intravitreal injection given monthly for 3 months then every other month if needed, for the first year.Patients may be treated monthly as needed. Patients in Cohort 1(the first 30 patients)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 24. Patients in Cohort 2(the remaining 20)will be eligible to receive treatment as needed with 2.0mg ranibizumab starting at month 12.Patients may receive 2.0mg ranibizumab for a period limited to 24 months following administration of the first 2.0mg dose. Patients completing 36 months will be eligible to be followed for an additional 24 months. Starting at Month 36, patients will be able to receive monthly, the assigned dose that they received/or could have received(if re-treatment criteria was met)at Month 35. 2/1/12 - the 2.0mg dose has been discontinued, all subjects will transition to the 0.5mg dose.
1991830|NCT00434577|Biological|Herpes Zoster vaccine GSK1437173A|Single or two-dose intramuscular injection.
1991831|NCT00434577|Biological|Placebo|Single intramuscular injection
1991861|NCT00348309|Drug|Rosiglitazone Extended Release 2mg|Rosiglitazone Extended Release 2mg OD
1991862|NCT00348309|Drug|Rosiglitazone Extended Release 8mg|Rosiglitazone Extended Release 8mg OD
1991863|NCT00348309|Other|Placebo|Placebo
1991864|NCT00348309|Other|Donepezil|Donepezil (At least 6 months of ongoing donepezil therapy for Alzheimer's disease, with stable dosing for at least the last 2 months (and with no intent to change for the duration of the study).
1991877|NCT00329797|Dietary Supplement|calcium carbonate|Given orally
1991878|NCT00329797|Dietary Supplement|calcium citrate|Given orally
1991879|NCT00329797|Dietary Supplement|calcium glucarate|Given orally
1991880|NCT00329797|Dietary Supplement|cholecalciferol|Given orally
1991881|NCT00329797|Drug|buserelin|Given concurrently
1991882|NCT00329797|Drug|calcium gluconate|Given orally
1991883|NCT00329797|Drug|goserelin acetate|Given concurrently
1991884|NCT00329797|Drug|leuprolide acetate|Given concurrently
1991885|NCT00329797|Drug|triptorelin|Given concurrently
1991886|NCT00329797|Drug|zoledronic acid|Given IV
1991887|NCT00329797|Radiation|brachytherapy|Given concurrently
1991888|NCT00329797|Radiation|radiation therapy|Given concurrently
1991889|NCT00323063|Drug|gemcitabine hydrochloride|Given IV
1991890|NCT00323063|Drug|imatinib mesylate|Given orally
1992260|NCT03322683|Procedure|Conventional physiotherapy treatmen|The PT group will treated during two weeks (ten days/week) with ultrasound therapy (US), transcutaneous electric nerve stimulation (TENS) and massage, in this order. Ultrasound will applied in pulse mode at an intensity of 1 megahertz for 10 minutes in the sub-occipital region and the vicinity of the trapezius muscles. TENS will applied with a pulse duration of 250 microseconds at a frequency of 80 Hertz for 20 minutes in the sub-occipital region and the trapezoids. Deep massage was applied at a slow speed for 20 minutes using sliding neutral creams. Massage therapy included gliding and kneading techniques applied over trapezius (upper, lower and middle fibers), splenius capitis and levator scapulae muscles with a therapeutic intention.
1992269|NCT03322644|Behavioral|Internet-based CBT intervention|The Internet-delivered Pancreatitis Pain Course consists of 5 lessons: 1) introduction, education, and symptom identification, 2) thought monitoring and challenging, 3) controlled breathing and pleasant activity scheduling, 4) activity pacing, and 5) relapse prevention and goal setting. Participants aim to complete one online lesson weekly for 5 weeks, and have up to 2 months to complete the course. Each lesson has a homework assignment to encourage participants to practice and apply skills. A coach who is part of the Seattle Children's Research Institute study team will make weekly contact with participants in the intervention arm through telephone or secure e-mail, for a period of between 10-15 minutes to encourage participants to work through the Course and apply the skills.
1992270|NCT03322631|Drug|LY3298176|Administered SC.
1992271|NCT03322631|Drug|Placebo|Administered SC.
1992272|NCT03322618|Biological|blood samples|7 tubes of 6 ml (42 ml of blood )
1992273|NCT03322592|Diagnostic Test|Rapid on-site evaluation (ROSE)|On-site evaluation of the acquired samples will be performed by pathologist
1992274|NCT03322592|Diagnostic Test|Histologic evaluation|Samples collected in the EUS-FNB without ROSE will be processed as histologic samples
1992275|NCT03322579|Device|Balloon dilatation Eustachian tuboplasty|Eustachian tuboplasty by balloon dilation involves the recanalization of the cartilaginous portion of the ET via the nasopharynx with a balloon catheter. This catheter is inflated to multiple atmospheres of pressure for a short amount of time and then removed.
1992276|NCT03322566|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
1992277|NCT03322566|Drug|Epacadostat|Epacadostat administered orally twice daily.
1992278|NCT03322566|Drug|Platinum-based chemotherapy|Investigator will select one of the following regimens: pemetrexed + cisplatin, pemetrexed + carboplatin, or paclitaxel + carboplatin.
1992279|NCT03322566|Drug|Placebo|Matching placebo administered orally twice daily.
1992280|NCT03322553|Device|GERD-X|Endoscopic full-thickness plication will be performed using the GERDX® system. All procedures will be performed under general anesthesia. Savary-guidewire will be placed into the stomach using a gastroscope. The GERDX® system will be introduced over the guidewire into the stomach and retroflexed. The GE junction will be visualized using another slim endoscope passed through a channel present in the GERD-X device. According to study protocol, at least 2 pretied transmural pledgeted sutures will be deployed to achieve a tight closure of gastro-esophageal junction around the GERD-X device.
1992281|NCT03322540|Drug|Pembrolizumab|Pembrolizumab administered intravenously every 3 weeks.
1992282|NCT03322540|Drug|Epacadostat|Epacadostat administered orally twice daily.
1992283|NCT03322540|Drug|Placebo|Matching placebo administered orally twice daily.
1992284|NCT03322514|Dietary Supplement|Inulin-Propionate Esters|Inulin (β(2-1) linked polymer of fructose) carrier with an ester linked to propionate (propionate ester). Thus, propionate is only released when the carrier molecule inulin is fermented by colon microflora.
1992285|NCT03322514|Dietary Supplement|Inulin|Inulin
1992286|NCT03322501|Behavioral|Provider Advice, Framed Messaging|The purpose of the study is to determine if an Ask, Advise, Connect (AAC) intervention model benefits tobacco control outcomes for pediatric primary care providers (pPCP's) and their young patients.
1992287|NCT03322488|Procedure|Fistulodesis|"Fistulodesis comprises the following treatment steps:
Curettage and/or brushing of the fistula tract
Mini-excision of the inner (endoanal) fistula opening
Flushing of fistula tract with acetylcysteine (Concentration: 100mg/ml, max. dosage: 20ml)
Flushing/ filling of fistula tract with doxycycline (Concentration: 20mg/ml, max. dosage: 10ml)
Filling the fistula tract with fibrin-glue (Evicel®). The maximum amount of Evicel® injected will be 20 ml of the combined product.
Surgical closure of inner (endoanal) fistula opening using a Z-suture (Vicryl 3.0)
Surgical closure of the outer fistula opening using a Z-suture (Vicryl 3.0)
Metronidazole and ciprofloxacin will be used at 500mg two times per day for 10 days after the intervention (baseline)."
1992288|NCT03322475|Device|PiQo4 laser system|The PiQo4 laser system
1992289|NCT03322462|Drug|18F-AV-1451|Subjects will receive single IV administration of 370 megabecquerel (MBq)(10 millicurie [mCi]) of 18F-AV-1451
1992290|NCT03322449|Other|Animal Diet|during one week participants will receive food products enriched in animal products and with high content of fat and protein
1992291|NCT03322449|Other|Plant Diet|during one week participants will receive plant products enriched in fiber and complex carbohydrates
1992292|NCT03321643|Drug|Atezolizumab|Given IV
1992293|NCT03321643|Drug|Gemcitabine|Given IV
1992294|NCT03321643|Other|Laboratory Biomarker Analysis|Correlative studies
1992295|NCT03321643|Drug|Oxaliplatin|Given IV
1992296|NCT03321643|Biological|Rituximab|Given IV
1992339|NCT03322072|Device|Real-Time Position Transponder Beacons|The anchored lung tracking beacons are passive electromagnetic transponder beacons which are placed immediately adjacent to a lung tumor using a bronchoscope. Three beacons will be placed in the small airways of the lung adjacent to the target tumor (within 3 cm of the tumor). Each beacon measures 2 mm in diameter and 8 mm in length and consists of a miniature electrical circuit that is encapsulated in a biocompatible glass capsule. Each beacon has an affixed five-legged anchoring system which expands to 5mm diameter once deployed. The Calypso transponder beacon is placed endobronchially using the working channel of a bronchoscope. Navigational bronchoscopy can be used to pre-plan the optimal location for each beacon to be placed within the airways by using a pre-bronchoscopy CT scan.
1992340|NCT03322059|Behavioral|Experimental|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals). They will also receive a donation to a cancer charity of their choice if they meet daily step goals.
1992341|NCT03322059|Behavioral|Control|Participants will receive a fitbit and lifestyle counseling to increase steps. Weekly newsletter for first 6 weeks, bi-weekly for remaining weeks with behavioral content designed to increase physical activity (e.g., barriers, SMART goals).
1992342|NCT03322046|Behavioral|Lifestyle Program|4 elements: 1) Laboratory test results with diagnostic report describing results, 2) Lifestyle plan generated in online portal with personalized nutritional information based on combination of laboratory results and personal preferences, 3) online or smartphone food journaling application, 4) telephone based lifestyle coaching with Registered Dietitian.
1992343|NCT03322033|Device|Valiant PS-IDE Stent Graft|Medtronic Valiant PS-IDE Stent Graft System with the Captivia Delivery System
1992344|NCT03322020|Radiation|Cyberknife boost 18 Gy|pelvis IMRT dose of 46 Gy/23 fx followed by Cyberknife boost 18 Gy/3 fx
1992345|NCT03322020|Radiation|Cyberknife boost 21 Gy|pelvis IMRT dose of 46 Gy/23 fx followed by Cyberknife boost 21 Gy/3 fx
1992346|NCT03322007|Device|Scrambler Therapy|external neuromodulation to relieve pain; the device was cleared by the FDA in 2009 for safety, considering it like a TENS unit
1992347|NCT03321994|Device|stereotaxic unit, navigation|CT-guided needle guidance using stereotaxic unit, navigation
1992348|NCT03321994|Device|conventional biopsy technique|CT-guided needle guidance using conventional biopsy technique
1992349|NCT03321981|Drug|MCLA-128|full length IgG1 bispecific antibody targeting HER2 and HER3
1992350|NCT03321981|Drug|Trastuzumab|humanised IgG1 monoclonal antibody
1992351|NCT03321981|Drug|Vinorelbine|antineoplastic drug of vinca alkaloid family
1992352|NCT03321981|Drug|Endocrine therapy|same endocrine therapy is administered as the last line of endocrine therapy
1992353|NCT03321968|Biological|Quadrivalent VLP Influenza Vaccine|30 µg/strain Quadrivalent VLP Influenza Vaccine
1992354|NCT03321955|Drug|Ziconotide 100 MCG(microgram)/ML Intrathecal Solution|Initial dose at time of the implant will be 1.2 mcg/day with dose increases of no more the .4 mcg/day planned for 3, 6, 8, 9, 10, 12 weeks and 4, 5 and 6 months.
1992355|NCT03321955|Diagnostic Test|Quantitative sensory testing|Quantitative sensory testing will be done using different types of sensory stimulation to objectively quantify sensation and pain tolerance. VonFrey fibers of various widths are used to detect sensation, a Neuropen pin prick iutilized to detect pain, along with a tuning fork to measure vibrationand a pressure guage to measure pressure felt on the skin. Cold/hot sensation is tested with Medoc Pathway system to quantitatively measure the temperature felt by patients to be done at baseline and 6 months,
1992356|NCT03321955|Diagnostic Test|Serum markers: Interleukin-1, Interleukin-6, and tumor necrosis factor|Increases in these biomarkers indicate nerve pain as they are released from macrophages in patients with damaged nerves.
1992357|NCT03321942|Drug|Treatment group|Adipose tissue-derived mesenchymal stem cells were used to treat patients with chronic renal failure on the basis of conventional treatment.
1992358|NCT03321942|Drug|Control group|Conventional treatment were used to treat patients with chronic renal failure.
1992359|NCT03321916|Device|577-nm PASCAL laser|The Topcon/Endpoint Management System™ is a cleared medical device commonly used in the treatment of ocular disorders.
1992360|NCT03321903|Device|Carlo Erba Ink Injection|Carlo Erba India ink is used in this study as a paramagnetic oxygen sensor that is injected into tissue, and which, when measured using EPR Oximetry, can provide sensitive, repeated, and direct measurements of tissue oxygen. Each study participant will receive at least one ink injection of 20-50µL of Carlo Erba India Ink. The ink injection will occur within 5mm of the body surface (i.e., skin or mucosa), and may be injected into tumor, postsurgical field of radiation, and/or adjacent normal tissue. Carlo Erba Ink is an aqueous suspension composed of charcoal powder, water for injection, and a suspending agent. Carlo Erba is the name of the manufacturer that supplies the charcoal.
1992361|NCT03321903|Other|EPR Oximetry Measurement|An oximetry measurement visit consists of ~ 30 minutes of continuous scans of tissue oxygen in vivo, using an oxygen sensor (i.e., India ink) injected into the tumor that is noninvasively scanned using EPR oximetry. Scans, converted into measurements of pO2, characterize the current tumor oxygen level at: (1) 'steady state' (while breathing room air), 2) response to hyperoxygenation therapy (inhaling oxygen-enriched air for 10 min), and 3) response to resuming inhaling room air. EPR measurements are repeated noninvasively throughout radiation or chemotherapy, to examine changes. The minimum number of visits depends on the patient's cohort; all may have additional measurements. If the ink injection is not surgically removed, EPR oximetry measurements can be repeated indefinitely.
1992362|NCT03321890|Drug|Chidamide|Oral, each taking 30 mg (6 tablets), medication twice a week, 30 minutes after breakfast
1992363|NCT03321890|Drug|prednisone|oral, 20mg / day,after breakfast
1992364|NCT03321890|Drug|Cyclophosphamide|oral, 50mg / day,after lunch
1992365|NCT03321890|Drug|etoposide|oral, 50mg / day,after dinner
1992366|NCT03321890|Drug|Methotrexate|oral, 10mg / times, once a week,after breakfast
1992367|NCT03321877|Drug|Change to dose of patient's regular medication|Dose reduction of the drug each patient was already taking
1992368|NCT03321864|Procedure|Transrectal ultrasound scan of prostate|Additional transrectal ultrasound whilst already under GA for transperineal biopsy.
1992369|NCT03321851|Device|V-sensor device user|Participants use device to detect the 5 vital signs (Blood Pressure, Pulse, Respiration, SpO2, Temperature).
1992383|NCT03321721|Other|Suture (nylon) for wound repair|suture of wound
1992386|NCT03321669|Procedure|Capsule endoscopy|Ingestion of capsule endoscopy for the diagnosis of small bowel lesions
1992387|NCT03321656|Drug|Tacrolimus|0.1-0.2 mg/kg/day orally divided into two doses every 12 hours orally
1992388|NCT03321656|Drug|Envarsus XR|0.07-0.14 mg/kg/day every morning orally
1992389|NCT03320070|Drug|repository corticotropin injection|Acthar administered twice weekly SC
1992390|NCT03320070|Drug|Placebo|Placebo administered twice weekly SC
1992391|NCT03321630|Drug|Lenvatinib|Lenvatinib 20 mg orally each day on days 1-7
1992392|NCT03321630|Drug|Pembrolizumab|Pembrolizumab 200mg intravenously, to be initiated on day 8, and continued every 3 weeks, in combination with daily lenvatinib 20 mg
1992393|NCT03321617|Drug|Pomaglumetad methionil|metabotropic glutamate 2/3 receptor (mGlu2/3R) agonist
1992394|NCT03321565|Other|Behavioral counseling and optional meal replacement program|Medical assessment and medical supervision of weight loss Measurements of metabolism and body composition Individualized exercise programs Personal training Support group meetings Individual psychotherapy A variety of nutritional plans including meal replacement options Nutrition education Long-term weight maintenance and relapse prevention programs
1992395|NCT03321552|Procedure|Percutaneous deep vein arterialization|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
1992396|NCT03321552|Device|LimFlow System|Creation of an arterio-venous fistula in the below-the-knee vasculature using the LimFlow System endovascular, minimally invasive approach
1992397|NCT03321539|Drug|CCRT+GP|Patients receive gemcitabine (1000mg/m2 on day 1 and day 8) and cisplatin (80mg/m2 separate injection on day 1) every three weeks for three cycles after the concurrent cisplatin (100mg/m2 separate injection on day 1) every three weeks for three cycles during radiotherapy.
1992398|NCT03321539|Drug|CCRT+PF|Patients receive cisplatin (80mg/m2 separate injection on day 1) and 5-fluorouracil (4000mg/m2 civ 96h) every four weeks for three cycles after the concurrent cisplatin (100mg/m2 separate injection on day 1) every three weeks for three cycles during radiotherapy.
1992399|NCT03321539|Radiation|Concurrent chemoradiotherapy|Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.
1992400|NCT03321526|Drug|JNJ-42847922|Participants will receive JNJ-42847922 capsule orally.
1992401|NCT03321526|Drug|Placebo Matching to JNJ-42847922|Participants will receive placebo capsule matching to JNJ-42847922 orally.
1992402|NCT03321526|Drug|Quetiapine XR|Participants will receive quetiapine XR capsule orally.
1992403|NCT03321526|Drug|Placebo Matching to Quetiapine XR|Participants will receive placebo capsule matching to quetiapine XR orally.
1992404|NCT03321526|Drug|Selective Serotonin Reuptake Inhibitor (SSRI)|Participants will receive SSRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
1992405|NCT03321526|Drug|Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)|Participants will receive SNRI antidepressant as a part of background therapy (at the same dose, without change, every day and at approximately the same time as prior to entering the study) throughout the screening, double-blind, and follow-up phases (approximately up to Week 26).
1992406|NCT03321513|Drug|intravitreous aflibercept|"Intravitreous aflibercept injection is made by Regeneron Pharmaceuticals, Inc. and is approved by the FDA for the treatment of neovascular age-related macular degeneration, macular edema due to central retinal vein occlusion, macular edema due to branch retinal vein occlusion, diabetic macular edema, and diabetic retinopathy in eyes with diabetic macular edema.
Study eyes assigned to receive aflibercept will receive a dose of 2.0 mg in 0.05 cc. Aflibercept will be obtained commercially by the clinical site. The physical, chemical, and pharmaceutical properties and formulation of aflibercept are provided in the Package Insert.
Intravitreous Injection Technique The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.
The injection will be performed using sterile technique"
1992407|NCT03321513|Drug|Bevacizumab + Deferred Aflibercept Group|"Bevacizumab is made by Genentech, Inc. and is approved by the FDA for the treatment of metastatic colorectal cancer as well as the treatment of non-squamous non-small cell lung cancer, glioblastoma, and metastatic renal cell carcinoma.
Study eyes assigned to receive bevacizumab will receive a dose of 1.25 mg provided by a single compounding pharmacy identified by the Network and distributed by the Network. The volume of the injections will be 0.05 cc.
Intravitreous injection technique: The injection is preceded by a povidone iodine prep of the conjunctiva. In general, topical antibiotics in the pre-, peri-, or post-injection period should not be used.
The injection will be performed using a sterile technique."
1992408|NCT03321500|Other|Versacryl soft liner|Versacryl has been used to construct different parts of complete and partial dentures . It can be used as thermo-elastic liner which consistency can be controlled to tailor the reline to each individual case, by adding or subtracting drops of liquid B, as explained in the directions for use. The reline can be re-adapted repeatedly, even by the patient if necessary.
1992460|NCT03321071|Behavioral|Healthy Summer Learners|"Physical Activity Component. The physical activity component of Healthy Summer Learners is designed to engage children in moderate-to-vigorous physical activity (MVPA) for at least 50% of the time. With 3 hours each day dedicated to physical activity, this translates into children accumulating 90 minutes of MVPA daily. This is 30 minutes above the 60 minutes of MVPA each day recommended by the Physical Activity Guidelines for Americans.
Nutrition Component. The nutrition component of Healthy Summer Learners is designed to provide healthy snacks and meals and nutrition education via standardized pre-existing curricula.
Food/Beverage Guidelines. Meals will follow the USDA Nutrition Standards for the National School Lunch and School Breakfast Programs.
Academic Component. The academic component will consist of existing, effective academic programs focused on Math and Reading."
1992461|NCT03321071|Behavioral|21st Century Summer Learning Center|Children in this condition will attend a 21st Century Summer Learning Program.
1992462|NCT03321058|Behavioral|Assessment|Assessment of patients' medication organisation and comprehension of generics
1992463|NCT03321045|Drug|[89Zr]-Df-Trastuzumab|[89Zr]-Df-Trastuzumab will be administered intravenously. The administered dose will be 2 mCi at the time of injection. The amount of injected drug is 5 mg of Trastuzumab.
1992464|NCT03321045|Diagnostic Test|PET/MRI Imaging|5-6 days post injection the patients will undergo PET/MRI imaging.
1992465|NCT03321032|Device|Polymer-free amphilimus-eluting stents|Cre8 coronary stent system (CID, Saluggia, Italy)
1992466|NCT03321032|Device|Biolinx Polymer-based zotarolimus-eluting stents|Resolute Onyx coronary stent system (Medtronic, Minneapolis, Minnesota, US)
1992471|NCT03321006|Device|Audio B-R 90 hearing aid device|Hearing aids will be the latest Audio B-R 90 devices manufactured by Phonak. Low amplification hearing aids will be programmed to a hearing threshold of 10dB across all frequencies; Full amplification hearing aids will have their gain determined by audiometric profile as per standard clinical practice
1992472|NCT03321006|Drug|Duloxetine|We opted to allow two potential medication choices so that study participation could be offered to individuals who had previously taken one medication and either not responded or not tolerated it. After 4 weeks if subjects do not meet remission criteria (HRSD≤10), the dose of study medication will be increased to escitalopram 20mg or duloxetine 60mg for the remaining 8 weeks of the study.
1992474|NCT03320980|Procedure|RALPPS|RALPPS: split-in-situ resection with radio-frequency ablation (RFA) instead of liver partition on the first stage and major liver resection on the second stage
1992475|NCT03320980|Procedure|portal vein embolization + major liver resection|PVE on the first stage and major liver resection on the second stage
1992476|NCT03320967|Diagnostic Test|Copeptin in plasma|Copeptin will be measured in EDTA-Plasma. Samples will be stored for batch analyses later.
1992478|NCT03320941|Drug|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally.
1992479|NCT03320941|Drug|Placebo|Placebo will be supplied as tablets to be taken orally.
1992480|NCT03320928|Other|Photochemotherapy|Retrospective evaluation of treatment outcome and risk for pulmonary mortality and relapse incidence
1992481|NCT03320915|Drug|Cholecalciferol|Cholecalciferol 5mg (200,000 IU) up to maximum of three times during 1 year follow-up period according to measured 25(OH)D3 level.
1992482|NCT03320902|Behavioral|Sudden death counselling|"The Sudden Death Counselling with included relatives at 1 month (+/-15 days) after the eventafter the event will be at the Europeen Georges Pompidou hospital in Paris.
The purpose of this Sudden Death Counselling is to provide to family members of sudden death victims information, support, referral and follow-up services relating to sudden death and their grief, if needed.
The bereaved people will tell their experience. The Sudden Death Counselling would help them to integrate life's losses by companioning them.
Cardiologist and psychologists will be present to listen to their pain and try to bring comfort by answering to their questionings."
1992483|NCT03320889|Other|Educational Intervention|Patients will be randomized to a group that receives the pamphlets only and a group that receives the pamphlets and has an expert educator review that pamphlets with them and answer questions.
1992485|NCT03320863|Device|Enso device|An active Enso device that delivers neuromodulation therapy.
1992486|NCT03320850|Drug|OnabotulinumtoxinA and Hydrogel admixture|BOTOX® (onabotulinumtoxinA) and Hydrogel admixture administered as a single intravesical instillation
1992487|NCT03320850|Drug|Placebo and Hydrogel admixture|Placebo and Hydrogel admixture administered as a single intravesical instillation
1992488|NCT03320837|Dietary Supplement|Infant formula|Breast milk substitute containing synbiotics
1992489|NCT03320837|Other|Breast milk|Breast milk
1992490|NCT03320811|Other|Data record|
1992491|NCT03320798|Other|Data record|
1992492|NCT03320772|Drug|TMVP1-ICG|Detection of SLN
1992493|NCT03320772|Drug|ICG|Detection of SLN
1992494|NCT03320759|Behavioral|Occupational therapy rehabilitation|Participants in the experimental arm will receive occupational therapy that is individualized to each participant's needs from week 4 post-decompression surgery until week 12.
1992526|NCT03320512|Behavioral|P3+|In P3+, participants receive all of P3 and the ability to text in the app with an adherence counselor, using Next Step Counseling (NSC). NSC is an interactive, client-centered motivational intervention to improve PrEP adherence. Key components of NSC include: review experiences with adherence, exploration of adherence facilitators and barriers, identification of adherence needs, identification of strategies to meet needs, and development of an adherence action plan. Participants will install P3+ on their phone. The adherence counselor feature will be unlocked for those in the P3+ arm. P3+ participants will have 24-hour access to all features of P3+. After intervention completion (month 3), P3+ participants who complete one activity in the app < 2 times per week on average over the intervention period will be eligible for re-randomization to their initial study condition arm or to receive LSPY, a more intensive adherence counseling approach, in order to evaluate the combined approach.
1992527|NCT03320512|Behavioral|Control|Control participants will receive the standard of care for receiving a prescription for PrEP.
1992528|NCT03320499|Procedure|echo doppler at the bed|we practise the echo doppler at the patient 's bed
1992529|NCT03320499|Procedure|echo doppler in the vascular exploration platform|as usual , practising echo doppler in the medical platform
1992530|NCT03320486|Drug|Dapaconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
1992531|NCT03320486|Drug|Ketoconazole|Application of 1 to 3 grams, depending on the lesion extension, per affected foot.
1992532|NCT03320473|Device|IC-8 IOL|The AcuFocus IC-8 intraocular lens (IC-8 IOL) is a one-piece hydrophobic acrylic posterior chamber IOL into which a circular mask with a small 1.36 mm central aperture has been embedded. The IOL mask works by extending the depth of focus and its design is based on the KAMRA corneal inlay, which operates under the principle of small aperture optics.
1992533|NCT03320460|Drug|Propionate clobetasol gel 0.05%|Patients will be treated with Propionate clobetasol gel 0.05% for 30 consecutive days and with placebo laser twice a week. Patients will be instructed to apply the propionate clobetasol gel 0.05% in the entire lesion three times/days. To prevent oral candidiasis, patients will use micostatin solution (Nystatin oral suspension 100,000 USP/ml) once a day during 4 weeks.
1992534|NCT03320460|Device|Photobiomodulation|Patients will be treated with localized PBM with a diode laser with continuous wave (laser λ = 660 nm; power 100mW;radiant energy: 177J/cm2; 5-s exposure time per point and 0.5J of energy per point) applied directly to the surrounding oral mucosa and to the center of OLP, always by the same operator, twice a week for 4 weeks, totaling 8 session. The number of points will be variable according to the lesion size. The output power of the laser equipment will be evaluated using a power meter (Laser Check; MMOptics LTDA, São Paulo, Brazil) before treatment to confirm the effective mean power as well as the doses applied during the procedure.
1992535|NCT03320460|Other|Placebo gel|Placebo gel for 30 consecutive days to mask the treatment
1992536|NCT03320460|Other|Placebo Photobiomodulation|Laser device will be positioned over the lesion but will be switched off to mask the treatment.
1992537|NCT03320447|Drug|lidocaine-prilocaine 5% cream application|The lesions were then cleansed with saline gauze, and a lidocaine-prilocaine 5% cream (EMLA®; Astra Pharmaceuticals, LP, Westborough, MA, USA) was applied to the treatment area for 30 min under occlusion
1992538|NCT03320447|Device|2940-nm Er:YAG AFL pretreatment|After the anesthetic cream was removed, AFL was performed using a 2940-nm Er:YAG AFL (Joule; Sciton, Inc., Palo Alto, CA, USA) with a 500 µm ablation depth, level 1 coagulation, 22% treatment density, and a single pulse
1992539|NCT03320447|Drug|methyl-aminolevulinate application|Immediately after the AFL, a 1-mm thick layer of methyl-aminolevulinate (16% Metvix® cream; PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of the surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm; 3M, Co., Saint Paul, MN, USA) for 3 h, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light.
1992540|NCT03320447|Device|Illuminating using red light-emitting diode lamps|Each treatment area was then separately illuminated using red light-emitting diode lamps (Aktilite CL128; Galderma S.A., Bruchsal, Germany) with peak emission at 632 nm and a total light dose of 37 J/cm2. Areas scheduled to receive MAL-PDT received the second treatment 7 days later. During the illumination, patients were asked to evaluate pain intensity using an 11-point visual analog scale.
1992541|NCT03320434|Drug|PRT 0.5%|Six drops in each eye over a 17 day period.
1992542|NCT03320434|Drug|PRT 1%|Six drops in each eye over a 17 day period.
1992543|NCT03320434|Drug|Patanol|Six drops in each eye over a 17 day period.
1992544|NCT03320434|Drug|Pred-forte|Four drops in each eye over a 3 day period.
1992545|NCT03320434|Drug|PRT 0%|Six drops in each eye over a 17 day period.
1992546|NCT03320421|Radiation|Radiation therapy|"Radiation to the whole breast: 43.5 Gy in 15 fractions in 3 weeks. Simultaneous radiation to the surgical cavity: 49.5 Gy in 15 fractions in 3 weeks.
Intensity modulated radiation treatment is used."
1992547|NCT03320395|Device|Small bowel RFA treatment|"The samples will be spread and fixed using needles. The prototype RFA-SB ablation catheter will be applied by the PI as follows to each section of duodenum, jejunum and ileum.
The treating paddle of the prototype RFA-SB catheter will be pushed on the small bowel mucosa exerting the same pressure that would be applied endoscopically.
12 J/cm2 will be applied every time with a 20 second interval between applications to simulate clinical practice.
There will be two single applications to two separate specimen sites. There will be two double applications to two separate specimen sites. There will be two triple applications to two separate specimen sites. There will be two quadruple applications to two separate specimen sites."
1992548|NCT03320382|Device|Multiple breath washout testing|Multiple breath washout testing will be completed on different devices over time
1992549|NCT03320369|Other|elemental diet therapy|elemental formula
1992550|NCT03320356|Other|the French version of the Oxford Shoulder Score|
1992551|NCT03320343|Other|MRI|3D morphological MRI and diffusion tensor imaging
1992552|NCT03320330|Biological|Anti-SEMA4D Monoclonal Antibody VX15/2503|Given IV
1992553|NCT03320330|Other|Laboratory Biomarker Analysis|Correlative studies
1992554|NCT03320330|Other|Pharmacological Study|Correlative studies
1992555|NCT03320317|Other|Learning session 1|Learn form international report, Explain key interventions, Explain BIC methodology, Retrospective patient record analysis, Team measures
1992598|NCT03319823|Drug|Combination Medication Treatment Group|"Combination Medication Treatment Group: Diabetics or sleep systolic blood pressure of ≥ 140 mm Hg, or awake systolic blood pressure of ≥ 160 mm Hg
Participants will be treated with starting doses of a long acting blood pressure regimen of Telmisartan 40 mg and Amlodipine 5 mg daily
After 2 weeks, the investigators will monitor chemistries/electrolytes with a fingerstick point of care device and repeat ambulatory blood pressure monitoring
If sleep systolic blood pressure is < 120 mm Hg, the investigators will continue treatment and repeat ambulatory blood pressure again in another 2 weeks to assess reproducibility
If sleep systolic blood pressure is > 120 mm Hg, the investigators will increase Telmisartan dose to 80 mg and the Amlodipine dose to 10 mg. Ambulatory blood pressure monitoring will be checked again after 2 weeks of therapy to verify efficacy."
1992599|NCT03319758|Other|Intact labial plate|Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. Thirty patients are recruited. They are divided into two groups: intact labial plate and compromised labial plate.
1992600|NCT03319758|Other|Compromised labial plate|Subjects in need of one implant replacing tooth to be removed in the maxilla within region 13-23 are included. Thirty patients are recruited. They are divided into two groups: intact labial plate and compromised labial plate.
1992601|NCT03318458|Other|Pilates|The duration of the intervention is 12 weeks, with 2 sessions per week of Pilates. Each session lasts approximately 1 hour and is structured in three parts: initial warm-up, which reviews the basic principles of the Pilates Method (centralization, concentration, movement control, breathing, movement precision and fluency) of 10 minutes duration, a 40-45 minute Pilates session and finally 10 minutes of guided relaxation. No complement was used (magic rings, fitball, elastic bands, etc.) during classes
1992604|NCT03319420|Drug|LO2A eye drops|Sodium hyaluronate
1992605|NCT03319420|Drug|Saline Solution|Saline
1992606|NCT03319264|Other|Dynamometry exam|Prehension strength of the main hand will be assessed thanks to dynamometry, in order to evaluate patient's muscular strength
1992607|NCT03319264|Other|Walking test|A 4 metres walking test will be performed to assess patient's walking speed
1992608|NCT03319264|Radiation|DXA measurement|DXA measurement will be performed to assess patient's body composition
1992609|NCT03319264|Other|SARQOL questionnaire|Patient's quality of life will be assessed thanks to the SARQOL questionnaire
1992610|NCT03319264|Behavioral|Life habits Questionnaire|Life habits Questionnaire
1992611|NCT03319134|Device|active HD-tDCS or sham HD-tDCS|1) active HD-tDCS with Retrieval Memory task, 2) sham HD-tDCS with Retrieval Memory task
1992612|NCT03318900|Procedure|Leukapheresis|Blood cells collected to be made into modified CD8+T cells then given back to participant in the treatment part of study.
1992613|NCT03318900|Drug|Utomilumab|Within 24 hours of T cell infusion by vein over 90 minutes, and Dose Level 1 will receive no Anti-CD137, Dose Level 2 0.3 mg/kg by vein over 90 minutes Dose Level 3 1.2 mg/kg by vein over 90 minutes
1992614|NCT03318900|Drug|Cyclophosphamide|Administered at 300 mg/m^2 intravenously 2 days prior to T cell infusion as an outpatient procedure.
1992615|NCT03318900|Biological|T Cell Infusion|Day 0, Administer T cells at a total dose of 10^10 cells/m^2.
1992616|NCT03318900|Drug|Interleukin-2|Low-dose IL-2 (250,000 U/m^2 subcutaneous every 12 hours) begin within 6 hours of T cell infusion and continue for a total of 14 days (28 doses).
1992617|NCT03318770|Drug|Dasatinib and blinatumomab|Patients treated frontline with the sequential administration of dasatinib and the bispecific monoclonal antibody blinatumomab according to the protocol LAL2116
1992618|NCT03318744|Drug|Aspirin|Aspirin is one of the most widely used antithrombotic agents to prevent recurrent ischemic stroke for patients with prior symptomatic ischemic stroke.
1992619|NCT03318744|Drug|Placebo Oral Tablet|Placebo resembling aspirin tablet will be be given to participants in control arm.
1992620|NCT03318705|Device|RS3000Adv|Nidek RS3000Adv device to be used to take images which will allow measurement of vascularization in participants
1992621|NCT03318679|Other|No intervention is planned.|None is planned
1992622|NCT03318601|Procedure|Blood taking|"Blood taking in 2 times :
J0 : 15 mL
J14 : 5 mL 20 mL in total volume"
1992624|NCT03316937|Procedure|Types of scalers|Scaling
1992629|NCT03318107|Device|Transvaginal probe using photoacoustic and ultrasound imaging|-Four optical wavelengths of 730nm, 780nm, 800 nm, and 830 nm will be used to acquire data
1992630|NCT03317977|Behavioral|Reach for Control|In Phase 1 (weeks 1-4), the CHW conducts an initial intake and then completes a comprehensive functional analysis (FA) of behavior to determine the causes of poor asthma management for each youth regarding asthma management. In Phase 2 (weeks 5-20) is a treatment phase and consists of a combination of mandatory cognitive-behavioral skills training (CBST) modules (received by all families) and flexible CBST modules chosen and individualized based on the results of the Phase 1 FA. This includes but not limited to In-vivo Asthma Skills Training, Improving Family Communication and Behavioral Contracting. Phase 3 (weeks 21-24) involves termination planning and relapse prevention
1992631|NCT03317977|Behavioral|MATCH|Managing Asthma Through Case Management in Home (MATCH) is the current intervention provided by WCHAP to youth with poorly controlled asthma and their families.
1992632|NCT03317925|Procedure|Renal Transplantation|Kidney transplantation and biomarkers that can identify injury after transplant.
1993887|NCT03111472|Other|Self-management guide for people with Parkinson's who fall and their informal caregivers|The self-management guide will be developed utilising information from people with Parkinson's, informal caregivers of people with Parkinson's, healthcare professionals and a systematic review of self-management interventions for people with Parkinson's who fall.
1993888|NCT03111420|Drug|P2Y12 inhibitor|Administration of P2Y12 inhibitor antiplatelet therapy
1992643|NCT03317470|Behavioral|Life Navigator|"The life navigator will contact women identified with unmet basic needs within two business days of completing the baseline survey.
The life navigator in our study will: (1) identify and assess women's needs; (2) jointly generate solutions to address the needs; (3) develop plans to carry out the solutions, including; (4) help prioritize among multiple needs; (5) identify community resources that could help solve the problem; (6) determine eligibility for services; (7) help women access available resources by scheduling appointments and provide appointment reminders; (8) prepare women to interact with service agencies and/or act as an advocate on their behalf; (9) provide instrumental support such as arranging transportation; (10) actively intervene to resolve barriers to basic needs solutions; (11) oversee follow-up of problem solving actions; and (12) review progress made towards resolving unmet basic needs and adapt solutions accordingly."
1992644|NCT03317470|Other|Follow-up survey|-5 questions about the acceptability of the basic needs survey
1992645|NCT03317470|Other|Follow-up survey (phase II participants only)|-7 questions about the effectiveness of the life navigator
1992646|NCT03317171|Dietary Supplement|Flavonoids, DHA, EPA|oral administration
1992647|NCT03317171|Dietary Supplement|placebo compound|oral administration
1992651|NCT03317119|Drug|Trametinib|Given PO
1992652|NCT03317119|Drug|Trifluridine/Tipiracil Hydrochloride Combination Agent TAS-102|Given PO
1992653|NCT03317119|Other|Laboratory Biomarker Analysis|Correlative studies
1992655|NCT03317002|Drug|AZD5718|Oral dose of AZD5718 (tablet)
1992656|NCT03317002|Drug|AZD5718|Oral dose of AZD5718 (tablet)
1992657|NCT03317002|Drug|Placebo|Matching placebo (tablet)
1992658|NCT03315338|Drug|CORT118335, 25 mg|CORT118335 is supplied as capsules for oral dosing
1992659|NCT03315338|Drug|CORT118335, dose to be determined|CORT118335 is supplied as capsules for oral dosing
1992660|NCT03315338|Drug|Prednisone Oral Tablet|"Challenge Agent, Dose and Route of Administration:
Standard release 25 mg tablets, orally administered."
1992661|NCT03315338|Drug|Glucose|75 g in 300 mL solution, orally administered
1992662|NCT03315338|Drug|Placebo oral capsule|"Reference Therapy, Dose and Route of Administration:
Placebo capsule, orally administered."
1992669|NCT03316352|Procedure|Ultrasound-assisted paramedian technique spinal anesthesia|Ultrasound-assisted paramedian technique will be used. A preprocedural ultrasound scan will be performed, and skin marking for spinal entry site will be done using ultrasound scan. Spinal anesthesia will be done according to skin marking using ultrasound, via paramedian approach.
1992670|NCT03316352|Procedure|Landmark-guided paramedian technique spinal anesthesia|Landmark-guided paramedian technique will be used. Spinal anesthesia will be done using conventional landmark-guided paramedian technique.
1992671|NCT03316352|Device|Ultrasound|A preprocedural ultrasound scan will be done using Portable Echocardiography system (Vivid-i, GE healthcare) with 4C-RS convex probe (2.0-5.5 MHz Frequency range).
1992672|NCT03316352|Drug|0.5% heavy bupivacaine|During spinal anesthesia, 0.5% heavy bupivacaine will be administered into intrathecal space. The dose of local anesthetic injected for spinal anesthesia will be at the discretion of the attending anesthesiologist. The dose range of intrathecal bupivacaine will be between 12 and 16 mg.
1992731|NCT03309540|Other|Physioterapy intervention|"In the experimental group (EGR), the 4MTOR® treatment method will be used for LBP. This 4MTOR® uses the following steps in a decision tree: T1 Testing (Physiotherapeutic examination), T2 Triggering (Manual Techniques), T3 Taping (Elastic Tape) and T4 Training (medical rehabilitation exercises).
The participants in the SGR received a sham multimodal physiotherapeutic intervention as control intervention, in which Sham technique were applied. The interventions consisted of combining Sham manual interventions, elastic tapes according to Kaze32 and Evidence Based Practice Therapy (Appendix III). The protocol in the SGR follows the similar steps: Testing, Taping, Triggering and Training like the 4MTOR®."
1992732|NCT03308851|Procedure|Piezocorticision|The piezocorticision is a procedure that aims to accelerate the movement of teeth during an orthodontic treatment. It consists of a local anaesthesia followed by an incision of the buccal mucosa and an incision in the alveolar bone with a piezotome.
1992733|NCT03308851|Procedure|Osteoperforation|The osteoperforation is a procedure that aims to accelerate the movement of teeth during orthodontic treatment. It consists of a local anaesthesia followed by perforations of the buccal mucosa and alveolar bone using a specific osteoperforation tool.
1992734|NCT03308396|Drug|Guadecitabine|Days 1-5 Dose 0: 60 mg/m^2 Dose -1: 45 mg/m^2
1992735|NCT03308396|Drug|Durvalumab|Day 8 Durvalumab (1500 mg IV)
1992736|NCT03308695|Drug|CS02 Tablet|Subjects are randomly assigned, in a 1:1:1:1 ratio, to receive the investigational product of CS02 Tablet at a total dose of 450 mg (225 mg BID), 300 mg (150 mg BID), 150 mg (75 mg BID), or CS02 PTM (placebo) Tablet BID daily combined with a stable dose of metformin monotherapy for 12 weeks.
1992737|NCT03308695|Drug|CS02 PTM (placebo)|Tablet BID daily combined with a stable dose of metformin monotherapy for 12 weeks.
1992738|NCT03308695|Drug|Metformin|Tablet BID daily combined with a stable dose of metformin monotherapy for 12 weeks.
1992746|NCT03306732|Drug|Thiamine hydrochloride (200mg) dissolved in 100 ml of normal saline|"After anesthesia induction
After separation from CPB
On the evening of the day of surgery (22:00)
On POD 1 twice a day at 8:00 and 22:00
On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)
On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
1992747|NCT03306732|Drug|Normal saline (100ml)|"After anesthesia induction
After separation from CPB
On the evening of the day of surgery (22:00)
On POD 1 twice a day at 8:00 and 22:00
On POD 2 twice a day at 8:00 and 22:00 (if patient is still in ICU)
On POD 3 twice a day at 8:00 and 22:00 (if patient is still in ICU)"
1992748|NCT03305406|Other|Focus groups|Focus groups will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
1992749|NCT03305406|Other|Interviews|Interviews will be conducted to gather information on clients view of a community support program focusing on healthy infant nutrition
1992750|NCT03305185|Combination Product|Schroth SSE with Bracing|Patients in this group will be prescribed an outpatient-based Schroth exercise program, as per our preliminary study. It consists of an individualised eight-week outpatient program that includes four initial private training sessions, once every two weeks, where exercises will be taught to the patient and their caregivers. A home exercise program will be instituted thereafter and patients will be required to return for supervised sessions once every two months.
1992751|NCT03305185|Device|Bracing alone|Patients in the control group will receive standard level of care for bracing, which consists of education on general exercises for spinal movement, strengthening, and balancing. These patients will only attend study assessments with no extra physiotherapy sessions.
1992752|NCT03304756|Drug|CAP|cisplatin (50 mg/m2) in combination with doxorubicin (50 mg/m2) and cyclophosphamide (500 mg/m2) every 21 days and for a total of 6 cycles
1992753|NCT03304522|Drug|VX-150|1250 mg total dose administered as 250-mg capsules orally
1992754|NCT03304522|Drug|Placebo|Matching Placebo
1992755|NCT03304210|Drug|IV paclitaxel (60 mg/m²)|Paclitaxel (Taxol) will be administered intraveneously. A dose of 60 mg/m² will be administered on day 1, 8, 15, every 4 weeks, 3 cycles.
1992756|NCT03304210|Procedure|PIPAC albumin bound nanoparticle paclitaxel|Albumin bound nanoparticle paclitaxel (Abraxane) will be administered intraperitoneally using the PIPAC technique. The administered dose will be determined in phase I of this clinical trial. PIPAC will be performed on day 21, every 4 weeks, 3 cycles.
1992757|NCT03303651|Procedure|Opioid administration in intervention groups|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by analgesia indices during general anesthesia in the experimental arms.
1992758|NCT03303651|Procedure|Opioid administration in control group|Elective surgery in radical open abdominal prostatectomy. Opioid titration is guided by clinical signs in the control group.
1992760|NCT03303248|Behavioral|Web-based Educational Intervention|A web-based educational tool, created for patients with congenital heart disease, will be given to patients using an ipad. This additional educational tool will be used after the standard of care visit with provider.
1992855|NCT03287622|Behavioral|Educational Intervention|This intervention provides scenario-tailored opioid risk message feedback immediately following interactive analgesic decision-making exercises.
1992856|NCT03287622|Behavioral|Nudge|Behavioral Nudge in this study is a simple, take-home kit (ziplock baggy of used coffee grounds) to be used to dispose of left-over prescription opioids
1992857|NCT03287544|Other|Combined rehabilitation|Linguistic training as well as communication training.
1992858|NCT03287544|Other|Linguistic rehabilitation|Rehabilitation only focused on linguistic processes.
1992859|NCT03287739|Behavioral|Assessment of behavioral biometric impairments|Assessment of behavioral biometric impairments
1992860|NCT03286114|Drug|Pembrolizumab|200mg IV every 21 days
1992861|NCT03285568|Drug|Palbociclib|Observe patients receiving palbociclib for dose adjustment and lab monitoring
1992865|NCT03284424|Biological|pembrolizumab|intravenous infusion
1992866|NCT03284944|Device|Small-Volume|"Small-volume (2 - 3 mL soft-draw Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes."
1992867|NCT03284944|Device|Standard-Volume|Standard-volume (4 - 6 mL Vacutainer tubes, Beckton Dickinson) ethylenediaminetetraacetic acid (EDTA), lithium-heparin, citrate, fluoride and silica tubes.
1992868|NCT03284645|Drug|Tenofovir Disoproxil Fumarate (TDF) 300 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 300 mg TDF, 300 mg 3TC and 600 mg EFV taken once daily.
1992869|NCT03284645|Drug|Abacavir (ABC) 600 mg + Lamivudine (3TC) 300 mg + Efavirenz (EFV) 600 mg|Fixed-dose combination of 600 mg ABC, 300 mg 3TC and 600 mg EFV taken once daily.
1992870|NCT03284645|Drug|Zidovudine (AZT) 300 mg + Lamivudine (3TC) 150 mg twice daily + Efavirenz (EFV) 600 mg once daily|Fixed-dose combination of 300 mg AZT and 150 mg 3TC taken twice daily, plus 600 mg EFV taken once daily.
1992872|NCT03284203|Device|SpiroPD|At the time of their initial study visit, study participants will be given a SpiroPD device for use at home following instruction in the hospital or clinic. Patient adherence to daily testing over one-month will be monitored using real-time capture Wi-Fi-data from the SpiroPD data portal.
1992874|NCT03283709|Device|Full-contour monolithic zirconia abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from monolithic multi-layered zirconia
1992875|NCT03283709|Device|Conventional abutment crowns|Subjects with RPD abutment teeth that require surveyed crowns will have them fabricated from noble or high noble metals, veneered with feldspathic porcelain
1992876|NCT03283722|Device|Profile 3D™ and CG Future® annuloplasty system|Patients suffering from mitral valve disease and indicated for a mitral valve repair procedure with Profile 3D™ and CG Future® annuloplasty system as part of standard of care, in accordance with the product label indications (instructions for use), contraindications, and warnings
1992877|NCT03282006|Drug|pivmecillinam|Oral treatment of bacteremic pyelonephritis following standard initial parenteral treatment
1992878|NCT03281161|Behavioral|Sun Safe Workplaces Program|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection policy promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
1992879|NCT03281161|Behavioral|Attention Control|A follow-up analysis of sun safe practices by employees and an economic evaluation of the SSW intervention was conducted with the work-sites who received occupational sun protection practice promotion materials in the prior trial. The analysis of sun safety practices of employees was done by preparing the protocols and measures for surveying employees and front-line supervisors by online and paper methods. The economic evaluation was a retrospective collection of cost information from the prior project ledgers and an in depth interview with the key contact manager at each work-site. No additional treatment was provided and the groups were evaluated based on their prior condition assignment.
1992880|NCT03282123|Drug|MDMA|80 to 120 mg MDMA
1992881|NCT03282123|Behavioral|Psychotherapy|Non-directive psychotherapy conducted during MDMA-assisted psychotherapy session
1992882|NCT03280563|Drug|Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody|Atezolizumab will be given as 840 milligrams (mg) via intravenous (IV) infusion on Days 1 and 15 of each 28-day cycle. This regimen will apply to all arms except when given with exemestane or tamoxifen in Stage 2, in which atezolizumab will be given as 1200 mg via IV infusion on Day 1 of each 21-day cycle.
1992883|NCT03280563|Drug|Bevacizumab|Bevacizumab will be given as 10 milligrams per kilogram (mg/kg) via IV infusion on Days 1 and 15 of each 28-day cycle in the regimen containing fulvestrant. When given with exemestane or tamoxifen, bevacizumab will be given as 15 mg/kg via IV infusion on Day 1 of each 21-day cycle.
1992884|NCT03280563|Drug|Cobimetinib|Cobimetinib will be given as 60 mg orally once a day (QD) on Days 1-21 of each 28-day cycle.
1992925|NCT03274245|Behavioral|Intervention Package|"Community Level:
Palla: songs and skits to increase knowledge of and motivation for latrine use, pit emptying, safe feces disposal;
Transect Walk: village walk to identify and mark feces in community;
Community meetings: sex-segregated meetings with village members to decide on an action plan to increase community cleanliness/reduce open defecation;
Wall painting: village map noting households that use latrines always.
Sub-Community level:
Mothers meeting: For caregivers with children under age 5, to provide knowledge of and hardware for safe child feces disposal.
Household Level:
Household visits: to those with latrines to motivate use;
Latrine repairs: for households with non-functional latrines to make functional."
1992926|NCT03274245|Other|Qualitative Research|"For villages receiving the intervention package, investigators will engage community members through qualitative interviews to gain their perception of the intervention, what they thought of the intervention activities, what information they recall, what aspects they enjoyed or disliked, if they had barriers to attendance or participation.
For the three villages not receiving the intervention, investigators will conduct qualitative interviews to determine additional barriers and determinants of latrine use to identify other potential intervention strategies."
1992927|NCT03272828|Device|Nobel Biocare titanium dental implants|See above
1992928|NCT03273907|Device|CyPass Micro-Stent implanted with CyPass 241-S applier|CyPass System (Model 241-S) consists of the CyPass Micro-Stent contained in a loading device (loader) and the CyPass applier.The CyPass Micro-Stent is an implantable medical device intended for long term use.
1992930|NCT03271554|Drug|Alectinib|According to local labeling the recommended dose of alectinib is 600 mg given orally, twice daily with food (total daily dose of 1200 mg).
1992932|NCT03272126|Drug|Vitamin D|vitamin D given as bolus versus daily dosing
1992933|NCT03272126|Drug|Placebo|identical looking as vitamin D
1992934|NCT03271983|Drug|Metronidazole gel 1|RLD gel
1992935|NCT03271983|Drug|Metronidazole gel 2|generic gel
1992936|NCT03271983|Drug|Metronidazole cream|generic cream
1992937|NCT03271736|Behavioral|Stepping-in-place exercise with external auditory cues|The stepping-in-place exercise includes 10-session training. In each session, subjects are asked for stepping for 50 steps. In auditory cued condition, the cued frequency is set at 110% of the usual walking cadence. While in non-cued condition, we ask the subjects to step according to their own internal rhythm.
1992938|NCT03271736|Device|Transcranial magnetic stimulation (TMS)|TMS is used to assess the cortical excitability of the motor cortex. The stimulation intensity is set at 130% of the motor threshold in single-pulse condition. In paired-pulse condition, the first stimulus is set at 80% of the motor threshold and the second stimulus is set at 130% of the motor threshold.
1992939|NCT03271502|Procedure|Total intravenous anesthesia|Total intravenous anesthesia with propofol and remifentanil
1992940|NCT03271502|Procedure|Inhalation anesthesia|Inhalation anesthesia with sevoflurane and remifentanil
1992941|NCT03271541|Drug|Bitopertin|Bitopertin will be administered orally once daily at doses up to 120 milligrams (mg).
1992942|NCT03270384|Device|Urotronic Drug Coated Balloon (DCB)|The Urotronic Drug Coated Balloon (DCB) is a guidewire compatible catheter with a tapered atraumatic tip. The distal end of the catheter has an inflatable balloon coated with a proprietary coating containing the drug paclitaxel that facilitates the drug's transfer to the urethral wall upon inflation.
1992946|NCT03270475|Other|exercise training|subjects complete 4-5 weeks of training
1992947|NCT03270852|Device|Enhanced reality|"This prototype is developed by investigators for the first time so that it have no trademark or manufacturer name yet.
The patient sits facing the horizontal desk with the ER therapy device, and then raises the wrist joint to the fixed base. The hand, wrist, and distal forearm to be treated are positioned below the ER medical camera so that the wrist is visible on the screen. Fix the wrist and wrist joint using Velcro. When treating the distal forearm, detach the wrist fixing Velcro."
1992948|NCT03270852|Other|No Enhanced reality|Identical rehabilitation without enhanced reality
1992949|NCT03268850|Other|Standard of Care|All patients participating in the study will continue to receive usual care. Kidney transplant (KT) candidates are advised that live donor kidney transplantation (LDKT) is their best treatment option and are encouraged to initiate living donor (LD) discussions with family members and friends.
1992950|NCT03268850|Behavioral|Wage Reimbursement 1.5|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to $1,500, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.
Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
1992951|NCT03268850|Behavioral|Wage Reimbursement 3.0|"Enrolled KT candidates will be informed that, in addition to the National Living Donor Assistance Center (NLDAC) program, their LD may be eligible to receive reimbursement for wages lost during the donation recovery period - up to $3,000, based on randomization. They will be given information describing the LW program, eligibility criteria, and application process to share with potential LDs. At the time of study enrollment, KT candidates will consent to the LD nurse coordinator informing all of their potential LDs about the study and the potential for reimbursement of LD lost wages.
Reimbursement will occur for those LDs who file an application, provide the required documentation, and meet eligibility criteria."
1992952|NCT03268070|Device|Repetitive TMS over contralateral premotor cortex.|Repetitive Transcranial magnetic stimulation (rTMS) will be applied over contralateral premotor cortex during motor training. TMS uses magnetism to excite neurons near the surface of the brain. Frequency of rTMS: 0.1 Hz; time of rTMS: 50 milliseconds before the onset of movement-related electromyography (EMG); device: Super Rapid 2 Transcranial Magnetic Stimulator.
1993025|NCT03253653|Device|Waterpipe smoking|In a repeated measures design, 50 adult male and female exclusive WP tobacco smokers will smoke WP tobacco weekly over a 3-week study period with 3 WP smoking practices as follows: 1) using room temperature water in the WP jar, 2) adding ice cubes to the water in the WP jar, and 3) using a charcoal-free electronic WP head to heat the tobacco. Six Spot first morning urine samples will be provided by participants. Two urine samples per each of the 3 smoking sessions. Urine samples will be provided on the day of the WP tobacco smoking session and the following day. Physiological measures will be taken at Baseline during the office visit and before and after each of the 3 WP tobacco smoking sessions.
1993026|NCT03254784|Drug|BMS-986165 Capsule|Oral capsule
1993027|NCT03254784|Drug|BMS-986165 Tablet|Oral tablet
1993028|NCT03253471|Drug|AL-611|AL-611 tablets
1993029|NCT03253471|Drug|Placebo|Placebo to Match AL-611
1993030|NCT03253926|Drug|Lorcaserin|Lorcaserin 10mg BID
1993031|NCT03253926|Drug|Placebo|Placebo capsule BID
1993032|NCT03253926|Drug|Marijuana|Smoked marijuana cigarette
1993033|NCT03253913|Drug|Sirolimus|Patients will be on a stable dose of sirolimus prior to enrolling and will continue that throughout the study.
1993034|NCT03253913|Drug|Resveratrol|Escalating doses of resveratrol will be given throughout the study. Patients will start at 250mg daily for 8 weeks, followed by 500mg daily for 8 weeks, and 500mg BID for the last 8 weeks.
1993043|NCT03253991|Device|MRgFUS treatment|ExAblate Transcranial MRgFUS Thalamotomy Treatment of Medication Refractory Essential Tremor Subjects
1993046|NCT03253042|Other|WBV exercise program|The intervention will consist of a 8-week whole-body vibration exercise program with the platform configured at a frequency of 40 Hz and peak-to-peak amplitude of 4 mm. The sessions will be held 2 times a week, consisting of 4 sets of 1 and a half minutes of exercise on the platform. Rest intervals of 1 minute between sets will be respected.
1993047|NCT03253042|Other|Sham WBV exercise program|The intervention will consist of a 8-week exercise program, but the platform will remain off at all sessions. A device will be attached to the side of the platform in order to produce a sound, similar to the sound produced by the vibrating platform when it is in operation.
1993050|NCT03251937|Device|Spectra WaveWriter SCS System|Multiple modalities of stimulation therapy
1993051|NCT03251781|Other|Pulmonary Rehabilitation|Pulmonary rehabilitation program (PRP) was conducted according to the guidelines of the American Thoracic Society/European Respiratory Society (Nici et al., 2006; Spruit et al., 2013). Physical training was conducted over 24 sessions supervised, three times a week. The program included aerobic training in treadmill (with 30 min load determined by the dyspnea sensation - 4 to 6 on the modified Borg scale) and localized training for upper limbs with free weights or elastic bands (movements performed based on the proprioceptive neuromuscular facilitation diagonals, performed in two series, lasting two minutes each) and lower limbs (quadriceps and triceps sural) with free weights and/or in the bodybuilding station.
1993056|NCT03251287|Drug|Sodium Nitrate|Single dose of 14mmol oral inorganic sodium nitrate
1993057|NCT03251287|Drug|Placebo|Single dose of oral matching placebo
1993058|NCT03251287|Diagnostic Test|Phosphorous Magnetic Resonance Spectroscopy|On the first visit day of this arm, participants will be lie inside an MRI scanner to take pictures of the heart. The thigh muscle will then be imaged before, during, and after kicking exercises.
1993164|NCT03240380|Behavioral|joint crisis plan|"Joint crisis plans are consensual written patient-clinic-agreements for future crisis intervention, especially for people with recurring severe mental illnesses. In case of relapse, they provide the hospital with contact information and detailed patient's preferences regarding medical, psychological and psychosocial measures. Thus JCPs aim to implement patient self-determination rights, prevent psychiatric coercion and foster self-management and recovery.
Between the patient and the clinic represented by the attending physician a joint crisis plan is to be negotiated and agreed upon on individual basis as part of inpatient care. If possible this is to be facilitated by peer counselors or another third party. If for an in-patient the process is not completed until the end of the hospital stay it becomes part of regular outpatient aftercare."
1993165|NCT03240380|Behavioral|crisis card|"Crisis cards are credit card-sized booklets to be kept preferably always at hand. They can contain important information: persons to contact, current medication, basic treatment preferences and hints to advance directives or other existing legal documents. They may be of use in the event of a mental health crisis and help to quickly receive appropriate support.
When the in-patient is to be released from the clinic, the attending physician and the patient together fill out a crisis card. Out-patients get their crisis cards during the next routine visit to their clinic doctor's office."
1993167|NCT03240120|Drug|Dabigatran etexilate|Pradaxa 150 mg hard capsules
1993168|NCT03240120|Drug|Tinzaparin|Tinzaparin 175 iu/kg daily will be started after the diagnosis of VTE is confirmed
1993170|NCT03239873|Biological|VARIVAX™ PE34 Process|Varicella virus vaccine live manufactured with a new passage extension process (PE34)
1993171|NCT03239873|Biological|VARIVAX™ 2016 Commercial Process|Varicella virus vaccine live manufactured with the 2016 commercial process
1993172|NCT03239873|Biological|M-M-R II™|Measles, Mumps, and Rubella virus vaccine live
1993173|NCT03239691|Drug|ACT-709478 for oral use|Hard gelatin capsules for oral administration formulated at strengths of 10 mg and 100 mg
1993174|NCT03239691|Drug|Placebo|Matching placebo available as matching capsules for oral administration
1993175|NCT03238235|Drug|givinostat|suspension of givinostat (10 mg/mL)
1993176|NCT03238235|Drug|placebo|suspension manufactured to mimic givinostat
1993177|NCT03236623|Other|Menthol Popsicle|The menthol popsicle composed of 0.05% menthol, 0.05% saccharin, 30ml ultrafiltered water and 2% cereal alcohol. The popsicle will have a support that will assist the patient in the administration of the intervention, giving him autonomy and safety in the application of the intervention.
1993178|NCT03236493|Drug|PF-06700841|PF-06700841 will be administered as tablet
1993179|NCT03236493|Drug|Placebo|Matching placebo will be administered as tablet
1993180|NCT03236571|Device|Rehabilitation program|The rehabilitation program will consist of a Personalized Training Program and a muscle building program.
1993181|NCT03236558|Procedure|Blood collection|Ten cc of peripheral blood will be taken from patients and healthy controls as soon as possible after T1D diagnosis of the former.
1993188|NCT03235076|Drug|BAY1101042|Single oral dose of 10 mg BAY 1101042 (given as 5 mg MR tablets)
1993189|NCT03234959|Device|CareToy intervention|Infants will perform goal directed activities inside the CareToy System
1993190|NCT03234959|Other|Infant Massage|Infants will received IM by their parents
1993194|NCT03234881|Behavioral|MOVE!|Participants randomized to the MOVE! arm will attend 16 weeks of 60-minute weekly groups that are led by a physical therapist, dietician, and/or clinical health psychologist. Clinicians utilize materials available online and encourage the use, but do not require or provide food diaries.
1993195|NCT03234881|Behavioral|MOVE!+gshCBT|Participants randomized to the MOVE!+gshCBT arm will attend the 16 weeks of 60-minute weekly MOVE! Treatment groups, along with 8 individual sessions over a 3-month period. Participants will also be given a patient treatment manual to read at home, food diaries that will be expected to be completed on a daily basis, and partake in a walking program to gradually increase daily physical activity.
1993196|NCT03234777|Behavioral|Whiteboard animation video|Developed via qualitative research with parents of children with acute gastroenteritis.
1993197|NCT03234777|Behavioral|Regular video|Developed by CDC
1993200|NCT03233854|Biological|Chimeric Antigen Receptor T-Cell Therapy|Given CD19/CD22 CAR T cells IV
1993201|NCT03233854|Drug|Cyclophosphamide|Given IV
1993202|NCT03233854|Drug|Fludarabine Phosphate|Given IV
1993203|NCT03233854|Other|Laboratory Biomarker Analysis|Correlative studies
1993204|NCT03233854|Other|Questionnaire Administration|Ancillary studies
1993206|NCT03232827|Behavioral|Flavored-Sweetened Waterpipe Tobacco|Pre-weighed flavored-sweetened waterpipe tobacco will be prepared.
1993270|NCT03222570|Behavioral|Interpersonal Psychotherapy for Depressed Adolescents|IPT-A is an evidence-based intervention that aims to decrease depressive symptoms by helping adolescents improve their relationships and interpersonal interactions. It addresses one or more of four interpersonal problem areas: grief, role disputes, role transitions, and interpersonal deficits. The primary treatment techniques in IPT-A include emotion identification/expression, linking interpersonal events to mood, communication analysis, communication skill building, decision analysis, role playing, and assignment of interpersonal experiments (i.e. homework). In clinical trials, depressed adolescents treated with IPT-A demonstrated fewer depressive symptoms and better psychosocial functioning post-treatment than adolescents in control conditions.
1993271|NCT03222570|Drug|Selective Serotonin Reuptake Inhibitor|Fluoxetine, escitalopram, citalopram, fluvoxamine, or sertraline
1993272|NCT03222570|Other|Usual Care|Therapists will implement therapy procedures that they usually use and believe to be effective in clinical practice. Therapists will use whatever methods they usually use to make decisions regarding the frequency of therapy sessions and whether to refer the adolescent to start an SSRI
1993273|NCT03219879|Behavioral|Telephone-administered continuation therapy|The intervention includes eight therapy sessions of approx. 50 minutes duration delivered over the telephone by trained psychotherapists over a time period of six months. The intervention is grounded in the principles of psychological continuation therapy and relapse prevention, and includes strategies such as transferring helpful elements of acute-phase cognitive-behavioral therapy (CBT) for depression to daily life. T-CT is offered in addition to usual care.
1993274|NCT03219879|Other|Usual care|Usual care without any study-related intervention
1993275|NCT03221283|Behavioral|Music therapy group|The experimental group received 13 group music sessions over a three-month period. Different method of music therapy will be used to improve the emotion experience, emotion regulation, emotional control and emotional expression.
1993276|NCT03221270|Device|tACS (alpha)|Neuroconn DC Stimulator
1993277|NCT03221270|Device|Sham tACS (alpha)|Neuroconn DC Stimulator
1993278|NCT03220581|Behavioral|Referral for care|referral for addictions support
1993279|NCT03220581|Behavioral|Behavioral therapy|therapy focused on monitoring gaming behavior and replacing it with other activities and communication skills
1993284|NCT03219268|Biological|MGD013|Anti-PD-1, anti-LAG-3 bispecific DART protein
1993286|NCT03219047|Drug|Investigator's Choice Drug Therapy|Participants treated with investigator's choice therapy or standard of care.
1993287|NCT03219047|Procedure|Xenograft|Xenograft developed and a suitable drug/regimen tested in the xenograft model.
1993288|NCT03219047|Drug|Xenograft Developed Drug Therapy|"Ibrutinib Exposed Group: If participant relapses on investigator's choice treatment, participant treated with therapy proven to be effective in participant's xenograft.
Ibrutinib Naive Group: Participants who respond but relapse/progress during Ibrutinib therapy, and have xenograft data available, directed to the salvage therapy proven effective in their simultaneous xenograft model."
1993289|NCT03219047|Drug|Ibrutinib|Participants treated with Ibrutinib at standard dose and schedule.
1993290|NCT03218956|Dietary Supplement|Dietary supplement: Protein intake|"Oral consumption of houly experimental meals. Includes 4 meals containing a mixture of free amino acids, carbohydrates from a flavored liquid, fat from corn oil and protein free cookies.
The last 4 meals will in addition contain labelled labelled 13C phenylalanine."
1993291|NCT03217188|Radiation|conventionally fractionated full dose re-irradiation|re-irradiation [70 Gy (RBE) in 2 Gy (RBE) fractions
1993292|NCT03217188|Radiation|hypofractionated palliative re-irradiation|"course or a hypofractionated palliative re-irradiation Quad Shot course (3.7 Gy (RBE) twice daily x 2 days, followed by a 4 week break [+/- 2 weeks], repeated up to 4 cycles)."
1993293|NCT03218683|Drug|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit
1993294|NCT03218683|Drug|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit
1993295|NCT03218683|Drug|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit
1993296|NCT03218683|Drug|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit
1993297|NCT03218683|Drug|AZD5991|AZD5991 will be administered intravenously for 9 cycles (each cycle 21 days) or until patient derives treatment benefit
1993298|NCT03218306|Device|Surgical Pleth Index|Effector site concentration of remifentanil based on SPI
1993299|NCT03218306|Other|Clinical guidance|Effector site concentration of remifentanil based on hemodynamic data
1993300|NCT03216850|Device|Sublingual microcirculation assessment|Non-invasive investigation of the endothelial glycocalyx in the sublingual microcirculation.
1993301|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
1993302|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500 mg|Tablets for oral administration, once daily, once per treatment period
1993303|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
1993304|NCT03216278|Drug|Dapagliflozin/metformin XR 5/500mg|Tablets for oral administration, once daily, once per treatment period
1993305|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
1993306|NCT03216278|Drug|Dapagliflozin/metformin XR 10/1000mg|Tablets for oral administration, once daily, once per treatment period
1993508|NCT03187041|Other|Sensation and Skin Surface Pressures Under Blood-Draw Tourniquets|"Phase 1: Skin surface pressures will be recorded by an investigator during each of the 10 applications of the tourniquet. All 10 tourniquet skin pressure measurements will take place in the Blood Draw clinic at the UCSD Medical Center in Hillcrest on the same day for a subject.
Phase 2: The same 20 subjects will be subjected to a prolonged blood-draw tourniquet application for a duration of 70 minutes. The purpose of phase 2 is to determine whether there is an effect on sensation from prolonged blood tourniquet use. External skin pressures will not exceed 60mmHg. During this prolonged tourniquet application the investigators will monitor changes in hand sensation at 10-minute intervals using Semmes-Weinstein monofilaments on three peripheral nerves of the hand (median, radian, and ulnar)."
1993516|NCT03184558|Drug|BGB324; pembrolizumab|BGB324 is an Axl kinase inhibitor; pembrolizumab is a PD-1 inhibitor.
1993518|NCT03184038|Procedure|Cognitive Assessment|Undergo assessment of neurocognitive function of subjects with 1-4 metastases vs 5-10 metastases
1993519|NCT03184038|Radiation|Stereotactic Radiosurgery|Undergo standard of care (SRS) Stereotactic Radiosurgery
1993520|NCT03184038|Radiation|Stereotactic Body Radiation Therapy|Undergo standard of care (SBRT) Stereotactic Body Radiation Therapy
1993521|NCT03181789|Biological|p24CE1/2 pDNA Vaccine|Administered bilaterally using the Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device
1993522|NCT03181789|Biological|p55^gag pDNA Vaccine|Administered bilaterally using the TDS-IM EP device
1993523|NCT03181789|Biological|IL-12 pDNA Adjuvant|Administered bilaterally using the TDS-IM EP device
1993524|NCT03181789|Biological|Placebo|Administered bilaterally using the TDS-IM EP device
1993525|NCT03181789|Device|Ichor Medical Systems Intramuscular TriGrid Delivery System (TDS-IM) electroporation (EP) device|The TDS-IM EP device will be used to administer study product(s).
1993527|NCT03181516|Biological|Bifidobacterium animalis subsp. lactis BB-12|Bifidobacterium animalis subsp. lactis BB-12-supplemented yogurt
1993528|NCT03181516|Other|Control|Yogurt without Bifidobacterium animalis subsp. lactis BB-12
1993529|NCT03181347|Procedure|RYGB|Roux-en-Y Gastric Bypass
1993530|NCT03181347|Procedure|SG|Sleeve Gastrectomy
1993531|NCT03181347|Behavioral|Dietary and behavioral|Dietary and activity modifications and excludes meal replacement or pharmacologic interventions
1993532|NCT03180762|Drug|JNJ-64140284 0.1 mg|0.1 mg of JNJ-64140284 will be administered as an oral solution.
1993533|NCT03180762|Drug|JNJ-64140284 0.5 mg|0.5 mg of JNJ-64140284 will be administered as an oral solution.
1993534|NCT03180762|Drug|JNJ-64140284 2.5 mg|2.5 mg of JNJ-64140284 will be administered as an oral solution.
1993535|NCT03180762|Drug|JNJ-64140284 10 mg|10 mg of JNJ-64140284 will be administered as an oral solution.
1993536|NCT03180762|Drug|JNJ-64140284 50 mg|50 mg of JNJ-64140284 will be administered as an oral solution.
1993537|NCT03180762|Drug|JNJ-64140284 150 mg|150 mg of JNJ-64140284 will be administered as an oral solution.
1993538|NCT03180762|Drug|JNJ-64140284 (dose to be determined [TBD])|JNJ-64140284 (dose to be determined) will be administered as an oral solution.
1993539|NCT03180762|Drug|Placebo|Matching placebo will be administered.
1993540|NCT03180216|Biological|Virus Specific T cells (VSTs)|"Pediatric and adult patients following any type of allogeneic transplant (HSCT) will receive VSTs as prophylaxis or treatment of reactivation or infection with CMV, adenovirus, EBV, HHV6, BK virus, JC virus, and/or HPIV3). The goal of this cell infusion will be to initiate an immune response against viral infections after HSCT.
VSTs will be generated using clinical grade overlapping peptides (Pepmixes) to directly stimulate PBMCs, growth promoting cytokines and the G-Rex culture device optimized for T cell expansion. Donor T-cells will be stimulated with overlapping peptide libraries encompassing pp65 and IE-1 (CMV), Hexon and Penton (Adenovirus), LMP2 and EBNA-1 (EBV), LgT and VP1 (BK virus), U54 and U90 (HHV6B), and Mat and NP (HPIV3)."
1993584|NCT03170947|Device|Custom Insoles|"Custom insoles will make with CAD-CAM using a laser scanning and casting for its construction. All this needs the assistance of a computer. From the digital image of a positive of the limb in foam the insole will be obtained.
Custom insoles make with direct adaptation technique (TAD) being of pvc resin. Once the resins are cut and with a temperature of 90º, they will be adapted to the foot (which will be protected with a sock) of the patient with the help of a vacuum. To this technique subtalar joint will be in a neutral position and metatarsal joints will be aligned."
1993543|NCT03179202|Device|Peripheral Nerve Stimulation (PNS) System|"The PNS System is an Investigational Device which delivers mild electrical stimulation to the muscles in the low back. The System includes up to four small wires (called Leads) that are placed through the skin into the muscles in the low back. It also includes up to four devices worn on the body that deliver stimulation (called Stimulators)."
1993544|NCT03179904|Drug|FASN Inhibitor TVB-2640|Given PO
1993545|NCT03179904|Other|Laboratory Biomarker Analysis|Correlative studies
1993546|NCT03179904|Drug|Paclitaxel|Given IV
1993547|NCT03179904|Biological|Trastuzumab|Given IV
1993552|NCT03177772|Behavioral|Pre-loss group therapy|The PLGT intervention will include CGGT treatment elements modified to address the pre-loss preparation of caregivers at risk for complicated grief, and will focus on the perceived relationship and attachment status between caregiver and care recipient, how memories of the life together, the illness and the death are interpreted, and strategies for preparing for life without the care recipient. These activities include elements of motivational interviewing, cognitive behavioral therapy and prolonged exposure therapy.
1993559|NCT03176888|Behavioral|Reduced-exertion, high-intensity interval training (REHIT)|As in arm/group description
1993560|NCT03176888|Behavioral|Cognitive behavioral therapy (CBT)|Up to six 30/40-minute sessions of face-to-face psychotherapy will be offered based on a cognitive model of adjustment to cancer utilizing cognitive and behavioral therapy techniques as described by Moorey & Greer (2012)
1993561|NCT03175965|Device|Somatosensory evoked potential|Somatosensory evoked potential on 24, 72 hours after cardiac arrest.
1993562|NCT03175055|Device|Phoenix|The study to assess safety and efficacy of Phoenix medical exoskeleton.
1993563|NCT03175120|Drug|Insulin degludec/liraglutide|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
1993564|NCT03175120|Drug|Insulin degludec|Administered subcutaneously (s.c., under the skin) once daily in combination with metformin for the treatment duration of 26 weeks.
1993565|NCT03175068|Behavioral|CBT|CBT works by changing people's attitudes and their behavior by focusing on the thoughts, images, beliefs and attitudes that are held (a person's cognitive processes) and how these processes relate to the way a person behaves, as a way of dealing with emotional problems.
1993566|NCT03175068|Behavioral|ST|Treatment designed to improve, reinforce, or sustain a patient's physiological well-being or psychological self-esteem and self-reliance
1993568|NCT03174795|Drug|RO7079901|Participants will receive RO7079901 2000 milligrams (mg) IV treatment, three times a day (TID) for up to 14 days.
1993569|NCT03174795|Drug|Meropenem|Participants will receive meropenem 2000 mg IV treatment TID for up to 14 days.
1993572|NCT03174756|Drug|Hypochlorous Acid|Mouthwashes of antiplaque agents
1993573|NCT03174756|Drug|Chlorhexidine|A disinfectant and topical anti-infective agent used also as mouthwash to prevent oral plaque.
1993574|NCT03174756|Other|Placebo|Sterile water as placebo
1993658|NCT03157713|Behavioral|Enhanced Usual Care|Patients will receive a food diary (BookFactory Food Diary), wearable fitness tracker (Fitbit Charge HR), exercise and nutrition education materials (American Heart Association's Walking For Better Health and How to Eat Healthy), and referral information for intensive weight loss programs. This information will comprise these commercial and hospital-based weight loss programs that are evidence-based: Weight Watchers and Jenny Craig; the Veterans Administration's MOVE! and TeleMOVE! programs; Bellevue Hospital's Medical Weight Management Clinic and Intensive Nutritional Treatment programs; and New York University Langone Medical Center's Weight Management Program. We will also provide brief instructions on how to use the food diary and Fitbit Charge HR.
1993659|NCT03157713|Behavioral|Outcome-based Financial Incentives|Patients will receive financial incentives for clinically significant weight loss, as confirmed at monthly weigh-ins. At 30 days, they will receive $50 if they lose ≥1.5% to <2.5% of baseline weight or $100 if they lose ≥2.5% of baseline weight. At 2 months and 3 months, they will receive $50 if they lose ≥2.5% to <5% of baseline weight or $100 if they lose ≥5% of baseline weight. At 4, 5, and 6 months, they will receive $100 if they lose ≥2.5% to <5% of baseline weight or $150 if they lose ≥5% of baseline weight. To employ the behavioral economic concept of regret aversion, patients will be given feedback at each assessment point about incentives they would have received had they achieved a loss of at least 2.5% of baseline weight.
1993660|NCT03157635|Drug|RO7112689|RO7112689 will be administered as per schedule described in individual arm.
1993661|NCT03157635|Drug|Placebo|Placebo will be administered as per schedule described in Part 1 placebo arm.
1993662|NCT03154580|Drug|N-acetyl cysteine|Participants will receive 4 capsules at 11:15am on each experimental session day.
1993663|NCT03155828|Device|CPAP|Women with diagnosed obstructive sleep apnea will be treated using continuous positive airway pressure as per standard of care.
1993677|NCT03155295|Other|Physical reality simulation|Using 3-D printing and polymer technology, the investigators will construct patient specific simulated hydrogel models designed from patients' imaging, incorporating the necessary anatomy, physiology and pathology specific to each patient. These models are constructed at the Laboratory for Simulation-based Translational Research at the Department of Urology. Group 1 urologists will rehearse the minimally-invasive partial nephrectomy (MIPN) surgery using these patient-specific models.
1993678|NCT03155295|Other|Virtual reality simulation|The DaVinci surgical skills simulator system uses a virtual reality surgical simulation platform that encompasses a variety of basic exercises specifically designed to give users the opportunity to improve their proficiency with the da Vinci surgeon console controls and basic robotic surgical skills. All urologists have already completed a basic robotic skills curriculum. Group 2 urologists will complete a refresher module on the virtual reality simulator.
1993679|NCT03155230|Other|no intervention|no intervention
1993680|NCT03155009|Drug|Alectinib|600 mg orally BID with food
1993681|NCT03154736|Other|Interview|Individual interview and group interview Socio-economic questionnaire
1993682|NCT03154567|Drug|Yohimbine|Yohimbine (0mg, 20mg, or 40 mg) will be administered at 11:00am on each of the experimental sessions.
1993683|NCT03154671|Other|Geriatric assessment and management|Each participant will receive a comprehensive geriatric assessment at baseline. Based on the issues identified, a tailored care plan will be developed with the participant to address the issues identified.
1993684|NCT03152552|Drug|LIK066|LIK066 will be supplied in different doses as tablets to be taken orally.
1993685|NCT03152552|Drug|Placebo|Placebo will be supplied as tablets and capsules to be taken orally.
1993686|NCT03152552|Drug|Empagliflozin|Empagliflozin will be supplied as capsules to be taken orally.
1993689|NCT03153267|Drug|Doxycycline 100 MG Oral Tablet bid, 7 days|Patients will receive doxycycline for 7 days.
1993690|NCT03153267|Drug|Doxycycline 100 MG Oral Tablet bid, 14 days|Patients will receive doxycycline for 14 days.
1993691|NCT03153267|Drug|Controls without a history of lyme disease.|No intervention.
1993692|NCT03153163|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered by IV infusion at a dose of 3.6 milligrams per kilogram (mg/kg) of body weight, every three weeks (Q3W) until death, disease progression or unmanageable toxicity.
1993791|NCT03132129|Diagnostic Test|Cardiovascular magnetic resonance (CMR) imaging and magnetic resonance spectroscopy|CMR scanning performed on a 3T MRI scanner. Standardised protocol incorporating cine functional assessment to determine LV mass, systolic function and left atrial volumes; global systolic strain and diastolic strain rates will be assessed by tagging and with tissue tracking analysis from cine images, adenosine rest and stress myocardial perfusion to assess reserve index and qualitative perfusion defects as previously described, aortic distensibility and pulse wave velocity to measure aortic stiffness, delayed contrast enhancement for assessment of LV fibrosis and evidence of previous myocardial infarction. Myocardial and liver triglyceride content will be assessed using the modified Hepafat® sequence or 1H MR spectroscopy at the inter ventricular septum.
1993792|NCT03132129|Diagnostic Test|Transthoracic echocardiography|Comprehensive transthoracic echocardiography, including: tissue Doppler indices of diastolic filling and speckle tracking for systolic and diastolic strain/strain rate, exclusion of valvular abnormalities, assessment of LV size and function.
1993793|NCT03132129|Diagnostic Test|Computed tomography coronary artery calcium scoring|Computed Tomography coronary calcium scoring to assess the presence of subclinical atherosclerosis and allow an estimate of atheroma burden.
1993794|NCT03132129|Diagnostic Test|Cardiopulmonary exercise testing|Physician supervised incremental symptom limited cardiopulmonary exercise tolerance test with ECG and haemodynamic monitoring.
1993795|NCT03131934|Biological|Autologous EBV-CTL transduced with vector SFG-CNA12|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the retroviral vector SFG-CNA12 conferring resistance to tacrolimus
1993796|NCT03131934|Biological|Autologous EBV-CTL transduced with control vector SFG-CNA8|Autologous EBV-specific cytotoxic T-cells (CTL) transduced with the control retroviral vector SFG-CNA8
1993797|NCT03131934|Procedure|Leucapheresis|Patients will undergo an unstimulated leucapheresis to isolate the required immune cells to produce the EBV-CTLs
1993798|NCT03131648|Drug|Tralokinumab|Tralokinumab is a human recombinant monoclonal antibody of the IgG4 subclass that specifically binds to human IL-13 and blocks interaction with the IL-13 receptors. It is presented as a liquid formulation for subcutaneous (SC) administration
1993799|NCT03131648|Drug|Placebo|Placebo contains the same excipients, in the same concentration only lacking tralokinumab
1993800|NCT03131479|Drug|LIK066|LIK066 tablets will be taken orally once daily.
1993801|NCT03131154|Drug|ADX-102 Ophthalmic Solution (0.5%)|ADX-102 Ophthalmic Solution (0.5%) administered for approximately four weeks.
1993802|NCT03131154|Drug|Vehicle of ADX-102 Ophthalmic Solution|Vehicle of ADX-102 Ophthalmic Solution administered for approximately four weeks.
1993803|NCT03129204|Behavioral|SAF-T|The Rosenzweig Center for Rapid Recovery has recently developed an adaptation of their Accelerated Resolution Therapy (ART) for psychological trauma and depression, called Sensation Awareness Focused Training (SĀF-T), as an approach to rapidly eliminate negative biological sensations of stress. SĀF-T is designed to elicit a calming response; interrupt negative thoughts, negative feelings, and negative behaviors; and ultimately serve as a self-management stress reduction tool for individuals.
1993805|NCT03130335|Procedure|BMA Injection|Bone marrow will be aspirated from the iliac crest and injected into the knee.
1993806|NCT03130335|Biological|BMA|Bone marrow will be aspirated from the iliac crest.
1993807|NCT03130257|Diagnostic Test|Blood Pressure Measurement|We are comparing 3 types of measuring blood pressure for making a new diagnosis of hypertension, clinic blood pressure, home blood pressure, and kiosk blood pressure measurements over a 3 week diagnostic time period
1993809|NCT03129178|Dietary Supplement|Concentrated beetroot juice|Acute and chronic supplementation of beetroot juice.
1993810|NCT03129776|Drug|Hyperpolarized 13C-Pyruvate|The new imaging method being tested is called Metabolic MRI, which provides pictures of the metabolism occurring within cancer cells. It also involves injection of a contrast agent, Hyperpolarized Pyruvate (13C) Injection, into the arm vein. The participants will be injected with the study drug at a dose of 0.43 ml/kg and then receive a MRI scan.
1993811|NCT03129776|Drug|18F-FDG|18F-FDG is a radiopharmaceutical used in medical imaging. The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which is correlated with certain types of tissue metabolism, particularly in cancer cells. The participant will be injected with the study drug at a dose of 5 MBq/kg to a maximum of 500 MBq and then receive a PET scan.
1993821|NCT03127514|Drug|AMX0035|AMX0035
1993822|NCT03127514|Other|Placebo|Matching Placebo Comparator
1993823|NCT03126227|Biological|AR101|AR101 powder provided in capsules
1993824|NCT03126227|Biological|Placebo|Placebo powder provided in capsules
1993825|NCT03126786|Drug|IVT aflibercept + SC CLS-TA|IVT aflibercept [2 mg (0.05 mL)] + SC CLS-TA [40 mg/mL]
1993826|NCT03126786|Drug|IVT Aflibercept + Sham SC|Intravitreal aflibercept [2 mg (0.05 mL)] + sham SC
1993827|NCT03126032|Other|GlycoCheck™-System|"Consecutive, sublingual measurements of endothelial glycocalyx with GlycoCheck™-System will be obtained at presentation, as well as during the inpatient treatment of the patients with suspected sepsis.
Blood sample will be drawn in all groups at time of assessment. Besides that, in patients with suspected sepsis blood samples will be drawn for further microbiologic and laboratory analysis at day 1 and day 7 of their hospital stay."
1993857|NCT03117829|Behavioral|Diet and Exercise|Diet and Exercise Study to Improve Brain Blood Flow
1993858|NCT03117660|Drug|Vitamin A|vitamin A daily X3-4 weeks
1993870|NCT03114228|Drug|Midostaurin|Midostaurin 50 mg (two 25 mg capsules) twice a day on days 8-21
1993871|NCT03114657|Drug|Crenezumab|Crenezumab will be administered as IV infusion q4w for 100 weeks.
1993872|NCT03114657|Drug|Placebo|Placebo will be administered as IV infusion q4w for 100 weeks.
1993873|NCT03112889|Drug|Sodium Valproate|Subjects will receive sodium valproate modified release 20mg/kg/day (maximum dose 2.0g/day) administered orally once daily for six months.
1993874|NCT03113695|Drug|Obinutuzumab|obinutuzumab 1000 mg x 8 doses (first dose split on Cycle 1 days 1 100mg and 2 900mg; then day 8 and 15 of cycle 1; then day 1 of cycles 2-6, each cycle being 28 days long)
1993875|NCT03113695|Drug|lenalidomide|lenalidomide PO daily. The starting dose of lenalidomide is 5 mg PO daily. Starting on C2D1, the dose increases every 2 weeks in 5 mg increments to a maximum of 25 mg PO daily. Patients will continue lenalidomide until disease progression, unacceptable toxicity, or subsequent therapy.
1993876|NCT03113695|Drug|HDMP|methylprednisolone 1000 mg/m2 (ie HDMP) on days 1-5 of cycles 1-4
1993878|NCT03112278|Procedure|Ceramic ultrathin occlusal veneers|Severely eroded teeth will be restored with ultrathin occlusal veneers made of ceramic (e.max CAD/Ivoclar Vivadent) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
1993879|NCT03112278|Procedure|Composite resin ultrathin occlusal veneers|Severely eroded teeth will be restored ultrathin occlusal veneers made of composite resin (Lava Ultimate/3M Espe) by technology CAD-CAM bonded to the teeth (0.6 - 1.2 mm thick).
1993880|NCT03112252|Other|no specifications. Depending on the patients|patients with allergic rhinitis
1993881|NCT03111901|Drug|Pembrolizumab|Pembrolizumab solution
1993882|NCT03111901|Drug|Interleukin-2|Interleukin-2 solution
1993903|NCT03107208|Drug|Glargine|A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).
1993904|NCT03107208|Device|Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)|All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.
1993905|NCT03108755|Drug|ASP7713|oral
1993906|NCT03108755|Drug|Placebo|oral
1993907|NCT03108664|Drug|SYL1001 ophthalmic solution|1 drop in the affected eye
1993908|NCT03108664|Drug|Vehicle opthalmic solution|1 drop in the affected eye
1993910|NCT03108170|Other|perineal massage program|The participant will perform digital massage of her perineal area 5 minutes daily starting four weeks before delivery till her actual labour day
1993911|NCT03108170|Other|Pelvic floor muscle exercise program|The participant will perform pelvic floor muscle exercise daily starting four weeks before delivery till her actual labour day
1993912|NCT03108170|Other|Educational pelvic floor dysfunction prevention program|This educational pelvic floor dysfunction prevention program includes instructions about: control of her weight, adequate cleaning for the perineal area, adequate fluid intake, smoking cessation, right posture and frequency of micturition and adequate ingestion of fiber to avoid constipation
1993913|NCT03107884|Drug|Metformin|A clinical oral dose of Metformin will be given to participant daily during bed rest
1993914|NCT03107884|Drug|Placebo|Placebo-comparator. The same quantity of non-active tablets will be given at the same time of day as the Metformin treatment group
1993915|NCT03106987|Drug|Active Comparator: Olaparib tablets|"Olaparib
300mg Olaparib tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
1993916|NCT03106987|Drug|Placebo|"Placebo
300mg placebo tablets taken orally twice daily (except where this dose and formulation was previously not tolerated) until objective radiological disease progression as per RECIST 1.1 or as long as in the Investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria."
1993917|NCT03107377|Drug|Amphora gel|5 g dose applied up to 1 hour prior to coitus
1993918|NCT03107377|Drug|Placebo|5 g dose applied up to 1 hour prior to coitus
1993919|NCT03107819|Diagnostic Test|Plasma and urine metabolomics|Through the use of high-pressure liquid chromatography and mass spectrometry, quantitative measurements of targeted metabolites associated with amino acids, methylation, acetylation and the tricarboxylic acid (TCA) cycle will be analyzed on the blood and urine specimens.
1993924|NCT03105284|Procedure|Liposuction|Fat harvest by liposuction (Colemans method)
1993926|NCT03104686|Other|Short pasta (dry)|50g available carbohydrate of penne pasta
1993927|NCT03104686|Other|Long pasta (dry)|50g available carbohydrate of spaghetti pasta
1993928|NCT03104686|Other|Bread|50g available carbohydrate of bread
1993929|NCT03104686|Other|Glucose|50g available carbohydrate of glucose monohydrate
1993930|NCT03103971|Biological|Autologous Human Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing CD4+/CD8+ T-lymphocytes|Given IV
1993931|NCT03103971|Drug|Cyclophosphamide|Given IV
1993932|NCT03103971|Drug|Fludarabine|Given IV
1993933|NCT03103971|Other|Laboratory Biomarker Analysis|Correlative studies
1993934|NCT03103971|Procedure|Leukapheresis|Undergo leukapheresis
1993935|NCT03103971|Other|Pharmacological Study|Correlative studies
1993936|NCT03103932|Other|Biomarker guided discharge algorithm|participants randomized to the biomarker guided discharge algorithm will follow a pre-determined care pathway for treatment of heart failure symptoms based on admission NTproBNP levels
1993937|NCT03103126|Behavioral|Combined resistance exercise and walking|Combined resistance exercise and walking
1993938|NCT03101592|Other|Three-month ART dispensing|Patients enrolled in the three-month ART dispensing arm will receive a 90-day supply of ART from their provider for the duration of the study.
1993939|NCT03101592|Other|Six-month ART dispensing|Patients enrolled in the six-month ART dispensing arm will receive a 180-day supply of ART from their provider for the duration of the study.
1993960|NCT03099252|Other|Parent-targeted BSweet2Babies video|The video portrays three babies having blood tests while being i) BF, ii) held SSC with the mother, and iii) receiving sucrose. The calming effects of these strategies are powerfully portrayed. Voice-over in user-friendly language explains how parents can help their babies by partnering with clinicians to use these strategies. As per the definition of patient-targeted and mediated interventions, this video is: i) patient (parent)-targeted, as it actively engages parents to improve their knowledge, positively affect their experience (during newborn screening), change their behavior and their baby's outcomes; ii) patient-mediated, as the video enables parents to change health professional behavior.
1993961|NCT03099252|Other|HCP-targeted resources|"publically-available poster developed jointly by the study CoPIs and BFI Ontario
the publically-available webinar presented by the CoPIs"
1993963|NCT03100981|Behavioral|Internet-delivered Mindfulness-Based Cognitive Therapy|"Internet-delivered Mindfulness-Based Cognitive Therapy is a trainer-assisted course based on the manual for Mindfulness-Based Cognitive Therapy for depression. The course consists of 8 modules, one per week, for 8 weeks and one additional week for flexibility for the participants. In total 9 weeks with weekly written contact to the personal instructor.
Each module has an overall theme with written theory, approximately 45 minutes of daily mindfulness practice and other daily assignments with the purpose of strengthening awareness in the everyday life."
1993964|NCT03100981|Behavioral|Waitlist control|"Participants in the control arm of the study will receive treatment as usual, which means that they are not offered interventions targeting psycho-social distress but also not prevented from participating in or seeking other psycho-social treatment during the course of the study.
After the 6-months follow-up time has passed participants will get the opportunity to participate in 8 weeks of therapist-assisted internet-delivered Mindfulness-Based Cognitive Therapy, if the intervention is found efficient."
1993965|NCT03097432|Drug|ORALVAC COMPACT BÄUME|
1993967|NCT03098017|Other|Short pasta (dry)|50g available carbohydrate portion of penne (~71g uncooked) will be cooked according to package instructions and served with 500mL water
1993968|NCT03098017|Other|Long pasta (dry)|50g available carbohydrate portion of spaghetti (~71g uncooked) will be cooked according to package instructions and served with 500mL water
1993969|NCT03098017|Other|Couscous|50g available carbohydrate portion of couscous (~70g uncooked) will be cooked according to package instructions and served with 500mL water
1993970|NCT03098017|Other|Glucose|50g available carbohydrate portion of glucose monohydrate (~55g) will be dissolved in 500mL water
1993971|NCT03096912|Drug|Ribociclib|Ribociclib Oral 600 mg x 1 a day 21 days on 1 week off in 28 days cycles
1993972|NCT03095859|Other|Physical rehabilitation.|Early mobility, aerobic exercise, upper and lower limb strength and flexibility training, trunk mobility and core strengthening, inclusive of respiratory therapy and education.
1993973|NCT03096847|Drug|ribociclib|All patients with oestrogen receptor positive advanced or metastatic breast cancer will be treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient will begin on Study Day 1 and will continue until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
1993974|NCT03096847|Drug|letrozole|All patients with oestrogen receptor positive advanced or metastatic breast cancer will be treated with oral ribociclib at a dose of 600mg daily and oral letrozole 2.5mg daily. The study treatment for an individual patient will begin on Study Day 1 and will continue until 80 weeks after the last patient enrolled the study or until disease progression, unacceptable toxicity, death or early discontinuation from the study for any other reason, whichever occurs first.
1993975|NCT03096847|Drug|goserelin|Premenopausal patients will additionally receive goserelin 3.6mg as monthly implant
1993976|NCT03096808|Radiation|Adaptive Radiotherapy|ART involved modification of the radiation treatment plan during treatment course to account for temporal variations in anatomy due to changes in tumor volume and/or patients' weight loss.
1993977|NCT03096366|Device|Blood flow restriction|With BFR, exercises will be performed at 30% one-rep max with the BFR cuff placed around the proximal thigh and inflated to 80% of limb occlusion pressure (avg: 150 mmHg).
1993978|NCT03096366|Other|Physical therapy|Physical therapy consists of two or three 90-minute sessions per week for 6 weeks and a minimum of 18 visits required for study inclusion.
1993979|NCT03094637|Drug|Azacitidine|75 mg/m2 either by vein over about 10-40 minutes or as an injection under the skin on Days 1-7 of each cycle.
1993980|NCT03094637|Drug|Pembrolizumab|200 mg by vein over about 30 minutes on Day 1 of Cycle 1, and then every 3 weeks after that.
1993984|NCT03094611|Drug|Inotuzumab ozogamicin|Participants receive Inotuzumab Ozogamicin at the dose of 0.8 mg/m2 on Day 1, and 0.5 mg/m2 on Days 8 and 15 of cycle 1. Subsequent cycles consist of Inotuzumab Ozogamicin at the dose of 0.6 mg/m2 on Day 1 and 0.3 mg/m2 on Day 8. A maximum of 6 cycles administered. Cycles are 28 days.
1993985|NCT03094676|Other|Massage|Approximately 12 minutes of massage will be performed in full. The massage will be performed on the lower (anterior) and trunk (posterior)
1993986|NCT03094676|Other|Exercise|A wingate protocol will be performed followed by 10 sets of 10 squats followed by jumps.
1994003|NCT03089424|Device|Placebo PBMT|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (without any dose, 0 J); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (without any dose, 0 J). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 0 J. At the end of the 12 treatment sessions, patients will receive a total dose of 0 J.
1994004|NCT03089424|Device|PBMT active|The PBMT treatments will be performed using the Multi Radiance Medical™ Super Pulsed Laser MR4™ console (Solon, OH, USA), with the LS50 (emitter with an area of 20 cm2) and SE25 (emitter with an area of 4 cm2) cluster probes as emitters. Nine sites will be irradiated at patient's lumbar region: 3 central sites, using the SE25 (3000 Hz of frequency, 3 minutes of irradiation per site, 24.75 J per site, a totalizing 74.25 J irradiated from SE25); and 6 sites in the same direction, but laterally (both sides, 3 at a side), using the LS50 (1000 Hz of frequency, 3 minutes of irradiation per site, 24.30 J per site, a total of 145.80 J irradiated from LS50). Patients will be treated during 12 sessions over a period of four weeks (three sessions/week). At each treatment session, patients will receive a total dose of 220.05 J. At the end of the 12 treatment sessions, patients will receive a total dose of 2640.60 J.
1994005|NCT03086330|Drug|Semaglutide|Semaglutide, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
1994006|NCT03086330|Drug|Placebo|Semaglutide placebo, gradually increased to 1.0 mg, injected once weekly under the skin (subcutaneously, s.c.) for 30 weeks
1994007|NCT03087513|Drug|Sugammadex Injection|1mls per 10kg basis-up to 100kg
1994008|NCT03087513|Drug|Placebos|0.9% saline-1mls per 10kg basis-up to 100kg
1994009|NCT03087071|Drug|Panitumumab|"Cohort 1 and 3: Panitumumab 6 mg/kg by vein on Day 1 of a 14 Day cycle.
Cohort 2: Panitumumab 4.8 mg/kg by vein on Day 1 of a 14 Day cycle."
1994010|NCT03087071|Drug|Trametinib|2 mg by mouth once a day.
1994011|NCT03086655|Behavioral|Tel-me-box with reminder features|Participants will meet with a study staff member to go over their daily routines, including their pill taking schedule, and to work out a plan for tailored reminders. The participant will choose from the reminders available and convey their preferences regarding when reminders should be sent for the TMB. Preferences will be stored in an online secure database. If requested by the participant, the reminder schedule and type of reminder can be reprogrammed by study staff via an online portal. When the reminder is reprogrammed the TMB receives a new configuration SMS to update the device reminder settings.
1994012|NCT03086655|Behavioral|Tel-me-box|Participants receive tel-me-box device with no reminder features added.
1994013|NCT03086317|Device|Standard Catheter-Directed Thrombolysis|Catheter-directed thrombolysis requires placement of a multi-sidehole infusion catheter within the pulmonary arterial thrombus burden, under angiographic guidance. Thrombolytic medications are slowly infused through the catheter, which is left in place for the duration of the treatment. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
1994014|NCT03086317|Device|Ultrasound-Accelerated Thrombolysis|USAT is a modification of standard catheter-directed thrombolysis utilizing a proprietary system of local high frequency, low-power ultrasound to dissociate the fibrin matrix of the thrombus, allowing deeper penetration of lytic medication. The treatment will be performed according to current standard of care and all technical considerations will be left to the discretion of the operator performing the procedure. All follow up is according to standard of care.
1996137|NCT02558062|Other|BAC ONE administration|BAC ONE will be administered to each patient during a bronchoscopy procedure. Fibre-based endomicroscopy and Cellvizio viewer software will be used to detect BAC ONE signal in the distal lung.
1994039|NCT03082313|Behavioral|Movement Intervention|At each visit, the caregiver will be reminded of the infant's movement rate and proportion of unilateral and bilateral movements from the last visit. The research team will help the caregiver to determine possible ways to achieve the goal of 1200 movements per hour of awake time, with 1/3 single leg movements and 2/3 bilateral leg movements. Strategies to increase leg movements will be encouraged based on the infant's developmental level and what they demonstrate a response to, including: shake a toy when infant moves legs, sing a line of a song when infant moves legs, change the position of the infant to encourage more leg movement, or lightly tickle the legs and feet of the infant. The intervention will use the GAME (Goals - Activity - Motor Enrichment) protocol, a motor learning, environmental enrichment intervention that has recently been shown to be effective for improving motor skills in infants at high risk of cerebral palsy compared to standard care.
1994040|NCT03081702|Drug|Hydroxychloroquine|Hydroxychloroquine is approved/used for the treatment of rheumatoid arthritis, and discoid and systemic lupus erythematosus, as well as suppressive treatment and treatment of acute attacks of malaria.
1994041|NCT03081702|Drug|Itraconazole|Itraconazole is approved and used for the treatment of certain systemic fungal infections.
1994043|NCT03080948|Behavioral|survey|Research assessments as part of this protocol will be scheduled during routine clinic visits
1994044|NCT03080948|Other|Saliva samples|Germline DNA analysis
1994045|NCT03081078|Behavioral|Volunteer support|Each participant will be matched with a pair of trained volunteers (under pre-determined safety measures), who will initiate caring contact via telephone or text messages at least twice a month for six months. Participants will be free to respond or not.
1994046|NCT03081078|Other|Mobile app|Participants will receive programmed care messages and reminders of community resources and healthcare contacts on a regular basis. The app will also provide simple self-help mood checking and relaxation exercises.
1994047|NCT03079687|Drug|Olaparib tablets|Patients will receive olaparib tablets 300mg (two 150mg tablets) twice daily.
1994048|NCT03079804|Other|Experimental MWM|Mobilization with Movement
1994049|NCT03079804|Other|Experimental Thrust|Mobilization grade 5 (Thrust)
1994050|NCT03079804|Other|Placebo|Procedures similar to Experimental MWM group, but without aplly any force
1994051|NCT03079037|Device|Stimulation|Traditional deep brain stimulation
1994054|NCT03078855|Dietary Supplement|Vitamin D|vitamin D3 2,000 IU daily
1994055|NCT03078855|Biological|rituximab|375 mg/m2 intravenous weekly
1994056|NCT03078855|Other|Placebo|methylcellulose
1994057|NCT03078608|Behavioral|Mindfulness meditation program (administered via mobile app)|Mobile app-based/online mindfulness meditation program
1994058|NCT03078608|Behavioral|Progressive muscle relaxation (via mobile app)|Mobile app-based/online progressive muscle relaxation program
1994059|NCT03078478|Drug|Insulin degludec|For subcutaneous (s.c., under the skin) injection once daily
1994060|NCT03078478|Drug|Insulin glargine|For subcutaneous (s.c., under the skin) injection once daily
1994061|NCT03077386|Behavioral|Community Health Worker Intervention|Patients will be matched to a CHW from their primary care practice. The CHW will conduct a needs assessment to determine the intensity of intervention and frequency of meetings needed. A CHW may perform any of the following: providing information directly to a patient's health care provider, translating to the patient's language, advocating for the patient, connecting the patient with resources (i.e., social, financial, insurance), helping patients set health--related goals, liaising with a patient's employer to make sure the patient's health needs are met, facilitating health care referrals and appointments, monitoring appointments, and facilitating transportation to appointments. These activities may require the CHW to be physically present at the patient's appointments or have direct contact with the patient's health care provider. Goal setting and social support will be provided in- person or over the telephone using motivational interviewing (MI) principles.
1994064|NCT03076723|Other|Change in shunt opening pressure|An individually determined change in shunt opening pressure is compared to no change in opening pressure.
1994065|NCT03076723|Other|Simulated change in shunt opening pressure|The shunt opening pressure is reset to the same setting.
1994066|NCT03075696|Drug|RO7082859|RO7082859 will be administered at a dose and as per the schedule specified in the respective arms.
1994067|NCT03075696|Drug|Obinutuzumab|Obinutuzumab 1000 mg single dose IV infusion on Day -7
1994068|NCT03075696|Drug|Tocilizumab|Tocilizumab will be administered as an IV infusion as per the methods described in the Summary of Product Characteristics (SmPC) or other similar local prescribing documents.
1994071|NCT03076021|Drug|Isotretinoin|Drug interaction study
1994072|NCT03076021|Drug|dextromethorphan|Drug interaction study
1994073|NCT03076060|Behavioral|Ketogenic diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.
Patients assigned to this arm will follow the KD."
1994074|NCT03076060|Behavioral|Sham Diet|"Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.
Patients assigned to this arm will follow the SD."
1996138|NCT02557581|Other|No training|
1994079|NCT03072758|Behavioral|Men's Club|"Interactive session: This will be a one-day five-hour session that will take place at the church, and will be facilitated by trained lactation nurses. This will involve a maximum of 10 male participants and will occur during the female partner's 3rd trimester. Male partners will (a) complete a structured questionnaire to determine baseline knowledge, attitudes and beliefs about breastfeeding practices, and (b) actively engage in educational information on the benefit of exclusive breastfeeding. At the end of the session, the participants will receive educational pamphlets on breastfeeding to reinforce all the information that had been provided.
Phone call reminders: Participants will receive weekly robocalls during the first six weeks following the birth of the infant to reinforce the benefits of exclusive breastfeeding. This will be an automated service that will deliver the calls at a specific time of the day the participants have indicated on their questionnaire."
1994080|NCT03072589|Drug|Regadenoson infusion|Dose escalation of Regadenoson when given as an infusion
1994081|NCT03068819|Drug|CIML NK Cell Infusion|-Day 0
1994082|NCT03068819|Procedure|CD3+ T Cell Product Infusion|-Day -1
1994083|NCT03068819|Procedure|Peripheral blood draw|-Screening, Day -3 (+/-2), Day 0, Day +7, Day +14, Day +28, Day +50, Day +100, 6 months, 9 months, 12 months, 18 months, 2 years, and at any clinically indicated bone marrow biopsy/aspirate collection
1994085|NCT03070340|Diagnostic Test|Breast Magnetic Resonance Imaging (MRI)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
1994086|NCT03070340|Diagnostic Test|Contrast Enhanced Mammography (CEDM)|All women who are scheduled for a post-NAT breast MRI and mammogram will be asked to enroll in the study. The addition of contrast to the FFDM (CEDM) would be the only intervention.
1994087|NCT03069261|Device|Indocyanine green angiography|
1994088|NCT03066947|Biological|BriaVax™|See above
1994089|NCT03066947|Drug|Cyclophosphamide|Low dose pre-treatment to reduce regulatory T cells
1994090|NCT03066947|Biological|Interferon-alpha-2b|Low dose given in the vaccine site to boost the immune response
1994092|NCT03067974|Drug|Ketamine Hcl 100Mg/Ml Inj|10mg/kg of Ketamine Hcl 100Mg/Ml Inj to be administered intranasally for pediatric procedural sedation
1994093|NCT03067545|Other|Step rate increase|increase the step rate during running by 10% steps per minute
1994099|NCT03066349|Other|Questionnaires|FertiQoL and HADS (Hospital Anxiety and Depression Scale) questionnaires
1994100|NCT03066258|Biological|RGX-314|RGX-314 is a recombinant adeno-associated virus (AAV) gene therapy vector carrying a coding sequence for a soluble anti-VEGF protein
1994101|NCT03066115|Drug|L-NMMA|See arm description.
1994102|NCT03066115|Drug|Ketorolac|See arm description.
1994103|NCT03066115|Drug|Ascorbic Acid|See arm description.
1994104|NCT03066115|Procedure|Intravenous Catheter|Two intravenous catheters will be placed for each study visit. One catheter will be used for the intravenous infusion of study drugs (L-NMMA, Ketorolac, and Ascorbic Acid). The second catheter will be used to draw intermittent blood samples at 8-specific time points throughout each study visit to ensure pharmaceutical efficacy and examine systemic physiologic blood variables of interest.
1994105|NCT03066115|Procedure|Transcranial Doppler Ultrasound|MCAv will be measured via the transtemporal window while BAv will be measured through the transforaminal window with 2-MHz transcranial Doppler ultrasound probes (TCD, Neurovision model 500M, Multigon Industries, Inc.; Yonkers, NY, USA)
1994110|NCT03064308|Other|Exercise Programme|Participants will complete the High-Intensity Functional Exercise (HIFE) programme. The programme improves lower-limb strength, balance and mobility and all the exercises can be performed by the individual at home and with minimal equipment.
1994111|NCT03065387|Drug|Neratinib|"Starting Dose of Neratinib - Dose Escalation Phase: 160 mg by mouth daily in a 28 day cycle.
Starting Dose of Neratinib - Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
1994112|NCT03065387|Drug|Everolimus|"Starting dose of Everolimus - Dose Escalation Phase: 5 mg by mouth every other day of a 28 day cycle.
Starting Dose of Everolimus - Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
1994113|NCT03065387|Drug|Palbociclib|"Starting dose of Palbociclib - Dose Escalation Phase: 75 mg by mouth every other day for 3 weeks followed by a 1-week rest period during each cycle.
Starting dose of Palbociclib - Dose Expansion Phase: Maximum tolerated dose from Dose Escalation Phase."
1994203|NCT03052920|Device|Cochlear implant|Participants who have failed a BiCROS or bilateral hearing aid trial and otherwise meet inclusion criteria will receive a cochlear implant at the poor hearing ear. Post-implant, participants will continue use of a hearing aid at the better ear and the cochlear implant at the poor ear.
1994206|NCT03052465|Other|Test soup meal feeding intervention|Cream of chicken soup (400g) (or mushroom for vegetarians) (Heinz, Wigan, UK) used as a test meal intervention. The nutrient content /100g is: energy (kcal) 51, protein (g) 1.5, carbohydrate (g) 4.7, fat (g) 2.93
1994208|NCT03051945|Drug|Ketamine Hydrochloride|Study drug will be infused while the participant sits or lies in a comfortable position. The dose of ketamine used does not cause unconsciousness but may cause perceptual disturbances.
1994209|NCT03051945|Other|Normal saline|Placebo
1994217|NCT03049306|Drug|Propranolol Oral Tablet|Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)
1994218|NCT03049306|Drug|Placebo Oral Tablet|Patients will receive Placebo tablet at 7 PM before sleep (on CPAP withdrawal nights only)
1994219|NCT03049306|Device|CPAP|Patients will sleep in the lab wearing CPAP
1994220|NCT03047876|Procedure|aortic arch surgery|Children, from neonatal age to late infancy, undergoing aortic arch surgery (n=20) will have cerebral perfusion measurements during surgery, including during the cooling and rewarming phase, whilst on cardiopulmonary bypass and during the recovery period in the intensive care unit
1994221|NCT03048825|Drug|Colchicine|Colchicine 0.5 mg twice daily
1994222|NCT03048825|Drug|Spironolactone|Spironolactone 25 mg once daily
1994223|NCT03048825|Device|SYNERGY Bioabsorbable Polymer Drug-Eluting Stent|Trial participants who receive a SYNERGY™ Bioabsorbable Polymer Drug-Eluting (everolimus) Stent during their index PCI for STEMI will be included in the SYNERGY Stent Registry.
1994224|NCT03048825|Drug|Colchicine-Placebo|Matching Colchicine-placebo twice daily
1994225|NCT03048825|Drug|Spironolactone-Placebo|Matching Spironolactone-Placebo once daily
1996139|NCT02557581|Other|Endurance training|
1996140|NCT02557581|Other|Resistance Training|
1996141|NCT02557581|Drug|Terbutaline|
1996142|NCT02557581|Drug|Clenbuterol|
1994236|NCT03047252|Device|SWORD Phoenix|"SWORD Phoenix will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:
STAGE 1 (Weeks 0-2) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and extensors Ice pack application after each session and throughout the day as needed STAGE 2 (weeks 3-6) Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors and extensors and knee stabilization Progression to standing exercises without support lying, sitting and standing (with support) Exercises with steps Ice pack application after each session and throughout the day as needed STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Multi-directional exercises"
1994237|NCT03047252|Other|Traditional Home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:
STAGE 1 (Weeks 0-2) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Gait training with bilateral support Open kinetic chain exercises without added resistance Strengthening of hip flexors and extensors Ice pack application STAGE 2 (weeks 3-6) Soft tissue massage Active assisted mobilisation of the knee to increase range of motion Open kinetic chain exercises with added resistance, progressing to closed kinetic chain exercises, with strengthening of knee flexors/ extensors and knee stabilisation Gait training with progressive withdrawal of external support Ice pack application STAGE 3 (Weeks 7-8) Eccentric strengthening exercises Exercises involving steps Weight-bearing exercises on uneven surfaces Ice pack application"
1994240|NCT03047148|Other|Data mining from records|The relevant data for this investigation is extracted from the patient records database as well as from the assessment results of the ongoing quality control process that were collected by the nursing staff of the postoperative recovery units.
1994241|NCT03046888|Procedure|Robot assisted pyelolithotomy|A 12-mm camera port is placed at the level of the umbilicus and lateral; this port is moved farther laterally in morbidly obese patients to allow for the instruments to reach the target organs. Two 8-mm robotic trocars are placed under direct vision and a 12-mm assistant port is placed in the midline a 5-8 cm above the umbilicus. For right-sided stones, an additional 5-mm port is placed in the midline just below the xiphoid process for liver retraction. Placement of the trocars can be changed according to surgeon preference. After reflecting the colon medially, the renal pelvis will be dissected and identified, a flexible cystoscope will be inserted via an assisted trocar and introduced into the renal pelvis through a minor incision. The kidney stones will then be extracted with a basket and either removed via the port or placed in a specimen retrieval bag.
1994242|NCT03046446|Drug|FX006 32 mg|Single intra-articular injection
1994243|NCT03044431|Procedure|Cell therapy|Each participant will receive cell therapy with stem cells harvested either from peripheral blood or from bone marrow plus peripheral blood; after harvest, cells are processed and returned to the patient via peripheral circulation on the same day.
1994244|NCT03045549|Device|SWORD Phoenix|"SWORD Phoenix will be used independently by the patients to perform rehabilitation sessions at home, under remote monitoring from the clinical team. A tailored rehabilitation program will be prescribed, based on the following principles:
STAGE 1 (Weeks 0-6) Open kinetic chain exercises without added resistance: lying, sitting and standing (with support) Strengthening of hip flexors and abductors (mainly) Ice pack application STAGE 2 (weeks 7-8) Open kinetic chain exercises with added resistance: lying, sitting (high chair) and standing (with progression to standing without support) Strengthening of hip flexors and abductors (mainly) Ice pack application after each session"
1994245|NCT03045549|Other|Traditional home-based rehabilitation|"Patients will perform 3 weekly rehabilitation sessions, with a duration of 1 hour, for 8 weeks, provided by a physical therapist. The rehabilitation program will respect the following principles:
STAGE 1 (Weeks 0-6) Soft tissue massage Active assisted mobilization of the hip joint to increase range of motion (avoiding internal rotation and adduction) Gait training with bilateral assistive devices Isometric exercises progressing to open chain, low-impact, concentric exercises with strengthening of hip abductors and flexors Ice pack application STAGE 2 (weeks 7-8) Soft tissue massage Gait training with progressive withdrawal of assistive devices Balance exercises with progression to one-leg support Open-chain strengthening exercises against resistance with progression to closed-chain exercises Ice pack application"
1994248|NCT03044782|Other|53-Item Survey|
1994249|NCT03043378|Behavioral|Questionnaires|Participants complete three questionnaires at consultation visit.
1994251|NCT03044158|Device|GeneXpert Omni|Onsite molecular testing with GeneXpert Omni as a replacement for microscopy
1994252|NCT03044158|Behavioral|Process re-design|Research and Uganda NTLP staff will engage health center staff in a discussion of how to re-organize clinical, laboratory and pharmacy services to enable same-day TB diagnosis and treatment.
1994253|NCT03044158|Other|Performance Feedback|Feedback of TB diagnostic evaluation quality indicators to health center staff
1994254|NCT03044106|Procedure|CLRT|CLRT is a novel method of laser stimulation on specific cranial reflex points that modulate muscle tone.
1994404|NCT03014960|Other|Online Cognitive Behavioral Therapy for Insomnia (CBT-I)|CBT-I is a psychological treatment designed to break the patterns of maladaptive thinking and behavior that maintain insomnia. CBT-I includes a range of techniques including a behavioral component (stimulus control, sleep restriction, relaxation) combined with a cognitive component (managing sleep related worries, the racing mind and intrusive thoughts) and an educational (sleep hygiene) component.
1996143|NCT02557581|Drug|Placebo|
1994255|NCT03044106|Device|Thor LX2 /810nm 200mW Single Probe Laser|"The treatment device to be used in this study is a Class IIIB 810nm 200mW near-infrared GAAlAS diode laser (THOR Photomedicine Ltd, Great Britain) that is currently marketed in the US. The laser probe is FDA-cleared and classified as a non-significant risk device. The spot size is 0.0364 cm2, and the treatment time is 30 seconds. Since the CRP is a line of 2 cm, for the purposes of calculating dosage, we will treat it as a series of 10 connected points each with a diameter of 2mm. With the scanning rate of 2cm/s, each point on the line will receive 1/10 of each pass, totaling 3s (out of 30s total) exposure time per point. The dose per point for this intervention is calculated to be approximately 1.65 J/cm2."
1994256|NCT03043833|Behavioral|The Wellbeing Course|"The Wellbeing Course (Titov et al., 2011) includes five online lessons:
Lesson 1 presents information on the prevalence of anxiety disorders and depression as well as on how they may interfere with life goals. This lesson also discusses how cognitive, behavioral and physical symptoms can contribute to poor emotional health.
Lesson 2 presents different strategies to generate realistic cognitions.
Lesson 3 describes strategies for physical de-arousal and for re-engaging in reinforcing activities.
Lesson 4 describes avoidance and safety behaviors in relation with anxiety and depression along with graded exposure.
Lesson 5 is about problem solving, relapse prevention and staying well.
For each lesson, a Do It Yourself guide is included as well vignettes and additional material."
1994257|NCT03043651|Drug|Oral Treprostinil|Sustained-release oral tablets for TID administration
1994258|NCT03043313|Drug|ErbB-2 Inhibitor ARRY-380|Given PO
1994259|NCT03043313|Other|Laboratory Biomarker Analysis|Correlative studies
1994260|NCT03043313|Biological|Trastuzumab|Given IV
1994261|NCT03043248|Drug|TRK-700|repeated oral administration
1994262|NCT03043248|Drug|Digoxin|single oral administration with/without TRK-700
1994263|NCT03043248|Drug|Midazolam|single oral administration with/without TRK-700
1994264|NCT03042416|Drug|18F-DOPA|18F-DOPA intravenous injection single dose
1994265|NCT03041844|Device|Low Frequency, Low Intensity Ultrasound|Therapeutic ultrasound (20 kHz, <100 mW/cm2 spatial peak-temporal peak)
1994266|NCT03041844|Device|Sham Applicator|Sham ultrasound applicator
1994267|NCT03041233|Other|Observation / Data Collection|"The following data will be reviewed / collected:
BASELINE VISIT: Patient demographics; Atrial fibrillation History; Cardiovascular history; Cardiac medical history.
ABLATION PROCEDURE: Devices used; Ablation parameters; Ablation success definition and result; Operator feedback (Device combination chosen, device maneuverability, ease of use in combination with other device); Number, experience and type of attending personnel; Definition of standard of care (follow-up procedures and occurrence).
6 and 12 MONTH FOLLOW-UP (+/- 30 DAYS): Recurrence of atrial arrhythmias: list of atrial arrhythmias since last visit, classify episodes, duration of the episodes; Changes in therapy; In case of Repeat Ablation Procedures, reconnections and new ablations will be recorded."
1994268|NCT03040466|Device|reusable fiberoptic ureteroscope|We will use reusable fiberoptic ureteroscopes for the treatment of kidney and ureter stones.
1994269|NCT03040466|Device|reusable digital ureteroscope|We will use reusable digital ureteroscopes for the treatment of kidney and ureter stones.
1994270|NCT03040466|Device|disposable digital ureteroscope|We will use disposable digital ureteroscopes for the treatment of kidney and ureter stones.
1994271|NCT03041116|Drug|fosmetpantotenate (RE-024)|Daily dosing
1994272|NCT03041116|Drug|Placebo|Daily dosing
1994273|NCT03039205|Drug|Clopidogrel|Clopidogrel 600 mg loading dose + 75 mg q.d. for 7 to 9 days
1994274|NCT03039205|Drug|Ticagrelor|Ticagrelor 180 mg loading dose + 90 mg b.i.d. for 7 to 9 days
1994275|NCT03039855|Device|TIARA valve and transapical delivery system|Transcatheter mitral valve replacement
1994276|NCT03039569|Behavioral|Text messaging|"The messages will consist of information on how to increase fruits and vegetables and reduce high-fat and sugary foods intake, increase the availability of fruits and vegetables and reduce high-fat and sugary foods in the home, strategies to increase diabetes self-management skills, and awareness of cardiovascular disease risk perception and knowledge. The text messages will be derived from the American Association of Diabetes Educator (AADE) handouts (Reducing Risks, Monitoring, Healthy Coping, Problem Solving, Taking Medication, Healthy Eating, and Exercise). The control group will not receive text messages"
1994277|NCT03039244|Other|Photodynamic therapy|After Scaling and root planing, periodontal pockets will receive the antimicrobial (aPDT) photodynamic therapy. Shortly phenothiazine hydrochloride photosensitizing is applied at a concentration of 10mg/mL from the pocket bottom to the gingival margin. After 1 minute, irrigation is performed from periodontal pockets with distilled water to remove excess dye. The stained area is then irradiated with a diode laser with 660 nm of wavelength and maximum power of 60 mW/cm², through a fiber-optic probe of 0.6 mm diameter. Exposure to radiation will occur at six sites per tooth under treatment, making the total time of 1 minute per element, or the equivalent of 10 seconds per site. The aPDT applications will be repeated in the same way until the second week in the days 2, 7 and 14.
1994278|NCT03039244|Other|Control Group|A sham procedure will be held simultaneously in pairs of contralateral teeth selected that will not receive the aPDT (control group).
1994279|NCT03039244|Device|Diode Laser|
1994280|NCT03037931|Drug|Ferric carboxymaltose|Intravenous Iron
1994281|NCT03037931|Drug|Placebos|Normal Saline Solution
1994282|NCT03038477|Drug|Durvalumab|1500mg of Durvalumab will be given every 4 weeks (Q4W) for 12 months in patients enrolled in Arm A.
1994283|NCT03037697|Other|TheraTogs Arm|TheraTogs Arm Received Soft Orthotic undergarments
1994284|NCT03037697|Other|Traditional Treatment|"Traditional treatment to Dyskinetic CP
1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board"
1994285|NCT03037671|Device|Continuous Glucose Monitor (CGM)|Participants will wear the continuous glucose monitor (GCM) device during the peri-HSCT period for the duration of their initial hospital admission. No intervention based on results.
1994286|NCT03037580|Drug|Oral treprostinil|Sustained-release oral tablets for TID administration
1994287|NCT03037580|Drug|Placebo|Placebo (sugar pill) for TID oral administration
1994288|NCT03035474|Other|Digital Engagement|Patient engagement to improve self-management/medication adherence
1994359|NCT03021187|Drug|semaglutide|Oral semaglutide administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
1994360|NCT03021187|Drug|semaglutide|Oral semaglutide (3 mg followed by 7 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
1994361|NCT03021187|Drug|semaglutide|Oral semaglutide (3 mg followed by 7 mg and finally 14 mg) administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
1994362|NCT03021187|Drug|placebo|Oral semaglutide placebo administered once-daily for 52 weeks as an add-on to the subjects' pre-trial insulin treatment
1994363|NCT03021057|Drug|pembrolizumab|200mg i.v. once every 3 weeks Number of Cycles: until progression or unacceptable toxicity develops
1994366|NCT03019926|Biological|Hydroxychloroquine dosage|Blood sample from a 6 ml tube, performed in the common practice.
1994367|NCT03019666|Biological|Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer Cells|"Cyclophosphamide 40 mg/kg x 1 day on Day -5
Fludarabine 25 mg/m^2 x 3 days (Day -5, Day -4, day-3)"
1994374|NCT03019016|Procedure|Right Colectomy|Robotic-assisted or laparoscopic right colectomy with intracorporeal or extracorporeal anastomosis either on or proximal to midtransverse colon.
1994375|NCT03019055|Biological|CAR-20/19-T|"CAR-20/19-T cells will be administered by IV injection. Patients will receive one of four dose levels based on the study schema. Cells will be given over 2 days, 30% on Day 0 and 70% on Day 1
Dose Level -1: 1.0 x10e5 CAR-20/19-T cells/kg
Dose Level 0: 2.5 x10e5 CAR-20/19-T cells/kg
Dose Level 1: 7.5 x10e5 CAR-20/19-T cells/kg
Dose Level 2: 2.5 x10e6 CAR-20/19-T cells/kg"
1994376|NCT03017456|Behavioral|Survivorship Care Plan|"SCP-Intervention: Patients in the SCP-Int arm will attend a one-time appointment with a trained oncology nurse while the patients in the UC arm will receive care according to the hospital standards for follow-up care. The intervention will be delivered during a regular follow-up appointment, face-to-face and will inform and educate patients on self-management and support as well as promote access to and coordination of post-treatment care. The appointment will focus on empowering the PC survivor to actively self-manage persistent treatment effects and to decrease their risk of late effects by providing effective health information, support, and self-management support. Nurses will integrate a number of active behavior change ingredients including the integration of motivational interviewing techniques which are effective in increasing healthy behaviors."
1994387|NCT03015246|Drug|Buprenorphine-Naloxone|To blind the varying maintenance doses, on each protocol day the participant will always take a total of 4 tablets at the same time, with a mixture of active and placebo tablets. Total daily doses will differ, depending on the periods/weeks within each study phase.
1994388|NCT03015246|Drug|Morphine|During each participant's first experimental week, one morphine dose will be administered orally at 9:00 pm the evening prior to each of the 3 inpatient experimental sessions.
1994389|NCT03015246|Drug|Yohimbine|Yohimbine (or matching placebo)will be administered at 12:00pm on each of the experimental sessions.
1994390|NCT03015246|Drug|Hydrocortisone|Hydrocortisone or matching placebo will be administered 45 min after Yohimbine.
1994391|NCT03015246|Drug|Matching Placebo for Yohimbine|Yohimbine (or matching placebo) will be administered at 12:00pm on each of the experimental sessions.
1994392|NCT03015246|Drug|Matching Placebo for Hydrocortisone|Hydrocortisone or matching placebo will be administered 45 min after Yohimbine.
1994393|NCT03016260|Biological|Infliximab|Anti-TNF alpha originator
1994394|NCT03016260|Biological|Adalimumab|Anti-TNF alpha originator
1994395|NCT03016260|Biological|Etanercept|Anti-TNF alpha originator
1994396|NCT03016260|Biological|Golimumab|Anti-TNF alpha originator
1994397|NCT03016260|Biological|Certolizumab Pegol|Anti-TNF alpha originator
1994398|NCT03016260|Biological|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilars
1994399|NCT03016260|Biological|Etanercept biosimilar|Anti-TNF alpha Etanercept biosimilar
1994400|NCT03016260|Biological|Infliximab biosimilar|Anti-TNF alpha Infliximab biosimilar
1994464|NCT02997202|Drug|gilteritinib|oral
1994465|NCT02997202|Drug|Placebo|oral
1994466|NCT02997085|Device|Live-Action 360° Video Virtual Reality|360° Video Virtual Reality (VVR) is made by filming with multiple HD cameras carefully arranged to capture all angles in a 360° area of a live action event. Then those angles are stitched together in post-production into a 360-degree texture sphere and the sphere is then mapped to the head tracker on the users head mounted display (HMD). Leading to the effect that when a user turns his head, the user's view of the live action video footage turns with them in real time allowing the user to look around anywhere in the 360 degrees of filmed footage of the live action event. Participants randomized to the Live-Action 360° VVR group will be outfitted with a Samsung Gear VR HMD and will view a 9-minute live-action 360° VVR video. The 9 minutes of footage will be alternating 30 second clips of central Texas locations.
1994467|NCT02997085|Device|CGI 360° Video Virtual Reality|Participants randomized to the CGI 360° VVR condition will also be outfitted with a Samsung Gear VR head mounted display. Participants will view the same content for the same duration as in the Live-Action 360° VVR condition, but the footage will be animated instead of live-action footage.
1994468|NCT02996266|Device|Targeted Temperature Management|Prophylactic normothermia
1994469|NCT02996266|Other|Standard Care|No intervention to control temperature unless fever occurs
1994470|NCT02996110|Biological|Nivolumab|
1994471|NCT02996110|Biological|Ipilimumab|
1994472|NCT02996110|Biological|Relatlimab|
1994474|NCT02995707|Drug|Thalidomide|thalidomide:50mg/d p.o at bedtime
1994475|NCT02994914|Other|Onco Geriatric Evaluation|"Seven tests will be performed by an onco geriatrician : Activities of Daily Living, Instrumental Activities Of Daily Living, Mini Mental State Examination, mini Geriatric Depression Scale, Mini Nutritional Assessment, Cumulative Illness Rating Scale-Geriatric, and  timed get up and go  tests. Those tests lead to a score, and this score will determine the scheme of patients radiotherapy."
1994476|NCT02993432|Device|Foley catheter filled to 80cc|A Foley catheter is inserted through the cervix and filled to 80cc
1994477|NCT02993432|Drug|prostaglandin of the clinician's choice|Insertion of the prostaglandin (Prostin (1mg dinoprostone vaginal gel) or Cervidil (10mg vaginal slow release insert)) of the clinicians choice into the vagina for the purpose of cervical ripening
1994478|NCT02993107|Biological|AR101|AR101 powder provided in capsules & sachets
1994479|NCT02994251|Drug|gemcitabine|1000 mg/m^2 of gemcitabine on Day 1 and 8, Dosages may be modified or delayed due to toxicities
1994480|NCT02994251|Drug|Cisplatin|25 mg/m^2 on Day 1 and 8, Dosages may be modified or delayed due to toxicities
1994481|NCT02994251|Drug|Conventional TACE (transarterial chemoembolization) with Doxorubicin/Mitomycin-C|If conventional transarterial chemoembolization (TACE) is warranted based on MRI assessment and the patient meets all the eligibility criteria for TACE therapy, then cTACE will be scheduled to take place during Week 3 of that cycle. Patients will always receive the first cTACE for study; follow-up cTACE will occur on demand.
1994490|NCT02992002|Other|Fluid Challenge|Infusion of a standardized amount of crystalloid solution (500 ml) to assess fluid responsiveness by means of changes in cardiac output, assessed by transpulmonary thermodilution.
1994491|NCT02991911|Biological|MEDI3726 Post-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, with a prior taxane-based chemotherapy in the mCRPC setting
1994492|NCT02991911|Biological|MEDI3726 Pre-Chemo|Single agent MEDI3726 after abiraterone or enzalutatmide, without a prior taxane-based chemotherapy in the mCRPC setting
1994493|NCT02991911|Biological|MEDI3726 & Enzalutamide Combo|MEDI3726 in combination with Enzalutatmide after prior treatment with abiraterone, with or without a prior taxane-based chemotherapy in the mCRPC setting
1994494|NCT02991326|Other|Osteopathic Manipulative Treatment|"The Osteopathic manipulative treatment will follow the approach bellow;
Fourth Ventricle Compression;
Temporal release, Masseter release, Lateral pterygoid release -intraoral approach making use of latex glove;
Pterygopalatine suture technique;
Sphenopalatine ganglion technique;
Sphenopalatine ligament technique;
Pterygomandibular ligament technique;
Craniosacral balancing;"
1994630|NCT02964143|Device|Cellular Matrix / A-CP HA|Treatment with 2 injections of Cellular Matrix / A-CP HA Kit, administered 2 months apart; Cellular Matrix / A-CP HA Kit is designed for the safe, rapid and extemporaneous preparation of a cellular matrix of autologous PRP combined with HA. The Cellular Matrix / A-CP HA Kit is a single-use medical device including hematology tubes (A-CP HA tube), designed for blood collection and PRP/HA preparation after 5 min centrifugation. This tube contains a non-crosslinked hyaluronic acid (MW 1550 kDa) solution, a gel acting as a cell separator, and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components. The HA, which migrates to the top of the gradient during centrifugation, can be mixed with PRP in order to give rise to a ready-to-use PRP/HA preparation.
1994631|NCT02964143|Device|Ostenil® Plus|Treatment with 2 injections of Ostenil® Plus, administered one week apart; Ostenil® Plus is a solution of sodium hyaluronate obtained by fermentation, containing 0.5% mannitol, a free radical scavenger, which helps to stabilize the chains of sodium hyaluronate. The product is intended to be used for pain and restricted mobility in degenerative and traumatic changes of the knee joint.
1994632|NCT02964143|Device|RegenKit-BCT-1|Treatment with 2 injections of RegenKit-BCT-1, administered 1 month apart; RegenKit-BCT-1 is designed for the safe, rapid and extemporaneous preparation of autologous platelet-rich plasma. RegenKit-BCT-1 is a single-use medical device including an hematology tube (Regen BCT tube), designed for blood collection and PRP preparation after 5 min centrifugation, and all necessary material for venipuncture and PRP injection. The Regen BCT tube contains a gel acting as a cell separator and a sodium citrate acting as an anticoagulant. During centrifugation, the separator gel moves to form a barrier that separates red blood cells from other blood components.
1994633|NCT02963922|Drug|Liraglutide 3.0 mg|Injected subcutaneously (s.c., under the skin) once daily
1994634|NCT02963922|Drug|Placebo|Injected subcutaneously (s.c., under the skin) once daily
1994639|NCT02963181|Drug|Yohimbine|Oral Yohimbine will be used to identify the integrity of post-ganglionic sympathetic nerves in patients with NOH
1994640|NCT02963181|Drug|Melatonin|"Monitor the effects of melatonin on supine hypertension in NOH patients with intact and denervated post-ganglionic nerves.
Identify the mechanistic pathway of melatonin in blood pressure regulation"
1994644|NCT02960542|Behavioral|HELP Prevent Cancer Intervention|This Behavioral: Lifestyle Weigh Loss Intervention involves a dietary weight-loss program and an increase in caloric expenditure through moderate physical activity. The primary treatment objectives for the weight-loss component of the intervention will be to decrease caloric intake in a nutritionally sound manner so as to produce a weight-loss of .3 kg/week for a total weight loss of 5-7%. The primary objective for the physical activity component of the intervention will be to promote an increase in home-based energy expenditure to an eventual goal of 180 minutes/week.
1994645|NCT02959528|Other|Working memory training|n-back training program
1994646|NCT02959528|Other|perceptual training|visual-perceptual training program
1994647|NCT02957955|Behavioral|High-Intensity Interval Training|Participants will complete supervised exercise sessions. Participants will attend on-site high-intensity interval training two times weekly for 12 weeks. Participants will complete six-minute walk test, cardiopulmonary exercise test, and six questionnaires: Short Form 36 Health Survey Questionnaire (SF-36), Minnesota Living with Heart Failure Questionnaire (MLHFQ), Beck Depression Inventory II (BDI-II), Beck Anxiety Inventory (BAI), Montreal Cognitive Assessment (MOCA), and Impact of Events Scale-Revised (IES-R) at baseline (week 1) and follow-up (after 12 weeks of intervention).
1994650|NCT02958527|Drug|venlafaxine|The usual adult starting dosage for oral use is 37.5 mg of venlafaxine once daily, which is increased to 75 mg once daily after a meal from 1 week later. The dose may be adjusted within a range not exceeding 225 mg/day according to the patient's age and symptoms. However, the dose should be increased by 75 mg/day at intervals of not less than 1 week.
1994654|NCT02956291|Device|Magnetic Resonance Fingerprinting|Non-contrast MRF acquisition will be acquired through the region of tumor in all patients. For patients receiving intravenous gadolinium based contrast, a post contrast MRF acquisition will also be acquired. This acquisition will be skipped in patients who do not receive or are not eligible for receiving IV contrast as a part of their clinical scan. The research scan will take approximately 10-15 minutes
1994662|NCT02950961|Behavioral|Collaborative Care for Women Veterans|This is a collaborative care model that focuses on identifying need for depression and/or anxiety care. Patients with possible anxiety and/or depression are referred to a care manager in primary care-mental health integration. The care manager then conducts a thorough assessment, offers the patient a variety of appropriate treatment options, and works with the patient to determine a care plan. One of the key options the investigators will be offering in this study is the Calm Tools for Living (CALM) intervention, which is focused on anxiety and which is rooted in patient preferences. Patients can choose web-based cognitive behavioral therapy (CBT) and/or pharmacologic treatment. In this study the investigators will be training appropriate MH providers in CALM and studying the ways in which the intervention needs to be tailored to women Veterans. The investigators will also examine the relative importance of patient preference with regard to engagement and retention in care.
1994663|NCT02950545|Device|Placebo Lenses|AcuVue Oasys Bandage Lenses with no prescription
1994664|NCT02950545|Device|Spherical Lenses|1-DAY ACUVUE® MOIST contact lenses
1994665|NCT02950545|Device|Toric Lenses|1-DAY ACUVUE® MOIST for ASTIGMATISM contact lenses
1994666|NCT02950454|Other|High intensity interval training|1.5 min intervals at 80-95% heart rate max on cycle ergometer 1.5 min intervals at nominal resistance on cycle ergometer
1994667|NCT02950454|Other|Continuous moderate exercise|20 min at 60-70% heart rate max on cycle ergometer
1994668|NCT02949050|Biological|subcutaneous allergen immunotherapy (SCIT)|20 patients who (prior to study enrollment and initiation) completed more than 1 year of timothy grass SCIT vs. 20 control patients who underwent corn pollen exposure for for greater than one year during the same prestudy time interval. Efficacy will be assessed by analyses of symptom score surveys and quality of life surveys.
1994669|NCT02949050|Biological|SCIT|Treatment group consists of patients who completed > 1 year of SCIT while control group patients did not undergo SCIT
1994670|NCT02948959|Drug|Dupilumab|Pharmaceutical form:Solution Route of administration: subcutaneous
1994671|NCT02948959|Other|Placebo|Pharmaceutical form:Solution Route of administration: subcutaneous
1994672|NCT02948959|Drug|Asthma Controller Therapies (incl. prednisone/prednisolone)|Pharmaceutical form:Aerosol, capsules, tablets, oral solution Route of administration: inhaled, oral
1994673|NCT02948959|Drug|Asthma Reliever Therapies|Pharmaceutical form:Nebulized, aerosol Route of administration: inhaled
1994674|NCT02948816|Behavioral|Facebook|Participants will spend 30 minutes on a Facebook page that is primarily non-food related posts.
1994675|NCT02948816|Behavioral|Facebook + Food|Participants will spend 30 minutes on a Facebook page that is food related posts.
1994676|NCT02948816|Behavioral|Colouring|Participants will spend 30 minutes colouring quietly.
1994677|NCT02947841|Other|Alternating stimulation|Two different, but equally efficacious, settings will be determined for each subject. The settings will differ by a minimum of two of the following parameters: electrode configuration, voltage, frequency and pulse width. The different settings will be named Setting A and Setting B. The treatment cohort will receive both Setting A and Setting B that will differ by the parameters listed above.
1994678|NCT02947841|Other|Placebo|The control cohort will receive Setting A but Setting B will be identical to Setting A.
1994681|NCT02946021|Device|Head and neck garments for pneumatic compression device.|Pneumatic compression device cleared for use by patients who are under medical supervision for the treatment of 1) lymphedema (primary or secondary); 2) edema resulting from mastectomies, trauma, sports injuries or post immobilization; 3) venous insufficiencies; 4) wounds and 5) stasis dermatitis, venous stasis ulcers, arterial leg ulcers and diabetic foot ulcers and treatment of head and neck lymphedema
1994682|NCT02946021|Drug|NIRFLI with ICG|Near-infrared Fluorescence Lymphatic Imaging following the off-label use of Indocyanine Green as a lymph contrast agent and the use of a custom designed fluorescence imager to dynamically follow lymphatic movement in subjects.
1994683|NCT02944773|Procedure|Facilitated tucking device|20 newborns are using a facilitated tucking device weight during the procedure to assess the level of stress
1994695|NCT02942355|Drug|anastrozole|Anastrozole by mouth daily
1994696|NCT02942355|Drug|Palbociclib|Palbociclib by mouth daily days 1-21 every 28 days
1994697|NCT02942212|Behavioral|Questionnaire|Participants complete a computerized questionnaire to assess demographics and smoking history.
1994698|NCT02942212|Behavioral|In-Depth Interviews|Participants take part in individual in-depth interviews discussing smoking history, attempts to quit, and suggestions for smoking cessation program. The interview should last 30-45 minutes and is audio-recorded.
1994699|NCT02942212|Other|Breath Test|Participants complete a breath test to assess the amount of cigarette smoke inhaled at baseline, weekly during study, and at 3 month follow up.
1994831|NCT02909504|Drug|Lithium|Eligible patients will receive lithium 300 mg twice daily and titrated in 300 mg increments every 7 days as tolerated to levels > 0.6 mEq/L
1994832|NCT02908282|Device|REMOGEN OMEGA|Lubricant eye drops: preservative-free, hypotonic microemulsion of polyunsaturated fatty acids and hydrating polymers provided in single-dose containers of 0.25 ml.
1994833|NCT02908282|Device|Povidone|Artificial tears: preservative-free eye drops containing 2% povidone.
1994834|NCT02908087|Drug|Victoza® (liraglutide)|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
1994835|NCT02908087|Drug|Placebo|Daily subcutaneous injections with increasing doses up to 1.8 mg per day. Duration of treatment 6 months. Duration of follow-up 6 months.
1994838|NCT02906930|Drug|semaglutide|Oral administration once daily.
1994839|NCT02906930|Drug|placebo|Oral administration once daily.
1994840|NCT02906917|Drug|Insulin degludec/insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
1994841|NCT02906917|Drug|Insulin glargine|Administered subcutaneously (s.c. under the skin) once daily.
1994842|NCT02906917|Drug|Insulin aspart|Administered subcutaneously (s.c. under the skin) once daily.
1994843|NCT02904616|Device|mobile spectrofluorimeter|
1994844|NCT02906176|Drug|Vfend (voriconazole) intravenous infusion|Vfend (voriconazole) 200 mg intravenous infusion during 1.5 h
1994845|NCT02906176|Drug|Vfend (voriconazole) tablet|Vfend (voriconazole) 200 mg tablet once
1994911|NCT02893514|Other|SUSIT Condition|Following completion of substance use screening, the tablet computer presents screening results (including level of risk) to the patient for each substance used, asks them to identify their drug of most concern (DOMC), and assesses readiness and confidence to change behavior. Results are delivered to the PCP at the point of care, paired with clinical decision support tailored to the patient's screening results. This information is delivered on the tablet computer, which is handed to the PCP by a Medical Assistant. CDS guides the PCP through a brief intervention specific to the DOMC, recommends clinical actions pertaining to the substance and risk level, and generates a printed summary for the patient. At each scheduled follow-up medical visit, the PCP receives a clinical reminder containing a summary of the patient's substance use and level of risk, paired with CDS that guides them through a follow-up brief intervention.
1994912|NCT02893072|Behavioral|Individualized medical nutrition therapy|The intervention group involves dietary and exercise advice and monitoring.
1994913|NCT02893241|Drug|Cafedrine/theodrenaline|
1994914|NCT02893241|Drug|Ephedrine|
1994915|NCT02891447|Procedure|Hyperthermic intraperitoneal chemoperfusion (HIPEC)|Mitomycin C 30 mg and Cisplatin 200 mg in 3-7 liters of infusate administered using a rolling pump with hyperthermia for 60 minutes.
1994916|NCT02891447|Drug|Sodium thiosulfate|Loading dose and 12 hour continuous infusion of sodium thiosulfate administered to limit the systemic toxicity of cisplatin.
1994924|NCT02889874|Radiation|Omission of radiation therapy|Omission of radiation therapy (adjuvant endocrine therapy only).
1994925|NCT02889809|Drug|Fluticasone furoate|Fluticasone furoate will be supplied as 50 mcg per blister dry white powder for inhalation using ELLIPTA inhaler.
1994926|NCT02889809|Drug|Placebo|Placebo will be supplied as dry white powder Lactose for inhalation using ELLIPTA inhaler.
1994927|NCT02889809|Drug|Montelukast|Montelukast will be supplied as 4 mg chewable tablet (5 year old subjects) and as 5 mg chewable tablet (>=6 year old subjects)
1994928|NCT02889809|Drug|Short Acting Beta 2 Agonist|Albuterol/salbutamol will be supplied as inhalation aerosol or nebulizer.
1994936|NCT02888743|Biological|Durvalumab|Given IV
1994937|NCT02888743|Other|Laboratory Biomarker Analysis|Correlative studies
1994938|NCT02888743|Radiation|Radiation Therapy|Undergo radiation therapy
1994939|NCT02888743|Biological|Tremelimumab|Given IV
1994940|NCT02889276|Other|Functional Resistance Training|Supervised group-based Functional Resistance Training
1994941|NCT02889276|Behavioral|Unsupervised activity|General activity to meet 150 minutes of moderate intensity activity per week
1994942|NCT02887690|Device|Modular Prosthetic Limb|
1994943|NCT02887547|Procedure|micro-osteoperforation|
1994944|NCT02887833|Other|Clinical biomarker (thermal sensory testing)|Thermal sensitivity testing: The area of CIBP and a corresponding unaffected (control) area will be assessed using warm and cool thermal rollers (Rolltemp, Somedic, Sweden). The control area will either be the contralateral side, or an area proximal to the affected site.
1994945|NCT02886975|Behavioral|low protein diet plus α-keto acid|0.4-0.6g of proteins per kilo of body weight per day, supplemented with α-keto acid tablets
1994950|NCT02886286|Drug|Bupivacaine|Patient-activated intrathecal bolus for incident pain
1994951|NCT02886286|Drug|Opioid|Patient-activated intrathecal bolus for incident pain
1995074|NCT02854995|Procedure|preputioplasty with intralesional injection of triamcinolone:|(ii) preputioplasty with intralesional injection of triamcinolone: this will be performed as described by Wilkinson et al.[5] Briefly, longitudinal incisions will be placed in the area of phimosis, and these will be sutured transversely to allow the prepuce to become retractile. A biopsy of an area of affected foreskin will be sent for histological analysis. The intention will be to perform three incisions (tri-radiate) but the final decision on how many will be made by the operating surgeon and based on the appearance of the prepuce and result of initial incision(s). Once the prepuce is felt to be freely retractile, 1 - 3 mL of triamcinolone (Adcortyl Bristol-Myers Squibb 10 mg/mL) will be injected intradermally around the circumference of the affected foreskin using a 25-gauge needle.
1995075|NCT02855931|Procedure|Middle turbinate resection|
1995076|NCT02855814|Other|Body Composition|No intervention. This is an observational, normative study of body composition variation in preterm infants
1995080|NCT02855541|Device|DeskCycle|A small cycling ergometer that can fit under a desk at the workplace.
1995081|NCT02854787|Drug|Phenylephrine|A bolus of 100 mcg
1995082|NCT02854787|Drug|Norepinephrine|A bolus of 0,2 mcg/kg
1995091|NCT02854215|Other|Collection of additional data with questionnaires|"questionnaires for quality of life measurements: QLQC30; QLQ-OV28
questionnaires for medico-economic purposes: ADL (activities of daily living); IADL (instrumental activities of daily living); EQ-5D3L; absenteeism questionnaire.
These questionnaires will be completed during the study time (5 or 6 times during the treatment, next every 4 months during the first two years and then every 6 months during the third year of follow-up)."
1995092|NCT02853929|Biological|Infanrix hexa|All subjects will receive Infanrix hexa co-administered with Prevenar13 as a booster dose.
1995093|NCT02853916|Dietary Supplement|500 mg InSea2®|
1995094|NCT02853916|Dietary Supplement|250 mg InSea2®|
1995095|NCT02853916|Dietary Supplement|Placebo|
1995096|NCT02853773|Other|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with artificially sweetened drinks
1995097|NCT02853773|Other|ingestion of a test meal with sweetener|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with sugary drinks drinks
1995098|NCT02853773|Other|ingestion of a test meal with water|participants will ingest a test meal containing 55% carbohydrate, 30% fat and 15% protein with waters
1995099|NCT02852707|Behavioral|Chronic exposure to unilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to specific unilateral overhead movement patterns of the dominant extremity (throwing arm), such as throwing or hitting a ball (asymmetrical overhead sports)."
1995100|NCT02852707|Behavioral|Chronic exposure to bilateral overhead sports activity|"Overhead sports athletes that have been chronically exposed (≥ 2 years) predominantly to bilateral overhead movement patterns of the upper extremities, such as swimmers (symmetrical overhead sports)."
1995101|NCT02852707|Behavioral|Not exposed|People not engaged in regular sports competition/exercise training.
1995102|NCT02852785|Behavioral|PNF D2 for flexion; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for flexion during low-to-moderate loading condition
1995103|NCT02852785|Behavioral|PNF D2 for flexion; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for flexion during moderate-to-high loading condition
1995104|NCT02852785|Behavioral|PNF D2 for extension; low-to-moderate loading condition|Exposure to upper extremity PNF D2 for extension during low-to-moderate loading condition
1995105|NCT02852785|Behavioral|PNF D2 for extension; moderate-to-high loading condition|Exposure to upper extremity PNF D2 for extension during moderate-to-high loading condition
1995106|NCT02852746|Behavioral|Performance measures of the upper extremity|Athletes will perform the unilateral seated shot put test (USSPT) and the upper quarter Y balance test (UQYBT) bilaterally.
1995107|NCT02852538|Behavioral|NEW FED TR|NEW FED TR is a five day treatment for adults with anorexia nervosa. It is a neurobiologically informed, interactive, family-based treatment that draws upon the specific etiological traits characterizing anorexia nervosa. It stands for Neurobiological research findings Enhanced With Family/Friends of those with Eating Disorders, addressing Trait Responses that both create a vulnerability to the illness and serve as markers for recovery through treatment (formerly reported as Temperament-Based Treatment).
1995109|NCT02851797|Drug|givinostat|suspension of givinostat (10 mg/mL)
1995110|NCT02851797|Drug|placebo|suspension manufactured to mimic givinostat
1995127|NCT02844595|Behavioral|Standard cognitive-behavioural smoking cessation treatment|"Standard cognitive-behavioural smoking cessation treatment is an effective treatment for tobacco dependence. The treatment elements are: treatment contract, self-report and graphic representation of cigarette consumption, information about tobacco, stimulus control, activities for the avoidance of withdrawal syndrome, physiological feedback (CO in expired air) on cigarette consumption, nicotine fading (change of cigarette brands each week progressively decreasing the intake of nicotine and tar), and relapse-prevention strategies (assertion training, problem solving training, change tobacco related misconceptions, management of anxiety and anger, exercise, weight control, self-reinforcing, and changing irrational beliefs).
Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
1995128|NCT02844595|Behavioral|Standard cognitive-behavioural smoking cessation treatment and behavioural activation|"Behavioural activation will be applied along with standard cognitive-behavioural smoking cessation treatment. The treatment elements are: those present in the standard cognitive-behavioural smoking cessation treatment, plus analysis of the relationship between behaviour and mood, identification of situations and behaviours that decrease mood, identifying avoidance behaviours, and identifying thoughts of rumination and worry, self-report of pleasant daily activities, pleasant activity scheduling to increase engagement in rewarding activities, and to reduce patterns of behavioural avoidance.
Treatment will be delivered in eight 60-minute sessions over 8 consecutive weeks."
1995129|NCT02844465|Device|Visualase MRI-Guided Laser Ablation|All subjects will undergo MRI-guided laser ablation of the amygdala and hippocampus with the Visualase System.
1995130|NCT02843568|Other|Laboratory Biomarker Analysis|Correlative studies
1995131|NCT02843568|Radiation|Standard fractionation|60-66y Gy delivered in 1.8-2.0 Gy fractions over 30-36 treatments
1995132|NCT02843568|Radiation|Stereotactic Body Radiation Therapy (SBRT)|40-60 Gy delivered in 5-20 Gy fractions over 3-8 treatments
1995133|NCT02843568|Procedure|Four Dimensional Computed Tomographic Imaging (4DCT)|Subjects undergo a total of 7 research-ordered four dimensional computed tomographic imaging (4DCT) scans: 1 at simulation, and 2 scans at each of the 3 post-radiation therapy time points (3, 6, and 12 months). 4DCT determines lung tissue elasticity and for standard of care radiation treatment planning.
1995134|NCT02843451|Drug|Milk Thistle|
1995135|NCT02843451|Drug|Placebo|
1995139|NCT02840929|Procedure|Second-look OGD|Second-look OGD within 16 to 24 hours after primary OGD
1995140|NCT02840929|Drug|Esomeprazole|
1995141|NCT02840851|Device|MRI|Participants will undergo a MRI scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory rate and PetCO2 will be measured.
1995142|NCT02840851|Device|TCD|Participants will undergo a TCD scan while two stepwise CO2 elevations are applied to the participant by adding fractional concentration of inspired CO2 (FICO2) at 4% and 6% each time. The end tidal CO2 (PetCO2) will be elevated and maintained constant for a few minutes at each target level. Breath-by-breath changes in respiratory and PetCO2 will be measured.
1995143|NCT02840396|Device|rTMS|repetitive TMS (rTMS) can lead to temporary increases or decreases (depending on the protocol used) in excitability of the targeted area. This change in excitability has been shown to last beyond the duration of the stimulation.
1995144|NCT02840396|Device|Sham rTMS|Sham rTMS (or placebo rTMS) refers to a control condition in which no physiological effect on the targeted cortical region occurs.
1995145|NCT02840370|Device|transcranial direct current stimulation|In tDCS, the prefrontal cortex is stimulated during 20minutes through a weak constant electric current (1-2 mA) through two electrodes in a non-invasive and painless manner.
1995146|NCT02840370|Device|Sham tDCS|S-tDCS refers to a control condition in which the subject will receive a brief current in the beginning in order to induce a similar sensation on the scalp as in tDCS, and then the stimulator remains off for the rest of the stimulation time.
1995147|NCT02840357|Other|Purple Wheat Convenience Bars|Whole grain convenience bars manufactured with purple wheat
1995148|NCT02840357|Other|Control Wheat Convenience Bars|Whole grain convenience bars manufactured with ordinary wheat
1995149|NCT02837848|Procedure|Coactivation Strengthening|Coactivation strengthening implies a recruitment of the pectoralis major and the latissimus dorsi while performing regular strengthening.
1995150|NCT02837848|Procedure|Regular Strengthening|Regular strengthening implies external rotation, internal rotation, flexion and abduction of the gleno-humeral joint and scapular protraction and retraction of the scapulothoracic joint strengthening.
1995151|NCT02839044|Dietary Supplement|Menaquinone-7|
1995152|NCT02839044|Dietary Supplement|Placebo|
1995155|NCT02837042|Drug|Pembrolizumab|Pembrolizumab will be administered intravenously every 3 weeks.
1995156|NCT02837549|Other|Occupational therapy treatment|This intervention includes various thermal modalities, manual therapy, Physiotouch (Healthy Life Devices Ltd) and education
1995157|NCT02836496|Drug|Mepolizumab 300 mg|Mepolizumab is available as lyophilized powder for injection reconstituted with Sterile Water for Injection, just prior to use.
1995158|NCT02836496|Drug|Placebo matching mepolizumab|Placebo is available as 0.9% sodium chloride solution
1995159|NCT02836496|Drug|Active OCS capsules (5 mg prednisolone or prednisone)|All subjects will be provided with 2 bottles of blinded OCS capsules, one containing 5mg OCS capsules (active OCS treatment) and a second one containing matching placebo capsules (placebo OCS treatment). These will be dispensed to each subject at each scheduled clinic visit and as needed. Subjects with an increase in blood eosinophils above the pre-specified threshold will be instructed to start blinded OCS treatment from one of the bottles provided (active treatment) unless the subject's HES therapy has already been increased due to a symptom flare within the past 2 weeks.
1995162|NCT02834949|Behavioral|Brief Motivational Intervention (BMI)|This session includes a discussion related to harm reduction and the student's autonomy to make decisions about the information provided in the session; an alcohol use decisional balance exercise; personalized alcohol-related feedback, and goal-setting. Elements included in the feedback are: (a) comparison of the student's perception of how much college students drink and actual student norms, (b) a comparison of the student's alcohol consumption vs. norms, (c) an estimate of the student's peak blood alcohol content in the past month, (d) alcohol-related problems experienced, (e) money spent on alcohol, and (f) calories consumed from alcohol. Participants discuss the personalized feedback with the clinician and review protective behavioral strategies if he or she indicates interest.
1995163|NCT02834949|Behavioral|Substance-Free Activity Session (SFAS)|The clinician initiates a discussion of the student's college and career goals. Students discuss the values that motivate them as well as how alcohol use may interfere with their ability to accomplish these goals. Students then receive information on graduation rates and income benefits for those who attend and excel in college. They receive personalized feedback on (a) the requirements for their major and intended career, (b) a list of extracurricular activities tailored to their goals, (c) a graph showing time they allocate to their activities, (d) information on stress and depressive symptoms (if applicable) and possible adaptive coping responses and (e) a list of substance-free recreational activities in which they would like to start or continuing engaging.
1995164|NCT02834949|Behavioral|Relaxation Session|The session includes a clinician-led diaphragmatic breathing exercise, followed by a progressive muscle relaxation protocol (~30 minutes). At the end of the session, participants will be asked about their reaction to the relaxation techniques and provided with relaxation training handouts.
1995168|NCT02833207|Drug|Drug Trial 1 (EDD)|"Drugs that increase blood flow and test EDD are: ACh, ISO, BK, ATP. Remaining drugs used to test mechanisms of EDD: L-NMMA, ketorolac, and BaCl2.
Details under study description."
1995169|NCT02833207|Drug|Drug Trial 2 (ROV)|"Tools used to increase blood flow: muscle contractions and ATP. Remaining drugs used to test mechanisms of ROV: L-NMMA, ketorolac, and BaCl2.
Details under study description."
1995177|NCT02831855|Drug|CP-690,550|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.
During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
1995178|NCT02831855|Drug|Methotrexate|"During the open-label run-in phase (Day 1 to Week 24), all subjects will receive one tablet open-label tofacitinib MR 11mg orally QD and open-label methotrexate capsule(s) orally every week at prior stabilized dose.
During the double-blind phase, subjects who are randomized to the treatment arm will receive the same dosage of tofacitinib and methotrexate as describe above."
1995179|NCT02831855|Drug|Placebo|During the double-blind phase, subjects who are randomized to the comparison arm will receive 11mg QD tofacitinib and the placebo capsules matching for methotrexate.
1995180|NCT02831101|Drug|Sufentanil|To evaluate, in the elderly, the impact of a concomitant administration of sufentanil during a step-wise propofol induction of anaesthesia on the depth of sedation measured using BIS and clinical sedation score.
1995181|NCT02831101|Drug|Placebo|To evaluate presence or absence of strong opioid (sufentanil) on BIS values in the elderly during propofol induction until the loss of consciousness
1995187|NCT02830061|Other|Interviews|Individual semi-structured interviews for 30-60 minutes using an interview schedule developed from an interpretative phenomenological analysis framework.
1995188|NCT02829970|Behavioral|SUCCEEDS Program|Participants will receive ADHD Psychoeducation, Brief Motivational Interviewing (BMI) and Behavioral Activation for Attention & Alcohol Disorders (BAAAD).
1995189|NCT02829970|Behavioral|Living a Healthy College Lifestyle|Participants will receive ADHD Psychoeducation, BMI and Supportive Counseling (SC).
1995193|NCT02826551|Drug|Marcaine|Pain control medication to theoretically reduce the amount of posterior knee pain that is common after ACL surgery by placing the injection into the posterior capsule of the knee during surgery. This is very easy and safe to accomplish as the surgeon will have direct visualization of the posterior capsule during the surgery.
1995194|NCT02826551|Other|Ice|
1995195|NCT02826551|Drug|Percocet|
1995196|NCT02826551|Device|Knee Brace and Crutches|
1995213|NCT02826369|Other|3.0 Tesla in Magnetic Resonance Imaging|"Eligible patient will have a standard MRI. The images taken before 4min30 and after 6min after to the injection of gadolimium contrast medium will be carried out with the standard image acquisition.
The images taken between 4min30 and 6min after the injection of gadolimium contrast medium will be carried out with the compressed sensing image acquisition."
1995214|NCT02827708|Drug|semaglutide|Oral administration once daily.
1995215|NCT02827708|Drug|placebo|Oral administration once daily.
1995216|NCT02827565|Other|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|10 ml blood sample
1995217|NCT02827760|Dietary Supplement|Synergy1|Inulin type fructans
1995218|NCT02827760|Dietary Supplement|Maltodextrin|
1995220|NCT02826213|Device|LifePort® perfusion device|Renal Perfusion with LifePort® perfusion device
1995221|NCT02826213|Device|Waves perfusion device|Renal Perfusion with Waves perfusion device
1995222|NCT02825940|Drug|Atezolizumab|Atezolizumab will be administered at a dose of 1200 mg IV q3w (in 21-day cycles), except for participants with NSCLC who will be administered atezolizumab at a dose of 1200 mg IV on Day 1.
1995223|NCT02825940|Drug|Gemcitabine|Gemcitabine will be administered to participants with NSCLC at a dose of 1250 mg/m^2 on Days 1 and 8.
1995224|NCT02825940|Drug|Cisplatin|Cisplatin will be administered to participants with NSCLC at a dose of 75 mg/m^2 on Day 1.
1995227|NCT02823288|Other|Sonke CHANGE intervention|"The Sonke CHANGE intervention is a multi-level model aimed at individual, group, community, and societal levels. Sonke's programming is comprised of three core components:
Workshops based on the premise that deeply held gender and sexuality beliefs can be critically examined and transformed in a reflective group setting. Workshops aim to challenge inequitable and harmful ideas about manhood and encourage men to take action to promote equality.
Community Action Teams (CATs) are comprised of interested men and women, who mobilize on a voluntary basis around issues in their neighborhoods. Methods include ambush theatre, murals painting, door to door campaigns, street soccer festivals, rallies, and community dialogues.
Local Advocacy is undertaken by CAT members, who aim to hold government and other duty bearers to account for VAWG prevention. CAT members join local community structures to advance community education and local government accountability."
1995230|NCT02823444|Other|Magnetic Resonance Angiography|"Subjects who agree to participate in the study and provide written informed consent will undergo three station (abdomen/pelvis, thighs, and calves/feet) contrast and non-contrast enhanced magnetic resonance angiography of the lower extremities. Study visits may be split into two imaging sessions to decrease the time the participant is in the scanner if necessary. For image quality review, several participant may undergo only abdomen/pelvis imaging.
Performance of the non-contrast magnetic resonance angiography requires placement of magnetic resonance imaging compatible electrocardiography leads on the patient's chest, so that the heart rate can be monitored and images can be obtained timed to each individual patient's heart beat. Electrocardiography monitoring/gating is performed routinely, and is not investigational."
1995234|NCT02822859|Device|Wright nebulizer|Roxon Medi-Tech, Montreal, QC, Canada
1995235|NCT02822859|Device|Bennett-Twin nebulizer|Puritan Bennett Corp., Carlsbad, CA, USA
1995236|NCT02822859|Device|Aeroneb Solo|Aerogen Ltd., Galway, Ireland
1995237|NCT02822768|Procedure|Packing|The patient will receive packing as part of their wound care
1995238|NCT02822768|Other|No packing|The patient will not receive packing as part of their wound care
1995239|NCT02822625|Drug|QUTENZA®|
1995240|NCT02822625|Other|hypnotic message|
1995241|NCT02822625|Other|music therapy|
1995242|NCT02822443|Behavioral|Psychological therapy (PT) as TAU with integrated emotion focused components (TAU - EFT)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on emotion-focused interventions.
1995243|NCT02822443|Behavioral|Psychological therapy (PT) as TAU with focus on self-regulation (TAU - SR)|25 (+/- 3) weekly sessions and up to three booster sessions of face-to-face outpatient psychotherapy; psychological therapy with focus on self-regulation without emotion-focused interventions
1995244|NCT02822170|Other|IV amino acids and in-bed cycle ergometry|IV amino acids and in-bed cycle ergometry
1995245|NCT02822001|Drug|Sugammadex|Sugammadex is a relatively new compound, a gamma--‐cyclodextrin molecule that forms an 8--‐membered ring. When administered to patients who received rocuronium--‐induced neuromuscular block, sugammadex binds free plasma rocuronium irreversibly, lowering the plasma concentration of free rocuronium. This promotes diffusion of free rocuronium from the neuromuscular junction back into the plasma, where the free rocuronium is again encapsulated. This removal of rocuronium from the neuromuscular junction reverses the neuromuscular block more rapidly and effectively than traditional anticholinesterases (neostigmine).
1995246|NCT02822001|Drug|Placebo|The patient's trachea will be then extubated, and postoperative anesthetic care will proceed as per usual routine.
1995247|NCT02822001|Device|Train-of-Four Monitoring|This involves delivery of small electrical impulses from a nerve stimulator via surface ECG electrodes to a peripheral nerve (usually the ulnar nerve at the wrist) and measuring the muscle contraction in the innervated muscle (usually the adductor pollicis muscle or the thumb. This testing is used routinely in many centers in awakening patients in the PACU, and it is not associated with any adverse effects or patient discomfort.
1995248|NCT02822001|Device|ExSpiron Respiratory Volume Monitoring|The ExSpiron is a non-invasive and safe device cleared by the FDA for monitoring MV, TV and RR. The device requires the application of monitoring PadSets to the patient's skin similar to EKG electrodes and, as such, poses minimal risk.In the proposed trial, we use the ExSpiron to assess the respiratory effects of residual NMB and the effects of sugammadex reversal in decreasing the incidence of pulmonary complications (CREs).
1995249|NCT02821286|Other|Observational study|Blood sampling
1995250|NCT02819843|Drug|TALIMOGENE LAHERPAREPVEC (TVEC)|
1995251|NCT02819843|Radiation|Hypofractionated Radiotherapy|
1995252|NCT02817724|Device|BENECA System|BENECA System is a mobile application whit aims to recover a healthy lifestyle in breast cancer survivors (in terms of energy balance: physical activity and dietary).
1995253|NCT02817724|Other|Supervised-occupational therapy program|It is a comprehensive program that covers most of the physical, cognitive and emotional needs of these patients after oncology treatment from occupational therapy perspective.
1995254|NCT02817880|Device|rTMS|
1995255|NCT02817880|Device|tDCS|
1995256|NCT02817880|Device|tsDCS|
1995258|NCT02817529|Device|Pulmonica|The Pulmonica is a specially constructed and tuned Pulmonary Harmonica that produces deep, resonant, meditative sounds that can be felt vibrating in the lungs and sinuses. Participants who will be instructed to inhale and exhale through Pulmonica at least ten times daily for up to six months.
1995259|NCT02817529|Device|RC-Cornet|RC-Cornet is an oscillatory positive expiratory pressure device, which is designed to aid in the loosening and removal of mucus build-up in the lungs. Participants who will be instructed to inhale and exhale through RC-Cornet at least ten times daily for up to six months.
1995261|NCT02815579|Other|Shamba Maisha Intervention|A) A microcredit loan (~$140) B) Agricultural implements to be purchased with the loan C) Education in financial management and sustainable farming practices
1995262|NCT02814435|Other|Questionnaire|The participants will answer two questionnaires. These are the NEI VFQ-25 and the DLTV (daily living tasks of vision).
1995347|NCT02789228|Biological|Tumor associated antigen lymphocytes (TAA-CTL)|Pediatric and adult patients who have high-risk solid tumors with known positivity for one or more Tumor Antigen Associated (TAA) (WT1, PRAME and/or survivin) will be eligible to receive Tumor Antigen Associated Cytotoxic T Lymphocytes (TAA CTL). The goal of this cell infusion will be to initiate an immune response against solid tumors that includes multiple antigens and may prevent tumor evasion (through decreased expression of a single antigen).
1995353|NCT02787590|Drug|Simvastatin|
1995354|NCT02787590|Drug|Matched Placebo (for Simvastatin)|
1995366|NCT02787265|Device|spinal cord stimulation|
1995367|NCT02786667|Drug|Rotigotine|6 months treatment with Rotigotine up to 8 mg per day with a titration period for one month
1995368|NCT02786667|Drug|Placebo|6 months treatment with Placebo up to 8 mg per day with a titration period for one month
1995369|NCT02786810|Drug|Sulfur hexafluoride type-a lipid microspheres|Used as a contrast to enhance renal ultrasound
1995372|NCT02784873|Other|High intensity interval training|High intensity interval training within a standard cardiac rehabilitation programme
1995373|NCT02785003|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
1995374|NCT02785003|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive ketamine therapy at a rate of 2 mcg/kg/hr dosed based on ideal body weight.
1995375|NCT02785003|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
1995471|NCT02755740|Other|receiving age and gender-specific SC advice|"After delivering the AWARD advice, the trained SCRA will seek consent from and refer adult female smokers (aged over 25 years) to our intensive smoking cessation telephone or face-to-face counselling interventions, which has already counselled 509 female smokers with a quit rate of 29.7% at 6-month and 26.7% at 3-year follow up. Female youth smokers will give consent and be referred to our Youth Quitline (5111 4333), a smoking cessation telephone counselling for young people aged 25 or below which has counselled 1257 smokers with a quit rate of 21.9% at 6 months. If necessary, the female smokers can be referred to other smoking cessation services (e.g., the integrated smoking cessation hotline by the Department of Health (1833-183)."
1995472|NCT02753881|Drug|whole liver lobe cTACE doxorubicin|Doxorubicin CTACE administered in a whole liver lobe manner.
1995473|NCT02753881|Drug|superselective cTACE doxorubicin|Doxorubicin CTACE administered in a super-selective (close to the tumor) manner.
1995474|NCT02752828|Drug|Insulin glargine/lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1995475|NCT02752828|Drug|Insulin glargine (HOE901)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1995476|NCT02752828|Drug|Oral anti-diabetic drugs|"Pharmaceutical form: tablet
Route of administration: oral"
1995478|NCT02751554|Drug|124I-PU-AD|
1995479|NCT02751554|Device|PET Scan|
1995480|NCT02751554|Other|Blood draws|
1995481|NCT02751216|Other|EEG recording + pain protocol|
1995482|NCT02751177|Genetic|KRAS, NRAS et BRAF mutation analysis from circulating plasma DNA|Mutation in plasma DNA vs tumor tissue
1995483|NCT02750943|Drug|Stannous Fluoride|Dentifrice containing 0.454% w/w stannous fluoride
1995484|NCT02750943|Drug|Sodium Monofluorophosphate|Dentifrice containing 1000ppm fluoride as sodium monofluorophosphate
1995485|NCT02750761|Drug|Tedizolid Phosphate (IV)|
1995486|NCT02750761|Drug|Tedizolid Phosphate (oral suspension)|
1995487|NCT02750514|Biological|Nivolumab|Arm associated with this intervention is closed. Nivolumab is no longer given as an active comparator.
1995488|NCT02750514|Drug|Dasatinib|
1995489|NCT02750514|Biological|Relatlimab|
1995490|NCT02750514|Biological|Ipilimumab|
1995491|NCT02750514|Drug|BMS-986205|Specified dose on specified days
1995492|NCT02750293|Drug|Cholecalciferol|Vitamin D preparation
1995493|NCT02750293|Drug|Placebo|placebo
1995494|NCT02749890|Drug|Insulin glargine/Lixisenatide (HOE901/AVE0010)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1995495|NCT02749890|Drug|Lixisenatide (AVE0010)|"Pharmaceutical form: solution
Route of administration: subcutaneous"
1995496|NCT02749890|Drug|Oral anti-diabetic drugs|"Pharmaceutical form: tablet
Route of administration: Oral"
1995497|NCT02747914|Device|Transcranial magnetic stimulation|
1995498|NCT02747914|Other|Conventional exercise|
1995504|NCT02747043|Drug|ABP 798|375 mg/m2, IV (in the vein)
1995505|NCT02747043|Drug|Rituximab|375 mg/m2, IV (in the vein)
1995506|NCT02746393|Other|Health Advocates Program|Provided services and support to address identified social needs from health advocate navigators.
1995507|NCT02746393|Other|211 Information Sheet|Receive a printed list of community resources to address social needs.
1995508|NCT02745236|Other|Nurse Practitioner Led-Care|Diagnosis and treatment plan decisions will be determined by Nurse Practitioner Led-Care.
1995509|NCT02745236|Other|Cardiologist Led-Care|Diagnosis and treatment plan decisions will be determined as per usual care by the Cardiologist
1995511|NCT02742454|Procedure|Standard 30-60 Seconds Cord Clamping|The infant will be stimulated to breathe after birth. If the infant is not breathing well, the cord will be clamped at 30 seconds. If the baby is breathing well, the cord will be clamped at 60 seconds. Ventilatory assistance will be given after cord clamping.
1995512|NCT02742454|Procedure|VentFirst 120 Seconds Cord Clamping|The infant will be stimulated to breathe after birth. If the infant is not breathing well, Positive Pressure Ventilation by face mask will be given starting at 30 seconds. If the baby is breathing well, Continuous Positive Airway Pressure (CPAP by face mask) will be given starting at 30 seconds. The cord will be clamped at 120 seconds.
1995712|NCT02673892|Other|Patient Oriented Discharge Summary|The PODS provides a written template for providers to engage patients and caregivers when reviewing important discharge instructions on medications, activity and diet restrictions, follow-up appointments and worrisome symptoms warranting emergency care. The PODS also uses plain and simple wording, large fonts, pictograms, and includes white space for patients to take notes and provides the option for translation of major headings into the most common spoken languages. As this will be a pragmatic design, we may make modifications to the process involved in completing the PODS, such as using pre-filled disease-specific information, if system processes and providers involved deem it more usable and feasible.
1995713|NCT02673476|Drug|ALS-008176|ALS-008176 tablets
1995714|NCT02673476|Drug|Placebo|Identical placebo tablets
1995715|NCT02672072|Other|Simulation during the study (5-day specific training with dedicated scenario done by an ICU expert simulation team)|
1995716|NCT02672072|Other|questionnaire to define the presence of job strain at 6 months|
1995717|NCT02672072|Other|questionnaire to define the presence of job strain at 12 months|
1995724|NCT02671305|Procedure|placental circulation intact|bedside assistance with placental circulation intact during first 3 minutes of life
1995725|NCT02671305|Procedure|cord milking|neonatal assistance in a standard setting after cord milking (milking four times 20 cm of cord)
1995726|NCT02671201|Other|Education|Different methods in education of emergency ultrasound
1995727|NCT02670915|Drug|Faster-acting insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
1995728|NCT02670915|Drug|insulin aspart|For subcutaneous (s.c., under the skin) injection once daily.
1995729|NCT02670915|Drug|insulin degludec|For subcutaneous (s.c., under the skin) injection once daily.
1995733|NCT02669381|Dietary Supplement|Phenylalanine intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
1995734|NCT02670083|Drug|Crenezumab|Crenezumab will be administered by IV infusion q4w for 100 weeks.
1995735|NCT02670083|Drug|Placebo|Placebo will be administered as IV infusion q4w for 100 weeks.
1995736|NCT02670226|Other|Samples|Blood samples, muscle biopsy
1995737|NCT02668237|Other|OptiPAC|Molecular and urinary tests.
1995738|NCT02668237|Other|Usual care|Antibiotics for prevention.
1995739|NCT02668029|Drug|oxygen|information already included in arm/group descriptions.
1995740|NCT02668029|Drug|medical air|Placebo
1995744|NCT02666586|Other|Faba bean powder smoothie|Breakfast smoothie with 32 g whole faba bean powder (300g).
1995745|NCT02666586|Other|Faba bean protein concentrate smoothie|Breakfast smoothie with 32 g faba bean protein concentrate.
1995746|NCT02666586|Other|Faba bean starch smoothie|Breakfast smoothie with 33 g faba bean starch.
1995747|NCT02666586|Other|Faba bean protein isolate smoothie|Breakfast smoothie with 32 g faba bean protein isolate.
1995748|NCT02666586|Other|Non-pulse smoothie smoothie|Control smoothie with 32 g corn maltodextrin without added faba bean fractions.
1995754|NCT02662088|Procedure|laparoscopic-lavage|
1995755|NCT02661646|Device|Advanced Pneumatic Compression Device|Advanced Pneumatic Compression Device
1995756|NCT02661529|Procedure|Transesophageal Echocardiogram (TEE)|Transesophageal echocardiography (TEE) is a test that produces pictures of the heart. TEE uses high-frequency sound waves (ultrasound) to make detailed pictures of the heart and the arteries that lead to and from it. Unlike a standard echocardiogram, the echo transducer that produces the sound waves for TEE is attached to a thin tube that passes through the mouth, down the throat and into the esophagus. Because the esophagus is so close to the upper chambers of the heart, very clear images of those heart structures and valves can be obtained.
1995757|NCT02661529|Procedure|Transthoracic Echocardiogram (TTE)|"An echocardiogram is a type of ultrasound test that uses high-pitched sound waves that are sent through a device called a transducer. The device picks up echoes of the sound waves as they bounce off the different parts of the heart. These echoes are turned into moving pictures of the heart that can be seen on a video screen.
Transthoracic echocardiogram (TTE) is the most common type of echocardiogram. Views of the heart are obtained by moving the transducer to different locations on the chest or abdominal wall."
1995877|NCT02630420|Drug|cetuximab and savolitinib|Dosage of combined cetuximab and savolitinib will be determine in Part 1 of the study, Part 2 will use the findings of Part 1 to further assess safety and to assess efficacy of this drug combination.
1995878|NCT02630316|Drug|Inhaled Treprostinil|Inhaled treprostinil (6 mcg/breath) administered four times daily
1995879|NCT02630316|Drug|Placebo|Placebo administered four times daily
1995884|NCT02627365|Behavioral|Individualized, interactive short messaging intervention|An Individualized, interactive short messaging intervention reminding study participants to take antiretroviral medication and report any problems.
1995885|NCT02627274|Drug|RO6874281|Participants will receive RO6874281, starting with 5 mg once weekly (QW) to a maximum of 50 mg QW, as a single administration by intravenous infusion over a minimum of 2 hours (120 minutes) with a maximum infusion rate of 25 mg/hour. Participants will receive RO6874281 until clinical disease progression, unacceptable toxicities, or withdrawal of consent. Participants may continue treatment with RO6874281 for a maximum of 24 months.
1995886|NCT02627105|Behavioral|Beef group|Subjects in the beef group will be asked to consume 4 or more servings of beef per week (and to avoid all other red meats) during the 6 month study.
1995887|NCT02627105|Behavioral|Non-beef group|Subjects in the non-beef group will be asked to avoid all red meats during the 6 month study.
1995889|NCT02624362|Behavioral|Therapeutic Suggestion|suggestions about potential beneficial effects of the odor are given
1995890|NCT02624362|Behavioral|Asthmogenic Suggestion|suggestions about potential negative effects of the odor are given
1995891|NCT02624362|Other|Phenylethyl Alcohol odor|Over the course of 15 minutes, participants, receive 15 short sniffs of Phenylethyl Alcohol odor
1995892|NCT02624570|Drug|Midostaurin|Midostaurin, also known as PKC412 is a multi-kinase inhibitor of FLT3 (fms-like tyrosine kinase-3)
1995893|NCT02623348|Behavioral|pedometer|pedometer-based physical activity recommendations
1995894|NCT02622828|Behavioral|Participant-identified community based activity|The Canadian Occupational Performance Measure (COPM) is a client-centered outcome measure designed to detect changes in performance and satisfaction in occupations that the individual has self-identified as being important and difficult to perform. The COPM will be used to set self-identified, community-based activities as treatment goals.
1995897|NCT02621424|Device|RTMS|stimulation of the brain with magnetic pulses
1995898|NCT02621424|Device|sham|sham noise to block the sound of stimulation
1995899|NCT02620709|Behavioral|Hula intervention|Hula and heart health education
1995902|NCT02620800|Drug|5FU|5 fluorouracil (5-FU) (180 mg/m^2/day for 14 days) by CIVI via ambulatory pump
1995903|NCT02620800|Drug|nab-paclitaxel|nab-paclitaxel (75 mg/m^2) as a 30-minute (min) IV infusion on Days 1, 8, and 15
1995904|NCT02620800|Drug|bevacizumab|bevacizumab (5 mg/kg) as an IV infusion on Days 1 and 15
1995905|NCT02620800|Drug|calcium leucovorin|calcium leucovorin (20 mg/m^2) IV bolus, on Days 1, 8, 15
1995906|NCT02620800|Drug|oxaliplatin|oxaliplatin (40 mg/m^2) as a 60-min IV infusion on Days 1, 8, and 15
1995907|NCT02619864|Drug|AZD2014|
1995964|NCT02600091|Behavioral|Mindfulness-Based Cognitive Therapy|The MBCT intervention is manualised and delivered to groups. The aim of the MBCT intervention is to increase mindfulness skills and to facilitate their use in relation to emotional wellbeing and diabetes self-management. Participants will attend on 8 occasions, once per week, for 2 hours. These meetings will have a standard structure. First, participants will describe their efforts to practice mindfulness at home over the previous week, followed by discussion of an educational topic relevant to the aims of the course. Finally, the group will do a mindfulness practice together, and the home practice for the following week will be set. In-between meetings, participants are asked to practice mindfulness by listening to an audio file or CD for about 30 minutes per day.
1995965|NCT02597660|Drug|Somatropin|Active drug
1995966|NCT02597660|Drug|Bacteriostatic saline|Placebo, the diluent used to reconstitute somatropin
1995967|NCT02597660|Other|Progressive exercise program|Over a 12 week period beginning at the second study visit patients will perform a standard of care eccentric exercise training regime. Each session consists of three bilateral exercises: leg press, back squat, and hack squat. Subjects will complete four sets in each exercise with a 2-3 minute rest between sets. The repetitions/loads are: 15 repetition maximum (RM) week 1, 12RM weeks 2-3, 10RM weeks 4-5, 8RM weeks 6-8 and 6RM weeks 9-12. All exercises are performed from complete 0º to 90º of knee flexion and back again. Each of the eccentric and concentric phases will occur over a period of 3 seconds, respectively for a total of 6 seconds per contraction.
1995968|NCT02597660|Procedure|Patellar tendon biopsy|Bilateral biopsies will be performed on an elective basis, although the investigators will aim to have 8 subjects in each group receive the biopsy. Biopsies will be obtained at the 26 week time point. The data obtained from the biopsy will help address the mechanism behind observed changes in outcome scores, physical measurements or imaging studies. The biopsy will be performed under ultrasound guidance and using sterile technique with a disposable 14G, 2cm biopsy instrument.
1995969|NCT02595970|Drug|Secukinumab|weekly sub cutaneous injections of 300 mg during the first month and then monthly until week 52 plus extension until 03/11/2016.
1995970|NCT02596178|Device|Electrical Impedance Tomography|Electrical impedance tomography capitalizes on changes in electrical impendence between air-filled versus tissue or fluid-filled spaces in order to characterize and quantify regional distribution of lung volume at the bedside.
1995983|NCT02597023|Drug|MitoQ|Mitoquinone pill, 20 mg/day
1995984|NCT02597023|Drug|Placebo|Placebo pill with inert excipient, 1 time/day
1995987|NCT02594527|Other|Volunteer-led physical activity session|Participants will be encouraged by volunteers to walk or perform chair-based exercises during their stay in hospital
1995988|NCT02595281|Other|Experimental arm|"Serum samples are collected:
at each neoadjuvant chemotherapy cycle
before surgery
at each adjuvant chemotherapy cycle
at each injection of bevacizumab as maintenance therapy
stop at the progression or after 24 months post chemotherapy"
1995989|NCT02593838|Other|CT-MPI and SPECT-MPI|All patients undergo CT-MPI plus SPECT-MPI
1995990|NCT02593526|Drug|Bumetanide|Diuretic
1995991|NCT02593526|Other|Cool Dialysate|Cool dialysate (35°C)
1996034|NCT02584387|Behavioral|3D Video Virtual Reality Exposure Therapy|The 3D video exposure therapy treatment will be administered using an oculus rift virtual reality headset. The oculus rift is a new, affordable virtual reality headset, which uses two different spherical lenses to induce a sense of stereoscopic 3D. Ortho-stereoscopic 3D refers to 3D videos that are designed to mimic the natural depth we normally see, as opposed to exaggerating it (i.e. Commercial 3D movies). To create these 3D videos, the UT 3D Department shot videos of live spiders using a stereoscopic 3D dual camera rig, which simultaneously shoots footage with two cameras positioned apart from each other in a way that mimics the natural pupillary distance between our right and left eyes. To create a sense of 3D depth, the footage of the right and left cameras is then projected on the two different lenses of the oculus rift, creating a sense of depth to the viewer through retinal disparity.
1996035|NCT02582788|Other|Bathing Additive|
1996036|NCT02582515|Drug|D-cycloserine|
1996037|NCT02582515|Drug|Placebo|
1996038|NCT02582476|Drug|Bumetanide|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
1996039|NCT02582476|Drug|Placebo|Participants will be randomly assigned to either bumetanide or placebo for the first visit. The assigned treatment will be taken by mouth at the onset of a focal attack defined as 40% decrement in ADM CMAP amplitude compared to the maximum CMAP amplitude recorded during or after the exercise. The second assessment will follow an identical protocol to the first, but with the other treatment administered.
1996042|NCT02580851|Other|diagnostic test - cardiac magnetic resonance imaging|
1996043|NCT02580851|Other|diagnostic test - coronary angiography|
1996046|NCT02579642|Drug|Ketamine|Low dose ketamine 0.2 mg/kg (or 0.5 mg/kg depending on results of interim analysis) administered with usual induction drugs for ECT
1996047|NCT02579642|Drug|Placebo|Normal saline administered with usual induction drugs for ECT
1996050|NCT02579096|Drug|Allopurinol|Patients will be titrated up to the dose that will lower to target uric acid levels.
1996051|NCT02579096|Drug|Febuxostat|Febuxostat will be titrated up to the dose that will lower to target uric acid levels.
1996052|NCT02579096|Drug|Placebo, vehicle control (Febuxostat-shaped)|Placebo in the shape of Febuxostat will be given with Allopurinol
1996053|NCT02579096|Drug|Placebo, vehicle control (Allopurinol-shaped)|Placebo in the shape of Allopurinol will be given with Febuxostat
1996054|NCT02579655|Behavioral|Copayment Elimination|Patients will receive preventive medications for their chronic conditions free of charge (without the 30% copayment seniors normally pay for their medications)
1996055|NCT02579655|Behavioral|Personalized Education|Tailored Education focusing on optimizing use and adherence to guideline recommended medications, as well as appropriate lifestyle
1996056|NCT02576561|Biological|TVGV-1|Antigen + Adjuvant
1996057|NCT02576561|Biological|GPI-0100|Adjuvant Alone
1996058|NCT02576561|Biological|Placebo|Placebo
1996067|NCT02574234|Other|Determination of apelin and inflammatory cytokines|A blood sample will be conducted at baseline, on day 1 and day 7 post operative to meter inflammatory cytokines (IL1B, IL1-ra, IL6) and apelin.
1996068|NCT02574234|Other|Assessment of cognitive functions|Evaluation of preoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale.
1996069|NCT02574234|Other|Liquid sampling cerebrospinal|Determination of the concentrations of inflammatory cytokines and apelin in cerebrospinal fluid perioperatively.
1996070|NCT02574234|Other|Postoperative delirium research|Using the scale Confusion Assessment Method (CAM) for screening and delirium diagnosis. This research will be daily lasted, during the first 7 days postoperative.
1996071|NCT02574234|Other|Residual cognitive dysfunction research|Evaluation of postoperative cognitive performance by achieving a IQCODE, an MMS and an IADL scale realised on day 1 and day 7 postoperative. Realization of the IQCODE and IADL three months after the operation in a telephone interview.
1996072|NCT02573974|Other|Samples|Blood samples, muscle biopsy and sample of hair
1996235|NCT02525029|Drug|Pregnyl®|"ARM 1: High-Risk aGVHD
Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for 4 doses through day 7:
If a complete or partial response, continue protocol treatment followed by hCG maintenance twice weekly for 10 doses beginning day 9 to 12.
If no response, the patient will be taken off study treatment
ARM 2: Steroid-Refractory aGVHD
Standard of care immunosuppression, plus Pregnyl® at assigned dose subcutaneously every other day for 7 doses through day 14:
If a complete or partial response, continue protocol treatment followed by hCG at the assigned dose maintenance twice weekly for 10 doses beginning day 15 to 17.
If no response, the patient will be taken off study treatment
Doses for both arms:
Phase 1: up to 5 dose levels of Pregnyl® will be tested; however dose levels -1 and -2 will be used only if dose level 1 proves too toxic.
Phase II: the dose of Pregnyl will be that identified as the MTD during phase I."
1996236|NCT02523833|Drug|Salbutamol|Salbutamol after spirometry, plethysmography and forced oscillation technique.
1996237|NCT02522767|Drug|Mesalamine|
1996238|NCT02522767|Drug|Placebo|
1996239|NCT02519738|Drug|Silver Nitrate|Silver nitrate to be applied 3 times weekly for a period of 3 weeks.
1996240|NCT02519738|Drug|Kenalog (Triamcinolone)|Triamcinolone will be applied as an ointment to the granulation tissue site three times daily for a total of three weeks.
1996241|NCT02519738|Other|Washcloth Abrasion|Gentle wash and abrasion with washcloth done once daily for a total of 3 weeks.
1996242|NCT02520466|Dietary Supplement|flavanol-rich drink vs flavanol-free drink|
1996243|NCT02519348|Biological|MEDI4736 + tremelimumab|MEDI4736 will be administered by IV infusion in combination with tremelimumab.
1996244|NCT02519348|Biological|MEDI4736|MEDI4736 will be administered by IV infusion.
1996245|NCT02519348|Biological|Tremelimumab|Tremelimumab will be administered by IV infusion.
1996246|NCT02518399|Other|Heat therapy|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for heat therapy sessions. In each session, subjects will be immersed in a 40°C hot tub for up to 90min in order to increase body core temperature to 38.5°C and, once there, maintain it between 38.5-39.0°C for 60min.
1996247|NCT02518399|Other|Thermoneutral water immersion|Subjects will report to the laboratory 4-5x per week for 8 weeks (36 sessions total) for thermoneutral water immersion sessions. In each session, subjects will be immersed in a 36°C tub for 90min in order to maintain body core temperature at a constant level.
1996248|NCT02518334|Other|Alcohol consumption|28 grams (2 drinks) of ethanol will be consumed either in the form of wine or vodka.
1996249|NCT02518113|Drug|LY3039478|Administered orally
1996250|NCT02518113|Drug|Dexamethasone|Administered orally
1996251|NCT02518113|Drug|Placebo|Administered orally
1996254|NCT02517463|Drug|Ulipristal acetate|This is an observational study on subjects taking a single intervention, i.e. ulipristal acetate for emergency contraception. The intervention is not randomised nor assigned by the investigator.
1996255|NCT02515760|Procedure|Bone marrow aspiration from the iliac crest|
1996256|NCT02515760|Device|Illinois bone marrow aspiration neddle|
1996260|NCT02514122|Drug|Ketamine|Patients will receive a subcutaneous injection of ketamine (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
1996261|NCT02514122|Drug|Saline|Patients will receive a subcutaneous injection of saline (at a dose of 0.02cc/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
1996262|NCT02514083|Drug|Ibrutinib|Ibrutinib
1996263|NCT02514083|Drug|Fludarabine|Fludarabine
1996270|NCT02513160|Drug|Beclomethasone Dipropionate 640|Beclomethasone Dipropionate 640 mcg BAI
1996271|NCT02513160|Drug|Placebo|"Placebo, taken in the morning and evening each day, was provided in matching BAI and MDI devices.
The placebo devices were identical to the devices used to deliver active drug."
1996272|NCT02513160|Drug|Beclomethasone dipropionate via 320 mcg BAI|Beclomethasone dipropionate treatment administered via breath-actuated inhaler (BAI) (320 mcg/day).
1996273|NCT02513160|Drug|albuterol/salbutamol|Each patient's current rescue medication was replaced with study-supplied albuterol/salbutamol hydrofluoroalkane (HFA) metered-dose inhaler (MDI) (90 mcg ex-actuator) or equivalent during the run-in and double-blind study periods.
1996274|NCT02513160|Drug|Beclomethasone dipropionate via 320 mcg MDI|Beclomethasone dipropionate treatment administered via metered-dose inhaler (MDI) (320 mcg/day).
1996456|NCT02475954|Other|Standard Care|Standard Care is defined as medical and psychiatric treatment provided by patients' personal doctors (e.g., neurologists, psychiatrists, therapists). Veterans will continue to receive routine clinical care and will remain on all depression treatments that they were receiving prior to their study (e.g., stable ADMs, established psychotherapy, clinical monitoring).
1996304|NCT02501889|Behavioral|Standard weight loss diet|Composition of prescribed diets will be based on individual preferences, with the goal of reduced energy intake and increased energy expenditure. During the 6-month intervention, study subjects will participate in individualized counseling and group sessions, with in-person, telephone, email and text message contacts to provide support and behavioral guidance and strategies. The overall content of the intervention consists of key elements of cognitive-behavioral therapy for obesity. The physical activity component emphasizes planned aerobic exercise, increased physical activity in the lifestyle, and strength training.
1996309|NCT02501629|Drug|Reslizumab|Reslizumab Subcutaneous Dosing
1996310|NCT02501629|Drug|Placebo|
1996311|NCT02501434|Drug|Continuous Low-Dose IV Unfractionated Heparin Infusion|Continuous intravenous infusion of a low-dose unfractionated heparin drip
1996312|NCT02501161|Drug|insulin degludec/liraglutide|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
1996313|NCT02501161|Drug|insulin glargine|Injected subcutaneously (under the skin) once daily for 104 weeks. Dose individually adjusted.
1996314|NCT02501941|Drug|ketamine|Ketamine will be used as a sedative alternative to other more conventional sedatives (such as propofol, versed, or dexmedetomidine) in 6 hour blocks of time. Ketamine will be titrated at the bedside based on clinically desired Riker Sedation-Agitation Scale target. Both groups will receive the drug in this multiple crossover design. The only difference between groups is which sedation regimen is started first to minimize any bias related to differences in physiology in the early post-operative phase.
1996315|NCT02500732|Drug|Atomoxetine|40mg PO the night before and the morning of the study tilt table test.
1996316|NCT02500732|Drug|Placebo|oral placebo capsule designed to blind the atomoxetine intervention
1996317|NCT02500602|Drug|doxazosin|active medication
1996318|NCT02500602|Drug|placebo|placebo pill
1996319|NCT02500407|Drug|BTCT4465A|Participants with B-cell NHL and CLL will receive BTCT4465A via IV infusion.
1996320|NCT02500407|Drug|Atezolizumab|Participants assigned to an atezolizumab combination arm will receive atezolizumab 1200 mg administered as an IV infusion concurrently with BTCT4465A.
1996321|NCT02500381|Drug|SRP-4045|"SRP-4045 30 mg/kg will be administered as an IV infusion once a week for up to 96 weeks.
In the Open-Label Period, all patients will receive IV infusions of SRP-4045 at 30 mg/kg/week for up to 96 weeks."
1996322|NCT02500381|Drug|SRP-4053|"SRP-4053 30 mg/kg will be administered as an IV infusion once a week for up to 96 weeks.
In the Open-Label Period, all patients will receive IV infusions of SRP-4053 at 30 mg/kg/week for up to 96 weeks."
1996323|NCT02500381|Drug|Placebo|"Placebo will be administered as an IV infusion once a week for up to 96 weeks.
In the Open-Label Period, all patients will receive IV infusions of either SRP-4045 or SRP-4053 at 30 mg/kg/week, according to genotype, for up to 96 weeks."
1996324|NCT02499614|Drug|Crizotinib|Eligible patients with ROS1 translocation or MET amplification will be treated with Crizotinib at the standard dose of 250 mg BID. The dose of crizotinib may be adjusted depending on the type and severity of toxicity encountered
1996327|NCT02498002|Device|Physical Activity Monitoring (Actiheart)|Monitor physical activity using an Actiheart monitor during the required periods.
1996328|NCT02498002|Other|Energy Intake Monitoring|Monitor energy intake by weighing and recording all foods/drinks consumed during the required periods.
1996329|NCT02498002|Other|Body Weight Monitoring|Monitor body weight during monitoring phase to ensure stability despite other monitoring activities.
1996330|NCT02498002|Procedure|Intravenous Cannulation|Fitting of an intravenous cannula to a vein on the forearm for blood sampling during laboratory protocols.
1996331|NCT02498002|Procedure|Adipose Tissue Biopsy|This is an optional feature which if included involves the removal of a 0.5 gram sample of adipose tissue from just below the skin using a needle.
1996332|NCT02498002|Drug|Lidocaine Hydrochloride|The anaesthetic that will be used to numb the site of the adipose tissue biopsy in the event it is included.
1996333|NCT02498002|Other|Post-Prandial Meal Tests|Consume two successive meals with regular blood samples throughout the ensuing hours (2-3 hours each).
1996334|NCT02498002|Radiation|DEXA Scan|Undergo a dual energy x-ray absorptiometry scan to examine body composition.
1996335|NCT02498002|Other|Actiheart Calibration|Submaximal treadmill test to calibrate monitoring equipment.
1996336|NCT02498002|Other|Daily Calorie Restriction|Reduce energy intake by 25% on a daily basis.
1996337|NCT02498002|Other|Intermittent Fasting with Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 150% of normal intake when feeding.
1996338|NCT02498002|Other|Intermittent Fasting without Weight Loss|Alternate between 24 hour cycles of fasting and feeding with 200% of normal intake when feeding.
1996343|NCT02497638|Drug|Metformin|One month run-in of 850 mg metformin once daily, followed by 850 mg twice daily of metformin until progression.
1996344|NCT02497638|Drug|Atorvastatin|Atorvastatin 20 mg once daily until progression.
1996457|NCT02476084|Other|Musculoskeletal Ultrasound Imaging|B-mode and PD musculoskeletal ultrasound examination of selected joints.
1996353|NCT02497755|Behavioral|App for smartphone|A smartphone app will send psychoeducation and reminders to patients to complete self-report data, will collect passive data, and will provide aggregated information to a provider dashboard.
1996354|NCT02497755|Device|smartphone|
1996355|NCT02495922|Drug|elotuzumab|10 mg/kg in the vein( i.v) on day 1,8 and 15 in induction cycle 1 and 2, on day 1 and 11 in induction cycle 3 and 4 (Arm B1 and B2). 10 mg/kg i.v. on day 1,8 and 15 in consolidation cycle 1 and 2 (Arm A2 and B2), 10 mg/kg i.v. on day 1 and15 in maintenance cycle 1-6, 10 mg/kg i.v. on day 1 in maintenance cycle 7-26 (Arm A2 and B2)
1996356|NCT02495922|Drug|Lenalidomide|25 mg per os on day 1-14 in induction cycle 1-4, 25 mg p.o. on day 1-14 in consolidation cycle 1 and 2, 10 mg p.o. on day 1-28 in maintenance cycle 1-3, 15 mg p.o. on day 1-28 in maintenance cycle 4-26 (all arms)
1996357|NCT02495922|Drug|Bortezomib|all arms: 1,3 mg/m^2 subcutaneous on day 1, 4, 8 and 11 in 4 induction cycles, 1,3 mg/m^2 subcutaneous on day 1, 8 and 15 in 2 cycles of consolidation
1996358|NCT02495922|Drug|Dexamethasone|"20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 and 15 in induction cycles 1 and 2. 20 mg per os on day 1,2 and 4,5 and 8,9 and 11,12 in induction cycles 3 and 4 (Arms A1 and A2).
8 mg per os and 12 mg i.v. on day 1, 8 and 15 and 20 mg per os on days 2,4,5, 9, 11 and 12 in induction cycles 1 and 2. 8 mg per os and 12 mg i.v. on day 1, and 11, 20 mg per os on days 2,4,5,8, 9, and 12 in induction cycles 3 and 4 (Arms B1 and B2).
20 mg per os on days 1,2, 8,9, 15 and 16 in both cycles of consolidation (Arms A1 and B1). 8 mg per os and 12 mg i.v. on days 1, 8 and 15 and 20 mg per os on days 2, 9 and 16 in both consolidation cycles (Arms A2 and B2).
12 mg per os on day 1 and 15 in maintenance cycles 1-6, 12 mg per os on day 1 of maintenance cycles 7 and following (Arms A1 and B1). 4 mg per os and 8 mg i.v. on day 1 and 15 in maintenance cycles 1-6, 4 mg per os and 8 mg i.v. on day 1 of maintenance cycles 7 and following (Arms A2 and B2)."
1996359|NCT02494453|Procedure|Research Cardiac MRI|Cardiac MRI has increasing utility in evaluating structural and functional cardiac pathologies. For detection of coronary artery disease, MRI outperforms SPECT and dobutamine stress echocardiography for the detection of ischemia. MRI also can detect wall-motion abnormalities and other dysfunction. Dynamic contrast-enhanced MRI (DCE-MRI) can evaluate microvascular parameters such as vessel permeability and fluid volume fraction as an assessment of tissue perfusion. Thus, cardiac MRI holds promise for early detection of subclinical cardiac abnormalities after radiotherapy and could potentially identify patients for intervention to prevent cardiac events. All patients will follow the protocol calendar requiring research MRIs, but will receive standard radiation treatment determined by their treating physician. In this study, treatment will not be altered based on the data collected from these MRIs.
1996360|NCT02494453|Procedure|Biomarkers|"Scant data exist on potential biomarkers of cardiac radiation exposure and damage. However, we have identified potential candidates based on other processes affecting heart function in a way similar to probable mechanisms of RT-related injury. For fibrosis and left ventricular dysfunction, these include galectin-3 and N-terminal-Pro brain natriuretic peptide. For myocyte destruction, troponin; for inflammation and oxidative stress, C-reactive protein, myeloperoxidase, and growth differentiation factor 15. Additional blood will be collected and stored for future assessment of other candidate biomarkers.
All patients will follow the calendar of protocol required research blood draws for biomarker collection, but will receive standard radiation treatment as clinically indicated by their treating physician. In this study, treatment will not be altered based upon the data collected from these samples."
1996361|NCT02494427|Device|CAD/CAM manufactured fixed unitary dental prostheses|
1996362|NCT02494427|Device|Conventionally manufactured unitary dental prostheses|
1996363|NCT02494336|Procedure|Trans-incisional rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered under direct visualization into the rectus sheath bilaterally by the attending surgeon. This will be done after closure of the fascial incision but prior to closure of the skin incision.
1996364|NCT02494336|Procedure|Laparoscopic guided rectus sheath block|After removal of the gallbladder, a predetermined volume of 0.2% ropivacaine (1cc/kg, max dose 10cc, divided into equal doses bilaterally) will be administered intra-abdominally under direct laparoscopic visualization into the rectus sheath bilaterally by the attending surgeon.
1996365|NCT02494336|Drug|Ropivacaine|Ropivacaine is a long-acting local anesthetic. It has been shown to be effective for peripheral nerve, caudal, and lumbar/thoracic epidural blocks and produce less motor blockade than bupivacaine after caudal administration. It will be the local anesthetic used to perform the rectus sheath block for both arms.
1996366|NCT02493764|Drug|Imipenem|Imipenem 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
1996367|NCT02493764|Drug|Relebactam|Relebactam 250 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
1996368|NCT02493764|Drug|Cilastatin|Cilastatin 500 mg as part of a FDC administered by IV every 6 hours for a minimum of 7 days, up to 14 days
1996387|NCT02490085|Other|24-hour intervention with multiple daily injections|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. The subjects will carry on with their normal insulin therapy. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
1996388|NCT02490085|Other|24-hour intervention with closed-loop strategy|Subjects will be admitted at the research clinical facility at 20:00. A cannula will be inserted into an arm or a hand vein for blood sampling purposes. A cartridge containing subject's usual fast acting insulin analog will be placed in the insulin pump. Closed-loop strategy will start at 21:00 until 21:00 the next day. Neither basal nor prandial insulin injections will be given. Two periods of walking of 15 minutes will be performed at 10:00 and 15:00. Meals will be served at 8:00, 12:00 and 17:00. The CHO content of meals will be adapted to subject's usual CHO intake. Venous blood samples (4 ml each) will be obtained for the measurement of the plasma glucose and insulin. Plasma glucagon and C-peptide will be measured every hour. Blood samples will be drawn every 20 minutes.
1996389|NCT02490085|Drug|Insulin|Subject's usual insulin analog will be used.
1996390|NCT02490085|Device|Insulin pump Accu-Chek Combo|During closed-loop intervention, the Accu-Chek Combo (Roche) insulin pump will be used
1996391|NCT02490085|Device|Dexcom G4 Platinum|In both visits, glucose levels will be measure with the Dexcom G4 Platinum (Dexcom)
1996392|NCT02489721|Device|PICC and Midline|Peripherally inserted central venous catheter
1996393|NCT02489448|Drug|MEDI4736|"The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.
Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments."
1996397|NCT02488863|Other|MRI Neuroimaging|MRI scans to be use to measure the structural and functional integrity of the brain.
1996398|NCT02488863|Other|Quantitative Sensory Testing|Vibratory Detection Thresholds, Tactile Detection Thresholds and Temporal Summation, Thermal Detection Thresholds, Pain Thresholds and Temporal Summation, Allodynia and Temporal Summation, and Punctate Pain Testing and Temporal Summation
1996399|NCT02488863|Other|Questionnaires|RAND 36-item Health Survey (SF-36), Multidimensional Pain Inventory (MPI), the Pittsburgh Sleep Quality Index (PSQI), the trait version of the State-Trait Anxiety Inventory (STAI), the trait version of the Positive and Negative Affect Schedule (PANAS) and the Pain Disability Index (PDI), NIH Cognition toolbox Dimensional Card Sort test, the Stroop Interference test, the Ruff Figural Fluency test, The Montreal Cognitive Assessment (MoCA), and the Center for Epidemiologic Studies Depression Scale (CES-D).
1996400|NCT02488863|Other|Physical Function Testing|Upper Limb Isometric Strength, Short physical performance battery (SPPB), 400 Meter Walk, and Knee Extension Isokinetic Strength
1996401|NCT02489045|Drug|SHAPE measurement (Sonazoid ultrasoud contrast agent)|Three vials with 48 µl of Sonazoid (GE Healthcare, Oslo, Norway) microbubbles (6 ml) will be prepared and drawn into a 10 ml syringe, placed in a syringe pump. Sonazoid will be co-infused at a rate of 0.024 µl/kg body weight/minute (suspension infusion rate of 0.18 ml/kg/hour) together with a 0.9% NaCl solution infused at a rate of at least 2 ml/min.
1996402|NCT02487823|Drug|BKM120 in combination with LH-RH agonists (suprefact) and bicalutamide|BKM 120, LH-RH agonists and Bicalutamide
1996403|NCT02487771|Drug|DHA|600 mg DHA capsule
1996413|NCT02486302|Drug|Etanercept|Etanercept shall be used according to clinical practice and in line with the summary of product characteristics.
1996414|NCT02484950|Biological|Mesenchymal stem cell augmentation in rotator cuff repair|Patients undergoing mesenchymal stem cell augmentation will receive a total injection of 6 milliliters (mL). Of this, 3 mL will be injected in the tendon at the junction between bone and tendon, while 3 mL will be injected in the bone at the site of the surgical footprint.
1996415|NCT02484950|Procedure|Standard arthroscopic rotator cuff repair|All patients will undergo full thickness rotator cuff repair using a double row, transosseous-equivalent (TOE) repair with anchor/suture technique. Acromioplasty will be performed in all patients. Alternate procedures such as biceps tenotomy/tenodesis and distal clavicle excision will be performed at the discretion of the surgeon and recorded.
1996416|NCT02484430|Other|Laboratory Biomarker Analysis|Correlative studies
1996417|NCT02484430|Other|Pharmacological Study|Correlative studies
1996418|NCT02484430|Drug|Sapanisertib|Given PO
1996430|NCT02483325|Drug|Allogeneic transplant conditioning|Allogeneic transplant
1996433|NCT02482350|Behavioral|Reading Training|"Healthy subjects read moving (scrolling) text faster than static text. This type of text, also called Times Square presentation, induces a form of involuntary eye movement called optokinetic nystagmus (OKN) in the reader and, when used as part of a rehabilitation program, has been shown to improve subsequent reading performance of static text."
1996434|NCT02481037|Other|Primary care clinical pathway|Installing a primary care clinical pathway for managing childhood asthma into clinicians' electronic medical record (EMR) to facilitate the use of best-evidence by practitioners.
1996435|NCT02481037|Other|Asthma education|Physicians will receive web-based education through an interactive learning module regarding best management for childhood asthma and use of the primary care clinical pathway. Chronic disease management (CDM) health professionals in practices will attend asthma education sessions delivered by an asthma educator. This training will be then used by the CDM professional to provide targeted and timely asthma education to parents and children with asthma.
1996436|NCT02481037|Other|EMR embedded dashboard|An EMR embedded dashboard will deliver real-time feedback to clinicians.
1996437|NCT02481778|Other|Blood sampling|
1996440|NCT02478996|Other|Internet-based exercise program|Patients undergo internet-based perioperative exercise program (iPEP), including daily endurance, resistance and ventilation training
1996442|NCT02478580|Drug|Nuvigil|Patients will receive Nuvigil before the surgery
1996443|NCT02478580|Drug|Placebo|Placebo will be given before surgery
1996458|NCT02476084|Other|Synovial biopsy|US guided synovial biopsy of an inflamed joint including wrists, MCP joints and knees.
1996586|NCT02444403|Behavioral|Police Education Program designed to align law enforcement and HIV prevention in Tijuana|"The 3.5-hour PEP course consists of 3 modules. Module I covers basic epidemiology, prevention and treatment of HIV, viral hepatitis and STIs, safe syringe disposal and fundamentals of addiction. Post-exposure protocols and appropriate follow-up procedures are outlined. Module II covers key provisions of Mexico's national drug policy (narcomenudeo, which defines amounts of drugs allowed for personal possession), as well as other legal provisions pertinent to HIV prevention, including the legality of syringe and condom possession. Module III covers public health-based interventions targeting PWID (SEPs, OST) and deconstructs myths typical among law enforcement (i.e., drug users do not care about their health, SEPs increase the risk of NSIs).
A sub-cohort sample will be invited to undergo pre- and post-PEP surveys with semi-annual follow-up for 2 years to assess self-reported NSIs (Aim 1), attitudinal and behavior changes (Aim 2) and mediators/moderators (Aim 3)."
1996587|NCT02443571|Radiation|Fluciclovine (18F)|Not applicable. This is an observational study.
1996590|NCT02443077|Procedure|Autologous Bone Marrow Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
1996591|NCT02443077|Procedure|Autologous Hematopoietic Stem Cell Transplantation|Undergo autologous hematopoietic progenitor cells or bone marrow transplant
1996592|NCT02443077|Drug|Carmustine|Given IV
1996593|NCT02443077|Drug|Cyclophosphamide|Given IV
1996594|NCT02443077|Drug|Cytarabine|Given IV
1996595|NCT02443077|Drug|Etoposide|Given IV
1996596|NCT02443077|Drug|Ibrutinib|Given PO
1996597|NCT02443077|Other|Laboratory Biomarker Analysis|Correlative studies
1996598|NCT02443077|Drug|Melphalan|Given IV
1996599|NCT02443077|Other|Placebo|Given PO
1996602|NCT02441166|Procedure|Mastocytosis diagnosis|Some samples will be extracted from bone marrow aspirate and peripheral blood on the inclusion day to do diagnosis tests. WHO criteria will be used as the reference standard.
1996603|NCT02438280|Device|AcceleDent, Vibrational Device|Participants will receive one of two vibrational units
1996605|NCT02438384|Behavioral|Video|This is a 10 minute interactive video which provided information to the viewer regarding the safe and effective use of analgesics for acute musculoskeletal pain at home. The focus is on acetaminophen, NSAIDs, and opioids.
1996606|NCT02438384|Behavioral|Phone follow-up|The call will be made by the study coordinator, who is a medical student. Any patients reporting a pain score in the past 24 hours of 4 or more will be re-contacted by an emergency physician with special training in geriatric pain management. This individual will provide recommendations to the patient regarding treatment options.
1996607|NCT02437656|Drug|Metformin|"J3 - J10 (7 days minimum) : 850 mg 2 times / day
J10 - 48h before surgery : 850 mg 3 times / day"
1996608|NCT02435615|Device|SaniSal Oral Fluid Collector|SaniSal is an oral fluid collector used to collect oral fluid from the mouth with an absorbant sponge.
1996609|NCT02435576|Radiation|Radiotherapy (primary or postoperative)|
1996610|NCT02435277|Drug|Low Metformin|1100 mg L Leucine in combination with 125 mg of Metformin BID
1996611|NCT02435277|Drug|Mid Metformin|1100 mg L Leucine in combination with 250mg Metformin BID
1996612|NCT02435277|Drug|High Metformin|1100 mg of L Leucine in combination with 500 mg Metformin BID
1996613|NCT02435277|Drug|Metformin|500 mg Metformin BID until day 14 with dose escalation at day 14 to 850 mg Metformin BID
1996615|NCT02434146|Drug|Topical Phenylephrine Solution|Given topically via spray
1996616|NCT02432456|Drug|Ketamine|All individuals randomized to the experimental arm of the trial will receive early ketamine therapy (within 6 hours of admission) at a rate of 0.15 mg/kg/hr dosed based on ideal body weight. Individuals in the control arm will receive our standard of care for thoracic trauma patients, however, they will receive an additional placebo infusion of normal saline.
1996617|NCT02432456|Drug|Placebo|Individuals enrolled into the control arm of the trial will receive a normal saline placebo infusion at a rate equivalent to the dosage of ketamine in the experimental arm.
1996618|NCT02432456|Procedure|Intercostal Nerve Block|All individuals enrolled into the trial will undergo an Intercostal Nerve Blockade as a part of the institutional standard of care for rib fractures. This procedure will be performed according to current standard protocols in the Emergency Department or on admission.
1996619|NCT02432456|Drug|Acetaminophen|All patients admitted to the hospital will be placed on scheduled acetaminophen 1000mg PO q 6 hours unless signs of liver disease/impairment or creatinine clearance < 35ml/min at which point dosage would be reduced to 650mg q 8 hours. Individuals unable to take oral medications would be placed on intravenous acetaminophen.
1996620|NCT02432456|Drug|Ibuprofen|All patients will be placed on scheduled Ibuprofen or an equivalent NSAID at dosage of 600mg every 6 hours. Patients must have a Glomerular Filtration Rate > 60 ml/min with no contraindications to NSAID therapy (e.g. Aspirin use, allergy/sensitivity, concurrent ACE inhibitor use, other nephrotoxins, etc)
1996621|NCT02432456|Drug|Pantoprazole|All individuals on scheduled Non-Steroidal Anti-Inflammatory Drug (NSAID) therapy will receive scheduled pantoprazole at 40mg daily. Individuals unable to take medications orally will be placed on intravenous therapy. Individuals with previous reaction or intolerance to pantoprazole will be placed on an equivalent proton pump inhibitor.
1996622|NCT02432456|Drug|Methocarbamol|All individuals enrolled in the trial will be placed on scheduled methocarbamol 500 mg orally every 6 hours while admitted. Individuals with previous intolerance to methocarbamol will be placed on a pharmacy directed equivalent.
1996623|NCT02432456|Drug|Opioid|"All individuals will receive as needed opiate therapy as an adjunct to the scheduled medications and ketamine/placebo solution. Choice in opiate therapy will be at the discretion of the attending trauma faculty. Dosage and adjustments will be in accordance with the institutional policy on appropriate opiate dosage adjustment."
1996624|NCT02432235|Drug|ADCT-301|intravenous infusion
1996691|NCT02414269|Genetic|iCasp9M28z T cell infusions|Administration through the pleural catheter- On day 0 patients will be treated with genetically modified T cells. Thirty to 60 minutes before T cell infusion, patients will be given 650 mg of acetaminophen orally and 25- 50 mg of diphenhydramine orally or intravenously, to prevent infusion-related reactions. The genetically modified T cells will be infused for at least 15 minutes and no more than 2 hours through the indwelling pleural catheter depending on the volume of the T cells. A physician will be available during the infusion. Please note, during formulation of iCasp9M28z T cells, under or over estimation of CAR modified T Cells may occur. Patient may receive an altered fractionation of the total dose or up to 35% over or under total cell dose with approval of the PI.
1996692|NCT02414269|Drug|cyclophosphamide|Patients will receive cyclophosphamide intravenously (at 1.5 g/m^2)
1996694|NCT02412982|Drug|Enoxaparin 40 mg q12h|Patients receive enoxaparin 40 mg every 12 hours. Dose will be escalated to enoxaparin 50 mg every 12 hours if steady state trough concentration is still subtherapeutic.
1996695|NCT02412982|Drug|Enoxaparin 30 mg q8h|Patients receive enoxaparin 30 mg every 8 hours.
1996696|NCT02410473|Other|Discarded blood samples|Will utilize the discarded blood from routine clinical blood samples to evaluate the input of the newer technologies that helped for the diagnostic of coagulopathy.
1996697|NCT02410473|Other|Discarded Urine Sample|Will utilized the discarded urine samples from the routinely placed Foley catheter to measure the indices of oxidative stress.
1996699|NCT02408692|Drug|ECx1|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). After this visit, women with a BMI of <25 kg/m2 will have completed study participation.
1996700|NCT02408692|Drug|ECx2|At the first treatment visit, all women will be given the study drug (1.5 mg of levonorgestrel) and several blood samples will be taken over 2.5 hours). For women with a BMI of 30kg/m2 and greater, one additional visit will be required and study drug (3 mg of levonorgestrel) will be given and several blood samples will be taken over 2.5 hours)
1996705|NCT02408120|Drug|Insulin glargine|"Half of total daily dose (TDD) will be given as insulin glargine and will be given once daily, at the same time of the day.
Daily insulin dose will be adjusted as follow:
If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change
If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day
If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day
If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day
If a patient develops hypoglycemia (BG <70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
1996706|NCT02408120|Drug|Insulin aspart|"Half of total daily dose will be given as insulin aspart and in three equally divided doses before each meal. To prevent hypoglycemia, if a subject is not able to eat, the dose of aspart will be held.
Daily insulin dose will be adjusted as follow:
If the fasting and pre-dinner BG is between 100 - 140 mg/dL in the absence of hypoglycemia the previous day: no change
If the fasting and pre-dinner BG is between 140 - 180 mg/dL in the absence of hypoglycemia: increase basal insulin by 10% every day
If the fasting and pre-dinner BG is >180 mg/dL in the absence of hypoglycemia the previous day: increase basal insulin dose by 20% every day
If the fasting and pre-dinner BG is between 70 - 99 mg/dL in the absence of hypoglycemia: decrease TDD (basal and prandial) insulin dose by 10% every day
If a patient develops hypoglycemia (BG <70 mg/dL), the insulin TDD (basal and prandial) should be decreased by 20%."
1996707|NCT02408120|Drug|Supplemental insulin aspart|"Insulin aspart will be administered following the supplemental insulin scale protocol.
For the arm receiving supplemental insulin aspart at BG levels greater than 140 mg/dL, then supplemental insulin scale is as follows:
BG >141-180 mg/dL; 2-4 units of insulin aspart
BG between 181-220 mg/dL; 3-6 units of insulin aspart
BG between 221-260 mg/dL; 4-8 units of insulin aspart
BG between 261-300 mg/dL; 5-10 units of insulin aspart
BG between 301-350 mg/dL; 6-12 units of insulin aspart
BG between 351-400 mg/dL; 7-14 units of insulin aspart
BG > 400 mg/dL; 8-16 units of insulin aspart
For the arm receiving supplemental insulin aspart at BG levels greater than 260 mg/dL, then supplemental insulin scale is as follows:
BG between 261-300 mg/dL; 5-10 units of insulin aspart
BG between 301-350 mg/dL; 6-12 units of insulin aspart
BG between 351-400 mg/dL; 7-14 units of insulin aspart
BG > 400 mg/dL; 8-16 units of insulin aspart"
1996756|NCT02388776|Device|ROTEM|A blood sample and reagents are placed into a small cup. A pin suspended from a wire is immersed into the sample. The pin rotates back and forth at a fixed angle. The movement of the pin is optically monitored and converted into a real time measurement that is represented graphically. Prior to clot formation, pin rotation is unhindered and is graphically represented as a straight line. As the subject's blood sample starts to clot, strands of clot form between the pin and the cup wall, restricting the movement of the pin depending on the strength of the clot. Graphically, this is represented as a symmetrical widening of the curve.
1996710|NCT02407223|Drug|Group 1: Placebo|Participants will receive placebo SC at Weeks 0, 4, 16, and 20. At Week 24, all participants (except those who early escaped) will crossover to receive ustekinumab 45 or 90 mg SC at Weeks 24 and 28 followed by every 12 weeks up to Week 52. At Week 16, participants in placebo group with < 10% improvement from baseline in both total back pain and morning stiffness measures at Week 12 and 16 will enter early escape to receive ustekinumab 45 mg or 90 mg at Weeks 16, 20, and 28 followed by every 12 weeks up to Week 52. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and 52 will be re-randomized to receive placebo or ustekinumab every 12 weeks up to Week 88. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or 52 will continue with ustekinumab every 12 weeks up to Week 88.
1996711|NCT02407223|Drug|Group 2: Ustekinumab 45 mg|Participants will receive ustekinumab 45 mg subcutaneously at Weeks 0 and 4, followed by every 12 weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will be re-randomized to receive either placebo or ustekinumab 45 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 45 mg every 12 weeks through Week 88.
1996712|NCT02407223|Drug|Group 3: Ustekinumab 90 mg|Participants will receive ustekinumab 90 mg subcutaneously at Weeks 0 and 4, followed by every four weeks through Week 52. At Weeks 20 and 24, participants will receive placebo subcutaneously to maintain the blind. At Week 52, participants who achieved inactive disease by ASDAS (ESR) <1.3 at both Week 40 and Week 52 will receive either placebo or ustekinumab 90 mg every 12 weeks in a blinded fashion. At Week 52, participants who did not achieve inactive disease by ASDAS (ESR) <1.3 at Week 40 or Week 52 will continue receiving ustekinumab 90 mg every 12 weeks through Week 88.
1996719|NCT02401815|Drug|PLX9486|PLX9486 tablets, 50mg
1996720|NCT02401815|Drug|PLX3397|PLX3397 capsules, 200mg
1996721|NCT02401815|Drug|Sunitinib|
1996722|NCT02401009|Other|HCT or other cellular therapies|Hematopoietic stem cell transplantation or other cellular infusion therapy
1996723|NCT02400190|Other|endocrine therapy alone without radiotherapy|Patients will not receive radiotherapy, which is the current standard for treatment for their type of breast cancer.
1996724|NCT02400138|Other|Respiratory training|Respiratory training will include training of the inspiratory and expiratory muscle seven times per week over eight weeks, during 40 minutes, divided into two 20-min sessions (morning and afternoon). Each 20-min session comprised 4-min sets of respiratory training, followed by 1-min rest between the sets. The training program will be carried-out with the Orygen Dual Valve regulated at 50% of the subjects' maximal inspiratory and expiratory pressure values. Once a week, the treating physiotherapist performed a home visit, measured the current values of inspiratory and expiratory strength, and progressed the load to 50% of the new values.
1996725|NCT02400138|Other|Control|The control/sham group will underwent exactly the same protocol and weekly monitoring at home, but the participants will receive the devices without resistance of the spring.
1996726|NCT02398721|Other|Fine Needle Aspiration Cytology|
1996727|NCT02398500|Biological|LMG324|IVT injection
1996728|NCT02398500|Biological|Ranibizumab 0.5 mg|IVT injection
1996729|NCT02398500|Biological|Sham|Fake injection used for masking purposes
1996730|NCT02397616|Other|high resolution esophageal manometry|high resolution esophageal manometry using liquid and solid swallows and a test meal.
1996731|NCT02396862|Drug|Available Recombinant, and Human Factor VIII products incl. Kogenate FS (Recombinant Factor VIII, BAY14-2222)|Recombinant and Human Factor VIII / Used on demand or prophylaxis of bleeds
1996732|NCT02395653|Drug|fentanyl|An opioid that has been administered parenterally as an anesthetic and analgesic for more than 20 years.
1996788|NCT02372864|Behavioral|Mindfulness based stress reduction (MBSR)|Mindfulness based stress reduction (MBSR) is a standardized eight-week psychosocial intervention delivered by certified trainers. The programme consists of a weekly class of two and half hours for a period of eight weeks and a full retreat day. Furthermore participants are asked to practice exercises at home for 45 minutes, six days a week. The MBSR class will consist of ten to twelve persons, starting at different weekdays and moments of the day. If during the inclusion process it becomes apparent that a group of participants (provided a sufficient group size) comes from a region (e.g. Friesland or Overijssel) with a considerable amount of traveling time to the UMCG, efforts will be made to start a MBSR training in the region with trainers from the UMCG.
1996789|NCT02372643|Other|clitoral, transvaginal and transrectal ultrasound|Doppler Ultrasound assessment of clitoral hemodynamics will be performed in all subjects. Transvaginal and transrectal ultrasound will be performed in subjects giving their consent to these procedures.
1996792|NCT02371551|Other|Blood/urine sampling|Routine chemistry profile
1996793|NCT02371551|Other|Conventional routine CT examination|Standard diagnostic examination
1996794|NCT02371551|Other|Contrast-enhanced renal ultrasonography (CEUS)|Study-specific diagnostic examination
1996795|NCT02371551|Other|Functional MRI|Study-specific diagnostic examination
1996796|NCT02371525|Behavioral|Prepmate|A novel multi-modal, technology-based intervention for pre-exposure prophylaxis (PrEP) adherence support .
1996797|NCT02369393|Behavioral|Behavioral Activation|Behavioral Activation intervention promotes the involvement in meaningful activities close to personal values.
1996798|NCT02369393|Behavioral|Physical Activity|Physical Activity intervention promotes the gradual increase of the frequency and intensity of PA levels, with special attention to motivational strategies.
1996807|NCT02366871|Drug|Oral apixaban|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
1996808|NCT02366871|Drug|Subcutaneous enoxaparin|To evaluate the incidence of major bleeding (including CRNM bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg BID compared to current standard of care, subcutaneous enoxaparin 40 mg QD for 28 days post surgery.
1996809|NCT02366975|Drug|Testosterone gel 2%|testosterone gel 2% (50mg/die).
1996810|NCT02366975|Other|Placebo|placebo gel
1996814|NCT02364531|Other|Abiraterone Acetate (ZYTIGA): Prostate Cancer Registry|Participants will not receive any intervention in this study. The chemotherapy-naive metastatic castrate-resistant prostate cancer (mCRPC) participants who, on failing conventional androgen deprivation therapy (ADT), are prescribed to initiate Abiraterone Acetate (ZYTIGA) therapy as part of their physician's treatment approach for their asymptomatic or mildly symptomatic disease, will be observed in this study. Participants will receive standard of care therapy.
1996826|NCT02361671|Other|Optic Nerve Sheath Diameter using an ultrasound|Optic nerve sheath diameter will be measured by ultrasound preoperatively on the day of surgery, Immediate postoperative period (within 24 hours) or 6-8 weeks after surgery on the follow-up visit.
1996827|NCT02361385|Other|this is not an interventional study|this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
1996829|NCT02359760|Procedure|Piezocision|Flapless corticotomies
1996830|NCT02358941|Behavioral|Neurofeedback training|In neurofeedback training, EEG-activity is visualized and fed back to the participant online on a computer screen. Successful regulation is rewarded by bonus points. The aim is to gain control over one's brain activity and to be able to switch to or to maintain a more wakeful, alert or focussed state.
1996831|NCT02358941|Behavioral|Computerized cognitive training|In computerized cognitive training, impaired neuropsychological functions, such as inhibition, working memory, distractibility, are directly trained by adaptive computerized software programs. We use training programs from a scientifically based training system for patients presenting problems with sustained, focussed or selective attention, working memory, inhibition, processing speed. Good performance / improvements are rewarded with bonus points.
1996832|NCT02357459|Drug|FX006|Single intra-articular injection
1996833|NCT02357459|Drug|Normal Saline|Single intra-articular injection
1996834|NCT02357459|Drug|TCA IR|Single intra-articular injection
1996835|NCT02358343|Behavioral|Engagement Interview|An Engagement Interview will comprise a one-on-one session with the patient, during which the health-care provider will use reflective statements and non-judgmental listening techniques, will explore barriers to treatment, and will help patient articulate ambivalence about engaging in treatment. This session will be enhanced with a 40-minute DVD that the subject will watch with the therapist in the dialysis facility. The subject will be encouraged to take the DVD home with them and watch it with their family members as well.
1996836|NCT02358343|Behavioral|Cognitive Behavioral Therapy|Cognitive Behavioral Therapy (CBT) is a short-term psychotherapy that will focus on how the individual is thinking, behaving, and communicating today rather than on their childhood experience. The therapist will assist the patient in identifying specific distortions (cognitive assessment) and biases in thinking and will provide guidance on how to change this thinking. During the course of intervention, study subjects will undergo assessment of severity of depressive symptoms using Quick Inventory of Depressive Symptoms - Self-Report (QIDS-SR) every two weeks for the first six weeks (weeks 0, 2, 4, and 6) and every three weeks for the next six weeks (weeks 9 and 12).
1996837|NCT02358343|Drug|Antidepressant Drug Therapy|The site investigators will prescribe sertraline drug at a starting dose of 25 mg oral tablets. Dose titration will be implemented using standardized assessments of depressive symptoms and drug side effects; and the research team and the patient make joint decisions to maintain, increase, or decrease the dose. This will help establish the highest effective but tolerable dose tailored for each patient. The QIDS-SR scale will be used to assess the clinical response for dose titration. The FIBSER scale will be used to assess side effects and the degree to which they interfere with day-to-day functions. The participant-specific dose at week 6, up to a maximum of 200 mg/d, will be continued for the remaining 6 weeks.
1996841|NCT02356003|Device|Low frequency repetitive transcranial magnetic stimulation|Baseline high-resolution anatomical magnetic resonance images will allow individualized neuronavigation (Brainsight 2, Rogue Research, Montreal QC) to co-register the transcranial magnetic stimulation Airfilm coil (Magistim, UK) precisely to the supplementary motor area as defined by functional magnetic resonance imaging. Interventional low frequency repetitive transcranial magnetic stimulation parameters will be: intensity 100% resting motor threshold, frequency 1 Hz, duration = 20 minutes (1200 stimulations). Treatments will occur on each weekday at the same time of day for three weeks (15 total). These are standard parameters for low frequency repetitive transcranial magnetic stimulation and are well tolerated in children.
1996842|NCT02346968|Other|Blood and urine sampling|Blood and urine sampling (in the context of routine sampling)
1996843|NCT02345577|Other|Stochastic whole body vibration (WBV) therapy - Physiotherapeutical intervention|Physiotherapeutical intervention
1996844|NCT02345577|Other|Stochastic whole body vibration (WBV) therapy - Sham physiotherapeutical intervention|Sham physiotherapeutical intervention
1996845|NCT02345772|Drug|fulvestrant 500 mg|Hormonal therapy with fulvestrant 500 mg will be administered intramuscularly on days 1, 15 of the first cycle, and thereafter on day 1 of every 28-day cycle for up to 5 cycles before surgery.
1996867|NCT02338947|Procedure|Off-Pump Coronary-Artery Bypass Grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. In order to reduce the risk of bleeding and transfusions an absorbable hemostat is used to sternal bone marrow and recovery of red blood cells in all patients. Off-pump surgery will be performed with the use of heart stabilizers. Patients will be heparinized with 250 IU/kg intravenously to achieve activated clotting time >200s. The proximal anastomosis will be performed according to protocol to be discussed with our advisor. The distal anastomosis will be constructed with the help of mechanical stabilizers and cardiac positioner. Intracoronary shunts will be used routinely.
1996868|NCT02338947|Procedure|On-Pump Coronary-Artery Bypass Grafting|Surgical access to the heart will be gained through a median sternotomy in all of the patients. On-pump surgery will be performed in normothermia, with the use of aortic cross-clamping and cold cardioplegic arrest. Patients will be heparinized with 500 IU/kg to achieve an activated clotting time >480 s. Heparin will be neutralized with 1 mg protamine sulfate per 5000 IU given. During the trial, there will be no changes in the 2 surgical techniques that followed a pre-established protocol.
1996869|NCT02339064|Drug|apomorphine infusion|Treatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
1996871|NCT02337634|Drug|Placebo|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
1996872|NCT02337634|Drug|Milk Thistle|Taken as two 150mg capsules BID for 2 weeks, then 300mg BID for remainder of the study.
1996873|NCT02337530|Drug|Selumetinib|
1996874|NCT02337530|Drug|Pemetrexed|
1996875|NCT02337530|Drug|Cisplatin|
1996876|NCT02337530|Drug|Carboplatin|
1996878|NCT02335099|Drug|ticagrelor|ticagrelor 90 mg twice a day for 6 months
1996879|NCT02335099|Drug|Placebo|1 pill twice a day for 6 months
1996880|NCT02333149|Dietary Supplement|Melatonin|"Children <40 kg will take one tablet, melatonin 3 mg, oral, 30 - 60 minutes prior to bedtime.
Children ≥40 kg will take two tablets, melatonin 3 mg, oral, 30-60 minutes prior to bedtime."
1996881|NCT02333149|Drug|Placebo|Placebo frequency and volume are identical to the experimental arm
1996882|NCT02332239|Behavioral|iDOVE Intervention (ED+text)|"In-ED brief session, introducing basic principles of cognitive behavioral theory and the structure of the text-message portion of the intervention
Eight-week longitudinal tailored text-message program"
1996883|NCT02332239|Behavioral|Control (EUC)|"In-ED brief session, discussing home safety & nutrition
Eight-week longitudinal home safety & nutrition text-message program"
1996884|NCT02331134|Drug|Filgrastim|Patients will receive 10 μg/kg/day of filgrastim subcutaneously in a 4-day mobilization schedule
1996885|NCT02329639|Genetic|genetic interaction analysis|VEGFR-2 rs11133360/IL-8 rs4073 genetic interaction analysis
1996886|NCT02328820|Other|Percutaneous coronary intervention (PCI)|For lesions with both FFR<=0.8 and CFR<2.0
1996887|NCT02328820|Other|Optimal medical therapy (OMT)|For lesions with FFR>0.8 or CFR>=2.0 or both
1996888|NCT02327793|Drug|Nitroglycerin|
1996889|NCT02327793|Drug|Labetalol|
1996890|NCT02326441|Drug|KX2-361|
1996892|NCT02323256|Other|Auditory steady-state response ASSR|comparison of ASSR amplitudes in response to amplitude-modulated sounds delivered at different intensities
1996893|NCT02323256|Other|Speech-ABR|
1996894|NCT02323256|Other|Acoustic Change Complex ACC|comparison of ACC complex in response to changes within speech stimulation
1996895|NCT02323256|Other|P1-N1-P2 complex and Mismatch Negativity MMN|comparison of amplitudes and latencies of P1-N1-P2 complex and MMN generated in response to the detection of changes in a series of auditory stimulation
1996896|NCT02322411|Device|Isometric Progressive Resistance Oropharyngeal Therapy|Isometric Progressive Resistance Oropharyngeal Therapy is an approach to oropharyngeal strengthening. This particular use of I-PRO therapy will be facilitated by the Swallow Strong device.
1996897|NCT02322411|Behavioral|Compensatory approaches|
1996900|NCT02321904|Procedure|Corneal Confocal Microscopy|Close-up pictures of the front part of the eye (the cornea)
1996901|NCT02321904|Procedure|Nerve Conduction Studies|The following assessments will be made: a) amplitude of nerve action potential (μV) and conduction velocity (m/s) of the sural sensory nerve by antidromic stimulation; b) motor nerve conduction velocity (m/s), maximum M-wave amplitude (mV) and motor nerve distal latency (ms) of the peroneal motor nerve; and c) tibial nerve conduction study will also be obtained if tolerated.
1996902|NCT02321904|Procedure|Quantitative sensory testing|Standardized vibratory and thermal stimulation levels applied to the subject's non-dominant big toe.
1996903|NCT02321904|Procedure|Neuropathy Symptom Score|A list of 18 motor, sensory and autonomic symptoms encountered in a diabetic patients with neuropathy obtained by interview.
1996904|NCT02321904|Procedure|Clinical nerve examination|Summated score of the lower extremities. Neurological examination assessing muscle strength, knee and ankle reflexes, sensation in the great toes will be evaluated for light touch-pressure, temperature, pin-prick, vibratory sense and joint position sense.
1996905|NCT02321930|Drug|tofacitinib 5mg po bid|
1996906|NCT02320682|Device|Surgery for Total Hip Arthroplasty (THA)|THA surgery where four prosthetic components will randomly be inserted. Randomly an Exeter or SP-CL femur component will be combined with randomly a Delta TT or Delta PF acetabular component.
1996907|NCT02320357|Drug|Treatment by clopidogrel|Peripheral blood will be obtained during the study
1996982|NCT02298582|Drug|intranasal fentanyl|During the two first sessions of care or rehabilitation, patients do not receive Pecfent® in order to assess their basal pain. During the following four sessions, patients will receive transmucosal fentanyl, 10 minutes before care. A titration of PecFent will be done at each session
1996908|NCT02320344|Behavioral|Partners in Care|"The diabetes self-management intervention is titled, Partners in Care, emphasizing that there are many individuals and groups that one can call upon to assist with managing one's diabetes. The content includes practical behavioral strategies to improve diabetes self-management practices. The 12 week curriculum provides a basic overview of diabetes and self-management activities, standards of care recommended by the American Diabetes Association, strategies to improve patient-provider communication, support needed for diabetes self-management, information about diabetes medications, and ways to avoid diabetes-related complications."
1996909|NCT02320331|Behavioral|PILI Lifestyle Program|A 12-week Individual-focused Behavioral Weight Loss Intervention. Our 12-week intervention is modeled after the Diabetes Prevention Program's (DPP) Lifestyle Intervention. Each of the 8 lessons of this 12-week intervention will be done in a group classroom setting via trained community peer educators for a total of 8 group meetings as outlined above. Lesson 1 through 4 will be done every week, once a week, for 4 weeks followed by every other week for the remaining 4 lessons (lessons 5 through 8). Each group meeting will have between 12 to 15 people and take 1 to 1 ½ hours to complete. After completing the 12-week behavioral weight loss intervention, participants will participate in an additional 6 lessons. A lesson will be done once-a-month. These 6 lessons will teach participants how to involve their family and friends in their healthy lifestyle changes.
1996911|NCT02319408|Radiation|Preoperative radiation|Lobectomy for lung cancer following preoperative radiation
1996912|NCT02319369|Drug|DS-3032b|DS-3032b will be administered as a single oral capsule or as a combination of multiple oral capsules containing 5 mg, 20 mg, 80 mg, and/or 200 mg DS-3032b
1996918|NCT02318836|Drug|Lofexidine Hydrochloride (HCl) tablets|Lofexidine HCl tablets (two 200 µg tablets) will be administered orally with 240 mL room temperature tap water as a single 400 µg dose in the morning on Day 1 after a 10 hour overnight fast.
1996920|NCT02316860|Other|Passive tilt test|Passive tilt test (without pharmacological provocation). After a horizontal supine rest period of 5 min, the tilt table was inclined at 60° head-up position for 30 min. A positive response was defined according to the European Society of Cardiology guidelines for the diagnosis and management of syncope
1996923|NCT02315976|Drug|Propatyl Nitrate|Propatyl nitrate 10mg administered orally, three times daily
1996924|NCT02316197|Drug|MSC2490484A|Initial starting dose at 100 mg (oral administration), once daily, subsequent doses and treatment regimens will be determined by the SMC (once or twice daily). MSC2490484A will be administered in continuous 21-day cycles in dose escalation or dose expansion cohorts, as long as they do not experience unacceptable toxicity or disease progression.
1996929|NCT02313506|Behavioral|Education session, Fitbit Flex, and remote coaching by a PT|Participants will receive a brief education session, use of a commercially available physical activity tracker (Fitbit Flex), and remote counselling by a PT. Intervention will be received immediately.
1996930|NCT02313506|Behavioral|Same intervention with a 1 month delay|The Delayed Intervention Group will receive the same intervention as the Immediate Intervention Group, but with a 1 Month delay.
1996931|NCT02313103|Drug|lofexidine HCl|400 micrograms
1996932|NCT02311920|Biological|Ipilimumab|Given IV
1996933|NCT02311920|Other|Laboratory Biomarker Analysis|Correlative studies
1996934|NCT02311920|Biological|Nivolumab|Given IV
1996935|NCT02311920|Drug|Temozolomide|Given PO
1996938|NCT02311959|Procedure|Nipple sparing mastectomy|"Standardized surgical procedure by :
Nipple sparing mastectomy with nipple core histopathology.
Immediate breast reconstruction (flap and/or implant).
+/- lymph node evaluation (sentinel node procedure or axillary dissection)."
1996983|NCT02296320|Drug|MEDI4893|MEDI4893 (high dose)
1996984|NCT02296320|Other|Placebo|Placebo
1996994|NCT02290184|Behavioral|PilAm Go4Health Weight-loss Program|This is a 3-month lifestyle intervention program promoting weight loss through physical activity and health diet using a mobile health application (app), pedometer to track daily step-counts, and social networking (in-person and virtual social networking through Facebook) to reduce risks for metabolic syndrome in Filipino Americans with type 2 diabetes on metformin. Subjects will be asked: 1) to use a mobile app diary every day to input their weight, and calories (food and drink intake) and 2) wear a pedometer everyday to monitor their physical activity (step-counts).
1996995|NCT02290028|Device|Sentus QP left ventricular lead|Implantation of quadripolar left ventricular lead in patients with CRT-D indication
1996996|NCT02289833|Drug|Trastuzumab Emtansine|Trastuzumab emtansine will be administered intravenously at a dose of 3.6 mg/kg on Day 1 of 21-day cycles until disease progression (as assessed by the investigator), unmanageable toxicity, or study termination by the Sponsor, whichever occurs first.
1996997|NCT02289456|Drug|nab-Paclitaxel|
1996998|NCT02289456|Drug|Carboplatin|
1997001|NCT02288819|Device|Weight monitoring|The body weight of patients is measured each morning in identical conditions on the same balance during 7 days
1997002|NCT02288819|Drug|Loop diuretic downtitration|"The patient's total daily maintenance dose of loop diuretics is downtitrated during 7 consecutive days.
In case of a total daily maintenance dose ≤40 mg furosemide OR ≤1 mg bumetanide OR ≤20 mg torsemide, the loop diuretic is completely stopped.
In case of a total daily maintenance dose >40 mg furosemide OR >1 mg bumetanide OR >20 mg torsemide, the loop diuretic dose is halved."
1997011|NCT02283671|Biological|Tolerogenic Dendritic cells loaded with myelin peptides|Somatic-cell therapy medicines application
1997012|NCT02284178|Other|Enhanced oropharyngeal suction|Deep oropharyngeal suction with catheter every 4 hours
1997013|NCT02284178|Other|Usual Care|Oral suction with suction swab every 4 hours
1997014|NCT02283411|Device|Abbott Sensor Based Glucose Monitoring System|Subjects will wear the Abbott Sensor Based Glucose Monitoring Systems and will receive no treatment except for safety purposes.
1997015|NCT02280226|Device|magnetic resonance imaging (MRI)|
1997018|NCT02278237|Behavioral|Video Module Education (VME)|
1997019|NCT02278185|Drug|Enzalutamide|Given PO
1997020|NCT02278185|Drug|leuprolide acetate|Given SC or IM
1997021|NCT02278185|Drug|goserelin acetate|Given SC or IM
1997022|NCT02278185|Drug|histrelin acetate|Given SC or IM
1997023|NCT02278185|Drug|triptorelin|Given SC or IM
1997024|NCT02278185|Drug|degarelix|Given SC or IM
1997025|NCT02277990|Device|TYRX Absorbable Antibacterial Envelope|
1997104|NCT02232854|Behavioral|Depression training/supervision program|"The intervention will be composed of:
Training of Primary Health Care teams to ensure compliance to the Clinical Guidelines of the Ministry of Health for the Treatment of Depression. Primary Health Care teams will undergo an Objective Structured Clinical Examination (OSCE) for evaluation.
After the training, a focus group between Primary Health Care teams and study researchers will be held in order to address barriers to clinical guidelines implementation.
Primary Health Care clinics' trained administrative staff will contact patients from a call-center to support treatment adherence.
Psychiatrists, using a web-based platform, will supervise the course of the program, the allocated treatments, the patients' progress, and their response to treatment."
1997105|NCT02231749|Biological|Nivolumab|
1997106|NCT02231749|Biological|Ipilimumab|
1997107|NCT02231749|Drug|Sunitinib|
1997108|NCT02229851|Drug|NNC0195-0092|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
1997109|NCT02229851|Drug|somatropin|Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
1997110|NCT02229851|Drug|placebo|Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Switch to NNC0195-0092 treatment in the extension period.
1997111|NCT02228070|Device|strabismus video goggles|
1997113|NCT02224729|Drug|Bendamustine hydrochloride|Given IV
1997114|NCT02224729|Drug|Bortezomib|Given SC
1997115|NCT02224729|Drug|Dexamethasone|Given PO
1997123|NCT02223637|Biological|Meningococcal quadrivalent CRM-197 conjugate vaccine|This pregnancy registry is strictly observational. Decisions of vaccination are made by health care providers.
1997135|NCT02216578|Drug|cabozantinib|Oral
1997136|NCT02217579|Dietary Supplement|Protein|A food containing 5 grams/serving of supplemental protein.
1997137|NCT02217579|Dietary Supplement|Prebiotic fiber|A food containing 8 grams/serving of supplemental prebiotic fiber.
1997138|NCT02217579|Dietary Supplement|Protein plus prebiotic fiber|A food containing supplemental protein (5 grams/serving) and prebiotic fiber (8 grams/serving).
1997139|NCT02217579|Dietary Supplement|Control|An isocaloric food not containing the test protein and fiber.
1997141|NCT02215616|Drug|Laquinimod|Laquinimod 0.5, 1.0, 1.5 mg
1997142|NCT02215616|Drug|Placebo|Placebo
1997143|NCT02214732|Behavioral|Mindfulness Based Cognitive Therapy|The modified MBCT program for pregnant women is an 8-session group intervention that aims to help women change their relationship to the thoughts, feelings, and bodily sensations that can lead to psychological distress. Participants are guided to recognize and disengage from unhelpful mind states characterized by self-perpetuating patterns of ruminative thought. The intervention was modified to address pregnant women's physical and emotional needs, as well as their risk of perinatal mood episodes.
1997144|NCT02214836|Device|Verasonics Data Acquisition System (VDAS)|Subjects will be imaged the Verasonics Data Acquisition System (VDAS) using conventional clinical outputs within FDA limits. The image processing has been modified. Stone location and size will be determined and compared to clinical determination of stone location and size.
1997148|NCT02209519|Drug|Metronidazole (male partner)|500 mg PO BID for 7 days
1997149|NCT02209519|Other|Placeob (male partner)|matching placebo capsules PO BID for 7 days
1997169|NCT02201108|Drug|Teriflunomide HMR1726|Pharmaceutical form:film-coated tablet Route of administration: oral
1997170|NCT02201108|Drug|Placebo|Pharmaceutical form:tablet Route of administration: oral
1997173|NCT02198378|Drug|MEOPA and paracetamol|The patient will be equipped with a facemask after he/she has been informed. The facemask is adapted to the patient. The patient breathes normally in the mask which is held in place by a member of the SMUR team who has received previous training in use of MEOPA. The gas flow received by the patient is adapted to his/her ventilation.
1997174|NCT02198378|Drug|Morphine|Bolus of 2 mg intravenously if EN = 4 or 5 and 3 mg bolus if EN> 6 followed by reinjection of 2mg every 5 minutes until effective analgesia.
1997184|NCT02192073|Procedure|Suprapectoral Biceps tenodesis|
1997185|NCT02192073|Procedure|Subpectoral biceps tenodesis|
1997186|NCT02190903|Other|General endotracheal anesthesia|"General Anesthesia
Patients randomized to receive general anesthesia induction of anesthesia with intravenous lidocaine, propofol, fentanyl citrate and vecuronium or cisatracurium, following dosing guidelines defined by protocol. Following tracheal intubation, anesthesia will be maintained with sevoflurane in oxygen and air as defined by protocol. End-tidal gas monitoring (for carbon dioxide and sevoflurane) and maintenance, monitoring, and reversal of neuromuscular blockade will be as per HUP and PPMC routine. Immediate postoperative analgesia will be via IV dilaudid dosed intraoperatively as defined by protocol."
1997187|NCT02190903|Other|Regional (spinal) Anesthesia|Patients randomized to receive spinal anesthesia will undergo spinal blockade using standard techniques and medications dosed as per protocol, and will include hyperbaric bupivicaine or tetracaine, fentanyl citrate, and epinephrine; algorithms for management of spinal-related hypotension will be defined by protocol. Intraoperative sedation will be achieved via continuous intravenous propofol infusion; supplemental oxygen will be provided by nasal cannula or facemask as needed. Propofol dose will be titrated to achieve light to moderate sedation, defined as a Richmond Agitation/Sedation Scale (RASS) score of -1 to -318. In the event of block failure induction and maintenance of general endotracheal anesthesia will occur via the procedures outlined above. For all patients, post-operative pain management will be via hydromorphone PCA or PRN hydromorphone bolus, followed by oral oxycodone and acetaminophen.
1997188|NCT02187783|Drug|LEE011|LEE011 600 mg (hard gelatin capsules) will be administered orally once daily for 3 weeks on/1 week off. A complete treatment cycle is defined as 28 days.
1997189|NCT02186275|Drug|Vitamin D3: 3000 or 4000 UI/day then 2,000 UI/day|"Weight at inclusion < 40 kg : 3 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance.
Weight at inclusion ≥ 40 kg : 4 capsules of 1000 UI per day at induction and 2 capsules of 1000 UI per day at maintenance."
1997190|NCT02186275|Drug|Vitamin D3 800 UI/day then 800 UI/day|"Weight < 40 kg: 2 capsules of 400 UI per day and 1 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance
Weight ≥ 40 kg: 2 capsules of 400 UI per day and 2 capsules of placebo at induction and 2 capsules of 400 UI per day at maintenance"
1997191|NCT02187198|Drug|Buprenorphine|
1997192|NCT02187003|Drug|Rivipansel|Rivipansel (GMI-1070) will be infused intravenously every 12 hours up to 15 doses maximum. Subjects aged 12 and over who weigh more than 40 kilograms will receive a dose of 1680 mg of rivipansel, followed by a dose of 840 mg of rivipansel every 12 hours. All subjects aged 6 to 11 years and any subject who weighs 40 kilograms or less, will receive weight-based dosing (mg/kg) of 40 mg/kg of rivipansel (maximum of 1680 mg) followed by a dose of 20 mg/kg of rivipansel (maximum of 840 mg) every 12 hours.
1997193|NCT02187003|Other|Placebo|Placebo (phosphate buffered saline) will be infused intravenously every 12 hours up to 15 doses maximum.
1997200|NCT02185560|Drug|Sorafenib (Nexavar, BAY43-9006)|Patients treated by Physician with Nexavar under approved local prescriptions
1997203|NCT02184104|Dietary Supplement|Caffeine|
1997233|NCT02168400|Device|Transcranial Direct Current Stimulation (tDCS)|TDCS will be performed with Neuroelectrics Starstim Enobio 20, an approved research device without an investigational device exemption due to meeting criteria for non-significant risk. It has built-in safety mechanisms which allow for immediate cessation of stimulation if the subject becomes uncomfortable. The current will be administered via two electrode sponges for 25 mins with 1-2 milliamperes. These administration protocols are in line with protocols that have outlined safe administration (Nitsche 2007; 2008). No side-effects have been reported with the exception of slight itching under the electrode and occasional occurrence of headache, fatigue, or nausea (Poreisz 2007). Electrodes placement: dorsolateral prefrontal cortex (DLPFC); cathode on left DLPFC, anode on right DLPFC.
1997234|NCT02167945|Drug|ABT-450/r/ABT-267|tablet
1997235|NCT02167945|Drug|ABT-333|tablet
1997236|NCT02167945|Drug|Ribavirin (RBV)|tablet
1997237|NCT02166476|Drug|Meropenem-Vaborbactam|Meropenem-vaborbactam
1997238|NCT02166476|Drug|Piperacillin-Tazobactam|Piperacillin-tazobactam
1997239|NCT02166476|Drug|Levofloxacin|Levofloxacin
1997240|NCT02166476|Drug|Saline|Saline
1997252|NCT02165722|Behavioral|4 Pillars Toolkit|"Behavioral: Pillar 1: Convenient Vaccination Services (e.g. use every visit [chronic and acute] as an opportunity to vaccinate; use express vaccination clinics and dedicated vaccination stations; use influenza vaccination as an opportunity to vaccinate for other vaccines).
Behavioral: Pillar 2: Patient Notification (e.g. use electronic reminders and social media for vaccination reminders; use physician recommendations).
Behavioral: Pillar 3: Enhanced Office Systems (e.g. implement Standing Order Programs; use EMR prompts; add vaccination status as a vital sign when rooming).
Behavioral: Pillar 4: Motivation (e.g. establish an office Immunization Champion to track goal progress, aided by research team feedback)."
1997253|NCT02165007|Drug|peripheral blood stem cell graft that are CD34+ selected|Before transplant patients will undergo reduced intensity preparatory regimen consisting of Hydroxyurea, ATG, Fludarabine, Thiotepa, Melphalan. Hydroxyurea will be given at Day -50 to -10, rabbit ATG day -9 to -7 (test dose ATG on day -10), Fludarabine day -8 to -4, Thiotepa Day -4, Melphalan day -3, -2, followed by infusion of a peripheral blood stem cell graft collected from haploidentical family donors that are CD34+ positively selected using the CliniMACS device. Sirolimus will be used for GVHD prophylaxis and given for 9 months post-transplant and then tapered off by one year
1997257|NCT02161783|Drug|Fludarabine|Fludarabine 30 mg/m2 IV over 1 hour given on days -6 through -2 of transplant.
1997258|NCT02161783|Drug|Cyclophosphamide|Cyclophosphamide 14.5 mg/kg IV over 1-2 hours given on days -6 and -5 from transplant. And Cyclophosphamide 50 mg/kg IV over 2 hours given on days +3 and +4 from transplant.
1997259|NCT02161783|Radiation|Total Body Irradiation|TBI 200cGy in a single fraction on day -1 from transplant.
1997260|NCT02161783|Biological|Hematopoietic stem cell infusion|Hematopoietic stem cell infusion given on day 0.
1997263|NCT02160535|Drug|OnabotulinumtoxinA|155 units of OnabotulinumtoxinA administered intramuscularly. Injections are divided across seven injection specific head/neck muscle areas every 12 weeks to prevent chronic migraine post traumatic headache
1997264|NCT02157038|Device|Pedometer|
1997265|NCT02157038|Device|MRI|
1997266|NCT02155218|Other|Standard Injection Rate|Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus.
1997267|NCT02155218|Other|Patient Tailored Injection Rate|"Normally an IV is placed in an arm and the gadolinium contrast (30-40 cc, depending on patient size) is administered through the IV with a power injector as a single bolus. Subjects will have a test bolus and main bolus. We will use a mathematical algorithm to rapidly analyze the test bolus and calculate a predicted best way to inject the main bolus - likely slower and multi-phasic, meaning different flow rates as the bolus injection evolves."
1997268|NCT02155218|Other|gadolinium contrast|
1997271|NCT02152982|Other|Laboratory Biomarker Analysis|Correlative studies
1997272|NCT02152982|Other|Placebo|Given PO
1997273|NCT02152982|Other|Quality-of-Life Assessment|Ancillary studies
1997274|NCT02152982|Drug|Temozolomide|Given PO
1997275|NCT02152982|Drug|Veliparib|Given PO
1997276|NCT02151383|Drug|Serelaxin|Serelaxin will be administered intravenously for up to 48 hours.
1997277|NCT02149264|Drug|Testosterone gel (FE 999303)|
1997278|NCT02149953|Dietary Supplement|Glycine Intake|Oral consumption of eight hourly experimental meals- Includes 4 tracer-free experimental meals containing a mixture of free amino acids, calories from a flavored liquid and protein free cookies and 4- labeled amino acid experimental meals.
1997279|NCT02149823|Drug|Syntocinon 24 Intranasal Units (IU)|
1997328|NCT02124226|Drug|Methotrexate|7.5 mg/week + folic acid the day after
1997329|NCT02124226|Drug|Placebo|matched placebo
1997330|NCT02123485|Device|Low frequency (1 hz) rTMS, as add-on to ECT|Right prefrontal Low frequency (1 hz) repetitive transcranial magnetic stimulation as add-on to ECT.
1997331|NCT02123485|Device|Sham-rTMS|Right prefrontal Low frequency (1 hz) sham-stimulation using af double blind placebo coil as add-on to ECT.
1997334|NCT02118623|Behavioral|Moderated discussion board|"All groups will have access to asynchronous, moderated discussion boards. Assignment to discussion board will be stratified by randomization group (Level 1, 2 or 3). Level 1 access to the discussion board will serve as our peer support control condition, although we do expect some modest benefit from this intervention alone.
The discussion boards will be moderated by research staff, who will be supervised by a trained clinician (masters levels or higher). Discussion boards will be asynchronous, with all posts screened by the moderator(s) before appearing to the group."
1997335|NCT02118623|Behavioral|Psychoeducation|"Online psychoeducation is only available to those randomized to Levels 2 and 3. The core modules of MoodSwings 2.0 will use videos and improved organization of content based on feedback from previous pilot work. Module topic areas include:
What is bipolar disorder? - Content about symptoms and diagnosis
Stress and triggers of illness
Medication and the biological basis of bipolar disorder
Depression - Symptoms, early detection and helpful strategies
Mania and hypomania - Symptoms, early detection and helpful strategies."
1997336|NCT02118623|Behavioral|Interactive Psychosocial Tools|"Online psychosocial tools are only available to those randomized to Level 3. They include structured mood monitoring, medication monitoring, and life charting visual tools. There are also interactive worksheets that encourage awareness of negative thoughts and strategies to challenge them, help participants weight the costs and benefits of different behaviours, problem solving and goal setting, and reinforcing self-affirmation. Participants have the opportunity to build a record of personal triggers of illness and illness profile - including early warning signs, and symptoms typically experienced during an episode of illness, as well as a personal relapse prevention plan."
1997359|NCT02111720|Behavioral|Maybe, Maybe Not|The goals of session one are to introduce participants to the intervention, to assess current decision context, to assist in the clarification of participant values, and to encourage the participant to set specific goals for disclosure decision-making. The goals for session two are to explore the participants' motivations to disclose or not to disclose and the potential costs and rewards of both disclosing and not disclosing. The goals for session three are to guide participants through disclosure decision making, and to support comfort/acceptance with decisions made. The goal of session four is to support the decision-making process. The booster session is used to reinforce the effects of the intervention through continued discussion of disclosure decisions in the preceding months, strategies used in disclosing, and rewards and costs of decision-making.
1997360|NCT02111720|Behavioral|Comprehensive Risk Counseling and Services|CRCS combines traditional case management and HIV risk-reduction in an individualized, client-centered program which focuses on the reduction of risk behavior and addresses a client's psychosocial and medical needs.CRCS focuses on seven core elements: recruitment and engagement; screening, enrolling, and assessing; prevention planning; risk reduction counseling; referrals and service coordination; monitoring; and discharge and maintenance. These core elements represent the framework of the intervention, and provide enough flexibility to allow implementation that most appropriately serves the needs of clients.
1997361|NCT02111707|Drug|Rectal indomethacin 100mg one time before or after ERCP|Patients will receive rectal indomethacin suppository 30 minutes before or immediately after ERCP for prevention of post-procedure pancreatitis. Patients will be randomized to the timing of administration.
1997362|NCT02110303|Drug|Ticagrelor|oral, 90mg tablets, twice daily, 12 month duration
1997363|NCT02110303|Drug|Placebo|Oral tablet (identical to ticagrelor), twice daily, 12 month duration
1997468|NCT02050308|Other|Honoring the Gift of Heart Health|"These sessions help American Indians learn about what they can do to prevent heart disease. We will emphasize the increase consumption of fruits and vegetables as well as addressing other heart healthy activities. Honoring the Gift of Heart Health is a user-friendly program developed especially for American Indians. The manual provides the how-to for leading group education sessions. It offers hands-on activities that help people build the skills they need to make simple, practical, and lasting changes to help them fight heart disease. The protocol will follow procedures as the I-ANBL arm, however, this fruit and vegetable arm will not include individually tailored components, but just interactive web-based materials related to increasing heart health, including certain activities."
1997469|NCT02050308|Drug|Nicotine gum, Patch, or Lozenge or Zyban® or Chantix®|Regardless of the intervention arm to which subjects are assigned, they will choose the option of nicotine replacement therapy they want, as long as they are eligible for it. All participants are offered the medications, but they do not have to take any medication to participate in the study.
1997477|NCT02048852|Other|Reduced Nicotine Content- Non Menthol|Switch from own brand of cigarette to a research cigarette with a Reduced Nicotine Content of 0.07mg nicotine yield without menthol.
1997478|NCT02048852|Other|Reduced Nicotine Content- Menthol|Switch from own brand of cigarette to Reduced nicotine level of each research cigarette to 0.07mg nicotine yield with Menthol
1997479|NCT02048852|Other|Conventional Nicotine Content- Menthol|Allow own brand of Conventional Nicotine-Menthol Cigarette
1997480|NCT02048852|Other|Conventional Nicotine Content- Non Menthol|Switch from own cigarette to a research cigarette which contains Conventional Nicotine yield.
1997481|NCT02047253|Drug|Carfilzomib|Carfilzomib will be administered on days 1, 2, 8, 9, 15, 16 within each 4 week cycle.
1997482|NCT02047253|Drug|Dexamethasone|Administered prior to administration of Study drug
1997483|NCT02047253|Drug|Acyclovir|Administered orally twice daily
1997484|NCT02045381|Procedure|MRI Group|A single research MRI
1997487|NCT02041494|Device|Ventralight|
1997488|NCT02041494|Device|Strattice|
1997497|NCT02037204|Other|Cartilage repair surgery|Single-stage surgery, After debridement, the cartilage defect is filled with the fibrin glue carrier containing autologous chondrons and allogeneic MSCs
1997501|NCT02035553|Drug|Pimavanserin tartrate|Pimavanserin tartrate, 40 mg (two 20 mg tablets), once daily by mouth (equivalent to 34 mg free base pimavanserin)
1997502|NCT02035553|Drug|Placebo|Placebo, two tablets, once daily by mouth
1997504|NCT02032277|Drug|Veliparib|Veliparib
1997505|NCT02032277|Drug|Carboplatin|Carboplatin
1997506|NCT02032277|Drug|Paclitaxel|Paclitaxel
1997507|NCT02032277|Drug|Doxorubicin|Doxorubicin
1997508|NCT02032277|Drug|Cyclophosphamide|Cyclophosphamide
1997509|NCT02032277|Drug|Placebo|Placebo for Veliparib
1997510|NCT02032277|Drug|Placebo|Placebo for Carboplatin
1997511|NCT02031627|Device|pneumatic compression 1 hour per day|Pneumatic compression treatment once per day (1 hour)
1997512|NCT02031627|Device|pneumatic compression - 2 hours per day|pneumatic compression treatment twice per day (am and pm = 2 hours)
1997513|NCT02031627|Device|pneumatic compression - 4 hours per day|pneumatic compression treatment twice per day consisting of 2 consecutive 1 hour treatments in the AM & PM (4 hours)
1997514|NCT02031536|Drug|everolimus|Given PO
1997662|NCT01973335|Drug|Combination therapy with acetazolamide and low-dose loop diuretics|"Patients receive 500 mg of intravenous acetazolamide immediately after randomization, with 250 mg intravenous acetazolamide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.
Patients receive 2 mg of intravenous bumetanide immediately after randomization, with 1 mg intravenous bumetanide administered on each consecutive day in the morning for as long as the patient is considered volume overloaded by his/her treating cardiologist.
If diuresis <1,5 L while the patient is still considered volume overloaded by his/her treating cardiologist, the dose of acetazolamide is maintained at 500 mg and the dose of bumetanide is maintained at 2mg.
In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
1997663|NCT01973335|Drug|High-dose loop diuretics|"Patients receive the double of their daily maintenance dose of oral loop diuretics converted to mg bumetanide as an intravenous bolus after randomization.
Patients continue to receive this dose daily on the next 3 days divided between two administrations with at least a 6 h interval for as long as they are considered volume overloaded by the treating cardiologist.
If diuresis <1,5 L while the patient is still considered volume overloaded by the treating cardiologist, the dose of bumetanide is doubled.
In case of therapy-refractory congestion, treatment is at the discretion of the treating physician, but addition of chlorthalidone 50 mg PO is recommended by the investigators as a first-line option."
1997664|NCT01973335|Drug|Upfront therapy with oral spironolactone|"Patients randomized to this group receive oral spironolactone (25mg) immediately after randomization and in the morning of each subsequent day unless the serum potassium level is >5 mmol/L.
Note: Investigators and treating physicians are blinded to treatment allocation for this arm, but no matching placebo is provided, so patients are not."
1997665|NCT01972568|Drug|Atacicept 75 milligram (mg)|Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
1997666|NCT01972568|Drug|Atacicept 150 mg|Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
1997667|NCT01972568|Drug|Placebo|Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
1997668|NCT01971476|Drug|volasertib|intravenous administration on day 1of a treatment course
1997674|NCT01968109|Biological|Relatlimab|
1997675|NCT01968109|Biological|Nivolumab|
1997678|NCT01965405|Drug|Bupropion|Participant will receive a prescription for Bupropion hydrochloride and will self-administer according to dosage instructions from the study psychiatrist.
1997679|NCT01965405|Behavioral|Brief Counseling|Participants are provided with brief counseling for smoking cessation.
1997680|NCT01965405|Behavioral|High-magnitude prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
1997681|NCT01965405|Behavioral|Monitored support to quit smoking|Brief supportive sessions and monitoring of smoking cessation efforts.
1997682|NCT01965405|Behavioral|No additional treatment|No additional treatment will be given.
1997683|NCT01965405|Behavioral|Prize contingency management for abstinence|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
1997684|NCT01965405|Behavioral|Low intensity prize contingency management|Prize based contingency management condition in which participants have the chance to win incentives (prizes) when they provide biological test results (expired carbon monoxide and cotinine) that are negative for recent smoking.
1997685|NCT01965184|Behavioral|Cognitive-Behavioral Therapy for Aggression|
1997686|NCT01965184|Behavioral|Supportive Psychotherapy (SPT)|
1997687|NCT01964989|Biological|Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
1997688|NCT01964989|Biological|Non-adjuvanted Trivalent Influenza Vaccine (TIV) / Quadrivalent Influenza Vaccine (QIV)|1 or 2 doses (naïve / non-naive subjects) 0.25 ml: ≥6 months to <36 months, 0.5 ml: ≥36 months to <72 months
1997730|NCT01947452|Behavioral|Social-Emotional Learning|Community organizations will provide 2 hours of social-emotional learning programming for 5 hours a day. The programming is based on cognitive behavioral therapy principles designed to help youth learn to understand and manage their emotions and behavior. It seeks to teach: self awareness (recognizing one's emotions and values as well as one's strengths and limitations), self management (managing emotions and behaviors to achieve one's goals), social awareness (showing understanding and empathy for others), relationship skills (forming positive relationships, working in teams, and dealing effectively with conflict), and responsible decision-making (making ethical, constructive choices about personal and social behavior).
1997732|NCT01944098|Drug|Lidocaine|
1997733|NCT01944098|Drug|Placebo|
1997740|NCT01940094|Drug|Prednisone 5 mg/day|Subjects will remain on daily prednisone dose of 5 mg
1997741|NCT01940094|Drug|Prednisone 0 mg/day|Subjects will taper their prednisone dose from 5 mg per day to 0 mg per day
1997742|NCT01939327|Drug|Lenalidomide/Rituximab|
1997743|NCT01936974|Drug|Gemcitabine|
1997744|NCT01936974|Drug|Bevacizumab|
1997745|NCT01936974|Drug|Carboplatin|
1997746|NCT01936974|Drug|Cisplatin|
1997747|NCT01936974|Drug|Oxaliplatin|
1997748|NCT01936909|Drug|Anakinra (weeks 1-2)|Anakinra 100 mg daily for weeks 1 and 2
1997749|NCT01936909|Drug|Anakinra (weeks 3-12)|
1997750|NCT01936909|Drug|Placebo|
1997752|NCT01935024|Other|Personalized Exercise Regimen|All exercise regimens include a stationary bicycle.
1997753|NCT01932372|Drug|Tofacitinib (Xeljanz)|5 mg Tablet BID
1997754|NCT01932372|Drug|Etanercept, other Biologics, Disease-modifying antirheumatic drugs (DMARDs), etc|Etanercept: 10 to 25 mg twice weekly, or 25 to 50 mg once weekly
1997764|NCT01924065|Procedure|Cardioversion|Electrical cardioversion
1997765|NCT01924065|Drug|Oral Anticoagulant|warfarin, dabigatran etexilate, rivaroxaban, apixaban, edoxaban usage
1997766|NCT01921517|Device|Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months at a frequency of 30 Hz and acceleration of 0.3 g.
1997767|NCT01921517|Device|Sham Low Magnitude Mechanical Stimulation|Mechanical stimulation for 10 minutes daily for 12 months using a sham device.
1997768|NCT01920594|Drug|GSK1278863|White, round biconvex, film coated tablet with unit dose strength of 100 mg for oral administration
1997769|NCT01920594|Drug|Placebo|White, round biconvex, film coated GSK1278863 matching placebo tablet for oral administration
1997770|NCT01920256|Other|Remote, personalized type 2 diabetes care.|Diabetes and comorbidities will be managed with 1 clinic visit per year and frequent adjustments made remotely.
1997771|NCT01920256|Other|Usual Endocrine care.|Diabetes and comorbidities management will provided by an endocrinologist
1997772|NCT01919970|Other|Cognitive Behavioral Therapy|This condition involves 12 weekly CBT sessions.
1997804|NCT01890980|Biological|WT-1-vaccine Montanide + GM-CSF|Treatment of 6 injections over 12 weeks, administered on weeks 0, 2, 4, 6, 8, and 10. All receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination and may be self administered with appropriate instruction. Participants keep a logbook noting the time and placement of the injection, and will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide which will be administered by a nurse (not self-administered) subcutaneously to the same anatomical site as the GM-CSF as marked by the patient or treating healthcare professional by a permanent marker pen.
1997805|NCT01890980|Biological|Montanide adjuvant + GM-CSF|Treatment of 6 injections over 12 weeks, administered on weeks 0, 2, 4, 6, 8, and 10. All receive Sargramostim (GM-CSF) (70 mcg) injected subcutaneously on days 0 and -2 of each vaccination and may be self administered with appropriate instruction. Participants keep a logbook noting the time and placement of the injection, and will also receive 1.0 ml of emulsion with Montanide alone or with WT-1 peptides plus Montanide which will be administered by a nurse (not self-administered) subcutaneously to the same anatomical site as the GM-CSF as marked by the patient or treating healthcare professional by a permanent marker pen.
1997806|NCT01888198|Behavioral|(EORTC QLQ-C30) questionnaire|
1997807|NCT01888198|Behavioral|EuroQol EQ-5D 7-item questionnaire|
1997813|NCT01885897|Biological|ALT-803|Given weekly IV at assigned dose level, ranging from 1mcg/kg to 30mcg/kg.
1997815|NCT01881568|Drug|Tranexamic Acid|Topical administration: 3g of Tranexamic Acid in 100mL of normal saline (0.9% sodium chloride)
1997816|NCT01881568|Drug|Tranexamic Acid|Intravenous administration of two dosis of Tranexamic Acid (15mg/kg of Tranexamic Acid in 100mL of normal saline each)
1997817|NCT01879566|Other|No intervention will be done. The study is observational|
1997818|NCT01878669|Drug|N-acetyl cysteine|
1997819|NCT01878669|Drug|Saline|
1997820|NCT01877655|Biological|ASP0113|intramuscular injection
1997821|NCT01877655|Drug|Placebo|intramuscular injection
1997826|NCT01877564|Drug|Metformin|
1997828|NCT01876420|Device|The CoreValve™ Evolut R TAV™ system|CoreValve™ Evolut R™ System which consists of the Evolut R™ Transcatheter Aortic Valve (26 & 29 mm sizes), EnVeo R™ Delivery Catheter System with Enveo InLine™ Sheath, and EnVeo R™ Loading System
1997834|NCT01874327|Behavioral|Baby JASPER|Intervention focuses on core deficits of joint attention, play, engagement, and regulation embedded within AEPS curriculum
1997835|NCT01874327|Behavioral|Standard Baby Classroom|Assessment, Education and Programming System (AEPS) for Infants and Children curriculum focused on early developmental milestones in fine and gross motor, cognitive, adaptive and social areas
1997836|NCT01871805|Drug|RO5424802|multiple escalating doses given orally twice daily
1997837|NCT01871805|Drug|RO5424802|Recommended Phase II dose (600 mg) given orally twice daily
1997838|NCT01872221|Procedure|Surgery (based on preoperative multimodal MRI) followed by the standard radio-chemotherapy stupp protocol|
1997839|NCT01868386|Radiation|Hypofractionated therapy|Shorter courses of increasing doses of radiation therapy will be assessed in each subsequent arm
1997923|NCT01825018|Behavioral|Social Network Leader Endorsement|Leaders of the 16 intervention condition networks will attend a 7-session intervention, with the first 5 sessions held weekly and the last 2 at biweekly intervals. Networks will include persons with differing care histories including PLH never in care, those who dropped out of care, and those who attend medical appointments irregularly or are inconsistent in adherence. Network leaders will be trained to tailor communications to each friend's care circumstances. Issues of current injecting drug users (IDUs) may differ from non-IDUs. Therefore, intervention content will be tailored based on formative phase findings, and groups for IDU network leaders will be held separately.
1997924|NCT01825018|Behavioral|HIV Counseling|At the baseline session, participants in the comparison condition will receive counseling about the benefits and availability of HIV care and the importance of treatment adherence.
1997934|NCT01820442|Drug|Lofexidine HCl|Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID [e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.
1997935|NCT01820442|Drug|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
1997936|NCT01819831|Radiation|proton radiation|proton radiation: 2 GyE/Day to isocenter, one treatment per day, 5 days per week for 25 treatments (=50 GyE to isocenter/25 fractions)
1997937|NCT01819831|Procedure|surgery (wide local excision; limb preservation surgery)|In areas with ample soft tissue that can be removed without compromising future function or wound closure, wide margins is the goal of treatment; associated rates of local failure are low in such instances. Margins will be determined by the surgeon; the goal is to achieve at least a 2 mm negative margin resection. However, smaller margins can be acceptable if it allows for limb-sparing surgery with conserved functional outcomes. Every effort will be made to have limb preservation surgery unless there is documented evidence of tumor progression during or after the course of radiation that would require amputation for an appropriate margin resection.
1997938|NCT01818479|Biological|stem cell transplant|Open label, dose finding trial with two treatment regimens, Busulfan and TBI with four dose escalation cohorts, to assess the efficacy of Treg/Tcon addback to partially matched related donor stem cells.
1997939|NCT01818479|Procedure|Stem cell transplant|
1997940|NCT01812278|Behavioral|ACT|
1997941|NCT01812278|Behavioral|CBT|
1997942|NCT01811992|Biological|Dose Escalation of Ad-hCMV-TK and Ad-hCMV-Flt3L|"Two adenoviral vectors will be used, each to deliver one of the therapeutic genes. Both vectors are human serotype 5, replication-defective, first generation adenoviral vectors deleted in E1a and E3 viral encoding regions. Each vector will constitutively express their respective therapeutic transgene (i.e. HSV1-TK or Flt3L) under the control of the human cytomegalovirus promoter (hCMV). Valacyclovir treatment will begin 1-3 days after vector administration at a dose of 2 grams given orally 3X per day for 14 days. A second course of valacyclovir will be given beginning Week 10.
Radiation and chemotherapy will be administered as per standard of care."
1997945|NCT01808365|Procedure|Posterior pharyngeal swab|Posterior pharyngeal swabs will be tested for the presence of N. meningitidis.
1997946|NCT01808365|Other|Data collection|Collection of socio-demographic data and recording of serious adverse events by interview of subjects or subjects' parents/legally acceptable representatives.
1997953|NCT01804530|Drug|PLX7486 TsOH|PLX7486 TsOH capsules, 50mg
1997954|NCT01804855|Behavioral|W82GO|MDT delivered obesity intervention integrating behavioural change methods in order to reduce obesity; improve nutrition; increase physical activity; improve sleep; reduce sedentarism and increase self-esteem
1997955|NCT01804855|Device|smartphone application|Behavior change smartphone application for adolescents aiming to reduce obesity
1998140|NCT01650649|Drug|Lofexidine-matching sugar pill|Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc)as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
1997963|NCT01797263|Other|Yoga|A 12-week yoga intervention modified for Veterans with fibromyalgia. Each weekly session will last approximately 75 minutes. The standardized sequence of yoga poses will be introduced to participants and the instructor will tailor them to the participant's needs and abilities. Deep breathing exercises will be taught and emphasized throughout every session. Participants will be encouraged to exercise according to their limits, rather than rigid adherence to posture techniques. The yoga intervention will be tailored to the individual. It will include low intensity, low impact modified poses adapted with pathophysiologic changes of fibromyalgia in mind. Participants will also be given a Playaway(c) device with guided relaxation exercise recorded on it and asked to listen to it three times a week to reinforce the in person yoga session content.
1997964|NCT01797263|Other|Structured Exercise|A 12-week group exercise session consisting of a graded aerobic exercise program. The program will start at low intensity with gradual increases in exercise intensity and duration. Each weekly session will last 75 minutes. The fitness instructor will teach participants to use a table-top ergometer at a sub-maximal level, determine baseline fitness, and develop an individualized exercise prescription. The fitness instructor will provide educational tips on exercise and selection of physical activities. Participants will be given a pedometer and heart rate monitor to track their exercise at home. They will also be given an exercise DVD to use at home.
1997965|NCT01793584|Procedure|Laparoscopic hysterectomy|LAVH, TLH
1997966|NCT01793584|Procedure|Abdominal hysterectomy|TAH
1997967|NCT01790984|Other|High sugar low starch diet|
1997968|NCT01790984|Other|Low sugar high starch diet|
1997969|NCT01790503|Drug|PLX3397|
1997970|NCT01790503|Radiation|Radiation Therapy|
1997971|NCT01790503|Drug|Temozolomide|
1997972|NCT01787916|Drug|Liraglutide|Liraglutide will be compared to placebo for 24 weeks in a cross-over design
1997973|NCT01783197|Drug|Paclitaxel|
1997974|NCT01783197|Drug|Carboplatin|
1997975|NCT01783197|Drug|Selumetinib|
1997976|NCT01783197|Drug|Pemetrexed|
1997977|NCT01783197|Drug|Cisplatin|
1997978|NCT01776255|Behavioral|Healthy Children, Strong Families|"Healthy Children, Strong Families is a series of 13 lessons mailed to primary caregivers of preschool aged children that provide education and activities related to obesity prevention. The lessons cover topics related to nutrition, physical activity, stress, sleep, and the home environment. Lessons include printed materials and small items (for example, an apple sectioner) that support activities in the lessons. Social support components via a monitored Facebook group and approximately semiweekly text messages sent to caregivers are included. The intervention spans 1 year."
1997979|NCT01776255|Behavioral|Child Safety|The Child Safety intervention is an active control condition consisting of monthly two-page newsletters covering various topics relevant to child safety such as choking, car safety seats, bike and pedestrian safety. The intervention spans 1 year.
1997980|NCT01776190|Device|UVA1 radiation treatment|
1997982|NCT01775787|Other|Nicotine with Tobacco Flavor|Randomly assigned to 18mg of nicotine with tobacco flavor for 7 to 10 days and then switched to other flavor for an additional 7 to 10 days.
1997983|NCT01775787|Other|Nicotine with Tobacco and Menthol Flavor|Randomly assigned to 18mg of nicotine with tobacco and menthol flavor for 7 to 10 days and then switched to other flavor for an additional 7 to 10 days.
1997984|NCT01773317|Other|Perturbation|All subjects complete study protocol. Subjects randomized to the perturbation group will complete the additional perturbation exercises
1997985|NCT01773317|Other|Control|Subjects will complete the study protocol (including nordic hamstrings, standing squats, drop jumps, triple single leg hopping, and tuck jumps)
1997988|NCT01764698|Behavioral|CALM-SUD|6-session group for anxiety disorders. Cognitive behavioral therapy including self-monitoring, relaxation, cognitive restructuring, exposure therapy, and relapse prevention. In addition, participants in this arm are also enrolled in an Intensive Outpatient Program for their substance use disorder. The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
1997989|NCT01764698|Behavioral|Treatment as usual|The program is run by an outpatient addictions facility and includes up to 16 weeks of groups that meet 3 to 4 times per week in addition to up to 10 individual sessions of therapy. The group model includes motivational interviewing, cognitive behavioral therapy, contingency management, and relapse prevention skills.
1997990|NCT01762579|Dietary Supplement|wheat flour|wheat flour is administered three times per day for 15 days
1997991|NCT01762579|Dietary Supplement|Xylose|Xylose will be administered three times per day for 15 days
1997992|NCT01762124|Device|Native Outflow Tract TPV|Transcatheter placement of a pulmonary valve
1998048|NCT01721525|Drug|Afatinib, Ribavirin, and weekly carboplatin/paclitaxel|Patients will receive oral daily afatinib (days 1 - 21, per dose escalation scheme) plus daily oral ribavirin (days 1- 21) and paclitaxel (80 mg/m2 intravenously, days 1 and 8) + carboplatin (AUC 1.5 intravenously, days 1 and 8) of a 21-day cycle. Ribavirin will be administered according to standard weight-based dosing for this drug (1). Subjects ≤75 kg receive Ribavirin 400 mg PO qAM and 600 mg PO qPM (= 1000 mg/day). Subjects > 75 kg receive Ribavirin 600 mg PO BID (=1200 mg/day). During the Dose Escalation portion of the study (Part 1), research bloodwork for pharmacokinetics is performed on days 1 and 8 of Cycle 1 only.
1998049|NCT01719146|Other|Specimen collection|At the beginning of each midweek hemodialysis session, a blood specimen (4 mL) will be drawn from the study subject. Out of this specimen a 1 mL serum sample will be frozen and stored. A 3 mL blood sample will be shipped overnight to WNERTA for laboratory testing.
1998050|NCT01719900|Dietary Supplement|Pulse fibre|Yellow pea hull fibre incorporated into a biscuit at 5 g/serving.
1998051|NCT01719900|Dietary Supplement|Control|Control biscuit with no yellow pea hull fibre.
1998052|NCT01717131|Procedure|Surgery for standard axillary node dissection|
1998053|NCT01717131|Other|No axillary lymph node dissection|No surgery on axillary lymph node
1998057|NCT01709409|Drug|Curosurf-Group1|Maximum of 3 doses are administered to infants diagnosed with RDS.
1998058|NCT01709409|Drug|BLES-group 2|Maximum of 3 doses are administered to infants with RDS
1998061|NCT01703507|Drug|Ipilimumab|Given IV
1998062|NCT01703507|Radiation|Whole-Brain Radiation Therapy (WBRT)|Undergo WBRT
1998063|NCT01703507|Radiation|Stereotactic Radiosurgery (SRS)|Undergo SRS
1998064|NCT01698905|Drug|nilotinib|Nilotinib will be labeled as AMN107 and supplied as 150 mg and/or 200 mg hard gelatin capsule. Nilotinib will not be dosed by weight or body surface area. Nilotinib will be administered orally at 300 mg twice daily (BID) or 400 mg BID, at approximately 12 hour intervals, and must not be taken with food. The capsules should be swallowed whole with water. No food should be consumed for at least 2 hours before the dose is taken and no additional food should be consumed for at least one hour after the dose is taken. Patients who were previously treated with 400 mg BID, and required subsequent permanent dose reduction to 400 mg QD will be allowed to enter this study on the same dose, 400 mg once daily.
1998065|NCT01697371|Radiation|Proton|"All patients will receive 3 fractions in no more than 14 days at the following levels: Level I = 12 Gy per fraction, total dose=36 Gy.
Level II = 16 Gy per fraction, total dose 48 Gy. Level III = 20 Gy per fraction, total dose 60 Gy. The dose per fraction to the PTV will start at dose level I (12 Gy), but may vary from 12 Gy to 20 Gy in 3 fractions over 14 days in 4 Gy increments"
1998066|NCT01697371|Radiation|Proton Radiation|
1998071|NCT01693250|Device|fitbit Ultra|Participants will be asked to wear the Fitbit device and use the app every day for three months. The app functions will include tracking of PA and dietary intake progress, setting individualized and realistic goals, monitoring progress related to reaching the goals, providing tips of everyday activities, and having interactive games related to PA and healthy diet.
1998072|NCT01693250|Device|Pedometer|adolescents in the control group will be given an Omron HJ-105 pedometer and a food diary and be asked to use them for three months.
1998073|NCT01690520|Drug|Cyclophosphamide|Given IV
1998074|NCT01690520|Drug|Cyclosporine|Given IV or PO
1998075|NCT01690520|Procedure|Double-Unit Umbilical Cord Blood Transplantation|Undergo double-unit unmanipulated umbilical cord blood transplant
1998076|NCT01690520|Procedure|Ex Vivo-Expanded Cord Blood Progenitor Cell Infusion|Given IV
1998077|NCT01690520|Drug|Fludarabine Phosphate|Given IV
1998078|NCT01690520|Other|Laboratory Biomarker Analysis|Correlative studies
1998079|NCT01690520|Drug|Mycophenolate Mofetil|Given IV or PO
1998080|NCT01690520|Drug|Thiotepa|Given IV
1998081|NCT01690520|Radiation|Total-Body Irradiation|Undergo high dose or middle intensity TBI
1998082|NCT01690520|Procedure|Umbilical Cord Blood Transplantation|Undergo single-unit unmanipulated umbilical cord blood transplant
1998083|NCT01685372|Biological|Fluzone High Dose|A single-dose of high-dose influenza vaccine will be administered to subjects randomized to this arm
1998084|NCT01685372|Biological|Fluzone|A single-dose of standard-dose influenza vaccine will be administered to subjects randomized to this arm
1998085|NCT01684709|Behavioral|Telemonitoring + self-management support|Weekly automated assessment calls with follow-up by a care manager and a CarePartner for 12 months. Baseline, 6 month, and 12 month follow-up
1998086|NCT01684904|Radiation|Proton radiation|
1998141|NCT01650545|Drug|Liposomal aerosol cyclosporine|inhaled form of immune suppression
1998142|NCT01650545|Other|standard immune suppression, oral|conventional drug
1998145|NCT01646684|Drug|SOM230|
1998146|NCT01646437|Drug|Polycap|Polycap (thiazide 25mg, atenolol 100mg, ramipril 10mg, simvastatin 40mg) taken once daily
1998147|NCT01646437|Drug|Aspirin|75 mg daily
1998148|NCT01646437|Drug|Vitamin D|60,000 IU monthly
1998149|NCT01646437|Drug|Matching Placebo|Matching Placebo
1998087|NCT01682811|Drug|Levulan (5-aminolevulinic acid) uptake.|"8 adult subjects will be needed, two subjects for each incubation time point, and one each for negative and positive controls. Multiple lesions for each subject may be treated in order to provide better estimations of fluorescence levels.
Tumors will be incubated with Levulan under occlusion for 3, 6, or 24 hrs. A minimum of three tumors per group on the same subject will be incubated with Levulan or vehicle only for three hours. Tumors will then be excised in the normal manner. A minimum of three untreated control tumors will be excised. Thus there will be three groups of tumors excised per subject. Tumors will be sectioned vertically and checked for PpIX using fluorescence microscopy. Negative controls will now consist of untreated tumors and tumors incubated with vehicle only for 3 hours on the same subjects as the Levulan treated tumors. Positive controls will consist of intralesional injection of saline-dissolved ALA approximately one hour before excision."
1998088|NCT01682811|Drug|Levulan (5-aminolevulinic acid) photodynamic therapy.|2-18 adult subjects with 3-8 lesions per (Levulan or control) group per subject. Controls will consist of lesions treated with vehicle only and light illumination, and will be paired with treatment lesions by the study doctor. Control lesions will be treated on the same subject as study lesions. Levulan will be incubated for 3-24 hours under occlusion, then gently rinsed with water and patted dry. Photoactivation of lesions treated with Levulan is then accomplished with 630 nm red light illumination. 630 nm light will be applied for varying periods of time in order to achieve a dose of 25, 50, or 100 J/cm2. There will be one treatment session per subject. Treatments will include a minimum of three test lesions and an additional three control lesions.
1998089|NCT01683422|Radiation|Proton, Gemcitabine, Erlotinib, Capecitabine|"Gemcitabine 1000 mg/m2 iv, days 1, 8, 15, 29, 36 and 43 Erlotinib 100 mg po qd days 1-43 Capecitabine 825mg/m2 po bid M-F, starting on day 1 of proton therapy until proton therapy completed.
Post-proton chemotherapy: To be started in 4 to 6 weeks after completion of proton chemotherapy. Oxaliplatin 130 mg/m2 po bid on days 2 to 15 for 14 days. The CapOx regimen (Capcitabine plus Oxaliplatin) is repeated every 3 weeks for 4 cycles."
1998090|NCT01683422|Radiation|Proton Radiation|
1998091|NCT01682512|Drug|BI 695500|
1998092|NCT01682512|Drug|BI 695500|
1998093|NCT01682512|Drug|rituximab|
1998094|NCT01682512|Drug|rituximab|
1998095|NCT01682512|Drug|rituximab|
1998096|NCT01681797|Device|Fluorescence angiography (Fluobeam™ imaging system developed by Fluoptics company)|Fluorescence angiography after intravenous injection of Infracyanine® (indocyanine green)
1998097|NCT01681771|Behavioral|Cognitive behaviour therapy|Internet based, weekly home task and weekly feedback provided by health care professional.
1998098|NCT01681771|Behavioral|Discussion group|Internet moderated discussion group. Patients will be provided weekly question which will be used by the participant to start discuss with each others.
1998099|NCT01680627|Behavioral|CASI|
1998100|NCT01680614|Behavioral|CASI|
1998102|NCT01675440|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
1998103|NCT01674933|Drug|Duraphat® Fluoride Varnish|0.25 ml per application will be painted on tooth surfaces by a Childsmile trained Extended Duties Dental Nurse, currently registered with the UK General Dental Council
1998104|NCT01674933|Behavioral|treatment as usual|includes supervised toothbrushing, distribution of toothbrushes and toothpaste and oral health advice given at nursery school.
1998105|NCT01670292|Other|HVLA-SM|High Velocity Low Amplitude Spinal Manipulation
1998106|NCT01666080|Drug|Busulfan|0.4 mg/kg (0.5 mg/kg if <4 years of age) intravenously (IV) every 6 hours on Days -8 and -7.
1998107|NCT01666080|Drug|Fludarabine|40 mg/m^2 intravenously (IV) over 1 hour on days -6 through -2.
1998108|NCT01666080|Radiation|Total body irradiation|200 cGy on Day -1
1998109|NCT01666080|Biological|Stem cell transplant|stem cell infusion on day 0
1998110|NCT01666080|Drug|Keppra|Keppra will be given for seizure prophylaxis during busulfan administration as per the standard institutional protocol.
1998111|NCT01665599|Drug|Testosterone gel (FE 999303)|
1998116|NCT01660711|Drug|5 Fluorouracil|2400 mg/m2 by continuous intravenous infusion over 46 hours
1998117|NCT01660711|Drug|Leucovorin|400 mg/m2 by IV infusion over 2 hours
1998118|NCT01660711|Drug|Irinotecan|180 mg/m² IV infusion on Day 1 over 90-120 minutes (infusion via a Y connector during the infusion of leucovorin)
1998119|NCT01660711|Drug|Oxaliplatin|85 mg/m² IV infusion on Day 1 over 2 hours
1998120|NCT01659151|Drug|High Dose Interleukin-2 (IL-2)|A high dose regimen of IL-2 will be given after participants receive the infusion of the T-cells.
1998121|NCT01659151|Procedure|ACT with TIL Infusion|Special immune T-cells will be taken from a sample of the participant's tumor tissue that will be surgically removed. Certain parts of these cells will be multiplied, or grown, in the laboratory. They will then be given back to the participant by an infusion in their veins. These cells are called tumor infiltrating lymphocytes (TIL).
1998122|NCT01659151|Drug|Vemurafenib|Vemurafenib is used to slow the growth of certain types of cancer cells. This drug will be given for about 3 weeks while T-cells are being grown in the lab and then again after T-cell infusion for up to 2 years.
1998123|NCT01659151|Drug|Lymphodepletion|"The purpose of lymphodepletion in this study is to temporarily reduce the number of normal lymphocytes circulating in the participant's body before they are given the T-cells that were grown in the lab. This is so that there will be more space for the lymphocytes (T-cells) that will be infused in their veins. Fludarabine and cyclophosphamide, 2 types of chemotherapy drugs will be used for what is called lymphodepletion."
1998150|NCT01645722|Procedure|Procedure/Surgery: Enriched Fat grafting|Fat grafting is a minimally invasive clinical procedure that has been widely used by plastic surgeons within reconstructive surgery for many years. Fat tissue to be used for grafting is harvested (usually from abdomen or thighs) in the operating room. The fat tissue is then sterilely centrifuged and allowed to decant before separating the fluid and oil layers from the fat tissue fraction. The aspirated fat is then injected into the amputation stump.In this study, we will concentrate the adipose stromal cells (ASCs) in the fat graft material to assess whether this modification will increase fat graft retention over time. The volume retention in areas treated with ASC concentrated fat grafts will be compared with regions treated with standard fat grafts in the same patient.
1998158|NCT01639495|Device|THERMOCOOL® SMARTTOUCH™ Catheter|AF Ablation
1998163|NCT01634217|Biological|iTreg|The iTregs will be infused at the assigned dose without a filter or pump slowly by gravity over 15-60 minutes. The iTregs should be given at least 4 hours before the peripheral blood stem cell (PBSC) infusion (MT2001-10).
1998164|NCT01634399|Drug|Torrent's Quetiapine Fumarate Tablets|
1998165|NCT01634269|Device|MDT-2111 TAVI 23 mm|Device: 23 mm MDT-2111 System for Transcatheter Aortic Valve Implantation (TAVI) Transcatheter Aortic Valve Implantation (TAVI) using the 23 mm MDT-2111 system.
1998166|NCT01629446|Drug|Lofexidine hydrochloride|Single Dose = Solution containing 400 μg lofexidine HCl and a tracer amount of 14C lofexidine
1998168|NCT01626469|Drug|Captopril|25mg Captopril
1998169|NCT01626469|Drug|placebo|placebo
1998170|NCT01624233|Drug|80 mg ixekizumab|Administered SC
1998174|NCT01621490|Biological|Nivolumab|
1998175|NCT01621490|Drug|Ipilimumab|
1998177|NCT01620008|Procedure|Delayed Cord Clamping|At birth, the infant will be placed on the maternal abdomen and the umbilical will either be cut immediately or after a 5 minute delay.
1998179|NCT01619657|Drug|6% Hypertonic Saline (HS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
1998180|NCT01619657|Drug|0.9% Isotonic Saline (IS), 4mL|Administered via inhalation twice daily for 52 weeks. The delivery system is a PARI LC SPRINT® Junior nebulizer with a baby bend, size-adapted PARI® Baby face mask size 0-3, connection tubing (2.2m) and a PARI JuniorBOY® SX compressor.
1998183|NCT01613222|Device|Pulse oximetry|Pulse oximetry measurement using SpO2 sensors, patient monitors, co-oximeters, and various modules.
1998184|NCT01612091|Device|Monitoring Messenger|Monitoring Messenger prototype device
1998185|NCT01612091|Device|Traditional tools|Paper based records, screenshots of monitors and therapy devices
1998186|NCT01610882|Device|Panda first followed by manual pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Panda will be used first, manual method 5 mins later.
1998187|NCT01610882|Device|Manual first followed by Panda pain assessment|Panda is a smart-phone based application designed to assess post-operative pain; manual method involves use of CAS/FPS-R on paper. Manual method will be used first, Panda 5 mins later.
1998188|NCT01608893|Drug|Carvedilol|6.25 po bid titrated to 25 mg bid as tolerated over a 1 month period
1998189|NCT01608893|Drug|Metoprolol|titrated to 50 mg po bid as tolerated over a 1 month period
1998194|NCT01601314|Drug|Magnesium Sulfate|"At the beginning of the neurosurgery, the subjects are going to receive one 4gr bolus in Sodium Chloride 100 mL, lasting 20 minutes, intravenously.
After that, a intravenously perfusion of Magnesium Sulfate 20 gr, in Sodium Chloride 1000 mL, lasting 24 hours, will be started."
1998195|NCT01601314|Other|Sodium Chloride|"At the beginning of the neurosurgery, the subjects are going to receive a bolus of Sodium Chloride 100 mL, lasting 20 minutes, intravenously.
After that, a intravenously perfusion of Sodium Chloride 1000 mL, lasting 24 hours, will be started."
1998235|NCT01565135|Behavioral|Multimodal Vaccine Program|"Efforts will be made to collaborate with private ob/gyn offices to develop a multimodal intervention to improve patients'immunization rates. As part of the overall intervention, intervention practices will agree to 1) purchase, stock, and administer influenza, HPV, and Tdap vaccines, if not already doing so and 2) track patients' vaccination status. In addition, intervention strategies adopted by intervention settings to improve immunization rates may include:
Patient education regarding the importance of vaccination, including encouragement of vaccination for family members
Practice-based reminder/recall
Seek to decrease missed opportunities for immunization by using either or both of the following: provider prompts and/or provider education and feedback"
1998236|NCT01565629|Behavioral|Computer assisted cognitive behavioral therapy.|Those who choose to participate will be required to attend 4 assessments - pre-treatment (week 0), mid-treatment (week 8), post-treatment, and a 4th assessment for a 3 month Follow-up. All children regardless of condition will follow the CCBT protocol (Camp Cope-A-lot), which is the computer-assisted intervention being examined in this study. The first 6 levels of this program are skill building levels to be completed by the user. The remaining 6 levels are completed with the therapist and consist of exposure tasks and rehearsal geared toward each child.
1998237|NCT01560923|Biological|Indoximod|Given twice daily (1200 mg total) by mouth for 6 months.
1998238|NCT01560923|Biological|Sipuleucel-T|Sipuleucel-T will be administered as standard of care. Given by infusion over 60 minutes at Week 0, 2 and 4. Patients will undergo leukapheresis at weeks 0, 2, and 4 with sipuleucel-T infused 3 days later (i.e. Monday/Thursday; Tuesday/Friday).
1998239|NCT01560923|Other|Placebo|Given in same manner as Indoximod; 1200 mg per day by mouth.
1998240|NCT01559948|Behavioral|Lumbopelvic stabilization exercise|The objective of this exercise program is to recruit and train the primary stabilizing muscles of the spine in order for them to more appropriately support the spine. Participants will then be asked to attend supervised physical therapy sessions twice a week for 2 weeks and once a week for another 2 weeks. They will be instructed to perform the exercises at home daily for a total of 12 weeks as well as complete a compliance log. Progression of the stabilization program will be determined by the physical therapist based on pre-established criteria.
1998241|NCT01559948|Device|Sacroiliac joint belt|Those participants randomly assigned to the lumbopelvic stabilization plus belt group will also receive a pelvic compression belt. They will be taught how to don/doff the belt and instructed to wear the belt during all waking hours for the first 4 weeks of the study. The belt should be worn low around the pelvis just above the greater trochanter. The treating physical therapist will monitor the placement of belts during each exercise session. Belt usage logs will be given to each participant to assess compliance with wearing the belt.
1998242|NCT01558934|Drug|Lofexidine HCl|Lofexidine HCl 0.2 mg tablets titrated in ascending doses of 0.2 mg QID (e.g. Day 1 0.2 mg QID, Day 2 0.4 QID, etc)as described in the treatment arm.
1998244|NCT01557244|Drug|Fesoterodine PR 4 mg|Fesoterodine 4 mg tablet once daily for 24 weeks
1998245|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine PR 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
1998246|NCT01557244|Drug|Fesoterodine PR 8 mg|Fesoterodine 8 mg tablet once daily for 24 weeks, the first week being 4 mg.
1998247|NCT01557244|Drug|Oxybutynin|Oxybutynin extended release tablets according to approved pediatric labeling for 12 weeks with dose titration phase for first 4 weeks to achieve dose optimisation.
1998248|NCT01557244|Drug|Fesoterodine PR|Fesoterodine 4 mg or 8 mg tablets once daily for 12 weeks after 12 weeks of oxybutinin. Those assigned to 8 mg will take 4 mg for the first week.
1998249|NCT01557244|Drug|Fesoterodine BIC 2 mg|Fesoterodine BIC 2 mg tablet once daily for 24 weeks.
1998250|NCT01557244|Drug|Fesoterodine BIC 4 mg|Fesoterodine BIC 4 mg tablet once daily for 24 weeks, with the first week being 2 mg.
1998251|NCT01555697|Drug|Memantine|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
1998252|NCT01555697|Drug|Placebo|Each participant receives a single pill of placebo or active drug (memantine, 10 or 20 mg) and completes about 6 hours of testing in the laboratory. One week later, that participant receives a single pill of the alternate comparator and is again tested in the laboratory. Thus, in total, each participant receives one placebo pill and one active pill, separated by one week.
1998255|NCT01549119|Biological|VAC-3S|Comparison of different doses of vaccine. Liquid form Volume: 0.5 mL - 2 X 0.5 mL for double-dose arm 3 vaccinations at one month apart
1998256|NCT01549119|Biological|Placebo|Comparison with experimental vaccine
1998263|NCT01541345|Device|Autogenous bone graft|Bone augmentation will be performed using autogenous bone from the retromolar or chin area followed by a fixation with titanium screws at the recipients site; filled with deproteinized bovine bone mineral (DBBM) particles (Bio-Oss®, Geistlich Pharma AG, Wolhusen, Switzerland) and covered with a collagen membrane (Bio-Gide®, Geistlich Pharma AG, Switzerland)
1998264|NCT01541345|Drug|InductOs|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane). One time application at augmentation surgery.
1998265|NCT01541345|Procedure|Augmentation surgery|CE-marked medical device Bio-Oss Spongiosa Block® (xenogenic bone) loaded with InductOs® (1.5 mg Dibotermin alfa / ml) covered with Bio-Gide® (collagen membrane)
1998275|NCT01538615|Behavioral|HOME Plus intervention|The HOME Plus program families will participate in monthly, two-hour group sessions for ten months at local community centers. Each session offers new ideas focusing on family meals, healthy eating, and reducing sedentary behavior. At each session, families prepare and eat a meal together and participate in small group discussions and activities for both parent and child groups to promote healthy behaviors in the home. Topics include planning healthy meals and snacks with your family, having meals with your family more often, and improving the healthfulness of the food available at home. Families also receive periodic supportive phone calls throughout the year using motivational interviewing techniques to promote healthy behaviors to prevent and reduce childhood obesity.
1998276|NCT01531374|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|
1998277|NCT01529554|Drug|Everolimus|(d0=7.5 mg, d1=7.5 mg. d2=7.5 mg, d3=5 mg, d4=5mg)
1998278|NCT01529554|Drug|Placebo|matched placebo tablets manufactured to be identical to verum tablets except content of everolimus
1998279|NCT01528982|Behavioral|Mindfulness|Subjects receive mindfulness training
1998280|NCT01528982|Behavioral|Cognition|Subject receive cognitive training
1998281|NCT01527500|Drug|LFG316|LFG316 20 mg/0.2 mL solution (in 2 mL vial) for IVT injection,
1998282|NCT01527500|Drug|Sham|Sham injection (akin to intravitreal injection but without intravitreal needle; no investigational drug given)
1998283|NCT01527500|Drug|LFG316 Lower dose|LFG316 20 mg/0.2 mL solution for IVT Injection
1998284|NCT01526603|Drug|Carboplatin|Carboplatin intravenously (IV), 425 mg/m2/dose (or if ≤ 12kg, 14.2 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant.
1998285|NCT01526603|Biological|Autologous stem cell infusion|On day 0 the stem cells will be infused immediately after thawing over 15-60 minutes per institutional guidelines.
1998286|NCT01526603|Biological|Granulocyte colony stimulating factor|Beginning on day 0 after infusion of the PBSC, patients will receive G-CSF subcutaneously (SQ) or IV (SQ preferred) 5 micrograms/kg once daily and continuing once daily until post-nadir absolute neutrophil count (ANC) > 2000/μL for 3 consecutive days.
1998287|NCT01526603|Radiation|Radiation therapy|It is suggested that patients who have a complete surgical resection of the primary tumor receive 21.6 Gy external beam radiation therapy (EBRT) to the post-induction chemotherapy, pre-operative primary tumor volume. It is suggested that patients who have an incomplete surgical resection of the primary tumor (residual soft tissue mass measuring >1 cm3) will receive 21.6 Gy EBRT to the postinduction chemotherapy, pre-operative primary tumor volume and an additional boost of 14.4 Gy EBRT to the gross residual tumor (total dose 36 Gy to gross residual tumor volume). Radiation should be given after stem cell transplantation and should start no sooner than 28 days post transplant.
1998288|NCT01526603|Drug|Isotretinoin (13-cis-retinoic acid)|Post-transplant maintenance therapy with cis-RA daily for 14 days every 28 days repeated for 6 months. This phase of the therapy can be initiated by the BMT team and continued by the referring physician. It is recommended to begin Isotretinoin at day 66 post-transplant and no later than day 100. For patients ≤12 kg, isotretinoin (accutane) should be administered at 5.33 mg/kg/dose divided twice daily. For patients >12 kg isotretinoin (accutane) should be administered at 160 mg/m^2/day divided twice a day. Patients should be considered for monoclonal antibody therapy against GD2, such as ch14.18 if such trials are available.
1998289|NCT01526603|Drug|Melphalan|Melphalan Intravenously (IV), 70 mg/m2/dose (or if ≤ 12 kg, 2.3 mg/kg/dose) once daily x 3 doses on days 7 through 5 pretransplant
1998290|NCT01526603|Drug|Etoposide|Etoposide intravenously (IV), 338 mg/m2/dose (or if ≤ 12kg, 11.3 mg/kg/dose) once daily x 4 doses on days 7 through 4 pretransplant
1998291|NCT01525602|Drug|PLX3397|PLX3397 tablets, 200mg
1998292|NCT01525602|Drug|Paclitaxel|Paclitaxel IV
1998293|NCT01524692|Drug|Dovitinib (TKI258)|500 mg orally on a 5-days on/2-days off schedule each week of a 4-week (28-day) cycle. Treatment will continue until progression as defined by RECIST, unacceptable adverse events, patient refusal to continue on study, or physician's decision to withdraw the patient.
1998294|NCT01523496|Drug|Vitamin D3|Vitamin D3, randomized to receive either 18,000 IU per month, 60,000 IU per month or 120,000 IU per month
1998295|NCT01523496|Drug|Vitamin D3|Vitamin D3 18,000IU/month; 60,000IU/month; 120,000IU/month
1998297|NCT01514370|Drug|IFN beta 1 a + curcumin (BCM 95)|IFN beta 1 a (44 mcg TIW) + curcumin (500 mg 2 times a day)
1998298|NCT01514370|Drug|IFN beta-1a + placebo|IFN beta-1a 44 mcg TIW + placebo (1 tablet 2 times per day)
1998420|NCT01379898|Drug|Phenoxybenzamine|Starting dosage of phenoxybenzamine in hypertensive subjects:20 mg q.d. (=10 mg b.i.d.) and in normotensive subjects 10 mg q.d. (in the evening). Dose escalation until blood pressure targets are reached, with a maximum dose of 140 mg q.d. (=70 mg b.i.d.)
1998303|NCT01506986|Drug|Lansoprazole 30mg, Clarithromycin 500mg, Metronidazole 400mg|All three medications will be taken orally, twice daily, for seven days.
1998304|NCT01506986|Drug|Placebo lansoprazole 30mg, clarithromycin 500mg, metronidazole 400mg|Medication to be taken orally, twice a day, for seven days.
1998305|NCT01505257|Behavioral|END-DSD|Multi-component intervention including 1) Nursing education regarding detection and management of delirium superimposed on dementia; 2) Computerized decision support and EHR; 3) A unit champion nurse for promotion of delirium assessment and management; 4) Feedback to nursing staff
1998306|NCT01498887|Drug|Fingolimod (FTY720)|Fingolimod will be used in two group of patients with treatment different characteristics at baseline
1998307|NCT01490892|Drug|3D HI and SHI of UCA|Perflutren injection, suspension (IV)0.25 ml followed by 3D Harmonic imaging (HI) then (IV) 20 micro-l/kg followed by 3D subharmonic imaging (SHI)
1998308|NCT01489813|Drug|Genistein|30 mg of genistein supplement by mouth three times daily (PO TID).
1998309|NCT01489813|Drug|Sugar pill|Sugar pills will be taken by mouth three times daily (PO TID).
1998311|NCT01487200|Drug|FX006|single intra-articular injection
1998312|NCT01487200|Drug|commercially available triamcinolone acetonide|single intra-articular injection
1998313|NCT01485978|Drug|Ramipril|Ramipril (Delix) tablets containing 2.5 mg ramipril, oral application with 1 to 6 mg per body surface area ramipril once daily for 3 years.
1998314|NCT01485978|Drug|placebo to ramipril|Oral application of placebo to ramipril, once daily with 1 to 6 mg per body surface area for 3 years or until disease progression.
1998315|NCT01485978|Drug|Ramipril|Oral treatment with 1 to 6 mg per body surface area ramipril once daily for 3 years as per protocol.
1998318|NCT01479257|Behavioral|Questionnaires|36 questionnaires at the first visit (a total of 474 questions) and 25 questionnaires at the second visit (a total of 278 questions), taking about 60 to 90 minutes to complete each visit.
1998319|NCT01479257|Device|Accelerometer|Small device worn on the hip for 7 consecutive days that measures physical activity.
1998320|NCT01479257|Device|Smart Phone|Questions on smart phone up to 5 times a day for 7 days taking about 5-7 minutes to complete each time.
1998321|NCT01478945|Device|311 nm NB-UVB light|"Narrowband UVB is now the most common form of phototherapy used to treat skin diseases. Narrow-band refers to a specific wavelength of ultraviolet (UV) radiation, 311 to 312 nm. Hospital NB-UVB usually involves whole body cabinets suitable for extensive, generalised vitiligo i.e. large or multiple lesions. Usually the whole body is exposed to the UVB for a short time (seconds to minutes). NB-UVB is also used in the treatment of many other skin conditions including psoriasis and eczema.
Hand held phototherapy units use the same lamp as the whole body units (TLO1) but only suitable for the treatment of smaller areas of skin i.e. early and focal lesions of vitiligo.
Early reports showed that these units are also safe and effective for the treatment of psoriasis of the scalp."
1998322|NCT01477307|Other|Hypocaloric diet|Eurodiet,standardized hypo-caloric diet, during 3 weeks
1998323|NCT01474265|Drug|Varenicline|0.5-2 mg per day, oral use
1998324|NCT01474265|Drug|Placebo|1-2 tablets per day, oral use
1998325|NCT01474265|Drug|Nicorette TX|10-15 mg per day, transdermal use (patches)
1998329|NCT01468285|Drug|betahistine dihydrochloride|betahistine dihydrochloride 24 mg tablet b.i.d. six weeks treatment
1998330|NCT01468285|Other|placebo|placebo tablets b.i.d., six weeks treatment
1998331|NCT01465659|Drug|temozolomide|Given PO
1998332|NCT01465659|Drug|pazopanib hydrochloride|Given PO
1998333|NCT01452230|Behavioral|Supervised physical activity|Supervised physical activity
1998334|NCT01450943|Device|SECONDARY dressing gauze and tape|SECONDARY dressing gauze and tape
1998335|NCT01450943|Procedure|debridement, irrigation|debridement, irrigation
1998336|NCT01450943|Device|Dermagraft?|Dermagraft per company protocol
1998337|NCT01450943|Device|Oasis?|Oasis per company protocol
1998338|NCT01449929|Drug|dolutegravir 50 mg OAD|1 x 50 mg tablet OAD
1998339|NCT01449929|Drug|darunavir 800mg OAD|2 x 400mg tablets OAD
1998340|NCT01449929|Drug|ritonavir 100mg OAD|1 x 100mg tablet OAD
1998374|NCT01414725|Other|Standard Physiotherapy Exercises|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist. The exercises will comprise a standardised programme of simple physiotherapy exercises which aim to improve trunk and pelvic stability, lower limb muscle length and strength, and balance and control of movement, as described by Barrett et al [2009]. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
1998375|NCT01414725|Other|Core Stability Training|Individualised face to face training sessions, delivered over 12 weeks, plus an individualised 15-minute daily home exercise programme will be provided. This will be undertaken by a neurological physiotherapist with experience in the delivery of core stability training to people with MS. Exercises will be progressed in response to the abilities of the individual. Each participant will receive a workbook with written and diagrammatic instructions describing their home exercise programme.
1998376|NCT01414725|Other|Relaxation|Three face to face individualised relaxation sessions, provided at 4 weekly intervals, plus a 15-minute home programme based around an audio relaxation CD. Weekly telephone contact / support will be provided.
1998377|NCT01411774|Behavioral|Cognitive-behavioral therapy|All patients will receive 10 sessions of therapy over 8 weeks using the evidence-based CBT protocol in POTS (2004). Sessions 1-4 will be held twice weekly; sessions 5-10 will be held on a weekly basis. Sessions 1-3 do not include exposures and are devoted to psychoeducation, cognitive therapy, and hierarchy development. Sessions 4-10 involve E/RP exercises specific to each youth.
1998378|NCT01411774|Drug|d-cycloserine|D-cycloserine will be encapsulated into 25mg with identical placebo capsules. Youth will take (1 or 2) DCS or identical placebo capsule 1 hour before sessions 4-10. A 0.7mg/kg dosage corresponds with dosages found to be effective in adult studies (50mg/estimated average adult weight of 70kg=.71mg/kg). Accordingly, doses for this study will be about 0.7mg/kg. Two dosing levels will be used based upon weight ranges to ensure comparable mg/kg levels: children weighing 25-45kg will be given a dosage of 25mg (~0.56-1.0 mg/kg/day), and children ≥46kg will be given 50mg provided in two 25mg capsules (~0.50-1.08mg/kg/day). Doses will be given 1 hour before therapy sessions 4-10.
1998379|NCT01411774|Drug|Pill placebo|The pill placebo will be identical to the active study medication in every respect (e.g., size, shape, number of capsules, etc.).
1998380|NCT01408693|Procedure|Trans-gluteal approach, CLAS|Classic lateral, trans-gluteal approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
1998381|NCT01408693|Procedure|Anterior minimal invasive approach, AMIS|Minimal invasive Hueter anterior approach. Device: Cemented unipolar hip hemiarthroplasty for the treatment of femoral neck fractures
1998382|NCT01401270|Behavioral|prize contingency management|Participants earn the chance to win prizes for the targeted behavior, cocaine abstinence.
1998383|NCT01392625|Biological|Autologous hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:
Group 1 (18 patients) Eighteen (18) patients will be treated with Auto-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
1998384|NCT01392625|Biological|Allogeneic hMSCs|"Cells will be administered via the Biosense Webster MyoStar NOGA Injection Catheter System will be tested in 18 patients via transendocardial injection:
Group 2 (18 patients) Eighteen (18) patients will be treated with Allo-hMSCs: 20 million cells/ml delivered in a dose of 0.5 ml per injection x 10 injections for a total of 1 x 108 (100 million) Auto-hMSCs."
1998406|NCT01381562|Drug|Drug: GSK2251052|Reconstituted, added to 250mL 0.9% NaCl solution and administered via IV infusion
1998407|NCT01381562|Drug|Meropenem|Reconstituted, added to 100mL 0.9% NaCl solution and administered via IV infusion
1998408|NCT01381562|Other|Placebo|saline placebo
1998411|NCT01381692|Drug|Bortezomib|Given IV or SC
1998412|NCT01381692|Drug|Dexamethasone|Given PO
1998413|NCT01381692|Other|Laboratory Biomarker Analysis|Correlative studies
1998414|NCT01381692|Other|Quality-of-Life Assessment|Ancillary studies
1998422|NCT01378377|Drug|MEK inhibitor MSC1936369B and Temsirolimus|"The starting dose of MSC1936369B will be 45mg QD.
The starting dose of Temsirolimus will be 12.5 mg/week
Dosing of MSC1936369B and Temsirolimus will occur in combination: MSC1936369B will be taken orally, QD, on days 1-15 and temsirolimus will be infused IV on days 1, 8 and 15 in successive 21-day cycles. Dose escalation will proceed until Maximum Tolerated Dose (MTD) is reached.
Number of Cycles: The treatment will be continued until disease progression, intolerable toxicity, investigator's decision to discontinue treatment, or withdrawal of consent by the subject."
1998423|NCT01378273|Drug|Epo|Enrollment will occur within 24 hours of birth. Study drug will be administered intravenously for the first 6 doses. Subjects in the Epo arm will then receive 400 U/kg/dose three times a week until they reach 32-6/7 weeks postmenstrual age. Control infants will receive sham injections.
1998424|NCT01378273|Other|Control|Subjects will receive 6 doses of vehicle intravenously during the first 2 weeks of life. Doses will be administered at 48 hour intervals from the time of enrollment. Following high dose administration, sham subcutaneous injections will be given three times a week through to 32-6/7 weeks postmenstrual age.
1998427|NCT01372774|Radiation|stereotactic radiosurgery|Undergo RT
1998428|NCT01372774|Radiation|whole-brain radiation therapy|Undergo radiotherapy (RT)
1998441|NCT01370941|Dietary Supplement|Drug A Chymosin|Five drops of chymosin is added to ½ a liter of milk. This is to be consumed during breakfast.
1998442|NCT01370941|Dietary Supplement|Drug B: Placebo|B: Five drops of placebo (water) is added to ½ a liter of milk. This is to be consumed during breakfast.
1998443|NCT01367444|Drug|SAR422459|Pharmaceutical form:Prefilled syringes Route of administration: subretinal injection
1998444|NCT01364870|Device|Placebo TENS|"Subjects randomized to the placebo group will use an EMPI TENS Select device that emits a current for 45 seconds then shuts off. They will be asked when they first feel the current, then the device will be turned down a half-point to provide treatment at a sub-sensory level. This unit displays an active indicator light suggesting to the subject that the unit is actively emitting current. At discharge, subject will be sent home with an adequate supply of batteries and asked to change batteries when the device goes below 4 bars, further suggesting that the device is actively working."
1998445|NCT01364870|Device|Intense TENS (EMPI Select TENS)|High-frequency intense TENS provided with the EMPI Select TENS. The generator emits a balanced, asymmetrical, biphasic waveform and has buttons for variation of frequency and amplitude. A rate modulation frequency of 50pps and 150pps every 0.5 seconds will be used with a pulse width of 150 microseconds (μs).
1998447|NCT01360229|Procedure|Acupuncture|Subjects will be randomized in a 1:1 ratio to receive real acupuncture. Acupuncture is a procedure in which specific body areas are pierced with fine needles for therapeutic purposes
1998448|NCT01360229|Other|Acupuncture to treat fatigue in Parkinson disease|Subjects will be randomized in a 1:1 ratio to receive sham acupuncture.
1998449|NCT01359007|Drug|Irinotecan, Oxaliplatin, Leucovorin, 5-FU|5-FU 2400 mg/m2 IV continuous infusion for 46-48 hours Days 1-3 for 2 weeks 5-FU 400 mg/m2 IV Bolus Day 1 Oxaliplatin 85 mg/m2 IV over 120min +/-30 min. Day 1 Irinotecan 180 mg/m2 IV to run over 90 min +/- 30 min Day 1 Leucovorin (Before bolus 5-FU) 400 mg/m2 IV over 120 min. +/- 30 Day 1 May give oxaliplatin and leucovorin concurrently
1998450|NCT01358201|Drug|vINCRISTINE|
1998451|NCT01358201|Drug|Dexamethasone|
1998452|NCT01358201|Drug|Methotrexate|
1998453|NCT01358201|Drug|Cytosine arabinoside|
1998455|NCT01355094|Device|KCI AbThera|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.
Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
1998505|NCT01311687|Drug|dexamethasone|"For Subjects ≤ 75 years of age:
40 mg of low-dose dexamethasone will be administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression
For Subjects > 75 years of age:
20 mg low-dose dexamethasone will be administered by mouth once per day on Days 1, 8, 15, and 22 of a 28-day cycle until disease progression"
1998456|NCT01355094|Device|"Stampede VAC"|"The time that the dressing will be left in place will be left to the discretion of the attending surgeon, but revised practice guidelines mandate either formal abdominal closure or dressing change at 24-96 hours from placement. Upon the first OA dressing change, the surgeon is free to utilize whatever temporary closure they choose.
Just prior to placement of the dressing, 16 ml (1 table spoon) of blood will be drawn from an existing arterial or venous line (this will qualify as Day 1). The same quantity of blood will be drawn on days 2, 3, 7 and 28 (or hospital discharge, whichever comes first). 15ml of peritoneal fluid will also be collected from the abdomen on the same days or until closure of the abdomen and removal of the dressing."
1998462|NCT01351740|Drug|atazanavir|switch to unboosted atazanavir 400 mg daily
1998463|NCT01351740|Drug|atazanavir/ritonavir|Continue current regimen of atazanavir 300 mg/ ritonavir 100 mg daily
1998464|NCT01352247|Procedure|Unicompartmental Knee Replacement|A partial knee replacement or UKR involves only the diseased area of the joint being replaced. The healthy compartment of the knee is retained and artificial implants are inserted in place of the diseased area. This is done via a minimally invasive surgical procedure.
1998465|NCT01352247|Procedure|Total Knee Replacement|A total knee replacement involves all surfaces of the knee being replaced. The procedure involves excising both diseased and normal femoral condyles, the tibial plateau and often the patella. This is done through a large skin incision which provides easy access to the knee joint. Each component will be replaced with an artificial implant, which may be cemented in position.
1998471|NCT01349049|Drug|PLX3397|Maximum Tolerated Dose of PLX3397 will be administered orally, twice daily.
1998472|NCT01349049|Drug|PLX3397|The drug product is available in capsule form, to be taken orally.
1998477|NCT01341301|Radiation|Total Body Irradiation|Undergo TBI
1998478|NCT01341301|Biological|Donor Lymphocyte Infusion (DLI)|Undergo DLI
1998479|NCT01341301|Drug|Cyclophosphamide|Given IV
1998480|NCT01341301|Drug|Tacrolimus|Given IV or PO
1998481|NCT01341301|Drug|Mycophenolate mofetil|Given IV or PO
1998482|NCT01341301|Procedure|Allogeneic hematopoietic stem cell transplantation|Undergo allogeneic HSCT
1998483|NCT01341301|Other|Laboratory biomarker analysis|Correlative studies
1998486|NCT01339455|Procedure|AHSCT|"AHSCT Procedure:
Mobilization and Harvesting:
Cyclophosphamide
Rituximab
GSCF
Dexamethasone
Apheresis
Conditioning and Infusion (3-4 weeks after Mobilization and Harvesting):
Cyclophosphamide
MESNA
Rabbit ATG
Rituximab
Methylprednisolone
Stem Cell infusion
GSCF"
1998488|NCT01336959|Drug|BCT197 Part A|
1998489|NCT01336959|Drug|Placebo|Placebo capsules
1998490|NCT01336959|Drug|BCT197 Part B|Randomized Double-blind BCT197
1998491|NCT01332097|Drug|BCT197|
1998492|NCT01332097|Drug|Prednisone placebo|capsules
1998493|NCT01332097|Drug|BCT197 placebo|capsules
1998495|NCT01327781|Other|Laboratory Biomarker Analysis|Correlative studies
1998496|NCT01327781|Other|Pharmacological Study|Correlative studies
1998497|NCT01327781|Other|Questionnaire Administration|Ancillary studies
1998498|NCT01327781|Drug|Z-Endoxifen Hydrochloride|Given PO
1998499|NCT01327274|Device|Magnetic Mini-Mover Procedure (Magnimplant)|This is a non-randomized study in which otherwise healthy patients, ages 8-14, with severe pectus excavatum (PSI > 3.5) will undergo the Magnetic Mini-Mover procedure outpatient surgery to both place and later explant the Magnimplant or Magnetic Mini-Mover device. Patients will be required to wear a custom-fitted orthotic brace, which houses the external magnet and records brace-wear compliance. They will undergo 3MP treatment for 18-24 months, enough to attempt to improve their PSI (< 3.25). Patients will be seen in clinic at least monthly until treatment is complete.
1998500|NCT01326104|Biological|TTRNA-xALT|TTRNA-xALT 3 x 10^7/kg by intravenous injection once.
1998501|NCT01326104|Biological|TTRNA-DCs|TTRNA-DCs 1 x 10^7 by intradermal injection every 2 weeks for 3 total doses.
1998503|NCT01315132|Device|Matched Sibling Allogeneic Transplantation|Patients undergoing myeloablative hematopoietic stem cell transplant from HLA identical related donors using cyclophosphamide tolerization
1998521|NCT01279811|Other|Crossover of vasopressors|"To evaluate the effect of different vasopressor agents on SCPP, a crossover intervention will be conducted on patients requiring either NORepinephrine or DOPamine post-operatively, once daily for 5 days while the catheter is in place. A subject on NORepinephrine will be switched over to DOPamine for 1 hr, and then switched back to NORepinephrine. Likewise, a subject on DOPamine will be switched over to NORepinephrine for 1 hr, and then switched back to DOPamine. Subjects on both vasopressors will have DOPamine stopped for 1 hr and NORepinephrine titrated up to maintain the same MAP for 1 hr, and then brought back to the original levels of both vasopressors. On the following day, the reverse will be carried out, with a stoppage of the NORepinephrine and maintenance solely on DOPamine."
1998522|NCT01277770|Drug|Steroid-Free Maintenance Immunosuppression|10 year follow-up of steroid-free maintenance immunosuppression
1998523|NCT01277770|Other|Infection After Kidney Transplantation|A cross-sectional study of infection after kidney transplantation (with emphasis on infection in steroid-free recipients).
1998524|NCT01277770|Drug|Evaluation of the DGF nomogram in Thymoglobulin|An evaluation of the DGF nomogram in Thymoglobulin treated recipients at the University of Minnesota
1998525|NCT01274117|Procedure|Transposition of the basilic vein and anastomosis with the brachial vein|One-stage vs two-stage transposition of the basilic vein
1998529|NCT01272960|Device|Post-Placenta Mirena Insertion|Mirena(R) intrauterine device will be inserted within 10 minutes of delivery of the placenta
1998538|NCT01266096|Drug|PET scan with 124I-cRGDY-PEG-dots|Five (5) patients with newly diagnosed or recurrent melanoma, and 18 malignant brain tumor patients (surgical (n=13) or non-surgical candidates (n=5)). Patients with either primary or metastatic brain tumors, will be i.v. injected with approximately 5 mCi (3.4-6.7 nanomoles) of 124I-cRGDY-PEG-dots (specific activity range 750.0 - 1450 mCi/mol) and undergo the microdosing study for purposes of collecting pharmacokinetic and dosimetry data. All studies will be performed using a dedicated scanner, which integrates a dedicated PET scanner and a spiral CT with proprietary fusion software.
1998539|NCT01264601|Biological|Trivalent Influenza Vaccine|Age appropriate dose of seasonal Trivalent Influenza Vaccine (TIV), either 0.25mL under age 3 or 0.5mL over the age of 3.
1998540|NCT01258855|Biological|Aldesleukin|Given IV
1998541|NCT01258855|Other|Laboratory Biomarker Analysis|Correlative studies
1998542|NCT01258855|Biological|Ziv-Aflibercept|Given IV
1998549|NCT01247324|Drug|Interferon beta-1a|
1998550|NCT01247324|Drug|Ocrelizumab-matching placebo|
1998551|NCT01247324|Drug|Ocrelizumab|
1998552|NCT01247324|Drug|Interferon beta-1a-matching placebo|
1998553|NCT01245062|Drug|GSK1120212|MEK inhibitor
1998554|NCT01245062|Drug|Chemotherapy|Investigator Choice of DTIC or paclitaxel
1998555|NCT01243177|Drug|Lacosamide|"Lacosamide:
Strengths: 50 mg / 100 mg
Form: tablets
Dosage: total daily target dose of 200 mg, 400 mg or 600 mg. 1 dose reduction was allowed from either 600 mg to 500 mg or from 400 mg to 300 mg total daily dose
Duration: up to 118 weeks"
1998556|NCT01243177|Drug|Carbamazepine-Controlled Release|"Carbamazepine-CR:
Strengths: 200 mg
Form: tablets
Dosage: total daily target dose of 400 mg, 800 mg or 1200 mg. 1 dose reduction was allowed from either 1200 mg to 1000 mg or from 800 mg to 600 mg total daily dose
Duration: up to 118 weeks"
1998557|NCT01243593|Procedure|Transversus Abdominis Plane Block|A block needle will be advanced in a medial to lateral direction until the tip is visualized in the transversus abdominis plane. After negative aspiration 0.4 ml/kg of bupivacaine 0.25% with 1:200 000 epinephrine will be injected. The total dose of bupivacaine will not exceed 2 mg/kg and the total volume will not be more than 20 ml.
1998558|NCT01243593|Procedure|Standard Anesthesia|Local field infiltration with bupivacaine 0.25% with 1:200 000 epinephrine 0.4 ml/kg before skin incision.
1998559|NCT01240902|Device|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)|Medtronic CoreValve® System Transcatheter Aortic Valve Implantation (TAVI)
1998560|NCT01240902|Device|Surgical Aortic Valve Replacement (SAVR)|Surgical Aortic Valve Replacement (SAVR)
1998561|NCT01237483|Drug|Erbitux|To begin 7 days before radiotherapy, loading dose 400 mg / m² in the first week then 250 mg / m² weekly for the duration of radiotherapy (for a total of 7 doses including the loading dose)
1998564|NCT01236547|Radiation|Intensity-Modulated Radiation Therapy|Undergo IMRT
1998565|NCT01236547|Drug|Paclitaxel|Given IV
1998566|NCT01236547|Drug|Pazopanib Hydrochloride|Given PO
1998567|NCT01236547|Other|Placebo|Given PO
1998568|NCT01233609|Drug|Valproic Acid|One to four 250mg softgels by mouth daily (dose determined by body weight)
1998580|NCT01230684|Procedure|Contrast Enhanced Ultrasound (Contrast Agent: OptisonTM)|The contrast agent will be prepared using a single, 3 mL vial of Optison and 57 mL saline combined in a sterile syringe. Contrast will be set to deliver a continuous infusion at 4 mL/min, via peripheral access. In the event that the above description of the administration of Optison is not adequate for lumen flow contrast enhancement the PI or Co-I will direct the study team to proceed to the secondary administration procedure. This will be done by the following: 0.5 mL of Optison will be injected into a peripheral vein. This may be repeated for further contrast enhancement as needed. The maximum total doses should not exceed 5.0 mL in any 10 minute period nor exceed 8.7 mL in any one patient study. We will follow the insert package dose. We will not not exceed 5.0 or 10 minutes or 8.7ml per patient (this will include the 0.5mL for initial). Therefore, no more that 8.2mL will given in this second administration procedure.
1998582|NCT01224288|Procedure|Perfusion CT scan|DCE-CT scans 4 weeks prior to and 8 weeks after starting treatment on study 2010-0085.
1998583|NCT01218698|Drug|Losartan Potassium Tablets|
1998584|NCT01218724|Drug|Losartan Potassium and Hydrochlorothiazide Tablets|
1998585|NCT01218711|Drug|Losartan Potassium and Hydrochlorothiazide Tablets|
1998586|NCT01217281|Procedure|Full Mouth Non-Surgical Periodontal Therapy|Non-surgical Periodontal Therapy provided in two sessions, one for the right half and one for the left half of the dentition. Treatment sessions are provided within one week. No antibiotics or other adjunctive medications are to be used
1998587|NCT01218022|Drug|Losartan Potassium Tablets|
1998591|NCT01214486|Drug|Raltegravir|Subjects should be on RAL 400mg twice daily at least 1 week. Subjects will be asked to come to the Specialty Clinic at two different points on the same day: at either 2, 4 or 6 hours after taking the drug, and at 10 or 12 hours after taking the drug. After completion of the first part of the study, subjects whose viral load is below the limit of detection (HIV RNA < 50 copies/mL) will be asked to switch to once a day RAL dosing (i.e. 800 mg once a day). Once the a subject has taken RAL once a day for at least three consecutive days, s/he will be asked to come to the Specialty Clinic at two different points in the same day to obtain blood by venous puncture. Blood will be obtained 2 or 4 hours after the dose and at 20-24 hours after the dose.
1998594|NCT01209078|Drug|GSK1322322|GSK1322322 1500mg BID
1998595|NCT01209078|Drug|Linezolid|Linezolid 600mg
1998596|NCT01209078|Drug|GSK1322322 placebo|Placebo
1998597|NCT01209078|Drug|Linezolid placebo|placebo
1998598|NCT01209000|Procedure|Kidney Biopsy|Patients scheduled to undergo a clinically indicated kidney biopsy will be requested to consent to an additional renal core, to be set aside until all clinical care is complete.
1998599|NCT01207076|Biological|90Y-AHN-12|"The intervention consists of two parts.
The dose of cold AHN-12 to achieve favorable biodistribution through imaging using 111In-AHN-12.
Dose escalation of nonradiolabeled AHN-12:
Dose level= -1 0.20 mg/kg, Dose level=1 0.40 mg/kg, Dose level=2 0.80 mg/kg, Dose level=3 1.20 mg/kg, Dose level=4 1.60 mg/kg, Dose level=5 2.00 mg/kg
Phase I therapeutic dosing of cold AHN-12 at dose established plus 90Y-AHN-12.
the starting 90Y-AHN-12 dose level will be 4 Gy with the dose escalated in increments of 4 Gy to a maximum of 20 Gy."
1998600|NCT01202851|Other|Relaxation Program|3 times a week, 60 minute sessions for 6 weeks.
1998601|NCT01202851|Behavioral|Questionnaires|Multiple questionnaires taken before, during and after radiotherapy/exercise intervention programs during course of study.
1998602|NCT01202851|Other|Saliva Testing|4 saliva samples per day for cortisol testing for 3 days before radiation therapy begins, for 3 days in the last week of radiation therapy, for 3 days in a row 3 months after radiation therapy ended, for 3 days in a row, for 6 months after radiation therapy ended, and for 12 months after radiation therapy ended.
1998603|NCT01202994|Drug|18F-Flutemetamol|"All subjects will undergo a PET scan with 18F-PIB, within six months of also undergoing an FDG-PET scan (PET scans will occur on separate days).
For the 18F-PIB PET scan: Approximately 185 MBq (5 mCi) of 18F-PIB will be injected intravenously and PET data collected for each subject.
The FDG-PET scan will follow the same procedures as routine scans obtained in a clinical setting (approximately 370 MBq of 18F-FDG will be injected intravenously and PET data collected for each subject). FDG-PET data will be used to correlate metabolic changes and for anatomic co-registration of 18F-PIB images."
1998604|NCT01201941|Other|e-Chasqui|"The laboratory component of the PIH-EMR, termed e-Chasqui, permits web-based entry of culture and DST results at all regional and central laboratories performing these tests. In addition, the system includes applications to assess quality control, generate aggregate reports, notify health centers of new results or contaminated samples, and track enrolled patients and the status of pending laboratory tests."
1998605|NCT01199211|Other|Exercise training, women, marathon|Prospective study with no intervention in women who have volunteered to run a full marathon or a half-marathon. Each subject will serve as own control. Each subject will be studies at 3 stages: baseline, after at least 12 weeks of training for the marathon (we will not provide training), 6 weeks after running the marathon.
1998606|NCT01199185|Behavioral|Smoking Cessation|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT).
1998694|NCT01088607|Drug|ursodeoxycholic acid (UDCA)|Pediatric PSC patients already receiving UDCA therapy will enter a four-phase trial consisting of baseline data collection (phase I, 4 weeks), 50% reduction in UDCA dose (phase II, 4 weeks), discontinuation of UDCA (phase III, 8 weeks) and reinstitution of therapy at a dose of 20 mg/kg/day (phase IV, 8 weeks). Surveillance and endpoint evaluation for each phase will include liver chemistries and clinical data. Comparisons will be made between baseline and the end of phase III (primary outcome) and between the end of phase III and the end of phase IV (secondary outcome). Serum cytokine biomarkers will be measured and compared between baseline and the end of phase III and between the end of phases III and IV.
1998695|NCT01087008|Drug|zoledronic acid|Zoledronic acid 4 mg every 4 weeks for a total of 12 treatments
1998607|NCT01199185|Behavioral|Smoking Cessation plus Weight Loss|All participants will receive a smoking cessation intervention via the Proactive TARGIT Quit Line. Participants will receive access to the TARGIT Smoking Cessation Handbook which will be a useful tool to guide them through the quitting process and highlight the major points reviewed in all counseling sessions. As part of TARGIT all participants will receive nicotine replacement therapy (NRT). Participants in the Intervention Group will also receive a Behavioral Weight Loss/ Weight Gain Prevention Intervention delivered via interactive technology. The Intervention group will receive 16 weekly webinar sessions beginning 7 weeks after randomization via Cisco WebEx. The webinar sessions will present the behavioral weight loss/ weight gain prevention program. After the 16 weekly sessions, the webinar sessions will then be scheduled monthly for the next 6 months then quarterly thereafter for 12 months.
1998619|NCT01190176|Procedure|Gynaecological follow-up|Subjects will receive a gynaecological follow-up with cytology and oncogenic HPV DNA testing every 12 months, for up to a maximum of four years.
1998620|NCT01190176|Biological|Cervarix™|Subjects received 3 doses of the HPV vaccine administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
1998621|NCT01190176|Biological|Placebo control|Subjects received 3 doses of the control [Al(OH)3] administered intramuscularly according to a 0, 1, 6 month vaccination schedule in the primary study HPV-015.
1998627|NCT01187199|Drug|Temsirolimus|Starting dose 12.5 mg by vein given on day 1, 8, and 15 of a 21 day cycle.
1998628|NCT01187199|Drug|Bevacizumab|Starting dose 5 mg/kg given by vein on day 1 of a 21 day cycle.
1998629|NCT01187199|Drug|Paclitaxel|Starting dose 30 mg/m2 given by vein on day 1 of a 21 day cycle.
1998630|NCT01187199|Drug|Sorafenib|Starting dose 200 mg by mouth daily for a 21 day cycle.
1998631|NCT01187199|Drug|Carboplatin|Starting dose AUC 2 by vein on day 1 of a 21 day cycle.
1998632|NCT01186692|Device|Melody® Transcatheter Pulmonary Valve|Transcatheter Pulmonary Valve replacement Transcatheter valve implantation into a RVOT conduit in patients with complex congenital heart defects where the conduit has become dysfunctional and where the patient needs invasive intervention.
1998634|NCT01177761|Procedure|physical exercise|Two sessions/week, 50 weeks/year over 12 years of high intensity exercise training
1998641|NCT01163084|Drug|Goserelin Acetate|Given SC
1998642|NCT01163084|Other|Laboratory Biomarker Analysis|Correlative studies
1998643|NCT01163084|Drug|Leuprolide Acetate|Given IM
1998644|NCT01163084|Drug|Vismodegib|Given PO
1998645|NCT01162109|Dietary Supplement|Zinc sulfate|"A group of 10 mechanically ventilated patients with severe sepsis will be randomized to receive 500mcg/kg IBW elemental zinc (IV) or placebo. The dose will be escalated by 250mcg/kg IBW every 10 subjects to ceiling dose of 1250 mcg/kg IBW or until toxicity develops.
A group of healthy volunteers will also receive IV zinc (as a single dose) and the PK will be compared to that in patients with sepsis."
1998648|NCT01156129|Drug|stool softener|ducosate sodium, Milk of Magnesia, dulcolax
1998649|NCT01156129|Device|Arm B: Acupressure bracelet|Bioband
1998650|NCT01156129|Dietary Supplement|sugar free gum|Orbit
1998651|NCT01149083|Drug|Carboplatin|Given IV
1998652|NCT01149083|Other|Laboratory Biomarker Analysis|Correlative studies
1998653|NCT01149083|Drug|Veliparib|Given PO
1998654|NCT01146665|Behavioral|Computer-based Personalized Assessment Feedback|This type of brief intervention targets norm misperceptions, for example summarizing a person's drinking in comparison to the average male or female in the general population. Theoretically, such normative feedback corrects norm misperceptions and motivates drinkers to re-evaluate their consumption patterns.
1998655|NCT01146665|Behavioral|Computer-based sham|Similar in format and duration as the Personalized Assessment Feedback but will engage youth in nutrition and exercise-related questions.
1998757|NCT00998400|Behavioral|CBT in combination with WBT and life style modification|CBT involves several essential features: identifying and correcting inaccurate thoughts associated with depressed feelings (cognitive restructuring); helping patients to engage more often in enjoyable activities (behavioral activation); enhancing problem-solving skills; providing instruction and guidance in specific strategies for solving problems. The techniques included in WBT may be used in overcoming impairments in environmental mastery, purpose in life, personal growth, autonomy, self-acceptance and positive relations with others. CM will consist of reviewing the patients' clinical status, and providing the patient with support and advice if necessary.
1998758|NCT00993031|Drug|Lopinavir/ritonavir|LPV 200mg/r 50mg
1998759|NCT00993031|Drug|Efavirenz|600mg
1998760|NCT00993031|Drug|Zidovudine|Zidovudine 300 mg
1998761|NCT00993031|Drug|Lamivudine|Lamivudine 150 mg
1998762|NCT00991640|Behavioral|2-day preceptorship on obesity management|
1998763|NCT00987389|Procedure|Plasma Exchange|Plasma exchange is a procedure whereby blood is taken from the body and separated by a machine into blood cells and plasma, which is the liquid part of blood. The plasma is discarded and the blood cells are returned to the body with a plasma substitute.
1998764|NCT00987389|Drug|Glucocorticoids|During the study, a standard glucocorticoids dose regimen will be compared to a reduced glucocorticoids dose regimen. All subjects' patients will receive the same glucocorticoids dose for the first two weeks then the dose will decrease following either a standard regimen or a reduced regimen.
1998774|NCT00972881|Biological|cetuximab|
1998775|NCT00972881|Drug|capecitabine|
1998776|NCT00972881|Drug|irinotecan hydrochloride|
1998777|NCT00972881|Procedure|neoadjuvant therapy|
1998778|NCT00972881|Procedure|therapeutic conventional surgery|
1998779|NCT00972881|Radiation|radiation therapy|
1998780|NCT00965263|Biological|TA-CD|TA-CD (82,360 μg; IM) were administered at weeks 1, 3, 5 and 9.
1998781|NCT00964288|Drug|GSK1014802 low dose|oral tablet
1998782|NCT00964288|Drug|Lidocaine|positive control
1998783|NCT00964288|Drug|GSK1014802 high dose|oral tablet
1998784|NCT00964288|Drug|Placebo|To match GSK drug and positive control
1998789|NCT00955201|Behavioral|Exercise|Structured aerobic exercise (treadmill).
1998790|NCT00955201|Behavioral|Exercise|Structured isokinetic strength exercise (dynameter).
1998795|NCT00944775|Behavioral|Exercise training|10-month exercise training program during hemodialysis sessions
1998801|NCT00939614|Drug|Lamotrigine|
1998802|NCT00939458|Drug|Lamotrigine|
1998805|NCT00937937|Drug|Dinaciclib|Given IV
1999014|NCT00574353|Radiation|Fluorine-18-Labeled Fluoro-Misonidazole Positron Emission|You will be scanned 2 to 3 times on the same day, but you will only be administered one dose of the FMISO tracer. The first scan will last about 30 minutes. Then you will have 1 to 3 hours to wait before you are scanned again. Some patients will undergo a second scan approximately one-and-a-half hours after the start of the first scan. This scan will last about 10 minutes. The final scan will occur between 2-4 hours after the start of the first scan. This final scan will also last about 10 minutes. During the PET scan, you may have a separate i.v. line put into your other arm so that we can take 2 to 3 blood samples. These samples will be less than half a teaspoon each. We are taking these blood samples to see how quickly FMISO leaves your blood stream. The first sample will be taken between 2 and 40 minutes after the FMISO is injected. The other two blood samples will be taken with each subsequent scan.
1999016|NCT00572936|Drug|prostaglandin|One drop, each eye, twice a day
1999017|NCT00570323|Drug|Arimidex|Aromatase inhibitors
1999018|NCT00570323|Drug|Faslodex|Hormone Receptor
1999019|NCT00569309|Biological|Streptococcus pneumoniae|Patients will receive 0.5 mL Prevnar in the deltoid muscle during weeks 9, 17, and 25 after autologous hematopoietic stem cell transplantation (HSCT)
1999020|NCT00569309|Other|laboratory correlative studies|Approximately 30-mL of blood will be collected and sent to the appropriate research lab(s) for processing.
1999021|NCT00569309|Other|quality-of-life assessment|Responses to Hospital Anxiety and Depression Scale, 9-item brief fatigue inventory 57, brief pain inventory, and the FACT-G. This should take each patient approximately 10-15 minutes to fill out all these surveys per instance.
1999032|NCT00552799|Drug|Penicillin VK|Biconcave tablet 250mg oral, b.d.
1999033|NCT00552799|Other|placebo|biconcave tablet matching active comparator as much as possible in size and shape
1999034|NCT00546390|Device|Blood Pressure Cuff|The blood pressure cuff will be inflated for 5 minutes and then deflated for 5 minutes. This will be done 4 times in a row.
1999035|NCT00534963|Procedure|cervical vs. uterine placement of balloon catheter|
1999036|NCT00530725|Procedure|chest drainage|may be a chest tube of chest drainage procedure of any type (ie formal tube, pig-tail catheter, etc)
1999037|NCT00530725|Other|close clinical observation|close clinical observation in an operating room or intensive care unit without active intervention
1999041|NCT00527644|Device|5mm spring clip|Microline Pentax 5mm Visu-Loc Clip Applier
1999042|NCT00522223|Behavioral|Questionnaire|"Participants who are treated with radiation therapy: Questionnaires 5 times.
Participants who undergo a radical hysterectomy: Questionnaires 4 times."
1999045|NCT00515021|Drug|Eplerenone (Morning vs. evening drug regimen)|"Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks or 50mg, by mouth, daily, in the evening x 2 weeks
100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks."
1999046|NCT00512551|Procedure|Tumor Biopsies|Biopsies of the cervical tumor performed first before any treatment is given, and the second about 48 hours after radiation treatment has began.
1999047|NCT00510367|Drug|5-Fluorouracil|500 mg/m^2 By Vein Daily x 2 Days
1999048|NCT00510367|Drug|Cyclophosphamide|500 mg/m^2 By Vein On Day 1
1999049|NCT00510367|Drug|Doxorubicin|50 mg/m^2 By Vein Over 72 Hours
1999050|NCT00508378|Behavioral|Interview|Interview regarding side-effects of chemotherapy, 30-45 minutes.
1999051|NCT00508378|Behavioral|Questionnaire|Quality of life survey and symptom assessment questionnaire, 15 minutes.
1999052|NCT00509002|Drug|Gefitinib|250 mg by mouth once a day, every day, at about same time in morning.
1999053|NCT00500890|Drug|Carboplatin|350 mg/m^2 by vein, Over 2 Hours x 2 Days
1999054|NCT00500890|Drug|Cyclophosphamide|1 g/m^2 by vein, Over 1 Hour x 2 Days
1999055|NCT00500890|Drug|Etoposide|100 mg/m^2 by vein, Over 1 Hour x 5 Days
1999056|NCT00500890|Drug|Vincristine|1.5 mg/m^2 (by vein)IV Push Over 15 Minutes On Day 5
1999057|NCT00500890|Radiation|Radiation Therapy|Radiation treatment over a period of about 6 weeks.
1999058|NCT00499083|Biological|therapeutic autologous dendritic cells|injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments. If, after a cycle(s) of chemotherapy, no tumor can be localized by ultrasound, the DCs will be injected where the tumor bed was localized by the clip or marker.
1999059|NCT00499083|Drug|aromatase inhibition therapy|Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
1999060|NCT00499083|Drug|cyclophosphamide|600 mg/m2 IV day 1 every 2 weeks for 4 cycles
1999061|NCT00499083|Drug|doxorubicin hydrochloride|60 mg/m2 IV day 1 every 2 weeks for 4 cycles
1999062|NCT00499083|Drug|paclitaxel|175 mg/m2 intravenously (IV) over at least 3 hours day 1 every 2 weeks for 4 cycles.
1999067|NCT00499083|Other|immunoenzyme technique|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.
CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
1999068|NCT00499083|Other|immunohistochemistry staining method|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.
CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
1999069|NCT00499083|Other|laboratory biomarker analysis|"Estrogen and progesterone receptor, Her2/neu testing: Tumor biopsy material (preferably the initial diagnostic biopsy if tissue is available) will be examined by Immunohistochemistry (IHC) with appropriate controls for estrogen, progesterone receptors and Her2/neu. If the IHC is 2+ or in the indeterminate range, further testing of over-expression of Her2/neu by fluorescent in situ hybridization (FISH) will be done . If this has already been done and reported by the referring hospital, it will not be repeated. These tests are standard of care.
CEA and Survivin testing: IHC for CEA and Survivin with appropriate controls will be done on the tumor biopsy material (preferably from the initial diagnostic biopsy).
COX-2 and VEGF A , T cell and Dendritic Cells: Tumor biopsymaterial (preferably from the initial diagnostic biopsy) will be stained by IHC with appropriate controls for COX-2, VEGF A, T cell and Dendritic Cell infiltration."
1999070|NCT00499083|Procedure|adjuvant therapy|Hormone manipulation Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
1999071|NCT00499083|Procedure|biopsy|Two tumor biopsies will be performed. The first tumor biopsy will be performed before apheresis for diagnostic purposes, and again after completion of the first four chemotherapy treatments. Patients will undergo local anesthesia with lidocaine and 1% epinephrine followed by 1-2 core biopsies of the breast primary and/or palpable axillary node with a 14 gauge, 16 cm. Bard needle or other similar needle. The procedure may be done under ultrasound guidance. If a metal clip or marker has not been previously placed in the tumor, it will be placed before treatment.
1999072|NCT00499083|Procedure|conventional surgery|Definitive breast surgery Surgery will occur two to four weeks after the last course of chemotherapy. Modified radical mastectomy or lumpectomy and standard axillary dissection could be performed and the specific procedure will be decided by the patient and physician team. If a sentinel node dissection was done prior to chemotherapy and was negative, no further node dissection is necessary. A standard node dissection will be necessary if no node assessment was done prior to chemotherapy or if the pre- chemotherapy sentinel node was positive.
1999073|NCT00499083|Procedure|neoadjuvant therapy|Chemotherapy: Paclitaxel (T) 175 mg/m2 intravenously (IV) over at least 3 hours day 1. Repeat every 2 weeks for 4 cycles. IT DCs will be injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.
1999074|NCT00499083|Radiation|radiation therapy|Radiation therapy Radiation is started two to four weeks after surgery for all patients receiving lumpectomy and those patients after mastectomy that the physician feels chest wall radiation is warranted (example: T3 or T4 breast lesion, four or more axillary nodes etc.). The exact doses and methods of administration will be determined by the treating radiation therapist, but should be standard breast radiotherapy and not partial breast or investigational methods.
1999075|NCT00496119|Radiation|Proton Beam Therapy|70 Gy once daily at 2 CGE per fraction, no sooner than 2 weeks after last surgery to remove tumor, for between 35-39 treatments.
1999076|NCT00496119|Radiation|Photon Beam Therapy|Photon beam therapy once daily, no sooner than 2 weeks after last surgery to remove tumor, for 35-39 treatments.
1999078|NCT00488566|Drug|GSK drug|GSK drug
1999079|NCT00488566|Other|Placebo|Placebo
1999080|NCT00488566|Other|Lamictal|Positive control
1999093|NCT00478426|Drug|Sunitinib Malate|Given PO
1999094|NCT00475007|Device|IBV® Valve System|The IBV Valve is a small, umbrella shaped device designed to redirect airflow to healthier areas of the lungs. It is implanted without incisions using a bronchoscope.
1999095|NCT00468923|Drug|Candesartan/HCT|Candesartan 16 mg/HCT 12.5 once daily
